<SEC-DOCUMENT>0001193125-23-067105.txt : 20230310
<SEC-HEADER>0001193125-23-067105.hdr.sgml : 20230310
<ACCEPTANCE-DATETIME>20230310111313
ACCESSION NUMBER:		0001193125-23-067105
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		346
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230310
DATE AS OF CHANGE:		20230310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GSK PLC
		CENTRAL INDEX KEY:			0001131399
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15170
		FILM NUMBER:		23722271

	BUSINESS ADDRESS:	
		STREET 1:		980 GREAT WEST ROAD
		CITY:			BRENTFORD MIDDLESEX
		STATE:			X0
		ZIP:			TW8 9GS
		BUSINESS PHONE:		011442080475000

	MAIL ADDRESS:	
		STREET 1:		980 GREAT WEST ROAD
		CITY:			BRENTFORD MIDDLESEX
		STATE:			X0
		ZIP:			TW8 9GS

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLAXOSMITHKLINE PLC
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d382677d20f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:gsk="http://www.gsk.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>20-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="max-width: auto">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001131399</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gsk-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_05_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_HorlicksMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:HorlicksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis" >gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:ForeignCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:OtherAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostRetirementBenefitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BangladeshConsumerHealthcareMemberifrsfullJointVenturesAxis_DisposalGroupsClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandTwentyBusinessDisposalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" >ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:BangladeshConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandTwentyTwoBusinessDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:SubsidiariesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ManufacturingMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ManufacturingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FirstInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:SecondInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ThirdInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FourthInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:AcquisitionsTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UsCashBalancePensionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:RetireeHealthcarePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:HIVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OncologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SpecialtyMedicineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:MeningitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:InfluenzaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ShinglesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:EstablishedVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:RespiratoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:GeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_ReducedTaxRateCancelledMemberGSKEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:EventAxis" >gsk:ReducedTaxRateCancelledMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:OtherAuditorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:HindustanUnileverLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:HorlicksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:FreeCashFlowMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:TsrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PipelineProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HorlicksMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:HorlicksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis" >gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:LaterThanOneYearAndNotLaterThanTenYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:AvailableIndefinitelyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:MajorRestructuringProvisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis" >gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:ForeignCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:OtherAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostRetirementBenefitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:SubsidiariesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ManufacturingMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ManufacturingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:MajorRestructuringProgrammesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FirstInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:SecondInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ThirdInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FourthInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenYenAppreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenYenAppreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenYenDepreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenYenDepreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:MedicxiVenturesILimitedPartnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:JapaneseYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:SgdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:HIVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OncologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SpecialtyMedicineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:MeningitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:InfluenzaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ShinglesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:EstablishedVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:RespiratoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:GeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LetterOfCredit1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:InLineWithOtherPharmaceuticalCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:LegacyProgrammesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:OtherAuditorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:ForeignExchangeRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:ForeignExchangeRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:FreeCashFlowMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:TsrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PipelineProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:LiquidationOrDisposalOfInterestInAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:PurposeAxis" >gsk:ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:AccruedInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:NetDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCurrentDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:GbMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:EventAxis" >gsk:IncreaseInTheHeadlineRateOfTaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:BankOverdrafts1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:FreeholdBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseholdLandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:LeaseholdLandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PlantAndMachineryMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndMachineryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:EquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis" >gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:LaterThanOneYearAndNotLaterThanTenYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:AvailableIndefinitelyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfIncreaseInDiscountRatesOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfDecreaseInDiscountRatesOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfLifeExpectancyRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:MajorRestructuringProvisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:ActuarialAssumptionForFutureHealthcareInflationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisMemberdeiLegalEntityAxis_VaccinesBusinessAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:VaccinesBusinessAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >gsk:RemainingBookValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_VaccinesMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:ERPSoftwareSystemsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:OtherComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:ERPSoftwareSystemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:OtherComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis" >gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:ForeignCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:OtherAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:CurrentPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:CurrentPeriodMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ProjectedPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ProjectedPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:OtherProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostRetirementBenefitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:CashFlowsInTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandAndTwentyTwoDisposalsDemergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandTwentyTwoBusinessDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:SubsidiariesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ManufacturingMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ManufacturingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >gsk:MajorRestructuringProgrammesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FirstInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:SecondInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ThirdInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FourthInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis" >gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >gsk:Wholesalers3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenYenAppreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenYenAppreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenYenDepreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenYenDepreciationOfYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:MedicxiVenturesILimitedPartnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndTwentyTwoBusinessAcquisitionsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandAndTwentyTwoBusinessAcquisitionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:JapaneseYenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:CADMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:SgdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingThreeToSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:SensitivityAnalysisForActuarialAssumptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis" >gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis" >gsk:SensitivityAnalysisForActuarialAssumptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis" >gsk:ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:HIVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OncologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SpecialtyMedicineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:MeningitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:InfluenzaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ShinglesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:EstablishedVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:SubTotalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PandemicVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:RespiratoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:GeneralMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LetterOfCredit1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoOperationsUkLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoWellcomeUkLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineCapitalPLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineExportLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineFinancePLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineHoldingsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIhcLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIntellectualPropertyNo.2LimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIntellectualPropertyNo.3LimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIntellectualPropertyNo.4LimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineResearchAndDevelopmentLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineServicesUnlimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineUnitedKingdomLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineUsTradingLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:SetFirstLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:SmithKlineBeechamLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareFinanceLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareUnitedKingdomNo.3LimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViiVHealthCareUnitedKingdomLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskNo.1ScottishLimitedPartnershipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >exch:BOFS</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskNo.2ScottishLimitedPartnershipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >exch:BOFS</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskNo.3ScottishLimitedPartnershipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >exch:BOFS</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:AffinivaxIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:CorixaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineCapitalIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineHoldingsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskEquityInvestmentsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:HumanGenomeSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:StiefelLaboratoriesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:TesaroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViiVHealthcareCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineB.v.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:NL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineGmbHAndCoKGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklinePharmaGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:AustriaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlinePharmaceuticalsSAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineSAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineSPAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:IT</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineSingleMemberA.e.b.e.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:GreeceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineTradingServicesLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:IE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskCapitalB.v.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:NL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GSKServicesSPZOOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:PL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GSKVaccinesGmbHMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GSKVaccinesSRLMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:IT</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:JscGlaxosmithklineTradingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:RU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:LaboratoireGlaxoSmithKlineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:LaboratoriosViiVHealthCareSLMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareSRLItalyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:IT</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViiVHealthcareSASMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSaudiArabiaLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:SaudiArabiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoWellcomeManufacturingPteLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:SG</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineThailandLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:ThailandMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineAustraliaPtyLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineBrasilLimitadaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineFarEastB.v.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:TW</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:TR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineKKMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:JP</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineKoreaLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:KR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:HK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklineMexicoS.a.DeC.v.Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:MX</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlinePakistanLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:PK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxosmithklinePharmaceuticalsLimitedIndiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:IN</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskEnterpriseManagementCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CN</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskPharmaVietnamCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:VietnamMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:IDBiomedicalCorporationOfQuebecMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareK.kMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:JP</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViivHealthcareUlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonUsaMemberifrsfullGeographicalAreasAxis_TopOfRangeMemberifrsfullRangeAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:NonUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:InLineWithOtherPharmaceuticalCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:SignificantAcquisitionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:LegacyProgrammesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwothousandtwentyoneacquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:ZeroPointFiveThreeFourNotesDue2023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:ThreePointZeroNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:ThreePointSixTwoFiveNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:ThreePointEightSevenFiveNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:ThreePointThreeSevenFiveNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:SixPointThreeSevenFiveNotesDue2038Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:FourPointTwoZeroZeroNotesDue2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:OtherAuditorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LongwoodFoundersFundLPMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:LongwoodFoundersFundLPMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ApolloTherapeuticsLLPMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ApolloTherapeuticsLLPMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:ForeignExchangeRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:ForeignExchangeRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:FreeCashFlowMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:TsrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PipelineProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMemberGSKAwardType1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >gsk:LiquidationOrDisposalOfInterestInAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:PurposeAxis" >gsk:ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:AccruedInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:NetDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LongTermBorrowingsDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ShortTermBorrowingsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCurrentDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:BankOverdrafts1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:GbMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:EventAxis" >gsk:IncreaseInTheHeadlineRateOfTaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DemergerOfConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:DemergerOfConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:SierraOncologyIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AffinivaxIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:InterestRateSensitivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignExchangeForwardContractsAndSwapsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AgreementTypeAxis" >gsk:SlpPartnershipAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GSKLPLtdMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GSKLPLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AffinivaxIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FinancialLiabilitesOneMemberifrsfullClassesOfLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis" >gsk:FinancialLiabilitesOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:GskPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskGp1LimitedsShareCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:BerkeleySquarePensionTrusteeCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskGp1LimitedsShareCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GskGp2LimitedsShareCapital.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:GskPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GskGp2LimitedsShareCapital.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GlaxoGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InvestmentInHaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:ScottishLimitedPartnershipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EsopTrustsMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:EsopTrustsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_DemergerMemberGSKEventAxis_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:EventAxis" >gsk:DemergerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FixedInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" >ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis" >ifrs-full:InternallyGeneratedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:RemainingBalanceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:VirBiotechnologyIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NimbusTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CureVacNVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CreditImpairmentOfFinancialInstrumentsAxis" >ifrs-full:FinancialInstrumentsCreditimpairedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:CommercialisedProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:PipelineAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VaccinesMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:OverseasMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis" >gsk:DerivativeFinancialAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BEifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CHifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:EuroCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DisabledEmployeesMemberGSKTitleOfIndividual1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfIndividual1Axis" >gsk:DisabledEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:EuroCommercialPaperProgrammeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AaOrAaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AorAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BbbOrBaaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BBPlusOrBaOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:VaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AAAOrAaaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShionogiViivHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:TesaroAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:MeningitisPortfolioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:DolutegravirMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:BenlystaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:BenlystaAxis" >gsk:AlectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:BenlystaAxis" >gsk:IteosMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:ShingrixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:OkairosMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:BMSAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:VirAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:FluarixFlulavalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:StiefelTradeNameMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:CurevacAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:LamisilMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:OthersProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PfizerMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:PfizerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis" >gsk:TradesAndOtherPayablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis" >gsk:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:JapaneseYenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermNotesMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ShortTermNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >ifrs-full:ExternalCreditGradesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:WholesalerInTheUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:LowerThanBBBBaa3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:Debt1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BankLoansAndOverdraftsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaperInADesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherBorrowingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePercentEuroMediumTermNotesTwoThousandTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherLongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:OtherProvisionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:OtherNonCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonInterestBearingMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:NonInterestBearingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInsuranceContractsAxis" >gsk:GroupCreditEnhancementsAndCreditInsuranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:AmortizedCostMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FourthInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:TreasurySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FreeIssueMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FreeIssueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FixedInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" >ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis" >ifrs-full:InternallyGeneratedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:RemainingBalanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis" >gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >ifrs-full:DerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:VirBiotechnologyIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NimbusTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:CureVacNVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CreditImpairmentOfFinancialInstrumentsAxis" >ifrs-full:FinancialInstrumentsCreditimpairedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:CommercialisedProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:PipelineAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:OverseasMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:OtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >ifrs-full:TradeReceivablesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis" >gsk:DerivativeFinancialAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:EuroCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BEifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CHifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:PerformanceSharePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DisabledEmployeesMemberGSKTitleOfIndividual1Axis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:TitleOfIndividual1Axis" >gsk:DisabledEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:EuroCommercialPaperProgrammeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AorAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BbbOrBaaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BBPlusOrBaOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis" >gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AAAOrAaaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShionogiViivHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:TesaroAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:MeningitisPortfolioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MomelotinibMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:MomelotinibMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AffinivaxAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:AffinivaxAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:DolutegravirMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:BenlystaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:BenlystaAxis" >gsk:AlectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:BenlystaAxis" >gsk:IteosMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:ShingrixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:OkairosMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:BMSAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_SperoMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:SperoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:VirAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:FluarixFlulavalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:StiefelTradeNameMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:CurevacAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:LamisilMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis" >gsk:OthersProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:PurposeAxis" >gsk:PostSeparationOfTheConsumerHealthcareBusinessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:PurposeAxis" >gsk:PostSeparationOfTheConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PfizerMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:PfizerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis" >gsk:TradesAndOtherPayablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis" >gsk:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:AaOrAaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingThreeToSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:EuroMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:JapaneseYenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:CADMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis" >gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >gsk:SgdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:CommercialOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis" >ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis" >ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermNotesMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:ShortTermNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >ifrs-full:ExternalCreditGradesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:WholesalerInTheUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NGifrsfullGeographicalAreasAxis_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:NG</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GbMemberifrsfullGeographicalAreasAxis_HalkBankMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:GbMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:HalkBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ECifrsfullGeographicalAreasAxis_ProdubancoMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:EC</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ProdubancoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_JTrustRoyalBankMemberifrsfullJointVenturesAxis_KHifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:KH</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:JTrustRoyalBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BancoDoBrasilMemberifrsfullJointVenturesAxis_BRifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:BR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:BancoDoBrasilMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BancoDeHondurasMemberifrsfullJointVenturesAxis_HNifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:HN</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:BancoDeHondurasMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BacSanJoseMemberifrsfullJointVenturesAxis_CRifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:BacSanJoseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:LowerThanBBBBaa3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BBB-OrBaaThreeRatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis_StateBankOfIndiaMemberifrsfullCounterpartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis" >gsk:StateBankOfIndiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis" >gsk:BBB-OrBaaThreeRatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >gsk:Debt1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AffinivaxMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BankLoansAndOverdraftsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaperInADesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherBorrowingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis" >gsk:NetInvestmentHedgedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePercentEuroMediumTermNotesTwoThousandTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:NewYorkStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis" >gsk:LondonStockExchangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherLongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:TradeAndOtherPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >ifrs-full:OtherProvisionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:OtherNonCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis" >gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:OtherProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:SierraOncologyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:AffinivaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonInterestBearingMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:NonInterestBearingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandThirtyOneAndThereafterMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis" >gsk:TwoThousandThirtyOneAndThereafterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInsuranceContractsAxis" >gsk:GroupCreditEnhancementsAndCreditInsuranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:AmortizedCostMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis" >gsk:ForeignExchangeContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaleonMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:HaleonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TransfereeAxis" >gsk:SLPPartneshipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AgreementTypeAxis" >gsk:SlpPartnershipAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:PharmaceuticalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >gsk:RemainingBookValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-31</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis" >gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_JPYsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:JPY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ViiVHealthCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:OtherAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GroupMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis" >ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:HorlicksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >gsk:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConsumerHealthCareBangladeshMemberGSKArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis" >gsk:ConsumerHealthCareBangladeshMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_20_2021To05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-20</xbrli:startDate> <xbrli:endDate>2021-05-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis" >ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-20</xbrli:startDate> <xbrli:endDate>2021-05-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-20</xbrli:startDate> <xbrli:endDate>2021-05-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis" >gsk:ConsumerHealthcareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_09_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:RetireeHealthcarePlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_17_2020To12_17_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-17</xbrli:startDate> <xbrli:endDate>2020-12-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UsCashBalancePensionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:HaleonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2022To12_31_2022_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >gsk:GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:TransfereeAxis" >gsk:SLPPartneshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_GskShareholdersMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskShareholdersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_GskAndGsksConsolidatedEsotTrustsMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskAndGsksConsolidatedEsotTrustsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:ScottishLimitedPartnershipsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskAggregateHoldingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_PfizerMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >gsk:PfizerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_GskHoldingMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskHoldingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskHoldingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-18</xbrli:startDate> <xbrli:endDate>2022-07-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >gsk:GskAggregateHoldingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:InvestmentAxis" >gsk:HaleonPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_26_2019To06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-06-26</xbrli:startDate> <xbrli:endDate>2019-06-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:SierraOncologyIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:SierraOncologyIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_15_2022To08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AffinivaxIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-15</xbrli:startDate> <xbrli:endDate>2022-08-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:AffinivaxIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:GlaxoSaudiArabiaLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis" >gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:InnovivaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_28_2020To09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-28</xbrli:startDate> <xbrli:endDate>2020-09-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_01_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:LiquidityRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:GileadSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >gsk:FourthInterimMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis" >gsk:GSKKoreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IntraGroupProfitMemberifrsfullJointOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCurrentDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:NetDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:AccruedInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:BankOverdrafts1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PlanAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:BankOverdrafts1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:NetDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:AccruedInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCurrentDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis" >gsk:OtherProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="gsk:AwardType1Axis" >gsk:AmericanDepositarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareValuePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LongTermBorrowingsDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ShortTermBorrowingsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis" >ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis" >gsk:IntraGroupProfitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:FairValueReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis" >ifrs-full:JointVenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:AssociatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis" >gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:AccruedInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >gsk:NetDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CashAndCashEquivalentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:CommercialPaper1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:BankOverdrafts1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:OtherCurrentDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis" >ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis" >gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis" >ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:SharePremiumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:NovartisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >gsk:OtherBusinessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >gsk:PlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis" >ifrs-full:VehiclesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis" >ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >gsk:RestOfWorldMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis" >ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis" >gsk:PostretirementBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >gsk:EsopTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131399</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_GBP" > <xbrli:measure>iso4217:GBP</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_KRW" > <xbrli:measure>iso4217:KRW</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_SAR" > <xbrli:measure>iso4217:SAR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segments" > <xbrli:measure>gsk:Segments</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_GBP_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:GBP</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Employee" > <xbrli:measure>gsk:Employee</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_wholesalers" > <xbrli:measure>gsk:wholesalers</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Plaintiffs" > <xbrli:measure>gsk:Plaintiffs</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_69045263" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045264" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045266" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045267" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045269" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045270" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045272" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045273" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045275" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045276" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045278" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045279" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045281" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045282" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045438" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045441" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045444" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045447" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045450" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69045453" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046380" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046381" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046383" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046384" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046386" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046387" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046389" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046390" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046392" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046393" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046395" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046396" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046398" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046399" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046401" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046402" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046404" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046405" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046407" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046408" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046410" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046411" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046413" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046414" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046416" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046417" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046419" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046420" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046422" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046423" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046500" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046501" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046502" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046503" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046504" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046505" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046506" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046507" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046508" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046509" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046515" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046516" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046517" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046518" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046519" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046520" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046521" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046522" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046523" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046524" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046530" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046531" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046532" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046533" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046534" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046535" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046536" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046537" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046538" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046539" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046545" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046546" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046547" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046548" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046549" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046550" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046551" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046552" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046553" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046554" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046560" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046561" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046562" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046563" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046564" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046565" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046566" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046567" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046568" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046569" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046575" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046576" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046577" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046578" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046579" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046580" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046581" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046582" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046583" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046584" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046590" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046591" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046592" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046593" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046594" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046595" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046596" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046597" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046598" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69046599" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69048662" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69048665" toRefs="FN_241566"/><ix:relationship fromRefs="Fact_69050196" toRefs="FN_241567"/></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the Securities and Exchange Commission on March 10, 2023 </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To12_31_2022">20-F</ix:nonNumeric></div> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-year-en"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To12_31_2022">2022</ix:nonNumeric></ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of event requiring this shell company report </div></div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Commission file number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2022To12_31_2022">1-15170</ix:nonNumeric></div> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">GSK plc</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:edgarprovcountryen">England</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Jurisdiction of incorporation or organization) </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">980 Great West Road, Brentford</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">Middlesex</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">TW8 9GS</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:countrynameen">England</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices) </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Victoria Whyte</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Secretary </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK plc </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">980 Great West Road</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Brentford</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">TW8 9GS</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:countrynameen">England</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">+<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">44 20</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">8047 5000</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelEmailAddress" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">company.secretary@gsk.com</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">(Name, Telephone, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-mail</div> and/or Facsimile number and Address of Company Contact Person) </div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of Each Class</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol(s)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name&#160;of&#160;Each&#160;Exchange&#160;On&#160;Which&#160;Registered</div></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">American Depositary Shares</ix:nonNumeric>, each representing 2 Ordinary Shares, Par value 31 <div style="vertical-align: top;;display:inline;;font-size:9.2px">1</div>&#8260;<div style="vertical-align: bottom;;display:inline;;font-size:9.2px">4</div> pence</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">GSK</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">0.534% Notes due 2023</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">GSK/23C</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">3.000% Notes due 2024</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">GSK/24</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">3.625% Notes due 2025</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">GSK/25</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">3.875% Notes due 2028</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">GSK/28</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">3.375% Notes due 2029</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">GSK/29</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">6.375% Notes due 2038</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">GSK/38</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">4.200% Notes due 2043</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">GSK/43</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Title of class) </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Title of class) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares of Par value 31 <div style="vertical-align: top;;display:inline;;font-size:9.2px">1</div>&#8260;<div style="vertical-align: bottom;;display:inline;;font-size:9.2px">4</div> pence each</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,311,343,341</ix:nonFraction></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;Yes&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934. </div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;Yes&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections. </div></div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. </div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;No </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;No </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or an emerging growth company. See definition of &#8220;accelerated filer,&#8221; &#8220;large accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act: </div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric>&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated</div> filer&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13 (a) of the Exchange Act.&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#8224;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.10D-1(b).&#160;&#160;</div><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 14%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 75%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">U.S.&#160;GAAP&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="P01_01_2022To12_31_2022">International Financial Reporting Standards</ix:nonNumeric> as issued</div></div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;">by the International Accounting Standards Board&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:right;"><div style="display:inline;">Other&#160;&#160;</div></td>
<td style="vertical-align: top; white-space: nowrap;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. </div></div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Item 17&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;&#160;&#160;Item 18&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act). </div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;Yes&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric></div>&#160;&#160;No </div></div><div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 20pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold" id="toc"><span style="text-decoration:underline">TABLE OF CONTENTS</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:91%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><a href="#shell_a382677_1">Part&#160;I</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_2">Item&#160;1. Identity of Directors, Senior Management and Advisers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_3">Item&#160;2. Offer Statistics and Expected Timetable</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_4">Item&#160;3. Key Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_5">Item&#160;4. Information on the Company</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_6">Item&#160;4A. Unresolved Staff Comments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_7">Item&#160;5. Operating and Financial Review and Prospects</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_8">Item&#160;6. Directors, Senior Management and Employees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_9">Item&#160;7. Major Shareholders and Related Party Transactions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_10">Item&#160;8. Financial Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_11">Item&#160;9. The Offer and Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_12">Item&#160;10. Additional Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_13">Item&#160;11. Quantitative and Qualitative Disclosures About Market Risk</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_14">Item&#160;12. Description of Securities Other than Equity Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><a href="#shell_a382677_15">Part&#160;II</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_16">Item&#160;13. Defaults, Dividend Arrearages and Delinquencies</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_17">Item&#160;14. Material Modifications to the Rights of Security Holders and Use of Proceeds</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_18">Item&#160;15. Controls and Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_19">Item&#160;16. [Reserved]</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_20">Item&#160;16A. Audit committee financial expert</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_21">Item&#160;16B. Code of Ethics</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_22">Item&#160;16C. Principal Accountant Fees and Services</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_23">Item&#160;16D. Exemptions from the Listing Standards for Audit Committees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_24">Item&#160;16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_25">Item&#160;16F. Change in Registrant&#8217;s Certifying Accountant</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_26">Item&#160;16G. Corporate Governance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_27">Item&#160;16H. Mine Safety Disclosure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_28">Item&#160;16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><a href="#shell_a382677_29">Part&#160;III</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_30">Item&#160;17. Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_31">Item&#160;18. Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><a href="#shell_a382677_32">Item&#160;19. Exhibits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><a href="#shell_a382677_33">Signatures </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Pursuant to Rule <span style="white-space:nowrap">12b-23(a)</span> of the Securities Exchange Act of 1934, as amended, the information for GSK plc&#8217;s Form <span style="white-space:nowrap">20-</span> F for the year ended December&#160;31, 2022 as set out below is being incorporated by reference from the &#8220;GSK Annual Report 2022&#8221; included as exhibit 15.2 to this Form <span style="white-space:nowrap">20-F</span> dated and submitted on March&#160;10, 2023 (the &#8220;GSK Annual Report 2022&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">All references in this Form <span style="white-space:nowrap">20-F</span> to the &#8220;Group,&#8221; &#8220;GSK,&#8221; &#8220;we&#8221; or &#8220;our&#8221; mean GSK plc and its subsidiaries; the &#8220;company&#8221; means GSK plc. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">References below to major headings include all information under such major headings, including subheadings, unless such reference is a reference to a subheading, in which case such reference includes only the information contained under such subheading. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">In addition to the information set out below, the information set forth under the headings &#8220;Cautionary statement regarding forward-looking statements&#8221; on page 317, &#8220;Directors&#8217; Report&#8221; on page 130, &#8220;Directors&#8217; statement of responsibilities&#8221; on pages 166 and 167, &#8220;Share capital and control&#8221; on pages 296 and 297, &#8220;Financial calendar 2023&#8221;, &#8220;Results announcements&#8221;, &#8220;Financial reports&#8221; and &#8220;Annual General Meeting 2023&#8221; on page 299, &#8220;Registrar&#8221; on page 302, &#8220;ADS Depositary&#8221;, &#8220;Donating shares to Save the Children&#8221;, &#8220;Contacts&#8221; and &#8220;Share scam alert&#8221; on page 303, &#8220;Section&#160;13(r) of the Exchange Act&#8221; on page 305 and &#8220;Glossary of terms&#8221; on page 315 in each case of the GSK Annual Report 2022 is incorporated by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Notice regarding limitations on Director Liability under English Law </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from certain portions of the GSK Annual Report 2022 incorporated by reference herein, namely &#8220;Directors&#8217; Report&#8221; (for which see page 130 thereof), the &#8220;Strategic Report&#8221; (pages 1 to 95 thereof, portions of which are incorporated by reference as described below) and the report on &#8220;Remuneration&#8221; (pages 132 to 164 portions of which are incorporated by reference as described below). These reports have been drawn up and presented in accordance with, and in reliance upon, English company law. Under English law, the Directors would be liable to the company, but not to any third party, if these sections of the GSK Annual Report 2022 contain errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Portions of the GSK Annual Report 2022 incorporated by reference herein contain references to our website. Information on our website or any other website referenced in the GSK Annual Report 2022 is not incorporated into this Form <span style="white-space:nowrap">20-F</span> and should not be considered to be part of this Form <span style="white-space:nowrap">20-F.</span> We have included any references to the website as an inactive textual reference only. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold" id="shell_a382677_1">PART I </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_2"><span style="font-weight:bold">Item&#160;1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Identity of Directors, Senior Management and Advisers </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_3"><span style="font-weight:bold">Item&#160;2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Offer Statistics and Expected Timetable </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_4"><span style="font-weight:bold">Item&#160;3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Key Information </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">3.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">[Reserved] </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">3.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Capitalization and indebtedness </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">3.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Reasons for the offer and use of proceeds </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">3.D</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Risk Factors </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Principal risks and uncertainties </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We outline below the principal risks and uncertainties relevant to GSK&#8217;s business, financial condition and operations that may affect our performance and ability to achieve our objectives. These are the risks that we believe could cause our actual results to differ materially from expected and historical results. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Operating in the biopharmaceutical sector carries various inherent risks and uncertainties that may affect our business. We must comply with a broad range of laws and regulations which apply to the research and development, manufacturing, testing, approval, distribution, sales, and marketing of pharmaceutical and vaccine products. These affect the cost of product development, the time required to reach the market and the likelihood of doing so successfully on an uninterrupted basis. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">As rules and regulations change, government interpretation evolves, and our business activities develop, the nature of a particular risk may also alter. Changes to regulatory regimes may be substantial. Any alteration in, and failure to comply with, applicable laws and regulations could materially and adversely affect our financial results. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Similarly, our global business exposes us to litigation and government investigations, including product liability litigation, patent and antitrust litigation and sales and marketing litigation. Litigation and government investigations, and the related provisions we may make for unfavourable outcomes and increases in related costs such as insurance premiums, could also materially and adversely affect our financial results. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">More detail on the status and various uncertainties in our significant unresolved disputes and potential litigation is set out in Note 47, &#8216;Legal proceedings&#8217; on pages 265 to 267 of the GSK Annual Report 2022, which is incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Patient safety </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK, including our third parties, potentially fails to appropriately collect, review, follow up, or report human safety information, including adverse events, from all potential sources or that GSK potentially fails to act on any relevant findings in a timely manner. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">GSK will not tolerate an unfavourable <span style="white-space:nowrap"><span style="white-space:nowrap">benefit-to-risk</span></span> profile for patients who use our products. As the most important consequence of ineffective pharmacovigilance is the potential for harm to patients, we maintain robust processes for managing human safety information, conducting timely safety signal detection, and ensuring appropriate measures are in place to manage risks to patients. GSK also intends to fully comply with pharmacovigilance and other relevant regulations worldwide. <span style="white-space:nowrap">Non-compliance</span> could result in inspection findings, regulatory scrutiny, civil or criminal sanctions and either temporary or permanent loss of product marketing authorisation. We regularly review and respond to all patient safety risks to limit the potential for reputational damage, loss of trust by patients and healthcare providers, product-related litigation, and loss of shareholder confidence. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We are fully accountable for safeguarding patients; our failure to do so effectively could result most importantly in harm to patients, as well as reputational damage and/or product liability litigation. We conduct internal safety surveillance and rely on access to safety information from external sources. Information on the safety and efficacy of our products in humans is collected during clinical development, with more comprehensive information incorporated from real-world use once our products are marketed. There are examples of regulatory agencies using real-world evidence from sources which may not be accessible to the industry to supplement and validate the evidence we use to support the safety and efficacy of our products. There is a potential emerging risk that technology companies or other data custodians may similarly draw and communicate conclusions about the safety of our products based on digital health data collected through their platforms that is inaccessible by either the industry or regulatory agencies. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Our licence to operate depends on our compliance with regulatory requirements worldwide, not only those directly related to patient safety but extending to privacy and information security regulations as well. Regulatory compliance depends on appropriate identification and management of human safety information by all employees and third parties acting on our behalf. We are pursuing innovative solutions to enhance our ability to perform pharmacovigilance, including Artificial Intelligence and Machine Learning technology to augment our capacity to manage increasing volumes of adverse event reports from varied sources, and advancing technical solutions for delivering safety information and risk minimisation measures to patients and health care providers. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The <span style="white-space:nowrap">COVID-19</span> pandemic has had an impact on pharmacovigilance activities by increasing public focus on safety and efficacy of medicines and vaccines, highlighting the importance of robust business continuity planning for uninterrupted safety oversight and regulatory compliance (including the ability to accommodate remote regulatory inspections), and accelerating automation to manage increasing volumes of adverse events. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Product quality </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of quality for development and commercial products; compliance with industry practices and regulations in manufacturing and distribution activities; and terms of GSK product licenses and supporting regulatory activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">A failure to ensure product quality could have <span style="white-space:nowrap">far-reaching</span> implications for patient safety, cause product launch delays, drug shortages or product recalls, and have regulatory, legal, and financial consequences. These could materially and adversely affect GSK&#8217;s reputation and financial results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The external environment for product quality remains challenging, with increased cyber-attacks and data breaches across the industry. Cyber-attacks remain a key risk to the integrity of product quality data and its audit trail. We met our commitments for the 2021 European Medicines Agency (EMA) requirements for licensing of Medical Devices. We continue to plan for the deployment of the New Annex 1 guidance for the manufacture of Sterile Medicinal products which was published&#160;&#160;&#160;&#160;in September 2022 and sets an expectation for compliance by August 2023. We are actively managing this implementation in the context of global equipment and component supply chain constraints affecting the industry. We are increasingly applying advanced digital technologies and insights to drive scientific excellence to enhance the development, manufacture and testing of our products. For example, we use new electronic documentation systems and advanced laboratory information management tools. Our quality organisations are aligned to make sure quality procedures and governance can facilitate the new company strategy. <span style="white-space:nowrap">Pre-pandemic</span> levels of <span style="white-space:nowrap">on-site</span> inspections have resumed, and we continue to take steps to ensure our inspection readiness. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Financial controls and reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK fails to comply with current tax laws, fails to report accurate financial information in compliance with accounting standards and applicable legislation, or incurs significant losses due to treasury activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-compliance</span> with existing or new financial or new ESG reporting and disclosure requirements, or changes to the recognition of income and expenses, could expose GSK to litigation and regulatory action and could materially and adversely affect our financial results. Failure to comply with changes in the substance or application of the laws governing transfer pricing, dividends, tax credits and intellectual property could also materially and adversely affect our financial results. Failure to comply with applicable sanctions laws and regulations could result in GSK being investigated by relevant government agencies and authorities and/or in legal proceedings against us. Government investigations and litigation, can be unpredictable and regardless of their outcome, may be costly, require significant management attention, and damage our reputation. Inconsistent application of treasury policies, transactional or settlement errors, or counterparty defaults could lead to significant losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We are required by the laws of various jurisdictions to publicly disclose our financial results and events that could materially affect the Group&#8217;s financial results. Regulators routinely review the financial statements of listed companies for compliance with new, revised, or existing accounting and regulatory requirements. We believe that we comply with the appropriate regulatory requirements concerning our financial statements and the disclosure of material information, including any transactions relating to business restructuring such as acquisitions and divestitures. However, should we be subject to an investigation into potential <span style="white-space:nowrap">non-compliance</span> with accounting and disclosure requirements, this could lead to restatements of previously reported results and significant penalties. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Our Treasury group deals daily in high value transactions, mostly foreign exchange, and cash management transactions. These transactions involve market volatility and counterparty risk. The Group&#8217;s effective tax rate reflects the locations of our activities and the value they generate, which determine the jurisdictions in which profits arise and the applicable tax rates. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">These may be higher or lower than the UK statutory rate and may reflect regimes that encourage innovation and investment in R&amp;D by providing tax incentives which, if changed, could affect GSK&#8217;s tax rate. In addition, the worldwide nature of our operations means that our cross-border supply routes, necessary to ensure supplies of medicines and vaccines, can result in conflicting claims from tax authorities as to the profits to be taxed in individual countries. This can lead to double taxation, with profits taxed in more than one country. The complexity of tax regulations also means that we may occasionally disagree with tax authorities on the technical interpretation of a particular area of tax law. The tax charge included in our financial statements is our best estimate of tax liability pending any audits by tax authorities. We expect there to be a continued focus on tax reform, driven by initiatives by the OECD and the EC to address the tax challenges arising from digitalisation of the economy. Together with domestic initiatives around the world, these may result in significant changes to established tax principles and an increase in tax authority disputes. Regardless of their merit or outcomes, these may be costly, divert management attention and adversely impact our reputation and relationship with key stakeholders. Laws, regulations, orders and other measures restrict dealings with certain countries, governments, government officials, entities, individuals, use of financial institutions and movement of funds. Circumvention of sanctions and export controls can be a criminal offence and GSK has a zero tolerance policy for breaches of its sanctions obligations. While we believe the Group complies with all applicable sanctions in all material respects, such laws are complex and continue to evolve rapidly. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Anti-bribery and corruption (ABAC) </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to comply with applicable laws, regulations, or internal requirements and to ensure appropriate controls and governance over bribery and corruption in business activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Failure to mitigate this risk could expose GSK and associated persons to governmental investigation, regulatory action, and civil and criminal liability. It may compromise GSK&#8217;s ability to supply its products under certain government contracts. In addition, failure to prevent bribery or corruption could have substantial implications for GSK&#8217;s reputation and the credibility of senior leaders. It might erode investor confidence in our governance, risk management and future performance, and have a consequential negative impact on share performance. It could also lead to the imposition of significant financial penalties and the imposition of additional reporting obligations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">There continues to be a strong enforcement appetite for foreign bribery investigations and prosecutions, with a particular focus on the conduct of multinational companies wherever they operate. Financial penalties handed down in proven corruption cases are often very significant. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Disruption to global supply chains and the commercial pressures caused by higher than usual inflation rates are likely to increase the risks of bribery and corruption in certain contexts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">However, greater transparency and collaboration among enforcement authorities, advances in technology and the use of data analytics are providing better platforms to streamline processes and detect potential issues. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Commercial practices </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially engage in commercial activities that fail to comply with laws, regulations, industry codes, and internal controls and requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Failure to engage in activities that are consistent with the letter and spirit of the law, industry regulations, or the Group&#8217;s requirements relating to sales and promotion of medicines and vaccines; with appropriate interactions with healthcare professionals (HCPs), organisations and patients; with legitimate and transparent transfers of value; and with pricing and competition (or antitrust) regulations in commercial practices, including trade channel activities and business tendering, could materially and adversely affect our ability to deliver our strategy and long-term priorities. Additionally, it may result in incomplete awareness of the risk/benefit profile of our products and possibly suboptimal treatment of patients and consumers; governmental investigation, regulatory action and legal proceedings brought against the Group by governmental and private plaintiffs which could result in government sanctions, and criminal and/or financial penalties. Any practices that are found to be misaligned with our values and expectations could also result in reputational harm and dilute the trust established with external stakeholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We operate in a highly regulated and extremely competitive biopharma industry, amongst peers who make significant product innovations and technical advances and intensify price competition. Additional external factors impacting our business operations include the ongoing effects of the <span style="white-space:nowrap">COVID-19</span> global pandemic, access limitations to our customers, macroeconomic inflationary dynamics, and pricing pressure across markets. To achieve our strategic objectives, we must continue to develop commercially viable new products and deliver additional uses for existing products that address the needs of patients, consumers, HCPs and payers. Financially, new products/indications carry with them an uncertainty with regards to future success. Product development is costly, lengthy, and uncertain, and carries with it the potential for failure at any stage. Even after successful product development, we face challenges in how we launch, and our competitors&#8217; products or pricing strategies could render our assets less competitive. We support product innovation through our continued focus on both <span style="white-space:nowrap">in-person</span> and virtual engagement, with a constant focus on our patient. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Once we have an approved medicine or vaccine, it is our obligation to provide important information to the healthcare community in various ways, always in a responsible, legal, and ethical manner. Appropriate product promotion ensures HCPs have access to the information they need, that patients and consumers have the facts about the medicines and vaccines they require, and that products are prescribed, recommended, or used in a manner that provides healthcare benefit. We are committed to the ethical and responsible commercialisation of our products in support of our purpose to improve the quality of human life and get ahead of disease together. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Scientific and patient engagement </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to engage externally to gain insights, educate and communicate on the science of our medicines and associated disease areas, and provide grants and donations in a legitimate and transparent manner compliant with laws, regulations, industry codes and internal controls and requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Without controls in place, the risk could result in real, perceived, or disguised promotion including <span style="white-space:nowrap">off-label</span> and prior- authorisation promotion, and real or perceived provision of medical advice. This in turn could lead to criminal investigations and penalties, civil litigation, or competitor complaints. At the same time, if we do not engage fully and appropriately, this could result in patient harm, failure to advance science and innovation, reputational damage, and financial loss. Such consequences may reduce the trust of the public, patients, healthcare professionals, payers, regulators and governments. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Scientific and patient engagements are diverse <span style="white-space:nowrap">non-promotional</span> activities directed at healthcare professionals, patients, payers, and external stakeholders. Such engagements aim to improve patient care through the exchange or provision of knowledge on the use of our products and related diseases. Scientific and patient engagement with external stakeholder groups is vital to GSK, as a research-based biopharma company that is ambitious for patients and is necessary to advance science and medicine. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We expect our activities to be scientifically sound and accurate, conducted ethically and transparently, and compliant with applicable codes, laws, and regulations. There are many industry and local codes and laws and other regulations that apply (such as Privacy, Data integrity). That means measured risk-taking, rooted in sound ethical considerations, and principles-based decision-making, training, communication, and monitoring of such activities are key to managing the risk and enabling full and appropriate engagement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Data ethics and privacy </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ethically collect; use; <span style="white-space:nowrap">re-use</span> through artificial intelligence, data analytics or automation; secure; share and destroy personal information in accordance with laws, regulations, and internal controls and requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-compliance</span> with data privacy laws globally could lead to harm to individuals and GSK. It could also damage trust between GSK and individuals, communities, business partners and government authorities. Many countries have increased the enforcement powers of their data protection authorities by allowing them to impose significant fines, impact cross-border data flows, or temporarily ban data processing. Many new national laws also enable individuals to bring collective legal actions against companies such as GSK for failure to follow data privacy laws. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Data protection and privacy legislation is diverse, with limited global harmonisation or simplification. It is challenging for multinationals to standardise their approach to compliance with data privacy laws. Governments are enforcing compliance with data protection and privacy laws more rigorously. The approach and focus of data protection and privacy regulators also differs between regions and countries, which further creates challenges for global organisations seeking to implement a single harmonised global privacy programme. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Increases in the volume of data processed and advances in technology have resulted in a greater focus on data governance and the ethical use of personal information, over and above compliance with data privacy laws. Companies seeking to foster innovation in artificial intelligence and other new technologies are faced with evolving decisions from global policymakers on how best to promote trust in these systems and avoid unintended outcomes or harmful impacts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Additionally, there are a number of emerging laws concerning the localisation of data, restrictions on international transfers and data security, which are changing existing frameworks that GSK has previously relied upon. This increasing trend for data sovereignty affects our ability to drive medical innovation and to effectively operate internationally. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Research practices </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to adequately conduct ethical and credible <span style="white-space:nowrap">pre-clinical</span> and clinical research, collaborate in research activities compliant with laws, regulations, and internal controls and requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The potential impacts of the risk include harm to human subjects, reputational damage, failure to obtain the necessary regulatory approvals for our products, governmental investigation, legal proceedings brought against the GSK by governmental and private plaintiffs (product liability suits and claims for damages), loss of revenue due to inadequate patent protection or inability to supply our products, and regulatory action such as fines, penalties, or loss of product authorisation. Poor data integrity and governance could compromise GSK&#8217;s R&amp;D efforts and negatively impact our reputation. Any of these could materially and adversely affect our financial results and damage the trust of patients and customers. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Research involving animals can raise ethical concerns. In many cases, however, research involving animals is the only way to investigate the effects of a potential new medicine in a living body other than in humans. Animal research provides critical information about the causes and mechanisms of diseases and therefore remains a vital part of our research. We continually seek ways in which we can minimise our use of animals in research, development, and testing, while complying with regulatory requirements and reducing the impact on the animals used. Human subject research is critical to assessing and demonstrating the safety and efficacy of our investigational products or further evaluating our products once they have been approved. This research includes clinical trials in healthy volunteers and patients and adheres to regulations and high ethical, medical, and scientific standards. We disclose the results of this research externally regardless of whether they reflect positively or negatively on our products, so that the scientific community can learn from the outcomes of our research. We also work with human biological samples which are fundamental to the discovery, development, and safety monitoring of our products. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We are committed to managing human biological samples in accordance with relevant laws, regulations, and ethical principles, and in a manner that respects the interests of sample donors. Data is pivotal to our R&amp;D strategy, and we are maximising the use of data to serve patients. Governing our data in accordance with relevant laws, regulations, contractual obligations, expectations, and our culture across privacy, information security, and data integrity is essential. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We use a wide variety of biological materials in the discovery, research, and development of our assets. Through the Convention on Biological Diversity (CBD) and the Nagoya Protocol, the international community has established a global framework regulating access to, and use of, genetic resources of <span style="white-space:nowrap">non-human</span> origin in research and development. We support the principles of access to, and benefit-sharing of, genetic resources as outlined in the CBD and the Nagoya Protocol. We also recognise the importance of appropriate, effective, and proportionate implementation measures at national and regional levels. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Environment, health, and safety (EHS) </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of the organisation&#8217;s assets, facilities, infrastructure, and business activities, including execution of hazardous activities, handling of hazardous materials, or release of substances harmful to the environment that disrupts supply or harms employees, third parties or the environment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Failure to manage EHS risks could lead to significant harm to people, the environment and the communities in which we operate, fines, inability to meet stakeholder expectations and regulatory requirements, litigation or regulatory action, and damage to the company&#8217;s reputation, which could materially and adversely affect our financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">GSK is subject to the health, safety and environmental laws of various jurisdictions. These laws impose duties to protect people, the environment and the communities in which we operate. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Information security </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance over unauthorised access, disclosure, theft, unavailability or corruption of GSK&#8217;s information, key systems or technology infrastructure. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Failure to adequately protect our information and systems may cause harm to our patients, workforce and customers, disruption to our business and/or loss of commercial or strategic advantage, regulatory sanction or damage to our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The external environment continues to be extremely challenging, making it hard to keep pace with increasingly sophisticated cyber threats. This is due to many factors including increased geopolitical conflict and digital nationalism, rising frequency and severity of data breaches and growing capability and sophistication of bad actors and cyber criminals. GSK&#8217;s business relies on operating a highly connected information network of internal and external systems, which hold confidential research and development, manufacturing, commercial, workforce and financial data. This means that our systems and information have been and will continue to be the target of cyber-attacks. Acceleration in the use of digital, data and analytics and cloud computing capabilities to drive GSK&#8217;s pipeline and performance requires us to continuously adapt and strengthen our controls and defensive capabilities. GSK also relies on third-party contractors, partners and suppliers who face similar cyber threats and this continues to be a vector of risk to manage as well. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Supply continuity </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to deliver a continuous supply of compliant finished product or respond effectively to a crisis incident in a timely manner to recover and sustain critical supply operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We recognise how important the continuity of supply of our products is to the patients who rely on them. Supply disruption can lead to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Product shortages and product recalls </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Regulatory intervention </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Reputational harm </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Lost sales revenue </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Consequently, we need sophisticated <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> supply chain management with robust crisis management and business continuity plans in place to respond. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We run our supply chains in a continually evolving, highly-regulated environment. There is no single set of global regulations which governs the manufacture and distribution of medicines, and we must adhere to the requirements in all those markets in which we licence, sell or manufacture our products. We rely upon our internal Quality Management System and our Internal Control Framework to ensure we continue to preserve our licence to operate. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Our complex <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> supply chains often involve third-party suppliers, from Active Pharmaceutical Ingredient (API) manufacturers and raw material suppliers through to Third-Party Logistics Providers and contract engineering firms. We embed integrated risk management into our sourcing and day to day business processes, alongside our Third-Party Oversight programme. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">External factors continued to challenge supply continuity in 2022. In the early part of the year <span style="white-space:nowrap">COVID-19</span> continued to disrupt our sourcing of biosciences materials across our Medicines and Vaccines supply chains (e.g. vials, syringes and <span style="white-space:nowrap">single-use</span> systems components). The Ukraine conflict has resulted in supply disruption to the region. To manage these disruptions, we deployed bespoke <span style="white-space:nowrap">de-risking</span> plans using crisis and continuity plans to manage the detail and mitigate the risk of supply continuity problems, e.g. by dual sourcing of materials or <span style="white-space:nowrap">re-routing</span> of shipments to avoid conflict zones. Keeping our patients supplied with their medicines is our priority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">New technology and modality platforms within supply chains are changing the requirements for the skillsets of people working in this field. We have implemented a new Chemistry, Manufacturing and Controls Operating Model in 2022. This brings cross-fertilisation of talent focus on the skills needed for the future for innovative manufacturing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Industrial relations are also a current risk to supply continuity, with the threat of industrial action being averted in our UK manufacturing sites through successful dialogue with unions. Continued business monitoring is in place to assess the risk of the spread of industrial relations challenges resulting from global cost of living pressures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Climate-related risks </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk definition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Failure in the management of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Physical climate and environmental risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Current and future regulatory requirements for environmental policies and taxes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Delivery and performance of management environmental objectives; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">leading to: reduced supply chain resilience; product life cycle management issues, loss of trust/reputation with employees, investors, customers, regulators and other stakeholders; increased costs; loss of sales or market access; negative impacts on the environment. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Risk impact </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">We recognise that the way we respond to climate change and manage environmental risks affects our ability to supply products to patients and consumers and could lead to harm to the environment and our reputation. For example, risks from increasing levels of water stress could lead to interruptions to supply of water to our sites and third-party supply sites, and increasing frequency of extreme weather events may cause disruptions to our and third-party supply sites, affecting our ability to supply products to patients and consumers. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Current and future regulatory responses to address climate change may result in increased costs and compliance obligations, including restricting our ability to manufacture certain products and/or requiring us to find alternatives for the manufacture of certain products. For example, regulations governing the use of high global warming potential (GWP) substances are being updated in the EU and were recently updated in the US, which will lead to increasing costs and could restrict GSK&#8217;s ability to manufacture its metered dose inhaler products that use a high GWP propellant. In addition, our ability to meet our target of reducing carbon emissions by 80% and 90% by 2030 and 2045, respectively, is based on our investment in an R&amp;D programme to reduce greenhouse gas emissions from metered dose inhalers, including successful clinical trials and obtaining regulatory approvals. Limitations in the jurisdictions in which we operate may also limit our access to renewable energy sources and electric vehicles, which may affect our ability to achieve reductions in emissions across our operations. Failure to meet fast-evolving regulatory requirements and stakeholder expectations could also result in litigation or regulatory actions or lead to increasing demand for low carbon medicines and vaccines, affecting demand for our products, which may have a material adverse impact on our financial results and longer term loss of trust, undermining the credibility of the company. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Context </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">It is increasingly understood that the interconnected effects of climate change, nature loss, and society&#8217;s impact on both are influencing human health. Internal and external expectations for companies to address their impact on the environment are increasing, as are the effects of climate change on operational resilience, in regard to access to energy, water and the natural resources used in products, along with potential cost increases from any regulatory changes or environmental taxes, such as carbon taxes in countries where GSK manufacturers and sources goods from third parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Risks associated with <span style="white-space:nowrap">COVID-19</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The potential impact of the <span style="white-space:nowrap">COVID-19</span> pandemic on GSK&#8217;s trading performance and all its principal risks is continually assessed. While GSK was encouraged by the uptake of its vaccines and medicines in 2022, the pandemic remains a dynamic ongoing risk, with the World Health Organization continuing to monitor the emergence of new variants. The current rate of infection is predominantly driven by the circulation of the BA.5 subvariant and its descendent lineages, which are still the dominant subvariants of Omicron globally. While <span style="white-space:nowrap">COVID-19</span> vaccines are being updated with Omicron variants to provide broader immunity against circulating and emerging variants, these subvariants and potential future variants of concern could potentially impact GSK&#8217;s trading results, clinical trials, supply continuity and its employees materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Risks relating to the separation of the Consumer Healthcare business </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On 18&#160;July 2022, GSK separated its Consumer Healthcare business from the Group to form Haleon, an independent listed company. Following the demerger, GSK continues to hold 6.0% of the shares of Haleon (including shares received by GSK&#8217;s consolidated ESOP trusts) and 7.5% remains held by certain Scottish Limited Partnerships set up to provide collateral for a funding mechanism pursuant to which GSK will provide additional funding for its UK defined benefit pension schemes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The realisation of the anticipated benefits of the separation is subject to a number of factors, including many which are outside the control of the Group. There can be no guarantee that the anticipated benefits of the separation will be realised in full or in part, or as to the timing of when any such benefits may be realised. In addition, even if the anticipated benefits of the separation are realised, the market price of the GSK shares may not reflect such benefits. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Following the separation, GSK&#8217;s business is smaller and less diversified than it was prior to the separation, with greater relative exposure to the global pharmaceuticals and vaccines markets and the risks associated with such markets. As a result of the reduction in GSK&#8217;s size, should any part of its business underperform, this may have a greater adverse impact on the Group than would have been the case prior to the separation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">In addition, the value of GSK&#8217;s retained investment in Haleon will be affected by changes in the market price of Haleon shares, and may decrease in value as a result of any decrease in the market price of Haleon shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The failure of GSK to realise any of the anticipated benefits of the separation, including the value of its retained investment in Haleon, could have a material adverse impact on the Group&#8217;s business, financial condition, results of operations and/or prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_5"><span style="font-weight:bold">Item&#160;4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Information on the Company </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">4.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">History and development of the company </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;About GSK&#8221; on page 317; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Head Office and Registered Office&#8221; on the outside back cover; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 41 &#8211; Acquisitions and disposals&#8221; on pages 237 to 241; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Demerger and Share Consolidation&#8221; on page 296 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. GSK&#8217;s Internet address is gsk.com. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">4.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Business overview </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">See Item 3.D &#8220;Risk factors&#8221; above. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">In addition, the information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Ahead Together&#8221; on page 1 (excluding the paragraph under the heading &#8220;We&#8217;re confident in our future&#8221;) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Chair&#8217;s statement&#8221; on pages 4 and 5 (excluding (i)&#160;the seventh paragraph on page 4 and (ii)&#160;the first paragraph under &#8220;Targets and governance&#8221; on page 5); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;CEO&#8217;s statement&#8221; on pages 6 and 7 (excluding the heading &#8220;Strong 2022 performance increases confidence in delivering growth through 2026 and beyond&#8221; and the paragraphs thereunder on page 6); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Business model&#8221; on pages 8 and 9 (excluding (i)&#160;the second paragraph under &#8220;Performance&#8221; on page 9 and (ii)&#160;the last paragraph at the bottom of page 9); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Our culture and people&#8221; on pages 10 and 11; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Our external environment&#8221; on pages 12 to 14; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Research and Development&#8221; on pages 15 to 28; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Performance: Vaccines&#8221; on pages 29 to 32; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Performance: Specialty Medicines&#8221; on pages 33 to 37 (excluding the fifth bullet under &#8220;Drivers of growth across the portfolio&#8221; on page 35); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Performance: General Medicines&#8221; on pages 38 to 40; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Responsible business&#8221; on pages 41 to 50 (excluding the second paragraph under the heading &#8220;2022 ESG Performance Rating&#8221; on page 42); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Climate-related financial disclosures&#8221; on pages 55 to 63 (excluding the third sentence in Note 2 to the table on page 62); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 6 &#8211; Turnover and segment information&#8221; on pages 195 to 197; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 41 &#8211; Acquisitions and disposals&#8221; on pages 237 to 241; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Pharmaceutical products, competition and intellectual property&#8221; on pages 282 and 283; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Vaccines products, competition and intellectual property&#8221; on page 284 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">4.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Organizational structure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 46 &#8211; Principal Group companies&#8221; on page 264; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Group companies&#8221; on pages 307 to 314 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">4.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Property, plant and equipment </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Property, plant and equipment&#8221; under &#8220;Financial position and resources&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;PP&amp;E, intangible asset and goodwill impairment by segment&#8221; and &#8220;PP&amp;E and intangible asset impairment reversals by segment&#8221; within &#8220;Note 6 &#8211; Turnover and segment information&#8221; on page 197; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 17 &#8211; Property, plant and equipment&#8221; on pages 208 and 209 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_6"><span style="font-weight:bold">Item&#160;4A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Unresolved Staff Comments </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_7"><span style="font-weight:bold">Item&#160;5.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Operating and Financial Review and Prospects </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">5.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Operating results </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Our external environment&#8221; on pages 12 to 14 of the GSK Annual Report 2022 is incorporated herein by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following tables reconcile Total results to Adjusted results. References to the reconciliations on pages 81 to 83 and page 277 of the GSK Annual Report 2022 should be read to refer to the information in these tables. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Adjusted results reconciliation &#8211; 31&#160;December 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL;text-align:center">Total<br />results</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Profit from<br />discontinued<br />operations</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />amortisation</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />impairment</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Major<br />restructuring</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Tranaction<br />related</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Divestments,<br />significant<br />legal and<br />other<br />items</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Adjusted<br />results</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit before taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(10,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit after taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(10,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(10,495</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(10,495</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.8</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">34.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(31.5</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">139.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">260.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(260.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Basic earnings per share (pence)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">371.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(260.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">34.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(31.5</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">139.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average number of shares (millions)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="21" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted gross profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(9,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted operating profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,488</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,062</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other operating (expense)/income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,457</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit before tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share of after tax losses of associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit after tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(242</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit attributable to shareholders</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Adjusted results reconciliation &#8211; 31&#160;December 2021 </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Total<br />results</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Profit from<br />discontinued<br />operations</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />amortisation</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />impairment</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Major<br />restructuring</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Tranaction<br />related</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Divestments,<br />significant<br />legal and<br />other<br />items</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Adjusted<br />results</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit before taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(502</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit after taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82.9</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15.2</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(21.2</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.3</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(26.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Basic earnings per share (pence)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">109.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(26.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15.2</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(21.2</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.3</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average number of shares (millions)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="21" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted gross profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted operating profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other operating (expense)/income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(602</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit before tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(752</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on disposal of interest in associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share of after tax losses of associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit after tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(153</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(81</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(179</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(918</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="33"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit attributable to shareholders</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL;font-weight:bold">Adjusted results reconciliation &#8211; 31&#160;December 2020 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Total<br />results</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Profit from<br />discontinued<br />operations</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />amortisation</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Intangible<br />asset<br />impairment</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Major<br />restructuring</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Tranaction<br />related</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Divestments,<br />significant<br />legal and<br />other<br />items</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Adjusted<br />results</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,662</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit before taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit after taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,873</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(876</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(876</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">122.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24.3</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19.0</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">114.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic earnings per share (pence) from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Basic earnings per share (pence)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">144.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24.3</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19.0</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">114.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average number of shares (millions)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="21" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted gross profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6,672</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted operating profit from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other operating (expense)/income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,678</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit before tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share of after tax losses of associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit after tax from continuing operations</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(142</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(38</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(125</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="32"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;font-weight:bold">The following adjustments are made in arriving at Adjusted profit attributable to shareholders</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:ARIAL;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Group financial review 2022 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Summary full year results </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Full&#160;year<br />2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />AER<br />%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER<br />%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Full&#160;year<br />2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Full&#160;year<br />2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total continuing operating profit<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total EPS<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">371.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">109.6p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">144.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total continuing EPS<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.8p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82.9p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">122.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total discontinued EPS<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">260.6p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26.7p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">22.0p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted operating profit<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted EPS<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">139.7p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.3p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">114.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash generated from operations attributable to continuing operations<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The amounts presented above for continuing operations and Adjusted results excludes the Consumer Healthcare business discontinued operation. The amounts presented for discontinued EPS are for the demerger of the Consumer Healthcare business. The presentation of continuing and discontinued operations under IFRS 5 are set out on page 192 of the GSK Annual Report 2022. The 2021 and 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) and the impact of the Share Consolidation implemented on 18&#160;July 2022 (see &#8220;Note 37 &#8211; Share capital and share premium account&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Adjusted results are <span style="white-space:nowrap">non-IFRS</span> measures excluding discontinued operations and other adjustments that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Adjusted results, AER growth, CER growth, free cash flow and other <span style="white-space:nowrap">non-IFRS</span> measures are defined below under &#8220;Reporting framework&#8221;. Adjusted results reconciliations are presented above on pages 11 to 13 above and free cash flow reconciliations are presented below on page 29 below. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Total Turnover </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total turnover in 2022 was &#163;29,324&#160;million, up 19% at AER, 13% at CER, reflecting strong performance in all three product groups. Sales of <span style="white-space:nowrap">COVID-19</span> solutions contributed 3% growth at AER and CER to Commercial Operations turnover. Specialty Medicines included &#163;2,309&#160;million sales of <span style="font-style:italic">Xevudy</span>, and double-digit growth across all therapy areas. Vaccines growth reflected strong <span style="font-style:italic">Shingrix </span>and Meningitis performance, partially offset by pandemic adjuvant sales in 2021. General Medicines reflected the recovery of the antibiotics market and the strong performance of <span style="font-style:italic">Trelegy </span>in respiratory across all regions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Specialty Medicines </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Specialty Medicines sales were &#163;11,269&#160;million, up 37% at AER, 29% at CER, driven by consistent double-digit growth in all therapy areas. Sales of Xevudy of &#163;2,309&#160;million contributed growth of 14% at AER and CER. Specialty Medicines, were &#163;8,960&#160;million up 23% at AER, 15% at CER without <span style="font-style:italic">Xevudy</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Vaccines </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccines turnover was &#163;7,937&#160;million, up 17% at AER, 11% at CER in total. Sales of pandemic adjuvant contributed 7% growth at AER and 6% CER to Commercial Operations turnover. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The performance reflected a favourable comparator, which was impacted by <span style="white-space:nowrap">COVID-19</span> related disruptions in several markets primarily in H1 2021, and strong commercial execution of <span style="font-style:italic">Shingrix</span>, particularly in the US and Europe. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">General Medicines </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General Medicines sales in the year were &#163;10,118&#160;million, up 5% at AER, 1% at CER, with the impact of generic competition in US, Europe and Japan offset by <span style="font-style:italic">Trelegy</span> growth in respiratory and the post-pandemic rebound of the antibiotic market since H2 2021, in Other General Medicines. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Total Continuing Operating Profit </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total operating profit from continuing operations was &#163;6,433&#160;million compared with &#163;4,357&#160;million in 2021. This included the &#163;0.9&#160;billion upfront income received from the settlement with Gilead Sciences, Inc. (Gilead), increased profits on turnover growth of 13% at CER and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Total continuing Adjusted operating profit </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted operating profit was &#163;8,151&#160;million, 26% higher at AER and 14% at CER than 2021. The Adjusted operating margin of 27.8% was 1.5 percentage points higher at AER and 0.3 percentage points higher at CER compared to 2021. This primarily reflected the impact from low margin <span style="white-space:nowrap">COVID-19</span> solutions sales (<span style="font-style:italic">Xevudy</span>). This was offset by operating leverage from strong sales growth, mix benefit, lower inventory adjustments and write-offs and higher royalty income. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total Earnings per Share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total EPS was 371.4p compared with 109.6p in 2021. The increase primarily reflected the profit after taxation for discontinued operations recognised on the Consumer Healthcare business demerger, upfront income received from the settlement with Gilead, increased profits and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;397&#160;million to Taxation in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total continuing Earnings per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total EPS from continuing operations was 110.8p compared with 82.9p in 2021. This primarily reflected the upfront income received from the settlement with Gilead, increased profits from turnover growth and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;430&#160;million to Taxation in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total discontinued Earnings per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">EPS from discontinued operations was 260.6p, compared with 26.7p in 2021. The increase primarily reflected the gain arising on the demerger of Consumer Healthcare recognised in Profit after taxation for discontinued operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted Earnings per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted EPS was 139.7p compared with 110.3p in 2021. Operating leverage from strong sales growth, beneficial mix and lower inventory adjustments and write-offs, higher royalty income and a lower effective tax rate was partly offset by increased investment behind launches, higher supply chain, freight and distribution costs and higher <span style="white-space:nowrap">non-controlling</span> interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Cash generated from operations attributable to continuing operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash generated from operations attributable to continuing operations for the year was &#163;7,944&#160;million (2021: &#163;7,249 million). The increase primarily reflected a significant increase in operating profit, favourable exchange impact and favourable timing of collections, partly offset by unfavourable timing of profit share payments for <span style="font-style:italic">Xevudy</span> sales, increased cash contributions to the UK defined benefit pension schemes, increased contingent consideration payments and a higher increase in inventory. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash flow </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash inflow from continuing operations was &#163;3,348&#160;million for 2022 (2021: &#163;3,301 million). The increase primarily reflected a significant increase in operating profit, favourable exchange, reduced purchases of intangible assets and favourable timing of collections. This was partly offset by unfavourable timing of profit share payments for <span style="font-style:italic">Xevudy</span> sales, increased cash contributions to pensions, increased contingent consideration payments, higher tax payments, lower proceeds from disposals, higher capital expenditure and a higher increase in inventory. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Financial performance </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Total results of the Group are set out below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">% of</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">% of</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(9,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(32.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(33.1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">67.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">66.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,488</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(18.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(20.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Royalty income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other operating (expenses)/income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">21.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on disposal of interest in associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share of <span style="white-space:nowrap">after-tax</span> (losses)/profits of associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit before taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from continuing operations for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations and other gains from the demerger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of discontinued operations distributed to shareholders on demerger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit after taxation for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per share from continuing operations (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.8</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82.9</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per share from discontinued operations (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">260.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total earnings per share (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">371.4</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">109.6</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per ADS from continuing operations (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per ADS from discontinued operations (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6.46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total earnings per ADS (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9.21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Adjusted results for the Group are set out below. Reconciliations between Total results and Adjusted results for 2022, 2021 and 2020 are set out above on pages 11 to 13. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">% of<br />turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">% of<br />turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(29.8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(29.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(27.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,062</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(17.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(18.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Royalty income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted<sup style="font-size:75%; vertical-align:top">(2) </sup>operating profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit attributable to <span style="white-space:nowrap">non-controlling</span> interest</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit after tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted earnings per share (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">139.7</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110.3</td>
<td style="white-space:nowrap;vertical-align:bottom">p&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) and the impact of the Share Consolidation implemented on 18&#160;July 2022 (see &#8220;Note 37 &#8211; Share capital and share premium account&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Adjusted results are <span style="white-space:nowrap">non-IFRS</span> measures excluding discontinued operations and other adjustments that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Adjusted results, AER growth, CER growth and other <span style="white-space:nowrap">non-IFRS</span> measures are defined below under &#8220;Reporting framework&#8221;. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Reporting framework </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total and Adjusted results </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group financial review discusses the operating and financial performance of the Group, its cash flows and financial position and our resources. The results for each year are compared primarily with the results of the preceding year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total results </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total reported results represent the Group&#8217;s overall performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK also uses a number of adjusted, <span style="white-space:nowrap">non-IFRS,</span> measures to report the performance of its business. Adjusted results and other <span style="white-space:nowrap">non-IFRS</span> measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results are defined below and other <span style="white-space:nowrap">non-IFRS</span> measures are defined below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK believes that Adjusted results, when considered together with Total results, provide investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allow the Group&#8217;s performance to be more easily compared against the majority of its peer companies. These measures are also used by management for planning and reporting purposes. They may not be directly comparable with similarly described measures used by other companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK encourages investors and analysts not to rely on any single financial measure but to review GSK&#8217;s Annual Reports, including the financial statements and notes, in their entirety. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Adjusted results </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted results exclude the profits from discontinued operations from the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) and the following items in relation to our continuing operations from Total results, together with the tax effects of all of these items: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">amortisation of intangible assets (excluding computer software and capitalised development costs) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">impairment of intangible assets (excluding computer software) and goodwill </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Major restructuring costs, which include impairments of tangible assets and computer software, (under specific Board approved programmes that are structural, of a significant scale and where the costs of individual or related projects exceed &#163;25 million) including integration costs following material acquisitions </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">transaction-related accounting or other adjustments related to significant acquisitions </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">proceeds and costs of disposals of associates, products and businesses; significant settlement income; significant legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations; other operating income other than royalty income, and other items </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Costs for all other ordinary course smaller scale restructuring and legal charges and expenses are retained within both Total and Adjusted results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As Adjusted results include the benefits of Major restructuring programmes but exclude significant costs (such as amortisation of intangible assets except for computer software and capitalised development costs, significant legal, major restructuring and transaction items), they should not be regarded as a complete picture of the Group&#8217;s financial performance, which is presented in its Total results. The exclusion of other Adjusting items may result in Adjusted earnings being materially higher or lower than Total earnings. In particular, when significant impairments, restructuring charges and legal costs are excluded, Adjusted earnings will be higher than Total earnings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK is undertaking a number of Major restructuring programmes in response to significant changes in the Group&#8217;s trading environment or overall strategy, or following material acquisitions. Costs, both cash and <span style="white-space:nowrap">non-cash,</span> of these programmes are provided for as individual elements are approved and meet the accounting recognition criteria. As a result, charges may be incurred over a number of years following the initiation of a Major restructuring programme. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Significant legal charges and expenses are those arising from the settlement of litigation or government investigations that are not in the normal course and are materially larger than more regularly occurring individual matters. They also include certain major legacy matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Reconciliations between Total and Adjusted results, providing further information on the key Adjusting items for 2022, 2021 and 2020, are set out on pages 11 to 13. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK provides earnings guidance to the investor community on the basis of Adjusted results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group&#8217;s performance with its peers. GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets, and therefore a reconciliation of the guidance for Adjusted results to equivalent guidance for Total results is not available without unreasonable effort. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Historical record of Adjusting items </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The reconciliations between Total and Adjusted operating profit from continuing operations over the last three years<sup style="font-size:75%; vertical-align:top">(1)</sup> can be summarised as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:80%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(2)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(2)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible amortisation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible impairment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Major restructuring</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transaction-related items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Divestments, significant legal and other items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,662</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted results</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The analysis of the impact of transaction-related items on operating profit for each of the last three years is as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(2)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(2)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Shionogi-ViiV Healthcare JV (including Shionogi preferential dividends)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ViiV Healthcare put options and Pfizer preferential dividends</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Novartis Vaccines business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on acquisition of Affinivax, Inc (Affinivax)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8211;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8211;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transaction-related items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Three year financial data is presented reflecting the restated results following the demerger of Consumer Healthcare business. The financial results of 2019 and 2018 are not restated and are not presented. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Full reconciliations between Total and Adjusted results for 2020&#8211;2022 including continuing and discontinued operations are set out above on pages 11 to 13 above. Further explanations on the Adjusting items for 2022 are reported on pages 27 to 29 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other <span style="white-space:nowrap">non-IFRS</span> measures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash flow </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash flow is defined as the net cash inflow/outflow from continuing operating activities less capital expenditure on property, plant and equipment and intangible assets, contingent consideration payments, net finance costs, and dividends paid to <span style="white-space:nowrap">non-controlling</span> interests plus proceeds from the sale of property, plant and equipment and intangible assets, and dividends received from joint ventures and associates. It is used by management for planning and reporting purposes and in discussions with and presentations to investment analysts and rating agencies. Free cash flow growth is calculated on a reported basis. A reconciliation of net cash inflow from continuing operating activities to free cash flow is set out on page 29 below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Working capital </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Working capital represents inventory and trade receivables less trade payables. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">CER and AER growth </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In order to illustrate underlying performance, it is the Group&#8217;s practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period. CER% represents growth at constant exchange rates. &#163;% or AER% represents growth at actual exchange rates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total net debt </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Net debt is defined as total borrowings less cash, cash equivalents, liquid investments, and short-term loans to third parties that are subject to an insignificant risk of change in value. Please see &#8220;Note 30 &#8211; Net Debt&#8221; to the financial statements incorporated by reference in Item 18 below for the calculation of net debt. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">Non-controlling</span> interests in ViiV Healthcare </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Trading profit allocations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As ViiV Healthcare is a subsidiary of the Group, 100% of its operating results (turnover, operating profit, profit after tax) are included within the Group income statement and then a portion of the earnings is allocated to the <span style="white-space:nowrap">non-controlling</span> interests owned by the other shareholders, in line with their respective equity shareholdings (Pfizer, Inc. (Pfizer) 11.7% and Shionogi&#160;&amp; Co. Ltd (Shionogi) 10%). Each of the shareholders, including GSK, is also entitled to preferential dividends determined by the performance of certain products that each shareholder contributed. As the relative performance of these products changes over time, the proportion of the overall earnings allocated to each shareholder also changes. In particular, the increasing proportion of sales of dolutegravir and cabotegravir-containing products has a favourable impact on the proportion of the preferential dividends that is allocated to GSK. Adjusting items are allocated to shareholders based on their equity interests. GSK was entitled to approximately 83% of the Total earnings and 82% of the Adjusted earnings of ViiV Healthcare for 2022. Remeasurements of the liabilities for the preferential dividends allocated to Pfizer and Shionogi are included within other operating income/(expense). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Acquisition-related arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As consideration for the acquisition of Shionogi&#8217;s interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi received the 10% equity stake in ViiV Healthcare and ViiV Healthcare also agreed to pay additional future cash consideration to Shionogi, contingent on the future sales performance of the products being developed by that joint venture, dolutegravir and cabotegravir. Under IFRS 3 `Business combinations&#8217;, GSK was required to provide for the estimated fair value of this contingent consideration at the time of acquisition and is required to update the liability to the latest estimate of fair value at each subsequent period end. The liability for the contingent consideration recognised in the balance sheet at the date of acquisition was &#163;659&#160;million. Subsequent <span style="white-space:nowrap">re-measurements</span> are reflected within other operating income/(expense) and within Adjusting items in the income statement in each period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash payments to settle the contingent consideration are made to Shionogi by ViiV Healthcare each quarter, based on the actual sales performance and other income of the relevant products in the previous quarter. These payments reduce the balance sheet liability and hence are not recorded in the income statement. The cash payments made to Shionogi by ViiV Healthcare in 2022 were &#163;1,100&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The cash payments are reflected in the cash flow statement partly in operating cash flows and partly within investing activities. The tax relief on these payments is reflected in the Group&#8217;s Adjusting items as part of the tax charge. The part of each payment relating to the original estimate of the fair value of the contingent consideration on the acquisition of the Shionogi-ViiV Healthcare joint venture in 2012 of &#163;659&#160;million is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition is reported within operating cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Movements in contingent consideration payable to Shionogi were as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration at beginning of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement through income statement and other movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash payments: operating cash flows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash payments: investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration at end of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Of the contingent consideration payable (on a <span style="white-space:nowrap">post-tax</span> basis) to Shionogi at 31&#160;December 2022, &#163;940&#160;million (31&#160;December 2021: &#163;937 million) is expected to be paid within one year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Exit rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. Under the original agreements, GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Pfizer put option and, as a result, in accordance with IFRS, GSK did not recognise a liability for the put option on its balance sheet. However, during Q1 2016, GSK notified Pfizer that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;1,070&#160;million. Consistent with this revised treatment, at the end of Q1 2016 GSK also recognised liabilities for the future preferential dividends anticipated to become payable to Pfizer and Shionogi on the Group&#8217;s balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pfizer has the right to require GSK to acquire its shareholding in ViiV Healthcare in certain circumstances at any time. A put option liability is therefore recorded on the Group&#8217;s balance sheet as a current liability. It is measured on the gross redemption basis derived from an internal valuation of the ViiV Healthcare business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The closing balances of the liabilities related to Pfizer&#8217;s shareholding are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pfizer put option</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the original agreements, Shionogi could also have requested GSK to acquire its shareholding in ViiV Healthcare in <span style="white-space:nowrap">six-month</span> windows commencing in 2017, 2020 and 2022. GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Shionogi put option and, as a result, GSK did not recognise a liability for the put option on its balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">However, during Q1 2016, GSK notified Shionogi that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;926&#160;million. In Q4 2016, Shionogi irrevocably agreed to waive its put option and as a result GSK <span style="white-space:nowrap">de-recognised</span> the liability for this put option on the Group&#8217;s balance sheet directly to equity. The value of the liability was &#163;1,244&#160;million when it was <span style="white-space:nowrap">de-recognised.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK also has a call option over Shionogi&#8217;s shareholding in ViiV Healthcare, which under the original agreements was exercisable in <span style="white-space:nowrap">six-month</span> windows commencing in 2027, 2030 and 2032. GSK has now irrevocably agreed to waive the first two exercise windows, but the last <span style="white-space:nowrap">six-month</span> window in 2032 remains. As this call option is at fair value, it has no value for accounting purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Settlement with Gilead </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy. Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion to ViiV Healthcare in February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir- containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027. Gilead&#8217;s obligation to pay royalties does not extend into any period of regulatory paediatric exclusivity, if awarded. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The impact of the settlement with Gilead on the contingent consideration liability (CCL)&#160;was to increase it by &#163;288&#160;million, on a <span style="white-space:nowrap">post-tax</span> basis in Q4 2021 due to the obligation ViiV Healthcare has to pay future cash consideration to Shionogi for its share of the upfront and of the future US sales performance of Biktarvy and products containing bictegravir. The liability which is discounted at 8% is &#163;5,890&#160;million at 31&#160;December 2022 on a <span style="white-space:nowrap">post-tax</span> basis. The impact of the settlement on the Pfizer put option liability was an increase of &#163;114&#160;million and was included in the <span style="white-space:nowrap">re-measurement</span> at 31&#160;December 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Reporting definitions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">COVID-19</span> solutions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">COVID-19</span> solutions include the sales of pandemic adjuvant and other <span style="white-space:nowrap">COVID-19</span> solutions including vaccine manufacturing and <span style="font-style:italic">Xevudy</span> and the associated costs but does not include reinvestment in R&amp;D. This categorisation is used by management and we believe is helpful to investors by providing clarity on the results of the Group by showing the contribution to growth from <span style="white-space:nowrap">COVID-19</span> solutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">General Medicines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General medicines are usually prescribed in the primary care or community settings by general healthcare practitioners. For GSK, this includes medicines in inhaled respiratory, dermatology, antibiotics and other diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Specialty Medicines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Specialty medicines are typically prescription medicines used to treat complex or rare chronic conditions. For GSK, this comprises medicines in infectious diseases, HIV, oncology, immunology and respiratory. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total Operating Margin </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total Operating margin is operating profit dividend by turnover. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Compound Annual Growth Rate (CAGR) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">CAGR is defined as the compound annual growth rate and shows the annualised average rate of revenue growth between a number of given years, assuming growth takes place at an exponentially compounded rate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Share Consolidation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Shareholders received 4 new Ordinary shares with a nominal value of 31<sup style="vertical-align:top">1</sup>&#8260;<sub style="vertical-align:bottom">4</sub> pence each for every 5 existing Ordinary shares which had a nominal value of 25 pence each. Earnings per share, diluted earnings per share, adjusted earnings per share and dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Earnings per share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Earnings per share has been retrospectively adjusted for the Share Consolidation on 18&#160;July 2022, applying a ratio of 4 new Ordinary shares for every 5 existing Ordinary shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total Earnings per share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless otherwise stated, Total earnings per share refers to Total basic earnings per share. The same principle applies to continuing and discontinued earnings per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Financial performance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Group turnover </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK has revised its operating segments during the year. Previously, GSK reported results under four segments: Pharmaceuticals; Pharmaceuticals R&amp;D; Vaccines and Consumer Healthcare. GSK now reports results under two segments namely Commercial Operations and Total R&amp;D. See &#8220;Note 6 &#8211; Turnover and segment information&#8221; to the financial statements incorporated by reference in Item 18 below for more details. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Commercial Operations segment has three product groups of Specialty Medicines, Vaccines and General Medicines. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Specialty Medicines products which includes GSK&#8217;s marketed products for HIV, oncology, immuno-inflammation, respiratory and other specialty medicines (including <span style="font-style:italic">Nucala</span>) and the <span style="white-space:nowrap">COVID-19</span> solution, <span style="font-style:italic">Xevudy</span>; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Vaccines products, including sales of GSK&#8217;s AS03 adjuvant as part of the pandemic solutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8211;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">General Medicines products, which include products previously reported as Established Pharmaceuticals and sales of <span style="font-style:italic">Trelegy Ellipta</span> and <span style="font-style:italic">Anoro Ellipta</span> (previously reported within the Respiratory category under Specialty products). These products are typically accessed by patients through primary care settings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Group turnover was &#163;29,324&#160;million in the year, up 19% at AER, 13% at CER. In 2022 sales of <span style="white-space:nowrap">COVID-19</span> solutions contributed 3% growth at AER and CER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Commercial operations Innovation sales (sales of products launched in the last five years including lifecycle innovation) amounted to &#163;12,690&#160;million in 2022 largely driven by sales of <span style="font-style:italic">Shingrix, Xevudy, Trelegy, Dovato, Nucala and Benlysta</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Specialty medicines turnover </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">HIV</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Oncology</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Immuno-inflammation, respiratory and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pandemic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Specialty medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">11,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">2021 has been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">HIV </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">HIV sales were &#163;5,749&#160;million with growth of 20% at AER, 12% at CER. The performance benefited from strong patient demand for the new HIV medicines (<span style="font-style:italic">Dovato</span>, <span style="font-style:italic">Cabenuva</span>, <span style="font-style:italic">Juluca</span>, <span style="font-style:italic">Rukobia</span> and <span style="font-style:italic">Apretude</span>), which contributed approximately three quarters of the growth. US pricing favourability and <span style="white-space:nowrap">year-end</span> inventory build together contributed one third of the growth which was partially offset by International tender decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">New HIV products delivered sales of over two billion to &#163;2,474&#160;million, up 78% at AER, 67% at CER, representing 43% of the total HIV portfolio compared to 29% last year. Growth was primarily driven by sales of <span style="font-style:italic">Dovato</span> and <span style="font-style:italic">Cabenuva</span>. <span style="font-style:italic">Dovato</span> recorded sales of &#163;1,375&#160;million up 75% at AER and 65% at CER and <span style="font-style:italic">Cabenuva</span>, the first long acting injectable for the treatment of <span style="white-space:nowrap">HIV-1</span> infection, recorded sales of &#163;340&#160;million. <span style="font-style:italic">Apretude</span>, the first long acting injectable for the prevention of <span style="white-space:nowrap">HIV-1</span> delivered sales of &#163;41&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Oncology </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Oncology sales were &#163;602&#160;million, up 23% at AER, 17% at CER. <span style="font-style:italic">Zejula</span> sales of &#163;463&#160;million were up 17% at AER, 12% at CER driven by the first line indication, but with diagnosis and treatment rates continuing to be impacted by the pandemic especially in the US. Sales of <span style="font-style:italic">Blenrep</span> of &#163;118&#160;million grew 33% at AER, 25% at CER, and included the impact of withdrawal from US market in Q4 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Immuno-inflammation, respiratory and other </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Immuno-inflammation, Respiratory and Other sales were &#163;2,609&#160;million up 29% at AER, 20% at CER on strong performance of <span style="font-style:italic">Benlysta</span> and <span style="font-style:italic">Nucala</span>. <span style="font-style:italic">Benlysta</span> sales were &#163;1,146&#160;million, up 31% at AER, 20% at CER, representing strong underlying demand in US and worldwide. <span style="font-style:italic">Nucala</span> sales were &#163;1,423&#160;million, up 25% at AER, 18% at CER, reflecting continued strong patient demand and the launch of additional indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Pandemic </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of <span style="font-style:italic">Xevudy</span> were &#163;2,309&#160;million, compared to &#163;958&#160;million sales in 2021. Sales were delivered in all regions, comprising &#163;828&#160;million in the US, &#163;456&#160;million in Europe, and &#163;1,025&#160;million in International. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Vaccines turnover </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Meningitis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Influenza</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shingles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Established Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pandemic Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,873</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,937</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Meningitis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Meningitis vaccines sales grew 16% at AER, 11% at CER to &#163;1,116&#160;million mainly driven by <span style="font-style:italic">Bexsero</span> up 16% at AER, 12% at CER to &#163;753&#160;million resulting from higher CDC (Center for Disease Control) demand and increased share in the US. <span style="font-style:italic">Menveo</span> sales were also up 27% AER, 18% CER to &#163;345&#160;million, primarily driven by post-pandemic vaccination <span style="white-space:nowrap">catch-up</span> and higher public demand in International, together with favourable pricing mix and share gain in the US. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Influenza </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Fluarix/FluLaval </span>sales grew by 5% AER but decreased 4% CER to &#163;714&#160;million, primarily driven by lower post-pandemic demand in Europe and the US, partly offset by lower expected returns in the US </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Shingles </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Shingrix</span> sales grew 72% at AER, 60% at CER to &#163;2,958&#160;million. All regions grew significantly reflecting post-pandemic rebound, strong uptake and new market launches with more than half of the growth contributed from outside of the US. In the US, <span style="font-style:italic">Shingrix</span> grew 46% at AER, 32% at CER to &#163;1,964&#160;million due to higher <span style="white-space:nowrap">non-retail</span> and retail demand and strong commercial execution. Germany and China contributed strongly to the <span style="font-style:italic">Shingrix</span> growth. <span style="font-style:italic">Shingrix</span> was launched in 9 markets during 2022 and is now available in 26 countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Established Vaccines </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Established Vaccines grew 4% AER but were stable at CER to &#163;3,085&#160;million mainly resulting from supply constraints in MMR/V vaccines and lower tender demand in International for <span style="font-style:italic">Synflorix</span>. This was offset by hepatitis vaccines demand rebound in the US and Europe and <span style="font-style:italic">Boostrix</span> post-pandemic demand recovery and increased share in the US. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Pandemic Vaccines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pandemic Vaccines decreased 86% AER and CER primarily reflecting comparison to 2021 pandemic adjuvant sales to the US and Canadian governments partly offset by GSK&#8217;s share of 2022 contracted European volumes related to the <span style="white-space:nowrap">COVID-19</span> booster vaccine developed through a collaboration with Sanofi Pasteur (Sanofi). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">General Medicines turnover </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Respiratory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other general medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">2021 has been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Respiratory </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Respiratory sales were &#163;6,548&#160;million, up 8% at AER, 3% at CER. The performance was driven by <span style="font-style:italic">Trelegy</span> sales of &#163;1,729&#160;million, up 42% AER, 32% CER, including strong growth across all regions. <span style="font-style:italic">Advair/Seretide</span> sales of &#163;1,159&#160;million decreased 15% at AER, 17% at CER predominantly reflecting the adverse impact of generic competition, with growth in certain International markets due to targeted promotion offsetting the decrease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other general medicines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Other General Medicines sales were &#163;3,570&#160;million, decreasing 1% at AER, 2% at CER. <span style="font-style:italic">Augmentin</span> sales were &#163;576&#160;million, up 35% at AER, 38% at CER, reflecting the post pandemic rebound of the antibiotic market since H2 2021 in the International and Europe regions. This partially offsets the ongoing adverse impact of generic competition, and approximately two percentage points impact at AER and CER from the divestment of cephalosporin products in Q4 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Turnover by regions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">US </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the US, sales were &#163;14,542&#160;million, up 22% at AER, 10% at CER. Sales of <span style="white-space:nowrap">COVID-19</span> solutions contributed 2% growth at AER and CER to US Commercial Operations turnover. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of <span style="font-style:italic">Xevudy</span> were &#163;828&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In Specialty Medicines, HIV sales of &#163;3,756&#160;million were up 30% at AER, 17% at CER. Growth benefited from strong patient demand for all new HIV products, pricing favourability and <span style="white-space:nowrap">year-end</span> inventory build. New HIV medicines (<span style="font-style:italic">Dovato</span>, <span style="font-style:italic">Cabenuva</span>, <span style="font-style:italic">Juluca</span>, <span style="font-style:italic">Rukobia</span> and <span style="font-style:italic">Apretude</span>) sales were &#163;1,685&#160;million up 88% at AER, 70% at CER. <span style="font-style:italic">Nucala</span> in respiratory and <span style="font-style:italic">Benlysta</span> in immunology both continued to grow double-digit and reflected ongoing strong patient demand. Oncology sales increased 14% at AER, 3% at CER with diagnosis and treatment rates continuing to be impacted by the pandemic for <span style="font-style:italic">Zejula</span>, and the withdrawal of <span style="font-style:italic">Blenrep</span> from the US market in Q4 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccine sales were &#163;4,243&#160;million, up 22% at AER, 10% at CER. Sales of pandemic adjuvant contributed 9% growth at AER and 8% CER to US Commercial Operations turnover. The performance was primarily driven by <span style="font-style:italic">Shingrix</span> sales of &#163;1,964&#160;million up 46% at AER, 32% at CER, mostly due to higher <span style="white-space:nowrap">non-retail</span> and retail demand and strong commercial execution. Demand recovery in Established Vaccines and share gains in Meningitis vaccines also contributed to growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General Medicines sales were &#163;3,572&#160;million up 10% at AER down 1% at CER. <span style="font-style:italic">Trelegy</span> was up 47% at AER, 32% at CER reflecting increased patient demand and growth of the single inhaler triple therapy market, and Flovent grew on launch of authorised generics in the year. Overall, there was a three- percentage point reduction in growth of US General Medicines due to prior period Returns and Rebates (RAR) adjustments in the year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Europe </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In Europe, sales were &#163;6,348&#160;million, up 18% at AER, 19% at CER. Sales of <span style="white-space:nowrap">COVID-19</span> solutions of &#163;513&#160;million contributed 8 percentage points of growth at AER and CER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In Specialty Medicines, HIV sales were &#163;1,310&#160;million up 10% at AER, 10% at CER primarily driven by strong patient demand for <span style="font-style:italic">Dovato</span>, <span style="font-style:italic">Cabenuva</span> and <span style="font-style:italic">Juluca</span>. <span style="font-style:italic">Dovato</span> delivered sales of &#163;478&#160;million, <span style="font-style:italic">Juluca</span> &#163;127&#160;million and <span style="font-style:italic">Cabenuva</span> &#163;40&#160;million. <span style="font-style:italic">Benlysta</span> in immunology, <span style="font-style:italic">Nucala</span> in respiratory, and Oncology medicines <span style="font-style:italic">Zejula</span>, <span style="font-style:italic">Blenrep</span> and <span style="font-style:italic">Jemperli</span> all continued to show strong double-digit growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccine sales were &#163;1,884&#160;million, up 31% at AER, 32% at CER. The performance was driven by <span style="font-style:italic">Shingrix</span> sales of &#163;688&#160;million, &gt;100% at AER and CER, particularly in Germany. Pandemic adjuvant sales of &#163;57&#160;million contributed four percentage points of growth at AER and CER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General Medicines sales of &#163;2,079&#160;million decreased 3% at AER and CER, reflecting the ongoing impact of generic competitive pressures on <span style="font-style:italic">Seretide</span> and the divestment in Q4 2021 of cephalosporin products which caused one percentage point of drag on growth at AER and CER. This was partly offset, however, by strong demand for <span style="font-style:italic">Trelegy</span> and the growth of <span style="font-style:italic">Augmentin</span> following the post-pandemic rebound of the antibiotic market since H2 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">International </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">International sales were &#163;8,434&#160;million, up 14% at AER and CER, including <span style="font-style:italic">Xevudy</span> sales of &#163;1,025&#160;million. Sales of <span style="white-space:nowrap">COVID-19</span> solutions contributed 7% AER and 8% CER growth to International Commercial Operations turnover. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In Specialty Medicines, HIV sales were &#163;683&#160;million, stable at AER and decreased 3% at CER, primarily driven by tender decline. Excluding tenders, International grew driven by strong <span style="font-style:italic">Dovato</span> growth. Combined <span style="font-style:italic">Tivicay</span> and <span style="font-style:italic">Triumeq </span>sales were &#163;506&#160;million, down 12% at AER and 15% at CER. <span style="font-style:italic">Nucala</span> sales of &#163;242&#160;million grew 24% at AER and 28% at CER reflecting strong market growth and patient uptake. <span style="font-style:italic">Benlysta</span> sales of &#163;114&#160;million grew 44% at AER, 43% at CER reflecting growth in the biological market in Japan and inclusion on China&#8217;s National Reimbursement Drug List. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccine sales were &#163;1,810&#160;million, down 3% at AER, 5% at CER, reflecting an 11 percentage points drag at AER and CER from <span style="white-space:nowrap">COVID-19</span> vaccine adjuvant sales in 2021. Growth excluding <span style="white-space:nowrap">COVID-19</span> solutions was driven by strong <span style="font-style:italic">Shingrix</span> <span style="white-space:nowrap">take-up</span> in China, Canada and Japan more than offsetting the impact of supply constraints in MMR/V vaccines and lower <span style="font-style:italic">Synflorix</span> tender demand across several markets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General Medicines sales were &#163;4,467&#160;million up 5% at AER and CER. Respiratory sales of &#163;1,955&#160;million increased 10% at AER, 9% at CER, with <span style="font-style:italic">Trelegy</span> sales up 47% at AER, 48% at CER reflecting strong demand and inclusion on China&#8217;s National Reimbursement Drug List. Sales of<span style="font-style:italic"> Advair/Seretide</span> were up 3% at AER, 1% at CER with the adverse impact of generic competition offset by growth in certain markets due to targeted promotion. Other General Medicines sales of &#163;2,512&#160;million increased 1% at AER, 2% at CER, and reflected growth of <span style="font-style:italic">Augmentin</span> following the post-pandemic rebound of the antibiotic market since H2 2021, partially offset by generic competition and price reductions in certain markets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Cost of sales </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cost of sales as a percentage of turnover was 32.6%, 0.5 percentage points lower at AER and 0.9 percentage points higher in CER terms than 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted cost of sales as a percentage of turnover was 29.8%, 0.1 percentage points higher at AER and 1.3 percentage points higher at CER compared with 2021. This primarily reflected higher sales of lower margin <span style="font-style:italic">Xevudy</span> compared to 2021 which included higher margin pandemic adjuvant sales, increasing cost of sales margin by 2.5 percentage points at AER and CER, as well as the impact of increased commodity prices and freight costs. This was partially offset by a favourable mix primarily from increased sales of <span style="font-style:italic">Shingrix</span> in the US and Europe and increased sales of HIV medicines in the US, lower inventory adjustments and write offs in Vaccines and continued contribution from restructuring savings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Selling, general and administration </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total SG&amp;A costs as a percentage of turnover were 28.6%, 0.1 percentage points lower at AER and stable at CER compared to 2021. This included a reduction in restructuring charges. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted SG&amp;A costs as a percentage of turnover were 27.7%, 0.4 percentage points higher at AER and 0.5 percentage points higher at CER than in 2021. Adjusted SG&amp;A costs increased 20% at AER, 15% at CER which primarily reflected an increased level of launch investment in Specialty Medicines particularly HIV and Vaccines including <span style="font-style:italic">Shingrix</span> to drive post-pandemic recovery demand and support market expansion. The growth in Adjusted SG&amp;A also reflected an unfavourable comparison to a beneficial legal settlement in 2021 as well as impairment provisions relating to Russia and Ukraine. This growth was partly offset by the continuing benefit of restructuring and tight control of ongoing costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Research and development </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,488</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,062</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total R&amp;D expenditure was &#163;5,488&#160;million up 9% at AER, 4% at CER. This included amortisation and impairments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted R&amp;D expenditure in the full-year increased by 12% at AER, and 6% at CER, to &#163;5,062&#160;million. This reflected continued increased investment across Vaccines clinical development, including investments into our mRNA technology platforms, continued investment in the late-stage portfolio and several early discovery programmes, as well as expenditure related to our recent acquisition of Affinivax, Inc (Affinivax). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, in Specialty Medicines, the level of R&amp;D investment increased to support the phase III respiratory programme for depemokimab, a potential new medicine to treat severe asthma, and bepirovirsen, our study in chronic hepatitis B, in preparation for the start of the phase III trial. In Oncology, investment increased in our early-stage immuno-oncology assets and in momelotinib (MMB), our potential new treatment of myelofibrosis patients with anaemia, acquired as part of the recent Sierra Oncology acquisition. These increases in investment were offset by decreases related to the completion of several late-stage clinical development programmes and reduced R&amp;D investment in <span style="white-space:nowrap">COVID-19</span> pandemic solutions versus 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Royalty income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Royalty income was &#163;758&#160;million (2021: &#163;417 million), up 82% at AER, 81% at CER, the increase primarily reflecting royalty income from Gilead under the settlement and licensing agreement with Gilead announced on 1&#160;February 2022 and Gardasil royalty income increasing to &#163;446&#160;million due to higher sales. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other operating income/(expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Net other operating expense was &#163;235&#160;million (2021: &#163;504 million) reflecting accounting charges of &#163;1,726&#160;million (2021: &#163;1,101 million) arising from the remeasurement of contingent consideration liabilities and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. This included a remeasurement charge of &#163;1,431&#160;million (2021: &#163;1,026 million) for the contingent consideration liability due to Shionogi, including the unwinding of the discount of &#163;410&#160;million and a charge for &#163;1,021&#160;million primarily from changes to exchange rates as well as adjustments to sales forecasts. This was partly offset by &#163;922&#160;million upfront income received from the settlement with Gilead, fair value gain on investments including &#163;229&#160;million on the retained stake in Haleon plc (Haleon), reflecting an increase in share price since listing and milestone income from disposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Operating profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total operating profit from continuing operations was &#163;6,433&#160;million compared with &#163;4,357&#160;million in 2021. Total operating margin was 21.9%, lower compared to 2021 due to the net impact of adjusting items described on page 11. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This included the &#163;922&#160;million upfront income received from the settlement with Gilead, increased profits on turnover growth of 19% at AER, 13% at CER and fair value gains on investments including &#163;229&#160;million on the retained stake in Haleon, partly offset by higher remeasurement charges for contingent consideration liabilities. Adjusted operating profit was &#163;8,151&#160;million, 26% higher at AER and 14% at CER than 2021 on a turnover increase of 13% at CER. The Adjusted operating margin of 27.8% was 1.5 percentage points higher at AER and 0.3 percentage points higher at CER compared to 2021. This primarily reflected the impact from low margin <span style="white-space:nowrap">COVID-19</span> solutions sales (<span style="font-style:italic">Xevudy</span>), which reduced Adjusted Operating profit growth by 3% AER and CER and reduced the Adjusted operating margin by approximately 1.4 percentage points at AER and approximately 1.3 percentage points at CER. This was offset by operating leverage from strong sales growth, mix benefit, lower inventory adjustments and write offs and higher royalty income. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Contingent consideration cash payments made to Shionogi and other companies reduce the balance sheet liability and hence are not recorded in the income statement. Total contingent consideration cash payments in 2022 amounted to &#163;1,137&#160;million (2021: &#163;856 million). These included cash payments made to Shionogi of &#163;1,100&#160;million (2021: &#163;826 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Adjusted operating profit by business </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Commercial Operations operating profit was &#163;13,590&#160;million, up 19% at AER and 10% at CER on a turnover increase of 13% at CER. The operating margin of 46.3% was 0.1 percentage points lower at AER, 1.2 percentage points lower at CER than in 2021. This primarily reflected strong sales of lower margin <span style="font-style:italic">Xevudy</span>, increased investment behind launches in Specialty Medicines including HIV and Vaccines plus higher commodity, freight and distribution costs as well as an adverse comparison to a favourable legal settlement in 2021. This was partly offset by leverage from strong sales growth, mix and lower inventory adjustments and write-offs, continued tight control of ongoing costs, benefits from continued restructuring and increased royalty income from Biktarvy and Gardasil sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">R&amp;D segment operating expenses were &#163;5,060&#160;million, up 11% at AER, 5% at CER, primarily reflecting increased investment in Vaccines including priority investments for mRNA, late stage portfolio and expenditure from the acquisition of Affinivax and in Specialty Medicines in early stage HIV and depemokimab. This was partly offset by decreases related to the completion of several late-stage clinical development programmes and reduced R&amp;D investment in <span style="white-space:nowrap">COVID-19</span> pandemic solutions versus 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Net finance costs </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:85%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL">Finance income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(789</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(735</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unwinding of discounts on provisions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurements and fair value movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance expense on lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other finance expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(879</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(769</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total net finance costs were &#163;803&#160;million compared with &#163;755&#160;million in 2021. Adjusted net finance costs were &#163;791&#160;million compared with &#163;752&#160;million in 2021. The increase is mainly driven by costs associated with the Sterling Notes repurchase in Q4 2022 and higher interest on tax offset by increased interest income due to higher interest rates and larger cash balances as a result of the Consumer Healthcare demerger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Share of after tax profits of associates and joint ventures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The share of after tax loss of associates and joint ventures was &#163;2&#160;million (2021: &#163;33&#160;million share of profit). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Loss on disposal of interest in associates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In 2021, the Group also reported a net loss on disposal of interests in associates of &#163;36&#160;million, primarily driven by a loss on disposal of our interest in the associate Innoviva Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Profit before tax </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Taking account of net finance costs, the share of profits of associates and loss on disposal of interest in associates, profit before taxation was &#163;5,628&#160;million compared with &#163;3,599&#160;million in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Taxation </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">UK current year charge</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Rest of world current year charge</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Charge/(credit) in respect of prior periods</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(784</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(848</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation on total profits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The charge of &#163;707&#160;million represented an effective tax rate on Total results of 12.6% (2021: 2.3%) and reflected the different tax effects of the various Adjusting items. Included in 2021 was a credit of &#163;430&#160;million resulting from the remeasurement of deferred tax assets following enactment of the proposed change of UK corporate income tax rates from 19% to 25%. Tax on Adjusted profit amounted to &#163;1,138&#160;million and represented an effective Adjusted tax rate of 15.5% (2021: 15.9%). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Issues related to taxation are described in Note 14 to the financial statements &#8216;Taxation&#8217;. The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods which are open and not yet agreed by tax authorities. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">Non-controlling</span> interests </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The allocation of Total profit from continuing operations to <span style="white-space:nowrap">non-controlling</span> interests amounted to &#163;460&#160;million (2021: &#163;200 million). The increase was primarily due to an increased allocation of ViiV Healthcare profits of &#163;416&#160;million (2021: &#163;197 million), including the Gilead upfront settlement income, partly offset by increased credits for remeasurement of contingent consideration liabilities, as well as higher net profits in some of the Group&#8217;s other entities with <span style="white-space:nowrap">non-controlling</span> interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The allocation of Adjusted earnings from continuing operations to <span style="white-space:nowrap">non-controlling</span> interests amounted to &#163;595&#160;million (2021: &#163;441 million). The increase in allocation primarily reflected an increased allocation of ViiV Healthcare profits of &#163;551&#160;million (2021: &#163;438 million), as well as higher net profits in some of the Group&#8217;s other entities with <span style="white-space:nowrap">non-controlling</span> interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Earnings per share from continuing operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total EPS from continuing operations was 110.8p compared with 82.9p in 2021. This primarily reflected the &#163;922&#160;million upfront income received from the settlement with Gilead, increased profits on turnover growth of 13% at CER and fair value gains on investments including the retained stake in Haleon, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;430&#160;million to Taxation in 2021 resulting from the remeasurement of deferred tax assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted EPS was 139.7p compared with 110.3p in 2021, up 27% at AER, 15% at CER on a 13% CER turnover increase. Operating leverage from growth in sales of Specialty Medicines including HIV and Vaccines, beneficial mix and lower inventory adjustments and write-offs, higher royalty income and a lower effective tax rate was partly offset by increased investment behind launches in Specialty Medicines including HIV and Vaccines plus higher supply chain costs, freight and distribution costs and higher <span style="white-space:nowrap">non-controlling</span> interests. Growth in lower margin <span style="white-space:nowrap">COVID-19</span> solutions sales reduced Adjusted EPS growth by 4% AER and 3% CER. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Profit and earnings per share from discontinued operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Discontinued operations include the Consumer Healthcare business and certain Corporate costs directly attributable to the Consumer Healthcare business. Profit after taxation from discontinued operations amounted to &#163;10,700&#160;million (2021: &#163;1,580 million). This includes &#163;10,084&#160;million for the gain arising on the demerger of Consumer Healthcare split between the amount distributed to shareholders on demerger of &#163;7,651&#160;million and profit after taxation on discontinued operations for the retained stake of &#163;2,433&#160;million. In addition, the Profit after taxation from discontinued operations for the Consumer Healthcare business was &#163;616&#160;million (2021: &#163;1,580 million). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">EPS from discontinued operations was 260.6p, compared with 26.7p in 2021. The increase primarily reflected the gain arising on the demerger of the Consumer Healthcare business. For further details see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below, discontinued operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total earnings per share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total EPS was 371.4p compared with 109.6p in 2021. The increase primarily reflected the profit after taxation for discontinued operations recognised on the Consumer Healthcare business demerger, upfront income received from the settlement with Gilead, increased profits and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;397&#160;million to Taxation in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Board has declared four interim dividends resulting in a total dividend for the year of 61.25p per share retrospectively adjusted for the share consolidation. The 2021 dividend per share was 100p retrospectively adjusted for the share consolidation. See &#8220;Note 16 &#8211; Dividends&#8221;, to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Dividend policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On 23&#160;June 2021, at the new GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60&#160;percent <span style="white-space:nowrap">pay-out</span> ratio through the investment cycle. The dividend policy, the total expected cash distribution, and the respective dividend <span style="white-space:nowrap">pay-out</span> ratios for GSK remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK has previously stated that it expected to declare a 27p per share dividend for the first half of 2022, a 22p per share dividend for the second half of 2022 and a 45p per share dividend for 2023 (before the Share Consolidation) but that these targeted dividends per share would increase in step with the Share Consolidation to maintain the same aggregate dividend <span style="white-space:nowrap">pay-out</span> in absolute Sterling terms. Accordingly, using the consolidation ratio, GSK&#8217;s expected dividend for the fourth quarter of 2022 converts to 13.75p per new ordinary share. This results in an expected total dividend for the second half of 2022 of 27.5p per new ordinary share. The expected dividend for 2023 converts to 56.5p per new ordinary share in line with the original expectation converted for the Share Consolidation and rounded up. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">COVID-19</span> solutions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Based on known binding agreements with governments, GSK does not anticipate any significant <span style="white-space:nowrap">COVID-19</span> pandemic-related sales or operating profit in 2023. Sales of <span style="white-space:nowrap">COVID-19</span> solutions were &#163;2.4&#160;billion in 2022 and therefore we expect a reduction in Turnover growth by approximately 9% and a reduction in Adjusted Operating profit growth by 6% to 7%. However, the Company continues to discuss future opportunities to support governments, healthcare systems, and patients whereby its <span style="white-space:nowrap">COVID-19</span> solutions can address the emergence of any new <span style="white-space:nowrap">COVID-19</span> variant of concern. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Profit from discontinued operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Discontinued operations include the Consumer Healthcare business and certain Corporate costs directly attributable to the Consumer Healthcare business. Profit after taxation from discontinued operations amounted to &#163;10,700&#160;million (2021: &#163;1,580 million). This includes &#163;10,084&#160;million for the gain arising on the demerger of Consumer Healthcare split between the amount distributed to shareholders on demerger of &#163;7,651&#160;million and profit after taxation on discontinued operations for the retained stake of &#163;2,433&#160;million. In addition, the Profit after taxation from discontinued operations for the Consumer Healthcare business was &#163;616&#160;million (2021: &#163;1,580 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Intangible asset amortisation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">See &#8220;Note 20 &#8211; Other intangible assets&#8221; to the financial statements incorporated by reference in Item 18 below for description and information on Intangible asset amortisation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Intangible asset impairment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">See &#8220;Note 20 &#8211; Other intangible assets&#8221; to the financial statements incorporated by reference in Item 18 below for description and information on Intangible asset impairment. No individual intangible asset accounted for a material impairment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Major restructuring and integration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long life cycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;D sites are likely to take several years to complete. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Major restructuring costs are those related to specific Board-approved Major restructuring programmes and are excluded from Adjusted results. Major restructuring programmes, including integration costs following material acquisitions, are those that are structural and are of a significant scale where the costs of individual or related projects exceed &#163;25&#160;million. Other ordinary course smaller-scale restructuring costs are retained within Total and Adjusted results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total Major restructuring charges incurred in 2022 were &#163;321&#160;million (2021<sup style="font-size:75%; vertical-align:top">(1)</sup>: &#163;424 million), analysed as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-</span><br />cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-</span><br />cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Separation preparation restructuring programme</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Significant acquisitions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legacy programmes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash charges of &#163;177&#160;million under the Separation Preparation programme primarily arose from the restructuring of some administrative functions as well as Global Supply Chain, R&amp;D functions and commercial. The <span style="white-space:nowrap">non-cash</span> charges of &#163;110&#160;million primarily reflected the write-down of assets in administrative and manufacturing locations and impairment of IT assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cash payments made in 2022 were &#163;388&#160;million (2021: &#163;551 million), &#163;332&#160;million (2021: &#163;428 million) relating to the Separation Preparation restructuring programme, &#163;17&#160;million relating to significant acquisitions (2021: &#163;nil) and &#163;39&#160;million (2021: &#163;123 million) relating to other legacy programmes including the settlement of certain charges accrued in previous quarters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The analysis of Major restructuring charges by income statement line was as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:86%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Major restructuring costs from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The benefit in 2022 from restructuring programmes was &#163;0.5&#160;billion, primarily relating to the Separation Preparation restructuring programme. The Group initiated in Q1 2020 a Separation Preparation programme to prepare for the separation of GSK into two companies: The programme aims were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Drive a common approach to R&amp;D with improved capital allocation </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Align and improve the capabilities and efficiency of global support functions to support GSK </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Further optimise the supply chain and product portfolio, including the divestment of <span style="white-space:nowrap">non-core</span> assets </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Prepare Consumer Healthcare to operate as a standalone company </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The programme delivered &#163;0.9&#160;billion of annual savings by 2022 and targets to deliver &#163;1.0&#160;billion by 2023, with total costs estimated at &#163;2.4&#160;billion, of which &#163;1.6&#160;billion is expected to be cash costs. The proceeds of divestments have largely covered the cash costs of the programme. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Transaction-related adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Transaction-related adjustments from continuing operations resulted in a net charge of &#163;1,750&#160;million (2021: &#163;1,143 million). This included a net &#163;1,726&#160;million accounting charge for the <span style="white-space:nowrap">re-measurement</span> of the contingent consideration liabilities and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL">Charge/(credit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Shionogi-ViiV Healthcare Joint Venture (including Shionogi preferential dividends)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ViiV Healthcare put options and Pfizer preferential dividends</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Novartis Vaccines business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on acquisition of Affinivax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total transaction-related charges</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The &#163;1,431&#160;million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi, as a result of the unwind of the discount for &#163;410&#160;million and a charge of &#163;1,021&#160;million primarily from adjustments to sales forecasts and the settlement with Gilead as well as updated exchange rate assumptions. The &#163;85&#160;million charge relating to the ViiV Healthcare put option and Pfizer preferential dividends represented an increase in the valuation of the put option as a result of the settlement with Gilead, offset by lower cash and updated exchange rate assumptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The ViiV Healthcare contingent consideration liability is fair valued under IFRS. An explanation of the accounting for the <span style="white-space:nowrap">non-controlling</span> interests in ViiV Healthcare is set out on pages 19 to 20 above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Divestments, significant legal charges and other items </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Divestments, significant legal charges and other items primarily included the &#163;922&#160;million upfront settlement income received from Gilead, a fair value gain on investments including &#163;229&#160;million on the retained stake in Haleon as well as milestone income and gains from a number of asset disposals, partly offset by certain other Adjusting items. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Discontinued operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">From Q2 2020, the Group started to report additional costs to prepare for establishment of the Consumer Healthcare business as an independent entity (&#8220;Separation costs&#8221;). These are presented as part of discontinued operations. Total separation costs incurred in 2022 were &#163;366&#160;million (2021: &#163;314 million). This includes &#163;103&#160;million relating to transaction costs incurred in connection with the demerger and preparatory admission costs related to the listing of Haleon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total separation costs to date are &#163;748&#160;million including &#163;141&#160;million relating to transaction costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Cash generation and conversion </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A summary of the consolidated cash flow statement is set out below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:81%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash inflow from operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash (outflow) from investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,772</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash inflow/(outflow) from financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in cash and bank overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(546</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,414</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at beginning of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exchange adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in cash and bank overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(546</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,414</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at end of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at end of year comprise:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(455</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total net cash inflow from operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total net cash generated from operating activities for the year was &#163;7,403&#160;million (2021: &#163;7,952 million). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The decrease primarily reflected unfavourable timing of profit share payments for <span style="font-style:italic">Xevudy </span>sales, increased cash contributions to UK pension schemes, increased contingent consideration payments for the settlement with Gilead and to Shionogi, plus a higher increase in inventory and a reduction in cash from discontinued operations. The decrease was primarily offset by a significant increase in operating profit including the upfront income from the settlement with Gilead, favourable exchange impact and favourable timing of collections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Reconciliation of net cash inflow from continuing operating activities to free cash inflow </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A reconciliation of net cash inflow from operating activities, which is the closest equivalent IFRS measure to free cash flow, is shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:81%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash inflow from continuing operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchase of property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(950</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchase of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,704</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from sale of property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from sale of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(784</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(758</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividends from joint ventures and associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration paid (reported in investing activities)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(114</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contribution from <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Distributions to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(521</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Free cash inflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Capital expenditure and financial investment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash payments for tangible and intangible fixed assets amounted to &#163;2,258&#160;million (2021: &#163;2,654 million) and disposals realised &#163;342&#160;million (2021: &#163;773 million). Cash payments to acquire equity investments amounted to &#163;143&#160;million (2021: &#163;162 million) and sales of equity investments realised &#163;238&#160;million (2021: &#163;202 million). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Free cash flow </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash flow is the amount of cash generated by the Group after meeting our obligations for contingent consideration, interest, tax and dividends paid to <span style="white-space:nowrap">non-controlling</span> interests, and after capital expenditure on property, plant and equipment and intangible assets. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Free cash inflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cash payments to Shionogi in relation to the ViiV Healthcare contingent consideration liability in the year were &#163;1,100&#160;million (2021: &#163;826 million), of which &#163;1,031&#160;million was recognised in cash flows from operating activities and &#163;69&#160;million was recognised in contingent consideration paid within investing cash flows. These payments are deductible for tax purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Future cash flow </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Over the long term, we expect that future cash generated from operations will be sufficient to fund our operating and debt servicing costs, normal levels of capital expenditure, obligations under existing licensing agreements, expenditure arising from restructuring programmes and other routine outflows including tax, pension contributions and dividends, subject to the &#8220;Principal risks and uncertainties&#8221; discussed under Item 3.D &#8220;Risk Factors&#8221; above. We may from time to time have additional demands for finance, such as for acquisitions. We have access to multiple sources of liquidity from short and long-term capital markets and financial institutions for such needs, in addition to the cash flow from operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Investment appraisal and capital allocation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have a strong framework for capital allocation, including a board to govern the allocation of capital between our businesses. We utilise a consistent cash return on invested capital (CROIC) methodology to prioritise investment across the Group as a whole, so that we can more effectively compare the returns from each of the businesses as we allocate capital between them. We also consider the impact on EPS and our credit profile where relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Financial position and resources </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Right of use assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investments in associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative financial instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <span style="white-space:nowrap">non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total <span style="white-space:nowrap">non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39.377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Inventories</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current tax recoverable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative financial instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current equity investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liquid investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets held for sale</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,952</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,289</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(958</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,263</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative financial instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(183</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(227</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current tax payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(489</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term provisions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(841</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,810</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,670</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,035</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,572</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Corporation tax payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(180</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(289</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pensions and other post-employment benefits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,579</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other provisions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(532</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative financial instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,779</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <span style="white-space:nowrap">non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(899</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(921</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total <span style="white-space:nowrap">non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27,240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(34,091</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(50,050</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(57,761</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Property, plant and equipment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our business is science-based, technology-intensive and highly regulated by governmental authorities. We allocate significant financial resources to the renewal and maintenance of our property, plant, equipment and vehicles to minimise risks of interruption to production and to ensure compliance with regulatory standards. A number of our processes use hazardous materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The total cost of our property, plant and equipment at 31&#160;December 2022 was &#163;19,451&#160;million, with a net book value of &#163;8,933&#160;million. Of this, land and buildings represented &#163;3,113&#160;million, plant, equipment and vehicles &#163;4,012&#160;million and assets in construction &#163;1,808&#160;million. In 2022, we invested &#163;1,245&#160;million in new property, plant and equipment. This was mainly related to a large number of projects for the renewal, improvement and expansion of facilities at various worldwide sites to support new product development and launches as well as to improve the efficiency of existing supply chains. Property is mainly held freehold. New investment is financed from our liquid resources. At 31&#160;December 2022, we had contractual commitments for future capital expenditure of &#163;743&#160;million. We believe that our property and plant facilities are adequate for our current requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We observe stringent procedures and use specialist skills to manage environmental risks from our activities. Environmental issues, sometimes dating from operations now modified or discontinued, are reported under &#8216;Environment&#8217; on pages 45 and 46 of the GSK Annual Report 2022 and in &#8220;Note 47 &#8211; Legal Proceedings&#8221; to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Right of use assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Right of use assets amounted to &#163;687&#160;million at 31&#160;December 2022 compared with &#163;740&#160;million at 31&#160;December 2021. The decrease in the year reflected the impact of depreciation and transfer to assets held for sale/distribution of &#163;192&#160;million and &#163;127&#160;million respectively, disposals and impairments amounting to &#163;75&#160;million, partly offset by additions through business combinations of &#163;53&#160;million and other additions of &#163;233&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Goodwill </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Goodwill decreased to &#163;7,046&#160;million at 31&#160;December 2022, from &#163;10,552&#160;million primarily as a result of transfer of assets held for sale/distribution of &#163;5,183&#160;million for the Consumer Healthcare demerger partially offset by an increase of &#163;1,127&#160;million for the acquisitions of Sierra Oncology and Affinivax. The values for Affinivax are provisional and are subject to change. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other intangible assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Other intangible assets include the cost of intangibles acquired from third parties and computer software. The net book value of other intangible assets as at 31&#160;December 2022 was &#163;14,318&#160;million (2021: &#163;30,079 million). The decrease primarily reflected transfer to assets held for sale/distribution of &#163;20,057&#160;million, impairment losses, net of reversals and amortisation of &#163;1,519&#160;million, offset by additions, net of disposals, write-offs of &#163;4,047&#160;million and exchange rate gains of &#163;1,628&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Investments in associates and joint ventures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We held investments in associates and joint ventures with a carrying value at 31&#160;December 2022 of &#163;74&#160;million (2021: &#163;88 million). See &#8220;Note 21 &#8211; Investments in associates and joint ventures&#8221; to the financial statements incorporated by reference in Item 18 below for more details. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Current equity investments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Current equity investments amounted to &#163;4,087&#160;million at 31&#160;December 2022 (2021: &#163;nil). Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at fair value through the profit and loss (FVTPL). They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. The investment of &#163;4,087&#160;million (2021: &#163;nil) represents the shares held in Haleon after the demerger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other investments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We held other investments with a carrying value at 31&#160;December 2022 of &#163;1,467&#160;million (2021: &#163;2,126 million). The most significant of these investments held at 31&#160;December 2022 were in Vir Biotechnology and Nimbus Discovery. These investments had a fair value at 31&#160;December 2022 of &#163;180&#160;million (2021: &#163;266 million) and &#163;139&#160;million (2021: &#163;32 million) respectively. The other investments included equity stakes in companies with which we have research collaborations, and which provide access to biotechnology developments of potential interest and interests in companies that arise from business divestments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Derivative financial instruments: assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We held current derivative financial assets at fair value of &#163;190&#160;million (2021: &#163;188 million) and <span style="white-space:nowrap">non-current</span> derivative financial assets held at fair value of &#163;nil (2021: &#163;18 million). The majority of these financial instruments related to foreign exchange contracts both designated and not designated as accounting hedges. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Inventories </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Inventories amounted to &#163;5,146&#160;million (2021: &#163;5,783) at 31&#160;December 2022. The decrease was mainly driven by the Consumer Healthcare demerger partially offset by vaccines stock build. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Trade and other receivables </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Trade and other receivables amounted to &#163;7,053&#160;million (2021: &#163;7,860 million) at 31&#160;December 2022. The decrease was mainly driven by the Consumer Healthcare demerger and lower pandemic adjuvant sales compared to last year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Deferred tax assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Deferred tax assets amounted to &#163;5,658&#160;million (2021: &#163;5,218 million) at 31&#160;December 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Derivative financial instruments: liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We held current and <span style="white-space:nowrap">non-current</span> derivative financial liabilities at fair value of &#163;183&#160;million (2021: &#163;228 million). This primarily related to foreign exchange contracts both designated and not designated as accounting hedges. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Trade and other payables </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, trade and other payables were &#163;16,263&#160;million compared with &#163;17,554&#160;million at 31&#160;December 2021. See &#8220;Note 29 &#8211; Trade and other payables&#8221; to the financial statements incorporated by reference in Item 18 below. The decrease was mainly driven by the Consumer Healthcare demerger and profit share collaborations offset by an increase in promotional activity in the regions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We carried deferred tax provisions and other short-term and <span style="white-space:nowrap">non-current</span> provisions of &#163;1,473&#160;million at 31&#160;December 2022 (2021: &#163;5,027 million). Other provisions at the <span style="white-space:nowrap">year-end</span> included &#163;218&#160;million (2021: &#163;196 million) related to legal and other disputes and &#163;351&#160;million (2021: &#163;652 million) related to Major restructuring programmes. Provision has been made for legal and other disputes, indemnified disposal liabilities, employee related liabilities and the costs of the restructuring programme to the extent that at the balance sheet date a legal or constructive obligation existed and could be reliably estimated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Pensions and other post-employment benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We account for pension and other post-employment arrangements in accordance with IAS 19. The net deficits were &#163;1,356&#160;million (2021: &#163;1,129 million) on pension arrangements and &#163;994&#160;million (2021: &#163;1,243 million) on unfunded post- employment liabilities. See &#8220;Note 31 &#8211; Pensions and other post-employment benefits&#8221; to the financial statements, incorporated by reference in Item 18 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other <span style="white-space:nowrap">non-current</span> liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Other <span style="white-space:nowrap">non-current</span> liabilities amounted to &#163;899&#160;million at 31&#160;December 2022 (2021: &#163;921 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Contingent consideration liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Contingent consideration amounted to &#163;7,068&#160;million at 31&#160;December 2022 (2021: &#163;6,076 million), of which &#163;5,890&#160;million (2021: &#163;5,559 million) represented the estimated present value of amounts payable to Shionogi relating to ViiV Healthcare, &#163;501&#160;million (2021: &#163;nil) represented the estimated present value of contingent consideration payable to the former shareholders of Affinivax and &#163;673&#160;million (2021: &#163;479 million) represented the estimated present value of contingent consideration payable to Novartis related to the Vaccines acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The liability due to Shionogi was &#163;263&#160;million in respect of preferential dividends. An explanation of the accounting for the <span style="white-space:nowrap">non-controlling</span> interests in ViiV Healthcare is set out on pages 19 to 20 above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Of the total contingent consideration payable (on a <span style="white-space:nowrap">post-tax</span> basis) at 31&#160;December 2022, &#163;940&#160;million (2021: &#163;937 million) is expected to be paid within one year. The consideration payable is expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, on a <span style="white-space:nowrap">post-tax</span> basis using <span style="white-space:nowrap">post-tax</span> discount rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Shionogi-ViiV Healthcare contingent consideration liability is discounted at 8% and the Novartis Vaccines contingent consideration liability is discounted partly at 7.5% and partly at 8.5%. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Net debt </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liquid investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,952</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,035</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,572</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net debt the end of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, net debt was &#163;17.2&#160;billion, compared with &#163;19.8&#160;billion at 31&#160;December 2021, comprising gross debt of &#163;21.0&#160;billion and cash and liquid investments of &#163;3.8&#160;billion. Net debt reduced by &#163;2.6&#160;billion primarily due to &#163;3.3&#160;billion free cash flow from continuing operations, &#163;0.2&#160;billion disposals of equity investments and &#163;7.2&#160;billion decrease from discontinued operations as result of demerger primarily reflecting &#163;7.1&#160;billion of <span style="white-space:nowrap">pre-separation</span> dividends attributable to GSK funded by Consumer Healthcare debt. This was partly offset by purchases of businesses of &#163;3.1&#160;billion, net of cash acquired, reflecting the acquisitions of Sierra Oncology and Affinivax, dividends paid to shareholders of &#163;3.5&#160;billion, net adverse exchange impacts of &#163;1.4&#160;billion from the translation of <span style="white-space:nowrap">non-Sterling</span> denominated debt and exchange on other financing items and &#163;0.1&#160;billion purchases of equity investments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, GSK had short-term borrowings (including overdrafts and lease liabilities) repayable within 12 months of &#163;4.0&#160;billion and &#163;1.9&#160;billion repayable in the subsequent year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, GSK&#8217;s cash and liquid investments were held as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bank balances and deposits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">US Treasury and Treasury repo only money market funds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liquidity funds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liquid investments &#8211; government securities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center">3,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center">4,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash and liquid investments of &#163;3.1&#160;billion (2021: &#163;2.9 billion) were held centrally at 31&#160;December 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The analysis of cash and gross debt after the effects of hedging is as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Liquid investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross debt &#8211; fixed</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,214</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#8211; floating</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,773</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,006</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Movements in net debt </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net debt at beginning of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,780</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in cash and bank overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,597</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in liquid investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net decrease in long-term loans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net decrease of short-term loans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Repayment of lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Debt of subsidiary undertaking acquired</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exchange adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,531</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other <span style="white-space:nowrap">non-cash</span> movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(207</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease/(increase) in net debt from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease/(increase) in net debt from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net debt at end of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Total equity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, total equity had decreased from &#163;21,342&#160;million at 31&#160;December 2021 to &#163;10,096&#160;million. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A summary of the movements in equity is set out below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:80%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total equity at beginning of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total comprehensive income for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-cash</span> distribution to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,960</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deconsolidation of former subsidiaries</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,045</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividends to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,467</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ordinary shares issued</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><span style="white-space:nowrap">Non-cash</span> dividends to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,526</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hedging gain/loss transferred to <span style="white-space:nowrap">non-financial</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transaction with <span style="white-space:nowrap">non-controlling</span> interest</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share-based incentive plans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax on share-based incentive plans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contributions from <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Distributions to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total equity at end of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Share purchases </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, GSK held 217.1&#160;million shares as Treasury shares (2021: 284.2&#160;million shares), at a cost of &#163;3,798&#160;million (2021: &#163;4,969 million), which has been deducted from retained earnings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">No ordinary shares were repurchased in the period 1&#160;January 2022 to 28&#160;February 2023 and the company does not expect to make any ordinary share repurchases in the remainder of 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In 2022, 77.1&#160;million Treasury shares were transferred to the Employee Share Ownership Plan (ESOP) Trusts, of which 50.3&#160;million shares were transferred prior to the share consolidation. Shares are held by the Trusts to satisfy future exercises of options and awards under the Group share option and award schemes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A proportion of the shares held by the Trusts are in respect of awards where the rules of the scheme require GSK to satisfy exercises through market purchases rather than the issue of new shares. The shares held by the Trusts are matched to options and awards granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, the ESOP Trusts held 59.9&#160;million (2021: 23.3 million) GSK shares against the future exercise of share options and share awards. The carrying value of &#163;353&#160;million (2021: &#163;27 million) has been deducted from other reserves. The market value of these shares was &#163;861&#160;million (2021: &#163;371 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Contractual obligations and commitments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Financial commitments are summarised in &#8220;Note 36 &#8211; Commitments&#8221; and in &#8220;Note 44 &#8211; Financial instruments and related disclosures&#8221; to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following table sets out our contractual obligations and commitments at 31&#160;December 2022 as they fall due for payment. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Total</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Under&#160;1&#160;yr</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="white-space:nowrap">1-3</span> yrs</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="white-space:nowrap">3-5</span> yrs</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">5 yrs+</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest on loans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance lease obligations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Future Finance Charges on leases</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease contracts that have not yet commenced</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property, plant&#160;&amp; equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchase commitments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pensions and post-retirement benefits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,578</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Commitments in respect of loans and future interest payable on loans are disclosed before taking into account the effect of derivatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have entered into a number of research collaborations to develop new compounds with other pharmaceutical companies. The terms of these arrangements can include upfront fees, equity investments, loans and commitments to fund specified levels of research. In addition, we will often agree to make further payments if future &#8216;milestones&#8217; are achieved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As some of these agreements relate to compounds in the early stages of development, the potential obligation to make milestone payments will continue for a number of years if the compounds move successfully through the development process. Generally, the closer the product is to marketing approval, the greater the probability of success. The amounts shown above within intangible assets represent the maximum that would be paid if all milestones were achieved. There was a decrease in the commitments in 2022 as a result of a reduction in outstanding loan commitments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. Scottish limited partnerships (&#8220;SLPs&#8221;) were established to provide a funding mechanism for each of GSK&#8217;s UK defined benefit pension schemes. The SLPs together hold shares representing 7.5% of the total issued share capital of Haleon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on Haleon shares, until it has received an aggregate amount equal to an agreed threshold (&#8220;Proceeds Threshold&#8221;). The Proceeds Thresholds total &#163;1,080&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or technical provisions deficits in the three schemes shown by the 31&#160;December 2020 valuations. Once the Proceeds Threshold has been reached the <span style="white-space:nowrap">GSK-controlled</span> General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. As at 31&#160;December 2022, &#163;345&#160;million remains outstanding to the UK Pension Trustees. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Contingent liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Other contingent liabilities are set out in &#8220;Note 35 &#8211; Contingent liabilities&#8221; to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following table sets out contingent liabilities, comprising performance guarantees, letters of credit and other items arising in the normal course of business, and when they are expected to expire. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Total</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Under&#160;1&#160;yr</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="white-space:nowrap">1-3&#160;yrs</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="white-space:nowrap">3-5&#160;yrs</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">5&#160;yrs+</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Guarantees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other contingent liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the normal course of business, we have provided various indemnification guarantees in respect of business disposals in which legal and other disputes have subsequently arisen. A provision is made where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome of the dispute and this is included in &#8220;Note 32 &#8211; Other provisions&#8221; to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We provide for the outcome of tax, legal and other disputes when an outflow of resources is considered probable and a reliable estimate of the outflow may be made. At 31&#160;December 2022, other than for those disputes where provision has been made, it was not possible to make a reliable estimate of the potential outflow of funds that might be required to settle disputes where the possibility of there being an outflow was more than remote. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The ultimate liability for such matters may vary significantly from the amounts provided and is dependent upon negotiations with the relevant tax authorities and the outcome of litigation proceedings, where relevant. This is discussed further in &#8216;Principal risks and uncertainties&#8217; under Item 3.D above on pages 3 to 8 above and &#8220;Note 47 &#8211; Legal proceedings&#8221; to the financial statements incorporated by reference in Item 18 below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Group Financial Review 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">2021 Financial performance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Financial performance growth commentary other than for growth in Group turnover is not available at CER without unreasonable effort. Growth in turnover is provided at both AER and CER; growth in all other line items is provided at AER only. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Total results of the Group are set out below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">% of</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">% of</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33.1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30.5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Royalty income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other operating (expenses)/income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on disposal of interest in associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share of <span style="white-space:nowrap">after-tax</span> (losses)/profits of associates and joint ventures</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit before taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from continuing operations for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations and other gains from the demerger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of discontinued operations distributed to shareholders on demerger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit after taxation from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit after taxation for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,873</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to <span style="white-space:nowrap">non-controlling</span> interests from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Profit attributable to shareholders from discontinued operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per share from continuing operations (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82.9p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per share from discontinued operations (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26.7p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.0p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total earnings per share (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109.6p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per ADS from continuing operations (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Earnings per ADS from discontinued operations (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total earnings per ADS (US$)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="5" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Adjusted results for the Group are set out below. Reconciliations between Total results and Adjusted results for 2021 and 2020 are set out on pages 12 and 13 above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">% of<br />turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">% of<br />turnover</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,672</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27.4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28.8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Royalty income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted<sup style="font-size:75%; vertical-align:top">(2)</sup> operating profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit attributable to shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit attributable to <span style="white-space:nowrap">non-controlling</span> interest</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted profit after tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted earnings per share (p)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110.3p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Adjusted results are <span style="white-space:nowrap">non-IFRS</span> measures excluding discontinued operations and other adjustments that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Adjusted results, AER growth, CER growth and other <span style="white-space:nowrap">non-IFRS</span> measures are defined below under &#8220;Reporting framework&#8221;. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Historical record of Adjusting items </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The reconciliations between Total and Adjusted operating profit from continuing operations for 2021<sup style="font-size:75%; vertical-align:top">(1)</sup> and 2020<sup style="font-size:75%; vertical-align:top">(1)</sup> can be summarised as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating profit from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible amortisation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible impairment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Major restructuring</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transaction-related items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Divestments, significant legal and other items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,662</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted results</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The analysis of the impact of transaction-related items on operating profit for each of the last three years is as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Shionogi-ViiV Healthcare JV (including Shionogi preferential dividends)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ViiV Healthcare put options and Pfizer preferential dividends</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Novartis Vaccines business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transaction-related items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Full reconciliations between Total and Adjusted results for 2021 and 2020 are set out on pages 12 and 13 above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">Non-controlling</span> interests in ViiV Healthcare </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Trading profit allocations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As ViiV Healthcare is a subsidiary of the Group, 100% of its operating results (turnover, operating profit, profit after tax) are included within the Group income statement and then a portion of the earnings is allocated to the <span style="white-space:nowrap">non-controlling</span> interests owned by the other shareholders, in line with their respective equity shareholdings (Pfizer, Inc. (Pfizer) 11.7% and Shionogi&#160;&amp; Co. Ltd (Shionogi) 10%). Each of the shareholders, including GSK, is also entitled to preferential dividends determined by the performance of certain products that each shareholder contributed. As the relative performance of these products changes over time, the proportion of the overall earnings allocated to each shareholder also changes. In particular, the increasing proportion of sales of dolutegravir and cabotegravir-containing products has a favourable impact on the proportion of the preferential dividends that is allocated to GSK. Adjusting items are allocated to shareholders based on their equity interests. GSK was entitled to approximately 86% of the Total earnings and 83% of the Adjusted earnings of ViiV Healthcare for 2021. Remeasurements of the liabilities for the preferential dividends allocated to Pfizer and Shionogi are included within other operating income/(expense). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Acquisition-related arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As consideration for the acquisition of Shionogi&#8217;s interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi received the 10% equity stake in ViiV Healthcare and ViiV Healthcare also agreed to pay additional future cash consideration to Shionogi, contingent on the future sales performance of the products being developed by that joint venture, dolutegravir and cabotegravir. Under IFRS 3 &#8216;Business combinations&#8217;, GSK was required to provide for the estimated fair value of this contingent consideration at the time of acquisition and is required to update the liability to the latest estimate of fair value at each subsequent period end. The liability for the contingent consideration recognised in the balance sheet at the date of acquisition was &#163;659&#160;million. Subsequent <span style="white-space:nowrap">re-measurements</span> are reflected within other operating income/(expense) and within Adjusting items in the income statement in each period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash payments to settle the contingent consideration are made to Shionogi by ViiV Healthcare each quarter, based on the actual sales performance and other income of the relevant products in the previous quarter. These payments reduce the balance sheet liability and hence are not recorded in the income statement. The cash payments made to Shionogi by ViiV Healthcare in 2021 were &#163;826 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The cash payments are reflected in the cash flow statement partly in operating cash flows and partly within investing activities. The tax relief on these payments is reflected in the Group&#8217;s Adjusting items as part of the tax charge. The part of each payment relating to the original estimate of the fair value of the contingent consideration on the acquisition of the Shionogi-ViiV Healthcare joint venture in 2012 of &#163;659&#160;million is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition is reported within operating cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Movements in contingent consideration payable to Shionogi were as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration at beginning of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement through income statement and other movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash payments: operating cash flows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash payments: investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(107</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration at end of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Of the contingent consideration payable (on a <span style="white-space:nowrap">post-tax</span> basis) to Shionogi at 31&#160;December 2021, &#163;937&#160;million (31&#160;December 2020: &#163;745 million) is expected to be paid within one year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Exit rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. Under the original agreements, GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Pfizer put option and, as a result, in accordance with IFRS, GSK did not recognise a liability for the put option on its balance sheet. However, during Q1 2016, GSK notified Pfizer that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;1,070&#160;million. Consistent with this revised treatment, at the end of Q1 2016 GSK also recognised liabilities for the future preferential dividends anticipated to become payable to Pfizer and Shionogi on the Group&#8217;s balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pfizer has the right to require GSK to acquire its shareholding in ViiV Healthcare in certain circumstances at any time. A put option liability is therefore recorded on the Group&#8217;s balance sheet as a current liability. It is measured on the gross redemption basis derived from an internal valuation of the ViiV Healthcare business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The closing balances of the liabilities related to Pfizer&#8217;s shareholding are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:86%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pfizer put option</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pfizer preferential dividend</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the original agreements, Shionogi could also have requested GSK to acquire its shareholding in ViiV Healthcare in <span style="white-space:nowrap">six-month</span> windows commencing in 2017, 2020 and 2022. GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Shionogi put option and, as a result, GSK did not recognise a liability for the put option on its balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">However, during Q1 2016, GSK notified Shionogi that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;926&#160;million. In Q4 2016, Shionogi irrevocably agreed to waive its put option and as a result GSK <span style="white-space:nowrap">de-recognised</span> the liability for this put option on the Group&#8217;s balance sheet directly to equity. The value of the liability was &#163;1,244&#160;million when it was <span style="white-space:nowrap">de-recognised.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK also has a call option over Shionogi&#8217;s shareholding in ViiV Healthcare, which under the original agreements was exercisable in <span style="white-space:nowrap">six-month</span> windows commencing in 2027, 2030 and 2032. GSK has now irrevocably agreed to waive the first two exercise windows, but the last <span style="white-space:nowrap">six-month</span> window in 2032 remains. As this call option is at fair value, it has no value for accounting purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Settlement with Gilead </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy. Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion to ViiV Healthcare in February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir- containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027. Gilead&#8217;s obligation to pay royalties does not extend into any period of regulatory paediatric exclusivity, if awarded. The settlement resulted in a <span style="white-space:nowrap">re-</span> measurement of the existing liabilities for contingent consideration and the Pfizer put option at the 2021 year end. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The impact of the settlement with Gilead on the contingent consideration liability (CCL)&#160;was to increase it by &#163;288&#160;million, on a <span style="white-space:nowrap">post-tax</span> basis in Q4 2021 due to the obligation ViiV Healthcare has to pay future cash consideration to Shionogi for its share of the upfront and of the future US sales performance of Biktarvy and products containing bictegravir. Including the impact of the settlement at 31&#160;December 2021, the liability which is discounted at 8% stood at &#163;5,559&#160;million, on a <span style="white-space:nowrap">post-tax</span> basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The impact of the settlement on the Pfizer put option liability was an increase of &#163;114&#160;million and was included in the <span style="white-space:nowrap">re-measurement</span> at 31&#160;December 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Reporting definitions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Reporting definitions are set out on pages 20 and 21 above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"><span style="font-style:italic">Group turnover</span></span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Specialty Medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General Medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consumer Healthcare<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Sales of products outside the perimeter of the Consumer Healthcare business related to sale of shares to Hindustan Unilever. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Group turnover was &#163;24,696&#160;million in 2021, up 1% at AER, 6% at CER compared to 2020. In 2021 sales of <span style="white-space:nowrap">COVID-19</span> solutions contributed growth of 6% at AER and 6% CER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Specialty Medicines turnover in the year was &#163;8,251&#160;million, up 18% AER, 25% CER. Sales of <span style="font-style:italic">Xevudy</span>, the monoclonal antibody treatment for <span style="white-space:nowrap">COVID-19</span> of &#163;958&#160;million contributed approximately 15 percentage points to Specialty Medicines growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccines turnover in the year decreased 3% at AER but grew 2% at CER to &#163;6,778&#160;million, primarily driven by pandemic adjuvant sales, partially offset by foreign exchange and lower demand for routine adult vaccination due to <span style="white-space:nowrap">COVID-19</span> vaccination programme deployment and disease circulation across regions, resulting in lower <span style="font-style:italic">Shingrix </span>and Hepatitis vaccines sales. Unfavourable US prior period RAR adjustments reduced overall Vaccines growth by approximately 2 percentage points, particularly in <span style="font-style:italic">Fluarix/ FluLaval </span>and <span style="font-style:italic">Shingrix </span>where the impact on product growth was a decrease of 7% and a decrease of 2% respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of pandemic adjuvant contributed 6% at AER, 7% at CER. Excluding these sales Vaccines turnover decreased 9% AER, 5% CER to &#163;6,331&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">General Medicines in the year decreased 6% at AER and 3% at CER to &#163;9,667&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Commercial Operations Innovation sales (sales of products launched in the last five years including lifecycle innovation) amounted to &#163;6,841&#160;million (excluding <span style="white-space:nowrap">COVID-19</span> solutions) in 2021 largely driven by sales of <span style="font-style:italic">Shingrix, Trelegy, Nucala, Benlysta, Dovato, Juluca, and Zejula.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Specialty Medicines turnover </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">HIV</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Oncology</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Immuno-inflammation, respiratory and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pandemic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Specialty medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">2021 and 2020 have been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">HIV </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">HIV sales were &#163;4,777&#160;million a decrease of 2% AER but growth of 3% CER for the year. <span style="font-style:italic">Triumeq </span>sales were &#163;1,882&#160;million, down 18% AER, 14% CER and <span style="font-style:italic">Tivicay </span>sales were &#163;1,381&#160;million, down 10% AER, 4% CER. The mature portfolio resulted in less than 1 percentage point of CER sales decrease. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">New HIV products <span style="font-style:italic">Juluca</span>, <span style="font-style:italic">Dovato</span>, <span style="font-style:italic">Rukobia </span>and <span style="font-style:italic">Cabenuva </span>delivered sales of &#163;1,387&#160;million representing 29% of the total HIV portfolio (18% in 2020). Sales of the two drug regimens <span style="font-style:italic">Juluca </span>and <span style="font-style:italic">Dovato </span>were &#163;517&#160;million and &#163;787&#160;million, respectively, with combined growth of 50% AER, 58% CER. <span style="font-style:italic">Rukobia </span>sales were &#163;45&#160;million. <span style="font-style:italic">Cabenuva</span>, the first long acting injectable, recorded &#163;38&#160;million of sales for the full year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the US, total sales were &#163;2,898&#160;million with a decrease of 4% AER, but growth of 3% CER. New HIV products delivered sales of &#163;896&#160;million, including: <span style="font-style:italic">Dovato </span>&#163;428&#160;million with growth of 87% AER, 99% CER, <span style="font-style:italic">Juluca </span>&#163;393&#160;million with growth of 2% AER, 8% CER, <span style="font-style:italic">Rukobia </span>&#163;43&#160;million and <span style="font-style:italic">Cabenuva </span>&#163;32&#160;million. Combined <span style="font-style:italic">Tivicay </span>and <span style="font-style:italic">Triumeq </span>sales were &#163;1,953&#160;million declining 16% AER, 11% CER. In Europe, total sales were &#163;1,194&#160;million with a decrease of 2% AER, but growth of 1% CER. New HIV products delivered sales of &#163;420&#160;million, including: Dovato sales of &#163;302&#160;million, which more than doubled at AER and CER, and <span style="font-style:italic">Juluca </span>&#163;111&#160;million with growth of 14% AER, 18% CER. Combined <span style="font-style:italic">Tivicay </span>and <span style="font-style:italic">Triumeq </span>sales were &#163;738&#160;million declining 21% AER, 19% CER. International continued to grow strongly with total sales of &#163;685&#160;million, with growth of 4% AER, 11% CER, driven by the <span style="font-style:italic">Tivicay </span>tender business and new HIV products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Oncology </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of <span style="font-style:italic">Zejula</span>, the PARP inhibitor treatment for ovarian cancer were &#163;395&#160;million, up 17% AER, 22% CER, impacted by ongoing lower diagnosis rates due to the <span style="white-space:nowrap">COVID-19</span> pandemic, particularly in the US. Sales included &#163;212&#160;million in the US and &#163;163&#160;million in Europe. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Blenrep </span>for the treatment of patients with relapsed or refractory multiple myeloma was approved and launched in the US and Europe in Q3 2020, with ongoing launches throughout Europe in 2021. <span style="font-style:italic">Blenrep </span>sales globally totalled &#163;89&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Immuno-inflammation, respiratory and other </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Immuno-inflammation, respiratory and other sales were &#163;2,027&#160;million, up 18% AER, 25% CER with <span style="font-style:italic">Benlysta </span>sales up 22% AER, 29% CER to &#163;874&#160;million, benefitting from lupus nephritis launches in US and Japan in H2 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of <span style="font-style:italic">Nucala </span>were &#163;1,142&#160;million in the year and grew 15% AER, 22% CER, with consistent, strong growth across all three regions. US sales were up 15% AER, 23% CER to &#163;690&#160;million and International sales of &#163;195&#160;million grew 23% AER, 34% CER. Europe sales of &#163;257&#160;million grew 8% AER, 11% CER. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Pandemic sales </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of Xevudy were &#163;958&#160;million in the year, reflecting the ongoing fulfilment of contracts across the world and most significantly in the US, which reported sales of &#163;602&#160;million. International recorded sales of &#163;287&#160;million and Europe &#163;69&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vaccines turnover </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Meningitis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Influenza</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shingles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Established Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pandemic Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vaccines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Meningitis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Meningitis sales decreased 7% AER, 2% CER to &#163;961&#160;million driven primarily by unrepeated International tender volumes for other meningitis vaccines. <span style="font-style:italic">Bexsero </span>sales were stable at AER, but grew 5% CER to &#163;650&#160;million, reflecting increased market share in the US. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Menveo </span>sales were up 3% AER, 9% CER to &#163;272&#160;million, primarily driven by 2020 cohort <span style="white-space:nowrap">catch-up</span> vaccinations and 2021 higher demand, as well as increased market share in the US. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Influenza </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Fluarix/FluLaval sales decreased 7% AER, 2% CER, to &#163;679&#160;million as a result of unfavourable prior period RAR movements in the US, partially offset by higher volume in the US and strong southern hemisphere demand in International. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Shingles </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Shingrix</span> decreased 13% AER, 9% CER to &#163;1,721&#160;million, primarily driven by lower demand in the US and International for routine adult vaccination due to <span style="white-space:nowrap">COVID-19</span> vaccination programme deployment and disease circulation. In Europe, sales growth was driven by Germany and launches in the UK, Spain and Italy. Shingrix was sold in 17 countries, including 9 markets launched during 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Established Vaccines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Hepatitis vaccines sales were down 20% AER, 16% CER to &#163;460&#160;million, adversely impacted by <span style="white-space:nowrap">de-prioritisation</span> of routine US adult vaccinations, increased Hepatitis B vaccine competition and unfavourable CDC stockpile movements in the US, and by <span style="white-space:nowrap">COVID-19</span> related travel restrictions in Europe and International. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of DTPa-containing vaccines (<span style="font-style:italic">Infanrix</span>, <span style="font-style:italic">Pediarix </span>and <span style="font-style:italic">Boostrix</span>) decreased 4% AER but grew 1% CER. <span style="font-style:italic">Infanrix/ Pediarix </span>sales decreased 14% AER, 9% CER to &#163;543&#160;million, reflecting lower tender volume in Europe and International as well as a change in recommendation for the dosing schedule in Germany, partly offset by increased demand in the US. <span style="font-style:italic">Boostrix </span>sales grew 9% AER, 14% CER to &#163;521&#160;million, largely driven by demand recovery and tender volumes in International, as well as higher demand and share in the US. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Rotarix </span>sales were down 3% AER but up 1% CER to &#163;541&#160;million, reflecting demand recovery in International and foreign exchange impacts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Synflorix </span>sales decreased by 11% AER, 8% CER to &#163;357&#160;million, primarily due to lower tender demand in Emerging markets. MMRV vaccines sales were stable at AER but grew 4% CER to &#163;260&#160;million, largely driven by higher demand in International. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Pandemic Vaccines</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pandemic vaccines sales of &#163;447&#160;million included &#163;444&#160;million of pandemic adjuvant sales to the US and Canadian governments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">General Medicines turnover</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />(revised)<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Respiratory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other general medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below) </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">2021 and 2020 have been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Respiratory </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total Respiratory sales were up 1% AER, 6% CER. The performance was driven by <span style="font-style:italic">Trelegy </span>sales of &#163;1,217&#160;million up 49% AER, 57% CER driven by growth in all regions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Advair/Seretide sales of &#163;1,357&#160;million continued to be eroded by generic competition, decreasing by 12% at AER, 7% at CER. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other general medicines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Other General Medicines sales were &#163;3,619&#160;million, down 15% at AER and 15% at CER primarily driven by a decline in Augmentin at 13% AER and 7% CER due to lower demand for antibiotics during the <span style="white-space:nowrap">COVID-19</span> Pandemic period. <span style="font-style:italic">Avodart</span> which declined 19% at AER and 25% at CER due to loss of exclusivity in Japan and Europe and the divestment of GSK&#8217;s cephalosporin products in Q4 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Turnover by regions</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">US </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the US, sales were &#163;11,914&#160;million, up 7% at AER, 14% at CER. Sales of <span style="font-style:italic">Xevudy</span> were &#163;602&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Europe </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In Europe, sales were &#163;5,370&#160;million, down 3% at AER, 1% at CER. Sales of <span style="font-style:italic">Xevudy</span> were &#163;69&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">International </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">International sales were &#163;7,412&#160;million, down 3% at AER, up 2% at CER. Sales of<span style="font-style:italic"> Xevudy</span> were &#163;287&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Cost of sales </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6,672</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:8%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cost of sales as a percentage of turnover was 33.1%, 0.5 percentage points higher at AER than 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted cost of sales as a percentage of turnover was 29.7%, 2.3 percentage points higher at AER compared with 2020. This primarily reflected higher pandemic sales (<span style="font-style:italic">Xevudy</span>) as well as higher supply chain costs in Vaccines resulting from lower demand and higher inventory adjustments, partly offset by price benefits, including the benefit from prior period RAR adjustments, a further contribution from restructuring savings across the business and favourable mix in Vaccines. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Selling, general and administration </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:8%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total SG&amp;A costs as a percentage of turnover were 28.6%, 1.9 percentage points lower at AER compared to 2020. This included a reduction in restructuring charges. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted SG&amp;A costs as a percentage of turnover were 27.3%, 1.5 percentage points lower at AER than in 2020. Adjusted SG&amp;A costs decreased 4% at AER which reflected the tight control of ongoing costs and reduced variable spending across all three businesses as a result of the <span style="white-space:nowrap">COVID-19</span> lockdowns, and the continuing benefit of restructuring in Commercial Operations and support functions. The decrease also reflected a favourable legal settlement in 2021 compared to increased legal costs in 2020 as well as <span style="white-space:nowrap">one-off</span> benefits in pensions and insurance which were partly offset by the <span style="white-space:nowrap">one-off</span> benefit from restructuring of post- retirement benefits in 2020. This was partly offset by increased investment behind launches in HIV and Vaccines. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Research and development </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:77%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Growth<br />&#163;%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(4,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:8%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total R&amp;D expenditure was &#163;5,019&#160;million up 5% at AER including an increase in impairments partly offset by a decrease in major restructuring charges. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted R&amp;D expenditure increased by 5% at AER to &#163;4,525&#160;million (18.3% of turnover), up 4% at AER, primarily driven by increased investment in our Specialty portfolios, including the early stage research projects. Efficiency savings continued from the implementation of the One R&amp;D programme for Research and Development as part of the Separation preparation restructuring programme. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The growth of the Specialty portfolio in 2021 was primarily driven by our two programmes for <span style="white-space:nowrap">COVID-19</span> treatment (Xevudy and otilimab) along with the other otilimab programme for rheumatoid arthritis, bepirovirsen, our HBV antisense oligonucleotide and depemokimab, our <span style="white-space:nowrap">anti-IL5</span> for asthma. This has been partly offset by reduced spend on daprodustat due to the completion of programmes. In Oncology, there is continued investment reflecting our commitment to synthetic lethality and in Blenrep, together with bintrafusp alfa, where we have accelerated <span style="white-space:nowrap">close-out</span> costs for the programme but this has been largely offset by a reduction in spend on feladilimab following the decision to terminate the programme in April. Vaccines increased investment in clinical programmes for meningitis and RSV and investment in our mRNA platform, partly offset by efficiency savings from the implementation of the One Development programme and variable spending as a result of <span style="white-space:nowrap">COVID-19</span> lockdowns. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Royalty income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Royalty income was &#163;417&#160;million (2020: &#163;321 million), up 30% AER primarily driven by higher sales of Gardasil. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Other operating income/(expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Net other operating expenses of &#163;504&#160;million (2020: &#163;1,463&#160;million income) primarily reflected accounting charges of &#163;1,101&#160;million (2020: &#163;1,234 million) arising from the <span style="white-space:nowrap">re-measurement</span> of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. This included a <span style="white-space:nowrap">re-measurement</span> charge of &#163;1,026&#160;million (2020: &#163;1,114 million) for the contingent consideration liability due to Shionogi, as a result of the unwinding of the discount for &#163;380&#160;million and a charge for &#163;646&#160;million primarily from adjustments to sales forecasts and the settlement with Gilead (see &#8220;Settlement with Gilead Sciences Inc. (Gilead)&#8221; above). This was partly offset by a number of asset disposals including the disposal of royalty rights on cabozantinib, the disposal of the cephalosporin business and fair value uplifts on investments. 2020 included the net profit on disposal of Horlicks and other Consumer Healthcare brands of &#163;2,815&#160;million, partly offset by the related loss on sale of the shares in Hindustan Unilever of &#163;476&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Operating profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total operating profit was &#163;4,357&#160;million compared with &#163;5,979&#160;million in 2020. This primarily reflected an unfavourable comparison to the net profit on disposal in Q2 2020 of Horlicks and other Consumer brands and resultant sale of shares in Hindustan Unilever. This was partly offset by lower major restructuring costs and lower <span style="white-space:nowrap">re-measurement</span> charges on the contingent consideration liabilities. Total operating margin was 17.6%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Excluding these and other Adjusting items, Adjusted operating profit was &#163;6,493&#160;million, 2% lower than 2020 at AER, on a turnover increase of 1% AER. The Adjusted operating margin of 26.3% was 1.0 percentage points lower at AER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The decrease in Adjusted operating profit reflected foreign exchange, lower sales in Vaccines, primarily <span style="font-style:italic">Shingrix</span>, higher supply chain costs in Vaccines and increased investment in R&amp;D across Vaccines and Specialty Medicines. This was partially offset by the benefit from incremental pandemic sales (<span style="font-style:italic">Xevudy </span>and adjuvant) contributing approximately 9% AER to Adjusted Operating profit growth. Adjusted Operating profit also benefited from sales growth in Commercial Operations including the benefit from prior period RAR adjustments and tight control of ongoing costs including reduced promotional and variable spending across all the business as a result of the <span style="white-space:nowrap">COVID-19</span> lockdowns, favourable legal settlements compared to increased legal costs in 2020 and benefits from continued restructuring across the business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Contingent consideration cash payments which are made to Shionogi and other companies reduce the balance sheet liability and hence are not recorded in the income statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total contingent consideration cash payments in 2021 amounted to &#163;856&#160;million (2020: &#163;885 million). This included cash payments made to Shionogi of &#163;826&#160;million (2020: &#163;858 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Adjusted operating profit by business </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Commercial Operations operating profit was &#163;11,467&#160;million, up 2% AER on a turnover increase of 2% AER. The operating margin of 46.4% was 0.2 percentage points lower at AER than in 2020. This primarily reflected price benefits in Commercial Operations, including the benefit from a prior period RAR adjustment, the tight control of ongoing costs, short term benefits to changes in ways of working, a favourable legal settlement in 2021 compared to increased legal costs in 2020, increased royalty income and the continuing benefit of restructuring. This was partly offset by support to launches in HIV and Vaccines and higher supply chain costs in Vaccines. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Research and Development operating expenses were &#163;4,567&#160;million, up 4% AER primarily driven by increased investment in our Specialty portfolios, including the early stage research projects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Net finance costs </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL">Finance income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(735</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(813</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unwinding of discounts on provisions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurements and fair value movements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Finance expense on lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other finance expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(769</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total net finance costs were &#163;755&#160;million compared with &#163;842&#160;million in 2020. Adjusted net finance costs were &#163;752&#160;million compared with &#163;838&#160;million in 2020. The decrease is primarily as a result of reduced interest expense from lower debt levels, favourable movements in foreign exchange rates, a premium paid on the early repayment and refinancing of bond debt in 2020 and reduced interest on tax partly offset by lower interest income on overseas cash post-closing of the divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"></span><span style="font-style:italic">Share of after tax profits of associates and joint ventures</span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The share of after tax profits of associates and joint ventures was &#163;33&#160;million (2020 &#8211; &#163;33 million). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Loss on disposal of interest in associates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The net loss on disposal of interests in associates was &#163;36&#160;million, primarily driven by a loss on disposal of our interest in the associate Innoviva Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Profit before tax </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Taking account of net finance costs, the share of profits of associates and loss on disposal of interest in associates, profit before taxation was &#163;3,599&#160;million compared with &#163;5,170&#160;million in 2020. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Taxation </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">UK current year charge</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Rest of world current year charge</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Charge/(credit) in respect of prior periods</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred taxation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(848</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Taxation on total profits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The charge of &#163;83&#160;million represented an effective tax rate on Total results of 2.3% (2020: 1.3%) and reflected the different tax effects of the various Adjusting items, including a credit of &#163;430&#160;million resulting from the revaluation of deferred tax assets following enactment of an increase in the headline rate of UK corporation tax (effective 1&#160;April 2023). 2020 reflected the disposal of Horlicks and other Consumer brands and the subsequent disposal of shares received in Hindustan Unilever. Tax on Adjusted profit amounted to &#163;918&#160;million and represented an effective Adjusted tax rate of 15.9% (2020: 13.9%). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Issues related to taxation are described in Note 14 to the financial statements &#8216;Taxation&#8217; incorporated by reference in Item 18 below. The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods which are open and not yet agreed by tax authorities. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"><span style="white-space:nowrap">Non-controlling</span> interests </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The allocation of Total earnings to <span style="white-space:nowrap">non-controlling</span> interests amounted to &#163;200&#160;million (2020: &#163;230 million). Allocation of ViiV Healthcare profits was &#163;196&#160;million (2020: &#163;223 million), including reduced credits for <span style="white-space:nowrap">re-measurement</span> of contingent consideration liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The allocation of Adjusted earnings to <span style="white-space:nowrap">non-controlling</span> interests amounted to &#163;441&#160;million (2020: &#163;481 million). The reduction in allocation primarily reflected a reduced allocation of ViiV Healthcare profits of &#163;438&#160;million (2020: &#163;474 million), partly offset by higher net profits in some of the Group&#8217;s other entities with <span style="white-space:nowrap">non-controlling</span> interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Earnings per share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total EPS from continuing operations was 82.9p compared with 122.4p in 2020. This primarily reflected an unfavourable comparison to the net profit on disposal in Q2 2020 of Horlicks and other Consumer Healthcare brands partly offset by the related loss on sale of the shares in Hindustan Unilever, partly offset by a credit of &#163;430&#160;million to Taxation in 2021 resulting from the revaluation of deferred tax assets following enactment of an increase in the headline rate of UK corporation tax (effective 1&#160;April 2023), lower major restructuring costs and lower remeasurement charges on the contingent consideration liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Adjusted EPS was 110.3p compared with 114.4p in 2020, down 4% AER primarily reflecting foreign exchange, lower sales in Vaccines, primarily <span style="font-style:italic">Shingrix</span>, higher supply chain costs in Vaccines, increased R&amp;D investment and a higher effective tax rate. This was offset by incremental pandemic sales, sales increases in Pharmaceuticals, tight cost control and favourable legal settlements and lower interest costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Major restructuring and integration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long life cycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;D sites are likely to take several years to complete. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Major restructuring costs are those related to specific Board-approved Major restructuring programmes and are excluded from Adjusted results. Major restructuring programmes, including integration costs following material acquisitions, are those that are structural and are of a significant scale where the costs of individual or related projects exceed &#163;25&#160;million. Other ordinary course smaller-scale restructuring costs are retained within Total and Adjusted results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total Major restructuring charges incurred in 2021 were &#163;424&#160;million (2020 &#8211; &#163;1,178 million), analysed as follows </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-</span><br />cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-</span><br />cash<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Separation preparation restructuring programme</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legacy programmes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash charges of &#163;353&#160;million under the Separation Preparation programme primarily arose from restructuring of some administrative functions as well as Global Supply chain, R&amp;D functions and Commercial. The <span style="white-space:nowrap">non-cash</span> charges of &#163;59&#160;million primarily reflected write-down of assets in administrative locations and R&amp;D sites. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cash payments made in 2021 were &#163;551&#160;million (2020: &#163;435 million), &#163;428&#160;million (2020: &#163;152 million) relating to the Separation Preparation restructuring programme, &#163;123&#160;million (2020: &#163;256 million) relating to other legacy programmes including the settlement of certain charges accrued in previous quarters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The analysis of Major restructuring charges by income statement line was as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:81%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Major restructuring costs from continuing operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:16%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The benefit in the 2021 from restructuring programmes was &#163;0.7&#160;billion, the benefit from the Separation Preparation restructuring programme was &#163;0.3&#160;billion and the benefit from the 2018 Restructuring programme was &#163;0.2&#160;billion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group initiated in Q1 2020 a <span style="white-space:nowrap">two-year</span> Separation Preparation programme to prepare for the separation of GSK into two companies: new GSK, a biopharma company with an R&amp;D approach focused on science related to the immune system, the use of genetics and new technologies, and a new leader in Consumer Healthcare. The programme aimed to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Drive a common approach to R&amp;D with improved capital allocation </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Align and improve the capabilities and efficiency of global support functions to support new GSK </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Further optimise the supply chain and product portfolio, including the divestment of <span style="white-space:nowrap">non-core</span> assets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">A strategic review of prescription dermatology is underway </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Prepare Consumer Healthcare to operate as a standalone company </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Legacy programmes included the 2018 major restructuring programme, including Tesaro, which cost &#163;1.5&#160;billion to the end of 2021, with cash costs of &#163;0.6&#160;billion and <span style="white-space:nowrap">non-cash</span> costs of &#163;0.9&#160;billion, and has delivered annual savings of around &#163;0.5&#160;billion by the end of 2021 (at 2019 rates). These savings were fully <span style="white-space:nowrap">re-invested</span> to help fund targeted increases in R&amp;D and commercial support of new products. The programme is substantially complete. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Transaction-related adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Transaction-related adjustments resulted in a net charge of &#163;1,143&#160;million (2020: &#163;1,237 million). This included a net &#163;1,101&#160;million accounting charge for the <span style="white-space:nowrap">re-measurement</span> of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL">Charge/(credit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Shionogi-ViiV Healthcare Joint Venture (including Shionogi preferential dividends)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ViiV Healthcare put options and Pfizer preferential dividends</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration on former Novartis Vaccines business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total transaction-related charges</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The &#163;1,026&#160;million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi, as a result of the unwind of the discount for &#163;380&#160;million and a charge of &#163;646&#160;million primarily from adjustments to sales forecasts and the settlement with Gilead as well as updated exchange rate assumptions. The &#163;48&#160;million charge relating to the ViiV Healthcare put option and Pfizer preferential dividends represented an increase in the valuation of the put option as a result of the settlement with Gilead, offset by lower cash and updated exchange rate assumptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">An explanation of the accounting for the <span style="white-space:nowrap">non-controlling</span> interests in ViiV Healthcare is set out above under &#8220;Reporting framework&#8221;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Divestments, significant legal charges and other items </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Divestments and other items also included gains from a number of asset disposals, including the disposal of royalty rights on cabozantinib, disposal of the cephalosporins business, fair value gains on investments and certain other Adjusting items, including the impact of the enactment of the increase in the headline rate of UK Corporate tax as discussed in &#8220;Note 14&#8212;Taxation&#8221; to the financial statements incorporated by reference in Item 18 below. In 2021 the net loss on disposal of interests in associates was &#163;36&#160;million, primarily driven by a loss on disposal of the interest in the associate Innoviva Inc. A charge of &#163;35&#160;million (2020: &#163;7 million) was recorded for significant legal matters arising in 2021. Significant legal cash payments were &#163;5&#160;million (2020: &#163;9 million). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Cash generation and conversion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A summary of the consolidated cash flow statement is set out below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:80%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash inflow from operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash (outflow) from investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total net cash inflow/(outflow) from financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(7,589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(10,132</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">(Increase)/Decrease in cash and bank overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,414</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at beginning of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exchange adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in cash and bank overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,414</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at end of year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and bank overdrafts at end of year comprise:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Overdrafts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(455</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The net cash inflow from operating activities for the year was &#163;7,952&#160;million (2020: &#163;8,441 million). The decrease primarily reflected , increased trade receivables, adverse timing of RAR, , a reduction in cash from discontinued operations including increased separation costs and reduced adjusted operating profit at AER partly offset by reduced tax payments including tax on disposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Reconciliation of net cash inflow from continuing operating activities to free cash inflow </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A reconciliation of net cash inflow from operating activities, which is the closest equivalent IFRS measure to free cash flow, is shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash inflow from continuing operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchase of property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(950</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(989</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchase of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,704</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(956</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from sale of property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from sale of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(758</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(824</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividends from joint ventures and associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contingent consideration paid (reported in investing activities)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(114</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(120</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Contribution from <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Distributions to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(442</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Free cash inflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 and 2020 results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Capital expenditure and financial investment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cash payments for tangible and intangible fixed assets amounted to &#163;2,654&#160;million (2020: &#163;1,945 million) and disposals realised &#163;773&#160;million (2020: &#163;392 million). Cash payments to acquire equity investments amounted to &#163;162&#160;million (2020: &#163;411 million), primarily relating to Vir Biotechnology, and sales of equity investments realised &#163;202&#160;million (2020: &#163;3,269 million). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Free cash flow </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Free cash flow is the amount of cash generated by the Group after meeting our obligations for contingent consideration, interest, tax and dividends paid to <span style="white-space:nowrap">non-controlling</span> interests, and after capital expenditure on property, plant and equipment and intangible assets. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:84%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020<sup style="font-size:75%; vertical-align:top">(1)</sup><br />&#163;m</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Free cash inflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:12%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see &#8220;Note 41 &#8211; Acquisitions and Disposals&#8221; to the financial statements incorporated by reference in Item 18 below). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Total cash payments to Shionogi in relation to the ViiV Healthcare contingent consideration liability in the year were &#163;826&#160;million (2020: &#163;858 million), of which &#163;721&#160;million was recognised in cash flows from operating activities and &#163;105&#160;million was recognised in contingent consideration paid within investing cash flows. These payments are deductible for tax purposes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Treasury policies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We report in Sterling and pay dividends out of Sterling cash flows. The role of Treasury is to monitor and manage the Group&#8217;s external and internal funding requirements and financial risks in support of our strategic objectives. GSK operates on a global basis, primarily through subsidiary companies, and we manage our capital to ensure that our subsidiaries are able to operate as going concerns and to optimise returns to shareholders through an appropriate balance of debt and equity. Treasury activities are governed by policies approved annually by the Board of Directors, and most recently on 12&#160;October 2022. A Treasury Management Group (TMG) meeting, chaired by our Chief Financial Officer, takes place on a regular basis to review Treasury activities. Its members receive management information relating to these activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Treasury operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The objective of GSK&#8217;s Treasury activities is to minimise the <span style="white-space:nowrap">post-tax</span> net cost of financial operations and reduce its volatility in order to benefit earnings and cash flows. GSK uses a variety of financial instruments to finance its operations and derivative financial instruments to manage market risks from these operations. Derivatives principally comprise foreign exchange forward contracts and swaps which are used to swap borrowings and liquid assets into currencies required for Group purposes, as well as interest rate swaps which are used to manage exposure to financial risks from changes in interest rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Derivatives are used exclusively for hedging purposes in relation to underlying business activities and not as trading or speculative instruments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Capital management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s financial strategy, implemented through the Group&#8217;s financial architecture, supports GSK&#8217;s strategic priorities and is regularly reviewed by the Board. We manage the capital structure of the Group through an appropriate mix of debt and equity. We continue to manage our financial policies to a credit profile that particularly targets short-term credit ratings of <span style="white-space:nowrap">A-1</span> and <span style="white-space:nowrap">P-1</span> while maintaining single A long-term ratings consistent with those targets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Liquidity risk management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s policy is to borrow centrally in order to meet anticipated funding requirements. Our cash flow forecasts and funding requirements are monitored by the TMG on a regular basis. Our strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each day, we sweep cash to or from number of global subsidiaries to central Treasury accounts for liquidity management purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Interest rate risk management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating interest rates over time. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Foreign exchange risk management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our objective is to minimise the exposure of overseas operating subsidiaries to transaction risk by matching local currency income with local currency costs where possible. Foreign currency transaction exposures arising on external and internal trade flows are selectively hedged. GSK&#8217;s internal trading transactions are matched centrally and we manage inter-company payment terms to reduce foreign currency risk. Where possible, we manage the cash surpluses or borrowing requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating currency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In order to reduce foreign currency translation exposure, we seek to denominate borrowings in the currencies of our principal assets and cash flows. These are primarily denominated in US Dollars, Euros and Sterling. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Borrowings can be swapped into other currencies as required. Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated as a hedge against the relevant assets. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Forward contracts in major currencies are also used to reduce exposure to the Group&#8217;s investment in overseas Group assets. The TMG reviews the ratio of borrowings to assets for major currencies regularly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Commodity risk management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our objective is to minimise income statement volatility arising from fluctuations in commodity prices, where practical and cost effective to do so. The TMG is authorised to approve the execution of certain financial derivatives to hedge commodity price exposures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Counterparty risk management </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We set global counterparty limits for each of our banking and investment counterparties based on long-term credit ratings from Moody&#8217;s and Standard and Poor&#8217;s. Usage of these limits is actively monitored and any breach of these limits would be reported to the Chief Financial Officer immediately. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, relationship banks and their credit ratings are reviewed regularly so that, when changes in ratings occur, changes can be made to investment levels or to authority limits as appropriate. All banking counterparty limits are reviewed at least annually. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Critical accounting policies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group consolidated financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The critical accounting policies relate to the following areas: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Turnover (Note 6) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Taxation (Note 14) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Legal and other disputes (Notes 47 and 32) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Contingent liabilities (Note 35) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Pensions and other post-employment benefits (Note 31). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Information on the judgements and estimates made in these areas is given in &#8220;Note 3 &#8211; Critical accounting judgements and key sources of estimation uncertainty&#8221; to the financial statements incorporated by reference in Item 18 below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Turnover </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In respect of the Turnover accounting policy, our largest business is US Commercial Operations, and the US market has the most complex arrangements for rebates, discounts and allowances. The following briefly describes the nature of the arrangements in existence in our US Commercial Operations: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">We have arrangements with certain indirect customers whereby the customer is able to buy products from wholesalers at reduced prices. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer&#8217;s contractual discounted price. Accruals for estimating chargebacks are calculated based on the terms of each agreement, historical experience and product growth rates </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Customer rebates are offered to key managed care and Group Purchasing Organisations and other direct and indirect customers. These arrangements require the customer to achieve certain performance targets relating to the value of product purchased, formulary status or <span style="white-space:nowrap">pre-determined</span> market shares relative to competitors. The accrual for customer rebates is estimated based on the specific terms in each agreement, historical experience and product growth rates </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">The US Medicaid programme is a state-administered programme providing assistance to certain poor and vulnerable patients. In 1990, the Medicaid Drug Rebate Program was established to reduce state and federal expenditure on prescription drugs. In 2010, the Patient Protection and Affordable Care Act became law. We participate by providing rebates to states. Accruals for Medicaid rebates are calculated based on the specific terms of the relevant regulations or the Patient Protection and Affordable Care Act </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Cash discounts are offered to customers to encourage prompt payment. These are accrued for at the time of invoicing and adjusted subsequently to reflect actual experience </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">We record an accrual for estimated sales returns by applying historical experience of customer returns to the amounts invoiced, together with market-related information such as stock levels at wholesalers, anticipated price increases and competitor activity </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A reconciliation of gross turnover to net turnover for US Commercial Operations is as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Margin<br />%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Margin<br />%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">&#163;m</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Margin<br />%</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gross turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Market-driven segments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,275</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,875</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Government mandated and state programmes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,218</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash discounts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(453</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Customer returns</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(253</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prior year adjustments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(768</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(560</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deductions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,518</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,422</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net turnover</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The reconciliation has been revised to include Vaccines as part of US Commercial Operations in all years. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Market-driven segments consist primarily of managed care and Medicare plans with which we negotiate contract pricing that is honoured via rebates and chargebacks. Mandated segments consist primarily of Medicaid and federal government programmes which receive government- mandated pricing via rebates and chargebacks. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Overall sales deduction as a percentage of sales is consistent year over year with sales growth coming primarily from <span style="font-style:italic">Trelegy</span> and Specialty Products including ViiV. Deductions within the year were split approximately as follows: General Medicines 70%, Specialty Medicines 20% and Vaccines 10%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, the total accrual for rebates, discounts, allowances and returns for US Commercial Operations amounted to &#163;5,855&#160;million (2021: &#163;5,044 million). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A monthly process is operated to monitor inventory levels at wholesalers for any abnormal movements. This process uses gross sales volumes, prescription volumes based on third party data sources and information received from key wholesalers. The aim of this is to maintain inventories at a consistent level from year to year based on the pattern of consumption. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On this basis, US Commercial Operations inventory levels at wholesalers and in other distribution channels at 31&#160;December 2022 were estimated to amount to approximately four weeks of turnover. This calculation uses third party information, the accuracy of which cannot be totally verified, but is believed to be sufficiently reliable for this purpose. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Legal and other disputes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In respect of the accounting policy for Legal and other disputes, the following briefly describes the process by which we determine the level of provision that is necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In accordance with the requirements of IAS 37, &#8216;Provisions, contingent liabilities and contingent assets&#8217;, we provide for anticipated settlement costs where an outflow of resources is considered probable and a reliable estimate may be made of the likely outcome of the dispute and legal and other expenses arising from claims against the Group. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may become involved in significant legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, appropriate disclosure about such cases would be included in the Annual Report, but no provision would be made. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This position could change over time and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Like many pharmaceutical companies, we are faced with various complex product liability, anti-trust and patent litigation, as well as investigations of our operations conducted by various governmental regulatory agencies. Throughout the year, the General Counsel of the Group, as head of the Group&#8217;s legal function, and the Senior Vice President and Head of Global Litigation for the Group, who is responsible for all litigation and government investigations, routinely brief the Chief Executive Officer, the Chief Financial Officer and the Board of Directors on the significant litigation pending against the Group and governmental investigations of the Group. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These meetings, as appropriate, detail the status of significant litigation and government investigations and review matters such as the number of claims notified to us, information on potential claims not yet notified, assessment of the validity of claims, progress made in settling claims, recent settlement levels and potential reimbursement by insurers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The meetings also include an assessment of whether or not there is sufficient information available for us to be able to make a reliable estimate of the potential outcomes of the disputes. Often, external counsel assisting us with various litigation matters and investigations will also assist in the briefing of the Board and senior management. Following these discussions, for those matters where it is possible to make a reliable estimate of the amount of a provision, if any, that may be required, the level of provision for legal and other disputes is reviewed and adjusted as appropriate. These matters are discussed further in &#8220;Note 47 &#8211; Legal proceedings&#8221; to the financial statements incorporated by reference in Item 18 below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">5.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Liquidity and capital resources </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Note 44 &#8211; Financial instruments and related disclosures&#8221; on pages 245 to 261 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings &#8220;Cash generation and conversion,&#8221; &#8220;Financial position and resources&#8221; and &#8220;Treasury policies&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Note 27 &#8211; Cash and cash equivalents&#8221; on page 216 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The Group has, in its opinion, sufficient working capital to meet its present requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL;font-weight:bold">Liquidity sources in the short-term </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Liquidity risk management&#8221; on page 245 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL;font-weight:bold">Liquidity sources in the long-term </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Cash generation and conversion,&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL;font-weight:bold">Material Cash Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 30 &#8211; Net debt&#8221; on pages 218 and 219; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 36 &#8211; Commitments&#8221; on page 232 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Loans: </span>At 31&#160;December 2022 the Group had &#163;20.1&#160;billion of borrowings of which &#163;3.8&#160;billion was repayable within one year and &#163;16.3&#160;billion was payable after one year. Interest payable on these loans amounted to &#163;6.3&#160;billion of which &#163;0.6&#160;billion was payable within one year and &#163;5.7&#160;billion was payable after more than one year. Commitments in respect of loans and future interest payable on loans are disclosed before taking into account the effect of derivatives. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Intangible assets commitments: </span>At 31&#160;December 2022, the Group had intangible assets commitments of &#163;10.7&#160;billion. Of these, &#163;0.3&#160;billion fall due within one year and &#163;10.4&#160;billion fall due after more than one year. The commitments include milestone payments, which are dependent on successful clinical development or on meeting specified sales targets, and which represent the maximum that would be paid if all milestones, however unlikely, are achieved. The amounts are not risk-adjusted or discounted. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">We have entered into a number of research collaborations to develop new compounds with other pharmaceutical companies. The terms of these arrangements can include upfront fees, equity investments, loans and commitments to fund specified levels of research. In addition, we will often agree to make further payments if future &#8216;milestones&#8217; are achieved. As some of these agreements relate to compounds in the early stages of development, the potential obligation to make milestone payments will continue for a number of years if the compounds move successfully through the development process. Generally, the closer the product is to marketing approval, the greater the probability of success. The amounts shown above within intangible assets represent the maximum that would be paid if all milestones were achieved. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"><span style="font-style:italic">Finance Lease obligations: </span></span>At 31&#160;December 2022 the Group had &#163;1.0&#160;billion of finance lease obligation of which &#163;0.2&#160;billion was payable within one year and &#163;0.8&#160;billion was payable after one year. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"><span style="font-style:italic">Property, plant and equipment: </span></span>At 31&#160;December 2022 the Group had property, plant and equipment commitments of &#163;0.7&#160;billion of which &#163;0.6&#160;billion was payable within one year and &#163;0.1&#160;billion was payable after one year. The information set forth under the heading &#8220;Property, plant and equipment&#8221; within &#8220;Financial position and resources&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"><span style="font-style:italic">Purchases commitments: </span></span>At 31&#160;December 2022 the Group had &#163;0.2&#160;billion of purchase commitments of which &#163;0.1&#160;billion was payable within one year and &#163;0.1&#160;billion was payable after one year. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Future finance charges on leases</span>: At 31&#160;December 2022 the Group had &#163;0.1&#160;billion of future finance charges most of which was payable after one year. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Investments</span>: At 31&#160;December 2022 the Group had &#163;0.1&#160;billion of investments commitments most of which was payable after one year. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Pensions: </span>In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. Scottish limited partnerships (&#8220;SLPs&#8221;) were established to provide a funding mechanism for each of GSK&#8217;s UK defined benefit pension schemes. The SLPs together hold shares representing 7.5% of the total issued share capital of Haleon. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on Haleon shares, until it has received an aggregate amount equal to an agreed threshold (&#8220;Proceeds Threshold&#8221;). The Proceeds Thresholds total &#163;1,080&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or technical provisions deficits in the three schemes shown by the 31&#160;December 2020 valuations. Once the Proceeds Threshold has been reached the <span style="white-space:nowrap">GSK-controlled</span> General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. As at 31&#160;December 2022, &#163;345&#160;million remains outstanding to the UK Pension Trustees. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">There was a decrease in the commitments in 2022 as a result of a reduction in outstanding loan commitments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">5.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Research and development, patents and licenses, etc. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Research and development&#8221; on pages 15 to 28; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Pharmaceuticals and Vaccines product development pipeline&#8221; on pages 278 to 281; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Pharmaceutical products, competition and intellectual property&#8221; on pages 282 and 283; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Vaccine products, competition and intellectual property&#8221; on page 284 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">5.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Trend information </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Group financial review 2022&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">5.E</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Critical Accounting Estimates </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_8">Item&#160;6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Directors, Senior Management and</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Employees</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Directors and senior management </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;The Board&#8221; on pages 97 to 100; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;GSK Leadership Team (GLT)&#8221; on pages 101 to 102 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Compensation </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth in the report on &#8220;Remuneration&#8221; on pages 132 to 164; excluding: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">the second paragraph under &#8220;GSK&#8217;s Remuneration policy 2022&#8221; on page 133; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">the heading and the information under the heading &#8220;How our performance measures align to our strategy&#8221; on page 135 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Board practices </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Engaging with shareholders&#8221; and &#8220;Board evolution&#8221; within the &#8220;Chair&#8217;s statement&#8221; on page 5; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Corporate governance&#8221; on pages 96 to 131, excluding: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">the first and second paragraphs within the &#8220;Chair&#8217;s governance statement&#8221; on page 104; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">the heading and the information under the heading &#8220;Section&#160;172 statement&#8221; on pages 112 to 114; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Service contracts and letters of appointment&#8221; on page 150 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Employees </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 9 &#8211; Employee costs&#8221; on page 200; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 31 &#8211; Pensions and other post-employment benefits&#8221; on pages 220 to 228; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Number of employees&#8221; under &#8220;Three year selected financial data&#8221; on page 277 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.E</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Share ownership </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 45 &#8211; Employee share schemes&#8221; on pages 262 and 263; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;2022 Total remuneration (audited)&#8221; on pages 136 to 137; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Vesting of PSP LTI awards&#8221; on pages 141 to 142; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;2020 PSP vesting&#8221; on page 142; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Performance of ongoing LTI awards&#8221; on page 142; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;2022 LTI awards&#8221; on page 143; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Directors&#8217; interests in shares (audited)&#8221; on pages 154 to 155 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">6.F</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_9">Item&#160;7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Major Shareholders and Related Party</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Transactions</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">7.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Major shareholders </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Change of control and essential contracts&#8221; within &#8220;Directors&#8217; Report&#8221; on page 130; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Share capital and control&#8221; on pages 296 and 297; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Analysis of shareholdings at 31&#160;December 2022&#8221; on page 298 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">7.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Related party transactions </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Note 40 &#8211; Related party transactions&#8221; on page 236 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Demerger Agreements&#8221; in Item 10.C of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">7.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Interests of experts and counsel </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_10">Item&#160;8.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Financial Information</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">8.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Consolidated Financial Statements and Other Financial Information: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">See Item 18 below. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">In addition, the information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Note 47 &#8211; Legal proceedings&#8221; on pages 265 to 267; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Dividends&#8221; on page 298 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">8.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Significant Changes </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Note 47 &#8211; Legal proceedings&#8221; on pages 265 to 267 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_11">Item&#160;9.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">The Offer and Listing</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Offer and listing details </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Market capitalisation&#8221; on page 297; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Nature of trading market&#8221; on page 297 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The trading symbol for GSK&#8217;s Ordinary Shares of 31 <sup style="vertical-align:top">1</sup>&#8260;<sub style="vertical-align:bottom">4</sub> pence each on the London Stock Exchange is GSK and the trading symbol for GSK&#8217;s ADSs on the New York Stock Exchange (the &#8220;NYSE&#8221;) is GSK. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Plan of distribution </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Markets </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">The second paragraph under &#8220;Share capital and control&#8221; on page 296; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Nature of trading market&#8221; on page 297 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Selling shareholders </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.E</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Dilution </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">9.F</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Expenses of the issue </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_12">Item&#160;10.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Additional Information</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">10.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Share Capital </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left">10.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Articles of Association of GSK plc </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The following is a summary of the principal provisions of the company&#8217;s Articles of Association (the &#8220;Articles&#8221;). Shareholders should not rely on this summary, but should instead refer to the current Articles which are filed with the Registrar of Companies in the UK and can be viewed on the company&#8217;s website. The Articles contain the fundamental provisions of the company&#8217;s constitution, and the rules for the internal management and control of the company. The company has no statement of objects in its Articles and accordingly its objects are unrestricted in accordance with the provisions of the Companies Act 2006. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(a) Voting </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">All resolutions put to the vote at general meetings, including electronic general meetings (see paragraph (h)), will be decided by poll.&#160;&#160;&#160;&#160;On a poll, every shareholder who is present in person or by proxy or, in the case of an electronic general meeting, who participates or is represented by proxy via an electronic platform shall have one vote for every Ordinary Share of which they are the holder. In the case of joint holders of a share, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and seniority shall be determined by the order in which the names stand on the register. Unless the Directors otherwise decide, the right to attend a general meeting and voting rights may not be exercised by a shareholder who has not paid to the company all calls and other sums then payable by them in respect of their Ordinary Shares. The right to attend a general meeting and voting rights may not be exercised by a shareholder who is subject to an order under Section&#160;794 of the Companies Act 2006 because they have failed to provide the company with information concerning their interests in Ordinary Shares within the prescribed period, as required by Section&#160;793 of the Companies Act 2006. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(b) Transfer of Ordinary Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Any shareholder may transfer their Ordinary Shares which are in certificated form by an instrument of transfer in any usual form or in any other form which the Directors may approve. Such instrument must be properly signed and stamped or certified (or otherwise shown to the satisfaction of the Directors as being exempt from stamp duty) and lodged with the company together with the relevant share certificate(s) and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Any member may transfer title to their uncertificated Ordinary Shares by means of a relevant system, such as CREST. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The transferor of a share is deemed to remain the holder until the transferee&#8217;s name is entered on the register. The Directors may decline to register any transfer of any Ordinary Share which is not fully paid. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Registration of a transfer of uncertificated Ordinary Shares may be refused in the circumstances set out in the uncertificated securities rules, and where, in the case of a transfer to joint holders, the number of joint holders to whom the uncertificated Ordinary Share is to be transferred exceeds four. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The Articles contain no other restrictions on the transfer of fully paid certificated Ordinary Shares provided: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the instrument of transfer is duly stamped or certified or otherwise shown to the satisfaction of the Directors to be exempt from stamp duty and is accompanied by the relevant share certificate and such other evidence of the right to transfer as the Directors may reasonably require; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the transfer, if to joint transferees, is in favour of not more than four transferees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the instrument of transfer is in respect of only one class of shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the holder of the Ordinary Shares is not subject to an order under Section&#160;794 of the Companies Act 2006. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Notice of refusal to register a transfer must be sent to the transferee within two months of the instrument of transfer being lodged. The Directors may decline to register a transfer of Ordinary Shares by a person holding 0.25&#160;per cent. or more of the existing Ordinary Shares if such person is subject to an order under Section&#160;794 Companies Act 2006, after failure to provide the company with information concerning interests in those Ordinary Shares required to be provided under Section&#160;793 of the Companies Act 2006, unless the transfer is carried out pursuant to an arm&#8217;s length sale. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Provisions in the Articles will not apply to uncertificated Ordinary Shares to the extent that they are inconsistent with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the holding of Ordinary Shares in uncertificated form; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the transfer of title to Ordinary Shares by means of a system such as CREST; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#160;&#160;&#160;&#160;(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">any provisions of the relevant regulations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(c) Dividends and distribution of assets on liquidation </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The profits of the company which are available for distribution and permitted by law to be distributed and which the company may by ordinary resolution from time to time declare, upon the recommendation of the Directors to distribute by way of dividend, in respect of any accounting reference period shall be distributed by way of dividend among holders of Ordinary Shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">If in their opinion the company&#8217;s financial position justifies such payments, the Directors may, as far as any applicable legislation allows, pay interim dividends on shares of any class of such amounts and in respect of such periods as they think fit. Except in so far as the rights attaching to, or the terms of issue of, any share otherwise provide, all dividends will be declared, apportioned and paid pro rata according to the amounts paid up on the shares during any portion of the period in respect of which the dividend is paid. As the company has only one class of Ordinary Shares, the holders of such Ordinary Shares will be entitled to participate in any surplus assets on a winding-up in proportion to their shareholdings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(d) Variation of rights and changes in capital </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Subject to the provisions of any statute (including any orders, regulations or other subordinate legislation made under it) from time to time in force concerning companies in so far as it applies to the company (the &#8220;Companies Acts&#8221;), the rights attached to any class of shares may be varied with the written consent of the holders of three-quarters in nominal value of the issued shares of that class (excluding any shares of that class held as treasury shares) or with the sanction of a special resolution passed at a separate meeting of the holders of shares of that class. At every such separate meeting, the provisions of the Articles relating to general meetings shall apply, except the necessary quorum shall be at least two persons entitled to vote and holding or representing as proxy at least <span style="white-space:nowrap">one-third</span> in nominal value of the issued shares of the relevant class (excluding any shares of that class held as treasury shares) (but provided that at any adjourned meeting one holder of shares of the relevant class present in person or by proxy shall be a quorum). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">If new shares are created or issued which rank equally with any other existing shares, or if the company purchases or redeems any of its own shares, the rights of existing shares will not be regarded as changed or abrogated unless the terms of the existing shares expressly say otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(e) Unclaimed dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">All dividends or other sums payable on or in respect of any Ordinary Shares which remain unclaimed may be invested or otherwise made use of by the Directors for the benefit of the company until claimed. Unless the Directors decide otherwise, any dividend or other sums payable on or in respect of any Ordinary Shares unclaimed after a period of six years from the date when declared or became due for payment will be forfeited and revert to the company. The company may stop sending dividend cheques or warrants by post, or employ such other means of payment in respect of any Ordinary Shares, if at least two consecutive payments have remained uncashed or are returned undelivered or if one payment has remained uncashed or is returned undelivered and the company cannot establish a new address for the holder after making reasonable enquiries; however, in either case, the company must resume sending cheques or warrants or employ such other means of payment if the holder or any person entitled to the Ordinary Shares by transmission requests the resumption in writing. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(f) Untraced shareholders </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The company may sell any certificated Ordinary Shares in the company after using reasonable efforts to trace the holder of, or person entitled by transmission to, the Ordinary Shares and sending a notice to the registered address or last known address of the holder or other person entitled in accordance with the requirements of the Articles and waiting for three months if the Ordinary Shares have been in issue for at least ten years and during that period at least three dividends have become payable on them and have not been claimed or satisfied and, so far as any Director is aware, the company has not received any communication from the holder of the Ordinary Shares or any person entitled to them by transmission. Upon any such sale, the company will become indebted to the former holder of the Ordinary Shares or the person entitled to them by transmission for an amount equal to the net proceeds of sale unless and until forfeited. If no valid claim for the money has been received by the company during a period of two years from the date on which the relevant shares were sold by the company, the money will be forfeited and will belong to the company. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(g) Limitations on rights of <span style="white-space:nowrap">non-resident</span> or foreign shareholders </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">There are no limitations imposed by the Articles on the rights of <span style="white-space:nowrap">non-resident</span> or foreign shareholders except that there is no requirement for the company to serve notices on shareholders outside the United Kingdom and the United States, if no postal address in the United States or United Kingdom has been provided to the company. The company may choose not to serve, send or supply any notice to a particular shareholder where it considers this necessary or appropriate to deal with legal, regulatory or practical problems in, or under the laws of, any territory. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(h) General meetings of shareholders </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The Articles rely on the Companies Act 2006 provisions dealing with the calling of general meeting. The company is required by the Companies Act 2006 to hold an annual general meeting each year. General meetings of shareholders may be called as necessary by the Directors and must be called promptly upon receipt of a requisition from shareholders. Under the Companies Act 2006, an annual general meeting must be called by notice of at least 21 clear days. A general meeting other than an annual general meeting may be called on not less than 14 clear days&#8217; notice provided a special resolution reducing the notice period to 14 clear days has been passed at the immediately preceding annual general meeting or a general meeting held since that annual general meeting. The Directors may determine that a general meeting shall be held as a physical meeting or in combination with an electronic platform or platforms that enables members to participate in the meeting without physically attending (an electronic general meeting). </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(i) Conflicts of interest </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The Directors may, subject to the provisions of the Articles, authorise any matter which would otherwise involve a Director breaching their duty under the Companies Acts to avoid conflicts of interest (each a &#8220;Conflict&#8221;). A Director seeking authorisation in respect of a Conflict shall declare to the other Directors the nature and extent of their Conflict as soon as is reasonably practicable and&#160;&#160;&#160;&#160;shall provide the other Directors with such details of the matter as are necessary to decide how to address the Conflict. The board may resolve to authorise the relevant Director in relation to any matter the subject of a Conflict, save that the relevant Director and any other Director with a similar interest shall not count towards the quorum nor vote on any resolution giving such authority, and, if the other Directors so decide, shall be excluded from any meeting of the Directors while the Conflict is under consideration. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">(j) Other Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Subject to the provisions of the Companies Acts, and provided the nature and extent of a Director&#8217;s interest has been declared to the Directors, a Director may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">be party to, or otherwise interested in, any contract with the company, or in which the company has a direct or indirect interest; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">hold any other office or place of profit with the company (except that of auditor) in conjunction with their office of director for such period and upon such terms, including remuneration, as the Directors may decide; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">act by themselves or through a firm with which they are associated in a professional capacity for the company or any other company in which the company may be interested (otherwise than as auditor); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">be or become a director of, or employed by, or otherwise be interested in any holding company or subsidiary company of the company or any other company in which the company may be interested; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">be or become a director of any other company in which the company does not have an interest and which cannot reasonably be regarded as giving rise to a conflict of interest at the time of their appointment as director of that other company. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">No contract in which a Director is interested shall be liable to be avoided, and any Director who is so interested is not liable to account to the company or its shareholders for any benefit realised by the contract by reason of the Director holding that office or of the fiduciary relationship thereby established. However, no Director may vote on, or be counted in the quorum, in relation to any resolution of the board relating specifically to their own appointment (including remuneration) or the terms of their termination of appointment or relating to any contract in which they have an interest (subject to certain exceptions). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Subject to the Companies Acts, the company may by ordinary resolution suspend or relax to any extent the provisions relating to directors&#8217; interests or restrictions on voting or ratify any transaction not duly authorised by reason of a contravention of such provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(k) Directors&#8217; remuneration </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Each of the Directors will be paid a fee at such rate as may from time to time be determined by the Directors, but the total fees paid to all of the directors for acting as directors (excluding any amounts paid under any other provision of the Articles) shall not exceed the higher of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:16%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">&#163;3&#160;million a year; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:16%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">any higher amount as the company may by ordinary resolution decide. Such fees may be satisfied in cash or in shares or any other <span style="white-space:nowrap">non-cash</span> form. Any Director who devotes special attention to the business or performs any services which the Directors consider to extend beyond the ordinary services of a Director shall be entitled to receive such remuneration (whether by way of salary, commission or otherwise) as the Directors may decide. Each Director may be paid reasonable travelling, hotel and other incidental expenses they incur in attending and returning from meetings of the Directors or committees of the Directors, or general meetings of the company, or otherwise incurred in connection with the performance of their duties for the company. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(l) Pensions and gratuities for Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The Directors or any committee authorised by the Directors may provide benefits by the payment of gratuities, pensions or insurance or in any other manner for any Director or former Director or their relations, connected persons or dependants, but no benefits (except those provided for by the Articles) may be granted to or in respect of a Director or former Director who has not been employed by or held an executive office or place of profit under the company or any of its subsidiary undertakings or their respective predecessors in business without the approval of an ordinary resolution of the company. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(m) Borrowing powers </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Subject to the provisions of the Companies Act 2006, the Directors may exercise all the company&#8217;s powers to borrow money; to mortgage or charge all or any of the company&#8217;s undertaking, property (present and future), and uncalled capital; to issue debentures and other securities; and to give security either outright or as collateral security for any debt, liability or obligation of the company or of any third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(n) Retirement and removal of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">A Director is subject to <span style="white-space:nowrap">re-election</span> at every annual general meeting of the company. In addition to any power of removal conferred by the Companies Acts the company may by special resolution remove any Director before the expiration of their period of office. No Director is required to retire by reason of their age, nor do any special formalities apply to the appointment or <span style="white-space:nowrap">re-election</span> of any Director who is over any age limit. No shareholding qualification for Directors shall be required. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(o) Vacation of office </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The office of a director shall be vacated if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they resign or offer to resign, and the board resolves to accept such offer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">their resignation is requested by all of the other directors and all of the other directors are not less than three in number; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they are or have been suffering from mental or physical ill health and the board resolves that their office be vacated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they are absent without permission of the board from meetings of the board (whether or not an alternate director appointed by them attends) for six consecutive months and the board resolves that their office is vacated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they become bankrupt or compounds with their creditors generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they are prohibited by law from being a director; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">they are removed from office pursuant to the Articles or the Companies Acts. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">(p) Share rights </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Subject to any rights attached to existing shares, shares may be issued with such rights and restrictions as the company may by ordinary resolution decide, or (if there is no such resolution or so far as it does not make specific provision) as the board may decide. Such rights and restrictions shall apply as if they were set out in the Articles. Redeemable shares may be issued, subject to any rights attached to existing shares. The board may determine the terms, conditions and manner of redemption of any redeemable share so issued. Such terms and conditions shall apply to the relevant shares as if they were set out in the Articles. Subject to the articles, any resolution passed by the shareholders and other shareholders&#8217; rights, the Board may decide how to offer, allot, grant options over or otherwise deal with any shares in the company. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Material contracts </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Agreements with Novartis </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On April&#160;22, 2014, GSK and Novartis AG (&#8220;Novartis&#8221;) entered into a three-part, inter-conditional transaction, which they executed, among other agreements, a share and business sale agreement relating to the vaccines business of Novartis. GSK&#8217;s shareholders approved the transaction on December&#160;18, 2014. The transaction closed on March&#160;2, 2015. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Under the terms of the shareholders&#8217; agreement, Novartis had the right to require GSK to purchase its shares in the consumer healthcare joint venture. On June&#160;1, 2018, GSK acquired 100% of the shares in GlaxoSmithKline Consumer Healthcare Holdings Limited (&#8220;GSK Consumer Healthcare&#8221;) following cancellation of Novartis&#8217;s shares under the terms of a put option implementation agreement among GSK, Novartis and GSK Consumer Healthcare, among others. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">GSK continues to have obligations to pay further sales and milestone-based consideration to Novartis under the share and business sale agreement relating to the vaccines business of Novartis. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Agreement with Pfizer </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On December&#160;19, 2018, GSK, GSK Consumer Healthcare and Pfizer Inc. (&#8220;Pfizer&#8221;) entered into a Stock and Asset Purchase Agreement (the &#8220;SAPA&#8221;) pursuant to which the parties agreed to form a consumer healthcare joint venture (the &#8220;GSK/Pfizer JV&#8221;) through the acquisition by GSK Consumer Healthcare from Pfizer of Pfizer&#8217;s consumer healthcare business and the transfer by GSK to GSK Consumer Healthcare of those parts of the GSK consumer healthcare business not already part of GSK Consumer Healthcare as of the date of the SAPA (with certain limited exceptions). As consideration for the acquisition of its consumer healthcare business, Pfizer received shares in GSK Consumer Healthcare representing a 32% ownership interest in the GSK/Pfizer JV. GSK retained a controlling interest in GSK Consumer Healthcare of 68%. On July&#160;31, 2019, the parties entered into an amendment to the SAPA, pursuant to which: (i)&#160;GSK Consumer Healthcare transferred by novation to GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited (&#8220;GSK Consumer Healthcare (No. 2)&#8221;) all rights, title, interest, obligations duties and liabilities of GSK Consumer Healthcare under and in respect of the SAPA, (ii)&#160;the parties released GSK Consumer Healthcare from its obligations under the SAPA in exchange for GSK Consumer Healthcare (No. 2)&#8217;s assumption thereof and (iii)&#160;certain other amendments to the SAPA and other arrangements in connection with the closing of the transaction, including in relation to the delayed legal completion of the transaction in a number of jurisdictions due to regulatory constraints. The transaction closed on July&#160;31, 2019. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Each of GSK and Pfizer gave customary and broadly reciprocal representations and warranties to each other under the SAPA. GSK and Pfizer agreed to indemnify each other and GSK Consumer Healthcare (No. 2) (as applicable) in respect of losses (other than certain losses arising from tax matters, which are subject to a specific indemnity under the SAPA) relating to: (i)&#160;certain liabilities which the parties agreed will be retained by GSK or Pfizer; (ii)&#160;any breach of their respective covenants or agreements under the SAPA or the related ancillary agreements implementing the SAPA; or (iii)&#160;any breach of their respective representations and warranties given under the SAPA or the related ancillary agreements implementing the SAPA as of the date of completion of the transaction. GSK Consumer Healthcare (No. 2) agreed to indemnify GSK and Pfizer in respect of losses (other than certain losses arising from tax matters, which are subject to a specific indemnity under the SAPA) relating to: (i)&#160;liabilities which GSK Consumer Healthcare (No. 2) agreed to assume in connection with the transaction; (ii)&#160;liabilities resulting from the conduct of GSK Consumer Healthcare&#8217;s business other than those liabilities that GSK agreed to retain in connection with the transaction; and (iii)&#160;any breach of GSK Consumer Healthcare (No.2)&#8217;s post-completion covenants or agreements under the SAPA or the related ancillary agreements implementing the SAPA. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On June&#160;1, 2022, GSK, Pfizer, GSK Consumer Healthcare (No. 2) and Haleon plc (&#8220;Haleon&#8221;) entered into the second amendment agreement to the SAPA to implement certain amendments in connection with the demerger of the Consumer Healthcare business (the &#8220;Demerger&#8221;) and to include Haleon in the SAPA indemnity framework by way of a guarantee given by Haleon with respect to the indemnification obligations of GSK Consumer Healthcare (No. 2) under the SAPA. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Demerger Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On June&#160;1, 2022, GSK and Haleon entered into a demerger agreement (the &#8220;Demerger Agreement&#8221;) to effect the Demerger and to govern aspects of the relationship between GSK and Haleon following completion of the Demerger, including in respect of, among other things, confidentiality and certain indemnity obligations in connection with the issuance of shares by Haleon in connection with the Demerger. The Demerger Agreement contains certain customary indemnities under which GSK indemnifies Haleon in respect of liabilities, losses demands, claims, costs, taxes and damages arising, directly or indirectly, from or in consequence of certain claims. The Demerger Agreement also sets out how guarantees given by the GSK group for the benefit of companies in the Haleon group (or vice versa) will be dealt with following the Demerger. In addition, on June&#160;1, 2022, GSK and Haleon entered into an exchange agreement with respect to the transfer by GSK of its B Ordinary Shares in GSK Consumer Healthcare to Haleon in exchange for the issuance of shares by Haleon. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On June&#160;1, 2022 GSK, GSK Consumer Healthcare and GSK Consumer Healthcare (No. 2) entered into an asset transfer framework agreement (the &#8220;Asset Transfer Framework Agreement&#8221;), setting out the framework for the transfer of certain businesses, assets, liabilities and employees that were excluded from the original perimeter of the GSK/Pfizer JV as contemplated in the SAPA and others that were included in the original perimeter of the GSK/Pfizer JV but had not yet legally transferred or to record the transfer of other assets under the SAPA, in each case from the GSK group to the Haleon group. The Asset Transfer Framework Agreement also sets out the framework for the transfer of certain businesses, assets, liabilities and employees from the Haleon group to the GSK group. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">On June&#160;1, 2022, GSK, Pfizer, Anacor Pharmaceuticals, Inc., Haleon, GSK Consumer Healthcare, PF Consumer Healthcare Holdings LLC and GSK Consumer Healthcare (No. 2) entered into a Separation <span style="white-space:nowrap">Co-operation</span> and Implementation Agreement (the &#8220;SCIA&#8221;). The SCIA detailed certain actions to be taken and arrangements to be implemented to effect completion of, or which otherwise related to, the Demerger. The SCIA recorded the obligations of the parties relating to such matters and contained certain terms on which relations between the parties are governed following completion of the Demerger. The parties to the SCIA agreed to <span style="white-space:nowrap">co-operate</span> to achieve completion of the Demerger and undertook to take all steps required, and to enter into (or procure the entry into of) all documents required, to effect the Demerger. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Further, on June&#160;1, 2022, GlaxoSmithKline Services Unlimited, GlaxoSmithKline LLC, GlaxoSmithKline Consumer Healthcare (Overseas) Limited and GlaxoSmithKline Consumer Healthcare Holdings (US) LLC entered into a Transition Services Agreement, pursuant to which each group agreed to provide limited services to the other on commercial terms and on an arms&#8217; length basis for a transitional period, effective from completion of the Demerger. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Finally, on June&#160;1, 2022, each of GlaxoSmithKline Trading Services Limited and GlaxoSmithKline Consumer Trading Services Limited entered into two Manufacturing and Supply Agreements with the other (each a &#8220;Manufacturing and Supply Agreement&#8221;). Pursuant to each Manufacturing and Supply Agreement, the parties agreed, to the extent required, to supply the other with pharmaceutical or Consumer Healthcare products (as the case may be) from the relevant manufacturing sites owned by each group after the Demerger on commercial terms and on an arms&#8217; length basis. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Following the completion of the Demerger on July&#160;18, 2022, GSK does not have material obligations under these agreements to be performed on or after the date of this annual report on Form <span style="white-space:nowrap">20-F.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Exchange controls </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Exchange controls and other limitations affecting security holders&#8221; on page 296 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.E</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Taxation </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Tax information for shareholders&#8221; on pages 299 to 301 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.F</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Dividends and paying agents </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.G</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Statement by experts </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.H</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Documents on display </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Documents on display&#8221; on page 299 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.I</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Subsidiary information </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">10.J</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Annual Report to Security Holders </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_13">Item&#160;11.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Quantitative and Qualitative Disclosures About Market</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Risk</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Treasury policies&#8221; in Item 5.A of this annual report on Form <span style="white-space:nowrap">20-F</span> is incorporated herein by reference. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Note 44 &#8211; Financial instruments and related disclosures&#8221; on pages 245 to 261 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_14">Item&#160;12.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Description of Securities Other than Equity</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Securities</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">12.A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Debt Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">12.B</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Warrants and Rights </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">12.C</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Other Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left">12.D</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">American Depositary Shares </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Fees and charges payable by ADR holders </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">JPMorgan Chase Bank, N.A. serves as the depositary (the &#8220;Depositary&#8221;) for GSK&#8217;s American Depositary Receipt (&#8220;ADR&#8221;) program. On July&#160;29, 2019, GSK and the Depositary amended and restated the deposit agreement and further amended the deposit agreement on&#160;&#160;&#160;&#160;March&#160;15, 2021 (the &#8220;Deposit Agreement&#8221;) between GSK, the Depositary and owners and holders of ADRs. Pursuant to the Deposit Agreement, ADR holders may be required to pay various fees to the Depositary, and the Depositary may refuse to provide any service for which a fee is assessed until the applicable fee has been paid. In particular, the Depositary, under the terms of the Deposit Agreement, shall charge (i)&#160;a fee of $5.00 per 100 American Depositary Shares (or portion thereof) for the issuance, delivery, reduction, cancellation or surrender (as the case may be) of American Depositary Shares (&#8220;ADSs&#8221;), (ii) a fee of U.S.$0.05 or less per ADS held (A)&#160;upon which any cash distribution is made pursuant to the Deposit Agreement or (B)&#160;in the case of an elective cash/stock dividend, upon which a cash distribution or an issuance of additional ADSs is made as a result of such elective dividend, (iii)&#160;a fee for the distribution or sale of securities, such fee being in an amount equal to the fee for the execution and delivery of ADSs referred to above which would have been charged as a result of the deposit of such securities but which securities or the net cash proceeds from the sale thereof are instead distributed by the Depositary to ADR holders entitled thereto, (iv)&#160;an aggregate fee of U.S.$0.05 or less per ADS per calendar year (or portion thereof) for services performed by the Depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against ADR holders as of the record date or record dates set by the Depositary during each calendar year and shall be payable at the sole discretion of the Depositary by billing such Holders or by deducting such charge from one or more cash dividends or other cash distributions), and (v)&#160;a fee for the reimbursement of such fees, charges and expenses as are incurred by the Depositary and/or any of its agents (including, without limitation, the agent or agents of the Depositary (the &#8220;Custodian&#8221;) and expenses incurred on behalf of ADR holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment)&#160;&#160;&#160;&#160;in connection with the servicing of the ordinary shares or other Deposited Securities, the sale of securities (including, without limitation, Deposited Securities), the delivery of Deposited Securities or otherwise in connection with the Depositary&#8217;s or its Custodian&#8217;s compliance with applicable law, rule or regulation (which fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the Depositary and shall be payable at the sole discretion of the Depositary by billing such ADR holders or by deducting such charge from one or more cash dividends or other cash distributions). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">GSK will pay other charges and out of pocket expenses of the Depositary and any agent of the Depositary (except the Custodian) as specified in written agreements from time to time between GSK and the Depositary, except (i)&#160;stock transfer or other taxes and other governmental charges (which are payable by ADR holders or persons depositing ordinary shares), (ii) SWIFT, cable, telex and facsimile transmission and delivery charges incurred at the request of persons depositing, or ADR holders delivering ordinary shares, ADRs or Deposited Securities (which are payable by such persons or ADR holders), (iii) transfer or registration fees for the registration or transfer of Deposited Securities on any applicable register in connection with the deposit or withdrawal of Deposited Securities (which are payable by persons depositing ordinary shares or ADR holders withdrawing Deposited Securities) and (iv)&#160;in connection with the conversion of foreign currency into U.S. dollars, the Depositary shall deduct out of such foreign currency the fees, expenses and other charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection with such conversion. The Depositary and/or its agent may act as principal for such conversion of foreign currency. Such charges may at any time and from time to time be changed by agreement between GSK and the Depositary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Direct and indirect payments by the Depositary </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The Depositary anticipates reimbursing GSK for certain expenses incurred by GSK that are related to the establishment and maintenance of the ADR program upon such terms and conditions as GSK and the Depositary may agree from time to time. The Depositary may make available to GSK a set amount or a portion of the Depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as GSK and the Depositary may agree from time to time. In 2022 the Depositary made payments of approximately $21.20&#160;million. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Under certain circumstances, including removal of the Depositary or termination of the ADR program by GSK, GSK is required to repay certain amounts paid to GSK and to compensate the Depositary for payments made or services provided on behalf of GSK. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold" id="shell_a382677_15">PART II </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_16">Item&#160;13.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Defaults, Dividend Arrearages and</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Delinquencies</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_17">Item&#160;14.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Material Modifications to the Rights of Security Holders and Use of</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Proceeds</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_18">Item&#160;15.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left"><span style="font-weight:bold">Controls and Procedures</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The information set forth under the heading &#8220;Internal control framework&#8221; on page 125 to 126 of the GSK Annual Report 2022 is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">US law and regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">A number of provisions of US law and regulation apply to the company because our shares are quoted on the NYSE in the form of American Depositary Shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">NYSE rules </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">In general, the NYSE rules permit the company to follow UK corporate governance practices instead of those applied in the USA, provided that we explain any significant variations. This explanation is contained in Item 16.G of this Form <span style="white-space:nowrap">20-F.</span> NYSE rules that came into effect in 2005 require us to file annual and interim written affirmations concerning the Audit&#160;&amp; Risk Committee and our statement on significant differences in corporate governance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Sarbanes-Oxley Act of 2002 </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Following a number of corporate and accounting scandals in the USA, Congress passed the Sarbanes-Oxley Act of 2002. Sarbanes-Oxley is a wide ranging piece of legislation concerned largely with financial reporting and corporate governance. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">As recommended by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the company has established a Disclosure Committee. The Committee reports to the CEO, the CFO and to the Audit&#160;&amp; Risk Committee. It is chaired by the Company Secretary and the members consist of senior managers from finance, legal, corporate communications and investor relations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">External legal counsel, the external auditors and internal experts are invited to attend its meetings periodically. It has responsibility for considering the materiality of information and, on a timely basis, determining the disclosure of that information. It has responsibility for the timely filing of reports with the SEC and the formal review of the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F.</span> In 2022 the Committee met 28 times. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Sarbanes-Oxley requires that this annual report on Form <span style="white-space:nowrap">20-F</span> contain a statement as to whether a member of our Audit&#160;&amp; Risk Committee (&#8220;ARC&#8221;) is an audit committee financial expert as defined by Sarbanes-Oxley. For a summary regarding the Board&#8217;s judgment on this matter, please refer to Item 16.A below and to page 98 in the biography for &#8220;Charles Bancroft&#8221; and the paragraph under &#8220;Financial Experience&#8221; under &#8220;FRC UK Corporate Governance Code&#8221; within &#8220;Corporate governance architecture&#8221; on page 109 of the GSK Annual Report 2022. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Additional disclosure requirements arise under section 302 and section 404 of Sarbanes-Oxley in respect of disclosure controls and procedures and internal control over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Section&#160;302: Corporate responsibility for financial reports </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Sarbanes-Oxley also introduced a requirement for the CEO and the CFO to complete formal certifications, confirming that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">they have each reviewed the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">based on their knowledge, the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F</span> contain no material misstatements or omissions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">based on their knowledge, the financial statements and other financial information fairly present, in all material respects, the financial condition, results of operations and cash flows as of the dates, and for the periods, presented in the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">they are responsible for establishing and maintaining disclosure controls and procedures that ensure that material information is made known to them, and have evaluated the effectiveness of these controls and procedures as at the <span style="white-space:nowrap">year-end,</span> the results of such evaluation being contained in the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">they are responsible for establishing and maintaining internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">they have disclosed in the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F</span> any changes in internal controls over financial reporting during the period covered by the GSK Annual Report 2022 and Form <span style="white-space:nowrap">20-F</span> that have materially affected, or are reasonably likely to affect materially, the company&#8217;s internal control over financial reporting; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">they have disclosed, based on their most recent evaluation of internal control over financial reporting, to the external auditors and the ARC, all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to affect adversely the company&#8217;s ability to record, process, summarize and report financial information, and any fraud (regardless of materiality) involving persons that have a significant role in the company&#8217;s internal control over financial reporting. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The Group has carried out an evaluation under the supervision and with the participation of its management, including the CEO and CFO, of the effectiveness of the design and operation of the Group&#8217;s disclosure controls and procedures as at 31&#160;December 2022. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">Based on the Group&#8217;s evaluation, the CEO and CFO have concluded that, as at December&#160;31, 2022, the disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in the reports that the Group files and submits under the US Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported as and when required and that it is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The CEO and CFO completed these certifications on March&#160;10, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL;font-weight:bold">Section&#160;404: Management&#8217;s annual report on internal control over financial reporting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">In accordance with the requirements of section 404 of Sarbanes-Oxley, the following report is provided by management in respect of the Company&#8217;s internal control over financial reporting (as defined in Rules <span style="white-space:nowrap">13a-15(f)</span> and <span style="white-space:nowrap">15d-15(f)</span> under the US Securities Exchange Act of 1934): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">management is responsible for establishing and maintaining adequate internal control over financial reporting for the Group. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control &#8211; Integrated Framework (2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">management has assessed the effectiveness of internal control over financial reporting, as at 31&#160;December 2022 and has concluded that such internal control over financial reporting was effective. In addition, there have been no changes in the Group&#8217;s internal control over financial reporting during 2022 that have materially affected, or are reasonably likely to affect materially, the Group&#8217;s internal control over financial reporting; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Deloitte LLP, which has audited the consolidated financial statements of the Group for the year ended December&#160;31, 2022, has also assessed the effectiveness of the Group&#8217;s internal control over financial reporting under Auditing Standard No.&#160;2201 of the Public Company Accounting Oversight Board (United States). Their audit report can be found below. </p></td></tr></table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">60 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="gsk-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677g0309011809629.jpg" style="width: 144px; height: 28px;"/></div> </div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the shareholders and the Board of Directors of GSK plc </div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have audited the internal control over financial reporting of GSK plc and subsidiaries (the &#8220;Group&#8221;) as at 31&#160;December 2022, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control &#8212; Integrated Framework (2013)</div></div>&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Group maintained, in all material respects, effective internal control over financial reporting as at 31&#160;December 2022, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control &#8212; Integrated Framework (2013)</div></div>&#160;issued by COSO. </div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as at and for the year ended 31&#160;December 2022, of the Group and our report dated 10&#160;March 2023, expressed an unqualified opinion on those financial statements. </div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Section</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;404: Management&#8217;s annual report on internal control over financial reporting</div></div>&#8221; included in Item 15 of the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> Our responsibility is to express an opinion on the Group&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definition and Limitations of Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with <div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;"></div>authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </div></div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">/s/ </div><ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2022To12_31_2022"><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">Deloitte LLP</div></ix:nonNumeric><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2022To12_31_2022"><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">London, United Kingdom</div></ix:nonNumeric> </div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10&#160;March 2023 </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-family:Arial,Helvetica,sans-serif;;display:inline;"><div style="letter-spacing: 0px; top: 0px; font-family: Arial, Helvetica, sans-serif;;display:inline;">61</div></div> </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_19" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">[Reserved] </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_20" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16A.<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit committee financial expert </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information set forth: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the last paragraph in the biography for &#8220;Charles Bancroft&#8221; on page 98; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the paragraph under &#8220;Financial Experience&#8221; under &#8220;FRC UK Corporate Governance Code&#8221; within &#8220;Corporate governance architecture&#8221; on page 109; and </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the fourth paragraph under &#8220;Sarbanes-Oxley Act of 2002&#8221; within &#8220;US law and regulation&#8221; on page 304 </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the GSK Annual Report 2022 is incorporated herein by reference. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_21" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.B</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Code of Ethics </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The information set forth under the heading &#8220;Code of Conduct and reporting lines&#8221; on page 129 of the GSK Annual Report 2022 is incorporated herein by reference. You will find the Code at this link: <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">https://www.gsk.com/en-gb/company/governance/compliance/#the-code</div></div>. </div></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No waivers were granted from a provision of our code of ethics to an officer or person described in Item 16.B(a) that relates to one or more of the items set forth in Item 16.B(b) in 2022. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_22" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.C</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal Accountant Fees and Services </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Audit Fees for 2021 and 2022 were paid to Deloitte LLP (PCAOB ID No.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2022To12_31_2022"><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">1147</div></ix:nonNumeric><div style="font-family: Arial, Helvetica, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">).</div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(a)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Fees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information set forth in the table under the heading &#8220;Fees payable to the company&#8217;s auditor and its associates&#8221;, in the rows named &#8220;Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002&#8221; and &#8220;Audit of the company&#8217;s subsidiaries&#8221; in Note 8 &#8211; &#8220;Operating profit&#8221; on page 199 of the GSK Annual Report 2022 is incorporated herein by reference. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit-Related Fees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information set forth in the table under the heading &#8220;Fees payable to the company&#8217;s auditor and its associates&#8221; in the row named &#8220;Audit-related and other assurance services&#8221; in Note 8 &#8211; &#8220;Operating profit&#8221; on page 199 of the GSK Annual Report 2022 is incorporated herein by reference. The other assurance services provided by the auditor related to agreed upon procedures and other assurance services outside of statutory audit requirements. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(c)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Fees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(d)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All Other Fees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(e)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The information set forth under the heading <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-audit</div> services&#8221; on page 129 of the GSK Annual Report 2022 is incorporated herein by reference. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.C(f)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_23" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.D</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exemptions from the Listing Standards for Audit Committees </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_24" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.E</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_25" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.F</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Registrant&#8217;s Certifying Accountant </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="shell_a382677_26" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.G</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Governance </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of New York Stock Exchange Corporate Governance Standards and GSK plc&#8217;s corporate governance practice. The application of the New York Stock Exchange&#8217;s (&#8220;NYSE&#8221;) corporate governance standards is restricted for foreign companies, recognizing that they have to comply with domestic requirements. As a foreign private issuer, GSK plc (&#8220;GSK&#8221; or the &#8220;Company&#8221;) must comply with the following NYSE standards: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the Company must satisfy the audit committee requirements of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the Chief Executive Officer (the &#8220;CEO&#8221;) must promptly notify the NYSE in writing after any executive officer of the Company becomes aware of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any applicable provisions of the NYSE&#8217;s corporate governance standards; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company must submit an annual affirmation to the NYSE affirming GSK&#8217;s compliance with applicable NYSE corporate governance standards, and submit interim affirmations to the NYSE notifying it of specified changes to the audit committee or a change to the status of the Company as a foreign private issuer; and </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4.</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company must provide a brief description of any significant differences between its corporate governance practices and those followed by US companies under the NYSE listing standards. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: ARIAL; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As a Company listed on the London Stock Exchange, GSK is required to comply with the UK Listing Authority&#8217;s Listing Rules (the &#8220;Listing Rules&#8221;) and to report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with the UK Corporate Governance Code (the &#8220;UK Code&#8221;). </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-family:Arial,Helvetica,sans-serif;;display:inline;"><div style="letter-spacing: 0px; top: 0px; font-family: Arial, Helvetica, sans-serif;;display:inline;">62</div></div></div> </div> </div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL">The table below discloses differences between GSK&#8217;s current domestic corporate governance practices, which are based on the UK Code, and the NYSE corporate governance standards, applicable to US companies. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;font-weight:bold;text-align:center">NYSE</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL;font-weight:bold;text-align:center">Corporate Governance Standards</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;font-weight:bold;text-align:center">Description of differences between GSK&#8217;s governance practice and the NYSE Corporate Governance</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL;font-weight:bold;text-align:center">Standards</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Director Independence (303A.01 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">1.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Listed companies must have a majority of independent directors (as defined in Section&#160;303A.02 of the NYSE Manual (see below).</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with the equivalent domestic requirements contained in the UK Corporate Governance Code (the &#8220;UK Code&#8221;), the latest version of which was issued in July 2018.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code provides that the board of directors of GSK (the &#8220;Board&#8221;) and its committees should have a combination of skills, experience and knowledge. Consideration should be given to the length of the service of the Board and membership should be regularly refreshed (Principle K). The Board should include an appropriate combination of Executive and <span style="white-space:nowrap">Non-Executive</span> Directors and, in particular, &#8220;independent&#8221; <span style="white-space:nowrap">Non-Executive</span> Directors (for the purpose of the UK Code) such that no one individual or small group of individuals can dominate the Board&#8217;s decision-making. There should be a clear division of responsibilities between the leadership of the Board and the executive leadership of GSK&#8217;s business (Principle G). At least half the Board, excluding the Chair, should comprise <span style="white-space:nowrap">Non-Executive</span> Directors determined by the Board to be independent (Provision 11). The roles of Chair and Chief Executive should not be exercised by the same individual. If, exceptionally, this is proposed by the Board, major shareholders should be consulted ahead of appointment (Provision 9).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The current Chair of the Board, Sir Jonathan Symonds, was considered independent on appointment (Provision 9).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Board considers that Elizabeth McKee Anderson, Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, Dr Jesse Goodman, Urs Rohner and Dr Vishal Sikka are independent for the purpose of the UK Code.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">A majority of the Board members are independent <span style="white-space:nowrap">Non-Executive</span> Directors and, in accordance with the requirements of the UK Code, the Board has appointed one of the independent <span style="white-space:nowrap">Non-Executive</span> Directors as Senior Independent Director to provide a sounding board for the Chair and act as an intermediary for other Directors and shareholders where necessary (Provision 12). In January 2012 the Board adopted a formal written role specification for the Senior Independent Director.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">NYSE Independence Tests (303A.02 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In order to tighten the definition of &#8220;independent director&#8221; for purposes of these standards:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(a)&#8194;&#8201;(i) No director qualifies as &#8220;independent&#8221; unless the board of directors affirmatively determines that the director has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(ii)&#8194;&#8201;&#8202;In addition, in affirmatively determining the independence of any director who will serve on the compensation committee of the listed company&#8217;s board of directors, the board of directors must consider all factors specifically relevant to determining whether a director has a relationship to the listed company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(A) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the listed company to such director; and</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(B) whether such director is affiliated with the listed company, a subsidiary of the listed company or an affiliate of a subsidiary of the listed company.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(b)&#8194;&#8201;In addition, a director is not independent if:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(i)&#8195;&#8202;The director is, or has been within the last three years, an employee of the listed company, or an immediate family member is, or has been within the last three years, an executive officer, of the listed company.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(ii)&#8194;&#8201;&#8202;The director has received, or has an immediate family member who has received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from the listed company, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such compensation is not contingent in any way on continued service).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(iii)&#8194;&#8202;(A) The director is a current partner or employee of a firm that is the listed company&#8217;s internal or external auditor; (B)&#160;the director has an immediate family member who is a current partner of such a firm; (C)&#160;the director has an immediate family member who is a current employee of such a firm and personally works on the listed company&#8217;s audit; or (D)&#160;the director or an immediate family member was within the last three years a partner or employee of such a firm and personally worked on the listed company&#8217;s audit within that time.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(iv)&#8194;&#8202;The director or an immediate family member is, or has been within the last three years, employed as an executive officer of another company where any of the listed company&#8217;s present executive officers at the same time serves or served on that company&#8217;s compensation committee.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(v)&#8194;&#8201;&#8202;The director is a current employee, or an immediate family member is a current executive officer, of a company that has made payments to, or received payments from, the listed company for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1&#160;million, or 2% of such other company&#8217;s consolidated gross revenues.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(For the purposes of these standards &#8220;executive officer&#8221; is defined to have the meaning specified for the term &#8220;officer&#8221; in Rule <span style="white-space:nowrap">16a-1(f)</span> under the Securities Exchange Act of 1934, as amended, the &#8220;Exchange Act&#8221;).</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with the corresponding domestic requirements contained in the UK Code, which sets out the principles for GSK to determine whether a director is independent.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Board is required to identify each <span style="white-space:nowrap">Non-Executive</span> Director it considers to be independent. Circumstances which are likely to impair, or could appear to impair a <span style="white-space:nowrap">non-executive</span> director&#8217;s independence include, but are not limited to, whether a director:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(a)&#8194;&#8201;is or has been an employee of GSK within the last five years;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(b)&#8194;&#8201;has, or has had within the last three years, a material business relationship with GSK either directly or as a partner, shareholder, director or senior employee of a body that has such a relationship with GSK;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(c)&#8194;&#8201;&#8202;has received or receives additional remuneration from GSK apart from a director&#8217;s fee, participates in GSK&#8217;s share option or a performance-related pay scheme, or is a member of GSK&#8217;s pension scheme;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(d)&#8194;&#8201;has close family ties with any of GSK&#8217;s advisers, directors or senior employees;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(e)&#8194;&#8201;holds cross-directorships or has significant links with other directors through involvement in other companies or bodies;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(f)&#8195;represents a significant shareholder; or</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(g)&#8194;&#8201;has served on the Board for more than nine years from the date of their first appointment.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Where any of these or other relevant circumstances apply, and the Board nonetheless considers that the <span style="white-space:nowrap">non-executive</span> director is independent, a clear explanation should be provided (Provision 10).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Board considers all its <span style="white-space:nowrap">Non-Executive</span> Directors to be independent in character and judgment and has concluded that all its <span style="white-space:nowrap">Non-Executive</span> Directors are independent within the meaning of the UK Code.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Chair satisfied the independence criteria on appointment in accordance with the UK Code (Provision 9). The Chair should not remain in post beyond nine years from the date of their first appointment to the Board. To facilitate effective succession planning and the development of a diverse board, this period can be extended for a limited time (Provision 19).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complied with the UK Code requirement, and its Articles of Association, that all Directors should be subject to annual election or <span style="white-space:nowrap">re-election</span> by shareholders (Provision 18) at its Annual General Meeting in 2022 and intends to comply with this requirement at its 2023 Annual General Meeting.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code also provides that the Board should undertake a formal and rigorous annual evaluation of its own performance and that of its committees, the Chair and individual Directors (Principle L and Provision 21). Annual evaluation of the Board should consider the Board&#8217;s composition, diversity and how effectively members work together to achieve objectives. Individual evaluation should demonstrate whether each director continues to contribute effectively (Principle L). GSK has complied with this requirement. In addition, the annual evaluation of the Board should be externally facilitated at least every three years and a statement should be made as to whether an external facilitator has any other connection with GSK or individual directors and the external facilitator should be identified in the Annual Report (Provision 21). Internally facilitated evaluations were conducted in 2015, 2016, 2018 and 2021. GSK conducted an externally facilitated evaluation in 2014, 2017, 2019, 2020 and 2022.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">The FRC&#8217;s Guidance on Board Effectiveness (&#8220;Guidance&#8221;) provides that all Directors should receive an induction on joining the Board and should regularly update and refresh their skills and knowledge. The Chair should ensure that new Directors receive a full, formal and tailored induction on joining the Board (Guidance, para 61, <span style="white-space:nowrap">75-76</span> &amp; 81). The Chair should act on the results of the annual evaluation by recognising the strengths and addressing any weaknesses of the Board. Each Director should engage with this process and take appropriate action when development needs have been identified (Provision&#160;22).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Executive Sessions (303A.03 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Meetings</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">3.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">To empower <span style="white-space:nowrap">non-management</span> directors to serve as a more effective check on management, the <span style="white-space:nowrap">non-management</span> directors of each listed company must meet at regularly scheduled executive sessions without management.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with the equivalent domestic requirements set out in the UK Code, which requires the Chair of GSK to hold meetings with the <span style="white-space:nowrap">Non-Executive</span> Directors without executives present (Provision 13). The <span style="white-space:nowrap">Non-Executive</span> Directors, led by the Senior Independent Director, also meet at least annually without the Chair present to appraise the Chair&#8217;s performance, and on other occasions as necessary (Provision 12).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">The UK Code provides that the Chair should promote a culture of openness and debate by facilitating the effective contribution of all <span style="white-space:nowrap">Non-Executive</span> Directors in particular, and constructive board relations between Executive and <span style="white-space:nowrap">Non-Executive</span> Directors (Principle F). In addition, the Chair should seek regular engagement with major shareholders in order to understand their views on governance and performance against the strategy. The Chair is responsible for ensuring that the Board as a whole has a clear understanding of the view of shareholders and stakeholders (Principle D and Provision 3). The Board should also understand the views of GSK&#8217;s other key stakeholders and keep engagement mechanisms under review so that they remain effective (Provision 5).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;font-weight:bold">Nominating / Corporate Governance Committee</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL;font-weight:bold">(303A.04 of the NYSE Manual)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Nominations Committee</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">4.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(a) Listed companies must have a nominating/corporate governance committee composed entirely of independent directors.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(b) The nominating/corporate governance committee must have a written charter that addresses:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(i)&#8195;&#8202;the committee&#8217;s purpose and responsibilities &#8211; which, at minimum, must be to: identify individuals qualified to become board members, consistent with criteria approved by the board, and to select, or to recommend that the board select, the director nominees for the next annual meeting of shareholders; develop and recommend to the board a set of corporate governance guidelines applicable to the corporation; and oversee the evaluation of the board and management; and</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(ii) an annual performance evaluation of the committee.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with the corresponding domestic requirements set out in the UK Code, which requires GSK to have a Nominations Committee that is comprised of a majority of independent <span style="white-space:nowrap">Non-Executive</span> Directors (Provision 17). In practice, GSK&#8217;s current Nominations&#160;&amp; Corporate Governance Committee is comprised entirely of independent directors within the meaning of the UK Code. The Chair of the Board should not chair the committee when it is dealing with the appointment of their successor (Provision 17).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s Nominations&#160;&amp; Corporate Governance Committee has written terms of reference in accordance with the UK Code. The terms of reference are available on GSK&#8217;s website and explain the Nominations&#160;&amp; Corporate Governance Committee&#8217;s role and the authority delegated to it by the Board (Guidance, para 63). The Nominations&#160;&amp; Corporate Governance Committee reviews the structure, size, diversity (including diversity of gender, social and ethnic backgrounds, and cognitive and personal strengths), and composition of the Board (evaluating the balance of skills, experience, independence and knowledge on the Board), leads the process for the appointment of members to the Board and the GSK Leadership Team (the &#8220;GLT&#8221;), and makes recommendations to the Board as appropriate. The Nominations&#160;&amp; Corporate Governance Committee also monitors the planning of succession for the Board and senior management (Provision 17).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The terms and conditions of appointment of the Chair and <span style="white-space:nowrap">Non-Executive</span> Directors are available for inspection (Guidance, para 96).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code requires that GSK&#8217;s Annual Report describes the work of the Nominations Committee in discharging its duties, including the process it has used in relation to appointments, its approach to succession planning and how both support developing a diverse pipeline (Provision 23). Open advertising and/or an external search consultancy should generally be used for the appointment of a chair or a <span style="white-space:nowrap">non-executive</span> director. If an external search consultancy is engaged it should be identified in the Annual Report and a statement should be made as to whether it has any other connection with GSK or individual directors (Provision 20). This section should also include a description of how the Board evaluation has been conducted, the Board&#8217;s policy on diversity and inclusion together with its objectives and linkage to GSK&#8217;s strategy, how it has been implemented and progress on achieving the objectives, and the gender balance of those in the senior management and their direct reports (Provision 23). GSK has complied with this requirement under the UK Code.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As described above, there is an annual Board evaluation exercise, which also includes evaluation of the Board&#8217;s committees and individual Directors (Principle L).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">The Board is responsible for regularly reviewing its corporate governance standards and practices. The Company Secretary oversees corporate governance matters for the Group. The Company Secretary is responsible for advising the Board on all corporate governance matters (Provision 16). Domestic requirements do not mandate GSK to establish a distinct corporate governance committee.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Compensation Committee (303A.05 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Remuneration Committee</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">5.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(a) Listed companies must have a compensation committee composed entirely of independent directors. Compensation committee members must satisfy the additional independence requirements specific to compensation committee membership set forth in Section&#160;2(a)(ii) in the Section titled &#8220;NYSE Independence Tests&#8221; above.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GSK complies with the equivalent domestic requirements set out in the UK Code, which requires GSK to have a Remuneration Committee comprising at least three independent <span style="white-space:nowrap">Non-Executive</span> Directors (Provision 32). In practice, GSK&#8217;s current Remuneration Committee is comprised entirely of independent directors within the meaning of the UK Code.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(b) The compensation committee must have a written charter that addresses:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(i) the committee&#8217;s purpose and responsibilities &#8211; which, at a minimum, must be to have direct responsibility to:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(A)&#8194;&#8202;review and approve corporate goals and objectives relevant to CEO compensation, evaluate the CEO&#8217;s performance in light of those goals and objectives, and, either as a committee or together with the other independent directors (as directed by the board), determine and approve the CEO&#8217;s compensation level based on this evaluation;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(B)&#8194;&#8202;make recommendations to the board with respect to <span style="white-space:nowrap">non-CEO</span> executive officer compensation, and incentive-compensation and equity-based plans that are subject to board approval; and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(C)&#8194;&#8202;prepare the disclosure required by Item 407(e)(5) of Regulation <span style="white-space:nowrap">S-K</span> under the Exchange Act;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(ii) an annual performance evaluation of the compensation committee.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(iii)&#160;The rights and responsibilities of the compensation committee set forth in Section&#160;303A.05(c).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(c)(i)&#160;The compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(ii)&#160;The compensation committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, independent legal counsel or other adviser retained by the compensation committee.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(iii)&#160;The listed company must provide for appropriate funding, as determined by the compensation committee, for payment of reasonable compensation to a compensation consultant, independent legal counsel or any other adviser retained by the compensation committee.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s Remuneration Committee has written terms of reference in accordance with the UK Code, which explain the Remuneration Committee&#8217;s role and the authority delegated to it by the Board and are available on GSK&#8217;s website (Guidance, para 63). The Remuneration Committee determines the terms of service and remuneration of the Executive Directors and members of the GLT and, with the assistance of external independent advisers, it evaluates and makes recommendations to the Board on overall executive remuneration policy (the Chair and the CEO are responsible for evaluating and making recommendations to the Board on the remuneration of <span style="white-space:nowrap">Non-Executive</span> Directors within the terms of the approved remuneration policy). It should review workforce remuneration and related policies and the alignment of incentives and rewards with culture, taking these into account when setting the policy for executive director remuneration (Provision 33). Where remuneration consultants are appointed, they should be identified in the Annual Report and a statement should be made as to whether they have any other connection with GSK or individual directors (Provision 35).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code provides that the Remuneration Committee:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(a)&#8194;&#8201;should take care to recognise and manage conflicts of interest when receiving views from Executive Directors or senior management, or consulting the Chief Executive about its proposals (Provision 35 &amp; Guidance, para 129) and should have delegated responsibility for setting remuneration for all Executive Directors and the Chair (Provision 33);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(b)&#8194;&#8201;should carefully consider the pension consequences and associated costs of basic salary increases and any other changes in pensionable remuneration, or contribution rates, particularly for Directors close to retirement (Provision 38);</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(iv)&#160;The compensation committee may select a compensation consultant, legal counsel or other adviser to the compensation committee only after taking into consideration, all factors relevant to that person&#8217;s independence from management, including the following:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(A)&#8194;&#8202;The provision of other services to the listed company by the person that employs the compensation consultant, legal counsel or other adviser;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(B)&#8194;&#8202;The amount of fees received from the listed company by the person that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the person that employs the compensation consultant, legal counsel or other adviser;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(C)&#8194;&#8202;The policies and procedures of the person that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(c)&#8194;&#8201;&#8202;should ensure that compensation commitments in Directors&#8217; terms of appointment do not reward poor performance (Provision 39). Remuneration schemes should promote long-term shareholdings by Executive Directors that support alignment with long-term shareholder interests. A formal policy should be developed for post-employment shareholding requirements encompassing both unvested and vested shares (Provision 36). Remuneration schemes and policies should enable the use of discretion to override formulaic outcomes and include provisions that would enable GSK to recover and/or withhold sums or share awards specifying the circumstances in which it would be appropriate to do so (Provision 37); and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(d)&#8194;&#8201;when determining Executive Director remuneration policy and practices, should address the following: (i)&#160;remuneration arrangements are transparent and promote</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(D)&#8194;&#8202;Any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the compensation committee;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(E)&#8194;&#8202;Any stock of the listed company owned by the compensation consultant, legal counsel or other adviser; and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(F)&#8194;&#8201;Any business or personal relationship of the compensation consultant, legal counsel, other adviser or the person employing the adviser with an executive officer of the listed company.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">effective engagement with shareholders and the workforce; (ii)&#160;the operation and rationale of remuneration structures are easy to understand; (iii)&#160;remuneration arrangements identify and mitigate reputational and other risks from excessive rewards and behavioural risks that can arise from target-based incentive plans; (iv)&#160;the range of possible values of rewards to individual Directors and any other limits or discretions are identified and explained at the time of approving the policy; (v)&#160;the link between individual awards, the delivery of strategy and the long-term performance of GSK should be clear; and (vi)&#160;incentive schemes should drive behaviours consistent with company purpose, values and strategy (Provision 40).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code requires that remuneration of <span style="white-space:nowrap">Non-Executive</span> Directors should not include share options or other performance-related elements, but should reflect the time commitment and responsibilities of the role (Provision 34).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code requires that notice or contract periods should be one year or less (Provision 39).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">As described above, there is an annual Board evaluation exercise, which also includes evaluation of the Board&#8217;s committees (Principle&#160;L).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Audit Committee (303A.06 and 303A.07 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Audit&#160;&amp; Risk Committee</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">6.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Listed companies must have an audit committee that satisfies the requirements of Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with equivalent domestic requirements set out in the UK Code, which require that GSK has an Audit&#160;&amp; Risk Committee that is comprised of at least three independent <span style="white-space:nowrap">Non-Executive</span> Directors (Provision 24). GSK considers all members of the Audit&#160;&amp; Risk Committee to be independent. The Board has also satisfied itself, in line with the UK Code, that at least one member of the Audit&#160;&amp; Risk Committee has recent and relevant financial experience and that the Audit&#160;&amp; Risk Committee as a whole has competence relevant to the sector in which GSK operates (Provision 24).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the UK Code, the main roles and responsibilities of the Audit&#160;&amp; Risk Committee include:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(a)&#8194;&#8201;monitoring the integrity of the financial statements of GSK and any formal announcements relating to GSK&#8217;s financial performance, reviewing significant financial reporting judgments contained in them (Provision 25);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(b)&#8194;&#8201;providing advice (where requested by the Board) on whether the Annual Report and accounts, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess GSK&#8217;s position and performance, business model and strategy (Provision 25);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(c)&#8194;&#8201;&#8202;reviewing GSK&#8217;s internal financial controls and internal control and risk management systems (Provision 25);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(d)&#8194;&#8201;monitoring and reviewing the effectiveness of GSK&#8217;s internal audit function (Provision 25);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(e)&#8194;&#8201;conducting the tender process and making recommendations to the Board regarding the appointment, <span style="white-space:nowrap">re-appointment</span> and removal of the external auditor and approving the remuneration and terms of engagement of the external auditor (Provision 25);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(f)&#8195;reviewing and monitoring the external auditor&#8217;s independence and objectivity and the effectiveness of the audit process, taking into consideration relevant UK professional and regulatory requirements (Provision 25);</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(g)&#8194;&#8201;developing and implementing policy on the engagement of external auditors to supply <span style="white-space:nowrap">non-audit</span> services, ensuring there is prior approval of <span style="white-space:nowrap">non-audit</span> services, considering the impact this may have on independence, taking into account the relevant regulations and ethical guidance regarding the provision of <span style="white-space:nowrap">non-audit</span> services by the external audit firm, and to report to the Board on any improvement or action required (Provision 25); and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(h)&#8194;&#8201;reporting to the Board on how it has discharged its responsibilities (Provision 25).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Audit&#160;&amp; Risk Committee is also the means by which the Board reviews arrangements by which the staff of GSK may, in confidence, raise concerns about possible improprieties in matters of financial reporting or other matters (Provision 6).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s Audit&#160;&amp; Risk Committee meets the requirements of Rule <span style="white-space:nowrap">10A-3</span> in that:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;each member of the Audit&#160;&amp; Risk Committee is deemed to be &#8220;independent&#8221; in accordance with the Exchange Act and applicable NYSE and UK requirements;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;the Audit&#160;&amp; Risk Committee, amongst other things, is responsible for recommending the appointment, compensation, maintenance of independence and oversight of the work of any registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for GSK, and each such accounting firm must report directly to the Audit&#160;&amp; Risk Committee;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;the Audit&#160;&amp; Risk Committee has established a procedure for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters, and for the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;the Audit&#160;&amp; Risk Committee has the authority to engage independent counsel and other advisors as it determines necessary to carry out its duties; and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;GSK must provide appropriate funding for the Audit&#160;&amp; Risk Committee.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">The Board has determined that Charles Bancroft has the appropriate qualifications and background to be an &#8220;Audit Committee Financial Expert&#8221; as defined in rules promulgated by the SEC under the Exchange Act.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">7.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(a) The audit committee must have a minimum of three members. All audit committee members must satisfy the requirements for independence set out in Section&#160;303A.02 and, in the absence of an applicable exemption, Rule <span style="white-space:nowrap">10A-3(b)(1)</span> under the Exchange Act.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(b) The audit committee must have a written charter that addresses:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(i)&#8195;&#8202;the committee&#8217;s purpose &#8211; which, at minimum, must be to:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(A)&#8194;&#8202;assist board oversight of (1)&#160;the integrity of the listed company&#8217;s financial statements, (2)&#160;the listed company&#8217;s compliance with legal and regulatory requirements, (3)&#160;the independent auditor&#8217;s qualifications and independence, and (4)&#160;the performance of the listed company&#8217;s internal audit function and independent auditors (if the listed company does not yet have an internal audit function because it is availing itself of a transition period pursuant to Section&#160;303A.00, the charter must provide that the committee will assist board oversight of the design and implementation of the internal audit function); and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(B)&#8194;&#8202;prepare disclosure required by Item 407(d)(3)(i) of Regulation <span style="white-space:nowrap">S-K</span> (regarding the audit committee&#8217;s review and discussion of financial statements and certain other audit matters with management and auditors)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(ii)&#8194;&#8201;&#8202;an annual performance evaluation of the audit committee; and</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK complies with the equivalent domestic requirements set out in the UK Code, which requires that the Audit&#160;&amp; Risk Committee should be comprised of a minimum of three independent <span style="white-space:nowrap">Non-Executive</span> Directors (Provision 24).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK&#8217;s Audit&#160;&amp; Risk Committee has written terms of reference in accordance with the UK Code. The terms of reference are available on GSK&#8217;s website and explain the Audit&#160;&amp; Risk Committee&#8217;s role and the authority delegated to it by the Board (Guidance, para 63).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Audit&#160;&amp; Risk Committee&#8217;s main responsibilities include monitoring and reviewing the financial reporting process, the system of internal control and risk management, overseeing the identification and management of risks, the external and internal process and for monitoring compliance with laws, regulations and ethical codes of practice, including review throughout the year of integrated assurance reports comprising business unit and associated consolidated internal audit reports. Where requested by the Board, the Audit&#160;&amp; Risk Committee should provide advice on the following areas which the directors as a whole are required to explain in the Annual Report:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;whether the annual report and accounts, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess GSK&#8217;s performance, business model and strategy (Principle M&#160;&amp; Provision 27); and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;when taking into account GSK&#8217;s position and principal risks, how the prospects of GSK have been assessed, over what period and why the period is regarded as appropriate. The Audit&#160;&amp; Risk Committee should also advise whether there is a reasonable expectation that GSK will be able to continue in operation and meet its liabilities when falling due over the said period, drawing attention to any qualifications or assumptions as necessary (Provision 31).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:1%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(iii)&#8194;&#8202;the duties and responsibilities of the audit committee &#8211; which, at a minimum, must include those set out in Rule <span style="white-space:nowrap">10A-3(b)(2),</span> (3), (4) and (5)&#160;of the Exchange Act as well as to:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(A) at least annually, obtain and review a report by the independent auditor describing: the firm&#8217;s internal quality-control procedures; any material issues raised by the most recent internal quality-control review, or peer review, of the firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years, respecting one or more independent audits carried out by the firm, and any steps taken to deal with any such issues; and (to assess the auditor&#8217;s independence) all relationships between the independent auditor and the listed company;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(B) meet to review and discuss the listed company&#8217;s annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing the listed company&#8217;s specific disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(C) discuss the listed company&#8217;s earnings press releases, as well as financial information and earnings guidance provided to analysts and rating agencies;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(D) discuss policies with respect to risk assessment and risk management;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(E) meet separately, periodically, with management, with internal auditors (or other personnel responsible for the internal audit function) and with independent auditors;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(F) review with the independent auditor any audit problems or difficulties and management&#8217;s response;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(G) set clear hiring policies for employees or former employees of the independent auditors; and</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:ARIAL">(H) report regularly to the board of directors.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:ARIAL">(c)&#8194;&#8201;&#8202;Each listed company must have an internal audit function.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The UK Code requires that a separate section of the Annual Report should describe the work of the Audit&#160;&amp; Risk Committee in discharging its responsibilities (Provision 26).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Annual Report should include:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;the significant issues that the committee considered in relation to the financial statements, and how these issues were addressed (Provision 26);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;an explanation of how it has assessed the effectiveness of the external audit process and the approach taken to the appointment or reappointment of the external auditor, information on the length of tenure of the current audit firm and when a tender was last conducted and advance notice of any retendering plans (Provision 26);</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;in the case of the Board not accepting the Audit&#160;&amp; Risk Committee&#8217;s recommendation on the external auditor appointment, reappointment or removal, a statement from the Audit&#160;&amp; Risk Committee explaining its recommendation and the reasons why the Board has taken a different position (Provision 26); and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:ARIAL">&#8226;&#8195;&#8202;if the external auditor provides <span style="white-space:nowrap">non-audit</span> services, an explanation of how auditor objectivity and independence are safeguarded (Provision 26).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Please see section 6 above for a description of the main role and responsibilities of the Audit&#160;&amp; Risk Committee.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">In accordance with the UK Code (Provision 25), the Audit&#160;&amp; Risk Committee monitors and reviews the effectiveness of GSK&#8217;s internal audit function.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:10pt">&#160;&#160;&#160;&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Shareholder Approval of Equity Compensation Plans (303A.08 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">8.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions thereto, except for employment inducement awards, certain grants, plans and amendments in the context of mergers and acquisitions, and certain specific types of plans. However, these exempt grants, plans and amendments may be made only with the approval of the listed company&#8217;s independent compensation committee or the approval of a majority of the listed company&#8217;s independent directors. Companies must also notify the Exchange in writing when they use one of these exemptions.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GSK complies with corresponding domestic requirements in the Listing Rules, which mandate that GSK must seek shareholder approval for employee share schemes and significant changes to existing schemes, save in circumstances permitted by the Listing Rules (Listing Rule 9.4). Please see section 5(c) above.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Corporate Governance Guidelines (303A.09 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">9.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Listed companies must adopt and disclose corporate governance guidelines.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GSK complies with corresponding domestic requirements in the Listing Rules and the UK Code, which require that GSK includes an explanation in its Annual Report of how it complies with the principles of the UK Code and a confirmation that it complies with the UK Code&#8217;s provisions or, where it does not, provides an explanation of how and why it does not comply (Listing Rule 9.8.6). In addition, GSK is required to make certain mandatory corporate governance statements in the Directors&#8217; Report in accordance with the FCA&#8217;s Disclosure Guidance and Transparency Rules, DGTR 7. GSK will comply with these requirements in its 2022 Annual Report.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Code of Business Conduct and Ethics (303A.10 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Code of Conduct</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">10.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Listed companies must adopt and disclose a code of business conduct and ethics for directors, officers and employees, and promptly disclose any waivers of the code for directors or executive officers.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GSK&#8217;s Code of Conduct for all employees, including the CEO, CFO and other senior financial officers, is available on GSK&#8217;s website.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Foreign Private Issuer Disclosure (303A.11 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">11.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Listed foreign private issuers must disclose any significant ways in which their corporate governance practices differ from those followed by domestic companies under NYSE listing standards.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Listed foreign private issuers are required to provide this disclosure in the English language and in their annual reports filed on Form <span style="white-space:nowrap">20-F.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK fulfils this requirement by publishing this disclosure in its Annual Report on Form <span style="white-space:nowrap">20-F.</span></p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">GSK fulfils this requirement by including this disclosure in its Annual Report on Form <span style="white-space:nowrap">20-F.</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Certification Requirements (303A.12 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">12.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Each listed company and its CEO must file certain annual and interim certifications regarding compliance with the corporate governance requirements and certain other matters (although foreign private issuers are only required to comply with a subset of these requirements).</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GSK fulfils this requirement by filing the required certifications each year.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">Related Party Transactions (314.00 of the NYSE Manual)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">13.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">A listed company&#8217;s audit committee, or another independent body of the board of directors, shall conduct a reasonable prior review and oversight of all related party transactions for potential conflicts of interest and will prohibit such a transaction if it determines it to be inconsistent with the interests of the company and its shareholders. In the case of foreign private issuers, the term &#8220;related party transactions&#8221; refers to transactions required to be disclosed pursuant to Form <span style="white-space:nowrap">20-F,</span> Item 7.B.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GSK fulfils this requirement in respect of Directors and Officers via the Nominations&#160;&amp; Corporate Governance Committee.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">In respect of any material transactions with other related parties (as set out in 314.00 of the NYSE Manual), the independent Directors of the Board (excluding the Executive Directors) fulfil this requirement. The Company&#8217;s Policy on Grant of Authority for Transactions reflects the requirement for the Board&#8217;s prior review and oversight in this regard.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_27">Item&#160;16.H<span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Mine Safety Disclosure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_28">Item&#160;16.I<span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold" id="shell_a382677_29">PART III </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_30">Item&#160;17<span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Financial Statements </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left" id="shell_a382677_31">Item&#160;18<span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Financial Statements </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">The information set forth under the headings: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Consolidated income statement&#8221; on page 182; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Consolidated statement of comprehensive income&#8221; on page 182; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Consolidated balance sheet&#8221; on page 183; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Consolidated statement of changes in equity&#8221; on page 184; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Consolidated cash flow statement&#8221; on page 185; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">&#8220;Notes to the financial statements&#8221; on pages 186 to 267 </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL">of the GSK Annual Report 2022 is incorporated herein by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g382677g0309011809629.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">To the shareholders and the Board of Directors of GSK plc </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Opinion on the Financial Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of GSK plc and subsidiaries (the &#8220;Group&#8221;) as at 31 December 2022 and 2021, the related consolidated income statements, statements of comprehensive income, statements of changes in equity, and cash flow statements, for each of the three years in the period ended 31 December 2022, and the related notes, included in Exhibit 15.2 on pages 182 to 267 (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Group as at 31 December 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended 31&#160;December 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Group&#8217;s internal control over financial reporting as at 31 December 2022, based on criteria established in <span style="font-style:italic">Internal Control &#8212; Integrated Framework (2013)</span>&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated 10&#160;March 2022, expressed an unqualified opinion on the Group&#8217;s internal control over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Basis for Opinion </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the Group&#8217;s management. Our responsibility is to express an opinion on the Group&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Critical Audit Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Valuation of the ViiV Healthcare Shionogi contingent consideration liability </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Accounts impacted: Contingent consideration liabilities and Other operating expense </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Refer to Notes 29, 33 and 44 to the financial statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group has completed a number of significant transactions which resulted in the recognition of material contingent consideration liabilities, which are a key source of estimation uncertainty. The most significant of these liabilities was the ViiV Healthcare Shionogi Contingent Consideration Liability (ViiV CCL). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group completed the acquisition of the remaining 50% interest in the Shionogi-ViiV Healthcare joint venture in 2012. Upon completion, the Group recognised a contingent consideration liability for the fair value of the expected future payments to be made to Shionogi. As at 31&#160;December 2022 the liability was valued at &#163;5,890&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We identified the ViiV CCL as a critical audit matter because of the significant estimates and assumptions relating to the sales forecasts used in valuing the ViiV CCL and the sensitivity of the valuation to these inputs. The most significant of these relate to sales forecasts in the United States (US) on certain products in the treatment portfolio. Such forecasts are based on an assessment of the expected launch dates, the ability to shift market practice and prescriber behaviour towards long-acting injectable treatments and <span style="white-space:nowrap">2-drug</span> regimens, the impact of healthcare reform and subsequent sales volumes and pricing. There is incremental challenge in forecasting sales associated with recently launched products due to the lack of historical actual data. The forecasts also required significant audit effort to perform appropriate audit procedures to challenge and evaluate the reasonableness of those forecasts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We performed the following audit procedures, amongst others, related to the sales forecasts: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Obtained the Group&#8217;s assessment of the key inputs and assumptions used in the forecasts and challenged the reasonableness of these, including through enquiries of key individuals from the senior leadership team, commercial strategy team and key personnel involved in the budgeting and forecasting process, and inspection of supporting evidence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Challenged the US volume assumptions made by the Group to estimate sales forecasts. This involved benchmarking forecast market share data against external data, such as total prescription volumes and new patient prescription volumes, in order to assess for any sources of contradictory evidence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Challenged the reasonableness of US pricing assumptions by the Group, by comparing the forecasted Returns and Rebates rate by product against the current rate, and assessing the forecasted Returns and Rebates against comparable products considering expected changes in payer policy and healthcare reform implications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Considered the results of clinical studies undertaken in the year by the Group and key competitors in order to assess whether these are corroborative or contradictory to assumptions used in the product portfolio sales forecasts in the US; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Benchmarked the Group&#8217;s sales forecasts against those included in reports from nine analysts and considered sales forecasts on both a total ViiV basis and an individual product basis, assessing against identified contradictory data; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested the controls over the key inputs and assumptions used in the valuation of the contingent consideration liability, including review controls over the sales forecasts of the treatment product portfolio used to value the ViiV CCL. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Valuation of US Returns and Rebates (RAR) accruals </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold">Accounts impacted: </span>Turnover and Trade and other payables </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Refer to Note 29 to the financial statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the US the Group sells to customers under various commercial and government mandated contracts and reimbursement arrangements that include rebates, chargebacks and a right of return for certain pharmaceutical products. As such, revenue recognition reflects <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments. These adjustments are known as the Returns and Rebates (RAR) accruals and are a source of significant estimation uncertainty which could have a material impact on reported revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In the US Pharmaceuticals business in 2022 $18,928&#160;million of RAR deductions were made to gross revenue of $36,953&#160;million, resulting in net revenue of $18,023&#160;million. The balance sheet accrual at 31&#160;December 2022 for the combined US Pharmaceuticals and Vaccines businesses amounted to $6,881&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The four most significant payer channels (also referred to as buying groups) to which the RAR accrual relates are managed healthcare organisations, Medicaid, Ryan White and Medicare Part D. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The two main causes of significant estimation uncertainty are: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">The utilisation rate, which is the portion of total sales that will be made into each payer channel, estimated by the Group in recording the accruals. The utilisation assumption is the most challenging of the key assumptions used to derive the accrual given that it is influenced by market demand and other factors outside the control of the Group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">The time lag between the point of sale and the point at which exact rebate amounts are known to the Group upon receipt of a claim. Those payer channels with the longest time lag result in a greater accrued period, and therefore, a greater level of estimation uncertainty in estimating the period end accrual. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The level of estimation uncertainty is also impacted by significant shifts in channel mix driven by changes in the competitive landscape, including competitor and generic product launches and other macroeconomic factors. As such, we focus on the utilisation assumptions for those products where we deem the level of estimation uncertainty to be the most significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Furthermore, auditing standards presume that a significant fraud risk exists in revenue recognition. In line with this presumption, we also focus on the <span style="white-space:nowrap">period-end</span> adjustments made to the RAR accruals. These adjustments reflected updates made to the initial assumptions included within the forecasted RAR rates and, in our view, present the greatest opportunity for fraud in revenue recognition (notwithstanding the existence of internal controls). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Audit procedures performed </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We performed the following audit procedures, amongst others, related to estimates in the RAR accruals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Challenged assumptions for a selection of utilisation rates, focusing on certain products where we concluded the accrual is most sensitive to these assumptions. Our challenge included comparison to historical utilisation rates, consideration of historical accuracy and drivers of market changes such as the impact of competition and macroeconomic trends; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Supplemented this with substantive analytical procedures by developing an independent expectation of the accrual balance for each of the key segments, based on historical claims received adjusted to reflect market changes in the period including an assessment of the time lag between the initial point of sale and the claim receipt. We then compared this independent expectation to those recorded to evaluate the appropriateness of the year ending accrual position; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Considered the historical accuracy of estimates and evaluated whether forecast assumptions had been appropriately updated in a selection of cases where the actual rebate claims differed to the amount accrued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Evaluated the appropriateness of, and completeness of, <span style="white-space:nowrap">period-end</span> adjustments to the liability made as part of the ongoing review of the estimated accrual; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested the key controls over the estimation of RAR accruals including the controls associated with the forecasting of utilisation rates process and the <span style="white-space:nowrap">month-end</span> accrual review controls. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="text-decoration:underline">Valuation of other intangible assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"><span style="font-style:italic">Accounts impacted: </span></span>Other intangible assets, Cost of sales, Research and development, and Selling, general and administration </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Refer to Notes 20 and 41 to the financial statements </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As at 31&#160;December 2022, the Group held &#163;13,663&#160;million of other intangible assets (including licenses, patents, trademarks, and trade names, but excluding goodwill and computer software). This includes &#163;2,964&#160;million of intangible assets acquired as part of business combinations with Sierra Oncology, Inc. and Affinivax Inc during the year. During 2022, impairment charges of &#163;330&#160;million were recorded. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">An individual intangible asset, or an intangible asset which forms part of a cash-generating unit, is impaired when its carrying amount exceeds its recoverable amount. The recoverable amount of these other intangible assets relies on certain assumptions and estimates of future trading performance which create estimation uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Future trading performance of intangible assets includes key assumptions such as sales pricing, volume, growth rates and probability of technical and regulatory success of ongoing clinical trials. This includes assumptions on timing of cash flows determined by anticipated launch year, peak year sales, subsequent sales erosion due to generic product competition and profit margin levels. In addition, due to the impact of uncertainty driven by ongoing global macroeconomic volatility, the valuation of intangible assets will also be affected by discount rate assumptions made by the Group. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We identified the valuation of other intangible assets as a critical audit matter due to the inherent judgements involved in estimating future cash flows. Auditing such assumptions and estimates required extensive audit effort to challenge and evaluate the reasonableness of forecasts and judgements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We performed the following audit procedures, amongst others, related to the future sales pricing, volume, growth rates and probability of technical and regulatory success, profit margin levels, and discount rates used in the assessment in the valuation of other intangible assets: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Inquired with the key individuals from the corporate development team, commercial forecasting leads, and key personnel involved in the assets research and development process to discuss and evaluate the Group&#8217;s evidence to support the future pricing, volume, sales growth rates and probability of regulatory and technical success; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Evaluated the key inputs and assumptions applied in estimating sales and profit margin forecasts, including benchmarking of forecasts against external market data. This included independent market research of therapeutic area price points, price growth rates, and anticipated competitor market landscape, currently and at the time of forecast regulatory approval, plus assessment of any sources of contradictory evidence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Inspected independent research and literature to consider corroborative and contradictory evidence to assess assumptions on probability of technical and regulatory success; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Compared the forecast sales and profit margin levels to the Plan data (asset by asset internal forecasts) approved by the GSK Leadership Team and the Board of Directors, where the <span style="white-space:nowrap">in-development</span> intangible asset is forecast to launch within the next <span style="white-space:nowrap">3-year</span> period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Assessed the historical accuracy of sales forecasts by performing retrospective reviews across marketed assets within the business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Considered whether events or transactions that occurred after the balance sheet date but before the reporting date affect the conclusions reached on the carrying values of the assets and associated disclosures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Engaged Internal Fair Valuation Specialists (IFVS) to assess the reasonableness of discount rates and valuation methodology; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested review controls over the key inputs and assumptions used in the valuation of other intangible assets. The controls encompass review of the valuation models, which contain a number of assumptions such as the probability of technical and regulatory success, launch dates plus other revenue and cost assumptions. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Valuation of uncertain tax positions, including transfer pricing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Accounts impacted: Corporation tax payable, Deferred tax liabilities and Taxation charge </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Refer to Note 14 to the financial statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group operates in numerous jurisdictions and there are open tax and transfer pricing matters and exposures with UK, US and overseas tax authorities that give rise to uncertain tax positions. There is a wide range of possible outcomes for provisions and contingencies. Certain judgements in respect of estimates of tax exposures and contingencies are required in order to assess the adequacy of tax provisions, which are sometimes complex as a result of the considerations required over multiple tax laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At 31&#160;December 2022, the Group has recorded provisions of &#163;858&#160;million in respect of uncertain tax positions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">With the support of tax specialists, we assessed the appropriateness of the uncertain tax provisions by performing the following audit procedures amongst others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Assessed and challenged provisions for uncertain tax positions through the evaluation of possible outcomes. Our procedures were focused on those jurisdictions where the Group has the greatest potential exposure and where the highest level of judgement is required; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Assessed the assumptions and judgements that are required to determine the range of possible outcomes for recognition and measurement of uncertain tax positions in compliance with the requirements of IFRIC 23; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Involved our transfer pricing specialists to evaluate the transfer pricing methodology of the Group and associated approach to provision recognition and measurement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Considered evidence such as the actual results from the recent tax authority audits and enquiries, third-party tax advice obtained by the Group and our tax specialists&#8217; own knowledge of market practice in relevant jurisdictions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested key controls over preparation, review and reporting of judgmental tax balances and transactions, which include provisions for uncertain tax provisions. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="text-decoration:underline">Consumer Healthcare Demerger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic"></span><span style="font-weight:bold"><span style="font-style:italic">Accounts impacted:</span></span><span style="font-style:italic"> Profit after taxation from discontinued operations and all balance sheet accounts </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-style:italic">Refer to Note 41 to the financial statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">On 18&#160;July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. The separation was effected by way of a demerger of 80.1% of GSK&#8217;s 68% holding in the Consumer Healthcare business to GSK shareholders. GSK retained 13.5% of Haleon (7.5% are held by Scottish Limited Partnership structures (SLPs)) which are recognised as an equity investment as set out in Note 22. The Group derecognised net assets and liabilities of &#163;12.9bn and recognised a gain on demerger of &#163;10.1bn. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Consumer Healthcare trading results to the demerger date have been presented as a part of discontinued operations and the comparative results have been restated on a consistent basis. At the demerger date the assets and liabilities of the Consumer business have been derecognised from the balance sheet, with the difference between the value of the net assets and the fair value of the demerged business recognised in the consolidated income statement as a gain on demerger. The cumulative exchange differences arising on translation of those Consumer Healthcare foreign currency net assets, previously included in other comprehensive income, have also been recognised in the consolidated income statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We identified the demerger of Consumer Healthcare as a critical audit matter because of the significant estimates related to calculating the gain on demerger and remeasuring the retained stake upon demerger, assessing the perimeters of the demerged business, validating the cumulative exchange differences arising on translation of the foreign currency net assets of the divested businesses, evaluating the Group&#8217;s tax treatment of the demerger and assessing the impact on relevant IT systems prior to the demerger. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our technical accounting, tax, and IT specialists, when performing audit procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The matter is also discussed in the Audit&#160;&amp; Risk Committee report within the Corporate Governance section of the Annual Report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We performed the following audit procedures, amongst others, related to the Consumer Healthcare demerger: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Consulted with technical accounting specialists to evaluate the entity&#8217;s accounting conclusions in respect of the relevant accounting standards for the demerger steps including: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">o</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the presentation of Consumer Healthcare results as a part of discontinued operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">o</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the calculation of the gain on demerger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">o</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">the retained stake upon demerger. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Recalculated the gain on demerger and the fair value of the Consumer Healthcare business at the demerger date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested the accuracy and completeness of the perimeters of the demerged business by inspecting legal agreements and recalculating the cumulative exchange differences arising on translation of the foreign currency net assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Engaged tax specialists to assess the impact of the demerger on the Group tax balances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Engaged IT specialists to assess the impact on the relevant IT systems prior to the demerger of Consumer Healthcare; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested key controls over IT and the reporting of the Consumer Healthcare Demerger including the review and approval of the accounting considerations, accuracy and completeness of transactions to the demerger date, the cumulative exchange reserve and the adjustments required in relation to the classification between continued and discontinued operations. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="text-decoration:underline">Valuation of the contingent liabilities and significant legal proceedings</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Accounts impacted:</span></span><span style="font-weight:bold"></span><span style="font-style:italic"> </span><span style="font-weight:bold">Contingent liabilities and Other operating expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold">Refer to Notes 35 and 47 to the financial statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">Critical Audit Matter Description </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group operates in an environment where it is subject to significant legal and administrative proceedings, including product liability, intellectual property, tax, anti-trust, consumer fraud and governmental regulations. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Group is currently exposed to a number of regulatory and litigation matters. In the current year, the Group classified the Zantac litigation as a significant legal matter due to the increase in cases. The Group&#8217;s provision for these matters is &#163;218m at 31&#160;December 2022. Other matters are disclosed as contingent liabilities where the criteria for recognising a provision under IAS 37 Provisions, Contingent Liabilities and Contingent Assets are not met. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We identified contingent liabilities and significant legal proceedings as a critical audit matter because of the significant judgement required by the Group in determining whether, under IAS 37, in particular in relation to the Zantac matter, as to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Whether the outcome will result in a probable outflow, particularly where the outcome of litigation is uncertain and subject to additional court proceedings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">The determination of a reliable estimate can be made of the amounts of the obligation; and </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">The nature and extent of any contingent liabilities and underlying significant estimation uncertainties disclosed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold"><span style="font-style:italic">How the Critical Audit Matter Was Addressed in the Audit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We performed the following audit procedures: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Tested the Group&#8217;s controls over the completeness of provisions, the robustness of the provision against the requirements of IAS 37, the appropriateness of judgements used to determine a &#8216;best estimate&#8217; and completeness and accuracy of data used in the process; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Evaluated the assessment of the provisions, associated probabilities, and potential outcomes in accordance with IAS 37; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Evaluated the methodology, data and significant judgements and assumptions used in the valuation of the provisions are appropriate in the context of the applicable financial reporting framework; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Inquired with and inspected correspondence from the Group&#8217;s internal and external counsel to assess the litigation matter and evaluate the Group&#8217;s significant judgements and assumptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Where no provision was made, we critically evaluated the Group&#8217;s conclusion supportive and contradictory evidence and the requirements of IAS 37, particularly with respect to the Zantac matter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">In respect of the Zantac matter, we inspected the evidence presented in relevant scientific studies and the outcomes of other product liability litigation in the same jurisdictions alongside the entity&#8217;s assessment of possible outcomes of each ongoing and future trials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt;text-align:left">Evaluated whether the disclosures made in the financial statements appropriately reflect the facts and critical accounting judgements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Deloitte LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Statutory Auditor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">London, United Kingdom </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">10&#160;March 2023 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="shell_a382677_32"><span style="font-weight:bold">Item&#160;19</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:left">Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:90%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex11.htm">Articles of Association of the Registrant as in effect on the date hereof. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119380519000654/e618555_ex99-a.htm">Amended and Restated Deposit Agreement among the Registrant and The Bank of New York Mellon, as Depositary, and the owners and holders from time to time of the American Depositary Shares issued thereunder, including the form of American Depositary Receipt, is incorporated by reference to the post-effective amendment to the Registration Statement on Form <span style="white-space:nowrap">F-6</span> (No. <span style="white-space:nowrap">333-232726)</span> filed with the Commission on July 19, 2019. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119380521000363/e620387_f6pos-gsk.htm">Amendment No. 1 to Deposit Agreement, including the Form of American Depositary Receipt, is incorporated by reference to the post-effective amendment No. 1 to the Registration Statement on Form F-6 filed with the Commission on March 15, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex23.htm">Description of the Registrant&#8217;s securities registered pursuant to Section&#160;12 of the Securities Exchange Act of 1934. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312519076716/d601746dex43.htm">UK Service Agreement between GlaxoSmithKline Services Unlimited and Emma N. Walmsley dated March&#160;29, 2017 is incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the Commission on March&#160;15, 2019 . </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312519076716/d601746dex45.htm">UK Service Agreement between GlaxoSmithKline Services Unlimited and Iain Mackay dated 18&#160;September 2018 is incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the Commission on March&#160;15, 2019. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312516510261/d32974dex49.htm">Share and Business Sale Agreement relating to the Vaccines Group made on April&#160;22, 2014, as amended and restated on May&#160;29, 2014, as amended on October&#160;9, 2014, and as further amended and restated on March&#160;1, 2015, between Novartis AG and GlaxoSmithKline plc is incorporated by reference to Exhibit 4.9 of the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the Commission on March 18, 2016. Confidential portions of this exhibit have been omitted pursuant to a request for confidential treatment and filed separately with the SEC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312519076716/d601746dex410.htm">Stock and Asset Purchase Agreement by and among Pfizer Inc., GlaxoSmithKline plc and GlaxoSmithKline Consumer Healthcare Holdings Limited dated as of December 19, 2018 is incorporated by reference to Exhibit 4.10 to the Registrant&#8217;s Annual Report on Form 20-F filed with the Commission on March 15, 2019. Confidential portions of this exhibit have been omitted pursuant to a request for confidential treatment and filed separately with the SEC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312520065064/d769953dex48.htm">Amendment Agreement dated July 31, 2019 to the Stock and Asset Purchase Agreement by and among Pfizer Inc., GlaxoSmithKline plc, GlaxoSmithKline Consumer Healthcare Holdings Limited and GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited dated as of July&#160;31, 2019 is incorporated by reference to Exhibit 4.8 to the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the Commission on March&#160;6, 2020. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex48.htm">Second Amendment Agreement dated June&#160;1, 2022 to the Stock and Asset Purchase Agreement by and among Pfizer Inc., GSK plc, GlaxoSmithKline Consumer Healthcare Holdings Limited and GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited dated as of 19&#160;December 2018. Certain confidential information contained in this exhibit has been omitted from this exhibit because it is both (i)&#160;not material and (ii)&#160;would likely cause competitive harm to the Registrant if publicly disclosed. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;8.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex152.htm">A list of the Registrant&#8217;s principal subsidiaries is incorporated by reference to the information set forth in Note 46 to the financial statements on page 264 of the GSK Annual Report 2022 included as Exhibit 15.2. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;12.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex121.htm">Certification Required by Rule <span style="white-space:nowrap">13a-14(a)</span> or <span style="white-space:nowrap">15d-14(a)</span> under the Securities Exchange Act of 1934 &#8211; Emma Walmsley. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;12.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex122.htm">Certification Required by Rule <span style="white-space:nowrap">13a-14(a)</span> or <span style="white-space:nowrap">15d-14(a)</span> under the Securities Exchange Act of 1934 &#8211; Iain Mackay. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;13.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex131.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (Subsections (a)&#160;and (b) of Section&#160;1350, Chapter 63 of Title 18, United States Code). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;15.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex151.htm">Consent of Deloitte LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;15.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382677dex152.htm">*GSK Annual Report 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1131399/000119312521096095/d134704dex22.htm">List of Subsidiary Issuers of Guaranteed Securities is incorporated by reference to Exhibit 22 to the Registration Statement on Form <span style="white-space:nowrap">F-3</span> filed with the Commission on March&#160;26, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Instance Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF**XBRL Taxonomy Extension Definition Linkbase Document 101.LAB**XBRL Taxonomy Extension Label Linkbase Document 101.PRE**XBRL Taxonomy Extension Presentation</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Linkbase Document </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">Certain of the information included within Exhibit 15.2, which is provided pursuant to Rule <span style="white-space:nowrap">12b-23(a)(3)</span> of the Securities Exchange Act of 1934, as amended, is incorporated by reference in this Form <span style="white-space:nowrap">20-F,</span> as specified elsewhere in this Form <span style="white-space:nowrap">20-F.</span> With the exception of the items and pages so specified, the GSK Annual Report 2022 is not deemed to be filed as part of this Form <span style="white-space:nowrap">20-F.</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:left">In accordance with Rule 402 of Regulation <span style="white-space:nowrap">S-T,</span> the information in these exhibits shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold" id="shell_a382677_33">Signature </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The registrant hereby certifies that it meets all of the requirements for filing on Form <span style="white-space:nowrap">20-F</span> and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">GSK plc</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">March 10, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Iain Mackay</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Iain Mackay</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;text-align:center">85 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d382677dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 1.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g382677g0224043354317.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Company No.&nbsp;3888792 </P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL" ALIGN="center"><B>(As adopted by
Special Resolution passed on 4&nbsp;May 2022) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>GSK plc </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Company No.&nbsp;3888792 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(As adopted by
Special Resolution passed on 4&nbsp;May 2022) </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>GSK PLC </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B><U>Page</U><B></B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Exclusion of Model Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Limited Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Change of Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Rights Attached to Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Redeemable Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Variation of Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Pari Passu Issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Payment of Commission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Trusts Not Recognised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Suspension of Rights Where <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> of Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Uncertificated Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Right to Share Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Replacement of Share Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Share Certificates Sent at Holder&#146;s Risk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Execution of Share Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">18.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Company&#146;s Lien on Shares Not Fully Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">19.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Enforcing Lien by Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">20.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Application of Proceeds of Sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">21.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">22.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Timing of Calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">23.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Liability of Joint Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">24.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Interest Due on <FONT STYLE="white-space:nowrap">Non-Payment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">25.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sums Due on Allotment Treated as Calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">26.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power to Differentiate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">27.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Payment of Calls in Advance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">28.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Notice if Call or Instalment Not Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">29.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Form of Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">30.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Forfeiture for <FONT STYLE="white-space:nowrap">Non-Compliance</FONT> with Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">31.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Notice after Forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">32.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sale of Forfeited Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">33.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Arrears to be Paid Notwithstanding Forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">34.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Statutory Declaration as to Forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">35.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">36.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Signing of Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">37.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Rights to Decline Registration of Partly Paid Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">38.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Other Rights to Decline Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">39.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">No Fee for Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">40.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Untraced Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">41.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Transmission on Death</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">42.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Entry of Transmission in Register</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">43.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Election of Person Entitled by Transmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">44.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Rights of Person Entitled by Transmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">45.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">Sub-division</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">46.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fractions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">47.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Omission or <FONT STYLE="white-space:nowrap">Non-Receipt</FONT> of Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">48.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Postponement of General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">49.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Resolutions of members at Annual General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">50.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Electronic General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">51.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">52.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Procedure if Quorum Not Present</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">53.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Security Arrangements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">54.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Confidential Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">55.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Chair of General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">56.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Orderly Conduct</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">57.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Entitlement to Attend and Speak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">58.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Adjournments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">59.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Notice of Adjournment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">60.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amendments to Resolutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">61.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amendments Ruled Out of Order</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">62.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Votes of Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">63.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Method of Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">64.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Votes of Joint Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">65.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Voting on Behalf of Incapable Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">66.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">No Right to Vote where Sums Overdue on Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">67.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Objections or Errors in Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">68.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Meaning of Approved Depositary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">69.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Appointment of Approved Depositaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">70.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Register of Approved Depositaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">71.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Approved Depositaries&#146; Attendance at General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">72.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Proxies of Appointed Depositaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">73.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Identifying Appointed Proxies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">74.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Appointment of Proxies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">75.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Receipt of Proxies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">76.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Maximum Validity of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">77.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Form of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">78.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cancellation of Proxy&#146;s Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">79.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Separate General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">80.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Number of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">81.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Directors&#146; Shareholding Qualification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">82.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power of Company to Appoint Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">83.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power of Board to Appoint Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">84.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Retirement of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">85.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Filling Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">86.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power of Removal by Special Resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">87.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Persons Eligible as Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">88.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Position of Retiring Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">89.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Vacation of Office by Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">29</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">90.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Alternate Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">29</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">91.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Executive Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">30</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">92.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Directors&#146; Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">31</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">93.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Additional Remuneration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">31</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">94.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">32</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">95.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Pensions and Gratuities for Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">32</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">96.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Conflicts of interest requiring board authorisation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">32</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">97.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Other conflicts of interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">33</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">98.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">34</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">99.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Quorum and voting requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">34</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">100.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">General</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">36</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">101.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">General Powers of Company Vested in Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">37</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">102.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Borrowing Powers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">37</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">103.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Agents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">37</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">104.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Delegation to Individual Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">38</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">105.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Registers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">38</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">106.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Provision for Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">38</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">107.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Board Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">38</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">108.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Notice of Board Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">39</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">109.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">39</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">110.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Directors below Minimum through Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">39</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">111.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Appointment of Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">39</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">112.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Competence of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">39</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">113.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">114.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Delegation to Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">115.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Participation in Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">116.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Resolution in Writing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">117.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Validity of Acts of Board or Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">118.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Use of Seals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">41</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">119.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Declaration of Dividends by Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">41</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">120.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Payment of Interim and Fixed Dividends by Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">41</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">121.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Calculation and Currency of Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">41</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">122.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Amounts Due on Shares may be Deducted from Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">123.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">No Interest on Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">124.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Payment Procedure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">125.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Uncashed Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">126.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Forfeiture of Unclaimed Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">127.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dividends Not in Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">128.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Scrip Dividends and Dividend Plans Generally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">129.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power to Capitalise Reserves and Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">47</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">130.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Settlement of Difficulties in Distribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">47</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">131.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Power to Choose Any Record Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">47</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">132.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Inspection of Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">48</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">133.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Summary Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">48</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">134.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Method of Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">48</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">135.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Record Date for Service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">49</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">136.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Members Resident Abroad or on Branch Registers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">49</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">137.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Service of Notice on Person Entitled by Transmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">138.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Deemed Delivery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">51</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">139.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Notice When Post Not Available</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">51</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">140.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Presumptions Where Documents Destroyed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">52</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">141.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Indemnity of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">53</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">ARTICLES OF ASSOCIATION </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">of </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">GSK PLC </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(adopted by Special Resolution passed on 4&nbsp;May 2022) </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Interpretation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Exclusion of Model Articles </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No articles set out in any statute, or in any statutory instrument or other subordinate legislation made under any statute, concerning
companies shall apply as the articles of the company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In these articles unless the context otherwise requires: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>address</U></B>&#148; includes a number or address used for the purposes of sending or receiving documents or information by
electronic means; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>these articles</U></B>&#148; means these articles of association as altered from time to time and the
expression &#147;<B><U>this article</U></B>&#148; shall be construed accordingly; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>associated company</U></B>&#148;
means any company (i)&nbsp;which is the company&#146;s holding company or (ii)&nbsp;in which the company or its holding company or any of the predecessors of the company or of such holding company has any interest whether direct or indirect or
(iii)&nbsp;which is in any way allied to or associated with the company or its holding company or any of the predecessors of the company or of such holding company, of (iv)&nbsp;which is a subsidiary undertaking or any other associated company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the auditors</U></B>&#148; means the auditors from time to time of the company or, in the case of joint auditors, any one of
them; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the Bank of England base rate</U></B>&#148; means the base lending rate most recently set by the Monetary Policy
Committee of the Bank of England in connection with its responsibilities under Part 2 of the Bank of England Act 1998; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the board</U></B>&#148; means the board of directors from time to time of the company or the directors present at a meeting
of the directors at which a quorum is present; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>certificated share</U></B>&#148; means a share which is not an
uncertificated share and references in these articles to a share being held in certificated form shall be construed accordingly; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>clear days</U></B>&#148; in relation to the period of a notice means that period excluding the day when the notice is served
or deemed to be served and the day for which it is given or on which it is to take effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the Companies
Acts</U></B>&#148; means every statute (including any orders, regulations or other subordinate legislation made under it) from time to time in force concerning companies in so far as it applies to the company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the holder</U></B>&#148; in relation to any shares means the person whose name is entered in the register as the holder of
those shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the office</U></B>&#148; means the registered office from time to time of the company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>paid up</U></B>&#148; means paid up or credited as paid up; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>participating class</U></B>&#148; means a class of shares title to which is permitted by an Operator to be transferred by
means of a relevant system; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>person entitled by transmission</U></B>&#148; means a person whose entitlement to a share
in consequence of the death or bankruptcy of a member or of any other event giving rise to its transmission by operation of law has been noted in the register; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>place</U></B>&#148; means, in relation to a general meeting or annual general meeting, the place of a physical meeting or
the electronic platform specified by the board in relation to an electronic general meeting and, where relevant, references to the place of a general meeting or annual general meeting include any combination of two or more such places; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the register</U></B>&#148; means the register of members of the company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>seal</U></B>&#148; means any common or official seal that the company may be permitted to have under the Companies Acts;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the secretary</U></B>&#148; means the secretary, or (if there are joint secretaries) any one of the joint secretaries,
of the company and includes an assistant or deputy secretary and any person appointed by the board to perform any of the duties of the secretary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the uncertificated securities rules</U></B>&#148; means any provision of the Companies Acts relating to the holding,
evidencing of title to, or transfer of uncertificated shares and any legislation, rules or other arrangements made under or by virtue of such provision; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>uncertificated share</U></B>&#148; means a share of a class which is at the relevant time a participating class, title to
which is recorded on the register as being held in uncertificated form and references in these articles to a share being held in uncertificated form shall be construed accordingly; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>United Kingdom</U></B>&#148; means Great Britain and Northern Ireland; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">references to a person being &#147;<B>present</B>&#148; at or
&#147;<B>attending</B>&#148; a general meeting or annual general meeting means present at a physical meeting or participating via the electronic platform specified by the board in relation to that meeting, and references to
&#147;<B>absence</B>&#148;, &#147;<B>refuse entry</B>&#148; and &#147;<B>eject</B>&#148; shall be read accordingly; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">references to a
document being <B><U>signed</U></B> or to <B><U>signature</U></B> include references to its being executed under hand or under seal or by any other method and, in the case of a communication in electronic form, such references are to its being
authenticated as specified by the Companies Acts; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">references to <B><U>writing</U></B> include references to any method of
representing or reproducing words in a legible and <FONT STYLE="white-space:nowrap">non-transitory</FONT> form whether sent or supplied in electronic form or otherwise and <B><U>written </U></B>shall be construed accordingly; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">words or expressions to which a particular meaning is given by the Companies Acts in force when these articles or any part of these
articles are adopted bear (if not inconsistent with the subject matter or context) the same meaning in these articles or that part (as the case may be) save that the word &#147;<B><U>company</U></B>&#148; shall include any body corporate; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">references to a <B><U>meeting</U></B> shall not be taken as requiring more than one person to be present if any quorum requirement can
be satisfied by one person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Headings are included only for convenience and shall not affect meaning. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Limited Liability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The liability of members of the company is limited to the amount, if any, unpaid on the shares in the company held by them. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Change of Name </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may change its name by resolution of the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Share Capital </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Rights Attached to Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to any rights attached to existing shares, any share may be issued with or have attached to it such rights and restrictions as
the company may by ordinary resolution decide or, if no such resolution has been passed or so far as the resolution does not make specific provision, as the board may decide. Such rights and restrictions shall apply to the relevant shares as if the
same were set out in these articles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Redeemable Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to any rights attached to existing shares, any share may be issued which is to be redeemed, or is liable to be redeemed at the
option of the company or the holder. The board may determine the terms, conditions and manner of redemption of any redeemable share so issued. Such terms and conditions shall apply to the relevant shares as if the same were set out in these
articles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Variation of Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of the Companies Acts, all or any of the rights attached to any existing class of shares may from time to time
(whether or not the company is being wound up) be varied either with the consent in writing of the holders of not less than three-fourths in nominal value of the issued shares of that class (excluding any shares of that class held as treasury
shares) or with the sanction of a special resolution passed at a separate general meeting of the holders of those shares. All the provisions of these articles as to general meetings of the company shall, with any necessary modifications, apply to
any such separate general meeting, but so that the necessary quorum shall be two persons entitled to vote and holding or representing by proxy not less than <FONT STYLE="white-space:nowrap">one-third</FONT> in nominal value of the issued shares of
the class (excluding any shares of that class held as treasury shares), (but so that at any adjourned meeting one holder entitled to vote and present in person or by proxy (whatever the number of shares held by them) shall be a quorum). The
foregoing provisions of this article shall apply to the variation of the special rights attached to some only of the shares of any class as if each group of shares of the class differently treated formed a separate class and their special rights
were to be varied. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Pari Passu Issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If new shares are created or issued which rank equally with any other existing shares, or if the company purchases or redeems any of its
own shares, the rights of the existing shares will not be regarded as changed or abrogated unless the terms of the existing shares expressly say otherwise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of these articles and to any resolution passed by the company and without prejudice to any rights attached to
existing shares, the board may offer, allot, grant options over or otherwise deal with or dispose of shares in the company to such persons, at such times and for such consideration and upon such terms as the board may decide. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Payment of Commission </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may in connection with the issue of any shares or the sale for cash of treasury shares exercise all powers of paying
commission and brokerage conferred or permitted by the Companies Acts. Any such commission or brokerage may be satisfied by the payment of cash or by the allotment of fully or partly-paid shares or other securities or partly in one way and partly in
the other. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Trusts Not Recognised </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Except as ordered by a court of competent jurisdiction or as required by law, no person shall be recognised by the company as holding
any share upon any trust and the company shall not be bound by or required in any way to recognise (even when having notice of it) any interest in any share or (except only as by these articles or by law otherwise provided) any other right in
respect of any share other than an absolute right to the whole of the share in the holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Suspension of Rights Where <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> of Interest
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where the holder of any shares in the company, or any other person appearing to be interested in those shares, fails
to comply within the relevant period with any statutory notice in respect of those shares or, in purported compliance with such a notice, has made a statement which is false or inadequate in a material particular, the company may give the holder of
those shares a further notice (a &#147;<B><U>restriction notice</U></B>&#148;) to the effect that from the service of the restriction notice those shares will be subject to some or all of the relevant restrictions, and from service of the
restriction notice those shares shall, notwithstanding any other provision of these articles, be subject to those relevant restrictions accordingly. For the purpose of enforcing the relevant restriction referred to in <U><FONT
STYLE="white-space:nowrap">sub-paragraph</FONT> (iii)</U>&nbsp;of the definition of &#147;relevant restrictions&#148;, the board may give notice to the relevant member requiring the member to change the relevant shares held in uncertificated form to
certificated form by the time stated in the notice and to keep them in certificated form for as long as the board requires. The notice may also state that the member may not change any of the relevant shares held in certificated form to
uncertificated form. If the member does not comply with the notice, the board may authorise any person to instruct the Operator to change the relevant shares held in uncertificated form to certificated form. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If after the service of a restriction notice in respect of any shares the board is satisfied that all information
required by any statutory notice relating to those shares or any of them from their holder or any other person appearing to be interested in the shares the subject of the restriction notice has been supplied, the company shall, within seven days,
cancel the restriction notice. The company may at any time at its discretion cancel any restriction notice or exclude any shares from it. The company shall cancel a restriction notice within seven days after receipt of a notice in writing that the
relevant shares have been transferred pursuant to an arm&#146;s length sale. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where any restriction notice is cancelled or ceases to have effect in relation to any shares, any moneys relating to
those shares which were withheld by reason of that notice shall be paid without interest to the person who would but for the notice have been entitled to them or as that person may direct. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any new shares in the company issued in right of any shares subject to a restriction notice shall also be subject to
the restriction notice, and the board may make any right to an allotment of the new shares subject to restrictions corresponding to those which will apply to those shares by reason of the restriction notice when such shares are issued.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any holder of shares on whom a restriction notice has been served may at any time request the company to give in
writing the reason why the restriction notice has been served, or why it remains uncancelled, and within 14 days of receipt of such a notice the company shall give that information accordingly. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where a person appearing to be interested in shares has been served with a statutory notice and the shares in which
they appear to be interested are held by an Approved Depositary, this article applies only to those shares which are held by the Approved Depositary in which that person appears to be interested and not (so far
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
as that person&#146;s apparent interest is concerned) to any other shares held by the Approved Depositary. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where a member who is an Approved Depositary has been served with a statutory notice, the obligations of that member
will be limited to disclosing to the company information relating to any person who appears to be interested in the shares held by it which has been recorded by it in accordance with the arrangement under which it was appointed as an Approved
Depositary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(H)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If a statutory notice is given by the company to a person appearing to be interested in any share, a copy shall at the
same time be given to the holder, but the failure or omission to do so or the <FONT STYLE="white-space:nowrap">non-receipt</FONT> of the copy by the holder shall not invalidate such notice. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">This article is in addition to, and shall not in any way prejudice or affect, the statutory rights of the company
arising from any failure by any person to give any information required by a statutory notice within the time specified in it. For the purpose of this article a statutory notice need not specify the relevant period, and may require any information
to be given before the expiry of the relevant period. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(J)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In this article: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">a sale is an &#147;<B><U>arm&#146;s length sale</U></B>&#148; if the board is satisfied that it is a bona fide sale of the whole of the
beneficial ownership of the shares to a party unconnected with the holder or with any person appearing to be interested in such shares and shall include a sale made by way of or in pursuance of acceptance of a takeover offer and a sale made through
a recognised investment exchange or any other stock exchange outside the United Kingdom. For this purpose an associate (within the definition of that expression in any statute relating to insolvency in force at the date of adoption of this article)
shall be included amongst the persons who are connected with the holder or any person appearing to be interested in such shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>person appearing to be interested</U></B>&#148; in any shares shall mean any person named in a response to a statutory
notice or otherwise notified to the company by a member as being so interested or shown in any register or record kept by the company under the Companies Acts as so interested or, taking into account a response or failure to respond in the light of
the response to any other statutory notice and any other relevant information in the possession of the company, any person whom the company knows or has reasonable cause to believe is or may be so interested; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>person with a 0.25</U></B><B><U></U></B><B><U>&nbsp;per cent. interest</U></B>&#148; means a person who holds, or is shown
in any register or record kept by the company under the Companies Acts as having an interest in, shares in the company which comprise in total at least 0.25&nbsp;per cent. in number or nominal value of the shares of the company (calculated exclusive
of any shares held as treasury shares), or of any class of such shares (calculated exclusive of any shares of that class held as treasury shares), in issue at the date of service of the restriction notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>relevant period</U></B>&#148; means a period of 14 days following service of a statutory notice; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>relevant restrictions</U></B>&#148; mean in the case of a restriction
notice served on a person with a 0.25&nbsp;per cent. interest that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the shares shall not confer on the holder any right to attend or vote either personally or by proxy at any general
meeting of the company or at any separate general meeting of the holders of any class of shares in the company or to exercise any other right conferred by membership in relation to general meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may withhold payment of all or any part of any dividends or other moneys payable in respect of the shares
and the holder shall not be entitled to receive shares in lieu of dividend; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may decline to register a transfer of any of the shares which are certificated shares, unless such a
transfer is pursuant to an arm&#146;s length sale, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">and in any other case mean only the restriction specified in
<U><FONT STYLE="white-space:nowrap">sub-paragraph</FONT> (i)</U>&nbsp;of this definition; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>statutory
notice</U></B>&#148; means a notice served by the company under the Companies Acts requiring particulars of interests in shares or of the identity of persons interested in shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Uncertificated Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Pursuant and subject to the uncertificated securities rules, the board may permit title to shares of any class to be
evidenced otherwise than by a certificate and title to shares of such a class to be transferred by means of a relevant system and may make arrangements for a class of shares (if all shares of that class are in all respects identical) to become a
participating class. Title to shares of a particular class may only be evidenced otherwise than by a certificate where that class of shares is at the relevant time a participating class. The board may also, subject to compliance with the
uncertificated securities rules, determine at any time that title to any class of shares may from a date specified by the board no longer be evidenced otherwise than by a certificate or that title to such a class shall cease to be transferred by
means of any particular relevant system. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In relation to a class of shares which is a participating class and for so long as it remains a participating class,
no provision of these articles shall apply or have effect to the extent that it is inconsistent in any respect with: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the holding of shares of that class in uncertificated form; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the transfer of title to shares of that class by means of a relevant system; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any provision of the uncertificated securities rules, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">and, without prejudice to the generality of this article, no provision of these articles shall apply or have effect to the extent that
it is in any respect inconsistent with the maintenance, keeping or entering up by the Operator, so long as that is permitted or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
required by the uncertificated securities rules, of an Operator register of securities in respect of that class of shares in uncertificated form. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Shares of a class which is at the relevant time a participating class may be changed from uncertificated to
certificated form, and from certificated to uncertificated form, in accordance with and subject as provided in the uncertificated securities rules. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If, under these articles or the Companies Acts, the company is entitled to sell, transfer or otherwise dispose of,
forfeit, <FONT STYLE="white-space:nowrap">re-allot,</FONT> accept the surrender of or otherwise enforce a lien over an uncertificated share, then, subject to these articles and the Companies Acts, such entitlement shall include the right of the
board to: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">require the holder of that uncertificated share by notice in writing to change that share from uncertificated to
certificated form within such period as may be specified in the notice and keep it as a certificated share for as long as the board requires; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">appoint any person to take such other steps, by instruction given by means of a relevant system or otherwise, in the
name of the holder of such share as may be required to effect the transfer of such share and such steps shall be as effective as they had been taken by the registered holder of that share; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture, <FONT
STYLE="white-space:nowrap">re-allotment</FONT> or surrender of that share or otherwise to enforce a lien in respect of that share. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Unless the board otherwise determines, shares which a member holds in uncertificated form shall be treated as separate
holdings from any shares which that member holds in certificated form. However shares held in uncertificated form shall not be treated as forming a class which is separate from certificated shares with the same rights. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Unless the board otherwise determines or the uncertificated securities rules otherwise require, any shares issued or
created out of or in respect of any uncertificated shares shall be uncertificated shares and any shares issued or created out of or in respect of any certificated shares shall be certificated shares. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company shall be entitled to assume that the entries on any record of securities maintained by it in accordance
with the uncertificated securities rules and regularly reconciled with the relevant Operator register of securities are a complete and accurate reproduction of the particulars entered in the Operator register of securities and shall accordingly not
be liable in respect of any act or thing done or omitted to be done by or on behalf of the company in reliance on such assumption; in particular, any provision of these articles which requires or envisages that action will be taken in reliance on
information contained in the register shall be construed to permit that action to be taken in reliance on information contained in any relevant record of securities (as so maintained and reconciled). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Right to Share Certificates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Every person (except a person to whom the company is not by law required to issue a certificate) whose name is entered in the register
as a holder of any certificated shares shall be entitled, without payment, to receive within the time limits prescribed by the Companies Acts (or, if earlier, within any prescribed time limit or within a time specified when the shares were issued)
one certificate for all those shares of any one class. In the case of a certificated share held jointly by several persons, the company shall not be bound to issue more than one certificate and delivery of a certificate to one of several joint
holders shall be sufficient delivery to all. A member who transfers some but not all of the shares comprised in a certificate shall be entitled to a certificate for the balance without charge to the extent the balance is to be held in certificated
form. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Replacement of Share Certificates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If a share certificate is defaced, worn out, lost or destroyed, it may be replaced on such terms (if any) as to evidence and indemnity
as the board may decide and, where it is defaced or worn out, after delivery of the old certificate to the company. Any two or more certificates representing shares of any one class held by any member shall at their request be cancelled and a single
new certificate for such shares issued in lieu. Any certificate representing shares of any one class held by any member may at their request be cancelled and two or more certificates for such shares may be issued instead. The board may require the
payment of any exceptional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of the company incurred in connection with the issue of any certificates under this article. Any one of two or more
joint holders may request replacement certificates under this article. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Share Certificates Sent at Holder&#146;s Risk </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Every share certificate sent in accordance with these articles will be sent at the risk of the member or other person entitled to the
certificate. The company will not be responsible for any share certificate lost or delayed in the course of delivery. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Execution of Share Certificates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Every share certificate shall be executed under a seal or in such other manner as the board, having regard to the terms of issue and any
listing requirements, may authorise and shall specify the number and class of the shares to which it relates and the amount or respective amounts paid up on the shares. The board may by resolution decide, either generally or in any particular case
or cases, that any signatures on any share certificates need not be autographic but may be applied to the certificates by some mechanical or other means or may be printed on them or that the certificates need not be signed by any person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Lien </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Company&#146;s Lien on Shares Not Fully Paid </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company shall have a first and paramount lien on every share (not being a fully paid share) for all amounts payable to the company
(whether presently or not) in respect of that share. The company&#146;s lien on a share shall extend to every amount payable in respect of it. The board may at any time either generally or in any particular case waive any lien that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
has arisen or declare any share to be wholly or in part exempt from the provisions of this article. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Enforcing Lien by Sale </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may sell, in such manner as the board may decide, any share on which the company has a lien if a sum in respect of which the
lien exists is presently payable and is not paid within 14 clear days after a notice has been served on the holder of the share or the person who is entitled by transmission to the share, demanding payment and stating that if the notice is not
complied with the share may be sold. For giving effect to the sale the board may authorise some person to sign an instrument of transfer of the share sold to or in accordance with the directions of the purchaser. The transferee shall not be bound to
see to the application of the purchase money, nor shall their title to the share be affected by any irregularity or invalidity in relation to the sale. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Application of Proceeds of Sale </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The net proceeds, after payment of the costs, of the sale by the company of any share on which it has a lien shall be applied in or
towards payment or discharge of the debt or liability in respect of which the lien exists so far as it is presently payable, and any residue shall (subject to a like lien for debts or liabilities not presently payable as existed upon the share prior
to the sale and upon surrender, if required by the company, for cancellation of the certificate for the share sold) be paid to the person who was entitled to the share at the time of the sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Calls on Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Calls </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the terms of issue, the board may from time to time make calls upon the members in respect of any moneys unpaid on their
shares (whether on account of the nominal amount of the shares or by way of premium) and not payable on a date fixed by or in accordance with the terms of issue, and each member shall (subject to the company serving upon them at least 14 clear
days&#146; notice specifying when and where payment is to be made) pay to the company as required by the notice the amount called on their shares. A call may be made payable by instalments. A call may be revoked or postponed, in whole or in part, as
the board may decide. A person upon whom a call is made shall remain liable jointly and severally with the successors in title to their shares for all calls made upon them notwithstanding the subsequent transfer of the shares in respect of which the
call was made. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Timing of Calls </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A call shall be deemed to have been made at the time when the resolution of the board authorising the call was passed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Liability of Joint Holders </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The joint holders of a share shall be jointly and severally liable to pay all calls in respect of the share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Interest Due on <FONT STYLE="white-space:nowrap">Non-Payment</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If a call remains unpaid after it has become due and payable, the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it is due and payable to the time of actual payment at such rate (not exceeding the Bank of England base rate by more than five percentage points) as the board may decide, and all expenses that have been incurred by the
company by reason of such <FONT STYLE="white-space:nowrap">non-payment,</FONT> but the board shall be at liberty in any case or cases to waive payment of the interest or expenses wholly or in part. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Sums Due on Allotment Treated as Calls </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any amount which becomes payable in respect of a share on allotment or on any other date fixed by or in accordance with the terms of
issue, whether in respect of the nominal amount of the share or by way of premium or as an instalment of a call, shall be deemed to be a call and, if it is not paid, all the provisions of these articles shall apply as if the sum had become due and
payable by virtue of a call. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power to Differentiate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may on or before the issue of shares differentiate between the allottees or holders as to the amount of calls to be paid and
the times of payment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Payment of Calls in Advance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may, if it thinks fit, receive from any member who is willing to advance them all or any part of the moneys uncalled and
unpaid upon any shares held by that member and on all or any of the moneys so advanced may (until they would, but for the advance, become presently payable) pay interest at such rate (not exceeding the Bank of England base rate by more than five
percentage points, unless the company by ordinary resolution shall otherwise direct) as the board may decide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Forfeiture of Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Notice if Call or Instalment Not Paid </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If any call or instalment of a call remains unpaid on any share after the day appointed for payment, the board may at any time serve a
notice on the holder requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued and any expenses incurred by the company by reason of such
<FONT STYLE="white-space:nowrap">non-payment.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Form of Notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The notice shall name a further day (not being less than 14 clear days from the date of the notice) on or before which, and the place
where, the payment required by the notice is to be made and shall state that in the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> on or before the day and at the place appointed, the shares in respect of which the call has been made
or instalment is payable will be liable to be forfeited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Forfeiture for <FONT STYLE="white-space:nowrap">Non-Compliance</FONT> with Notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the notice is not complied with, any share in respect of which it was given may, at any time before payment of all calls or
instalments and interest and expenses due in respect of it have been made, be forfeited by a resolution of the board to that effect and the forfeiture shall include all dividends declared and other moneys payable in respect of the forfeited shares
and not paid before the forfeiture. The board may accept the surrender of any share liable to be forfeited and, in that event, references in these articles to forfeiture shall include surrender. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>31.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Notice after Forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">When any share has been forfeited, notice of the forfeiture shall be served upon the person who was before forfeiture the holder of the
share but no forfeiture shall be invalidated by any omission or neglect to give notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>32.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Sale of Forfeited Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Until cancelled in accordance with the requirements of the Companies Acts, a forfeited share shall be deemed to be the property of the
company and may be sold or otherwise disposed of either to the person who was, before forfeiture, the holder or to any other person upon such terms and in such manner as the board shall decide. The board may for the purposes of the disposal
authorise some person to sign an instrument of transfer to the designated transferee. The company may receive the consideration (if any) given for the share on its disposal. At any time before a sale or disposition the forfeiture may be cancelled by
the board on such terms as the board may decide. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>33.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Arrears to be Paid Notwithstanding Forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A person whose shares have been forfeited shall cease to be a member in respect of them and shall surrender to the company for
cancellation the certificate for the forfeited shares but shall remain liable to pay to the company all moneys which at the date of the forfeiture were payable by them to the company in respect of those shares with interest thereon at such rate (not
exceeding the Bank of England base rate by more than five percentage points) as the board may decide from the date of forfeiture until payment, and the company may enforce payment without being under any obligation to make any allowance for the
value of the shares forfeited or for any consideration received on their disposal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>34.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Statutory Declaration as to Forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A statutory declaration that the declarant is a director of the company or the secretary and that a share has been forfeited on a
specified date shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the share. The declaration shall (subject to the signing of an instrument of transfer if necessary) constitute a good title to
the share and the person to whom the share is sold or otherwise disposed of shall not be bound to see to the application of the purchase money (if any) nor shall their title to the share be affected by any irregularity or invalidity in the
proceedings relating to the forfeiture, sale or disposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Transfer of Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>35.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Transfer </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to such of the restrictions of these articles as may be applicable: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any member may transfer all or any of their uncertificated shares by means of a relevant system in such manner
provided for, and subject as provided in, the uncertificated securities rules, and accordingly no provision of these articles shall apply in respect of an uncertificated share to the extent that it requires or contemplates the effecting of a
transfer by an instrument in writing or the production of a certificate for the share to be transferred; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any member may transfer all or any of their certificated shares by an instrument of transfer in any usual form or in
any other form which the board may approve. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The transferor of a share shall be deemed to remain the holder of the share concerned until the name of the transferee
is entered in the register in respect of it. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>36.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Signing of Transfer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The instrument of transfer of a certificated share shall be signed by or on behalf of the transferor and (in the case of a partly paid
share) the transferee. All instruments of transfer, when registered, may be retained by the company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>37.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Rights to Decline Registration of Partly Paid Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board can decline to register any transfer of any share which is not a fully paid share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>38.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Other Rights to Decline Registration </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Registration of a transfer of an uncertificated share may be refused in the circumstances set out in the
uncertificated securities rules, and where, in the case of a transfer to joint holders, the number of joint holders to whom the uncertificated share is to be transferred exceeds four. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may decline to register any transfer of a certificated share unless: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the instrument of transfer is duly stamped or duly certified or otherwise shown to the satisfaction of the board to be
exempt from stamp duty and is left at the office or such other place as the board may from time to time determine accompanied (save in the case of a transfer by a person to whom the company is not required by law to issue a certificate and to whom a
certificate has not been issued) by the certificate for the share to which it relates and such other evidence as the board may reasonably require to show the right of the person signing the instrument of transfer to make the transfer and, if the
instrument of transfer is signed by some other person on their behalf, the authority of that person so to do; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the instrument of transfer is in respect of only one class of share; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of a transfer to joint holders, the number of joint holders to whom the share is to be transferred does
not exceed four. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For all purposes of these articles relating to the registration of transfers of shares, the renunciation of the
allotment of any shares by the allottee in favour of some other person shall be deemed to be a transfer and the board shall have the same powers of refusing to give effect to such a renunciation as if it were a transfer. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>39.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>No Fee for Registration </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No fee shall be charged by the company for registering any transfer, document or instruction relating to or affecting the title to any
share or for making any other entry in the register. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>40.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Untraced Shareholders </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company may sell any certificated shares in the company on behalf of the holder of, or person entitled by
transmission to, the shares at the best price reasonably obtainable at the time of sale if: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the shares have been in issue either in certificated or uncertificated form throughout the qualifying period and at
least three cash dividends have become payable on the shares during the qualifying period; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">no cash dividend payable on the shares has either been claimed by presentation to the paying bank of the relevant
cheque or warrant or been satisfied by the transfer of funds to a bank account designated by the holder of, or person entitled by transmission to, the shares or by the transfer of funds by means of a relevant system at any time during the relevant
period; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">so far as any director of the company at the end of the relevant period is then aware, the company has not at any time
during the relevant period received any communication from the holder of, or person entitled by transmission to, the shares; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">on or after the expiry of the qualifying period, the company has sent a notice to the registered address or last known
address of the member or person concerned, of its intention to sell such share and before sending such a notice to the member or other person concerned, the company must have used reasonable efforts to trace the member or other person entitled,
engaging, if considered appropriate by the company, a professional asset reunification company or other tracing agent, and at least a period of three months has elapsed from the date of sending such notices. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company shall also be entitled to sell at the best price reasonably obtainable at the time of sale any additional
certificated shares in the company issued either in certificated or uncertificated form during the qualifying period in right of any share to which <U>paragraph (A)</U>&nbsp;of this article applies (or in right of any share so issued), if the
criteria in <U>paragraph (A)(ii)</U> to <U>(iv)</U>&nbsp;are satisfied in relation to the additional shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">To give effect to any sale of shares pursuant to this article the board may authorise some person to transfer the
shares in question and an instrument of transfer signed by that person shall be as effective as if it had been signed by the holder of, or person entitled by transmission to, the shares. The purchaser shall not be bound to see to the application of
the purchase moneys nor shall their title to the shares be affected by any irregularity or invalidity in the proceedings relating to the sale. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The net proceeds of sale shall belong to the company and, upon their receipt, the company shall record the name of the
member, or (if known) the person who would have been entitled to the shares by law, as a creditor for the money in its accounts, unless and until forfeited under this article. No trust shall be created in respect of the debt and no interest shall be
payable in respect of it and the company shall not be required to account for any moneys earned from the net proceeds which may be employed in the business of the company or as it thinks fit. If no valid claim for the money has been received by the
company during a period of two years from the date on which the relevant shares were sold by the company under this article, the money will be forfeited and will belong to the company. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For the purpose of this article: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the qualifying period</U></B>&#148; means the period of 10 years immediately preceding the date of sending the notice
referred to in <U>paragraph</U><U></U><U>&nbsp;(A)(iv)</U> above; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<B><U>the relevant period</U></B>&#148; means the
period beginning at the commencement of the qualifying period and ending on the date when all the requirements of <U>paragraphs</U><U></U><U>&nbsp;(A)(i)</U> to<U>&nbsp;(iv)</U> above have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Transmission of Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>41.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Transmission on Death </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If a member dies, the survivor or survivors, where that member was a joint holder, and their personal representatives, where that member
was a sole holder or the only survivor of joint holders, shall be the only persons recognised by the company as having any title to that member&#146;s shares; but nothing contained in these articles shall release the estate of a deceased holder from
any liability in respect of any share held by that member solely or jointly with other persons. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>42.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Entry of Transmission in Register </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Where the entitlement of a person to a certificated share in consequence of the death or bankruptcy of a member or of any other event
giving rise to its transmission by operation of law is proved to the satisfaction of the board, the board shall within two months after proof cause the entitlement of that person to be noted in the register. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>43.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Election of Person Entitled by Transmission </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any person entitled by transmission to a share may, subject as provided elsewhere in these articles, elect either to become the holder
of the share or to have some person nominated by them registered as the holder. If they elect to be registered themselves, they shall give </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
notice to the company to that effect. If they elect to have another person registered and the share is a certificated share, they shall sign an instrument of transfer of the share to that person.
If they elect to have themselves or another person registered and the share is an uncertificated share, they shall take any action the board may require (including, without limitation, the signing of any document and the giving of any instruction by
means of a relevant system) to enable themselves or that person to be registered as the holder of the share. The board may at any time require the person to elect either to be registered themselves or to transfer the share and if the requirements
are not complied with within 60 days of being issued the board may withhold payment of all dividends and other moneys payable in respect of the share until the requirements have been complied with. All the provisions of these articles relating to
the transfer of, and registration of transfers of, shares shall apply to the notice or transfer as if the death or bankruptcy of the member or other event giving rise to the transmission had not occurred and the notice or transfer was given or
signed by the member. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>44.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Rights of Person Entitled by Transmission </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Where a person becomes entitled by transmission to a share, the rights of the holder in relation to that share shall cease, but the
person entitled by transmission to the share may give a good discharge for any dividends or other moneys payable in respect of it and shall have the same rights in relation to the share as they would have had if they were the holder of it save that,
until they become the holder, they shall not be entitled in respect of the share (except with the authority of the board) to receive notice of, or to attend or vote at, any general meeting of the company or at any separate general meeting of the
holders of any class of shares in the company or to exercise any other right conferred by membership in relation to general meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Alteration
of Share Capital </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>45.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Sub-division</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any resolution authorising the company to <FONT STYLE="white-space:nowrap">sub-divide</FONT> its shares or any of them may determine
that, as between the shares resulting from the <FONT STYLE="white-space:nowrap">sub-division,</FONT> any of them may have any preference or advantage or be subject to any restriction as compared with the others. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>46.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Fractions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Whenever as a result of a consolidation, consolidation and <FONT STYLE="white-space:nowrap">sub-division</FONT> or <FONT
STYLE="white-space:nowrap">sub-division</FONT> of shares any holders would become entitled to fractions of a share, the board may deal with the fractions as it thinks fit including by ignoring fractions altogether or by aggregating and selling them
or by dealing with them in some other way.&nbsp;For the purposes of effecting any such sale, the board may arrange for the shares representing the fractions to be entered in the register as certificated shares.&nbsp;The board may sell shares
representing fractions to any person, including the company and may authorise some person to transfer or deliver the shares to, or in accordance with the directions of, the purchaser.&nbsp;The person to whom any shares are transferred or delivered
shall not be bound to see to the application of the purchase money nor shall their title to the shares be affected by any irregularity in, or invalidity of, the proceedings relating to the sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notice of General Meetings </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>47.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Omission or <FONT STYLE="white-space:nowrap">Non-Receipt</FONT> of Notice </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The accidental omission to give any notice of a meeting or the accidental omission to send or supply any document or
other information relating to any meeting to, or the <FONT STYLE="white-space:nowrap">non-receipt</FONT> (even if the company becomes aware of such <FONT STYLE="white-space:nowrap">non-receipt)</FONT> of any such notice, document or other
information by, any person entitled to receive the notice, document or other information shall not invalidate the proceedings at that meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A member present in person or by proxy at a meeting shall be deemed to have received proper notice of that meeting
and, where applicable, of the purpose of that meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>48.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Postponement of General Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the board, in its absolute discretion, considers that it is impractical or undesirable for any reason to hold a general meeting on
the date or at the time or place specified in the notice calling the general meeting, it may postpone or move the general meeting to another date, time and/or place. When a meeting is so postponed, notice of the date, time and place of the postponed
meeting shall be published on the company&#146;s website and by means of a regulatory information service, which together shall be deemed to constitute reasonable notice of such postponement, and the board shall take reasonable steps to ensure that
notice of the date, time and place of any postponed meeting is provided to any member trying to attend the meeting at the original time and place. Notice of the business to be transacted at such rearranged meeting shall not be required. If a meeting
is rearranged in this way, the appointment of a proxy will be valid if it is received as required by these articles not less than 48 hours before the time appointed for holding the rearranged meeting. The board may also postpone or move the
rearranged meeting under this article. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>49.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Resolutions of members at Annual General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If, on or before, 31st January in any year any members shall, in accordance with the Companies Acts, require the
company, in relation to the Annual General Meeting to be held in that year, to give notice of a resolution which may properly be moved or require the company to circulate a statement in acceptable form, the company shall circulate that resolution or
statement with the notice of the Annual General Meeting without cost to the requisitionists. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If any such requisition is made in accordance with the Companies Acts after 31st January in any year and prior to the
Annual General Meeting to be held in that year, the company shall require that the requisitionists deposit or tender a sum sufficient to meet the Company&#146;s reasonable expenses in complying with such requisition in accordance with the Companies
Acts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Proceedings at General Meetings (including Annual General Meetings) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>50.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Electronic General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may determine that a general meeting shall be held as a physical meeting or in combination with an
electronic platform or platforms that enables members to participate in the meeting without physically attending. A general meeting held partially on an electronic platform in combination with a physical meeting is referred in these articles as an
&#147;<B>electronic general meeting</B>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may make arrangements for an electronic platform to permit members or their proxies who are not present
together at the same physical place to attend, speak and vote at an electronic general meeting by electronic means, and to permit directors or others to attend and speak, and the chair of the meeting to preside, at an electronic general meeting by
electronic means. That meeting shall be duly constituted and its proceedings valid if the chair of the general meeting is satisfied that adequate facilities are available throughout the electronic general meeting to ensure that members attending the
electronic general meeting (i)&nbsp;may participate in the business of the general meeting; (ii)&nbsp;hear all persons who speak at the meeting whether by the use of microphones, loudspeakers, audio-visual communications equipment or otherwise; and
(iii)&nbsp;be heard by all other persons present at the meeting, but under no circumstances shall the inability of one or more members or proxies to access, or continue to access, the facilities for participation in the meeting despite adequate
facilities being made available by the company, affect the validity of the meeting or any business conducted at the meeting, provided that the meeting is quorate. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The notice of an electronic general meeting shall specify the physical place of that meeting and shall specify the
electronic platform and arrangements by which members or their proxies may participate in the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A member who is entitled to vote and who participates or is represented by a proxy by means of a specified electronic
platform at an electronic general meeting shall be counted in the quorum for that general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may make arrangements for any documents which are required to be made available to the meeting to be
accessible electronically to members or their proxies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Nothing in these articles prevents a general meeting being held only at a physical location, however a general meeting
cannot be held solely on an electronic platform. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>51.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Quorum </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">No business shall be transacted at any general meeting unless a quorum is present when the meeting proceeds to
business, but the absence of a quorum shall not preclude the choice or appointment of a chair of the meeting which shall not be treated as part of the business of the meeting. Save as otherwise provided by these articles, two members present in
person or by proxy and entitled to vote shall be a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
quorum for all purposes. A shareholder which is a company is to be considered present if it is represented by a duly authorised representative. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If the directors so determine, any or all members (or their proxies) may participate in a general meeting by means of
a conference telephone, video teleconference equipment or any communication equipment which allows all persons participating in the meeting to speak to and hear each other. A person so participating shall be deemed to be present in person at the
meeting and shall be entitled to vote or be counted in a quorum accordingly. A meeting which takes place by conference telephone, video teleconference or other such communication equipment will be treated as taking place at the place where the chair
is. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>52.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Procedure if Quorum Not Present </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If within five minutes (or such longer time not exceeding one hour as the chair of the meeting may decide to wait) after the time
appointed for the commencement of the meeting a quorum is not present, or if during the meeting a quorum ceases to be present, the meeting: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">if convened by or upon the requisition of members, shall be dissolved; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in any other case, it shall stand adjourned to such other day (being not less than ten days later, excluding the day
on which the meeting is adjourned and the day for which it is reconvened) and at such other time or place as the chair of the meeting may decide. At any adjourned meeting one member present in person or by proxy and entitled to vote (whatever the
number of shares held by that person) shall be a quorum and any notice of an adjourned meeting shall state that one member present in person or by proxy and entitled to vote (whatever the number of shares held by that person) shall be a quorum.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>53.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Security Arrangements </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The directors or the secretary may take any action and may put in place any arrangements both before and during any
meeting that the directors or the secretary consider appropriate for: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the health and/or safety of people attending a meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">proper and orderly conduct of a meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the meeting to reflect the wishes of the majority. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">This includes the power to refuse entry to, or eject from meetings, any person who fails to comply with any
arrangements made or any person who in the opinion of the directors or the secretary is acting in a manner that threatens the health and/or safety of people attending the meeting and/or the proper and orderly conduct at a meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may direct that persons wishing to attend any general meeting should submit to such searches or other health
and/or security arrangements or restrictions (including, without limitation, a requirement that such persons refrain from taking electronic equipment into a general meeting) as the board shall consider appropriate
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
in the circumstances and the board shall be entitled in its absolute discretion to, or to authorise some one or more persons who shall include a director or the secretary or the chair of the
meeting to, refuse entry to, or to eject from, such general meeting any person who fails to submit to such health arrangements or searches or otherwise to comply with such security arrangements or restrictions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>54.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Confidential Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No shareholder at any general meeting is entitled to require disclosure of or any information about any detail of the company&#146;s
trading, or any matter that is or may be in the nature of a trade secret, commercial secret or secret process, or that may relate to the conduct of the business of the company, if the directors decide it would be inexpedient in the interests of the
company to make that information public. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>55.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Chair of General Meeting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The chair (if any) of the board or, in their absence, the deputy chair (if any) shall preside as chair at every general meeting. If more
than one deputy chair is present they shall agree amongst themselves who is to take the chair or, if they cannot agree, the deputy chair who has been in office as a director longest shall take the chair. If there is no chair or deputy chair, or if
at any meeting neither the chair nor any deputy chair is present within five minutes after the time appointed for the commencement of the meeting, or if neither the chair nor any deputy chair is willing to act as chair, the directors present shall
choose one of their number to act, or if one director only is present, that director shall preside as chair of the meeting if willing to act. If no director is present, or if each of the directors present declines to take the chair, the persons
present and entitled to vote shall appoint one of their number to be chair of the meeting. Nothing in these articles shall restrict or exclude any of the powers or rights of a chair of a meeting which are given by law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>56.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Orderly Conduct </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The chair of the meeting shall take such action or give directions for such action to be taken as the chair thinks fit
to promote the orderly conduct of the business of the meeting. The chair&#146;s decision on points of order, matters of procedure or arising incidentally from the business of the meeting shall be final as shall be the chair&#146;s determination as
to whether any point or matter is of such a nature. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The directors may arrange for any people who they consider cannot be seated in the main meeting room, where the chair
will be, to attend and take part in a general meeting in an overflow room or rooms. Any overflow room will have a live video link from the main room, and a <FONT STYLE="white-space:nowrap">two-way</FONT> sound link. The notice of the meeting does
not have to give details of any arrangements under this Article. The directors may decide how to divide people between the main room and any overflow room. If any overflow room is used, the meeting will be treated as being held, and taking place, in
the main room. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>57.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Entitlement to Attend and Speak </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Each director shall be entitled to attend and speak at any general meeting of the company. The chair of the meeting may invite any
person to attend and speak at any general meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
of the company where the chair considers that this will assist in the deliberations of the meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>58.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Adjournments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The chair of the meeting may at any time without the consent of the meeting adjourn any meeting (whether or not it has commenced or a
quorum is present) either to a later time on the same day or to another time or place where it appears to them that (a)&nbsp;the members entitled to vote and wishing to attend cannot be conveniently accommodated in the place appointed for the
meeting (b)&nbsp;the conduct of persons present prevents or is likely to prevent the orderly continuation of business (c)&nbsp;in relation to an electronic general meeting, the electronic platforms or arrangements for that meeting become inadequate
for the purpose of ensuring that members can participate properly and in an orderly and secure way or (d)&nbsp;an adjournment is otherwise necessary so that the business of the meeting may be properly conducted. In addition, the chair of the meeting
may at any time with the consent of any meeting at which a quorum is present (and shall if so directed by the meeting) adjourn the meeting either sine die or to another time or place. When a meeting is adjourned sine die the time and place for the
adjourned meeting shall be fixed by the board. No business shall be transacted at any adjourned meeting except business which might properly have been transacted at the meeting had the adjournment not taken place. Any meeting may be adjourned more
than once. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>59.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Notice of Adjournment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the continuation of an adjourned meeting is to take place three months or more after it was adjourned or if business is to be
transacted at an adjourned meeting the general nature of which was not stated in the notice of the original meeting, notice of the adjourned meeting shall be given as in the case of an original meeting. Except as provided in this article, it shall
not be necessary to give any notice of an adjourned meeting or of the business to be transacted at an adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Amendments </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>60.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Amendments to Resolutions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In the case of a resolution duly proposed as a special resolution no amendment thereto (other than an amendment to correct a patent
error) may be considered or voted upon and in the case of a resolution duly proposed as an ordinary resolution no amendment thereto (other than an amendment to correct a patent error) may be considered or voted upon unless either at least two
working days prior to the date appointed for holding the meeting or adjourned meeting at which such ordinary resolution is to be proposed notice in writing of the terms of the amendment and intention to move the same has been received by the company
at its office or the chair of the meeting in their absolute discretion decides that it may be considered or voted upon. With the consent of the chair of the meeting, an amendment may be withdrawn by its proposer before it is put to the vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>61.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Amendments Ruled Out of Order </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If an amendment shall be proposed to any resolution under consideration but shall be ruled out of order by the chair of the meeting the
proceedings on the substantive resolution shall not be invalidated by any error in such ruling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Voting </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>62.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Votes of Members </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to any special terms as to voting upon which any shares may be issued or may at the relevant time be held and to any other
provisions of these articles, members shall be entitled to vote at a general meeting as provided in the Companies Acts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>63.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Method of Voting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">At any general meeting, including any electronic general meeting, a resolution put to the vote of the meeting shall be decided on a
poll, which shall be taken in such manner as the chair of the meeting shall direct, including by means of electronic vote casters.&nbsp;The result of the vote shall be deemed to be the resolution of the meeting at which the vote was demanded. A vote
to elect the chair of the meeting or to adjourn the meeting must be taken immediately at the meeting. Any other vote may be taken at any other time (within 30 days of the meeting) and place determined by the chair. The chair can appoint scrutineers
(who need not be shareholders) and set a day, time and place for the result of the poll to be declared. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>64.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Votes of Joint Holders </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In the case of joint holders of a share the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to
the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand in the register in respect of the joint holding. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>65.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Voting on Behalf of Incapable Member </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A member in respect of whom an order has been made by any competent court or official on the ground that they are or may be suffering
from a mental disorder or is otherwise incapable of managing their affairs may vote at any general meeting of the company and may exercise any other right conferred by membership in relation to general meetings by or through any person authorised in
such circumstances to do so on their behalf (and that person may vote by proxy), provided that evidence to the satisfaction of the board of the authority of the person claiming to exercise the right to vote or such other right has been received by
the company not later than the last time at which appointments of proxy should have been received in order to be valid for use at that meeting or on the holding of that poll. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>66.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>No Right to Vote where Sums Overdue on Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No member shall, unless the board otherwise decides, be entitled in respect of any share held by them to attend or vote (either
personally or by proxy) at any general meeting of the company or to exercise any other right conferred by membership in relation to general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
meetings unless all calls or other sums presently payable by them in respect of that share have been paid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>67.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Objections or Errors in Voting </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any objection shall be raised to the qualification of any voter, or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any votes have been counted which ought not to have been counted or which might have been rejected, or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any votes are not counted which ought to have been counted, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">the objection or error shall not vitiate the decision of the meeting or adjourned meeting on any resolution unless it is raised or
pointed out at the meeting or, as the case may be, the adjourned meeting at which the vote objected to is given or tendered or at which the error occurs. Any objection or error shall be referred to the chair of the meeting and shall only vitiate the
decision of the meeting on any resolution if the chair decides that the same may have affected the decision of the meeting. The decision of the chair on such matters shall be conclusive. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company will not be obliged to check whether a proxy or company representative has voted in accordance with a
shareholder&#146;s instructions and if a proxy or company representative fails to do so, this will not affect the decision of the meeting (or adjourned meeting) or poll. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Approved Depositaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>68.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Meaning of Approved Depositary </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In these articles, unless the context otherwise requires, &#147;<B><U>Approved Depositary</U></B>&#148; means a person
approved by the board and appointed: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to hold the company&#146;s shares or any rights or interests in any of the company&#146;s shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to issue securities, documents of title or other documents which evidence that the holder of them owns or is entitled
to receive the shares, rights or interests held by the Approved Depository, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">and shall include a nominee acting
for a person appointed to do these things. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The trustees of any scheme or arrangements for or principally for the benefit of employees of the company and its
associated companies will be deemed to be an Approved Depositary for the purposes of these articles unless the board resolves otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">References in these articles to an Approved Depositary or to shares held by it refer only to an Approved Depositary
and to its shares held in its capacity as an Approved Depositary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>69.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Appointment of Approved Depositaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to these articles and to applicable law, an Approved Depositary may appoint as its proxy or proxies in relation to any ordinary
shares which it holds, anyone it thinks fit and may determine the manner and terms of any such appointment. Each appointment must state the number and class of shares to which it relates and the total number of shares of each class in respect of
which appointments exist at any one time, which must not exceed the total number of shares of each such class registered in the name of the Approved Depositary or its nominee (the &#147;<B><U>Depositary Shares</U></B>&#148;) at that time. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>70.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Register of Approved Depositaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Approved Depositary must keep a register (the &#147;<B><U>Proxy Register</U></B>&#148;) of each person it has appointed as a proxy
under <U>Article 72</U> (an &#147;<B><U>Appointed Proxy</U></B>&#148;) and the number of Depositary Shares (their &#147;<B><U>Appointed Number</U></B>&#148;) to which the appointment relates. The directors will determine the requisite information to
be recorded in the Proxy Register relating to each Appointed Proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any person authorised by the company may inspect the Proxy
Register during usual business hours and the Approved Depositary will give such person any information which that person requests as to the contents of the Proxy Register. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>71.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Approved Depositaries&#146; Attendance at General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">An Appointed Proxy may only attend a general meeting if they provide the company with written evidence of their
appointment as such. This must be in a form agreed between the directors and the Approved Depositary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to applicable law and to these articles, and so long as the Approved Depositary or a nominee of the Approved
Depositary holds at least their Appointed Number of shares, an Appointed Proxy is entitled to attend a general meeting which holders of that class of shares are entitled to attend, and they are entitled to the same rights, and subject to the same
obligations, in relation to their Appointed Number of Depositary Shares as if they had been validly appointed in accordance with <U>Articles 74 to 78</U> by the registered holder of these shares as its proxy in relation to those shares.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>72.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Proxies of Appointed Depositaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">An Appointed Proxy may appoint another person as their proxy for their Appointed Number of Depositary Shares, provided the appointment
is made and deposited in accordance with <U>Articles 74 to 78</U>. These articles apply to that appointment and to the person so appointed as though those Depositary Shares were registered in the name of the Appointed Proxy and the appointment was
made by them in that capacity. The directors may require such evidence as they think appropriate to decide that such appointment is effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>73.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Identifying Appointed Proxies </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For the purposes of determining who is entitled as an Appointed Proxy to exercise the rights conferred by <U>Articles
71 and 72</U> and the number of Depositary Shares in respect of which a person is to be treated as having been appointed as an Appointed Proxy for these purposes, the Approved Depositary may decide that the Appointed Proxies who are so entitled are
the persons entered in the Proxy Register at a time and on a date (a &#147;<B><U>Record Time</U></B>&#148;) agreed between the Approved Depositary and the company. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">When a Record Date is decided for a particular purpose: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">an Appointed Proxy is to be treated as having been appointed for that purpose for the number and class of shares
appearing against their name in the Proxy Register as at the Record Time; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">changes to entries in the Proxy Register after the Record Time will be ignored for this purpose.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Except for recognising the rights given in relation to General Meetings by appointments made by Appointed Proxies
pursuant to <U>Article 72</U>, the company is entitled to treat any person entered in the Proxy Register as an Appointed Proxy as the only person (other than the Approved Depositary) who has any interest in the Depositary Shares in respect of which
the Appointed Proxy has been appointed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">At a general meeting the chair has the final decision as to whether any person has the right to vote or exercise any
other right relating to any Depositary Shares. In any other situation, the directors have the final decision as to whether any person has the right to exercise any right relating to any Depositary Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Proxies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>74.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Appointment of Proxies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The appointment of a proxy shall be in writing signed by the appointor or their duly authorised attorney or, if the appointor is a
corporation, shall either be executed under its seal or signed by an officer, attorney or other person authorised to sign it. If a member appoints more than one proxy and the proxy forms appointing those proxies would give those proxies the apparent
right to exercise votes on behalf of the member in a general meeting over more shares than are held by the member, then each of those proxy forms will be invalid and none of the proxies so appointed will be entitled to attend, speak or vote at the
relevant general meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>75.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Receipt of Proxies </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The appointment of a proxy must: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of an appointment made in hard copy form, be received at the office (or such other place in the United
Kingdom or in the United States as may be specified by the company for the receipt of appointments of proxy in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
hard copy form) not less than 48 hours (or such shorter time as the board may determine) before the time appointed for holding the meeting or adjourned meeting at which the person named in the
appointment proposes to vote together with (if required by the board) any authority under which it is made or a copy of the authority, certified notarially or in accordance with the Powers of Attorney Act 1971 or in some other manner approved by the
board; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of an appointment made by electronic means, be received at the address specified by the company for the
receipt of appointments of proxy by electronic means not less than 48 hours (or such shorter time as the board may determine) before the time appointed for holding the meeting or adjourned meeting at which the person named in the appointment
proposes to vote. Any authority pursuant to which such an appointment is made or a copy of the authority, certified notarially or in accordance with the Powers of Attorney Act 1971 or in some other manner approved by the board, must, if required by
the board, be received at such address or at the office (or such other place in the United Kingdom as may be specified by the company for the receipt of such documents) not less than 48 hours (or such shorter time as the board may determine) before
the time appointed for holding the meeting or adjourned meeting at which the person named in the appointment proposes to vote; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of an appointment delivered by an Approved Depositary (except in respect of a proxy appointed in
accordance with <U>Article 69</U>) be delivered to the appropriate place referred to in (i)&nbsp;or (ii) above, as appropriate, depending on whether the appointment is made in hard copy or electronic form; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of a vote taken more than 48 hours subsequently to the date of the meeting or adjourned meeting, be
received as aforesaid not less than 24 hours (or such shorter time as the board may determine) before the time appointed for the taking of the vote; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in the case of a vote taken not more than 48 hours subsequently to the date of the meeting or adjourned meeting, be
received as aforesaid by the time at which the vote was demanded (or at such later time as the board may determine), </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">and an appointment of a proxy which is not, or in respect of which the authority or copy thereof is not, received in a manner so
permitted shall be invalid. When two or more valid but differing appointments of a proxy are received in respect of the same share for use at the same meeting or poll, the one which is last received (regardless of its date or of the date of its
signature) shall be treated as replacing and revoking the others as regards that share; if the company is unable to determine which was last received, none of them shall be treated as valid in respect of that share. The appointment of a proxy shall
not preclude a member from attending and voting in person at the meeting or poll concerned. The proceedings at a general meeting shall not be invalidated where an appointment of a proxy in respect of that meeting is sent in electronic form as
provided in these articles, but because of a technical problem it cannot be read by the recipient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may at its discretion determine that in calculating the periods mentioned in this article no account shall
be taken of any part of a day that is not a working day. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>76.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Maximum Validity of Proxy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No appointment of a proxy shall be valid after 12 months have elapsed from the date of its receipt save that, unless the contrary is
stated in it, an appointment of a proxy shall be valid for use at an adjourned meeting or vote after a meeting or an adjourned meeting even after 12 months, if it was valid for the original meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>77.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Form of Proxy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The appointment of a proxy shall be in any usual form or in such other form as the board may approve. The appointment of a proxy shall
be deemed to confer authority to vote on any amendment of a resolution put to, or any other business which may properly come before, the meeting for which it is given as the proxy thinks fit. The appointment of a proxy shall, unless the contrary is
stated in it, be valid as well for any adjournment of the meeting as for the meeting to which it relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>78.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Cancellation of Proxy&#146;s Authority </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A vote given by a proxy or by the duly authorised representative of a corporation shall be valid notwithstanding the previous
determination of the authority of the person voting, unless notice in writing of the determination was received by the company at the office (or such other place or address as was specified by the company for the receipt of appointments of proxy)
not later than the last time at which an appointment of a proxy should have been received in order to be valid for use at the meeting at which the vote was given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Class&nbsp;Meetings </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>79.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Separate General Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The provisions of these articles relating to general meetings shall apply, with any necessary modifications to any separate general
meeting of the holders of shares of a class convened otherwise than in connection with the variation or abrogation of the rights attached to the shares of that class. For this purpose, a general meeting at which no holder of a share other than an
ordinary share may, in their capacity as a member, attend or vote shall also constitute a separate general meeting of the holders of the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Appointment, Retirement and Removal of Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>80.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Number of Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Unless otherwise determined by ordinary resolution of the company, the directors (disregarding alternate directors) shall be not less
than two nor more than 24 in number. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>81.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Directors&#146; Shareholding Qualification </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No shareholding qualification for directors shall be required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>82.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power of Company to Appoint Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of these articles, the company may by ordinary resolution elect any person who is willing to act to be a
director, either to fill a vacancy or as an addition to the existing board, but so that the total number of directors shall not at any time exceed any maximum number fixed by or in accordance with these articles. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>83.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power of Board to Appoint Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of these articles, the board may appoint any person who is willing to act to be a director, either to fill a
vacancy or as an addition to the existing board, but so that the total number of directors shall not at any time exceed any maximum number fixed by or in accordance with these articles. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>84.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Annual Retirement of Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">At every annual general meeting all the directors at the date of the notice convening the annual general meeting shall retire from
office and may offer themselves for <FONT STYLE="white-space:nowrap">re-appointment</FONT> by the members. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>85.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Filling Vacancies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of these articles, at the meeting at which a director retires the company can pass an ordinary resolution to <FONT
STYLE="white-space:nowrap">re-appoint</FONT> the director or to elect some other eligible person in their place. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>86.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power of Removal by Special Resolution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition to any power of removal conferred by the Companies Acts, the company may by special resolution remove any director before
the expiration of their period of office and may (subject to these articles) by ordinary resolution appoint another person who is willing to act to be a director in their place. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>87.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Persons Eligible as Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No person other than a director retiring at the meeting shall be appointed or <FONT STYLE="white-space:nowrap">re-appointed</FONT> a
director at any general meeting unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they are recommended by the board; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">not less than seven nor more than 42 days before the day appointed for the meeting, notice in writing by a member
qualified to vote at the meeting (not being the person to be proposed) has been given to the secretary of the intention to propose that person for appointment or <FONT STYLE="white-space:nowrap">re-appointment</FONT> together with confirmation in
writing by that person of their willingness to be appointed or <FONT STYLE="white-space:nowrap">re-appointed.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>88.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Position of Retiring Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A director who retires at an annual general meeting may, if willing to continue to act, be
<FONT STYLE="white-space:nowrap">re-appointed.</FONT> If they are <FONT STYLE="white-space:nowrap">re-appointed</FONT> they are treated as continuing in office throughout. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
they are not <FONT STYLE="white-space:nowrap">re-appointed,</FONT> they shall retain office until the end of the meeting or (if earlier) when a resolution is passed to appoint someone in their
place or when a resolution to <FONT STYLE="white-space:nowrap">re-appoint</FONT> the director is put to the meeting and lost. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>89.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Vacation of Office by Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Without prejudice to the provisions for retirement contained in these articles, the office of a director shall be vacated if: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they resign their office by notice in writing sent to or received at the office or at an address specified by the
company for the purposes of communication by electronic means or tendered at a meeting of the board; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by notice in writing sent to or received at the office or at an address specified by the company for the purposes of
communication by electronic means or tendered at a meeting of the board, they offer to resign and the board resolves to accept such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by notice in writing sent to or received at the office or at an address specified by the company for the purposes of
communication by electronic means or tendered at a meeting of the board, their resignation is requested by all of the other directors and all of the other directors are not less than three in number; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they are or has been suffering from mental or physical ill health and the board resolves that their office is vacated;
or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they are absent without the permission of the board from meetings of the board (whether or not an alternate director
appointed by them attends) for six consecutive months and the board resolves that their office is vacated; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they become bankrupt or compounds with their creditors generally; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they are prohibited by law from being a director; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">they cease to be a director by virtue of the Companies Acts or is removed from office pursuant to these articles.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the office of a director is vacated for any reason, they shall cease to be a member of any committee or <FONT
STYLE="white-space:nowrap">sub-committee</FONT> of the board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>90.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Alternate Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Each director may appoint any person to be their alternate and may at their discretion remove an alternate director so
appointed. If the alternate director is not already a director, the appointment, unless previously approved by the board, shall have effect only upon and subject to its being so approved. Any appointment or removal of an alternate director shall be
effected by notice in writing signed by the appointor and sent to or received at the office or at an address specified by the company for the purpose of communication by electronic means or tendered at a meeting of the board, or in any other manner
approved by the board. An alternate director shall be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
entitled to receive notice of all meetings of the board or of committees of the board of which their appointor is a member. They shall also be entitled to attend and vote as a director at any
such meeting at which the director appointing them is not personally present and at such meeting to exercise and discharge all the functions, powers, rights and duties of their appointor as a director and for the purposes of the proceedings at such
meeting the provisions of these articles shall apply as if they were a director. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Every person acting as an alternate director shall (except as regards power to appoint an alternate and remuneration)
be subject in all respects to the provisions of these articles relating to directors and shall during their appointment be an officer of the company. An alternate director shall alone be responsible to the company for their acts and defaults and
shall not be deemed to be the agent of or for the director appointing them. An alternate director may be paid expenses and shall be entitled to be indemnified by the company to the same extent as if they were a director. An alternate director shall
not be entitled to receive from the company any fee in their capacity as an alternate director but the company shall, if so requested in writing by the appointor, pay to the alternate director any part of the fees or remuneration otherwise due to
the appointor. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A director or any other person may act as an alternate director to represent more than one director. Every person
acting as an alternate director shall have one vote for each director for whom they act as alternate, in addition to their own vote if they are also a director but they shall count as only one for the purposes of determining whether a quorum is
present. Signature by an alternate director of any resolution in writing of the board or a committee of the board shall, unless the notice of their appointment provides to the contrary, be as effective as signature by their appointor.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">An alternate director shall cease to be an alternate director: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">if their appointor ceases for any reason to be a director except that, if at any meeting any director retires but is <FONT
STYLE="white-space:nowrap">re-appointed</FONT> at the same meeting, any appointment made by them pursuant to this article which was in force immediately before their retirement shall remain in force as though they had not retired; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">on the happening of any event which if they were a director would cause them to vacate their office as director; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">if they resign their office by notice in writing to the company. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>91.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Executive Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board or any committee authorised by the board may from time to time appoint one or more directors to hold any employment or
executive office with the company for such period and upon such other terms as the board or any committee authorised by the board may in its discretion decide and may revoke or terminate any appointment so made. Any revocation or termination of the
appointment shall be without prejudice to any claim for damages that the director may have against the company or the company may have against the director for any breach of any contract of service between them and the company which may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
involved in the revocation or termination. A director so appointed shall receive such remuneration (whether by way of salary, commission, participation in profits or otherwise) as the board or
any committee authorised by the board may decide, and either in addition to or in lieu of their remuneration as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Fees, Remuneration,
Expenses and Pensions </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>92.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Directors&#146; Fees </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The directors can decide on the amount, timing and manner of payment of fees to be paid by the company to the
directors for acting as directors, but the total fees paid to all of the directors for acting as directors (excluding any amounts paid under any other provision of these articles) shall not exceed the higher of: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">&pound;3&nbsp;million a year; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any higher amount as the company may by ordinary resolution decide. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">These fees can be satisfied in cash or in any other form. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If the directors decide to satisfy any of these fees in shares or in any other
<FONT STYLE="white-space:nowrap">non-cash</FONT> form, the value of the shares or other assets to be counted towards this limit will be their value at the time the entitlement to them is first allocated, or provisionally allocated, to the director.
This value will be taken into account for the purpose of the limit in the year in which the entitlement is first allocated, or provisionally allocated, and not in any later year when the fees, shares or other assets are actually paid or delivered to
the director. This paragraph applies even if: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the director&#146;s entitlement to the fees, or to receive the assets, is subject to conditions which will, or may, be
fulfilled at a later time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the fees, shares or other assets are to be, or may be, paid or delivered to the director at a later time or the
director elects, agrees or is required to receive the cash equivalent of the shares or other assets as determined by reference to their value at such later time; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the company has not paid for the relevant shares or other assets at the time the director first becomes, or becomes
provisionally, entitled to them, and their value subsequently changes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Unless an ordinary resolution is passed saying otherwise, the fees will be divided between some or all of the
directors in the way that they decide. If they fail to decide, the fees will be shared equally by the directors, except that any director holding office as a director for only part of the period covered by the fee is only entitled to a pro rata
share covering that part period. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>93.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Additional Remuneration </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The directors can award extra fees to any director who devotes special attention to the business of the company or performs any services
which the directors consider to extend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
beyond the ordinary duties of a director. Extra fees can take the form of salary, commission or other benefits or can be paid in some other way. This is decided on by the directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>94.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Expenses </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Each director may be paid their reasonable travelling, hotel and incidental expenses of attending and returning from
meetings of the board or committees of the board or general meetings of the company or any other meeting which as a director they are entitled to attend and shall be paid all other costs and expenses properly and reasonably incurred by them in the
conduct of the company&#146;s business or in the discharge of their duties as a director. The company may also fund a director&#146;s or former director&#146;s expenditure for the purposes permitted under the Companies Acts and may do anything to
enable a director or former director of the company to avoid incurring such expenditure as provided in the Companies Acts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The directors can award extra pay to any director who, at the request of the directors, performs special services or
goes or lives abroad for any purposes of the company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>95.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Pensions and Gratuities for Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board or any committee authorised by the board may exercise all the powers of the company to provide benefits, either by the payment
of gratuities or pensions or by insurance or in any other manner whether similar to the foregoing or not, for any director or former director or the relations, or dependants of, or persons connected to, any director or former director, provided that
no benefits (except such as may be provided for by any other article) may be granted to or in respect of a director or former director who has not been employed by, or held an executive office or place of profit under, the company or any body
corporate which is or has been its subsidiary undertaking or any predecessor in business of the company or any such body corporate without the approval of an ordinary resolution of the company. No director or former director shall be accountable to
the company or the members for any benefit provided pursuant to this article and the receipt of any such benefit shall not disqualify any person from being or becoming a director of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Directors&#146; Interests </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>96.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Conflicts of interest requiring board authorisation </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may, subject to the quorum and voting requirements set out in this article, authorise any matter which would
otherwise involve a director breaching their duty under the Companies Acts to avoid conflicts of interest (&#147;<B><U>Conflict</U></B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A director seeking authorisation in respect of a Conflict shall declare to the board the nature and extent of their
interest in a Conflict as soon as is reasonably practicable. The director shall provide the board with such details of the relevant matter as are necessary for the board to decide how to address the Conflict together with such additional information
as may be requested by the board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any director (including the relevant director) may propose that the relevant director be authorised in relation to any
matter the subject of a Conflict. Such proposal and any authority given by the board shall be effected in the same way that any other matter may be proposed to and resolved upon by the board under the provisions of these articles save that:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the relevant director and any other director with a similar interest shall not count towards the quorum nor vote on
any resolution giving such authority; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the relevant director and any other director with a similar interest may, if the other members of the board so decide,
be excluded from any board meeting while the Conflict is under consideration. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where the board gives authority in relation to a Conflict, or where any of the situations described in <U>Article
97(B)</U> apply in relation to a director (&#147;<B><U>Relevant Situation</U></B>&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may (whether at the relevant time or subsequently)&nbsp;(a) require that the relevant director is excluded
from the receipt of information, the participation in discussion and/or the making of decisions (whether at meetings of the board or otherwise) related to the Conflict or Relevant Situation; and (b)&nbsp;impose upon the relevant director such other
terms for the purpose of dealing with the Conflict or Relevant Situation as it may determine; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the relevant director will be obliged to conduct themselves in accordance with any terms imposed by the board in
relation to the Conflict or Relevant Situation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may provide that where the relevant director obtains (otherwise than through their position as a director of
the company) information that is confidential to a third party, the director will not be obliged to disclose that information to the company, or to use or apply the information in relation to the company&#146;s affairs, where to do so would amount
to a breach of that confidence; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the terms of the authority shall be recorded in writing (but the authority shall be effective whether or not the terms
are so recorded); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may revoke or vary such authority at any time but this will not affect anything done by the relevant
director prior to such revocation in accordance with the terms of such authority. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>97.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Other conflicts of interest </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If a director is in any way directly or indirectly interested in a proposed contract with the company or a contract
that has been entered into by the company, they must declare the nature and extent of that interest to the directors in accordance with the Companies Acts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Provided they have declared their interest in accordance with <U>paragraph (A)</U>, a director may:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">be party to, or otherwise interested in, any contract with the company or in which the company has a direct or
indirect interest; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">hold any other office or place of profit with the company (except that of auditor) in conjunction with their office of
director for such period and upon such terms, including as to remuneration, as the board may decide; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">act by themselves or through a firm with which they are associated in a professional capacity for the company or any
other company in which the company may be interested (otherwise than as auditor); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">be or become a director or other officer of, or employed by or otherwise be interested in any holding company or
subsidiary company of the company or any other company in which the company may be interested; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">be or become a director of any other company in which the company does not have an interest and which cannot
reasonably be regarded as giving rise to a conflict of interest at the time of their appointment as a director of that other company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>98.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Benefits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A director shall not, by reason of their office or of the fiduciary relationship thereby established, be liable to account to the
company or the members for any remuneration, profit or other benefit realised by reason of their having any type of interest authorised under <U>Article 96(A)</U> or permitted under <U>Article 97(B)</U> and no contract shall be liable to be avoided
on the grounds of a director having any type of interest authorised under <U>Article 96(A)</U> or permitted under <U>Article 97(B)</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>99.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Quorum and voting requirements </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A director shall not vote on or be counted in the quorum in relation to any resolution of the board concerning their
own appointment, or the settlement or variation of the terms or the termination of their own appointment, as the holder of any office or place of profit with the company or any other company in which the company is interested. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where proposals are under consideration concerning the appointment, or the settlement or variation of the terms or the
termination of the appointment, of two or more directors to offices or places of profit with the company or any other company in which the company is interested, a separate resolution may be put in relation to each director and in that case each of
the directors concerned shall be entitled to vote and be counted in the quorum in respect of each resolution unless it concerns their own appointment or the settlement or variation of the terms or the termination of their own appointment or the
appointment of another director to an office or place of profit with a company in which the company is interested and the director seeking to vote or be counted in the quorum has a Relevant Interest in it. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A director shall not vote on, or be counted in the quorum in relation to, any resolution of the board in respect of
any contract in which that director has an interest and, if that director shall do so, that director&#146;s vote shall not be counted, but this prohibition shall not apply to any resolution where that interest cannot reasonably be regarded as likely
to give rise to a conflict of interest or where that interest arises only from one or more of the following matters: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the giving to them of any guarantee, indemnity or security in respect of money lent or obligations undertaken by them
or by any other person at the request of or for the benefit of the company or any of its subsidiary undertakings; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the giving to a third party of any guarantee, indemnity or security in respect of a debt or obligation of the company
or any of its subsidiary undertakings for which they themselves have assumed responsibility in whole or in part under a guarantee or indemnity or by the giving of security; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the giving to them of any other indemnity where all other directors are also being offered indemnities on
substantially the same terms; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the funding by the company of their expenditure on defending proceedings or the doing by the company of anything to
enable them to avoid incurring such expenditure where all other directors are being offered substantially the same arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">where the company or any of its subsidiary undertakings is offering securities in which offer the director is or may
be entitled to participate as a holder of securities or in the underwriting or <FONT STYLE="white-space:nowrap">sub-underwriting</FONT> of which the director is to participate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any contract in which they are interested by virtue of their interest in shares or debentures or other securities of
the company or by reason of any other interest in or through the company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any contract concerning any other company (not being a company in which the director has a Relevant Interest) in which
they are interested directly or indirectly whether as an officer, shareholder, creditor or otherwise howsoever; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any contract concerning the adoption, modification or operation of a pension fund, superannuation or similar scheme or
retirement, death or disability benefits scheme or employees&#146; share scheme which relates both to directors and employees of the company or of any of its subsidiary undertakings and does not provide in respect of any director as such any
privilege or advantage not accorded to the employees to which the fund or scheme relates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any contract for the benefit of employees of the company or of any of its subsidiary undertakings under which they
benefit in a similar manner to the employees and which does not accord to any director as such any privilege or advantage not accorded to the employees to whom the contract relates; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any contract for the purchase or maintenance of insurance against any liability for, or for the benefit of, any
director or directors or for, or for the benefit of, persons who include directors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A company shall be deemed to be one in which a director has a Relevant Interest if and so long as (but only if and so
long as) they are to their knowledge (either directly or indirectly) the holder of or beneficially interested in one per cent. or more of any class of the equity share capital of that company (calculated exclusive of any shares of that class in that
company held as treasury shares) or of the voting rights available to members of that company. In relation to an alternate director, an interest of their appointor shall be treated as an interest of the alternate director without prejudice to any
interest which the alternate director has otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where a company in which a director has a Relevant Interest is interested in a contract, the director also shall be
deemed interested in that contract. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If any question shall arise at any meeting of the board as to the interest of a director (other than the chair of the
meeting) in a contract and whether it is likely to give rise to a conflict of interest or as to the entitlement of any director (other than the chair of the meeting) to vote or be counted in the quorum and the question is not resolved by their
voluntarily agreeing to abstain from voting or not to be counted in the quorum, the question shall be referred to the chair of the meeting and their ruling in relation to the director concerned shall be conclusive except in a case where the nature
or extent of the director&#146;s interest (so far as it is known to them) has not been fairly disclosed to the board. If any question shall arise in respect of the chair of the meeting, the question shall be decided by a resolution of the board (for
which purpose the chair of the meeting shall be counted in the quorum but shall not vote on the matter) and the resolution shall be conclusive except in a case where the nature or extent of the interest of the chair of the meeting (so far as it is
known to them) has not been fairly disclosed to the board. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to these articles, the board may also cause any voting power conferred by the shares in any other company held
or owned by the company or any power of appointment to be exercised in such manner in all respects as it thinks fit, including the exercise of the voting power or power of appointment in favour of the appointment of the directors or any of them as
directors or officers of the other company, or in favour of the payment of remuneration to the directors or officers of the other company. Subject to these articles, a director may also vote on and be counted in the quorum in relation to any of such
matters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>100.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>General </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">References in <U>Articles 96 to 99</U> to: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a contract include references to any proposed contract and to any transaction or arrangement or proposed transaction
or arrangement whether or not constituting a contract; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a conflict of interest include a conflict of interest and duty and a conflict of duties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company may by ordinary resolution suspend or relax the provisions of <U>Articles 95 to 98</U> to any extent or
ratify any contract not properly authorised by reason of a contravention of any of the provisions of <U>Articles 96 to 99</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Powers and Duties of the Board </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>101.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>General Powers of Company Vested in Board </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the these articles and to any directions given by the company in general meeting by special resolution, the business of the
company shall be managed by the board which may exercise all the powers of the company whether relating to the management of the business of the company or not.&nbsp;No alteration of these articles and no special resolution shall invalidate any
prior act of the board which would have been valid if that alteration had not been made or that resolution had not been passed.&nbsp;The powers given by this article shall not be limited by any special power given to the board by any other article.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>102.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Borrowing Powers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the provisions of the Companies Acts, the directors may exercise all the powers of the company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to borrow money; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to mortgage or charge all or any of the company&#146;s undertaking, property (present and future) and uncalled
capital; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to issue debentures and other securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">to give security either outright or as collateral security for any debt, liability or obligation of the company or of
any third party. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>103.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Agents </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board can appoint anyone as the company&#146;s attorney by granting a power of attorney or by authorising them in
some other way. Attorneys can either be appointed directly by the board or the board can give someone else the power to select attorneys. The board or the persons who are authorised by it to select attorneys can decide on the purposes, powers,
authorities and discretions of attorneys. But they cannot give an attorney any power, authority or discretion which the board does not have under these articles. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board can decide how long a power of attorney will last for and attach any conditions to it. The power of attorney
can include any provisions which the board decides on for the protection and convenience of anybody dealing with the attorney. The power of attorney can allow the attorney to grant any or all of their power, authority or discretion to any other
person. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board can: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">delegate any of its authority, powers or discretions to any manager or agent of the company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">allow managers or agents to delegate to another person; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">remove any people it has appointed in any of these ways; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">cancel or change anything that it has delegated, although this will not affect anybody who acts in good faith who has
not had any notice of any cancellation or change. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any appointment or delegation by the board which is referred to in this article can be on any conditions decided on by
the board. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The ability of the board to delegate under this article applies to all its powers and is not limited because certain
articles refer to powers being exercised by the board or by a committee authorised by the board while other articles do not. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>104.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Delegation to Individual Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may entrust to and confer upon any director any of its powers, authorities and discretions (with power to <FONT
STYLE="white-space:nowrap">sub-delegate)</FONT> upon such terms and conditions and with such restrictions as it thinks fit, and either collaterally with, or to the exclusion of, its own powers, authorities and discretions and may from time to time
revoke or vary all or any of them but no person dealing in good faith and without notice of the revocation or variation shall be affected by it. The power to delegate contained in this article shall be effective in relation to the powers,
authorities and discretions of the board generally and shall not be limited by the fact that in certain articles, but not in others, express reference is made to particular powers, authorities or discretions being exercised by the board or by a
committee authorised by the board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>105.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Registers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may keep an overseas or local or other register in any place and the board may make and vary such regulations as it may
think fit respecting the keeping of the register. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>106.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Provision for Employees </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may exercise any power conferred by the Companies Acts to make provision for the benefit of persons employed or formerly
employed by the company or any of its subsidiaries in connection with the cessation or the transfer to any person of the whole or part of the undertaking of the company or that subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Proceedings of the Board </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>107.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Board Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may meet for the despatch of business, adjourn and otherwise regulate its meetings as it thinks fit. A director at any time
may, and the secretary on the requisition of a director at any time shall, summon a board meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>108.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Notice of Board Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Notice of a board meeting shall be deemed to be properly given to a director if it is given to them personally or by word of mouth or
sent in writing to them at their last known address or any other address given by them to the company for this purpose. A director may waive their entitlement to notice of any meeting either prospectively or retrospectively and any retrospective
waiver shall not affect the validity of the meeting or of any business conducted at the meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>109.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Quorum </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The quorum necessary for the transaction of the business of the board may be fixed by the board and, unless so fixed at any other
number, shall be two. Subject to the provisions of these articles, any director who ceases to be a director at a board meeting may continue to be present and to act as a director and be counted in the quorum until the termination of the board
meeting if no other director objects and if otherwise a quorum of directors would not be present. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>110.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Directors below Minimum through Vacancies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The continuing directors or a sole continuing director may act notwithstanding any vacancy in their number but, if and so long as the
number of directors is reduced below the minimum number fixed by or in accordance with these articles or is below the number fixed by or in accordance with these articles as the quorum or there is only one continuing director, the continuing
directors or director may act for the purpose of filling vacancies or of summoning general meetings of the company but not for any other purpose. If there are no directors or director able or willing to act, then any two members (excluding any
member holding shares as treasury shares) may summon a general meeting for the purpose of appointing directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>111.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Appointment of Chair </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may appoint a director to be the chair or a deputy chair of the board, and may at any time remove them from that office. The
chair of the board or failing the chair a deputy chair shall act as chair at every meeting of the board. If more than one deputy chair is present they shall agree amongst themselves who is to take the chair or, if they cannot agree, the deputy chair
who has been in office as a director longest shall take the chair. But if no chair of the board or deputy chair is appointed, or if at any meeting neither the chair nor any deputy chair is present within five minutes after the time appointed for
holding the meeting, the directors present may choose one of their number to be chair of the meeting. References in these articles to a deputy chair include, if no one has been appointed to that title, a person appointed to a position with another
title which the board designates as equivalent to the position of deputy chair. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>112.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Competence of Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A meeting of the board at which a quorum is present shall be competent to exercise all the powers, authorities and discretions vested in
or exercisable by the board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>113.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Voting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Questions arising at any meeting shall be determined by a majority of votes. In the case of an equality of votes the chair of the
meeting shall have a second or casting vote. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>114.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Delegation to Committees </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may delegate any of its powers, authorities and discretions (with power to
<FONT STYLE="white-space:nowrap">sub-delegate)</FONT> to any committee, consisting of such person or persons (whether a member or members of its body or not) as it thinks fit, provided that the majority of persons on any committee or <FONT
STYLE="white-space:nowrap">sub-committee</FONT> must be directors. References in these articles to committees include <FONT STYLE="white-space:nowrap">sub-committees</FONT> permitted under this article. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any committee so formed shall, in the exercise of the powers, authorities and discretions so delegated, conform to any
regulations which may be imposed on it by the board. The meetings and proceedings of any committee consisting of two or more members shall be governed by the provisions contained in these articles for regulating the meetings and proceedings of the
board so far as the same are applicable and are not superseded by any regulations imposed by the board. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The power to delegate contained in this article shall be effective in relation to the powers, authorities and
discretions of the board generally and shall not be limited by the fact that in certain articles, but not in others, express reference is made to particular powers, authorities or discretions being exercised by the board or by a committee authorised
by the board. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>115.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Participation in Meetings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">All or any of the members of the board may participate in a meeting of the board by means of a conference telephone or any communication
equipment which allows all persons participating in the meeting to speak to and hear each other or by a series of telephone calls from the chair of the meeting. A person so participating shall be deemed to be present in person at the meeting and
shall be entitled to vote and be counted in a quorum accordingly. Any such meeting will be treated as taking place where the chair is located. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>116.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Resolution in Writing </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">A resolution in writing signed by all the directors who are at the relevant time entitled to receive notice of a meeting of the board
and who would be entitled to vote on the resolution at a meeting of the board (if that number is sufficient to constitute a quorum) shall be as valid and effectual as a resolution passed at a meeting of the board properly called and constituted. The
resolution may be contained in one document or in several documents in like form each signed by one or more of the directors concerned. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>117.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Validity of Acts of Board or Committee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">All acts done by the board or by any committee or by any person acting as a director or member of a committee shall, notwithstanding
that it is afterwards discovered that there was some defect in the appointment of any member of the board or committee or person so acting or that they or any of them were disqualified from holding office or had vacated office
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
or were not entitled to vote, be as valid as if each such member or person had been properly appointed and was qualified and had continued to be a director or member of the committee and had been
entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Seals </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>118.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Use of Seals </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board shall provide for the custody of every seal of the company. A seal shall only be used by the authority of the board or of a
committee of the board authorised by the board in that behalf. Subject as otherwise provided in these articles, and to any resolution of the board or committee of the board dispensing with the requirement for any counter-signature on any occasion,
any instrument to which the common seal is applied shall be signed by at least one director and the secretary, or by at least two directors or by one director in the presence of a witness who attests the signature or by such other person or persons
as the board may approve. Any instrument to which an official seal is applied need not, unless the board otherwise decides or the law otherwise requires, be signed by any person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Dividends and Other Payments </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>119.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Declaration of Dividends by Company </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may by ordinary resolution from time to time declare dividends in accordance with the respective rights of the members, but
no dividend shall exceed the amount recommended by the board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>120.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Payment of Interim and Fixed Dividends by Board </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may pay such interim dividends as appear to the board to be justified by the financial position of the company and may also
pay any dividend payable at a fixed rate at intervals settled by the board whenever the financial position of the company, in the opinion of the board, justifies its payment. If the board acts in good faith, it shall not incur any liability to the
holders of any shares for any loss they may suffer in consequence of the payment of an interim or fixed dividend on any other class of shares ranking pari passu with or after those shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>121.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Calculation and Currency of Dividends </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Except in so far as the rights attaching to, or the terms of issue of, any share otherwise provide:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">all dividends shall be declared and paid according to the amounts paid up on the share in respect of which the
dividend is paid, but no amount paid up on a share in advance of calls shall be treated for the purposes of this article as paid up on the share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">all dividends shall be apportioned and paid pro rata according to the amounts paid up on the share during any portion
or portions of the period in respect of which the dividend is paid; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">dividends may be declared or paid in any currency. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may decide the basis of conversion for any currency conversions that may be required and how any costs
involved are to be met. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The board may also decide that a particular Approved Depositary should be able to receive dividends in a currency
other than the currency in which it is declared and may make arrangements accordingly. In particular, if an Approved Depositary has chosen or agreed to receive dividends in another currency, the directors may make arrangements with that Approved
Depositary for payment to be made to them for value on the date on which the relevant dividend is paid, or a later date decided on by the directors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>122.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Amounts Due on Shares may be Deducted from Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may deduct from any dividend or other moneys payable to a member by the company on or in respect of any shares all sums of
money (if any) presently payable by that member to the company on account of calls or otherwise in respect of shares of the company. Sums so deducted can be used to pay amounts owing to the company in respect of the shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>123.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>No Interest on Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Subject to the rights attaching to, or the terms of issue of, any shares, no dividend or other moneys payable by the company on or in
respect of any share shall bear interest against the company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>124.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Payment Procedure </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any dividend or other sum payable in cash by the company in respect of a share may be paid: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by inter-bank transfer or by other electronic means (including payment through CREST) directly to an account with a
bank or other financial institution (or other organisations operating deposit accounts if allowed by the company) named in a written instruction from the persons entitled to receive the payment under this article; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by sending a cheque, warrant or similar financial instrument by post addressed to the holder at their registered
address; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by sending a cheque, warrant or similar financial instrument payable to someone else named in a written instruction
from the shareholder (or all joint shareholders) and sent by post to the address specified in that instruction; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">in some other way requested in writing by the shareholder (or all joint shareholders) and agreed with the company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In respect of payment of any dividend or other money, the directors can decide and notify shareholders that:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">one or more of the payment means described in <U>paragraph (A)</U>&nbsp;above will be used for payment and, where more
than one means will be used, a shareholder (or all joint shareholders) may elect to receive payment by one of the means so notified in the manner prescribed by the directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">one or more of such means will be used for the payment unless a shareholder (or all joint shareholders) elects for
another means of payment in the manner prescribed by the directors; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">one or more of such means will be used for the payment and that shareholders will not be able to elect to receive the
payment by any other means. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a shareholder (or all joint shareholders) does not specify an address, or does not specify an account of a type
prescribed by the directors, or does not specify other details, and in each case that information is necessary in order to make payment of the dividend or other money in the way in which under this article the directors have decided that the payment
is to be made or by which the shareholder (or all joint shareholders) has validly elected to receive the payment; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">payment cannot be made by the company using the information provided by the shareholder (or all joint shareholders),
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">then the dividend or other money will be treated as unclaimed for the purposes of these articles. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For joint shareholders or persons jointly entitled to shares by law, payment can be made to the shareholder whose name
stands first in the register. The company can then rely on a receipt for a dividend or other money paid on shares from any one of them on behalf of them all. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Cheques, warrants and similar financial instruments are sent, and payment in any other way is made, at the risk of the
person who is entitled to the money. The company is treated as having paid a dividend if the cheque, warrant or similar financial instrument is cleared or if a payment is made through CREST, bank transfer or other electronic means. The company will
not be responsible for any payment which is lost or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Where a person is entitled by transmission to a share, any dividend or other sum payable by the company in respect of
the share may be paid as if that person were a holder of the share and that person&#146;s address noted in the register were that person&#146;s registered address and where two or more persons are so entitled,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
any one of them may give effectual receipts for any dividends or other moneys payable or property distributable on or in respect of the shares. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>125.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Uncashed Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may cease to send any cheque, warrant or similar financial instrument through the post or to employ any other means of
payment, including payment by means of a relevant system, for any dividend payable on any shares in the company which is normally paid in that manner on those shares if in respect of at least two consecutive dividends payable on those shares the
cheques, warrants or similar financial instruments have been returned undelivered or remain uncashed during or at the end of the period for which the same are valid or that means of payment has failed. In addition, the company may cease to send any
cheque, warrant or similar financial instrument through the post or may cease to employ any other means of payment if, in respect of one dividend payable on those shares, the cheque, warrant or similar financial instrument has been returned
undelivered or remains uncashed during or at the end of the period for which the same is valid or that means of payment has failed and reasonable enquiries have failed to establish any new postal address or account of the holder. Subject to the
provisions of these articles, the company must recommence sending cheques, warrants or similar financial instruments or employing such other means in respect of dividends payable on those shares if the holder or person entitled by transmission
requests such recommencement in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>126.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Forfeiture of Unclaimed Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">All dividends or other sums payable on or in respect of any shares which remain unclaimed may be invested or otherwise made use of by
the board for the benefit of the company until claimed. Any dividend or other sum unclaimed after a period of 6 years from the date when it was declared or became due for payment shall be forfeited and shall revert to the company unless the board
decides otherwise and the payment by the board of any unclaimed dividend or other sum payable on or in respect of a share into a separate account shall not constitute the company a trustee in respect of it. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>127.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Dividends Not in Cash </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any general meeting declaring a dividend may, upon the recommendation of the board, by ordinary resolution direct, and the board may in
relation to any interim dividend direct, that it shall be satisfied wholly or partly by the distribution of assets, and in particular of paid up shares or debentures of any other company, and where any difficulty arises in regard to the distribution
the board may settle it as it thinks expedient, and in particular may authorise any person to sell and transfer any fractions or may ignore fractions altogether, and may fix the value for distribution purposes of any assets or any part thereof to be
distributed and may determine that cash shall be paid to any members upon the footing of the value so fixed in order to secure equality of distribution and may vest any assets to be distributed in trustees as may seem expedient to the board. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>128.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Scrip Dividends and Dividend Plans Generally </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The board may, if authorised by an ordinary resolution of the company, offer any holders of ordinary shares (excluding any member
holding shares as treasury shares) the right to elect to receive ordinary shares, credited as fully paid, instead of cash in respect of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
whole (or some part, to be determined by the board) of any dividend specified by the ordinary resolution. The following provisions shall apply: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">an ordinary resolution may specify some or all of a particular dividend (whether or not already declared) or may
specify some or all of any dividends declared or paid within a specified period, but such period may not end later than the third anniversary of the date of the meeting at which the ordinary resolution is passed; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the entitlement of each holder of ordinary shares to new ordinary shares shall be such that the relevant value of the
entitlement shall be as nearly as possible equal to (but not greater than) the cash amount (disregarding any tax credit) of the dividend that such holder elects to forgo. For this purpose &#147;<B><U>relevant value</U></B>&#148; shall be calculated
by reference to the average of the middle market quotations for the company&#146;s ordinary shares on the London Stock Exchange as derived from the Daily Official List (or any other publication of a recognised investment exchange showing quotations
for the company&#146;s ordinary shares) on such five consecutive dealing days as the board shall determine provided that the first of such days shall be on or after the day on which the ordinary shares are first quoted &#147;ex&#148; the relevant
dividend or in such other manner as may be determined by or in accordance with the ordinary resolution. A certificate or report by the auditors as to the amount of the relevant value in respect of any dividend shall be conclusive evidence of that
amount and in giving such a certificate or report the auditors may rely on advice or information from brokers or other sources of information as they think fit; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">no fraction of any ordinary share shall be allotted. The board may make such provisions as it thinks fit for any
fractional entitlements including provisions whereby, in whole or in part, the benefit thereof accrues to the company and/or under which fractional entitlements are accrued and/or retained without interest and in each case accumulated on behalf of
any holder of ordinary shares and such accruals or retentions are applied to the allotment by way of bonus to or cash subscription on behalf of such holder of fully paid ordinary shares and/or provisions whereby cash payments may be made to such
holders in respect of their fractional entitlements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board, if it intends to offer an election in respect of any dividend, shall give notice to the holders of ordinary
shares of the right of election offered to them, and specify the procedure to be followed which, for the avoidance of doubt, may include an election by means of a relevant system and the place at which, and the latest time by which, elections must
be lodged in order for elections to be effective; no such notice need be given to holders of ordinary shares who have previously given election mandates in accordance with this article and whose mandates have not been revoked; the accidental
omission to give notice of any right of election to, or the non receipt (even if the company becomes aware of such <FONT STYLE="white-space:nowrap">non-receipt)</FONT> of any such notice by, any holder of ordinary shares entitled to the same shall
neither invalidate any offer of an election nor give rise to any claim, suit or action; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board shall not proceed with any election unless the company has sufficient reserves or funds that may be
capitalised, and the board has authority to allot sufficient shares, to give effect to it after the basis of allotment is determined; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may exclude or restrict from any offer any shareholder who is an Approved Depositary or a nominee for an
Approved Depositary if the offer or exercise of the right to or by the persons on whose behalf the Approved Depositary holds the shares would suffer legal or practical problems of the kind mentioned in <U>Article 128(vii)</U>. If other shareholders
(other than those excluded under <U>Article 128(vii)</U>) have the right to opt for new shares, the directors must be satisfied that an appropriate dividend reinvestment plan or similar arrangement is available to a substantial majority of the
people on whose behalf the Approved Depositary holds shares or that such arrangement will be available promptly and the first sentence of this <U>Article 128(vi)</U> does not apply until the directors are satisfied of this; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may exclude from any offer or make other arrangement in relation to any holders of ordinary shares where the
board believes that such exclusion or arrangement is necessary or expedient in relation to legal or practical problems under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory, or the board
believes that for any other reason the offer should not be made to them; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the dividend (or that part of the dividend in respect of which a right of election has been offered) shall not be
payable on ordinary shares in respect of which an election has been made (for the purposes of this article &#147;<B><U>the elected ordinary shares</U></B>&#148;) and instead additional ordinary shares shall be allotted to the holders of the elected
ordinary shares on the basis of allotment calculated as stated. For such purpose the board shall capitalise, out of any amount standing to the credit of any reserve or fund (including the retained earnings) at the relevant time whether or not the
same is available for distribution as the board may determine, a sum equal to the aggregate nominal amount of the additional ordinary shares to be allotted on that basis and apply it in paying up in full the appropriate number of ordinary shares for
allotment and distribution to the holders of the elected ordinary shares on that basis. The board may do all acts and things considered necessary or expedient to give effect to any such capitalisation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the additional ordinary shares when allotted shall rank pari passu in all respects with the fully-paid ordinary shares
then in issue except that they will not be entitled to participation in the relevant dividend; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">unless the board otherwise determines, or unless the uncertificated securities rules otherwise require, the new
ordinary share or shares which a member has elected to receive instead of cash in respect of the whole (or some part) of the specified dividend declared or paid in respect of their elected ordinary shares shall be in uncertificated form (in respect
of the member&#146;s elected ordinary shares which were in uncertificated form on the date of the member&#146;s election) and in certificated form (in respect of the member&#146;s elected ordinary shares which were in certificated form on the date
of the member&#146;s election); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may also from time to time establish or vary a procedure for election mandates, which, for the avoidance of
doubt, may include an election by means of a relevant system, under which a holder of ordinary shares may elect in respect of future rights of election offered to that holder under this article until the election mandate is revoked or deemed to be
revoked in accordance with the procedure; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the board may decide how any costs relating to making new shares available in place of a cash dividend will be met,
including deciding to deduct an amount from the entitlement of a shareholder under this article; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">at any time before new ordinary shares are allotted instead of cash in respect of any part of a dividend, the board
may determine that such new ordinary shares will not be allotted. Any such determination may be made before or after any election has been made by holders of ordinary shares in respect of the relevant dividend. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Capitalisation of Reserves </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>129.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power to Capitalise Reserves and Funds </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may, upon the recommendation of the board, at any time and from time to time pass an ordinary resolution to the effect that
it is desirable to capitalise all or any part of any amount standing to the credit of any reserve or fund (including retained earnings) at the relevant time whether or not the same is available for distribution and accordingly that the amount to be
capitalised be set free for distribution among the members or any class of members who would be entitled to it if it were distributed by way of dividend and in the same proportions, on the footing that it is applied either in or towards paying up
the amounts unpaid at the relevant time on any shares in the company held by those members respectively or in paying up in full shares, debentures or other obligations of the company to be allotted and distributed credited as fully paid up among
those members, or partly in one way and partly in the other, but so that, for the purposes of this article: (i)&nbsp;a share premium account and a capital redemption reserve, and any reserve or fund representing unrealised profits, may be applied
only in paying up in full shares of the company that are to be allotted and distributed as fully paid up; and (ii)&nbsp;where the amount capitalised is applied in paying up in full shares that are to be allotted and distributed as fully paid up, the
company will also be entitled to participate in the relevant distribution in relation to any shares of the relevant class held by it as treasury shares and the proportionate entitlement of the relevant class of members to the distribution will be
calculated accordingly.&nbsp;The board may authorise any person to enter into an agreement with the company on behalf of the persons entitled to participate in the distribution and the agreement shall be binding on those persons. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>130.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Settlement of Difficulties in Distribution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Where any difficulty arises in regard to any distribution of any capitalised reserve or fund the board may settle the matter as it
thinks expedient and in particular may authorise any person to sell and transfer any fractions or may resolve that the distribution should be as nearly as may be practicable in the correct proportion but not exactly so or may ignore fractions
altogether, and may determine that cash payments shall be made to any members in order to adjust the rights of all parties, as may seem expedient to the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Record Dates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>131.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Power to Choose Any Record Date </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Notwithstanding any other provision of these articles, the company or the board may fix any date as the record date for any dividend,
distribution, allotment or issue and such record date may be on or at any time before or after any date on which the dividend, distribution, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
allotment or issue is declared, paid or made. The power to fix any such record date shall include the power to fix a time on the chosen date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Records and Summary Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>132.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Inspection of Records </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">No member in their capacity as such shall have any right of inspecting any accounting record or book or document of the company except
as conferred by law, ordered by a court of competent jurisdiction or authorised by the board or by ordinary resolution of the company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>133.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Summary Financial Statements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">The company may send or supply copies of its strategic reports with supplementary materials to its members instead of copies of its full
accounts and reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Service of Notices, Documents and Other Information </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>134.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Method of Service </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document (including a share certificate) or other information may be served on or sent or supplied to any
member by the company: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">personally; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by sending it through the post addressed to the member at their registered address or by leaving it at that address
addressed to the member; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by means of a relevant system; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">where appropriate, by sending or supplying it in electronic form to an address notified by the member to the company
for that purpose; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">where appropriate, by making it available on a website and notifying the member of its availability in accordance with
this article; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">by any other means authorised in writing by the member. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In the case of joint holders of a share, service, sending or supply of any notice, document or other information on or to one of the
joint holders shall for all purposes be deemed a sufficient service on or sending or supplying to all the joint holders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In the case of joint holders of a share, anything to be agreed or specified in relation to any notice, document or
other information to be served on or sent or supplied to them may be agreed or specified by any one of the joint holders and the agreement or specification of the senior shall be accepted to the exclusion of that of the other joint holders and, for
this purpose, seniority shall be determined by the order in which the names stand in the register in respect of the joint holding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If any member, including any joint holder, who is without a United Kingdom or United States postal address provides
the company with such postal address is entitled to have notice or documents served or supplied to them at that address. If such a member fails to provide the company with a United Kingdom or United States postal address they may be ignored for the
purposes of sufficient service or supply of any notice or documents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">If on three consecutive occasions any notice, document or other information served on or sent or supplied to a member
has been returned undelivered, such member shall not thereafter be entitled to receive notices, documents or other information from the company until they shall have communicated with the company and supplied to the company (or its agent) a new
registered address, or a postal address within the United Kingdom or the United States for the service of notices and the despatch or supply of documents and other information, or shall have informed the company of an address for the service of
notices and the despatch or supply of documents and other information in electronic form. For these purposes, any notice, document or other information sent by post shall be treated as returned undelivered if the notice, document or other
information is served, sent or supplied back to the company (or its agents) and a notice, document or other information served, sent or supplied in electronic form shall be treated as returned undelivered if the company (or its agents) receives
notification that the notice, document or other information was not delivered to the address to which it was sent. For the avoidance of doubt, a notice, document or other information served, sent or supplied in electronic form shall not be treated
as a failure to deliver if the company (or its agents) receives an out of office notification from such member. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The company may at any time and in its sole discretion choose (a)&nbsp;to serve, send or supply notices, documents or
other information in hard copy form alone to some or all members; and (b)&nbsp;not to serve, send or supply any notice, document or other information to a particular member where it considers this necessary or appropriate to deal with legal,
regulatory or practical problems in, or under the laws of, any territory. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>135.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Record Date for Service </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Any notice, document or other information may be served, sent or supplied by the company by reference to the register as it stands at
any time not more than 15 days before the date of service, sending or supply. No change in the register after that time shall invalidate that service, sending or supply. Where any notice, document or other information is served on or sent or
supplied to any person in respect of a share in accordance with these articles, no person deriving any title or interest in that share shall be entitled to any further service, sending or supply of that notice, document or other information. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>136.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Members Resident Abroad or on Branch Registers </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any member whose registered address is not within the United Kingdom or the United States and who gives to the company
a postal address within the United Kingdom or the United States at which notices, documents or other information may be served upon, or sent or supplied to, them shall be entitled to have notices, documents or other information served on or sent or
supplied to them at that address </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
or, where applicable, by making them available on a website and notifying the holder at that address. Any member whose registered address is not within the United Kingdom or the United States and
who gives to the company an address for the purposes of communications by electronic means may, subject to these articles, have notices, documents or other information served on or sent or supplied to them at that address or, where applicable, by
making them available on a website and notifying the holder at that address. Otherwise, a member whose registered address is not within the United Kingdom or the United States shall not be entitled to receive any notice, document or other
information from the company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For a member registered on a branch register, notices, documents or other information can be posted or despatched in
the United Kingdom, the United States or in the country where the branch register is kept. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>137.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Service of Notice on Person Entitled by Transmission </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">This article applies where a member has died or become bankrupt or is in liquidation, or where someone else has
otherwise become entitled by law to that member&#146;s shares, but is still registered as a member, it applies whether that member is registered as a sole or joint member. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A person who is entitled by transmission to a share, and who proves this to the reasonable satisfaction of the
directors, upon supplying the company with a postal address within the United Kingdom or the United States for the service of notices and the despatch or supply of documents and other information, shall be entitled to have served upon or sent or
supplied to them at such address any notice, document or other information to which they would have been entitled if they were the holder of that share or, where applicable, to be notified at that address of the availability of the notice, document
or other information on a website. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">A person who is entitled by transmission to a share, and who proves this to the reasonable satisfaction of the
directors, upon supplying the company with an address for the purposes of communications by electronic means for the service of notices and the despatch or supply of documents and other information, may have served on, sent or supplied to them at
such address any notice, document or other information to which they would have been entitled if they were the holder of that share or, where applicable, may be notified at that address of the availability of the notice, document or other
information on a website. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">In either case under <U>paragraphs (B)</U><U></U><U>&nbsp;and (C)</U> above, such service, sending or supply shall for
all purposes be deemed a sufficient service, sending or supply of such notice, document or other information on all persons interested (whether jointly with or as claimants through or under that person) in the share. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Otherwise, any notice, document or other information served on or sent or supplied to any member pursuant to these
articles shall, notwithstanding that the member is then dead or bankrupt or that any other event giving rise to the transmission of the share by operation of law has occurred and whether or not the company has notice of the death, bankruptcy or
other event, be deemed to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
have been properly served, sent or supplied in respect of any share registered in the name of that member as sole or joint holder. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>138.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Deemed Delivery </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document or other information, if served, sent or supplied by the company by post, shall be deemed to have
been received on the day following that on which it was posted if first class post was used or 48 hours after it was posted if first class post was not used and, in proving that a notice, document or other information was served, sent or supplied,
it shall be sufficient to prove that the notice, document or other information was properly addressed, prepaid and put in the post. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document or other information not served, sent or supplied by post but left by the company at a registered
address or at an address (other than an address for the purposes of communications by electronic means) notified to the company in accordance with these articles by a person who is entitled by transmission to a share shall be deemed to have been
received on the day it was so left. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document or other information served, sent or supplied by the company by means of a relevant system shall
be deemed to have been received when the company or any sponsoring system-participant acting on its behalf sends the issuer-instruction relating to the notice, document or other information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document or other information served, sent or supplied by the company using electronic means shall be
deemed to have been received on the day on which it was sent notwithstanding that the company subsequently sends a hard copy of such notice, document or information by post. Any notice, document or other information made available on a website shall
be deemed to have been received on the day on which the notice, document or other information was first made available on the website or, if later, when a notice of availability is received or deemed to have been received pursuant to this article.
In proving that a notice, document or other information served, sent or supplied by electronic means was served, sent or supplied, it shall be sufficient to prove that it was properly addressed. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Any notice, document or other information served, sent or supplied by the company by any other means authorised in
writing by the member concerned shall be deemed to have been received when the company has carried out the action it has been authorised to take for that purpose. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>139.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Notice When Post Not Available </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If there is a suspension or curtailment of postal services within the United Kingdom, the United States or some part of either the
United Kingdom or the United States, the company need only give notice of a general meeting to those members with whom the company can communicate by electronic means and who have provided the company with an address for this purpose.&nbsp;The
company shall also advertise the notice in at least one newspaper with a national circulation and make it available on its website from the date of such advertisement until the conclusion of the meeting or any adjournment thereof.&nbsp;If at least
six clear days prior to the meeting the sending or supply of notices by post in hard copy form has again </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">
become generally possible, the company shall send or supply confirmatory copies of the notice by post to those members who would otherwise receive the notice in hard copy form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Destruction of Documents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>140.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Presumptions Where Documents Destroyed </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">If the company destroys or deletes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any share certificate which has been cancelled at any time after a period of one year has elapsed from the date of
cancellation, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any instruction concerning the payment of dividends or other moneys in respect of any share or any notification of
change of name or address at any time after a period of two years has elapsed from the date the instruction or notification was recorded by the company, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any instrument of transfer of shares or Operator-instruction for the transfer of shares which has been registered by
the company at any time after a period of six years has elapsed from the date of registration, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any instrument of proxy which has been used for the purpose of a poll at any time after a period of one year has
elapsed from the date of use, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any instrument of proxy which has not been used for the purpose of a poll at any time after a period of one month has
elapsed from the end of the meeting to which the instrument of proxy relates, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">any other document on the basis of which any entry is made in the register at any time after a period of six years has
elapsed from the date the entry was first made in the register in respect of it, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:ARIAL" ALIGN="justify">and the company destroys or
deletes the document or instruction in good faith and without express notice that its preservation was relevant to a claim, it shall be presumed irrebuttably in favour of the company that every share certificate so destroyed was a valid certificate
and was properly cancelled, that every instrument of transfer or Operator-instruction so destroyed or deleted was a valid and effective instrument of transfer or instruction and was properly registered and that every other document so destroyed was
a valid and effective document and that any particulars of it which are recorded in the books or records of the company were correctly recorded. If the documents relate to uncertificated shares, the company must comply with any requirements of the
uncertificated securities rules which limit its ability to destroy these documents. Nothing contained in this article shall be construed as imposing upon the company any liability which, but for this article, would not exist or by reason only of the
destruction of any document of the kind mentioned above before the relevant period mentioned in this article has elapsed or of the fact that any other condition precedent to its destruction mentioned above has not been fulfilled. References in this
article to the destruction of any document include references to its disposal in any manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Indemnity and Insurance </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>141.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Indemnity of Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">To the extent permitted by the Companies Acts, every director or former director or other officer of the company or of
any associated company shall be indemnified by the company out of its own funds against all costs, charges, losses, expenses and liabilities incurred by them in performing their duties and/or in exercising their powers and/or in supposedly doing
these things and/or otherwise in relation to or in connection with their duties, powers or office. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">To the extent permitted by the Companies Acts, every director or former director or other officer of the company or of
any associated company is exempted from any liability to the company where that liability would be covered by the indemnity in <U>Article 141(A)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Without prejudice to <U>Article 141(A)</U>, the company may purchase and maintain insurance against any liability for
any persons who are or were at any time directors, officers or employees of the company or of any associated company or trustees of any pension fund or employee share scheme in which employees of any such company are interested.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">No director or former director of the company or of any associated company shall be accountable to the company or the
members for any benefit provided pursuant to this article and the receipt of any such benefit shall not disqualify the person from being or becoming a director of the company. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">For the purposes of this article, no person appointed or employed by the company or an associated company as an
auditor is an officer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>3
<FILENAME>d382677dex23.htm
<DESCRIPTION>EX-2.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 2.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>DESCRIPTION OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTERED UNDER
SECTION 12 OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE EXCHANGE ACT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As of
December&nbsp;31, 2022, GSK plc (&#147;GSK,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148;) had ordinary shares, American Depositary Receipts and debt securities registered pursuant to Section&nbsp;12(b) of the
Securities Exchange Act of 1934 (the &#147;Act&#148;). </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>A. Description of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:ARIAL"><I>This summary of the general terms and provisions of our ordinary shares does not purport to be complete and is subject to and qualified in its entirety
by reference to our Articles of Association (the &#147;Articles&#148;), which are incorporated herein by reference to the Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed on [</I><FONT STYLE="font-family:Times New Roman">&#9679;</FONT><FONT
STYLE="font-family:ARIAL"><I></I></FONT><I>], 2023 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-15170).</FONT> </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK has ordinary shares in
issue which are in registered form and are governed by the laws of England and Wales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The holders of ordinary shares have statutory <FONT
STYLE="white-space:nowrap">pre-emption</FONT> rights under the UK Companies Act 2006 (the &#147;Companies Act&#148;) on the issuance of new ordinary shares or rights to subscribe for, or to convert into, ordinary shares. Under the Companies Act,
such <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights may be <FONT STYLE="white-space:nowrap">dis-applied</FONT> by special resolution of the shareholders of GSK. The shareholders of GSK passed a special resolution on May&nbsp;4, 2022 to
allow Directors to be empowered to (i)&nbsp;disapply <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights in relation to an allotment of equity securities that is otherwise made on a <FONT STYLE="white-space:nowrap">pre-emptive</FONT> basis in
order to deal appropriately with fractional entitlements, jurisdictional issues and other legal, regulatory or practical problems and (ii)&nbsp;allot equity securities for cash and/or to sell ordinary shares held by GSK as treasury shares for cash
up to an amount of &pound;63,548,425 in nominal share capital as if <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights did not apply. This authorization is set to expire at the end of GSK&#146;s Annual General Meeting held in 2023 (or, if
earlier, close of business on June&nbsp;30, 2023). As at December&nbsp;31, 2022 there were 4,311,343,341 ordinary shares of 31 <SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> pence each in issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our Articles contain provisions to the following effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Dividends
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">All ordinary shares rank pari passu in respect of dividends and other distributions of profits. Subject to the provisions of the Articles and
applicable legislation, GSK at any general meeting may declare dividends on the ordinary shares by ordinary resolution, but such dividends may not exceed the amount recommended by the board of directors of GSK (the &#147;Board&#148;). The Board may
also pay interim or fixed rate dividends if it appears they are justified by our financial position. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">All unclaimed dividends payable in respect of
any share may be invested or otherwise made use of by the Board for the benefit of GSK until claimed. If a dividend is not claimed after 6 years of it being declared or becoming payable, it is forfeited and reverts to us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK may, if authorized by an ordinary resolution, offer any holders of ordinary shares (excluding any member holding shares as treasury shares) the right
to elect to receive ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part, to be determined by the Board) of any dividend specified by the ordinary resolution. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to any special terms as to voting upon
which any shares may be issued or may at the relevant time be held and to any other provisions of the Articles, members shall be entitled to vote at a general meeting as provided in the Companies Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">At any general meeting, a resolution that is put to the vote of the meeting shall be decided on a poll, which shall be taken in such manner as the chair
of the meeting shall direct, including by means of electronic vote casters. The result of the vote shall be deemed to be the resolution of the meeting at which the vote was demanded. A vote to elect the chair of the meeting or to adjourn the meeting
must be taken immediately at the meeting. Any other vote may be taken at any other time (within 30 days of the meeting) and place determined by the chair. In the case of joint holders, only the vote of the senior holder (as determined by order in
the share register) or his or her proxy may be counted. If any sum payable remains unpaid in relation to a member&#146;s shareholding, that member is not entitled to vote that share or exercise any other right in relation to a meeting of GSK unless
the Board determines otherwise. For a proxy vote to be valid, the Board must have received satisfactory evidence such that the authority of the person claiming to exercise the right to vote or such other right has been received by the Company not
later than the last time at which appointments of proxy should have been received in order to be valid for use at that meeting or on the holding of that poll. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Any objection or error shall be referred to the chair of the meeting and shall only vitiate the
decision of the meeting on any resolution if the chair decides that the objection or error may have affected the decision of the meeting. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Transfers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Ordinary shares may be held in either certificated or uncertificated form. Certificated ordinary shares shall be transferred in any usual or
other form approved by the Board and executed by or on behalf of the transferor. Transfers of uncertificated ordinary shares shall be made in accordance with the Companies Act and Uncertificated Securities Regulations 2001, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Board is not bound to register (i)&nbsp;a transfer of partly paid ordinary shares, (ii)&nbsp;uncertificated shares in the circumstances set out in the
Companies Act and Uncertificated Securities Regulations 2001 and (iii)&nbsp;transfers of uncertificated securities to joint holders where the number of such joint holders exceeds four. The Board may also decline to register an instrument of transfer
of certificated ordinary shares unless (i)&nbsp;it is duly stamped, duly certified or otherwise shown to the satisfaction of the Board to be exempt from stamp duty and deposited at the prescribed place and accompanied by the share certificate(s) and
such other evidence as reasonably required by the Board to evidence right to transfer, (ii)&nbsp;it is in respect of one class of shares only, and (iii)&nbsp;in the case of a transfer to joint holders, the number of joint holders to whom the share
is to be transferred does not exceed four. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to any rights attached to existing shares, any share may be issued on terms that it is, at our option or the option of the holder of such share,
redeemable. The directors are authorized to determine the terms, conditions and manner of redemption of any such shares under the Articles. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Calls on capital
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The directors may make calls upon the members in respect of any monies unpaid on their shares. A person upon whom a call is made remains
liable even if the shares in respect of which the call is made have been transferred. Interest will be chargeable on any unpaid amount called at a rate determined by the Board (not exceeding the Bank of England base rate by more than 5%). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If a member fails to pay any call or installment of a call in full (following notice from the Board that such failure will result in forfeiture of the
relevant shares), such shares (including any dividends declared but not paid) may be forfeited by a resolution of the Board, and will become the property of GSK. Forfeiture shall not absolve a previous member for amounts payable by him/her (which
may continue to accrue interest). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK also has a lien over all of our partly paid shares for all monies payable or called on such shares and over the
debts and liabilities of a member to GSK. If any monies which are the subject of the lien remain unpaid after a notice from the Board demanding payment, we may sell such shares. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Other Shareholder Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">On a distribution of capital
on a <FONT STYLE="white-space:nowrap">winding-up,</FONT> the ordinary shares rank pari passu with each other but behind the rights of all of GSK&#146;s creditors. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Variation of Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The rights attached to any class of
shares may be varied either with the consent in writing of the holders of at least 75% in nominal value of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that
class. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If new shares are created or issued which rank equally with any other existing shares, or if the Company purchases or redeems any of its own
shares, the rights of the existing shares will not be regarded as changed or abrogated unless the terms of the existing shares expressly say otherwise. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Limitations on Share Ownership </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">There are no limitations
on the rights of shareholders to own ordinary shares. In addition, there are no restrictions imposed by the Articles or (subject to the effect of any economic sanctions or UK or EU merger control laws that may be in force from time to time) by
current UK laws which relate to <FONT STYLE="white-space:nowrap">non-residents</FONT> or foreign shareholders and which limit the rights of such <FONT STYLE="white-space:nowrap">non-residents</FONT> or foreign shareholders to hold or (when entitled
to do so) exercise voting rights on the ordinary shares. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>B. Description of American Depositary Shares </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL"><I>This summary of the general terms and provisions of our American Depositary Shares
(&#147;ADSs&#148;) does not purport to be complete and is subject to and qualified in its entirety by our Form <FONT STYLE="white-space:nowrap">F-6</FONT> filed on July&nbsp;19, 2019, as amended on March&nbsp;15, 2021 (Commission file <FONT
STYLE="white-space:nowrap">No.&nbsp;333-232726),</FONT> including the exhibits thereto. In the following description, a &#147;Holder&#148; is the person registered with the Depositary (as defined below). </I></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">American Depositary Receipts (&#147;ADRs&#148;)
evidencing ADSs are issuable pursuant to an amended and restated deposit agreement dated July&nbsp;19, 2019, between GSK, and JPMorgan Chase Bank, N.A., as depositary (the &#147;Depositary&#148;), and the Holders of the ADRs, as amended on
March&nbsp;15, 2021 (the &#147;Deposit Agreement&#148;). The principal executive office of the Depositary is 383 Madison Avenue, Floor 11, New York, New York 10179. Each ADS represents the right to receive two ordinary shares of GSK. An ADR may
evidence any number of ADSs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our American Depositary Receipts are admitted to trading on the New York Stock Exchange under the symbol
&#147;GSK&#148;. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary or, if the
deposited securities are registered in the name of or held by its nominee, its nominee, subject to and in accordance with the constituent documents of GSK irrevocably appointed each Holder for the time being on the record date (the &#147;Voting
Record Date&#148;) fixed by the Depositary in respect of any meeting (at which holders of deposited securities are entitled to vote) as its proxy to attend, vote and speak at the relevant meeting (or any adjournment thereof) in respect of the
deposited securities represented by the ADS registered on the books of the Depositary in the name of such Holder on the Voting Record Date. In respect of any such meeting each such Holder can appoint any person as its substitute proxy to attend,
vote and speak on behalf of the Holder subject to and in accordance with the provisions of the Deposit Agreement and the constituent documents of GSK. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As soon as practicable after receipt of notice of any meeting at which the holders of deposited securities are entitled to vote, or of solicitation of
consents or proxies from holders of deposited securities, the Depositary shall fix the Voting Record Date in respect of such meeting or solicitation. The Depositary or, if GSK so determines, GSK, shall distribute to Holders of record on such Voting
Record Date: (a)&nbsp;such information as is contained in such notice of meeting or in the solicitation materials, (b)&nbsp;an ADR proxy card in a form prepared by the Depositary, (c)&nbsp;a statement that each Holder at the close of business on the
Voting Record Date will be entitled, subject to any applicable law, GSK&#146;s constituent documents and the provisions of or governing the deposited securities, either (i)&nbsp;to use such ADR proxy card in order to attend, vote and speak at such
meeting as the proxy of the Depositary or its nominee solely with respect to the ordinary shares or other deposited securities represented by ADSs evidenced by such Holder&#146;s ADRs or (ii)&nbsp;to appoint any other person as the substitute proxy
of such Holder, solely with respect to the ordinary shares or other deposited securities represented by ADSs evidenced by such Holder&#146;s ADRs, or (iii)&nbsp;to renounce the proxy initially provided by the Depositary or its nominee to such Holder
or such Holder&#146;s substitute proxy and to provide voting instructions to the Depositary as to the exercise of the voting rights pertaining to the ordinary shares or other deposited securities represented by ADSs evidenced by their respective
ADRs (&#147;Voting Instructions&#148;), and (d)&nbsp;if the Depositary is to be given Voting Instructions by such Holder, a brief statement as to the manner in which Voting Instructions may be given to the Depositary. Each Holder shall be solely
responsible for the forwarding of voting information to the persons or entities having a beneficial ownership interest in ADSs (the &#147;Beneficial Owners&#148;) registered in such Holder&#146;s name. There is no guarantee that Holders and
Beneficial Owners generally or any Holder or Beneficial Owner in particular will receive the notice described above with sufficient time to enable such Holder or Beneficial Owner to return any voting instructions to the Depositary in a timely manner
or for the Holder to arrange to attend, vote and/or speak at the relevant meeting. GSK shall provide notice to the Depositary of such vote or meeting in a timely manner and at least 30 days prior to the date of such vote or meeting (unless less than
30 days&#146; notice of the meeting has been given in accordance with GSK&#146;s Articles of Association and English law, in which case GSK will provide to the Depositary such advance notice of the meeting as may be possible under the
circumstances); provided that if the Depositary receives less than 30 days&#146; notice of such vote or meeting, the Depositary shall only make such distribution to the extent it deems it to be practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon actual receipt by the ADR department responsible for proxies and voting instructions (including, without limitation, instructions of any entity or
entities acting on behalf of the nominee for the Depositary Trust Company (&#147;DTC&#148;)) of Voting Instructions of a Holder on the Voting Record Date in the manner and on or before the time established by the Depositary for such purpose, the
Depositary shall endeavor, insofar as practicable and permitted under applicable law, the provisions of GSK&#146;s constituent documents and the provisions of the deposited securities, to vote or cause to be voted the deposited securities
represented by the ADSs evidenced by such Holder&#146;s ADRs in accordance with such Voting Instructions insofar as practicable and permitted under the provisions of or governing deposited securities. The Depositary will not itself exercise any
voting discretion in respect of any deposited securities. Ordinary shares or other deposited securities represented by ADSs for which no specific Voting Instructions are received by the Depositary from the Holder shall not be voted by the Depositary
but may be directly voted by such Holder in attendance at meetings of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
shareholders as proxy for the Depositary or its nominee, subject to, and in accordance with, the Deposit Agreement and GSK&#146;s constituent documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Holders and their substitute proxy (other than the Depositary) shall only be permitted to attend, vote and speak at meetings at which holders of deposited
securities are entitled to vote as the proxy of the Depositary or its nominee with respect to the whole number of ordinary shares represented by the ADSs evidenced by ADRs held by such Holders on the record date set by the Depositary. For the
avoidance of doubt, when the Depositary receives Voting Instructions from a substitute proxy of a Holder (including, without limitation, instructions from Broadridge Financial Solutions or any other entity acting on behalf of participants and/or
customers of participants within DTC) or their agents, and such registered Holder has notified the Depositary that it holds ADRs on behalf of such substitute proxies, the Depositary shall treat such Voting Instructions as coming from an entity that
holds ADRs on behalf of such substitute proxies and the Depositary shall vote or cause to be voted the deposited securities in accordance with such instructions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Holders are strongly encouraged to forward their Voting Instructions as soon as possible. Voting Instructions will not be deemed received until such time
as the ADR department responsible for proxies and voting has received such Voting Instructions notwithstanding that such Voting Instructions may have been physically received by the Depositary prior to such time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding anything contained in the Deposit Agreement or any ADR, the Depositary may, to the extent not prohibited by any law, rule or regulation or
the rules and/or requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the Depositary in connection with any meeting of or solicitation of consents or proxies from holders of deposited
securities, distribute to the Holders a notice, after consulting GSK as to the form of such notice to the extent practicable, that provides Holders with, or otherwise publicizes to Holders, instructions on how to retrieve such materials or receive
such materials upon request (i.e., by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials). </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Procedures for Transmitting Notices, Reports and Proxy Soliciting Material </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In addition to the procedures for transmitting notices discussed above under &#147;Voting&#148;, the Depositary or its agent will keep, at a designated
transfer office (the &#147;Transfer Office&#148;), (i) a register (the &#147;ADR Register&#148;) for the registration, registration of transfer, combination and <FONT STYLE="white-space:nowrap">split-up</FONT> of ADRs and (ii)&nbsp;facilities for
the delivery and receipt of ADRs. Title to an ADR (and to deposited securities represented by the ADSs), when properly endorsed (in the case of ADRs in certificated form) or upon delivery to the Depositary of proper instruments of transfer, is
transferable by delivery with the same effect as in the case of negotiable instruments under the laws of the State of New York; provided that the Depositary, notwithstanding any notice to the contrary, may treat the person in whose name such ADR is
registered on the ADR Register as the absolute owner hereof for all purposes and neither the Depositary nor GSK will have any obligation or be subject to any liability under the Deposit Agreement or any ADR to any Beneficial Owner, unless such
Beneficial Owner is the Holder hereof. Such ADR is transferable on the ADR Register and may be split into other ADRs or combined with other ADRs into one ADR, evidencing the aggregate number of ADSs surrendered for
<FONT STYLE="white-space:nowrap">split-up</FONT> or combination, by the Holder hereof or by duly authorized attorney upon surrender of this ADR at the Transfer Office properly endorsed (in the case of ADRs in certificated form) or upon delivery to
the Depositary of proper instruments of transfer and duly stamped as may be required by applicable law; provided that the Depositary may close the ADR Register at any time or from time to time when deemed expedient by it and it shall also close the
issuance book portion of the ADR Register when reasonably requested by GSK in order to enable GSK to comply with applicable law. At the request of a Holder, the Depositary shall, for the purpose of substituting a certificated ADR with a Direct
Registration ADR (defined below), or vice versa, execute and deliver a certificated ADR or a Direct Registration ADR, as the case may be, for any authorized number of ADSs requested, evidencing the same aggregate number of ADSs as those evidenced by
the certificated ADR or Direct Registration ADR, as the case may be, substituted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Deposit Agreement, the provisions of or governing deposited
securities and any written communications from GSK, which are both received by the custodian or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities, are available for inspection by
Holders at the offices of the Depositary and its agent or agents (the &#147;Custodian&#148;), at the Transfer Office, on the U.S. Securities and Exchange Commission&#146;s (the &#147;Commission&#148;) website, or upon request from the Depositary
(which request may be refused by the Depositary at its discretion). The Depositary will distribute copies of such communications (or English translations or summaries thereof) to Holders when furnished by GSK. GSK is subject to the periodic
reporting requirements of the Act and accordingly files certain reports with the Commission. Such reports and other information may be inspected and copied through the Commission&#146;s EDGAR system or at public reference facilities maintained by
the Commission located at the date hereof at 100 F Street, NE, Washington, DC 20549. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Direct Registration ADR&#148; means an ADR, the ownership
of which is recorded on the Direct Registration System. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Direct Registration System&#148; means the system for the uncertificated registration
of ownership of securities established by DTC and utilized by the Depositary pursuant to which the Depositary may record the ownership of ADRs without the issuance of a certificate, which ownership shall be evidenced by periodic statements issued by
the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
Depositary to the Holders entitled thereto. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Sale or Exercising of Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary will distribute to each Holder entitled thereto on the record date set by the Depositary therefor at such Holder&#146;s address shown on
the ADR Register, in proportion to the number of deposited securities (on which the following distributions on deposited securities are received by the Custodian) represented by ADSs evidenced by such Holder&#146;s ADRs: (i)&nbsp;warrants or other
instruments in the discretion of the Depositary representing rights to acquire additional ADRs in respect of any rights to subscribe for additional Shares or rights of any nature available to the Depositary as a result of a distribution on deposited
securities (&#147;Rights&#148;), to the extent that GSK timely furnishes to the Depositary evidence satisfactory to the Depositary that the Depositary may lawfully distribute the same (GSK has no obligation to so furnish such evidence), or
(ii)&nbsp;to the extent GSK does not so furnish such evidence and sales of Rights are practicable, any U.S. dollars available to the Depositary from the net proceeds of sales of Rights as in the case of cash, or (iii)&nbsp;to the extent GSK does not
so furnish such evidence and such sales cannot practicably be accomplished by reason of the nontransferability of the Rights, limited markets therefor, their short duration or otherwise, nothing (and any Rights may lapse). </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Deposit or Sale of Securities Resulting from Dividends, Splits or Plans of Reorganization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If GSK makes a dividend payable at the election of the holders of ordinary shares in either cash or additional ordinary shares that it wishes to be made
available to the Holders, GSK shall give notice thereof to the Depositary at least 30 days prior to the proposed distribution stating whether or not it wishes such elective distribution to be made available to the Holders. The Depositary shall make
such elective distribution available to the Holders only if, among other things, GSK has timely requested that the elective distribution is available to the Holders and the Depositary shall have determined that such distribution is reasonably
practicable. If the conditions for making the elective distribution available to the Holders are satisfied, the Depositary will establish procedures to enable the Holders to elect the receipt of either cash or additional ADSs. If the conditions for
making the elective distribution available to the Holders are not satisfied, the Depositary will, to the extent permitted by law, distribute either cash or additional ADSs to the Holders on the basis of the same determination as is made in the local
market in respect of the ordinary shares for which no election is made. There can be no assurance that Holders generally, or any Holder in particular, will be given the opportunity to receive elective distributions on the same terms and conditions
as the holders of ordinary shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">To the extent the Depositary deems distribution of securities or property available to the Depositary resulting
from any distribution on deposited securities (other than cash, ordinary shares or Rights) not to be equitable and practicable, the Depositary may distribute any U.S. dollars available to the Depositary from net proceeds of sale of such securities
or property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary may, in its discretion, and shall if reasonably requested by GSK, distribute additional or amended ADRs or cash,
securities or property to reflect any change in par value, <FONT STYLE="white-space:nowrap">split-up,</FONT> consolidation, cancellation or other reclassification of deposited securities, any ordinary share distributions or other distributions not
distributed to Holders or any cash, securities or property available to the Depositary in respect of deposited securities from (and the Depositary is hereby authorized to surrender any deposited securities to any person and, irrespective of whether
such deposited securities are surrendered or otherwise cancelled by operation of law, rule, regulation or otherwise, to sell by public or private sale any property received in connection with) any recapitalization, reorganization, merger,
consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all the assets of the Company. To the extent the Depositary does not amend ADRs or make a distribution to Holders to reflect any of the foregoing, or the net
proceeds thereof, whatever cash, securities or property results from any of the foregoing shall constitute deposited securities and each ADS evidenced by this ADR shall automatically represent its pro rata interest in the deposited securities as
then constituted. Promptly upon the occurrence of any of the aforementioned changes affecting deposited securities, GSK shall notify the Depositary in writing of such occurrence and as soon as practicable after receipt of such notice from GSK, may
instruct the Depositary to give notice thereof, at GSK&#146;s expense, to Holders in accordance with the provisions hereof. Upon receipt of such instruction, the Depositary shall give notice to the Holders in accordance with the terms thereof, as
soon as reasonably practicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">For all cash dividends and other cash distributions that are made available to the Depositary after the date that
will be published on www.adr.com (as updated by the Depositary from time to time, &#147;ADR.com&#148;) and communicated to then current Holders by mail, the Depositary will distribute any cash to Holders solely via electronic funds transfer
(&#147;EFT&#148;), except as otherwise provided in this paragraph. In order to receive such amounts, Holders must provide their bank deposit details to the Depositary in accordance with the instructions provided by the Depositary for this purpose.
Subject to the last sentence of this paragraph, all such amounts owing to Holders who do not provide such bank deposit details shall be held by the Depositary on behalf of such Holders until such bank deposit details have been provided. All amounts
so held by the Depositary will be reported for tax purposes as if paid to all Holders as of the date that funds are first made available to Holders and will neither accrue interest nor be invested for Holders while they are being held. A Holder will
be unable to receive cash dividends or other cash distributions to which it is entitled until such time as such Holder either (i)&nbsp;provides its bank deposit details to the Depositary in accordance with the instructions provided by the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
Depositary for this purpose, (ii)&nbsp;transfers such Holder&#146;s ADS position into DTC or (iii)&nbsp;cancels its ADSs (whereupon, in the case of a transfer to DTC or a cancellation, such
Holder will receive a check for the aggregate amount of cash dividends and/or cash distributions being held on its behalf). Notwithstanding the foregoing, the Depositary shall, if instructed by GSK, distribute cash dividends and other cash
distributions by check or by such other means as GSK and the Depositary may agree. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Foreign Exchange Related Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">To facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other
corporate actions, the Depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A. (the &#147;Bank&#148;) and/or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S.
dollars (&#147;FX Transactions&#148;). For certain currencies, FX Transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For other currencies, FX Transactions are routed directly to and
managed by an unaffiliated local custodian (or other third party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such FX Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The foreign exchange rate applied to an FX Transaction will be either (a)&nbsp;a published benchmark rate, or (b)&nbsp;a rate determined by a third party
local liquidity provider, in each case plus or minus a spread, as applicable. The Depositary will disclose which foreign exchange rate and spread, if any, apply to such currency on ADR.com. Such applicable foreign exchange rate and spread may (and
neither the Depositary, the Bank nor any of their affiliates is under any obligation to ensure that such rate does not) differ from rates and spreads at which comparable transactions are entered into with other customers or the range of foreign
exchange rates and spreads at which the Bank or any of its affiliates enters into foreign exchange transactions in the relevant currency pair on the date of the FX Transaction. Additionally, the timing of execution of an FX Transaction varies
according to local market dynamics, which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors. Furthermore, the Bank and its affiliates may manage the associated risks of their position in
the market in a manner they deem appropriate without regard to the impact of such activities on GSK, the Depositary, Holders or Beneficial Owners. The spread applied does not reflect any gains or losses that may be earned or incurred by the Bank and
its affiliates as a result of risk management or other hedging related activity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">To the extent the Company provides U.S. dollars to the Depositary,
neither the Bank nor any of its affiliates will execute an FX Transaction. In such case, the Depositary will distribute the U.S. dollars received from the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of FX Transactions will be provided by the
Depositary on ADR.com. The Company, Holders and Beneficial Owners each acknowledge and agree that the terms applicable to FX Transactions disclosed from time to time on ADR.com will apply to any FX Transaction executed pursuant to the Deposit
Agreement. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Amendment and Termination of the Deposit Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The form of ADRs evidencing ADSs and any provisions of the Deposit Agreement relating to those ADRs may be amended by GSK and the Depositary. Any
amendment that imposes or increases any fees or charges, other than taxes and other governmental charges, transfer or registration fees, transmission costs, delivery costs or other such expenses, or that otherwise prejudices any substantial existing
right of the Holders or Beneficial Owners, will not take effect as to any ADRs until 30 days after notice of the amendment has been given to the Holders. Every Holder and Beneficial Owner of any ADR, at the time an amendment becomes effective, will
be deemed to continue to hold such ADR and to consent and agree to the amendment and to be bound by the Deposit Agreement or the ADR as amended. No amendment may impair the right of any Holder to surrender ADRs and receive in return the deposited
securities represented by the ADSs. If any governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the Deposit Agreement or the form of ADR to ensure compliance therewith, GSK
and the Depositary may amend or supplement the Deposit Agreement and the ADR at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the Deposit Agreement in such circumstances may become effective
before a notice of such amendment or supplement is given to Holders or within any other period of time as required for compliance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Whenever GSK
directs, the Depositary has agreed to terminate the Deposit Agreement as to ADRs evidencing ADSs by mailing a termination notice to the Holders then outstanding at least 30 days before the date fixed in the notice of termination. The Depositary may
likewise terminate the Deposit Agreement as to ADRs evidencing ADSs by mailing a termination notice to GSK and the Holders then outstanding at least 30 days before the date of termination, under the following circumstances: (i)&nbsp;in the event of
GSK&#146;s bankruptcy or insolvency, (ii)&nbsp;if the ordinary shares cease to be listed on an internationally recognized stock exchange, (iii)&nbsp;if GSK effects (or will effect) a redemption of all or substantially all of the deposited
securities, or a cash or share distribution representing a return of all or substantially all of the value of the deposited securities, or (iv)&nbsp;there occurs a merger, consolidation, sale of assets or other transaction as a result of which
securities or other property are delivered in exchange for or in lieu of deposited securities, except where such transaction was commenced, announced by GSK or notified to the Depositary prior to the effective date of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
the Deposit Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">After the date so fixed for termination, the Depositary and its agents
will perform no further acts under the Deposit Agreement and this ADR, except to receive and hold (or sell) distributions on deposited securities and deliver deposited securities being withdrawn. As soon as practicable after the date so fixed for
termination, the Depositary shall use its reasonable efforts to sell the deposited securities and shall thereafter (as long as it may lawfully do so) hold in an account (which may be a segregated or unsegregated account) the net proceeds of such
sales, together with any other cash then held by it under the Deposit Agreement, without liability for interest, in trust for the pro rata benefit of the Holders of ADRs not theretofore surrendered. After making such sale, the Depositary shall be
discharged from all obligations in respect of the Deposit Agreement and this ADR, except to account for such net proceeds and other cash. After the date so fixed for termination, GSK shall be discharged from all obligations under the Deposit
Agreement except for its obligations to the Depositary and its agents. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Rights of Holders to Inspect the Transfer Books of the Depositary and the List of
Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary will keep books for the registration and transfer of ADRs as well as facilities for the delivery and receipt of ADRs
at the Transfer Office. These books will be open for inspection by Holders at all reasonable times. However, this inspection may not be for the purpose of communicating with Holders in the interest of a business or object other than GSK business or
a matter related to the Deposit Agreement or the ADRs. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Restrictions on the Right to Transfer or Withdraw the Underlying Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As a condition precedent to the issue, registration, registration of transfer, <FONT STYLE="white-space:nowrap">split-up</FONT> or combination of any ADR,
the delivery of any distribution in respect thereof, or the withdrawal of any deposited securities, GSK, the Depositary, or custodian may require payment of a sum sufficient to reimburse it for any tax or other governmental charge and any stock
transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to ordinary shares or other deposited securities being registered) and payment of any applicable fees as therein provided, may require the
production of proof satisfactory to it as to the identity and genuineness of any signature, as well as such other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial or other
ownership of any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the Deposit Agreement and ADR, as it may deem necessary or proper, and may also require compliance with any
regulations the Depositary may establish consistent with the provisions of the Deposit Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The issuance of ADRs, the acceptance of deposits of
ordinary shares, the registration, registration of transfer, <FONT STYLE="white-space:nowrap">split-up</FONT> or combination of ADRs or the withdrawal of deposited securities may be suspended, generally or in particular instances, when the ADR
Register or any register for deposited securities is closed or when any such action is deemed advisable by the Depositary or GSK at any time or from time to time. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Limitations on the Depositary&#146;s Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The
Depositary shall not incur any liability to any Holder or Beneficial Owners of ADRs, if by reason of any provision of any present or future law, rule, regulation, fiat, order or decree of the U.S., England, Wales or any other country or
jurisdiction, or of any governmental or regulatory authority or any securities exchange or market or automated quotation system, or the provisions of or governing any deposited securities, or by reason of any provision, present or future, of the
Company&#146;s charter, or by reason of any act of God or war or terrorism or other circumstances beyond its control, the Depositary shall be prevented or forbidden from or be subject to any civil or criminal penalty on account of doing or
performing any act or thing which by the terms of the Deposit Agreement it is provided shall be done or performed; nor shall the Depositary incur any liability to any Holder or Beneficial Owner of any ADR by reason of any <FONT
STYLE="white-space:nowrap">non-performance</FONT> or delay, caused as aforesaid, in the performance of any act or thing which by the terms of the Deposit Agreement it is provided shall or may be done or performed, or by reason of any exercise of, or
failure to exercise, any discretion provided for in the Deposit Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary assumes no obligation nor shall it be subject to any
liability under the Deposit Agreement to any Holders or Beneficial Owners of any ADR (including, without limitation, liability with respect to the validity or worth of any deposited securities), except that it agrees to perform its obligations
specifically set forth in the Deposit Agreement without gross negligence or willful misconduct. The Depositary shall not be a fiduciary or have any fiduciary duty to Holders or Beneficial Owners. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary and its agents shall not be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any
deposited securities or in respect of the ADRs. The Depositary shall not be liable to Holders or Beneficial Owners for any action or <FONT STYLE="white-space:nowrap">non-action</FONT> by it in reliance upon the advice of or information from the
Company, legal counsel, accountants, any person presenting ordinary shares for deposit, any Holder or any other person believed by it to be competent to give such advice or information. The Depositary shall not be liable for the acts or omissions
made by, or the insolvency of, any securities depository, clearing agency or settlement system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary shall not be responsible for, and
shall incur no liability in connection with or arising from, the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
insolvency of any custodian that is not a branch or affiliate of JPMorgan Chase Bank, N.A. The Depositary shall not have any liability for the price received in connection with any sale of
securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection with any such sale or
proposed sale. The Depositary shall not be liable for any acts or omissions to act on the part of the custodian, except to the extent that any Holder has incurred liability directly as a result of the custodian having (i)&nbsp;committed fraud or
willful misconduct in the provision of custodial services to the Depositary or (ii)&nbsp;failed to use reasonable care in the provision of custodial services to the Depositary as determined in accordance with the standards prevailing in the
jurisdiction in which the custodian is located. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary and its respective agents may rely and shall be protected in acting upon any written
notice, request, direction, instruction or document believed by it to be genuine and to have been signed, presented or given by the proper party or parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary shall be under no obligation to inform Holders or Beneficial Owners about the requirements of the laws, rules or regulations or any changes
therein or thereto of any country or jurisdiction or of any governmental or regulatory authority or any securities exchange or market or automated quotation system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary and its agents will not be responsible for any failure to carry out any Voting Instructions to vote any of the Deposited Securities, for
the manner in which any such vote is cast, any act or omission to act on the part of Holders, Beneficial Owners, the Company or its agents in connection with voting at a meeting, or for the effect of any such vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary may rely upon instructions from the Company or its counsel in respect of any approval or license required for any currency conversion,
transfer or distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary and its agents may own and deal in any class of securities of the Company and its affiliates and in ADRs.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding anything to the contrary set forth in the Deposit Agreement or any ADR, the Depositary shall have no liability or responsibility
under the Deposit Agreement, any ADR or any related agreement, for any period prior to the effective date of the Deposit Agreement or for any act or omission of the predecessor to the Depositary or any of its agents (including the Custodian as
defined in the Prior Deposit Agreement), under or in connection with this Deposit Agreement, any ADRs or any related agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding
anything to the contrary set forth in the Deposit Agreement or any ADR, the Depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the Deposit Agreement, any
Holder or Holders, any ADR or ADRs or otherwise related hereto or thereto to the extent such information is requested or required by or pursuant to any lawful authority, including without limitation laws, rules, regulations, administrative or
judicial process, banking, securities or other regulators. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary shall not be liable for the failure by any Holder or Beneficial Owner to
obtain the benefits of credits or refunds of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax paid against such Holder&#146;s or Beneficial Owner&#146;s income tax liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary is under no obligation to provide the Holders and Beneficial Owners, or any of them, with any information about the tax status of the
Company. The Depositary shall not incur any liability for any tax or tax consequences that may be incurred by Holders and Beneficial Owners on account of their ownership or disposition of the ADRs or ADSs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary shall not incur any liability for the content of any information submitted to it by or on behalf of the Company for distribution to the
Holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities, for the validity or worth of the deposited securities, for the credit-worthiness of any third party,
for allowing any rights to lapse upon the terms of the Deposit Agreement or for the failure or timeliness of any notice from the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding anything to the contrary set forth in the Deposit Agreement or any ADR, the may use third party delivery services and providers of
information regarding matters such as pricing, proxy voting, corporate actions, class action litigation and other services in connection herewith and the Deposit Agreement, and use local agents to provide extraordinary services such as attendance at
annual meetings of issuers of securities. Although the Depositary will use reasonable care (and cause their agents to use reasonable care) in the selection and retention of such third party providers and local agents, they will not be responsible
for any errors or omissions made by them in providing the relevant information or services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Depositary shall not be liable for any acts or
omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">By holding an ADS or an interest therein, Holders and Beneficial Owners each irrevocably agree that any legal suit, action or proceeding against or
involving the Depositary, arising out of or based upon the Deposit Agreement, the ADSs or the transactions contemplated herein, therein or hereby, may only be instituted in a state or federal court in New
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
York, New York, and by holding an ADS or an interest therein each irrevocably waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and
irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Company has agreed to indemnify the
Depositary and its agents under certain circumstances and the Depositary has agreed to indemnify the Company under certain circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The
Depositary shall not be liable to Holders or Beneficial Owners for any indirect, special, punitive or consequential damages (including, without limitation, legal fees and expenses) or lost profits, in each case of any form incurred by any person or
entity (including, without limitation, Holders and Beneficial Owners), whether or not foreseeable and regardless of the type of action in which such a claim may be brought. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>C. Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Each series of debt securities listed on the New York Stock Exchange and set forth on the cover page to GSK&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022 has been issued by either GlaxoSmithKline Capital Inc. (&#147;GSK Capital Inc.&#148;) or GlaxoSmithKline Capital plc (&#147;GSK Capital plc&#148;) and guaranteed by
GSK. Each of these series of notes and related guarantees were issued pursuant to an effective registration statement and a related prospectus and prospectus supplement setting forth the terms of the relevant series of notes and related guarantees.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The following table sets forth the name of the series, interest rate, dates of the registration statements, dates of the base prospectuses and dates
of issuance for each relevant series of notes (the &#147;Notes&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Series / Interest Rate</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Statement</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Date of Base</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Prospectus</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL"><B>Date&nbsp;of&nbsp;Issuance</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">0.534% Notes due 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-223982</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;28,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>October&nbsp;1,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">3.000% Notes due 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-223982</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;28, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;25, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">3.375% Notes due 2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-223982</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;28, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;25, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">3.625% Notes due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-223982</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;28, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>May&nbsp;15, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">3.875% Notes due 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-223982</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;28, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>May&nbsp;15, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">4.200% Notes due 2043</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-172621</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;4, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;18, 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">6.375% Notes due 2038</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-149531</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;4, 2008</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>May&nbsp;13, 2008</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Pursuant to an Agreement of Resignation, Appointment and Acceptance dated April&nbsp;12, 2017 by and among GSK
Capital plc, Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas, Deutsche Bank Trust Company Americas has become the successor trustee to Law Debenture Trust Company of New York under the indenture dated as of
April&nbsp;6, 2004 among GSK, GSK Capital plc and Law Debenture Trust Company of New York, as amended and supplemented. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Pursuant to an Agreement of
Resignation, Appointment and Acceptance dated April&nbsp;12, 2017 by and among GSK Capital Inc., Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas, Deutsche Bank Trust Company Americas has become the successor trustee
to Law Debenture Trust Company of New York under the indenture dated as of April&nbsp;6, 2004 among GSK, GSK Capital Inc. and Law Debenture Trust Company of New York, as amended and supplemented. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The paying agent under the indentures governing the Notes is the trustee under the relevant indenture. The address of the trustee and paying agent in
relation to the Notes is 60 Wall Street, 16th Floor, New York, NY 10005. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL"><I>The summary set out below of the general terms and provisions of the
Notes does not purport to be complete and is subject to and qualified by reference to, all of the definitions and provisions of the relevant indenture governing the applicable series of Notes, any supplement to the relevant indenture and the form of
the instrument representing each series of Notes. Certain terms, unless otherwise defined herein, have the meaning given to them in the relevant indenture governing the applicable series of Notes. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>1. Notes offered pursuant to the Base Prospectus dated March&nbsp;28, 2018 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left"><B><U>Prospectus Supplement (September 28, 2020) &#150; 0.534% Notes due 2023</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of the Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the 0.534% Notes due 2023 (for purposes of this &#147;Description of the Notes&#148; only, the &#147;Notes&#148;) pursuant to an
indenture, dated as of April&nbsp;6, 2004, among GSK, as guarantor, GSK Capital plc, as issuer, and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
Deutsche Bank Trust Company Americas, as trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated
April&nbsp;12, 2017, among GSK Capital plc, Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas), as amended and supplemented by a first supplemental indenture, dated as of March&nbsp;21, 2014 and as further amended and
supplemented by a second supplemental indenture dated as of May&nbsp;15, 2018 (for purposes of this description of the Notes only, the &#147;Indenture&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the Notes in the initial aggregate principal amount of $1,250,000,000. The Notes will mature on October&nbsp;1, 2023 unless
redeemed or purchased prior to such date as described below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes are fully and unconditionally guaranteed by GSK. If, for any reason, GSK
Capital plc does not make any required payment in respect of the Notes when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. You will be entitled
to payment under the guarantee of GSK without taking any action whatsoever against us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the Notes in book-entry form only, in
minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As used herein, &#147;business day&#148; means any day other than
a Saturday, a Sunday or a day on which banking institutions in the City of New York or London, England are authorized or obligated by law, regulation or executive order to be closed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We or any of our subsidiaries may at any time and from time to time purchase the Notes in the open market or by tender or by private agreement, if
applicable law allows. The Notes purchased by us or any of our subsidiaries may be held, resold or surrendered by the purchaser thereof through us to the trustee or any paying agent for cancellation. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes will bear interest at the interest rate
shown in the table above and accrue interest from October&nbsp;1, 2020, or from the most recent date to which interest has been paid (or provided for), to but not including the next date upon which interest is required to be paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Interest is payable on the Notes twice a year, on April&nbsp;1 and October&nbsp;1, commencing April&nbsp;1, 2021, to the person in whose name a Note is
registered at the close of business on the March&nbsp;17 or September&nbsp;16 that precedes the date on which interest will be paid. Interest on the Notes will be paid on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting
of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an interest payment date or redemption date, or the maturity date, for the Notes,
as the case may be, would fall on a day that is not a business day, then the required payment will be made on the next succeeding business day, but no additional interest shall be paid unless we fail to make payment on such next succeeding business
day. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to certain exceptions, if we are
required to withhold or deduct any amount for or on account of any U.K. or U.S. withholding tax from any payment made on the Notes, we will pay additional amounts on those payments so that the amount received by noteholders will equal the amount
that would have been received if no such taxes had been applicable. See &#147;&#151;Payment of Additional Amounts.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As contemplated by the last
paragraph under &#147;Description of Debt Securities&#151;Defeasance&#148; below, the satisfaction of certain conditions will permit us to omit to comply with some or all of our obligations, covenants and agreements under the Indenture with respect
to the Notes. In addition, we may omit to comply with certain covenants through covenant defeasance. We refer you to the information under &#147;Description of Debt Securities&#151; Defeasance&#148; below for more information on how we may do this.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Except as described herein, the Indenture does not contain any covenants or other provisions designed to protect holders of the Notes against a
reduction in our creditworthiness in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the Notes, including, among other things, through the incurrence of additional
indebtedness. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The
provisions of the Indenture described under &#147;Description of Debt Securities&#151;Covenants&#151;Payment of Additional Amounts&#148; do not apply to the Notes. The following payment of additional amounts provisions apply to the Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under or with respect to the Notes will be free and clear of and without withholding or deduction for or on account of any present or
future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or on behalf of (i)&nbsp;the government of the United Kingdom or of any territory of the United Kingdom or by any authority or
agency therein or thereof having the power to tax or (ii)&nbsp;the government of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
the United States or any state or territory of the United States or by any authority or agency therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148;
unless we are required to withhold or deduct Taxes by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any
payment made with respect to the Notes, we will pay such additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the
holder would have received if the Taxes had not been withheld or deducted; provided that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the Notes (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation) and the
United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor,
beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or business therein or
having or having had a permanent establishment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or premium, if any, or interest on the Notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction
in, the rate of deduction or withholding of such Taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of the Notes (where presentation is required) for payment on a
date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the Notes had been made to a paying agent other than the
paying agent to which the presentation was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed solely by reason of the holder or beneficial owner owning or having owned, actually or constructively, 10%
or more of the total combined voting power of all classes of our stock entitled to vote; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for a failure by the holder or beneficial owner (or any financial institution through
which the holder or beneficial owner holds any security through which payment on the security is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into and
complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the Notes or any successor or amended version of such
provisions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or premium, if any, or interest on the Notes to any such holder who is a fiduciary or
a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled
to such additional amounts had it been the holder of such Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the Indenture that at least one paying agent for the Notes will be
located outside the United Kingdom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the Indenture and the
payment of all amounts in respect of the Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:ARIAL"><B>Tax Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the event of changes in U.K. or U.S. withholding taxes applicable to payments of interest, we may redeem the Notes in whole (but not in part) at any
time prior to maturity, at a price equal to 100% of their principal amount plus accrued interest to the redemption date. See &#147;Description of Debt Securities&#151;Optional Redemption for Tax Reasons&#148; below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Prior to October&nbsp;1, 2022 (the &#147;Par Call Date&#148;), we may redeem the Notes, in whole or in part, at our option at any time and from time to
time at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed on that redemption date; and (ii)&nbsp;as determined by the quotation agent (as defined below), the sum of the present values of the
remaining scheduled payments of principal of and interest on the Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the Notes matured on the
Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360 day year consisting of twelve 30 day months) at the Treasury Rate plus 0.100%, plus accrued and unpaid interest, if any, thereon to, but excluding, the
redemption date. On or after the Notes Par Call Date, we may redeem the Notes, in whole or in part, at our option at any time and from time to time at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued
and unpaid interest, if any, thereon to, but excluding, the redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding the foregoing, installments of interest on the Notes to
be redeemed that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the
Notes and the Indenture, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Issue&#148; means the United States Treasury security selected by the quotation
agent as having a maturity comparable to the remaining term of the Notes to be redeemed, assuming such Notes matured on the Par Call Date, that would be utilized, at the time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the remaining term of such Notes, assuming such Notes matured on the Par Call Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date, (i)&nbsp;the average of four Reference Treasury Dealer Quotations (as
defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (ii)&nbsp;if the quotation agent for the Notes obtains fewer than four such Reference Treasury Dealer Quotations, the
average of all such quotations, or (iii)&nbsp;if only one Reference Treasury Dealer Quotation is received, the quotation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Quotation agent&#148;
means any Reference Treasury Dealer appointed by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of BofA Securities, Inc., Citigroup
Global Markets Inc., Credit Suisse Securities (USA) LLC and Morgan Stanley&nbsp;&amp; Co. LLC (or their respective affiliates that are Primary Treasury Dealers) and their respective successors; provided, however, that if any of the foregoing shall
cease to be a primary U.S. government securities dealer in the United States (a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer, and (ii)&nbsp;any other Primary Treasury Dealer selected by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined
by us, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the
third business day preceding such redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per annum equal to
the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notice of any redemption will be mailed at least 15 days but not more than 60 days before the redemption date to each registered holder of the Notes
to be redeemed by us or by the trustee on our behalf. We will give notice of any such redemption to any exchange on which such Notes are listed. On and after any redemption date, interest will cease to accrue on the Notes or portions thereof called
for redemption. On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued interest on the Notes to be redeemed on that date. If less than all of the Notes are
to be redeemed, the Notes to be redeemed shall be selected by lot by The Depository Trust Company (&#147;DTC&#148;), in the case of Notes represented by a global security, or by the trustee by such method as the trustee deems to be fair and
appropriate, in the case of Notes that are not represented by a global security. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The events of default under the Indenture with respect to the Notes are defined under &#147;Description of Debt Securities&#151;Events of Default&#148;
below. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Further Issuances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We initially offered the Notes
in the aggregate principal amount of $1,250,000,0000. We may from time to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
time, without the consent of the holders of the Notes, create and issue further debt securities of the same series having the same terms and conditions in all respects as the Notes being offered
hereby, except for the issue date, the issue price and, in certain cases, the first payment of interest thereon. Any such additional debt securities shall be issued under a separate CUSIP or ISIN number unless the additional debt securities are
issued pursuant to a &#147;qualified reopening&#148; of the original series, are otherwise treated as part of the same &#147;issue&#148; of debt instruments as the original series or are issued with no more than a de minimis amount of original
discount, in each case for U.S. federal income tax purposes. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the Notes in the form of one or more fully registered global securities. We deposited these global securities with, or on behalf of, DTC and
register these securities in the name of DTC&#146;s nominee. Direct and indirect participants in DTC will record beneficial ownership of the Notes by individual investors. The transfer of ownership of beneficial interests in a global security will
be effected only through records maintained by DTC or its nominee, or by participants or persons that hold through participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Investors may elect
to hold beneficial interests in the global securities through either DTC, Clearstream Banking S.A. (&#147;Clearstream&#148;) or Euroclear Bank SA/NV (&#147;Euroclear&#148;) if they are participants in these systems, or indirectly through
organizations which are participants in these systems. Beneficial interests in the global securities will be held in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon receipt of any payment in respect of a global security, DTC or its nominee will immediately credit participants&#146; accounts with amounts
proportionate to their respective beneficial interests in the principal amount of the global security as shown in the records of DTC or its nominee. Payments by participants to owners of beneficial interests in a global security held through
participants will be governed by standing instructions and customary practices and will be the responsibility of those participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">DTC holds
securities of institutions that have accounts with it or its participants. Through its maintenance of an electronic book-entry system, DTC facilitates the clearance and settlement of securities transactions among its participants and eliminates the
need to deliver securities certificates physically. DTC&#146;s participants include securities brokers and dealers, including the underwriters of this offering, banks, trust companies, clearing corporations and other organizations. DTC is partially
owned by some of these participants or their representatives. Access to DTC&#146;s book-entry system is also available to others such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a
participant, either directly or indirectly. DTC agrees with and represents to its participants that it will administer its book-entry system in accordance with its rules and bylaws and requirements of law. The rules applicable to DTC and its
participants are on file with the U.S. Securities and Exchange Commission&#146;s (the &#147;Commission&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream and Euroclear hold
interests on behalf of their participants through customers&#146; securities accounts in Clearstream&#146;s and Euroclear&#146;s names on the books of their respective depositaries, which in turn will hold interests in customers&#146; securities
accounts in the depositaries&#146; names on the books of DTC. At the date of the prospectus supplement, Citibank, N.A. acts as U.S. depositary for Clearstream and JPMorgan Chase Bank, N.A. acts as U.S. depositary for Euroclear, or, collectively, the
&#147;U.S. Depositaries.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream holds securities for its participating organizations, or &#147;Clearstream Participants,&#148; and
facilitates the clearance and settlement of securities transactions between Clearstream Participants through electronic book-entry changes in accounts of Clearstream Participants, thereby eliminating the need for physical movement of certificates.
Clearstream provides to Clearstream Participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic
markets in several countries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream is registered as a bank in Luxembourg and as such is subject to regulation by the Commission de
Surveillance du Secteur Financier and the Banque Centrale du Luxembourg, which supervise and oversee the activities of Luxembourg banks. Clearstream Participants are worldwide financial institutions, including underwriters, securities brokers and
dealers, banks, trust companies and clearing corporations, and may include the underwriters or their affiliates. Indirect access to Clearstream is available to other institutions that clear through or maintain a custodial relationship with a
Clearstream Participant. Clearstream has established an electronic bridge with Euroclear as the operator of the Euroclear System, or the &#147;Euroclear Operator,&#148; in Brussels to facilitate settlement of trades between Clearstream and the
Euroclear Operator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to the Notes held beneficially through Clearstream will be credited to cash accounts of Clearstream
Participants in accordance with its rules and procedures, to the extent received by the U.S. Depositary for Clearstream. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear holds securities
and book-entry interests in securities for participating organizations, or &#147;Euroclear Participants&#148; and facilitates the clearance and settlement of securities transactions between Euroclear Participants, and between Euroclear Participants
and participants of certain other securities intermediaries through electronic book-entry </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
changes in accounts of such participants or other securities intermediaries. Euroclear provides Euroclear Participants with, among other things, safekeeping, administration, clearance and
settlement, securities lending and borrowing, and related services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear Participants are investment banks, securities brokers and dealers,
banks, central banks, supranationals, custodians, investment managers, corporations, trust companies and certain other organizations and may include the underwriters or their affiliates. <FONT STYLE="white-space:nowrap">Non-participants</FONT> in
Euroclear may hold and transfer beneficial interests in a global security through accounts with a Euroclear Participant or any other securities intermediary that holds a book-entry interest in a global security through one or more securities
intermediaries standing between such other securities intermediary and Euroclear. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to Notes held beneficially through
Euroclear will be credited to the cash accounts of Euroclear Participants in accordance with the Terms and Conditions, to the extent received by the U.S. Depositary for Euroclear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers between Euroclear Participants and Clearstream Participants will be effected in the ordinary way in accordance with their respective rules and
operating procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Cross-market transfers between DTC&#146;s participating organizations, or the &#147;DTC Participants,&#148; on the one hand,
and Euroclear Participants or Clearstream Participants, on the other hand, will be effected through DTC in accordance with DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by its U.S. Depositary; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. Depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global security in DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement applicable to DTC. Euroclear Participants and Clearstream Participants may not deliver
instructions directly to their respective U.S. Depositaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Due to time zone differences, the securities accounts of a Euroclear Participant or
Clearstream Participant purchasing an interest in a global security from a DTC Participant in DTC will be credited, and any such crediting will be reported, to the relevant Euroclear Participant or Clearstream Participant during the securities
settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a
Euroclear Participant or Clearstream Participant to a DTC Participant will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or
Clearstream following DTC&#146;s settlement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The information in this section concerning DTC, Euroclear and Clearstream and their book-entry
systems has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy or completeness of that information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">None of us, any of the underwriters and the trustee will have any responsibility for the performance by DTC, Euroclear or Clearstream or their respective
participants of their respective obligations under the rules and procedures governing their operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Although DTC, Clearstream and Euroclear have
agreed to the foregoing procedures in order to facilitate transfers of securities among participants of DTC, Clearstream and Euroclear, they are under no obligations to perform or continue to perform such procedures and they may discontinue the
procedures at any time. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Initial settlement for the Notes was made in immediately available funds. Secondary market trading between DTC participants will occur in the ordinary way
in accordance with DTC rules and will be settled in immediately available funds using DTC&#146;s <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement System. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>b. <U>Prospectus Supplement (March 19, 2019) &#150;3.000% Notes due 2024 and 3.375% Notes due 2029</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of the Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the 3.000% Notes due 2024 (the &#147;2024 notes&#148;) and the 3.375% Notes due 2029 (the &#147;2029 Notes&#148;) pursuant to an
indenture, dated as of April&nbsp;6, 2004, among GSK, as guarantor, GSK Capital plc, as issuer, and Deutsche Bank Trust Company Americas, as trustee (as successor to Law Debenture Trust Company of New York,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
pursuant to an Instrument of Resignation, Appointment and Acceptance dated April&nbsp;12, 2017, among GSK Capital plc, Law Debenture Trust Company of New York and Deutsche Bank Trust Company
Americas), as amended and supplemented by a first supplemental indenture, dated as of March&nbsp;21, 2014 and as further amended and supplemented by a second supplemental indenture dated as of May&nbsp;15, 2018 (for purposes of this description of
the 2024 Notes and the 2029 Notes only, the &#147;Indenture&#148;). References in this &#147;Description of the Notes&#148; to the &#147;Notes&#148; refer to the 2024 Notes and the 2029 Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the 2024 Notes in the initial aggregate principal amount of$1,000,000,000. The 2024 Notes will mature on June&nbsp;1, 2024 unless
redeemed or purchased prior to such date as described below. GSK Capital plc issued the 2029 Notes in the initial aggregate principal amount of $1,000,000,000. The 2029 Notes will mature on June&nbsp;1, 2029 unless redeemed or purchased prior to
such date as described below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes are fully and unconditionally guaranteed by GSK. If, for any reason, GSK Capital plc does not make any
required payment in respect of the Notes when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. You will be entitled to payment under the guarantee
of GSK without taking any action whatsoever against us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital plc issued the Notes in book-entry form only, in minimum denominations of $2,000
and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As used herein, &#147;business day&#148; means any day other than a Saturday, a Sunday or a day
on which banking institutions in the City of New York or London, England are authorized or obligated by law, regulation or executive order to be closed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We or any of our subsidiaries may at any time and from time to time purchase the Notes of any series in the open market or by tender or by private
agreement, if applicable law allows. The Notes of any such series purchased by us or any of our subsidiaries may be held, resold or surrendered by the purchaser thereof through us to the trustee or any paying agent for cancellation. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes each bear interest at the applicable
interest rate shown in the table above and accrue interest from March&nbsp;25, 2019, or from the most recent date to which interest has been paid (or provided for), to but not including the next date upon which interest is required to be paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Interest is payable on each of the 2024 Notes and the 2029 Notes twice a year, on June&nbsp;1 and December&nbsp;1, commencing December&nbsp;1, 2019, to
the person in whose name a 2024 Note or a 2029 Note, respectively, is registered at the close of business on the May&nbsp;17 or November 16th that precedes the date on which interest will be paid. Interest on the 2024 Notes and the 2029 Notes will
be paid on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an interest payment date or redemption date, or the maturity date, for the Notes, as the case may be, would fall on a day that is not a business day,
then the required payment will be made on the next succeeding business day, but no additional interest shall be paid unless we fail to make payment on such next succeeding business day. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to certain exceptions, if we are required to
withhold or deduct any amount for or on account of any U.K. or U.S. withholding tax from any payment made on the Notes, we will pay additional amounts on those payments so that the amount received by noteholders will equal the amount that would have
been received if no such taxes had been applicable. See &#147;&#151;Payment of Additional Amounts.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As contemplated by the last paragraph under
&#147;Description of Debt Securities&#151;Defeasance&#148; below, the satisfaction of certain conditions will permit us to omit to comply with some or all of our obligations, covenants and agreements under the Indenture with respect to the Notes of
any or all series, as applicable. In addition, we may omit to comply with certain covenants through covenant defeasance. We refer you to the information under &#147;Description of Debt Securities&#151;Defeasance&#148; below for more information on
how we may do this. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Except as described herein, the Indenture does not contain any covenants or other provisions designed to protect holders of the
Notes against a reduction in our creditworthiness in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the Notes, including, among other things, through the incurrence of
additional indebtedness. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The provisions of the Indenture described under &#147;Description of Debt Securities&#151;Covenants&#151;Payment of Additional Amounts&#148; do not apply
to the Notes. The following payment of additional amounts provisions apply to the Notes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under or with respect to the Notes will be free and clear of and without
withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or on behalf of (i)&nbsp;the government of the United Kingdom or of
any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax or (ii)&nbsp;the government of the United States or any state or territory of the United States or by any authority or agency therein or
thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If
we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the Notes, we will pay such additional amounts as may be necessary so that the net amount received by each holder (including additional
amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been withheld or deducted; provided that no additional amounts will be payable with respect to Taxes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the applicable Notes (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation)
and the United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor,
beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or business therein or
having or having had a permanent establishment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or premium, if any, or interest on the applicable Notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction
in, the rate of deduction or withholding of such Taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of the applicable Notes (where presentation is required) for
payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the applicable Notes had been made to a paying agent other
than the paying agent to which the presentation was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed solely by reason of the holder or beneficial owner owning or having owned, actually or constructively, 10%
or more of the total combined voting power of all classes of our stock entitled to vote; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for a failure by the holder or beneficial owner (or any financial institution through
which the holder or beneficial owner holds any security through which payment on the security is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into and
complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the applicable Notes or any successor or amended version of
such provisions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or premium, if any, or interest on any Notes to any such holder who is a fiduciary or
a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled
to such additional amounts had it been the holder of such Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the Indenture that at least one paying agent for the Notes will be
located outside the United Kingdom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the Indenture and the
payment of all amounts in respect of the Notes. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Tax Redemption </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the event of changes in U.K. or U.S. withholding taxes applicable to payments of interest, we may
redeem the Notes of a series in whole (but not in part) at any time prior to maturity, at a price equal to 100% of their principal amount plus accrued interest to the redemption date. See &#147;Description of Debt Securities&#151;Optional Redemption
for Tax Reasons&#148; below. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Make-Whole Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Prior to May&nbsp;1, 2024 (the date that is one month prior to the scheduled maturity date for the 2024 Notes) (the &#147;2024 Notes Par Call Date&#148;),
we may redeem the 2024 Notes, in whole or in part, at our option at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2024 Notes to be redeemed on that redemption date; and
(ii)&nbsp;as determined by the quotation agent (as defined below), the sum of the present values of the remaining scheduled payments of principal of and interest on the 2024 Notes to be redeemed on that redemption date (not including any portion of
such payments of interest accrued as of the redemption date) that would be due if the 2024 Notes matured on the 2024 Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360 day year consisting of twelve 30 day
months) at the Treasury Rate plus 0.125%, plus accrued and unpaid interest thereon to, but excluding, the redemption date. On or after the 2024 Notes Par Call Date, we may redeem the 2024 Notes, in whole or in part, at our option at any time and
from time to time at a redemption price equal to 100% of the principal amount of the 2024 Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Prior to March&nbsp;1, 2029 (the date that is three months prior to the scheduled maturity date for the 2029 Notes) (the &#147;2029 Notes Par Call
Date&#148;), we may redeem the 2029 Notes, in whole or in part, at our option at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2029 Notes to be redeemed on that redemption date;
and (ii)&nbsp;as determined by the quotation agent (as defined below), the sum of the present values of the remaining scheduled payments of principal of and interest on the 2029 Notes to be redeemed on that redemption date (not including any portion
of such payments of interest accrued as of the redemption date) that would be due if the 2029 Notes matured on the 2029 Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360 day year consisting of twelve 30
day months) at the Treasury Rate plus 0.150%, plus accrued and unpaid interest thereon to, but excluding, the redemption date. On or after the 2029 Notes Par Call Date, we may redeem the 2029 Notes, in whole or in part, at our option at any time and
from time to time at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The 2024 Notes Par Call Date and the 2029 Notes Par Call Date are each referred to herein as a &#147;Par Call Date.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notwithstanding the foregoing, installments of interest on the Notes to be redeemed that are due and payable on an interest payment date falling on or
prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the Notes and the Indenture, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Issue&#148; means the United States Treasury security selected by the quotation agent as having a maturity comparable to the
remaining term of the Notes of the applicable series to be redeemed, assuming such Notes matured on the applicable Par Call Date, that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new
issues of corporate debt securities of comparable maturity to the remaining term of such Notes, assuming such Notes matured on the applicable Par Call Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date, (i)&nbsp;the average of four Reference Treasury Dealer Quotations (as
defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (ii)&nbsp;if the quotation agent for the Notes obtains fewer than four such Reference Treasury Dealer Quotations, the
average of all such quotations, or (iii)&nbsp;if only one Reference Treasury Dealer Quotation is received, the quotation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Quotation agent&#148;
means any Reference Treasury Dealer appointed by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of Deutsche Bank Securities Inc.,
Goldman Sachs&nbsp;&amp; Co. LLC, HSBC Securities (USA) Inc. and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (or their respective affiliates that are Primary Treasury Dealers) and their respective successors; provided, however, that
if any of the foregoing shall cease to be a primary U.S. government securities dealer in the United States (a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer, and (ii)&nbsp;any other Primary Treasury
Dealer selected by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption
date, the average, as determined by us, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent by such Reference Treasury Dealer at 5:00
p.m., New York City time, on the third business day preceding such redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Treasury Rate&#148; means, with respect to any redemption
date, the rate per annum equal to the semi-annual </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable
Treasury Price for that redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notice of any redemption will be mailed at least 15 days but not more than 60 days before the redemption
date to each registered holder of the Notes of the applicable series to be redeemed by us or by the trustee on our behalf. Notice of redemption will be published in a daily newspaper of general circulation in the United States, and we will give
notice of any such redemption to any exchange on which such Notes are listed. On and after any redemption date, interest will cease to accrue on the Notes or portions thereof called for redemption. On or before the redemption date, we will deposit
with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued interest on the Notes to be redeemed on that date. If less than all of the Notes of the applicable series are to be redeemed, the Notes to be redeemed
shall be selected by lot by The Depository Trust Company (&#147;DTC&#148;), in the case of Notes represented by a global security, or by the trustee by such method as the trustee deems to be fair and appropriate, in the case of Notes that are not
represented by a global security. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The
events of default under the Indenture, as applicable, with respect to the Notes are defined under &#147;Description of Debt Securities&#151;Events of Default&#148; below. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Further Issuances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We initially offered the 2024 Notes in the
aggregate principal amount of $1,000,000,0000 and the 2029 Notes in the aggregate principal amount of $1,000,000,0000. We may from time to time, without the consent of the holders of a series of Notes, create and issue further debt securities of the
same series having the same terms and conditions in all respects as the applicable Notes being offered hereby, except for the issue date, the issue price and the first payment of interest thereon. Any such additional debt securities shall be issued
under a separate CUSIP or ISIN number unless the additional debt securities are issued pursuant to a &#147;qualified reopening&#148; of the original series, are otherwise treated as part of the same &#147;issue&#148; of debt instruments as the
original series or are issued with no more than a <I>de minimis </I>amount of original discount, in each case for U.S. federal income tax purposes. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry
System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the Notes of each series in the form of one or more fully registered global securities. We deposited these global securities
with, or on behalf of, DTC and register these securities in the name of DTC&#146;s nominee. Direct and indirect participants in DTC will record beneficial ownership of the Notes by individual investors. The transfer of ownership of beneficial
interests in a global security will be effected only through records maintained by DTC or its nominee, or by participants or persons that hold through participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Investors may elect to hold beneficial interests in the global securities through either DTC, Clearstream Banking S.A. (&#147;Clearstream&#148;) or
Euroclear Bank SA/NV (&#147;Euroclear&#148;) if they are participants in these systems, or indirectly through organizations which are participants in these systems. Beneficial interests in the global securities will be held in minimum denominations
of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon receipt of any payment in respect of a global security, DTC or its nominee will
immediately credit participants&#146; accounts with amounts proportionate to their respective beneficial interests in the principal amount of the global security as shown in the records of DTC or its nominee. Payments by participants to owners of
beneficial interests in a global security held through participants will be governed by standing instructions and customary practices and will be the responsibility of those participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">DTC holds securities of institutions that have accounts with it or its participants. Through its maintenance of an electronic book-entry system, DTC
facilitates the clearance and settlement of securities transactions among its participants and eliminates the need to deliver securities certificates physically. DTC&#146;s participants include securities brokers and dealers, including the
underwriters of this offering, banks, trust companies, clearing corporations and other organizations. DTC is partially owned by some of these participants or their representatives. Access to DTC&#146;s book-entry system is also available to others
such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly. DTC agrees with and represents to its participants that it will administer its book-entry
system in accordance with its rules and bylaws and requirements of law. The rules applicable to DTC and its participants are on file with the U.S. Securities and Exchange Commission&#146;s (the &#147;Commission&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream and Euroclear hold interests on behalf of their participants through customers&#146; securities accounts in Clearstream&#146;s and
Euroclear&#146;s names on the books of their respective depositaries, which in turn will hold interests in customers&#146; securities accounts in the depositaries&#146; names on the books of DTC. At the date of the prospectus supplement, Citibank,
N.A. acts as U.S. depositary for Clearstream and JPMorgan Chase Bank, N.A. acts as U.S. depositary for Euroclear, or, collectively, the &#147;U.S. Depositaries.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream holds securities for its participating organizations, or &#147;Clearstream
Participants,&#148; and facilitates the clearance and settlement of securities transactions between Clearstream Participants through electronic book-entry changes in accounts of Clearstream Participants, thereby eliminating the need for physical
movement of certificates. Clearstream provides to Clearstream Participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream
interfaces with domestic markets in several countries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream is registered as a bank in Luxembourg and as such is subject to regulation by the
Commission de Surveillance du Secteur Financier and the Banque Centrale du Luxembourg, which supervise and oversee the activities of Luxembourg banks. Clearstream Participants are worldwide financial institutions, including underwriters, securities
brokers and dealers, banks, trust companies and clearing corporations, and may include the underwriters or their affiliates. Indirect access to Clearstream is available to other institutions that clear through or maintain a custodial relationship
with a Clearstream Participant. Clearstream has established an electronic bridge with Euroclear as the operator of the Euroclear System, or the &#147;Euroclear Operator,&#148; in Brussels to facilitate settlement of trades between Clearstream and
the Euroclear Operator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to the Notes of a series held beneficially through Clearstream will be credited to cash accounts
of Clearstream Participants in accordance with its rules and procedures, to the extent received by the U.S. Depositary for Clearstream. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear
holds securities and book-entry interests in securities for participating organizations, or &#147;Euroclear Participants&#148; and facilitates the clearance and settlement of securities transactions between Euroclear Participants, and between
Euroclear Participants and participants of certain other securities intermediaries through electronic book-entry changes in accounts of such participants or other securities intermediaries. Euroclear provides Euroclear Participants with, among other
things, safekeeping, administration, clearance and settlement, securities lending and borrowing, and related services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear Participants are
investment banks, securities brokers and dealers, banks, central banks, supranationals, custodians, investment managers, corporations, trust companies and certain other organizations and may include the underwriters or their affiliates. <FONT
STYLE="white-space:nowrap">Non-participants</FONT> in Euroclear may hold and transfer beneficial interests in a global security through accounts with a Euroclear Participant or any other securities intermediary that holds a book-entry interest in a
global security through one or more securities intermediaries standing between such other securities intermediary and Euroclear. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with
respect to Notes of a series held beneficially through Euroclear will be credited to the cash accounts of Euroclear Participants in accordance with the Terms and Conditions, to the extent received by the U.S. Depositary for Euroclear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers between Euroclear Participants and Clearstream Participants will be effected in the ordinary way in accordance with their respective rules and
operating procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Cross-market transfers between DTC&#146;s participating organizations, or the &#147;DTC Participants,&#148; on the one hand,
and Euroclear Participants or Clearstream Participants, on the other hand, will be effected through DTC in accordance with DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by its U.S. Depositary; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. Depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global security in DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement applicable to DTC. Euroclear Participants and Clearstream Participants may not deliver
instructions directly to their respective U.S. Depositaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Due to time zone differences, the securities accounts of a Euroclear Participant or
Clearstream Participant purchasing an interest in a global security from a DTC Participant in DTC will be credited, and any such crediting will be reported, to the relevant Euroclear Participant or Clearstream Participant during the securities
settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a
Euroclear Participant or Clearstream Participant to a DTC Participant will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or
Clearstream following DTC&#146;s settlement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The information in this section concerning DTC, Euroclear and Clearstream and their book-entry
systems has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy or completeness of that information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">None of us, any of the underwriters and the trustee will have any responsibility for the performance by DTC, Euroclear or Clearstream or their respective
participants of their respective obligations under the rules and procedures governing their operations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Although DTC, Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate
transfers of securities among participants of DTC, Clearstream and Euroclear, they are under no obligations to perform or continue to perform such procedures and they may discontinue the procedures at any time. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Initial settlement for the Notes was made in immediately available funds. Secondary market trading between DTC participants will occur in the ordinary way
in accordance with DTC rules and will be settled in immediately available funds using DTC&#146;s <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement System. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>c. <U>Prospectus Supplement (May 10, 2018) &#150;3.625% Notes due 2025 and 3.875% Notes due 2028</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of the Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital Inc. issued the 3.625% Notes due 2025 (&#147;2025 Notes&#148;) and the 3.875% Notes due 2028 (&#147;2028 Notes&#148;) pursuant to an
indenture, dated as of April&nbsp;6, 2004, among GSK, as guarantor, GSK Capital Inc., as issuer, and Deutsche Bank Trust Company Americas, as trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation,
Appointment and Acceptance dated April&nbsp;12, 2017, among GSK Capital Inc., Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas), as amended and supplemented by a first supplemental indenture, dated as of
March&nbsp;18, 2013, as further amended and supplemented by a second supplemental indenture dated as of March&nbsp;21, 2014 and as further amended and supplemented by a third supplemental indenture which was entered into on May&nbsp;15, 2018 (for
purposes of this description of the 2025 Notes and the 2028 Notes only, the &#147;GSK Capital Inc. Indenture&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital Inc. issued the 2025
Notes in the initial aggregate principal amount of $1,000,000,000. The 2025 Notes will mature on May&nbsp;15, 2025 unless redeemed or purchased prior to such date as described below. GSK Capital Inc. issued the 2028 Notes in the initial aggregate
principal amount of $1,750,000,000. The 2028 Notes will mature on May&nbsp;15, 2028 unless redeemed or purchased prior to such date as described below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">References in this &#147;Description of the Notes&#148; to the &#147;Notes&#148; refer to the 2025 Notes and the 2028 Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes are fully and unconditionally guaranteed by GSK. If, for any reason, GSK Capital Inc does not make any required payment in respect of the Notes
when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. You will be entitled to payment under the guarantee of GSK without taking any action
whatsoever against us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">GSK Capital Inc. issued the Notes in book-entry form only, in minimum denominations of $2,000 and integral multiples of $1,000
in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Business day&#148; means any day other than a Saturday, a Sunday or a day on which banking institutions in the City of New
York or London, England are authorized or obligated by law, regulation or executive order to be closed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We or any of our subsidiaries may at any time
and from time to time purchase the Notes of any series in the open market or by tender or by private agreement, if applicable law allows. The Notes of any such series purchased by us or any of our subsidiaries may be held, resold or surrendered by
the purchaser thereof through us to the trustee or any paying agent for cancellation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The Notes each bear interest at the applicable interest rate shown in the table above and accrue interest from May&nbsp;15, 2018, or from the most recent
date to which interest has been paid (or provided for), to but not including the next date upon which interest is required to be paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Interest is
payable on each of the 2025 Notes and the 2028 Notes twice a year, on May&nbsp;15 and November&nbsp;15, commencing November&nbsp;15, 2018, to the person in whose name a 2025 Note, or a 2028 Note, respectively, is registered at the close of business
on the April&nbsp;30 or October&nbsp;31 that precedes the date on which interest will be paid. Interest on the Notes is paid on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve
<FONT STYLE="white-space:nowrap">30-day</FONT> months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an interest payment date or redemption date, or the maturity date, for any series of Notes,
as the case may be, would fall on a day that is not a business day, then the required payment will be made on the next succeeding business day, but no additional interest shall be paid unless we fail to make payment on such next succeeding business
day. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to certain exceptions, if we are required to withhold or deduct any amount for or on account of any U.K. or U.S. withholding tax from any payment
made on the Notes, we will pay additional amounts on those payments so that the amount received by noteholders will equal the amount that would have been received if no such taxes had been applicable. See &#147;&#151;Payment of Additional
Amounts.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As contemplated by the last paragraph under &#147;Description of Debt Securities&#151;Defeasance&#148; below, the satisfaction of
certain conditions will permit us to omit to comply with some or all of our obligations, covenants and agreements under the GSK Capital Inc. Indenture with respect to the Notes of any or all series, as applicable. In addition, we may omit to comply
with certain covenants through covenant defeasance. We refer you to the information under &#147;Description of Debt Securities&#151;Defeasance&#148; below for more information on how we may do this. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Except as described herein, the GSK Capital Inc. Indenture does not contain any covenants or other provisions designed to protect holders of the Notes
against a reduction in our creditworthiness in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the Notes, including, among other things, through the incurrence of
additional indebtedness. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The provisions of the GSK Capital Inc. Indenture described under &#147;Description of Debt Securities&#151;Covenants&#151;Payment of Additional
Amounts&#148; below do not apply to the Notes. The following payment of additional amounts provisions apply to the Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under
or with respect to the Notes will be free and clear of and without withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or
on behalf of (i)&nbsp;the government of the United Kingdom or of any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax or (ii)&nbsp;the government of the United States or any state or territory
of the United States or by any authority or agency therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the Notes, we will pay such
additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been
withheld or deducted; provided that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the applicable Notes (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation)
and the United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor,
beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or business therein or
having or having had a permanent establishment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or premium, if any, or interest on the applicable Notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction
in, the rate of deduction or withholding of such Taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of the applicable Notes (where presentation is required) for
payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the applicable Notes had been made to a paying agent other
than the paying agent to which the presentation was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed solely by reason of the holder or beneficial owner owning or having owned, actually or constructively, 10%
or more of the total combined voting power of all classes of our stock entitled to vote; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for a failure by the holder or beneficial owner (or any financial institution through
which the holder or beneficial owner holds any security through which payment on the security is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into and
complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the applicable Notes or any successor or amended version of
such provisions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or premium, if any, or interest on any Notes to any such holder who is a fiduciary or
a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled
to such additional amounts had it been the holder of such Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the GSK Capital Inc. Indenture that at least one paying agent for
the Notes will be located outside the United Kingdom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the
GSK Capital Inc. Indenture and the payment of all amounts in respect of the Notes. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Tax Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the event of changes in U.K. or U.S. withholding taxes applicable to payments of interest, we may redeem the Notes of a series in whole (but not in
part) at any time prior to maturity, at a price equal to 100% of their principal amount plus accrued interest to the redemption date. See &#147;Description of Debt Securities&#151;Optional Redemption for Tax Reasons&#148; below. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Make-Whole Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may redeem the 2025 Notes
and/or the 2028 Notes in whole or in part, at our option at any time and from time to time, prior to maturity, at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes of the applicable series to be redeemed on
that redemption date; and (ii)&nbsp;as determined by the quotation agent (as defined below), the sum of the present values of the remaining scheduled payments of principal of and interest on the Notes of the applicable series being redeemed on that
redemption date (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semi-annual basis (assuming a 360 day year consisting of twelve 30 day months) at the Treasury
Rate, plus 0.150% in the case of the 2025 Notes, and 0.150% in the case of the 2028 Notes, plus, in each case, accrued and unpaid interest thereon to, but excluding, the date of redemption. Notwithstanding the foregoing, installments of interest on
the Notes to be redeemed that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date
according to the Notes and the GSK Capital Inc. Indenture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Issue&#148; means the United States Treasury security selected
by the quotation agent as having a maturity comparable to the remaining term (as measured from the date of redemption) of the Notes of the applicable series to be redeemed that would be utilized, at the time of selection and in accordance with
customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date, (i)&nbsp;the average of four Reference Treasury Dealer Quotations (as
defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (ii)&nbsp;if the quotation agent for the Notes obtains fewer than four such Reference Treasury Dealer Quotations, the
average of all such quotations, or (iii)&nbsp;if only one Reference Treasury Dealer Quotation is received, the quotation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Quotation agent&#148;
means any Reference Treasury Dealer appointed by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of Citigroup Global Markets Inc.,
Goldman Sachs&nbsp;&amp; Co. LLC, J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (or their respective affiliates that are Primary Treasury Dealers) and their respective successors; provided, however, that
if any of the foregoing shall cease to be a primary U.S. government securities dealer in the United States (a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer, and (ii)&nbsp;any other Primary Treasury
Dealer selected by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption
date, the average, as determined by us, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent by such Reference Treasury Dealer at 5:00
p.m., New York City time, on the third business day preceding such redemption date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per annum equal to the
semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notice of any redemption will be mailed at least 15 days but not more than 60 days before the redemption date to each registered holder of the Notes of
the applicable series to be redeemed by us or by the trustee on our behalf. Notice of redemption will be published in a daily newspaper of general circulation in the United States, and we will give notice of any such redemption to any exchange on
which such Notes are listed. On and after any redemption date, interest will cease to accrue on the Notes or portions thereof called for redemption. On or before the redemption date, we will deposit with a paying agent (or the trustee) money
sufficient to pay the redemption price of and accrued interest on the Notes to be redeemed on that date. If less than all of the Notes of the applicable series are to be redeemed, the Notes to be redeemed shall be selected by lot by The Depository
Trust Company (&#147;DTC&#148;), in the case of Notes represented by a global security, or by the trustee by such method as the trustee deems to be fair and appropriate, in the case of Notes that are not represented by a global security. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The events of default under the GSK Capital
Inc. Indenture with respect to the Notes are defined under &#147;Description of Debt Securities&#151;Events of Default&#148; below. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Further Issuances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We initially offered the 2025 Notes in the aggregate principal amount of $1,000,000,000 and the 2028 Notes in the aggregate principal amount of
$1,750,000,000. We may from time to time, without the consent of the holders of a series of Notes, create and issue further debt securities of the same series having the same terms and conditions in all respects as the applicable Notes being offered
hereby, except for the issue date, the issue price and the first payment of interest thereon. Any such additional debt securities shall be issued under a separate CUSIP or ISIN number unless the additional debt securities are issued pursuant to a
&#147;qualified reopening&#148; of the original series, are otherwise treated as part of the same &#147;issue&#148; of debt instruments as the original series or are issued with no more than a <I>de minimis </I>amount of original discount, in each
case for U.S. federal income tax purposes. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the Notes of each series in the form of one or more fully registered global securities. We deposited these global securities with, or on behalf
of, DTC and register these securities in the name of DTC&#146;s nominee. Direct and indirect participants in DTC will record beneficial ownership of the Notes by individual investors. The transfer of ownership of beneficial interests in a global
security will be effected only through records maintained by DTC or its nominee, or by participants or persons that hold through participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Investors may elect to hold beneficial interests in the global securities through either DTC, Clearstream Banking S.A. (&#147;Clearstream&#148;) or
Euroclear Bank SA/NV (&#147;Euroclear&#148;) if they are participants in these systems, or indirectly through organizations which are participants in these systems. Beneficial interests in the global securities will be held in minimum denominations
of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon receipt of any payment in respect of a global security, DTC or its nominee will
immediately credit participants&#146; accounts with amounts proportionate to their respective beneficial interests in the principal amount of the global security as shown in the records of DTC or its nominee. Payments by participants to owners of
beneficial interests in a global security held through participants will be governed by standing instructions and customary practices and will be the responsibility of those participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">DTC holds securities of institutions that have accounts with it or its participants. Through its maintenance of an electronic book-entry system, DTC
facilitates the clearance and settlement of securities transactions among its participants and eliminates the need to deliver securities certificates physically. DTC&#146;s participants include securities brokers and dealers, including the
underwriters of this offering, banks, trust companies, clearing corporations and other organizations. DTC is partially owned by some of these participants or their representatives. Access to DTC&#146;s book-entry system is also available to others
such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly. DTC agrees with and represents to its participants that it will administer its book-entry
system in accordance with its rules and bylaws and requirements of law. The rules applicable to DTC and its participants are on file with the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream and Euroclear hold interests on behalf of their participants through customers&#146; securities accounts in Clearstream&#146;s and
Euroclear&#146;s names on the books of their respective depositaries, which in turn will hold interests in customers&#146; securities accounts in the depositaries&#146; names on the books of DTC. At the date of the prospectus supplement, Citibank,
N.A. acts as U.S. depositary for Clearstream and JPMorgan Chase Bank, N.A. acts as U.S. depositary for Euroclear, or, collectively, the &#147;U.S. Depositaries.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream holds securities for its participating organizations, or &#147;Clearstream
Participants,&#148; and facilitates the clearance and settlement of securities transactions between Clearstream Participants through electronic book-entry changes in accounts of Clearstream Participants, thereby eliminating the need for physical
movement of certificates. Clearstream provides to Clearstream Participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream
interfaces with domestic markets in several countries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream is registered as a bank in Luxembourg and as such is subject to regulation by the
Commission de Surveillance du Secteur Financier and the Banque Centrale du Luxembourg, which supervise and oversee the activities of Luxembourg banks. Clearstream Participants are worldwide financial institutions, including underwriters, securities
brokers and dealers, banks, trust companies and clearing corporations, and may include the underwriters or their affiliates. Indirect access to Clearstream is available to other institutions that clear through or maintain a custodial relationship
with a Clearstream Participant. Clearstream has established an electronic bridge with Euroclear as the operator of the Euroclear System, or the &#147;Euroclear Operator,&#148; in Brussels to facilitate settlement of trades between Clearstream and
the Euroclear Operator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to the Notes of a series held beneficially through Clearstream will be credited to cash accounts
of Clearstream Participants in accordance with its rules and procedures, to the extent received by the U.S. Depositary for Clearstream. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear
holds securities and book-entry interests in securities for participating organizations, or &#147;Euroclear Participants&#148; and facilitates the clearance and settlement of securities transactions between Euroclear Participants, and between
Euroclear Participants and participants of certain other securities intermediaries through electronic book-entry changes in accounts of such participants or other securities intermediaries. Euroclear provides Euroclear Participants with, among other
things, safekeeping, administration, clearance and settlement, securities lending and borrowing, and related services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear Participants are
investment banks, securities brokers and dealers, banks, central banks, supranationals, custodians, investment managers, corporations, trust companies and certain other organizations and may include the underwriters or their affiliates. <FONT
STYLE="white-space:nowrap">Non-participants</FONT> in Euroclear may hold and transfer beneficial interests in a global security through accounts with a Euroclear Participant or any other securities intermediary that holds a book-entry interest in a
global security through one or more securities intermediaries standing between such other securities intermediary and Euroclear. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with
respect to Notes of a series held beneficially through Euroclear will be credited to the cash accounts of Euroclear Participants in accordance with the Terms and Conditions, to the extent received by the U.S. Depositary for Euroclear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers between Euroclear Participants and Clearstream Participants will be effected in the ordinary way in accordance with their respective rules and
operating procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Cross-market transfers between DTC&#146;s participating organizations, or the &#147;DTC Participants,&#148; on the one hand,
and Euroclear Participants or Clearstream Participants, on the other hand, will be effected through DTC in accordance with DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by its U.S. Depositary; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. Depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global security in DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement applicable to DTC. Euroclear Participants and Clearstream Participants may not deliver
instructions directly to their respective U.S. Depositaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Due to time zone differences, the securities accounts of a Euroclear Participant or
Clearstream Participant purchasing an interest in a global security from a DTC Participant in DTC will be credited, and any such crediting will be reported, to the relevant Euroclear Participant or Clearstream Participant during the securities
settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a
Euroclear Participant or Clearstream Participant to a DTC Participant will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or
Clearstream following DTC&#146;s settlement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The information in this section concerning DTC, Euroclear and Clearstream and their book-entry
systems has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy or completeness of that information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">None of us, any of the underwriters and the trustee will have any responsibility for the performance by DTC, Euroclear or Clearstream or their respective
participants of their respective obligations under the rules and procedures governing their operations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Although DTC, Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate
transfers of securities among participants of DTC, Clearstream and Euroclear, they are under no obligation to perform or continue to perform such procedures and they may discontinue the procedures at any time. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Initial settlement for the Notes was made in immediately available funds. Secondary market trading between DTC participants will occur in the ordinary way
in accordance with DTC rules and will be settled in immediately available funds using DTC&#146;s <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement System. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left"><B><U>Base Pros</U>p<U>ectus &#150; March 28</U>,<U> 2018</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of Debt Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As used in this &#147;Description of Debt Securities,&#148; &#147;debt securities&#148; means the debentures, notes, bonds, guarantees and other evidences
of indebtedness that GSK issues or that a finance subsidiary issues and GSK fully and unconditionally guarantees and, in each case, the trustee authenticates and delivers under the applicable indenture. The debt securities will be our direct
unsecured obligations and will rank equally and ratably without preference among themselves and at least equally with all of our other unsecured and unsubordinated indebtedness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities will be issued in one or more series under an indenture dated as of March&nbsp;4, 2008 between GSK and Deutsche Bank Trust Company
Americas, as trustee (the &#147;trustee&#148;) (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated April&nbsp;12, 2017 among GSK, the trustee and Law Debenture Trust
Company of New York), as supplemented by a first supplemental indenture dated as of March&nbsp;21, 2014 between GSK and the trustee (for purposes of this &#147;Description of Debt Securities,&#148; the &#147;GSK plc Indenture&#148;), an indenture
dated as of April&nbsp;6, 2004 among GSK Capital plc, GSK, as guarantor, and the trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated April&nbsp;12, 2017 among
GSK Capital plc, the guarantor, the trustee and Law Debenture Trust Company of New York), as supplemented by a first supplemental indenture dated as of March&nbsp;21, 2014 among GSK Capital plc, the guarantor and the trustee (for purposes of this
&#147;Description of Debt Securities,&#148; the &#147;GSK Capital plc Indenture&#148;), or an indenture dated as of April&nbsp;6, 2004 among GSK Capital Inc., the guarantor and the trustee (as successor to Law Debenture Trust Company of New York,
pursuant to an Instrument of Resignation, Appointment and Acceptance dated April&nbsp;12, 2017, among GSK Capital Inc., the guarantor, the trustee and Law Debenture Trust Company of New York), as supplemented by a first supplemental indenture dated
as of March&nbsp;18, 2013 among GSK Capital Inc., the guarantor and the trustee and a second supplemental indenture dated as of March&nbsp;21, 2014 among GSK Capital Inc., the guarantor and the trustee (for purposes of this &#147;Description of Debt
Securities,&#148; the &#147;GSK Capital Inc. Indenture&#148;). Each of the GSK plc Indenture, the GSK Capital plc Indenture and the GSK Capital Inc. Indenture has been qualified under the Trust Indenture Act of 1939, as amended (the &#147;Trust
Indenture Act&#148;). In the following discussion, we sometimes refer to these indentures collectively as the &#147;indentures.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">This
&#147;Description of Debt Securities&#148; briefly outlines the provisions of the indentures and is qualified in its entirety by reference to the indentures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The terms of the indentures will include both those stated in the indentures and those made part of the indentures by the Trust Indenture Act. The
indentures have been filed as exhibits to the registration statement of which the base prospectus forms a part, and you should read the indentures for provisions that may be important to you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not contain any covenants or other provisions designed to protect holders of the debt securities against a reduction in the
creditworthiness of GSK or the finance subsidiaries in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the debt securities. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Issuances in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not limit the amount of
debt securities that may be issued. The debt securities may be issued in one or more series with the same or various maturities, at a price of 100% of their principal amount or at a premium or a discount. Not all debt securities of any one series
need be issued at the same time, and, unless otherwise provided, any series may be reopened, without the consents of the holders of debt securities of that series, for issuances of additional debt securities of that series. Except in the limited
circumstances described below under &#147;&#151;Covenants&#151;Limitation on Liens,&#148; the debt securities will not be secured by any property or assets of GSK, as issuer or guarantor, or the finance subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The terms of any authorized series of debt securities will be described in a prospectus supplement. These terms will include some or all of the following:
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the title, aggregate principal amount and denominations of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the date or dates on which principal will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the percentage of the principal amount at which the debt securities will be issued and whether the debt securities will be
&#147;original issue discount&#148; securities for U.S. federal income tax purposes. If original issue discount debt securities are issued (generally, securities that are issued at a substantial discount below their principal amount), the special
U.S. federal income tax and other considerations of a purchase of original issue discount debt securities will be described; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the rate or rates, which may be fixed or variable, at which the debt securities will bear interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the interest payment dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any optional or mandatory redemption terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether any sinking fund is required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the currency in which the debt securities will be denominated or principal, premium or interest will be payable, if other
than U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether the debt securities are to be issued as individual certificates to each holder or in the form of global certificates
held by a depositary on behalf of beneficial owners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">information describing any book-entry features; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the names and duties of any <FONT STYLE="white-space:nowrap">co-trustees,</FONT> depositaries, authenticating agents, paying
agents, transfer agents or registrars for any series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the applicability of the defeasance and covenant defeasance provisions described herein, or any modifications of those
provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any deletions from, modifications of or additions to the events of default or covenants with respect to the debt securities;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other terms, conditions, rights or preferences of the debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities that have a maturity of less than one year from their date of issue and in respect of which the proceeds are to be received by us in the
United Kingdom will have a minimum denomination of &pound;100,000 (or its equivalent in another currency). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement relating to any
series of debt securities may add to or change statements contained in the base prospectus. The prospectus supplement may also include, if applicable, a discussion of certain U.S. federal income tax and U.K. income tax considerations. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>GSK Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities issued by the GSK Capital Inc.
or GSK Capital plc (the &#147;finance subsidiaries&#148;) will be fully and unconditionally guaranteed by GSK. If for any reason the applicable finance subsidiary does not make any required payment in respect of its debt securities when due, whether
on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. The holder of a guaranteed debt security will be entitled to payment under the applicable guarantee of GSK
without taking any action whatsoever against the finance subsidiary. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Payment and Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities will be issued only as registered securities, which means that the name of the holder will be entered in a register that will be kept
by the trustee or another agent appointed by us. Unless stated otherwise in a prospectus supplement, and except as described under &#147;&#151;Book-Entry System&#148; below, payments of principal, interest and additional amounts, if any, will be
made at the office of the paying agent or agents named in the prospectus supplement or by check mailed to you at your address as it appears in the register. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless other procedures are described in a prospectus supplement and except as described under &#147;&#151;Book Entry System&#148; below, you will be able
to transfer registered debt securities at the office of the transfer agent or agents named in the prospectus supplement. You may also exchange registered debt securities at the office of the transfer agent for an equal aggregate principal amount of
registered debt securities of the same series having the same maturity date, interest rate and other terms as long as the debt securities are issued in authorized denominations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Neither we nor the trustee will impose any service charge for any transfer or exchange of a debt security; however, we may ask you to pay any taxes or
other governmental charges in connection with a transfer or exchange of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities may be issued under a book-entry system in the form of one or more global securities. The global securities will be registered in the name
of a depositary or its nominee and deposited with that depositary or its custodian. Unless stated otherwise in the prospectus supplement, The Depository Trust Company, New York, New York, or DTC, will be the depositary if a depositary is used. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:9pt; font-family:ARIAL">DTC has advised us as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC is a limited-purpose trust company organized under the New York Banking Law, a &#147;banking organization&#148; within
the meaning of the New York Banking Law, a member of the Federal Reserve System, a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code and a &#147;clearing agency&#148; registered pursuant to the provisions of
Section&nbsp;17A of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC was created to hold securities of its participants and to facilitate the clearance and settlement of securities
transactions, such as through transfers and pledges, among its participants in such securities through electronic book-entry changes to accounts of its participants, thereby eliminating the need for physical movement of securities certificates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC&#146;s participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain
other organizations, some of whom (and/or their representatives) own DTC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">access to DTC&#146;s book-entry system is also available to others, such as banks, brokers, dealers and trust companies that
clear through or maintain a custodial relationship with a participant, either directly or indirectly; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the DTC rules applicable to its participants are on file with U.S. Securities and Exchange Commission.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">According to DTC, the foregoing information with respect to DTC has been provided to the financial community for informational
purposes only and is not intended to serve as a representation, warranty or contract modification of any kind. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Following the issuance of a global
security in registered form, the depositary will credit the accounts of its participants with the debt securities upon our instructions. Only persons who hold directly or indirectly through financial institutions that are participants in the
depositary can hold beneficial interests in the global securities. Since the laws of some jurisdictions require certain types of purchasers to take physical delivery of such securities in definitive form, you may encounter difficulties in your
ability to own, transfer or pledge beneficial interests in a global security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">So long as the depositary or its nominee is the registered owner of a
global security, we and the trustee will treat the depositary as the sole owner or holder of the debt securities for purposes of the applicable indenture. Therefore, except as set forth below, you will not be entitled to have debt securities
registered in your name or to receive physical delivery of certificates representing the debt securities. Accordingly, you will have to rely on the procedures of the depositary and the participant in the depositary through whom you hold your
beneficial interest in order to exercise any rights of a holder under the indenture. We understand that under existing practices, the depositary would act upon the instructions of a participant or authorize that participant to take any action that a
holder is entitled to take. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will make all payments of principal, interest and additional amounts, if any, on the debt securities to the
depositary. It is expected that the depositary will then credit participants&#146; accounts proportionately with these payments on the payment date and that the participants will in turn credit their customers&#146; accounts in accordance with their
customary practices. Neither we nor the trustee will be responsible for making any payments to participants or customers of participants or for maintaining any records relating to the holdings of or payments to participants and their customers, and
you will have to rely on the procedures of the depositary and its participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Global securities are generally not transferable. Physical
certificates will be issued to beneficial owners in lieu of a global security only in the special situations described in the sixth paragraph under the heading &#147;Legal Ownership of Debt Securities&#151;Global Securities&#148; below. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We and the finance subsidiaries
have agreed in the indentures not to consolidate with or merge with or into any other person or convey or transfer all or substantially all of our respective properties and assets to any person (except that the finance subsidiaries may merge into
us), unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we or the applicable finance subsidiary, as the case may be, are the continuing person, or the successor expressly assumes
by supplemental indenture our obligations under the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the continuing person is a U.S. or U.K. company or is organized and validly existing under the laws of a
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
jurisdiction that is a member country of the Organisation for Economic Cooperation and Development (or any successor) and, if it is not a U.S. or U.K. company, the continuing person agrees by
supplemental indenture to be bound by a covenant comparable to that described below under &#147;&#151;Covenants&#151; Payment of Additional Amounts&#148; with respect to taxes imposed in the continuing person&#146;s jurisdiction of organization (in
which case the continuing person will benefit from a redemption option comparable to that described below under &#147;&#151;Optional Redemption for Tax Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the
consolidation, merger or sale); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">immediately after the transaction, no default under the debt securities has occurred and is continuing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we deliver to the trustee an officer&#146;s certificate and, if neither we nor the applicable subsidiary are the continuing
person, an opinion of counsel, in each case stating, among other things, that the transaction and the supplemental indenture, if required, comply with these provisions and the indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under or with respect to the debt securities will be free and clear of and without withholding or deduction for or on account of any
present or future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or on behalf of the government of the United Kingdom or of any territory of the United Kingdom or by any authority or
agency therein or thereof having the power to tax or (ii)&nbsp;solely with respect to debt securities issued under the GSK Capital Inc. Indenture, the government of the United States or any state or territory of the United States or by any authority
or agency therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the debt securities, we will pay such
additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been
withheld or deducted; <I>provided </I>that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the debt securities (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation)
and the United Kingdom or, solely with respect to debt securities issued under the GSK Capital Inc. Indenture, the United States or, as applicable, any political subdivision or territory or possession thereof or therein or area subject to its
jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled
thereof or a national thereof or being or having been present or engaged in trade or business therein or having or having had a permanent establishment therein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or interest on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction
in, the rate of deduction or withholding of such Taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of a debt security (where presentation is required) for payment on
a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed on a payment to an individual and are required to be made pursuant to European Council Directive 2003/48/EC
or any other Directive implementing the conclusions of the ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, or any law implementing or complying with, or introduced in order to
conform to, such Directive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the relevant debt securities had been made to a paying agent
other than the paying agent to which the presentation was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for a failure by the holder or beneficial owner (or any financial institution through
which the holder or beneficial owner holds any debt security through which payment on the debt security is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into
and complying with an agreement with the U.S. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
Internal Revenue Service or any other governmental authority) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the Notes or
any successor or amended version of such provisions, or any agreement entered into pursuant to Section&nbsp;1471(b) of the U.S. Internal Revenue Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any
intergovernmental agreement entered into in connection with the implementation of such Sections of the U.S. Internal Revenue Code (or any law implementing such intergovernmental agreement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">solely with respect to debt securities issued under the GSK Capital Inc. Indenture, that are imposed solely by reason of the
holder or beneficial owner owning or having owned, actually or constructively, 10% or more of the total combined voting power of all classes of the Company&#146;s stock entitled to vote; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or interest on any debt security to any such holder who is a fiduciary or a
partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled to
such additional amounts had it been the holder of the debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in each indenture that at least one paying agent for each series
of debt securities will be located outside the United Kingdom. We have also agreed that if we maintain a paying agent with respect to a particular series of debt securities in any member state of the European Union, we will maintain a paying agent
in at least one member state (other than the United Kingdom) that will not be obliged to withhold or deduct taxes pursuant to any law implementing European Council Directive 2003/48/EC or any other Directive implementing the conclusions of the
ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, provided there is at least one member state that does not require a paying agent to withhold or deduct pursuant to such
Directive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the indentures and the payment of all amounts in
respect of the debt securities. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Limitation on Liens </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the indentures not to incur or assume (or permit any of our subsidiaries to incur or assume) any lien on or with respect to any of our
or our subsidiaries&#146; property, assets or revenues, present or future, to secure any relevant indebtedness (as this term is defined below) without making (or causing our subsidiaries to make) effective provision for securing the debt securities
equally and ratably with such relevant indebtedness as to such property, assets or revenues, for as long as such relevant indebtedness is so secured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The
restrictions on liens will not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens arising by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of any person, which liens are existing at the time such person becomes a subsidiary;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of a person existing at the time such person is merged with or into or consolidated
with us or any of our subsidiaries or at the time of a sale, lease or other disposition to us of the properties of a person as an entirety or substantially as an entirety. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">For purposes of the limitation on liens covenant, the term &#147;relevant indebtedness&#148; means any of our debt that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is in the form of or represented by bonds, notes, loan stock, depositary receipts or other securities issued (otherwise than
to constitute or by banks or other lending institutions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is denominated in, or confers any right of payment by reference to, any currency other than the currency of the country in
which the issuer of the indebtedness has its principal place of business, or is denominated in or by reference to the currency of such country but more than 20% of which is placed or offered for subscription or sale by or on behalf of, or by
agreement with, the issuer outside such country; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">at its date of issue is, or is intended by the issuer to become, quoted, listed, traded or dealt in on any stock exchange, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or other securities market. </P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Additional
Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may be subject to additional covenants, including restrictive covenants in respect of a particular series of debt securities.
Such additional covenants will be set forth in the applicable prospectus supplement and, to the extent necessary, in the supplemental indenture or board resolution relating to that series of debt securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Redemption for Tax Reasons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:ARIAL">We may redeem any series of debt securities in whole but not in part at any time, on giving not less than 30 nor more than 60 days&#146; notice of such
redemption, at a redemption price equal to the principal amount plus accrued interest, if any, to the date fixed for redemption (except in the case of discounted debt securities, which may be redeemed at the redemption price specified by the terms
of each series of such debt securities), if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine that, as a result of any change in or amendment to the laws or any regulations or rulings promulgated
thereunder of the United Kingdom (or of any political subdivision or taxing authority thereof) or, solely with respect to debt securities issued under the GSK Capital Inc. Indenture, the United States (or of any political subdivision or taxing
authority thereof), or any change in the application or official interpretation of such laws, regulations or rulings, or any change in the application or official interpretation of, or any execution of or amendment to, any treaty or treaties
affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the issue date or such other date specified in the debt securities of that series: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we would be required to pay additional amounts (as described under &#147;&#151;Covenants&#150;&#150;Payment of Additional
Amounts&#148; above) with respect to that series of debt securities on the next succeeding interest payment date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to us; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the
applicable finance subsidiary directly from the guarantor (or any affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the applicable finance subsidiary or the guarantor (or any affiliate);
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine, based upon an opinion of independent counsel of recognized standing that, as a result of any action taken by
any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom (or any political subdivision or taxing authority thereof) or, solely with respect to debt securities issued under the
GSK Capital Inc. Indenture, the United States (or any political subdivision or taxing authority thereof) (whether or not such action was taken or brought with respect to GSK, as issuer or guarantor, or the applicable finance subsidiary, as the case
may be), which action is taken or brought on or after the issue date or such other date specified in the debt securities of that series, there is a substantial probability that the circumstances described above would exist; provided, however, that
such notice of redemption may be given earlier than 90 days prior to the earliest date on which we would be obligated to pay such additional amounts. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will also pay to each holder, or make available for payment to each such holder, on the redemption date any additional amounts resulting from the
payment of such redemption price. Prior to the publication of any notice of redemption, we will deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an officer&#146;s certificate stating that we are entitled to effect a redemption and setting forth a statement of facts
showing that the conditions precedent of the right so to redeem have occurred; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an opinion of counsel to the effect that the conditions specified above have been satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Any notice of redemption will be irrevocable once we deliver the officer&#146;s certificate to the trustee. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless otherwise specified in a prospectus
supplement, an event of default with respect to a series of debt securities occurs upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of the principal (or premium, if any) of any debt security of that series when due (including as a
sinking fund installment), and, in the case of technical or administrative difficulties, the continuance of that default for more than two business days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of interest on, or any additional amounts payable in respect of, any debt security of that series when
due and payable, and the continuance of that default for 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in performing any other covenant in the indenture applicable to that series for 90 days after the receipt of written
notice specifying such default from the trustee or from the holders of 25% in principal amount of the debt securities of that series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default under any bond, debenture, note or other evidence of indebtedness for money borrowed of GSK or either finance
subsidiary, as the case may be (not including any indebtedness for which recourse is limited to property purchased), having in any particular case an outstanding principal amount in excess of &pound;100,000,000 (or its equivalent in any other
currency) where any such failure results in such indebtedness being accelerated and becoming due and payable prior to its stated maturity and such acceleration shall </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
not have been rescinded or annulled or such indebtedness shall not have been discharged; provided that there shall not be deemed to be an Event of Default if such acceleration is rescinded or
annulled or such payment is made within 10 days after there has been given to GSK and either finance subsidiary by the trustee or to either finance subsidiary, GSK and the trustee by the holders of 25% or more in aggregate principal amount of the
debt securities of such series a written notice specifying such default and requiring it to be remedied and stating that such notice is a &#147;Notice of Default&#148; hereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">certain events of bankruptcy, insolvency or reorganization of GSK or either finance subsidiary, as the case may be;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other event of default provided with respect to that particular series of debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Any additional or different events of default applicable to a particular series of debt securities will be described in the prospectus supplement relating
to such series. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">An event of default with respect to a particular series of debt securities will not necessarily constitute an event of default with
respect to any other series of debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The trustee may withhold notice to the holders of debt securities of any default (except in the
payment of principal, premium or interest) if it, in good faith considers such withholding of notice to be in the best interests of the holders. A default is any event which is an event of default described above or would be an event of default but
for the giving of notice or the passage of time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default occurs and continues, the trustee or the holders of the aggregate principal
amount of the debt securities specified below may require us to repay immediately, or accelerate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the entire principal of the debt securities of such series; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">if the debt securities are original issue discount securities, such portion of the principal as may be described in the
applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If the event of default occurs because of a default in a payment of principal or interest on the
debt securities of any series, then the trustee or the holders of at least 25% of the aggregate principal amount of debt securities of that series can accelerate that series of debt securities. If the event of default occurs because of a failure to
perform any other covenant in the applicable indenture or any covenant for the benefit of one or more, but not all, of the series of debt securities, then the trustee or the holders of at least 25% of the aggregate principal amount of debt
securities of all series affected, voting as one class, can accelerate all of the affected series of debt securities. If the event of default occurs because of bankruptcy proceedings, then all of the debt securities under the indenture will be
accelerated automatically. Therefore, except in the case of a default on a payment of principal or interest on the debt securities of your series or a default due to our bankruptcy or insolvency, it is possible that you may not be able to accelerate
the debt securities of your series because of the failure of holders of other series to take action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The holders of a majority of the aggregate
principal amount of the debt securities of all affected series, voting as one class, can rescind this accelerated payment requirement or waive any past default or event of default or allow noncompliance with any provision of the applicable
indenture. However, they cannot waive a default in payment of principal of, premium, if any, or interest on any of the debt securities when due otherwise than as a result of acceleration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">After an event of default, the trustee must exercise the same degree of care a prudent person would exercise under the circumstances in the conduct of her
or his own affairs. Subject to these requirements, the trustee is not obligated to exercise any of its rights or powers under the applicable indenture at the request, order or direction of any holders, unless the holders offer the trustee indemnity
satisfactory to it. If they provide this indemnity, the holders of a majority in principal amount of all affected series of debt securities, voting as one class, may direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any power conferred upon the trustee, for any series of debt securities. However, the trustee may refuse to follow any direction that conflicts with law or the indenture or is unduly prejudicial to the rights
of other holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">No holder will be entitled to pursue any remedy with respect to the indenture unless the trustee fails to act for 60 days after it
is given: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">notice of default by that holder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">a written request to enforce the indenture by the holders of not less than 25% in principal amount of all outstanding debt
securities of any affected series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an indemnity to the trustee, reasonably satisfactory to the trustee; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL">and during this <FONT STYLE="white-space:nowrap">60-day</FONT> period the holders of a majority in principal amount of all outstanding debt securities of
such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
affected series do not give a direction to the trustee that is inconsistent with the enforcement request. These provisions will not prevent any holder of debt securities from enforcing payment of
the principal of (and premium, if any) and interest on the debt securities at the relevant due dates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default with respect to a series
of debt securities occurs and is continuing, the trustee will mail to the holders of those debt securities a notice of the event of default within 90 days after it occurs. However, except in the case of a default in any payment in respect of a
series of debt securities, the trustee shall be protected in withholding notice of an event of default if it determines in good faith that this is in the interests of the holders of the relevant debt securities. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Modification of the Indentures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In general, rights and
obligations of us and the holders under the indentures may be modified if the holders of a majority in aggregate principal amount of the outstanding debt securities of each series affected by the modification consent to such modification. However,
each of the indentures provides that, unless each affected holder agrees, an amendment cannot: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any adverse change to any payment term of a debt security such as extending the maturity date, extending the date on
which we have to pay interest or make a sinking fund payment, reducing the interest rate, reducing the amount of principal we have to repay, changing the currency in which we have to make any payment of principal, premium or interest, modifying any
redemption or repurchase right, or right to convert or exchange any debt security, to the detriment of the holder and impairing any right of a holder to bring suit for payment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">waive any payment default; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">reduce the percentage of the aggregate principal amount of debt securities needed to make any amendment to the applicable
indenture or to waive any covenant or default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any other change to the amendment provisions of the applicable indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">However, if we and the trustee agree, the applicable indenture may be amended without notifying any holders or seeking their consent if the amendment does
not materially and adversely affect any holder. We and the trustee are permitted to make modifications and amendments to the applicable indenture without the consent of any holder of debt securities for any of the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to cure any ambiguity, defect or inconsistency in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with sections of the indenture governing when we may merge and substitute obligors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with any requirements of the U.S. Securities and Exchange Commission in connection with the qualification of the
indenture under the Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to evidence and provide for the acceptance by a successor trustee of appointment under the indenture with respect to the
debt securities of any or all series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to establish the form or forms or terms of the debt securities of any series or of the coupons appertaining to such debt
securities as permitted under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for a further guarantee from a third party on outstanding debt securities of any series and the debt securities
of any series that may be issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to change or eliminate any provision of the indenture; provided that any such change or elimination will become effective
only when there are no outstanding debt securities of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to supplement any of the provisions of the indenture to such extent as will be necessary to permit or facilitate the
defeasance and discharge of any series of debt securities pursuant to the indenture; provided that any such action will not adversely affect the interests of the holders of such or any other series of debt securities in any material respect; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to make any change that does not materially and adversely affect the rights of any holder of the debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The term defeasance means
discharge from some or all of the obligations under the indentures. If we deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
due to the stated maturity date or a redemption date of the debt securities of a particular series, then at our option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will be discharged from our respective obligations with respect to the debt securities of such series; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will no longer be under any obligation to comply with the restrictive covenants, if any, contained in the applicable
indenture and any supplemental indenture or board resolution with respect to the debt securities of such series, and the events of default relating to failures to comply with covenants will no longer apply to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If this happens, the holders of the debt securities of the affected series will not be entitled to the benefits of the applicable indenture except for
registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities. Instead, the holders will only be able to rely on the deposited funds or obligations for payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We must deliver to the trustee an opinion of counsel to the effect that the deposit and related defeasance would not cause the holders of the debt
securities to recognize income, gain or loss for U.S. federal income tax purposes. We may, in lieu of an opinion of counsel, deliver a ruling to such effect received from or published by the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Substitution of Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may at our option at any time,
without the consent of any holders of debt securities, cause GSK or any other subsidiary of GSK to assume the obligations of the applicable finance subsidiary under any series of debt securities, <I>provided </I>that the new obligor executes a
supplemental indenture in which it agrees to be bound by the terms of those debt securities and the relevant indenture. If the new obligor is not a U.S. or U.K. company, it must be organized and validly existing under the laws of a jurisdiction that
is a member country of the Organisation for Economic Cooperation and Development (or any successor) and it must also agree in the supplemental indenture to be bound by a covenant comparable to that described above under &#147;&#151; Covenants&#151;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payment of Additional Amounts&#148; with respect to taxes imposed in its jurisdiction of organization (in which case the new obligor will benefit
from a redemption option comparable to that described above under &#147;&#151;Optional Redemption for Tax Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the substitution). In the case of such a substitution,
the applicable finance subsidiary will be relieved of any further obligation under the assumed series of debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">For U.S. federal income tax
purposes, a substitution of obligors as described above generally would be treated as a deemed taxable exchange of debt securities for new debt securities issued by the new obligor. As discussed further in the applicable prospectus supplement, a
United States person who holds debt securities or owns a beneficial interest therein generally will recognize capital gain or loss in an amount equal to the difference between the issue price of the new debt securities and such person&#146;s
adjusted tax basis in the debt securities. Such persons should consult their own tax advisors regarding the tax consequences of a deemed taxable exchange in the event of a substitution of obligors. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Deutsche Bank Trust Company
Americas, 60 Wall Street, 16th Floor, New York, NY 10005, will be the trustee. The trustee will be required to perform only those duties that are specifically set forth in the indentures, except when a default has occurred and is continuing with
respect to the debt <B>s</B>ecurities. After a default, the trustee must exercise the same degree of care that a prudent person would exercise under the circumstances in the conduct of her or his own affairs. Subject to these requirements, the
trustee will be under no obligation to exercise any of the powers vested in it by the indentures at the request of any holder of debt securities unless the holder offers the trustee indemnity satisfactory to it against the costs, expenses and
liabilities that might be incurred by exercising those powers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities, the related guarantees and the indentures will be governed by and construed in accordance with the laws of the State of New York.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Legal Ownership of Debt Securities </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>&#147;Street
Name&#148; and Other Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We generally will not recognize investors who hold debt securities in accounts at banks or brokers as legal
holders of those debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Holding securities in accounts at banks or brokers is called holding in &#147;street name.&#148; If an investor
holds debt securities in street name, we recognize only the bank or broker or the financial institution the bank or broker uses to hold </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
the debt securities. These intermediary banks, brokers and other financial institutions pass along principal, interest and other payments on the debt securities, either because they agree to do
so in their customer agreements or because they are legally required to do so. If you hold debt securities in street name, you should check with your own institution to find out: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it handles payments and notices with respect to securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would handle voting if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how and when you should notify it to exercise on your behalf any rights or options that may exist under the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether and how you can instruct it to send you securities registered in your own name so you can be a direct holder as
described below; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would pursue rights under the debt securities if there were a default or other event triggering the need for holders
to act to protect their interests. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Registered Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligations, as well as the obligations of the trustee and those of any third parties employed by us or the trustee, extend only to persons who are
registered as holders of debt securities. As noted above, we do not have obligations directly to you if you hold in street name or through other indirect means, either because you choose to hold debt securities in that manner or because the debt
securities are issued in the form of global securities as described below. For example, once we make payment to the registered holder, we have no further responsibility for the payment even if that holder is legally required to pass the payment
along to you but does not do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">A
global security is a special type of indirectly held security. If we choose to issue debt securities in the form of global securities, the ultimate beneficial owners of the debt securities will be indirect holders. We do this by requiring that the
global security be registered in the name of a financial institution we select and by requiring that the debt securities represented by the global security not be registered in the name of any other holder except in the special situations described
below. The financial institution that acts as the sole registered holder of the global security is called the depositary. Any person wishing to own a debt security may do so indirectly through an account with a broker, bank or other financial
institution that in turn has an account with the depositary. The prospectus supplement will indicate whether your series of debt securities will be issued only as global securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers of debt securities represented by the global security will be made only on the records of the depositary or its nominee by transferring such
debt securities from the account of one broker, bank or financial institution to the account of another broker, bank or financial institution. These transfers are made electronically only and are also known as book-entry transfers. Securities in
global form are sometimes also referred to as being in book-entry form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As an indirect holder, your rights relating to a global security will be
governed by the account rules of your broker, bank or financial institution and of the depositary, as well as general laws relating to securities transfers. We will not recognize you as a holder of debt securities and instead will deal only with the
depositary that holds the global security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">You should be aware that if debt securities are issued only in the form of a global security: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">except in very limited circumstances described below, you will not have any right to have debt securities registered in your
own name; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you cannot receive physical certificates for your interest in the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you will be a street name holder and must look to your own broker, bank or financial institution for payments on the debt
securities and protection of your legal rights relating to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you may not be able to sell interests in the debt securities to some insurance companies and other institutions that are
required by law to own securities in the form of physical certificates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary&#146;s policies will govern payments, transfers, exchanges and other matters relating to your indirect
interest in the global security. We and the trustee will have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in the global security. We and the trustee also will not supervise the
depositary in any way; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary will require that indirect interests in the global security be purchased or sold within its system using <FONT
STYLE="white-space:nowrap">same-day</FONT> funds for settlement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In a few special circumstances described below, the global security will terminate and the indirect
interests in it will be exchanged for registered debt securities represented by physical certificates. After that exchange, the choice of whether to hold debt securities in registered form or in street name will be up to you. You must consult your
broker, bank or financial institution to find out how to have your interests in debt securities transferred to your name, so that you will be a registered holder of the debt securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless we specify otherwise in the prospectus supplement, the special circumstances for termination of a global security are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">when the depositary notifies us that it is unwilling or unable to continue as depositary and we do not or cannot appoint a
successor depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary ceases to be a clearing agency registered under the Exchange Act and we do not appoint a successor depositary
within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an event of default has occurred and is continuing and beneficial owners representing a majority in principal amount of the
applicable series of debt securities have advised the depositary to cease acting as the depositary; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we decide we do not want to have the debt securities of that series represented by a global security. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement may also list additional circumstances for terminating a global security that would apply only to the particular series of debt
securities covered by the prospectus supplement. When a global security terminates, the depositary (and not us or the trustee) is responsible for deciding the names of the institutions that will be the initial registered holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>The Term &#147;Holder&#148; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the descriptions of the debt
securities included herein, when we refer to the &#147;holder&#148; of a given debt security as being entitled to certain rights or payments, or being permitted to take certain actions, we are in all cases referring to the registered holder of the
debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">While you would be the registered holder if you held a certificated security registered in your name, it is likely that the holder
will actually be either the broker, bank or other financial institutions where you have your street name account, or, in the case of a global security, the depositary. If you are an indirect holder, you will need to coordinate with the institution
through which you hold your interest in a debt security in order to determine how the provisions involving holders described in the descriptions of the debt securities included herein will actually apply to you. For example, if the debt security in
which you hold a beneficial interest in street name can be repaid at the option of the holder, you cannot exercise the option yourself by following the procedures described in the prospectus supplement. Instead, you would need to cause the
institution through which you hold your interest to take those actions on your behalf. Your institution may have procedures and deadlines different from or additional to those described in the prospectus supplement relating to the debt security.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>2. Notes offered pursuant to the Base Prospectus dated March&nbsp;4, 2011 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><U>a. Prospectus Supplement (March 13, 2013) &#150;4.200% Notes due 2043</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of the Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the 4.200% Notes due 2043 pursuant to an indenture, dated April&nbsp;6, 2004, among GSK, as guarantor, GSK Capital Inc., as issuer, and Law
Debenture Trust Company of New York, the trustee for the notes (as successor to Citibank, N.A., pursuant to an Instrument of Resignation, Appointment and Acceptance dated December&nbsp;27, 2007 among GSK Capital Inc., GSK, Law Debenture Trust
Company of New York and Citibank, N.A.), as supplemented by a first supplemental indenture thereto dated March&nbsp;18, 2013 (for purposes of this description of the notes only, the &#147;indenture&#148;). References in this &#147;Description of the
Notes&#148; to the &#147;notes&#148; refer to the 4.200% Notes due 2043. The notes are each a&nbsp;&nbsp;&nbsp;&nbsp;series of our debt securities. GSK Capital Inc. issued the notes in the aggregate principal amount of $500,000,000. The notes will
mature on March&nbsp;18, 2043 unless redeemed or repurchased prior to such date as permitted below. GSK Capital Inc. issued the notes only in book-entry form, in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The notes each bear interest at the applicable interest rate shown in the table above and accrue interest from March&nbsp;18, 2013, or from the most
recent date to which interest has been paid (or provided for), to but not including the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
next date upon which interest is required to be paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Interest is payable on the notes twice a
year, on March&nbsp;18 and September&nbsp;18, commencing September&nbsp;18, 2013, to the person in whose name a note is registered at the close of business on the March&nbsp;3 or September&nbsp;3 that precedes the date on which interest will be
paid. Interest on the notes is paid on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. &#147;Business day&#148; means any day other than a Saturday, a
Sunday or a day on which banking institutions in the City of New York or London, England are authorized or obligated by law, regulation or executive order to be closed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an interest payment date or redemption date, or the maturity date, for the notes, as the case may be, would fall on a day that is not a business day,
then the interest payment date or redemption date, or the maturity date, as the case may be, will be postponed to the next succeeding business day, but no additional interest shall be paid unless we fail to make payment on such next succeeding
business day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The notes are fully and unconditionally guaranteed by GSK. If, for any reason, GSK Capital Inc. does not make any required payment in
respect of the notes when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. You will be entitled to payment under the guarantee of GSK without
taking any action whatsoever against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to certain exceptions, if we are required to withhold or deduct any amount for or on account of any U.K. or U.S. withholding tax from any payment
made on the notes, we will pay additional amounts on those payments so that the amount received by noteholders will equal the amount that would have been received if no such taxes had been applicable. See &#147;&#151;Payment of Additional
Amounts.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As contemplated by the last paragraph under &#147;Description of Debt Securities&#151;Defeasance&#148; below, the satisfaction of
certain conditions will permit us to omit to comply with some or all of our obligations, covenants and agreements under the indenture with respect to the notes. In addition, we may omit to comply with certain covenants through covenant defeasance.
We refer you to the information under &#147;Description of Debt Securities&#151; Defeasance&#148; below for more information on how we may do this. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Except as described herein, the indenture for the notes does not contain any covenants or other provisions designed to protect holders of the notes
against a reduction in our creditworthiness in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the notes, including, among other things, through the incurrence of
additional indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The provisions of the indenture described under &#147;Description of Debt Securities&#151;Covenants&#151;Payment of Additional Amounts&#148; below do not
apply to the notes. The following payment of additional amounts provisions apply to the notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under or with respect to the notes
will be free and clear of and without withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or on behalf of (i)&nbsp;the
government of the United Kingdom or of any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax&nbsp;&nbsp;&nbsp;&nbsp;or (ii)&nbsp;the government of the United States or any state or territory of
the United States or by any authority or agency therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the notes, we will pay such
additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been
withheld or deducted; provided that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the notes (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation) and the
United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor,
beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or business therein or
having or having had a permanent establishment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or premium, if any, or interest on the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction
in, the rate of deduction or withholding of such Taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of notes (where presentation is required) for payment on a date
more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed on a payment to an individual and are required to be made pursuant to European Council Directive 2003/48/EC
or any other Directive implementing the conclusions of the ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, or any law implementing or complying with, or introduced in order to
conform to, such Directive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the relevant notes had been made to a paying agent other
than the paying agent to which the presentation was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed solely by reason of the holder or beneficial owner owning or having owned, actually or constructively, 10%
or more of the total combined voting power of all classes of our stock entitled to vote; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for a failure by the holder or beneficial owner (or any financial institution through
which the holder or beneficial owner holds any Security through which payment on the security is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into and
complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the Notes or any successor or amended version of such
provisions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or premium, if any, or interest on any notes to any such holder who is a fiduciary
or a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been
entitled to such additional amounts had it been the holder of notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the indenture that at least one paying agent for the notes
will be located outside the United Kingdom. We have also agreed that if we maintain a paying agent with respect to the notes in any member state of the European Union, we will maintain a paying agent in at least one member state that will not be
obliged to withhold or deduct taxes pursuant to any law implementing European Council Directive 2003/48/EC or any other Directive implementing the conclusions of the ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT>
2000 on the taxation of savings income, provided there is at least one member state that does not require a paying agent to withhold or deduct pursuant to such Directive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the indenture and the payment of all amounts in respect of the
notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Make-Whole Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may redeem the
notes, in whole or in part, at our option at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed on that redemption date; and (ii)&nbsp;as determined by the
quotation agent (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest on the notes being redeemed on that redemption date (not including any portion of such payments of interest accrued as of
the date of redemption), discounted to the date of redemption on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months) at the Treasury Rate,
plus 0.175%, plus accrued and unpaid interest thereon to, but excluding, the date of redemption. Notwithstanding the foregoing, installments of interest on notes to be redeemed that are due and payable on an interest payment date falling on or prior
to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the notes and the indenture. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Issue&#148; means the United States Treasury security selected by the quotation agent as having a maturity comparable to the
remaining term (as measured from the date of redemption) of the notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of
comparable maturity to the remaining term of such notes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date, (i)&nbsp;the average
of four Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (ii)&nbsp;if the quotation agent for the notes obtains fewer than four
such Reference Treasury Dealer Quotations, the average of all such quotations, or (iii)&nbsp;if only one Reference Treasury Dealer Quotation is received, the quotation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Quotation agent&#148; means any Reference Treasury Dealer appointed by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of Deutsche Bank Securities Inc., Goldman, Sachs&nbsp;&amp; Co., J.P. Morgan Securities LLC and
UBS Securities LLC (or their respective affiliates that are Primary Treasury Dealers) and their respective successors; provided, however, that if any of the foregoing shall cease to be a primary U.S. government securities dealer in the United States
(a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer, and (ii)&nbsp;any other Primary Treasury Dealer selected by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined
by us, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the
third business day preceding such redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per annum equal to
the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notice of any redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each registered holder of the notes
to be redeemed by us or by the trustee on our behalf. Notice of redemption will be published in a daily newspaper of general circulation in the United States, and we will give notice of any such redemption to any exchange on which such notes are
listed. On and after any redemption date, interest will cease to accrue on the notes or portions thereof called for redemption. On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the
redemption price of and accrued interest on the notes to be redeemed on that date. If less than all of the notes are to be redeemed, the notes to be redeemed shall be selected by lot by The Depository Trust Company (&#147;DTC&#148;), in the case of
notes represented by a global security, or by the trustee by such method as the trustee deems to be fair and appropriate, in the case of notes that are not represented by a global security. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The definitions of an event of default with
respect to a series of debt securities under &#147;Description of Debt Securities&#151;Events of Default&#148; below do not apply to the notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The following are
events of default under the indenture with respect to the notes of a series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of the principal of (or premium, if any, on) any such note when due, and, in the case of technical or
administrative difficulties, the continuance of that default for more than two business days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of interest on, or any additional amounts payable in respect of, any such note when due and payable, and
the continuance of that default for 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in performing any other covenant in the indenture applicable to any such note for 90 days after the receipt of
written notice specifying such default from the trustee or from the holders of 25% in principal amount of such notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default under any bond, debenture, note or other evidence of indebtedness for money borrowed of GSK or GSK Capital Inc. (not
including any indebtedness for which recourse is limited to property purchased), having in any particular case an aggregate outstanding principal amount in excess of &pound;100,000,000 (or its equivalent in any other currency) whether such
indebtedness now exists or shall hereafter be created, which default results in such indebtedness becoming or being accelerated and declared due and payable prior to its stated maturity and such acceleration shall not have been rescinded or annulled
or such indebtedness shall not have been discharged; provided that there shall not be deemed to be an event of default if such acceleration is rescinded or annulled or such payment is made within 10 days after the receipt of written notice
specifying such default from the trustee or from the holders of 25% in principal amount of such notes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">certain events of bankruptcy, insolvency or reorganization of GSK or GSK Capital Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Because the applicable threshold amount of indebtedness the acceleration of which would give rise to an event of default under the indenture is lower,
and the number of days that must pass before the ongoing default in the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
performance of any covenant under the indenture other than the payment of principal, interest or additional amounts that would give rise to an event of default under the indenture is lower, for
each series of debt securities issued under the indenture before the date of the first supplemental indenture, the acceleration of outstanding indebtedness of GSK or GSK Capital Inc. or the ongoing default in the performance of any covenant in the
indenture other than payment of principal, premium, interest or additional amounts may constitute an event of default with respect to one or more of such previously issued series, but may not constitute an event of default under the respective terms
of the notes offered by the prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Further Issuances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We initially offered the notes in the aggregate principal amount of $500,000,000. We may from time to time, without the consent of the holders of a series
of notes, create and issue further notes of the same series having the same terms and conditions in all respects as the applicable notes being offered hereby, except for the issue date, the issue price and the first payment of interest thereon. We
will not issue any further notes unless such further notes have no more than a <I>de minimis </I>amount of original issue discount or such issuance would constitute a &#147;qualified reopening&#148; for U.S. federal income tax purposes. Additional
notes issued in this matter will be consolidated with and will form a single series with the notes being offered hereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the notes of each series in the form of one or more fully registered global securities. We deposited these global securities with, or on behalf
of, DTC and register these securities in the name of DTC&#146;s nominee. Direct and indirect participants in DTC will record beneficial ownership of the notes by individual investors. The transfer of ownership of beneficial interests in a global
security will be effected only through records maintained by DTC or its nominee, or by participants or persons that hold through participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Investors may elect to hold beneficial interests in the global securities through either DTC, Clearstream Banking S.A. (&#147;Clearstream&#148;) or
Euroclear Bank SA/NV (&#147;Euroclear&#148;) if they are participants in these systems, or indirectly through organizations which are participants in these systems. Beneficial interests in the global securities will be held in minimum denominations
of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon receipt of any payment in respect of a global security, DTC or its nominee will
immediately credit participants&#146; accounts with amounts proportionate to their respective beneficial interests in the principal amount of the global security as shown in the records of DTC or its nominee. Payments by participants to owners of
beneficial interests in a global security held through participants will be governed by standing instructions and customary practices and will be the responsibility of those participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">DTC holds securities of institutions that have accounts with it or its participants. Through its maintenance of an electronic book-entry system, DTC
facilitates the clearance and settlement of securities transactions among its participants and eliminates the need to deliver securities certificates physically. DTC&#146;s participants include securities brokers and dealers, including the
underwriters of this offering, banks, trust companies, clearing corporations and other organizations. DTC is partially owned by some of these participants or their representatives. Access to DTC&#146;s book-entry system is also available to others
such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly. DTC agrees with and represents to its participants that it will administer its book-entry
system in accordance with its rules and bylaws and requirements of law. The rules applicable to DTC and its participants are on file with the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream and Euroclear hold interests on behalf of their participants through customers&#146; securities accounts in Clearstream&#146;s and
Euroclear&#146;s names on the books of their respective depositaries, which in turn will hold interests in customers&#146; securities accounts in the depositaries&#146; names on the books of DTC. At the date of the prospectus supplement, Citibank,
N.A. acts as U.S. depositary for Clearstream and JPMorgan Chase Bank, N.A. acts as U.S. depositary for Euroclear, or, collectively, the &#147;U.S. Depositaries.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream holds securities for its participating organizations, or &#147;Clearstream Participants,&#148; and facilitates the clearance and settlement of
securities transactions between Clearstream Participants through electronic book-entry changes in accounts of Clearstream Participants, thereby eliminating the need for physical movement of certificates. Clearstream provides to Clearstream
Participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream is registered as a bank in Luxembourg and as such is subject to regulation by the Commission de Surveillance du Secteur Financier and the
Banque Centrale du Luxembourg, which supervise and oversee the activities of Luxembourg banks. Clearstream Participants are worldwide financial institutions, including underwriters, securities brokers and dealers, banks, trust companies and clearing
corporations, and may include the underwriters or their affiliates. Indirect access to Clearstream is available to other institutions that clear through or maintain a custodial relationship with a Clearstream Participant. Clearstream has established
an electronic bridge with Euroclear as the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
operator of the Euroclear system, or the &#147;Euroclear Operator,&#148; in Brussels to facilitate settlement of trades between Clearstream and the Euroclear Operator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to the notes of a series held beneficially through Clearstream will be credited to cash accounts of Clearstream Participants in
accordance with its rules and procedures, to the extent received by the U.S. Depositary for Clearstream. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear holds securities and book-entry
interests in securities for participating organizations, or &#147;Euroclear Participants&#148; and facilitates the clearance and settlement of securities transactions between Euroclear Participants, and between Euroclear Participants and
participants of certain other securities intermediaries through electronic book-entry changes in accounts of such participants or other securities intermediaries. Euroclear provides Euroclear Participants with, among other things, safekeeping,
administration, clearance and settlement, securities lending and borrowing, and related services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear Participants are investment banks,
securities brokers and dealers, banks, central banks, supranationals, custodians, investment managers, corporations, trust companies and certain other organizations and may include the underwriters or their affiliates.
<FONT STYLE="white-space:nowrap">Non-participants</FONT> in Euroclear may hold and transfer beneficial interests in a global security through accounts with a Euroclear Participant or any other securities intermediary that holds a book-entry interest
in a global security through one or more securities intermediaries standing between such other securities intermediary and Euroclear. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions
with respect to notes of a series held beneficially through Euroclear will be credited to the cash accounts of Euroclear Participants in accordance with the Terms and Conditions, to the extent received by the U.S. Depositary for Euroclear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers between Euroclear Participants and Clearstream Participants will be effected in the ordinary way in accordance with their respective rules and
operating procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Cross-market transfers between DTC&#146;s participating organizations, or the &#147;DTC Participants,&#148; on the one hand,
and Euroclear Participants or Clearstream Participants, on the other hand, will be effected through DTC in accordance with DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by its U.S. Depositary; however, such cross-
market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such
system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. Depositary to take action to effect final settlement on its behalf by delivering or receiving
interests in the global security in DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement applicable to DTC. Euroclear Participants and Clearstream Participants
may not deliver instructions directly to their respective U.S. Depositaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Due to time zone differences, the securities accounts of a Euroclear
Participant or Clearstream Participant purchasing an interest in a global security from a DTC Participant in DTC will be credited, and any such crediting will be reported, to the relevant Euroclear Participant or Clearstream Participant during the
securities settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or
through a Euroclear Participant or Clearstream Participant to a DTC Participant will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for
Euroclear or Clearstream following DTC&#146;s settlement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The information in this section concerning DTC, Euroclear and Clearstream and their
book-entry systems has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy of that information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">None of us, any of the underwriters and the trustee will have any responsibility for the performance by DTC, Euroclear or Clearstream or their respective
participants of their respective obligations under the rules and procedures governing their operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Although DTC, Clearstream and Euroclear have
agreed to the foregoing procedures in order to facilitate transfers of securities among participants of DTC, Clearstream and Euroclear, they are under no obligation to perform or continue to perform such procedures and they may discontinue the
procedures at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Initial settlement for the notes was made in immediately available funds. Secondary market trading between DTC participants will occur in the ordinary way
in accordance with DTC rules and will be settled in immediately available funds using DTC&#146;s <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement System. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>b. <U>Base Pros</U>p<U>ectus &#150; March 4</U>,<U> 2011</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of Debt Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As used in this &#147;Description of Debt Securities,&#148; &#147;debt securities&#148; means the debentures, notes, bonds, guarantees and other evidences
of indebtedness that GSK issues or that GSK Capital Inc. or GSK Capital plc (the &#147;finance subsidiaries&#148;) issues and GSK fully and unconditionally guarantees and, in each case, the trustee authenticates and delivers under the applicable
indenture. The debt securities will be our direct unsecured obligations and will rank equally and ratably without preference among themselves and at least equally with all of our other unsecured and unsubordinated indebtedness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities will be issued in one or more series under an indenture between GSK and Law Debenture Trust Company of New York, as trustee, or under
indentures among the finance subsidiaries, Law Debenture Trust Company of New York, as trustee (as successor to Citibank, N.A., pursuant to Instruments of Resignation, Appointment and Acceptance among the finance subsidiaries, the guarantor, Law
Debenture Trust Company of New York and Citibank, N.A.), and GSK, as guarantor. The indentures applicable to GSK, GSK Capital Inc. and GSK Capital plc will each be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture
Act. In the following discussion, we sometimes refer to these indentures collectively as the &#147;indentures.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">This &#147;Description of Debt
Securities&#148; briefly outlines the provisions of the indentures and is qualified in its entirety by reference to the indentures. The terms of the indentures will include both those stated in the indentures and those made part of the indentures by
the Trust Indenture Act. The forms of the indentures have been filed as exhibits to the registration statement of which the base prospectus forms a part, and you should read the indentures for provisions that may be important to you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not contain any covenants or other provisions designed to protect holders of the debt securities against a reduction in the
creditworthiness of GSK or the finance subsidiaries in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Issuances in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not limit the amount of
debt securities that may be issued. The debt securities may be issued in one or more series with the same or various maturities, at a price of 100% of their principal amount or at a premium or a discount. Not all debt securities of any one series
need be issued at the same time, and, unless otherwise provided, any series may be reopened, without the consents of the holders of debt securities of that series, for issuances of additional debt securities of that series. Except in the limited
circumstances described below under &#147;&#151; Covenants &#151; Limitation on Liens,&#148; the debt securities will not be secured by any property or assets of GSK, as issuer or guarantor, or the finance subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The terms of any authorized series of debt securities will be described in a prospectus supplement. These terms will include some or all of the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the title, aggregate principal amount and denominations of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the date or dates on which principal will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the percentage of the principal amount at which the debt securities will be issued and whether the debt securities will be
&#147;original issue discount&#148; securities for U.S. federal income tax purposes. If original issue discount debt securities are issued (generally, securities that are issued at a substantial discount below their principal amount), the special
U.S. federal income tax and other considerations of a purchase of original issue discount debt securities will be described; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the rate or rates, which may be fixed or variable, at which the debt securities will bear interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the interest payment dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any optional or mandatory redemption terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether any sinking fund is required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the currency in which the debt securities will be denominated or principal, premium or interest will be payable, if other
than U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether the debt securities are to be issued as individual certificates to each holder or in the form of global certificates
held by a depositary on behalf of beneficial owners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">information describing any book-entry features; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the names and duties of any <FONT STYLE="white-space:nowrap">co-trustees,</FONT> depositaries, authenticating agents, paying
agents, transfer agents or registrars for any series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the applicability of the defeasance and covenant defeasance provisions described herein, or any modifications of those
provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any deletions from, modifications of or additions to the events of default or covenants with respect to the debt securities;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other terms, conditions, rights or preferences of the debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities that have a maturity of less than one year from their date of issue and in respect of which the proceeds are to be received by us in the
United Kingdom will have a minimum denomination of &pound;100,000 (or its equivalent in another currency). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement relating to any
series of debt securities may add to or change statements contained in the base prospectus. The prospectus supplement may also include, if applicable, a discussion of certain U.S. federal income tax and U.K. income tax considerations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>GSK Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities issued by the finance
subsidiaries will be fully and unconditionally guaranteed by GSK. If for any reason the applicable finance subsidiary does not make any required payment in respect of its debt securities when due, whether on the normal due date, on acceleration,
redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. The holder of a guaranteed debt security will be entitled to payment under the applicable guarantee of GSK without taking any action whatsoever against
the finance subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Payment and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt
securities will be issued only as registered securities, which means that the name of the holder will be entered in a register that will be kept by the trustee or another agent appointed by us. Unless stated otherwise in a prospectus supplement, and
except as described under &#147;&#151; Book-Entry System&#148; below, payments of principal, interest and additional amounts, if any, will be made at the office of the paying agent or agents named in the prospectus supplement or by check mailed to
you at your address as it appears in the register. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless other procedures are described in a prospectus supplement and except as described under
&#147;&#151; Book Entry System&#148; below, you will be able to transfer registered debt securities at the office of the transfer agent or agents named in the prospectus supplement. You may also exchange registered debt securities at the office of
the transfer agent for an equal aggregate principal amount of registered debt securities of the same series having the same maturity date, interest rate and other terms as long as the debt securities are issued in authorized denominations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Neither we nor the trustee will impose any service charge for any transfer or exchange of a debt security; however, we may ask you to pay any taxes or
other governmental charges in connection with a transfer or exchange of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities may be issued under a book-entry system in the form of one or more global securities. The global securities will be registered in the name
of a depositary or its nominee and deposited with that depositary or its custodian. Unless stated otherwise in the prospectus supplement, The Depository Trust Company, New York, New York, or DTC, will be the depositary if a depositary is used. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:2%; font-size:9pt; font-family:ARIAL">DTC has advised us as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC is a limited-purpose trust company organized under the New York Banking Law, a &#147;banking organization&#148; within
the meaning of the New York Banking Law, a member of the Federal Reserve System, a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code and a &#147;clearing agency&#148; registered pursuant to the provisions of
Section&nbsp;17A of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC was created to hold securities of its participants and to facilitate the clearance and settlement of securities
transactions, such as through transfers and pledges, among its participants in such securities through electronic book-entry changes to accounts of its participants, thereby eliminating the need for physical movement of securities certificates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC&#146;s participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain
other organizations, some of whom (and/or their representatives) own DTC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">access to DTC&#146;s book-entry system is also available to others, such as banks, brokers, dealers and
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the DTC rules applicable to its participants are on file with the U.S. Securities and Exchange Commission.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">According to DTC, the foregoing information with respect to DTC has been provided to the financial community for informational
purposes only and is not intended to serve as a representation, warranty or contract modification of any kind. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Following the issuance of a global
security in registered form, the depositary will credit the accounts of its participants with the debt securities upon our instructions. Only persons who hold directly or indirectly through financial institutions that are participants in the
depositary can hold beneficial interests in the global securities. Since the laws of some jurisdictions require certain types of purchasers to take physical delivery of such securities in definitive form, you may encounter difficulties in your
ability to own, transfer or pledge beneficial interests in a global security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">So long as the depositary or its nominee is the registered owner of a
global security, we and the trustee will treat the depositary as the sole owner or holder of the debt securities for purposes of the applicable indenture. Therefore, except as set forth below, you will not be entitled to have debt securities
registered in your name or to receive physical delivery of certificates representing the debt securities. Accordingly, you will have to rely on the procedures of the depositary and the participant in the depositary through whom you hold your
beneficial interest in order to exercise any rights of a holder under the indenture. We understand that under existing practices, the depositary would act upon the instructions of a participant or authorize that participant to take any action that a
holder is entitled to take. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will make all payments of principal, interest and additional amounts, if any, on the debt securities to the
depositary. It is expected that the depositary will then credit participants&#146; accounts proportionately with these payments on the payment date and that the participants will in turn credit their customers&#146; accounts in accordance with their
customary practices. Neither we nor the trustee will be responsible for making any payments to participants or customers of participants or for maintaining any records relating to the holdings of participants and their customers, and you will have
to rely on the procedures of the depositary and its participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Global securities are generally not transferable. Physical certificates will be
issued to beneficial owners in lieu of a global security only in the special situations described in the sixth paragraph under the heading &#147;Legal Ownership of Debt Securities &#151; Global Securities&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We and the finance subsidiaries
have agreed in the indentures not to consolidate with or merge with or into any other person or convey or transfer all or substantially all of our respective properties and assets to any person (except that the finance subsidiaries may merge into
us), unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we or the applicable finance subsidiary, as the case may be, are the continuing person, or the successor expressly assumes
by supplemental indenture our obligations under the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the continuing person is a U.S. or U.K. company or is organized and validly existing under the laws of a jurisdiction that
is a member country of the Organisation for Economic Cooperation and Development (or any successor) and, if it is not a U.S. or U.K. company, the continuing person agrees by supplemental indenture to be bound by a covenant comparable to that
described below under &#147;&#151; Covenants &#151; Payment of Additional Amounts&#148; with respect to taxes imposed in the continuing person&#146;s jurisdiction of organization (in which case the continuing person will benefit from a redemption
option comparable to that described below under &#147;&#151; Optional Redemption for Tax Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the consolidation, merger or sale); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">immediately after the transaction, no default under the debt securities has occurred and is continuing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we deliver to the trustee an officer&#146;s certificate and, if neither we nor the applicable subsidiary are the continuing
person, an opinion of counsel, in each case stating, among other things, that the transaction and the supplemental indenture, if required, comply with these provisions and the indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments made by us under or with respect to the debt securities will be free and clear of and without withholding or deduction for or on account of any
present or future tax, duty, levy, impost, assessment or other governmental charge of any nature whatsoever imposed or levied by or on behalf of the government of the United Kingdom or of any territory of the United Kingdom or by any authority or
agency therein or thereof having the power to tax or (ii)&nbsp;the government of the United States or any state or territory of the United States or by any authority or agency </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the debt securities, we will pay such
additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been
withheld or deducted; <I>provided </I>that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">that would not have been imposed but for the
existence of any present or former connection between such holder or beneficial owner of the debt securities (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if
such holder or beneficial owner is an estate, trust, partnership or corporation) and the United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including,
without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national
thereof or being or having been present or engaged in trade or business therein or having or having had a permanent establishment therein; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or interest on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to
exemption from, or reduction in, the rate of deduction or withholding of such Taxes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">at least 30 days before the first payment date with respect to which such additional amounts shall be payable, we have
notified such recipient in writing that such recipient is required to comply with such requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of a debt security (where presentation is required) for payment on
a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed on a payment to an individual and are required to be made pursuant to European Council Directive 2003/48/EC
or any other Directive implementing the conclusions of the ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, or any law implementing or complying with, or introduced in order to
conform to, such Directive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the relevant debt securities had been made to a paying agent
other than the paying agent to which the presentation was made; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or interest on any debt security to any such holder who is a fiduciary or a
partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled to
such additional amounts had it been the holder of the debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in each indenture that at least one paying agent for each series
of debt securities will be located outside the United Kingdom. We have also agreed that if we maintain a paying agent with respect to a particular series of debt securities in any member state of the European Union, we will maintain a paying agent
in at least one member state (other than the United Kingdom) that will not be obliged to withhold or deduct taxes pursuant to any law implementing European Council Directive 2003/48/EC or any other Directive implementing the conclusions of the
ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, provided there is at least one member state that does not require a paying agent to withhold or deduct pursuant to such
Directive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the indentures and the payment of all amounts in
respect of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Limitation on Liens </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the indentures not to incur or assume (or permit any of our subsidiaries to incur or assume) any lien on or with respect to any of our
or our subsidiaries&#146; property, assets or revenues, present or future, to secure </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
any relevant indebtedness (as this term is defined below) without making (or causing our subsidiaries to make) effective provision for securing the debt securities equally and ratably with such
relevant indebtedness as to such property, assets or revenues, for as long as such relevant indebtedness is so secured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The restrictions on liens will not apply to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens arising by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of any person, which liens are existing at the time such person becomes a subsidiary;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of a person existing at the time such person is merged with or into or consolidated
with us or any of our subsidiaries or at the time of a sale, lease or other disposition to us of the properties of a person as an entirety or substantially as an entirety. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:9pt; font-family:ARIAL">For purposes of the limitation on liens covenant, the term &#147;relevant indebtedness&#148; means any of our debt that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is in the form of or represented by bonds, notes, loan stock, depositary receipts or other securities issued (otherwise than
to constitute or represent advances made by banks or other lending institutions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is denominated in, or confers any right of payment by reference to, any currency other than the currency of the country in
which the issuer of the indebtedness has its principal place of business, or is denominated in or by reference to the currency of such country but more than 20% of which is placed or offered for subscription or sale by or on behalf of, or by
agreement with, the issuer outside such country; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">at its date of issue is, or is intended by the issuer to become, quoted, listed, traded or dealt in on any stock exchange, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or other securities market. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><I>Additional
Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may be subject to additional covenants, including restrictive covenants in respect of a particular series of debt securities.
Such additional covenants will be set forth in the applicable prospectus supplement and, to the extent necessary, in the supplemental indenture or board resolution relating to that series of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Redemption for Tax Reasons </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may redeem any series
of debt securities in whole but not in part at any time, on giving not less than 30 nor more than 60 days&#146; notice of such redemption, at a redemption price equal to the principal amount plus accrued interest, if any, to the date fixed for
redemption (except in the case of discounted debt securities, which may be redeemed at the redemption price specified by the terms of each series of such debt securities), if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine that, as a result of any change in or amendment to the laws or any regulations or rulings promulgated
thereunder of the United Kingdom (or of any political subdivision or taxing authority thereof) or the United States (or of any political subdivision or taxing authority thereof), or any change in the application or official interpretation of such
laws, regulations or rulings, or any change in the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or
amendment becomes effective on or after the issue date or such other date specified in the debt securities of that series: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we would be required to pay additional amounts (as described under &#147;&#151; Covenants &#151; Payment of Additional
Amounts&#148; above) with respect to that series of debt securities on the next succeeding interest payment date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to us; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the
applicable finance subsidiary directly from the guarantor (or any affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the applicable finance subsidiary or the guarantor (or any affiliate);
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine, based upon an opinion of independent counsel of recognized standing that, as a result of any action taken by
any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom (or any political subdivision or taxing authority thereof) or the United States (or any political subdivision or taxing
authority thereof) (whether or not such action was taken or brought with respect to GSK, as issuer or guarantor, or the applicable finance subsidiary, as the case may be), which action is taken or brought on or after the issue date or such other
date specified in the debt securities of that series, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
redemption may be given earlier than 90 days prior to the earliest date on which we would be obligated to pay such additional amounts. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will also pay to each holder, or make available for payment to each such holder, on the redemption date any additional amounts resulting from the
payment of such redemption price. Prior to the publication of any notice of redemption, we will deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an officer&#146;s certificate stating that we are entitled to effect a redemption and setting forth a statement of facts
showing that the conditions precedent of the right so to redeem have occurred; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an opinion of counsel to the effect that the conditions specified above have been satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Any notice of redemption will be irrevocable once we deliver the officer&#146;s certificate to the trustee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless otherwise specified in a prospectus
supplement, an event of default with respect to a series of debt securities occurs upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of the principal (or premium, if any) of any debt security of that series when due (including as a
sinking fund installment), and, in the case of technical or administrative difficulties, the continuance of that default for more than two business days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of interest on, or any additional amounts payable in respect of, any debt security of that series when
due and payable, and the continuance of that default for 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in performing any other covenant in the indenture applicable to that series for 60 days after the receipt of written
notice specifying such default from the trustee or from the holders of 25% in principal amount of the debt securities of that series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default under any bond, debenture, note or other evidence of indebtedness for money borrowed of GSK or either finance
subsidiary, as the case may be (not including any indebtedness for which recourse is limited to property purchased), having in any particular case an outstanding principal amount in excess of $25,000,000 (or its equivalent in any other currency)
where any such failure results in such indebtedness being accelerated and becoming due and payable prior to its stated maturity and such acceleration shall not have been rescinded or annulled or such indebtedness shall not have been discharged;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">certain events of bankruptcy, insolvency or reorganization of GSK or either finance subsidiary, as the case may be;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other event of default provided with respect to that particular series of debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Any additional or different events of default applicable to a particular series of debt securities will be described in the prospectus supplement
relating to such series. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">An event of default with respect to a particular series of debt securities will not necessarily constitute an event of
default with respect to any other series of debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The trustee may withhold notice to the holders of debt securities of any default (except
in the payment of principal, premium or interest) if it, in good faith, considers such withholding of notice to be in the best interests of the holders. A default is any event which is an event of default described above or would be an event of
default but for the giving of notice or the passage of time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default occurs and continues, the trustee or the holders of the aggregate
principal amount of the debt securities specified below may require us to repay immediately, or accelerate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the entire principal of the debt securities of such series; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">if the debt securities are original issue discount securities, such portion of the principal as may be described in the
applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If the event of default occurs because of a default in a payment of principal or interest on the
debt securities of any series, then the trustee or the holders of at least 25% of the aggregate principal amount of debt securities of that series can accelerate that series of debt securities. If the event of default occurs because of a failure to
perform any other covenant in the applicable indenture or any covenant for the benefit of one or more, but not all, of the series of debt securities, then the trustee or the holders of at least 25% of the aggregate principal amount of debt
securities of all series affected, voting as one class, can accelerate all of the affected series of debt securities. If the event of default occurs because of bankruptcy proceedings, then all of the debt securities under the indenture will be
accelerated automatically. Therefore, except in the case of a default on a payment of principal or interest on the debt securities of your series or a default due to our bankruptcy or insolvency, it is possible that you may not be able to accelerate
the debt securities of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
your series because of the failure of holders of other series to take action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The holders of a
majority of the aggregate principal amount of the debt securities of all affected series, voting as one class, can rescind this accelerated payment requirement or waive any past default or event of default or allow noncompliance with any provision
of the applicable indenture. However, they cannot waive a default in payment of principal of, premium, if any, or interest on any of the debt securities when due otherwise than as a result of acceleration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">After an event of default, the trustee must exercise the same degree of care a prudent person would exercise under the circumstances in the conduct of her
or his own affairs. Subject to these requirements, the trustee is not obligated to exercise any of its rights or powers under the applicable indenture at the request, order or direction of any holders, unless the holders offer the trustee reasonable
indemnity. If they provide this reasonable indemnity, the holders of a majority in principal amount of all affected series of debt securities, voting as one class, may direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any power conferred upon the trustee, for any series of debt securities. However, the trustee may refuse to follow any direction that conflicts with law or the indenture or is unduly prejudicial to the rights
of other holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">No holder will be entitled to pursue any remedy with respect to the indenture unless the trustee fails to act for 60 days after it
is given: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">notice of default by that holder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">a written request to enforce the indenture by the holders of not less than 25% in principal amount of all outstanding debt
securities of any affected series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an indemnity to the trustee, satisfactory to the trustee; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">and during this <FONT STYLE="white-space:nowrap">60-day</FONT> period the holders of a majority in principal amount of all outstanding debt securities of such affected
series do not give a direction to the trustee that is inconsistent with the enforcement request. These provisions will not prevent any holder of debt securities from enforcing payment of the principal of (and premium, if any) and interest on the
debt securities at the relevant due dates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default with respect to a series of debt securities occurs and is continuing, the trustee
will mail to the holders of those debt securities a notice of the event of default within 90 days after it occurs. However, except in the case of a default in any payment in respect of a series of debt securities, the trustee shall be protected in
withholding notice of an event of default if it determines in good faith that this is in the interests of the holders of the relevant debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Modification of the Indentures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In general, rights and
obligations of us and the holders under the indentures may be modified if the holders of a majority in aggregate principal amount of the outstanding debt securities of each series affected by the modification consent to such modification. However,
each of the indentures provides that, unless each affected holder agrees, an amendment cannot: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any adverse change to any payment term of a debt security such as extending the maturity date, extending the date on
which we have to pay interest or make a sinking fund payment, reducing the interest rate, reducing the amount of principal we have to repay, changing the currency in which we have to make any payment of principal, premium or interest, modifying any
redemption or repurchase right, or right to convert or exchange any debt security, to the detriment of the holder and impairing any right of a holder to bring suit for payment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">waive any payment default; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">reduce the percentage of the aggregate principal amount of debt securities needed to make any amendment to the applicable
indenture or to waive any covenant or default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any other change to the amendment provisions of the applicable indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">However, if we and the trustee agree, the applicable indenture may be amended without notifying any holders or seeking their consent if the amendment
does not materially and adversely affect any holder. We and the trustee are permitted to make modifications and amendments to the applicable indenture without the consent of any holder of debt securities for any of the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to cure any ambiguity, defect or inconsistency in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with sections of the indenture governing when we may merge and substitute obligors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with any requirements of the U.S. Securities and Exchange Commission in connection with the qualification of the
indenture under the Trust Indenture Act; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to evidence and provide for the acceptance by a successor trustee of appointment under the indenture with respect to the
debt securities of any or all series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to establish the form or forms or terms of the debt securities of any series or of the coupons appertaining to such debt
securities as permitted under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for a further guarantee from a third party on outstanding debt securities of any series and the debt securities
of any series that may be issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to change or eliminate any provision of the indenture; provided that any such change or elimination will become effective
only when there are no outstanding debt securities of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to supplement any of the provisions of the indenture to such extent as will be necessary to permit or facilitate the
defeasance and discharge of any series of debt securities pursuant to the indenture; provided that any such action will not adversely affect the interests of the holders of such or any other series of debt securities in any material respect; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to make any change that does not materially and adversely affect the rights of any holder of the debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The term defeasance means
discharge from some or all of the obligations under the indentures. If we deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a
redemption date of the debt securities of a particular series, then at our option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will be discharged from our respective obligations with respect to the debt securities of such series; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will no longer be under any obligation to comply with the restrictive covenants, if any, contained in the applicable
indenture and any supplemental indenture or board resolution with respect to the debt securities of such series, and the events of default relating to failures to comply with covenants will no longer apply to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If this happens, the holders of the debt securities of the affected series will not be entitled to the benefits of the applicable indenture except for
registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities. Instead, the holders will only be able to rely on the deposited funds or obligations for payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We must deliver to the trustee an opinion of counsel to the effect that the deposit and related defeasance would not cause the holders of the debt
securities to recognize income, gain or loss for U.S. federal income tax purposes. We may, in lieu of an opinion of counsel, deliver a ruling to such effect received from or published by the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Substitution of Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may at our option at any time,
without the consent of any holders of debt securities, cause GSK or any other subsidiary of GSK to assume the obligations of the applicable finance subsidiary under any series of debt securities, provided that the new obligor executes a supplemental
indenture in which it agrees to be bound by the terms of those debt securities and the relevant indenture. If the new obligor is not a U.S. or U.K. company, it must be organized and validly existing under the laws of a jurisdiction that is a member
country of the Organisation for Economic Cooperation and Development (or any successor) and it must also agree in the supplemental indenture to be bound by a covenant comparable to that described above under &#147;&#151; Covenants &#151; Payment of
Additional Amounts&#148; with respect to taxes imposed in its jurisdiction of organization (in which case the new obligor will benefit from a redemption option comparable to that described above under &#147;&#151; Optional Redemption for Tax
Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the substitution). In the case of such substitution, the applicable finance subsidiary will be relieved of any further obligation under the assumed series of debt
securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">For U.S. federal income tax purposes, a substitution of obligors as described above generally would be treated as a deemed taxable
exchange of debt securities for new debt securities issued by the new obligor. As discussed further in the applicable prospectus supplement, a United States person who holds debt securities or owns a beneficial interest therein generally will
recognize capital gain or loss in an amount equal to the difference between the issue price of the new debt securities and such person&#146;s adjusted tax basis in the debt securities. Such persons should consult their own tax advisors regarding the
tax consequences of a deemed taxable exchange in the event of a substitution of obligors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Information Concerning the Trustee </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Law Debenture Trust Company of New York will be the trustee. The trustee will be required to perform
only those duties that are specifically set forth in the indentures, except when a default has occurred and is continuing with respect to the debt securities. After a default, the trustee must exercise the same degree of care that a prudent person
would exercise under the circumstances in the conduct of her or his own affairs. Subject to these requirements, the trustee will be under no obligation to exercise any of the powers vested in it by the indentures at the request of any holder of debt
securities unless the holder offers the trustee reasonable indemnity against the costs, expenses and liabilities that might be incurred by exercising those powers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities, the related guarantees and
the indentures will be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Legal Ownership of Debt Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>&#147;Street Name&#148; and Other Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We
generally will not recognize investors who hold debt securities in accounts at banks or brokers as legal holders of those debt securities. Holding securities in accounts at banks or brokers is called holding in &#147;street name.&#148; If an
investor holds debt securities in street name, we recognize only the bank or broker or the financial institution the bank or broker uses to hold the debt securities. These intermediary banks, brokers and other financial institutions pass along
principal, interest and other payments on the debt securities, either because they agree to do so in their customer agreements or because they are legally required to do so. If you hold debt securities in street name, you should check with your own
institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it handles payments and notices with respect to securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would handle voting if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how and when you should notify it to exercise on your behalf any rights or options that may exist under the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether and how you can instruct it to send you securities registered in your own name so you can be a direct holder as
described below; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would pursue rights under the debt securities if there were a default or other event triggering the need for holders
to act to protect their interests. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Registered Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligations, as well as the obligations of the trustee and those of any third parties employed by us or the trustee, extend only to persons who are
registered as holders of debt securities. As noted above, we do not have obligations to you if you hold in street name or through other indirect means, either because you choose to hold debt securities in that manner or because the debt securities
are issued in the form of global securities as described below. For example, once we make payment to the registered holder, we have no further responsibility for the payment even if that holder is legally required to pass the payment along to you as
a street name customer but does not do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">A global security is a special type of indirectly held security. If we choose to issue debt securities in the form of global securities, the ultimate
beneficial owners of the debt securities will be indirect holders. We do this by requiring that the global security be registered in the name of a financial institution we select and by requiring that the debt securities represented by the global
security not be registered in the name of any other holder except in the special situations described below. The financial institution that acts as the sole registered holder of the global security is called the depositary. Any person wishing to own
a debt security may do so indirectly through an account with a broker, bank or other financial institution that in turn has an account with the depositary. The prospectus supplement will indicate whether your series of debt securities will be issued
only as global securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers of debt securities represented by the global security will be made only on the records of the depositary or its
nominee by transferring such debt securities from the account of one broker, bank or financial institution to the account of another broker, bank or financial institution. These transfers are made electronically only and are also known as book-
entry transfers. Securities in global form are sometimes also referred to as being in book-entry form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As an indirect holder, your rights relating to
a global security will be governed by the account rules of your </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
broker, bank or financial institution and of the depositary, as well as general laws relating to securities transfers. We will not recognize you as a holder of debt securities and instead will
deal only with the depositary that holds the global security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">You should be aware that if debt securities are issued only in the form of a global
security: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you cannot have debt securities registered in your own name; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you cannot receive physical certificates for your interest in the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you will be a street name holder and must look to your own broker, bank or financial institution for payments on the debt
securities and protection of your legal rights relating to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you may not be able to sell interests in the debt securities to some insurance companies and other institutions that are
required by law to own securities in the form of physical certificates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary&#146;s policies will govern payments, transfers, exchanges and other matters relating to your indirect
interest in the global security. We and the trustee will have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in the global security. We and the trustee also will not supervise the
depositary in any way; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary will require that indirect interests in the global security be purchased or sold within its system using <FONT
STYLE="white-space:nowrap">same-day</FONT> funds for settlement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In a few special situations described below, the global security
will terminate and the indirect interests in it will be exchanged for registered debt securities represented by physical certificates. After that exchange, the choice of whether to hold debt securities in registered form or in street name will be up
to you. You must consult your broker, bank or financial institution to find out how to have your interests in debt securities transferred to your name, so that you will be a registered holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless we specify otherwise in the prospectus supplement, the special situations for termination of a global security are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">when the depositary notifies us that it is unwilling or unable to continue as depositary and we do not or cannot appoint a
successor depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary ceases to be a clearing agency registered under the Exchange Act and we do not appoint a successor depositary
within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an event of default has occurred and is continuing and beneficial owners representing a majority in principal amount of the
applicable series of debt securities have advised the depositary to cease acting as the depositary; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we decide we do not want to have the debt securities of that series represented by a global security. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of debt
securities covered by the prospectus supplement. When a global security terminates, the depositary (and not us or the trustee) is responsible for deciding the names of the institutions that will be the initial registered holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>The Term &#147;Holder&#148; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the descriptions of the debt
securities included herein, when we refer to the &#147;holder&#148; of a given debt security as being entitled to certain rights or payments, or being permitted to take certain actions, we are in all cases referring to the registered holder of the
debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">While you would be the registered holder if you held a certificated security registered in your name, it is likely that the holder
will actually be either the broker, bank or other financial institution where you have your street name account, or, in the case of a global security, the depositary. If you are an indirect holder, you will need to coordinate with the institution
through which you hold your interest in a debt security in order to determine how the provisions involving holders described in this prospectus and any prospectus supplement will actually apply to you. For example, if the debt security in which you
hold a beneficial interest in street name can be repaid at the option of the holder, you cannot exercise the option yourself by following the procedures described in the prospectus supplement. Instead, you would need to cause the institution through
which you hold your interest to take those actions on your behalf. Your institution may have procedures and deadlines different from or additional to those described in the prospectus supplement relating to the debt security. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>3. Notes offered pursuant to the Base Prospectus dated March&nbsp;4, 2008<U> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><U>a. Prospectus Supplement (May 6, 2008) &#150; 6.375% Notes due 2038</U> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of the Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the 6.375% Notes due 2038 pursuant to an
indenture, dated April&nbsp;6, 2004, among GSK, as guarantor, GSK Capital Inc., as issuer, and Law Debenture Trust Company of New York, the trustee for the notes (as successor to Citibank, N.A., pursuant to an Instrument of Resignation, Appointment
and Acceptance dated December&nbsp;27, 2007 among GSK Capital Inc., GSK, Law Debenture Trust Company of New York and Citibank, N.A.) (for purposes of this description of the 6.375% Notes due 2038 only, the &#147;indenture&#148;). References in this
&#147;Description of the Notes&#148; to the &#147;notes&#148; refer to the 6.375% Notes due 2038. The notes are a series of our debt securities. GSK Capital Inc. issued the notes in the aggregate principal amount of $2,750,000,000. The notes will
mature on May&nbsp;15, 2038. GSK Capital Inc. issued the notes only in book-entry form, in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The notes are fully and unconditionally guaranteed by GSK. If, for any reason, GSK Capital Inc. does not make any required payment in respect of the notes
when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. You will be entitled to payment under the guarantee of GSK without taking any action
whatsoever against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Interest Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The notes bear
interest at the applicable interest rate shown in the table above and accrued interest from May&nbsp;13, 2008, or from the most recent date to which interest has been paid (or provided for), to but not including the next date upon which interest is
required to be paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Interest is payable on the notes twice a year, on May&nbsp;15 and November&nbsp;15, commencing November&nbsp;15, 2008, to the
person in whose name a note is registered at the close of business on the May&nbsp;1 or November&nbsp;1 that precedes the date on which interest will be paid. Interest on the notes are paid on the basis of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. &#147;Business day&#148; means any day other than a Saturday, a Sunday or a day on which banking institutions in the
City of New York or London, England are authorized or obligated by law, regulation or executive order to be closed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an interest payment date or
redemption date, or the maturity date, for the notes, as the case may be, would fall on a day that is not a business day, then the interest payment date or redemption date, or the maturity date, as the case may be, will be postponed to the next
succeeding business day, but no additional interest shall be paid unless we fail to make payment on such next succeeding business day. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Subject to certain exceptions, if we are required to withhold or deduct any amount for or on account of any U.K. or U.S. withholding tax from any payment
made on the notes, we will pay additional amounts on those payments so that the amount received by noteholders will equal the amount that would have been received if no such taxes had been applicable. See &#147;Description of Debt Securities &#151;
Covenants &#151; Payment of Additional Amounts&#148; below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As contemplated by the last paragraph under &#147;Description of Debt Securities &#151;
Defeasance&#148; below, the satisfaction of certain conditions will permit us to omit to comply with some or all of our obligations, covenants and agreements under the indenture with respect to the notes. In addition, we may omit to comply with
certain covenants through covenant defeasance. We refer you to the information under &#147;Description of Debt Securities &#151; Defeasance&#148; below for more information on how we may do this. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Except as described herein, the indenture for the notes does not contain any covenants or other provisions designed to protect holders of the notes
against a reduction in our creditworthiness in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the notes, including, among other things, through the incurrence of
additional indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Make-Whole Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may redeem the notes, in whole or in part, at our option at any time and from time to time at a redemption price equal to the greater of (i) 100% of
the principal amount of the notes to be redeemed on that redemption date; and (ii)&nbsp;as determined by the quotation agent (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest on the notes
being redeemed on that redemption date (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semi-annual basis (assuming a
<FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months) at the Treasury Rate, plus 0.25%, plus accrued and unpaid interest thereon to, but excluding, the date of redemption.
Notwithstanding the foregoing, installments of interest on notes to be redeemed that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of
the close of business on the relevant record date according to the notes and the indenture. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Issue&#148; means the United States Treasury security selected by the
quotation agent as having a maturity comparable to the remaining term (as measured from the date of redemption) of the notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the remaining term of the notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Comparable Treasury Price&#148;
means, with respect to any redemption date, (i)&nbsp;the average of four Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or
(ii)&nbsp;if the quotation agent for the notes obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations, or (iii)&nbsp;if only one Reference Treasury Dealer Quotation is received, the quotation.
&#147;Quotation agent&#148; means any Reference Treasury Dealer appointed by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of
Citigroup Global Markets Inc., J.P. Morgan Securities Inc. and Lehman Brothers Inc. (or their respective affiliates that are Primary Treasury Dealers) and their respective successors; provided, however, that if any of the foregoing shall cease to be
a primary U.S. government securities dealer in New York City (a &#147;Primary Treasury Dealer&#148;), we will substitute therefor another Primary Treasury Dealer, and (ii)&nbsp;any other Primary Treasury Dealer selected by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined
by us, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the
third business day preceding such redemption date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per annum equal to
the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Notice of any redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each registered holder of the notes
to be redeemed by us or by the trustee on our behalf. Notice of redemption will be published in a daily newspaper of general circulation in the United States, and we will give notice of any such redemption to any exchange on which the notes are
listed. On and after any redemption date, interest will cease to accrue on the notes or portions thereof called for redemption. On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the
redemption price of and accrued interest on the notes to be redeemed on that date. If less than all of the notes are to be redeemed, the notes to be redeemed shall be selected by lot by The Depository Trust Company (&#147;DTC&#148;), in the case of
notes represented by a global security, or by the trustee by such method as the trustee deems to be fair and appropriate, in the case of notes that are not represented by a global security. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Further Issuances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We initially offered the notes in the
aggregate principal amount of $2,750,000,000. We may from time to time, without the consent of the holders of a series of notes, create and issue further notes of the same series having the same terms and conditions in all respects as the applicable
notes being offered hereby, except for the issue date, the issue price and the first payment of interest thereon. We will not issue any further notes unless such further notes have no more than a <I>de minimis </I>amount of original issue discount
or such issuance would constitute a &#147;qualified reopening&#148; for U.S. federal income tax purposes. Additional notes issued in this manner will be consolidated with and will form a single series with the notes being offered hereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We issued the notes of each series in the
form of one or more fully registered global securities. We deposited these global securities with, or on behalf of, DTC and register these securities in the name of DTC&#146;s nominee. Direct and indirect participants in DTC will record beneficial
ownership of the notes by individual investors. The transfer of ownership of beneficial interests in a global security will be effected only through records maintained by DTC or its nominee, or by participants or persons that hold through
participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Investors may elect to hold beneficial interests in the global securities through either DTC, Clearstream Banking S.A.
(&#147;Clearstream&#148;) or Euroclear Bank SA/NV (&#147;Euroclear&#148;) if they are participants in these systems, or indirectly through organizations which are participants in these systems. Beneficial interests in the global securities will be
held in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Upon receipt of any payment in respect of a global
security, DTC or its nominee will immediately credit participants&#146; accounts with amounts proportionate to their respective beneficial interests in the principal amount of the global security as shown in the records of DTC or its nominee.
Payments by participants to owners of beneficial interests in a global security held through participants will be governed by standing instructions and customary practices and will be the responsibility of those participants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">DTC holds securities of institutions that have accounts with it or its participants. Through its maintenance of an electronic book-entry system, DTC
facilitates the clearance and settlement of securities transactions among its participants and eliminates the need to deliver securities certificates physically. DTC&#146;s participants include securities brokers and dealers, including the
underwriters of this offering, banks, trust companies, clearing corporations and other organizations. DTC is owned by a number of its participants and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
by the New York Stock Exchange, Inc., the American Stock Exchange, Inc. and the National Association of Securities Dealers, Inc. Access to DTC&#146;s book-entry system is also available to others
such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly. DTC agrees with and represents to its participants that it will administer its book-entry
system in accordance with its rules and bylaws and requirements of law. The rules applicable to DTC and its participants are on file with the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream and Euroclear hold interests on behalf of their participants through customers&#146; securities accounts in Clearstream&#146;s and
Euroclear&#146;s names on the books of their respective depositaries, which in turn will hold interests in customers&#146; securities accounts in the depositaries&#146; names on the books of DTC. At the date of the prospectus supplement, Citibank,
N.A. acts as U.S. depositary for Clearstream and JPMorgan Chase Bank, N.A. acts as U.S. depositary for Euroclear, or, collectively, the &#147;U.S. Depositaries.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream holds securities for its participating organizations, or &#147;Clearstream Participants,&#148; and facilitates the clearance and settlement of
securities transactions between Clearstream Participants through electronic book-entry changes in accounts of Clearstream Participants, thereby eliminating the need for physical movement of certificates. Clearstream provides to Clearstream
Participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Clearstream is registered as a bank in Luxembourg and as such is subject to regulation by the Commission de Surveillance du Secteur Financier and the
Banque Centrale du Luxembourg, which supervise and oversee the activities of Luxembourg banks. Clearstream Participants are worldwide financial institutions, including underwriters, securities brokers and dealers, banks, trust companies and clearing
corporations, and may include the underwriters or their affiliates. Indirect access to Clearstream is available to other institutions that clear through or maintain a custodial relationship with a Clearstream Participant. Clearstream has established
an electronic bridge with Euroclear as the operator of the Euroclear System, or the &#147;Euroclear Operator,&#148; in Brussels to facilitate settlement of trades between Clearstream and the Euroclear Operator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions with respect to the notes of a series held beneficially through Clearstream will be credited to cash accounts of Clearstream Participants in
accordance with its rules and procedures, to the extent received by the U.S. Depositary for Clearstream. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear holds securities and book-entry
interests in securities for participating organizations, or &#147;Euroclear Participants&#148; and facilitates the clearance and settlement of securities transactions between Euroclear Participants, and between Euroclear Participants and
participants of certain other securities intermediaries through electronic book-entry changes in accounts of such participants or other securities intermediaries. Euroclear provides Euroclear Participants with, among other things, safekeeping,
administration, clearance and settlement, securities lending and borrowing, and related services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Euroclear Participants are investment banks,
securities brokers and dealers, banks, central banks, supranationals, custodians, investment managers, corporations, trust companies and certain other organizations and may include the underwriters or their affiliates.
<FONT STYLE="white-space:nowrap">Non-participants</FONT> in Euroclear may hold and transfer beneficial interests in a global security through accounts with a Euroclear Participant or any other securities intermediary that holds a book-entry interest
in a global security through one or more securities intermediaries standing between such other securities intermediary and Euroclear. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Distributions
with respect to notes of a series held beneficially through Euroclear will be credited to the cash accounts of Euroclear Participants in accordance with the Terms and Conditions, to the extent received by the U.S. Depositary for Euroclear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers between Euroclear Participants and Clearstream Participants will be effected in the ordinary way in accordance with their respective rules and
operating procedures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Cross-market transfers between DTC&#146;s participating organizations, or the &#147;DTC Participants,&#148; on the one hand,
and Euroclear Participants or Clearstream Participants, on the other hand, will be effected through DTC in accordance with DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by its U.S. Depositary; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. Depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global security in DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement applicable to DTC. Euroclear Participants and Clearstream Participants may not deliver
instructions directly to their respective U.S. Depositaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Due to time zone differences, the securities accounts of a Euroclear Participant or
Clearstream Participant purchasing an interest in a global security from a DTC Participant in DTC will be credited, and any such crediting will be reported to the relevant Euroclear Participant or Clearstream Participant during the securities
settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a
Euroclear Participant or Clearstream Participant to a DTC Participant will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or
Clearstream following DTC&#146;s settlement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The information in this section concerning DTC, Euroclear and Clearstream and their book-entry
systems has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy of that information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">None of
us, any of the underwriters and the trustee will have any responsibility for the performance by Euroclear or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
Clearstream or their respective participants of their respective obligations under the rules and procedures governing their operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Although DTC, Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of securities among participants of DTC,
Clearstream and Euroclear, they are under no obligation to perform or continue to perform such procedures and they may discontinue the procedures at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Initial settlement for the notes was made in immediately available funds.
Secondary market trading between DTC participants will occur in the ordinary way in accordance with DTC rules and will be settled in immediately available funds using DTC&#146;s <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement
System. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B><U>b. Base Prospectus &#150; March&nbsp;4, 2008 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Description of Debt Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As used in this &#147;Description of Debt Securities,&#148; &#147;debt securities&#148; means the debentures, notes, bonds, guarantees and other evidences
of indebtedness that GSK issues or that GSK Capital Inc. or GSK Capital plc (the &#147;finance subsidiaries&#148;) issues and GSK fully and unconditionally guarantees and, in each case, the trustee authenticates and delivers under the applicable
indenture. The debt securities will be our direct unsecured obligations and will rank equally and ratably without preference among themselves and at least equally with all of our other unsecured and unsubordinated indebtedness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities will be issued in one or more series under an indenture between GSK and Law Debenture Trust Company of New York, as trustee, or under
indentures among the finance subsidiaries, Law Debenture Trust Company of New York, as trustee (as successor to Citibank, N.A., pursuant to Instruments of Resignation, Appointment and Acceptance among the finance subsidiaries, the guarantor, Law
Debenture Trust Company of New York and Citibank, N.A.), and GSK, as guarantor. The indentures applicable to GSK, GSK Capital Inc. and GSK Capital plc will each be qualified under the Trust Indenture Act of 1939, as amended. In the following
discussion, we sometimes refer to these indentures collectively as the &#147;indentures.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">This &#147;Description of Debt Securities&#148;
briefly outlines the provisions of the indentures. The terms of the indentures will include both those stated in the indentures and those made part of the indentures by the Trust Indenture Act. The forms of the indentures have been filed as exhibits
to the registration statement of which this &#147;Description of Debt Securities&#148; forms a part, and you should read the indentures for provisions that may be important to you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not contain any covenants or other provisions designed to protect holders of the debt securities against a reduction in the
creditworthiness of GSK or the finance subsidiaries in the event of a highly leveraged transaction or that would prohibit other transactions that might adversely affect holders of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Issuances in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The indentures do not limit the amount of
debt securities that may be issued. The debt securities may be issued in one or more series with the same or various maturities, at a price of 100% of their principal amount or at a premium or a discount. Not all debt securities of any one series
need be issued at the same time, and, unless otherwise provided, any series may be reopened, without the consents of the holders of debt securities of that series, for issuances of additional debt securities of that series. Except in the limited
circumstances described below under &#147;&#151; Covenants &#151; Limitation on Liens,&#148; the debt securities will not be secured by any property or assets of GSK, as issuer or guarantor, or the finance subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The terms of any authorized series of debt securities will be described in a prospectus supplement. These terms will include some or all of the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the title, aggregate principal amount and denominations of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the date or dates on which principal will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the percentage of the principal amount at which the debt securities will be issued and whether the debt securities will be
&#147;original issue discount&#148; securities for U.S. federal income tax purposes. If original issue discount debt securities are issued (generally, securities that are issued at a substantial discount below their principal amount), the special
U.S. federal income tax and other considerations of a purchase of original issue discount debt securities will be described; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the rate or rates, which may be fixed or variable, at which the debt securities will bear interest; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the interest payment dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any optional or mandatory redemption terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether any sinking fund is required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the currency in which the debt securities will be denominated or principal, premium or interest will be payable, if other
than U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether the debt securities are to be issued as individual certificates to each holder or in the form of global certificates
held by a depositary on behalf of beneficial owners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">information describing any book-entry features; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the names and duties of any <FONT STYLE="white-space:nowrap">co-trustees,</FONT> depositaries, authenticating agents, paying
agents, transfer agents or registrars for any series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the applicability of the defeasance and covenant defeasance provisions described herein, or any modifications of those
provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any deletions from, modifications of or additions to the events of default or covenants with respect to the debt securities;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other terms, conditions, rights or preferences of the debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities that have a maturity of less than one year from their date of issue and in respect of which the proceeds are to be received by us in the
United Kingdom will have a minimum denomination of &pound;100,000 (or its equivalent in another currency). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement relating to any
series of debt securities may add to or change statements contained in the base prospectus. The prospectus supplement may also include, if applicable, a discussion of certain U.S. federal income tax and U.K. income tax considerations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>GSK Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities issued by the finance
subsidiaries will be fully and unconditionally guaranteed by GSK. If for any reason the applicable finance subsidiary does not make any required payment in respect of its debt securities when due, whether on the normal due date, on acceleration,
redemption or otherwise, GSK will cause the payment to be made to or to the order of the trustee. The holder of a guaranteed debt security will be entitled to payment under the applicable guarantee of GSK without taking any action whatsoever against
the finance subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Payment and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt
securities will be issued only as registered securities, which means that the name of the holder will be entered in a register that will be kept by the trustee or another agent appointed by us. Unless stated otherwise in a prospectus supplement, and
except as described under &#147;&#151; Book-Entry System&#148; below, payments of principal, interest and additional amounts, if any, will be made at the office of the paying agent or agents named in the prospectus supplement or by check mailed to
you at your address as it appears in the register. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless other procedures are described in a prospectus supplement and except as described under
&#147;&#151; Book Entry System&#148; below, you will be able to transfer registered debt securities at the office of the transfer agent or agents named in the prospectus supplement. You may also exchange registered debt securities at the office of
the transfer agent for an equal aggregate principal amount of registered debt securities of the same series having the same maturity date, interest rate and other terms as long as the debt securities are issued in authorized denominations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Neither we nor the trustee will impose any service charge for any transfer or exchange of a debt security; however, we may ask you to pay any taxes or
other governmental charges in connection with a transfer or exchange of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Debt securities may be issued under a book-entry system in the form of one or more global securities. The global securities will be registered in the name
of a depositary or its nominee and deposited with that depositary or its custodian. Unless stated otherwise in the prospectus supplement, The Depository Trust Company, New York, New York, or DTC, will be the depositary if a depositary is used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">DTC has advised us as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC is a limited-purpose trust company organized under the New York Banking Law, a &#147;banking organization&#148; within
the meaning of the New York Banking Law, a member of the Federal Reserve System, a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code and a &#147;clearing
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">
agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC was created to hold securities of its participants and to facilitate the clearance and settlement of securities
transactions, such as through transfers and pledges, among its participants in such securities through electronic book-entry changes to accounts of its participants, thereby eliminating the need for physical movement of securities certificates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">DTC&#146;s participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain
other organizations, some of whom (and/or their representatives) own DTC; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">access to DTC&#146;s book-entry system is also available to others, such as banks, brokers, dealers and trust companies that
clear through or maintain a custodial relationship with a participant, either directly or indirectly. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">According to DTC, the
foregoing information with respect to DTC has been provided to the financial community for informational purposes only and is not intended to serve as a representation, warranty or contract modification of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Following the issuance of a global security in registered form, the depositary will credit the accounts of its participants with the debt securities upon
our instructions. Only persons who hold directly or indirectly through financial institutions that are participants in the depositary can hold beneficial interests in the global securities. Since the laws of some jurisdictions require certain types
of purchasers to take physical delivery of such securities in definitive form, you may encounter difficulties in your ability to own, transfer or pledge beneficial interests in a global security. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">So long as the depositary or its nominee is the registered owner of a global security, we and the trustee will treat the depositary as the sole owner or
holder of the debt securities for purposes of the applicable indenture. Therefore, except as set forth below, you will not be entitled to have debt securities registered in your name or to receive physical delivery of certificates representing the
debt securities. Accordingly, you will have to rely on the procedures of the depositary and the participant in the depositary through whom you hold your beneficial interest in order to exercise any rights of a holder under the indenture. We
understand that under existing practices, the depositary would act upon the instructions of a participant or authorize that participant to take any action that a holder is entitled to take. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will make all payments of principal, interest and additional amounts, if any, on the debt securities to the depositary. It is expected that the
depositary will then credit participants&#146; accounts proportionately with these payments on the payment date and that the participants will in turn credit their customers&#146; accounts in accordance with their customary practices. Neither we nor
the trustee will be responsible for making any payments to participants or customers of participants or for maintaining any records relating to the holdings of participants and their customers, and you will have to rely on the procedures of the
depositary and its participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Global securities are generally not transferable. Physical certificates will be issued to beneficial owners in lieu
of a global security only in the special situations described in the sixth paragraph under the heading &#147;Legal Ownership of Debt Securities &#151; Global Securities&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We and the finance subsidiaries
have agreed in the indentures not to consolidate with or merge with or into any other person or convey or transfer all or substantially all of our respective properties and assets to any person (except that the finance subsidiaries may merge into
us), unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we or the applicable finance subsidiary, as the case may be, are the continuing person, or the successor expressly assumes
by supplemental indenture our obligations under the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the continuing person is a U.S. or U.K. company or is organized and validly existing under the laws of a jurisdiction that
is a member country of the Organisation for Economic Cooperation and Development (or any successor) and, if it is not a U.S. or U.K. company, the continuing person agrees by supplemental indenture to be bound by a covenant comparable to that
described below under &#147;&#151; Covenants &#151; Payment of Additional Amounts&#148; with respect to taxes imposed in the continuing person&#146;s jurisdiction of organization (in which case the continuing person will benefit from a redemption
option comparable to that described below under &#147;&#151; Optional Redemption for Tax Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the consolidation, merger or sale); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">immediately after the transaction, no default under the debt securities has occurred and is continuing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we deliver to the trustee an officer&#146;s certificate and, if neither we nor the applicable subsidiary are the continuing
person, an opinion of counsel, in each case stating, among other things, that the transaction and the supplemental indenture, if required, comply with these provisions and the indenture. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Payment of Additional Amounts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Payments
made by us under or with respect to the debt securities will be free and clear of and without withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any nature
whatsoever imposed or levied by or on behalf of the government of the United Kingdom or of any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax or (ii)&nbsp;the government of the United States
or any state or territory of the United States or by any authority or agency therein or thereof having the power to tax, which we refer to collectively as &#147;Taxes,&#148; unless we are required to withhold or deduct Taxes by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If we are required to withhold or deduct any amount for or on account of Taxes from any payment made with respect to the debt securities, we will pay such
additional amounts as may be necessary so that the net amount received by each holder (including additional amounts) after such withholding or deduction will not be less than the amount the holder would have received if the Taxes had not been
withheld or deducted; provided that no additional amounts will be payable with respect to Taxes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the existence of any present or former connection between such holder or beneficial
owner of the debt securities (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, trust, partnership or corporation)
and the United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor,
beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or business therein or
having or having had a permanent establishment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or
other governmental charges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">payable other than by withholding from payments of principal of or interest on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any
certification, identification, information, documentation or other reporting requirement to the extent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to
exemption from, or reduction in, the rate of deduction or withholding of such Taxes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">at least 30 days before the first payment date with respect to which such additional amounts shall be payable, we have
notified such recipient in writing that such recipient is required to comply with such requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed but for the presentation of a debt security (where presentation is required) for payment on
a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that are imposed on a payment to an individual and are required to be made pursuant to European Council Directive 2003/48/EC
or any other Directive implementing the conclusions of the ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, or any law implementing or complying with, or introduced in order to
conform to, such Directive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">that would not have been imposed if presentation for payment of the relevant debt securities had been made to a paying agent
other than the paying agent to which the presentation was made; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any combination of the foregoing items; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">nor shall additional amounts be paid with respect to any payment of the principal of or interest on any debt security to any such holder who is a fiduciary or a
partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled to
such additional amounts had it been the holder of the debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in each indenture that at least one paying agent for each series
of debt securities will be located outside the United Kingdom. We have also agreed that if we maintain a paying agent with respect to a particular series of debt securities in any member state of the European Union, we will maintain a paying agent
in at least one member state (other than the United Kingdom) that will not be obliged to withhold or deduct taxes pursuant to any law implementing European Council Directive 2003/48/EC or any other Directive implementing the conclusions of the
ECOFIN Council meeting of November <FONT STYLE="white-space:nowrap">26-27,</FONT> 2000 on the taxation of savings income, provided there is at least one </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
member state that does not require a paying agent to withhold or deduct pursuant to such Directive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligation to pay additional amounts if and when due will survive the termination of the indentures and the payment of all amounts in respect of the
debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Limitation on Liens </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We have agreed in the indentures not to incur or assume (or permit any of our subsidiaries to incur or assume) any lien on or with respect to any of our
or our subsidiaries&#146; property, assets or revenues, present or future, to secure any relevant indebtedness (as this term is defined below) without making (or causing our subsidiaries to make) effective provision for securing the debt securities
equally and ratably with such relevant indebtedness as to such property, assets or revenues, for as long as such relevant indebtedness is so secured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The
restrictions on liens will not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens arising by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of any person, which liens are existing at the time such person becomes a subsidiary;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">liens on property, assets or revenues of a person existing at the time such person is merged with or into or consolidated
with us or any of our subsidiaries or at the time of a sale, lease or other disposition to us of the properties of a person as an entirety or substantially as an entirety. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">For purposes of the limitation on liens covenant, the term &#147;relevant indebtedness&#148; means any of our debt that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is in the form of or represented by bonds, notes, loan stock, depositary receipts or other securities issued (otherwise than
to constitute or represent advances made by banks or other lending institutions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">is denominated in, or confers any right of payment by reference to, any currency other than the currency of the country in
which the issuer of the indebtedness has its principal place of business, or is denominated in or by reference to the currency of such country but more than 20% of which is placed or offered for subscription or sale by or on behalf of, or by
agreement with, the issuer outside such country; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">at its date of issue is, or is intended by the issuer to become, quoted, listed, traded or dealt in on any stock exchange, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or other securities market. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:9pt; font-family:ARIAL"><B><I>Additional Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may be subject
to additional covenants, including restrictive covenants in respect of a particular series of debt securities. Such additional covenants will be set forth in the applicable prospectus supplement and, to the extent necessary, in the supplemental
indenture or board resolution relating to that series of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Optional Redemption for Tax Reasons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may redeem any series of debt securities in whole but not in part at any time, on giving not less than 30 nor more than 60 days&#146; notice of such
redemption, at a redemption price equal to the principal amount plus accrued interest, if any, to the date fixed for redemption (except in the case of discounted debt securities, which may be redeemed at the redemption price specified by the terms
of each series of such debt securities), if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine that, as a result of any change in or amendment to the laws or any regulations or rulings promulgated
thereunder of the United Kingdom (or of any political subdivision or taxing authority thereof) or the United States (or of any political subdivision or taxing authority thereof), or any change in the application or official interpretation of such
laws, regulations or rulings, or any change in the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or
amendment becomes effective on or after the issue date or such other date specified in the debt securities of that series: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we would be required to pay additional amounts (as described under &#147;&#151; Covenants &#151; Payment of Additional
Amounts&#148; above) with respect to that series of debt securities on the next succeeding interest payment date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to us; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the
applicable finance subsidiary directly from the guarantor (or any affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the applicable finance subsidiary or the guarantor (or any affiliate);
or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we determine, based upon an opinion of independent counsel of recognized standing that, as a result of any action taken by
any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom (or any political subdivision or taxing authority thereof) or the United States (or any political subdivision or taxing
authority thereof) (whether or not such action was taken or brought with respect to GSK, as issuer or guarantor, or the applicable finance subsidiary, as the case may be), which action is taken or brought on or after the issue date or such other
date specified in the debt securities of that series, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest
date on which we would be obligated to pay such additional amounts. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We will also pay to each holder, or make available for payment
to each such holder, on the redemption date any additional amounts resulting from the payment of such redemption price. Prior to the publication of any notice of redemption, we will deliver to the trustee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an officer&#146;s certificate stating that we are entitled to effect a redemption and setting forth a statement of facts
showing that the conditions precedent of the right so to redeem have occurred; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an opinion of counsel to the effect that the conditions specified above have been satisfied. Any notice of redemption will
be irrevocable once we deliver the officer&#146;s certificate to the trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless otherwise specified in a prospectus supplement, an event of default with respect to a series of debt securities occurs upon: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of the principal (or premium, if any) of any debt security of that series when due (including as a
sinking fund installment), and, in the case of technical or administrative difficulties, the continuance of that default for more than two business days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in payment of interest on, or any additional amounts payable in respect of, any debt security of that series when
due and payable, and the continuance of that default for 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default in performing any other covenant in the indenture applicable to that series for 60 days after the receipt of written
notice from the trustee or from the holders of 25% in principal amount of the debt securities of that series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">default under any bond, debenture, note or other evidence of indebtedness for money borrowed of GSK or either finance
subsidiary, as the case may be (not including any indebtedness for which recourse is limited to property purchased), having in any particular case an outstanding principal amount in excess of $25,000,000 (or its equivalent in any other currency)
where any such failure results in such indebtedness being accelerated and becoming due and payable prior to its stated maturity and such acceleration shall not have been rescinded or annulled or such indebtedness shall not have been discharged;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">certain events of bankruptcy, insolvency or reorganization of GSK or either finance subsidiary, as the case may be;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">any other event of default provided with respect to that particular series of debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Any additional or different events of default applicable to a particular series of debt securities will be described in the prospectus supplement relating
to such series. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">An event of default with respect to a particular series of debt securities will not necessarily constitute an event of default with
respect to any other series of debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The trustee may withhold notice to the holders of debt securities of any default (except in the
payment of principal, premium or interest) if it, in good faith, considers such withholding of notice to be in the best interests of the holders. A default is any event which is an event of default described above or would be an event of default but
for the giving of notice or the passage of time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default occurs and continues, the trustee or the holders of the aggregate principal
amount of the debt securities specified below may require us to repay immediately, or accelerate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the entire principal of the debt securities of such series; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">if the debt securities are original issue discount securities, such portion of the principal as may be described in the
applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If the event of default occurs because of a default in a payment of principal or interest on the
debt securities of any series, then the trustee or the holders of at least 25% of the aggregate principal amount of debt securities of that series can accelerate that series of debt securities. If the event of default occurs because of a failure to
perform any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
other covenant in the applicable indenture or any covenant for the benefit of one or more, but not all, of the series of debt securities, then the trustee or the holders of at least 25% of the
aggregate principal amount of debt securities of all series affected, voting as one class, can accelerate all of the affected series of debt securities. If the event of default occurs because of bankruptcy proceedings, then all of the debt
securities under the indenture will be accelerated automatically. Therefore, except in the case of a default on a payment of principal or interest on the debt securities of your series or a default due to our bankruptcy or insolvency, it is possible
that you may not be able to accelerate the debt securities of your series because of the failure of holders of other series to take action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The
holders of a majority of the aggregate principal amount of the debt securities of all affected series, voting as one class, can rescind this accelerated payment requirement or waive any past default or event of default or allow noncompliance with
any provision of the applicable indenture. However, they cannot waive a default in payment of principal of, premium, if any, or interest on any of the debt securities when due otherwise than as a result of acceleration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">After an event of default, the trustee must exercise the same degree of care a prudent person would exercise under the circumstances in the conduct of her
or his own affairs. Subject to these requirements, the trustee is not obligated to exercise any of its rights or powers under the applicable indenture at the request, order or direction of any holders, unless the holders offer the trustee reasonable
indemnity. If they provide this reasonable indemnity, the holders of a majority in principal amount of all affected series of debt securities, voting as one class, may direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any power conferred upon the trustee, for any series of debt securities. However, the trustee may refuse to follow any direction that conflicts with law or the indenture or is unduly prejudicial to the rights
of other holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">No holder will be entitled to pursue any remedy with respect to the indenture unless the trustee fails to act for 60 days after it
is given: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">notice of default by that holder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">a written request to enforce the indenture by the holders of not less than 25% in principal amount of all outstanding debt
securities of any affected series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an indemnity to the trustee, satisfactory to the trustee; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">and during this <FONT STYLE="white-space:nowrap">60-day</FONT> period the holders of a majority in principal amount of all outstanding debt securities of such affected
series do not give a direction to the trustee that is inconsistent with the enforcement request. These provisions will not prevent any holder of debt securities from enforcing payment of the principal of (and premium, if any) and interest on the
debt securities at the relevant due dates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If an event of default with respect to a series of debt securities occurs and is continuing, the trustee
will mail to the holders of those debt securities a notice of the event of default within 90 days after it occurs. However, except in the case of a default in any payment in respect of a series of debt securities, the trustee shall be protected in
withholding notice of an event of default if it determines in good faith that this is in the interests of the holders of the relevant debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Modification of the Indentures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In general, rights and
obligations of us and the holders under the indentures may be modified if the holders of a majority in aggregate principal amount of the outstanding debt securities of each series affected by the modification consent to such modification. However,
each of the indentures provides that, unless each affected holder agrees, an amendment cannot: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any adverse change to any payment term of a debt security such as extending the maturity date, extending the date on
which we have to pay interest or make a sinking fund payment, reducing the interest rate, reducing the amount of principal we have to repay, changing the currency in which we have to make any payment of principal, premium or interest, modifying any
redemption or repurchase right, or right to convert or exchange any debt security, to the detriment of the holder and impairing any right of a holder to bring suit for payment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">waive any payment default; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">reduce the percentage of the aggregate principal amount of debt securities needed to make any amendment to the applicable
indenture or to waive any covenant or default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">make any other change to the amendment provisions of the applicable indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">However, if we and the trustee agree, the applicable indenture may be amended without notifying any holders or seeking their consent if the amendment does
not materially and adversely affect any holder. We and the trustee are permitted to make modifications and amendments to the applicable indenture without the consent of any holder of debt securities for any of the following purposes: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to cure any ambiguity, defect or inconsistency in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with sections of the indenture governing when we may merge and substituted obligors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to comply with any requirements of the U.S. Securities and Exchange Commission in connection with the qualification of the
indenture under the Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to evidence and provide for the acceptance by a successor trustee of appointment under the indenture with respect to the
debt securities of any or all series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to establish the form or forms or terms of the debt securities of any series or of the coupons appertaining to such debt
securities as permitted under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to provide for a further guarantee from a third party on outstanding debt securities of any series and the debt securities
of any series that may be issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to change or eliminate any provision of the indenture; provided that any such change or elimination will become effective
only when there are no outstanding debt securities of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to supplement any of the provisions of the indenture to such extent as will be necessary to permit or facilitate the
defeasance and discharge of any series of debt securities pursuant to the indenture; provided that any such action will not adversely affect the interests of the holders of such or any other series of debt securities in any material respect; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">to make any change that does not materially and adversely affect the rights of any holder of the debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The term defeasance means
discharge from some or all of the obligations under the indentures. If we deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a
redemption date of the debt securities of a particular series, then at our option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will be discharged from our respective obligations with respect to the debt securities of such series; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we will no longer be under any obligation to comply with the restrictive covenants, if any, contained in the applicable
indenture and any supplemental indenture or board resolution with respect to the debt securities of such series, and the events of default relating to failures to comply with covenants will no longer apply to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">If this happens, the holders of the debt securities of the affected series will not be entitled to the benefits of the applicable indenture except for
registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities. Instead, the holders will only be able to rely on the deposited funds or obligations for payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We must deliver to the trustee an opinion of counsel to the effect that the deposit and related defeasance would not cause the holders of the debt
securities to recognize income, gain or loss for U.S. federal income tax purposes. We may, in lieu of an opinion of counsel, deliver a ruling to such effect received from or published by the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Substitution of Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We may at our option at any time,
without the consent of any holders of debt securities, cause GSK or any other subsidiary of GSK to assume the obligations of the applicable finance subsidiary under any series of debt securities, <I>provided </I>that the new obligor executes a
supplemental indenture in which it agrees to be bound by the terms of those debt securities and the relevant indenture. If the new obligor is not a U.S. or U.K. company, it must be organized and validly existing under the laws of a jurisdiction that
is a member country of the Organisation for Economic Cooperation and Development (or any successor) and it must also agree in the supplemental indenture to be bound by a covenant comparable to that described above under &#147;&#151; Covenants &#151;
Payment of Additional Amounts&#148; with respect to taxes imposed in its jurisdiction of organization (in which case the new obligor will benefit from a redemption option comparable to that described above under &#147;&#151; Optional Redemption for
Tax Reasons&#148; in the event of changes in taxes in that jurisdiction after the date of the substitution). In the case of such a substitution, the applicable finance subsidiary will be relieved of any further obligation under the assumed series of
debt securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">For U.S. federal income tax purposes, a substitution of obligors as described above generally would be treated as a deemed taxable
exchange of debt securities for new debt securities issued by the new obligor. As discussed further in the applicable prospectus supplement, a United States person who holds debt securities or owns a beneficial interest therein generally will
recognize capital gain or loss in an amount equal to the difference between the issue price </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
of the new debt securities and such person&#146;s adjusted tax basis in the debt securities. Such persons should consult their own tax advisors regarding the tax consequences of a deemed taxable
exchange in the event of a substitution of obligors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Law Debenture Trust Company of New York will be the trustee. The trustee will be required to perform only those duties that are specifically set forth in
the indentures, except when a default has occurred and is continuing with respect to the debt securities. After a default, the trustee must exercise the same degree of care that a prudent person would exercise under the circumstances in the conduct
of her or his own affairs. Subject to these requirements, the trustee will be under no obligation to exercise any of the powers vested in it by the indentures at the request of any holder of debt securities unless the holder offers the trustee
reasonable indemnity against the costs, expenses and liabilities that might be incurred by exercising those powers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The debt securities, the related guarantees and the indentures will be governed by and construed in accordance with the laws of the State of New York.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Legal Ownership of Debt Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>&#147;Street
Name&#148; and Other Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">We generally will not recognize investors who hold debt securities in accounts at banks or brokers as legal
holders of those debt securities. Holding securities in accounts at banks or brokers is called holding in &#147;street name.&#148; If an investor holds debt securities in street name, we recognize only the bank or broker or the financial institution
the bank or broker uses to hold the debt securities. These intermediary banks, brokers and other financial institutions pass along principal, interest and other payments on the debt securities, either because they agree to do so in their customer
agreements or because they are legally required to do so. If you hold debt securities in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it handles payments and notices with respect to securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would handle voting if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how and when you should notify it to exercise on your behalf any rights or options that may exist under the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">whether and how you can instruct it to send you securities registered in your own name so you can be a direct holder as
described below; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">how it would pursue rights under the debt securities if there were a default or other event triggering the need for holders
to act to protect their interests. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Registered Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Our obligations, as well as the obligations of the trustee and those of any third parties employed by us or the trustee, extend only to persons who are
registered as holders of debt securities. As noted above, we do not have obligations to you if you hold in street name or through other indirect means, either because you choose to hold debt securities in that manner or because the debt securities
are issued in the form of global securities as described below. For example, once we make payment to the registered holder, we have no further responsibility for the payment even if that holder is legally required to pass the payment along to you as
a street name customer but does not do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">A global security is a special type of indirectly held security. If we choose to issue debt securities in the form of global securities, the ultimate
beneficial owners of the debt securities will be indirect holders. We do this by requiring that the global security be registered in the name of a financial institution we select and by requiring that the debt securities represented by the global
security not be registered in the name of any other holder except in the special situations described below. The financial institution that acts as the sole registered holder of the global security is called the depositary. Any person wishing to own
a debt security may do so indirectly through an account with a broker, bank or other financial institution that in turn has an account with the depositary. The prospectus supplement will indicate whether your series of debt securities will be issued
only as global securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Transfers of debt securities represented by the global security will be made only on the records of the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">
depositary or its nominee by transferring such debt securities from the account of one broker, bank or financial institution to the account of another broker, bank or financial institution. These
transfers are made electronically only and are also known as book- entry transfers. Securities in global form are sometimes also referred to as being in book-entry form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">As an indirect holder, your rights relating to a global security will be governed by the account rules of your broker, bank or financial institution and
of the depositary, as well as general laws relating to securities transfers. We will not recognize you as a holder of debt securities and instead will deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">You should be aware that if debt securities are issued only in the form of a global security: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you cannot have debt securities registered in your own name; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you cannot receive physical certificates for your interest in the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you will be a street name holder and must look to your own broker, bank or financial institution for payments on the debt
securities and protection of your legal rights relating to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">you may not be able to sell interests in the debt securities to some insurance companies and other institutions that are
required by law to own securities in the form of physical certificates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary&#146;s policies will govern payments, transfers, exchanges and other matters relating to your indirect
interest in the global security. We and the trustee will have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in the global security. We and the trustee also will not supervise the
depositary in any way; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary will require that indirect interests in the global security be purchased or sold within its system using <FONT
STYLE="white-space:nowrap">same-day</FONT> funds for settlement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In a few special situations described below, the global security
will terminate and the indirect interests in it will be exchanged for registered debt securities represented by physical certificates. After that exchange, the choice of whether to hold debt securities in registered form or in street name will be up
to you. You must consult your broker, bank or financial institution to find out how to have your interests in debt securities transferred to your name, so that you will be a registered holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">Unless we specify otherwise in the prospectus supplement, the special situations for termination of a global security are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">when the depositary notifies us that it is unwilling or unable to continue as depositary and we do not or cannot appoint a
successor depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">the depositary ceases to be a clearing agency registered under the Exchange Act and we do not appoint a successor depositary
within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">an event of default has occurred and is continuing and beneficial owners representing a majority in principal amount of the
applicable series of debt securities have advised the depositary to cease acting as the depositary; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">we decide we do not want to have the debt securities of that series represented by a global security. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">The prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of debt
securities covered by the prospectus supplement. When a global security terminates, the depositary (and not us or the trustee) is responsible for deciding the names of the institutions that will be the initial registered holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>The Term &#147;Holder&#148; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">In the descriptions of the debt
securities included herein, when we refer to the &#147;holder&#148; of a given debt security as being entitled to certain rights or payments, or being permitted to take certain actions, we are in all cases referring to the registered holder of the
debt security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:ARIAL">While you would be the registered holder if you held a certificated security registered in your name, it is likely that the holder
will actually be either the broker, bank or other financial institution where you have your street name account, or, in the case of a global security, the depositary. If you are an indirect holder, you will need to coordinate with the institution
through which you hold your interest in a debt security in order to determine how the provisions involving holders described in this prospectus and any prospectus supplement will actually apply to you. For example, if the debt security in which you
hold a beneficial interest in street name can be repaid at the option of the holder, you cannot exercise the option yourself by following the procedures described in the prospectus supplement. Instead, you would need to cause the institution through
which you hold your interest to take those actions on your behalf. Your institution may have procedures and deadlines different from or additional to those described in the prospectus supplement relating to the debt security. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>d382677dex48.htm
<DESCRIPTION>EX-4.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND
(II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SECOND AMENDMENT AGREEMENT</B> (this
&#147;<U>Agreement</U>&#148;) is made and entered into as of the 1st day of June 2022, by and among (1)&nbsp;Pfizer Inc., a Delaware corporation (&#147;<U>Seller Parent</U>&#148;), (2) GSK plc, a public limited liability company incorporated under
the laws of England and Wales (&#147;<U>Purchaser Parent</U>&#148;, and together with Seller Parent, the &#147;<U>Parents</U>&#148;), (3) GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited, a company incorporated under the laws of England
and Wales (&#147;<U>New Purchaser</U>&#148;), and (4)&nbsp;Haleon plc, a company incorporated under the laws of England and Wales (&#147;<U>New Purchaser Parent</U>&#148;, and together with New Purchaser, Seller Parent and Purchaser Parent, the
&#147;<U>Parties</U>&#148;). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the SAPA (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Seller Parent, Purchaser Parent and GlaxoSmithKline Consumer Healthcare Holdings Limited, a company incorporated under the
laws of England and Wales (&#147;<U>Initial Purchaser</U>&#148;), entered into that certain Stock and Asset Purchase Agreement, dated as of December&nbsp;19, 2018, and amended by that certain amendment agreement, dated as of July&nbsp;31, 2019, by
and among Seller Parent, Purchaser Parent, Initial Purchaser and New Purchaser (the &#147;<U>SAPA Amendment Agreement</U>&#148;) (as so amended, the &#147;<U>SAPA</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Closing under the SAPA occurred on July&nbsp;31, 2019; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Seller Parent, Purchaser Parent, New Purchaser Parent and New Purchaser desire to amend the SAPA and agree to certain other
arrangements, in each case as set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants and agreements
set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Conditions Precedent and Effective Date</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Agreement, other than those arising under Sections 1, 13(a) and 13(c), shall be
conditional upon the passing of the Related Party Transactions Resolution at the general meeting of Purchaser Parent Shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the approval of the Related Party Transactions Resolution is not satisfied in accordance with clause
(a)&nbsp;above by 31&nbsp;December 2022, or if Purchaser Parent abandons the Separation Transaction (as defined in the Demerger Agreement) by providing notice of the same in writing to New Purchaser Parent and Seller Parent at any time prior to the
Demerger Time, this Agreement shall automatically terminate and be of no further force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be effective from the Demerger Time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Section&nbsp;1: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Related Party Transactions Resolution</B>&#148; means the ordinary resolution numbered 2 set out in
the notice of general meeting of Purchaser Parent, which is set out in the Circular; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Purchaser Parent Shareholders</B>&#148; means holders of ordinary shares of 25 pence each in the share
capital of Purchaser Parent, from time to time; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Circular</B>&#148; means the circular to be dated with the Posting Date and to be sent to the
shareholders of Purchaser Parent in connection with the proposed demerger of the predominant part of Purchaser Parent&#146;s interest in the consumer healthcare business operated by New Purchaser and its subsidiaries, including a notice of general
meeting of Purchaser Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Posting Date</B>&#148; means the date of this Agreement (or such other date as may be determined by
Purchaser Parent and notified to New Purchaser Parent and Seller Parent as the date for the issue and dispatch of the Circular). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax Matters </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A new Section 6.5(m) shall be added to Article VI of the SAPA as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#147;(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Purchaser Parent hereby guarantees, as a primary obligor and not as a surety, the full and punctual payment
and performance of the obligations of Purchaser under Section 6.5(c) of this Agreement. This guarantee shall be a full, unconditional, irrevocable, absolute and continuing guarantee of payment and performance (and not just of collection) of the
obligations of Purchaser under Section 6.5(c) (the &#147;Guaranteed Tax Obligations&#148;). If Purchaser fails, for any reason, to perform or pay any Guaranteed Tax Obligation, in whole or in part, upon becoming due, New Purchaser Parent shall
promptly pay to Seller Parent or Purchaser Parent, as applicable, by wire transfer of immediately available funds the amount of such Guaranteed Tax Obligation due and unpaid by Purchaser. New Purchaser Parent shall pay such Guaranteed Tax Obligation
within five (5) Business Days of receipt of demand for payment from Seller Parent or Purchaser Parent, as applicable. Seller Parent or Purchaser Parent may enforce New Purchaser Parent&#146;s obligations under this Section 6.5(m) without first suing
Purchaser or joining Purchaser in any suit against New Purchaser Parent, or enforcing any rights and remedies against Purchaser, or otherwise pursuing or asserting any claims or rights against Purchaser. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Purchaser Parent hereby represents and warrants to Seller Parent and Purchaser Parent that New Purchaser
Parent is ready, able, and willing to fully perform, and otherwise be responsible for, any and all Guaranteed Tax Obligations.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Access to Records</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A new Section&nbsp;6.8(d) shall be added to Article VI of the SAPA as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;(d)&nbsp;&nbsp;&nbsp;&nbsp;The Parties acknowledge and agree that, to the extent that any member of the GSK Group or any member of the
JVCo Group has any rights or obligations under the Long Term Access Agreement in relation to access to or retention of any Retained Records (as defined in the Long Term Access Agreement), each of (i)&nbsp;the Purchaser Parent and its Affiliates (for
the avoidance of doubt, other than any member of the JVCo Group), on the one hand, and (ii)&nbsp;Purchaser and its Affiliates (for the avoidance of doubt, other than any member of the GSK Group), on the other hand, shall have no further obligations
or Liabilities as between each other under this Section&nbsp;6.8 on or after the LTAA Commencement Date in respect of such Retained Records (as defined under the Long Term Access Agreement), without prejudice to the respective rights and obligations
of such Parties prior to the LTAA Commencement Date.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Business IP and Registration Transfers</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.10 of the SAPA shall be amended and restated in its entirety to state: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Section 6.10 <U>Transfer of Business IP and Registrations</U>. Notwithstanding anything to the contrary in this Agreement or any
Ancillary Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) until the Demerger Time, Purchaser Parent shall be responsible for preparing and filing all
instruments and documents necessary to effect the assignment of the Business IP that is owned by Seller Parent or its Subsidiaries, Product Registrations and Manufacturing Registrations to Purchaser and its Affiliates, including all costs and
expenses of preparing and recording country-specific assignments and legalization of signatures (where required); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
following the Demerger Time, Purchaser shall be responsible for preparing and filing all instruments and documents necessary to effect the assignment of the Business IP that is owned by Seller Parent or its Subsidiaries, Product Registrations and
Manufacturing Registrations to Purchaser and its Affiliates, including all costs and expenses of preparing and recording country-specific assignments and legalization of signatures (where required); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) subject to <U>Section</U><U></U><U>&nbsp;2.2</U> and <U>Section</U><U></U><U>&nbsp;6.4</U>, Seller Parent shall, and shall
cause its Affiliates to, cooperate with the foregoing as set forth herein and in <U>Section</U><U></U><U>&nbsp;6.4</U>; provided that, notwithstanding anything to the contrary herein, such obligation of Seller Parent to cooperate shall expire
twenty-four (24)&nbsp;months following the Closing Date.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Guarantee Release</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Sections 6.13(c) and (d)&nbsp;shall be added to Article VI of the SAPA as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;(c)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting Section&nbsp;6.13(d) in any respect, Purchaser shall use its reasonable best efforts to cause
itself, one of its Affiliates or Subsidiaries to be substituted in all respects for the Sellers and any of their respective Affiliates and for the Sellers and their respective Affiliates to be released, effective as of the Demerger Time, in respect
of all Liabilities and obligations of the Sellers and any of their respective Affiliates under or related to each of the Seller Parent Demerger Guarantees and Seller Parent Demerger LCs and the Sellers shall reasonably cooperate in Purchaser&#146;s
efforts. For any Seller Parent Demerger Guarantee or Seller Parent Demerger LC for which Purchaser or any of its Affiliates, as applicable, is not substituted in all respects for the Sellers and their respective Affiliates (or for which the Sellers
and their respective Affiliates are not released), effective as of the Demerger Time, Purchaser shall continue to use its reasonable best efforts, and shall cause its Affiliates to use their reasonable best efforts, to effect such substitution and
release after the Demerger Time, and the Sellers shall continue to reasonably cooperate in Purchaser&#146;s efforts; provided that none of Sellers or any of their Affiliates shall have any obligation to make payments or incur any costs or expenses,
grant any concession or incur any other Liability in connection with such cooperation pursuant to this Section&nbsp;6.13 except to the extent Purchaser agrees to promptly reimburse Sellers and their Affiliates, or agrees to fully indemnify the
Sellers and their Affiliates for any such Liabilities to Seller Parent&#146;s reasonable satisfaction, as applicable. Without limiting the foregoing, neither Purchaser nor any of its Affiliates shall extend, renew, increase its obligations under or
transfer to a third party any Contract containing or underlying a Seller Parent Demerger Guarantee or Seller Parent Demerger LC or any Contract to which any Seller Parent Demerger Guarantee or Seller Parent Demerger LC relates or pursuant to which
any Seller Parent Demerger Guarantee or Seller Parent Demerger LC was issued or required to be issued unless, prior to or concurrently with such extension, renewal, increase or transfer, Purchaser or an Affiliate of Purchaser is substituted in all
respects for the Sellers and each of their respective Affiliates, and the Sellers and their respective Affiliates are released, in respect of all Liabilities and obligations of the Sellers and each of their respective Affiliates under or in respect
of such Seller Parent Demerger Guarantee or Seller Parent Demerger LC. In no event shall Seller Parent or any of its Affiliates be obligated to pay any money to any Person to effect the substitutions described in this Section&nbsp;6.13(c). The
Parties agree that neither Seller Parent nor any of the Retained Subsidiaries will have any obligation to renew any Seller Parent Demerger LCs after the expiration of any such letter of credit. Neither the Seller Demerger Parent Guarantees nor the
Seller Parent Demerger LCs shall be deemed Purchased Assets hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting Section&nbsp;6.13(c) in
any respect, from and after the Demerger Time, Purchaser and its Subsidiaries, including the Conveyed Subsidiaries (and their Subsidiaries), jointly and severally, shall indemnify and hold harmless the Seller Parent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Indemnified Parties against any Liabilities that the Sellers or any of their respective Affiliates suffer, incur or are liable for by reason of or arising out of or in consequence of (i)&nbsp;the
Sellers or any of their respective Affiliates issuing, making payment under, being required to pay or reimburse the issuer of or any other Person in connection with, or being a party to, any Seller Parent Demerger Guarantee or Seller Parent Demerger
LC, (ii)&nbsp;any claim or demand for payment made on the Sellers or any of their respective Affiliates with respect to any Seller Parent Demerger Guarantee or Seller Parent Demerger LC or (iii)&nbsp;any Action by any Person who is or claims to be
entitled to the benefit of or claims to be entitled to payment, reimbursement or indemnity with respect to any Seller Parent Demerger Guarantee or Seller Parent Demerger LC.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Section&nbsp;6.13(e) shall be added to Article VI of the SAPA as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;(e)&nbsp;&nbsp;&nbsp;&nbsp;The Parties acknowledge and agree that each of (i)&nbsp;the Purchaser Parent and its Affiliates (other than
any member of the JVCo Group) on one hand, and (ii)&nbsp;Purchaser and its Affiliates (other than any member of the GSK Group) on the other hand, shall have no further obligations or Liabilities solely as between each other under this
Section&nbsp;6.13 on and from the Demerger Time, including any obligations on Purchaser Parent to reasonably cooperate with Purchaser&#146;s efforts in accordance with the provisions set out in Section&nbsp;6.13(a), without prejudice to the
respective rights and obligations of such Parties prior to the Demerger Time and, for the avoidance of doubt, without prejudice to Purchaser&#146;s and its Affiliates&#146; continuing obligations to Seller Parent and its Subsidiaries
hereunder.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following new defined terms shall be inserted in alphabetical order in Section&nbsp;1.1 of the SAPA:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Seller Parent Demerger Guarantee</U>&#148; means all obligations of Seller Parent or any of the Retained
Subsidiaries under any Contract, instrument or other commitment, obligation or arrangement (other than Seller Parent Demerger LCs) or other obligation in existence as of the Demerger Time in respect of the New Consumer Healthcare Business, any
Consumer Healthcare Group Company (as defined in the Demerger Agreement) or any Liabilities or obligations of any Consumer Healthcare Group Company for which Seller Parent or any of the Retained Subsidiaries is or may be liable, as guarantor,
indemnitor, original tenant, primary obligor, Person required to provide financial support or collateral in any form whatsoever, or otherwise (including by reason of performance guarantees).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Seller Parent Demerger LC</U>&#148; means all letters of credit issued by or for the account of Seller Parent or the Retained
Subsidiaries on behalf of or in favor of any Consumer Healthcare Group Company or the New Consumer Healthcare Business in existence as of the Demerger Time, and all obligations (including reimbursement obligations) of Seller Parent or the Retained
Subsidiaries in respect of the foregoing.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Litigation Notices and Cooperation</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Section&nbsp;6.17(d) shall be added to Article VI of the SAPA as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#147;(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the Demerger Time: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Seller Parent shall not be required to comply with its notification obligations to Purchaser Parent
under Section&nbsp;6.17(b)(iii); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Purchaser Parent shall not be required to comply with its
notification obligations to Seller Parent under Section&nbsp;6.17(b)(iv); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Seller Parent shall not be required to comply
with its cooperation and access obligations under Section&nbsp;6.17(c) with respect to Purchaser Parent; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Purchaser Parent shall not be required to comply with its cooperation and access obligations under
Section&nbsp;6.17(c) with respect to Seller Parent, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in each case, without prejudice to the respective rights and obligations of such
Parties (i)&nbsp;prior to the Demerger Time and (ii)&nbsp;with respect to Purchaser and its Affiliates.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnity for New Consumer Healthcare Business</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;7.2 of the SAPA shall be amended and restated in its entirety to state: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Section 7.2 <U>Indemnification by Purchaser</U>. Subject to the provisions of this <U>Article VII</U>, from and after the Closing,
Purchaser agrees to indemnify and hold harmless the Seller Parent Indemnified Parties and the Purchaser Parent Indemnified Parties (collectively, the &#147;<U>Parent Indemnified Parties</U>&#148;) (a) from and against any and all Losses (other than
Taxes arising out of a Tax Claim, which are the subject of <U>Section</U><U></U><U>&nbsp;6.5(d)</U>) that any such Parent Indemnified Party suffers or incurs to the extent resulting from (i)&nbsp;any Assumed Liability; (ii)&nbsp;any Purchaser
Liability; or (iii)&nbsp;any New Consumer Healthcare Business Liability, and (b)&nbsp;from and against any and all Losses (other than Taxes arising out of a Tax Claim, which are the subject of <U>Section</U><U></U><U>&nbsp;6.5(d)</U>) that any such
Parent Indemnified Party suffers or incurs to the extent resulting from any breach following the Closing by Purchaser of any covenant or agreement expressly made by Purchaser in this Agreement or in any Ancillary Implementing Agreement, in its
capacity as a Party hereto (and not in its capacity as an Affiliate or Subsidiary of Purchaser Parent), which covenant or agreement by its terms contemplates actions or imposes obligations following the Closing, <U>provided</U> that to the extent
that any of the Parent Indemnified Parties have a claim under clause 14.2 (<I>Indemnification</I>) of the Asset Transfer Framework Agreement, such Parent Indemnified Party shall have no claim, and the Purchaser shall have no liability, under this
Section&nbsp;7.2 in respect of the same Loss.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following new defined terms shall be inserted in alphabetical order in Section&nbsp;1.1 of the SAPA:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Asset Transfer Framework Agreement</U>&#148; means the asset transfer framework agreement entered into
between Purchaser Parent, Purchaser and Initial Purchaser on or about 1 June 2022.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>New Consumer Healthcare
Business</U>&#148; means the past, present or future ownership, operation, use or conduct following the Closing by, or for the benefit of, Purchaser and its Affiliates (for the avoidance of doubt, excluding the GSK Group) of the Business and the
Purchaser Business, including, for the avoidance of doubt, any extensions, amendments, additions, acquisitions or developments to such businesses (for the avoidance of doubt, whether pursuant to the Asset Transfer Framework Agreement or
otherwise).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>New Consumer Healthcare Business Liability</U>&#148; means any and all Liabilities to the extent
resulting from or arising out of the New Consumer Healthcare Business by, or for the benefit of, Purchaser and its Affiliates (for the avoidance of doubt, excluding the GSK Group), other than (a)&nbsp;Liabilities identified as Purchaser Parent
Retained Liabilities in <U>clauses (a)</U>&nbsp;through <U>(f)</U> of the definition of &#147;Purchaser Parent Retained Liabilities&#148; (provided, that the reference in clause (a) of such definition to &#147;any Purchaser Ancillary Agreement&#148;
is hereby amended to state &#147;(i) any Purchaser Ancillary Agreement, (ii) any Transaction Document (as defined in the Demerger Agreement) between Purchaser Parent or any of its Affiliates, on the one hand, and any member of the JVCo Group, on the
other hand, which survives the Demerger Time and (iii) any agreements that survive the Demerger Time pursuant to Schedule 2 to the Deed of Termination (as defined in the Demerger Agreement)&#148;), whether arising prior to, on or after the Closing;
and (b)&nbsp;Liabilities identified as Retained Liabilities in <U>clauses (a)</U>&nbsp;through <U>(g)</U> of <U>Section</U><U></U><U>&nbsp;2.5</U>, whether arising prior to, on or after the Closing.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>New Purchaser Parent Guarantee</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Section&nbsp;7.12 shall be added to Article VII of the SAPA as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Section 7.12 <U>New Purchaser Parent Guarantee</U>. New Purchaser Parent hereby guarantees, as a primary obligor and not as a surety, the
full and punctual payment and performance of the obligations of Purchaser under Section&nbsp;7.2 of this Agreement. This guarantee shall be a full, unconditional, irrevocable, absolute and continuing guarantee of payment and performance (and not
just of collection) of the obligations of Purchaser under Section&nbsp;7.2 (the &#147;<U>Guaranteed Obligations</U>&#148;). If Purchaser fails, for any reason, to perform or pay any Guaranteed Obligation, in whole or in part, upon becoming due, New
Purchaser Parent shall promptly pay to the relevant Parent Indemnified Parties by wire transfer of immediately available funds the amount of such Guaranteed Obligation due and unpaid by Purchaser. New Purchaser Parent shall pay such Guaranteed
Obligation within five (5)&nbsp;Business Days of receipt of demand for payment from any Parent Indemnified Party. Any Parent Indemnified Party may enforce New Purchaser Parent&#146;s obligations under this Section&nbsp;7.12 without first suing
Purchaser or joining Purchaser in any suit against New Purchaser Parent, or enforcing any rights and remedies against Purchaser, or otherwise pursuing or asserting any claims or rights against Purchaser.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Purchaser Parent hereby represents and warrants to Seller Parent and Purchaser Parent that New Purchaser
Parent is ready, able, and willing to fully perform, and otherwise be responsible for, any and all Guaranteed Obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties acknowledge and agree that, for the purposes of Article VII of the SAPA, New Purchaser Parent shall
be deemed a &#147;Purchaser Indemnified Party&#148; and, for the avoidance of doubt, all provisions in Article VII of the SAPA that are applicable to Purchaser shall apply equally to New Purchaser Parent in its capacity as a guarantor pursuant to
this Section 8. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Swiss Pension Plan</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.6(t) of the SAPA shall be amended and restated in its entirety to state: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#147;(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Swiss Pension Liabilities</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Purchaser Parent and Purchaser shall use its reasonable best efforts to procure that as soon as is
practicable after Closing, and in any event before the date of completion of any Listing Transaction or sale (direct or indirect) of the stock or assets of GlaxoSmithKline Consumer Healthcare AG and Novartis Consumer Health SA (together the
&#147;<U>Swiss CH Entities</U>&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GlaxoSmithKline AG and ViiV Healthcare GmbH (the &#147;<U>Swiss GSK Entities</U>&#148;) shall establish a
pension plan in Switzerland that has been duly authorised by local taxation and regulatory authorities (the &#147;<U>New Swiss Plan</U>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The board of the Personalvorsorgestiftung der GlaxoSmithKline Schweiz (the &#147;<U>Swiss Plan</U>&#148;)<B>
</B>shall transfer to the New Swiss Plan such part of the assets of the Swiss Plan (the &#147;<U>Swiss Transferred Assets</U>&#148;) as are attributable to those members of the Swiss Plan other than the Remaining Members (as defined below) (the
&#147;<U>Swiss Transferring </U><U>Beneficiaries</U>&#148;) and the Swiss Transferring Liability (as defined below) as of the Swiss Transfer Date (as defined below); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Swiss Transfer Date, the New Swiss Plan shall assume the Liability to provide benefits in respect of
the Swiss Transferring Beneficiaries that are equivalent in value to those to which the Swiss Transferring Beneficiaries were entitled in the Swiss Plan immediately before the Swiss Transfer Date (the &#147;<U>Swiss Transferring
Liability</U>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The date of the completion of the transfer from the Swiss Plan to the New Swiss Plan of the Swiss
Transferred Assets is the &#147;<U>Swiss Transfer Date</U>&#148;. For the avoidance of doubt, any adjustment payment made subsequent to such transfer will not be taken into account for the purposes of this definition. Each of Purchaser Parent and
Purchaser shall use its reasonable best efforts to assist and cooperate with each other to take, or cause to be taken, all actions and to do all things necessary for the establishment of the plan and the transfer of assets and Liabilities. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 45 days following the Swiss Transfer Date, Purchaser Parent shall calculate the following amount (the
&#147;<U>Swiss Pension Adjustment</U>&#148;) and confirm such amount, together with its calculations and any other information reasonably required by Seller Parent to confirm the accuracy of such determination, in writing to Seller Parent:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the value of the Liabilities of the Swiss Plan, as of the Swiss Transfer Date, in respect of (i)&nbsp;Purchaser
Business Employees, (ii)&nbsp;Former Purchaser Business Employees, and (iii)&nbsp;former employees who are not Business Employees or Former Business Employees who are in receipt of a pension from the Swiss Plan which is secured by insurance policies
issued to the Swiss Plan (together the &#147;<U>Remaining Members</U>&#148;) by reference to the methodology and assumptions used for calculating the Liabilities of the Swiss CH Entities in the Swiss Plan in the opening positions for
Purchaser&#146;s financial statements as of July&nbsp;31, 2019, which shall be consistent with the methodology and assumptions used for calculating the Purchaser Pension Liabilities in the GlaxoSmithKline Consumer Healthcare Holdings Limited Annual
Report 2018, with financial assumptions updated for market conditions as of the Swiss Transfer Date (the &#147;<U>Swiss CH Liability Value</U>&#148;); <U>less</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the value of the assets of the Swiss Plan in respect of the Remaining Members as of the Swiss Transfer Date
(the &#147;<U>Swiss CH Asset Value</U>&#148;); <U>less</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the net pension Liability attributable to the Swiss CH Entities in the opening positions for Purchaser&#146;s
financial statements as of July&nbsp;31, 2019, which shall be consistent with the methodology and assumptions used for calculating the Purchaser Pension Liabilities in the GlaxoSmithKline Consumer Healthcare Holdings Limited Annual Report 2018, with
financial assumptions updated for market conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Seller Parent shall, within 45 days following receipt of the calculation of the Swiss Pension Adjustment and
such information as it reasonably requires to verify it, in writing either confirm its agreement to such calculation (including the value of the Swiss CH Liability Value and the Swiss CH Asset Value) or notify Purchaser Parent in writing that it
disagrees with the calculation, explaining why and providing its alternative calculation with any supporting documentation (including any alternative valuation of the Swiss CH Liability Value and the Swiss CH Asset Value). Where Seller Parent
disagrees with Purchaser Parent&#146;s calculations the provisions of <U>Section</U><U></U><U>&nbsp;6.6(e)(vi)</U> shall apply <I>mutatis mutandis</I>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 30 days following either confirmation by Seller Parent of its agreement of the Swiss Pension Adjustment
or the determination of the Swiss Pension Adjustment in accordance with <U>Section</U><U></U><U>&nbsp;6.6(e)(vi)</U>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Swiss Pension Adjustment is [***], Purchaser Parent shall pay to Purchaser or such of its Subsidiaries
as Purchaser shall nominate an amount equal to the Swiss Pension Adjustment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Swiss Pension Adjustment is a negative amount [***], Purchaser shall pay to Purchaser Parent or such of
its Subsidiaries as Purchaser Parent shall nominate an absolute value equal to the Swiss Pension Adjustment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of this Agreement, (A)&nbsp;the Swiss Transferring Liability shall be Purchaser Parent Retained
Liabilities; and (B)&nbsp;any Liabilities of or related to the Swiss Plan that do not transfer to the New Swiss Plan pursuant to this <U>Section</U><U></U><U>&nbsp;6.6(t)</U> shall be Purchaser Assumed Employee Liabilities. From and following the
Swiss Transfer Date, Purchaser Parent and its Subsidiaries shall have no Liabilities in respect of the Swiss Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Purchaser shall pay to Purchaser Parent the amount of any Tax Benefit actually realized by Purchaser or its
Subsidiaries in the taxable year in which the payment pursuant to <U>Section</U><U></U><U>&nbsp;6.6(t)(iv)(A)</U> is made or the subsequent two taxable years arising from any Tax Item in respect of any amount paid into the Swiss Plan up to an amount
equal to that resulting from the true up under <U>Section</U><U></U><U>&nbsp;6.6(t)(iv)(A)</U> in respect of the Swiss Transferring Liability within fifteen (15)&nbsp;days of the filing of the Tax Return with respect to which the Tax Benefit is
actually realized (or, if the Tax Benefit is in the form of an increased cash Tax refund, within fifteen (15)&nbsp;days of the receipt of such cash Tax refund from the applicable Governmental Authority).&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Notices</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;10.1 of the SAPA shall be amended by replacing the wording from &#147;To Purchaser Parent or
Purchaser&#148; to &#147;Fax: (212) <FONT STYLE="white-space:nowrap">446-4900&#148;</FONT> with the following: </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Certain Representations and Warranties</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Seller Parent hereby represents and warrants to Purchaser Parent, New Purchaser Parent and New Purchaser that:
Seller Parent has all requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder; the execution and delivery by Seller Parent of this Agreement, and the performance by Seller Parent of its
obligations hereunder, have been duly authorized by all requisite corporate action; and this Agreement has been duly executed and delivered by Seller Parent and, assuming this Agreement has been duly executed and delivered by Purchaser Parent, New
Purchaser Parent and New Purchaser, constitutes a legal, valid and binding obligation of Seller Parent, enforceable against Seller Parent in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or similar Laws affecting creditors&#146; rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Purchaser Parent hereby represents and warrants to Seller Parent, New Purchaser Parent and New Purchaser that:
Purchaser Parent has all requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder; the execution and delivery by Purchaser Parent of this Agreement, and the performance by Purchaser
Parent of its obligations hereunder, have been duly authorized by all requisite corporate action; and this Agreement has been duly executed and delivered by Purchaser Parent and, assuming this Agreement has been duly executed and delivered by Seller
Parent, New Purchaser Parent and New Purchaser, constitutes a legal, valid and binding obligation of Purchaser Parent, enforceable against Purchaser Parent in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors&#146; rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Purchaser Parent hereby represents and warrants to Seller Parent and Purchaser Parent that: New Purchaser
Parent has all requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder; the execution and delivery by New Purchaser Parent of this Agreement, and the performance by New Purchaser Parent
of its obligations hereunder, have been duly authorized by all requisite corporate action; and this Agreement has been duly executed and delivered by New Purchaser Parent and, assuming this Agreement has been duly executed and delivered by New
Purchaser, Seller Parent and Purchaser Parent, constitutes a legal, valid and binding obligation of New Purchaser Parent, enforceable against New Purchaser Parent in accordance with its terms, except as enforcement may be limited by bankruptcy,
insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors&#146; rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Purchaser hereby represents and warrants to Seller Parent and Purchaser Parent that: New Purchaser has all
requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder; the execution and delivery by New Purchaser of this Agreement, and the performance by New Purchaser of its obligations hereunder,
have been duly authorized by all requisite corporate action; and this Agreement has been duly executed and delivered by New Purchaser and, assuming this Agreement has been duly executed and delivered by New Purchaser Parent, Seller Parent and
Purchaser Parent, constitutes a legal, valid and binding obligation of New Purchaser, enforceable against New Purchaser in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent
conveyance, moratorium or similar Laws affecting creditors&#146; rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties hereby acknowledge and agree that, for all purposes under the SAPA, as amended by the terms of this
Agreement, references to a &#147;Party&#148; or the &#147;Parties&#148; in the SAPA, as applicable, shall be deemed to include New Purchaser Parent from and after the effectiveness of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following new defined terms shall be inserted in alphabetical order in Section&nbsp;1.1 of the SAPA:
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Demerger Agreement</U>&#148; means the demerger agreement entered into
between Purchaser Parent and New Purchaser Parent entered into on or about 1 June 2022 pursuant to which Purchaser Parent intends to demerge the predominant part of its interest in its consumer healthcare business by way of an indirect dividend
demerger.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Demerger Completion Steps</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Purchaser Parent delivering to New Purchaser Parent a duly executed transfer of the Relevant GSKCHHL Shares (as
defined in the Demerger Agreement) in favour of New Purchaser Parent, together with the relevant share certificate(s); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the entry into the register of members of the New Purchaser Parent of the names of the Qualifying GSK Shareholders
(as defined in the Demerger Agreement) to whom Haleon Demerger Shares (as defined in the Demerger Agreement) are to be allotted and issued pursuant to that agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;each of Purchaser Parent and New Purchaser Parent delivering, or procuring the delivery of, a duly executed
counterpart of each of the Ancillary Agreements (as defined in the Demerger Agreement) (other than those Ancillary Agreements that have already been entered into prior to completion of the Demerger Agreement) to which they or any members of their
respective Groups are party in the agreed form.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Demerger Time</U>&#148; means the time at which the last of the
Demerger Completion Steps is completed.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>GSK Group</U>&#148; means Purchaser Parent and its Subsidiaries, other than
members of the JVCo Group.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>JVCo Group</U>&#148; means, prior to the Demerger Time, Purchaser and its Subsidiaries
and, from and after the Demerger Time, New Purchaser Parent and its Subsidiaries (including Purchaser and its Subsidiaries).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>LTAA Commencement Date</U>&#148; has the meaning given in the term &#147;Commencement Date&#148; in the Long Term Access
Agreement.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Long Term Access Agreement</U>&#148; means the agreement in relation to the long term access of
information and records between Purchaser Parent and New Purchaser Parent entered into on or about 1 June 2022.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous Provisions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution, delivery and effectiveness of this Agreement shall not constitute a waiver or amendment of any
provision of the SAPA, except as specifically set forth herein. Except as herein expressly amended, all of the terms, conditions and provisions of the SAPA and any of the documents, schedules or exhibits referred to therein shall remain in full
force and effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall form a part of the SAPA for all purposes. Any reference in the SAPA to &#147;this
Agreement&#148;, &#147;hereof&#148;, &#147;herein&#148;, and &#147;hereunder&#148; and words or expressions of similar import, and any reference to the SAPA contained in any notice, request, certificate, or other document executed prior to,
concurrently with or after the execution and delivery of this Agreement, including any Ancillary Agreement, shall be deemed to be a reference to the SAPA as amended hereby (and as may be further amended, modified, restated, supplemented or extended
from time to time in accordance with the terms thereof) unless the context shall otherwise require. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions set forth in Sections 10.1 (<I>Notices</I>) (as amended by Section [10] above), 10.2
(<I>Amendment; Waiver</I>), 10.3 (<I>Assignment</I>), 10.4 (<I>Entire Agreement</I>) (as amended hereby), 10.5 (<I>Parties in Interest</I>), 10.7 (<I>Expenses</I>), 10.10 (<I>Governing Law; Jurisdiction</I>), 10.11 (<I>Counterparts</I>), 10.12
(<I>Headings</I>), 10.13 (<I>Severability</I>), 10.14 (<I>Rules of Construction</I>), 10.15 (<I>Specific Performance</I>), 10.16 (<I>Affiliate Status</I>), and 10.17 <I>(Waiver of Conflict Regarding Representation; Nonassertion of Attorney-Client
Privilege)</I> of the SAPA shall apply <I>mutatis mutandis </I>to this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed or caused this Agreement to be executed
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Deborah Baron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deborah Baron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SVP World Wide Business Development</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Second Amendment Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GSK PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Redfern</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Redfern</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorised Attorney</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GLAXOSMITHKLINE CONSUMER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>HEALTHCARE HOLDINGS (NO.2) LIMITED</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Redfern</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Redfern</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Second Amendment Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HALEON PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amanda Mellor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amanda Mellor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorised Attorney</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Second Amendment Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>d382677dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 12.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Section&nbsp;302 Certificate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form of Certification Required by Rule <FONT
STYLE="white-space:nowrap">13a-14(a)</FONT> or <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> under the Securities Exchange Act of 1934 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">I, Emma Walmsley,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of GSK plc;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during
the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in the
company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Date: March 10, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Emma Walmsley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Emma Walmsley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>d382677dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 12.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Section&nbsp;302 Certificate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form of Certification Required by Rule <FONT
STYLE="white-space:nowrap">13a-14(a)</FONT> or <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> under the Securities Exchange Act of 1934 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">I, Iain Mackay,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of GSK plc;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during
the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in the
company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;10, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Iain Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Iain Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>d382677dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 13.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Section&nbsp;906 Certificate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Certification Pursuant to Section&nbsp;906
of the Sarbanes-Oxley Act of 2002 (Subsections (a)&nbsp;and (b) of Section&nbsp;1350, Chapter 63 of Title 18, United States Code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;906
of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b) of Section&nbsp;1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of GSK plc, a public limited company incorporated under English law (the
&#147;<U>company</U>&#148;), does hereby certify, to such officer&#146;s knowledge, that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT>
for the year ended December&nbsp;31, 2022 (the &#147;<U>Form <FONT STYLE="white-space:nowrap">20-F</FONT></U>&#148;) of the company fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and
information contained in the Form <FONT STYLE="white-space:nowrap">20-F</FONT> fairly presents, in all material respects, the financial condition and results of operations of the company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;10, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Emma Walmsley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Emma Walmsley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;10, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Iain Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Iain Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>d382677dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Exhibit 15.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We consent to the
incorporation by reference in Registration Statement Nos. <FONT STYLE="white-space:nowrap">333-254756,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">333-254756-01</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">333-254756-02</FONT></FONT> on Form <FONT STYLE="white-space:nowrap">F-3</FONT> of GSK plc, GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc and Registration Statement Nos.
<FONT STYLE="white-space:nowrap">333-88966,</FONT> <FONT STYLE="white-space:nowrap">333-100388,</FONT> <FONT STYLE="white-space:nowrap">333-162702,</FONT> and <FONT STYLE="white-space:nowrap">333-235651</FONT> on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> of GSK plc, of our reports dated 10&nbsp;March 2023, relating to the financial statements of GSK plc and the effectiveness of GSK plc&#146;s internal control over financial reporting appearing in this
Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended 31&nbsp;December 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ Deloitte LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">London, United Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">10&nbsp;March 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>9
<FILENAME>d382677dex152.htm
<DESCRIPTION>EX-15.2
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:gsk="http://www.gsk.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>EX-15.2</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
 <div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" id="hidden69044974" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">7 Years</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" id="hidden69044975" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">3 Years</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" id="hidden69049915" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Other operating income/ (expense)</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" id="hidden69049944" contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" id="hidden69049946" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" id="hidden69049945" contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" id="hidden69049947" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" id="hidden69049948" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" id="hidden69049949" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" id="hidden69049975" contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Discontinued operations</ix:nonNumeric><ix:nonFraction name="ifrs-full:ParValuePerShare" id="hidden69050743" contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP_per_Share" decimals="4">0.3125</ix:nonFraction><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" id="hidden69050893" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Intangible assets </ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gsk-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: right; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit 15.2 </div></div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_cov.jpg" style="width: 778px; height: 1100px;"/></div> </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_toc.jpg" style="width: 755px; height: 1068px;"/></div> </div></div><div style="font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="margin: -700pt 20% 0pt 6%; font-family: ARIAL; font-size: 18pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. </div></div><div style="margin: 6pt 20% 0pt 6%; font-family: ARIAL; font-size: 18pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. </div></div><div style="margin: 6pt 20% 0pt 6%; font-family: ARIAL; font-size: 18pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We are a company where outstanding people can thrive. </div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 60pt; margin-bottom: 0pt; margin-left: 6%;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Contents </div></div><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 81%; font-family: ARIAL; font-size: 8pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 99%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="4" style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#ex15_2tx382677_1" style="color: white;">Strategic report</a></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_2" style="color: white;">Ahead Together</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">01</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_3" style="color: white;">2022 performance and key performance indicators</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">02</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_4" style="color: white;">Chair&#8217;s statement</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">04</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_5" style="color: white;">CEO&#8217;s statement</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">06</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_6" style="color: white;">Business model</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">08</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_7" style="color: white;">Our culture and people</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_8" style="color: white;">Our external environment</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_9" style="color: white;">Research and development</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_10" style="color: white;">Commercial operations:</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_11" style="color: white;">Performance: Vaccines</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">29</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_12" style="color: white;">Performance: Specialty Medicines</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_13" style="color: white;">Performance: General Medicines</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_14" style="color: white;">Responsible business</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_15" style="color: white;">Risk management</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">51</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_16" style="color: white;">2022 principal risks summary</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">53</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_17" style="color: white;">Climate-related financial disclosures</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">55</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_18" style="color: white;">Nature-related financial disclosure</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">62</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_19" style="color: white;">Employees by gender</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">63</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_20" style="color: white;">Viability statement</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_21" style="color: white;">Group financial review</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="width: 32%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 79%; font-family: ARIAL; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="4" style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#ex15_2tx382677_22" style="color: white;">Corporate governance</a></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_23" style="color: white;">The Board and GSK Leadership Team</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">97</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_24" style="color: white;">Chair&#8217;s governance statement</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">103</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_25" style="color: white;">Corporate governance architecture</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">107</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_26" style="color: white;">Ahead Together &#8211; Board oversight</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">110</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_27" style="color: white;">Key decisions and engagements</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">112</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_28" style="color: white;">Board committee reports</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">117</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_29" style="color: white;">Directors&#8217; report</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">130</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="4" style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#ex15_2tx382677_30" style="color: white;">Remuneration report</a></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_31" style="color: white;">Chair&#8217;s annual statement</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">133</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_32" style="color: white;">Annual report on remuneration</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">136</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_33" style="color: white;">2022 remuneration policy summary</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">158</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="4" style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#ex15_2tx382677_34" style="color: white;">Financial statements</a></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_35" style="color: white;">Directors&#8217; statement of responsibilities</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">166</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_37" style="color: white;">Financial statements</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">182</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_38" style="color: white;">Notes to the financial statements</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">186</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_39" style="color: white;">Financial statements of GSK plc prepared under UK&#160;GAAP</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">268</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 75%; font-family: ARIAL; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="4" style="height: 3.75pt; border-top-color: rgb(255, 255, 255); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#ex15_2tx382677_40" style="color: white;">Investor information</a></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_42" style="color: white;">Financial record</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">274<br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_43" style="color: white;">Product development pipeline</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">278</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_44" style="color: white;">Products, competition and intellectual property</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">282</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_45" style="color: white;">Principal risks and uncertainties</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">285</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_46" style="color: white;">Share capital and control </a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">296</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_47" style="color: white;">Dividends</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_48" style="color: white;">Financial calendar 2023</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_49" style="color: white;">Annual General Meeting 2023</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_50" style="color: white;">Tax information for shareholders</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_51" style="color: white;">Shareholder services and contacts</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">302</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_52" style="color: white;">US law and regulation</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">304</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_53" style="color: white;">Group companies</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">307</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_54" style="color: white;">Glossary of terms</a></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">315</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 60pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 60pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin: 0pt 9% 0pt 6%; font-family: ARIAL; font-size: 7pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cautionary statement </div></div></div></div><div style="margin: 0pt 9% 0pt 6%; font-family: ARIAL; font-size: 7pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">See the inside back cover of this document for the cautionary statement regarding forward-looking statements. </div></div><div style="margin: 6pt 9% 0pt 6%; font-family: ARIAL; font-size: 7pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-IFRS</div> measures </div></div></div></div><div style="margin: 0pt 18% 0pt 6%; font-family: ARIAL; font-size: 7pt;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We use a number of adjusted, non-International Financial Reporting Standards (IFRS) measures to report the performance of our business. Total reported results represent the Group&#8217;s overall performance under IFRS. Adjusted results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results and other non-IFRS measures are defined on pages 69 and 70 and reconciliations to the nearest IFRS measures are on pages 81 to 85. </div></div><div style="font-size: 48pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 48pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td id="ex15_2tx382677_1" style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_01a.jpg" style="width: 721px; height: 289px;"/></div> </div></div><div id="ex15_2tx382677_2" style="text-align: center; font-family: ARIAL; font-size: 42pt; margin-top: 20pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ahead Together </div></div></div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 42pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 was a landmark year for GSK. Following the demerger of our consumer healthcare business to form Haleon in July, we are now a fully focused biopharma company. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">At the heart of this is our R&amp;D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. </div></div><div style="font-family: ARIAL; font-size: 12pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">We&#8217;re confident in our future </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Our bold ambitions for patients are reflected in our commitments to a step-change in growth and performance over the period to 2026. This means more GSK vaccines and medicines, including innovative new products, will reach more people than ever before. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Being a responsible business means getting ahead of disease together in the right way </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">That&#8217;s why environmental, social and governance (ESG) impacts are embedded in our strategy and support our sustainable performance and long-term growth. They help us build trust with our stakeholders, reduce risk to our operations and deliver positive social impact. </div></div><div style="font-family: ARIAL; font-size: 12pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Culture at GSK is something we all own </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we&#8217;ll deliver for our patients, shareholders and GSK people. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_01b.jpg" style="width: 37px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">01</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div id="ex15_2tx382677_3" style="font-family: ARIAL; font-size: 21pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2022 performance and key performance indicators </div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 30pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial </div></div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">We delivered a step-change in commercial execution with growth across the portfolio. Prioritised investment and cost discipline supported strong growth in operating profit and earnings per share (EPS). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_02a.jpg" style="width: 724px; height: 820px;"/></div> </div></div><div style="font-family: ARIAL; font-size: 7pt; margin-top: 18pt; margin-bottom: 0pt;">We use a number of adjusted, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IFRS,</div> measures to report the performance of its business. Adjusted results and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IFRS</div> measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IFRS</div> measures are defined on pages 69 and 70. AER &#8211; actual exchange rate; CER &#8211; constant exchange rate. </div><div style="font-family: ARIAL; font-size: 7pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 and 2021 comparative results presented in the tables above have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business. The presentation of continuing and discontinued operations under IFRS 5 are set out on page 192. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 70%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 2%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 39%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 54%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03c.jpg" style="width: 17px; height: 17px;"/></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: middle;">Key&#160;performance&#160;indicator&#160;attributable&#160;to&#160;continuing&#160;operations</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03b.jpg" style="width: 19px; height: 19px;"/></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: middle;">Linked&#160;to&#160;executive&#160;remuneration.&#160;See&#160;pages&#160;136&#160;to&#160;139&#160;for&#160;more&#160;details</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">02</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance summary and key performance indicators continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and development </div></div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">We continued to strengthen the late-stage pipeline with regulatory approvals, positive data read-outs and strategic business development. </div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 30%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 4%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 29%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 4%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 29%; font-family: ARIAL;"></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Innovation sales (&#163;bn) <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03a.jpg" style="width: 40px; height: 19px;"/></div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: middle;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Innovative pipeline</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: middle;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Phase III starts <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03b.jpg" style="width: 19px; height: 19px;"/></div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;12.7bn</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 36pt; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 36pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">sales of products launched in the last five years including lifecycle innovation</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">vaccines and specialty medicines based on the science of the immune system</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">including for depemokimab in eosinophilic disease, and cobolimab for second-line non-small cell lung cancers</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&gt;20</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">18</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">new approvals since 2017</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">in phase III/registration</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">new collaborations and acquisitions including with Affinivax, Sierra Oncology and Spero Therapeutics</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: middle;">Pipeline value and progress <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03a.jpg" style="width: 40px; height: 19px;"/></div> are not reported externally because of their commercial sensitivity.</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Responsible business </div></div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">We continue to be recognised for our environmental and sustainability leadership. Our ESG Performance Rating <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03c.jpg" style="width: 17px; height: 17px;"/></div> is on track based on 83% of all performance metrics being met or exceeded. The metrics cover our six new focus areas: access to healthcare, global health and health security, environment <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03b.jpg" style="width: 19px; height: 19px;"/></div> , diversity, equity and inclusion <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03b.jpg"/></div> , ethical standards, and product governance (see pages 41 to 50). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 30%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">1st</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2nd</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 36pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">13%</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">in the Access to Medicine Index for 8th consecutive time</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">in the pharmaceuticals industry for the S&amp;P Global Corporate Sustainability Assessment, with a score of 86 (as at 17 February 2023)</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">reduction in indirect scope 3<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">1</div> carbon emissions</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Culture </div></div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Culture progress <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_03c.jpg" style="width: 17px; height: 17px;"/></div> &#8211; ambitious for patients, accountable for impact and do the right thing &#8211; is measured through our employee surveys. Our employee engagement score was 81% in 2022 compared to 78% in 2021. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Read more on page 10</div></div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 7pt; margin-top: 72pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">1 &#160;&#160;based on latest available data for scope 3 emissions between 2020-2021 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_01b.jpg" style="width: 37px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">03</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div id="ex15_2tx382677_4" style="font-family: ARIAL; font-size: 21pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Chair&#8217;s statement </div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 was one of the most important years in GSK&#8217;s history with </div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">strong operational and financial performance and the successful </div></div><div style="font-family: ARIAL; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">demerger of Consumer Healthcare. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">As I said last year, the programme of change Emma and her team are delivering is designed to fundamentally reconstruct and strengthen GSK&#8217;s operational capability. Clear, ambitious priorities have been set to sharpen commercial execution and cost discipline; improve the pipeline and R&amp;D productivity; tackle the Group&#8217;s structure and capital allocation capacity; and shift GSK&#8217;s culture to be more competitive and performance focused. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We are seeing clear evidence of success of this strategic transformation. But, as always, there is more to do. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We delivered the demerger and separation of GSK&#8217;s Consumer Healthcare business to form Haleon, a separate company listed in London, in July. This was the largest demerger in Europe for 20 years and the culmination of a huge amount of work over several years. </div></div></div><div style="width: 32%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We have created two attractive and competitive businesses with compelling investment propositions: a world-leading consumer healthcare business, and a newly focused GSK with a strengthened balance sheet to enable increased investment in R&amp;D and future growth. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We are already seeing evidence of the benefits of a simpler, more focused, business model. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operational performance for GSK in 2022 was excellent, with strong growth in sales of vaccines and specialty medicines and double-digit growth in operating profit and EPS. This is the start of a new, sustained period of growth for the Group, with sales and operating profit forecast to grow by more than 5% and 10% CAGR<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">1</div>, respectively over the period to 2026. The Board is very confident in delivery of these targets, underpinned by the improvement we are seeing in the Group&#8217;s commercial execution and competitiveness. </div></div></div><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Increasing R&amp;D productivity and building a culture of performance, which take longer to embed, are critical levers of longer-term value creation for GSK. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4.5pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in R&amp;D </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt; margin-left: 4.5pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We are making good progress in R&amp;D. In the past five years, over 20 new medicines and vaccines have been approved and more than 18 new medicines are currently in late-stage clinical trial development. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4.5pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">It was good to see clear progress in our pipeline reflected in important milestones during 2022. Our respiratory syncytial virus (RSV) vaccine candidate for older adults achieved exceptional phase III results, and the US Food and Drug Administration (FDA) approval of our long-acting HIV medicine administered every two months reaffirms GSK&#8217;s leadership in next-generation HIV treatment and prevention. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4.5pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We also remain ambitious to support the pipeline and future growth through business development, with acquisitions of Sierra Oncology and Affinivax completed during the year. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 30%; font-family: ARIAL;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_04.jpg" style="width: 506px; height: 426px;"/></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">I was delighted by the seamless transition of Tony Wood into the Chief Scientific Officer role in August, replacing Hal Barron. Tony is an outstanding and highly respected scientist and has been a key architect in rebuilding our pipeline.</div></div><div style="font-size: 216pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 216pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">1 &#160;&#160;Compound annual growth rate</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">04</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Chair&#8217;s statement continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Engaging with shareholders </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board and management continue to maintain very significant engagement with shareholders. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">It is clear from these conversations that the vast majority of shareholders support the strategy the company is implementing. Nevertheless &#8211; and despite the progress that is being made &#8211; the Board recognises that there is more to do to increase investor confidence in the ability of the Group to sustain growth over the next decade. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">This is important as GSK has underperformed in terms of TSR and share price performance for many years and the Board understands the need to deliver on this. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">In the short term, this means consistent, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-on-year</div></div> delivery of the targets for sales and operating profit, including successful launch of the company&#8217;s key new product opportunities such as the RSV vaccine in 2023. </div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Looking beyond 2026, successful delivery and strengthening of the late-stage pipeline is critical across vaccines and specialty medicines, including for our long-acting HIV portfolio, supported by targeted business development. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Longer term, the Board is confident that the progress the company is making to develop industry-leading AI and machine learning capabilities, and application of deep understanding of genetics, can provide us with an edge to be able to identify, develop and launch products that make a difference for patients and deliver value for our shareholders. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> litigation </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt;">The Group&#8217;s share price performance in the second half of the year was impacted by the uncertainties associated with the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> product liability litigation in the US. </div></div><div style="width: 32%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">While this is disappointing, the company remains clear on its position on these matters, namely that the scientific consensus is that there is no consistent or reliable evidence that <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> (ranitidine) increases the risk of any cancer. The decision in December by the US Federal Court in Southern Florida to dismiss all claims and cases relating to ranitidine was very welcome and GSK will continue to defend itself vigorously against claims brought at the State level. </div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Targets and governance </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board did not adopt the targets for sales and operating profit growth lightly. These commitments were a very important demonstration of our confidence in the business and our determination to be held accountable for delivery. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">In line with this, we introduced a new remuneration policy in 2022 linking executive remuneration to reward for outperformance. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We engaged extensively with shareholders to develop these proposals, recognising the new reward system is a fundamental part of the architecture of GSK post-separation to ensure we build a performance culture and generate sustained delivery of shareholder value. While we were pleased the policy achieved a positive shareholder vote, we recognise a sizeable minority of shareholders voted against. We will continue to engage with shareholders to demonstrate why we believe incentivising outperformance against the targets will ultimately be rewarded through shareholder value creation. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating responsibly </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating responsibly is a foundation stone on which GSK has been built. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed to ensuring ESG considerations are properly embedded into our strategy. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">This supports long-term growth, reduces risk and helps us build trust with stakeholders. The Board was pleased to see continued progress in many ESG areas during 2022, including GSK again topping the independent Access to Medicines Index. </div></div></div><div style="width: 31%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board evolution </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Delivery of the demerger obviously resulted in changes to the Board, including departures of Vindi Banga and Vivienne Cox to Haleon and the retirement of Laurie Glimcher. I would like to thank them all for their significant contributions to GSK over recent years. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We committed to using the opportunity of the demerger to deepen the GSK Board&#8217;s biopharma experience and credentials. I was delighted to welcome Dr Vishal Sikka and Elizabeth McKee Anderson to the Board during the year. Vishal is a world-leading technologist and Elizabeth has deep commercial expertise, across both large and specialty biopharma. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Together with the continued involvement of Hal Dietz and Hal Barron, I believe the scientific credentials of GSK&#8217;s Board are among the strongest in the industry. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">We also look forward to the future appointment of the highly experienced Julie Brown as our new CFO, starting 1&#160;May 2023. I would like to thank outgoing CFO Iain Mackay for his outstanding work and support over the last four years. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">I would also like to note the appointments of Anne Beal, who joined the Board in May 2021 as Chair of the Corporate Responsibility Committee, and Charles Bancroft, currently Audit &amp; Risk Committee Chair, as our new Senior Independent Director. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Finally, I would like to thank all employees, partners, shareholders and customers for their support and commitment through the last year and I look forward to what promises to be an exciting 2023 for GSK. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_05.jpg" style="width: 209px; height: 68px;"/></div> </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Chair </div></div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_01b.jpg" style="width: 37px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">05</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_5" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">CEO&#8217;s statement </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">2022 was a landmark year for GSK. We enter 2023 with strong </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">momentum and as a focused global biopharma company. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Creating a focused global biopharma company </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">2022 was a landmark year for GSK. We successfully delivered the demerger of Haleon which is the most significant corporate change for the company in 20 years, and began a new chapter of competitive and profitable growth. We enter 2023 with strong momentum and as a focused global biopharma company with the ambition and purpose to unite science, technology and talent, to get ahead of disease together. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strong 2022 performance increases confidence in delivering growth through 2026 and beyond </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Group sales were &#163;29.3&#160;billion in 2022, up 13% CER, driven by strong growth in both Vaccines and Specialty Medicines. Adjusted operating profit grew 14% and adjusted EPS by 15% (both CER). </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Reflecting the huge progress we have made to improve the competitiveness of our commercial execution, we now have 10 products exceeding &#163;1&#160;billion in annual sales, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> alone delivered a record year with &#163;3&#160;billion of sales. HIV sales, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, were &#163;5.7&#160;billion, up 12% CER. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Vaccines and Specialty Medicines now represent nearly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of our sales, compared to 46% in 2017, and we are well on track to achieve our target of 75% of revenues from Vaccines and Specialty Medicines by 2026. This evolving portfolio, together with prioritised investment in innovation and good cost discipline, is reflected in the further expansion of our operating margin. </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4.5pt; font-size:9pt; font-family:ARIAL">Strong operational performance has enabled us to increase annual investment in R&amp;D to over &#163;5&#160;billion and, through the demerger, we have also significantly strengthened GSK&#8217;s balance sheet, creating additional flexibility to invest in growth and innovation. In 2022, we acquired the Boston-based vaccine company, Affinivax, which gave us access to the disruptive MAPS technology &#8211; for higher valency and broader coverage in a single vaccine &#8211; and a phase II next-generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-valent</div> vaccine for pneumococcal disease. We also acquired Sierra Oncology, including the myelofibrosis treatment, momelotinib, which we hope to see approved in 2023, and signed an exclusive licence agreement with Spero Therapeutics for tebipenem, a novel oral antibiotic in late-stage development for complicated urinary tract infections (cUTIs). We expect to do more targeted business development in 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4.5pt; font-size:9pt; font-family:ARIAL">In addition, we generated over &#163;3.3&#160;billion of free cash flow in 2022, supporting investments and a dividend of 61.25 pence per share for the year. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:30%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">
<img alt="LOGO" src="g382677f_06.jpg"/> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Our strong momentum underpins our confidence in delivering the ambitious sales and profit outlooks we have set for 2026. At the same time, we continue to build a stronger portfolio and pipeline based on science of the immune system, to absorb the loss of revenues from future patent expirations, and to put us in a strong position to deliver growth through the decade and beyond.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">06</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">CEO&#8217;s statement continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovation supports future growth </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We now have a pipeline of 69 vaccines and specialty medicines, many with the potential to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-or</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class.</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In August, Tony Wood took up his new role as GSK&#8217;s Chief Scientific Officer, succeeding Hal Barron. With his proven expertise in science, data and new technologies, Tony is well placed to capture the value and opportunities we see with our R&amp;D approach. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are focused across four core therapeutic areas: infectious diseases; HIV; immunology/respiratory and oncology. Overall, infectious diseases and HIV represent around <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of our pipeline and our primary focus for R&amp;D. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In infectious diseases, we have developed a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> vaccine for RSV in older adults. We were excited to present the phase III results in late 2022, which demonstrated 94%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div> efficacy against severe disease &#8211; an exceptional result. The world has been waiting more than 50 years for an RSV vaccine, so this is a significant scientific achievement. We have submitted this data to regulators and hope to see approval during 2023. Alongside our existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> capabilities, such as adjuvants, MAPS through our Affinivax acquisition and our collaboration with CureVac in mRNA, we now have the broadest suite of vaccine platform technologies of any company in the sector. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also made important advances in the clinical development of two late-stage assets: gepotidacin, a new novel antibiotic for uncomplicated urinary tract infections (uUTIs), and bepirovirsen, which has the potential to provide a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> functional cure for chronic hepatitis B, where there remains a significant unmet medical need. One in three people around the globe have been infected with the virus and more than 300&#160;million are living with chronic hepatitis B infection today. Current standard of care for chronic hepatitis B achieves functional cure for very few patients, fewer than 5%. </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">With bepirovirsen, which is now undergoing final stage trials, and other assets in our pipeline, we aim to be at the forefront of a new wave of treatments for this ancient disease. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In HIV, we launched <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>, the first and only long-acting injectable for HIV prevention which, alongside <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>, the first and only complete long-acting HIV treatment regimen, means we are changing the landscape for HIV patients. We also made further progress during the year in the development of next-generation pipeline options, including presenting promising early-stage data for N6LS, our new broadly neutralising antibody, and we look forward to providing further visibility on these pipeline options during 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In immunology/respiratory, we increased R&amp;D investment to support the phase III programme for depemokimab, a promising potential new long-acting medicine to treat severe asthma &#8211; an area in which GSK has long-standing expertise and proven commercial capability. In oncology, we reported very positive data for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> as a potential treatment for patients with primary advanced or recurrent endometrial cancer. Following discussions with the FDA, we took the decision to withdraw <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> from the US market in November, based on the previously announced outcome of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DREAMM-3</div> trial. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Building trust, reducing risk and delivering positive social impact </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to running a responsible business, which builds trust and reduces risk to deliver sustainable health impact at scale, shareholder returns and to support our people to thrive. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As we set out later in this report, we are making good progress in strengthening our culture, which is key to how we deliver our ambition and purpose. We are committed to making GSK a place where talented people can thrive, with a culture where we are all ambitious for patients, accountable for impact, and do the right thing. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In June 2022, we introduced our new Code, which sets out our culture, as well as commitments GSK and our people make, so we can deliver our ambition and purpose in the right way. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our ESG focus is on: access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, and product governance. In 2022, we made excellent progress, maintaining our number one position in the Access to Medicines Index for the 8th consecutive time and ranking 2nd in the S&amp;P Corporate Sustainability Assessment for the pharmaceutical industry. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As I talked about last year, investors and other stakeholders are demanding transparent reporting of performance on ESG matters. We are introducing a new ESG Performance Rating, to track delivery. I am pleased to report that our performance in 2022 is &#8216;on track&#8217; with details set out on page 42. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As Jon has made clear on the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> product liability litigation in the US, the scientific consensus is that there is no consistent or reliable evidence that <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> (ranitidine) increases the risk of any cancer. We will continue to defend ourselves vigorously in the State cases. From my perspective, it is important that as we do that, the company does not get distracted from our main priority &#8211; continuing to deliver on our strategy for patients, shareholders and our people. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Looking ahead with confidence </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As we enter 2023, I believe GSK has compelling prospects. As ever, its our people who fuel this confidence and I want to thank them for all they have achieved during 2022 and the strong momentum they are delivering. I am very optimistic for the future and excited by what we can achieve together. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_07.jpg"/> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chief Executive Officer</div></div> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Vaccine efficacy (VE) 94% (1 of 12,466 versus 17 of 12,494) </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">07</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_6" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Business model </div></div><div style="margin-top:30pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">Our ambition is to positively impact the health of 2.5&#160;billion people </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">by the end of 2030. We aim to do this by developing transformational </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">vaccines and medicines and making them available at responsible prices </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">that are accessible for patients and sustainable for our business. </div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Central to our success are our people: experts in science, </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">technology, manufacturing, regulation, intellectual property </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and commercialisation... </div></div></div></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:32pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">69,400</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&gt;80</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">24,000</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">GSK people</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">countries worldwide</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">suppliers working directly</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">with GSK</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt"></td>
<td colspan="2" style="height:14.25pt"></td>
<td colspan="2" style="height:14.25pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:32pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;5.5bn</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">4</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">R&amp;D investment in 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">manufacturing sites</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">global R&amp;D centres</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">up by 9% at AER, 4% at CER</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">...who are identifying, researching, developing and </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">testing ground-breaking discoveries, and manufacturing </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and commercialising... </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty Medicines</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 3em; font-size: 9pt; font-family: ARIAL; line-height: normal;">We deliver one and a half million doses of our vaccines every day; and around 40% of the world&#8217;s children receive a GSK vaccine each year.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 3em; font-size: 9pt; font-family: ARIAL; line-height: normal;">Our portfolio of specialty medicines prevent and treat diseases, from HIV and respiratory diseases, to immuno- inflammation diseases like lupus, to cancer. Many are first or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 3em; font-size: 9pt; font-family: ARIAL; line-height: normal;">Our portfolio of more than 150 products encompasses all of GSK&#8217;s primary care medicines, supplied in 112 countries worldwide.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt"></td>
<td colspan="2" style="height:14.25pt"></td>
<td colspan="2" style="height:14.25pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top">
<img alt="LOGO" src="g382677f_08a.jpg"/> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">
<img alt="LOGO" src="g382677f_08b.jpg"/> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">
<img alt="LOGO" src="g382677f_08c.jpg"/> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">08</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Business model continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">...products that improve the health of millions of people </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">around the world in our core therapeutic areas... </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:22%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Infectious diseases </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are a world leader in infectious diseases like shingles and meningitis, which, including HIV, account for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the vaccines and medicines in our pipeline. </div></div><div style="position:relative;float:left; margin-left:3%; width:23%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our goal is to minimise the impact of HIV on people&#8217;s lives through treatment, prevention and ultimately cure. </div></div><div style="position:relative;float:left; margin-left:3%; width:23%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Immunology/respiratory </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re unlocking the science of the immune system to understand how it reacts to diseases like lupus, eosinophilic asthma and other inflammatory diseases. </div></div><div style="position:relative;float:left; margin-left:3%; width:23%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our emerging portfolio in oncology will potentially bring new cancer therapies to the patients who need them most. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">...steered by our long-term priorities... </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We develop new medicines and vaccines where they are needed, with better, faster and smarter R&amp;D. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re combining the power of genetic and genomic insights into the causes of disease, with the speed and scale of artificial intelligence and machine learning. </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;ve made commitments to growth and a significant step-change in delivery. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are confident in our ability to sustain growth through the decade and beyond. </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trust </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We deliver our strategy responsibly: always considering the ESG impacts of everything we do from lab to patient, helping to build trust with our stakeholders, reduce risk to our operations and deliver positive social impact. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">...and creating value for: </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patients </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:32pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2.3bn </div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">packs of medicines and </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">doses of vaccines delivered </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:32pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">61.25p </div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">per share dividend </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Society </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:32pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;1.3bn </div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">corporate income tax paid; in </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">addition we pay duties, levies, </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">transactional and employment taxes </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our people </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">All our people are supported to grow, be well and do work that really matters. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reinvestment </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; margin-right:10%; font-size:9pt; font-family:ARIAL">The returns we make enable us to reinvest in discovering and developing new vaccines and medicines so we can continue getting ahead of disease. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Company directors are required by law to promote the success of their organisation for the benefit of both shareholders and their wider stakeholders, including employees, suppliers and the community. Information on the issues, factors and stakeholders that the Board considers relevant to complying with Section&#160;172 (a) to (f)&#160;of the Companies Act 2006 can be found on page 112. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div> Our business model is supported by our ESG strategy,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div> Our strategy is supported by a robust framework for</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;&#160;described on page 42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;monitoring and managing risk, described on pages 51 and 52</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">09</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_7" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Our culture and people </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">GSK&#8217;s purpose &#8211; to unite science, technology and talent to </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">get Ahead of disease Together &#8211; puts our people at the heart </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">of our success. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our culture </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to making GSK a place where people can thrive, with a culture where we are all ambitious for patients, accountable for impact, and do the right thing. This means we support our people to do things better and faster, focusing on what matters most. It means setting clear objectives and accountability for results and giving everyone the support and space they need to succeed. It means doing everything responsibly with care and integrity, because people and patients around the world count on us. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">During 2022, we have dedicated significant leadership energy in bringing to life our Ahead Together purpose, strategy and culture across GSK. We have also placed real emphasis on individual ownership of the culture and the small changes we each need to make it a reality. This change has been supported by team conversation guides and simple tools used globally to support better and faster decision making, greater clarity of accountabilities and more ambitious, focused objectives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In June, we introduced The Code. This sets out our culture as well as the commitments GSK and our people make so we can deliver on our ambition in the right way. GSK people sign up to The Code annually and personally commit &#8216;I&#8217;m in&#8217;. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">See The Code on gsk.com<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">1</div> </div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Making GSK a place where people thrive </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Core to our Ahead Together ambition is to make GSK a place where people thrive. Although how people thrive is very individual, we also believe there are common themes that matter for all. Firstly, a belief in our purpose and a desire to live our culture and contribute to delivering our ambition. Secondly, feeling included and able to be yourself with opportunities to keep growing, with the support, feedback and space needed to succeed. And finally, feeling good, with positive mental, physical, financial and social wellbeing. This all requires GSK to be a place where people feel welcome and valued, with an environment (including our policies, workplaces and ways of working) which wholeheartedly enables and supports each person to deliver at their best. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supporting our people managers </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our people managers play a crucial role in helping their teams to thrive and bring culture to life. We expect people managers to Motivate, Focus, Care for and Develop their teams. Over the last two years we have delivered First Line Leader training, anchored in these four areas, to over 80% of this population. In addition, in 2022, we launched a new senior leader programme, Leading Leaders, to further build on our leadership development at more senior levels of the organisation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In preparation for 2023, we brought all people managers together in a virtual event to bring to life our biggest priorities and support managers in setting focused, ambitious objectives with their teams, aligned to our Innovation, Performance, Trust and Culture priorities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Focusing on diversity, equity and inclusion </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are continuing our focus on building a more diverse organisation and an equitable and inclusive culture so that everyone feels welcome, valued and included. We are delivering our leadership representation aspirations, have implemented annual diversity, equity and inclusion (DEI) training for all, and invested in development tools to build more inclusive leaders. We support an award-winning leadership development programme, Accelerating Difference, to support women and ethnically diverse leaders. We have also continued to evolve our people policies, processes and practices to support recruitment, retention and development of a more diverse workforce. More details on our aspirational targets for DEI for our people, business and suppliers, can be found in the Responsible Business section on page 47. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Driving Performance with Choice </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Performance with Choice &#8211; our approach to hybrid working for those in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">office-based</div> roles (about a quarter of our people) continues to allow us to find the right balance of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> and remote working. This framework, balanced in driving collective and individual performance, as well as supporting individual flexibility, is supporting personal wellbeing, driving performance and making us attractive as an employer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This year we have been clear in our expectations so that we spend enough time together in person to help us continue to build our sense of community, connectedness, enable development and better achieve our Ahead Together ambition. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">https://www.gsk.com/en-gb/company/governance/compliance/#the-code</div></div> </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Our culture and people continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Developing outstanding people </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to developing outstanding people and giving people opportunities to grow. All GSK people are expected to have an agreed development plan, regardless of grade or role, that is underpinned by a robust conversation to understand the space and support needed for them to succeed. We continue to invest in development initiatives and training that can be accessed by all through our Keep Growing Campus &#8211; a central platform for our training and knowledge sharing. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we have also redesigned our talent framework &#8211; focusing our reviews for our people against performance, living our culture and future potential. This gives us a simpler assessment process, in line with our culture, to support placing our best people in our most critical roles, with strong and diverse succession plans. This allows us to spend more time on development and action planning and less on process. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Health and wellbeing improvements </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have announced improvements to our health and wellbeing benefits, to better support people through different life stages and to make sure our offerings are fair and inclusive. These include a new global minimum standard of 18 weeks&#8217; parental leave for primary and secondary carers for all forms of family, a new global minimum standard for care of a family member for end of life or serious health emergencies, insured benefits to include same sex partners wherever possible, a new financial wellbeing service and mental health training &#8211; available to everyone. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In November, we gave a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> discretionary payment to our people who were feeling the greatest impact of rising <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-of-living</div></div> challenges. This payment was given to almost half of our global workforce in 47 of our 83 countries, using consistent criteria to determine eligible countries. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Understanding how our people experience GSK </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We regularly measure how our people experience GSK, including progress in our culture focus areas and as a place to work. This includes an annual survey for all employees featuring questions on engagement, confidence, inclusivity, our culture focus areas and trust priorities. We also run a series of pulse surveys each year, with a statistically significant population, to get timely insights on our culture progress as well as hot topics of the moment. Over the last year, our progress is demonstrated by increased engagement at 81% in 2022, up from 78% in 2021, confidence in delivery of our ambitions, and positive trends in Ambitions for Patients, Accountability for Impact, Doing the Right Thing, and measures of inclusion. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To measure the effectiveness of our global manager population, their teams provide feedback via an annual One80 survey. Managers receive anonymised aggregate feedback on their effectiveness in motivating their team, focusing people on what matters most, leading with care, inclusive leadership and supporting performance and development. In 2022, 77% of our managers were rated as highly effective by their reports. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recognising and rewarding our people </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Sharing our success and recognising and rewarding our people, not just on the progress we have made but how we have made it, continues to be an important part of our culture. In addition to our bonus scheme that rewards performance across the company, each year we award 10% of our population with extra &#8216;Ahead Together&#8217; awards for those delivering exceptional performance in line with our culture. And 5% of people are identified as Missed Performance for those that do not deliver on their objectives or live the culture. This year, in addition to our annual bonus and long-term incentive structure, we also gave a special thank you to all our people (excluding the GSK Leadership Team (GLT)), allowing us to recognise in real time what we achieved together in preparation for separation and the unprecedented transformation of GSK: everyone received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> week&#8217;s salary in March, separate to our 2021 bonus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay-out.</div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We remain energised to continually live and evolve our culture in line with the internal and external environment. It is part of everyone&#8217;s objectives, starting at the top, with all leadership team members having ambitious goals to embed and grow culture, and shows up in how we act every day. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_8" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Our external environment </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">Here, we set out five major themes that have influenced our environment &#8211; </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">and how we work with governments, regulators and industry partners to keep </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">providing medicines and vaccines to patients worldwide. </div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Life sciences continue to be shaped by new technology </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Rapid advances in science and technology are changing life sciences R&amp;D. This is particularly evident in the expansion of artificial intelligence and machine learning (AI/ML), which has the potential to transform outcomes for patients by making R&amp;D more precise and productive. Research has identified nearly 270 companies working in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-driven</div> drug discovery industry.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div> We&#8217;re investing in building our own AI/ML capabilities and forging partnerships to further strengthen our position. Other biopharma companies are also collaborating with AI organisations, with 46 partnerships struck in 2022, compared to 28 in 2016.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">The pivotal role of innovation in managing the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">underscored the potential of new technologies and approaches to improve patient outcomes. Growth areas include next-generation vaccines, where there has been a substantial increase in assets in development, driven by the advancement of mRNA and DNA vaccine technology.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Greater use of new technologies and digital tools, as well as growth of decentralised trials, is accelerating a drive towards modernisation of clinical trial and regulatory processes.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Governments and regulators are continuing to build on lessons learned from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and expand international collaboration on complex trials and further develop policies and</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">infrastructure for responsible access to public datasets. As AI/ML advances, different regulatory approaches on the use of AI in medicines are emerging.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Collaboration is also needed to create common models and standards for AI regulation that support innovation and benefit patients.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div>&#8201;&#8201;Read about our focus on data and platform technologies on pages 18 and 19</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_12a.jpg"/> </div></td></tr></table><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Geopolitical tensions prompt countries to shift their priorities and focus </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Scientific and technological advances offer significant promise for patients. But geopolitical tensions are putting pressure on the systems needed to deliver this innovation. Rising nationalism and friction between countries, due to the conflict in Ukraine and tensions between the US and China, bring potential risk and disruption. In the face of these tensions, governments are taking more interventionist actions to protect their domestic economic competitiveness, strengthen national security, create domestic jobs and improve public health.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">There were notable examples of solidarity during the year. Constructive World Trade Organization discussions about reducing tariffs demonstrated</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">that governments recognise the importance of minimising trade friction. But domestic interests remain the priority with governments encouraging companies to localise and shorten value chains<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div>, prioritising strategic resilience over efficiency. Policies to restrict trade and secure access to essential items including medical goods have persisted. For example, in 2022, governments introduced over 150 harmful policy interventions affecting trade in pharmaceutical goods.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">4</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">In an environment defined by tensions, trade disruption and economic uncertainty, health and life sciences continue to be viewed as sectors of strategic importance for governments across advanced markets, including</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">the US, Europe and the UK. In March 2022, the US enacted a new federal agency &#8211; Advanced Research Projects Agency for Health &#8211; to improve the government&#8217;s ability to speed biomedical and health research. Life sciences was earmarked as a key strength in the UK government&#8217;s new Growth Plan.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">5</div> Given their potential to bolster economic productivity and protect lives, healthcare and life sciences are likely to be subject to more muscular industrial policy interventions such as additional support for R&amp;D, as well as state scrutiny over supply chain resilience.</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_12b.jpg"/> </div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="3" style="vertical-align:top"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">1&#8194;&#8201;&#8201;AI in biopharma research: A time to focus and scale | McKinsey 10&#160;October 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">2&#8194;&#8201;&#8201;Deep Pharma Intelligence, Artificial Intelligence for Drug Discovery Landscape Overview Q3 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">3&#8194;&#8201;&#8201;KPMG Singapore, six key trends impacting global supply chains in 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">4&#8194;&#8201;&#8201;Global Trade Alert</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">5&#8194;&#8201;&#8201;HM Treasury, The Growth Plan 2022, September 2022</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Our external environment continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Economic slowdown as energy crisis and inflation bite </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Lockdowns at the height of the pandemic weighed on economies worldwide and the outlook continued to weaken in 2022. Global growth was forecast to slow to 3.2% in 2022<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div> amid surging inflation, heightened geopolitical uncertainty and tightening financial conditions. Energy prices soared across Europe due to increased demand and restricted supply, contributing to rising inflation. This has had immediate and challenging consequences for individuals and businesses.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">With energy prices climbing, governments have staged significant and costly interventions to protect households, seek alternative energy sources, and invest in renewable energy infrastructure. Government interventions on this scale risk growing fiscal deficits and put pressure on other areas of public spending, including healthcare. During the pandemic, healthcare spending increased as governments rolled out</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">vaccination programmes. But spending is estimated to have fallen in real terms during 2022 as it failed to keep pace with inflation.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">7</div> Medicines spending is expected to return to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-pandemic</div> growth rates by 2024, albeit with pricing and value under increasing scrutiny over the next few years due to economic pressures and geopolitical disruption.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">8</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">As governments meet economic headwinds, cost containment measures are on the rise, with healthcare budgets facing significant pressures in the UK, EU and other advanced markets. In August 2022, the US President signed into law the Inflation Reduction Act. This includes provisions to drive down US national debt through higher taxes, lowering energy costs, and lowering drug prices. Parts of the Act that focus on patients are welcome as they bring benefits to people who would otherwise face challenges accessing important vaccines. But there are</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">concerns over negotiation provisions, allowing the federal health secretary to negotiate prices of certain expensive drugs each year for Medicare. This could potentially limit investment in innovation.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">As well as cost containment, we are also seeing more examples of innovative contracting to support prudent stewardship of healthcare spending. Companies and payers are continuing to explore innovative pricing models, which facilitate patient access and support payer confidence in the value of a medicine or vaccine at the time of launch.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div>&#8201;&#8201;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Read more about pricing and access on<br/>page 43</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_13a.jpg"/> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Green transition disrupted but long-term momentum remains </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The energy crisis has not only weakened economies, but also disrupted the green transition. Amid concerns over reliability, supply and affordability, policymakers face conflicting priorities. While energy transition is necessary to mitigate climate change, immediate energy needs are driving renewed investment in traditional fossil fuel energy sources. European countries announced plans to revert to higher coal usage to produce electricity, while the US has taken steps such as reopening oil and gas leasing on public lands.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Investor sentiment, particularly in the US, has seen similar shifts as the ESG agenda becomes increasingly polarised and politicised. During the year, Florida and Texas implemented measures banning their pension funds from investing through any asset managers that have policies on excluding fossil fuels or taking ESG factors into account.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Against this fractured backdrop, corporate net zero efforts remain in the spotlight with stakeholder expectations on credibility and transparency on net zero continuing to rise. But voluntary commitments and coalitions are being tested with, for example, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">UN-backed</div> Race to Zero dropping its explicit bar on support for new coal projects.</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Despite the disruption seen during 2022, getting ahead of climate change remains a long-term investor and societal expectation, and a government priority. This was reinforced by the $369&#160;billion clean energy investment in the US Inflation Reduction Act. Any setback to the energy transition is likely to be time-limited, so companies must continue to demonstrate leadership on the issue and remain committed to cutting<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>their climate impact.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div>&#8201;&#8201;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Read more about climate and nature on<br/>pages 45 and 46</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_13b.jpg"/> </div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">6&#8194;&#8201;&#8201;IMF, World Economic Outlook, October 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">7&#8194;&#8201;&#8201;Economist Intelligence Unit, Healthcare outlook 2023 (eiu.com)</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1.5em; text-indent: -1.5em; font-size: 7pt; font-family: ARIAL; line-height: normal;">8&#8194;&#8201;&#8201;IQVIA, Global Use of Medicines 2023</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Our external environment continued </div></div><div style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Access in focus as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> shines light on health inequity </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> demonstrated the value of the life sciences sector and the potential for delivering innovative interventions at speed. But the pandemic also raised questions about the pace at which medicines and vaccines could be rolled out, shining a light on inequalities in access and healthcare outcomes both within and between countries. Around 26% of people in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> countries are partially or fully vaccinated against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> compared with 80% in high-income countries.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">9</div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Scrutiny of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine rollout has reignited the debate around the intersection between intellectual property (IP) rights and access to medicines and vaccines. This was evidenced by the TRIPS waiver, agreed in June 2022, which temporarily removes developing country obligations on patent protections for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines. Such a step doesn&#8217;t address inequitable access and instead undermines industry&#8217;s ability to partner, invest at risk, and respond quickly to </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">future pandemics. </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Industry has sought to encourage a more holistic approach to realising equitable and timely access during future pandemics. This recognises the multiple factors that enable access, such as sustainable funding and free trade. The international pharmaceutical industry, along with biotechs and vaccine manufacturers based in developing countries, united behind a vision for access in future pandemics, known as the Berlin Declaration. This outlined industry&#8217;s willingness to reserve an allocation of real-time production for distribution to priority populations during future pandemics. The success of such an approach will rely on having a strong innovation ecosystem; removal of regulatory and trade barriers to export; procurement mechanisms for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> and middle-income countries; and robust health systems. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">More resilient health systems are needed not only to counter the increasing threat of infectious disease emergencies, but also to manage the growing burden of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-communicable</div> diseases. Delays to cancer diagnosis </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">and treatment during the pandemic could have an adverse effect on survival for years to come. As health systems continue to manage the long-term repercussions of the pandemic, there is an opportunity to move towards new models of care that enable earlier action to prevent, diagnose and treat disease. Investing in prevention to get ahead of disease has a clear return. It improves health outcomes, is cost-effective, and contributes to healthier lives, societies and economies. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">See pages 43 to 45 for more on pricing and access, and global health and health security</div></div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_14.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Our position </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In a challenging economic and political landscape, it&#8217;s more important than ever that we invest in a pipeline of vaccines and specialty medicines that will meet changing and unmet healthcare needs. At the same time, we have to work with governments, regulators and industry partners to make sure these medicines and vaccines can reach patients, bringing value to both the people who need them and payers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Scientific innovation and improving health remain a critical pathway to sustainable economic growth. We therefore continue to work with our peers and governments to make sure that the policy and regulatory environment stimulates and sustains innovation. This includes, for example, </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">advocating for appropriate IP protections; a balanced regulatory framework that supports the discovery and delivery of vaccines and medicines developed through emerging technologies; and reinforcing the importance of global, diversified supply chains. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As the pricing environment becomes tougher, we are well placed to offer a differentiated, high-value pipeline across prevention and treatment of disease. This is built on using new technology and techniques to make our R&amp;D faster and smarter. Demand for data and real-world evidence to support continued reimbursement of new products is likely to increase. We continue to work with payers to design innovative solutions that manage their </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">risk and uncertainty, while also recognising the full health, social and economic value of innovative medicines and vaccines. We also continue to collaborate with global health partners to increase our reach to patients in lower income countries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To support delivery of innovative medicines and vaccines, we continue to advocate for investment in resilient healthcare systems around the world. More robust infrastructure is needed to support, for example, routine life-course immunisation. Getting ahead of future pandemics, and managing them more effectively when they do happen, starts with investing in health systems and improving public health now. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">9</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Financial Times, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine tracker: the global race to vaccinate, as at 23&#160;December 2022 </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div id="ex15_2tx382677_9" style="margin-top:0pt; margin-bottom:0pt; font-size:44pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Research and </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:44pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">development </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">Science and technology have never before opened up so many possibilities </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">for new vaccines and medicines for patients. In 2022, we&#8217;ve continued to </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">harness the science of the immune system alongside genetics, genomics </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">and advanced technology to continue to strengthen our pipeline. </div><div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_15.jpg"/> </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Highlights </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:36pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&gt;</div>20</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2/3rds</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">vaccines and medicines</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">in the pipeline</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">new approvals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">since 2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">of our pipeline comes from</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: ARIAL; line-height: normal;">infectious diseases and HIV</div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:7pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="2" style="height:7.5pt"></td>
<td colspan="2" style="height:7.5pt"></td>
<td colspan="2" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> RSV older adults candidate vaccine filed in US, EU, Japan</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> interim <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-year</div> data presented at ID Week 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Continued progress in development of long-acting HIV treatments; positive phase II data on N6LS broadly-neutralising antibody presented at HIV Glasgow</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Pivotal phase III trials for gepotidacin antibiotic for uUTIs stopped early for efficacy</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Positive phase IIb data for bepirovirsen, our investigational treatment for chronic hepatitis B, and started phase III study in early 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Expansion of depemokimab phase III programme with trials for long-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> inhibitor in three additional eosinophil-driven diseases</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Business development including: acquisition of Affinivax giving access to disruptive MAPS technology and phase II next-generation vaccine for pneumococcal disease; acquisition of Sierra Oncology adding momelotinib for myelofibrosis patients with anaemia (regulatory submission EU, US); and exclusive licence with Spero Therapeutics giving access to tebipenem HBr, a late-stage antibiotic for cUTIs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;vertical-align:top">&#160;</td></tr></table></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our R&amp;D approach </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">R&amp;D is central to our purpose to get ahead of disease together. By combining the science of the immune system, genetics, genomics, advanced technologies and outstanding talent, we discover and develop vaccines and medicines to make a transformational impact on people&#8217;s lives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, R&amp;D expenditure was &#163;5,488&#160;million, up 9% at AER, 4% at CER, from 2021 and we have strengthened our pipeline and platform capabilities through strategic business development. This means we have 22 vaccines and 47 medicines in development (see page 28). Many have the potential to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class.</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our late-stage R&amp;D aligns to four therapeutic areas: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">infectious diseases, see page 20 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">HIV, see page 23 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">immunology/respiratory, see page 24 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">oncology, see page 25 </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our research team takes an approach that follows the science to identify opportunities with the greatest probability of success to lead to differentiated vaccines and medicines, including opportunities outside these four areas. Our scientists prioritise genetically identified targets that are at least twice as likely to succeed in the clinic. They also prioritise infectious disease targets and immune-modulators that have greater lifecycle opportunities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Prioritising execution and technology </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our priorities are: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">flawless execution of our late-stage pipeline and acceleration of our organically derived pipeline </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">doubling down on technology to deliver further innovation faster </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">finding new ways to help patients through lifecycle innovation </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">targeted business development to push towards new discoveries </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Flawless execution and acceleration of our pipeline </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our pipeline, across all phases, has 69 potential vaccines and medicines, more than 70% of them modulating the immune system and more than 70% with human genetic validation. In 2022, we started 16 phase I programmes, moved nine candidates into phase II and started five phase III programmes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also achieved industry-leading milestones, including the approval and launch of the first long-acting HIV medicines and the FDA priority review of the exceptional RSV older adult vaccine candidate with a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> profile. We also presented new data at IDWeek 2022 showing that <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> can provide at least 10 years of protection against shingles in the over 50s, and completed our acquisition of Affininax. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have made significant progress in improving key measures of productivity. We reduced overall cycle times by 20% from the start of new drug discovery projects through to the end of phase I (for 2019-2021 compared to 2016-2018), and we now have a phase I portfolio that includes many potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> medicines. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Doubling down on technology to deliver further innovation faster </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We believe the combination of science and technology holds the key to fundamentally transforming medical discovery, improving success rates and shaping how we treat and prevent even the most challenging diseases. This is why technology plays a growing role in progressing our R&amp;D towards vaccines and medicines not previously thought possible. It covers: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">data technology, which helps us to understand the patient and human biology, choose targets and design clinical trials. We have access to large, rich datasets thanks to our data-focused collaborations, including our recent collaboration with Tempus (see page 19) as well as established partnerships, for example with 23andMe, the UK Biobank, and the Laboratory of Genomic Research with the University of California (see page 18) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">platform technology, for the efficient design and development of new vaccines and medicines. We have access to a broad set of platform technologies, including an unrivalled suite within vaccines like mRNA, MAPS and adjuvant science, and a growing investment in oligonucleotides (see page 19) </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finding new ways to help patients through lifecycle innovation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We look to innovate throughout the lifecycle of our vaccines and medicines by exploring new ways for them to treat patients. Examples include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approval in the US for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div>, for immunisation during pregnancy to prevent whooping cough in newborn babies </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">FDA approval for a new, more convenient presentation of our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div> vaccine to prevent gastroenteritis caused by rotavirus </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix</div></div>, our vaccine against measles, mumps and rubella, in the US for children over 12 months </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approval of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-dose</div> regimen for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>, our human papillomavirus vaccine for girls aged 9 to 14, in China </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approval in China for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> to treat adults with active lupus nephritis (LN) and FDA approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> for paediatric patients with active LN </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">continue to develop a new monoclonal antibody, depemokimab, under development for its high affinity and long-acting suppression of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> function </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pushing towards new discoveries through strategic business development </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We work with commercial organisations and academic institutions to find new research and discovery opportunities, access new technology platforms or to progress the development of our pipeline. We remain agile and ambitious, looking for opportunities that address high unmet medical needs and complement our R&amp;D strategy. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We look to grow our pipeline through acquisitions. In 2022, these included Affinivax adding a novel class of next-generation pneumococcal vaccine candidates and innovative MAPS technology (see page 20), and Sierra Oncology adding momelotinib for the treatment of mylefibrosis (see page 25). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also announced five new collaborations, giving us access to exciting new vaccines, medicines and technologies, and deepening our understanding of how to prevent and treat disease. We partnered with precision medicine company Tempus, with oncology being a first area of focus. We added to our pipeline through new partnerships with Mersana Therapeutics for an option to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> and commercialise their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056</div> immunosynthen antibody-drug conjugate in oncology, with WuXi to progress <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> engaging antibodies for oncology and with Zheming to progress a phase I TLR8 agonist for hepatitis B virus (HBV). We announced a new partnership with Wave Life Sciences to drive discovery and development of oligonucleotide therapeutics, including a programme for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">alpha-1-antitrypsin</div></div> deficiency with a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-editing</div> mechanism of action, and we also announced an exclusive licence agreement with Spero Therapeutics for tebipenem HBr, a late-stage antibiotic that may treat cUTIs. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Genetics, genomics and advanced technologies </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">To get ahead of disease, we use innovative tools to maximise our chances of success and accelerate the pace of discovery. Genomics and the predictive power of AI/ML are changing how we find the right medicines for the right patients. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Advanced technologies and real-world data are bringing patients into the discovery and development process earlier. This, in turn, improves how researchers can integrate data into decision making. For diseases like cancer or neurological conditions, we&#8217;re investigating how tools like genetic validation, wearables, genomics and AI/ML can provide important insights that make us better at choosing drug targets and the specific groups of patients in which to study them. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Data produced using these tools helps us: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">select novel targets that are genetically validated and so more likely to become approved medicines and vaccines </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">design clinical trials to include the patients most likely to benefit from our potential medicines and vaccines </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">recruit these patients faster, and accelerate the pace of our clinical trials </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Improving drug discovery with the power of genomics and partnerships </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Today, more than 70% of the projects in our pipeline are supported by human genetic evidence, informed by the large genetic datasets from our ongoing collaborations with the UK Biobank, 23andMe and FinnGen. In 2022, we were a founding member in the creation of Our Future Health, an ambitious UK effort aiming to recruit up to five million people to capture a wide range of medical and genetic information. We&#8217;re also working with Genes&#160;&amp; Health and Discover Me South Africa to further expand this work and ensure a diverse and robust genetic representation of diseases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In our collaboration with the consumer genetics and research company 23andMe we have approximately 50 active joint drug discovery programmes for genetically validated targets. In 2022, we extended our collaboration for a fifth year to identify and validate additional new drug targets until July 2023. This year we also took on sole development responsibility for phase I of the collaboration programme consisting of an investigational antibody targeting CD96 as a novel immuno-oncology agent. This is an investigational antibody that is currently being evaluated for cancer alongside other GSK medicines. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Several collaborations in functional genomics are providing further insight to improve our target selection. We work with a range of institutions innovating in this fast-moving field, from CRISPR pioneers to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-ups.</div> In the US, this includes dedicated genomics research centres, such as the Altius Institute in Seattle and the Broad Institute affiliated with MIT and Harvard University in Boston. We continue to partner with Adrestia, a British biotech, and with Open Targets, a UK consortium where we&#8217;re a founding member. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">These advances complement the progress we&#8217;re making at the genomics lab we founded in 2019 with CRISPR pioneers at the University of California in San Francisco. The Laboratory for Genomic Research is now advancing a portfolio of 16 active technology and biology projects. By automating and advancing CRISPR, our scientists work side by side with academic researchers to uncover new knowledge about disease mechanisms for immunology, oncology and neurology. Scientists are creating new technologies that stem from CRISPR, and they are identifying additional applications of these technologies to find better starting points for new medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">CRISPR and other tools contribute to the data we have to understand the underlying causes of disease. Other information sources range from tissue and blood samples to human behaviour from wearable technology. Our proprietary AI/ML capabilities help our researchers interpret this volume of data and also make connections and predictions that help identify which targets are most likely to succeed. As assets move through our pipeline, both AI/ML and functional genomics continue to play a role, including in optimising clinical trial design, for example as happening now with bepivorisen. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Building <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> AI/ML teams and expanding our collaborations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">AI/ML enables us to generate deeper insights from our own research data and our collaborations. Our work in applied AI/ML primarily focuses on two areas in R&amp;D: at the early discovery stage to find genetically validated targets, and at the clinical stage to match patients with the right medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;ve built one of the largest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> functions dedicated to AI/ML, and we work with partners to lead the way in these fields. Our AI/ML team includes more than 160 experts based at key GSK R&amp;D sites, including London, San Francisco, Tel Aviv, Philadelphia and Boston. Combining our team with the resources and expertise of our partners helps us collect more data, find patterns in genetic data faster than we could before and, ultimately, helps us increase our success rates in making life-changing medicines. We continue to expand our partnerships with world leader data aggregation companies such as Tempus to further complement our internally generated data. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our models are becoming more and more advanced with every iteration. We&#8217;ve created a new imaging tool using AI/ML that we are using to inform target selection and potential business development opportunities in a challenging and complex disease area, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> steatohepatitis (NASH). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Also, through a partnership with King&#8217;s College London, we&#8217;re using tumour models alongside digital pathology and AI to develop personalised immuno-oncology treatments for several solid cancers, including lung, gastrointestinal and women&#8217;s cancers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Oxford-GSK</div> Institute of Molecular and Computational Medicine (IMCM), which we established in partnership with Oxford University in December 2021, combines human genetics with functional genomics and ML to focus on neurological diseases like ALS, Alzheimer&#8217;s and Parkinson&#8217;s. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our collaborations in data technology complement our existing capabilities and resources and include ongoing work with Cerebras, the pioneer in high performance AI computer systems, and NVIDIA, a global leader in AI hard and software. In 2022, we started two other data collaborations: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">PathAI, a global leader in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-powered</div> pathology, aimed at accelerating R&amp;D in oncology and NASH. We&#8217;ll combine our predictive and data-driven approach to drug discovery and trials with PathAI&#8217;s models to build algorithms that uncover new insights. We&#8217;ll integrate these into trials to help us predict which patients will be impacted most </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Tempus, which enables access to their library of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-identified</div> patient data. Tempus&#8217; dataset draws from its work with over 40% of oncologists in the US at academic medical centres and community hospitals. We will work with Tempus to improve clinical trial design, speed up enrolment and identify drug targets, with an initial focus on oncology </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Platform technology across vaccines and medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our work to use technology to drive drug discovery also includes expanding our platform capabilities. These technologies allow us to broaden the range of options for future medicines and vaccines, going beyond existing modalities like small molecules, antibodies and adjuvants to help immune responses to vaccines, but importantly also ensure we remain highly competitive by being faster and more confident in identifying new medicines from our genetically validated targets. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We develop these technologies ourselves and through external collaborations. Key areas for new medicine and vaccine technologies that we&#8217;re actively investing in include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">MAPS (multiple antigen presenting system), a novel and highly efficient vaccine technology platform that potentially enables broader coverage, generating higher antibody responses. MAPS has mainly been directed at preventing pneumococcal disease and has also shown promise in addressing other infectious disease pathogens, including those that cause hospital-acquired infections </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">mRNA, which was validated by the launch of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines in 2020 and could potentially be applied across a number of diseases. We&#8217;re progressing the development of the mRNA technology <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house,</div> in parallel with our CureVac collaboration. We&#8217;re currently evaluating a second generation mRNA backbone, which we developed with CureVac, in a phase I trial featuring modified mRNA vaccine candidates targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and flu. Based on the promising preliminary analysis of these studies, evaluating safety, reactogenicity and immunogenicity, we are preparing to move these candidates into late-stage clinical testing </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">RNAi and oligonucleotides including: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARO-HSD,</div> a phase II programme for NASH, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> from Arrowhead in 2021, consisting of an RNA interference (RNAi) molecule against a genetically validated target; and bepirovirsen, an anti-sense oligonucleotide designed to recognise HBV DNA, in phase III, which we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> from Ionis in 2019. We also announced a collaboration with Wave Life Sciences, which allows us to advance up to eight preclinical programmes using Wave&#8217;s PRISM oligonucelotide platform and includes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> of a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-editing</div> oligonucleotide to treat liver and lung disease caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">alpha-1-antitrypsin</div></div> deficiency </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">monoclonal antibodies (mAbs) such as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-developed</div> with Vir Biotechnology, as well as other research programmes </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">new ways to understand the biology and pharmacology of genetically validated targets and how best to intervene in their disease processes. Our Chemical Biology group has developed several such methods, including chemogenomic libraries, encoded libraries, and reactive fragments, in part in collaboration with the Francis Crick Institute. These novel technologies help find critical starting points for drug discovery projects </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">natural products derived from the biosphere, such as the collaboration we started with LifeMine Therapeutics in 2022, which gives us access to its platform for proprietary evolutionary-derived genomic drug discovery </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies for multiple auto-immune diseases that are advancing through preclinical phases </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">digitisation to optimise each phase of vaccine development and production. Working with Siemens and Atos, two of the world&#8217;s leading digital transformation and technology companies, we&#8217;ve developed a &#8216;digital twin&#8217;, a complete and real-time simulation of the vaccine manufacturing process. </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Infectious diseases </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Two-thirds</div> of the vaccines and medicines in our pipeline address the global public health burden of infectious diseases, such as those caused by HIV, RSV, meningococci, hepatitis B, rotavirus and antibiotic resistant bacteria. These diseases cause significant morbidity and mortality and put strain on global healthcare systems. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we generated pivotal data for our RSV candidate vaccine for older adults and positive interim analysis readout for gepotidacin, our antibiotic to treat uUTIs and gonorrhoea. Both have the potential to be first and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class.</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also sought opportunities to boost our pipeline through business development. In 2022, we completed our acquisition of the clinical-stage biopharmaceutical company Affinivax. It has pioneered a novel class of next-generation pneumococcal vaccine candidates. These include a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-valent</div> vaccine candidate for adults, which has completed phase II, and a paediatric version currently in phase II. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-plus</div> valent pneumococcal vaccine programme is in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development. These vaccines incorporate the MAPS technology (see page 19). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our new partnership with Spero Therapeutics, Inc. gave us an exclusive licence agreement for tebipenem HBr, a late-stage antibiotic being developed by Spero. This is the first oral carbapenem antibiotic, and it has the potential to treat cUTIs. With a clear FDA regulatory path to potential approval, tebipenem HBr will address an unmet medical need for a novel oral antibiotic as an alternative to intravenous hospital therapy for drug-resistant cUTIs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">RSV is a major cause of acute respiratory illness in older adults and is currently one of the major infectious diseases without a vaccine. RSV can worsen underlying conditions and cause pneumonia. It leads to approximately 420,000 hospitalisations and over 29,000 deaths a year in adults in industrialised countries. Around 94% of people hospitalised with RSV have underlying comorbidities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we became the first company to announce positive phase III efficacy data for a RSV older adult vaccine candidate. Interim results from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARESVI-006</div> phase III pivotal trial showed vaccine efficacy of over 94%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div> observed against RSV lower respiratory tract disease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(RSV-LRTD)</div> in adults with at least one comorbidity of interest and in those with severe disease. Overall vaccine efficacy against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RSV-LRTD</div> was 82.6%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>, meeting the trial&#8217;s primary endpoint. Consistent high vaccine efficacy was observed across a range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> secondary endpoints, including against severe disease, in adults aged <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">70-79</div> and across RSV A and B strains. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The vaccine was generally well tolerated, with a favourable safety profile. These data were presented as part of the Infectious Disease Society of America&#8217;s IDWeek 2022 annual meeting in Washington, DC, in October. We also shared positive data on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-administration</div> of our RSV older adult vaccine candidate with a flu vaccine, a key finding for practical immunisation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Based on these data, the vaccine candidate was granted Priority Review by the FDA. It was also accepted for accelerated assessment by the European Medicines Agency (EMA) and for review by the Japanese Ministry of Health, Labour and Welfare (MHLW). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re committed to finding solutions for people at high risk of the serious consequences of RSV infection. In 2022, we started a clinical trial exploring the effect of the RSV older adult vaccine candidate in people aged <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50-59,</div> including those at increased risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RSV-LRTD,</div> compared to people 60 and over. We also began two further flu <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-administration</div> trials. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARESVI-006</div> trial will also continue to evaluate an annual revaccination schedule and longer-term protection over multiple seasons. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shingles </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Approximately one in three adults develop shingles, a painful and potentially serious illness. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> is the first approved shingles vaccine to combine a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-live</div> antigen with one of our adjuvants. It may help overcome the natural <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">age-related</div> decline in immunity that contributes to the challenge of protecting people aged 50 and over from this disease. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> is now available in 26 countries, and we&#8217;ve continued to broaden access to it in 2022. In Japan, where <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> is already approved for people over 50, we&#8217;ve also submitted an application to extend the indications to include over <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">18-year-olds</div> at risk, such as those with immune suppression and immune deficiency. The US Cancer Network has recommended <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> for cancer survivors over 19, and the vaccine has a preferential recommendation from the Brazilian Immunization Society. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We presented new data at IDWeek 2022 showing that <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> can provide at least 10 years of protection against shingles in the over 50s. In the primary endpoint analysis, the interim data showed overall efficacy of more than 80%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div> in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period of approximately six to ten years after initial vaccination. No new safety concerns were identified during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period. These data significantly add to the real-world evidence demonstrating the long-term benefit of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">VE 94.1% (1 of 12,466 versus 17 of 12,494); 94.6% (1 of 4,937 versus 18 of 4,861); VE 82.6% (7 of 12,466 versus 40 of 12,494) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">VE 81.6% (52 cases in 32673.8 f/u years versus 283 cases* in 32673.8 f/u years); *cases for the placebo group are estimated from the ZOE-50/70 placebo groups to assess vaccine efficacy during ZOE-LTFU study; f/u: follow up; (95% confidence interval [CI]: 75.2&#8211;86.6) </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Meningitis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Around 1.2&#160;million people develop invasive meningococcal disease (IMD) each year. It can be fatal, and 10&#8211;20% of survivors will have long-term disabilities such as brain damage, deafness, nervous system problems or loss of limbs. Bacterial meningitis is also of particular concern. One in 10 people who are diagnosed with bacterial meningitis end up dying, and 1 in 5 are left with severe complications. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div>, our meningitis B vaccine, and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div>, our meningitis ACWY vaccine, are registered in more than 60 countries, and together protect against most forms of IMD. Since launch, more than 150&#160;million doses of these vaccines have been distributed. In 2022, we received FDA approval in the US and ANVISA approval in Brazil for a fully liquid, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-use</div></div> single vial presentation of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div>. This gives healthcare providers a more convenient option by removing the need to reconstitute the vaccine. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our investigational first generation MenABCWY candidate pentavalent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(5-in-1)</div></div> vaccine combines the technologies used in our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div> vaccines. The goal of introducing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-in-1</div></div> meningitis vaccine is to protect people against the five serotypes that cause most disease with just one vaccine, not two. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-in-1</div></div> meningitis vaccine has the potential to help improve vaccination rates by providing a more convenient way to prevent IMD. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">MenABCWY is currently in phase III development, in a trial spanning five countries with 3,650 participants aged <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-25.</div> We expect results in early 2023. New multivalent vaccines like this have the potential to support the global strategy to defeat meningitis by 2030, set out in the World Health Organization&#8217;s Global Road Map. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">A second-generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-in-1</div></div> meningitis vaccine is currently in phase II and is aimed at improving protection against B strains and allowing for broader age indications globally. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">By the end of 2022, more than 650&#160;million cases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> had been reported around the world, and there had been over 6.5&#160;million deaths. The disease continues to challenge healthcare systems. We and our innovation partners have been part of the response, developing treatments and vaccines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> with </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> (sotrovimab) is our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> monoclonal antibody treatment, developed with Vir Biotechnology. It works by preventing the virus from entering and infecting healthy cells in the body. It has been an important part of early treatment to prevent high-risk patients from developing severe disease. With Vir, we developed sotrovimab from discovery to approval in less than 1.5 years. We have delivered over two million doses of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> to over 30 countries including government purchases to meet current and future need. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Providing solutions with new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our pandemic adjuvant technology is part of several protein-based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines we&#8217;ve developed, such as with Sanofi and SK bioscience, which are now licensed in some markets. These vaccines are important new options to help protect against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chronic hepatitis B </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Chronic hepatitis B (CHB) is a major global health issue with approximately 300&#160;million people infected and approximately 900,000 people dying annually due to liver complications, including cirrhosis and liver cancer. The mainstay of therapy includes nucleoside/nucleotide analogues (NA) which are often taken for life because they suppress but rarely clear the virus. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Bepirovirsen is the only drug in development as a monotherapy for CHB that works to reduce virus replication, suppress surface antigen and stimulate the immune system. In November 2022, phase II full-study data published in The New England Journal of Medicine demonstrated that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and HBV DNA in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> of patients followed for six months after discontinuation of their bepirovirsen. Levels of HBsAg and HBV DNA together are key efficacy measures. When HBsAg and HBV DNA remain undetectable for more than six months without medications, patients are considered to have a functional cure, an outcome associated with significant decreased risk developing cirrhosis, hepatocellular carcinoma and death. Currently, standard of care treatment with NA rarely achieves functional cure, which is why new therapies are needed for patients diagnosed with chronic HBV. Our phase III study which started in early 2023 will build our understanding of how bepirovirsen works. Our aim for bepirovirsen is for it to become a potential monotherapy or the backbone of future therapy for hepatitis B patients. We are exploring potential sequential treatment trials and expect to share data later in 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other infectious diseases </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diptheria, tetanus and pertussis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Since 2010, there have been up to 48,000 cases of pertussis (whooping cough) in the US each year, with infants more likely to experience complications from the disease. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div>, our tetanus, diphtheria and pertussis vaccine (Tdap), received approval from the FDA in October 2022 for immunisation during the third trimester of pregnancy for the prevention of whooping cough in newborn infants. This makes it the first vaccine in the US approved specifically for use during pregnancy. The vaccine is approved in 80 countries, including in the EU, Canada, Australia and New Zealand. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rotavirus </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In November 2022, the FDA approved the new fully liquid presentation of our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div> vaccine to prevent gastroenteritis caused by rotavirus. This new presentation makes it more convenient for healthcare providers to prepare <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div> by removing the need to reconstitute the dose at the point of use. We expect it to be commercially available in early 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Varicella </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In February 2022, we started a phase II study in the US with children aged <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-15</div> months to compare the safety and immunogenicity of our varicella (chickenpox) new strain candidate vaccine with the vaccine currently available. The aim is to develop a vaccine that fits the Advisory Committee for Immunization Practices&#8217; (ACIP) recommended US immunisation schedule and offers healthcare professionals and parents an alternative to the current vaccine. This varicella new strain vaccine could also be used as a component of the measles-mumps-rubella-varicella vaccine in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herpes simplex virus </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have started a phase I study to investigate the potential of GSK 3943104A, an immunotherapeutic against herpes simplex virus (HSV). The aim is to offer a better solution for people with the virus than current standard of care. The study is gathering safety and immunogenicity data on GSK 3943104A in healthy people. Phase II development will focus on safety and immunogenicity, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> efficacy. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Human papillomavirus </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Human papillomavirus (HPV) is a common sexually transmitted infection &#8211; around 14&#160;million people a year become infected in the US alone. It often has no symptoms but can cause genital warts or cancer. We&#8217;ve begun a phase I/II study of our next-generation adjuvanted vaccine, developed in collaboration with Innovax, to protect against nine types of HPV. The study is evaluating the reactogenicity, safety and immunogenicity of an adjuvanted vaccine candidate for girls and women aged <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-26.</div> The aim is to identify the most effective vaccine formulation to take into phase III trials. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also received approval in China for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>, our human papillomavirus vaccine for girls aged nine to 14, in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-dose</div> regimen. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pneumococcal disease </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Pneumococcal disease is the term for any illness caused by the bacterium Streptococcus pneumoniae, a leading cause of acute bacterial disease worldwide. Our acquisition of Affinivax adds a novel class of next-generation pneumococcal vaccine candidates that incorporate MAPS technology (see pages 19 and 20). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Antibiotics and antimicrobial resistance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the top 10 global health threats. By undermining the effectiveness of antibiotics, it contributes to around 1.2&#160;million worldwide deaths a year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re using our expertise in developing prevention and treatment options to focus on pathogens that have the highest probability of developing AMR, as identified by the Centers for Disease Control (CDC) and the WHO. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progressing towards a new treatment for urinary tract infections and gonorrhoea </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are developing gepotidacin, a novel mechanism topoisomerase inhibitor, for uncomplicated UTIs and gonorrhoea, in partnership with the Biomedical Advanced Research and Development Authority (BARDA) in the US. In early November, we received positive results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EAGLE-2</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EAGLE-3</div> phase III trials evaluating gepotidacin, in female adults and adolescents with uUTIs. Following a recommendation by the Independent Data Monitoring Committee (IDMC) we stopped the trials early for efficacy and plan to submit a New Drug Application to the FDA in 2023. We are also studying gepotidacin as a potential treatment for urogenital gonorrhoea (GC) in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EAGLE-3</div> phase III trial, with potential to read out in the second half of 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In November 2022, we started a phase I/II study to evaluate the safety and efficacy of a new vaccine candidate for gonorrhoea prevention. This vaccine candidate, based on our proprietary GMMA (generalised modules for membrane antigens), aims at protecting adolescents and adults against gonorrhoea infections. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we also started a phase Ib study of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> FimH antagonist, a novel molecule that blocks binding of E. coli bacteria to the bladder epithelium, as a treatment for recurrent urinary tract infection. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investigating our salmonella vaccine </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In July 2022, we started a phase I study with the University of Oxford to investigate our candidate vaccine for invasive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-typhoidal</div> salmonellosis (iNTS). The vaccine uses our generalised modules for membrane antigens (GMMA) technology. To explore its potential, we&#8217;re partnering with Vacc-iNTS, a consortium of 12 partners from eight countries, including some where iNTS is endemic. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">In recent years, we&#8217;ve made breakthroughs in treating and preventing HIV to transform patients&#8217; lives. We&#8217;re now building on these achievements with new products, including long-acting injectables which, for many, means significantly reducing therapy to just a few times a year. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">HIV is one of the world&#8217;s biggest health threats, with 1.5&#160;million new cases in 2021, including approximately 38,000 in the US. Around 38&#160;million people were living with HIV worldwide in 2021, over half of them in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-Saharan</div> Africa. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In HIV, our work is through ViiV Healthcare, the world&#8217;s only specialist HIV pharmaceutical company, which we majority own, with Pfizer and Shionogi as shareholders. Our goal is to treat, prevent and eventually cure HIV. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transforming the experience of patients living with HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">With our portfolio of 17 antiretroviral medicines, we&#8217;re transforming the experience of people living with HIV. Instead of taking medicine orally every day, our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> (cabotegravir, rilpivirine) long-acting injectable regimen allows some patients to only have treatment six times a year. The treatment has established ViiV Healthcare as the industry leader in long-acting HIV medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> is approved for dosing every two months in the US, and in Europe as the combination of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vocabria</div></div> (cabotegravir) and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rekambys</div></div> (rilpivirine). This combination received marketing approval in Japan in 2022, again for dosage every two months. The FDA has also approved a label update for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> that means patients no longer have to take cabotegravir and rilpivirine tablets for a month before starting <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> injections. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">ViiV&#8217;s dolutegravir is the world&#8217;s most widely prescribed integrase inhibitor for HIV, taken by around 21&#160;million people, or three out of four of those currently on HIV medications. It&#8217;s the foundation for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-drug</div> regimen oral therapies, which are as effective as three-drug regimens and allow people to take fewer drugs while still maintaining viral suppression. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Working to prevent HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Preventing HIV is a central part of ViiV Healthcare&#8217;s work. In late 2021, we received FDA approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div> (cabotegravir), the first and only long-acting injectable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-exposure</div> prophylaxis (PrEP) option to reduce the risk of sexually acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HIV-1.</div> This approval was based on results from two pivotal phase III studies, HIV Prevention Trials Network (HPTN) 083 and 084, demonstrating superiority over the established standard of care. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In August 2022, we announced more data showing the continued superior efficacy of cabotegravir long-acting for PrEP over daily tablets. The unblinded portion of the HPTN 084 trial with women in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-Saharan</div> Africa showed a substantially lower rate of HIV acquisition. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Offering a range of options for people living with HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We offer different medicines to meet the varying needs of people living with HIV. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our portfolio of antiretrovirals also includes <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div>, which contain dolutegravir. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div> now has US approval in a dispersible once-daily tablet formulation for children weighing 10kg and above and the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion recommending marketing authorisation for<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Triumeq PD</div></div> for children 14kg and above at the end of 2022. With 1.7&#160;million children living with the virus, it&#8217;s important that this medicine, the first fixed-dose tablet regimen for children, is now available in a form that&#8217;s easier for them to take. The FDA has also lowered the minimum weight at which a child can be prescribed the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div> tablet from 40kg to 25kg. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our commitment is to leave no person with HIV behind. That includes working to develop medicines for heavily treatment-experienced adults who have very few treatment options because of safety concerns, intolerance, or resistance. In 2022, we announced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">five-year</div> data for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div> (fostemsavir), a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> attachment inhibitor. In the ongoing BRIGHTE study, week 240 data shows that these patients can take fostemsavir as part of their antiretroviral regimen and keep their virus suppressed over the long term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exploring more ways to improve the lives of people living with HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re exploring new types of long-acting therapy, based on cabotegravir, that could give people living with HIV the option to take medicine at home. These involve combining cabotegravir with other assets in our early-stage pipeline to create medicines that patients can administer themselves. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re also investigating ultra-long-acting medicines with dosing every three months or longer. Based on studies in 2022 and 2023, we will choose partners for cabotegravir and begin phase IIb and phase III studies of these combinations in 2024. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In October 2022, we announced positive phase IIa data for N6LS, a novel broadly neutralising antibody (bNAb). A study showed strong antiviral efficacy at two dosing levels. bNAbs can recognise different strains of HIV and stop them entering healthy cells, and so block the virus from replicating. They offer a potentially new approach to treatment and may help us combat treatment resistance in our efforts to end the HIV epidemic. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">A European study of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vocabria</div></div> (cabotegravir injection) and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rekambys</div></div> (rilpivirine long-acting injectable suspension) showed the treatment was well received by people living with HIV and by clinic staff. In the CARISEL study, 81% of participants said the injectable treatment was less stigmatising than daily tablets, and the combination showed a high clinical effectiveness and a low rate of viral failure. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Immunology/respiratory </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">For 50 years, we have been leaders in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD), and we&#8217;ve sold products for respiratory problems since the 1880s. Now we draw on our expertise in the science of the immune system to develop medicines for immune-mediated conditions including lupus, eosinophilic-driven diseases such as severe eosinophilic asthma and other inflammatory diseases. Our innovative medicines help millions of people with immune and respiratory conditions. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Widening access to </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Benlysta</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> beyond systemic lupus erythematosus (SLE) to include lupus nephritis (LN) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">SLE is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissue in many parts of the body. It causes symptoms like swollen joints, fever, hair loss and facial rash, along with potential long-term complications including irreversible damage to vital organs like the heart and kidneys. SLE affects around five million people worldwide. LN, the kidney inflammation caused by lupus, can progress to kidney failure if left untreated. Approximately 40% of patients with SLE develop LN. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our innovative research into the role of B cells in autoimmune conditions led to the development of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> (belimumab), the only biologic approved for both SLE and LN. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> is a monoclonal antibody that targets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-lymphocyte</div> stimulator (BLyS), an underlying cause of SLE and LN, reducing autoantibody levels to help treat the short-term symptoms of inflammation and prevent irreversible damage to vital organs. In 2022, we received approval in China for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> to treat adults with active LN. We also received FDA approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> for paediatric patients with active LN. These followed earlier approvals for adult treatment in markets including EU member states, Japan and Brazil. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our ambition is to improve outcomes for lupus patients with a &#8216;treat to target&#8217; approach that aims for remission or reduced disease activity. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovating to treat eosinophil-driven diseases </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Eosinophil-driven diseases are associated with heightened levels of eosinophils, a type of white blood cell. Increased levels of eosinophils in the blood or tissue can cause a range of symptoms across a variety of conditions. When eosinophils infiltrate certain tissues, they can cause inflammation and organ damage which, over time, can affect patients&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> life. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Eosinophil-driven diseases are associated with poor symptom control such as worsening asthma, and can cause breathing difficulties and interfere with taste, smell and sleep. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> monoclonal antibody <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> (mepolizumab), targets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-5</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(IL-5)</div> to reduce the number of eosinophils. It&#8217;s the only treatment in the US and Europe with indications across four eosinophilic diseases, including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> was approved in the US, Japan and Europe as a 40mg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-filled</div> syringe for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-11-year-olds</div></div> with SEA. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-filled</div> syringe allows healthcare professionals or caregivers to administer <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> at home. Previously, children could only receive the medicine in hospitals or physicians&#8217; offices, as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-filled</div> syringes were only available in adult strength. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also continue to develop a new monoclonal antibody, depemokimab, under development for its high affinity and long-acting suppression of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> function. Current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> inhibitors are dosed every four weeks or every eight weeks. Depemokimab is designed to be administered every six months, which means it has the potential to be the first biologic to deliver ultra-long-acting treatment for patients with SEA. In 2022, we began phase III trials of depemokimab for CRSwNP, EGPA and HES, following initiation of trials in SEA in 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Otilimab </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Data from the ContRAst programme examining otilimab as a potential treatment for rheumatoid arthritis showed limited efficacy and did not support a suitable benefit/risk profile. As a result, we decided not to progress with regulatory submissions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other clinical advances </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We moved two antibodies from phase I to phase II: anti-CCL17 &#8211; a novel anti-cytokine antibody for pain in both osteoarthritis and diabetic peripheral neuropathy, representing a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-NSAID</div> analgesic therapy; and anti-IL18 &#8211; a novel anti-cytokine antibody for atopic dermatitis which was identified with the use of human genetics and human translational studies. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Cancer remains a leading cause of death with unmet patient need. We have an emerging portfolio in oncology and will develop programmes using the science of the immune system with human genetics and new technology. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In oncology, we take a balanced and pragmatic approach to investment in our research areas of immuno-oncology, tumour cell-targeting therapies and synthetic lethality. We have 11 investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also grow our oncology pipeline through targeted business development with acquisitions and collaborations. In 2022, we acquired Sierra Oncology, a biopharmaceutical company focused on therapies for rare forms of blood cancer, such as myelofibrosis. We also entered into an exclusive global licence option agreement with Mersana in a range of HER2-expressing tumours, such as breast, gastric and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancers, and an expanded global, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licence and collaboration agreement with SpringWorks Therapeutics for multiple myeloma. In 2022, we also expanded our existing collaboration with precision medicine partner Tempus, with an initial focus in oncology (see page 19). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Positive readouts for </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Jemperli</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Colorectal cancer is the third most common form of cancer, with over 1.9&#160;million new cases in 2020. We&#8217;re exploring an immunotherapy treatment with curative intent using <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli </div></div>(dostarlimab) in a subset of rectal cancer. At ASCO 2022 breakthrough findings were presented and published in The New England Journal of Medicine by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received treatment with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> as a neoadjuvant treatment for mismatch <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">repair-deficient</div> locally advanced rectal cancer. In February 2023 the FDA Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 that the two proposed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> trials would be sufficient to characterise the benefits and risks of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> in the curative-intent setting for patients with mismatch <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">repair-deficient/microsatellite</div> instability-high locally advanced rectal cancer. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In late 2022, our phase II PERLA study comparing <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> plus chemotherapy to pembrolizumab plus chemotherapy for metastatic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-squamous</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancer returned positive data. The results support our ambition for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> to be the backbone of our immuno-oncology programme, either alone or combined with standard of care and novel cancer therapies, especially for patients with limited treatment options. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our phase III COSTAR trial is studying <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> in combination with cobolimab, an investigational selective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-TIM-3</div></div> monoclonal antibody, and chemotherapy in patients with advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancer who have progressed on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-(L)1</div></div> therapy and chemotherapy. The combination has the potential to be the first of its kind. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CD226 axis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our work focused in immuno-oncology aims to help the immune system recognise and kill cancer cells more effectively. We&#8217;re investigating how <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div>, in combination with novel assets targeting the CD226 axis, can support anti-tumour activity. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are the only company with access to antibodies targeting all three checkpoints on the CD226 axis, including PVRIG, TIGIT and CD96. We&#8217;re executing a comprehensive development plan that will combine these investigational antibodies with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div>, in both doublet and triplet therapies. In addition to several early phase trials that are underway, our phase II platform study in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancer began dosing patients with an initial combination of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> and our TIGIT antibody, partnered with iTeos Therapeutics. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gynaecologic and breast cancers </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2020, nearly 1.4&#160;million women around the world were diagnosed with a gynaecologic cancer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We continue to explore the potential for our existing treatments to advance the standard of care for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-treat</div></div> gynaecologic cancers, both alone and in combination with each other and other agents. In second-line endometrial cancer, the FDA granted full approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> in February 2023 for the treatment of adult patients with mismatch <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">repair-deficient</div> (dMMR) recurrent or advanced endometrial cancer, as determined by an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In December 2022, we announced positive headline results from the planned interim analysis, or Part 1, of our RUBY phase III trial investigating <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> in combination with chemotherapy as a frontline treatment for advanced or recurrent endometrial cancer. It showed a statistically significant and clinically meaningful progression-free survival (PFS) benefit in the prespecified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">dMMR/MSI-H</div> patient subgroup and in the overall population. In Part 2 of the RUBY study, we will assess <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> in combination with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> in the same setting, with initial results anticipated in the second half of 2023. Our FIRST trial, is evaluating this combination as a potential new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> maintenance therapy for ovarian cancer with results expected in the second half of 2023.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our phase III trial, ZEST, is exploring the efficacy and safety of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> (niraparib) as an early-stage treatment for breast cancer. The trial uses circulating tumour DNA technology for the first time in a pivotal breast cancer study. This offers the potential to detect tumour cells earlier at the molecular level and identify women at higher risk of recurrence. This means therapy with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> could start when the burden of disease is still low and may create an opportunity to slow or stop the cancer&#8217;s progress more effectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investigating </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Zejula</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> for lung cancer </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re evaluating <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> in our phase III ZEAL lung cancer trial, which is investigating <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> maintenance therapy for patients with advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancer (squamous and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-squamous</div> histologies), after they have received platinum-based chemotherapy. The trial is studying the efficacy and safety of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> in combination with the standard of care treatment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Blood cancers </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Myelofibrosis is a rare blood cancer that affects around 20,000 patients in the US, most of whom either have anaemia when they&#8217;re diagnosed or develop it eventually. Patients often need transfusions, and around 30% stop treatment because of anaemia. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Momelotinib may address the significant medical needs of myelofibrosis patients with anaemia by reducing dependence on transfusions while still treating other symptoms of the disease and enlarged spleen. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">A New Drug Application and Marketing Authorisation Application for momelotinib is currently under review with the FDA and EMA, respectively. Momelotinib is not currently approved in any market. We anticipate a US launch in 2023. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Multiple myeloma is the world&#8217;s third most common blood cancer, with more than 175,000 people developing it every year. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> (belantamab mafodotin) is for patients with relapsed or refractory multiple myeloma who have received at least four other therapies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> is approved in Europe and Hong Kong. Our DREAMM trials are investigating its potential in earlier lines of treatment, together with standard and novel therapies, as well as exploring dosing and scheduling modifications. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In November 2022, we announced we would withdraw <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> from the US market following the request of the FDA. This request was based on the outcome of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DREAMM-3</div> confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations. Other trials in the DREAMM clinical trial programme will continue. They are designed to demonstrate the benefit of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> in combination with novel therapies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> treatments in earlier lines of therapy and dosing optimisation to maintain efficacy while reducing corneal events. We anticipate data from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DREAMM-7</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DREAMM-8</div> phase III trials in the second half of 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Early science and other collaborations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we announced an exclusive global licence option agreement to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> and commercialise Mersana Therapeutics&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056</div> immunosynthen antibody-drug conjugate that targets a novel epitope of HER2. It&#8217;s designed to activate the innate immune system through STING signalling in immune cells in tumours, and tumour cells themselves. Mersana has initiated a phase I clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056</div> to investigate its potential in a range of HER2-expressing tumours, such as breast, gastric, colorectal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small-cell</div> lung cancers. The FDA has granted an orphan drug designation to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056</div> for the treatment of gastric cancer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Additionally, to further enhance our tumour-cell targeting portfolio, we entered into an agreement with WuXi Biologics for exclusive licences for up to four <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-</div> and multi-specific <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> engaging (TCE) antibodies developed using WuXi Biologics&#8217; proprietary technology platforms. This deal allows us to access potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> TCE antibodies that have been optimised for effective tumor killing with a desirable safety profile. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">1</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">At the request of the FDA, in late 2022, we restricted the second-line ovarian cancer maintenance indication for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula </div></div>in the US to only the patient population with deleterious or suspected deleterious germline BRCA mutations (gBRCAmut) </div></td>
<td style="width:14.25pt">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity driven </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">As well as our portfolio across therapy areas, we pursue other opportunities where the emerging science indicates the potential for important new opportunities to have major impact in addressing unmet need. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transforming the treatment of anaemia with daprodustat </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Over 700&#160;million people suffer from chronic kidney disease (CKD) worldwide, and an estimated one in seven of them has anaemia. For many, the treatment options are limited. When left untreated or undertreated, anaemia of CKD is associated with poor clinical outcomes and leads to a substantial burden on patients and healthcare systems. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Daprodustat is our oral treatment in a class of medicines called oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). It&#8217;s based on human genetics and Nobel Prize-winning science showing how cells sense and adapt to oxygen availability. Daprodustat offers a potentially easier oral treatment than the current injection-based standard of care, while still managing haemoglobin levels effectively. It&#8217;s approved as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Duvroq</div></div> in Japan. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In October 2022, we reported that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with anaemia of CKD with a 13 to 3 vote. In adult <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-dialysis</div> patients with anaemia of CKD, the CRDAC did not support that the benefit of treatment with daprodustat outweighs the risks with a 5 to 11 vote. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">On 1&#160;February 2023, the FDA approved daprodustat under the name <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jesduvroq</div></div> for the treatment of anaemia of chronic kidney disease in adults on dialysis. In March 2022, the EMA validated the marketing authorisation application for daprodustat, which is currently under regulatory review with a decision anticipated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2023.</div> </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progressing towards a new treatment for cholestatic pruritus in primary biliary cholangitis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Linerixibat is our ileal bile acid transporter (IBAT) inhibitor to potentially treat cholestatic pruritus in patients with primary biliary cholangitis (PBC). This is a rare autoimmune liver disease affecting approximately 15 per 100,000 people. Significant numbers of PBC patients suffer with cholestatic pruritus, a debilitating itch, and there has been no new pharmacologic therapy in this area in 60 years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our development programme demonstrates how we are using digital technology to modernise drug development, using novel platforms to run our studies with the potential to increase trial diversity. An example of this is a new decentralised clinical trial (DCT) design with the potential to improve patient recruitment and retention in GLISTEN, the phase III trial of linerixibat for cholestatic pruritus in patients with PBC. This is an emerging trial model where assessment of patients can occur at a patient&#8217;s own home, improving accessibility for patients who may not live near to a specialist. This is a first and we expect this innovation to continue. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Linerixibat has received Orphan Drug Designation in Europe and the US. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Research and development continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pipeline overview </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have 69 assets in development, of which 18 are late-stage. </div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #f36f21">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase III/Registration</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> infants US (recombinant protein) MenB</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">SKYCovione (SK Bioscience)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>COVID-19<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">4</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3536819 (conjugated, recombinant protein) MenABCWY 1st gen</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3844766<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div>RSV older adults</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">gepotidacin<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(BTI inhibitor) uUTI and GC</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">bepirovirsen<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(HBV ASO) HBV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">tebipenem pivoxil<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(antibacterial carbapenem) cUTI<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">10</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(sotrovimab/VIR-7831 monoclonal antibody) COVID-19</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-BCMA ADC) multiple myeloma</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-PD-1) 1L endometrial cancer<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(PARP inhibitor) ovarian, lung and breast cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">momelotinib<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(JAK1, JAK2 and ACVR1 inhibitor) myelofibrosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">cobolimab<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-TIM-3) NSCLC</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">latozinemab<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(AL001, anti-sortilin) frontotemporal dementia<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2,9</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">depemokimab<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(LA anti- IL5) asthma<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> (anti-IL5) COPD</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">daprodustat (HIF-PHI) anaemia of chronic kidney disease<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">12</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1.5pt solid rgb(243, 111, 33); font-size: 9pt; font-family: ARIAL; line-height: normal;">linerixibat (IBAT inhibitor) cholestatic pruritus in primary biliary cholangitis</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase II</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3437949<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div>malaria fractional dose</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4406371 (live, attenuated) MMRV new strain</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3536852<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(GMMA) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shigella</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3528869<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(viral vector with recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div> therapeutic HBV<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4023393 (conjugated, recombinant protein) MenABCWY 2nd gen<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4178116 (live, attenuated) varicella new strain</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">5101955<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(MAPS) pneumococcal 24-valent &#8211; paediatric</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">5101956<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(MAPS) pneumococcal 24-valent &#8211; adults</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4106647<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(protein-adiuvant)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div>HPV<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3036656<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(leucyl t-RNA inhibitor) tuberculosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">sanfetrinem cilexetil<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(serine beta lactamase inhibitor) tuberculosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">BVL-GSK098<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(ethionamide booster) tuberculosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">VIR-2482<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(neutralising monoclonal antibody)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">5 </div>influenza</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3640254 (maturation inhibitor) HIV<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">13</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3810109<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(broadly neutralising antibody) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4428859<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-TIGIT) cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> (anti-BLyS) Systemic sclerosis associated interstitial lung disease<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">10</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4532990<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(HSD17B13 siRNA) non-alcoholic steatohepatitis<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">10</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #f36f21">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase I</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">2904545<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. difficile</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4429016<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(bioconjugated, recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">K. pneumoniae</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3993129 (recombinant subunit)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div>CMV<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4382276<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(mRNA) flu</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4396687<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(mRNA) COVID-19</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4077164<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(bivalent GMMA) iNTS (typhimurium + enteritidis)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3943104<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(recombinant protein)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3 </div>Therapeutic HSV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4348413 (GMMA) gonorrhoea<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3536867<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(bivalent conjugate) Salmonella (typhoid + paratyphoid A)</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">2556286<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(Mtb inhibitor) tuberculosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3186899<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(CRK-12 inhibitor) visceral leishmaniasis<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">7</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3494245<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(proteasome inhibitor) visceral leishmaniasis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3772701<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">P falciparum </div></div>whole cell inhibitor) malaria</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3882347<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(FimH antagonist) uUTI</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3923868 (PI4k<div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">b</div></div> inhibitor) viral COPD exacerbations</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4182137<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(VIR-7832 monoclonal antibody) COVID-19<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">6</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3965193 (PAPD5/7 inhibitor) HBV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">5251738<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(TLR8 agonist) HBV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3739937 (maturation inhibitor) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">cabotegravir (400 mg/ml formulation) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4004280 (capsid protein inhibitor) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4011499 (capsid protein inhibitor) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4524184<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(integrase inhibitor) HIV</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3745417 (STING agonist) cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4074386<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-LAG3) cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">6097608<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-CD96) cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4381562<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-PVRIG) cancer</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">XMT-2056<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1,11 </div>(STING agonist ADC) cancer (wholly owned by</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Mersana Therapeutics)</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4527226<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(AL101, anti-sortilin) neurodegenerative diseases</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3858279<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-CCL17) osteoarthritis pain</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">1070806 (anti-IL18) atopic dermatitis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">3888130<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(anti-IL7) multiple sclerosis</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">4172239<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1 </div>(DNMT1 inhibitor) &#8211; sickle cell disease<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">8</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(167, 169, 172); line-height: normal;">&#160;</div></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Only the most advanced indications are shown for each asset. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">In-licence or other alliance relationship with third party </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Additional indications or candidates also under investigation </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Adjuvanted </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">4</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK contributing pandemic adjuvant </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">5</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK has exclusive option to co-develop post phase II </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">6</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">In phase I/II study </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">7</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Transition activities underway to enable further progression by partner </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">8</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Imminent study start </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">9</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Phase III trial in patients with progranulin gene mutation </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">10</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Phase II or III study start expected in 2023 </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">11</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK has an exclusive global license option to co-develop and commercialise the candidate </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">12</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">FDA approved in February 2023 </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">13</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Will not progress to phase III </div></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">MenB: meningitis B; RSV: respiratory syncytial virus; uUTI: uncomplicated urinary tract infection; GC: urogenital gonorrhoea; HBV: hepatitis B virus; cUTI: complicated urinary tract infection; ADC: Antibody drug conjugate NSCLC: non-small cell lung cancer; LA: long-acting ;COPD: chronic obstructive pulmonary disease; MMRV: measles, mumps, rubella &amp; varicella; HSV: herpes simplex virus; siRNA: small interfering RNA; HPV: human papillomavirus; MAPS: multiple antigen presenting system; CMV: cytomegalovirus; GMMA: generalised modules for membrane antigens; iNTS: invasive non-typhoidal salmonella; ASO: antisense oligonucleotide </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_29.jpg"/> </div><div style="font-size:-830pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:-830pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div id="ex15_2tx382677_10" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 32pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Commercial operations</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div id="ex15_2tx382677_11" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 22pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: Vaccines</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">Our broad vaccines portfolio targets infectious diseases</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">at every stage of life, helping to protect people from</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">meningitis, shingles, flu, polio and many more.</div><div style="font-size: 530pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Herpes zoster virus (shingles)</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">29&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="font-size: 36pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: Vaccines </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:26%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key products</div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="23" style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 36pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;7.9bn</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;">+17% AER, +11% CER</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_30.jpg"/> </div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Product</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Disease</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total revenue</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Key information</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Herpes zoster</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(shingles)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;2,958m&#160;+72%&#160;AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+60% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Record sales year. Now launched in 26 markets</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">group B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;753m +16% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+12% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Approved in France for National Immunisation Programme in 2022. Now available in 50 markets</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix, FluLaval</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Seasonal</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">influenza</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;714m +5% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-4% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Joint first to market with Sanofi in US enabling vaccinations to begin in July 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diphtheria,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">tetanus,&#160;acellular</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">pertussis&#160;booster</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;594m +14% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+7% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US approval for maternal immunisation indication in 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Infanrix, Pediarix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diphtheria,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">tetanus,&#160;pertussis,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">polio,&#160;hepatitis&#160;B,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">haemophilus</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">influenza&#160;type&#160;B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;594m +9% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+3% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediarix </div></div>leads in the US in market share by volume</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Engerix,&#160;Twinrix,</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Havrix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Hepatitis</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;571m +24% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+16% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Travel and routine immunisation for hepatitis recovering as expected in 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rotavirus</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;527m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-3%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-3% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix </div></div>fully liquid in the US and approved in France for National Immunisation Programme in 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">group A, C, W</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">and Y</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;345m +27% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+18% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo </div></div>fully liquid in the US and Brazil in 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Invasive disease,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">pneumonia,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">acute otitis</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">media</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;305m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-15%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-15% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax acquisition for next-generation PCV of 24 valents and greater</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix, Priorix Tetra, Varilrix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Measles,&#160;mumps,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">rubella and</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">chickenpox</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;188m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-28%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-29% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US approval for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix </div></div>in 2022 supporting continued expansion of our established portfolio</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Human&#160;papilloma</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">virus</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;117m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-15%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-20% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">China approval for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-dose</div> schedule in 2022</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:1pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We achieved strong growth in vaccines in 2022, driven by record sales for our shingles vaccine, and continued geographic expansion of our meningitis vaccine. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Vaccines turnover was &#163;7,937&#160;million, up 17% at AER, 11% at CER in total, and up 24% at AER, 17% at CER excluding pandemic adjuvant sales. The performance reflected a favourable comparator, which was impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> related disruptions in several markets primarily in H1 2021, and strong commercial execution of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>, particularly in the US and Europe. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> sales grew 72% at AER, 60% at CER to &#163;2,958&#160;million. All regions grew significantly reflecting post-pandemic rebound, strong uptake and new market launches with more than half of the growth contributed from outside of the US. In the US, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> grew 46% at AER, 32% at CER to &#163;1,964&#160;million due to higher <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-retail</div> and retail demand and strong commercial execution. Germany and China contributed strongly to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> growth. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> was launched in nine markets during 2022 and is now available in 26 countries. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Meningitis vaccines sales grew 16% at AER, 11% at CER to &#163;1,116&#160;million mainly driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> up 16% at AER, 12% at CER to &#163;753&#160;million resulting from higher CDC demand and increased share in the US. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div> sales were also up 27% AER, 18% CER to &#163;345&#160;million, primarily driven by post-pandemic vaccination <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> and higher public demand in International, together with favourable pricing mix and share gain in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix</div></div>/<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FluLaval</div></div> sales grew by 5% AER but decreased 4% CER to &#163;714&#160;million, primarily driven by lower post-pandemic demand in Europe and the US, partly offset by lower expected returns in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Established Vaccines grew 4% AER but was stable at CER to &#163;3,085&#160;million mainly resulting from supply constraints in MMR/V vaccines and lower tender demand in International for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>. This was offset by hepatitis vaccines demand rebound in the US and Europe and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div> post-pandemic demand recovery and increased share in the US. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: Vaccines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Pandemic vaccines decreased 86% AER and CER primarily reflecting comparison to 2021 pandemic adjuvant sales to the US and Canadian governments partly offset by GSK&#8217;s share of 2022 contracted European volumes related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> booster vaccine developed through a collaboration with Sanofi Pasteur (Sanofi). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our strategy for growth </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Vaccines play a critical role in our growth. We aim to reach 1.3&#160;billion people with vaccines by 2031, a significant contribution to our overall ambition to positively impact the health of 2.5&#160;billion people. We will achieve this through growth of our existing adult and paediatric vaccines and new launches. Our focus is on accelerating the vaccines pipeline, particularly RSV and MenABCWY, ensuring manufacturing capability and capacity for RSV, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> and our established portfolio, and entering new markets. We also prioritise targeted business development which complements our existing vaccine portfolio and gives us access to new patients. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Vaccines are complex and highly technical both to develop and manufacture. As such there is no established generic industry and they therefore do not generally face the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8216;patent cliff&#8217;. This longer lifecycle means that vaccines can remain in use for decades after their initial authorisation. For example <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Infanrix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Engerix</div></div> are beyond their patents but remain important parts of our portfolio in terms of contribution to performance. And importantly, our vaccines have a strong efficacy profile with 90% of our portfolio by sales having an efficacy level of above 90% &#8211; helping to protect our portfolio from potential disruption from new technologies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our portfolio of more than 20 marketed vaccines is one of the industry&#8217;s broadest, helping to protect people throughout their lives against diseases, including meningitis, shingles, flu, polio, measles and many more. We deliver one and a half million doses of our vaccines every day; and around 40% of the world&#8217;s children receive a GSK vaccine each year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The full benefits of vaccination go beyond the health of individuals. Vaccination programmes help minimise health inequity and reduce costs to the healthcare system, potentially promoting economic growth and societal wellbeing. With our acquisition of Affinivax and, if we get approval, the future launch of our RSV vaccine for older adults, we are well positioned in the adult vaccination segment, which will be a key growth driver of the global vaccines market. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our established platform technologies, and the new platforms we&#8217;re building, such as the MAPS and mRNA technologies, are a key part of our vaccines growth strategy and are enabling us to tackle the most complex diseases from birth throughout adulthood (see page&#160;19). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Drivers of growth across the portfolio </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Record annual sales for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> were driven by strong demand in existing markets and geographic expansion. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> continues to be recommended for adults and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-risk</div> groups in countries around the world, driving its uptake. By 2024, we aim to have launched in 35 markets which make up about 90% of the vaccine market by value. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We continue to strengthen our leadership position in meningitis vaccines with an aim to double sales by 2031 through continued market share growth, the geographic expansion of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> and the anticipated launch of our pentavalent vaccine. During the year, France approved <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> for its National Immunisation Programme and we also launched <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> in Taiwan and received marketing authorisation in South Korea, making <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> available in a total of 50 countries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We remain committed to growing our established portfolio, which represents about half of our total vaccines business. We continue to seek to expand the availability of our vaccines in markets around the world; our lifecycle management strategy has strengthened our presence in the US. For example, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix</div></div>, our measles, mumps and rubella vaccine, has been protecting people worldwide for 25 years; its launch in the US this year underscores how it remains an important part of our established portfolio. Also in the US, we received FDA approval for fully liquid formulations of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div>, our rotavirus vaccine and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div>, our meningitis ACWY vaccine. We were also first to receive FDA approval for a vaccine given in pregnancy, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div> maternal, which can be administered in the third trimester to help prevent whooping cough in young babies (see page 22). </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: Vaccines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Meeting the needs of healthcare professionals and patients (HCPs) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">From the age of about 50, our immune system starts to decline and becomes less effective, leading to increased vulnerability to infectious diseases. Given this, we are focusing our efforts on helping to keep older adults healthy. We want to improve physician-patient dialogue on vaccination, to raise awareness in adults of vaccine-preventable diseases and to increase access to vaccination beyond the physician&#8217;s office. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our Vaccine Study 2022 Report explored attitudes and beliefs of HCPs and those over 50 years to vaccination. The study showed that HCPs are a patient&#8217;s number one source of information about vaccines. But HCPs can&#8217;t always meet their patients&#8217; needs because they lack time, want to avoid conflict or don&#8217;t have enough information and training. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To ease some of the pressure on HCPs, we&#8217;ve started a digital channel partnership with NextDoor in the US, providing vaccination information directly to patients. We&#8217;ve also launched a consumer campaign about the importance of vaccination. We&#8217;re working directly with HCPs through a series of Vaccinology Master Classes, helping to better equip them for conversations with their patients about vaccines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">With US research company IQVIA, we also launched Vaccine Track, a data platform to help improve adult vaccination nationwide. The platform gives HCPs information about the uptake of recommended adult immunisations. With this data, HCPs can target their efforts to increase discussion about vaccination and improve coverage in areas showing a relative decline in immunisation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re working with expert groups on adult vaccination calendars which show HCPs and their patients which vaccines they&#8217;re eligible for. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we launched a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-ever</div> shingles awareness week with the International Federation on Ageing, reaching more than 900&#160;million people globally. Such campaigns remain an important way of increasing awareness of vaccine preventable diseases, prompting patients to seek HCP guidance on next steps, including preventative options. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Globally, governments, policymakers and healthcare providers are recognising the potential advantages of having increased access to vaccination through additional channels such as vaccination centres as well as retail pharmacies. We&#8217;re working with pharmacy chains to provide information for patients as they consider their vaccination options. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strengthening our manufacturing network to support vaccines growth </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, our 12 manufacturing sites in nine countries produced and delivered over 500&#160;million vaccine doses. This was despite supply challenges with incoming materials and shipping impacts caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the global economic environment and the conflict in Ukraine. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our sites are routinely inspected by multiple regulatory agencies. In 2022, there were 45 inspections by health authorities across our manufacturing sites. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are preparing our manufacturing and supply capabilities to support both our inline product growth and our pipeline products pending approval. This includes our RSV vaccine for older adults. In 2022, the RSV production facility in Wavre, Belgium, produced the first doses for the market at a 100% success rate. To be ready for demand, we announced a <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>70&#160;million investment in a second manufacturing facility for RSV antigen production in Belgium. Also in Belgium, we invested in more capacity for lyophilised products as well as building our internal mRNA capabilities. Following the acquisition of Affinivax, we are adding MAPS to our production technology platforms by using capabilities at our Singapore site as well as new investments at GSK Binney Street in Cambridge, Boston. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Overall, we&#8217;re focused on increasing the control and robustness of our supply chain. A good example of this is the manufacturing of key adjuvants (AS01, AS03). We&#8217;ve brought production of MPL and QS21 (components of AS01) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> at Hamilton. We&#8217;ve also formulated over 200 batches of adjuvant in Belgium since 2020 for current and future key assets such as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mosquirix</div></div> or our RSV candidate vaccine for older adults. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Throughout the year we invested in modernising, digitising and automating our manufacturing network. For example, our quality control laboratories at all our sites went completely paperless. We&#8217;ll transition more than 50 production lines at 10 sites to electronic batch records by 2025 as we build on our digital capability for better operational efficiency, compliance, yield and shorter lead times. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_33.jpg"/> </div><div style="font-size:-840pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:-840pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><div style="font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 32pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Commercial operations</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div id="ex15_2tx382677_12" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 22pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: Specialty Medicines</div></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">We continue to be global leaders in HIV medicines, focus on pioneering</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">treatments for immune-mediated conditions and respiratory diseases,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL; text-align: center; line-height: normal;">and have an emerging portfolio of cancer medicines.</div><div style="font-size: 500pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HIV virus</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">33&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: Specialty Medicines </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:28%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key marketed products</div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="26" style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 36pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;11.3bn</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;">+37% AER, +29% CER</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_34.jpg"/> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Product</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Disease</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;revenue</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Key information</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;2,309m&#160;&gt;100%</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">AER;&#160;&gt;100%&#160;CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Monoclonal antibody treatment. Delivered more than two million doses to over 30 countries since approval</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV&#160;treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#163;1,799m&#160;-4%&#160;AER;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-11% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir-based fixed dose combination tablets. Marketed in 67 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eosinophil-driven</div></div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">diseases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,423m&#160;+25%&#160;AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+18% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The only treatment to be indicated in the US and Europe for use across four eosinophil-driven diseases (see page&#160;24)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,381m flat% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-7% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir tablet for use in combination with other antiretroviral agents. Marketed in 71 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,375m +75% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+65% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-drug</div> regimen. Now launched in over 50 markets</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lupus and lupus</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">nephritis</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,146m +31% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+20% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Only biologic approved to treat both SLE and LN, in the US, Europe and elsewhere</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;636m +23% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+14% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-drug</div> regimen. Marketed in 30 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ovarian cancer</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;463m +17% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+12% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">PARP inhibitor commercially available in 1L maintenance in 29 markets and in 2L maintenance in 29 markets</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Vocabria&#160;+</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rekambys&#160;in</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe&#160;and&#160;Japan)</div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;340m &gt;100% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&gt;100% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">First and only complete long-acting injectable regimen (cabotegravir, rilpivirine). Launched in over 20 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Blood cancer &#8211;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">multiple&#160;myeloma</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;118m +33% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+25% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">An antibody-drug conjugate commercially available in 19 countries for patients with relapsed or refractory multiple myeloma</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV treatment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;82m +82% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+64% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Extended-release tablets for people living with multi-drug resistant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HIV-1</div> for use in combination with other antiretrovirals. Approved in the US, Canada and Europe</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV prevention</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;41m</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">First and only long-acting injectable (cabotegravir) for HIV prevention. Launched in the US in 2022</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Endometrial</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">cancer</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;21m &gt;100% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&gt;100% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1-blocking</div></div> antibody available in 15 countries that is continuing to be investigated for future monotherapy and combination regimens in multiple tumour types</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Specialty Medicines sales were &#163;11,269&#160;million, up 37% at AER, 29% at CER, driven by consistent double-digit growth in all therapy areas. Specialty Medicines, excluding sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>, were &#163;8,960&#160;million up 23% at AER, 15% at CER. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">HIV sales were &#163;5,749&#160;million with growth of 20% at AER, 12% at CER. The performance benefited from strong patient demand for the new HIV medicines (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>), which contributed approximately three quarters of the growth. US pricing favourability and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> inventory build together contributed one third of the growth which was partially offset by International tender decline. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">New HIV products delivered sales of over two billion to &#163;2,474&#160;million, up 78% at AER, 67% at CER, representing 43% of the total HIV portfolio compared to 29% last year. Growth was primarily driven by sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> recorded sales of &#163;1,375&#160;million up 75% at AER and 65% at CER and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> recorded sales of &#163;340&#160;million. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div> delivered sales of &#163;41&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Immuno-inflammation, Respiratory and Other sales were &#163;2,609&#160;million up 29% at AER, 20% at CER on strong performance of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> sales were &#163;1,146&#160;million, up 31% at AER, 20% at CER, representing strong underlying demand in US and worldwide. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> sales were &#163;1,423&#160;million, up 25% at AER, 18% at CER, reflecting continued strong patient demand and the launch of additional indications. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: Specialty Medicines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Oncology sales were &#163;602&#160;million, up 23% at AER, 17% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> sales of &#163;463&#160;million were up 17% at AER, 12% at CER driven by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> indication, but with diagnosis and treatment rates continuing to be impacted by the pandemic especially in the US. Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> of &#163;118&#160;million grew 33% at AER, 25% at CER, and included the impact of withdrawal from US market in Q4 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> were &#163;2,309&#160;million, compared to &#163;958&#160;million sales in 2021. Sales were delivered in all regions, comprising &#163;828&#160;million in the US, &#163;456&#160;million in Europe, and &#163;1,025&#160;million in International. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our strategy for growth </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our portfolio of Specialty Medicines is focused on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We&#8217;re leaders in infectious diseases and HIV innovation and we&#8217;re also building our positions in immunology and oncology. In the next five years, we expect Specialty Medicines and HIV as a part of Specialty to continue to be an important part of our growth. The increasing convergence of disease prevention and treatment and our expertise in vaccines and medicines mean we are uniquely placed to focus on connections between treatment and prevention. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We do this by accelerating our pipeline as well as prioritising strategic business development which complements are existing portfolio, such as our acquisition of Sierra Oncology and global licence agreement with Mersana Therapeutics. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Drivers of growth across the portfolio </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In HIV, our strategy for growth now and in the future is built on our innovative portfolio of medicines that are transforming the HIV treatment and prevention landscape. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Launched in 2019, our dolutegravir-based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-drug</div> regimen, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, continues to build positive momentum, benefiting over 143,000 people living with HIV globally and delivering &#163;1,375&#160;million of revenue in 2022. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Our long-acting therapies are also central to our growth and are delivering results as they launch across our markets. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">In 2021 we launched the only long-acting treatment regimen, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> (known as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vocabria</div></div> + <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rekambys</div></div> in Europe and other markets). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-inferior</div> to daily anti-viral therapy and dosed once every two months, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> addresses the challenges associated with daily oral therapy of stigma, adherence and daily pill fatigue. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">In January 2022 we launched <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div> in the US. It&#8217;s the only long-acting medicine for HIV prevention offering superior efficacy to daily oral prevention (FTC/TDF tablets) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-monthly</div> dosing. The launch was supported by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">direct-to-consumer</div></div> campaign, as well as innovative community-driven interventions focused on reaching key populations who could benefit most from a preventative option. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">By 2026 we estimate our long-acting regimens <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div> will generate around &#163;2&#160;billion of sales, representing around a third of HIV net sales. </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In immunology/respiratory, we continue to see strong demand from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> for systemic lupus erythematosus and lupus nephritis in adults and children continues to perform strongly, with around 9,000 US patients initiating therapy in 2022. It also became China&#8217;s only biologic medicine of its kind, helping around 12,500 patients in 2022. We&#8217;re focused on supporting earlier identification and greater urgency to treat patients before lupus progresses and organ damage occurs (see page 24) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>, the only targeted biologic therapy approved for use across four eosinophilic diseases, continues to be a driver of growth. We expanded access to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> in 2022 with approvals in Europe, Japan and the US for a 40mg syringe for use at home with children. This follows earlier approvals for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-home</div> use for adults. The evidence behind <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> continues to grow, and in 2022 we shared <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REALITI-A,</div> the real-world study with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> in patients with severe eosinophilic asthma, demonstrating how <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> inhibition in everyday practice can help to achieve treatment goals. Our pioneering work in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> inhibition continues with the research into depemokimab, a monoclonal antibody specifically engineered with an increased affinity for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-5</div> and a longer duration of action to allow longer periods of time between injections (see page 24) </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In oncology, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> is the only monotherapy PARP inhibitor approved in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> therapy for newly diagnosed patients with advanced ovarian cancer, regardless of biomarker. This group of patients represents a significant area of growth as healthcare providers are using PARPs more in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-line</div> setting. Since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> we have seen the number of patients presenting to their doctors with ovarian cancer symptoms decline and the volume of newly diagnosed ovarian cancer patients is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-20%</div> below <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-COVID</div> (2019)&#160;monthly averages. We expect that numbers will increase again as patients return to normal health practices. We&#8217;re now working to develop other combination therapies with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> (see page 26). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Daprodustat, our treatment for anaemia of chronic kidney disease, is the market-leading and preferred <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HIF-PHI</div> in Japan, where it&#8217;s available as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Duvroq</div></div>. In February 2023 daprodustat was approved as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jesduvroq</div></div> in the US for adults on dialysis. We are seeking approval in the EU and expect to have a decision <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2023</div> (see page 27). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> treatment <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>, developed with Vir Biotechnology, continued to play an important role in pandemic response for vulnerable patients in 2022. To date we have delivered more than two million doses to over 30 countries, generating over &#163;3&#160;billion in sales. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: Specialty Medicines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Building our commercial capabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are delivering growth across our portfolio by continuing to focus on disciplined commercial and medical execution, capability enhancement, competitive resourcing in customer-facing activity and rigorous investment allocation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Attaining and keeping leading positions in our markets means attracting and retaining the best people in our industry. We&#8217;ve focused on developing our leaders internally and we recruit specific marketing and commercial experts from outside the business. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Over the last year, 67% of senior commercial leadership appointments in Specialty Medicines were internal. We recruited senior people externally to drive growth in oncology and supplement our specialty global marketing capability in our top 10 markets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;ve also focused on strengthening sales execution capability in our markets. We appointed 16 general managers in 2022, bringing fresh leadership into 26% of these positions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maintaining strong links with healthcare professionals and patients </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Connecting with HCPs and patients helps us to meet their needs. It also helps us to keep them informed about clinical data, products in our pipeline and upcoming launches. The more effectively we interact, the better they understand the science behind our products, their benefits and how best to use them. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have scaled up our use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">data-led</div> omnichannel communication platforms to reach more patients <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">face-to-face</div></div> and digitally. To date, we&#8217;ve digitally enabled 27 brands and 447 campaigns across 44 markets, doubling our efforts compared to last year, and resulting in incremental growth and market share. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our use of digital, data and analytics in 2022 extends to driving Medical Affairs effectiveness. Advanced analytics and text mining has produced medical insights which allow for high-quality scientific engagement with experts to improve patient outcomes. We&#8217;ll continue to prioritise use of omnichannel communication platforms in Medical Affairs to engage HCPs on the latest scientific advances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Managing our global supply chain </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our supply chain is a global network that enabled us to produce and deliver 1.8&#160;billion packs in 2022. We&#8217;ve streamlined our network to make it smaller, more agile and more resilient, with the capacity and capability to bring the next generation of medicines to patients all over the globe. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Amid geopolitical uncertainties, we&#8217;re focused on the availability of energy and commodities, and on managing constraints around freight and other resources needed to supply medicines to patients. Despite these challenges, our programme of productivity and efficiency improvements remains on track. This year we delivered &#163;23&#160;million in savings through the programme, taking the cumulative total to &#163;62&#160;million. Our target for the programme is to deliver &#163;119&#160;million in savings by 2025. These savings support improvements in gross margin. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have 25 sites manufacturing medicines in our GSK network. Overall, site productivity has increased by 3.9% year on year over the last three years. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strengthening our manufacturing base </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Modern manufacturing facilities help us launch specialty medicines quickly so we can build and strengthen our market positions and performance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In June 2022, we opened our new manufacturing facility at Barnard Castle in the UK. It is sustainably designed, paperless and fully automated, using robotic aseptic filling technology to increase efficiency. The facility will manufacture many of the existing and new biopharmaceutical assets in our pipeline. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: Specialty Medicines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We also opened our expanded facility at Upper Merion, Pennsylvania, which is now one of the most advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> facilities for the manufacture of bulk drug substances and able to manufacture a wide range of biopharmaceutical pipeline assets, including monoclonal antibodies. Our expanded facility at Rockville, Maryland, is on target to start manufacturing in 2023. This facility combines <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> systems, large-scale stainless steel manufacturing and automation to produce our lupus treatment, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div>. The investment of more than $150&#160;million will increase capacity at Rockville by around 50%. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;re also investing over &#163;60&#160;million in our new oral solid dose facility at Ware in the UK to help us deliver new products at pace, in partnership with R&amp;D. Product performance qualification (the first set of batches that confirm the commercial manufacturing process performs as expected) is due to start in the second half of 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Streamlining our supply chain helps us control costs and allocate more capital to developing, launching and marketing medicines. This includes investing in AI/ML which helps us to optimise yield, inventory and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-full</div> (OTIF) delivery. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maintaining a consistent and reliable supply </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">A reliable, high-quality supply of products is essential for us to meet patients&#8217; needs and maintain our performance. We routinely update our quality management system (QMS) to keep pace with the evolving regulatory environment and new scientific understanding of our products and processes. We&#8217;ve also made our policies and procedures simpler to understand and implement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We&#8217;ve improved deviation rates, and reliability of supply remains strong with an OTIF measure of 97.2% across our full supply chain and 99.4% for Specialty Medicines. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For information on product governance and data on recalls, regulatory inspections and audits, see pages 49 and 50 </div></div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supporting our Innovation ambition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our Specialty Medicines supply chain continues to support our innovation strategy by delivering launch products across therapy areas and regions worldwide. We are making our internal and external network flexible enough to enable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-time</div> launches of our upcoming medicines. We&#8217;re also working with R&amp;D by investing in rapid knowledge transfer from chemistry manufacturing&#160;&amp; control project teams to manufacturing sites. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Following a successfully managed rapid launch of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> therapeutic <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> (sotrovimab), by the end of 2022 over two million doses of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> had been supplied globally. We are also preparing for the successful launch and supply of late-stage assets like daprodustat and momelotinib (if approved) in 2023. Our Specialty Medicines supply chain will support multiple late-stage clinical programmes and further upcoming launches in the second half of 2023 and 2024. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For details about the General Medicines supply chain, see page 40 </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_38.jpg"/> </div><div style="font-size:-830pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:-830pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;GSK Annual Report 2022 </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:32pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Commercial operations </div></div><div id="ex15_2tx382677_13" style="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: General Medicines </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">From antibiotics to inhaled medicines for asthma and COPD, we have </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">over 150 general medicine products, many of them leaders in their class, </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">making life better for millions of people worldwide. </div><div style="margin-top:598pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Escherichia coli (E. coli) bacteria </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;38 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:36pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 20pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Performance: General Medicines </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:33%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key marketed products</div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="18" style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 36pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#163;10.1bn</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;">+5% AER, +1% CER</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_39.jpg"/> </div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Product</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Disease</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total revenue</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Key information</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy&#160;Ellipta</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">COPD, asthma</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,729m&#160;+42%&#160;AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+32% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Most prescribed single inhaler triple therapy worldwide, reaching an estimated 5.1&#160;million patients since launch</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Seretide/Advair</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asthma,&#160;COPD</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#163;1,159m&#160;-15%&#160;AER;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-17% CER</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">One of the market-leading ICS/LABA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">2 </div>treatments worldwide</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Relvar/Breo</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ellipta</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asthma,&#160;COPD</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;1,145m&#160;+2%&#160;AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-2% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">One of the leading ICS/LABA treatments worldwide powered by its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hour,</div> sustained efficacy and the convenience of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ellipta </div></div>inhaler device</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asthma,&#160;COPD</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;771m +7% AER;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+2% CER</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Global market-leading SABA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">3 </div>reliever</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Common&#160;bacterial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">infections</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;576m&#160;+35%&#160;AER;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+38% CER</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Global leader in oral antibiotics available in over 95 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Epilepsy,&#160;bipolar</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">disorder</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;511m +7% AER;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+1% CER</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">No.&#160;1 brand by sales value in the global lamotrigine market</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro Ellipta</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">COPD</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;483m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-4%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-9% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Global market leader in the LAMA/LABA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">1 </div>class approved in over 70 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avodart&#160;&amp;</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Duodart</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benign&#160;prostatic</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">hyperplasia&#160;(BPH)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;330m <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-1%</div> AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">-3% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market leaders by sales value in the global dutasteride and dutasteride+tamsulosin FDC<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">4 </div>market respectively, approved in over 85 countries</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avamys/</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Veramyst</div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Allergic rhinitis</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;321m +8% AER;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+6% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Global leader in the inhaled corticosteroids prescription class</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="8" style="height:3pt"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermovate,</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Betnovate,</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cutivate,&#160;Eumovate</div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inflammatory</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">skin conditions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;200m 0%AER,</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">+1% CER</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Global leader in topical corticosteroids across 60 markets globally</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">1 LABA/LAMA: long-acting beta agonists/long-acting muscarinic antagonists</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">2 ICS/LABA: inhaled corticosteroid/long-acting beta agonists</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">3 SABA: short-acting beta agonist</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">4 FDC: fixed dose combination</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top">Key information source IQVIA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">General Medicines sales in the year were &#163;10,118&#160;million, up 5% at AER, 1% at CER, with the impact of generic competition in US, Europe and Japan offset by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> growth in respiratory and the post-pandemic rebound of the antibiotic market since H2 2021, in Other General Medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Respiratory sales were &#163;6,548&#160;million, up 8% at AER, 3% at CER. The performance was driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> sales of &#163;1,729&#160;million, up 42% AER, 32% CER, including strong growth across all regions. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advair/Seretide</div></div> sales of &#163;1,159&#160;million decreased 15% at AER, 17% at CER predominantly reflecting the adverse impact of generic competition, with growth in certain International markets due to targeted promotion offsetting the decrease. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Other General Medicines sales were &#163;3,570&#160;million, decreasing 1% at AER, 2% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> sales were &#163;576&#160;million, up 35% at AER, 38% at CER, reflecting the post-pandemic rebound of the antibiotic market since H2 2021 in the International and Europe regions. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This partially offsets the ongoing adverse impact of generic competition, and approximately two percentage points impact at AER and CER from the divestment of cephalosporin products in Q4 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our strategy for impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The General Medicines portfolio encompasses our primary care medicines from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> R&amp;D assets to growth and established products. In 2022, General Medicines contributed over one third of GSK&#8217;s sales, helping to fuel growth and investment in R&amp;D. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our combination of more than 150 products, several of which are market leaders, are expected to impact the lives of millions of patients over the next 10 years. Our products are supplied in more than 112 countries worldwide, delivering over 80% of our total medicines supply volume. Every day, these medicines improve health and make life better for millions of people all over the world. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:46pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance: General Medicines continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">With expected growth from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro</div></div>, the established products portfolio in emerging markets and, if successful, gepotidacin and, tebipenem, we are committed to positively impacting more lives every day. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We continue to focus on maximising investment in our growth brands and new opportunities, while managing the expected decline of other products in mature markets as they lose their exclusivity. The decline in established products is well managed, through targeted investments towards growth opportunities and reflects continued strong demand for our core products. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Drivers of growth across the portfolio </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our main sources of growth in General Medicines in 2022 were <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div>. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, our single inhaler triple-therapy for asthma and COPD, has continued to accelerate strongly, with growth in all regions including the US and is the third biggest growth driver (excluding <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>) across GSK&#8217;s portfolio this year. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, is now prescribed in more than 63 countries, with dual indications in key markets. Several new approvals were received in 2022, further expanding <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy&#8217;s</div></div> availability to asthma patients in Argentina, Taiwan, New Zealand, Oman, Bahrain, South Korea and Kuwait, and COPD patients in Kuwait and Indonesia. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> leads market share in our two largest markets, US and Japan, with market shares significantly exceeding the next largest competitor. In 2022 the competitive market position for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> was further strengthened by a network meta-analysis of the triple therapy class demonstrating differentiation among the COPD single-inhaler triple therapies. We continue to expect <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> to be a key driver of growth in General Medicines in the coming years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro</div></div> is approved in approximately 70 countries for the treatment of symptomatic COPD. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro</div></div> remains the global market leader in the LAMA/LABA class, with continued growth in global sales <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ex-US).</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro</div></div> has a robust clinical data profile which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> data within the LAMA/LABA class and versus other common initial maintenance therapy options, such as LAMA. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> is a global leader in oral antibiotics and available in 95 countries. It has reached over 2.5&#160;billion patients since launching 41 years ago, and continues to grow strongly in emerging markets. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> grew 35% AER, 38% CER to &#163;576&#160;million with recovery in key emerging markets and Europe, recovering stronger than any competitor post-pandemic. Today, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> is still being recognised for its impact and recently won the bronze in the best pharmaceutical product category for the Prix Galien Golden Jubilee awards in October 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Two important products in our late-stage pipeline, anticipated to be future growth drivers for General Medicines, include gepotidacin, for uUTIs and urogenital gonorrhoea, and tebipenem HBr, a late-stage antibiotic licensed exclusively from Spero Therapeutics, that may treat cUTIs (see pages 20 and 22). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximising commercial capabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have a targeted investment strategy to deliver returns, backing our largest opportunities, both branded and geographic, to maximise launches in new medicines and indications. In parallel, we target our investments appropriately to optimise returns in mature brands where there is a broader range of opportunity and risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We continue to invest in omnichannel and digital customer engagement. Digital plays an important role in how we connect with our customers, and this is especially important in General Medicines given our expansive global footprint. Our data-driven customer experience (DDCX) programme for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> was recognised externally by the International Customer Experience Awards (iCXA) across all sectors. In 2021, among 120 companies and 353 initiatives entered, we won three silver awards for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> competing across all industries, in the following categories: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">&#8211; Best <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Business-to-Business</div></div> Customer Experience Strategy </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">&#8211; Business Change and Transformation </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">&#8211; Customer Experience Team of the Year </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maintaining an efficient supply chain </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Demand for many products in our General Medicines portfolio increased significantly as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> lockdowns lifted and global markets recovered from the effects of the pandemic. We increased packs supplied from 1.60&#160;billion in 2021 to 1.64&#160;billion in 2022. This growth demonstrated the resilience of our General Medicines brands. We anticipate this further increasing to 1.67&#160;billion in 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To keep our supply chain lean, we continue to simplify our portfolio by standardising packaging and formats and discontinuing products. By the end of 2022, General Medicines had reduced the number of brands in the portfolio by a further 9% from 194 to 177, and we plan to further discontinue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-priority</div> brands in 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have also taken key decisions as part of our focus on productivity and efficiency, for example to outsource the manufacture of amoxicillin. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We rigorously benchmark the performance of our General Medicines supply chain against the competition and make thoughtful choices on how we optimise both our cost and cash footprint for the portfolio. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For more about our global supply chain, which also covers Specialty Medicines, see pages 36 and 37 </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div id="ex15_2tx382677_14" style="margin-top:0pt; margin-bottom:0pt; font-size:44pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Responsible business </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">Our approach to ESG is an integral part of our strategy </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">and investment case. It helps us build trust and create </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">value for our shareholders and society &#8211; so we can </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center">get ahead of disease together. </div><div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_41.jpg"/> </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Responsible business </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Being a responsible business means getting ahead of disease together in the right way. We therefore need to consider ESG impacts across everything we do, from the lab to the patient. That&#8217;s why ESG is embedded in our strategy and supports our sustainable performance and long-term growth. It helps us build trust with and deliver returns to our stakeholders, reduce risk to our operations and deliver positive social impact. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our six ESG focus areas </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We can only deliver on our purpose if we embed ESG into everything that we do. We have identified six ESG focus areas that address what is most material to our business and the issues that matter to our stakeholders. These focus areas are core to our strategy and are the areas where we can have the greatest positive impact on some of society&#8217;s most urgent challenges. These focus areas are: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Access to healthcare </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Global health and health security </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Environment </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Diversity, equity and inclusion </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Ethical standards </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Product governance </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our approach is guided by extensive stakeholder engagement and the key issues relevant to our industry and company. The results of our most recent materiality assessment reaffirmed that the most material issues for our business were well aligned with our six ESG focus areas. We are aware, however, that being a responsible business is not a static requirement and our operating environment continues to change at pace. We will continue to adapt, respond and proactively change our approach, to ensure GSK continues to deliver strong ESG performance. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our ESG Performance Rating </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To support the integration of ESG into strategy delivery and to make our ESG performance measurable and verifiable, we have introduced a new ESG Performance Rating. The rating is one of our corporate KPIs and measures progress against key metrics aligned to each of our six focus areas. In 2022, this included 23 metrics, and we cover our performance against these in this section of the report. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The metrics were developed with stakeholder input, and our understanding of the key issues for our industry and our company. We are committed to ensuring that our ESG Performance Rating responds to stakeholder expectations, so we will continue to review the metrics as our business and external expectations change. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To create the ESG Performance Rating, management sought metrics that: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Are well defined to ensure we have a standardised approach </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Can be used consistently in future years </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Are ambitious and achievable </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Can be externally assured </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Are meaningful for stakeholders </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GLT is accountable for delivering progress against the metrics and regularly reviews performance along with the Board&#8217;s Corporate Responsibility Committee (CRC). Each individual metric is assessed as either: on track (metric met or exceeded); on track with work to do (at least 80% of metric has been achieved); or off track (metric missed by more than 20%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In addition, in order to calculate the overall ESG Performance Rating, performance across all metrics is aggregated to a single score to illustrate whether we are on track, on track with work to do, or off track. This rating is defined below: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">On track: </div></div>70% of all metrics are on track </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">On track with work to do:</div></div> more than 50% of all metrics are either on track, or on track with work to do </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Off track: </div></div>more than 50% of all metrics are off track </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:7pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 4pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 ESG Performance Rating</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Our 2022 ESG Performance Rating is <div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">on track</div>, based on 83% of all performance metrics being met or exceeded.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 9pt; font-family: ARIAL; line-height: normal;">Assessment of performance against our annual targets has been reviewed, and the overall ESG Performance Rating score has been externally assured for 2022.</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.5em; font-size: 6pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td></tr></table></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:7pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 4pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.5em; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External benchmarking</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 9pt; font-family: ARIAL; line-height: normal;">Detailed below is how we perform in key ESG ratings that we are frequently asked about by investors:</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; margin-left: 1.56em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Access to Medicines:</div></div> Ranked 1st in the Access to Medicines Index in 2022 and an industry leader in the 2021 Antimicrobial Resistance Benchmark</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 1pt; margin-left: 1.56em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">S&amp;P Corporate Sustainability Assessment:</div></div> Ranked 2nd in the pharmaceuticals industry with a score of 86 (as at 17&#160;February 2023) and included in the DJSI World and Europe indices</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FTSE4Good:</div></div> Member of FTSE4Good Index since 2004</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CDP:</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-</div> in Climate change, B in Water security, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-</div> in Forests (palm oil) and B in Forests (timber)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sustainalytics:</div></div> Low risk rating</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MSCI:</div></div> AA rating</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Moody&#8217;s ESG solutions:</div></div> Ranked 2nd in the pharmaceuticals sector</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 1pt; margin-left: 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ISS Corporate Rating:</div></div> B+ rating</div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:4pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For full details of progress against our six focus areas, our latest materiality assessment and our ESG Performance Rating and 23 metrics, please see our ESG Performance Report</div></div> </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Access </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Our ambition is to positively impact the health of 2.5&#160;billion people by the end of 2030. We will achieve this by developing vaccines and medicines and making them available through responsible pricing, strategic access programmes and partnerships. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Make our products available at value-based prices that are sustainable for our business and implement access strategies that increase the use of our medicines and vaccines to treat and protect underserved people. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Develop and externally publish pricing and access principles </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Progress towards our 2030 goal of reaching 1.3&#160;billion people in lower income countries with our products </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Putting the right value on innovation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We follow a set of pricing and access principles, published for the first time in 2022. These help us to get the balance right between responsible pricing and a sustainable, profitable business that allows us to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-invest</div> financial returns in future innovation, while ensuring people can access medicines and vaccines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, in the US, through GSK and ViiV Healthcare&#8217;s Patient Assistance Programs Foundation, we provided prescribed medicines and vaccines to more than 78,000 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> uninsured, underinsured and Medicare Part D patients. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In the US, during the year, our combined average net price (after discounts, rebates or other allowances) for our pharmaceutical and vaccines portfolio increased by 1.4%, while the average list price increased by 3.8% compared to 4.9% (list) for the industry, which demonstrates we are responsible in our pricing decisions<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>. Over the past five years, the average net price for our products decreased by 1.1% annually, while the average list price rose by 3.9% compared to 5.0% (list) for the industry<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reaching patients in lower income countries </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our goal is to reach 1.3&#160;billion people in lower income countries with our products by the end of 2030, through access initiatives such as voluntary licensing, donations and our work with Gavi, the Vaccine Alliance. In 2022, we reached 73&#160;million people with our products and supplied an additional 533&#160;million doses of albendazole<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div>. In 2022, we ranked first in the Access to Medicines Index for the eighth consecutive time. </div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Industry averages are sourced from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Drug Channels </div></div>annual brand-name drug list change report </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 73&#160;million figure includes people reached with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>, OPV and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mosquirix </div></div>vaccines and people with access to a generic dolutegravir product through our voluntary licensing agreements; however it does not include people reached through albendazole, for which an assessment will be made in 2025 by the WHO and GSK </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have been a partner with Gavi since its foundation in 2000. We reserve our lowest vaccine prices for Gavi and similar organisations and, in 2022, we passed the milestone of supplying Gavi with more than one billion vaccines since 2010. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our partnership includes supplying <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>, a critical vaccine in lower income countries for addressing cervical cancer. In 2022, we supplied around 40&#160;million doses of our pneumococcal vaccine, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>, to eight Gavi-eligible countries at our lowest price. Our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div> vaccine against rotavirus reaches children across 27 Gavi-eligible countries and four former Gavi countries. Since March 2021, as well as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>, we have also offered <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div> through the Humanitarian Mechanism, to civil society organisations serving refugees and working in other emergency situations. We are also a long-standing supplier of oral polio vaccines (OPV) through UNICEF and, in 2022 alone, supplied around 95&#160;million doses to help eradicate polio. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Neglected tropical diseases </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we donated 533 million doses of albendazole, a medicine used to help eliminate lymphatic filariasis and treat soil-transmitted helminths. We have also extended our soil-transmitted helminths commitment to include preschool children and made an additional commitment to donate albendazole for treatment of echinococcosis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, ViiV Healthcare and the Medicines Patent Pool (MPP) signed a new voluntary licensing agreement to allow generic manufacturers to develop, manufacture and supply cabotegravir long-acting for HIV pre-exposure prophylaxis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">ViiV Healthcare also has voluntary licensing agreements with 17 generic manufacturers to produce and sell low-cost single or fixed-dose combination products containing our HIV medicine dolutegravir for adults in 95 low- and middle-income countries, with one direct licence and the others via the MPP. There are similar agreements with 14 generic manufacturers for children, covering 123 countries. As a result of these voluntary licence agreements, around 21 million people living with HIV across 122 countries had access to a generic product containing dolutegravir by the end of 2022. This is at least 80% of people living with HIV on antiretrovirals in low- and middle-income countries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, ViiV Healthcare donated around 7,200 packs of antiretroviral medicines to NGO partners and national HIV and AIDS programmes to support people living with HIV who have been impacted by the conflict in Ukraine. ViiV has also provided over &#163;800,000 through its Positive Action programme to support 11 community-based organisations with humanitarian response activities, both within Ukraine and in surrounding countries hosting refugees. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Positive Action, ViiV Healthcare&#8217;s community grant-giving programme, celebrated its 30th anniversary in 2022 with a year-long campaign to showcase the people at the heart of the programme, the partners in implementation and the progress made through collaboration. It invested more than &#163;12.6&#160;million in 2022, reaching approximately 392,000 people and providing 137 grants across 33 countries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Malaria </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Working with our partners, more than 1.2&#160;million children in Africa have now received at least one dose of our malaria vaccine, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mosquirix </div></div>(RTS,S/AS01 E). In September 2022, the WHO awarded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-qualification</div> to the vaccine. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This is a prerequisite for UN agencies to procure the vaccine, and an important step in rolling it out in countries with moderate to high <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">P. falciparum</div></div> malaria transmission. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK, PATH and Bharat Biotech have agreed a product transfer to help ensure long-term supply of the RTS,S malaria vaccine. We have committed to supply up to 18&#160;million doses over the next three years, in addition to our donation of up to 10&#160;million doses to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">WHO-coordinated</div> Malaria Vaccine Implementation Programme in Ghana, Kenya and Malawi. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Global health and health security </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">We use our expertise to address the biggest health challenges for underserved people around the world. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To develop novel products and technologies to treat and prevent priority diseases, including pandemic threats. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Progress three Global Health pipeline assets to address priority WHO diseases </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Global health R&amp;D </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In June 2022, GSK, including ViiV Healthcare, announced a &#163;1&#160;billion investment in R&amp;D to help us get ahead of infectious diseases in lower income countries. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-year</div> investment will support R&amp;D on new medicines and vaccines to prevent and treat tuberculosis (TB), malaria, HIV, enteric diseases, and neglected tropical diseases, and to reduce AMR. In 2022, we progressed 12 Global Health pipeline assets to address priority WHO diseases, including malaria and TB, exceeding our target of three. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We want to discover shorter, simpler and safer treatments for TB. In 2022, alongside our partners and through public-private research consortiums, we continued to progress our pipeline of novel TB medicines. In 2022, we announced positive phase IIa study results for GSK3036656, a new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> candidate medicine for patients with TB. Results of the study demonstrated the potential for the candidate to become a component of simpler treatment regimens in the future. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In partnership with BioVersys, the University of Lille and the Innovative Medicines Initiative (IMI) project, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TRIC-TB,</div> we also successfully completed phase I trials of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BVL-GSK098,</div> which has the potential to help tackle drug resistance by boosting the activity of an existing antibiotic. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">With our partners, we&#8217;ve brought two products for the prevention and treatment of malaria to market &#8211; the world&#8217;s first vaccine against malaria, and a single-dose, radical cure for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">P. vivax </div></div>malaria. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In March 2022, the Australian regulator, the Therapeutic Goods Administration, approved the use of single-dose medicine tafenoquine in children aged two and above in combination with chloroquine for the radical cure of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">P. vivax</div></div> malaria. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The FDA approved <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PD</div></div>, the first dispersible single tablet formulation containing dolutegravir for children weighing more than 10kg, which increases the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">age-appropriate</div> treatment options for children living with HIV. At the end of 2022, the CHMP of the EMA also issued a positive opinion recommending marketing authorisation for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq PD</div></div> for children 14kg and above. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Invasive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-typhoidal</div> salmonella disease can be life-threatening for children in Africa and is a key driver of AMR. We&#8217;re using our innovative vaccine technology in partnership with the University of Oxford and Vacc-iNTS, to develop a potential candidate vaccine using our Generalised Modules for Membrane Antigens technology. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To help support global R&amp;D, in December 2022, we announced the fourth call for proposals as part of the Africa Open Lab. The call for proposals is aimed at African early-career scientists who are based in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-Saharan</div> Africa, with a focus on infectious diseases which disproportionately affect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-Saharan</div> populations, such as malaria, TB and neglected tropical diseases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Getting ahead of antimicrobial resistance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have more than 30 R&amp;D projects across medicines and vaccines that are relevant to AMR, ranging from early- to late-stage development. These include gepotidacin, which could be the first novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years; and in 2022, we announced an exclusive licence agreement with Spero Therapeutics for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections. 13 of these projects target pathogens deemed &#8216;critical&#8217; or &#8216;urgent&#8217; by the WHO and the US CDC. See page 22 for more about our R&amp;D pipeline. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Surveillance is central to tackling AMR. In 2022, we shared data from our long-running Survey of Antibiotic Resistance (SOAR) study, which tracks community-acquired respiratory infections, with the new AMR Register, developed by Vivli. In 2022, we also worked with the AMR Industry Alliance to publish a new Antibiotic Manufacturing Standard. This provides clear guidance to manufacturers in the global antibiotic supply chain to help ensure that their antibiotics are made responsibly and in compliance with scientifically robust discharge limits. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report </div></div></td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Future pandemic preparedness </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In July 2022, GSK, along with other major biopharmaceutical companies, signed up to the Berlin Declaration. This sets out the industry&#8217;s vision for equitable access during future pandemics. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The declaration stated the sector&#8217;s willingness to reserve an allocation of real-time production of medicines and vaccines for distribution to priority populations, as determined by health authorities, during future pandemics. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, GSK concluded a series of contracts under which we would provide at least 200&#160;million doses of pandemic influenza vaccine to governments around the world. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In February 2022, we extended our pandemic influenza vaccine stockpile contract with the United States government. This was followed by a renewed agreement, in June 2022, for supply of pandemic influenza vaccines to the WHO, and in July 2022, a contract with the government of Canada for both seasonal and pandemic influenza vaccines. We signed an agreement with Europe for the reservation and future production and supply of pandemic influenza vaccines. We are also continuing to partner with the BARDA to manufacture and assess the safety and immunogenicity of pandemic influenza vaccine candidates. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environment </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">We continue to work hard to do more to protect the environment, often in partnership with others. We&#8217;ve set clear and measurable targets to help achieve our goals. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Commit to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The following metrics are included in our ESG Performance Rating and support delivery of our carbon and nature ambitions: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Climate </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Operational emissions reduction (scope 1 and 2 market-based emissions) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Industrialisation of green <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin</div></div> initiated, and clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> data available to support regulatory submissions </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Percentage of carbon offset volume in project pipeline </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Water </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Average of the percentage of GSK sites and suppliers compliant with wastewater active pharmaceutical ingredient limits and the percentage of suppliers that are compliant with the AMR Industry Alliance Common Antibiotic Manufacturing Framework and discharge limits </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#8211; Waste and materials </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Operational waste and material reduction at our sites </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Biodiversity </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Number of high-risk materials implementing sustainable sourcing roadmaps </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Climate </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have set a clear pathway to a net zero impact on climate with ambitious goals for 2030 and 2045. We have updated our climate targets to be in line with the new Science Based Targets initiative (SBTi) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Net-Zero</div> Standard. By 2030, we aim to reduce carbon emissions across all scopes by 80%, against a 2020 baseline, with the remaining 20% offset through investment in high-quality nature-based solutions. We have also now set a longer-term target to reduce carbon emissions by at least 90% with the remainder tackled through high-quality offsets by 2045. For additional context on these changes see pages 16 and 17 of the ESG Performance Report. </div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Targets<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>: </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">80% reduction in carbon emissions and investment in nature-based solutions for the remaining 20% of our footprint by 2030 (all scopes)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">100% renewable electricity by 2025 (scope 2) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Net zero emissions across our full value chain by 2045 (all scopes)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div> </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Targets are measured against a 2020 baseline </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Previously stated as net zero by 2030 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">This is a new longer-term target, aligned to the SBTi <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Net-Zero</div> Standard definition of net zero </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> </div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance </div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we reduced our scope 1 and 2 carbon emissions by 6% compared with 2021. This was primarily through increasing our use of renewable electricity and continued delivery of energy efficiency across our sites, such as the installation of new solar panels, upgraded lighting and replacing chillers to reduce the use of ozone depleting refrigerant. As a member of RE100, we have committed to source 100% renewable electricity by 2025. In 2022, we reached 73%, an increase of 6% since 2021 and 28% since 2020. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Following the demerger of our Consumer Healthcare business, we are restating our value chain carbon footprint for our baseline year 2020. In 2021 (our latest available data), our scope 3 emissions reduced by 13% compared with 2020. These reductions reflect the evolution of our product portfolio. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Approximately 29% of our total emissions footprint comes from the goods and services that we buy. In September 2022, we launched a Sustainable Procurement Programme, which will require our suppliers to, among other things, disclose emissions, set carbon reduction targets aligned with 1.5<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">o</div>C, and switch to renewable power and heat. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are also working with our peers through the Energize programme to encourage the use of renewable energy throughout the pharmaceutical sector&#8217;s supply chain. In 2022, nine suppliers formed the first Energize buyer&#8217;s cohort, who together will purchase two terawatt-hours of renewable electricity. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">See pages 55 to 62 for our disclosure on climate risk and resilience in line with the Task Force on Climate-related Financial Disclosures (TCFD) framework. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to working towards our goal of having a net positive impact on nature by 2030, by reducing our environmental impacts across water, waste and materials, and biodiversity and by investing in protecting and restoring nature. </div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Targets<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>: </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Achieve good water stewardship at 100% of our sites by 2025<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Reduce overall water use in our operations by 20% by 2030 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Be water neutral in our own operations and at key suppliers in water-stressed regions by 2030<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Zero impact active pharmaceutical ingredient (API) levels for all sites and key suppliers by 2030<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Zero operational waste, including eliminating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> plastics, by 2030<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">4</div> </div></td></tr></table><div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Targets are measured against a 2020 baseline </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">See our Environment Basis of reporting for definition </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Zero impact against predicted no effect concentrations </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">4</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Where regulatory obligations allow, and excluding plastics which are critical to product discovery and development and health&#160;&amp; safety </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="break-inside: avoid; font-size: 0px;">
<td style="width:7.5pt;vertical-align:top;text-align:left;"></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">25% environmental impact reduction for our products and packaging by 2030 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">10% waste reduction from our supply chain by 2030 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Positive impact on biodiversity at all sites by 2030 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">100% agricultural, forestry and marine-derived materials sustainably sourced and deforestation free by 2030 </div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Performance </div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we reduced overall water use in our operations by 5% since 2021 and by 1% in sites in high water stress regions. This is a decrease of 23% for overall water use and 6% for sites in high water stress regions against our 2020 baseline. This achieved our 2030 overall water use reduction target, which we will now review. 100% of our sites are now good water stewards, in line with the Alliance for Water Stewardship&#8217;s definition. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have initially identified three water basins in water-stressed areas in Algeria, India and Pakistan where we have manufacturing sites, and where we aim to be water neutral. At our manufacturing facility in Nashik, India, we have built plants for rainwater harvesting. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, 100% of our sites and 98% of our suppliers that manufacture antibiotics complied with AMR Alliance industry standards on safe discharges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we continued to reduce the waste from our sites and increase the amount of materials recovered through circular routes like reuse or recycling. We are also targeting materials across our existing product portfolio. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are progressing our plans for net positive biodiversity at our own sites by investing in individual site action plans that improve habitats, protect species and improve soil and water quality. In 2022, we completed baseline biodiversity assessments for 80% of our sites. We have commenced biodiversity uplift projects at our three largest R&amp;D facilities. We have also completed a full assessment of our biodiversity impact (across the entire value chain) and will be taking targeted actions to address the highly-stressed areas. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lead-up</div> to the UN Convention on Biological Diversity, the critical COP15 conference in Canada at the end of 2022, we worked with partners to call for mandatory disclosure by businesses and financial institutions of their impacts and dependencies on nature. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are part of the LEAF Coalition (Lowering Emissions by Accelerating Forest finance), a private-public effort to protect tropical forests. We are also testing a framework for voluntary carbon credits from the Voluntary Carbon Market Integrity Initiative, which is working to establish a globally-standardised benchmark to guide the use of carbon credits by companies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">See pages 62 to 63 for how we plan to disclose on our impacts and dependencies on nature in line with the emerging Taskforce on Nature-related Financial Disclosures (TNFD) framework. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diversity, equity and inclusion </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Diversity, equity and inclusion (DEI) are central to our purpose of getting ahead of disease together. Being an inclusive and diverse business &#8211; and doing business inclusively &#8211; makes us more successful, making the most of our people&#8217;s potential and increasing our positive impact. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Create a diverse, equitable and inclusive workplace; enhance recruitment of diverse patient populations in our clinical trials; and support diverse communities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">75% of phase III trials initiated in 2022 will have proactive plans in place designed to enrol appropriately diverse trial participants, consistent with disease epidemiology </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Performance towards 2025 aspirations through fair and equitable opportunities: </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">have women hold at least 45% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VP-and-above</div></div> roles globally by the end of 2025 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">have at least 30% ethnically diverse leaders in our roles at VP and above in the US, and increase the percentage of Black or African American, and Hispanic or Latinx <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VP-and-above</div></div> leaders year on year </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">have at least 18% ethnically diverse leaders in our roles at VP and above in the UK, and increase the percentage of Black <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VP-and-above</div></div> leaders year on year </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Improve <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-on-year</div></div> spend with certified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> diverse-owned suppliers </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Building an inclusive business </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to improving diversity in clinical trial enrolment and are already using our disease insights to set diversity enrolment goals. At the end of 2022, 100% of GSK&#8217;s phase III trials had a diversity plan in place to enrol the groups most affected by the disease being studied, based on epidemiology data. For example, in our hepatitis B trials, a disease that disproportionately affects people of African and Asian descent, 52% of participants are of Asian origin, and we are actively working to improve the representation of participants of African descent. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our supplier diversity programme is well established in the US, and an expansion plan is being developed for the UK. We have a target to increase spend annually with certified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> diverse-owned suppliers. This was significantly exceeded in 2022 through a combination of spend increases with selected suppliers in marketing, sales and technology, as well as identification of new global diverse suppliers and a strong multi-year strategy of engagement with key advocacy groups. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GSK Science in the Summer</div></div> initiative offers free, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hands-on</div> STEM learning to students in traditionally under-represented groups in STEM careers or from under-resourced communities in the US. In 2022, it reached more than 30,000 students nationwide. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nurturing all our people </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, 42% of women held <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VP-and-above</div></div> roles globally, compared with 40% in 2021. Women made up 47% of all employees in 2022, and 50% of all management roles. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We published our sixth UK gender pay gap report in 2022. Our gender pay gap for all permanent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">UK-based</div> GSK employees is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-1.36%</div> (mean), compared to the national average of 13.9%. We published our first UK ethnicity pay gap report for 2022 using the same approach as our gender pay gap. Our ethnicity pay gap for all permanent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">UK-based</div> GSK employees is 0.06% (mean), at this time there is no national average comparator. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In those countries that meet our criteria for data confidentiality and anonymity, we disclose the race and ethnicity of our people at each level and set aspirational targets. Currently, the US and the UK meet those criteria. In the US in 2022, we have 31.3% of ethnically diverse leaders at VP level and above, reaching our 2025 aspirational target of at least 30%, and increasing the percentage of Black or African American and Hispanic or Latinx people in those roles year on year. In the UK in 2022, we have 14.3% of ethnically diverse leaders at VP and above, continuing to make progress towards our 2025 aspirational target of reaching at least 18%. Black representation at VP and above remains flat and we will be focused in our efforts to achieve our aspiration for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-on-year</div></div> growth. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are members of the UK government&#8217;s Disability Confident scheme and are an active member of the Valuable 500 pledge, a grouping of 500 global companies committed to placing disability inclusion on the leadership agenda. We are delivering on the scheme&#8217;s objectives through our long-term, measurable, disability confidence plan, which includes educating our people on the issue. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we introduced a new global minimum standard of 18 weeks&#8217; parental leave for primary and secondary carers for all forms of family, a new global minimum standard for care of a family member for end of life or serious health emergencies, insured benefits to include same sex partners wherever possible, a new financial wellbeing service and mental health training &#8211; available to everyone. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This year, we were recognised as a Gold employer within Stonewall&#8217;s Top Global Employers Index. Our Allyship programme received an award recognising the tangible impact the campaign has had on the lives of LGBT+ employees. We also achieved the Human Rights Campaign Foundation&#8217;s Best Places to Work for LGBT+ Equality standard in 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ethical standards </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our culture guides our people to do the right thing and Speak Up about any concerns they have. It is important that all our people live up to this, and we expect the same of our suppliers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Promote ethical behaviour across our business by supporting our employees to do the right thing and working with suppliers that share our standards and operate in a responsible way. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">100% of employees and complementary workers complete GSK&#8217;s 2022 mandatory training </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Percentage of employees who believe they &#8216;can and do Speak Up if things don&#8217;t feel right&#8217; is above the general industry benchmark<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Number of employees leaving GSK&#8217;s employment for misconduct in the last 12 months versus the three-year rolling average </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">80% of direct high-risk suppliers achieve GSK&#8217;s minimum EcoVadis score or have an improvement plan in place </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supporting GSK people to do the right thing </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we launched our new Code of Conduct which reflects our purpose to unite science, technology and talent to get ahead of disease together. Our new Code sets out the commitments we make as a company and to each other to deliver on our purpose and ambitions. In 2022, 100% of employees and 98% of complementary workers completed the accompanying global mandatory learning curriculum where due by year end. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Those in certain high-risk roles or geographic regions also complete additional anti-bribery and corruption (ABAC) training. In 2022, 100% of employees and 96% of complementary workers completed this training where due by year end. Our approach to managing ABAC risk, and other risks relating to ethical standards, forms part of our well embedded risk management framework, which is described in detail on pages 51 to 52. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting and investigating concerns </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This year, we have updated how we report the breakdown of types of policy violations to provide more granularity by case class. In 2022, we saw an overall decrease in disciplinary cases, attributed to, in part, a revision to our procedures for discipline regarding late completion of mandatory training, now reported under the employee conduct category. </div><div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The general industry benchmark is 65% according to 2022 research by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">KornFerry</div></div> </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Upholding our commitment to human rights </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are signatories to the UN Global Compact and our Human Rights Position statement lays out our commitment to the UN Guiding Principles on Business and Human Rights. During the year, we established a Human Rights Steering Group, which has a formal reporting mechanism to the Board&#8217;s Corporate Responsibility Committee. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we developed guidance to enhance supplier visits to help employees better understand labour and human rights <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliances.</div> To support this guidance, we also developed and delivered labour rights training to environment, health and safety (EHS) and procurement employees to better equip them to spot human rights issues when visiting suppliers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to the application of fair and equitable pay practices, which includes ensuring that all employees globally receive pay that is competitive in their local markets and sufficient to support a sustainable standard of living. In 2022, we completed the first global living wage review in partnership with the Fair Wage Foundation. We assessed the pay of all our employees (over 75,000 people in 87 countries) and differences were detected in fewer than 200 cases, in 11 countries. All necessary adjustments will be made by the end of the first quarter of 2023. We will be factoring the living wage data into our standard compensation processes to ensure that we continue to offer a fair wage, and have built an annual living wage review into our standard cycle. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Working with third parties </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We expect our third parties to meet our ABAC and labour rights standards and to comply with our standards on quality, health and safety, and the environment. See pages 285 to 295 for further information. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We updated our Third-Party Risk Management (TPRM) programme, which evaluates and mitigates risks introduced by third parties engaged by GSK to provide goods or services. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, for our high-risk third parties &#8211; determined by location in high-risk markets and size of spend &#8211; we performed 7,168 assessments across 20 risk areas. Over 62% of these assessments presented risks in one or more areas. Most of these third parties are goods and services providers (77%), distributors and wholesalers (5%), contract manufacturers and suppliers (1%) and direct material suppliers (1%). We also use tools to assess how suppliers manage risks, including EcoVadis desktop assessments. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We visit sites, in person or virtually, to help suppliers better understand and control their risks. The relaxation of travel restrictions has allowed us to increase in-person visits to identify and reduce risk, enabling us to conduct 50 physical visits across 63 priority suppliers this year<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>. We completed warehouse safety surveys for 54 priority suppliers, 38 contract manufacturing suppliers and 15 large warehouses that hold stock this year. These surveys have generated corrective and preventative action plans, all of which we expect to complete in 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we conducted 47 supplier audits, compared with 49 in 2021, following industry standard Pharmaceutical Supply Chain Initiative guidelines, with any corrective and preventative actions tracked to completion. We have also trained more than 600 supplier employees on EHS and ESG fundamentals in 2022, revised EHS contractual obligations, tracked management actions to completion and have helped suppliers improve their EcoVadis scores<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div>. See page 293 for further information. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Data and engagement </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have created a new digital, privacy and information security team within Legal and Compliance, to streamline support and provide expertise around GSK&#8217;s digital and data strategy. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Privacy and the ethical use of data are part of the global mandatory learning curriculum Living our Code that all our people have to complete. We ensure that key privacy personnel have certifications and sufficient training and experience to carry out their roles effectively. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are investing in our AI/ML capability to, for example, help analyse patients&#8217; genetic data. We are mindful that AI and machine learning can raise ethical issues and are subject to evolving decisions from policymakers on how best to promote trust in these systems and avoid unintended outcomes or harmful impacts. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In R&amp;D, we have oversight boards and a new advisory panel that oversees controls to manage how we use or re-use data and respond to bioethical questions in our research activities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Political engagement </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As a major multinational company, we seek to contribute to public policy debate, especially in relation to life sciences and healthcare. In all of our political engagements, we are committed to ensuring that we adhere to the highest ethical standards and legislative requirements. We do not make corporate political contributions, nor do we sponsor party political meetings anywhere around the world. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report</div></div> </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product governance </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Ensuring the quality, safety and reliable supply of our products is critical to protecting patients and delivering health impact. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our commitment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We commit to maintaining robust quality and safety processes, and using data and new technologies responsibly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How we assess performance </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Average number of critical and major findings by FDA/ MHRA/EMA regulators<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div> </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Percentage of inspections from all regulators with no critical findings or official action indicated </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Number of FDA warning letters </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Total number of Class I/II external product recalls across all markets </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">Register and disclose all human subject research of GSK products. Specifically, register protocol summaries for studies initiated in 2022; and disclose results summaries for studies with results due in 2022 </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Progress in 2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A focus on quality management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our GSK Quality Management System is a detailed and specific framework which describes how we comply with regulatory requirements and other standards across our markets. It addresses global and local regulations across manufacturing and distribution processes, and is based on principles defined by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Our EHS priority suppliers are API suppliers who are, or will be, medically-, R&amp;D- or revenue-critical to GSK, or are high spend suppliers </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 600 supplier employees trained includes data from our previous Consumer Healthcare business </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">We consider any observations from the FDA as major </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;"></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Responsible business continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inspections, recalls and audit </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022, we had 122 regulatory inspections at our manufacturing sites and local operating companies, compared with 111 in 2021. We remain prepared for inspections from regulators and received no warning letters from the US FDA or critical findings from the Medicines and Healthcare products Regulatory Agency (MHRA) and EMA regulators in 2022; however we received one critical finding from the Chinese regulator<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>. We continue to learn from and respond to all inspection findings, taking the necessary action to address them. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Throughout 2022, we had no Class I product recalls. There were fewer Class II and III recalls than in 2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div>. We will not hesitate to voluntarily recall products to protect patients. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Working with our suppliers on quality </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We expect all our contract manufacturers and suppliers to comply with GSK standards, and regularly conduct audits to verify that they do. In 2022, we conducted 1,060 quality audits of suppliers, with an increased focus on API suppliers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have a comprehensive quality oversight model that is aligned to our Quality Management System and uses a risk-based approach to assess, qualify, manage and monitor our third-party suppliers, driving continuous performance. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maintaining pharmacovigilance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Pharmacovigilance aims to protect those who use medicines and vaccines and support public health programmes with reliable, comprehensive information on the overall benefit-risk balance of our products. We have a well established and rigorous worldwide system to monitor and review the safety of our products throughout clinical development and after regulatory approval. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vigilance against falsified medicines and vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have a robust approach to handling all falsified product incidents, ensuring that cases of confirmed counterfeit products are reported to the WHO and to relevant regulatory authorities. We actively participate in legal proceedings against illegal actors, provide regular training to customs and local authorities and we monitor online marketplaces and social media to request takedowns of sites illicitly selling prescription-only medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committed to transparency </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As part of our commitment we have made 7,377 protocol summaries and 6,295 summaries of results available since the set-up of the GSK trial register in 2004. We have also listed 2,559 studies for data sharing via www.vivli.org and www.clinicalstudydatarequest.com. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For full details of our progress against our six focus areas, please see our ESG Performance Report</div></div> </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Critical finding from one inspection by the Chinese regulator of a third-party manufacturing facility used by GSK </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Class I recalls are triggered by a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. Class II recalls address the use of or exposure to a violative product which may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Class III recalls relate to the use of or exposure to a violative product which is not likely to cause adverse health consequences </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_15" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Risk management </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">Our Board continuously reviews and oversees our risk management and </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">internal control framework, which reflects who we are as a responsible </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">biopharma company with bold ambitions for patients. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Managing our risks in line with our long-term priorities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our well embedded risk management and internal control framework gives our Board the ability to evaluate and oversee how the company manages principal and emerging risks in line with our strategy and long-term priorities as a fully-focused biopharma company, following this year&#8217;s demerger of Haleon. Our company-wide policy sets out the requirements, roles and responsibilities for the management and governance of risks and controls, as well as supporting guidance on the essential elements of our internal control framework. We routinely evaluate our framework for improvements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board oversight of risk appetite and management systems </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Board oversees our risk management system and establishes our risk appetite, supported by the Audit&#160;&amp; Risk Committee (ARC). The Corporate Responsibility Committee (CRC) and Science Committee further assess the effectiveness of risk management strategies that fall within their defined remits. Our Risk Oversight&#160;&amp; Compliance Council (ROCC) helps the ARC, CRC and Science Committee to oversee the risks, and the strategies used to address them. Alongside this, risk management and compliance boards across the Group promote the &#8216;tone from the top&#8217;, establish our risk culture and oversee the effectiveness of risk management activities, while also communicating information about internal controls. Management is held accountable for delivering on its objectives in line with the established risk appetite pertaining to principal risks. An enterprise risk owner is responsible for each principal risk, overseen by a GLT member. Risk owners report risk and mitigation to ROCC and the appropriate Board committee each quarter. Legal and Compliance support these efforts by advising on our business strategies, activities, risks and controls, and Audit &amp; Assurance provides assessments of the adequacy and effectiveness of our framework. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assessing emerging and current risks </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our risk assessment process considers the likelihood and impact of risks, and the timescale over which a risk could occur. As well as considering current risks, we evaluate emerging risks that could affect our ability to achieve our long-term priorities &#8211; that is, risks on the three-year horizon, in line with our viability statement. We also define risks as &#8216;emerging&#8217; if we need to know more about how likely they are to materialise, or what impact they would have if they did. We&#8217;ll evaluate whether to investigate further before classifying them as principal risks. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our risk management and compliance boards at all levels of the organisation identify emerging risks on an ongoing basis, and ROCC discusses emerging risks at each meeting. At the same time, we scan the risk horizon throughout the year to identify external trends that may be opportunities and/or emerging risks and monitor our business activities and internal environment. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">ROCC conducts an annual risk review to assess principal and emerging risks for the company. This review is supported by extensive analysis of external trends and insights, senior-level interviews and recommendations from risk management and compliance boards and risk owners. ROCC shares this annual review with the ARC and Board for assessment, forming the basis for the following year&#8217;s risk management focus. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Enabling effective risk management, in line with our culture </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We define enterprise risk plans that include a description of the risk, its context, our assessment, risk appetite, how we will treat the risk, and the actions businesses need to take in line with our internal control framework to mitigate the risk. These plans enable our Board committees to assess the effectiveness of our risk management strategies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We report risks to ROCC and the Board committees every quarter, to drive more dynamic, data-driven discussions, agile risk management strategies and oversight. We report on existing control measures, implementation, emerging risks, external insights and key risk indicators, with risk reporting thresholds aligned to risk appetite. We include risks and mitigations associated with relevant events around us, such as COVID-19 and geopolitical tensions. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our Code sets out the overarching expectations for our employees and complementary workers. Our risk management framework complements our culture and Speak Up processes in making sure that we identify and mitigate risks effectively. We monitor our most important risks and take action to address issues. Our annual confirmation exercise checks that key risks are well managed, or that actions are in place to address gaps. Our principal risks include controls for responding to problems within their risk plans. We also have business continuity planning embedded in our framework and our critical processes, so we can continue business operations in the event of a crisis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our current risks </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The table starting on page 53 shows our current principal risks and respective trends, assessments and mitigation activities for the year. These are not in order of significance. For full risk definitions, potential impact, context and mitigating activities, see Principal risks and uncertainties on pages 285 to 295. The Separation principal risk was removed in July 2022 following successful demerger and analysis of any residual risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Other risks, not at the level of principal risks, and opportunities, related to ESG, including environmental sustainability and climate change, are managed through our six focus areas, as described in our ESG Performance Report. Additional information on climate-related risk management is in our climate-related financial disclosures, see pages 55 to 61. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COVID-19 pandemic </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The potential impact of the COVID-19 pandemic on GSK&#8217;s trading performance and all its principal risks is continually assessed, with appropriate mitigation plans put in place on an as-needed basis. In 2022, GSK was encouraged by the uptake of its vaccines and medicines. The company remains confident in the underlying demand for its vaccines and medicines, especially given the significant number of COVID-19 vaccinations and boosters administered worldwide. However, the pandemic remains a dynamic ongoing risk, with the WHO continuing to monitor the emergence of new variants. The current rate of infection is predominantly driven by the circulation of the BA.5 subvariant and its descendent lineages, which are still the dominant subvariants of Omicron globally. While COVID-19 vaccines are being updated with Omicron variants to provide broader immunity against circulating and emerging variants, these subvariants and potential future variants of concern could potentially impact GSK&#8217;s trading results, clinical trials, supply continuity and its employees materially. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Changes to our risks for 2023 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In our December 2022 annual risk review, the ARC agreed to ROCC&#8217;s recommendation of our principal risks for 2023, which remain largely unchanged. We identified a new principal risk, Legal Matters, which brings into greater focus a range of legal risks. As a result, Anti-bribery and Corruption will no longer be a stand-alone principal risk in 2023. Additionally, we expanded our Information Security principal risk to explicitly include cyber risks. We also identified data management as a new emerging risk for 2023, which we will evaluate during the year. The 2022 emerging risks of geopolitical tensions and healthcare reform were embedded in our risk management activities throughout the year and will not be reported separately for 2023. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Viability statement, see page 64 </div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ARC report, see page 124 </div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Internal control framework, see page 125 </div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Legal proceedings, see page 265 </div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Environment, see page 45 </div></div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Climate-related financial disclosures report, see page 55 </div></div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_16" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2022 Principal risks summary </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:67%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Risk</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trend versus</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">prior year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Assessment and mitigation activities</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patient</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">safety</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment remains stable. The regulatory environment remains challenging, with recent examples of evolving regulatory requirements related to safety reporting for clinical trials. Also, there is a risk that external parties, including regulatory agencies and technology companies, may reach conclusions and communicate information about the safety of our products based on real-world evidence that is not available to us. This could inhibit our ability to make timely decisions and take appropriate action in relation to the safety of our products, or to confirm or refute conclusions asserted by external parties.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable. We continue to balance resources between change programmes while maintaining routine activities. In 2022, we&#8217;ve allocated resources to optimise pharmacovigilance operations, advance innovative solutions for safety case management, and simplify key safety processes. Change initiatives have the short-term potential to distract focus from our key business priorities. However, such changes will reduce our overall risk exposure by increasing workload capacity and organisational capability.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">quality</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment is stabilising and remains high following COVID-19, with regulators resuming multiple on-site inspections to check that product quality expectations are met. There continues to be a focus on data governance and data integrity requirements, and on evaluation of products for the presence of nitrosamines. The regulatory environment is evolving with respect to continued use of titanium dioxide in medicines, with the EMA due to make a decision on potential discontinuation in 2024.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure has stabilised as we return to pre-pandemic levels of health authority inspections. We continue with inspection readiness programmes to ensure full preparedness. We&#8217;ve continued to invest in technology and digital platforms to strengthen our controls around good data management practices. We&#8217;ve completed all nitrosamine product assessments in line with regulatory expectations.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">controls and</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">reporting</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">The external risk environment remains challenging due to political uncertainty, proposed increases in the obligations of directors and auditors, increasing threats of cyber attacks and fraud, and increasing ESG disclosure requirements.</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Our risk exposure remains stable due to our ongoing focus on the resilience of personnel and the testing of our internal control framework. We implement optimal risk mitigation through transformational programmes, technology, centralised processes, and risk and control assessments, and maintain effective tax and treasury strategies. We continually strengthen our control frameworks and collaborate with external bodies on setting standards.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-bribery</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and corruption</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(ABAC)</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment remains stable. The enforcement of anti-corruption laws and regulations remains a priority in many countries, in particular the US and the UK, with a continued focus on investigating the use of third parties to bribe foreign public officials. As a result, rigorous anti-bribery and corruption controls are expected. Disruption to global supply chains and the commercial pressures caused by higher-than-usual inflation rates may increase the risks of bribery and corruption in certain contexts in the coming years.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable as we continuously improve our ABAC programme to make sure that our controls match evolving and emerging risks. We&#8217;ve enhanced our mandatory ABAC training for all employees, and we provide role- and risk-tailored ABAC training on an ongoing basis. We also impose stringent ABAC training requirements on certain third parties who provide services for or on our behalf.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">practices</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment has stabilised. Macroeconomic factors such as energy price increases, inflationary pressure, and ongoing effects of the COVID-19 pandemic contribute to a challenging environment for all stakeholders. Competitive pressure remains intense across therapy areas and market segments. Governments remain focused on initiatives to drive down medicine and vaccine costs for consumers.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable. We have a mature and robust control environment, which has evolved to match the competitive enhancements to our commercial practices, including higher volumes of engagement with healthcare professionals and strengthened sales force incentive schemes.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 Principal risks summary continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:67%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Risk</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trend versus</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">prior year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Assessment and mitigation activities</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scientific</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and patient</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">engagement</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment remains stable. It continues to be characterised by complex, dynamic disease areas and treatments with increased patient-centric focus during all phases of the product lifecycle, increasing diversity of engagement platforms and more virtual engagements.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable. We continue to mitigate risk by modernising and adjusting our engagement practices and internal controls to the rapidly evolving environment. We have internal networks to foster collaboration and best practice sharing, as well as the identification of emerging risks associated with scientific and patient engagement activities.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Data ethics</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and privacy</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment continues to increase as the global landscape of data protection, privacy and cyber laws develops. Given that the current pace of technology-focused innovation is expected to continue, companies need to be mindful of relevant potential legislation and regulations. The increasing trend for data sovereignty, initially affecting tech companies, could affect healthcare companies in their ability to drive medical innovation and to effectively operate internationally.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure is increasing in the context of an unstable privacy regulatory environment and our multinational footprint, as we re-align with our digital transformation and focus on data-driven science. Laws in our key markets such as the US, EU, UK, China and India continue to evolve, including those relating to international data transfer mechanisms.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">practices</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment remains stable. Research remains critical to the development of safe and effective products. Advances in technology, use of data, societal expectations and ethical considerations and new entrants to the sector continue to influence the environment. Global regulations and quality standards continue to evolve, and are particularly impactful when expectations change or there are country-specific requirements.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable, as laws and regulations are continually evolving. We continue to perform robust risk scanning and assessments that inform the evolution of our control framework in response to regulatory changes, ensuring clear accountabilities for actions.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environment,</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">health and</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">safety</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(EHS)</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">The external risk environment remains stable. Manufacturing sites are operating at full staffing levels. Work location arrangements have been made to maintain the safety and wellbeing of employees affected by the Ukraine conflict.</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Our risk exposure remains stable. We&#8217;ve continued to focus on safety leadership training, embedding our Life Saving Rules, and adhering to our EHS standards. We&#8217;re introducing our Safety Leadership Experience across Global Supply Chain, and R&amp;D operations. This programme trains leaders to take EHS accountability and make sure all our people understand the importance of adhering to our EHS standards.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">security</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment continues to rise as digital footprints increase and threats from hackers become more sophisticated. Growing geopolitical conflicts have significantly increased cyber risk to large corporations. Governments are tightening regulatory frameworks with regards to data and information, and we are seeing a rise in enforcement of them.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure continues to increase as we operate in an increasingly digital healthcare ecosystem and continue to expand our own digital footprint. In response, our cyber security maturity programme continues to improve our controls and governance to identify, protect, detect, respond to and recover from cyber incidents.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supply</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">continuity</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53b.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The external risk environment is increasing due to unpredictable external forces that put pressure on the resilience of our supply chains. These include geopolitical tensions and growing nationalistic approaches (including US-China decoupling).</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_53a.jpg"/> </div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Our risk exposure remains stable. Across our Medicines and Vaccines supply chains, we continue to focus on strategic materials planning parameters, adapting to changes in the external environment, including inventory strategies, safety stocks and hedging. We&#8217;re making a concerted effort to stabilise and accelerate newly acquired assets and we&#8217;re focusing on making sure we recruit the right people to support our future portfolio.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_17" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Climate-related financial disclosures </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK climate-related financial disclosures are consistent with the recommendations and recommended disclosures of the Task Force on Climate-related Financial Disclosures (TCFD) including the TCFD all-sector guidance, and in compliance with the requirements of LR 9.8.6R.(8) (UK Listing Rules). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK has been reporting on climate-related financial disclosures in accordance with the TCFD recommendations since 2019, with the purpose of building trust and connecting both our strategic and financial disclosures to climate change. This year we have updated the climate scenarios used to model transition and physical risks, which enabled us to extend the timeframe to model risks to 2050 where data was available and to broaden the scope to include GSK&#8217;s supply chain. We will continue to monitor for emerging risks and new data to include in future assessments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Governance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Board considers climate-related matters throughout the year assessing the risk management processes in place and challenging and endorsing the business plan and budgets, including overseeing major capital expenditures, acquisitions and divestments. The Committee that exercises oversight, provides guidance and reviews our ESG performance, including climate-related risks and opportunities, and environmental performance against targets is the CRC. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Committee is supported by GLT and ROCC which receive quarterly updates on environmental sustainability, including climate. Regular attendees include the CEO, and the President Global Supply Chain. See the CRC report on page 107 for further details of the Board architecture. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022 the CRC met four times. Key areas of focus were: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">discussed climate-related issues on three separate occasions with management, including: progress in delivering against our climate ambitions; implications of the geopolitical landscape; key milestones and decisions required to achieve net zero targets </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">reviewed mid-year performance for key environmental metrics, including climate-related metrics, as part of reviewing GSK&#8217;s ESG Performance Rating </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approved GSK&#8217;s TCFD statement and public environmental reporting and disclosures </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022 the Remuneration Committee, with the support of the CRC, introduced a 10% measure into GSK&#8217;s long-term incentive plan opportunity for senior leaders based on key metrics related to GSK&#8217;s ESG performance. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">These metrics include climate-related metrics such as reduction in scope 1 &amp; 2 emissions and reaching key milestones in the R&amp;D programme to reduce greenhouse gas emissions (GHG) in metered dose inhalers for asthma and chronic obstructive pulmonary disease, see page 148. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Leadership Team (GLT) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The GLT meets regularly and is an opportunity for members to discuss strategic, financial and reputational matters. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Regis Simard, President, Global Supply Chain and GLT member has management responsibility for environmental sustainability, which includes climate change. He is responsible for governance and oversight of risks and opportunities and ensures there is an effective framework in place to manage the risks and opportunities across each of our business units along with delivering on the commitments made to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045 across our entire value chain. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Regis is supported by GSK&#8217;s Vice President (VP) Sustainability who regularly reviews progress with him and who co-chairs the quarterly GSK Sustainability Council. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022 GLT reviewed and discussed the mid-year performance for key environmental metrics, including climate-related ones, as part of reviewing GSK&#8217;s ESG Performance Rating. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Sustainability Council </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Sustainability Council, held quarterly, is attended by senior leaders from across the business who play a key role in delivering our commitment to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045 across our entire value chain. Members include leaders from procurement, finance, HR, Compliance, R&amp;D and manufacturing. The Council is co-chaired by the President Global Supply Chain and the VP Sustainability and supported by the global sustainability team who provides specialist expertise and advice to the business. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2022 the Council: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">received monthly performance dashboards covering key performance metrics and escalations of any potential concerns or issues </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">held quarterly performance reviews across all areas of programme delivery and focused reviews of aspects of the programme such as the implementation of the sustainable sourcing strategy, and recommendations for refreshing GSK&#8217;s Science Based Target commitments. The Council reviews include decisions on interventions or support required to maintain progress towards 2030 targets </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">reviewed insights on ESG trends and regulations </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">approved the proposed Sustainability Data Strategy </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In order to address the key priorities of the climate impact from GSK&#8217;s metered dose inhaler, a specific council was established in 2022 and is attended by senior leaders from across the commercial, supply chain, regulatory and R&amp;D businesses aligned to GSK&#8217;s respiratory business. This council is chaired by the President Global Supply Chain and is the decision-making body for: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the programme to reduce the climate impact of metered dose inhalers which contribute to approximately 50% of GSK&#8217;s total GHG emissions by up to 90%, if the clinical trials are successful </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">advocacy and engagement with regulators and policymakers </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">industrialisation strategy and progress </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other business support </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Sustainability Programme Steering Team co-ordinates the sustainability programme and associated workstreams and has oversight for monitoring performance and progress of the enablers required to deliver the sustainability programme </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">business unit sustainability councils meet quarterly to review business unit performance and delivery against the company sustainability ambition </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Capital Allocations Board (CAB) which includes the CFO and Group Financial Controller reviews climate-related capital expenditure as part of its annual planning and capital allocation process </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Finance Sustainability Network includes leaders from across Finance, Sustainability and Procurement and focuses on key financial enablers to deliver the sustainability programme </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strategy </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK&#8217;s commitment to a net zero, nature positive, healthier planet is embedded in GSK&#8217;s strategic long-term priorities, always considering the social, environmental and governance impacts of everything we do from laboratory to patient. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">There are many teams across GSK involved in this process, to ensure that we make sound strategic decisions. The process for identifying and assessing climate-related risks and opportunities is set out under Risk Management as part of this TCFD section. To achieve our climate ambition, active holistic management of all climate-related risk components is important. In addition to risk, we also continue to identify opportunities for GSK. These risks and opportunities are described further in the table on pages 58 and&#160;59. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In order to achieve reductions in emissions across our operations by 2030, as part of our transition plans, we are focusing on: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">maximising energy efficiency in our sites </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">transitioning to 100% renewable electricity by 2025 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">increasing the use of electric vehicles by our sales fleet </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Supply chain emissions are a shared challenge across our sector, and we are working with our peers on collaborative initiatives such as: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Activate programme to help Active Pharmaceutical Ingredients (API) suppliers accelerate decarbonisation initiatives </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Energize programme to encourage the use of renewable energy throughout the pharmaceutical sector&#8217;s supply chain </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">the Manufacture 2030 initiative to encourage suppliers to measure, manage and reduce their emissions </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In September 2022, we launched a Sustainable Procurement Programme which will require our suppliers to disclose emissions and set carbon reduction targets aligned with 1.5&#176;C. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The use of our metered dose inhalers by patients for asthma and chronic obstructive pulmonary disease makes up around 50% of our total climate impact. We are investing in an R&amp;D programme to reduce greenhouse gas emissions from this vital medicine that could potentially reduce the climate impact by up to 90%. If the clinical studies confirm that the new propellant could be an appropriate replacement, GSK will work on securing approval from regulators in markets where the new product could be made available to patients. This process can take time, but GSK is focused on meeting our commitment and we have made considerable investments towards achieving this goal. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Science Based Targets initiative (SBTi) accredited our climate targets, set prior to our demerger, as aligned to the 1.5&#176;C pathway. Our reduction pathway to 2030 is significantly more ambitious and we are currently seeking reaccreditation from the SBTi for our targets as a fully focused biopharma company. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We recognise that the global energy crisis as described on page 13 is disrupting and delaying the green transition across the world. This may impact the pace of decarbonisation in the short term but any setback to the energy transition is expected to be time-limited. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In 2021, we developed a three-year plan to further embed climate risk analysis across material areas of our business and focused on risks impacting our direct operations. In 2022, we updated the climate scenarios used to model transition and physical risks, which enabled us to extend the timeframe to model climate risks out to 2050 where data was available and to broaden the scope to include GSK&#8217;s sites and suppliers across all geographies with a strategic revenue dependency aligned to other supply chain risk management processes. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We will continue to monitor for emerging risks and new data to include in future assessments, using external parties to provide horizon scanning insights on ESG trends and regulations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK prioritised scenario modelling of the following risks in 2022: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">changes to regulations governing the supply of high global warming potential (GWP) substances by the EU, UK and US governments could restrict GSK&#8217;s ability to manufacture metered dose inhalers </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">future regulatory policy responses to address climate change could lead to the imposition of carbon taxes by countries where GSK manufactures and sources goods from third parties </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">increasing levels of water stress that could lead to interruptions to supply of water to GSK and third-party supply sites </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">increasing frequency and impact of extreme weather events that could cause disruption to GSK and third-party supplier sites </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Climate scenarios </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We reviewed and updated our climate scenarios, developing four climate scenarios. We used three of these scenarios for modelling transition risks (Net Zero, Low Carbon and Current Trajectory), and three scenarios for modelling physical risks (Low Carbon, Current Trajectory, and Breach of Planetary Boundaries). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net zero scenario (SSP 1 &#8211; RCP 1.9) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This scenario sets out a narrow but achievable pathway for the global energy sector to achieve net zero CO<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:7.5px">2</div> emissions by 2050<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>. It does not rely on emissions reduction from outside the energy sector to achieve its goal. The scenario is consistent with limiting the global temperature rise to 1.5&#176;C without a temperature overshoot. Net zero means huge declines in the use of coal, oil and gas and a shift to renewable energy sources. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Low carbon scenario (SSP 1 &#8211; RCP 2.6) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In this scenario, all current net zero pledges are achieved in full and there are extensive efforts to realise near-term emissions reductions; advanced economies reach net zero emissions by 2050, China around 2060, and all other countries by 2070 at the latest<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">2</div>. The scenario is consistent with limiting the global temperature rise to below 2&#176;C. With some level of net negative emissions after 2070, the temperature rise could be reduced to 1.5&#176;C in 2100. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current trajectory scenario (SSP2 &#8211; RCP4.5) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This scenario sets out to show to what extent announced ambitions and targets are on the path to deliver the emissions reductions required to achieve net zero emissions by 2050<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">3</div>. The temperature rise will exceed 2&#176;C by 2100, with a more noticeable shift to happen in the latter half of the century. A net zero pledge for emissions within the scenario does not necessarily mean that CO<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:7.5px">2</div> emissions from the energy sector need to reach net zero, there is an allocation for carbon offsetting within the pledges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Breach of planetary boundaries scenarios </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(SSP 5 &#8211; RCP 8.5) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This scenario is not aligned to any of the pledges laid out within the Paris Agreement and is one where countries are unable to meet the United Nations Sustainable Development Goals. This scenario will have the most severe physical consequences for the planet. The temperature rise will exceed 4&#176;C by 2100, leading to high loss of biodiversity and species extinction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Each risk and opportunity was analysed including how they are being managed by GSK and the metrics and targets in place and the potential impact on our profit using a low (&lt;&#163;100 million), medium (&#163;100 million-&#163;250 million) or high (&gt;&#163;250 million) threshold. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Due to the inherent uncertainty, and the nature of the risks across GSK strategy and business model, the climate-related issues are monitored within these time horizons: short term (less than 3 years); medium term (3-10 years) and long term (&gt; 10 years). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In comparison to the 2021 disclosure, we have extended the timeframe for climate risk assessments out to 2050 where data is available to be able to differentiate between the potential long-term outcomes in different climate scenarios. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Based on the different climate scenarios analysis performed and taking into consideration the climate risk and opportunities identified across all geographies, as described in the table below, we have tested the resilience of GSK&#8217;s business strategy and did not identify any material impact to our business resilience. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">IEA Net Zero emissions scenario, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">https://www.iea.org/reports/global-energy-</div><br/>and-climate-model/net-zero-emissions-by-2050-scenario-nze last accessed 17&#160;November 2022 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">IEA World Energy Outlook 2021, Chapter 2, p94, download report from https://www.iea.org/reports/world-energy-outlook-2021/overview, last accessed 17&#160;November 2022 </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">IEA Announced Pledges, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">https://www.iea.org/reports/global-energy-and-</div><br/>climate-model/announced-pledges-scenario-aps last accessed 17&#160;November&#160;2022 </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:17%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Physical risk/</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">description</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.67em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK response</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Scenario</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Potential<br/>financial&#160;impact/</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">timeframe</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Metrics</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Targets</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The risk from increasing levels of water stress leading to interruptions to supply of water to GSK sites and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party</div> supply sites.</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">GSK and its third-party suppliers use freshwater as the main source of water to manufacture medicines and vaccines. If water availability was restricted at a factory, then production operations would be interrupted.</div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We have identified three water basins in water-stressed areas in Algeria, India and Pakistan where we have manufacturing sites, and where we aim to be water neutral.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">At our manufacturing facility in Nashik, India we have built plants for rainwater harvesting.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">The climate scenario analysis has identified a number of sites and supplier sites located in water basins that could become water stressed by 2040 which have been added to a watch list. We will monitor changes to the risk levels and update our site water risk assessments appropriately.</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Medium<br/>(&#163;100m-<br/>&#163;250)m/<br/>Long&#160;term<br/>(&gt;&#160;10&#160;years)</div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Sites that have achieved water stewardship</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Total supplied water</div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Achieve good&#160;water stewardship at&#160;100% of our&#160;sites by 2025</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Reduce overall&#160;water use in our operations by&#160;20%&#160;by 2030</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Breach&#160;of<br/>planetary<br/>boundaries</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low<br/>(&lt;&#160;&#163;100m)/<br/>long&#160;term<br/>(&gt;&#160;10&#160;years)</div></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Increasing frequency of extreme weather events causing disruption to GSK and third-party supplier sites.</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Extreme weather events from any one of precipitation (rainfall), flood from precipitation, tidal flood, extreme wind, wildfire, extreme heat or extreme cold can result in short-term interruptions to manufacturing at GSK or supplier sites.</div></td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">The climate scenario modelling indicated that of the seven physical perils, flood from rainfall presents the highest likelihood of an acute interruption. However, the risk of flooding from rainfall and from the other extreme weather events is expected to remain very low.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We have performed risk assessments for our manufacturing and other operations and have business continuity plans in place which are reviewed annually to respond to the impacts of extreme weather events including adopting appropriate mitigation plans.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">GSK has a well established loss prevention and risk engineering programme to identify a range of risks that could impact our sites and where flood risks exist, we have taken action to mitigate the risk.</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low<br/>carbon<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td rowspan="5" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="5" style="vertical-align:middle;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low<br/>(&lt; &#163;100m)/</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Long term<br/>(&gt;&#160;10&#160;years)</div></td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Business continuity plans are reviewed annually</div></td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Where climate- related risks to business continuity are&#160;identified,</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">we have taken action to mitigate the risk</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Breach of<br/>planetary<br/>boundaries<br/>scenario</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regulations governing the use of high global warming potential (GWP) substances are being updated in the EU and UK and were updated recently in the US.</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">This could lead to increasing costs and restrict the ability to manufacture our metered dose inhaler (MDI) products that use a high GWP propellant (HFA134a).</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We are investing in an R&amp;D programme to reduce greenhouse gas emissions from metered dose inhalers used to treat asthma and COPD and have made good progress towards reformulating an alternative gas that could potentially reduce the climate impact by up to 90%, if the clinical trials are successful.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-right: 0.63em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We already have a portfolio of Dry Powder Inhaler products that do not use propellants that are not impacted by this risk.</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory<br/>scenario</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">High<br/>(&gt;&#160;&#163;250m)/<br/>medium<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(3-10&#160;years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">On/off track against delivery of key milestones on the R&amp;D programme plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">80% and&#160;90% reduction in&#160;carbon emissions (all&#160;scopes) by 2030 and&#160;2045, respectively</div></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:17%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transitional&#160;risk/</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">description</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.67em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK response</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Scenario</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Potential<br/>financial&#160;impact/</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">timeframe</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Metrics</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Targets</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Future regulatory policy responses to address climate change could lead to the imposition of carbon taxes by countries where GSK manufactures and source goods from third parties.</div></div></div></div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">GSK is managing this risk by reducing Scope&#160;1 and 2 emissions through the following:</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;GSK&#8217;s energy efficiency programme</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Transitioning to 100% renewable electricity by 2025</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Investigating options for renewable heat technology</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Transitioning sales fleet to electric vehicles by 2030</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Using shadow carbon pricing on capital investments of US$ 100 per tonne of GHG emissions</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">GSK is managing this risk by reducing Scope 3 emissions through the following:</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;R&amp;D programmes to reduce greenhouse gas emissions from metered dose inhalers</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;The new supply chain programme requiring our suppliers to take action on carbon, set targets aligned with 1.5&#176;C and switch to renewable power and heat</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Collaborating with sector peers in the Energize and Activate programmes and the Manufacture 2030 initiative</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em 1pt; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Joining the Sustainable Markets Initiative Health Systems Task Force to reduce healthcare supply chain emissions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Net zero<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Medium<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#163;100-250m)</div><br/>in both<br/>medium (3-10<br/>years) and<br/>long term<br/>(&gt;&#160;10&#160;years)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Scope 1 &amp; 2&#160;carbon emissions</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Scope 3 carbon emissions</div></td>
<td rowspan="3" style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">80% and&#160;90% reduction in&#160;carbon emissions (all&#160;scopes) by 2030 and&#160;2045, respectively</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low<br/>carbon<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Medium<br/>(&#163;100-250m)<br/>in the medium<br/>(3-10 year)<br/>term falling to<br/>low (&lt; &#163;100m)<br/>in the long<br/>term (&gt; 10<br/>years)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low (&lt; &#163;100)/<br/>in the medium<br/>(3-10 years)<br/>and long term<br/>(&gt; 10 years)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Opportunities</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.67em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK response</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Scenario</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Potential<br/>profit&#160;impact/<br/>timeframe</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Metrics</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Targets</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At COP26 in November 2021, more than 50 countries around the world committed to provide low carbon healthcare systems.</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">This could lead to increasing demand for low carbon medicines and vaccines.</div></td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We are reducing our own Scope 1 &amp; 2 carbon emissions which in turn reduces the Scope 3 footprint of our customers and suppliers; for example, at our site in Irvine in Scotland, a closed loop heat system has helped to drive reductions in operating costs, and onsite renewables and biogas will provide 85% of its energy.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We have an Eco-design programme to reduce the impacts of all our products and packaging.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We are investing in an R&amp;D programme to reduce greenhouse gas emissions from metered dose inhalers used to treat asthma and COPD and have made good progress towards reformulating an alternative gas that could potentially reduce the climate impact by up to 90% if the clinical trials are successful.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">We have a portfolio of dry powder inhaler products that have low carbon footprints.</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Net zero<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td rowspan="5" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="5" style="vertical-align:middle;background-color:#e7e7e8">Low<br/>&lt; &#163;100m/<br/>Long<br/>(&gt;&#160;10&#160;years)</td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Scope 1 &amp; 2&#160;and 3 carbon emissions</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Total waste and materials</div></td>
<td rowspan="5" style="vertical-align:bottom">&#160;</td>
<td rowspan="5" style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">80% and&#160;90% reduction in&#160;carbon emissions (all&#160;scopes) by 2030 and&#160;2045, respectively</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Zero<br/>operational<br/>waste</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Low<br/>carbon<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory<br/>scenario</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">There have been several reports exploring the impact of climate change and health showing that climate change affects water- and vector-borne diseases.</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">This could lead to an increasing demand for new medicines and vaccines.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">In September 2022, GSK and Microsoft announced an innovative collaboration with the Centre for Health and Disease Studies (CHDS) Nepal. The pilot project, which will leverage Microsoft&#8217;s Premonition systems and GSK&#8217;s expertise in health and disease, will investigate how AI and robotics can support local community response to vector-borne diseases and climate change.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-right: 1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">In July 2022, GSK&#8217;s annual Palio conference explored the role of vaccines in finding solutions for global healthcare to protect people and the planet.</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Current<br/>trajectory<br/>scenario</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Long<br/>(&gt;&#160;10&#160;years)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Not applicable</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Not applicable</div></td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:3pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">59</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As described in the Risk management section on page 51, GSK&#8217;s risk management policies are designed to address all types of risks, including the Group principal risks and uncertainties and our climate risk assessment follows the same policy and framework. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The nature of the risks and opportunities from climate change depends not only on the physical aspects of climate change, but also regulatory and commercial changes in the markets in which GSK operates, including pressures to reduce the climate impact of GSK&#8217;s metered dose inhaler medicines. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">In terms of GSK climate risk management policies, a specific and dedicated environmental sustainability risk management plan was put in place in 2020. The risk management plan covers expectations that GSK is addressing its impact on the environment, and that the environment has increasing impacts on operational resilience such as access to energy, water and the natural resources used in products, along with any anticipated cost increases from regulatory changes or environmental taxes. Policy developments at global and national level are monitored for their potential impact. For example, as a result of the UN Montreal Protocol 2016 Kigali amendment that mandates a global phase down of the use of high global warming potential hydrofluoroalkane gases, governments are introducing or proposing to introduce quota restrictions to HFA134a that is used by GSK to manufacture metered dose inhalers used to treat asthma and COPD. GSK has been part of an industry consultation with the UK Department for Environment, Food&#160;&amp; Rural Affairs as the UK government develops its UK specific regulations on the control of F-gases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK has policies and procedures in place to identify risks from climate change when things change, for example to assess the climate impact of merger and acquisition activity, or the construction of new buildings, or major capital expenditure. Furthermore, an internal control framework has been established for environmental sustainability, including the appointment of dedicated senior leaders for environmental sustainability to ensure that governance processes are in place and effective. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">For the purposes of our TCFD disclosures we have made use of the TCFD distinction between &#8220;physical&#8221; and &#8220;transition&#8221; climate-related risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Risks which may be identified include potential effects on operations at asset level, performance at business level and developments at regional level from extreme weather or the transition to a lower carbon economy. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Physical risks are typically identified at the asset or project level and are managed depending on the level of risk assessed. Increasing levels of water stress is a physical risk and could reduce the availability of water for our operations in affected locations. This is an important risk as GSK uses freshwater as the main source of water to manufacture medicines and vaccines. If water availability was restricted at a factory, then production operations could be interrupted. We perform water stewardship risk assessments for our manufacturing sites and update them every three years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Transition risks are typically identified at enterprise level and at market level. Currently the transitions risks which are a priority for GSK are regulatory and commercial risks which we manage through our investment decisions and through our sustainability transformation programme. From a legal point of view, we consider risks which may arise from product claims based on environmental performance. To manage this risk, we use external accreditation processes and organisations to review the evidence used to support environmental claims for our products criteria. From a technological point of view, GSK has developed tools to incorporate eco-design principles into the design and development of new products and to identify opportunities to reduce the environmental impacts of existing products. Our communications and governance affairs team manages corporate reputation through identification and monitoring of climate-related issues and then undertake both proactive and reactive engagement with relevant stakeholder groups to communicate GSK&#8217;s position. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">On an annual basis a cross-functional team from GSK&#8217;s business units, sustainability team and finance perform a review of risks from climate change to identify any new or emerging risks and to determine if an updated risk assessment is required for any existing risks. Climate-related risks are considered from a strategic and operational perspective to ensure we maintain a comprehensive view of the different types of climate risks we face and the different time horizons in which they may affect GSK. This review is approved by the VP Sustainability and Finance VPs from each of GSK&#8217;s business units. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The identified risks are assessed by a climate risk working group who consider the likelihood and financial impact of each risk on GSK under different climate scenarios. The impact assessments are approved by the President, Global Supply Chain who has company level responsibility for Environmental Sustainability, the VP Sustainability and Finance VPs from each of GSK&#8217;s business units. The results are shared with Business Unit Risk Management Control Boards (RMCB) and the Finance RMCB to ensure risks are both contextualised with other business risks and managed appropriately. This allows management to take a holistic view and optimise risk mitigation responses, to ensure that responses to climate-related risks are properly integrated into the relevant businesses&#8217; and functions&#8217; activities. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Metrics and targets </div></div></div></div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK commits to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045 across our entire value chain. GSK reports progress in reducing Scope 1 &amp; 2 carbon emissions, Scope 3 carbon emissions<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">1</div>, energy use, </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">water, waste annually in our ESG Performance Report for detailed performance data and other environmental KPI and in our public responses to the CDP Climate, Water and Forest questionnaires. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:83%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.&#8202;Disclose the metrics used by the organisation to assess climate risks and opportunities in line with its strategy and risk management process</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">GSK has considered the key metrics following the guidance of Tables A1.1 and A1.2 as well as the metrics consistent with cross-industry, climate-related metrics as described in TCFD. Based on that, our strategic metrics are:</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 1 &amp; 2 emissions (market-based and location-based approach), described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 3 emissions, described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;% renewably sourced electricity, described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Total supplied water, described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Total waste and materials, described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;ESG composite metric, as part of our senior leaders&#8216; remuneration policy see page 148</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Sites that have achieved water stewardship, described in the table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Our ESG Performance Report includes additional metrics used to support the strategic metrics listed above.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.&#8202;Disclose Scope 1, 2 and if applicable Scope 3 GHG emissions and related risks</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">In Energy and carbon emissions, see table below</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 1 emissions from energy</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 1 from other sources</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 2 emissions (market-based)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 2 emissions (location-based)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 3 emissions metrics</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Scope 1 &amp; 2 emissions from intensity metrics</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Prioritised physical and transition risks are included in the Strategy Section on page 56.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.&#8202;Describe the targets used by the organisation to manage climate-related risks and opportunities and performance against targets</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Our targets (measured against a 2020 baseline where applicable) are:</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;80% reduction in carbon emissions and investment in nature-based solutions for the remaining 20% of our footprint by 2030 (all scopes)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;100% renewable electricity by 2025 (Scope 2)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Net zero emissions across our full value chain by 2045 (all scopes)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Achieve good water stewardship at 100% of our sites by 2025</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Reduce overall water use in our operations by 20% in 2030</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Zero operational waste by 2030.</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Be water neutral in our own operations and at key suppliers in water-stressed regions by 2030</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">The performance against our targets can be found on pages 45 and 46.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">1</div></div></td></tr></table><div style="font-size:190pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">See Basis of Reporting 2022 in the ESG resources section of GSK.com </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#160;&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">(https://www.gsk.com/en-gb/responsibility/esg-resources/) for detailed </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#160;&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">methodologies for measuring and reporting all GSK environmental KPIs </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Metrics data </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Carbon emissions<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">1,2</div> </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Carbon emissions &#8216;000 tonnes CO<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:5.4px">2</div>e</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 1 emissions (from energy)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">320</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">333</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">355</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 1 emissions (other<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">3</div>)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">306</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">358</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 2 emissions (market-based)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">88</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">169</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 2 emissions (location-based)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">265</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">285</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 3 emissions<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">4</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">8,624</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">9,949</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">UK Scope 1 &amp; 2 emissions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">111</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">138</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Other metrics</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 1 and 2 emissions from energy/sales revenue (tonnes CO<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:7.1px">2</div>e/&#163;m)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">18.8</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">21.5</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Scope 1 and 2 emissions from energy/FTE (tonnes CO<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:7.1px">2</div>e/FTE)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">6.5</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">7.2</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Total energy used (GWh)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,759</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">2,871</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">3,085</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">UK energy used (GWh)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">735</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">% renewably sourced electricity</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">73%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">63%</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">46%</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Total supplied water million m<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">3</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">7.9</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">9.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Total waste and materials &#8216;000 metric tonne</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57.2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">63.1</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">63.0</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">% sites that have achieved water stewardship</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">100%</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">89%</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">All data reported excludes our previous Consumer Healthcare business unless otherwise specified </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Carbon emissions are calculated according to the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (revised edition). GSK uses market-based Scope 2 emissions for reporting purposes and reports Scope 3 emissions across all 15 categories in our ESG Performance Report. We ask external assurance providers, Deloitte, to provide limited assurance to ISAE 3000 for energy, Scope 1, 2 and selected Scope 3 carbon emission data, water and wastewater data. Methodologies for reporting and measurements are provided in the Basis of Reporting 2022 in the ESG resources section of gsk.com<br/> (https://www.gsk.com/en-gb/responsibility/esg-resources/) </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">&#8216;Other&#8217; refers to emissions from sales force vehicles, propellant emissions released during manufacture of inhalers (the majority of propellant emissions, released during patient use, are included in Scope 3 carbon emissions), on-site waste, or wastewater treatment and refrigerant gas losses </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">4</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">We collect and publish Scope 3 data across 15 categories. The most recent Scope 3 data available is for 2021 as the process of compiling the 2022 data is not yet complete, except for 2022 Scope 3 emissions from patient use of inhalers which are disclosed in the ESG Performance Report. We will publish this data once it becomes available and it will be included in the 2023 ESG Performance Report </div></td></tr></table><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_18" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature-related financial disclosure </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">At GSK we are committed to playing our part to minimise our impact and dependencies on nature, as well as helping to protect and restore nature. We have performed a full assessment of our impacts on nature across our value chain and are setting targets to reduce these pressures in line with evolving guidance from Science Based Targets for Nature (SBTN). In line with our commitment to nature and building on the achievements of our climate-related financial disclosures, GSK is currently piloting the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD) ahead of the launch of the TNFD&#8217;s final framework expected in September 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As part of the pilot, we are working to understand how we can utilise the TNFD guidelines to report the risks that our impacts and dependencies on nature present to our business. We are making an initial disclosure with a particular focus on strategy, metrics and targets. Some early findings from the results of our in-progress analysis are included below. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strategy </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are committed to have a net positive impact on nature by 2030 by reducing our environmental impacts across water, waste and materials biodiversity and by investing in nature protection and restoration. In 2022, we conducted an assessment of GSK&#8217;s nature-related risks and opportunities, in line with the latest TNFD guidance from November 2022. By following the latest TNFD LEAP (Locate, Evaluate, Assess and Prepare) methodology, we have been able to better understand the magnitude of GSK&#8217;s physical and transitional risks across each Nature pressure. We will continue to refine our assessment, following the methodology from TNFD, and will look to report against it once the final version is available. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Additionally, GSK is one of the first companies to conduct a materiality assessment for its full value chain, in line with the SBTN methodology, to better understand our impacts and dependencies. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Risk management continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This process has clearly indicated that to achieve Net Nature Positive by 2030 requires us to build a portfolio of pressure-specific initiatives that drive action in targeted landscapes and regions of impact. As part of our commitment, we acknowledge that collaboration across different stakeholders will continue to be an imperative in this multi-year journey. Ultimately, the direction provided by the SBTN technical guidance will help shape our strategy to ensure we minimise our impacts and dependencies on nature globally. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Metrics and targets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To address GSK&#8217;s pressures on Nature, we have existing targets across water, waste, materials and biodiversity (see page 46). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our targets will continue to evolve as we incorporate the findings of our materiality assessment and progress towards achieving Net Nature Positive by 2030. To support progress, we actively engage with external partners including the SBTN and World Business Council for Sustainable Development to ensure targets and metrics are meaningful and robust. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Addressing our impacts on the natural world and understanding the impacts of the changing state of nature globally on GSK is no small undertaking, but we are proud to be pioneering the use of nature-related financial disclosures in our industry. Ultimately, delivering positive outcomes for the environment is fundamental to delivering positive outcomes on human health. At GSK we are excited to continue on this path, uniting science, technology and talent to get ahead of disease together. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-financial information statement </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The following aligns to the non-financial reporting requirements contained in sections 414CA and 414CB of the Companies Act 2006. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of the business model</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">Business model</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">08</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Social matters</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Access</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">Global health and health security</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">44</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Our culture and people</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Employee engagement</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Diversity, equity and inclusion</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Wellbeing and development</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Gender pay gap</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Ethical standards</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Board diversity</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Human rights</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Human rights</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Working with third parties</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">Data and engagement</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">49</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-bribery and corruption</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Ethical standards</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">Reporting and investigating concerns</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">48</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental matters</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Environment</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Climate-related financial disclosures</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Nature-related financial disclosure</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Policy, due diligence and outcomes</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Risk management</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Principal risks and uncertainties</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">Viability statement</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">Audit &amp; Risk Committee report</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">124</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-financial key performance indicators</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;vertical-align:top">2022 performance and key performance indicators</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;">03</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="BORDER-TOP:0.75pt solid #f36f21;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="4" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our policies</div></div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top">All of our public policies, codes and standards are available on gsk.com</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_19" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees by gender </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Male</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Board</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Management*</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">8,318</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">8,201</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,519</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">All employees</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">36,782</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #a7a9ac;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;text-align:right;">32,618</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #a7a9ac;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,400</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #a7a9ac;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Senior managers as defined in the Companies Act 2006 (Strategic Report and Directors&#8217; Report) Regulations 2013 </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">63</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk management continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_20" style="font-family: ARIAL; font-size: 18pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Viability statement </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with provision 31 of the 2018 revision of the Code, GSK has assessed the prospects of the Group over a longer period than the 12 months required by the &#8216;Going Concern&#8217; provision. The Directors confirm that they have a reasonable expectation that GSK will continue to operate and meet its liabilities, as they fall due, over the next three years. The Directors&#8217; assessment has been made with reference to GSK&#8217;s current position and prospects, our strategy, the Board&#8217;s risk appetite and GSK&#8217;s principal risks and how these are managed, as detailed on pages 51 to 54 in the Strategic report. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board reviews our internal controls and risk management policies and approves our governance structure and code of conduct. It also appraises and approves major financing, investment and licensing decisions, and evaluates and monitors the performance and prospects of GSK as a whole. The focus is largely on improving our long-term financial performance through delivery of our company&#8217;s business strategies and aligned priorities. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board reviews GSK&#8217;s strategy and makes significant capital investment decisions over a long-term time horizon, based on a multi-year assessment of return on capital, the performance of the company, and the market opportunities in medicines and vaccines. This approach is aligned to GSK&#8217;s model of achieving balanced growth by investing in high quality, innovative products for patients and healthcare providers. However, since many internal and external parameters become increasingly unpredictable over longer time horizons, GSK focuses its detailed, bottom-up Plan on a three-year cycle. The Plan is reviewed at least annually by the Directors, who approve business forecasts showing expected financial impact. The Directors believe that a three-year assessment period for the Viability statement is most appropriate as it aligns with the Group&#8217;s well established business planning processes that balance the long-term nature of investments in medicines and vaccines with an assessment of the period over which analysis of near-term business performance is realistically visible. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Plan has been stress tested in a series of robust operational and principal risk downside scenarios as part of the Board&#8217;s review on risk. The Plan assumes the next several years to be challenging for the healthcare industry with continued pressure on pricing of pharmaceuticals. GSK assumes no premature loss of exclusivity for key products over the period and for all anticipated launches to proceed as planned. Despite the ongoing recovery of healthcare systems from the impact of the COVID-19 Pandemic, uncertain economic conditions prevail across many markets in which GSK operates. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The downside scenarios consider GSK&#8217;s cash flows, sustainability of dividends, funding strategy, insurance provision and recovery as well as other key financial ratios over the period. These metrics have been subject to sensitivity analysis, which involves flexing a number of the main assumptions underlying the forecasts both individually and in combination, along with mitigating actions that could realistically be taken to avoid or reduce the impact or occurrence of the underlying risk. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The following hypothetical downside scenarios have been evaluated: </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Scenario 1: Business performance risks. These include key performance risks, including lower sales from new products, greater adverse impact from generic competition and other competitive launches to other GSK products, as well as possible supply and manufacturing challenges. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Scenario 2: External and macroeconomic risks. This scenario reflects incremental risks to the business driven by outside factors, such as more intense competition, increased pricing pressure in both the US and Europe as well as the potential impact of material negative changes in the macroeconomic and healthcare environment. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Scenario 3: Principal risks. This scenario includes a severe assessment of the potential loss impact from the principal risks related to patient safety, product quality, supply chain continuity and environmental harm as well as anti-bribery and corruption and any consequent regulatory actions, fines or significant litigation, all of which could fundamentally threaten our operations. These risks are managed through mitigating activities described on pages 285&#160;to&#160;295. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Scenario 4: Put option exercise. This scenario evaluates the additional funding requirements assuming the earliest potential exercise of the outstanding put option held by our partner in the HIV business. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The three-year review also makes certain assumptions about the normal level of capital recycling likely to occur and considers whether additional financing facilities will be required and the respective level of funding flexibility and headroom. </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The results of this stress testing show that certain combinations of these hypothetical scenarios could increase funding demands on GSK and require mitigating changes to the Group&#8217;s funding strategy. However, in light of the liquidity available to the Group and based on this analysis, the Directors have a reasonable expectation that, even under these most severe stress tests, the Group will be able to continue in operation and meet its liabilities as they fall due over the three-year period of assessment. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">64</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc"></a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_65.jpg"/> </div><div style="margin-top: -810pt; margin-bottom: 0pt; margin-right: 11%; font-size: 7.5pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div id="ex15_2tx382677_21" style="margin-top:100pt; margin-bottom:0pt; margin-left:12%; font-size:60pt; font-family:ARIAL"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Group financial </div></div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:60pt; font-family:ARIAL"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">review </div></div><div style="font-size: 17pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:87.3%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:38%"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In this section</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_55" style="color:White">Summary full year results</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">66</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_56" style="color:White">Financial performance</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">68</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_57" style="color:White">Reporting framework</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_58" style="color:White">Adjusting items</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">81</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_59" style="color:White">Cash generation and conversion</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">86</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_60" style="color:White">Financial position and resources</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_61" style="color:White">Approach to tax</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">92</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_62" style="color:White">Treasury policies</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">93</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_63" style="color:White">Critical accounting policies</a></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">94</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr></table></div><div style="font-size: 165pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top: 165pt; margin-bottom: 0pt; margin-right: 11%; font-size: 7.5pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">65 </div></div><div style="font-size: 100pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="font-size: 24pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Group financial review </div></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_55" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Summary full year results </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Full&#160;year&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Growth</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">AER</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Growth</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">CER</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Full&#160;year&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div>&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Full&#160;year&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div>&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,696&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total continuing operating profit<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,357&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,979&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total EPS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">371.4p</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109.6p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total continuing EPS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8p</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.9p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total discontinued EPS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6p</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26.7p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22.0p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted operating profit<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,151&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,493&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,656&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted EPS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139.7p</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.3p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash generated from operations attributable to continuing operations<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,944&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,249&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,674&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Free cash flow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,348&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,301&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,683&#160;</div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The amounts presented above for continuing operations and Adjusted results excludes the Consumer Healthcare business discontinued operation. The amounts presented for discontinued EPS are for the demerger of the Consumer Healthcare business. The presentation of continuing and discontinued operations under IFRS 5 are set out on page 192. The 2021 and 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238) and the impact of the Share Consolidation implemented on 18&#160;July 2022 (see page 233). </div></td></tr></table><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Turnover </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total turnover in 2022 was &#163;29,324&#160;million, up 19% at AER, 13% at CER, reflecting strong performance in all three product groups. Commercial Operations turnover, excluding COVID-19 solution sales, grew 16% at AER, 10% at CER. Specialty Medicines included &#163;2,309&#160;million sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>, and double-digit growth across all therapy areas. Vaccines growth reflected strong <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> and Meningitis performance, partially offset by pandemic adjuvant sales in 2021. General Medicines reflected the recovery of the antibiotics market and the strong performance of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> in respiratory across all regions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty Medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Specialty Medicines sales were &#163;11,269&#160;million, up 37% at AER, 29% at CER, driven by consistent double-digit growth in all therapy areas. Specialty Medicines, excluding sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>, were &#163;8,960&#160;million up 23% at AER, 15% at CER. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vaccines turnover was &#163;7,937&#160;million, up 17% at AER, 11% at CER in total, and up 24% at AER, 17% at CER excluding pandemic adjuvant sales. The performance reflected a favourable comparator, which was impacted by COVID-19 related disruptions in several markets primarily in H1 2021, and strong commercial execution of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>, particularly in the US and Europe. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">General Medicines sales in the year were &#163;10,118&#160;million, up 5% at AER, 1% at CER, with the impact of generic competition in US, Europe and Japan offset by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> growth in respiratory and the post-pandemic rebound of the antibiotic market since H2 2021, in Other General Medicines. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Continuing Operating Profit </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total operating profit from continuing operations was &#163;6,433&#160;million compared with &#163;4,357&#160;million in 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This included the &#163;0.9 billion upfront income received from the settlement with Gilead Sciences, Inc. (Gilead), increased profits on turnover growth of 13% at CER and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total continuing Adjusted operating profit </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted operating profit was &#163;8,151&#160;million, 26% higher at AER and 14% at CER than 2021. The Adjusted operating margin of 27.8% was 1.5 percentage points higher at AER and 0.3 percentage points higher at CER compared to 2021. This primarily reflected the impact from low margin COVID-19 solutions sales (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>). This was offset by operating leverage from strong sales growth, mix benefit, lower inventory adjustments and write-offs and higher royalty income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Earnings per Share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total EPS was 371.4p compared with 109.6p in 2021. The increase primarily reflected the profit after taxation for discontinued operations recognised on the Consumer Healthcare business demerger, upfront income received from the settlement with Gilead, increased profits and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;397&#160;million to Taxation in 2021. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total continuing Earnings per Share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total EPS from continuing operations was 110.8p compared with 82.9p in 2021. This primarily reflected the upfront income received from the settlement with Gilead, increased profits from turnover growth and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;430&#160;million to Taxation in 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total discontinued Earnings per Share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">EPS from discontinued operations was 260.6p, compared with 26.7p in 2021. The increase primarily reflected the gain arising on the demerger of Consumer Healthcare recognised in Profit after taxation for discontinued operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted Earnings per Share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted EPS was 139.7p compared with 110.3p in 2021. Operating leverage from strong sales growth, beneficial mix and lower inventory adjustments and write-offs, higher royalty income and a lower effective tax rate was partly offset by increased investment behind launches, higher supply chain, freight and distribution costs and higher non-controlling interests. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash generated from operations attributable to continuing operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash generated from operations attributable to continuing operations for the year was &#163;7,944&#160;million (2021: &#163;7,249 million). The increase primarily reflected a significant increase in operating profit, favourable exchange impact and favourable timing of collections, partly offset by unfavourable timing of profit share payments for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> sales, increased cash contributions to the UK defined benefit pension schemes, increased contingent consideration payments and a higher increase in inventory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Free cash flow </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Free cash inflow from continuing operations was &#163;3,348&#160;million for 2022 (2021: &#163;3,301 million). The increase primarily reflected a significant increase in operating profit, favourable exchange, reduced purchases of intangible assets and favourable timing of collections. This was partly offset by unfavourable timing of profit share payments for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> sales, increased cash contributions to pensions, increased contingent consideration payments, higher tax payments, lower proceeds from disposals, higher capital expenditure and a higher increase in inventory. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_56" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Total results of the Group are set out below. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1) </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% of<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;turnover</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">% of<br/>&#160;&#160;&#160;&#160;&#160;&#160;turnover</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,554</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(32.6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,163</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(33.1</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,770</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67.4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,372</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28.6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,488</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,019</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">758</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other operating (expenses)/income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(235</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(504</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating profit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net finance costs</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(803</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of after-tax (losses)/profits of associates and joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit before taxation</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,628</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(707</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit after taxation from continuing operations for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,516</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains from the demerger</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,049</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">1,580</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,651</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit after taxation from discontinued operations</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,700</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,580</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit after taxation for the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,621</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interests from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">460</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,461</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interests from discontinued operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">205</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,495</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,069</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,621</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to non-controlling interests</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">665</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to shareholders</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,956</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,385</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,621</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from continuing operations (p)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8p</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.9p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations (p)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6p</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.7p</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total earnings per share (p)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">371.4p</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">109.6p</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per ADS from continuing operations (US$)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per ADS from discontinued operations (US$)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.46</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.73</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total earnings per ADS (US$)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.21</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.02</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Adjusted results for the Group are set out below. Reconciliations between Total results and Adjusted results for 2022 and 2021 are set out on pages 81 to 82. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1) </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% of<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;turnover</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">% of<br/>&#160;&#160;&#160;&#160;&#160;&#160;turnover</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,741</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29.8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,128</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,062</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17.3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,525</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">758</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">417</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted operating profit</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,151</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.8</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,493</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.3</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted profit attributable to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,625</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted profit attributable to non-controlling interest</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">595</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">441</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted profit after tax</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,220</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,856</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted earnings per share (p)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139.7p</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">110.3p</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238) and the impact of the Share Consolidation implemented on 18&#160;July 2022 (see page 233). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">68</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_57" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting framework </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total and Adjusted results </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group financial review discusses the operating and financial performance of the Group, its cash flows and financial position and our resources. The results for each year are compared primarily with the results of the preceding year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total results </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total reported results represent the Group&#8217;s overall performance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK also uses a number of adjusted, non-IFRS, measures to report the performance of its business. Adjusted results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results are defined below and other non-IFRS measures are defined on page 70. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK believes that Adjusted results, when considered together with Total results, provide investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allow the Group&#8217;s performance to be more easily compared against the majority of its peer companies. These measures are also used by management for planning and reporting purposes. They may not be directly comparable with similarly described measures used by other companies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK encourages investors and analysts not to rely on any single financial measure but to review GSK&#8217;s Annual Reports, including the financial statements and notes, in their entirety. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted results </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted results exclude the profits from discontinued operations from the Consumer Healthcare business (see details on page 238) and the following items in relation to our continuing operations from Total results, together with the tax effects of all of these items: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">amortisation of intangible assets (excluding computer software and capitalised development costs) </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">impairment of intangible assets (excluding computer software) and goodwill </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Major restructuring costs, which include impairments of tangible assets and computer software, (under specific Board approved programmes that are structural, of a significant scale and where the costs of individual or related projects exceed &#163;25 million) including integration costs following material acquisitions </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">transaction-related accounting or other adjustments related to significant acquisitions </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">proceeds and costs of disposals of associates, products and businesses; significant settlement income; significant legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations; other operating income other than royalty income, and other items </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Costs for all other ordinary course smaller scale restructuring and legal charges and expenses are retained within both Total and Adjusted results. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As Adjusted results include the benefits of Major restructuring programmes but exclude significant costs (such as amortisation of intangible assets except for computer software and capitalised development costs, significant legal, major restructuring and transaction items), they should not be regarded as a complete picture of the Group&#8217;s financial performance, which is presented in its Total results. The exclusion of other Adjusting items may result in Adjusted earnings being materially higher or lower than Total earnings. In particular, when significant impairments, restructuring charges and legal costs are excluded, Adjusted earnings will be higher than Total earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK is undertaking a number of Major restructuring programmes in response to significant changes in the Group&#8217;s trading environment or overall strategy, or following material acquisitions. Costs, both cash and non-cash, of these programmes are provided for as individual elements are approved and meet the accounting recognition criteria. As a result, charges may be incurred over a number of years following the initiation of a Major restructuring programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Significant legal charges and expenses are those arising from the settlement of litigation or government investigations that are not in the normal course and are materially larger than more regularly occurring individual matters. They also include certain major legacy matters. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Reconciliations between Total and Adjusted results, providing further information on the key Adjusting items for 2022, 2021 and 2020, are set out on pages 81 to 83. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK provides earnings guidance to the investor community on the basis of Adjusted results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group&#8217;s performance with its peers. GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting framework </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical record of Adjusting items </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reconciliations between Total and Adjusted operating profit from continuing operations over the last three years<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div> can be summarised as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total operating profit from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible amortisation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">739</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible impairment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">296</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Major restructuring</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction-related items</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,750</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Divestments, significant legal and other items</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,388</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,662</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted results</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,151</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,493</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,656</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of the impact of transaction-related items on operating profit for each of the last three years is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration on former Shionogi-ViiV Healthcare JV (including Shionogi preferential dividends)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;1,431</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare put options and Pfizer preferential dividends</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration on former Novartis Vaccines business</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">193</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration on acquisition of Affinivax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other adjustments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction-related items</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;1,750</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,143</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;1,237</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Three year financial data is presented reflecting the restated results following the demerger of Consumer Healthcare business. The financial results of 2019 and 2018 are not restated and are not presented. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Full reconciliations between Total and Adjusted results for 2020&#8211;2022 including continuing and discontinued operations are set out on pages 81 to 83. Further explanations on the Adjusting items for 2022 are reported on pages 84 to 85. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other non-IFRS measures </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Free cash flow </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Free cash flow is defined as the net cash inflow/outflow from continuing operating activities less capital expenditure on property, plant and equipment and intangible assets, contingent consideration payments, net finance costs, and dividends paid to non-controlling interests plus proceeds from the sale of property, plant and equipment and intangible assets, and dividends received from joint ventures and associates. It is used by management for planning and reporting purposes and in discussions with and presentations to investment analysts and rating agencies. Free cash flow growth is calculated on a reported basis. A reconciliation of net cash inflow from continuing operating activities to free cash flow is set out on page 86. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Working capital </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Working capital represents inventory and trade receivables less trade payables. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CER and AER growth </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In order to illustrate underlying performance, it is the Group&#8217;s practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period. CER% represents growth at constant exchange rates. &#163;% or AER% represents growth at actual exchange rates. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Return on capital employed </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Return on capital employed is calculated as total profit before taxation as a percentage of average net assets over the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total net debt </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net debt is defined as total borrowings less cash, cash equivalents, liquid investments, and short-term loans to third parties that are subject to an insignificant risk of change in value. Please see Note 30 &#8216;Net Debt&#8217; for the calculation of net debt. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Operating Margin </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total Operating margin is operating profit dividend by turnover. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compound Annual Growth Rate (CAGR) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">CAGR is defined as the compound annual growth rate and shows the annualised average rate of revenue growth between a number of given years, assuming growth takes place at an exponentially compounded rate. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting framework </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-controlling interests in ViiV Healthcare </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trading profit allocations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As ViiV Healthcare is a subsidiary of the Group, 100% of its operating results (turnover, operating profit, profit after tax) are included within the Group income statement and then a portion of the earnings is allocated to the non-controlling interests owned by the other shareholders, in line with their respective equity shareholdings (Pfizer, Inc. (Pfizer) 11.7% and Shionogi&#160;&amp; Co. Ltd (Shionogi) 10%). Each of the shareholders, including GSK, is also entitled to preferential dividends determined by the performance of certain products that each shareholder contributed. As the relative performance of these products changes over time, the proportion of the overall earnings allocated to each shareholder also changes. In particular, the increasing proportion of sales of dolutegravir and cabotegravir-containing products has a favourable impact on the proportion of the preferential dividends that is allocated to GSK. Adjusting items are allocated to shareholders based on their equity interests. GSK was entitled to approximately 83% of the Total earnings and 82% of the Adjusted earnings of ViiV Healthcare for 2022. Remeasurements of the liabilities for the preferential dividends allocated to Pfizer and Shionogi are included within other operating income/(expense). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition-related arrangements </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As consideration for the acquisition of Shionogi&#8217;s interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi received the 10% equity stake in ViiV Healthcare and ViiV Healthcare also agreed to pay additional future cash consideration to Shionogi, contingent on the future sales performance of the products being developed by that joint venture, dolutegravir and cabotegravir. Under IFRS 3 `Business combinations&#8217;, GSK was required to provide for the estimated fair value of this contingent consideration at the time of acquisition and is required to update the liability to the latest estimate of fair value at each subsequent period end. The liability for the contingent consideration recognised in the balance sheet at the date of acquisition was &#163;659 million. Subsequent re-measurements are reflected within other operating income/(expense) and within Adjusting items in the income statement in each period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash payments to settle the contingent consideration are made to Shionogi by ViiV Healthcare each quarter, based on the actual sales performance and other income of the relevant products in the previous quarter. These payments reduce the balance sheet liability and hence are not recorded in the income statement. The cash payments made to Shionogi by ViiV Healthcare in 2022 were &#163;1,100 million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cash payments are reflected in the cash flow statement partly in operating cash flows and partly within investing activities. The tax relief on these payments is reflected in the Group&#8217;s Adjusting items as part of the tax charge. The part of each payment relating to the original estimate of the fair value of the contingent consideration on the acquisition of the Shionogi-ViiV Healthcare joint venture in 2012 of &#163;659&#160;million is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition is reported within operating cash flows. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Movements in contingent consideration payable to Shionogi were as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration at beginning of the year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,559</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement and</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">other movements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,431</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,031</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(69</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration at end of the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,890</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,559</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the contingent consideration payable (on a post-tax basis) to Shionogi at 31&#160;December 2022, &#163;940&#160;million (31 December 2021: &#163;937 million) is expected to be paid within one year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exit rights </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. Under the original agreements, GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Pfizer put option and, as a result, in accordance with IFRS, GSK did not recognise a liability for the put option on its balance sheet. However, during Q1 2016, GSK notified Pfizer that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;1,070 million. Consistent with this revised treatment, at the end of Q1 2016 GSK also recognised liabilities for the future preferential dividends anticipated to become payable to Pfizer and Shionogi on the Group&#8217;s balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pfizer has the right to require GSK to acquire its shareholding in ViiV Healthcare in certain circumstances at any time. A put option liability is therefore recorded on the Group&#8217;s balance sheet as a current liability. It is measured on the gross redemption basis derived from an internal valuation of the ViiV Healthcare business. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The closing balances of the liabilities related to Pfizer&#8217;s shareholding are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pfizer put option</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,093</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,008</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting framework </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the original agreements, Shionogi could also have requested GSK to acquire its shareholding in ViiV Healthcare in six-month windows commencing in 2017, 2020 and 2022. GSK had the unconditional right, so long as it made no subsequent distribution to its shareholders, to withhold its consent to the exercise of the Shionogi put option and, as a result, GSK did not recognise a liability for the put option on its balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">However, during Q1 2016, GSK notified Shionogi that it had irrevocably given up this right and accordingly recognised the liability for the put option on the Group&#8217;s balance sheet during Q1 2016 at an initial value of &#163;926 million. In Q4 2016, Shionogi irrevocably agreed to waive its put option and as a result GSK de-recognised the liability for this put option on the Group&#8217;s balance sheet directly to equity. The value of the liability was &#163;1,244&#160;million when it was de-recognised. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK also has a call option over Shionogi&#8217;s shareholding in ViiV Healthcare, which under the original agreements was exercisable in six-month windows commencing in 2027, 2030 and 2032. GSK has now irrevocably agreed to waive the first two exercise windows, but the last six-month window in 2032 remains. As this call option is at fair value, it has no value for accounting purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Settlement with Gilead </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy. Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25 billion to ViiV Healthcare in February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027. Gilead&#8217;s obligation to pay royalties does not extend into any period of regulatory paediatric exclusivity, if awarded. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The impact of the settlement with Gilead on the contingent consideration liability (CCL) was to increase it by &#163;288&#160;million, on a post-tax basis in Q4 2021 due to the obligation ViiV Healthcare has to pay future cash consideration to Shionogi for its share of the upfront and of the future US sales performance of Biktarvy and products containing bictegravir. The liability which is discounted at 8% is &#163;5,890&#160;million at 31&#160;December 2022 on a post-tax basis. The impact of the settlement on the Pfizer put option liability was an increase of &#163;114&#160;million and was included in the re-measurement at 31&#160;December 2021. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting definitions </div></div></div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COVID-19 solutions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">COVID-19 solutions include the sales of pandemic adjuvant and other COVID-19 solutions including vaccine manufacturing and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> and the associated costs but does not include reinvestment in R&amp;D. This categorisation is used by management and we believe is helpful to investors by providing clarity on the results of the Group by showing the contribution to growth from COVID-19 solutions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">General medicines are usually prescribed in the primary care or community settings by general healthcare practitioners. For GSK, this includes medicines in inhaled respiratory, dermatology, antibiotics and other diseases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty Medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Specialty medicines are typically prescription medicines used to treat complex or rare chronic conditions. For GSK, this comprises medicines in infectious diseases, HIV, oncology, immunology and respiratory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Consolidation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shareholders received 4 new Ordinary shares with a nominal value of 31<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">1</div>/<div style="font-size:75%; vertical-align:bottom;display:inline;;font-size:7.1px">4</div> pence each for every 5 existing Ordinary shares which had a nominal value of 25 pence each. Earnings per share, diluted earnings per share, adjusted earnings per share and dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnings per share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Earnings per share has been retrospectively adjusted for the Share Consolidation on 18&#160;July 2022, applying a ratio of 4 new Ordinary shares for every 5 existing Ordinary shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Earnings per share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Unless otherwise stated, Total earnings per share refers to Total basic earnings per share. The same principle applies to continuing and discontinued earnings per share. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover by business </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_73a.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover by geographic region </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_73c.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has revised its operating segments during the year. Previously, GSK reported results under four segments: Pharmaceuticals; Pharmaceuticals R&amp;D; Vaccines and Consumer Healthcare. GSK now reports results under two segments namely Commercial Operations and Total R&amp;D. See Note 6 to the consolidated financial statements for more details. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Commercial Operations segment has three product groups of Specialty Medicines, Vaccines and General Medicines. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Specialty Medicines products which includes GSK&#8217;s marketed products for HIV, oncology, immuno-inflammation, respiratory and other specialty medicines (including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>) and the pandemic solution, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>; </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Vaccines products, including sales of GSK&#8217;s AS03 adjuvant as part of the pandemic solutions; </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">General Medicines products, which include products previously reported as Established Pharmaceuticals and sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy Ellipta</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro Ellipta</div></div> (previously reported within the Respiratory category under Specialty products). These products are typically accessed by patients through primary care settings. </td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Group turnover was &#163;29,324&#160;million in the year, up 19% at AER, 13% at CER. In 2022 sales grew 16% at AER, 10% CER excluding COVID-19 solutions. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty medicines </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover (&#163;bn) </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_73b.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty medicines turnover </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_73d.jpg"/> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">CER%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,749</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,777</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Oncology</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">489</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Immuno-inflammation, respiratory and other</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,609</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,027</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,960</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7,293</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,309</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">958</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Specialty medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8,251</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">2021 has been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">HIV sales were &#163;5,749&#160;million with growth of 20% at AER, 12% at CER. The performance benefited from strong patient demand for the new HIV medicines (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>), which contributed approximately three quarters of the growth. US pricing favourability and year-end inventory build together contributed one third of the growth which was partially offset by International tender decline. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">New HIV products delivered sales of over two billion to &#163;2,474&#160;million, up 78% at AER, 67% at CER, representing 43% of the total HIV portfolio compared to 29% last year. Growth was primarily driven by sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> recorded sales of &#163;1,375&#160;million up 75% at AER and 65% at CER and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>, the first long acting injectable for the treatment of HIV-1 infection, recorded sales of &#163;340 million. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>, the first long acting injectable for the prevention of HIV-1 delivered sales of &#163;41 million. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">73</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Oncology sales were &#163;602&#160;million, up 23% at AER, 17% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div> sales of &#163;463&#160;million were up 17% at AER, 12% at CER driven by the first line indication, but with diagnosis and treatment rates continuing to be impacted by the pandemic especially in the US. Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> of &#163;118&#160;million grew 33% at AER, 25% at CER, and included the impact of withdrawal from US market in Q4 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Immuno-inflammation, respiratory and other </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Immuno-inflammation, Respiratory and Other sales were &#163;2,609&#160;million up 29% at AER, 20% at CER on strong performance of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> sales were &#163;1,146&#160;million, up 31% at AER, 20% at CER, representing strong underlying demand in US and worldwide. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> sales were &#163;1,423&#160;million, up 25% at AER, 18% at CER, reflecting continued strong patient demand and the launch of additional indications. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pandemic </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> were &#163;2,309&#160;million, compared to &#163;958&#160;million sales in 2021. Sales were delivered in all regions, comprising &#163;828&#160;million in the US, &#163;456&#160;million in Europe, and &#163;1,025&#160;million in International. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover (&#163;bn) </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_74a.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines turnover </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_74b.jpg"/> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth<br/>&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth<br/>CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,116</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">961</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Influenza</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">714</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">679</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shingles</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,958</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,721</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">60</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Established Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,085</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,970</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,873</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,331</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">64</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">447</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,778</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Meningitis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Meningitis vaccines sales grew 16% at AER, 11% at CER to &#163;1,116&#160;million mainly driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div> up 16% at AER, 12% at CER to &#163;753&#160;million resulting from higher CDC (Center for Disease Control) demand and increased share in the US. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div> sales were also up 27% AER, 18% CER to &#163;345&#160;million, primarily driven by post-pandemic vaccination catch-up and higher public demand in International, together with favourable pricing mix and share gain in the US. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Influenza </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/FluLaval</div></div> sales grew by 5% AER but decreased 4% CER to &#163;714&#160;million, primarily driven by lower post-pandemic demand in Europe and the US, partly offset by lower expected returns in the US. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shingles </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> sales grew 72% at AER, 60% at CER to &#163;2,958 million. All regions grew significantly reflecting post-pandemic rebound, strong uptake and new market launches with more than half of the growth contributed from outside of the US. In the US, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> grew 46% at AER, 32% at CER to &#163;1,964&#160;million due to higher non-retail and retail demand and strong commercial execution. Germany and China contributed strongly to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> growth. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> was launched in 9 markets during 2022 and is now available in 26 countries. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Established Vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Established Vaccines grew 4% AER but were stable at CER to &#163;3,085&#160;million mainly resulting from supply constraints in MMR/V vaccines and lower tender demand in International for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>. This was offset by hepatitis vaccines demand rebound in the US and Europe and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div> post-pandemic demand recovery and increased share in the US. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pandemic Vaccines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pandemic Vaccines decreased 86% AER and CER primarily reflecting comparison to 2021 pandemic adjuvant sales to the US and Canadian governments partly offset by GSK&#8217;s share of 2022 contracted European volumes related to the COVID-19 booster vaccine developed through a collaboration with Sanofi Pasteur (Sanofi). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover (&#163;bn) </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_75.jpg"/> </div><div style="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines turnover </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<br/>&#163;m</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;">Growth<br/>&#163;%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;">Growth<br/>CER%</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,548</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,048</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other general medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,570</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,619</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">General medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,667</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">2021 has been revised to reflect changes to product groups previously reported as Established Pharmaceuticals. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Respiratory </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Respiratory sales were &#163;6,548&#160;million, up 8% at AER, 3% at CER. The performance was driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> sales of &#163;1,729&#160;million, up 42% AER, 32% CER, including strong growth across all regions. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advair/Seretide</div></div> sales of &#163;1,159&#160;million decreased 15% at AER, 17% at CER predominantly reflecting the adverse impact of generic competition, with growth in certain International markets due to targeted promotion offsetting the decrease. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other general medicines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other General Medicines sales were &#163;3,570&#160;million, decreasing 1% at AER, 2% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> sales were &#163;576&#160;million, up 35% at AER, 38% at CER, reflecting the post pandemic rebound of the antibiotic market since H2 2021 in the International and Europe regions. This partially offsets the ongoing adverse impact of generic competition, and approximately two percentage points impact at AER and CER from the divestment of cephalosporin products in Q4 2021. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">75</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover by regions </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the US, sales were &#163;14,542&#160;million, up 22% at AER, 10% at CER. Sales adjusted for COVID-19 solutions were up 24% AER, 12% CER. Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> were &#163;828 million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In Specialty, HIV sales of &#163;3,756&#160;million were up 30% at AER, 17% at CER. Growth benefited from strong patient demand for all new HIV products, pricing favourability and year-end inventory build. New HIV medicines (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>) sales were &#163;1,685&#160;million up 88% at AER, 70% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> in respiratory and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> in immunology both continued to grow double-digit and reflected ongoing strong patient demand. Oncology sales increased 14% at AER, 3% at CER with diagnosis and treatment rates continuing to be impacted by the pandemic for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div>, and the withdrawal of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> from the US market in Q4 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vaccine sales were &#163;4,243&#160;million, up 22% at AER, 10% at CER, excluding the impact of pandemic adjuvant sales in 2021, sales increased 31% at AER, 18% at CER. The performance was primarily driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> sales of &#163;1,964&#160;million up 46% at AER, 32% at CER, mostly due to higher non-retail and retail demand and strong commercial execution. Demand recovery in Established Vaccines and share gains in Meningitis vaccines also contributed to growth. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">General Medicines sales were &#163;3,572&#160;million up 10% at AER down 1% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> was up 47% at AER, 32% at CER reflecting increased patient demand and growth of the single inhaler triple therapy market, and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Flovent</div></div> grew on launch of authorised generics in the year. Overall, there was a three-percentage point reduction in growth of US General Medicines due to prior period Returns and Rebates (RAR) adjustments in the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In Europe, sales were &#163;6,348&#160;million, up 18% at AER, 19% at CER, including COVID-19 solution sales of &#163;513&#160;million contributing 8 percentage points of growth at AER and CER. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In Specialty Medicines, HIV sales were &#163;1,310&#160;million up 10% at AER, 10% at CER primarily driven by strong patient demand for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> delivered sales of &#163;478&#160;million, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div> &#163;127&#160;million and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> &#163;40 million. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> in immunology, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> in respiratory, and Oncology medicines <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div> all continued to show strong double-digit growth. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vaccine sales were &#163;1,884&#160;million, up 31% at AER, 32% at CER. The performance was driven by <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> sales of &#163;688&#160;million, &gt;100% at AER and CER, particularly in Germany. Pandemic adjuvant sales of &#163;57&#160;million contributed four percentage points of growth at AER and CER. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">General Medicines sales of &#163;2,079&#160;million decreased 3% at AER and CER, reflecting the ongoing impact of generic competitive pressures on <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Seretide</div></div> and the divestment in Q4 2021 of cephalosporin products which caused one percentage point of drag on growth at AER and CER. This was partly offset, however, by strong demand for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> and the growth of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> following the post-pandemic rebound of the antibiotic market since H2 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">International sales were &#163;8,434&#160;million, up 14% at AER and CER, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> sales of &#163;1,025 million. Sales grew 7% AER and 6% CER excluding sales of COVID-19 solutions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In Specialty, HIV sales were &#163;683&#160;million, stable at AER and decreased 3% at CER, primarily driven by tender decline. Excluding tenders, International grew driven by strong <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> growth. Combined <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div> sales were &#163;506&#160;million, down 12% at AER and 15% at CER. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div> sales of &#163;242&#160;million grew 24% at AER and 28% at CER reflecting strong market growth and patient uptake. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div> sales of &#163;114&#160;million grew 44% at AER, 43% at CER reflecting growth in the biological market in Japan and inclusion on China&#8217;s National Reimbursement Drug List. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vaccine sales were &#163;1,810&#160;million, down 3% at AER, 5% at CER, reflecting an 11 percentage points drag at AER and CER from COVID-19 vaccine adjuvant sales in 2021. Growth excluding COVID-19 solutions was driven by strong <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> take-up in China, Canada and Japan more than offsetting the impact of supply constraints in MMR/V vaccines and lower <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div> tender demand across several markets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">General Medicines sales were &#163;4,467&#160;million up 5% at AER and CER. Respiratory sales of &#163;1,955&#160;million increased 10% at AER, 9% at CER, with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> sales up 47% at AER, 48% at CER reflecting strong demand and inclusion on China&#8217;s National Reimbursement Drug List. Sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advair/Seretide</div></div> were up 3% at AER, 1% at CER with the adverse impact of generic competition offset by growth in certain markets due to targeted promotion. Other General Medicines sales of &#163;2,512&#160;million increased 1% at AER, 2% at CER, and reflected growth of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div> following the post-pandemic rebound of the antibiotic market since H2 2021, partially offset by generic competition and price reductions in certain markets. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost of sales </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">CER%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,554</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,163</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,741</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,346</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total cost of sales as a percentage of turnover was 32.6%, 0.5 percentage points lower at AER and 0.9 percentage points higher in CER terms than 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted cost of sales as a percentage of turnover was 29.8%, 0.1 percentage points higher at AER and 1.3 percentage points higher at CER compared with 2021. This primarily reflected higher sales of lower margin <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div> compared to 2021 which included higher margin pandemic adjuvant sales, increasing cost of sales margin by 2.5 percentage points at AER and CER, as well as the impact of increased commodity prices and freight costs. This was partially offset by a favourable mix primarily from increased sales of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> in the US and Europe and increased sales of HIV medicines in the US, lower inventory adjustments and write offs in Vaccines and continued contribution from restructuring savings. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selling, general and administration </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth<br/>&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth<br/>CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,372</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,070</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted selling, general and administration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,128</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,749</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total SG&amp;A costs as a percentage of turnover were 28.6%, 0.1 percentage points lower at AER and stable at CER compared to 2021. This included a reduction in restructuring charges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted SG&amp;A costs as a percentage of turnover were 27.7%, 0.4 percentage points higher at AER and 0.5 percentage points higher at CER than in 2021. Adjusted SG&amp;A costs increased 20% at AER, 15% at CER which primarily reflected an increased level of launch investment in Specialty Medicines particularly HIV and Vaccines including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> to drive post-pandemic recovery demand and support market expansion. The growth in Adjusted SG&amp;A also reflected an unfavourable comparison to a beneficial legal settlement in 2021 as well as impairment provisions relating to Russia and Ukraine. This growth was partly offset by the continuing benefit of restructuring and tight control of ongoing costs. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and development </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Growth</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">CER%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total research and development</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,488</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,019</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,062</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,525</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total R&amp;D expenditure was &#163;5,488&#160;million up 9% at AER, 4% at CER. This included amortisation and impairments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted R&amp;D expenditure in the full-year increased by 12% at AER, and 6% at CER, to &#163;5,062 million. This reflected continued increased investment across Vaccines clinical development, including investments into our mRNA technology platforms, continued investment in the late-stage portfolio and several early discovery programmes, as well as expenditure related to our recent acquisition of Affinivax, Inc (Affinivax). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, in Specialty Medicines, the level of R&amp;D investment increased to support the phase III respiratory programme for depemokimab, a potential new medicine to treat severe asthma, and bepirovirsen, our study in chronic hepatitis B, in preparation for the start of the phase III trial. In Oncology, investment increased in our early-stage immuno-oncology assets and in momelotinib (MMB), our potential new treatment of myelofibrosis patients with anaemia, acquired as part of the recent Sierra Oncology acquisition. These increases in investment were offset by decreases related to the completion of several late-stage clinical development programmes and reduced R&amp;D investment in COVID-19 pandemic solutions versus 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Royalty income </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Royalty income was &#163;758&#160;million (2021: &#163;417 million), up 82% at AER, 81% at CER, the increase primarily reflecting royalty income from Gilead under the settlement and licensing agreement with Gilead announced on 1&#160;February 2022 and Gardasil royalty income increasing to &#163;446&#160;million due to higher sales. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">77</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other operating income/(expense) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net other operating expense was &#163;235&#160;million (2021: &#163;504 million) reflecting accounting charges of &#163;1,726&#160;million (2021: &#163;1,101 million) arising from the remeasurement of contingent consideration liabilities and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. This included a remeasurement charge of &#163;1,431&#160;million (2021: &#163;1,026 million) for the contingent consideration liability due to Shionogi, including the unwinding of the discount of &#163;410&#160;million and a charge for &#163;1,021&#160;million primarily from changes to exchange rates as well as adjustments to sales forecasts. This was partly offset by &#163;922&#160;million upfront income received from the settlement with Gilead, fair value gain on investments including &#163;229&#160;million on the retained stake in Haleon plc (Haleon), reflecting an increase in share price since listing and milestone income from disposals. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating profit </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total operating profit from continuing operations was &#163;6,433&#160;million compared with &#163;4,357&#160;million in 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This included the &#163;922&#160;million upfront income received from the settlement with Gilead, increased profits on turnover growth of 19% at AER, 13% at CER and fair value gains on investments including &#163;229&#160;million on the retained stake in Haleon, partly offset by higher remeasurement charges for contingent consideration liabilities. Adjusted operating profit was &#163;8,151&#160;million, 26% higher at AER and 14% at CER than 2021 on a turnover increase of 13% at CER. The Adjusted operating margin of 27.8% was 1.5 percentage points higher at AER and 0.3 percentage points higher at CER compared to 2021. This primarily reflected the impact from low margin COVID-19 solutions sales (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>), which reduced Adjusted Operating profit growth by 3% AER and CER and reduced the Adjusted operating margin by approximately 1.4 percentage points at AER and approximately 1.3 percentage points at CER. This was offset by operating leverage from strong sales growth, mix benefit, lower inventory adjustments and write offs and higher royalty income. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Contingent consideration cash payments made to Shionogi and other companies reduce the balance sheet liability and hence are not recorded in the income statement. Total contingent consideration cash payments in 2022 amounted to &#163;1,137&#160;million (2021: &#163;856 million). These included cash payments made to Shionogi of &#163;1,100&#160;million (2021: &#163;826 million). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted operating profit by business </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Commercial Operations operating profit was &#163;13,590&#160;million, up 19% at AER and 10% at CER on a turnover increase of 13% at CER. The operating margin of 46.3% was 0.1 percentage points lower at AER, 1.2 percentage points lower at CER than in 2021. This primarily reflected strong sales of lower margin <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div>, increased investment behind launches in Specialty Medicines including HIV and Vaccines plus higher commodity, freight and distribution costs as well as an adverse comparison to a favourable legal settlement in 2021. This was partly offset by leverage from strong sales growth, mix and lower inventory adjustments and write-offs, continued tight control of ongoing costs, benefits from continued restructuring and increased royalty income from Biktarvy and Gardasil sales. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">R&amp;D segment operating expenses were &#163;5,060&#160;million, up 11% at AER, 5% at CER, primarily reflecting increased investment in Vaccines including priority investments for mRNA, late stage portfolio and expenditure from the acquisition of Affinivax and in Specialty Medicines in early stage HIV and depemokimab. This was partly offset by decreases related to the completion of several late-stage clinical development programmes and reduced R&amp;D investment in COVID-19 pandemic solutions versus 2021. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net finance costs </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance income</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest and other income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Finance expense</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(789</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(735</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discounts on provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurements and fair value movements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense on lease liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(33</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(879</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(769</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total net finance costs were &#163;803&#160;million compared with &#163;755&#160;million in 2021. Adjusted net finance costs were &#163;791&#160;million compared with &#163;752&#160;million in 2021. The increase is mainly driven by costs associated with the Sterling Notes repurchase in Q4 2022 and higher interest on tax offset by increased interest income due to higher interest rates and larger cash balances as a result of the Consumer Healthcare demerger. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share of after tax profits of associates and joint ventures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The share of after tax loss of associates and joint ventures was &#163;2&#160;million (2021: &#163;33&#160;million share of profit). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss on disposal of interest in associates </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2021, the Group also reported a net loss on disposal of interests in associates of &#163;36&#160;million, primarily driven by a loss on disposal of our interest in the associate Innoviva Inc. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit before tax </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Taking account of net finance costs, the share of profits of associates and loss on disposal of interest in associates, profit before taxation was &#163;5,628&#160;million compared with &#163;3,599&#160;million in 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK current year charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">200</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of world current year charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,351</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">593</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge/(credit) in respect of prior periods</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,491</div></div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">931</div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total deferred taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(784</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(848</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation on total profits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The charge of &#163;707&#160;million represented an effective tax rate on Total results of 12.6% (2021: 2.3%) and reflected the different tax effects of the various Adjusting items. Included in 2021 was a credit of &#163;430&#160;million resulting from the remeasurement of deferred tax assets following enactment of the proposed change of UK corporate income tax rates from 19% to 25%. Tax on Adjusted profit amounted to &#163;1,138&#160;million and represented an effective Adjusted tax rate of 15.5% (2021: 15.9%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Issues related to taxation are described in Note 14 to the financial statements &#8216;Taxation&#8217;. The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods which are open and not yet agreed by tax authorities. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-controlling interests </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The allocation of Total profit from continuing operations to non-controlling interests amounted to &#163;460&#160;million (2021: &#163;200 million). The increase was primarily due to an increased allocation of ViiV Healthcare profits of &#163;416&#160;million (2021: &#163;197 million), including the Gilead upfront settlement income, partly offset by increased credits for remeasurement of contingent consideration liabilities, as well as higher net profits in some of the Group&#8217;s other entities with non-controlling interests. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The allocation of Adjusted earnings from continuing operations to non-controlling interests amounted to &#163;595&#160;million (2021: &#163;441 million). The increase in allocation primarily reflected an increased allocation of ViiV Healthcare profits of &#163;551&#160;million (2021: &#163;438 million), as well as higher net profits in some of the Group&#8217;s other entities with non-controlling interests. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnings per share from continuing operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total EPS from continuing operations was 110.8p compared with 82.9p in 2021. This primarily reflected the &#163;922&#160;million upfront income received from the settlement with Gilead, increased profits on turnover growth of 13% at CER and fair value gains on investments including the retained stake in Haleon, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;430&#160;million to Taxation in 2021 resulting from the remeasurement of deferred tax assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Adjusted EPS was 139.7p compared with 110.3p in 2021, up 27% at AER, 15% at CER on a 13% CER turnover increase. Operating leverage from growth in sales of Specialty Medicines including HIV and Vaccines, beneficial mix and lower inventory adjustments and write-offs, higher royalty income and a lower effective tax rate was partly offset by increased investment behind launches in Specialty Medicines including HIV and Vaccines plus higher supply chain costs, freight and distribution costs and higher non-controlling interests. Growth in lower margin COVID-19 solutions sales reduced Adjusted EPS growth by 4% AER and 3% CER. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">79</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit and earnings per share from discontinued operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Discontinued operations include the Consumer Healthcare business and certain Corporate costs directly attributable to the Consumer Healthcare business. Profit after taxation from discontinued operations amounted to &#163;10,700&#160;million (2021: &#163;1,580 million). This includes &#163;10,084&#160;million for the gain arising on the demerger of Consumer Healthcare split between the amount distributed to shareholders on demerger of &#163;7,651&#160;million and profit after taxation on discontinued operations for the retained stake of &#163;2,433 million. In addition, the Profit after taxation from discontinued operations for the Consumer Healthcare business was &#163;616&#160;million (2021: &#163;1,580 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">EPS from discontinued operations was 260.6p, compared with 26.7p in 2021. The increase primarily reflected the gain arising on the demerger of the Consumer Healthcare business. For further details see page&#160;238. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total earnings per share </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total EPS was 371.4p compared with 109.6p in 2021. The increase primarily reflected the profit after taxation for discontinued operations recognised on the Consumer Healthcare business demerger, upfront income received from the settlement with Gilead, increased profits and fair value gains on investments, partly offset by higher remeasurement charges for contingent consideration liabilities and an unfavourable comparison due to a credit of &#163;397&#160;million to Taxation in 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividends </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board has declared four interim dividends resulting in a total dividend for the year of 61.25p per share retrospectively adjusted for the share consolidation. The 2021 dividend per share was 100p retrospectively adjusted for the share consolidation. See Note 16 to the financial statements, &#8216;Dividends&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividend policy </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 23&#160;June 2021, at the new GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60 percent pay-out ratio through the investment cycle. The dividend policy, the total expected cash distribution, and the respective dividend pay-out ratios for GSK remain unchanged. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has previously stated that it expected to declare a 27p&#160;per share dividend for the first half of 2022, a 22p&#160;per share dividend for the second half of 2022 and a 45p&#160;per share dividend for 2023 (before the Share Consolidation) but that these targeted dividends per share would increase in step with the Share Consolidation to maintain the same aggregate dividend pay-out in absolute Sterling terms. Accordingly, using the consolidation ratio, GSK&#8217;s expected dividend for the fourth quarter of 2022 converts to 13.75p&#160;per new ordinary share. This results in an expected total dividend for the second half of 2022 of 27.5p&#160;per new ordinary share. The expected dividend for 2023 converts to 56.5p&#160;per new ordinary share in line with the original expectation converted for the Share Consolidation and rounded up. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Guidance and Outlook </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK expects 2023 turnover to increase between 6 to 8&#160;per cent, Adjusted operating profit to increase between 10 to 12&#160;per cent and Adjusted earnings per share to increase between 12 to 15&#160;per cent. This guidance is provided at CER and excludes any contributions from COVID-19 solutions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In outlining the guidance for 2023, the Group has made certain assumptions about the healthcare sector, the different markets in which the Group operates and the delivery of revenues and financial benefits from its current portfolio, pipeline and restructuring programmes. Due to the phasing of quarterly results in 2022 and the resulting comparators, GSK expects turnover and Adjusted operating profit growth to be slightly lower in the first half of 2023 including a challenging comparator in Q1 2022 and somewhat higher in the second half, relative to full-year expectations. Despite the ongoing recovery of healthcare systems from the impact of the COVID-19 pandemic, uncertain economic conditions prevail across many markets in which GSK operates and we continue to expect to see variability in performance between quarters. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We expect sales of Specialty Medicines to increase mid to high single-digit per cent, sales of Vaccines to increase mid-teens per cent and sales of General Medicines to decrease slightly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COVID-19 solutions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Based on known binding agreements with governments, GSK does not anticipate any significant COVID-19 pandemic-related sales or operating profit in 2023. Sales of COVID-19 solutions were &#163;2.4 billion in 2022 and therefore we expect a reduction in Turnover growth by approximately 9% and a reduction in Adjusted Operating profit growth by 6% to 7%. However, the Company continues to discuss future opportunities to support governments, healthcare systems, and patients whereby its COVID-19 solutions can address the emergence of any new COVID-19 variant of concern. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_58" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusting items </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted results reconciliation</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December 2022</div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">results</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Profit&#160;from</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">discon-<br/>tinued<br/>operations</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>amortisation<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>impairment<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/>restructuring<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Transaction-<br/>related</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Divestments,<br/>significant<br/>legal and<br/>other items<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Adjusted<br/>results<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">29,324</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">29,324</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,554</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">648</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,741</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">19,770</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">648</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">20,583</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,488</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">296</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">39</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,062</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">758</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">758</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other operating (expense)/income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(235</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1692</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,457</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,433</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">296</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">321</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,388</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8,151</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net finance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of after-tax losses of associates and joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,628</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">296</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">323</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,378</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7,358</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(242</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax rate</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">12.6%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">15.5%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>Profit after taxation from continuing operations<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,921</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,508</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,220</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3,049</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,049</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,651</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,651</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,700</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10,700</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total profit after taxation for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15,621</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10,700</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,508</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,220</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interests from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">460</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">595</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,461</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,373</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,266</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,625</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interest from discontinued operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">205</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(205</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,495</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10,495</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15,621</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10,700</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,508</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,220</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to non-controlling interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">665</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(205</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">595</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to shareholders</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14,956</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10,495</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,373</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,625</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,621</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,700</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">589</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">232</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,508</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,266</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,220</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">110.8p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">14.6p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5.8p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5.9p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">34.1p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(31.5)p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">139.7p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">260.6p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(260.6)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">371.4p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(260.6)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14.6p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5.8p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5.9p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34.1p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31.5)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">139.7p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average number of shares (millions)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,026</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,026</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">81</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted results reconciliation<br/>31&#160;December 2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">(1) </div></div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/>results<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Profit from<br/>discon-<br/>tinued<br/>operations<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>amortisation<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>impairment<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/>restructuring<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Transaction-<br/>related</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Divestments,<br/>significant<br/>legal&#160;and<br/>other&#160;items<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Adjusted<br/>results<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">24,696</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">24,696</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">660</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,346</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">16,533</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">660</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17,350</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,019</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,525</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">417</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">417</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other operating (expense)/income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(504</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,106</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(602</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,357</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">761</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,143</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,493</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net finance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(752</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of after-tax profits of associates and joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3,599</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">761</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">426</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,143</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(502</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,774</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(153</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(179</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(918</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax rate</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.3%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">15.9%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from continuing operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,516</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total profit after taxation for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interests from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3,316</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">723</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,415</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interest from discontinued operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">511</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(511</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,069</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,069</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to non-controlling interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">711</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(511</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">241</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">441</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to shareholders</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,385</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,069</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">723</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,415</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,096</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,580</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">608</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">347</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(845</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">82.9p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">15.2p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6.6p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.7p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">18.1p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(21.2)p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">110.3p</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.7p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26.7)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">109.6p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26.7)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15.2p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6.6p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8.7p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18.1p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21.2)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">110.3p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average number of shares (millions)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,003</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,003</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238) and the impact of Share Consolidation implemented on 18&#160;July 2022 (see page 233). </td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial performance</div></div> continued </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted results reconciliation<br/>31&#160;December 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">(1) </div></div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/>results<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Profit from<br/>discon-<br/>tinued<br/>operations<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>amortisation<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/>asset<br/>impairment<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/>restructuring<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Transaction-<br/>related</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Divestments,<br/>significant<br/>legal&#160;and<br/>other&#160;items<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Adjusted<br/>results<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">24,354</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">24,354</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,929</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">649</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">585</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,672</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">16,425</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">649</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">585</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17,682</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,793</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,322</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">321</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">321</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other operating (expense)/income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,463</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,215</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,678</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,979</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,178</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,237</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,662</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,656</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net finance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of after-tax profits of associates and joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,170</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,180</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,237</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,660</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,851</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(142</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax rate</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1.3%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">13.9%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from continuing operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,103</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,006</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,035</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total profit after taxation for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,388</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,006</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,035</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interests from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,873</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,554</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to non-controlling interest from discontinued operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">409</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(409</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(876</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,388</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,006</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,035</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to non-controlling interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">639</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(409</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">251</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">481</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to shareholders</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,749</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(876</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,554</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,388</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,285</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">582</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,066</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,785</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,035</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14.6p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.1p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.3p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.0p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70.0)p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114.4p</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22.0p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22.0)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">144.4p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22.0)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14.6p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4.1p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">24.3p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">19.0p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(70.0)p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">114.4p</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average number of shares (millions)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,981</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,981</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238) and the impact of Share Consolidation implemented on 18&#160;July 2022 (see page 233). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusting items</div></div> continued </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profit from discontinued operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Discontinued operations include the Consumer Healthcare business and certain Corporate costs directly attributable to the Consumer Healthcare business. Profit after taxation from discontinued operations amounted to &#163;10,700&#160;million (2021: &#163;1,580 million). This includes &#163;10,084&#160;million for the gain arising on the demerger of Consumer Healthcare split between the amount distributed to shareholders on demerger of &#163;7,651&#160;million and profit after taxation on discontinued operations for the retained stake of &#163;2,433 million. In addition, the Profit after taxation from discontinued operations for the Consumer Healthcare business was &#163;616&#160;million (2021: &#163;1,580 million). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible asset amortisation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">See page 211 for description and information on Intangible asset amortisation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible asset impairment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">See page 211 for description and information on Intangible asset impairment. No individual intangible asset accounted for a material impairment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major restructuring and integration </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long life cycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;D sites are likely to take several years to complete. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Major restructuring costs are those related to specific Board-approved Major restructuring programmes and are excluded from Adjusted results. Major restructuring programmes, including integration costs following material acquisitions, are those that are structural and are of a significant scale where the costs of individual or related projects exceed &#163;25 million. Other ordinary course smaller-scale restructuring costs are retained within Total and Adjusted results. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total Major restructuring charges incurred in 2022 were &#163;321&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;424 million), analysed as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-<br/>cash<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Non-<br/>cash<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation preparation restructuring programme&#160;&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">177</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">287</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">353</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">412</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Significant acquisitions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">206</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">115</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">385</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">39</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash charges of &#163;177&#160;million under the Separation Preparation programme primarily arose from the restructuring of some administrative functions as well as Global Supply Chain, R&amp;D functions and commercial. The non-cash charges of &#163;110&#160;million primarily reflected the write-down of assets in administrative and manufacturing locations and impairment of IT assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total cash payments made in 2022 were &#163;388&#160;million (2021: &#163;551 million), &#163;332&#160;million (2021: &#163;428 million) relating to the Separation Preparation restructuring programme, &#163;17&#160;million relating to significant acquisitions (2021: &#163;nil) and &#163;39&#160;million (2021: &#163;123 million) relating to other legacy programmes including the settlement of certain charges accrued in previous quarters. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of Major restructuring charges by income statement line was as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">102</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">180</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Major restructuring costs from continuing operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </td></tr></table><div style="margin-top:9pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The benefit in 2022 from restructuring programmes was &#163;0.5 billion, primarily relating to the Separation Preparation restructuring programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group initiated in Q1 2020 a Separation Preparation programme to prepare for the separation of GSK into two companies: The programme aims were: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Drive a common approach to R&amp;D with improved capital allocation </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Align and improve the capabilities and efficiency of global support functions to support GSK </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Further optimise the supply chain and product portfolio, including the divestment of non-core assets </div></td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#8211; Prepare Consumer Healthcare to operate as a standalone company </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The programme delivered &#163;0.9 billion of annual savings by 2022 and targets to deliver &#163;1.0 billion by 2023, with total costs estimated at &#163;2.4 billion, of which &#163;1.6 billion is expected to be cash costs. The proceeds of divestments have largely covered the cash costs of the programme. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">84</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusting items</div></div> continued </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction-related adjustments </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Transaction-related adjustments from continuing operations resulted in a net charge of &#163;1,750&#160;million (2021: &#163;1,143 million). This included a net &#163;1,726&#160;million accounting charge for the re-measurement of the contingent consideration liabilities and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charge/(credit)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Contingent consideration on former Shionogi-ViiV Healthcare Joint Venture (including Shionogi preferential dividends)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,431</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,026</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare put options and Pfizer preferential dividends</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom: 3pt; vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal; white-space: nowrap;">Contingent consideration on former Novartis Vaccines business</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); white-space: nowrap;">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">193</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Contingent consideration on acquisition of Affinivax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other adjustments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total transaction-related charges</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,750</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,143</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The &#163;1,431&#160;million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi, as a result of the unwind of the discount for &#163;410&#160;million and a charge of &#163;1,021&#160;million primarily from adjustments to sales forecasts and the settlement with Gilead as well as updated exchange rate assumptions. The &#163;85&#160;million charge relating to the ViiV Healthcare put option and Pfizer preferential dividends represented an increase in the valuation of the put option as a result of the settlement with Gilead, offset by lower cash and updated exchange rate assumptions. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ViiV Healthcare contingent consideration liability is fair valued under IFRS. An explanation of the accounting for the non-controlling interests in ViiV Healthcare is set out on page 71. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Divestments, significant legal charges and other items </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Divestments, significant legal charges and other items primarily included the &#163;922&#160;million upfront settlement income received from Gilead, a fair value gain on investments including &#163;229&#160;million on the retained stake in Haleon as well as milestone income and gains from a number of asset disposals, partly offset by certain other Adjusting items. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discontinued operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From Q2 2020, the Group started to report additional costs to prepare for establishment of the Consumer Healthcare business as an independent entity (&#8220;Separation costs&#8221;). These are presented as part of discontinued operations. Total separation costs incurred in 2022 were &#163;366&#160;million (2021: &#163;314 million). This includes &#163;103&#160;million relating to transaction costs incurred in connection with the demerger and preparatory admission costs related to the listing of Haleon. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total separation costs to date are &#163;748&#160;million including &#163;141&#160;million relating to transaction costs. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_59" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash generation and conversion </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summary of the consolidated cash flow statement is set out below. </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net cash inflow from operating activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,403</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,952</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net cash (outflow) from investing activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,772</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,777</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net cash inflow/(outflow) from financing activities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">823</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,589</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease in cash and bank overdrafts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(546</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,414</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and bank overdrafts at beginning of year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,819</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,262</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(29</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease in cash and bank overdrafts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(546</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,414</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and bank overdrafts at end of year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,819</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and bank overdrafts at end of year comprise:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,274</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(298</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(455</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,819</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of net cash inflow from continuing operating activities to free cash inflow </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A reconciliation of net cash inflow from operating activities, which is the closest equivalent IFRS measure to free cash flow, is shown below. </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash inflow from continuing operating activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,634</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,277</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,143</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(950</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,115</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,704</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from sale of property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">132</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from sale of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">641</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net finance costs</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(784</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(758</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends from joint ventures and associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration paid (reported in investing activities)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(79</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(114</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contribution from non-controlling interests</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to non-controlling interests</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(521</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(239</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Free cash inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,348</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,301</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital expenditure and financial investment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash payments for tangible and intangible fixed assets amounted to &#163;2,258&#160;million (2021: &#163;2,654 million) and disposals realised &#163;342&#160;million (2021: &#163;773 million). Cash payments to acquire equity investments amounted to &#163;143&#160;million (2021: &#163;162 million) and sales of equity investments realised &#163;238&#160;million (2021: &#163;202 million). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Free cash flow </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Free cash flow is the amount of cash generated by the Group after meeting our obligations for contingent consideration, interest, tax and dividends paid to non-controlling interests, and after capital expenditure on property, plant and equipment and intangible assets. </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Free cash inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,348</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,301</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="font-size:8pt;width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total cash payments to Shionogi in relation to the ViiV Healthcare contingent consideration liability in the year were &#163;1,100&#160;million (2021: &#163;826 million), of which &#163;1,031&#160;million was recognised in cash flows from operating activities and &#163;69&#160;million was recognised in contingent consideration paid within investing cash flows. These payments are deductible for tax purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Future cash flow </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Over the long term, we expect that future cash generated from operations will be sufficient to fund our operating and debt servicing costs, normal levels of capital expenditure, obligations under existing licensing agreements, expenditure arising from restructuring programmes and other routine outflows including tax, pension contributions and dividends, subject to the &#8216;Principal risks and uncertainties&#8217; discussed on pages 285 to 295. We may from time to time have additional demands for finance, such as for acquisitions. We have access to multiple sources of liquidity from short and long-term capital markets and financial institutions for such needs, in addition to the cash flow from operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investment appraisal and capital allocation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have a strong framework for capital allocation, including a board to govern the allocation of capital between our businesses. We utilise a consistent cash return on invested capital (CROIC) methodology to prioritise investment across the Group as a whole, so that we can more effectively compare the returns from each of the businesses as we allocate capital between them. We also consider the impact on EPS and our credit profile where relevant. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">86</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_60" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial position and resources </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-current assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,933</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">687</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,318</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,467</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,658</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,676</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total non-current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39,377</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">60,429</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current tax recoverable</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">405</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,053</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,087</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,769</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18,674</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60,146</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">79,103</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term borrowings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,952</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(958</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16,263</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(183</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(227</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current tax payable</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(471</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(489</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term provisions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(652</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(841</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,810</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,670</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Long-term borrowings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporation tax payable</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(180</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and other post-employment benefits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,579</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(532</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,779</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-current liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(899</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(921</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total non-current liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27,240</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(34,091</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(50,050</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57,761</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21,342</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total equity</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21,342</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our business is science-based, technology-intensive and highly regulated by governmental authorities. We allocate significant financial resources to the renewal and maintenance of our property, plant, equipment and vehicles to minimise risks of interruption to production and to ensure compliance with regulatory standards. A number of our processes use hazardous materials. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The total cost of our property, plant and equipment at 31&#160;December 2022 was &#163;19,451&#160;million, with a net book value of &#163;8,933 million. Of this, land and buildings represented &#163;3,113&#160;million, plant, equipment and vehicles &#163;4,012&#160;million and assets in construction &#163;1,808 million. In 2022, we invested &#163;1,245&#160;million in new property, plant and equipment. This was mainly related to a large number of projects for the renewal, improvement and expansion of facilities at various worldwide sites to support new product development and launches as well as to improve the efficiency of existing supply chains. Property is mainly held freehold. New investment is financed from our liquid resources. At 31&#160;December 2022, we had contractual commitments for future capital expenditure of &#163;743 million. We believe that our property and plant facilities are adequate for our current requirements. <br/></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Right of use assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Right of use assets amounted to &#163;687&#160;million at 31&#160;December 2022 compared with &#163;740&#160;million at 31&#160;December 2021. The decrease in the year reflected the impact of depreciation and transfer to assets held for sale/distribution of &#163;192&#160;million and &#163;127&#160;million respectively, disposals and impairments amounting to &#163;75&#160;million, partly offset by additions through business combinations of &#163;53&#160;million and other additions of &#163;233 million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill decreased to &#163;7,046&#160;million at 31&#160;December 2022, from &#163;10,552&#160;million primarily as a result of transfer of assets held for sale/distribution of &#163;5,183&#160;million for the Consumer Healthcare demerger partially offset by an increase of &#163;1,127&#160;million for the acquisitions of Sierra Oncology and Affinivax. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other intangible assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other intangible assets include the cost of intangibles acquired from third parties and computer software. The net book value of other intangible assets as at 31&#160;December 2022 was &#163;14,318&#160;million (2021: &#163;30,079 million). The decrease primarily reflected transfer to assets held for sale/distribution of &#163;19,957 million, impairment losses, net of reversals and amortisation of &#163;1,519&#160;million, offset by additions, net of disposals, write-offs of &#163;4,047&#160;million and exchange rate gains of &#163;1,628 million. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">87</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial position and resources</div></div> continued </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investments in associates and joint ventures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We held investments in associates and joint ventures with a carrying value at 31&#160;December 2022 of &#163;74&#160;million (2021: &#163;88 million). See Note 21 to the financial statements, &#8216;Investments in associates and joint ventures&#8217; for more details. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current equity investments </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments amounted to &#163;4,087&#160;million at 31&#160;December 2022 (2021: &#163;nil). Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at fair value through the profit and loss (FVTPL). They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. The investment of &#163;4,087&#160;million (2021: &#163;nil) represents the shares held in Haleon after the demerger. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other investments </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We held other investments with a carrying value at 31 December 2022 of &#163;1,467&#160;million (2021: &#163;2,126 million). The most significant of these investments held at 31&#160;December 2022 were in Vir Biotechnology and Nimbus Discovery. These investments had a fair value at 31&#160;December 2022 of &#163;180&#160;million (2021: &#163;266 million) and &#163;139&#160;million (2021: &#163;32 million) respectively. The other investments included equity stakes in companies with which we have research collaborations, and which provide access to biotechnology developments of potential interest and interests in companies that arise from business divestments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative financial instruments: assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We held current derivative financial assets at fair value of &#163;190&#160;million (2021: &#163;188 million) and non-current derivative financial assets held at fair value of &#163;nil (2021: &#163;18 million). The majority of these financial instruments related to foreign exchange contracts both designated and not designated as accounting hedges. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventories </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Inventories amounted to &#163;5,146&#160;million (2021: &#163;5,783) at 31&#160;December 2022. The decrease was mainly driven by the Consumer Healthcare demerger partially offset by vaccines stock build. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trade and other receivables </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other receivables amounted to &#163;7,053&#160;million (2021: &#163;7,860 million) at 31&#160;December 2022. The decrease was mainly driven by the Consumer Healthcare demerger and lower pandemic adjuvant sales compared to last year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred tax assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets amounted to &#163;5,658&#160;million (2021: &#163;5,218 million) at 31&#160;December 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative financial instruments: liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We held current and non-current derivative financial liabilities at fair value of &#163;183&#160;million (2021: &#163;228 million). This primarily related to foreign exchange contracts both designated and not designated as accounting hedges. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trade and other payables </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, trade and other payables were &#163;16,263&#160;million compared with &#163;17,554&#160;million at 31&#160;December 2021. See Note 29 to the financial statements, &#8216;Trade and other payables&#8217;. The decrease was mainly driven by the Consumer Healthcare demerger and profit share collaborations offset by an increase in promotional activity in the regions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provisions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We carried deferred tax provisions and other short-term and non-current provisions of &#163;1,473&#160;million at 31&#160;December 2022 (2021: &#163;5,027 million). Other provisions at the year-end included &#163;218&#160;million (2021: &#163;196 million) related to legal and other disputes and &#163;351&#160;million (2021: &#163;652 million) related to Major restructuring programmes. Provision has been made for legal and other disputes, indemnified disposal liabilities, employee related liabilities and the costs of the restructuring programme to the extent that at the balance sheet date a legal or constructive obligation existed and could be reliably estimated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We account for pension and other post-employment arrangements in accordance with IAS 19. The net deficits were &#163;1,356&#160;million (2021: &#163;1,129 million) on pension arrangements and &#163;994&#160;million (2021: &#163;1,243 million) on unfunded post-employment liabilities. See Note 31 to the financial statements, &#8216;Pensions and other post-employment benefits&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other non-current liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other non-current liabilities amounted to &#163;899&#160;million at 31&#160;December 2022 (2021: &#163;921 million). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contingent consideration liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Contingent consideration amounted to &#163;7,068&#160;million at 31&#160;December 2022 (2021: &#163;6,076 million), of which &#163;5,890&#160;million (2021: &#163;5,559 million) represented the estimated present value of amounts payable to Shionogi relating to ViiV Healthcare, &#163;501&#160;million (2021: &#163;nil) represented the estimated present value of contingent consideration payable to the former shareholders of Affinivax and &#163;673&#160;million (2021: &#163;479 million) represented the estimated present value of contingent consideration payable to Novartis related to the Vaccines acquisition. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The liability due to Shionogi was &#163;263&#160;million in respect of preferential dividends. An explanation of the accounting for the non-controlling interests in ViiV Healthcare is set out on page 71. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the total contingent consideration payable (on a post-tax basis) at 31&#160;December 2022, &#163;940&#160;million (2021: &#163;937 million) is expected to be paid within one year. The consideration payable is expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, on a post-tax basis using post-tax discount rates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Shionogi-ViiV Healthcare contingent consideration liability is discounted at 8% and the Novartis Vaccines contingent consideration liability is discounted partly at 7.5% and partly at 8.5%. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">88</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial position and resources</div></div> continued </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity profile of bond debt</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_89.jpg"/> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net debt </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,274&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short term borrowings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,952</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,601)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Long term borrowings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt the end of the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, net debt was &#163;17.2 billion, compared with &#163;19.8 billion at 31&#160;December 2021, comprising gross debt of &#163;21.0 billion and cash and liquid investments of &#163;3.8 billion. Net debt reduced by &#163;2.6 billion primarily due to &#163;3.3 billion free cash flow from continuing operations, &#163;0.2 billion disposals of equity investments and &#163;7.2 billion decrease from discontinued operations as result of demerger primarily reflecting &#163;7.1 billion of pre-separation dividends attributable to GSK funded by Consumer Healthcare debt. This was partly offset by purchases of businesses of &#163;3.1 billion, net of cash acquired, reflecting the acquisitions of Sierra Oncology and Affinivax, dividends paid to shareholders of &#163;3.5 billion, net adverse exchange impacts of &#163;1.4 billion from the translation of non-Sterling denominated debt and exchange on other financing items and &#163;0.1 billion purchases of equity investments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, GSK had short-term borrowings (including overdrafts and lease liabilities) repayable within 12 months of &#163;4.0 billion and &#163;1.9 billion repayable in the subsequent year. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, GSK&#8217;s cash and liquid investments were held as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,825&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,253&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,395&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,274&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments &#8211; government securities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">61&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,790&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,335&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash and liquid investments of &#163;3.1 billion (2021: &#163;2.9 billion) were held centrally at 31&#160;December 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of cash and gross debt after the effects of hedging is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,274&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross debt &#8211; fixed</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,214</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,167)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.13em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; floating</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,773</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,006)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net debt</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in net debt </div></div></div></div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net debt at beginning of year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease in cash and bank overdrafts</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,597</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,504)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease in liquid investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net decrease in long-term loans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">569</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net decrease of short-term loans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,053</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,003&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of lease liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt of subsidiary undertaking acquired</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,531</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-cash movements</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(134)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,536</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(158)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,177</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,100&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net debt at end of year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">89</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial position and resources</div></div> continued </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total equity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, total equity had decreased from &#163;21,342&#160;million at 31&#160;December 2021 to &#163;10,096 million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summary of the movements in equity is set out below: </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total equity at beginning of year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,342&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,808&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income for the year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,790&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,759&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-cash distribution to non-controlling interests</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,960)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deconsolidation of former subsidiaries</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,045)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,467)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,999)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares issued</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in non-controlling interests</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-cash dividends to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,526)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Hedging gain/loss transferred to non-financial assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction with non-controlling interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">357&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on share-based incentive plans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8)</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contributions from non-controlling interests</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to non-controlling interests</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,409)</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(642)</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total equity at end of year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21,342&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share purchases </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, GSK held 217.1&#160;million shares as Treasury shares (2021: 284.2&#160;million shares), at a cost of &#163;3,798&#160;million (2021: &#163;4,969 million), which has been deducted from retained earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">No ordinary shares were repurchased in the period 1&#160;January 2023 to 9&#160;March&#160;2023 and the company does not expect to make any ordinary share repurchases in the remainder of 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, 77.1&#160;million Treasury shares were transferred to the Employee Share Ownership Plan (ESOP) Trusts, of which 50.3&#160;million shares were transferred prior to share consolidation. Shares are held by the Trusts to satisfy future exercises of options and awards under the Group share option and award schemes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A proportion of the shares held by the Trusts are in respect of awards where the rules of the scheme require GSK to satisfy exercises through market purchases rather than the issue of new shares. The shares held by the Trusts are matched to options and awards granted. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the ESOP Trusts held 59.9&#160;million (2021: 23.3 million) GSK shares against the future exercise of share options and share awards. The carrying value of &#163;353&#160;million (2021: &#163;27 million) has been deducted from other reserves. The market value of these shares was &#163;861&#160;million (2021: &#163;371 million). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual obligations and commitments </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial commitments are summarised in Note 36 to the financial statements, &#8216;Commitments&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table sets out our contractual obligations and commitments at 31&#160;December 2022 as they fall due for payment. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total&#160;<br/>&#163;m&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Under&#160;1&#160;yr&#160;<br/>&#163;m&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3&#160;yrs&#160;</div><br/>&#163;m&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5&#160;yrs&#160;</div><br/>&#163;m&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">5&#160;yrs+&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,086&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,786&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,213&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,259&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,828&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest on loans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,322&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">594&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">961&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,666&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,008&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">167&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">328&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">177&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">336&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Future Finance Charges on leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease contracts that have not yet commenced</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">396&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,659&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">317&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">590&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,616&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,136&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant&#160;&amp; equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">743&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">612&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase commitments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and post-retirement benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">345&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">345&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">40,004&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,011&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,578&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,126&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23,289&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Commitments in respect of loans and future interest payable on loans are disclosed before taking into account the effect of derivatives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have entered into a number of research collaborations to develop new compounds with other pharmaceutical companies. The terms of these arrangements can include upfront fees, equity investments, loans and commitments to fund specified levels of research. In addition, we will often agree to make further payments if future &#8216;milestones&#8217; are achieved. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As some of these agreements relate to compounds in the early stages of development, the potential obligation to make milestone payments will continue for a number of years if the compounds move successfully through the development process. Generally, the closer the product is to marketing approval, the greater the probability of success. The amounts shown above within intangible assets represent the maximum that would be paid if all milestones were achieved. There was a decrease in the commitments in 2022 as a result of a reduction in outstanding loan commitments. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial position and resources</div></div> continued </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. Scottish limited partnerships (&#8220;SLPs&#8221;) were established to provide a funding mechanism for each of GSK&#8217;s UK defined benefit pension schemes. The SLPs together hold shares representing 7.5% of the total issued share capital of Haleon. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on Haleon shares, until it has received an aggregate amount equal to an agreed threshold (&#8220;Proceeds Threshold&#8221;). The Proceeds Thresholds total &#163;1,080&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or technical provisions deficits in the three schemes shown by the 31&#160;December 2020 valuations. Once the Proceeds Threshold has been reached the GSK-controlled General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. As at 31&#160;December 2022, &#163;345&#160;million remains outstanding to the UK Pension Trustees. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contingent liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other contingent liabilities are set out in Note 35 to the financial statements, &#8216;Contingent liabilities&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table sets out contingent liabilities, comprising performance guarantees, letters of credit and other items arising in the normal course of business, and when they are expected to expire. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Under&#160;1&#160;yr</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;1-3&#160;yrs</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;3-5&#160;yrs</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;5&#160;yrs+</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Guarantees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other contingent</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">46</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the normal course of business, we have provided various indemnification guarantees in respect of business disposals in which legal and other disputes have subsequently arisen. A provision is made where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome of the dispute and this is included in Note 32 to the financial statements, &#8216;Other provisions&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We provide for the outcome of tax, legal and other disputes when an outflow of resources is considered probable and a reliable estimate of the outflow may be made. At 31&#160;December 2022, other than for those disputes where provision has been made, it was not possible to make a reliable estimate of the potential outflow of funds that might be required to settle disputes where the possibility of there being an outflow was more than remote. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ultimate liability for such matters may vary significantly from the amounts provided and is dependent upon negotiations with the relevant tax authorities and the outcome of litigation proceedings, where relevant. This is discussed further in &#8216;Principal risks and uncertainties&#8217; on pages 285 to 295 and Note 47 to the financial statements, &#8216;Legal proceedings&#8217;. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div><div id="ex15_2tx382677_61" style="margin-top: 10pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Approach to tax</div> </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Business makes a major contribution to the public purse through its tax contribution. This includes direct taxes (such as corporate income tax) and indirect taxes (such as VAT and customs duties) as well as other taxes (such as employment taxes and property taxes). It is therefore important that companies explain their approach to tax. This helps inform dialogue about tax and tax policy. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are supportive of efforts to ensure companies are appropriately transparent about how their tax affairs are managed. As part of that, our Tax Strategy is set out in detail within the Public policies section of our website. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We support the exchange of country-by-country reporting (CBCR) data between tax authorities as, validated against existing information held on taxpayers, it will support their ability to ensure multinational groups pay the right amount of tax in the right places. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As a global biopharmaceutical company, we have a substantial business and employment presence in many countries around the world and pay a significant amount of tax. This includes corporate income tax and other business taxes, and tax associated with our employees. We also collect a significant amount of tax on behalf of governments along our supply chain, including from our employees. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are subject to taxation throughout our supply chain. The worldwide nature of our operations means that our cross-border supply routes, necessary to ensure supplies of medicines into numerous countries, can result in conflicting claims from tax authorities as to the profits to be taxed in individual countries. This can lead to double taxation (with profits taxed in more than one country). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Profits are recognised in territories by reference to the activities performed there and the value they generate. To ensure the profits recognised in jurisdictions are aligned to the activity undertaken there, and in line with current OECD guidelines, we base our transfer pricing policy on the arm&#8217;s length principle and support our transfer prices with economic analysis and reports. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We do not engage in artificial tax arrangements &#8211; those without business or commercial substance. We do not seek to avoid tax by the use of &#8216;tax havens&#8217; or transactions we would not fully disclose to a tax authority. We have a zero-tolerance approach to tax evasion and the facilitation of tax evasion. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tax risk in all countries in which we operate is managed through robust internal policies, processes, training and compliance programmes. Our Board of Directors and the Audit&#160;&amp; Risk Committee are responsible for approving our tax policies and risk management arrangements as part of our wider internal control framework. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We seek to maintain open and constructive relationships with tax authorities worldwide, meeting regularly to discuss our tax affairs and real time business updates wherever possible. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We also monitor government debate on tax policy in our key jurisdictions so that we can understand and share an informed point of view regarding any potential future changes in tax law. Where relevant, we provide pragmatic and constructive business input to tax policy makers either directly or through industry trade bodies, advocating reform to support economic growth and job creation as well as the needs of our patients and other key stakeholders. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, the Group corporate tax charge was &#163;707&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;83 million) on profits before tax of &#163;5,628&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;3,599 million) representing an effective tax rate of 12.6% (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: 2.3%). We made cash tax payments of &#163;1,310&#160;million in the year (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;972 million). In addition to the taxes we pay on our profits, we pay duties, levies, transactional and employment taxes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Adjusted tax rate for 2022 was 15.5% (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: 15.9%). The rate has benefited from the closure of open issues with tax authorities in various jurisdictions. Subject to any material changes in our product mix, or other material changes in tax regulations or laws in the countries in which we operate, the Group&#8217;s average effective Adjusted tax rate for 2023 is expected to be around 15%. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s Total tax rate for 2022 of 12.6% (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: 2.3%) was lower than the Adjusted tax rate reflecting the different tax effects of various Adjusting items. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK Government has confirmed that the Spring Finance Bill 2023 will include legislation introducing a 15% global minimum corporate income tax rate, to have effect from 2024. The detail of the measures and how they are to be accounted for is still being finalised and so it is not possible to accurately quantify the impact for GSK at this stage. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Further details about our corporate tax charges for the year are set out in Note 14. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">92</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div><div id="ex15_2tx382677_62" style="margin-top: 10pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Treasury policies</div> </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We report in Sterling and pay dividends out of Sterling cash flows. The role of Treasury is to monitor and manage the Group&#8217;s external and internal funding requirements and financial risks in support of our strategic objectives. GSK operates on a global basis, primarily through subsidiary companies, and we manage our capital to ensure that our subsidiaries are able to operate as going concerns and to optimise returns to shareholders through an appropriate balance of debt and equity. Treasury activities are governed by policies approved annually by the Board of Directors, and most recently on 12&#160;October 2022. A Treasury Management Group (TMG) meeting, chaired by our Chief Financial Officer, takes place on a regular basis to review Treasury activities. Its members receive management information relating to these activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury operations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The objective of GSK&#8217;s Treasury activities is to minimise the post-tax net cost of financial operations and reduce its volatility in order to benefit earnings and cash flows. GSK uses a variety of financial instruments to finance its operations and derivative financial instruments to manage market risks from these operations. Derivatives principally comprise foreign exchange forward contracts and swaps which are used to swap borrowings and liquid assets into currencies required for Group purposes, as well as interest rate swaps which are used to manage exposure to financial risks from changes in interest rates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives are used exclusively for hedging purposes in relation to underlying business activities and not as trading or speculative instruments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s financial strategy, implemented through the Group&#8217;s financial architecture, supports GSK&#8217;s strategic priorities and is regularly reviewed by the Board. We manage the capital structure of the Group through an appropriate mix of debt and equity. We continue to manage our financial policies to a credit profile that particularly targets short-term credit ratings of A-1 and P-1 while maintaining single A long-term ratings consistent with those targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s long-term credit rating with Standard and Poor&#8217;s is A (stable outlook) and with Moody&#8217;s Investor Services (&#8216;Moody&#8217;s&#8217;) is A2 (stable outlook). Our short-term credit ratings are A-1 and P-1 with Standard and Poor&#8217;s and Moody&#8217;s respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s policy is to borrow centrally in order to meet anticipated funding requirements. Our cash flow forecasts and funding requirements are monitored by the TMG on a regular basis. Our strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each day, we sweep cash to or from number of global subsidiaries to central Treasury accounts for liquidity management purposes. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating interest rates over time. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the Board. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our objective is to minimise the exposure of overseas operating subsidiaries to transaction risk by matching local currency income with local currency costs where possible. Foreign currency transaction exposures arising on external and internal trade flows are selectively hedged. GSK&#8217;s internal trading transactions are matched centrally and we manage inter-company payment terms to reduce foreign currency risk. Where possible, we manage the cash surpluses or borrowing requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating currency. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In order to reduce foreign currency translation exposure, we seek to denominate borrowings in the currencies of our principal assets and cash flows. These are primarily denominated in US Dollars, Euros and Sterling. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Borrowings can be swapped into other currencies as required. Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated as a hedge against the relevant assets. Forward contracts in major currencies are also used to reduce exposure to the Group&#8217;s investment in overseas Group assets. The TMG reviews the ratio of borrowings to assets for major currencies regularly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commodity risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our objective is to minimise income statement volatility arising from fluctuations in commodity prices, where practical and cost effective to do so. The TMG is authorised to approve the execution of certain financial derivatives to hedge commodity price exposures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Counterparty risk management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We set global counterparty limits for each of our banking and investment counterparties based on long-term credit ratings from Moody&#8217;s and Standard and Poor&#8217;s. Usage of these limits is actively monitored and any breach of these limits would be reported to the Chief Financial Officer immediately. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, relationship banks and their credit ratings are reviewed regularly so that, when changes in ratings occur, changes can be made to investment levels or to authority limits as appropriate. All banking counterparty limits are reviewed at least annually. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">93</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #ec660a">&#160;</div><div id="ex15_2tx382677_63" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Critical accounting policies </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group consolidated financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The critical accounting policies relate to the following areas: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Turnover </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Taxation (Note 14) </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Legal and other disputes (Notes 47) </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Contingent liabilities (Note 35) </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Pensions and other post-employment benefits (Note 31) </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Information on the judgements and estimates made in these areas is given in Note 3 to the financial statements, &#8216;Critical accounting judgements and key sources of estimation uncertainty&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In respect of the Turnover accounting policy, our largest business is US Commercial Operations, and the US market has the most complex arrangements for rebates, discounts and allowances. The following briefly describes the nature of the arrangements in existence in our US Commercial Operations: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">We have arrangements with certain indirect customers whereby the customer is able to buy products from wholesalers at reduced prices. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer&#8217;s contractual discounted price. Accruals for estimating chargebacks are calculated based on the terms of each agreement, historical experience and product growth rates </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Customer rebates are offered to key managed care and Group Purchasing Organisations and other direct and indirect customers. These arrangements require the customer to achieve certain performance targets relating to the value of product purchased, formulary status or pre-determined market shares relative to competitors. The accrual for customer rebates is estimated based on the specific terms in each agreement, historical experience and product growth rates </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The US Medicaid programme is a state-administered programme providing assistance to certain poor and vulnerable patients. In 1990, the Medicaid Drug Rebate Program was established to reduce state and federal expenditure on prescription drugs. In 2010, the Patient Protection and Affordable Care Act became law. We participate by providing rebates to states. Accruals for Medicaid rebates are calculated based on the specific terms of the relevant regulations or the Patient Protection and Affordable Care Act </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Cash discounts are offered to customers to encourage prompt payment. These are accrued for at the time of invoicing and adjusted subsequently to reflect actual experience </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">We record an accrual for estimated sales returns by applying historical experience of customer returns to the amounts invoiced, together with market-related information such as stock levels at wholesalers, anticipated price increases and competitor activity </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A reconciliation of gross turnover to net turnover for US Commercial Operations is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Margin<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">Margin<br/>%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">Margin<br/>%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,814</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market-driven segments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,275</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,875</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government mandated and state programmes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,218</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash discounts</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(536</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(453</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Customer returns</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(255</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(253</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Prior year adjustments</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">780</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other items</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(768</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(560</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total deductions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,272</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(51</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,518</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,422</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net turnover</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,542</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,914</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,148</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reconciliation has been revised to include Vaccines as part of US Commercial Operations in all years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Market-driven segments consist primarily of managed care and Medicare plans with which we negotiate contract pricing that is honoured via rebates and chargebacks. Mandated segments consist primarily of Medicaid and federal government programmes which receive government-mandated pricing via rebates and chargebacks. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">94</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Group financial review continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Critical accounting policies</div></div></div><div style="font-family: ARIAL; color: rgb(113, 98, 88); letter-spacing: 0px; top: 0px;;display:inline;"> continued </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Overall sales deduction as a percentage of sales is consistent year over year with sales growth coming primarily from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div> and Specialty Products including ViiV. Deductions within the year were split approximately as follows: General Medicines 70%, Specialty Medicines 20% and Vaccines 10%. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the total accrual for rebates, discounts, allowances and returns for US Commercial Operations amounted to &#163;5,855&#160;million (2021: &#163;5,044 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A monthly process is operated to monitor inventory levels at wholesalers for any abnormal movements. This process uses gross sales volumes, prescription volumes based on third party data sources and information received from key wholesalers. The aim of this is to maintain inventories at a consistent level from year to year based on the pattern of consumption. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On this basis, US Commercial Operations inventory levels at wholesalers and in other distribution channels at 31&#160;December 2022 were estimated to amount to approximately four weeks of turnover. This calculation uses third party information, the accuracy of which cannot be totally verified, but is believed to be sufficiently reliable for this purpose. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In respect of the accounting policy for Legal and other disputes, the following briefly describes the process by which we determine the level of provision that is necessary. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In accordance with the requirements of IAS 37, &#8216;Provisions, contingent liabilities and contingent assets&#8217;, we provide for anticipated settlement costs where an outflow of resources is considered probable and a reliable estimate may be made of the likely outcome of the dispute and legal and other expenses arising from claims against the Group. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We may become involved in significant legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, appropriate disclosure about such cases would be included in the Annual Report, but no provision would be made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This position could change over time and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial statements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Like many pharmaceutical companies, we are faced with various complex product liability, anti-trust and patent litigation, as well as investigations of our operations conducted by various governmental regulatory agencies. Throughout the year, the General Counsel of the Group, as head of the Group&#8217;s legal function, and the Senior Vice President and Head of Global Litigation for the Group, who is responsible for all litigation and government investigations, routinely brief the Chief Executive Officer, the Chief Financial Officer and the Board of Directors on the significant litigation pending against the Group and governmental investigations of the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These meetings, as appropriate, detail the status of significant litigation and government investigations and review matters such as the number of claims notified to us, information on potential claims not yet notified, assessment of the validity of claims, progress made in settling claims, recent settlement levels and potential reimbursement by insurers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The meetings also include an assessment of whether or not there is sufficient information available for us to be able to make a reliable estimate of the potential outcomes of the disputes. Often, external counsel assisting us with various litigation matters and investigations will also assist in the briefing of the Board and senior management. Following these discussions, for those matters where it is possible to make a reliable estimate of the amount of a provision, if any, that may be required, the level of provision for legal and other disputes is reviewed and adjusted as appropriate. These matters are discussed further in Note 47 to the financial statements, &#8216;Legal proceedings&#8217;. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #ec660a">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strategic report </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Strategic report was approved by the Board of Directors on </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Chief Financial Officer </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_01b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">95</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="" src="g382677f_96.jpg" style="width: 778px; height: 1100px;"/><br/></div><div style="font-size:-850pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:-850pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:89%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:27%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:27%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:27%"></td></tr>
<tr style="font-size:1pt">
<td style="height:24pt"></td>
<td colspan="2" style="height:24pt"></td>
<td colspan="2" style="height:24pt"></td>
<td colspan="2" style="height:24pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="font-size: 7.5pt; color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:54.75pt"></td>
<td colspan="2" style="height:54.75pt"></td>
<td colspan="2" style="height:54.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="vertical-align:top"><div id="ex15_2tx382677_22" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 60pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Corporate</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 60pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">governance</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:4.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In this section</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_64a" style="color:White">The Board and GSK Leadership Team</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;97</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_65" style="color:White">Chair&#8217;s governance statement</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;103</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_66" style="color:White">Corporate governance architecture</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;107</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_67" style="color:White">Ahead Together &#8211; Board oversight</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;110</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_68" style="color:White">Key decisions and engagements</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;112</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_69" style="color:White">Board committee reports</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;117</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_70" style="color:White">Directors&#8217; report</a></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;130</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:351.75pt"></td>
<td colspan="2" style="height:351.75pt"></td>
<td colspan="2" style="height:351.75pt"></td>
<td colspan="2" style="height:351.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr></table></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:36pt; margin-top:0pt; margin-bottom:0pt"><br/></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 20pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_64a" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_23a" style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div id="ex15_2tx382677_23" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>The Board </div></div><div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:64%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds, CBE</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Non-Executive Chair</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 64</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> British</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;September 2019</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_97a.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jon has extensive international financial, life sciences and governance experience.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jon served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG. His governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc, Non-Executive Chair of Proteus Digital Health Inc and Non-Executive Director of Rubius Therapeutics, Inc.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jon is a Fellow of the Institute of Chartered Accountants in England and Wales.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-Executive Director, Genomics England Limited having previously served as its Chairman; Non-Executive Chair, Energy Aspects; Member, European Round Table for Industry; Senior Advisor to Chatham House.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dame Emma Walmsley</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Executive Officer</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 53</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> British</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;January 2017</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Chief Executive Officer from</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1&#160;April 2017</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to her appointment as GSK&#8217;s CEO, Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis, from its creation in March 2015. Emma joined GSK in 2010 from L&#8217;Oreal, having worked for 17 years in a variety of roles in Paris, London, New York and Shanghai. Emma was previously a Non-Executive Director of Diageo plc.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma holds an MA in Classics and Modern Languages from Oxford University.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Independent director, Microsoft, Inc.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Financial Officer</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 61</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> British</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 14&#160;January 2019</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Chief Financial Officer from</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1&#160;April 2019</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to joining GSK, Iain was Group Finance Director at HSBC Holdings plc, a position he held for eight years. A chartered accountant, Iain has lived and worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse. Iain was previously a Trustee of the British Heart Foundation and Chair of its Audit and Risk Committee.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain holds an MA in Business Studies and Accounting and holds an Honorary Doctorate from Aberdeen University in Scotland.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain is a member of the Institute of Chartered Accountants of Scotland.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain will step down as CFO and Executive Director on 1 May 2023. He will continue as an employee and leave the company on 31 December 2023.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Non-Executive Director, Chair of Audit &amp; Risk Committee and member of Remuneration Committee, National Grid plc; Member, Court of the University of Aberdeen and Chair of its Remuneration Committee; Member, The 100 Group and Chair of its Stakeholder Communications and Reporting Committee.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Elizabeth (Liz) McKee Anderson</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent Non-Executive Director</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 65</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;September 2022</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_97b.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liz brings significant experience in commercial biopharmaceuticals and is a seasoned biotech board member. Her significant experience in commercial biopharmaceuticals, both operationally and at Board level, as well as her deep understanding of the biotechnology sector are invaluable to GSK as a pure biopharma company.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to her current roles, Liz served as Worldwide Vice President and commercial leader in infectious diseases and vaccines and also for immunology and oncology at Janssen Pharmaceuticals, and as Vice President and General Manager at Wyeth Vaccines. Liz was also previously a Board member of Bavarian Nordic A/S and of Huntsworth Plc.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Board Member, BioMarin Pharmaceutical, Inc; Board Member, Revolution Medicines, Inc; Board Member, Insmed, Inc; Trustee, The Wistar Institute; Director, Aro Biotherapeutics Company.</div></td></tr></table><div style="margin-top:180pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL"><div style="font-family: ARIAL; font-size: 7.5pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key</div></div> </div><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="LOGO" src="g382677f_97c.jpg"/> Committee Chair
<img alt="LOGO" src="g382677f_97d.jpg"/> Corporate Responsibility
<img alt="LOGO" src="g382677f_97e.jpg"/> Science
<img alt="LOGO" src="g382677f_97f.jpg"/> Nominations&#160;&amp; Corporate Governance
<img alt="LOGO" src="g382677f_97g.jpg"/> Audit&#160;&amp; Risk
<img alt="LOGO" src="g382677f_97h.jpg"/> Remuneration </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size: 40pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">97</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 64%;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charles Bancroft</div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Independent Non-Executive</div></div><div style="font-family: ARIAL; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 63</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;May 2020</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Independent Non-Executive Director</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">from 18&#160;July 2022</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_98a.jpg" style="width: 54px; height: 17px;"/></div> </div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charlie has a wealth of financial and management experience in global biopharma.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charlie retired from a successful career at Bristol Myers Squibb (BMS) in March 2020 where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held positions of increasing responsibility within the finance organisation and had commercial operational responsibility for Latin America, Middle East, Africa, Canada, Japan and several Pacific Rim countries. He was appointed Chief Financial Officer in 2010, Chief Financial Officer and Executive Vice President, Global Business Operations in 2016 and Executive Vice President and Head of Integration and Strategy &amp; Business Development in 2019. Charlie successfully steered BMS through a period of strategic transformation, including its $74 billion acquisition of Celgene. Charlie also served as a member of the Board of Colgate-Palmolive Company from 2017 until March 2020.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Member, Kodiak Sciences Inc; Board Member, BioVector Inc; Advisory Board Member, Drexel University&#8217;s LeBow College of Business.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board determined that Charlie has recent and relevant financial experience and agreed that he has the appropriate qualifications and background to be an audit committee financial expert.</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 12pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron</div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive Director</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 60</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;January 2018</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Scientific Officer and</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">President, R&amp;D from 1&#160;April 2018</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Transitioned to the role of Non-Executive</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director on 1&#160;August 2022</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_98b.jpg" style="width: 19px; height: 19px;"/></div> </div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 12pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Hal joined GSK in 2018 as Chief Scientific Officer and President, R&amp;D. On 1 August 2022, he transitioned to the role of Non-Executive Director, with additional responsibilities to support R&amp;D.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to joining GSK, Hal was President, R&amp;D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Hal was a Non-Executive Director and Chair of the Science &amp; Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. Hal previously served as a Non-Executive Board Director of GRAIL, Inc and an Advisory Board Member of Verily Life Sciences LLC.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">CEO and Board Co-Chair, Altos Labs Inc; Associate Adjunct Professor, Epidemiology &amp; Biostatistics, University of California, San Francisco.</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Anne Beal</div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Independent Non-Executive Director</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 60</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 6&#160;May 2021</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_98c.jpg" style="width: 52px; height: 16px;"/></div> </div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Anne brings extensive healthcare experience to the Board as a physician and entrepreneur combined with a passion for patient advocacy. She is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to her current roles, Anne spent six years at Harvard Medical School and Massachusetts General Hospital, where she was an instructor in paediatrics. She has also held leadership roles at the Commonwealth Fund and the Aetna Foundation. Anne was previously Deputy Executive Director and Chief Engagement Officer for The Patient-Centered Outcomes Research Institute in the US and Chief Patient Officer and Global Head of Patient Solutions at Sanofi.</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder and CEO, AbsoluteJOI Skincare; Board Member, AcademyHealth; Board Member, Prolacta Bioscience.</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 180pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="color: rgb(243, 111, 33); font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Key</div></div></div> <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97c.jpg" style="width: 13px; height: 13px;"/></div> Committee Chair <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97d.jpg" style="width: 15px; height: 15px;"/></div> Corporate Responsibility <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97e.jpg" style="width: 15px; height: 15px;"/></div> Science <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97f.jpg" style="width: 15px; height: 15px;"/></div> Nominations&#160;&amp; Corporate Governance <div style="font-style:italic;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97g.jpg" style="width: 15px; height: 15px;"/></div></div> Audit&#160;&amp; Risk <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_97h.jpg" style="width: 15px; height: 15px;"/></div> Remuneration </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc"></a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">The Board continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:64%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Harry (Hal) C Dietz</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">and Scientific&#160;&amp; Medical Expert</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 64</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;January 2022</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_99a.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33);;display:inline;"><div style="font-weight: bold;;display:inline;">Skills and experience</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;">Hal brings extensive experience in the field of human genetics which is central to GSK&#8217;s approach to R&amp;D. He is a former President of the American Society of Human Genetics and is recognised as the world&#8217;s leading authority on a genetic disorder known as Marfan Syndrome. He also brings experience in development of novel therapies, in particular in relation to disease-modifying treatments for fibrotic and neurodegenerative diseases. In total, Hal has authored 282 original publications in peer-reviewed journals across his career.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;">As a physician scientist, he has dedicated his entire career to the care and study of individuals with heritable connective tissue disorders with primary perturbations of extracellular matrix homeostasis and function. His lab has identified the genes for many of these conditions, for which he uses model systems to elucidate disease mechanisms.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;">Hal has received multiple prestigious awards including the Curt Stern Award from the American Society of Human Genetics, the Colonel Harland Sanders Lifetime Achievement Award in Medical Genetics, the Taubman Prize for excellence in translational medical science, the Harrington Prize from the American Society for Clinical Investigation and the Harrington Discovery Institute, the Pasarow Award in Cardiovascular Research, the InBev-Baillet Latour Health Prize from the country of Belgium, and the Research Achievement Award from the American Heart Association.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;">He is an inductee of the American Society for Clinical Investigation, American Association for the Advancement of Science, Association of American Physicians, National Academy of Medicine, and National Academy of Sciences.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33);;display:inline;"><div style="font-weight: bold;;display:inline;">External appointments</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;">Victor A. McKusick Professor of Paediatrics, Medicine, and Molecular Biology &amp; Genetics in the Department of Genetic Medicine, The Johns Hopkins University School of Medicine; Investigator, Howard Hughes Medical Institute; Consultant and Chair of Scientific Advisory Board, Aytu Biopharma; Independent Chair, GSK&#8217;s Human Genetics Scientific Advisory Board; founded and previously Scientific Adviser to Blade Therapeutics.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Jesse Goodman</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">and Scientific&#160;&amp; Medical Expert</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 71</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;January 2016</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_99b.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jesse brings scientific and public health expertise to the Board&#8217;s deliberations. He has a wealth of experience spanning science, medicine, vaccines, regulation and public health, and has a proven record in addressing pressing public health needs from both the academic and federal sectors.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jesse previously served in senior leadership positions at the US Food and Drug Administration (FDA), including most recently as the FDA&#8217;s Chief Scientist and previously as Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research (CBER).</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Jesse played a leadership role in developing the FDA&#8217;s Regulatory Science and Medical Countermeasures Initiatives and has worked collaboratively with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led the FDA&#8217;s response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. Jesse was previously a member of both the Scientific Advisory Committee and the Regulatory and Legal Working Group of the Coalition for Epidemic Preparedness Innovations (CEPI).</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Professor of Medicine and Attending Physician, Infectious Diseases, Georgetown University and directs the Georgetown University Center on Medical Product Access, Safety and Stewardship (COMPASS); Board Member (formerly President), United States Pharmacopeia (USP); Board Member, Scientific Counselors for Infectious Diseases, Centers for Disease Control and Prevention (CDC); Board Member, Intellia Therapeutics Inc; Member, US National Academy of Medicine; Board Member, Adaptive Phage Therapeutics, Inc.</div></td></tr></table><div style="margin-top:180pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Key</div></div></div>
<img alt="LOGO" src="g382677f_97c.jpg"/> Committee Chair
<img alt="LOGO" src="g382677f_97d.jpg"/> Corporate Responsibility
<img alt="LOGO" src="g382677f_97e.jpg"/> Science
<img alt="LOGO" src="g382677f_97f.jpg"/> Nominations&#160;&amp; Corporate Governance
<img alt="LOGO" src="g382677f_97g.jpg"/> Audit&#160;&amp; Risk
<img alt="LOGO" src="g382677f_97h.jpg"/> Remuneration </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">99</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">The Board continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:64%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Urs Rohner</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 63</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> Swiss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 1&#160;January 2015</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_100a.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Urs has a broad business, banking and legal background and extensive senior level experience at multinational companies.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Urs has served as Chairman on a number of Boards, most recently for Credit Suisse Group from 2011 until April 2021. Prior to joining Credit Suisse in 2004, Urs served as Chairman of the Executive Board and CEO of ProSieben and ProSiebenSat.1 Media AG. This followed a number of years in private practice at major law firms in Switzerland and the US, having been admitted to the bars of the canton of Zurich in Switzerland in 1986 and the state of New York in the US in 1990.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Member, International Advisory Board, Investcorp; Chair, Vega Cyber Associates AG.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Vishal Sikka</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age:</div></div> 55</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nationality:</div></div> American</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointed:</div></div> 18&#160;July 2022</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">
<img alt="LOGO" src="g382677f_100b.jpg"/> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vishal has a distinguished background in technology and particularly in the field of Artificial Intelligence (AI) and Machine Learning, which is central to GSK&#8217;s approach to R&amp;D. He is the founder and CEO of Vianai Systems, Inc, a Silicon Valley-based company that provides advanced technological software and services in AI and Machine Learning to large enterprises around the world.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to founding Vianai Systems, Vishal served as CEO of Infosys Limited and as a member of the Executive Board of SAP SE. Vishal has a PhD in Artificial Intelligence from Stanford University and has <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-authored</div> several research abstracts related to AI, technology and database management.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External appointments</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Founder and CEO, Vianai Systems, Inc; Board Member, Oracle Corporation; Member, Supervisory Board, BMW AG.</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Key</div></div></div>
<img alt="LOGO" src="g382677f_97c.jpg"/> Committee Chair
<img alt="LOGO" src="g382677f_97d.jpg"/> Corporate Responsibility
<img alt="LOGO" src="g382677f_97e.jpg"/> Science
<img alt="LOGO" src="g382677f_97f.jpg"/> Nominations&#160;&amp; Corporate Governance
<img alt="LOGO" src="g382677f_97g.jpg"/> Audit&#160;&amp; Risk
<img alt="LOGO" src="g382677f_97h.jpg"/> Remuneration </div><div style="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors departing during 2022 </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:22%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:55%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Manvinder&#160;Singh&#160;(Vindi)&#160;Banga&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Sept 2016 to July 2022</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">Retired from the Board on appointment to the Haleon plc Board effective on demerger</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Dame Vivienne Cox</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1&#160;July&#160;2016&#160;to&#160;18&#160;July&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Lynn Elsenhans</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1&#160;July 2012&#160;to&#160;18&#160;July&#160;2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Retired from the Board after nine years of service</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Dr Laurie Glimcher</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Sept 2017 to 10 Oct 2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Retired from the Board after over five years of service</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">GSK Leadership Team (GLT) </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:64%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Executive Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Emma joined GSK in 2010 and the GLT in 2011. See Board biographies on pages 97 to 100.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">1 </div></div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Financial Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Iain joined GSK and the GLT in 2019. See Board biographies on pages 97 to 100.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diana Conrad</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief People Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diana was appointed Chief People Officer and member of the GLT in April 2019. She was previously Senior Vice President, HR, Pharmaceuticals R&amp;D from 2016 where she played a key strategic role as leader of the R&amp;D people and culture agenda to support its transformation.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diana joined GSK Canada&#8217;s HR team in 2000 where she held several roles of increasing responsibility before becoming Senior Vice President, HR for Consumer Healthcare in 2009.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to joining GSK, she held HR roles in companies including GE Capital, Gennum Corporation and Zenon Environmental Laboratories. Diana has an Honours Bachelor of Arts from McMaster University in Canada.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">James Ford</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">SVP and Group General Counsel,</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Legal and Compliance</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">James joined the GLT in 2018, when he was appointed Senior Vice President and Group General Counsel, later taking responsibility for Compliance, Corporate Security and Investigations in 2021. He joined GSK in 1995 and has served as General Counsel Consumer Healthcare, General Counsel Global Pharmaceuticals, Vice President of Corporate Legal and was Acting Head of Global Ethics and Compliance. Prior to GSK, James was a solicitor at Clifford Chance and DLA. He holds a law degree from the University of East Anglia and a Diploma in Competition Law from King&#8217;s College. He is qualified as a solicitor in England and Wales and is an attorney at the New York State Bar. James is based in London and has practised law and lived in the US, Singapore and Hong Kong. James was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-chair</div> of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> Civil Justice Reform Group 2019-2022, and is a director of the European General Counsel Association and the Association of Corporate Counsel.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sally Jackson</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">SVP, Global Communications<br/>and CEO Office</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sally joined the GLT in March 2019 as Senior Vice President, Global Communications and CEO Office. She leads our Communications and Government Affairs function globally and is also the CEO&#8217;s Chief of Staff.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prior to this, Sally was Senior Vice President, Office of the CEO and CFO and she previously served as Head of Investor Relations. She joined GSK in 2001.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sally holds a degree in Natural Sciences from the University of Cambridge.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Luke Miels</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Commercial Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Luke joined GSK and the GLT in 2017. As Chief Commercial Officer he is responsible for our commercial portfolio of medicines and vaccines. Luke also <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-chairs</div> the Portfolio Investment Board with Tony Wood and is a member of the ViiV Healthcare Board. Outside of GSK, Luke is a member of the Singapore Economic Development Board.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">He previously worked for AstraZeneca as Executive Vice President of their European business and, prior to that, was Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs. Before that, he was head of Asia for Roche, based in Shanghai and then Singapore. Prior to that he held roles of increasing seniority at Roche and Sanofi-Aventis in the US, Europe and Asia.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Luke holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and a MBA from the Macquarie University, Sydney.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shobie Ramakrishnan</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Digital and Technology Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shobie joined the GLT in 2021 when she was appointed Chief Digital and Technology Officer. She joined GSK in 2018 and has deep and broad experience in both biotech and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hi-tech</div> companies and, most recently, has led Digital and Technology for GSK&#8217;s Global Commercial organisation, transforming the company&#8217;s capabilities in digital, data and analytics and playing a pivotal role in establishing a more agile commercial operating model. Before joining GSK, Shobie held senior technology leadership roles in organisations including AstraZeneca, Salesforce, Genentech and Roche. She is a former member of the board of directors at Remediant and is a member of the board of directors at SustainableIT.org.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shobie holds a Bachelor&#8217;s degree in Electronics Engineering from Vellore Institute of Technology, University of Madras, India.</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL">1 Iain Mackay will step down from the Board and GLT from 2023. He will be succeeded as CFO by Julie Brown. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Leadership Team continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:64%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Skills and experience</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">David Redfern</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">President, Corporate Development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">David joined the GLT as Chief Strategy Officer in 2008 and is responsible for corporate development and strategic planning. Previously, he was Senior Vice President, Northern Europe with responsibility for GSK&#8217;s pharmaceutical businesses in that region and, before that, he was Senior Vice President for Central and Eastern Europe. He joined GSK in 1994. David was appointed Chairman of the Board of ViiV Healthcare Limited in 2011 and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director of the Aspen Pharmacare Holdings Limited Board in 2015.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">He has a Bachelor of Science degree from Bristol University and is a Chartered Accountant.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regis Simard</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">President, Global Supply Chain</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Regis joined the GLT in 2018, when he became President, Pharmaceuticals Supply Chain.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">He is responsible for the manufacturing and supply of GSK&#8217;s medicines and vaccines. In addition, he leads Quality and Environment, Health, Safety and Sustainability at a corporate level. Regis joined GSK in 2005 as a Site Director in France, rising to become Senior Vice President of Global Pharmaceuticals Manufacturing before his current role. Previously, he held senior positions at Sony, Konica Minolta and Tyco Healthcare. He is a member of the Board of ViiV Healthcare.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">He is a mechanical engineer and holds an MBA.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phil Thomson</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">President, Global Affairs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Phil joined the GLT in 2011. He was appointed President, Global Affairs in 2017, and has responsibility for the Group&#8217;s strategic approach to stakeholder engagement, reputation and policy development. Previously, Phil was Senior Vice President, Communications and Government Affairs. He joined Glaxo Wellcome as a commercial trainee in 1996.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Phil is also Chair of The Whitehall&#160;&amp; Industry Group and holds a degree in English, History and Russian Studies from Durham University.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deborah Waterhouse</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">CEO, ViiV Healthcare and President,</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">GSK Global Health</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deborah was appointed to the GLT in January 2020. She became Chief Executive Officer of ViiV Healthcare in April 2017. In addition to ViiV, Deborah also leads GSK&#8217;s Global Health organisation.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deborah joined GSK in 1996 and, prior to ViiV, was the Senior Vice President of Primary Care within GSK&#8217;s US business. She has a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe and held roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deborah is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director of Schroders plc and holds a degree in Economic History and English Literature from Liverpool University.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tony Wood</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chief Scientific Officer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tony was appointed Chief Scientific Officer (CSO) designate on 19&#160;January 2022 and became CSO, Head of R&amp;D and a member of GLT on 1&#160;August 2022. He joined GSK from Pfizer in 2017 as Senior Vice President, Medicinal Science and Technology, responsible for all science and technology platforms driving the delivery of new innovation.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tony has led large-scale global organisations in drug discovery and development in multiple therapeutic areas, including immunology, oncology and infectious diseases. During his time at Pfizer, Tony was responsible for the invention of a new antiretroviral medication used to treat HIV infection. He is a Fellow of the Academy of Medical Sciences, an Honorary Fellow of the Royal Society of Chemistry (RSC), the highest honour given by the RSC, and a Fellow of the Royal Society of Biology.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tony has a BSc in chemistry and PhD in organic synthesis from the University of Newcastle, and was a postdoctoral fellow at Imperial College, London. He is also currently a visiting professor at IMCM Oxford.</div></td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GLT members departing during 2022 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL">Hal Barron was a member of the GLT and Chief Scientific Officer until 1&#160;August 2022, when he transitioned to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director. Roger Connor was a member of the GLT and President, Global Vaccines until 1&#160;December 2022, when he left the company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">102</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 20pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_24" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_65" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Chair&#8217;s governance statement </div></div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 was one of the most important years in GSK&#8217;s recent history which saw the delivery of strong operational and financial performance, the successful demerger of Consumer Healthcare and the establishment of new GSK as a fully focused global biopharma company. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There was an intensity to the Board&#8217;s work in supporting and overseeing this, which required a number of additional meetings to be scheduled, as illustrated below. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 10.00pt #e7e7e8;border-radius:6pt; background-color:;padding-top:2pt;padding-bottom:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:97%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Board activity</div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 4pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-demerger</div> (1 January to 17 July)</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Routine</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional*&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Board</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nominations&#160;&amp; Corporate Governance</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Science</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporate Responsibility</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Audit&#160;&amp; Risk</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Remuneration</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Chairs&#8217;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">5</td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">*Additional activity: </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3.75pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Development and approval of demerger documentation and forecast </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3.75pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Haleon plc (Haleon): Chair appointment and Board development </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3.75pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK Remuneration policy development and investor approval </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3.75pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK Board development and CSO succession </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3.75pt">&#160;</td>
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Business development </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:98%;border:0">
<tr style="font-size: 0px;">
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 4pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Post-demerger (18 July to 31 December)</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #f36f21;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Routine</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional*&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Board</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nominations&#160;&amp; Corporate Governance</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Science</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporate Responsibility</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Audit&#160;&amp; Risk</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Remuneration</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Chairs&#8217;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1</td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">*Additional activity: </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">CFO succession </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div>litigation </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Business development </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executing the demerger and creating new GSK </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board&#8217;s work in the first half of the year was primarily occupied in overseeing the smooth execution of the demerger of Consumer Healthcare from GSK, resulting in the creation of two strong businesses. This culminated in the approval of the GSK Circular and the Haleon Prospectus which were overwhelmingly approved by shareholders at the General Meeting in July, with over 99% of votes cast in favour. This work </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">included, at its heart, a robust focus on shareholder value creation embodied in the ambitions for both companies. These were communicated in the investor updates in February 2022 for Haleon and previously in June 2021 for GSK. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 10.00pt #e7e7e8;border-radius:6pt; background-color:;padding-top:2pt;padding-bottom:3pt"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:60%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45em; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 separation process</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 1.53em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Disciplined Board approach to deliver demerger</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1.53em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Creation of world-leading consumer healthcare business with competitive long-term growth prospects and compelling financial proposition</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1.53em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Newly focused GSK with strengthened balance sheet for investment in pipeline/R&amp;D</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 1pt; margin-left: 1.53em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Both companies with clear targets for upper-quartile growth, set out at Investor Updates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 5em; text-align: center; line-height: normal;">
<img alt="LOGO" src="g382677f_103b.jpg"/> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td></tr></table></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:45pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Chair&#8217;s governance statement continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At our investor updates, we set out what we believed to be competitive financial aspirations for new GSK. Namely: cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> growth of 5% and operating profit growth of 10% (excluding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> solutions), together with an aspiration of &#163;31&#160;billion to &#163;33&#160;billion of sales by 2031. This was not an ambition that the Board entered into lightly. It was a very important demonstration of the confidence the Board has in the business and our determination to be held accountable for a step-change in improved performance. 2022&#8217;s strong operational and financial performance is a good platform to progress from. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Similarly, for Haleon, the focus was on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> growth aspiration to signal that the business had upper quartile growth potential. This view was robustly tested when an unsolicited conditional and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> proposal to acquire the Consumer Healthcare business was received. In exercising its fiduciary duties all proposals were evaluated but rejected by the Board as they were not in the best interests of shareholders. This is because the proposals fundamentally undervalued the Haleon business and its future prospects. The Board was confident that Haleon could deliver sustained organic sales growth in the range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-6%</div> CER over the medium term. It has been very pleasing to see that since separation, Haleon has subsequently announced strong performance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A key part of our aspiration for GSK was the restructuring of the GSK balance sheet with an appropriate level of debt for Haleon. This sought to ensure the competitiveness of both companies on separation and GSK&#8217;s ability to continue to invest in external as well as internal science was improved. The refinancing of approximately &#163;10&#160;billion of indebtedness was successfully completed in the first quarter of 2022. This timing was opportune given the current environment. GSK received &#163;7.1&#160;billion of pre-separation dividends attributable to GSK funded by Consumer Healthcare debt and we continue to hold 13.5% of Haleon shares, which will be divested in due course. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">R&amp;D and business development </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I have also previously described the succession process we followed for the CSO transition from Dr Hal Barron to Dr Tony Wood. We are very pleased with how smooth this process has been and that we are making good progress in R&amp;D. The Board receives regular reports on R&amp;D from Dr Wood as well as from the Science Committee, following its reviews. Progress is achieved by organic and inorganic business development (BD). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We now have an efficient Board cadence for BD to support R&amp;D. The scientific screening of a target is undertaken first by the Science Committee, well in advance of the Board&#8217;s consideration. This is to ensure that we are confident with the scientific rationale underpinning a deal before progressing to the Board. If the proposal is for a late or later stage target or asset, we then also undertake a commercial review of the forecasts and the commercial assumptions underpinning it. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We consider deals in respect of their contribution to our ambitions for the periods: to 2026, 2026 to 2031, and beyond. The Board can then review the proposal knowing that these important aspects have been established. We then focus on the value associated with the transaction and how it contributes to furthering our strategy and plan. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, this process included the appraisal and approval of the acquisitions of: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sierra Oncology</div></div>, a biopharmaceutical company focused on targeted therapies for rare forms of cancer. The acquisition included momelotinib, a new medicine with a unique dual mechanism of action intended to address the critical unmet medical needs of myelofibrosis patients with anaemia </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Affinivax</div></div>, a clinical stage biopharmaceutical company providing GSK with access to a next generation pneumococcal vaccine candidate and a highly innovative Multiple Antigen Presenting System, known as MAPS </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other transactions reviewed by the Board included: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a licensing agreement with Spero Therapeutics for tebipenem HBr, a late-stage antibiotic targeted to treat complicated urinary tract infections; a significant unmet medical need </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a collaboration with Wave Life Sciences, bringing together Wave&#8217;s oligonucleotide platform and GSK&#8217;s expertise in genetics and genomics </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a collaboration with Tempus to provide GSK with access to Tempus&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-enabled</div> platform, including its library of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-identified</div> patient data &#8211; one of the world&#8217;s largest sources of clinical and molecular data </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholder perspectives and engagement </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board believes in the importance of maintaining a high and continuous level of engagement with shareholders. During 2022 and up to the date of publication of this Report, I held 27 individual meetings with a range of investors, who make up approximately 35% of the company&#8217;s share register. Charles Bancroft, who was appointed our new SID after the demerger, has held 14 introductory meetings with shareholders making up over 25% of our register. We were also pleased to be able to hold our Annual Governance Meeting in London in December 2022 as an &#8216;in person&#8217; meeting once again. We extended an invitation to shareholders representing holdings totalling approximately 50% of our share register to this event and were pleased that representatives of over 25% participated virtually or in person. It is of prime importance for us to maintain a clear understanding of investors&#8217; views on the company&#8217;s performance. These meetings help achieve that and provide a key input to our Board planning. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">104</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Chair&#8217;s governance statement continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 10.00pt #e7e7e8;border-radius:6pt; background-color:;padding-top:2pt;padding-bottom:3pt"><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; padding-top:3pt; margin-left:1%; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023 Board priorities </div></div></div></div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1%; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Externally facilitated Board review to agree priorities and ways of working </div></div><div style="margin-top:6pt; margin-bottom:0pt; padding-bottom:3pt; margin-left:1%; font-size:8.5pt; font-family:ARIAL">Focus on value creation, governance and oversight of Ahead Together strategy: </div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Delivery of performance targets </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Execution of R&amp;D pipeline and business development </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Long-term R&amp;D strategy and approach </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">People/Talent/Culture </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">ESG Leadership </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt">&#160;</td>
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div>litigation &#8211; defence and mitigation </td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt">&#160;</td>
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="width:0.75pt;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;">Focus on shareholder value creation </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">
<img alt="LOGO" src="g382677f_105.jpg"/> </div></div> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New GSK Board priorities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When I joined the Board in September 2019, GSK was entering a period of significant transition in the run up to the separation of the Group. The Board engaged in a structured, externally facilitated appraisal of our governance and the architecture of the Board and its committees. The output of this was a Board agenda that was focused and linked directly to the business needs of innovation, pipeline, performance, culture and separation, and a refined committee architecture that reinforced these priorities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following separation, it was time to set new Board priorities. Ms Hall of No 4, a business advisory company, was engaged to facilitate this work following the success of her previous review. This work comprised two key aspects: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a review of our current ways of working, with recommendations for further improvement and establishing priorities for the Board agenda for the next three to five years </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">an evaluation of the Board and its committees during 2022 </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board is now aligned with management to deliver our new Ahead Together purpose, strategy and culture, with a strong emphasis on value creation over three time periods: near-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2023-26)</div> based around delivering our public commitments; medium- to long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2026-31);</div> and beyond. Our Board programme for 2023 has been set accordingly. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The report of the formal independent external 2022 Board and committee performance review is set out on page 111. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board culture and decision-making </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board fully supported our new purpose, strategy and the performance culture for new GSK. We are now well-positioned to deliver on our public commitments for growth and to create sustainable long-term value. All Board discussions focus on the powerful combination of Science, Technology and Talent and realising GSK&#8217;s desired culture. These support our aim to be: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">ambitious for patients </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">accountable for impact </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">doing the right thing </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">They also frame Board discussions when considering strategic decisions and actions to be taken. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Connecting with the business and our people </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> restrictions, the Board is now able to meet together in person. Time is set aside to enable our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors to have more informal time, together with the GLT members presenting to them and to meet with other colleagues at each meeting location. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Board and Board committees </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board&#8217;s agenda seeks to be focused and not to duplicate work. Each committee remit defines its agenda to support our priorities. Our Committee Chairs continue to be responsible for sharing with the Board the work their committees undertake and the main issues they are overseeing. They also highlight specific committee papers which they believe would benefit the Board&#8217;s wider understanding. Non-Executive Directors may attend any committee meeting and have full access to agendas and papers. From time to time the Chairs&#8217; Committee, or a more specific Board committee, may be convened for a specific topic. This creates flexibility and enables the Board to be more agile, if required. Given the increased biopharma expertise of the new Board, management has also been sharing proposals and opportunities at an earlier stage to facilitate more efficient decision-making. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following is a snapshot of aspects of our Board committees, work in 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit&#160;&amp; Risk Committee:</div></div> assisted in the establishment of a robust internal control and risk management control framework for Haleon as an independent listed company. It also confirmed that GSK&#8217;s framework remained fit for our new future. The Committee took a lead role in completing the scrutiny of and then subsequently recommending to the Board the demerger and listing documents for shareholder approval at the General Meeting in July 2022. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">105</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Chair&#8217;s governance statement continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;">Since the demerger, the Group&#8217;s share price performance in the second half of the year was impacted by the uncertainties associated with the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> product liability litigation in the US. The Committee continues to have primary Board accountability for the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> litigation, including accounting, disclosure and communication assessments on behalf of the Board. The Committee has a clear remit and recommends decisions on the navigation of the litigation to the Board, as appropriate. I would reiterate at this point that the company remains very confident in its position on these matters and will defend itself vigorously against any claims brought. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nominations&#160;&amp; Corporate Governance Committee:</div></div> </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">supported the demerger of the Consumer Healthcare business by assisting the Haleon Chair designate in completing the composition of the Haleon Board. This included the transfer, on demerger, of two of our serving Directors, Vindi Banga and Dame Vivienne Cox. The Committee felt strongly that their particular skills and experience would be valuable to Haleon and that they would also importantly provide continuity for the new Haleon Board. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Committee&#8217;s other focus was on continuing to complete the composition of the new GSK Board and changes to the GLT. The key focus was in deepening the Board&#8217;s scientific and biopharma skills. The Committee selected new Directors with a strong emphasis on life sciences and technology to help deepen our biopharma expertise and experience: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Vishal Sikka</div></div> is a world-leading technologist in the field of advanced enterprise technologies with extraordinary credentials in AI and machine learning </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liz McKee Anderson</div></div> has deep commercial expertise across both large and specialty biopharma and has specific experience of global commercialisation and market access in specialisms such as respiratory, immunology, vaccines and HIV </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Julie Brown</div></div>, will join GSK in April as our incoming CFO. She has considerable listed pharmaceuticals and commercial experience </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board now has scientific credentials ideally suited to its new purpose and which are among the strongest in the industry. We have moved away from the broader experience on the Board I originally joined in 2019. I am pleased at how the debate and discussion in Board and committee meetings has evolved to our new purpose and is deeper and more enriched as a result. The Committee will continue to recruit diverse Directors with scientific and biopharma expertise to meet the evolving needs of the Board to oversee the company&#8217;s strategy as a global biopharma business. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Science Committee:</div></div> Good progress has been made in R&amp;D. The Committee continues to support the ambitious and agile development of our pipeline, both organically and through smart business development, by overseeing and reviewing our application of science. The Committee supported the seamless transition of leadership of R&amp;D to Dr Tony Wood from Dr Hal Barron. Tony&#8217;s role as a key architect in rebuilding our pipeline was key to this. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Corporate Responsibility Committee:</div></div> The new culture at GSK is something that we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. The Committee continues to focus its oversight on evolving the company&#8217;s ESG performance. I am pleased that we are able to report that we are <div style="color: rgb(243, 111, 33); font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">on track</div><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"> against our new ESG rating and reassured by the further enhancements to our ESG reporting and data oversight. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration Committee:</div></div> Our focused new Remuneration policy is a fundamental part of the architecture of new GSK post-separation. It is critical we now build a strong performance culture to generate sustained delivery of shareholder value. Our new policy seeks to achieve this key linkage between executive remuneration rewarding outperformance. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">We engaged extensively with shareholders and shareholder representative bodies as we developed the new policy to recognise the importance of the new reward system to support new GSK&#8217;s success. The final policy was modified to reflect the feedback we received, whilst recognising the sizeable minority of shareholders who voted against it. We will continue to engage with shareholders to demonstrate the importance we place on rewarding over-performance in the policy at this crucial next stage of new GSK&#8217;s development. The strong operational and financial performance of the company in 2022 is an encouraging start. However, GSK has underperformed in terms of TSR and share price performance for many years. The new policy is firmly focused on addressing and reversing this trend and the outturns of awards in 2022 recognise the significant improvement in performance. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall good progress was made in 2022. However, your Board is clear that there is more to do to increase investor confidence in the ability of the Group to sustain growth over the next decade. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Thank you for your continued support and I look forward to connecting with you during the year, whether at our Annual General Meeting in May, or otherwise, to share our continued progress. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair</div></div> </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9 March 2023</div></div> </div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div id="ex15_2tx382677_25" style="font-family: ARIAL; font-size: 22pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_66" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Corporate governance architecture </div></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_107.jpg" style="width: 730px; height: 157px;"/></div> </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our corporate governance architecture is a framework designed to improve the effectiveness of the Board and to support its oversight of the GSK Leadership Team (GLT) in the delivery of our strategy. It continues to evolve to support our infrastructure and priorities as a pure biopharma business. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK&#8217;s internal control and risk management arrangements are an integral part of our overall corporate governance framework and are described on pages 51 to 64 and pages 125 and 126. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">To ensure the framework&#8217;s optimal effectiveness it requires: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">a clear division of responsibilities for individual and collective Board roles described on the next page </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">the appropriate distribution of workload to the Board committee with the requisite focus and skills </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">highly committed Board Directors motivated to discharge their roles and responsibilities for the success of the company </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="border-radius: 6pt; padding-top: 2pt; padding-bottom: 3pt; margin-right: 0%; margin-left: 0%; max-width: 100%; background-color: rgb(231, 231, 232);"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 97%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 12%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 60%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 6%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee roles</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Role and focus</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Membership</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">report</div></div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">on page</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chairs&#8217;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Acts on behalf of the Board between its scheduled meetings to take decisions on urgent matters in accordance with matters and authority delegated to it by the Board from time to time</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sir Jonathan Symonds (Company Chair)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Independent Director</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Chairs of the Board&#8217;s committees</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#8211;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Corporate Responsibility</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Considers GSK&#8217;s Trust priority and has oversight of our responsible business approach and ESG strategy, performance and reporting. This reflects the most important issues for responsible and sustainable business growth. It has oversight of the views and interests of our internal and external stakeholders and reviews issues that have the potential for serious impact upon GSK&#8217;s business and reputation</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Anne Beal (Chair)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Jesse Goodman</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Vishal Sikka</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">117-118</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Science</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Supports the Board in its understanding of the key strategic themes, upon which the company&#8217;s R&amp;D strategy is based, and of external transactions, by performing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> reviews of the underlying scientific assumptions to give the Board technical assurance. It also undertakes more <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> risk oversight of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D-related</div> risks</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Dietz (Chair from 1&#160;January 2023)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Jesse Goodman (Chair to 31 December 2022)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Barron</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">118-120</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 1.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 1.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 1.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nominations &amp; Corporate Governance</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Reviews the structure, size and composition of the Board, the appointment of members to Board committees and the appointment of Corporate Officers. It makes recommendations to the Board as appropriate. It also plans and assesses orderly succession for Executive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors and reviews management&#8217;s Succession Plan to ensure its adequacy</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Is responsible for reporting to the Board, overseeing and monitoring corporate governance arrangements and for making recommendations to the Board to ensure the company&#8217;s standards and arrangements are consistent with existing corporate governance standards and emerging best practice. It also reviews Board and GLT conflicts of interest</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sir Jonathan Symonds (Chair)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charles Bancroft</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Anne Beal</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Urs Rohner</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">120-124</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit&#160;&amp; Risk</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews the financial reporting process, the integrity of the company&#8217;s financial statements, the external and internal audit process, the system of internal control and the identification and management of risks, and the company&#8217;s process for monitoring compliance with laws, regulations and ethical codes of practice. It also oversees ESG data reporting and assurance</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Initiates audit tenders, the selection and appointment of the external auditor, setting its remuneration and exercising oversight of its work</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charles Bancroft (Chair)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth McKee Anderson</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Urs Rohner</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">124-129</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td>
<td colspan="2" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sets the company&#8217;s Remuneration policy having regard to GSK&#8217;s workforce remuneration so that GSK is able to recruit, retain and motivate its executives</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Remuneration policy is regularly reviewed to ensure that it is consistent with the company&#8217;s scale and scope of operations, supports the business strategy and growth plans, is aligned to the wider workforce and helps drive the creation of shareholder value</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 1pt; line-height: normal;">(The Chair and the CEO are responsible for evaluating and making recommendations to the Board on the remuneration arrangements and policy for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Urs Rohner (Chair)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charles Bancroft</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Anne Beal</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth McKee</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Anderson</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">132-164</td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td colspan="7" style="vertical-align: top;"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Board committee has written terms of reference which are approved by the Board and are reviewed at least annually to ensure that they comply with the latest legal and regulatory requirements and reflect best practice developments. The current full terms of reference of each Board committee are available on gsk.com. Board and committee meeting attendance for 2022 and oversight of the company&#8217;s policy on external appointments is set out on page 109.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-size: 44pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 44pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_99c.jpg" style="width: 35px; height: 902px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">107</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Corporate governance architecture continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_108.jpg"/> </div><div style="font-size:-767pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:-767pt; margin-bottom:0pt; font-size:1pt; font-family:ARIAL">&#160; </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:99%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#8201;&#8201;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leadership</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Chair</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jonathan Symonds</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;leads and manages the business of the Board</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;provides direction and focus</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;ensures a clear structure for effective operation of the Board and its committees</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;maintains a dialogue with shareholders about the governance of the company</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;sets the Board agenda and ensures sufficient time is allocated to promote effective debate to support sound decision-making</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;ensures the Board receives accurate, timely and clear information</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;meets continuously with each Non-Executive Director to discuss individual contributions and performance, together with training and development needs</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;shares peer feedback that is provided as part of the Board evaluation process</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;meets regularly with all the Non-Executive Directors independently of the Executive Directors</div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8201;The Chair&#8217;s role description is available on gsk.com</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Chief Executive Officer</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;is responsible for the management of the Group and its business</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;develops the Group&#8217;s strategic direction for consideration and approval by the Board</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;implements the agreed strategy</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;is supported by members of the GLT</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;maintains a continual and active dialogue with shareholders in respect of the company&#8217;s performance</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8201;The Chief Executive Officer&#8217;s role description is available on gsk.com</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Independent oversight and rigorous challenge</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-Executive Directors</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;provide a strong independent element to the Board</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;constructively support and challenge management and scrutinise its performance in achieving agreed deliverables</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;shape proposals on strategy and offer specialist advice to management</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;each has a letter of appointment setting out the terms and conditions of their directorship</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;devote such time as is necessary to the proper performance of their duties</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;are expected to attend all meetings as required</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Independence statement </div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Board considers all of its Non-Executive Directors who are identified on pages 97 to 100, with the exception of Dr Hal Barron, to be independent after being assessed against Provision 10 of the Financial Reporting Council's (FRC) UK Corporate Governance Code (Code).</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The independence and commitment of Dr Jesse Goodman and Urs Rohner, who have each served on the Board for over six years, has been subjected to a rigorous review.</div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8201;GSK&#8217;s Non-Executive Director role description is available on gsk.com</div></div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Senior Independent Director</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charles Bancroft</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;acts as a sounding board for the Chair and a trusted intermediary for other Directors</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;together with the Non-Executive Directors, leads the annual review of the Chair&#8217;s performance, taking into account the views of the Executive Directors</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;discusses the results of the Chair&#8217;s effectiveness review with the Chair</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;leads the search and appointment process and makes the recommendation to the Board for a new Chair</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;acts as an additional point of contact for shareholders, maintains an understanding of the issues and concerns of major shareholders through meetings with investors and briefings from the Company Secretary and Investor Relations</div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">+</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8201;GSK&#8217;s Senior Independent Non-Executive Director&#8217;s role description is available on gsk.com</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:135pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:98%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:3%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Company&#160;Secretary</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Victoria Whyte</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;is secretary to the Board and all Board committees</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;supports the Board and Committee Chairs in annual agenda planning</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;ensures information is made available to Board members in a timely fashion</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;supports the Chair in designing and delivering Board inductions</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;coordinates continuing business awareness and training requirements for the Non-Executive Directors</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;undertakes internal Board and committee evaluations at the request of the Chair</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;advises the Directors on Board practice and procedures, and corporate governance matters</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;chairs the Group&#8217;s Disclosure Committee</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;operates a Board-approved appointments policy that reflects the Board and external appointment requirements of the Code</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;is a point of contact for shareholders on all corporate governance matters</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> </div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">108</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Corporate governance architecture continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:6pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:97%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td colspan="25" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="24" style="padding-bottom:1pt ;vertical-align:top"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Board and committee attendance</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chairs&#8217;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Corporate<br/>Responsibility</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Science</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nominations&#160;&amp;<br/>Corporate<br/>Governance</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit&#160;&amp;&#160;Risk</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total number of routine meetings</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current members</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Attended</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sir Jonathan Symonds</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Elizabeth McKee Anderson</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Barron</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charles Bancroft</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Anne Beal</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1&#160;(3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5 (5)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Harry C Dietz</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Jesse Goodman</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Urs Rohner</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Vishal Sikka</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Retired members</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vindi Banga</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4 (5)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dame Vivienne Cox</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1 (1)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lynn Elsenhans</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1 (1)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3 (3)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Laurie Glimcher</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5 (5)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2 (2)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5 (5)</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Number of additional meetings</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:4pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="42" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The numbers in brackets denote the number of meetings which these individuals were eligible to attend. See Board and committee changes during 2022 on page&#160;123. Details of committee members&#8217; skills and experience are included in their biographies under &#8216;The Board&#8217; on pages 97 to 100.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"></div></td></tr></table></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:6pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:6pt; margin-bottom:0pt; margin-left:5pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FRC UK Corporate Governance Code </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; margin-left:5pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial experience </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; margin-left:5pt; font-size:8.5pt; font-family:ARIAL">In accordance with the FRC&#8217;s Code, the Board has determined that Charles Bancroft has recent and relevant financial experience. It has also agreed that he has the appropriate qualifications and background to be an audit committee financial expert as defined by the Sarbanes-Oxley Act of 2002, and has determined that he is independent within the meaning of the Securities Exchange Act of 1934, as amended. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:5pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; margin-left:5pt; font-size:8.5pt; font-family:ARIAL">The Board is pleased to report that in 2022 it was in full compliance with the provisions of the FRC&#8217;s Code, with the exception of Code provision 38. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:6pt; margin-bottom:0pt; margin-right:4pt; font-size:8.5pt; font-family:ARIAL">Provision 38 requires alignment of pension rates for executive directors with those available to the local workforce. Since 1&#160;January 2023, current Executive Directors&#8217; pension rates have been aligned to the wider workforce local to them. This replicates the requirement for pension arrangements for any new Executive Directors appointed to GSK. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-right:4pt; font-size:8.5pt; font-family:ARIAL">In addition, provision 38 requires that only base salary should be pensionable. US pension arrangements for employees allow basic salary and bonus to be pensionable. Following Dr Hal Barron&#8217;s transition to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director with effect from 1&#160;August 2022, this FRC Code requirement has also been met. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-right:4pt; font-size:8.5pt; font-family:ARIAL">The Board is also pleased to report that it has consistently applied the principles of the FRC&#8217;s Code, as set out in the pages of this and the Remuneration report. A copy of the Code is available on the FRC&#8217;s website, www.frc.org.uk. &#160;<br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;">All our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors are expected to devote such time as is necessary for the performance of their duties. Each Director is required to attend a minimum of 75% of scheduled Board and committees meetings. However, it is recognised that there may be rare occasions when this is not possible. Special allowance is given during the first year of Board membership while calendars are aligned. There was a high attendance record at scheduled Board and committee meetings for all our Directors who served during 2022, as set out above. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Board Directors&#8217; external appointments are governed by a Board approved policy. External appointments can help Board and GLT members widen their expertise and knowledge and hence perform their roles more effectively. When proposing new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director appointments to the Board for approval, the Board takes into account other demands on the individuals&#8217; time. Prior to appointment to the Board, an individual is required to disclose significant commitments they may have with an indication of the time involved. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All additional prospective external appointments for serving Board Directors are considered and approved by the Board, noting the nature of the role and type of organisation, time commitment and any potential conflicts that are envisaged. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Company Secretary maintains a register of commitments and potential conflicts. The Board is satisfied that given Directors&#8217; other interests, each has sufficient time to carry out their role. Our Executive or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors may undertake a maximum of one, or up to four listed company directorships, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_67" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_26" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Ahead Together &#8211; Board oversight </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board discharges its responsibilities through an annual programme of meetings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, papers and presentations were provided to the Board (and its committees) which were focused on the strengthening of the fundamental elements of the business to move Ahead Together in pursuit of the company&#8217;s strategy to deliver GSK&#8217;s growth-based performance ambitions, oversee the demerger and listing of Haleon, establishing GSK as a pure biopharma business and drive our ESG leadership priorities. In doing so, these papers and presentations also highlighted the relevant stakeholder impacts and perspectives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These materials enable the Board&#8217;s effective decision-making, input and oversight of business performance and governance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The key items of business considered critical to GSK&#8217;s long-term success through the achievement of GSK&#8217;s key priorities are highlighted below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:84%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Areas of focus in 2022</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="7" style="vertical-align:top"><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demerger&#160;and</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">listing&#160;of&#160;Haleon</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The Board&#8217;s preparation for the demerger as a value-based process included:</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">discussing strategy and plans for Consumer Healthcare for the period up to and beyond its separation as Haleon</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving regular performance reports</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">scrutinising and overseeing the Consumer Healthcare Capital Markets Day approach and materials</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">supporting appointments to the Haleon Board, including the transition of Vindi Banga and Dame Vivienne Cox to Haleon</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">scrutinising and responding to an unsolicited proposal for the Consumer Healthcare business in advance of the demerger</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving the GSK Shareholder Circular recommending the demerger and overseeing the Haleon Prospectus</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">approval of the demerger and subsequent GSK share consolidation</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="7" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Build GSK as a</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">pure biopharma</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">business</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Board&#8217;s oversight of the creation of GSK as a pure biopharma business and delivery of a step-change in performance included:</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">regularly discussing and scrutinising transformation plans for GSK</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">scutinising updates on R&amp;D strategy, progress and progression of the company&#8217;s pipeline</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">requesting the Remuneration Committee renew the Remuneration policy&#8217;s focus to incentivise overdelivery and reward a new performance culture</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Board and management succession planning, including approval of the appointment of a new Chief Scientific Officer, the transition of Dr Hal Barron to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director, and the appointment of two new independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors and a new Chief Financial Officer</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approval of Charles Bancroft as successor to Vindi Banga in the role of Senior Independent Director</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">approval of a change in approach to workforce engagement</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="10" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ahead Together</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211; further</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">strengthening&#160;the</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fundamentals of</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value creation</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Board&#8217;s oversight of the fundamentals of commercial execution, cost base management, capital allocation, pipeline and culture included:</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">setting and approving the Board&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-24</div> priorities</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving regular progress updates and providing input into the company&#8217;s Vaccines mRNA strategy and plan</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving and discussing commercial strategy performance reports from Pharmaceuticals, Vaccines and ViiV Healthcare</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving updates on R&amp;D strategy and pipeline progress</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving business development transactions, acquisitions and strategic partnerships with third parties including: Sierra Oncology, Affinivax, Mersana Therapeutics, Spero Therapeutics, Wave Life Sciences and Tempus</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving quarterly reports from the CEO, CFO and CSO</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">scrutinising the Group&#8217;s financial performance</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">setting the company&#8217;s new name, purpose and simplified culture, through a new Code of Conduct</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="9" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Enhancing</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ESG leadership</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Board&#8217;s oversight of our new culture and embedding ESG at our core:</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving and supporting the new GSK culture</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving the Responsible Business section of the Annual Report</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving the Task Force on Climate-related Financial Disclosures section in the Annual Report</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">final approval of our Pricing and Access Policy principles</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">overseeing GSK&#8217;s overall response to the situation in Ukraine</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="15" style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regular corporate governance oversight</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Board&#8217;s programme of governance included:</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">reviewing the quarterly financial results, dividend proposals, earnings guidance, investor materials, results announcements and receiving reports from the external auditor</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving the final 2021 Annual Report and Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">setting the annual budget, and the forward-looking three-year plan</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">conducting an annual review of the Board&#8217;s enterprise risk responsibility framework and enterprise-wide risks</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">undertaking an annual Board evaluation and implementing its agreed outcomes</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">reviewing and continuing to evolve the Board&#8217;s governance architecture</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">evaluating the CEO&#8217;s 2021 performance, and setting her 2022 objectives</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">reviewing the talent and succession plans annually</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving reports on Board committee work</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">engaging with GSK&#8217;s stakeholders and the wider workforce to gather and understand their views on the company&#8217;s activities and operation</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">reviewing the employee PULSE survey results</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">receiving reports on wider corporate governance and regulatory developments, and the Company Secretary&#8217;s report</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">approving the company&#8217;s modern slavery statement and gender pay gap positioning</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(196, 190, 185); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">reviewing stakeholder perception research</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Ahead Together &#8211; Board oversight continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board performance </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board evaluates its performance, and that of its committees, every year. The evaluation is normally carried out externally every third year, with the last one being facilitated in 2020 by Jan Hall of No 4, a business advisory company which does not have any other connection with GSK. The Board felt it would be helpful for No 4 to conduct the 2022 evaluation following the completion of the demerger of Haleon and the formation of GSK as a new biopharma company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preparation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">No 4 met with the Chair and CEO in advance of the evaluation,<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>for an update on how the Board is operating to understand GSK&#8217;s future priorities, and to agree the review&#8217;s objectives, scope and timetable. The Company Secretary also provided No 4 with access to Board and committee materials, and other information. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interviews </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During November and December 2022, No 4 conducted confidential and detailed interviews with the Board, selected GLT members, the Company Secretary, GSK&#8217;s external auditor and our incoming and outgoing independent remuneration adviser, to seek their views on the Board&#8217;s effectiveness. These meetings reflected an agreed discussion guideline that was sent to each participant beforehand. This included key topics from the Financial Reporting Council&#8217;s 2018 Guidance on Board Effectiveness and the relevant requirements of its 2018 UK Corporate Governance Code. However, this did not limit the feedback each participant could give. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Review </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Review sought to determine the Board&#8217;s priorities over the next three to five years and how they should be built into the Board&#8217;s agenda. The evaluation results and suggested next steps were included in a summary report, compiled by No 4 and discussed initially with the Chair, CEO and the Senior Independent Director (SID). The Review was presented to the Board in January 2023 which covered the following main areas of the effectiveness review: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Overall review of the Board </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Board organisation, agenda and information </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Board dynamics, challenge and input </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Future strategy development </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Performance delivery </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Action points </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">After due consideration and discussion the following action points to further improve performance in 2023 were agreed: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The key area of focus for the Board should continue to be R&amp;D (organic and inorganic). Meeting the pipeline goals, and therefore delivering shareholder value, is seen by all as the top priority </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The importance of the Science Committee in working with the CSO to help optimise the pipeline </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Supporting the onboarding of the new CFO, Julie Brown </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Board succession planning would be progressed to ensure a broad range of diverse candidates for consideration as successor for the Remuneration Committee Chair </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board committees </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The review of the Board committees focused on their progress. It involved virtual interviews with committee members conducted by No 4 on behalf of the respective Committee Chairs. Each committee was considered to operate effectively and the following further enhancements were agreed: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The importance of optimising concise feedback by Committee Chairs to the full Board following each committee meeting </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Following agreement of the overall Board priorities and the Board agenda, Committee Chairs agreed to review the main areas of responsibility for their committees in line with the Board priorities and incorporate them into their committee programmes for 2023 </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">In particular, the importance of the Science Committee in supporting organic and inorganic R&amp;D and evolving the ways in which the committee works with the CSO and his team </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The SID and No 4 sought feedback on the Chair&#8217;s performance from the Directors individually and collectively. This concluded that the Chair was operating effectively in leading the Board. The results of the review were then noted by No 4 and discussed by the Chair and the SID. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">111</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_27" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_68" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Key decisions and engagements </div></div><div style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section&#160;172 statement </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Board members are required by law to promote the success of their organisation for the benefit of both shareholders and their wider stakeholders, including employees, suppliers and the community. This statement meets this requirement, as set out in Section&#160;172 and Section&#160;414CZA of the Companies Act 2006 (the Act). It states how, during the year, our Directors addressed the matters set out in Section&#160;172(1) (a) to (f)&#160;of the Act when performing their duties. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board considers that the statement focuses on those risks and opportunities that are strategically important to GSK, and consistent with the Group&#8217;s size and complexity. This allows it to properly understand the potential impacts of the decisions it makes on all stakeholders. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Engagement with our main stakeholder groups, including our patients, shareholders, consumers, customers and employees at all levels and across the organisation, are summarised throughout the pages of our strategic report. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In particular, the Board&#8217;s continuous engagement with our investors and people is set out in this section on pages 114 to 116, and the company&#8217;s corporate governance architecture and processes are summarised on pages 107 to 109. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This summary sets out how the Board considered all relevant matters in making the principal decisions that contributed to the formation of two attractive and viable businesses with compelling investment propositions, through: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">delivering the separation of Haleon from GSK with a strong focus on shareholder value (the Demerger) and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; text-align: left; line-height: normal;">building GSK as a pure biopharma company that is ambitious for patients, accountable for impact and does the right thing (new GSK) </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The Demerger represented a key step in a multi-year transformation of GSK to improve focus, performance and competitiveness, and to maximise value for shareholders. The Demerger also provided the right opportunity to implement the legal change of name of the company from GlaxoSmithKline plc to GSK plc. This was designed to mark the new GSK brand and culture and protect and build it for the future. The change was made in May 2022. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-radius:5pt; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto;background-color:#e7e7e8">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.8em; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a) Long-term results</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The likely consequences of any decision in the long term</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-size: 9pt; font-family: ARIAL; line-height: normal;">At the end of May 2022, the Board assessed the company&#8217;s readiness to proceed with the Demerger and approved the GSK Circular and agreed the Haleon Prospectus to be sent to shareholders as the final stage of the Demerger.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-size: 9pt; font-family: ARIAL; line-height: normal;">The Board exercised its Section&#160;172 duties by reviewing the work of management and the Audit&#160;&amp; Risk, Corporate Responsibility, Remuneration and Transformation&#160;&amp; Separation committees in progressing the separation since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020.</div> This included;</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;extensive consultations held with the key stakeholders, and sharing the long-term growth ambitions at the investor events for GSK in June 2021 and Haleon in February 2022</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;considering and rejecting the unsolicited, conditional and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> proposals received to acquire the Consumer Healthcare business</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; font-size: 9pt; font-family: ARIAL; line-height: normal;">In recommending these proposals to create two independent companies to most effectively serve their patients and customers respectively, the Board firmly believed that its decision would establish:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin: 0pt 1em 0pt 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;a newly independent global leader in consumer health with a focused strategy to drive penetration growth across its portfolio, capitalising on new and emerging growth opportunities, underpinned by strong execution and financial discipline. Haleon, as an independent company, would be able to deliver sustainable above-market growth, moderate sustainable adjusted operating margin expansion in the medium term with attractive returns to shareholders</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin: 0pt 1em 0pt 0.89em; text-indent: -0.89em; font-size: 9pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;new GSK, a pure biopharmaceuticals company with a portfolio focused on Vaccines, Specialty Medicines and General Medicines with clearly defined financial ambitions, a clear ambition to deliver large-scale and long-term positive human health impact and a strong balance sheet enabling a growth-oriented capital allocation policy and attractive shareholder returns</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 9pt; font-family: ARIAL; line-height: normal;">The Board believed that the Demerger would unlock the potential of both businesses, strengthen the balance sheet of new GSK and its ability to invest in growth and maximise long-term return for shareholders.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Shareholders duly approved the two resolutions proposed at the General Meeting held on 6&#160;July 2022 and the Demerger was then effected on 18&#160;July 2022.</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">112</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Key decisions and engagements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="border-radius:5pt; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto;background-color:#e7e7e8">
<tr style="font-size: 0px;">
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(b) Our workforce</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:12pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The interests of the Group&#8217;s employees</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Board had continual regard to the interests of our people who were either remaining with new GSK or departing to form Haleon. It achieved this by using various employee voice mechanisms described on pages 10, 11 and 115 to help explain the future shape of these companies, understand and assess the impact of these changes on the organisation and how they were being experienced by our people.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Significant focus was dedicated in bringing to life new GSK&#8217;s Ahead Together purpose, strategy and culture for our people across the Group. A strong emphasis has been given to individual ownership of our new culture. This was formally launched in June 2022 with events held around the company&#8217;s locations globally.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">These were attended by GLT members and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Board members including the Chair.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">In 2022, in addition to our annual bonus and long-term incentive structure, the Board also gave a special thank you to all our people (excluding GLT), allowing us to recognise what we had achieved together in preparation for the Demerger and the transformation of the company into a pure biopharma company. As a result, everyone received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> payment equivalent to a week&#8217;s salary in March, separate to our 2021 bonus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay-out.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">We also ensured that the treatment of awards or options held by GSK employees, and for departing Haleon employees, delivered a fair outcome in accordance with the rules of those share schemes as part of the Demerger and the GSK share consolidation.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(243, 111, 33); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(c) Our business relationships</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The importance of developing the Group&#8217;s business relationships with suppliers, customers and others</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">A key imperative for the Board of GSK as a responsible business is to ensure the company develops and monitors these partnerships to ultimately serve patients. The benefits of these relationships and how they can support the achievement of our ambitions are described in the pages of our strategic report, for example:</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;achieving our Ahead Together ambition to positively impact the health of 2.5&#160;billion people by the end of 2030, requires the development of vaccines and medicines and making them available through responsible pricing, strategic access programmes and partnerships</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;ethical behaviour is promoted across our business by supporting our people to do the right thing and working with suppliers that share our standards and operate in a responsible way. Our new Code of Conduct seeks to set out expectations in this regard</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;our third parties are expected to meet our ABAC and labour rights standards and to comply with our standards on quality, health and safety, and the environment. Approximately 29% of our total emissions footprint comes from the goods and services that we buy. In September 2022, in support of our net zero carbon impact on climate ambition, we launched our Sustainable Procurement Programme. This will require our suppliers to, among other things, disclose emissions, set carbon reduction targets, and switch to renewable power and heat</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(243, 111, 33); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(d) The community and the environment</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The impact of the Group&#8217;s operations on the community and our environment</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Our approach to making a positive impact has been guided by extensive stakeholder engagement on the key issues relevant to new GSK and, prior to the demerger, Haleon&#8217;s respective industries and the nature of the companies themselves. The Board has sought to achieve this by:</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;in preparation for the Demerger, working with Haleon&#8217;s management team in developing its own distinctive responsible business approach and ESG framework bespoke to the needs of its customers and the communities it serves. This also involved scrutinising this framework and the proposed targets, including environmental sustainability targets. These were presented at Haleon&#8217;s investor update in February 2022</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;establishing the six areas of ESG focus for new GSK as a global biopharma company that are fundamental to our DNA and success. These six areas, detailed on pages&#160;42&#160;to&#160;50, directly contribute to long-term shareholder value by contributing to our health impact, supporting thriving people and reducing risk. The environment is one of our principal ESG focus areas. In 2022, an environmental scorecard measure was introduced into our long-term incentive plans to incentivise and reward progress on delivering against our net zero impact on climate and net positive impact on nature public ambitions by 2030</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Board has also been focused on new GSK&#8217;s Ahead Together ambition to impact the lives of 2.5&#160;billion patients over the next ten years. Human capital is key to GSK and as such we are seeking to strengthen early STEM education investments to further support a long-term diverse talent pool and increase the positive impact of volunteering activities within the communities in which we serve.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:4pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">113</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Key decisions and engagements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="border-radius:5pt; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto;background-color:#e7e7e8">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(e) Our reputation</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Our desire to maintain our reputation for high standards of business conduct</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">This duty guided the Board&#8217;s approach to the Demerger and the creation of new GSK. This was achieved by:</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;the transformation of the company, initially launched in early 2020. This included fundamentally reviewing our structure, cost base, ways of working and the effectiveness of both our biopharma and consumer healthcare businesses and implementing targeted enhancements in advance of the Demerger</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;choosing the optimal form of separation through a Demerger with the same listing location and structure for Haleon as GSK. As a result, Haleon should operate to the same premium listed, legal and corporate governance standards, in an environment with common business and ethical values to GSK</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;extensive legal and financial due diligence and engagement with key regulators, investors and other key stakeholders, which was undertaken in preparing the GSK Circular, the Haleon Prospectus and the Haleon 20-F</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;reaching an agreement with the trustees of the GSK UK Pension Schemes on a package of measures (including funding and protections) in relation to the Demerger and the GSK UK Pension Schemes&#8217; triennial actuarial valuations</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;ensuring that GSK remained as one company in how we operated until the point of Demerger, with the overriding emphasis on driving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> growth and improving margin</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;implementing plans for the six areas of ESG focus for new GSK, outlined to investors in June 2021 to help retain and develop further GSK&#8217;s reputation for ESG leadership and responsible business conduct</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;developing a distinctive and holistic responsible business case and ESG framework for Haleon which was outlined to investors in February 2022. This supported Haleon&#8217;s purpose, strategy and culture as a premium UK listed company, with a focus on the key responsible business issues</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;ensuring that the Board and our people in new GSK commit annually to our new Code of Conduct introduced in June 2022. This Code sets out our Board endorsed Ahead Together purpose and culture, as well as the performance commitments our people make so we can all deliver on the company&#8217;s ambitions in the right way</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(243, 111, 33); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(f) Fairness between our shareholders</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our aim to act fairly as between members of the Group</div></div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;each shareholder receiving a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> shareholding in Haleon after the Demerger, with the receipt of one Haleon share for each GSK share held. Additionally, all Haleon shares from the inception of the Demerger had equal rights to participate in capital, dividend and profit distributions by Haleon</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;the GSK Share Consolidation achieved consistency in the GSK share price pre- and post-Demerger to enable comparability between the new GSK earnings per share and share price with previous periods. It also preserved, as far as reasonably possible, the value of share options and awards granted to our people after the Demerger</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">It was of fundamental importance that the Board was able to ensure that shareholders were treated fairly up to, on and after the Demerger. This was demonstrated by:</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;deciding on the most appropriate capital structures required for the two companies to be competitive, on which stock exchanges Haleon should list, and whether, and to what extent, to distribute shares in Haleon to GSK&#8217;s shareholders and retain any stake in Haleon</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;each shareholder having a right to vote on a one vote for one share basis at the General Meeting for the Demerger and the new GSK share consolidation, and related party transactions resolutions. To ensure that as many shareholders as possible could participate in the meeting, shareholders were able to ask questions and vote either electronically or in person. Voting majorities in excess of 99% were recorded for each resolution</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approach to continuous engagement </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our stakeholders rightly have high expectations of us. The dynamic operating environment presents many challenges and opportunities. The Board aims to make sure that being commercially successful is balanced and aligned with meeting our stakeholders&#8217; expectations, upholding our reputation, maintaining our licence to operate and building trust. The Board engages with or is briefed on the views of our stakeholders, to ensure it identifies and responds to their expectations effectively and appropriately. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">How we engage with our main stakeholder groups &#8211; including patients, shareholders, consumers, customers and employees &#8211; across the company is covered in the pages of our strategic report. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board placed two of our main stakeholders at the heart of our renewed culture, with our people all being ambitious for patients, accountable for impact, and doing the right thing. Our culture is described on pages 10 and 11 of the strategic report. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The influence and importance of different stakeholder groups can vary, depending on the matter being considered. Certain stakeholders&#8217; interests can be in conflict, meaning the Board needs to make balanced judgements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Continuous stakeholder engagement and feedback helps us identify emerging issues. It also enables the Board to make decisions in the context of what is relevant and important to each of them. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">114</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Key decisions and engagements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our principal Board committees, and the GLT, undertake engagement on the Board&#8217;s behalf in accordance with their remit. This means that they can build a detailed understanding of how our actions or plans are/or may impact stakeholders. These insights are then shared with the Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In particular, the Board receives briefings on stakeholders&#8217; perspectives from the work of the Corporate Responsibility Committee, which is discussed on pages 117 and 118. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Board members regularly receive: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the CEO&#8217;s Board Report </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a specific External Stakeholders&#8217; Report. This provides strategic insights based on an analysis of key developments, achievements and risks impacting our reputation and the perceptions of all our external stakeholders </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a regular Investor Relations Report which summarises investor perceptions </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#8211; regular corporate governance, litigation and regulatory updates </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board also learns of stakeholder views through: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Engagement and feedback events such as:</div></div> the quarterly investor results calls, the Annual General Meeting, employee survey reports, through the Board&#8217;s workforce engagement activities, and from experts presenting at Board or committee meetings. In addition to the Chair&#8217;s investor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">check-in</div> meetings which he holds on an ongoing basis, our new SID, Charles Bancroft, joined him for some meetings. Charles also met individually with investors to introduced himself and gain a personal understanding of issues and any views they may have. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other opportunities:</div></div> Board members also gain wider stakeholder views during the annual strategy meeting with the GLT, as part of the annual review of strategy, budget and planning process. This includes a review of specific aspects of the company&#8217;s policies or strategy. In addition, Board members are encouraged to meet individually with employees, shareholders and other key stakeholders during their induction, and then on an ongoing basis. They are encouraged to report to the Board on such experiences where relevant and material. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our people </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have well-established and strong engagement mechanisms with our colleagues, which are described on pages 10 and 11 and are monitored regularly by the Board. Three key governance channels help communicate what our people are thinking to the Board: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">regular Board updates from our Chief People Officer and the CEO on culture and talent </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">feedback from a range of pulse surveys of varying sizes of employee groups to help check sentiment and culture more quickly and frequently and provide valuable insights on the impact of major initiatives, events or communications </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">direct engagement by the Board. Prior to the demerger, our designated Workforce Engagement Director, Dame Vivienne Cox, had a specific mandate to connect with our people </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Workforce engagement:</div></div> Dame Vivienne concluded her workforce engagement activities in the first half of the year. This was prior to her transfer to the Haleon Board in July 2022 on the separation of the Consumer Healthcare business. Her programme of visits was conducted on the same basis as she described in previous Annual Reports. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dame Vivienne provided a focus for employee engagement as our designated Workforce Engagement Director from December 2018. Her tenure coincided in its entirety with the programme to transform GSK into a focused biopharma company and the demerger of Consumer Healthcare to form Haleon. She continued to take questions and gather feedback for the Board from employees on the future strategy, shape and culture of the two new independent companies in the build up to separation. In doing so, during 2022 she held listening events with a cross-section of: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consumer Healthcare employees in April 2022 prior to their transfer to Haleon and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Digital and Tech employees in June 2022 that were helping to ensure a strong and secure technology platform for both companies </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Prior to separation, the Board reviewed its formal workforce engagement arrangements. It was decided to move from a specific Workforce Engagement Director model and apply an &#8216;alternative arrangement&#8217; to the three methods set out in the FRC&#8217;s Code. Given that the new GSK Board was recently refreshed in terms of tenure, with over half of the independent Non-Executive Directors (NEDs) having served for less than three years, and with GSK&#8217;s renewed purpose and focus as a global biopharma company, it was considered important to adopt a collective Board engagement model. This was agreed to be the most effective approach to ensure newer Board members meet our people and hear their views. This has been implemented by: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a return to direct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> receptions with local employees, following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> restrictions during Board site visits. During the second half of 2022 these included: Stevenage, UK (as one of our two global R&amp;D hubs), Boston, US, and our Global HQ in Brentford </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Chair undertaking a range of site visits, including: Raleigh Durham, US, to meet with our ViiV employees, King&#8217;s Cross, London where he met with our Artificial Intelligence and Machine Learning team, as well as our Respiratory supply chain employees based in Ware, UK and Aranda, Spain </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Chair and Corporate Responsibility Committee Chair meeting with leaders of our employee resource groups (ERGs) to discuss how they experience GSK as well as hearing their views on progress with our diversity, equity and inclusion (DEI) agenda and ambitions </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">utilising a variety of bespoke engagements that have enabled a broad and open dialogue and facilitated first hand engagement discussions between the NEDs and our people individually and as part of small groups, encompassing perspectives on our strategy, purpose and Ahead Together culture, and DEI </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">115</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Key decisions and engagements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our shareholders </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board seeks to directly engage with and be directly accountable to institutional investors and private retail shareholders. It seeks to discharge this direct and continuous accountability in several ways. These include regular communications, the Annual General Meeting, General Meeting and our Annual Governance Meeting, and through the work of our Investor Relations team, the Chair, Sir Jonathan Symonds, and our Company Secretary, Victoria Whyte. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, our CEO, Emma Walmsley, and CFO, Iain Mackay, gave quarterly results presentations to institutional investors, analysts and the media by webcast. They are also regularly joined by the CSO, the Chief Commercial Officer, and CEO, ViiV Healthcare and GSK Global Health. They are able to provide investors with more detailed insights into their specific areas of responsibility. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Through regular meetings, Emma and Iain have an ongoing and active dialogue with institutional shareholders about our performance, plans and objectives. In 2022 the CEO held a total of 92 engagements with major shareholders, representing approximately 40% of the company&#8217;s share register. The CFO held a total of 113 such engagements with investors making up nearly 40% of the company&#8217;s share register. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Chair has always maintained a constant dialogue with shareholders too &#8211; including fund and portfolio managers &#8211; as well as engaging with governance and ESG professionals. During 2022 and up to the date of publication of this Report, the Chair held 27 meetings with a range of investors, who make up approximately 35% of the company&#8217;s share register. This enables him to gain a current understanding of investor views, insights and perspectives of the company. He discusses the many aspects of Board governance, oversight and succession. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Charles Bancroft was appointed our new SID in July 2022, after the demerger of the Consumer Healthcare business. He has been introducing himself to our shareholders to seek their views on GSK and discuss any key matters of importance. From his appointment as SID to the date of publication of this Report he had 14 meetings with investors making up over 25% of our share register. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Chair, CEO and the rest of the Board had a particular focus in 2022 on communicating the final process for demerging Haleon, the ambitions for GSK as a global biopharma business beyond the demerger and progression of our pipeline over three key focus periods: to 2026, 2026 to 2031 and 2031 and beyond. They also sought investors feedback on our new Remuneration policy. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Governance Meeting </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This year&#8217;s event was a hybrid meeting in central London. Institutional shareholders, key investment industry bodies and proxy advisory firms were invited. Over 14 institutional shareholders attended the event, representing approximately 25% of the company&#8217;s issued share capital. The Chair was joined by our new SID, Committee Chairs and GSK&#8217;s external audit partner and his successor. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We shared with investors the priorities and focus of the Board and its committees in 2022 and the progress made against them. This included: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the execution of a clear plan for separation of Haleon from GSK with strong focus on shareholder value creation </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the creation of two attractive and viable businesses with compelling investment propositions </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">building two highly-qualified Boards to complement the world class management teams </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-architecting</div> the GSK Board </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">supporting the Haleon Board build </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the approval of a new binding Remuneration policy aligned to delivery of GSK&#8217;s public growth and ESG commitments announced at the Investor Update in June 2021 and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">continuous engagement with shareholders and other stakeholders </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The meeting was well-received and shareholder feedback was shared subsequently with the full Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual General Meeting </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We were pleased to be able to hold a hybrid meeting at the Sofitel Heathrow in May 2022. This was the first meeting we were able to hold for in person attendance since the onset of the COVID-19 pandemic. We were pleased to see an increase in attendance by our shareholders compared to the 2021 AGM that had been held virtually at our registered office in Brentford. 94 shareholders joined the meeting in person and 68 shareholders joined virtually to watch or listen to updates from our Chair and the CEO, to ask questions, and vote. With the exception of our proposed Remuneration policy resolution which received shareholder approval of 62%, all our proposed resolutions were approved by shareholders, with majorities ranging from 91% to 99%. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our AGM this year will be held once again in a hybrid format at the Sofitel Heathrow. Shareholders will also have the flexibility to be able to watch and listen, vote and ask questions at the meeting virtually via the Lumi platform and to ask questions via a video connection. See further details on page 299. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Meeting </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, the Board convened a General Meeting at Sofitel Heathrow on 6 July 2022 to seek shareholder approvals to authorise the demerger of Haleon and the related share consolidation for GSK. The Chair, CEO and CFO were present in person with the Company Secretary while the rest of the Board joined the meeting virtually. 46 shareholders joined the meeting in person and 99 shareholders joined virtually. Both resolutions were approved by shareholders with majorities in excess of 99%. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_69" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_28" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Board committee reports </div></div><div style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Corporate Responsibility Committee report </div></div></div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Anne Beal </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Corporate Responsibility Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I am pleased to present this report, which is my first as Chair of the Corporate Responsibility Committee (the Committee). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I joined the Committee in May 2021 and succeeded Lynn Elsenhans as Chair in July 2022 after a comprehensive transition and handover. During her time as Chair, Lynn made an outstanding contribution in overseeing, shaping and embedding our Trust priority and our approach as a responsible business, and, more recently, establishing the six areas of ESG focus for GSK as a pure biopharma company. These six areas &#8211; detailed on pages 42 to 50 &#8211; directly contribute to long-term shareholder value by contributing to our health impact, supporting thriving people and reducing risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I have been drawing on my extensive healthcare experience as a physician and public health expert &#8211; including my time as Chief Patient Officer of Sanofi combined with my passion for patient advocacy, to continue building on the Committee&#8217;s work. I have framed the work and scrutiny of the Committee on the following questions: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">how do we as a company and Committee know how we are performing across our ESG focus areas? </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">can we challenge ourselves to further improve our performance? </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">how we can best report to our key stakeholders on what we have done and the level of impact we have made? </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Driving the Board&#8217;s oversight for enhanced ESG performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A central element of the Committee&#8217;s work over the last 12 months has been devoted to accelerating improvements in how ESG performance is understood and managed. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee agreed the introduction and disclosure of a new ESG Performance Rating &#8211; one of our company KPIs as a key management tool to drive delivery of ESG across our six ESG focus areas. This rating has been derived from assessing the performance of a number of stretching, independently assured metrics across the focus areas to arrive at a single composite measure. The Committee has regularly monitored the company&#8217;s progress against these metrics during the course of the year. We recommended to the Board the publication of a final <div style="font-family: ARIAL; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">on track</div></div></div><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"> ESG Rating for 2022 alongside the other ESG disclosures in this Annual Report and our ESG Performance Report. Further details can be found on page 42 of the strategic report and within the ESG performance report, available on gsk.com. </div></div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ESG performance deep dives </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Throughout the year the Committee has discussed with management the following areas of our ESG focus. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Access and pricing principles:</div></div> The Committee reviewed and recommended to the Board the adoption and publication of GSK&#8217;s Pricing and Access Principles (Principles). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The principles are a high-level articulation of management&#8217;s current approach to pricing and access. They have been prepared with extensive internal and external consultation and had been validated with key audiences including patient advocacy groups drawn from the US and UK. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee, as part of its detailed input on these Principles, made sure that they captured: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the impact value of GSK&#8217;s innovation in terms of economic benefit </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">health equity within and between countries </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the importance of the supply network for access and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">that the Principles are sufficiently flexible to evolve over time and are subject to regular review </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diversity, Equity and Inclusion (DEI):</div></div> The Committee continues to regularly assess the progress of GSK&#8217;s DEI approach and the key metrics identified to drive performance. Metrics to support some of these areas form part of the new ESG Performance Rating, which can be explored further on page 47. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This work includes efforts to further increase our leadership diversity, build a diverse talent pipeline and foster an inclusive culture. The Committee was pleased to note the strong overall progress that was being made towards the gender and ethnicity aspirations for 2025. In particular, it was pleased that the US ethnic diversity aspiration of at least 30% had already been exceeded this year, while further work was being undertaken to increase Black VP representation in the UK. I firmly believe that GSK is doing some outstanding work in this area and have been pleased with how the Committee&#8217;s feedback is being utilised by management to further improve performance for maximum impact. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee also reviewed progress on efforts to broaden diversity of our clinical trial participants, grow our supplier diversity, improve health equity within countries and expand equitable access to STEM education. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environment:</div></div> The Committee has recently reviewed progress on the company&#8217;s ambition for net zero impact on climate and net positive impact on nature. The Committee is satisfied that good progress is being made to date, with a dual focus on maximising the success of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-flight</div> initiatives and developing targeted actions to maintain momentum against stretching ambitions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Human rights:</div></div> The Committee has reviewed management&#8217;s approach and progress on Human Rights including supply chain and third party interactions. We have also considered the complex and rapidly evolving legal and regulatory landscape for Human Rights. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">117</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ESG disclosures and reporting:</div></div> GSK&#8217;s capability in respect of ESG reporting is continually evolving as we challenge ourselves on how best to report clearly and concisely on our performance. This is taking place against greater scrutiny on ESG from all stakeholders, with ESG reporting increasingly moving from voluntary to mandatory. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee considers that GSK has a strong and mature ESG reporting approach, but there is an opportunity to bring the level of control of ESG data up to the same level as controls for financial data. With this in mind, the Committee has approved establishing an ESG data assurance hub to further strengthen ESG data oversight. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Collaborating with other Board committees </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There has been a careful division of responsibilities and allocation of the workload between this Committee and the Remuneration Committee, in respect of the introduction of specific ESG targets into our short- and long-term incentive plans from the beginning of 2022. We have been monitoring and helping the Remuneration Committee determine vesting outcomes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Audit &amp; Risk Committee (ARC) supported the Committee in its discussions over the introduction, measurement and disclosure of the ESG Performance Rating. The Committee will also work closely with the ARC from this year onwards over the implementation and operation of enhanced ESG data assurance oversight and determinations, which the ARC Chair sets out further in his report on page 125. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Anne Beal </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Corporate Responsibility Committee Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Science Committee report </div></div></div></div><div style="margin-top:20pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Jesse Goodman </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Science Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I am pleased to present this report as Chair of the Science Committee (the Committee) on our activities during 2022. It is the first since the demerger of Consumer Healthcare as Haleon in July 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key activities in 2022 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As a result of the demerger, GSK is now a pure biopharma business with a goal of uniting Science, Technology and Talent to better prevent and treat disease. In R&amp;D, we are combining the power of genetic and genomic insights into what causes disease, with the speed and scale of Artificial Intelligence and Machine Learning to make better predictions about who a treatment might work for, and why. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This renewed focus has been evident in the Committee&#8217;s discussions for some time and I am excited for the future opportunities it brings for GSK and its patients. The Committee&#8217;s key activities in 2022 can be split into the following key areas, which are covered in more detail below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pipeline reviews:</div></div> monitoring of GSK&#8217;s pipeline </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scientific deep-dives: </div></div>discussion and analysis of the key scientific themes which drive the company&#8217;s R&amp;D strategy </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business development:</div></div> undertaking technical reviews and assurance of the underlying science of potential business development transactions </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pipeline progress </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fundamental to GSK&#8217;s achievement of its growth ambitions is the delivery of a successful pipeline, which the Committee has continued to monitor throughout the year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2021, the Committee participated in the Chief Scientific Officer (CSO) succession planning process. This led to the appointment of Dr Tony Wood in August 2022. Dr Wood has since continued to build on the outstanding progress made by Dr Hal Barron. Prior to his appointment as CSO, Dr Wood was integrally involved in delivering R&amp;D productivity improvement and helped develop GSK&#8217;s current R&amp;D approach focused on the science of the immune system, human genetics and advanced technologies. Consequently, he was well-placed to implement a pipeline to deliver on GSK&#8217;s bold ambitions for patients. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An exceptional milestone during this year was the very positive results from our late-stage respiratory syncytial virus vaccine candidate. The vaccine demonstrated unprecedented efficacy in older adults and has the potential to help reduce disease and death from a major respiratory infection which has not, until now, been vaccine preventable. Our regulatory submission for the vaccine has been accepted for review in Japan, accepted by the European Medicines Agency under accelerated assessment and was submitted to and granted Priority Review status by the US Food and Drug Administration (FDA). </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">118</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee was also delighted with the positive phase III results for gepotidacin, a novel oral antibiotic, in the treatment of uncomplicated urinary tract infections. This is an important step in GSK&#8217;s continued scientific commitment and investment to address antimicrobial resistance (AMR). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our licensing agreement with Spero Therapeutics (see below) provides further evidence of our continued leadership and focus in tackling infectious diseases and AMR. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A number of key approvals were also obtained during the year: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FDA approval of </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Boostrix</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> for immunisation during pregnancy for the prevention of whooping cough in newborn infants </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FDA approval of </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Menveo</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y and W </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FDA approval of </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Priorix</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> for the prevention of measles, mumps and rubella in individuals 12 months of age and older </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As well as having an exciting late-stage pipeline, we also now have a robust early-stage portfolio with a number of innovative programmes capable of transforming the lives of patients. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business development transactions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK is viewing research and development holistically and placing great importance on external as well as internal innovation to source promising new medicines and vaccines. During the year, the Committee continued to assess business development transactions from a scientific perspective. The acceleration of business development will be key to support GSK&#8217;s organic pipeline growth. Transactions reviewed by the Committee during the year include: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sierra Oncology:</div></div> The acquisition of Sierra Oncology, a biopharmaceutical company focused on targeted therapies for rare forms of cancer. The acquisition included momelotinib, a new medicine with a unique dual mechanism of action intended to address the critical unmet medical needs of myelofibrosis patients with anaemia. A new drug application for momelotinib for the treatment of myelofibrosis was accepted in August 2022 by the FDA and in December 2022 by the EMA. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Affinivax:</div></div> The acquisition of Affinivax, a clinical-stage biopharmaceutical company, providing GSK with access to a next generation pneumococcal vaccine candidate and highly innovative Multiple Antigen Presenting System (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MAPS</div></div>) technology. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mersana Therapeutics:</div></div> The collaboration with Mersana Therapeutics for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and commercialisation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056,</div> a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> HER2 STING antibody drug conjugate, initially for the treatment of advanced breast cancer. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Spero Therapeutics:</div></div> The licensing agreement with Spero Therapeutics for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections. There is a significant unmet medical need for a novel oral antibiotic that can potentially provide an alternative to intravenous therapy, particularly for patients with multi-drug resistant organisms. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wave Life Sciences:</div></div> This collaboration brings together Wave&#8217;s PRISM<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">TM</div> oligonucleotide platform and GSK&#8217;s expertise in genetics and genomics to drive the discovery and development of oligonucleotide therapeutics focusing on novel genetic targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tempus: </div></div>The collaboration with Tempus provides GSK with access to Tempus&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-enabled</div> platform including its library of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-identified</div> patient data &#8211; one of the world&#8217;s largest sources of clinical and molecular data. Through its own leading AI/ML capability, GSK will work with Tempus both to identify new drug targets and improve clinical trial design, speeding up enrolment and completion, and accelerating the development of personalised treatments for patients. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s dedicated AI/ML team is the largest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> strategic function in the biopharma industry. Collaborations between R&amp;D and Technology within GSK have become increasingly important in drug discovery, enabling GSK to more rapidly and effectively design new vaccines and medicines. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scientific deep-dives </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee also dedicated a significant proportion of its time to discussing some of the most exciting and innovative areas of science which have been driving the company&#8217;s R&amp;D strategy. Deep-dives undertaken during the year include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Phase 1 Pipeline review </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">RNA based therapeutics and vaccines </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Oncology </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In particular, the Committee&#8217;s discussion of RNA, including oligonucleotide therapeutics, provided important insights into emerging science with the potential to transform the lives of patients. In November 2022, the company published positive results from a phase IIb trial evaluating the safety and efficacy of bepirovirsen &#8211; a potentially transformative treatment for people living with chronic hepatitis B. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The results offer an early indication that bepirovirsen might be a potential treatment, either as monotherapy or in combination with other drugs, that could result in a functional cure. GSK&#8217;s expertise in human genetics, functional genomics and AI/ML to identify novel, genetically validated targets, as well as our recent collaboration with Wave Life Sciences referred to above, demonstrate that we are well-positioned to become a leader in oligo-based therapeutics. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee changes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As previously mentioned, in August 2022 Dr Tony Wood succeeded Dr Hal Barron as CSO. Tony is an outstanding and highly respected scientist and the Committee had engaged with him regularly in advance of his appointment. Dr Barron transitioned to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director and member of the Committee. The Committee, and GSK, will therefore continue to benefit from his expert advice and support on scientific matters. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dr Laurie Glimcher retired from the Board in October 2022. I would like to thank Laurie for her valuable expertise and scientific insights contributed to the Committee during her tenure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Finally, having chaired the Committee since its inception over six years ago, my rotation as Chair concluded effective 1&#160;January 2023. Dr Hal Dietz, who joined the Committee on 1&#160;January 2022, has succeeded me as Committee Chair. His experience in human genetics, which is central to GSK&#8217;s approach in R&amp;D, has already proven invaluable in the Committee&#8217;s discussions. He is an excellent successor in the role of Chair. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">It has been a privilege to work with GSK&#8217;s outstanding scientists and leaders, as well as my fellow Committee members, and to chair the Committee during what has been a transformational period, both for the company and the scientific fields in which we operate. I remain a member of the Committee and look forward to continuing the progress outlined today. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Jesse Goodman </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Science Committee Chair (2017-2022) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nominations&#160;&amp; Corporate Governance </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee report </div></div></div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jonathan Symonds </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Nominations&#160;&amp; Corporate Governance Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I am pleased to present my fourth report as Chair of the Nominations&#160;&amp; Corporate Governance Committee (the Committee). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key activities in 2022 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, the Committee continued its important role in the process of: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">delivering the demerger of Haleon from the Group as a key Board governance workstream and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">creating two attractive and viable businesses with compelling investment propositions, directed and overseen by highly capable boards </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This was achieved in an orderly and targeted manner by building two highly-qualified boards to complement their world class leadership teams through: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">supporting the shaping and creation of the Haleon Board; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">restructuring the GSK Board with a new focus and expertise for a pure biopharma business </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Haleon Board appointments </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In my report last year, I described the work of the Committee in appointing the CEO, CFO and Chair designates of Haleon. I also disclosed that two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> members of the GSK Board were expected to transfer to the Haleon Board on completion of the demerger. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee subsequently supported the Haleon Chair, Sir Dave Lewis, in finalising the search for and the appointment of high calibre <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors to complete the Haleon Board and its committees. The Board subsequently endorsed the Committee&#8217;s recommendation to transition Vindi Banga and Dame Vivienne Cox to the Haleon Board on completion of the demerger. The Committee considered that the Haleon Board would benefit from both their knowledge and experience. They would also provide important continuity for Haleon post-demerger. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Separately, the company&#8217;s Consumer Healthcare joint venture partner (Pfizer) exercised its right to appoint two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors to the Haleon Board. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shaping our new biopharma Board </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I previously described the process to transition the GSK Board as<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>a pure focused global biopharma company and the work undertaken by the Committee in designing and planning the optimal structure and composition of the new biopharma Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee wanted to ensure that new Non-Executive Director appointments would further deepen the biopharma skills, expertise and experience on the Board. A global search process was activated to appoint directors with deep life sciences commercial expertise and Artificial Intelligence and Machine Learning (AI/ML) expertise. A diverse list of such candidates was identified, shortlisted and then interviewed by Committee members, the CEO, CSO and our Chief People Officer. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">120</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following careful review, the Committee was pleased to recommend the appointment of two high calibre individuals, Dr Vishal Sikka and Elizabeth McKee Anderson, as independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors with effect from 18&#160;July and 1&#160;September 2022, respectively. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vishal has a very distinguished background as a world-leading technologist and most particularly in the field of AI/ML, which is not only central to GSK&#8217;s approach to R&amp;D, but is also embraced across the Group. Meanwhile, Liz brings significant commercial understanding and experience in commercial biopharmaceuticals and is a seasoned biotech board member. Their contributions are already proving invaluable to the Board as a fully focused biopharma company. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Further details of Vishal and Liz&#8217;s experience and biographies can be found on pages 100 and 97. The rationale for their appointments was included in the company&#8217;s announcements on 4 May and 24 August 2022 respectively. They are available on gsk.com. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dr Hal Dietz was appointed to the Board at the end of 2021, he joined the Board as a designated Scientific and Medical Expert on 1&#160;January 2022. He has extensive experience in the field of human genetics, which is also central to GSK&#8217;s approach to R&amp;D. The recruitment process for his appointment by the Committee was described in my report last year. After a year on the Board, Dr Dietz began his rotation as Science Committee Chair from 1&#160;January 2023 in succession to Dr Jesse Goodman. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Senior Independent Director (SID) succession </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Vindi Banga performed the role of SID for over six years. Vindi&#8217;s transition to the Haleon Board on completion of the demerger created the opportunity to appoint a successor. The Committee determined that Charles Bancroft, having served two years on the Board, with experience of working with investors from his role as CFO at Bristol Myers Squibb, a deep understanding of the pharma industry, his experience as a non-executive director of listed companies and having sufficient time to dedicate to the role, made him the ideal successor. He succeeded Vindi with effect from 18&#160;July 2022. The Board fully endorsed his appointment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Continuing to shape the GSK Board for the future </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Management succession planning </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I previously described the work of the Committee in the appointment of Dr Tony Wood as successor to Dr Hal Barron as CSO and a member of GLT. The transition of Drs Wood and Barron into the roles of CSO and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Independent</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director took effect as planned on 1&#160;August 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CFO succession </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When our CFO, Iain Mackay, advised the Board of his intention to step down from the Board and leave the company, the Committee activated its CFO succession plan. A targeted search of high-quality executives for CFO succession had already been undertaken against a role profile for the next CFO for GSK as a pure biotech. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee proposed, and the Board approved, the appointment of Ms Julie Brown as successor to Iain Mackay as CFO. Julie, currently Chief Operating and Financial Officer at Burberry Group plc, will join GSK in April 2023 and will work with Iain to transition his responsibilities. She will take on responsibilities as CFO and as an Executive Director on 1&#160;May 2023. Our CFO succession process is described in more detail below. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the Committee&#8217;s view, the ideal successor to Iain was a proven CFO of a global public company with deep biopharmaceutical experience. He or she would need to be an effective business partner to the CEO in the successful delivery of GSK&#8217;s growth ambitions. It was also important to the Committee that the successor be a good fit with our new culture and have a high energy and a positive mindset. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A thorough global search was initiated against this agreed profile. A shortlist of viable candidates was identified for the role. The CEO, other members of the Committee, the Chief People Officer and I met with Julie and there was unanimous support that she be recommended as Iain&#8217;s successor. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board is looking forward to welcoming Julie to GSK. She is a highly respected CFO with extensive experience in the biopharma and medtech sectors. Further details of Julie&#8217;s experience and the rationale for her appointment are included in the company&#8217;s announcement on 24&#160;September 2022, which is available on gsk.com. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GLT changes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition to the new CSO and CFO, the Committee has also reviewed the following internal senior executive changes to the GLT to help bring further simplification and alignment of the GLT in these areas: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Luke Miels, Chief Commercial Officer, assumed full accountability for strategic commercial product development of vaccines, alongside his current accountabilities for strategic product development in Specialty and General Medicines and the commercial performance of the GSK portfolio in markets </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Regis Simard, President Global Supply Chain, assumed accountability for both Vaccines and Medicines supply </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Deborah Waterhouse, Chief Executive Officer ViiV Healthcare, assumed overall accountability for GSK Global Health </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Roger Connor, President of Vaccines and Global Health, left GSK to progress a new role in healthcare, outside biopharma </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee continues to review our talent and succession pipelines and development plans for key management roles and their successors. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director succession planning </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee regularly reviews the Board&#8217;s composition and skills. It will be working with the Science Committee for the potential to add a further Scientific and Medical Expert, as the Board seeks to further contribute to our biopharma skills and expertise to support our growth ambitions. The Committee is also looking to identify a successor to Urs Rohner, our Remuneration Committee Chair, who is due to retire from the Board in 2024. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I look forward to providing further updates on these roles next year. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">121</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Composition and tenure </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_122a.jpg"/> </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board seeks to balance its composition and tenure, and that of its committees, and to refresh them over time. This enables the Board to benefit from the experience of longer-serving Directors as well as the fresh perspectives and insights from newer appointees. Our Non-Executive Directors are now drawn from industries and backgrounds most relevant to a </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">pure biopharma company, including life sciences, the pharmaceuticals industry, R&amp;D and Tech, vaccines and healthcare, medical research and academia and financial services. Collectively they have a wealth of experience of complex businesses with global reach. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diversity, equity and inclusion </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_122b.jpg"/> </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Target female representation on Board is 40%. Data from GSK Annual Report published in the first quarter of each year. Current female representation is 27.2% at the date of publication. This is expected to rise to 36% in May 2023 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-CFO</div> succession </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are committed to the diversity of our Board, just as GSK is committed to equal opportunities for all employees at all levels of our organisation. The Board and management seek to encourage a diverse and inclusive culture throughout the company. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An effective Board needs a range and balance of skills, experience, knowledge, ethnicity, gender, social-economic backgrounds and independence, with individuals who are prepared to challenge each other collaboratively. This mix needs to be complemented by a diversity of personal Board </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">attributes, including character, intellect, judgement, honesty and courage. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee is responsible for developing measurable objectives and monitoring progress towards their achievement to assist the implementation of the Board&#8217;s diversity policy (Policy), including gender and ethnic diversity. As a minimum, we seek to align our Policy objectives with the Financial Conduct Authority, FTSE Women Leaders Review and Parker Review diversity targets and ensure that they are consistent with our public diversity, equity and inclusion (DEI) aspirations. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-radius:5pt; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto;background-color:#e7e7e8">
<tr style="font-size: 0px;">
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;vertical-align:bottom"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board and GLT gender diversity</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diversity objective</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">At least 40% of Board positions held by women</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">Below&#160;objective&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">27.2%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">At least one woman either in the Chair, SID role on the Board and/or one</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">Met objective</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">One Director (CEO)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">woman in the Chief Executive Officer or Finance Director role by the end of 2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">At least 40% of GLT positions held by women</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">Met objective</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">41.7%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">At least one Board Director is ethnically diverse</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">Exceed objective</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top">Two Directors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td>
<td colspan="2" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In May 2023, when Julie Brown becomes our new CFO, female Board representation will stand at 36%. GSK will then have one of the very few <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">all-female</div> Executive Boards running a FTSE 100 company. We also expect to fully restore our Board gender diversity to meet or exceed 40% by 2024. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board has been pleased that for many years its gender representation objective has been in excess of the target of over 40% of Board positions being held by women. This is illustrated on the previous page of my Committee report. The composition and diversity of the Board is currently in a transitional period following the demerger and the reshaping of the Board for the new biopharma company, the transfer of Board members to Haleon and the retirement of two female Board Directors. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We also continue to oversee the developing pipeline of direct reports to the GLT by gender and from ethnically diverse backgrounds. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of GSK&#8217;s representation of women and ethnically diverse leaders is covered on page 47, as part of the diversity of our global workforce. Progress against our DEI commitments, including gender and ethnicity, is illustrated in our ESG Performance Report on gsk.com. This good progress has also been incentivised by the introduction of an ESG: DEI measure in the annual bonus arrangements for our Executive Directors and other GLT members. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Board committee and GLT membership and role changes in 2022 </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Director/GLT member</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Membership/Role</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appointment date</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retirement&#160;date</div></div></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Elizabeth McKee Anderson</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Audit&#160;&amp; Risk and Remuneration committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">1&#160;September</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dr Hal Barron</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Science Committee (following transition to role of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">1&#160;August</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Charles Bancroft</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Science Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">8&#160;February (stepped&#160;down&#160;after<br/>Dr Hal Dietz joined the Committee)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Senior Independent Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Remuneration Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Vindi Banga</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Audit&#160;&amp; Risk, Nominations&#160;&amp; Corporate Governance and Remuneration committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18&#160;July</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Senior Independent Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dr Anne Beal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Corporate Responsibility Committee Chair</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">4&#160;May</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Nominations&#160;&amp; Corporate Governance and Remuneration committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Audit&#160;&amp; Risk Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">25&#160;October</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dame Vivienne Cox</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Corporate Responsibility and Remuneration committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Dr Hal Dietz</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Science Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1&#160;January</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Science Committee Chair</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">1&#160;January&#160;2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Lynn Elsenhans</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Corporate Responsibility Committee Chair</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4&#160;May</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Audit&#160;&amp; Risk, Corporate Responsibility and Nominations &amp; Corporate Governance committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18&#160;July</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dr Jesse Goodman</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Science Committee Chair</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">31&#160;December</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dr Laurie Glimcher</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Audit&#160;&amp; Risk and Science committees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">10&#160;October</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Urs Rohner</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Audit&#160;&amp; Risk Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Dr Vishal Sikka</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Corporate Responsibility Committee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">18&#160;July</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Roger Connor</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">President, Global Vaccines</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">1&#160;December</td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Dr Tony Wood</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Scientific Officer and GLT member</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1&#160;August</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1px">
<td colspan="7" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #efedec;border-radius:5pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt"><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; padding-top:2pt; margin-left:5pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ways of working </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; margin-left:5pt; margin-right:5pt; font-size:8.5pt; font-family:ARIAL">The Committee seeks to follow best practice in all the appointments it recommends, agreeing the criteria for each role, the most appropriate interview panel, before then considering a comprehensive and diverse long list of candidates. Shortlisted candidates are interviewed and assessed against the chosen criteria. Due diligence is then undertaken before the Committee makes its final recommendation. Executive search firms are appointed in accordance with the company&#8217;s procurement policy based on their expertise relative to each role. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:5pt; margin-right:5pt; font-size:8.5pt; font-family:ARIAL">The Committee has agreed that only search firms who are signatories to the Voluntary Code of Conduct of Executive Search Firms on gender diversity and best practice will be engaged. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:5pt; margin-right:5pt; font-size:8.5pt; font-family:ARIAL">The Committee worked with a number of executive search firms in 2022, who provided additional consultancy services to the company as outlined below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt">&#160;</td>
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Korn Ferry: general recruitment, executive search and assessment services, coaching and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HR-related</div> services </div></td>
<td style="width:4.5pt">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt">&#160;</td>
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Egon Zehnder: executive search, assessment and coaching services to specific senior executives </div></td>
<td style="width:4.5pt">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt">&#160;</td>
<td style="width:6.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Heidrick&#160;&amp; Struggles: executive search services </div></td>
<td style="width:4.5pt">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; padding-bottom:2pt; margin-left:5pt; margin-right:5pt; font-size:8.5pt; font-family:ARIAL">The Committee reviewed the potential for conflicts of interest and judged that there were appropriate safeguards against such conflicts. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I look forward to reporting further progress in next year&#8217;s report. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Nominations&#160;&amp; Corporate Governance Committee Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit&#160;&amp; Risk Committee report </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charles Bancroft </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Audit&#160;&amp; Risk Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I am pleased to present this report, which is my second as Chair of the Audit&#160;&amp; Risk Committee (the Committee). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In my report last year, I spoke about my initial, very favourable, impressions of the people, processes, systems and culture at GSK that underpin the successful management of financial reporting, audit, litigation and compliance risks. I am pleased to report that GSK continues to exhibit a strong compliance culture with a consistent tone and engagement from the top that runs throughout the organisation, and the financial reporting and controls framework remains robust and did not require any fundamental changes during the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key activities in 2022 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key decisions:</div></div> As usual, it has been a busy year for the Committee. Not only working through its regular programme of activities, but making important decisions in support of the Board&#8217;s progression of its key priorities, in summary: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">recommended to the Board approval of the planned separation of our Consumer Healthcare business in July 2022, based on the Committee&#8217;s awareness and review of the transaction and Haleon&#8217;s operational readiness, and the approval of final issuance of public documents and entry into associated legal agreements </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">exercised oversight for the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> product liability litigation by which I provided regular reports to the Board on progress </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">conducted a robust review process, together with the CFO, to select and appoint a replacement to the current lead audit partner, who under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">five-year</div> audit partner rotation rules, rotates off after the publication of this Annual Report. Further details are set out on page&#160;128 </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Completion of the demerger </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">I highlighted, in my report last year, details of the technical work of the Committee as a key demerger governance workstream. This included overseeing the evolution of financial reporting matters, risk and controls and the public documents associated with delivering the demerger and listing to form Haleon. This work continued and intensified through the first half of 2022 to the point at which the Committee was able to complete its review processes and recommend the approval of the GSK Circular, Haleon Prospectus and Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> and associated documents and matters to the Board. Separately, the Committee reviewed the processes to establish financial reporting systems and development of a robust internal control and risk management framework for Haleon. This was a significant and critical demerger workstream that was successfully delivered months prior to the demerger on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">business-as-usual</div></div> basis. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">124</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information and cyber security </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This is one of our principal risks which is regularly on the Committee&#8217;s agenda. During 2022 the Committee oversaw the merging of programme deliverables into an updated Cyber Maturity Plan (CMP) with additional capabilities to continue to get ahead of a dynamic threat environment. The Committee has also reviewed the benchmarking of our target cyber maturity against an industry best-practice framework, known as the National Institute of Standards and Technology Cyber Security Framework (NIST-CSF) and these learnings have been incorporated into the CMP. The Committee will continue to perform regular assessments of delivery against the Plan to further enhance the capabilities and maturity of our cyber security framework. I am pleased that the Committee&#8217;s oversight in this area has been further strengthened this year with the expertise of my fellow Board Director colleague, Dr Vishal Sikka, who advises the Committee on this enterprise risk. Vishal has a distinguished career in the Tech industry and served as CEO of Infosys Limited and provides the Committee and management with valuable insights. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key risk indicators </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For several years now, our Compliance function has worked with risk owners and management to develop and report to the Committee on key risk indicators (KRIs) at an enterprise level and across our markets. As a core part of this process, we have been using enhancements in our technology and data analytics capabilities to employ a more data-driven approach to risk management across a constantly evolving risk landscape to further strengthen our compliance oversight and culture. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Earlier this year, the Committee examined a review of our principal risks resulting in a simplified process with fewer KRIs, new KRIs, some revised definitions, and prioritisation of the most meaningful indicators for the company. The Committee was pleased to note that this simpler approach would result in more focus on fewer KRIs reported to Risk Oversight&#160;&amp; Compliance Council (ROCC) which then reports to the Committee, with a greater focus being brought to bear on escalation of issues or concerns that are material to GSK. Meanwhile, operational data, monitoring findings and other established risks would continue to be analysed by risk owners to ensure appropriate risk mitigation continues and escalation, if necessary. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Zantac</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> litigation oversight </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, primary oversight for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> litigation, the related accounting, disclosure and communication assessments has continued to be undertaken by the Committee. I then report the Committee&#8217;s conclusions on these matters to the Board. The Committee continues to receive regular legally privileged updates. In December 2022, we welcomed the ruling by the United States District Court (Southern District of Florida) which dismissed all federal cases alleging the five remaining cancers in the Multi-District Litigation. We will continue to defend all claims brought at State level vigorously based on the science. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit quality indicators </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Audit Quality Indicators (AQIs) are quantitative and qualitative measures of external audit quality at an audit <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">firm-level,</div> an engagement level and from a management or company perspective. Together with our lead audit partner, I was pleased to participate in a project carried out by the FRC to identify the most useful engagement level AQIs relevant for the audit to help improve transparency and drive audit quality improvements. Our engagement with the FRC focused on our most recent Annual Report and considered the interactions between the auditor and the Committee during the audit process. We had a constructive dialogue and one which I hope was helpful to the FRC in progressing its work in promoting key drivers of audit quality. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee aims in 2023 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee&#8217;s remit has expanded from 2023 onwards as the Board has requested that it exercise oversight and review of GSK&#8217;s ESG data assurance work. In doing so, the Committee is currently overseeing the build and implementation of a new dedicated ESG data assurance hub in our Finance organisation to support this. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The hub will ensure minimum standards of controls, governance and data quality to assure the accuracy of ESG data in support of the company&#8217;s performance against ESG metrics and compliance with new ESG reporting requirements. Meanwhile, our Corporate Responsibility Committee, on behalf of the Board, continues to exercise oversight of ESG strategy, performance assessment and reporting. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Internal control framework </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board recognises its obligation to present a fair, balanced and understandable assessment of GSK&#8217;s current position and prospects. Reflecting this responsibility, it is accountable for evaluating and approving the effectiveness of GSK&#8217;s internal controls, including financial, operational and compliance controls, and risk management processes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We ensure the reliability of our financial reporting, and compliance with laws and regulations, through our internal control framework. This is a comprehensive enterprise-wide risk management model which supports the Board&#8217;s continuous identification, evaluation and management of the Group&#8217;s principal and emerging risks, as required by the FRC&#8217;s Code. The framework is designed to manage the risk of GSK not achieving its business objectives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fit-for-purpose</div></div> framework &#8211; complemented by our corporate culture and Speak Up processes &#8211; ensures that the risks associated with our business activities are actively and effectively controlled in line with our agreed risk appetite. We believe GSK&#8217;s framework provides reasonable, but not absolute, assurance against material misstatement or loss. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">125</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board mandates the Group&#8217;s ROCC of senior leaders to assist the Committee in overseeing risk management and internal control activities. It also provides the business with a framework for risk management and upward escalation of significant risks. Risk Management and Compliance Boards (RMCBs) across the Group promote the &#8216;tone from the top&#8217; and establish our risk culture, as well as ensuring effective oversight of internal controls and risk management processes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each principal risk has an assigned risk owner, drawn from senior management, who is accountable for managing the principal risk with oversight from a GLT member, which includes setting and implementing risk mitigation plans. Risk owners report quarterly on their respective risk management approach and progress at the ROCC and the appropriate Board Committee. Our Compliance function assists the ROCC and RMCBs. Compliance is responsible for advancing enterprise-wide risk management and for developing risk-based and ethically sound working practices. It also actively promotes ethical behaviours by enabling all employees to operate in line with our culture and comply with applicable laws and regulations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Audit&#160;&amp; Assurance (A&amp;A) function provides independent assurance to senior management and the Board on the effectiveness of risk management Group-wide, in line with an agreed assurance plan. This helps senior management and the Board to meet their oversight and advisory responsibilities in fulfilling GSK&#8217;s strategic objectives and building trust with patients and other stakeholders. A&amp;A has a dual reporting line to the CFO and the Committee. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee receives regular reports from principal risk owners, Compliance and A&amp;A on areas of significant risk to the Group and on related internal controls. These reports assess the internal control environment within each principal risk area, including enhancements to strengthen controls. Following consideration of these reports, the Committee reports annually to the Board on the effectiveness of GSK&#8217;s internal controls. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, through the authority delegated to the Committee, the Board conducted a robust assessment of the Group&#8217;s principal risks. This assessment, which was in line with the FRC&#8217;s Code, included consideration of the nature and extent of risk the Board is willing to take in achieving GSK&#8217;s strategic objectives. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board, via the Committee, also oversaw the effectiveness of our internal control environment and risk management processes across the Group for the whole year, up to the approval date of this Annual Report. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A review of the Group&#8217;s risk management approach is further discussed in the &#8216;Risk management&#8217; section of the strategic report on pages&#160;51&#160;to&#160;64. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The management of each principal risk is explained in &#8216;Principal risks and uncertainties&#8217; on pages 285 to 295. The Group&#8217;s viability is discussed in the Group risk management section of the strategic report on page 64. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant issues relating to the financial statements </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In considering GSK&#8217;s quarterly financial results announcements and the financial results in the 2022 Annual Report, the Committee reviewed the significant issues and management judgements in determining those results. It reviewed management papers setting out the key areas of risk, actions taken to quantify the effects of the relevant issues, and judgements made by management on the appropriate accounting required to address those issues in the financial statements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The significant issues considered in relation to the financial statements for the year ended 31&#160;December 2022 are set out in the following table, with a summary of the financial outcomes where appropriate. The Committee and the external auditor have discussed the significant issues addressed by the Committee during the year and the areas of particular audit focus, as described in the Independent Auditor&#8217;s Report on pages 168 to 181. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">126</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:68%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Significant issues considered by the Committee</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">in relation to the financial statements</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How the issue was addressed by the Committee</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Going concern basis for the preparation</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of the financial statements</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee considered the outcome of management&#8217;s half-yearly and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> reviews of current and forecast net debt positions and the various financing facilities and options available to the Group. The Committee also considered management&#8217;s review of the impacts of the current economic environment and climate change impacts. Following consideration of these assessments, which included stress testing and viability scenarios, sources of liquidity and funding, forecasts and estimates, the Committee confirmed that the application of the going concern basis for the preparation of the financial statements continued to be appropriate.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue recognition, including returns</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and rebates (RAR) accruals</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee reviewed management&#8217;s approach to the timing of recognition of revenue and accruals for customer returns and rebates. The RAR accrual for US Commercial Operations was &#163;5.9&#160;billion at 31&#160;December 2022 and the Committee reviewed the basis on which the accrual had been made and concurred with management&#8217;s judgements on the amounts involved. A fuller description of the process operated in US Commercial Operations in determining the level of accrual necessary is set out in &#8216;Critical accounting policies&#8217; on pages 94 and 95.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provisions for legal matters, including investigations into the Group&#8217;s</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">commercial practices</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee received detailed reports on actual and potential litigation from both internal and external legal counsel including the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div>litigation, together with a number of detailed updates on investigations into the Group&#8217;s commercial practices. Management outlined the levels of provision and corresponding disclosure considered necessary in respect of potential adverse litigation outcomes and also those areas where it was not yet possible to determine if a provision was necessary, or its amount. At 31&#160;December 2022, the provision for legal matters was &#163;0.2&#160;billion, see Note 32 to the financial statements, &#8216;Other provisions&#8217; for more details.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provisions for uncertain tax positions</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee considered current tax disputes and areas of potential risk and concurred with management&#8217;s judgement on the levels of tax contingencies required. At 31&#160;December 2022, a tax payable liability of &#163;0.6&#160;billion, including provisions for uncertain tax positions, was recognised on the Group&#8217;s balance sheet.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairments of intangible assets</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee reviewed management&#8217;s process for reviewing and testing goodwill and other intangible assets for potential impairment. The Committee accepted management&#8217;s judgements on the intangible assets that required writing down and the resulting impairment charge of &#163;402&#160;million in 2022. See Note 20 to the financial statements, &#8216;Other intangible assets&#8217; for more details.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Valuation of contingent consideration</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">in relation to ViiV Healthcare</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee considered management&#8217;s judgement that it was necessary to increase the liability to pay contingent consideration primarily as a result of updated exchange rate assumptions as well as increases in sales forecasts and the unwind of the discount. After cash payments of nearly &#163;1.1&#160;billion in the year, at 31&#160;December 2022, the Groups&#8217; balance sheet included a contingent consideration liability of &#163;5.9&#160;billion in relation to ViiV Healthcare. See Note 33 to the financial statements, &#8216;Contingent consideration liabilities&#8217; for more details.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ViiV Healthcare put option</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee reviewed and agreed the accounting for the Pfizer put option and concurred with management&#8217;s judgement on the valuation of the put option of &#163;1.1&#160;billion at 31&#160;December 2022.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consumer Healthcare demerger</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Committee reviewed management&#8217;s process for presenting Consumer Healthcare as a discontinued operation and the subsequent demerger accounting. The gain on the demerger of &#163;10.1&#160;billion included significant values relating to the fair value of assets distributed and ownership in Haleon retained, the net assets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">distributed/de-recognised</div> and the cumulative foreign exchange recycled. See Note 41 &#8216;Acquisitions and Disposals&#8217; to the financial statements for more details.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">127</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effectiveness and quality of external audit process </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee is committed to ensuring that GSK receives a high-quality and effective external audit. In evaluating Deloitte&#8217;s performance during 2021, prior to making a recommendation on its reappointment in early 2022, the Committee reviewed the effectiveness of its performance against the criteria which it agreed with management at the beginning of 2021. The detailed criteria used for judging the effectiveness of Deloitte as external auditor are available on gsk.com. These are based on the audit approach and strategy, ensuring a high-quality independent audit, effective partnership and value for money. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee monitors engagements with external stakeholders relevant to the Committee&#8217;s areas of oversight, including the FRC and Securities and Exchange Commission. During the year the FRC&#8217;s Audit Quality Review (AQR) team reviewed Deloitte&#8217;s audit of the Group&#8217;s 2021 financial statements as part of its annual inspection of audit firms. The Committee received and reviewed the final report from the AQR team which identified no key findings, assessed the audit as requiring limited improvement and noted several areas of good practice. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee sought to ensure that Deloitte would deliver a smooth, thorough and efficiently-executed audit for 2022. In undertaking its review, the Committee considered: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the overall quality of the audit </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the independence of Deloitte </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">whether Deloitte exhibited an appropriate level of challenge and scepticism in its work </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deloitte&#8217;s length of tenure was not taken into account when assessing its independence and objectivity, given it only commenced its role as auditor in 2018. However, the Committee did consider how effectively it had assumed its role as auditor. The Committee also considered feedback on the 2022 external audit, through a survey of Committee members and the financial management team at corporate and business unit level. The survey covered the: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">effectiveness of the auditor&#8217;s challenge </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">integrity of Deloitte </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">transparency of its reporting to management and the Committee </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">clarity of the auditor&#8217;s communications and ways of working </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">alignment of the 2021 audit to the Group&#8217;s investment in Systems, Applications and Products (SAP) </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">quality of the audit team&#8217;s leadership and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">skills and experience of the audit team </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee Chair regularly meets independently with the audit partners. The Committee also meets with the auditor privately at the end of each meeting to discuss progress, as appropriate. Having reviewed the above feedback, and noted any areas of improvement to be implemented by the audit team for 2023, the Committee was satisfied with the: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#8211; effectiveness of the auditor and the external audit process and </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">auditor&#8217;s independence, qualifications, objectivity, expertise and resources </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee therefore agreed to recommend the reappointment of Deloitte to the Board at the forthcoming AGM. In making its recommendation, the Committee was free from the influence of any third party. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Auditor&#8217;s reappointment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External auditor </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:45%"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">External auditor appointment</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Last tender</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">May &#8211; December 2016</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Transition year</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2017</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">First shareholder approval of current auditor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">May 2018</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">First audited Annual Report and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Year ending 31&#160;December 2018</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">New lead audit engagement partner</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Next audit tender required by regulations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2026 (to take effect from 2028)</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no contractual or similar obligations restricting the Group&#8217;s choice of external auditor. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit partner rotation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The external auditor is required to rotate the audit engagement partner for GSK every five years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our current audit partner is due to step down from their position after the audit of GSK&#8217;s financial statements for 2022 has been concluded. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">After a robust review process by the Committee, together with the involvement of the CFO, to select their replacement, the Committee approved the appointment of the next audit engagement partner with effect from the financial year commencing on 1&#160;January 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee is satisfied that Deloitte has been managing an orderly handover to the new audit engagement partner to ensure there is a seamless transition and maintenance of high levels of audit quality and effectiveness. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit tender </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee considers that during 2022 the company complied with the mandatory audit processes and audit committee responsibility provisions of the Competition and Markets Authority Statutory Audit Services Order 2014. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As Deloitte continues to maintain its independence and objectivity, and the Committee remains satisfied with its performance, GSK does not intend to tender the external auditor contract before the end of the current required period of 10 years identified above and considers that this is in the best interests of shareholders. The Committee is mindful that the 2023 financial year will see a new CFO for GSK and audit partner for Deloitte, which will help further mitigate the risks of any over-familiarity between the company and the auditor. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Board committee reports continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-audit</div> services </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Management operates on the presumption that other accountancy firms will provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services to GSK. However, where the external auditor&#8217;s skills and experience make it the only suitable supplier of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> support &#8211; such as for audit-related matters, tax and other services &#8211; it may be used, in the best interests of the company. In line with GSK&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services policy, the Committee ensures that auditor objectivity and independence are safeguarded by reviewing and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approving</div> the external auditor&#8217;s provision of such services. The company policy complies with the FRC&#8217;s 2019 Revised Ethical Standard and the Sarbanes-Oxley Act of 2002. It observes the following core policy features on engaging the external auditor for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services: </div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services policy, key features: </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:39%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Process:</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services over &#163;50,000 are put to competitive tender with other financial services providers, in line with the Group&#8217;s procurement process, unless the skills and experience of the external auditor make it the only suitable supplier.</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Safeguards:</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="padding-bottom:2pt ;vertical-align:top">Adequate safeguards are established so that the objectivity and independence of the Group audit are not threatened or compromised.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fee cap:</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The total fee payable for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services should not exceed 50% of the annual audit fee, except in special circumstances where there would be a clear advantage in the auditor undertaking the additional work.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Prohibitions:</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK&#8217;s policy includes a &#8216;whitelist&#8217; of permitted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services in line with the relevant regulations. Any service not on this list is prohibited.</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom: 0.375pt; vertical-align: top;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-approval:</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> as set out in the table below to ensure services approved are consistent with GSK&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> policy for permissible services. This process ensures all services fall within the scope of services permitted and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the Committee and does not represent a delegation of authority for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Value</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than &#163;50,000</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between &#163;25,000 and</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#163;50,000</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Under &#163;25,000</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-approver</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Committee Chair and CFO</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Group Financial Controller</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Designate of the Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial Controller</div></td></tr></table><div style="margin-top:20pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Audit and other services comparison (&#163;m) </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_129.jpg"/> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">Note 8 to the financial statements provides further details of fees payable to the company&#8217;s auditor. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fees paid to the company&#8217;s auditor and its associates are set out overleaf. Further details are given in Note 8 to the financial statements, &#8216;Operating profit&#8217; on page 199. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, fees for audit-related and other assurance services of &#163;6.3&#160;million included &#163;4.4&#160;million related to the continued work in the year associated with Deloitte&#8217;s reporting accountant role in preparing for the demerger of the Consumer Healthcare business. Including audit fees in respect of the GSK pension schemes of &#163;0.2&#160;million, fees for audit-related and other assurance services represent 31.6% of the annual audit service fee (2021: 15.2%). Excluding the demerger work and quarterly review work, fees for audit-related and other assurance services would have represented 4.4% of the annual audit fee. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee&#8217;s rationale for originally hiring Deloitte to undertake the reporting accountant role is set out on page 115 of GSK&#8217;s 2021 Annual Report. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee considered the level of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services incurred as part of its annual review of Deloitte&#8217;s independence set out on the previous page and was satisfied that the auditor continued to be independent and exercised objectivity throughout 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair, balanced and understandable assessment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The need for an annual report to be fair, balanced and understandable is one of the key compliance requirements for a company&#8217;s financial statements. To ensure that GSK&#8217;s Annual Report meets this requirement, we have a well-established and documented process governing the coordination and review of Group-wide contributions to the publication. This runs in parallel with the process followed by the external auditor. The Committee received a summary of management&#8217;s approach to GSK&#8217;s 2022 Annual Report to ensure it met the requirements of the FRC&#8217;s Code. This enabled the Committee, and the Board, to confirm that GSK&#8217;s 2022 Annual Report as a whole is fair, balanced and understandable and provides the necessary information for shareholders to assess the company&#8217;s position and performance, business model and strategy. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Code of Conduct and reporting lines </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have a number of well-established policies (including a new Code of Conduct), which are available on gsk.com, together with details of our confidential Speak Up lines for reporting and investigating unlawful conduct. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charles Bancroft </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Audit&#160;&amp; Risk Committee Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">129</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_70" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_29" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Directors&#8217; report </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:44%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; powers </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Directors&#8217; powers are determined by UK legislation and our Articles of Association, which contain rules about the appointment and replacement of Directors. They provide that Directors may be appointed by an ordinary resolution of the members or by a resolution of the Board, provided that, if appointed by the Board, the Director retires at the next Annual General Meeting following their appointment. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Articles also provide that all Directors are required to seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> annually at the Annual General Meeting in accordance with the FRC&#8217;s Code. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A Director will cease to be a Director if he or she: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">becomes bankrupt </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">ceases to be a Director by virtue of the Companies Act or the Articles </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">suffers mental or physical ill health and the Board resolves that he or she shall cease to be a Director </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">has missed Directors&#8217; meetings for a continuous period of six months without permission and the Board resolves that he or she shall cease to be a Director </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">is prohibited from being a Director by law </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">resigns, or offers to resign and the Board accepts that offer </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">is required to resign by the Board </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; conflicts of interest </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All Directors have a duty under the Companies Act 2006 to avoid a situation in which they have, or could have, a direct or indirect conflict of interest or possible conflict with the company. Our Articles provide a general power for the Board to authorise such conflicts. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Board reviews any new potential or actual conflict, which is recorded by the Company Secretary. Directors are not counted in the quorum for the authorisation of their own actual or potential conflicts. The Nominations&#160;&amp; Corporate Governance Committee reviews the Register of Conflicts on an annual basis which the Board subsequently approves. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On a continuing basis, the Directors are responsible for informing the Company Secretary of any such new actual or potential conflicts that may arise or if there are any changes in circumstances that may affect an authorisation previously given. Even when provided with authorisation, a Director is not absolved from his or her statutory duty to promote the success of the company. If an actual conflict arises post-authorisation, the Board may choose to exclude the Director from receipt of the relevant information and participation in the debate, or suspend the Director from the Board, or, as a last resort, require the Director to resign. </div></div><div style="position:relative;float:left; margin-left:3%; width:45%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Nominations&#160;&amp; Corporate Governance Committee reviewed the register of potential conflict authorisations (the Register of Conflicts) in January 2022. The Committee reported to the Board that the conflicts had been appropriately authorised and that the process for authorisation continued to operate effectively. The Committee then recommended the approval of the Register of Conflicts to the Board which it subsequently approved. Except as described in Note 40 to the financial statements, &#8216;Related party transactions&#8217;, during or at the end of the financial year no Director or Person Closely Associated had any material interest in any contract of significance with a Group company. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Articles prohibit a Director from voting on any resolution concerning his or her appointment or the terms or termination of his or her appointment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Independent advice </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company has an agreed procedure for Directors to take independent legal and/or financial advice at the company&#8217;s expense where they deem it necessary. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indemnification of Directors </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Qualifying third party indemnity provisions (as defined in the Companies Act 2006) are in force for the benefit of Directors and former Directors who held office during 2022 and up to the approval and signature of the Annual Report. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change of control and essential contracts </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We do not have contracts or other arrangements which individually are fundamental to the ability of the business to operate effectively. Neither is the company party to any material agreements that would take effect, be altered, or terminate upon a change of control following a takeover bid. We do not have agreements with any Director that would provide compensation for loss of office or employment resulting from a takeover, except that provisions of the company&#8217;s share plans may cause options and awards granted under such plans to vest on a takeover. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of the termination provisions in the Executive Directors&#8217; service contracts are given in the full version of the company&#8217;s 2022 Remuneration policy which is available on gsk.com in the Investors section. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">130</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Directors&#8217; report continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:20%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="BORDER-TOP:0.75pt solid #f36f21;vertical-align:top"><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Content of the Directors&#8217; report</div></div></div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">For the purposes of the UK Companies Act 2006, the Directors&#8217; report of GSK plc for the year ended 31&#160;December 2022 comprises:</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; report</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Pages</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporate governance report</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">96 to 131</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Employee engagement</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">115</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Directors&#8217; statements of responsibilities</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">166 and 167</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Investor information</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">273 to 314</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="3" style="vertical-align:top">The strategic report sets out those matters required to be disclosed in the Directors&#8217; report which are considered to be of strategic importance:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strategic report</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Pages</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Risk management objectives and policies</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">51&#160;to&#160;64&#160;and<br/>285 to 295</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Likely future developments of the company</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 to 95</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Research and development activities</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">15 to 28</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Business relationships</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">49 and 50</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Diversity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">47</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Provision of information to and consultations with employees</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">10, 11 and 47</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Carbon emissions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">45 and 46</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Section&#160;172 statement</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">112 to 114<br/>and<br/>throughout<br/>10 to 63</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following information is also incorporated into the Directors&#8217; report: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:36%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Location in Annual Report</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Interest capitalised</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Financial statements,<br/>Notes 17 and 20</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Publication of unaudited financial information</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Group financial review,<br/>page 65</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Details of any long-term incentive schemes</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Remuneration report</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Waiver of emoluments by a Director</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Waiver of future emoluments by a Director</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Non <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-emptive</div> issues of equity for cash</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Non <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-emptive</div> issues of equity for cash by any unlisted major subsidiary undertaking</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Parent company participation in a placing by a listed subsidiary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Provision of services by a controlling shareholder</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shareholder waiver of dividends</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Financial statements,<br/>Notes 16 and 45</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shareholder waiver of future dividends</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Financial statements,<br/>Notes 16 and 44</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Agreements with controlling shareholders</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not applicable</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Directors&#8217; report </div></div></div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that Report shall be subject to the limitations and restrictions provided by such law. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">was approved by the Board of Directors on 9 March 2023 and signed on its behalf by: </div></td></tr></table><div style="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">131</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_132.jpg"/> </div><div style="font-size:-830pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top: -830pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL"><div style="color: rgb(244, 241, 240); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;GSK Annual Report 2022 </div></div></div></div><div id="ex15_2tx382677_30" style="margin-top:90pt; margin-bottom:0pt; font-size:60pt; font-family:ARIAL"><div style="color: rgb(244, 241, 240); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Remuneration </div></div><div style="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:89%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:3%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:57%"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In this section</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_71" style="color:White">Committee Chair&#8217;s annual statement</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">133</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_72" style="color:White">Annual report on remuneration</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">136</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_73" style="color:White">2022 Remuneration policy summary</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">158</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table></div><div style="margin-top: 450pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;132 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:36pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 20pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Remuneration report </div></div><div id="ex15_2tx382677_71" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_31" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Committee Chair&#8217;s annual statement </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dear Shareholder, </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On behalf of the Remuneration Committee, I am pleased to present our Remuneration report for 2022. This includes my annual statement, explaining the Committee&#8217;s work this year, our annual report on remuneration for 2022, a summary of our Remuneration policy which was approved by shareholders at the 2022 AGM, and details of how we propose to operate the Policy this year. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK&#8217;s Remuneration policy 2022 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As detailed last year, we introduced a new Remuneration policy in 2022 to better link executive remuneration to delivery of outperformance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The new arrangements were designed to reward the delivery of the bold new performance ambitions set out at our Investor Update in 2021 &#8211; to deliver sales growth of more than 5% CAGR and adjusted operating profit growth of more than 10% CAGR from 2021 to 2026. These ambitions represent a step-change in performance for the Group and achievement of them should deliver top quartile performance for our sector. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee concluded that the design of its existing Remuneration policy framework remained fit for purpose. However, given that driving long-term performance through consistent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-on-year</div></div> improvement was the main aim behind these targets, changing the short-term Annual Bonus plan was determined to be the key imperative. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The main change to the plan was to significantly reduce the Annual Bonus opportunity for below-target performance while increasing the Annual Bonus opportunity for &#8216;exceptional performance&#8217; to 300% of salary. The increase in overall Annual Bonus opportunity does not increase the cash reward opportunity, as any incremental reward is delivered in the form of shares deferred for three years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee is very aware of the sensitivity amongst stakeholders to levels of executive pay. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We engaged extensively with shareholders to gain their views and feedback on these changes. Please see the table below which sets out the full details of this process. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As a result, we made adjustments to quantum, clarity on disclosure of outcomes, and transparency in relation to the targets set, that all feature in the final policy. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At the 2022 AGM, the new policy was approved with 62% of shareholders voting in favour, but the Committee recognises that a significant minority of shareholders voted against. Following the AGM, the Committee ensured continued consultation with shareholders to understand the full range of views, including those who voted against the proposals. The Committee thanks shareholders for their feedback and remains committed to engaging on remuneration. It continues to believe that incentivising outperformance against stretching targets will create long-term value for shareholders. Noting that no new issues were raised, the Committee is comfortable that no further change is required to the Annual Bonus plan. The Committee will review with shareholders the evolving needs of the business in advance of the renewal of our Remuneration policy in 2025. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Two administrative amendments to the 2022 Remuneration policy are being proposed for shareholder approval at the 2023 AGM. Further details are set out on page 163. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 remuneration outcomes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The very strong operating performance for GSK in the first year of the new remuneration arrangements has highlighted the importance of incentivising exceptional performance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As set out earlier in the Annual Report, in 2022 the Group delivered strong sales growth of Vaccines and Specialty Medicines and double-digit growth in operating profit and earnings per share. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:7pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:98%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="9" style="vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Remuneration policy engagement</div></div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td colspan="9" style="vertical-align:top">Details of the extensive consultation by the Committee and company Chairs regarding the 2022 Remuneration policy prior to the 2022 AGM vote and continuing engagement with shareholders afterwards, are set out below.</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Engagement events</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dates</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Investor</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">participation</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Share&#160;capital&#160;&#160;&#160;&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">represented</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top">Initial individual consultation meetings</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">October&#160;to</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">5&#160;of&#160;the&#160;largest</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">12%</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">November&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">15&#160;shareholders&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">2021 Annual&#160;Governance&#160;Meeting:</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: middle; padding-bottom: 0.375pt;">invitations</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">November&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">60 investors</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">50%</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">attendance</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">December 2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">13 investors</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">15%</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Follow-up</div> letter after Annual Governance Meeting to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-attendees,</div> setting out</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">January&#160;to&#160;February&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">30 investors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">35%</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top">proposed Remuneration policy asking for input via meeting with the Remuneration</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Committee and company Chairs</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top">Letter circulated advising how feedback was incorporated into the final Remuneration</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">March 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">40 investors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">45%</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">policy to be submitted to the 2022 Annual General Meeting for binding approval</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Meetings held with shareholders prior to AGM</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">January&#160;to&#160;April&#160;2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">11 investors</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">16%</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">2022&#160;Annual&#160;Governance&#160;Meeting:</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: middle; padding-bottom: 0.375pt;">invitations</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">November&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">60 investors</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">50%</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">attendance</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">December 2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">14 investors</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">25%</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">Meetings held after the AGM to the publication of this Annual Report</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">May&#160;2022&#160;to February&#160;2023</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">20 meetings</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">35%</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="9" style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The principal proxy advisory firms were also consulted throughout the Remuneration policy process. This included invitations to the Annual Governance Meeting, receipt of engagement letters and meetings with the company and Remuneration Committee Chairs.</div></td></tr></table></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">133</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Committee Chair&#8217;s annual statement continued </div></div><div style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Remuneration awards for the year reflect this excellent operating performance, alongside successful delivery of the demerger of Consumer Healthcare to form Haleon, the largest demerger in Europe for over 20 years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Annual Bonus </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Bonus outcomes for the CEO and CFO were each determined by reference to performance against stretching total sales, adjusted operating profit and diversity, equity and inclusion (DEI) targets as well as the Committee&#8217;s assessment of their individual performance against specific strategic and operational measures. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The total sales growth rate was 3.4% above the target growth rate of 6.5% and the adjusted operating profit growth rate was 3.9% above the target growth rate of 12.8%. This led to an overall payout under the financial elements of 149.5% of salary. The targets were set with consideration given to analyst consensus, hence the Committee is comfortable that the payout represents exceptional performance. The full target range is set out on page 139. When combined with the assessment of the non-financial elements, the overall payout was 249.5% of salary for the CEO (149.5% of salary delivered in deferred shares) and 227.5% of salary for the CFO (127.5% of salary delivered in deferred shares). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee believes the Bonus outcomes appropriately reflect the overall performance achieved in 2022. Full details are provided on page 139. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-term incentive (LTI) awards </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">52% of the 2020 Performance Share Plan (PSP) award vested. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Targets were set against pipeline progress (20%), innovation sales (20%), adjusted free cash flow (30%) and relative TSR (30%). Disappointingly there was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-vesting</div> under relative TSR. However, strong performance against other metrics was evidenced with full vesting under the cash flow element and partial vesting under pipeline progress and innovation sales. This reflects progress in R&amp;D, including positive data for the company&#8217;s potential new RSV vaccine, and strong sales from products launched over the last five years, including shingles vaccine <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div> which generated sales of &#163;3&#160;billion during the year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following a review of contextual factors including previous payouts, the Committee believes that the formulaic outcomes appropriately reflect performance in the round having considered the experience of all stakeholders including shareholders and our employees. The Committee did not deem it necessary to exercise discretion. Incentive awards in relation to 2022 were made in accordance with the 2022 Remuneration policy. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration policy implementation for 2023 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Bonus and LTI performance measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following changes to the bonus in 2022, for 2023 we are maintaining the performance measures in our incentive plans as they continue to align with our strategic goals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Annual Bonus measures will be: annual total sales growth (30%); annual adjusted operating profit growth (30%); personal performance against strategic and operational measures (30%); ESG: diversity, equity and inclusion (DEI) (10%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">LTI measures will be: relative TSR (30%), total sales growth over three&#160;years (20%); adjusted operating profit growth over three&#160;years (20%); pipeline progress (20%); and ESG: environment composite scorecard&#160;(10%). </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_134.jpg"/> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The nature of the strategic and operational objectives for each Executive Director will be in line with those agreed for the 2022 Annual Bonus. These focus particularly on individual areas of accountability to deliver the company&#8217;s strategy. For example, the CEO has clear pipeline delivery objectives. Each Executive&#8217;s objectives also require demonstration of their contribution to leading and living our culture of performance with integrity which the Board believes is a critical lever of long-term value creation for GSK. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee has reflected at length on investor input regarding the most appropriate ESG measures to focus on. One theme which arose during consultation was the possibility of introducing a metric on access to medicines. However, as GSK is already an industry leader in this area, and as it is deeply engrained in the company&#8217;s culture and values, the Committee felt that it was not necessary to include this as a specific metric in incentives. Instead, the Committee has selected measures aimed at specific GSK challenges and opportunities in environmental sustainability and DEI. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Performance targets have been calibrated to consider a number of internal and external reference points, in particular analyst consensus has been considered for financial metrics where available. The Committee is therefore satisfied that the targets set for 2023 are sufficiently stretching. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee agreed that the CEO should receive a 4% salary increase for 2023 which is lower than the average increase to the wider workforce in the UK of 5%. In addition to the 5% average salary increase, the company has implemented a number of monetary and non-monetary initiatives for our colleagues in reaction to the cost of living crisis as explained in my statement. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Workforce fairness </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In setting executive pay it is important that the Committee does so with a good understanding of the Group&#8217;s wider workforce pay approach, with an emphasis on fairness and equity. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">To that end, on an annual basis, I meet with senior Human Resources Leaders from across the company to understand perspectives on pay and GSK&#8217;s remuneration arrangements for the wider workforce. This year was the fourth such annual meeting held. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">134</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Committee Chair&#8217;s annual statement continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_135.jpg"/> </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At the meeting, we discussed how GSK continues to support its diversity aspiration through fair pay processes and proactive reviews and enhancements to its employee benefits. These included: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">new global minimum standards for parental leave and for care of a family member </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">review of medical and insured benefits with a focus on equity for same sex couples wherever legally possible and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">new financial education support </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Given the very challenging economic environment and cost of living pressures in many countries, management has taken action to support current employees and to attract talent, through competitive salary increases, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> support payments to staff at lower grades, and enhancements to workforce wellbeing programmes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At the start of 2022, changes were also made to the Annual Bonus plan below the GLT level to reflect a greater focus on performance. The new plan has been generally well received and first payments will be made in Q1 2023. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Director changes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In August 2022, Dr Hal Barron transitioned, as planned, from his role as CSO to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-independent</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director. Dr Barron was contractually entitled to receive a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> target bonus in respect of 2022. He did not receive an LTI grant in 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We also announced the appointment of Julie Brown as CFO from May 2023, when Iain Mackay will step down from the Board. As previously communicated, Mr Mackay will continue to receive his base salary until he leaves GSK at the end of the year and will be eligible to receive an Annual Bonus in respect of 2023. He will not be eligible to receive any further LTI awards and will receive no salary increase in 2023. Full details of his retirement arrangements including the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-flight</div> LTI awards can be found on page 149. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our new CFO, Julie Brown&#8217;s salary of &#163;915,335 was preliminarily set in line with that of her predecessor in September 2022. Her salary upon joining has been increased by 4% to &#163;951,948. This is in line with the increase agreed for the CEO and is below that which has been awarded to the UK wider workforce. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGM </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Finally, I would like to again thank shareholders for their valued input and engagement. I welcome all further feedback and look forward to receiving your support for this report at our Annual General Meeting on 3&#160;May 2023. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Urs Rohner </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Remuneration Committee Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9 March 2023 </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px #e7e7e8;border-radius:7pt; background-color:#e7e7e8;padding-top:2pt;padding-bottom:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:98%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top"><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; text-indent: 0.5em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consideration of potential windfall gains</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee is aware of the guidance from investor bodies around considering a potential executive benefit arising from share award grants around the time of the stock market fall at the onset of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic in March 2020.</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Our Remuneration Policy contains sufficient flexibility to reduce the vesting of awards if required.</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">However, the Committee determined that no reduction is required in respect of the awards granted in March 2020. In making this determination, the Committee considered the share price at the following points:</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1.76em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;The share price at the time of the February 2020 award of &#163;16.81</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1.76em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;The share price over the final quarter of 2022 of &#163;13.99</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 1.76em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;The share price at the time of the March 2019 award (grant previous to the 2020 award) of &#163;15.09</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 3pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Whilst there have been upward and downward movements in GSK&#8217;s share price over the period, taking these above points into consideration the Committee was satisfied that there was no risk of windfall gains.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">135</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_32" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_72" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Annual report on remuneration </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Total remuneration (audited) </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_136.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Total remuneration (audited) </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr&#160;Hal&#160;Barron,&#160;former&#160;CSO</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma&#160;Walmsley,&#160;CEO</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay, CFO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(to 31&#160;July 2022)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(2) </div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Fixed pay</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;Salary</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,260&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">915&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">889&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,332&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">1,883&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;Benefits</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">131&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">291&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">242&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">107&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">145&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;Pension</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">253&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">183&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">178&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">651&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;Total fixed pay</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,644&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,602</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,389&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">1,309&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,629&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2,679&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:4pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Pay for performance</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;Annual bonus<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,143&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,082&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">1,573&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,177&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">3,483&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;Vesting of PSP LTI awards<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(3) </div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(4)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,666&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,854&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2,408&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,381&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">6,371&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">&#160;Total pay for performance<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(5) </div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,809&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,601</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,936&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">3,981&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,558&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">9,854&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:4pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Total remuneration</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#163;8,453&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#163;8,203</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#163;5,325&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#163;5,290&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;$7,187&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;$12,533&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:2%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:97%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes:</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top">(1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The mandatory Deferred Annual Bonus Plan (DABP) bonus deferrals for 2022 and 2023 are set out on page 154. The payment shown for Dr Barron represents a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> payment in respect of 1&#160;January 2022 to 31&#160;July 2022, in lieu of an Annual Bonus opportunity.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top">(2)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Dr Barron transitioned from his role as CSO to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director on 1&#160;August 2022. Salary above includes the basic salary earned for his time as CSO from 1&#160;January to 31&#160;July 2022 plus payment in lieu of accrued holiday not taken, in accordance with GSK&#8217;s standard all employee US holiday pay policy. His <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director fees earned from 1&#160;August to 31&#160;December 2022 were $177,107. Please see page 153 for further details.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top">(3)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The PSP vesting figure for the CEO is inclusive of a top-up award (25% of salary) made in May 2020 following the vote in favour of the Remuneration policy at the company&#8217;s 2020 AGM. This award will not vest until May 2023 and the final actual value received for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-22</div> PSP will be restated in the 2023 Annual Report.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top">(4)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The 2020 PSP was valued based on the vesting prices on 10&#160;February 2023 of &#163;14.78 and the ADS price of $35.727. The share and ADS prices on 14&#160;February 2020, the main date of grant were &#163;16.686 and $43.74. In respect of the top-up award for the CEO, the share price was &#163;16.814. Of the vested amounts for the Executive Directors, nothing was attributable to share price appreciation over the performance period. The Committee did not exercise any discretion in relation to the vesting of the awards or share price changes. The value for Dr Hal Barron is illustrative as the award will not vest until August 2023 in accordance with the terms of the Executive and Senior Management Recoupment Policy. The actual value received will be restated in the 2023 Annual Report.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top">(5)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The Committee may in specific circumstances, and in line with stated principles, apply malus/clawback, as it determines appropriate. Following due consideration by the Committee, there has been no recovery of sums paid (clawback) or reduction of outstanding awards or vesting levels (malus) applied during 2022 in respect of any of the CEO, CFO or the former CSO.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">136</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Total remuneration (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following sections provide details of each element of 2022 &#8216;Total remuneration&#8217;, and how the Committee implemented the company&#8217;s shareholder-approved Remuneration policy during the year in terms of fixed and performance pay: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fixed pay (audited) </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below sets out the base salaries of the Executive Directors over the last two years compared to increases for the UK and US workforce. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td rowspan="3" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">effective</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2021&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">UK&#160;&amp; US employees</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">1&#160;April</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">3%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;">&#8211;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;1,259,855&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#163;1,223,160</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">1&#160;January</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">3%</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;915,335&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#163;888,675</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Dr Hal Barron<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$2,026,549&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">$1,967,523</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">With effect from 1 August 2022, Dr Barron transitioned to a Non-Executive Director role and has not received a salary since that date. He receives Non-Executive Director fees as described on page 153. Dr Barron&#8217;s 2021 base salary was increased by 8% from $1,821,781 to $1,967,523 with effect from 1 August 2021. See page 126 of the 2021 Annual Report for further details. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of salary levels for 2023 are provided on page 147. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefits </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK remuneration reporting regulations require the company to add into each Executive Director&#8217;s total benefits all items which are deemed by tax authorities to be a taxable benefit for them. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These comprise: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee benefits</div></div> in line with the policy for other employees, which may vary by location and role </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business-related services</div></div> provided to employees to assist or enable them to carry out their role, which a tax authority has deemed to be a taxable &#8220;benefit&#8221; to the individual. Because these are business expenses, the company meets the tax which arises on them and therefore the items are shown grossed up for tax. These include business travel and other related business costs </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides an analysis of Total benefits (grossed up for tax) received by the Executive Directors in 2022 and 2021. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;Benefits</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;Benefits</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefits available to employees</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Business-related services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">131</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">134</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefits available to employees</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">156</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Business-related services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">135</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">111</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">291</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">242</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefits available to employees</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Business-related services</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accommodation whilst on business travel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">107</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes:</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">(1)&#160;&#160;&#160;&#160;2021 represents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> refund of accommodation costs relating to 2020.</td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">137</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:36pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fixed pay (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:60pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From 1&#160;January 2023, pension arrangements for Executive Directors were aligned to the wider workforce. Further details are given on page 147. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:66%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Director</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Member since</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension arrangements in 2022</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2010</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pension contributions of 20% of base salary and matching contributions of up to 5% on the first</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2019</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#163;13,333 of salary, with a cash payment of 20% of base salary in lieu of pension on salary in excess of &#163;13,333 in line with plan rates.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2018-July 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Member of the 401(k) plan open to all US employees and the Executive Supplemental Savings Plan (ESSP), a savings scheme open to US executives to accrue benefits above the 401(k) plan limits.</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">He received 38% of base salary, less a contribution to the 401(k) and ESSP equivalent to 5% of total base salary and bonus (net of the bonus deferred under the DABP). In addition, in line with the wider US workforce, from 1&#160;January 2021, a combined contribution rate under the 401(k) and ESSP plans of 11% (7% core contribution plus a match of up to 4%) of total base salary and bonus (net of the bonus deferred under the DABP).</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table shows the breakdown of the pension values included in Total remuneration on page 136. They are calculated in accordance with the methodology set out in the UK Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008 (as amended) (Remuneration regulations). </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma&#160;Walmsley</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Jan-Jul&#160;2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension remuneration values</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK defined contribution</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US defined benefit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(134</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employer cash contributions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">242</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">180</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total pension remuneration value</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">253</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">183</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">651</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dr Hal Barron is now a deferred member of the US style defined benefit plan. Further details regarding the 2022 pension values for Dr Barron are set out in the table below. His accrued benefit (ie the annual pension accrued to date) for 2022 was calculated as the increase in the accrued benefit, adjusted for inflation and multiplied by 20 to reflect the fact that the benefit will be received over a number of years. The normal retirement age under the Cash Balance Pension Plan is age 65. Dr Barron has not received any additional benefit for retiring early. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accrued pension&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension&#160;remuneration&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;July&#160;2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December&#160;2021&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value&#160;for&#160;2022&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron pension values</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$000&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US &#8211; Funded</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">2&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US &#8211; Unfunded</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">194</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">187&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(128)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">196</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">189&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(134)&#160;</div></div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">138</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance (audited) </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Bonus </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_139.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Annual Bonus performance against measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table shows the Annual Bonuses earned compared to the bonus opportunity for 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Bonus opportunity</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;Bonus&#160;outcome</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strategic&#160;and</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;sales</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">operating</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">operational</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Target</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximum</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">growth</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">profit&#160;growth</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">measures</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ESG</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">bonus</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">salary</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(%&#160;of&#160;salary)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">bonus</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">100</div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">300</div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#163;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,259,855</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">71</div></div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">79</div></div></td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;background-color:#e7e7e8"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">249.5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,143,340</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;915,335</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">227.5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,082,390</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of the mandatory deferral by Executive Directors into the DABP for the 2022 bonus are set out on page 147. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dr Barron received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;on-target&#8217;</div> payment for 2022 of $1,177,064 in lieu of a bonus opportunity. This is because he transitioned to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director role on 1&#160;August 2022. This contractual payment, in accordance with the company&#8217;s Remuneration policy, is included in his remuneration for 2022 under Annual Bonus in the table on page 136. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 financial performance measures </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Performance&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Target&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Target</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outcome</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Positioning&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">weighting&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">growth&#160;rate</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">growth&#160;rate</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">achieved&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total sales growth</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">30%&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.5%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.9%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">+3.4%&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted operating profit growth</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">30%&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.8%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.8%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">+3.9%&#160;</div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These targets were set following consideration of analyst consensus as well as internal budgets. The annual targets for 2022 exceeded the long-term sales and profit targets stated in our Investor Update of 5% and 10% respectively. The Committee is therefore comfortable that over achievement of these represents exceptional performance. Threshold and maximum performance targets were set at 1% below and 5% above target growth respectively. The total sales and adjusted operating profit targets and outcomes for the purposes of the Annual Bonus calculation are based on CER and exclude the commercial benefit from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> solutions. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt;background-color:#e7e7e8">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;Overview of performance against financial performance measures</div></div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">2022 saw a step-change in commercial execution; earnings guidance was updated during the year as momentum grew. This was driven by strong sales growth across Specialty Medicines and Vaccines, exceeding guidance for sales and operating profit </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Delivered full-year reported Group sales of &#163;29.3&#160;billion (+19% AER, +13% CER) with Specialty growth of 37% AER, 29% CER with double-digit growth across all Specialty therapy areas and Vaccines growth of 17% AER, 11% with a record year for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>. The outcome was adjusted to exclude the benefit from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> solutions </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Adjusted Group operating profit of &#163;8,151&#160;million above target, driven by higher sales supported by prioritised investment and effective cost control. The outcome was adjusted to exclude the commercial benefit from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> solutions </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Adjusted EPS of 139.7p (+27% AER, +15% CER) was ahead of guidance excluding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> solutions </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:36pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 strategic and operational measures performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee received and considered a performance assessment report for each Executive Director showing the extent of their achievement against the individual personal strategic and operational measures agreed by the Committee for them to support the delivery of our strategic commitments during 2022. The Committee also reviewed Dr Hal Barron&#8217;s performance in July 2022 before the release of his contractual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;on-target&#8217;</div> bonus payment. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As with the financial elements of the Annual Bonus, the Committee was satisfied that the scale of Executive Directors&#8217; achievements this year was of an exceptional nature. In particular, these achievements relate to the pipeline, commercial execution and Haleon demerger. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:24%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:72%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Strategic and operational measures</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Performance achieved</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="5" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The Committee determined that the CEO clearly exceeded or met her individual objectives</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Strengthen pipeline and build<br/>GSK&#8217;s reputation for Innovation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">47 potential new medicines and 22 vaccine candidates in development, with 18 now in phase 3/registration. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Two-thirds</div> of pipeline now focused on infectious diseases</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Significant progress to strengthen pipeline and advance key assets (including RSV OA vaccine, bepirovirsen, gepotidican, daprodustat and depemokimab) more than offset termination decisions on otilimab and RSV maternal</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Continued progress in development of long-acting HIV treatments including launch of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div>, for HIV prevention and positive data for new broadly neutralising antibody N6LS</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Successful business development to support future growth and focus in Vaccines and Specialty Medicines including Affinivax, Sierra Oncology and Spero Therapeutics</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Demonstrate continued</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">commercial execution</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">excellence</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Step-change in commercial execution, with double-digit sales growth across Specialty Medicines and Vaccines</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 products now exceeding &#163;1&#160;billion in annual sales, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta </div></div>and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato </div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Strong momentum for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix </div></div>(sales +60% to &#163;3 billion), reflecting post pandemic rebound, new geographic launches and excellent commercial execution</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Complete separation and</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">unlocked value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Haleon successfully demerged on schedule from GSK on 18&#160;July 2022. Largest demerger in Europe for 20 years</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meaningful progress in value recognition prior to impact of market uncertainty following <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div>litigation</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Demonstrate strong</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Environmental, Social and</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Governance (ESG) credentials<br/>and build trust in future delivery</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sustained leading ESG performance, with delivery against Global Health, Environment and Inclusion and Diversity commitments</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Maintained sector-leading rankings in key ESG indices. Ranked number 1 in Access to Medicines Index for the 8th consecutive time and 2nd in S&amp;P Corporate Sustainability Assessment for the pharmaceutical industry</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Demonstrate strong culture</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">and leadership</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Drove rapid ownership of new culture; launch and roll out of new internal GSK Code, Talent Management and Performance with Choice programmes</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee engagement up to 81% (versus 78% in 2021)</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Continued development and succession planning for leadership team, with Tony Wood appointed CSO and new Chief Financial Officer Designate appointed</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="5" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The Committee determined that the CFO successfully met his individual objectives</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demonstrate financial leadership</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Group financial targets exceeded: total sales &#163;29.3&#160;billion (+19% AER, +13% CER, +10% excl COVID); adjusted operating margin 27.8%; adjusted operating profit growth +26% AER, +14% CER, +17% excl COVID</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted EPS 139.7p (+15% CER)</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cost discipline and cash flow</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">management</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prioritised investment and cost discipline supported strong growth in operating profit and EPS.</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transformation programme delivering &#163;0.9&#160;billion annual savings by end 2022, on track to deliver &#163;1&#160;billion by end 2023</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash generated from operations &#163;7.9&#160;billion and free cash flow of &#163;3.3&#160;billion</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Complete separation and</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">unlocked value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Haleon successfully demerged on schedule from GSK on 18&#160;July 2022. Largest demerger in Europe for 20 years</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meaningful progress in value recognition prior to impact of market uncertainty following <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div>litigation</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Demonstrate strong culture</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">and leadership</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">Finance and Tech engagement, confidence, culture and inclusivity employee survey scores all increased versus 2021</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 ESG: diversity, equity and inclusion (DEI) performance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our first Annual Bonus ESG measure reinforces achievement of our DEI ambitions, as set out on page 47. DEI is an important business imperative and aspirational targets could be set to warrant additional reward. To stay on track for the 2025 Aspirational Targets for diversity of senior leadership, the Committee agreed interim, annual aspirational targets including global gender representation and US and UK race and ethnicity representation. These interim, annual aspirations were agreed by the Committee for the CEO. An internal governance team comprising members of Reward and Legal audited their performance against these interim aspirations for consideration by the Committee. These interim aspirations were achieved in 2022 and at year end we had 42% gender representation and 31.3% US ethnicity and 14.3% UK ethnicity in our VP and above employee population which are above or on track to meet the 2025 Aspirations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, most directorates also performed strongly against their respective contributions to our Aspirations. However, not all directorates achieved their expected contributions to the aspirational targets including Finance. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">140</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vesting of PSP LTI awards </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following sets out the performance achieved for the company&#8217;s PSP and includes an update on performance of outstanding awards. In line with the Committee&#8217;s agreed principles, actual performance against each measure is carefully reviewed and adjustments are made, as appropriate, to ensure that the vesting outcome reflects genuine underlying business performance and has been delivered in line with our culture and responsible business priorities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Overall, 52% of the 2020 PSP award vested. Targets were set against pipeline progress (20%), innovation sales (20%), adjusted free cash flow (30%) and relative TSR (30%). Disappointingly there was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-vesting</div> under relative TSR. However, strong performance against other metrics was evidenced with full vesting under the cash flow element and partial vesting under pipeline progress and innovation sales. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-22</div> period, significant progress was achieved in accelerating the delivery of our pipeline, notably the company&#8217;s RSV vaccine, depemokimab and niraparib. Robust oversight resulted in a number of assets being discontinued as resources were reprioritised to focus on those with the greatest potential. Major approvals in the period included: niraparib, for ovarian cancer; sotrovimab (emergency use authorization) for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19;</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div> for HIV treatment and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div> for HIV <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-exposure</div> prevention. Innovation sales, in the period, reflected particularly strong performance of HIV medicines and our shingles vaccine, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div>. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:23%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outcome and vesting level</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance&#160;measures</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% of</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% of</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and&#160;relative&#160;weighting</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="11" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance&#160;targets</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outcome</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">maximum</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;award</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="12" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pipeline progress</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20%)</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="11" style="vertical-align:top">The pipeline progress measure targets rewarding strengthening of our pipeline through progression of high quality assets into pivotal trials and the achievement of regulatory approvals in major markets. Points based on achievement are allocated to these two equally weighted elements.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LTI&#160;award</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Threshold</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximum</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top;background-color:#e7e7e8"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">16.5 points</div></td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top;background-color:#e7e7e8"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">88%</div></td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">13.8%</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measure</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">75%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">19 points</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">50%</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pivotal&#160;Trial&#160;starts</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top">10</td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top">13 points</td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top">14&#160;points</td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top">15&#160;points</td>
<td style=" BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt dotted #000000;vertical-align:top">18&#160;points</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major&#160;regulatory</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18 points</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">19 points</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20 points</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">22 points</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">approval&#160;milestones</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="12" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovation sales<br/>(20%)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="11" style="vertical-align:top">The innovation sales measure recognises the importance of launching new products successfully and that driving their performance is key to our commercial success. This measure aggregates three-year sales for new innovative products launched in the three-year performance period and the preceding two years, ie <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-22.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">&#163;15.368&#160;billion</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">41%</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">8.2%</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="6" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovation sales (billion)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% vesting</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximum</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;18.132</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">100%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;16.484</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">75%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;15.660</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">50%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Threshold</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;14.836</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">25%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&lt;&#163;14.836</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:3pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="12" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjusted free cash flow (AFCF) performance</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30%)</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="11" style="vertical-align:top">In line with the company&#8217;s agreed principles, the AFCF figures included adjustments for a number of material distorting items, including legal settlements, exchange rate movements and special pension contributions.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">&#163;13.08&#160;billion</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">100%</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;">30%</td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Original<br/>target&#160;(billion)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Revised&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: center; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">target (billion)</div></div><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:3.3px">(1) <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;vesting</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximum</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;11.84</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top;text-align:center;">&#163;10.47&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">100%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;11.33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top;text-align:center;">&#163;10.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">75%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;10.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top;text-align:center;">&#163;9.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">50%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Threshold</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#163;9.99</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="vertical-align:top;text-align:center;">&#163;8.83&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">25%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&lt;&#163;9.99</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:center;">&lt;&#163;8.83&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="11" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 2.15em; text-indent: -2.15em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">(1)&#8194;&#8201;&#8201;The revised target has been further adjusted since the 2021 Annual Report as noted overleaf.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="6" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Relative&#160;TSR</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TSR&#160;ranking&#160;within&#160;comparator&#160;group</div></div><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:3.3px">(2) <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% vesting</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Ranked 9th</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">0%</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;;text-align:right;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">0%</div></td>
<td style="white-space: nowrap; vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">performance</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maximum</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1st,&#160;2nd,&#160;3rd</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">100%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30%)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4th</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">70%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5th</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">40%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Threshold</div></div><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:4.2px">(3)<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Median</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">25%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">6th&#160;to&#160;10th</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">0%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; background-color: rgb(231, 231, 232); padding-bottom: 0.375pt;"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="12" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="11" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -2em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">(2)&#8194;&#8201;TSR comparator group: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson&#160;&amp;&#160;Johnson, Merck&#160;&amp; Co, Novartis, Pfizer, Roche Holdings and Sanofi.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="11" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -2em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">(3)&#8194;&#8201;The vesting schedule is based on delivering 25% vesting for median performance. In a comparator group of ten companies, median falls between two companies.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="5" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="font-size: 8.5pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total vesting in respect of 2020 awards</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;text-align:right;">52%</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">141</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Adjusted free cash flow (AFCF) target was revised in line with the disclosure on page 131 of the 2021 Annual Report. It has been further restated to take account of the demerger by removing the share of target cash flows related to Consumer Healthcare following the demerger in 2022, revised phasing of the Future Ready programme restructuring cash payments based on detailed programme planning undertaken in 2022, and revised timing of divestments. As a result, the target was decreased by &#163;0.99&#160;billion to &#163;9.10&#160;billion. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee did not exercise any discretion in relation to the vesting of the awards or share price changes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 PSP vesting </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vested<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value of<br/>vested&#160;shares<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">410,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;248,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;3,666,163</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">207,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#163;1,854,116</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Barron &#8211; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pro-rated</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(3) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">203,981</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">122,634</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">$4,381,400</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The vested number of shares and the value it represented at vesting includes dividend reinvestments during the performance period. These are based on the vesting price of &#163;14.78 and the closing ADS price of $35.727 on 10 February 2023. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The shares granted for Emma Walmsley include the additional &#8216;top-up&#8217; award made in May 2020 which will not vest until May 2023. The final actual value received and any amount attributable to share price appreciation over the performance period will be restated in the 2023 Annual Report. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The PSP award for Dr Hal Barron will not vest until August 2023 under the terms of the Executive &amp; Senior Manager Financial Recoupment Policy. </div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance of ongoing LTI awards </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee also reviewed the performance of the PSP awards granted to Executive Directors in 2021 and 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following charts provide an estimate of the vesting levels of the 2021 and 2022 awards, taking into account performance to 31&#160;December 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Actual vesting levels will only be determined based on performance over the full three-year performance periods. The indications below should therefore not be regarded as predictions of the final vesting levels </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The AFCF measure target, threshold and associated vesting scales for the 2021 awards have been adjusted. The net overall impact is a decrease in the target of &#163;3.02&#160;billion to &#163;5.64&#160;billion for the 2021 award </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The adjustments took into account of the following items: the removal of the share of target cash flows relating to Consumer Healthcare in 2022 and 2023 following the demerger in 2022, revised phasing of the Future Ready programme restructuring cash payments, and revised timing of divestments </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">There were no changes to other measures </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_142.jpg"/> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For threshold performance 25% of each award will vest in respect of each performance measure. Individual 2021 LTI award levels appear on page&#160;131 of the 2021 Annual Report. They are set out below for the 2022 LTI awards. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 LTI awards </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The 2022 DABP awards, in respect of the deferral of 2021 bonus, and the 2022 PSP awards are both shown in the table below. </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;DABP&#160;awards</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 PSP awards</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td colspan="9" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/>%&#160;of&#160;total&#160;bonus<br/>deferred</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Face&#160;value<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of&#160;award</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Award&#160;level&#160;as&#160;%<br/>of base salary</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Face&#160;value</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of&#160;award</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)(3)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: top; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;72,399&#160;shares</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#163;1.138m</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">575%</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;461,059&#160;shares</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#163;7.2m</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: top;">&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: top;;text-align:right;">50%</td>
<td style="padding-bottom: 0.375pt; white-space: nowrap; vertical-align: top;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50,056&#160;shares</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#163;0.786m</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">400%</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">233,028 shares</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#163;3.7m</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr Hal Barron</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(4) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40,617 ADS&#160;&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;text-align:right;">$1.741m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The face values of the DABP awards have been calculated based on a share price of &#163;15.712 and an ADS price of $42.87, being the closing prices on 14&#160;February 2022 (the day before grant). These are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-cost</div> options for the UK Executive Directors and restricted shares for the US Executive Director. No performance conditions are attached to the DABP awards, as they reflect the mandatory three-year deferrals in respect of the Annual Bonus for 2021. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The face values of the PSP awards have been calculated based on a share price of &#163;15.712, being the closing price on 14&#160;February 2022 (the day before grant). These are conditional shares, based on the performance measures outlined above. Dr Barron did not receive a 2022 PSP award given his transition to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director role on 1&#160;August 2022. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The performance period for the 2022 PSP awards is from 1&#160;January 2022 to 31&#160;December 2024. Awards vest at 25% of maximum for threshold performance. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(4)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dr Barron&#8217;s DABP award will vest as normal three years after the date it was granted. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical vesting for LTI plans </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table summarises LTI vesting by performance measure for GSK over the last ten years. </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2011</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2012</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2013</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2014</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2015</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2016</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2017</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2018</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2019</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Relative TSR</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Adjusted free cash flow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Innovation sales (previously R&amp;D new product)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Pipeline progress</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13.8</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Business diversification</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Total vested %</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Malus and clawback policy </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For details of our existing policy on malus and clawback, please refer to the company&#8217;s 2022 Remuneration policy report on page 147 of the 2021 Annual Report, available on gsk.com. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee reviews and discloses whether it (or the Recoupment Committee) has exercised malus or clawback.Disclosure is only made when the matter has been the subject of public reports of misconduct, where it has been fully resolved, where it is legally permissible to disclose and where it can be made without unduly prejudicing the company and therefore shareholders. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In line with these disclosure guidelines, neither the Committee (nor the Recoupment Committee) exercised malus or clawback during 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An administrative amendment is proposed to the malus and clawback section of the 2022 Remuneration policy for shareholder approval at the 2023 AGM, as described on page 163. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other policies </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For details of our existing policies on recruitment remuneration, loss of office and termination payments, please refer to the 2022 Remuneration policy report on pages 144 to 152 of the 2021 Annual Report, available on gsk.com. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">143</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; pay in a wider setting </div></div></div></div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Internal context </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration structure for employees compared to Executive Directors and GLT during 2022 </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:8%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Element</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wider workforce pay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comparison with Executive Director and GLT pay</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;The market competitiveness of base salaries across the company is assessed at a local market level. The competitiveness of roles, which is measured against the external market and internal peers, is kept under regular review</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Increases may also be made to reflect a change in scope of an individual&#8217;s role, responsibilities or experience</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;For our Executive Directors and the GLT, following a performance review, increases in base salaries are considered in line with market practice, the average increase for the wider employee population and other comparotor tools.</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Increases may also be made to reflect a change in scope of an individual&#8217;s role, responsibilities or experience</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;In agreeing increases for Executive Directors and the GLT, the Committee is mindful of the multiplier effect on the individual&#8217;s total remuneration</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and benefits</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;The company seeks to provide an appropriate pension and benefits package that is aligned to competitive market practices in those countries in which the company operates and where our employees are based</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Our Executive Directors and the GLT are eligible to receive benefits broadly in line with the policy for other employees, which may vary by location</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Pension arrangements are structured in accordance with where the Executive Director or GLT member is expected to retire. Current and future Executive Directors&#8217; pension arrangements have been aligned to the wider workforce in their location since 1&#160;January 2023</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Bonus</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;With the exception of our sales force, who participate in separate arrangements, our wider workforce participates in a plan based on performance against four business and financial measures. These are structured to reflect the priorities of each specific business area</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;This plan is designed to reward our employees&#8217; collective contribution to business achievement. Separate mechanisms are in place to recognise outstanding individual performance or to address under-performance</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Our Executive Directors and the GLT participate in a plan based on an assessment of a combination of stretching financial/business, ESG: DEI and personal objectives</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;For Executive Directors, any bonus up to 200% of salary is paid 50% in cash and 50% in shares deferred for three years. Any bonus earned in excess of this (up to a maximum of 300% of salary) would be delivered fully in shares deferred for three years</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;For GLT members, any bonus up to 170% of salary is paid 75% in cash and 25% in shares deferred for three years. Any bonus earned in excess of this (up to a maximum of 255% of salary) would be delivered fully in shares deferred for three years</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Clawback and/or malus provisions apply</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LTI&#160;plans</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Our employees at Senior Vice President (SVP) and Vice President (VP) level participate in the same PSP as our Executive Directors and the GLT with the same performance targets and periods</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Clawback and/or malus provisions apply</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Our SVP and VP employees, together with Directors and Managers below the GLT, receive annual Share Value Plan awards of restricted shares</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Our Executive Directors and the GLT are granted annual PSP awards with the same performance targets and periods as employees</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Executive Directors are required to hold vested awards for an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Clawback and/or malus provisions apply</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8201;Executive Directors and the GLT do not receive Share Value Plan awards following appointment</div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">All-employee</div> share plans </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">UK Executive Directors may participate in His Majesty&#8217;s Revenue&#160;&amp; Customs approved <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">all-employee</div> share plans along with the wider UK workforce, namely the company&#8217;s Share Save and Share Reward plans. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Participants of the company&#8217;s Share Save plan may save up to &#163;250 a month for three years and at the end of the period have the option to buy GSK shares at a discount of up to 20% to the share price at the start of the savings contract. Participants of the Share Reward plan contribute up to &#163;125 a month to purchase GSK shares which the company then matches on a one for one basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For further details see page 154. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dilution limits </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All awards are made under plans which incorporate dilution limits consistent with the guidelines published by the Investment Association (IA). These limits are 10% in any rolling <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period for all plans and 5% in any rolling <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period for executive share plans (granted to senior executives). Estimated dilution from existing awards made over the last ten years up to 31&#160;December 2022 is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_144.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">144</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; pay in a wider setting </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CEO pay ratios &#8211; Option A methodology </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:20%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial&#160;year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Lower quartile</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">P25</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Median</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">P50</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Upper quartile<br/>P75</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">144:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">106:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">67:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">154:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">108:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">67:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2020</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">130:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">96:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">62:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2019</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">160:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">119:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">73:1</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK continues to use the Option A methodology because it is the most robust and statistically accurate way to calculate the three ratios from the options available in the Remuneration regulations. The pay ratio is broadly similar to 2021 with the reduction at P25 influenced by the change in workforce composition following the Consumer Healthcare demerger. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The pay ratios above are calculated using actual earnings for the CEO and UK employees. The CEO&#8217;s total single figure remuneration of &#163;8,453,253 for 2022 and &#163;8,203,422 for 2021 are detailed on page 136. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total remuneration for all UK full-time equivalent employees on </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">31&#160;December 2022 has been calculated in line with the single figure methodology. This reflects their actual earnings received in 2022 (excluding business expenses), which were used to produce the percentile calculation under Option A of the Remuneration regulations. Business expenses have been excluded as they are reimbursed to employees and are not sufficiently substantial in value to significantly impact the ratios. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows the salary, and total pay and benefits for each of the percentiles. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:28%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P25</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P50</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P75</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Salary</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37,776</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37,251</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36,924</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">34,510&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">52,107</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">51,492</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50,000</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">47,029&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">74,905</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">72,997</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">70,203</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">66,561</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total pay and benefits</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">58,883</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">53,151</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54,133</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50,467&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">79,428</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">76,234</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">73,340</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">68,200&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">126,594</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122,852</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">113,830</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110,638</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee believes that the median pay ratio is consistent with the company&#8217;s pay, reward and progression policies. The base salaries of all employees, including the Executive Directors, are set with reference to a range of factors including market practice, experience and performance in role. </div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supplemental and additional ratios </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The CEO pay ratio is likely to vary, potentially significantly, over time since it will be driven largely by CEO variable pay outcomes. In line with our reward principles, the CEO has a larger portion of her pay based on performance than the individuals at P25, P50 and P75. This means that depending on GSK&#8217;s performance the ratio could increase or decrease significantly. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee believes that our senior executives should have a significant proportion of their pay linked directly to performance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In light of this we have also provided supplemental ratios, where LTI compensation has been excluded. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We believe this provides an additional view as LTIs formed a substantial percentage of the CEO&#8217;s total remuneration, which is highly variable and dependent on business performance. The CEO&#8217;s 2022 total remuneration excluding LTI compensation is &#163;4,787,090. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CEO pay ratios (less LTI awards) </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:20%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option&#160;A&#160;Methodology</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial&#160;year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P25</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P50</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">P75</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">81:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">60:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">40:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">73:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">51:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">34:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2020</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">51:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">38:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">26:1</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2019</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">65:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">48:1</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">32:1</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Relative importance of spend on pay </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table shows total employee pay and the Group&#8217;s dividends paid to shareholders. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2021</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total employee pay</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,693</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,680</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid in the year</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13.3)</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,467</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,999</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The figures in the table above, which reflect payments made during each year and the impact of movements in exchange rates, are as set out on pages 200 and 207. However, cash dividends declared in respect of 2022 were &#163;2,468 million (2021: &#163;4,011 million) a decrease of 38.5%. Please see Note 16 to the financial statements for further details. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total employee pay is based on 69,130 employees, the average number of people employed during 2022 (2021: 71,345). Please see Note 9 to the financial statements for further details. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no share repurchases made by the company during 2022 and 2021. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">145</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; pay in a wider setting </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">External context </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comparator groups </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The Committee used two pay comparator groups when considering executive pay for 2022. The European cross-industry comparator group is the primary comparator group used for the CEO and CFO. The Global pharmaceutical comparator group is the secondary group for the CEO and is also used to measure relative TSR performance. </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:28%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">European cross-industry comparator group</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Roche Holding AG</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Linde</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Deutsche Telekom</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Novartis</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Sanofi</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Kering</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">LVMH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">AstraZeneca</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Heineken</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Anheuser-Busch InBev</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Diageo</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">BASF</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Unilever</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Siemens</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Vinci</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">SAP</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Christian Dior</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Adidas</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">L&#8217;Oreal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inditex</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Bayer</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Novo Nordisk A/S</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">BAT</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Safran</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top">Airbus</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Volkswagen</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">Reckitt Benckiser</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Global pharmaceutical comparator group</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">France</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sanofi</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Switzerland</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Novartis</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Roche Holdings</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">UK</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">AstraZeneca</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">US</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">AbbVie<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amgen<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bristol-Myers&#160;Squibb</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Eli Lilly</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Johnson&#160;&amp;&#160;Johnson</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Merck&#160;&amp; Co</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pfizer</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">AbbVie and Amgen are included for remuneration benchmarking, but are not included in the relative TSR comparator group. </div></td></tr></table><div style="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 target CEO total remuneration positioning </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When reviewing the CEO&#8217;s remuneration, the Committee&#8217;s primary comparator group is the European cross-industry comparator group. It also references pay for the Global pharmaceutical comparator group. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_146b.jpg"/> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">Remuneration includes salary and the expected value of incentives based on the Committee&#8217;s agreed benchmarking methodology. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TSR Performance graph </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following graph sets out the performance of the company relative to the FTSE 100 Index and to the Global pharmaceutical performance comparator group for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period to 31&#160;December 2022. These indices were selected for comparison purposes as they reflect both the primary index of which GSK is a constituent and the industry in which it operates. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_146a.jpg"/> </div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">This index comprises AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson&#160;&amp; Johnson, Merck&#160;&amp; Co, Novartis, Pfizer, Roche Holdings and Sanofi. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historic CEO remuneration </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emma&#160;Walmsley</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;000</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2019</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2018</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2017</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Total remuneration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,453</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8,203</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,031</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8,094</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,887</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">4,883<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">% of maximum</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Annual Bonus award<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(2) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">77%</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Vesting of LTI awards</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52%</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">67%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">67%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">59%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">69%</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Sir Andrew Witty</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#163;000</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2017</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2016</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2015</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2014</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2013</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Total remuneration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">715<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(2)</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,830</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,661</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,902</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">7,207</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">% of maximum</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Annual Bonus award<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(2) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(2) </div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">88%</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Vesting of LTI awards</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(3) </div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">33%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">31%</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Emma Walmsley&#8217;s total remuneration includes her pay for the period 1&#160;January to 31&#160;March 2017, before she became CEO. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Sir Andrew Witty received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> payment for 2017 in lieu of a variable bonus opportunity, in accordance with the 2014 Remuneration policy. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">PSP and DABP awards for Sir Andrew Witty granted in 2015 did not vest until April 2018, in accordance with the terms of the Executive financial recoupment policy. </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implementation of Remuneration policy for 2023 </div></div></div></div><div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fixed Pay </div></div></div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee is very aware of the sensitivity amongst stakeholders to levels of Executive pay. Before reviewing Executive Directors&#8217; salary, it considered the average increases being awarded to employees below the level of Executive Directors and was mindful of the multiplier effect of increases in base pay. After due consideration of the wider economic context, individual performance and market positioning it was agreed that it was appropriate to award increases below that of the wider workforce to the CEO. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, in addition to the 5% average salary increase, the company has implemented a number of monetary initiatives for our colleagues in the wider workforce, in reaction to the cost of living crisis, which can be found on pages 134 and 135. </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Base salary</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%&#160;change</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wider workforce<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;1,310,249</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;915,335</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Based on the average increase budget for employees below the level of GLT in the UK. </div></td></tr></table><div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">As a known leaver on 31 December 2023, Mr Mackay is not eligible to receive a salary increase. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefits </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">No significant changes to the provision of benefits are proposed for 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For full details of the policy in relation to benefits, please refer to the 2022 Remuneration policy report on page 144 of the 2021 Annual Report. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides an overview of the pension arrangements for each Executive Director in 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Executive Directors&#8217; pensions were reduced to align with the wider UK workforce effective 1&#160;January 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any new Executive Director&#8217;s pension will be aligned to the appropriate wider workforce on appointment. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:27%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:72%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2023 Pension contribution</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Emma Walmsley<br/>Iain Mackay</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.07em; text-indent: -1.07em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8194;7% of base salary contribution to defined contribution plan and a further 3% in matched contributions on the first &#163;26,666 of salary in accordance with the terms of the plan and</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.07em; text-indent: -1.07em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8194;7% of base salary as a cash payment in lieu of pension contribution on salary in excess of &#163;26,666, or</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1.07em; text-indent: -1.07em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8194;7% of base salary as a cash payment in lieu of pension contribution</div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pay for performance </div></div></div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Bonus </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are no changes to the operation of the Annual Bonus plan. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For full details of the policy please refer to pages 145 and 146 of the 2021 Annual Report. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus&#160;opportunity&#160;%&#160;of&#160;salary</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Target</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Maximum</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">100</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">300&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">50% of the equivalent of the first 200% of salary is deferred, and any portion in excess of 200% is deferred in full. </div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="14" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighting&#160;of&#160;performance&#160;measures&#160;%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total&#160;sales</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">growth</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjusted</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">operating</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;profit&#160;growth</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;Strategic&#160;and</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">operational</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">measures</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;ESG:&#160;diversity,</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity and</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">inclusion</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma&#160;Walmsley</div></td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">30</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">30</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">30</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle;text-align:right;">10</td>
<td rowspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Inevitably, targets linked directly to our financial and strategic plan are commercially sensitive. The Committee does not consider it appropriate to disclose Annual Bonus targets during the year, as it may result in competitive harm. However, details of the performance targets will, as usual, be disclosed on a retrospective basis in the 2023 Annual Report. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred Annual Bonus Plan (DABP) 2023 awards </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides details of the mandatory deferral into the DABP of the 2022 Annual Bonus payments and the associated awards granted. The shares awarded have no performance conditions, but must be held for three years, regardless of continued employment. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;bonus&#160;deferred</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DABP&#160;awards</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">into&#160;shares&#160;%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">59.9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">125,482</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">56.0</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">77,751</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance Share Plan (PSP) 2023 awards </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides details of awards granted under the PSP. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;of&#160;salary</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">501,927</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LTI performance measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The measures and weightings for the 2023 awards remain unchanged from those used for the 2022 awards. The weightings for the five LTI measures are: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:97%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LTI measure</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measure</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighting</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Innovation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Pipeline progress</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Performance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">Relative TSR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">Total sales growth</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Adjusted operating profit growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trust</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">ESG: environment</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10%</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">147</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual report on remuneration continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implementation of Remuneration policy for 2023 </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="border-radius: 8pt; border: 1px solid rgb(231, 231, 232); border-image: none; padding-top: 2pt; padding-bottom: 3pt; margin-right: 0%; margin-left: 0%; max-width: 100%; background-color: rgb(231, 231, 232);"><div style="padding-top: 0pt; font-family: ARIAL; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt;"><div style="font-family: ARIAL; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Innovation </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Pipeline progress measure seeks to reward acceleration and strengthening of the pipeline. This is based on two equally weighted elements of our key assets or indications measured over a three-year performance period. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 10pt;">Points are allocated for successful assets in each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-measure</div> based upon their forecast commercial value (peak year sales) at the end of the performance period. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 10pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-measures</div> for the 2023 award will vest as follows: </div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pivotal trial starts </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Focuses mainly on phase III registrational trial starts, but may also include phase II starts. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 96%; font-family: ARIAL; font-size: 7.5pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance level</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Points</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payout</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Below Threshold</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&lt;12</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">Nil</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Threshold</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">25%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">50%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">75%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Maximum</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">100%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major regulatory approvals </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 96%; font-family: ARIAL; font-size: 7.5pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance level</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Points</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payout</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Below Threshold</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&lt;17</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">Nil</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Threshold</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">25%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">50%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">75%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Maximum</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">100%</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-family: ARIAL; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 10pt;"><div style="font-family: ARIAL; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">The Pipeline progress measure is commercially sensitive at the time of grant. At the end of the performance period we will provide disclosure of what has been achieved. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-right: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-right: 10pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Relative TSR will continue to be measured against GSK&#8217;s Global pharmaceutical comparator group (see page 146). The total sales growth and adjusted operating profit growth measures recognise the importance of our commercial ambitions and the Committee has set targets that align with those ambitions. The targets for total sales growth and adjusted operating profit growth are commercially sensitive at the time of grant. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 6pt; margin-right: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ESG: environment </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-right: 10pt; margin-bottom: 0pt;">The ESG: environment measure is based on the goal of having a Nature Net Positive and Climate Net Zero impact by 2030 (see pages 45 and 46). The targets for the ESG: environment measure for the 2023 grant are based on a series of Nature goals relating to Water, Waste&#160;&amp; Materials reduction, Biodiversity impact and Climate goals that incorporate Scope 1 &amp; 2 emission reduction targets, carbon offsetting and our industrialisation of green <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin</div></div>. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-right: 10pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESG: environment measure includes six key performance measures: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">3x Climate ambitions </div></div></td>
<td style="width: 9.75pt;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">3x Nature ambitions </div></div></td>
<td style="width: 9.75pt;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-right: 10pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">To achieve: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">75% vesting, all six measures must have met their 2025 targets </div></div></td>
<td style="width: 9.75pt;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">100% vesting, two of the six measures, at least one in Climate and one in Nature, must have exceeded their 2025 targets </div></div></td>
<td style="width: 9.75pt;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholdings versus Share Ownership Requirement (SOR) (audited) </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;">To align the interests of Executive Directors with those of shareholders, they are required to build and maintain significant holdings of shares in GSK over time. Executive Directors are required to continue to satisfy these Share Ownership Requirements (SOR) by holding 100% of their SOR for the first 12 months after leaving GSK and not less than 50% of their SOR for months <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-24</div> after leaving GSK. </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value of holdings as % of salary</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">SOR</div></div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;of&#160;salary</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;March&#160;2023</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December&#160;2022</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Iain Mackay</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">300</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">406</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;">Shares subject to performance conditions are excluded from each Executive Director&#8217;s SOR calculation until the end of the performance period. These vested shares are then included as part of the Director&#8217;s SOR to the extent that the performance conditions are met. The value of the holdings has been calculated on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> basis. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;">Emma Walmsley and Iain Mackay, at the date of publication of this Report, exceed their SOR. Dr Hal Barron exceeded his SOR prior to his transition to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director role on 1&#160;August 2022. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The company has processes in place to ensure that each Executive Director maintains their SOR after leaving GSK. Each Executive Director agrees to the terms of the SOR as part of their service contract. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">148</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implementation of Remuneration policy for 2023 </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Termination arrangements for Executive Directors </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As announced during 2022, Iain Mackay will step down as CFO and Executive Director on 1&#160;May 2023, continue as an employee and leave the company on 31&#160;December 2023. </div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:24%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:74%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration&#160;element</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Summary of treatment</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Annual Bonus</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Eligible to receive bonuses which will be determined by the Committee based on a combination of business and individual performance for his service during 2022 and 2023.</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">PSP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Not eligible to receive any further PSP awards.</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Outstanding&#160;PSP&#160;and&#160;DABP&#160;awards</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">All existing LTI awards will be retained and PSP awards will be pro-rated for time.</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">DABP deferred bonus awards</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Awards in respect of bonuses deferred in 2022 and prior years will vest at their normal vesting dates.</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition to the above, Iain Mackay will be required to maintain his SOR in accordance with the company&#8217;s Remuneration policy. </div><div style="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration arrangements for Julie Brown </div></div></div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee considered the remuneration arrangements that would be appropriate to enable the company to recruit and retain an experienced CFO within the criteria for the role in the company&#8217;s 2022 Remuneration policy. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Given Julie Brown&#8217;s wealth of experience as a CFO and of the industry, it was agreed that her remuneration should be set in line with Iain Mackay&#8217;s remuneration, as follows: </div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration&#160;element</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Salary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#163;951,948</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ms Brown&#8217;s salary was preliminarily set in line with that of her predecessor in September 2022 (&#163;915,335) and her salary upon joining will be 4% higher than this figure, in line with the increase agreed for the CEO. The comparator group for pay for the CFO remains the European cross-industry comparator group as set out on page&#160;146.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Annual Bonus</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#163;951,948</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> bonus would be 100%, with a maximum of 300% for incremental exceptional performance as for Mr Mackay.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Award&#160;of&#160;Long&#160;Term&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Incentives (LTIs)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#163;1,903,896&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">This assumes an expected value of 50% of an award of performance shares under the PSP at a 4x multiple of base salary as for Mr Mackay.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share Ownership</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Requirement&#160;(SOR)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">300%&#160;of salary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">This is in line with the 2022 Remuneration policy.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Pension</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Pension arrangements will be in line with those of the wider UK workforce in accordance with GSK&#8217;s commitment from 1&#160;January 2023.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Benefits</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Benefits will be in line with GSK&#8217;s policy and arrangements for other executives to support them in undertaking their role.</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee sought to ensure Ms Brown was compensated on a like-for-like basis as far as possible when concluding her buyout payments, which are set out below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a sum (the Bonus Buyout) equivalent to Ms Brown&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> Burberry bonus for the period from 1&#160;April 2022 to 31&#160;March 2023, which she will forego on leaving Burberry </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">a sum (the LTI Buyout) equivalent to the aggregate value of (i)&#160;her outstanding Burberry LTIs and SIP shares, which will be lost on leaving Burberry, at a price equivalent to the average price of such shares for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-month</div> period ended on 7&#160;September 2022, and (ii)&#160;the value of any dividend equivalents accruing on those shares between their date of award and her departure from Burberry. Given that the Burberry LTIs are not subject to a performance measure, and only to a performance underpin, no discount will be applied to the value of the shares so calculated </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee agreed that these payments would be made in stages over a two year period as follows, as cash amounts equivalent to: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Bonus Buyout and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of 85% of the LTI Buyout will be paid to her in the first payroll following the commencement of her employment with GSK </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of 85% of the LTI Buyout will be paid to her in the first payroll following the first anniversary of the commencement of her employment and </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of 85% of the LTI Buyout will be paid to her in the first payroll following the second anniversary of the commencement of her employment </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, she will be paid an amount equivalent to 15% of the LTI Buyout in the first payroll following the commencement of her employment. Ms Brown has agreed that she will invest the net of tax proceeds of this 15% tranche in GSK shares at the first reasonably available opportunity, subject to dealing clearance, and that she will then hold those shares for a period of at least two years. Ms Brown&#8217;s SOR as CFO will be three times her base salary which she will be required to build over time. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">149</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration governance </div></div></div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee role and membership </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These details are available on page 107 and are incorporated by reference into this Report. The Chair, CEO, Chief People Officer, Head of Reward, Group Financial Controller and the Company Secretary assisted the Committee during the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adviser to the Committee </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company undertook a full commercial tender process during 2022 and appointed Willis Towers Watson LLP (WTW) as independent adviser to the Committee with effect from 1&#160;December 2022. WTW replaced PricewaterhouseCoopers LLP (PwC) who served as independent adviser up to 1&#160;December 2022 and for over four years in total. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Both WTW and PwC are members of the Remuneration Consultants&#8217; Group and, as such, voluntarily operate under the code of conduct in relation to executive remuneration consulting in the UK. The code of conduct can be found at www.remunerationconsultantsgroup.com. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">WTW provided additional market data to the Committee and other HR consulting services to the company prior to and after their appointment as independent Committee advisers. During the year, in addition to providing consultancy services to the Committee, PwC also provided other consulting and assurance services to the company prior to WTW&#8217;s appointment. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In line with the protocols agreed and set by the Committee Chair under which WTW and PwC provided their advice, the Committee is satisfied that such advice has been objective and independent. During their respective tenures in 2022, PwC and WTW have provided independent commentary on matters under consideration by the Committee and updates on market practice and legislative requirements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee also reviewed the potential for conflicts of interest and judged that there were appropriate safeguards against such conflicts. WTW&#8217;s and PwC&#8217;s fees for advice during that period, which were charged on a time and materials basis, were &#163;4,000 and &#163;162,945 respectively. The Committee is satisfied that these fees did not compromise either firm&#8217;s independence. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of consideration of shareholder views </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee engages in regular dialogue with shareholders and holds annual meetings with GSK&#8217;s largest investors to discuss and take feedback on its Remuneration policy practices and governance matters. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 AGM voting </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of voting levels in respect of our Remuneration arrangements are set out below. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;votes</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">cast&#160;(billion)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;votes</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">for (%)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;votes</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">against&#160;(%)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Votes</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;withheld</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">(million)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">2022 AGM</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Remuneration report</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">91.05</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8.95</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">12.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Remuneration policy</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">61.76</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38.24</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Service contracts and letters of appointment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below sets out the dates of the Executive Directors&#8217; service contracts, which are available for review at the company&#8217;s registered office and on gsk.com, with the exception of Julie Brown, whose contract will be available on gsk.com following her appointment. Each Executive Director&#8217;s service contract contains a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> notice period. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:23%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:23%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;contract&#160;&#160;&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effective&#160;date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry&#160;date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Emma Walmsley</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">29.03.17</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">01.04.17</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">30.06.34</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Iain Mackay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">18.09.18</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">14.01.19</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">n/a</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Julie Brown</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">25.09.22</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">01.05.23</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">n/a</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors have letters of appointment, which are available to view at the company&#8217;s registered office. Each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director is expected to serve on the Board until the end of the AGM following the third anniversary of their appointment. This is subject to election and subsequent annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election.</div> Subject to mutual agreement, they are each expected to serve a further three years, and up to nine years from appointment in line with the provisions of the FRC&#8217;s UK Corporate Governance Code, subject to annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election.</div> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration governance </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:3%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"><div style="font-size: 10pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committee focus during 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"><div style="color: rgb(113, 98, 88); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Items discussed</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration policy</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee sets the Remuneration policy for shareholder approval and then determines the remuneration of the Executive Directors, the Chair and other corporate officers in line with that policy.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Prepared and agreed the proposed 2022 Remuneration policy</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Remuneration impact of Consumer Healthcare demerger</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Shareholder and advisory body engagement on new Remuneration policy. See page 133 for further details</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Review and consideration of shareholder and proxy adviser feedback</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Amendments to the proposed Remuneration policy following careful consideration of shareholder feedback</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Continued engagement with shareholders</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary review</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee periodically reviews and considers the remuneration environment for Executive Directors and GLT and approves, when appropriate, annual adjustments as necessary having regard to performance, market positioning and the remuneration of the wider workforce.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Executive Director and GLT benchmarking, competitiveness and GSK comparator groups</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;GLT and Company Secretary salary review and recommendations for 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Executive Director salary review and recommendations for 2023</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Setting remuneration for Julie Brown, the new CFO</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Review of company Chair&#8217;s fee</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Bonus</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee is responsible for setting specific performance measures for the Annual Bonus and for assessments of performance against these measures.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;CEO, Executive Directors and GLT 2021 bonus recommendations and 2022 CEO and Executive Directors&#8217; bonus objectives</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Proposed new Annual Bonus performance measures aligned with June 2021 Investor Update commitments</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LTI plans</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee is responsible for approving LTI plan rule changes, grants, assessments of performance, and the vesting of LTI awards for the Executive Directors, GLT and below (including interim awards).</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;LTI performance outcomes and award vesting for the CEO, Executive Directors, GLT and below</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Confirmation of LTI grants for the CEO, Executive Directors, GLT and below</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Proposed new performance conditions aligned with June 2021 Investor Update commitments</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Governance and other areas of focus</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Committee adheres to a robust remuneration governance framework, ensuring alignment between internal actions and external reporting/compliance requirements.</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Remuneration considerations and Committee programme for 2022</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Review of Terms of Reference</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Committee evaluation annual review</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;2021 Remuneration report</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Confirmation of 2022 Group Budget for remuneration purposes</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;AGM and Remuneration report feedback, the external remuneration environment and performance target disclosure for incentive plans</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;2022 Remuneration report disclosures, including CEO pay ratio</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Annual Governance Meeting key Committee messages</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Committee Chair consultation with employee representatives on setting pay and wider workforce pay practices</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0.94em; text-indent: -0.94em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">&#8211;&#8201;&#8202;Remuneration adviser tender process</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">151</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees </div></div></div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company aims to provide the Chair and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors with fees that are competitive with those paid by other companies of equivalent size and complexity, subject to the limits contained in its Articles of Association. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair&#8217;s fees </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Chair&#8217;s fee was set at &#163;700,000 per annum, nearly four years ago in September 2019 when he was first appointed to the Board. It has remained unchanged since that time. After a review of independently sourced data by the Committee in January 2023 it was agreed that it was appropriate to increase his fees by &#163;35,000 to &#163;735,000 from 1&#160;January 2023 &#8211; a 5% increase from the rate originally set in 2019. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022 the Chair invested approximately 25% of his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> fees in notional shares under the GSK NED share allocation plan (NED plan). Since September 2022 he invests approximately 25% of his net fees in the purchase of GSK shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees that applied during 2022 are set out in the table below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Per&#160;annum&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Standard annual fee</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;95,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental fees</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Chair of the Audit&#160;&amp; Risk Committee</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;80,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Senior Independent Director</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;50,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Scientific&#160;&amp; Medical Experts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;30,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Chairs of the Remuneration, Corporate Responsibility and Science committees and Workforce Engagement Director</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;40,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Science Committee members undertaking significant additional responsibilities on behalf of GSK to support R&amp;D</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">Up&#160;to&#160;&#163;200,000&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director undertaking intercontinental travel to meetings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;7,500&#160;per&#160;meeting&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Standard annual fee for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director annual fee was last increased in 2020. Following a review of independently sourced data and recognising the ever-increasing workload for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors it was agreed that it was appropriate to increase the standard annual fee by &#163;3,800 (4%) from &#163;95,000 to &#163;98,800 per annum from 1&#160;January 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">With a view to further simplicity, creating greater transparency of the overall standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director fee and based on review of independent data, going forward the intercontinental travel allowance of &#163;7,500 per meeting will be added to the standard fee. Ordinarily, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors are expected to travel overseas to attend two meetings per year and so can expect to receive two travel allowance payments totalling &#163;15,000. The Chair does not receive this allowance. This amount will now be added to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director standard fee from 1&#160;January 2023 bringing the total standard fee to &#163;113,800. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director Share Ownership Requirement </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following approval of the new Remuneration policy at the last AGM, in July 2022 it was agreed to implement a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director share ownership requirement (SOR) of at least one times the annual standard fee (or the Chair&#8217;s fee) to be maintained until after retirement from the Board. The Chair, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-US</div> based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors and newly appointed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors commenced purchasing shares or ADS in the market towards their new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director SOR from September 2022. US <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors began purchasing ADS towards their SOR from 1&#160;January 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shareholder approval will be sought at the AGM for an administrative amendment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director section of the Remuneration policy to allow the notional shares or ADS previously allocated under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director plan to be delivered to the Chair and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors at such time as the Committee and Board considers appropriate after any applicable tax withholding. This would be subject to the Chair and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors undertaking to hold these shares or ADS until they retire from the Board. This change will not only give the company greater operational flexibility, it will also reduce the administrative burden of operating the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director plan, and will ensure that the Chair and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors directly maintain a meaningful and prudent level of investment which closer aligns their interests with shareholders. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company does not expect to make any significant changes to the fee structure for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors during the remainder of the 2022 Remuneration policy period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 Total fees (audited) </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The audited table below sets out the value of fees and benefits received by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors in the form of cash and shares or ADS. Further details of the NED plan are set out on page 155. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors fees paid in a currency other than Sterling are converted using an average exchange rate that is reviewed from time to time. The average exchange rates were updated in 2022. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors fees were converted to US Dollars using an exchange rate of $1.3481 in 2022. Benefits comprise the grossed up cash value of travel and subsistence costs incurred in the normal course of business, in relation to attendance at Board and Committee meetings and in fulfilling their role as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="8" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="8" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fixed&#160;fees</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fixed&#160;fees</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">emoluments (000) (audited)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cash</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Shares/ADS</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total&#160;pay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cash</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Shares/ADS</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total&#160;pay</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sir Jonathan Symonds</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;525</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;175</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;10</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;710</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;525</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;175</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;3</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;703</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Elizabeth McKee Anderson</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$35</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$8</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$43</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charles Bancroft</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$287</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$10</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$297</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$210</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$215</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Barron</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$150</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$16</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$11</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$177</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Anne Beal</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$138</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$46</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$15</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$199</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$62</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$21</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$83</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Dietz</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$174</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$58</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$2</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$234</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Jesse Goodman</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$182</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$61</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$31</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$274</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$164</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$55</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$23</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$242</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Urs Rohner</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;112</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;31</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;23</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;166</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;101</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;34</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;11</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;146</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Vishal Sikka</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$58</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$58</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retired Directors</div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vindi Banga<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;65</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;22</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;4</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;91</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;109</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;36</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;1</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;146</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dame Vivienne Cox<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;55</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;18</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;1</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;74</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;101</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;34</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;1</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;136</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lynn Elsenhans<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$74</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$25</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$23</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$122</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$134</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$45</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$5</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$184</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Laurie Glimcher<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$136</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$20</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$156</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$165</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$13</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">$178</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Retired from the Board on 18&#160;July 2022. </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Retired from the Board on 13&#160;October 2022. </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">153</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual report on remuneration continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Directors&#8217; interests in shares (audited) </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Directors&#8217; interests in shares </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The interests of the Executive Directors of the company in office during 2022 and their persons closely associated (PCA) are shown in the table below: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="18" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As at 31&#160;December 2022</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="12" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unvested share plan interests</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total directors&#8217; interests</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interests</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not&#160;subject&#160;to&#160;performance</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">performance</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;3&#160;March&#160;2023<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December&#160;2022<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares/ADS<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares/ADS<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(3,7)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Options<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(4,7)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares/ADS<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(5)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,503,484</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">1,334,155</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">493,081</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">656,084</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">184,990</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,550,844</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Iain Mackay</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">471,595</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">284,967</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">157,965</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">127,002</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">783,978</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ADS</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Barron</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">552,499</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">547,374</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">306,004</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">241,370</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">348,459</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total directors&#8217; interests</div></div> includes beneficial interests and unvested share plan interests not subject to performance. For Emma Walmsley and Iain Mackay, the balance as at 3&#160;March&#160;2023 includes shares/ADS awarded in 2020 under the PSP and the DABP which vested in February 2023 less those sold to satisfy tax liabilities on the vested amounts where relevant. ADS awarded in 2020 under the PSP and the DABP to Dr Hal Barron will not vest until August 2023 in accordance with the terms of the Executive and Senior Management Recoupment Policy. Executive Directors&#8217; shareholdings against their SOR are outlined on page 148. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial interests</div></div> includes shares/ADS held by the Executive Directors and their PCAs. For Emma Walmsley, this includes 2,166 shares purchased through the GSK Share Reward plan. Iain Mackay does not currently participate in the Share Reward plan. As a US employee, Dr Hal Barron was not eligible to participate in the Share Reward plan which is only open to UK employees. Dr Barron&#8217;s beneficial interests include ADS and notional ADS held by way of his investments in the GSK 401(k) plan and the Executive Supplemental Savings Plan (ESSP). Further details on Dr Barron&#8217;s membership of these plans can be found on page 138. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unvested shares/ADS not subject to performance</div></div> represent PSP shares/ADS which have vested but are subject to an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> holding period. Unvested ADS not subject to performance for Dr Barron also represent bonus deferrals (as described in note 7 below). </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">4)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unvested options not subject to performance</div></div> represent bonus deferrals under the DABP which are awarded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-cost</div> options (as described in note 7 below). This figure excludes 790 options held by Emma Walmsley under the GSK Share Save plan. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unvested shares/ADS subject to performance</div></div> represent unvested PSP awards. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">6)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vested but unexercised options:</div></div> None of the Directors hold vested but unexercised options. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">7)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">DABP:</div></div> The table below shows bonus deferrals and subsequent reinvestment of dividends under the DABP. The amounts represent the gross shares/ADS balances prior to the sale of any shares/ADS to satisfy tax liabilities on vesting. As UK employees, bonus deferrals under the DABP are granted as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-cost</div> options to Emma Walmsley and Iain Mackay. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 98%; font-family: ARIAL; font-size: 7.5pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">DABP (Bonus deferrals)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;March&#160;2023</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;31&#160;December&#160;2022</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;1&#160;January&#160;2022</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">251,541</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">184,990</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">176,801</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Iain Mackay</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">164,988</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">127,002</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">71,972</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">ADS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Barron</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">104,563</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">103,600</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">101,801</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">8)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options exercised in 2022:</div></div> The following table sets out details of options (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-cost</div> options under the DABP) exercised during 2022 by Executive Directors. Iain Mackay did not exercise any options during the year. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 98%; font-family: ARIAL; font-size: 7.5pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Market&#160;price</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Type of award</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;grant</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">under option</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;exercise</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Grant&#160;price</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">at exercise</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Gain&#160;on&#160;exercise</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Emma Walmsley</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferral award &#8211; DABP</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.02.2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.02.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#163;0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#163;16.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#163;1,164,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Save</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">29.11.2018</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">744</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">25.02.22</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#163;12.09</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#163;15.82</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#163;2,775</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 8pt; margin-bottom: 0pt; margin-left: 2%;">In respect of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">nil-cost</div> options awarded in 2019 under the DABP, the bonus which is deferred by the Executive Director was recorded as remuneration (under Annual Bonus) in the Total remuneration table in respect of 2018. The number of shares under option includes the initial award amount together with reinvested dividends accrued to the date of exercise. </div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">In respect of options under the GSK Share Save plan, the remuneration receivable by an Executive Director is calculated on the date that the options first vest. The remuneration is the difference between the amount the Executive Director is required to pay to buy the shares and the total value of the shares on the vesting date. If the Executive Director chooses not to exercise the options on the vesting date, any subsequent increase or decrease in the amount realised will be due to movements in the share price between the vesting date and the date of exercise. This increase or decrease in value is the result of an investment decision by the Executive Director and, as such, is not recorded as remuneration. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual report on remuneration continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors&#8217; interests in shares (audited) </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; interests in shares </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;">The interests of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors of the company in office during 2022 and their persons closely associated (PCA) are shown in the table below: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="18" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share allocation plan for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;">&#160;</td>
<td colspan="8" style="height: 1.5pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;">&#160;</td>
<td colspan="20" style="height: 1.5pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;directors&#8217;&#160;interests&#160;as&#160;at</div></div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares/ADS</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interests at</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividends</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Elected&#160;&amp;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">reinvested</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;or</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">allocated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3&#160;March</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">or date of</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">or date of</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">after</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;of</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">for share</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">during</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;January</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">retirement</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">retirement</div></div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(2)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">year end</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">retirement</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">consolidation<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(4)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;year</div></div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(3)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sir Jonathan Symonds</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,045</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">68,316</div></div></td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">33,925</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">728</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">34,391</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(8,598</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">15,273</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">27,716</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Vindi Banga<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(5) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">93,391</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">57,440</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">35,951</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(8,987</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12,266</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">32,672</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dame Vivienne Cox<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(5) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,252</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12,252</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(3,062</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">4,767</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">10,547</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Urs Rohner</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,710</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,317</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">798</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">392</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">18,519</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(4,630</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">6,722</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">16,427</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">ADS</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth McKee Anderson</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Charles Bancroft</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,804</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,564</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">240</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">15,564</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(2,617</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">10,715</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">7,466</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Anne Beal</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,800</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,777</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,777</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(233</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,507</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">503</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Barron</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">552,499</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">547,374</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">306,004</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Hal Dietz</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,593</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,575</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,575</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(164</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,739</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Lynn Elsenhans<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(5) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47,692</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">46,892</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(11,722</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">14,631</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">43,983</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Laurie Glimcher<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(6) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,408</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">27,408</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(6,430</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">11,186</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">22,652</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Jesse Goodman</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,614</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,375</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">238</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12,375</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(2,846</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">4,999</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">10,222</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Vishal Sikka</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,147</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,147</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,147</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; font-family: ARIAL; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total directors&#8217; interests</div></div> include beneficial interests and any notional shares/ADS received as all or part of their fees under the NED plan. Dividends received on notional shares/ADS under the NED Plan during the year and in January 2023 were converted into notional shares/ADS as at 12&#160;January 2023. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial interests</div></div> includes shares/ADS held by the Non-Executive Directors and their PCAs. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional shares/ADS allocated during the year </div></div>under the NED plan includes (i) dividends reinvested during the year; and (ii) the reinvestment, on demerger, of an amount equivalent to the value of the Haleon plc shares/ADS attributable to the Non-Executive Directors&#8217; notional allocation of GSK plc shares/ADS (see note 4 below).<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">4)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">To align as closely as possible the treatment of Non-Executive Directors in respect of their NED plan allocations with those of shareholders on the demerger and share consolidation, NED plan allocations were adjusted as follows: (a) an amount equivalent to the value of the Haleon plc shares/ ADS attributable to the Non-Executive Directors&#8217; notional holding of GSK plc shares/ADSs was reinvested so as to increase those notional allocations of GSK plc shares/ADS on 18 July 2022; and (b) all notional GSK share/ADS allocations in the NED plan, including allocations arising under (a), were consolidated at a ratio of four new notional GSK shares/ADS for every five notional GSK shares/ADS held as at 18 July 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Vindi Banga, Dame Vivienne Cox and Lynn Elsenhans all retired from the Board on 18 July 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">6)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Laurie Glimcher retired from the Board on 13 October 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_99c.jpg" style="width: 35px; height: 902px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">155</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Annual report on remuneration continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Percentage change in remuneration of Directors </div></div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;percentage&#160;change</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021&#160;percentage&#160;change</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020&#160;percentage&#160;change</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Salary/fee<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Benefits<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bonus<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Salary/fee<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Benefits<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bonus<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Salary/fee<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Benefits<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bonus<br/>%</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK employees<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.26</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">44.81</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4.85</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.1</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Directors</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2,3) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emma Walmsley</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2.2</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38.2</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">94.6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26.6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(33.4</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Iain Mackay</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">32.4</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">56.1</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">94.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11.5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Barron<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(4) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(29.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(66.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5.4</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">150.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100.1</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(91.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(34.9</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2,5,6) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sir Jonathan Symonds</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">233.3</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">50.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">201.7</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Elizabeth McKee Anderson</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charles Bancroft</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36.7</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">156.1</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Barron<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(4) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Anne Beal</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">121.7</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Hal Dietz</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Jesse Goodman</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34.8</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(12.5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(65.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Urs Rohner</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5.9</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">109.1</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">175.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">16.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(69.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Vishal Sikka</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2,5,6) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vindi Banga</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(40.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">300.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4.6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(50.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23.6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(50.0</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dame Vivienne Cox</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45.9</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(50.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">55.4</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(75.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lynn Elsenhans</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(44.7</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">360.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(75.0</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(12.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(73.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dr Laurie Glimcher</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17.6</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">53.8</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(61.8</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(18.2</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(55.3</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">This table is provided in accordance with Schedule 8 of The Companies (Directors&#8217; Remuneration Policy and Directors&#8217; Remuneration Report) Regulations 2019. The UK employee population was considered to be the most relevant comparison as it most closely reflects the economic environment encountered by the majority of the Executive Directors. </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Percentage changes have been calculated based on the 2022 Total remuneration table on page 136 for Executive Directors and the 2022 Total fees table on page 153 for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors. Increases in benefits for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors are due to increased travel costs following the return to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> meetings <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-COVID-19.</div> </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Further information on Executive Directors&#8217; salary and benefits can be found on page 137. </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(4)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dr Hal Barron transitioned to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director role on 1&#160;August 2022. </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(5)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Fees of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors include fees received as cash and in the form of shares or ADS under the terms of the NED plan. </div></td></tr></table><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(6)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">See page 123 for details of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director changes during the year. </div></td></tr></table><div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 8pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Directors and Senior Management </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">Further information is provided on compensation and interests of Directors and Senior Management as a group (the group). For this purpose, the group is defined as the Executive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors, other members of the GLT and the Company Secretary. For the financial year 2022, the following table sets out aggregate remuneration for the group for the periods during which they served in that capacity. </div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 97%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remuneration for 2022</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total compensation paid</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,807,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate decrease in accrued pension benefits (net of inflation)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate payments to defined contribution schemes</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1,739,677</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2022, members of the group were awarded shares and ADS under the company&#8217;s various LTI plans, as set out in the table below. To align the interests of Senior Management with those of shareholders, Executive Directors and GLT members are required to build and maintain significant holdings of shares in GSK over time. GLT members are required to hold shares to an equivalent multiple of two times their base salary, and must continue to satisfy these share ownership requirements for a minimum of 12 months after leaving GSK. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Awards</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividend&#160;reinvestment&#160;awards</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Awarded during 2022</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ADS</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ADS</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Share Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,973,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,484</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">317,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Investment Awards<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(1,2) </div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">419</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Value Plan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(2) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">16,380</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10.5pt; vertical-align: top;;text-align:left;">1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Notional shares and ADS. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10.5pt; vertical-align: top;;text-align:left;">2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Directors are not eligible to receive Deferred Investment Awards or participate in the Share Value Plan. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">156</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual report on remuneration continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors and Senior Management </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">At 3 March 2023, the group and their PCAs had the following interests in shares and ADS of the company. Interests awarded under the various LTI plans are described in Note 44 to the financial statements, &#8216;Employee share schemes&#8217; on pages 262 to 263. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interests at 3 March 2023</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ADS</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Owned</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,533,721</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">409,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Unexercised options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8211;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Annual Bonus Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">842,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Share Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,084,743</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;617,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Investment Awards<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(1,2) </div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">280,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Value Plan<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(2) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">68,345</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5,740</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Notional shares. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Directors are not eligible to receive Deferred Investment Awards or participate in the Share Value Plan. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="border-radius: 10pt; border: 1px solid rgb(231, 231, 232); border-image: none; padding-top: 2pt; padding-bottom: 3pt; margin-right: 0%; margin-left: 0%; max-width: 100%; background-color: rgb(231, 231, 232);"><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin: 0pt 2%; padding-top: 3pt; font-family: ARIAL; font-size: 11pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees in respect of Executive Directors&#8217; external appointments </div></div></div></div><div style="margin: 6pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CEO </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;">Emma Walmsley is an independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of Microsoft Corporation. During 2022, she received $360,208, of which $125,208 was delivered as cash and $235,000 as stock options under the Microsoft Corporation&#8217;s Deferred Compensation Plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors. </div><div style="margin: 8pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CFO </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;">On 11&#160;July 2022, Iain Mackay became an independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of National Grid plc. During 2022, he received &#163;33,330 in fees which was delivered as cash. </div><div style="padding-bottom: 3pt; font-family: ARIAL; font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments to past Directors (audited) </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">No payments were made to past Directors in 2022 with the exception of the value of the deferred bonus and accrued dividends made to Simon Dingemans, as described on page 142 of the 2021 Annual Report. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments for loss of office (audited) </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">No loss of office payments were made during 2022. </div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="border-radius: 10pt; border: 1px solid rgb(231, 231, 232); border-image: none; padding-top: 2pt; padding-bottom: 3pt; margin-right: 0%; margin-left: 0%; max-width: 100%; background-color: rgb(231, 231, 232);"><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin: 0pt 2%; padding-top: 3pt; font-family: ARIAL; font-size: 11pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">How our Remuneration policy continues to reflect Provision 40 of the UK Corporate Governance Code (the Code) </div></div></div></div><div style="margin: 6pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clarity and simplicity </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The remuneration arrangements for the Executive Directors are set out in a clear and simple way in the Remuneration policy. Whilst compiling and before finalising the Remuneration policy, the Committee consulted extensively with 40 shareholders representing 45% of our issued share capital, to ensure its full understanding of their views on the policy and transparency and clarity of the proposals and how they would be implemented. The fixed remuneration elements (salary, benefits and pension) are closely aligned with wider workforce arrangements and our pay for performance plans (Annual Bonus and Long-term incentive) reward delivery of financial, strategic and ESG objectives in the short and long term. </div></div><div style="margin: 8pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">In line with the Code, we operate both deferral and post-vesting holding arrangements, in addition to operating malus and clawback provisions. The Committee retains discretion to adjust award outcomes (to zero if appropriate) should it consider the payout determined does not appropriately reflect the overall position and performance of the company. </div></div><div style="margin: 8pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Predictability and proportionality </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Remuneration policy defines maximum limits on the total Annual Bonus and Long-term incentive opportunities, and payouts under these elements are linked to fulfilment of performance conditions that support the company&#8217;s publicly stated ambitions. Through its implementation, maximum reward under our short- and long-term plans are only achievable for material outperformance against our stated ambitions. </div></div><div style="margin: 8pt 2% 0pt; font-family: ARIAL; font-size: 9pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Alignment to culture </div></div></div></div><div style="margin: 2pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK&#8217;s purpose, strategy and culture continue to be directly reflected in the performance conditions set under the Annual Bonus and Long-term incentive. In particular, we have introduced an ESG measure in both our short- and long-term plans. These currently reinforce our diversity, equity and inclusion aspirations for 2025, and our Nature Net Positive and Climate Net Zero ambition by 2030. Our Share Ownership Requirements strengthen the focus on our strategic aims, and ensure alignment with the interests and experiences of shareholders, both during and after employment. </div></div><div style="margin: 6pt 2% 0pt; font-family: ARIAL; font-size: 8.5pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Committee believes the Remuneration policy has been operated as intended in terms of company performance and quantum during 2022. </div></div><div style="margin: 0pt 2%; padding-bottom: 3pt; font-family: ARIAL; font-size: 3pt;"><div style="font-family: ARIAL; font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_99c.jpg"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">157</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_33" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_73" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>2022 Remuneration policy summary </div></div><div style="margin-top:24pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company&#8217;s Remuneration policy was approved on 4&#160;May 2022 at GSK&#8217;s Annual General Meeting and has operated as intended since its approval. The full policy is available at gsk.com in the Investors section. Two administrative amendments to the company&#8217;s Remuneration policy are being proposed for binding shareholder approval at GSK&#8217;s 2023 Annual General Meeting, as described on page 163. </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Executive Director Remuneration policy </div></div><div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:81%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 12pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Salary</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">To provide a core reward for the role. Set at a level appropriate to secure and retain high calibre individuals needed to deliver the Group&#8217;s strategic priorities.</div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td rowspan="2" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Individual&#8217;s role, experience, performance and independently sourced data for relevant comparator groups considered when determining salary levels.</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Salary increases typically take effect in the first quarter of each year.</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Salaries are normally paid in the currency of the Executive Director&#8217;s home country.</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">There is no formal maximum limit and, ordinarily, salary increases will be broadly in line with the average increases for the wider GSK workforce.</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">However, increases may be higher to reflect a change in the scope of the individual&#8217;s role, responsibilities or experience. Salary adjustments may also reflect wider market conditions in the geography in which the individual operates.</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Details of current salary levels are set out in the Annual report on remuneration.</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance measures</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The overall performance of the individual is a key consideration when determining salary increases.</td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:81%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Benefits</div></div></div></div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Levels are set to recruit and retain high calibre individuals to execute the business strategy.</div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Executive Directors are eligible to receive benefits in line with the policy for other employees which may vary by location. These include, but are not limited to, car allowances, healthcare, life assurance/death in service (where not provided as part of the individual&#8217;s pension arrangements), personal financial advice and contractual post-retirement benefits. In line with the policy for other employees, Executive Directors may be eligible to receive overseas relocation allowances and international transfer-related benefits when required. Executive Directors in the UK are also eligible to participate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">all-employee</div> share schemes (e.g. Share Save and Share Reward plans), under which they are subject to the same terms as all other employees. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In order to recognise the high business travel requirements of the role, Executive Directors are also entitled to car travel and exceptionally may be accompanied by their spouse/partner on business trips. Other benefits include expenses incurred in the ordinary course of business, which are deemed to be taxable benefits on the individual. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where an Executive Director is based outside the UK, but is required to travel to the UK to fulfil the responsibilities of their role and to attend Board Meetings, they may be subject to tax on their business travel expenses to and from the UK and on the provision of any accommodation in the UK. Although in reality it represents a business expense, the tax treatment requires that their travel and accommodation expenses are then included as benefits. Because of the business context, the tax liabilities will be covered by the company on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grossed-up</div> basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Benefit provision is tailored to reflect market practice in the geography in which the Executive Director is based and different policies may apply if current or future Executive Directors are based in a different country. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There is no formal maximum limit as benefits costs can fluctuate depending on changes in provider cost and individual circumstances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of current benefits and costs are set out in the Annual report on remuneration. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance measure </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">None </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">158</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 Remuneration policy summary continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Director Remuneration policy</div></div> continued </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:81%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Pension</div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Pension arrangements provide a competitive level of retirement income.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension arrangements provide a competitive level of retirement income. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension arrangements are structured in accordance with the plans operated in the country in which the individual is likely to retire. Where the individual chooses not to become a member of the pension plan, cash in lieu of the relevant pension contribution is paid instead. Executive Directors in the UK are entitled either to join the defined contribution pension plan or to receive a cash payment in lieu of pension contribution. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where an individual is a member of a GSK legacy defined benefit plan, a defined contribution plan or an alternative pension plan arrangement and is subsequently appointed to the Board, he or she may remain a member of that plan. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The policy for all current Executive Directors is: </div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">UK: </div></div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">20% of base salary contribution to defined contribution plan and further 5% in matched contributions subject to any relevant cap and in line with implementation principles for other members of the plan; and </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">20% of base salary as a cash payment in lieu of pension contribution for the portion above the relevant cap; </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">or</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"></div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">20% of base salary as a cash payment in lieu of pension contribution. </div></td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From 1&#160;January 2023, any current UK Directors who are still in role will have their pension arrangements aligned to new Executive Directors&#8217; arrangements as follows. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any new Executive Directors in the UK will receive from date of appointment: </div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">7% of base salary contribution to defined contribution plan and further 3% in matched contributions subject to any relevant cap and in line with implementation principles for other members of the plan; and </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">7% of base salary as a cash payment in lieu of pension contribution for the portion above the relevant cap; </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">or</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"></div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">7% of base salary as a cash payment in lieu of pension contribution. </div></td></tr></table><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">US<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: </div></div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Supplemental Cash Balance pension plan, providing annual contribution of 38% of base salary, less 5% of total base salary and bonus (net of the bonus deferred under the DABP)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(3).</div> </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK 401(k) plan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div> and the ESSP<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div> with core contributions of 7% of salary and bonus<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div> and matched contributions of 4% of salary and bonus<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>. </div></td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From 1&#160;January 2023, any current US Executive Directors who are still in role will have their pension arrangements aligned to new Executive Directors&#8217; arrangements as follows. </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any new Executive Directors in the US will receive from date of appointment: </div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK 401(k) plan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div> and the ESSP<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div> with core contributions of 7% of salary and bonus<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div> and matched contributions of 4% of salary and bonus<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>. </div></td></tr></table><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Global:</div></div> </div><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Eligible for appropriate equivalent arrangement not in excess of the US/UK arrangements. </div></td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">None. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">In the event of any change to the plans operated in the US, a similar treatment would be provided under any successor arrangements introduced within the market </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Less bonus deferred under the DABP </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 5% offset is equal to the contribution to the 401(k) and ESSP which was moved from the pension plans, in line with the wider US workforce, from 1&#160;January 2021 </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:81%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="font-size: 12pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Annual Bonus</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">To incentivise and recognise execution of the business strategy on an annual basis. Rewards the achievement of stretching annual financial, strategic and operational measures.</td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial, operational and business targets are set at the start of the year by the Committee and bonus levels are determined by the Committee based on performance against those targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Strategic and operational measures are set at the start of the year by the Committee and performance against those measures is assessed by the Committee. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Executive Directors are required to defer part of any bonus earned into shares, or ADS as appropriate, for three years. 50% of the equivalent of the first 200% of salary is deferred, and any portion in excess of 200% is deferred in full. Deferred bonus shares are eligible for dividend equivalents up to the date of vesting. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The Committee may adjust the formulaic vesting outcome (either up or down) to ensure that the overall outcome reflects underlying business performance over the vesting period. Clawback and/or malus provisions apply as described on page 147 of the 2021 Annual Report. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The maximum bonus opportunity for Executive Directors is 300% of salary. Below 99% of target performance, the bonus payout on the financial measures will be nil. For target performance, the bonus payout will be 100% of salary. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 Remuneration policy summary continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:30pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Director Remuneration policy</div></div> continued </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance measures </div></div></div></div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Based on a combination of financial targets and individual/strategic and ESG performance objectives, with the majority of the bonus assessed against the financial measures. The weighting between different measures will be determined each year according to business priorities. Further details, including the measures to be used in the financial year, are provided in the Annual report on remuneration. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selection of Annual Bonus measures </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Annual Bonus is designed to drive the achievement of GSK&#8217;s annual financial, strategic and operational measures. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For this reason the majority of the Annual Bonus opportunity is based on a formal review of performance against stretching financial targets, with the remainder of the bonus subject to assessment of individual performance against the key strategic and operational measures which are aligned to the company&#8217;s key objectives for that financial year and/or assessment of performance against ESG targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Annual Bonus financial targets are set by reference to internal budget and external consensus targets. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:79%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Performance</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Share Plan (PSP)</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top">To incentivise and recognise delivery of the longer term business priorities, financial growth and increases in shareholder value compared to other pharmaceutical companies. In addition, to provide alignment with shareholder interests, a retention element, to encourage long-term shareholding and discourage excessive risk taking.</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Conditional awards are made annually with vesting dependent on the achievement of performance conditions over three years and are subject to an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> holding period. PSP targets are set by reference to internal budget and external consensus targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Awards are eligible for dividend equivalents up to the date of vesting and release. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee may adjust the formulaic vesting outcome (either up or down) to ensure that the overall outcome reflects underlying business performance over the vesting period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Clawback and/or malus provisions apply as described on page 147 of the 2021 Annual Report. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The normal maximum award limits that may be granted under the PSP to an individual in any one year are set out in the table below: </div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;of&#160;salary</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CEO</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">600</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CFO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other Executive Directors</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Based on a combination of financial, share price related and strategic and ESG performance conditions which are aligned to the company&#8217;s strategic plan. For all measures, 25% of awards will vest at threshold performance. Further details, including the performance targets attached to the PSP in respect of each year, and the weightings of the targets for the 2022 PSP awards are provided in the Annual report on remuneration. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selection of Long-term incentive measures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee selects performance measures which focus Executive Directors&#8217; long-term remuneration on the delivery of GSK&#8217;s key strategic priorities over the longer term. In addition to setting robust targets, the Committee has implemented a number of safeguards to ensure the targets are met in a sustainable way and performance reflects genuine achievement against targets and therefore represents the delivery of value for shareholders. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For each performance measure, the impact of any acquisition or divestment will be quantified and adjusted for after the event. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any major adjustment in the calculation of performance measures will be disclosed to shareholders on vesting. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Audit&#160;&amp; Risk Committee chair and other members, who are also members of the Remuneration Committee, provide input on the Audit&#160;&amp; Risk Committee&#8217;s review of the Group&#8217;s performance and oversight of any risk factors relevant to remuneration decisions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of the rationale behind the performance measures selected and how they are calculated are set out in the 2021 Annual report on remuneration. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">160</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 Remuneration policy summary continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Executive Director Remuneration policy</div></div> continued </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto;background-color:#e7e7e8">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="6" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Ownership Requirements</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">No change</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:top">To align the interests of Executive Directors with those of shareholders, they are required to build and maintain significant holdings of shares in GSK over time. The requirements for each Executive Director are as follows:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0.5em; font-size: 8pt; font-family: ARIAL; line-height: normal;">As a minimum, Executive Directors are required to maintain 100% of their share ownership requirements to the end of the first year following retirement from the company and 50% to the end of the second year.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;salary&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CEO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">650&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other Executive Directors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">300&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For details of our policy on clawback and malus, approach to recruitment remuneration, loss of office and termination payments, please refer to the full 2022 Remuneration policy report on pages 144 to 152 of the 2021 Annual Report, available on gsk.com in the Investors section </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Differences between Remuneration policy for Executive Directors and other employees </div></div></div></div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When setting remuneration for the Executive Directors, the Committee considers the company&#8217;s strategic priorities, prevailing market conditions for global talent, the competitive environment (through comparison with the remuneration of executives at companies of similar size, complexity and international reach) and the positioning and relativities of pay and employment conditions across the broader GSK workforce. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In particular, the Committee considers the range of base salary rises for the workforces of those parts of GSK where the Executive Directors are employed. This is considered to be the most relevant comparison as these populations reflect most closely the economic environments encountered by the individuals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The same principles apply to the Remuneration policy for Executive Directors and other employees although the remuneration offered to Executive Directors under this policy has a stronger emphasis on performance-related pay than that offered to other employees of the Group. </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Salary and benefits (including pension) are tailored to the local market </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The Annual Bonus plan applies to the wider employee population and is based on business performance </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">A combination of performance-related and restricted share plans apply to the wider employee population </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">All-employee</div> share plans are available to employees in the UK, including the HM Revenue&#160;&amp; Customs approved UK Share Save and Share Reward plans </div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">While employees are not directly consulted in respect of the Remuneration policy, Urs Rohner, the Committee Chair, meets with senior HR representatives from across the business to review employee feedback. Dame Vivienne Cox, an Independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director, engages with employees on various topics, including remuneration, in her role as Workforce Engagement Director. Board members engage with employees around during Board meetings where they are encouraged to share their views on the company, management and remuneration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Since approval of the Policy in May 2022, the Board has evolved its approach to workforce engagement. Further details are provided on page 115. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the wider organisation, we have aligned our performance and reward systems with our Innovation, Performance and responsible business priorities and with a culture anchored in purpose and performance. Our performance system evaluates employees on both &#8216;what&#8217; they need to do and &#8216;how&#8217; they do it. Also, for our most senior people we disincentivise unethical working practices using a clawback mechanism that allows us to recover performance-related pay. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">161</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">2022 Remuneration policy summary continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director Remuneration policy 2022 </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:11%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:68%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td colspan="5" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt;background-color:#e7e7e8">
<td colspan="5" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Non-Executive</div> Directors&#8217; fees</div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="2" style="height:7.5pt"></td>
<td colspan="2" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Element</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Purpose and link to strategy</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operation</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair&#8217;s fees</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">To provide an inclusive flat rate fee that is competitive with those paid by other companies of equivalent size and complexity subject to the limits contained in GSK&#8217;s Articles of Association.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">There is no formal maximum. However, fees are reviewed annually and set by reference to a review of the Chair&#8217;s performance and independently sourced market data.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The Committee is responsible for evaluating and making recommendations to the Board on the fees payable to the Chair. The Chair does not participate in discussions in respect of their fees.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic fees</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top">As above</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">There is no formal maximum. As with the Chair, fees are reviewed annually and set by reference to independently sourced data.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The Chair and CEO are responsible for evaluating and making recommendations to the Board on the fees payable to the company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fee payment</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Alignment&#160;with&#160;shareholders</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Fees are paid in cash. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (including the Chair) were required to invest at least 25% of their total net fees in shares or ADS of the company. The company has since replaced the 25% minimum investment requirement with a minimum share or ADS ownership requirement of at least one times the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director&#8217;s (or Chair&#8217;s) gross annual standard fees to be retained until their retirement from the Board. An administrative amendment to this section of the Remuneration policy is proposed for binding shareholder approval at the 2023 AGM as described on page 163.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supplemental&#160;&#160;&#160;&#160; fees</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top">To compensate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (other than the Chair) for taking on additional Board responsibilities or undertaking intercontinental travel.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additional fees for the Senior Independent Director, Committee Chairs, Scientific and Medical Experts, the Workforce Engagement Director role and intercontinental travel.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The company has the authority to pay an additional fee, up to the equivalent of the Committee Chair supplement to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director, should the company require significant additional time commitment in exceptional or unforeseen circumstances.</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">The company has the authority to pay an additional fee of up to &#163;200,000 to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (excluding the Chair) who are members of the Science Committee for undertaking additional responsibilities on behalf of GSK and to support R&amp;D.</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefits</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">To facilitate execution of responsibilities and duties required by the role.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Travel and subsistence costs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors are incurred in the normal course of business in relation to meetings on Board and Committee matters and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-hosted</div> events. For overseas-based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors, this includes travel to meetings in the UK. In the event it is necessary for business purposes, whilst not normal practice, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors may be accompanied by their spouse or partner to these meetings or events. The costs associated with the above are all met by the company and, in some instances, they are deemed to be taxable and therefore treated as benefits for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director.</td></tr></table><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt;background-color:#e7e7e8">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Approach to recruitment remuneration</div></div></div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following policy and principles apply to the roles of Chair and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director. It seeks to ensure alignment with shareholders through the requirement to invest in company shares and ADS. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chair </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fees will be set at a level that is competitive with those paid by other companies of equivalent size and complexity. Fees will be paid partly in shares. </div><div style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fee levels for new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors will be set on the same basis as for existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors of the company, subject to local laws and regulations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the event of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director with a different role and responsibilities being appointed, fee levels will be benchmarked and set by reference to comparable roles in companies of equivalent size and complexity. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="font-size:1pt;background-color:#e7e7e8">
<td style="BORDER-TOP:1.50pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt;background-color:#e7e7e8">
<td style="vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Loss of office</div></div></div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Chair and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors are not entitled to receive any payments in respect of fees for loss of office when they retire or step down from the Board. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">162</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Administrative amendments to the 2022 Remuneration policy </div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proposed amendments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Two administrative amendments to the company&#8217;s 2022 Remuneration policy (Policy), which was approved at last year&#8217;s AGM, are being proposed as ordinary resolutions for binding shareholder approval at the AGM on 3 May 2023. The Policy is subject to renewal in respect of remuneration for 2025. Given that these changes are purely administrative, a full consultation with employees was not undertaken on these amendments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; minimum share ownership requirement </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors section of the 2022 Policy includes a requirement for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (including the Chair) to invest a minimum of 25% of their net basic fees in shares or ADS of the company. The Policy also states that, should the company replace this requirement, any shares or ADS previously acquired in accordance with this 25% minimum investment requirement would: (i)&#160;continue to be held under those previous arrangements, (ii)&#160;count towards any expected minimum ownership requirement; and (iii)&#160;be delivered or released following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director&#8217;s (or Chair&#8217;s) retirement from the Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company has since replaced the 25% minimum investment requirement, as set out in the 2021 Annual Report, with a minimum share or ADS ownership requirement of at least one times the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director&#8217;s (or Chair&#8217;s) gross Annual Standard Fees to be retained until their retirement from the Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shareholder approval will be sought to amend the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors section of the Policy to allow the shares or ADS acquired under the previous 25% minimum investment requirement to be delivered or released to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director (or Chair) at such time as the Board (excluding that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director or the Chair) considers appropriate (subject to any applicable tax withholding), rather than continue to be held under the previous arrangements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This is subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (or the Chair) undertaking to the company to hold such shares or ADS in the company until they retire from the Board. This will give the company greater operational flexibility, and reduce the administrative burden, in the implementation of the new minimum share ownership requirement whilst ensuring that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors (and the Chair) continue to maintain a meaningful and prudent level of investment which aligns their interests with shareholders. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clawback and malus </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shareholder approval will be sought to amend the Clawback and malus section of the Policy to expressly refer to the company&#8217;s ability to update its clawback policies, and to make disclosures in relation to clawback, in each case as required by applicable regulatory requirements, including the recently adopted Securities and Exchange Commission (SEC) rules (and the New York Stock Exchange (NYSE) listing standards implementing those rules) on clawback in the event of an accounting restatement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The SEC adopted new rules, in late 2022, which require the NYSE (amongst others) to adopt new listing standards that require a listed company to clawback erroneously awarded incentive-based compensation whenever it is required to prepare an accounting restatement that corrects an error in a previously issued financial statement, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. These new listing standards are expected to become effective in late 2023. GSK shares are listed and traded on the NYSE in the form of ADS and GSK will, as a result, be subject to the new listing standards which are expected to require clawback in circumstances that are wider than those currently provided for by the company&#8217;s policies. The related SEC rules will also require GSK to make certain disclosures in connection with its clawback policy in its annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> (including filing a copy of the clawback policy with the SEC). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The proposed changes to the `Clawback and malus&#8217; element of the Policy are intended to ensure clarity by expressly referring to the company&#8217;s ability to update its clawback policies, and to make disclosures in relation to clawback, in each case as required by applicable regulatory requirements (including the SEC and NYSE requirements). The Committee will update its current recoupment policies as required to meet the new NYSE listing standards and the related SEC disclosure requirements once they become effective. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_99c.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Operation and scope of Remuneration policy </div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Remuneration policy (Policy) is set out on pages 144 to 152 of the 2021 Annual Report and it is intended that the Policy for GSK&#8217;s Executive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors will operate for a period of three years from the date of approval at the company&#8217;s Annual General Meeting on 4&#160;May 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee wrote the Policy principally in relation to the remuneration arrangements for the Executive Directors, whilst taking into account the possible recruitment of a replacement or an additional Executive Director during the operation of the Policy. The Committee intends the Policy to operate for the period set out above in its entirety. However, it may after due consideration seek to change the Policy during this period, but only if it believes it is appropriate to do so for the long-term success of the company, after consultation with shareholders and having sought shareholder approval at a general meeting. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee reserves the right to make any remuneration payments and/or payments for loss of office (including exercising any discretions available to it in connection with such payments) notwithstanding that they are not in line with the Policy where the terms of the payment were agreed: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">(i)&#160;before the AGM on 7&#160;May 2014 (the date the company&#8217;s first shareholder-approved Directors&#8217; Remuneration policy came into effect); </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">(ii) before the Policy came into effect, provided that the terms of the payment were consistent with the shareholder-approved Remuneration policy in force at the time they were agreed; or </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">(iii)&#160;at a time when the relevant individual was not a Director of the company and, in the opinion of the Committee, the payment was not in consideration for the individual becoming a Director of the company. For these purposes &#8216;payments&#8217; includes the Committee satisfying awards of variable remuneration and, in relation to an award over shares or ADS, the terms of the payment are &#8216;agreed&#8217; at the time the award is granted. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Performance Share Plan (PSP) awards are subject to the terms of the PSP plan rules under which the award has been granted. The Committee may adjust or amend awards only in accordance with the provisions of the plan rules. This includes making adjustments to reflect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> corporate events, such as a change in the company&#8217;s capital structure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Committee may also make minor amendments to the Policy (for regulatory, exchange control, tax or administrative purposes or to take account of a change in legislation) without obtaining shareholder approval for such amendments. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Basis of preparation </div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Annual report on remuneration has been prepared in accordance with the Companies Act 2006 and The Large and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Medium-sized</div> Companies and Groups (Accounts and Reports) (Amendment) Regulations 2013 (the Regulations). In accordance with the Regulations, the following parts of the Annual report on remuneration are subject to audit: total remuneration figures for Executive Directors including further details for each element of remuneration (salary, benefits, pension, Annual Bonus and Long-term incentive awards); <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees and emoluments received in the year; Directors&#8217; interests in shares, including interests in GSK share plans; payments to past Directors; payments for loss of office; and share ownership requirements and holdings, for which the opinion thereon is expressed on page 181. The remaining sections of the Annual report on remuneration are not subject to audit nor are the pages referred to from within the audited sections. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Annual report on remuneration has been approved by the Board of Directors and signed on its behalf by: </div><div style="margin-top:24pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Urs Rohner </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Remuneration Committee Chair </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">9&#160;March 2023 </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">164</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_165.jpg" style="width: 778px; height: 1100px;"/></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: -820pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 88%; font-family: ARIAL; font-size: 8.5pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 34%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 31%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td colspan="5" style="vertical-align: top;"><div id="ex15_2tx382677_34" style="font-family: ARIAL; font-size: 60pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Financial</div></div><div style="font-family: ARIAL; font-size: 60pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">statements</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 4pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In this section</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_74" style="color: white;">Directors&#8217; statement of responsibilities</a></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;166</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_76" style="color: white;">Financial statements</a></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;182</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_77" style="color: white;">Notes to the financial statements</a></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;186</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_78" style="color: white;">Financial statements of GSK plc<br/>prepared under UK&#160;GAAP</a></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;268</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 255pt; font-size: 0px;"></td>
<td colspan="2" style="height: 255pt; font-size: 0px;"></td>
<td colspan="2" style="height: 255pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div id="ex15_2tx382677_35" style="font-family: ARIAL; font-size: 22pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_74" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Directors&#8217; statement of responsibilities </div></div><div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Directors are responsible for preparing the Annual Report, the Remuneration report and the Group and parent company financial statements in accordance with applicable law and regulations. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">UK company law requires the Directors to prepare financial statements for each financial year. The Directors are required to prepare the Group consolidated financial statements in accordance with International Accounting Standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The Directors have elected to prepare the parent company financial statements in accordance with United Kingdom Accounting Standards and applicable law (United Kingdom Generally Accepted Accounting Practice) (Financial Reporting Standard 101 Reduced Disclosure Framework). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and its profit or loss for that period. In preparing the financial statements, the Directors are required to: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">select suitable accounting policies and then apply them consistently; </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">make judgements and accounting estimates that are reasonable and prudent; </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">state that the Group financial statements comply with IFRS, as issued by the IASB and in conformity with the requirements of the Companies Act 2006; </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">state with regard to the parent company financial statements that applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the parent company financial statements; and </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Group and the parent company will continue in business. </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing the Group financial statements, International Accounting Standard 1 requires that directors properly select and apply accounting policies; present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information; provide additional disclosures when compliance with the specific requirements in IFRS Standards are insufficient to enable users to understand the impact of particular transactions, other event and conditions on the entity&#8217;s financial position and financial performance; and make an assessment of the company&#8217;s ability to continue as a going concern. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company&#8217;s transactions and disclose with reasonable accuracy at any time the financial position of the Group and to enable them to ensure that the Group financial statements and the Remuneration report comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group financial statements for the year ended 31&#160;December 2022, comprising principal statements and supporting notes, are set out in the &#8216;Financial statements&#8217; on pages 182 to 267 of this report. The parent company financial statements for the year ended 31&#160;December 2022, comprising the balance sheet and the statement of changes in equity for the year ended 31&#160;December 2022 and supporting notes, are set out on pages&#160;268&#160;to&#160;272. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The responsibilities of the auditor in relation to the financial statements are set out in the Independent Auditor&#8217;s report on pages 168 to 181. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements for the year ended 31&#160;December 2022 are included in the Annual Report, which is published in printed form and made available on our website. The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company&#8217;s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of the current Directors, whose names and functions are listed in the Corporate Governance section of the Annual Report 2022 confirms that, to the best of his or her knowledge: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">the Group financial statements, which have been prepared in accordance with IFRS, as issued by the IASB and in conformity with the requirements of Companies Act 2006, give a true and fair view of the assets, liabilities, financial position and profit of the Group; </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">the Strategic report and risk sections of the Annual Report, which represent the management report, include a fair review of the development and performance of the business and the position of the company and the Group taken as a whole, together with a description of the principal risks and uncertainties that it faces; and </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="width: 0.75pt; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">the annual report and financial statement, taken as a whole, are fair, balanced and understandable and provide the information necessary for shareholders to assess the company&#8217;s position and performance, business model and strategy. </td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">166</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors&#8217; statement of responsibilities continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disclosure of information to auditor </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Directors in office at the date of this Annual Report have each confirmed that: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">so far as he or she is aware, there is no relevant audit information of which the company&#8217;s auditor is unaware; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7.5pt; vertical-align: top;;text-align:left;">&#8211;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">he or she has taken all the steps that he or she ought to have taken as a Director to make himself or herself aware of any relevant audit information and to establish that the company&#8217;s auditor is aware of that information. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">This confirmation is given and should be interpreted in accordance with the provisions of section 418 of the Companies Act 2006. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Going concern basis </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Pages 66 to 95 and pages 55 to 61 contain information on the performance of the Group, its financial position, cash flows, net debt position, borrowing facilities and climate related risks. Further information, including Treasury risk management policies, exposures to market and credit risk and hedging activities, is given in Note 44 to the financial statements, &#8216;Financial instruments and related disclosures&#8217;. Having assessed the principal risks and other matters considered in connection with the viability statement, the Directors considered it appropriate to adopt the going concern basis of accounting in preparing the financial statements. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Internal control </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board, through the Audit&#160;&amp; Risk Committee, has reviewed the assessment of risks and the internal control framework that operates in GSK and has considered the effectiveness of the system of internal control in operation in the Group for the year covered by this Annual Report and up to the date of its approval by the Board of Directors. Further detail on the review of internal controls is set out in the Governance report on page 125. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The 2018 UK Corporate Governance Code </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board considers that GSK plc applies the principles and complies with the provisions of the UK Corporate Governance Code maintained by the Financial Reporting Council, as described in the Corporate Governance section on pages 97 to 131. The Board further considers that the Annual Report, taken as a whole, is fair, balanced and understandable, and provides the information necessary for shareholders to assess the Group&#8217;s position and performance, business model and strategy. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">As required by the Financial Conduct Authority&#8217;s Listing Rules, the auditor has considered the Directors&#8217; statement of compliance in relation to those points of the UK Corporate Governance Code which are specified for their review. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Report </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Annual Report for the year ended 31&#160;December 2022, comprising the Report of the Directors, the Remuneration report, the Financial statements and Additional information for investors, has been approved by the Board of Directors and signed on its behalf by </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Chair </div></div><div style="font-family: ARIAL; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">9 March 2023 </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">167</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">168</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">169</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">170</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">171</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">172</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">173</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">174</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">175</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">176</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">177</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">178</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">179</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">180</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This page is intentionally left blank </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">181</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_37" style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;"><div id="ex15_2tx382677_76" style="display:inline;"></div>Consolidated income statement </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">for the year ended 31&#160;December 2022 </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:89%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notes</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,354</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,554</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,163</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,929</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GrossProfit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,770</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GrossProfit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,533</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GrossProfit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,425</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,372</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,070</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,437</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,488</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,019</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,793</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Royalty income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RevenueFromRoyalties" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">758</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RevenueFromRoyalties" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">417</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RevenueFromRoyalties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other operating (expense)/income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">235</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">504</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,463</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating profit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,433</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,357</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,979</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">879</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">769</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">874</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of after tax (loss)/profits of associates and joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit before taxation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,628</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,599</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,170</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Profit after taxation from continuing operations</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,921</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,516</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,103</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,049</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,580</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,285</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,651</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,700</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,580</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,285</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total profit after taxation for the year</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,621</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,096</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,388</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">460</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">230</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,461</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,316</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,873</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests from discontinued operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">205</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">511</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">409</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,495</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,069</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">876</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,621</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,096</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,388</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">665</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">711</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">639</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit attributable to shareholders</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,956</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,385</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,749</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,621</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,096</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,388</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share (pence) from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">110.8</ix:nonFraction>p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.9</ix:nonFraction>p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">122.4</ix:nonFraction>p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share (pence) from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">260.6</ix:nonFraction>p</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">26.7</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">22.0</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Basic earnings per share (pence)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">371.4</ix:nonFraction>p</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">109.6</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">144.4</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share (pence) from continued operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">109.2</ix:nonFraction>p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">81.8</ix:nonFraction>p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">120.9</ix:nonFraction>p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share (pence) from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">257.0</ix:nonFraction>p</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">26.4</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.7</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total diluted earnings per share (pence)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">366.2</ix:nonFraction>p</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">108.2</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">142.6</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statement of comprehensive income </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">for the year ended 31&#160;December 2022 </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:89%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notes</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit for the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,621</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,096</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,388</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Other comprehensive income/(expense) for the year</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to continuing operations income statement:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">339</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">416</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax on fair value movements on cash flow hedges</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">355</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">363</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to continuing operations income statement:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">754</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">911</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">131</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement (losses)/gains on defined benefit plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">786</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">940</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">164</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement losses/(gains) on defined benefit plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:FairValueMovementsOnCashFlowHedgesNotReclassified" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:FairValueMovementsOnCashFlowHedgesNotReclassified" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:FairValueMovementsOnCashFlowHedgesNotReclassified" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,307</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,007</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive expense for the year from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,187</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">438</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">644</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive income for the year from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">356</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">101</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">326</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income for the year</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,790</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,759</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,358</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income for the year attributable to:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,153</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,068</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,753</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">637</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">691</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">605</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,790</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,759</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,358</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">182</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheet </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">as at 31&#160;December 2022 </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Notes</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,933</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,932</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">687</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,046</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,318</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,467</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,658</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentDerivativeFinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentDerivativeFinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,194</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,676</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39,377</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60,429</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventories</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Inventories" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Inventories" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current tax recoverable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">405</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">486</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,053</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,087</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,723</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current assets</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,769</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,674</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60,146</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">79,103</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term borrowings</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,952</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherCurrentFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,289</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherCurrentFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">958</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,263</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">227</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current tax payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">471</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term provisions</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">652</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">841</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22,810</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,670</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Long-term borrowings</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,035</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporation tax payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">289</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,556</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and other post-employment benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,579</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">532</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,779</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">899</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">921</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,240</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34,091</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50,050</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57,761</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,096</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,342</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Equity</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share capital</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share premium account</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,440</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retained earnings</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,363</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reserves</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,448</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,463</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shareholders&#8217; equity</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,598</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,055</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">502</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,287</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total equity</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,096</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,342</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements on pages 182 to 267 were approved by the Board on 9 March 2023 and signed on its behalf by </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL">Chair </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">183</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statement of changes in equity </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">for the year ended 31&#160;December 2022 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;</td>
<td colspan="17" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Shareholders&#8217; equity</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Share</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;capital</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Share</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;earnings</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reserves*</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;equity</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2019</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,357</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit for the year</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">639</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,388</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,137</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,004</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">970</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income for the year</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,616</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,137</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,753</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">605</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,358</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,208</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contributions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">131</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Realised profits after taxation on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of associates and joint ventures realised profits on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares issued</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">381</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on share-based incentive plans</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,755</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,587</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,808</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit for the year</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,096</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">771</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">337</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">771</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,068</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">691</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,759</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">642</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contributions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares issued</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Realised after tax profits on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of associates and joint ventures realised profits on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">367</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">367</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">367</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransactionsWithNoncontoliingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on share-based incentive plans</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,055</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,287</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,342</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit for the year</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,956</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,956</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,621</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">714</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">803</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">831</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income for the year</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,867</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">714</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,153</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">637</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,790</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,409</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> distribution to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,960</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NoncashDistributionsToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,960</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contributions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deconsolidation of former subsidiaries</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,045</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,467</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> dividend to shareholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15,526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15,526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NonCashDividendToShareholders" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15,526</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Realised after tax losses on disposal or liquidation of equity investments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of associates and joint ventures realised profits on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares issued</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">911</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">911</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:SharesAcquiredByEsopTrusts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">357</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on share-based incentive plans</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Hedging gain after taxation transferred to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingGainLossTransferredToNonFinancialAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,440</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,363</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,448</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,598</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">502</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,096</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">an analysis of Other reserves is presented as part of Note 38, &#8216;Movements in equity&#8217;. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">184</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Consolidated cash flow statement </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL">for the year ended 31&#160;December 2022 </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Notes</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow from operating activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from continuing operations for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,921</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,516</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjustments reconciling profit after tax to operating cash flows</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,023</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3733</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,571</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash generated from operations attributable to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,944</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,674</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,310</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">972</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,086</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash inflow from continuing operating activities</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,634</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,277</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,588</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash generated from operations attributable to discontinued operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">932</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation paid from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net operating cash flows attributable to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">769</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,675</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,853</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total net cash inflows from operating activities</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,403</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,952</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,441</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow from investing activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of property, plant and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,143</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">950</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from sale of property, plant and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,115</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,704</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">956</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from sale of intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">143</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase of businesses, net of cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,108</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from sale of equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">238</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration paid</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">79</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposal of businesses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:PurchaseOfInvestmentInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:PurchaseOfInvestmentInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:PurchaseOfInvestmentInAssociatesAndJointVentures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Proceeds from disposal of associates and joint ventures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ProceedsFromDisposalOfAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ProceedsFromDisposalOfAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ProceedsFromDisposalOfAssociatesAndJointVentures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest received</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in liquid investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInLiquidInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInLiquidInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInLiquidInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends from associates and joint ventures</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsReceivedClassifiedAsInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from continuing investing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,981</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash investing cash flows attributable to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,791</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">806</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total net cash (outflow)/inflow from investing activities</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8,772</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,777</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,161</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow from financing activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issue of share capital</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of long-term loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,594</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issue of long-term notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,025</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of short-term loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,074</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in/(repayment of) other short-term loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,021</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,594</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">202</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest paid</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">848</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid to shareholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,467</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">521</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">442</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contributions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other financing items</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">376</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from continuing financing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,251</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net financing cash flows attributable to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,074</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">463</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total net cash inflow/(outflow) from financing activities</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">823</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,589</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,132</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">(Increase)/decrease in cash and bank overdrafts</div></div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,414</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">470</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and bank overdrafts at the beginning of year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,819</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(Decrease) in cash and bank overdrafts in the year</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">546</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,414</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">470</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and bank overdrafts at the end of year</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,425</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,819</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,262</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and bank overdrafts at end of year comprise:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,723</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">298</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">455</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,030</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,425</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,819</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,262</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business<br/> (see Note 41). </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">185</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_38" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;"><div id="ex15_2tx382677_77" style="display:inline;"></div>Notes to the financial statements </div></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049497"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">1. Presentation of the financial statements </div></div></ix:nonNumeric> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049497" continuedAt="TextSelectionAppend_69049497_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of business </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK is a global biopharma group which makes innovative vaccines and specialty medicines to prevent and treat disease. GSK&#8217;s R&amp;D focuses on the science of the immune system, human genetics and advanced technologies primarily in the following four therapeutic areas: infectious diseases, HIV, oncology and immunology/respiratory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance with applicable law and IFRS </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards as issued by the IASB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Composition of financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consolidated financial statements are drawn up in Sterling, the functional currency of GSK plc, and in accordance with IFRS accounting presentation. The financial statements comprise: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated income statement </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated statement of comprehensive income </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated balance sheet </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated statement of changes in equity </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated cash flow statement </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Notes to the financial statements. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Composition of the Group </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A list of the subsidiaries and associates which, in the opinion of the Directors, principally affected the amount of profit or net assets of the Group is given in Note 46, &#8216;Principal Group companies&#8217;. </div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049497_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial period </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="ifrs-full:PeriodCoveredByFinancialStatements" contextRef="P01_01_2022To12_31_2022">These financial statements cover the financial year from 1 January to <ix:nonNumeric name="gsk:DateOfEndOfReportingPeriod2022" contextRef="P01_01_2022To12_31_2022" format="ixt:date-day-monthname-year-en">31 December 2022</ix:nonNumeric>, with comparative figures for the financial years from 1 January to 31 December 2021 and, where appropriate, from 1 January to 31 December 2020.</ix:nonNumeric> Income statement and cash flow comparatives have been restated on a consistent basis from those previously published to reflect the classification of the Consumer Healthcare business as a discontinued operation (see Note&#160;41). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting principles and policies </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared using the historical cost convention modified by the revaluation of certain items, as stated in the accounting policies, and on a going concern basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared in accordance with the Group&#8217;s accounting policies approved by the Board and described in Note 2, &#8216;Accounting principles and policies&#8217;. Information on the application of these accounting policies, including areas of estimation and judgement is given in Note 3, &#8216;Critical accounting judgements and key sources of estimation uncertainty&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </div><ix:nonNumeric name="gsk:DescriptionOfAccountingStandardsApplied" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent company financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of the parent company, GSK plc, have been prepared in accordance with UK&#160;GAAP and with UK accounting presentation. The company balance sheet is presented on page 268 and the accounting policies are given on pages 269 to 272. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049499"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2. Accounting principles and policies </div></div></ix:nonNumeric> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049499" continuedAt="TextSelectionAppend_69049499_1"><ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049501"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consolidated financial statements include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the assets and liabilities, and the results and cash flows, of the company and its subsidiaries, including ESOP Trusts </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of the results and net assets of associates and joint ventures </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of assets, liabilities, revenue and expenses of joint operations. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of entities consolidated are made up to 31&#160;December each year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Entities over which the Group has the power to direct the relevant activities so as to affect the returns to the Group, generally through control over the financial and operating policies, are accounted for as subsidiaries. </div></ix:nonNumeric> </ix:continuation><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_1" continuedAt="TextSelectionAppend_69049499_2"><ix:continuation id="TextSelection_69049501" continuedAt="TextSelectionAppend_69049501_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the Group has the ability to exercise joint control over, and rights to, the net assets of entities, the entities are accounted for as joint ventures. Where the Group has the ability to exercise joint control over an arrangement, but has rights to specified assets and obligations for specified liabilities of the arrangement, the arrangement is accounted for as a joint operation. Where the Group has the ability to exercise significant influence over entities, they are accounted for as associates. The results and assets and liabilities of associates and joint ventures are incorporated into the consolidated financial statements using the equity method of accounting. The assets, liabilities, revenue and expenses of joint operations are included in the consolidated financial statements in accordance with the Group&#8217;s rights and obligations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Interests acquired in entities are consolidated from the date the Group acquires control and interests sold are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date control ceases. </div></ix:continuation></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">186</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_2" continuedAt="TextSelectionAppend_69049499_3"><ix:continuation id="TextSelectionAppend_69049501_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Transactions and balances between subsidiaries are eliminated and no profit before tax is taken on sales between subsidiaries until the products are sold to customers outside the Group. The relevant proportion of profits on transactions with joint ventures, joint operations and associates is also deferred until the products are sold to third parties. Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests are recorded directly in equity. Deferred tax relief on unrealised intra-Group profit is accounted for only to the extent that it is considered recoverable. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business combinations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognised in the income statement. Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition date is reported within operating cash flows. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the consideration transferred, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in the period in which they are incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is capitalised as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and associates. Goodwill is denominated in the currency of the operation acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognised directly in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where not all of the equity of a subsidiary is acquired the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest is recognised either at fair value or at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of the net assets of the subsidiary, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis. Changes in the Group&#8217;s ownership percentage of subsidiaries are accounted for within equity. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049504"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign currency translation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Foreign currency transactions are booked in the functional currency of the Group company at the exchange rate ruling on the date of transaction. Foreign currency monetary assets and liabilities are retranslated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On consolidation, assets and liabilities, including related goodwill, of overseas subsidiaries, associates and joint ventures, are translated into Sterling at rates of exchange ruling at the balance sheet date. The results and cash flows of overseas subsidiaries, associates and joint ventures are translated into Sterling using average rates of exchange. </div></ix:nonNumeric> </ix:continuation><div style="font-size:11pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_3" continuedAt="TextSelectionAppend_69049499_4"><ix:continuation id="TextSelection_69049504"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Exchange adjustments arising when the opening net assets and the profits for the year retained by overseas subsidiaries, associates and joint ventures are translated into Sterling, less exchange differences arising on related foreign currency borrowings which hedge the Group&#8217;s net investment in these operations, are taken to a separate component of equity within Retained Earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When translating into Sterling the assets, liabilities, results and cash flows of overseas subsidiaries, associates and joint ventures which are reported in currencies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hyper-inflationary</div> economies, adjustments are made where material to reflect current price levels. Any loss on net monetary assets is charged to the consolidated income statement. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049506"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that GSK enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, vaccine and (prior to the demerger of the Consumer Healthcare business) consumer healthcare products. The average duration of a sales order is less than 12 months. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue is recognised when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Estimates associated with returns and rebates are revisited at each reporting date or when they are resolved and revenue is adjusted accordingly. Please refer to Note 3 for the details on rebates, discounts and allowances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has entered into collaborative agreements, typically with other pharmaceutical or biotechnology companies to develop, produce and market drug candidates and vaccines that do not qualify as joint arrangements. When GSK has control over the commercialisation activities, the Group recognises turnover and cost of sales on a gross basis. Profit sharing amounts and royalties due to the counterparty are recorded within cost of sales. Cost of sales includes profit sharing costs and royalties due to the counterparty of &#163;<ix:nonFraction name="gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,635</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">640</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction> million). When the counterparty controls the commercialisation activities and records the sale, the Group is not deemed principal in the customer contract and instead records its share of gross profit as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> income, on a net basis, within turnover. The nature of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> activities is such that the Group records <ix:nonFraction name="gsk:CostOfSalesOnCoPromotionalActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> costs of sales. Commercial Operations turnover includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> revenue of &#163;<ix:nonFraction name="gsk:RevenueFromCoPromotionalActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3 </ix:nonFraction>million (2021: &#163;<ix:nonFraction name="gsk:RevenueFromCoPromotionalActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7 </ix:nonFraction>million; 2020: &#163;<ix:nonFraction name="gsk:RevenueFromCoPromotionalActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction> million). Reimbursements to and from the counterparty under collaboration agreements for &#8216;selling, general and administration&#8217; and &#8216;research and development&#8217; costs are recorded net in the respective lines in the Consolidated income statement. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">187</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies</div></div> continued </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_4" continuedAt="TextSelectionAppend_69049499_5"><ix:continuation id="TextSelection_69049506"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other operating income and royalty income </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK enters into development and marketing collaborations and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licences</div> of the Group&#8217;s compounds or products to other parties. These contracts give rise to fixed and variable consideration from upfront payments, development milestones, sales-based milestones and royalties. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Income dependent on the achievement of a development milestone is recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, which is usually when the related event occurs. Sales-based milestone income is recognised when it is highly probable that the sales threshold will be reached. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occurs. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For all revenue, if the time between the recognition of revenue and payment from the customer is expected to be more than one year and the impact is material, the amount of consideration is discounted using appropriate discount rates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Value added tax and other sales taxes are excluded from revenue. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. Manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs between validation and the achievement of normal production are expensed as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Advertising and promotion expenditure is charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shipment costs on inter-company transfers are charged to cost of sales; distribution costs on sales to customers are included in selling, general and administration expenditure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Restructuring costs are recognised and provided for, where appropriate, in respect of the direct expenditure of a business reorganisation where the plans are sufficiently detailed and well advanced, and where appropriate communication to those affected has been undertaken. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Software as a service (SaaS) configuration costs are expensed as they are incurred where the software being configured is controlled by the SaaS provider. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and development </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group&#8217;s policy. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049509"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Environmental expenditure related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible is charged to the income statement. The Group recognises its liability on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">site-by-site</div></div> basis when it can be reliably estimated. </div></ix:nonNumeric> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_5" continuedAt="TextSelectionAppend_69049499_6"><ix:continuation id="TextSelection_69049509"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This liability includes the Group&#8217;s portion of the total costs and also a portion of other potentially responsible parties&#8217; costs when it is probable that they will not be able to satisfy their respective shares of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> obligation. Recoveries of reimbursements are recorded as assets when virtually certain. </div></ix:continuation><ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Provision is made for the anticipated settlement costs of legal or other disputes against the Group where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome. In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover asserted and unasserted claims. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In certain cases, an incurred but not reported (IBNR) actuarial technique is used to determine this estimate. In addition, provision is made for legal or other expenses arising from claims received or other disputes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases is included but no provision is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Costs associated with claims made by the Group against third parties are charged to the income statement as they are incurred. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of providing pensions under defined benefit schemes are calculated using the projected unit credit method and spread over the period during which benefit is expected to be derived from the employees&#8217; services, consistent with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension obligations are measured as the present value of estimated future cash flows discounted at rates reflecting the yields of high-quality corporate bonds. Pension scheme assets are measured at fair value at the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of other post-employment liabilities are calculated in<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>a similar way to defined benefit pension schemes and spread over the period during which benefit is expected to be derived from the employees&#8217; services, in accordance with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The service cost of providing retirement benefits to employees during the year, together with the cost of any curtailment, is charged to operating profit in the year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Actuarial gains and losses and the effect of changes in actuarial assumptions are recognised in the statement of comprehensive income in the year in which they arise. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s contributions to defined contribution plans are charged to the income statement as incurred. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">188</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies</div></div> continued </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_6" continuedAt="TextSelectionAppend_69049499_7"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee share plans </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Incentives in the form of shares are provided to employees under share option and share award schemes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair values of these options and awards are calculated at their grant dates using a Black-Scholes option pricing model and charged to the income statement over the relevant vesting periods. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group provides finance to ESOP Trusts to purchase company shares to meet the obligation to provide shares when employees exercise their options or awards. Costs of running the ESOP Trusts are charged to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shares held by the ESOP Trusts are deducted from other reserves. A transfer is made between other reserves and retained earnings over the vesting periods of the related share options or awards to reflect the ultimate proceeds receivable from employees on exercise. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Property, plant and equipment (PP&amp;E) is stated at the cost of purchase or construction, less provisions for depreciation and impairment. Financing costs are capitalised within the cost of qualifying assets in construction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Depreciation is calculated to write off the cost less residual value of PP&amp;E, excluding freehold land, using the straight-line basis over the expected useful life. Residual values and lives are reviewed, and where appropriate adjusted annually. <ix:nonNumeric name="gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049897">The normal expected useful lives of the major categories of PP&amp;E are:</ix:nonNumeric> </div><ix:continuation id="TextSelection_69049897"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:45%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Freehold buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">20 to 50 years</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Leasehold land and buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_LeaseholdLandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">Lease term or 20 to 50 years</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Plant and machinery</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_PlantAndMachineryMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">10 to 20 years</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equipment and vehicles</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_EquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">3 to 10 years</ix:nonNumeric></td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On disposal of PP&amp;E, the cost and related accumulated depreciation and impairments are removed from the financial statements and the net amount, less any proceeds, is taken to the income statement. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049517"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group recognises right of use assets under lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. Rights to use assets owned by third parties under lease agreements are capitalised at the inception of the lease and recognised on the consolidated balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The corresponding liability to the lessor is recognised as a lease obligation within short and long-term borrowings. The carrying amount is subsequently increased to reflect interest on the lease liability and reduced by lease payments made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For calculating the discounted lease liability on leases with annual payments of &#163;<ix:nonFraction name="gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" contextRef="PAsOn12_31_2022_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2 </ix:nonFraction>million or more, the implicit rate in the lease is used. If this is not available, the incremental borrowing rate with a lease specific adjustment is used. If neither of these is available, and for leases with annual payments of less than &#163;<ix:nonFraction name="gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" contextRef="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2 </ix:nonFraction>million, the incremental borrowing rate is used. The incremental borrowing rate is calculated at the rate of interest at which GSK would have been able to borrow for a similar term and with a similar security the funds necessary to obtain a similar asset in a similar market. </div></ix:nonNumeric> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_7" continuedAt="TextSelectionAppend_69049499_8"><ix:continuation id="TextSelection_69049517"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Finance costs are charged to the income statement so as to produce a constant periodic rate of charge on the remaining balance of the obligations for each accounting period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Variable rents are not part of the lease liability and the right of use asset. These payments are charged to the income statement as incurred. Lease rental costs for short-term and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> leases which are not capitalised are also charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-lease</div> components are accounted for separately from the lease components in plant and equipment leases but are not separately accounted for in land and buildings or vehicle leases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If modifications or reassessments of lease obligations occur, the lease liability and right of use asset are remeasured. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Right of use assets where title is expected to pass to GSK at a point in the future are depreciated on a basis consistent with similar owned assets. In other cases, right of use assets are depreciated over the shorter of the useful life of the asset or the lease term. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is stated at cost less impairments. Goodwill is deemed to have an indefinite useful life and is tested for impairment at least annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the fair value of the interest acquired in an entity&#8217;s assets, liabilities and contingent liabilities exceeds the consideration paid, this excess is recognised immediately as a gain in the income statement. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049521"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other intangible assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Intangible assets are stated at cost less provisions for amortisation and impairments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and marketing rights separately acquired or acquired as part of a business combination are amortised over their estimated useful lives, generally not exceeding <ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">30</ix:nonNumeric> years, using the straight-line basis, from the time they are available for use. The estimated useful lives for determining the amortisation charge take into account patent lives (exclusivity period), where applicable, as well as the value obtained from periods of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity.</div> For Pharmaceutical intangible assets, depending on the characteristics, competitive environment and estimated long-term profits of the asset, between <ix:nonFraction name="gsk:AmortisableProportionOverExclusivityPeriod" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% to <ix:nonFraction name="gsk:AmortisableProportionOverExclusivityPeriod" contextRef="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">90</ix:nonFraction>% of the book value is amortised over the exclusivity period on a straight-line basis and the remaining book value is amortised over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity</div> period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P12_31_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">5</ix:nonNumeric>-<ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_TopOfRangeMemberifrsfullRangeAxis">15</ix:nonNumeric></div> years on a straight-line basis. For Vaccines intangible assets, cost is usually amortised over the exclusivity period plus <ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_VaccinesMemberifrsfullSegmentsAxis">10 years, or 30 years</ix:nonNumeric> if no exclusivity period is granted, on a straight-line basis. Asset lives are reviewed, and where appropriate adjusted, annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Contingent milestone payments are recognised at the point that the contingent event becomes probable. Any development costs incurred by the Group and associated with acquired licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> or marketing rights are written off to the income statement when incurred, unless the criteria for recognition of an internally generated intangible asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">189</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_8" continuedAt="TextSelectionAppend_69049499_9"><ix:continuation id="TextSelection_69049521"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Acquired in process R&amp;D and marketed products are valued independently as part of the fair value of businesses acquired from third parties where they have a value which is substantial and long term and where the brands either are contractual or legal in nature or can be sold separately from the rest of the businesses acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of acquiring and developing computer software for internal use and internet sites for external use are capitalised as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset controlled by the Group. ERP systems software is amortised over <span style="-sec-ix-hidden:hidden69044974">seven</span> to <ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">ten years</ix:nonNumeric> and other computer software over <span style="-sec-ix-hidden:hidden69044975">three</span> to <ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">five years</ix:nonNumeric> using the straight-line basis. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying values of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available for use are tested for impairment annually. Any provision for impairment is charged to the income statement in the year concerned. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Impairments of goodwill are not reversed. Impairment losses on other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investments in associates, joint ventures and joint operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in associates and joint ventures are carried in the consolidated balance sheet at the Group&#8217;s share of their net assets at date of acquisition and of their post-acquisition retained profits or losses and other comprehensive income together with any goodwill arising on the acquisition. The Group recognises the assets, liabilities, revenue and expenses of joint operations in accordance with its rights and obligations. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventories </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realisable value. Cost is generally determined on a first in, first out basis. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-launch</div> inventory is held as an asset when there is a high probability of regulatory approval for the product. Before that point a provision is made against the carrying value to reduce it to its recoverable amount; the provision is then reversed at the point when a high probability of regulatory approval is determined. </div></ix:nonNumeric> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_9" continuedAt="TextSelectionAppend_69049499_10"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div></div></div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial assets are measured at amortised cost, fair value through other comprehensive income (FVTOCI) or fair value through profit or loss (FVTPL). The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. For financial assets other than trade receivables a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> expected credit loss (ECL) allowance is recorded on initial recognition. If there is subsequent evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are recognised in the income statement on financial assets measured at amortised cost and at fair value through other comprehensive income apart from equity investments. </div></ix:nonNumeric> <ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current equity investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. Dividend income is recognised in the income statement when the Group&#8217;s right to receive payment is established. Purchases and sales of Current equity investments are accounted for on the trade date. </div></ix:nonNumeric> <ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other investments comprise equity investments and investments in limited life funds. The Group has elected to designate the majority of its equity investments as measured at FVTOCI. They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in limited life funds are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends on equity investments and distributions from funds are recognised in the income statement when the Group&#8217;s right to receive payment is established. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Purchases and sales of Other investments are accounted for on the trade date. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_10" continuedAt="TextSelectionAppend_69049499_11"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trade receivables </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables are measured in accordance with the business model under which each portfolio of trade receivables is held. The Group has portfolios in each of the three business models under IFRS 9: to collect the contractual cash flows where there is no factoring agreement in place (measured at amortised cost), to sell the contractual cash flows where the trade receivables will be sold under a factoring agreement (measured at FVTPL), and both to collect and to sell the contractual cash flows where the trade receivables may be sold under a factoring arrangement (measured at FVTOCI). Trade receivables measured at amortised cost are carried at the original invoice amount less allowances for expected credit losses. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether, and the extent to which, settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Subsequent recoveries of amounts previously provided for or written off are credited to the income statement. Long-term receivables are discounted where the effect is material. </div></ix:nonNumeric> <ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash held in deposit accounts is measured at amortised cost. Investments in money market funds are held at fair value through profit or loss because the funds fail the solely payments of principal and interest (SPPI) test. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative financial instruments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by GSK are foreign currency swaps, interest rate swaps, foreign exchange forward contracts and options. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial assets and liabilities, including derivatives embedded in host contracts which have been separated from the host contract, are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading</div></div> and are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement. </div></ix:nonNumeric> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_11" continuedAt="TextSelectionAppend_69049499_12"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedge accounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives designated as hedging instruments are classified at inception of hedge relationship as cash flow hedges, net investment hedges or fair value hedges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective and accumulated in the cash flow hedge reserve. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in the cash flow hedge reserve are reclassified to the income statement when the hedged item affects profit or loss, or if the hedged forecast transaction is to purchase a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset, the amount deferred in the cash flow hedge reserve is transferred directly from equity and included in the carrying value of the recognised <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net investment hedges are accounted for in a similar way to cash flow hedges which are reclassified to the income statement when the hedged item affects profit or loss. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049537"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current tax is provided at the amounts expected to be paid, applying tax rates that have been enacted or substantively enacted by the balance sheet date. The tax charge for the period is recognised in the income statement, the statement of comprehensive income or directly in equity, according to the accounting treatment of the related transaction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company and its subsidiaries intend to settle their current tax assets and liabilities on a net basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are not recognised if the temporary differences arise from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction (other than a business combination) that affects neither the accounting nor the taxable profit or loss. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">191</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Accounting principles and policies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_12" continuedAt="TextSelectionAppend_69049499_13"><ix:continuation id="TextSelection_69049537"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where an uncertain tax position is identified, management will make a judgement as to what the probable outcome will be, assuming the relevant tax authority has full knowledge of the situation. Where it is assessed that an economic outflow is probable to arise, a provision is made for the best estimate of the liability. In estimating any such liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice. </div></ix:continuation><ix:nonNumeric name="gsk:DescriptionOfAccountingPolicyForDiscountingExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the time value of money is material, balances are discounted to current values using appropriate discount rates. The unwinding of the discounts is recorded in finance income and finance expense. </div></ix:nonNumeric> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049499_13"><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets and liabilities held for sale or distribution and discontinued operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal groups are classified as held for sale or distribution if their carrying amount will be recovered principally through sale or a distribution to shareholders rather than through continuing use, they are available for sale or distribution in their present condition and the sale or distribution is considered highly probable. Assets held in Assets held for sale or distribution are measured at the lower of their carrying amount and fair value less costs to sell or distribute. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets included in Assets held for sale or distribution are not depreciated or amortised. Assets and liabilities classified as held for sale or distribution are presented in current assets and current liabilities separately from the other assets and liabilities in the balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A discontinued operation is a component of the Group that has been disposed of, distributed or is classified as held for sale or distribution and that represents a separate major line of business. The results of discontinued operations are presented separately in the Consolidated income statement, the Consolidated statement of other comprehensive income and the Consolidated statement of cash flows and comparatives are restated on a consistent basis. </div></ix:nonNumeric> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049630"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">3. Critical accounting judgements and key sources of<br/> estimation uncertainty </div></div></ix:nonNumeric> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049630" continuedAt="TextSelectionAppend_69049630_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In preparing the financial statements, management is required to make judgements about when or how items should be recognised in the financial statements and estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. The following are considered to be the critical accounting judgements and key sources of estimation uncertainty. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Reported Group turnover for 2022 was &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction> million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Gross turnover is reduced by rebates, discounts, allowances and product returns given or expected to be given, which vary by product arrangements and buying groups. These arrangements with purchasing organisations are dependent upon the submission of claims some time after the initial recognition of the sale. Accruals are made at the time of sale for the estimated rebates, discounts or allowances payable or returns to be made, based on available market information and historical experience. </div></ix:continuation><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:continuation id="TextSelectionAppend_69049630_1" continuedAt="TextSelectionAppend_69049630_2"><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049630_2" continuedAt="TextSelectionAppend_69049630_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales of pharmaceutical and vaccine products in the US have complex arrangements for rebates, discounts and allowances. Turnover of Commercial Operations products in the US for 2022 of &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,542</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,914</ix:nonFraction> million) was after recording deductions of &#163;<ix:nonFraction name="gsk:CustomerReturnsDiscountsAndRebates" contextRef="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,272</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CustomerReturnsDiscountsAndRebates" contextRef="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,518</ix:nonFraction> million) for rebates, allowances, returns and other discounts. At 31&#160;December 2022, the total accrual amounted to &#163;<ix:nonFraction name="gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" contextRef="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,855</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" contextRef="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,044</ix:nonFraction> million). Due to the nature of these accruals it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, returns and other revenue accruals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As there can be significant variability in final outcomes, the Group applies a constraint when measuring the variable element within revenue, so that revenue is recognised at a suitably cautious amount. The objective of the constraint is to ensure that it is highly probable that a significant reversal of revenue will not occur when the uncertainties are resolved. The constraint is applied by making suitably cautious estimates of the inputs and assumptions used in estimating the variable consideration. Because the amounts are estimated they may not fully reflect the final outcome, and the amounts are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The constraints applied in recognising revenue mean that the risk of a material downward adjustment to revenue in the next financial year is low. </div></ix:continuation><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">192</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. Critical accounting judgements and key sources of estimation uncertainty </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049630_3" continuedAt="TextSelectionAppend_69049630_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The level of accrual for rebates and returns is reviewed and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Market conditions are evaluated using wholesaler and other third-party analyses, market research data and internally generated information. It is reasonably possible that there could be a significant adjustment within the next 12 months to recognise additional revenue, if actual outcomes are better than the cautious constrained estimates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The amount of turnover recognised in the year from performance obligations satisfied in previous periods is set out in Note&#160;6, &#8216;Turnover and segment information&#8217;, and is an indication of the level of sensitivity in the estimate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Future events could cause the assumptions on which the accruals are based to change, which could materially affect the future results of the Group. </div></ix:continuation><ix:continuation id="TextSelectionAppend_69049630_4" continuedAt="TextSelectionAppend_69049630_5"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tax charge for the year was &#163;<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction> million). At December 2022, current tax payable was &#163;<ix:nonFraction name="ifrs-full:CurrentTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">471</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:CurrentTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">489</ix:nonFraction> million), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> corporation tax payable was &#163;<ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction> million) and current tax recoverable was &#163;<ix:nonFraction name="ifrs-full:CurrentTaxAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">405</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:CurrentTaxAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">486</ix:nonFraction>&#160;million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has open tax issues with a number of revenue authorities. Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the outcome of the dispute. If insufficient information is available, no provision is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If sufficient information is available, in estimating a potential tax liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group had recognised provisions of &#163;<ix:nonFraction name="gsk:UncertainTaxPositionsRecognised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">551</ix:nonFraction>&#160;million in respect of uncertain tax positions (2021: &#163;<ix:nonFraction name="gsk:UncertainTaxPositionsRecognised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">858</ix:nonFraction> million). Due to the number of uncertain tax positions held and the number of jurisdictions to which these relate, it is not practicable to give meaningful sensitivity estimates. No uncertain tax position is individually significant to the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Factors affecting the tax charge in future years are set out in Note 14, &#8216;Taxation&#8217;. GSK continues to believe that it has made adequate provision for the liabilities likely to arise from open assessments. Where open issues exist, the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of negotiations with the relevant tax authorities or, if necessary, litigation proceedings. </div></ix:continuation><div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:continuation id="TextSelectionAppend_69049630_5" continuedAt="TextSelectionAppend_69049630_6">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049630_6" continuedAt="TextSelectionAppend_69049630_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Legal costs for the year were &#163;<ix:nonFraction name="gsk:LegalCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">144</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="gsk:LegalCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million). At 31&#160;December 2022 provisions for legal and other disputes amounted to &#163;<ix:nonFraction name="ifrs-full:LegalProceedingsProvision" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:LegalProceedingsProvision" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction> million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the likely outcome of the dispute and the legal and other expenses arising from claims against the Group. If insufficient information is available, no provision is made and disclosure of the claim is given. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The estimated provisions take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. Details of the status and various uncertainties involved in the significant unresolved disputes are set out in Note 47, &#8216;Legal proceedings&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company&#8217;s Directors, having taken legal advice, have established provisions after taking into account the relevant facts and circumstances of each matter and in accordance with accounting requirements. In respect of product liability claims related to certain products, there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases would be provided, but no provision would be made and no contingent liability can be quantified. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. The position could change over time and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions reported in the Group&#8217;s financial statements by a material amount. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contingent consideration </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The 2022 income statement charge for contingent consideration was &#163;<ix:nonFraction name="gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,645</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,063</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the liability for contingent consideration amounted to &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction> million). Of this amount, &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,890</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,559</ix:nonFraction> million) related to the acquisition of the former Shionogi-ViiV Healthcare joint venture in 2012. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any contingent consideration included in the consideration payable for a business combination is recorded at fair value at the date of acquisition. These fair values are generally based on risk-adjusted future cash flows discounted using appropriate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> discount rates. The fair values are reviewed on a regular basis, at least annually, and any changes are reflected in the income statement. See Note 33, &#8216;Contingent consideration liabilities&#8217;. </div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">193</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. Critical accounting judgements and key sources of estimation uncertainty </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049630_7" continuedAt="TextSelectionAppend_69049630_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_69049630_8" continuedAt="TextSelectionAppend_69049630_9"><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Judgement </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where a surplus on a defined benefit scheme arises, or there is potential for a surplus to arise from committed future contributions, the rights of the Trustees to prevent the Group obtaining a refund of that surplus in the future are considered in determining whether it is necessary to restrict the amount of the surplus that is recognised. Two UK schemes are in surplus (2021: three UK schemes), with a combined surplus of &#163;<ix:nonFraction name="gsk:DefinedBenefitPlanSurplusNet" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="gsk:DefinedBenefitPlanSurplusNet" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">606</ix:nonFraction> million). There are further recognised pension surpluses totalling &#163;<ix:nonFraction name="gsk:PensionSurplus" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction>&#160;million spread across five countries (2021: &#163;<ix:nonFraction name="gsk:PensionSurplus" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">135</ix:nonFraction>&#160;million across six countries). GSK has made the judgement that these amounts meet the requirements of recoverability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of providing pensions and other post-employment benefits are assessed on the basis of assumptions selected by management. These assumptions include future earnings and pension increases, discount rates, expected long-term rates of return on assets and mortality rates, and are disclosed in Note 31, &#8216;Pensions and other post-employment benefits&#8217;. </div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049630_9"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. A sensitivity analysis is provided in Note 31, &#8216;Pensions and other post-employment benefits&#8217;, a <ix:nonFraction name="gsk:PercentageOfDecreaseInDiscountRate" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction>% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#163;<ix:nonFraction name="gsk:IncreaseInPlanDeficit" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction>&#160;million and an increase in the annual pension cost of approximately &#163;<ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million. Similarly, a <ix:nonFraction name="gsk:PercentageOfIncreaseInDiscountRate" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction>% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#163;<ix:nonFraction name="gsk:DecreaseInPlanDeficit" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">400</ix:nonFraction>&#160;million and a decrease in the annual pension cost of approximately &#163;<ix:nonFraction name="gsk:DecreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million. A <ix:nonFraction name="gsk:PercentageOfDecreaseInDiscountRate" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.75</ix:nonFraction>% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#163;<ix:nonFraction name="gsk:IncreaseInPlanDeficit" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,341</ix:nonFraction>&#160;million and an increase in the annual pension cost of approximately &#163;<ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction>&#160;million. Similarly, a <ix:nonFraction name="gsk:PercentageOfIncreaseInDiscountRate" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.75</ix:nonFraction>% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#163;<ix:nonFraction name="gsk:DecreaseInPlanDeficit" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,147</ix:nonFraction>&#160;million and a decrease in the annual pension cost of approximately &#163;<ix:nonFraction name="gsk:DecreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction>&#160;million. The selection of different assumptions could affect the future results of the Group. </div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049622"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">4. New accounting requirements</div></div></ix:nonNumeric><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049622" continuedAt="TextSelectionAppend_69049622_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amendments to accounting standards issued by the IASB and adopted in the year ended 31&#160;December 2022 did not have a material impact on the results or financial position of the Group.</div></ix:continuation><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049622_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 31&#160;December 2022 reporting periods and have not been adopted early by the Group. These standards, amendments and interpretations are not expected to have a material impact on the results or financial position of the Group in future reporting periods.</div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049950"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">5. Exchange rates </div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group uses the average of exchange rates prevailing during the period to translate the results and cash flows of overseas subsidiaries, joint ventures and associates into Sterling and period end rates to translate the net assets of those entities. <ix:nonNumeric name="gsk:SignificantCurrenciesAndTheRelevantExchangeRates" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050750">The currencies which most influence these translations and the relevant exchange rates were:</ix:nonNumeric> </div></ix:nonNumeric> <div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049950" continuedAt="TextSelectionAppend_69049950_1"><ix:continuation id="TextSelection_69050750" continuedAt="TextSelectionAppend_69050750_1">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Average rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.24</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2020To12_31_2020_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.17</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2020To12_31_2020_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">161</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2020To12_31_2020_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">137</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation></ix:continuation><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049950_1"><ix:continuation id="TextSelectionAppend_69050750_1">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Period end rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2020_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2020_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2022_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">159</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2021_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">155</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn12_31_2020_JPYsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">141</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation></ix:continuation><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">194</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049951"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">6. Turnover and segment information </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the GSK Leadership Team (GLT). <ix:nonNumeric name="ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments" contextRef="P01_01_2022To12_31_2022">GSK has revised its operating segments from Q1 2022 and from Q2 2022. Previously GSK reported results under <ix:nonFraction name="gsk:NumberOfReportableOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Segments" decimals="0" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> segments: Pharmaceuticals, Pharmaceuticals R&amp;D, Vaccines and Consumer Healthcare. For the first quarter 2022, GSK reported results under three segments: Commercial Operations, Total R&amp;D and Consumer Healthcare. From Q2 2022, GSK reports under <ix:nonFraction name="gsk:NumberOfOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Segments" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> segments from continuing operations as the demerger of the Consumer Healthcare segment was completed on 18&#160;July 2022.</ix:nonNumeric> Members of the GLT are responsible for each segment. Comparative information has been retrospectively revised on a consistent basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">R&amp;D investment is essential for the sustainability of the business. However for segment reporting the Commercial Operating profits exclude allocations of globally funded R&amp;D. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Total R&amp;D segment is the responsibility of the Chief Scientific Officer and is reported as a separate segment. The operating costs of this segment includes R&amp;D activities across Specialty Medicines, including HIV and Vaccines. It includes R&amp;D and some SG&amp;A costs relating to regulatory and other functions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s management reporting process allocates intra-Group profit on a product sale to the segment in which that sale is recorded, and the profit analyses below have been presented on that basis. </div><ix:nonNumeric name="gsk:DisclosureOfTurnoverBySegmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by segment</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,232</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,354</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This business was excluded from the Consumer Healthcare Joint Venture but was included in the Consumer Healthcare segment performance in 2020. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For 2022, product sales are reported within three product groups: Specialty Medicines, Vaccines and General Medicines. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfProductsAndServicesExplanatory" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercial Operations:</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,749</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,777</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,876</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Oncology</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">602</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">489</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">372</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflammation,</div> respiratory and other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,609</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,027</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,721</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,960</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,293</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,969</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,309</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">958</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Specialty Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,269</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,251</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,969</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,116</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">961</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,029</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Influenza</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">714</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">679</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">733</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shingles</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,958</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,721</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,989</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Established Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,085</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,970</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,231</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,873</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,331</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,982</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">447</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,937</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,778</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,982</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,548</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,048</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,006</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,570</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,619</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,275</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,118</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,667</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,281</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Commercial Operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,232</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the Commercial Operations segment.</div></td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">195</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Turnover and segment information </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:continuation id="TextSelection_69049951" continuedAt="TextSelectionAppend_69049951_1"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">During 2022, sales were made to <ix:nonFraction name="gsk:NumberOfWholesalers" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_wholesalers" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> US wholesalers of &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,045</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,159</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,928</ix:nonFraction> million), &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,161</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,081</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,085</ix:nonFraction> million) and &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,227</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,670</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,795</ix:nonFraction> million) respectively, after allocating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">final-customer</div> discounts to the wholesalers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Revenue recognised in the year from performance obligations satisfied in previous periods totalled &#163;<ix:nonFraction name="ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,601</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,438</ix:nonFraction> million) including &#163;<ix:nonFraction name="gsk:RevenueFromChangesToEstimatesOfRARAccruals" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">898</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(1)</div>: &#163;<ix:nonFraction name="gsk:RevenueFromChangesToEstimatesOfRARAccruals" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">949</ix:nonFraction> million) impacting turnover arising from changes to prior year estimates of RAR (returns and rebates) accruals, &#163;<ix:nonFraction name="gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">115</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction> million) of milestone income and &#163;<ix:nonFraction name="gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">588</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">428</ix:nonFraction> million) of royalty income recognised in the current year. </div> <ix:nonNumeric name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049611"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment profit<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,590</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,297</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,060</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,530</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">379</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">407</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment profit and operating profit</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,718</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,136</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">677</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Operating profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,433</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">879</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits/(losses) of associates and joint ventures</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,628</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,599</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation for the year from continuing operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,921</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,516</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,103</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other reconciling items between segment profit and operating profit comprise items not specifically allocated to segment profit. These include impairment and amortisation of intangible assets; major restructuring costs, which include impairments of tangible assets and computer software; transaction-related adjustments related to significant acquisitions; proceeds and costs of disposals of products and businesses, significant legal charges and expenses on the settlement of litigation and government investigations, other operating income other than royalty income and other items. Please refer to the detail of Other reconciling items between segment profit and operating profit in the analysis of adjusting items (Group financial review). </div> <ix:continuation id="TextSelection_69049611" continuedAt="TextSelectionAppend_69049611_1"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation and amortisation by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">829</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">904</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">467</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">378</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">355</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,296</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">739</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">761</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">724</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,147</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,122</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,050</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:continuation></ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 91%; border: 0px; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 91%; border: 0px; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Turnover and segment information </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:continuation id="TextSelectionAppend_69049951_1" continuedAt="TextSelectionAppend_69049951_2"><ix:continuation id="TextSelectionAppend_69049611_1">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E, intangible asset and goodwill impairment by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment and total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">420</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">392</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">583</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">540</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">712</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E and intangible asset impairment reversals by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment reversals and total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 7.5pt; width: 742.547px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility: hidden; line-height: 0pt; color: white;">
<td style="width: 542.188px;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6.875px;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6.3125px;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6.32812px;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-size: 6.5pt;">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating assets by segment</div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(revised)<div style="font-size: 6.5px; vertical-align: top;;display:inline;">(2)</div></div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,288</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,440</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,299</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,461</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,587</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,901</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">264</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,504</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,208</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,851</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetOperatingAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39,613</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="1" style="height:9.75pt">&#160;</td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,197</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NetDebt" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:InvestmentsInJointVenturesAndAssociates" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:InvestmentsInJointVenturesAndAssociates" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current Equity Investment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,087</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current and deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CurrentAndDeferredTaxation" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,176</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CurrentAndDeferredTaxation" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,479</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale (excluding cash and cash equivalents)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,096</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,342</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr> </table> </ix:continuation> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Commercial Operations segment includes the Shionogi-ViiV Healthcare contingent consideration liability of &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_ShionogiViivHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,890</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_ShionogiViivHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,559</ix:nonFraction> million) and the Pfizer put option of &#163;<ix:nonFraction name="gsk:PutOption" contextRef="PAsOn12_31_2022_PfizerMemberdeiLegalEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,093</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:PutOption" contextRef="PAsOn12_31_2021_PfizerMemberdeiLegalEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,008</ix:nonFraction> million). </div> </ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><ix:continuation id="TextSelectionAppend_69049951_2"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Geographical information </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK is regarded as being the Group&#8217;s country of domicile. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by location of customer</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">695</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">656</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">659</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,542</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,914</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,148</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,087</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,126</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,547</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External turnover</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,324</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,696</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,354</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location of subsidiary</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,134</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,618</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,024</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,852</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Belgium</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022_BEifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,415</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021_BEifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,065</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Switzerland</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022_CHifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021_CHifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,552</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,559</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,390</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31,166</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">51,477</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables. There are no other countries with individually material external revenue or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the new segments. </div> </td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 91%; border: 0px; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">197</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">7. Other operating income/(expense) </div></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Upfront settlement income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UpfrontSettlementIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69050196">922</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">256</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045263">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045264">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposal of businesses and assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DisposalOfBusinessesAndAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">215</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DisposalOfBusinessesAndAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045266">552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DisposalOfBusinessesAndAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045267">2,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements on contingent consideration recognised in business combinations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,607</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045269">1,058</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045270">1,286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of ViiV Healthcare put option liabilities and preferential dividends</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045272">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045273">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments on derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045275">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045276">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:MiscellaneousOtherOperatingIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:MiscellaneousOtherOperatingIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045278">17</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:MiscellaneousOtherOperatingIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045279">62</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">235</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045281">504</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045282">1,463</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"><ix:footnote id="FN_241566" xml:lang="en-US">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</ix:footnote> </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"><ix:footnote id="FN_241567" xml:lang="en-US">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy concerning ViiV Healthcare&#8217;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $<ix:nonFraction name="gsk:UpfrontPayment" contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:num-dot-decimal">1.25</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:UpfrontPayment" contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">922</ix:nonFraction> million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a <ix:nonFraction name="gsk:PercentageOfRoyaltyPayableOnFutureSales" contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement.</ix:footnote> </div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fair value remeasurement on equity investments in 2022 included a gain/loss of &#163;<ix:nonFraction name="gsk:GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction>&#160;million from the remeasurement of the Group&#8217;s retained investment in Haleon plc to fair value at 31&#160;December 2022 from the initial recognition fair value <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(five-day</div> average share price after the demerger). See details in Note 22. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2022 includes milestone income and the reversal of provisions no longer required. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2021 included a net gain on disposal of the rights to the royalty stream for cabozantinib and a net gain on disposal of the cephalosporin antibiotic brands to Sandoz. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2020 included a net profit on disposal of the Horlicks and other Consumer Healthcare nutritional brands and two subsidiaries in India and Bangladesh of &#163;<ix:nonFraction name="gsk:DisposalOfBusinessesAndAssets" contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_HorlicksMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,815</ix:nonFraction>&#160;million, which reflected reversal of &#163;<ix:nonFraction name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" contextRef="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction>&#160;million of embedded derivative gains on the value of the shares taken in prior years. This was partly offset by the related &#163;<ix:nonFraction name="gsk:LossOnSaleOfBusiness" contextRef="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">476</ix:nonFraction>&#160;million loss on the shares in Hindustan Unilever Limited, including fair value remeasurement losses between their acquisition as consideration for the divestment of GSK Consumer Healthcare Limited in India and their subsequent disposal. Other operating income also included an increase in profit and milestone income from a number of asset disposals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fair value remeasurements on contingent consideration recognised as business combinations included &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,431</ix:nonFraction>&#160;million related to the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_NovartisMemberdeiLegalEntityAxis_VaccinesBusinessAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">193</ix:nonFraction>&#160;million payable to Novartis related to the Vaccines acquisition, together with fair value movements on related hedging contracts. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">198</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">8. Operating profit </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The following items have been included in operating profit:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee costs (Note 9)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,693</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,680</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,555</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Advertising</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">735</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">433</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">361</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distribution costs</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DistributionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DistributionCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">169</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DistributionCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">176</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">885</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">855</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">822</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of property, plant and equipment, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">176</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">179</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">182</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfRightOfUseAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfRightOfUseAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfRightOfUseAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,086</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,088</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,046</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfIntangibleAssetsNetOfReversal" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">365</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfIntangibleAssetsNetOfReversal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">435</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfIntangibleAssetsNetOfReversal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">230</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets held for sale, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of goodwill allocated to a disposal group, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net foreign exchange (gains)/losses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventories:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of inventories included in cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,137</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,885</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,934</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">687</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">800</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">607</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of prior year write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfInventoryWritedown" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">483</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfInventoryWritedown" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">325</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfInventoryWritedown" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">250</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variable lease payments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fees payable to the company&#8217;s auditor and its associates in relation to the Group (see below)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">26.9</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">31.7</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">29.9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reversals of prior year write-downs of inventories principally arise from the reassessment of usage or demand expectations prior to inventory expiration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net foreign exchange (gains)/losses include a net loss of &#163;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million gain; 2020: &#163;<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="P01_01_2020To12_31_2020_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction>&#160;million loss) arising from the recycling of exchange on liquidation or disposal of overseas subsidiaries. The recycling of exchange on disposal of overseas associates of a loss of &#163;<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociates" contextRef="P01_01_2022To12_31_2022_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil </ix:nonFraction>(2021: &#163;<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociates" contextRef="P01_01_2021To12_31_2021_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million) is reported through loss on disposal of interest in associates. The recycling of exchange on disposal of overseas subsidiaries does not include recycling of exchange on disposal of Consumer Healthcare subsidiaries as this is reported as Profit after taxation on demerger of discontinued operations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Included within operating profit are Major restructuring charges of &#163;<ix:nonFraction name="ifrs-full:ExpenseOfRestructuringActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ExpenseOfRestructuringActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:ExpenseOfRestructuringActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,178</ix:nonFraction> million), see Note 10, &#8216;Major restructuring costs&#8217;. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Fees payable to the company&#8217;s auditor and its associates:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2022To12_31_2022_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2021To12_31_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2020To12_31_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of the company&#8217;s subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2022To12_31_2022_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.7</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2021To12_31_2021_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.5</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2020To12_31_2020_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.5</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.6</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForOtherAssuranceServices" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.3</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForOtherAssuranceServices" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForOtherAssuranceServices" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services, audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">26.9</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">31.7</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">29.9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The other assurance services provided by the auditor related to agreed upon procedures and other assurance services outside of statutory audit requirements.<ix:nonNumeric name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" escape="true" continuedAt="TextSelection_69049601"> In addition to the above, fees paid to the auditor in respect of the GSK pension schemes were: </ix:nonNumeric></div><ix:continuation id="TextSelection_69049601"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were immaterial fees of &#163;<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="P01_01_2022To12_31_2022_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million paid in 2022 (versus 2021: &#163;<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="P01_01_2021To12_31_2021_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>; 2020 &#163;<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="P01_01_2020To12_31_2020_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million) to other auditors in respect of audits of certain of the company&#8217;s subsidiaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Audit related and other assurance services include &#163;<ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="P01_01_2022To12_31_2022_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="P01_01_2021To12_31_2021_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million) due to reporting accountant work performed in preparation for the Consumer Healthcare demerger. </div><div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">199</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfEmployeeCostsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">9. Employee costs </div></div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,110</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">763</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs, including augmentations (Note 31)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostEmploymentBenefitExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">369</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PostEmploymentBenefitExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PostEmploymentBenefitExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Severance and other costs from integration and restructuring activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">137</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">269</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">520</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,693</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,680</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,555</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group provides benefits to employees, commensurate with local practice in individual countries, including in some markets, healthcare insurance, subsidised car schemes and personal life assurance. </div> <ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cost of share-based incentive plans is analysed as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share Value Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">243</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Performance Share Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share option plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash settled and other plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfNumberOfEmployeesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average number of persons employed by the Group (including Directors) during the year: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> Number</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Manufacturing</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_ManufacturingMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">22,946</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2021To12_31_2021_ManufacturingMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">23,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_ManufacturingMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">24,536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">34,642</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">36,909</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">37,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">11,542</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">10,874</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">10,744</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total Continuing Operations</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">69,130</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">71,345</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">73,257</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued Operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromDiscontinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">21,292</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromDiscontinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">20,616</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AverageNumberOfEmployeesFromDiscontinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">22,628</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AverageNumberOfEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">90,422</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageNumberOfEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">91,961</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageNumberOfEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Employee" decimals="0" scale="0" format="ixt:num-dot-decimal">95,885</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Note: Consumer Healthcare divested on 18 July 2022 is shown as Discontinued Operations in the above table. </div> </ix:nonNumeric> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average monthly number of Group employees excludes temporary and contract staff. The numbers of Group employees at the end of each financial year are given in the financial record on page 277. </div> <ix:nonNumeric name="gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The compensation of the Directors and senior management (members of the GLT) in aggregate, was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:KeyManagementPersonnelCompensationSocialSecurityCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:KeyManagementPersonnelCompensationSocialSecurityCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:KeyManagementPersonnelCompensationSocialSecurityCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">66</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Further information on the remuneration of the Directors is given in the sections of the Annual Report on remuneration labelled as audited within pages 133 to 164. </div> <div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:nonNumeric></div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">200</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfMajorRestructuringCostsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049963"><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">10. Major restructuring costs </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;D sites, are likely to take several years to complete. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Major restructuring costs are those related to specific Board-approved Major restructuring programmes, including integration costs following material acquisitions, which are structural and are of a significant scale where the costs of individual or related projects exceed &#163;<ix:nonFraction name="gsk:RestructuringCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In January 2020, the Board approved a Separation Preparation programme to prepare for the separation of GSK into two companies. Materially all of the Separation Preparation restructuring programme has been included as part of continuing operations. The legacy Consumer Healthcare Joint Venture integration programme is now included as part of discontinued operations. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">After the acquisition of Sierra Oncology (July 2022) and Affinivax (August 2022), the Board approved a Major restructuring programme for the Integration of significant acquisitions designed to integrate and achieve synergies. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The total restructuring costs of &#163;<ix:nonFraction name="gsk:TotalRestructuringCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction>&#160;million in 2022 were incurred in the following areas: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Restructuring costs to prepare for separation of GSK into two companies </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Continued transformation of central functions, including GSK technology platforms and interfaces, to deliver greater digital synergies, simplification of applications and staff reductions </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The integration of acquisitions. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050736">The analysis of the costs charged to operating profit from continuing operations under these programmes was as follows:</ix:nonNumeric></div> <ix:continuation id="TextSelection_69050736"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in provision for Major restructuring programmes (see Note <div style="display:inline;">32</div>)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">606</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amount of provision reversed unused (see Note 32)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfProvisionsForCostOfRestructuring" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">111</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfProvisionsForCostOfRestructuring" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReversalOfProvisionsForCostOfRestructuring" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses recognised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">347</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges/(credit)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherMaterialNoncashItems" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherMaterialNoncashItems" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherMaterialNoncashItems" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other cash costs</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherCostsCashSettlement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">179</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherCostsCashSettlement" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherCostsCashSettlement" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">234</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,178</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:continuation> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Provision reversals of &#163;<ix:nonFraction name="gsk:IncreaseDecreaseProvisionReversalRestructuring" contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">111</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="gsk:IncreaseDecreaseProvisionReversalRestructuring" contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction>&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="gsk:IncreaseDecreaseProvisionReversalRestructuring" contextRef="P01_01_2020To12_31_2020_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction> million) reflected provision releases mainly related to the Separation Preparation programme. Asset impairments of &#163;<ix:nonFraction name="gsk:AssetImpairments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction>&#160;million and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> credit of &#163;<ix:nonFraction name="gsk:OtherNonCashCredit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction>&#160;million principally comprised fixed asset write-downs of manufacturing facilities and accelerated depreciation where asset lives have been shortened in the supply chain manufacturing network as a result of the Major restructuring programmes, offset by profit on disposals. All other charges have been or will be settled in cash and include site closure costs, consultancy and project management costs. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="gsk:DisclosureOfRestructuringCostsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050739">The analysis of Major restructuring charges from continuing operations by programme was as follows:</ix:nonNumeric></div> <ix:continuation id="TextSelection_69050739" continuedAt="TextSelectionAppend_69050739_1"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:84%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">287</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Significant acquisitions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">206</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">115</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">353</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">412</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashRestructuringCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">385</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NonCashRestructuringCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RestructuringCosts1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table></ix:continuation> </ix:nonNumeric> <ix:continuation id="TextSelectionAppend_69050739_1"><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">201</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10. Major restructuring costs </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" contextRef="P01_01_2022To12_31_2022" escape="true"><ix:continuation id="TextSelection_69049963"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of Major restructuring charges from continuing operations by income statement line was as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">585</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">277</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">395</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ResearchAndDevelopmentExpenses" contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ResearchAndDevelopmentExpenses" contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ResearchAndDevelopmentExpenses" contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">198</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">321</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CostChargedToOperatingProfit" contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,178</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:continuation></ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfFinanceIncomeExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">11. Finance income </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfInterestIncomeExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains arising from the forward element of forward contracts in net investment hedge relationships</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherFinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">12. Finance expense </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfFinanceCostExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">789</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045438">735</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">811</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial instruments mandatorily measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">743</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045441">565</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">382</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retranslation of loans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ReTranslationOfLoan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">761</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ReTranslationOfLoan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69048662">565</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ReTranslationOfLoan" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">384</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of hedges from other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045444">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discounts on provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045447">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on lease liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69048665">27</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherFinanceIncomeCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherFinanceIncomeCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69045450">3</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherFinanceIncomeCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">879</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69045453">769</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">874</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfAssociatesAndJointVenturesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">13. Associates and joint ventures </div></div><ix:nonNumeric name="gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits and losses of associates and joint ventures is set out below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses of joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">2021 and 2020 comparatives have not been restated, as the demerged Consumer Healthcare business contained no associates or joint ventures. </div></td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following the disposal of Innoviva, Inc in May 2021 (see details in Note 41), at 31&#160;December 2022 and 31&#160;December 2021 the Group held no significant individual associates. At 31&#160;December 2020, the Group held one significant associate, Innoviva, Inc. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Summarised income statement information in respect of Innoviva until May 2021 is set out below. The Group&#8217;s 2021 share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates and other comprehensive income included a profit of &#163;<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></ix:nonFraction>&#160;million and other comprehensive income of &#163;<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil in respect of Innoviva. </div> <ix:nonNumeric name="gsk:DisclosureOfGroupHeldSignificantAssociateExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The results of Innoviva included in the summarised income statement information below represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information at the balance sheet date. Figures for 2021 include share of Innoviva&#8217;s turnover, profit and total comprehensive income until the date of the disposal. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">108</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">174</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">174</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="gsk:DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Aggregated financial information in respect of GSK&#8217;s share of other associated undertakings and joint ventures is set out below: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of total comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s sales to associates and joint ventures were &#163;<ix:nonFraction name="gsk:SalesToAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil in 2022 (2021: &#163;<ix:nonFraction name="gsk:SalesToAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil; 2020: &#163;<ix:nonFraction name="gsk:SalesToAssociatesAndJointVentures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Please refer to the Balance sheet information on associates and joint ventures in Note 21. </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">203</div></div></td></tr></table></div></div> </div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfIncomeTaxExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049954"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL;text-indent: 0px;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">14. Taxation </div></div> <ix:nonNumeric name="gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group&#8217;s tax charge is the sum of the total current and deferred tax expense. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Taxation charge based on profits for the year</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">119</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,351</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">593</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">745</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge/(credit) in respect of prior periods</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">219</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,491</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">931</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">711</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">784</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">848</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">644</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In 2022, GSK made corporate income tax payments globally of &#163;<ix:nonFraction name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;billion for continuing and discontinued operations, of which &#163;<ix:nonFraction name="ifrs-full:IncomeTaxesPaidRefund" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction>&#160;million was UK corporation tax paid to HMRC. These amounts are for corporate income tax only, and do not include the various other business taxes borne by GSK each year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The deferred tax credits in each period reflect current year losses where offset against taxable profits in future periods is probable and the release of deferred tax liabilities. The latter relates primarily to the unwind of deferred tax liabilities on intangible assets. The deferred tax credit in 2021 also reflected the impact of the remeasurement of deferred tax assets and liabilities following enactment of the increase in the headline rate of UK corporation tax from <ix:nonFraction name="gsk:HeadlineUkTaxRateEffective2023" contextRef="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">19</ix:nonFraction>% to <ix:nonFraction name="gsk:HeadlineUkTaxRateEffective2023" contextRef="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>%. </div> <ix:nonNumeric name="gsk:DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049959"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for the year. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 59%;"><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"></div></td> </tr>
<tr style="font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 7.5pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of taxation on Group profits</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>%</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,628</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,599</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,170</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK statutory rate of taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,069</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">19.0</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">685</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">19.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">984</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">19.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Differences in overseas taxation rates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">318</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TaxRateEffectOfForeignTaxRates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.6</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">302</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxRateEffectOfForeignTaxRates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">363</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxRateEffectOfForeignTaxRates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefit of intellectual property incentives</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">600</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">10.7</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">382</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">10.6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">516</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">9.9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">2.1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">2.8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfResearchAndDevelopmentCredits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">2.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Permanent differences on disposals, acquisitions and transfers</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">275</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">316</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">6.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">82</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">90</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year current tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TaxEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">219</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TaxEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year deferred tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">4.1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">281</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">7.8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">283</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">5.5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in Tax Rates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfChangeInTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfChangeInTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfChangeInTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">353</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfChangeInTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">9.8</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxEffectOfChangeInTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">163</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxRateEffectOfChangeInTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">3.1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax charge/tax rate</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AverageEffectiveTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.6</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageEffectiveTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.3</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageEffectiveTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">As a global biopharmaceutical company, we have a substantial business and employment presence in many countries around the world. The impact of differences in overseas taxation rates arose from profits being earned in countries with tax rates higher than the UK statutory rate, the most significant of which in 2022 were the US, Belgium, Germany and Japan. This adverse impact was offset by the benefit of intellectual property incentives such as the UK Patent Box and Belgian Innovation Income Deduction regimes, which provide a reduced rate of corporation tax on profits earned from qualifying patents. We claim these incentives in the manner intended by the relevant statutory or regulatory framework. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In 2021, &#8216;Changes in tax rates&#8217; included credits in relation to the enactment of the increase in the headline rate of UK corporate income tax from <ix:nonFraction name="gsk:HeadlineUkTaxRateEffective2023" contextRef="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">19</ix:nonFraction>% to <ix:nonFraction name="gsk:HeadlineUkTaxRateEffective2023" contextRef="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% (effective 2023). In 2020, &#8216;Changes in tax rates&#8217; included credits in relation to the UK, where a reduction in the corporate income tax rate from <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_ReducedTaxRateCancelledMemberGSKEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">19</ix:nonFraction>% to <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">17</ix:nonFraction>% was cancelled, and India, where the tax treatment of dividends changed with effect from 1&#160;April 2020. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Permanent differences on disposals, acquisitions and transfers in 2022 includes tax on internal restructuring to simplify the group structure. The tax credit in 2020 reflected the tax impact of the disposal of Horlicks and other Consumer Healthcare brands to, and subsequent disposal of shares received in, Hindustan Unilever. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group&#8217;s 2022 tax rate has also been influenced by updates to estimates of prior period tax liabilities following closure of open issues with tax authorities in various jurisdictions. </div> <ix:continuation id="TextSelection_69049959"> <div style="font-size: 50pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/>&#160; &#160; &#160;&#160;</div></div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">204</div></div></td> </tr> </table> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14. Taxation </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:continuation id="TextSelection_69049954" continuedAt="TextSelectionAppend_69049954_1"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Future tax charges, and therefore our effective tax rate, may be affected by factors such as acquisitions, disposals, restructurings, the location of research and development activity, tax regime reforms and resolution of open matters as we continue to bring our tax affairs up to date around the world. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK Government has confirmed that the Spring Finance Bill 2023 will include legislation introducing a <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% global minimum corporate income tax rate, to have effect from 2024 in line with the OECD&#8217;s Pillar Two model framework. The detail of the measures and how they are to be accounted for is still being finalised and so it is not possible to accurately quantify the impact for GSK at this stage. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Tax on items charged to equity and statement of comprehensive income</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">167</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">277</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total credit to equity and statement of comprehensive income</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">268</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All of the above items have been charged to the statement of comprehensive income except for tax on share-based payments. </div> <div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issues relating to taxation </div></div></div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The integrated nature of the Group&#8217;s worldwide operations involves significant investment in research and strategic manufacture at a limited number of locations, with consequential cross-border supply routes into numerous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-markets.</div> In line with current OECD guidelines, we base our transfer pricing policy on the arm&#8217;s length principle and support our transfer prices with economic analysis and reports. However, different tax authorities may seek to attribute further profit to activities being undertaken in their jurisdiction potentially resulting in double taxation. The Group also has open items in several jurisdictions concerning such matters as the deductibility of particular expenses and the tax treatment of certain business transactions. GSK applies a risk based approach to determine the transactions most likely to be subject to challenge and the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The calculation of the Group&#8217;s total tax charge therefore necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. At 31&#160;December 2022 the Group had recognised provisions of &#163;<ix:nonFraction name="gsk:ProvisionsForUncertainTaxPosition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">551</ix:nonFraction>&#160;million in respect of such uncertain tax positions (2021: &#163;<ix:nonFraction name="gsk:ProvisionsForUncertainTaxPosition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">858</ix:nonFraction> million). The net decrease in recognised provisions during 2022 was driven by the reassessment of estimates, the agreement of a number of open issues with tax authorities in various jurisdictions and amounts related to discontinued operations. Whilst the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with the relevant tax authorities, or litigation where appropriate, the Group continues to consider that it has made appropriate provision for periods which are open and not yet agreed by the tax authorities. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A provision for deferred tax liabilities of &#163;<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">157</ix:nonFraction>&#160;million as at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction> million) has been made in respect of taxation that would be payable on the remittance of profits by certain overseas subsidiaries. Whilst the aggregate amount of unremitted profits at the balance sheet date was approximately &#163;<ix:nonFraction name="gsk:UnremittedEarnings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-9" scale="9" format="ixt:num-dot-decimal">16</ix:nonFraction>&#160;billion (2021: &#163;<ix:nonFraction name="gsk:UnremittedEarnings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-9" scale="9" format="ixt:num-dot-decimal">15</ix:nonFraction> billion), the majority of these unremitted profits would not be subject to tax (including withholding tax) on repatriation, as UK legislation relating to company distributions provides for exemption from tax for most overseas profits, subject to certain exceptions. Deferred tax is not provided on temporary differences of &#163;<ix:nonFraction name="gsk:UnremittedProfitsForWhichDeferredTaxNotProvided" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">660</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:UnremittedProfitsForWhichDeferredTaxNotProvided" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">831</ix:nonFraction> million) arising on unremitted profits as management has the ability to control any future reversal and does not consider such a reversal to be probable. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">205</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14. Taxation </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="gsk:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049728"></ix:nonNumeric><ix:continuation id="TextSelectionAppend_69049954_1"><ix:continuation id="TextSelection_69049728"><div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Movement in deferred tax assets and liabilities </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Accelerated<br/> capital<br/> allowances<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/> assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Contingent</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">consideration<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Intra-Group</div><br/> profit</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Pensions&#160;&amp;<br/> other post<br/> employment<br/> benefits</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax<br/> losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> option<br/> and&#160;award<br/> schemes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">net<br/> temporary<br/> differences<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,024</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">312</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Acquisitions/Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">640</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Acquisitions/Disposals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">637</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer of assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">819</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">992</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,099</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,661</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,642</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,369</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax liabilities in relation to intangible assets predominately relate to temporary differences arising as a result of historic business combinations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group continues to recognise deferred tax assets on future obligations in respect of contingent consideration amounts payable to minority shareholders. These payments are tax deductible at the point in time at which payment is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A deferred tax asset is recognised on intra-Group profits arising on inter-company inventory which are eliminated within the consolidated accounts. As intra-Group profits are not eliminated from the individual entities&#8217; tax returns a temporary difference arises that will reverse at the point in time inventory is sold externally. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The deferred tax asset recognised on tax losses of &#163;<ix:nonFraction name="gsk:DeferredTaxAssetsRecognizedOnTradingLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,661</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:DeferredTaxAssetsRecognizedOnTradingLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,450</ix:nonFraction> million) relates to trading losses. Such deferred tax assets are recognised where it is probable that future taxable profit will be available to utilise losses, as supported by long-range product level forecasts. Current forecasts indicate the assets will be utilised by around 2030. Other net temporary differences included accrued expenses for which a tax deduction is only available on a paid basis. </div><ix:nonNumeric name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are recognised on the balance sheet as follows:</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,658</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">289</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,556</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,369</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,662</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrecognised tax losses</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax&#160;losses<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Unrecognised<br/> deferred tax<br/> asset</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax&#160;losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Unrecognised<br/> deferred tax<br/> asset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trading losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Within 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">967</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">175</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">390</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,203</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TaxLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,658</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnTradingLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">303</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capital losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CapitalLosses" contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,326</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses" contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">548</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalLosses" contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,356</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses" contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CapitalLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,326</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">548</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,356</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">557</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets are only recognised where it is probable that future taxable profit will be available to utilise losses. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">206</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">15. Earnings per share </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:EarningsPerShareExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> pence</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">110.8</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">122.4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">260.6</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">26.7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">22.0</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total basic earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">371.4</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">109.6</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">144.4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">109.2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">81.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">120.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">257.0</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">26.4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total diluted earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">366.2</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">108.2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="3" scale="-2" format="ixt:num-dot-decimal">142.6</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37).</div></td></tr></table></ix:nonNumeric><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Basic earnings per share has been calculated by dividing the profit attributable to shareholders by the weighted average number of shares in issue during the period after deducting shares held by the ESOP Trusts and Treasury shares. The trustees have waived their rights to cash dividends on the GSK shares held by the ESOP Trusts. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Diluted earnings per share has been calculated after adjusting the weighted average number of shares used in the basic calculation to assume the conversion of all potentially dilutive shares. A potentially dilutive share forms part of the employee share schemes where its exercise price is below the average market price of GSK shares during the period and any performance conditions attaching to the scheme have been met at the balance sheet date. </div><ix:nonNumeric name="gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted average number of shares in issue</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> millions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,026</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dilution for share options and awards</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,084</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,052</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,030</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Restated to reflect the impact share consolidation (see <div style="display:inline;"><div style="display:inline;">N</div>ote</div> 37). </div></td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfDividendsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">16. Dividends </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfInterimDividendExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:19%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paid/payable</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">First interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">1 July 2022</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">17.50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">704</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">8 July 2021</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">9 July 2020</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Second interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">6 October 2022</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">16.25</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">654</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">7 October 2021</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">8 October 2020</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">12 January 2023</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">13.75</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">555</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">13 January 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">14 January 2021</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">23.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fourth interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">13 April 2023</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">13.75</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">555</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">7 April 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">28.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonNumeric name="gsk:DividendsPaidDate" contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis" format="ixt:date-day-monthname-year-en">8 April 2021</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">28.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP_per_Share" decimals="4" scale="-2" format="ixt:num-dot-decimal">61.25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,468</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP_per_Share" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,011</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinarySharesPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP_per_Share" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DividendsPaidOrdinaryShares" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,989</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The estimate for the fourth interim dividend for 2021 disclosed in the 2021 annual report was &#163;<ix:nonFraction name="ifrs-full:CurrentDividendPayables" contextRef="PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,152</ix:nonFraction>&#160;million, &#163;<ix:nonFraction name="gsk:AdditionalProvisionForDividendPayable" contextRef="P10_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;million less than the dividend that was ultimately paid. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">&#160;Dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. See details in Note 37. </div></td></tr></table></ix:nonNumeric><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="gsk:DescriptionOfInterimDividendRecognitonAndPayment" contextRef="P01_01_2022To12_31_2022">Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2022 financial statements recognise those dividends paid in 2022, namely the third and fourth interim dividends for 2021, and the first and second interim dividends for 2022.</ix:nonNumeric> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The demerger of the Consumer Healthcare business was effected by GSK declaring an interim dividend in specie of Haleon plc shares. The fair value of the distribution was &#163;<ix:nonFraction name="gsk:FairValueOfAssetdistributedAsDividendInSpecie" contextRef="P01_01_2022To12_31_2022_DemergerOfConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,526</ix:nonFraction>&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="gsk:DisclosureOfDividendsPaidExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049775">The amounts recognised in each year were as follows:</ix:nonNumeric></div><ix:continuation id="TextSelection_69049775"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash dividends to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashDividendsPaidToShareholdersRecognizedInYear" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,467</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashDividendsPaidToShareholdersRecognizedInYear" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashDividendsPaidToShareholdersRecognizedInYear" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends in specie to shareholders in Haleon plc shares (Note 41)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,526</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DividendsRecognisedInYear" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,993</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendsRecognisedInYear" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,999</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendsRecognisedInYear" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,977</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">207</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049960"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">17. Property, plant and equipment </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Plant,<br/> equipment<br/> and&#160;vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Assets in<br/> construction<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,488</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,483</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">576</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,205</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,174</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">906</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">74</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,212</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,778</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,050</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,153</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,245</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">291</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,067</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,959</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,343</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,648</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,953</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,850</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,451</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,450</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">291</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">982</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,062</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,025</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">501</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">952</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">228</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#f4f1f0">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">376</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,130</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#f4f1f0">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,506</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,275</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,469</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,744</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">857</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">112</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">821</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">472</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">774</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,846</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,535</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,941</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,518</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,898</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,414</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,864</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,176</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,667</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,558</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,707</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,932</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,113</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,012</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,808</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,933</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">208</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17. Property, plant and equipment </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:continuation id="TextSelection_69049960"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><br/></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate for capitalised borrowing costs in the year was <ix:nonFraction name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% (2021: <ix:nonFraction name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%). Disposals and write-offs in the year included a number of assets with nil net book value that are no longer in use in the business. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The impairment losses principally arose from decisions to rationalise facilities and were calculated based on fair value less costs of disposal. The fair value less costs of disposal valuation methodology uses significant inputs which are not based on observable market data, and therefore this valuation technique is classified as level 3 of the fair value hierarchy. These calculations determine the net present value of the projected risk-adjusted, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows of the relevant asset or cash generating unit, applying a discount rate of the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> weighted average cost of capital (WACC) of <ix:nonFraction name="gsk:WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>%, adjusted where appropriate for specific segment, country and currency risk. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Assets that continue to be used by the Group are generally assessed as part of their associated cash generating unit on a value in use basis. For value in use calculations, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows do not include the impact of future uncommitted restructuring plans or improvements. Where an impairment is indicated and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> cash flow calculation is expected to give a materially different result, the test would be reperformed using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> cash flows and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate. The Group WACC is equivalent to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate of approximately <ix:nonFraction name="gsk:WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">9</ix:nonFraction>%. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The net impairment losses have been charged to cost of sales: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction> million), R&amp;D: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction> million) and SG&amp;A: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction> million), and included &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction> million) arising from the Major restructuring programmes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Reversals of impairment arose from subsequent reviews of the impaired assets where the conditions which gave rise to the original impairments were deemed no longer to apply. All of the reversals have been credited to cost of sales. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction> million) of computer software was reclassified from assets in construction to intangible assets on becoming ready for use. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">18. Right of use assets </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Plant and<br/> equipment<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2020_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">830</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">215</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">213</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">70</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">633</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">740</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RightOfUseAssetsExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherAdditionsToRightOfUseAssets" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherAdditionsToRightOfUseAssets" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherAdditionsToRightOfUseAssets" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherAdditionsToRightOfUseAssets" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetDisposal" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:RightOfUseAssetImpairments" contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">687</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> </ix:nonNumeric> <div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has entered into some commitments for lease contracts that have not yet commenced. See Note 36. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An analysis of lease liabilities is set out in Note 30, &#8216;Net debt&#8217;. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">19. Goodwill </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations (Note 41)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionalRecognitionGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other movements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,183</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,046</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,597</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,046</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="gsk:DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All Goodwill is allocated to the Group&#8217;s segments as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:89.5%;border:0">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,148</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total R&amp;D</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">898</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,046</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2021, prior to changes in the Group&#8217;s segment reporting (Note 6) Goodwill was allocated as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pharmaceuticals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,060</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,552</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill of &#163;<ix:nonFraction name="ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,183</ix:nonFraction>&#160;million allocated to Consumer Healthcare was transferred to &#8216;assets held for sale/distribution&#8217; prior to the Consumer Healthcare demerger (Note 41). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" contextRef="P01_01_2022To12_31_2022">The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of disposal is calculated using a discounted cash flow approach, with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> discount rate applied to the projected risk-adjusted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows and terminal value.</ix:nonNumeric> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount rate used is based on the Group WACC of <ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% (2021: <ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.5</ix:nonFraction>%), as most cash generating units have integrated operations across large parts of the Group. The discount rate is adjusted where appropriate for specific segment, country and currency risks. The valuation methodology uses significant inputs which are not based on observable market data, therefore this valuation technique is classified as level 3 in the fair value hierarchy.</div> <div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The R&amp;D segment is evaluated on an arms length pricing model, see assumptions below.</div></div><br/></div><ix:nonNumeric name="ifrs-full:DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049977"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8.5pt;;display:inline;">Details relating to the discounted cash flow models used in the impairment tests are as follows:</div></div></ix:nonNumeric></div> <ix:continuation id="TextSelection_69049977"><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:21%"></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Valuation basis</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><ix:nonNumeric name="ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" contextRef="P01_01_2022To12_31_2022">Fair value less costs of disposal</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Key assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <ix:nonNumeric name="ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" contextRef="P01_01_2022To12_31_2022"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Sales growth rates</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Profit margins</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rate</div></ix:nonNumeric> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Determination of assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <ix:nonNumeric name="ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" contextRef="P01_01_2022To12_31_2022"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Growth rates are internal forecasts based on both internal and external market information.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Margins reflect past experience, adjusted for expected changes.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rates based on management&#8217;s estimate of future long-term average growth rates.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rates based on Group WACC, adjusted where appropriate.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rates based on appropriate rates for each jurisdiction.</div></ix:nonNumeric> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Period of specific projected cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><ix:nonNumeric name="ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" contextRef="P01_01_2022To12_31_2022">Five years</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate and discount rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Terminal growth rate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Discount&#160;rate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Commercial operations</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">R&amp;D</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Vaccines</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Consumer Healthcare</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% p.a.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr></table></ix:continuation> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The terminal growth rate does not exceed the long-term projected growth rates for relevant markets, reflects the impact of future generic competition and take account of new product launches. Goodwill is monitored for impairment at the segmental level and the valuations indicated sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment of the related goodwill. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">210</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049961"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">20. Other intangible assets </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer<br/> software</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Licences,<br/> patents,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;amortised<br/> brands etc.</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Indefinite&#160;life</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">brands</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,838</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">157</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">346</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,410</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,594</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">935</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,156</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,439</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">42,489</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">934</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,109</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CapitalisedDevelopmentCosts" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">317</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,964</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,964</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">775</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">236</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19,772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20,781</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,959</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,717</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,676</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,932</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,254</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">956</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,181</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">737</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">307</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">340</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">931</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,135</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">554</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,223</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9,181</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,404</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,760</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">362</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">455</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">362</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,779</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">141</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">402</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">270</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">81</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,873</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,954</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,742</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12,410</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,304</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12,054</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13,358</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,053</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,403</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,368</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,824</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">964</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,697</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,418</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30,079</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value at 31&#160;December 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">655</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,663</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,318</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The weighted average interest rate for capitalised borrowing costs in the year was <ix:nonFraction name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% (2021: <ix:nonFraction name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The net book value of computer software included &#163;<ix:nonFraction name="ifrs-full:ComputerSoftware" contextRef="PAsOn12_31_2022_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">479</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ComputerSoftware" contextRef="PAsOn12_31_2021_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">526</ix:nonFraction> million) of internally generated costs. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The carrying value at 31&#160;December 2022 of intangible assets, for which impairments have been charged in the year following those impairments, was &#163;<ix:nonFraction name="gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">694</ix:nonFraction> million). The carrying value at 31&#160;December 2022 of intangible assets, for which impairment reversals have been charged in the year following those impairment reversals, was &#163;<ix:nonFraction name="gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">776</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">104</ix:nonFraction> million). No individual intangible asset accounted for a material impairment. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The patent expiry dates of the Group&#8217;s most significant assets, where relevant, are set out on pages 282 to 284. Please refer to Note 2 to the Group&#8217;s accounting policy and estimate of the useful life for intangible assets over the exclusivity and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity</div> periods. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">211</div></div></td></tr></table> </div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20. Other intangible assets </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049804"></ix:nonNumeric><ix:continuation id="TextSelection_69049961"><ix:continuation id="TextSelection_69049804"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortisation</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;impairment&#160;losses</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a) </div>&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">663</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">116</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">66</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">307</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">299</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">373</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,086</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:AmortisationOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,088</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">367</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><ix:nonFraction name="gsk:NetImpairmentLossesOtherIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">438</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table></ix:continuation><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Licences, patents, amortised brands etc. includes a large number of acquired licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> agreements and marketing rights, which are either marketed or in use, or still in development. Note 41, &#8216;Acquisitions and disposals&#8217; gives details of additions through business combinations in the year. <ix:nonNumeric name="gsk:DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049962">The book values of the largest individual items are as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_69049962"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tesaro Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,858</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis portfolio</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,855</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,889</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Momelotinib</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MomelotinibMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,499</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AffinivaxAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,473</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,150</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">541</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Alector Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">509</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">509</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">iTeos Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">444</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">288</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">268</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Okairos</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">202</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">BMS Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Spero</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_SperoMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vir Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">159</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/FluLaval</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">147</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Stiefel trade name</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">142</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CureVac Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lamisil<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,932</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,797</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,663</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,697</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Disposed of as part of the Consumer Healthcare demerger (Note 41). </div></td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;July 2022, GSK completed the acquisition of Sierra Oncology Inc, The main asset is momelotinib. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 15&#160;August 2022, GSK completed the acquisition of Affinivax, Inc. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Indefinite life brands related to healthcare brands used within the Consumer Healthcare business. Indefinite life brands were disposed of as part of the Consumer Healthcare demerger (Note 41). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group do not consider that any reasonably possible changes in the key assumptions would cause the recoverable amount of the Intangible assets disclosed above to fall below their carrying values. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">212</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">21. Investments in associates and <div style="letter-spacing: 0px; top: 0px;;display:inline;">joint</div> ventures </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2020_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">349</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">364</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AdditionsInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AdditionsInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdditionsInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AdditionsInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AdditionsInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DisposalsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DisposalsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">278</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DisposalsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">278</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of interest in associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit/(loss) after tax recognised in the consolidated income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">64</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric> <div style="margin-block: 0em;"></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 20&#160;May 2021, the Group agreed with Innoviva Inc to sell all of its shares in Innoviva back to Innoviva for &#163;<ix:nonFraction name="gsk:DisposalOfInterestInAssociate" contextRef="P05_20_2021To05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">277</ix:nonFraction>&#160;million. Following settlement of the transaction, GSK <ix:nonFraction name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" contextRef="PAsOn05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>longer held any Innoviva stock. A loss of &#163;<ix:nonFraction name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction>&#160;million (including &#163;<ix:nonFraction name="gsk:RecyclingOfExchangeDifferencesInAssociate" contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million of recycling of exchange differences in Innoviva) is presented in Loss on disposal of interest in associates in the 2021 Consolidated income statement. The transaction did not include any changes in Innoviva&#8217;s commercial interest in royalties paid by GSK. Loss on disposal of interest in associates in 2021 also includes a &#163;<ix:nonFraction name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" contextRef="P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million gain from a disposal of another immaterial associate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Please refer to the Income statement information on associates and joint ventures in Note 13. </div></ix:nonNumeric> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfCurrentEquityInvestmentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">22. Current equity investments </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"></div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2021_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PurchasesFairValueMeasurementAssets" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,852</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" contextRef="PAsOn12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,087</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments represent Haleon <div style="letter-spacing: 0px; top: 0px;;display:inline;">plc</div> shares held after the demerger of Consumer Healthcare. Shares are held for trading and measured at fair value through profit or loss (FVTPL) based on the Haleon plc share price. Changes in fair value after the demerger are presented as Other operating income/expense in continuing operations. The Group&#8217;s investment in Haleon plc at the end of December 2022 is held by Glaxo Group Limited (<ix:nonFraction name="gsk:PercentageOfOwnership" contextRef="P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.4</ix:nonFraction>%), Scottish Limited Partnerships (SLPs) which were set up to collateralise agreed additional funding for GSK&#8217;s UK Defined Benefit pension schemes (<ix:nonFraction name="gsk:PercentageOfOwnership" contextRef="P01_01_2022To12_31_2022_InvestmentInHaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>%) (Note 31) and the ESOP Trusts (<ix:nonFraction name="gsk:PercentageOfOwnership" contextRef="P01_01_2022To12_31_2022_EsopTrustsMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.6</ix:nonFraction>%). Net fair value movement through profit or loss of &#163;<ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction>&#160;million includes a fair value gain of &#163;<ix:nonFraction name="gsk:FairValueGainThroughProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction>&#160;million and &#163;<ix:nonFraction name="gsk:OtherAdjustmentsOfFairValueMeasurementAssets" contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;million of other adjustments. </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div>
<img alt="LOGO" src="g382677f_167.jpg"/> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">213</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">23. Other investments </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,126</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2020_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2020_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2020_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdditionsToOtherInvestments" contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">716</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">902</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">902</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments" contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments" contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsOtherInvestments" contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsOtherInvestments" contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsOtherInvestments" contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsOtherInvestments" contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,153</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,467</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" contextRef="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,126</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Non-current other investments comprise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> equity investments which are recorded at fair value at each balance sheet date. For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price. For other investments, the fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments, recent financing rounds and discounted cash flows of the underlying net assets. Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net fair value movements include the impact of other exchange gains of &#163;<ix:nonFraction name="gsk:AdjustmentsForForeignExchangeOtherInvestments" contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">134</ix:nonFraction>&#160;million through Other comprehensive income and &#163;<ix:nonFraction name="gsk:AdjustmentsForForeignExchangeOtherInvestments" contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil through profit or loss (2021: gains of &#163;<ix:nonFraction name="gsk:AdjustmentsForForeignExchangeOtherInvestments" contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million through Other comprehensive income and &#163;<ix:nonFraction name="gsk:AdjustmentsForForeignExchangeOtherInvestments" contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million through profit or loss). Other investments include listed investments of &#163;<ix:nonFraction name="gsk:ListedInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">823</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:ListedInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,736</ix:nonFraction> million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has elected to designate the majority of its equity investments as measured at fair value through Other comprehensive income (FVTOCI). The most significant of these investments held at 31&#160;December 2022 were in Vir Biotechnology, Inc. which had a fair value at 31&#160;December 2022 of &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2022_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2021_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">266</ix:nonFraction> million) and Nimbus Therapeutics, LLC which had a fair value at 31&#160;December 2022 of &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2022_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">139</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2021_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction> million). The fair value of the investment in CureVac N.V., disclosed as a significant investment at 31&#160;December 2021, was &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2022_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="gsk:InvestmentFairValue" contextRef="PAsOn12_31_2021_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">380</ix:nonFraction> million). The other investments include equity stakes in companies with which GSK has research collaborations and in companies which provide access to biotechnology developments of potential interest. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On disposal of equity investments measured at FVTOCI, the accumulated fair value movements are reclassified from the fair value reserve to retained earnings. Investments measured at FVTOCI with a fair value of &#163;<ix:nonFraction name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" contextRef="PAsOn12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" contextRef="PAsOn12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction> million) were disposed of during the year. The cumulative gain on these investments after tax was &#163;<ix:nonFraction name="ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction> million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain other investments, such as investments in funds with limited lives and investments acquired with an intention to sell, are measured at fair value through profit or loss (FVTPL). </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">214</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">24. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div> <ix:nonNumeric name="gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts receivable under insurance contracts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesRelatedToInsuranceContracts" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">857</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="gsk:ReceivablesRelatedToInsuranceContracts" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">108</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,194</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,676</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amounts receivable under insurance contracts are held at cash surrender value with movements through profit or loss. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the other receivables of &#163;<ix:nonFraction name="ifrs-full:OtherNoncurrentReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">108</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:OtherNoncurrentReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction> million), &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction> million) is classified as financial assets of which &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction> million) is classified as fair value through profit or loss. On the remaining balance of &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction> million), the expected credit loss allowance was immaterial at 31&#160;December 2022 and 2021. </div></ix:nonNumeric> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfInventoriesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">25. Inventories </div></div> <ix:nonNumeric name="gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Raw materials and consumables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RawMaterialsAndConsumablesUsed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,576</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RawMaterialsAndConsumablesUsed" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:WorkInProgress" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,286</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WorkInProgress" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,889</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinishedGoods" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,284</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinishedGoods" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Inventories" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,146</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Inventories" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,783</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric></ix:nonNumeric> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfTradesAndOtherReceivableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">26. Trade and other receivables </div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade receivables, net of loss allowance</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,452</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,246</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accrued income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AccruedIncomeOtherThanContractAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AccruedIncomeOtherThanContractAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prepayments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest receivable</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestReceivable" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestReceivable" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee loans and advances</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:EmployeeLoansAndAdvances" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EmployeeLoansAndAdvances" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,226</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,053</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,860</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no trade or other receivable balances (2021: &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction>) due from associates and joint ventures. The most significant component of other receivables comprises receivables for taxes other than corporate income tax. Other significant balances within other receivables are royalties receivable and amounts receivable from collaboration partners. </div> <ix:nonNumeric name="ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss allowance - trade receivables</div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExpectedCreditLossAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpectedCreditLossAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExpectedCreditLossAllowanceExchangeAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceExchangeAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInExpectedCreditLossesAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInExpectedCreditLossesAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Subsequent recoveries of amounts provided for</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceUtilised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceUtilised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExpectedCreditLossAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpectedCreditLossAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the total trade receivables balance, &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction> million) is considered credit impaired, against which a &#163;<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction> million) expected credit loss allowance has been applied. No amount was purchased or originated credit impaired. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the other receivables of &#163;<ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,226</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,266</ix:nonFraction> million), &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">683</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">553</ix:nonFraction> million) is classified as financial assets of which &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction> (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>) is classified as held at fair value through profit or loss. At 31&#160;December 2022 an expected credit loss allowance of &#163;<ix:nonFraction name="ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction> million) was recognised in respect of financial assets with no charge reported in profit or loss during the year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For more discussion on credit risk practices, please refer to Note 44. </div></ix:nonNumeric><br/> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/><br/></div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="font-weight:bold;display:inline;">215</div></td> </tr> </table> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049529"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">27. Cash and cash equivalents </div></div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash at bank and in hand</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">879</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term deposits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,844</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,847</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,723</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,274</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:continuation id="TextSelection_69049529">During 2022 &#163;<ix:nonFraction name="ifrs-full:AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,421</ix:nonFraction>&#160;million was transferred to assets held for sale relating to the Consumer Healthcare business that was demerged during the year (see Note 41). Cash and cash equivalents included &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;billion (2021: &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.2</ix:nonFraction> billion) not available for general use due to restrictions applying in the subsidiaries where it is held. Restrictions include exchange controls and taxes on repatriation.</ix:continuation> </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049538"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">28. Assets held for sale </div></div><ix:nonNumeric name="gsk:DisclosureOfAssetsHeldForSaleExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherAssetsNet" contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" contextRef="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets and disposal groups are transferred to assets held for sale when it is expected that their carrying amounts will be recovered principally through disposal and a sale is considered highly probable. They are held at the lower of carrying amount and fair value less costs to sell. </div></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:continuation id="TextSelection_69049538">In Q2 2022, the Consumer Healthcare business was classified as held for sale. Following completion of the demerger of the Consumer Healthcare business in Q3 2022, a total of &#163;<ix:nonFraction name="gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" contextRef="P01_01_2022To09_30_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">12.9</ix:nonFraction>&#160;billion of net assets and liabilities were distributed/derecognised as part of the gain on the demerger.</ix:continuation> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">29. Trade and other payables </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric name="gsk:SummaryOfTradePayablesExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050727">&#160;</ix:nonNumeric></div><ix:continuation id="TextSelection_69050727">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,866</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WagesAndSalariesPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,488</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WagesAndSalariesPayable" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,470</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare put option</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PutOptionPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,093</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PutOptionPayable" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">418</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">299</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContractLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">307</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Customer return and rebate accruals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CustomerReturnAndRebateAccruals" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,627</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CustomerReturnAndRebateAccruals" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other accruals</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherAccruals" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,346</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherAccruals" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,242</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,263</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,554</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other payables included &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction> (2021: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>) due to associates and joint ventures. The Group provides limited supplier financing arrangements to certain customers. The amounts involved at 31&#160;December 2022 were not material. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Revenue recognised in the year that was included in deferred income at 1&#160;January 2022 was &#163;<ix:nonFraction name="ifrs-full:RevenueAndOperatingIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:RevenueAndOperatingIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Customer return and rebate accruals are provided for by the Group at the point of sale in respect of estimated rebates, discounts or allowances payable to customers as more fully described in the Group financial review on page 94. At 31&#160;December 2022, Customer return and rebate accruals included &#163;<ix:nonFraction name="gsk:CustomerReturnAndRebateAccruals" contextRef="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,717</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CustomerReturnAndRebateAccruals" contextRef="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,044</ix:nonFraction> million) in respect of US Commercial Operations. Accruals are made at the time of sale but the actual amounts paid are based on claims made some time after the initial recognition of the sale. As the amounts are estimated, they may not fully reflect the final outcome and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The level of accrual is reviewed and adjusted quarterly in light of historical experience of actual amounts paid and any changes in arrangements. Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pfizer&#8217;s put option over its shareholding in ViiV Healthcare is currently exercisable. Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. The amount of the liability for this put option, which is held on the gross redemption basis, is derived from an internal valuation of the ViiV Healthcare business, utilising both discounted forecast future cash flow and multiples-based methodologies. </div><ix:nonNumeric name="gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:top"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability and loss/(gain) in Income statement</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecast*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">149</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" contextRef="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" contextRef="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">66</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">103</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInFinancialLiability" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">* The sales forecast is for ViiV Healthcare sales only in respect of the ViiV Healthcare put option. </div></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other accruals includes interest accrued on financial liabilities at amortised cost of &#163;<ix:nonFraction name="gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">207</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">244</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An explanation of the accounting for ViiV Healthcare is set out on page 71. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">217</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #ec660a">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfBorrowingsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049670"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">30. Net debt </div></div><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049573"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:43%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Listing exchange</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:LiquidInvestmentsCurrent" contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:LiquidInvestmentsCurrent" contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,723</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,274</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,790</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,335</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,191</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank loans, overdrafts and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BankLoansoverdraftsAndOther" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">448</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BankLoansoverdraftsAndOther" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.850% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,483</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.875% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,113</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">665</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,038</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">167</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,952</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,601</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.800% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">926</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">629</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">925</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">420</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">926</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% US$ US Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">829</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">739</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">884</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">836</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">663</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">627</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.625% US$ US Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">827</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">738</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">620</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">587</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">885</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">838</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">442</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% &#163; Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">595</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.875% US$ US Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,450</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,294</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% &#163; Euro Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">744</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">743</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">822</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">733</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">441</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">418</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.750% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2030</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">663</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">628</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">616</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2033<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">640</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">984</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.375% US$ US Medium Term Note 2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">412</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">368</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.625% &#163; Euro Medium Term Note 2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">744</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">744</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% US$ US Medium Term Note 2038</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,264</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,022</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% &#163; Euro Medium Term Note 2039<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">695</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">695</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2042</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">472</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">987</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.200% US$ US Medium Term Note 2043</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">408</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">364</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.250% &#163; Euro Medium Term Note 2045</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">366</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">789</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other long-term borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">841</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">812</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,035</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,572</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,197</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Partially purchased and cancelled on 13&#160;February 2023. </div></td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:continuation id="TextSelection_69049573"> </ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom: 7pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div>
<img alt="LOGO" src="g382677dsp001b.jpg"/> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">218</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30. Net debt </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelection_69049670"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Liquid investments are classified as financial assets at amortised cost. At 31&#160;December 2022, they included US Treasury Notes and other government bonds. The effective interest rate on liquid investments at 31&#160;December 2022 was approximately <ix:nonFraction name="gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction>% (2021: approximately <ix:nonFraction name="gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction>%). Liquid investment balances at 31&#160;December 2022 earning interest at floating rates amount to &#163;<ix:nonFraction name="gsk:LiquidInvestments" contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:LiquidInvestments" contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction> million). Liquid investment balances at 31&#160;December 2022 earning interest at fixed rates amount to &#163;<ix:nonFraction name="gsk:LiquidInvestments" contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" xsi:nil="true"></ix:nonFraction>nil (2021: &#163;<ix:nonFraction name="gsk:LiquidInvestments" contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Balances reported within cash and cash equivalents have an original maturity of three months or less. The effective interest rate on cash and cash equivalents at 31&#160;December 2022 was approximately <ix:nonFraction name="gsk:EffectiveInterestRateOnCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.1</ix:nonFraction>% (2021: approximately <ix:nonFraction name="gsk:EffectiveInterestRateOnCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.6</ix:nonFraction>%). Cash and cash equivalents at 31&#160;December 2022 earning interest at floating and fixed rates amounted to &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,441</ix:nonFraction>&#160;million and &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million respectively (2021: &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,906</ix:nonFraction>&#160;million and &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction> million) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing holdings amounted to &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2022_NonInterestBearingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">272</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn12_31_2021_NonInterestBearingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">329</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s policy regarding the credit quality of cash and cash equivalents is set out in Note 44, &#8216;Financial instruments and related disclosures&#8217;. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Short-term borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">GSK has a $<ix:nonFraction name="gsk:CommercialPaperAuthorized" contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" decimals="INF" scale="9" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:CommercialPaperAuthorized" contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">8.3</ix:nonFraction> billion) US commercial paper programme, of which $<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction> million) was in issue at 31&#160;December 2022 (2021: $<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2021_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>nil). GSK has a &#163;<ix:nonFraction name="gsk:CommercialPaperAuthorized" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-9" scale="9" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;billion Euro commercial paper programme, of which <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction> million) was in issue at 31&#160;December 2022 (2021: <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">300</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction> million)). In February 2022 GSK cancelled the &#163;<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;billion three year and $<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.1</ix:nonFraction> billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities in September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#163;<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.6</ix:nonFraction>&#160;billion and $<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.8</ix:nonFraction> billion) respectively. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate on commercial paper borrowings at 31&#160;December 2022 was <ix:nonFraction name="gsk:WeightedAverageInterestRateOnBorrowings" contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:WeightedAverageInterestRateOnBorrowings" contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.5</ix:nonFraction></ix:nonFraction>% (2021: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-<ix:nonFraction name="gsk:WeightedAverageInterestRateOnBorrowings" contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:WeightedAverageInterestRateOnBorrowings" contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction>%).</div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate on current bank loans and overdrafts at 31&#160;December 2022 was <ix:nonFraction name="gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.8</ix:nonFraction></ix:nonFraction>% (2021: <ix:nonFraction name="gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.9</ix:nonFraction></ix:nonFraction>%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-swap</div> interest rate of notes classified as short-term at 31&#160;December 2022 was <ix:nonFraction name="gsk:AverageEffectivePreSwapInterestRateShortTerm" contextRef="PAsOn12_31_2022_ShortTermNotesMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.4</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:AverageEffectivePreSwapInterestRateShortTerm" contextRef="PAsOn12_31_2021_ShortTermNotesMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>%). </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-term borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end,</div> GSK had long-term borrowings of &#163;<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">17.0</ix:nonFraction>&#160;billion (2021: &#163;<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">20.6</ix:nonFraction> billion), of which &#163;<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">11.1</ix:nonFraction>&#160;billion (2021: &#163;<ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">11.7</ix:nonFraction> billion) fell due in more than five years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, three bonds were repaid earlier than original maturity, those being the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">2.800</ix:nonFraction>% US$ US Medium Term Note 2023, the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">3.375</ix:nonFraction>% US$ US Medium Term Note 2023 and the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.000</ix:nonFraction>% US$ US Medium Term Note 2023. Also, during 2022 GSK undertook a tender on outstanding Sterling Notes, repaying face values of &#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">292</ix:nonFraction>&#160;million on the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">3.375</ix:nonFraction>% &#163; Euro Medium Term Note 2027, &#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million on the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">5.250</ix:nonFraction>% &#163; Euro Medium Term Note 2033, &#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">522</ix:nonFraction>&#160;million on the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">5.250</ix:nonFraction>% &#163; Euro Medium Term Note 2042 and &#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">429</ix:nonFraction>&#160;million on the <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">4.250</ix:nonFraction>% &#163; Euro Medium Term Note 2045. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-swap</div> interest rate of all notes in issue at 31&#160;December 2022 was approximately <ix:nonFraction name="gsk:AverageEffectivePreSwapInterestRateNotesIssued" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.5</ix:nonFraction>% (2021: approximately <ix:nonFraction name="gsk:AverageEffectivePreSwapInterestRateNotesIssued" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.3</ix:nonFraction>%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Long-term borrowings repayable after five years carry interest at effective rates between <ix:nonFraction name="gsk:CarryInterestAtEffectiveRates" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.4</ix:nonFraction>% and <ix:nonFraction name="gsk:CarryInterestAtEffectiveRates" contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.4</ix:nonFraction>%, with repayment dates ranging from <ix:nonNumeric name="gsk:RepaymentYear" contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis">2027</ix:nonNumeric>&#160;to <ix:nonNumeric name="gsk:RepaymentYear" contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis">2045</ix:nonNumeric>. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Both effective rates exclude the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> premiums associated with the early repayment of the Sterling Notes. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pledged assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group held pledged investments in US Treasury Notes with a par value of $<ix:nonFraction name="gsk:PledgedInvestments" contextRef="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="gsk:PledgedInvestments" contextRef="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction> million), (2021: $<ix:nonFraction name="gsk:PledgedInvestments" contextRef="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="gsk:PledgedInvestments" contextRef="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">42</ix:nonFraction> million)) as security against irrevocable letters of credit issued on the Group&#8217;s behalf in respect of the Group&#8217;s self-insurance activity. Provisions in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 32, &#8216;Other provisions&#8217;. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease liabilities </div></div></div></div><ix:nonNumeric name="gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The maturity analysis of discounted lease liabilities recognised on the Group balance sheet is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due within one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">167</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">80</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due after five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">336</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseObligationsGross" contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">341</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total lease liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,008</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">219</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049721"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">31. Pensions and other post-employment benefits </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory" contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Pension and other post-employment costs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046392">185</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046393">239</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046395">40</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046396">58</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other overseas pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2022To12_31_2022_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">154</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2021To12_31_2021_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046404">153</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2020To12_31_2020_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046405">170</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046413">37</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046414">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">369</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046407">415</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046408">466</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Analysed as:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Funded defined benefit/hybrid pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2022To12_31_2022_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2021To12_31_2021_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046416">231</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2020To12_31_2020_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046417">318</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded defined benefit pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2022To12_31_2022_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2021To12_31_2021_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046419">23</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2020To12_31_2020_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046420">30</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046398">37</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046399">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2022To12_31_2022_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">236</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2021To12_31_2021_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046422">291</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" contextRef="P01_01_2020To12_31_2020_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046423">347</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined contribution pension schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DisclosureOfDefinedContributionPlans" contextRef="P01_01_2022To12_31_2022_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisclosureOfDefinedContributionPlans" contextRef="P01_01_2021To12_31_2021_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046380">124</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisclosureOfDefinedContributionPlans" contextRef="P01_01_2020To12_31_2020_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046381">119</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">369</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046410">415</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PostemploymentBenefitExpensePlans" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046411">466</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">104</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046383">106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046384">128</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">90</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046386">136</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046387">167</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">42</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046389">49</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046390">52</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">236</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046401">291</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046402">347</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK entities operate pension arrangements which cover the Group&#8217;s material obligations to provide pensions to retired employees. These arrangements have been developed in accordance with local practices in the countries concerned. Pension benefits can be provided by state schemes; by defined contribution schemes, whereby retirement benefits are determined by the value of funds arising from contributions paid in respect of each employee; or by defined benefit schemes, whereby retirement benefits are based on employee pensionable remuneration and length of service. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension costs of defined benefit schemes for accounting purposes have been calculated using the projected unit credit method. In certain countries pension benefits are provided on an unfunded basis, some administered by trustee companies. Formal, independent, actuarial valuations of the Group&#8217;s main plans are undertaken regularly, normally at least every three years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Remeasurement movements in the year are recognised through the statement of comprehensive income. Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. Discount rates are selected to reflect the term of the expected benefit payments. Projected inflation rates and pension increases are long-term predictions based on the yield gap between long-term index-linked and fixed interest Gilts. In the UK, mortality rates are determined by adjusting the SAPS S3 standard mortality tables to reflect recent scheme experience. These rates are then projected to reflect improvements in life expectancy in line with the CMI 2021 projections with a long-term rate of improvement of <ix:nonFraction name="gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% per year for both males and females. In the US, mortality rates are calculated using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRI-2012</div> white collar table adjusted to reflect recent experience. These rates are projected using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MP-2020</div> to allow for future improvements in life expectancy. </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">220</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelection_69049721" continuedAt="TextSelectionAppend_69049721_1"><ix:nonNumeric name="gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2042 for an individual then at the age of 60 is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td>
<td colspan="4" style="height:0.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:MalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">27.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:FemalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">28.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:MalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">27.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:FemalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">28.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Projected for 2042</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:MalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis" format="ixt-sec:duryear">28.5</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:FemalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis" format="ixt-sec:duryear">29.5</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:MalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">28.8</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:FemalePensionersAverageLifeExpectancyAtSixty" contextRef="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis" format="ixt-sec:duryear">30.1</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The assets of funded schemes are generally held in separately administered trusts, either as specific assets or as a proportion of a general fund, or are insurance contracts. Assets are invested in different classes in order to maintain a balance between risk and return. Investments are diversified to limit the financial effect of the failure of any individual investment. The physical asset allocation strategy for three of the four UK plans is <ix:nonFraction name="gsk:AllocationToReturnSeekingAssets" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">36</ix:nonFraction>% in return-seeking assets and <ix:nonFraction name="gsk:AllocationToLiabilityMatchingAssets" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">64</ix:nonFraction>% in liability-matching assets. During 2019, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-in</div> insurance contract was purchased to cover substantially all of the obligations of the other UK plan. At 31&#160;December 2022, the value of the insurance contract was &#163;<ix:nonFraction name="gsk:TotalValueOfTheInsuranceContract" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">402</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:TotalValueOfTheInsuranceContract" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">570</ix:nonFraction> million). The asset allocation of the US plans is currently set at <ix:nonFraction name="gsk:AllocationToReturnSeekingAssets" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% return-seeking assets and <ix:nonFraction name="gsk:AllocationToLiabilityMatchingAssets" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% liability-matching assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The pension plans are exposed to risk that arises because the estimated market value of the plans&#8217; assets might decline, the investment returns might reduce, or the estimated value of the plans&#8217; liabilities might increase. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In line with the agreed mix of return-seeking assets to generate future returns and liability-matching assets to better match future pension obligations, the Group has defined an overall long-term investment strategy for the plans, with investments across a broad range of assets. The main market risks within the asset and hedging portfolio are against credit risk, interest rates, long-term inflation, equities, property, currency and bank counterparty risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The plan liabilities are a series of future cash flows with relatively long duration. On an IAS 19 basis, these cash flows are sensitive to changes in the expected long-term inflation rate and the discount rate (AA corporate bond yield curve) where an increase in long-term inflation corresponds with an increase in the liabilities, and an increase in the discount rate corresponds with a decrease in the liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The interest rate risk and credit rate risk in the US are partially hedged. The targets are based on an accounting measure of the plan liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For the UK plans, there is an interest rate and inflation hedging strategy in place. The targets are based on an economic measure of the plan liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the UK, the defined benefit pension schemes operated for the benefit of former Glaxo Wellcome employees and former SmithKline Beecham employees remain separate. These schemes were closed to new entrants in 2001 and subsequent UK employees are entitled to join a defined contribution scheme. In addition, the Group operates a number of post-retirement healthcare schemes, the principal one of which is in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following a period of consultation with impacted employees, it was announced on 17&#160;December 2020 that the UK defined benefit plans would be closed to future accrual effective from 31&#160;March 2022. As a result, post closure the accrued benefits of active participants will be revalued in line with inflation (RPI for the legacy Glaxo Wellcome plans and CPI for the legacy SmithKline Beecham plans subject to the relevant caps for each arrangement) rather than capped pay increases. In addition, all defined benefit plan participants who were still active at 1&#160;April 2022 received a defined pension contribution of &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset" contextRef="P12_17_2020To12_17_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> each. The effect of closure and the defined contribution enhancement together resulted in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> cost of &#163;<ix:nonFraction name="gsk:DefinedBenefitObligationAtPastServiceCost" contextRef="PAsOn12_31_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction>&#160;million in 2020. As announced, the plan was closed to new entrants at 31&#160;March 2022. From 1&#160;April 2022, former defined benefits plans employees were transferred to the defined contribution plans. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">It was announced on 9&#160;September 2020 that the US cash balance pension plans would be closed to future accrual from 1&#160;January 2021. This change resulted in a credit of &#163;<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn01_01_2021_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction>&#160;million. On 1&#160;June 2020 and 9&#160;September 2020, two amendments were made to the retiree healthcare plans in the US resulting in a credit of &#163;<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn09_09_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has applied the following financial assumptions in assessing the defined benefit liabilities:</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Rest of World</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rate of increase of future earnings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.40</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.80</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.30</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.40</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfDiscountRates" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected pension increases</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.10</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.40</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash balance credit/conversion rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.90</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.80</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ActuarialAssumptionOfCashBalanceCreditRate" contextRef="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inflation rate</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.10</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.20</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.80</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.25</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.30</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.90</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.30</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sensitivity analysis detailing the effect of changes in assumptions is provided on page 228. The analysis provided reflects the assumption changes which have the most material impact on the results of the Group. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">221</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049721_1" continuedAt="TextSelectionAppend_69049721_2"><ix:nonNumeric name="gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31&#160;December 2022 in relation to the defined benefit pension and post-retirement healthcare schemes were as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,169</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">261</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">872</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046500">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046501">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046502">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046503">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046504">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046515">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046516">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046517">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046518">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046519">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046530">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046531">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046532">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046533">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046534">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046545">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046546">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046547">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046548">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046549">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046560">15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046561">12</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046562">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046563">29</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046564">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046575">98</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046576">41</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046577">116</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046578">255</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046579">36</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046590">572</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046591">98</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046592">186</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046593">856</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046594">68</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046505">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046506">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046507">125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046508">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046509">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046520">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046521">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046522">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046523">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046524">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046535">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046536">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046537">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046538">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046539">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046550">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046551">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046552">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046553">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046554">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046565">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046566">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046567">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046568">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_69046569">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046580">163</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046581">58</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046582">127</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046583">348</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046584">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement losses recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_69046595">51</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046596">96</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046597">45</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046598">90</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_69046599">73</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts included within past service costs in the UK included &#163;<ix:nonFraction name="gsk:AugmentationCostsIncludedInPastServiceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;<ix:nonFraction name="gsk:AugmentationCostsIncludedInPastServiceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;<ix:nonFraction name="gsk:AugmentationCostsIncludedInPastServiceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction> million) of augmentation costs which arose from Major restructuring programmes, together with a charge of &#163;<div style="display:inline;"><ix:nonFraction name="gsk:AugmentationCostsFromRestructuringProgrammes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction></div> (2021: &#163;<div style="display:inline;"><ix:nonFraction name="gsk:AugmentationCostsFromRestructuringProgrammes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction></div>; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;<ix:nonFraction name="gsk:AugmentationCostsFromRestructuringProgrammes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction> million) in relation to the impact of the closure of the defined benefit schemes to future accrual. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2020, the past service credit of &#163;<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction> million in the US reflected the closure of the cash balance pension plans from 1 January 2021. Amendments to the retiree healthcare plan in the US in 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div> resulted in a credit of &#163;<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction> million to past service costs in post-retirement benefits in 2020. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">These numbers do not include remeasurement gains/(losses) related to the demerged Consumer Healthcare business. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">222</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049721_2" continuedAt="TextSelectionAppend_69049721_3"><ix:nonNumeric name="gsk:DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the table below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan" contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan" contextRef="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan" contextRef="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Pensions and other post-employment benefits:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in deficit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,585</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,287</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">994</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,243</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,363</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,579</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,113</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,650</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">In the event of a plan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wind-up,</div> GSK believes the UK pension scheme rules provide the company with the right to a refund of surplus assets following the full settlement of plan liabilities. As a result, the net surplus in the UK defined benefit pension schemes is recognised in full. </div><ix:nonNumeric name="ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049793"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other defined benefit pension schemes in the Group are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric><ix:continuation id="TextSelection_69049793" continuedAt="TextSelectionAppend_69049793_1">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:85%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,159</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,101</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">605</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,692</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,595</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,048</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,329</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">691</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,694</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">645</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">375</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,014</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,144</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,117</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,030</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,353</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,500</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">770</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">483</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,356</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">770</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">603</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,585</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">770</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">483</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,356</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,710</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,513</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table></ix:continuation><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The multi-asset funds comprise investments in pooled investment vehicles that are invested across a range of asset classes, increasing diversification within the growth portfolio. The value of funds in this asset class with a quoted market price is &#163;<ix:nonFraction name="gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">211</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The &#8216;Other (liabilities)/assets&#8217; category comprises cash and mark to market values of derivative positions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Index-linked gilts held as part of a UK repo programme are included in government bonds. The related loan of &#163;<ix:nonFraction name="gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,376</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">513</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">650</ix:nonFraction> million) is deducted within &#8216;Other assets&#8217;. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">223</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049721_3" continuedAt="TextSelectionAppend_69049721_4"><ix:continuation id="TextSelectionAppend_69049793_1"> <div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:85%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;Rest&#160;of&#160;World<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">731</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">502</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,503</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">975</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">984</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,334</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,524</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,932</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asset&#160;ceiling&#160;restrictions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DefinedBenefitPensionAssetCeilingRestrictions" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DefinedBenefitPensionAssetCeilingRestrictions" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,299</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,248</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,644</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,191</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">333</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">724</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">738</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,129</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">273</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">724</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">873</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,870</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">333</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">724</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">738</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,129</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">541</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:85%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2020&#160;&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,911</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,075</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MultiAssetFunds" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,075</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">585</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,066</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,333</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,055</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">758</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,206</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,858</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,445</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,007</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,310</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">276</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">810</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,018</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,104</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">353</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">810</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,124</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,287</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">276</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">810</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,018</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:SurplusDeficitInPlan" contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,104</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,092</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">159</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,428</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:continuation></ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">224</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049721_4" continuedAt="TextSelectionAppend_69049721_5"> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfMovementsInFairValuesOfAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in fair values of assets</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,432</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">372</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">836</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,056</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">641</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">248</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">999</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,206</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">153</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">262</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">312</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">618</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">982</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,524</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,906</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,062</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">408</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">370</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExpensesNetDefinedBenefitLiabilityAsset" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,883</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">755</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">919</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">117</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">624</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">649</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,080</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">135</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,014</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,260</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,870</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,144</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PlanAssetsAtFairValue" contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During March 2022, GSK transferred <ix:nonFraction name="gsk:SubsidiariesSharesTransferredToFundPensionSchemes" contextRef="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,004</ix:nonFraction> GSK Consumer Healthcare Holdings Limited (GSKCHH) C Ordinary Shares (representing <ix:nonFraction name="gsk:PercentageOfOwnershipInterestRepresentedByTransfer" contextRef="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.03</ix:nonFraction>%. (in aggregate) of GSK&#8217;s interest in GSKCHH to three Scottish Limited Partnerships (&#8220;SLPs&#8221;), each providing a funding mechanism for a separate GSK UK defined benefit pension scheme. As part of the steps relating to the demerger and separation, the SLPs transferred their applicable portion of GSKCHH C Ordinary Shares to Haleon plc (&#8220;Haleon&#8221;) in consideration for shares in Haleon. The SLPs together hold shares representing <ix:nonFraction name="gsk:PercentageOfOwneshipInterestHeldByTheTransferee" contextRef="PAsOn12_31_2022_HaleonMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>% of the total issued share capital of Haleon. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on the Haleon shares until it has received an aggregate amount equal to an agreed threshold (&#8220;Proceeds Threshold&#8221;). The Proceeds Thresholds total &#163;<ix:nonFraction name="gsk:MaximumProceedsThresholdAmount" contextRef="P03_01_2022To12_31_2022_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,080</ix:nonFraction>&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or &#8220;technical provisions&#8221; deficits in the three pension schemes shown by the 31&#160;December 2020 valuations. Once the applicable Proceeds Threshold has been reached the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-controlled</div> General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. If a pension scheme does not receive aggregate cash equal to the applicable Proceeds Threshold within 18 months after separation, then the trustee of that pension scheme will have the ability to require the SLP to instruct a broker to liquidate any remaining Haleon shares on behalf of the SLP in accordance with an agreed mandate. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, the Group made additional funding contributions to the UK pension schemes of &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">691</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction> million) but <ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> additional funding (2021: &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>; 2020: &#163;<ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>) to the US schemes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As at 31&#160;December 2022, total cash contributions totalling &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">735</ix:nonFraction>&#160;million were made towards the Proceeds Thresholds leaving a principal amount of &#163;<ix:nonFraction name="gsk:RemainingAmountDueToBeContributed" contextRef="PAsOn12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction>&#160;million outstanding to the UK pension schemes. The cash contributions of &#163;<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" contextRef="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">735</ix:nonFraction>&#160;million include voluntary cash contributions made by GSK in Q4 2022 to two of the UK defined benefit pension schemes totalling &#163;<ix:nonFraction name="gsk:VoluntaryCashContributionsMadeToThePlan" contextRef="P01_01_2022To12_31_2022_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">334</ix:nonFraction>&#160;million in response to the market volatility in the UK gilt markets. <br/></div> </ix:continuation> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677f_167.jpg"/><br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="font-weight:bold;display:inline;">225</div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:continuation id="TextSelectionAppend_69049721_5" continuedAt="TextSelectionAppend_69049721_6"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The outstanding accelerated contributions were collateralised by the creation of three Scottish Limited Partnerships (SLPs), into which GSK inserted a total of <ix:nonFraction name="gsk:SubsidiarySharesTransferredIntoLimitedPartnerships" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">692,593,037</ix:nonFraction> Haleon ordinary shares across the three SLPs. Each of the three principal UK defined benefit pension schemes (two benefiting current and former Glaxo Welcome employees, with the third benefiting current and former SmithKline Beecham employees) has an interest in one of the SLPs as shown below: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:33%"></td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">General Partner</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Limited Partners</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No. 1) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP1 Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Scheme</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No. 2) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP1 Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Fund</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK (No. 3) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK GP2 Ltd</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">SmithKline Beecham Pension Plan Trustee Ltd acting on behalf of the SmithKline Beecham Pension Plan</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under each of the SLP partnership agreements, the limited partners have no involvement in the management of the business and shall not take any part in the control of SLP. The general partner (in all cases, controlled by GSK plc) is responsible for the management and control of each SLP and, as such, each SLP is consolidated into the results of the Group. Each SLP therefore takes advantage of the exemption in Regulation 7 of The Partnership (Accounts) Regulations 2008 Act to not prepare and deliver audited accounts to the UK registrar. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the SLP partnership agreement, distributions will be made from partnership income to the defined benefit pension schemes if equivalent payments have not already been made to the three defined benefit pension schemes by another GSK entity. To date, &#163;<ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">735</ix:nonFraction>&#160;million has been paid to the defined benefit pension schemes by GSK under this structure and once contributions under this structure reach &#163;<ix:nonFraction name="gsk:MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,080</ix:nonFraction>&#160;million, the defined benefit pension schemes interests&#8217; in the SLPs ends. The remaining economic interest in the SLPs will be held by GSK LP Ltd, a <ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKLPLtdMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% owned subsidiary of GSK plc. At 31&#160;December 2022, &#163;<ix:nonFraction name="gsk:AdditionalContributionDueToBePaid" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction>&#160;million of these additional contributions remains to be paid. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Employer contributions for 2023, excluding special funding contributions stated above, are estimated to be approximately &#163;<ix:nonFraction name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million in respect of defined benefit pension schemes and &#163;<ix:nonFraction name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction>&#160;million in respect of post-retirement benefits. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in defined benefit obligations</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,353</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2019_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,418</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">70</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">291</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">408</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">39</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">785</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,161</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">641</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">248</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">999</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,310</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,363</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">216</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">289</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">439</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">618</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">982</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,191</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,243</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">495</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">125</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">388</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,011</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">621</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">649</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,080</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">135</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,117</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,031</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,352</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,500</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">994</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">226</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements continued</div></div></div></div> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="display:inline;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:continuation id="TextSelectionAppend_69049721_6" continuedAt="TextSelectionAppend_69049721_7"> <div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The defined benefit pension obligation is analysed as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Funded</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,887</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,419</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,504</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">613</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">772</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">806</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,500</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,191</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,310</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The liability for the US post-retirement healthcare scheme has been assessed using the same assumptions as for the US pension scheme, together with the assumption for future medical inflation of <ix:nonFraction name="gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation" contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation" contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.25</ix:nonFraction>%) in 2022, grading down to <ix:nonFraction name="gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation" contextRef="PAsOn12_31_2022_TwoThousandThirtyOneAndThereafterMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% in 2031 and thereafter. At 31&#160;December 2022, the US post-retirement healthcare scheme obligation was &#163;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">870</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,059</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,124</ix:nonFraction> million). Post-retirement benefits are unfunded. </div> <ix:nonNumeric name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The movement in the net defined benefit liability is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,129</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,104</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,921</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">65</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">291</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Return on plan assets, excluding amounts included in interest</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,883</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,056</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">92</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">69</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,868</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">716</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,340</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience (loss)/gain</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">949</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">215</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">110</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employer contributions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">919</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">312</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">313</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expenses</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,356</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,129</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,104</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The remeasurements included within post-retirement benefits are detailed below: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">219</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">93</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience gains</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="gsk:DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The defined benefit pension obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,390</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,196</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,660</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,540</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,115</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,257</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,570</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,880</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,393</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,500</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,191</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,310</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="gsk:DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The post-retirement benefit obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">494</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">551</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">688</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">808</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">994</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,243</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DefinedBenefitObligationAtPresentValue" contextRef="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,363</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average duration of the defined benefit obligation is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">years</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension benefits</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">16</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2022To12_31_2022_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2021To12_31_2021_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WeightedAverageDurationOfDefinedBenefitObligations" contextRef="P01_01_2020To12_31_2020_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Membership numbers are not restated as the disclosure relates to the post-retirement benefit obligations. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">227</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31. Pensions and other post-employment benefits </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049721_7"><div style="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sensitivity analysis </div></div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The effect of changes in assumptions used on the benefit obligations and on the 2023 annual defined benefit pension and post-retirement costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of the plan memberships. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Discount rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,341</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Inflation rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">290</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">945</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">827</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">1 year<br/> increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Life expectancy</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInAnnualPensionCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreasePensionObligations" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">1%</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">increase<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Rate of future healthcare inflation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInPostretirementBenefitsObligation" contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049886"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">32. Other provisions </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Legal<br/> and&#160;other<br/> disputes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/> &#160;restructuring<br/> programmes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Employee<br/> related<br/> provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Other<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,471</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">555</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversed unused</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">261</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">539</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistribution" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistribution" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistribution" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistribution" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferToAssetsHeldForSaleDistribution" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications and other movements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to Pension obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToPensionObligations" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransferToPensionObligations" contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToPensionObligations" contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransferToPensionObligations" contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferToPensionObligations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">309</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled within one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">652</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled after one year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherLongtermProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">532</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">309</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049886" continuedAt="TextSelectionAppend_69049886_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in a substantial number of legal and other disputes, including notification of possible claims, as set out in Note 47, &#8216;Legal proceedings&#8217;. Provisions for legal and other disputes include amounts relating to product liability, anti-trust, government investigations, contract terminations and self insurance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in significant legal proceedings in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, the Group would provide appropriate disclosures about such cases, but no provision would be made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The net charge for the year of &#163;<ix:nonFraction name="gsk:AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">133</ix:nonFraction>&#160;million (including reversals and estimated insurance recoveries) primarily related to provisions for product liability cases, commercial disputes and various other government investigations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount on the provision is &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million in 2022 (2021: &#163;nil). The discount was calculated using risk-adjusted projected cash flows and risk-free rates of return. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s position could change over time, and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial accounts. </div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049886_1" continuedAt="TextSelectionAppend_69049886_2"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">It is in the nature of the Group&#8217;s business that a number of these matters may be the subject of negotiation and litigation over many years. Litigation proceedings, including the various appeal procedures, often take many years to reach resolution, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-court</div></div> settlement discussions can also often be protracted. Indemnified disputes will result in a provision charge and a corresponding receivable. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is in potential settlement discussions in a number of the disputes for which amounts have been provided and, based on its current assessment of the progress of these disputes, estimates that &#163;<ix:nonFraction name="ifrs-full:ShorttermLegalProceedingsProvision" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction>&#160;million of the amount provided at 31&#160;December 2022 will be settled within one year. At 31&#160;December 2022, it was expected that &#163;nil (2021: &#163;<ix:nonFraction name="gsk:LegalProceedingsAndOtherDisputesProvisionEstimated" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="INF" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction> million) of the provision made for legal and other disputes will be reimbursed by third parties. For a discussion of legal issues, See Note 47, &#8216;Legal proceedings&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major restructuring programmes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, the Group had two major restructuring programmes in progress: the Separation Preparation programme which focused on preparing for the separation of GSK into two new companies and the Significant Acquisitions programme which is focused on the integration of recent acquisitions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Restructuring provisions primarily include severance costs when management has made a formal decision to eliminate certain positions and this has been communicated to the groups of employees affected and appropriate consultation procedures completed, where appropriate. No provision is made for staff severance payments that are paid immediately. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount on the provisions increased by &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" contextRef="P01_01_2022To12_31_2022_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million in 2022 (2021: increased by &#163;<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" contextRef="P01_01_2021To12_31_2021_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction> million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension augmentation includes &#163;<ix:nonFraction name="gsk:PensionObligationProvisions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million relating to the defined benefit plan arising from staff redundancies, as shown in Note 30, &#8216;Pensions and other post-employment benefits&#8217;. </div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049886_2" continuedAt="TextSelectionAppend_69049886_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee related provisions </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Employee related provisions include obligations for certain medical benefits to disabled employees and their spouses in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the provision for these benefits amounted to &#163;<ix:nonFraction name="ifrs-full:ProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2022_DisabledEmployeesMemberGSKTitleOfIndividual1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">66</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ProvisionsForEmployeeBenefits" contextRef="PAsOn12_31_2021_DisabledEmployeesMemberGSKTitleOfIndividual1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction> million). Other employee benefits reflect a variety of provisions for severance costs, jubilee awards and other long-service benefits. </div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049886_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Given the nature of these provisions, the amounts are likely to be settled over many years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other provisions </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Included in other provisions are provisions for onerous contracts, insurance provisions and a number of other provisions including vehicle insurance and regulatory matters. </div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">230</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:nonNumeric name="gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">33. Contingent consideration liabilities </div></div> <ix:nonNumeric name="gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2019_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2019_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">339</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2019_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,479</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,275</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">765</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,359</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,869</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2021To12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,063</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">742</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,645</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movement through reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Initial recognition from business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,058</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">79</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,890</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">673</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the contingent consideration payable at 31&#160;December 2022, &#163;<ix:nonFraction name="gsk:ContingentConsiderationLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,289</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:ContingentConsiderationLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">958</ix:nonFraction> million) is expected to be paid within one year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture, Affinivax and the Novartis Vaccines business are expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, shown above. The Shionogi-ViiV Healthcare contingent consideration liability is discounted at <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">8</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">8</ix:nonFraction>%), the Affinivax contingent consideration liability is discounted at <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.9</ix:nonFraction>% and the Novartis Vaccines contingent consideration liability is discounted at <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2022_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2021_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>%) for commercialised products and at <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ContingentConsiderationPayableDiscountedPercentage" contextRef="PAsOn12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%) for pipeline assets. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Shionogi-ViiV Healthcare and Novartis Vaccines contingent consideration liabilities are calculated principally based on the forecast sales performance of specified products over the lives of those products. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Affinivax contingent consideration is based upon two potential milestone payments, each of $<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:GainLossOnDisposalOfInterestInAssociate" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.5</ix:nonFraction> billion) which will be paid if certain pediatric clinical development milestones are achieved. </div> <ix:nonNumeric name="gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">and loss/(gain) in Income statement</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Shionogi-</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">ViiV</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;Healthcare</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Novartis</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">556</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">103</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">834</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">154</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">555</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">833</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">153</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseInSalesForecastAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">199</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">214</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">65</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">328</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">101</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseInDiscountRateAmount" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">411</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">645</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">347</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">38</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfUSDollar" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AppreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">130</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DepreciationOfEuro" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in probability of milestone success</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">82</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in probability of milestone success</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseInProbabilityOfMilestoneSuccess" contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The sales forecast is for ViiV Healthcare sales only in respect of the Shionogi-ViiV Healthcare contingent consideration. </div> </td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An explanation of the accounting for ViiV Healthcare is set out on page 71. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">231</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">34. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accruals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Accruals" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Accruals" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentPayables" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">805</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentPayables" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">823</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">899</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">921</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other payables includes a number of employee-related liabilities including employee savings plans.</div> </ix:nonNumeric> <div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">35. Contingent liabilities </div></div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, contingent liabilities where GSK has a present obligation as a result of a past event, comprising guarantees and other items arising in the normal course of business, amounted to &#163;<ix:nonFraction name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction> million). At 31&#160;December 2022, &#163;<ix:nonFraction name="ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million) of financial assets were pledged as collateral for contingent liabilities. Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow. If it is not possible to meaningfully assess whether the outcomes will result in a probable outflow, or to quantify or reliably estimate the liability, if any, no provision is recorded. Descriptions of the significant legal and other disputes to which the Group is a party are set out in Note 47, &#8216;Legal proceedings&#8217;. </div> </ix:nonNumeric> <div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfCommitmentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">36. Commitments </div></div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual obligations and commitments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contracted for but not provided in the financial statements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,659</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,082</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">743</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">616</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfInvestments" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase commitments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">161</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">484</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and post-retirement benefits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfPensions" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfPensions" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest on loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,322</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,603</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Future finance charges on leases</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">153</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease contracts that have not yet commenced</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">395</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;<ix:nonFraction name="gsk:ContractualObligationsAndCommitments" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,909</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ContractualObligationsAndCommitments" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,188</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The commitments related to intangible assets include milestone payments, which are dependent on successful clinical development or on meeting specified sales targets, and which represent the maximum that would be paid if all milestones, however unlikely, are achieved. The amounts are not risk-adjusted or discounted. The net decrease in intangible asset commitments in 2022 is mainly attributable to the termination of certain agreements, offset by a number of new R&amp;D collaborations including collaborations with Spero Therapeutics, Inc., Wuxi Biologics Ireland Limited, SpringWorks Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, GSK reached an agreement with the trustees of the UK pension schemes to make additional contributions of &#163;<ix:nonFraction name="gsk:AdditionalContributionWereToBeMadeTowards2020PensionDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,080</ix:nonFraction>&#160;million, to eliminate the pension deficit identified at the 31&#160;December 2020 actuarial funding valuation. Prior to the Consumer Healthcare demerger, GSK agreed to collateralise this commitment and accelerate funding with additional contributions (see Note 31). At 31&#160;December 2022, &#163;<ix:nonFraction name="gsk:AdditionalContributionUnpaid" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction>&#160;million of these additional contributions remained unpaid. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group also has other commitments which principally relate to revenue payments to be made under licences and other alliances. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Commitments in respect of future interest payable on loans are disclosed before taking into account the effect of interest rate swaps. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">232</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">37. Share capital and share premium account </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following completion of the Consumer Healthcare business demerger on <ix:nonNumeric name="gsk:ConsumerHealthcareBusinessDemerger" contextRef="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" format="ixt:date-day-monthname-year-en">18 July 2022</ix:nonNumeric>, GSK plc Ordinary shares were consolidated to maintain share price comparability before and after demerger. The consolidation was approved by GSK shareholders at a General Meeting held on <ix:nonNumeric name="gsk:DateOfShareConsolidationApproval" contextRef="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" format="ixt:date-day-monthname-year-en">6 July 2022</ix:nonNumeric>. Shareholders received <ix:nonFraction name="gsk:SharesReceivedForEveryFiveExistingShares" contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4</ix:nonFraction> new Ordinary shares with a nominal value of <span style="-sec-ix-hidden:hidden69050743">31</span><div style="vertical-align:top;display:inline;;font-size:7.8px">1</div>&#8260;<div style="vertical-align:bottom;display:inline;;font-size:7.8px">4</div> pence each for every <ix:nonFraction name="gsk:SurrenderedSharesForEveryFourNewSharesReceived" contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5</ix:nonFraction> existing Ordinary share which had a nominal value of <ix:nonFraction name="gsk:ParValueOfSharesSurrenderedInLieuOfNewShares" contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">25</ix:nonFraction> pence each. Earnings per share, diluted earnings per share, adjusted earnings per share and dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary&#160;shares&#160;of&#160;25p&#160;each&#160;pre-share&#160;consolidation</div><br/> Ordinary&#160;shares&#160;of&#160;31<div style="vertical-align:top;display:inline;;font-size:6px">1</div>&#8260;<div style="vertical-align:bottom;display:inline;;font-size:6px">4</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">p&#160;each&#160;post-share&#160;consolidation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share capital issued and fully paid:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,383,102,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,087,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,385,189,617</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,825,442</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,387,015,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impact of share consolidation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ImpactOfShareConsolidationShares" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,077,403,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,731,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,311,343,341</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,347</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,440</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, of the issued share capital, <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">59,878,735</ix:nonFraction> shares were held in the ESOP Trusts, <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn12_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">217,124,760</ix:nonFraction> shares were held as Treasury shares and <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn12_31_2022_FreeIssueMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,034,339,846</ix:nonFraction> shares were in free issue. All issued shares are fully paid and there are <ix:nonFraction name="ifrs-full:NumberOfSharesAuthorised" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares authorised but not in issue. The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 45, &#8216;Employee share schemes&#8217;. </div> </ix:nonNumeric> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfMovementsInEquityExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049978"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">38. Movements in equity </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Retained earnings and other reserves amounted to &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,811</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,407</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,960</ix:nonFraction> million) of which &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">463</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">476</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="gsk:RetainedEarningsAndOtherReserves" contextRef="PAsOn12_31_2020_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">440</ix:nonFraction> million) related to associates and joint ventures<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <ix:nonNumeric name="gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049606"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cumulative translation exchange in equity is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Net translation exchange included in:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Retained<br/> earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Fair&#160;value<br/> reserve</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-<br/> &#160;&#160;&#160;&#160;&#160;&#160;controlling<br/> interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;translation<br/> exchange</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">524</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">652</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">93</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">709</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">803</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">993</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">85</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToContinuingOperations" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">692</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToContinuingOperations" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToContinuingOperations" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">906</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to discontinued operations<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">263</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">375</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">531</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">(a) Includes &#163;(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_DemergerMemberGSKEventAxis_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">554</ix:nonFraction>)&#160;million reclassification to the Consolidated income statement of exchange movements related to the demerger of the Consumer Healthcare business. </div></ix:nonNumeric></ix:nonNumeric><ix:continuation id="TextSelection_69049606"> </ix:continuation> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677f_167.jpg"/><br/></div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">233</div></div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38. Movements in equity </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <ix:continuation id="TextSelection_69049978" continuedAt="TextSelectionAppend_69049978_1"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of other comprehensive income by equity category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">754</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">754</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">786</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">786</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">464</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">695</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperations" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,187</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">375</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">356</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">714</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">831</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">239</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">239</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">911</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">911</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement losses on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">941</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">941</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">771</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">337</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,348</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,348</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement gains on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">187</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">187</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">69</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">69</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">133</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,137</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">970</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Information on net investment hedges is provided in part (d) of Note 44 &#8216;Financial instruments and related disclosures&#8217;. </div> </ix:continuation> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">234</div></div></td> </tr> </table> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38. Movements in equity </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049608"> </ix:nonNumeric><ix:continuation id="TextSelectionAppend_69049978_1"><ix:continuation id="TextSelection_69049608"><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The analysis of other reserves is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ESOP&#160;Trust</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">shares</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Fair&#160;value</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2019_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">135</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">409</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,129</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,355</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,100</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2020To12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,117</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">609</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">609</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">529</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">529</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">195</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,302</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,129</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,205</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Transferred to income and expenses in the year on impairments of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">168</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">168</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">780</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">770</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">383</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,129</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,463</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ExchangeAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Balances derecognised on demerger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BalanceAmountDerecognisedOnDemerger" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BalanceAmountDerecognisedOnDemerger" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:BalanceAmountDerecognisedOnDemerger" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">169</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BalanceAmountDerecognisedOnDemerger" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BalanceAmountDerecognisedOnDemerger" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">169</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">698</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">141</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetFairValueMovements" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">557</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,200</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,200</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">911</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:WritedownOfSharesHeldByEsopTrusts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">911</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">353</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">308</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,129</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,448</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table> </ix:continuation> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other reserves include various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-distributable</div> merger and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-merger</div> reserves amounting to &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,849</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,849</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,849</ix:nonFraction> million). Other reserves also include the capital redemption reserve created as a result of the share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back</div> programme amounting to &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2022_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">280</ix:nonFraction>&#160;million at 31&#160;December 2022 (2021: &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2021_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">280</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn12_31_2020_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">280</ix:nonFraction> million). </div></ix:continuation> <div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049612"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">39. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests </div></div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests includes the following individually material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests are individually not material. </div> <ix:nonNumeric name="gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ViiV Healthcare </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK holds <ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInAssociate" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction>% of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group,</div> giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information available at the latest practicable date in respect of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> is as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,619</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,637</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,848</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,528</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,087</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">762</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,622</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,070</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">795</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,716</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,796</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,354</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,711</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,070</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,507</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,762</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,121</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,983</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,472</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,745</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,593</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,675</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,086</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash inflow from operating activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,442</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,128</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,249</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from investing activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">174</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">287</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">294</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from financing activities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,718</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,608</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,483</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in cash and bank overdrafts in the year</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInCashAndBankOverdrafts" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInCashAndBankOverdrafts" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInCashAndBankOverdrafts" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">528</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:nonNumeric></div> <ix:continuation id="TextSelection_69049612" continuedAt="TextSelectionAppend_69049612_1"><ix:exclude> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div> <div style="clear: both; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049612_1" continuedAt="TextSelectionAppend_69049612_2"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">235</div></div></td></tr></table> </ix:exclude></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_69049612_2" continuedAt="TextSelectionAppend_69049612_3"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049612_3" continuedAt="TextSelectionAppend_69049612_4"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049612_4" continuedAt="TextSelectionAppend_69049612_5"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049612_5" continuedAt="TextSelectionAppend_69049612_6"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_69049612_6" continuedAt="TextSelectionAppend_69049612_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:continuation><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049612_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The above financial information relates to the ViiV Healthcare group on a stand-alone basis, before the impact of Group-related adjustments, primarily related to the recognition of preferential dividends. The profit after taxation of &#163;<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,528</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,087</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">762</ix:nonFraction> million) is stated after charging preferential dividends payable to GSK and Pfizer and after a charge of &#163;<ix:nonFraction name="gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,483</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,218</ix:nonFraction>&#160;million; 2020: &#163;<ix:nonFraction name="gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,112</ix:nonFraction> million) for remeasurement of contingent consideration payable. This consideration is expected to be paid over a number of years. </div><ix:nonNumeric name="gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the ViiV Healthcare group are included in GSK&#8217;s financial statements: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of profit for the year attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">415</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">480</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">224</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DividendsPaidToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">419</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">611</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">570</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">539</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> </ix:nonNumeric> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consumer Healthcare Joint Venture </div></div></div></div> <ix:nonNumeric name="gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" escape="true"> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK held <ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInAssociate" contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction>% of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> until the demerger on 18&#160;July 2022 (see details in Note 41), giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information in respect of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> at 31&#160;December 2021 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:91%;border:0">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:97%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29,200</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,251</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34,451</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,238</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,733</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,971</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26,480</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The above financial information relates to the former Consumer Healthcare Joint Venture on a stand-alone basis, before the impact of Group-related adjustments and the classification of cash pooling accounts with Group companies outside the Consumer Healthcare Joint Venture but after Major restructuring charges. </div> <ix:nonNumeric name="gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the Consumer Healthcare Joint Venture were included in GSK&#8217;s financial statements in prior years: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,609</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="PAsOn12_31_2020_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,538</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfRelatedPartyExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">40. Related party transactions </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, there were <ix:nonFraction name="gsk:LoansReceivableMadeByEntityRelatedPartyTransactions" contextRef="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> loans due to GSK from related parties (2021: &#163;<ix:nonFraction name="gsk:LoansReceivableMadeByEntityRelatedPartyTransactions" contextRef="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.6</ix:nonFraction>&#160;million was due from Medicxi Ventures I LP). Cash distributions were received from investment in Medicxi Ventures I LP of &#163;<ix:nonFraction name="ifrs-full:InvestmentIncome" contextRef="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction>&#160;million (2021: Medicxi Ventures I LP of &#163;<ix:nonFraction name="ifrs-full:InvestmentIncome" contextRef="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.5</ix:nonFraction>&#160;million, Longwood Founders Fund, LP of &#163;<ix:nonFraction name="ifrs-full:InvestmentIncome" contextRef="P01_01_2022To12_31_2022_LongwoodFoundersFundLPMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million and Apollo Therapeutics LLP of &#163;<ix:nonFraction name="ifrs-full:InvestmentIncome" contextRef="P01_01_2022To12_31_2022_ApolloTherapeuticsLLPMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As part of the joint venture agreement with Qura Therapeutics LLC, the Group has an obligation to fund the joint venture up to <ix:nonNumeric name="gsk:AgreementExtensionPeriod" contextRef="P06_26_2019To06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">April 2025</ix:nonNumeric>, with both GSK and its joint venture partner committing financial support in the amount of &#163;<ix:nonFraction name="gsk:InvestmentObligation" contextRef="PAsOn06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.6</ix:nonFraction>&#160;million. At December 2022, the outstanding liability due to Qura was &#163;<ix:nonFraction name="gsk:LoansReceivableMadeByEntityRelatedPartyTransactions" contextRef="P01_01_2022To12_31_2022_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.3</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:LoansReceivableMadeByEntityRelatedPartyTransactions" contextRef="P01_01_2021To12_31_2021_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.7</ix:nonFraction> million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group had no other significant related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The aggregate compensation of the Directors and GLT is given in Note 9, &#8216;Employee costs&#8217;. </div> </ix:nonNumeric><br/> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/><br/></div></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-weight:bold;display:inline;">236</div></td></tr></table> </div></div> <div></div> </div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049672"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">41. Acquisitions and disposals </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of the acquisition and disposal of significant subsidiaries, associates, joint ventures and other businesses are given below: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;July 2022, GSK completed the acquisition of <ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of Sierra Oncology, Inc., a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.6</ix:nonFraction> billion). The main asset is momelotinib which targets the medical needs of myelofibrosis patients with anaemia. Total transaction costs were &#163;<ix:nonFraction name="gsk:PaymentsMadeForTransactionCostsAndOther" contextRef="P07_01_2022To07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction>&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 15&#160;August 2022, GSK completed the acquisition of <ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of Affinivax, Inc. a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts focused on pneumococcal vaccine candidates. The consideration for the acquisition comprised an upfront payment of $<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.8</ix:nonFraction> billion) as adjusted for working capital acquired paid upon closing and two potential milestone payments each of $<ix:nonFraction name="gsk:BusinessCombinationPotentialMilestonePaymentPerTranche" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:BusinessCombinationPotentialMilestonePaymentPerTranche" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.5</ix:nonFraction> billion) to be paid upon the achievement of certain paediatric clinical development milestones. The estimated fair value of the contingent consideration payable was &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction>&#160;million. The values are provisional and are subject to change. The total transaction costs were &#163;<ix:nonFraction name="gsk:PaymentsMadeForTransactionCostsAndOther" contextRef="P08_15_2022To08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction>&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Since acquisition, no sales arising from the Sierra Oncology or Affinivax businesses have been included in Group turnover and no revenue is expected until regulatory approval is received on the acquired assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK continues to support the ongoing development of the acquired assets and consequently these assets will be loss making until regulatory approval on these assets is received. The development of these assets has been integrated into the Group&#8217;s existing R&amp;D activities, so it is impracticable to quantify these development costs or the impact on Total profit after taxation for the period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill of &#163;<ix:nonFraction name="ifrs-full:AdditionalRecognitionGoodwill" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,127</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:AdditionalRecognitionGoodwill" contextRef="P01_01_2022To12_31_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">162</ix:nonFraction>&#160;million for Sierra Oncology and &#163;<ix:nonFraction name="ifrs-full:AdditionalRecognitionGoodwill" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">965</ix:nonFraction>&#160;million for Affinivax), which is not expected to be deductible for tax purposes, has been recognised. The goodwill represents workforce in place, and specific synergies available to GSK from the business combinations. The goodwill has been allocated to the Group&#8217;s Commercial Operations and R&amp;D segments, (refer to Note 19 &#8216;Goodwill&#8217; for allocation methodology). </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Sierra<br/> Oncology<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,497</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,467</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,964</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">175</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">109</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">117</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxationRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxationRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">236</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TaxationRecognizedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">495</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,435</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,307</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,742</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">162</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">965</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,127</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,597</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,272</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,869</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,597</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,790</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,387</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of contingent consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 24&#160;November 2022 GSK signed an agreement to buy out the <ix:nonFraction name="gsk:BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in Glaxo Saudi Arabia Ltd for SAR<ix:nonFraction name="gsk:BusinessCombinationConsiderationPayableForStepAcquisition" contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_SAR" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="gsk:BusinessCombinationConsiderationPayableForStepAcquisition" contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction>&#160;million), to be paid in 2023. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></div><ix:continuation id="TextSelection_69049672" continuedAt="TextSelectionAppend_69049672_1"><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div><ix:exclude>
<img alt="LOGO" src="g382677f_167.jpg"/></ix:exclude> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_1" continuedAt="TextSelectionAppend_69049672_2"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">237</div></div></td></tr></table></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_69049672_2" continuedAt="TextSelectionAppend_69049672_3"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_3" continuedAt="TextSelectionAppend_69049672_4"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_4" continuedAt="TextSelectionAppend_69049672_5"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049672_5" continuedAt="TextSelectionAppend_69049672_6"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>GSK Annual Report 2022</ix:exclude> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41. Acquisitions and disposals </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demerger of Consumer Healthcare business </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 18&#160;July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. The separation was effected by way of a demerger of <ix:nonFraction name="gsk:PercentageOfOwnershipDivested" contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">80.1</ix:nonFraction>% of GSK&#8217;s <ix:nonFraction name="gsk:PercentageofGSKHolding" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction>% holding in the Consumer Healthcare business to GSK shareholders. Following the demerger, <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskShareholdersMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">54.5</ix:nonFraction>% of Haleon was held in aggregate by GSK shareholders, <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskAndGsksConsolidatedEsotTrustsMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.0</ix:nonFraction>% remains held by GSK (including shares received by GSK&#8217;s consolidated ESOP trusts) and <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.5</ix:nonFraction>% remains held by certain Scottish Limited Partnerships (SLPs) set up to provide collateral for a funding mechanism pursuant to which GSK will provide additional funding for GSK&#8217;s UK defined benefit pension schemes (Note 31). The aggregate ownership by GSK (including ownership by the ESOP trusts and SLPs) after the demerger of <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.5</ix:nonFraction>% was measured at fair value with changes through profit or loss. Pfizer continued to hold <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_PfizerMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">32</ix:nonFraction>% of Haleon after the demerger. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under IFRIC 17 &#8216;Distributions of Non-cash Assets to Owners&#8217; a liability and an equity distribution are measured at the fair value of the assets to be distributed when the dividend is appropriately authorised and it is no longer at the entity&#8217;s discretion. The liability and equity movement, and associated gain on distribution were recognised in Q3 2022 when the demerger distribution was authorised and occurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The asset distributed was the <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_GskHoldingMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">54.5</ix:nonFraction>% ownership of the Consumer Healthcare business. The net carrying value of the Consumer Healthcare business in the consolidated financial statements, including the retained <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.5</ix:nonFraction>% and net of the amount attributable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, was approximately &#163;<ix:nonFraction name="gsk:CarryingValueOfInvestmentNetOfNonControllingInterest" contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.0</ix:nonFraction>&#160;billion at the end of June. GSK&#8217;s &#163;<ix:nonFraction name="gsk:LiabilityEliminatedOnDemerger" contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">6.3</ix:nonFraction>&#160;billion share of the shareholder loans made in Q1 2022 in advance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-separation</div> dividends was eliminated in the consolidated financial statements. The assets distributed were reduced by Consumer Healthcare transactions up to 18&#160;July that principally included <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-separation</div> dividends declared and settled after the end of Q2 2022 and before 18&#160;July 2022. Those dividends included: &#163;<ix:nonFraction name="gsk:DividendFundedByDebtFinancing" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">10.4</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:DividendFundedByDebtFinancingAttributableToGsk" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">7.1</ix:nonFraction>&#160;billion attributable to GSK) of dividends funded by Consumer Healthcare debt that was partially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-lent</div> during Q1 2022 and dividends of &#163;<ix:nonFraction name="gsk:DividendsDistributedFromCashBalance" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:DividendsDistributedFromCashBalanceAttributableToGsk" contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;billion attributable to GSK) from available cash balances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of the <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">54.5</ix:nonFraction>% ownership of the Consumer Healthcare business distributed was &#163;<ix:nonFraction name="gsk:FairValueOfTheAssetsDistributed" contextRef="PAsOn07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">15.5</ix:nonFraction>&#160;billion. This was measured by reference to the quoted average Haleon share price over the first five days of trading, this being a fair value measured with observable inputs which was considered to be representative of the fair value at the distribution date. A gain on distribution of this fair value less book value of the attributable net assets of the Consumer Healthcare business of &#163;<ix:nonFraction name="gsk:GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" contextRef="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">7.7</ix:nonFraction>&#160;billion was recorded in the Income Statement in 2022. There was an additional gain of &#163;<ix:nonFraction name="gsk:AdditionalGainOnRemeasurementOfRetainedStake" contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;billion to remeasure the retained <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.5</ix:nonFraction>% from its book value to fair value of &#163;<ix:nonFraction name="gsk:FairValueOfHolding" contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.9</ix:nonFraction>&#160;billion using the same fair value methodology as used for the distributed shares. The gain on distribution and on remeasurement of the retained stake upon demerger was presented as part of discontinued operations. Any future gains or losses on the retained stake in Haleon will be recognised in continuing operations. In addition, there was a reclassification of the Group&#8217;s share of cumulative exchange differences arising on translation of the foreign currency net assets of the divested subsidiaries and offsetting net investment hedges from reserves into the Income Statement of &#163;<ix:nonFraction name="gsk:ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" contextRef="P07_18_2022To07_18_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;billion. The total gain on demerger of Consumer Healthcare was &#163;<ix:nonFraction name="gsk:GainOnDemergerOfDiscontinuedOperation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">10.1</ix:nonFraction>&#160;billion. These transactions were presented in profit from discontinued operations in 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the Consumer Healthcare business distributed (54.5%)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FairValueOfTheConsumerHealthcareBusinessDistributed" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the retained ownership in Haleon plc (13.5%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:FairValueOfTheRetainedOwnershipInHaleonPlc" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,853</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TotalfairValueOfDistributedandRetainBusiness" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the net assets and liabilities distributed/de-recognised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12,887</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest de-recognised</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CarryingAmountOfTheNciDerecognized" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,038</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on demerger before exchange movements and transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">554</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total gain on the demerger of Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GainOnDemergerOfDiscontinuedOperation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,084</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div><ix:exclude>
<img alt="LOGO" src="g382677dsp001b.jpg"/></ix:exclude> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">238</div></div></td></tr></table></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_69049672_6" continuedAt="TextSelectionAppend_69049672_7"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_7" continuedAt="TextSelectionAppend_69049672_8"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_8" continuedAt="TextSelectionAppend_69049672_9"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049672_9" continuedAt="TextSelectionAppend_69049672_10"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table></ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41. Acquisitions and disposals </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Consumer Healthcare was presented as a discontinued operation as at 30&#160;June 2022 and disclosed as such in the interim financial statements. The Consolidated Income Statement and Consolidated Cash Flow Statement distinguish discontinued operations from continuing operations. Comparative figures have been restated on a consistent basis. Financial information relating to the operations of Consumer Healthcare for the period is set out below and includes financial information until 18&#160;July 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This financial information differs both in purpose and basis of preparation from the Historical Financial Information and the Interim Financial Information included in the Haleon prospectus and from that which will be published by Haleon on 2&#160;March 2023. As a result, whilst the two sets of financial information are similar, they are not the same because of certain differences in accounting and disclosure under IFRS. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:FinancialInformationRelatingToDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total results</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,581</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,418</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,745</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,730</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,575</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,947</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">851</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,843</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,798</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">235</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">263</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">513</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax rate %</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.6</ix:nonFraction>%</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.3</ix:nonFraction>%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.5</ix:nonFraction>%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">616</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,580</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,285</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other gains/(losses) on demerger</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:OtherGainsLossesOnDemerger" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,433</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherGainsLossesOnDemerger" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:OtherGainsLossesOnDemerger" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,651</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation on demerger of discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,700</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,580</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,285</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in discontinued operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">205</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">511</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">409</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,495</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,069</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">876</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP_per_Share" decimals="1" scale="0" format="ixt:num-dot-decimal">260.6</ix:nonFraction>p</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP_per_Share" decimals="1" scale="0" format="ixt:num-dot-decimal">26.7</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis" unitRef="Unit_GBP_per_Share" decimals="1" scale="0" format="ixt:num-dot-decimal">22.0</ix:nonFraction>p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other business disposals </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no other material business disposals in 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;demerger</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">- other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,392</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">284</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">933</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:CashOutflowInflowExcludingTransactionCosts" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,108</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:CashOutflowInflowExcludingTransactionCosts" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">933</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:CashOutflowInflowExcludingTransactionCosts" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">79</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">141</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,187</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,074</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;)</div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash consideration for business acquisitions included &#163;<ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2022To12_31_2022_TwoThousandAndTwentyTwoBusinessAcquisitionsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;million related to other business acquisition activity. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK completed no material business acquisitions in 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business disposals </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK made a number of business disposals for net cash consideration received in the year of &#163;<ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million. <ix:nonNumeric name="gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory" contextRef="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis" escape="true" continuedAt="TextSelection_69049696">The profit on the disposal of the businesses in the year of &#163;<ix:nonFraction name="gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" contextRef="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction>&#160;million was calculated as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_69049696"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration including currency forwards, purchase adjustments and deferred consideration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets sold:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DisposalsOtherNetAssets" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DisposalGroupAssetsNet" contextRef="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deal costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DealCostsPayable" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals in 2021</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:GainLossOnDisposalsOfBusiness" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><ix:exclude><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:exclude><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">239</div></div></td></tr></table></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_69049672_10" continuedAt="TextSelectionAppend_69049672_11"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_11" continuedAt="TextSelectionAppend_69049672_12"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_12" continuedAt="TextSelectionAppend_69049672_13"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049672_13" continuedAt="TextSelectionAppend_69049672_14"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>GSK Annual Report 2022</ix:exclude> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41. Acquisitions and disposals </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Associates and joint ventures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 20&#160;May 2021 GSK agreed with Innoviva, Inc. (&#8220;Innoviva&#8221;) to sell all of its approximately <ix:nonFraction name="gsk:InvestmentOwnedNumberOfSharesDisposedOff" contextRef="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction>&#160;million shares of common stock of Innoviva back to Innoviva at a price of $<ix:nonFraction name="gsk:DisposalOfInterestInAssociatesConsiderationReceivablePerShare" contextRef="PAsOn05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.25</ix:nonFraction> per share, raising gross proceeds of approximately $<ix:nonFraction name="gsk:GrossProceedsFromDisposalOfInterestInAssociates" contextRef="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">392</ix:nonFraction>&#160;million. Following settlement of the transaction, GSK will no longer hold any Innoviva stock. See details in Note 21 &#8216;Investment in associates and joint ventures&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK completed one smaller business acquisition when it acquired <ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% of Pfizer Biotech Corporation Taiwan, a part of Pfizer&#8217;s consumer healthcare business, which was not previously recognised as part of the Consumer Healthcare Joint Venture, on 28&#160;September 2020 for non cash consideration of &#163;<ix:nonFraction name="gsk:PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" contextRef="P09_28_2020To09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction>&#160;million. T<ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis" escape="true" continuedAt="TextSelection_69049698">his represented goodwill of &#163;<ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction>&#160;million, cash of &#163;<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction>&#160;million and other assets acquired of &#163;<ix:nonFraction name="ifrs-full:OtherAssets" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction>&#160;million less <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#163;<ix:nonFraction name="ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;million and net liabilities of &#163;<ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million. </ix:nonNumeric></div><ix:continuation id="TextSelection_69049698"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NonControllingInterestRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> consideration (settlement of a promissory note)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NoncashConsiderationForSettlementOfAPromissoryNote" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business disposals </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed public company. GSK received a <ix:nonFraction name="gsk:PercentageOfOwnershipDistributed" contextRef="P01_01_2020To12_31_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.7</ix:nonFraction>% equity stake in Hindustan Unilever and &#163;<ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P04_01_2020To04_01_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">395</ix:nonFraction>&#160;million in cash. GSK disposed of its equity stake in Hindustan Unilever during May 2020. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The divestment in Bangladesh closed on 30&#160;June 2020. Total cash consideration received was &#163;<ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_BangladeshConsumerHealthcareMemberifrsfullJointVenturesAxis_DisposalGroupsClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">177</ix:nonFraction>&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cash divested as part of the disposal of the India and Bangladesh Consumer Healthcare entities was &#163;<ix:nonFraction name="gsk:CashTransferredOnDisposal" contextRef="PAsOn12_31_2020_ConsumerHealthCareBangladeshMemberGSKArrangementTypeAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">478</ix:nonFraction>&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">240</div></div></td></tr></table></ix:exclude></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_69049672_14" continuedAt="TextSelectionAppend_69049672_15"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_69049672_15" continuedAt="TextSelectionAppend_69049672_16"><div><div style="background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049672_16" continuedAt="TextSelectionAppend_69049672_17"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049672_17" continuedAt="TextSelectionAppend_69049672_18"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049672_18"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41. Acquisitions and disposals </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The profit on the disposal of the businesses in the year of &#163;<ix:nonFraction name="gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,795</ix:nonFraction>&#160;million <div style="display:inline;">was </div>calculated as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Horlicks</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">divestment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration receivable including currency forwards and purchase adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">157</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">649</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equity investment in Hindustan Unilever Limited</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalOfEquity" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,124</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalOfEquity" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalOfEquity" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,124</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,616</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">157</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,773</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets disposed:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsGoodwill" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">142</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsGoodwill" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsGoodwill" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">143</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsIntangibleAssets" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsIntangibleAssets" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsIntangibleAssets" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsInventory" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsInventory" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsInventory" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">478</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">481</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DisposalsOtherNetLiabilitiesOrAssets" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">155</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalsOtherNetLiabilitiesOrAssets" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DisposalsOtherNetLiabilitiesOrAssets" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">154</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupAssetsNet" contextRef="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">536</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupAssetsNet" contextRef="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">126</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupAssetsNet" contextRef="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">662</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnEmbeddedDerivativeTransaction" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnEmbeddedDerivativeTransaction" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnEmbeddedDerivativeTransaction" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupLiabilityNet" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">288</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupLiabilityNet" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DisposalGroupLiabilityNet" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">316</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalsOfBusiness" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,792</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalsOfBusiness" contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainLossOnDisposalsOfBusiness" contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,795</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The exposure to share price movements embedded in the agreement to merge GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever Limited as part of the divestment of Horlicks and other nutrition products in India and a number of other countries was recognised as a derivative between signing of the agreement in 2018 and completion of the transaction in 2020. &#163;<ix:nonFraction name="gsk:GainLossOnEmbeddedDerivativeTransaction" contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction>&#160;million is recorded as a cost in the table above for the derecognition of the derivative asset. This largely reflects fair value gains recognised in the Income Statement in prior periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Associates and joint ventures </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, GSK made investments into associates of &#163;<ix:nonFraction name="gsk:CashInvestmentsInJointVenturesAndAssociates" contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;million and &#163;<ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;million was paid in cash. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">investments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received/(paid)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">786</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" contextRef="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DeferredConsiderationReceived" contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransactionCostsOnDisposal" contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents acquired/(divested)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">481</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table></ix:nonNumeric><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Other includes Consumer Healthcare disposals where the income statement impact is not restated. </div></td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div>
<img alt="LOGO" src="g382677f_167.jpg"/> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">241</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><ix:nonNumeric name="gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; margin-left:5%; text-indent:-5%; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">42. Adjustments reconciling Total profit after tax to operating cash&#160;flows </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit after tax from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,921</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,516</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on profits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">707</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates and joint ventures</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense net of finance income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncomeCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">803</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncomeCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">755</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncomeCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,061</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,034</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,086</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment and assets written off</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdjustmentsForImpairmentAndAssetsWrittenOff" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">481</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForImpairmentAndAssetsWrittenOff" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForImpairmentAndAssetsWrittenOff" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of businesses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfBusinesses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfBusinesses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfBusinesses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">185</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">279</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on sale of investments in associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfEquityInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfEquityInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForProfitOnSaleOfEquityInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in working capital:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase)in inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">269</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">158</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">279</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">494</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Increase) in other receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">458</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration paid (see Note 33)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,058</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">742</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> increase in contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,628</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,063</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">885</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension and other provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">962</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">346</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">283</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">170</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,944</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,674</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">932</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,994</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,422</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash generated from operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,876</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,243</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,096</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"></div>
<img alt="LOGO" src="g382677dsp001b.jpg"/> <div style="margin-top: 1em; margin-bottom: 1em"></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">242</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050754"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">43. Reconciliation of net cash flow to movement in net debt</div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt, at beginning of year, as adjusted</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2019" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in cash and bank overdrafts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,597</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,504</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in liquid investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseIncreaseInLiquidInvestment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseIncreaseInLiquidInvestment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseIncreaseInLiquidInvestment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in long-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,025</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of short-term Notes</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,074</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RepaymentsOfCurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of/(increase in) other short-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,021</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,594</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of medium term notes (MTNs)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,594</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of lease liabilities</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PaymentsOfFinanceLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">202</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PaymentsOfFinanceLeaseLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:PaymentsOfFinanceLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt of subsidiary undertakings acquired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DebtOfSubsidiaryUndertakingsAcquired" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:ExchangeOnNetDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,531</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ExchangeOnNetDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ExchangeOnNetDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> movements</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:OtherAdjustmentsForNoncashItemsToNetDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:OtherAdjustmentsForNoncashItemsToNetDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:OtherAdjustmentsForNoncashItemsToNetDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,536</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">158</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,177</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,100</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,027</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net debt at end of year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,197</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,780</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfAnalysisOfChangesInNetDebtExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049724">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis&#160;of&#160;changes&#160;in&#160;net&#160;debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;fair&#160;value</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Demerger</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">At</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" contextRef="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,861</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,734</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,723</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" contextRef="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">450</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">137</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">298</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" contextRef="PAsOn12_31_2021_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,425</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" contextRef="PAsOn12_31_2021_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">407</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,496</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7,052</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:LiquidInvestmentsCashAndCashEquivalents" contextRef="PAsOn12_31_2021_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,818</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">545</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,425</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">909</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,191</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,146</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">167</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" contextRef="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" contextRef="PAsOn12_31_2021_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,073</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,654</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" contextRef="PAsOn12_31_2021_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,559</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,466</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,145</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,615</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,559</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,789</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,654</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,194</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">725</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">243</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">841</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" contextRef="PAsOn12_31_2021_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">243</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,035</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" contextRef="PAsOn12_31_2021_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">777</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,059</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,236</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,572</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,222</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">249</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,615</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,059</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,667</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,035</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,287</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,618</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,424</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,197</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">865</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">207</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">670</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">640</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,983</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,450</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">301</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">912</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">718</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,710</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,670</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,888</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:nonNumeric></ix:nonNumeric></div> <ix:continuation id="TextSelection_69049724" continuedAt="TextSelectionAppend_69049724_1"><ix:continuation id="TextSelection_69050754" continuedAt="TextSelectionAppend_69050754_1"><ix:exclude> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69050754_1" continuedAt="TextSelectionAppend_69050754_2"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">243</div></div></td> </tr> </table> </ix:exclude></ix:continuation></ix:continuation> </div> </div> </div> <ix:continuation id="TextSelectionAppend_69049724_1" continuedAt="TextSelectionAppend_69049724_2"><ix:continuation id="TextSelectionAppend_69050754_2" continuedAt="TextSelectionAppend_69050754_3"><div></div></ix:continuation></ix:continuation> </div> <div> <div style="background-color:white;display: inline;"> <ix:continuation id="TextSelectionAppend_69049724_2" continuedAt="TextSelectionAppend_69049724_3"><ix:continuation id="TextSelectionAppend_69050754_3" continuedAt="TextSelectionAppend_69050754_4"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_69050754_4" continuedAt="TextSelectionAppend_69050754_5"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69050754_5" continuedAt="TextSelectionAppend_69050754_6"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_69049724_3" continuedAt="TextSelectionAppend_69049724_4"><ix:continuation id="TextSelectionAppend_69050754_6" continuedAt="TextSelectionAppend_69050754_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>GSK Annual Report 2022</ix:exclude> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"><ix:exclude>Notes to the financial statements continued</ix:exclude></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:continuation></ix:continuation><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69050754_7"><ix:continuation id="TextSelectionAppend_69049724_4"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43. Reconciliation of net cash flow to movement in net debt </div></div>continued</ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis of changes in net debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;in&#160;fair&#160;value<br/> &#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;Cash&#160;flow<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;31&#160;December</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,274</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,030</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">574</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">456</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,262</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,414</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CashAndCashEquivalentsAndNetOfOverdrafts" contextRef="PAsOn12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,818</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">243</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,596</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">203</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">94</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,695</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,694</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,210</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,145</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22,538</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,760</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">887</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">812</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,425</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReclassificationOfNetDebt" contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,694</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,572</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,780</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">314</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">778</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,838</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">753</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">244</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26,441</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">342</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">157</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">775</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ChangeInFairValueOfNetDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,976</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,983</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> </ix:continuation></ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">For further information on significant changes in net debt see Note 30, &#8216;Net debt&#8217;. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">244</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049729"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures</div></div></div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div></ix:nonNumeric> <div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049729" continuedAt="TextSelectionAppend_69049729_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The objective of GSK&#8217;s Treasury activities is to <div style="letter-spacing: 0px; top: 0px;;display:inline;">minimise </div>the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> net cost of financial operations and reduce its volatility to benefit earnings and cash flows. GSK uses a variety of financial instruments to finance its operations and derivative financial instruments to manage market risks from these operations. Derivatives principally comprise foreign exchange forward contracts and swaps which are used to swap borrowings and liquid assets into currencies required for Group purposes as well as interest rate swaps which are used to manage exposure to financial risks from changes in interest rates. These financial instruments reduce the uncertainty of foreign currency transactions and interest payments. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives are used exclusively for hedging purposes in relation to underlying business activities and not as trading or speculative instruments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s financial strategy supports the Group&#8217;s strategic priorities and is regularly reviewed by the Board. GSK manages the capital structure of the Group through an appropriate mix of debt and equity. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The capital structure of the Group consists of net debt of &#163;<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">17.2</ix:nonFraction>&#160;billion (see Note 30, &#8216;Net debt&#8217;) and total equity, including items related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests, of &#163;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">10.1</ix:nonFraction>&#160;billion (see &#8216;Consolidated statement of changes in equity&#8217; on page 184). Total capital, including that provided by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests, is &#163;<ix:nonFraction name="gsk:EquityAndDebtNet" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">27.3</ix:nonFraction>&#160;billion. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group continues to manage its financial policies to a credit profile that particularly targets short-term credit ratings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-1</div> while maintaining single A long-term ratings consistent with those targets. The Group&#8217;s long-term credit rating with Standard&#160;&amp; Poor&#8217;s is A (stable outlook) and with Moody&#8217;s Investor Services (&#8216;Moody&#8217;s&#8217;) it is A2 (stable outlook). The Group&#8217;s short-term credit ratings are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-1</div> with Standard &amp; Poor&#8217;s and Moody&#8217;s respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s policy is to borrow centrally in order to meet anticipated funding requirements. The strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. Each day, we sweep cash to or from a number of global subsidiaries and central Treasury accounts for liquidity management purposes. GSK utilises both physical and notional cash pool arrangements as appropriate by location and currency. For notional cash pools, liquidity is drawn against foreign currency balances to provide both local funding and central liquidity as required and with balances actively managed and maintained to appropriate levels. As balances in notional pooling arrangements are not settled across currencies, gross cash and overdraft balances are reported. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, GSK had &#163;<ix:nonFraction name="ifrs-full:Borrowings" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-9" scale="9" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;billion of borrowings repayable within one year and held &#163;<ix:nonFraction name="gsk:CashAndCashEquivalentsAndLiquidInvestments" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.8</ix:nonFraction>&#160;billion of cash and cash equivalents and liquid investments of which &#163;<ix:nonFraction name="gsk:CashAndCashEquivalentsAndLiquidInvestmentsHeld" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.1</ix:nonFraction>&#160;billion was held centrally. </div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_1" continuedAt="TextSelectionAppend_69049729_2"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has access to short-term finance under a $<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">8.3</ix:nonFraction> billion) US commercial paper programme; $<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction> million) was in issue at 31&#160;December 2022 (2021: $<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>). GSK has access to short-term finance under a &#163;<ix:nonFraction name="ifrs-full:CommercialPapersIssued" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-9" scale="9" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;billion Euro commercial paper programme; <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction> million) was in issue at 31&#160;December 2022 (2021: <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">300</ix:nonFraction>&#160;million (&#163;<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction> million)). In February 2022 GSK cancelled the &#163;<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;billion three year and $<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.1</ix:nonFraction> billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities of September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#163;<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.6</ix:nonFraction>&#160;billion and $<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;billion (&#163;<ix:nonFraction name="ifrs-full:UndrawnBorrowingFacilities" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.8</ix:nonFraction> billion) respectively. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These committed facilities were undrawn at 31&#160;December 2022. GSK considers this level of committed facilities to be adequate, given current liquidity requirements. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has a &#163;<ix:nonFraction name="gsk:AmountHeldAtEuropeanMediumTermNoteProgramme" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">20.0</ix:nonFraction> billion Euro Medium Term Note programme and at 31 December 2022, &#163;<ix:nonFraction name="gsk:NotesIssuedAtEuropeanMediumTermNoteProgramme" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">10.3</ix:nonFraction> billion of notes were in issue under this programme. The Group also had $<ix:nonFraction name="gsk:NotesIssuedUnderUsShelfRegistration" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">9.7</ix:nonFraction> billion (&#163;<ix:nonFraction name="gsk:NotesIssuedUnderUsShelfRegistration" contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">8.1</ix:nonFraction> billion) of notes in issue at 31 December 2022 under a US shelf registration. GSK is currently in the process of renewing its US shelf registration statement in order to maintain access to the US debt markets. GSK&#8217;s borrowings mature at dates between 2023 and 2045. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The put option owned by Pfizer in ViiV Healthcare is exercisable. In reviewing liquidity requirements GSK considers that sufficient financing options are available should the put option be exercised. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating rates over time. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s main interest rate risk arises from borrowings and investments with floating rates and refinancing of maturing fixed rate debt where any changes in interest rates will affect future cash flows or the fair values of financial instruments. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the Board. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#8217;s net interest charge. Short-term borrowings including bank facilities are exposed to the risk of future changes in market interest rates as are the majority of cash and liquid investments. </div> </ix:continuation> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677f_167.jpg"/><br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="font-weight:bold;display:inline;">245</div></td></tr></table></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_2" continuedAt="TextSelectionAppend_69049729_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s objective is to minimise the exposure of overseas operating subsidiaries to transaction risk by matching local currency income with local currency costs where possible. Foreign currency transaction exposures arising on external and internal trade flows are selectively hedged. GSK&#8217;s internal trading transactions are matched centrally and inter-company payment terms are managed to reduce foreign currency risk. Where possible, GSK manages the cash surpluses or borrowing requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating currency. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In order to reduce foreign currency translation exposure, the Group seeks to denominate borrowings in the currencies of our principal assets and cash flows. These are primarily denominated in US Dollars, Euros and Sterling. Borrowings can be swapped into other currencies as required. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated as a hedge against the relevant assets. Forward contracts in major currencies are also used to reduce exposure to the Group&#8217;s investment in overseas assets (see &#8216;Net investment hedges&#8217; section of this note for further details). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Credit risk is the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group and arises on cash and cash equivalents and favourable derivative financial instruments held with banks and financial institutions as well as credit exposures to wholesale and retail customers, including outstanding receivables. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group considers its maximum credit risk at 31&#160;December 2022 to be &#163;<ix:nonFraction name="ifrs-full:MaximumExposureToCreditRisk" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,180</ix:nonFraction>&#160;million (31&#160;December 2021: &#163;<ix:nonFraction name="ifrs-full:MaximumExposureToCreditRisk" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,417</ix:nonFraction> million) which is the total of the Group&#8217;s financial assets with the exception of &#8217;Other investments&#8217; (comprising equity investments) which bear equity risk rather than credit risk. See page 249 for details on the Group&#8217;s total financial assets. At 31&#160;December 2022, GSK&#8217;s greatest concentration of credit risk was &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;billion with a wholesaler in the US (2021: &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;billion with a wholesaler in the US). See page 247 for further information on the Group&#8217;s credit risk exposure in respect of the three largest US wholesaler customers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There has been no change in the estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for financial assets at amortised cost or at FVTOCI since the adoption of IFRS 9 at the start of the 2018 reporting period. </div> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_3" continuedAt="TextSelectionAppend_69049729_4"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury-related credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK sets global counterparty limits for each of GSK&#8217;s banking and investment counterparties based on long-term credit ratings from Moody&#8217;s and Standard&#160;&amp; Poor&#8217;s. Usage of these limits is actively monitored. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK actively manages its exposure to credit risk, reducing surplus cash balances wherever possible. This is part of GSK&#8217;s strategy to regionalise cash management and to concentrate cash centrally as much as possible. The table below sets out the credit exposure to counterparties by rating for liquid investments, cash and cash equivalents and derivatives. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The gross asset position on each derivative contract is considered for the purpose of this table, although, under ISDA agreements, the amount at risk is the net position with each counterparty. Table (e)&#160;on page 257 sets out the Group&#8217;s financial assets and liabilities on an offset basis. </div> </ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">246</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_4" continuedAt="TextSelectionAppend_69049729_5"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, &#163;<ix:nonFraction name="gsk:CashHeldAtUnratedCounterparties" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CashHeldAtUnratedCounterparties" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction> million) of cash is categorised as held with unrated or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-investment</div> grade rated counterparties (lower than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BBB-/Baa3)</div> of which &#163;<ix:nonFraction name="gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction> (2021: &#163;<ix:nonFraction name="gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction> million) is cash in transit. The remaining exposure is concentrated in overseas banks used for local cash management or investment purposes, including: &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_NGifrsfullGeographicalAreasAxis_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction>&#160;million in Nigeria held with United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank; &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_GbMemberifrsfullGeographicalAreasAxis_HalkBankMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;million with Halk Bank in the UK; &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_ECifrsfullGeographicalAreasAxis_ProdubancoMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million with Produbanco in Ecuador; &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_JTrustRoyalBankMemberifrsfullJointVenturesAxis_KHifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million with J Trust Royal Bank in Cambodia; &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_BancoDoBrasilMemberifrsfullJointVenturesAxis_BRifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million with Banco Do Brasil in Brazil; &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_BancoDeHondurasMemberifrsfullJointVenturesAxis_HNifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million with Banco de Honduras in Honduras; and &#163;<ix:nonFraction name="ifrs-full:CreditExposure" contextRef="PAsOn12_31_2022_BacSanJoseMemberifrsfullJointVenturesAxis_CRifrsfullGeographicalAreasAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million with BAC San Jos&#233; in Costa Rica. Of the &#163;<ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction>&#160;million of bank balances and deposits held with BBB/Baa rated counterparties, &#163;<ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million was held with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BBB-/Baa3</div> rated counterparties, including balances or deposits of &#163;<ix:nonFraction name="ifrs-full:BalancesWithBanks" contextRef="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis_StateBankOfIndiaMemberifrsfullCounterpartiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million with State Bank of India in India. These banks are used for local investment purposes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK measures expected credit losses over cash and cash equivalents as a function of individual counterparty credit ratings and associated 12&#160;month default rates. Expected credit losses over cash and cash equivalents and third-party financial derivatives are deemed to be immaterial and no such loss has been experienced during 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Credit ratings are assigned by Standard&#160;&amp; Poor&#8217;s and Moody&#8217;s respectively. Where the opinions of the two rating agencies differ, GSK assigns the lower rating of the two to the counterparty. Where local rating agency or Fitch data is the only source available, the ratings are converted to global ratings equivalent to those of Standard&#160;&amp; Poor&#8217;s or Moody&#8217;s using published conversion tables. These credit ratings form the basis of the assessment of the expected credit loss on Treasury-related balances held at amortised cost being bank balances and deposits and Government securities. </div> <ix:nonNumeric name="ifrs-full:DisclosureOfExternalCreditExposuresExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,215</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,324</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:LiquidityFunds" contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:LiquidityFunds" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,253</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GovernmentSecurities" contextRef="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:GovernmentSecurities" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DerivativeFinancialAssets" contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">188</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DerivativeFinancialAssets" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">188</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,399</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,403</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,978</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,687</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:BankBalancesAndDepositHeldWithCounterparties" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,825</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:LiquidityFunds" contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,395</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:LiquidityFunds" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,395</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GovernmentSecurities" contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">60</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GovernmentSecurities" contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GovernmentSecurities" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DerivativeFinancialAssets" contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DerivativeFinancialAssets" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,449</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,887</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">78</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">54</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RatedCreditExposures" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,535</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric> </ix:continuation> <div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_5" continuedAt="TextSelectionAppend_69049729_6"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s centrally managed cash reserves amounted to &#163;<ix:nonFraction name="gsk:CashReserves" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.1</ix:nonFraction>&#160;billion at 31&#160;December 2022, all available within three months. This includes &#163;<ix:nonFraction name="gsk:CashManagedForSubsidiaryCompany" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_GBP" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;billion of cash managed by the Group for ViiV Healthcare, a <ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction>% owned subsidiary. The Group has invested centrally managed liquid assets in bank deposits, Aaa/AAA rated US Treasury and Treasury repo only money market funds and Aaa/AAA rated liquidity funds. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholesale and retail credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Outside the US, no customer accounts for more than <ix:nonFraction name="gsk:PercentageOfAccountsReceivableByMajorCustomer" contextRef="P01_01_2022To12_31_2022_NonUsaMemberifrsfullGeographicalAreasAxis_TopOfRangeMemberifrsfullRangeAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Group&#8217;s trade receivables balance. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the US, in line with other pharmaceutical companies, the Group sells its products through a small number of wholesalers in addition to hospitals, pharmacies, physicians and other groups. Sales to the three largest wholesalers amounted to approximately <ix:nonFraction name="gsk:ConcentrationsOfRiskRevenuePercentage" contextRef="P01_01_2022To12_31_2022_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">79</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ConcentrationsOfRiskRevenuePercentage" contextRef="P01_01_2021To12_31_2021_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%) of the sales of the US Commercial Operations business in 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group had trade receivables due from these three wholesalers totalling &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,001</ix:nonFraction>&#160;million or <ix:nonFraction name="gsk:PercentageOfAccountsReceivableByMajorCustomer" contextRef="P01_01_2022To12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% of total trade receivables (2021: &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,430</ix:nonFraction>&#160;million or <ix:nonFraction name="gsk:PercentageOfAccountsReceivableByMajorCustomer" contextRef="P01_01_2021To12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">39</ix:nonFraction>%). The Group is exposed to a concentration of credit risk in respect of these wholesalers such that, if one or more of them encounters financial difficulty, it could materially and adversely affect the Group&#8217;s financial results. </div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_6" continuedAt="TextSelectionAppend_69049729_7"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This concentration of trade receivables is reflective of standard market practice in the US pharmaceuticals sector where a significant portion of sales are made to these three wholesalers, as disclosed in Note 6. GSK&#8217;s assessment is that there is limited credit risk associated with these customers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s credit risk monitoring activities relating to these wholesalers include a review of their quarterly financial information and Standard&#160;&amp; Poor&#8217;s credit ratings, development of GSK internal risk ratings, and establishment and periodic review of credit limits. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All new customers are subject to a credit vetting process and existing customers will be subject to a review at least annually. The vetting process and subsequent reviews involve obtaining information including the customer&#8217;s status as a government or private sector entity, audited financial statements, credit bureau reports, debt rating agency (eg Moody&#8217;s, Standard&#160;&amp; Poor&#8217;s) reports, payment performance history (from trade references, industry credit groups) and bank references. </div> </ix:continuation></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <br/> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677f_167.jpg" style="width: 39px; height: 914px;"/><br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL;font-weight:bold;text-align:right">247</div><div style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_7" continuedAt="TextSelectionAppend_69049729_8"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables consist of amounts due from a large number of customers, spread across diverse industries and geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable and, where appropriate, credit insurance is purchased or factoring arrangements put in place. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amount of information obtained is proportional to the level of exposure being considered. The information is evaluated quantitatively (i.e. credit score) and qualitatively (i.e. judgement) in conjunction with the customer&#8217;s credit requirements to determine a credit limit. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables are grouped into customer segments that have similar loss patterns to assess credit risk while other receivables and other financial assets are assessed individually. Historical and forward-looking information is considered to determine the appropriate expected credit loss allowance. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group believes there is no further credit risk provision required in excess of the allowance for expected credit losses (see Note 26, &#8216;Trade and other receivables&#8217;). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit enhancements </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group uses credit enhancements including factoring and credit insurance to minimise the credit risk of the trade receivables in the Group. At 31&#160;December 2022, &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">332</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">315</ix:nonFraction> million) of trade receivables were insured in order to protect the receivables from loss due to credit risks such as default, insolvency and bankruptcy. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each Group entity assesses the credit risk of its private customers to determine if credit insurance is required. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Factoring arrangements are managed locally by entities and are used to mitigate risk arising from large credit risk concentrations. All factoring arrangements are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recourse.</div> </div> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049729_8" continuedAt="TextSelectionAppend_69049729_9"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value of financial assets and liabilities excluding lease liabilities </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table on page 249 presents the carrying amounts and the fair values of the Group&#8217;s financial assets and liabilities excluding lease liabilities at 31&#160;December 2022 and 31&#160;December 2021. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair values of the financial assets and liabilities are included at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following methods and assumptions are used to measure the fair values of significant financial instruments carried at fair value on the balance sheet: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Other investments &#8211; equity investments traded in an active market determined by reference to the relevant stock exchange quoted bid price; other equity investments determined by reference to the current market value of similar instruments, recent financing rounds or the discounted cash flows of the underlying net assets </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Trade receivables carried at fair value &#8211; based on invoiced amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Interest rate swaps, foreign exchange forward contracts, swaps and options &#8211; based on the present value of contractual cash flows or option valuation models using market sourced data (exchange rates or interest rates) at the balance sheet date </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Cash and cash equivalents carried at fair value &#8211; based on net asset value of the funds </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Contingent consideration for business acquisitions and divestments &#8211; based on present values of expected future cash flows. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following methods and assumptions are used to estimate the fair values of significant financial instruments which are not measured at fair value on the balance sheet: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Receivables and payables, including put options, carried at amortised cost &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Liquid investments &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Cash and cash equivalents carried at amortised cost &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Long-term loans &#8211; based on quoted market prices (a level 1 fair value measurement) in the case of European and US Medium Term Notes; approximates to the carrying amount in the case of other fixed rate borrowings and floating rate bank loans </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Short-term loans, overdrafts and commercial paper &#8211; approximates to the carrying amount because of the short maturity of these instruments. </div></td></tr></table> </ix:continuation> </div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">248</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_9" continuedAt="TextSelectionAppend_69049729_10"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Notes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Fair <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;<br/> &#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,789</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,789</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,324</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,324</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,153</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,153</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,401</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,401</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,399</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,399</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,734</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,734</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,543</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,543</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings excluding obligations under lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bonds in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,322</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,035</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,017</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,930</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bank loans and overdrafts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">447</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">447</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; commercial paper in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">443</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other borrowings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total borrowings excluding lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">f&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,979</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,605</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLease" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,158</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,442</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,068</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">45,058</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">48,760</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net financial assets and financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetFinancialAssetsLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">25,708</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">25,334</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetFinancialAssetsLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">31,515</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">35,217</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The valuation methodology used to measure fair value in the above table is described and categorised on page 248. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other receivables, Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets, Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities are reconciled to the relevant Notes on pages 251 to 252. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">249</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_10" continuedAt="TextSelectionAppend_69049729_11"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value of investments in GSK shares </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Employee Share Ownership Plan (ESOP) Trusts held GSK shares with a carrying value of &#163;<ix:nonFraction name="gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">354</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction> million) and a market value of &#163;<ix:nonFraction name="gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">861</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">373</ix:nonFraction> million) based on quoted market price. The shares are held by the ESOP Trusts to satisfy future exercises of options and awards under employee incentive schemes. In 2022, the carrying value, which is the lower of cost or expected proceeds, of these shares has been recognised as a deduction from other reserves. At 31&#160;December 2022, GSK held Treasury shares at a cost of &#163;<ix:nonFraction name="ifrs-full:TreasuryShares" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,797</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TreasuryShares" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,969</ix:nonFraction> million) which has been deducted from retained earnings. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a) Financial instruments held at fair value </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables categorise the Group&#8217;s financial assets and liabilities held at fair value by the valuation methodology applied in determining their fair value. Where possible, quoted prices in active markets are used (Level 1). Where such prices are not available, the asset or liability is classified as Level&#160;2, provided all significant inputs to the valuation model used are based on observable market data. If one or more of the significant inputs to the valuation model is not based on observable market data, the instrument is classified as Level&#160;3. Other investments classified as Level&#160;3 in the tables below comprise equity investments in unlisted entities with which the Group has entered into research collaborations and investments which provide access to biotechnology developments of potential interest. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">823</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,153</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,087</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,401</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,399</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,399</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,309</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,567</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">657</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,533</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,251</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,927</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">199</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,449</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,185</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,202</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">419</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssetsAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,806</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,304</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" escape="true" continuedAt="TextSelection_69049836"></ix:nonNumeric><ix:continuation id="TextSelectionAppend_69049729_11" continuedAt="TextSelectionAppend_69049729_12"><ix:continuation id="TextSelection_69049836"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Movements in the year for financial instruments measured using Level&#160;3 valuation methods are presented below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:FinancialAssetsAndLiabilities" contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,657</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:FinancialAssetsAndLiabilities" contextRef="PAsOn12_31_2020_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,064</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">46</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses recognised in the income statement</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,627</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,024</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains recognised in other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">185</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration related to business acquisitions in the period</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">482</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlement of contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PaymentOfContingentConsiderationLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,137</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:PaymentOfContingentConsiderationLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">856</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:AdditionsFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">97</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AdditionsFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and settlements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfers from Level&#160;3</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">694</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:FinancialAssetsAndLiabilities" contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,411</ix:nonFraction></div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="gsk:FinancialAssetsAndLiabilities" contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,657</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the total net losses of &#163;<ix:nonFraction name="gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,627</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,024</ix:nonFraction> million) attributable to Level&#160;3 financial instruments which were recognised in the income statement, &#163;<ix:nonFraction name="gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,623</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,024</ix:nonFraction> million) were in respect of financial instruments which were held at the end of the year and were reported in Other operating income/expense. Charges of &#163;<ix:nonFraction name="gsk:RemeasurementOfTheContingentConsiderationPayable" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,431</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:RemeasurementOfTheContingentConsiderationPayable" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,026</ix:nonFraction> million) arose from remeasurement of the contingent consideration payable for the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#163;<ix:nonFraction name="gsk:RemeasurementOfTheContingentConsiderationPayable" contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">231</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:RemeasurementOfTheContingentConsiderationPayable" contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction> million) arose from remeasurement of the contingent consideration payable for the acquisition of the Novartis Vaccines business. The acquisition of Affinivax in 2022 resulted in the addition of &#163;<ix:nonFraction name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction>&#160;million of contingent consideration to Level&#160;3 financial liabilities, with a further &#163;<ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction>&#160;million remeasurement charge arising for the period between acquisition and 31&#160;December 2022. There were <ix:nonFraction name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" contextRef="P01_01_2022To12_31_2022_FinancialLiabilitesOneMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> transfers into or out of Level&#160;3 financial instruments in the year (2021 &#8211; transfers related to equity instruments which transferred to a Level&#160;1 valuation methodology as a result of listing on a recognised stock exchange during the year). Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net gains and losses include the impact of other exchange movements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial liabilities measured using Level&#160;3 valuation methods at 31&#160;December included &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,890</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,559</ix:nonFraction> million) in respect of contingent consideration payable for the acquisition in 2012 of the former Shionogi-ViiV Healthcare joint venture. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products and movements in certain foreign currencies. A further &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">673</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">479</ix:nonFraction> million) is in respect of contingent consideration for the acquisition in 2015 of the Novartis Vaccines business. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products, the achievement of certain milestone targets and movements in certain foreign currencies. As a result of the Group&#8217;s acquisition of Affinivax in 2022, contingent consideration payable of &#163;<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">501</ix:nonFraction>&#160;million is recognised at 31&#160;December 2022. This consideration is expected to be paid over a number of years and will vary in line with the achievement of certain development milestones and movements in the USD/GBP exchange rate. Sensitivity analysis on these balances is provided in Note 33, &#8216;Contingent consideration liabilities&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(b) Trade and other receivables and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets in scope of IFRS 9 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table reconciles financial instruments within Trade and other receivables and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial assets are predominantly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> earning. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> instruments include tax receivables, pension surplus balances and prepayments, which are outside the scope of IFRS 9. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables (Note&#160;26)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,166</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">887</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,053</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-current assets (Note&#160;24)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,160</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,194</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,632</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,676</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,810</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,200</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,047</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,247</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,851</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,876</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,660</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,536</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other receivables include trade receivables of &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,452</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,246</ix:nonFraction> million). The Group has portfolios in each of the three business models under IFRS 9: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction> million), measured at FVTPL, is held to sell the contractual cash flows as the receivables will be sold under a factoring arrangement, &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,327</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,943</ix:nonFraction> million), measured at FVTOCI, is held to either collect or sell the contractual cash flows as the receivables may be sold under a factoring agreement, and &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2022_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,075</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn12_31_2021_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,244</ix:nonFraction> million), measured at amortised cost, is held to collect the contractual cash flows and there is no factoring agreement in place. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">251</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_12" continuedAt="TextSelectionAppend_69049729_13"><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(c) Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities in scope of IFRS 9 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table reconciles financial instruments within Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial liabilities are predominantly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> instruments include payments on account, tax and social security payables and provisions which do not arise from contractual obligations to deliver cash or another financial asset, which are outside the scope of IFRS 9. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At&#160;FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-<br/> financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;At&#160;FVTPL</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial<br/> &#160;&#160;instruments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables (Note&#160;29)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,198</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,263</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions (Note&#160;32)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,121</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities (Note&#160;33)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities (Note&#160;34)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">815</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">899</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">869</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">921</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,068</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,212</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,280</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,134</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25,414</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,076</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,596</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,672</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,350</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26,022</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(d) Derivative financial instruments and hedging programmes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives are only used for economic hedging purposes and not as speculative investments and are classified as &#8216;held for trading&#8217;, other than designated and effective hedging instruments, and are presented as current assets or liabilities if they are expected to be settled within 12 months after the end of the reporting period, otherwise they are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> The Group has the following derivative financial instruments: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Fair&#160;value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Interest rate swap contracts<br/> (principal amount &#8211; &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt-sec:numwordsen">nil </ix:nonFraction>(2021: &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,996</ix:nonFraction> million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsNoncurrent" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsNoncurrent" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">167</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">160</ix:nonFraction> million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,197</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,469</ix:nonFraction> million))</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:HedgingInstrumentsLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">106</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentsLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsNoncurrent" contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsNoncurrent" contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts<br/> (principal amount &#8211; &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,908</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,728</ix:nonFraction> million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:HedgingInstrumentAssetsCurrent" contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives classified as held for trading</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">77</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:HedgingInstrumentLiabilitiesCurrent" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total derivative instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:HedgingInstrumentLiabilities" contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:HedgingInstrumentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">206</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:HedgingInstrumentLiabilities" contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">252</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_13" continuedAt="TextSelectionAppend_69049729_14"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022 and 31&#160;December 2021, the Group had no designated fair value hedges. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net investment hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, certain foreign exchange contracts were designated as net investment hedges in respect of the foreign currency translation risk arising on consolidation of the Group&#8217;s net investment in its European (Euro), Singaporean (SGD), Canadian (CAD) and Japanese (JPY) foreign operations as shown in the table above. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying value of bonds on page 249 included &#163;<ix:nonFraction name="gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,322</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,982</ix:nonFraction> million) that were designated as hedging instruments in net investment hedges. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flow hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2021 and 2022, the Group entered into forward foreign exchange contracts which have been designated as cash flow hedges. These were entered into to hedge the foreign exchange exposure arising on cash flows from Euro denominated coupon payments relating to notes issued under the Group&#8217;s European Medium Term Note programme, and to hedge foreign currency payments due on collaboration or licensing arrangements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group manages its cash flow interest rate risk by using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">floating-to-fixed</div></div> interest rate swaps. In addition, the Group carries a balance in reserves that arose from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-hedging</div> fluctuations in long-term interest rates when pricing bonds issued in prior years and in the current year. The balance is reclassified to finance costs over the life of these bonds. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the current year, the Group has designated certain foreign exchange forward contracts and swaps as cash flow and net investment hedges. Foreign exchange derivative financial assets and liabilities are presented in the line &#8216;Derivative financial instruments&#8217; (either as assets or liabilities) on the Consolidated balance sheet. The following tables detail the foreign exchange forward contracts and swaps outstanding at the end of the reporting period, as well as information on the related hedged items. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments to ensure that an economic relationship exists between the hedged item and hedging instrument. The Group enters into hedge relationships where the critical terms of the hedging instrument match exactly with the terms of the hedged item, and so a qualitative assessment of effectiveness is performed. If changes in circumstances affect the terms of the hedged item such that the critical terms no longer match exactly with the critical terms of the hedging instrument, the Group uses the hypothetical derivative method to assess effectiveness. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The main source of hedge ineffectiveness in these hedging relationships is the effect of the counterparty and the Group&#8217;s own credit risk on the fair value of the foreign exchange forward contracts and swaps, which is not reflected in the fair value of the hedged item attributable to changes in foreign exchange rates and ineffectiveness on rolling the cash flow hedges of the divestments mentioned above. No other sources of ineffectiveness emerged from these hedging relationships. <ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> ineffectiveness was recorded from cash flow hedges in 2022 (2021: &#163;<ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>). <ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> ineffectiveness was recorded from net investment hedges (2021: &#163;<ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction>). </div><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" contextRef="P01_01_2022To12_31_2022_ForeignExchangeForwardContractsAndSwapsMemberifrsfullHedgingInstrumentsAxis" escape="true" continuedAt="TextSelection_69050885"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:89%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> currency</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.23</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">USD</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.14</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</ix:nonNumeric></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">167</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction>&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">253</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_14" continuedAt="TextSelectionAppend_69049729_15"><ix:continuation id="TextSelection_69050885" continuedAt="TextSelectionAppend_69050885_1"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic<br/> change in<br/> value for<br/> calculating<br/> hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">160.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">JPY</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis">CAD</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">SGD</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,341</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,322</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,981</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6,851</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">617</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for calculating hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow hedge reserve/foreign<br/> currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Balance&#160;in&#160;cash&#160;flow&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve&#160;arising&#160;from&#160;hedging&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">relationships&#160;for&#160;which&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">accounting is no longer&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">applied&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from a highly probable forecast transaction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">617</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,120</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for<br/> calculating</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">USD</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.17</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">578</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">SGD</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">155.19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">JPY</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="gsk:DescriptionOfForeignCurrency" contextRef="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</ix:nonNumeric></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,998</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,982</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">459</ix:nonFraction>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,719</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5,176</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,118</ix:nonFraction>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">254</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_15" continuedAt="TextSelectionAppend_69049729_16"><ix:continuation id="TextSelectionAppend_69050885_1"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for&#160;calculating&#160;hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow&#160;hedge&#160;reserve/foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on<br/> Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,117</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" contextRef="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">873</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#163;<ix:nonFraction name="ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction> million) of balances in the ca<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>h flow hedge reserve arise from hedging relationships for which hedge accounting is no longer applied. </div><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line&#160;item&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><span style="-sec-ix-hidden:hidden69050893">Intangible</span></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets&#160;</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"></div><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense&#160;</div></ix:nonNumeric></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">617</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">194</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="-sec-ix-hidden:hidden69049975">Discontinued</span></div><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;">operations<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit&#160;or&#160;loss<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Line item in&#160;<br/> profit or loss&#160;<br/> in&#160;which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049915">Other </span>operating income/ (expense)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Other operating income/ (expense)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ix:nonNumeric>&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,117</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(<ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonNumeric name="ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ix:nonNumeric></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" contextRef="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassified to the Consolidated income statement on demerger of the Consumer Healthcare business </div></div></div></td></tr></table></ix:nonNumeric></ix:continuation><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">255</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_16" continuedAt="TextSelectionAppend_69049729_17"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group manages its cash flow interest rate risk by using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">floating-to-fixed</div></div> interest rate swaps, where at quarterly intervals the difference between fixed contract rates and floating rate interest amounts calculated by reference to the agreed notional principal amounts are exchanged. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are none of these swaps outstanding a<div style="display:inline;">t</div> 31&#160;December 2022. At 31&#160;December 2021, the interest rate risk on an element of future debt issuance had been managed by entering into forward starting interest rate swaps, effectively to lock in the interest rates on the debt in advance. These were closed out at the time of issuing the debt, and the resulting gain or loss held in the Cash flow hedge reserve and reclassified to income statement as the interest payments on the debt impacted the income statement until the debt was derecognised on demerger of the Consumer Healthcare business in July 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Forward starting interest rate swaps </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The forward starting interest rate contracts, exchanging floating interest for fixed interest, <div style="display:inline;">were</div> designated as cash flow hedges to hedge the interest variability of the interest cash flows associated with the future fixed rate debt. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate swaps </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" contextRef="P01_01_2022To12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" escape="true" continuedAt="TextSelection_69050887">The following tables provide information regarding interest rate swap and forward starting interest rate swap contracts outstanding and the related hedged items at 31&#160;December 2021. There were no such swaps at 31&#160;December 2022. Interest rate swap contract assets and liabilities are presented in the line &#8216;Derivative financial instruments&#8217; (either as assets or liabilities) on the Consolidated balance sheet.</ix:nonNumeric> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#163;<ix:nonFraction name="ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" contextRef="PAsOn12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction>&#160;million (2021: &#163;<ix:nonFraction name="ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction> million) of balances in the cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied. </div><ix:continuation id="TextSelection_69050887"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fair value for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Average</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">recognising</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Fair value&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">contracted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">principal</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">assets/&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fixed rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(liabilities)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AverageFixedInterestRateOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="6" scale="-2" format="ixt:num-dot-decimal">1.1038</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">668</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DerivativeFinancialAssetsLiabilities" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AverageFixedInterestRateOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="6" scale="-2" format="ixt:num-dot-decimal">1.3385</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">935</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DerivativeFinancialAssetsLiabilities" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 30 years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:AverageFixedInterestRateOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="6" scale="-2" format="ixt:num-dot-decimal">1.4515</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NominalAmountOfHedgingInstrument" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_pure" decimals="-6" scale="6" format="ixt:num-dot-decimal">393</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="gsk:DerivativeFinancialAssetsLiabilities" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction>&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;in</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">cash flow</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value used for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge&#160;reserve</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">calculating</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">for continuing</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedges</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">after tax</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rate</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ReserveOfCashFlowHedgesContinuingHedges" contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:continuation></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">256</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_17" continuedAt="TextSelectionAppend_69049729_18"><ix:nonNumeric name="gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" contextRef="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future<br/> cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer<br/> expected to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item<br/> affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049944">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049945">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)<br/> recognised&#160;in<br/> reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness<br/> is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expected to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049946">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049947">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income&#160;or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049948">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"></div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049949">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&gt;30 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" contextRef="PAsOn12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(e) Offsetting of financial assets and liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial assets and liabilities are offset and the net amount reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. There are also arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be offset in certain circumstances, such as bankruptcy or the termination of a contract. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables set out the financial assets and liabilities that are offset, or subject to enforceable master netting arrangements and other similar agreements but not offset, as at 31&#160;December 2022 and 31&#160;December 2021. The column &#8216;Net amount&#8217; shows the impact on the Group&#8217;s balance sheet if all offset rights were exercised. </div><ix:nonNumeric name="ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69050890"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross<br/> financial<br/> assets/<br/> (liabilities)<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross<br/> financial<br/> (liabilities)/<br/> assets&#160;set&#160;off</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Net&#160;financial<br/> assets/<br/> (liabilities)&#160;per</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">balance&#160;sheet</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related<br/> amounts&#160;not<br/> set off in the<br/> balance&#160;sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,166</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">190</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">257</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_18" continuedAt="TextSelectionAppend_69049729_19"><ix:continuation id="TextSelection_69050890"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net&#160;financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">amounts&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">balance</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,832</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,829</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">206</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">206</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,431</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">228</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amounts which do not meet the criteria for offsetting on the balance sheet but could be settled net in certain circumstances principally relate to derivative transactions under ISDA (International Swaps and Derivatives Association) agreements where each party has the option to settle amounts on a net basis in the event of default of the other party. As there is presently not a legally enforceable right of offset, these amounts have not been offset in the balance sheet, but have been presented separately in the table above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(f) Debt interest rate repricing table </div></div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfDebtSecuritiesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as all classes of borrowings other than lease liabilities. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating and fixed rate debt less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,785</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,714</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,030</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,490</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,505</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,736</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,001</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,953</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,979</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:Debt" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,158</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Original issuance profile:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fixed rate interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,355</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating rate interest</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,624</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">803</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,979</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:InterestBearingDebt" contextRef="PAsOn12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,158</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">258</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_19" continuedAt="TextSelectionAppend_69049729_20"><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(g) Sensitivity analysis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tables below illustrate the estimated impact on the income statement and equity as a result of hypothetical market movements in foreign exchange and interest rates in relation to the Group&#8217;s financial instruments. The range of variables chosen for the sensitivity analysis reflects management&#8217;s view of changes which are reasonably possible over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange sensitivity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group operates internationally and is primarily exposed to foreign exchange risk in relation to Sterling against movements in US&#160;Dollar, Euro and Japanese Yen. Foreign exchange risk arises from the translation of financial assets and liabilities which are not in the functional currency of the entity that holds them. Based on the Group&#8217;s net financial assets and liabilities as at 31&#160;December, a weakening and strengthening of Sterling against these currencies, with all other variables held constant, is illustrated in the tables below. The tables exclude financial instruments that expose the Group to foreign exchange risk where this risk is fully hedged with another financial instrument. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">99</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">155</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The equity impact, shown below, for foreign exchange sensitivity relates to derivative and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial instruments hedging the Group&#8217;s net investments in its European (Euro) foreign operations and cash flow hedges of its foreign exchange exposure arising on Euro denominated coupon payments relating to notes issued under the Group&#8217;s European Medium Term Note programme. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:ForeignExchangeSensitivityEquityImpactTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,290</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">964</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation in Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,034</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,515</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,080</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">814</ix:nonFraction>&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,557</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,176</ix:nonFraction>&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">259</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_20" continuedAt="TextSelectionAppend_69049729_21"><ix:nonNumeric name="ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk" contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tables below present the Group&#8217;s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the composition of net debt as shown in Note 30 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect future foreign currency cash flows. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">999</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">767</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,570</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,199</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">444</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">698</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">846</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">661</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,222</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">959</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">375</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">542</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate sensitivity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is exposed to interest rate risk on its outstanding borrowings and investments where any changes in interest rates will affect future cash flows or the fair values of financial instruments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#8217;s net interest charge, although the majority of cash and liquid investments earn floating rates of interest. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below hypothetically shows the Group&#8217;s sensitivity to changes in interest rates in relation to Sterling, US Dollar and Euro floating rate financial assets and liabilities. A 1% (100 basis points) movement in USD interest rates would cause an increase of &#163;<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction> to equity (2021: &#163;<ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">197</ix:nonFraction> million). A 1.5% (150 basis points) movement in USD interest rates would cause an increase of &#163;<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">nil</ix:nonFraction> to equity (2021: &#163;<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">297</ix:nonFraction> million). A 1% (100 basis points) or 1.5% (150 basis points) movement in EUR or Sterling interest rates is <ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="gsk:IncreaseDecreaseInEquityThroughInterestRateMovements." contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t deemed to have a material effect on equity. </div><ix:nonNumeric name="ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk" contextRef="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis" escape="true"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of interest rate movements</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">55</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Euro interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Euro interest rates</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements" contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><ix:continuation id="TextSelectionAppend_69049729_21"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(h) Contractual cash flows for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial liabilities and derivative instruments </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables provide an analysis of the anticipated contractual cash flows including interest payable for the Group&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial liabilities on an undiscounted basis. For the purpose of this table, debt is defined as all classes of borrowings except for lease liabilities. Interest is calculated based on debt held at 31&#160;December without taking account of future issuance. Floating rate interest is estimated using the prevailing interest rate at the balance sheet date. Cash flows in foreign currencies are translated using spot rates at 31 December. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in net debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">594</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15,362</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,934</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,097</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,034</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,063</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,856</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,134</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,199</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,086</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,322</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,008</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">146</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,553</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">51,115</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and&#160;other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities not<br/> in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,399</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,745</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">620</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">935</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,804</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,188</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,938</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,939</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,703</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,438</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,033</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,639</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,571</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,392</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankBorrowingsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,296</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,603</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FinanceLeaseLiability" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,015</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:FutureFinanceChargeOnFinanceLeases" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,377</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">56,444</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides an analysis of the anticipated contractual cash flows for the Group&#8217;s derivative instruments excluding equity options which do not give rise to cash flows, and other embedded derivatives, which are not material, using undiscounted cash flows. Cash flows in foreign currencies are translated using spot rates at 31 December. The gross cash flows of foreign exchange contracts are presented for the purpose of this table although, in practice, the Group uses standard settlement arrangements to reduce its liquidity requirements on these instruments. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash inflows</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash outflows&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash inflows</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash outflows&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> &#160;&#160;&#160;&#160;exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&#160;<br/> &#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign<br/> exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward&#160;<br/> starting&#160;<br/> &#160;&#160;&#160;&#160;interest&#160;rate&#160;<br/> swaps&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign&#160;<br/> &#160;&#160;&#160;&#160;exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> and&#160;swaps&#160;<br/> &#163;m&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,418</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,410</ix:nonFraction>)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction>)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,290</ix:nonFraction>)</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction>&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">259</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">220</ix:nonFraction>)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,418</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,410</ix:nonFraction>)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,252</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">337</ix:nonFraction>)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(<ix:nonFraction name="gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">41,290</ix:nonFraction>)</td></tr></table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">261</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049733"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45. Employee share schemes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK operates several employee share schemes, including the Share Value Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost after a three-year vesting period and the Performance Share Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost, subject to the achievement by the Group of specified performance targets. The granting of these restricted share awards has replaced the granting of options to employees as the cost of the schemes more readily equates to the potential gain to be made by the employee. The Group also operates savings related share option schemes, whereby options are granted to employees to acquire shares in GSK plc at a discounted price. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Grants of restricted share awards are normally exercisable at the end of the three-year vesting or performance period. Awards are normally granted to employees to acquire shares or ADS in GSK plc but in some circumstances may be settled in cash. Grants under savings-related share option schemes are normally exercisable after three years&#8217; saving. In accordance with UK practice, the majority of options under the savings-related share option schemes are granted at a price <ix:nonFraction name="gsk:AtPercentageBelowMarketPrice" contextRef="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% below the market price ruling at the date of grant. Options under historical share option schemes were granted at the market price ruling at the date of grant. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The value of the plans for participating employees has been maintained after the demerger of the Consumer Healthcare business through the effect of the share consolidation (see Note 37). The total charge for share-based incentive plans in 2022 was &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">314</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction>&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">330</ix:nonFraction> million). Of this amount, &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">243</ix:nonFraction>&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction>million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">266</ix:nonFraction> million) arose from the Share Value Plan. See Note 9, &#8216;Employee Costs&#8217; for further details. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated to reflect on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business. See Note&#160;41. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK share award schemes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Value Plan </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the Share Value Plan, share awards are granted to certain employees at no cost. The awards vest after two and a half to three years and there are no performance criteria attached. The fair value of these awards is determined based on the closing share price on the day of grant, after deducting the expected future dividend yield of <ix:nonFraction name="gsk:ExpectedFutureDividendYieldPercentageShareGranted" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.2</ix:nonFraction>% (2021: <ix:nonFraction name="gsk:ExpectedFutureDividendYieldPercentageShareGranted" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.8</ix:nonFraction>%; 2020: <ix:nonFraction name="gsk:ExpectedFutureDividendYieldPercentageShareGranted" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.0</ix:nonFraction>%) over the duration of the award. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfEmployeeShareValuePlanExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares and ADS issuable</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shares<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ADS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2019_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2019_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,633</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">34.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,353</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,416</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,116</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">36.68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,074</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,776</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">30.64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,538</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,718</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,975</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfOutstandingShareAwards" contextRef="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,429</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated to reflect the demerger of the Consumer Healthcare business and aid year on year volume comparability of awards granted to GSK employees. </div></td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance Share Plan </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the Performance Share Plan, share awards are granted to Directors and senior executives at no cost. The percentage of each award that vests is based upon the performance of the Group over a defined measurement period with dividends reinvested during the same period. For awards granted from 2016 to 2019, the performance conditions are based on three equally weighted measures over a three-year performance period. These were adjusted free cash flow, TSR and R&amp;D new product performance. For awards granted from 2020, the performance conditions are based on four measures over a <ix:nonNumeric name="gsk:EquallyWeightedMeasuresOverPerformancePeriod" contextRef="P01_01_2022To12_31_2022_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMemberGSKAwardType1Axis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> performance period. These are adjusted free cash flow (<ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2022To12_31_2022_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2021To12_31_2021_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2020To12_31_2020_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction></ix:nonFraction></ix:nonFraction>%), TSR (<ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2022To12_31_2022_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2021To12_31_2021_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2020To12_31_2020_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction></ix:nonFraction></ix:nonFraction>%), R&amp;D new product performance (<ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2022To12_31_2022_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2021To12_31_2021_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2020To12_31_2020_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction></ix:nonFraction>%) and pipeline progress (<ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2020To12_31_2020_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2021To12_31_2021_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:PercentageOfPerformanceSharePlan" contextRef="P01_01_2022To12_31_2022_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction></ix:nonFraction>%). For awards granted from 2022, the performance conditions are based on five measures over a three-year performance period. These are TSR (<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div>%), pipeline progress (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%), profit measure (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%), sale measure (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%) and ESG environment (<div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>%). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of the awards is determined based on the closing share price on the day of grant. For TSR performance elements, this is adjusted by the likelihood of that condition being met, as assessed at the time of grant. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, awards for the continuing business were made of <ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million shares at a weighted fair value of &#163;<ix:nonFraction name="gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">13.36</ix:nonFraction> and <ix:nonFraction name="gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million ADS at a weighted fair value of $<ix:nonFraction name="gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">35.88</ix:nonFraction>. At 31&#160;December 2022, there were outstanding awards over <ix:nonFraction name="gsk:NumberOfOutstandingAwards" contextRef="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction>&#160;million shares and <ix:nonFraction name="gsk:NumberOfOutstandingAwards" contextRef="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;million ADS. <br/></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> </ix:nonNumeric></div><ix:continuation id="TextSelection_69049733" continuedAt="TextSelectionAppend_69049733_1"><div style="position:relative;float:left; margin-left:3%;width: 6%;padding-right:0%;padding-bottom: 8pt;overflow:visible;padding-top: 14pt;"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/><br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:continuation><ix:continuation id="TextSelectionAppend_69049733_1" continuedAt="TextSelectionAppend_69049733_2"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr>
<td style="width:100%">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-weight:bold;display:inline;">262</div></td></tr></table></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_69049733_2" continuedAt="TextSelectionAppend_69049733_3"><div></div></ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_69049733_3" continuedAt="TextSelectionAppend_69049733_4"><div style="clear:both;max-height:0pt;"></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_69049733_4" continuedAt="TextSelectionAppend_69049733_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049733_5" continuedAt="TextSelectionAppend_69049733_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049733_6" continuedAt="TextSelectionAppend_69049733_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div></ix:exclude></ix:continuation> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_69049733_7" continuedAt="TextSelectionAppend_69049733_8">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table></ix:continuation><ix:continuation id="TextSelectionAppend_69049733_8" continuedAt="TextSelectionAppend_69049733_9"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_69049733_9" continuedAt="TextSelectionAppend_69049733_10"><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049733_10"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45. Employee share schemes </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share options and savings-related options </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For the purposes of valuing savings-related options to arrive at the share-based payment charge, a Black-Scholes option pricing model has been used. <ix:nonNumeric name="gsk:DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049735">The assumptions used in the model are as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_69049735"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;Grant</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.37</ix:nonFraction>%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.74</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.07</ix:nonFraction>)%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:DividendYieldShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.3</ix:nonFraction>%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendYieldShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.8</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:DividendYieldShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.2</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">36</ix:nonFraction>%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">27</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">27</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected life</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric name="gsk:ExpectedLifeOfShareOptionsGranted" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">3</ix:nonNumeric>&#160;years</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric name="gsk:ExpectedLifeOfShareOptionsGranted" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">3</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric name="gsk:ExpectedLifeOfShareOptionsGranted" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" format="ixt-sec:duryear">3</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Savings-related options grant price (including <ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPriceDiscount" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPriceDiscount" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPriceDiscount" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction></ix:nonFraction>% discount)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;<ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPrice" contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.39</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPrice" contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.07</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:SavingsRelatedOptionsGrantPrice" contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.34</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom: 0.375pt; vertical-align: bottom;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding for the Share Save Plan</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Savings-related</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">share option schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/> 000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Weighted<br/> exercise<br/> price</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,803</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.38</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Range of exercise prices on options outstanding at year end</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.34</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;&#160;&#160;&#160;&#163;<ix:nonFraction name="gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">14.15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average market price on exercise during year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;<ix:nonFraction name="gsk:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">16.15</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average remaining contractual life</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:WeightedAverageRemainingContractualLifeOfOutstandingShareOption" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;years</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Options over <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million shares were granted during the year under the savings-related share option scheme at a weighted average fair value of &#163;<ix:nonFraction name="gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.34</ix:nonFraction>. At 31&#160;December 2022, <ix:nonFraction name="gsk:NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.3</ix:nonFraction>&#160;million of the savings-related share options were not exercisable. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There has been no change in the effective exercise price of any outstanding options during the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Share Ownership Plan Trusts </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group sponsors Employee Share Ownership Plan (ESOP) Trusts to acquire and hold shares in GSK plc to satisfy awards made under employee incentive plans and options granted under employee share option schemes. The trustees of the ESOP Trusts purchase shares with finance provided by the Group by way of loans or contributions. The costs of running the ESOP Trusts are charged to the income statement. Shares held by the ESOP Trusts are deducted from other reserves and amortised down to the value of proceeds, if any, receivable from employees on exercise by a transfer to retained earnings. The trustees have waived their rights to dividends on the shares held by the ESOP Trusts. </div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share award schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NumberOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,814</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,065</ix:nonFraction></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NominalValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NominalValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CarryingValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">353</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CarryingValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:MarketValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">860</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MarketValueOfSharesHeldForShareAwardSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">371</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share option schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NumberOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">65</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NumberOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:NominalValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:NominalValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:CarryingValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:CarryingValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="gsk:MarketValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="gsk:MarketValueOfSharesHeldForShareOptionSchemes" contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">263</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="gsk:DisclosureOfPrincipalGroupCompaniesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;"><div style="font-weight:bold;display:inline;">46. Principal Group companies </div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049633"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following represent the principal subsidiaries and their countries of incorporation of the Group at 31&#160;December 2022. The equity share capital of these entities is shown in the percentage columns. All companies are incorporated in their principal country of operation except where stated. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric><ix:continuation id="TextSelection_69049633"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Group Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Operations UK Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Wellcome UK Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Capital plc</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Export Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Finance plc</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Holdings Limited</ix:nonNumeric><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline IHC Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.2) Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.3) Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.4) Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property Development Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Research &amp; Development Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Services Unlimited</ix:nonNumeric><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline UK Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline US Trading Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Setfirst Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">SmithKline Beecham Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare Finance Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare UK (No.3) Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Viiv Healthcare UK Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Scotland</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.1) Scottish Limited Partnership</ix:nonNumeric><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.2) Scottish Limited Partnership</ix:nonNumeric><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.3) Scottish Limited Partnership</ix:nonNumeric><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(d) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Affinivax, Inc</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Corixa Corporation</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline Capital Inc.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline Holdings (Americas) Inc.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline LLC</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GSK Equity Investments, Limited</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Human Genome Sciences, Inc</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Stiefel Laboratories, Inc</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Tesaro, Inc.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare Company</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"></div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline AG</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Switzerland</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">GlaxoSmithKline B.V.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">Netherlands</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Biologicals SA</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Belgium</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline GmbH &amp; Co. KG</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Pharma GmbH</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Austria</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Pharmaceuticals SA</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Belgium</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline S.A.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Spain</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">GlaxoSmithKline S.p.A.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">Italy</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis">GlaxoSmithKline Single Member A.E.B.E.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis">Greece</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis">GlaxoSmithKline Trading Services Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis">Republic of Ireland</ix:nonNumeric>)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">GSK Capital B.V.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">Netherlands</ix:nonNumeric>)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis">GSK Services Sp z o.o.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis">Poland</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK Vaccines GmbH</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">GSK Vaccines S.r.l.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">Italy</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis">JSC GlaxoSmithKline Trading</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis">Russia</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Laboratoire GlaxoSmithKline</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">France</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Laboratorios ViiV Healthcare, S.L.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Spain</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare GmbH</ix:nonNumeric> </div>(<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare S.r.l.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Italy</ix:nonNumeric>)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare SAS</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">France</ix:nonNumeric>)</div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction> <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Others</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis">Glaxo Saudi Arabia Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis">Saudi Arabia</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis">Glaxo Wellcome Manufacturing Pte Ltd</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis">Singapore</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis">GlaxoSmithKline (Thailand) Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis">Thailand</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Australia Pty Ltd</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Brasil Limitada</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Brazil</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis">GlaxoSmithKline Far East B.V.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis">Taiwan</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis">Turkey</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Inc.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis">GlaxoSmithKline K.K.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis">Japan</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis">GlaxoSmithKline Korea Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis">Republic of Korea</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis">GlaxoSmithKline Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis">Hong Kong</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis">GlaxoSmithKline Mexico S.A. de C.V.</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis">Mexico</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis">GlaxoSmithKline Pakistan Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis">Pakistan</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis">GlaxoSmithKline Pharmaceuticals Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis">India</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK Enterprise Management Co, Ltd</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">China</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis">GSK Pharma Vietnam Company Limited</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis">Vietnam</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ID Biomedical Corporation of Quebec</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare K.K</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Japan</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><ix:nonNumeric name="ifrs-full:NameOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare ULC</ix:nonNumeric> (<ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ix:nonNumeric>)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">78.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Directly held wholly-owned subsidiary of GSK plc. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Tax resident in UK. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP <div style="display:inline;">1</div> Limited&#8217;s share capital is <div style="display:inline;"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" contextRef="P01_01_2022To12_31_2022_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">99</ix:nonFraction></div>% indirectly owned by GSK plc and <div style="display:inline;"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" contextRef="P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction></div>% owned by Berkeley Square Pension Trustee Company Limited. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#8217;s share capital is <div style="display:inline;"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" contextRef="P01_01_2022To12_31_2022_GskGp2LimitedsShareCapital.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></div>% indirectly owned by GSK plc. </div></td></tr></table></ix:continuation><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The subsidiaries and associates listed above principally affect the figures in the Group&#8217;s financial statements. Each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Captial BV and GlaxoSmithKline LLC, is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Capital BV and GlaxoSmithKline LLC. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">See pages 307 to 314 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">264</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(243, 111, 33);">&#160;</div> <ix:nonNumeric name="gsk:DisclosureOfLegalProceedingsExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_69049958"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47. Legal proceedings </div></div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:nonNumeric> <div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelection_69049958" continuedAt="TextSelectionAppend_69049958_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in significant legal and administrative proceedings, principally product liability, intellectual property, tax, anti-trust, consumer fraud and governmental investigations. The most significant of these matters, other than tax matters, are described below. The Group makes provision for these proceedings on a regular basis as summarised in Note 2, &#8216;Accounting principles and policies&#8217; and Note 32, &#8216;Other provisions&#8217;. Note 2 also describes when disclosure is made of proceedings for which there is no provision. Legal expenses incurred and provisions related to legal claims are charged to selling, general and administration costs. The Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group&#8217;s aggregate provision for legal and other disputes (not including tax matters described in Note 14, &#8216;Taxation&#8217;) was &#163;<ix:nonFraction name="ifrs-full:LegalProceedingsProvision" contextRef="PAsOn12_31_2022" unitRef="Unit_GBP" decimals="-6" scale="6" format="ixt:num-dot-decimal">218</ix:nonFraction>&#160;million. There can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial statements. If this were to happen, it could have a material adverse impact on the results of operations of the Group in the reporting period in which the judgements are incurred or the settlements entered into. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intellectual property </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Intellectual property claims include challenges to the validity and enforceability of the Group&#8217;s patents on various products or processes as well as assertions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement</div> of those patents. A loss in any of these cases could result in loss of patent protection for the product at issue. The consequences of any such loss could be a significant decrease in sales of that product and could materially affect future results of operations for the Group. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coreg </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2014, GSK initiated suit against Teva for inducing infringement of its patent relating to the use of carvedilol (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coreg</div></div>) in decreasing mortality caused by congestive heart failure. In June 2017, the case proceeded to a jury trial in the US District Court for the District of Delaware. The jury returned a verdict in GSK&#8217;s favour, awarding GSK lost profits and reasonable royalties for a total award of $235.51&#160;million. On 29&#160;March 2018, the trial judge ruled on post-trial motions filed by Teva and found that substantial evidence at trial did not support the jury&#8217;s finding of induced infringement, overturning the jury award. GSK appealed, and on 2&#160;October 2020, a divided panel of the Court of Appeals for the Federal Circuit reversed the district court&#8217;s ruling and reinstated the jury award in GSK&#8217;s favour. </div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049958_1" continuedAt="TextSelectionAppend_69049958_2"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 2&#160;December 2020, Teva filed a petition for rehearing en banc. The court granted Teva&#8217;s petition, but only for a rehearing by the three-member panel that issued the original decision. On 5&#160;August 2021, the original panel issued its rehearing opinion where the majority again reinstated the jury&#8217;s damages award of $<ix:nonFraction name="gsk:DamagesAwardedToGSK" contextRef="PAsOn08_05_2021" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal">235.51</ix:nonFraction>&#160;million in GSK&#8217;s favour. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Teva again filed a petition for rehearing en banc which was rejected by the Court of Appeals for the Federal Circuit on 11&#160;February 2022. On 11&#160;July 2022, Teva filed a petition for writ of certiorari with the Supreme Court of the United States seeking to overturn the Federal Court decision. On 3&#160;October 2022, the Supreme Court invited the United States Solicitor General to file briefs expressing the views of the United States. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dolutegravir Proceedings </div></div></div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Tivicay/Triumeq </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In September 2021, ViiV Healthcare received a paragraph IV letter from Lupin relating to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div> 5mg dosage for oral suspension, challenging only the crystal form patent. On 2&#160;November 2021, ViiV Healthcare filed suit against Lupin in the US District Court for the District of Delaware. No trial date has yet been set. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Dovato </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In September 2019, ViiV Healthcare received a paragraph IV letter from Cipla relating to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> and challenging only the crystal form patent. On 4&#160;November 2019, ViiV Healthcare filed suit against Cipla in the US District Court for the District of Delaware. A settlement has been reached in the case. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Juluca </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In January 2020, ViiV Healthcare received a paragraph IV letter from Lupin relating to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div> and challenging the crystal form patent as well as a patent relating to the combination of dolutegravir and rilpivirine that expires on 24&#160;January 2031. On 28&#160;February 2020, ViiV Healthcare filed suit against Lupin on both patents. A settlement has been reached with Lupin. Additionally, on 12&#160;June 2020, Cipla sent ViiV Healthcare a paragraph IV letter related to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, and on 22&#160;July 2020, ViiV Healthcare filed suit against Cipla in federal court in Delaware. The court has not set a trial date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product liability </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is currently a defendant in a number of product liability lawsuits. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avandia </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are two pending US class actions brought by third-party payers which assert claims under the Racketeer Influenced and Corrupt Organizations Act (RICO) and state consumer protection laws. In December 2019, the Third Circuit Court of Appeals reversed the summary judgements granted in favour of the Group and remanded the third-party payer cases back to district court. Discovery is underway in the district court but no trial dates have yet been set. It is possible that a class certification hearing will be held in 2023. </div> </ix:continuation></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">265</div></div></td> </tr> </table> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47. Legal proceedings </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049958_2" continuedAt="TextSelectionAppend_69049958_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2019, the Group was contacted by several regulatory authorities regarding the detection of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-Nitroso-dimethylamine</div> (NDMA) in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> (ranitidine) products. Based on information available at the time and correspondence with regulators, the Group made the decision to suspend the release, distribution and supply of all dose forms of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> to all markets pending the outcome of the ongoing tests and investigations. Also, as a precautionary action, the Group made the decision to initiate a voluntary pharmacy/retail level recall of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> products globally. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 30&#160;April 2020, the European Medicines Agency (EMA) recommended the suspension of ranitidine medicines. Following the publication of the EMA&#8217;s recommendation, the Company communicated a decision not to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-enter</div> the market. In the US, FDA requested that all manufacturers withdraw ranitidine products from the market. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has been named as a defendant in approximately 4,500 personal injury cases in US state courts and the federal Zantac Multidistrict Litigation (MDL)&#160;court proceeding in the Southern District of Florida. There are approximately <ix:nonFraction name="gsk:LossContingencyNumberOfPlaintiffs" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Plaintiffs" decimals="0" scale="0" format="ixt:num-dot-decimal">84,000</ix:nonFraction> plaintiffs named in these cases. A significant majority of these plaintiffs were named in a series of multi-plaintiff complaints filed in Delaware state court and most of these plaintiffs were previously in the MDL Census Registry. They were removed because they allege a cancer other than the 5 cancers being pursued by the MDL plaintiffs. In the MDL, plaintiffs originally identified 10 different types of cancers they wished to pursue. Plaintiffs subsequently dropped 5 of the 10 cancers, and proceeded only as to bladder, esophageal, gastric, liver, and pancreatic cancers, although plaintiffs in state courts continue to pursue claims beyond the 5 designated cancers. There are 46,697 unfiled claims relating to the Group and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendants</div> (32,970 mapped to the Group) concerning the 5 designated cancers in the MDL Census Registry. There are also over 2,000 California state court cases subject to an agreement between the Group and the plaintiffs which suspends the statute of limitations to allow the plaintiffs to bring their claims at a later date. These filed and unfiled counts are subject to change. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 6&#160;December 2022, the court presiding over the federal MDL proceeding granted Defendants&#8217; Daubert motions, finding that Plaintiffs&#8217; experts&#8217; causation opinions regarding whether <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> can cause the five cancers at issue in the MDL (liver, bladder, pancreatic, esophageal, and stomach) are unreliable and thus inadmissible. Without expert causation opinions, the MDL Court granted summary judgment to GSK and the other brand defendants. The MDL Court found that &#8220;there is no scientist outside this litigation who concluded ranitidine causes cancer, and the plaintiffs&#8217; scientists within this litigation systemically utilized unreliable methodologies,&#8221; and failed to use &#8220;consistent, objective, science-based standards for the even-handed evaluation of data.&#8221; This ruling effectively dismissed approximately 2,200 filed cases in the MDL and is binding on all of the claims in the Census Registry. Plaintiffs have indicated they will appeal the MDL decision. </div> </ix:continuation></div> <div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049958_3" continuedAt="TextSelectionAppend_69049958_4"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the California <div style="font-style:italic;display:inline;">Zantac</div> litigation Cases JCCP 5150 (JCCP), the Court held a Sargon hearing regarding the admissibility of expert witness testimony, including the testimony of general and specific causation expert witnesses, for the first bellwether trial. The hearing occurred over a four-day period in February and March 2023. The first bellwether trial, which is a bladder cancer case, was expected to start on 27 February 2023 in the California JCCP, however the Court has moved the trial date to 24 July 2023. Three other California bellwether trials have been scheduled for May, August and October 2023, although these dates are likely to be extended as well.</div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Illinois Supreme Court recently consolidated all Illinois ranitidine cases in Cook County for pretrial proceedings with trial dates to be set at a later date, including the previously scheduled Madison County trial. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Beyond the personal injury actions, class actions alleging economic injury and a third-party payer class action also have been filed in federal court. Plaintiffs have moved to stay the class actions pending appeal of the Daubert ruling. Defendants oppose the request for stay and are asking the Court to dismiss the class actions. Outside the US, there are seven class actions pending against the Group in Canada, along with a class action in Israel. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Given the complex ownership and marketing of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> prescription and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (OTC) medicine over many years, numerous claims involve several defendants. As a result, some defendants have served one another, including the Group, with notice of potential indemnification claims about possible liabilities connected particularly with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> OTC. Given the early stage of the proceedings, the Group cannot meaningfully assess what liability, if any, it may have, nor can it meaningfully assess the liability of other parties under relevant indemnification provisions. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In addition, on 20&#160;March 2020, the Department of Justice (DOJ) sent the Group notice of a civil investigation it had opened into allegations of False Claims Act violations by the Group related to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div>. On 18&#160;June 2020, the DOJ served a Civil Investigative Demand on the Group, formalizing its request for documents. On the same day, the New Mexico Attorney General filed a lawsuit against multiple defendants, including the Group, alleging violations of state consumer protection and false advertising statutes, among other claims. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL;text-indent: 0px;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group was a defendant in over 400 product liability cases involving <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> pending in a Multidistrict Litigation (MDL)&#160;proceeding in the District of Massachusetts. The cases alleged that children suffered birth defects due to their mothers&#8217; ingestion of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> and/or generic ondansetron for pregnancy- related nausea and vomiting. Plaintiffs asserted that the Group sold <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> knowing it was unsafe for pregnant women, failed to warn of the risks and illegally marketed <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label&#8221;</div> for use by pregnant women. </div> </ix:continuation></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </div> <div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div> </div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">266</div></div></td> </tr> </table> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the financial statements continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47. Legal proceedings </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049958_4" continuedAt="TextSelectionAppend_69049958_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;June 2021, the MDL Court granted the Group&#8217;s motion for summary judgment on federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-emption</div> grounds. The Court found that the FDA was fully informed of all relevant safety information regarding <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> and had repeatedly rejected any attempt to add a birth defect warning to the label. At that time, the Court granted judgment for the Group in all cases pending in the MDL (approximately 431 cases) and closed the MDL proceeding. Plaintiffs appealed this decision and, on 9&#160;January 2023, the United States Court of Appeals for the First Circuit affirmed the district court&#8217;s decision in favour of the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There remains one state court case and four proposed class actions in Canada. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales and marketing and regulation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s marketing and promotion of its Pharmaceutical and Vaccine products are the subject of certain governmental investigations and private lawsuits brought by litigants under various theories of law. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Korea &#8211; Proceedings under Fair Trade Laws </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In August 2020, GSK Korea was indicted under Korea&#8217;s Monopoly Regulation and Fair Trade laws in relation to government tenders of HPV (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>) and PCV (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>) vaccines in 2018 and 2019. The prosecutor alleged that GSK Korea, through the actions of at least one of its employees, interfered with the tender process under the National Immunisation Programme by using &#8220;straw bidders.&#8221; </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A former GSK Korea employee was also charged in his individual capacity by the prosecutor in relation to the same matter. Further, a number of wholesalers are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendants</div> in the proceedings. On 1&#160;February 2023, the court rendered a guilty verdict in respect of all defendants. GSK Korea was fined KRW <ix:nonFraction name="gsk:FinePayable" contextRef="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis" unitRef="Unit_KRW" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction>&#160;million which is approximately &#163;<ix:nonFraction name="gsk:FinePayable" contextRef="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis" unitRef="Unit_GBP" decimals="0" scale="0" format="ixt:num-dot-decimal">45,000</ix:nonFraction>. Appeal proceedings are ongoing. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Korea Fair Trade Commission also has commenced proceedings regarding the same matter. GSK Korea is cooperating with the authorities on these matters. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-trust/competition </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain governmental actions and private lawsuits have been brought against the Group alleging violation of competition or anti-trust laws. </div></ix:continuation></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><ix:continuation id="TextSelectionAppend_69049958_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal </div></div></div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Purported classes of direct purchasers filed suit in the US District Court for the District of New Jersey alleging that the Group and Teva Pharmaceuticals unlawfully conspired to delay generic competition for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div>, resulting in overcharges to the purchasers, by entering into an allegedly anti-competitive reverse payment settlement to resolve patent infringement litigation. A separate count accuses the Group of monopolising the market. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 13&#160;December 2018, the trial judge granted plaintiffs&#8217; class certification motion, certifying a class of direct purchasers. The Group filed a Rule 23(f) motion in the Court of Appeals for the Third Circuit, challenging the class certification decision. On 22&#160;April 2020, the Court of Appeals vacated the lower court&#8217;s grant of class certification and remanded the issue back to the lower court for further analysis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 9&#160;October 2020, the district court heard argument on plaintiffs&#8217; renewed motion for class certification after remand. On 9&#160;April 2021, the district court denied Plaintiffs&#8217; motion for class certification of the putative direct purchaser class, leaving a potential class of brand-only purchasers. Plaintiffs moved to supplement their expert report and seek additional discovery to support the addition of certain generic purchasers. On 21&#160;January 2022, the district court denied Plaintiffs&#8217; motion to supplement their expert report and seek additional discovery and held that the issue of generic purchasers had already been decided and denied in the court&#8217;s ruling on decertification. The parties have conducted briefing on class certification as to the remaining brand-only purchasers, with plaintiffs also seeking to add a smaller category of purchasers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;February 2023, the district court denied Plaintiffs&#8217; renewed class certification motion. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> complaint was filed in the US District Court for the Eastern District of Pennsylvania on 2&#160;February 2023 by a group of alleged purchasers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial and corporate </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in certain contractual and/or commercial disputes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Royalty Dispute </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In October 2012, Tesaro, Inc. (now a wholly owned subsidiary of GSK) entered into two worldwide patent license agreements with AstraZeneca UK Limited related to niraparib (later approved as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div>). In May 2021, AstraZeneca filed a lawsuit against Tesaro in the High Court, England and Wales alleging that Tesaro failed to pay some of the royalties due under the license agreements. Tesaro has counterclaimed based on a calculated overpayment. A trial is scheduled for March 2023. </div></ix:continuation></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48. Post balance sheet events </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There is no material post balance sheet event that requires an adjustment or a disclosure within the financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">267</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_78" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;"><div id="ex15_2tx382677_39" style="display:inline;"></div>Company balance sheet &#8211; UK&#160;GAAP </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(254, 124, 1); letter-spacing: 0px; top: 0px;;display:inline;">(including FRS 101 &#8216;Reduced Disclosure Framework&#8217;) as at 31&#160;December 2022 </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fixed assets &#8211; investments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">E</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,881</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54,995</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">F</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,748</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,720</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash at bank</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,768</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #c4beb9;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,737</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #c4beb9;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">G</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(545</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(598</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total current liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(545</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(598</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,223</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,139</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets less current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40,104</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">57,134</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Provisions for liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">H</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">I</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(645</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(458</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39,446</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56,664</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:24pt">&#160;</td>
<td colspan="4" style="height:24pt">&#160;</td>
<td colspan="4" style="height:24pt">&#160;</td>
<td colspan="4" style="height:24pt">&#160;</td>
<td colspan="4" style="height:24pt">&#160;</td>
<td colspan="4" style="height:24pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Capital and reserves</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">J</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,347</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share premium account</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">J</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,440</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,301</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">K</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,420</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,420</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retained earnings:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50,596</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49,653</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit/(loss) for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">710</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,942</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Treasury shares transferred to the ESOP Trust</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,089</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends in specie</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,689</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid to shareholders</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,467</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,999</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">K</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,239</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50,596</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equity shareholders&#8217; funds</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39,446</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56,664</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The financial statements on pages 268 to 272 were approved by the Board on 9 March 2023 and signed on its behalf by </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Sir Jonathan Symonds </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Chair </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">GSK plc </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Registered number: 3888792 </div><div style="margin-top:20pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Company statement of changes in equity </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><div style="color: rgb(254, 124, 1); letter-spacing: 0px; top: 0px;;display:inline;">for the year ended 31&#160;December 2022 </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Share<br/> capital<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Share&#160;premium<br/> account</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Other<br/> reserves<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Retained<br/> earnings<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> equity<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,346</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,281</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,420</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49,653</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55,700</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit and Total comprehensive income attributable to shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,942</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,942</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,999</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,999</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares issued under employee share schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,347</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,301</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,420</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50,596</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,664</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit and Total comprehensive income attributable to shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">710</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">710</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Treasury shares transferred to the ESOP Trust</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,089</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,089</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends to shareholders (Note D)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,467</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,467</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends in specie (Note D)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(15,689</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,689</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares issued under employee share schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">139</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,347</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,440</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,420</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33,239</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39,446</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">268</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;">Notes to the company balance sheet &#8211; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">UK&#160;GAAP </div><div style="font-family: ARIAL; font-size: 14pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">(including FRS 101 &#8216;Reduced Disclosure Framework&#8217;)</div><div style="font-family: ARIAL; font-size: 22pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A) Presentation of the financial statements </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of business </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK plc is the parent company of GSK, a major global biopharma group which makes innovative vaccines and specialty medicines to prevent and treat disease. GSK&#8217;s R&amp;D focuses on the science of the immune system, human genetics and advanced technologies primarily in the following four therapeutic areas: infectious diseases, HIV, oncology and immunology/respiratory. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preparation of financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements, which are prepared using the historical cost convention (as modified to include the revaluation of certain financial instruments) and on a going concern basis, are prepared in accordance with Financial Reporting Standard 101 &#8216;Reduced Disclosure Framework&#8217; and with UK accounting presentation and the Companies Act 2006 as at 31&#160;December 2022, with comparative figures as at 31&#160;December 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As permitted by section 408 of the Companies Act 2006, the income statement of the company is not presented in this Annual Report. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company is included in the Group financial statements of GSK plc, which are publicly available. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following exemptions from the requirements of IFRS have been applied in the preparation of these financial statements, in accordance with FRS 101: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraphs 45(b) and 46 to 52 of IFRS 2, &#8216;Share-based payment&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">IFRS 7, &#8216;Financial Instruments &#8211; Disclosures&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraphs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91-99</div> of IFRS 13, &#8216;Fair value measurement&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraph 38 of IAS 1, &#8216;Presentation of financial statements&#8217; comparative information requirements in respect of paragraph 79(a)&#160;(iv) of IAS 1 </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraphs 10(d), 10(f), 16, 38(A), 38 (B to D), 40 (A to D), 111 and 134 to 136 of IAS 1, &#8216;Presentation of financial statements&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">IAS 7, &#8216;Statement of cash flows&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraph 30 and 31 of IAS 8, &#8216;Accounting policies, changes in accounting estimates and errors&#8217; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Paragraph 17 of IAS 24, &#8216;Related party disclosures&#8217; and the further requirement in IAS 24 to disclose related party transactions entered into between two or more members of a Group. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting convention and standards </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The balance sheet has been prepared using the historical cost convention and complies with applicable UK accounting standards. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting principles and policies </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The preparation of the balance sheet in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet. Actual amounts could differ from those estimates. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The balance sheet has been prepared in accordance with the company&#8217;s accounting policies approved by the Board and described in Note B. These policies have been consistently applied, unless otherwise stated. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key accounting judgements and estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">No key accounting judgements or estimates were required in the current year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B) Accounting policies </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign currency transactions </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Foreign currency transactions are recorded at the exchange rate ruling on the date of transaction. Foreign currency assets and liabilities are translated at rates of exchange ruling at the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividends paid and received </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends paid and received are included in the financial statements in the period in which the related dividends are actually paid or received. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investments in subsidiary companies </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in subsidiary companies are held at cost less any provision for impairment and also includes a capital contribution in relation to movements in contingent consideration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying value of investments are reviewed for impairment when there is an indication that the investment might be impaired. One of the assessment methods used is to compare the carrying value of each investment against its share of the net assets value of the investment or against its share of the valuation of the subsidiary based on expected discounted cash flows. The total amount of investments is also evaluated against the Group&#8217;s valuation on the basis of overall market capitalisation. Any impairment charge is recognised in the income statement in the year concerned. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets held for sale/distribution </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets are held for disposal/demerger only if available for immediate disposal/demerger in their present condition, a disposal/demerger is highly probable and expected to be completed within one year from the date of classification. Such assets are measured at the lower of carrying value and fair value less the cost of disposal. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-based payments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The issuance by the company to its subsidiaries of a grant over the company&#8217;s shares, represents additional capital contributions by the company in its subsidiaries. An additional investment in subsidiaries results in a corresponding increase in shareholders&#8217; equity. The additional capital contribution is based on the fair value of the grant issued, allocated over the underlying grant&#8217;s vesting period. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">269</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the company balance sheet &#8211; UK&#160;GAAP </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">(including FRS 101 &#8216;Reduced Disclosure Framework&#8217;) continued </div></div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current tax is provided at the amounts expected to be paid applying tax rates that have been enacted or substantively enacted by the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are only recognised to the extent that they are considered recoverable against future taxable profits. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the temporary differences are expected to be realised or settled. Deferred tax liabilities and assets are not discounted. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial guarantees </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Liabilities relating to guarantees issued by the company on behalf of its subsidiaries are initially recognised at fair value and amortised over the life of the guarantee. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C) Operating profit </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A fee of &#163;12,600 (2021: &#163;12,600) relating to the audit of the company has been charged in operating profit. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D) Dividends </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Directors declared four interim dividends resulting in a dividend for the year of 61.25 pence adjusted for the share consolidation. For further details, see Note 16 to the Group financial statements, &#8216;Dividends&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition, the demerger of the Consumer Healthcare business was implemented by GSK declaring an interim dividend as follows. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividend in specie of Haleon plc shares distributed to external shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividend in specie of Haleon plc shares distributed to the ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15,689</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E) Fixed assets &#8211; investments </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GlaxoSmithKline Services Unlimited</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">637</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GlaxoSmithKline Holdings (One) Limited</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GlaxoSmithKline Holdings Limited</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,888</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GlaxoSmithKline Consumer Healthcare Holdings Limited</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GlaxoSmithKline Mercury Limited</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shares in GSK LP Limited</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,493</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,069</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,376</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capital contribution relating to share-based payments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,139</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contribution relating to contingent consideration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">673</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">480</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,881</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">54,995</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The investments in GlaxoSmithKline Consumer Healthcare Holdings Limited were derecognised of as part of the demerger of the Consumer Healthcare business, which was executed in specie shares (see Note 41 to the Group financial statements). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">F) Trade and other receivables </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts due within one year:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK Corporation tax recoverable</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other debtors</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts owed by Group undertakings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,422</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,319</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,424</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts due after more than one year:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts owed by Group undertakings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">392</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,748</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,720</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The movement in the Amounts owed by Group undertakings in the period, as reflected within Notes F and G, primarily reflects the receipt of dividend income from subsidiaries including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-demerger</div> dividend from GlaxoSmithKline Consumer Healthcare Holdings Limited and utilisation of the company&#8217;s current account to fund the payment of interim dividends. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">270</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Notes to the company balance sheet &#8211; UK&#160;GAAP</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">(including FRS 101 &#8216;Reduced Disclosure Framework&#8217;) continued</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">G) Trade and other payables </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts due within one year:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other creditors</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">396</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">457</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration payable</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporation tax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts owed to Group undertakings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">545</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">598</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company has guaranteed debt issued by its subsidiary companies from one of which it receives fees. In aggregate, the company has outstanding guarantees over &#163;19.5&#160;billion of debt instruments (2021: &#163;22.4 billion). The amounts due from the subsidiary company in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within &#8216;Trade and other receivables&#8217; (see Note&#160;26). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">H) Provisions for liabilities </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(42</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The provisions relate to a number of legal and other disputes in which the company is currently involved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">I) Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration payable</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">458&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The contingent consideration relates to the amount payable for the acquisition in 2015 of the Novartis Vaccines portfolio. The current year liability is included within &#8216;Trade and other payables&#8217;. For further details, see Note 33 to the Group financial statements, &#8216;Contingent consideration liabilities&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">J) Share capital and share premium account </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Share<br/>premium<br/>account</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Share capital issued and fully paid</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,385,189,617</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,346</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,281</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,825,442</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,387,015,059</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,301</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impact of share consolidation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,077,403,011</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,731,293</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trust</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">114</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,311,343,341</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,347</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,440</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, of the issued share capital, 59,878,735 shares were held in the ESOP Trusts, 217,124,760 shares were held as Treasury shares and 4,034,339,846 shares were in free issue. All issued shares are fully paid and there are no shares authorised but not in issue. The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 45, &#8216;Employee share schemes&#8217;. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_167.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">271</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notes to the company balance sheet &#8211; UK&#160;GAAP </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">(including FRS 101 &#8216;Reduced Disclosure Framework&#8217;) continued </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">K) Retained earnings and other reserves </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The profit of GSK plc for the year was &#163;710&#160;million (2021: &#163;4,942&#160;million profit). After dividends paid and distributed in specie of &#163;19,156&#160;million (including the Consumer Healthcare business demerger dividend of &#163;15,689 million) (2021: &#163;3,999 million), and the effect of &#163;1,089&#160;million Treasury shares transferred to a subsidiary company (2021: &#163;nil) retained earnings at 31&#160;December 2022 stood at &#163;33,239&#160;million (2021: &#163;50,596 million), of which &#163;8,140&#160;million was unrealised (2021: &#163;38,896 million). Dividends to shareholders are paid out of the realised profits of the company, which at 31&#160;December 2022 amounted to &#163;25,099&#160;million (2021: &#163;11,700 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other reserves includes a capital redemption reserve and a reserve reflecting historical contributions of shares in the company which were issued to satisfy share option awards granted to employees of subsidiary companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">L) Divestment </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 18&#160;July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon plc, an independent listed company. The separation was effected by way of a demerger of 80.1% of GSK&#8217;s 68% holding in the Consumer Healthcare business to GSK shareholders. Following the demerger, 54.47% of Haleon plc is held in aggregate by GSK Shareholders, 6.03% is held by GSK (including shares received by GSK&#8217;s consolidated ESOT trusts) and 7.5% is held by three Scottish Limited Partnerships (SLPs) set up to provide collateral for a funding mechanism pursuant to which GSK will provide additional funding for GSK&#8217;s UK Pension Schemes. The aggregate ownership by GSK (including ownership by the ESOT trust and SLPs) after the demerger is 13.53%. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following completion of the Consumer Healthcare business demerger, on 18&#160;July 2022, GSK plc Ordinary shares were consolidated in order to maintain share price comparability before and after demerger. The consolidation was approved by GSK plc shareholders at a General Meeting held on 6&#160;July 2022. Shareholders of GSK plc received 4 new Ordinary shares with a nominal value of 31.25 pence each for each existing 5 Ordinary share which had a nominal value of 25 pence each. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">M) Group companies </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">See pages 307 to 314 for a complete list of subsidiaries, associates, joint ventures and other significant shareholdings, which forms part of these financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">272</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g382677f_273.jpg"/> </div><div style="margin-top: -810pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_40" style="margin-top:65pt; margin-bottom:0pt; margin-left:11%; font-size:60pt; font-family:ARIAL"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Investor </div></div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:60pt; font-family:ARIAL"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">information </div></div><div style="font-size:19pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:19pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160; </div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:88.5%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:57%"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In this section</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_79" style="color:White">Commercial Operations turnover </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">274</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_80" style="color:White">Three year record </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">276</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_81" style="color:White">Product development pipeline </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">278</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_82" style="color:White">Products, competition and intellectual property </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">282</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_83" style="color:White">Principal risks and uncertainties </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">285</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_84" style="color:White">Share capital and control </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">296</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_85" style="color:White">Dividends </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">298</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_86" style="color:White">Financial calendar 2023 </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_87" style="color:White">Annual General Meeting 2023 </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_88" style="color:White">Tax information for shareholders </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">299</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td>
<td colspan="2" style="height:4.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_89" style="color:White">Shareholder services and contacts </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">302</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_90" style="color:White">US law and regulation </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">304</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_92" style="color:White">Group companies </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">307</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#ex15_2tx382677_93" style="color:White">Glossary of terms </a></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top;text-align:right;"><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">315</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table></div><div style="margin-top: 285pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">273&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div id="ex15_2tx382677_41" style="margin-top:0pt; margin-bottom:0pt; font-size:21pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_42" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Financial record </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_79" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Commercial Operations turnover by therapeutic area 2022 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">HIV</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,749</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,756</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,310</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">683</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">-</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir products</div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5,191</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3,311</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,239</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">641</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,381</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">823</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">273</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">285</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,799</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,217</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">361</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">221</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">636</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">494</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,375</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">777</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">478</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">294</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">95</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">31</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Oncology</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">313</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">253</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">463</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">235</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflamm.</div> respiratory and other</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,609</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,830</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">366</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">413</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,146</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">949</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,423</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">881</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">242</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">40</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Specialty Medicines excl. pandemic</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,960</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,899</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,929</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,132</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Pandemic</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,309</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">828</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">456</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,025</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2,309</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">828</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">456</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,025</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Specialty Medicines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,727</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,385</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,157</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Meningitis</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,116</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">573</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">362</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">181</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">753</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">333</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">337</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">240</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">85</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(62</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(62</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Influenza</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">714</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">549</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(44</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(44</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">108</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/Flulaval</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">714</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">549</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">108</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Shingles</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,958</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,964</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">688</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">306</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shringrix</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2,958</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">60</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">46</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">688</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">306</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Established vaccines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,085</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,157</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">720</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,208</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Infanrix, Pediarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">594</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">327</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">136</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">594</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hepatitis</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">571</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">142</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">527</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">310</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">305</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix, Priorix Tetra, Varilrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">188</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">117</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">189</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">133</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Vaccines excluding pandemic</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,873</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,243</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,827</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,803</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Pandemic vaccines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic adjuvant</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">64</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Vaccines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,243</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,884</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,810</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Respiratory</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,548</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,209</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,384</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,955</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Arnuity Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">483</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">85</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avamys/Veramyst</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">321</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">256</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Flixotide/Flovent</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">545</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">353</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">74</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incruse Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">196</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Relvar/Breo Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,145</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">498</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">347</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Seretide/Advair</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,159</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">308</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">287</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">564</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,729</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,253</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">240</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">411</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">116</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">244</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other Respiratory</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">143</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">30</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">112</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Other General Medicines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,570</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">363</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">695</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,512</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dermatology</div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">376</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">270</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">576</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">425</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avodart</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">265</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">137</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,777</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">99</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">221</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,457</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">General Medicines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,572</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,079</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,467</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total Commercial Operations</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,542</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,348</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,434</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">274</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Financial record continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Commercial Operations turnover by therapeutic area 2021 </div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#163;%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">CER%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">HIV</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,777</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,898</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">685</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir products</div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">4,567</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2,774</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,151</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,381</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">763</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,882</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,190</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">452</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">240</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">517</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">393</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">111</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">787</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">428</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">302</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">127</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Oncology</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">489</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">274</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">195</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&gt;100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">395</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">212</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(&gt;100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-Inflamm.</div> respiratory and other</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,027</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,417</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">325</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">285</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">874</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">727</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,142</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">690</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Specialty Medicines excl. pandemic</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,293</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,589</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,714</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">990</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Pandemic</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">958</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">287</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">958</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">602</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">69</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">287</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Specialty Medicines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,251</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,191</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,783</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,277</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Meningitis</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">961</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">453</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">354</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">650</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">253</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">328</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">272</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">39</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(66</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(65</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(69</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(68</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Influenza</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">679</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">456</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/Flulaval</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">679</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">456</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">101</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">122</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Shingles</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,721</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,344</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">281</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">96</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shringrix</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,721</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,344</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">281</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">54</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">96</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Established vaccines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,970</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">977</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">700</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,293</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Infanrix, Pediarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">543</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">116</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">521</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">270</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">111</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hepatitis</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">460</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">541</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">111</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">312</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">357</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">312</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix, Priorix Tetra, Varilrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">113</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">150</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">24</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">104</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Vaccines excluding pandemic</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,331</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,230</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,436</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,665</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Pandemic vaccines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">447</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">242</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">205</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic adjuvant</div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">444</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">242</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Vaccines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,778</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,472</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,436</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,870</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Respiratory</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,048</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,920</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,344</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,784</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Arnuity Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">504</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">149</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avamys/Veramyst</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">298</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Flixotide/Flovent</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">444</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">275</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incruse Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">205</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Relvar/Breo Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,121</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">488</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">334</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Seretide/Advair</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,357</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">486</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">322</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">549</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy Ellipta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,217</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">854</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">718</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">390</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">108</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other Respiratory</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">137</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">110</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Other General Medicines</div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,619</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">331</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">807</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,481</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dermatology</div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">399</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&gt;(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">426</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">302</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avodart</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#eceded"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div></div></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">478</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">134</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,984</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">99</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">322</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">1,563</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">General Medicines</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,667</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">3,251</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">2,151</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">4,265</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#eceded"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total Commercial Operations</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,696</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">11,914</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">5,370</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#eceded">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded;text-align:right;">7,412</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#eceded">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">275</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Financial record continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_80" style="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Three-year selected financial data </div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A record of financial performance is provided, analysed in accordance with current reporting practice. The information included in the selected financial data (except for number of employees and adjusted results) is prepared in accordance with International Accounting Standards in conformity with the requirements of the Companies Act 2006 and also with IFRS as issued by the International Accounting Standards Board. Three year financial data is presented reflecting the restated results following the demerger of the Consumer Healthcare business. The financial results of 2019 and 2018 are not restated and are not presented here. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover by geographic region</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,542</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,914</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,148</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Europe</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,348</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,370</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,545</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">International</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,434</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,412</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,661</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group turnover by product group</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Specialty Medicines</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,251</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,778</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">General Medicines</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,667</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10,281</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specialty Medicines turnover</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,749</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,777</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,876</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Oncology</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">489</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">372</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflammation</div> and other</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,609</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,027</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,309</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">958</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,251</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vaccines turnover</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,116</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">961</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,029</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Influenza</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">714</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">679</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">733</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shingles</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,958</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,989</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Established Vaccines</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,085</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,970</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,231</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">64</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">447</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,778</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General Medicines</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,548</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,048</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,006</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,570</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,619</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,275</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,667</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10,281</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial results &#8211; Total</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from continuing operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,516</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,103</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,049</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,651</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,700</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation for the year</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,621</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,096</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,388</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">82.9p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122.4p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26.7p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22.0p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total basic earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">371.4p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">109.6p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">144.4p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109.2p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">81.8p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">120.9p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">257.0p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26.4p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21.7p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total diluted earnings per share</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">366.2p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">108,2p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">142.6p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK has revised its operating segments during the year. See Note 6 to the consolidated financial statements for more details. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed public company, GSK completed the divestment of Bangladesh on 30&#160;June 2020. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and the impact of Share Consolidation (see Note 37) of the consolidated financial statements. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">276</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Financial record continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three year selected financial data </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial results &#8211; Adjusted</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Continuing operating profit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,151</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,493</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,656</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Continuing profit before taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,358</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,774</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,851</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Continuing profit after taxation</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,220</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,856</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,035</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reconciliations between Total and Adjusted operating profit over the last three years can be summarised as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total continuing operating profit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,357</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,979</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible asset amortisation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">739</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">761</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">724</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible asset impairment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">296</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">200</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Major restructuring</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction-related items</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,750</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,143</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,237</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Divestments, significant legal and other items</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,388</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(539</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,662</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted continuing operating profit</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,151</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,493</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,656</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reconciliation between total and Adjusted earnings per share over the last three years can be summarised as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pence<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total continuing earnings per share</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">82.9p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122.4p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible asset amortisation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.6p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15.2p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.6p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible asset impairment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.8p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6.6p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4.1p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Major restructuring</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8.7p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24.3p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction-related items</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34.1p</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">18.1p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19.0p</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Divestments, significant legal and other items</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(31.5)p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21.2)p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(70.0)p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Adjusted continuing earnings per share</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139.7p</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110.3p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">114.4p</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Return on capital employed</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/m</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25.8</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">35.6</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For 2021 and 2022 return on capital employed is calculated as total profit before taxation as a percentage of average net assets over the year and is not restated. Return on capital employed is not calculated for 2022 as it is not meaningful (n/m) as the average net assets over the year include Consumer Healthcare. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance sheet</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39,377</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60,429</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60,184</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,769</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">18,674</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20,247</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60,146</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">79,103</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">80,431</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22,810</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(23,670</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(22,148</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27,240</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34,091</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(37,475</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(50,050</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(57,761</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(59,623</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,342</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20,808</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shareholders&#8217; equity</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,598</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15,055</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14,587</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(502</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,287</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,221</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total equity</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,342</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20,808</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of employees</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1) </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,946</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14,289</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15,706</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Europe</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,800</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">38,809</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">40,711</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">International</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25,654</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36,998</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37,649</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,400</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">90,096</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">94,066</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Manufacturing</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23,292</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32,141</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33,848</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,310</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">34,846</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36,391</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,605</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,014</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,730</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:3pt"></td>
<td colspan="4" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,193</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,095</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,097</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,400</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">90,096</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">94,066</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The geographic distribution of employees in the table above is based on the location of GSK&#8217;s subsidiary companies. The number of employees is the number of permanent employed staff at the end of the financial period. It excludes those employees who are employed and managed by GSK on a contract basis. </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The employee numbers have not been restated for the purposes of the Consumer Healthcare demerger. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">277</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Pipeline, products and competition </div></div><div style="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_43" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_81" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Pharmaceuticals and Vaccines product development pipeline </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:40%"></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:7.5pt;background-color:#e7e7e8"></td>
<td colspan="2" style="height:7.5pt;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Key&#160;&#160;</div></div></div></td>
<td rowspan="2" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="2" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8224;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#094;</div></td>
<td rowspan="2" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="2" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-license</div> or other alliance relationship with third party</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare, a global specialist HIV company with</div></td>
<td rowspan="2" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="2" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">EUA</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Phase I</div></td>
<td rowspan="3" style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td rowspan="3" style="vertical-align:top;background-color:#e7e7e8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Emergency Use Authorisation</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Evaluation of clinical pharmacology, usually conducted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">in volunteers</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">GSK, Pfizer, Inc. and Shionogi Limited as shareholders,</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">is responsible for developing and delivering HIV medicines</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Phase II</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Determination of dose and initial evaluation of efficacy,</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">BLA</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Biological Licence Application</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">conducted in a small number of patients</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">MAA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Marketing Authorisation Application (Europe)</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Phase&#160;III</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Large comparative study (compound versus placebo</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">NDA</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">New Drug Application (US)</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">and/or established treatment) in patients to establish</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">A</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Approved</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">clinical benefit and safety</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">S</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8">Submitted</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:10%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:8%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Achieved&#160;regulatory<br/>review milestones</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compound</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mechanism of Action/Vaccine Type</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAA</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NDA/BLA&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">momelotinib<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">JAK1, JAK2 and ACVR1 inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">myelofibrosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Registration</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">S:Nov22</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">S:Jun22</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Anti-Programmed Cell Death protein 1 receptor</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1L endometrial cancer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">(dostarlimab)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(PD-1)</div> antibody</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1L endometrial cancer combination with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula </div></div>(niraparib)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-small</div> cell lung cancer<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">1 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(niraparib)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Poly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ADP-ribose)</div> polymerase (PARP) 1/2 inhibitor</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1L maintenance ovarian cancer combination with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli </div></div>(dostarlimab)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1L maintenance non small cell lung cancer (NSCLC) combination with pembrolizumab</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-metastatic,</div> select biomarker population Breast Cancer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(</div></div>belantamab</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">ADC targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> maturation antigen</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2L+ multiple myeloma combination with Pomalyst and dexamethasone</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">mafodotin)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2L+ multiple myeloma combination with Velcade and dexamethasone</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Multiple myeloma in combination with</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">II</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">anti-cancer treatments (platform study)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">1L multiple myeloma combination with Velcade, Revlimid and dexamethasone</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">cobolimab<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-T-cell</div></div> immunoglobulin and mucin <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">domain-3</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TIM-3)</div> antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-small</div> cell lung cancer combination with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli </div></div>(dostarlimab) and docetaxel</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4428859 (EOS884448)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">anti-TIGIT</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-small</div> cell lung cancer combination with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli </div></div>(platform study)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4074386<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Anti-lymphocyte activation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gene-3</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(LAG-3)</div> antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Cancer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4381562<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">anti-PVRIG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Cancer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">3745417</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">STING cytosolic DNA pathway agonist</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Advanced solid tumors</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">I</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Myeloid malignancies</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">6097608<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">anti-CD96</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Cancer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XMT-2056</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">2 </div>(wholly owned by Mersana Therapeutics)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">STING agonist ADC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cancer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV&#094;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">HIV integrase strand transfer inhibitor (long-acting)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">HIV <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-exposure</div> prophylaxis</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Approved</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">S:Jun22</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A:&#160;Dec21</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">(cabotegravir)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection (400 mg/ml formulation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3640254</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV maturation inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">3 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3810109<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV broadly neutralising antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3739937</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV maturation inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4004280</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV capsid protein inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4011499</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV capsid protein inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4524184<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV integrase inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HIV infection</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Brand names appearing in italics are trade marks owned by or licensed to the GSK group of companies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Footnotes </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-registrational</div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK has an exclusive global license option to co-develop and commercialize the candidate </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">will not progress to Phase 3 </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">278</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Pipelines, products and competition continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pharmaceuticals and Vaccines product development pipeline </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:28%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Achieved&#160;regulatory<br/>review milestones</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compound</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mechanism of Action/Vaccine Type</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAA</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NDA/BLA&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Infectious&#160;Diseases</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy </div></div>(sotrovimab)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Anti-spike protein antibody</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Approved</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A:Dec21</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">EUA:</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">May21<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">4 </div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix </div></div>(MMR vaccine)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Live attenuated</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Measles, mumps, rubella prophylaxis (US)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Approved</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">A:&#160;Jun22</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo </div></div>vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Conjugated-liquid formulation</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Meningococcal A, C, W, Y disease prophylaxis in adolescents</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Approved</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">A: Oct22</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix </div></div>vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Live attenuated, PCV (Porcine circovirus) free</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Rotavirus prophylaxis (US)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Approved</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">A:&#160;Nov22</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="color: rgb(249, 179, 135); letter-spacing: 0px; top: 0px;;display:inline;">VidPrevtyn Beta</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Recombinant protein-adjuvanted vaccine</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Approved</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A:&#160;Nov22</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">(Sanofi)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">5</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3844766</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(RSV vaccine)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Respiratory syncytial virus prophylaxis in older adult population 60 years of age and older Respiratory syncytial virus prophylaxis in older adult population <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50-59</div> years of age</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Registration</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">III</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">S:Oct22</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">S:&#160;Oct22</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">SKYCovione</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(SK Bioscience)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">5</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein nanoparticle-adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Registration<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">6</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">S:Jul22</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">gepotidacin<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Triazaacenaphthylene bacterial type II</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Uncomplicated urinary tract infection (uUTI)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">topoisomerase inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Urogenital gonorrhea (GC)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">bepirovirsen<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">HBV antisense</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Hepatitis B</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Hepatitis B sequential therapy with Pegylated Interferon</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero </div></div>vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Meningococcal B disease prophylaxis 2 months of age and older (US)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3536819</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Men ABCWY vaccine)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; conjugated vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Meningococcal A, B, C, W, Y disease prophylaxis in adolescents</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">tebipenem pivoxil<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Antibacterial carbapenem</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Complicated urinary tract infection (UTI)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">7 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3036656<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Leucyl <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">t-RNA</div> synthetase inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Tuberculosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BVL-GSK098</div><div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Ethionamide booster</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Tuberculosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VIR-2482</div><div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">8</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Neutralizing monoclonal antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Influenza</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3437949<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Malaria fractional dose)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Malaria prophylaxis (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plasmodium falciparum</div></div>)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3536852<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Generalized Modules for Membrane Antigens (GMMA) vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Shigella diarrhea prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3528869<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Therapeutic HBV)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Prime-boost with viral vector <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-</div> or sequentially administrated with adjuvanted recombinant proteins</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Treatment of chronic Hepatitis B infections &#8211; aims at functional cure by controlling and resolving the clinical sequelae of the infection and reducing the need for further treatment</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4023393</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Men ABCWY, 2nd Gen)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; conjugated vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Meningococcal A, B, C, W, Y disease prophylaxis in adolescents and children 6 weeks and older</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4178116</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Varicella new strain)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Live attenuated vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization for the prevention of varicella in individuals from 12 months of age and older</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">sanfetrinem cilexetil<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Serine beta lactamase inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Tuberculosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4106647<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein-adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization of girls and women, boys and men <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(9-45</div> years), for the prevention of cancer, genital warts and precancerous or dysplastic lesions (girls, boys AIN only) caused by Human papillomavirus (HPV)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Brand names appearing in italics are trade marks owned by or licensed to the GSK group of companies. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Footnotes </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">4</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">As of Apr22, sotrovimab is no longer authorized to treat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in U.S. due to increases in the proportion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> cases caused by the Omicron BA.2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-variant</div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">5</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK is contributing pandemic adjuvant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines collaborations </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">6</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Approved in South Korea (Jun22) </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">7</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Phase 2 or 3 study start expected in 2023 </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">8</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK has exclusive option to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> post Phase 2 </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">279</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Pipelines, products and competition continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pharmaceuticals and Vaccines product development pipeline </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:8%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Achieved&#160;regulatory<br/>review milestones</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compound</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mechanism of Action/Vaccine Type</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAA</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NDA/BLA&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Infectious Diseases continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4388067</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(CHBV ASO combo)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Targeted Immunotherapy (viral vector; adjuvanted recombinant proteins) &amp; Direct Acting Antiviral (GSK&#8217;s bepirovirsen)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Treatment of chronic Hepatitis B virus infection in individuals &gt;18 years without decompensated cirrhosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">5101955<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Vaccine using Multiple Antigen Presenting System (MAPS) platform</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Prevention of pneumonia and invasive pneumococcal disease caused by the Streptococcus pneumoniae 24 serotypes included in the vaccine in children aged 6 weeks &#8211; 17 years.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">5101956<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Vaccine using Multiple Antigen Presenting System (MAPS) platform</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prevention of pneumonia and invasive pneumococcal disease caused by the Streptococcus pneumoniae 24 serotypes included in the vaccine in adults aged 18 years and older</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4406371</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(MMRV new strain)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Live attenuated vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3882347<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">FimH antagonist</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Uncomplicated urinary tract infection (uUTI)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3186899<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">9</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CRK-12</div> inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Visceral leishmaniasis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3494245<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Proteasome inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Visceral leishmaniasis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">2556286<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Mtb cholesterol dependent inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Tuberculosis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4182137 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(VIR-7832)</div><div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Anti-spike protein antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3923868</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">PI4K beta inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Viral COPD exacerbations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">2904545<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization for the prevention of the primary <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. difficile </div></div>diseases and for prevention of recurrences</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4429016<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein &#8211; bioconjugated &#8211; adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Klebsiella pneumoniae </div></div>prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3993129</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Recombinant subunit &#8211; adjuvanted vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cytomegalovirus (CMV)&#160;infection prophylaxis in females <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-49</div> years of age</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4382276<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">mRNA vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization for the prevention of disease caused by influenza viruses in adults 18 years and older</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4396687<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">mRNA vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization to prevent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> disease caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> virus in individuals 12 years and older</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3943104<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Therapeutic HSV)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Recombinant protein-adjuvanted</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization to suppress recurrence of Genital Herpes in adults aged 18 years and older.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4077164<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Bivalent Generalized Modules for Membrane Antigens (GMMA) vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Invasive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-typhoidal</div> salmonella</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4077164<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Bivalent Generalized Modules for Membrane Antigens (GMMA) vaccine and typhoid conjugate vaccine (TCV)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Invasive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-typhoidal</div> salmonella and typhoid fever</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3536867<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Bivalent Typhoid and Paratyphoid A conjugate</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Salmonella typhoid and paratyphoid (A)&#160;enteric fever</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3965193</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">PAPD5/PAPD7 inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Hepatitis B</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">5251738<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">TLR8 agonist</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Hepatitis B</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3772701<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">P falciparum </div></div>whole cell inhibitor (pyrrolidine amides)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Malaria</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4348413</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Generalized Modules for Membrane Antigens (GMMA) vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Active immunization to prevent gonorrhea in individuals age 16 years and older, regardless of previous gonorrhea infection history</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Brand names appearing in italics are trade marks owned by or licensed to the GSK group of companies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Footnotes </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">9</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Transition activities underway to enable further progression by partner </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">280</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Pipelines, products and competition continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pharmaceuticals and Vaccines product development pipeline </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Achieved&#160;regulatory<br/>review milestones</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compound</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mechanism of Action/Vaccine Type</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NDA/BLA&#160;&#160;&#160;&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Immunology and Respiratory</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nucala </div></div>(mepolizumab)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-IL5</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">COPD</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">depemokimab<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-IL5</div> (long-acting)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Asthma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chronic rhinosinusitis with nasal polyps (CRSwNP)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Eosinophilic granulomatosis with polyangiitis (EGPA)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Hypereosinophilic syndrome (HES)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">latozinemab<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Anti-Sortilin monoclonal antibody</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Frontotemporal Dementia (FTD) due to</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">III</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Heterozygous Mutations in the Progranulin Gene Amyotrophic Lateral Sclerosis (ALS)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">II</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Frontotemporal Dementia (FTD) due to Mutations in the C9orf72 Gene</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(belimumab)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">B lymphocyte stimulator monoclonal antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">Systemic sclerosis associated interstitial lung disease<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">7 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">3858279<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Anti-CCL17</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Osteoarthritis pain</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4527226 (AL101)<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Anti-sortilin monoclonal antibody</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Neurodegenerative disease</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">1070806</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Anti-IL18</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Atopic dermatitis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3888130<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-IL7</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Multiple sclerosis (MS)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity Driven</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jesduvroq</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(daprodustat)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">Prolyl hydroxylase inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">Anaemia of chronic kidney disease</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">Approved</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">S:Feb22</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:middle">A:Feb23</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">linerixibat</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Ileal bile acid transporter (IBAT) inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">Cholestatic pruritus in PBC (primary biliary cholangitis)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">III</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">4532990<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">HSD17B13 silencer</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-alcoholic</div> steatohepatitis (NASH)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">7 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">II</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #7f7f7f;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">4172239<div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">DNMT1 inhibitor</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sickle cell disease<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">10 </div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">I</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Brand names appearing in italics are trade marks owned by or licensed to the GSK group of companies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Footnotes </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9pt;vertical-align:top;text-align:left;">7</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Phase 2 or 3 study start expected in 2023 </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9pt;vertical-align:top;text-align:left;">10</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Imminent study start </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">281</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Pipelines, products and competition continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_44" style="font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_82" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Pharmaceutical products, competition and intellectual property </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 17%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 17%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 19%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 12%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 12%; font-family: ARIAL;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: bottom;"><div style="font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent expiry dates<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">1 </div></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Products</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compounds</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication(s)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">competitor brands</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EU</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Respiratory</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anoro Ellipta</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">umeclidinium bromide/ vilanterol trifenatate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">COPD</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Spiolto/Stiolto Respimat,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Utibron/Ultibro</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Breezhaler, Duaklir</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Genuair</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Bevespi Aerosphere,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Brimica Genuair</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027-2030</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2022-2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avamys/Veramyst</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">fluticasone furoate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Allergic rhinitis</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Dymista, Xhance, Nasonex,&#160;Fluticasone Gx</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Relvar/Breo Ellipta</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">fluticasone furoate/vilanterol trifenatate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Asthma, COPD</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Symbicort, Foster, Budesonide/Formoterol Gx&#160;Sirdupla, Dulera</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027-2030</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2022-2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Seretide/Advair</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">salmeterol xinafoate/ fluticasone propionate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Asthma, COPD</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Symbicort, Foster,<br/>Budesonide/<br/>Formoterol Gx<br/>Sirdupla, Dulera</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">expired</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">(<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diskus </div></div>device)</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2023-2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(HFA-device)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">expired</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">(<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diskus </div></div>device)</div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">expired</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(HFA-device)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trelegy Ellipta</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">fluticasone furoate/vilanterol trifenatate umeclidinium bromide</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">COPD, asthma</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Trimbow pMDI/<br/>NEXThaler, Breztri<br/>Aerosphere, Trixeo<br/>Aerosphere, Enerzair<br/>Breezhaler</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027-2030</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2022-2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(device)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ventolin HFA</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Salbutamol sulphate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Asthma, COPD</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">generic companies</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2023-2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(HFA-device)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">expired</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(HFA-device)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Xevudy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">sotrovimab</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Early treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-COV,</div><br/>bamlanivimab/<br/>etesevimab, Evusheld</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2041</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NBE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">NA</td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td colspan="3" style="padding-bottom: 2pt; vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Central nervous system</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">lamotrigine</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Epilepsy, bipolar disorder</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Vimpat, Trokendi XR, Inovelon,&#160;Keppra</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Keppra</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">levetiracetam</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Epilepsy</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Briviact, Vimpat,<br/>Lamictal, Depakene,<br/>Depacon</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">NA</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">NA</td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td colspan="3" style="padding-bottom: 2pt; vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cardiovascular and urogenital</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avodart&#160;&amp; Duodart</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">dutasteride dutasteride&#160;+&#160;tamsulosin</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Benign prostatic hyperplasia&#160;(BPH)</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products,<br/>Finasteride, Alpha</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Blockers</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-bacterials</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Augmentin</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Amoxicillin&#160;trihydrate/potassium clavulanate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Common bacterial infections</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">(Clavam, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Moxikind-CV,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Enhancin, Curam,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Calamox)</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Oral Cephalosporins</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8211; Cefuroxime axetil,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cefixime, Cefpodoxime,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cefdinir, Cephalexin</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Oral Macrolides &#8211; Azithromycin,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Clarithromycin</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">NA</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">expired</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6.75pt; vertical-align: top;;text-align:left;">1</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes Supplementary Protection Certificates which were granted in multiple countries in EU (including the UK) and patent term extensions granted in the US. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">282</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Pipelines, products and competition continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pharmaceutical products, competition and intellectual property </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 17%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 17%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 19%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 12%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="width: 12%; font-family: ARIAL;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: bottom;"><div style="font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent expiry dates<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">1 </div></div></div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Products</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compounds</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication(s)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">competitor brands</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EU</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dermatology</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermovate,</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Betnovate,</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cutivate,</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eumovate</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Clobetasol propionate, Betamethasone valerate, Fluticasone propionate, Clobetasone butyrate</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Inflammatory skin conditions</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other topical</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">corticosteroids like</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Mometasone furoate,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Methylprednisolone</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">aceponate and</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Hydrocortisone.</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Not marketed</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">in US</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Expired</td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">niraparib</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">ovarian cancer</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Lynparza, Rubraca</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2031</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blenrep</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">belantamab mafodotin</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">relapsed/refractory</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">multiple myeloma</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Sarclisa, Xpovio</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">2032</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">2032</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jemperli</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">dostarlimab</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">dMMR recurrent or advanced endometrial cancer, solid tumours</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Keytruda</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2034</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NBE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2034</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NBE)</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflammation</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta, Benlysta</div></div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(SC and IV)</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">belimumab</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">systemic&#160;lupus&#160;erythematosus, lupus nephritis</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Lupkynis, Saphnelo</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">2025</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">2026</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jesduvroq, Duvroq</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Daprodustat</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">anaemia of chronic kidney disease</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Evrenzo (roxadustat), vadadustat</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: rgb(243, 111, 33); font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIV</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Apretude</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Cabotegravir</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV prevention</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Descovy, Truvada</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cabenuva/Vocabria +&#160;Rekambys</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Cabotegravir, rilpivirine</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Descovy, Genvoya,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Odefsey, Biktarvy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rukobia</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Fostemsavir</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Trogarzo</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Dolutegravir, lamivudine</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Descovy, Genvoya,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Odefsey, Biktarvy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Dolutegravir, rilpivirine</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Descovy, Genvoya,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Odefsey, Biktarvy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Triumeq</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">Dolutegravir, lamivudine and abacavir</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Descovy, Genvoya,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Odefsey, Biktarvy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(167, 169, 172); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 1.5pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Dolutegravir</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">HIV/AIDS</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Isentress, Prezista</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Symtuza, Reyataz,</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Biktarvy</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(NCE)</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6.75pt; vertical-align: top;;text-align:left;">1</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">See Note 47 to the financial statements, &#8216;Legal proceedings&#8217;. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6.75pt; vertical-align: top;;text-align:left;">2</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes Supplementary Protection Certificates which were granted in multiple countries in EU (including the UK), and patent term extensions granted in the US. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6.75pt; vertical-align: top;;text-align:left;">a</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Related compounds/indications are measles, mumps and rubella vaccine/prophylaxisb. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6.75pt; vertical-align: top;;text-align:left;">b</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Related compound is varicella vaccine. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_275.jpg" style="width: 36px; height: 906px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">283</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Pipelines, products and competition continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Vaccine products, competition and intellectual property </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:17%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:17%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Patent expiry dates<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">2</div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Products</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compounds</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication(s)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">competitor brands</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EU</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bexsero</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top;white-space:nowrap">meningococcal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">group-B</div> vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Meningitis group B prevention</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Trumenba</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2027</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2028</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Boostrix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">diphtheria, tetanus, acellular pertussis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">diphtheria, tetanus, acellular Pertussis booster vaccination</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Adacel</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Infanrix Hexa/Pediarix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type B (EU)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Prophylaxis against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type B (EU)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Pentacel, Pediacel, Pentaxim, Pentavac, Hexaxim, Hexyon Vaxelis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">HPV 16 &amp; 18 virus like particles (VLPs), AS04 adjuvant (MPL + aluminium hydroxide)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">human papilloma virus type 16 and 18</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Gardasil (Silgard)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2028</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix Tetra</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">split inactivated influenza antigens (2 virus subtypes A and 2 subtype B)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">seasonal influenza prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Intenza, Flumist QIV, Vaxigrip QIV, Fluzone QIV, Fluzone High Dose</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FluLaval</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">split inactivated influenza antigens (2 virus subtypes A and 2 subtype B)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">seasonal influenza prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Vaxigrip, Mutagrip, Fluzone, Influvac, Aggripal, Fluad, Intenza, Flumist</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Menveo</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">meningococcal group A, C, W- 135 and Y conjugate vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Meningitis group A, C, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-135</div> and Y prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Nimenrix, Menactra</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2025</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2025</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priorix, Priorix Tetra<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">a,b </div>Varilrix<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">b </div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">live attenuated measles, mumps, rubella and varicella vaccine</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">measles, mumps, rubella and chickenpox prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">MMR II <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(M-M-RVaxPro)</div></div> Proquad, Varivax</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">expired</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rotarix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Human rotavirus RIX4414 strain</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Rotavirus prophylaxis</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Rotateq</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2026</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">conjugated pneumococcal polysaccharide</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Prophylaxis against invasive disease, pneumonia, acute otitis media</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">Prevenar (Prevnar)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">NA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #a7a9ac;vertical-align:top">2026</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">zoster vaccine recombinant, adjuvanted</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">herpes zoster (shingles)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zostavax</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2029</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2031</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">See Note 47 to the financial statements, &#8216;Legal proceedings&#8217;. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Includes Supplementary Protection Certificates which were granted in multiple countries in EU (including the UK), and patent term extensions granted in the US. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">a</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Related compounds/indications are measles, mumps and rubella vaccine/prophylaxisb. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:6.75pt;vertical-align:top;text-align:left;">b</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">Related compound is varicella vaccine. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">284</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div id="ex15_2tx382677_45" style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_83" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Principal risks and uncertainties </div></div><div style="font-size:20pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We outline below the principal risks and uncertainties relevant to GSK&#8217;s business, financial condition and operations that may affect our performance and ability to achieve our objectives. These are the risks that we believe could cause our actual results to differ materially from expected and historical results. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Operating in the biopharmaceutical sector carries various inherent risks and uncertainties that may affect our business. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We must comply with a broad range of laws and regulations which apply to the research and development, manufacturing, testing, approval, distribution, sales, and marketing of pharmaceutical and vaccine products. These affect the cost of product development, the time required to reach the market and the likelihood of doing so successfully on an uninterrupted basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As rules and regulations change, government interpretation evolves, and our business activities develop, the nature of a particular risk may also alter. Changes to regulatory regimes may be substantial. Any alteration in, and failure to comply with, applicable laws and regulations could materially and adversely affect our financial results. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Similarly, our global business exposes us to litigation and government investigations, including product liability litigation, patent and antitrust litigation and sales and marketing litigation. Litigation and government investigations, and the related provisions we may make for unfavourable outcomes and increases in related costs such as insurance premiums, could also materially and adversely affect our financial results. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">More detail on the status and various uncertainties in our significant unresolved disputes and potential litigation is set out in Note 47, &#8216;Legal proceedings.&#8217; </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">More details regarding our risk management framework and how we identify our principal risks can be found on pages 51 to 54 and incorporated herein. Other risks, not at the level of principal risk, and opportunities, related to Environmental, Social, and Governance (ESG), including environmental sustainability and climate change, are managed through our six focus areas, as described in our ESG Performance Report. Additional information on climate related risk management is in our climate related financial disclosure. See pages 55 to 62. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">UK regulations require a description of principal risks and uncertainties and explanation of how these are being managed or mitigated. Below is a description of each of our principal risks together with a summary of how we manage each risk across our businesses. They are not listed in order of significance and are consistent with the principal risks detailed on pages 53 to 54. In July 2022, the Board agreed that Separation was no longer a principal risk following the successful demerger and analysis of any residual risk. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patient safety </div></div></div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK, including our third parties, potentially fails to appropriately collect, review, follow up, or report human safety information, including adverse events, from all potential sources or that GSK potentially fails to act on any relevant findings in a timely manner. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK will not tolerate an unfavourable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">benefit-to-risk</div></div> profile for patients who use our products. As the most important consequence of ineffective pharmacovigilance is the potential for harm to patients, we maintain robust processes for managing human safety information, conducting timely safety signal detection, and ensuring appropriate measures are in place to manage risks to patients. GSK also intends to fully comply with pharmacovigilance and other relevant regulations worldwide. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> could result in inspection findings, regulatory scrutiny, civil or criminal sanctions and either temporary or permanent loss of product marketing authorisation. We regularly review and respond to all patient safety risks to limit the potential for reputational damage, loss of trust by patients and healthcare providers, product-related litigation, and loss of shareholder confidence. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are fully accountable for safeguarding patients; our failure to do so effectively could result most importantly in harm to patients, as well as reputational damage and/or product liability litigation. We conduct internal safety surveillance and rely on access to safety information from external sources. Information on the safety and efficacy of our products in humans is collected during clinical development, with more comprehensive information incorporated from real-world use once our products are marketed. There are examples of regulatory agencies using real-world evidence from sources which may not be accessible to the industry to supplement and validate the evidence we use to support the safety and efficacy of our products. There is a potential emerging risk that technology companies or other data custodians may similarly draw and communicate conclusions about the safety of our products based on digital health data collected through their platforms that is inaccessible by either the industry or regulatory agencies. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">285</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patient safety continued </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our licence to operate depends on our compliance with regulatory requirements worldwide, not only those directly related to patient safety but extending to privacy and information security regulations as well. Regulatory compliance depends on appropriate identification and management of human safety information by all employees and third parties acting on our behalf. We are pursuing innovative solutions to enhance our ability to perform pharmacovigilance, including Artificial Intelligence and Machine Learning technology to augment our capacity to manage increasing volumes of adverse event reports from varied sources, and advancing technical solutions for delivering safety information and risk minimisation measures to patients and health care providers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had an impact on pharmacovigilance activities by increasing public focus on safety and efficacy of medicines and vaccines, highlighting the importance of robust business continuity planning for uninterrupted safety oversight and regulatory compliance (including the ability to accommodate remote regulatory inspections), and accelerating automation to manage increasing volumes of adverse events. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Chief Medical Officer is accountable for the Patient Safety enterprise risk and human safety matters, in collaboration with the Head of Global Safety. A cross-enterprise safety governance board oversees implementation of our control framework, including risk management. Our Global Safety Board ensures that we address human safety proactively throughout a product&#8217;s lifecycle. Our global policy on management of human safety information requires that all employees immediately report issues relating to the safety of our products. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Third Party Oversight framework ensures that third parties who may encounter human safety information are identified and trained appropriately. We manage safety information for all products and from all sources in compliance with global regulations. This information allows us to detect safety signals for our products and take timely action on information that changes a product&#8217;s risk/benefit profile. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any actions are discussed beforehand with regulatory authorities, and can include updating the prescribing information, communicating with healthcare providers, restricting product prescribing/availability to help assure safe use, and carrying out further clinical trials. In certain cases, it may be appropriate to stop clinical trials or to withdraw a product (or a specific batch) from the market. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, we completed the simplification and optimisation of our core patient safety processes, which we expect to improve cross-functional stakeholder engagement in safety activities across GSK. We began automated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> processing of individual case safety reports to deliver better case quality and consistency as well as enhanced efficiency. Our Pharmacovigilance Operations model expanded to ensure connectivity between central and local safety teams. We have created resources for R&amp;D leaders that enable them to advocate the need for industry access to safety data from all sources as the best way to safeguard patients. In 2023, we will transition from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-vendor</div> to a single-vendor model for key operational activities which will improve efficiency and reduce the risk of regulatory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance.</div> We will also expand our Global Safety team to include additional expertise to optimise our strategy and approach to product-related risk mitigation/ minimisation. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product quality </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of quality for development and commercial products; compliance with industry practices and regulations in manufacturing and distribution activities; and terms of GSK product licenses and supporting regulatory activities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A failure to ensure product quality could have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">far-reaching</div> implications for patient safety, cause product launch delays, drug shortages or product recalls, and have regulatory, legal, and financial consequences. These could materially and adversely affect GSK&#8217;s reputation and financial results. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The external environment for product quality remains challenging, with increased cyber-attacks and data breaches across the industry. Cyber-attacks remain a key risk to the integrity of product quality data and its audit trail. We met our commitments for the 2021 European Medicines Agency (EMA) requirements for licensing of Medical Devices. We continue to plan for the deployment of the New Annex 1 guidance for the manufacture of Sterile Medicinal products which was published in September 2022 and sets an expectation for compliance by August 2023. We are actively managing this implementation in the context of global equipment and component supply chain constraints effecting the industry. We are increasingly applying advanced digital technologies and insights to drive scientific excellence to enhance the development, manufacture and testing of our products. For example, we use new electronic documentation systems and advanced laboratory information management tools. Our quality organisations are aligned to make sure quality procedures and governance can facilitate the new company strategy. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-pandemic</div> levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> inspections have resumed, and we continue to take steps to ensure our inspection readiness. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">286</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product quality continued </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We align an extensive global network of quality and compliance professionals, from site-level to senior management within each business unit to provide oversight and assist with the delivery of quality performance and operational compliance. We deliver this management oversight through a hierarchy of quality councils, an independent chief product quality officer and a global product quality office that oversees product quality risk across the company. We have developed and implemented a single quality management system that defines the quality standards and systems for our businesses associated with the development and commercialisation of our vaccines, specialty, and general medicines. A consolidation of regulatory requirements from markets across the world augments this system, which means it meets external expectations for product quality in the markets we supply. Our system is based on the internationally recognised principles from the ICH Q10 pharmaceutical quality system framework. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We routinely update our quality management system (QMS), so it keeps pace with the evolving external regulatory environment and new scientific understanding of our products and processes. We have also made our policies and procedures simpler to understand and implement and adopted innovative tools to make them more user-friendly. We regularly train staff in regulatory expectations and learnings from inspections and existing procedures so they can maintain Current Good Manufacturing Practice standards. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have implemented a risk-based approach to assessing and managing third party suppliers that provide materials used in our finished products. We expect contract manufacturers that make our products to comply with GSK standards and regularly conduct audits to provide us with assurance that they do. We have product incident committee processes in place to investigate product issues and make recommendations on remediation activities including, where necessary, the recall of medicines and vaccines to protect our patients and the public. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our established complaint process ensures we respond appropriately to product quality issues raised by patients. Independent functions review and triage allegations of noncompliance or misconduct received through formal and informal &#8216;Speak Up&#8217; channels. Global disciplinary and enforcement procedures apply to any breaches of our standards, and are initiated, as appropriate, following investigations. We use key risk indicators to support risk management activities and provide GSK&#8217;s Leadership Team and Risk Oversight and Compliance Council with an integrated assessment of product quality performance. We have completed all product assessments for the presence of nitrosamines and reported as necessary to all Health Authorities. We have also developed mitigation plans which will be executed throughout 2023 per the regulatory requirements. We are actively working with industry bodies and the European Regulatory Authorities to complete the safety evaluation of Titanium Dioxide in Medicines as well as identifying any potential substitutes. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial controls and reporting </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK fails to comply with current tax laws, fails to report accurate financial information in compliance with accounting standards and applicable legislation, or incurs significant losses due to treasury activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> with existing or new financial or new ESG reporting and disclosure requirements, or changes to the recognition of income and expenses, could expose GSK to litigation and regulatory action and could materially and adversely affect our financial results. Failure to comply with changes in the substance or application of the laws governing transfer pricing, dividends, tax credits and intellectual property could also materially and adversely affect our financial results. Failure to comply with applicable sanctions laws and regulations could result in GSK being investigated by relevant government agencies and authorities and/or in legal proceedings against us. Government investigations and litigation, can be unpredictable and regardless of their outcome, may be costly, require significant management attention, and damage our reputation. Inconsistent application of treasury policies, transactional or settlement errors, or counterparty defaults could lead to significant losses. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are required by the laws of various jurisdictions to publicly disclose our financial results and events that could materially affect the Group&#8217;s financial results. Regulators routinely review the financial statements of listed companies for compliance with new, revised, or existing accounting and regulatory requirements. We believe that we comply with the appropriate regulatory requirements concerning our financial statements and the disclosure of material information, including any transactions relating to business restructuring such as acquisitions and divestitures. However, should we be subject to an investigation into potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with accounting and disclosure requirements, this could lead to restatements of previously reported results and significant penalties. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Treasury group deals daily in high value transactions, mostly foreign exchange, and cash management transactions. These transactions involve market volatility and counterparty risk. The Group&#8217;s effective tax rate reflects the locations of our activities and the value they generate, which determine the jurisdictions in which profits arise and the applicable tax rates. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">287</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial controls and reporting continued </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These may be higher or lower than the UK statutory rate and may reflect regimes that encourage innovation and investment in R&amp;D by providing tax incentives which, if changed, could affect GSK&#8217;s tax rate. In addition, the worldwide nature of our operations means that our cross-border supply routes, necessary to ensure supplies of medicines and vaccines, can result in conflicting claims from tax authorities as to the profits to be taxed in individual countries. This can lead to double taxation, with profits taxed in more than one country. The complexity of tax regulations also means that we may occasionally disagree with tax authorities on the technical interpretation of a particular area of tax law. The tax charge included in our financial statements is our best estimate of tax liability pending any audits by tax authorities. We expect there to be a continued focus on tax reform, driven by initiatives by the OECD and the EC to address the tax challenges arising from digitalisation of the economy. Together with domestic initiatives around the world, these may result in significant changes to established tax principles and an increase in tax authority disputes. Regardless of their merit or outcomes, these may be costly, divert management attention and adversely impact our reputation and relationship with key stakeholders. Laws, regulations, orders and other measures restrict dealings with certain countries, governments, government officials, entities, individuals, use of financial institutions and movement of funds. Circumvention of sanctions and export controls can be a criminal offence and GSK seeks to comply with its sanctions obligations. While we believe the Group complies with all applicable sanctions in all material respects, such laws are complex and continue to evolve rapidly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We keep up to date with the latest developments in financial reporting requirements by reviewing updates from regulators, working with our external auditor and legal advisors and performing and responding to emerging risks. Financial results are reviewed and approved by regional management, before being reviewed by GSK&#8217;s Group Financial Controller and Chief Financial Officer (CFO). This allows our Financial Controller and CFO to assess the evolution of the business over time, and to evaluate its performance to plan. Significant judgements are reviewed and confirmed by senior management. We integrate technical or organisational transformation, newly acquired activities and external risks into our risk assessments and apply appropriate controls and reviews. We maintain a control environment designed to identify material errors in financial reporting and disclosure. We have a standardised global financial reporting operating model. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The design and operating effectiveness of key financial reporting controls are regularly reviewed by management and tested by external third parties. The few locations which are not on the standard model apply a minimum standard set of controls which are reviewed by management and monitored independently. This gives us assurance that controls over key financial reporting and disclosure processes are operating effectively. Our Global Finance Risk Management and Controls (FRMC) group provides extra support during significant transformations, such as system deployment or management/ structural reorganisations. We add operational resources and adapt programme timelines to ensure processes and controls are maintained during significant changes. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Disclosure Committee, reporting to the Board, reviews GSK&#8217;s quarterly results and annual report. Throughout the year, in consultation with its legal advisors, the Disclosure Committee also determines whether it is necessary to disclose publicly information about the Group through stock exchange announcements. The Treasury Management Group meets regularly to ensure that liquidity, interest rate, counterparty, foreign currency transaction and foreign currency translation risks are all managed in line with the prudent approach detailed in the risk strategies and policies adopted by our Board. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Counterparty exposure is subject to defined limits approved by the Board for both credit rating and individual counterparties. The Middle Office within Treasury monitor the management of counterparty risk in line with agreed policy with oversight from a corporate compliance officer, operating independently of Treasury. Further details on mitigation of Treasury risks can be found on pages 246 to 248. We manage tax risk through robust internal policies, processes, training, and compliance programmes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We maintain open and constructive relationships with tax authorities worldwide. We monitor government debate on tax policy in our key jurisdictions, so that we can understand any potential future changes in tax law and share an informed point of view. Where relevant, we provide pragmatic and constructive business input to tax policy makers, either directly or through industry trade bodies. This includes advocating reform to support economic growth and job creation, as well as the needs of our patients and other key stakeholders. Our tax affairs are managed on a global basis by a team of tax professionals, led by the Global Head of Tax, who work closely with the business on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> basis. The Global Tax team is suitably qualified for the roles they perform, and we support their training needs so they can provide up to date technical advice in line with their responsibilities. We submit tax returns according to statutory time limits and engage proactively with tax authorities to ensure our tax affairs are current, entering into continuous audit programmes and advance pricing agreements where appropriate. These arrangements provide long-term certainty for both tax authorities and GSK over the tax treatment of our business, based on full disclosure of all relevant facts. We seek to resolve any differences of interpretation in tax legislation with tax authorities in a cooperative manner. In exceptional cases, we may have to resolve disputes through formal proceedings. GSK is committed to complying with all applicable sanctions, laws and regulations, and has deployed a programme to enable management of sanctions risk. The programme, jointly led by GSK Finance and Legal&#160;&amp; Compliance, is made up of various systems and controls including, but not limited to, policies and procedures, training and awareness, screening, monitoring and risk reporting. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">288</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-bribery and corruption (ABAC)</div></div> </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to comply with applicable laws, regulations, or internal requirements and to ensure appropriate controls and governance over bribery and corruption in business activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Failure to mitigate this risk could expose GSK and associated persons to governmental investigation, regulatory action, and civil and criminal liability. It may compromise GSK&#8217;s ability to supply its products under certain government contracts. In addition, failure to prevent bribery or corruption could have substantial implications for GSK&#8217;s reputation and the credibility of senior leaders. It might erode investor confidence in our governance, risk management and future performance, and have a consequential negative impact on share performance. It could also lead to the imposition of significant financial penalties and the imposition of additional reporting obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There continues to be a strong enforcement appetite for foreign bribery investigations and prosecutions, with a particular focus on the conduct of multinational companies wherever they operate. Financial penalties handed down in proven corruption cases are often very significant. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disruption to global supply chains and the commercial pressures caused by higher than usual inflation rates are likely to increase the risks of bribery and corruption in certain contexts. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">However, greater transparency and collaboration among enforcement authorities, advances in technology and the use of data analytics are providing better platforms to streamline processes and detect potential issues. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have an enterprise-wide ABAC programme designed to ensure compliance with applicable laws and regulations prohibiting bribery and corruption and related offences. It builds on our business standards and culture to form a comprehensive and practical approach to compliance that responds to the evolving nature of our business. GSK&#8217;s ABAC Governance Board oversees and provides programme governance and enterprise risk management which includes representation from key functional areas. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We continue to enhance our controls around third-party engagements to ensure that they are sufficient to meet evolving and emerging risks. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We plan to continue with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-transaction ABAC due diligence, and to increase the capabilities in the organisation around the onboarding, continual monitoring and management of third parties. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We continue to assess and understand our money laundering risk exposure and mitigate any existing risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Code of Conduct, culture, and commitment to zero tolerance towards bribery and corruption are integral to how we mitigate this risk. In light of the complexity and geographic breadth of the risk, we constantly evolve our oversight of activities and data, reinforce to our workforce GSK&#8217;s clear expectations regarding acceptable behaviours, and maintain regular communications with local markets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We built our ABAC programme based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> principles to help us manage risk from the top down and the bottom up. For example, the programme includes senior-level commitment from our Board and leadership, and a data analytics programme to create and embed local key risk indicators to enable targeted intervention and risk management activities. We continue to actively consider improvements to the programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ABAC programme is underpinned by our global ABAC policy and other written standards and controls which address the business activities that give rise to bribery and corruption risks and establish due diligence requirements for the engagement of third parties. The programme also mandates enhanced controls over interactions with government officials and during business development transactions. We have a dedicated team responsible for the programme&#8217;s implementation and evolution. The ABAC team works with other groups across the organisation to address and improve controls and monitoring requirements. Audit&#160;&amp; Assurance and independent business monitoring teams complement the ABAC team&#8217;s work and provide added assurance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We use issues found during oversight and assurance exercises and investigations to identify areas for specific intervention in our markets and to drive the continuous improvement of the programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We provide mandatory ABAC training at least annually to employees and relevant third parties differentiated according to seniority, roles and responsibilities, and geographic location. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Formal and informal &#8216;Speak Up&#8217; channels are available to report misconduct or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance.</div> The central investigations team reviews and triages allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> and triggers investigation as appropriate. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">289</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial practices </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially engage in commercial activities that fail to comply with laws, regulations, industry codes, and internal controls and requirements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Failure to engage in activities that are consistent with the letter and spirit of the law, industry regulations, or the Group&#8217;s requirements relating to sales and promotion of medicines and vaccines; with appropriate interactions with healthcare professionals (HCPs), organisations and patients; with legitimate and transparent transfers of value; and with pricing and competition (or antitrust) regulations in commercial practices, including trade channel activities and business tendering, could materially and adversely affect our ability to deliver our strategy and long-term priorities. Additionally, it may result in incomplete awareness of the risk/benefit profile of our products and possibly suboptimal treatment of patients and consumers; governmental investigation, regulatory action and legal proceedings brought against the Group by governmental and private plaintiffs which could result in government sanctions, and criminal and/or financial penalties. Any practices that are found to be misaligned with our values and expectations could also result in reputational harm and dilute the trust established with external stakeholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We operate in a highly regulated and extremely competitive biopharma industry, amongst peers who make significant product innovations and technical advances and intensify price competition. Additional external factors impacting our business operations include the ongoing effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic, access limitations to our customers, macroeconomic inflationary dynamics, and pricing pressure across markets. To achieve our strategic objectives, we must continue to develop commercially viable new products and deliver additional uses for existing products that address the needs of patients, consumers, HCPs and payers. Financially, new products/indications carry with them an uncertainty with regards to future success. Product development is costly, lengthy, and uncertain, and carries with it the potential for failure at any stage. Even after successful product development, we face challenges in how we launch, and our competitors&#8217; products or pricing strategies could render our assets less competitive. We support product innovation through our continued focus on both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> and virtual engagement, with a constant focus on our patient. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Once we have an approved medicine or vaccine, it is our obligation to provide important information to the healthcare community in various ways, always in a responsible, legal, and ethical manner. Appropriate product promotion ensures HCPs have access to the information they need, that patients and consumers have the facts about the medicines and vaccines they require, and that products are prescribed, recommended, or used in a manner that provides healthcare benefit. We are committed to the ethical and responsible commercialisation of our products in support of our purpose to improve the quality of human life and get ahead of disease together. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">To achieve our strategic objectives, we must meet price expectations of payers, HCPs, consumers, and the community. Our culture provides a guide for how we lead and make decisions. We constantly strive to do the right thing and deliver quality medicines and vaccines and sustain reliable supply to meet customer needs. In doing so, we seek to ensure our actions reflect GSK&#8217;s values, behaviours, and purpose. We understand the impact of data on our industry and strive to become an organisation that makes data-driven decisions; this approach is aligned to our efforts to become more agile and work at pace. GSK has acted to enhance and improve our policies and standards, application of data analytics and our channel activities. We have evolved policies and standards incrementally to ensure that commercial activities that we undertake or are conducted on our behalf are executed within our established governance. We train employees on relevant information with a focus on interactive learning and elements of behavioural science. All our commercial activities worldwide must conform to high ethical, regulatory, and industry standards. Where local standards differ from global ones, we apply those that are most stringent. Where the standards of an acquired company or joint venture partner differ from our global standards, we remediate legacy policies and implement revisions, so they align. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our businesses continue to use our internal control framework to support the assessment and management of risks. Business unit risk management and compliance boards, which manage risks across global and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-country</div> business activities, oversee commercial activities and their monitoring programmes. All promotional materials and activities must be reviewed and approved according to our policies and standards and conducted in accordance with local laws and regulations; these requirements seek to ensure that such materials and activities fairly represent the Group&#8217;s products or services. Where necessary, in the event of misconduct, we have disciplined employees, up to and including termination of contract, and clawed back remuneration from senior management. We have continued to evolve our incentive programme for sales representatives to better recognise and reward individual effort. In nearly all markets, the capped variable pay element of representatives&#8217; compensation is evaluated on the basis of individual sales targets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We allow fair-market value payments to be made by GSK to expert practitioners to speak about our innovative medicines and vaccines during a restricted period in a product&#8217;s lifecycle, or when new and competitive data is published. To support this, we have rolled out a global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> process across GSK in 2022 to drive consistent ways of working and efficiencies and strengthen controls through automation and use of data. Where permitted we report payments to individual HCPs as part of our commitment to transparency and responsible disclosure. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">290</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scientific and patient engagement </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to engage externally to gain insights, educate and communicate on the science of our medicines and associated disease areas, and provide grants and donations in a legitimate and transparent manner compliant with laws, regulations, industry codes and internal controls and requirements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Without controls in place, the risk could result in real, perceived, or disguised promotion including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> and prior-authorisation promotion, and real or perceived provision of medical advice. This in turn could lead to criminal investigations and penalties, civil litigation, or competitor complaints. At the same time, if we do not engage fully and appropriately, this could result in patient harm, failure to advance science and innovation, reputational damage, and financial loss. Such consequences may reduce the trust of the public, patients, healthcare professionals, payers, regulators, and governments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Scientific and patient engagements are diverse <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-promotional</div> activities directed at healthcare professionals, patients, payers, and external stakeholders. Such engagements aim to improve patient care through the exchange or provision of knowledge on the use of our products and related diseases. Scientific and patient engagement with external stakeholder groups is vital to GSK, as a research-based biopharma company that is ambitious for patients and is necessary to advance science and medicine. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We expect our activities to be scientifically sound and accurate, conducted ethically and transparently, and compliant with applicable codes, laws, and regulations. There are many industry and local codes and laws and other regulations that apply (such as Privacy, Data integrity). That means measured risk-taking, rooted in sound ethical considerations, and principles-based decision-making, training, communication, and monitoring of such activities are key to managing the risk and enabling full and appropriate engagement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Chief Medical Officer (CMO) oversees all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-promotional</div> scientific and patient engagement as enterprise risk owner. The GSK Code of Practice is the key internal policy for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-promotional</div> engagement activities. These activities include scientific interactions, support for medical education, advice seeking, gathering insights on unmet needs of patients, scientific communication of our research, and disease awareness. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Since the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic we have seen a continued increase in virtual engagements (e.g. with external experts, advisory boards, patient advocacy, patient engagements and scientific congresses). We further developed and modernised our digital approach to HCPs, our patient engagement framework and insight-gathering, and applied our internal principles and policies to this rapidly changing and growing environment. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We continuously improve our internal controls and networks to identify emerging risks early and to support staff to conduct activities in compliance with GSK&#8217;s culture and policies, local laws, and regulations, while building effective risk management and management monitoring systems. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Data ethics and privacy </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ethically collect; use; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-use</div> through artificial intelligence, data analytics or automation; secure; share and destroy personal information in accordance with laws, regulations, and internal controls and requirements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> with data privacy laws globally could lead to harm to individuals and GSK. It could also damage trust between GSK and individuals, communities, business partners and government authorities. Many countries have increased the enforcement powers of their data protection authorities by allowing them to impose significant fines, impact cross-border data flows, or temporarily ban data processing. Many new national laws also enable individuals to bring collective legal actions against companies such as GSK for failure to follow data privacy laws. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Data protection and privacy legislation is diverse, with limited global harmonisation or simplification. It is challenging for multinationals to standardise their approach to compliance with data privacy laws. Governments are enforcing compliance with data protection and privacy laws more rigorously. The approach and focus of data protection and privacy regulators also differs between regions and countries, which further creates challenges for global organisations seeking to implement a single harmonised global privacy programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Increases in the volume of data processed and advances in technology have resulted in a greater focus on data governance and the ethical use of personal information, over and above compliance with data privacy laws. Companies seeking to foster innovation in artificial intelligence and other new technologies are faced with evolving decisions from global policymakers on how best to promote trust in these systems and avoid unintended outcomes or harmful impacts. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">291</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Data ethics and privacy continued </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Additionally, there are a number of emerging laws concerning the localisation of data, restrictions on international transfers and data security, which are changing existing frameworks that GSK has previously relied upon. This increasing trend for data sovereignty affects our ability to drive medical innovation and to effectively operate internationally. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our General Counsel is GSK&#8217;s Enterprise Risk Owner (ERO), and chairs our Privacy Governance Board, which oversees GSK&#8217;s overall data privacy operating model. Each GSK business area has appointed a risk owner accountable for overseeing its privacy risks, supported by privacy leaders within their business. In countries where local data privacy laws require appointment of a Data Protection Officer (DPO), GSK has made such appointments, including an EU DPO. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As a result of GSK&#8217;s focus on technology, data-driven science, use of artificial intelligence/machine learning and evolving global data strategy, we have sought to address the key risks by creating a new team with Group Legal and Compliance responsible for advising on global digital privacy and cybersecurity strategy. The ERO has appointed a Head of Digital, Privacy and Cybersecurity (Head of DPC), who has <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> accountability for designing and implementing the control framework. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Head of DPC leads a global, cross-functional core team of digital- and privacy-qualified attorneys and privacy compliance professionals, supported by a network of privacy leaders within business units/functions, privacy contracts locally, and the wider Legal and Compliance team. GSK has a global privacy framework based on the EU General Data Protection Regulation, which is deployed in every market based on factors including the robustness of local privacy legislation, established data protection authorities, and GSK&#8217;s footprint. Beyond those countries, we are deploying a proportionate control framework to set up minimum privacy standards irrespective of any applicable legislation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our core team is responsible for: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">operating and improving the centralised global privacy control framework </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">continuously assessing and providing relevant and proportionate controls and aid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deployed</div> markets </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">monitoring new, or changing, laws and adapting the privacy framework accordingly </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">deploying a comprehensive training programme to drive greater awareness and accountability for managing personal information across the entire organisation </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We certify key GSK privacy network roles have sufficient training and experience to carry out their roles effectively. We continuously improve our processes, such as issue identification, reporting and handling, through monitoring. Our core team works with the business to ensure we build in privacy controls into all existing and new business initiatives, as well as ensuring we meet our accountability obligations in accordance with global data protection and privacy laws. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research practices </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to adequately conduct ethical and credible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical research, collaborate in research activities compliant with laws, regulations, and internal controls and requirements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The potential impacts of the risk include harm to human subjects, reputational damage, failure to obtain the necessary regulatory approvals for our products, governmental investigation, legal proceedings brought against the GSK by governmental and private plaintiffs (product liability suits and claims for damages), loss of revenue due to inadequate patent protection or inability to supply our products, and regulatory action such as fines, penalties, or loss of product authorisation. Poor data integrity and governance could compromise GSK&#8217;s R&amp;D efforts and negatively impact our reputation. Any of these could materially and adversely affect our financial results and damage the trust of patients and customers. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Research involving animals can raise ethical concerns. In many cases, however, research involving animals is the only way to investigate the effects of a potential new medicine in a living body other than in humans. Animal research provides critical information about the causes and mechanisms of diseases and therefore remains a vital part of our research. We continually seek ways in which we can minimise our use of animals in research, development, and testing, while complying with regulatory requirements and reducing the impact on the animals used. Human subject research is critical to assessing and demonstrating the safety and efficacy of our investigational products or further evaluating our products once they have been approved. This research includes clinical trials in healthy volunteers and patients and adheres to regulations and high ethical, medical, and scientific standards. We disclose the results of this research externally regardless of whether they reflect positively or negatively on our products, so that the scientific community can learn from the outcomes of our research. We also work with human biological samples which are fundamental to the discovery, development, and safety monitoring of our products. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">292</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research practices continued </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We are committed to managing human biological samples in accordance with relevant laws, regulations, and ethical principles, and in a manner that respects the interests of sample donors. Data is pivotal to our R&amp;D strategy, and we are maximising the use of data to serve patients. Governing our data in accordance with relevant laws, regulations, contractual obligations, expectations, and our culture across privacy, information security, and data integrity is essential. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We use a wide variety of biological materials in the discovery, research, and development of our assets. Through the Convention on Biological Diversity (CBD) and the Nagoya Protocol, the international community has established a global framework regulating access to, and use of, genetic resources of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-human</div> origin in research and development. We support the principles of access to, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">benefit-sharing</div> of, genetic resources as outlined in the CBD and the Nagoya Protocol. We also recognise the importance of appropriate, effective, and proportionate implementation measures at national and regional levels. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Research Practices risk is overseen by an enterprise framework that seeks to strengthen governance across R&amp;D. Under the leadership of the Research Practices Enterprise Risk Owner, management of the risk takes a pragmatic approach to information sharing, streamlining risk identification and escalation while ensuring ownership of risk mitigation stays with the business. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We have an established Office of Animal Welfare, Ethics and Strategy and Risk (OAWESR), led by our Chief Veterinary Officer, which supports the humane and responsible care of animals, carries out ethical reviews and independent scientific reviews of animal studies, and shares knowledge and advocates for the application of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-animal</div> alternatives. The OAWESR provides a framework of animal welfare governance; defines and provides oversight for training in animal care; promotes the replacement, refinement and reduction of animal research; conducts quality assessments; manages a programme of external animal diligence; and develops and deploys strategies for reproducing experiments and translating them to human clinical end points. Ensuring we implement and maintain proper data governance controls remains an important priority, especially as our scientific strategy is evolving to take advantage of the breadth of our data (for example: genomics and artificial intelligence and machine learning). We focus on building data integrity, privacy and usage controls into our internal control framework. Quality assurance teams conduct audits to provide independent business monitoring of our internal controls. Our R&amp;D organisation maintains and controls <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-publication</div> procedures to guard against public disclosure before patent applications are filed. In addition, because a lack of data integrity in preparing patent application data and information can lead to a loss of patent protection, legal experts collaborate with R&amp;D to support the review process for new patent applications. Our R&amp;D organisation also collaborates with legal experts throughout the development of our assets to take account of any relevant third-party patent rights. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environment, health, and safety (EHS) </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of the organization&#8217;s assets, facilities, infrastructure, and business activities, including execution of hazardous activities, handling of hazardous materials, or release of substances harmful to the environment that disrupts supply or harms employees, third parties or the environment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Failure to manage EHS risks could lead to significant harm to people, the environment and the communities in which we operate, fines, inability to meet stakeholder expectations and regulatory requirements, litigation or regulatory action, and damage to the company&#8217;s reputation, which could materially and adversely affect our financial results. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK is subject to the health, safety and environmental laws of various jurisdictions. These laws impose duties to protect people, the environment and the communities in which we operate. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The GSK Leadership Team is responsible for EHS governance and risk oversight. They ensure there is an effective control framework <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;in-place&#8217;</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;in-use&#8217;</div> to manage the EHS risks, impacts, and legal compliance issues in each of our businesses. This includes assigning responsibility to senior managers for providing and maintaining our controls and for ensuring that tiered monitoring and governance processes are in place within their business units. Function leaders ensure that the EHS control framework is implemented effectively in their respective business area, that it is compliant with applicable laws and regulations, and that it is adequately resourced, maintained, communicated, and monitored. Every employee and qualified contractor acting on behalf of GSK is personally responsible for ensuring that they follow all applicable local standard operating procedures. Our risk-based, proactive approach is articulated in our global EHS policy and detailed in our global EHS standards, against which we audit all our operations to ensure compliance. We ensure hazards are appropriately controlled through the design of facilities, equipment and systems. These rigorous procedures, when applied correctly, put effective barriers in place to protect employees&#8217; health and safety. In 2020 we created a safety improvement plan, focusing on Life Saving Rules, Safety Leadership and Warehouse Safety. All significant milestones for these programmes were delivered in 2022 according to plan. Our Safety Leadership Experience and warehouse improvements will continue implementation into 2023. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">293</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information security </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance over unauthorised access, disclosure, theft, unavailability or corruption of GSK&#8217;s information, key systems or technology infrastructure. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Failure to adequately protect our information and systems may cause harm to our patients, workforce and customers, disruption to our business and/or loss of commercial or strategic advantage, regulatory sanction or damage to our reputation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The external environment continues to be extremely challenging, making it hard to keep pace with increasingly sophisticated cyber threats. This is due to many factors including increased geopolitical conflict and digital nationalism, rising frequency and severity of data breaches and growing capability and sophistication of bad actors and cyber criminals. GSK&#8217;s business relies on operating a highly connected information network of internal and external systems, which hold confidential research and development, manufacturing, commercial, workforce and financial data. This means that our systems and information have been and will continue to be the target of cyberattacks. Acceleration in the use of digital, data and analytics and cloud computing capabilities to drive GSK&#8217;s pipeline and performance requires us to continuously adapt and strengthen our controls and defensive capabilities. GSK also relies on third-party contractors, partners and suppliers who face similar cyber threats and this continues to be a vector of risk to manage as well. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cyber Security Office and Cyber Maturity Programme </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has a Cyber Security Office and our Chief Information Security Officer is responsible for identifying and putting in place measures to help GSK mitigate and manage cyber security risks. This includes active monitoring and initiating remediation or other actions in response to cyber security intelligence and threats, while also enhancing our capabilities through an ongoing programme of investment in people, process and technology to improve our ability to prevent, detect, respond and recover from any cyber security incidents. A risk based Third-party security risk management program is also in place to aid in assessing cyber security risk during selection of third parties and also provide ongoing monitoring of our external partner and supplier ecosystem. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information Security Governance </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Cyber Security Office periodically provides updates on key information security risks and issues, as well as progress reports on the Cyber Maturity Programme to both the Risk Oversight&#160;&amp; Compliance Council and the Audit&#160;&amp; Risk Committee. The Information Security Enterprise Risk Plan and Cyber Maturity Programme are overseen by the Chief Digital and Technology Officer as well as the Chief Financial Officer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cyber Security Awareness, Training and Readiness </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cyber Security Awareness and Training programs including phishing simulation programs are in place to increase awareness of cyber related risks and reinforce the message that security is everyone&#8217;s responsibility at GSK. Periodic crisis simulation tabletop exercises are planned at various levels of the organisation to test our ability to respond to cyber incidents. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance with various governmental cyber security regulations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Cyber Security Office, with the General Counsel&#8217;s guidance, works to stay abreast of various emergent governmental regulations, emergent trends and compliance expectations regarding cyber security or information security. As new regulatory guidance becomes available, remedial compliance related actions are put in place as appropriate. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">294</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Principal risks and uncertainties continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supply continuity </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk definition </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The risk that GSK or our third parties potentially fail to deliver a continuous supply of compliant finished product or respond effectively to a crisis incident in a timely manner to recover and sustain critical supply operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk impact </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We recognise how important the continuity of supply of our products is to the patients who rely on them. Supply disruption can lead to: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Product shortages and product recalls </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Regulatory intervention </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Reputational harm </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Lost sales revenue </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Consequently, we need sophisticated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> supply chain management with robust crisis management and business continuity plans in place to respond. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Context </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We run our supply chains in a continually evolving, highly-regulated environment. There is no single set of global regulations which governs the manufacture and distribution of medicines, and we must adhere to the requirements in all those markets in which we licence, sell or manufacture our products. We rely upon our internal Quality Management System and our Internal Control Framework to ensure we continue to preserve our licence to operate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our complex <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> supply chains often involve third-party suppliers, from Active Pharmaceutical Ingredient (API) manufacturers and raw material suppliers through to Third-Party Logistics Providers and contract engineering firms. We embed integrated risk management into our sourcing and day to day business processes, alongside our Third-Party Oversight programme. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">External factors continued to challenge supply continuity in 2022. In the early part of the year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> continued to disrupt our sourcing of biosciences materials across our Medicines and Vaccines supply chains (e.g. vials, syringes and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> systems components). The Ukraine conflict has resulted in supply disruption to the region. To manage these disruptions, we deployed bespoke <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-risking</div> plans using crisis and continuity plans to manage the detail and mitigate the risk of supply continuity problems, e.g. by dual sourcing of materials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-routing</div> of shipments to avoid conflict zones. Keeping our patients supplied with their medicines is our priority. </div><div style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">New technology and modality platforms within supply chains are changing the requirements for the skillsets of people working in this field. We have implemented a new Chemistry, Manufacturing and Controls Operating Model in 2022. This brings cross-fertilisation of talent focus on the skills needed for the future for innovative manufacturing. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Industrial relations are also a current risk to supply continuity, with the threat of industrial action being averted in our UK manufacturing sites through successful dialogue with unions. Continued business monitoring is in place to assess the risk of the spread of industrial relations challenges resulting from global cost of living pressures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mitigating activities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk Management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Our Medicines and Vaccine supply chains are set up to ensure sustainable global supply. The GSK Internal Control Framework drives our approach to risk management, and it has been designed to identify emerging new risks and support clear decision making. Risk oversight is managed through a hierarchy of Risk Management and Compliance Boards to assure risk mitigation (including identifying new and emerging threats). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventory Management </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Supply chain governance committees in Medicines and Vaccines closely monitor the inventory status and delivery of our products. Our core commercial cycle links supply chain forecasting with our commercial ambition. It is designed to reduce the risk of demand fluctuations and manage temporary shortages in supply. We periodically review each node of our supply chains to ensure we hold adequate safety stocks, whilst balancing working capital. We put particular emphasis on mitigating supply risks associated with medically-critical, high-revenue products and new product launches, for example using dual sourcing for key products or APIs. We use the monthly Performance Management Process across our supply chains to monitor business activity and highlight adverse trends in supply, operations, budget and workforce capability. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business continuity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Crisis management and business continuity plans are in place across our supply chains, which include authorised response and recovery strategies, key areas of responsibility and clear communication routes. We regularly use business continuity plans to manage potential supply disruptions. Our manufacturing sites have crisis management plans in place. These plans are tested at least annually to ensure maintenance of core skills in crisis management. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">295</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Shareholder information </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Demerger and Share Consolidation </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">On Monday 18&#160;July 2022, the company completed the demerger of the Consumer Healthcare business from the Group to form the Haleon Group (Demerger). Under the terms of the Demerger, shareholders received one Haleon plc share for each GSK plc share held at the record time of 6.00 pm (UK) on Friday 15&#160;July 2022. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Demerger, the company consolidated its share capital (Share Consolidation). The Share Consolidation took effect on Tuesday 19&#160;July 2022 and resulted in shareholders receiving four new GSK plc shares of nominal value 31<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">1</div>/<div style="font-size: 75%; vertical-align: bottom;;display:inline;;font-size:7.1px">4</div> pence each for every five GSK plc shares of nominal value 25 pence each held at the record time of 8.00pm (UK) on Monday 18&#160;July 2022. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The circular in relation to the Demerger and the Share Consolidation (Circular) and the prospectus regarding the admission of Haleon&#8217;s ordinary shares to the premium listing segment of the Official List of the Financial Conduct Authority (FCA) and trading on the Main Market of the London Stock Exchange (LSE) were published by the company and Haleon plc respectively on Wednesday 1&#160;June 2022. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_46" style="font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_84" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Share capital and control </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of our issued share capital and the number of shares held in Treasury as at 31&#160;December 2022 can be found in Note 37 to the financial statements, &#8216;Share capital and share premium account&#8217;. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Ordinary Shares are listed on the LSE and are also quoted on the New York Stock Exchange (NYSE) in the form of American Depositary Shares (ADS). Each ADS represents two Ordinary Shares. For details of listed debt and where it is listed refer to Note 30 to the financial statements, &#8216;Net debt&#8217;. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Ordinary Shares and ADS are entitled to receive dividends (when declared) and the company&#8217;s Annual Report. They are also entitled to attend, speak, appoint proxies and exercise voting rights at general meetings of the company. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no restrictions on the transfer, or limitations on the holding, of Ordinary Shares and ADS and no requirements to obtain approval prior to any transfers. No Ordinary Shares or ADS carry any special rights with regard to control of the company and there are no restrictions on voting rights. Major shareholders have the same voting rights per share as all other shareholders. There are no known arrangements under which financial rights are held by a person other than the holder of the shares and no known agreements on restrictions on share transfers or on voting rights. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares acquired through the Group&#8217;s employee share plans rank equally with the other shares in issue and have no special rights. The trustees of our Employee Share Ownership Plan trusts have waived their rights to dividends on shares held by those trusts. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exchange controls and other limitations affecting holders </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;">Other than certain economic sanctions, which may be in force from time to time, there are currently no applicable laws, decrees or regulations in force in the UK restricting the import or export of capital or restricting the remittance of dividends or other payments to holders of the company&#8217;s shares who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of the UK. </div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;">Similarly, other than certain economic sanctions which may be in force from time to time, there are no limitations relating only to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of the UK under English law or the company&#8217;s Articles of Association on the right to be a holder of, and to vote in respect of, the company&#8217;s shares. </div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interests in voting rights </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than as stated below, as far as we are aware, there are no persons with significant direct or indirect holdings in the company. Information provided to the company pursuant to the FCA&#8217;s Disclosure Guidance and Transparency Rules (DTR 5) is published on a Regulatory Information Service and on the company&#8217;s website, gsk.com. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The company has received notifications in accordance with DTR 5 of the following notifiable interests in the voting rights in the company&#8217;s issued share capital: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">31&#160;December 2022</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">3&#160;March&#160;2023</td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">No. of</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">voting</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">rights</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage<br/>of&#160;total</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">voting</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">rights<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1) </div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">No. of</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;voting</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">rights</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Percentage<br/>of&#160;total</div></div><div style="text-align: right; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">voting<br/>rights<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1) </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 3pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">BlackRock, Inc</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">231,975,400<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(2)</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5.69%</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">231,975,400<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(2)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5.69%</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 3pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Dodge&#160;&amp; Cox</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">253,464,108<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(3)</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5.04%</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">253,464,108<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(3)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 3pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5.04%</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage of total voting rights at the date of notification to the company. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprising an indirect interest in 229,134,683 Ordinary Shares and a holding of 2,840,717 Qualifying Financial Instruments (Contracts for Difference). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12pt; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprising an indirect interest in 99,377,874 Ordinary Shares and 154,086,234 ADS. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The company has not acquired or disposed of any interests in its own shares during the period under review. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">296</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder information continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital and control </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back</div> programme </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board has been authorised to issue and allot Ordinary Shares under Article 9 of the company&#8217;s Articles of Association. The power under Article 9 and the authority for the company to make purchases of its own shares are subject to shareholder authorities which are sought on an annual basis at our Annual General Meeting (AGM). Any shares purchased by the company may be cancelled, held as Treasury shares or used for satisfying share options and grants under the Group&#8217;s employee share plans. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our programme covers purchases of shares for cancellation or to be held as Treasury shares, in accordance with the authority renewed by shareholders at the AGM in May 2022, when the company was authorised to purchase a maximum of just over 508&#160;million shares. Details of shares purchased, cancelled, held as Treasury shares and subsequently transferred from Treasury to satisfy awards under the Group&#8217;s employee share plans are disclosed in Note 37 to the financial statements, &#8216;Share capital and share premium account&#8217;. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining specific share repurchase levels, the company considers the development of free cash flow during the year. No Treasury shares have been purchased since 2014. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;">The company confirms that it does not currently intend to make any market purchases in 2023. The company will review the potential for future share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-backs</div> in line with its usual annual cycle and subject to return and ratings criteria. </div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market capitalisation </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The market capitalisation, based on shares in issue excluding Treasury shares, of GSK at 31&#160;December 2022 was &#163;58.9&#160;billion. At that date, GSK was the 10<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.1px">th</div> largest company by market capitalisation in the FTSE index. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="color: rgb(243, 111, 33); font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share price</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;<br/>&#163;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>&#163;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;<br/>&#163;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">At 1&#160;January</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.25&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.79&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">At 31&#160;December</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.38&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.42&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12)%&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24.6)%&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">High during the year</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.31&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.46&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Low during the year</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.96&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap; background-color: rgb(231, 231, 232);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">11.91</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12.92&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The table above sets out middle market closing prices. The company&#8217;s share price decreased by 12% in 2022. This compares with an increase in the FTSE 100 index of 1% during the year. The middle market closing share price on 3 March 2023 was &#163;14.42. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share price trend in the three years ended 31&#160;December 2022 </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_297.jpg" style="width: 321px; height: 266px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature of trading market </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets out, for the periods indicated, the high and low middle market closing prices for the company&#8217;s Ordinary Shares on the LSE and for the ADS on the NYSE. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ADS</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="8" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="6" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">UK&#163; per share</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">US$ per share</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;High</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Low</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;High</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Low</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">March 2023*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">February 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">January 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">December 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">November 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">October 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">September 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 31&#160;December 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">14.92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">13.20</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">37.92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">30.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 30&#160;September 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">18.23</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">12.96</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">44.53</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">28.67</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 30&#160;June 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">18.31</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">16.72</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">47.70</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">41.98</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 31&#160;March 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">17.27</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">15.01</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">47.66</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">40.17</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 31&#160;December 2021</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">16.19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">13.80</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">44.44</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">38.13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 30&#160;September 2021</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">15.26</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">13.83</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">42.33</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">38.05</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 30&#160;June 2021</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">14.36</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">12.78</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">40.66</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">35.82</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232); font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(231, 231, 232);"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter ended 31&#160;March 2021</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">14.14</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">11.91</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">39.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);;text-align:right;">33.61</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(231, 231, 232);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended 31&#160;December 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended 31&#160;December 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended 31&#160;December 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended 31&#160;December 2018</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">16.22</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">12.43</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">41.94</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">35.49</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">* to 3 March 2023 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_275.jpg" style="width: 36px; height: 906px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">297</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder information continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Analysis of shareholdings at 31&#160;December 2022 </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">Number&#160;of<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;accounts</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">%&#160;of&#160;total<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;accounts</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%&#160;of&#160;total<br/>shares</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Number&#160;of<br/>shares</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding of shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 1,000</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,478,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">1,001 to 5,000</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,184,737</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">5,001 to 100,000</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,944</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,490,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">100,001 to 1,000,000</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237,893,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Over 1,000,000</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">333</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">0.52</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">92.32</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">3,980,296,567</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">64,375</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">4,311,343,341</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Held by</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Institutional and Corporate holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,660,734,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Individuals and other corporate bodies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">580,447,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Guaranty Nominees Limited (ADR Programme)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">853,035,897</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Held as Treasury shares by GSK</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">5.04</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">217,124,760</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">JP Morgan Chase Bank NA is the Depositary for the company&#8217;s American Depository Receipt (ADR) programme. The company&#8217;s ADS are listed on the NYSE. Ordinary Shares representing the company&#8217;s ADR programme, which is managed by the Depositary, are registered in the name of Guaranty Nominees Limited. At 3 March 2023, Guaranty Nominees Limited held 852,687,041 Ordinary Shares representing 20.82% of the issued share capital (excluding Treasury shares). </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">At 3 March 2023, the number of holders of Ordinary Shares in the US was 852 with holdings of 716,804 Ordinary Shares, and the number of registered holders of ADS was 16,757 with holdings of 426,343,520 ADS. Certain of these Ordinary Shares and ADS were held by brokers or other nominees. As a result, the number of holders of record or registered holders in the US is not representative of the number of beneficial holders or of the residence of beneficial holders. </div></div><div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_47" style="font-family: ARIAL; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_85" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Dividends </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The company pays dividends quarterly and continues to return cash to shareholders through its dividend policy. Dividends remain an essential component of total shareholder return and GSK recognises the importance of dividends to shareholders. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;">On 23&#160;June 2021, at the new GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60&#160;percent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay-out</div> ratio through the investment cycle. The dividend policy, the total expected cash distribution, and the respective dividend <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay-out</div> ratios for GSK remain unchanged. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividends per share </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below sets out the dividend per share and per ADS for the last five years. The dividend per ADS is translated into US dollars at applicable exchange rates. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 8%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Year</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">pence</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US$<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)&#160;&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.25</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8211;<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(3) </div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.16</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.12</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.01</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="2" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">2.08</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14.25pt; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) will be charged by the Depository. The amounts shown are the dividends paid per ADS before the annual fee is charged. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14.25pt; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted for the Share Consolidation (2022 only; prior years have not been adjusted). Dividends declared and paid in respect of 2022 were 14p per share for Q1 2022, 16.25p per share for Q2 2022 and 13.75p per share for Q3 2022. A dividend of 13.75p per share has been declared for Q4 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14.25pt; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Q4 2022 ordinary dividend receivable by ADS holders will be calculated based on the exchange rate on 13&#160;April 2023. The cumulative dividend receivable by ADS holders for Q1, Q2 and Q3 2022 was $1.05. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;">GSK has previously stated that it expected to declare a 27p per share dividend for the first half of 2022, a 22p per share dividend for the second half of 2022 and a 45p per share dividend for 2023 (before the Share Consolidation) but that these targeted dividends per share would increase in step with the Share Consolidation to maintain the same aggregate dividend <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay-out</div> in absolute Pound&#160;Sterling terms. Accordingly, using the consolidation ratio, GSK&#8217;s expected dividend for the fourth quarter of 2022 converts to 13.75p per new Ordinary Share, this results in an expected total dividend for the second half of 2022 of 27.5p per new Ordinary Share. The expected dividend for 2023 is now 56.5p per new Ordinary Share, in line with the original expectation converted for the Share Consolidation and rounded up. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of the dividends declared, the amounts and the payment dates are given in Note 16 to the financial statements, &#8216;Dividends&#8217;. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023 Dividend calendar </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%; font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td>
<td style="font-family: ARIAL;"></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-dividend</div> date</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">Record date</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">Payment date</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Q4 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23&#160;February&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24&#160;February&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13&#160;April&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Q1 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18&#160;May 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19&#160;May 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13&#160;July 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Q2 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17&#160;August 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18&#160;August 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12&#160;October&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Q3 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16&#160;November&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17&#160;November&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11&#160;January 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Q4 2023</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">22&#160;February 2024</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">23&#160;February 2024</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">11&#160;April 2024</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">298</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder information continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_48" style="font-family: ARIAL; font-size: 18pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_86" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Financial calendar 2023 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 98%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: ARIAL; font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">Event</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;">Date</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter 1 Results announcement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26&#160;April 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual General Meeting</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3&#160;May 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter 2 Results announcement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26&#160;July 2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Quarter 3 Results announcement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1&#160;November&#160;2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Preliminary/Quarter 4 Results announcement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31&#160;January 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Report publication</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">February/March&#160;2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td>
<td colspan="4" style="height: 3pt; font-family: ARIAL; font-size: 0px;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Report distribution</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">March 2024</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about the company, including the share and ADS price, is available on our website at gsk.com. Information made available on the website does not constitute part of this Annual Report. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Results announcements </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Results announcements are issued to the LSE and are available on its news service. They are also sent to the US Securities and Exchange Commission (SEC) and the NYSE, issued to the media and made available on our website. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial reports </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The company publishes an Annual Report which is made available on our website from the date of publication. Shareholders may elect to receive notification by email of the publication of Annual Reports by registering on www.shareview.co.uk, and may also elect to receive a printed copy of the Annual Report by contacting our registrar, Equiniti Limited. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Copies of previous Annual Reports are available on our website. Printed copies can also be obtained from our registrar (see page 302 for the contact details). </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_49" style="font-family: ARIAL; font-size: 18pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_87" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Annual General Meeting 2023 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Annual General Meeting (AGM) will be held at 2.30pm (UK time) on Wednesday, 3&#160;May 2023 at the Sofitel London Heathrow, Terminal 5, London Heathrow Airport, TW6 2GD and will also be broadcast live for you to join electronically. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The AGM is the company&#8217;s principal forum for communication with private shareholders. In addition to the formal AGM business, there will be a presentation by the CEO on the performance of the Group and its future development. There will be an opportunity for questions to be asked of the Board and Chairs of the Board&#8217;s Committees will be available to take questions relating to their roles. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Further details on how to access the AGM electronically or attend in person, ask questions and vote, can be found in the notice of Annual General Meeting 2023 (AGM Notice) which is available on our website at gsk.com. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Investors holding shares through a nominee service should arrange with that service for them to be appointed as a proxy in respect of their shareholding to attend and vote at the meeting electronically. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">ADS holders wishing to attend the meeting electronically should refer to the AGM Notice for details on how to request a proxy appointment from the Depositary, JP Morgan Chase Bank NA. This will enable them to attend, ask questions and vote, all electronically, on the business to be transacted at the meeting. ADS holders are reminded that if they do not instruct the Depositary as to the way in which the shares represented by their ADS should be voted by completing and returning the voting card provided by the Depositary, their shares will not be voted. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Documents on display </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Articles of Association of the company and Directors&#8217; service contracts or, where applicable, letters of appointment between Directors and the company or any of its subsidiaries (and any side letters relating to severance terms and pension arrangements) are available for inspection at the company&#8217;s registered office and will be made available for inspection at the AGM. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(243, 111, 33); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="ex15_2tx382677_50" style="font-family: ARIAL; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_88" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Tax information for shareholders </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of certain UK tax and US federal income tax consequences for holders of shares and ADS who are citizens of the UK or the US is set out below. It is not a complete analysis of all the possible tax consequences of the purchase, ownership or sale of these securities. It is intended only as a general guide. Holders are advised to consult their advisers with respect to the tax consequences of the purchase, ownership or sale of their shares or ADS and the consequences under state and local tax laws in the US and the implications of the current UK/US tax conventions. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">US holders of ADS generally will be treated as the owners of the underlying shares for the purposes of the current UK/US double taxation conventions relating to income and gains (Income Tax Convention), estate and gift taxes (Estate and Gift Tax Convention), and for the purposes of the Internal Revenue Code of 1986, as amended. </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677f_275.jpg" style="width: 36px; height: 906px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">299</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">GSK Annual Report 2022 </div></div></div><div style="font-family: ARIAL; font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder information continued </div></div></div><div style="font-family: ARIAL; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax information for shareholders </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 48%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">UK shareholders </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">This summary only applies to a UK resident shareholder that holds shares as capital assets. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation of dividends </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">For the 2022/23 UK tax year, UK resident individuals are entitled to a dividend tax allowance of up to &#163;2,000, so that the first &#163;2,000 of dividends received in a tax year will be free of tax. Dividends in excess of this allowance will be taxed at 8.75% for basic rate taxpayers, 33.75% for higher rate taxpayers and 39.35% for additional rate taxpayers. Note that from 6&#160;April 2023 the dividend allowance will be reduced to &#163;1,000, and that from 6&#160;April 2024 the dividend allowance will be reduced again to &#163;500 </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">UK resident shareholders that are corporation taxpayers should note that dividends payable on ordinary shares are generally entitled to exemption from corporation tax. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation of capital gains </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">UK resident shareholders may be liable for UK tax on gains on the disposal of shares or ADS. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">For disposals by individuals in the 2022/23 UK tax year, a taxable capital gain accruing on a disposal of shares or ADS will be taxed at 10% for basic rate taxpayers, or 20% if, after all allowable deductions, the individual&#8217;s taxable income for the year exceeds the basic rate income tax banding. Note this is following the use of any exemptions available to the individual taxpayer such as the annual exempt amount. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporation taxpayers may be entitled to an indexation allowance which applies to reduce capital gains to the extent that such gains arise due to inflation. Indexation allowance may reduce a chargeable gain but will not create an allowable loss. For assets acquired on or before 1&#160;January 2018, legislation in the Finance Act 2018 freezes the level of indexation allowance that is given in calculating a company&#8217;s chargeable gains at the value that would apply to the disposal of an asset in December 2017. For assets acquired from 1&#160;January 2018 onwards, legislation in the Finance Act 2018 removes any indexation allowance on disposal. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inheritance tax </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;">Individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(UK-domiciled</div> or otherwise) shareholders may be liable to UK inheritance tax on the transfer of shares or ADS. Exposure to a UK Inheritance tax charge typically occurs on death of the asset owner. However, transfers of shares (other than commercial sales) within 7 years of death remain relevant to any inheritance tax exposure at death. Further, transfers to a trust arrangement during lifetime can give rise to an immediate inheritance tax charge. </div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax may be charged on the amount by which the value of the shareholder&#8217;s estate is reduced as a result of any transfer by way of lifetime gift or other disposal at less than full market value. In the case of a bequest on death, tax may be charged on the value of the shares at the date of the shareholder&#8217;s death. Where an exposure to UK inheritance tax and US estate or gift tax exists careful planning must be undertaken to understand the opportunity to utilise the US/UK Estate and Gift Double Tax Convention to manage tax credits and avoid double taxation. </div></div></div><div style="width: 49%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The overall exposure will be dependent on the specific circumstances of each situation and it&#8217;s also important to note that tax charges may arise in other jurisdictions. Bespoke advice tailored to an individual&#8217;s personal circumstances should therefore be obtained from a tax professional. </div></div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stamp duty and stamp duty reserve tax </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;">UK stamp duty and/or stamp duty reserve tax (SDRT) will, subject to certain exemptions, be payable on the transfer of shares at a rate of 0.5% (rounded up to the nearest &#163;5 in the case of stamp duty) of the consideration for the transfer. Notwithstanding this, provided that an instrument is executed in pursuance of the agreement that gave rise to the charge to SDRT and that instrument is stamped within six years of the agreement (including being stamped as exempt) any SDRT charge should be cancelled and any SDRT which has already been paid will be repaid. Where listed shares are transferred to a company connected to the transferor the chargeable consideration will be deemed to be not less than the market value of the shares transferred. This market value override also applies where <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-listed</div> shares are transferred to a company connected to the transferor where the consideration includes an issue of shares. </div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US shareholders </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">This summary only applies to a shareholder (who is a citizen or resident of the US or a domestic corporation or a person that is otherwise subject to US federal income tax on a net income basis in respect of the shares or ADS) that holds shares or ADS as capital assets, is not resident in the UK for UK tax purposes and does not hold shares for the purposes of a trade, profession or vocation that is carried on in the UK through a branch or agency. </div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;">The summary also does not address the tax treatment of holders that are subject to special tax rules, such as banks, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> entities, insurance companies, dealers in securities or currencies, persons that hold shares or ADS as part of an integrated investment (including a &#8216;straddle&#8217;) comprised of a share or ADS and one or more other positions, and persons that own (directly, indirectly or constructively) 10% or more of the company&#8217;s stock (by vote or value), nor does it address tax treatment that may be applicable as a result of international income tax treaties. </div><div style="font-family: ARIAL; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation of dividends </div></div></div></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The gross amount of dividends received is treated as foreign source dividend income for US tax purposes. It is not eligible for the dividend received deduction allowed to US corporations. Dividends on ADS are payable in US dollars; dividends on Ordinary Shares are payable in Sterling. Dividends paid in Sterling will be included in income in the US dollar amount calculated by reference to the exchange rate on the day the dividends are received by the holder. Subject to certain exceptions for short-term or hedged positions, an individual eligible US holder will be subject to US taxation at a maximum federal rate of 23.8% plus applicable state and local tax in respect of qualified dividends. A qualified dividend as defined by the US Internal Revenue Service (IRS) is a dividend that meets the following criteria: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Must be issued by a US corporation, a corporation incorporated in a US possession, or a corporation that is eligible for the benefits of a comprehensive income tax treaty deemed satisfactory, as published by the IRS. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 6%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; margin-left: 3%; float: left; position: relative;"><div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/></div> </div></div></div><div style="height: 0pt; clear: both; font-size: 0pt; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: ARIAL; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td></tr>
<tr style="font-family: ARIAL; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">300</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Shareholder information continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax information for shareholders </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The dividends are not of a type listed by the IRS as dividends that do not qualify. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The required dividend holding period has been met. The shares must have been owned by you for more than 60 days of the &#8216;holding period&#8217; &#8211; which is defined as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">121-day</div> period that begins 60 days before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-dividend</div> date, or the day in which the stock trades without the dividend priced in. For example, if a stock&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-dividend</div> date is 1&#160;October, the shares must be held for more than 60 days in the period between 2&#160;August and 30&#160;November of that year in order to count as a qualified dividend. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends that are not qualified are subject to taxation at the US federal graduated tax rates, at a maximum rate of 40.8%. Some types of dividends are automatically excluded from being qualified dividends, even if they meet the other requirements. These include (but are not limited to): </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Capital gains distributions </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">2.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dividends on bank deposits </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">3.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dividends held by a corporation in an Employee Stock Ownership Plan (ESOP) </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">4.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dividends paid by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> corporations. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">US state and local tax rates on qualified and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> dividends may vary and would be assessed in addition to the federal tax rates communicated above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation of capital gains </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Generally, US holders will not be subject to UK capital gains tax, but will be subject to US tax on capital gains realised on the sale or other disposal of shares or ADS. Such gains will be long-term capital gains (subject to reduced rates of taxation for individual holders) if the shares or ADS were held for more than one year, from the date the shares were vested/released. Short-term capital gains can be subject to taxation of rates of up to 40.8%, whereas long-term capital gains may be subject to rates of up to 23.8%. State and local tax rates on capital gains may also apply. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information reporting and backup withholding </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends and payments of the proceeds on a sale of shares or<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>ADS, paid within the US or through certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-related</div> financial intermediaries, are subject to information reporting and may be subject to backup withholding unless the US holder is a corporation or other exempt recipient or provides a taxpayer identification number and certifies that no loss of exemption has occurred. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-US</div> holders generally are not subject to information reporting or backup withholding, but may be required to provide a certification of their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-US</div> status in connection with payments received. Any amounts withheld will be allowed as a refund or credit against a holder&#8217;s US federal income tax liability provided the required information is furnished to the IRS. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estate and gift taxes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the Estate and Gift Tax Convention, a US shareholder is not generally subject to UK inheritance tax. However, a US holder may be subject to US federal estate and gift tax. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stamp duty </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">UK stamp duty and/or SDRT will, subject to certain exemptions, be payable on any transfer of shares to the ADS custodian or depository at a rate of 1.5% of the amount of any consideration provided (if transferred on sale), or their value (if transferred for no consideration). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">However, no stamp duty or SDRT should be payable on the transfer of, or agreement to transfer an ADS or on transfers within the clearance service. Notwithstanding the above, where the clearance service operator has made an election under s97A Finance Act 1986, broadly the 1.5% stamp duty/ SDRT charge should not arise on the transfer into the clearance service, but transfers to, and within, the system (where there is a change in beneficial ownership) would attract a 0.5% charge. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demerger and Share Consolidation </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summary of certain UK and US tax consequences in respect of the Demerger and Share Consolidation relevant to the company&#8217;s shareholders who are resident (or, in the case of individuals, resident and domiciled) in the UK for UK tax purposes or who are citizens of or resident in the US for US tax purposes is set out in Part 6 of the Circular (pages 83 to 87). The Circular, along with other information regarding the Demerger and Share Consolidation can be found at gsk.com in the demerger section. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Further information on the tax base cost allocation to assist UK shareholders apportion their base cost between their GSK plc shares and Haleon plc shares for UK capital gains tax purposes following the Demerger, including a worked example, can be found in the Tax section at gsk.com in the demerger section. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">301</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Other statutory disclosures </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_51" style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_89" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Shareholder services and contacts </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registrar </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company&#8217;s registrar is: </div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Equiniti Limited </div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Aspect House, Spencer Road, Lancing, BN99 6DA </div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">www.shareview.co.uk </div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +44 (0)371 384 2991* </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Equiniti provides a range of services for shareholders: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:24%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:28%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Service</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">What it offers</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">How to participate</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Dividend Reinvestment Plan (DRIP)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">As an alternative to receiving cash dividends you may choose to reinvest your dividends to buy more GSK shares.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">A DRIP election form, Terms and Conditions and information on fees can be downloaded from www.shareview.co.uk or requested by contacting Equiniti.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Dividend payment direct to your bank account (Bank Mandate)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">All dividends are paid directly into your bank or building society account. To receive your cash dividends, you must provide Equiniti with your bank or building society account details. This is a quick and secure method of payment.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">A dividend bank mandate form can be downloaded from www.shareview.co.uk or requested by contacting Equiniti.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Dividend payment direct to bank account for overseas shareholders (Overseas Payment Service)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equiniti can convert your dividend into your local currency and send it direct to your local bank account. The Overseas Payment Service is available in approximately 100 countries worldwide.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">More information on the Overseas Payment Service (including information on fees) can be found at www.shareview.co.uk or by contacting Equiniti.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Electronic communications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shareholders may elect to receive electronic notifications of company communications including our Annual Report, dividend payments, dividend confirmations and the availability of online voting for all general meetings. Each time GSK publishes shareholder documents you will receive an email containing a link to the document or relevant website.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Please register at www.shareview.co.uk.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Shareview portfolio service</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">This enables you to create a free online portfolio to view your share balance and movements, update your address and dividend payment instructions and register your votes for our general meetings.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Please register at www.shareview.co.uk.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Deduplication of publications or mailings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">If you receive duplicate copies of mailings, you may have more than one account. Please contact Equiniti and they will arrange for your accounts to be merged into one for your convenience and to avoid waste and unnecessary costs.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Please contact Equiniti.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Share dealing service<div style="font-size: 75%; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"><br/></div>(please note that market trading hours are from 8.00am to 4.30pm UK time,Monday to Friday (excluding public holidays in England and Wales))</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shareholders may trade shares, either held in certificated form or in our Corporate Sponsored Nominee, online, by telephone or via postal dealing service provided by Equiniti Financial Services Limited.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More information on the share dealing service (including information on fees) can be found at www.shareview.co.uk/dealing</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">For online transactions, please log on to: www.shareview.co.uk/dealing.</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">For telephone transactions, please call: 0345 603 7037 (in the UK) or +44 (0)345 603 7037 (outside the UK). Lines are open from 8.00am to 4.30pm UK time, Monday to Friday (excluding UK public holidays).</div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">For postal transactions, please call: 0371 384 2991* to request a dealing form.</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Corporate Sponsored Nominee Account</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">This is a convenient way to manage your shares without requiring a share certificate. The service provides a facility for you to hold your shares in a nominee account sponsored by the company. You will continue to receive dividend payments and can attend and vote at the company&#8217;s general meetings. Shareholders&#8217; names do not appear on the publicly available share register and the service is free to join.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">An application form can be requested from www.shareview.co.uk or by contacting Equiniti.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Individual Savings Accounts (ISAs)<div style="font-size: 75%; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5pt; vertical-align: top;;display:inline;;font-size:5.5px">&#8224;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equiniti Financial Services Limited provide the EQi Flexible ISA to hold GSK shares.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Details (including information on fees) are available from www.eqi.co.uk or can be requested by calling the Equiniti Customer Experience Team on 0345 0700 720. Lines are open 8:00am to 5:30pm, UK time Monday to Friday (excluding UK public holidays).</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Lines are open from 8.30am to 5.30pm, UK time Monday to Friday (excluding public holidays in England and Wales). Please use the country code when dialling from outside the UK. </div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;"><div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; vertical-align: top;;display:inline;;font-size:4.4px">&#8224;</div></div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The provision of share dealing details is not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing should be obtained from a stockbroker or independent financial adviser. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">302</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Shareholder information continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders services and contacts </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ADS Depositary </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ADR programme is administered by JP Morgan Chase Bank, NA: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Regular Correspondence: </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">EQ Shareowner Services </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">P.O. Box 64504 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">St. Paul, MN 55164-0504 </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Delivery of Stock Certificates and Overnight Mail: </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">EQ Shareowner Services </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">1110 Centre Pointe Curve, Suite 101 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Mendota Heights, MN 55120-4100 </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">shareowneronline.com/informational/contact-us/</div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From the US: +1 877 353 1154 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">From outside the US: +1 651 453 2128 </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Depository also provides Global Invest Direct, a direct ADS purchase/sale and dividend reinvestment plan for ADS holders. For details on how to enrol please visit www.adr.com or call the above helpline number to obtain an enrolment pack. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Donating shares to Save the Children </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2013, GSK embarked on an ambitious global partnership with Save the Children to share our expertise and resources with the aim of finding innovative ways to reduce the number of children dying from preventable diseases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shareholders with a small number of shares, the value of which makes it uneconomical to sell, may wish to consider donating them to Save the Children. Donated shares will be aggregated and sold on behalf of Save the Children who will use the funds raised to help them reach the above goal.<div style="font-family: ARIAL; font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 5.5pt; vertical-align: top;;display:inline;;font-size:6.1px">&#8224;</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">To obtain a share donation form, please contact our registrar, Equiniti, which is managing the donation and sale of UK shares to Save the Children free of charge. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;"><div style="font-size: 75%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; vertical-align: top;;display:inline;;font-size:4.4px">&#8224;</div></div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The provision of share dealing details is not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing should be obtained from a stockbroker or independent financial adviser. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Exchange announcement notifications </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">We provide shareholders with a service to receive automatic email notifications when we publish a stock exchange announcement. To receive email notifications, please sign up for announcements at gsk.com in the Investors section. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contacts </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investor relations </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investor relations may be contacted as follows: </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">UK </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">980 Great West Road </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Brentford, Middlesex, TW8 9GS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +44 (0)20 8047 5000 </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">2929 Walnut Street </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Philadelphia PA 19104 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +1 888 825 5249 (US toll free) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +1 215 751 4000 (outside the US) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Response Center </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +1 888 825 5249 (US toll free) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +1 215 751 4600 (outside the US) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share scam alert </div></div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If you receive an unsolicited telephone call offering to sell or buy your shares, please take extra care. The caller may be part of a highly organised financial scam. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If you are a UK shareholder, please contact the Financial Conduct Authority at www.fca.org.uk/consumers or on its consumer helpline: </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: 0800 111 6768 (in the UK)* </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Tel: +44 207 066 1000 (outside the UK)* </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Lines are open from 8.00am to 6.00pm, UK time, Monday to Friday, except UK public holidays, and 9.00am to 1.00pm on Saturdays. </div></td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">303</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_52" style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_90" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>US law and regulation </div></div><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A number of provisions of US law and regulation apply to the company because our shares are quoted on the NYSE in the form of ADS. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NYSE rules </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In general, the NYSE rules permit the company to follow UK corporate governance practices instead of those applied in the US, provided that we explain any significant variations. This explanation is contained in our Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F,</div> which can be accessed from the SEC&#8217;s EDGAR database or via our website. NYSE rules require us to file annual and interim written affirmations concerning our Audit&#160;&amp; Risk Committee (ARC) and our statement on significant differences in corporate governance. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sarbanes-Oxley Act of 2002 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following a number of corporate and accounting scandals in the US, Congress passed the Sarbanes-Oxley Act of 2002. Sarbanes-Oxley is a wide-ranging piece of legislation concerned largely with financial reporting and corporate governance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As recommended by the SEC, the company has an established Disclosure Committee. The Committee reports to the CEO, the CFO and to the ARC. It is chaired by the Company Secretary and its members consist of senior managers from finance, legal, corporate communications and investor relations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where appropriate, external legal counsel, the external auditors, our sponsor bank, and internal experts are invited to attend the Disclosure Committee&#8217;s meetings periodically. The Committee has responsibility for considering the materiality of information and, on a timely basis, determining the disclosure of that information. It has responsibility for the timely filing of reports with the SEC and the formal review of the Annual Report and Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> In 2022, the Committee met 28 times, including for the purpose of receiving relevant and appropriate training. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sarbanes-Oxley requires that the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> contains a statement as to whether a member of the ARC is an audit committee financial expert, as defined in rules under Sarbanes-Oxley. Such a statement for the relevant members of the ARC (Charles Bancroft) is included in the Board Committee information area of the Corporate Governance report on page 109 and in his biography on page 98. Additional disclosure requirements arise under section 302 and section 404 of Sarbanes-Oxley in respect of disclosure controls and procedures and internal control over financial reporting. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section&#160;302: Corporate responsibility for financial reports </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sarbanes-Oxley requires for the CEO and the CFO to complete formal certifications, confirming that: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">they have each reviewed the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F;</div> </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">based on their knowledge, the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> contains no material misstatements or omissions; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">based on their knowledge, the financial statements and other financial information fairly present, in all material respects, the financial condition, results of operations and cash flows as of the dates, and for the periods, presented in the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F;</div> </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">they are responsible for establishing and maintaining disclosure controls and procedures that ensure that material information is made known to them, and have evaluated the effectiveness of these controls and procedures as at the year end, the results of such evaluation being contained in the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F;</div> </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">they are responsible for establishing and maintaining internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">they have disclosed in the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> any changes in internal controls over financial reporting during the period covered by the annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> that have materially affected, or are reasonably likely to affect materially, the company&#8217;s internal control over financial reporting, and they have disclosed, based on their most recent evaluation of internal control over financial reporting, to the external auditor and the ARC, all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to affect adversely the company&#8217;s ability to record, process, summarise and report financial information, and any fraud (regardless of materiality) involving persons that have a significant role in the company&#8217;s internal control over financial reporting. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has carried out an evaluation under the supervision and with the participation of its management, including the CEO and CFO, of the effectiveness of the design and operation of the Group&#8217;s disclosure controls and procedures as at 31&#160;December 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">304</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US law and regulation </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The CEO and CFO expect to complete these certifications and report their conclusions on the effectiveness of disclosure controls and procedures in March 2023, following which the certifications will be filed with the SEC as part of our Group&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section&#160;404: Management&#8217;s annual report on internal control over financial reporting </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In accordance with the requirements of section 404 of Sarbanes-Oxley, the following report is provided by management in respect of the company&#8217;s internal control over financial reporting (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the US Securities Exchange Act of 1934, as amended (the Exchange Act)): </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">management is responsible for establishing and maintaining adequate internal control over financial reporting for the Group. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework, Internal Control &#8211; Integrated Framework (2013)&#160;issued by the Committee of Sponsoring Organisations of the Treadway Commission (COSO); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">there have been no changes in the Group&#8217;s internal control over financial reporting during 2022 that have materially affected, or are reasonably likely to materially affect, the Group&#8217;s internal control over financial reporting; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">management has assessed the effectiveness of internal control over financial reporting as at 31&#160;December 2022 and its conclusion will be filed as part of the Group&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F;</div> and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Deloitte LLP, which has audited the consolidated financial statements of the Group for the year ended 31&#160;December 2022, has also assessed the effectiveness of the Group&#8217;s internal control over financial reporting under Auditing Standard 2201 of the Public Company Accounting Oversight Board (United States). Their audit report will be filed with the Group&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section&#160;13(r) of the Exchange Act </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Section&#160;13(r) of the Exchange Act requires issuers to make specific disclosure in their annual reports of certain types of dealings with Iran, including transactions or dealings with government-owned <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or-controlled</div> entities, as well as dealings with entities sanctioned for activities related to terrorism or proliferation of weapons of mass destruction, even when those activities are not prohibited by US law and do not involve US persons. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group exports certain pharmaceutical, vaccine and consumer products to Iran, via sales by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-US</div> entities that are not subsidiaries of a US entity, to two privately held Iranian distributors. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group does not regularly receive information regarding the identity of its distributors&#8217; downstream customers and intermediaries in Iran, and it is possible that these parties include entities, such as government-owned hospitals and pharmacies, that are owned directly or indirectly by the Iranian government or by persons or entities sanctioned in connection with terrorism or proliferation activities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Because the Group does not regularly receive information regarding the identity of its distributors&#8217; downstream customers it cannot establish the proportion of gross revenue or sales potentially attributable to entities affiliated with the Iranian government or parties sanctioned for disclosable activities. As a result, the Group is reporting the entire gross revenues (&#163;8.7 million) and net profits (&#163;3.7 million) from the Group&#8217;s sales to Iran in 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is also aware that some hospitals or other medical facilities in Lebanon may be affiliated with or controlled by Hezbollah or other groups that are designated by the United States pursuant to Executive Order 13224. Again, the Group does not deal directly with such hospitals or facilities and instead sells through distributors. The Group is unable to establish the proportion of gross revenue or sales potentially attributable to reportable activities. As a result, the Group is reporting the entire gross revenues (&#163;6.3 million) and net losses (&#163;0.2 million) from the Group&#8217;s sales to Lebanon in 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Unless noted, the Group intends to continue the activities described above. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In addition to Section&#160;13(r) of the Exchange Act, US law generally restricts dealings by US persons and dealings that otherwise are subject to US jurisdiction with certain countries or territories that are subject to comprehensive sanctions, currently Crimea, Cuba, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> Donetsk People&#8217;s Republic, Iran, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> Luhansk People&#8217;s Republic, North Korea and Syria, as well as with the Government of Venezuela (though not with the country of Venezuela as a whole). The Group does business, via <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-US</div> entities (which are not owned or controlled by US entities), in certain such jurisdictions. While we believe the Group complies with all applicable US sanctions in all material respects, such laws are complex and continue to evolve rapidly. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">305</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Donations to political organisations and political expenditure </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">To ensure a consistent approach to political contributions across the Group, in 2009 a global policy was introduced to voluntarily stop all corporate political contributions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the period from 1&#160;January 2009 to 31&#160;December 2022, the Group did not make any political donations to EU or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-EU</div> organisations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Notwithstanding the introduction of this policy, in accordance with the Federal Election Campaign Act in the US, we continue to support an employee-operated Political Action Committee (PAC) that facilitates voluntary political donations by eligible GSK employees. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The PAC is not controlled by GSK. Decisions on the amounts and recipients of contributions are governed by the PAC Board of Directors. Contributions to the PAC are made by participating eligible employees exercising their legal right to pool their resources and make political contributions, which are subject to strict limitations under US law. In 2022, a total of US$360,950 (2021: US$298,000) was donated to political organisations by the GSK employee PAC. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">English law requires prior shareholder approval for political contributions to EU political parties and independent election candidates as well as for any EU political expenditure. The definitions of political donations, political expenditure and political organisations used in the legislation are, however, quite broad. In particular, the definition of EU political organisations may extend to bodies such as those concerned with policy review, law reform, the representation of the business community and special interest groups such as those concerned with the environment, which the company and its subsidiaries might wish to support. </div></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As a result, the definitions may cover legitimate business activities not in the ordinary sense considered to be political donations or political expenditure, nor are they designed to support any political party or independent election candidate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Therefore, notwithstanding our policy, and while we do not intend to make donations to any EU political parties or organisations, nor to incur any EU political expenditure, we annually seek shareholder authorisation for any inadvertent expenditure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The authority is a precautionary measure to ensure that the company and its subsidiaries do not inadvertently breach the legislation. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This authorisation process, for expenditure of up to &#163;100,000 each year, dates back to the AGM held in May 2001, following the introduction of the Political Parties, Elections and Referendums Act 2000. The authority has since been renewed annually. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">306</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div id="ex15_2tx382677_53" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_92" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Group companies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In accordance with Section&#160;409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31&#160;December 2022 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GSK plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office and are tax resident in their country of incorporation. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1506369 Alberta ULC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3500 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">855-2nd</div> Street SW, Calgary AB T2P 4J8, Canada</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Action Potential Venture Capital Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Adechsa GmbH (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, 6341, Baar, Switzerland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Affinivax Securities Corporation</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o Affinivax, Inc., 301 Binney Street, Cambridge MA 02142, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Affinivax, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Allen&#160;&amp; Hanburys Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Allen&#160;&amp; Hanburys Pharmaceutical Nigeria Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">49, Town Planning Way, Ilupeju, Lagos, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Allen Pharmazeutika Gesellschaft m.b.H.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wienerbergstra&#223;e 7, Wien, 1100, Austria, Austria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">BEECHAM GROUP p.l.c</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">5p Ordinary B;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">20p Ordinary A</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Beecham Pharmaceuticals (Pte) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">38 Quality Road, Jurong Industrial Estate, Jurong, 618809, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda,</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Beecham S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Avenue Fleming 20, 1300 Wavre, Belgium</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Biovesta Ila&#231;lari Ltd. Sti. (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nominative</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">B&#252;y&#252;kdere Caddesi No.&#160;173, 1.Levent Plaza B Blok, 1.Levent, Istanbul, 34394, Turkey</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cascan GmbH&#160;&amp; Co. KG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munich, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cellzome GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Meyerhofstrasse 1, 69117, Heidelberg, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cellzome Limited (in liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Charles Midgley Limited (in liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Clarges Pharmaceuticals Limited (in liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Preference</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Clarges Pharmaceutical Trustees Limited (ii) (iv)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Colleen Corporation</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corixa Corporation</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Dealcyber Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Desarrollo Energia Solar Alternativa S.L.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Duncan Pharmaceuticals Philippines Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23rd Floor, The Finance Centre, 26th Street Corner 9th Avenue, Bonifacio Global City, Taguig City, 1634, Philippines</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Etex Farmaceutica Ltda</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Social Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av. Andr&#233;s Bello 2457, Costanera Center, Torre 2, Piso 20, Providencia, Santiago, 7510689, Chile</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Genelabs Technologies, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento CA 95833, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Group Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Kabushiki Kaisha (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-8-1</div></div> Akasaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Minato-ku,</div> Tokyo, Japan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Laboratories (Nigeria) Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">82 Marine Road, Apapa, Lagos, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Laboratories Limited (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">55 Baker Street, London, W1U 7EU, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo New Zealand Pension Plan Trustee Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Level&#160;2 E.2, Generator at GridAKL, 12 Madden Street, Wynyard Quarter, Auckland, 1010, New Zealand</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Operations UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Properties BV</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van Wijckstraat 55h, 3811 LP, Amersfoort, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Trustees Limited (in liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">55 Baker Street, London, W1U 7EU, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Verwaltungs GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munich, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome Farmaceutica, Limitada</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome Manufacturing Pte Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Pioneer Sector 1, Jurong Industrial Estate, Jurong, 628413, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome Production</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome Vidhyasom Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12th Floor Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">307</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome, S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Poligono Industrial Allendeduero, Avenida de Extremadura, 3, Aranda de Duero, 09400, Burgos, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo, S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo-Allenburys (Nigeria) Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">41 Creek Road, Apapa, Lagos, PMB 1401, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxochem Pte Ltd (iii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 Rochester Park, 139234, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline - Produtos Farmaceuticos, Limitada</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Cambodia) Co., Ltd.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">5th Floor DKSH Building, No.797 Preah Monivong Boulevard (Co, Sangkat Phsar Deum Thakov, Khan Chamkarmon, Phnom Penh, Cambodia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (China) Investment Co Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Room 901, 902, 903, 905, 908, 909 and 910, Unit 901, Floor 9, No.&#160;56 Mid 4th East Ring Road, Chaoyang District, Beijing, China</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (China) R&amp;D Company Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F1-3,</div> No.18 Building, 999 Huanke Road, Pilot Free Trade Zone, Shanghai, 201210, China</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (GSK) S.R.L.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-5</div> Costache Negri Street, Opera Center One, 5th and 6th floors, Zone 1, District 5, Bucharest, Romania</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Ireland) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Israel) Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">25 Basel Street, PO Box 10283, Petach-Tikva, 49002, Israel</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Malta) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1, First Floor, De La Cruz Avenue, Qormi, QRM2458, Malta</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Private) Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Unit 3, 20 Anthony Road, Msasa, Harare, Zimbabwe</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Thailand) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12th Floor Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline AB</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Hemvarnsg. 9, 171 54, Solna, Sweden</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline AG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Talstrasse <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5,</div> 3053 Muenchenbuchsee, Switzerland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Angola Unipessoal Limitada</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Luanda, Bairro Petrangol, Estrada de Cacuaco n &#176; 288, Angola</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Argentina S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tucum&#225;n 1, piso 4, Buenos Aires, C1049AAA, Argentina</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline AS</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Drammensveien 288, Oslo, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NO-0283,</div> Norway</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Australia Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline B.V.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van, Wijckstraat 55h, 3811 LP Amersfoort, The Netherlands, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Beteiligungs GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Biologicals Kft.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2100 G&#246;d&#246;ll&#245;, Homoki Nagy Istv&#225;n utca 1, Hungary</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Biologicals S.A.S.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">637 Rue des Aulnois, Saint-Amand Les Eaux, 59230, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Biologicals SA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary; Preference</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rue de l&#8217;Institut 89 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1330</div> Rixensart, Belgium</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Brasil Limitada</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Estrada dos Banderiantes, 8464, Rio de Janeiro, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">22783-110,</div> Brazil</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Capital Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wilmington Trust SP Services, Inc., 1100 N. Market Street, 4th Floor, Wilmington DE 19890, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Capital plc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Caribbean Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Chile Farmaceutica Limitada</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Social Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av Andr&#233;s Bello 2457, Torre 2, piso 20, Providencia, Santiago, Regi&#243;n Metropolitana, Chile</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Colombia S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Avenida El Dorado, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#69B-45/Piso</div> 9, Bogota, Colombia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Consumer Holding B.V. (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van Wijckstraat 55h, 3811 LP, Amersfoort, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline d.o.o Sarajevo &#8211; u likvidaciji (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zmja od Bosne broj <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-7a,</div> Sarajevo, 71000, Bosnia and Herzegovina</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline d.o.o.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ulica Damira Tomljanovica Gavrana 15, Zagreb, Croatia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline doo Beograd-Novi Beograd &#8211; U LIKVIDACIJI (In liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Milutin Milankovic, 1J, Novi Beograd, Belgrade, 11070, Serbia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Ecuador S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av 10 De Agosto <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N36-239,</div> y Naciones Unidas, Edificio Electroectuatoriana, 2do piso, Quito, Ecuador</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline El Salvador S.A. de C.V.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Municipio de San Salvador, Departamento de San Salvador, El Salvador</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline EOOD</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">16 Nedelcho Bonchev str., Sofia, 1592, Bulgaria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Export Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Export Panama S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Panama City, Republic of Panama, Panama</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Far East B.V.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van Wijckstraat 55h, 3811 LP, Amersfoort, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Finance plc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline GmbH&#160;&amp; Co. KG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Guatemala S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3ra. Av. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-78</div> Zona 10, Torre Citibank, Nivel 8, Guatemala City, Guatemala</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Holding AS</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Drammensveien 288, Oslo, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NO-0283,</div> Norway</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Holdings (Americas) Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wilmington Trust SP Services Inc., 1100 North Market Street, 4th Floor, Wilmington, Delaware, 19890</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Holdings (One) Limited (i)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Holdings Limited (i)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">308</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Holdings Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Honduras S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tegucigalpa, MDC, Honduras</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline IHC Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nominative</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">B&#252;y&#252;kdere Caddesi No. 173, 1.Levent Plaza B Blok, 1.Levent, Istanbul, 34394, Turkey</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Class A Common;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Class C Preference</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100 Milverton Drive, Suite 800 , Mississauga ON L5R 4H1, Canada</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Insurance Ltd.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o Trinity Corporate Services Ltd., Trinity Hall, 43 Cedar Avenue, Hamilton, Hamilton, HM12, Bermuda</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property (No.2) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property Development Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property Holdings Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">A Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">B Ordinary</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Deferred;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property Management Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Investigaci&#243;n y Desarrollo, S.L.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa 2 Parque Tecnol&#243;gico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Investments Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline K.K.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-8-1</div></div> Akasaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Minato-ku,</div> Tokyo, Japan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Korea Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">9F LS Yongsan Tower, 92 Hangang-daero, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yongsan-gu,</div> Seoul, 04386, Korea, Republic of</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Latin America, S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Panama City, Republic of Panama, Panama</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Lietuva UAB</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ukmerges st. 120, Vilnius, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LT-08105,</div> Lithuania</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23/F., Tower 6, The Gateway, 9 Canton Road, Tsimshatsui, Kowloon, Hong Kong</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Manufacturing SpA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Viale dell&#8217;Agricoltura 7, 37135, Verona, Italy</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Maroc S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">42-44</div> Angle Bd, Rachidi et Abou Hamed El Glaza, Casablanca, Morocco</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Medical and Healthcare Products Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">H-1124,</div> Csorsz utca 43, Budapest, Hungary</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Mercury Limited (i)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Mexico S.A. de C.V.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary A;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary B</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av. Real Mayorazgo 130 Piso 20, Colonia Xoco, Alcaldia Benito Ju&#225;rez, Ciudad de Mexico, 03330, Mexico</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline NZ Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Level 2 E.2, Generator @GridAKL, 12 Madden Street, Wynyard Quarter, Auckland, 1010, New Zealand</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Oy</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Piispansilta 9A, P.O. Box 24, Espoo, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FIN-02230,</div> Finland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Peru S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av. V&#237;ctor Andr&#233;s Bela&#250;nde N&#176;147, V&#237;a Principal N&#176;133, Piso 7, Distrito de San Isidro, Lima, Lima, Per&#250;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharma A/S</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Vallensb&#230;k Company House III , Delta Park 37, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DK-2665,</div> Valle, Denmark</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharma GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wienerbergstra&#223;e 7, Wien, 1100, Austria, Austria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceutical Kenya Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Likoni Road, Nairobi, 78392 - 00507, Kenya</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceutical Nigeria Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Industrial Avenue, Ilupeju, Ikeja, Lagos, PM B 21218, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceutical Sdn Bhd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceuticals (Pvt) Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">121 Galle Road, Kaldemulla, Moratuwa, Sri Lanka</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceuticals Costa Rica S.A</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Autopista Florencia del Castillo, kil&#243;metro siete, Oficentro TerraCampus, edificio uno, cuarto piso, San Diego, Cartago, 30302, Costa Rica</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceuticals SA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Site Apollo, Avenue Pascal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-4-6,</div></div> Wavre, 1300, Belgium</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceuticals Ukraine LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Chartered Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Pavla Tychyny avenue, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-V,</div> Kiev, 02152, Ukraine</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Philippines Inc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23rd Floor, The Finance Centre, 26th Street Corner 9th Avenue, Bonifacio Global City, Taguig City, 1634, Philippines</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pte Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 Rochester Park, 139234, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Puerto Rico, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company Puerto Rico Inc., c/o RVM Professional Services, LLC, A4 Reparto Mendoza, Humacao, 00791, Puerto Rico</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Republica Dominicana S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Blue Mall Tower, Floor 23 Ave., Winston Churchill 95, Santo Domingo, Dominican Republic</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Research &amp; Development Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline S.p.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Viale dell&#8217;Agricoltura 7, 37135, Verona, Italy</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline s.r.o.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Hvezdova 1734/2c, Prague, 4 140 00, Czech Republic</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Services GmbH &amp; Co. KG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">309</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Services Unlimited (i)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Single Member A.E.B.E.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">266 Kifissias Avenue, Halandri, Athens, 152 32, Greece</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline SL LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline SL LP (ii) (viii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Slovakia s.r.o., v likvid&#225;cii (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">KPMG Slovensko Advisory k.s., Dvo&#345;&#225;kovo n&#225;bre&#382;ie 10, 811 02 Bratislava, Slovakia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline South Africa (Pty) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Trading Services Limited (iii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Tunisia S.A.R.L.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Immeuble REGUS, Lot B17, Centre Urbain Nord, Tunis, Tunisia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Uruguay S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Registered Provisory Stock</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Salto 1105, CP 11.200 Montevideo, Uruguay</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline US Trading Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Venezuela C.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Calle Altagracia, edificio P&amp;G, piso Mezzanina, torre Torre Sur, Urbanizacion Sorokaima, La Trinidad, Caracas, 1080, Venezuela, Bolivarian Republic of</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Vietnam Limited Liability Company (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Metropolitan, 235 Dong Khoi Street, District 1, 7th Floor Unit 701, Ho Chi Minh City, Vietnam</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlycoVaxyn AG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Common;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Preferred A;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Preferred B;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Preferred C</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Grabenstrasse 3, 8952 Schlieren, Switzerland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Groupe GlaxoSmithKline</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No.3) Scottish Limited Partnership (x)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Biopharma Argentina S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nominative Non Endorseable Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tucum&#225;n 1, piso 4, Buenos Aires, C1049AAA, Argentina</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Business Service Centre Sdn Bhd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Level&#160;6, Quill 9, 112 Jalan Prof. Khoo Kay Kim, Petaling Jaya,, 46300 Selangor, Malaysia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Capital K.K.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-8-1</div></div> Akasaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Minato-ku,</div> Tokyo, Japan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Commercial Sp. z o.o.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ul. Rzymowskiego 53, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">02-697,</div> Warsaw, Poland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK d.o.o., Ljubljana</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ameri&#353;ka ulica 8,, Ljubljana, 1000, Slovenia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Enterprise Management Co, Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Floor 4, 18 Lane 999 Huanke Road, No.&#160;1358 Zhongke Road, Shanghai, China</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Equity Investments, Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Units</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 2595 Interstate Drive, Suite 103, Harrisburg PA 17110, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Finance (No 2) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Finance (No 3) plc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK India Global Services Private Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Level&#160;1, 2 &amp; 3 Luxor North Tower, Bagmane Capital Business Park Outer Ring Road, Bangalore, Karnataka, 560037, India</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK International Holding and Finance BV</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van Wijckstraat 55h, 3811 LP, Amersfoort, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Kazakhstan LLP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Participation interest</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">273, Furmanov Street, Almaty, Medeu District, 050059, Kazakhstan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Pharma India Private Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1, Battery House, Bhulabhai Desai Raod, Mumbai, Maharashtra, 400026, India</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Pharma Vietnam Company Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Chartered Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Unit 702/703 7th Floor, The Metropolitan Tower, 235 Dong Khoi Street, Ben Nghe Ward, District 1, Ho Chi Minh, Vietnam</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Pharmaceutical Trading S.A. (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Bucharest, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-5</div> Costache Negri Street, Opera Center One, 5th floor, discussions room 01, District 5, Romania</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK PSC Poland sp. z o.o.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equal and indivisible shares</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ul. Grunwaldzka 189, Pozna&#324;, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-322,</div> Pol</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Services Sp z o.o.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ul. Grunwaldzka 189, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-322,</div> Poznan, Poland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Vaccines BV</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Hullenbergweg 85, 1101 CL, Amsterdam, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Vaccines GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Emil-von-Behring-Str.76,</div></div></div> 35041 Marburg, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Vaccines Institute for Global Health S.r.l.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Via Fiorentina 1, 53100, Siena, Italy</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Vaccines S.r.l.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Via Fiorentina 1, 53100, Siena, Italy</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Vaccines Vertriebs GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rudolf-Diesel-Ring 27, 83607, Holzkirchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Human Genome Sciences, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ID Biomedical Corporation of Quebec</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2323, boul. Du Parc Technologique, Qu&#233;bec Qu&#233;bec G1P 4R8, Canada</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Instituto Luso Farmaco, Limitada (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">InterPharma Dienstleistungen GmbH (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wienerbergstra&#223;e 7, Wien, 1100, Austria, Austria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">J&amp;J Technologies, LC (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 100 Shockoe Slip, 2nd Floor, Richmond VA 23219, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">JSC GlaxoSmithKline Trading</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Leningradskiy Prospect 37A, Building 4, Floor 3, Premises XV, Room 1, 125167, Moscow, Russian Federation</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">310</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratoire GlaxoSmithKline</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratoire Pharmaceutique Alg&#233;rien LPA Production SPA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zone Industrielle Est, Boudouaou, Boumerdes, Algeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratoire Pharmaceutique Alg&#233;rien SPA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zone Industrielle Est, Boudouaou, Boumerdes, Algeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratoires Paucourt (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratoires Saint-Germain (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios Dermatologicos Darier, S.A de C.V.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary A;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary B</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Av. Real Mayorazgo 130 Piso 20, Colonia Xoco, Alcaldia Benito Ju&#225;rez, Ciudad de Mexico, 03330, Mexico</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios Farmaceuticos Stiefel (Portugal) LTDA (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios Stiefel de Venezuela SA</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Calle Altagracia, Edificio P&amp;G, Nivel Mezzanina, Piso Mezzanina, local Torre Sur, Urbanizacion Sorokaima, La Trinidad, Caracas, 1080, Venezuela, Bolivarian Republic of</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios Stiefel Ltda.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Professor Joao Cavalheiro Salem, no.1077, Bairro de Bonsucesso, Municipality of Guarulhos, Sao Paulo, CEP <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">07243-580,</div> Brazil</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios Wellcome De Portugal Limitada (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Montrose Pharma Company Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">H-1124,</div> Csorsz utca 43, Budapest, Hungary</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">PT Glaxo Wellcome Indonesia</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Class A;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Class B</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">JL. Pulobuaran Raya Kav.III/DD 2,3,4 KWS. Industri, Pulogadung, Jatinegara, Cakung, Jakarta Timur, Indonesia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Setfirst Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sierra Oncology Australia Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o Maddocks Lawyers, Angel Place, Level 27, 123 Pitt Street Sydney 2000, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sierra Oncology Canada ULC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">355 Burrard Street, Suite 1000, Vancouver, British Columbia V6C 2G8, Canada</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sierra Oncology Canada, LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sierra Oncology, LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common Stock</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sitari Pharma, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common Stock</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Smith Kline &amp; French Portuguesa-Produtos Farmaceuticos, LDA (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (Bangladesh) Private Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">House-2/A,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Road-138,Gulshan-1,</div></div> Dhaka, 1212, Bangladesh</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (Cork) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (Manufacturing) Limited (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Egypt L.L.C.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Amoun Street, El Salam City, Cairo, Egypt</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Farma, S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Legacy H Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pension Plan Trustee Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pension Trustees Limited (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">55 Baker Street, London, W1U 7EU, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pharma GmbH &amp; Co KG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pharma Verwaltungs GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pharmaceuticals (Pty) Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Pharmaceuticals Co.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Senior Executive Pension Plan Trustee Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel GmbH &amp; Co. KG</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership Capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Laboratories Legacy (Ireland) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Unit 2 Building 2500, Avenue 2000 Cork Airport Business Park, Cork, Ireland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Laboratories Limited (In liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Laboratories Pte Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Pioneer Sector, 628413, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Laboratories, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Maroc SARL</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">275 Boulevard Zerktouni, Casablanca, Morocco</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Research (Australia) Holdings Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Research Australia Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel West Coast LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Strebor Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">311</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="3" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholly owned subsidiaries continued</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tesaro Bio GmbH (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Poststrasse 6, 6300 Zug, Switzerland</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tesaro Bio Netherlands B.V</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Joop Geesinkweg 901, 1114 AB, Amsterdam-Duivendrecht, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tesaro Development, Ltd.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Clarendon House, 2 Church Street, Hamilton HM11, Bermuda</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tesaro, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Sydney Ross Co. (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, Princeton South Corporate Center, Suite 160, 100 Charles Ewing Blvd, Ewing NJ 08628, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">UCB Pharma Asia Pacific Sdn Bhd (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">12th Floor, Menara Symphony, No.&#160;5, Jalan Prof. Khoo Kay Kim,, Seksyen 13, 46200 Petaling Jaya, Malaysia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wellcome Consumer Healthcare Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wellcome Consumer Products Limited (In Liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Wellcome Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt"></td>
<td colspan="2" style="height:18pt"></td>
<td colspan="2" style="height:18pt"></td>
<td colspan="2" style="height:18pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Effective&#160;%<br/>Ownership</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="5" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsidiaries where the effective interest is less than 100%</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Amoun Pharmaceutical Industries Co. S.A.E.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">New Monetary Shares (99.5%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">90.71%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">El Salam City 11491, PO Box 3001, Cairo, Egypt</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Biddle Sawyer Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">75.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">252 Dr Annie Besant Road, Mumbai, 400030, India</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">British Pharma Group Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Capital (50%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Galvani Bioelectronics Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">55.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Galvani Bioelectronics Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">A Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">B Ordinary (0%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">55.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Saudi Arabia Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">75.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">PO Box 22617, Area No 56 to 73, Warehouse City, First Stage Al Khomrah, Jeddah 21416, Saudi Arabia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline (Tianjin) Co. Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">90.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">No.&#160;65, the Fifth Avenue, Tai Feng Industrial Park, Tianjin Economic and Technolog, Tianjin, 300457, China</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Alg&#233;rie S.P.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">99.99%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zone Industrielle Est, Boudouaou, Wilaya de Boumerdes, Algeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Consumer Nigeria plc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">46.42%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1 Industrial Avenue, Ilupeju, Ikeja, Lagos, PM B 21218, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pakistan Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">82.59%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Sykes Building, 35 Dockyard Road, West Wharf, Karachi, 74000, Pakistan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Pharmaceuticals Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">75.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">252 Dr Annie Besant Road, Mumbai,, 400030, India</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline S.A.E.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">91.20%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Boomerang Office Building - Land No.&#160;46, Zone (J) - 1st District, Town Center - 5th Tagammoe, New Cairo City, Egypt</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No.1) Scottish Limited Partnership (ix)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No. 2) Scottish Limited Partnership (ix)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Laboratorios ViiV Healthcare, S.L.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, 28760, Madrid, Spain</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Modern Pharma Trading Company L.L.C.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">91.20%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Amoun Street, PO Box 3001, El Salam City, Cairo, 11491, Egypt</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PHIVCO-1</div> LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PHIVCO-2</div> LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shionogi-ViiV Healthcare LLC (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham-Biomed O.O.O.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Participation Interest</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">97.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Leningradskiy Prospect 37A, Building 4, Floor 2, Premises XIV, Room 42, 125167, Moscow, Russian Federation</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Egypt LLC (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">99.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Amoun Street, PO Box 3001, El Salam City, Cairo, 11491, Egypt</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare (South Africa) (Proprietary) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV HealthCare BV</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Van Asch van, Wijckstraat 55h, 3811 LP Amersfoort, The Netherlands, Netherlands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Company</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Finance 1 Limited (In liquidation)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">c/o BDO LLP, 5 Temple Square, Temple Street, Liverpool, L2 5RH, United Kingdom</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Finance 2 Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Finance Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Redeemable Preference</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Prinzregentenplatz 9, 81675, Munchen, Germany</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare GmbH</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Talstrasse <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5,</div> 3053 Muenchenbuchsee, Switzerland</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">312</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:28%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:36%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Effective&#160;%<br/>Ownership</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="7" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="7" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsidiaries where the effective interest is less than 100% continued</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Hong Kong Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23/F Tower 6, The Gateway, 9 Canton Road, Harbour City, Tsimshatsui, Kowloon, Hong Kong</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare K.K.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-8-1</div></div> Akasaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Minato-ku,</div> Tokyo, Japan</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">A Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">B Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">C Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">D1 Preference;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">D2 Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Deferred;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">E 5% Cumulative Preference</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Pty Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">1061 Mountain Highway, Boronia Victoria VIC 3155, Australia</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Puerto Rico, LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interests</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company Puerto Rico Inc., c/o RVM Professional Services, LLC, A4 Reparto Mendoza, Humacao, Puerto Rico, 00791</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare S.r.l.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quotas</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Viale dell&#8217;Agricoltura 7, 37135, Verona, Italy</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare SAS</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23 rue Fran&#231;ois Jacob, 92500, Rueil-Malmaison, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare sprl</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Site Apollo, Avenue Pascal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-4-6,</div></div> Wavre, 1300, Belgium</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Trading LLC (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Participation Interest</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Leningradskiy Prospect 37A, Building 4, Floor 2, Premises XIV, Room 28, 125167, Moscow, Russian Federation</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Trading Services UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK (No.3) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK (No.4) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK (No.5) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK (No.6) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK (No.7) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare ULC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3500 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">855-2nd</div> Street SW, Calgary AB T2P 4J8, Canada</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Venture LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">LLC Interest</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiVHIV Healthcare Unipessoal Lda</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Quota</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1495-131,</div> Alges, Portugal</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Winster Pharmaceuticals Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">46.42%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2A Association Avenue, Ilupeju Industrial Estate, Lagos, PO Box 3199, Nigeria</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Effective&#160;%<br/>Ownership</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="5" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Associates</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Landholding Company, Inc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Common</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">39.93%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">23rd Floor, The Finance Centre, 26th Street Corner 9th Avenue, Bonifacio Global City, Taguig City, 1634, Philippines</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Index Ventures Life VI (Jersey) LP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(25%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">25.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">44 Esplanade, St Helier, Jersey, JE4 9WG, Channel Islands</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Kurma Biofund II FCPR</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(32.06%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">32.06%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">24 rue Royale, 5th Floor, 75008, Paris, France</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Longwood Fund I, LP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(35%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">35.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Prudential Tower, Suite 1555, 800 Boylston Street, Boston, MA 02199</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Medicxi Ventures I LP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(26.19%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">26.19%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">44 Esplanade, St Helier, Jersey, JE4 9WG, Channel Islands</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="5" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Joint Ventures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Chiron Panacea Vaccines Private Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity Shares</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">708/718, 7th Floor, A Wing, Sagar Tech Plaza, Saki Naka, Andheri East, Mumbai, Maharashtra, 400072, India</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Qualivax Pte. Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">80 Robinson Road, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#02-00,</div> 068898, Singapore</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Qura Therapeutics, LLC</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Units</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">39.15%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation Service Company, 251 Little Falls Drive, Wilmington DE 19808, United States</td></tr>
<tr style="font-size:1pt">
<td colspan="5" style="height:3.75pt"></td>
<td colspan="2" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td colspan="5" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: 9pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other significant holdings</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Axon Therapies, Inc</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Common (3.39%);</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Series&#160;A&#160;Preference&#160;(16.10%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">20.03%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">315 west 36th street, New York 10018, USA</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Alpheus Medical, Inc.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Series&#160;A&#160;Preference&#160;(13.8%)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;A-1&#160;Preference&#160;(7.29%)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">21.09%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3510 Hopkins Place, North Oakdale, Minnesota 55128, USA</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Global Farm S.A.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">A Shares (0%)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">B Shares (0%)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">C Shares (100%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">20.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Mendoza 1259, Ciudad Aut&#243;noma de Buenos Aires, Argentina</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Longwood Fund II, LP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(20.03%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">20.03%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Prudential Tower, Suite 1555, 800 Boylston Street, Boston, MA 02199</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Sanderling Ventures VII, L.P. A63</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(25.25%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">25.25%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">400 S. El Camino Real, Suite 1200, San Mateo, CA 94402</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SR One Capital Fund <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-B,</div> LP</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Partnership&#160;Interest&#160;(44%)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">44.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Corporation service company, 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">313</div></div></td></tr></table></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Other statutory disclosures continued </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Group companies </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following UK subsidiaries will take advantage of the audit exemption set out within Section 479A of the Companies Act 2006 for the period ended 31&#160;December 2022. Unless otherwise stated, the undertakings listed below are owned, either directly or indirectly, by GSK plc. </div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:22%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:10%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Name</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Security</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Effective %</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ownership&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">Registered address</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Company&#160;&#160;&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Number</div></td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<td colspan="9" style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">UK registered subsidiaries exempted from audit</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Burroughs Wellcome International Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">543757</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Domantis Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3907643</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Edinburgh Pharmaceutical Industries Limited (ii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary; Preference;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shewalton Road, Irvine, Ayrshire, KA11 5AP, United Kingdom</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SC005534</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Eskaylab Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">99025</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">480080</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxo Wellcome International B.V. (iii)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">30150600</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Glaxochem (UK) Unlimited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary B;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary C</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">4299472</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property (No.3) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">11480952</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property (No.4) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">11721880</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline Intellectual Property (No.5) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">11959399</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GlaxoSmithKline International Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2298366</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK Capital B.V. (iii) (v)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">81761198</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP 1 Limited (iv)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">A Shares;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">B Shares (0%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">99.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ, United Kingdom</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SC721605</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP 2 Limited (iv)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ, United Kingdom</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SC721606</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK LP Limited (iv)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">13879411</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Montrose Fine Chemical Company Ltd.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shewalton Road, Irvine, Ayrshire, KA11 5AP, United Kingdom</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SC190635</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">PHIVCO UK II Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">6944229</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">PHIVCO UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">6944223</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Smith Kline&#160;&amp; French Laboratories Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">52207</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (Export) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2860752</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (H)&#160;Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cumulative</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">Ordinary</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">3296131</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham (Investments) Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">302065</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Marketing and Technical Services Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">494385</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Nominees Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">503868</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">SmithKline Beecham Overseas Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">2552828</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stiefel Laboratories (U.K.) Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">831160</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tesaro UK Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">7890847</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Wellcome Foundation Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100.00%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">194814</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td>
<td colspan="2" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">ViiV Healthcare Overseas Limited</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">78.30%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">980 Great West Road, Brentford, Middlesex, TW8 9GS, England</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">7027385</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">In accordance with Section 479C of the Companies Act 2006, the company will guarantee debts and liabilities of the above UK subsidiary undertakings. As at 31 December 2022 the total sum of these debts and liabilities is &#163;1,266 million (2021 &#8211; &#163;876 million) </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Key </div></div></div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Directly owned by GSK plc. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Dormant entity. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Tax resident in the UK. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Exempt under Regulation 7 of the Partnership (Accounts) Regulations 2008 from the requirement to deliver to the registrar financial statements of the qualifying partnership(s) of which the entity is a member in accordance with the Companies Act. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Incorporated in the Netherlands </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(vi)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated as a subsidiary in accordance with Section 1162 (4)(a) of the Companies Act 2006 on the grounds of dominant influence. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(vii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Principal business address in Puerto Rico. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(viii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Exempt from the provisions of Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-6</div> of the Partnership (Accounts) Regulation 2008, in accordance with the exemptions noted in Regulation 7 of that Regulation. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(ix)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP 1 Limited&#8217;s share capital is 99% indirectly owned by GSK plc and 1% owned by Berkeley Square Pension Trustee Company Limited. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(x)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#8217;s share capital is 100% indirectly owned by GSK plc. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">314</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div id="ex15_2tx382677_54" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div id="ex15_2tx382677_93" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Glossary of terms </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:62%"></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Terms used in the Annual Report</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US equivalent or brief description</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Accelerated capital allowances</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Tax allowance in excess of depreciation arising from the purchase of fixed assets that delay the charging and payment of tax. The equivalent of tax depreciation.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">American Depositary Receipt (ADR)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Receipt evidencing title to an ADS. Each GSK ADR represents two Ordinary Shares.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">American Depositary Shares (ADS)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Listed on the New York Stock Exchange; represents two Ordinary Shares.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Basic earnings per share</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Basic income per share.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Called up share capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary Shares, issued and fully paid.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">CER growth</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Growth at constant exchange rates.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The company</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK plc.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Currency swap</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">An exchange of two currencies, coupled with a subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-exchange</div> of those currencies, at agreed exchange rates and dates.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Defined benefit plan</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Pension plan with specific employee benefits, often called &#8216;final salary scheme&#8217;.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Defined contribution plan</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Pension plan with specific contributions and a level of pension dependent upon the growth of the pension fund.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Derivative financial instrument</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">A financial instrument that derives its value from the price or rate of some underlying item.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Diluted earnings per share</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Diluted income per share.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Employee Share Ownership Plan Trusts</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Trusts established by the Group to satisfy share-based employee incentive plans.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Equity Shareholders&#8217; funds</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shareholders&#8217; equity.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Finance lease</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Capital lease.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Freehold</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ownership with absolute rights in perpetuity.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The Group</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK plc and its subsidiary undertakings.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK plc and its subsidiary undertakings.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Hedging</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The reduction of risk, normally in relation to foreign currency or interest rate movements, by making <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-setting</div> commitments.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Intangible fixed assets</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Assets without physical substance, such as computer software, brands, licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and marketing rights purchased from outside parties.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary share</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">A fully paid up ordinary share in the capital of the company.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Profit</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Income.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Profit attributable to shareholders</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net income.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Share capital</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Ordinary Shares, capital stock or common stock issued and fully paid.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Share option</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Stock option.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Share premium account</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-up</div> capital or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> surplus (not distributable).</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Shares in issue</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">The number of shares outstanding.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Subsidiary</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">An entity in which GSK exercises control.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Treasury share</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Treasury stock.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Turnover</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Revenue.</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"></td>
<td colspan="2" style="height:3pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">UK Corporate Governance Code</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">As required by the UK Listing Authority, the company has disclosed in the Annual Report how it has applied the best practice corporate governance provisions of the Financial Reporting Council&#8217;s UK Corporate Governance Code.</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677f_275.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">315</div></div></td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022 </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%; text-indent: -2%; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Shareholder information continued </div></div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">Index </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">2022 Remuneration policy summary</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Access</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Accounting principles and policies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Acquisitions and disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Adjustments reconciling Total profit after tax to operating cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Annual General Meeting 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Approach to tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Associates and joint ventures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Audit&#160;&amp; Risk Committee Report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Business model</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Cash generation and conversion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">CEO&#8217;s statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">06</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chair&#8217;s statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chair&#8217;s Governance statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Chair&#8217;s Remuneration annual statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Climate-related financial disclosure</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Commitments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Consolidated balance sheet</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Consolidated cash flow statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Consolidated income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Consolidated statement of changes in equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Consolidated statement of comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Contingent liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Corporate governance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Corporate Responsibility Committee Report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Critical accounting judgements and key sources of estimation uncertainty</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Critical accounting policies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Data and engagement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Demerger of Consumer Healthcare business</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Directors and senior management</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Directors&#8217; interests in shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Directors&#8217; report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Directors&#8217; statement of responsibilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Dividends</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Donations to political organisations and political expenditure</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Earnings per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Employee costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Employee share schemes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Environment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Ethical standards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Exchange rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Finance expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Finance income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Financial calendar 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Financial instruments and related disclosures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Financial performance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Financial position and resources</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Financial statements of GSK plc, prepared under UK&#160;GAAP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">General Medicines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">38,75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Glossary of terms</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Group companies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Group financial review</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">GSK Leadership Team</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Independent Auditor&#8217;s report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Innovation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Inventories</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Investor relations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Key performance indicators&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Legal proceedings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Major restructuring costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Movements in equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Net debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">New accounting requirements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Nominations Committee Report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests in ViiV Healthcare</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> information statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Notes to the financial statements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other operating income/(expense)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Our culture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Our external environment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Our long-term priorities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Pensions and other post-employment benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Performance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Pharmaceutical products, competition and intellectual property</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Pipeline</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Post balance sheet events</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Presentation of the financial statements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Principal Group companies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Principal risks and uncertainties</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Reconciliation of net cash flow to movement in net debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Registrar</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Related party transactions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Reliable supply</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Remuneration governance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Remuneration report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Reporting framework</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Responsible business</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Risk management</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Science and technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Science Committee report</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Section&#160;172 statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Share capital and control</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Share capital and share premium account</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Share Consolidation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Shareholder information</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Shareholder services and contacts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Specialty Medicines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">33,73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Stakeholder engagement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Task Force on Climate-related Financial Disclosures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Tax information for shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Three-year selected financial data</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">The Board</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Treasury policies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Trust</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Turnover and segment information</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">US law and regulation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">29,74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Vaccine products, competition and intellectual property</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: ARIAL; line-height: normal;">Viability statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">316</div></div></td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">About GSK </div></div><div style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:29%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline plc was incorporated as an English public limited company on 6&#160;December 1999. We were formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc. GSK acquired these two English companies on 27&#160;December 2000 as part of the merger arrangements. Effective 15&#160;May 2022 GlaxoSmithKline plc changed its name to GSK plc. On 18&#160;July 2022, GSK plc, separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 12pt; font-family: ARIAL; line-height: normal;">Our shares are listed on the London Stock Exchange and the New York Stock Exchange.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">www.gsk.com</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">Brand names appearing in italics throughout this report are trade marks either owned by and/or licensed to GSK or associated companies. All other trade marks are the property of their respective owners.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">Printed sustainably in the UK by Pureprint, a CarbonNeutral<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">&#174;</div> company with FSC<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">&#174;</div> chain of custody and an ISO 14001 certified environmental management system recycling over 99% of all dry waste.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;">Printed on Arena ECO 50 EW Smooth, a wood free uncoated paper, ECF with FSC certification and made from 50% recycled fibre.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">
<img alt="LOGO" src="g382677f_317.jpg"/> </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Download PDFs:</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; Annual Report 2022</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 2pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; ESG Performance Report 2022</div></td></tr></table><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.00pt #e0e0e0;border-radius:10pt; background-color:#e0e0e0;padding-top:2pt;padding-bottom:3pt"><div style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5pt; font-size: 6pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Cautionary statement regarding forward-looking statements </div></div><div style="margin-top:2pt; margin-bottom:0pt; margin-left:5pt; font-size:6pt; font-family:ARIAL">The Group&#8217;s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document, and any other written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group&#8217;s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as &#8216;anticipate&#8217;, &#8216;estimate&#8217;, &#8216;expect&#8217;, &#8216;intend&#8217;, &#8216;will&#8217;, &#8216;project&#8217;, &#8216;plan&#8217;, &#8216;believe&#8217;, &#8216;target&#8217; and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. </div><div style="margin-top:4pt; margin-bottom:0pt; margin-left:5pt; font-size:6pt; font-family:ARIAL">Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group&#8217;s control or precise estimate. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. </div><div style="margin-top:4pt; margin-bottom:0pt; margin-left:5pt; font-size:6pt; font-family:ARIAL">Such factors include, but are not limited to, those discussed under &#8216;Principal risks and uncertainties&#8217; on pages 285 to 295 of this Annual Report and any </div></div><div style="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">impacts of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this Annual Report. </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">A number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IFRS</div> measures are used to report the performance of our business. These measures are defined on pages 69 to 70 and a reconciliation of Adjusted results to Total results is set out on pages 81 to 85. </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">The information in this document does not constitute an offer to sell or an invitation to buy shares in GSK plc or an invitation or inducement to engage in any other investment activities. Past performance cannot be relied upon as a guide to future performance. Nothing in this Annual Report should be construed as a profit forecast. </div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 6pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Assumptions related to 2023 guidance </div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">In outlining the guidance for 2023, the Group has made certain assumptions about the healthcare sector, the different markets in which the Group operates and the delivery of revenues and financial benefits from its current portfolio, pipeline and restructuring programmes. Due to the phasing of quarterly results in 2022 and the resulting comparators, GSK expects turnover and Adjusted operating profit growth to be slightly lower in the first half of 2023 including a challenging comparator in Q1 2022 and somewhat higher in the second half, relative to full-year expectations. Despite the recovery of healthcare systems, uncertain economic conditions prevail across many markets in which GSK operates and we continue to expect to see variability in performance between quarters. </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">We expect sales of Specialty Medicines to increase mid to high single-digit per cent, sales of Vaccines to increase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> per cent and sales of General Medicines to decrease slightly. </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">These planning assumptions as well as operating profit guidance and dividend expectations assume no material interruptions to supply of the Group&#8217;s products, no material mergers, acquisitions or disposals, no material litigation or investigation costs for the Company (save for those that are already recognised or for which provisions have been made) and no change in the Group&#8217;s shareholdings in ViiV Healthcare. The assumptions also assume no material </div></div><div style="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; margin-right:5pt; font-size:6pt; font-family:ARIAL">changes in the healthcare environment or unexpected significant changes in pricing as a result of government or competitor action. The 2023 guidance factors in all divestments and product exits announced to date. </div><div style="margin-top:4pt; margin-bottom:0pt; margin-right:5pt; font-size:6pt; font-family:ARIAL">The Group&#8217;s guidance assumes successful delivery of the Group&#8217;s integration and restructuring plans. Material costs for investment in new product launches and R&amp;D have been factored into the expectations given. Given the potential development options in the Group&#8217;s pipeline, the outlook may be affected by additional data-driven R&amp;D investment decisions. The guidance is given on a constant currency basis. </div><div style="margin-top:4pt; margin-bottom:0pt; margin-right:5pt; font-size:6pt; font-family:ARIAL">All outlooks, ambitions and expectations should be read together with pages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div> of the Stock Exchange announcement relating to an update to investors dated 23&#160;June 2021, paragraph 19 of Part 7 of the Circular to shareholders relating to the demerger of Haleon dated 1&#160;June 2022 and the Guidance, assumptions and cautionary statements in the Group&#8217;s Q4 2022 earnings release. </div><div style="margin-top: 4pt; margin-bottom: 0pt; margin-right: 5pt; font-size: 6pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Notice regarding limitations on Director Liability under English Law </div></div><div style="margin-top:2pt; margin-bottom:0pt; margin-right:5pt; font-size:6pt; font-family:ARIAL">Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Directors&#8217; Report (for which see page 117), the Strategic report and the Remuneration report. Under English law the Directors would be liable to the company, but not to any third party, if one or more of these reports contained errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would otherwise not be liable. Pages 97, 131, 166 to 167, and 285 to 314 inclusive comprise the Directors&#8217; Report, pages 1 to 95 inclusive comprise the Strategic report and pages 133 to 164 inclusive comprise the Remuneration report, each of which have been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with these reports shall be subject to the limitations and restrictions provided by such law. </div><div style="margin-top: 4pt; margin-bottom: 0pt; margin-right: 5pt; font-size: 6pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Website </div></div><div style="margin-top:2pt; margin-bottom:0pt; margin-right:5pt; font-size:6pt; font-family:ARIAL">GSK&#8217;s website www.gsk.com gives additional information on the Group. Notwithstanding the references we make in this Annual Report to GSK&#8217;s website, none of the information made available on the website constitutes part of this Annual Report or shall be deemed to be incorporated by reference herein. </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right;"><div style="font-weight:bold;display:inline;">&#160;&#160;317&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top">
<img alt="LOGO" src="g382677f_318a.jpg"/> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right;">
<img alt="LOGO" src="g382677f_318b.jpg"/> </td></tr></table><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:120pt; margin-bottom:0pt; font-size:29pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">We unite science, technology<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:29pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">and talent to get ahead </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:29pt; font-family:ARIAL;text-align:center"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">of disease together. </div></div><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Head Office and Registered Office</div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">GSK plc</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">980 Great West Road</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Brentford, Middlesex TW8 9GS</div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">United Kingdom</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: ARIAL; line-height: normal;">Tel: +44 (0)20 8047 5000</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Registered number: 3888792</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">
<img alt="LOGO" src="g382677f_318c.jpg"/> </td></tr></table></div></div></div></div></div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>gsk-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-March-2023 [08:38:39] {PM}-->
<schema targetNamespace="http://www.gsk.com/20221231" elementFormDefault="qualified" xmlns:gsk="http://www.gsk.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://www.xbrl.org/2003/XLink" xmlns:currency="http://www.xbrl.org/2003/XLink" xmlns:exch="http://www.xbrl.org/2003/XLink" xmlns:naics="http://www.xbrl.org/2003/XLink" xmlns:sic="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://www.xbrl.org/2003/XLink" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.gsk.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedIncomeStatement" id="ConsolidatedIncomeStatement">
<link:definition>1002 - Statement - Consolidated income statement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome" id="ConsolidatedStatementOfComprehensiveIncome">
<link:definition>1003 - Statement - Consolidated statement of comprehensive income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedBalanceSheet" id="ConsolidatedBalanceSheet">
<link:definition>1004 - Statement - Consolidated balance sheet</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity" id="ConsolidatedStatementOfChangesInEquity">
<link:definition>1005 - Statement - Consolidated statement of changes in equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedCashFlowStatement" id="ConsolidatedCashFlowStatement">
<link:definition>1006 - Statement - Consolidated cash flow statement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatements" id="PresentationOfTheFinancialStatements">
<link:definition>1007 - Disclosure - Presentation of the financial statements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPolicies" id="AccountingPrinciplesAndPolicies">
<link:definition>1008 - Disclosure - Accounting principles and policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" id="CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty">
<link:definition>1009 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NewAccountingRequirements" id="NewAccountingRequirements">
<link:definition>1010 - Disclosure - New accounting requirements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ExchangeRates" id="ExchangeRates">
<link:definition>1011 - Disclosure - Exchange rates</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformation" id="TurnoverAndSegmentInformation">
<link:definition>1012 - Disclosure - Turnover and segment information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpense" id="OtherOperatingIncomeExpense">
<link:definition>1013 - Disclosure - Other operating income/(expense)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OperatingProfit" id="OperatingProfit">
<link:definition>1014 - Disclosure - Operating profit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCosts" id="EmployeeCosts">
<link:definition>1015 - Disclosure - Employee costs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCosts" id="MajorRestructuringCosts">
<link:definition>1016 - Disclosure - Major restructuring costs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceIncome" id="FinanceIncome">
<link:definition>1017 - Disclosure - Finance income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceExpense" id="FinanceExpense">
<link:definition>1018 - Disclosure - Finance expense</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVentures" id="AssociatesAndJointVentures">
<link:definition>1019 - Disclosure - Associates and joint ventures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/Taxation" id="Taxation">
<link:definition>1020 - Disclosure - Taxation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EarningsPerShare" id="EarningsPerShare">
<link:definition>1021 - Disclosure - Earnings per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/Dividends" id="Dividends">
<link:definition>1022 - Disclosure - Dividends</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
<link:definition>1023 - Disclosure - Property, plant and equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/RightOfUseAssets" id="RightOfUseAssets">
<link:definition>1024 - Disclosure - Right of use assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/Goodwill" id="Goodwill">
<link:definition>1025 - Disclosure - Goodwill</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssets" id="OtherIntangibleAssets">
<link:definition>1026 - Disclosure - Other intangible assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures" id="InvestmentsInAssociatesAndJointVentures">
<link:definition>1027 - Disclosure - Investments in associates and joint ventures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CurrentEquityInvestments" id="CurrentEquityInvestments">
<link:definition>1028 - Disclosure - Current equity investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherInvestments" id="OtherInvestments">
<link:definition>1029 - Disclosure - Other investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentAssets" id="OtherNonCurrentAssets">
<link:definition>1030 - Disclosure - Other non-current assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/Inventories" id="Inventories">
<link:definition>1031 - Disclosure - Inventories</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherReceivables" id="TradeAndOtherReceivables">
<link:definition>1032 - Disclosure - Trade and other receivables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
<link:definition>1033 - Disclosure - Cash and cash equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssetsHeldForSale" id="AssetsHeldForSale">
<link:definition>1034 - Disclosure - Assets held for sale</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1035 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NetDebt" id="NetDebt">
<link:definition>1036 - Disclosure - Net debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits" id="PensionsAndOtherPostEmploymentBenefits">
<link:definition>1037 - Disclosure - Pensions and other post-employment benefits</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherProvisions" id="OtherProvisions">
<link:definition>1038 - Disclosure - Other provisions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilities" id="ContingentConsiderationLiabilities">
<link:definition>1039 - Disclosure - Contingent consideration liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilities" id="OtherNonCurrentLiabilities">
<link:definition>1040 - Disclosure - Other non-current liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentLiabilities" id="ContingentLiabilities">
<link:definition>1041 - Disclosure - Contingent liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/Commitments" id="Commitments">
<link:definition>1042 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount" id="ShareCapitalAndSharePremiumAccount">
<link:definition>1043 - Disclosure - Share capital and share premium account</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquity" id="MovementsInEquity">
<link:definition>1044 - Disclosure - Movements in equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NonControllingInterests" id="NonControllingInterests">
<link:definition>1045 - Disclosure - Non-controlling interests</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1046 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals" id="AcquisitionsAndDisposals">
<link:definition>1047 - Disclosure - Acquisitions and disposals</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows" id="AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows">
<link:definition>1048 - Disclosure - Adjustments reconciling profit after tax to operating cash flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt" id="ReconciliationOfNetCashFlowToMovementInNetDebt">
<link:definition>1049 - Disclosure - Reconciliation of net cash flow to movement in net debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures" id="FinancialInstrumentsAndRelatedDisclosures">
<link:definition>1050 - Disclosure - Financial instruments and related disclosures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemes" id="EmployeeShareSchemes">
<link:definition>1051 - Disclosure - Employee share schemes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PrincipalGroupCompanies" id="PrincipalGroupCompanies">
<link:definition>1052 - Disclosure - Principal Group companies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/LegalProceedings" id="LegalProceedings">
<link:definition>1053 - Disclosure - Legal proceedings</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PostBalanceSheetEvents" id="PostBalanceSheetEvents">
<link:definition>1054 - Disclosure - Post balance sheet events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies" id="AccountingPrinciplesAndPoliciesPolicies">
<link:definition>1055 - Disclosure - Accounting principles and policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables" id="AccountingPrinciplesAndPoliciesTables">
<link:definition>1056 - Disclosure - Accounting principles and policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ExchangeRatesTables" id="ExchangeRatesTables">
<link:definition>1057 - Disclosure - Exchange rates (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTables" id="TurnoverAndSegmentInformationTables">
<link:definition>1058 - Disclosure - Turnover and segment information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseTables" id="OtherOperatingIncomeExpenseTables">
<link:definition>1059 - Disclosure - Other operating income/(expense) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OperatingProfitTables" id="OperatingProfitTables">
<link:definition>1060 - Disclosure - Operating profit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCostsTables" id="EmployeeCostsTables">
<link:definition>1061 - Disclosure - Employee costs (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCostsTables" id="MajorRestructuringCostsTables">
<link:definition>1062 - Disclosure - Major restructuring costs (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceIncomeTables" id="FinanceIncomeTables">
<link:definition>1063 - Disclosure - Finance income (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceExpenseTables" id="FinanceExpenseTables">
<link:definition>1064 - Disclosure - Finance expense (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesTables" id="AssociatesAndJointVenturesTables">
<link:definition>1065 - Disclosure - Associates and joint ventures (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationTables" id="TaxationTables">
<link:definition>1066 - Disclosure - Taxation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
<link:definition>1067 - Disclosure - Earnings per share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/DividendsTables" id="DividendsTables">
<link:definition>1068 - Disclosure - Dividends (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
<link:definition>1069 - Disclosure - Property, plant and equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/RightOfUseAssetsTables" id="RightOfUseAssetsTables">
<link:definition>1070 - Disclosure - Right of use assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/GoodwillTables" id="GoodwillTables">
<link:definition>1071 - Disclosure - Goodwill (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssetsTables" id="OtherIntangibleAssetsTables">
<link:definition>1072 - Disclosure - Other intangible assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables" id="InvestmentsInAssociatesAndJointVenturesTables">
<link:definition>1073 - Disclosure - Investments in associates and joint ventures (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsTables" id="CurrentEquityInvestmentsTables">
<link:definition>1074 - Disclosure - Current equity investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherInvestmentsTables" id="OtherInvestmentsTables">
<link:definition>1075 - Disclosure - Other investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsTables" id="OtherNonCurrentAssetsTables">
<link:definition>1076 - Disclosure - Other non-current assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1077 - Disclosure - Inventories (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesTables" id="TradeAndOtherReceivablesTables">
<link:definition>1078 - Disclosure - Trade and other receivables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
<link:definition>1079 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssetsHeldForSaleTables" id="AssetsHeldForSaleTables">
<link:definition>1080 - Disclosure - Assets held for sale (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1081 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NetDebtTables" id="NetDebtTables">
<link:definition>1082 - Disclosure - Net debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables" id="PensionsAndOtherPostEmploymentBenefitsTables">
<link:definition>1083 - Disclosure - Pensions and other post-employment benefits (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherProvisionsTables" id="OtherProvisionsTables">
<link:definition>1084 - Disclosure - Other provisions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables" id="ContingentConsiderationLiabilitiesTables">
<link:definition>1085 - Disclosure - Contingent consideration liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables" id="OtherNonCurrentLiabilitiesTables">
<link:definition>1086 - Disclosure - Other non-current liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CommitmentsTables" id="CommitmentsTables">
<link:definition>1087 - Disclosure - Commitments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables" id="ShareCapitalAndSharePremiumAccountTables">
<link:definition>1088 - Disclosure - Share capital and share premium account (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquityTables" id="MovementsInEquityTables">
<link:definition>1089 - Disclosure - Movements in equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NonControllingInterestsTables" id="NonControllingInterestsTables">
<link:definition>1090 - Disclosure - Non-controlling interests (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsTables" id="AcquisitionsAndDisposalsTables">
<link:definition>1091 - Disclosure - Acquisitions and disposals (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables" id="AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables">
<link:definition>1092 - Disclosure - Adjustments reconciling profit after tax to operating cash flows (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables" id="ReconciliationOfNetCashFlowToMovementInNetDebtTables">
<link:definition>1093 - Disclosure - Reconciliation of net cash flow to movement in net debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables" id="FinancialInstrumentsAndRelatedDisclosuresTables">
<link:definition>1094 - Disclosure - Financial instruments and related disclosures (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesTables" id="EmployeeShareSchemesTables">
<link:definition>1095 - Disclosure - Employee share schemes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesTables" id="PrincipalGroupCompaniesTables">
<link:definition>1096 - Disclosure - Principal Group companies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail" id="PresentationOfTheFinancialStatementsAdditionalInformationDetail">
<link:definition>1097 - Disclosure - Presentation of the Financial Statements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail" id="AccountingPrinciplesAndPoliciesAdditionalInformationDetail">
<link:definition>1098 - Disclosure - Accounting Principles and Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail" id="AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<link:definition>1099 - Disclosure - Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail" id="CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail">
<link:definition>1100 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail" id="ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail">
<link:definition>1101 - Disclosure - Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail" id="TurnoverAndSegmentInformationAdditionalInformationDetail">
<link:definition>1102 - Disclosure - Turnover and Segment Information - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail" id="TurnoverAndSegmentInformationTurnoverBySegmentDetail">
<link:definition>1103 - Disclosure - Turnover and Segment Information - Turnover by Segment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail" id="TurnoverAndSegmentInformationTurnoverByProductServiceDetail">
<link:definition>1104 - Disclosure - Turnover and Segment Information - Turnover by Product &amp; Service (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail" id="TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail">
<link:definition>1105 - Disclosure - Turnover and Segment Information - Segment Profit and Operating Profit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail" id="TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail">
<link:definition>1106 - Disclosure - Turnover and Segment Information - Summary of Geographical Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail" id="OtherOperatingIncomeExpenseAdditionalInformationDetail">
<link:definition>1107 - Disclosure - Other operating income/(expense) - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" id="OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail">
<link:definition>1108 - Disclosure - Other operating income/(expense) - Information about Other Operating Income Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail" id="OperatingProfitAdditionalInformationDetail">
<link:definition>1109 - Disclosure - Operating Profit - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail" id="OperatingProfitSummaryOfInformationAboutProfitLossDetail">
<link:definition>1110 - Disclosure - Operating Profit - Summary of Information About Profit Loss (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail" id="OperatingProfitSummaryOfAuditorsRemunerationDetail">
<link:definition>1111 - Disclosure - Operating Profit - Summary of Auditors Remuneration (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail" id="EmployeeCostsSummaryOfEmployeeCostsDetail">
<link:definition>1112 - Disclosure - Employee Costs - Summary of Employee Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail" id="EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail">
<link:definition>1113 - Disclosure - Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" id="EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail">
<link:definition>1114 - Disclosure - Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" id="EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail">
<link:definition>1115 - Disclosure - Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail" id="MajorRestructuringCostsAdditionalInformationDetail">
<link:definition>1116 - Disclosure - Major Restructuring Costs - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" id="MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail">
<link:definition>1117 - Disclosure - Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail" id="MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail">
<link:definition>1118 - Disclosure - Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" id="MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail">
<link:definition>1119 - Disclosure - Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail" id="FinanceIncomeSummaryOfFinanceIncomeDetail">
<link:definition>1120 - Disclosure - Finance Income - Summary of Finance Income (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail" id="FinanceExpenseSummaryOfFinanceCostDetail">
<link:definition>1121 - Disclosure - Finance Expense - Summary of Finance Cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail" id="AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail">
<link:definition>1122 - Disclosure - Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail" id="AssociatesAndJointVenturesAdditionalInformationDetail">
<link:definition>1123 - Disclosure - Associates and joint ventures - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail" id="AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail">
<link:definition>1124 - Disclosure - Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail" id="AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail">
<link:definition>1125 - Disclosure - Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" id="TaxationSummaryOfTaxationChargeBasedOnProfitsDetail">
<link:definition>1126 - Disclosure - Taxation - Summary of Taxation Charge Based on Profits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationAdditionalInformationDetail" id="TaxationAdditionalInformationDetail">
<link:definition>1127 - Disclosure - Taxation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" id="TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail">
<link:definition>1128 - Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" id="TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail">
<link:definition>1129 - Disclosure - Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail" id="TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition>1130 - Disclosure - Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail" id="TaxationSummaryOfNetDeferredTaxAssetDetail">
<link:definition>1131 - Disclosure - Taxation - Summary of Net Deferred Tax Asset (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail" id="TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail">
<link:definition>1132 - Disclosure - Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" id="EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<link:definition>1133 - Disclosure - Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" id="EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail">
<link:definition>1134 - Disclosure - Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail" id="DividendsSummaryOfInterimFinancialReportingDetail">
<link:definition>1135 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical" id="DividendsSummaryOfInterimFinancialReportingDetailParenthetical">
<link:definition>1136 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/DividendsAdditionalInformationDetail" id="DividendsAdditionalInformationDetail">
<link:definition>1137 - Disclosure - Dividends - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail" id="DividendsSummaryOfDividendsToShareholdersDetail">
<link:definition>1138 - Disclosure - Dividends - Summary of Dividends to Shareholders (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" id="PropertyPlantAndEquipmentAdditionalInformationDetail">
<link:definition>1139 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" id="PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail">
<link:definition>1140 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail" id="RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail">
<link:definition>1141 - Disclosure - Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/GoodwillAdditionalInformationDetail" id="GoodwillAdditionalInformationDetail">
<link:definition>1142 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail" id="GoodwillSummaryOfChangesInGoodwillDetail">
<link:definition>1143 - Disclosure - Goodwill - Summary of Changes in Goodwill (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail" id="GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail">
<link:definition>1144 - Disclosure - Goodwill - Summary of Goodwill Allocated to Segments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail" id="GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail">
<link:definition>1145 - Disclosure - Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail" id="OtherIntangibleAssetsAdditionalInformationDetail">
<link:definition>1146 - Disclosure - Other Intangible Assets - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail" id="OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail">
<link:definition>1147 - Disclosure - Other Intangible Assets - Summary of Other Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail" id="OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail">
<link:definition>1148 - Disclosure - Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail" id="OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail">
<link:definition>1149 - Disclosure - Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail" id="InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail">
<link:definition>1150 - Disclosure - Investments in Associates and Joint Ventures - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail" id="InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail">
<link:definition>1151 - Disclosure - Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail" id="CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail">
<link:definition>1152 - Disclosure - Current Equity Investments - Summary of Current Equity Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail" id="CurrentEquityInvestmentsAdditionalInformationDetail">
<link:definition>1153 - Disclosure - Current Equity Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail" id="OtherInvestmentsAdditionalInformationDetail">
<link:definition>1154 - Disclosure - Other Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail" id="OtherInvestmentsScheduleOfOtherInvestmentsDetail">
<link:definition>1155 - Disclosure - Other Investments - Schedule of Other Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail" id="OtherNonCurrentAssetsAdditionalInformationDetail">
<link:definition>1156 - Disclosure - Other Non-Current Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" id="OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<link:definition>1157 - Disclosure - Other Non-Current Assets - Summary of Other Non-Current Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail" id="InventoriesSummaryOfInventoriesDetail">
<link:definition>1158 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" id="TradeAndOtherReceivablesAdditionalInformationDetail">
<link:definition>1159 - Disclosure - Trade and Other Receivables - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" id="TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<link:definition>1160 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail" id="TradeAndOtherReceivablesSummaryOfLossAllowanceDetail">
<link:definition>1161 - Disclosure - Trade and Other Receivables - Summary of Loss Allowance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail" id="CashAndCashEquivalentsAdditionalInformationDetail">
<link:definition>1162 - Disclosure - Cash and cash equivalents - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" id="CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<link:definition>1163 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail" id="AssetsHeldForSaleAdditionalInformationDetail">
<link:definition>1164 - Disclosure - Assets Held for Sale - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" id="AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail">
<link:definition>1165 - Disclosure - Assets Held for Sale - Summary of Assets Held for Sale (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail" id="TradeAndOtherPayablesAdditionalInformationDetail">
<link:definition>1166 - Disclosure - Trade and Other Payables - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1167 - Disclosure - Trade and Other Payables - Summary of Trade and Other Payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail" id="TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail">
<link:definition>1168 - Disclosure - Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NetDebtAdditionalInformationDetail" id="NetDebtAdditionalInformationDetail">
<link:definition>1169 - Disclosure - Net Debt - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail" id="NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail">
<link:definition>1170 - Disclosure - Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail" id="NetDebtScheduleOfFinanceLeaseObligationsDetail">
<link:definition>1171 - Disclosure - Net Debt - Schedule of Finance Lease Obligations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail">
<link:definition>1172 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail" id="PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail">
<link:definition>1173 - Disclosure - Pensions and Other Post-employment Benefits - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail">
<link:definition>1174 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail">
<link:definition>1175 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail">
<link:definition>1176 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail">
<link:definition>1177 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail" id="PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail">
<link:definition>1178 - Disclosure - Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail">
<link:definition>1179 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail">
<link:definition>1180 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail">
<link:definition>1181 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail">
<link:definition>1182 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail">
<link:definition>1183 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail">
<link:definition>1184 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail">
<link:definition>1185 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail" id="PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail">
<link:definition>1186 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail" id="OtherProvisionsAdditionalInformationDetail">
<link:definition>1187 - Disclosure - Other provisions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail" id="OtherProvisionsSummaryOfOtherProvisionsDetail">
<link:definition>1188 - Disclosure - Other Provisions - Summary of Other Provisions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail" id="ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail">
<link:definition>1189 - Disclosure - Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail" id="ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail">
<link:definition>1190 - Disclosure - Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail" id="ContingentConsiderationLiabilitiesAdditionalInformationDetail">
<link:definition>1191 - Disclosure - Contingent Consideration Liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" id="OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail">
<link:definition>1192 - Disclosure - Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail" id="ContingentLiabilitiesAdditionalInformationDetail">
<link:definition>1193 - Disclosure - Contingent Liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CommitmentsAdditionalInformationDetail" id="CommitmentsAdditionalInformationDetail">
<link:definition>1194 - Disclosure - Commitments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" id="CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail">
<link:definition>1195 - Disclosure - Commitments - Schedule of Contractual Obligations and Commitments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail" id="ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail">
<link:definition>1196 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail" id="ShareCapitalAndSharePremiumAccountAdditionalInformationDetail">
<link:definition>1197 - Disclosure - Share Capital and Share Premium Account - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail" id="MovementsInEquityAdditionalInformationDetail">
<link:definition>1198 - Disclosure - Movements in Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail" id="MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail">
<link:definition>1199 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail" id="MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail">
<link:definition>1200 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" id="MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail">
<link:definition>1201 - Disclosure - Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail" id="MovementsInEquityAnalysisOfOtherReservesDetail">
<link:definition>1202 - Disclosure - Movements in Equity - Analysis of Other Reserves (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail" id="NonControllingInterestsAdditionalInformationDetail">
<link:definition>1203 - Disclosure - Non-controlling interests - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail" id="NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail">
<link:definition>1204 - Disclosure - Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1205 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail" id="AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail">
<link:definition>1206 - Disclosure - Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail" id="AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail">
<link:definition>1207 - Disclosure - Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail" id="AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail">
<link:definition>1208 - Disclosure - Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail" id="AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail">
<link:definition>1209 - Disclosure - Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail" id="AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail">
<link:definition>1210 - Disclosure - Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" id="AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail">
<link:definition>1211 - Disclosure - Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail" id="AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail">
<link:definition>1212 - Disclosure - Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail" id="ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail">
<link:definition>1213 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail" id="ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail">
<link:definition>1214 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail" id="FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail">
<link:definition>1215 - Disclosure - Financial instruments and related disclosures - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail">
<link:definition>1216 - Disclosure - Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail">
<link:definition>1217 - Disclosure - Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail">
<link:definition>1218 - Disclosure - Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail">
<link:definition>1219 - Disclosure - Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail" id="FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail">
<link:definition>1220 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail" id="FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail">
<link:definition>1221 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail" id="FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail">
<link:definition>1222 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail" id="FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail">
<link:definition>1223 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail">
<link:definition>1224 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail">
<link:definition>1225 - Disclosure - Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail">
<link:definition>1226 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail" id="FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail">
<link:definition>1227 - Disclosure - Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail" id="FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail">
<link:definition>1228 - Disclosure - Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail" id="FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail">
<link:definition>1229 - Disclosure - Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail" id="FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail">
<link:definition>1230 - Disclosure - Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail">
<link:definition>1231 - Disclosure - Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail" id="FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail">
<link:definition>1232 - Disclosure - Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail" id="EmployeeShareSchemesAdditionalInformationDetail">
<link:definition>1233 - Disclosure - Employee Share Schemes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail" id="EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail">
<link:definition>1234 - Disclosure - Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail" id="EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail">
<link:definition>1235 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail" id="EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail">
<link:definition>1236 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail" id="EmployeeShareSchemesSummaryOfOptionOutstandingDetail">
<link:definition>1237 - Disclosure - Employee Share Schemes - Summary of Option Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail" id="EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail">
<link:definition>1238 - Disclosure - Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail" id="PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail">
<link:definition>1239 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail" id="PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail">
<link:definition>1240 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail" id="LegalProceedingsAdditionalInformationDetail">
<link:definition>1241 - Disclosure - Legal Proceedings - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1" id="ConsolidatedStatementOfComprehensiveIncomeAlternate1">
<link:definition>1242 - Statement - Consolidated statement of comprehensive income Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gsk-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="TitleOfEachClassAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TitleOfEachClassAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TitleOfEachClassDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TitleOfEachClassDomain" substitutionGroup="xbrli:item" />
<element name="ThreePointSixTwoFiveNotesDue2025Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointSixTwoFiveNotesDue2025Member" substitutionGroup="xbrli:item" />
<element name="ThreePointEightSevenFiveNotesDue2028Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointEightSevenFiveNotesDue2028Member" substitutionGroup="xbrli:item" />
<element name="ThreePointThreeSevenFiveNotesDue2029Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointThreeSevenFiveNotesDue2029Member" substitutionGroup="xbrli:item" />
<element name="SixPointThreeSevenFiveNotesDue2038Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SixPointThreeSevenFiveNotesDue2038Member" substitutionGroup="xbrli:item" />
<element name="ThreePointZeroNotesDue2024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointZeroNotesDue2024Member" substitutionGroup="xbrli:item" />
<element name="ZeroPointFiveThreeFourNotesDue2023Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointFiveThreeFourNotesDue2023Member" substitutionGroup="xbrli:item" />
<element name="FourPointTwoZeroZeroNotesDue2043Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FourPointTwoZeroZeroNotesDue2043Member" substitutionGroup="xbrli:item" />
<element name="AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AmericanDepositarySharesMember" substitutionGroup="xbrli:item" />
<element name="RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossOnDisposalOfInterestInAssociate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnDisposalOfInterestInAssociate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMovementsOnCashFlowHedgesNotReclassified" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WritedownOfSharesHeldByEmployeeStockOwnershipPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NoncashDistributionsToNoncontrollingInterests" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NoncashDistributionsToNoncontrollingInterests" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashDividendToShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NonCashDividendToShareholders" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="HedgingGainLossTransferredToNonFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_HedgingGainLossTransferredToNonFinancialAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionsWithNoncontoliingInterests" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransactionsWithNoncontoliingInterests" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SharesAcquiredByEsopTrusts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SharesAcquiredByEsopTrusts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromRepaymentsOfOtherCurrentBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLiquidInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInLiquidInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PurchaseOfInvestmentInAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromDisposalOfAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashFromUsedInOperationsBeforeTaxesContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TextBlockAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfEmployeeCostsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeCostsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMajorRestructuringCostsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfMajorRestructuringCostsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAssociatesAndJointVenturesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrentEquityInvestmentsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTradesAndOtherReceivableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTradesAndOtherReceivableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContingentConsiderationLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareCapitalAndSharePremiumExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMovementsInEquityExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfMovementsInEquityExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" substitutionGroup="xbrli:item" />
<element name="ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPrincipalGroupCompaniesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLegalProceedingsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLegalProceedingsExplanatory" substitutionGroup="xbrli:item" />
<element name="StatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_StatementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="StatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_StatementsLineItems" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForDiscountingExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingStandardsApplied" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingStandardsApplied" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" substitutionGroup="xbrli:item" />
<element name="SignificantCurrenciesAndTheRelevantExchangeRates" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SignificantCurrenciesAndTheRelevantExchangeRates" substitutionGroup="xbrli:item" />
<element name="CommercialOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CommercialOperationsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTurnoverBySegmentExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTurnoverBySegmentExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" substitutionGroup="xbrli:item" />
<element name="OperatingProfitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OperatingProfitLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutProfitLossExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfNumberOfEmployeesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfNumberOfEmployeesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRestructuringCostsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfRestructuringCostsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfGroupHeldSignificantAssociateExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfIncomeTaxExpenseBenefitsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfInterimDividendExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInterimDividendExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDividendsPaidExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDividendsPaidExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutRightOfUseAssets" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfScheduleOfOtherInvestmentExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" substitutionGroup="xbrli:item" />
<element name="SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationOfInventoriesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAssetsHeldForSaleExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAssetsHeldForSaleExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" substitutionGroup="xbrli:item" />
<element name="SummaryOfTradePayablesExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SummaryOfTradePayablesExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLeaseObligationsExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" substitutionGroup="xbrli:item" />
<element name="PostretirementBenefitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PostretirementBenefitsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMovementsInFairValuesOfAssetsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContractualObligationsAndCommitmentsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" substitutionGroup="xbrli:item" />
<element name="ConsumerHealthCareJointVentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ConsumerHealthCareJointVentureMember" substitutionGroup="xbrli:item" />
<element name="ViiVHealthCareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViiVHealthCareMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" substitutionGroup="xbrli:item" />
<element name="DisclosureOfProfitOnDisposalOfBusinessesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" substitutionGroup="xbrli:item" />
<element name="FinancialInformationRelatingToDiscontinuedOperations" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="TwothousandtwentyoneacquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwothousandtwentyoneacquisitionMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandTwentyAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandTwentyTwoAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAnalysisOfChangesInNetDebtExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" substitutionGroup="xbrli:item" />
<element name="ForeignExchangeSensitivityEquityImpactTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ForeignExchangeSensitivityEquityImpactTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" substitutionGroup="xbrli:item" />
<element name="ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" substitutionGroup="xbrli:item" />
<element name="ForeignExchangeForwardContractsAndSwapsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ForeignExchangeForwardContractsAndSwapsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfEmployeeShareValuePlanExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeShareValuePlanExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" substitutionGroup="xbrli:item" />
<element name="PresentationOfTheFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PresentationOfTheFinancialStatementsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" substitutionGroup="xbrli:item" />
<element name="DateOfEndOfReportingPeriod2022" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DateOfEndOfReportingPeriod2022" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAccountingPrinciplesAndPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RemainingBookValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RemainingBookValueMember" substitutionGroup="xbrli:item" />
<element name="ERPSoftwareSystemsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ERPSoftwareSystemsMember" substitutionGroup="xbrli:item" />
<element name="OtherComputerSoftwareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherComputerSoftwareMember" substitutionGroup="xbrli:item" />
<element name="VaccinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VaccinesMember" substitutionGroup="xbrli:item" />
<element name="PharmaceuticalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PharmaceuticalsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAccountingPrinciplesAndPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="CostOfSalesOnCoPromotionalActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CostOfSalesOnCoPromotionalActivities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueFromCoPromotionalActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RevenueFromCoPromotionalActivities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortisableProportionOverExclusivityPeriod" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AmortisableProportionOverExclusivityPeriod" substitutionGroup="xbrli:item" />
<element name="PlantAndMachineryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PlantAndMachineryMember" substitutionGroup="xbrli:item" />
<element name="EquipmentAndVehiclesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EquipmentAndVehiclesMember" substitutionGroup="xbrli:item" />
<element name="FreeholdBuildingsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FreeholdBuildingsMember" substitutionGroup="xbrli:item" />
<element name="LeaseholdLandAndBuildingsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LeaseholdLandAndBuildingsMember" substitutionGroup="xbrli:item" />
<element name="ShionogiViiVHealthcareJointVentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShionogiViiVHealthcareJointVentureMember" substitutionGroup="xbrli:item" />
<element name="LegalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_LegalCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CustomerReturnsDiscountsAndRebates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CustomerReturnsDiscountsAndRebates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfIncreaseInDiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfIncreaseInDiscountRate" substitutionGroup="xbrli:item" />
<element name="DecreaseInPlanDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseInPlanDeficit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInPlanDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInPlanDeficit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UncertainTaxPositionsRecognised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_UncertainTaxPositionsRecognised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfDecreaseInDiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfDecreaseInDiscountRate" substitutionGroup="xbrli:item" />
<element name="GainLossOnContingentConsiderationAndPutOptionLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DefinedBenefitPlanSurplusNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DefinedBenefitPlanSurplusNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInAnnualPensionCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInAnnualPensionCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DecreaseInAnnualPensionCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseInAnnualPensionCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PensionSurplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PensionSurplus" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" substitutionGroup="xbrli:item" />
<element name="SegmentConsolidationItemAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SegmentConsolidationItemAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SegmentConsolidationItemMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SegmentConsolidationItemMember" substitutionGroup="xbrli:item" />
<element name="USPharmaceuticalsAndVaccinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_USPharmaceuticalsAndVaccinesMember" substitutionGroup="xbrli:item" />
<element name="SensitivityAnalysisForActuarialAssumptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SensitivityAnalysisForActuarialAssumptionsMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionPercentageRateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionPercentageRateAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ActuarialAssumptionPercentageRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionPercentageRateMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionPercentageRateChangeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionPercentageRateChangeMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfForeignExchangeRatesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfForeignExchangeRatesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfForeignExchangeRatesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfForeignExchangeRatesLineItems" substitutionGroup="xbrli:item" />
<element name="RevenueFromChangesToEstimatesOfRARAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RevenueFromChangesToEstimatesOfRARAccruals" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfWholesalers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfWholesalers" substitutionGroup="xbrli:item" />
<element name="PutOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PutOption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfReportableOperatingSegments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfReportableOperatingSegments" substitutionGroup="xbrli:item" />
<element name="MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfOperatingSegments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfOperatingSegments" substitutionGroup="xbrli:item" />
<element name="Wholesalers1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_Wholesalers1Member" substitutionGroup="xbrli:item" />
<element name="Wholesalers2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_Wholesalers2Member" substitutionGroup="xbrli:item" />
<element name="Wholesalers3Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_Wholesalers3Member" substitutionGroup="xbrli:item" />
<element name="ShionogiViivHealthcareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShionogiViivHealthcareMember" substitutionGroup="xbrli:item" />
<element name="PfizerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PfizerMember" substitutionGroup="xbrli:item" />
<element name="ConsumerHealthcareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ConsumerHealthcareMember" substitutionGroup="xbrli:item" />
<element name="InfluenzaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InfluenzaMember" substitutionGroup="xbrli:item" />
<element name="RespiratoryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RespiratoryMember" substitutionGroup="xbrli:item" />
<element name="EstablishedVaccinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EstablishedVaccinesMember" substitutionGroup="xbrli:item" />
<element name="HIVMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HIVMember" substitutionGroup="xbrli:item" />
<element name="ShinglesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShinglesMember" substitutionGroup="xbrli:item" />
<element name="MeningitisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MeningitisMember" substitutionGroup="xbrli:item" />
<element name="SubTotalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SubTotalMember" substitutionGroup="xbrli:item" />
<element name="OncologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OncologyMember" substitutionGroup="xbrli:item" />
<element name="ImmunoInflammationRespiratoryAndOtherMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ImmunoInflammationRespiratoryAndOtherMember" substitutionGroup="xbrli:item" />
<element name="SpecialtyMedicineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SpecialtyMedicineMember" substitutionGroup="xbrli:item" />
<element name="PandemicVaccinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PandemicVaccinesMember" substitutionGroup="xbrli:item" />
<element name="PandemicMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PandemicMember" substitutionGroup="xbrli:item" />
<element name="OtherGeneralMedicinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherGeneralMedicinesMember" substitutionGroup="xbrli:item" />
<element name="GeneralMedicinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GeneralMedicinesMember" substitutionGroup="xbrli:item" />
<element name="InvestmentsInJointVenturesAndAssociates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_InvestmentsInJointVenturesAndAssociates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetOperatingAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NetOperatingAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImpairmentReversalsBySegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ImpairmentReversalsBySegmentAbstract" substitutionGroup="xbrli:item" />
<element name="CurrentAndDeferredTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CurrentAndDeferredTaxation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchAndDevelopmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
<element name="CustomerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CustomerMember" substitutionGroup="xbrli:item" />
<element name="RestOfWorldMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RestOfWorldMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOtherOperatingIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOtherOperatingIncomeExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherOperatingIncomeExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfOtherOperatingIncomeExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="DisposalOfBusinessesAndAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalOfBusinessesAndAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossOnSaleOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_LossOnSaleOfBusiness" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_UpfrontPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfRoyaltyPayableOnFutureSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PercentageOfRoyaltyPayableOnFutureSales" substitutionGroup="xbrli:item" />
<element name="GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GileadSciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GileadSciencesIncMember" substitutionGroup="xbrli:item" />
<element name="VaccinesBusinessAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VaccinesBusinessAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="HorlicksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HorlicksMember" substitutionGroup="xbrli:item" />
<element name="NovartisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NovartisMember" substitutionGroup="xbrli:item" />
<element name="HindustanUnileverLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HindustanUnileverLimitedMember" substitutionGroup="xbrli:item" />
<element name="AcquirerAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AcquirerAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AcquirerDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AcquirerDomain" substitutionGroup="xbrli:item" />
<element name="InvestmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvestmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentDomain" substitutionGroup="xbrli:item" />
<element name="HaleonPlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HaleonPlcMember" substitutionGroup="xbrli:item" />
<element name="RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontSettlementIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_UpfrontSettlementIncome" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfOperatingProfitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOperatingProfitTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfOperatingProfitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOperatingProfitLineItems" substitutionGroup="xbrli:item" />
<element name="GainLossOnDisposalOfInterestInAssociates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnDisposalOfInterestInAssociates" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiquidationOrDisposalOfOverseasSubsidiaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" substitutionGroup="xbrli:item" />
<element name="OtherAuditorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherAuditorsMember" substitutionGroup="xbrli:item" />
<element name="LiquidationOrDisposalOfInterestInAssociatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidationOrDisposalOfInterestInAssociatesMember" substitutionGroup="xbrli:item" />
<element name="PurposeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PurposeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PurposeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PurposeDomain" substitutionGroup="xbrli:item" />
<element name="ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" substitutionGroup="xbrli:item" />
<element name="LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="ImpairmentOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ImpairmentOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImpairmentOfIntangibleAssetsNetOfReversal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ImpairmentOfIntangibleAssetsNetOfReversal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfAuditorsRemunerationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAuditorsRemunerationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfAuditorsRemunerationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAuditorsRemunerationLineItems" substitutionGroup="xbrli:item" />
<element name="AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AuditorsRemunerationForOtherAssuranceServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AuditorsRemunerationForOtherAssuranceServices" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PostEmploymentBenefitExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PostEmploymentBenefitExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EmployeesBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EmployeesBenefitAbstract" substitutionGroup="xbrli:item" />
<element name="ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashSettledAndOtherPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashSettledAndOtherPlansMember" substitutionGroup="xbrli:item" />
<element name="ShareOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="PerformanceSharePlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PerformanceSharePlansMember" substitutionGroup="xbrli:item" />
<element name="ShareValuePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareValuePlanMember" substitutionGroup="xbrli:item" />
<element name="ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfEmployeeCostsAndNumbersTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeCostsAndNumbersTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfEmployeeCostsAndNumbersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" substitutionGroup="xbrli:item" />
<element name="AverageNumberOfEmployeesFromContinuingOperations" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AverageNumberOfEmployeesFromContinuingOperations" substitutionGroup="xbrli:item" />
<element name="AverageNumberOfEmployeesFromDiscontinuingOperations" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" substitutionGroup="xbrli:item" />
<element name="ManufacturingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ManufacturingMember" substitutionGroup="xbrli:item" />
<element name="SellingGeneralAndAdministrationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SellingGeneralAndAdministrationMember" substitutionGroup="xbrli:item" />
<element name="KeyManagementPersonnelCompensationSocialSecurityCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MajorRestructuringCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MajorRestructuringCostsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRestructuringCostsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfRestructuringCostsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RestructuringCostsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringCostsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RestructuringCostsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringCostsDomain" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRestructuringCostsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfRestructuringCostsLineItems" substitutionGroup="xbrli:item" />
<element name="AssetImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AssetImpairments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalRestructuringCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TotalRestructuringCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherNonCashCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherNonCashCredit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseProvisionReversalRestructuring" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseProvisionReversalRestructuring" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ArrangementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ArrangementTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ArrangementTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ArrangementTypeDomain" substitutionGroup="xbrli:item" />
<element name="SeparationPreparationProgrammeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SeparationPreparationProgrammeMember" substitutionGroup="xbrli:item" />
<element name="CostChargedToOperatingProfit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CostChargedToOperatingProfit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherCostsCashSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherCostsCashSettlement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashRestructuringCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NonCashRestructuringCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashRestructuringCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashRestructuringCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringCosts1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringCosts1" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegacyProgrammesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LegacyProgrammesMember" substitutionGroup="xbrli:item" />
<element name="SignificantAcquisitionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SignificantAcquisitionsMember" substitutionGroup="xbrli:item" />
<element name="RestructuringChargesByTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringChargesByTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RestructuringChargesByTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RestructuringChargesByTypeDomain" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRestructuringCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfRestructuringCostsAbstract" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CostOfMajorRestructuringMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CostOfMajorRestructuringMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialIncomeAndExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialIncomeAndExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfFinancialIncomeAndExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinanceExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinanceExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="ReTranslationOfLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReTranslationOfLoan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" substitutionGroup="xbrli:item" />
<element name="AssociatesAndJointVentureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssociatesAndJointVentureAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfJointVenturesAndAssociatesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfJointVenturesAndAssociatesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfJointVenturesAndAssociatesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfJointVenturesAndAssociatesLineItems" substitutionGroup="xbrli:item" />
<element name="SalesToAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SalesToAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InnovivaIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InnovivaIncMember" substitutionGroup="xbrli:item" />
<element name="OtherAssociatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherAssociatesMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpenseBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IncomeTaxExpenseBenefitsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxExpenseBenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IncomeTaxExpenseBenefitsLineItems" substitutionGroup="xbrli:item" />
<element name="CurrentTaxExpensesincomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxExpensesincomeAbstract" substitutionGroup="xbrli:item" />
<element name="ProvisionsForUncertainTaxPosition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProvisionsForUncertainTaxPosition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsRecognizedOnTradingLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxAssetsRecognizedOnTradingLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnremittedProfitsForWhichDeferredTaxNotProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnremittedEarnings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_UnremittedEarnings" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="HeadlineUkTaxRateEffective2023" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_HeadlineUkTaxRateEffective2023" substitutionGroup="xbrli:item" />
<element name="LegalEntity1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LegalEntity1Axis" substitutionGroup="xbrldt:dimensionItem" />
<element name="Entity1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_Entity1Member" substitutionGroup="xbrli:item" />
<element name="GbMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GbMember" substitutionGroup="xbrli:item" />
<element name="OverseasMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OverseasMember" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EventDomain" substitutionGroup="xbrli:item" />
<element name="IncreaseInTheHeadlineRateOfTaxMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInTheHeadlineRateOfTaxMember" substitutionGroup="xbrli:item" />
<element name="ReducedTaxRateCancelledMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ReducedTaxRateCancelledMember" substitutionGroup="xbrli:item" />
<element name="DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" substitutionGroup="xbrli:item" />
<element name="TaxEffectOfBenefitOfIntellectualPropertyIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxEffectOfResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxEffectOfResearchAndDevelopmentCredits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxRateEffectOfChangeInTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfChangeInTaxRate" substitutionGroup="xbrli:item" />
<element name="TaxRateEffectOfResearchAndDevelopmentCredits" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfResearchAndDevelopmentCredits" substitutionGroup="xbrli:item" />
<element name="TaxRateEffectOfReassessmentsOfPriorYearEstimates" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" substitutionGroup="xbrli:item" />
<element name="TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" substitutionGroup="xbrli:item" />
<element name="TaxEffectOfChangeInTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxEffectOfChangeInTaxRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfReassessmentsOfPriorYearEstimates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" substitutionGroup="xbrli:item" />
<element name="TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" substitutionGroup="xbrli:item" />
<element name="TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" substitutionGroup="xbrli:item" />
<element name="DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" substitutionGroup="xbrli:item" />
<element name="DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentTaxationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxationAbstract" substitutionGroup="xbrli:item" />
<element name="CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MovementInDeferredTaxAssetsAndLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PensionsAndOtherPostemploymentBenefitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PensionsAndOtherPostemploymentBenefitsMember" substitutionGroup="xbrli:item" />
<element name="ShareOptionAndAwardSchemesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareOptionAndAwardSchemesMember" substitutionGroup="xbrli:item" />
<element name="AcceleratedCapitalAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AcceleratedCapitalAllowancesMember" substitutionGroup="xbrli:item" />
<element name="IntraGroupProfitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IntraGroupProfitMember" substitutionGroup="xbrli:item" />
<element name="MovementInDeferredTaxAssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxReformsPeriodOfApplicationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TaxReformsPeriodOfApplicationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TaxReformsPeriodOfApplicationDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TaxReformsPeriodOfApplicationDomain" substitutionGroup="xbrli:item" />
<element name="OriginationAndReversalOfTemporaryDifferencesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OriginationAndReversalOfTemporaryDifferencesMember" substitutionGroup="xbrli:item" />
<element name="LaterThanOneYearAndNotLaterThanTenYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LaterThanOneYearAndNotLaterThanTenYearMember" substitutionGroup="xbrli:item" />
<element name="AvailableIndefinitelyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AvailableIndefinitelyMember" substitutionGroup="xbrli:item" />
<element name="TaxLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TaxLosses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnrecognisedDeferredTaxAssetOnCapitalLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrecognisedDeferredTaxAssetOnTradingLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CapitalLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CapitalLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfDividendsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDividendsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDividendsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDividendsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDividendsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDividendsLineItems" substitutionGroup="xbrli:item" />
<element name="DividendsPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendsPaidDate" substitutionGroup="xbrli:item" />
<element name="SecondInterimMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SecondInterimMember" substitutionGroup="xbrli:item" />
<element name="ThirdInterimMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThirdInterimMember" substitutionGroup="xbrli:item" />
<element name="FirstInterimMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FirstInterimMember" substitutionGroup="xbrli:item" />
<element name="FourthInterimMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FourthInterimMember" substitutionGroup="xbrli:item" />
<element name="AdditionalProvisionForDividendPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionalProvisionForDividendPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfAssetdistributedAsDividendInSpecie" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_FairValueOfAssetdistributedAsDividendInSpecie" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DescriptionOfInterimDividendRecognitonAndPayment" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfInterimDividendRecognitonAndPayment" substitutionGroup="xbrli:item" />
<element name="ContinuingAndDiscontinuedOperationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ContinuingAndDiscontinuedOperationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ContinuingAndDiscontinuedOperationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ContinuingAndDiscontinuedOperationMember" substitutionGroup="xbrli:item" />
<element name="DemergerOfConsumerHealthcareBusinessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DemergerOfConsumerHealthcareBusinessMember" substitutionGroup="xbrli:item" />
<element name="CashDividendsPaidToShareholdersRecognizedInYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashDividendsPaidToShareholdersRecognizedInYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DividendsRecognisedInYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendsRecognisedInYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SellingGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SellingGeneralAndAdministrativeExpensesMember" substitutionGroup="xbrli:item" />
<element name="MajorRestructuringProgrammesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MajorRestructuringProgrammesMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" substitutionGroup="xbrli:item" />
<element name="WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentAndVehiclesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PropertyPlantAndEquipmentAndVehiclesMember" substitutionGroup="xbrli:item" />
<element name="RightOfUseAssetImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RightOfUseAssetImpairments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RightOfUseAssetsExchangeAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RightOfUseAssetsExchangeAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetDisposal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RightOfUseAssetDisposal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsToRightOfUseAssetsThroughBusinessCombinations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherAdditionsToRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherAdditionsToRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PlantAndEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PlantAndEquipmentMember" substitutionGroup="xbrli:item" />
<element name="IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IntangibleAssetsForWhichImpairmentsHaveBeenCharged" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IntangibleAssetsForWhichImpairmentsHaveBeenReversed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BenlystaAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BenlystaAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BenlystaDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BenlystaDomain" substitutionGroup="xbrli:item" />
<element name="CapitalisedDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CapitalisedDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortisationOtherIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AmortisationOtherIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetImpairmentLossesOtherIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetImpairmentLossesOtherIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicencesAndFranchisesAmortisedBrandsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LicencesAndFranchisesAmortisedBrandsMember" substitutionGroup="xbrli:item" />
<element name="BrandsWithIndefiniteUsefulLifeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BrandsWithIndefiniteUsefulLifeMember" substitutionGroup="xbrli:item" />
<element name="OthersProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OthersProductsMember" substitutionGroup="xbrli:item" />
<element name="OkairosMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OkairosMember" substitutionGroup="xbrli:item" />
<element name="TesaroAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TesaroAssetsMember" substitutionGroup="xbrli:item" />
<element name="LamisilMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LamisilMember" substitutionGroup="xbrli:item" />
<element name="DolutegravirMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DolutegravirMember" substitutionGroup="xbrli:item" />
<element name="BMSAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BMSAssetsMember" substitutionGroup="xbrli:item" />
<element name="StiefelTradeNameMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_StiefelTradeNameMember" substitutionGroup="xbrli:item" />
<element name="BenlystaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BenlystaMember" substitutionGroup="xbrli:item" />
<element name="MeningitisPortfolioMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MeningitisPortfolioMember" substitutionGroup="xbrli:item" />
<element name="FluarixFlulavalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FluarixFlulavalMember" substitutionGroup="xbrli:item" />
<element name="CurevacAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurevacAssetsMember" substitutionGroup="xbrli:item" />
<element name="VirAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VirAssetsMember" substitutionGroup="xbrli:item" />
<element name="AffinivaxAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AffinivaxAssetsMember" substitutionGroup="xbrli:item" />
<element name="MomelotinibMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MomelotinibMember" substitutionGroup="xbrli:item" />
<element name="ShingrixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShingrixMember" substitutionGroup="xbrli:item" />
<element name="SperoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SperoMember" substitutionGroup="xbrli:item" />
<element name="IteosMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IteosMember" substitutionGroup="xbrli:item" />
<element name="AlectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AlectorMember" substitutionGroup="xbrli:item" />
<element name="InvestmentsInAssociatesAndJointVenturesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentsInAssociatesAndJointVenturesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" substitutionGroup="xbrli:item" />
<element name="DisposalOfInterestInAssociate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalOfInterestInAssociate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RecyclingOfExchangeDifferencesInAssociate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RecyclingOfExchangeDifferencesInAssociate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalsInAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsInAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsInInvestmentsInAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CurrentEquityInvestmentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentEquityInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="CurrentEquityInvestmentsMeasuredAsFVTPLMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="NetFairValueMovementsThroughProfitOrLossCurrentInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfOwnership" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfOwnership" substitutionGroup="xbrli:item" />
<element name="OtherAdjustmentsOfFairValueMeasurementAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherAdjustmentsOfFairValueMeasurementAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueGainThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_FairValueGainThroughProfitOrLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InvestmentInHaleonPlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentInHaleonPlcMember" substitutionGroup="xbrli:item" />
<element name="GlaxoGroupLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoGroupLimitedMember" substitutionGroup="xbrli:item" />
<element name="ScottishLimitedPartnershipsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ScottishLimitedPartnershipsMember" substitutionGroup="xbrli:item" />
<element name="EsopTrustsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EsopTrustsMember" substitutionGroup="xbrli:item" />
<element name="OtherInvestments1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherInvestments1Abstract" substitutionGroup="xbrli:item" />
<element name="OtherInvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherInvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" substitutionGroup="xbrli:item" />
<element name="EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" substitutionGroup="xbrli:item" />
<element name="OtherInvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherInvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="ListedInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ListedInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InvestmentFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_InvestmentFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForForeignExchangeOtherInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForForeignExchangeOtherInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="VirBiotechnologyIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VirBiotechnologyIncMember" substitutionGroup="xbrli:item" />
<element name="NimbusTherapeuticsLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NimbusTherapeuticsLLCMember" substitutionGroup="xbrli:item" />
<element name="CureVacNVMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CureVacNVMember" substitutionGroup="xbrli:item" />
<element name="InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" substitutionGroup="xbrli:item" />
<element name="DisposalsAndSettlementsOtherInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsAndSettlementsOtherInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetFairValueMovementsThroughProfitOrLossOtherInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionsToOtherInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionsToOtherInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherInvestmentsNoncurrentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherInvestmentsNoncurrentMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOtherNoncurrentAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherNoncurrentAssetsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfOtherNonCurrentAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOtherNonCurrentAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="OtherNonCurrentReceivablesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherNonCurrentReceivablesMember" substitutionGroup="xbrli:item" />
<element name="RemainingBalanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RemainingBalanceMember" substitutionGroup="xbrli:item" />
<element name="ReceivablesRelatedToInsuranceContracts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ReceivablesRelatedToInsuranceContracts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfTradeAndOtherReceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTradeAndOtherReceivablesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfTradeAndOtherReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTradeAndOtherReceivablesLineItems" substitutionGroup="xbrli:item" />
<element name="ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssociatesAndJointVenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssociatesAndJointVenturesMember" substitutionGroup="xbrli:item" />
<element name="OtherReceivableMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherReceivableMember" substitutionGroup="xbrli:item" />
<element name="EmployeeLoansAndAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_EmployeeLoansAndAdvances" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExpectedCreditLossAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ExpectedCreditLossAllowance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInExpectedCreditLossesAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExpectedCreditLossAllowanceUtilised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExpectedCreditLossAllowanceUtilised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExpectedCreditLossAllowanceExchangeAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExpectedCreditLossAllowanceExchangeAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashAndCashEquivalentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashAndCashEquivalentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashAndCashEquivalentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashAndCashEquivalentsLineItems" substitutionGroup="xbrli:item" />
<element name="ConsumerHealthcareBusinessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ConsumerHealthcareBusinessMember" substitutionGroup="xbrli:item" />
<element name="AccruedFixedAssetRelatedCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AccruedFixedAssetRelatedCostsAbstract" substitutionGroup="xbrli:item" />
<element name="GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfAssetsHeldForSaleAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfAssetsHeldForSaleAbstract" substitutionGroup="xbrli:item" />
<element name="AssetsHeldForSaleTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssetsHeldForSaleTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AssetsHeldForSaleLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssetsHeldForSaleLineItems" substitutionGroup="xbrli:item" />
<element name="OtherAssetsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_OtherAssetsNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfTradeAndOtherPayablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTradeAndOtherPayablesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfTradeAndOtherPayablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfTradeAndOtherPayablesLineItems" substitutionGroup="xbrli:item" />
<element name="CustomerReturnAndRebateAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CustomerReturnAndRebateAccruals" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="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" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WagesAndSalariesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WagesAndSalariesPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PutOptionPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PutOptionPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_OtherAccruals" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInFinancialLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInFinancialLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrencyRiskTenCentDepreciationOfEuroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenCentDepreciationOfEuroMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenCentDepreciationOfUSDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenCentAppreciationOfUSDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenCentAppreciationOfEuroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenCentAppreciationOfEuroMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenCentDepreciationOfEuroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenCentDepreciationOfUsDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenCentAppreciationOfEuroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenCentAppreciationOfUsDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfNetDebtAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfNetDebtAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDebtTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDebtTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommercialPaper1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CommercialPaper1Member" substitutionGroup="xbrli:item" />
<element name="LetterOfCredit1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LetterOfCredit1Member" substitutionGroup="xbrli:item" />
<element name="TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="NonInterestBearingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NonInterestBearingMember" substitutionGroup="xbrli:item" />
<element name="ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" substitutionGroup="xbrli:item" />
<element name="FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" substitutionGroup="xbrli:item" />
<element name="FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" substitutionGroup="xbrli:item" />
<element name="ShortTermNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShortTermNotesMember" substitutionGroup="xbrli:item" />
<element name="UsCommercialPaperProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UsCommercialPaperProgramMember" substitutionGroup="xbrli:item" />
<element name="EuroCommercialPaperProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EuroCommercialPaperProgramMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDebtLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDebtLineItems" substitutionGroup="xbrli:item" />
<element name="EffectiveInterestRateOnAvailableForSaleFinancialInvestments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" substitutionGroup="xbrli:item" />
<element name="EffectiveInterestRateOnCashAndCashEquivalents" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_EffectiveInterestRateOnCashAndCashEquivalents" substitutionGroup="xbrli:item" />
<element name="AverageEffectivePreSwapInterestRateNotesIssued" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AverageEffectivePreSwapInterestRateNotesIssued" substitutionGroup="xbrli:item" />
<element name="LiquidInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiquidInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AverageEffectivePreSwapInterestRateShortTerm" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AverageEffectivePreSwapInterestRateShortTerm" substitutionGroup="xbrli:item" />
<element name="CarryInterestAtEffectiveRates" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CarryInterestAtEffectiveRates" substitutionGroup="xbrli:item" />
<element name="CommercialPaperAuthorized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CommercialPaperAuthorized" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" substitutionGroup="xbrli:item" />
<element name="RepaymentYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RepaymentYear" substitutionGroup="xbrli:item" />
<element name="WeightedAverageInterestRateOnBorrowings" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_WeightedAverageInterestRateOnBorrowings" substitutionGroup="xbrli:item" />
<element name="PledgedInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PledgedInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PostSeparationOfTheConsumerHealthcareBusinessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" substitutionGroup="xbrli:item" />
<element name="FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" substitutionGroup="xbrli:item" />
<element name="SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" substitutionGroup="xbrli:item" />
<element name="OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" substitutionGroup="xbrli:item" />
<element name="OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" substitutionGroup="xbrli:item" />
<element name="FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" substitutionGroup="xbrli:item" />
<element name="OtherLongtermBorrowingsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherLongtermBorrowingsMember" substitutionGroup="xbrli:item" />
<element name="FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" substitutionGroup="xbrli:item" />
<element name="OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" substitutionGroup="xbrli:item" />
<element name="SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" substitutionGroup="xbrli:item" />
<element name="ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" substitutionGroup="xbrli:item" />
<element name="TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" substitutionGroup="xbrli:item" />
<element name="Debt1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_Debt1Member" substitutionGroup="xbrli:item" />
<element name="LondonStockExchangeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LondonStockExchangeMember" substitutionGroup="xbrli:item" />
<element name="NewYorkStockExchangeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NewYorkStockExchangeMember" substitutionGroup="xbrli:item" />
<element name="BankLoansoverdraftsAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BankLoansoverdraftsAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiquidInvestmentsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiquidInvestmentsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LongtermBorrowingsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LongtermBorrowingsAbstract" substitutionGroup="xbrli:item" />
<element name="FinanceLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FinanceLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FinanceLeaseObligationsGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FinanceLeaseObligationsGross" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfPensionAndOtherPostEmploymentPlanTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedContributionPlans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedContributionPlans" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PostemploymentBenefitExpensePlans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PostemploymentBenefitExpensePlans" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DefinedBenefitSchemesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedBenefitSchemesMember" substitutionGroup="xbrli:item" />
<element name="OtherOverseasPensionPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherOverseasPensionPlansMember" substitutionGroup="xbrli:item" />
<element name="DefinedContributionPensionSchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedContributionPensionSchemeMember" substitutionGroup="xbrli:item" />
<element name="UsDefinedBenefitAndDefinedContributionPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UsDefinedBenefitAndDefinedContributionPlansMember" substitutionGroup="xbrli:item" />
<element name="UnfundedPostRetirementPensionPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UnfundedPostRetirementPensionPlansMember" substitutionGroup="xbrli:item" />
<element name="FundedDefinedBenefitPensionPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FundedDefinedBenefitPensionPlansMember" substitutionGroup="xbrli:item" />
<element name="UkDefinedBenefitAndDefinedContributionPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UkDefinedBenefitAndDefinedContributionPlansMember" substitutionGroup="xbrli:item" />
<element name="UnfundedDefinedBenefitPensionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UnfundedDefinedBenefitPensionPlanMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UsCashBalancePensionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UsCashBalancePensionPlanMember" substitutionGroup="xbrli:item" />
<element name="UkDefinedBenefitPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UkDefinedBenefitPlansMember" substitutionGroup="xbrli:item" />
<element name="RetireeHealthcarePlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RetireeHealthcarePlansMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" substitutionGroup="xbrli:item" />
<element name="AugmentationCostsIncludedInPastServiceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AugmentationCostsIncludedInPastServiceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AugmentationCostsFromRestructuringProgrammes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AugmentationCostsFromRestructuringProgrammes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ActuarialAssumptionOfExpectedRatesOfMedicalInflation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" substitutionGroup="xbrli:item" />
<element name="AllocationToLiabilityMatchingAssets" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AllocationToLiabilityMatchingAssets" substitutionGroup="xbrli:item" />
<element name="LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AllocationToReturnSeekingAssets" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AllocationToReturnSeekingAssets" substitutionGroup="xbrli:item" />
<element name="TotalValueOfTheInsuranceContract" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_TotalValueOfTheInsuranceContract" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DefinedBenefitObligationAtPastServiceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DefinedBenefitObligationAtPastServiceCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfOwnershipInterestRepresentedByTransfer" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfOwnershipInterestRepresentedByTransfer" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwneshipInterestHeldByTheTransferee" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PercentageOfOwneshipInterestHeldByTheTransferee" substitutionGroup="xbrli:item" />
<element name="RemainingAmountDueToBeContributed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_RemainingAmountDueToBeContributed" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="VoluntaryCashContributionsMadeToThePlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_VoluntaryCashContributionsMadeToThePlan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalContributionDueToBePaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AdditionalContributionDueToBePaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SubsidiariesSharesTransferredToFundPensionSchemes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SubsidiariesSharesTransferredToFundPensionSchemes" substitutionGroup="xbrli:item" />
<element name="MaximumProceedsThresholdAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MaximumProceedsThresholdAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SubsidiarySharesTransferredIntoLimitedPartnerships" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirtyOneAndThereafterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandThirtyOneAndThereafterMember" substitutionGroup="xbrli:item" />
<element name="AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AgreementTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementTypeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AgreementTypeMember" substitutionGroup="xbrli:item" />
<element name="SlpPartnershipAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SlpPartnershipAgreementMember" substitutionGroup="xbrli:item" />
<element name="GSKLPLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GSKLPLtdMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" substitutionGroup="xbrli:item" />
<element name="SchemeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SchemeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SchemeMember" substitutionGroup="xbrli:item" />
<element name="TransfereeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TransfereeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TransfereeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TransfereeMember" substitutionGroup="xbrli:item" />
<element name="SLPPartneshipsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SLPPartneshipsMember" substitutionGroup="xbrli:item" />
<element name="ClassOfCommonStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ClassOfCommonStockAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ClassOfCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ClassOfCommonStockMember" substitutionGroup="xbrli:item" />
<element name="HaleonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HaleonMember" substitutionGroup="xbrli:item" />
<element name="CurrentPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentPeriodMember" substitutionGroup="xbrli:item" />
<element name="ProjectedPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ProjectedPeriodMember" substitutionGroup="xbrli:item" />
<element name="FemalePensionersAverageLifeExpectancyAtSixty" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_FemalePensionersAverageLifeExpectancyAtSixty" substitutionGroup="xbrli:item" />
<element name="MalePensionersAverageLifeExpectancyAtSixty" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MalePensionersAverageLifeExpectancyAtSixty" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfCashBalanceCreditRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfCashBalanceCreditRate" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDefinedBenefitPensionAndPostRetirementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" substitutionGroup="xbrli:item" />
<element name="ExpensesNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ExpensesNetDefinedBenefitLiabilityAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" substitutionGroup="xbrli:item" />
<element name="OtherNoncurrentAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherNoncurrentAssetsMember" substitutionGroup="xbrli:item" />
<element name="GroupMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GroupMember" substitutionGroup="xbrli:item" />
<element name="CorporateBondsContributedToFairValueOfPlanAssetsListed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MultiAssetFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_MultiAssetFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InsuranceContractsAmountContributedToFairValueOfPlanAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PropertyAmountContributedToFairValueOfPlanAssetsListed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GovernmentBondsContributedToFairValueOfPlanAssetsListed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DefinedBenefitPensionAssetCeilingRestrictions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DefinedBenefitPensionAssetCeilingRestrictions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DefinedBenefitObligationDeferredMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedBenefitObligationDeferredMember" substitutionGroup="xbrli:item" />
<element name="DefinedBenefitObligationRetiredMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedBenefitObligationRetiredMember" substitutionGroup="xbrli:item" />
<element name="DefinedBenefitObligationActiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DefinedBenefitObligationActiveMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PostRetirementBenefitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PostRetirementBenefitMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" substitutionGroup="xbrli:item" />
<element name="WeightedAverageDurationOfDefinedBenefitObligations" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_WeightedAverageDurationOfDefinedBenefitObligations" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreasePensionObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreasePensionObligations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInPostretirementBenefitsObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInPostretirementBenefitsObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInAnnualPostretirementBenefitsCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ActuarialAssumptionOfLifeExpectancyRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionForFutureHealthcareInflationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionForFutureHealthcareInflationMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" substitutionGroup="xbrli:item" />
<element name="ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" substitutionGroup="xbrli:item" />
<element name="TitleOfIndividual1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TitleOfIndividual1Axis" substitutionGroup="xbrldt:dimensionItem" />
<element name="GovernmentGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GovernmentGrantsDomain" substitutionGroup="xbrli:item" />
<element name="DisabledEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisabledEmployeesMember" substitutionGroup="xbrli:item" />
<element name="LegalAndOtherDisputesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LegalAndOtherDisputesMember" substitutionGroup="xbrli:item" />
<element name="MajorRestructuringProvisionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MajorRestructuringProvisionsMember" substitutionGroup="xbrli:item" />
<element name="LegalProceedingsAndOtherDisputesProvisionEstimated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PensionObligationProvisions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PensionObligationProvisions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EmployeeRelatedProvisionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EmployeeRelatedProvisionsMember" substitutionGroup="xbrli:item" />
<element name="OtherProvisionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherProvisionMember" substitutionGroup="xbrli:item" />
<element name="TransferToPensionObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransferToPensionObligations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransferToAssetsHeldForSaleDistribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransferToAssetsHeldForSaleDistribution" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfFairValueOfContingentConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" substitutionGroup="xbrli:item" />
<element name="RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContingentConsiderationPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ContingentConsiderationPaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherBusinessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherBusinessMember" substitutionGroup="xbrli:item" />
<element name="AffinivaxMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AffinivaxMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="NovartisVaccinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NovartisVaccinesMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskTenPercentageIncreaseInSalesForecastsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskOnePercentageDecreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskTenPercentageDecreaseInSalesForecastsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" />
<element name="OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskOnePercentageIncreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" substitutionGroup="xbrli:item" />
<element name="AppreciationOfEuro" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AppreciationOfEuro" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AppreciationOfUSDollar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AppreciationOfUSDollar" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInProbabilityOfMilestoneSuccess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInProbabilityOfMilestoneSuccess" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DecreaseInProbabilityOfMilestoneSuccess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseInProbabilityOfMilestoneSuccess" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInSalesForecastAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInSalesForecastAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInDiscountRateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseInDiscountRateAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DecreaseInSalesForecastAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseInSalesForecastAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DecreaseInDiscountRateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseInDiscountRateAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DepreciationOfEuro" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DepreciationOfEuro" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DepreciationOfUSDollar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DepreciationOfUSDollar" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfFairValueOfContingentConsiderationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueOfContingentConsiderationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfFairValueOfContingentConsiderationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationPayableDiscountedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContingentConsiderationPayableDiscountedPercentage" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContingentConsiderationLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommercialisedProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CommercialisedProductsMember" substitutionGroup="xbrli:item" />
<element name="PipelineAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PipelineAssetsMember" substitutionGroup="xbrli:item" />
<element name="OtherNoncurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherNoncurrentLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfCommitmentsAbstract" substitutionGroup="xbrli:item" />
<element name="AdditionalContributionUnpaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AdditionalContributionUnpaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalContributionWereToBeMadeTowards2020PensionDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfContractualObligationsAndCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" substitutionGroup="xbrli:item" />
<element name="ContractualObligationsAndCommitmentsOfPensions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitmentsOfPensions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsAndCommitmentsOfInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitmentsOfInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsAndCommitmentsOfFutureFinanceCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsAndCommitmentsOfPurchaseCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsAndCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsAndCommitmentsOfInterestOnLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractualObligationsLeaseContractsThatHaveNotYetCommenced" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfClassesShareCapitalAndSharePremiumTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" substitutionGroup="xbrli:item" />
<element name="NumberOfTreasurySharesTransferredToEmployeeShareTrusts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" substitutionGroup="xbrli:item" />
<element name="ImpactOfShareConsolidationShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ImpactOfShareConsolidationShares" substitutionGroup="xbrli:item" />
<element name="FreeIssueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FreeIssueMember" substitutionGroup="xbrli:item" />
<element name="EmployeeShareOwnershipPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EmployeeShareOwnershipPlanMember" substitutionGroup="xbrli:item" />
<element name="ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" substitutionGroup="xbrli:item" />
<element name="DateOfShareConsolidationApproval" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DateOfShareConsolidationApproval" substitutionGroup="xbrli:item" />
<element name="ConsumerHealthcareBusinessDemerger" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ConsumerHealthcareBusinessDemerger" substitutionGroup="xbrli:item" />
<element name="SharesReceivedForEveryFiveExistingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_SharesReceivedForEveryFiveExistingShares" substitutionGroup="xbrli:item" />
<element name="SurrenderedSharesForEveryFourNewSharesReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_SurrenderedSharesForEveryFourNewSharesReceived" substitutionGroup="xbrli:item" />
<element name="ParValueOfSharesSurrenderedInLieuOfNewShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" substitutionGroup="xbrli:item" />
<element name="DetailsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DetailsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DetailsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DetailsMember" substitutionGroup="xbrli:item" />
<element name="MiscellaneousComponentsOfEquityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MiscellaneousComponentsOfEquityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MiscellaneousComponentsOfEquityDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MiscellaneousComponentsOfEquityDomain" substitutionGroup="xbrli:item" />
<element name="NonDistributableMergerAndPreMergerReservesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NonDistributableMergerAndPreMergerReservesMember" substitutionGroup="xbrli:item" />
<element name="RetainedEarningsAndOtherReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_RetainedEarningsAndOtherReserves" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueReserveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FairValueReserveMember" substitutionGroup="xbrli:item" />
<element name="MovementInTranslationExchangeAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MovementInTranslationExchangeAttributableToContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_MovementInTranslationExchangeAttributableToContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DemergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DemergerMember" substitutionGroup="xbrli:item" />
<element name="ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EsopTrustMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EsopTrustMember" substitutionGroup="xbrli:item" />
<element name="NetFairValueMovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NetFairValueMovements" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExchangeAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WritedownOfSharesHeldByEsopTrusts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_WritedownOfSharesHeldByEsopTrusts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransferredToRetainedEarningsOnDisposalOfEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransferredToIncomeExpensesImpairmentsOfEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BalanceAmountDerecognisedOnDemerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_BalanceAmountDerecognisedOnDemerger" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfNonControllingInterestsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfNonControllingInterestsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfNoncontrollingInterestsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfNoncontrollingInterestsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfNoncontrollingInterestsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfNoncontrollingInterestsLineItems" substitutionGroup="xbrli:item" />
<element name="RemeasurementsOfContingentConsiderationPayableForAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInCashAndBankOverdrafts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInCashAndBankOverdrafts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LongwoodFoundersFundLPMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LongwoodFoundersFundLPMember" substitutionGroup="xbrli:item" />
<element name="MedicxiVenturesILimitedPartnerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MedicxiVenturesILimitedPartnerMember" substitutionGroup="xbrli:item" />
<element name="ApolloTherapeuticsLLPMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ApolloTherapeuticsLLPMember" substitutionGroup="xbrli:item" />
<element name="QuraTherapeuticsLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_QuraTherapeuticsLLCMember" substitutionGroup="xbrli:item" />
<element name="AgreementExtensionPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AgreementExtensionPeriod" substitutionGroup="xbrli:item" />
<element name="LoansReceivableMadeByEntityRelatedPartyTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InvestmentObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_InvestmentObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashInvestmentsInJointVenturesAndAssociates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashInvestmentsInJointVenturesAndAssociates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossOnEmbeddedDerivativeTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnEmbeddedDerivativeTransaction" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsMadeForTransactionCostsAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PaymentsMadeForTransactionCostsAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationPotentialMilestonePaymentPerTranche" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InvestmentOwnedNumberOfSharesDisposedOff" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_InvestmentOwnedNumberOfSharesDisposedOff" substitutionGroup="xbrli:item" />
<element name="DividendsDistributedFromCashBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendsDistributedFromCashBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrossProceedsFromDisposalOfInterestInAssociates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GrossProceedsFromDisposalOfInterestInAssociates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageofGSKHolding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageofGSKHolding" substitutionGroup="xbrli:item" />
<element name="DividendFundedByDebtFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendFundedByDebtFinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfTheAssetsDistributed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfTheAssetsDistributed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfHolding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfHolding" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalOfInterestInAssociatesConsiderationReceivablePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" substitutionGroup="xbrli:item" />
<element name="CarryingValueOfInvestmentNetOfNonControllingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="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" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashTransferredOnDisposal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashTransferredOnDisposal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" substitutionGroup="xbrli:item" />
<element name="LiabilityEliminatedOnDemerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilityEliminatedOnDemerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOnDemergerOfDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainOnDemergerOfDiscontinuedOperation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DividendFundedByDebtFinancingAttributableToGsk" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendFundedByDebtFinancingAttributableToGsk" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DividendsDistributedFromCashBalanceAttributableToGsk" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfOwnershipDistributed" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfOwnershipDistributed" substitutionGroup="xbrli:item" />
<element name="AdditionalGainOnRemeasurementOfRetainedStake" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionalGainOnRemeasurementOfRetainedStake" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationConsiderationPayableForStepAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BusinessCombinationConsiderationPayableForStepAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfOwnershipDivested" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfOwnershipDivested" substitutionGroup="xbrli:item" />
<element name="GskHoldingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskHoldingMember" substitutionGroup="xbrli:item" />
<element name="GskShareholdersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskShareholdersMember" substitutionGroup="xbrli:item" />
<element name="GskAndGsksConsolidatedEsotTrustsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskAndGsksConsolidatedEsotTrustsMember" substitutionGroup="xbrli:item" />
<element name="GskAggregateHoldingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskAggregateHoldingMember" substitutionGroup="xbrli:item" />
<element name="BangladeshConsumerHealthcareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BangladeshConsumerHealthcareMember" substitutionGroup="xbrli:item" />
<element name="GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" substitutionGroup="xbrli:item" />
<element name="AffinivaxIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AffinivaxIncMember" substitutionGroup="xbrli:item" />
<element name="SierraOncologyIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SierraOncologyIncMember" substitutionGroup="xbrli:item" />
<element name="PfizerBiotechCorporationTaiwanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PfizerBiotechCorporationTaiwanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyTwoBusinessAcquisitionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSaudiArabiaLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSaudiArabiaLimitedMember" substitutionGroup="xbrli:item" />
<element name="ConsumerHealthCareBangladeshMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ConsumerHealthCareBangladeshMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyBusinessDisposalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandTwentyBusinessDisposalsMember" substitutionGroup="xbrli:item" />
<element name="AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyOneBusinessDisposalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" substitutionGroup="xbrli:item" />
<element name="NetAssetsAcquiredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NetAssetsAcquiredAbstract" substitutionGroup="xbrli:item" />
<element name="NonControllingInterestRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeaseLiabilitiesRecognizedAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxationRecognizedAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_TaxationRecognizedAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NoncashConsiderationForSettlementOfAPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NoncashConsiderationForSettlementOfAPromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SierraOncologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SierraOncologyMember" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TotalfairValueOfDistributedandRetainBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_TotalfairValueOfDistributedandRetainBusiness" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfTheRetainedOwnershipInHaleonPlc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfTheConsumerHealthcareBusinessDistributed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CarryingAmountOfTheNciDerecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CarryingAmountOfTheNciDerecognized" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherGainsLossesOnDemerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherGainsLossesOnDemerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupLiabilityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalGroupLiabilityNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalOfEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalOfEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalsOtherNetAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsOtherNetAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalsInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsInventory" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalsGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsGoodwill" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DealCostsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DealCostsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalsIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupAssetsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DisposalGroupAssetsNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalsOtherNetLiabilitiesOrAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsOtherNetLiabilitiesOrAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnDisposalsOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainLossOnDisposalsOfBusiness" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionCostsOnDisposal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransactionCostsOnDisposal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyBusinessDisposalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandTwentyBusinessDisposalMember" substitutionGroup="xbrli:item" />
<element name="AcquisitionsTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AcquisitionsTwoThousandAndTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyTwoDisposalsDemergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" substitutionGroup="xbrli:item" />
<element name="CashFlowsInTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashFlowsInTwoThousandAndTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoBusinessDisposalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandTwentyTwoBusinessDisposalsMember" substitutionGroup="xbrli:item" />
<element name="AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" substitutionGroup="xbrli:item" />
<element name="DeferredConsiderationReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DeferredConsiderationReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashOutflowInflowExcludingTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_CashOutflowInflowExcludingTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForProfitOnSaleOfEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForProfitOnSaleOfIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ChangesInWorkingCapitalAbstract" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForImpairmentAndAssetsWrittenOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForProfitOnSaleOfBusinesses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForProfitOnSaleOfBusinesses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsOfFinanceLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PaymentsOfFinanceLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DecreaseIncreaseInLiquidInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseIncreaseInLiquidInvestment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExchangeOnNetDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExchangeOnNetDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherAdjustmentsForNoncashItemsToNetDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_OtherAdjustmentsForNoncashItemsToNetDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtOfSubsidiaryUndertakingsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DebtOfSubsidiaryUndertakingsAcquired" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DecreaseIncreaseInNetDebtFromContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DecreaseIncreaseInNetDebtFromDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReclassificationOfNetDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReclassificationOfNetDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfNetDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ChangeInFairValueOfNetDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiquidInvestmentsCashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiquidInvestmentsCashAndCashEquivalents" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAndCashEquivalentsAndNetOfOverdrafts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashAndCashEquivalentsAndNetOfOverdrafts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeFinancialInstrumentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DerivativeFinancialInstrumentsMember" substitutionGroup="xbrli:item" />
<element name="BankOverdrafts1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BankOverdrafts1Member" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashAndCashEquivalentMember" substitutionGroup="xbrli:item" />
<element name="LiquidInvestmentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="CashAndBankOverdraftsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashAndBankOverdraftsMember" substitutionGroup="xbrli:item" />
<element name="LiquidInvestmentsAttributedToContinuingOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" substitutionGroup="xbrli:item" />
<element name="LiquidInvestmentsAttributedToDiscontinuedOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" substitutionGroup="xbrli:item" />
<element name="LiquidInvestmentsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LiquidInvestmentsCashAndCashEquivalentsMember" substitutionGroup="xbrli:item" />
<element name="EuropeanUsMediumTermNotesAndBankFacilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" substitutionGroup="xbrli:item" />
<element name="OtherCurrentDebtMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherCurrentDebtMember" substitutionGroup="xbrli:item" />
<element name="ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" substitutionGroup="xbrli:item" />
<element name="ShortTermBorrowingsAttributedToContinuingOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" substitutionGroup="xbrli:item" />
<element name="LongTermBorrowingsContinuingOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LongTermBorrowingsContinuingOperationsMember" substitutionGroup="xbrli:item" />
<element name="LongTermBorrowingsDiscontinuedOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LongTermBorrowingsDiscontinuedOperationsMember" substitutionGroup="xbrli:item" />
<element name="NetDebtMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NetDebtMember" substitutionGroup="xbrli:item" />
<element name="AccruedInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AccruedInterestMember" substitutionGroup="xbrli:item" />
<element name="EuroCommercialPaperProgrammeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EuroCommercialPaperProgrammeMember" substitutionGroup="xbrli:item" />
<element name="BBB-OrBaaThreeRatedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BBB-OrBaaThreeRatedMember" substitutionGroup="xbrli:item" />
<element name="BbbOrBaaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BbbOrBaaMember" substitutionGroup="xbrli:item" />
<element name="LowerThanBBBBaa3Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LowerThanBBBBaa3Member" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" substitutionGroup="xbrli:item" />
<element name="BondsInDesignatedHedgingRelationshipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BondsInDesignatedHedgingRelationshipMember" substitutionGroup="xbrli:item" />
<element name="DueFromThreeWholesalersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DueFromThreeWholesalersMember" substitutionGroup="xbrli:item" />
<element name="StateBankOfIndiaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_StateBankOfIndiaMember" substitutionGroup="xbrli:item" />
<element name="NonUsaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NonUsaMember" substitutionGroup="xbrli:item" />
<element name="InLineWithOtherPharmaceuticalCompaniesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InLineWithOtherPharmaceuticalCompaniesMember" substitutionGroup="xbrli:item" />
<element name="JTrustRoyalBankMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_JTrustRoyalBankMember" substitutionGroup="xbrli:item" />
<element name="BacSanJoseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BacSanJoseMember" substitutionGroup="xbrli:item" />
<element name="BancoDoBrasilMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BancoDoBrasilMember" substitutionGroup="xbrli:item" />
<element name="BancoDeHondurasMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BancoDeHondurasMember" substitutionGroup="xbrli:item" />
<element name="ProdubancoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ProdubancoMember" substitutionGroup="xbrli:item" />
<element name="HalkBankMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HalkBankMember" substitutionGroup="xbrli:item" />
<element name="UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" substitutionGroup="xbrli:item" />
<element name="NovartisVaccinesBusinessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NovartisVaccinesBusinessMember" substitutionGroup="xbrli:item" />
<element name="WholesalerInTheUsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_WholesalerInTheUsMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="WholesaleAndRetailCreditRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_WholesaleAndRetailCreditRiskMember" substitutionGroup="xbrli:item" />
<element name="ForeignExchangeRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ForeignExchangeRiskMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePercentMovementInUSDInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="TypeOfIncomeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TypeOfIncomeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfIncomeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TypeOfIncomeDomain" substitutionGroup="xbrli:item" />
<element name="CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BankBalancesAndDepositHeldWithCounterparties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BankBalancesAndDepositHeldWithCounterparties" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConcentrationsOfRiskRevenuePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ConcentrationsOfRiskRevenuePercentage" substitutionGroup="xbrli:item" />
<element name="EquityAndDebtNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_EquityAndDebtNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAndCashEquivalentsAndLiquidInvestmentsHeld" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmountHeldAtEuropeanMediumTermNoteProgramme" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashHeldAtUnratedCounterpartiesCashInTransitElement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashHeldAtUnratedCounterparties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashHeldAtUnratedCounterparties" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashReserves" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAndCashEquivalentsAndLiquidInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashAndCashEquivalentsAndLiquidInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInIncomeThroughInterestRateMovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfAccountsReceivableByMajorCustomer" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfAccountsReceivableByMajorCustomer" substitutionGroup="xbrli:item" />
<element name="NotesIssuedAtEuropeanMediumTermNoteProgramme" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NotesIssuedUnderUsShelfRegistration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NotesIssuedUnderUsShelfRegistration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInEquityThroughInterestRateMovements." type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="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." substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RemeasurementOfTheContingentConsiderationPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_RemeasurementOfTheContingentConsiderationPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashManagedForSubsidiaryCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CashManagedForSubsidiaryCompany" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GroupCreditEnhancementsAndCreditInsuranceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GroupCreditEnhancementsAndCreditInsuranceMember" substitutionGroup="xbrli:item" />
<element name="InterestRateSensitivityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateSensitivityMember" substitutionGroup="xbrli:item" />
<element name="EventBasisAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EventBasisAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventBasisDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EventBasisDomain" substitutionGroup="xbrli:item" />
<element name="NetInvestmentHedgedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NetInvestmentHedgedMember" substitutionGroup="xbrli:item" />
<element name="AmortizedCostMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AmortizedCostMember" substitutionGroup="xbrli:item" />
<element name="ForeignExchangeContractsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ForeignExchangeContractsMember" substitutionGroup="xbrli:item" />
<element name="FinancialLiabilitesOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FinancialLiabilitesOneMember" substitutionGroup="xbrli:item" />
<element name="AAAOrAaaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AAAOrAaaMember" substitutionGroup="xbrli:item" />
<element name="AaOrAaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AaOrAaMember" substitutionGroup="xbrli:item" />
<element name="AorAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AorAMember" substitutionGroup="xbrli:item" />
<element name="BBPlusOrBaOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BBPlusOrBaOneMember" substitutionGroup="xbrli:item" />
<element name="UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GovernmentSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_GovernmentSecurities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LiquidityFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_LiquidityFunds" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TradeAndOtherPayableMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TradeAndOtherPayableMember" substitutionGroup="xbrli:item" />
<element name="OtherNonCurrentLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherNonCurrentLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="BankLoansAndOverdraftsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BankLoansAndOverdraftsMember" substitutionGroup="xbrli:item" />
<element name="OtherBorrowingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherBorrowingMember" substitutionGroup="xbrli:item" />
<element name="OtherBondsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherBondsMember" substitutionGroup="xbrli:item" />
<element name="CommercialPaperInADesignatedHedgingRelationshipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CommercialPaperInADesignatedHedgingRelationshipMember" substitutionGroup="xbrli:item" />
<element name="OtherCommercialPaperMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherCommercialPaperMember" substitutionGroup="xbrli:item" />
<element name="BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BorrowingsExcludingObligationsUnderFinanceLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_BorrowingsExcludingObligationsUnderFinanceLease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetFinancialAssetsLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NetFinancialAssetsLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetFinancialAssetsFinancialLiabilitiesAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherReceivableMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TradeAndOtherReceivableMember" substitutionGroup="xbrli:item" />
<element name="DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" substitutionGroup="xbrli:item" />
<element name="HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalents1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CashAndCashEquivalents1Member" substitutionGroup="xbrli:item" />
<element name="OtherInvestmentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_OtherInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="CurrentEquityAndOtherInvestmentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrentEquityAndOtherInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ContingentConsiderationLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialAssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="PaymentOfContingentConsiderationLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PaymentOfContingentConsiderationLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsFairValueMeasurementAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FinancialAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FinancialAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FinancialInstrumentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FinancialInstrumentsMember" substitutionGroup="xbrli:item" />
<element name="NonFinancialInstrumentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NonFinancialInstrumentsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" substitutionGroup="xbrli:item" />
<element name="EmbeddedAndOtherDerivativesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EmbeddedAndOtherDerivativesMember" substitutionGroup="xbrli:item" />
<element name="HedgingInstrumentsLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_HedgingInstrumentsLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="HedgingInstrumentLiabilitiesNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_HedgingInstrumentLiabilitiesNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="HedgingInstrumentLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_HedgingInstrumentLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="HedgingInstrumentAssetsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_HedgingInstrumentAssetsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="HedgingInstrumentAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_HedgingInstrumentAssetsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetInvestmentHedgesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NetInvestmentHedgesMember" substitutionGroup="xbrli:item" />
<element name="JapaneseYenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_JapaneseYenMember" substitutionGroup="xbrli:item" />
<element name="EuroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EuroMember" substitutionGroup="xbrli:item" />
<element name="SgdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SgdMember" substitutionGroup="xbrli:item" />
<element name="CADMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CADMember" substitutionGroup="xbrli:item" />
<element name="DescriptionOfForeignCurrency" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DescriptionOfForeignCurrency" substitutionGroup="xbrli:item" />
<element name="ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BuyForeignCurrencyOverSixMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BuyForeignCurrencyOverSixMonthsMember" substitutionGroup="xbrli:item" />
<element name="BuyForeignCurrencyThreeToSixMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BuyForeignCurrencyThreeToSixMonthsMember" substitutionGroup="xbrli:item" />
<element name="SellForeignCurrencyOverSixMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SellForeignCurrencyOverSixMonthsMember" substitutionGroup="xbrli:item" />
<element name="BuyForeignCurrencyLessThanThreeMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BuyForeignCurrencyLessThanThreeMonthsMember" substitutionGroup="xbrli:item" />
<element name="VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" substitutionGroup="xbrli:item" />
<element name="SellForeignCurrencyLessThanThreeMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SellForeignCurrencyLessThanThreeMonthsMember" substitutionGroup="xbrli:item" />
<element name="BorrowingsLessThanThreeMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BorrowingsLessThanThreeMonthsMember" substitutionGroup="xbrli:item" />
<element name="BorrowingsOverSixMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BorrowingsOverSixMonthsMember" substitutionGroup="xbrli:item" />
<element name="VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" substitutionGroup="xbrli:item" />
<element name="BorrowingThreeToSixMonthsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BorrowingThreeToSixMonthsMember" substitutionGroup="xbrli:item" />
<element name="PrehedgingOfLongtermInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PrehedgingOfLongtermInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="VariabilityInCashFlowsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VariabilityInCashFlowsMember" substitutionGroup="xbrli:item" />
<element name="MoreThanFiveYearsNotLaterThanTenYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" substitutionGroup="xbrli:item" />
<element name="MaturedInThePastPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MaturedInThePastPeriodMember" substitutionGroup="xbrli:item" />
<element name="MoreThanTenYearsNotLaterThanThirtyYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" substitutionGroup="xbrli:item" />
<element name="MoreThanThirtyYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_MoreThanThirtyYearsMember" substitutionGroup="xbrli:item" />
<element name="DerivativeFinancialAssetsLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DerivativeFinancialAssetsLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AverageFixedInterestRateOfHedgingInstrument" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_AverageFixedInterestRateOfHedgingInstrument" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DerivativeFinancialAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DerivativeFinancialAssetsMember" substitutionGroup="xbrli:item" />
<element name="TradesAndOtherPayablesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TradesAndOtherPayablesMember" substitutionGroup="xbrli:item" />
<element name="DerivativeFinancialLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DerivativeFinancialLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDebtInterestRateRepricingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDebtInterestRateRepricingAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDebtInterestRateRepricingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDebtInterestRateRepricingTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDebtInterestRateRepricingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfDebtInterestRateRepricingLineItems" substitutionGroup="xbrli:item" />
<element name="Debt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_Debt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestBearingDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_InterestBearingDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FloatingAndFixedRateDebtMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FloatingAndFixedRateDebtMember" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrencyRiskTenYenAppreciationOfYenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenYenAppreciationOfYenMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenYenAppreciationOfYenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskTenYenDepreciationOfYenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskTenYenDepreciationOfYenMember" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskFifteenYenDepreciationOfYenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" substitutionGroup="xbrli:item" />
<element name="NonDerivativesFinancialLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_NonDerivativesFinancialLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="FutureFinanceChargeOnFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FutureFinanceChargeOnFinanceLeases" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrument1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DebtInstrument1Axis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DebtInstrumentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DebtInstrumentDomain" substitutionGroup="xbrli:item" />
<element name="PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfEmployeeShareSchemesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeShareSchemesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfEmployeeShareSchemesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfEmployeeShareSchemesLineItems" substitutionGroup="xbrli:item" />
<element name="ExpectedFutureDividendYieldPercentageShareGranted" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExpectedFutureDividendYieldPercentageShareGranted" substitutionGroup="xbrli:item" />
<element name="NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="EquallyWeightedMeasuresOverPerformancePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_EquallyWeightedMeasuresOverPerformancePeriod" substitutionGroup="xbrli:item" />
<element name="NumberOfOutstandingAwards" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfOutstandingAwards" substitutionGroup="xbrli:item" />
<element name="NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="AtPercentageBelowMarketPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_AtPercentageBelowMarketPrice" substitutionGroup="xbrli:item" />
<element name="WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfPerformanceSharePlan" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_PercentageOfPerformanceSharePlan" substitutionGroup="xbrli:item" />
<element name="WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="SavingsRelatedShareOptionSchemesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SavingsRelatedShareOptionSchemesMember" substitutionGroup="xbrli:item" />
<element name="FreeCashFlowMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_FreeCashFlowMember" substitutionGroup="xbrli:item" />
<element name="PipelineProgressMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_PipelineProgressMember" substitutionGroup="xbrli:item" />
<element name="TsrMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TsrMember" substitutionGroup="xbrli:item" />
<element name="RAndDNewProductPerformanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_RAndDNewProductPerformanceMember" substitutionGroup="xbrli:item" />
<element name="AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" substitutionGroup="xbrli:item" />
<element name="AwardType1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AwardType1Axis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EquityAwardDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_EquityAwardDomain" substitutionGroup="xbrli:item" />
<element name="TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" substitutionGroup="xbrli:item" />
<element name="NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="NumberOfOutstandingShareAwards" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfOutstandingShareAwards" substitutionGroup="xbrli:item" />
<element name="NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ShareOptionsAndSavingsRelatedOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareOptionsAndSavingsRelatedOptionsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" substitutionGroup="xbrli:item" />
<element name="SavingsRelatedOptionsGrantPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SavingsRelatedOptionsGrantPrice" substitutionGroup="xbrli:item" />
<element name="ExpectedLifeOfShareOptionsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_ExpectedLifeOfShareOptionsGranted" substitutionGroup="xbrli:item" />
<element name="DividendYieldShareOptionsGranted" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_DividendYieldShareOptionsGranted" substitutionGroup="xbrli:item" />
<element name="SavingsRelatedOptionsGrantPriceDiscount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_SavingsRelatedOptionsGrantPriceDiscount" substitutionGroup="xbrli:item" />
<element name="ShareOptionSchemesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ShareOptionSchemesMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="WeightedAverageRemainingContractualLifeOfOutstandingShareOption" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesHeldForShareOptionSchemes" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfSharesHeldForShareOptionSchemes" substitutionGroup="xbrli:item" />
<element name="MarketValueOfSharesHeldForShareAwardSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_MarketValueOfSharesHeldForShareAwardSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NominalValueOfSharesHeldForShareOptionSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NominalValueOfSharesHeldForShareOptionSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MarketValueOfSharesHeldForShareOptionSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_MarketValueOfSharesHeldForShareOptionSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NominalValueOfSharesHeldForShareAwardSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NominalValueOfSharesHeldForShareAwardSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CarryingValueOfSharesHeldForShareOptionSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CarryingValueOfSharesHeldForShareOptionSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSharesHeldForShareAwardSchemes" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_NumberOfSharesHeldForShareAwardSchemes" substitutionGroup="xbrli:item" />
<element name="CarryingValueOfSharesHeldForShareAwardSchemes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_CarryingValueOfSharesHeldForShareAwardSchemes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SaudiArabiaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SaudiArabiaMember" substitutionGroup="xbrli:item" />
<element name="AustriaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_AustriaMember" substitutionGroup="xbrli:item" />
<element name="ThailandMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ThailandMember" substitutionGroup="xbrli:item" />
<element name="GreeceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GreeceMember" substitutionGroup="xbrli:item" />
<element name="VietnamMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_VietnamMember" substitutionGroup="xbrli:item" />
<element name="GlaxoOperationsUkLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoOperationsUkLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineCapitalIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineCapitalIncMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineBrasilLimitadaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineBrasilLimitadaMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineCapitalPLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineCapitalPLCMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineSAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineSAMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineBiologicalsSAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineBiologicalsSAMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineAustraliaPtyLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineAustraliaPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineExportLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineExportLimitedMember" substitutionGroup="xbrli:item" />
<element name="GSKVaccinesGmbHMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GSKVaccinesGmbHMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineFinancePLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineFinancePLCMember" substitutionGroup="xbrli:item" />
<element name="CorixaCorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_CorixaCorporationMember" substitutionGroup="xbrli:item" />
<element name="GSKServicesSPZOOMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GSKServicesSPZOOMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlinePakistanLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlinePakistanLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineResearchAndDevelopmentLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineIncMember" substitutionGroup="xbrli:item" />
<element name="HumanGenomeSciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_HumanGenomeSciencesIncMember" substitutionGroup="xbrli:item" />
<element name="SetFirstLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SetFirstLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineGmbHAndCoKGMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineGmbHAndCoKGMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineSPAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineSPAMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineServicesUnlimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineServicesUnlimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineLLCMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineTradingServicesLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineTradingServicesLimitedMember" substitutionGroup="xbrli:item" />
<element name="LaboratoriosViiVHealthCareSLMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LaboratoriosViiVHealthCareSLMember" substitutionGroup="xbrli:item" />
<element name="GSKVaccinesSRLMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GSKVaccinesSRLMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineHoldingsLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineHoldingsLimitedMember" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareFinanceLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareFinanceLimitedMember" substitutionGroup="xbrli:item" />
<element name="ViiVHealthcareSASMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViiVHealthcareSASMember" substitutionGroup="xbrli:item" />
<element name="ViiVHealthCareUnitedKingdomLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViiVHealthCareUnitedKingdomLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineKKMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineKKMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineKoreaLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineKoreaLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineLimitedMember" substitutionGroup="xbrli:item" />
<element name="StiefelLaboratoriesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_StiefelLaboratoriesIncMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklinePharmaceuticalsLimitedIndiaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" substitutionGroup="xbrli:item" />
<element name="SmithKlineBeechamLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_SmithKlineBeechamLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlineUnitedKingdomLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" substitutionGroup="xbrli:item" />
<element name="LaboratoireGlaxoSmithKlineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_LaboratoireGlaxoSmithKlineMember" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareSRLItalyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareSRLItalyMember" substitutionGroup="xbrli:item" />
<element name="IDBiomedicalCorporationOfQuebecMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_IDBiomedicalCorporationOfQuebecMember" substitutionGroup="xbrli:item" />
<element name="GlaxoWellcomeManufacturingPteLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoWellcomeManufacturingPteLtdMember" substitutionGroup="xbrli:item" />
<element name="TesaroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_TesaroMember" substitutionGroup="xbrli:item" />
<element name="ViiVHealthcareCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViiVHealthcareCompanyMember" substitutionGroup="xbrli:item" />
<element name="GskEquityInvestmentsLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskEquityInvestmentsLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoWellcomeUkLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoWellcomeUkLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineUsTradingLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineUsTradingLimitedMember" substitutionGroup="xbrli:item" />
<element name="JscGlaxosmithklineTradingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_JscGlaxosmithklineTradingMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIntellectualPropertyNo.2LimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineAgMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineAgMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineB.v.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineB.v.Member" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklinePharmaGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklinePharmaGmbhMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineSingleMemberA.e.b.e.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" substitutionGroup="xbrli:item" />
<element name="GskCapitalB.v.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskCapitalB.v.Member" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareGmbhMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineThailandLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineThailandLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineFarEastB.v.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineFarEastB.v.Member" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineMexicoS.a.DeC.v.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" substitutionGroup="xbrli:item" />
<element name="GskEnterpriseManagementCoLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskEnterpriseManagementCoLtdMember" substitutionGroup="xbrli:item" />
<element name="GskPharmaVietnamCompanyLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskPharmaVietnamCompanyLimitedMember" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareK.kMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareK.kMember" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareUlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareUlcMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIntellectualPropertyNo.3LimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIhcLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIhcLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIntellectualPropertyNo.4LimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxosmithklineIntellectualPropertyLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxosmithklineIntellectualPropertyLimitedMember" substitutionGroup="xbrli:item" />
<element name="GlaxoSmithKlinePharmaceuticalsSAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GlaxoSmithKlinePharmaceuticalsSAMember" substitutionGroup="xbrli:item" />
<element name="GskNo.1ScottishLimitedPartnershipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskNo.1ScottishLimitedPartnershipMember" substitutionGroup="xbrli:item" />
<element name="GskNo.2ScottishLimitedPartnershipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskNo.2ScottishLimitedPartnershipMember" substitutionGroup="xbrli:item" />
<element name="GskNo.3ScottishLimitedPartnershipMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskNo.3ScottishLimitedPartnershipMember" substitutionGroup="xbrli:item" />
<element name="ViivHealthcareUnitedKingdomNo.3LimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" substitutionGroup="xbrli:item" />
<element name="GskGp1LimitedsShareCapitalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskGp1LimitedsShareCapitalMember" substitutionGroup="xbrli:item" />
<element name="GskGp2LimitedsShareCapital.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskGp2LimitedsShareCapital.Member" substitutionGroup="xbrli:item" />
<element name="GskPlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GskPlcMember" substitutionGroup="xbrli:item" />
<element name="BerkeleySquarePensionTrusteeCompanyLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLegalProceedingsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLegalProceedingsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLegalProceedingsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLegalProceedingsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfLegalProceedingsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_DisclosureOfLegalProceedingsLineItems" substitutionGroup="xbrli:item" />
<element name="DamagesAwardedToGSK" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_DamagesAwardedToGSK" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossContingencyNumberOfPlaintiffs" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gsk_LossContingencyNumberOfPlaintiffs" substitutionGroup="xbrli:item" />
<element name="FinePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gsk_FinePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GSKKoreaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gsk_GSKKoreaMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>gsk-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-March-2023 [08:38:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedIncomeStatement" roleURI="http://www.gsk.com/role/ConsolidatedIncomeStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfComprehensiveIncome" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedBalanceSheet" roleURI="http://www.gsk.com/role/ConsolidatedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedCashFlowStatement" roleURI="http://www.gsk.com/role/ConsolidatedCashFlowStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitSummaryOfAuditorsRemunerationDetail" roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfEmployeeCostsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncomeSummaryOfFinanceIncomeDetail" roleURI="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpenseSummaryOfFinanceCostDetail" roleURI="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" roleURI="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsSummaryOfOtherProvisionsDetail" roleURI="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" roleURI="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfComprehensiveIncomeAlternate1" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedIncomeStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:to="loc_ifrs-full_ProfitLossBeforeTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_RevenueFromRoyalties" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_GrossProfit" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="loc_ifrs-full_Revenue" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="loc_ifrs-full_CostOfSales" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_FinanceIncome" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_FinanceCosts" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_GSK_GainLossOnDisposalOfInterestInAssociate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_GSK_GainLossOnDisposalOfInterestInAssociate" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedIncomeStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xlink:label="loc_GSK_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="loc_GSK_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:label="loc_GSK_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="loc_GSK_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" use="optional" order="16" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_IssuedCapital" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_SharePremium" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_RetainedEarnings" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_OtherReserves" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_NoncontrollingInterests" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="loc_ifrs-full_Assets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_CurrentAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_Inventories" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets" xlink:label="loc_ifrs-full_CurrentTaxAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentTaxAssets" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CashAndCashEquivalents" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_NoncurrentAssets" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_Goodwill" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_DeferredTaxAssets" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_OtherNoncurrentAssets" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_RightofuseAssets" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="loc_ifrs-full_Liabilities" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_CurrentLiabilities" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-full_ShorttermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_ShorttermBorrowings" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentTaxLiabilities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_OtherShorttermProvisions" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_NoncurrentLiabilities" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_LongtermBorrowings" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_DeferredTaxLiabilities" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherLongtermProvisions" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities" use="optional" order="43" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedCashFlowStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:label="loc_GSK_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_GSK_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xlink:label="loc_GSK_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:to="loc_GSK_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:label="loc_GSK_CashFromUsedInOperationsBeforeTaxesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:to="loc_GSK_CashFromUsedInOperationsBeforeTaxesContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedCashFlowStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_GSK_ProceedsFromRepaymentsOfOtherCurrentBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_GSK_ProceedsFromRepaymentsOfOtherCurrentBorrowings" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedCashFlowStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xlink:label="loc_GSK_PurchaseOfInvestmentInAssociatesAndJointVentures" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_GSK_PurchaseOfInvestmentInAssociatesAndJointVentures" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInLiquidInvestments" xlink:label="loc_GSK_IncreaseDecreaseInLiquidInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_GSK_IncreaseDecreaseInLiquidInvestments" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xlink:label="loc_GSK_ProceedsFromDisposalOfAssociatesAndJointVentures" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_GSK_ProceedsFromDisposalOfAssociatesAndJointVentures" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="34" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfBusinessesAndAssets" xlink:label="loc_GSK_DisposalOfBusinessesAndAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_GSK_DisposalOfBusinessesAndAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xlink:label="loc_GSK_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_GSK_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontSettlementIncome" xlink:label="loc_GSK_UpfrontSettlementIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="loc_GSK_UpfrontSettlementIncome" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:label="loc_GSK_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForOtherAssuranceServices" xlink:label="loc_GSK_AuditorsRemunerationForOtherAssuranceServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:to="loc_GSK_AuditorsRemunerationForOtherAssuranceServices" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_WagesAndSalaries" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-full_SocialSecurityContributions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_SocialSecurityContributions" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostEmploymentBenefitExpense" xlink:label="loc_GSK_PostEmploymentBenefitExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_GSK_PostEmploymentBenefitExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_TerminationBenefitsExpense" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xlink:label="loc_GSK_KeyManagementPersonnelCompensationSocialSecurityCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_GSK_KeyManagementPersonnelCompensationSocialSecurityCosts" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_GSK_CostChargedToOperatingProfit" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xlink:label="loc_GSK_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_GSK_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xlink:label="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-full_ImpairmentLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_ifrs-full_ImpairmentLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherMaterialNoncashItems" xlink:label="loc_ifrs-full_OtherMaterialNoncashItems" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_ifrs-full_OtherMaterialNoncashItems" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCostsCashSettlement" xlink:label="loc_GSK_OtherCostsCashSettlement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_GSK_OtherCostsCashSettlement" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_GSK_CostChargedToOperatingProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_ifrs-full_CostOfSales" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentExpenses" xlink:label="loc_GSK_ResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_CostChargedToOperatingProfit" xlink:to="loc_GSK_ResearchAndDevelopmentExpenses" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xlink:label="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_OtherFinanceIncome" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReTranslationOfLoan" xlink:label="loc_GSK_ReTranslationOfLoan" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="loc_GSK_ReTranslationOfLoan" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_GSK_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_GSK_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_GSK_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_GSK_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_GSK_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_GSK_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_GSK_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_GSK_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="loc_GSK_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="loc_ifrs-full_WeightedAverageShares" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesRelatedToInsuranceContracts" xlink:label="loc_GSK_ReceivablesRelatedToInsuranceContracts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="loc_GSK_ReceivablesRelatedToInsuranceContracts" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="loc_ifrs-full_OtherNoncurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="loc_ifrs-full_OtherNoncurrentReceivables" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_TradeReceivables" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:label="loc_ifrs-full_AccruedIncomeOtherThanContractAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_AccruedIncomeOtherThanContractAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-full_Prepayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_Prepayments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="loc_ifrs-full_InterestReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_InterestReceivable" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeLoansAndAdvances" xlink:label="loc_GSK_EmployeeLoansAndAdvances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_GSK_EmployeeLoansAndAdvances" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_OtherReceivables" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="loc_ifrs-full_Cash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssetsNet" xlink:label="loc_GSK_OtherAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="loc_GSK_OtherAssetsNet" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WagesAndSalariesPayable" xlink:label="loc_GSK_WagesAndSalariesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_GSK_WagesAndSalariesPayable" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOptionPayable" xlink:label="loc_GSK_PutOptionPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_GSK_PutOptionPayable" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_OtherCurrentPayables" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_ContractLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_GSK_CustomerReturnAndRebateAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_GSK_CustomerReturnAndRebateAccruals" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAccruals" xlink:label="loc_GSK_OtherAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_GSK_OtherAccruals" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="loc_ifrs-full_OtherShorttermProvisions" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="loc_ifrs-full_OtherLongtermProvisions" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-full_Accruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="loc_ifrs-full_Accruals" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xlink:label="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="loc_ifrs-full_OtherNoncurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherNoncurrentPayables" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitments" xlink:label="loc_GSK_ContractualObligationsAndCommitments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInvestments" xlink:label="loc_GSK_ContractualObligationsAndCommitmentsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsAndCommitmentsOfInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xlink:label="loc_GSK_ContractualObligationsAndCommitmentsOfPurchaseCommitments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsAndCommitmentsOfPurchaseCommitments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPensions" xlink:label="loc_GSK_ContractualObligationsAndCommitmentsOfPensions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsAndCommitmentsOfPensions" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xlink:label="loc_GSK_ContractualObligationsAndCommitmentsOfInterestOnLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsAndCommitmentsOfInterestOnLoans" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xlink:label="loc_GSK_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xlink:label="loc_GSK_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_ContractualObligationsAndCommitments" xlink:to="loc_GSK_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xlink:label="loc_GSK_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_GSK_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xlink:label="loc_GSK_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_GSK_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xlink:label="loc_GSK_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_GSK_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xlink:label="loc_GSK_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_GSK_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" use="optional" order="13" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredConsiderationReceived" xlink:label="loc_GSK_DeferredConsiderationReceived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_GSK_DeferredConsiderationReceived" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_GSK_TransactionCostsOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_GSK_TransactionCostsOnDisposal" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsLiabilities" xlink:label="loc_GSK_NetFinancialAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_NetFinancialAssetsLiabilities" xlink:to="loc_ifrs-full_FinancialAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_NetFinancialAssetsLiabilities" xlink:to="loc_ifrs-full_FinancialLiabilities" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:label="loc_GSK_NetFinancialAssetsFinancialLiabilitiesAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GSK_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xlink:label="loc_GSK_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_GSK_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xlink:label="loc_GSK_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_GSK_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" use="optional" order="10" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xlink:label="loc_GSK_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_GSK_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xlink:label="loc_GSK_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_GSK_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xlink:label="loc_GSK_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_GSK_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xlink:label="loc_GSK_FairValueMovementsOnCashFlowHedgesNotReclassified" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_GSK_FairValueMovementsOnCashFlowHedgesNotReclassified" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xlink:label="loc_GSK_AverageNumberOfEmployeesFromDiscontinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="loc_GSK_AverageNumberOfEmployeesFromDiscontinuingOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromContinuingOperations" xlink:label="loc_GSK_AverageNumberOfEmployeesFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="loc_GSK_AverageNumberOfEmployeesFromContinuingOperations" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_ifrs-full_ApplicableTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xlink:label="loc_GSK_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xlink:label="loc_GSK_TaxRateEffectOfResearchAndDevelopmentCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfResearchAndDevelopmentCredits" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xlink:label="loc_GSK_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xlink:label="loc_GSK_TaxRateEffectOfReassessmentsOfPriorYearEstimates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfReassessmentsOfPriorYearEstimates" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfChangeInTaxRate" xlink:label="loc_GSK_TaxRateEffectOfChangeInTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfChangeInTaxRate" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:label="loc_GSK_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="loc_GSK_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" use="optional" order="9" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>gsk-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-March-2023 [08:38:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CoverPage" roleURI="http://www.gsk.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfChangesInEquity" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedCashFlowStatement" roleURI="http://www.gsk.com/role/ConsolidatedCashFlowStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesPolicies" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTables" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitTables" roleURI="http://www.gsk.com/role/OperatingProfitTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsTables" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsTables" roleURI="http://www.gsk.com/role/NonControllingInterestsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsTables" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresTables" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PresentationOfTheFinancialStatementsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail" roleURI="http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTurnoverBySegmentDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTurnoverByProductServiceDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitSummaryOfAuditorsRemunerationDetail" roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncomeSummaryOfFinanceIncomeDetail" roleURI="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TaxationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfInterimFinancialReportingDetail" roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfInterimFinancialReportingDetailParenthetical" roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/DividendsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail" roleURI="http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.gsk.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillSummaryOfChangesInGoodwillDetail" roleURI="http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail" roleURI="http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail" roleURI="http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsScheduleOfOtherInvestmentsDetail" roleURI="http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesSummaryOfLossAllowanceDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" roleURI="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtAdditionalInformationDetail" roleURI="http://www.gsk.com/role/NetDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail" roleURI="http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtScheduleOfFinanceLeaseObligationsDetail" roleURI="http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsSummaryOfOtherProvisionsDetail" roleURI="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAdditionalInformationDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail" roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail" roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAnalysisOfOtherReservesDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail" roleURI="http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfOptionOutstandingDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#LegalProceedingsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedIncomeStatement" roleURI="http://www.gsk.com/role/ConsolidatedIncomeStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfComprehensiveIncome" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfEmployeeCostsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpenseSummaryOfFinanceCostDetail" roleURI="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfNetDeferredTaxAssetDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentLiabilitiesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" roleURI="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PresentationOfTheFinancialStatements" roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPolicies" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPolicies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesTables" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NewAccountingRequirements" roleURI="http://www.gsk.com/role/NewAccountingRequirements" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRates" roleURI="http://www.gsk.com/role/ExchangeRates" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformation" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformation" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpense" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpense" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseTables" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfit" roleURI="http://www.gsk.com/role/OperatingProfit" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCosts" roleURI="http://www.gsk.com/role/MajorRestructuringCosts" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncome" roleURI="http://www.gsk.com/role/FinanceIncome" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncomeTables" roleURI="http://www.gsk.com/role/FinanceIncomeTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpense" roleURI="http://www.gsk.com/role/FinanceExpense" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpenseTables" roleURI="http://www.gsk.com/role/FinanceExpenseTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVentures" roleURI="http://www.gsk.com/role/AssociatesAndJointVentures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesTables" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCosts" roleURI="http://www.gsk.com/role/EmployeeCosts" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsTables" roleURI="http://www.gsk.com/role/EmployeeCostsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Taxation" roleURI="http://www.gsk.com/role/Taxation" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationTables" roleURI="http://www.gsk.com/role/TaxationTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShare" roleURI="http://www.gsk.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareTables" roleURI="http://www.gsk.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Dividends" roleURI="http://www.gsk.com/role/Dividends" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipment" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Goodwill" roleURI="http://www.gsk.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillTables" roleURI="http://www.gsk.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVentures" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesTables" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestments" roleURI="http://www.gsk.com/role/OtherInvestments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsTables" roleURI="http://www.gsk.com/role/OtherInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssets" roleURI="http://www.gsk.com/role/OtherNonCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsTables" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Inventories" roleURI="http://www.gsk.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InventoriesTables" roleURI="http://www.gsk.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssets" roleURI="http://www.gsk.com/role/OtherIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsTables" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalents" roleURI="http://www.gsk.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSale" roleURI="http://www.gsk.com/role/AssetsHeldForSale" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleTables" roleURI="http://www.gsk.com/role/AssetsHeldForSaleTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayables" roleURI="http://www.gsk.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefits" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisions" roleURI="http://www.gsk.com/role/OtherProvisions" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsTables" roleURI="http://www.gsk.com/role/OtherProvisionsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilities" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilitiesTables" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebt" roleURI="http://www.gsk.com/role/NetDebt" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtTables" roleURI="http://www.gsk.com/role/NetDebtTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentLiabilities" roleURI="http://www.gsk.com/role/ContingentLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccount" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountTables" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquity" roleURI="http://www.gsk.com/role/MovementsInEquity" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RelatedPartyTransactions" roleURI="http://www.gsk.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtTables" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposals" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Commitments" roleURI="http://www.gsk.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsTables" roleURI="http://www.gsk.com/role/CommitmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosures" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterests" roleURI="http://www.gsk.com/role/NonControllingInterests" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemes" roleURI="http://www.gsk.com/role/EmployeeShareSchemes" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesTables" roleURI="http://www.gsk.com/role/EmployeeShareSchemesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompanies" roleURI="http://www.gsk.com/role/PrincipalGroupCompanies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesTables" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#LegalProceedings" roleURI="http://www.gsk.com/role/LegalProceedings" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PostBalanceSheetEvents" roleURI="http://www.gsk.com/role/PostBalanceSheetEvents" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilities" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesTables" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityTables" roleURI="http://www.gsk.com/role/MovementsInEquityTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfDividendsToShareholdersDetail" roleURI="http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsTables" roleURI="http://www.gsk.com/role/DividendsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesTables" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedBalanceSheet" roleURI="http://www.gsk.com/role/ConsolidatedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitSummaryOfInformationAboutProfitLossDetail" roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssets" roleURI="http://www.gsk.com/role/RightOfUseAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssetsTables" roleURI="http://www.gsk.com/role/RightOfUseAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebt" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivables" roleURI="http://www.gsk.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestments" roleURI="http://www.gsk.com/role/CurrentEquityInvestments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsTables" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRatesTables" roleURI="http://www.gsk.com/role/ExchangeRatesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsTables" roleURI="http://www.gsk.com/role/MajorRestructuringCostsTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_505016" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_505013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentInformationTable_505013" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1069485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_505013" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1069485" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1069485" xlink:to="loc_dei_AddressTypeDomain_1069488" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1069485" xlink:to="loc_dei_AddressTypeDomain_1069488_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1069491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1069488" xlink:to="loc_dei_BusinessContactMember_1069491" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassAxis" xlink:label="loc_gsk_TitleOfEachClassAxis_514849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_505013" xlink:to="loc_gsk_TitleOfEachClassAxis_514849" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassDomain" xlink:label="loc_gsk_TitleOfEachClassDomain_514850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_TitleOfEachClassAxis_514849" xlink:to="loc_gsk_TitleOfEachClassDomain_514850" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassDomain" xlink:label="loc_gsk_TitleOfEachClassDomain_514850_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_TitleOfEachClassAxis_514849" xlink:to="loc_gsk_TitleOfEachClassDomain_514850_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFiveNotesDue2025Member" xlink:label="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member_514858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member_514858" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFiveNotesDue2028Member" xlink:label="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member_514859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member_514859" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFiveNotesDue2029Member" xlink:label="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member_514860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member_514860" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFiveNotesDue2038Member" xlink:label="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member_514861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member_514861" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroNotesDue2024Member" xlink:label="loc_gsk_ThreePointZeroNotesDue2024Member_629615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointZeroNotesDue2024Member_629615" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourNotesDue2023Member" xlink:label="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member_862545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member_862545" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoZeroZeroNotesDue2043Member" xlink:label="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member_514862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member_514862" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_514866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_AmericanDepositarySharesMember_514866" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_505088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityFilerCategory_505088" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_507052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityIncorporationStateCountryCode_507052" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_507054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressAddressLine1_507054" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_507057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressCityOrTown_507057" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_505089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityShellCompany_505089" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_505079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentType_505079" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_505080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AmendmentFlag_505080" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_505081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentPeriodEndDate_505081" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_505082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentFiscalYearFocus_505082" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_505083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentFiscalPeriodFocus_505083" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_505084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_TradingSymbol_505084" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_505085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityRegistrantName_505085" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_505090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCurrentReportingStatus_505090" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_505091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityVoluntaryFilers_505091" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_507061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityFileNumber_507061" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_514778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressCountry_514778" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_514820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCentralIndexKey_514820" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_514821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_CurrentFiscalYearEndDate_514821" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_514822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_514822" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_514826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_514826" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_514827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityEmergingGrowthCompany_514827" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_514842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentAnnualReport_514842" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_514843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentTransitionReport_514843" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_514846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentShellCompanyReport_514846" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_832775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_IcfrAuditorAttestationFlag_832775" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_1069493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentRegistrationStatement_1069493" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1069494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_ContactPersonnelName_1069494" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_514863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_Security12bTitle_514863" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_514865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_SecurityExchangeName_514865" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_514873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressPostalZipCode_514873" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_514874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityInteractiveDataCurrent_514874" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_514876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentAccountingStandard_514876" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_1069501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_ContactPersonnelEmailAddress_1069501" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1069504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_CityAreaCode_1069504" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1069505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_LocalPhoneNumber_1069505" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_2146646319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorName_2146646319" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_2146646320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorFirmId_2146646320" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_2146646321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorLocation_2146646321" use="optional" order="54" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="loc_ifrs-full_DividendsPaid_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DividendsPaid_142" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xlink:label="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan_150" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_151" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_138" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_Equity_134" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_136" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments_146" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ComprehensiveIncome_137" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_124" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_124" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" xlink:to="loc_ifrs-full_RestatedMember_121" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_121_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" xlink:to="loc_ifrs-full_RestatedMember_121_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_124" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_119" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_119" xlink:to="loc_ifrs-full_EquityMember_120" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_120_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_119" xlink:to="loc_ifrs-full_EquityMember_120_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_SharePremiumMember_126" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_IssuedCapitalMember_125" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_130" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_OtherReservesMember_128" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_129" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_RetainedEarningsMember_127" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:label="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_144" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xlink:label="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity_139" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashDistributionsToNoncontrollingInterests" xlink:label="loc_gsk_NoncashDistributionsToNoncontrollingInterests_2146645026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_NoncashDistributionsToNoncontrollingInterests_2146645026" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary_2146645027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary_2146645027" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashDividendToShareholders" xlink:label="loc_gsk_NonCashDividendToShareholders_2146645028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_NonCashDividendToShareholders_2146645028" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingGainLossTransferredToNonFinancialAssets" xlink:label="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets_2146645029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets_2146645029" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ProfitLoss_135" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_147" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionsWithNoncontoliingInterests" xlink:label="loc_gsk_TransactionsWithNoncontoliingInterests_1306645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_TransactionsWithNoncontoliingInterests_1306645" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IssueOfEquity_148" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_152" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesAcquiredByEsopTrusts" xlink:label="loc_gsk_SharesAcquiredByEsopTrusts_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_SharesAcquiredByEsopTrusts_149" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedCashFlowStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_170" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_178" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_173" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_169" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_171" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_174" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_175" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_177" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_1701247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_1701247" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_172" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_176" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_167" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_1701248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_1701248" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2146643292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2146643292" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_201" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_513682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_CashAndCashEquivalents_513682" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_164" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_165" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_183" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_191" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities_192" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_179" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInLiquidInvestments" xlink:label="loc_gsk_IncreaseDecreaseInLiquidInvestments_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_IncreaseDecreaseInLiquidInvestments_190" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_184" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_193" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_181" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_180" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_182" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xlink:label="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures_188" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_534718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_534718" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_1701245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_1701245" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_1701246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_1701246" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xlink:label="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures_1306873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures_1306873" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_186" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_187" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_200" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_195" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax_1701243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax_1701243" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax_1701244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax_1701244" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_198" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations_1702773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations_1702773" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations_1702770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations_1702770" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations_1702771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations_1702771" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations_2146645004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations_2146645004" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_2147449765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_2147449765" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_1701237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_1701237" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3046" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory_3075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory_3075" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_3058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_3058" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_3064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_3064" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3052" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_3050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_3050" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory_3073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory_3073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_3060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_3060" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory_3056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory_3056" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory_3068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory_3068" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_3062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_3062" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_3054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_3054" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_3067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_3067" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_3070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_3070" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_3071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_3071" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory_3057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory_3057" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3066" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3055" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_3051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_3051" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_3059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_3059" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_3061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_3061" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory_3072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory_3072" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_3063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_3063" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_3065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_3065" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_3069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_3069" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingStandardsApplied" xlink:label="loc_gsk_DescriptionOfAccountingStandardsApplied_3049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingStandardsApplied_3049" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_3053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_3053" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_StatementsTable_3047" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3047" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_3044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" xlink:to="loc_ifrs-full_RestatedMember_3044" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_3044_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" xlink:to="loc_ifrs-full_RestatedMember_3044_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_3074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_3074" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_2146644942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_2146644942" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock_2146644944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock_2146644944" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_3113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_3113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTurnoverBySegmentExplanatory" xlink:label="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory_1192288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory_1192288" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_gsk_StatementsTable_3107" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_3104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3107" xlink:to="loc_ifrs-full_SegmentsAxis_3104" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_3105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_3104" xlink:to="loc_ifrs-full_SegmentsMember_3105" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_3105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_3104" xlink:to="loc_ifrs-full_SegmentsMember_3105_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_3105" xlink:to="loc_gsk_CommercialOperationsMember_1701331" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_3114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_3114" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_3112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_3112" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OperatingProfitLineItems" xlink:label="loc_gsk_OperatingProfitLineItems_3128" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_3132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OperatingProfitLineItems_3128" xlink:to="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_3132" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_OperatingProfitLineItems_3128" xlink:to="loc_gsk_StatementsTable_3129" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_3126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3129" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_3126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3126" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3127_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3126" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3127_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_3130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3127" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_3130" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory_3131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OperatingProfitLineItems_3128" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory_3131" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3276" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory_3292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory_3292" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_3281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_3281" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory_3282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory_3282" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory_3290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory_3290" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_3286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_3286" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xlink:label="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory_3285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory_3285" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory_3284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory_3284" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory_3283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory_3283" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_3293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_3293" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xlink:label="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory_3288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory_3288" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory_3287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory_3287" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_3289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_3289" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory_3291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory_3291" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_StatementsTable_3277" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_3274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3277" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_3274" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3274" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3275" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3275_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3274" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3275_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_3278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3275" xlink:to="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_3278" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_3280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3275" xlink:to="loc_gsk_PostretirementBenefitsMember_3280" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3368" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3368" xlink:to="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3373" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3368" xlink:to="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3372" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_3368" xlink:to="loc_gsk_StatementsTable_3369" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_3366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3369" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_3366" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_3366" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_3366" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_3371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_3371" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_3370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" xlink:to="loc_gsk_ViiVHealthCareMember_3370" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_534835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_534835" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_534835" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_534835" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwothousandtwentyoneacquisitionMember" xlink:label="loc_gsk_TwothousandtwentyoneacquisitionMember_1702774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwothousandtwentyoneacquisitionMember_1702774" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyAcquisitionMember_831376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwoThousandTwentyAcquisitionMember_831376" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702775" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702697" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_514743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_514743" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xlink:label="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory_3352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory_3352" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xlink:label="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory_3351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory_3351" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations_1702702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations_1702702" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3390" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_3404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_3404" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_3399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_3399" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory_3397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory_3397" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xlink:label="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock_3406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock_3406" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_StatementsTable_3391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3387" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_3388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3387" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_3388" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_3388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3387" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_3388_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_3395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_3388" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_3395" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:label="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_3396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_3388" xlink:to="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_3396" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_3392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_TypesOfRisksAxis_3392" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_3393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3392" xlink:to="loc_ifrs-full_TypesOfRisksMember_3393" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_3393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3392" xlink:to="loc_ifrs-full_TypesOfRisksMember_3393_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_3412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_3393" xlink:to="loc_ifrs-full_CurrencyRiskMember_3412" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_3411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_3393" xlink:to="loc_ifrs-full_InterestRateRiskMember_3411" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_3394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_3394" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock_1320687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock_1320687" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_1320689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_1320689" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3398" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3409" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory_3403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory_3403" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_3408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_3408" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory_2147449910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory_2147449910" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory_2147449912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory_2147449912" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_3410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_3410" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xlink:label="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency_2147449939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency_2147449939" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory_2146643090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory_2146643090" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PeriodCoveredByFinancialStatements" xlink:label="loc_ifrs-full_PeriodCoveredByFinancialStatements_513761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" xlink:to="loc_ifrs-full_PeriodCoveredByFinancialStatements_513761" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" xlink:to="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_506259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" xlink:to="loc_ifrs-full_RestatedMember_506259" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_506259_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" xlink:to="loc_ifrs-full_RestatedMember_506259_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfEndOfReportingPeriod2022" xlink:label="loc_gsk_DateOfEndOfReportingPeriod2022_534847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" xlink:to="loc_gsk_DateOfEndOfReportingPeriod2022_534847" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfSalesOnCoPromotionalActivities" xlink:label="loc_gsk_CostOfSalesOnCoPromotionalActivities_1223809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_CostOfSalesOnCoPromotionalActivities_1223809" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_237" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1223908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" xlink:to="loc_ifrs-full_CarryingAmountMember_1223908" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1223908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" xlink:to="loc_ifrs-full_CarryingAmountMember_1223908_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBookValueMember" xlink:label="loc_gsk_RemainingBookValueMember_1223909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1223908" xlink:to="loc_gsk_RemainingBookValueMember_1223909" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ERPSoftwareSystemsMember" xlink:label="loc_gsk_ERPSoftwareSystemsMember_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_gsk_ERPSoftwareSystemsMember_240" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesAndFranchisesMember" xlink:label="loc_ifrs-full_LicencesAndFranchisesMember_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_ifrs-full_LicencesAndFranchisesMember_238" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComputerSoftwareMember" xlink:label="loc_gsk_OtherComputerSoftwareMember_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_gsk_OtherComputerSoftwareMember_241" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_1223903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_SegmentsAxis_1223903" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1223904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_1223903" xlink:to="loc_ifrs-full_SegmentsMember_1223904" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1223904_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_1223903" xlink:to="loc_ifrs-full_SegmentsMember_1223904_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_1223910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_1223904" xlink:to="loc_gsk_VaccinesMember_1223910" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_1223905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_1223904" xlink:to="loc_gsk_PharmaceuticalsMember_1223905" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_RangeAxis_234" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_234" xlink:to="loc_ifrs-full_RangesMember_235" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_234" xlink:to="loc_ifrs-full_RangesMember_235_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_235" xlink:to="loc_ifrs-full_BottomOfRangeMember_243" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_235" xlink:to="loc_ifrs-full_TopOfRangeMember_242" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xlink:label="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales_1223807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales_1223807" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromCoPromotionalActivities" xlink:label="loc_gsk_RevenueFromCoPromotionalActivities_2146643019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_RevenueFromCoPromotionalActivities_2146643019" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xlink:label="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments_2146643018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments_2146643018" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisableProportionOverExclusivityPeriod" xlink:label="loc_gsk_AmortisableProportionOverExclusivityPeriod_2146643017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_AmortisableProportionOverExclusivityPeriod_2146643017" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_249_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_249_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndMachineryMember" xlink:label="loc_gsk_PlantAndMachineryMember_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_PlantAndMachineryMember_253" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquipmentAndVehiclesMember" xlink:label="loc_gsk_EquipmentAndVehiclesMember_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_EquipmentAndVehiclesMember_254" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeholdBuildingsMember" xlink:label="loc_gsk_FreeholdBuildingsMember_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_FreeholdBuildingsMember_251" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseholdLandAndBuildingsMember" xlink:label="loc_gsk_LeaseholdLandAndBuildingsMember_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_LeaseholdLandAndBuildingsMember_252" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_250" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalCosts" xlink:label="loc_gsk_LegalCosts_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_LegalCosts_276" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnsDiscountsAndRebates" xlink:label="loc_gsk_CustomerReturnsDiscountsAndRebates_511685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_CustomerReturnsDiscountsAndRebates_511685" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_JointVenturesAxis_267" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_267" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_267" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_265_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_289" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_258" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_258_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_258_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:label="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_513807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_258" xlink:to="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_513807" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_259" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_259" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_259" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" xlink:to="loc_ifrs-full_BusinessCombinationsMember_287" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_268" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_268_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_511672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_gsk_SegmentConsolidationItemAxis_511672" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_511673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SegmentConsolidationItemAxis_511672" xlink:to="loc_gsk_SegmentConsolidationItemMember_511673" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_511673_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SegmentConsolidationItemAxis_511672" xlink:to="loc_gsk_SegmentConsolidationItemMember_511673_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_USPharmaceuticalsAndVaccinesMember" xlink:label="loc_gsk_USPharmaceuticalsAndVaccinesMember_511677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_SegmentConsolidationItemMember_511673" xlink:to="loc_gsk_USPharmaceuticalsAndVaccinesMember_511677" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_2146646297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_2146646297_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SensitivityAnalysisForActuarialAssumptionsMember" xlink:label="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember_2146646298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" xlink:to="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember_2146646298" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateAxis" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xlink:label="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember_2146646302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" xlink:to="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember_2146646302" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateChangeMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateChangeMember_2146646301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateChangeMember_2146646301" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfIncreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfIncreaseInDiscountRate_847135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PercentageOfIncreaseInDiscountRate_847135" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInPlanDeficit" xlink:label="loc_gsk_DecreaseInPlanDeficit_847136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DecreaseInPlanDeficit_847136" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets" xlink:label="loc_ifrs-full_CurrentTaxAssets_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxAssets_273" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_272" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_274" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_279" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInPlanDeficit" xlink:label="loc_gsk_IncreaseInPlanDeficit_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_IncreaseInPlanDeficit_285" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UncertainTaxPositionsRecognised" xlink:label="loc_gsk_UncertainTaxPositionsRecognised_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_UncertainTaxPositionsRecognised_275" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfDecreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfDecreaseInDiscountRate_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PercentageOfDecreaseInDiscountRate_284" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_Revenue_270" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xlink:label="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities_278" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvision" xlink:label="loc_ifrs-full_LegalProceedingsProvision_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_LegalProceedingsProvision_277" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPlanSurplusNet" xlink:label="loc_gsk_DefinedBenefitPlanSurplusNet_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DefinedBenefitPlanSurplusNet_283" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInAnnualPensionCost" xlink:label="loc_gsk_IncreaseInAnnualPensionCost_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_IncreaseInAnnualPensionCost_286" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInAnnualPensionCost" xlink:label="loc_gsk_DecreaseInAnnualPensionCost_847138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DecreaseInAnnualPensionCost_847138" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionSurplus" xlink:label="loc_gsk_PensionSurplus_1306694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PensionSurplus_1306694" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xlink:label="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment_511692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment_511692" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesLineItems" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesTable" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" xlink:to="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" xlink:to="loc_srt_CurrencyAxis_309" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_309" xlink:to="loc_currency_AllCurrenciesDomain_308" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_309" xlink:to="loc_currency_AllCurrenciesDomain_308_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="loc_currency_JPY_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_JPY_314" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_EUR_313" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_USD_312" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_315" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_316" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromChangesToEstimatesOfRARAccruals" xlink:label="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals_330" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_srt_MajorCustomersAxis_323" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="loc_ifrs-full_MajorCustomersMember_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_323" xlink:to="loc_ifrs-full_MajorCustomersMember_324" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="loc_ifrs-full_MajorCustomersMember_324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_323" xlink:to="loc_ifrs-full_MajorCustomersMember_324_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers1Member" xlink:label="loc_gsk_Wholesalers1Member_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers1Member_338" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers2Member" xlink:label="loc_gsk_Wholesalers2Member_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers2Member_339" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers3Member" xlink:label="loc_gsk_Wholesalers3Member_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers3Member_340" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_ifrs-full_SegmentsAxis_325" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_325" xlink:to="loc_ifrs-full_SegmentsMember_326" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_325" xlink:to="loc_ifrs-full_SegmentsMember_326_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViivHealthcareMember" xlink:label="loc_gsk_ShionogiViivHealthcareMember_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_326" xlink:to="loc_gsk_ShionogiViivHealthcareMember_341" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_ifrs-full_GeographicalAreasAxis_321" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_321" xlink:to="loc_ifrs-full_GeographicalAreasMember_322" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_321" xlink:to="loc_ifrs-full_GeographicalAreasMember_322_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_322" xlink:to="loc_country_US_337" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1188675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_dei_LegalEntityAxis_1188675" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1188675" xlink:to="loc_dei_EntityDomain_1188676" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188676_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1188675" xlink:to="loc_dei_EntityDomain_1188676_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerMember" xlink:label="loc_gsk_PfizerMember_1188677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1188676" xlink:to="loc_gsk_PfizerMember_1188677" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfWholesalers" xlink:label="loc_gsk_NumberOfWholesalers_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfWholesalers_332" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_Revenue_333" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_334" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_329" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOption" xlink:label="loc_gsk_PutOption_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_PutOption_335" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_331" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfReportableOperatingSegments" xlink:label="loc_gsk_NumberOfReportableOperatingSegments_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfReportableOperatingSegments_327" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xlink:label="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments_328" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_847129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_847129" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOperatingSegments" xlink:label="loc_gsk_NumberOfOperatingSegments_2146644993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfOperatingSegments_2146644993" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xlink:to="loc_ifrs-full_SegmentsAxis_350" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_350" xlink:to="loc_ifrs-full_SegmentsMember_351" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_351_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_350" xlink:to="loc_ifrs-full_SegmentsMember_351_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_351" xlink:to="loc_gsk_ConsumerHealthcareMember_356" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_351" xlink:to="loc_gsk_CommercialOperationsMember_1701357" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xlink:to="loc_gsk_SegmentConsolidationItemAxis_349" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SegmentConsolidationItemAxis_349" xlink:to="loc_gsk_SegmentConsolidationItemMember_348" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SegmentConsolidationItemAxis_349" xlink:to="loc_gsk_SegmentConsolidationItemMember_348_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" xlink:to="loc_ifrs-full_Revenue_352" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xlink:to="loc_ifrs-full_SegmentsAxis_363" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_363" xlink:to="loc_ifrs-full_SegmentsMember_364" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_363" xlink:to="loc_ifrs-full_SegmentsMember_364_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_364" xlink:to="loc_gsk_ConsumerHealthcareMember_378" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_364" xlink:to="loc_gsk_CommercialOperationsMember_1701362" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_1701367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_VaccinesMember_1701367" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_361" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_361" xlink:to="loc_ifrs-full_ProductsAndServicesMember_362" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_361" xlink:to="loc_ifrs-full_ProductsAndServicesMember_362_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InfluenzaMember" xlink:label="loc_gsk_InfluenzaMember_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_InfluenzaMember_375" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RespiratoryMember" xlink:label="loc_gsk_RespiratoryMember_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_RespiratoryMember_370" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstablishedVaccinesMember" xlink:label="loc_gsk_EstablishedVaccinesMember_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_EstablishedVaccinesMember_377" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HIVMember" xlink:label="loc_gsk_HIVMember_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_HIVMember_371" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShinglesMember" xlink:label="loc_gsk_ShinglesMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_ShinglesMember_376" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisMember" xlink:label="loc_gsk_MeningitisMember_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_MeningitisMember_374" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubTotalMember" xlink:label="loc_gsk_SubTotalMember_832236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_SubTotalMember_832236" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OncologyMember" xlink:label="loc_gsk_OncologyMember_506596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_OncologyMember_506596" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImmunoInflammationRespiratoryAndOtherMember" xlink:label="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember_1701364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember_1701364" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SpecialtyMedicineMember" xlink:label="loc_gsk_SpecialtyMedicineMember_1701365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_SpecialtyMedicineMember_1701365" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicVaccinesMember" xlink:label="loc_gsk_PandemicVaccinesMember_1308314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_PandemicVaccinesMember_1308314" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicMember" xlink:label="loc_gsk_PandemicMember_1308310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_PandemicMember_1308310" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGeneralMedicinesMember" xlink:label="loc_gsk_OtherGeneralMedicinesMember_1701368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_OtherGeneralMedicinesMember_1701368" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GeneralMedicinesMember" xlink:label="loc_gsk_GeneralMedicinesMember_1701369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_GeneralMedicinesMember_1701369" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" xlink:to="loc_ifrs-full_Revenue_365" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_398" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_InvestmentsInJointVenturesAndAssociates_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_InvestmentsInJointVenturesAndAssociates_397" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xlink:label="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_393" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NetAssetsLiabilities_401" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingAssets" xlink:label="loc_gsk_NetOperatingAssets_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_NetOperatingAssets_395" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentReversalsBySegmentAbstract" xlink:label="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_405" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpenseAbstract" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_394" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_ifrs-full_SegmentsAxis_391" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_391" xlink:to="loc_ifrs-full_SegmentsMember_392" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_392_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_391" xlink:to="loc_ifrs-full_SegmentsMember_392_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_ConsumerHealthcareMember_418" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_CommercialOperationsMember_1701355" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_1701356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_ResearchAndDevelopmentMember_1701356" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146645000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146645000" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146645000_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146645000_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_2146643062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContinuingOperationsMember_2146645000" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_2146643062" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_gsk_SegmentConsolidationItemAxis_390" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SegmentConsolidationItemAxis_390" xlink:to="loc_gsk_SegmentConsolidationItemMember_387" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_387_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SegmentConsolidationItemAxis_390" xlink:to="loc_gsk_SegmentConsolidationItemMember_387_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_404" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="loc_ifrs-full_UnallocatedAmountsMember_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_UnallocatedAmountsMember_403" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="loc_ifrs-full_OperatingSegmentsMember_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_OperatingSegmentsMember_402" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_ProfitLossAbstract_389" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_406" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_FinanceCosts_408" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_FinanceIncome_407" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_410" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_413" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociate_409" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_411" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_412" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_400" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentAndDeferredTaxation" xlink:label="loc_gsk_CurrentAndDeferredTaxation_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_CurrentAndDeferredTaxation_399" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-full_NetDebt_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NetDebt_396" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146643064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146643064" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerMember" xlink:label="loc_gsk_CustomerMember_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" xlink:to="loc_gsk_CustomerMember_429" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xlink:to="loc_ifrs-full_GeographicalAreasAxis_425" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_425" xlink:to="loc_ifrs-full_GeographicalAreasMember_426" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_425" xlink:to="loc_ifrs-full_GeographicalAreasMember_426_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_gsk_RestOfWorldMember_432" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_US_431" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_GB_430" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="loc_country_CH_1224021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_CH_1224021" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="loc_country_BE_1224019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_BE_1224019" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_428" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" xlink:to="loc_ifrs-full_Revenue_427" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_454" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_456" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GileadSciencesIncMember" xlink:label="loc_gsk_GileadSciencesIncMember_1703439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" xlink:to="loc_gsk_GileadSciencesIncMember_1703439" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_447" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_447" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_447" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesBusinessAcquisitionMember" xlink:label="loc_gsk_VaccinesBusinessAcquisitionMember_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" xlink:to="loc_gsk_VaccinesBusinessAcquisitionMember_455" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_829229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_829229" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_829230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_829229" xlink:to="loc_ifrs-full_ProductsAndServicesMember_829230" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_829230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_829229" xlink:to="loc_ifrs-full_ProductsAndServicesMember_829230_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_829232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_829230" xlink:to="loc_gsk_HorlicksMember_829232" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_829224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_SegmentsAxis_829224" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_829226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_829224" xlink:to="loc_ifrs-full_SegmentsMember_829226" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_829226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_829224" xlink:to="loc_ifrs-full_SegmentsMember_829226_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_829227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_829226" xlink:to="loc_gsk_ConsumerHealthcareMember_829227" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1188681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_dei_LegalEntityAxis_1188681" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1188681" xlink:to="loc_dei_EntityDomain_1188682" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188682_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1188681" xlink:to="loc_dei_EntityDomain_1188682_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisMember" xlink:label="loc_gsk_NovartisMember_1188683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1188682" xlink:to="loc_gsk_NovartisMember_1188683" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HindustanUnileverLimitedMember" xlink:label="loc_gsk_HindustanUnileverLimitedMember_1188684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1188682" xlink:to="loc_gsk_HindustanUnileverLimitedMember_1188684" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerAxis" xlink:label="loc_gsk_AcquirerAxis_1306995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_gsk_AcquirerAxis_1306995" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerDomain" xlink:label="loc_gsk_AcquirerDomain_1306996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_AcquirerAxis_1306995" xlink:to="loc_gsk_AcquirerDomain_1306996" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerDomain" xlink:label="loc_gsk_AcquirerDomain_1306996_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_AcquirerAxis_1306995" xlink:to="loc_gsk_AcquirerDomain_1306996_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_1703440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_gsk_InvestmentAxis_1703440" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1703441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_InvestmentAxis_1703440" xlink:to="loc_gsk_InvestmentDomain_1703441" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1703441_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_InvestmentAxis_1703440" xlink:to="loc_gsk_InvestmentDomain_1703441_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonPlcMember" xlink:label="loc_gsk_HaleonPlcMember_1703442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_InvestmentDomain_1703441" xlink:to="loc_gsk_HaleonPlcMember_1703442" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfBusinessesAndAssets" xlink:label="loc_gsk_DisposalOfBusinessesAndAssets_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_DisposalOfBusinessesAndAssets_453" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossOnSaleOfBusiness" xlink:label="loc_gsk_LossOnSaleOfBusiness_829223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_LossOnSaleOfBusiness_829223" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontPayment" xlink:label="loc_gsk_UpfrontPayment_1701340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_UpfrontPayment_1701340" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfRoyaltyPayableOnFutureSales" xlink:label="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales_1701341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales_1701341" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xlink:label="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss_1702776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss_1702776" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_829222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_829222" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitLineItems" xlink:label="loc_gsk_DisclosureOfOperatingProfitLineItems_480" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_600700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_600700" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitTable" xlink:label="loc_gsk_DisclosureOfOperatingProfitTable_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_gsk_DisclosureOfOperatingProfitTable_481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xlink:label="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" xlink:to="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember_486" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAuditorsMember" xlink:label="loc_gsk_OtherAuditorsMember_1188685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" xlink:to="loc_gsk_OtherAuditorsMember_1188685" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xlink:label="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember_1306764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" xlink:to="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember_1306764" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_1306789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_gsk_PurposeAxis_1306789" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_1306791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_PurposeAxis_1306789" xlink:to="loc_gsk_PurposeDomain_1306791" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_1306791_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_PurposeAxis_1306789" xlink:to="loc_gsk_PurposeDomain_1306791_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" xlink:label="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember_1306797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_PurposeDomain_1306791" xlink:to="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember_1306797" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseOfRestructuringActivities" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_485" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_484" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_1306781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_1306781" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociates" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociates_1306760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociates_1306760" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationLineItems" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationTable" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" xlink:to="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_491" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_491" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_492" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_491" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_492_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_492" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_502" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" xlink:to="loc_ifrs-full_ParentMember_503" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="loc_ifrs-full_SubsidiariesMember_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" xlink:to="loc_ifrs-full_SubsidiariesMember_504" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="loc_ifrs-full_AuditorsRemunerationAbstract_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" xlink:to="loc_ifrs-full_AuditorsRemunerationAbstract_489" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_496" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices_629585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices_629585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForOtherAssuranceServices_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_gsk_AuditorsRemunerationForOtherAssuranceServices_499" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xlink:label="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xlink:label="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" xlink:to="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_518_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashSettledAndOtherPlansMember" xlink:label="loc_gsk_CashSettledAndOtherPlansMember_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_CashSettledAndOtherPlansMember_524" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionPlanMember" xlink:label="loc_gsk_ShareOptionPlanMember_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_ShareOptionPlanMember_523" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PerformanceSharePlansMember" xlink:label="loc_gsk_PerformanceSharePlansMember_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_PerformanceSharePlansMember_522" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_ShareValuePlanMember_521" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_520" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromContinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations_2146643069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations_2146643069" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations_2146643068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations_2146643068" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_531" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersTable" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" xlink:to="loc_ifrs-full_SegmentsAxis_529" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_529" xlink:to="loc_ifrs-full_SegmentsMember_530" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_529" xlink:to="loc_ifrs-full_SegmentsMember_530_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ManufacturingMember" xlink:label="loc_gsk_ManufacturingMember_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_ManufacturingMember_532" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_ResearchAndDevelopmentMember_534" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrationMember" xlink:label="loc_gsk_SellingGeneralAndAdministrationMember_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_SellingGeneralAndAdministrationMember_533" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetImpairments" xlink:label="loc_gsk_AssetImpairments_588652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_AssetImpairments_588652" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalRestructuringCosts" xlink:label="loc_gsk_TotalRestructuringCosts_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_TotalRestructuringCosts_544" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_512046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_512055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_512055" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_512055" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_512055" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsAxis" xlink:label="loc_gsk_RestructuringCostsAxis_512115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_gsk_RestructuringCostsAxis_512115" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_512116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_RestructuringCostsAxis_512115" xlink:to="loc_gsk_RestructuringCostsDomain_512116" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_512116_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_RestructuringCostsAxis_512115" xlink:to="loc_gsk_RestructuringCostsDomain_512116_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_512049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_512049" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_512049_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_512049_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_512067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_gsk_ArrangementTypeAxis_512067" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_512070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ArrangementTypeAxis_512067" xlink:to="loc_gsk_ArrangementTypeDomain_512070" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_512070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ArrangementTypeAxis_512067" xlink:to="loc_gsk_ArrangementTypeDomain_512070_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SeparationPreparationProgrammeMember" xlink:label="loc_gsk_SeparationPreparationProgrammeMember_588634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ArrangementTypeDomain_512070" xlink:to="loc_gsk_SeparationPreparationProgrammeMember_588634" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCashCredit" xlink:label="loc_gsk_OtherNonCashCredit_588654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_OtherNonCashCredit_588654" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseProvisionReversalRestructuring" xlink:label="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring_588633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring_588633" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts" xlink:label="loc_gsk_RestructuringCosts_860667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_RestructuringCosts_860667" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashRestructuringCharges" xlink:label="loc_gsk_NonCashRestructuringCharges_514004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_NonCashRestructuringCharges_514004" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_506905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_506907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xlink:to="loc_gsk_ArrangementTypeAxis_506907" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_506908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ArrangementTypeAxis_506907" xlink:to="loc_gsk_ArrangementTypeDomain_506908" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_506908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ArrangementTypeAxis_506907" xlink:to="loc_gsk_ArrangementTypeDomain_506908_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegacyProgrammesMember" xlink:label="loc_gsk_LegacyProgrammesMember_1702452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_LegacyProgrammesMember_1702452" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SignificantAcquisitionsMember" xlink:label="loc_gsk_SignificantAcquisitionsMember_2146644852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_SignificantAcquisitionsMember_2146644852" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SeparationPreparationProgrammeMember" xlink:label="loc_gsk_SeparationPreparationProgrammeMember_753263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_SeparationPreparationProgrammeMember_753263" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeAxis" xlink:label="loc_gsk_RestructuringChargesByTypeAxis_506922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xlink:to="loc_gsk_RestructuringChargesByTypeAxis_506922" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeDomain" xlink:label="loc_gsk_RestructuringChargesByTypeDomain_506923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_RestructuringChargesByTypeAxis_506922" xlink:to="loc_gsk_RestructuringChargesByTypeDomain_506923" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeDomain" xlink:label="loc_gsk_RestructuringChargesByTypeDomain_506923_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_RestructuringChargesByTypeAxis_506922" xlink:to="loc_gsk_RestructuringChargesByTypeDomain_506923_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashRestructuringCharges" xlink:label="loc_gsk_CashRestructuringCharges_514003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_CashRestructuringCharges_514003" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts1" xlink:label="loc_gsk_RestructuringCosts1_506932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_RestructuringCosts1_506932" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_gsk_CostChargedToOperatingProfit_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_gsk_CostChargedToOperatingProfit_563" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_560" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentExpenses" xlink:label="loc_gsk_ResearchAndDevelopmentExpenses_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_gsk_ResearchAndDevelopmentExpenses_561" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_ifrs-full_CostOfSales_559" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_556" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsAxis" xlink:label="loc_gsk_RestructuringCostsAxis_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_556" xlink:to="loc_gsk_RestructuringCostsAxis_557" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_RestructuringCostsAxis_557" xlink:to="loc_gsk_RestructuringCostsDomain_558" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_RestructuringCostsAxis_557" xlink:to="loc_gsk_RestructuringCostsDomain_558_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfMajorRestructuringMember" xlink:label="loc_gsk_CostOfMajorRestructuringMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_RestructuringCostsDomain_558" xlink:to="loc_gsk_CostOfMajorRestructuringMember_564" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_572" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseTable" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" xlink:to="loc_ifrs-full_RestatedMember_569" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_569_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" xlink:to="loc_ifrs-full_RestatedMember_569_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_571" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome_1306738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_OtherFinanceIncome_1306738" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_FinanceIncome_578" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xlink:label="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations_573" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xlink:to="loc_ifrs-full_JointVenturesAxis_602" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_602" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_601_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_602" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_601_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesMember" xlink:label="loc_ifrs-full_JointVenturesMember_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" xlink:to="loc_ifrs-full_JointVenturesMember_607" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_600" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_600_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_600" xlink:to="loc_ifrs-full_AssociatesMember_606" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_605" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_615" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SalesToAssociatesAndJointVentures" xlink:label="loc_gsk_SalesToAssociatesAndJointVentures_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_gsk_SalesToAssociatesAndJointVentures_616" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_512234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_512234" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesTable" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_512223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_512223" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_512223_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_512223_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" xlink:to="loc_gsk_InnovivaIncMember_617" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_ProfitLoss_625" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_ComprehensiveIncome_627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_622" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_622_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_622_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_622" xlink:to="loc_gsk_InnovivaIncMember_628" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_Revenue_624" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_633" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_633_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_633_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssociatesMember" xlink:label="loc_gsk_OtherAssociatesMember_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_633" xlink:to="loc_gsk_OtherAssociatesMember_639" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_ProfitLoss_636" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_ComprehensiveIncome_638" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_637" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsLineItems" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxExpensesincomeAbstract" xlink:label="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" xlink:to="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_650" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_648" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_651" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_649" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_647" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsTable" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsTable_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsTable_646" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_646" xlink:to="loc_ifrs-full_GeographicalAreasAxis_643" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_643" xlink:to="loc_ifrs-full_GeographicalAreasMember_644" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_643" xlink:to="loc_ifrs-full_GeographicalAreasMember_644_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_644" xlink:to="loc_country_GB_652" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_644" xlink:to="loc_ifrs-full_ForeignCountriesMember_653" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsLineItems" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProvisionsForUncertainTaxPosition" xlink:label="loc_gsk_ProvisionsForUncertainTaxPosition_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_ProvisionsForUncertainTaxPosition_668" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xlink:label="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses_674" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xlink:label="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided_671" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_669" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsTable" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsTable_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_588910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_588910" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_588910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_588910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalEntity1Axis" xlink:label="loc_gsk_LegalEntity1Axis_588904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_gsk_LegalEntity1Axis_588904" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Entity1Member" xlink:label="loc_gsk_Entity1Member_588905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_LegalEntity1Axis_588904" xlink:to="loc_gsk_Entity1Member_588905" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Entity1Member" xlink:label="loc_gsk_Entity1Member_588905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_LegalEntity1Axis_588904" xlink:to="loc_gsk_Entity1Member_588905_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_GeographicalAreasAxis_657" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_657" xlink:to="loc_ifrs-full_GeographicalAreasMember_658" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_657" xlink:to="loc_ifrs-full_GeographicalAreasMember_658_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_658" xlink:to="loc_country_GB_663" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GbMember" xlink:label="loc_gsk_GbMember_829255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_658" xlink:to="loc_gsk_GbMember_829255" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OverseasMember" xlink:label="loc_gsk_OverseasMember_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" xlink:to="loc_gsk_OverseasMember_662" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_831076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_gsk_EventAxis_831076" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_831078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_EventAxis_831076" xlink:to="loc_gsk_EventDomain_831078" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_831078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_EventAxis_831076" xlink:to="loc_gsk_EventDomain_831078_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInTheHeadlineRateOfTaxMember" xlink:label="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember_1306771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EventDomain_831078" xlink:to="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember_1306771" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReducedTaxRateCancelledMember" xlink:label="loc_gsk_ReducedTaxRateCancelledMember_831079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EventDomain_831078" xlink:to="loc_gsk_ReducedTaxRateCancelledMember_831079" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_588837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_RangeAxis_588837" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_588838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_588837" xlink:to="loc_ifrs-full_RangesMember_588838" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_588838_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_588837" xlink:to="loc_ifrs-full_RangesMember_588838_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_588841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_588838" xlink:to="loc_ifrs-full_BottomOfRangeMember_588841" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedEarnings" xlink:label="loc_gsk_UnremittedEarnings_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_UnremittedEarnings_670" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_588916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_ApplicableTaxRate_588916" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_665" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeadlineUkTaxRateEffective2023" xlink:label="loc_gsk_HeadlineUkTaxRateEffective2023_1316191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_HeadlineUkTaxRateEffective2023_1316191" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2146643283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2146643283" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:label="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" xlink:to="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_734" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_733" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_736" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_735" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_512400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_512400" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xlink:label="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation_589873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation_589873" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xlink:label="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset_2146643273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset_2146643273" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" xlink:to="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_720" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_720" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_721" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_721_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_720" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_721_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_721" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_740" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionAndAwardSchemesMember" xlink:label="loc_gsk_ShareOptionAndAwardSchemesMember_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_gsk_ShareOptionAndAwardSchemesMember_742" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_747" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcceleratedCapitalAllowancesMember" xlink:label="loc_gsk_AcceleratedCapitalAllowancesMember_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_gsk_AcceleratedCapitalAllowancesMember_746" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_748" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointOperationsAxis" xlink:label="loc_ifrs-full_JointOperationsAxis_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_JointOperationsAxis_723" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointOperationsMember" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointOperationsAxis_723" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointOperationsMember" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_722_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointOperationsAxis_723" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_722_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntraGroupProfitMember" xlink:label="loc_gsk_IntraGroupProfitMember_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" xlink:to="loc_gsk_IntraGroupProfitMember_741" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_514499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" xlink:to="loc_ifrs-full_RestatedMember_514499" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_514499_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" xlink:to="loc_ifrs-full_RestatedMember_514499_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_716" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_716_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_716_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationMember" xlink:label="loc_ifrs-full_ContingentConsiderationMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_716" xlink:to="loc_ifrs-full_ContingentConsiderationMember_732" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_718" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_718" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_719" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_719_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_718" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_719_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_719" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_739" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationAxis" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationDomain" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" xlink:to="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationDomain" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationDomain_728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" xlink:to="loc_gsk_TaxReformsPeriodOfApplicationDomain_728_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OriginationAndReversalOfTemporaryDifferencesMember" xlink:label="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" xlink:to="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember_743" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxLosses" xlink:label="loc_gsk_TaxLosses_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_TaxLosses_763" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses_766" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses_764" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" xlink:to="loc_ifrs-full_MaturityAxis_759" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_759" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_756" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_756_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_759" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_756_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xlink:label="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember_760" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_761" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AvailableIndefinitelyMember" xlink:label="loc_gsk_AvailableIndefinitelyMember_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_gsk_AvailableIndefinitelyMember_762" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalLosses" xlink:label="loc_gsk_CapitalLosses_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_CapitalLosses_765" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_2146643083" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_770" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_769" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2146643280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2146643280" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_2146643279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_2146643279" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_2146643278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_2146643278" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_2146643277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_2146643277" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_2146643084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_EarningsPerShareTable_2146643084" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_2146643082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_2146643084" xlink:to="loc_gsk_EventAxis_2146643082" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_EventAxis_2146643082" xlink:to="loc_gsk_EventDomain_2146643081" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_EventAxis_2146643082" xlink:to="loc_gsk_EventDomain_2146643081_default" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_780" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsPaidDate" xlink:label="loc_gsk_DividendsPaidDate_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_gsk_DividendsPaidDate_787" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_788" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_gsk_DisclosureOfDividendsTable_781" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDividendsTable_781" xlink:to="loc_ifrs-full_MaturityAxis_782" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_782" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_779" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_779_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_782" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_779_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SecondInterimMember" xlink:label="loc_gsk_SecondInterimMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_SecondInterimMember_784" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThirdInterimMember" xlink:label="loc_gsk_ThirdInterimMember_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_ThirdInterimMember_785" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FirstInterimMember" xlink:label="loc_gsk_FirstInterimMember_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_FirstInterimMember_783" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourthInterimMember" xlink:label="loc_gsk_FourthInterimMember_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_FourthInterimMember_786" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinaryShares" xlink:label="loc_ifrs-full_DividendsPaidOrdinaryShares_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_ifrs-full_DividendsPaidOrdinaryShares_789" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_1306903" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_1306902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1306903" xlink:to="loc_gsk_DisclosureOfDividendsTable_1306902" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1306907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDividendsTable_1306902" xlink:to="loc_ifrs-full_MaturityAxis_1306907" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1306909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1306907" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1306909" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1306909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1306907" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1306909_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourthInterimMember" xlink:label="loc_gsk_FourthInterimMember_1306913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1306909" xlink:to="loc_gsk_FourthInterimMember_1306913" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionForDividendPayable" xlink:label="loc_gsk_AdditionalProvisionForDividendPayable_1306915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1306903" xlink:to="loc_gsk_AdditionalProvisionForDividendPayable_1306915" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDividendPayables" xlink:label="loc_ifrs-full_CurrentDividendPayables_1306914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1306903" xlink:to="loc_ifrs-full_CurrentDividendPayables_1306914" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_1702393" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_1702390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1702393" xlink:to="loc_gsk_DisclosureOfDividendsTable_1702390" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDividendsTable_1702390" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerOfConsumerHealthcareBusinessMember" xlink:label="loc_gsk_DemergerOfConsumerHealthcareBusinessMember_1702397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" xlink:to="loc_gsk_DemergerOfConsumerHealthcareBusinessMember_1702397" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfAssetdistributedAsDividendInSpecie" xlink:label="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie_1702398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1702393" xlink:to="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie_1702398" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfInterimDividendRecognitonAndPayment" xlink:label="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1702393" xlink:to="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment_792" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_829" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage_840" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_837" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage_839" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_588583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_588583" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" xlink:to="loc_ifrs-full_ComputerSoftwareMember_843" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_832" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_832_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_832_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_MeasurementAxis_831" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_831" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_824" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_824_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_831" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_824_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_ResearchAndDevelopmentMember_834" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_835" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProgrammesMember" xlink:label="loc_gsk_MajorRestructuringProgrammesMember_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_MajorRestructuringProgrammesMember_836" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSalesMember" xlink:label="loc_ifrs-full_CostOfSalesMember_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_ifrs-full_CostOfSalesMember_833" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_815" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment_812" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_810" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_808" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_817" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_809" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_814" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" xlink:to="loc_ifrs-full_CarryingAmountMember_799" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" xlink:to="loc_ifrs-full_CarryingAmountMember_799_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_807" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_806" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_804" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_805" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" xlink:to="loc_ifrs-full_RestatedMember_512816" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" xlink:to="loc_ifrs-full_RestatedMember_512816_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_803_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_803_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyPlantAndEquipmentAndVehiclesMember" xlink:label="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember_820" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="loc_ifrs-full_ConstructionInProgressMember_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_ifrs-full_ConstructionInProgressMember_821" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_ifrs-full_LandAndBuildingsMember_819" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_811" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_813" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_816" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_512807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_512807" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_512861" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetImpairments" xlink:label="loc_gsk_RightOfUseAssetImpairments_589038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetImpairments_589038" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetsExchangeAdjustments" xlink:label="loc_gsk_RightOfUseAssetsExchangeAdjustments_588981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetsExchangeAdjustments_588981" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_512872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_512872" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_588868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_588868" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetDisposal" xlink:label="loc_gsk_RightOfUseAssetDisposal_588999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetDisposal_588999" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_626580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_RightofuseAssets_626580" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xlink:label="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations_2146644856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations_2146644856" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdditionsToRightOfUseAssets" xlink:label="loc_gsk_OtherAdditionsToRightOfUseAssets_2146644857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_OtherAdditionsToRightOfUseAssets_2146644857" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xlink:label="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution_1702427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution_1702427" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_512858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_StatementsTable_512858" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_512858" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1309976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1309976" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_1309972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_ifrs-full_VehiclesMember_1309972" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndEquipmentMember" xlink:label="loc_gsk_PlantAndEquipmentMember_1309975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_gsk_PlantAndEquipmentMember_1309975" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_512858" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2146643072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2146643072" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2146643072_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2146643072_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="loc_ifrs-full_RightofuseAssetsMember_2146643071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2146643072" xlink:to="loc_ifrs-full_RightofuseAssetsMember_2146643071" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_871" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_871" xlink:to="loc_ifrs-full_ProductsAndServicesMember_872" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_872_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_871" xlink:to="loc_ifrs-full_ProductsAndServicesMember_872_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_872" xlink:to="loc_gsk_ConsumerHealthcareMember_877" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xlink:label="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined_873" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_874" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702528" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_854" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xlink:label="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest_1306977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest_1306977" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="loc_ifrs-full_AdditionalRecognitionGoodwill_512926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_AdditionalRecognitionGoodwill_512926" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_Goodwill_853" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" xlink:to="loc_ifrs-full_CarryingAmountMember_849" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_849_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" xlink:to="loc_ifrs-full_CarryingAmountMember_849_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_849" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_852" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702525" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" xlink:to="loc_ifrs-full_SegmentsAxis_861" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_861" xlink:to="loc_ifrs-full_SegmentsMember_862" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_861" xlink:to="loc_ifrs-full_SegmentsMember_862_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_ConsumerHealthcareMember_866" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_2146643271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_CommercialOperationsMember_2146643271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_2146643270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_ResearchAndDevelopmentMember_2146643270" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_PharmaceuticalsMember_864" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_VaccinesMember_865" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" xlink:to="loc_ifrs-full_Goodwill_863" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_882" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_882" xlink:to="loc_ifrs-full_ProductsAndServicesMember_883" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_882" xlink:to="loc_ifrs-full_ProductsAndServicesMember_883_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_ConsumerHealthcareMember_892" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_PharmaceuticalsMember_890" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_VaccinesMember_891" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1702530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_CommercialOperationsMember_1702530" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_2146643263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_ResearchAndDevelopmentMember_2146643263" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:label="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_887" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal_886" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_889" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_888" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections_885" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal_884" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftware" xlink:label="loc_ifrs-full_ComputerSoftware_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_ifrs-full_ComputerSoftware_933" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationAxis" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_MethodsOfGenerationAxis_928" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationMember" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_928" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_929" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationMember" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_929_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_928" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_929_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InternallyGeneratedMember" xlink:label="loc_ifrs-full_InternallyGeneratedMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_929" xlink:to="loc_ifrs-full_InternallyGeneratedMember_937" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaAxis" xlink:label="loc_gsk_BenlystaAxis_1224325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_gsk_BenlystaAxis_1224325" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1225406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_BenlystaAxis_1224325" xlink:to="loc_gsk_BenlystaDomain_1225406" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1225406_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_BenlystaAxis_1224325" xlink:to="loc_gsk_BenlystaDomain_1225406_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1702519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1702519" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1702519" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1702519" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_RangeAxis_930" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_930" xlink:to="loc_ifrs-full_RangesMember_931" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_930" xlink:to="loc_ifrs-full_RangesMember_931_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_932" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged_1315900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged_1315900" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed_1315904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed_1315904" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_914" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_913" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_916" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_908" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_915" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_907" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" xlink:to="loc_ifrs-full_CarryingAmountMember_896" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" xlink:to="loc_ifrs-full_CarryingAmountMember_896_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_905" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_903" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_906" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_904" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" xlink:to="loc_ifrs-full_ComputerSoftwareMember_920" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LicencesAndFranchisesAmortisedBrandsMember" xlink:label="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember_513096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" xlink:to="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember_513096" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BrandsWithIndefiniteUsefulLifeMember" xlink:label="loc_gsk_BrandsWithIndefiniteUsefulLifeMember_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" xlink:to="loc_gsk_BrandsWithIndefiniteUsefulLifeMember_923" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalisedDevelopmentCosts" xlink:label="loc_gsk_CapitalisedDevelopmentCosts_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_CapitalisedDevelopmentCosts_909" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_918" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_513097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_513097" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisationOtherIntangibleAssets" xlink:label="loc_gsk_AmortisationOtherIntangibleAssets_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_AmortisationOtherIntangibleAssets_910" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:label="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_911" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xlink:label="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill_1702499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill_1702499" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_gsk_ResearchAndDevelopmentMember_950" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_949" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSalesMember" xlink:label="loc_ifrs-full_CostOfSalesMember_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_ifrs-full_CostOfSalesMember_948" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_1323994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xlink:to="loc_gsk_SegmentConsolidationItemAxis_1323994" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1323995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1323994" xlink:to="loc_gsk_SegmentConsolidationItemMember_1323995" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1323995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1323994" xlink:to="loc_gsk_SegmentConsolidationItemMember_1323995_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisationOtherIntangibleAssets" xlink:label="loc_gsk_AmortisationOtherIntangibleAssets_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" xlink:to="loc_gsk_AmortisationOtherIntangibleAssets_946" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:label="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" xlink:to="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_947" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesAndFranchisesMember" xlink:label="loc_ifrs-full_LicencesAndFranchisesMember_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" xlink:to="loc_ifrs-full_LicencesAndFranchisesMember_968" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityMember" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" xlink:to="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityMember" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" xlink:to="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OthersProductsMember" xlink:label="loc_gsk_OthersProductsMember_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_OthersProductsMember_967" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OkairosMember" xlink:label="loc_gsk_OkairosMember_847149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_OkairosMember_847149" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroAssetsMember" xlink:label="loc_gsk_TesaroAssetsMember_847146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_TesaroAssetsMember_847146" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LamisilMember" xlink:label="loc_gsk_LamisilMember_827483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_LamisilMember_827483" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DolutegravirMember" xlink:label="loc_gsk_DolutegravirMember_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_DolutegravirMember_961" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BMSAssetsMember" xlink:label="loc_gsk_BMSAssetsMember_624739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_BMSAssetsMember_624739" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelTradeNameMember" xlink:label="loc_gsk_StiefelTradeNameMember_513189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_StiefelTradeNameMember_513189" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaMember" xlink:label="loc_gsk_BenlystaMember_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_BenlystaMember_962" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisPortfolioMember" xlink:label="loc_gsk_MeningitisPortfolioMember_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_MeningitisPortfolioMember_960" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FluarixFlulavalMember" xlink:label="loc_gsk_FluarixFlulavalMember_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_FluarixFlulavalMember_963" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurevacAssetsMember" xlink:label="loc_gsk_CurevacAssetsMember_1307052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_CurevacAssetsMember_1307052" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirAssetsMember" xlink:label="loc_gsk_VirAssetsMember_1307051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_VirAssetsMember_1307051" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxAssetsMember" xlink:label="loc_gsk_AffinivaxAssetsMember_1702486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_AffinivaxAssetsMember_1702486" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MomelotinibMember" xlink:label="loc_gsk_MomelotinibMember_1702487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_MomelotinibMember_1702487" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShingrixMember" xlink:label="loc_gsk_ShingrixMember_2146643092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_ShingrixMember_2146643092" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SperoMember" xlink:label="loc_gsk_SperoMember_2146643091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_SperoMember_2146643091" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaAxis" xlink:label="loc_gsk_BenlystaAxis_1224820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_gsk_BenlystaAxis_1224820" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1224821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_BenlystaAxis_1224820" xlink:to="loc_gsk_BenlystaDomain_1224821" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1224821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_BenlystaAxis_1224820" xlink:to="loc_gsk_BenlystaDomain_1224821_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IteosMember" xlink:label="loc_gsk_IteosMember_1224300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_BenlystaDomain_1224821" xlink:to="loc_gsk_IteosMember_1224300" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AlectorMember" xlink:label="loc_gsk_AlectorMember_1224302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_BenlystaDomain_1224821" xlink:to="loc_gsk_AlectorMember_1224302" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_959" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_1224499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_1224499" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" xlink:to="loc_gsk_InnovivaIncMember_1019" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociate" xlink:label="loc_gsk_DisposalOfInterestInAssociate_1224394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_gsk_DisposalOfInterestInAssociate_1224394" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:label="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_1224480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_1224480" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_1014" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RecyclingOfExchangeDifferencesInAssociate" xlink:label="loc_gsk_RecyclingOfExchangeDifferencesInAssociate_1224485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_gsk_RecyclingOfExchangeDifferencesInAssociate_1224485" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" xlink:to="loc_ifrs-full_AssociatesMember_1006" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xlink:to="loc_ifrs-full_JointVenturesAxis_996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_996" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_996" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_994_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesMember" xlink:label="loc_ifrs-full_JointVenturesMember_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" xlink:to="loc_ifrs-full_JointVenturesMember_1005" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInAssociatesAndJointVentures" xlink:label="loc_gsk_DisposalsInAssociatesAndJointVentures_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_DisposalsInAssociatesAndJointVentures_1000" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_997" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_1003" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures_829266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures_829266" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures_999" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures_1001" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xlink:label="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries_1307077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries_1307077" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_998" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146644904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146644904" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146644904_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146644904_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMember_2146644905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2146644904" xlink:to="loc_gsk_CurrentEquityInvestmentsMember_2146644905" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146644908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" xlink:to="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146644908" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644909" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementAssets_2146644911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_PurchasesFairValueMeasurementAssets_2146644911" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146644912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146644912" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_2146643051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_2146643051" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_2146644922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_gsk_InvestmentAxis_2146644922" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_2146644923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_InvestmentAxis_2146644922" xlink:to="loc_gsk_InvestmentDomain_2146644923" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_2146644923_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_InvestmentAxis_2146644922" xlink:to="loc_gsk_InvestmentDomain_2146644923_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentInHaleonPlcMember" xlink:label="loc_gsk_InvestmentInHaleonPlcMember_2147450176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_InvestmentDomain_2146644923" xlink:to="loc_gsk_InvestmentInHaleonPlcMember_2147450176" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_2146644926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_srt_OwnershipAxis_2146644926" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146644927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_2146644926" xlink:to="loc_srt_OwnershipDomain_2146644927" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146644927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_2146644926" xlink:to="loc_srt_OwnershipDomain_2146644927_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoGroupLimitedMember" xlink:label="loc_gsk_GlaxoGroupLimitedMember_2146644928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_GlaxoGroupLimitedMember_2146644928" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScottishLimitedPartnershipsMember" xlink:label="loc_gsk_ScottishLimitedPartnershipsMember_2146644929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_ScottishLimitedPartnershipsMember_2146644929" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustsMember" xlink:label="loc_gsk_EsopTrustsMember_2146644930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_EsopTrustsMember_2146644930" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146643213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" xlink:to="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146643213" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146643217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146643217" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146643217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146643217_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMember_2146643216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2146643217" xlink:to="loc_gsk_CurrentEquityInvestmentsMember_2146643216" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnership" xlink:label="loc_gsk_PercentageOfOwnership_2146644932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_PercentageOfOwnership_2146644932" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146643212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146643212" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xlink:label="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets_2146643048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets_2146643048" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueGainThroughProfitOrLoss" xlink:label="loc_gsk_FairValueGainThroughProfitOrLoss_2146643047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_FairValueGainThroughProfitOrLoss_2146643047" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsLineItems" xlink:label="loc_gsk_OtherInvestmentsLineItems_1060" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_1072" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ListedInvestments" xlink:label="loc_gsk_ListedInvestments_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_ListedInvestments_1068" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentFairValue" xlink:label="loc_gsk_InvestmentFairValue_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_InvestmentFairValue_1070" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForForeignExchangeOtherInvestments" xlink:label="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments_626928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments_626928" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsTable" xlink:label="loc_gsk_OtherInvestmentsTable_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_OtherInvestmentsTable_1061" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" xlink:to="loc_ifrs-full_FinancialAssetsMember_1059" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1059_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" xlink:to="loc_ifrs-full_FinancialAssetsMember_1059_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1059" xlink:to="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1066" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1059" xlink:to="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1067" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_626935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_626935" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_626935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_626935_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirBiotechnologyIncMember" xlink:label="loc_gsk_VirBiotechnologyIncMember_1309704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_VirBiotechnologyIncMember_1309704" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NimbusTherapeuticsLLCMember" xlink:label="loc_gsk_NimbusTherapeuticsLLCMember_2146643209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_NimbusTherapeuticsLLCMember_2146643209" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CureVacNVMember" xlink:label="loc_gsk_CureVacNVMember_2146643166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_CureVacNVMember_2146643166" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_847240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_MaturityAxis_847240" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_847241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_847240" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_847241" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_847241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_847240" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_847241_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_1702455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CounterpartiesAxis_1702455" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_1702456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_1702455" xlink:to="loc_ifrs-full_CounterpartiesMember_1702456" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_1702456_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_1702455" xlink:to="loc_ifrs-full_CounterpartiesMember_1702456_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_1071" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsLineItems" xlink:label="loc_gsk_OtherInvestmentsLineItems_1041" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsOtherInvestments" xlink:label="loc_gsk_DisposalsAndSettlementsOtherInvestments_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_DisposalsAndSettlementsOtherInvestments_1051" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xlink:label="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome_1048" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsTable" xlink:label="loc_gsk_OtherInvestmentsTable_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_OtherInvestmentsTable_1042" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1042" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1040" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1040_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1040_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1040" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1043" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1040" xlink:to="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1044" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1702428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_OtherInvestmentsTable_1042" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1702428" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1702429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1702428" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1702429" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1702429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1702428" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1702429_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsNoncurrentMember" xlink:label="loc_gsk_OtherInvestmentsNoncurrentMember_1702430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1702429" xlink:to="loc_gsk_OtherInvestmentsNoncurrentMember_1702430" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1045" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments_1049" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToOtherInvestments" xlink:label="loc_gsk_AdditionsToOtherInvestments_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_AdditionsToOtherInvestments_1047" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments_2146643055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments_2146643055" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:label="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNoncurrentAssetsTable" xlink:label="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" xlink:to="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentReceivablesMember" xlink:label="loc_gsk_OtherNonCurrentReceivablesMember_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" xlink:to="loc_gsk_OtherNonCurrentReceivablesMember_1093" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1092" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1092_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBalanceMember" xlink:label="loc_gsk_RemainingBalanceMember_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1092" xlink:to="loc_gsk_RemainingBalanceMember_1097" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1092" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1096" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" xlink:to="loc_ifrs-full_FinancialAssets_1095" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="loc_ifrs-full_OtherNoncurrentReceivables_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" xlink:to="loc_ifrs-full_OtherNoncurrentReceivables_1094" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xlink:label="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount_1132" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" xlink:to="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" xlink:to="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsCreditimpairedMember" xlink:label="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" xlink:to="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember_1126" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1124" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1124_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1124_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1124" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1134" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1133" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" xlink:to="loc_ifrs-full_TradeReceivablesMember_1125" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherReceivableMember" xlink:label="loc_gsk_OtherReceivableMember_1191803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" xlink:to="loc_gsk_OtherReceivableMember_1191803" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2146644873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_SegmentsAxis_2146644873" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2146644874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_2146644873" xlink:to="loc_ifrs-full_SegmentsMember_2146644874" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2146644874_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_2146644873" xlink:to="loc_ifrs-full_SegmentsMember_2146644874_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xlink:label="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired_1130" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_1129" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_FinancialAssets_1131" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_OtherReceivables_1128" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_TradeReceivables_1127" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xlink:label="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance_1146" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowance" xlink:label="loc_gsk_ExpectedCreditLossAllowance_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowance_1143" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xlink:label="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance_1145" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" xlink:to="loc_ifrs-full_RestatedMember_1140" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_1140_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" xlink:to="loc_ifrs-full_RestatedMember_1140_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceUtilised" xlink:label="loc_gsk_ExpectedCreditLossAllowanceUtilised_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceUtilised_1147" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xlink:label="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments_1144" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xlink:label="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale_2146643165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale_2146643165" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsLineItems" xlink:label="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xlink:label="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer_2146644883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" xlink:to="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer_2146644883" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xlink:label="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" xlink:to="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup_1158" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsTable" xlink:label="loc_gsk_CashAndCashEquivalentsTable_2146644884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" xlink:to="loc_gsk_CashAndCashEquivalentsTable_2146644884" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_CashAndCashEquivalentsTable_2146644884" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_2146644888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_2146644888" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xlink:label="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2146644891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" xlink:to="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2146644891" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2147451068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_SegmentsAxis_2147451068" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2147451069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_2147451068" xlink:to="loc_ifrs-full_SegmentsMember_2147451069" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2147451069_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_2147451068" xlink:to="loc_ifrs-full_SegmentsMember_2147451069_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_2147451071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_2147451069" xlink:to="loc_gsk_ConsumerHealthcareMember_2147451071" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleLineItems" xlink:label="loc_gsk_AssetsHeldForSaleLineItems_1163" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_1172" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssetsNet" xlink:label="loc_gsk_OtherAssetsNet_2146643150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_gsk_OtherAssetsNet_2146643150" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1166" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleTable" xlink:label="loc_gsk_AssetsHeldForSaleTable_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_gsk_AssetsHeldForSaleTable_1164" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_AssetsHeldForSaleTable_1164" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_1165" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1204_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:label="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" xlink:to="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_1215" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_gsk_SegmentConsolidationItemAxis_1211" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1211" xlink:to="loc_gsk_SegmentConsolidationItemMember_1209" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1211" xlink:to="loc_gsk_SegmentConsolidationItemMember_1209_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_USPharmaceuticalsAndVaccinesMember" xlink:label="loc_gsk_USPharmaceuticalsAndVaccinesMember_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_SegmentConsolidationItemMember_1209" xlink:to="loc_gsk_USPharmaceuticalsAndVaccinesMember_1217" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_srt_StatementGeographicalAxis_1213" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1213" xlink:to="loc_srt_SegmentGeographicalDomain_1212" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1213" xlink:to="loc_srt_SegmentGeographicalDomain_1212_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1216" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_gsk_CustomerReturnAndRebateAccruals_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_gsk_CustomerReturnAndRebateAccruals_1218" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_ifrs-full_RevenueAndOperatingIncome_1220" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1214" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost_2147457482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost_2147457482" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WagesAndSalariesPayable" xlink:label="loc_gsk_WagesAndSalariesPayable_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_WagesAndSalariesPayable_1191" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_gsk_CustomerReturnAndRebateAccruals_1196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_CustomerReturnAndRebateAccruals_1196" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOptionPayable" xlink:label="loc_gsk_PutOptionPayable_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_PutOptionPayable_1193" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" xlink:to="loc_ifrs-full_SegmentsAxis_1188" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_1188" xlink:to="loc_ifrs-full_SegmentsMember_1189" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_1188" xlink:to="loc_ifrs-full_SegmentsMember_1189_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1192" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1190" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAccruals" xlink:label="loc_gsk_OtherAccruals_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_OtherAccruals_1197" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_OtherCurrentPayables_1194" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1198" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_ContractLiabilities_1195" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInFinancialLiability" xlink:label="loc_gsk_IncreaseDecreaseInFinancialLiability_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_gsk_IncreaseDecreaseInFinancialLiability_1229" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1225" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1225" xlink:to="loc_ifrs-full_TypesOfRisksMember_1226" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1225" xlink:to="loc_ifrs-full_TypesOfRisksMember_1226_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_1236" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_1234" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_1233" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_1235" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_1231" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_1232" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_1307434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_1307434" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644997" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644998" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645008" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember_2146645015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember_2146645015" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember_2146645018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember_2146645018" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645005" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645007" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645003" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesMember" xlink:label="loc_ifrs-full_ValuationTechniquesMember_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" xlink:to="loc_ifrs-full_ValuationTechniquesMember_1227" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesMember" xlink:label="loc_ifrs-full_ValuationTechniquesMember_1227_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" xlink:to="loc_ifrs-full_ValuationTechniquesMember_1227_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_1307441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_1307441" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_1307432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_1307432" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtLineItems" xlink:label="loc_gsk_DisclosureOfDebtLineItems_1629" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xlink:label="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments_1648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments_1648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnCashAndCashEquivalents" xlink:label="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents_1650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents_1650" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateNotesIssued" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued_1665" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestments" xlink:label="loc_gsk_LiquidInvestments_1649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_LiquidInvestments_1649" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings_1664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_LongtermBorrowings_1664" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateShortTerm" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm_1662" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryInterestAtEffectiveRates" xlink:label="loc_gsk_CarryInterestAtEffectiveRates_1666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CarryInterestAtEffectiveRates_1666" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtTable" xlink:label="loc_gsk_DisclosureOfDebtTable_1630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_DisclosureOfDebtTable_1630" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1623" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1624" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1624_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaper1Member" xlink:label="loc_gsk_CommercialPaper1Member_1643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_CommercialPaper1Member_1643" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LetterOfCredit1Member" xlink:label="loc_gsk_LetterOfCredit1Member_1644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_LetterOfCredit1Member_1644" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643135" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonInterestBearingMember" xlink:label="loc_gsk_NonInterestBearingMember_1191874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_NonInterestBearingMember_1191874" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643134" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643133" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643132" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_2146643131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_2146643131" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_2146643130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_2146643130" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:label="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_2146643129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_2146643129" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_1639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_1639" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_1635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_1639" xlink:to="loc_ifrs-full_InterestRateTypesMember_1635" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_1635_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_1639" xlink:to="loc_ifrs-full_InterestRateTypesMember_1635_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_1674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_1635" xlink:to="loc_ifrs-full_FloatingInterestRateMember_1674" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FixedInterestRateMember" xlink:label="loc_ifrs-full_FixedInterestRateMember_1675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_1635" xlink:to="loc_ifrs-full_FixedInterestRateMember_1675" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_MaturityAxis_1636" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1636" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1622" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1622_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1636" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1622_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1640" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermNotesMember" xlink:label="loc_gsk_ShortTermNotesMember_2146646183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_gsk_ShortTermNotesMember_2146646183" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643123" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2146643119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2146643119" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1307524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1307524" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1307524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1307524_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCommercialPaperProgramMember" xlink:label="loc_gsk_UsCommercialPaperProgramMember_1647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" xlink:to="loc_gsk_UsCommercialPaperProgramMember_1647" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgramMember" xlink:label="loc_gsk_EuroCommercialPaperProgramMember_847236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" xlink:to="loc_gsk_EuroCommercialPaperProgramMember_847236" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1633" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1633" xlink:to="loc_ifrs-full_GeographicalAreasMember_1634" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1634_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1633" xlink:to="loc_ifrs-full_GeographicalAreasMember_1634_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_RangeAxis_1637" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_1637" xlink:to="loc_ifrs-full_RangesMember_1638" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_1637" xlink:to="loc_ifrs-full_RangesMember_1638_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_1638" xlink:to="loc_ifrs-full_BottomOfRangeMember_1676" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_1677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_1638" xlink:to="loc_ifrs-full_TopOfRangeMember_1677" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1625" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1625" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1625" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_2146643122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_gsk_PurposeAxis_2146643122" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_PurposeAxis_2146643122" xlink:to="loc_gsk_PurposeDomain_2146643121" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643121_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_PurposeAxis_2146643122" xlink:to="loc_gsk_PurposeDomain_2146643121_default" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:label="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_PurposeDomain_2146643121" xlink:to="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643120" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2146643127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2146643127" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2146643126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2146643127" xlink:to="loc_ifrs-full_TypesOfRisksMember_2146643126" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2146643126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2146643127" xlink:to="loc_ifrs-full_TypesOfRisksMember_2146643126_default" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_2146643125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2146643126" xlink:to="loc_ifrs-full_LiquidityRiskMember_2146643125" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperAuthorized" xlink:label="loc_gsk_CommercialPaperAuthorized_1653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CommercialPaperAuthorized_1653" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_1654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_CommercialPapersIssued_1654" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xlink:label="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts_1660" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RepaymentYear" xlink:label="loc_gsk_RepaymentYear_1667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_RepaymentYear_1667" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnBorrowings" xlink:label="loc_gsk_WeightedAverageInterestRateOnBorrowings_1659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_WeightedAverageInterestRateOnBorrowings_1659" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PledgedInvestments" xlink:label="loc_gsk_PledgedInvestments_1668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_PledgedInvestments_1668" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate_2146643137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_BorrowingsInterestRate_2146643137" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2146643136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_NotionalAmount_2146643136" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_534851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_CashAndCashEquivalents_534851" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_2146643128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_2146643128" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:label="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643009" use="optional" order="74" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtLineItems" xlink:label="loc_gsk_DisclosureOfDebtLineItems_1572" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_Borrowings_1582" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsAbstract" xlink:label="loc_ifrs-full_BorrowingsAbstract_1566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_BorrowingsAbstract_1566" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_1577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_CommercialPapersIssued_1577" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansoverdraftsAndOther" xlink:label="loc_gsk_BankLoansoverdraftsAndOther_1578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_gsk_BankLoansoverdraftsAndOther_1578" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-full_ShorttermBorrowings_1581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_ShorttermBorrowings_1581" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_513126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_513126" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_1571" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1613" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_ifrs-full_CurrentAssets_1615" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCurrent" xlink:label="loc_gsk_LiquidInvestmentsCurrent_1612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_gsk_LiquidInvestmentsCurrent_1612" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtTable" xlink:label="loc_gsk_DisclosureOfDebtTable_1573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_gsk_DisclosureOfDebtTable_1573" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1567" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1567" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1568" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1568_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1567" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1568_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xlink:label="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember_1607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember_1607" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_1606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_1606" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:label="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_1608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_1608" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember_1605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember_1605" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember_1596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember_1596" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xlink:label="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember_1601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember_1601" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xlink:label="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember_1603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember_1603" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLongtermBorrowingsMember" xlink:label="loc_gsk_OtherLongtermBorrowingsMember_1610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OtherLongtermBorrowingsMember_1610" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember_1594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember_1594" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember_1593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember_1593" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1592" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_1598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_1598" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_1602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_1602" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember_1600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember_1600" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember_1597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember_1597" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember_1604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember_1604" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember_1599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember_1599" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_1590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_1590" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember_588937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember_588937" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember_588935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember_588935" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xlink:label="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember_588936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember_588936" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember_1595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember_1595" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1591" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember_829656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember_829656" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_588933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_588933" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember_829660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember_829660" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember_831234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember_831234" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember_829658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember_829658" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643145" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643144" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643143" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643142" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643141" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xlink:label="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember_2146643140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember_2146643140" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt1Member" xlink:label="loc_gsk_Debt1Member_1611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" xlink:to="loc_gsk_Debt1Member_1611" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis_1574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_dei_EntityListingsExchangeAxis_1574" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain_1575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_1574" xlink:to="loc_dei_ExchangeDomain_1575" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain_1575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_1574" xlink:to="loc_dei_ExchangeDomain_1575_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LondonStockExchangeMember" xlink:label="loc_gsk_LondonStockExchangeMember_1617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_1575" xlink:to="loc_gsk_LondonStockExchangeMember_1617" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NewYorkStockExchangeMember" xlink:label="loc_gsk_NewYorkStockExchangeMember_1616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_1575" xlink:to="loc_gsk_NewYorkStockExchangeMember_1616" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongtermBorrowingsAbstract" xlink:label="loc_gsk_LongtermBorrowingsAbstract_1223885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_gsk_LongtermBorrowingsAbstract_1223885" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_1618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_LongtermBorrowingsAbstract_1223885" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_1618" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings_1619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_LongtermBorrowingsAbstract_1223885" xlink:to="loc_ifrs-full_LongtermBorrowings_1619" use="optional" order="60" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseLiability" xlink:label="loc_gsk_FinanceLeaseLiability_1692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" xlink:to="loc_gsk_FinanceLeaseLiability_1692" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseObligationsGross" xlink:label="loc_gsk_FinanceLeaseObligationsGross_1690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" xlink:to="loc_gsk_FinanceLeaseObligationsGross_1690" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" xlink:to="loc_ifrs-full_MaturityAxis_1683" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1683" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1680" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1680_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1683" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1680_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1687" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_1684" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1689" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1688" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1685" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1686" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedContributionPlans" xlink:label="loc_gsk_DisclosureOfDefinedContributionPlans_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_DisclosureOfDefinedContributionPlans_1253" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1240" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1241" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1241_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitSchemesMember" xlink:label="loc_gsk_DefinedBenefitSchemesMember_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedBenefitSchemesMember_1251" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherOverseasPensionPlansMember" xlink:label="loc_gsk_OtherOverseasPensionPlansMember_1246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_OtherOverseasPensionPlansMember_1246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedContributionPensionSchemeMember" xlink:label="loc_gsk_DefinedContributionPensionSchemeMember_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedContributionPensionSchemeMember_1252" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember_534895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember_534895" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedPostRetirementPensionPlansMember" xlink:label="loc_gsk_UnfundedPostRetirementPensionPlansMember_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UnfundedPostRetirementPensionPlansMember_1247" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_1250" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FundedDefinedBenefitPensionPlansMember" xlink:label="loc_gsk_FundedDefinedBenefitPensionPlansMember_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_FundedDefinedBenefitPensionPlansMember_1248" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember_534890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember_534890" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedDefinedBenefitPensionPlanMember" xlink:label="loc_gsk_UnfundedDefinedBenefitPensionPlanMember_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UnfundedDefinedBenefitPensionPlanMember_1249" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_1254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_CostOfSales_1254" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1257" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_1256" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xlink:label="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed_1259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed_1259" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpensePlans" xlink:label="loc_gsk_PostemploymentBenefitExpensePlans_1258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_PostemploymentBenefitExpensePlans_1258" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1255" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsIncludedInPastServiceCosts" xlink:label="loc_gsk_AugmentationCostsIncludedInPastServiceCosts_1280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AugmentationCostsIncludedInPastServiceCosts_1280" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1262" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1262" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1263" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1263_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1262" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1263_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_1272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1263" xlink:to="loc_ifrs-full_OtherAssetsMember_1272" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1264" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1264" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1265" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1264" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1265_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_PostretirementBenefitsMember_1275" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1274" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCashBalancePensionPlanMember" xlink:label="loc_gsk_UsCashBalancePensionPlanMember_832149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_UsCashBalancePensionPlanMember_832149" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitPlansMember" xlink:label="loc_gsk_UkDefinedBenefitPlansMember_846655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_UkDefinedBenefitPlansMember_846655" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetireeHealthcarePlansMember" xlink:label="loc_gsk_RetireeHealthcarePlansMember_832150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_RetireeHealthcarePlansMember_832150" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1273" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1268" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1268" xlink:to="loc_ifrs-full_GeographicalAreasMember_1269" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1269_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1268" xlink:to="loc_ifrs-full_GeographicalAreasMember_1269_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1269" xlink:to="loc_country_GB_1288" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1269" xlink:to="loc_country_US_1289" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1271" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1271_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandThirtyOneAndThereafterMember" xlink:label="loc_gsk_TwoThousandThirtyOneAndThereafterMember_2146643093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_1271" xlink:to="loc_gsk_TwoThousandThirtyOneAndThereafterMember_2146643093" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeAxis" xlink:label="loc_gsk_AgreementTypeAxis_2146645117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_AgreementTypeAxis_2146645117" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeMember" xlink:label="loc_gsk_AgreementTypeMember_2146645118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_AgreementTypeAxis_2146645117" xlink:to="loc_gsk_AgreementTypeMember_2146645118" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeMember" xlink:label="loc_gsk_AgreementTypeMember_2146645118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_AgreementTypeAxis_2146645117" xlink:to="loc_gsk_AgreementTypeMember_2146645118_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SlpPartnershipAgreementMember" xlink:label="loc_gsk_SlpPartnershipAgreementMember_2146645119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_AgreementTypeMember_2146645118" xlink:to="loc_gsk_SlpPartnershipAgreementMember_2146645119" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKLPLtdMember" xlink:label="loc_gsk_GSKLPLtdMember_2147451140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" xlink:to="loc_gsk_GSKLPLtdMember_2147451140" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember_2146643111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" xlink:to="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember_2146643111" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeAxis" xlink:label="loc_gsk_SchemeAxis_2146643101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_SchemeAxis_2146643101" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeMember" xlink:label="loc_gsk_SchemeMember_2146643100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_SchemeAxis_2146643101" xlink:to="loc_gsk_SchemeMember_2146643100" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeMember" xlink:label="loc_gsk_SchemeMember_2146643100_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_SchemeAxis_2146643101" xlink:to="loc_gsk_SchemeMember_2146643100_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeAxis" xlink:label="loc_gsk_TransfereeAxis_2146643110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_TransfereeAxis_2146643110" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeMember" xlink:label="loc_gsk_TransfereeMember_2146643109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_TransfereeAxis_2146643110" xlink:to="loc_gsk_TransfereeMember_2146643109" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeMember" xlink:label="loc_gsk_TransfereeMember_2146643109_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_TransfereeAxis_2146643110" xlink:to="loc_gsk_TransfereeMember_2146643109_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SLPPartneshipsMember" xlink:label="loc_gsk_SLPPartneshipsMember_2146643108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_TransfereeMember_2146643109" xlink:to="loc_gsk_SLPPartneshipsMember_2146643108" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockAxis" xlink:label="loc_gsk_ClassOfCommonStockAxis_2146643107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_ClassOfCommonStockAxis_2146643107" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockMember" xlink:label="loc_gsk_ClassOfCommonStockMember_2146643106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ClassOfCommonStockAxis_2146643107" xlink:to="loc_gsk_ClassOfCommonStockMember_2146643106" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockMember" xlink:label="loc_gsk_ClassOfCommonStockMember_2146643106_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ClassOfCommonStockAxis_2146643107" xlink:to="loc_gsk_ClassOfCommonStockMember_2146643106_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_2146643104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_srt_OwnershipAxis_2146643104" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146643103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_2146643104" xlink:to="loc_srt_OwnershipDomain_2146643103" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146643103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_2146643104" xlink:to="loc_srt_OwnershipDomain_2146643103_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonMember" xlink:label="loc_gsk_HaleonMember_2146643102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2146643103" xlink:to="loc_gsk_HaleonMember_2146643102" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsFromRestructuringProgrammes" xlink:label="loc_gsk_AugmentationCostsFromRestructuringProgrammes_1281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AugmentationCostsFromRestructuringProgrammes_1281" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1287" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_601244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_601244" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1283" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_1285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_1285" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation_1286" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xlink:label="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage_1276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage_1276" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToLiabilityMatchingAssets" xlink:label="loc_gsk_AllocationToLiabilityMatchingAssets_1278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AllocationToLiabilityMatchingAssets_1278" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets_1282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets_1282" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_832159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_832159" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToReturnSeekingAssets" xlink:label="loc_gsk_AllocationToReturnSeekingAssets_1277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AllocationToReturnSeekingAssets_1277" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="loc_ifrs-full_SurplusDeficitInPlan_832156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_SurplusDeficitInPlan_832156" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalValueOfTheInsuranceContract" xlink:label="loc_gsk_TotalValueOfTheInsuranceContract_601239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_TotalValueOfTheInsuranceContract_601239" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationAtPastServiceCost" xlink:label="loc_gsk_DefinedBenefitObligationAtPastServiceCost_832161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_DefinedBenefitObligationAtPastServiceCost_832161" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xlink:label="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished_858149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished_858149" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_2146645112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_2146645112" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2146645116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2146645116" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset_2146645114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset_2146645114" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xlink:label="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer_2146643147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer_2146643147" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xlink:label="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee_2146643146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee_2146643146" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_2146643117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_2146643117" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingAmountDueToBeContributed" xlink:label="loc_gsk_RemainingAmountDueToBeContributed_2146643116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_RemainingAmountDueToBeContributed_2146643116" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VoluntaryCashContributionsMadeToThePlan" xlink:label="loc_gsk_VoluntaryCashContributionsMadeToThePlan_2146643115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_VoluntaryCashContributionsMadeToThePlan_2146643115" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionDueToBePaid" xlink:label="loc_gsk_AdditionalContributionDueToBePaid_2146643114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AdditionalContributionDueToBePaid_2146643114" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xlink:label="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes_2146643148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes_2146643148" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumProceedsThresholdAmount" xlink:label="loc_gsk_MaximumProceedsThresholdAmount_2146643118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MaximumProceedsThresholdAmount_2146643118" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xlink:label="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships_2146645110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships_2146645110" use="optional" order="77" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FemalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty_1302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" xlink:to="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty_1302" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xlink:to="loc_ifrs-full_MaturityAxis_1298" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1298" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1293" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1298" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1293_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentPeriodMember" xlink:label="loc_gsk_CurrentPeriodMember_1299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1293" xlink:to="loc_gsk_CurrentPeriodMember_1299" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProjectedPeriodMember" xlink:label="loc_gsk_ProjectedPeriodMember_1300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1293" xlink:to="loc_gsk_ProjectedPeriodMember_1300" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1296" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1296" xlink:to="loc_ifrs-full_GeographicalAreasMember_1297" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1296" xlink:to="loc_ifrs-full_GeographicalAreasMember_1297_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1297" xlink:to="loc_country_GB_1303" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1297" xlink:to="loc_country_US_1304" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" xlink:to="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty_1301" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_1313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_1313" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfCashBalanceCreditRate" xlink:label="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate_1314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate_1314" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1312" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_1311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_1311" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_1315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_1315" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1309" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1309" xlink:to="loc_ifrs-full_GeographicalAreasMember_1310" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1309" xlink:to="loc_ifrs-full_GeographicalAreasMember_1310_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_country_US_1317" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_gsk_RestOfWorldMember_1318" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_country_GB_1316" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1331" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1321" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1321" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1322" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1321" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1322_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1322" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1329" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1322" xlink:to="loc_gsk_PostretirementBenefitsMember_1330" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1325" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1325" xlink:to="loc_ifrs-full_GeographicalAreasMember_1326" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1325" xlink:to="loc_ifrs-full_GeographicalAreasMember_1326_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_country_US_1339" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_country_GB_1338" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_gsk_RestOfWorldMember_1340" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember_2146642977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" xlink:to="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember_2146642977" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1337" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1334" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1333" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1332" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1335" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xlink:label="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits_1336" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1355" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1346" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1346" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1347" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1346" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1347_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1347" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1353" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1347" xlink:to="loc_gsk_PostretirementBenefitsMember_1354" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1345_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1345_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_1350" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1352" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_1357" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1358" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed_1376" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1382" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MultiAssetFunds" xlink:label="loc_gsk_MultiAssetFunds_1373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_MultiAssetFunds_1373" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_1381" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets_1379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets_1379" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted_1372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted_1372" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1362_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1370" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_1369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_1369" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupMember" xlink:label="loc_gsk_GroupMember_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" xlink:to="loc_gsk_GroupMember_1385" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1367" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1367" xlink:to="loc_ifrs-full_GeographicalAreasMember_1368" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1367" xlink:to="loc_ifrs-full_GeographicalAreasMember_1368_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_gsk_RestOfWorldMember_1388" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_country_US_1387" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_country_GB_1386" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed_1371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed_1371" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted_1375" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted_1377" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1384" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="loc_ifrs-full_SurplusDeficitInPlan_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_SurplusDeficitInPlan_1383" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed_1374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed_1374" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed_1378" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAssetCeilingRestrictions" xlink:label="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions_1307086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions_1307086" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets_1380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets_1380" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_1401" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1410" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1411" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1402" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1403" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1406" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1404" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1405" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_1412" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1395" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1395" xlink:to="loc_ifrs-full_GeographicalAreasMember_1396" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1396_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1395" xlink:to="loc_ifrs-full_GeographicalAreasMember_1396_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_country_GB_1415" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_gsk_RestOfWorldMember_1417" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_country_US_1416" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1391" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1391" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1392" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1392_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1391" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1392_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1392" xlink:to="loc_gsk_PostretirementBenefitsMember_1400" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1392" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1399" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember" xlink:label="loc_ifrs-full_PlanAssetsMember_1418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" xlink:to="loc_ifrs-full_PlanAssetsMember_1418" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_631025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_631025" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1407" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1409" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1408" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights_832506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights_832506" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset_2146645105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset_2146645105" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1421" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1421" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1422" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1421" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1422_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1422" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1426" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_1425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1422" xlink:to="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_1425" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1427" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1445" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1446" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1445" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1446_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1446" xlink:to="loc_gsk_PostretirementBenefitsMember_1449" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1452" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1453" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1451" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1450" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationDeferredMember" xlink:label="loc_gsk_DefinedBenefitObligationDeferredMember_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationDeferredMember_1466" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationRetiredMember" xlink:label="loc_gsk_DefinedBenefitObligationRetiredMember_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationRetiredMember_1465" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationActiveMember" xlink:label="loc_gsk_DefinedBenefitObligationActiveMember_1464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationActiveMember_1464" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1457" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1457" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1458" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1457" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1458_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1458" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1462" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1463" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1476" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationActiveMember" xlink:label="loc_gsk_DefinedBenefitObligationActiveMember_1477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationActiveMember_1477" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationRetiredMember" xlink:label="loc_gsk_DefinedBenefitObligationRetiredMember_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationRetiredMember_1478" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationDeferredMember" xlink:label="loc_gsk_DefinedBenefitObligationDeferredMember_1479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationDeferredMember_1479" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1470" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1470" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1471" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1470" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1471_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1471" xlink:to="loc_gsk_PostretirementBenefitsMember_1475" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" xlink:to="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1482" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1482" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1482" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1483_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1483" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1486" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostRetirementBenefitMember" xlink:label="loc_gsk_PostRetirementBenefitMember_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1483" xlink:to="loc_gsk_PostRetirementBenefitMember_1487" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageDurationOfDefinedBenefitObligations" xlink:label="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" xlink:to="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations_1488" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInAnnualPensionCost" xlink:label="loc_gsk_IncreaseInAnnualPensionCost_1499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseInAnnualPensionCost_1499" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreasePensionObligations" xlink:label="loc_gsk_IncreaseDecreasePensionObligations_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreasePensionObligations_1501" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xlink:label="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation_1502" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_1491" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_1491" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_1492" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_1492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_1491" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_1492_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xlink:label="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember_1496" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xlink:label="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember_1497" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember_847464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember_847464" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember_847466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember_847466" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember_847471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember_847471" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember_847467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember_847467" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember_847469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember_847469" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember_2146643095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember_2146643095" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember_2146643094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember_2146643094" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember_2146643007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember_2146643007" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xlink:label="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost_1500" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xlink:label="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated_1551" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfIndividual1Axis" xlink:label="loc_gsk_TitleOfIndividual1Axis_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_gsk_TitleOfIndividual1Axis_1547" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentGrantsDomain" xlink:label="loc_gsk_GovernmentGrantsDomain_1544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_TitleOfIndividual1Axis_1547" xlink:to="loc_gsk_GovernmentGrantsDomain_1544" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentGrantsDomain" xlink:label="loc_gsk_GovernmentGrantsDomain_1544_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_TitleOfIndividual1Axis_1547" xlink:to="loc_gsk_GovernmentGrantsDomain_1544_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisabledEmployeesMember" xlink:label="loc_gsk_DisabledEmployeesMember_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_GovernmentGrantsDomain_1544" xlink:to="loc_gsk_DisabledEmployeesMember_1554" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_1541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_1541" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1541" xlink:to="loc_ifrs-full_OtherProvisionsMember_1545" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1541" xlink:to="loc_ifrs-full_OtherProvisionsMember_1545_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalAndOtherDisputesMember" xlink:label="loc_gsk_LegalAndOtherDisputesMember_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1545" xlink:to="loc_gsk_LegalAndOtherDisputesMember_1555" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProvisionsMember" xlink:label="loc_gsk_MajorRestructuringProvisionsMember_1307404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1545" xlink:to="loc_gsk_MajorRestructuringProvisionsMember_1307404" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1064372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1064372" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1064372_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1064372_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xlink:label="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions_1548" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions_1549" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionObligationProvisions" xlink:label="loc_gsk_PensionObligationProvisions_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_PensionObligationProvisions_1552" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="loc_ifrs-full_ShorttermLegalProceedingsProvision_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_ShorttermLegalProceedingsProvision_1550" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_ProvisionsForEmployeeBenefits_1546" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_1525" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_1527" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_1519" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1519" xlink:to="loc_ifrs-full_OtherProvisionsMember_1522" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1519" xlink:to="loc_ifrs-full_OtherProvisionsMember_1522_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeRelatedProvisionsMember" xlink:label="loc_gsk_EmployeeRelatedProvisionsMember_1537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_EmployeeRelatedProvisionsMember_1537" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalAndOtherDisputesMember" xlink:label="loc_gsk_LegalAndOtherDisputesMember_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_LegalAndOtherDisputesMember_1535" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherProvisionMember" xlink:label="loc_gsk_OtherProvisionMember_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_OtherProvisionMember_1538" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="loc_ifrs-full_RestructuringProvisionMember_1536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_ifrs-full_RestructuringProvisionMember_1536" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" xlink:to="loc_ifrs-full_RestatedMember_512840" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" xlink:to="loc_ifrs-full_RestatedMember_512840_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1524" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1529" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherProvisions_1523" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_512904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_512904" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherShorttermProvisions_1532" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_1528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_1528" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherLongtermProvisions_1533" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToPensionObligations" xlink:label="loc_gsk_TransferToPensionObligations_1530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_gsk_TransferToPensionObligations_1530" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_1526" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistribution" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistribution_2146645084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_gsk_TransferToAssetsHeldForSaleDistribution_2146645084" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_2049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_2049" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_2050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_2050" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2048" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPaid" xlink:label="loc_gsk_ContingentConsiderationPaid_2051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_ContingentConsiderationPaid_2051" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2047" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisMember" xlink:label="loc_gsk_NovartisMember_2055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_NovartisMember_2055" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBusinessMember" xlink:label="loc_gsk_OtherBusinessMember_2056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_OtherBusinessMember_2056" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2054" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_AffinivaxMember_1702425" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination_2146643281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination_2146643281" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xlink:label="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfEuro" xlink:label="loc_gsk_AppreciationOfEuro_2088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_AppreciationOfEuro_2088" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesMember" xlink:label="loc_gsk_NovartisVaccinesMember_2091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_NovartisVaccinesMember_2091" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_AffinivaxMember_1702446" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViivHealthcareMember" xlink:label="loc_gsk_ShionogiViivHealthcareMember_2146643260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_ShionogiViivHealthcareMember_2146643260" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2146645009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_RangeAxis_2146645009" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2146645010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2146645009" xlink:to="loc_ifrs-full_RangesMember_2146645010" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2146645010_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2146645009" xlink:to="loc_ifrs-full_RangesMember_2146645010_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2078" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2078" xlink:to="loc_ifrs-full_TypesOfRisksMember_2079" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2079_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2078" xlink:to="loc_ifrs-full_TypesOfRisksMember_2079_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2095" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2092" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2094" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember_2147451159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember_2147451159" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2093" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember_2147451160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember_2147451160" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember_2147451165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember_2147451165" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember_2146643286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember_2146643286" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember_2147451161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember_2147451161" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember_2147451162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember_2147451162" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645020" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645021" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645022" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645023" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember_2147451163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember_2147451163" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember_2146643285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember_2146643285" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfUSDollar" xlink:label="loc_gsk_AppreciationOfUSDollar_2086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_AppreciationOfUSDollar_2086" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess_1702475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess_1702475" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess_1702476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess_1702476" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInSalesForecastAmount" xlink:label="loc_gsk_IncreaseInSalesForecastAmount_2080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInSalesForecastAmount_2080" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInDiscountRateAmount" xlink:label="loc_gsk_IncreaseInDiscountRateAmount_2082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInDiscountRateAmount_2082" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInSalesForecastAmount" xlink:label="loc_gsk_DecreaseInSalesForecastAmount_2081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInSalesForecastAmount_2081" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInDiscountRateAmount" xlink:label="loc_gsk_DecreaseInDiscountRateAmount_2083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInDiscountRateAmount_2083" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfEuro" xlink:label="loc_gsk_DepreciationOfEuro_2089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DepreciationOfEuro_2089" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfUSDollar" xlink:label="loc_gsk_DepreciationOfUSDollar_2087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DepreciationOfUSDollar_2087" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPayableDiscountedPercentage" xlink:label="loc_gsk_ContingentConsiderationPayableDiscountedPercentage_2067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_ContingentConsiderationPayableDiscountedPercentage_2067" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesCurrent" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesCurrent_2065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesCurrent_2065" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1320669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1320669" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1320669" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1320669" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialisedProductsMember" xlink:label="loc_gsk_CommercialisedProductsMember_1192112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" xlink:to="loc_gsk_CommercialisedProductsMember_1192112" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineAssetsMember" xlink:label="loc_gsk_PipelineAssetsMember_1192116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" xlink:to="loc_gsk_PipelineAssetsMember_1192116" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_AffinivaxMember_1702440" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2069" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesMember" xlink:label="loc_gsk_NovartisVaccinesMember_2146646271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_NovartisVaccinesMember_2146646271" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_RangeAxis_2063" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2063" xlink:to="loc_ifrs-full_RangesMember_2064" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2064_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2063" xlink:to="loc_ifrs-full_RangesMember_2064_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate_1702443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociate_1702443" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_2146644878" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_2146644877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_2146644878" xlink:to="loc_gsk_StatementsTable_2146644877" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionUnpaid" xlink:label="loc_gsk_AdditionalContributionUnpaid_2146646575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_2146644878" xlink:to="loc_gsk_AdditionalContributionUnpaid_2146646575" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xlink:label="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit_2146643256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_2146644878" xlink:to="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit_2146643256" use="optional" order="3" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_1714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_1714" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_Equity_1704" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:label="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1701" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1701" xlink:to="loc_ifrs-full_EquityMember_1705" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1701" xlink:to="loc_ifrs-full_EquityMember_1705_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_1716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1705" xlink:to="loc_ifrs-full_SharePremiumMember_1716" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1705" xlink:to="loc_ifrs-full_IssuedCapitalMember_1717" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1700" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1700_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1700_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_1706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1700" xlink:to="loc_ifrs-full_OrdinarySharesMember_1706" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_IssueOfEquity_1713" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1707" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xlink:label="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts_1711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts_1711" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xlink:label="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes_1710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes_1710" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpactOfShareConsolidationShares" xlink:label="loc_gsk_ImpactOfShareConsolidationShares_2146643197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_ImpactOfShareConsolidationShares_2146643197" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_NumberOfSharesIssued_1731" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:label="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1727" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1727" xlink:to="loc_ifrs-full_EquityMember_1730" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1730_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1727" xlink:to="loc_ifrs-full_EquityMember_1730_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="loc_ifrs-full_TreasurySharesMember_1733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_ifrs-full_TreasurySharesMember_1733" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeIssueMember" xlink:label="loc_gsk_FreeIssueMember_1734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_FreeIssueMember_1734" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeShareOwnershipPlanMember" xlink:label="loc_gsk_EmployeeShareOwnershipPlanMember_1732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_EmployeeShareOwnershipPlanMember_1732" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xlink:label="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember_2147451203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember_2147451203" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsAxis" xlink:label="loc_gsk_DetailsAxis_2146646584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_gsk_DetailsAxis_2146646584" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsMember" xlink:label="loc_gsk_DetailsMember_2146646585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_DetailsAxis_2146646584" xlink:to="loc_gsk_DetailsMember_2146646585" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsMember" xlink:label="loc_gsk_DetailsMember_2146646585_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_DetailsAxis_2146646584" xlink:to="loc_gsk_DetailsMember_2146646585_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_2146647266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" xlink:to="loc_ifrs-full_OrdinarySharesMember_2146647266" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_2146644919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_ParValuePerShare_2146644919" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfShareConsolidationApproval" xlink:label="loc_gsk_DateOfShareConsolidationApproval_2147451197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_DateOfShareConsolidationApproval_2147451197" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessDemerger" xlink:label="loc_gsk_ConsumerHealthcareBusinessDemerger_2147451199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_ConsumerHealthcareBusinessDemerger_2147451199" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_2146643067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_2146643067" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesReceivedForEveryFiveExistingShares" xlink:label="loc_gsk_SharesReceivedForEveryFiveExistingShares_2146643052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_SharesReceivedForEveryFiveExistingShares_2146643052" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SurrenderedSharesForEveryFourNewSharesReceived" xlink:label="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived_2146643050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived_2146643050" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xlink:label="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares_2146643049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares_2146643049" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetainedEarningsAndOtherReserves" xlink:label="loc_gsk_RetainedEarningsAndOtherReserves_1746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" xlink:to="loc_gsk_RetainedEarningsAndOtherReserves_1746" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" xlink:to="loc_ifrs-full_OtherReserves_1747" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1737" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1737" xlink:to="loc_ifrs-full_EquityMember_1738" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1737" xlink:to="loc_ifrs-full_EquityMember_1738_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1738" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1743" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityAxis" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xlink:to="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityDomain" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" xlink:to="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityDomain" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" xlink:to="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRedemptionReserveMember" xlink:label="loc_ifrs-full_CapitalRedemptionReserveMember_1745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" xlink:to="loc_ifrs-full_CapitalRedemptionReserveMember_1745" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDistributableMergerAndPreMergerReservesMember" xlink:label="loc_gsk_NonDistributableMergerAndPreMergerReservesMember_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" xlink:to="loc_gsk_NonDistributableMergerAndPreMergerReservesMember_1744" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1757" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_1758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_1758" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1750" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1750" xlink:to="loc_ifrs-full_EquityMember_1751" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1751_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1750" xlink:to="loc_ifrs-full_EquityMember_1751_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueReserveMember" xlink:label="loc_gsk_FairValueReserveMember_1755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_gsk_FairValueReserveMember_1755" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_1756" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_ifrs-full_RetainedEarningsMember_1754" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_627250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" xlink:to="loc_ifrs-full_RestatedMember_627250" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_627250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" xlink:to="loc_ifrs-full_RestatedMember_627250_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_632963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_632963" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations_2146643190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations_2146643190" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations_2146643189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations_2146643189" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_2146644959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_2146644959" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_2146643042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_2146643042" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_2146643188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_gsk_EventAxis_2146643188" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_EventAxis_2146643188" xlink:to="loc_gsk_EventDomain_2146643187" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_EventAxis_2146643188" xlink:to="loc_gsk_EventDomain_2146643187_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerMember" xlink:label="loc_gsk_DemergerMember_2146643186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EventDomain_2146643187" xlink:to="loc_gsk_DemergerMember_2146643186" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146643181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146643181" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146643181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146643181_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_2146643180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContinuingOperationsMember_2146643181" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_2146643180" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1768" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1768" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1763" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1763" xlink:to="loc_ifrs-full_EquityMember_1766" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1766_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1763" xlink:to="loc_ifrs-full_EquityMember_1766_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_OtherReservesMember_1787" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_RetainedEarningsMember_1786" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_1788" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1778" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_1776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_1776" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_1777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_1777" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_1770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_1770" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges_1769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges_1769" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_1784" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_1781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_1781" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations_1702477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations_1702477" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_1785" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1783" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xlink:label="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments_1782" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests_1780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests_1780" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations_2146646278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations_2146646278" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xlink:label="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges_2147457542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges_2147457542" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_ifrs-full_OtherReserves_1799" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovements" xlink:label="loc_gsk_NetFairValueMovements_1806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_NetFairValueMovements_1806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xlink:label="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves_1807" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeAdjustments" xlink:label="loc_gsk_ExchangeAdjustments_1802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_ExchangeAdjustments_1802" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1794" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1794" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1791" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1791" xlink:to="loc_ifrs-full_EquityMember_1792" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1791" xlink:to="loc_ifrs-full_EquityMember_1792_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustMember" xlink:label="loc_gsk_EsopTrustMember_1795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_gsk_EsopTrustMember_1795" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_ifrs-full_OtherReservesMember_1798" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesMember" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesMember_1797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesMember_1797" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueReserveMember" xlink:label="loc_gsk_FairValueReserveMember_1796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_gsk_FairValueReserveMember_1796" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEsopTrusts" xlink:label="loc_gsk_WritedownOfSharesHeldByEsopTrusts_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_WritedownOfSharesHeldByEsopTrusts_1808" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments_1804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments_1804" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xlink:label="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments_2146643174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments_2146643174" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BalanceAmountDerecognisedOnDemerger" xlink:label="loc_gsk_BalanceAmountDerecognisedOnDemerger_2146643066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_BalanceAmountDerecognisedOnDemerger_2146643066" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_624971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_624971" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2142" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xlink:label="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition_627358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition_627358" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsTable" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2138" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2138" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2138" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" xlink:to="loc_gsk_ViiVHealthCareMember_2145" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_2147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_2147" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_2118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncontrollingInterests_2118" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_2125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Assets_2125" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2132" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2122" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_2124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CurrentAssets_2124" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_2126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CurrentLiabilities_2126" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2130" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsTable" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2112" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2112" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2112" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_2135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_2135" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" xlink:to="loc_gsk_ViiVHealthCareMember_2134" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterests_2117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterests_2117" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndBankOverdrafts" xlink:label="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts_2133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts_2133" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2131" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_2123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncurrentAssets_2123" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2120" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_2119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Revenue_2119" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_2116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_2116" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_2128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Liabilities_2128" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_2129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NetAssetsLiabilities_2129" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_2127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncurrentLiabilities_2127" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_2121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_2121" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentIncome" xlink:label="loc_ifrs-full_InvestmentIncome_600763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_ifrs-full_InvestmentIncome_600763" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementExtensionPeriod" xlink:label="loc_gsk_AgreementExtensionPeriod_627141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_AgreementExtensionPeriod_627141" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1812" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1812" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1812" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongwoodFoundersFundLPMember" xlink:label="loc_gsk_LongwoodFoundersFundLPMember_1837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_LongwoodFoundersFundLPMember_1837" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MedicxiVenturesILimitedPartnerMember" xlink:label="loc_gsk_MedicxiVenturesILimitedPartnerMember_1833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_MedicxiVenturesILimitedPartnerMember_1833" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ApolloTherapeuticsLLPMember" xlink:label="loc_gsk_ApolloTherapeuticsLLPMember_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_ApolloTherapeuticsLLPMember_1836" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_QuraTherapeuticsLLCMember" xlink:label="loc_gsk_QuraTherapeuticsLLCMember_1838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_QuraTherapeuticsLLCMember_1838" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xlink:label="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions_1826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions_1826" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentObligation" xlink:label="loc_gsk_InvestmentObligation_1316185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_InvestmentObligation_1316185" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashInvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_CashInvestmentsInJointVenturesAndAssociates_1950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CashInvestmentsInJointVenturesAndAssociates_1950" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember_1937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" xlink:to="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember_1937" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_srt_OwnershipAxis_1934" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1934" xlink:to="loc_srt_OwnershipDomain_1935" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1934" xlink:to="loc_srt_OwnershipDomain_1935_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskHoldingMember" xlink:label="loc_gsk_GskHoldingMember_1704264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskHoldingMember_1704264" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskShareholdersMember" xlink:label="loc_gsk_GskShareholdersMember_1704236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskShareholdersMember_1704236" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAndGsksConsolidatedEsotTrustsMember" xlink:label="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember_1704238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember_1704238" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScottishLimitedPartnershipsMember" xlink:label="loc_gsk_ScottishLimitedPartnershipsMember_1704239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_ScottishLimitedPartnershipsMember_1704239" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAggregateHoldingMember" xlink:label="loc_gsk_GskAggregateHoldingMember_1704241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskAggregateHoldingMember_1704241" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1928" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1928" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1929" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1929_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1928" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1929_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1933" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1933_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1933_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_1930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_JointVenturesAxis_1930" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_1930" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_1930" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BangladeshConsumerHealthcareMember" xlink:label="loc_gsk_BangladeshConsumerHealthcareMember_1224218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" xlink:to="loc_gsk_BangladeshConsumerHealthcareMember_1224218" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_dei_LegalEntityAxis_1931" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1931" xlink:to="loc_dei_EntityDomain_1924" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1924_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1931" xlink:to="loc_dei_EntityDomain_1924_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerMember" xlink:label="loc_gsk_PfizerMember_1961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1924" xlink:to="loc_gsk_PfizerMember_1961" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1919" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1919" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1919" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xlink:label="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember_1968" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_1704187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_AffinivaxIncMember_1704187" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyIncMember" xlink:label="loc_gsk_SierraOncologyIncMember_1704171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_SierraOncologyIncMember_1704171" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_860580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_HorlicksMember_860580" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerBiotechCorporationTaiwanMember" xlink:label="loc_gsk_PfizerBiotechCorporationTaiwanMember_829348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_PfizerBiotechCorporationTaiwanMember_829348" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_1307797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_ifrs-full_BusinessCombinationsMember_1307797" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember_1704206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember_1704206" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSaudiArabiaLimitedMember" xlink:label="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643178" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1925_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1925_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" xlink:to="loc_ifrs-full_AssociatesMember_1962" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_858156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_ArrangementTypeAxis_858156" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_858157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ArrangementTypeAxis_858156" xlink:to="loc_gsk_ArrangementTypeDomain_858157" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_858157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ArrangementTypeAxis_858156" xlink:to="loc_gsk_ArrangementTypeDomain_858157_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareBangladeshMember" xlink:label="loc_gsk_ConsumerHealthCareBangladeshMember_1223887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ArrangementTypeDomain_858157" xlink:to="loc_gsk_ConsumerHealthCareBangladeshMember_1223887" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_1307810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" xlink:to="loc_gsk_InnovivaIncMember_1307810" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalsMember_831827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_TwoThousandTwentyBusinessDisposalsMember_831827" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307811" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307795" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_1704230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_1704230" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_1704225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_InvestmentAxis_1704225" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1704226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_InvestmentAxis_1704225" xlink:to="loc_gsk_InvestmentDomain_1704226" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1704226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_InvestmentAxis_1704225" xlink:to="loc_gsk_InvestmentDomain_1704226_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonPlcMember" xlink:label="loc_gsk_HaleonPlcMember_1704228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_InvestmentDomain_1704226" xlink:to="loc_gsk_HaleonPlcMember_1704228" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_1960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_1960" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1951" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_1956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_Goodwill_1956" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_1943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_1943" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xlink:label="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted_589087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted_589087" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_513891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_CashTransferred_513891" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:label="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_858471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_858471" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_513890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_513890" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsMadeForTransactionCostsAndOther" xlink:label="loc_gsk_PaymentsMadeForTransactionCostsAndOther_625042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PaymentsMadeForTransactionCostsAndOther_625042" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="loc_ifrs-full_AdditionalRecognitionGoodwill_1704207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_AdditionalRecognitionGoodwill_1704207" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets_829339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_OtherAssets_829339" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xlink:label="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche_1704200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche_1704200" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_829344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_NetAssetsLiabilities_829344" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xlink:label="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration_846656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration_846656" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentOwnedNumberOfSharesDisposedOff" xlink:label="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff_1307799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff_1307799" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsDistributedFromCashBalance" xlink:label="loc_gsk_DividendsDistributedFromCashBalance_1704271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendsDistributedFromCashBalance_1704271" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GrossProceedsFromDisposalOfInterestInAssociates" xlink:label="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates_1307801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates_1307801" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xlink:label="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves_2146645107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves_2146645107" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageofGSKHolding" xlink:label="loc_gsk_PercentageofGSKHolding_2146645633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageofGSKHolding_2146645633" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancing" xlink:label="loc_gsk_DividendFundedByDebtFinancing_2146645637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendFundedByDebtFinancing_2146645637" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheAssetsDistributed" xlink:label="loc_gsk_FairValueOfTheAssetsDistributed_1704283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_FairValueOfTheAssetsDistributed_1704283" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfHolding" xlink:label="loc_gsk_FairValueOfHolding_1704291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_FairValueOfHolding_1704291" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xlink:label="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare_1307800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare_1307800" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest_2147450239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest_2147450239" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashTransferredOnDisposal" xlink:label="loc_gsk_CashTransferredOnDisposal_2147451214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CashTransferredOnDisposal_2147451214" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xlink:label="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired_2146643177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired_2146643177" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2146645006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2146645006" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilityEliminatedOnDemerger" xlink:label="loc_gsk_LiabilityEliminatedOnDemerger_2146645067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_LiabilityEliminatedOnDemerger_2146645067" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xlink:label="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount_2146645077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount_2146645077" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerOfDiscontinuedOperation" xlink:label="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645106" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancingAttributableToGsk" xlink:label="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk_2146645640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk_2146645640" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk_2146645641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk_2146645641" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDistributed" xlink:label="loc_gsk_PercentageOfOwnershipDistributed_1944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageOfOwnershipDistributed_1944" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalGainOnRemeasurementOfRetainedStake" xlink:label="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake_2146645104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake_2146645104" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xlink:label="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition_2146643175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition_2146643175" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDivested" xlink:label="loc_gsk_PercentageOfOwnershipDivested_2146643076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageOfOwnershipDivested_2146643076" use="optional" order="101" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_513875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_Goodwill_513875" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsAcquiredAbstract" xlink:label="loc_gsk_NetAssetsAcquiredAbstract_513865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NetAssetsAcquiredAbstract_513865" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_513871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_513871" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_625078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_RightofuseAssets_625078" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate_513868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate_513868" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate_513874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate_513874" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_513866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_513866" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_829311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_829311" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate_829315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate_829315" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_513867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_513867" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate_513869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate_513869" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate_513881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate_513881" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate_1702846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate_1702846" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxationRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_TaxationRecognizedAsOfAcquisitionDate_1702848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_TaxationRecognizedAsOfAcquisitionDate_1702848" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xlink:label="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote_846833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote_846833" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_513850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_JointVenturesAxis_513850" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_513850" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_513850" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_513861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_513861" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_513861" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_513861" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerBiotechCorporationTaiwanMember" xlink:label="loc_gsk_PfizerBiotechCorporationTaiwanMember_846657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" xlink:to="loc_gsk_PfizerBiotechCorporationTaiwanMember_846657" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" xlink:to="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702807" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyMember" xlink:label="loc_gsk_SierraOncologyMember_1702801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" xlink:to="loc_gsk_SierraOncologyMember_1702801" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" xlink:to="loc_gsk_AffinivaxMember_1702802" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_513880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_513880" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1702865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1702865" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_1702867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_1702867" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1702958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1702958" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1702959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1702959" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1702953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_Revenue_1702953" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_1702954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_OperatingExpense_1702954" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_1702955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_1702955" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1702956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1702956" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_1702950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" xlink:to="loc_ifrs-full_ContinuingOperationsMember_1702950" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_1702950_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" xlink:to="loc_ifrs-full_ContinuingOperationsMember_1702950_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_1702951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContinuingOperationsMember_1702950" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_1702951" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1702957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1702957" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1702960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1702960" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702961" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1702962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1702962" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:label="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_2146645056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_2146645056" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGainsLossesOnDemerger" xlink:label="loc_gsk_OtherGainsLossesOnDemerger_2146645055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_OtherGainsLossesOnDemerger_2146645055" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_829408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_ifrs-full_JointVenturesAxis_829408" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_829408" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_829408" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherMember" xlink:label="loc_gsk_OtherMember_829413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" xlink:to="loc_gsk_OtherMember_829413" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_829410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" xlink:to="loc_gsk_HorlicksMember_829410" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_829376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_829376" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_829376" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_829376" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalMember_2146645402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" xlink:to="loc_gsk_TwoThousandTwentyBusinessDisposalMember_2146645402" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307828" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupLiabilityNet" xlink:label="loc_gsk_DisposalGroupLiabilityNet_829407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_DisposalGroupLiabilityNet_829407" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfEquity" xlink:label="loc_gsk_DisposalOfEquity_829387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_DisposalOfEquity_829387" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_829390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_829390" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_829391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_AssetsAbstract_829391" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetAssets" xlink:label="loc_gsk_DisposalsOtherNetAssets_829399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsOtherNetAssets_829399" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInventory" xlink:label="loc_gsk_DisposalsInventory_829396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsInventory_829396" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_829398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_ifrs-full_CashTransferred_829398" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsGoodwill" xlink:label="loc_gsk_DisposalsGoodwill_829392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsGoodwill_829392" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DealCostsPayable" xlink:label="loc_gsk_DealCostsPayable_1307821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DealCostsPayable_1307821" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsIntangibleAssets" xlink:label="loc_gsk_DisposalsIntangibleAssets_829393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsIntangibleAssets_829393" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_829394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_829394" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupAssetsNet" xlink:label="loc_gsk_DisposalGroupAssetsNet_829401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalGroupAssetsNet_829401" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetLiabilitiesOrAssets" xlink:label="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets_2146643006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets_2146643006" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_829404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_829404" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:label="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_829403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_829403" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xlink:label="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments_829381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments_829381" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusiness" xlink:label="loc_gsk_GainLossOnDisposalsOfBusiness_829417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_GainLossOnDisposalsOfBusiness_829417" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_gsk_TransactionCostsOnDisposal_829402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_TransactionCostsOnDisposal_829402" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_1991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_1991" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1989" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_gsk_TransactionCostsOnDisposal_589055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_TransactionCostsOnDisposal_589055" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember_846665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember_846665" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember_1703287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember_1703287" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember_1706862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember_1706862" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember_1706864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember_1706864" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember_849156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember_849156" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1977" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1977" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1977" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_1994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_ifrs-full_BusinessCombinationsMember_1994" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307844" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307842" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredConsiderationReceived" xlink:label="loc_gsk_DeferredConsiderationReceived_1990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_DeferredConsiderationReceived_1990" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1993" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashOutflowInflowExcludingTransactionCosts" xlink:label="loc_gsk_CashOutflowInflowExcludingTransactionCosts_846667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_CashOutflowInflowExcludingTransactionCosts_846667" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_512799" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_1874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_1874" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_1875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_1875" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsOfFinanceLeaseLiabilities" xlink:label="loc_gsk_PaymentsOfFinanceLeaseLiabilities_1876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_PaymentsOfFinanceLeaseLiabilities_1876" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_1873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_1873" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_Borrowings_1870" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInLiquidInvestment" xlink:label="loc_gsk_DecreaseIncreaseInLiquidInvestment_1872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInLiquidInvestment_1872" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeOnNetDebt" xlink:label="loc_gsk_ExchangeOnNetDebt_1877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_ExchangeOnNetDebt_1877" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xlink:label="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations_1871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations_1871" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xlink:label="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt_1878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt_1878" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtOfSubsidiaryUndertakingsAcquired" xlink:label="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired_589110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired_589110" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_512796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_StatementsTable_512796" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_StatementsTable_512796" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" xlink:to="loc_ifrs-full_RestatedMember_512802" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512802_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" xlink:to="loc_ifrs-full_RestatedMember_512802_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1702502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1702502" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations_2146645059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations_2146645059" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations_2146645060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations_2146645060" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfNetDebt" xlink:label="loc_gsk_ReclassificationOfNetDebt_1900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_ReclassificationOfNetDebt_1900" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" xlink:to="loc_ifrs-full_FinancialAssetsMember_1888" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" xlink:to="loc_ifrs-full_FinancialAssetsMember_1888_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialInstrumentsMember" xlink:label="loc_gsk_DerivativeFinancialInstrumentsMember_1908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_DerivativeFinancialInstrumentsMember_1908" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankOverdrafts1Member" xlink:label="loc_gsk_BankOverdrafts1Member_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_BankOverdrafts1Member_1906" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentMember" xlink:label="loc_gsk_CashAndCashEquivalentMember_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_CashAndCashEquivalentMember_1904" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsMember" xlink:label="loc_gsk_LiquidInvestmentsMember_1903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsMember_1903" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndBankOverdraftsMember" xlink:label="loc_gsk_CashAndBankOverdraftsMember_1907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_CashAndBankOverdraftsMember_1907" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember_2146645074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember_2146645074" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember_2146645075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember_2146645075" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember_2146643085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember_2146643085" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1883" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1883" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1884" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1884_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1883" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1884_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaper1Member" xlink:label="loc_gsk_CommercialPaper1Member_1891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_CommercialPaper1Member_1891" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xlink:label="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember_1892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember_1892" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_513538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_513538" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCurrentDebtMember" xlink:label="loc_gsk_OtherCurrentDebtMember_1893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_OtherCurrentDebtMember_1893" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember_2146645092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember_2146645092" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember_2146645076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember_2146645076" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsContinuingOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsContinuingOperationsMember_2146643258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_LongTermBorrowingsContinuingOperationsMember_2146643258" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsDiscontinuedOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember_2146643257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember_2146643257" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="loc_ifrs-full_ShorttermBorrowingsMember_1910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_ShorttermBorrowingsMember_1910" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetDebtMember" xlink:label="loc_gsk_NetDebtMember_1912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_gsk_NetDebtMember_1912" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AccruedInterestMember" xlink:label="loc_gsk_AccruedInterestMember_1914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_gsk_AccruedInterestMember_1914" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_1913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_1913" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_1911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_1911" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_1897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_1897" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_1901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_1901" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_1898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_1898" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1307577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_InterestExpense_1307577" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xlink:label="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities_2146643259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities_2146643259" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ChangeInFairValueOfNetDebt" xlink:label="loc_gsk_ChangeInFairValueOfNetDebt_1307579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_ChangeInFairValueOfNetDebt_1307579" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations_2146642988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations_2146642988" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations_2146642982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations_2146642982" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations_2146642981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations_2146642981" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations_2146642980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations_2146642980" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations_2146642979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations_2146642979" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalents" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalents_2146642968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiquidInvestmentsCashAndCashEquivalents_2146642968" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1896" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xlink:label="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts_2146642969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts_2146642969" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_2234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_Borrowings_2234" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2262" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:label="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2252" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConcentrationsOfRiskRevenuePercentage" xlink:label="loc_gsk_ConcentrationsOfRiskRevenuePercentage_2259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_ConcentrationsOfRiskRevenuePercentage_2259" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAndDebtNet" xlink:label="loc_gsk_EquityAndDebtNet_2236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_EquityAndDebtNet_2236" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_2248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_2248" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld_2238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld_2238" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme_2245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme_2245" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure_2249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_CreditExposure_2249" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_2240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_CommercialPapersIssued_2240" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2270" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BalancesWithBanks" xlink:label="loc_ifrs-full_BalancesWithBanks_2253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_BalancesWithBanks_2253" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2263" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xlink:label="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement_2251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement_2251" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2256" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterparties" xlink:label="loc_gsk_CashHeldAtUnratedCounterparties_2250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashHeldAtUnratedCounterparties_2250" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashReserves" xlink:label="loc_gsk_CashReserves_2254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashReserves_2254" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestments" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments_2237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments_2237" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectiveness_589409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_GainLossOnHedgeIneffectiveness_589409" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2272" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfAccountsReceivableByMajorCustomer" xlink:label="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer_2257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer_2257" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_857491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TradeReceivables_857491" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2197" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2197" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2198" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2198_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2197" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2198_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCommercialPaperProgramMember" xlink:label="loc_gsk_UsCommercialPaperProgramMember_2231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2198" xlink:to="loc_gsk_UsCommercialPaperProgramMember_2231" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgrammeMember" xlink:label="loc_gsk_EuroCommercialPaperProgrammeMember_847270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2198" xlink:to="loc_gsk_EuroCommercialPaperProgrammeMember_847270" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="loc_ifrs-full_ExternalCreditGradesAxis_2208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ExternalCreditGradesAxis_2208" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2208" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2208" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBB-OrBaaThreeRatedMember" xlink:label="loc_gsk_BBB-OrBaaThreeRatedMember_2281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_BBB-OrBaaThreeRatedMember_2281" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BbbOrBaaMember" xlink:label="loc_gsk_BbbOrBaaMember_2280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_BbbOrBaaMember_2280" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesMember" xlink:label="loc_ifrs-full_ExternalCreditGradesMember_2279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_ifrs-full_ExternalCreditGradesMember_2279" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LowerThanBBBBaa3Member" xlink:label="loc_gsk_LowerThanBBBBaa3Member_2146643026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_LowerThanBBBBaa3Member_2146643026" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2229" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" xlink:to="loc_ifrs-full_FinancialAssetsMember_2209" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" xlink:to="loc_ifrs-full_FinancialAssetsMember_2209_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_858229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2209" xlink:to="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_858229" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2194" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2194" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2195" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2195_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2194" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2195_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BondsInDesignatedHedgingRelationshipMember" xlink:label="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2195" xlink:to="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2230" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DueFromThreeWholesalersMember" xlink:label="loc_gsk_DueFromThreeWholesalersMember_2146643039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2195" xlink:to="loc_gsk_DueFromThreeWholesalersMember_2146643039" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_2200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_CounterpartiesAxis_2200" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_2201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_2200" xlink:to="loc_ifrs-full_CounterpartiesMember_2201" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_2201_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_2200" xlink:to="loc_ifrs-full_CounterpartiesMember_2201_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StateBankOfIndiaMember" xlink:label="loc_gsk_StateBankOfIndiaMember_2233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_2201" xlink:to="loc_gsk_StateBankOfIndiaMember_2233" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2210" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2210" xlink:to="loc_ifrs-full_GeographicalAreasMember_2211" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2211_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2210" xlink:to="loc_ifrs-full_GeographicalAreasMember_2211_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NG" xlink:label="loc_country_NG_2287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_NG_2287" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GbMember" xlink:label="loc_gsk_GbMember_589301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_gsk_GbMember_589301" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonUsaMember" xlink:label="loc_gsk_NonUsaMember_2285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_gsk_NonUsaMember_2285" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_2286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_US_2286" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_EC" xlink:label="loc_country_EC_1310394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_EC_1310394" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HN" xlink:label="loc_country_HN_1310395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_HN_1310395" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KH" xlink:label="loc_country_KH_1310396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_KH_1310396" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="loc_country_BR_2146643235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_BR_2146643235" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR" xlink:label="loc_country_CR_2146643234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_CR_2146643234" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_SegmentsAxis_2219" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_2219" xlink:to="loc_ifrs-full_SegmentsMember_2220" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_2219" xlink:to="loc_ifrs-full_SegmentsMember_2220_default" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InLineWithOtherPharmaceuticalCompaniesMember" xlink:label="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember_2146642997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_2220" xlink:to="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember_2146642997" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_MaturityAxis_2216" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2216" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2192" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2216" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2192_default" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2227" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember_2226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_NotLaterThanThreeMonthsMember_2226" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643124" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_2214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_JointVenturesAxis_2214" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_2214" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_2214" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206_default" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2282" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JTrustRoyalBankMember" xlink:label="loc_gsk_JTrustRoyalBankMember_2146643035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_JTrustRoyalBankMember_2146643035" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BacSanJoseMember" xlink:label="loc_gsk_BacSanJoseMember_2146643034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BacSanJoseMember_2146643034" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDoBrasilMember" xlink:label="loc_gsk_BancoDoBrasilMember_2146643033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BancoDoBrasilMember_2146643033" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDeHondurasMember" xlink:label="loc_gsk_BancoDeHondurasMember_2146643032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BancoDeHondurasMember_2146643032" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProdubancoMember" xlink:label="loc_gsk_ProdubancoMember_2146643031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_ProdubancoMember_2146643031" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HalkBankMember" xlink:label="loc_gsk_HalkBankMember_2146643030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_HalkBankMember_2146643030" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xlink:label="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember_2146643029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember_2146643029" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesBusinessMember" xlink:label="loc_gsk_NovartisVaccinesBusinessMember_2146643028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_NovartisVaccinesBusinessMember_2146643028" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesalerInTheUsMember" xlink:label="loc_gsk_WholesalerInTheUsMember_2146643027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_WholesalerInTheUsMember_2146643027" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2196" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2196" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2196" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204_default" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" xlink:to="loc_gsk_AffinivaxMember_1702594" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_2146643158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" xlink:to="loc_gsk_AffinivaxIncMember_2146643158" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2224" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2224" xlink:to="loc_ifrs-full_TypesOfRisksMember_2225" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2225_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2224" xlink:to="loc_ifrs-full_TypesOfRisksMember_2225_default" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_2296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_ifrs-full_CreditRiskMember_2296" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_2295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_ifrs-full_LiquidityRiskMember_2295" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember_2146642993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember_2146642993" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember_2146642995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember_2146642995" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember_2146642996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember_2146642996" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesaleAndRetailCreditRiskMember" xlink:label="loc_gsk_WholesaleAndRetailCreditRiskMember_2146643000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_WholesaleAndRetailCreditRiskMember_2146643000" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeRiskMember" xlink:label="loc_gsk_ForeignExchangeRiskMember_2146643004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_ForeignExchangeRiskMember_2146643004" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember_2146642990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember_2146642990" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeAxis" xlink:label="loc_gsk_TypeOfIncomeAxis_589337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_TypeOfIncomeAxis_589337" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeDomain" xlink:label="loc_gsk_TypeOfIncomeDomain_589338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_TypeOfIncomeAxis_589337" xlink:to="loc_gsk_TypeOfIncomeDomain_589338" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeDomain" xlink:label="loc_gsk_TypeOfIncomeDomain_589338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_TypeOfIncomeAxis_589337" xlink:to="loc_gsk_TypeOfIncomeDomain_589338_default" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207_default" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" xlink:to="loc_gsk_ViiVHealthCareMember_2283" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInsuranceContractsAxis" xlink:label="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceContractsMember" xlink:label="loc_ifrs-full_InsuranceContractsMember_2212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" xlink:to="loc_ifrs-full_InsuranceContractsMember_2212" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceContractsMember" xlink:label="loc_ifrs-full_InsuranceContractsMember_2212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" xlink:to="loc_ifrs-full_InsuranceContractsMember_2212_default" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xlink:label="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember_2291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InsuranceContractsMember_2212" xlink:to="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember_2291" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2223" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2223" xlink:to="loc_ifrs-full_InterestRateTypesMember_2213" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2223" xlink:to="loc_ifrs-full_InterestRateTypesMember_2213_default" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateSensitivityMember" xlink:label="loc_gsk_InterestRateSensitivityMember_2146642994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_2213" xlink:to="loc_gsk_InterestRateSensitivityMember_2146642994" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisAxis" xlink:label="loc_gsk_EventBasisAxis_1224336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_EventBasisAxis_1224336" use="optional" order="119" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisDomain" xlink:label="loc_gsk_EventBasisDomain_1224341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_EventBasisAxis_1224336" xlink:to="loc_gsk_EventBasisDomain_1224341" use="optional" order="120" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisDomain" xlink:label="loc_gsk_EventBasisDomain_1224341_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_EventBasisAxis_1224336" xlink:to="loc_gsk_EventBasisDomain_1224341_default" use="optional" order="121" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" use="optional" order="122" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572" use="optional" order="123" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572_default" use="optional" order="124" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_589422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_589422" use="optional" order="125" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_589424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_589422" xlink:to="loc_ifrs-full_TypesOfHedgesMember_589424" use="optional" order="126" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_589424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_589422" xlink:to="loc_ifrs-full_TypesOfHedgesMember_589424_default" use="optional" order="127" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:label="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_589431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_589431" use="optional" order="128" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_589425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_ifrs-full_CashFlowHedgesMember_589425" use="optional" order="129" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgedMember" xlink:label="loc_gsk_NetInvestmentHedgedMember_2146643038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_gsk_NetInvestmentHedgedMember_2146643038" use="optional" order="130" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" use="optional" order="131" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_857501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_857501" use="optional" order="132" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_857501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_857501_default" use="optional" order="133" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortizedCostMember" xlink:label="loc_gsk_AmortizedCostMember_857504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_gsk_AmortizedCostMember_857504" use="optional" order="134" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_858228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_858228" use="optional" order="135" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_858221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_858221" use="optional" order="136" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1310372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1310372" use="optional" order="137" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1310374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1310372" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1310374" use="optional" order="138" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1310374_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1310372" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1310374_default" use="optional" order="139" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_1310379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_1310374" xlink:to="loc_gsk_ForeignExchangeContractsMember_1310379" use="optional" order="140" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_1310378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_1310374" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_1310378" use="optional" order="141" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_RangeAxis_2217" use="optional" order="142" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2217" xlink:to="loc_ifrs-full_RangesMember_2218" use="optional" order="143" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2218_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2217" xlink:to="loc_ifrs-full_RangesMember_2218_default" use="optional" order="144" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2218" xlink:to="loc_ifrs-full_TopOfRangeMember_2293" use="optional" order="145" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_2146643244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_PurposeAxis_2146643244" use="optional" order="146" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_PurposeAxis_2146643244" xlink:to="loc_gsk_PurposeDomain_2146643243" use="optional" order="147" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643243_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_PurposeAxis_2146643244" xlink:to="loc_gsk_PurposeDomain_2146643243_default" use="optional" order="148" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:label="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_PurposeDomain_2146643243" xlink:to="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643242" use="optional" order="149" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" use="optional" order="150" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2146643155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" xlink:to="loc_ifrs-full_LiabilitiesMember_2146643155" use="optional" order="151" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2146643155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" xlink:to="loc_ifrs-full_LiabilitiesMember_2146643155_default" use="optional" order="152" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitesOneMember" xlink:label="loc_gsk_FinancialLiabilitesOneMember_2146643154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_2146643155" xlink:to="loc_gsk_FinancialLiabilitesOneMember_2146643154" use="optional" order="153" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_858220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_858220" use="optional" order="154" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_631030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_Equity_631030" use="optional" order="155" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme_2246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme_2246" use="optional" order="156" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedUnderUsShelfRegistration" xlink:label="loc_gsk_NotesIssuedUnderUsShelfRegistration_2247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_NotesIssuedUnderUsShelfRegistration_2247" use="optional" order="157" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_NotionalAmount_2239" use="optional" order="158" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="loc_ifrs-full_TreasuryShares_2264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TreasuryShares_2264" use="optional" order="159" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_2241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_2241" use="optional" order="160" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied_1307532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied_1307532" use="optional" order="161" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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." xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements._1307539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements._1307539" use="optional" order="162" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfTheContingentConsiderationPayable" xlink:label="loc_gsk_RemeasurementOfTheContingentConsiderationPayable_2266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_RemeasurementOfTheContingentConsiderationPayable_2266" use="optional" order="163" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2146643160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2146643160" use="optional" order="164" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_2146643159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_2146643159" use="optional" order="165" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_2146643157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_2146643157" use="optional" order="166" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xlink:label="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments_2271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments_2271" use="optional" order="167" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xlink:label="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement_2146643036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement_2146643036" use="optional" order="168" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashManagedForSubsidiaryCompany" xlink:label="loc_gsk_CashManagedForSubsidiaryCompany_2255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashManagedForSubsidiaryCompany_2255" use="optional" order="169" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:label="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643245" use="optional" order="170" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xlink:label="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense_2146643003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense_2146643003" use="optional" order="171" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_2310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_2310" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RatedCreditExposures" xlink:label="loc_ifrs-full_RatedCreditExposures_2311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_ifrs-full_RatedCreditExposures_2311" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xlink:label="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds_2307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds_2307" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:label="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2306" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentSecurities" xlink:label="loc_gsk_GovernmentSecurities_2309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_GovernmentSecurities_2309" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresTable" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="loc_ifrs-full_ExternalCreditGradesAxis_2303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xlink:to="loc_ifrs-full_ExternalCreditGradesAxis_2303" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2303" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2303" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AAAOrAaaMember" xlink:label="loc_gsk_AAAOrAaaMember_2312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AAAOrAaaMember_2312" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AaOrAaMember" xlink:label="loc_gsk_AaOrAaMember_2313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AaOrAaMember_2313" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BbbOrBaaMember" xlink:label="loc_gsk_BbbOrBaaMember_2315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_BbbOrBaaMember_2315" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AorAMember" xlink:label="loc_gsk_AorAMember_2314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AorAMember_2314" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBPlusOrBaOneMember" xlink:label="loc_gsk_BBPlusOrBaOneMember_2316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_BBPlusOrBaOneMember_2316" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2304" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2304" xlink:to="loc_ifrs-full_TypesOfRisksMember_2305" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2305_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2304" xlink:to="loc_ifrs-full_TypesOfRisksMember_2305_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_2317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2305" xlink:to="loc_ifrs-full_CreditRiskMember_2317" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidityFunds" xlink:label="loc_gsk_LiquidityFunds_2308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_LiquidityFunds_2308" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayableMember" xlink:label="loc_gsk_TradeAndOtherPayableMember_2373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_gsk_TradeAndOtherPayableMember_2373" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentLiabilitiesMember" xlink:label="loc_gsk_OtherNonCurrentLiabilitiesMember_2375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_gsk_OtherNonCurrentLiabilitiesMember_2375" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_2374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_ifrs-full_OtherProvisionsMember_2374" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2320" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2320" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2321" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2321_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2320" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2321_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BondsInDesignatedHedgingRelationshipMember" xlink:label="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2332" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansAndOverdraftsMember" xlink:label="loc_gsk_BankLoansAndOverdraftsMember_2334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_BankLoansAndOverdraftsMember_2334" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBorrowingMember" xlink:label="loc_gsk_OtherBorrowingMember_2336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherBorrowingMember_2336" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBondsMember" xlink:label="loc_gsk_OtherBondsMember_2333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherBondsMember_2333" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xlink:label="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember_2335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember_2335" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCommercialPaperMember" xlink:label="loc_gsk_OtherCommercialPaperMember_1706563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherCommercialPaperMember_1706563" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2328" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2328_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2353" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_2354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_2354" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2356" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2355" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" xlink:to="loc_ifrs-full_FinancialAssetsMember_2329" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2329_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" xlink:to="loc_ifrs-full_FinancialAssetsMember_2329_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2361" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_2367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_2367" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsMember" xlink:label="loc_gsk_LiquidInvestmentsMember_2362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_LiquidInvestmentsMember_2362" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2365" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2366" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalents1Member" xlink:label="loc_gsk_CashAndCashEquivalents1Member_2363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_CashAndCashEquivalents1Member_2363" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsMember" xlink:label="loc_gsk_OtherInvestmentsMember_2360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_OtherInvestmentsMember_2360" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityAndOtherInvestmentsMember" xlink:label="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643020" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2331" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2331_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesMember" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesMember_2378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2331" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesMember_2378" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_513637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2331" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_513637" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue_2337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue_2337" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_2347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialLiabilities_2347" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2351" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_2349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_2349" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_2338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialAssets_2338" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLease" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease_2343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease_2343" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsLiabilities" xlink:label="loc_gsk_NetFinancialAssetsLiabilities_2348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_NetFinancialAssetsLiabilities_2348" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:label="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue_2352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue_2352" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_2401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_2401" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" xlink:to="loc_ifrs-full_FinancialAssetsMember_2392" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2392_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" xlink:to="loc_ifrs-full_FinancialAssetsMember_2392_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2411" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_513802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_513802" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalents1Member" xlink:label="loc_gsk_CashAndCashEquivalents1Member_2413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_CashAndCashEquivalents1Member_2413" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsMember" xlink:label="loc_gsk_OtherInvestmentsMember_2408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_OtherInvestmentsMember_2408" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2409" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2412" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_513804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_513804" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_2410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_2410" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityAndOtherInvestmentsMember" xlink:label="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643021" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2394" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2394_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2394_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesMember" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesMember_2420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesMember_2420" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2417" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember_2146645772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" xlink:to="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember_2146645772" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_2399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_2399" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_2398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_2398" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2400" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2391" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2391_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2391_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2391" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2404" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2391" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2403" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_MeasurementAxis_2396" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_2396" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2383" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_2396" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2383_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2383" xlink:to="loc_ifrs-full_AtFairValueMember_2397" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2402" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentOfContingentConsiderationLiabilities" xlink:label="loc_gsk_PaymentOfContingentConsiderationLiabilities_2432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_PaymentOfContingentConsiderationLiabilities_2432" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities_2429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities_2429" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities_2433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities_2433" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities_2430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities_2430" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialAssetsAndLiabilities" xlink:label="loc_gsk_FinancialAssetsAndLiabilities_2428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_FinancialAssetsAndLiabilities_2428" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities_2434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities_2434" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xlink:label="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities_2435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities_2435" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2427" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_2146643221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_2146643221" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities_2146643070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities_2146643070" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2444" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2444_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_2450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_2450" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2451" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2452" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialInstrumentsMember" xlink:label="loc_gsk_FinancialInstrumentsMember_2453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_gsk_FinancialInstrumentsMember_2453" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonFinancialInstrumentsMember" xlink:label="loc_gsk_NonFinancialInstrumentsMember_2454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_gsk_NonFinancialInstrumentsMember_2454" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" xlink:to="loc_ifrs-full_FinancialAssetsMember_2445" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2445_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" xlink:to="loc_ifrs-full_FinancialAssetsMember_2445_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_2456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2445" xlink:to="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_2456" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_2447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_2447" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_2449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_FinancialAssets_2449" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_2446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_2446" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialInstrumentsMember" xlink:label="loc_gsk_FinancialInstrumentsMember_2488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_gsk_FinancialInstrumentsMember_2488" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonFinancialInstrumentsMember" xlink:label="loc_gsk_NonFinancialInstrumentsMember_2489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_gsk_NonFinancialInstrumentsMember_2489" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2486" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2490" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2479" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2479_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2479_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member_2491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2479" xlink:to="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member_2491" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-full_TradeAndOtherPayables_2480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_TradeAndOtherPayables_2480" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_2482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_2482" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_2481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_OtherProvisions_2481" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_2485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_FinancialLiabilities_2485" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2483" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentLiabilities" xlink:label="loc_ifrs-full_HedgingInstrumentLiabilities_2509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_ifrs-full_HedgingInstrumentLiabilities_2509" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentsLiabilities" xlink:label="loc_gsk_HedgingInstrumentsLiabilities_534846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentsLiabilities_534846" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2500" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2500" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2501" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2500" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2501_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2514" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmbeddedAndOtherDerivativesMember" xlink:label="loc_gsk_EmbeddedAndOtherDerivativesMember_2516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_gsk_EmbeddedAndOtherDerivativesMember_2516" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_gsk_ForeignExchangeContractsMember_2515" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2498" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2498_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2498_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2498" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2511" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2498" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2510" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_2512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_2512" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember_2513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember_2513" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2502" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2502" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2503" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2502" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2503_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2503" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2518" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2503" xlink:to="loc_gsk_NetInvestmentHedgesMember_2519" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesNoncurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent_2507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent_2507" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesCurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesCurrent_2508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentLiabilitiesCurrent_2508" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentAssets" xlink:label="loc_ifrs-full_HedgingInstrumentAssets_2506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_ifrs-full_HedgingInstrumentAssets_2506" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsCurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsCurrent_2505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentAssetsCurrent_2505" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsNoncurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsNoncurrent_2504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentAssetsNoncurrent_2504" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2526" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2526" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2527" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2527_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2526" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2527_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2527" xlink:to="loc_gsk_ForeignExchangeContractsMember_2534" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2527" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2533" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2528" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2528" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2529" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2528" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2529_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2529" xlink:to="loc_gsk_NetInvestmentHedgesMember_2537" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2529" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2536" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_590153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_MaturityAxis_590153" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_590154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_590153" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_590154" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_590154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_590153" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_590154_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_590155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_590154" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_590155" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_590156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_590154" xlink:to="loc_ifrs-full_LaterThanOneYearMember_590156" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2525" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2525_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2525" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2532" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2525" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2531" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2530" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_2548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_2548" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2546" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2546" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2547" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2547_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2546" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2547_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2547" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2563" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2547" xlink:to="loc_gsk_NetInvestmentHedgesMember_2564" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_600826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_srt_CurrencyAxis_600826" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_600827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_600826" xlink:to="loc_currency_AllCurrenciesDomain_600827" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_600827_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_600826" xlink:to="loc_currency_AllCurrenciesDomain_600827_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JapaneseYenMember" xlink:label="loc_gsk_JapaneseYenMember_600831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_JapaneseYenMember_600831" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroMember" xlink:label="loc_gsk_EuroMember_600829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_EuroMember_600829" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SgdMember" xlink:label="loc_gsk_SgdMember_600832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_SgdMember_600832" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CADMember" xlink:label="loc_gsk_CADMember_2146643170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_CADMember_2146643170" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2544" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2544" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2545" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2544" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2545_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2545" xlink:to="loc_gsk_ForeignExchangeContractsMember_2562" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_HedgedItemsAxis_2542" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_2542" xlink:to="loc_ifrs-full_HedgedItemsMember_2543" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2543_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_2542" xlink:to="loc_ifrs-full_HedgedItemsMember_2543_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyOverSixMonthsMember_2556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyOverSixMonthsMember_2556" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyThreeToSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember_2555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember_2555" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyOverSixMonthsMember_2559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_SellForeignCurrencyOverSixMonthsMember_2559" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember_2554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember_2554" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2561" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember_2557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember_2557" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsLessThanThreeMonthsMember" xlink:label="loc_gsk_BorrowingsLessThanThreeMonthsMember_2146645886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingsLessThanThreeMonthsMember_2146645886" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsOverSixMonthsMember" xlink:label="loc_gsk_BorrowingsOverSixMonthsMember_2146645903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingsOverSixMonthsMember_2146645903" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2560" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingThreeToSixMonthsMember" xlink:label="loc_gsk_BorrowingThreeToSixMonthsMember_2146643171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingThreeToSixMonthsMember_2146643171" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_2551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_2551" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2550" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfForeignCurrency" xlink:label="loc_gsk_DescriptionOfForeignCurrency_2549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_DescriptionOfForeignCurrency_2549" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xlink:label="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges_2553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges_2553" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2552" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xlink:label="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1_2146643169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1_2146643169" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments_2581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments_2581" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax_2579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax_2579" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_HedgedItemsAxis_2570" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_2570" xlink:to="loc_ifrs-full_HedgedItemsMember_2571" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2571_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_2570" xlink:to="loc_ifrs-full_HedgedItemsMember_2571_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2582" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PrehedgingOfLongtermInterestRatesMember" xlink:label="loc_gsk_PrehedgingOfLongtermInterestRatesMember_2585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_PrehedgingOfLongtermInterestRatesMember_2585" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2583" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsMember" xlink:label="loc_gsk_VariabilityInCashFlowsMember_2584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsMember_2584" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="loc_ifrs-full_PastDueStatusAxis_1307907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_PastDueStatusAxis_1307907" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="loc_ifrs-full_PastDueStatusMember_1307908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_PastDueStatusAxis_1307907" xlink:to="loc_ifrs-full_PastDueStatusMember_1307908" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="loc_ifrs-full_PastDueStatusMember_1307908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_PastDueStatusAxis_1307907" xlink:to="loc_ifrs-full_PastDueStatusMember_1307908_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:label="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307910" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaturedInThePastPeriodMember" xlink:label="loc_gsk_MaturedInThePastPeriodMember_1307947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MaturedInThePastPeriodMember_1307947" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307912" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanThirtyYearsMember_1307915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanThirtyYearsMember_1307915" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2572" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2572" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2573" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2572" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2573_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2574" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2574" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2575" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2574" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2575_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2575" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2587" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:label="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_2588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2575" xlink:to="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_2588" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments_2576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments_2576" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness_2578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness_2578" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss_2577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss_2577" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xlink:label="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets_2146643168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets_2146643168" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax_2580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax_2580" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem_2146643167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem_2146643167" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2607" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsLiabilities" xlink:label="loc_gsk_DerivativeFinancialAssetsLiabilities_2606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_gsk_DerivativeFinancialAssetsLiabilities_2606" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges_2608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges_2608" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_MaturityAxis_2598" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2598" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2591" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2591_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2598" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2591_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:label="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307918" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanThirtyYearsMember_1307921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanThirtyYearsMember_1307921" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307920" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_HedgedItemsAxis_2594" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_2594" xlink:to="loc_ifrs-full_HedgedItemsMember_2595" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2595_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_2594" xlink:to="loc_ifrs-full_HedgedItemsMember_2595_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PrehedgingOfLongtermInterestRatesMember" xlink:label="loc_gsk_PrehedgingOfLongtermInterestRatesMember_1307930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_2595" xlink:to="loc_gsk_PrehedgingOfLongtermInterestRatesMember_1307930" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2596" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2596" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2597" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2597_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2596" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2597_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2597" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2610" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageFixedInterestRateOfHedgingInstrument" xlink:label="loc_gsk_AverageFixedInterestRateOfHedgingInstrument_2603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_gsk_AverageFixedInterestRateOfHedgingInstrument_2603" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2604" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness_2605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness_2605" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets_2624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets_2624" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2628" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2626" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2625" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2623" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2622" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2621" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities_2627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities_2627" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2620" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_2615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_2615" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_2615_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_2615_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsMember" xlink:label="loc_gsk_DerivativeFinancialAssetsMember_2630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_2615" xlink:to="loc_gsk_DerivativeFinancialAssetsMember_2630" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_2615" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2629" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradesAndOtherPayablesMember" xlink:label="loc_gsk_TradesAndOtherPayablesMember_2631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" xlink:to="loc_gsk_TradesAndOtherPayablesMember_2631" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialLiabilitiesMember" xlink:label="loc_gsk_DerivativeFinancialLiabilitiesMember_2632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" xlink:to="loc_gsk_DerivativeFinancialLiabilitiesMember_2632" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2619" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingLineItems" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt" xlink:label="loc_gsk_Debt_2648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" xlink:to="loc_gsk_Debt_2648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestBearingDebt" xlink:label="loc_gsk_InterestBearingDebt_2649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" xlink:to="loc_gsk_InterestBearingDebt_2649" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingTable" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" xlink:to="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xlink:to="loc_ifrs-full_MaturityAxis_2639" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2639" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2635" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2635_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2639" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2635_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2644" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2643" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2646" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2645" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2642" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_2641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanOneYearMember_2641" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_2647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_2647" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2640" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2640" xlink:to="loc_ifrs-full_InterestRateTypesMember_2638" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2640" xlink:to="loc_ifrs-full_InterestRateTypesMember_2638_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FixedInterestRateMember" xlink:label="loc_ifrs-full_FixedInterestRateMember_2652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_ifrs-full_FixedInterestRateMember_2652" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_2653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_ifrs-full_FloatingInterestRateMember_2653" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FloatingAndFixedRateDebtMember" xlink:label="loc_gsk_FloatingAndFixedRateDebtMember_2651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_gsk_FloatingAndFixedRateDebtMember_2651" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2658" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2658" xlink:to="loc_ifrs-full_TypesOfRisksMember_2659" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2659_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2658" xlink:to="loc_ifrs-full_TypesOfRisksMember_2659_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2665" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2662" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember_2664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember_2664" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember_2146645320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember_2146645320" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645319" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645323" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2666" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2663" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember_2668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember_2668" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember_2146645327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember_2146645327" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures_513656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures_513656" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures_2660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures_2660" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures_2661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures_2661" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2673" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2673" xlink:to="loc_ifrs-full_TypesOfRisksMember_2674" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2673" xlink:to="loc_ifrs-full_TypesOfRisksMember_2674_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember_2676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember_2676" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember_2678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember_2678" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember_2677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember_2677" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember_2146643164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember_2146643164" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember_2146643163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember_2146643163" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember_2146643162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember_2146643162" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2675" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FutureFinanceChargeOnFinanceLeases" xlink:label="loc_gsk_FutureFinanceChargeOnFinanceLeases_2697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_gsk_FutureFinanceChargeOnFinanceLeases_2697" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_2694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_2694" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseLiability" xlink:label="loc_gsk_FinanceLeaseLiability_2696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_gsk_FinanceLeaseLiability_2696" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_2699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_2699" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_2698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_2698" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2684" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2684" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2685" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2684" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2685_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDerivativesFinancialLiabilitiesMember" xlink:label="loc_gsk_NonDerivativesFinancialLiabilitiesMember_2700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2685" xlink:to="loc_gsk_NonDerivativesFinancialLiabilitiesMember_2700" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xlink:to="loc_ifrs-full_MaturityAxis_2686" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2686" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2681" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2681_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2686" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2681_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2688" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2687" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_2693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_2693" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2690" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2689" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2691" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2692" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_2695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_2695" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_ifrs-full_MaturityAxis_2710" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2710" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2703" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2703_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2710" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2703_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2713" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1307548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1307548" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1307549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1307549" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2711" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1307547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1307547" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2712" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" xlink:to="loc_ifrs-full_FinancialAssetsMember_2709" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2709_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" xlink:to="loc_ifrs-full_FinancialAssetsMember_2709_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember" xlink:label="loc_ifrs-full_DerivativesMember_2718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_2709" xlink:to="loc_ifrs-full_DerivativesMember_2718" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrument1Axis" xlink:label="loc_gsk_DebtInstrument1Axis_2705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_gsk_DebtInstrument1Axis_2705" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrumentDomain" xlink:label="loc_gsk_DebtInstrumentDomain_2706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_DebtInstrument1Axis_2705" xlink:to="loc_gsk_DebtInstrumentDomain_2706" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrumentDomain" xlink:label="loc_gsk_DebtInstrumentDomain_2706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_DebtInstrument1Axis_2705" xlink:to="loc_gsk_DebtInstrumentDomain_2706_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:label="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_2715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DebtInstrumentDomain_2706" xlink:to="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_2715" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DebtInstrumentDomain_2706" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2714" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" xlink:to="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2717" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" xlink:to="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2716" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedFutureDividendYieldPercentageShareGranted" xlink:label="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted_2729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted_2729" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2728" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesTable" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PerformanceSharePlansMember" xlink:label="loc_gsk_PerformanceSharePlansMember_2739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_PerformanceSharePlansMember_2739" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedShareOptionSchemesMember" xlink:label="loc_gsk_SavingsRelatedShareOptionSchemesMember_2737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_SavingsRelatedShareOptionSchemesMember_2737" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeCashFlowMember" xlink:label="loc_gsk_FreeCashFlowMember_831714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_FreeCashFlowMember_831714" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_2738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_ShareValuePlanMember_2738" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineProgressMember" xlink:label="loc_gsk_PipelineProgressMember_831717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_PipelineProgressMember_831717" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TsrMember" xlink:label="loc_gsk_TsrMember_846664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_TsrMember_846664" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RAndDNewProductPerformanceMember" xlink:label="loc_gsk_RAndDNewProductPerformanceMember_831716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_RAndDNewProductPerformanceMember_831716" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" xlink:label="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember_1223852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember_1223852" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AwardType1Axis" xlink:label="loc_gsk_AwardType1Axis_2721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_gsk_AwardType1Axis_2721" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_AwardType1Axis_2721" xlink:to="loc_gsk_EquityAwardDomain_2724" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2724_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_AwardType1Axis_2721" xlink:to="loc_gsk_EquityAwardDomain_2724_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xlink:label="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember_1192170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EquityAwardDomain_2724" xlink:to="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember_1192170" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_2736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EquityAwardDomain_2724" xlink:to="loc_gsk_AmericanDepositarySharesMember_2736" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1317301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1317301" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1317301_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1317301_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement_2735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement_2735" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquallyWeightedMeasuresOverPerformancePeriod" xlink:label="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod_1192169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod_1192169" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingAwards" xlink:label="loc_gsk_NumberOfOutstandingAwards_2732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfOutstandingAwards_2732" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2730" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AtPercentageBelowMarketPrice" xlink:label="loc_gsk_AtPercentageBelowMarketPrice_2727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_AtPercentageBelowMarketPrice_2727" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:label="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2731" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2733" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfPerformanceSharePlan" xlink:label="loc_gsk_PercentageOfPerformanceSharePlan_831713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_PercentageOfPerformanceSharePlan_831713" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement_2734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement_2734" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement_2751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement_2751" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:label="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2753" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AwardType1Axis" xlink:label="loc_gsk_AwardType1Axis_2742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xlink:to="loc_gsk_AwardType1Axis_2742" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gsk_AwardType1Axis_2742" xlink:to="loc_gsk_EquityAwardDomain_2745" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2745_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gsk_AwardType1Axis_2742" xlink:to="loc_gsk_EquityAwardDomain_2745_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_2754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_EquityAwardDomain_2745" xlink:to="loc_gsk_AmericanDepositarySharesMember_2754" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_2755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" xlink:to="loc_gsk_ShareValuePlanMember_2755" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingShareAwards" xlink:label="loc_gsk_NumberOfOutstandingShareAwards_2748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfOutstandingShareAwards_2748" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2749" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement_2750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement_2750" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:label="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" xlink:to="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2767" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPrice" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPrice_2766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_SavingsRelatedOptionsGrantPrice_2766" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2762" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2764" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedLifeOfShareOptionsGranted" xlink:label="loc_gsk_ExpectedLifeOfShareOptionsGranted_2765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_ExpectedLifeOfShareOptionsGranted_2765" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendYieldShareOptionsGranted" xlink:label="loc_gsk_DividendYieldShareOptionsGranted_2763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_DividendYieldShareOptionsGranted_2763" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:label="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" xlink:to="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2775" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPriceDiscount" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount_2774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" xlink:to="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount_2774" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_2784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_2784" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_2787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_2787" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_2786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_2786" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xlink:label="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption_2788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption_2788" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionSchemesMember" xlink:label="loc_gsk_ShareOptionSchemesMember_2791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" xlink:to="loc_gsk_ShareOptionSchemesMember_2791" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedShareOptionSchemesMember" xlink:label="loc_gsk_SavingsRelatedShareOptionSchemesMember_2793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" xlink:to="loc_gsk_SavingsRelatedShareOptionSchemesMember_2793" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xlink:to="loc_ifrs-full_RangeAxis_2780" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2780" xlink:to="loc_ifrs-full_RangesMember_2781" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2781_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2780" xlink:to="loc_ifrs-full_RangesMember_2781_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2781" xlink:to="loc_ifrs-full_BottomOfRangeMember_2790" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2781" xlink:to="loc_ifrs-full_TopOfRangeMember_2789" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement_2785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement_2785" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeShareOwnershipPlanMember" xlink:label="loc_gsk_EmployeeShareOwnershipPlanMember_2808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" xlink:to="loc_gsk_EmployeeShareOwnershipPlanMember_2808" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareOptionSchemes_2804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NumberOfSharesHeldForShareOptionSchemes_2804" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes_2803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes_2803" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes_2805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes_2805" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes_2807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes_2807" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes_2801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes_2801" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes_2806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes_2806" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareAwardSchemes_2800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NumberOfSharesHeldForShareAwardSchemes_2800" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes_2802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes_2802" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2814" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2814" xlink:to="loc_ifrs-full_GeographicalAreasMember_2815" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2814" xlink:to="loc_ifrs-full_GeographicalAreasMember_2815_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_2885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_ifrs-full_CountryOfDomicileMember_2885" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA_2890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CA_2890" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="loc_country_BR_2889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_BR_2889" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="loc_country_AU_2888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_AU_2888" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="loc_country_BE_2899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_BE_2899" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="loc_country_FR_2900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_FR_2900" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="loc_country_SG_2896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_SG_2896" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_country_HK_2891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_HK_2891" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE_2901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_DE_2901" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL" xlink:label="loc_country_PL_2904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_PL_2904" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU" xlink:label="loc_country_RU_2906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_RU_2906" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="loc_country_CH_2908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CH_2908" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="loc_country_CN_2892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CN_2892" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="loc_country_NL_2903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_NL_2903" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES" xlink:label="loc_country_ES_2907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_ES_2907" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="loc_country_IE_2905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IE_2905" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN" xlink:label="loc_country_IN_2893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IN_2893" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="loc_country_IT_2902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IT_2902" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP_2894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_JP_2894" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="loc_country_KR_2897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_KR_2897" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PK" xlink:label="loc_country_PK_2895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_PK_2895" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_2886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_US_2886" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR" xlink:label="loc_country_TR_2898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_TR_2898" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SaudiArabiaMember" xlink:label="loc_gsk_SaudiArabiaMember_2146643224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_SaudiArabiaMember_2146643224" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AustriaMember" xlink:label="loc_gsk_AustriaMember_2146643223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_AustriaMember_2146643223" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThailandMember" xlink:label="loc_gsk_ThailandMember_2146643222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_ThailandMember_2146643222" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GreeceMember" xlink:label="loc_gsk_GreeceMember_2146643220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_GreeceMember_2146643220" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TW" xlink:label="loc_country_TW_2146643194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_TW_2146643194" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX" xlink:label="loc_country_MX_2146643192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_MX_2146643192" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VietnamMember" xlink:label="loc_gsk_VietnamMember_2146643191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_VietnamMember_2146643191" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_BOFS" xlink:label="loc_exch_BOFS_2146643201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_exch_BOFS_2146643201" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoGroupLimitedMember" xlink:label="loc_gsk_GlaxoGroupLimitedMember_2818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoGroupLimitedMember_2818" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoOperationsUkLimitedMember" xlink:label="loc_gsk_GlaxoOperationsUkLimitedMember_2819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoOperationsUkLimitedMember_2819" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalIncMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalIncMember_2836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineCapitalIncMember_2836" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBrasilLimitadaMember" xlink:label="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember_2849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember_2849" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalPLCMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalPLCMember_2820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineCapitalPLCMember_2820" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSAMember" xlink:label="loc_gsk_GlaxoSmithKlineSAMember_2882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineSAMember_2882" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBiologicalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlineBiologicalsSAMember_2865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineBiologicalsSAMember_2865" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xlink:label="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember_2847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember_2847" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineExportLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineExportLimitedMember_2824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineExportLimitedMember_2824" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesGmbHMember" xlink:label="loc_gsk_GSKVaccinesGmbHMember_2873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKVaccinesGmbHMember_2873" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsIncMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsIncMember_2839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineHoldingsIncMember_2839" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineFinancePLCMember" xlink:label="loc_gsk_GlaxoSmithKlineFinancePLCMember_2825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineFinancePLCMember_2825" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorixaCorporationMember" xlink:label="loc_gsk_CorixaCorporationMember_2835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_CorixaCorporationMember_2835" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKServicesSPZOOMember" xlink:label="loc_gsk_GSKServicesSPZOOMember_2879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKServicesSPZOOMember_2879" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePakistanLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlinePakistanLimitedMember_2861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlinePakistanLimitedMember_2861" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember_2827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember_2827" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineIncMember" xlink:label="loc_gsk_GlaxoSmithKlineIncMember_2851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineIncMember_2851" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HumanGenomeSciencesIncMember" xlink:label="loc_gsk_HumanGenomeSciencesIncMember_2841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_HumanGenomeSciencesIncMember_2841" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SetFirstLimitedMember" xlink:label="loc_gsk_SetFirstLimitedMember_2830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_SetFirstLimitedMember_2830" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineGmbHAndCoKGMember" xlink:label="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember_2872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember_2872" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSPAMember" xlink:label="loc_gsk_GlaxoSmithKlineSPAMember_2875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineSPAMember_2875" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineServicesUnlimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember_2828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember_2828" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLLCMember" xlink:label="loc_gsk_GlaxoSmithKlineLLCMember_2840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineLLCMember_2840" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineTradingServicesLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember_2880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember_2880" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoriosViiVHealthCareSLMember" xlink:label="loc_gsk_LaboratoriosViiVHealthCareSLMember_2883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_LaboratoriosViiVHealthCareSLMember_2883" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesSRLMember" xlink:label="loc_gsk_GSKVaccinesSRLMember_2876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKVaccinesSRLMember_2876" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember_2826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember_2826" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareFinanceLimitedMember" xlink:label="loc_gsk_ViivHealthcareFinanceLimitedMember_590391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareFinanceLimitedMember_590391" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareSASMember" xlink:label="loc_gsk_ViiVHealthcareSASMember_2870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthcareSASMember_2870" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareUnitedKingdomLimitedMember" xlink:label="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember_2833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember_2833" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKKMember" xlink:label="loc_gsk_GlaxoSmithKlineKKMember_2859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineKKMember_2859" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKoreaLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineKoreaLimitedMember_2863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineKoreaLimitedMember_2863" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineLimitedMember_2853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineLimitedMember_2853" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelLaboratoriesIncMember" xlink:label="loc_gsk_StiefelLaboratoriesIncMember_2844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_StiefelLaboratoriesIncMember_2844" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" xlink:label="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember_590513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember_590513" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SmithKlineBeechamLimitedMember" xlink:label="loc_gsk_SmithKlineBeechamLimitedMember_2831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_SmithKlineBeechamLimitedMember_2831" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember_2829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember_2829" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoireGlaxoSmithKlineMember" xlink:label="loc_gsk_LaboratoireGlaxoSmithKlineMember_2869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_LaboratoireGlaxoSmithKlineMember_2869" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareSRLItalyMember" xlink:label="loc_gsk_ViivHealthcareSRLItalyMember_831808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareSRLItalyMember_831808" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IDBiomedicalCorporationOfQuebecMember" xlink:label="loc_gsk_IDBiomedicalCorporationOfQuebecMember_2852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_IDBiomedicalCorporationOfQuebecMember_2852" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeManufacturingPteLtdMember" xlink:label="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember_2862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember_2862" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroMember" xlink:label="loc_gsk_TesaroMember_587841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_TesaroMember_587841" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareCompanyMember" xlink:label="loc_gsk_ViiVHealthcareCompanyMember_2845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthcareCompanyMember_2845" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEquityInvestmentsLimitedMember" xlink:label="loc_gsk_GskEquityInvestmentsLimitedMember_831772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskEquityInvestmentsLimitedMember_831772" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeUkLimitedMember" xlink:label="loc_gsk_GlaxoWellcomeUkLimitedMember_1306965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoWellcomeUkLimitedMember_1306965" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineUsTradingLimitedMember" xlink:label="loc_gsk_GlaxosmithklineUsTradingLimitedMember_1306964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineUsTradingLimitedMember_1306964" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JscGlaxosmithklineTradingMember" xlink:label="loc_gsk_JscGlaxosmithklineTradingMember_1306969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_JscGlaxosmithklineTradingMember_1306969" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember_2146643254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember_2146643254" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_2146643249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_AffinivaxIncMember_2146643249" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineAgMember" xlink:label="loc_gsk_GlaxosmithklineAgMember_2146643248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineAgMember_2146643248" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineB.v.Member" xlink:label="loc_gsk_GlaxosmithklineB.v.Member_2146643247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineB.v.Member_2146643247" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaGmbhMember" xlink:label="loc_gsk_GlaxosmithklinePharmaGmbhMember_2146643246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklinePharmaGmbhMember_2146643246" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xlink:label="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member_2146643239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member_2146643239" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskCapitalB.v.Member" xlink:label="loc_gsk_GskCapitalB.v.Member_2146643238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskCapitalB.v.Member_2146643238" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareGmbhMember" xlink:label="loc_gsk_ViivHealthcareGmbhMember_2146643237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareGmbhMember_2146643237" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineThailandLimitedMember" xlink:label="loc_gsk_GlaxosmithklineThailandLimitedMember_2146643233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineThailandLimitedMember_2146643233" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineFarEastB.v.Member" xlink:label="loc_gsk_GlaxosmithklineFarEastB.v.Member_2146643232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineFarEastB.v.Member_2146643232" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xlink:label="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member_2146643231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member_2146643231" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xlink:label="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member_2146643230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member_2146643230" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEnterpriseManagementCoLtdMember" xlink:label="loc_gsk_GskEnterpriseManagementCoLtdMember_2146643229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskEnterpriseManagementCoLtdMember_2146643229" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPharmaVietnamCompanyLimitedMember" xlink:label="loc_gsk_GskPharmaVietnamCompanyLimitedMember_2146643228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskPharmaVietnamCompanyLimitedMember_2146643228" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareK.kMember" xlink:label="loc_gsk_ViivHealthcareK.kMember_2146643227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareK.kMember_2146643227" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUlcMember" xlink:label="loc_gsk_ViivHealthcareUlcMember_2146643226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareUlcMember_2146643226" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember_2146643253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember_2146643253" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIhcLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIhcLimitedMember_2146643255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIhcLimitedMember_2146643255" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember_2146643252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember_2146643252" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember_2146643251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember_2146643251" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember_2146643250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember_2146643250" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSaudiArabiaLimitedMember" xlink:label="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643236" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember_2146643240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember_2146643240" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.1ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.1ScottishLimitedPartnershipMember_2146643200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.1ScottishLimitedPartnershipMember_2146643200" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.2ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.2ScottishLimitedPartnershipMember_2146643199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.2ScottishLimitedPartnershipMember_2146643199" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.3ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.3ScottishLimitedPartnershipMember_2146643198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.3ScottishLimitedPartnershipMember_2146643198" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xlink:label="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember_2146643056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember_2146643056" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="loc_ifrs-full_NameOfSubsidiary_2817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_NameOfSubsidiary_2817" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_1223870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_1223870" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_1247804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_1247804" use="optional" order="115" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2914" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2914" xlink:to="loc_ifrs-full_GeographicalAreasMember_2915" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2915_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2914" xlink:to="loc_ifrs-full_GeographicalAreasMember_2915_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp1LimitedsShareCapitalMember" xlink:label="loc_gsk_GskGp1LimitedsShareCapitalMember_2146643204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" xlink:to="loc_gsk_GskGp1LimitedsShareCapitalMember_2146643204" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp2LimitedsShareCapital.Member" xlink:label="loc_gsk_GskGp2LimitedsShareCapital.Member_2146643203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" xlink:to="loc_gsk_GskGp2LimitedsShareCapital.Member_2146643203" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146643207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_dei_LegalEntityAxis_2146643207" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146643206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146643207" xlink:to="loc_dei_EntityDomain_2146643206" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146643206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146643207" xlink:to="loc_dei_EntityDomain_2146643206_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPlcMember" xlink:label="loc_gsk_GskPlcMember_2146643205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146643206" xlink:to="loc_gsk_GskPlcMember_2146643205" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xlink:label="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember_2146643202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146643206" xlink:to="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember_2146643202" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_2146643208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" xlink:to="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_2146643208" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsLineItems" xlink:label="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsTable" xlink:label="loc_gsk_DisclosureOfLegalProceedingsTable_3015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_3016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_GeographicalAreasAxis_3016" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_3017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_3016" xlink:to="loc_ifrs-full_GeographicalAreasMember_3017" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_3017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_3016" xlink:to="loc_ifrs-full_GeographicalAreasMember_3017_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_3013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_3013" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_3013_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_3013_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1307791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_RangeAxis_1307791" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1307792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_1307791" xlink:to="loc_ifrs-full_RangesMember_1307792" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1307792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_1307791" xlink:to="loc_ifrs-full_RangesMember_1307792_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKKoreaMember" xlink:label="loc_gsk_GSKKoreaMember_2146643002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" xlink:to="loc_gsk_GSKKoreaMember_2146643002" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvision" xlink:label="loc_ifrs-full_LegalProceedingsProvision_3020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_ifrs-full_LegalProceedingsProvision_3020" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DamagesAwardedToGSK" xlink:label="loc_gsk_DamagesAwardedToGSK_1315692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_DamagesAwardedToGSK_1315692" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossContingencyNumberOfPlaintiffs" xlink:label="loc_gsk_LossContingencyNumberOfPlaintiffs_2146643262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_LossContingencyNumberOfPlaintiffs_2146643262" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinePayable" xlink:label="loc_gsk_FinePayable_2146643046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_FinePayable_2146643046" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>gsk-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-March-2023 [08:38:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassAxis" xlink:label="loc_gsk_TitleOfEachClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TitleOfEachClassAxis" xml:lang="en-US">Title Of Each Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TitleOfEachClassAxis" xlink:to="lab_gsk_TitleOfEachClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TitleOfEachClassAxis" xml:lang="en-US">Title of Each Class.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassDomain" xlink:label="loc_gsk_TitleOfEachClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TitleOfEachClassDomain" xml:lang="en-US">Title Of Each Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TitleOfEachClassDomain" xlink:to="lab_gsk_TitleOfEachClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TitleOfEachClassDomain" xml:lang="en-US">Title of Each Class.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFiveNotesDue2025Member" xlink:label="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointSixTwoFiveNotesDue2025Member" xml:lang="en-US">Three Point Six Two Five Notes due 2025 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointSixTwoFiveNotesDue2025Member" xml:lang="en-US">3.625% Notes due 2025 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member" xlink:to="lab_gsk_ThreePointSixTwoFiveNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointSixTwoFiveNotesDue2025Member" xml:lang="en-US">3.625% Notes due 2025.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFiveNotesDue2028Member" xlink:label="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointEightSevenFiveNotesDue2028Member" xml:lang="en-US">Three Point Eight Seven Five Notes due 2028 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointEightSevenFiveNotesDue2028Member" xml:lang="en-US">3.875% Notes due 2028 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member" xlink:to="lab_gsk_ThreePointEightSevenFiveNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointEightSevenFiveNotesDue2028Member" xml:lang="en-US">3.875% Notes due 2028.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFiveNotesDue2029Member" xlink:label="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointThreeSevenFiveNotesDue2029Member" xml:lang="en-US">Three Point Three Seven Five Notes due 2029 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointThreeSevenFiveNotesDue2029Member" xml:lang="en-US">3.375% Notes due 2029 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member" xlink:to="lab_gsk_ThreePointThreeSevenFiveNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointThreeSevenFiveNotesDue2029Member" xml:lang="en-US">3.375% Notes due 2029.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFiveNotesDue2038Member" xlink:label="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SixPointThreeSevenFiveNotesDue2038Member" xml:lang="en-US">Six Point Three Seven Five Notes due 2038 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SixPointThreeSevenFiveNotesDue2038Member" xml:lang="en-US">6.375% Notes due 2038 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member" xlink:to="lab_gsk_SixPointThreeSevenFiveNotesDue2038Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SixPointThreeSevenFiveNotesDue2038Member" xml:lang="en-US">6.375% Notes due 2038.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroNotesDue2024Member" xlink:label="loc_gsk_ThreePointZeroNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointZeroNotesDue2024Member" xml:lang="en-US">Three Point Zero Notes due 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointZeroNotesDue2024Member" xml:lang="en-US">3.000% Notes due 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointZeroNotesDue2024Member" xlink:to="lab_gsk_ThreePointZeroNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointZeroNotesDue2024Member" xml:lang="en-US">Three Point Zero Notes Due 2023.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourNotesDue2023Member" xlink:label="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointFiveThreeFourNotesDue2023Member" xml:lang="en-US">Zero Point Five Three Four Notes Due 2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointFiveThreeFourNotesDue2023Member" xml:lang="en-US">0.534% Notes due 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member" xlink:to="lab_gsk_ZeroPointFiveThreeFourNotesDue2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointFiveThreeFourNotesDue2023Member" xml:lang="en-US">0.534% Notes due 2023.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoZeroZeroNotesDue2043Member" xlink:label="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FourPointTwoZeroZeroNotesDue2043Member" xml:lang="en-US">Four Point Two Zero Zero Notes due 2043 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FourPointTwoZeroZeroNotesDue2043Member" xml:lang="en-US">4.200% Notes due 2043 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member" xlink:to="lab_gsk_FourPointTwoZeroZeroNotesDue2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FourPointTwoZeroZeroNotesDue2043Member" xml:lang="en-US">4.200% Notes due 2043.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AmericanDepositarySharesMember" xml:lang="en-US">American Depositary Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AmericanDepositarySharesMember" xml:lang="en-US">American Depositary Shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AmericanDepositarySharesMember" xlink:to="lab_gsk_AmericanDepositarySharesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xml:lang="en-US">Profit or loss [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Share of after tax (loss)/profits of associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Share of after-tax profits/(losses) of associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Share of after-tax profit / losses of associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Share of after tax profits and losses of associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xml:lang="en-US">Profit/(loss) after tax recognised in the consolidated income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax charge for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Total tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax charge/tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Total profit attributable to&#160;non-controlling&#160;interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Profit after taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xml:lang="en-US">Profit after taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfSales" xml:lang="en-US">Cost of sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CostOfSales" xml:lang="en-US">Cost of sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CostOfSales" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Total diluted earnings per share (pence)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Total diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:label="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xml:lang="en-US">Remeasurement Of Discontinued Operations Distributed To Shareholders On Demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xml:lang="en-US">Re-measurement&#160;of discontinued operations distributed to shareholders on demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xml:lang="en-US">Remeasurement of discontinued operations distributed to shareholders on demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:to="lab_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xml:lang="en-US">Re-measurement of discontinued operations distributed to shareholders on demerger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xml:lang="en-US">Profit (loss) from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xml:lang="en-US">Profit after taxation from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xml:lang="en-US">Profit after taxation from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xml:lang="en-US">Profit after taxation for the year from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xml:lang="en-US">Total profit after tax from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xlink:label="loc_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xml:lang="en-US">Profit Loss From Discontinued Operations And Other Gains Losses From Demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xml:lang="en-US">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xlink:to="lab_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xml:lang="en-US">Profit loss from discontinued operations and other gains losses from demerger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Total profit attributable to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit (loss) before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit before taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit before taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit before tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Total Basic earnings per share (pence)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Total basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Revenue" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Revenue" xml:lang="en-US">Turnover</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xml:lang="en-US">Royalty income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xml:lang="en-US">Royalty income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties" xlink:to="lab_ifrs-full_RevenueFromRoyalties" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xml:lang="en-US">Other operating income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xml:lang="en-US">Other operating (expense)/income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xml:lang="en-US">Other operating income expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Total profit after taxation for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Total profit after taxation for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Total profit for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit after taxation for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit after taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Share of after-tax losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociate" xml:lang="en-US">Gain (Loss) On Disposal Of Interest In Associate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociate" xml:lang="en-US">Loss on disposal of interest in associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociate" xml:lang="en-US">Milestone Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnDisposalOfInterestInAssociate" xlink:to="lab_gsk_GainLossOnDisposalOfInterestInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociate" xml:lang="en-US">Gain (Loss) on disposal of Interest in associates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Finance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Finance expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Finance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_FinanceCosts" xml:lang="en-US">Finance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Profit (loss) from operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Operating profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Operating profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Diluted earnings per share (pence) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Diluted earnings per share from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossProfit" xml:lang="en-US">Gross profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="lab_ifrs-full_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xml:lang="en-US">Profit (loss) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xml:lang="en-US">Profit after taxation from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xml:lang="en-US">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare until 18 July 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Profit (loss) from continuing operations attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Profit attributable to non-controlling interests from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Share of profit for the year attributable to non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" xml:lang="en-US">Income from continuing operations attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" xml:lang="en-US">Profit attributable to shareholders from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xml:lang="en-US">Income from discontinued operations attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xml:lang="en-US">Profit attributable to shareholders from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xml:lang="en-US">Earnings attributable to shareholders from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Basic earnings (loss) per share from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Basic earnings per share (pence) from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Basic earnings per share from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Basic earnings per share (pence) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Basic earnings per share from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xml:lang="en-US">Earnings per share from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Diluted earnings per share (pence) from continued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Diluted earnings per share from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Profit (loss) from discontinued operations attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Profit attributable to&#160;non-controlling&#160;interests from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xml:lang="en-US">Non-controlling&#160;interest in discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xml:lang="en-US">Statement of comprehensive income [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Comprehensive income attributable to [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Total comprehensive income for the year attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xml:lang="en-US">Non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xml:lang="en-US">Total comprehensive income income/(expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Share of total comprehensive income/(expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Comprehensive income, attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income/(expense) for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that may be subsequently reclassified to continuing operations income statement:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that may be subsequently reclassified to income statement:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xml:lang="en-US">Gains (losses) on exchange differences on translation, before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xml:lang="en-US">Exchange movements on overseas net assets and net investment hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xml:lang="en-US">Gains (losses) on cash flow hedges, before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xml:lang="en-US">Fair value movements on cash flow hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xml:lang="en-US">Income tax relating to cash flow hedges included in other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xml:lang="en-US">Deferred tax on fair value movements on cash flow hedges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xml:lang="en-US">Tax on fair value movements on cash flow hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xml:lang="en-US">Reclassification adjustments on cash flow hedges, before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xml:lang="en-US">Reclassification of cash flow hedges to income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Items that may be subsequently reclassified to continuing operations income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xml:lang="en-US">Reclassification adjustments on exchange differences on translation, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xml:lang="en-US">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xml:lang="en-US">Reclassification of exchange from other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that will not be reclassified to continuing operations income statement:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that will not be reclassified to income statement:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xml:lang="en-US">Other comprehensive income, before tax, gains (losses) from investments in equity instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xml:lang="en-US">Fair value movements on equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xml:lang="en-US">Income tax relating to investments in equity instruments included in other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xml:lang="en-US">Tax on fair value movements on equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Items that will not be reclassified to continuing operations income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xlink:label="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xml:lang="en-US">Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans Restated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xml:lang="en-US">Remeasurement (losses)/gains on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xlink:to="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xml:lang="en-US">Other comprehensive income before tax gains losses on remeasurements of defined benefit plans restated.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xml:lang="en-US">Exchange Movements On Overseas Net Assets Of Non Controlling Interests Restated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xml:lang="en-US">Exchange movements on overseas net assets of non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xlink:to="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xml:lang="en-US">Exchange movements on overseas net assets of non controlling interests restated.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xlink:label="loc_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xml:lang="en-US">Income Tax Relating To Remeasurements Of Defined Benefit Plans Of Other Comprehensive Income Restated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xml:lang="en-US">Tax on remeasurement losses/(gains) on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xlink:to="lab_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xml:lang="en-US">Income tax relating to remeasurements of defined benefit plans of other comprehensive income restated.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xlink:label="loc_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xml:lang="en-US">Fair value movements on cash flow hedges not reclassified</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xml:lang="en-US">Fair value movements on cash flow hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xlink:to="lab_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xml:lang="en-US">Fair value movements on cash flow hedges not reclassified.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xlink:label="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xml:lang="en-US">Other Comprehensive Expense Income For The Year From Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xml:lang="en-US">Other comprehensive expense for the year from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xlink:to="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xml:lang="en-US">Other comprehensive expense income for the year from continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xlink:label="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xml:lang="en-US">Other Comprehensive Expense Income For The Year From Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xml:lang="en-US">Other comprehensive income for the year from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xlink:to="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xml:lang="en-US">Other comprehensive expense income for the year from discontinued operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale or as held for distribution to owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Inventories" xml:lang="en-US">Current inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Inventories" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Inventories" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xml:lang="en-US">Current derivative financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Other current financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Total cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xml:lang="en-US">Current financial assets at fair value through profit or loss, classified as held for trading</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xml:lang="en-US">Current equity investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xml:lang="en-US">At 31 December</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xml:lang="en-US">At 1 January</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:to="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets" xlink:label="loc_ifrs-full_CurrentTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxAssets" xml:lang="en-US">Current tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxAssets" xml:lang="en-US">Current tax recoverable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTaxAssets" xml:lang="en-US">Tax recoverable, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssets" xlink:to="lab_ifrs-full_CurrentTaxAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xml:lang="en-US">Current tax liabilities, non-current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xml:lang="en-US">Corporation tax payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xml:lang="en-US">Tax payable, non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Provision for deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xml:lang="en-US">Non-current derivative financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other noncurrent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LongtermBorrowings" xml:lang="en-US">Non-current portion of non-current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_LongtermBorrowings" xml:lang="en-US">Long-term borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LongtermBorrowings" xml:lang="en-US">Long-term borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xml:lang="en-US">Other non-current provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xml:lang="en-US">Other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xml:lang="en-US">To be settled after one year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLongtermProvisions" xlink:to="lab_ifrs-full_OtherLongtermProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Total non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Non-current provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Pensions and other post-employment benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xml:lang="en-US">Other non-current financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xml:lang="en-US">Contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xml:lang="en-US">Assets (liabilities)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xml:lang="en-US">Net assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xml:lang="en-US">Net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-full_ShorttermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermBorrowings" xml:lang="en-US">Current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ShorttermBorrowings" xml:lang="en-US">Short-term borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermBorrowings" xlink:to="lab_ifrs-full_ShorttermBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Other current provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Short-term provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">To be settled within one year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherShorttermProvisions" xlink:to="lab_ifrs-full_OtherShorttermProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xml:lang="en-US">Current derivative financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Total trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xml:lang="en-US">Other current financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xml:lang="en-US">Contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherCurrentFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xml:lang="en-US">Current tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xml:lang="en-US">Current tax payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xml:lang="en-US">Tax payable, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilities" xlink:to="lab_ifrs-full_CurrentTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Retained earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Retained earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremium" xml:lang="en-US">Share premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharePremium" xml:lang="en-US">Share premium account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves, beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves, ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Issued capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xml:lang="en-US">Equity attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xml:lang="en-US">Shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterests" xml:lang="en-US">Non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterests" xml:lang="en-US">Non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterests" xml:lang="en-US">Non-controlling interest in the Consolidated balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests" xlink:to="lab_ifrs-full_NoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Total equity including non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Other non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Other non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xml:lang="en-US">Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Goodwill" xml:lang="en-US">Goodwill Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Goodwill" xml:lang="en-US">Goodwill Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Other intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Right of use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Net book value, beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Net book value, end of the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xml:lang="en-US">Investments accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xml:lang="en-US">Investments in associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Non-current investments other than investments accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Other investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xml:lang="en-US">Non-current derivative financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Total non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xml:lang="en-US">Statement of changes in equity [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="loc_ifrs-full_DividendsPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaid" xml:lang="en-US">Dividends recognised as distributions to owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DividendsPaid" xml:lang="en-US">Dividends to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaid" xlink:to="lab_ifrs-full_DividendsPaid" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xlink:label="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xml:lang="en-US">Write-down of shares held by ESOP Trusts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xml:lang="en-US">Write-down of shares held by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xlink:to="lab_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xml:lang="en-US">Write-down of shares held by ESOP trusts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Share-based incentive plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xml:lang="en-US">Dividends recognised as distributions to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xml:lang="en-US">Distributions to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive (expense)/income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Share of other comprehensive income/(expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Total other comprehensive (expense)/income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income/(expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xml:lang="en-US">Share of associates and joint ventures realised profits on disposal of equity investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xml:lang="en-US">Share of associates and joint ventures realised profits on disposal of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xlink:to="lab_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xml:lang="en-US">Share of associates and joint ventures realised profits on disposal of equity investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:label="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xml:lang="en-US">Profit (loss) on disposal of investments and changes in value of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xml:lang="en-US">Realised after tax losses on disposal or liquidation of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:to="lab_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xlink:label="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xml:lang="en-US">Increase through other contributions by noncontrolling interests, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xml:lang="en-US">Contributions from non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xlink:to="lab_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xml:lang="en-US">The increase in equity through other contributions by non-controlling interests.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashDistributionsToNoncontrollingInterests" xlink:label="loc_gsk_NoncashDistributionsToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NoncashDistributionsToNoncontrollingInterests" xml:lang="en-US">Noncash Distributions To Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NoncashDistributionsToNoncontrollingInterests" xml:lang="en-US">Non-cash distribution to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NoncashDistributionsToNoncontrollingInterests" xlink:to="lab_gsk_NoncashDistributionsToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NoncashDistributionsToNoncontrollingInterests" xml:lang="en-US">Noncash distributions to noncontrolling interests.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xml:lang="en-US">Increase (decrease) through disposal of subsidiary, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xml:lang="en-US">Deconsolidation of former subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashDividendToShareholders" xlink:label="loc_gsk_NonCashDividendToShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonCashDividendToShareholders" xml:lang="en-US">Non Cash Dividend To Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NonCashDividendToShareholders" xml:lang="en-US">Non-cash dividend to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonCashDividendToShareholders" xlink:to="lab_gsk_NonCashDividendToShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonCashDividendToShareholders" xml:lang="en-US">Non-cash dividend to shareholders.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingGainLossTransferredToNonFinancialAssets" xlink:label="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingGainLossTransferredToNonFinancialAssets" xml:lang="en-US">Hedging Gain Loss Transferred To Non Financial Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HedgingGainLossTransferredToNonFinancialAssets" xml:lang="en-US">Hedging gain after taxation transferred to non-financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets" xlink:to="lab_gsk_HedgingGainLossTransferredToNonFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingGainLossTransferredToNonFinancialAssets" xml:lang="en-US">Hedging gain loss transferred to non financial assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xml:lang="en-US">Increase (decrease) through other changes, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xml:lang="en-US">Changes to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionsWithNoncontoliingInterests" xlink:label="loc_gsk_TransactionsWithNoncontoliingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransactionsWithNoncontoliingInterests" xml:lang="en-US">Transactions with noncontoliing interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TransactionsWithNoncontoliingInterests" xml:lang="en-US">Transactions with non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransactionsWithNoncontoliingInterests" xlink:to="lab_gsk_TransactionsWithNoncontoliingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransactionsWithNoncontoliingInterests" xml:lang="en-US">Transactions with non-contoliing interests.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issue of equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issued under employee share schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xml:lang="en-US">Decrease (increase) through tax on share-based payment transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xml:lang="en-US">Tax on share-based incentive plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesAcquiredByEsopTrusts" xlink:label="loc_gsk_SharesAcquiredByEsopTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SharesAcquiredByEsopTrusts" xml:lang="en-US">Shares Acquired By ESOP Trusts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_SharesAcquiredByEsopTrusts" xml:lang="en-US">Shares acquired by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SharesAcquiredByEsopTrusts" xlink:to="lab_gsk_SharesAcquiredByEsopTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SharesAcquiredByEsopTrusts" xml:lang="en-US">Shares acquired by ESOP trusts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremiumMember" xml:lang="en-US">Share premium [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharePremiumMember" xml:lang="en-US">Share premium [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Issued capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Share capital [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non-controlling interests [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non- controlling interests [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Other reserves [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Other reserves [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xml:lang="en-US">Equity attributable to owners of parent [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xml:lang="en-US">Total [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Retained earnings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Retained earnings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of cash flows [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flow from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xml:lang="en-US">Repayments of current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xml:lang="en-US">Repayment of short-term loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xml:lang="en-US">Repayment of short-term Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfCurrentBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Cash flows from (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Total net cash inflow/(outflow) from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Net cash outflow from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xml:lang="en-US">Interest paid, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from non-current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Issue of long-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Increase in long-term loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xml:lang="en-US">Proceeds from (Repayments of) Other Current Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xml:lang="en-US">Increase in/(repayment of) other short-term loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xml:lang="en-US">Repayment of/(increase in) other short-term loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:to="lab_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xml:lang="en-US">Proceeds from (repayments of) other current borrowings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xml:lang="en-US">Dividends paid to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xml:lang="en-US">Dividends paid to non-controlling interests, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xml:lang="en-US">Distributions to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xml:lang="en-US">Other financing items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash outflow from continuing financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Repayment of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xml:lang="en-US">Contributions from non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="lab_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuing shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Issue of share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Net financing cash flows attributable to discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xml:lang="en-US">Repayments of non-current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xml:lang="en-US">Repayment of long-term loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">(Increase)/decrease in cash and bank overdrafts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Increase/(Decrease) in cash and bank overdrafts in the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xml:lang="en-US">Cash and bank overdrafts at end of year comprise:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xml:lang="en-US">Bank overdrafts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xml:lang="en-US">Overdrafts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xml:lang="en-US">Cash and bank overdrafts at the end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xml:lang="en-US">Cash and bank overdrafts at the beginning of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flow from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xml:lang="en-US">Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xml:lang="en-US">Interest received, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xml:lang="en-US">Interest received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xml:lang="en-US">Dividends received, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xml:lang="en-US">Dividends from associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInLiquidInvestments" xlink:label="loc_gsk_IncreaseDecreaseInLiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInLiquidInvestments" xml:lang="en-US">Increase decrease in liquid investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_IncreaseDecreaseInLiquidInvestments" xml:lang="en-US">Decrease/(increase) in liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInLiquidInvestments" xlink:to="lab_gsk_IncreaseDecreaseInLiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInLiquidInvestments" xml:lang="en-US">Increase decrease in liquid investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xml:lang="en-US">Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sale of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Cash flows from (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Total net cash (outflow)/inflow from investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Net cash outflow from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sales of property, plant and equipment, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sale of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sales of intangible assets, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sale of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xlink:label="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xml:lang="en-US">Purchase Of Investment In Associates And Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xml:lang="en-US">Investments in associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xlink:to="lab_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xml:lang="en-US">Purchase of investment in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xml:lang="en-US">Other inflows (outflows) of cash, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xml:lang="en-US">Contingent consideration paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash outflow from continuing investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash flows from (used in) investing activities, discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash investing cash flows attributable to discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xlink:label="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xml:lang="en-US">Proceeds From Disposal Of Associates And Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xml:lang="en-US">Proceeds from disposal of associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xlink:to="lab_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xml:lang="en-US">Proceeds from disposal of associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of businesses, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xml:lang="en-US">Disposal of businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flow from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLoss" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLoss" xml:lang="en-US">Adjustments reconciling profit after tax to operating cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLoss" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xml:lang="en-US">Cash Flows From Used In Operating Activities Continuing Operations Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xml:lang="en-US">Net cash inflow from continuing operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:to="lab_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xml:lang="en-US">Cash flows from used in operating activities continuing operations net of tax.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xml:lang="en-US">Cash Flows From Used In Operating Activities Discontinued Operations Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net operating cash flows attributable to discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xlink:to="lab_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xml:lang="en-US">Cash flows from used in operating activities discontinued operations net of tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Cash flows from (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Total net cash inflows from operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Net cash inflow from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Income Taxes Paid Refund Classified As Operating Activities Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Taxation paid from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xlink:to="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Income taxes paid refund classified as operating activities discontinued operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xml:lang="en-US">Cash From Used In Operations Before Taxes Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xml:lang="en-US">Cash generated from operations attributable to continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:to="lab_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xml:lang="en-US">Cash from used in operations before taxes continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xml:lang="en-US">Income Taxes Paid Refund Classified As Operating Activities Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xml:lang="en-US">Taxation paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xlink:to="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xml:lang="en-US">Income taxes paid refund classified as operating activities continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xml:lang="en-US">Cash From Used In Operations Before Tax Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xml:lang="en-US">Cash generated from operations attributable to discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xlink:to="lab_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xml:lang="en-US">Cash from used in operations before tax discontinued operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TextBlockAbstract" xlink:to="lab_gsk_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Presentation of the financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Accounting principles and policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Critical accounting judgements and key sources of estimation uncertainty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xml:lang="en-US">New accounting requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xml:lang="en-US">Exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xml:lang="en-US">Disclosure of entity's operating segments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xml:lang="en-US">Turnover and segment information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xml:lang="en-US">Other operating income/(expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xml:lang="en-US">Disclosure of profit (loss) from operating activities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xml:lang="en-US">Operating profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsExplanatory" xlink:label="loc_gsk_DisclosureOfEmployeeCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeCostsExplanatory" xml:lang="en-US">Disclosure of employee costs [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeCostsExplanatory" xml:lang="en-US">Employee costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeCostsExplanatory" xlink:to="lab_gsk_DisclosureOfEmployeeCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeCostsExplanatory" xml:lang="en-US">The disclosure of employee costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMajorRestructuringCostsExplanatory" xlink:label="loc_gsk_DisclosureOfMajorRestructuringCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsExplanatory" xml:lang="en-US">Disclosure of major restructuring costs [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsExplanatory" xml:lang="en-US">Major restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMajorRestructuringCostsExplanatory" xlink:to="lab_gsk_DisclosureOfMajorRestructuringCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsExplanatory" xml:lang="en-US">Disclosure of major restructuring costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xml:lang="en-US">Disclosure of finance income [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xml:lang="en-US">Finance income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Finance expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of Associates and Joint Ventures Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xlink:to="lab_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of Associates and Joint Ventures Explanatory</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Disclosure of income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDividendsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDividendsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDividendsExplanatory" xml:lang="en-US">Disclosure of dividends [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDividendsExplanatory" xml:lang="en-US">Dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDividendsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDividendsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xml:lang="en-US">Disclosure of goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Other intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xml:lang="en-US">Investments in associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xlink:label="loc_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xml:lang="en-US">Disclosure Of Current Equity Investments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xml:lang="en-US">Current equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xlink:to="lab_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xml:lang="en-US">Disclosure of current equity investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xml:lang="en-US">Disclosure of investments other than investments accounted for using equity method [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xml:lang="en-US">Other investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xml:lang="en-US">Disclosure of other non-current assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xml:lang="en-US">Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xml:lang="en-US">Disclosure of inventories [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xlink:label="loc_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xml:lang="en-US">Disclosure Of Trades And Other Receivable [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xlink:to="lab_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xml:lang="en-US">The entire disclosure of trade and other receivables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xml:lang="en-US">Disclosure of non-current assets held for sale and discontinued operations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xml:lang="en-US">Disclosure of borrowings [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xml:lang="en-US">Net debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xml:lang="en-US">Pensions and other post-employment benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xml:lang="en-US">Other provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Disclosure Of Contingent Consideration Liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:to="lab_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">The disclosure of contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" xml:lang="en-US">Disclosure of other non-current liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xml:lang="en-US">Disclosure of contingent liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xml:lang="en-US">Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Disclosure of commitments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xlink:label="loc_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">Disclosure of Share Capital And Share Premium [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">Share capital and share premium account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xlink:to="lab_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">The entire disclosure of share capital and share premium.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementsInEquityExplanatory" xlink:label="loc_gsk_DisclosureOfMovementsInEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMovementsInEquityExplanatory" xml:lang="en-US">Disclosure of Movements in Equity Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMovementsInEquityExplanatory" xml:lang="en-US">Movements in equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMovementsInEquityExplanatory" xlink:to="lab_gsk_DisclosureOfMovementsInEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMovementsInEquityExplanatory" xml:lang="en-US">Disclosure of Movements in Equity Explanatory</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xml:lang="en-US">Disclosure of non-controlling interests [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xml:lang="en-US">Non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Disclosure of related party [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xml:lang="en-US">Disclosure of business combinations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xml:lang="en-US">Acquisitions and disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:label="loc_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Disclosure of adjustments reconciling profit after tax to operating cash flows explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Adjustments reconciling profit after tax to operating cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:to="lab_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Disclosure of adjustments reconciling profit after tax to operating cash flows.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:label="loc_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Reconciliation Of Net Cash Flow To Movement In Net Debt Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Reconciliation of net cash flow to movement in net debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:to="lab_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Reconciliation of net cash flow to movement in net debt explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Financial instruments and related disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Employee share schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xlink:label="loc_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xml:lang="en-US">Disclosure of Principal Group Companies [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xml:lang="en-US">Principal Group companies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xlink:to="lab_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xml:lang="en-US">Disclosure of Principal Group Companies Explanatory</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsExplanatory" xlink:label="loc_gsk_DisclosureOfLegalProceedingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLegalProceedingsExplanatory" xml:lang="en-US">Disclosure of Legal Proceedings Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfLegalProceedingsExplanatory" xml:lang="en-US">Legal proceedings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLegalProceedingsExplanatory" xlink:to="lab_gsk_DisclosureOfLegalProceedingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLegalProceedingsExplanatory" xml:lang="en-US">Disclosure of legal proceedings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Post balance sheet events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_StatementsTable" xml:lang="en-US">Statements [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_StatementsTable" xml:lang="en-US">Statement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_StatementsTable" xlink:to="lab_gsk_StatementsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_StatementsLineItems" xml:lang="en-US">Statements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_StatementsLineItems" xml:lang="en-US">Statement [LineItems]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_StatementsLineItems" xlink:to="lab_gsk_StatementsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xml:lang="en-US">Description of accounting policy for discounting [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xml:lang="en-US">Discounting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xml:lang="en-US">The description of the entity's accounting policy for discounting .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Pensions and other post-employment benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xml:lang="en-US">Impairment of non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Foreign currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xml:lang="en-US">Description of accounting policy for basis of consolidation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xml:lang="en-US">Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xml:lang="en-US">The description of the entity's accounting policy for basis of consolidation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xml:lang="en-US">Description of accounting policy for hedging [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xml:lang="en-US">Hedge accounting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xml:lang="en-US">Description of accounting policy for environment related expense [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xml:lang="en-US">Environmental expenditure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xml:lang="en-US">Description Of Accounting Policy For Other Investment [Text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xml:lang="en-US">Other investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xml:lang="en-US">Description Of Accounting Policy For Other Investment [Text block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xml:lang="en-US">Description of accounting policy for goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xml:lang="en-US">Description of accounting policy for expenses [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xml:lang="en-US">Expenditure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xml:lang="en-US">Description of accounting policy for financial assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xml:lang="en-US">Financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xml:lang="en-US">Description of accounting policy for cash and cash equivalents explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xml:lang="en-US">The description of the entity's accounting policy for cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xml:lang="en-US">Description of accounting policy for borrowings [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xml:lang="en-US">Borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xml:lang="en-US">Description of Accounting Policy for Legal and other Disputes [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xml:lang="en-US">Legal and other disputes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xml:lang="en-US">Description of accounting policy for legal and other disputes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xml:lang="en-US">Description of accounting policy for business combinations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xml:lang="en-US">Business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Employee share plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xml:lang="en-US">Description of accounting policy for derivative financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Other intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Investments in associates, joint ventures and joint operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingStandardsApplied" xlink:label="loc_gsk_DescriptionOfAccountingStandardsApplied" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingStandardsApplied" xml:lang="en-US">Description Of Accounting Standards Applied</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingStandardsApplied" xml:lang="en-US">Parent company financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingStandardsApplied" xlink:to="lab_gsk_DescriptionOfAccountingStandardsApplied" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingStandardsApplied" xml:lang="en-US">The description of the entity's accounting policy for accounting standards applied.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xml:lang="en-US">Assets and liabilities held for sale or distribution and discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Current Equity Investments Explanatory [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xml:lang="en-US">Current equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xlink:to="lab_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Current Equity Investments Explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Summary of Expected Useful Lives of Property Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">The disclosure of estimated useful lives of property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xlink:label="loc_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xml:lang="en-US">Significant Currencies And The Relevant Exchange Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xml:lang="en-US">Summary of Currencies Translations and Relevant Exchange Rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xlink:to="lab_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xml:lang="en-US">The disclosure of detailed information about significant currencies and the relevant exchange rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SegmentsAxis" xml:lang="en-US">Segments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SegmentsAxis" xml:lang="en-US">Segments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SegmentsMember" xml:lang="en-US">Segments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SegmentsMember" xml:lang="en-US">Segments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsMember" xlink:to="lab_ifrs-full_SegmentsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CommercialOperationsMember" xml:lang="en-US">Commercial Operations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CommercialOperationsMember" xml:lang="en-US">Commercial Operations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CommercialOperationsMember" xml:lang="en-US">Commercial Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CommercialOperationsMember" xlink:to="lab_gsk_CommercialOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CommercialOperationsMember" xml:lang="en-US">Commercial operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xml:lang="en-US">Disclosure of operating segments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xml:lang="en-US">Disclosure of operating segments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xml:lang="en-US">Disclosure of operating segments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xml:lang="en-US">Segment Profit and Operating Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTurnoverBySegmentExplanatory" xlink:label="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTurnoverBySegmentExplanatory" xml:lang="en-US">Disclosure Of Turnover By Segment Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTurnoverBySegmentExplanatory" xml:lang="en-US">Turnover by Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory" xlink:to="lab_gsk_DisclosureOfTurnoverBySegmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTurnoverBySegmentExplanatory" xml:lang="en-US">Disclosure of turnover by segment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xml:lang="en-US">Disclosure of geographical areas [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xml:lang="en-US">Summary of Geographical Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xml:lang="en-US">Disclosure of products and services [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xml:lang="en-US">Turnover by Product &amp; Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Other Operating Income Expense Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xml:lang="en-US">Summary Information about Other Operating Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xml:lang="en-US">Disclosure of detailed information about other operating income (expense).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xml:lang="en-US">Defined benefit plans [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xml:lang="en-US">Defined benefit plans [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xml:lang="en-US">Defined benefit plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xml:lang="en-US">Defined benefit plans [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember" xlink:to="lab_ifrs-full_DefinedBenefitPlansMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PensionDefinedBenefitPlansMember" xml:lang="en-US">Pension defined benefit plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PensionDefinedBenefitPlansMember" xml:lang="en-US">Pension schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PensionDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_PensionDefinedBenefitPlansMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OperatingProfitLineItems" xlink:label="loc_gsk_OperatingProfitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OperatingProfitLineItems" xml:lang="en-US">Operating Profit [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OperatingProfitLineItems" xlink:to="lab_gsk_OperatingProfitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OperatingProfitLineItems" xml:lang="en-US">Operating profit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xml:lang="en-US">Disclosure of auditors' remuneration [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xml:lang="en-US">Summary of Auditors Remuneration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Profit Loss Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xml:lang="en-US">Summary of Information About Profit Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xml:lang="en-US">Disclosure of detailed information about profit (loss).</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xml:lang="en-US">Disclosure of Detailed Information about Share Based Payment Arrangements Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xml:lang="en-US">Summary of Cost of Share-based Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xml:lang="en-US">Share based payment arrangements.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xlink:label="loc_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xml:lang="en-US">Disclosure of Compensation of Directors and Senior Management Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xml:lang="en-US">Summary of Compensation of the Directors and Senior Management</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xlink:to="lab_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xml:lang="en-US">Disclosure of compensation of directors and senior management.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xml:lang="en-US">Disclosure of detailed information about employee costs explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xml:lang="en-US">Summary of Employee Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xml:lang="en-US">The disclosure of detailed information about employee costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNumberOfEmployeesExplanatory" xlink:label="loc_gsk_DisclosureOfNumberOfEmployeesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfNumberOfEmployeesExplanatory" xml:lang="en-US">Disclosure Of Number Of Employees [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfNumberOfEmployeesExplanatory" xml:lang="en-US">Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfNumberOfEmployeesExplanatory" xlink:to="lab_gsk_DisclosureOfNumberOfEmployeesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfNumberOfEmployeesExplanatory" xml:lang="en-US">Disclosure of number of employees.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xlink:label="loc_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xml:lang="en-US">Disclosure Of Major Restructuring Costs Charged To Operating Profit Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xml:lang="en-US">Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xlink:to="lab_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xml:lang="en-US">Summary of Analysis of the costs charged to operating profit from continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsExplanatory" xlink:label="loc_gsk_DisclosureOfRestructuringCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfRestructuringCostsExplanatory" xml:lang="en-US">Disclosure Of Restructuring Costs Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfRestructuringCostsExplanatory" xml:lang="en-US">Summary of Major Restructuring Charges From Continuing Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfRestructuringCostsExplanatory" xlink:to="lab_gsk_DisclosureOfRestructuringCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfRestructuringCostsExplanatory" xml:lang="en-US">Summary of Major Restructuring Charges from continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xml:lang="en-US">Disclosure Of Detailed Information About Major Restructuring Charges Explanatory TextBlock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xml:lang="en-US">Summary of Major Restructuring Charges from Continuing Operations by Income Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xml:lang="en-US">Summary of analysis of Major restructuring charges from continuing operations by income statement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterestIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInterestIncomeExplanatory" xml:lang="en-US">Disclosure of interest income [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInterestIncomeExplanatory" xml:lang="en-US">Summary of Finance Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterestIncomeExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xml:lang="en-US">Disclosure of finance cost [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xml:lang="en-US">Summary of Finance Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of Aggregated Financial Information of associates and joint ventures [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Summary of Aggregated Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xlink:to="lab_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">The disclosure of aggregated financial information of associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of Share of After Tax Profits and Losses of Associates and Joint Ventures Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Summary of After Tax Profits and Losses of Associates and Joint Ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xlink:to="lab_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of share of after tax profits and losses of associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" xml:lang="en-US">Disclosure of Group Held Significant Associate Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" xml:lang="en-US">Summary of Group Held for Significant Associate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" xlink:to="lab_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory" xml:lang="en-US">Disclosure of group held significant associate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xml:lang="en-US">Disclosure of deferred taxes [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xml:lang="en-US">Summary of Deferred Tax Assets and Liabilities Recognised on the Balance Sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xml:lang="en-US">Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xlink:label="loc_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xml:lang="en-US">Disclosure of reconciliation of actual tax charge and profit charged at uk tax rate explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xml:lang="en-US">Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xlink:to="lab_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xml:lang="en-US">The disclosure of reconciliation of actual tax charge and profit charged at UK tax rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xlink:label="loc_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xml:lang="en-US">Disclosure Of Income Tax Expense Benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xml:lang="en-US">Summary of Taxation Charge Based on Profits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xlink:to="lab_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xml:lang="en-US">The disclosure of income tax expense benefits.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xlink:label="loc_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xml:lang="en-US">Disclosure Of Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xml:lang="en-US">Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xlink:to="lab_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xml:lang="en-US">Disclosure of current and deferred tax relating to items charged or credited directly to equity and comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xml:lang="en-US">Disclosure of movement in deferred tax assets and liabilities explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xml:lang="en-US">Summary of Movement in Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xlink:to="lab_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xml:lang="en-US">The disclosure of movement in deferred tax assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xlink:label="loc_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xml:lang="en-US">Disclosure of Weighted Average Numbers of Shares Earnings Per Share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xml:lang="en-US">Schedule of Numbers of Shares Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xlink:to="lab_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xml:lang="en-US">Disclosure of weighted average numbers of shares earnings per share explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Summary of Basic and Diluted Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInterimDividendExplanatory" xlink:label="loc_gsk_DisclosureOfInterimDividendExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInterimDividendExplanatory" xml:lang="en-US">Disclosure Of Interim Dividend Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfInterimDividendExplanatory" xml:lang="en-US">Summary of Interim Financial Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInterimDividendExplanatory" xlink:to="lab_gsk_DisclosureOfInterimDividendExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInterimDividendExplanatory" xml:lang="en-US">Disclosure of interim dividend explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsPaidExplanatory" xlink:label="loc_gsk_DisclosureOfDividendsPaidExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDividendsPaidExplanatory" xml:lang="en-US">Disclosure of dividends paid [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDividendsPaidExplanatory" xml:lang="en-US">Summary of Dividends to Shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDividendsPaidExplanatory" xlink:to="lab_gsk_DisclosureOfDividendsPaidExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDividendsPaidExplanatory" xml:lang="en-US">The disclosure of dividends paid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Summary of Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" xml:lang="en-US">Disclosure Of Detailed Information About Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" xml:lang="en-US">Summary of Disclosure of Detailed Information About Right Of Use Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets" xml:lang="en-US">Disclosure Of Detailed Information About Right Of Use Assets</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xlink:label="loc_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xml:lang="en-US">Disclosure Of Allocation Of Goodwill To Segments Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xml:lang="en-US">Summary of Goodwill Allocated to Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xlink:to="lab_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xml:lang="en-US">Disclosure of allocation of goodwill to segments explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xml:lang="en-US">Summary of Changes in Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" xml:lang="en-US">Disclosure of information for cash-generating units [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" xml:lang="en-US">Schedule of Discounted Cash Flow Models Used in Impairment Tests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xml:lang="en-US">Schedule of Amortisation and Impairment Losses, Net of Reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Summary of Other Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xlink:label="loc_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure Of Licences Included In Intangible Assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xml:lang="en-US">Summary of Book Values of Largest Individual Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xlink:to="lab_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xml:lang="en-US">The disclosure of licences included in intangible assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of detailed information of investments in associates and joint ventures [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Schedule of Investments in Associates and Joint Ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xml:lang="en-US">Disclosure of investments in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Current Equity Investments Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xml:lang="en-US">Summary of Current Equity Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xml:lang="en-US">Disclosure of detailed information about&#160;current equity investments explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xlink:label="loc_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xml:lang="en-US">Disclosure of Schedule of Other Investment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xml:lang="en-US">Schedule of Other Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xlink:to="lab_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xml:lang="en-US">Disclosure of schedule of other investment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xlink:label="loc_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xml:lang="en-US">Summary Of Receivables In Other Non Current Assets Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xml:lang="en-US">Summary of Other Non-Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xlink:to="lab_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xml:lang="en-US">Summary of receivables in other non current assets explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xml:lang="en-US">Disclosure Of Detailed Information Of Inventories [Text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xml:lang="en-US">Summary of Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xml:lang="en-US">Disclosure of detailed information of inventories.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xml:lang="en-US">Disclosure of allowance for credit losses [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xml:lang="en-US">Summary of Loss Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Summary of Trade and Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">Disclosure of detailed information about cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">Summary of Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">The disclosure for detailed information about cash and cash equivalent.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssetsHeldForSaleExplanatory" xlink:label="loc_gsk_DisclosureOfAssetsHeldForSaleExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAssetsHeldForSaleExplanatory" xml:lang="en-US">Disclosure of Assets Held for Sale Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAssetsHeldForSaleExplanatory" xml:lang="en-US">Summary of Assets Held for Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAssetsHeldForSaleExplanatory" xlink:to="lab_gsk_DisclosureOfAssetsHeldForSaleExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAssetsHeldForSaleExplanatory" xml:lang="en-US">Disclosure of assets held for sale explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xlink:label="loc_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xml:lang="en-US">Disclosure Of Income Statement And Balance Sheet Sensitivity Of Put Option To Reasonably Possible Changes In Key Assumption [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xml:lang="en-US">Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xlink:to="lab_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xml:lang="en-US">Disclosure of income statement and balance sheet sensitivity of put option to reasonably possible changes in key assumption.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SummaryOfTradePayablesExplanatoryTextBlock" xlink:label="loc_gsk_SummaryOfTradePayablesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SummaryOfTradePayablesExplanatoryTextBlock" xml:lang="en-US">Summary Of Trade Payables Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SummaryOfTradePayablesExplanatoryTextBlock" xml:lang="en-US">Summary of Trade and Other Payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SummaryOfTradePayablesExplanatoryTextBlock" xlink:to="lab_gsk_SummaryOfTradePayablesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SummaryOfTradePayablesExplanatoryTextBlock" xml:lang="en-US">Summary of trade payables explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xlink:label="loc_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Lease Obligations Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xml:lang="en-US">Schedule of Lease Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xlink:to="lab_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xml:lang="en-US">Disclosure of lease obligations explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xml:lang="en-US">Schedule of Current Assets, Short and Long Term Borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Defined Benefit Pension and Post-retirement Healthcare Scheme [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Defined benefit pension and post-retirement healthcare scheme. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:to="lab_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Defined benefit pension and post-retirement healthcare scheme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostretirementBenefitsMember" xml:lang="en-US">Post-retirement benefits [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PostretirementBenefitsMember" xml:lang="en-US">Post-retirement benefits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostretirementBenefitsMember" xlink:to="lab_gsk_PostretirementBenefitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostretirementBenefitsMember" xml:lang="en-US">Post-retirement benefits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xml:lang="en-US">Disclosure of information about maturity profile of defined benefit obligation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xml:lang="en-US">Summary of Weighted Average Duration of Defined Benefit Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xml:lang="en-US">Disclosure of defined benefit plans [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xml:lang="en-US">Summary of Analysis of Defined Benefit Pension Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xml:lang="en-US">Disclosure of average life expectancy assumptions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xml:lang="en-US">Summary of Average Life Expectancy Assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xlink:to="lab_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xml:lang="en-US">The disclosure of average life expectancy assumptions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">Disclosure Of Defined Benefit Pension Obligation Analysed By Membership Category Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">Summary of Defined Benefit Pension Obligation Analysed by Membership Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">Disclosure of defined benefit pension obligation analysed by membership category explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xml:lang="en-US">Disclosure of fair value of plan assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xml:lang="en-US">Summary of Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xlink:label="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xml:lang="en-US">Disclosure Of Balance Sheet Presentation Of Defined Benefit Pension And Post Retirement Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xml:lang="en-US">Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xlink:to="lab_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xml:lang="en-US">Disclosure of balance sheet presentation of defined benefit Pension and post retirement explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xml:lang="en-US">Disclosure of defined benefit pension and post retirement charges explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xml:lang="en-US">Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xml:lang="en-US">The disclosure of defined benefit pension and post retirement charges.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xml:lang="en-US">Disclosure of Defined Benefit Plan Actuarial Assumptions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xml:lang="en-US">Summary of Financial Assumptions in Assessing Defined Benefit Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xml:lang="en-US">Disclosure of defined benefit plan actuarial assumptions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xml:lang="en-US">Summary of Changes In Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xlink:label="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xml:lang="en-US">Disclosure Of Movement In Defined Benefit Liability [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xml:lang="en-US">Summary of Movements in Defined Benefit Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xlink:to="lab_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xml:lang="en-US">Disclosure of movement in defined benefit liability.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" xml:lang="en-US">Disclosure Of Movements In Fair Values Of Assets Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" xml:lang="en-US">Summary of Movements in Fair Values of Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" xlink:to="lab_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory" xml:lang="en-US">Disclosure of movements in fair values of assets explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xml:lang="en-US">Summary of Net Defined Benefit Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">Disclosure Of Post Retirement Benefit Obligation Analysed By Membership Category Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">Summary of Post-Retirement Benefit Obligation Analysed By Membership Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xlink:to="lab_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xml:lang="en-US">The disclosure of post retirement benefit obligation analysed by membership category explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xml:lang="en-US">Disclosure of other provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xml:lang="en-US">Summary of Other Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Disclosure of fair value of contingent consideration liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Summary of Fair Value of Contingent Consideration Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xlink:to="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">The disclosure of fair value of contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xml:lang="en-US">Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xlink:to="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration Explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xlink:label="loc_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xml:lang="en-US">Disclosure Of Other Non current Liabilities Details Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xml:lang="en-US">Summary of Other Noncurrent Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xlink:to="lab_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xml:lang="en-US">The disclosure of other non current liabilities details.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xlink:label="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xml:lang="en-US">Disclosure Of Contractual Obligations And Commitments Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xml:lang="en-US">Schedule of Contractual Obligations and Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xlink:to="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xml:lang="en-US">Disclosure Of Contractual Obligations And Commitments Explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">Disclosure of classes of share capital and share premium explanatory[text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">Summary of Share Capital and Share Premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xlink:to="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xml:lang="en-US">Disclosure of classes of share capital and share premium.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" xml:lang="en-US">Summary of Other Comprehensive Income by Equity Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Disclosure of reserves within equity [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Summary of Analysis of Other Reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xlink:label="loc_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xml:lang="en-US">Disclosure Of Cumulative Translation Exchange In Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xml:lang="en-US">Summary of Cumulative Translation Exchange in Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xlink:to="lab_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xml:lang="en-US">Disclosure of cumulative translation exchange in equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConsumerHealthCareJointVentureMember" xml:lang="en-US">Consumer Health Care Joint Venture [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ConsumerHealthCareJointVentureMember" xml:lang="en-US">Consumer health care joint venture [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConsumerHealthCareJointVentureMember" xlink:to="lab_gsk_ConsumerHealthCareJointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConsumerHealthCareJointVentureMember" xml:lang="en-US">Consumer health care joint venture.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViiVHealthCareMember" xml:lang="en-US">Vii V Health Care [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViiVHealthCareMember" xml:lang="en-US">ViiV healthcare [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViiVHealthCareMember" xlink:to="lab_gsk_ViiVHealthCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViiVHealthCareMember" xml:lang="en-US">Vii V health care.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Schedule of Information about the Amounts Attributable to Non Controlling Interests Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Schedule of Amount Attributable to Joint Venture Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:to="lab_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Schedule of information about the amounts attributable to non controlling interests explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Disclosure Of Financial Information About The Amounts Attributable To Non Controlling Interests Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Summarised Financial Information of Joint Venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:to="lab_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xml:lang="en-US">Disclosure Of Financial Information About The Amounts Attributable To Non Controlling Interests Explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xml:lang="en-US">Disclosure of detailed information about business combination [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xml:lang="en-US">Disclosure of detailed information about business combination [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Disclosure Of Profit After Taxation On Demerger Of Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Summary of Profit After Taxation on Demerger of Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:to="lab_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Disclosure of&#160;profit after taxation on demerger of discontinued operations .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xml:lang="en-US">Disclosure of detailed information about business combination [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xml:lang="en-US">Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xlink:label="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xml:lang="en-US">Disclosure of profit on disposal of businesses [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xml:lang="en-US">Summary of Profit on Disposal of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xlink:to="lab_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xml:lang="en-US">Disclosure of profit on disposal of businesses.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xlink:label="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xml:lang="en-US">Disclosure Of Cash Flows From Business Combinations [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xml:lang="en-US">Summary of Cash Flows from Business Combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xlink:to="lab_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xml:lang="en-US">The entire disclosure Of Cash Flows From Business Combinations Explanatory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialInformationRelatingToDiscontinuedOperations" xml:lang="en-US">Financial Information Relating To Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FinancialInformationRelatingToDiscontinuedOperations" xml:lang="en-US">Summary of Financial Information Relating to Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations" xlink:to="lab_gsk_FinancialInformationRelatingToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialInformationRelatingToDiscontinuedOperations" xml:lang="en-US">Disclosure of&#160;financial information relating to discontinued operations .</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwothousandtwentyoneacquisitionMember" xlink:label="loc_gsk_TwothousandtwentyoneacquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwothousandtwentyoneacquisitionMember" xml:lang="en-US">TwoThousandTwentyOneAcquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwothousandtwentyoneacquisitionMember" xml:lang="en-US">2021 Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwothousandtwentyoneacquisitionMember" xlink:to="lab_gsk_TwothousandtwentyoneacquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwothousandtwentyoneacquisitionMember" xml:lang="en-US">Two thousand twenty one acquisition .</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandTwentyAcquisitionMember" xml:lang="en-US">Two Thousand Twenty Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandTwentyAcquisitionMember" xml:lang="en-US">2020 Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandTwentyAcquisitionMember" xlink:to="lab_gsk_TwoThousandTwentyAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandTwentyAcquisitionMember" xml:lang="en-US">Two Thousand Twenty Acquisition</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyTwoAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandTwentyTwoAcquisitionMember" xml:lang="en-US">Two Thousand Twenty Two Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandTwentyTwoAcquisitionMember" xml:lang="en-US">2022 Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:to="lab_gsk_TwoThousandTwentyTwoAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandTwentyTwoAcquisitionMember" xml:lang="en-US">Twothous and twenty two acquisition .</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:label="loc_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Schedule of Adjustments Reconciling Profit After Tax to Operating Cash Flows Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Summary of Cash Generated from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:to="lab_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xml:lang="en-US">Schedule of adjustments reconciling profit after tax to operating cash flows.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:label="loc_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Disclosure of Reconciliation of Net Cash Flow to Movement in Net Debt Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Summary of Net Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:to="lab_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xml:lang="en-US">Disclosure of reconciliation of net cash flow to movement in net debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xlink:label="loc_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xml:lang="en-US">Disclosure Of Analysis Of Changes In Net Debt Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xml:lang="en-US">Summary of Analysis of Changes in Net Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xlink:to="lab_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xml:lang="en-US">Disclosure of analysis of changes in net debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xml:lang="en-US">Disclosure of debt instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xml:lang="en-US">Summary of Debt Interest Rate Repricing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xml:lang="en-US">Summary of Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xml:lang="en-US">Disclosure of external credit grades [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xml:lang="en-US">Summary of External Credit Exposure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xlink:label="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xml:lang="en-US">Foreign Exchange Sensitivity Equity Impact [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xml:lang="en-US">Foreign exchange sensitivity impact on equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xlink:to="lab_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xml:lang="en-US">Foreign exchange sensitivity equity impact.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xml:lang="en-US">Disclosure of Detailed Information about Effectiveness of Hedging Relationships and Amounts reclassified from hedging reserve to profit or loss text block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xml:lang="en-US">Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xml:lang="en-US">Disclosure of Detailed Information about Effectiveness of Hedging Relationships and Amounts reclassified from hedging reserve to profit or loss [text block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xml:lang="en-US">Summary of Offsetting of Financial Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xml:lang="en-US">Summary of Financial Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Summary of Anticipated Contractual Cash Flows Including Interest Payable for the Non-Derivative Financial Liabilities on Undiscounted Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xml:lang="en-US">Disclosure of detailed information about hedging instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xml:lang="en-US">Summary of Fair Values of Derivatives Held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Sensitivity analysis for types of market risk [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Sensitivity Analysis for Each Type of Market Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:to="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xml:lang="en-US">Disclosure Of Financial Liabilities And Non Financial Liabilities Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xml:lang="en-US">Reconciliation of Financial Instruments Within Trade and Other Payables, Other Provisions, Other Non-current Liabilities and Contingent Consideration Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xlink:to="lab_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xml:lang="en-US">Disclosure of financial liabilities and non financial liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xml:lang="en-US">Disclosure Of Financial Assets And Non Financial Assets Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xml:lang="en-US">Reconciliation of financial instruments with Trade and other receivables and Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xlink:to="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xml:lang="en-US">Disclosure Of Financial Assets And Non Financial Assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xml:lang="en-US">Summary of Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xlink:label="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xml:lang="en-US">Foreign Exchange Sensitivity Impact Of Non Functional Currency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xml:lang="en-US">Foreign exchange sensitivity impact on income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xlink:to="lab_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xml:lang="en-US">Foreign exchange sensitivity impact of non-functional currency</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xml:lang="en-US">Disclosure of detailed information about hedged items [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xml:lang="en-US">Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xml:lang="en-US">Hedging instruments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xml:lang="en-US">Hedging instruments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xml:lang="en-US">Hedging instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xml:lang="en-US">Hedging instruments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsMember" xlink:to="lab_ifrs-full_HedgingInstrumentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateSwapContractMember" xml:lang="en-US">Interest rate swap contract [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateSwapContractMember" xml:lang="en-US">Interest rate swap contract [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestRateSwapContractMember" xml:lang="en-US">Forward starting interest rate swaps [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateSwapContractMember" xlink:to="lab_ifrs-full_InterestRateSwapContractMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:label="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ForeignExchangeForwardContractsAndSwapsMember" xml:lang="en-US">Foreign Exchange Forward Contracts and Swaps [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ForeignExchangeForwardContractsAndSwapsMember" xml:lang="en-US">Foreign Exchange Forward Contracts and Swaps [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:to="lab_gsk_ForeignExchangeForwardContractsAndSwapsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ForeignExchangeForwardContractsAndSwapsMember" xml:lang="en-US">Foreign Exchange Forward Contracts and Swaps [member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateRiskMember" xml:lang="en-US">Interest rate risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateRiskMember" xml:lang="en-US">Interest rate risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xml:lang="en-US">All levels of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xml:lang="en-US">All levels of fair value hierarchy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xml:lang="en-US">Level 3 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xlink:label="loc_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xml:lang="en-US">Disclosure of Employee Share Value Plan [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xml:lang="en-US">Schedule of Number of Shares and ADS Issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xlink:to="lab_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xml:lang="en-US">Disclosure of employee share value plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xml:lang="en-US">Disclosure Of Share Options And Savings Related Options Outstanding Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xml:lang="en-US">Summary of Option Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xlink:to="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xml:lang="en-US">The disclosure of share options and savings related options outstanding.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xlink:label="loc_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xml:lang="en-US">Disclosure Of Shares Held For Share Award Schemes And Shares Option Schemes Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xml:lang="en-US">Summary of Shares Held for Share Award Schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xlink:to="lab_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xml:lang="en-US">Disclosure of shares held for share award schemes and shares option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xlink:label="loc_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xml:lang="en-US">Disclosure Of Share Options Assumptions Related To Savings Related Schemes [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xml:lang="en-US">Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xlink:to="lab_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xml:lang="en-US">Disclosure of share options outstanding savings related schemes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xml:lang="en-US">Disclosure of subsidiaries [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xml:lang="en-US">Schedule of Principal Subsidiaries and Their Countries of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PresentationOfTheFinancialStatementsAbstract" xlink:label="loc_gsk_PresentationOfTheFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PresentationOfTheFinancialStatementsAbstract" xml:lang="en-US">Presentation Of The Financial Statements [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PresentationOfTheFinancialStatementsAbstract" xlink:to="lab_gsk_PresentationOfTheFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PresentationOfTheFinancialStatementsAbstract" xml:lang="en-US">Presentation Of The Financial Statements [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xml:lang="en-US">Disclosure of adjustment for each financial statement line item affected by application IFRS16table [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xlink:to="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xml:lang="en-US">Disclosure of adjustment for each financial statement line item affected by application IFRS 16 [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xml:lang="en-US">Disclosure of adjustment for each financial statement line item affected by application IFRS 16 line items [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xlink:to="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xml:lang="en-US">Disclosure of adjustment for each financial statement line item affected by application IFRS 16 [line items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PeriodCoveredByFinancialStatements" xlink:label="loc_ifrs-full_PeriodCoveredByFinancialStatements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PeriodCoveredByFinancialStatements" xml:lang="en-US">Period covered by financial statements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PeriodCoveredByFinancialStatements" xml:lang="en-US">Period covered by financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PeriodCoveredByFinancialStatements" xlink:to="lab_ifrs-full_PeriodCoveredByFinancialStatements" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfEndOfReportingPeriod2022" xlink:label="loc_gsk_DateOfEndOfReportingPeriod2022" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DateOfEndOfReportingPeriod2022" xml:lang="en-US">Date Of End Of Reporting Period 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_DateOfEndOfReportingPeriod2022" xml:lang="en-US">Date of end of reporting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DateOfEndOfReportingPeriod2022" xlink:to="lab_gsk_DateOfEndOfReportingPeriod2022" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DateOfEndOfReportingPeriod2022" xml:lang="en-US">Date of end of reporting period 2022.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="loc_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xml:lang="en-US">Disclosure of voluntary change in accounting policy [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="lab_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xml:lang="en-US">Disclosure of accounting principles and policies [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xml:lang="en-US">Disclosure of accounting principles and policies [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xlink:to="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xml:lang="en-US">Disclosure of accounting principles and policies [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBookValueMember" xlink:label="loc_gsk_RemainingBookValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemainingBookValueMember" xml:lang="en-US">Remaining Book Value [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemainingBookValueMember" xlink:to="lab_gsk_RemainingBookValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemainingBookValueMember" xml:lang="en-US">Remaining book value [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ERPSoftwareSystemsMember" xlink:label="loc_gsk_ERPSoftwareSystemsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ERPSoftwareSystemsMember" xml:lang="en-US">ERP Software Systems [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ERPSoftwareSystemsMember" xml:lang="en-US">ERP software systems [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ERPSoftwareSystemsMember" xlink:to="lab_gsk_ERPSoftwareSystemsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ERPSoftwareSystemsMember" xml:lang="en-US">ERP software systems.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesAndFranchisesMember" xlink:label="loc_ifrs-full_LicencesAndFranchisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LicencesAndFranchisesMember" xml:lang="en-US">Licences and franchises [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LicencesAndFranchisesMember" xml:lang="en-US">Licences and franchises [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_LicencesAndFranchisesMember" xml:lang="en-US">Licences, patents, amortised brands etc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesAndFranchisesMember" xlink:to="lab_ifrs-full_LicencesAndFranchisesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComputerSoftwareMember" xlink:label="loc_gsk_OtherComputerSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComputerSoftwareMember" xml:lang="en-US">Other computer software [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherComputerSoftwareMember" xml:lang="en-US">Other computer software [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComputerSoftwareMember" xlink:to="lab_gsk_OtherComputerSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComputerSoftwareMember" xml:lang="en-US">Other computer software.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VaccinesMember" xml:lang="en-US">Vaccines [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VaccinesMember" xml:lang="en-US">Vaccines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VaccinesMember" xlink:to="lab_gsk_VaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VaccinesMember" xml:lang="en-US">Vaccines.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PharmaceuticalsMember" xml:lang="en-US">Pharmaceuticals [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PharmaceuticalsMember" xml:lang="en-US">Pharmaceuticals [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PharmaceuticalsMember" xlink:to="lab_gsk_PharmaceuticalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PharmaceuticalsMember" xml:lang="en-US">Pharmaceuticals.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" xml:lang="en-US">Disclosure of accounting principles and policies [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" xml:lang="en-US">Disclosure of accounting principles and policies [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" xlink:to="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems" xml:lang="en-US">Disclosure of accounting principles and policies [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfSalesOnCoPromotionalActivities" xlink:label="loc_gsk_CostOfSalesOnCoPromotionalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CostOfSalesOnCoPromotionalActivities" xml:lang="en-US">Cost of sales on co promotional activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CostOfSalesOnCoPromotionalActivities" xml:lang="en-US">Cost of sales on co promotional activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CostOfSalesOnCoPromotionalActivities" xlink:to="lab_gsk_CostOfSalesOnCoPromotionalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CostOfSalesOnCoPromotionalActivities" xml:lang="en-US">Cost of sales on co promotional activities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Description of useful life, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xlink:label="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xml:lang="en-US">Profit Sharing Costs And Royalties Due To The Counterparty Included In Cost Of Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xml:lang="en-US">Profit sharing costs and royalties due to the counterparty included in cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xlink:to="lab_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xml:lang="en-US">Profit sharing costs and royalties due to the counterparty included in cost of sales.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromCoPromotionalActivities" xlink:label="loc_gsk_RevenueFromCoPromotionalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RevenueFromCoPromotionalActivities" xml:lang="en-US">Revenue From Co Promotional Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RevenueFromCoPromotionalActivities" xml:lang="en-US">Revenue from co-promotional activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RevenueFromCoPromotionalActivities" xlink:to="lab_gsk_RevenueFromCoPromotionalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RevenueFromCoPromotionalActivities" xml:lang="en-US">Revenue from co-promotional activities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xlink:label="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xml:lang="en-US">Threshold For Applying Implicit Rate Of Interest To Annual Lease Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xml:lang="en-US">Lease liability on leases with annual payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xlink:to="lab_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xml:lang="en-US">Threshold for applying implicit rate of interest to annual lease payments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisableProportionOverExclusivityPeriod" xlink:label="loc_gsk_AmortisableProportionOverExclusivityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AmortisableProportionOverExclusivityPeriod" xml:lang="en-US">Amortisable Proportion Over Exclusivity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AmortisableProportionOverExclusivityPeriod" xml:lang="en-US">Amortisation rate, Intangible assets other than goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AmortisableProportionOverExclusivityPeriod" xlink:to="lab_gsk_AmortisableProportionOverExclusivityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AmortisableProportionOverExclusivityPeriod" xml:lang="en-US">Amortisable proportion over exclusivity period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndMachineryMember" xlink:label="loc_gsk_PlantAndMachineryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PlantAndMachineryMember" xml:lang="en-US">Plant and machinery [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PlantAndMachineryMember" xml:lang="en-US">Plant and machinery [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PlantAndMachineryMember" xlink:to="lab_gsk_PlantAndMachineryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PlantAndMachineryMember" xml:lang="en-US">Plant and machinery.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquipmentAndVehiclesMember" xlink:label="loc_gsk_EquipmentAndVehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquipmentAndVehiclesMember" xml:lang="en-US">Equipment And Vehicles [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquipmentAndVehiclesMember" xml:lang="en-US">Equipment and vehicles [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquipmentAndVehiclesMember" xlink:to="lab_gsk_EquipmentAndVehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquipmentAndVehiclesMember" xml:lang="en-US">Equipment and vehicles.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeholdBuildingsMember" xlink:label="loc_gsk_FreeholdBuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FreeholdBuildingsMember" xml:lang="en-US">Freehold buildings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FreeholdBuildingsMember" xml:lang="en-US">Freehold buildings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FreeholdBuildingsMember" xlink:to="lab_gsk_FreeholdBuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FreeholdBuildingsMember" xml:lang="en-US">Freehold buildings.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseholdLandAndBuildingsMember" xlink:label="loc_gsk_LeaseholdLandAndBuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LeaseholdLandAndBuildingsMember" xml:lang="en-US">Leasehold land and buildings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LeaseholdLandAndBuildingsMember" xml:lang="en-US">Leasehold land and buildings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LeaseholdLandAndBuildingsMember" xlink:to="lab_gsk_LeaseholdLandAndBuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LeaseholdLandAndBuildingsMember" xml:lang="en-US">Leasehold land and buildings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xml:lang="en-US">Description of useful life, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xml:lang="en-US">Useful lives of property plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xml:lang="en-US">Disclosure of changes in accounting estimates [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xml:lang="en-US">Disclosure of changes in accounting estimates [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xml:lang="en-US">Disclosure of changes in accounting estimates [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_JointVenturesAxis" xml:lang="en-US">Joint ventures [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_JointVenturesAxis" xml:lang="en-US">Joint ventures [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xml:lang="en-US">Entity's total for joint ventures [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xml:lang="en-US">Entity's total for joint ventures [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:to="lab_ifrs-full_EntitysTotalForJointVenturesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShionogiViiVHealthcareJointVentureMember" xml:lang="en-US">Shionogi-ViiV Healthcare Joint Venture [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShionogiViiVHealthcareJointVentureMember" xml:lang="en-US">Shionogi ViiV healthcare joint venture [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ShionogiViiVHealthcareJointVentureMember" xml:lang="en-US">Shionogi-ViiV Healthcare JV [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShionogiViiVHealthcareJointVentureMember" xlink:to="lab_gsk_ShionogiViiVHealthcareJointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShionogiViiVHealthcareJointVentureMember" xml:lang="en-US">Shionogi-ViiV healthcare joint venture.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xml:lang="en-US">Disclosure of changes in accounting estimates [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xml:lang="en-US">Disclosure of changes in accounting estimates [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalCosts" xlink:label="loc_gsk_LegalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LegalCosts" xml:lang="en-US">Legal costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LegalCosts" xml:lang="en-US">Legal costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LegalCosts" xlink:to="lab_gsk_LegalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LegalCosts" xml:lang="en-US">Legal costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnsDiscountsAndRebates" xlink:label="loc_gsk_CustomerReturnsDiscountsAndRebates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CustomerReturnsDiscountsAndRebates" xml:lang="en-US">Customer Returns Discounts And Rebates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CustomerReturnsDiscountsAndRebates" xml:lang="en-US">Incidental deductions to turnover</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CustomerReturnsDiscountsAndRebates" xlink:to="lab_gsk_CustomerReturnsDiscountsAndRebates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CustomerReturnsDiscountsAndRebates" xml:lang="en-US">Customer returns discounts and rebates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfIncreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfIncreaseInDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfIncreaseInDiscountRate" xml:lang="en-US">Percentage Of Increase In Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfIncreaseInDiscountRate" xml:lang="en-US">Percentage of increase in discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfIncreaseInDiscountRate" xlink:to="lab_gsk_PercentageOfIncreaseInDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfIncreaseInDiscountRate" xml:lang="en-US">Percentage of increase in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInPlanDeficit" xlink:label="loc_gsk_DecreaseInPlanDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseInPlanDeficit" xml:lang="en-US">Decrease In Plan Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseInPlanDeficit" xml:lang="en-US">Net pension deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseInPlanDeficit" xlink:to="lab_gsk_DecreaseInPlanDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseInPlanDeficit" xml:lang="en-US">Decrease in plan deficit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Contingent liabilities recognised in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Contingent consideration liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Contingent consideration liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInPlanDeficit" xlink:label="loc_gsk_IncreaseInPlanDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInPlanDeficit" xml:lang="en-US">Increase In Plan Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseInPlanDeficit" xml:lang="en-US">Net pension deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInPlanDeficit" xlink:to="lab_gsk_IncreaseInPlanDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInPlanDeficit" xml:lang="en-US">Increase in plan deficit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UncertainTaxPositionsRecognised" xlink:label="loc_gsk_UncertainTaxPositionsRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UncertainTaxPositionsRecognised" xml:lang="en-US">Uncertain tax positions recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UncertainTaxPositionsRecognised" xml:lang="en-US">Uncertain tax position charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UncertainTaxPositionsRecognised" xlink:to="lab_gsk_UncertainTaxPositionsRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UncertainTaxPositionsRecognised" xml:lang="en-US">Uncertain tax positions recognised.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfDecreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfDecreaseInDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfDecreaseInDiscountRate" xml:lang="en-US">Percentage of decrease in discount rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfDecreaseInDiscountRate" xml:lang="en-US">Percentage of decrease in discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfDecreaseInDiscountRate" xlink:to="lab_gsk_PercentageOfDecreaseInDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfDecreaseInDiscountRate" xml:lang="en-US">Percentage of decrease in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xlink:label="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xml:lang="en-US">Gain (loss) on contingent consideration and put option liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xml:lang="en-US">Contingent consideration and put option liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xlink:to="lab_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xml:lang="en-US">Gain (loss) on contingent consideration and put option liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvision" xlink:label="loc_ifrs-full_LegalProceedingsProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LegalProceedingsProvision" xml:lang="en-US">Legal proceedings provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LegalProceedingsProvision" xml:lang="en-US">Provision for legal and other disputes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LegalProceedingsProvision" xml:lang="en-US">Provisions for legal and other disputes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LegalProceedingsProvision" xlink:to="lab_ifrs-full_LegalProceedingsProvision" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPlanSurplusNet" xlink:label="loc_gsk_DefinedBenefitPlanSurplusNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitPlanSurplusNet" xml:lang="en-US">Defined benefit plan surplus net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitPlanSurplusNet" xml:lang="en-US">Surplus on UK defined benefit schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitPlanSurplusNet" xlink:to="lab_gsk_DefinedBenefitPlanSurplusNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitPlanSurplusNet" xml:lang="en-US">Defined benefit plan surplus net.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInAnnualPensionCost" xlink:label="loc_gsk_IncreaseInAnnualPensionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInAnnualPensionCost" xml:lang="en-US">Increase in annual pension cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseInAnnualPensionCost" xml:lang="en-US">Increased annual pension cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseInAnnualPensionCost" xml:lang="en-US">(Decrease)/Increase in annual pension cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInAnnualPensionCost" xlink:to="lab_gsk_IncreaseInAnnualPensionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInAnnualPensionCost" xml:lang="en-US">Increase in annual pension cost.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInAnnualPensionCost" xlink:label="loc_gsk_DecreaseInAnnualPensionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseInAnnualPensionCost" xml:lang="en-US">Decrease In Annual Pension Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseInAnnualPensionCost" xml:lang="en-US">Decrease in annnual pension cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseInAnnualPensionCost" xlink:to="lab_gsk_DecreaseInAnnualPensionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseInAnnualPensionCost" xml:lang="en-US">Decrease in annual pension cost.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionSurplus" xlink:label="loc_gsk_PensionSurplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PensionSurplus" xml:lang="en-US">Pension surplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PensionSurplus" xml:lang="en-US">Pension surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PensionSurplus" xlink:to="lab_gsk_PensionSurplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PensionSurplus" xml:lang="en-US">Pension surplus.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xlink:label="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xml:lang="en-US">Customer Return And Rebate Accruals Inclusive Of Cash Discount And Channel Management Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xml:lang="en-US">Customer return and rebate accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xlink:to="lab_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xml:lang="en-US">Customer return and rebate accruals, includes (only in Dec 31, 2022) Cash discount and Channel Management Payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xml:lang="en-US">Assets and liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xml:lang="en-US">Assets and liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xml:lang="en-US">Assets and liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xml:lang="en-US">Assets and liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:label="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xml:lang="en-US">Estimated Rebates Discounts or Allowance Payable To Customer [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xml:lang="en-US">Estimated rebates, discounts or allowances payable to customers [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:to="lab_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xml:lang="en-US">Estimated rebates discounts or allowance payable to customer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsMember" xml:lang="en-US">Business combinations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsMember" xml:lang="en-US">Business combinations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsMember" xlink:to="lab_ifrs-full_BusinessCombinationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="lab_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInstrumentMember" xml:lang="en-US">Types of instrument [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfInstrumentMember" xml:lang="en-US">Types of instrument [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInstrumentMember" xlink:to="lab_ifrs-full_TypesOfInstrumentMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SegmentConsolidationItemAxis" xml:lang="en-US">Segment Consolidation Item [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SegmentConsolidationItemAxis" xml:lang="en-US">Segment consolidation items [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SegmentConsolidationItemAxis" xlink:to="lab_gsk_SegmentConsolidationItemAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SegmentConsolidationItemAxis" xml:lang="en-US">Segment consolidation item.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SegmentConsolidationItemMember" xml:lang="en-US">Segment Consolidation Item [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SegmentConsolidationItemMember" xml:lang="en-US">Entity's total for segment consolidation items [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SegmentConsolidationItemMember" xlink:to="lab_gsk_SegmentConsolidationItemMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SegmentConsolidationItemMember" xml:lang="en-US">Segment consolidation item.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_USPharmaceuticalsAndVaccinesMember" xlink:label="loc_gsk_USPharmaceuticalsAndVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_USPharmaceuticalsAndVaccinesMember" xml:lang="en-US">U S Pharmaceuticals And Vaccines [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_USPharmaceuticalsAndVaccinesMember" xml:lang="en-US">US Pharmaceuticals and vaccines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_USPharmaceuticalsAndVaccinesMember" xlink:to="lab_gsk_USPharmaceuticalsAndVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_USPharmaceuticalsAndVaccinesMember" xml:lang="en-US">US Pharmaceuticals and vaccines.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xml:lang="en-US">Actuarial assumptions [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xml:lang="en-US">Actuarial assumptions [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xml:lang="en-US">Actuarial assumptions [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xml:lang="en-US">Actuarial assumptions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember" xlink:to="lab_ifrs-full_ActuarialAssumptionsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SensitivityAnalysisForActuarialAssumptionsMember" xlink:label="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SensitivityAnalysisForActuarialAssumptionsMember" xml:lang="en-US">Sensitivity Analysis For Actuarial Assumptions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_SensitivityAnalysisForActuarialAssumptionsMember" xml:lang="en-US">Sensitivity analysis for actuarial assumptions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember" xlink:to="lab_gsk_SensitivityAnalysisForActuarialAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SensitivityAnalysisForActuarialAssumptionsMember" xml:lang="en-US">Sensitivity analysis for actuarial assumptions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateAxis" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionPercentageRateAxis" xml:lang="en-US">Actuarial Assumption Percentage Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateAxis" xlink:to="lab_gsk_ActuarialAssumptionPercentageRateAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionPercentageRateMember" xml:lang="en-US">Actuarial Assumption Percentage Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateMember" xlink:to="lab_gsk_ActuarialAssumptionPercentageRateMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xlink:label="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xml:lang="en-US">Actuarial Assumption Of Discount Rates at Zero Point Seven Five Percent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xml:lang="en-US">Discount Rate at 0.75% [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xlink:to="lab_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateChangeMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateChangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionPercentageRateChangeMember" xml:lang="en-US">Actuarial Assumption Percentage Rate Change [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ActuarialAssumptionPercentageRateChangeMember" xml:lang="en-US">Actuarial assumption percentage rate change [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateChangeMember" xlink:to="lab_gsk_ActuarialAssumptionPercentageRateChangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ActuarialAssumptionPercentageRateChangeMember" xml:lang="en-US">Actuarial assumption percentage rate change.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="loc_ifrs-full_ForeignExchangeRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignExchangeRatesAbstract" xml:lang="en-US">Foreign exchange rates [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeRatesAbstract" xlink:to="lab_ifrs-full_ForeignExchangeRatesAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesTable" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesTable" xml:lang="en-US">Disclosure Of Foreign Exchange Rates [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesTable" xml:lang="en-US">Disclosure Of Foreign Exchange Rates [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesTable" xlink:to="lab_gsk_DisclosureOfForeignExchangeRatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesTable" xml:lang="en-US">Disclosure Of Foreign Exchange Rates [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesLineItems" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesLineItems" xml:lang="en-US">Disclosure of foreign exchange rates [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesLineItems" xml:lang="en-US">Disclosure of foreign exchange rates [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems" xlink:to="lab_gsk_DisclosureOfForeignExchangeRatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfForeignExchangeRatesLineItems" xml:lang="en-US">Disclosure of foreign exchange rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average foreign exchange rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Closing foreign exchange rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Period end rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="loc_currency_JPY" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_JPY" xml:lang="en-US">Japan, Yen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_JPY" xml:lang="en-US">Yen [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro Member Countries, Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD" xml:lang="en-US">United States of America, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_USD" xml:lang="en-US">USD [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xml:lang="en-US">Disclosure of operating segments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xml:lang="en-US">Disclosure of operating segments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xml:lang="en-US">Disclosure of operating segments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromChangesToEstimatesOfRARAccruals" xlink:label="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RevenueFromChangesToEstimatesOfRARAccruals" xml:lang="en-US">Revenue from changes to estimates of RAR accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RevenueFromChangesToEstimatesOfRARAccruals" xml:lang="en-US">Turnover from changes to estimates of RAR accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals" xlink:to="lab_gsk_RevenueFromChangesToEstimatesOfRARAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RevenueFromChangesToEstimatesOfRARAccruals" xml:lang="en-US">Revenue from changes to estimates of RAR accruals.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfWholesalers" xlink:label="loc_gsk_NumberOfWholesalers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfWholesalers" xml:lang="en-US">Number of wholesalers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfWholesalers" xml:lang="en-US">Number of wholesalers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfWholesalers" xlink:to="lab_gsk_NumberOfWholesalers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfWholesalers" xml:lang="en-US">Number of wholesalers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xml:lang="en-US">Revenue from performance obligations satisfied or partially satisfied in previous periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xml:lang="en-US">Revenue recognised in year from performance obligations satisfied in previous periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:to="lab_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOption" xlink:label="loc_gsk_PutOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PutOption" xml:lang="en-US">Put Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PutOption" xml:lang="en-US">Pfizer put option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PutOption" xlink:to="lab_gsk_PutOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PutOption" xml:lang="en-US">Put option.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Royalty Income Recognised From Performance Obligations Satisfied In Previous Periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Royalty income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:to="lab_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Royalty income recognised from performance obligations satisfied in previous periods.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfReportableOperatingSegments" xlink:label="loc_gsk_NumberOfReportableOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfReportableOperatingSegments" xml:lang="en-US">Number of reportable operating segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfReportableOperatingSegments" xml:lang="en-US">Number of reportable operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfReportableOperatingSegments" xlink:to="lab_gsk_NumberOfReportableOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfReportableOperatingSegments" xml:lang="en-US">Number of reportable operating segments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xlink:label="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xml:lang="en-US">Description of factors used to identify entity's reportable segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xml:lang="en-US">Description of factors used to identify entity's reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xlink:to="lab_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Milestone Income Recognised From Performance Obligations Satisfied In Previous Periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Milestone income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:to="lab_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xml:lang="en-US">Milestone income recognised from performance obligations satisfied in previous periods.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOperatingSegments" xlink:label="loc_gsk_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfOperatingSegments" xlink:to="lab_gsk_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Major customers [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="loc_ifrs-full_MajorCustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorCustomersMember" xml:lang="en-US">Customers [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MajorCustomersMember" xml:lang="en-US">Customers [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersMember" xlink:to="lab_ifrs-full_MajorCustomersMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers1Member" xlink:label="loc_gsk_Wholesalers1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Wholesalers1Member" xml:lang="en-US">Wholesalers 1 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_Wholesalers1Member" xml:lang="en-US">Wholesalers 1 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Wholesalers1Member" xlink:to="lab_gsk_Wholesalers1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Wholesalers1Member" xml:lang="en-US">Wholesalers 1.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers2Member" xlink:label="loc_gsk_Wholesalers2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Wholesalers2Member" xml:lang="en-US">Wholesalers 2 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_Wholesalers2Member" xml:lang="en-US">Wholesalers 2 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Wholesalers2Member" xlink:to="lab_gsk_Wholesalers2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Wholesalers2Member" xml:lang="en-US">Wholesalers 2.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers3Member" xlink:label="loc_gsk_Wholesalers3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Wholesalers3Member" xml:lang="en-US">Wholesalers 3 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_Wholesalers3Member" xml:lang="en-US">Wholesalers 3 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Wholesalers3Member" xlink:to="lab_gsk_Wholesalers3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Wholesalers3Member" xml:lang="en-US">Wholesalers 3.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViivHealthcareMember" xlink:label="loc_gsk_ShionogiViivHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShionogiViivHealthcareMember" xml:lang="en-US">Shionogi ViiV Healthcare [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShionogiViivHealthcareMember" xml:lang="en-US">Shionogi-ViiV Healthcare [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ShionogiViivHealthcareMember" xml:lang="en-US">Shionogi ViiV healthcare [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShionogiViivHealthcareMember" xlink:to="lab_gsk_ShionogiViivHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShionogiViivHealthcareMember" xml:lang="en-US">Shionogi ViiV healthcare.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">US [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerMember" xlink:label="loc_gsk_PfizerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PfizerMember" xml:lang="en-US">Pfizer [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PfizerMember" xml:lang="en-US">Pfizer [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PfizerMember" xlink:to="lab_gsk_PfizerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PfizerMember" xml:lang="en-US">Pfizer.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConsumerHealthcareMember" xml:lang="en-US">Consumer Healthcare [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ConsumerHealthcareMember" xml:lang="en-US">Consumer Healthcare [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConsumerHealthcareMember" xlink:to="lab_gsk_ConsumerHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConsumerHealthcareMember" xml:lang="en-US">Consumer healthcare.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesAbstract" xml:lang="en-US">Disclosure of products and services [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesTable" xml:lang="en-US">Disclosure of products and services [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesTable" xml:lang="en-US">Disclosure of products and services [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesLineItems" xml:lang="en-US">Disclosure of products and services [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesLineItems" xml:lang="en-US">Disclosure of products and services [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xml:lang="en-US">Products and services [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xml:lang="en-US">Products and services [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xml:lang="en-US">Products and services [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xml:lang="en-US">Products and services [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InfluenzaMember" xlink:label="loc_gsk_InfluenzaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InfluenzaMember" xml:lang="en-US">Influenza [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InfluenzaMember" xml:lang="en-US">Influenza [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InfluenzaMember" xlink:to="lab_gsk_InfluenzaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InfluenzaMember" xml:lang="en-US">Influenza.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RespiratoryMember" xlink:label="loc_gsk_RespiratoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RespiratoryMember" xml:lang="en-US">Respiratory [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RespiratoryMember" xml:lang="en-US">Respiratory [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RespiratoryMember" xlink:to="lab_gsk_RespiratoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RespiratoryMember" xml:lang="en-US">Respiratory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstablishedVaccinesMember" xlink:label="loc_gsk_EstablishedVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EstablishedVaccinesMember" xml:lang="en-US">Established Vaccines [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EstablishedVaccinesMember" xml:lang="en-US">Established vaccines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EstablishedVaccinesMember" xlink:to="lab_gsk_EstablishedVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EstablishedVaccinesMember" xml:lang="en-US">Established vaccines.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HIVMember" xlink:label="loc_gsk_HIVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HIVMember" xml:lang="en-US">HIV [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HIVMember" xml:lang="en-US">HIV [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HIVMember" xlink:to="lab_gsk_HIVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HIVMember" xml:lang="en-US">HIV.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShinglesMember" xlink:label="loc_gsk_ShinglesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShinglesMember" xml:lang="en-US">Shingles [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShinglesMember" xml:lang="en-US">Shingles [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShinglesMember" xlink:to="lab_gsk_ShinglesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShinglesMember" xml:lang="en-US">Shingles.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisMember" xlink:label="loc_gsk_MeningitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MeningitisMember" xml:lang="en-US">Meningitis [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MeningitisMember" xml:lang="en-US">Meningitis [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MeningitisMember" xlink:to="lab_gsk_MeningitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MeningitisMember" xml:lang="en-US">Meningitis.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubTotalMember" xlink:label="loc_gsk_SubTotalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SubTotalMember" xml:lang="en-US">Sub Total [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SubTotalMember" xml:lang="en-US">Sub Total [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SubTotalMember" xlink:to="lab_gsk_SubTotalMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OncologyMember" xlink:label="loc_gsk_OncologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OncologyMember" xml:lang="en-US">Oncology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_OncologyMember" xml:lang="en-US">Oncology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OncologyMember" xlink:to="lab_gsk_OncologyMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImmunoInflammationRespiratoryAndOtherMember" xlink:label="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImmunoInflammationRespiratoryAndOtherMember" xml:lang="en-US">Immuno inflammation respiratory and other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImmunoInflammationRespiratoryAndOtherMember" xml:lang="en-US">Immuno-inflammation, respiratory and other [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember" xlink:to="lab_gsk_ImmunoInflammationRespiratoryAndOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImmunoInflammationRespiratoryAndOtherMember" xml:lang="en-US">Immuno inflammation respiratory and other [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SpecialtyMedicineMember" xlink:label="loc_gsk_SpecialtyMedicineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SpecialtyMedicineMember" xml:lang="en-US">Specialty Medicine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SpecialtyMedicineMember" xml:lang="en-US">Specialty Medicines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SpecialtyMedicineMember" xlink:to="lab_gsk_SpecialtyMedicineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SpecialtyMedicineMember" xml:lang="en-US">Specialty Medicines.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicVaccinesMember" xlink:label="loc_gsk_PandemicVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PandemicVaccinesMember" xml:lang="en-US">Pandemic Vaccines [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PandemicVaccinesMember" xml:lang="en-US">Pandemic Vaccines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PandemicVaccinesMember" xlink:to="lab_gsk_PandemicVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PandemicVaccinesMember" xml:lang="en-US">Pandemic vaccines member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicMember" xlink:label="loc_gsk_PandemicMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PandemicMember" xml:lang="en-US">Pandemic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PandemicMember" xml:lang="en-US">Pandemic [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PandemicMember" xlink:to="lab_gsk_PandemicMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PandemicMember" xml:lang="en-US">Pandemic [Member].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGeneralMedicinesMember" xlink:label="loc_gsk_OtherGeneralMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherGeneralMedicinesMember" xml:lang="en-US">Other General Medicines [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherGeneralMedicinesMember" xml:lang="en-US">Other General Medicines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherGeneralMedicinesMember" xlink:to="lab_gsk_OtherGeneralMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherGeneralMedicinesMember" xml:lang="en-US">Other General Medicines [Member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GeneralMedicinesMember" xlink:label="loc_gsk_GeneralMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GeneralMedicinesMember" xml:lang="en-US">General Medicines [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GeneralMedicinesMember" xml:lang="en-US">General Medicines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GeneralMedicinesMember" xlink:to="lab_gsk_GeneralMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GeneralMedicinesMember" xml:lang="en-US">General Medicines Member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xml:lang="en-US">Derivative financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xml:lang="en-US">Derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_InvestmentsInJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Investments In Joint Ventures And Associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Investments in associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentsInJointVenturesAndAssociates" xlink:to="lab_gsk_InvestmentsInJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Investments in joint ventures and associates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xlink:label="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xml:lang="en-US">Changes in intangible assets and goodwill [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xml:lang="en-US">PP&amp;E, intangible asset and goodwill impairment by segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xml:lang="en-US">Impairment loss recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xml:lang="en-US">Total impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingAssets" xlink:label="loc_gsk_NetOperatingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetOperatingAssets" xml:lang="en-US">Net operating assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetOperatingAssets" xml:lang="en-US">Net operating assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetOperatingAssets" xlink:to="lab_gsk_NetOperatingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetOperatingAssets" xml:lang="en-US">Net operating assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentReversalsBySegmentAbstract" xlink:label="loc_gsk_ImpairmentReversalsBySegmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpairmentReversalsBySegmentAbstract" xml:lang="en-US">Impairment Reversals by Segment [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImpairmentReversalsBySegmentAbstract" xml:lang="en-US">PP&amp;E and intangible asset impairment reversals by segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpairmentReversalsBySegmentAbstract" xlink:to="lab_gsk_ImpairmentReversalsBySegmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpairmentReversalsBySegmentAbstract" xml:lang="en-US">Impairment reversals by segment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xml:lang="en-US">Total impairment reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpenseAbstract" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpenseAbstract" xml:lang="en-US">Depreciation and amortisation expense [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpenseAbstract" xml:lang="en-US">Depreciation and amortisation by segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xml:lang="en-US">Depreciation and amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xml:lang="en-US">Total depreciation and amortisation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAbstract" xml:lang="en-US">Profit (loss) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAbstract" xml:lang="en-US">Segment profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xml:lang="en-US">Assets held for sale (excluding cash and cash equivalents)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xml:lang="en-US">Total assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentAndDeferredTaxation" xlink:label="loc_gsk_CurrentAndDeferredTaxation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentAndDeferredTaxation" xml:lang="en-US">Current and deferred taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentAndDeferredTaxation" xml:lang="en-US">Current and deferred taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentAndDeferredTaxation" xlink:to="lab_gsk_CurrentAndDeferredTaxation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentAndDeferredTaxation" xml:lang="en-US">Current and deferred taxation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-full_NetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetDebt" xml:lang="en-US">Net debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NetDebt" xml:lang="en-US">Net debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDebt" xlink:to="lab_ifrs-full_NetDebt" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ResearchAndDevelopmentMember" xml:lang="en-US">Research and development [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ResearchAndDevelopmentMember" xml:lang="en-US">Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ResearchAndDevelopmentMember" xml:lang="en-US">Research and development [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ResearchAndDevelopmentMember" xlink:to="lab_gsk_ResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ResearchAndDevelopmentMember" xml:lang="en-US">Research and development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xml:lang="en-US">Continuing and discontinued operations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lab_ifrs-full_ContinuingAndDiscontinuedOperationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContinuingOperationsMember" xml:lang="en-US">Continuing operations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContinuingOperationsMember" xlink:to="lab_ifrs-full_ContinuingOperationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DiscontinuedOperationsMember" xml:lang="en-US">Discontinued operations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscontinuedOperationsMember" xlink:to="lab_ifrs-full_DiscontinuedOperationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xml:lang="en-US">Segment Reconciling Items [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xml:lang="en-US">Other Reconciling Items between Segment Profit and Operating Profit [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:to="lab_ifrs-full_MaterialReconcilingItemsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="loc_ifrs-full_UnallocatedAmountsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnallocatedAmountsMember" xml:lang="en-US">Unallocated amounts [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UnallocatedAmountsMember" xml:lang="en-US">Corporate and Other Unallocated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnallocatedAmountsMember" xlink:to="lab_ifrs-full_UnallocatedAmountsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="loc_ifrs-full_OperatingSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xml:lang="en-US">Operating segments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xml:lang="en-US">Operating Segments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingSegmentsMember" xlink:to="lab_ifrs-full_OperatingSegmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasAbstract" xml:lang="en-US">Disclosure of geographical areas [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xml:lang="en-US">Disclosure of geographical areas [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xml:lang="en-US">Disclosure of geographical areas [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerMember" xlink:label="loc_gsk_CustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CustomerMember" xml:lang="en-US">Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CustomerMember" xml:lang="en-US">Customer [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CustomerMember" xlink:to="lab_gsk_CustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CustomerMember" xml:lang="en-US">Customer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xml:lang="en-US">Disclosure of geographical areas [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xml:lang="en-US">Disclosure of geographical areas [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xml:lang="en-US">Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:to="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestOfWorldMember" xml:lang="en-US">Rest Of World [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RestOfWorldMember" xml:lang="en-US">Rest of World [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestOfWorldMember" xlink:to="lab_gsk_RestOfWorldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RestOfWorldMember" xml:lang="en-US">Rest of world.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB" xml:lang="en-US">UK [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="loc_country_CH" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CH" xml:lang="en-US">SWITZERLAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CH" xml:lang="en-US">Switzerland [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="loc_country_BE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BE" xml:lang="en-US">BELGIUM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_BE" xml:lang="en-US">Belgium [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BE" xlink:to="lab_country_BE" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xml:lang="en-US">Disclosure of other operating income expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xlink:to="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xml:lang="en-US">Disclosure of other operating income expense.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xml:lang="en-US">Disclosure Of Other Operating Income Expense [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xml:lang="en-US">Disclosure Of Other Operating Income Expense [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xlink:to="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xml:lang="en-US">Disclosure of other operating income expense table.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xml:lang="en-US">Disclosure Of Other Operating Income Expense [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xml:lang="en-US">Disclosure of other operating income expense [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xlink:to="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xml:lang="en-US">Disclosure of other operating income expense line items.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Increase (decrease) in contingent liabilities recognised in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Fair value remeasurements on contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Fair value remeasurements on contingent consideration recognised in business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfBusinessesAndAssets" xlink:label="loc_gsk_DisposalOfBusinessesAndAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalOfBusinessesAndAssets" xml:lang="en-US">Disposal of businesses and assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalOfBusinessesAndAssets" xml:lang="en-US">Disposal of businesses and assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalOfBusinessesAndAssets" xlink:to="lab_gsk_DisposalOfBusinessesAndAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalOfBusinessesAndAssets" xml:lang="en-US">Disposal of businesses and assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossOnSaleOfBusiness" xlink:label="loc_gsk_LossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LossOnSaleOfBusiness" xml:lang="en-US">Loss on sale of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LossOnSaleOfBusiness" xlink:to="lab_gsk_LossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LossOnSaleOfBusiness" xml:lang="en-US">Loss on sale of business</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontPayment" xlink:label="loc_gsk_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UpfrontPayment" xml:lang="en-US">upfront payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UpfrontPayment" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UpfrontPayment" xlink:to="lab_gsk_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UpfrontPayment" xml:lang="en-US">upfront payment</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfRoyaltyPayableOnFutureSales" xlink:label="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfRoyaltyPayableOnFutureSales" xml:lang="en-US">Percentage of royalty payable on future sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfRoyaltyPayableOnFutureSales" xml:lang="en-US">Percentage of royalty payable on future sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales" xlink:to="lab_gsk_PercentageOfRoyaltyPayableOnFutureSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfRoyaltyPayableOnFutureSales" xml:lang="en-US">Percentage of royalty payable on future sales</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xlink:label="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gain or Loss on Remeasurement of Investments Measured at Fair Value through Profit or Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gain or loss on remeasurement of investments measured at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xlink:to="lab_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gain or loss on remeasurement of investments measured at fair value through profit or loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gains on change in fair value of derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gains on embedded derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GileadSciencesIncMember" xlink:label="loc_gsk_GileadSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GileadSciencesIncMember" xml:lang="en-US">Gilead Sciences Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GileadSciencesIncMember" xml:lang="en-US">Gilead Sciences, Inc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GileadSciencesIncMember" xlink:to="lab_gsk_GileadSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GileadSciencesIncMember" xml:lang="en-US">Gilead sciences Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesBusinessAcquisitionMember" xlink:label="loc_gsk_VaccinesBusinessAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VaccinesBusinessAcquisitionMember" xml:lang="en-US">Vaccines Business Acquisition [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VaccinesBusinessAcquisitionMember" xml:lang="en-US">Vaccines business acquisition [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VaccinesBusinessAcquisitionMember" xlink:to="lab_gsk_VaccinesBusinessAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VaccinesBusinessAcquisitionMember" xml:lang="en-US">Vaccines business acquisition.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HorlicksMember" xml:lang="en-US">Horlicks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HorlicksMember" xml:lang="en-US">Horlicks [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HorlicksMember" xlink:to="lab_gsk_HorlicksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HorlicksMember" xml:lang="en-US">Horlicks</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisMember" xlink:label="loc_gsk_NovartisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NovartisMember" xml:lang="en-US">Novartis [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NovartisMember" xml:lang="en-US">Novartis [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NovartisMember" xlink:to="lab_gsk_NovartisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NovartisMember" xml:lang="en-US">Novartis.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HindustanUnileverLimitedMember" xlink:label="loc_gsk_HindustanUnileverLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HindustanUnileverLimitedMember" xml:lang="en-US">Hindustan Unilever Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HindustanUnileverLimitedMember" xml:lang="en-US">Hindustan Unilever Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HindustanUnileverLimitedMember" xlink:to="lab_gsk_HindustanUnileverLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HindustanUnileverLimitedMember" xml:lang="en-US">Hindustan unilever limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerAxis" xlink:label="loc_gsk_AcquirerAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AcquirerAxis" xml:lang="en-US">Acquirer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AcquirerAxis" xlink:to="lab_gsk_AcquirerAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerDomain" xlink:label="loc_gsk_AcquirerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AcquirerDomain" xml:lang="en-US">Acquirer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AcquirerDomain" xlink:to="lab_gsk_AcquirerDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentAxis" xml:lang="en-US">Investment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentAxis" xlink:to="lab_gsk_InvestmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentAxis" xml:lang="en-US">Investment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentDomain" xml:lang="en-US">Investment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentDomain" xlink:to="lab_gsk_InvestmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentDomain" xml:lang="en-US">Investment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonPlcMember" xlink:label="loc_gsk_HaleonPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HaleonPlcMember" xml:lang="en-US">Haleon plc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HaleonPlcMember" xlink:to="lab_gsk_HaleonPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HaleonPlcMember" xml:lang="en-US">Haleon plc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xlink:label="loc_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xml:lang="en-US">Remeasurement of put option liabilities and preferential dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xml:lang="en-US">Remeasurement of ViiV Healthcare put option liabilities and preferential dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xlink:to="lab_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xml:lang="en-US">Remeasurement of put option liabilities and preferential dividends</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xml:lang="en-US">Gains (losses) recognised in profit or loss, fair value measurement, entity's own equity instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xml:lang="en-US">Fair value remeasurements of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xml:lang="en-US">Fair value adjustments on derivative financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xml:lang="en-US">Miscellaneous other operating income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontSettlementIncome" xlink:label="loc_gsk_UpfrontSettlementIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UpfrontSettlementIncome" xml:lang="en-US">Upfront Settlement Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UpfrontSettlementIncome" xml:lang="en-US">Upfront settlement income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UpfrontSettlementIncome" xlink:to="lab_gsk_UpfrontSettlementIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UpfrontSettlementIncome" xml:lang="en-US">Upfront settlement income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitTable" xlink:label="loc_gsk_DisclosureOfOperatingProfitTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOperatingProfitTable" xml:lang="en-US">Disclosure of operating profit [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOperatingProfitTable" xml:lang="en-US">Disclosure of operating profit [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable" xlink:to="lab_gsk_DisclosureOfOperatingProfitTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOperatingProfitTable" xml:lang="en-US">Disclosure of operating profit [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitLineItems" xlink:label="loc_gsk_DisclosureOfOperatingProfitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOperatingProfitLineItems" xml:lang="en-US">Disclosure of Operating Profit [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOperatingProfitLineItems" xml:lang="en-US">Disclosure of Operating Profit [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems" xlink:to="lab_gsk_DisclosureOfOperatingProfitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOperatingProfitLineItems" xml:lang="en-US">Disclosure of Operating Profit [line items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xml:lang="en-US">Professional fees expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xml:lang="en-US">Another audit fee of the company's subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense" xlink:to="lab_ifrs-full_ProfessionalFeesExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseOfRestructuringActivities" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xml:lang="en-US">Expense of restructuring activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xml:lang="en-US">Major restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:to="lab_ifrs-full_ExpenseOfRestructuringActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xml:lang="en-US">Foreign exchange gain (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xml:lang="en-US">Net foreign exchange gains (losses)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xml:lang="en-US">Net foreign exchange (gains)/losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xml:lang="en-US">Auditor's remuneration for other services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xml:lang="en-US">All other services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForOtherServices" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociates" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociates" xml:lang="en-US">Gain Loss On Disposal Of Interest In Associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociates" xml:lang="en-US">Gain loss on disposal of interest in associates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnDisposalOfInterestInAssociates" xlink:to="lab_gsk_GainLossOnDisposalOfInterestInAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnDisposalOfInterestInAssociates" xml:lang="en-US">Gain loss on disposal of interest in associates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xlink:label="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xml:lang="en-US">Liquidation Or Disposal Of Overseas Subsidiary [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xml:lang="en-US">Liquidation Or Disposal Of Overseas Subsidiary [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xlink:to="lab_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xml:lang="en-US">Liquidation or disposal of overseas subsidiary.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAuditorsMember" xlink:label="loc_gsk_OtherAuditorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAuditorsMember" xml:lang="en-US">Other Auditors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAuditorsMember" xml:lang="en-US">Other Auditors [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAuditorsMember" xlink:to="lab_gsk_OtherAuditorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAuditorsMember" xml:lang="en-US">Other auditors.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xml:lang="en-US">Associates [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xml:lang="en-US">Associates [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xml:lang="en-US">Entity's total for associates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xml:lang="en-US">Entity's total for associates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:to="lab_ifrs-full_EntitysTotalForAssociatesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xlink:label="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xml:lang="en-US">Liquidation Or Disposal Of Interest In Associates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xml:lang="en-US">Liquidation Or Disposal Of Interest In Associates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xlink:to="lab_gsk_LiquidationOrDisposalOfInterestInAssociatesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PurposeAxis" xml:lang="en-US">Purpose [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PurposeAxis" xlink:to="lab_gsk_PurposeAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PurposeDomain" xml:lang="en-US">Purpose [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PurposeDomain" xlink:to="lab_gsk_PurposeDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" xlink:label="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" xml:lang="en-US">Reporting Accountant Work Performed In Connection With Consumer Healthcare Demerger [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" xlink:to="lab_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Short-term lease charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xml:lang="en-US">Classes of current inventories [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xml:lang="en-US">Inventories:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xml:lang="en-US">Cost of inventories recognised as expense during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xml:lang="en-US">Cost of inventories included in cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="loc_ifrs-full_ReversalOfInventoryWritedown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReversalOfInventoryWritedown" xml:lang="en-US">Reversal of inventory write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ReversalOfInventoryWritedown" xml:lang="en-US">Reversal of prior year write-down of inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfInventoryWritedown" xlink:to="lab_ifrs-full_ReversalOfInventoryWritedown" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="loc_ifrs-full_InventoryWritedown2011" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InventoryWritedown2011" xml:lang="en-US">Inventory write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InventoryWritedown2011" xml:lang="en-US">Write-down of inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoryWritedown2011" xlink:to="lab_ifrs-full_InventoryWritedown2011" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdvertisingExpense" xlink:label="loc_ifrs-full_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdvertisingExpense" xml:lang="en-US">Advertising expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdvertisingExpense" xml:lang="en-US">Advertising</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdvertisingExpense" xlink:to="lab_ifrs-full_AdvertisingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Variable lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" xml:lang="en-US">Lease and Sublease Payments Recognized as Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" xml:lang="en-US">Operating lease rentals:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" xlink:to="lab_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract" xml:lang="en-US">Lease and sublease payments recognized as expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-full_AuditorsRemuneration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemuneration" xml:lang="en-US">Auditor's remuneration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AuditorsRemuneration" xml:lang="en-US">Fees payable to the company's auditor and its associates in relation to the Group</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="lab_ifrs-full_AuditorsRemuneration" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DistributionCosts" xlink:label="loc_ifrs-full_DistributionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DistributionCosts" xml:lang="en-US">Distribution costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DistributionCosts" xml:lang="en-US">Distribution costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DistributionCosts" xlink:to="lab_ifrs-full_DistributionCosts" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfRightOfUseAssets" xlink:label="loc_gsk_ImpairmentOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpairmentOfRightOfUseAssets" xml:lang="en-US">Impairment Of Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ImpairmentOfRightOfUseAssets" xml:lang="en-US">Impairment of right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpairmentOfRightOfUseAssets" xlink:to="lab_gsk_ImpairmentOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpairmentOfRightOfUseAssets" xml:lang="en-US">Impairment Of Right Of Use Assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment of property, plant and equipment, net of reversals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee costs (Note 0)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee benefits expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xml:lang="en-US">Depreciation, right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xml:lang="en-US">Depreciation of right of use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xml:lang="en-US">Low value lease charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xml:lang="en-US">Impairment of goodwill allocated to a disposal group, net of reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Charge for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xlink:label="loc_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xml:lang="en-US">Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment Held For Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xml:lang="en-US">Impairment of property, plant and equipment held for sale, net of reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xlink:to="lab_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xml:lang="en-US">Impairment loss recognised in profit or loss property plant and equipment held for sale.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xlink:label="loc_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xml:lang="en-US">Impairment Of Intangible Assets Net Of Reversal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xml:lang="en-US">Impairment of intangible assets, net of reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xlink:to="lab_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xml:lang="en-US">Impairment of intangible assets net of reversal.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xml:lang="en-US">Analysis of income and expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationTable" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationTable" xml:lang="en-US">Disclosure Of Auditors Remuneration [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationTable" xml:lang="en-US">Disclosure Of Auditors Remuneration [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable" xlink:to="lab_gsk_DisclosureOfAuditorsRemunerationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationTable" xml:lang="en-US">Disclosure Of Auditors Remuneration [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationLineItems" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationLineItems" xml:lang="en-US">Disclosure Of Auditors Remuneration [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationLineItems" xml:lang="en-US">Disclosure Of Auditors Remuneration [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationLineItems" xlink:to="lab_gsk_DisclosureOfAuditorsRemunerationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAuditorsRemunerationLineItems" xml:lang="en-US">Disclosure of auditors remuneration..</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="loc_ifrs-full_AuditorsRemunerationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemunerationAbstract" xml:lang="en-US">Auditor's remuneration [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AuditorsRemunerationAbstract" xml:lang="en-US">Auditor's remuneration [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract" xlink:to="lab_ifrs-full_AuditorsRemunerationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xml:lang="en-US">Auditor's remuneration for audit services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xml:lang="en-US">Audit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForAuditServices" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xml:lang="en-US">Auditors Remuneration For Audit Related And Other Assurance Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xml:lang="en-US">Total audit services, audit-related and other assurance services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:to="lab_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xml:lang="en-US">Auditors remuneration for audit related and other assurance services.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForOtherAssuranceServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AuditorsRemunerationForOtherAssuranceServices" xml:lang="en-US">Auditors Remuneration For Other Assurance Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AuditorsRemunerationForOtherAssuranceServices" xml:lang="en-US">Audit-related and other assurance services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AuditorsRemunerationForOtherAssuranceServices" xlink:to="lab_gsk_AuditorsRemunerationForOtherAssuranceServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AuditorsRemunerationForOtherAssuranceServices" xml:lang="en-US">Auditor's remuneration for other assurance services.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParentMember" xml:lang="en-US">Parent [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ParentMember" xml:lang="en-US">GSK PLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParentMember" xlink:to="lab_ifrs-full_ParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="loc_ifrs-full_SubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SubsidiariesMember" xml:lang="en-US">Subsidiaries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SubsidiariesMember" xml:lang="en-US">Subsidiaries [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubsidiariesMember" xlink:to="lab_ifrs-full_SubsidiariesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xml:lang="en-US">Short-term employee benefits expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostEmploymentBenefitExpense" xlink:label="loc_gsk_PostEmploymentBenefitExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostEmploymentBenefitExpense" xml:lang="en-US">Post Employment Benefit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_PostEmploymentBenefitExpense" xml:lang="en-US">Pension and other post-employment costs, including augmentations (Note 31)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostEmploymentBenefitExpense" xlink:to="lab_gsk_PostEmploymentBenefitExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostEmploymentBenefitExpense" xml:lang="en-US">The amount of post-employment benefit expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Cost of share-based incentive plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-full_SocialSecurityContributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SocialSecurityContributions" xml:lang="en-US">Social security contributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SocialSecurityContributions" xml:lang="en-US">Social security costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TerminationBenefitsExpense" xml:lang="en-US">Termination benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TerminationBenefitsExpense" xml:lang="en-US">Severance and other costs from integration and restructuring activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TerminationBenefitsExpense" xlink:to="lab_ifrs-full_TerminationBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WagesAndSalaries" xml:lang="en-US">Wages and salaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WagesAndSalaries" xml:lang="en-US">Wages and salaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeesBenefitAbstract" xlink:label="loc_gsk_EmployeesBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EmployeesBenefitAbstract" xml:lang="en-US">Employees Benefit [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EmployeesBenefitAbstract" xlink:to="lab_gsk_EmployeesBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EmployeesBenefitAbstract" xml:lang="en-US">Employees Benefit [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xlink:label="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xml:lang="en-US">Expense From Sharebased Payment Transactions With Employees [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xml:lang="en-US">Expense From Sharebased Payment Transactions With Employees [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xlink:to="lab_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xml:lang="en-US">Expense From Sharebased Payment Transactions With Employees [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashSettledAndOtherPlansMember" xlink:label="loc_gsk_CashSettledAndOtherPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashSettledAndOtherPlansMember" xml:lang="en-US">Cash settled and other plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashSettledAndOtherPlansMember" xml:lang="en-US">Cash settled and other plans [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashSettledAndOtherPlansMember" xlink:to="lab_gsk_CashSettledAndOtherPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashSettledAndOtherPlansMember" xml:lang="en-US">Cash settled and other plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionPlanMember" xlink:label="loc_gsk_ShareOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareOptionPlanMember" xml:lang="en-US">Share Option Plan [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareOptionPlanMember" xml:lang="en-US">Share option plans [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareOptionPlanMember" xlink:to="lab_gsk_ShareOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareOptionPlanMember" xml:lang="en-US">Share option plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PerformanceSharePlansMember" xlink:label="loc_gsk_PerformanceSharePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PerformanceSharePlansMember" xml:lang="en-US">Performance Share Plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PerformanceSharePlansMember" xml:lang="en-US">Performance Share Plan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PerformanceSharePlansMember" xlink:to="lab_gsk_PerformanceSharePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PerformanceSharePlansMember" xml:lang="en-US">Performance share plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareValuePlanMember" xml:lang="en-US">Share Value Plan [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareValuePlanMember" xml:lang="en-US">Share Value Plan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareValuePlanMember" xlink:to="lab_gsk_ShareValuePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareValuePlanMember" xml:lang="en-US">Share value plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xlink:label="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xml:lang="en-US">Expense From Share Based Payment Transactions With Employees [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xml:lang="en-US">Expense from share based payment transactions with employees [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xlink:to="lab_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xml:lang="en-US">Expense From Share Based Payment Transactions With Employees [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersTable" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersTable" xml:lang="en-US">Disclosure of Employee Costs and Numbers [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersTable" xml:lang="en-US">Disclosure of Employee Costs and Numbers [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable" xlink:to="lab_gsk_DisclosureOfEmployeeCostsAndNumbersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersTable" xml:lang="en-US">Disclosure of employee costs and numbers.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xml:lang="en-US">Disclosure of Employee Costs and Numbers [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xml:lang="en-US">Disclosure of employee costs and numbers [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xlink:to="lab_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xml:lang="en-US">Disclosure of employee costs and numbers line items.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromContinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AverageNumberOfEmployeesFromContinuingOperations" xml:lang="en-US">Average Number Of Employees From Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AverageNumberOfEmployeesFromContinuingOperations" xml:lang="en-US">Continuing Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations" xlink:to="lab_gsk_AverageNumberOfEmployeesFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AverageNumberOfEmployeesFromContinuingOperations" xml:lang="en-US">Average number of employees from continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xml:lang="en-US">Average Number Of Employees From Discontinuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xml:lang="en-US">Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xlink:to="lab_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xml:lang="en-US">Average number of employees from discontinuing operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xml:lang="en-US">Average number of employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xml:lang="en-US">Average number of employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="lab_ifrs-full_AverageNumberOfEmployees" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ManufacturingMember" xlink:label="loc_gsk_ManufacturingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ManufacturingMember" xml:lang="en-US">Manufacturing [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ManufacturingMember" xml:lang="en-US">Manufacturing [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ManufacturingMember" xlink:to="lab_gsk_ManufacturingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ManufacturingMember" xml:lang="en-US">Manufacturing.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrationMember" xlink:label="loc_gsk_SellingGeneralAndAdministrationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SellingGeneralAndAdministrationMember" xml:lang="en-US">Selling, General and Administration [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SellingGeneralAndAdministrationMember" xml:lang="en-US">Selling, general and administration [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SellingGeneralAndAdministrationMember" xlink:to="lab_gsk_SellingGeneralAndAdministrationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SellingGeneralAndAdministrationMember" xml:lang="en-US">Selling, General and Administration.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xlink:label="loc_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xml:lang="en-US">Key management personnel compensation, social security costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xml:lang="en-US">Social security costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xlink:to="lab_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xml:lang="en-US">Key management personnel compensation, social security costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Pension and other post-employment costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Wages and salaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Cost of share-based incentive plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringCostsAbstract" xlink:label="loc_gsk_MajorRestructuringCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MajorRestructuringCostsAbstract" xml:lang="en-US">Major Restructuring Costs [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MajorRestructuringCostsAbstract" xml:lang="en-US">Major Restructuring Costs [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MajorRestructuringCostsAbstract" xlink:to="lab_gsk_MajorRestructuringCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MajorRestructuringCostsAbstract" xml:lang="en-US">Major Restructuring Costs [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfRestructuringCostsTable" xml:lang="en-US">Disclosure of restructuring costs [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfRestructuringCostsTable" xml:lang="en-US">Disclosure of restructuring costs [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable" xlink:to="lab_gsk_DisclosureOfRestructuringCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfRestructuringCostsTable" xml:lang="en-US">Disclosure of restructuring costs table.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsAxis" xlink:label="loc_gsk_RestructuringCostsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringCostsAxis" xml:lang="en-US">Restructuring Costs [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RestructuringCostsAxis" xml:lang="en-US">Restructuring Costs [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringCostsAxis" xlink:to="lab_gsk_RestructuringCostsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RestructuringCostsAxis" xml:lang="en-US">Restructuring costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringCostsDomain" xml:lang="en-US">Restructuring Costs [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RestructuringCostsDomain" xml:lang="en-US">Restructuring Costs [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringCostsDomain" xlink:to="lab_gsk_RestructuringCostsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RestructuringCostsDomain" xml:lang="en-US">Restructuring Costs [domain]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfRestructuringCostsLineItems" xml:lang="en-US">Disclosure of restructuring costs [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfRestructuringCostsLineItems" xml:lang="en-US">Disclosure of restructuring costs [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems" xlink:to="lab_gsk_DisclosureOfRestructuringCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfRestructuringCostsLineItems" xml:lang="en-US">Disclosure of restructuring costs line items.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetImpairments" xlink:label="loc_gsk_AssetImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssetImpairments" xml:lang="en-US">Asset Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AssetImpairments" xml:lang="en-US">Asset impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssetImpairments" xlink:to="lab_gsk_AssetImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssetImpairments" xml:lang="en-US">Asset impairments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalRestructuringCosts" xlink:label="loc_gsk_TotalRestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TotalRestructuringCosts" xml:lang="en-US">Total Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TotalRestructuringCosts" xml:lang="en-US">Total restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TotalRestructuringCosts" xlink:to="lab_gsk_TotalRestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TotalRestructuringCosts" xml:lang="en-US">Total restructuring costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCashCredit" xlink:label="loc_gsk_OtherNonCashCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherNonCashCredit" xml:lang="en-US">Other Non Cash Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherNonCashCredit" xml:lang="en-US">Other&#160;non-cash&#160;credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherNonCashCredit" xlink:to="lab_gsk_OtherNonCashCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherNonCashCredit" xml:lang="en-US">Other&#160;non cash&#160;credit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseProvisionReversalRestructuring" xlink:label="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseProvisionReversalRestructuring" xml:lang="en-US">Increase Decrease Provision Reversal Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseProvisionReversalRestructuring" xml:lang="en-US">Increase decrease provision reversal restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring" xlink:to="lab_gsk_IncreaseDecreaseProvisionReversalRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseProvisionReversalRestructuring" xml:lang="en-US">Increase decrease provision reversal restructuring.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts" xlink:label="loc_gsk_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RestructuringCosts" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringCosts" xlink:to="lab_gsk_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RestructuringCosts" xml:lang="en-US">Major restructuring costs considered to be significant.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ArrangementTypeAxis" xml:lang="en-US">Arrangement Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ArrangementTypeAxis" xml:lang="en-US">Arrangement Type [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ArrangementTypeAxis" xlink:to="lab_gsk_ArrangementTypeAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ArrangementTypeDomain" xml:lang="en-US">Arrangement Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ArrangementTypeDomain" xml:lang="en-US">Arrangement Type [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ArrangementTypeDomain" xlink:to="lab_gsk_ArrangementTypeDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SeparationPreparationProgrammeMember" xlink:label="loc_gsk_SeparationPreparationProgrammeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SeparationPreparationProgrammeMember" xml:lang="en-US">Separation Preparation Programme [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SeparationPreparationProgrammeMember" xml:lang="en-US">Separation Preparation programme [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SeparationPreparationProgrammeMember" xlink:to="lab_gsk_SeparationPreparationProgrammeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SeparationPreparationProgrammeMember" xml:lang="en-US">Separation preparation programme.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherMaterialNoncashItems" xlink:label="loc_ifrs-full_OtherMaterialNoncashItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherMaterialNoncashItems" xml:lang="en-US">Other material non-cash items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherMaterialNoncashItems" xml:lang="en-US">Other non-cash charges/(credit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherMaterialNoncashItems" xlink:to="lab_ifrs-full_OtherMaterialNoncashItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_gsk_CostChargedToOperatingProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CostChargedToOperatingProfit" xml:lang="en-US">Cost Charged to Operating Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_CostChargedToOperatingProfit" xml:lang="en-US">Cost charged to operating profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CostChargedToOperatingProfit" xlink:to="lab_gsk_CostChargedToOperatingProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CostChargedToOperatingProfit" xml:lang="en-US">Cost charged to operating profit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xlink:label="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xml:lang="en-US">Reversal of provisions for cost of restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xml:lang="en-US">Amount of provision reversed unused</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xlink:to="lab_ifrs-full_ReversalOfProvisionsForCostOfRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-full_ImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLoss" xml:lang="en-US">Impairment loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLoss" xml:lang="en-US">Impairment losses recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLoss" xlink:to="lab_ifrs-full_ImpairmentLoss" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xlink:label="loc_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xml:lang="en-US">Increase decrease in provision for major restructuring programmes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xml:lang="en-US">Increase in provision for Major restructuring programmes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xlink:to="lab_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xml:lang="en-US">Increase decrease in provision for major restructuring programmes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCostsCashSettlement" xlink:label="loc_gsk_OtherCostsCashSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherCostsCashSettlement" xml:lang="en-US">Other Costs Cash Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherCostsCashSettlement" xml:lang="en-US">Other cash costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherCostsCashSettlement" xlink:to="lab_gsk_OtherCostsCashSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherCostsCashSettlement" xml:lang="en-US">Other costs cash settlement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashRestructuringCharges" xlink:label="loc_gsk_NonCashRestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonCashRestructuringCharges" xml:lang="en-US">Non cash restructuring Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonCashRestructuringCharges" xlink:to="lab_gsk_NonCashRestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonCashRestructuringCharges" xml:lang="en-US">Non cash restructuring charges</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashRestructuringCharges" xlink:label="loc_gsk_CashRestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashRestructuringCharges" xml:lang="en-US">Cash Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CashRestructuringCharges" xml:lang="en-US">Cash restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashRestructuringCharges" xlink:to="lab_gsk_CashRestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashRestructuringCharges" xml:lang="en-US">Cash restructuring charges.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts1" xlink:label="loc_gsk_RestructuringCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringCosts1" xml:lang="en-US">Restructuring Costs1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_RestructuringCosts1" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringCosts1" xlink:to="lab_gsk_RestructuringCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RestructuringCosts1" xml:lang="en-US">Restructuring costs1.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegacyProgrammesMember" xlink:label="loc_gsk_LegacyProgrammesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LegacyProgrammesMember" xml:lang="en-US">Legacy programmes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LegacyProgrammesMember" xml:lang="en-US">Legacy Programmes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LegacyProgrammesMember" xlink:to="lab_gsk_LegacyProgrammesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SignificantAcquisitionsMember" xlink:label="loc_gsk_SignificantAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SignificantAcquisitionsMember" xml:lang="en-US">Significant Acquisitions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SignificantAcquisitionsMember" xlink:to="lab_gsk_SignificantAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SignificantAcquisitionsMember" xml:lang="en-US">Significant acquisitions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeAxis" xlink:label="loc_gsk_RestructuringChargesByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringChargesByTypeAxis" xml:lang="en-US">Restructuring Charges By Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringChargesByTypeAxis" xlink:to="lab_gsk_RestructuringChargesByTypeAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeDomain" xlink:label="loc_gsk_RestructuringChargesByTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RestructuringChargesByTypeDomain" xml:lang="en-US">Restructuring Charges By Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RestructuringChargesByTypeDomain" xlink:to="lab_gsk_RestructuringChargesByTypeDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsAbstract" xlink:label="loc_gsk_DisclosureOfRestructuringCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfRestructuringCostsAbstract" xml:lang="en-US">Disclosure of restructuring costs [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfRestructuringCostsAbstract" xlink:to="lab_gsk_DisclosureOfRestructuringCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfRestructuringCostsAbstract" xml:lang="en-US">Disclosure of restructuring costs abstract.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentExpenses" xlink:label="loc_gsk_ResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ResearchAndDevelopmentExpenses" xml:lang="en-US">Research and Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ResearchAndDevelopmentExpenses" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ResearchAndDevelopmentExpenses" xlink:to="lab_gsk_ResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ResearchAndDevelopmentExpenses" xml:lang="en-US">Research and development expenses</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfMajorRestructuringMember" xlink:label="loc_gsk_CostOfMajorRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CostOfMajorRestructuringMember" xml:lang="en-US">Cost Of Major Restructuring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CostOfMajorRestructuringMember" xml:lang="en-US">Cost of major restructuring [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CostOfMajorRestructuringMember" xlink:to="lab_gsk_CostOfMajorRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CostOfMajorRestructuringMember" xml:lang="en-US">Cost of major restructuring [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseTable" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseTable" xml:lang="en-US">Disclosure Of Financial Income and Expense [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseTable" xml:lang="en-US">Disclosure Of Financial Income and Expense [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable" xlink:to="lab_gsk_DisclosureOfFinancialIncomeAndExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseTable" xml:lang="en-US">Disclosure Of Financial Income and Expense [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xml:lang="en-US">Disclosure Of Financial Income and Expense [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xml:lang="en-US">Disclosure Of Financial Income and Expense [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xlink:to="lab_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xml:lang="en-US">Disclosure Of Financial Income and Expense [line items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xml:lang="en-US">Interest income on financial assets designated at fair value through profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xml:lang="en-US">Financial assets measured at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xml:lang="en-US">Interest revenue for financial assets measured at amortised cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xml:lang="en-US">Financial assets measured at amortised cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:to="lab_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinanceIncome" xml:lang="en-US">Other finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherFinanceIncome" xml:lang="en-US">Other finance income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncome" xlink:to="lab_ifrs-full_OtherFinanceIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xlink:label="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xml:lang="en-US">Gains (losses) on ineffectiveness of hedges of net investments in foreign operations recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xml:lang="en-US">Net gains arising from the forward element of forward contracts in net investment hedge relationships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xlink:to="lab_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinanceExpenseAbstract" xlink:label="loc_gsk_DisclosureOfFinanceExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinanceExpenseAbstract" xml:lang="en-US">Disclosure of finance expense [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinanceExpenseAbstract" xml:lang="en-US">Disclosure of finance expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinanceExpenseAbstract" xlink:to="lab_gsk_DisclosureOfFinanceExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinanceExpenseAbstract" xml:lang="en-US">Disclosure of finance expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestCostsAbstract" xlink:label="loc_ifrs-full_InterestCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestCostsAbstract" xml:lang="en-US">Interest costs [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestCostsAbstract" xml:lang="en-US">Finance expense arising on:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestCostsAbstract" xlink:to="lab_ifrs-full_InterestCostsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xml:lang="en-US">Reclassification adjustments on cash flow hedges, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xml:lang="en-US">Reclassification of hedges from other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xml:lang="en-US">Expense due to unwinding of discount on provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xml:lang="en-US">Unwinding of discounts on provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xml:lang="en-US">Interest expense on lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xml:lang="en-US">Finance expense arising on lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss, mandatorily measured at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xml:lang="en-US">Net losses arising from: Financial instruments mandatorily measured at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xlink:to="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xml:lang="en-US">Other finance income (cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xml:lang="en-US">Other finance expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncomeCost" xlink:to="lab_ifrs-full_OtherFinanceIncomeCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xml:lang="en-US">Interest expense for financial liabilities not at fair value through profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xml:lang="en-US">Financial liabilities at amortised cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReTranslationOfLoan" xlink:label="loc_gsk_ReTranslationOfLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReTranslationOfLoan" xml:lang="en-US">Retranslation of loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_ReTranslationOfLoan" xml:lang="en-US">Retranslation of loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReTranslationOfLoan" xlink:to="lab_gsk_ReTranslationOfLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReTranslationOfLoan" xml:lang="en-US">Re translation of loan</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xml:lang="en-US">Disclosure of Financial Information of Associates and Joint Ventures [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xml:lang="en-US">Disclosure of Financial Information of Associates and Joint Ventures [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xlink:to="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xml:lang="en-US">Disclosure of financial information of associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure Of Financial Information Of Associates And Joint Ventures [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure Of Financial Information Of Associates And Joint Ventures [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:to="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure of financial information of associates and joint ventures table.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesMember" xlink:label="loc_ifrs-full_JointVenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_JointVenturesMember" xml:lang="en-US">Joint ventures [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_JointVenturesMember" xml:lang="en-US">Joint ventures [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesMember" xlink:to="lab_ifrs-full_JointVenturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssociatesMember" xml:lang="en-US">Associates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssociatesMember" xml:lang="en-US">Associates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssociatesMember" xlink:to="lab_ifrs-full_AssociatesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of Financial Information of Associates and Joint Ventures [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of financial information of associates and joint ventures [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:to="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of financial information of associates and joint ventures [line items].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVentureAbstract" xlink:label="loc_gsk_AssociatesAndJointVentureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssociatesAndJointVentureAbstract" xml:lang="en-US">Associates And Joint Venture [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssociatesAndJointVentureAbstract" xlink:to="lab_gsk_AssociatesAndJointVentureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssociatesAndJointVentureAbstract" xml:lang="en-US">Associates And Joint Venture [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesTable" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesTable" xml:lang="en-US">Disclosure Of Joint Ventures And Associates [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesTable" xml:lang="en-US">Disclosure Of Joint Ventures And Associates [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable" xlink:to="lab_gsk_DisclosureOfJointVenturesAndAssociatesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesTable" xml:lang="en-US">Disclosure of joint ventures and associates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xml:lang="en-US">Disclosure Of Joint Ventures And Associates [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xml:lang="en-US">Disclosure of joint ventures and associates [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xlink:to="lab_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xml:lang="en-US">Disclosure Of Joint Ventures And Associates [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SalesToAssociatesAndJointVentures" xlink:label="loc_gsk_SalesToAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SalesToAssociatesAndJointVentures" xml:lang="en-US">Sales to associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SalesToAssociatesAndJointVentures" xml:lang="en-US">Sales to associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SalesToAssociatesAndJointVentures" xlink:to="lab_gsk_SalesToAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SalesToAssociatesAndJointVentures" xml:lang="en-US">Sales to associates and joint ventures</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InnovivaIncMember" xml:lang="en-US">Innoviva Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InnovivaIncMember" xml:lang="en-US">Innoviva Inc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InnovivaIncMember" xlink:to="lab_gsk_InnovivaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InnovivaIncMember" xml:lang="en-US">Innoviva Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssociatesMember" xlink:label="loc_gsk_OtherAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAssociatesMember" xml:lang="en-US">Other Associates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAssociatesMember" xml:lang="en-US">Other associates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAssociatesMember" xlink:to="lab_gsk_OtherAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAssociatesMember" xml:lang="en-US">Other Associates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsTable" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsTable" xml:lang="en-US">Income Tax Expense Benefits [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsTable" xml:lang="en-US">Income Tax Expense Benefits [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable" xlink:to="lab_gsk_IncomeTaxExpenseBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsTable" xml:lang="en-US">Income Tax Expense Benefits [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignCountriesMember" xml:lang="en-US">Foreign countries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ForeignCountriesMember" xml:lang="en-US">Rest of World [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignCountriesMember" xlink:to="lab_ifrs-full_ForeignCountriesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsLineItems" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsLineItems" xml:lang="en-US">Income Tax Expense Benefits [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsLineItems" xml:lang="en-US">Income tax expense benefits [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems" xlink:to="lab_gsk_IncomeTaxExpenseBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncomeTaxExpenseBenefitsLineItems" xml:lang="en-US">Income Tax Expense Benefits [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxExpensesincomeAbstract" xlink:label="loc_gsk_CurrentTaxExpensesincomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxExpensesincomeAbstract" xml:lang="en-US">Current tax expenses income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrentTaxExpensesincomeAbstract" xml:lang="en-US">Current tax expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract" xlink:to="lab_gsk_CurrentTaxExpensesincomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentTaxExpensesincomeAbstract" xml:lang="en-US">Current tax expenses (income).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xml:lang="en-US">Deferred tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xml:lang="en-US">Deferred taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xml:lang="en-US">Adjustments for current tax of prior periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xml:lang="en-US">Charge/(credit) in respect of prior periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xml:lang="en-US">Current taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProvisionsForUncertainTaxPosition" xlink:label="loc_gsk_ProvisionsForUncertainTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProvisionsForUncertainTaxPosition" xml:lang="en-US">Provisions for Uncertain Tax Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProvisionsForUncertainTaxPosition" xml:lang="en-US">Provisions For Uncertain Tax Position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProvisionsForUncertainTaxPosition" xlink:to="lab_gsk_ProvisionsForUncertainTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProvisionsForUncertainTaxPosition" xml:lang="en-US">Provisions for uncertain tax position.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xlink:label="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xml:lang="en-US">Deferred Tax Assets Recognized On Trading Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xml:lang="en-US">Deferred tax assets recognized on trading losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xlink:to="lab_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xml:lang="en-US">Deferred tax assets recognized on trading losses.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xlink:label="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xml:lang="en-US">Unremitted profits for which deferred tax not provided</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xml:lang="en-US">Unremitted profits for which deferred tax not provided</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xlink:to="lab_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xml:lang="en-US">Unremitted profits for which deferred tax not provided.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedEarnings" xlink:label="loc_gsk_UnremittedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnremittedEarnings" xml:lang="en-US">Unremitted Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnremittedEarnings" xml:lang="en-US">Unremitted profits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnremittedEarnings" xlink:to="lab_gsk_UnremittedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnremittedEarnings" xml:lang="en-US">Unremitted earnings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">UK statutory rate of taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xml:lang="en-US">Income taxes paid (refund)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xml:lang="en-US">Payments of corporation tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeadlineUkTaxRateEffective2023" xlink:label="loc_gsk_HeadlineUkTaxRateEffective2023" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HeadlineUkTaxRateEffective2023" xml:lang="en-US">Headline UK Tax Rate Effective 2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HeadlineUkTaxRateEffective2023" xml:lang="en-US">Headline UK tax rate effective 2023.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HeadlineUkTaxRateEffective2023" xlink:to="lab_gsk_HeadlineUkTaxRateEffective2023" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HeadlineUkTaxRateEffective2023" xml:lang="en-US">Headline UK tax rate effective 2023.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xml:lang="en-US">Income taxes paid, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xml:lang="en-US">Income taxes paid, classified as operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalEntity1Axis" xlink:label="loc_gsk_LegalEntity1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LegalEntity1Axis" xml:lang="en-US">legal Entity 1 [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_LegalEntity1Axis" xml:lang="en-US">legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LegalEntity1Axis" xlink:to="lab_gsk_LegalEntity1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LegalEntity1Axis" xml:lang="en-US">legal Entity 1</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Entity1Member" xlink:label="loc_gsk_Entity1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Entity1Member" xml:lang="en-US">Entity 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_Entity1Member" xml:lang="en-US">Entity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Entity1Member" xlink:to="lab_gsk_Entity1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Entity1Member" xml:lang="en-US">Entity 1</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GbMember" xlink:label="loc_gsk_GbMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GbMember" xml:lang="en-US">GB [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GbMember" xml:lang="en-US">Uk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GbMember" xlink:to="lab_gsk_GbMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GbMember" xml:lang="en-US">GB.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OverseasMember" xlink:label="loc_gsk_OverseasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OverseasMember" xml:lang="en-US">Overseas [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OverseasMember" xml:lang="en-US">Overseas [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OverseasMember" xlink:to="lab_gsk_OverseasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OverseasMember" xml:lang="en-US">Overseas.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EventAxis" xlink:to="lab_gsk_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EventAxis" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EventDomain" xlink:to="lab_gsk_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EventDomain" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInTheHeadlineRateOfTaxMember" xlink:label="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInTheHeadlineRateOfTaxMember" xml:lang="en-US">Increase In The Headline Rate Of Tax [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember" xlink:to="lab_gsk_IncreaseInTheHeadlineRateOfTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInTheHeadlineRateOfTaxMember" xml:lang="en-US">Increase in the headline rate of tax.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReducedTaxRateCancelledMember" xlink:label="loc_gsk_ReducedTaxRateCancelledMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReducedTaxRateCancelledMember" xml:lang="en-US">Reduced Tax Rate Cancelled [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReducedTaxRateCancelledMember" xlink:to="lab_gsk_ReducedTaxRateCancelledMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReducedTaxRateCancelledMember" xml:lang="en-US">Reduced tax rate cancelled.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xlink:label="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xml:lang="en-US">Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xml:lang="en-US">Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xlink:to="lab_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xml:lang="en-US">Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xml:lang="en-US">Average effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xml:lang="en-US">Tax charge/tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xlink:label="loc_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Tax Effect Of Benefit Of Intellectual Property Incentives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Benefit of intellectual property incentives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xlink:to="lab_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Tax effect of benefit of intellectual property incentives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xml:lang="en-US">Other permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xml:lang="en-US">Tax effect of foreign tax rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xml:lang="en-US">Differences in overseas taxation rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfResearchAndDevelopmentCredits" xlink:label="loc_gsk_TaxEffectOfResearchAndDevelopmentCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">Tax Effect of Research and Development Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">R&amp;D credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxEffectOfResearchAndDevelopmentCredits" xlink:to="lab_gsk_TaxEffectOfResearchAndDevelopmentCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">Tax effect of research and development credits.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfChangeInTaxRate" xlink:label="loc_gsk_TaxRateEffectOfChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfChangeInTaxRate" xml:lang="en-US">Tax Rate Effect Of Change In Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TaxRateEffectOfChangeInTaxRate" xml:lang="en-US">Changes in Tax Rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfChangeInTaxRate" xlink:to="lab_gsk_TaxRateEffectOfChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfChangeInTaxRate" xml:lang="en-US">Tax rate effect of change in tax rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xml:lang="en-US">Other permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xlink:label="loc_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">Tax Rate Effect of Research and Development Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">R&amp;D credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xlink:to="lab_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xml:lang="en-US">Tax rate effect of research and development credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Tax expense (income) at applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">UK statutory rate of taxation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Tax rate %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xlink:label="loc_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Tax Rate Effect of Reassessments of Prior Year Estimates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Re-assessments of prior year current tax estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xlink:to="lab_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Tax rate effect of reassessments of prior year estimates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xlink:label="loc_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Tax Rate Effect of Benefit of Intellectual Property Incentives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Benefit of intellectual property incentives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xlink:to="lab_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xml:lang="en-US">Tax rate effect of benefit of intellectual property incentives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xml:lang="en-US">Tax rate effect of foreign tax rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xml:lang="en-US">Differences in overseas taxation rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfChangeInTaxRate" xlink:label="loc_gsk_TaxEffectOfChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxEffectOfChangeInTaxRate" xml:lang="en-US">Tax Effect Of Change In Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxEffectOfChangeInTaxRate" xml:lang="en-US">Changes in Tax Rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxEffectOfChangeInTaxRate" xlink:to="lab_gsk_TaxEffectOfChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxEffectOfChangeInTaxRate" xml:lang="en-US">Tax effect of change in tax rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xlink:label="loc_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Tax Effect Of Reassessments Of Prior Year Estimates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Re-assessments of prior year current tax estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xlink:to="lab_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xml:lang="en-US">Tax effect of reassessments of prior year estimates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xlink:label="loc_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Tax Rate Effect Of Permanent Differences On Disposals Acquisitions and Transfers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Permanent differences on disposals, acquisitions and transfers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xlink:to="lab_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Tax Rate Effect Of Permanent Differences On Disposals Acquisitions and Transfers.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xlink:label="loc_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Tax Rate Effect Of Permanent Differences Percentage On Disposals Acquisitions and Transfers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Permanent differences on disposals, acquisitions and transfers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xlink:to="lab_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xml:lang="en-US">Tax Rate Effect Of Permanent Differences Percentage On Disposals Acquisitions and Transfers.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:label="loc_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Tax Rate Effect Of ReassessmentsOf Prior Year Deferred Tax Estimates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Re-assessments of prior year deferred tax estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:to="lab_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Tax rate effect of reassessments&#160;of prior year deferred tax estimates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:label="loc_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Tax Effect Of ReassessmentsOf Prior Year Deferred Tax Estimates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Re-assessments of prior year deferred tax estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:to="lab_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xml:lang="en-US">Tax effect of reassessments&#160;of prior year deferred tax estimates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" xlink:label="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" xml:lang="en-US">Tax On Items Charged To Equity And Statement Of Comprehensive Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" xml:lang="en-US">Tax On Items Charged To Equity And Statement Of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xlink:label="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xml:lang="en-US">Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xml:lang="en-US">Deferred taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xlink:to="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xml:lang="en-US">Deferred tax relating to items charged or credited directly to equity and comprehensive income [abstract].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Total equity and comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Deferred Tax On Share Based Payments Charged Or Credited Directly To Equity And Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:to="lab_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Deferred tax on share based payments charged or credited directly to equity and comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred Tax Relating To Defined Benefit Plans Charged Or Credited Directly To Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xlink:to="lab_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred tax relating to defined benefit plans charged or credited directly to comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred Tax Relating to Fair Value Movements on Cash Flow Hedges Charged or Credited Directly to Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Fair value movements on cash flow hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:to="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred tax relating to fair value movements on cash flow hedges charged or credited directly to comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred Tax Relating to Fair Value Movements on Equity Investments Charged or Credited Directly to Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Fair value movements on equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:to="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Deferred tax relating to fair value movements on equity investments charged or credited directly to comprehensive income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Current and deferred tax relating to items credited (charged) directly to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Total credit to equity and statement of comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lab_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxationAbstract" xlink:label="loc_gsk_CurrentTaxationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxationAbstract" xml:lang="en-US">Current Taxation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentTaxationAbstract" xml:lang="en-US">Current taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxationAbstract" xlink:to="lab_gsk_CurrentTaxationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Current tax relating to items credited (charged) directly to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xml:lang="en-US">Total equity and comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lab_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Current Tax On Defined Benefit Plans Charged Or Credited Directly To Equity And Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:to="lab_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Current tax on defined benefit plans charged or credited directly to equity and comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Current Tax On Share Based Payments Charged Or Credited Directly To Equity And Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:to="lab_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Current tax on share based payments charged or credited directly to equity and comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Current Tax On Fair Value Movements On Equity Investments Charged Or Credited Directly To Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:to="lab_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Current tax on fair value movements on equity investments charged or credited directly to comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Current Tax On Fair Value Movements On Cash Flow Hedges Charged Or Credited Directly To Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:to="lab_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xml:lang="en-US">Current tax on fair value movements on cash flow hedges charged or credited directly to comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xml:lang="en-US">Movement In Deferred Tax Assets And Liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xml:lang="en-US">Movement In Deferred Tax Assets And Liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xlink:to="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xml:lang="en-US">Movement in deferred tax assets and liabilities table.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PensionsAndOtherPostemploymentBenefitsMember" xml:lang="en-US">Pensions and other post-employment benefits [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PensionsAndOtherPostemploymentBenefitsMember" xml:lang="en-US">Pensions and other post-employment benefits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:to="lab_gsk_PensionsAndOtherPostemploymentBenefitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PensionsAndOtherPostemploymentBenefitsMember" xml:lang="en-US">Pensions and other post-employment benefits.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionAndAwardSchemesMember" xlink:label="loc_gsk_ShareOptionAndAwardSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareOptionAndAwardSchemesMember" xml:lang="en-US">Share Option and Award Schemes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareOptionAndAwardSchemesMember" xml:lang="en-US">Share option and award schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareOptionAndAwardSchemesMember" xlink:to="lab_gsk_ShareOptionAndAwardSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareOptionAndAwardSchemesMember" xml:lang="en-US">Share option and award schemes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xml:lang="en-US">Unused tax losses [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xml:lang="en-US">Tax losses [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcceleratedCapitalAllowancesMember" xlink:label="loc_gsk_AcceleratedCapitalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AcceleratedCapitalAllowancesMember" xml:lang="en-US">Accelerated Capital Allowances [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AcceleratedCapitalAllowancesMember" xml:lang="en-US">Accelerated capital allowances [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AcceleratedCapitalAllowancesMember" xlink:to="lab_gsk_AcceleratedCapitalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AcceleratedCapitalAllowancesMember" xml:lang="en-US">Accelerated capital allowances.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xml:lang="en-US">Other temporary differences [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xml:lang="en-US">Other temporary differences [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:to="lab_ifrs-full_OtherTemporaryDifferencesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointOperationsAxis" xlink:label="loc_ifrs-full_JointOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_JointOperationsAxis" xml:lang="en-US">Joint operations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_JointOperationsAxis" xml:lang="en-US">Joint operations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointOperationsAxis" xlink:to="lab_ifrs-full_JointOperationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointOperationsMember" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForJointOperationsMember" xml:lang="en-US">Entity's total for joint operations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForJointOperationsMember" xml:lang="en-US">Entity's total for joint operations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember" xlink:to="lab_ifrs-full_EntitysTotalForJointOperationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntraGroupProfitMember" xlink:label="loc_gsk_IntraGroupProfitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IntraGroupProfitMember" xml:lang="en-US">Intra Group Profit [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IntraGroupProfitMember" xml:lang="en-US">Intra group profit [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IntraGroupProfitMember" xlink:to="lab_gsk_IntraGroupProfitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IntraGroupProfitMember" xml:lang="en-US">Intra group profit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xml:lang="en-US">Movement In Deferred Tax Assets And Liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xml:lang="en-US">Movement In Deferred Tax Assets And Liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xml:lang="en-US">Movement in deferred tax assets and liabilities line items</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:label="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xml:lang="en-US">Changes in deferred tax liability (asset) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xml:lang="en-US">Changes in deferred tax liability (asset) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xml:lang="en-US">Increase (decrease) through net exchange differences, deferred tax liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xml:lang="en-US">Deferred tax liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xml:lang="en-US">At 1 January 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xml:lang="en-US">At 31 December 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Credit/(charge) to statement of comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:to="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xml:lang="en-US">Deferred tax relating to items charged or credited directly to equity and comprehensive income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xml:lang="en-US">Credit/(charge) to income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xml:lang="en-US">Acquisitions/Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xlink:label="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xml:lang="en-US">Increase Decrease Through Research And Development Credits Utilisation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xml:lang="en-US">R&amp;D credits utilisation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xlink:to="lab_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xml:lang="en-US">Increase decrease through research and development credits utilisation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xlink:label="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xml:lang="en-US">Increase Decrease Through Transfer Of Assets Held For Sale Or Distribution Deferred Tax Liability Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xml:lang="en-US">Transfer of assets held for sale/ distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xlink:to="lab_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xml:lang="en-US">Increase decrease through transfer of assets held for sale or distribution deferred tax liability asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationMember" xlink:label="loc_ifrs-full_ContingentConsiderationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xml:lang="en-US">Contingent consideration [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xml:lang="en-US">Contingent Consideration [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationMember" xlink:to="lab_ifrs-full_ContingentConsiderationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xml:lang="en-US">Classes of assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xml:lang="en-US">Classes of assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xml:lang="en-US">Assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xml:lang="en-US">Assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationAxis" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationAxis" xml:lang="en-US">Tax reforms period of application [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationAxis" xml:lang="en-US">Tax reforms period of application [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationAxis" xlink:to="lab_gsk_TaxReformsPeriodOfApplicationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationAxis" xml:lang="en-US">Axis that defines period of applications for tax reforms.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationDomain" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationDomain" xml:lang="en-US">Tax reforms period of application [domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationDomain" xml:lang="en-US">Tax reforms period of application [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationDomain" xlink:to="lab_gsk_TaxReformsPeriodOfApplicationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxReformsPeriodOfApplicationDomain" xml:lang="en-US">Domain member that defines period of applications for tax reforms.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OriginationAndReversalOfTemporaryDifferencesMember" xlink:label="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OriginationAndReversalOfTemporaryDifferencesMember" xml:lang="en-US">Origination and reversal of temporary differences [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OriginationAndReversalOfTemporaryDifferencesMember" xml:lang="en-US">Origination and reversal of temporary differences [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember" xlink:to="lab_gsk_OriginationAndReversalOfTemporaryDifferencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OriginationAndReversalOfTemporaryDifferencesMember" xml:lang="en-US">Origination and reversal of temporary differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xlink:label="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xml:lang="en-US">Later Than One Year And Not Later Than Ten Year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xml:lang="en-US">Within 10 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xlink:to="lab_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xml:lang="en-US">Later than one year and not later than ten year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanTenYearsMember" xml:lang="en-US">Later than ten years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanTenYearsMember" xml:lang="en-US">Greater Than Ten Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTenYearsMember" xlink:to="lab_ifrs-full_LaterThanTenYearsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AvailableIndefinitelyMember" xlink:label="loc_gsk_AvailableIndefinitelyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AvailableIndefinitelyMember" xml:lang="en-US">Available Indefinitely [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AvailableIndefinitelyMember" xml:lang="en-US">Available indefinitely [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AvailableIndefinitelyMember" xlink:to="lab_gsk_AvailableIndefinitelyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AvailableIndefinitelyMember" xml:lang="en-US">Available indefinitely.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxLosses" xlink:label="loc_gsk_TaxLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxLosses" xml:lang="en-US">Tax losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxLosses" xml:lang="en-US">Tax losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxLosses" xlink:to="lab_gsk_TaxLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxLosses" xml:lang="en-US">Tax losses.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xml:lang="en-US">Unrecognised deferred tax asset on capital losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xml:lang="en-US">Capital losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xlink:to="lab_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xml:lang="en-US">Unrecognised deferred tax asset on capital losses</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xml:lang="en-US">Unrecognised deferred tax asset on trading losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xml:lang="en-US">Unrecognised deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xlink:to="lab_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xml:lang="en-US">Unrecognised deferred tax asset on trading losses</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalLosses" xlink:label="loc_gsk_CapitalLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CapitalLosses" xml:lang="en-US">Capital Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CapitalLosses" xml:lang="en-US">Tax losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CapitalLosses" xlink:to="lab_gsk_CapitalLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CapitalLosses" xml:lang="en-US">Capital Losses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareTable" xml:lang="en-US">Earnings per share [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xml:lang="en-US">Earnings per share [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xml:lang="en-US">Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xml:lang="en-US">Weighted average number of shares in issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Dilution for share options and awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsAbstract" xlink:label="loc_gsk_DisclosureOfDividendsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDividendsAbstract" xml:lang="en-US">Disclosure of Dividends [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDividendsAbstract" xml:lang="en-US">Disclosure of Dividends [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDividendsAbstract" xlink:to="lab_gsk_DisclosureOfDividendsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDividendsAbstract" xml:lang="en-US">Disclosure of dividends.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDividendsTable" xml:lang="en-US">Disclosure of Dividends [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDividendsTable" xml:lang="en-US">Disclosure of Dividends [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDividendsTable" xlink:to="lab_gsk_DisclosureOfDividendsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDividendsTable" xml:lang="en-US">Disclosure of Dividends [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDividendsLineItems" xml:lang="en-US">Disclosure of Dividends [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDividendsLineItems" xml:lang="en-US">Disclosure of dividends [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDividendsLineItems" xlink:to="lab_gsk_DisclosureOfDividendsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDividendsLineItems" xml:lang="en-US">Disclosure of dividends.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsPaidDate" xlink:label="loc_gsk_DividendsPaidDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendsPaidDate" xml:lang="en-US">Dividends Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendsPaidDate" xml:lang="en-US">Paid/payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendsPaidDate" xlink:to="lab_gsk_DividendsPaidDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendsPaidDate" xml:lang="en-US">Dividends paid date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xml:lang="en-US">Dividends paid, ordinary shares per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xml:lang="en-US">Dividend per share (pence)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinaryShares" xlink:label="loc_ifrs-full_DividendsPaidOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaidOrdinaryShares" xml:lang="en-US">Dividends paid, ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DividendsPaidOrdinaryShares" xml:lang="en-US">Total dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinaryShares" xlink:to="lab_ifrs-full_DividendsPaidOrdinaryShares" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SecondInterimMember" xlink:label="loc_gsk_SecondInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SecondInterimMember" xml:lang="en-US">Second Interim [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SecondInterimMember" xml:lang="en-US">Second interim [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SecondInterimMember" xlink:to="lab_gsk_SecondInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SecondInterimMember" xml:lang="en-US">Second interim.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThirdInterimMember" xlink:label="loc_gsk_ThirdInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThirdInterimMember" xml:lang="en-US">Third Interim [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThirdInterimMember" xml:lang="en-US">Third interim [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThirdInterimMember" xlink:to="lab_gsk_ThirdInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThirdInterimMember" xml:lang="en-US">Third interim.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FirstInterimMember" xlink:label="loc_gsk_FirstInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FirstInterimMember" xml:lang="en-US">First Interim [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FirstInterimMember" xml:lang="en-US">First interim [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FirstInterimMember" xlink:to="lab_gsk_FirstInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FirstInterimMember" xml:lang="en-US">First interim.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourthInterimMember" xlink:label="loc_gsk_FourthInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FourthInterimMember" xml:lang="en-US">Fourth Interim [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FourthInterimMember" xml:lang="en-US">Fourth interim [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FourthInterimMember" xlink:to="lab_gsk_FourthInterimMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FourthInterimMember" xml:lang="en-US">Fourth interim.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionForDividendPayable" xlink:label="loc_gsk_AdditionalProvisionForDividendPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalProvisionForDividendPayable" xml:lang="en-US">Additional Provision For Dividend Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionalProvisionForDividendPayable" xml:lang="en-US">Additional provision for dividend payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalProvisionForDividendPayable" xlink:to="lab_gsk_AdditionalProvisionForDividendPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalProvisionForDividendPayable" xml:lang="en-US">Additional provision for dividend payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDividendPayables" xlink:label="loc_ifrs-full_CurrentDividendPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentDividendPayables" xml:lang="en-US">Current dividend payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentDividendPayables" xml:lang="en-US">Provision for dividend payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDividendPayables" xlink:to="lab_ifrs-full_CurrentDividendPayables" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfAssetdistributedAsDividendInSpecie" xlink:label="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfAssetdistributedAsDividendInSpecie" xml:lang="en-US">Fair Value Of Asset Distributed As Dividend In Specie</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfAssetdistributedAsDividendInSpecie" xml:lang="en-US">Fair Value of Asset Distributed as Dividend in Specie</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie" xlink:to="lab_gsk_FairValueOfAssetdistributedAsDividendInSpecie" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfAssetdistributedAsDividendInSpecie" xml:lang="en-US">Fair&#8203; value&#8203; of asset &#8203;distributed as dividend in specie.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfInterimDividendRecognitonAndPayment" xlink:label="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfInterimDividendRecognitonAndPayment" xml:lang="en-US">Description Of Interim Dividend Recogniton And Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfInterimDividendRecognitonAndPayment" xml:lang="en-US">Description of compliance with IFRSs applied For interim financial report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment" xlink:to="lab_gsk_DescriptionOfInterimDividendRecognitonAndPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfInterimDividendRecognitonAndPayment" xml:lang="en-US">Description of interim dividend recogniton and payment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationAxis" xml:lang="en-US">Continuing And Discontinued Operation [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationAxis" xml:lang="en-US">Continuing and discontinued operations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationAxis" xml:lang="en-US">Continuing And Discontinued Operation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis" xlink:to="lab_gsk_ContinuingAndDiscontinuedOperationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationAxis" xml:lang="en-US">Continuing and discontinued operation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationMember" xml:lang="en-US">Continuing And Discontinued Operation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationMember" xml:lang="en-US">Continuing operations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember" xlink:to="lab_gsk_ContinuingAndDiscontinuedOperationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContinuingAndDiscontinuedOperationMember" xml:lang="en-US">Continuing and discontinued operation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerOfConsumerHealthcareBusinessMember" xlink:label="loc_gsk_DemergerOfConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DemergerOfConsumerHealthcareBusinessMember" xml:lang="en-US">Demerger of Consumer Healthcare Business [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DemergerOfConsumerHealthcareBusinessMember" xlink:to="lab_gsk_DemergerOfConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DemergerOfConsumerHealthcareBusinessMember" xml:lang="en-US">Demerger of consumer healthcare business.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashDividendsPaidToShareholdersRecognizedInYear" xlink:label="loc_gsk_CashDividendsPaidToShareholdersRecognizedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashDividendsPaidToShareholdersRecognizedInYear" xml:lang="en-US">Cash Dividends Paid to Shareholders Recognized in Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashDividendsPaidToShareholdersRecognizedInYear" xml:lang="en-US">Cash dividends to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashDividendsPaidToShareholdersRecognizedInYear" xlink:to="lab_gsk_CashDividendsPaidToShareholdersRecognizedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashDividendsPaidToShareholdersRecognizedInYear" xml:lang="en-US">Cash dividends paid to shareholders recognized in year.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsRecognisedInYear" xlink:label="loc_gsk_DividendsRecognisedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendsRecognisedInYear" xml:lang="en-US">Dividends recognised in year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendsRecognisedInYear" xml:lang="en-US">Dividends to shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendsRecognisedInYear" xlink:to="lab_gsk_DividendsRecognisedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendsRecognisedInYear" xml:lang="en-US">Dividends recognised in year</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xlink:label="loc_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xml:lang="en-US">Dividend Paid To Shareholders On Demergerd Entity Recognized In Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xml:lang="en-US">Dividends in specie to shareholders in Haleon plc shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xlink:to="lab_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xml:lang="en-US">Dividend paid to shareholders on demergerd entity recognized in year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xml:lang="en-US">Computer software [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xml:lang="en-US">Computer software [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_gsk_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling general and administrative expenses [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling general and administrative expenses [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_gsk_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling general and administrative expenses.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProgrammesMember" xlink:label="loc_gsk_MajorRestructuringProgrammesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MajorRestructuringProgrammesMember" xml:lang="en-US">Major Restructuring Programmes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MajorRestructuringProgrammesMember" xml:lang="en-US">Major restructuring programmes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MajorRestructuringProgrammesMember" xlink:to="lab_gsk_MajorRestructuringProgrammesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MajorRestructuringProgrammesMember" xml:lang="en-US">Major restructuring programmes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSalesMember" xlink:label="loc_ifrs-full_CostOfSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfSalesMember" xml:lang="en-US">Cost of sales [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CostOfSalesMember" xml:lang="en-US">Cost of sales [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSalesMember" xlink:to="lab_ifrs-full_CostOfSalesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xml:lang="en-US">Weighted Average Cost Of Capital Pre Tax Discount Rate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xml:lang="en-US">Weighted average cost of capital pre-tax discount rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xlink:to="lab_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xml:lang="en-US">Weighted average cost of capital pre- tax discount rate percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xml:lang="en-US">Weighted average interest rate for capitalised borrowing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xml:lang="en-US">Weighted average cost of capital after tax discount rate percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xml:lang="en-US">Weighted average cost of capital post tax discount rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xlink:to="lab_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xml:lang="en-US">Weighted average cost of capital after tax discount rate percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xml:lang="en-US">Assets in construction reclassified to intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xml:lang="en-US">Reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xml:lang="en-US">Depreciation, amortisation, and impairment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xml:lang="en-US">Accumulated impairment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xml:lang="en-US">Impairment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedImpairmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Gross carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Cost [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Depreciation and amortisation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyPlantAndEquipmentAndVehiclesMember" xlink:label="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PropertyPlantAndEquipmentAndVehiclesMember" xml:lang="en-US">Property Plant and Equipment and Vehicles [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PropertyPlantAndEquipmentAndVehiclesMember" xml:lang="en-US">Plant, equipment and vehicles [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember" xlink:to="lab_gsk_PropertyPlantAndEquipmentAndVehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PropertyPlantAndEquipmentAndVehiclesMember" xml:lang="en-US">Property plant and equipment and vehicles.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="loc_ifrs-full_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xml:lang="en-US">Construction in progress [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xml:lang="en-US">Assets in construction [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConstructionInProgressMember" xlink:to="lab_ifrs-full_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xml:lang="en-US">Land and buildings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xml:lang="en-US">Land and buildings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember" xlink:to="lab_ifrs-full_LandAndBuildingsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xml:lang="en-US">Increase (decrease) through other changes, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xml:lang="en-US">Capitalised borrowing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Other additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xml:lang="en-US">Decrease through classified as held for sale, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xml:lang="en-US">Disposals and retirements, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xml:lang="en-US">Disposals and write-offs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Reversal of impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions through business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetImpairments" xlink:label="loc_gsk_RightOfUseAssetImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RightOfUseAssetImpairments" xml:lang="en-US">Right Of Use Asset Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RightOfUseAssetImpairments" xml:lang="en-US">Impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RightOfUseAssetImpairments" xlink:to="lab_gsk_RightOfUseAssetImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RightOfUseAssetImpairments" xml:lang="en-US">Right of use asset disposal.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetsExchangeAdjustments" xlink:label="loc_gsk_RightOfUseAssetsExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RightOfUseAssetsExchangeAdjustments" xml:lang="en-US">Right of Use Assets Exchange Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RightOfUseAssetsExchangeAdjustments" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RightOfUseAssetsExchangeAdjustments" xlink:to="lab_gsk_RightOfUseAssetsExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RightOfUseAssetsExchangeAdjustments" xml:lang="en-US">Right of use assets exchange adjustments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">Additions to right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetDisposal" xlink:label="loc_gsk_RightOfUseAssetDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RightOfUseAssetDisposal" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RightOfUseAssetDisposal" xlink:to="lab_gsk_RightOfUseAssetDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RightOfUseAssetDisposal" xml:lang="en-US">Right of use asset disposal.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xlink:label="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xml:lang="en-US">Additions To Right of use Assets Through Business Combinations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xml:lang="en-US">Additions through business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xlink:to="lab_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xml:lang="en-US">Additions to right of use assets through business combinations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdditionsToRightOfUseAssets" xlink:label="loc_gsk_OtherAdditionsToRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAdditionsToRightOfUseAssets" xml:lang="en-US">Other Additions To Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAdditionsToRightOfUseAssets" xml:lang="en-US">Other additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAdditionsToRightOfUseAssets" xlink:to="lab_gsk_OtherAdditionsToRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAdditionsToRightOfUseAssets" xml:lang="en-US">Other additions to right of use assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xlink:label="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xml:lang="en-US">Right Of Use Asset Transfer to Assets Held for Sale or Distribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xlink:to="lab_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xml:lang="en-US">Right of use asset transfer to assets held for sale or distribution.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_VehiclesMember" xml:lang="en-US">Vehicles [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndEquipmentMember" xlink:label="loc_gsk_PlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PlantAndEquipmentMember" xml:lang="en-US">Plant And Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PlantAndEquipmentMember" xml:lang="en-US">Plant and equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PlantAndEquipmentMember" xlink:to="lab_gsk_PlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="loc_ifrs-full_RightofuseAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xml:lang="en-US">Right-of-use assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xml:lang="en-US">Right-of-use assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssetsMember" xlink:to="lab_ifrs-full_RightofuseAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xml:lang="en-US">Disclosure of Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xlink:label="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xml:lang="en-US">Description of basis on which unit's recoverable amount has been determined</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xml:lang="en-US">Description of basis on which unit's recoverable amount has been determined</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xlink:to="lab_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xml:lang="en-US">Discount rate applied to cash flow projections</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xml:lang="en-US">Discount rate applied to cash flow projections</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xml:lang="en-US">Decrease through classified as held for sale, goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xml:lang="en-US">Goodwiil&#160;Transfer to assets held for sale/distribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:to="lab_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xml:lang="en-US">Increase (decrease) through net exchange differences, goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xlink:label="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xml:lang="en-US">Increase In Goodwill Due To Pension Liabilities Payment To Non Controlling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xml:lang="en-US">Other movements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xlink:to="lab_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xml:lang="en-US">Increase &#8203;in goodwill&#8203; due &#8203;to pension &#8203;liabilities &#8203;payment to &#8203;non&#8203; controlling &#8203;interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="loc_ifrs-full_AdditionalRecognitionGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionalRecognitionGoodwill" xml:lang="en-US">Additional recognition, goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionalRecognitionGoodwill" xml:lang="en-US">Additions through business combinations (Note &#8226;)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalRecognitionGoodwill" xlink:to="lab_ifrs-full_AdditionalRecognitionGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:label="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xml:lang="en-US">Explanation of period over which management has projected cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xml:lang="en-US">Period of specific projected cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:to="lab_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xml:lang="en-US">Description of key assumptions on which management has based determination of fair value less costs of disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xml:lang="en-US">Determination of assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xlink:to="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xml:lang="en-US">Terminal growth rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xml:lang="en-US">Description of key assumptions on which management has based cash flow projections</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xml:lang="en-US">Key assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xml:lang="en-US">Description of valuation techniques used to measure fair value less costs of disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xml:lang="en-US">Valuation basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xlink:to="lab_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationAxis" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MethodsOfGenerationAxis" xml:lang="en-US">Methods of generation [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MethodsOfGenerationAxis" xml:lang="en-US">Methods of generation [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis" xlink:to="lab_ifrs-full_MethodsOfGenerationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationMember" xlink:label="loc_ifrs-full_MethodsOfGenerationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MethodsOfGenerationMember" xml:lang="en-US">Methods of generation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MethodsOfGenerationMember" xml:lang="en-US">Methods of generation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MethodsOfGenerationMember" xlink:to="lab_ifrs-full_MethodsOfGenerationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InternallyGeneratedMember" xlink:label="loc_ifrs-full_InternallyGeneratedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InternallyGeneratedMember" xml:lang="en-US">Internally generated [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InternallyGeneratedMember" xml:lang="en-US">Internally generated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InternallyGeneratedMember" xlink:to="lab_ifrs-full_InternallyGeneratedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftware" xlink:label="loc_ifrs-full_ComputerSoftware" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerSoftware" xml:lang="en-US">Computer software</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComputerSoftware" xml:lang="en-US">Net book value of computer software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftware" xlink:to="lab_ifrs-full_ComputerSoftware" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xml:lang="en-US">Intangible Assets, For Which Impairments Have Been Charged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xml:lang="en-US">Intangible assets, for which impairments have been charged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xlink:to="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xml:lang="en-US">Intangible assets, for which impairments have been charged.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xml:lang="en-US">Intangible Assets For Which Impairments Have Been Reversed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xml:lang="en-US">Intangible assets, for which impairments have been charged or reversed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xlink:to="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xml:lang="en-US">Intangible assets, for which impairments have been charged or reversed</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaAxis" xlink:label="loc_gsk_BenlystaAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BenlystaAxis" xml:lang="en-US">Benlysta [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BenlystaAxis" xlink:to="lab_gsk_BenlystaAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BenlystaDomain" xml:lang="en-US">Benlysta [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BenlystaDomain" xlink:to="lab_gsk_BenlystaDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xml:lang="en-US">Intangible assets with indefinite useful life [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xml:lang="en-US">Intangible assets with indefinite useful life [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xml:lang="en-US">Intangible assets with indefinite useful life [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xml:lang="en-US">Intangible Assets with Indefinite Useful Life [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Other additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Impairment of intangible assets held for sale, net of reversals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Reversal of impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Disposals, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Disposals and asset write-offs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xml:lang="en-US">Disposals and asset write-offs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalisedDevelopmentCosts" xlink:label="loc_gsk_CapitalisedDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CapitalisedDevelopmentCosts" xml:lang="en-US">Capitalised development costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CapitalisedDevelopmentCosts" xml:lang="en-US">Capitalised development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CapitalisedDevelopmentCosts" xlink:to="lab_gsk_CapitalisedDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CapitalisedDevelopmentCosts" xml:lang="en-US">Capitalised development costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xml:lang="en-US">Reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions through business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisationOtherIntangibleAssets" xlink:label="loc_gsk_AmortisationOtherIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AmortisationOtherIntangibleAssets" xml:lang="en-US">Amortisation Other Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_AmortisationOtherIntangibleAssets" xml:lang="en-US">Charge for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AmortisationOtherIntangibleAssets" xml:lang="en-US">Amortisation of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AmortisationOtherIntangibleAssets" xlink:to="lab_gsk_AmortisationOtherIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AmortisationOtherIntangibleAssets" xml:lang="en-US">Amortisation other intangible assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:label="loc_gsk_NetImpairmentLossesOtherIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetImpairmentLossesOtherIntangibleAssets" xml:lang="en-US">Net Impairment Losses Other Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_NetImpairmentLossesOtherIntangibleAssets" xml:lang="en-US">Impairment losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetImpairmentLossesOtherIntangibleAssets" xml:lang="en-US">Impairment of intangible assets, net of reversals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:to="lab_gsk_NetImpairmentLossesOtherIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetImpairmentLossesOtherIntangibleAssets" xml:lang="en-US">Net impairment losses other intangible assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xlink:label="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xml:lang="en-US">Decrease Through Classified As Held For Sale or Distribution Intangible Assets And Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xlink:to="lab_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xml:lang="en-US">Decrease through classified as held for sale or distribution intangible assets and goodwill.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LicencesAndFranchisesAmortisedBrandsMember" xlink:label="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LicencesAndFranchisesAmortisedBrandsMember" xml:lang="en-US">Licences And Franchises Amortised Brands [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LicencesAndFranchisesAmortisedBrandsMember" xml:lang="en-US">Licences And Franchises Amortised Brands [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember" xlink:to="lab_gsk_LicencesAndFranchisesAmortisedBrandsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BrandsWithIndefiniteUsefulLifeMember" xlink:label="loc_gsk_BrandsWithIndefiniteUsefulLifeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BrandsWithIndefiniteUsefulLifeMember" xml:lang="en-US">Brands with Indefinite Useful Life [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BrandsWithIndefiniteUsefulLifeMember" xml:lang="en-US">Brands with indefinite useful life [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BrandsWithIndefiniteUsefulLifeMember" xlink:to="lab_gsk_BrandsWithIndefiniteUsefulLifeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BrandsWithIndefiniteUsefulLifeMember" xml:lang="en-US">Brands with Indefinite Useful Life.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsMaterialToEntityAxis" xml:lang="en-US">Intangible assets material to entity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsMaterialToEntityAxis" xml:lang="en-US">Intangible assets material to entity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:to="lab_ifrs-full_IntangibleAssetsMaterialToEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityMember" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsMaterialToEntityMember" xml:lang="en-US">Intangible assets material to entity [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsMaterialToEntityMember" xml:lang="en-US">Intangible assets material to entity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember" xlink:to="lab_ifrs-full_IntangibleAssetsMaterialToEntityMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OthersProductsMember" xlink:label="loc_gsk_OthersProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OthersProductsMember" xml:lang="en-US">Others Products [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OthersProductsMember" xml:lang="en-US">Others products [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OthersProductsMember" xlink:to="lab_gsk_OthersProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OthersProductsMember" xml:lang="en-US">Others products.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OkairosMember" xlink:label="loc_gsk_OkairosMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OkairosMember" xml:lang="en-US">Okairos [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OkairosMember" xml:lang="en-US">Okairos [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OkairosMember" xlink:to="lab_gsk_OkairosMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OkairosMember" xml:lang="en-US">Okairos.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroAssetsMember" xlink:label="loc_gsk_TesaroAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TesaroAssetsMember" xml:lang="en-US">Tesaro Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TesaroAssetsMember" xml:lang="en-US">Tesaro assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TesaroAssetsMember" xlink:to="lab_gsk_TesaroAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TesaroAssetsMember" xml:lang="en-US">Tesaro assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LamisilMember" xlink:label="loc_gsk_LamisilMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LamisilMember" xml:lang="en-US">Lamisil [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LamisilMember" xml:lang="en-US">Lamisil [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LamisilMember" xlink:to="lab_gsk_LamisilMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LamisilMember" xml:lang="en-US">Lamisil [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DolutegravirMember" xlink:label="loc_gsk_DolutegravirMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DolutegravirMember" xml:lang="en-US">Dolutegravir [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DolutegravirMember" xml:lang="en-US">Dolutegravir [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DolutegravirMember" xlink:to="lab_gsk_DolutegravirMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DolutegravirMember" xml:lang="en-US">Dolutegravir [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BMSAssetsMember" xlink:label="loc_gsk_BMSAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BMSAssetsMember" xml:lang="en-US">B M S Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BMSAssetsMember" xml:lang="en-US">BMS Assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BMSAssetsMember" xlink:to="lab_gsk_BMSAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BMSAssetsMember" xml:lang="en-US">BMS Assets [Member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelTradeNameMember" xlink:label="loc_gsk_StiefelTradeNameMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_StiefelTradeNameMember" xml:lang="en-US">Stiefel Trade Name [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_StiefelTradeNameMember" xml:lang="en-US">Stiefel trade name [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_StiefelTradeNameMember" xlink:to="lab_gsk_StiefelTradeNameMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaMember" xlink:label="loc_gsk_BenlystaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BenlystaMember" xml:lang="en-US">Benlysta [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BenlystaMember" xml:lang="en-US">Benlysta [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BenlystaMember" xlink:to="lab_gsk_BenlystaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BenlystaMember" xml:lang="en-US">Benlysta [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisPortfolioMember" xlink:label="loc_gsk_MeningitisPortfolioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MeningitisPortfolioMember" xml:lang="en-US">Meningitis Portfolio [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MeningitisPortfolioMember" xml:lang="en-US">Meningitis Portfolio [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MeningitisPortfolioMember" xlink:to="lab_gsk_MeningitisPortfolioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MeningitisPortfolioMember" xml:lang="en-US">Meningitis portfolio.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FluarixFlulavalMember" xlink:label="loc_gsk_FluarixFlulavalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FluarixFlulavalMember" xml:lang="en-US">Fluarix FluLaval [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FluarixFlulavalMember" xml:lang="en-US">Fluarix FluLaval [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FluarixFlulavalMember" xlink:to="lab_gsk_FluarixFlulavalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FluarixFlulavalMember" xml:lang="en-US">Fluarix FluLaval [Member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurevacAssetsMember" xlink:label="loc_gsk_CurevacAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurevacAssetsMember" xml:lang="en-US">Curevac Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurevacAssetsMember" xlink:to="lab_gsk_CurevacAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirAssetsMember" xlink:label="loc_gsk_VirAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VirAssetsMember" xml:lang="en-US">Vir Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VirAssetsMember" xlink:to="lab_gsk_VirAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxAssetsMember" xlink:label="loc_gsk_AffinivaxAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AffinivaxAssetsMember" xml:lang="en-US">Affinivax Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AffinivaxAssetsMember" xlink:to="lab_gsk_AffinivaxAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AffinivaxAssetsMember" xml:lang="en-US">Affinivax assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MomelotinibMember" xlink:label="loc_gsk_MomelotinibMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MomelotinibMember" xml:lang="en-US">Momelotinib [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MomelotinibMember" xlink:to="lab_gsk_MomelotinibMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MomelotinibMember" xml:lang="en-US">Momelotinib.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShingrixMember" xlink:label="loc_gsk_ShingrixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShingrixMember" xml:lang="en-US">Shingrix [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShingrixMember" xlink:to="lab_gsk_ShingrixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShingrixMember" xml:lang="en-US">Shingrix.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SperoMember" xlink:label="loc_gsk_SperoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SperoMember" xml:lang="en-US">Spero [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SperoMember" xlink:to="lab_gsk_SperoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SperoMember" xml:lang="en-US">Spero.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IteosMember" xlink:label="loc_gsk_IteosMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IteosMember" xml:lang="en-US">iTeos [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IteosMember" xlink:to="lab_gsk_IteosMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IteosMember" xml:lang="en-US">iTeos [Member].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AlectorMember" xlink:label="loc_gsk_AlectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AlectorMember" xml:lang="en-US">Alector [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AlectorMember" xlink:to="lab_gsk_AlectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AlectorMember" xml:lang="en-US">Alector [Member].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xml:lang="en-US">Investments In Associates And Joint Ventures [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xlink:to="lab_gsk_InvestmentsInAssociatesAndJointVenturesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xml:lang="en-US">Investments in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure of Investments in Associates and Joint Ventures [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure of Investments in Associates and Joint Ventures [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:to="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xml:lang="en-US">Disclosure of Investments in Associates and Joint Ventures [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of Investments in Associates and Joint Ventures [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of Investments in Associates and Joint Ventures [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:to="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xml:lang="en-US">Disclosure of investments in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociate" xlink:label="loc_gsk_DisposalOfInterestInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalOfInterestInAssociate" xml:lang="en-US">Disposal Of Interest In Associate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalOfInterestInAssociate" xml:lang="en-US">Disposal of interest in associate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalOfInterestInAssociate" xlink:to="lab_gsk_DisposalOfInterestInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalOfInterestInAssociate" xml:lang="en-US">Disposal of interest in associate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:label="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xml:lang="en-US">Other income (expense) from subsidiaries, jointly controlled entities and associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xml:lang="en-US">Gain on disposal of interest in associates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:to="lab_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xml:lang="en-US">Number of shares in entity held by entity or by its subsidiaries or associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xml:lang="en-US">Number of shares owned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RecyclingOfExchangeDifferencesInAssociate" xlink:label="loc_gsk_RecyclingOfExchangeDifferencesInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RecyclingOfExchangeDifferencesInAssociate" xml:lang="en-US">Recycling Of Exchange Differences In Associate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RecyclingOfExchangeDifferencesInAssociate" xml:lang="en-US">Recycling of exchange differences in associate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RecyclingOfExchangeDifferencesInAssociate" xlink:to="lab_gsk_RecyclingOfExchangeDifferencesInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RecyclingOfExchangeDifferencesInAssociate" xml:lang="en-US">Recycling of exchange differences in associate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xml:lang="en-US">Aggregated individually immaterial associates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:to="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInAssociatesAndJointVentures" xlink:label="loc_gsk_DisposalsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsInAssociatesAndJointVentures" xml:lang="en-US">Disposals in Associates and Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsInAssociatesAndJointVentures" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsInAssociatesAndJointVentures" xlink:to="lab_gsk_DisposalsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsInAssociatesAndJointVentures" xml:lang="en-US">Disposals in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xml:lang="en-US">Beginning of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xml:lang="en-US">Ending of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Fair Value Adjustment Investments In Associates And Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Net fair value movements through Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xlink:to="lab_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Fair value Adjustment investments in associates and joint ventures</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Additions in Investments in associates and joint ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xlink:to="lab_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Additions in investments in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Distributions Received in Investments in Associates and Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Distributions received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xlink:to="lab_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xml:lang="en-US">Distributions received in investments in associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xlink:label="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xml:lang="en-US">Impairment Of Investments In Associates Joint Ventures And Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xml:lang="en-US">Impairment of interest in associates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xlink:to="lab_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xml:lang="en-US">Impairment of investments in associates joint ventures and subsidiaries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xml:lang="en-US">Disclosure Of Detailed Information About Current Equity Investments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xml:lang="en-US">Disclosure of detailed information about current equity investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xml:lang="en-US">Disclosure Of Detailed Information About Current Equity Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xml:lang="en-US">Disclosure of detailed information about current equity investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentEquityInvestmentsMember" xml:lang="en-US">Current Equity Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentEquityInvestmentsMember" xml:lang="en-US">Current [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentEquityInvestmentsMember" xlink:to="lab_gsk_CurrentEquityInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentEquityInvestmentsMember" xml:lang="en-US">Current equity investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xml:lang="en-US">Categories of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xml:lang="en-US">Categories of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xml:lang="en-US">Financial assets, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xml:lang="en-US">Financial assets, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xml:lang="en-US">Current Equity Investments Measured As FVTPL [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xml:lang="en-US">Investments measured at FVTPL 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:to="lab_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xml:lang="en-US">Current equity investments measured as FVTPL.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xml:lang="en-US">Disclosure Of Detailed Information About Current Equity Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:to="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xml:lang="en-US">Disclosure of detailed information about current equity investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchasesFairValueMeasurementAssets" xml:lang="en-US">Purchases, fair value measurement, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PurchasesFairValueMeasurementAssets" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesFairValueMeasurementAssets" xlink:to="lab_ifrs-full_PurchasesFairValueMeasurementAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xml:lang="en-US">Net Fair Value Movements Through Profit Or Loss Current Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xml:lang="en-US">Net fair value movements through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:to="lab_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xml:lang="en-US">Net fair value movements through profit or loss current investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnership" xlink:label="loc_gsk_PercentageOfOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfOwnership" xml:lang="en-US">Percentage of ownership</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfOwnership" xml:lang="en-US">Percentage of ownership</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfOwnership" xlink:to="lab_gsk_PercentageOfOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfOwnership" xml:lang="en-US">Percentage of ownership.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xlink:label="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xml:lang="en-US">Other Adjustments of Fair Value Measurement Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xml:lang="en-US">Other Adjustments of Fair Value Measurement Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xlink:to="lab_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xml:lang="en-US">Other adjustments of fair value measurement assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueGainThroughProfitOrLoss" xlink:label="loc_gsk_FairValueGainThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueGainThroughProfitOrLoss" xml:lang="en-US">Fair Value Gain Through Profit Or Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueGainThroughProfitOrLoss" xml:lang="en-US">Fair value gain through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueGainThroughProfitOrLoss" xlink:to="lab_gsk_FairValueGainThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueGainThroughProfitOrLoss" xml:lang="en-US">Fair value gain through profit or loss.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentInHaleonPlcMember" xlink:label="loc_gsk_InvestmentInHaleonPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentInHaleonPlcMember" xml:lang="en-US">Investment In Haleon Plc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentInHaleonPlcMember" xml:lang="en-US">Investment in Haleon plc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentInHaleonPlcMember" xlink:to="lab_gsk_InvestmentInHaleonPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentInHaleonPlcMember" xml:lang="en-US">Investment in haleon plc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoGroupLimitedMember" xlink:label="loc_gsk_GlaxoGroupLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoGroupLimitedMember" xml:lang="en-US">Glaxo Group Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoGroupLimitedMember" xml:lang="en-US">Glaxo Group Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoGroupLimitedMember" xlink:to="lab_gsk_GlaxoGroupLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoGroupLimitedMember" xml:lang="en-US">Glaxo Group Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScottishLimitedPartnershipsMember" xlink:label="loc_gsk_ScottishLimitedPartnershipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ScottishLimitedPartnershipsMember" xml:lang="en-US">Scottish Limited Partnerships [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ScottishLimitedPartnershipsMember" xlink:to="lab_gsk_ScottishLimitedPartnershipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ScottishLimitedPartnershipsMember" xml:lang="en-US">Scottish limited partnerships.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustsMember" xlink:label="loc_gsk_EsopTrustsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EsopTrustsMember" xml:lang="en-US">ESOP Trusts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EsopTrustsMember" xlink:to="lab_gsk_EsopTrustsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EsopTrustsMember" xml:lang="en-US">ESOP trusts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestments1Abstract" xlink:label="loc_gsk_OtherInvestments1Abstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherInvestments1Abstract" xml:lang="en-US">Other investments 1 [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherInvestments1Abstract" xlink:to="lab_gsk_OtherInvestments1Abstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherInvestments1Abstract" xml:lang="en-US">Other investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsTable" xlink:label="loc_gsk_OtherInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherInvestmentsTable" xml:lang="en-US">Other investments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherInvestmentsTable" xml:lang="en-US">Other investments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherInvestmentsTable" xlink:to="lab_gsk_OtherInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherInvestmentsTable" xml:lang="en-US">Other investments [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Equity investments measured at fair value through other comprehensive income [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Equity investments measured at fair value through other comprehensive income (FVTOCI) [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Equity investments measured at fair value through other comprehensive income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Equity investments measured at fair value through profit or loss [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Equity investments measured at fair value through profit or loss (FVTPL) [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:to="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Equity investments measured at fair value through profit or loss.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsLineItems" xlink:label="loc_gsk_OtherInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherInvestmentsLineItems" xml:lang="en-US">Other investments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherInvestmentsLineItems" xml:lang="en-US">Other investments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherInvestmentsLineItems" xlink:to="lab_gsk_OtherInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherInvestmentsLineItems" xml:lang="en-US">Other investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xml:lang="en-US">Cumulative gain (loss) on disposal of investments in equity instruments designated at fair value through other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xml:lang="en-US">Cumulative gain loss on disposal of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ListedInvestments" xlink:label="loc_gsk_ListedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ListedInvestments" xml:lang="en-US">Listed investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ListedInvestments" xml:lang="en-US">Listed investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ListedInvestments" xlink:to="lab_gsk_ListedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ListedInvestments" xml:lang="en-US">Listed investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentFairValue" xlink:label="loc_gsk_InvestmentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentFairValue" xml:lang="en-US">Investment fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentFairValue" xml:lang="en-US">Investment fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentFairValue" xlink:to="lab_gsk_InvestmentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentFairValue" xml:lang="en-US">Investment fair value.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForForeignExchangeOtherInvestments" xlink:label="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForForeignExchangeOtherInvestments" xml:lang="en-US">Adjustments For Foreign Exchange Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForForeignExchangeOtherInvestments" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments" xlink:to="lab_gsk_AdjustmentsForForeignExchangeOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForForeignExchangeOtherInvestments" xml:lang="en-US">Adjustments for foreign exchange other investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xml:lang="en-US">Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xml:lang="en-US">Fair value of investment disposed during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:to="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirBiotechnologyIncMember" xlink:label="loc_gsk_VirBiotechnologyIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VirBiotechnologyIncMember" xml:lang="en-US">Vir Biotechnology Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_VirBiotechnologyIncMember" xml:lang="en-US">Vir Biotechnology, Inc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VirBiotechnologyIncMember" xlink:to="lab_gsk_VirBiotechnologyIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VirBiotechnologyIncMember" xml:lang="en-US">Vir biotechnology inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NimbusTherapeuticsLLCMember" xlink:label="loc_gsk_NimbusTherapeuticsLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NimbusTherapeuticsLLCMember" xml:lang="en-US">Nimbus Therapeutics LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NimbusTherapeuticsLLCMember" xml:lang="en-US">Nimbus Therapeutics, LLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NimbusTherapeuticsLLCMember" xlink:to="lab_gsk_NimbusTherapeuticsLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NimbusTherapeuticsLLCMember" xml:lang="en-US">Nimbus therapeutics LLC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CureVacNVMember" xlink:label="loc_gsk_CureVacNVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CureVacNVMember" xml:lang="en-US">Cure Vac N V [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CureVacNVMember" xml:lang="en-US">CureVac N.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CureVacNVMember" xlink:to="lab_gsk_CureVacNVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CureVacNVMember" xml:lang="en-US">CureVac N.V</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CounterpartiesAxis" xml:lang="en-US">Counterparties [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CounterpartiesAxis" xml:lang="en-US">Counterparties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CounterpartiesMember" xml:lang="en-US">Counterparties [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CounterpartiesMember" xml:lang="en-US">Counterparties [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Investments designated as measured at FVTOCI [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Investments measured at fair value through profit or loss [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Investments measured at FVTPL [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:to="lab_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xml:lang="en-US">Investments measured at fair value through profit or loss.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsOtherInvestments" xlink:label="loc_gsk_DisposalsAndSettlementsOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsAndSettlementsOtherInvestments" xml:lang="en-US">Disposals and Settlements Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsAndSettlementsOtherInvestments" xml:lang="en-US">Disposals and settlements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsAndSettlementsOtherInvestments" xlink:to="lab_gsk_DisposalsAndSettlementsOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsAndSettlementsOtherInvestments" xml:lang="en-US">Disposals and settlements other investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xlink:label="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xml:lang="en-US">Net Fair Value Movements Investments Through Other Comprehensive Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xml:lang="en-US">Net fair value movements through Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xlink:to="lab_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xml:lang="en-US">Net fair value movements investments through other comprehensive income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Investments other than investments accounted for using equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Ending of other investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xml:lang="en-US">Beginning of other investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xml:lang="en-US">Net fair value movements through profit or loss other investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xml:lang="en-US">Net fair value movements through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xlink:to="lab_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xml:lang="en-US">Net fair value movements through profit or loss other investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToOtherInvestments" xlink:label="loc_gsk_AdditionsToOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionsToOtherInvestments" xml:lang="en-US">Additions To Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionsToOtherInvestments" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionsToOtherInvestments" xlink:to="lab_gsk_AdditionsToOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionsToOtherInvestments" xml:lang="en-US">Additions to other investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xml:lang="en-US">Increase Decrease Through Exchange Adjustments Of Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xlink:to="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xml:lang="en-US">Increase (decrease) through exchange adjustments of other investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsNoncurrentMember" xlink:label="loc_gsk_OtherInvestmentsNoncurrentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherInvestmentsNoncurrentMember" xml:lang="en-US">Other Investments Noncurrent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherInvestmentsNoncurrentMember" xml:lang="en-US">Non-current [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherInvestmentsNoncurrentMember" xlink:to="lab_gsk_OtherInvestmentsNoncurrentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherInvestmentsNoncurrentMember" xml:lang="en-US">Other investments non-current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousNoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MiscellaneousNoncurrentAssetsAbstract" xml:lang="en-US">Miscellaneous non-current assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_MiscellaneousNoncurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNoncurrentAssetsTable" xlink:label="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherNoncurrentAssetsTable" xml:lang="en-US">Disclosure Of Other Non-current Assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOtherNoncurrentAssetsTable" xml:lang="en-US">Disclosure Of Other Non-current Assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable" xlink:to="lab_gsk_DisclosureOfOtherNoncurrentAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherNoncurrentAssetsTable" xml:lang="en-US">Schedule disclosing information related to other non-current assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:label="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xml:lang="en-US">Disclosure Of Other Non Current Assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xml:lang="en-US">Disclosure Of Other Non Current Assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:to="lab_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xml:lang="en-US">Disclosure of other non-current assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Total financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="loc_ifrs-full_OtherNoncurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentReceivables" xml:lang="en-US">Other non-current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherNoncurrentReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentReceivables" xlink:to="lab_ifrs-full_OtherNoncurrentReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial instruments, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial Instruments, Class [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentReceivablesMember" xlink:label="loc_gsk_OtherNonCurrentReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherNonCurrentReceivablesMember" xml:lang="en-US">Other Non Current Receivables [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherNonCurrentReceivablesMember" xml:lang="en-US">Other Non Current Receivables [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherNonCurrentReceivablesMember" xlink:to="lab_gsk_OtherNonCurrentReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherNonCurrentReceivablesMember" xml:lang="en-US">Other non current receivables.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBalanceMember" xlink:label="loc_gsk_RemainingBalanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemainingBalanceMember" xml:lang="en-US">Remaining Balance [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RemainingBalanceMember" xml:lang="en-US">Remaining Balance [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemainingBalanceMember" xlink:to="lab_gsk_RemainingBalanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemainingBalanceMember" xml:lang="en-US">Remaining balance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xml:lang="en-US">Financial assets at fair value through profit or loss, mandatorily measured at fair value, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xml:lang="en-US">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesRelatedToInsuranceContracts" xlink:label="loc_gsk_ReceivablesRelatedToInsuranceContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReceivablesRelatedToInsuranceContracts" xml:lang="en-US">Receivables Related To Insurance Contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReceivablesRelatedToInsuranceContracts" xml:lang="en-US">Amounts receivable under insurance contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReceivablesRelatedToInsuranceContracts" xlink:to="lab_gsk_ReceivablesRelatedToInsuranceContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReceivablesRelatedToInsuranceContracts" xml:lang="en-US">Receivables related to insurance contracts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xml:lang="en-US">Non-current net defined benefit asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xml:lang="en-US">Pension schemes in surplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xml:lang="en-US">Post-retirement benefits/Pension schemes in deficit and surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:to="lab_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xml:lang="en-US">Raw materials and consumables used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xml:lang="en-US">Raw materials and consumables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="lab_ifrs-full_RawMaterialsAndConsumablesUsed" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinishedGoods" xml:lang="en-US">Current finished goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WorkInProgress" xml:lang="en-US">Current work in progress</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WorkInProgress" xml:lang="en-US">Work in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xml:lang="en-US">Trade and other receivables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesTable" xml:lang="en-US">Disclosure of Trade and Other Receivables [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesTable" xml:lang="en-US">Disclosure of Trade and Other Receivables [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:to="lab_gsk_DisclosureOfTradeAndOtherReceivablesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesTable" xml:lang="en-US">Disclosure of trade and other receivables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xml:lang="en-US">Credit impairment of financial instruments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xml:lang="en-US">Credit impairment of financial instruments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xml:lang="en-US">Credit impairment of financial instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xml:lang="en-US">Credit impairment of financial instruments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsCreditimpairedMember" xlink:label="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialInstrumentsCreditimpairedMember" xml:lang="en-US">Financial instruments credit-impaired [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialInstrumentsCreditimpairedMember" xml:lang="en-US">Financial instruments credit-impaired [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember" xlink:to="lab_ifrs-full_FinancialInstrumentsCreditimpairedMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xml:lang="en-US">Disclosure of trade and other receivables [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xml:lang="en-US">Disclosure of trade and other receivables [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:to="lab_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xml:lang="en-US">Disclosure of trade and other receivables [line items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xlink:label="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xml:lang="en-US">Financial assets with modified contractual cash flows while loss allowance measured at lifetime expected credit losses for which loss allowance changed during reporting period to 12-month expected credit losses, gross carrying amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xml:lang="en-US">Expected credit loss allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xlink:to="lab_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xlink:label="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xml:lang="en-US">Expected credit loss allowance on trade receivables credit impaired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xml:lang="en-US">Expected credit loss allowance on trade receivables credit impaired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xlink:to="lab_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xml:lang="en-US">Expected credit loss allowance on trade receivables credit impaired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xml:lang="en-US">Total trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="lab_ifrs-full_TradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReceivables" xml:lang="en-US">Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeReceivables" xml:lang="en-US">Trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeReceivables" xml:lang="en-US">Trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_TradeReceivables" xml:lang="en-US">Trade receivables, net of loss allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivables" xlink:to="lab_ifrs-full_TradeReceivables" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssociatesAndJointVenturesMember" xml:lang="en-US">Associates and joint ventures [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AssociatesAndJointVenturesMember" xml:lang="en-US">Associates and joint ventures [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssociatesAndJointVenturesMember" xlink:to="lab_gsk_AssociatesAndJointVenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssociatesAndJointVenturesMember" xml:lang="en-US">Associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeReceivablesMember" xml:lang="en-US">Trade receivables [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeReceivablesMember" xml:lang="en-US">Trade and other receivables [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherReceivableMember" xlink:label="loc_gsk_OtherReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherReceivableMember" xml:lang="en-US">Other Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherReceivableMember" xml:lang="en-US">Other receivable [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherReceivableMember" xlink:to="lab_gsk_OtherReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherReceivableMember" xml:lang="en-US">Other receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-full_Prepayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Prepayments" xml:lang="en-US">Prepayments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Prepayments" xml:lang="en-US">Prepayments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Prepayments" xlink:to="lab_ifrs-full_Prepayments" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeLoansAndAdvances" xlink:label="loc_gsk_EmployeeLoansAndAdvances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EmployeeLoansAndAdvances" xml:lang="en-US">Employee Loans And Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EmployeeLoansAndAdvances" xml:lang="en-US">Employee loans and advances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EmployeeLoansAndAdvances" xlink:to="lab_gsk_EmployeeLoansAndAdvances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EmployeeLoansAndAdvances" xml:lang="en-US">Employee loans and advances.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="loc_ifrs-full_InterestReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestReceivable" xml:lang="en-US">Interest receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestReceivable" xml:lang="en-US">Interest receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivable" xlink:to="lab_ifrs-full_InterestReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:label="loc_ifrs-full_AccruedIncomeOtherThanContractAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccruedIncomeOtherThanContractAssets" xml:lang="en-US">Accrued income other than contract assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccruedIncomeOtherThanContractAssets" xml:lang="en-US">Accrued income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:to="lab_ifrs-full_AccruedIncomeOtherThanContractAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xlink:label="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xml:lang="en-US">Subsequent recoveries of amounts provided for expected credit loss allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xml:lang="en-US">Subsequent recoveries of amounts provided for</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xlink:to="lab_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xml:lang="en-US">Subsequent recoveries of amounts provided for expected credit loss allowance.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowance" xlink:label="loc_gsk_ExpectedCreditLossAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedCreditLossAllowance" xml:lang="en-US">Expected credit loss allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowance" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowance" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedCreditLossAllowance" xlink:to="lab_gsk_ExpectedCreditLossAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedCreditLossAllowance" xml:lang="en-US">Expected credit loss allowance.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xlink:label="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xml:lang="en-US">Increase decrease in expected credit losses allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xml:lang="en-US">Charge for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xlink:to="lab_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xml:lang="en-US">Increase decrease in expected credit losses allowance.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceUtilised" xlink:label="loc_gsk_ExpectedCreditLossAllowanceUtilised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedCreditLossAllowanceUtilised" xml:lang="en-US">Expected credit loss allowance utilised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowanceUtilised" xml:lang="en-US">Utilised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedCreditLossAllowanceUtilised" xlink:to="lab_gsk_ExpectedCreditLossAllowanceUtilised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedCreditLossAllowanceUtilised" xml:lang="en-US">Expected credit loss allowance utilised.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xlink:label="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xml:lang="en-US">Expected credit loss allowance exchange adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xlink:to="lab_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xml:lang="en-US">Expected credit loss allowance exchange adjustments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xlink:label="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xml:lang="en-US">Expected Credit Loss Allowance Transfer To Assets Held For Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xml:lang="en-US">Transfer to assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xlink:to="lab_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xml:lang="en-US">Expected credit loss allowance transfer to assets held for sale.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and cash equivalents [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsTable" xlink:label="loc_gsk_CashAndCashEquivalentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentsTable" xml:lang="en-US">Cash And Cash Equivalents [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentsTable" xlink:to="lab_gsk_CashAndCashEquivalentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentsTable" xml:lang="en-US">Cash And Cash Equivalents.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsLineItems" xlink:label="loc_gsk_CashAndCashEquivalentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentsLineItems" xml:lang="en-US">Cash And Cash Equivalents [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems" xlink:to="lab_gsk_CashAndCashEquivalentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentsLineItems" xml:lang="en-US">Cash And Cash Equivalents.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xlink:label="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xml:lang="en-US">Assets transferred to structured entities, at time of transfer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xml:lang="en-US">Transferred to assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xlink:to="lab_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xlink:label="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xml:lang="en-US">Cash and cash equivalents held by entity unavailable for use by group</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xml:lang="en-US">Cash and cash equivalents not available for general use</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xlink:to="lab_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConsumerHealthcareBusinessMember" xml:lang="en-US">Consumer Healthcare Business [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConsumerHealthcareBusinessMember" xlink:to="lab_gsk_ConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConsumerHealthcareBusinessMember" xml:lang="en-US">Consumer healthcare business.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xml:lang="en-US">Short-term deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash at bank and in hand</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AccruedFixedAssetRelatedCostsAbstract" xlink:label="loc_gsk_AccruedFixedAssetRelatedCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AccruedFixedAssetRelatedCostsAbstract" xml:lang="en-US">Accrued Fixed Asset Related Costs [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AccruedFixedAssetRelatedCostsAbstract" xlink:to="lab_gsk_AccruedFixedAssetRelatedCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AccruedFixedAssetRelatedCostsAbstract" xml:lang="en-US">Accrued Fixed Asset Related Costs [abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xlink:label="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xml:lang="en-US">Gain On Demerger Before Exchange Movements And Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xml:lang="en-US">Gain on demerger before exchange movements and transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xlink:to="lab_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xml:lang="en-US">Net assets and liabilities distributed / derecognised as part of gain on the demerger.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssetsHeldForSaleAbstract" xlink:label="loc_gsk_DisclosureOfAssetsHeldForSaleAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfAssetsHeldForSaleAbstract" xml:lang="en-US">Disclosure Of Assets Held For Sale [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfAssetsHeldForSaleAbstract" xlink:to="lab_gsk_DisclosureOfAssetsHeldForSaleAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfAssetsHeldForSaleAbstract" xml:lang="en-US">Disclosure of assets held for sale.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleTable" xlink:label="loc_gsk_AssetsHeldForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssetsHeldForSaleTable" xml:lang="en-US">Assets Held For Sale [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AssetsHeldForSaleTable" xml:lang="en-US">Assets Held For Sale [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssetsHeldForSaleTable" xlink:to="lab_gsk_AssetsHeldForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssetsHeldForSaleTable" xml:lang="en-US">Assets Held For Sale [table]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleLineItems" xlink:label="loc_gsk_AssetsHeldForSaleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssetsHeldForSaleLineItems" xml:lang="en-US">Assets Held For Sale [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AssetsHeldForSaleLineItems" xml:lang="en-US">Assets Held For Sale [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssetsHeldForSaleLineItems" xlink:to="lab_gsk_AssetsHeldForSaleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssetsHeldForSaleLineItems" xml:lang="en-US">Disclosure Of Assets Held For Sale [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssetsNet" xlink:label="loc_gsk_OtherAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAssetsNet" xml:lang="en-US">Other Assets Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAssetsNet" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAssetsNet" xlink:to="lab_gsk_OtherAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAssetsNet" xml:lang="en-US">Other assets net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xml:lang="en-US">Assets and liabilities classified as held for sale [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xml:lang="en-US">Assets held for sale [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract" xml:lang="en-US">Trade and other payables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherPayablesAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesTable" xml:lang="en-US">Disclosure of trade and other payables [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesTable" xml:lang="en-US">Disclosure of trade and other payables [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:to="lab_gsk_DisclosureOfTradeAndOtherPayablesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesTable" xml:lang="en-US">Schedule disclosing information related to disclosure of trade and other payables.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesLineItems" xml:lang="en-US">Disclosure of trade and other payables [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesLineItems" xml:lang="en-US">Disclosure of trade and other payables [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:to="lab_gsk_DisclosureOfTradeAndOtherPayablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfTradeAndOtherPayablesLineItems" xml:lang="en-US">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with disclosure of trade and other payables.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_gsk_CustomerReturnAndRebateAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CustomerReturnAndRebateAccruals" xml:lang="en-US">Customer Return And Rebate Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CustomerReturnAndRebateAccruals" xml:lang="en-US">Customer return and rebate accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CustomerReturnAndRebateAccruals" xlink:to="lab_gsk_CustomerReturnAndRebateAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CustomerReturnAndRebateAccruals" xml:lang="en-US">Customer return and rebate accruals.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueAndOperatingIncome" xml:lang="en-US">Revenue and other operating income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueAndOperatingIncome" xml:lang="en-US">Revenue recognized in deferred income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAndOperatingIncome" xlink:to="lab_ifrs-full_RevenueAndOperatingIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" xml:lang="en-US">Interest Accrued On Financial Liabilities At Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" xml:lang="en-US">Interest accrued on financial liabilities at amortized cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" xlink:to="lab_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost" xml:lang="en-US">Interest accrued on financial liabilities at amortized cost .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WagesAndSalariesPayable" xlink:label="loc_gsk_WagesAndSalariesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WagesAndSalariesPayable" xml:lang="en-US">Wages And Salaries Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WagesAndSalariesPayable" xml:lang="en-US">Wages and salaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WagesAndSalariesPayable" xlink:to="lab_gsk_WagesAndSalariesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WagesAndSalariesPayable" xml:lang="en-US">Wages and salaries payable.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOptionPayable" xlink:label="loc_gsk_PutOptionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PutOptionPayable" xml:lang="en-US">Put Option payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PutOptionPayable" xml:lang="en-US">ViiV Healthcare put option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PutOptionPayable" xlink:to="lab_gsk_PutOptionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PutOptionPayable" xml:lang="en-US">Put option payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xml:lang="en-US">Current payables on social security and taxes other than income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xml:lang="en-US">Social security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xml:lang="en-US">Trade payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xml:lang="en-US">Trade payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAccruals" xlink:label="loc_gsk_OtherAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAccruals" xml:lang="en-US">Other Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAccruals" xml:lang="en-US">Other accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAccruals" xlink:to="lab_gsk_OtherAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAccruals" xml:lang="en-US">Other accruals.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentPayables" xml:lang="en-US">Other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentPayables" xml:lang="en-US">Other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables" xlink:to="lab_ifrs-full_OtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContractLiabilities" xml:lang="en-US">Contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContractLiabilities" xml:lang="en-US">Deferred income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" xlink:label="loc_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" xml:lang="en-US">Disclosure Of Indicative Basis In Income Statement and Balance sheet Put Option To Reasonably Changes In Key Assumption [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" xlink:to="lab_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" xml:lang="en-US">Disclosure of indicative basis in income statement and balance sheet put option to reasonably changes in key assumption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xml:lang="en-US">Disclosure of information about activities subject to rate regulation [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xml:lang="en-US">Disclosure of information about activities subject to rate regulation [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xml:lang="en-US">Disclosure of information about activities subject to rate regulation [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xml:lang="en-US">Disclosure of information about activities subject to rate regulation [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInFinancialLiability" xlink:label="loc_gsk_IncreaseDecreaseInFinancialLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInFinancialLiability" xml:lang="en-US">Increase decrease in financial liability.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInFinancialLiability" xml:lang="en-US">Increase/(decrease) in financial liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInFinancialLiability" xlink:to="lab_gsk_IncreaseDecreaseInFinancialLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInFinancialLiability" xml:lang="en-US">Increase decrease in financial liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xml:lang="en-US">Currency risk ten cent depreciation of Euro [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xml:lang="en-US">10 cent depreciation of Euro [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:to="lab_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xml:lang="en-US">Euro exchange rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xml:lang="en-US">Currency risk ten cent depreciation of US Dollar [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xml:lang="en-US">10 cent depreciation of US Dollar [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:to="lab_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xml:lang="en-US">US Dollar exchange rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xml:lang="en-US">Currency Risk Ten Cent Appreciation Of US Dollar [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xml:lang="en-US">10 cent appreciation of the US Dollar [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:to="lab_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xml:lang="en-US">Currency risk 10 cent appreciation of US dollar.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xml:lang="en-US">Currency Risk Ten Cent Appreciation Of Euro [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xml:lang="en-US">10 cent appreciation of the Euro [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xml:lang="en-US">10 cent appreciation of Euro [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:to="lab_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xml:lang="en-US">Currency risk 10 cent appreciation of Euro.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Ten Percentage Increase In Sales Forecasts Or Sales Multiple Applied [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">10% increase in sales forecasts or sales multiple applied [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:to="lab_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Ten Percentage Increase In Sales Forecasts Or Sales Multiple Applied [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Ten Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">10% decrease in sales forecasts or sales multiple applied [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:to="lab_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Ten Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xml:lang="en-US">Discount rate, measurement input [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:to="lab_ifrs-full_DiscountRateMeasurementInputMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Fifteen Percentage Increase In Sales Forecasts Or Sales Multiple Applied [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">15% increase in sales forecasts or sales multiple applied [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:to="lab_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Fifteen Percentage Increase In Sales Forecasts Or Sales Multiple Applied</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Fifteen Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">15% decrease in sales forecasts or sales multiple applied [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:to="lab_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xml:lang="en-US">Currency Risk Fifteen Percentage Decrease In Sales Forecasts Or Sales Multiple Applied</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xml:lang="en-US">Currency Risk Fifteen Cent Depreciation Of Euro [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xml:lang="en-US">15 cent depreciation of Euro [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:to="lab_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xml:lang="en-US">Currency Risk Fifteen Cent Depreciation Of Euro</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xml:lang="en-US">Currency Risk One Fifty Basis Points increase in discount rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xml:lang="en-US">1.50% (150 basis points) increase in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xlink:to="lab_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xml:lang="en-US">Currency Risk One Fifty Basis Points increase in discount rate</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xml:lang="en-US">Currency Risk One Fifty Basis Points Decrease In Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xml:lang="en-US">1.50% (150 basis points) decrease in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xlink:to="lab_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xml:lang="en-US">Currency Risk One Fifty Basis Points Decrease In Discount Rate</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xml:lang="en-US">Currency Risk Fifteen Cent Depreciation Of US Dollar [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xml:lang="en-US">15 cent depreciation of US Dollar [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:to="lab_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xml:lang="en-US">Currency Risk Fifteen Cent Depreciation Of US Dollar</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xml:lang="en-US">Currency Risk Fifteen Cent Appreciation Of Euro [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xml:lang="en-US">15 cent appreciation of the Euro [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xml:lang="en-US">15 cent appreciation of Euro [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:to="lab_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xml:lang="en-US">Currency Risk Fifteen Cent Appreciation Of Euro</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xml:lang="en-US">Currency Risk Fifteen Cent Appreciation Of US Dollar [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xml:lang="en-US">15 cent appreciation of the US Dollar [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xml:lang="en-US">15 cent appreciation of US Dollar [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:to="lab_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xml:lang="en-US">Currency Risk Fifteen Cent Appreciation Of US Dollar</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:to="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesMember" xlink:label="loc_ifrs-full_ValuationTechniquesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xml:lang="en-US">Valuation techniques [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xml:lang="en-US">Valuation techniques [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesMember" xlink:to="lab_ifrs-full_ValuationTechniquesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfNetDebtAbstract" xml:lang="en-US">Disclosure of net debt [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract" xlink:to="lab_gsk_DisclosureOfNetDebtAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfNetDebtAbstract" xml:lang="en-US">Disclosure of net debt abstract.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtTable" xlink:label="loc_gsk_DisclosureOfDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDebtTable" xml:lang="en-US">Disclosure Of Debt [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDebtTable" xml:lang="en-US">Disclosure of debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDebtTable" xlink:to="lab_gsk_DisclosureOfDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDebtTable" xml:lang="en-US">Disclosure of debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xml:lang="en-US">Borrowings by name [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xml:lang="en-US">Borrowings by name [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xml:lang="en-US">Borrowings by name [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xml:lang="en-US">Borrowings by name [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaper1Member" xlink:label="loc_gsk_CommercialPaper1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CommercialPaper1Member" xml:lang="en-US">Commercial Paper 1 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CommercialPaper1Member" xml:lang="en-US">Commercial paper [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CommercialPaper1Member" xlink:to="lab_gsk_CommercialPaper1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CommercialPaper1Member" xml:lang="en-US">Commercial paper.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LetterOfCredit1Member" xlink:label="loc_gsk_LetterOfCredit1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LetterOfCredit1Member" xml:lang="en-US">Letter Of Credit 1 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LetterOfCredit1Member" xml:lang="en-US">Letter of credit 1 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LetterOfCredit1Member" xlink:to="lab_gsk_LetterOfCredit1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LetterOfCredit1Member" xml:lang="en-US">Letter of credit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Two Point Eight Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">2.800% US$ US Medium Term Note 2023 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Two point eight percentage US medium term note two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonInterestBearingMember" xlink:label="loc_gsk_NonInterestBearingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonInterestBearingMember" xml:lang="en-US">Non Interest Bearing [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NonInterestBearingMember" xml:lang="en-US">Non interest bearing [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonInterestBearingMember" xlink:to="lab_gsk_NonInterestBearingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonInterestBearingMember" xml:lang="en-US">Non Interest Bearing</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Three Point Three Seven Five Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">3.375% US$ US Medium Term Note 2023 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Three point three seven five percentage US medium term note two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Zero Percent European Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.000% &#8364; European Medium Term Note 20230.000% &#8364; European Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero point zero percent european medium term note two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">Three Point Three Seven Five Percent Euro Medium Term Note Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">3.375% Euro Medium Term Note 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:to="lab_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">Three point three seven five percent European medium term note two thousand twenty seven.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xml:lang="en-US">Five Point Two Five Percent Euro Medium Term Note Two Thousand Thirty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xml:lang="en-US">5.250% Euro Medium Term Note 2033 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:to="lab_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xml:lang="en-US">Five point two five percent European medium term note two thousand thirty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xml:lang="en-US">Five Point Two Five Percent Euro Term Note Two Thousand Forty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xml:lang="en-US">5.250% Euro Medium Term Note 2042 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:to="lab_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xml:lang="en-US">Five point two five percent European term note two thousand forty two.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:label="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xml:lang="en-US">Four Point Two Five Percent Euro Medium Term Note Two Thousand Forty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xml:lang="en-US">4.250% Euro Medium Term Note 2045 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:to="lab_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xml:lang="en-US">Four point two five percent European medium term note two thousand forty five.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xml:lang="en-US">Types of interest rates [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xml:lang="en-US">Types of interest rates [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateTypesMember" xml:lang="en-US">Interest rate types [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateTypesMember" xml:lang="en-US">Interest rate types [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xml:lang="en-US">Floating interest rate [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xml:lang="en-US">Floating interest rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FixedInterestRateMember" xlink:label="loc_ifrs-full_FixedInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FixedInterestRateMember" xml:lang="en-US">Fixed interest rate [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FixedInterestRateMember" xml:lang="en-US">Fixed interest rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xml:lang="en-US">Later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xml:lang="en-US">Later than 5 years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xml:lang="en-US">Greater than five years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermNotesMember" xlink:label="loc_gsk_ShortTermNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShortTermNotesMember" xml:lang="en-US">Short Term Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShortTermNotesMember" xml:lang="en-US">Short-term notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShortTermNotesMember" xlink:to="lab_gsk_ShortTermNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShortTermNotesMember" xml:lang="en-US">Short-term notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xml:lang="en-US">Later than one year and not later than three years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Not later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Not later than 1 year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Non Current [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCommercialPaperProgramMember" xlink:label="loc_gsk_UsCommercialPaperProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UsCommercialPaperProgramMember" xml:lang="en-US">US Commercial Paper Program [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UsCommercialPaperProgramMember" xml:lang="en-US">US commercial paper program [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UsCommercialPaperProgramMember" xlink:to="lab_gsk_UsCommercialPaperProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UsCommercialPaperProgramMember" xml:lang="en-US">US commercial paper programme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgramMember" xlink:label="loc_gsk_EuroCommercialPaperProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EuroCommercialPaperProgramMember" xml:lang="en-US">EURO Commercial Paper Program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EuroCommercialPaperProgramMember" xlink:to="lab_gsk_EuroCommercialPaperProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EuroCommercialPaperProgramMember" xml:lang="en-US">Euro commercial paper program.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtLineItems" xlink:label="loc_gsk_DisclosureOfDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDebtLineItems" xml:lang="en-US">Disclosure of debt [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDebtLineItems" xml:lang="en-US">Disclosure of debt [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDebtLineItems" xlink:to="lab_gsk_DisclosureOfDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDebtLineItems" xml:lang="en-US">Disclosure of debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xlink:label="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xml:lang="en-US">Effective Interest Rate On Available For Sale Financial Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xml:lang="en-US">Effective Interest rate on liquid investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xlink:to="lab_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xml:lang="en-US">Effective interest rate on available for sale financial investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnCashAndCashEquivalents" xlink:label="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EffectiveInterestRateOnCashAndCashEquivalents" xml:lang="en-US">Effective Interest Rate On Cash And Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EffectiveInterestRateOnCashAndCashEquivalents" xml:lang="en-US">Effective Interest rate on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents" xlink:to="lab_gsk_EffectiveInterestRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EffectiveInterestRateOnCashAndCashEquivalents" xml:lang="en-US">Effective interest rate on cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateNotesIssued" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateNotesIssued" xml:lang="en-US">Average Effective Pre Swap Interest Rate Notes Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateNotesIssued" xml:lang="en-US">Average effective pre-swap interest rate notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued" xlink:to="lab_gsk_AverageEffectivePreSwapInterestRateNotesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateNotesIssued" xml:lang="en-US">Average effective pre swap interest rate issued.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestments" xlink:label="loc_gsk_LiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestments" xml:lang="en-US">Liquid Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidInvestments" xml:lang="en-US">Liquid investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestments" xlink:to="lab_gsk_LiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidInvestments" xml:lang="en-US">Liquid investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateShortTerm" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateShortTerm" xml:lang="en-US">Average effective pre swap interest rate short term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateShortTerm" xml:lang="en-US">Average effective pre-swap interest rate on short term notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm" xlink:to="lab_gsk_AverageEffectivePreSwapInterestRateShortTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AverageEffectivePreSwapInterestRateShortTerm" xml:lang="en-US">Average effective pre swap interest rate short term.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryInterestAtEffectiveRates" xlink:label="loc_gsk_CarryInterestAtEffectiveRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryInterestAtEffectiveRates" xml:lang="en-US">Carry Interest At Effective Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryInterestAtEffectiveRates" xml:lang="en-US">Interest at effective rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryInterestAtEffectiveRates" xlink:to="lab_gsk_CarryInterestAtEffectiveRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryInterestAtEffectiveRates" xml:lang="en-US">Carry interest at effective rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperAuthorized" xlink:label="loc_gsk_CommercialPaperAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CommercialPaperAuthorized" xml:lang="en-US">Commercial paper authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CommercialPaperAuthorized" xml:lang="en-US">Commercial paper authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CommercialPaperAuthorized" xlink:to="lab_gsk_CommercialPaperAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CommercialPaperAuthorized" xml:lang="en-US">Commercial paper authorized.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CommercialPapersIssued" xml:lang="en-US">Commercial papers issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CommercialPapersIssued" xml:lang="en-US">Commercial paper issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CommercialPapersIssued" xml:lang="en-US">Commercial paper</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CommercialPapersIssued" xml:lang="en-US">Short-term finance access</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommercialPapersIssued" xlink:to="lab_ifrs-full_CommercialPapersIssued" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xlink:label="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xml:lang="en-US">Weighted average interest rate on current bank loans and overdrafts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xml:lang="en-US">Weighted average interest rate on current bank loans and overdrafts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xlink:to="lab_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xml:lang="en-US">Weighted average interest rate on current bank loans and overdrafts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RepaymentYear" xlink:label="loc_gsk_RepaymentYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RepaymentYear" xml:lang="en-US">Repayment Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RepaymentYear" xml:lang="en-US">Repayment dates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RepaymentYear" xlink:to="lab_gsk_RepaymentYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RepaymentYear" xml:lang="en-US">Repayment year.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnBorrowings" xlink:label="loc_gsk_WeightedAverageInterestRateOnBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageInterestRateOnBorrowings" xml:lang="en-US">Weighted Average Interest Rate On Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageInterestRateOnBorrowings" xml:lang="en-US">Weighted average interest rate of borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageInterestRateOnBorrowings" xlink:to="lab_gsk_WeightedAverageInterestRateOnBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageInterestRateOnBorrowings" xml:lang="en-US">Weighted average interest rate on borrowings.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PledgedInvestments" xlink:label="loc_gsk_PledgedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PledgedInvestments" xml:lang="en-US">Pledged Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PledgedInvestments" xml:lang="en-US">Pledged investments value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PledgedInvestments" xlink:to="lab_gsk_PledgedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PledgedInvestments" xml:lang="en-US">Pledged Investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xml:lang="en-US">Borrowings, interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xml:lang="en-US">Borrowings, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotionalAmount" xml:lang="en-US">Notional amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NotionalAmount" xml:lang="en-US">Drawn amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotionalAmount" xml:lang="en-US">Issue amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xml:lang="en-US">Undrawn borrowing facilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xml:lang="en-US">Revolving credit facilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xml:lang="en-US">Revolving credit facilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:to="lab_ifrs-full_UndrawnBorrowingFacilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:label="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xml:lang="en-US">Cancelled committed facilities replaced with revolving credit facilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xml:lang="en-US">Cancelled committed facilities and replaced with revolving credit facilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:to="lab_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xml:lang="en-US">Cancelled committed facilities replaced with revolving credit facilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:label="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xml:lang="en-US">Post Separation of the Consumer Healthcare Business [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xml:lang="en-US">Post separation of the consumer healthcare business [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:to="lab_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xml:lang="en-US">Post separation of the consumer healthcare business member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiquidityRiskMember" xml:lang="en-US">Liquidity risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiquidityRiskMember" xml:lang="en-US">Liquidity risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember" xlink:to="lab_ifrs-full_LiquidityRiskMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xlink:label="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xml:lang="en-US">Four Point Two Percent US Medium Term Note Two Thousand Forty Three [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xml:lang="en-US">4.200% US$ US Medium Term Note 2043 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xlink:to="lab_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xml:lang="en-US">Four point two percent US medium term note forty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xml:lang="en-US">Six Point Three Seven Five Percent Euro Medium Term Note Two Thousand Thirty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xml:lang="en-US">6.375% Euro Medium Term Note 2039 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xlink:to="lab_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xml:lang="en-US">Six point three seven five percent European medium term note two thousand thirty nine.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xml:lang="en-US">One Percent Euro Medium Term Notes Two Thousand twenty six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xml:lang="en-US">1.000% &#8364; Euro Medium Term Note 2026 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xlink:to="lab_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xml:lang="en-US">One percent European medium term note two thousand twenty six.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xlink:label="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xml:lang="en-US">One Point Seven Five Zero Percentage Euro Medium Term Note Two Thousand Thirty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xml:lang="en-US">1.750% Euro Medium Term Note 2030 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xlink:to="lab_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xml:lang="en-US">One point seven five zero percentage European medium term note two thousand thirty.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xlink:label="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xml:lang="en-US">Five Point Three Seven Five Percent US Medium Term Note Two Thousand Thirty Four [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xml:lang="en-US">5.375% US Medium Term Note 2034 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xlink:to="lab_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xml:lang="en-US">Five point three seven five percent US medium term note two thousand thirty four.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLongtermBorrowingsMember" xlink:label="loc_gsk_OtherLongtermBorrowingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherLongtermBorrowingsMember" xml:lang="en-US">Other LongTerm Borrowings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherLongtermBorrowingsMember" xml:lang="en-US">Other LongTerm Borrowings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherLongtermBorrowingsMember" xlink:to="lab_gsk_OtherLongtermBorrowingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherLongtermBorrowingsMember" xml:lang="en-US">Other long term borrowings.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">Four Point Zero Zero Percent Euro Medium Term Note Two Thousand Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">4.000% &#8364; Euro Medium Term Note 2025 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:to="lab_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">Four point zero zero percent European medium term note two thousand twenty five.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xml:lang="en-US">One Point Three Seven Five Percent Euro Medium Term Notes Two Thousand Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xml:lang="en-US">1.375% &#8364; Euro Medium Term Note 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xlink:to="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xml:lang="en-US">One point three seven five percent European medium term notes thousand twenty four.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xml:lang="en-US">One point three seven five Percent Euro Medium Term Notes Two Thousand twenty nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xml:lang="en-US">1.375% &#8364; Euro Medium Term Note 2029 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xlink:to="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xml:lang="en-US">1.375% European Medium Term Note 2029</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xml:lang="en-US">One Point Two Five Percentage Euro Medium Term Note Two Thousand Twenty Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xml:lang="en-US">1.250% Euro Medium Term Note 2026 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xlink:to="lab_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xml:lang="en-US">One point two five percentage European medium term note two thousand twenty six.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xml:lang="en-US">Six Point Three Seven Five Percent US Medium Term Note Two Thousand Thirty Eight [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xml:lang="en-US">6.375% US Medium Term Note 2038 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xlink:to="lab_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xml:lang="en-US">Six point three seven five percent US medium term note two thousand thirty eight.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">Three Point Eight Seven Five Percentage U- S- Medium Term Note Two Thousand Twenty Eight [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">3.875% US$ US Medium Term Note 2028 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xlink:to="lab_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">Three point eight seven five percentage US medium term note two thousand twenty eight.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">Two Point Eight Five Percent US Medium Term Note Two Thousand Twenty Two [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">2.850% US$ US Medium Term Note 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:to="lab_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">Two Point Eight Five Percent US Medium Term Note Two Thousand Twenty Two [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xml:lang="en-US">Three Point Three Seven Five Percent US Medium Term Note Two Thousand Twenty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xml:lang="en-US">3.375% US$ US Medium Term Note 2029 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xlink:to="lab_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xml:lang="en-US">Three Point Three Seven Five Percent US Medium Term Note Two Thousand Twenty Nine.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Zero Percentage Euro Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.000% &#8364; Euro Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Zero Percentage European Medium Term Note Two Thousand Twenty Three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xlink:label="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xml:lang="en-US">Three Point Zero Percent US Medium Term Note Two Thousand Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xml:lang="en-US">3.000% US$ US Medium Term Note 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xlink:to="lab_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xml:lang="en-US">Three Point Zero Percent US Medium Term Note Two Thousand Twenty Four.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">Three point six two five percent US medium term note two thousand twenty five [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">3.625% US$ US Medium Term Note 2025 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xlink:to="lab_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">Three point six two five percent US medium term note two thousand twenty five.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xml:lang="en-US">Zero Point One Two Five Percent Euro Medium Term Note Two Thousands And Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xml:lang="en-US">0.125% &#8364; Euro Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xlink:to="lab_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xml:lang="en-US">Zero Point One Two Five Percent European Medium Term Note Two Thousands And Twenty Three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">Two Point Eight Seven Five Percent US Medium Term Note Two Thousand Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">2.875% US$ US Medium Term Note 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:to="lab_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xml:lang="en-US">Two Point Eight Seven Five Percent US Medium Term Note Two Thousand Twenty Two.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">One Point Six Two Five Euro Medium Term Note Two Thousand Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">1.625% Euro Medium Term Note 2035 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:to="lab_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xml:lang="en-US">One Point Six Two Five European Medium Term Note Two Thousand Twenty Five.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Five Three Four US Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.534% US$ US Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Five Three Four US Medium Term Note Two Thousand Twenty Three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">One Point Two Five Euro Medium Term Note Two Thousand Twenty Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">1.25% Euro Medium Term Note 2028 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xlink:to="lab_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xml:lang="en-US">One Point Two Five European Medium Term Note Two Thousand Twenty Eight.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point One Two Five Percent European Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.125% &#8364; European Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero point one two five percent european medium term note two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Five Three Four Percent Us Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.534% US$ Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero point five three four percent us medium term note two thousand twenty three .</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero Point Zero Percent Us Medium Term Note Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">0.000% US$ US Medium Term Note 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:to="lab_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xml:lang="en-US">Zero point zero percent us medium term note two thousand twenty three.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">Three Point Zero Percent Euro Medium Term Note Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">3.000% &#8364; Euro Medium Term Note 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:to="lab_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xml:lang="en-US">Three point zero percent euro medium term note two thousand twenty seven.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xlink:label="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xml:lang="en-US">Three Point One Two Five Percent Euro Medium Term Note Two Thousand Thirty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xml:lang="en-US">3.125% &#8364; Euro Medium Term Note 2032 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xlink:to="lab_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xml:lang="en-US">Three point one two five percent euro medium term note two thousand thirty two.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt1Member" xlink:label="loc_gsk_Debt1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Debt1Member" xml:lang="en-US">Debt 1 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_Debt1Member" xml:lang="en-US">Net debt [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Debt1Member" xlink:to="lab_gsk_Debt1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Debt1Member" xml:lang="en-US">Debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityListingsExchangeAxis" xml:lang="en-US">Entity Listings, Exchange [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityListingsExchangeAxis" xml:lang="en-US">Entity Listings, Exchange [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ExchangeDomain" xml:lang="en-US">Exchange [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_ExchangeDomain" xml:lang="en-US">Exchange [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LondonStockExchangeMember" xlink:label="loc_gsk_LondonStockExchangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LondonStockExchangeMember" xml:lang="en-US">London Stock Exchange [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LondonStockExchangeMember" xml:lang="en-US">London Stock Exchange [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LondonStockExchangeMember" xlink:to="lab_gsk_LondonStockExchangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LondonStockExchangeMember" xml:lang="en-US">London Stock Exchange [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NewYorkStockExchangeMember" xlink:label="loc_gsk_NewYorkStockExchangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NewYorkStockExchangeMember" xml:lang="en-US">New York Stock Exchange [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NewYorkStockExchangeMember" xml:lang="en-US">New York Stock Exchange [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NewYorkStockExchangeMember" xlink:to="lab_gsk_NewYorkStockExchangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NewYorkStockExchangeMember" xml:lang="en-US">New York Stock Exchange.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Borrowings" xml:lang="en-US">Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_Borrowings" xml:lang="en-US">Net debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_ifrs-full_Borrowings" xml:lang="en-US">Net debt, at beginning of year, as adjusted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_ifrs-full_Borrowings" xml:lang="en-US">Net debt at end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Borrowings" xml:lang="en-US">Borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsAbstract" xlink:label="loc_ifrs-full_BorrowingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsAbstract" xml:lang="en-US">Borrowings [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsAbstract" xml:lang="en-US">Short-term borrowings:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAbstract" xlink:to="lab_ifrs-full_BorrowingsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansoverdraftsAndOther" xlink:label="loc_gsk_BankLoansoverdraftsAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BankLoansoverdraftsAndOther" xml:lang="en-US">Bank LoansOverdrafts And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_BankLoansoverdraftsAndOther" xml:lang="en-US">Bank loans, overdrafts and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BankLoansoverdraftsAndOther" xlink:to="lab_gsk_BankLoansoverdraftsAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BankLoansoverdraftsAndOther" xml:lang="en-US">Bank loans and overdrafts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCurrent" xlink:label="loc_gsk_LiquidInvestmentsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsCurrent" xml:lang="en-US">Liquid Investments Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidInvestmentsCurrent" xml:lang="en-US">Liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsCurrent" xlink:to="lab_gsk_LiquidInvestmentsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidInvestmentsCurrent" xml:lang="en-US">Liquid investments current.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongtermBorrowingsAbstract" xlink:label="loc_gsk_LongtermBorrowingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LongtermBorrowingsAbstract" xml:lang="en-US">Longterm borrowings [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LongtermBorrowingsAbstract" xml:lang="en-US">Long-term borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LongtermBorrowingsAbstract" xlink:to="lab_gsk_LongtermBorrowingsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Non-current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xml:lang="en-US">Later than three years and not later than four years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xml:lang="en-US">Between 3 and 4 Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Later than four years and not later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Between 4 and 5 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">Later than one year and not later than two years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">Between 1 and 2 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xml:lang="en-US">Later than two years and not later than three years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xml:lang="en-US">Between 2 and 3 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseLiability" xlink:label="loc_gsk_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinanceLeaseLiability" xml:lang="en-US">Finance Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_FinanceLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_FinanceLeaseLiability" xml:lang="en-US">Obligations under finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinanceLeaseLiability" xlink:to="lab_gsk_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinanceLeaseLiability" xml:lang="en-US">Finance Lease Liability.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseObligationsGross" xlink:label="loc_gsk_FinanceLeaseObligationsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinanceLeaseObligationsGross" xml:lang="en-US">Finance Lease Obligations Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_FinanceLeaseObligationsGross" xml:lang="en-US">Total future rental payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinanceLeaseObligationsGross" xlink:to="lab_gsk_FinanceLeaseObligationsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinanceLeaseObligationsGross" xml:lang="en-US">Finance Lease Obligations, Gross.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xml:lang="en-US">Disclosure of pension and other post employment plan [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xml:lang="en-US">Disclosure of pension and other post employment plan [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xlink:to="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xml:lang="en-US">Disclosure of pension and other post employment plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xml:lang="en-US">Disclosure of pension and other post employment plan [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xml:lang="en-US">Disclosure of pension and other post employment plan [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xlink:to="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xml:lang="en-US">Disclosure of pensions and other post employment plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedContributionPlans" xlink:label="loc_gsk_DisclosureOfDefinedContributionPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedContributionPlans" xml:lang="en-US">Disclosure Of Defined Contribution Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedContributionPlans" xml:lang="en-US">Pension and other post-employment cost Analysed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedContributionPlans" xlink:to="lab_gsk_DisclosureOfDefinedContributionPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedContributionPlans" xml:lang="en-US">Disclosure of defined contribution plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xml:lang="en-US">Post-employment benefit expense, defined benefit plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xml:lang="en-US">Defined benefit pension and post retirement cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xml:lang="en-US">US post retirement healthcare scheme obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xlink:label="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xml:lang="en-US">Post-employment benefit expense, defined benefit plans analysed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xml:lang="en-US">Pension and other post-employment cost Analysed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xlink:to="lab_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xml:lang="en-US">Post-employment benefit expense, defined benefit plans analysed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpensePlans" xlink:label="loc_gsk_PostemploymentBenefitExpensePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostemploymentBenefitExpensePlans" xml:lang="en-US">Postemployment Benefit Expense Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PostemploymentBenefitExpensePlans" xml:lang="en-US">Pension and other post-employment cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostemploymentBenefitExpensePlans" xlink:to="lab_gsk_PostemploymentBenefitExpensePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostemploymentBenefitExpensePlans" xml:lang="en-US">Postemployment benefit expense plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitSchemesMember" xlink:label="loc_gsk_DefinedBenefitSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitSchemesMember" xml:lang="en-US">Defined Benefit Schemes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitSchemesMember" xml:lang="en-US">Defined benefit schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitSchemesMember" xlink:to="lab_gsk_DefinedBenefitSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitSchemesMember" xml:lang="en-US">Defined benefit schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherOverseasPensionPlansMember" xlink:label="loc_gsk_OtherOverseasPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherOverseasPensionPlansMember" xml:lang="en-US">Other Overseas Pension Plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherOverseasPensionPlansMember" xml:lang="en-US">Other overseas pension schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherOverseasPensionPlansMember" xlink:to="lab_gsk_OtherOverseasPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherOverseasPensionPlansMember" xml:lang="en-US">Other overseas pension plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedContributionPensionSchemeMember" xlink:label="loc_gsk_DefinedContributionPensionSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedContributionPensionSchemeMember" xml:lang="en-US">Defined contribution pension scheme [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedContributionPensionSchemeMember" xml:lang="en-US">Defined contribution pension scheme [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedContributionPensionSchemeMember" xlink:to="lab_gsk_DefinedContributionPensionSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedContributionPensionSchemeMember" xml:lang="en-US">Defined contribution pension scheme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xml:lang="en-US">US Defined Benefit and Defined Contribution Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xlink:to="lab_gsk_UsDefinedBenefitAndDefinedContributionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xml:lang="en-US">US defined benefit and defined contribution plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedPostRetirementPensionPlansMember" xlink:label="loc_gsk_UnfundedPostRetirementPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnfundedPostRetirementPensionPlansMember" xml:lang="en-US">Unfunded post retirement pension plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnfundedPostRetirementPensionPlansMember" xml:lang="en-US">Unfunded post retirement healthcare schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnfundedPostRetirementPensionPlansMember" xlink:to="lab_gsk_UnfundedPostRetirementPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnfundedPostRetirementPensionPlansMember" xml:lang="en-US">Unfunded post retirement pension plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FundedDefinedBenefitPensionPlansMember" xlink:label="loc_gsk_FundedDefinedBenefitPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FundedDefinedBenefitPensionPlansMember" xml:lang="en-US">Funded defined benefit pension plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FundedDefinedBenefitPensionPlansMember" xml:lang="en-US">Funded defined benefit pension plans [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FundedDefinedBenefitPensionPlansMember" xlink:to="lab_gsk_FundedDefinedBenefitPensionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FundedDefinedBenefitPensionPlansMember" xml:lang="en-US">Funded defined benefit pension plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xml:lang="en-US">UK Defined Benefit and Defined Contribution Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xlink:to="lab_gsk_UkDefinedBenefitAndDefinedContributionPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xml:lang="en-US">UK defined benefit and defined contribution plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedDefinedBenefitPensionPlanMember" xlink:label="loc_gsk_UnfundedDefinedBenefitPensionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnfundedDefinedBenefitPensionPlanMember" xml:lang="en-US">Unfunded defined benefit pension plan [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UnfundedDefinedBenefitPensionPlanMember" xml:lang="en-US">Unfunded defined benefit pension plan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnfundedDefinedBenefitPensionPlanMember" xlink:to="lab_gsk_UnfundedDefinedBenefitPensionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnfundedDefinedBenefitPensionPlanMember" xml:lang="en-US">Unfunded defined benefit pension plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xml:lang="en-US">Disclosure of Pensions and Other Post-employment Benefits [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xml:lang="en-US">Disclosure of Pensions and Other Post-employment Benefits [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xlink:to="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xml:lang="en-US">Disclosure of Pensions and Other Post-employment Benefits [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAssetsMember" xml:lang="en-US">Other assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherAssetsMember" xml:lang="en-US">Other assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsMember" xlink:to="lab_ifrs-full_OtherAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCashBalancePensionPlanMember" xlink:label="loc_gsk_UsCashBalancePensionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UsCashBalancePensionPlanMember" xml:lang="en-US">US cash balance pension plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UsCashBalancePensionPlanMember" xml:lang="en-US">US cash balance pension plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UsCashBalancePensionPlanMember" xlink:to="lab_gsk_UsCashBalancePensionPlanMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitPlansMember" xlink:label="loc_gsk_UkDefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UkDefinedBenefitPlansMember" xml:lang="en-US">UK defined benefit plans [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UkDefinedBenefitPlansMember" xlink:to="lab_gsk_UkDefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UkDefinedBenefitPlansMember" xml:lang="en-US">UK defined benefit plans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetireeHealthcarePlansMember" xlink:label="loc_gsk_RetireeHealthcarePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RetireeHealthcarePlansMember" xml:lang="en-US">Retiree healthcare plans [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RetireeHealthcarePlansMember" xml:lang="en-US">Retiree healthcare plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RetireeHealthcarePlansMember" xlink:to="lab_gsk_RetireeHealthcarePlansMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xml:lang="en-US">Wholly unfunded defined benefit plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xml:lang="en-US">Unfunded [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xml:lang="en-US">Disclosure of Pensions and Other Post-employment Benefits [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xml:lang="en-US">Disclosure of Pensions and Other Post-employment Benefits [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xlink:to="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xml:lang="en-US">Line items represent pensions and other post-employment benefits.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsIncludedInPastServiceCosts" xlink:label="loc_gsk_AugmentationCostsIncludedInPastServiceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AugmentationCostsIncludedInPastServiceCosts" xml:lang="en-US">Augmentation Costs Included In Past Service Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AugmentationCostsIncludedInPastServiceCosts" xml:lang="en-US">Augmentation costs included in past service costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AugmentationCostsIncludedInPastServiceCosts" xlink:to="lab_gsk_AugmentationCostsIncludedInPastServiceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AugmentationCostsIncludedInPastServiceCosts" xml:lang="en-US">Augmentation costs included in past service costs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsFromRestructuringProgrammes" xlink:label="loc_gsk_AugmentationCostsFromRestructuringProgrammes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AugmentationCostsFromRestructuringProgrammes" xml:lang="en-US">Augmentation Costs From Restructuring Programmes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AugmentationCostsFromRestructuringProgrammes" xml:lang="en-US">Augmentation costs arising from major restructuring programmes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AugmentationCostsFromRestructuringProgrammes" xlink:to="lab_gsk_AugmentationCostsFromRestructuringProgrammes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AugmentationCostsFromRestructuringProgrammes" xml:lang="en-US">Augmentation costs from restructuring programmes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Past service cost, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Past service cost/(credit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Past service cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Contributions to plan by employer, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Additional contributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Employer contributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Employer contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xml:lang="en-US">Estimate of contributions expected to be paid to plan for next annual reporting period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xml:lang="en-US">Employer contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:to="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" xml:lang="en-US">Actuarial assumption of expected rates of medical inflation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" xml:lang="en-US">Assumption for future medical inflation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" xlink:to="lab_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation" xml:lang="en-US">The expected rate of medical inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xlink:label="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xml:lang="en-US">Mortality Projections Model, Long-Term Improvement Parameter, Per Year, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xml:lang="en-US">Long term rate of improvement per year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xlink:to="lab_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xml:lang="en-US">Mortality projections model, long-term improvement parameter, per year, percentage.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToLiabilityMatchingAssets" xlink:label="loc_gsk_AllocationToLiabilityMatchingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AllocationToLiabilityMatchingAssets" xml:lang="en-US">Allocation To Liability Matching Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AllocationToLiabilityMatchingAssets" xml:lang="en-US">Percentage allocated to liability matching assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AllocationToLiabilityMatchingAssets" xlink:to="lab_gsk_AllocationToLiabilityMatchingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AllocationToLiabilityMatchingAssets" xml:lang="en-US">Allocation to liability matching assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Loans on structured debt amount contributed to fair value of plan assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Loans on structured debt amount contributed to fair value of plan assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xlink:to="lab_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Loans on structured debt amount contributed to fair value of plan assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Contributions to plan, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Contributions to plan, net defined benefit liability (asset)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToReturnSeekingAssets" xlink:label="loc_gsk_AllocationToReturnSeekingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AllocationToReturnSeekingAssets" xml:lang="en-US">Allocation To Return Seeking Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AllocationToReturnSeekingAssets" xml:lang="en-US">Percentage allocated to return seeking assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AllocationToReturnSeekingAssets" xlink:to="lab_gsk_AllocationToReturnSeekingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AllocationToReturnSeekingAssets" xml:lang="en-US">Allocation to return seeking assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="loc_ifrs-full_SurplusDeficitInPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SurplusDeficitInPlan" xml:lang="en-US">Surplus (deficit) in plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SurplusDeficitInPlan" xml:lang="en-US">Accrual of Future pension plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SurplusDeficitInPlan" xml:lang="en-US">Net surplus/(obligation)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SurplusDeficitInPlan" xlink:to="lab_ifrs-full_SurplusDeficitInPlan" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalValueOfTheInsuranceContract" xlink:label="loc_gsk_TotalValueOfTheInsuranceContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TotalValueOfTheInsuranceContract" xml:lang="en-US">Total Value of the Insurance Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TotalValueOfTheInsuranceContract" xml:lang="en-US">Total value of the insurance contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TotalValueOfTheInsuranceContract" xlink:to="lab_gsk_TotalValueOfTheInsuranceContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TotalValueOfTheInsuranceContract" xml:lang="en-US">Total value of the insurance contract.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationAtPastServiceCost" xlink:label="loc_gsk_DefinedBenefitObligationAtPastServiceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitObligationAtPastServiceCost" xml:lang="en-US">Defined benefit obligation at past service cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_DefinedBenefitObligationAtPastServiceCost" xml:lang="en-US">Defined benefit obligation, at past service cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitObligationAtPastServiceCost" xlink:to="lab_gsk_DefinedBenefitObligationAtPastServiceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitObligationAtPastServiceCost" xml:lang="en-US">Defined benefit obligation at past service cost.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xlink:label="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xml:lang="en-US">Fair Value Of Investments In Assets Where Price Quotations Published</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xml:lang="en-US">Fair value of investments in fund assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xlink:to="lab_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xml:lang="en-US">Fair value of investments in Fund Assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Payments from plan, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Benefits paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Maximum Contributions To Plan In Net Defined Benefit Liability Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Maximum contributions to plan in net defined benefit liability asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xlink:to="lab_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Maximum contributions to plan in net defined benefit liability asset.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xlink:label="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xml:lang="en-US">Percentage Of Ownership Interest Represented By Transfer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xml:lang="en-US">Percentage of ownership interest represented by transfer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xlink:to="lab_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xml:lang="en-US">Percentage of owneship interest represented by transfer.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xlink:label="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xml:lang="en-US">Percentage Of Owneship Interest Held By The Transferee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xml:lang="en-US">Percentage of ownership interest held by the transferee company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xlink:to="lab_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xml:lang="en-US">Percentage of owneship interest held by the transferee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Cash and cash equivalents, amount contributed to fair value of plan assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Cash And cash equivalents contributed to fair value of plan assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingAmountDueToBeContributed" xlink:label="loc_gsk_RemainingAmountDueToBeContributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemainingAmountDueToBeContributed" xml:lang="en-US">Remaining Amount Due To Be Contributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RemainingAmountDueToBeContributed" xml:lang="en-US">Remaining amount due to be contributed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemainingAmountDueToBeContributed" xlink:to="lab_gsk_RemainingAmountDueToBeContributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemainingAmountDueToBeContributed" xml:lang="en-US">Remaining amount due to be contributed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VoluntaryCashContributionsMadeToThePlan" xlink:label="loc_gsk_VoluntaryCashContributionsMadeToThePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VoluntaryCashContributionsMadeToThePlan" xml:lang="en-US">Voluntary Cash Contributions Made To The Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VoluntaryCashContributionsMadeToThePlan" xml:lang="en-US">Voluntary Cash Contributions Made To The Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VoluntaryCashContributionsMadeToThePlan" xlink:to="lab_gsk_VoluntaryCashContributionsMadeToThePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VoluntaryCashContributionsMadeToThePlan" xml:lang="en-US">Voluntary cash contributions made to the plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionDueToBePaid" xlink:label="loc_gsk_AdditionalContributionDueToBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalContributionDueToBePaid" xml:lang="en-US">Additional Contribution Due To Be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionalContributionDueToBePaid" xml:lang="en-US">Additional contributions due to be paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalContributionDueToBePaid" xlink:to="lab_gsk_AdditionalContributionDueToBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalContributionDueToBePaid" xml:lang="en-US">Additional contribution due to be paid.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xlink:label="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xml:lang="en-US">Subsidiaries Shares Transferred To Fund Pension Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xml:lang="en-US">Subsidiary shares transferred to fund pension schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xlink:to="lab_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xml:lang="en-US">Subsidiaries shares transferred to fund pension schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumProceedsThresholdAmount" xlink:label="loc_gsk_MaximumProceedsThresholdAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MaximumProceedsThresholdAmount" xml:lang="en-US">Maximum Proceeds Threshold Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MaximumProceedsThresholdAmount" xml:lang="en-US">Proceeds threshold to be received by partnerships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MaximumProceedsThresholdAmount" xlink:to="lab_gsk_MaximumProceedsThresholdAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MaximumProceedsThresholdAmount" xml:lang="en-US">Maximum proceeds threshold amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xlink:label="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xml:lang="en-US">Subsidiary Shares Transferred Into Limited Partnerships</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xml:lang="en-US">Subsidiary shares transferred into Limited Partnerships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xlink:to="lab_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xml:lang="en-US">Subsidiary shares transferred into limited partnerships.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandThirtyOneAndThereafterMember" xlink:label="loc_gsk_TwoThousandThirtyOneAndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandThirtyOneAndThereafterMember" xml:lang="en-US">Two Thousand Thirty One And Thereafter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandThirtyOneAndThereafterMember" xml:lang="en-US">2031 and thereafter [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandThirtyOneAndThereafterMember" xlink:to="lab_gsk_TwoThousandThirtyOneAndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandThirtyOneAndThereafterMember" xml:lang="en-US">Two thousand thirty one and thereafter.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeAxis" xlink:label="loc_gsk_AgreementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AgreementTypeAxis" xml:lang="en-US">Agreement Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AgreementTypeAxis" xml:lang="en-US">Agreement Type [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AgreementTypeAxis" xlink:to="lab_gsk_AgreementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AgreementTypeAxis" xml:lang="en-US">Agreement type.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeMember" xlink:label="loc_gsk_AgreementTypeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AgreementTypeMember" xml:lang="en-US">Agreement Type [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AgreementTypeMember" xml:lang="en-US">Agreement Type [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AgreementTypeMember" xlink:to="lab_gsk_AgreementTypeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AgreementTypeMember" xml:lang="en-US">Agreement type.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SlpPartnershipAgreementMember" xlink:label="loc_gsk_SlpPartnershipAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SlpPartnershipAgreementMember" xml:lang="en-US">SLP Partnership Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SlpPartnershipAgreementMember" xml:lang="en-US">SLP Partnership Agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SlpPartnershipAgreementMember" xlink:to="lab_gsk_SlpPartnershipAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SlpPartnershipAgreementMember" xml:lang="en-US">SLP partnership agreement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKLPLtdMember" xlink:label="loc_gsk_GSKLPLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GSKLPLtdMember" xml:lang="en-US">G S K L P Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GSKLPLtdMember" xml:lang="en-US">GSK LP Ltd [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GSKLPLtdMember" xlink:to="lab_gsk_GSKLPLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GSKLPLtdMember" xml:lang="en-US">GSK LP Ltd.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xml:lang="en-US">Glaxo Smith Kline Consumer Healthcare Holdings Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeAxis" xlink:label="loc_gsk_SchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SchemeAxis" xml:lang="en-US">Scheme [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SchemeAxis" xlink:to="lab_gsk_SchemeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SchemeAxis" xml:lang="en-US">Scheme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeMember" xlink:label="loc_gsk_SchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SchemeMember" xml:lang="en-US">Scheme [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SchemeMember" xlink:to="lab_gsk_SchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SchemeMember" xml:lang="en-US">Scheme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeAxis" xlink:label="loc_gsk_TransfereeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransfereeAxis" xml:lang="en-US">Transferee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransfereeAxis" xlink:to="lab_gsk_TransfereeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransfereeAxis" xml:lang="en-US">Transferee.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeMember" xlink:label="loc_gsk_TransfereeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransfereeMember" xml:lang="en-US">Transferee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransfereeMember" xlink:to="lab_gsk_TransfereeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransfereeMember" xml:lang="en-US">Transferee.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SLPPartneshipsMember" xlink:label="loc_gsk_SLPPartneshipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SLPPartneshipsMember" xml:lang="en-US">SLP Partneships [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SLPPartneshipsMember" xlink:to="lab_gsk_SLPPartneshipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SLPPartneshipsMember" xml:lang="en-US">SLP partneships.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockAxis" xlink:label="loc_gsk_ClassOfCommonStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ClassOfCommonStockAxis" xml:lang="en-US">Class Of Common Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ClassOfCommonStockAxis" xlink:to="lab_gsk_ClassOfCommonStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ClassOfCommonStockAxis" xml:lang="en-US">Class of common stock.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockMember" xlink:label="loc_gsk_ClassOfCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ClassOfCommonStockMember" xml:lang="en-US">Class Of Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ClassOfCommonStockMember" xlink:to="lab_gsk_ClassOfCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ClassOfCommonStockMember" xml:lang="en-US">Class of common stock.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonMember" xlink:label="loc_gsk_HaleonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HaleonMember" xml:lang="en-US">Haleon [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HaleonMember" xlink:to="lab_gsk_HaleonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HaleonMember" xml:lang="en-US">Haleon.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentPeriodMember" xlink:label="loc_gsk_CurrentPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentPeriodMember" xml:lang="en-US">Current Period [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrentPeriodMember" xml:lang="en-US">Current. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentPeriodMember" xlink:to="lab_gsk_CurrentPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentPeriodMember" xml:lang="en-US">Current period.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProjectedPeriodMember" xlink:label="loc_gsk_ProjectedPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProjectedPeriodMember" xml:lang="en-US">Projected Period [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProjectedPeriodMember" xml:lang="en-US">Projected at 2042 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProjectedPeriodMember" xlink:to="lab_gsk_ProjectedPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProjectedPeriodMember" xml:lang="en-US">Projected period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xml:lang="en-US">Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FemalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FemalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Female Pensioners Average Life Expectancy At Sixty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FemalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Female Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty" xlink:to="lab_gsk_FemalePensionersAverageLifeExpectancyAtSixty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FemalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Female pensioners average life expectancy at sixty.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Male Pensioners Average Life Expectancy At Sixty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Male Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty" xlink:to="lab_gsk_MalePensionersAverageLifeExpectancyAtSixty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MalePensionersAverageLifeExpectancyAtSixty" xml:lang="en-US">Male pensioners average life expectancy at sixty.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xml:lang="en-US">Disclosure of defined benefit plan actuarial assumptions [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xml:lang="en-US">Disclosure of defined benefit plan actuarial assumptions [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xml:lang="en-US">Disclosure of defined benefit plan actuarial assumptions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xml:lang="en-US">Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xml:lang="en-US">Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xml:lang="en-US">Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xml:lang="en-US">Expected pension increases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfCashBalanceCreditRate" xlink:label="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfCashBalanceCreditRate" xml:lang="en-US">Actuarial Assumption Of Cash Balance Credit Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfCashBalanceCreditRate" xml:lang="en-US">Cash balance credit/conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate" xlink:to="lab_gsk_ActuarialAssumptionOfCashBalanceCreditRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ActuarialAssumptionOfCashBalanceCreditRate" xml:lang="en-US">Actuarial assumption of cash balance credit rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xml:lang="en-US">Actuarial assumption of discount rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xml:lang="en-US">Rate of increase of future earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xml:lang="en-US">Actuarial assumption of expected rates of inflation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xml:lang="en-US">Inflation rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xml:lang="en-US">Disclosure Of Defined Benefit Pension And Post Retirement [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xml:lang="en-US">Disclosure Of Defined Benefit Pension And Post Retirement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xml:lang="en-US">Disclosure of defined benefit pension and post retirement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xml:lang="en-US">Disclosure Of Defined Benefit Pension And Post Retirement [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xml:lang="en-US">Disclosure Of Defined Benefit Pension And Post Retirement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:to="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xml:lang="en-US">Disclosure of defined benefit pension and post retirement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Current service cost, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Current service cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Service cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xml:lang="en-US">Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xml:lang="en-US">Remeasurement gains/(losses) recorded in the statement of comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xml:lang="en-US">Remeasurement losses\gains on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gains (losses) arising from settlements, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gains from settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Settlements and curtailments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Settlements and curtailments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Interest expense (income), net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Net interest (income)/cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Interest cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Expenses Net Defined Benefit Liability Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:to="lab_gsk_ExpensesNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Expenses net defined benefit liability asset.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xlink:label="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xml:lang="en-US">Net Operating Charge for Pensions and Other Post Retirement Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xml:lang="en-US">Net operating cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xlink:to="lab_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xml:lang="en-US">Net operating charge for pensions and other post retirement benefits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xml:lang="en-US">Net defined benefit liability (asset) [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xml:lang="en-US">Net defined benefit liability (asset) [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xml:lang="en-US">Net defined benefit liability (asset) [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xml:lang="en-US">Net defined benefit liability (asset) [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Continuing Operations Defined Benefit Pension And Postretirement Healthcare Scheme [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:to="lab_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xml:lang="en-US">Continuing operations defined benefit pension and post-retirement healthcare scheme. [member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xml:lang="en-US">Non-current net defined benefit liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xml:lang="en-US">Post-retirement benefits/Pension schemes in deficit and surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherNoncurrentAssetsMember" xlink:to="lab_gsk_OtherNoncurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupMember" xlink:label="loc_gsk_GroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GroupMember" xml:lang="en-US">Group [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GroupMember" xml:lang="en-US">Group [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GroupMember" xlink:to="lab_gsk_GroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GroupMember" xml:lang="en-US">Group.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Corporate Bonds Contributed To Fair Value Of Plan Assets Listed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Corporate bonds, listed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xlink:to="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Corporate bonds contributed to fair value of plan assets listed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Defined benefit obligation, at present value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Present value of scheme obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Obligations beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Obligations ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Defined benefit obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Defined benefit pension obligation analysed by membership category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xml:lang="en-US">Post-retirement benefit obligation analysed by membership category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:to="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MultiAssetFunds" xlink:label="loc_gsk_MultiAssetFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MultiAssetFunds" xml:lang="en-US">Multi asset funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MultiAssetFunds" xml:lang="en-US">Multi-asset funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MultiAssetFunds" xlink:to="lab_gsk_MultiAssetFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MultiAssetFunds" xml:lang="en-US">Multi asset funds</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xml:lang="en-US">Plan assets, at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xml:lang="en-US">Fair value of assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xml:lang="en-US">Assets, ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xml:lang="en-US">Assets, beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue" xlink:to="lab_ifrs-full_PlanAssetsAtFairValue" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Insurance contracts amount contributed to fair value of plan assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Insurance contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Insurance contracts amount contributed to fair value of plan assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Equity Instruments Amount Contributed To Fair Value Of Plan Assets Unlisted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Equity, unlisted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:to="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Equity instruments amount contributed to fair value of plan assets unlisted.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Equity Instruments Amount contributed To Fair Value Of Plan Assets Listed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Equities, listed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xlink:to="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Equity instruments amount contributed to fair value of plan assets listed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Property Amount Contributed To Fair Value Of Plan Assets Unlisted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Property, unlisted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:to="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Property amount contributed to fair value of plan assets unlisted.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Corporate Bonds Contributed To Fair Value Of Plan Assets Unlisted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Corporate bonds, unlisted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xlink:to="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xml:lang="en-US">Corporate bonds contributed to fair value of plan assets unlisted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Return on plan assets excluding interest income or expense, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Actual return on plan assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Return on plan assets, excluding amounts included in interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Property Amount Contributed To Fair Value Of Plan Assets Listed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Property, listed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xlink:to="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Property amount contributed to fair value of plan assets listed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Government Bonds Contributed To Fair Value Of Plan Assets Listed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Government bonds, listed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xlink:to="lab_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xml:lang="en-US">Government bonds contributed to fair value of plan assets listed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAssetCeilingRestrictions" xlink:label="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitPensionAssetCeilingRestrictions" xml:lang="en-US">Defined Benefit Pension Asset Ceiling Restrictions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitPensionAssetCeilingRestrictions" xml:lang="en-US">Asset Ceiling Restrictions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions" xlink:to="lab_gsk_DefinedBenefitPensionAssetCeilingRestrictions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitPensionAssetCeilingRestrictions" xml:lang="en-US">Defined benefit pension asset ceiling restrictions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Other Liabilities Assets Amount Contributed To Fair Value Of Plan Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Other (liabilities)/assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xlink:to="lab_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xml:lang="en-US">Other liabilities assets amount contributed to fair value of plan assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember" xlink:label="loc_ifrs-full_PlanAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PlanAssetsMember" xml:lang="en-US">Plan assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PlanAssetsMember" xml:lang="en-US">Plan Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xml:lang="en-US">Present value of defined benefit obligation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xml:lang="en-US">Present value of defined benefit obligation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:to="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Scheme participants' contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Exchange adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Remeasurement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xml:lang="en-US">Increase (decrease) through business combinations and disposals, reimbursement rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Transfer To Assets Held For Sale Distribution Net Defined Benefit Liability Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xlink:to="lab_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Transfer to assets held for sale/distribution net defined benefit liability (asset).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xml:lang="en-US">Disclosure of defined benefit plans [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xml:lang="en-US">Disclosure of defined benefit plans [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xml:lang="en-US">Disclosure of defined benefit plans [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xml:lang="en-US">Disclosure of defined benefit plans [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xml:lang="en-US">Wholly or partly funded defined benefit plans [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xml:lang="en-US">Funded [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xml:lang="en-US">Net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xml:lang="en-US">Ending of net defined benefit liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xml:lang="en-US">Beginning of net defined benefit liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" xml:lang="en-US">Remeasurements:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">(Loss)/gain from change in financial assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gain/(loss) from change in financial assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Actuarial gains (losses) arising from experience adjustments, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Experience gains/(losses)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Experience gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Adjustments In Expenses Net Defined Benefit Liability Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" xlink:to="lab_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Adjustments in expenses net defined benefit liability asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gain from change in demographic assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Gain from change in demographic assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Increase (decrease) through business combinations and disposals, net defined benefit liability (asset)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xml:lang="en-US">Categories of financial liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xml:lang="en-US">Categories of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xml:lang="en-US">Financial liabilities, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xml:lang="en-US">Financial liabilities, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationDeferredMember" xlink:label="loc_gsk_DefinedBenefitObligationDeferredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitObligationDeferredMember" xml:lang="en-US">Defined Benefit Obligation Deferred [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitObligationDeferredMember" xml:lang="en-US">Deferred [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitObligationDeferredMember" xlink:to="lab_gsk_DefinedBenefitObligationDeferredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitObligationDeferredMember" xml:lang="en-US">Defined benefit obligation deferred.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationRetiredMember" xlink:label="loc_gsk_DefinedBenefitObligationRetiredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitObligationRetiredMember" xml:lang="en-US">Defined Benefit Obligation Retired [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitObligationRetiredMember" xml:lang="en-US">Retired [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitObligationRetiredMember" xlink:to="lab_gsk_DefinedBenefitObligationRetiredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitObligationRetiredMember" xml:lang="en-US">Defined benefit obligation retired.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationActiveMember" xlink:label="loc_gsk_DefinedBenefitObligationActiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DefinedBenefitObligationActiveMember" xml:lang="en-US">Defined Benefit Obligation Active [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DefinedBenefitObligationActiveMember" xml:lang="en-US">Active [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DefinedBenefitObligationActiveMember" xlink:to="lab_gsk_DefinedBenefitObligationActiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DefinedBenefitObligationActiveMember" xml:lang="en-US">Defined benefit obligation active.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" xlink:to="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" xml:lang="en-US">Disclosure of information about maturity profile of defined benefit obligation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xlink:to="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xml:lang="en-US">Disclosure of information about maturity profile of defined benefit obligation</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostRetirementBenefitMember" xlink:label="loc_gsk_PostRetirementBenefitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PostRetirementBenefitMember" xml:lang="en-US">Post Retirement Benefit [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PostRetirementBenefitMember" xml:lang="en-US">Post retirement benefit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PostRetirementBenefitMember" xlink:to="lab_gsk_PostRetirementBenefitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PostRetirementBenefitMember" xml:lang="en-US">Post retirement benefit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xlink:to="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xml:lang="en-US">Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageDurationOfDefinedBenefitObligations" xlink:label="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageDurationOfDefinedBenefitObligations" xml:lang="en-US">Weighted average duration of defined benefit obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageDurationOfDefinedBenefitObligations" xml:lang="en-US">Weighted average duration of the defined benefit obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations" xlink:to="lab_gsk_WeightedAverageDurationOfDefinedBenefitObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageDurationOfDefinedBenefitObligations" xml:lang="en-US">Weighted average duration of defined benefit obligations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreasePensionObligations" xlink:label="loc_gsk_IncreaseDecreasePensionObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreasePensionObligations" xml:lang="en-US">Increase Decrease Pension Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreasePensionObligations" xml:lang="en-US">(Decrease)/Increase in pension obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreasePensionObligations" xlink:to="lab_gsk_IncreaseDecreasePensionObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreasePensionObligations" xml:lang="en-US">Increase Decrease Pension Obligations</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xlink:label="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xml:lang="en-US">Increase Decrease in post-retirement benefits obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xml:lang="en-US">(Decrease)/Increase in post-retirement benefits obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xlink:to="lab_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xml:lang="en-US">Increase Decrease in post-retirement benefits obligation</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xlink:label="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xml:lang="en-US">Increase Decrease in annual post-retirement benefits cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xml:lang="en-US">Increase/(decrease) in annual post-retirement benefits cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xlink:to="lab_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xml:lang="en-US">Increase Decrease in annual post-retirement benefits cost</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xlink:label="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xml:lang="en-US">Actuarial Assumption Of Life Expectancy Rates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xml:lang="en-US">Actuarial assumptions of 1 year increase in life expectancy [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xlink:to="lab_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xml:lang="en-US">Actuarial assumption of life expectancy rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xlink:label="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xml:lang="en-US">Actuarial assumption for future healthcare inflation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xml:lang="en-US">Actuarial assumptions of 1% increase of rate of future healthcare inflation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xlink:to="lab_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xml:lang="en-US">Actuarial assumption for future healthcare inflation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xml:lang="en-US">Actuarial assumption of decrease in discount rates one [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xml:lang="en-US">Actuarial assumptions of 0.25% decrease in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xlink:to="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xml:lang="en-US">Actuarial assumption of increase in discount rates Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xml:lang="en-US">Actuarial assumptions of 0.75% increase in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xlink:to="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xml:lang="en-US">Actuarial Assumption Of Decrease In Expected Rates Of Inflation One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xml:lang="en-US">Actuarial assumptions of 0.25% decrease in inflation rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xlink:to="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xml:lang="en-US">Actuarial assumption of decrease in discount rates Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xml:lang="en-US">Actuarial assumptions of 0.75% decrease in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xlink:to="lab_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xml:lang="en-US">Actuarial Assumption Of Increase In Expected Rates Of Inflation One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xml:lang="en-US">Actuarial assumptions of 0.25% increase in inflation rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xlink:to="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xml:lang="en-US">Actuarial Assumption Of Increase In Expected Rates Of Inflation Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xml:lang="en-US">Actuarial assumptions of 0.75% decrease in inflation rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xlink:to="lab_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xml:lang="en-US">Actuarial Assumption Of Decrease In Expected Rates Of Inflation Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xml:lang="en-US">Actuarial assumptions of 0.75% increase in inflation rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xlink:to="lab_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xml:lang="en-US">Actuarial Assumption Of Increase In Discount Rates One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xml:lang="en-US">Actuarial assumptions of 0.25% increase in discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xlink:to="lab_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xml:lang="en-US">Disclosure of other provisions [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xml:lang="en-US">Disclosure of other provisions [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xml:lang="en-US">Disclosure of other provisions [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfIndividual1Axis" xlink:label="loc_gsk_TitleOfIndividual1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TitleOfIndividual1Axis" xml:lang="en-US">Title of individual 1 [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TitleOfIndividual1Axis" xml:lang="en-US">Title of individual 1 [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TitleOfIndividual1Axis" xlink:to="lab_gsk_TitleOfIndividual1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TitleOfIndividual1Axis" xml:lang="en-US">Title of individual 1.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentGrantsDomain" xlink:label="loc_gsk_GovernmentGrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GovernmentGrantsDomain" xml:lang="en-US">Government Grants [domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GovernmentGrantsDomain" xml:lang="en-US">Government Grants [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GovernmentGrantsDomain" xlink:to="lab_gsk_GovernmentGrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GovernmentGrantsDomain" xml:lang="en-US">Government grants domain.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisabledEmployeesMember" xlink:label="loc_gsk_DisabledEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisabledEmployeesMember" xml:lang="en-US">Disabled Employees [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisabledEmployeesMember" xml:lang="en-US">Disabled employees [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisabledEmployeesMember" xlink:to="lab_gsk_DisabledEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisabledEmployeesMember" xml:lang="en-US">Disabled employees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xml:lang="en-US">Classes of other provisions [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xml:lang="en-US">Classes of other provisions [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherProvisionsMember" xml:lang="en-US">Other provisions [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherProvisionsMember" xml:lang="en-US">Other provisions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalAndOtherDisputesMember" xlink:label="loc_gsk_LegalAndOtherDisputesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LegalAndOtherDisputesMember" xml:lang="en-US">Legal And Other Disputes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LegalAndOtherDisputesMember" xml:lang="en-US">Legal and other disputes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LegalAndOtherDisputesMember" xlink:to="lab_gsk_LegalAndOtherDisputesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LegalAndOtherDisputesMember" xml:lang="en-US">Legal and other disputes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProvisionsMember" xlink:label="loc_gsk_MajorRestructuringProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MajorRestructuringProvisionsMember" xml:lang="en-US">Major Restructuring Provisions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MajorRestructuringProvisionsMember" xlink:to="lab_gsk_MajorRestructuringProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MajorRestructuringProvisionsMember" xml:lang="en-US">Major Restructuring Provisions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xml:lang="en-US">Disclosure of other provisions [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xml:lang="en-US">Disclosure of other provisions [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xlink:label="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xml:lang="en-US">Legal Proceedings And Other Disputes Provision Estimated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xml:lang="en-US">Legal proceedings and other disputes provision estimated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xlink:to="lab_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xml:lang="en-US">Legal proceedings and other disputes provision estimated.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xlink:label="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xml:lang="en-US">Additional provisions net of reversals and recoveries other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xml:lang="en-US">Charges on other provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xlink:to="lab_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xml:lang="en-US">Additional provisions net of reversals and recoveries other provisions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xml:lang="en-US">Increase (decrease) through change in discount rate, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xml:lang="en-US">Discount on the provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionObligationProvisions" xlink:label="loc_gsk_PensionObligationProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PensionObligationProvisions" xml:lang="en-US">Pension Obligation Provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PensionObligationProvisions" xml:lang="en-US">Pension augmentations arising from staff redundancies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PensionObligationProvisions" xlink:to="lab_gsk_PensionObligationProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PensionObligationProvisions" xml:lang="en-US">Pension obligation provisions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="loc_ifrs-full_ShorttermLegalProceedingsProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermLegalProceedingsProvision" xml:lang="en-US">Current legal proceedings provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermLegalProceedingsProvision" xml:lang="en-US">Short term legal proceedings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermLegalProceedingsProvision" xlink:to="lab_ifrs-full_ShorttermLegalProceedingsProvision" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProvisionsForEmployeeBenefits" xml:lang="en-US">Provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProvisionsForEmployeeBenefits" xml:lang="en-US">Provision for employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_ProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeRelatedProvisionsMember" xlink:label="loc_gsk_EmployeeRelatedProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EmployeeRelatedProvisionsMember" xml:lang="en-US">Employee Related Provisions [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EmployeeRelatedProvisionsMember" xml:lang="en-US">Employee Related Provisions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EmployeeRelatedProvisionsMember" xlink:to="lab_gsk_EmployeeRelatedProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EmployeeRelatedProvisionsMember" xml:lang="en-US">Employee related provisions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherProvisionMember" xlink:label="loc_gsk_OtherProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherProvisionMember" xml:lang="en-US">Other Provision [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherProvisionMember" xml:lang="en-US">Other Provision [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherProvisionMember" xlink:to="lab_gsk_OtherProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherProvisionMember" xml:lang="en-US">Other provision.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="loc_ifrs-full_RestructuringProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RestructuringProvisionMember" xml:lang="en-US">Restructuring provision [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RestructuringProvisionMember" xml:lang="en-US">Major Restructuring Programmes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestructuringProvisionMember" xlink:to="lab_ifrs-full_RestructuringProvisionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xml:lang="en-US">Additional provisions, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xml:lang="en-US">Charge for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="lab_ifrs-full_AdditionalProvisionsOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xml:lang="en-US">Increase through adjustments arising from passage of time, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xml:lang="en-US">Unwinding of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xml:lang="en-US">Reclassifications and other movements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherProvisions" xml:lang="en-US">Other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_OtherProvisions" xml:lang="en-US">Other provisions, beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherProvisions" xml:lang="en-US">Other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_OtherProvisions" xml:lang="en-US">Other provisions, ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_OtherProvisions" xml:lang="en-US">Other provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="lab_ifrs-full_OtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xml:lang="en-US">Acquisitions through business combinations, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xml:lang="en-US">Additions through business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xml:lang="en-US">Provision used, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xml:lang="en-US">Utilised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToPensionObligations" xlink:label="loc_gsk_TransferToPensionObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransferToPensionObligations" xml:lang="en-US">Transfer To Pension Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_TransferToPensionObligations" xml:lang="en-US">Transfer to Pension obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransferToPensionObligations" xlink:to="lab_gsk_TransferToPensionObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransferToPensionObligations" xml:lang="en-US">Transfer to pension obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xml:lang="en-US">Unused provision reversed, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xml:lang="en-US">Reversed unused</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:to="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistribution" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistribution" xml:lang="en-US">Transfer to Assets Held for Sale Distribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistribution" xml:lang="en-US">Transfer to assets held for sale/distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransferToAssetsHeldForSaleDistribution" xlink:to="lab_gsk_TransferToAssetsHeldForSaleDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransferToAssetsHeldForSaleDistribution" xml:lang="en-US">Transfer to assets held for sale/distribution.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xml:lang="en-US">Disclosure Of Fair Value Of Contingent Consideration [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xlink:to="lab_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xml:lang="en-US">Disclosure of fair value of contingent consideration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xml:lang="en-US">Disclosure of contingent liabilities in business combination [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xml:lang="en-US">Disclosure of contingent liabilities in business combination [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xml:lang="en-US">Disclosure of contingent liabilities in business combination [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xml:lang="en-US">Disclosure of contingent liabilities in business combination [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Remeasurement through income statement increase (decrease) in contingent liabilities recognised in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Remeasurement through income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Remeasurement through income statement Increase (decrease) in contingent liabilities recognised in business combination</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xml:lang="en-US">Adjustments For Decrease Increase In Contingent Consideration Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xml:lang="en-US">Cash payments: operating cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xml:lang="en-US">Contingent consideration paid (see Note 0)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xlink:to="lab_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xml:lang="en-US">Adjustments for decrease increase in contingent consideration paid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">New liabilities, contingent liabilities recognised in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Initial recognition from business combinations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">New liabilities contingent liabilities recognized in business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPaid" xlink:label="loc_gsk_ContingentConsiderationPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContingentConsiderationPaid" xml:lang="en-US">Contingent consideration paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_ContingentConsiderationPaid" xml:lang="en-US">Cash payments: investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContingentConsiderationPaid" xlink:to="lab_gsk_ContingentConsiderationPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContingentConsiderationPaid" xml:lang="en-US">Contingent consideration paid.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Exchange Movement Through Reserves Contingent Liabilities Recognised In Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Exchange movement through reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xml:lang="en-US">Exchange movement through reserves contingent liabilities recognised in business combination.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBusinessMember" xlink:label="loc_gsk_OtherBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherBusinessMember" xml:lang="en-US">Other business [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherBusinessMember" xml:lang="en-US">Other [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherBusinessMember" xlink:to="lab_gsk_OtherBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherBusinessMember" xml:lang="en-US">Other business.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AffinivaxMember" xml:lang="en-US">Affinivax [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AffinivaxMember" xml:lang="en-US">Affinivax [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AffinivaxMember" xlink:to="lab_gsk_AffinivaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AffinivaxMember" xml:lang="en-US">Affinivax [Member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" xlink:to="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [abstract].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xlink:to="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xml:lang="en-US">Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesMember" xlink:label="loc_gsk_NovartisVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NovartisVaccinesMember" xml:lang="en-US">Novartis Vaccines [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NovartisVaccinesMember" xml:lang="en-US">Novartis vaccines [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NovartisVaccinesMember" xlink:to="lab_gsk_NovartisVaccinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NovartisVaccinesMember" xml:lang="en-US">Novartis vaccines.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">Other Risk Ten Percentage Increase In Sales Forecasts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">10% increase in sales forecasts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" xlink:to="lab_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">Other risk ten percentage increase in sales forecasts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">Other Risk Fifteen Percentage Increase In Sales Forecasts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">15% increase in sales forecasts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xlink:to="lab_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xml:lang="en-US">Other risk fifteen percentage increase in sales forecasts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xml:lang="en-US">Other Risk One Percentage Decrease In Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xml:lang="en-US">1% decrease in discount rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xlink:to="lab_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xml:lang="en-US">Other risk one percentage decrease in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xml:lang="en-US">Other Risk One Point Five Percentage Increase In Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xml:lang="en-US">1.5% increase in discount rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xlink:to="lab_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xml:lang="en-US">Other risk one point two five percentage increase in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">Other Risk Ten Percentage Decrease In Sales Forecasts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">10% decrease in sales forecasts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" xlink:to="lab_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">Other risk ten percentage decrease in sales forecasts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">Other Risk Fifteen Percentage Decrease In Sales Forecasts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">15% decrease in sales forecasts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xlink:to="lab_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xml:lang="en-US">Other risk fifteen percentage decrease in sales forecasts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xml:lang="en-US">Other Risk One Percentage Increase In Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xml:lang="en-US">1% increase in discount rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xlink:to="lab_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xml:lang="en-US">Other risk one percentage increase in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xml:lang="en-US">Other Risk One Point Five Percentage Decrease In Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xml:lang="en-US">1.5% decrease in discount rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xlink:to="lab_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xml:lang="en-US">Other risk one point five percentage decrease in discount rate.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xlink:label="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xml:lang="en-US">Increase Decrease Through Change In Probability Of Milestones Success Contingent Liabilities Recognised In Business Combination [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xml:lang="en-US">Disclosure of sensitivity of key model input to measure contingent consideration [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xlink:to="lab_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xml:lang="en-US">Increase decrease through change in probability of milestones success contingent liabilities recognised in business combination.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfEuro" xlink:label="loc_gsk_AppreciationOfEuro" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AppreciationOfEuro" xml:lang="en-US">Appreciation Of Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AppreciationOfEuro" xml:lang="en-US">Appreciation of Euro</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AppreciationOfEuro" xlink:to="lab_gsk_AppreciationOfEuro" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AppreciationOfEuro" xml:lang="en-US">Appreciation of euro.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfUSDollar" xlink:label="loc_gsk_AppreciationOfUSDollar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AppreciationOfUSDollar" xml:lang="en-US">Appreciation Of US Dollar</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AppreciationOfUSDollar" xml:lang="en-US">Appreciation of US Dollar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AppreciationOfUSDollar" xlink:to="lab_gsk_AppreciationOfUSDollar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AppreciationOfUSDollar" xml:lang="en-US">Appreciation of US dollar.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">Increase In Probability Of Milestone Success</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">10% increase in probability of milestone success</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess" xlink:to="lab_gsk_IncreaseInProbabilityOfMilestoneSuccess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">Increase in probability of milestone success.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">Decrease In Probability Of Milestone Success</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">10% decrease in probability of milestone success</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess" xlink:to="lab_gsk_DecreaseInProbabilityOfMilestoneSuccess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseInProbabilityOfMilestoneSuccess" xml:lang="en-US">decrease in probability of milestone success.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInSalesForecastAmount" xlink:label="loc_gsk_IncreaseInSalesForecastAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInSalesForecastAmount" xml:lang="en-US">Increase In Sales Forecast Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseInSalesForecastAmount" xml:lang="en-US">Increase in sales forecasts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInSalesForecastAmount" xlink:to="lab_gsk_IncreaseInSalesForecastAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInSalesForecastAmount" xml:lang="en-US">Increase in sales forecast amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInDiscountRateAmount" xlink:label="loc_gsk_IncreaseInDiscountRateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseInDiscountRateAmount" xml:lang="en-US">Increase In Discount Rate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseInDiscountRateAmount" xml:lang="en-US">Increase in discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseInDiscountRateAmount" xlink:to="lab_gsk_IncreaseInDiscountRateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseInDiscountRateAmount" xml:lang="en-US">Increase in discount rate amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInSalesForecastAmount" xlink:label="loc_gsk_DecreaseInSalesForecastAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseInSalesForecastAmount" xml:lang="en-US">Decrease In Sales Forecast Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseInSalesForecastAmount" xml:lang="en-US">Decrease in sales forecasts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseInSalesForecastAmount" xlink:to="lab_gsk_DecreaseInSalesForecastAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseInSalesForecastAmount" xml:lang="en-US">Decrease in sales forecast amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInDiscountRateAmount" xlink:label="loc_gsk_DecreaseInDiscountRateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseInDiscountRateAmount" xml:lang="en-US">Decrease In Discount Rate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseInDiscountRateAmount" xml:lang="en-US">Decrease in discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseInDiscountRateAmount" xlink:to="lab_gsk_DecreaseInDiscountRateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseInDiscountRateAmount" xml:lang="en-US">Decrease in discount rate amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfEuro" xlink:label="loc_gsk_DepreciationOfEuro" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DepreciationOfEuro" xml:lang="en-US">Depreciation Of Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DepreciationOfEuro" xml:lang="en-US">Depreciation of Euro</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DepreciationOfEuro" xlink:to="lab_gsk_DepreciationOfEuro" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DepreciationOfEuro" xml:lang="en-US">Depreciation of euro.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfUSDollar" xlink:label="loc_gsk_DepreciationOfUSDollar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DepreciationOfUSDollar" xml:lang="en-US">Depreciation Of US Dollar</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DepreciationOfUSDollar" xml:lang="en-US">Depreciation of US Dollar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DepreciationOfUSDollar" xlink:to="lab_gsk_DepreciationOfUSDollar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DepreciationOfUSDollar" xml:lang="en-US">Depreciation of US dollar.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationTable" xml:lang="en-US">Disclosure Of Fair Value Of Contingent Consideration [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationTable" xml:lang="en-US">Disclosure Of Fair Value Of Contingent Consideration [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable" xlink:to="lab_gsk_DisclosureOfFairValueOfContingentConsiderationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationTable" xml:lang="en-US">Disclosure of fair value of contingent consideration.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xml:lang="en-US">Disclosure of fair value of contingent consideration [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xml:lang="en-US">Disclosure of fair value of contingent consideration [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xlink:to="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xml:lang="en-US">Disclosure of fair value of contingent consideration.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPayableDiscountedPercentage" xlink:label="loc_gsk_ContingentConsiderationPayableDiscountedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContingentConsiderationPayableDiscountedPercentage" xml:lang="en-US">Contingent Consideration Payable Discounted Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContingentConsiderationPayableDiscountedPercentage" xml:lang="en-US">Contingent consideration liability discount percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContingentConsiderationPayableDiscountedPercentage" xlink:to="lab_gsk_ContingentConsiderationPayableDiscountedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContingentConsiderationPayableDiscountedPercentage" xml:lang="en-US">Consideration payable discounted percentage.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesCurrent" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesCurrent" xml:lang="en-US">Contingent consideration liabilities current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesCurrent" xml:lang="en-US">Contingent consideration payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContingentConsiderationLiabilitiesCurrent" xlink:to="lab_gsk_ContingentConsiderationLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesCurrent" xml:lang="en-US">Contingent consideration liabilities current.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialisedProductsMember" xlink:label="loc_gsk_CommercialisedProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CommercialisedProductsMember" xml:lang="en-US">Commercialised Products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CommercialisedProductsMember" xlink:to="lab_gsk_CommercialisedProductsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineAssetsMember" xlink:label="loc_gsk_PipelineAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PipelineAssetsMember" xml:lang="en-US">Pipeline Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PipelineAssetsMember" xlink:to="lab_gsk_PipelineAssetsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentLiabilitiesAbstract" xlink:label="loc_gsk_OtherNoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherNoncurrentLiabilitiesAbstract" xml:lang="en-US">Other non-current liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherNoncurrentLiabilitiesAbstract" xlink:to="lab_gsk_OtherNoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherNoncurrentLiabilitiesAbstract" xml:lang="en-US">Other non-current liabilities [abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xlink:label="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xml:lang="en-US">Non-current accrued income other than non-current contract assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xml:lang="en-US">Deferred income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xlink:to="lab_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="loc_ifrs-full_OtherNoncurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentPayables" xml:lang="en-US">Other non-current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherNoncurrentPayables" xml:lang="en-US">Other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentPayables" xlink:to="lab_ifrs-full_OtherNoncurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-full_Accruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Accruals" xml:lang="en-US">Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Accruals" xml:lang="en-US">Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Accruals" xlink:to="lab_ifrs-full_Accruals" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xml:lang="en-US">Disclosure of contingent liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xml:lang="en-US">Financial assets pledged as collateral for liabilities or contingent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xml:lang="en-US">Financial assets were pledged as collateral for contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:to="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xml:lang="en-US">Estimated financial effect of contingent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xml:lang="en-US">Contingent liabilities, comprising guarantees, discounted bills and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCommitmentsAbstract" xlink:label="loc_gsk_DisclosureOfCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfCommitmentsAbstract" xml:lang="en-US">Disclosure of Commitments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfCommitmentsAbstract" xlink:to="lab_gsk_DisclosureOfCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfCommitmentsAbstract" xml:lang="en-US">Disclosure of commitments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionUnpaid" xlink:label="loc_gsk_AdditionalContributionUnpaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalContributionUnpaid" xml:lang="en-US">Additional Contribution Unpaid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionalContributionUnpaid" xml:lang="en-US">Additional contribution unpaid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalContributionUnpaid" xlink:to="lab_gsk_AdditionalContributionUnpaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalContributionUnpaid" xml:lang="en-US">Additional contribution unpaid.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xlink:label="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xml:lang="en-US">Additional Contribution Were To Be Made Towards 2020 Pension Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xml:lang="en-US">Additional contribution towards pension scheme to eliminate the pension deficit identified at the 31 December 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xlink:to="lab_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xml:lang="en-US">Additional contribution were to be made towards 2020 pension deficit.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" xlink:label="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" xml:lang="en-US">Disclosure Of Contractual Obligations And Commitments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" xlink:to="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" xml:lang="en-US">Disclosure Of Contractual Obligations And Commitments [abstract].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPensions" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfPensions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPensions" xml:lang="en-US">Contractual Obligations And Commitments Of Pensions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPensions" xml:lang="en-US">Pensions and post-retirement benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitmentsOfPensions" xlink:to="lab_gsk_ContractualObligationsAndCommitmentsOfPensions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPensions" xml:lang="en-US">Contractual obligations and commitments of pensions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInvestments" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInvestments" xml:lang="en-US">Contractual Obligations And Commitments Of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInvestments" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitmentsOfInvestments" xlink:to="lab_gsk_ContractualObligationsAndCommitmentsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInvestments" xml:lang="en-US">Contractual obligations and commitments of investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xml:lang="en-US">Contractual Obligations And Commitments of Future Finance Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xml:lang="en-US">Future finance charges on leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xlink:to="lab_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xml:lang="en-US">Contractual obligations and commitments of future finance charges</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xml:lang="en-US">Contractual Obligations And Commitments Of Purchase Commitments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xml:lang="en-US">Purchase commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xlink:to="lab_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xml:lang="en-US">Contractual obligations and commitments of purchase commitments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xml:lang="en-US">Contractual commitments for acquisition of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:to="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitments" xlink:label="loc_gsk_ContractualObligationsAndCommitments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitments" xml:lang="en-US">Contractual Obligations And Commitments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitments" xml:lang="en-US">Total contractual obligations and commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitments" xlink:to="lab_gsk_ContractualObligationsAndCommitments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitments" xml:lang="en-US">Contractual obligations and commitments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xml:lang="en-US">Contractual Obligations And Commitments Of Interest On Loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xml:lang="en-US">Interest on loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xlink:to="lab_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xml:lang="en-US">Contractual obligations and commitments of interest on loans.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xlink:label="loc_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xml:lang="en-US">Contractual Obligations Lease Contracts That Have Not Yet Commenced</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xml:lang="en-US">Lease contracts that have not yet commenced</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xlink:to="lab_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xml:lang="en-US">Contractual obligations lease contracts that have not yet commenced.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xml:lang="en-US">Disclosure Of Classes Of Share Capital And Share Premium [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xlink:to="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xml:lang="en-US">Disclosure Of Classes Of Share Capital And Share Premium [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:label="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xml:lang="en-US">Disclosure Of Classes Share Capital And Share Premium [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xml:lang="en-US">Disclosure Of Classes Share Capital And Share Premium [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:to="lab_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xml:lang="en-US">Disclosure of classes share capital and share premium.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xml:lang="en-US">Disclosure Of Classes Of Share Capital And Share Premium [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xml:lang="en-US">Disclosure Of Classes Of Share Capital And Share Premium [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:to="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xml:lang="en-US">Disclosure Of Classes Of Share Capital And Share Premium [line items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xml:lang="en-US">Ordinary shares acquired by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Number of shares issued and fully paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Share capital issued and fully paid beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Share capital issued and fully paid ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xlink:label="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xml:lang="en-US">Number Of Treasury Shares transferred to employee share trusts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xml:lang="en-US">Ordinary shares acquired by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xlink:to="lab_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xml:lang="en-US">Number of treasury shares transferred to employee share trusts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xlink:label="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xml:lang="en-US">Number of shares issued and fully paid under employee share schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xml:lang="en-US">Issued under employee share schemes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xlink:to="lab_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xml:lang="en-US">Number of shares issued and fully paid under employee share schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpactOfShareConsolidationShares" xlink:label="loc_gsk_ImpactOfShareConsolidationShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ImpactOfShareConsolidationShares" xml:lang="en-US">Impact Of Share Consolidation Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ImpactOfShareConsolidationShares" xml:lang="en-US">Impact of share consolidation (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ImpactOfShareConsolidationShares" xlink:to="lab_gsk_ImpactOfShareConsolidationShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ImpactOfShareConsolidationShares" xml:lang="en-US">Impact of share consolidation shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="loc_ifrs-full_TreasurySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TreasurySharesMember" xml:lang="en-US">Treasury shares [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TreasurySharesMember" xml:lang="en-US">Treasury shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeIssueMember" xlink:label="loc_gsk_FreeIssueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FreeIssueMember" xml:lang="en-US">Free Issue [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FreeIssueMember" xml:lang="en-US">Free issue [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FreeIssueMember" xlink:to="lab_gsk_FreeIssueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FreeIssueMember" xml:lang="en-US">Free issue.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeShareOwnershipPlanMember" xlink:label="loc_gsk_EmployeeShareOwnershipPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EmployeeShareOwnershipPlanMember" xml:lang="en-US">Employee Share Ownership Plan [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EmployeeShareOwnershipPlanMember" xml:lang="en-US">Employee share ownership plan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EmployeeShareOwnershipPlanMember" xlink:to="lab_gsk_EmployeeShareOwnershipPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EmployeeShareOwnershipPlanMember" xml:lang="en-US">Employee share ownership plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xlink:label="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xml:lang="en-US">Share consolidation as a result of Consumer Healthcare business demerger [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xml:lang="en-US">Share consolidation as a result of Consumer Healthcare business demerger [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xlink:to="lab_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xml:lang="en-US">Share consolidation as a result of Consumer Healthcare business demerger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Number of shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Share capital issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value of newly issues shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfShareConsolidationApproval" xlink:label="loc_gsk_DateOfShareConsolidationApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DateOfShareConsolidationApproval" xml:lang="en-US">Date of share consolidation approval</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DateOfShareConsolidationApproval" xml:lang="en-US">Date of share consolidation approval</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DateOfShareConsolidationApproval" xlink:to="lab_gsk_DateOfShareConsolidationApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DateOfShareConsolidationApproval" xml:lang="en-US">Date of share consolidation approval.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessDemerger" xlink:label="loc_gsk_ConsumerHealthcareBusinessDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConsumerHealthcareBusinessDemerger" xml:lang="en-US">Consumer Healthcare business demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ConsumerHealthcareBusinessDemerger" xml:lang="en-US">Consumer Healthcare business demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConsumerHealthcareBusinessDemerger" xlink:to="lab_gsk_ConsumerHealthcareBusinessDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConsumerHealthcareBusinessDemerger" xml:lang="en-US">Consumer Healthcare business demerger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xml:lang="en-US">Number of shares authorised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xml:lang="en-US">Number Of Shares Authorised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesReceivedForEveryFiveExistingShares" xlink:label="loc_gsk_SharesReceivedForEveryFiveExistingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SharesReceivedForEveryFiveExistingShares" xml:lang="en-US">Shares Received For Every Five Existing Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SharesReceivedForEveryFiveExistingShares" xml:lang="en-US">Share received for every five existing shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SharesReceivedForEveryFiveExistingShares" xlink:to="lab_gsk_SharesReceivedForEveryFiveExistingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SharesReceivedForEveryFiveExistingShares" xml:lang="en-US">Shares received for every five existing shares.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SurrenderedSharesForEveryFourNewSharesReceived" xlink:label="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SurrenderedSharesForEveryFourNewSharesReceived" xml:lang="en-US">Surrendered Shares For Every Four New Shares Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SurrenderedSharesForEveryFourNewSharesReceived" xml:lang="en-US">Surrendered shares for every four new shares received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived" xlink:to="lab_gsk_SurrenderedSharesForEveryFourNewSharesReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SurrenderedSharesForEveryFourNewSharesReceived" xml:lang="en-US">Surrendered shares for every four new shares received.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xlink:label="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xml:lang="en-US">Par Value Of Shares Surrendered In Lieu Of New Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xml:lang="en-US">Par value of shares surrendered in lieu of new shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xlink:to="lab_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xml:lang="en-US">Par value of shares surrendered in lieu of new shares.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsAxis" xlink:label="loc_gsk_DetailsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DetailsAxis" xml:lang="en-US">Details [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DetailsAxis" xlink:to="lab_gsk_DetailsAxis" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsMember" xlink:label="loc_gsk_DetailsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DetailsMember" xml:lang="en-US">Details [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DetailsMember" xlink:to="lab_gsk_DetailsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityAxis" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityAxis" xml:lang="en-US">Miscellaneous Components Of Equity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityAxis" xml:lang="en-US">Miscellaneous Components Of Equity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityAxis" xlink:to="lab_gsk_MiscellaneousComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityAxis" xml:lang="en-US">Miscellaneous Components Of Equity.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityDomain" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityDomain" xml:lang="en-US">Miscellaneous Components Of Equity [domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityDomain" xml:lang="en-US">Miscellaneous Components Of Equity [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityDomain" xlink:to="lab_gsk_MiscellaneousComponentsOfEquityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MiscellaneousComponentsOfEquityDomain" xml:lang="en-US">Miscellaneous Components Of Equity [domain]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRedemptionReserveMember" xlink:label="loc_ifrs-full_CapitalRedemptionReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalRedemptionReserveMember" xml:lang="en-US">Capital redemption reserve [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CapitalRedemptionReserveMember" xml:lang="en-US">Capital redemption reserve [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalRedemptionReserveMember" xlink:to="lab_ifrs-full_CapitalRedemptionReserveMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDistributableMergerAndPreMergerReservesMember" xlink:label="loc_gsk_NonDistributableMergerAndPreMergerReservesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonDistributableMergerAndPreMergerReservesMember" xml:lang="en-US">Non distributable merger and pre merger reserves [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_NonDistributableMergerAndPreMergerReservesMember" xml:lang="en-US">Non-distributable merger and pre-merger reserves [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonDistributableMergerAndPreMergerReservesMember" xlink:to="lab_gsk_NonDistributableMergerAndPreMergerReservesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonDistributableMergerAndPreMergerReservesMember" xml:lang="en-US">Non-distributable merger and pre-merger reserves.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetainedEarningsAndOtherReserves" xlink:label="loc_gsk_RetainedEarningsAndOtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RetainedEarningsAndOtherReserves" xml:lang="en-US">Retained Earnings And Other Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RetainedEarningsAndOtherReserves" xml:lang="en-US">Retained earnings and other reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RetainedEarningsAndOtherReserves" xlink:to="lab_gsk_RetainedEarningsAndOtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RetainedEarningsAndOtherReserves" xml:lang="en-US">Retained earnings and other reserves.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueReserveMember" xlink:label="loc_gsk_FairValueReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueReserveMember" xml:lang="en-US">Fair Value Reserve [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueReserveMember" xml:lang="en-US">Fair value reserve [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueReserveMember" xlink:to="lab_gsk_FairValueReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueReserveMember" xml:lang="en-US">Fair value reserve.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xml:lang="en-US">Reserve of exchange differences on translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Exchange movements on overseas net assets and net investment hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xml:lang="en-US">Movement In Translation Exchange Attributable To Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xml:lang="en-US">Movement attributable to discontinued operations(a)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xlink:to="lab_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xml:lang="en-US">Movement in translation exchange attributable to discontinued operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xml:lang="en-US">Movement In Translation Exchange Attributable To Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xml:lang="en-US">Movement attributable to continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xlink:to="lab_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xml:lang="en-US">Movement in translation exchange attributable to continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerMember" xlink:label="loc_gsk_DemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DemergerMember" xml:lang="en-US">Demerger [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DemergerMember" xlink:to="lab_gsk_DemergerMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xml:lang="en-US">Exchange movements on overseas net assets and net investment hedges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xml:lang="en-US">Exchange movements on overseas net assets and net investment hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xlink:to="lab_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xml:lang="en-US">Exchange movements on overseas net assets and net investment hedges.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xml:lang="en-US">Income tax relating to remeasurements of defined benefit plans included in other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xml:lang="en-US">Tax on remeasurement losses/(gains) on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xml:lang="en-US">Fair value movements on equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperations" xml:lang="en-US">Comprehensive income from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperations" xml:lang="en-US">Other comprehensive (expense)/income for the year from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations" xlink:to="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xlink:label="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xml:lang="en-US">Other comprehensive income deferred tax on fair value movements on equity investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xml:lang="en-US">Tax on fair value movements on equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xlink:to="lab_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xml:lang="en-US">Other comprehensive income deferred tax on fair value movements on equity investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xml:lang="en-US">Exchange movements on overseas net assets of non controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xml:lang="en-US">Exchange movements on overseas net assets of non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xlink:to="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xml:lang="en-US">Exchange movements on overseas net assets of non-controlling interests.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xml:lang="en-US">Comprehensive income from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xml:lang="en-US">Other comprehensive (expense)/income for the year from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xlink:to="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xlink:label="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xml:lang="en-US">Other Comprehensive Income Before Tax Gains Losses On Cash Flow Hedges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xml:lang="en-US">Fair value movements on cash flow hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xlink:to="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xml:lang="en-US">Other Comprehensive Income Before Tax Gains Losses On Cash Flow Hedges.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustMember" xlink:label="loc_gsk_EsopTrustMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EsopTrustMember" xml:lang="en-US">ESOP Trust [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EsopTrustMember" xml:lang="en-US">ESOP trust shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EsopTrustMember" xlink:to="lab_gsk_EsopTrustMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EsopTrustMember" xml:lang="en-US">ESOP Trust.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesMember" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesMember" xml:lang="en-US">Reserve of cash flow hedges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesMember" xml:lang="en-US">Cash Flow Hedges Reserve [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfCashFlowHedgesMember" xlink:to="lab_ifrs-full_ReserveOfCashFlowHedgesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovements" xlink:label="loc_gsk_NetFairValueMovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFairValueMovements" xml:lang="en-US">Net Fair Value Movements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_NetFairValueMovements" xml:lang="en-US">Net fair value movement in the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFairValueMovements" xlink:to="lab_gsk_NetFairValueMovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFairValueMovements" xml:lang="en-US">Net fair value movements.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xlink:label="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xml:lang="en-US">Ordinary Shares Acquired By Esop Trusts Included In Other Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xml:lang="en-US">Ordinary shares acquired by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xlink:to="lab_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xml:lang="en-US">Ordinary shares acquired by Esop trusts included in other reserves.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeAdjustments" xlink:label="loc_gsk_ExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeAdjustments" xml:lang="en-US">Exchange Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_ExchangeAdjustments" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeAdjustments" xlink:to="lab_gsk_ExchangeAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeAdjustments" xml:lang="en-US">Exchange adjustments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEsopTrusts" xlink:label="loc_gsk_WritedownOfSharesHeldByEsopTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WritedownOfSharesHeldByEsopTrusts" xml:lang="en-US">Writedown Of Shares Held By Esop Trusts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WritedownOfSharesHeldByEsopTrusts" xml:lang="en-US">Write-down of shares held by ESOP Trusts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WritedownOfSharesHeldByEsopTrusts" xlink:to="lab_gsk_WritedownOfSharesHeldByEsopTrusts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WritedownOfSharesHeldByEsopTrusts" xml:lang="en-US">Writedown of shares held by Esop trusts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xml:lang="en-US">Transferred to Retained earnings on disposal of equity investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xml:lang="en-US">Transferred to retained earnings in the year on disposal of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xlink:to="lab_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xml:lang="en-US">Transferred to retained earnings on disposal of equity investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xlink:label="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xml:lang="en-US">Transferred To Income Expenses Impairments Of Equity Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xml:lang="en-US">Transferred to income and expenses in the year on impairments of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xlink:to="lab_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xml:lang="en-US">Transferred to income expenses impairments of equity investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BalanceAmountDerecognisedOnDemerger" xlink:label="loc_gsk_BalanceAmountDerecognisedOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BalanceAmountDerecognisedOnDemerger" xml:lang="en-US">Balance amount derecognised on demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_BalanceAmountDerecognisedOnDemerger" xml:lang="en-US">Balances derecognised on demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BalanceAmountDerecognisedOnDemerger" xlink:to="lab_gsk_BalanceAmountDerecognisedOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BalanceAmountDerecognisedOnDemerger" xml:lang="en-US">Balance amount derecognised on demerger.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNonControllingInterestsAbstract" xlink:label="loc_gsk_DisclosureOfNonControllingInterestsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfNonControllingInterestsAbstract" xml:lang="en-US">Disclosure Of Non Controlling Interests [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfNonControllingInterestsAbstract" xlink:to="lab_gsk_DisclosureOfNonControllingInterestsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfNonControllingInterestsAbstract" xml:lang="en-US">Disclosure of non controlling interests.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsTable" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsTable" xml:lang="en-US">Disclosure of Non-controlling Interests [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsTable" xml:lang="en-US">Disclosure of Non-controlling Interests [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable" xlink:to="lab_gsk_DisclosureOfNoncontrollingInterestsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsTable" xml:lang="en-US">Disclosure of non-controlling interests.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsLineItems" xml:lang="en-US">Disclosure of noncontrolling interests [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsLineItems" xml:lang="en-US">Disclosure of noncontrolling interests [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:to="lab_gsk_DisclosureOfNoncontrollingInterestsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfNoncontrollingInterestsLineItems" xml:lang="en-US">Disclosure of non-controlling interests Line Items</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xml:lang="en-US">Proportion of ownership interest in associate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xml:lang="en-US">Percentage of common stock held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xlink:label="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xml:lang="en-US">Remeasurements Of Contingent Consideration Payable For Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xlink:to="lab_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xml:lang="en-US">Remeasurements of contingent consideration payable for acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterests" xml:lang="en-US">Dividends paid to non-controlling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterests" xml:lang="en-US">Dividends paid to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndBankOverdrafts" xlink:label="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInCashAndBankOverdrafts" xml:lang="en-US">Increase Decrease In Cash And Bank Overdrafts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_IncreaseDecreaseInCashAndBankOverdrafts" xml:lang="en-US">(Decrease)/increase in cash and bank overdrafts in the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts" xlink:to="lab_gsk_IncreaseDecreaseInCashAndBankOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInCashAndBankOverdrafts" xml:lang="en-US">Increase (decrease) in cash and bank overdrafts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xml:lang="en-US">Disclosure of transactions between related parties [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xml:lang="en-US">Disclosure of transactions between related parties [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongwoodFoundersFundLPMember" xlink:label="loc_gsk_LongwoodFoundersFundLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LongwoodFoundersFundLPMember" xml:lang="en-US">Longwood Founders Fund LP [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LongwoodFoundersFundLPMember" xml:lang="en-US">Longwood Founders Fund LP [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LongwoodFoundersFundLPMember" xlink:to="lab_gsk_LongwoodFoundersFundLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LongwoodFoundersFundLPMember" xml:lang="en-US">Longwood Founders Fund LP.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MedicxiVenturesILimitedPartnerMember" xlink:label="loc_gsk_MedicxiVenturesILimitedPartnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MedicxiVenturesILimitedPartnerMember" xml:lang="en-US">Medicxi VenturesI Limited Partner [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MedicxiVenturesILimitedPartnerMember" xml:lang="en-US">Medicxi Ventures I Limited Partner [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MedicxiVenturesILimitedPartnerMember" xlink:to="lab_gsk_MedicxiVenturesILimitedPartnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MedicxiVenturesILimitedPartnerMember" xml:lang="en-US">Medicxi Ventures I Limited Partner.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ApolloTherapeuticsLLPMember" xlink:label="loc_gsk_ApolloTherapeuticsLLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ApolloTherapeuticsLLPMember" xml:lang="en-US">Apollo Therapeutics LLP [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ApolloTherapeuticsLLPMember" xml:lang="en-US">Apollo Therapeutics LLP [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ApolloTherapeuticsLLPMember" xlink:to="lab_gsk_ApolloTherapeuticsLLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ApolloTherapeuticsLLPMember" xml:lang="en-US">Apollo Therapeutics LLP.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_QuraTherapeuticsLLCMember" xlink:label="loc_gsk_QuraTherapeuticsLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_QuraTherapeuticsLLCMember" xml:lang="en-US">Qura Therapeutics LLC [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_QuraTherapeuticsLLCMember" xml:lang="en-US">Qura Therapeutics LLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_QuraTherapeuticsLLCMember" xlink:to="lab_gsk_QuraTherapeuticsLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_QuraTherapeuticsLLCMember" xml:lang="en-US">Qura Therapeutics LLC.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentIncome" xlink:label="loc_ifrs-full_InvestmentIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentIncome" xml:lang="en-US">Investment income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InvestmentIncome" xml:lang="en-US">Income from investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentIncome" xlink:to="lab_ifrs-full_InvestmentIncome" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementExtensionPeriod" xlink:label="loc_gsk_AgreementExtensionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AgreementExtensionPeriod" xml:lang="en-US">Agreement extension period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AgreementExtensionPeriod" xml:lang="en-US">Agreement extension</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AgreementExtensionPeriod" xlink:to="lab_gsk_AgreementExtensionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AgreementExtensionPeriod" xml:lang="en-US">Agreement extension.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xlink:label="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xml:lang="en-US">Loans Receivable Made By Entity Related Party Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xml:lang="en-US">Loans outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xlink:to="lab_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xml:lang="en-US">Loans receivable made by entity related party transactions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentObligation" xlink:label="loc_gsk_InvestmentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentObligation" xml:lang="en-US">Investment Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentObligation" xml:lang="en-US">Investment obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentObligation" xlink:to="lab_gsk_InvestmentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentObligation" xml:lang="en-US">Investment obligation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis" xml:lang="en-US">Consolidated structured entities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xml:lang="en-US">Entity's total for consolidated structured entities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xml:lang="en-US">Disposal groups classified as held for sale [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xml:lang="en-US">Disposal groups classified as held for sale [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:to="lab_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashInvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_CashInvestmentsInJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashInvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Cash investments in joint ventures and associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashInvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Cash investment in associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashInvestmentsInJointVenturesAndAssociates" xlink:to="lab_gsk_CashInvestmentsInJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashInvestmentsInJointVenturesAndAssociates" xml:lang="en-US">Cash investments in joint ventures and associates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xml:lang="en-US">Non-controlling interest in acquiree recognised at acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xml:lang="en-US">Non controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:to="lab_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xml:lang="en-US">Cash consideration paid (received)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xml:lang="en-US">Cash consideration received/(paid)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xml:lang="en-US">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xml:lang="en-US">Total consideration value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:to="lab_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xlink:label="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xml:lang="en-US">Gain Loss On Disposals Of Business Including Signed But Not Completed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xml:lang="en-US">Total profit on disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xlink:to="lab_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xml:lang="en-US">Gain loss on disposals of business including signed but not completed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashTransferred" xml:lang="en-US">Cash transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashTransferred" xml:lang="en-US">Cash consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_CashTransferred" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:label="loc_gsk_GainLossOnEmbeddedDerivativeTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnEmbeddedDerivativeTransaction" xml:lang="en-US">Gain Loss on Embedded Derivative Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GainLossOnEmbeddedDerivativeTransaction" xml:lang="en-US">Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:to="lab_gsk_GainLossOnEmbeddedDerivativeTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnEmbeddedDerivativeTransaction" xml:lang="en-US">Gain loss on embedded derivative transaction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xml:lang="en-US">Percentage of voting equity interests acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xml:lang="en-US">Percentage acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsMadeForTransactionCostsAndOther" xlink:label="loc_gsk_PaymentsMadeForTransactionCostsAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PaymentsMadeForTransactionCostsAndOther" xml:lang="en-US">Payments Made For Transaction Costs And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_PaymentsMadeForTransactionCostsAndOther" xml:lang="en-US">Payments Made For Transaction Costs And Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PaymentsMadeForTransactionCostsAndOther" xlink:to="lab_gsk_PaymentsMadeForTransactionCostsAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PaymentsMadeForTransactionCostsAndOther" xml:lang="en-US">Transaction costs and other.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssets" xlink:to="lab_ifrs-full_OtherAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xlink:label="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xml:lang="en-US">Business Combination Potential Milestone Payment Per Tranche</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xml:lang="en-US">Business combination potential milestone payment per tranche</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xlink:to="lab_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xml:lang="en-US">Business combination potential milestone payment per tranche.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xlink:label="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xml:lang="en-US">Portion of Consideration Paid Received Consisting Non Cash Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xml:lang="en-US">Non-cash consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xlink:to="lab_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xml:lang="en-US">Portion of consideration paid received consisting non cash consideration.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentOwnedNumberOfSharesDisposedOff" xlink:label="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InvestmentOwnedNumberOfSharesDisposedOff" xml:lang="en-US">Investment Owned Number Of Shares Disposed Off</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InvestmentOwnedNumberOfSharesDisposedOff" xml:lang="en-US">Investment owned number of shares disposed off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff" xlink:to="lab_gsk_InvestmentOwnedNumberOfSharesDisposedOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InvestmentOwnedNumberOfSharesDisposedOff" xml:lang="en-US">Investment owned number of shares disposed off.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsDistributedFromCashBalance" xlink:label="loc_gsk_DividendsDistributedFromCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendsDistributedFromCashBalance" xml:lang="en-US">Dividends Distributed From Cash Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendsDistributedFromCashBalance" xml:lang="en-US">Dividends distributed from cash balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendsDistributedFromCashBalance" xlink:to="lab_gsk_DividendsDistributedFromCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendsDistributedFromCashBalance" xml:lang="en-US">Dividends distributed from cash balance.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GrossProceedsFromDisposalOfInterestInAssociates" xlink:label="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GrossProceedsFromDisposalOfInterestInAssociates" xml:lang="en-US">Gross Proceeds From Disposal Of Interest In Associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GrossProceedsFromDisposalOfInterestInAssociates" xml:lang="en-US">Gross proceeds from disposal of interest in associates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates" xlink:to="lab_gsk_GrossProceedsFromDisposalOfInterestInAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GrossProceedsFromDisposalOfInterestInAssociates" xml:lang="en-US">Gross proceeds from disposal of interest in associates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xlink:label="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xml:lang="en-US">Reclassification Of Cumulative Exchange Differences Arising On Translation Of Foreign Currency Net Assets Of Divested Subsidiaries And Offsetting Net Investment Hedges Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xml:lang="en-US">Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xlink:to="lab_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xml:lang="en-US">Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageofGSKHolding" xlink:label="loc_gsk_PercentageofGSKHolding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageofGSKHolding" xml:lang="en-US">Percentage of GSK Holding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageofGSKHolding" xml:lang="en-US">Percentage of GSK holding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageofGSKHolding" xlink:to="lab_gsk_PercentageofGSKHolding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageofGSKHolding" xml:lang="en-US">Percentage of GSK holding.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancing" xlink:label="loc_gsk_DividendFundedByDebtFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendFundedByDebtFinancing" xml:lang="en-US">Dividend Funded By Debt Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendFundedByDebtFinancing" xml:lang="en-US">Dividend funded by debt financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendFundedByDebtFinancing" xlink:to="lab_gsk_DividendFundedByDebtFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendFundedByDebtFinancing" xml:lang="en-US">Dividend funded by debt financing.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheAssetsDistributed" xlink:label="loc_gsk_FairValueOfTheAssetsDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfTheAssetsDistributed" xml:lang="en-US">Fair Value of the Assets Distributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfTheAssetsDistributed" xml:lang="en-US">Fair value of the assets distributed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfTheAssetsDistributed" xlink:to="lab_gsk_FairValueOfTheAssetsDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfTheAssetsDistributed" xml:lang="en-US">Fair value of the assets distributed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfHolding" xlink:label="loc_gsk_FairValueOfHolding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfHolding" xml:lang="en-US">Fair Value of Holding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfHolding" xml:lang="en-US">Fair value of holding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfHolding" xlink:to="lab_gsk_FairValueOfHolding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfHolding" xml:lang="en-US">Fair value of holding.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xlink:label="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xml:lang="en-US">Disposal Of Interest In Associates Consideration Receivable Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xml:lang="en-US">Disposal of interest in associates consideration receivable per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xlink:to="lab_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xml:lang="en-US">Disposal of interest in associates consideration receivable per share.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" xml:lang="en-US">Carrying Value Of Investment Net Of Non Controlling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" xml:lang="en-US">Carrying Value Of Investment Net Of Non Controlling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" xlink:to="lab_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest" xml:lang="en-US">Carrying value of investment net of non controlling interest.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashTransferredOnDisposal" xlink:label="loc_gsk_CashTransferredOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashTransferredOnDisposal" xml:lang="en-US">Cash Transferred On Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashTransferredOnDisposal" xml:lang="en-US">Cash transferred on disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashTransferredOnDisposal" xlink:to="lab_gsk_CashTransferredOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashTransferredOnDisposal" xml:lang="en-US">Cash transferred on disposal.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xlink:label="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xml:lang="en-US">Business Combination Step Acquisition Remaining Equity Interest Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xml:lang="en-US">Business combination step acquisition remaining equity interest acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xlink:to="lab_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xml:lang="en-US">Business combination step acquisition remaining equity interest acquired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilityEliminatedOnDemerger" xlink:label="loc_gsk_LiabilityEliminatedOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilityEliminatedOnDemerger" xml:lang="en-US">Liability Eliminated On Demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiabilityEliminatedOnDemerger" xml:lang="en-US">Liability Eliminated On Demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilityEliminatedOnDemerger" xlink:to="lab_gsk_LiabilityEliminatedOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilityEliminatedOnDemerger" xml:lang="en-US">Liability eliminated on demerger.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xlink:label="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xml:lang="en-US">Gain On Distribution Of Fair Value Less Book Value Of The Attributable Net Assets Of Discontinued Business Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xml:lang="en-US">Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xlink:to="lab_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xml:lang="en-US">Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerOfDiscontinuedOperation" xlink:label="loc_gsk_GainOnDemergerOfDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainOnDemergerOfDiscontinuedOperation" xml:lang="en-US">Gain On Demerger Of Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainOnDemergerOfDiscontinuedOperation" xml:lang="en-US">Total gain on the demerger of Consumer Healthcare</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainOnDemergerOfDiscontinuedOperation" xlink:to="lab_gsk_GainOnDemergerOfDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainOnDemergerOfDiscontinuedOperation" xml:lang="en-US">Gain on demerger of discontinued operation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancingAttributableToGsk" xlink:label="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendFundedByDebtFinancingAttributableToGsk" xml:lang="en-US">Dividend Funded By Debt Financing Attributable To GSK</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendFundedByDebtFinancingAttributableToGsk" xml:lang="en-US">Dividend funded by debt financing attributable to GSK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk" xlink:to="lab_gsk_DividendFundedByDebtFinancingAttributableToGsk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendFundedByDebtFinancingAttributableToGsk" xml:lang="en-US">Dividend funded by debt financing attributable to GSK.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" xml:lang="en-US">Dividends Distributed From Cash Balance Attributable To GSK</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" xml:lang="en-US">Dividends&#8203; distributed from&#8203; cash balance attributable to GSK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" xlink:to="lab_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendsDistributedFromCashBalanceAttributableToGsk" xml:lang="en-US">Dividends&#8203; distributed from&#8203; cash balance attributable to GSK.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDistributed" xlink:label="loc_gsk_PercentageOfOwnershipDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfOwnershipDistributed" xml:lang="en-US">Percentage Of Ownership Distributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfOwnershipDistributed" xml:lang="en-US">Percentage Of Ownership Distributed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfOwnershipDistributed" xlink:to="lab_gsk_PercentageOfOwnershipDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfOwnershipDistributed" xml:lang="en-US">Ownership of the Consumer Healthcare business distributed.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalGainOnRemeasurementOfRetainedStake" xlink:label="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionalGainOnRemeasurementOfRetainedStake" xml:lang="en-US">Additional Gain On Remeasurement Of Retained Stake</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdditionalGainOnRemeasurementOfRetainedStake" xml:lang="en-US">Additional gain amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake" xlink:to="lab_gsk_AdditionalGainOnRemeasurementOfRetainedStake" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionalGainOnRemeasurementOfRetainedStake" xml:lang="en-US">Additional gain on remeasurement of retained stake.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xlink:label="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xml:lang="en-US">Business Combination Consideration Payable For Step Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xlink:to="lab_gsk_BusinessCombinationConsiderationPayableForStepAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xml:lang="en-US">Business combination consideration payable for step acquisition.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDivested" xlink:label="loc_gsk_PercentageOfOwnershipDivested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfOwnershipDivested" xml:lang="en-US">Percentage Of Ownership divested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfOwnershipDivested" xml:lang="en-US">Percentage Of Ownership Divested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfOwnershipDivested" xlink:to="lab_gsk_PercentageOfOwnershipDivested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfOwnershipDivested" xml:lang="en-US">Ownership of the Consumer Healthcare business divested.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskHoldingMember" xlink:label="loc_gsk_GskHoldingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskHoldingMember" xml:lang="en-US">GSK Holding [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskHoldingMember" xlink:to="lab_gsk_GskHoldingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskHoldingMember" xml:lang="en-US">GSK holding.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskShareholdersMember" xlink:label="loc_gsk_GskShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskShareholdersMember" xml:lang="en-US">GSK Shareholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskShareholdersMember" xlink:to="lab_gsk_GskShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskShareholdersMember" xml:lang="en-US">GSK shareholders.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAndGsksConsolidatedEsotTrustsMember" xlink:label="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskAndGsksConsolidatedEsotTrustsMember" xml:lang="en-US">GSK and GSKs Consolidated ESOT Trusts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember" xlink:to="lab_gsk_GskAndGsksConsolidatedEsotTrustsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskAndGsksConsolidatedEsotTrustsMember" xml:lang="en-US">GSK and GSK's consolidated ESOT trusts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAggregateHoldingMember" xlink:label="loc_gsk_GskAggregateHoldingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskAggregateHoldingMember" xml:lang="en-US">GSK Aggregate Holding [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskAggregateHoldingMember" xlink:to="lab_gsk_GskAggregateHoldingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskAggregateHoldingMember" xml:lang="en-US">GSK aggregate holding.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BangladeshConsumerHealthcareMember" xlink:label="loc_gsk_BangladeshConsumerHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BangladeshConsumerHealthcareMember" xml:lang="en-US">Bangladesh Consumer Healthcare [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BangladeshConsumerHealthcareMember" xml:lang="en-US">Bangladesh Consumer Healthcare [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BangladeshConsumerHealthcareMember" xlink:to="lab_gsk_BangladeshConsumerHealthcareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BangladeshConsumerHealthcareMember" xml:lang="en-US">Bangladesh Consumer Healthcare.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xlink:label="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xml:lang="en-US">GSK Consumer HealthcareLimitedWithHindustanUnileverLimited[member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xml:lang="en-US">GSK Consumer Healthcare Limited With Hindustan Unilever Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xlink:to="lab_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xml:lang="en-US">GSK Consumer HealthcareLimitedWithHindustanUnileverLimited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AffinivaxIncMember" xml:lang="en-US">Affinivax, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AffinivaxIncMember" xml:lang="en-US">Affinivax, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AffinivaxIncMember" xlink:to="lab_gsk_AffinivaxIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AffinivaxIncMember" xml:lang="en-US">Affinivax, Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyIncMember" xlink:label="loc_gsk_SierraOncologyIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SierraOncologyIncMember" xml:lang="en-US">Sierra Oncology Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SierraOncologyIncMember" xlink:to="lab_gsk_SierraOncologyIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SierraOncologyIncMember" xml:lang="en-US">Sierra oncology inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerBiotechCorporationTaiwanMember" xlink:label="loc_gsk_PfizerBiotechCorporationTaiwanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PfizerBiotechCorporationTaiwanMember" xml:lang="en-US">Pfizer Biotech Corporation Taiwan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PfizerBiotechCorporationTaiwanMember" xml:lang="en-US">Pfizer Biotech Corporation Taiwan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PfizerBiotechCorporationTaiwanMember" xlink:to="lab_gsk_PfizerBiotechCorporationTaiwanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PfizerBiotechCorporationTaiwanMember" xml:lang="en-US">Pfizer Biotech Corporation Taiwan</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xml:lang="en-US">Two Thousand and Twenty Two Business Acquisitions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xml:lang="en-US">2022 Business acquisitions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xlink:to="lab_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xml:lang="en-US">Two thousand and twenty two business acquisitions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSaudiArabiaLimitedMember" xlink:label="loc_gsk_GlaxoSaudiArabiaLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSaudiArabiaLimitedMember" xml:lang="en-US">Glaxo Saudi Arabia Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSaudiArabiaLimitedMember" xml:lang="en-US">Glaxo Saudi Arabia Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSaudiArabiaLimitedMember" xlink:to="lab_gsk_GlaxoSaudiArabiaLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSaudiArabiaLimitedMember" xml:lang="en-US">Glaxo saudi arabia limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareBangladeshMember" xlink:label="loc_gsk_ConsumerHealthCareBangladeshMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConsumerHealthCareBangladeshMember" xml:lang="en-US">Consumer Health Care Bangladesh [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConsumerHealthCareBangladeshMember" xlink:to="lab_gsk_ConsumerHealthCareBangladeshMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConsumerHealthCareBangladeshMember" xml:lang="en-US">Consumer Health Care Bangladesh [Member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalsMember" xml:lang="en-US">Two Thousand Twenty Business Disposals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalsMember" xml:lang="en-US">2020 disposals [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandTwentyBusinessDisposalsMember" xlink:to="lab_gsk_TwoThousandTwentyBusinessDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalsMember" xml:lang="en-US">TwoThousandTwentyBusinessDisposalsMember</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xml:lang="en-US">Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xml:lang="en-US">Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:to="lab_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xml:lang="en-US">Associates And Joint Ventures Two Thousand And Twenty One Disposals</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xml:lang="en-US">Two Thousand And Twenty One Business Disposals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xml:lang="en-US">2021 disposals [Member ]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:to="lab_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xml:lang="en-US">Two Thousand And Twenty One Business Disposals</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsAcquiredAbstract" xlink:label="loc_gsk_NetAssetsAcquiredAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetAssetsAcquiredAbstract" xml:lang="en-US">Net Assets Acquired [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_NetAssetsAcquiredAbstract" xml:lang="en-US">Net assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetAssetsAcquiredAbstract" xlink:to="lab_gsk_NetAssetsAcquiredAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Trade and other payables recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xml:lang="en-US">Inventory recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xml:lang="en-US">Non Controlling Interest Recognised As Of Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xlink:to="lab_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xml:lang="en-US">Non-controlling interest recognised as of acquisition date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xml:lang="en-US">Customer-related intangible assets recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xml:lang="en-US">Net Assets Liabilities Excluding Goodwill As Of Acquisition Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xlink:to="lab_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xml:lang="en-US">NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Trade And Other Receivables Recognised As Of Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xlink:to="lab_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xml:lang="en-US">Trade and other receivables recognised as of acquisition date.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xml:lang="en-US">Lease liabilities Recognized As Of Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xlink:to="lab_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xml:lang="en-US">Lease liabilities Recognized As Of Acquisition Date</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxationRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_TaxationRecognizedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TaxationRecognizedAsOfAcquisitionDate" xml:lang="en-US">Taxation Recognized As Of Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TaxationRecognizedAsOfAcquisitionDate" xml:lang="en-US">Taxation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TaxationRecognizedAsOfAcquisitionDate" xlink:to="lab_gsk_TaxationRecognizedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TaxationRecognizedAsOfAcquisitionDate" xml:lang="en-US">Taxation Recognized As Of Acquisition Date</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xlink:label="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xml:lang="en-US">NonCash consideration for Settlement of a Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xml:lang="en-US">Non-cash consideration (settlement of a promissory note)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xlink:to="lab_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xml:lang="en-US">Non cash consideration for settlement of a promissory note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xml:lang="en-US">Total consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xml:lang="en-US">Net Assets Liabilities Including Goodwill As Of Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xlink:to="lab_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xml:lang="en-US">Net assets liabilities including goodwill as of acquisition date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xml:lang="en-US">Consideration transferred, acquisition-date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xml:lang="en-US">Total cash consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xml:lang="en-US">Contingent consideration recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xml:lang="en-US">Fair value of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyMember" xlink:label="loc_gsk_SierraOncologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SierraOncologyMember" xml:lang="en-US">Sierra Oncology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SierraOncologyMember" xlink:to="lab_gsk_SierraOncologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SierraOncologyMember" xml:lang="en-US">Sierra Oncology [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xlink:label="loc_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xml:lang="en-US">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xml:lang="en-US">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xlink:to="lab_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xml:lang="en-US">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalfairValueOfDistributedandRetainBusiness" xlink:label="loc_gsk_TotalfairValueOfDistributedandRetainBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TotalfairValueOfDistributedandRetainBusiness" xml:lang="en-US">Total Fair Value Of Distributed And Retain Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TotalfairValueOfDistributedandRetainBusiness" xml:lang="en-US">Total fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TotalfairValueOfDistributedandRetainBusiness" xlink:to="lab_gsk_TotalfairValueOfDistributedandRetainBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TotalfairValueOfDistributedandRetainBusiness" xml:lang="en-US">Total&#8203; fair&#8203; value of&#8203; distributed&#8203; and&#8203; retain&#8203; business.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xlink:label="loc_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xml:lang="en-US">Carrying amount of the net assets and liabilities distributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xml:lang="en-US">Carrying amount of the net assets and liabilities distributed/de-recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xlink:to="lab_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xml:lang="en-US">Carrying amount of the net assets and liabilities distributed</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xlink:label="loc_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xml:lang="en-US">Fair value of the retained ownership in Haleon plc</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xml:lang="en-US">Fair value of the retained ownership in Haleon plc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xlink:to="lab_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xml:lang="en-US">Fair value of the retained ownership in Haleon plc</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xlink:label="loc_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xml:lang="en-US">Fair value of the Consumer Healthcare business distributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xml:lang="en-US">Fair value of the Consumer Healthcare business distributed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xlink:to="lab_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xml:lang="en-US">Fair value of the Consumer Healthcare business distributed</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingAmountOfTheNciDerecognized" xlink:label="loc_gsk_CarryingAmountOfTheNciDerecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingAmountOfTheNciDerecognized" xml:lang="en-US">Carrying amount of the NCI derecognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingAmountOfTheNciDerecognized" xml:lang="en-US">Carrying amount of the non-controlling interest de-recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingAmountOfTheNciDerecognized" xlink:to="lab_gsk_CarryingAmountOfTheNciDerecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingAmountOfTheNciDerecognized" xml:lang="en-US">Carrying amount of the NCI derecognized</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xml:lang="en-US">Disclosure of Financial Information Relating To Discontinued Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xlink:to="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xml:lang="en-US">Disclosure of financial information relating to discontinued operations [Table].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xml:lang="en-US">Disclosure of Financial Information Relating To Discontinued Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xlink:to="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xml:lang="en-US">Disclosure of financial information relating to discontinued operations [Line Item].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OperatingExpense" xml:lang="en-US">Operating expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OperatingExpense" xml:lang="en-US">Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Profit after taxation on demerger of discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Profit after taxation on demerger of discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:to="lab_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xml:lang="en-US">Profit after taxation on demerger of discontinued operations</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGainsLossesOnDemerger" xlink:label="loc_gsk_OtherGainsLossesOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherGainsLossesOnDemerger" xml:lang="en-US">Other Gains(Losses) On Demerger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherGainsLossesOnDemerger" xml:lang="en-US">Other gains/(losses) on demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherGainsLossesOnDemerger" xlink:to="lab_gsk_OtherGainsLossesOnDemerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherGainsLossesOnDemerger" xml:lang="en-US">Other gains/(losses) on demerger.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupLiabilityNet" xlink:label="loc_gsk_DisposalGroupLiabilityNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalGroupLiabilityNet" xml:lang="en-US">Disposal Group Liability Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalGroupLiabilityNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalGroupLiabilityNet" xlink:to="lab_gsk_DisposalGroupLiabilityNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalGroupLiabilityNet" xml:lang="en-US">Disposal group liability net.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfEquity" xlink:label="loc_gsk_DisposalOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalOfEquity" xml:lang="en-US">Disposal of equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalOfEquity" xml:lang="en-US">Equity investment in Hindustan Unilever Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalOfEquity" xlink:to="lab_gsk_DisposalOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalOfEquity" xml:lang="en-US">disposal of equity</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Net assets sold:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetAssets" xlink:label="loc_gsk_DisposalsOtherNetAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsOtherNetAssets" xml:lang="en-US">Disposals Other Net Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_gsk_DisposalsOtherNetAssets" xml:lang="en-US">Other net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsOtherNetAssets" xlink:to="lab_gsk_DisposalsOtherNetAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsOtherNetAssets" xml:lang="en-US">Disposals other net assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInventory" xlink:label="loc_gsk_DisposalsInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsInventory" xml:lang="en-US">Disposals Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsInventory" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsInventory" xlink:to="lab_gsk_DisposalsInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsInventory" xml:lang="en-US">Disposals inventory.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsGoodwill" xlink:label="loc_gsk_DisposalsGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsGoodwill" xml:lang="en-US">Disposals Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsGoodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsGoodwill" xlink:to="lab_gsk_DisposalsGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsGoodwill" xml:lang="en-US">Disposals goodwill.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DealCostsPayable" xlink:label="loc_gsk_DealCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DealCostsPayable" xml:lang="en-US">Deal Costs Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DealCostsPayable" xml:lang="en-US">Deal costs payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DealCostsPayable" xlink:to="lab_gsk_DealCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DealCostsPayable" xml:lang="en-US">Deal Costs Payable</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsIntangibleAssets" xlink:label="loc_gsk_DisposalsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsIntangibleAssets" xml:lang="en-US">Disposals Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsIntangibleAssets" xlink:to="lab_gsk_DisposalsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsIntangibleAssets" xml:lang="en-US">Disposals intangible assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xml:lang="en-US">Disposals, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupAssetsNet" xlink:label="loc_gsk_DisposalGroupAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalGroupAssetsNet" xml:lang="en-US">Disposal Group Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_gsk_DisposalGroupAssetsNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalGroupAssetsNet" xlink:to="lab_gsk_DisposalGroupAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalGroupAssetsNet" xml:lang="en-US">Disposal group assets, net.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetLiabilitiesOrAssets" xlink:label="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsOtherNetLiabilitiesOrAssets" xml:lang="en-US">Disposals Other Net Liabilities Or Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisposalsOtherNetLiabilitiesOrAssets" xml:lang="en-US">Other net (liabilities)/assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets" xlink:to="lab_gsk_DisposalsOtherNetLiabilitiesOrAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsOtherNetLiabilitiesOrAssets" xml:lang="en-US">Disposals other net liabilities or assets.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xlink:label="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xml:lang="en-US">Cash consideration including currency forwards and purchase adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xml:lang="en-US">Cash consideration including currency forwards, purchase adjustments and deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xlink:to="lab_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xml:lang="en-US">Cash consideration including currency forwards and purchase adjustments</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusiness" xlink:label="loc_gsk_GainLossOnDisposalsOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainLossOnDisposalsOfBusiness" xml:lang="en-US">Gain Loss on Disposals of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainLossOnDisposalsOfBusiness" xml:lang="en-US">Gain on disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainLossOnDisposalsOfBusiness" xlink:to="lab_gsk_GainLossOnDisposalsOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainLossOnDisposalsOfBusiness" xml:lang="en-US">Gain loss on disposals of business.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_gsk_TransactionCostsOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransactionCostsOnDisposal" xml:lang="en-US">Transaction Costs On Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TransactionCostsOnDisposal" xml:lang="en-US">Deal and transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_TransactionCostsOnDisposal" xml:lang="en-US">Transaction costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransactionCostsOnDisposal" xlink:to="lab_gsk_TransactionCostsOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransactionCostsOnDisposal" xml:lang="en-US">Transaction costs on disposal.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherMember" xlink:label="loc_gsk_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherMember" xml:lang="en-US">Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherMember" xlink:to="lab_gsk_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherMember" xml:lang="en-US">Other Member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalMember" xml:lang="en-US">Two Thousand Twenty Business Disposal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalMember" xml:lang="en-US">2020 Business disposals [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandTwentyBusinessDisposalMember" xlink:to="lab_gsk_TwoThousandTwentyBusinessDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandTwentyBusinessDisposalMember" xml:lang="en-US">Two thousand twenty business disposal.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xml:lang="en-US">Acquisitions Two Thousand and Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xml:lang="en-US">2022 Acquisitions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xlink:to="lab_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xml:lang="en-US">2022 Acquisitions.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xml:lang="en-US">Two Thousand And Twenty Two Disposals Demerger [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xml:lang="en-US">2022 disposals demerger [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xlink:to="lab_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xml:lang="en-US">Two thousand and twenty two disposals demerger.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xml:lang="en-US">Cash Flows In Two Thousand And Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xml:lang="en-US">Cash flows in 2022 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xlink:to="lab_gsk_CashFlowsInTwoThousandAndTwentyTwoMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xml:lang="en-US">Two Thousand Twenty Two Business Disposals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xml:lang="en-US">2022 disposals [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xlink:to="lab_gsk_TwoThousandTwentyTwoBusinessDisposalsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xml:lang="en-US">Associates And Joint Ventures Two Thousand Twenty Two Disposals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xml:lang="en-US">Associates and joint ventures 2022 disposals [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xlink:to="lab_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xml:lang="en-US">Associates And Joint Ventures Two Thousand Twenty Two Disposals</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xml:lang="en-US">Cash and cash equivalents acquired/(divested)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredConsiderationReceived" xlink:label="loc_gsk_DeferredConsiderationReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DeferredConsiderationReceived" xml:lang="en-US">Deferred consideration received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DeferredConsiderationReceived" xml:lang="en-US">Net deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DeferredConsiderationReceived" xlink:to="lab_gsk_DeferredConsiderationReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DeferredConsiderationReceived" xml:lang="en-US">Deferred consideration received.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashOutflowInflowExcludingTransactionCosts" xlink:label="loc_gsk_CashOutflowInflowExcludingTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashOutflowInflowExcludingTransactionCosts" xml:lang="en-US">Cash Outflow Inflow Excluding Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashOutflowInflowExcludingTransactionCosts" xml:lang="en-US">Cash outflow/inflow excluding transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashOutflowInflowExcludingTransactionCosts" xlink:to="lab_gsk_CashOutflowInflowExcludingTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashOutflowInflowExcludingTransactionCosts" xml:lang="en-US">Cash outflow inflow excluding transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Adjustments for share-based payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Share-based incentive plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xml:lang="en-US">Adjustments for depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xml:lang="en-US">Adjustments for fair value losses (gains)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xml:lang="en-US">Fair value adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xml:lang="en-US">Adjustments For Profit On Sale Of Equity Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xml:lang="en-US">Profit on sale of equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xlink:to="lab_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xml:lang="en-US">Adjustments for profit on sale of equity investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xml:lang="en-US">Adjustments For Decrease Increase In Other Non Cash Contingent Consideration Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xml:lang="en-US">Other non-cash increase in contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xlink:to="lab_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xml:lang="en-US">Adjustments for decrease increase in other non cash increase in contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xml:lang="en-US">Adjustments For Profit On Sale Of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xml:lang="en-US">Profit on sale of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xlink:to="lab_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xml:lang="en-US">Adjustments for profit on sale of intangible assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xml:lang="en-US">Adjustments for amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xml:lang="en-US">Amortisation of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForAmortisationExpense" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ChangesInWorkingCapitalAbstract" xlink:label="loc_gsk_ChangesInWorkingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes In Working Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes in working capital:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ChangesInWorkingCapitalAbstract" xlink:to="lab_gsk_ChangesInWorkingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ChangesInWorkingCapitalAbstract" xml:lang="en-US">Changes In Working Capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xml:lang="en-US">Increase in trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xml:lang="en-US">Increase in trade payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xml:lang="en-US">Decrease/(increase)in inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xml:lang="en-US">Cash flows from (used in) operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xml:lang="en-US">Total cash generated from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xlink:label="loc_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xml:lang="en-US">Adjustments For Impairment And Assets Written Off</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xml:lang="en-US">Impairment and assets written off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xlink:to="lab_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xml:lang="en-US">Adjustments for impairment and assets written off.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfBusinesses" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfBusinesses" xml:lang="en-US">Adjustments For Profit On Sale Of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfBusinesses" xml:lang="en-US">Profit on sale of businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForProfitOnSaleOfBusinesses" xlink:to="lab_gsk_AdjustmentsForProfitOnSaleOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForProfitOnSaleOfBusinesses" xml:lang="en-US">Adjustments for profit on sale of businesses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xml:lang="en-US">(Increase) in other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xml:lang="en-US">Other adjustments to reconcile profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xml:lang="en-US">Adjustments for income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xml:lang="en-US">Tax on profits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xlink:label="loc_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xml:lang="en-US">Adjustments For Share Of After Tax Profits Of Associates And Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xml:lang="en-US">Share of after-tax profits of associates and joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xlink:to="lab_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xml:lang="en-US">Adjustments for share of after tax profits of associates and joint ventures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xml:lang="en-US">Increase/(decrease) in pension and other provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xml:lang="en-US">Increase in other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncomeCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" xml:lang="en-US">Adjustments for finance income (cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" xml:lang="en-US">Finance expense net of finance income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" xml:lang="en-US">Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" xml:lang="en-US">Loss on sale of investments in associates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Operating cash flow from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Operating cash flow from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsOfFinanceLeaseLiabilities" xlink:label="loc_gsk_PaymentsOfFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PaymentsOfFinanceLeaseLiabilities" xml:lang="en-US">Payments of finance lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_PaymentsOfFinanceLeaseLiabilities" xml:lang="en-US">Repayment of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PaymentsOfFinanceLeaseLiabilities" xlink:to="lab_gsk_PaymentsOfFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PaymentsOfFinanceLeaseLiabilities" xml:lang="en-US">Payments of finance lease liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInLiquidInvestment" xlink:label="loc_gsk_DecreaseIncreaseInLiquidInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseIncreaseInLiquidInvestment" xml:lang="en-US">Decrease Increase In Liquid Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseIncreaseInLiquidInvestment" xml:lang="en-US">Increase/(decrease) in liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseIncreaseInLiquidInvestment" xlink:to="lab_gsk_DecreaseIncreaseInLiquidInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseIncreaseInLiquidInvestment" xml:lang="en-US">Decrease increase in liquid investment.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeOnNetDebt" xlink:label="loc_gsk_ExchangeOnNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExchangeOnNetDebt" xml:lang="en-US">Exchange On Net Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExchangeOnNetDebt" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExchangeOnNetDebt" xlink:to="lab_gsk_ExchangeOnNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExchangeOnNetDebt" xml:lang="en-US">Exchange on net debt to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xlink:label="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xml:lang="en-US">Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes For Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xml:lang="en-US">Increase in cash and bank overdrafts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xlink:to="lab_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xml:lang="en-US">Increase decrease in cash and cash equivalents before effect of exchange rate changes for continuing operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xlink:label="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xml:lang="en-US">Other adjustments for non-cash items to net debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xml:lang="en-US">Other non-cash movements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xlink:to="lab_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xml:lang="en-US">Other adjustments for non-cash items to net debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtOfSubsidiaryUndertakingsAcquired" xlink:label="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DebtOfSubsidiaryUndertakingsAcquired" xml:lang="en-US">Debt of subsidiary undertakings acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DebtOfSubsidiaryUndertakingsAcquired" xml:lang="en-US">Debt of subsidiary undertakings acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired" xlink:to="lab_gsk_DebtOfSubsidiaryUndertakingsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DebtOfSubsidiaryUndertakingsAcquired" xml:lang="en-US">Debt of subsidiary undertakings acquired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xml:lang="en-US">Repayments of bonds, notes and debentures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xml:lang="en-US">Repayment of medium term notes (MTNs)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xml:lang="en-US">Decrease Increase In Net Debt From Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xml:lang="en-US">Decrease/(increase) in net debt from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xlink:to="lab_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xml:lang="en-US">Decrease Increase In Net Debt From Continuing Operations.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xml:lang="en-US">Decrease Increase In Net Debt From Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xml:lang="en-US">Decrease/(increase) in net debt from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xlink:to="lab_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xml:lang="en-US">Decrease Increase In Net Debt From Discontinued Operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfNetDebt" xlink:label="loc_gsk_ReclassificationOfNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReclassificationOfNetDebt" xml:lang="en-US">Reclassification of net debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_ReclassificationOfNetDebt" xml:lang="en-US">Reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReclassificationOfNetDebt" xlink:to="lab_gsk_ReclassificationOfNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReclassificationOfNetDebt" xml:lang="en-US">Reclassification of net debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Cash flow</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Increase (decrease) through other changes, liabilities arising from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense" xlink:to="lab_ifrs-full_InterestExpense" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xlink:label="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Increase (decrease) through Demerger dividend, liabilities arising from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Demerger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xlink:to="lab_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Increase (decrease) through Demerger dividend, liabilities arising from financing activities</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ChangeInFairValueOfNetDebt" xlink:label="loc_gsk_ChangeInFairValueOfNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ChangeInFairValueOfNetDebt" xml:lang="en-US">Change In Fair Value Of Net Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ChangeInFairValueOfNetDebt" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ChangeInFairValueOfNetDebt" xlink:to="lab_gsk_ChangeInFairValueOfNetDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ChangeInFairValueOfNetDebt" xml:lang="en-US">Change in fair value of net debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xml:lang="en-US">Liabilities Arising From Financing Activities Attributed To Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xlink:to="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xml:lang="en-US">The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xml:lang="en-US">Liabilities Arising From Financing Activities Adjusted For Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xml:lang="en-US">Beginning balance adjusted for discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xlink:to="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xml:lang="en-US">The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities, opening balance as on 01.01.22 adjusted for amounts attributed to discontinued operations". [Refer: Cash flows from (used in) financing activities; Liabilities]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xml:lang="en-US">Liabilities Arising From Financing Activities Attributable To Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xlink:to="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xml:lang="en-US">The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributed to discontinued operations; Liabilities].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xml:lang="en-US">Liabilities Arising From Financing Activities Attributable To Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xlink:to="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xml:lang="en-US">The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xml:lang="en-US">Liabilities Arising From Financing Activities Attributed To Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xlink:to="lab_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xml:lang="en-US">The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to discontinued operations; Liabilities].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalents" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalents" xml:lang="en-US">Liquid Investments Cash And Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalents" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsCashAndCashEquivalents" xlink:to="lab_gsk_LiquidInvestmentsCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalents" xml:lang="en-US">Liquid investments cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Liabilities arising from financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xlink:label="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xml:lang="en-US">Cash And Cash Equivalents And Net Of Overdrafts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xlink:to="lab_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xml:lang="en-US">Cash and cash equivalents and net of overdrafts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialInstrumentsMember" xlink:label="loc_gsk_DerivativeFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DerivativeFinancialInstrumentsMember" xml:lang="en-US">Derivative financial instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DerivativeFinancialInstrumentsMember" xml:lang="en-US">Derivative financial instruments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DerivativeFinancialInstrumentsMember" xlink:to="lab_gsk_DerivativeFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DerivativeFinancialInstrumentsMember" xml:lang="en-US">Derivative financial instruments [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankOverdrafts1Member" xlink:label="loc_gsk_BankOverdrafts1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BankOverdrafts1Member" xml:lang="en-US">Bank Overdrafts 1 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BankOverdrafts1Member" xml:lang="en-US">Overdrafts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BankOverdrafts1Member" xlink:to="lab_gsk_BankOverdrafts1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BankOverdrafts1Member" xml:lang="en-US">Bank overdrafts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentMember" xlink:label="loc_gsk_CashAndCashEquivalentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentMember" xml:lang="en-US">Cash and Cash Equivalent [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashAndCashEquivalentMember" xml:lang="en-US">Cash and cash equivalents [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentMember" xlink:to="lab_gsk_CashAndCashEquivalentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentMember" xml:lang="en-US">Cash and cash equivalent.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsMember" xlink:label="loc_gsk_LiquidInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsMember" xml:lang="en-US">Liquid Investments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidInvestmentsMember" xml:lang="en-US">Liquid Investments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsMember" xlink:to="lab_gsk_LiquidInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidInvestmentsMember" xml:lang="en-US">Liquid investments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndBankOverdraftsMember" xlink:label="loc_gsk_CashAndBankOverdraftsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndBankOverdraftsMember" xml:lang="en-US">Cash and Bank Overdrafts [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashAndBankOverdraftsMember" xml:lang="en-US">Cash and cash equivalents and overdrafts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndBankOverdraftsMember" xlink:to="lab_gsk_CashAndBankOverdraftsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndBankOverdraftsMember" xml:lang="en-US">Cash and bank overdrafts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" xml:lang="en-US">Liquid Investments Attributed to Continuing Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" xlink:to="lab_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" xml:lang="en-US">Liquid Investments Attributed to Discontinued Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" xlink:to="lab_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xml:lang="en-US">Liquid Investments, Cash And Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xml:lang="en-US">Liquid investments, cash and cash equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xlink:to="lab_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xml:lang="en-US">Liquid investments, cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xlink:label="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xml:lang="en-US">European/US Medium Term Notes and Bank Facilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xml:lang="en-US">European/US Medium Term Notes &amp; Bank Facilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xlink:to="lab_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xml:lang="en-US">European US Medium Term Notes and Bank Facilities [member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xml:lang="en-US">Lease liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xml:lang="en-US">Lease liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCurrentDebtMember" xlink:label="loc_gsk_OtherCurrentDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherCurrentDebtMember" xml:lang="en-US">Other Current Debt [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherCurrentDebtMember" xml:lang="en-US">Other [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherCurrentDebtMember" xlink:to="lab_gsk_OtherCurrentDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherCurrentDebtMember" xml:lang="en-US">Other current debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" xml:lang="en-US">Short Term Borrowings Attributed to Discontinued Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" xlink:to="lab_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" xml:lang="en-US">Short Term Borrowings Attributed to Continuing Operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" xlink:to="lab_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsContinuingOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsContinuingOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LongTermBorrowingsContinuingOperationsMember" xml:lang="en-US">Long term borrowings continuing operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LongTermBorrowingsContinuingOperationsMember" xlink:to="lab_gsk_LongTermBorrowingsContinuingOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LongTermBorrowingsContinuingOperationsMember" xml:lang="en-US">Long term borrowings continuing operations</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsDiscontinuedOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LongTermBorrowingsDiscontinuedOperationsMember" xml:lang="en-US">Long term borrowings discontinued operations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember" xlink:to="lab_gsk_LongTermBorrowingsDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LongTermBorrowingsDiscontinuedOperationsMember" xml:lang="en-US">Long term borrowings discontinued operations</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xml:lang="en-US">Liabilities arising from financing activities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xml:lang="en-US">Liabilities arising from financing activities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xml:lang="en-US">Liabilities arising from financing activities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xml:lang="en-US">Liabilities arising from financing activities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="loc_ifrs-full_ShorttermBorrowingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermBorrowingsMember" xml:lang="en-US">Short-term borrowings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermBorrowingsMember" xml:lang="en-US">Short-term borrowings [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermBorrowingsMember" xlink:to="lab_ifrs-full_ShorttermBorrowingsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetDebtMember" xlink:label="loc_gsk_NetDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetDebtMember" xml:lang="en-US">Net Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetDebtMember" xml:lang="en-US">Net Debt [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetDebtMember" xlink:to="lab_gsk_NetDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetDebtMember" xml:lang="en-US">Net debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AccruedInterestMember" xlink:label="loc_gsk_AccruedInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AccruedInterestMember" xml:lang="en-US">Accrued interest [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AccruedInterestMember" xml:lang="en-US">Accrued interest [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AccruedInterestMember" xlink:to="lab_gsk_AccruedInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AccruedInterestMember" xml:lang="en-US">Accrued interest [member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xml:lang="en-US">Assets held to hedge liabilities arising from financing activities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xml:lang="en-US">Assets held to hedge liabilities arising from financing activities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:to="lab_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xml:lang="en-US">Long-term borrowings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xml:lang="en-US">Long Term Borrowings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember" xlink:to="lab_ifrs-full_LongtermBorrowingsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgrammeMember" xlink:label="loc_gsk_EuroCommercialPaperProgrammeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EuroCommercialPaperProgrammeMember" xml:lang="en-US">Euro Commercial Paper Programme [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EuroCommercialPaperProgrammeMember" xml:lang="en-US">Euro Commercial Paper Program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EuroCommercialPaperProgrammeMember" xlink:to="lab_gsk_EuroCommercialPaperProgrammeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EuroCommercialPaperProgrammeMember" xml:lang="en-US">Euro Commercial Paper Programme.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="loc_ifrs-full_ExternalCreditGradesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExternalCreditGradesAxis" xml:lang="en-US">External credit grades [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExternalCreditGradesAxis" xml:lang="en-US">External credit grades [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis" xlink:to="lab_ifrs-full_ExternalCreditGradesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForExternalCreditGradesMember" xml:lang="en-US">Entity's total for external credit grades [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForExternalCreditGradesMember" xml:lang="en-US">Entity's total for external credit grades [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="lab_ifrs-full_EntitysTotalForExternalCreditGradesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBB-OrBaaThreeRatedMember" xlink:label="loc_gsk_BBB-OrBaaThreeRatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BBB-OrBaaThreeRatedMember" xml:lang="en-US">BBB -Or Baa Three Rated [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BBB-OrBaaThreeRatedMember" xml:lang="en-US">BBB -/ Baa3 Rated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BBB-OrBaaThreeRatedMember" xlink:to="lab_gsk_BBB-OrBaaThreeRatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BBB-OrBaaThreeRatedMember" xml:lang="en-US">BBB -/ Baa3 rated.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BbbOrBaaMember" xlink:label="loc_gsk_BbbOrBaaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BbbOrBaaMember" xml:lang="en-US">BBB Or Baa [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BbbOrBaaMember" xml:lang="en-US">BBB/Baa [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BbbOrBaaMember" xlink:to="lab_gsk_BbbOrBaaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BbbOrBaaMember" xml:lang="en-US">BBB/Baa.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesMember" xlink:label="loc_ifrs-full_ExternalCreditGradesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExternalCreditGradesMember" xml:lang="en-US">External credit grades [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExternalCreditGradesMember" xml:lang="en-US">External credit grades [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExternalCreditGradesMember" xlink:to="lab_ifrs-full_ExternalCreditGradesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LowerThanBBBBaa3Member" xlink:label="loc_gsk_LowerThanBBBBaa3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LowerThanBBBBaa3Member" xml:lang="en-US">Lower Than BBB Baa3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LowerThanBBBBaa3Member" xml:lang="en-US">Lower than BBB-/Baa3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LowerThanBBBBaa3Member" xlink:to="lab_gsk_LowerThanBBBBaa3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LowerThanBBBBaa3Member" xml:lang="en-US">Lower than BBB-/Baa3.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xml:lang="en-US">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xml:lang="en-US">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:to="lab_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xml:lang="en-US">Trade and other receivables and other noncurrent assets in scope of IFRS 9.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BondsInDesignatedHedgingRelationshipMember" xlink:label="loc_gsk_BondsInDesignatedHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BondsInDesignatedHedgingRelationshipMember" xml:lang="en-US">Bonds In A Designated Hedging Relationship [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BondsInDesignatedHedgingRelationshipMember" xml:lang="en-US">Bonds In A Designated Hedging Relationship [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BondsInDesignatedHedgingRelationshipMember" xlink:to="lab_gsk_BondsInDesignatedHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BondsInDesignatedHedgingRelationshipMember" xml:lang="en-US">Bonds in a designated hedging relationship.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DueFromThreeWholesalersMember" xlink:label="loc_gsk_DueFromThreeWholesalersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DueFromThreeWholesalersMember" xml:lang="en-US">Due From Three Wholesalers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DueFromThreeWholesalersMember" xlink:to="lab_gsk_DueFromThreeWholesalersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DueFromThreeWholesalersMember" xml:lang="en-US">Due from three wholesalers.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StateBankOfIndiaMember" xlink:label="loc_gsk_StateBankOfIndiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_StateBankOfIndiaMember" xml:lang="en-US">State Bank Of India [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_StateBankOfIndiaMember" xml:lang="en-US">State Bank of India [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_StateBankOfIndiaMember" xlink:to="lab_gsk_StateBankOfIndiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_StateBankOfIndiaMember" xml:lang="en-US">State Bank of India.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NG" xlink:label="loc_country_NG" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_NG" xml:lang="en-US">NIGERIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_NG" xml:lang="en-US">Nigeria [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_NG" xlink:to="lab_country_NG" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonUsaMember" xlink:label="loc_gsk_NonUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonUsaMember" xml:lang="en-US">Non USA .[member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NonUsaMember" xml:lang="en-US">Non USA [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonUsaMember" xlink:to="lab_gsk_NonUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonUsaMember" xml:lang="en-US">Non USA .[member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_EC" xlink:label="loc_country_EC" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_EC" xml:lang="en-US">ECUADOR</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_EC" xml:lang="en-US">Ecuador [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_EC" xlink:to="lab_country_EC" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HN" xlink:label="loc_country_HN" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_HN" xml:lang="en-US">HONDURAS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_HN" xml:lang="en-US">Honduras [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_HN" xlink:to="lab_country_HN" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KH" xlink:label="loc_country_KH" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_KH" xml:lang="en-US">CAMBODIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_KH" xml:lang="en-US">Cambodia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KH" xlink:to="lab_country_KH" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="loc_country_BR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BR" xml:lang="en-US">BRAZIL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR" xlink:label="loc_country_CR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CR" xml:lang="en-US">COSTA RICA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_CR" xml:lang="en-US">Costa Rica</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CR" xlink:to="lab_country_CR" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InLineWithOtherPharmaceuticalCompaniesMember" xlink:label="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InLineWithOtherPharmaceuticalCompaniesMember" xml:lang="en-US">In Line With Other Pharmaceutical Companies [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InLineWithOtherPharmaceuticalCompaniesMember" xml:lang="en-US">In Line with Other Pharmaceutical Companies [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember" xlink:to="lab_gsk_InLineWithOtherPharmaceuticalCompaniesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InLineWithOtherPharmaceuticalCompaniesMember" xml:lang="en-US">In line with other pharmaceutical companies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanThreeMonthsMember" xml:lang="en-US">Not later than three months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotLaterThanThreeMonthsMember" xml:lang="en-US">Not later than three months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_NotLaterThanThreeMonthsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JTrustRoyalBankMember" xlink:label="loc_gsk_JTrustRoyalBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_JTrustRoyalBankMember" xml:lang="en-US">J Trust Royal Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_JTrustRoyalBankMember" xlink:to="lab_gsk_JTrustRoyalBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_JTrustRoyalBankMember" xml:lang="en-US">J trust royal bank.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BacSanJoseMember" xlink:label="loc_gsk_BacSanJoseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BacSanJoseMember" xml:lang="en-US">BAC San Jose [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BacSanJoseMember" xlink:to="lab_gsk_BacSanJoseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BacSanJoseMember" xml:lang="en-US">BAC san jose.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDoBrasilMember" xlink:label="loc_gsk_BancoDoBrasilMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BancoDoBrasilMember" xml:lang="en-US">Banco Do Brasil [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BancoDoBrasilMember" xlink:to="lab_gsk_BancoDoBrasilMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BancoDoBrasilMember" xml:lang="en-US">Banco do brasil.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDeHondurasMember" xlink:label="loc_gsk_BancoDeHondurasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BancoDeHondurasMember" xml:lang="en-US">Banco De Honduras [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BancoDeHondurasMember" xlink:to="lab_gsk_BancoDeHondurasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BancoDeHondurasMember" xml:lang="en-US">Banco de honduras.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProdubancoMember" xlink:label="loc_gsk_ProdubancoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ProdubancoMember" xml:lang="en-US">Produbanco [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ProdubancoMember" xlink:to="lab_gsk_ProdubancoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ProdubancoMember" xml:lang="en-US">Produbanco.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HalkBankMember" xlink:label="loc_gsk_HalkBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HalkBankMember" xml:lang="en-US">Halk Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HalkBankMember" xlink:to="lab_gsk_HalkBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HalkBankMember" xml:lang="en-US">Halk bank.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xlink:label="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xml:lang="en-US">United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xlink:to="lab_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xml:lang="en-US">United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesBusinessMember" xlink:label="loc_gsk_NovartisVaccinesBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NovartisVaccinesBusinessMember" xml:lang="en-US">Novartis Vaccines Business [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NovartisVaccinesBusinessMember" xlink:to="lab_gsk_NovartisVaccinesBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NovartisVaccinesBusinessMember" xml:lang="en-US">Novartis vaccines business.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesalerInTheUsMember" xlink:label="loc_gsk_WholesalerInTheUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WholesalerInTheUsMember" xml:lang="en-US">Wholesaler In The US [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WholesalerInTheUsMember" xlink:to="lab_gsk_WholesalerInTheUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WholesalerInTheUsMember" xml:lang="en-US">Wholesaler in the US.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditRiskMember" xml:lang="en-US">Credit Risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditRiskMember" xml:lang="en-US">Credit risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember" xlink:to="lab_ifrs-full_CreditRiskMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Point Five Percent Movement In USD Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) movement in USD interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) movement in USD interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Point Five Percent Movement In EUR Or Sterling Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) movement in EUR or Sterling interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) movement in EUR or Sterling interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Percent Movement In EUR Or Sterling Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">1% (100 basis points) movement in EUR or Sterling interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xml:lang="en-US">1% (100 basis points) movement in EUR or Sterling interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesaleAndRetailCreditRiskMember" xlink:label="loc_gsk_WholesaleAndRetailCreditRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WholesaleAndRetailCreditRiskMember" xml:lang="en-US">Wholesale and retail credit risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WholesaleAndRetailCreditRiskMember" xlink:to="lab_gsk_WholesaleAndRetailCreditRiskMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeRiskMember" xlink:label="loc_gsk_ForeignExchangeRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ForeignExchangeRiskMember" xml:lang="en-US">Foreign exchange risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ForeignExchangeRiskMember" xml:lang="en-US">Foreign exchange risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ForeignExchangeRiskMember" xlink:to="lab_gsk_ForeignExchangeRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ForeignExchangeRiskMember" xml:lang="en-US">Foreign exchange risk.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Percent Movement In USD Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xml:lang="en-US">1% (100 basis points) movement in USD interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xml:lang="en-US">1% (100 basis points) movement in USD interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeAxis" xlink:label="loc_gsk_TypeOfIncomeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TypeOfIncomeAxis" xml:lang="en-US">Type Of Income [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TypeOfIncomeAxis" xlink:to="lab_gsk_TypeOfIncomeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TypeOfIncomeAxis" xml:lang="en-US">Type Of Income.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeDomain" xlink:label="loc_gsk_TypeOfIncomeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TypeOfIncomeDomain" xml:lang="en-US">Type Of Income [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TypeOfIncomeDomain" xlink:to="lab_gsk_TypeOfIncomeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TypeOfIncomeDomain" xml:lang="en-US">Type Of Income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Carrying Value Of Shares Held By Trust Under Employee Share Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Carrying value of shares held by trust under employee share ownership plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:to="lab_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Carrying value of shares held by trust under employee share ownership plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:label="loc_gsk_BankBalancesAndDepositHeldWithCounterparties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BankBalancesAndDepositHeldWithCounterparties" xml:lang="en-US">Bank Balances And Deposit Held With Counterparties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_BankBalancesAndDepositHeldWithCounterparties" xml:lang="en-US">Bank balances and deposits held with counter parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BankBalancesAndDepositHeldWithCounterparties" xml:lang="en-US">Bank balances and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:to="lab_gsk_BankBalancesAndDepositHeldWithCounterparties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BankBalancesAndDepositHeldWithCounterparties" xml:lang="en-US">Bank balances and deposit held with counter parties.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConcentrationsOfRiskRevenuePercentage" xlink:label="loc_gsk_ConcentrationsOfRiskRevenuePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ConcentrationsOfRiskRevenuePercentage" xml:lang="en-US">Concentrations of risk revenue percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ConcentrationsOfRiskRevenuePercentage" xml:lang="en-US">Percentage of sales of US Commercial Operation business to three largest wholesalers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ConcentrationsOfRiskRevenuePercentage" xlink:to="lab_gsk_ConcentrationsOfRiskRevenuePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ConcentrationsOfRiskRevenuePercentage" xml:lang="en-US">Concentrations of risk revenue percentage.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAndDebtNet" xlink:label="loc_gsk_EquityAndDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityAndDebtNet" xml:lang="en-US">Equity And Debt Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityAndDebtNet" xml:lang="en-US">Total capital including that provided by non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityAndDebtNet" xlink:to="lab_gsk_EquityAndDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityAndDebtNet" xml:lang="en-US">The amount of total capital consisting of equity and net debt</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xml:lang="en-US">Maximum exposure to credit risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xml:lang="en-US">Maximum exposure to credit risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:to="lab_ifrs-full_MaximumExposureToCreditRisk" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xml:lang="en-US">Cash and cash equivalents and liquid investments held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xml:lang="en-US">Cash and cash equivalents and liquid investments held centrally</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xlink:to="lab_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xml:lang="en-US">Cash and cash equivalents and liquid investments held.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Amount Held At European Medium Term Note Programme</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Amount held at European medium term note programme</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xlink:to="lab_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Amount held at European medium term note programme.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditExposure" xml:lang="en-US">Credit exposure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditExposure" xml:lang="en-US">Concentration of credit risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditExposure" xlink:to="lab_ifrs-full_CreditExposure" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BalancesWithBanks" xlink:label="loc_ifrs-full_BalancesWithBanks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BalancesWithBanks" xml:lang="en-US">Balances with banks</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BalancesWithBanks" xml:lang="en-US">Balances or deposits with banks</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BalancesWithBanks" xlink:to="lab_ifrs-full_BalancesWithBanks" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Fair Value Of Shares Held By Trust Under Employee Share Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Market value of shares held by trust under employee share ownership plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:to="lab_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xml:lang="en-US">Fair value of shares held by trust under employee share ownership plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xlink:label="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xml:lang="en-US">Cash Held At Unrated Counterparties Cash In Transit Element</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xml:lang="en-US">Cash in transit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xlink:to="lab_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xml:lang="en-US">Cash held at unrated counterparties cash in transit element.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterparties" xlink:label="loc_gsk_CashHeldAtUnratedCounterparties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashHeldAtUnratedCounterparties" xml:lang="en-US">Cash Held At Unrated Counterparties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashHeldAtUnratedCounterparties" xml:lang="en-US">Amount of cash held at unrated counter parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashHeldAtUnratedCounterparties" xlink:to="lab_gsk_CashHeldAtUnratedCounterparties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashHeldAtUnratedCounterparties" xml:lang="en-US">Cash held at unrated counterparties.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashReserves" xlink:label="loc_gsk_CashReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashReserves" xml:lang="en-US">Cash Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashReserves" xml:lang="en-US">Cash reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashReserves" xlink:to="lab_gsk_CashReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashReserves" xml:lang="en-US">Cash reserves.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestments" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestments" xml:lang="en-US">Cash and cash equivalents and liquid investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestments" xml:lang="en-US">Cash and cash equivalents and liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments" xlink:to="lab_gsk_CashAndCashEquivalentsAndLiquidInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalentsAndLiquidInvestments" xml:lang="en-US">Cash and cash equivalents and liquid investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnHedgeIneffectiveness" xml:lang="en-US">Gain (loss) on hedge ineffectiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainLossOnHedgeIneffectiveness" xml:lang="en-US">Ineffectiveness of hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnHedgeIneffectiveness" xlink:to="lab_ifrs-full_GainLossOnHedgeIneffectiveness" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" xml:lang="en-US">Increase decrease in income through interest rate movements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" xml:lang="en-US">Impact on equity through interest rate movements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" xml:lang="en-US">Increase/(decrease) in income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" xlink:to="lab_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements" xml:lang="en-US">Increase (decrease) in income through interest rate movements.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfAccountsReceivableByMajorCustomer" xlink:label="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfAccountsReceivableByMajorCustomer" xml:lang="en-US">Percentage of accounts receivable by major customer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfAccountsReceivableByMajorCustomer" xml:lang="en-US">Maximum percentage of trade receivables balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer" xlink:to="lab_gsk_PercentageOfAccountsReceivableByMajorCustomer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfAccountsReceivableByMajorCustomer" xml:lang="en-US">Percentage of accounts receivable by major customer.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Notes Issued At European Medium Term Note Programme</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Notes issued at European medium term note programme</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xlink:to="lab_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xml:lang="en-US">Notes issued at European medium term note programme.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedUnderUsShelfRegistration" xlink:label="loc_gsk_NotesIssuedUnderUsShelfRegistration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NotesIssuedUnderUsShelfRegistration" xml:lang="en-US">Notes Issued Under US Shelf Registration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NotesIssuedUnderUsShelfRegistration" xml:lang="en-US">Notes issued under us shelf registration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NotesIssuedUnderUsShelfRegistration" xlink:to="lab_gsk_NotesIssuedUnderUsShelfRegistration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NotesIssuedUnderUsShelfRegistration" xml:lang="en-US">Notes issued under US shelf registration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="loc_ifrs-full_TreasuryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TreasuryShares" xml:lang="en-US">Treasury shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TreasuryShares" xml:lang="en-US">Treasury shares at cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xml:lang="en-US">Reserve of cash flow hedges, hedging relationships for which hedge accounting is no longer applied</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xml:lang="en-US">Cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xlink:to="lab_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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." xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." xml:lang="en-US">Increase (decrease) in equity through interest rate movements.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." xml:lang="en-US">Impact on equity through interest rate movements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." xlink:to="lab_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements." xml:lang="en-US">Increase (decrease) in equity through interest rate movements.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfTheContingentConsiderationPayable" xlink:label="loc_gsk_RemeasurementOfTheContingentConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RemeasurementOfTheContingentConsiderationPayable" xml:lang="en-US">Remeasurement of the Contingent Consideration Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RemeasurementOfTheContingentConsiderationPayable" xml:lang="en-US">Remeasurement of the contingent consideration payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RemeasurementOfTheContingentConsiderationPayable" xlink:to="lab_gsk_RemeasurementOfTheContingentConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RemeasurementOfTheContingentConsiderationPayable" xml:lang="en-US">Remeasurement of the contingent consideration payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xml:lang="en-US">Gain loss measured in profit or loss fair value measurement liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xml:lang="en-US">Liabilities transferred out of level three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:to="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xlink:label="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xml:lang="en-US">Carrying Value Of Bonds That Were Designated As Hedging Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xml:lang="en-US">Carrying value of bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xlink:to="lab_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xml:lang="en-US">carrying value of bonds that were designated as hedging instruments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xlink:label="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xml:lang="en-US">Gains Losses Attributable To Level 3 Of Fair Value Hierarchy Recognised In Income statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xml:lang="en-US">Total net losses on financial instruments held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xlink:to="lab_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xml:lang="en-US">Gains losses attributable to level 3 of fair value hierarchy recognised in income statement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashManagedForSubsidiaryCompany" xlink:label="loc_gsk_CashManagedForSubsidiaryCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashManagedForSubsidiaryCompany" xml:lang="en-US">Cash Managed For Subsidiary Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashManagedForSubsidiaryCompany" xml:lang="en-US">Cash managed by group for subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashManagedForSubsidiaryCompany" xlink:to="lab_gsk_CashManagedForSubsidiaryCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashManagedForSubsidiaryCompany" xml:lang="en-US">Cash managed for subsidiary company.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xlink:label="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xml:lang="en-US">Losses attributable to level 3 financial instruments reported in other operating income expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xml:lang="en-US">Total net losses on financial instruments held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xlink:to="lab_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xml:lang="en-US">Losses attributable to level 3 financial instruments reported in other operating income expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInsuranceContractsAxis" xlink:label="loc_ifrs-full_TypesOfInsuranceContractsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInsuranceContractsAxis" xml:lang="en-US">Types of insurance contracts [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfInsuranceContractsAxis" xml:lang="en-US">Types of insurance contracts [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInsuranceContractsAxis" xlink:to="lab_ifrs-full_TypesOfInsuranceContractsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceContractsMember" xlink:label="loc_ifrs-full_InsuranceContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InsuranceContractsMember" xml:lang="en-US">Types of insurance contracts [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InsuranceContractsMember" xml:lang="en-US">Types of insurance contracts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InsuranceContractsMember" xlink:to="lab_ifrs-full_InsuranceContractsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xlink:label="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xml:lang="en-US">Group Credit Enhancements And Credit Insurance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xml:lang="en-US">Group credit enhancements and credit insurance [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xlink:to="lab_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xml:lang="en-US">Group credit enhancements and credit insurance.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateSensitivityMember" xlink:label="loc_gsk_InterestRateSensitivityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateSensitivityMember" xml:lang="en-US">Interest Rate Sensitivity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateSensitivityMember" xml:lang="en-US">Interest rate sensitivity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateSensitivityMember" xlink:to="lab_gsk_InterestRateSensitivityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateSensitivityMember" xml:lang="en-US">Interest rate sensitivity.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisAxis" xlink:label="loc_gsk_EventBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EventBasisAxis" xml:lang="en-US">Event Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EventBasisAxis" xlink:to="lab_gsk_EventBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EventBasisAxis" xml:lang="en-US">Event basis.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisDomain" xlink:label="loc_gsk_EventBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EventBasisDomain" xml:lang="en-US">Event Basis [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EventBasisDomain" xlink:to="lab_gsk_EventBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EventBasisDomain" xml:lang="en-US">Event basis.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xml:lang="en-US">Types of hedges [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xml:lang="en-US">Types of hedges [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesAxis" xlink:to="lab_ifrs-full_TypesOfHedgesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xml:lang="en-US">Hedges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xml:lang="en-US">Hedges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesMember" xlink:to="lab_ifrs-full_TypesOfHedgesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:label="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xml:lang="en-US">Hedges of net investment in foreign operations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xml:lang="en-US">Hedges of net investment in foreign operations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xml:lang="en-US">Hedges of net investment in foreign operations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:to="lab_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xml:lang="en-US">Cash flow hedges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xml:lang="en-US">Cash flow hedges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xml:lang="en-US">Cash Flow Hedges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowHedgesMember" xlink:to="lab_ifrs-full_CashFlowHedgesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgedMember" xlink:label="loc_gsk_NetInvestmentHedgedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetInvestmentHedgedMember" xml:lang="en-US">Net Investment Hedged [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetInvestmentHedgedMember" xlink:to="lab_gsk_NetInvestmentHedgedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetInvestmentHedgedMember" xml:lang="en-US">Net investment hedged.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortizedCostMember" xlink:label="loc_gsk_AmortizedCostMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AmortizedCostMember" xml:lang="en-US">Amortized Cost [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AmortizedCostMember" xlink:to="lab_gsk_AmortizedCostMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial Assets at Fair Value Through Profit or Loss, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ForeignExchangeContractsMember" xml:lang="en-US">Foreign Exchange Contracts [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ForeignExchangeContractsMember" xml:lang="en-US">Foreign Exchange Contracts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ForeignExchangeContractsMember" xlink:to="lab_gsk_ForeignExchangeContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ForeignExchangeContractsMember" xml:lang="en-US">Foreign exchange contracts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xml:lang="en-US">Classes of liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesMember" xml:lang="en-US">Liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitesOneMember" xlink:label="loc_gsk_FinancialLiabilitesOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialLiabilitesOneMember" xml:lang="en-US">Financial Liabilites One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialLiabilitesOneMember" xlink:to="lab_gsk_FinancialLiabilitesOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialLiabilitesOneMember" xml:lang="en-US">Financial liabilites one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresAbstract" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresAbstract" xml:lang="en-US">Disclosure of external credit grades [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresAbstract" xlink:to="lab_ifrs-full_DisclosureOfExternalCreditExposuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresTable" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresTable" xml:lang="en-US">Disclosure of external credit grades [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresTable" xml:lang="en-US">Disclosure of external credit grades [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable" xlink:to="lab_ifrs-full_DisclosureOfExternalCreditExposuresTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AAAOrAaaMember" xlink:label="loc_gsk_AAAOrAaaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AAAOrAaaMember" xml:lang="en-US">AAA Or Aaa [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AAAOrAaaMember" xml:lang="en-US">AAA/Aaa [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AAAOrAaaMember" xlink:to="lab_gsk_AAAOrAaaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AAAOrAaaMember" xml:lang="en-US">AAA/Aaa.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AaOrAaMember" xlink:label="loc_gsk_AaOrAaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AaOrAaMember" xml:lang="en-US">AA Or Aa [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AaOrAaMember" xml:lang="en-US">AA/Aa [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AaOrAaMember" xlink:to="lab_gsk_AaOrAaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AaOrAaMember" xml:lang="en-US">AA /Aa.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AorAMember" xlink:label="loc_gsk_AorAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AorAMember" xml:lang="en-US">A or A [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AorAMember" xml:lang="en-US">A/A [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AorAMember" xlink:to="lab_gsk_AorAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AorAMember" xml:lang="en-US">A/A.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBPlusOrBaOneMember" xlink:label="loc_gsk_BBPlusOrBaOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BBPlusOrBaOneMember" xml:lang="en-US">BB Plus Or Ba One [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BBPlusOrBaOneMember" xml:lang="en-US">BB+/Ba1 and Below/Unrated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BBPlusOrBaOneMember" xlink:to="lab_gsk_BBPlusOrBaOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BBPlusOrBaOneMember" xml:lang="en-US">BB+/Ba1 and Below/Unrated.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xml:lang="en-US">Disclosure of external credit grades [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xml:lang="en-US">Disclosure of external credit grades [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xlink:to="lab_ifrs-full_DisclosureOfExternalCreditExposuresLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="loc_ifrs-full_DerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xml:lang="en-US">Derivative financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xml:lang="en-US">Third party financial derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialAssets" xlink:to="lab_ifrs-full_DerivativeFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RatedCreditExposures" xlink:label="loc_ifrs-full_RatedCreditExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RatedCreditExposures" xml:lang="en-US">Rated credit exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_RatedCreditExposures" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RatedCreditExposures" xlink:to="lab_ifrs-full_RatedCreditExposures" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xlink:label="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xml:lang="en-US">US Treasury And Treasury Repo Only Money Market Funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xml:lang="en-US">US Treasury and Treasury repo only money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xlink:to="lab_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xml:lang="en-US">Us treasury and treasury repo only money market funds.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentSecurities" xlink:label="loc_gsk_GovernmentSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GovernmentSecurities" xml:lang="en-US">Government Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GovernmentSecurities" xml:lang="en-US">Government securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GovernmentSecurities" xlink:to="lab_gsk_GovernmentSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GovernmentSecurities" xml:lang="en-US">Government securities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidityFunds" xlink:label="loc_gsk_LiquidityFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LiquidityFunds" xml:lang="en-US">Liquidity Funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LiquidityFunds" xml:lang="en-US">Liquidity funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LiquidityFunds" xlink:to="lab_gsk_LiquidityFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LiquidityFunds" xml:lang="en-US">Liquidity funds.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayableMember" xlink:label="loc_gsk_TradeAndOtherPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradeAndOtherPayableMember" xml:lang="en-US">Trade and Other Payable [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TradeAndOtherPayableMember" xml:lang="en-US">Trade and other payable [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradeAndOtherPayableMember" xlink:to="lab_gsk_TradeAndOtherPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradeAndOtherPayableMember" xml:lang="en-US">Trade and other payable.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentLiabilitiesMember" xlink:label="loc_gsk_OtherNonCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherNonCurrentLiabilitiesMember" xml:lang="en-US">Other non current liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherNonCurrentLiabilitiesMember" xml:lang="en-US">Other non current liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherNonCurrentLiabilitiesMember" xlink:to="lab_gsk_OtherNonCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherNonCurrentLiabilitiesMember" xml:lang="en-US">Other non current liabilities .</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansAndOverdraftsMember" xlink:label="loc_gsk_BankLoansAndOverdraftsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BankLoansAndOverdraftsMember" xml:lang="en-US">Bank loans and overdrafts [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BankLoansAndOverdraftsMember" xml:lang="en-US">Bank Loans and Overdrafts [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BankLoansAndOverdraftsMember" xlink:to="lab_gsk_BankLoansAndOverdraftsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BankLoansAndOverdraftsMember" xml:lang="en-US">Bank loans and overdrafts.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBorrowingMember" xlink:label="loc_gsk_OtherBorrowingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherBorrowingMember" xml:lang="en-US">Other Borrowing [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherBorrowingMember" xml:lang="en-US">Other Borrowing [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherBorrowingMember" xlink:to="lab_gsk_OtherBorrowingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherBorrowingMember" xml:lang="en-US">Other Borrowing [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBondsMember" xlink:label="loc_gsk_OtherBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherBondsMember" xml:lang="en-US">Other Bonds [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherBondsMember" xml:lang="en-US">Other Bonds [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherBondsMember" xlink:to="lab_gsk_OtherBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherBondsMember" xml:lang="en-US">Other bonds.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xlink:label="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xml:lang="en-US">Commercial paper in a designated hedging relationship [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xml:lang="en-US">Commercial paper in a designated hedging relationship [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xlink:to="lab_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xml:lang="en-US">Commercial paper in a designated hedging relationship.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCommercialPaperMember" xlink:label="loc_gsk_OtherCommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherCommercialPaperMember" xml:lang="en-US">Other Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherCommercialPaperMember" xml:lang="en-US">Other commercial paper [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherCommercialPaperMember" xlink:to="lab_gsk_OtherCommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherCommercialPaperMember" xml:lang="en-US">Other commercial paper.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xml:lang="en-US">Borrowings Excluding Obligations Under Finance Lease At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xml:lang="en-US">Borrowings excluding obligations under finance leases fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xlink:to="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xml:lang="en-US">Borrowings excluding obligations under finance lease at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Total financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xml:lang="en-US">Financial liabilities, at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xml:lang="en-US">Total financial liabilities fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xml:lang="en-US">Financial liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets, at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xml:lang="en-US">Total financial assets fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLease" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLease" xml:lang="en-US">Borrowings Excluding Obligations Under Finance Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLease" xml:lang="en-US">Borrowings excluding obligations under finance leases:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease" xlink:to="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BorrowingsExcludingObligationsUnderFinanceLease" xml:lang="en-US">Borrowings excluding obligations under finance lease.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsLiabilities" xlink:label="loc_gsk_NetFinancialAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFinancialAssetsLiabilities" xml:lang="en-US">Net Financial Assets Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_NetFinancialAssetsLiabilities" xml:lang="en-US">Net financial assets and financial liabilities excluding lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFinancialAssetsLiabilities" xlink:to="lab_gsk_NetFinancialAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFinancialAssetsLiabilities" xml:lang="en-US">Net financial assets liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:label="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xml:lang="en-US">Net financial assets financial liabilities at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xml:lang="en-US">Net financial assets and financial liabilities fair value excluding lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:to="lab_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xml:lang="en-US">Net financial assets and financial liabilities at fair values.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xml:lang="en-US">Financial assets at amortised cost, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xml:lang="en-US">Financial assets at amortised cost, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:to="lab_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradeAndOtherReceivableMember" xml:lang="en-US">Trade And Other Receivable [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TradeAndOtherReceivableMember" xml:lang="en-US">Trade and other receivable [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradeAndOtherReceivableMember" xlink:to="lab_gsk_TradeAndOtherReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradeAndOtherReceivableMember" xml:lang="en-US">Trade and other receivable.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xml:lang="en-US">Derivatives designated and effective as hedging instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xml:lang="en-US">Derivatives designated and effective as hedging instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xml:lang="en-US">Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:to="lab_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xml:lang="en-US">Derivatives designated and effective as hedging instruments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xml:lang="en-US">Held for trading derivatives that are not in a designated and effective hedging relationship [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xml:lang="en-US">Held for trading derivatives that are not in a designated and effective hedging relationship [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:to="lab_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xml:lang="en-US">Held for trading derivatives that are not in a designated and effective hedging relationship.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalents1Member" xlink:label="loc_gsk_CashAndCashEquivalents1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CashAndCashEquivalents1Member" xml:lang="en-US">Cash and cash equivalents [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CashAndCashEquivalents1Member" xml:lang="en-US">Cash and cash equivalents [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CashAndCashEquivalents1Member" xlink:to="lab_gsk_CashAndCashEquivalents1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CashAndCashEquivalents1Member" xml:lang="en-US">Cash and cash equivalents.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsMember" xlink:label="loc_gsk_OtherInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_OtherInvestmentsMember" xml:lang="en-US">Other investments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_OtherInvestmentsMember" xml:lang="en-US">Other investments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_OtherInvestmentsMember" xlink:to="lab_gsk_OtherInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_OtherInvestmentsMember" xml:lang="en-US">Other investments [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityAndOtherInvestmentsMember" xlink:label="loc_gsk_CurrentEquityAndOtherInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrentEquityAndOtherInvestmentsMember" xml:lang="en-US">Current Equity And Other Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_CurrentEquityAndOtherInvestmentsMember" xml:lang="en-US">Current equity investments and Other investments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrentEquityAndOtherInvestmentsMember" xlink:to="lab_gsk_CurrentEquityAndOtherInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrentEquityAndOtherInvestmentsMember" xml:lang="en-US">Current equity and other investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xml:lang="en-US">Classes of financial liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xml:lang="en-US">Classes of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xml:lang="en-US">Financial liabilities, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xml:lang="en-US">Financial liabilities, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesMember" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesMember" xml:lang="en-US">Contingent Consideration Liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesMember" xml:lang="en-US">Contingent Consideration Liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ContingentConsiderationLiabilitiesMember" xlink:to="lab_gsk_ContingentConsiderationLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ContingentConsiderationLiabilitiesMember" xml:lang="en-US">Contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xml:lang="en-US">Financial Liabilities at Amortised Cost, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xml:lang="en-US">Disclosure of financial assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial Liabilities at Fair Value Through Profit or Loss, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Financial liabilities at fair value through other comprehensive income [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Financial Liabilities at Fair Value Through Other Comprehensive Income [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lab_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Financial liabilities at fair value through other comprehensive income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At Fair Value [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure of financial assets and liabilities line Items.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" xml:lang="en-US">Disclosure of fair value measurement of assets and liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" xlink:to="lab_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" xml:lang="en-US">Disclosure of fair value measurement of assets and liabilities [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xml:lang="en-US">Disclosure Of Fair Value Measurements Of Assets And Liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xml:lang="en-US">Disclosure Of Fair Value Measurements Of Assets And Liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xlink:to="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xml:lang="en-US">Disclosure of fair value measurements of assets and liabilities</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure of fair value measurements of assets and liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure of fair value measurements of assets and liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xlink:to="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure of fair value measurements of assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentOfContingentConsiderationLiabilities" xlink:label="loc_gsk_PaymentOfContingentConsiderationLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PaymentOfContingentConsiderationLiabilities" xml:lang="en-US">Payment of Contingent Consideration Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PaymentOfContingentConsiderationLiabilities" xml:lang="en-US">Settlement of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PaymentOfContingentConsiderationLiabilities" xlink:to="lab_gsk_PaymentOfContingentConsiderationLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PaymentOfContingentConsiderationLiabilities" xml:lang="en-US">Payment of contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Gains (losses) recognised in profit or loss, fair value measurement, assets and liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Net losses recognised in the income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xlink:to="lab_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Gains (losses) recognised in profit or loss, fair value measurement, assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Additions Fair Value Measurement Assets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xlink:to="lab_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Additions fair value measurement assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xml:lang="en-US">Gains Losses Recognised In Other Comprehensive Income Fair Value Measuremen tAssets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xml:lang="en-US">Net gains recognised in other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xlink:to="lab_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xml:lang="en-US">Gains losses recognized in other comprehensive income fair value measurement assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialAssetsAndLiabilities" xlink:label="loc_gsk_FinancialAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialAssetsAndLiabilities" xml:lang="en-US">Financial Assets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_gsk_FinancialAssetsAndLiabilities" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_gsk_FinancialAssetsAndLiabilities" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialAssetsAndLiabilities" xlink:to="lab_gsk_FinancialAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialAssetsAndLiabilities" xml:lang="en-US">Financial Assets And Liabilities</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Disposals and Settlements Fair Value Measurement Assets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Disposals and settlements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xlink:to="lab_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Disposals and Settlements Fair Value Measurement Assets And Liabilities</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xlink:label="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xml:lang="en-US">Transfers Out Of Level Three Of Fair Value Hierarchy Assets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xml:lang="en-US">Transfers from Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xlink:to="lab_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xml:lang="en-US">Transfers out of level three of fair value hierarchy assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xml:lang="en-US">Increase (decrease) in contingent consideration asset (liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xml:lang="en-US">Contingent consideration related to business acquisitions in the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Increase Decrease Through Exchange Adjustments Of Fair Value Measurement Assets And Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Exchange adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xlink:to="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xml:lang="en-US">Increase decrease through exchange adjustments of fair value measurement assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" xml:lang="en-US">Disclosure Of Financial Assets And Non Financial Assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" xlink:to="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" xml:lang="en-US">Disclosure Of Financial Assets And Non Financial Assets [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets and non financial assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets and non financial assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xlink:to="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets and non financial assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xml:lang="en-US">Amortised cost [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialInstrumentsMember" xlink:label="loc_gsk_FinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinancialInstrumentsMember" xml:lang="en-US">Financial Instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FinancialInstrumentsMember" xml:lang="en-US">Financial Instruments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinancialInstrumentsMember" xlink:to="lab_gsk_FinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinancialInstrumentsMember" xml:lang="en-US">Financial Instruments [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonFinancialInstrumentsMember" xlink:label="loc_gsk_NonFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonFinancialInstrumentsMember" xml:lang="en-US">Non Financial Instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NonFinancialInstrumentsMember" xml:lang="en-US">Non Financial Instruments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonFinancialInstrumentsMember" xlink:to="lab_gsk_NonFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonFinancialInstrumentsMember" xml:lang="en-US">Non financial instruments.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets and non financial assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets and non financial assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xlink:to="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets and non-financial assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of financial liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of financial liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of financial liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of financial liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-full_TradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayables" xlink:to="lab_ifrs-full_TradeAndOtherPayables" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xml:lang="en-US">Trade And Other Payables Other Provisions And Other Noncurrent Liabilities In Scope Of IFRS 9 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xml:lang="en-US">Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xlink:to="lab_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xml:lang="en-US">Trade and other payables, other provisions and other non-current liabilities in scope of IFRS 9.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xml:lang="en-US">Disclosure of detailed information about hedging instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about hedging instruments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about hedging instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmbeddedAndOtherDerivativesMember" xlink:label="loc_gsk_EmbeddedAndOtherDerivativesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EmbeddedAndOtherDerivativesMember" xml:lang="en-US">Embedded And Other Derivatives [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EmbeddedAndOtherDerivativesMember" xml:lang="en-US">Embedded and Other Derivatives [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EmbeddedAndOtherDerivativesMember" xlink:to="lab_gsk_EmbeddedAndOtherDerivativesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EmbeddedAndOtherDerivativesMember" xml:lang="en-US">Embedded and other derivatives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xml:lang="en-US">Financial assets at fair value through profit or loss, classified as held for trading, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xml:lang="en-US">Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xml:lang="en-US">Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss that meet definition of held for trading, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xml:lang="en-US">Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about hedging instruments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about hedging instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentLiabilities" xlink:label="loc_ifrs-full_HedgingInstrumentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgingInstrumentLiabilities" xml:lang="en-US">Hedging instrument, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_HedgingInstrumentLiabilities" xml:lang="en-US">Total derivative instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentLiabilities" xlink:to="lab_ifrs-full_HedgingInstrumentLiabilities" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentsLiabilities" xlink:label="loc_gsk_HedgingInstrumentsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingInstrumentsLiabilities" xml:lang="en-US">Hedging Instruments Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_HedgingInstrumentsLiabilities" xml:lang="en-US">Financial liabilities, current and Non current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingInstrumentsLiabilities" xlink:to="lab_gsk_HedgingInstrumentsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingInstrumentsLiabilities" xml:lang="en-US">Hedging instruments liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesNoncurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesNoncurrent" xml:lang="en-US">Hedging instrument, liabilities noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesNoncurrent" xml:lang="en-US">Financial liabilities non current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent" xlink:to="lab_gsk_HedgingInstrumentLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesNoncurrent" xml:lang="en-US">Hedging instrument, liabilities noncurrent</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesCurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesCurrent" xml:lang="en-US">Hedging instrument, liabilities current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesCurrent" xml:lang="en-US">Financial Liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingInstrumentLiabilitiesCurrent" xlink:to="lab_gsk_HedgingInstrumentLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingInstrumentLiabilitiesCurrent" xml:lang="en-US">Hedging instrument, liabilities current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentAssets" xlink:label="loc_ifrs-full_HedgingInstrumentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgingInstrumentAssets" xml:lang="en-US">Hedging instrument, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_HedgingInstrumentAssets" xml:lang="en-US">Financial assets, current and Non current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentAssets" xlink:to="lab_ifrs-full_HedgingInstrumentAssets" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsCurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingInstrumentAssetsCurrent" xml:lang="en-US">Hedging Instrument Assets Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HedgingInstrumentAssetsCurrent" xml:lang="en-US">Financial assets, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingInstrumentAssetsCurrent" xlink:to="lab_gsk_HedgingInstrumentAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingInstrumentAssetsCurrent" xml:lang="en-US">Hedging Instrument Assets Current</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsNoncurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HedgingInstrumentAssetsNoncurrent" xml:lang="en-US">Hedging Instrument Assets Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HedgingInstrumentAssetsNoncurrent" xml:lang="en-US">Financial assets, Non current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HedgingInstrumentAssetsNoncurrent" xlink:to="lab_gsk_HedgingInstrumentAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HedgingInstrumentAssetsNoncurrent" xml:lang="en-US">Hedging Instrument Assets Noncurrent</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NetInvestmentHedgesMember" xml:lang="en-US">Net Investment Hedges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NetInvestmentHedgesMember" xml:lang="en-US">Net Investment Hedges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NetInvestmentHedgesMember" xlink:to="lab_gsk_NetInvestmentHedgesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NetInvestmentHedgesMember" xml:lang="en-US">Net investment hedges.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Current [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Later Than One Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NominalAmountOfHedgingInstrument" xml:lang="en-US">Nominal amount of hedging instrument</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_NominalAmountOfHedgingInstrument" xml:lang="en-US">Principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NominalAmountOfHedgingInstrument" xml:lang="en-US">Notional value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NominalAmountOfHedgingInstrument" xml:lang="en-US">Notional principal value &#163;m</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NominalAmountOfHedgingInstrument" xlink:to="lab_ifrs-full_NominalAmountOfHedgingInstrument" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" xml:lang="en-US">Disclosure of detailed information about hedged items [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xml:lang="en-US">Disclosure of detailed information about hedged items [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xml:lang="en-US">Disclosure of detailed information about hedged items [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JapaneseYenMember" xlink:label="loc_gsk_JapaneseYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_JapaneseYenMember" xml:lang="en-US">Japanese Yen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_JapaneseYenMember" xlink:to="lab_gsk_JapaneseYenMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroMember" xlink:label="loc_gsk_EuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EuroMember" xml:lang="en-US">EURO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EuroMember" xlink:to="lab_gsk_EuroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EuroMember" xml:lang="en-US">EURO [Member].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SgdMember" xlink:label="loc_gsk_SgdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SgdMember" xml:lang="en-US">SGD [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SgdMember" xlink:to="lab_gsk_SgdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SgdMember" xml:lang="en-US">SGD.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CADMember" xlink:label="loc_gsk_CADMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CADMember" xml:lang="en-US">CAD [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CADMember" xlink:to="lab_gsk_CADMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CADMember" xml:lang="en-US">CAD.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xml:lang="en-US">Disclosure of detailed information about hedged items [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xml:lang="en-US">Disclosure of detailed information about hedged items [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xml:lang="en-US">Financial instruments designated as hedging instruments, at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xml:lang="en-US">Carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:to="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfForeignCurrency" xlink:label="loc_gsk_DescriptionOfForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DescriptionOfForeignCurrency" xml:lang="en-US">Description of foreign currency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DescriptionOfForeignCurrency" xml:lang="en-US">Foreign currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DescriptionOfForeignCurrency" xlink:to="lab_gsk_DescriptionOfForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DescriptionOfForeignCurrency" xml:lang="en-US">Description of foreign currency.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xlink:label="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xml:lang="en-US">Reserve of cash flow hedges or exchange differences on translation continuing hedges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xml:lang="en-US">Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xlink:to="lab_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xml:lang="en-US">A component of equity representing the reserve of cash flow hedges or the reserve of exchange differences on translation in relation to continuing hedges.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xml:lang="en-US">Gain (loss) on change in fair value of hedged item used as basis for recognising hedge ineffectiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xml:lang="en-US">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xml:lang="en-US">Change in value used for calculating hedge ineffectiveness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:to="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xlink:label="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xml:lang="en-US">Reserve Of Cash Flow Hedges, Hedging Relationships For Which Hedge Accounting Is No Longer Applied 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xml:lang="en-US">Balance in cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xlink:to="lab_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xml:lang="en-US">Reserve of cash flow hedges, hedging relationships for which hedge accounting is no longer applied 1.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgedItemsAxis" xml:lang="en-US">Hedged items [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HedgedItemsAxis" xml:lang="en-US">Hedged items [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsAxis" xlink:to="lab_ifrs-full_HedgedItemsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HedgedItemsMember" xml:lang="en-US">Hedged items [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HedgedItemsMember" xml:lang="en-US">Hedged items [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsMember" xlink:to="lab_ifrs-full_HedgedItemsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BuyForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Buy Foreign Currency over six months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BuyForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Buy Foreign Currency over 6 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BuyForeignCurrencyOverSixMonthsMember" xlink:to="lab_gsk_BuyForeignCurrencyOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BuyForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Buy Foreign Currency over six months [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyThreeToSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BuyForeignCurrencyThreeToSixMonthsMember" xml:lang="en-US">Buy Foreign Currency three to six months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BuyForeignCurrencyThreeToSixMonthsMember" xml:lang="en-US">Buy Foreign Currency 3 to 6 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember" xlink:to="lab_gsk_BuyForeignCurrencyThreeToSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BuyForeignCurrencyThreeToSixMonthsMember" xml:lang="en-US">Buy Foreign Currency three to six months [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SellForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Sell Foreign Currency over six months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SellForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Sell Foreign Currency over 6 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SellForeignCurrencyOverSixMonthsMember" xlink:to="lab_gsk_SellForeignCurrencyOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SellForeignCurrencyOverSixMonthsMember" xml:lang="en-US">Sell Foreign Currency over six months [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Buy Foreign Currency Less than three months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Buy Foreign Currency Less than 3 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xlink:to="lab_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Buy Foreign Currency Less than three months [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xml:lang="en-US">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xml:lang="en-US">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:to="lab_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xml:lang="en-US">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SellForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Sell Foreign Currency Less than three months [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SellForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Sell Foreign Currency Less than 3 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember" xlink:to="lab_gsk_SellForeignCurrencyLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SellForeignCurrencyLessThanThreeMonthsMember" xml:lang="en-US">Sell Foreign Currency Less than three months [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsLessThanThreeMonthsMember" xlink:label="loc_gsk_BorrowingsLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BorrowingsLessThanThreeMonthsMember" xml:lang="en-US">Borrowings Less Than Three Months [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BorrowingsLessThanThreeMonthsMember" xml:lang="en-US">Borrowings Less than 3 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BorrowingsLessThanThreeMonthsMember" xlink:to="lab_gsk_BorrowingsLessThanThreeMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BorrowingsLessThanThreeMonthsMember" xml:lang="en-US">Borrowings less than three months.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsOverSixMonthsMember" xlink:label="loc_gsk_BorrowingsOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BorrowingsOverSixMonthsMember" xml:lang="en-US">Borrowings Over Six Months [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BorrowingsOverSixMonthsMember" xml:lang="en-US">Borrowings Over 6 months [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BorrowingsOverSixMonthsMember" xlink:to="lab_gsk_BorrowingsOverSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BorrowingsOverSixMonthsMember" xml:lang="en-US">Borrowings over six months.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xml:lang="en-US">Variability in cash flows from a highly probable forecast transaction [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xml:lang="en-US">Variability in cash flows from a highly probable forecast transaction [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:to="lab_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xml:lang="en-US">Variability in cash flows from a highly probable forecast transaction [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingThreeToSixMonthsMember" xlink:label="loc_gsk_BorrowingThreeToSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BorrowingThreeToSixMonthsMember" xml:lang="en-US">Borrowing Three to Six Months [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BorrowingThreeToSixMonthsMember" xml:lang="en-US">Borrowing 3 to 6 months [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BorrowingThreeToSixMonthsMember" xlink:to="lab_gsk_BorrowingThreeToSixMonthsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BorrowingThreeToSixMonthsMember" xml:lang="en-US">Borrowing three to six months.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PrehedgingOfLongtermInterestRatesMember" xlink:label="loc_gsk_PrehedgingOfLongtermInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PrehedgingOfLongtermInterestRatesMember" xml:lang="en-US">Pre-hedging of long-term interest rates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PrehedgingOfLongtermInterestRatesMember" xml:lang="en-US">Pre-hedging of long-term interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PrehedgingOfLongtermInterestRatesMember" xlink:to="lab_gsk_PrehedgingOfLongtermInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PrehedgingOfLongtermInterestRatesMember" xml:lang="en-US">Pre-hedging of long-term interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsMember" xlink:label="loc_gsk_VariabilityInCashFlowsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VariabilityInCashFlowsMember" xml:lang="en-US">Variability in cash flows [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VariabilityInCashFlowsMember" xml:lang="en-US">Variability in cash flows [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VariabilityInCashFlowsMember" xlink:to="lab_gsk_VariabilityInCashFlowsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VariabilityInCashFlowsMember" xml:lang="en-US">Variability in cash flows.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="loc_ifrs-full_PastDueStatusAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PastDueStatusAxis" xml:lang="en-US">Past due status [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastDueStatusAxis" xlink:to="lab_ifrs-full_PastDueStatusAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="loc_ifrs-full_PastDueStatusMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PastDueStatusMember" xml:lang="en-US">Past due status [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PastDueStatusMember" xlink:to="lab_ifrs-full_PastDueStatusMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:label="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xml:lang="en-US">More than Five Years Not Later Than Ten Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:to="lab_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xml:lang="en-US">More than five years not later than ten years Member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaturedInThePastPeriodMember" xlink:label="loc_gsk_MaturedInThePastPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MaturedInThePastPeriodMember" xml:lang="en-US">Matured in the past period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MaturedInThePastPeriodMember" xlink:to="lab_gsk_MaturedInThePastPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MaturedInThePastPeriodMember" xml:lang="en-US">Matured in the past.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xml:lang="en-US">More than Ten Years Not Later Than Thirty Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:to="lab_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xml:lang="en-US">More than ten years not later than thirty years member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanThirtyYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MoreThanThirtyYearsMember" xml:lang="en-US">More Than Thirty Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MoreThanThirtyYearsMember" xlink:to="lab_gsk_MoreThanThirtyYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MoreThanThirtyYearsMember" xml:lang="en-US">More than thirty years member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xml:lang="en-US">Description of line item in statement of comprehensive income that includes reclassification adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xml:lang="en-US">Line item in profit or loss in which reclassification adjustment is included</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xlink:to="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xml:lang="en-US">Reclassification adjustments on cash flow hedges for which hedged future cash flows are no longer expected to occur, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xml:lang="en-US">Hedged future cash flows no longer expected to occur</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xml:lang="en-US">Reserve of gains and losses on hedging instruments that hedge investments in equity instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xml:lang="en-US">Hedging gains/(losses) recognised in reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xlink:to="lab_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xml:lang="en-US">Description of line item in statement of comprehensive income that includes recognised hedge ineffectiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xml:lang="en-US">Line item in profit or loss in which hedge ineffectiveness is included</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xlink:to="lab_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xml:lang="en-US">Gain (loss) on hedge ineffectiveness recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xml:lang="en-US">Amount of hedge ineffectiveness recognised in profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xlink:label="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xml:lang="en-US">Accumulated fair value hedge adjustment on hedged item included in carrying amount, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xml:lang="en-US">Due to hedged item affecting balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xlink:to="lab_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xml:lang="en-US">Reclassification adjustments on cash flow hedges for which hedged item affected profit or loss, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xml:lang="en-US">Due to hedged item affecting profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xml:lang="en-US">Description of line item in statement of financial position that includes hedged item</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xml:lang="en-US">Line item in balance sheet in which reclassification adjustment is included</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xlink:to="lab_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsLiabilities" xlink:label="loc_gsk_DerivativeFinancialAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DerivativeFinancialAssetsLiabilities" xml:lang="en-US">Derivative financial assets (liabilities)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DerivativeFinancialAssetsLiabilities" xml:lang="en-US">Fair value assets/ (liabilities) &#163;m</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DerivativeFinancialAssetsLiabilities" xlink:to="lab_gsk_DerivativeFinancialAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DerivativeFinancialAssetsLiabilities" xml:lang="en-US">Derivative financial assets liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xml:lang="en-US">Reserve of cash flow hedges, continuing hedges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xml:lang="en-US">Balance in cash flow hedge reserve for continuing hedges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xlink:to="lab_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageFixedInterestRateOfHedgingInstrument" xlink:label="loc_gsk_AverageFixedInterestRateOfHedgingInstrument" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AverageFixedInterestRateOfHedgingInstrument" xml:lang="en-US">Average Fixed Interest Rate Of Hedging Instrument</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AverageFixedInterestRateOfHedgingInstrument" xml:lang="en-US">Average contracted fixed rate %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AverageFixedInterestRateOfHedgingInstrument" xlink:to="lab_gsk_AverageFixedInterestRateOfHedgingInstrument" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AverageFixedInterestRateOfHedgingInstrument" xml:lang="en-US">Average Fixed Interest Rate Of Hedging Instrument</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xml:lang="en-US">Gain (loss) on change in fair value of hedging instrument used as basis for recognising hedge ineffectiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xml:lang="en-US">Change in fair value for recognising hedge ineffectiveness &#163;m</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:to="lab_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" xml:lang="en-US">Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xml:lang="en-US">Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xml:lang="en-US">Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:to="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xml:lang="en-US">Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xml:lang="en-US">Types of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xml:lang="en-US">Types of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_TypesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsTypeMember" xml:lang="en-US">Financial assets, type [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsTypeMember" xml:lang="en-US">Financial assets, type [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember" xlink:to="lab_ifrs-full_FinancialAssetsTypeMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsMember" xlink:label="loc_gsk_DerivativeFinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DerivativeFinancialAssetsMember" xml:lang="en-US">Derivative Financial Assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DerivativeFinancialAssetsMember" xml:lang="en-US">Derivative financial assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DerivativeFinancialAssetsMember" xlink:to="lab_gsk_DerivativeFinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DerivativeFinancialAssetsMember" xml:lang="en-US">Derivative financial assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" xml:lang="en-US">Types of financial liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" xml:lang="en-US">Types of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesTypeMember" xml:lang="en-US">Financial liabilities, type [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesTypeMember" xml:lang="en-US">Financial liabilities, type [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesTypeMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradesAndOtherPayablesMember" xlink:label="loc_gsk_TradesAndOtherPayablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TradesAndOtherPayablesMember" xml:lang="en-US">Trades and other payables [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TradesAndOtherPayablesMember" xml:lang="en-US">Trades and other payables [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TradesAndOtherPayablesMember" xlink:to="lab_gsk_TradesAndOtherPayablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TradesAndOtherPayablesMember" xml:lang="en-US">Trades and other payables.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialLiabilitiesMember" xlink:label="loc_gsk_DerivativeFinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DerivativeFinancialLiabilitiesMember" xml:lang="en-US">Derivative financial liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DerivativeFinancialLiabilitiesMember" xml:lang="en-US">Derivative financial liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DerivativeFinancialLiabilitiesMember" xlink:to="lab_gsk_DerivativeFinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DerivativeFinancialLiabilitiesMember" xml:lang="en-US">Derivative financial liabilities [member]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:to="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities line items.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xml:lang="en-US">Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xml:lang="en-US">Related amounts not set off in the balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xlink:to="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xml:lang="en-US">Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xml:lang="en-US">Net financial assets/(liabilities)per balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:to="lab_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial assets set off against financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial (Liabilities)/assets set off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xml:lang="en-US">Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xml:lang="en-US">Net financial assets/(liabilities)per balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:to="lab_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial assets/(liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xml:lang="en-US">Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xml:lang="en-US">Related amounts not set off in the balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xlink:to="lab_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial liabilities set off against financial assets subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial (Liabilities)/assets set off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial assets subject to offsetting, enforceable master netting arrangements or similar agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xml:lang="en-US">Gross financial assets/(liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:to="lab_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingAbstract" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingAbstract" xml:lang="en-US">Disclosure of debt interest rate repricing [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingAbstract" xlink:to="lab_gsk_DisclosureOfDebtInterestRateRepricingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingAbstract" xml:lang="en-US">Disclosure of debt interest rate repricing [abstract]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingTable" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingTable" xml:lang="en-US">Disclosure of debt interest rate repricing [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingTable" xml:lang="en-US">Disclosure of debt interest rate repricing [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable" xlink:to="lab_gsk_DisclosureOfDebtInterestRateRepricingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingTable" xml:lang="en-US">Disclosure of debt interest rate repricing [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xml:lang="en-US">Later than five years and not later than ten years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xml:lang="en-US">Between Five and Ten Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingLineItems" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingLineItems" xml:lang="en-US">Disclosure of debt interest rate repricing [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingLineItems" xml:lang="en-US">Disclosure of debt interest rate repricing [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems" xlink:to="lab_gsk_DisclosureOfDebtInterestRateRepricingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfDebtInterestRateRepricingLineItems" xml:lang="en-US">Disclosure of debt interest rate repricing [line items]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt" xlink:label="loc_gsk_Debt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_Debt" xml:lang="en-US">Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_Debt" xml:lang="en-US">Total debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_Debt" xlink:to="lab_gsk_Debt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_Debt" xml:lang="en-US">Debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestBearingDebt" xlink:label="loc_gsk_InterestBearingDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestBearingDebt" xml:lang="en-US">Interest bearing debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_InterestBearingDebt" xml:lang="en-US">Total interest bearing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestBearingDebt" xlink:to="lab_gsk_InterestBearingDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestBearingDebt" xml:lang="en-US">Interest bearing debt.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FloatingAndFixedRateDebtMember" xlink:label="loc_gsk_FloatingAndFixedRateDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FloatingAndFixedRateDebtMember" xml:lang="en-US">Floating and fixed rate debt [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FloatingAndFixedRateDebtMember" xml:lang="en-US">Floating and Fixed Rate Debt [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FloatingAndFixedRateDebtMember" xlink:to="lab_gsk_FloatingAndFixedRateDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FloatingAndFixedRateDebtMember" xml:lang="en-US">Floating and fixed rate debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase decrease in Equity through foreign currency exchange exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xml:lang="en-US">(Increase)/decrease in Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xlink:to="lab_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase (decrease) in Equity through foreign currency exchange exposures</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase decrease in income through foreign currency exchange exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase/(decrease) in income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xlink:to="lab_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase (decrease) in income through foreign currency exchange exposures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase decrease in net debt through foreign currency exchange exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xml:lang="en-US">(Increase)/decrease in net debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xlink:to="lab_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xml:lang="en-US">Increase (decrease) in net debt through foreign currency exchange exposures.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenYenAppreciationOfYenMember" xml:lang="en-US">Currency Risk Ten Yen Appreciation Of Yen [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenYenAppreciationOfYenMember" xml:lang="en-US">10 Yen appreciation of the Yen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember" xlink:to="lab_gsk_CurrencyRiskTenYenAppreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenYenAppreciationOfYenMember" xml:lang="en-US">10 Yen appreciation of the Yen.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xml:lang="en-US">Currency Risk Fifteen Yen Appreciation Of Yen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xml:lang="en-US">15 Yen appreciation of the Yen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xlink:to="lab_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskTenYenDepreciationOfYenMember" xml:lang="en-US">Currency Risk Ten Yen depreciation Of Yen [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskTenYenDepreciationOfYenMember" xml:lang="en-US">10 Yen depreciation of Yen [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember" xlink:to="lab_gsk_CurrencyRiskTenYenDepreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CurrencyRiskTenYenDepreciationOfYenMember" xml:lang="en-US">Currency risk ten yen depreciation of yen.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xml:lang="en-US">Currency Risk Fifteen Yen depreciation Of Yen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xml:lang="en-US">15 Yen depreciation of Yen [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xlink:to="lab_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">Interest rate risk one percent increase in sterling interest rates [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">1% (100 basis points) increase in sterling interest rates [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">1% (100 basis points) increase in sterling interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">Interest rate risk one percent increase in Euro interest rates[member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">1% (100 Basis Points) Increase in Euro Interest Rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">1% (100 basis points) increase in Euro interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">Interest rate risk one percent increase in US dollar interest rates[member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">1% (100 Basis Points) Increase in US Dollar Interest Rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">1% (100 basis points) increase in US Dollar interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Point Five Percent Increase In Sterling Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) increase in Sterling interest rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xml:lang="en-US">Interest rate risk one point five percent increase in sterling interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Point Five Percent Increase In Us Dollar Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) increase in US Dollar interest rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xml:lang="en-US">Interest rate risk one point five percent increase in us dollar interest rates.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">Interest Rate Risk One Point Five Percent Increase In Euro Interest Rates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">1.5% (150 basis points) increase in Euro interest rates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xlink:to="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xml:lang="en-US">Interest rate risk one point five percent increase in euro interest rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDerivativesFinancialLiabilitiesMember" xlink:label="loc_gsk_NonDerivativesFinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NonDerivativesFinancialLiabilitiesMember" xml:lang="en-US">Non Derivatives Financial Liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NonDerivativesFinancialLiabilitiesMember" xml:lang="en-US">Non Derivatives Financial Liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NonDerivativesFinancialLiabilitiesMember" xlink:to="lab_gsk_NonDerivativesFinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NonDerivativesFinancialLiabilitiesMember" xml:lang="en-US">Non derivatives financial liabilities.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FutureFinanceChargeOnFinanceLeases" xlink:label="loc_gsk_FutureFinanceChargeOnFinanceLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FutureFinanceChargeOnFinanceLeases" xml:lang="en-US">Future Finance Charge On Finance Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_FutureFinanceChargeOnFinanceLeases" xml:lang="en-US">Finance charge on obligations under finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FutureFinanceChargeOnFinanceLeases" xlink:to="lab_gsk_FutureFinanceChargeOnFinanceLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FutureFinanceChargeOnFinanceLeases" xml:lang="en-US">Future Finance Charge On Finance Leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xml:lang="en-US">Bank borrowings, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:to="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xml:lang="en-US">Trade and other payables, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xml:lang="en-US">Trade payables and other liabilities not in net debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xml:lang="en-US">Interest expense on borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xml:lang="en-US">Interest on debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember" xlink:label="loc_ifrs-full_DerivativesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DerivativesMember" xml:lang="en-US">Derivatives [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DerivativesMember" xml:lang="en-US">Derivative Instruments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrument1Axis" xlink:label="loc_gsk_DebtInstrument1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DebtInstrument1Axis" xml:lang="en-US">Debt Instrument 1 [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DebtInstrument1Axis" xml:lang="en-US">Debt Instrument 1 [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DebtInstrument1Axis" xlink:to="lab_gsk_DebtInstrument1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DebtInstrument1Axis" xml:lang="en-US">Debt instrument 1.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrumentDomain" xlink:label="loc_gsk_DebtInstrumentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DebtInstrumentDomain" xml:lang="en-US">Debt Instrument [domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DebtInstrumentDomain" xml:lang="en-US">Debt Instrument [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DebtInstrumentDomain" xlink:to="lab_gsk_DebtInstrumentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DebtInstrumentDomain" xml:lang="en-US">Debt Instrument [domain]</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Payables On Derivative Financial Instruments Undiscounted Cash Flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:to="lab_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Payables on derivative financial instruments undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Receivables On Derivative Financial Instruments Undiscounted Cash Flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:to="lab_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xml:lang="en-US">Receivables on derivative financial instruments undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xml:lang="en-US">Disclosure of fair value of plan assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesTable" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesTable" xml:lang="en-US">Disclosure Of Employee Share Schemes [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesTable" xml:lang="en-US">Disclosure Of Employee Share Schemes [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable" xlink:to="lab_gsk_DisclosureOfEmployeeShareSchemesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesTable" xml:lang="en-US">Disclosure Of Employee Share Schemes [table].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesLineItems" xml:lang="en-US">Disclosure of employee share schemes [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesLineItems" xml:lang="en-US">Disclosure of employee share schemes [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems" xlink:to="lab_gsk_DisclosureOfEmployeeShareSchemesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfEmployeeShareSchemesLineItems" xml:lang="en-US">Disclosure of employee share schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedFutureDividendYieldPercentageShareGranted" xlink:label="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedFutureDividendYieldPercentageShareGranted" xml:lang="en-US">Expected Future Dividend Yield Percentage Share Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedFutureDividendYieldPercentageShareGranted" xml:lang="en-US">Expected future dividend yield percentage share granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted" xlink:to="lab_gsk_ExpectedFutureDividendYieldPercentageShareGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedFutureDividendYieldPercentageShareGranted" xml:lang="en-US">Expected future dividend yield percentage share granted.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Number Of Share Options Not Exercisable In Share Based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Number share options were not exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xlink:to="lab_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Number of share options not exercisable in share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquallyWeightedMeasuresOverPerformancePeriod" xlink:label="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquallyWeightedMeasuresOverPerformancePeriod" xml:lang="en-US">Equally Weighted Measures Over Performance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquallyWeightedMeasuresOverPerformancePeriod" xml:lang="en-US">Equally weighted measures over performance period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod" xlink:to="lab_gsk_EquallyWeightedMeasuresOverPerformancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquallyWeightedMeasuresOverPerformancePeriod" xml:lang="en-US">Equally weighted measures over performance period.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingAwards" xlink:label="loc_gsk_NumberOfOutstandingAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfOutstandingAwards" xml:lang="en-US">Number of awards outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfOutstandingAwards" xml:lang="en-US">Number of outstanding awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfOutstandingAwards" xlink:to="lab_gsk_NumberOfOutstandingAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfOutstandingAwards" xml:lang="en-US">The number of awards outstanding in a share-based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number Of Share Awards Granted In Sharebased Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of awards granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of shares, Awards granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:to="lab_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share awards granted in sharebased payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AtPercentageBelowMarketPrice" xlink:label="loc_gsk_AtPercentageBelowMarketPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AtPercentageBelowMarketPrice" xml:lang="en-US">At Percentage Below Market Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AtPercentageBelowMarketPrice" xml:lang="en-US">Share options granted at percentage below market price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AtPercentageBelowMarketPrice" xlink:to="lab_gsk_AtPercentageBelowMarketPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AtPercentageBelowMarketPrice" xml:lang="en-US">At percentage below market price.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:label="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xml:lang="en-US">Weighted Average Fair Value at Measurement Date Share Awards Granted Per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xml:lang="en-US">Weighted average fair value of awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xml:lang="en-US">Weighted fair value, Awards granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:to="lab_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xml:lang="en-US">Weighted average fair value at measurement date share awards granted per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfPerformanceSharePlan" xlink:label="loc_gsk_PercentageOfPerformanceSharePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PercentageOfPerformanceSharePlan" xml:lang="en-US">Percentage Of Performance Share Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PercentageOfPerformanceSharePlan" xml:lang="en-US">Percentage of performance share plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PercentageOfPerformanceSharePlan" xlink:to="lab_gsk_PercentageOfPerformanceSharePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PercentageOfPerformanceSharePlan" xml:lang="en-US">Percentage of performance share plan.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average fair value of share option granted in share based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average fair value of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xlink:to="lab_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average fair value of share option granted in share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedShareOptionSchemesMember" xlink:label="loc_gsk_SavingsRelatedShareOptionSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SavingsRelatedShareOptionSchemesMember" xml:lang="en-US">Savings Related Share Option Schemes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SavingsRelatedShareOptionSchemesMember" xml:lang="en-US">Savings-Related Share Option Schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SavingsRelatedShareOptionSchemesMember" xlink:to="lab_gsk_SavingsRelatedShareOptionSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SavingsRelatedShareOptionSchemesMember" xml:lang="en-US">Savings related share option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeCashFlowMember" xlink:label="loc_gsk_FreeCashFlowMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FreeCashFlowMember" xml:lang="en-US">Free Cash Flow [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_FreeCashFlowMember" xml:lang="en-US">Free Cash Flow [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FreeCashFlowMember" xlink:to="lab_gsk_FreeCashFlowMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FreeCashFlowMember" xml:lang="en-US">Free cash flow Member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineProgressMember" xlink:label="loc_gsk_PipelineProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_PipelineProgressMember" xml:lang="en-US">Pipeline Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_PipelineProgressMember" xml:lang="en-US">Pipeline Progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_PipelineProgressMember" xlink:to="lab_gsk_PipelineProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_PipelineProgressMember" xml:lang="en-US">Pipeline progress Member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TsrMember" xlink:label="loc_gsk_TsrMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TsrMember" xml:lang="en-US">TSR [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TsrMember" xlink:to="lab_gsk_TsrMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TsrMember" xml:lang="en-US">TSR</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RAndDNewProductPerformanceMember" xlink:label="loc_gsk_RAndDNewProductPerformanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_RAndDNewProductPerformanceMember" xml:lang="en-US">R And D New Product Performance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_RAndDNewProductPerformanceMember" xml:lang="en-US">R&amp;D New Product Performance [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_RAndDNewProductPerformanceMember" xlink:to="lab_gsk_RAndDNewProductPerformanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_RAndDNewProductPerformanceMember" xml:lang="en-US">R&amp;D new product performance Member.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" xlink:label="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" xml:lang="en-US">Adjusted Free Cash Flow TSR and RD New Product Performance [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" xlink:to="lab_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AwardType1Axis" xlink:label="loc_gsk_AwardType1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AwardType1Axis" xml:lang="en-US">Award Type 1 [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AwardType1Axis" xml:lang="en-US">Award type.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AwardType1Axis" xlink:to="lab_gsk_AwardType1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AwardType1Axis" xml:lang="en-US">Information by award type pertaining to equity-based compensation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_EquityAwardDomain" xml:lang="en-US">Equity Award [domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_EquityAwardDomain" xml:lang="en-US">Equity Award [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_EquityAwardDomain" xlink:to="lab_gsk_EquityAwardDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_EquityAwardDomain" xml:lang="en-US">Equity-based compensation award.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xlink:label="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xml:lang="en-US">Two Thousand Sixteen To Two Thousand Nineteen Performance Conditions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xml:lang="en-US">2016 to 2019 Performance conditions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xlink:to="lab_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number Of Share Awards Forfeited In Sharebased Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of shares, Awards cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share awards forfeited in sharebased payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingShareAwards" xlink:label="loc_gsk_NumberOfOutstandingShareAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfOutstandingShareAwards" xml:lang="en-US">Number Of Outstanding Share Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_gsk_NumberOfOutstandingShareAwards" xml:lang="en-US">Number of shares, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_gsk_NumberOfOutstandingShareAwards" xml:lang="en-US">Number of shares, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfOutstandingShareAwards" xlink:to="lab_gsk_NumberOfOutstandingShareAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfOutstandingShareAwards" xml:lang="en-US">Number Of Outstanding Share Awards</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share awards exercised in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">Number of shares, Awards exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xlink:to="lab_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">The number of share awards exercised in a share-based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xml:lang="en-US">Disclosure Of Share Options And Savings Related Options [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xml:lang="en-US">Disclosure Of Share Options And Savings Related Options [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:to="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xml:lang="en-US">Disclosure Of Share Options And Savings Related Options [table].</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:label="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareOptionsAndSavingsRelatedOptionsMember" xml:lang="en-US">Share Options And Savings Related Options [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareOptionsAndSavingsRelatedOptionsMember" xml:lang="en-US">Share Options and Savings-Related Options [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:to="lab_gsk_ShareOptionsAndSavingsRelatedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareOptionsAndSavingsRelatedOptionsMember" xml:lang="en-US">Share options and savings related options.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xml:lang="en-US">Disclosure of share options and savings related options [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xml:lang="en-US">Disclosure of share options and savings related options [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:to="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xml:lang="en-US">Disclosure of share options and savings related options.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPrice" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPrice" xml:lang="en-US">Savings Related Options Grant Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPrice" xml:lang="en-US">Savings-related options grant price (including 20% discount)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SavingsRelatedOptionsGrantPrice" xlink:to="lab_gsk_SavingsRelatedOptionsGrantPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPrice" xml:lang="en-US">Savings related options grant price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free interest rate, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Expected volatility, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedLifeOfShareOptionsGranted" xlink:label="loc_gsk_ExpectedLifeOfShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ExpectedLifeOfShareOptionsGranted" xml:lang="en-US">Expected Life of Share Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ExpectedLifeOfShareOptionsGranted" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ExpectedLifeOfShareOptionsGranted" xlink:to="lab_gsk_ExpectedLifeOfShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ExpectedLifeOfShareOptionsGranted" xml:lang="en-US">Expected life of share options granted.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendYieldShareOptionsGranted" xlink:label="loc_gsk_DividendYieldShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DividendYieldShareOptionsGranted" xml:lang="en-US">Dividend Yield Share Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DividendYieldShareOptionsGranted" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DividendYieldShareOptionsGranted" xlink:to="lab_gsk_DividendYieldShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DividendYieldShareOptionsGranted" xml:lang="en-US">Dividend yield share options granted.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPriceDiscount" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPriceDiscount" xml:lang="en-US">Savings Related Options Grant Price Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPriceDiscount" xml:lang="en-US">Savings-related options grant price discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount" xlink:to="lab_gsk_SavingsRelatedOptionsGrantPriceDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SavingsRelatedOptionsGrantPriceDiscount" xml:lang="en-US">Savings related options grant price discount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionSchemesMember" xlink:label="loc_gsk_ShareOptionSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ShareOptionSchemesMember" xml:lang="en-US">Share Option Schemes [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ShareOptionSchemesMember" xml:lang="en-US">Share Option Schemes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ShareOptionSchemesMember" xlink:to="lab_gsk_ShareOptionSchemesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ShareOptionSchemesMember" xml:lang="en-US">Share option schemes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option exercised in share based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average market price on exercise during year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:to="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option exercised in share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option exercisable in share based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Range of exercise prices on options outstanding at year end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:to="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option exercisable in share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xlink:label="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xml:lang="en-US">Weighted average remaining contractual life of outstanding share option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xml:lang="en-US">Weighted average remaining contractual life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xlink:to="lab_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xml:lang="en-US">Weighted average remaining contractual life of outstanding share option.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option outstanding in share based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xml:lang="en-US">Share option schemes - shares Weighted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xlink:to="lab_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price of share option outstanding in share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Number Of Shares Held For Share Option Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Shares held for share option schemes, Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfSharesHeldForShareOptionSchemes" xlink:to="lab_gsk_NumberOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Number of shares held for share option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Market Value Of Shares Held For Share Award Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Shares held for share award schemes, Market value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes" xlink:to="lab_gsk_MarketValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Market value of shares held for share award schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Nominal Value Of Shares Held For Share Option Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Shares held for share option schemes, Nominal value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes" xlink:to="lab_gsk_NominalValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Nominal value of shares held for share option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Market Value Of Shares Held For Share Option Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Shares held for share option schemes, Market value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes" xlink:to="lab_gsk_MarketValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_MarketValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Market value of shares held for share option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Nominal Value Of Shares Held For Share Award Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Shares held for share award schemes, Nominal value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes" xlink:to="lab_gsk_NominalValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NominalValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Nominal Value Of Shares Held For Share Award Schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Carrying Value Of Shares Held For Share Option Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Shares held for share option schemes, Carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xlink:to="lab_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xml:lang="en-US">Carrying value of shares held for share option schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_NumberOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Number Of Shares Held For Share Award Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_NumberOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Shares held for share award schemes, Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_NumberOfSharesHeldForShareAwardSchemes" xlink:to="lab_gsk_NumberOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_NumberOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Number of shares held for share award schemes.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Carrying Value Of Shares Held For Share Award Schemes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Shares held for share award schemes, Carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xlink:to="lab_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xml:lang="en-US">Carrying value of shares held for share award schemes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xml:lang="en-US">Disclosure of subsidiaries [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xml:lang="en-US">Disclosure of subsidiaries [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xml:lang="en-US">Disclosure of subsidiaries [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CountryOfDomicileMember" xml:lang="en-US">Country of domicile [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CountryOfDomicileMember" xml:lang="en-US">England [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CountryOfDomicileMember" xlink:to="lab_ifrs-full_CountryOfDomicileMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CA" xml:lang="en-US">CANADA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CA" xml:lang="en-US">Canada [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_AU" xml:lang="en-US">Australia [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="loc_country_FR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_FR" xml:lang="en-US">FRANCE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_FR" xml:lang="en-US">France [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="loc_country_SG" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_SG" xml:lang="en-US">SINGAPORE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_SG" xml:lang="en-US">Singapore [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_SG" xlink:to="lab_country_SG" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_country_HK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_HK" xml:lang="en-US">HONG KONG</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_HK" xml:lang="en-US">Hong Kong[member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_HK" xlink:to="lab_country_HK" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DE" xml:lang="en-US">GERMANY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_DE" xml:lang="en-US">Germany [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL" xlink:label="loc_country_PL" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_PL" xml:lang="en-US">POLAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_PL" xml:lang="en-US">Poland [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU" xlink:label="loc_country_RU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_RU" xml:lang="en-US">RUSSIAN FEDERATION</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_RU" xml:lang="en-US">Russia [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="loc_country_CN" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CN" xml:lang="en-US">CHINA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CN" xml:lang="en-US">China [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="loc_country_NL" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_NL" xml:lang="en-US">NETHERLANDS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_NL" xml:lang="en-US">Netherlands [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_NL" xlink:to="lab_country_NL" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES" xlink:label="loc_country_ES" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_ES" xml:lang="en-US">SPAIN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_ES" xml:lang="en-US">Spain [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="loc_country_IE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IE" xml:lang="en-US">IRELAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IE" xml:lang="en-US">Ireland [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN" xlink:label="loc_country_IN" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IN" xml:lang="en-US">INDIANA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IN" xml:lang="en-US">India [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="loc_country_IT" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IT" xml:lang="en-US">ITALY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IT" xml:lang="en-US">Italy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_JP" xml:lang="en-US">JAPAN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_JP" xml:lang="en-US">Japan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="loc_country_KR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_KR" xml:lang="en-US">KOREA, REPUBLIC OF</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_KR" xml:lang="en-US">Republic of Korea [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PK" xlink:label="loc_country_PK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_PK" xml:lang="en-US">PAKISTAN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_PK" xml:lang="en-US">Pakistan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PK" xlink:to="lab_country_PK" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR" xlink:label="loc_country_TR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_TR" xml:lang="en-US">TURKEY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_TR" xml:lang="en-US">Turkey [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SaudiArabiaMember" xlink:label="loc_gsk_SaudiArabiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SaudiArabiaMember" xml:lang="en-US">Saudi Arabia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SaudiArabiaMember" xml:lang="en-US">Saudi Arabia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SaudiArabiaMember" xlink:to="lab_gsk_SaudiArabiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SaudiArabiaMember" xml:lang="en-US">Saudi Arabia</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AustriaMember" xlink:label="loc_gsk_AustriaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_AustriaMember" xml:lang="en-US">Austria [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_AustriaMember" xml:lang="en-US">Austria [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_AustriaMember" xlink:to="lab_gsk_AustriaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_AustriaMember" xml:lang="en-US">Austria</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThailandMember" xlink:label="loc_gsk_ThailandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ThailandMember" xml:lang="en-US">Thailand [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ThailandMember" xml:lang="en-US">Thailand [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ThailandMember" xlink:to="lab_gsk_ThailandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ThailandMember" xml:lang="en-US">Thailand</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GreeceMember" xlink:label="loc_gsk_GreeceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GreeceMember" xml:lang="en-US">Greece [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GreeceMember" xml:lang="en-US">Greece [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GreeceMember" xlink:to="lab_gsk_GreeceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GreeceMember" xml:lang="en-US">Greece</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TW" xlink:label="loc_country_TW" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_TW" xml:lang="en-US">TAIWAN, PROVINCE OF CHINA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_TW" xml:lang="en-US">Taiwan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TW" xlink:to="lab_country_TW" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX" xlink:label="loc_country_MX" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_MX" xml:lang="en-US">MEXICO</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_MX" xml:lang="en-US">Mexico [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VietnamMember" xlink:label="loc_gsk_VietnamMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_VietnamMember" xml:lang="en-US">Vietnam [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_VietnamMember" xml:lang="en-US">Vietnam [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_VietnamMember" xlink:to="lab_gsk_VietnamMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_VietnamMember" xml:lang="en-US">Vietnam.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_BOFS" xlink:label="loc_exch_BOFS" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_exch_BOFS" xml:lang="en-US">BANK OF SCOTLAND PLC - SYSTEMATIC INTERNALISER [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_exch_BOFS" xml:lang="en-US">Scotland [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_BOFS" xlink:to="lab_exch_BOFS" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoOperationsUkLimitedMember" xlink:label="loc_gsk_GlaxoOperationsUkLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoOperationsUkLimitedMember" xml:lang="en-US">Glaxo Operations UK Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoOperationsUkLimitedMember" xml:lang="en-US">Glaxo Operations UK Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoOperationsUkLimitedMember" xlink:to="lab_gsk_GlaxoOperationsUkLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoOperationsUkLimitedMember" xml:lang="en-US">Glaxo Operations UK Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalIncMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineCapitalIncMember" xml:lang="en-US">Glaxo Smith Kline Capital Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineCapitalIncMember" xml:lang="en-US">GlaxoSmithKline Capital Inc. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineCapitalIncMember" xlink:to="lab_gsk_GlaxoSmithKlineCapitalIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineCapitalIncMember" xml:lang="en-US">GlaxoSmithKline Capital Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBrasilLimitadaMember" xlink:label="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineBrasilLimitadaMember" xml:lang="en-US">Glaxo Smith Kline Brasil Limitada [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineBrasilLimitadaMember" xml:lang="en-US">GlaxoSmithKline Brasil Limitada [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember" xlink:to="lab_gsk_GlaxoSmithKlineBrasilLimitadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineBrasilLimitadaMember" xml:lang="en-US">GlaxoSmithKline Brasil Limitada.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalPLCMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalPLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineCapitalPLCMember" xml:lang="en-US">Glaxo Smith Kline Capital PLC [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineCapitalPLCMember" xml:lang="en-US">GlaxoSmithKline Capital PLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineCapitalPLCMember" xlink:to="lab_gsk_GlaxoSmithKlineCapitalPLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineCapitalPLCMember" xml:lang="en-US">GlaxoSmithKline Capital PLC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSAMember" xlink:label="loc_gsk_GlaxoSmithKlineSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineSAMember" xml:lang="en-US">Glaxo Smith Kline S A [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineSAMember" xml:lang="en-US">GlaxoSmithKline S.A. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineSAMember" xlink:to="lab_gsk_GlaxoSmithKlineSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineSAMember" xml:lang="en-US">GlaxoSmithKline S.A.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBiologicalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlineBiologicalsSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineBiologicalsSAMember" xml:lang="en-US">Glaxo Smith Kline Biologicals S A [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineBiologicalsSAMember" xml:lang="en-US">GlaxoSmithKline Biologicals SA [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineBiologicalsSAMember" xlink:to="lab_gsk_GlaxoSmithKlineBiologicalsSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineBiologicalsSAMember" xml:lang="en-US">GlaxoSmithKline Biologicals SA.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xlink:label="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xml:lang="en-US">Glaxo Smith Kline Australia Pty Ltd [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xml:lang="en-US">GlaxoSmithKline Australia Pty Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xlink:to="lab_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xml:lang="en-US">GlaxoSmithKline Australia Pty Ltd.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineExportLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineExportLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineExportLimitedMember" xml:lang="en-US">Glaxo Smith Kline Export Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineExportLimitedMember" xml:lang="en-US">GlaxoSmithKline Export Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineExportLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineExportLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineExportLimitedMember" xml:lang="en-US">GlaxoSmithKline Export Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesGmbHMember" xlink:label="loc_gsk_GSKVaccinesGmbHMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GSKVaccinesGmbHMember" xml:lang="en-US">G S K Vaccines Gmb H [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GSKVaccinesGmbHMember" xml:lang="en-US">GSK Vaccines GmbH [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GSKVaccinesGmbHMember" xlink:to="lab_gsk_GSKVaccinesGmbHMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GSKVaccinesGmbHMember" xml:lang="en-US">GSK Vaccines GmbH.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsIncMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsIncMember" xml:lang="en-US">Glaxo Smith Kline Holdings Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsIncMember" xml:lang="en-US">GlaxoSmithKline Holdings (Americas) Inc. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineHoldingsIncMember" xlink:to="lab_gsk_GlaxoSmithKlineHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsIncMember" xml:lang="en-US">GlaxoSmithKline Holdings (Americas) Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineFinancePLCMember" xlink:label="loc_gsk_GlaxoSmithKlineFinancePLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineFinancePLCMember" xml:lang="en-US">Glaxo Smith Kline Finance PLC [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineFinancePLCMember" xml:lang="en-US">GlaxoSmithKline Finance PLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineFinancePLCMember" xlink:to="lab_gsk_GlaxoSmithKlineFinancePLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineFinancePLCMember" xml:lang="en-US">GlaxoSmithKline Finance PLC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorixaCorporationMember" xlink:label="loc_gsk_CorixaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_CorixaCorporationMember" xml:lang="en-US">Corixa Corporation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_CorixaCorporationMember" xml:lang="en-US">Corixa Corporation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_CorixaCorporationMember" xlink:to="lab_gsk_CorixaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_CorixaCorporationMember" xml:lang="en-US">Corixa Corporation.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKServicesSPZOOMember" xlink:label="loc_gsk_GSKServicesSPZOOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GSKServicesSPZOOMember" xml:lang="en-US">G S K Services S P Z O O [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GSKServicesSPZOOMember" xml:lang="en-US">GSK Services Sp z o.o. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GSKServicesSPZOOMember" xlink:to="lab_gsk_GSKServicesSPZOOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GSKServicesSPZOOMember" xml:lang="en-US">GSK Services Sp z o.o.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePakistanLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlinePakistanLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlinePakistanLimitedMember" xml:lang="en-US">Glaxo Smith Kline Pakistan Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlinePakistanLimitedMember" xml:lang="en-US">GlaxoSmithKline Pakistan Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlinePakistanLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlinePakistanLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlinePakistanLimitedMember" xml:lang="en-US">GlaxoSmithKline Pakistan Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xml:lang="en-US">Glaxo Smith Kline Research And Development Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xml:lang="en-US">GlaxoSmithKline Research &amp; Development Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xml:lang="en-US">GlaxoSmithKline Research and Development Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineIncMember" xlink:label="loc_gsk_GlaxoSmithKlineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineIncMember" xml:lang="en-US">Glaxo Smith Kline Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineIncMember" xml:lang="en-US">GlaxoSmithKline Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineIncMember" xlink:to="lab_gsk_GlaxoSmithKlineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineIncMember" xml:lang="en-US">GlaxoSmithKline Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HumanGenomeSciencesIncMember" xlink:label="loc_gsk_HumanGenomeSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_HumanGenomeSciencesIncMember" xml:lang="en-US">Human Genome Sciences Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_HumanGenomeSciencesIncMember" xml:lang="en-US">Human Genome Sciences, Inc. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_HumanGenomeSciencesIncMember" xlink:to="lab_gsk_HumanGenomeSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_HumanGenomeSciencesIncMember" xml:lang="en-US">Human Genome Sciences, Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SetFirstLimitedMember" xlink:label="loc_gsk_SetFirstLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SetFirstLimitedMember" xml:lang="en-US">Set First Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SetFirstLimitedMember" xml:lang="en-US">Setfirst Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SetFirstLimitedMember" xlink:to="lab_gsk_SetFirstLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SetFirstLimitedMember" xml:lang="en-US">Setfirst Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineGmbHAndCoKGMember" xlink:label="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineGmbHAndCoKGMember" xml:lang="en-US">Glaxo Smith Kline Gmb H And Co K G [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineGmbHAndCoKGMember" xml:lang="en-US">GlaxoSmithKline GmbH and Co. KG [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember" xlink:to="lab_gsk_GlaxoSmithKlineGmbHAndCoKGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineGmbHAndCoKGMember" xml:lang="en-US">GlaxoSmithKline GmbH and Co. KG.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSPAMember" xlink:label="loc_gsk_GlaxoSmithKlineSPAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineSPAMember" xml:lang="en-US">Glaxo Smith Kline S P A [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineSPAMember" xml:lang="en-US">GlaxoSmithKline S.p.A. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineSPAMember" xlink:to="lab_gsk_GlaxoSmithKlineSPAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineSPAMember" xml:lang="en-US">GlaxoSmithKline S.p.A.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineServicesUnlimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineServicesUnlimitedMember" xml:lang="en-US">Glaxo Smith Kline Services Unlimited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineServicesUnlimitedMember" xml:lang="en-US">GlaxoSmithKline Services Unlimited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineServicesUnlimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineServicesUnlimitedMember" xml:lang="en-US">GlaxoSmithKline Services Unlimited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLLCMember" xlink:label="loc_gsk_GlaxoSmithKlineLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineLLCMember" xml:lang="en-US">Glaxo Smith Kline L L C [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineLLCMember" xml:lang="en-US">GlaxoSmithKline LLC [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineLLCMember" xlink:to="lab_gsk_GlaxoSmithKlineLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineLLCMember" xml:lang="en-US">GlaxoSmithKline LLC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineTradingServicesLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineTradingServicesLimitedMember" xml:lang="en-US">Glaxo Smith Kline Trading Services Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GlaxoSmithKlineTradingServicesLimitedMember" xml:lang="en-US">GlaxoSmithKline Trading Services Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineTradingServicesLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineTradingServicesLimitedMember" xml:lang="en-US">GlaxoSmithKline Trading Services Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoriosViiVHealthCareSLMember" xlink:label="loc_gsk_LaboratoriosViiVHealthCareSLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LaboratoriosViiVHealthCareSLMember" xml:lang="en-US">Laboratorios Vii V Health Care S L [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LaboratoriosViiVHealthCareSLMember" xml:lang="en-US">Laboratorios ViiV Healthcare, S.L. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LaboratoriosViiVHealthCareSLMember" xlink:to="lab_gsk_LaboratoriosViiVHealthCareSLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LaboratoriosViiVHealthCareSLMember" xml:lang="en-US">Laboratorios ViiV Healthcare, S.L.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesSRLMember" xlink:label="loc_gsk_GSKVaccinesSRLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GSKVaccinesSRLMember" xml:lang="en-US">G S K Vaccines S R L [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GSKVaccinesSRLMember" xml:lang="en-US">GSK Vaccines S.r.l. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GSKVaccinesSRLMember" xlink:to="lab_gsk_GSKVaccinesSRLMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GSKVaccinesSRLMember" xml:lang="en-US">GSK Vaccines S.r.l.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsLimitedMember" xml:lang="en-US">Glaxo Smith Kline Holdings Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsLimitedMember" xml:lang="en-US">GlaxoSmithKline Holdings Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineHoldingsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineHoldingsLimitedMember" xml:lang="en-US">GlaxoSmithKline Finance PLC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareFinanceLimitedMember" xlink:label="loc_gsk_ViivHealthcareFinanceLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareFinanceLimitedMember" xml:lang="en-US">ViiV Healthcare Finance Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareFinanceLimitedMember" xlink:to="lab_gsk_ViivHealthcareFinanceLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareFinanceLimitedMember" xml:lang="en-US">ViiV Healthcare Finance Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareSASMember" xlink:label="loc_gsk_ViiVHealthcareSASMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViiVHealthcareSASMember" xml:lang="en-US">Vii V Healthcare SAS [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViiVHealthcareSASMember" xml:lang="en-US">ViiV Healthcare SAS [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViiVHealthcareSASMember" xlink:to="lab_gsk_ViiVHealthcareSASMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViiVHealthcareSASMember" xml:lang="en-US">ViiV Healthcare SAS.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareUnitedKingdomLimitedMember" xlink:label="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViiVHealthCareUnitedKingdomLimitedMember" xml:lang="en-US">Vii V Health Care United Kingdom Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViiVHealthCareUnitedKingdomLimitedMember" xml:lang="en-US">ViiV Healthcare UK Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember" xlink:to="lab_gsk_ViiVHealthCareUnitedKingdomLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViiVHealthCareUnitedKingdomLimitedMember" xml:lang="en-US">ViiV Healthcare UK Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKKMember" xlink:label="loc_gsk_GlaxoSmithKlineKKMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineKKMember" xml:lang="en-US">Glaxo Smith Kline K K [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineKKMember" xml:lang="en-US">GlaxoSmithKline K.K. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineKKMember" xlink:to="lab_gsk_GlaxoSmithKlineKKMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineKKMember" xml:lang="en-US">GlaxoSmithKline K.K.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKoreaLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineKoreaLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineKoreaLimitedMember" xml:lang="en-US">Glaxo Smith Kline Korea Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineKoreaLimitedMember" xml:lang="en-US">GlaxoSmithKline Korea Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineKoreaLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineKoreaLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineKoreaLimitedMember" xml:lang="en-US">GlaxoSmithKline Korea Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineLimitedMember" xml:lang="en-US">Glaxo Smith Kline Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineLimitedMember" xml:lang="en-US">GlaxoSmithKline Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineLimitedMember" xml:lang="en-US">GlaxoSmithKline Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelLaboratoriesIncMember" xlink:label="loc_gsk_StiefelLaboratoriesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_StiefelLaboratoriesIncMember" xml:lang="en-US">Stiefel Laboratories Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_StiefelLaboratoriesIncMember" xml:lang="en-US">Stiefel Laboratories, Inc. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_StiefelLaboratoriesIncMember" xlink:to="lab_gsk_StiefelLaboratoriesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_StiefelLaboratoriesIncMember" xml:lang="en-US">Stiefel Laboratories, Inc.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" xlink:label="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" xml:lang="en-US">GlaxoSmithKline Pharmaceuticals Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" xlink:to="lab_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SmithKlineBeechamLimitedMember" xlink:label="loc_gsk_SmithKlineBeechamLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_SmithKlineBeechamLimitedMember" xml:lang="en-US">Smith Kline Beecham Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_SmithKlineBeechamLimitedMember" xml:lang="en-US">SmithKline Beecham Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_SmithKlineBeechamLimitedMember" xlink:to="lab_gsk_SmithKlineBeechamLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_SmithKlineBeechamLimitedMember" xml:lang="en-US">SmithKline Beecham Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xml:lang="en-US">Glaxo Smith Kline United Kingdom Limited [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xml:lang="en-US">GlaxoSmithKline UK Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xlink:to="lab_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xml:lang="en-US">GlaxoSmithKline UK Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoireGlaxoSmithKlineMember" xlink:label="loc_gsk_LaboratoireGlaxoSmithKlineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LaboratoireGlaxoSmithKlineMember" xml:lang="en-US">Laboratoire Glaxo Smith Kline [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_LaboratoireGlaxoSmithKlineMember" xml:lang="en-US">Laboratoire GlaxoSmithKline [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LaboratoireGlaxoSmithKlineMember" xlink:to="lab_gsk_LaboratoireGlaxoSmithKlineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LaboratoireGlaxoSmithKlineMember" xml:lang="en-US">Laboratoire GlaxoSmithKline.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareSRLItalyMember" xlink:label="loc_gsk_ViivHealthcareSRLItalyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareSRLItalyMember" xml:lang="en-US">ViiV Healthcare S R L Italy [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViivHealthcareSRLItalyMember" xml:lang="en-US">ViiV Healthcare S.r.l. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareSRLItalyMember" xlink:to="lab_gsk_ViivHealthcareSRLItalyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareSRLItalyMember" xml:lang="en-US">ViiV Healthcare S.r.l. (Italy).</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IDBiomedicalCorporationOfQuebecMember" xlink:label="loc_gsk_IDBiomedicalCorporationOfQuebecMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_IDBiomedicalCorporationOfQuebecMember" xml:lang="en-US">I D Biomedical Corporation Of Quebec [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_IDBiomedicalCorporationOfQuebecMember" xml:lang="en-US">ID Biomedical Corporation of Quebec [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_IDBiomedicalCorporationOfQuebecMember" xlink:to="lab_gsk_IDBiomedicalCorporationOfQuebecMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_IDBiomedicalCorporationOfQuebecMember" xml:lang="en-US">ID Biomedical Corporation of Quebec.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeManufacturingPteLtdMember" xlink:label="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoWellcomeManufacturingPteLtdMember" xml:lang="en-US">Glaxo Wellcome Manufacturing Pte Ltd [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoWellcomeManufacturingPteLtdMember" xml:lang="en-US">Glaxo Wellcome Manufacturing Pte Ltd. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember" xlink:to="lab_gsk_GlaxoWellcomeManufacturingPteLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoWellcomeManufacturingPteLtdMember" xml:lang="en-US">Glaxo Wellcome Manufacturing Pte Ltd.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroMember" xlink:label="loc_gsk_TesaroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_TesaroMember" xml:lang="en-US">Tesaro [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_TesaroMember" xml:lang="en-US">Tesaro, Inc. [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_TesaroMember" xlink:to="lab_gsk_TesaroMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_TesaroMember" xml:lang="en-US">Tesaro.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareCompanyMember" xlink:label="loc_gsk_ViiVHealthcareCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViiVHealthcareCompanyMember" xml:lang="en-US">Vii V Healthcare Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_ViiVHealthcareCompanyMember" xml:lang="en-US">ViiV Healthcare Company [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViiVHealthcareCompanyMember" xlink:to="lab_gsk_ViiVHealthcareCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViiVHealthcareCompanyMember" xml:lang="en-US">ViiV Healthcare Company.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEquityInvestmentsLimitedMember" xlink:label="loc_gsk_GskEquityInvestmentsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskEquityInvestmentsLimitedMember" xml:lang="en-US">GSK Equity Investments Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskEquityInvestmentsLimitedMember" xml:lang="en-US">GSK Equity Investments, Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskEquityInvestmentsLimitedMember" xlink:to="lab_gsk_GskEquityInvestmentsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskEquityInvestmentsLimitedMember" xml:lang="en-US">GSK Equity Investments, Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeUkLimitedMember" xlink:label="loc_gsk_GlaxoWellcomeUkLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoWellcomeUkLimitedMember" xml:lang="en-US">Glaxo Wellcome UK Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoWellcomeUkLimitedMember" xlink:to="lab_gsk_GlaxoWellcomeUkLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoWellcomeUkLimitedMember" xml:lang="en-US">Glaxo Wellcome UK Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineUsTradingLimitedMember" xlink:label="loc_gsk_GlaxosmithklineUsTradingLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineUsTradingLimitedMember" xml:lang="en-US">GlaxoSmithKline US Trading Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineUsTradingLimitedMember" xlink:to="lab_gsk_GlaxosmithklineUsTradingLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineUsTradingLimitedMember" xml:lang="en-US">GlaxoSmithKline US Trading Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JscGlaxosmithklineTradingMember" xlink:label="loc_gsk_JscGlaxosmithklineTradingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_JscGlaxosmithklineTradingMember" xml:lang="en-US">JSC GlaxoSmithKline Trading [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_JscGlaxosmithklineTradingMember" xlink:to="lab_gsk_JscGlaxosmithklineTradingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_JscGlaxosmithklineTradingMember" xml:lang="en-US">JSC GlaxoSmithKline Trading.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.2) Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.2) Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xlink:to="lab_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.2) Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineAgMember" xlink:label="loc_gsk_GlaxosmithklineAgMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineAgMember" xml:lang="en-US">GlaxoSmithKline AG [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineAgMember" xml:lang="en-US">GlaxoSmithKline AG [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineAgMember" xlink:to="lab_gsk_GlaxosmithklineAgMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineAgMember" xml:lang="en-US">GlaxoSmithKline AG.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineB.v.Member" xlink:label="loc_gsk_GlaxosmithklineB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineB.v.Member" xml:lang="en-US">GlaxoSmithKline B.V. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineB.v.Member" xml:lang="en-US">GlaxoSmithKline B.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineB.v.Member" xlink:to="lab_gsk_GlaxosmithklineB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineB.v.Member" xml:lang="en-US">GlaxoSmithKline B.V.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaGmbhMember" xlink:label="loc_gsk_GlaxosmithklinePharmaGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklinePharmaGmbhMember" xml:lang="en-US">GlaxoSmithKline Pharma GmbH [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklinePharmaGmbhMember" xml:lang="en-US">GlaxoSmithKline Pharma GmbH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklinePharmaGmbhMember" xlink:to="lab_gsk_GlaxosmithklinePharmaGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklinePharmaGmbhMember" xml:lang="en-US">GlaxoSmithKline Pharma GmbH.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xlink:label="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xml:lang="en-US">GlaxoSmithKline Single Member A.E.B.E. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xml:lang="en-US">GlaxoSmithKline Single Member A.E.B.E. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xlink:to="lab_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xml:lang="en-US">GlaxoSmithKline Single Member A.E.B.E.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskCapitalB.v.Member" xlink:label="loc_gsk_GskCapitalB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskCapitalB.v.Member" xml:lang="en-US">GSK Capital B.V. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskCapitalB.v.Member" xml:lang="en-US">GSK Capital B.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskCapitalB.v.Member" xlink:to="lab_gsk_GskCapitalB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskCapitalB.v.Member" xml:lang="en-US">GSK Capital B.V.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareGmbhMember" xlink:label="loc_gsk_ViivHealthcareGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareGmbhMember" xml:lang="en-US">ViiV Healthcare GmbH [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViivHealthcareGmbhMember" xml:lang="en-US">ViiV Healthcare GmbH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareGmbhMember" xlink:to="lab_gsk_ViivHealthcareGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareGmbhMember" xml:lang="en-US">ViiV Healthcare GmbH.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineThailandLimitedMember" xlink:label="loc_gsk_GlaxosmithklineThailandLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineThailandLimitedMember" xml:lang="en-US">GlaxoSmithKline (Thailand) Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineThailandLimitedMember" xml:lang="en-US">GlaxoSmithKline (Thailand) Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineThailandLimitedMember" xlink:to="lab_gsk_GlaxosmithklineThailandLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineThailandLimitedMember" xml:lang="en-US">GlaxoSmithKline (Thailand) Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineFarEastB.v.Member" xlink:label="loc_gsk_GlaxosmithklineFarEastB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineFarEastB.v.Member" xml:lang="en-US">GlaxoSmithKline Far East B.V. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineFarEastB.v.Member" xml:lang="en-US">GlaxoSmithKline Far East B.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineFarEastB.v.Member" xlink:to="lab_gsk_GlaxosmithklineFarEastB.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineFarEastB.v.Member" xml:lang="en-US">GlaxoSmithKline Far East B.V.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xlink:label="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xml:lang="en-US">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xml:lang="en-US">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xlink:to="lab_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xml:lang="en-US">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xlink:label="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xml:lang="en-US">GlaxoSmithKline Mexico S.A. de C.V. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xml:lang="en-US">GlaxoSmithKline Mexico S.A. de C.V. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xlink:to="lab_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xml:lang="en-US">GlaxoSmithKline Mexico S.A. de C.V.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEnterpriseManagementCoLtdMember" xlink:label="loc_gsk_GskEnterpriseManagementCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskEnterpriseManagementCoLtdMember" xml:lang="en-US">GSK Enterprise Management Co, Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskEnterpriseManagementCoLtdMember" xml:lang="en-US">GSK Enterprise Management Co, Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskEnterpriseManagementCoLtdMember" xlink:to="lab_gsk_GskEnterpriseManagementCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskEnterpriseManagementCoLtdMember" xml:lang="en-US">GSK Enterprise Management Co, Ltd.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPharmaVietnamCompanyLimitedMember" xlink:label="loc_gsk_GskPharmaVietnamCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskPharmaVietnamCompanyLimitedMember" xml:lang="en-US">GSK Pharma Vietnam Company Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskPharmaVietnamCompanyLimitedMember" xml:lang="en-US">GSK Pharma Vietnam Company Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskPharmaVietnamCompanyLimitedMember" xlink:to="lab_gsk_GskPharmaVietnamCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskPharmaVietnamCompanyLimitedMember" xml:lang="en-US">GSK Pharma Vietnam Company Limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareK.kMember" xlink:label="loc_gsk_ViivHealthcareK.kMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareK.kMember" xml:lang="en-US">ViiV Healthcare K.K [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViivHealthcareK.kMember" xml:lang="en-US">ViiV Healthcare K.K [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareK.kMember" xlink:to="lab_gsk_ViivHealthcareK.kMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareK.kMember" xml:lang="en-US">ViiV Healthcare K.K.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUlcMember" xlink:label="loc_gsk_ViivHealthcareUlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareUlcMember" xml:lang="en-US">ViiV Healthcare ULC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViivHealthcareUlcMember" xml:lang="en-US">ViiV Healthcare ULC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareUlcMember" xlink:to="lab_gsk_ViivHealthcareUlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareUlcMember" xml:lang="en-US">ViiV Healthcare ULC.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.3) Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.3) Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xlink:to="lab_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.3) Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIhcLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIhcLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIhcLimitedMember" xml:lang="en-US">GlaxoSmithKline IHC Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIhcLimitedMember" xml:lang="en-US">GlaxoSmithKline IHC Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIhcLimitedMember" xlink:to="lab_gsk_GlaxosmithklineIhcLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIhcLimitedMember" xml:lang="en-US">GlaxoSmithKline IHC Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.4) Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.4) Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xlink:to="lab_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property (No.4) Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Development Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Development Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xlink:to="lab_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Development Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xml:lang="en-US">GlaxoSmithKline Intellectual Property Limited</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xml:lang="en-US">Glaxo Smith Kline Pharmaceuticals S A [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xml:lang="en-US">GlaxoSmithKline Pharmaceuticals SA [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xlink:to="lab_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xml:lang="en-US">GlaxoSmithKline Pharmaceuticals S.A.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.1ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.1ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskNo.1ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.1) Scottish Limited Partnership [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskNo.1ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.1) Scottish Limited Partnership [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskNo.1ScottishLimitedPartnershipMember" xlink:to="lab_gsk_GskNo.1ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskNo.1ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (no.1) scottish limited partnership.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.2ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.2ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskNo.2ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.2) Scottish Limited Partnership [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskNo.2ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.2) Scottish Limited Partnership [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskNo.2ScottishLimitedPartnershipMember" xlink:to="lab_gsk_GskNo.2ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskNo.2ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (no.2) scottish limited partnership.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.3ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.3ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskNo.3ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.3) Scottish Limited Partnership [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskNo.3ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (No.3) Scottish Limited Partnership [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskNo.3ScottishLimitedPartnershipMember" xlink:to="lab_gsk_GskNo.3ScottishLimitedPartnershipMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskNo.3ScottishLimitedPartnershipMember" xml:lang="en-US">GSK (no.3) scottish limited partnership.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xlink:label="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xml:lang="en-US">ViiV Healthcare United Kingdom No.3 Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xml:lang="en-US">ViiV Healthcare UK No.3 Limited [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xlink:to="lab_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xml:lang="en-US">ViiV healthcare united kingdom no.3 limited.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xml:lang="en-US">Disclosure of subsidiaries [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xml:lang="en-US">Disclosure of subsidiaries [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="loc_ifrs-full_NameOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NameOfSubsidiary" xml:lang="en-US">Name of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NameOfSubsidiary" xml:lang="en-US">Name of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NameOfSubsidiary" xlink:to="lab_ifrs-full_NameOfSubsidiary" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xml:lang="en-US">Country of incorporation of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xml:lang="en-US">Country of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xml:lang="en-US">Proportion of voting rights held in subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xml:lang="en-US">Proportion of voting rights held in subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp1LimitedsShareCapitalMember" xlink:label="loc_gsk_GskGp1LimitedsShareCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskGp1LimitedsShareCapitalMember" xml:lang="en-US">GSK GP 1 Limiteds Share Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskGp1LimitedsShareCapitalMember" xml:lang="en-US">GSK GP 1 Limiteds Share Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskGp1LimitedsShareCapitalMember" xlink:to="lab_gsk_GskGp1LimitedsShareCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskGp1LimitedsShareCapitalMember" xml:lang="en-US">GSK gp 1 limiteds share capital.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp2LimitedsShareCapital.Member" xlink:label="loc_gsk_GskGp2LimitedsShareCapital.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskGp2LimitedsShareCapital.Member" xml:lang="en-US">GSK GP 2 Limiteds Share Capital. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GskGp2LimitedsShareCapital.Member" xml:lang="en-US">GSK GP 2 Limiteds Share Capital. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskGp2LimitedsShareCapital.Member" xlink:to="lab_gsk_GskGp2LimitedsShareCapital.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskGp2LimitedsShareCapital.Member" xml:lang="en-US">GSK GP 2 limited's share capital.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPlcMember" xlink:label="loc_gsk_GskPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GskPlcMember" xml:lang="en-US">GSK Plc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_GskPlcMember" xml:lang="en-US">GSK plc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GskPlcMember" xlink:to="lab_gsk_GskPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GskPlcMember" xml:lang="en-US">GSK plc Member</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xlink:label="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xml:lang="en-US">Berkeley Square Pension Trustee Company Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xml:lang="en-US">Berkeley Square Pension Trustee Company Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xlink:to="lab_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xml:lang="en-US">Berkeley square pension trustee company limited.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsAbstract" xlink:label="loc_gsk_DisclosureOfLegalProceedingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLegalProceedingsAbstract" xml:lang="en-US">Disclosure Of Legal Proceedings [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLegalProceedingsAbstract" xlink:to="lab_gsk_DisclosureOfLegalProceedingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLegalProceedingsAbstract" xml:lang="en-US">Disclosure of legal proceedings.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsTable" xlink:label="loc_gsk_DisclosureOfLegalProceedingsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLegalProceedingsTable" xml:lang="en-US">Disclosure Of Legal Proceedings [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfLegalProceedingsTable" xml:lang="en-US">Disclosure Of Legal Proceedings [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable" xlink:to="lab_gsk_DisclosureOfLegalProceedingsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLegalProceedingsTable" xml:lang="en-US">Disclosure of legal proceedings</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsLineItems" xlink:label="loc_gsk_DisclosureOfLegalProceedingsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DisclosureOfLegalProceedingsLineItems" xml:lang="en-US">Disclosure of Legal Proceedings [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DisclosureOfLegalProceedingsLineItems" xml:lang="en-US">Disclosure of Legal Proceedings [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems" xlink:to="lab_gsk_DisclosureOfLegalProceedingsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DisclosureOfLegalProceedingsLineItems" xml:lang="en-US">Disclosure of legal proceedings line items.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DamagesAwardedToGSK" xlink:label="loc_gsk_DamagesAwardedToGSK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_DamagesAwardedToGSK" xml:lang="en-US">Damages Awarded To G S K</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_DamagesAwardedToGSK" xml:lang="en-US">Damages&#8203; Awarded to GSK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_DamagesAwardedToGSK" xlink:to="lab_gsk_DamagesAwardedToGSK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_DamagesAwardedToGSK" xml:lang="en-US">Damages&#8203; Awarded to GSK.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossContingencyNumberOfPlaintiffs" xlink:label="loc_gsk_LossContingencyNumberOfPlaintiffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_LossContingencyNumberOfPlaintiffs" xml:lang="en-US">Loss Contingency Number Of Plaintiffs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_gsk_LossContingencyNumberOfPlaintiffs" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_LossContingencyNumberOfPlaintiffs" xlink:to="lab_gsk_LossContingencyNumberOfPlaintiffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_LossContingencyNumberOfPlaintiffs" xml:lang="en-US">Loss contingency, number of plaintiffs.</label>
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinePayable" xlink:label="loc_gsk_FinePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_FinePayable" xml:lang="en-US">Fine Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_FinePayable" xlink:to="lab_gsk_FinePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_FinePayable" xml:lang="en-US">Fine payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xml:lang="en-US">Classes of contingent liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xml:lang="en-US">Classes of contingent liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xml:lang="en-US">Contingent liabilities [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xml:lang="en-US">Contingent liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember" xlink:to="lab_ifrs-full_ContingentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKKoreaMember" xlink:label="loc_gsk_GSKKoreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_gsk_GSKKoreaMember" xml:lang="en-US">GSK Korea [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_gsk_GSKKoreaMember" xml:lang="en-US">GSK Korea [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gsk_GSKKoreaMember" xlink:to="lab_gsk_GSKKoreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_gsk_GSKKoreaMember" xml:lang="en-US">GSK Korea.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>gsk-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-March-2023 [08:38:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CoverPage" roleURI="http://www.gsk.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedIncomeStatement" roleURI="http://www.gsk.com/role/ConsolidatedIncomeStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfComprehensiveIncome" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedBalanceSheet" roleURI="http://www.gsk.com/role/ConsolidatedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedStatementOfChangesInEquity" roleURI="http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ConsolidatedCashFlowStatement" roleURI="http://www.gsk.com/role/ConsolidatedCashFlowStatement" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PresentationOfTheFinancialStatements" roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPolicies" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPolicies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NewAccountingRequirements" roleURI="http://www.gsk.com/role/NewAccountingRequirements" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRates" roleURI="http://www.gsk.com/role/ExchangeRates" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformation" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformation" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpense" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpense" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfit" roleURI="http://www.gsk.com/role/OperatingProfit" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCosts" roleURI="http://www.gsk.com/role/EmployeeCosts" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCosts" roleURI="http://www.gsk.com/role/MajorRestructuringCosts" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncome" roleURI="http://www.gsk.com/role/FinanceIncome" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpense" roleURI="http://www.gsk.com/role/FinanceExpense" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVentures" roleURI="http://www.gsk.com/role/AssociatesAndJointVentures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Taxation" roleURI="http://www.gsk.com/role/Taxation" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShare" roleURI="http://www.gsk.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Dividends" roleURI="http://www.gsk.com/role/Dividends" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipment" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssets" roleURI="http://www.gsk.com/role/RightOfUseAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Goodwill" roleURI="http://www.gsk.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssets" roleURI="http://www.gsk.com/role/OtherIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVentures" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestments" roleURI="http://www.gsk.com/role/CurrentEquityInvestments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestments" roleURI="http://www.gsk.com/role/OtherInvestments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssets" roleURI="http://www.gsk.com/role/OtherNonCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Inventories" roleURI="http://www.gsk.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivables" roleURI="http://www.gsk.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalents" roleURI="http://www.gsk.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSale" roleURI="http://www.gsk.com/role/AssetsHeldForSale" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayables" roleURI="http://www.gsk.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebt" roleURI="http://www.gsk.com/role/NetDebt" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefits" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisions" roleURI="http://www.gsk.com/role/OtherProvisions" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilities" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilities" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentLiabilities" roleURI="http://www.gsk.com/role/ContingentLiabilities" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#Commitments" roleURI="http://www.gsk.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccount" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquity" roleURI="http://www.gsk.com/role/MovementsInEquity" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterests" roleURI="http://www.gsk.com/role/NonControllingInterests" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RelatedPartyTransactions" roleURI="http://www.gsk.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposals" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebt" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosures" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemes" roleURI="http://www.gsk.com/role/EmployeeShareSchemes" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompanies" roleURI="http://www.gsk.com/role/PrincipalGroupCompanies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#LegalProceedings" roleURI="http://www.gsk.com/role/LegalProceedings" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PostBalanceSheetEvents" roleURI="http://www.gsk.com/role/PostBalanceSheetEvents" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesPolicies" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesTables" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRatesTables" roleURI="http://www.gsk.com/role/ExchangeRatesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTables" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseTables" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitTables" roleURI="http://www.gsk.com/role/OperatingProfitTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsTables" roleURI="http://www.gsk.com/role/EmployeeCostsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsTables" roleURI="http://www.gsk.com/role/MajorRestructuringCostsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncomeTables" roleURI="http://www.gsk.com/role/FinanceIncomeTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpenseTables" roleURI="http://www.gsk.com/role/FinanceExpenseTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesTables" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationTables" roleURI="http://www.gsk.com/role/TaxationTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareTables" roleURI="http://www.gsk.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsTables" roleURI="http://www.gsk.com/role/DividendsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssetsTables" roleURI="http://www.gsk.com/role/RightOfUseAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillTables" roleURI="http://www.gsk.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsTables" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesTables" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsTables" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsTables" roleURI="http://www.gsk.com/role/OtherInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsTables" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InventoriesTables" roleURI="http://www.gsk.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleTables" roleURI="http://www.gsk.com/role/AssetsHeldForSaleTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesTables" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtTables" roleURI="http://www.gsk.com/role/NetDebtTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsTables" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsTables" roleURI="http://www.gsk.com/role/OtherProvisionsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesTables" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilitiesTables" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsTables" roleURI="http://www.gsk.com/role/CommitmentsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountTables" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityTables" roleURI="http://www.gsk.com/role/MovementsInEquityTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsTables" roleURI="http://www.gsk.com/role/NonControllingInterestsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsTables" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtTables" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresTables" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesTables" roleURI="http://www.gsk.com/role/EmployeeShareSchemesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesTables" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesTables" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PresentationOfTheFinancialStatementsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail" roleURI="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail" roleURI="http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTurnoverBySegmentDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationTurnoverByProductServiceDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail" roleURI="http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" roleURI="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitSummaryOfInformationAboutProfitLossDetail" roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OperatingProfitSummaryOfAuditorsRemunerationDetail" roleURI="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfEmployeeCostsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" roleURI="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" roleURI="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" roleURI="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceIncomeSummaryOfFinanceIncomeDetail" roleURI="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinanceExpenseSummaryOfFinanceCostDetail" roleURI="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail" roleURI="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TaxationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfNetDeferredTaxAssetDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail" roleURI="http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" roleURI="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfInterimFinancialReportingDetail" roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfInterimFinancialReportingDetailParenthetical" roleURI="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/DividendsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#DividendsSummaryOfDividendsToShareholdersDetail" roleURI="http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" roleURI="http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail" roleURI="http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.gsk.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillSummaryOfChangesInGoodwillDetail" roleURI="http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail" roleURI="http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail" roleURI="http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail" roleURI="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CurrentEquityInvestmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherInvestmentsScheduleOfOtherInvestmentsDetail" roleURI="http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherReceivablesSummaryOfLossAllowanceDetail" roleURI="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" roleURI="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail" roleURI="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtAdditionalInformationDetail" roleURI="http://www.gsk.com/role/NetDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail" roleURI="http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NetDebtScheduleOfFinanceLeaseObligationsDetail" roleURI="http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail" roleURI="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherProvisionsSummaryOfOtherProvisionsDetail" roleURI="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentConsiderationLiabilitiesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" roleURI="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ContingentLiabilitiesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" roleURI="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ShareCapitalAndSharePremiumAccountAdditionalInformationDetail" roleURI="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAdditionalInformationDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail" roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail" roleURI="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#MovementsInEquityAnalysisOfOtherReservesDetail" roleURI="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail" roleURI="http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" roleURI="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail" roleURI="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail" roleURI="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail" roleURI="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesAdditionalInformationDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfOptionOutstandingDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail" roleURI="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail" roleURI="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="gsk-20221231.xsd#LegalProceedingsAdditionalInformationDetail" roleURI="http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_505011" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_505013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_505011" xlink:to="loc_dei_DocumentInformationTable_505013" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassAxis" xlink:label="loc_gsk_TitleOfEachClassAxis_514849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_505013" xlink:to="loc_gsk_TitleOfEachClassAxis_514849" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfEachClassDomain" xlink:label="loc_gsk_TitleOfEachClassDomain_514850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassAxis_514849" xlink:to="loc_gsk_TitleOfEachClassDomain_514850" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_514866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_AmericanDepositarySharesMember_514866" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourNotesDue2023Member" xlink:label="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member_862545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ZeroPointFiveThreeFourNotesDue2023Member_862545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroNotesDue2024Member" xlink:label="loc_gsk_ThreePointZeroNotesDue2024Member_629615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointZeroNotesDue2024Member_629615" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFiveNotesDue2025Member" xlink:label="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member_514858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointSixTwoFiveNotesDue2025Member_514858" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFiveNotesDue2028Member" xlink:label="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member_514859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointEightSevenFiveNotesDue2028Member_514859" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFiveNotesDue2029Member" xlink:label="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member_514860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_ThreePointThreeSevenFiveNotesDue2029Member_514860" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFiveNotesDue2038Member" xlink:label="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member_514861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_SixPointThreeSevenFiveNotesDue2038Member_514861" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoZeroZeroNotesDue2043Member" xlink:label="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member_514862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfEachClassDomain_514850" xlink:to="loc_gsk_FourPointTwoZeroZeroNotesDue2043Member_514862" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1069485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_505013" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1069485" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1069485" xlink:to="loc_dei_AddressTypeDomain_1069488" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1069491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1069488" xlink:to="loc_dei_BusinessContactMember_1069491" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_505016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_505013" xlink:to="loc_dei_DocumentInformationLineItems_505016" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_505079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentType_505079" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_505080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AmendmentFlag_505080" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_505081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentPeriodEndDate_505081" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_505082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentFiscalYearFocus_505082" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_505083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentFiscalPeriodFocus_505083" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_505085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityRegistrantName_505085" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_514820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCentralIndexKey_514820" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_514821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_CurrentFiscalYearEndDate_514821" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_505088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityFilerCategory_505088" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_514842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentAnnualReport_514842" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_514843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentTransitionReport_514843" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_507061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityFileNumber_507061" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_514846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentShellCompanyReport_514846" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_507054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressAddressLine1_507054" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_507057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressCityOrTown_507057" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_514778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressCountry_514778" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_507052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityIncorporationStateCountryCode_507052" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_514873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityAddressPostalZipCode_514873" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_514827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityEmergingGrowthCompany_514827" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_505089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityShellCompany_505089" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_514826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_514826" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_514822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_514822" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_505091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityVoluntaryFilers_505091" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_505090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityCurrentReportingStatus_505090" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_514874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_EntityInteractiveDataCurrent_514874" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_514876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentAccountingStandard_514876" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_505084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_TradingSymbol_505084" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_514863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_Security12bTitle_514863" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_514865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_SecurityExchangeName_514865" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_832775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_IcfrAuditorAttestationFlag_832775" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_1069493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_DocumentRegistrationStatement_1069493" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1069494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_ContactPersonnelName_1069494" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_1069501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_ContactPersonnelEmailAddress_1069501" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1069504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_CityAreaCode_1069504" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1069505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_LocalPhoneNumber_1069505" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_2146646319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorName_2146646319" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_2146646320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorFirmId_2146646320" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_2146646321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_505016" xlink:to="loc_dei_AuditorLocation_2146646321" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedIncomeStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_Revenue_20" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_CostOfSales_21" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_GrossProfit_22" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_23" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_24" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_RevenueFromRoyalties_25" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_26" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_27" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_FinanceIncome_28" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_FinanceCosts_29" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociate_30" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_31" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_32" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_33" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_1701159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_1701159" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger" xlink:label="loc_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger_1701165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger_1701165" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:label="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_1701171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_1701171" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1701174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1701174" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLoss_34" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_1701175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_1701175" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent_1701176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent_1701176" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1701177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1701177" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1701180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1701180" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_35" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_36" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_ProfitLoss_37" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_1701181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_1701181" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1701182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1701182" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_38" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_1701184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_1701184" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_1701185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_1701185" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_19" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_39" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_ifrs-full_ProfitLoss_65" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_505041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_505041" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_505041" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_45" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_46" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_51" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_53" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_52" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_505049" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_55" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated_56" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments_57" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome_534714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome_534714" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated" xlink:label="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated_59" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated" xlink:label="loc_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated_60" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueMovementsOnCashFlowHedgesNotReclassified" xlink:label="loc_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified_2146643088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified_2146643088" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_43" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_61" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations" xlink:label="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations_1702730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations_1702730" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations" xlink:label="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations_1702732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations_1702732" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_512686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_ifrs-full_ComprehensiveIncome_512686" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_41" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_44" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_44" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_62" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_44" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_63" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_44" xlink:to="loc_ifrs-full_ComprehensiveIncome_64" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_72" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_96" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_505051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_RightofuseAssets_505051" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_Goodwill_97" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_98" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_99" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_100" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_DeferredTaxAssets_101" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_102" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_103" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_72" xlink:to="loc_ifrs-full_NoncurrentAssets_104" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_69" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_Inventories_74" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets" xlink:label="loc_ifrs-full_CurrentTaxAssets_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_CurrentTaxAssets_75" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_76" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_77" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644860" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_78" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_CashAndCashEquivalents_79" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_80" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_69" xlink:to="loc_ifrs-full_CurrentAssets_81" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_Assets_114" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_70" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-full_ShorttermBorrowings_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_ShorttermBorrowings_82" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities_83" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_84" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_85" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_86" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_OtherShorttermProvisions_87" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_70" xlink:to="loc_ifrs-full_CurrentLiabilities_88" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_LongtermBorrowings_105" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_106" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_107" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_108" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_OtherLongtermProvisions_109" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_110" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_111" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_112" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_73" xlink:to="loc_ifrs-full_NoncurrentLiabilities_113" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_Liabilities_115" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_NetAssetsLiabilities_116" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_68" xlink:to="loc_ifrs-full_EquityAbstract_71" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_IssuedCapital_89" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_SharePremium_90" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_RetainedEarnings_91" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_OtherReserves_92" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_93" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_NoncontrollingInterests_94" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_71" xlink:to="loc_ifrs-full_Equity_95" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_118" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_118" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_124" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_124" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_119" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_119" xlink:to="loc_ifrs-full_EquityMember_120" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_IssuedCapitalMember_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_SharePremiumMember_126" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_RetainedEarningsMember_127" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_OtherReservesMember_128" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_120" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_130" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_124" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_122" xlink:to="loc_ifrs-full_RestatedMember_121" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_124" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_Equity_134" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ProfitLoss_135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_136" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ComprehensiveIncome_137" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_138" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashDistributionsToNoncontrollingInterests" xlink:label="loc_gsk_NoncashDistributionsToNoncontrollingInterests_2146645026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_NoncashDistributionsToNoncontrollingInterests_2146645026" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity" xlink:label="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity_139" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_147" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary_2146645027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary_2146645027" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="loc_ifrs-full_DividendsPaid_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DividendsPaid_142" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:label="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_144" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashDividendToShareholders" xlink:label="loc_gsk_NonCashDividendToShareholders_2146645028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_NonCashDividendToShareholders_2146645028" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments_146" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IssueOfEquity_148" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan" xlink:label="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan_150" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesAcquiredByEsopTrusts" xlink:label="loc_gsk_SharesAcquiredByEsopTrusts_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_SharesAcquiredByEsopTrusts_149" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_151" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionsWithNoncontoliingInterests" xlink:label="loc_gsk_TransactionsWithNoncontoliingInterests_1306645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_TransactionsWithNoncontoliingInterests_1306645" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_152" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingGainLossTransferredToNonFinancialAssets" xlink:label="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets_2146645029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_gsk_HedgingGainLossTransferredToNonFinancialAssets_2146645029" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_123" xlink:to="loc_ifrs-full_Equity_153" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ConsolidatedCashFlowStatement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_156" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_1701237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_156" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_1701237" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_1701237" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_2147449765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_2147449765" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_195" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations_1702770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations_1702770" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations_1702771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations_1702771" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax_1701243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax_1701243" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations" xlink:label="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations_2146645004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations_2146645004" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations" xlink:label="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations_1702773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations_1702773" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax" xlink:label="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax_1701244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax_1701244" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_160" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_198" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_179" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_180" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_182" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_183" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_186" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_184" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_534718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_534718" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_187" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurchaseOfInvestmentInAssociatesAndJointVentures" xlink:label="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures_188" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromDisposalOfAssociatesAndJointVentures" xlink:label="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures_1306873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures_1306873" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsInvestingActivities_191" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInLiquidInvestments" xlink:label="loc_gsk_IncreaseDecreaseInLiquidInvestments_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_gsk_IncreaseDecreaseInLiquidInvestments_190" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities_192" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_1701245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_1701245" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_1701246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_1701246" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_159" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_193" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_167" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2146643292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2146643292" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_169" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_170" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_171" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_172" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_173" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_174" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_175" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_176" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_177" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_1701247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_1701247" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_1701248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_1701248" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_178" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_2146643288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_158" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_2146643288" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_513719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_513719" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_200" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_201" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_202" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_1701242" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_513682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_CashAndCashEquivalents_513682" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_164" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract_157" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_165" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PresentationOfTheFinancialStatements">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3040" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_3041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3040" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_3041" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPolicies">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3082" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_3083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3082" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_3083" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3088" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_3089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3088" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_3089" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NewAccountingRequirements">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3091" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_3092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3091" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_3092" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ExchangeRates">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3094" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_3095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3094" xlink:to="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_3095" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformation">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3100" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_3101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3100" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_3101" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpense">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3116" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_3117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3116" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_3117" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfit">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3122" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_3123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3122" xlink:to="loc_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_3123" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCosts">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3134" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsExplanatory" xlink:label="loc_gsk_DisclosureOfEmployeeCostsExplanatory_3135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3134" xlink:to="loc_gsk_DisclosureOfEmployeeCostsExplanatory_3135" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCosts">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3143" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMajorRestructuringCostsExplanatory" xlink:label="loc_gsk_DisclosureOfMajorRestructuringCostsExplanatory_3144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3143" xlink:to="loc_gsk_DisclosureOfMajorRestructuringCostsExplanatory_3144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceIncome">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3150" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory_3151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3150" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory_3151" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceExpense">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3156" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_3157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3156" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_3157" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVentures">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3162" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory_3163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3162" xlink:to="loc_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory_3163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/Taxation">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3170" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_3171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3170" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_3171" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShare">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3181" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_3182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3181" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_3182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/Dividends">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3188" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDividendsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDividendsExplanatory_3189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3188" xlink:to="loc_ifrs-full_DisclosureOfDividendsExplanatory_3189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipment">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3195" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_3196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3195" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_3196" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RightOfUseAssets">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_512847" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_512848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_512847" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_512848" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3201" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory_3202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3201" xlink:to="loc_ifrs-full_DisclosureOfGoodwillExplanatory_3202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssets">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3209" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_3210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3209" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_3210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3218" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_3219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3218" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_3219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestments">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_2146644894" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCurrentEquityInvestmentsTextBlock" xlink:label="loc_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock_2146644895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_2146644894" xlink:to="loc_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock_2146644895" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestments">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3225" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_3226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3225" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_3226" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssets">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3232" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_3233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3232" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_3233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/Inventories">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3238" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_3239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3238" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_3239" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3244" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradesAndOtherReceivableTextBlock" xlink:label="loc_gsk_DisclosureOfTradesAndOtherReceivableTextBlock_1317815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3244" xlink:to="loc_gsk_DisclosureOfTradesAndOtherReceivableTextBlock_1317815" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3251" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_3252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3251" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_3252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSale">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3257" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_3258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3257" xlink:to="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_3258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3263" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_3264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3263" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_3264" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebt">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3307" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_3308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3307" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_3308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3270" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_3271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3270" xlink:to="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_3271" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisions">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3295" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_3296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3295" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_3296" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilities">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3355" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory_3356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3355" xlink:to="loc_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory_3356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentLiabilities">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3301" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory_3302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3301" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory_3302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentLiabilities">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3314" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_3315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3314" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_3315" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/Commitments">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3375" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_3376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3375" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_3376" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3317" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory" xlink:label="loc_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory_3318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3317" xlink:to="loc_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory_3318" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquity">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3324" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementsInEquityExplanatory" xlink:label="loc_gsk_DisclosureOfMovementsInEquityExplanatory_3325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3324" xlink:to="loc_gsk_DisclosureOfMovementsInEquityExplanatory_3325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterests">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3362" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_3363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3362" xlink:to="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_3363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3331" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_3332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3331" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_3332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposals">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3347" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_3348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3347" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_3348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3334" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:label="loc_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory_3335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3334" xlink:to="loc_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory_3335" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3340" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:label="loc_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory_1188608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3340" xlink:to="loc_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory_1188608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3382" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_3383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3382" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_3383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemes">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3414" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3414" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompanies">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3423" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPrincipalGroupCompaniesExplanatory" xlink:label="loc_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory_3424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3423" xlink:to="loc_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory_3424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/LegalProceedings">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3429" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsExplanatory" xlink:label="loc_gsk_DisclosureOfLegalProceedingsExplanatory_3430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3429" xlink:to="loc_gsk_DisclosureOfLegalProceedingsExplanatory_3430" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PostBalanceSheetEvents">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3432" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_3433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3432" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_3433" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3043" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3043" xlink:to="loc_gsk_StatementsTable_3047" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3047" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_3044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_3045" xlink:to="loc_ifrs-full_RestatedMember_3044" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3047" xlink:to="loc_gsk_StatementsLineItems_3046" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingStandardsApplied" xlink:label="loc_gsk_DescriptionOfAccountingStandardsApplied_3049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingStandardsApplied_3049" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_3050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_3050" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_3051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_3051" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3052" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_3053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_3053" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_3054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory_3054" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3055" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory_3056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory_3056" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory_3057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory_3057" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_3058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_3058" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_3059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_3059" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_3060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_3060" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_3061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_3061" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_3062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_3062" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_3063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_3063" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_3064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_3064" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_3065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_3065" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3066" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_3067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_3067" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock_2146644944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock_2146644944" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory_3068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory_3068" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_3069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_3069" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_3070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_3070" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_3071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_3071" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory_3072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory_3072" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory_3073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory_3073" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_3074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_3074" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory" xlink:label="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory_3075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory_3075" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_2146644942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3046" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_2146644942" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3085" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_3086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3085" xlink:to="loc_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory_3086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ExchangeRatesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3097" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SignificantCurrenciesAndTheRelevantExchangeRates" xlink:label="loc_gsk_SignificantCurrenciesAndTheRelevantExchangeRates_2146645271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3097" xlink:to="loc_gsk_SignificantCurrenciesAndTheRelevantExchangeRates_2146645271" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3103" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3103" xlink:to="loc_gsk_StatementsTable_3107" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_3104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3107" xlink:to="loc_ifrs-full_SegmentsAxis_3104" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_3105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_3104" xlink:to="loc_ifrs-full_SegmentsMember_3105" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_3105" xlink:to="loc_gsk_CommercialOperationsMember_1701331" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3107" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTurnoverBySegmentExplanatory" xlink:label="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory_1192288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_gsk_DisclosureOfTurnoverBySegmentExplanatory_1192288" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_3112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_3112" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_3113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_3113" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_3114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_3106" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_3114" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpenseTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3119" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory_3120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3119" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory_3120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3125" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3125" xlink:to="loc_gsk_StatementsTable_3129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_3126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3129" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_3126" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3126" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3127" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_3130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3127" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_3130" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OperatingProfitLineItems" xlink:label="loc_gsk_OperatingProfitLineItems_3128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3129" xlink:to="loc_gsk_OperatingProfitLineItems_3128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory_3131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OperatingProfitLineItems_3128" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory_3131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_3132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OperatingProfitLineItems_3128" xlink:to="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_3132" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3137" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory_3138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3137" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory_3138" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_3139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3137" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_3139" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNumberOfEmployeesExplanatory" xlink:label="loc_gsk_DisclosureOfNumberOfEmployeesExplanatory_3140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3137" xlink:to="loc_gsk_DisclosureOfNumberOfEmployeesExplanatory_3140" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory" xlink:label="loc_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory_3141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3137" xlink:to="loc_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory_3141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3146" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory" xlink:label="loc_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory_2147449859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3146" xlink:to="loc_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory_2147449859" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock_2147449874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3146" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock_2147449874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsExplanatory" xlink:label="loc_gsk_DisclosureOfRestructuringCostsExplanatory_2147449869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3146" xlink:to="loc_gsk_DisclosureOfRestructuringCostsExplanatory_2147449869" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceIncomeTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3153" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterestIncomeExplanatory_3154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3153" xlink:to="loc_ifrs-full_DisclosureOfInterestIncomeExplanatory_3154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceExpenseTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3159" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_3160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3159" xlink:to="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_3160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3165" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory_3166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3165" xlink:to="loc_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory_3166" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory_3167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3165" xlink:to="loc_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory_3167" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory_3168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3165" xlink:to="loc_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory_3168" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3173" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory" xlink:label="loc_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory_3174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory_3174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory" xlink:label="loc_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory_3175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory_3175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory" xlink:label="loc_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory_3176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory_3176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory_3177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory_3177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_3178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_3178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_3179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3173" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_3179" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3184" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_3185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3184" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_3185" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory" xlink:label="loc_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory_3186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3184" xlink:to="loc_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory_3186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3191" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInterimDividendExplanatory" xlink:label="loc_gsk_DisclosureOfInterimDividendExplanatory_1188626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3191" xlink:to="loc_gsk_DisclosureOfInterimDividendExplanatory_1188626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsPaidExplanatory" xlink:label="loc_gsk_DisclosureOfDividendsPaidExplanatory_3193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3191" xlink:to="loc_gsk_DisclosureOfDividendsPaidExplanatory_3193" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipmentTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3198" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_3199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3198" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_3199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RightOfUseAssetsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_512850" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets_512852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_512850" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets_512852" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3204" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_3205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3204" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_3205" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory" xlink:label="loc_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory_3206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3204" xlink:to="loc_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory_3206" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory_3207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3204" xlink:to="loc_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory_3207" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3212" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_3213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3212" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_3213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_3214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3212" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_3214" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory" xlink:label="loc_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory_3215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3212" xlink:to="loc_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory_3215" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3221" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory_3222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3221" xlink:to="loc_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory_3222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestmentsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_2146644897" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock_2146644898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_2146644897" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock_2146644898" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestmentsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3228" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory" xlink:label="loc_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory_3229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3228" xlink:to="loc_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory_3229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3235" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory" xlink:label="loc_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory_3236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3235" xlink:to="loc_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory_3236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3241" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory_3242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3241" xlink:to="loc_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory_3242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3247" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_1316027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3247" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_1316027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory_3249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3247" xlink:to="loc_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory_3249" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3254" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_3255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3254" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_3255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3260" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssetsHeldForSaleExplanatory" xlink:label="loc_gsk_DisclosureOfAssetsHeldForSaleExplanatory_3261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3260" xlink:to="loc_gsk_DisclosureOfAssetsHeldForSaleExplanatory_3261" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3266" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SummaryOfTradePayablesExplanatoryTextBlock" xlink:label="loc_gsk_SummaryOfTradePayablesExplanatoryTextBlock_1317844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3266" xlink:to="loc_gsk_SummaryOfTradePayablesExplanatoryTextBlock_1317844" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory" xlink:label="loc_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory_3268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3266" xlink:to="loc_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory_3268" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3310" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_3311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3310" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_3311" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock" xlink:label="loc_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock_3312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3310" xlink:to="loc_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock_3312" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3273" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3273" xlink:to="loc_gsk_StatementsTable_3277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_3274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3277" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_3274" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_3274" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3275" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_3278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3275" xlink:to="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_3278" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_3280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3275" xlink:to="loc_gsk_PostretirementBenefitsMember_3280" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3277" xlink:to="loc_gsk_StatementsLineItems_3276" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_3281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_3281" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory_3282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory_3282" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory_3283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory_3283" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory_3284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory_3284" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory" xlink:label="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory_3285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory_3285" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_3286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_3286" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory_3287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory_3287" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory" xlink:label="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory_3288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory_3288" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_3289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_3289" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory_3290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory_3290" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory" xlink:label="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory_3291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory_3291" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory_3292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory_3292" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_3293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3276" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_3293" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3298" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_3299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3298" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_3299" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3358" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory_3359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3358" xlink:to="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory_3359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory_3360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3358" xlink:to="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory_3360" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3304" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory" xlink:label="loc_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory_3305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3304" xlink:to="loc_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory_3305" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CommitmentsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3378" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory" xlink:label="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory_3379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3378" xlink:to="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory_3379" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3320" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory_3321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3320" xlink:to="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory_3321" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3327" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock" xlink:label="loc_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock_534762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3327" xlink:to="loc_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock_534762" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory_3328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3327" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory_3328" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_3329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3327" xlink:to="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_3329" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3365" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3365" xlink:to="loc_gsk_StatementsTable_3369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_3366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3369" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_3366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_3366" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_3370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" xlink:to="loc_gsk_ViiVHealthCareMember_3370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_3371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_3367" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_3371" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3369" xlink:to="loc_gsk_StatementsLineItems_3368" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3368" xlink:to="loc_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3372" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory" xlink:label="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3368" xlink:to="loc_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory_3373" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3350" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3350" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_534835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_534835" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_534835" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyAcquisitionMember_831376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwoThousandTwentyAcquisitionMember_831376" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwothousandtwentyoneacquisitionMember" xlink:label="loc_gsk_TwothousandtwentyoneacquisitionMember_1702774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwothousandtwentyoneacquisitionMember_1702774" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_534836" xlink:to="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702775" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_534834" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_514743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_514743" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702697" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations_1702702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_FinancialInformationRelatingToDiscontinuedOperations_1702702" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory" xlink:label="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory_3351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory_3351" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory" xlink:label="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory_3352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_534839" xlink:to="loc_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory_3352" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3337" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory" xlink:label="loc_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory_3338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3337" xlink:to="loc_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory_3338" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3343" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory" xlink:label="loc_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory_3344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3343" xlink:to="loc_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory_3344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory" xlink:label="loc_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory_3345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3343" xlink:to="loc_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory_3345" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3385" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_3391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3385" xlink:to="loc_gsk_StatementsTable_3391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_3388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3387" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_3388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_3395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_3388" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_3395" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:label="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_3396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_3388" xlink:to="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_3396" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_3389" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_3394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3386" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_3394" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_3392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_ifrs-full_TypesOfRisksAxis_3392" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_3393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3392" xlink:to="loc_ifrs-full_TypesOfRisksMember_3393" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_3411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_3393" xlink:to="loc_ifrs-full_InterestRateRiskMember_3411" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_3412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_3393" xlink:to="loc_ifrs-full_CurrencyRiskMember_3412" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_3390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_3391" xlink:to="loc_gsk_StatementsLineItems_3390" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory_3397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory_3397" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3398" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_3399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_3399" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory_2147449912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory_2147449912" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory" xlink:label="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory_2147449910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory_2147449910" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory_3403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory_3403" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_3404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_3404" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock_1320687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock_1320687" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_1320689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_1320689" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency" xlink:label="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency_2147449939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency_2147449939" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeSensitivityEquityImpactTextBlock" xlink:label="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock_3406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_gsk_ForeignExchangeSensitivityEquityImpactTextBlock_3406" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory_2146643090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory_2146643090" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_3408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_3408" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_3409" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_3410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_3390" xlink:to="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_3410" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3417" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareValuePlanExplanatory" xlink:label="loc_gsk_DisclosureOfEmployeeShareValuePlanExplanatory_3418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3417" xlink:to="loc_gsk_DisclosureOfEmployeeShareValuePlanExplanatory_3418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory" xlink:label="loc_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory_3419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3417" xlink:to="loc_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory_3419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory_3420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3417" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory_3420" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory" xlink:label="loc_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory_3421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3417" xlink:to="loc_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory_3421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompaniesTables">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_3426" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_3427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_3426" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_3427" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PresentationOfTheFinancialStatementsAbstract" xlink:label="loc_gsk_PresentationOfTheFinancialStatementsAbstract_204" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PresentationOfTheFinancialStatementsAbstract_204" xlink:to="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_506259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_506258" xlink:to="loc_ifrs-full_RestatedMember_506259" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems" xlink:label="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable_506247" xlink:to="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PeriodCoveredByFinancialStatements" xlink:label="loc_ifrs-full_PeriodCoveredByFinancialStatements_513761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" xlink:to="loc_ifrs-full_PeriodCoveredByFinancialStatements_513761" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfEndOfReportingPeriod2022" xlink:label="loc_gsk_DateOfEndOfReportingPeriod2022_534847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems_506271" xlink:to="loc_gsk_DateOfEndOfReportingPeriod2022_534847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="loc_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_229" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_229" xlink:to="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_230" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesAndFranchisesMember" xlink:label="loc_ifrs-full_LicencesAndFranchisesMember_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_ifrs-full_LicencesAndFranchisesMember_238" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ERPSoftwareSystemsMember" xlink:label="loc_gsk_ERPSoftwareSystemsMember_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_gsk_ERPSoftwareSystemsMember_240" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComputerSoftwareMember" xlink:label="loc_gsk_OtherComputerSoftwareMember_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_233" xlink:to="loc_gsk_OtherComputerSoftwareMember_241" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_RangeAxis_234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_234" xlink:to="loc_ifrs-full_RangesMember_235" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_235" xlink:to="loc_ifrs-full_TopOfRangeMember_242" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_235" xlink:to="loc_ifrs-full_BottomOfRangeMember_243" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_1223903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_SegmentsAxis_1223903" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1223904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_1223903" xlink:to="loc_ifrs-full_SegmentsMember_1223904" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_1223905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_1223904" xlink:to="loc_gsk_PharmaceuticalsMember_1223905" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_1223910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_1223904" xlink:to="loc_gsk_VaccinesMember_1223910" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1223908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1223907" xlink:to="loc_ifrs-full_CarryingAmountMember_1223908" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBookValueMember" xlink:label="loc_gsk_RemainingBookValueMember_1223909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1223908" xlink:to="loc_gsk_RemainingBookValueMember_1223909" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable_232" xlink:to="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_237" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments" xlink:label="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments_2146643018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments_2146643018" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales" xlink:label="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales_1223807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales_1223807" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfSalesOnCoPromotionalActivities" xlink:label="loc_gsk_CostOfSalesOnCoPromotionalActivities_1223809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_CostOfSalesOnCoPromotionalActivities_1223809" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromCoPromotionalActivities" xlink:label="loc_gsk_RevenueFromCoPromotionalActivities_2146643019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_RevenueFromCoPromotionalActivities_2146643019" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisableProportionOverExclusivityPeriod" xlink:label="loc_gsk_AmortisableProportionOverExclusivityPeriod_2146643017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems_231" xlink:to="loc_gsk_AmortisableProportionOverExclusivityPeriod_2146643017" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_245" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_245" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_246" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeholdBuildingsMember" xlink:label="loc_gsk_FreeholdBuildingsMember_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_FreeholdBuildingsMember_251" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseholdLandAndBuildingsMember" xlink:label="loc_gsk_LeaseholdLandAndBuildingsMember_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_LeaseholdLandAndBuildingsMember_252" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndMachineryMember" xlink:label="loc_gsk_PlantAndMachineryMember_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_PlantAndMachineryMember_253" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquipmentAndVehiclesMember" xlink:label="loc_gsk_EquipmentAndVehiclesMember_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_249" xlink:to="loc_gsk_EquipmentAndVehiclesMember_254" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_248" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_247" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_256" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_256" xlink:to="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_259" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_259" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_264" xlink:to="loc_ifrs-full_BusinessCombinationsMember_287" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_JointVenturesAxis_267" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_267" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_265" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_289" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_257" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_258" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:label="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_513807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_258" xlink:to="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_513807" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_261" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_268" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_511672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_gsk_SegmentConsolidationItemAxis_511672" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_511673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemAxis_511672" xlink:to="loc_gsk_SegmentConsolidationItemMember_511673" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_USPharmaceuticalsAndVaccinesMember" xlink:label="loc_gsk_USPharmaceuticalsAndVaccinesMember_511677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemMember_511673" xlink:to="loc_gsk_USPharmaceuticalsAndVaccinesMember_511677" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_2146646296" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SensitivityAnalysisForActuarialAssumptionsMember" xlink:label="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember_2146646298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_2146646297" xlink:to="loc_gsk_SensitivityAnalysisForActuarialAssumptionsMember_2146646298" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateAxis" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateAxis_2146646299" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionPercentageRateChangeMember" xlink:label="loc_gsk_ActuarialAssumptionPercentageRateChangeMember_2146646301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" xlink:to="loc_gsk_ActuarialAssumptionPercentageRateChangeMember_2146646301" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember" xlink:label="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember_2146646302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ActuarialAssumptionPercentageRateMember_2146646300" xlink:to="loc_gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember_2146646302" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_263" xlink:to="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_Revenue_270" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_272" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets" xlink:label="loc_ifrs-full_CurrentTaxAssets_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxAssets_273" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_274" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UncertainTaxPositionsRecognised" xlink:label="loc_gsk_UncertainTaxPositionsRecognised_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_UncertainTaxPositionsRecognised_275" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalCosts" xlink:label="loc_gsk_LegalCosts_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_LegalCosts_276" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvision" xlink:label="loc_ifrs-full_LegalProceedingsProvision_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_LegalProceedingsProvision_277" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities" xlink:label="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities_278" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_279" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPlanSurplusNet" xlink:label="loc_gsk_DefinedBenefitPlanSurplusNet_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DefinedBenefitPlanSurplusNet_283" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfDecreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfDecreaseInDiscountRate_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PercentageOfDecreaseInDiscountRate_284" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInPlanDeficit" xlink:label="loc_gsk_IncreaseInPlanDeficit_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_IncreaseInPlanDeficit_285" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnsDiscountsAndRebates" xlink:label="loc_gsk_CustomerReturnsDiscountsAndRebates_511685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_CustomerReturnsDiscountsAndRebates_511685" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment" xlink:label="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment_511692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment_511692" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfIncreaseInDiscountRate" xlink:label="loc_gsk_PercentageOfIncreaseInDiscountRate_847135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PercentageOfIncreaseInDiscountRate_847135" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInPlanDeficit" xlink:label="loc_gsk_DecreaseInPlanDeficit_847136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DecreaseInPlanDeficit_847136" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionSurplus" xlink:label="loc_gsk_PensionSurplus_1306694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_PensionSurplus_1306694" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInAnnualPensionCost" xlink:label="loc_gsk_IncreaseInAnnualPensionCost_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_IncreaseInAnnualPensionCost_286" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInAnnualPensionCost" xlink:label="loc_gsk_DecreaseInAnnualPensionCost_847138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_262" xlink:to="loc_gsk_DecreaseInAnnualPensionCost_847138" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="loc_ifrs-full_ForeignExchangeRatesAbstract_307" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesTable" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ForeignExchangeRatesAbstract_307" xlink:to="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" xlink:to="loc_srt_CurrencyAxis_309" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_309" xlink:to="loc_currency_AllCurrenciesDomain_308" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_USD_312" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_EUR_313" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="loc_currency_JPY_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_308" xlink:to="loc_currency_JPY_314" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfForeignExchangeRatesLineItems" xlink:label="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesTable_311" xlink:to="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_315" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfForeignExchangeRatesLineItems_310" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_316" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_318" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_318" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_srt_MajorCustomersAxis_323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="loc_ifrs-full_MajorCustomersMember_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_323" xlink:to="loc_ifrs-full_MajorCustomersMember_324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers1Member" xlink:label="loc_gsk_Wholesalers1Member_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers1Member_338" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers2Member" xlink:label="loc_gsk_Wholesalers2Member_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers2Member_339" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Wholesalers3Member" xlink:label="loc_gsk_Wholesalers3Member_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_324" xlink:to="loc_gsk_Wholesalers3Member_340" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_ifrs-full_GeographicalAreasAxis_321" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_321" xlink:to="loc_ifrs-full_GeographicalAreasMember_322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_322" xlink:to="loc_country_US_337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_ifrs-full_SegmentsAxis_325" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_325" xlink:to="loc_ifrs-full_SegmentsMember_326" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViivHealthcareMember" xlink:label="loc_gsk_ShionogiViivHealthcareMember_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_326" xlink:to="loc_gsk_ShionogiViivHealthcareMember_341" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1188675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_dei_LegalEntityAxis_1188675" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1188675" xlink:to="loc_dei_EntityDomain_1188676" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerMember" xlink:label="loc_gsk_PfizerMember_1188677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1188676" xlink:to="loc_gsk_PfizerMember_1188677" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_320" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfReportableOperatingSegments" xlink:label="loc_gsk_NumberOfReportableOperatingSegments_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfReportableOperatingSegments_327" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments" xlink:label="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments_328" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_329" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RevenueFromChangesToEstimatesOfRARAccruals" xlink:label="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_RevenueFromChangesToEstimatesOfRARAccruals_330" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_847129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_847129" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods" xlink:label="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods_331" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfWholesalers" xlink:label="loc_gsk_NumberOfWholesalers_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfWholesalers_332" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_Revenue_333" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_334" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOption" xlink:label="loc_gsk_PutOption_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_PutOption_335" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOperatingSegments" xlink:label="loc_gsk_NumberOfOperatingSegments_2146644993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_319" xlink:to="loc_gsk_NumberOfOperatingSegments_2146644993" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_345" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_345" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xlink:to="loc_gsk_SegmentConsolidationItemAxis_349" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemAxis_349" xlink:to="loc_gsk_SegmentConsolidationItemMember_348" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xlink:to="loc_ifrs-full_SegmentsAxis_350" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_350" xlink:to="loc_ifrs-full_SegmentsMember_351" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_351" xlink:to="loc_gsk_ConsumerHealthcareMember_356" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_351" xlink:to="loc_gsk_CommercialOperationsMember_1701357" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_347" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_346" xlink:to="loc_ifrs-full_Revenue_352" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract_358" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xlink:to="loc_ifrs-full_SegmentsAxis_363" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_363" xlink:to="loc_ifrs-full_SegmentsMember_364" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_364" xlink:to="loc_gsk_CommercialOperationsMember_1701362" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_364" xlink:to="loc_gsk_ConsumerHealthcareMember_378" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_361" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_361" xlink:to="loc_ifrs-full_ProductsAndServicesMember_362" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HIVMember" xlink:label="loc_gsk_HIVMember_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_HIVMember_371" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OncologyMember" xlink:label="loc_gsk_OncologyMember_506596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_OncologyMember_506596" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImmunoInflammationRespiratoryAndOtherMember" xlink:label="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember_1701364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_ImmunoInflammationRespiratoryAndOtherMember_1701364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicMember" xlink:label="loc_gsk_PandemicMember_1308310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_PandemicMember_1308310" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SpecialtyMedicineMember" xlink:label="loc_gsk_SpecialtyMedicineMember_1701365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_SpecialtyMedicineMember_1701365" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisMember" xlink:label="loc_gsk_MeningitisMember_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_MeningitisMember_374" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InfluenzaMember" xlink:label="loc_gsk_InfluenzaMember_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_InfluenzaMember_375" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShinglesMember" xlink:label="loc_gsk_ShinglesMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_ShinglesMember_376" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstablishedVaccinesMember" xlink:label="loc_gsk_EstablishedVaccinesMember_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_EstablishedVaccinesMember_377" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PandemicVaccinesMember" xlink:label="loc_gsk_PandemicVaccinesMember_1308314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_PandemicVaccinesMember_1308314" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_1701367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_VaccinesMember_1701367" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubTotalMember" xlink:label="loc_gsk_SubTotalMember_832236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_SubTotalMember_832236" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RespiratoryMember" xlink:label="loc_gsk_RespiratoryMember_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_RespiratoryMember_370" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGeneralMedicinesMember" xlink:label="loc_gsk_OtherGeneralMedicinesMember_1701368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_OtherGeneralMedicinesMember_1701368" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GeneralMedicinesMember" xlink:label="loc_gsk_GeneralMedicinesMember_1701369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_362" xlink:to="loc_gsk_GeneralMedicinesMember_1701369" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_360" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_359" xlink:to="loc_ifrs-full_Revenue_365" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_382" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_382" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_ifrs-full_SegmentsAxis_391" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_391" xlink:to="loc_ifrs-full_SegmentsMember_392" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_ConsumerHealthcareMember_418" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1701355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_CommercialOperationsMember_1701355" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_1701356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_392" xlink:to="loc_gsk_ResearchAndDevelopmentMember_1701356" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_gsk_SegmentConsolidationItemAxis_390" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemAxis_390" xlink:to="loc_gsk_SegmentConsolidationItemMember_387" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="loc_ifrs-full_OperatingSegmentsMember_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_OperatingSegmentsMember_402" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="loc_ifrs-full_UnallocatedAmountsMember_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_UnallocatedAmountsMember_403" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemMember_387" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_404" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146645000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146644999" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146645000" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_2146643062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingOperationsMember_2146645000" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_2146643062" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_386" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_ProfitLossAbstract_389" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_406" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_FinanceIncome_407" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_FinanceCosts_408" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociate_409" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_410" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_411" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_412" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_389" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_413" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpenseAbstract" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpenseAbstract_384" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_394" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract" xlink:label="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract_383" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_393" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentReversalsBySegmentAbstract" xlink:label="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ImpairmentReversalsBySegmentAbstract_388" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_405" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingAssets" xlink:label="loc_gsk_NetOperatingAssets_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_NetOperatingAssets_395" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-full_NetDebt_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NetDebt_396" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_InvestmentsInJointVenturesAndAssociates_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_InvestmentsInJointVenturesAndAssociates_397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146643064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146643064" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_398" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentAndDeferredTaxation" xlink:label="loc_gsk_CurrentAndDeferredTaxation_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_gsk_CurrentAndDeferredTaxation_399" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_400" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_385" xlink:to="loc_ifrs-full_NetAssetsLiabilities_401" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasAbstract_420" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasAbstract_420" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_421" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerMember" xlink:label="loc_gsk_CustomerMember_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_424" xlink:to="loc_gsk_CustomerMember_429" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xlink:to="loc_ifrs-full_GeographicalAreasAxis_425" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_425" xlink:to="loc_ifrs-full_GeographicalAreasMember_426" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_GB_430" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_US_431" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_gsk_RestOfWorldMember_432" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="loc_country_BE_1224019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_BE_1224019" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="loc_country_CH_1224021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_426" xlink:to="loc_country_CH_1224021" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_423" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" xlink:to="loc_ifrs-full_Revenue_427" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_422" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_428" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_446" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseTable" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_446" xlink:to="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_448" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_456" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GileadSciencesIncMember" xlink:label="loc_gsk_GileadSciencesIncMember_1703439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_452" xlink:to="loc_gsk_GileadSciencesIncMember_1703439" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_447" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_447" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesBusinessAcquisitionMember" xlink:label="loc_gsk_VaccinesBusinessAcquisitionMember_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_451" xlink:to="loc_gsk_VaccinesBusinessAcquisitionMember_455" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_829224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_SegmentsAxis_829224" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_829226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_829224" xlink:to="loc_ifrs-full_SegmentsMember_829226" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_829227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_829226" xlink:to="loc_gsk_ConsumerHealthcareMember_829227" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_829229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_829229" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_829230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_829229" xlink:to="loc_ifrs-full_ProductsAndServicesMember_829230" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_829232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_829230" xlink:to="loc_gsk_HorlicksMember_829232" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1188681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_dei_LegalEntityAxis_1188681" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1188682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1188681" xlink:to="loc_dei_EntityDomain_1188682" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisMember" xlink:label="loc_gsk_NovartisMember_1188683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1188682" xlink:to="loc_gsk_NovartisMember_1188683" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HindustanUnileverLimitedMember" xlink:label="loc_gsk_HindustanUnileverLimitedMember_1188684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1188682" xlink:to="loc_gsk_HindustanUnileverLimitedMember_1188684" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerAxis" xlink:label="loc_gsk_AcquirerAxis_1306995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_gsk_AcquirerAxis_1306995" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquirerDomain" xlink:label="loc_gsk_AcquirerDomain_1306996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AcquirerAxis_1306995" xlink:to="loc_gsk_AcquirerDomain_1306996" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_1703440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_gsk_InvestmentAxis_1703440" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1703441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentAxis_1703440" xlink:to="loc_gsk_InvestmentDomain_1703441" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonPlcMember" xlink:label="loc_gsk_HaleonPlcMember_1703442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentDomain_1703441" xlink:to="loc_gsk_HaleonPlcMember_1703442" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseTable_450" xlink:to="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfBusinessesAndAssets" xlink:label="loc_gsk_DisposalOfBusinessesAndAssets_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_DisposalOfBusinessesAndAssets_453" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_454" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_829222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_829222" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossOnSaleOfBusiness" xlink:label="loc_gsk_LossOnSaleOfBusiness_829223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_LossOnSaleOfBusiness_829223" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontPayment" xlink:label="loc_gsk_UpfrontPayment_1701340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_UpfrontPayment_1701340" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfRoyaltyPayableOnFutureSales" xlink:label="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales_1701341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_PercentageOfRoyaltyPayableOnFutureSales_1701341" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss" xlink:label="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss_1702776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems_449" xlink:to="loc_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss_1702776" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract" xlink:label="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UpfrontSettlementIncome" xlink:label="loc_gsk_UpfrontSettlementIncome_2146643293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_gsk_UpfrontSettlementIncome_2146643293" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments_435" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfBusinessesAndAssets" xlink:label="loc_gsk_DisposalOfBusinessesAndAssets_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_gsk_DisposalOfBusinessesAndAssets_436" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_437" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends" xlink:label="loc_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends_438" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_440" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_441" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract_434" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_444" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_479" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitTable" xlink:label="loc_gsk_DisclosureOfOperatingProfitTable_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_479" xlink:to="loc_gsk_DisclosureOfOperatingProfitTable_481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_483" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember" xlink:label="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" xlink:to="loc_gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember_486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAuditorsMember" xlink:label="loc_gsk_OtherAuditorsMember_1188685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_482" xlink:to="loc_gsk_OtherAuditorsMember_1188685" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1306763" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidationOrDisposalOfInterestInAssociatesMember" xlink:label="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember_1306764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1306774" xlink:to="loc_gsk_LiquidationOrDisposalOfInterestInAssociatesMember_1306764" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_1306789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_gsk_PurposeAxis_1306789" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_1306791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeAxis_1306789" xlink:to="loc_gsk_PurposeDomain_1306791" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember" xlink:label="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember_1306797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeDomain_1306791" xlink:to="loc_gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember_1306797" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOperatingProfitLineItems" xlink:label="loc_gsk_DisclosureOfOperatingProfitLineItems_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitTable_481" xlink:to="loc_gsk_DisclosureOfOperatingProfitLineItems_480" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_484" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseOfRestructuringActivities" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_485" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_600700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_600700" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociates" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociates_1306760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociates_1306760" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_1306781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOperatingProfitLineItems_480" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_1306781" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_460" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdvertisingExpense" xlink:label="loc_ifrs-full_AdvertisingExpense_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_AdvertisingExpense_467" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DistributionCosts" xlink:label="loc_ifrs-full_DistributionCosts_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_DistributionCosts_468" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_469" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_470" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_506809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_506809" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfRightOfUseAssets" xlink:label="loc_gsk_ImpairmentOfRightOfUseAssets_506810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_gsk_ImpairmentOfRightOfUseAssets_506810" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_471" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfIntangibleAssetsNetOfReversal" xlink:label="loc_gsk_ImpairmentOfIntangibleAssetsNetOfReversal_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_gsk_ImpairmentOfIntangibleAssetsNetOfReversal_472" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale" xlink:label="loc_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale_829240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale_829240" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_600699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_600699" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_473" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ClassesOfInventoriesAbstract_461" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_461" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_463" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="loc_ifrs-full_InventoryWritedown2011_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_461" xlink:to="loc_ifrs-full_InventoryWritedown2011_464" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="loc_ifrs-full_ReversalOfInventoryWritedown_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_461" xlink:to="loc_ifrs-full_ReversalOfInventoryWritedown_465" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_506811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_506811" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_506812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_506812" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_506813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_506813" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_460" xlink:to="loc_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract_462" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-full_AuditorsRemuneration_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract_462" xlink:to="loc_ifrs-full_AuditorsRemuneration_477" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_488" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationTable" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_488" xlink:to="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_490" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" xlink:to="loc_ifrs-full_ParentMember_503" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="loc_ifrs-full_SubsidiariesMember_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_495" xlink:to="loc_ifrs-full_SubsidiariesMember_504" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_491" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_491" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_492" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_492" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_502" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAuditorsRemunerationLineItems" xlink:label="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationTable_494" xlink:to="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="loc_ifrs-full_AuditorsRemunerationAbstract_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAuditorsRemunerationLineItems_493" xlink:to="loc_ifrs-full_AuditorsRemunerationAbstract_489" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_496" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForOtherAssuranceServices_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_gsk_AuditorsRemunerationForOtherAssuranceServices_499" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices" xlink:label="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices_629585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_489" xlink:to="loc_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices_629585" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_ifrs-full_WagesAndSalaries_508" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-full_SocialSecurityContributions_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_ifrs-full_SocialSecurityContributions_509" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostEmploymentBenefitExpense" xlink:label="loc_gsk_PostEmploymentBenefitExpense_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_gsk_PostEmploymentBenefitExpense_510" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_511" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_ifrs-full_TerminationBenefitsExpense_512" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_507" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_513" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeesBenefitAbstract" xlink:label="loc_gsk_EmployeesBenefitAbstract_515" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable" xlink:label="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_515" xlink:to="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_519" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_ShareValuePlanMember_521" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PerformanceSharePlansMember" xlink:label="loc_gsk_PerformanceSharePlansMember_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_PerformanceSharePlansMember_522" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionPlanMember" xlink:label="loc_gsk_ShareOptionPlanMember_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_ShareOptionPlanMember_523" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashSettledAndOtherPlansMember" xlink:label="loc_gsk_CashSettledAndOtherPlansMember_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_518" xlink:to="loc_gsk_CashSettledAndOtherPlansMember_524" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems" xlink:label="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable_517" xlink:to="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems_516" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_520" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeesBenefitAbstract" xlink:label="loc_gsk_EmployeesBenefitAbstract_526" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersTable" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_526" xlink:to="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" xlink:to="loc_ifrs-full_SegmentsAxis_529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_529" xlink:to="loc_ifrs-full_SegmentsMember_530" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ManufacturingMember" xlink:label="loc_gsk_ManufacturingMember_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_ManufacturingMember_532" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrationMember" xlink:label="loc_gsk_SellingGeneralAndAdministrationMember_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_SellingGeneralAndAdministrationMember_533" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_530" xlink:to="loc_gsk_ResearchAndDevelopmentMember_534" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeCostsAndNumbersLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersTable_528" xlink:to="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromContinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations_2146643069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_gsk_AverageNumberOfEmployeesFromContinuingOperations_2146643069" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageNumberOfEmployeesFromDiscontinuingOperations" xlink:label="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations_2146643068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations_2146643068" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageNumberOfEmployees" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems_527" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_531" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeesBenefitAbstract" xlink:label="loc_gsk_EmployeesBenefitAbstract_536" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_536" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_537" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_KeyManagementPersonnelCompensationSocialSecurityCosts" xlink:label="loc_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_536" xlink:to="loc_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts_538" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_536" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_539" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_536" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_540" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EmployeesBenefitAbstract_536" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_541" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringCostsAbstract" xlink:label="loc_gsk_MajorRestructuringCostsAbstract_543" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_512046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_543" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_512046" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_512049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_512048" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_512049" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_512055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_512055" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_512055" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_512057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_512067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_gsk_ArrangementTypeAxis_512067" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_512070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeAxis_512067" xlink:to="loc_gsk_ArrangementTypeDomain_512070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SeparationPreparationProgrammeMember" xlink:label="loc_gsk_SeparationPreparationProgrammeMember_588634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeDomain_512070" xlink:to="loc_gsk_SeparationPreparationProgrammeMember_588634" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsAxis" xlink:label="loc_gsk_RestructuringCostsAxis_512115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_gsk_RestructuringCostsAxis_512115" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_512116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_RestructuringCostsAxis_512115" xlink:to="loc_gsk_RestructuringCostsDomain_512116" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_512046" xlink:to="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalRestructuringCosts" xlink:label="loc_gsk_TotalRestructuringCosts_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_TotalRestructuringCosts_544" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts" xlink:label="loc_gsk_RestructuringCosts_860667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_RestructuringCosts_860667" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseProvisionReversalRestructuring" xlink:label="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring_588633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_IncreaseDecreaseProvisionReversalRestructuring_588633" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetImpairments" xlink:label="loc_gsk_AssetImpairments_588652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_AssetImpairments_588652" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCashCredit" xlink:label="loc_gsk_OtherNonCashCredit_588654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_512132" xlink:to="loc_gsk_OtherNonCashCredit_588654" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringCostsAbstract" xlink:label="loc_gsk_MajorRestructuringCostsAbstract_546" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes" xlink:label="loc_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes_547" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfProvisionsForCostOfRestructuring" xlink:label="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_ifrs-full_ReversalOfProvisionsForCostOfRestructuring_548" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-full_ImpairmentLoss_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_ifrs-full_ImpairmentLoss_549" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherMaterialNoncashItems" xlink:label="loc_ifrs-full_OtherMaterialNoncashItems_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_ifrs-full_OtherMaterialNoncashItems_550" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCostsCashSettlement" xlink:label="loc_gsk_OtherCostsCashSettlement_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_gsk_OtherCostsCashSettlement_551" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_gsk_CostChargedToOperatingProfit_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_546" xlink:to="loc_gsk_CostChargedToOperatingProfit_552" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringCostsAbstract" xlink:label="loc_gsk_MajorRestructuringCostsAbstract_506898" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_506905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MajorRestructuringCostsAbstract_506898" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_506905" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_506907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xlink:to="loc_gsk_ArrangementTypeAxis_506907" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_506908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeAxis_506907" xlink:to="loc_gsk_ArrangementTypeDomain_506908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SeparationPreparationProgrammeMember" xlink:label="loc_gsk_SeparationPreparationProgrammeMember_753263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_SeparationPreparationProgrammeMember_753263" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegacyProgrammesMember" xlink:label="loc_gsk_LegacyProgrammesMember_1702452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_LegacyProgrammesMember_1702452" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SignificantAcquisitionsMember" xlink:label="loc_gsk_SignificantAcquisitionsMember_2146644852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeDomain_506908" xlink:to="loc_gsk_SignificantAcquisitionsMember_2146644852" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeAxis" xlink:label="loc_gsk_RestructuringChargesByTypeAxis_506922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xlink:to="loc_gsk_RestructuringChargesByTypeAxis_506922" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringChargesByTypeDomain" xlink:label="loc_gsk_RestructuringChargesByTypeDomain_506923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_RestructuringChargesByTypeAxis_506922" xlink:to="loc_gsk_RestructuringChargesByTypeDomain_506923" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_506905" xlink:to="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashRestructuringCharges" xlink:label="loc_gsk_CashRestructuringCharges_514003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_CashRestructuringCharges_514003" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonCashRestructuringCharges" xlink:label="loc_gsk_NonCashRestructuringCharges_514004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_NonCashRestructuringCharges_514004" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCosts1" xlink:label="loc_gsk_RestructuringCosts1_506932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_506931" xlink:to="loc_gsk_RestructuringCosts1_506932" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsAbstract" xlink:label="loc_gsk_DisclosureOfRestructuringCostsAbstract_554" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsTable" xlink:label="loc_gsk_DisclosureOfRestructuringCostsTable_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsAbstract_554" xlink:to="loc_gsk_DisclosureOfRestructuringCostsTable_556" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsAxis" xlink:label="loc_gsk_RestructuringCostsAxis_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_556" xlink:to="loc_gsk_RestructuringCostsAxis_557" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestructuringCostsDomain" xlink:label="loc_gsk_RestructuringCostsDomain_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_RestructuringCostsAxis_557" xlink:to="loc_gsk_RestructuringCostsDomain_558" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostOfMajorRestructuringMember" xlink:label="loc_gsk_CostOfMajorRestructuringMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_RestructuringCostsDomain_558" xlink:to="loc_gsk_CostOfMajorRestructuringMember_564" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfRestructuringCostsLineItems" xlink:label="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsTable_556" xlink:to="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_ifrs-full_CostOfSales_559" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentExpenses" xlink:label="loc_gsk_ResearchAndDevelopmentExpenses_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_gsk_ResearchAndDevelopmentExpenses_561" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CostChargedToOperatingProfit" xlink:label="loc_gsk_CostChargedToOperatingProfit_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfRestructuringCostsLineItems_555" xlink:to="loc_gsk_CostChargedToOperatingProfit_563" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_566" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseTable" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_566" xlink:to="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_570" xlink:to="loc_ifrs-full_RestatedMember_569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialIncomeAndExpenseLineItems" xlink:label="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseTable_568" xlink:to="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost" xlink:label="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost_571" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_572" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations" xlink:label="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations_573" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome" xlink:label="loc_ifrs-full_OtherFinanceIncome_1306738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_OtherFinanceIncome_1306738" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems_567" xlink:to="loc_ifrs-full_FinanceIncome_578" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinanceExpenseAbstract" xlink:label="loc_gsk_DisclosureOfFinanceExpenseAbstract_582" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestCostsAbstract" xlink:label="loc_ifrs-full_InterestCostsAbstract_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinanceExpenseAbstract_582" xlink:to="loc_ifrs-full_InterestCostsAbstract_583" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss_584" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue_586" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReTranslationOfLoan" xlink:label="loc_gsk_ReTranslationOfLoan_829253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_gsk_ReTranslationOfLoan_829253" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_587" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_588" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_506949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_506949" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_589" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestCostsAbstract_583" xlink:to="loc_ifrs-full_FinanceCosts_590" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_597" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_597" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_603" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_600" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_600" xlink:to="loc_ifrs-full_AssociatesMember_606" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xlink:to="loc_ifrs-full_JointVenturesAxis_602" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_602" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesMember" xlink:label="loc_ifrs-full_JointVenturesMember_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_601" xlink:to="loc_ifrs-full_JointVenturesMember_607" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_599" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_598" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_605" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVentureAbstract" xlink:label="loc_gsk_AssociatesAndJointVentureAbstract_609" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesTable" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssociatesAndJointVentureAbstract_609" xlink:to="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_610" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_613" xlink:to="loc_gsk_InnovivaIncMember_617" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_512223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_512222" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_512223" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfJointVenturesAndAssociatesLineItems" xlink:label="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesTable_612" xlink:to="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_615" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SalesToAssociatesAndJointVentures" xlink:label="loc_gsk_SalesToAssociatesAndJointVentures_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_gsk_SalesToAssociatesAndJointVentures_616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_512234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfJointVenturesAndAssociatesLineItems_611" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_512234" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_619" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_619" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_623" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_622" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_622" xlink:to="loc_gsk_InnovivaIncMember_628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_621" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_Revenue_624" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_ProfitLoss_625" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_620" xlink:to="loc_ifrs-full_ComprehensiveIncome_627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_630" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract_630" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_634" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_633" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssociatesMember" xlink:label="loc_gsk_OtherAssociatesMember_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_633" xlink:to="loc_gsk_OtherAssociatesMember_639" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable_632" xlink:to="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_ProfitLoss_636" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_637" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems_631" xlink:to="loc_ifrs-full_ComprehensiveIncome_638" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_641" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsTable" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsTable_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_641" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsTable_646" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_646" xlink:to="loc_ifrs-full_GeographicalAreasAxis_643" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_643" xlink:to="loc_ifrs-full_GeographicalAreasMember_644" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_644" xlink:to="loc_country_GB_652" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_644" xlink:to="loc_ifrs-full_ForeignCountriesMember_653" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsLineItems" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_646" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxExpensesincomeAbstract" xlink:label="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_645" xlink:to="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_647" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_648" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_649" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_650" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxExpensesincomeAbstract_534844" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_651" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_655" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsTable" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsTable_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_655" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsTable_660" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_GeographicalAreasAxis_657" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_657" xlink:to="loc_ifrs-full_GeographicalAreasMember_658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_658" xlink:to="loc_country_GB_663" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GbMember" xlink:label="loc_gsk_GbMember_829255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_658" xlink:to="loc_gsk_GbMember_829255" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_661" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OverseasMember" xlink:label="loc_gsk_OverseasMember_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_656" xlink:to="loc_gsk_OverseasMember_662" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_588837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_RangeAxis_588837" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_588838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_588837" xlink:to="loc_ifrs-full_RangesMember_588838" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_588841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_588838" xlink:to="loc_ifrs-full_BottomOfRangeMember_588841" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalEntity1Axis" xlink:label="loc_gsk_LegalEntity1Axis_588904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_gsk_LegalEntity1Axis_588904" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Entity1Member" xlink:label="loc_gsk_Entity1Member_588905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_LegalEntity1Axis_588904" xlink:to="loc_gsk_Entity1Member_588905" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_588910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_588910" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_588910" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_588911" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_831076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_gsk_EventAxis_831076" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_831078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventAxis_831076" xlink:to="loc_gsk_EventDomain_831078" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReducedTaxRateCancelledMember" xlink:label="loc_gsk_ReducedTaxRateCancelledMember_831079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventDomain_831078" xlink:to="loc_gsk_ReducedTaxRateCancelledMember_831079" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInTheHeadlineRateOfTaxMember" xlink:label="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember_1306771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventDomain_831078" xlink:to="loc_gsk_IncreaseInTheHeadlineRateOfTaxMember_1306771" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncomeTaxExpenseBenefitsLineItems" xlink:label="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsTable_660" xlink:to="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_665" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProvisionsForUncertainTaxPosition" xlink:label="loc_gsk_ProvisionsForUncertainTaxPosition_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_ProvisionsForUncertainTaxPosition_668" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_669" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedEarnings" xlink:label="loc_gsk_UnremittedEarnings_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_UnremittedEarnings_670" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnremittedProfitsForWhichDeferredTaxNotProvided" xlink:label="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided_671" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxAssetsRecognizedOnTradingLosses" xlink:label="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_DeferredTaxAssetsRecognizedOnTradingLosses_674" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_588916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_ApplicableTaxRate_588916" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeadlineUkTaxRateEffective2023" xlink:label="loc_gsk_HeadlineUkTaxRateEffective2023_1316191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_gsk_HeadlineUkTaxRateEffective2023_1316191" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2146643283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncomeTaxExpenseBenefitsLineItems_659" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2146643283" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract" xlink:label="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_678" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_679" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_680" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives" xlink:label="loc_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives_681" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfResearchAndDevelopmentCredits" xlink:label="loc_gsk_TaxEffectOfResearchAndDevelopmentCredits_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxEffectOfResearchAndDevelopmentCredits_682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers" xlink:label="loc_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers_1317843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers_1317843" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_686" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfReassessmentsOfPriorYearEstimates" xlink:label="loc_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates_687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:label="loc_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates_2146643282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates_2146643282" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxEffectOfChangeInTaxRate" xlink:label="loc_gsk_TaxEffectOfChangeInTaxRate_589779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxEffectOfChangeInTaxRate_589779" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_689" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_ApplicableTaxRate_690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_691" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives" xlink:label="loc_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives_692" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfResearchAndDevelopmentCredits" xlink:label="loc_gsk_TaxRateEffectOfResearchAndDevelopmentCredits_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfResearchAndDevelopmentCredits_693" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers" xlink:label="loc_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers_696" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_697" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates" xlink:label="loc_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates_698" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates" xlink:label="loc_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates_2146643284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates_2146643284" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxRateEffectOfChangeInTaxRate" xlink:label="loc_gsk_TaxRateEffectOfChangeInTaxRate_589760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_gsk_TaxRateEffectOfChangeInTaxRate_589760" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract_677" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_700" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract" xlink:label="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract_702" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxationAbstract" xlink:label="loc_gsk_CurrentTaxationAbstract_514832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract_702" xlink:to="loc_gsk_CurrentTaxationAbstract_514832" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxationAbstract_514832" xlink:to="loc_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_705" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxationAbstract_514832" xlink:to="loc_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_706" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome_829256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxationAbstract_514832" xlink:to="loc_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome_829256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome_829260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxationAbstract_514832" xlink:to="loc_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome_829260" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CurrentTaxationAbstract_514832" xlink:to="loc_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_707" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract" xlink:label="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract_702" xlink:to="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" xlink:to="loc_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_708" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" xlink:to="loc_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome_709" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" xlink:to="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome_710" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" xlink:to="loc_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome_711" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract_703" xlink:to="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_712" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract_702" xlink:to="loc_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_704" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_714" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_714" xlink:to="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointOperationsAxis" xlink:label="loc_ifrs-full_JointOperationsAxis_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_JointOperationsAxis_723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointOperationsMember" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointOperationsAxis_723" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntraGroupProfitMember" xlink:label="loc_gsk_IntraGroupProfitMember_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_722" xlink:to="loc_gsk_IntraGroupProfitMember_741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_720" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_721" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_740" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationAxis" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxReformsPeriodOfApplicationDomain" xlink:label="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationAxis_727" xlink:to="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OriginationAndReversalOfTemporaryDifferencesMember" xlink:label="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TaxReformsPeriodOfApplicationDomain_728" xlink:to="loc_gsk_OriginationAndReversalOfTemporaryDifferencesMember_743" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_729" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcceleratedCapitalAllowancesMember" xlink:label="loc_gsk_AcceleratedCapitalAllowancesMember_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_gsk_AcceleratedCapitalAllowancesMember_746" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_747" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_730" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_748" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_718" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_718" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_719" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_719" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_739" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_715" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_716" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationMember" xlink:label="loc_ifrs-full_ContingentConsiderationMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_716" xlink:to="loc_ifrs-full_ContingentConsiderationMember_732" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_731" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionAndAwardSchemesMember" xlink:label="loc_gsk_ShareOptionAndAwardSchemesMember_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_gsk_ShareOptionAndAwardSchemesMember_742" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_514499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_514498" xlink:to="loc_ifrs-full_RestatedMember_514499" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable_725" xlink:to="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:label="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems_724" xlink:to="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_733" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_734" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_735" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome" xlink:label="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome_736" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_512400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_512400" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation" xlink:label="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation_589873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation_589873" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset" xlink:label="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset_2146643273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset_2146643273" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_717" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_738" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_750" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_750" xlink:to="loc_ifrs-full_DeferredTaxAssets_751" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_750" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_752" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_750" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_753" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_755" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_755" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" xlink:to="loc_ifrs-full_MaturityAxis_759" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_759" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_756" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaterThanOneYearAndNotLaterThanTenYearMember" xlink:label="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_gsk_LaterThanOneYearAndNotLaterThanTenYearMember_760" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_761" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AvailableIndefinitelyMember" xlink:label="loc_gsk_AvailableIndefinitelyMember_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_756" xlink:to="loc_gsk_AvailableIndefinitelyMember_762" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_758" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxLosses" xlink:label="loc_gsk_TaxLosses_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_TaxLosses_763" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnTradingLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses_764" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalLosses" xlink:label="loc_gsk_CapitalLosses_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_CapitalLosses_765" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses" xlink:label="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_757" xlink:to="loc_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses_766" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_768" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_2146643084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_768" xlink:to="loc_ifrs-full_EarningsPerShareTable_2146643084" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_2146643082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_2146643084" xlink:to="loc_gsk_EventAxis_2146643082" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventAxis_2146643082" xlink:to="loc_gsk_EventDomain_2146643081" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_2146643083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_2146643084" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_2146643083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2146643280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2146643280" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_2146643279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_2146643279" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_769" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_2146643278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_2146643278" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_2146643277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_2146643277" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_2146643083" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_770" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_772" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_772" xlink:to="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_773" xlink:to="loc_ifrs-full_WeightedAverageShares_774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_773" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_775" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_773" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsAbstract" xlink:label="loc_gsk_DisclosureOfDividendsAbstract_778" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_778" xlink:to="loc_gsk_DisclosureOfDividendsTable_781" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_781" xlink:to="loc_ifrs-full_MaturityAxis_782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_782" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_779" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FirstInterimMember" xlink:label="loc_gsk_FirstInterimMember_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_FirstInterimMember_783" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SecondInterimMember" xlink:label="loc_gsk_SecondInterimMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_SecondInterimMember_784" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThirdInterimMember" xlink:label="loc_gsk_ThirdInterimMember_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_ThirdInterimMember_785" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourthInterimMember" xlink:label="loc_gsk_FourthInterimMember_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_779" xlink:to="loc_gsk_FourthInterimMember_786" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_781" xlink:to="loc_gsk_DisclosureOfDividendsLineItems_780" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsPaidDate" xlink:label="loc_gsk_DividendsPaidDate_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_gsk_DividendsPaidDate_787" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_788" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidOrdinaryShares" xlink:label="loc_ifrs-full_DividendsPaidOrdinaryShares_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_780" xlink:to="loc_ifrs-full_DividendsPaidOrdinaryShares_789" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsAbstract" xlink:label="loc_gsk_DisclosureOfDividendsAbstract_1306900" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_1306902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_1306900" xlink:to="loc_gsk_DisclosureOfDividendsTable_1306902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1306907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_1306902" xlink:to="loc_ifrs-full_MaturityAxis_1306907" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1306909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1306907" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1306909" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourthInterimMember" xlink:label="loc_gsk_FourthInterimMember_1306913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1306909" xlink:to="loc_gsk_FourthInterimMember_1306913" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_1306903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_1306902" xlink:to="loc_gsk_DisclosureOfDividendsLineItems_1306903" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDividendPayables" xlink:label="loc_ifrs-full_CurrentDividendPayables_1306914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1306903" xlink:to="loc_ifrs-full_CurrentDividendPayables_1306914" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionForDividendPayable" xlink:label="loc_gsk_AdditionalProvisionForDividendPayable_1306915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1306903" xlink:to="loc_gsk_AdditionalProvisionForDividendPayable_1306915" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsAbstract" xlink:label="loc_gsk_DisclosureOfDividendsAbstract_791" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsTable" xlink:label="loc_gsk_DisclosureOfDividendsTable_1702390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_791" xlink:to="loc_gsk_DisclosureOfDividendsTable_1702390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_1702390" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1702394" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerOfConsumerHealthcareBusinessMember" xlink:label="loc_gsk_DemergerOfConsumerHealthcareBusinessMember_1702397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1702395" xlink:to="loc_gsk_DemergerOfConsumerHealthcareBusinessMember_1702397" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsLineItems" xlink:label="loc_gsk_DisclosureOfDividendsLineItems_1702393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsTable_1702390" xlink:to="loc_gsk_DisclosureOfDividendsLineItems_1702393" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfInterimDividendRecognitonAndPayment" xlink:label="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1702393" xlink:to="loc_gsk_DescriptionOfInterimDividendRecognitonAndPayment_792" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfAssetdistributedAsDividendInSpecie" xlink:label="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie_1702398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsLineItems_1702393" xlink:to="loc_gsk_FairValueOfAssetdistributedAsDividendInSpecie_1702398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDividendsAbstract" xlink:label="loc_gsk_DisclosureOfDividendsAbstract_794" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashDividendsPaidToShareholdersRecognizedInYear" xlink:label="loc_gsk_CashDividendsPaidToShareholdersRecognizedInYear_1702399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_794" xlink:to="loc_gsk_CashDividendsPaidToShareholdersRecognizedInYear_1702399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear" xlink:label="loc_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear_1702402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_794" xlink:to="loc_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear_1702402" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsRecognisedInYear" xlink:label="loc_gsk_DividendsRecognisedInYear_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDividendsAbstract_794" xlink:to="loc_gsk_DividendsRecognisedInYear_795" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_823" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_823" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_826" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_832" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_MeasurementAxis_831" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_831" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_824" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSalesMember" xlink:label="loc_ifrs-full_CostOfSalesMember_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_ifrs-full_CostOfSalesMember_833" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_ResearchAndDevelopmentMember_834" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_835" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProgrammesMember" xlink:label="loc_gsk_MajorRestructuringProgrammesMember_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_824" xlink:to="loc_gsk_MajorRestructuringProgrammesMember_836" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_825" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_830" xlink:to="loc_ifrs-full_ComputerSoftwareMember_843" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_828" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_837" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage_839" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage" xlink:label="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage_840" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_829" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_588583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_827" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_588583" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_797" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_797" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_800" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_ifrs-full_LandAndBuildingsMember_819" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyPlantAndEquipmentAndVehiclesMember" xlink:label="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_gsk_PropertyPlantAndEquipmentAndVehiclesMember_820" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="loc_ifrs-full_ConstructionInProgressMember_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_803" xlink:to="loc_ifrs-full_ConstructionInProgressMember_821" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_798" xlink:to="loc_ifrs-full_CarryingAmountMember_799" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_804" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_805" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_806" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_799" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_807" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512815" xlink:to="loc_ifrs-full_RestatedMember_512816" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_802" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_808" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_809" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_512807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_512807" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_810" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_811" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment_812" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_813" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_814" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_815" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_816" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_817" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_801" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_818" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_512856" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_512858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_512856" xlink:to="loc_gsk_StatementsTable_512858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_512858" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1309969" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1309976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1309976" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PlantAndEquipmentMember" xlink:label="loc_gsk_PlantAndEquipmentMember_1309975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_gsk_PlantAndEquipmentMember_1309975" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="loc_ifrs-full_VehiclesMember_1309972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1309970" xlink:to="loc_ifrs-full_VehiclesMember_1309972" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_512858" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2146643072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2146643073" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2146643072" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="loc_ifrs-full_RightofuseAssetsMember_2146643071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2146643072" xlink:to="loc_ifrs-full_RightofuseAssetsMember_2146643071" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_512861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_512858" xlink:to="loc_gsk_StatementsLineItems_512861" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_626580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_RightofuseAssets_626580" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetsExchangeAdjustments" xlink:label="loc_gsk_RightOfUseAssetsExchangeAdjustments_588981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetsExchangeAdjustments_588981" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations" xlink:label="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations_2146644856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations_2146644856" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_588868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_588868" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdditionsToRightOfUseAssets" xlink:label="loc_gsk_OtherAdditionsToRightOfUseAssets_2146644857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_OtherAdditionsToRightOfUseAssets_2146644857" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_512872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_512872" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution" xlink:label="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution_1702427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution_1702427" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetDisposal" xlink:label="loc_gsk_RightOfUseAssetDisposal_588999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetDisposal_588999" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RightOfUseAssetImpairments" xlink:label="loc_gsk_RightOfUseAssetImpairments_589038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_gsk_RightOfUseAssetImpairments_589038" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_626581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512861" xlink:to="loc_ifrs-full_RightofuseAssets_626581" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_868" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_868" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_871" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_871" xlink:to="loc_ifrs-full_ProductsAndServicesMember_872" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_872" xlink:to="loc_gsk_ConsumerHealthcareMember_877" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_870" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined" xlink:label="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined_873" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_874" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_869" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702528" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_847" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_847" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_848" xlink:to="loc_ifrs-full_CarryingAmountMember_849" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_849" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_851" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_Goodwill_853" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_854" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="loc_ifrs-full_AdditionalRecognitionGoodwill_512926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_AdditionalRecognitionGoodwill_512926" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest" xlink:label="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest_1306977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest_1306977" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill" xlink:label="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill_1702525" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_850" xlink:to="loc_ifrs-full_Goodwill_856" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_858" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_858" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" xlink:to="loc_ifrs-full_SegmentsAxis_861" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_861" xlink:to="loc_ifrs-full_SegmentsMember_862" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_PharmaceuticalsMember_864" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_VaccinesMember_865" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_ConsumerHealthcareMember_866" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_2146643270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_ResearchAndDevelopmentMember_2146643270" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_2146643271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_862" xlink:to="loc_gsk_CommercialOperationsMember_2146643271" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_860" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_859" xlink:to="loc_ifrs-full_Goodwill_863" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_879" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract_879" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_882" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_882" xlink:to="loc_ifrs-full_ProductsAndServicesMember_883" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PharmaceuticalsMember" xlink:label="loc_gsk_PharmaceuticalsMember_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_PharmaceuticalsMember_890" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VaccinesMember" xlink:label="loc_gsk_VaccinesMember_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_VaccinesMember_891" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_ConsumerHealthcareMember_892" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialOperationsMember" xlink:label="loc_gsk_CommercialOperationsMember_1702530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_CommercialOperationsMember_1702530" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_2146643263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_883" xlink:to="loc_gsk_ResearchAndDevelopmentMember_2146643263" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_881" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal_884" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections_885" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal" xlink:label="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal_886" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:label="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_887" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_888" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_880" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_889" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_925" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_925" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationAxis" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_MethodsOfGenerationAxis_928" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MethodsOfGenerationMember" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_928" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_929" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InternallyGeneratedMember" xlink:label="loc_ifrs-full_InternallyGeneratedMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_929" xlink:to="loc_ifrs-full_InternallyGeneratedMember_937" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_RangeAxis_930" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_930" xlink:to="loc_ifrs-full_RangesMember_931" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaAxis" xlink:label="loc_gsk_BenlystaAxis_1224325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_gsk_BenlystaAxis_1224325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1225406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_BenlystaAxis_1224325" xlink:to="loc_gsk_BenlystaDomain_1225406" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1307061" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1307062" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1309141" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1309142" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1702519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1702519" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1702519" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1702520" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_927" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_932" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftware" xlink:label="loc_ifrs-full_ComputerSoftware_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_ifrs-full_ComputerSoftware_933" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged_1315900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged_1315900" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed" xlink:label="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed_1315904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_926" xlink:to="loc_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed_1315904" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_894" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_894" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_897" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" xlink:to="loc_ifrs-full_ComputerSoftwareMember_920" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LicencesAndFranchisesAmortisedBrandsMember" xlink:label="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember_513096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_900" xlink:to="loc_gsk_LicencesAndFranchisesAmortisedBrandsMember_513096" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_895" xlink:to="loc_ifrs-full_CarryingAmountMember_896" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_903" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_904" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_905" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_896" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_906" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_901" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BrandsWithIndefiniteUsefulLifeMember" xlink:label="loc_gsk_BrandsWithIndefiniteUsefulLifeMember_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_902" xlink:to="loc_gsk_BrandsWithIndefiniteUsefulLifeMember_923" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_899" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_907" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_908" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CapitalisedDevelopmentCosts" xlink:label="loc_gsk_CapitalisedDevelopmentCosts_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_CapitalisedDevelopmentCosts_909" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisationOtherIntangibleAssets" xlink:label="loc_gsk_AmortisationOtherIntangibleAssets_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_AmortisationOtherIntangibleAssets_910" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:label="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_911" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_913" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_513097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_513097" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_914" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_915" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_916" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill" xlink:label="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill_1702499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill_1702499" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_918" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_898" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_919" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_941" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_941" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_942" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSalesMember" xlink:label="loc_ifrs-full_CostOfSalesMember_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_ifrs-full_CostOfSalesMember_948" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_gsk_SellingGeneralAndAdministrativeExpensesMember_949" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ResearchAndDevelopmentMember" xlink:label="loc_gsk_ResearchAndDevelopmentMember_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_945" xlink:to="loc_gsk_ResearchAndDevelopmentMember_950" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_1323994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xlink:to="loc_gsk_SegmentConsolidationItemAxis_1323994" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1323995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1323994" xlink:to="loc_gsk_SegmentConsolidationItemMember_1323995" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_944" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortisationOtherIntangibleAssets" xlink:label="loc_gsk_AmortisationOtherIntangibleAssets_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" xlink:to="loc_gsk_AmortisationOtherIntangibleAssets_946" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetImpairmentLossesOtherIntangibleAssets" xlink:label="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_943" xlink:to="loc_gsk_NetImpairmentLossesOtherIntangibleAssets_947" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_952" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_952" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_953" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesAndFranchisesMember" xlink:label="loc_ifrs-full_LicencesAndFranchisesMember_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_958" xlink:to="loc_ifrs-full_LicencesAndFranchisesMember_968" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityAxis" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntityMember" xlink:label="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityAxis_956" xlink:to="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroAssetsMember" xlink:label="loc_gsk_TesaroAssetsMember_847146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_TesaroAssetsMember_847146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MeningitisPortfolioMember" xlink:label="loc_gsk_MeningitisPortfolioMember_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_MeningitisPortfolioMember_960" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DolutegravirMember" xlink:label="loc_gsk_DolutegravirMember_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_DolutegravirMember_961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaMember" xlink:label="loc_gsk_BenlystaMember_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_BenlystaMember_962" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LamisilMember" xlink:label="loc_gsk_LamisilMember_827483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_LamisilMember_827483" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BMSAssetsMember" xlink:label="loc_gsk_BMSAssetsMember_624739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_BMSAssetsMember_624739" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FluarixFlulavalMember" xlink:label="loc_gsk_FluarixFlulavalMember_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_FluarixFlulavalMember_963" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OkairosMember" xlink:label="loc_gsk_OkairosMember_847149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_OkairosMember_847149" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OthersProductsMember" xlink:label="loc_gsk_OthersProductsMember_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_OthersProductsMember_967" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelTradeNameMember" xlink:label="loc_gsk_StiefelTradeNameMember_513189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_StiefelTradeNameMember_513189" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirAssetsMember" xlink:label="loc_gsk_VirAssetsMember_1307051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_VirAssetsMember_1307051" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurevacAssetsMember" xlink:label="loc_gsk_CurevacAssetsMember_1307052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_CurevacAssetsMember_1307052" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxAssetsMember" xlink:label="loc_gsk_AffinivaxAssetsMember_1702486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_AffinivaxAssetsMember_1702486" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MomelotinibMember" xlink:label="loc_gsk_MomelotinibMember_1702487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_MomelotinibMember_1702487" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SperoMember" xlink:label="loc_gsk_SperoMember_2146643091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_SperoMember_2146643091" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShingrixMember" xlink:label="loc_gsk_ShingrixMember_2146643092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsMaterialToEntityMember_957" xlink:to="loc_gsk_ShingrixMember_2146643092" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaAxis" xlink:label="loc_gsk_BenlystaAxis_1224820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_gsk_BenlystaAxis_1224820" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BenlystaDomain" xlink:label="loc_gsk_BenlystaDomain_1224821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_BenlystaAxis_1224820" xlink:to="loc_gsk_BenlystaDomain_1224821" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IteosMember" xlink:label="loc_gsk_IteosMember_1224300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_BenlystaDomain_1224821" xlink:to="loc_gsk_IteosMember_1224300" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AlectorMember" xlink:label="loc_gsk_AlectorMember_1224302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_BenlystaDomain_1224821" xlink:to="loc_gsk_AlectorMember_1224302" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_955" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_954" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_959" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract_1008" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract_1008" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1009" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1012" xlink:to="loc_gsk_InnovivaIncMember_1019" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1224495" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_1224499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1224496" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_1224499" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1307121" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_1307122" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_1011" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_1014" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociate" xlink:label="loc_gsk_DisposalOfInterestInAssociate_1224394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_gsk_DisposalOfInterestInAssociate_1224394" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:label="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_1224480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_1224480" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RecyclingOfExchangeDifferencesInAssociate" xlink:label="loc_gsk_RecyclingOfExchangeDifferencesInAssociate_1224485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_1010" xlink:to="loc_gsk_RecyclingOfExchangeDifferencesInAssociate_1224485" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsInAssociatesAndJointVenturesAbstract" xlink:label="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract_990" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentsInAssociatesAndJointVenturesAbstract_990" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_991" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_995" xlink:to="loc_ifrs-full_AssociatesMember_1006" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xlink:to="loc_ifrs-full_JointVenturesAxis_996" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_996" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesMember" xlink:label="loc_ifrs-full_JointVenturesMember_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_994" xlink:to="loc_ifrs-full_JointVenturesMember_1005" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems" xlink:label="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable_993" xlink:to="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_997" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_998" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures_999" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInAssociatesAndJointVentures" xlink:label="loc_gsk_DisposalsInAssociatesAndJointVentures_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_DisposalsInAssociatesAndJointVentures_1000" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures_1001" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures" xlink:label="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures_829266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures_829266" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries" xlink:label="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries_1307077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries_1307077" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_1003" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems_992" xlink:to="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_1004" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract_2146644900" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract_2146644900" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146644904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146644903" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146644904" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMember_2146644905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2146644904" xlink:to="loc_gsk_CurrentEquityInvestmentsMember_2146644905" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146644906" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146644908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2146644907" xlink:to="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146644908" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644901" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644909" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_2146643051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_2146643051" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementAssets_2146644911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_PurchasesFairValueMeasurementAssets_2146644911" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146644912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146644912" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644902" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading_2146644910" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract_2146644915" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract_2146644915" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2146643215" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146643213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2146643214" xlink:to="loc_gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember_2146643213" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2146643217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2146643218" xlink:to="loc_ifrs-full_FinancialAssetsMember_2146643217" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityInvestmentsMember" xlink:label="loc_gsk_CurrentEquityInvestmentsMember_2146643216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2146643217" xlink:to="loc_gsk_CurrentEquityInvestmentsMember_2146643216" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_2146644922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_gsk_InvestmentAxis_2146644922" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_2146644923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentAxis_2146644922" xlink:to="loc_gsk_InvestmentDomain_2146644923" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentInHaleonPlcMember" xlink:label="loc_gsk_InvestmentInHaleonPlcMember_2147450176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentDomain_2146644923" xlink:to="loc_gsk_InvestmentInHaleonPlcMember_2147450176" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_2146644926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_srt_OwnershipAxis_2146644926" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146644927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_2146644926" xlink:to="loc_srt_OwnershipDomain_2146644927" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoGroupLimitedMember" xlink:label="loc_gsk_GlaxoGroupLimitedMember_2146644928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_GlaxoGroupLimitedMember_2146644928" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScottishLimitedPartnershipsMember" xlink:label="loc_gsk_ScottishLimitedPartnershipsMember_2146644929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_ScottishLimitedPartnershipsMember_2146644929" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustsMember" xlink:label="loc_gsk_EsopTrustsMember_2146644930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2146644927" xlink:to="loc_gsk_EsopTrustsMember_2146644930" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems" xlink:label="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable_2146644916" xlink:to="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueGainThroughProfitOrLoss" xlink:label="loc_gsk_FairValueGainThroughProfitOrLoss_2146643047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_FairValueGainThroughProfitOrLoss_2146643047" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsOfFairValueMeasurementAssets" xlink:label="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets_2146643048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_OtherAdjustmentsOfFairValueMeasurementAssets_2146643048" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnership" xlink:label="loc_gsk_PercentageOfOwnership_2146644932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_PercentageOfOwnership_2146644932" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146643212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems_2146644917" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments_2146643212" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestments1Abstract" xlink:label="loc_gsk_OtherInvestments1Abstract_1055" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsTable" xlink:label="loc_gsk_OtherInvestmentsTable_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestments1Abstract_1055" xlink:to="loc_gsk_OtherInvestmentsTable_1061" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1056" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VirBiotechnologyIncMember" xlink:label="loc_gsk_VirBiotechnologyIncMember_1309704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_VirBiotechnologyIncMember_1309704" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CureVacNVMember" xlink:label="loc_gsk_CureVacNVMember_2146643166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_CureVacNVMember_2146643166" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NimbusTherapeuticsLLCMember" xlink:label="loc_gsk_NimbusTherapeuticsLLCMember_2146643209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1058" xlink:to="loc_gsk_NimbusTherapeuticsLLCMember_2146643209" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1057" xlink:to="loc_ifrs-full_FinancialAssetsMember_1059" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1059" xlink:to="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1066" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1059" xlink:to="loc_gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1067" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_626935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_626933" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_626935" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_847240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_MaturityAxis_847240" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_847241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_847240" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_847241" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_1702455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_CounterpartiesAxis_1702455" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_1702456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_1702455" xlink:to="loc_ifrs-full_CounterpartiesMember_1702456" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1702463" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1702464" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsLineItems" xlink:label="loc_gsk_OtherInvestmentsLineItems_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1061" xlink:to="loc_gsk_OtherInvestmentsLineItems_1060" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ListedInvestments" xlink:label="loc_gsk_ListedInvestments_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_ListedInvestments_1068" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentFairValue" xlink:label="loc_gsk_InvestmentFairValue_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_InvestmentFairValue_1070" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_1071" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_1072" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForForeignExchangeOtherInvestments" xlink:label="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments_626928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1060" xlink:to="loc_gsk_AdjustmentsForForeignExchangeOtherInvestments_626928" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestments1Abstract" xlink:label="loc_gsk_OtherInvestments1Abstract_1038" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsTable" xlink:label="loc_gsk_OtherInvestmentsTable_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestments1Abstract_1038" xlink:to="loc_gsk_OtherInvestmentsTable_1042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1042" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1039" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1040" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1040" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_1043" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember" xlink:label="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1040" xlink:to="loc_gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember_1044" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1702428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1042" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1702428" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1702429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1702428" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1702429" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsNoncurrentMember" xlink:label="loc_gsk_OtherInvestmentsNoncurrentMember_1702430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1702429" xlink:to="loc_gsk_OtherInvestmentsNoncurrentMember_1702430" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsLineItems" xlink:label="loc_gsk_OtherInvestmentsLineItems_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsTable_1042" xlink:to="loc_gsk_OtherInvestmentsLineItems_1041" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1045" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments_2146643055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments_2146643055" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsToOtherInvestments" xlink:label="loc_gsk_AdditionsToOtherInvestments_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_AdditionsToOtherInvestments_1047" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome" xlink:label="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome_1048" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments" xlink:label="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments_1049" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsOtherInvestments" xlink:label="loc_gsk_DisposalsAndSettlementsOtherInvestments_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_gsk_DisposalsAndSettlementsOtherInvestments_1051" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherInvestmentsLineItems_1041" xlink:to="loc_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_1053" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousNoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1086" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNoncurrentAssetsTable" xlink:label="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1086" xlink:to="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1088" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentReceivablesMember" xlink:label="loc_gsk_OtherNonCurrentReceivablesMember_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1089" xlink:to="loc_gsk_OtherNonCurrentReceivablesMember_1093" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1087" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1092" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1092" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1096" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingBalanceMember" xlink:label="loc_gsk_RemainingBalanceMember_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1092" xlink:to="loc_gsk_RemainingBalanceMember_1097" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:label="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherNoncurrentAssetsTable_1091" xlink:to="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="loc_ifrs-full_OtherNoncurrentReceivables_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" xlink:to="loc_ifrs-full_OtherNoncurrentReceivables_1094" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOtherNonCurrentAssetsLineItems_1090" xlink:to="loc_ifrs-full_FinancialAssets_1095" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousNoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1080" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesRelatedToInsuranceContracts" xlink:label="loc_gsk_ReceivablesRelatedToInsuranceContracts_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1080" xlink:to="loc_gsk_ReceivablesRelatedToInsuranceContracts_1081" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1080" xlink:to="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1082" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="loc_ifrs-full_OtherNoncurrentReceivables_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1080" xlink:to="loc_ifrs-full_OtherNoncurrentReceivables_1083" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousNoncurrentAssetsAbstract_1080" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_1084" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_1099" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1099" xlink:to="loc_ifrs-full_RawMaterialsAndConsumablesUsed_1100" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1099" xlink:to="loc_ifrs-full_WorkInProgress_1101" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1099" xlink:to="loc_ifrs-full_FinishedGoods_1102" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1099" xlink:to="loc_ifrs-full_Inventories_1103" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1114" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1114" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1116" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1123" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditImpairmentOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis_1119" xlink:to="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsCreditimpairedMember" xlink:label="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CreditImpairmentOfFinancialInstrumentsMember_1120" xlink:to="loc_ifrs-full_FinancialInstrumentsCreditimpairedMember_1126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1117" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="loc_ifrs-full_TradeReceivablesMember_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" xlink:to="loc_ifrs-full_TradeReceivablesMember_1125" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherReceivableMember" xlink:label="loc_gsk_OtherReceivableMember_1191803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1118" xlink:to="loc_gsk_OtherReceivableMember_1191803" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1115" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1124" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1124" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_1134" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2146644873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_ifrs-full_SegmentsAxis_2146644873" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2146644874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_2146644873" xlink:to="loc_ifrs-full_SegmentsMember_2146644874" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1122" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_TradeReceivables_1127" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_OtherReceivables_1128" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_1129" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired" xlink:label="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired_1130" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_FinancialAssets_1131" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount" xlink:label="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1121" xlink:to="loc_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount_1132" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_TradeReceivables_1106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:label="loc_ifrs-full_AccruedIncomeOtherThanContractAssets_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_AccruedIncomeOtherThanContractAssets_1107" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-full_Prepayments_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_Prepayments_1108" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="loc_ifrs-full_InterestReceivable_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_InterestReceivable_1109" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeLoansAndAdvances" xlink:label="loc_gsk_EmployeeLoansAndAdvances_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_gsk_EmployeeLoansAndAdvances_1110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_OtherReceivables_1111" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1105" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_1112" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1137" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1137" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1141" xlink:to="loc_ifrs-full_RestatedMember_1140" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherReceivablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesTable_1139" xlink:to="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowance" xlink:label="loc_gsk_ExpectedCreditLossAllowance_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowance_1143" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceExchangeAdjustments" xlink:label="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceExchangeAdjustments_1144" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInExpectedCreditLossesAllowance" xlink:label="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance_1145" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale" xlink:label="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale_2146643165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale_2146643165" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance" xlink:label="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance_1146" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowanceUtilised" xlink:label="loc_gsk_ExpectedCreditLossAllowanceUtilised_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowanceUtilised_1147" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedCreditLossAllowance" xlink:label="loc_gsk_ExpectedCreditLossAllowance_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherReceivablesLineItems_1138" xlink:to="loc_gsk_ExpectedCreditLossAllowance_1148" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_1156" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsTable" xlink:label="loc_gsk_CashAndCashEquivalentsTable_2146644884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1156" xlink:to="loc_gsk_CashAndCashEquivalentsTable_2146644884" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CashAndCashEquivalentsTable_2146644884" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644886" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_2146644888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644887" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_2146644888" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsLineItems" xlink:label="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CashAndCashEquivalentsTable_2146644884" xlink:to="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup" xlink:label="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" xlink:to="loc_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup_1158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer" xlink:label="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer_2146644883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_CashAndCashEquivalentsLineItems_2146644885" xlink:to="loc_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer_2146644883" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_1151" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1151" xlink:to="loc_ifrs-full_Cash_1152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1151" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1153" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1151" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1154" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AccruedFixedAssetRelatedCostsAbstract" xlink:label="loc_gsk_AccruedFixedAssetRelatedCostsAbstract_1174" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AccruedFixedAssetRelatedCostsAbstract_1174" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1176" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1177" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1180" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1175" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2147451068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_SegmentsAxis_2147451068" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2147451069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_2147451068" xlink:to="loc_ifrs-full_SegmentsMember_2147451069" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareMember" xlink:label="loc_gsk_ConsumerHealthcareMember_2147451071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_2147451069" xlink:to="loc_gsk_ConsumerHealthcareMember_2147451071" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1179" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xlink:label="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2146644891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1178" xlink:to="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2146644891" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfAssetsHeldForSaleAbstract" xlink:label="loc_gsk_DisclosureOfAssetsHeldForSaleAbstract_1160" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleTable" xlink:label="loc_gsk_AssetsHeldForSaleTable_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfAssetsHeldForSaleAbstract_1160" xlink:to="loc_gsk_AssetsHeldForSaleTable_1164" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssetsHeldForSaleTable_1164" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1161" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1162" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_1165" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssetsHeldForSaleLineItems" xlink:label="loc_gsk_AssetsHeldForSaleLineItems_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssetsHeldForSaleTable_1164" xlink:to="loc_gsk_AssetsHeldForSaleLineItems_1163" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1166" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAssetsNet" xlink:label="loc_gsk_OtherAssetsNet_2146643150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_gsk_OtherAssetsNet_2146643150" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AssetsHeldForSaleLineItems_1163" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_1172" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_1202" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_1202" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1205" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1208" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1216" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1203" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember" xlink:label="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1204" xlink:to="loc_gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember_1215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_srt_StatementGeographicalAxis_1213" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1213" xlink:to="loc_srt_SegmentGeographicalDomain_1212" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemAxis" xlink:label="loc_gsk_SegmentConsolidationItemAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_gsk_SegmentConsolidationItemAxis_1211" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SegmentConsolidationItemMember" xlink:label="loc_gsk_SegmentConsolidationItemMember_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemAxis_1211" xlink:to="loc_gsk_SegmentConsolidationItemMember_1209" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_USPharmaceuticalsAndVaccinesMember" xlink:label="loc_gsk_USPharmaceuticalsAndVaccinesMember_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SegmentConsolidationItemMember_1209" xlink:to="loc_gsk_USPharmaceuticalsAndVaccinesMember_1217" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1207" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1214" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="loc_ifrs-full_RevenueAndOperatingIncome_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_ifrs-full_RevenueAndOperatingIncome_1220" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_gsk_CustomerReturnAndRebateAccruals_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_gsk_CustomerReturnAndRebateAccruals_1218" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost_2147457482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1206" xlink:to="loc_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost_2147457482" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_1185" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesTable" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_1185" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" xlink:to="loc_ifrs-full_SegmentsAxis_1188" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_1188" xlink:to="loc_ifrs-full_SegmentsMember_1189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfTradeAndOtherPayablesLineItems" xlink:label="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesTable_1187" xlink:to="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1190" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WagesAndSalariesPayable" xlink:label="loc_gsk_WagesAndSalariesPayable_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_WagesAndSalariesPayable_1191" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1192" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PutOptionPayable" xlink:label="loc_gsk_PutOptionPayable_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_PutOptionPayable_1193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_OtherCurrentPayables_1194" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_ContractLiabilities_1195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CustomerReturnAndRebateAccruals" xlink:label="loc_gsk_CustomerReturnAndRebateAccruals_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_CustomerReturnAndRebateAccruals_1196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAccruals" xlink:label="loc_gsk_OtherAccruals_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_gsk_OtherAccruals_1197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfTradeAndOtherPayablesLineItems_1186" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract" xlink:label="loc_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract_1222" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract_1222" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ValuationTechniquesMember" xlink:label="loc_ifrs-full_ValuationTechniquesMember_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1228" xlink:to="loc_ifrs-full_ValuationTechniquesMember_1227" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1225" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1225" xlink:to="loc_ifrs-full_TypesOfRisksMember_1226" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_1231" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644997" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_1232" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember" xlink:label="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember_2146644998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_1307434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_1307434" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember_2146645015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember_2146645015" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember" xlink:label="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember_2146645018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember_2146645018" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_1233" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645003" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_1234" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645005" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_1235" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645007" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_1236" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1226" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645008" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable_1224" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInFinancialLiability" xlink:label="loc_gsk_IncreaseDecreaseInFinancialLiability_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_gsk_IncreaseDecreaseInFinancialLiability_1229" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_1307432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities_1307432" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_1307441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems_1223" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities_1307441" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract_1621" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtTable" xlink:label="loc_gsk_DisclosureOfDebtTable_1630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract_1621" xlink:to="loc_gsk_DisclosureOfDebtTable_1630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_MaturityAxis_1636" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1636" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1622" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1640" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2146643119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2146643119" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermNotesMember" xlink:label="loc_gsk_ShortTermNotesMember_2146646183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_gsk_ShortTermNotesMember_2146646183" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1622" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643123" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1623" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1624" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaper1Member" xlink:label="loc_gsk_CommercialPaper1Member_1643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_CommercialPaper1Member_1643" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LetterOfCredit1Member" xlink:label="loc_gsk_LetterOfCredit1Member_1644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_LetterOfCredit1Member_1644" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonInterestBearingMember" xlink:label="loc_gsk_NonInterestBearingMember_1191874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_NonInterestBearingMember_1191874" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_2146643134" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643133" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643132" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_2146643131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_2146643131" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_2146643130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_2146643130" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:label="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_2146643129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1624" xlink:to="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_2146643129" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_1639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_1639" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_1635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_1639" xlink:to="loc_ifrs-full_InterestRateTypesMember_1635" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_1674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_1635" xlink:to="loc_ifrs-full_FloatingInterestRateMember_1674" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FixedInterestRateMember" xlink:label="loc_ifrs-full_FixedInterestRateMember_1675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_1635" xlink:to="loc_ifrs-full_FixedInterestRateMember_1675" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_RangeAxis_1637" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_1637" xlink:to="loc_ifrs-full_RangesMember_1638" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_1638" xlink:to="loc_ifrs-full_BottomOfRangeMember_1676" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_1677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_1638" xlink:to="loc_ifrs-full_TopOfRangeMember_1677" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1627" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCommercialPaperProgramMember" xlink:label="loc_gsk_UsCommercialPaperProgramMember_1647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" xlink:to="loc_gsk_UsCommercialPaperProgramMember_1647" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgramMember" xlink:label="loc_gsk_EuroCommercialPaperProgramMember_847236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1628" xlink:to="loc_gsk_EuroCommercialPaperProgramMember_847236" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1626" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1632" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1633" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1633" xlink:to="loc_ifrs-full_GeographicalAreasMember_1634" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1625" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1625" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1631" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1307524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1307523" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1307524" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_2146643122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_gsk_PurposeAxis_2146643122" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeAxis_2146643122" xlink:to="loc_gsk_PurposeDomain_2146643121" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:label="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeDomain_2146643121" xlink:to="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643120" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2146643127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2146643127" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2146643126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2146643127" xlink:to="loc_ifrs-full_TypesOfRisksMember_2146643126" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_2146643125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2146643126" xlink:to="loc_ifrs-full_LiquidityRiskMember_2146643125" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtLineItems" xlink:label="loc_gsk_DisclosureOfDebtLineItems_1629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1630" xlink:to="loc_gsk_DisclosureOfDebtLineItems_1629" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments" xlink:label="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments_1648" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestments" xlink:label="loc_gsk_LiquidInvestments_1649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_LiquidInvestments_1649" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EffectiveInterestRateOnCashAndCashEquivalents" xlink:label="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents_1650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_EffectiveInterestRateOnCashAndCashEquivalents_1650" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperAuthorized" xlink:label="loc_gsk_CommercialPaperAuthorized_1653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CommercialPaperAuthorized_1653" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_1654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_CommercialPapersIssued_1654" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:label="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643009" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnBorrowings" xlink:label="loc_gsk_WeightedAverageInterestRateOnBorrowings_1659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_WeightedAverageInterestRateOnBorrowings_1659" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts" xlink:label="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts_1660" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateShortTerm" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_AverageEffectivePreSwapInterestRateShortTerm_1662" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings_1664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_LongtermBorrowings_1664" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageEffectivePreSwapInterestRateNotesIssued" xlink:label="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_AverageEffectivePreSwapInterestRateNotesIssued_1665" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryInterestAtEffectiveRates" xlink:label="loc_gsk_CarryInterestAtEffectiveRates_1666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_CarryInterestAtEffectiveRates_1666" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RepaymentYear" xlink:label="loc_gsk_RepaymentYear_1667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_RepaymentYear_1667" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PledgedInvestments" xlink:label="loc_gsk_PledgedInvestments_1668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_gsk_PledgedInvestments_1668" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_534851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_CashAndCashEquivalents_534851" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_2146643128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_2146643128" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2146643136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_NotionalAmount_2146643136" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate_2146643137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1629" xlink:to="loc_ifrs-full_BorrowingsInterestRate_2146643137" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract_1565" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtTable" xlink:label="loc_gsk_DisclosureOfDebtTable_1573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract_1565" xlink:to="loc_gsk_DisclosureOfDebtTable_1573" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1569" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt1Member" xlink:label="loc_gsk_Debt1Member_1611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1570" xlink:to="loc_gsk_Debt1Member_1611" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis_1574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_dei_EntityListingsExchangeAxis_1574" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain_1575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_1574" xlink:to="loc_dei_ExchangeDomain_1575" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NewYorkStockExchangeMember" xlink:label="loc_gsk_NewYorkStockExchangeMember_1616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_1575" xlink:to="loc_gsk_NewYorkStockExchangeMember_1616" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LondonStockExchangeMember" xlink:label="loc_gsk_LondonStockExchangeMember_1617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_1575" xlink:to="loc_gsk_LondonStockExchangeMember_1617" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1567" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1567" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1568" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_1590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_1590" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember" xlink:label="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_588933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember_588933" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1591" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember_829656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember_829656" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember_1592" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember_588935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember_588935" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember" xlink:label="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember_588936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember_588936" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember_1593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember_1593" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember_1594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember_1594" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember_1595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember_1595" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember_1596" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember" xlink:label="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember_1597" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_1598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember_1598" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember_831234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember_831234" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember_1599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember_1599" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember" xlink:label="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember_588937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember_588937" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember" xlink:label="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember_829658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember_829658" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember" xlink:label="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember_1600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember_1600" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember" xlink:label="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember_1601" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_1602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember_1602" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember" xlink:label="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember_1603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember_1603" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember" xlink:label="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember_829660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember_829660" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember_1604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember_1604" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember" xlink:label="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember_1605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember_1605" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember" xlink:label="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_1606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember_1606" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember" xlink:label="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember_1607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember_1607" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember" xlink:label="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_1608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember_1608" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLongtermBorrowingsMember" xlink:label="loc_gsk_OtherLongtermBorrowingsMember_1610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_OtherLongtermBorrowingsMember_1610" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember" xlink:label="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember_2146643140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember_2146643140" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember" xlink:label="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember_2146643141" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643142" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember_2146643143" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643144" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember" xlink:label="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1568" xlink:to="loc_gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember_2146643145" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtLineItems" xlink:label="loc_gsk_DisclosureOfDebtLineItems_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtTable_1573" xlink:to="loc_gsk_DisclosureOfDebtLineItems_1572" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_1571" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCurrent" xlink:label="loc_gsk_LiquidInvestmentsCurrent_1612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_gsk_LiquidInvestmentsCurrent_1612" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1613" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1571" xlink:to="loc_ifrs-full_CurrentAssets_1615" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsAbstract" xlink:label="loc_ifrs-full_BorrowingsAbstract_1566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_BorrowingsAbstract_1566" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_CommercialPapersIssued_1577" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansoverdraftsAndOther" xlink:label="loc_gsk_BankLoansoverdraftsAndOther_1578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_gsk_BankLoansoverdraftsAndOther_1578" use="optional" order="52" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_513126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_513126" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-full_ShorttermBorrowings_1581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_1566" xlink:to="loc_ifrs-full_ShorttermBorrowings_1581" use="optional" order="54" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongtermBorrowingsAbstract" xlink:label="loc_gsk_LongtermBorrowingsAbstract_1223885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_gsk_LongtermBorrowingsAbstract_1223885" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_1618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_LongtermBorrowingsAbstract_1223885" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_1618" use="optional" order="56" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-full_LongtermBorrowings_1619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_LongtermBorrowingsAbstract_1223885" xlink:to="loc_ifrs-full_LongtermBorrowings_1619" use="optional" order="57" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtLineItems_1572" xlink:to="loc_ifrs-full_Borrowings_1582" use="optional" order="58" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract_1679" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract_1679" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" xlink:to="loc_ifrs-full_MaturityAxis_1683" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1683" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1680" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_1684" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1685" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1686" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1687" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1688" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1680" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1689" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_1682" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseObligationsGross" xlink:label="loc_gsk_FinanceLeaseObligationsGross_1690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" xlink:to="loc_gsk_FinanceLeaseObligationsGross_1690" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseLiability" xlink:label="loc_gsk_FinanceLeaseLiability_1692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_1681" xlink:to="loc_gsk_FinanceLeaseLiability_1692" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1239" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1239" xlink:to="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1240" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1241" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember_534890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UkDefinedBenefitAndDefinedContributionPlansMember_534890" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsDefinedBenefitAndDefinedContributionPlansMember" xlink:label="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember_534895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UsDefinedBenefitAndDefinedContributionPlansMember_534895" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherOverseasPensionPlansMember" xlink:label="loc_gsk_OtherOverseasPensionPlansMember_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_OtherOverseasPensionPlansMember_1246" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedPostRetirementPensionPlansMember" xlink:label="loc_gsk_UnfundedPostRetirementPensionPlansMember_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UnfundedPostRetirementPensionPlansMember_1247" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FundedDefinedBenefitPensionPlansMember" xlink:label="loc_gsk_FundedDefinedBenefitPensionPlansMember_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_FundedDefinedBenefitPensionPlansMember_1248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnfundedDefinedBenefitPensionPlanMember" xlink:label="loc_gsk_UnfundedDefinedBenefitPensionPlanMember_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_UnfundedDefinedBenefitPensionPlanMember_1249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember_1250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitSchemesMember" xlink:label="loc_gsk_DefinedBenefitSchemesMember_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedBenefitSchemesMember_1251" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedContributionPensionSchemeMember" xlink:label="loc_gsk_DefinedContributionPensionSchemeMember_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1241" xlink:to="loc_gsk_DefinedContributionPensionSchemeMember_1252" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems" xlink:label="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable_1243" xlink:to="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedContributionPlans" xlink:label="loc_gsk_DisclosureOfDefinedContributionPlans_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_DisclosureOfDefinedContributionPlans_1253" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_CostOfSales_1254" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1255" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_1256" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1257" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpensePlans" xlink:label="loc_gsk_PostemploymentBenefitExpensePlans_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_PostemploymentBenefitExpensePlans_1258" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed" xlink:label="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems_1242" xlink:to="loc_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed_1259" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1261" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1261" xlink:to="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1268" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1268" xlink:to="loc_ifrs-full_GeographicalAreasMember_1269" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1269" xlink:to="loc_country_GB_1288" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1269" xlink:to="loc_country_US_1289" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1262" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1262" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1263" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_1272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1263" xlink:to="loc_ifrs-full_OtherAssetsMember_1272" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1264" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1264" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1265" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1273" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1274" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_PostretirementBenefitsMember_1275" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UkDefinedBenefitPlansMember" xlink:label="loc_gsk_UkDefinedBenefitPlansMember_846655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_UkDefinedBenefitPlansMember_846655" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCashBalancePensionPlanMember" xlink:label="loc_gsk_UsCashBalancePensionPlanMember_832149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_UsCashBalancePensionPlanMember_832149" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetireeHealthcarePlansMember" xlink:label="loc_gsk_RetireeHealthcarePlansMember_832150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1265" xlink:to="loc_gsk_RetireeHealthcarePlansMember_832150" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1270" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1271" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandThirtyOneAndThereafterMember" xlink:label="loc_gsk_TwoThousandThirtyOneAndThereafterMember_2146643093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_1271" xlink:to="loc_gsk_TwoThousandThirtyOneAndThereafterMember_2146643093" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeAxis" xlink:label="loc_gsk_AgreementTypeAxis_2146645117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_AgreementTypeAxis_2146645117" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementTypeMember" xlink:label="loc_gsk_AgreementTypeMember_2146645118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AgreementTypeAxis_2146645117" xlink:to="loc_gsk_AgreementTypeMember_2146645118" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SlpPartnershipAgreementMember" xlink:label="loc_gsk_SlpPartnershipAgreementMember_2146645119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AgreementTypeMember_2146645118" xlink:to="loc_gsk_SlpPartnershipAgreementMember_2146645119" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeAxis" xlink:label="loc_gsk_SchemeAxis_2146643101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_SchemeAxis_2146643101" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SchemeMember" xlink:label="loc_gsk_SchemeMember_2146643100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_SchemeAxis_2146643101" xlink:to="loc_gsk_SchemeMember_2146643100" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_2146643104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_srt_OwnershipAxis_2146643104" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2146643103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_2146643104" xlink:to="loc_srt_OwnershipDomain_2146643103" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonMember" xlink:label="loc_gsk_HaleonMember_2146643102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2146643103" xlink:to="loc_gsk_HaleonMember_2146643102" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockAxis" xlink:label="loc_gsk_ClassOfCommonStockAxis_2146643107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_ClassOfCommonStockAxis_2146643107" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ClassOfCommonStockMember" xlink:label="loc_gsk_ClassOfCommonStockMember_2146643106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ClassOfCommonStockAxis_2146643107" xlink:to="loc_gsk_ClassOfCommonStockMember_2146643106" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeAxis" xlink:label="loc_gsk_TransfereeAxis_2146643110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_TransfereeAxis_2146643110" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfereeMember" xlink:label="loc_gsk_TransfereeMember_2146643109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TransfereeAxis_2146643110" xlink:to="loc_gsk_TransfereeMember_2146643109" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SLPPartneshipsMember" xlink:label="loc_gsk_SLPPartneshipsMember_2146643108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TransfereeMember_2146643109" xlink:to="loc_gsk_SLPPartneshipsMember_2146643108" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643113" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember_2146643111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643112" xlink:to="loc_gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember_2146643111" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147451133" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKLPLtdMember" xlink:label="loc_gsk_GSKLPLtdMember_2147451140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147451134" xlink:to="loc_gsk_GSKLPLtdMember_2147451140" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems" xlink:label="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable_1267" xlink:to="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage" xlink:label="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage_1276" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToReturnSeekingAssets" xlink:label="loc_gsk_AllocationToReturnSeekingAssets_1277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AllocationToReturnSeekingAssets_1277" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AllocationToLiabilityMatchingAssets" xlink:label="loc_gsk_AllocationToLiabilityMatchingAssets_1278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AllocationToLiabilityMatchingAssets_1278" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsIncludedInPastServiceCosts" xlink:label="loc_gsk_AugmentationCostsIncludedInPastServiceCosts_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AugmentationCostsIncludedInPastServiceCosts_1280" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AugmentationCostsFromRestructuringProgrammes" xlink:label="loc_gsk_AugmentationCostsFromRestructuringProgrammes_1281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AugmentationCostsFromRestructuringProgrammes_1281" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalValueOfTheInsuranceContract" xlink:label="loc_gsk_TotalValueOfTheInsuranceContract_601239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_TotalValueOfTheInsuranceContract_601239" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_601244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_601244" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets_1282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets_1282" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1283" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_1285" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation_1286" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_1287" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="loc_ifrs-full_SurplusDeficitInPlan_832156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_SurplusDeficitInPlan_832156" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_832159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_832159" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationAtPastServiceCost" xlink:label="loc_gsk_DefinedBenefitObligationAtPastServiceCost_832161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_DefinedBenefitObligationAtPastServiceCost_832161" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished" xlink:label="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished_858149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished_858149" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiarySharesTransferredIntoLimitedPartnerships" xlink:label="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships_2146645110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships_2146645110" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_2146645112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_2146645112" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset_2146645114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset_2146645114" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2146645116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2146645116" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SubsidiariesSharesTransferredToFundPensionSchemes" xlink:label="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes_2146643148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_SubsidiariesSharesTransferredToFundPensionSchemes_2146643148" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipInterestRepresentedByTransfer" xlink:label="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer_2146643147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_PercentageOfOwnershipInterestRepresentedByTransfer_2146643147" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwneshipInterestHeldByTheTransferee" xlink:label="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee_2146643146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_PercentageOfOwneshipInterestHeldByTheTransferee_2146643146" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaximumProceedsThresholdAmount" xlink:label="loc_gsk_MaximumProceedsThresholdAmount_2146643118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_MaximumProceedsThresholdAmount_2146643118" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_2146643117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets_2146643117" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemainingAmountDueToBeContributed" xlink:label="loc_gsk_RemainingAmountDueToBeContributed_2146643116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_RemainingAmountDueToBeContributed_2146643116" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VoluntaryCashContributionsMadeToThePlan" xlink:label="loc_gsk_VoluntaryCashContributionsMadeToThePlan_2146643115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_VoluntaryCashContributionsMadeToThePlan_2146643115" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionDueToBePaid" xlink:label="loc_gsk_AdditionalContributionDueToBePaid_2146643114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems_1266" xlink:to="loc_gsk_AdditionalContributionDueToBePaid_2146643114" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1292" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1292" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1296" xlink:to="loc_ifrs-full_GeographicalAreasMember_1297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1297" xlink:to="loc_country_GB_1303" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1297" xlink:to="loc_country_US_1304" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xlink:to="loc_ifrs-full_MaturityAxis_1298" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1298" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1293" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentPeriodMember" xlink:label="loc_gsk_CurrentPeriodMember_1299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1293" xlink:to="loc_gsk_CurrentPeriodMember_1299" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProjectedPeriodMember" xlink:label="loc_gsk_ProjectedPeriodMember_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1293" xlink:to="loc_gsk_ProjectedPeriodMember_1300" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1295" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" xlink:to="loc_gsk_MalePensionersAverageLifeExpectancyAtSixty_1301" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FemalePensionersAverageLifeExpectancyAtSixty" xlink:label="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty_1302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1294" xlink:to="loc_gsk_FemalePensionersAverageLifeExpectancyAtSixty_1302" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1306" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1306" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1309" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1309" xlink:to="loc_ifrs-full_GeographicalAreasMember_1310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_country_GB_1316" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_country_US_1317" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1310" xlink:to="loc_gsk_RestOfWorldMember_1318" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable_1308" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_1311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_1311" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_1312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_1313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_1313" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfCashBalanceCreditRate" xlink:label="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate_1314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_gsk_ActuarialAssumptionOfCashBalanceCreditRate_1314" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems_1307" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_1315" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1320" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1320" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1325" xlink:to="loc_ifrs-full_GeographicalAreasMember_1326" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_country_GB_1338" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_country_US_1339" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1326" xlink:to="loc_gsk_RestOfWorldMember_1340" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1321" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1321" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1322" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1329" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1322" xlink:to="loc_gsk_PostretirementBenefitsMember_1330" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1327" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember" xlink:label="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember_2146642977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1328" xlink:to="loc_gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember_2146642977" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1324" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1331" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1332" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1333" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1334" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1335" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits" xlink:label="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits_1336" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1323" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1337" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1343" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1343" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1344" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_1350" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1345" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1352" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1346" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1346" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1347" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1347" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1353" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1347" xlink:to="loc_gsk_PostretirementBenefitsMember_1354" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1349" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan_1355" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_1357" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1348" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1358" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1360" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1360" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1367" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1367" xlink:to="loc_ifrs-full_GeographicalAreasMember_1368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_country_GB_1386" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_country_US_1387" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1368" xlink:to="loc_gsk_RestOfWorldMember_1388" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1363" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupMember" xlink:label="loc_gsk_GroupMember_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1366" xlink:to="loc_gsk_GroupMember_1385" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_1361" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_1369" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionsAndOtherPostemploymentBenefitsMember" xlink:label="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_1362" xlink:to="loc_gsk_PensionsAndOtherPostemploymentBenefitsMember_1370" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1365" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed_1371" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted_1372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted_1372" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MultiAssetFunds" xlink:label="loc_gsk_MultiAssetFunds_1373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_MultiAssetFunds_1373" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed_1374" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted_1375" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed_1376" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted" xlink:label="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted_1377" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed" xlink:label="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed_1378" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets_1379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets_1379" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets" xlink:label="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets_1380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets_1380" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_1381" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitPensionAssetCeilingRestrictions" xlink:label="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions_1307086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_gsk_DefinedBenefitPensionAssetCeilingRestrictions_1307086" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1382" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="loc_ifrs-full_SurplusDeficitInPlan_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_SurplusDeficitInPlan_1383" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1364" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1384" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1390" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1390" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1391" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1391" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1392" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1392" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1399" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1392" xlink:to="loc_gsk_PostretirementBenefitsMember_1400" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1395" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1395" xlink:to="loc_ifrs-full_GeographicalAreasMember_1396" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="loc_country_GB_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_country_GB_1415" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_country_US_1416" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RestOfWorldMember" xlink:label="loc_gsk_RestOfWorldMember_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1396" xlink:to="loc_gsk_RestOfWorldMember_1417" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_1397" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsMember" xlink:label="loc_ifrs-full_PlanAssetsMember_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" xlink:to="loc_ifrs-full_PlanAssetsMember_1418" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_631025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_1398" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_631025" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems" xlink:label="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable_1394" xlink:to="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_1401" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1402" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1403" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights_832506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights_832506" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1404" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1405" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1406" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpensesNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_gsk_ExpensesNetDefinedBenefitLiabilityAsset_1407" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1408" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1409" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1410" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_1411" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset_2146645105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset_2146645105" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_1412" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_1413" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems_1393" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1414" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1420" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1420" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1421" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1421" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1422" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1422" xlink:to="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_1425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1422" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_1426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1424" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1423" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1427" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_1431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_1431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_1432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_1433" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset_1434" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_1435" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_1436" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_1437" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1438" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1439" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1440" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_1441" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_2146643097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_2146643097" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset_1442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_1430" xlink:to="loc_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset_1442" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_513479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1429" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_513479" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1444" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1444" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1445" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1446" xlink:to="loc_gsk_PostretirementBenefitsMember_1449" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_1448" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_1450" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_1451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_1452" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_1447" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_1453" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1455" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1455" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1456" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationActiveMember" xlink:label="loc_gsk_DefinedBenefitObligationActiveMember_1464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationActiveMember_1464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationRetiredMember" xlink:label="loc_gsk_DefinedBenefitObligationRetiredMember_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationRetiredMember_1465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationDeferredMember" xlink:label="loc_gsk_DefinedBenefitObligationDeferredMember_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1461" xlink:to="loc_gsk_DefinedBenefitObligationDeferredMember_1466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1457" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1457" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1458" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1462" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1460" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1459" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1463" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1468" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1468" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1469" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationActiveMember" xlink:label="loc_gsk_DefinedBenefitObligationActiveMember_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationActiveMember_1477" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationRetiredMember" xlink:label="loc_gsk_DefinedBenefitObligationRetiredMember_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationRetiredMember_1478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DefinedBenefitObligationDeferredMember" xlink:label="loc_gsk_DefinedBenefitObligationDeferredMember_1479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_1474" xlink:to="loc_gsk_DefinedBenefitObligationDeferredMember_1479" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1470" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1470" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1471" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostretirementBenefitsMember" xlink:label="loc_gsk_PostretirementBenefitsMember_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1471" xlink:to="loc_gsk_PostretirementBenefitsMember_1475" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_1473" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_1472" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_1476" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract_1481" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract_1481" xlink:to="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1482" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PensionDefinedBenefitPlansMember" xlink:label="loc_ifrs-full_PensionDefinedBenefitPlansMember_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1483" xlink:to="loc_ifrs-full_PensionDefinedBenefitPlansMember_1486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostRetirementBenefitMember" xlink:label="loc_gsk_PostRetirementBenefitMember_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_1483" xlink:to="loc_gsk_PostRetirementBenefitMember_1487" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems" xlink:label="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable_1485" xlink:to="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageDurationOfDefinedBenefitObligations" xlink:label="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems_1484" xlink:to="loc_gsk_WeightedAverageDurationOfDefinedBenefitObligations_1488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1490" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_1490" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_1491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_1491" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_1492" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember_2146643007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember_2146643007" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember_847464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember_847464" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember_847466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember_847466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember_847467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember_847467" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember_847469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember_847469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember_847471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember_847471" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfLifeExpectancyRatesMember" xlink:label="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfLifeExpectancyRatesMember_1496" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionForFutureHealthcareInflationMember" xlink:label="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionForFutureHealthcareInflationMember_1497" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember_2146643094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember_2146643094" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember" xlink:label="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember_2146643095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_1492" xlink:to="loc_gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember_2146643095" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1494" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInAnnualPensionCost" xlink:label="loc_gsk_IncreaseInAnnualPensionCost_1499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseInAnnualPensionCost_1499" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost" xlink:label="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost_1500" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreasePensionObligations" xlink:label="loc_gsk_IncreaseDecreasePensionObligations_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreasePensionObligations_1501" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInPostretirementBenefitsObligation" xlink:label="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_1493" xlink:to="loc_gsk_IncreaseDecreaseInPostretirementBenefitsObligation_1502" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_1540" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_1540" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_1541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_1541" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1541" xlink:to="loc_ifrs-full_OtherProvisionsMember_1545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalAndOtherDisputesMember" xlink:label="loc_gsk_LegalAndOtherDisputesMember_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1545" xlink:to="loc_gsk_LegalAndOtherDisputesMember_1555" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MajorRestructuringProvisionsMember" xlink:label="loc_gsk_MajorRestructuringProvisionsMember_1307404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1545" xlink:to="loc_gsk_MajorRestructuringProvisionsMember_1307404" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TitleOfIndividual1Axis" xlink:label="loc_gsk_TitleOfIndividual1Axis_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_gsk_TitleOfIndividual1Axis_1547" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentGrantsDomain" xlink:label="loc_gsk_GovernmentGrantsDomain_1544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TitleOfIndividual1Axis_1547" xlink:to="loc_gsk_GovernmentGrantsDomain_1544" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisabledEmployeesMember" xlink:label="loc_gsk_DisabledEmployeesMember_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_GovernmentGrantsDomain_1544" xlink:to="loc_gsk_DisabledEmployeesMember_1554" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1064372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1064370" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1064372" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1543" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions" xlink:label="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions_1548" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions_1549" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="loc_ifrs-full_ShorttermLegalProceedingsProvision_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_ShorttermLegalProceedingsProvision_1550" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalProceedingsAndOtherDisputesProvisionEstimated" xlink:label="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated_1551" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PensionObligationProvisions" xlink:label="loc_gsk_PensionObligationProvisions_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_gsk_PensionObligationProvisions_1552" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1542" xlink:to="loc_ifrs-full_ProvisionsForEmployeeBenefits_1546" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_1518" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_1518" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_1519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_1522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_1519" xlink:to="loc_ifrs-full_OtherProvisionsMember_1522" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LegalAndOtherDisputesMember" xlink:label="loc_gsk_LegalAndOtherDisputesMember_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_LegalAndOtherDisputesMember_1535" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="loc_ifrs-full_RestructuringProvisionMember_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_ifrs-full_RestructuringProvisionMember_1536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeRelatedProvisionsMember" xlink:label="loc_gsk_EmployeeRelatedProvisionsMember_1537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_EmployeeRelatedProvisionsMember_1537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherProvisionMember" xlink:label="loc_gsk_OtherProvisionMember_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_1522" xlink:to="loc_gsk_OtherProvisionMember_1538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512839" xlink:to="loc_ifrs-full_RestatedMember_512840" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_1521" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherProvisions_1523" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1524" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_1525" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_1526" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_1527" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_1528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_1528" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToAssetsHeldForSaleDistribution" xlink:label="loc_gsk_TransferToAssetsHeldForSaleDistribution_2146645084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_gsk_TransferToAssetsHeldForSaleDistribution_2146645084" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_512904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_512904" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1529" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferToPensionObligations" xlink:label="loc_gsk_TransferToPensionObligations_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_gsk_TransferToPensionObligations_1530" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherProvisions_1531" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherShorttermProvisions_1532" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLongtermProvisions" xlink:label="loc_ifrs-full_OtherLongtermProvisions_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherLongtermProvisions_1533" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1520" xlink:to="loc_ifrs-full_OtherProvisions_1534" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract_2042" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract_2042" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2043" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2054" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_AffinivaxMember_1702425" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisMember" xlink:label="loc_gsk_NovartisMember_2055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_NovartisMember_2055" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBusinessMember" xlink:label="loc_gsk_OtherBusinessMember_2056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2046" xlink:to="loc_gsk_OtherBusinessMember_2056" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable_2045" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2047" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2048" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_2049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination_2049" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination_2146643281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination_2146643281" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_2050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_2050" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPaid" xlink:label="loc_gsk_ContingentConsiderationPaid_2051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_gsk_ContingentConsiderationPaid_2051" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems_2044" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2053" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract_2073" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract_2073" xlink:to="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2074" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_AffinivaxMember_1702446" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesMember" xlink:label="loc_gsk_NovartisVaccinesMember_2091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_NovartisVaccinesMember_2091" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViivHealthcareMember" xlink:label="loc_gsk_ShionogiViivHealthcareMember_2146643260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2077" xlink:to="loc_gsk_ShionogiViivHealthcareMember_2146643260" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2078" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2078" xlink:to="loc_ifrs-full_TypesOfRisksMember_2079" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember_2147451159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskTenPercentageIncreaseInSalesForecastsMember_2147451159" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember_2147451160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember_2147451160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember_2147451161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskTenPercentageDecreaseInSalesForecastsMember_2147451161" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember" xlink:label="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember_2147451162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember_2147451162" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember_2147451163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember_2147451163" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember_2146643286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember_2146643286" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember_2147451165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember_2147451165" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember" xlink:label="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember_2146643285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember_2146643285" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2092" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645020" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2093" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645021" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2094" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645022" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2095" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2079" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645023" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2146645009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_ifrs-full_RangeAxis_2146645009" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2146645010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2146645009" xlink:to="loc_ifrs-full_RangesMember_2146645010" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems" xlink:label="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable_2076" xlink:to="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInSalesForecastAmount" xlink:label="loc_gsk_IncreaseInSalesForecastAmount_2080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInSalesForecastAmount_2080" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInSalesForecastAmount" xlink:label="loc_gsk_DecreaseInSalesForecastAmount_2081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInSalesForecastAmount_2081" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInDiscountRateAmount" xlink:label="loc_gsk_IncreaseInDiscountRateAmount_2082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInDiscountRateAmount_2082" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInDiscountRateAmount" xlink:label="loc_gsk_DecreaseInDiscountRateAmount_2083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInDiscountRateAmount_2083" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfUSDollar" xlink:label="loc_gsk_AppreciationOfUSDollar_2086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_AppreciationOfUSDollar_2086" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfUSDollar" xlink:label="loc_gsk_DepreciationOfUSDollar_2087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DepreciationOfUSDollar_2087" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AppreciationOfEuro" xlink:label="loc_gsk_AppreciationOfEuro_2088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_AppreciationOfEuro_2088" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DepreciationOfEuro" xlink:label="loc_gsk_DepreciationOfEuro_2089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DepreciationOfEuro_2089" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess_1702475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_IncreaseInProbabilityOfMilestoneSuccess_1702475" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseInProbabilityOfMilestoneSuccess" xlink:label="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess_1702476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems_2075" xlink:to="loc_gsk_DecreaseInProbabilityOfMilestoneSuccess_1702476" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationAbstract" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract_2058" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationTable" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationAbstract_2058" xlink:to="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2059" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesMember" xlink:label="loc_gsk_NovartisVaccinesMember_2146646271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_NovartisVaccinesMember_2146646271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2069" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2062" xlink:to="loc_gsk_AffinivaxMember_1702440" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_RangeAxis_2063" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2063" xlink:to="loc_ifrs-full_RangesMember_2064" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1190663" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1190664" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1320669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1320669" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1320669" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialisedProductsMember" xlink:label="loc_gsk_CommercialisedProductsMember_1192112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" xlink:to="loc_gsk_CommercialisedProductsMember_1192112" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineAssetsMember" xlink:label="loc_gsk_PipelineAssetsMember_1192116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1320670" xlink:to="loc_gsk_PipelineAssetsMember_1192116" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueOfContingentConsiderationLineItems" xlink:label="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationTable_2061" xlink:to="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesCurrent" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesCurrent_2065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesCurrent_2065" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationPayableDiscountedPercentage" xlink:label="loc_gsk_ContingentConsiderationPayableDiscountedPercentage_2067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_ContingentConsiderationPayableDiscountedPercentage_2067" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalOfInterestInAssociate" xlink:label="loc_gsk_GainLossOnDisposalOfInterestInAssociate_1702443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems_2060" xlink:to="loc_gsk_GainLossOnDisposalOfInterestInAssociate_1702443" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentLiabilitiesAbstract" xlink:label="loc_gsk_OtherNoncurrentLiabilitiesAbstract_1559" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-full_Accruals_1560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherNoncurrentLiabilitiesAbstract_1559" xlink:to="loc_ifrs-full_Accruals_1560" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets" xlink:label="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets_1561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherNoncurrentLiabilitiesAbstract_1559" xlink:to="loc_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets_1561" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="loc_ifrs-full_OtherNoncurrentPayables_1562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherNoncurrentLiabilitiesAbstract_1559" xlink:to="loc_ifrs-full_OtherNoncurrentPayables_1562" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_1563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_OtherNoncurrentLiabilitiesAbstract_1559" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_1563" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1694" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1694" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_1695" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_1696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1694" xlink:to="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_1696" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfCommitmentsAbstract" xlink:label="loc_gsk_DisclosureOfCommitmentsAbstract_2170" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_2146644877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfCommitmentsAbstract_2170" xlink:to="loc_gsk_StatementsTable_2146644877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_2146644878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_2146644877" xlink:to="loc_gsk_StatementsLineItems_2146644878" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit" xlink:label="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit_2146643256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_2146644878" xlink:to="loc_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit_2146643256" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalContributionUnpaid" xlink:label="loc_gsk_AdditionalContributionUnpaid_2146646575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_2146644878" xlink:to="loc_gsk_AdditionalContributionUnpaid_2146646575" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract" xlink:label="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_2160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_2160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_2161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_2161" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInvestments" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfInvestments_2162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitmentsOfInvestments_2162" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments_2163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments_2163" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfPensions" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfPensions_2164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitmentsOfPensions_2164" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans_2166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans_2166" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges" xlink:label="loc_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges_624885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges_624885" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced" xlink:label="loc_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced_2146643196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced_2146643196" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContractualObligationsAndCommitments" xlink:label="loc_gsk_ContractualObligationsAndCommitments_2168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract_2159" xlink:to="loc_gsk_ContractualObligationsAndCommitments_2168" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract_1698" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:label="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract_1698" xlink:to="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1701" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1701" xlink:to="loc_ifrs-full_EquityMember_1705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1705" xlink:to="loc_ifrs-full_SharePremiumMember_1716" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1705" xlink:to="loc_ifrs-full_IssuedCapitalMember_1717" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1699" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1700" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_1706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1700" xlink:to="loc_ifrs-full_OrdinarySharesMember_1706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1703" xlink:to="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1707" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ImpactOfShareConsolidationShares" xlink:label="loc_gsk_ImpactOfShareConsolidationShares_2146643197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_ImpactOfShareConsolidationShares_2146643197" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes" xlink:label="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes_1710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes_1710" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts" xlink:label="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts_1711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts_1711" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1712" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_Equity_1704" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_IssueOfEquity_1713" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_1714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_1714" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1702" xlink:to="loc_ifrs-full_Equity_1715" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract_1726" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable" xlink:label="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract_1726" xlink:to="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1727" xlink:to="loc_ifrs-full_EquityMember_1730" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeShareOwnershipPlanMember" xlink:label="loc_gsk_EmployeeShareOwnershipPlanMember_1732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_EmployeeShareOwnershipPlanMember_1732" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="loc_ifrs-full_TreasurySharesMember_1733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_ifrs-full_TreasurySharesMember_1733" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeIssueMember" xlink:label="loc_gsk_FreeIssueMember_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_FreeIssueMember_1734" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember" xlink:label="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember_2147451203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1730" xlink:to="loc_gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember_2147451203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsAxis" xlink:label="loc_gsk_DetailsAxis_2146646584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_gsk_DetailsAxis_2146646584" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DetailsMember" xlink:label="loc_gsk_DetailsMember_2146646585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DetailsAxis_2146646584" xlink:to="loc_gsk_DetailsMember_2146646585" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2146647263" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_2146647266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2146647264" xlink:to="loc_ifrs-full_OrdinarySharesMember_2146647266" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems" xlink:label="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable_1729" xlink:to="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_NumberOfSharesIssued_1731" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_2146644919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_ParValuePerShare_2146644919" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ParValueOfSharesSurrenderedInLieuOfNewShares" xlink:label="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares_2146643049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares_2146643049" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SurrenderedSharesForEveryFourNewSharesReceived" xlink:label="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived_2146643050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_SurrenderedSharesForEveryFourNewSharesReceived_2146643050" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SharesReceivedForEveryFiveExistingShares" xlink:label="loc_gsk_SharesReceivedForEveryFiveExistingShares_2146643052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_SharesReceivedForEveryFiveExistingShares_2146643052" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_2146643067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_2146643067" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DateOfShareConsolidationApproval" xlink:label="loc_gsk_DateOfShareConsolidationApproval_2147451197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_DateOfShareConsolidationApproval_2147451197" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessDemerger" xlink:label="loc_gsk_ConsumerHealthcareBusinessDemerger_2147451199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems_1728" xlink:to="loc_gsk_ConsumerHealthcareBusinessDemerger_2147451199" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_1736" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_1736" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1742" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityAxis" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xlink:to="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MiscellaneousComponentsOfEquityDomain" xlink:label="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityAxis_1739" xlink:to="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDistributableMergerAndPreMergerReservesMember" xlink:label="loc_gsk_NonDistributableMergerAndPreMergerReservesMember_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" xlink:to="loc_gsk_NonDistributableMergerAndPreMergerReservesMember_1744" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalRedemptionReserveMember" xlink:label="loc_ifrs-full_CapitalRedemptionReserveMember_1745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_MiscellaneousComponentsOfEquityDomain_1740" xlink:to="loc_ifrs-full_CapitalRedemptionReserveMember_1745" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1737" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1737" xlink:to="loc_ifrs-full_EquityMember_1738" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesMember" xlink:label="loc_gsk_AssociatesAndJointVenturesMember_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1738" xlink:to="loc_gsk_AssociatesAndJointVenturesMember_1743" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1742" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RetainedEarningsAndOtherReserves" xlink:label="loc_gsk_RetainedEarningsAndOtherReserves_1746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" xlink:to="loc_gsk_RetainedEarningsAndOtherReserves_1746" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1741" xlink:to="loc_ifrs-full_OtherReserves_1747" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_1749" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_1749" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1753" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1750" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1750" xlink:to="loc_ifrs-full_EquityMember_1751" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_ifrs-full_RetainedEarningsMember_1754" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueReserveMember" xlink:label="loc_gsk_FairValueReserveMember_1755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_gsk_FairValueReserveMember_1755" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1751" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_1756" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_627250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_627248" xlink:to="loc_ifrs-full_RestatedMember_627250" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1753" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1757" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_1758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_1758" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_632963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_632963" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_1760" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToContinuingOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations_2146643189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_gsk_MovementInTranslationExchangeAttributableToContinuingOperations_2146643189" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations" xlink:label="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations_2146643190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1752" xlink:to="loc_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations_2146643190" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_2146644943" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_2146644943" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_2146643181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_2146643182" xlink:to="loc_ifrs-full_ContinuingOperationsMember_2146643181" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_2146643180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingOperationsMember_2146643181" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_2146643180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2146643185" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2146643184" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventAxis" xlink:label="loc_gsk_EventAxis_2146643188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_gsk_EventAxis_2146643188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventDomain" xlink:label="loc_gsk_EventDomain_2146643187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventAxis_2146643188" xlink:to="loc_gsk_EventDomain_2146643187" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DemergerMember" xlink:label="loc_gsk_DemergerMember_2146643186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventDomain_2146643187" xlink:to="loc_gsk_DemergerMember_2146643186" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_2146644960" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_2146643042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_2146644961" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_2146643042" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_2146644947" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_2146644959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2146644951" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_2146644959" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_1762" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_1762" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1768" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1768" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1763" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1763" xlink:to="loc_ifrs-full_EquityMember_1766" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_RetainedEarningsMember_1786" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_OtherReservesMember_1787" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1766" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_1788" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1768" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges_1769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges_1769" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_1770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_1770" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_1776" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_1777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax_1777" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1764" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1778" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1767" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests" xlink:label="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests_1780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests_1780" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_1781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_1781" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments" xlink:label="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments_1782" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_1783" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_1784" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges" xlink:label="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges_2147457542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges_2147457542" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations_1702477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperations_1702477" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations_2146646278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations_2146646278" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_1765" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_1785" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_1790" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_1790" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1794" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1794" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1791" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1791" xlink:to="loc_ifrs-full_EquityMember_1792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EsopTrustMember" xlink:label="loc_gsk_EsopTrustMember_1795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_gsk_EsopTrustMember_1795" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueReserveMember" xlink:label="loc_gsk_FairValueReserveMember_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_gsk_FairValueReserveMember_1796" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesMember" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesMember_1797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesMember_1797" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1792" xlink:to="loc_ifrs-full_OtherReservesMember_1798" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1794" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_ifrs-full_OtherReserves_1799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeAdjustments" xlink:label="loc_gsk_ExchangeAdjustments_1802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_ExchangeAdjustments_1802" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments" xlink:label="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments_1804" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFairValueMovements" xlink:label="loc_gsk_NetFairValueMovements_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_NetFairValueMovements_1806" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves" xlink:label="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves_1807" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WritedownOfSharesHeldByEsopTrusts" xlink:label="loc_gsk_WritedownOfSharesHeldByEsopTrusts_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_WritedownOfSharesHeldByEsopTrusts_1808" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BalanceAmountDerecognisedOnDemerger" xlink:label="loc_gsk_BalanceAmountDerecognisedOnDemerger_2146643066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_BalanceAmountDerecognisedOnDemerger_2146643066" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments" xlink:label="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments_2146643174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments_2146643174" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1793" xlink:to="loc_ifrs-full_OtherReserves_1809" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNonControllingInterestsAbstract" xlink:label="loc_gsk_DisclosureOfNonControllingInterestsAbstract_2137" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsTable" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNonControllingInterestsAbstract_2137" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2138" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" xlink:to="loc_gsk_ViiVHealthCareMember_2145" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_2147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2141" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_2147" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2140" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2142" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_624971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_624971" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition" xlink:label="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition_627358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2139" xlink:to="loc_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition_627358" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNonControllingInterestsAbstract" xlink:label="loc_gsk_DisclosureOfNonControllingInterestsAbstract_2111" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsTable" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNonControllingInterestsAbstract_2111" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2112" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2112" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" xlink:to="loc_gsk_ViiVHealthCareMember_2134" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareJointVentureMember" xlink:label="loc_gsk_ConsumerHealthCareJointVentureMember_2135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2115" xlink:to="loc_gsk_ConsumerHealthCareJointVentureMember_2135" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNoncontrollingInterestsLineItems" xlink:label="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsTable_2114" xlink:to="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_2116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests_2116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToNoncontrollingInterests" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterests_2117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterests_2117" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_2118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncontrollingInterests_2118" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_2119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Revenue_2119" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2120" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_2121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_2121" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2122" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_2123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncurrentAssets_2123" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_2124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CurrentAssets_2124" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_2125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Assets_2125" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_2126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CurrentLiabilities_2126" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_2127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NoncurrentLiabilities_2127" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_2128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_Liabilities_2128" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_2129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_NetAssetsLiabilities_2129" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2130" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2131" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2132" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndBankOverdrafts" xlink:label="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts_2133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNoncontrollingInterestsLineItems_2113" xlink:to="loc_gsk_IncreaseDecreaseInCashAndBankOverdrafts_2133" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1811" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1811" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1813" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MedicxiVenturesILimitedPartnerMember" xlink:label="loc_gsk_MedicxiVenturesILimitedPartnerMember_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_MedicxiVenturesILimitedPartnerMember_1833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ApolloTherapeuticsLLPMember" xlink:label="loc_gsk_ApolloTherapeuticsLLPMember_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_ApolloTherapeuticsLLPMember_1836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongwoodFoundersFundLPMember" xlink:label="loc_gsk_LongwoodFoundersFundLPMember_1837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_LongwoodFoundersFundLPMember_1837" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_QuraTherapeuticsLLCMember" xlink:label="loc_gsk_QuraTherapeuticsLLCMember_1838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1817" xlink:to="loc_gsk_QuraTherapeuticsLLCMember_1838" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1812" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1812" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1816" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_1815" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LoansReceivableMadeByEntityRelatedPartyTransactions" xlink:label="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions_1826" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentIncome" xlink:label="loc_ifrs-full_InvestmentIncome_600763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_ifrs-full_InvestmentIncome_600763" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AgreementExtensionPeriod" xlink:label="loc_gsk_AgreementExtensionPeriod_627141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_AgreementExtensionPeriod_627141" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentObligation" xlink:label="loc_gsk_InvestmentObligation_1316185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_1814" xlink:to="loc_gsk_InvestmentObligation_1316185" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_1916" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_1916" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1919" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1919" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember" xlink:label="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember_1968" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerBiotechCorporationTaiwanMember" xlink:label="loc_gsk_PfizerBiotechCorporationTaiwanMember_829348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_PfizerBiotechCorporationTaiwanMember_829348" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_860580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_HorlicksMember_860580" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_1307797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_ifrs-full_BusinessCombinationsMember_1307797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyIncMember" xlink:label="loc_gsk_SierraOncologyIncMember_1704171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_SierraOncologyIncMember_1704171" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_1704187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_AffinivaxIncMember_1704187" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember_1704206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember_1704206" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSaudiArabiaLimitedMember" xlink:label="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1926" xlink:to="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643178" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1936" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssociatesMember" xlink:label="loc_ifrs-full_AssociatesMember_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_1925" xlink:to="loc_ifrs-full_AssociatesMember_1962" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1917" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember_1937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1918" xlink:to="loc_ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember_1937" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1920" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalsMember_831827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_TwoThousandTwentyBusinessDisposalsMember_831827" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307795" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307811" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthcareBusinessMember" xlink:label="loc_gsk_ConsumerHealthcareBusinessMember_1704230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1921" xlink:to="loc_gsk_ConsumerHealthcareBusinessMember_1704230" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1932" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1933" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_dei_LegalEntityAxis_1931" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1931" xlink:to="loc_dei_EntityDomain_1924" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerMember" xlink:label="loc_gsk_PfizerMember_1961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1924" xlink:to="loc_gsk_PfizerMember_1961" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_1930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_JointVenturesAxis_1930" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_1930" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BangladeshConsumerHealthcareMember" xlink:label="loc_gsk_BangladeshConsumerHealthcareMember_1224218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_1927" xlink:to="loc_gsk_BangladeshConsumerHealthcareMember_1224218" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_srt_OwnershipAxis_1934" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1934" xlink:to="loc_srt_OwnershipDomain_1935" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskShareholdersMember" xlink:label="loc_gsk_GskShareholdersMember_1704236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskShareholdersMember_1704236" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAndGsksConsolidatedEsotTrustsMember" xlink:label="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember_1704238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskAndGsksConsolidatedEsotTrustsMember_1704238" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ScottishLimitedPartnershipsMember" xlink:label="loc_gsk_ScottishLimitedPartnershipsMember_1704239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_ScottishLimitedPartnershipsMember_1704239" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskAggregateHoldingMember" xlink:label="loc_gsk_GskAggregateHoldingMember_1704241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskAggregateHoldingMember_1704241" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskHoldingMember" xlink:label="loc_gsk_GskHoldingMember_1704264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1935" xlink:to="loc_gsk_GskHoldingMember_1704264" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1928" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1928" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1929" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_513639" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_513640" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeAxis" xlink:label="loc_gsk_ArrangementTypeAxis_858156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_ArrangementTypeAxis_858156" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ArrangementTypeDomain" xlink:label="loc_gsk_ArrangementTypeDomain_858157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeAxis_858156" xlink:to="loc_gsk_ArrangementTypeDomain_858157" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConsumerHealthCareBangladeshMember" xlink:label="loc_gsk_ConsumerHealthCareBangladeshMember_1223887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ArrangementTypeDomain_858157" xlink:to="loc_gsk_ConsumerHealthCareBangladeshMember_1223887" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1307806" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InnovivaIncMember" xlink:label="loc_gsk_InnovivaIncMember_1307810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1307808" xlink:to="loc_gsk_InnovivaIncMember_1307810" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentAxis" xlink:label="loc_gsk_InvestmentAxis_1704225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_gsk_InvestmentAxis_1704225" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentDomain" xlink:label="loc_gsk_InvestmentDomain_1704226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentAxis_1704225" xlink:to="loc_gsk_InvestmentDomain_1704226" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HaleonPlcMember" xlink:label="loc_gsk_HaleonPlcMember_1704228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_InvestmentDomain_1704226" xlink:to="loc_gsk_HaleonPlcMember_1704228" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1923" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_1943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_1943" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDistributed" xlink:label="loc_gsk_PercentageOfOwnershipDistributed_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageOfOwnershipDistributed_1944" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfOwnershipDivested" xlink:label="loc_gsk_PercentageOfOwnershipDivested_2146643076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageOfOwnershipDivested_2146643076" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashInvestmentsInJointVenturesAndAssociates" xlink:label="loc_gsk_CashInvestmentsInJointVenturesAndAssociates_1950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CashInvestmentsInJointVenturesAndAssociates_1950" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1951" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration" xlink:label="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration_846656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration_846656" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_1956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_Goodwill_1956" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_1960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_1960" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_513890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_513890" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_513891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_CashTransferred_513891" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted" xlink:label="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted_589087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted_589087" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsMadeForTransactionCostsAndOther" xlink:label="loc_gsk_PaymentsMadeForTransactionCostsAndOther_625042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PaymentsMadeForTransactionCostsAndOther_625042" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-full_OtherAssets_829339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_OtherAssets_829339" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_829344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_NetAssetsLiabilities_829344" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:label="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_858471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_858471" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InvestmentOwnedNumberOfSharesDisposedOff" xlink:label="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff_1307799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_InvestmentOwnedNumberOfSharesDisposedOff_1307799" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare" xlink:label="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare_1307800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare_1307800" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GrossProceedsFromDisposalOfInterestInAssociates" xlink:label="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates_1307801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GrossProceedsFromDisposalOfInterestInAssociates_1307801" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationPotentialMilestonePaymentPerTranche" xlink:label="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche_1704200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche_1704200" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="loc_ifrs-full_AdditionalRecognitionGoodwill_1704207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_AdditionalRecognitionGoodwill_1704207" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageofGSKHolding" xlink:label="loc_gsk_PercentageofGSKHolding_2146645633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_PercentageofGSKHolding_2146645633" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancing" xlink:label="loc_gsk_DividendFundedByDebtFinancing_2146645637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendFundedByDebtFinancing_2146645637" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationConsiderationPayableForStepAcquisition" xlink:label="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition_2146643175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationConsiderationPayableForStepAcquisition_2146643175" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired" xlink:label="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired_2146643177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired_2146643177" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendsDistributedFromCashBalance" xlink:label="loc_gsk_DividendsDistributedFromCashBalance_1704271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendsDistributedFromCashBalance_1704271" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheAssetsDistributed" xlink:label="loc_gsk_FairValueOfTheAssetsDistributed_1704283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_FairValueOfTheAssetsDistributed_1704283" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfHolding" xlink:label="loc_gsk_FairValueOfHolding_1704291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_FairValueOfHolding_1704291" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2146645006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2146645006" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilityEliminatedOnDemerger" xlink:label="loc_gsk_LiabilityEliminatedOnDemerger_2146645067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_LiabilityEliminatedOnDemerger_2146645067" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount" xlink:label="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount_2146645077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount_2146645077" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionalGainOnRemeasurementOfRetainedStake" xlink:label="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake_2146645104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_AdditionalGainOnRemeasurementOfRetainedStake_2146645104" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerOfDiscontinuedOperation" xlink:label="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645106" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves" xlink:label="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves_2146645107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves_2146645107" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendFundedByDebtFinancingAttributableToGsk" xlink:label="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk_2146645640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendFundedByDebtFinancingAttributableToGsk_2146645640" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk_2146645641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_DividendsDistributedFromCashBalanceAttributableToGsk_2146645641" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest_2147450239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest_2147450239" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashTransferredOnDisposal" xlink:label="loc_gsk_CashTransferredOnDisposal_2147451214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1922" xlink:to="loc_gsk_CashTransferredOnDisposal_2147451214" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_513848" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_513848" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_513850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_JointVenturesAxis_513850" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_513850" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_513851" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_513861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_513861" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_513861" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PfizerBiotechCorporationTaiwanMember" xlink:label="loc_gsk_PfizerBiotechCorporationTaiwanMember_846657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" xlink:to="loc_gsk_PfizerBiotechCorporationTaiwanMember_846657" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoAcquisitionMember" xlink:label="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_513862" xlink:to="loc_gsk_TwoThousandTwentyTwoAcquisitionMember_1702807" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1702804" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SierraOncologyMember" xlink:label="loc_gsk_SierraOncologyMember_1702801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" xlink:to="loc_gsk_SierraOncologyMember_1702801" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1702806" xlink:to="loc_gsk_AffinivaxMember_1702802" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_513849" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsAcquiredAbstract" xlink:label="loc_gsk_NetAssetsAcquiredAbstract_513865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NetAssetsAcquiredAbstract_513865" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_513866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_513866" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_513867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_513867" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_625078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_RightofuseAssets_625078" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate_513868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_InventoryRecognisedAsOfAcquisitionDate_513868" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate_513869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate_513869" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_829311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_829311" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate_1702846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate_1702846" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_513871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_513871" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TaxationRecognizedAsOfAcquisitionDate" xlink:label="loc_gsk_TaxationRecognizedAsOfAcquisitionDate_1702848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_TaxationRecognizedAsOfAcquisitionDate_1702848" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate_829315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate_829315" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonControllingInterestRecognisedAsOfAcquisitionDate" xlink:label="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate_513874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_NetAssetsAcquiredAbstract_513865" xlink:to="loc_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate_513874" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-full_Goodwill_513875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_Goodwill_513875" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate" xlink:label="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate_513881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate_513881" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1702865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1702865" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_1702867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_1702867" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NoncashConsiderationForSettlementOfAPromissoryNote" xlink:label="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote_846833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_gsk_NoncashConsiderationForSettlementOfAPromissoryNote_846833" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_513880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_513864" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_513880" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_1702884" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheConsumerHealthcareBusinessDistributed" xlink:label="loc_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed_1702885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed_1702885" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfTheRetainedOwnershipInHaleonPlc" xlink:label="loc_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc_1702886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc_1702886" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TotalfairValueOfDistributedandRetainBusiness" xlink:label="loc_gsk_TotalfairValueOfDistributedandRetainBusiness_2146645051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_TotalfairValueOfDistributedandRetainBusiness_2146645051" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed" xlink:label="loc_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed_1702887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed_1702887" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingAmountOfTheNciDerecognized" xlink:label="loc_gsk_CarryingAmountOfTheNciDerecognized_1702888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_CarryingAmountOfTheNciDerecognized_1702888" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts" xlink:label="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2147451088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts_2147451088" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries" xlink:label="loc_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries_1702891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries_1702891" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainOnDemergerOfDiscontinuedOperation" xlink:label="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702884" xlink:to="loc_gsk_GainOnDemergerOfDiscontinuedOperation_2146645054" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TextBlockAbstract" xlink:label="loc_gsk_TextBlockAbstract_1702947" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TextBlockAbstract_1702947" xlink:to="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" xlink:to="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="loc_ifrs-full_ContinuingOperationsMember_1702950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingAndDiscontinuedOperationsAxis_1702949" xlink:to="loc_ifrs-full_ContinuingOperationsMember_1702950" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="loc_ifrs-full_DiscontinuedOperationsMember_1702951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingOperationsMember_1702950" xlink:to="loc_ifrs-full_DiscontinuedOperationsMember_1702951" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable_1702948" xlink:to="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1702953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_Revenue_1702953" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_1702954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_OperatingExpense_1702954" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_1702955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_1702955" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1702956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1702956" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1702957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1702957" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1702958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_1702958" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherGainsLossesOnDemerger" xlink:label="loc_gsk_OtherGainsLossesOnDemerger_2146645055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_OtherGainsLossesOnDemerger_2146645055" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger" xlink:label="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_2146645056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger_2146645056" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations" xlink:label="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations_1702961" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1702959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests_1702959" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1702960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_1702960" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1702962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems_1702952" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1702962" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_829370" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_829370" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_829376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_829376" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_829376" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyBusinessDisposalMember" xlink:label="loc_gsk_TwoThousandTwentyBusinessDisposalMember_2146645402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_829377" xlink:to="loc_gsk_TwoThousandTwentyBusinessDisposalMember_2146645402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_829408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_ifrs-full_JointVenturesAxis_829408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_829408" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HorlicksMember" xlink:label="loc_gsk_HorlicksMember_829410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" xlink:to="loc_gsk_HorlicksMember_829410" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherMember" xlink:label="loc_gsk_OtherMember_829413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_829409" xlink:to="loc_gsk_OtherMember_829413" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1307826" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1307827" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307828" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_829373" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments" xlink:label="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments_829381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments_829381" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalOfEquity" xlink:label="loc_gsk_DisposalOfEquity_829387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_DisposalOfEquity_829387" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_829390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations_829390" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_829391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_AssetsAbstract_829391" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsGoodwill" xlink:label="loc_gsk_DisposalsGoodwill_829392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsGoodwill_829392" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsIntangibleAssets" xlink:label="loc_gsk_DisposalsIntangibleAssets_829393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsIntangibleAssets_829393" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_829394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_829394" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsInventory" xlink:label="loc_gsk_DisposalsInventory_829396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsInventory_829396" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_829398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_ifrs-full_CashTransferred_829398" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetAssets" xlink:label="loc_gsk_DisposalsOtherNetAssets_829399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsOtherNetAssets_829399" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsOtherNetLiabilitiesOrAssets" xlink:label="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets_2146643006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalsOtherNetLiabilitiesOrAssets_2146643006" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupAssetsNet" xlink:label="loc_gsk_DisposalGroupAssetsNet_829401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DisposalGroupAssetsNet_829401" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DealCostsPayable" xlink:label="loc_gsk_DealCostsPayable_1307821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_829391" xlink:to="loc_gsk_DealCostsPayable_1307821" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_gsk_TransactionCostsOnDisposal_829402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_TransactionCostsOnDisposal_829402" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnEmbeddedDerivativeTransaction" xlink:label="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_829403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_GainLossOnEmbeddedDerivativeTransaction_829403" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_829404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_829404" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalGroupLiabilityNet" xlink:label="loc_gsk_DisposalGroupLiabilityNet_829407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_DisposalGroupLiabilityNet_829407" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainLossOnDisposalsOfBusiness" xlink:label="loc_gsk_GainLossOnDisposalsOfBusiness_829417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_829374" xlink:to="loc_gsk_GainLossOnDisposalsOfBusiness_829417" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_1976" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_1976" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1977" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1977" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="loc_ifrs-full_BusinessCombinationsMember_1994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_ifrs-full_BusinessCombinationsMember_1994" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyOneBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_gsk_TwoThousandAndTwentyOneBusinessDisposalsMember_1307842" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1982" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember_1307844" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationAxis" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContinuingAndDiscontinuedOperationMember" xlink:label="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationAxis_1978" xlink:to="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AcquisitionsTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember_846665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_AcquisitionsTwoThousandAndTwentyTwoMember_846665" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember" xlink:label="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember_849156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember_849156" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember" xlink:label="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember_1703287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember_1703287" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashFlowsInTwoThousandAndTwentyTwoMember" xlink:label="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember_1706862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_CashFlowsInTwoThousandAndTwentyTwoMember_1706862" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandTwentyTwoBusinessDisposalsMember" xlink:label="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember_1706864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ContinuingAndDiscontinuedOperationMember_1979" xlink:to="loc_gsk_TwoThousandTwentyTwoBusinessDisposalsMember_1706864" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1981" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_1989" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DeferredConsiderationReceived" xlink:label="loc_gsk_DeferredConsiderationReceived_1990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_DeferredConsiderationReceived_1990" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashOutflowInflowExcludingTransactionCosts" xlink:label="loc_gsk_CashOutflowInflowExcludingTransactionCosts_846667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_CashOutflowInflowExcludingTransactionCosts_846667" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_1991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_1991" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransactionCostsOnDisposal" xlink:label="loc_gsk_TransactionCostsOnDisposal_589055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_gsk_TransactionCostsOnDisposal_589055" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1980" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1993" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_2146645019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_2146645019" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_1843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_1843" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures" xlink:label="loc_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures_1844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures_1844" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_1845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_1845" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_1846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_1846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_1847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_1847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForImpairmentAndAssetsWrittenOff" xlink:label="loc_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff_1848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff_1848" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfBusinesses" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfBusinesses_1849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForProfitOnSaleOfBusinesses_1849" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets_1850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets_1850" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates_1851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates_1851" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForProfitOnSaleOfEquityInvestments" xlink:label="loc_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments_1852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments_1852" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ChangesInWorkingCapitalAbstract" xlink:label="loc_gsk_ChangesInWorkingCapitalAbstract_1225367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_ChangesInWorkingCapitalAbstract_1225367" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ChangesInWorkingCapitalAbstract_1225367" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1856" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_1857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ChangesInWorkingCapitalAbstract_1225367" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_1857" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_ChangesInWorkingCapitalAbstract_1225367" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1858" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_1859" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_1860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid_1860" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities" xlink:label="loc_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities_1861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities_1861" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_1862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_1862" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_1863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_1863" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_1864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_1864" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_1865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_1865" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_1866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_1866" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_2146643074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_2146643074" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_2146643075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_2146643075" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1840" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_1855" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract_1869" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsTable" xlink:label="loc_gsk_StatementsTable_512796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract_1869" xlink:to="loc_gsk_StatementsTable_512796" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_512796" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_512802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_512801" xlink:to="loc_ifrs-full_RestatedMember_512802" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StatementsLineItems" xlink:label="loc_gsk_StatementsLineItems_512799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsTable_512796" xlink:to="loc_gsk_StatementsLineItems_512799" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_Borrowings_1870" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations" xlink:label="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations_1871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations_1871" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInLiquidInvestment" xlink:label="loc_gsk_DecreaseIncreaseInLiquidInvestment_1872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInLiquidInvestment_1872" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_1873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_1873" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_1874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_1874" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings" xlink:label="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_1875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings_1875" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1702502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1702502" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentsOfFinanceLeaseLiabilities" xlink:label="loc_gsk_PaymentsOfFinanceLeaseLiabilities_1876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_PaymentsOfFinanceLeaseLiabilities_1876" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtOfSubsidiaryUndertakingsAcquired" xlink:label="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired_589110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DebtOfSubsidiaryUndertakingsAcquired_589110" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExchangeOnNetDebt" xlink:label="loc_gsk_ExchangeOnNetDebt_1877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_ExchangeOnNetDebt_1877" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherAdjustmentsForNoncashItemsToNetDebt" xlink:label="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt_1878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_OtherAdjustmentsForNoncashItemsToNetDebt_1878" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromContinuingOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations_2146645059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations_2146645059" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations" xlink:label="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations_2146645060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations_2146645060" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_StatementsLineItems_512799" xlink:to="loc_ifrs-full_Borrowings_1880" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfNetDebtAbstract" xlink:label="loc_gsk_DisclosureOfNetDebtAbstract_1882" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfNetDebtAbstract_1882" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_1888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1885" xlink:to="loc_ifrs-full_FinancialAssetsMember_1888" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsMember" xlink:label="loc_gsk_LiquidInvestmentsMember_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsMember_1903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentMember" xlink:label="loc_gsk_CashAndCashEquivalentMember_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_CashAndCashEquivalentMember_1904" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankOverdrafts1Member" xlink:label="loc_gsk_BankOverdrafts1Member_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_BankOverdrafts1Member_1906" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndBankOverdraftsMember" xlink:label="loc_gsk_CashAndBankOverdraftsMember_1907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_CashAndBankOverdraftsMember_1907" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialInstrumentsMember" xlink:label="loc_gsk_DerivativeFinancialInstrumentsMember_1908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_DerivativeFinancialInstrumentsMember_1908" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalentsMember" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember_2146643085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsCashAndCashEquivalentsMember_2146643085" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember_2146645074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsAttributedToContinuingOperationsMember_2146645074" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember_2146645075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_1888" xlink:to="loc_gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember_2146645075" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1883" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1883" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1884" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaper1Member" xlink:label="loc_gsk_CommercialPaper1Member_1891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_CommercialPaper1Member_1891" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember" xlink:label="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember_1892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember_1892" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_513538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_513538" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCurrentDebtMember" xlink:label="loc_gsk_OtherCurrentDebtMember_1893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_OtherCurrentDebtMember_1893" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsContinuingOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsContinuingOperationsMember_2146643258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_LongTermBorrowingsContinuingOperationsMember_2146643258" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LongTermBorrowingsDiscontinuedOperationsMember" xlink:label="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember_2146643257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_LongTermBorrowingsDiscontinuedOperationsMember_2146643257" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember_2146645076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember_2146645076" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember" xlink:label="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember_2146645092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1884" xlink:to="loc_gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember_2146645092" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1889" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="loc_ifrs-full_ShorttermBorrowingsMember_1910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_ShorttermBorrowingsMember_1910" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_1911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_1911" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetDebtMember" xlink:label="loc_gsk_NetDebtMember_1912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_gsk_NetDebtMember_1912" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_1913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_1913" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AccruedInterestMember" xlink:label="loc_gsk_AccruedInterestMember_1914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1890" xlink:to="loc_gsk_AccruedInterestMember_1914" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1887" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations_2146642988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations_2146642988" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations_2146642980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations_2146642980" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations_2146642982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations_2146642982" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsCashAndCashEquivalents" xlink:label="loc_gsk_LiquidInvestmentsCashAndCashEquivalents_2146642968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiquidInvestmentsCashAndCashEquivalents_2146642968" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations_2146642979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations_2146642979" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations" xlink:label="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations_2146642981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations_2146642981" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1896" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_1897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_1897" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_1898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_1898" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1307577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_InterestExpense_1307577" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ChangeInFairValueOfNetDebt" xlink:label="loc_gsk_ChangeInFairValueOfNetDebt_1307579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_ChangeInFairValueOfNetDebt_1307579" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReclassificationOfNetDebt" xlink:label="loc_gsk_ReclassificationOfNetDebt_1900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_ReclassificationOfNetDebt_1900" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities" xlink:label="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities_2146643259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities_2146643259" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_1901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_1901" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndNetOfOverdrafts" xlink:label="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts_2146642969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_gsk_CashAndCashEquivalentsAndNetOfOverdrafts_2146642969" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1886" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1902" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2191" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2191" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2221" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareMember" xlink:label="loc_gsk_ViiVHealthCareMember_2283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2207" xlink:to="loc_gsk_ViiVHealthCareMember_2283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_2219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_SegmentsAxis_2219" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_2220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_2219" xlink:to="loc_ifrs-full_SegmentsMember_2220" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InLineWithOtherPharmaceuticalCompaniesMember" xlink:label="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember_2146642997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_2220" xlink:to="loc_gsk_InLineWithOtherPharmaceuticalCompaniesMember_2146642997" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2197" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2197" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2198" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsCommercialPaperProgramMember" xlink:label="loc_gsk_UsCommercialPaperProgramMember_2231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2198" xlink:to="loc_gsk_UsCommercialPaperProgramMember_2231" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroCommercialPaperProgrammeMember" xlink:label="loc_gsk_EuroCommercialPaperProgrammeMember_847270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2198" xlink:to="loc_gsk_EuroCommercialPaperProgrammeMember_847270" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInsuranceContractsAxis" xlink:label="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceContractsMember" xlink:label="loc_ifrs-full_InsuranceContractsMember_2212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInsuranceContractsAxis_2222" xlink:to="loc_ifrs-full_InsuranceContractsMember_2212" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GroupCreditEnhancementsAndCreditInsuranceMember" xlink:label="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember_2291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InsuranceContractsMember_2212" xlink:to="loc_gsk_GroupCreditEnhancementsAndCreditInsuranceMember_2291" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_2200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_CounterpartiesAxis_2200" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_2201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_2200" xlink:to="loc_ifrs-full_CounterpartiesMember_2201" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StateBankOfIndiaMember" xlink:label="loc_gsk_StateBankOfIndiaMember_2233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_2201" xlink:to="loc_gsk_StateBankOfIndiaMember_2233" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_RangeAxis_2217" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2217" xlink:to="loc_ifrs-full_RangesMember_2218" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2218" xlink:to="loc_ifrs-full_TopOfRangeMember_2293" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2223" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2223" xlink:to="loc_ifrs-full_InterestRateTypesMember_2213" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateSensitivityMember" xlink:label="loc_gsk_InterestRateSensitivityMember_2146642994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_2213" xlink:to="loc_gsk_InterestRateSensitivityMember_2146642994" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="loc_ifrs-full_ExternalCreditGradesAxis_2208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ExternalCreditGradesAxis_2208" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2208" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesMember" xlink:label="loc_ifrs-full_ExternalCreditGradesMember_2279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_ifrs-full_ExternalCreditGradesMember_2279" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BbbOrBaaMember" xlink:label="loc_gsk_BbbOrBaaMember_2280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_BbbOrBaaMember_2280" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBB-OrBaaThreeRatedMember" xlink:label="loc_gsk_BBB-OrBaaThreeRatedMember_2281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_BBB-OrBaaThreeRatedMember_2281" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LowerThanBBBBaa3Member" xlink:label="loc_gsk_LowerThanBBBBaa3Member_2146643026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2205" xlink:to="loc_gsk_LowerThanBBBBaa3Member_2146643026" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2224" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2224" xlink:to="loc_ifrs-full_TypesOfRisksMember_2225" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_2295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_ifrs-full_LiquidityRiskMember_2295" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_2296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_ifrs-full_CreditRiskMember_2296" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember_2146642990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember_2146642990" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember_2146642993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember_2146642993" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember_2146642996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember_2146642996" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember_2146642995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember_2146642995" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesaleAndRetailCreditRiskMember" xlink:label="loc_gsk_WholesaleAndRetailCreditRiskMember_2146643000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_WholesaleAndRetailCreditRiskMember_2146643000" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeRiskMember" xlink:label="loc_gsk_ForeignExchangeRiskMember_2146643004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2225" xlink:to="loc_gsk_ForeignExchangeRiskMember_2146643004" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_MaturityAxis_2216" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2216" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2192" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember_2226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_NotLaterThanThreeMonthsMember_2226" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2227" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2192" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_2146643124" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2210" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2210" xlink:to="loc_ifrs-full_GeographicalAreasMember_2211" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonUsaMember" xlink:label="loc_gsk_NonUsaMember_2285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_gsk_NonUsaMember_2285" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_2286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_US_2286" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NG" xlink:label="loc_country_NG_2287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_NG_2287" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GbMember" xlink:label="loc_gsk_GbMember_589301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_gsk_GbMember_589301" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_EC" xlink:label="loc_country_EC_1310394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_EC_1310394" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HN" xlink:label="loc_country_HN_1310395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_HN_1310395" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KH" xlink:label="loc_country_KH_1310396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_KH_1310396" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR" xlink:label="loc_country_CR_2146643234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_CR_2146643234" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="loc_country_BR_2146643235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2211" xlink:to="loc_country_BR_2146643235" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2215" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2193" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2229" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_2214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_JointVenturesAxis_2214" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_2214" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShionogiViiVHealthcareJointVentureMember" xlink:label="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_ShionogiViiVHealthcareJointVentureMember_2282" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WholesalerInTheUsMember" xlink:label="loc_gsk_WholesalerInTheUsMember_2146643027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_WholesalerInTheUsMember_2146643027" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NovartisVaccinesBusinessMember" xlink:label="loc_gsk_NovartisVaccinesBusinessMember_2146643028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_NovartisVaccinesBusinessMember_2146643028" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember" xlink:label="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember_2146643029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember_2146643029" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HalkBankMember" xlink:label="loc_gsk_HalkBankMember_2146643030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_HalkBankMember_2146643030" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ProdubancoMember" xlink:label="loc_gsk_ProdubancoMember_2146643031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_ProdubancoMember_2146643031" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDeHondurasMember" xlink:label="loc_gsk_BancoDeHondurasMember_2146643032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BancoDeHondurasMember_2146643032" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BancoDoBrasilMember" xlink:label="loc_gsk_BancoDoBrasilMember_2146643033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BancoDoBrasilMember_2146643033" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BacSanJoseMember" xlink:label="loc_gsk_BacSanJoseMember_2146643034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_BacSanJoseMember_2146643034" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JTrustRoyalBankMember" xlink:label="loc_gsk_JTrustRoyalBankMember_2146643035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2206" xlink:to="loc_gsk_JTrustRoyalBankMember_2146643035" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2199" xlink:to="loc_ifrs-full_FinancialAssetsMember_2209" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_858229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2209" xlink:to="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_858229" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2194" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2194" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2195" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BondsInDesignatedHedgingRelationshipMember" xlink:label="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2195" xlink:to="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2230" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DueFromThreeWholesalersMember" xlink:label="loc_gsk_DueFromThreeWholesalersMember_2146643039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2195" xlink:to="loc_gsk_DueFromThreeWholesalersMember_2146643039" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2196" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2196" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxMember" xlink:label="loc_gsk_AffinivaxMember_1702594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" xlink:to="loc_gsk_AffinivaxMember_1702594" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_2146643158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2204" xlink:to="loc_gsk_AffinivaxIncMember_2146643158" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeAxis" xlink:label="loc_gsk_TypeOfIncomeAxis_589337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_TypeOfIncomeAxis_589337" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TypeOfIncomeDomain" xlink:label="loc_gsk_TypeOfIncomeDomain_589338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_TypeOfIncomeAxis_589337" xlink:to="loc_gsk_TypeOfIncomeDomain_589338" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_589422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_589422" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_589424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_589422" xlink:to="loc_ifrs-full_TypesOfHedgesMember_589424" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_589425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_ifrs-full_CashFlowHedgesMember_589425" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:label="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_589431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_589431" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgedMember" xlink:label="loc_gsk_NetInvestmentHedgedMember_2146643038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_589424" xlink:to="loc_gsk_NetInvestmentHedgedMember_2146643038" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_857501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_857500" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_857501" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmortizedCostMember" xlink:label="loc_gsk_AmortizedCostMember_857504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_gsk_AmortizedCostMember_857504" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_858221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_858221" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_858228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_857501" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_858228" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_858571" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_858572" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisAxis" xlink:label="loc_gsk_EventBasisAxis_1224336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_EventBasisAxis_1224336" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EventBasisDomain" xlink:label="loc_gsk_EventBasisDomain_1224341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EventBasisAxis_1224336" xlink:to="loc_gsk_EventBasisDomain_1224341" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1310372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1310372" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1310374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1310372" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1310374" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_1310378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_1310374" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_1310378" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_1310379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_1310374" xlink:to="loc_gsk_ForeignExchangeContractsMember_1310379" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeAxis" xlink:label="loc_gsk_PurposeAxis_2146643244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_gsk_PurposeAxis_2146643244" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PurposeDomain" xlink:label="loc_gsk_PurposeDomain_2146643243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeAxis_2146643244" xlink:to="loc_gsk_PurposeDomain_2146643243" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PostSeparationOfTheConsumerHealthcareBusinessMember" xlink:label="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_PurposeDomain_2146643243" xlink:to="loc_gsk_PostSeparationOfTheConsumerHealthcareBusinessMember_2146643242" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2146643155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2146643156" xlink:to="loc_ifrs-full_LiabilitiesMember_2146643155" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitesOneMember" xlink:label="loc_gsk_FinancialLiabilitesOneMember_2146643154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_2146643155" xlink:to="loc_gsk_FinancialLiabilitesOneMember_2146643154" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2203" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_2234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_Borrowings_2234" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_631030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_Equity_631030" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAndDebtNet" xlink:label="loc_gsk_EquityAndDebtNet_2236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_EquityAndDebtNet_2236" use="optional" order="111" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestments" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments_2237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashAndCashEquivalentsAndLiquidInvestments_2237" use="optional" order="112" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld" xlink:label="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld_2238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld_2238" use="optional" order="113" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_NotionalAmount_2239" use="optional" order="114" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="loc_ifrs-full_CommercialPapersIssued_2240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_CommercialPapersIssued_2240" use="optional" order="115" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_2241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_2241" use="optional" order="116" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmountHeldAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme_2245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme_2245" use="optional" order="117" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme" xlink:label="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme_2246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme_2246" use="optional" order="118" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NotesIssuedUnderUsShelfRegistration" xlink:label="loc_gsk_NotesIssuedUnderUsShelfRegistration_2247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_NotesIssuedUnderUsShelfRegistration_2247" use="optional" order="119" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_2248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_2248" use="optional" order="120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure_2249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_CreditExposure_2249" use="optional" order="121" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterparties" xlink:label="loc_gsk_CashHeldAtUnratedCounterparties_2250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashHeldAtUnratedCounterparties_2250" use="optional" order="122" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement" xlink:label="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement_2251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement_2251" use="optional" order="123" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:label="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2252" use="optional" order="124" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BalancesWithBanks" xlink:label="loc_ifrs-full_BalancesWithBanks_2253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_BalancesWithBanks_2253" use="optional" order="125" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashReserves" xlink:label="loc_gsk_CashReserves_2254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashReserves_2254" use="optional" order="126" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashManagedForSubsidiaryCompany" xlink:label="loc_gsk_CashManagedForSubsidiaryCompany_2255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CashManagedForSubsidiaryCompany_2255" use="optional" order="127" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_2256" use="optional" order="128" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfAccountsReceivableByMajorCustomer" xlink:label="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer_2257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_PercentageOfAccountsReceivableByMajorCustomer_2257" use="optional" order="129" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ConcentrationsOfRiskRevenuePercentage" xlink:label="loc_gsk_ConcentrationsOfRiskRevenuePercentage_2259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_ConcentrationsOfRiskRevenuePercentage_2259" use="optional" order="130" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2262" use="optional" order="131" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan" xlink:label="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan_2263" use="optional" order="132" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="loc_ifrs-full_TreasuryShares_2264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TreasuryShares_2264" use="optional" order="133" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RemeasurementOfTheContingentConsiderationPayable" xlink:label="loc_gsk_RemeasurementOfTheContingentConsiderationPayable_2266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_RemeasurementOfTheContingentConsiderationPayable_2266" use="optional" order="134" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense" xlink:label="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense_2146643003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense_2146643003" use="optional" order="135" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2270" use="optional" order="136" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments" xlink:label="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments_2271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments_2271" use="optional" order="137" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2272" use="optional" order="138" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectiveness_589409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_GainLossOnHedgeIneffectiveness_589409" use="optional" order="139" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_857491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TradeReceivables_857491" use="optional" order="140" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_858220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_858220" use="optional" order="141" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied_1307532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied_1307532" use="optional" order="142" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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." xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements._1307539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements._1307539" use="optional" order="143" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement" xlink:label="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement_2146643036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement_2146643036" use="optional" order="144" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities" xlink:label="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities_2146643245" use="optional" order="145" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2146643160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_2146643160" use="optional" order="146" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_2146643159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_2146643159" use="optional" order="147" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_2146643157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2202" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_2146643157" use="optional" order="148" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresAbstract" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresAbstract_2299" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresTable" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresAbstract_2299" xlink:to="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="loc_ifrs-full_ExternalCreditGradesAxis_2303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xlink:to="loc_ifrs-full_ExternalCreditGradesAxis_2303" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExternalCreditGradesAxis_2303" xlink:to="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AAAOrAaaMember" xlink:label="loc_gsk_AAAOrAaaMember_2312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AAAOrAaaMember_2312" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AaOrAaMember" xlink:label="loc_gsk_AaOrAaMember_2313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AaOrAaMember_2313" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AorAMember" xlink:label="loc_gsk_AorAMember_2314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_AorAMember_2314" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BbbOrBaaMember" xlink:label="loc_gsk_BbbOrBaaMember_2315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_BbbOrBaaMember_2315" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BBPlusOrBaOneMember" xlink:label="loc_gsk_BBPlusOrBaOneMember_2316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForExternalCreditGradesMember_2302" xlink:to="loc_gsk_BBPlusOrBaOneMember_2316" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2304" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2304" xlink:to="loc_ifrs-full_TypesOfRisksMember_2305" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_2317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2305" xlink:to="loc_ifrs-full_CreditRiskMember_2317" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExternalCreditExposuresLineItems" xlink:label="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresTable_2301" xlink:to="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankBalancesAndDepositHeldWithCounterparties" xlink:label="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_BankBalancesAndDepositHeldWithCounterparties_2306" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds" xlink:label="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds_2307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds_2307" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidityFunds" xlink:label="loc_gsk_LiquidityFunds_2308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_LiquidityFunds_2308" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GovernmentSecurities" xlink:label="loc_gsk_GovernmentSecurities_2309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_gsk_GovernmentSecurities_2309" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_2310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_2310" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RatedCreditExposures" xlink:label="loc_ifrs-full_RatedCreditExposures_2311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfExternalCreditExposuresLineItems_2300" xlink:to="loc_ifrs-full_RatedCreditExposures_2311" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2319" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2319" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2320" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2320" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2321" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BondsInDesignatedHedgingRelationshipMember" xlink:label="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_BondsInDesignatedHedgingRelationshipMember_2332" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBondsMember" xlink:label="loc_gsk_OtherBondsMember_2333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherBondsMember_2333" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BankLoansAndOverdraftsMember" xlink:label="loc_gsk_BankLoansAndOverdraftsMember_2334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_BankLoansAndOverdraftsMember_2334" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CommercialPaperInADesignatedHedgingRelationshipMember" xlink:label="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember_2335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_CommercialPaperInADesignatedHedgingRelationshipMember_2335" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherCommercialPaperMember" xlink:label="loc_gsk_OtherCommercialPaperMember_1706563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherCommercialPaperMember_1706563" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherBorrowingMember" xlink:label="loc_gsk_OtherBorrowingMember_2336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2321" xlink:to="loc_gsk_OtherBorrowingMember_2336" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2325" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2331" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesMember" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesMember_2378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2331" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesMember_2378" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_513637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2331" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_513637" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2324" xlink:to="loc_ifrs-full_FinancialAssetsMember_2329" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityAndOtherInvestmentsMember" xlink:label="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643020" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsMember" xlink:label="loc_gsk_OtherInvestmentsMember_2360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_OtherInvestmentsMember_2360" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2361" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LiquidInvestmentsMember" xlink:label="loc_gsk_LiquidInvestmentsMember_2362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_LiquidInvestmentsMember_2362" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalents1Member" xlink:label="loc_gsk_CashAndCashEquivalents1Member_2363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_CashAndCashEquivalents1Member_2363" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2365" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2366" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_2367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2329" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_2367" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2323" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayableMember" xlink:label="loc_gsk_TradeAndOtherPayableMember_2373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_gsk_TradeAndOtherPayableMember_2373" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_2374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_ifrs-full_OtherProvisionsMember_2374" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNonCurrentLiabilitiesMember" xlink:label="loc_gsk_OtherNonCurrentLiabilitiesMember_2375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2330" xlink:to="loc_gsk_OtherNonCurrentLiabilitiesMember_2375" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2322" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2328" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2353" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_2354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_2354" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2355" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2328" xlink:to="loc_gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2356" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2327" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue_2337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue_2337" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_2338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialAssets_2338" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsExcludingObligationsUnderFinanceLease" xlink:label="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease_2343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_BorrowingsExcludingObligationsUnderFinanceLease_2343" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_2347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialLiabilities_2347" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsLiabilities" xlink:label="loc_gsk_NetFinancialAssetsLiabilities_2348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_NetFinancialAssetsLiabilities_2348" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_2349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_2349" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2351" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue" xlink:label="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue_2352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2326" xlink:to="loc_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue_2352" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_2382" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_2382" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_MeasurementAxis_2396" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_2396" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2383" xlink:to="loc_ifrs-full_AtFairValueMember_2397" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2395" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_2398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_2398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_2399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_2399" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2384" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2400" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2386" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2417" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember_2146645772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2393" xlink:to="loc_gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember_2146645772" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2385" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2391" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2391" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2403" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2391" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2404" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2388" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2394" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ContingentConsiderationLiabilitiesMember" xlink:label="loc_gsk_ContingentConsiderationLiabilitiesMember_2420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_ContingentConsiderationLiabilitiesMember_2420" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_513802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_513802" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_513804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2394" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_513804" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2387" xlink:to="loc_ifrs-full_FinancialAssetsMember_2392" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherInvestmentsMember" xlink:label="loc_gsk_OtherInvestmentsMember_2408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_OtherInvestmentsMember_2408" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrentEquityAndOtherInvestmentsMember" xlink:label="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_CurrentEquityAndOtherInvestmentsMember_2146643021" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2409" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_OtherNoncurrentAssetsMember" xlink:label="loc_gsk_OtherNoncurrentAssetsMember_2410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_OtherNoncurrentAssetsMember_2410" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember" xlink:label="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember_2411" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember" xlink:label="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember_2412" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CashAndCashEquivalents1Member" xlink:label="loc_gsk_CashAndCashEquivalents1Member_2413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2392" xlink:to="loc_gsk_CashAndCashEquivalents1Member_2413" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_2390" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_2401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_2401" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2389" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_2402" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract_2422" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract_2422" xlink:to="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2426" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_2427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2423" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_2427" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable_2425" xlink:to="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialAssetsAndLiabilities" xlink:label="loc_gsk_FinancialAssetsAndLiabilities_2428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_FinancialAssetsAndLiabilities_2428" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities_2146643070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities_2146643070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities_2429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities_2429" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities" xlink:label="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities_2430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities_2430" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_2146643221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_2146643221" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PaymentOfContingentConsiderationLiabilities" xlink:label="loc_gsk_PaymentOfContingentConsiderationLiabilities_2432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_PaymentOfContingentConsiderationLiabilities_2432" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdditionsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities_2433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities_2433" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities" xlink:label="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities_2434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities_2434" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities" xlink:label="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities_2435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities_2435" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialAssetsAndLiabilities" xlink:label="loc_gsk_FinancialAssetsAndLiabilities_2437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems_2424" xlink:to="loc_gsk_FinancialAssetsAndLiabilities_2437" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract_2439" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract_2439" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2440" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2444" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_2450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_2450" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_2451" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2452" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialInstrumentsMember" xlink:label="loc_gsk_FinancialInstrumentsMember_2453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_gsk_FinancialInstrumentsMember_2453" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonFinancialInstrumentsMember" xlink:label="loc_gsk_NonFinancialInstrumentsMember_2454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2444" xlink:to="loc_gsk_NonFinancialInstrumentsMember_2454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2441" xlink:to="loc_ifrs-full_FinancialAssetsMember_2445" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_2456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2445" xlink:to="loc_gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member_2456" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems" xlink:label="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable_2443" xlink:to="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_2446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_2446" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_2447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_2447" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_2449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems_2442" xlink:to="loc_ifrs-full_FinancialAssets_2449" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_2473" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_2473" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2474" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_2490" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinancialInstrumentsMember" xlink:label="loc_gsk_FinancialInstrumentsMember_2488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_gsk_FinancialInstrumentsMember_2488" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonFinancialInstrumentsMember" xlink:label="loc_gsk_NonFinancialInstrumentsMember_2489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2478" xlink:to="loc_gsk_NonFinancialInstrumentsMember_2489" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_2479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_2475" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_2479" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member" xlink:label="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member_2491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_2479" xlink:to="loc_gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member_2491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2477" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-full_TradeAndOtherPayables_2480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_TradeAndOtherPayables_2480" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="loc_ifrs-full_OtherProvisions_2481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_OtherProvisions_2481" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_2483" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_2482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_2482" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_2485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2476" xlink:to="loc_ifrs-full_FinancialLiabilities_2485" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2493" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2493" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2495" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_2512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_2512" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember_2513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2499" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember_2513" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2494" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2498" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2498" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2510" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2498" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2511" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2502" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2502" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2503" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2503" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2518" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2503" xlink:to="loc_gsk_NetInvestmentHedgesMember_2519" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2500" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2500" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2501" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2514" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_gsk_ForeignExchangeContractsMember_2515" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmbeddedAndOtherDerivativesMember" xlink:label="loc_gsk_EmbeddedAndOtherDerivativesMember_2516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2501" xlink:to="loc_gsk_EmbeddedAndOtherDerivativesMember_2516" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2497" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsNoncurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsNoncurrent_2504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentAssetsNoncurrent_2504" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentAssetsCurrent" xlink:label="loc_gsk_HedgingInstrumentAssetsCurrent_2505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentAssetsCurrent_2505" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentAssets" xlink:label="loc_ifrs-full_HedgingInstrumentAssets_2506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_ifrs-full_HedgingInstrumentAssets_2506" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesNoncurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent_2507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentLiabilitiesNoncurrent_2507" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentLiabilitiesCurrent" xlink:label="loc_gsk_HedgingInstrumentLiabilitiesCurrent_2508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentLiabilitiesCurrent_2508" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HedgingInstrumentsLiabilities" xlink:label="loc_gsk_HedgingInstrumentsLiabilities_534846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_gsk_HedgingInstrumentsLiabilities_534846" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentLiabilities" xlink:label="loc_ifrs-full_HedgingInstrumentLiabilities_2509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2496" xlink:to="loc_ifrs-full_HedgingInstrumentLiabilities_2509" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2521" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2521" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_2525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2522" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_2525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2525" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember_2531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_2525" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember_2532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2526" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2526" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2527" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2527" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2533" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2527" xlink:to="loc_gsk_ForeignExchangeContractsMember_2534" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2528" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2528" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2529" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2529" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2536" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2529" xlink:to="loc_gsk_NetInvestmentHedgesMember_2537" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_590153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_MaturityAxis_590153" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_590154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_590153" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_590154" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_590155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_590154" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_590155" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_590156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_590154" xlink:to="loc_ifrs-full_LaterThanOneYearMember_590156" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2524" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems_2523" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2530" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract_2539" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract_2539" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2544" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2544" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeContractsMember" xlink:label="loc_gsk_ForeignExchangeContractsMember_2562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2545" xlink:to="loc_gsk_ForeignExchangeContractsMember_2562" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2546" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2546" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2547" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2547" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2563" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NetInvestmentHedgesMember" xlink:label="loc_gsk_NetInvestmentHedgesMember_2564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2547" xlink:to="loc_gsk_NetInvestmentHedgesMember_2564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_HedgedItemsAxis_2542" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_2542" xlink:to="loc_ifrs-full_HedgedItemsMember_2543" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember_2554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyLessThanThreeMonthsMember_2554" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyThreeToSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember_2555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyThreeToSixMonthsMember_2555" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BuyForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_BuyForeignCurrencyOverSixMonthsMember_2556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BuyForeignCurrencyOverSixMonthsMember_2556" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyLessThanThreeMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember_2557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_SellForeignCurrencyLessThanThreeMonthsMember_2557" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SellForeignCurrencyOverSixMonthsMember" xlink:label="loc_gsk_SellForeignCurrencyOverSixMonthsMember_2559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_SellForeignCurrencyOverSixMonthsMember_2559" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2560" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2561" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsLessThanThreeMonthsMember" xlink:label="loc_gsk_BorrowingsLessThanThreeMonthsMember_2146645886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingsLessThanThreeMonthsMember_2146645886" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingThreeToSixMonthsMember" xlink:label="loc_gsk_BorrowingThreeToSixMonthsMember_2146643171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingThreeToSixMonthsMember_2146643171" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BorrowingsOverSixMonthsMember" xlink:label="loc_gsk_BorrowingsOverSixMonthsMember_2146645903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2543" xlink:to="loc_gsk_BorrowingsOverSixMonthsMember_2146645903" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_600826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_srt_CurrencyAxis_600826" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_600827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_600826" xlink:to="loc_currency_AllCurrenciesDomain_600827" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EuroMember" xlink:label="loc_gsk_EuroMember_600829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_EuroMember_600829" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SgdMember" xlink:label="loc_gsk_SgdMember_600832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_SgdMember_600832" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CADMember" xlink:label="loc_gsk_CADMember_2146643170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_CADMember_2146643170" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JapaneseYenMember" xlink:label="loc_gsk_JapaneseYenMember_600831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_600827" xlink:to="loc_gsk_JapaneseYenMember_600831" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2541" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_2548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_2548" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DescriptionOfForeignCurrency" xlink:label="loc_gsk_DescriptionOfForeignCurrency_2549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_DescriptionOfForeignCurrency_2549" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2550" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_2551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_2551" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2552" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges" xlink:label="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges_2553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges_2553" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1" xlink:label="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1_2146643169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2540" xlink:to="loc_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1_2146643169" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2567" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract_2567" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesAxis" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_2574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_2574" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfHedgesMember" xlink:label="loc_ifrs-full_TypesOfHedgesMember_2575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_2574" xlink:to="loc_ifrs-full_TypesOfHedgesMember_2575" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="loc_ifrs-full_CashFlowHedgesMember_2587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2575" xlink:to="loc_ifrs-full_CashFlowHedgesMember_2587" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember" xlink:label="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_2588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_2575" xlink:to="loc_ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember_2588" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2572" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2572" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2573" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_HedgedItemsAxis_2570" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_2570" xlink:to="loc_ifrs-full_HedgedItemsMember_2571" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember_2582" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember" xlink:label="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember_2583" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VariabilityInCashFlowsMember" xlink:label="loc_gsk_VariabilityInCashFlowsMember_2584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_VariabilityInCashFlowsMember_2584" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PrehedgingOfLongtermInterestRatesMember" xlink:label="loc_gsk_PrehedgingOfLongtermInterestRatesMember_2585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2571" xlink:to="loc_gsk_PrehedgingOfLongtermInterestRatesMember_2585" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="loc_ifrs-full_PastDueStatusAxis_1307907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_PastDueStatusAxis_1307907" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="loc_ifrs-full_PastDueStatusMember_1307908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PastDueStatusAxis_1307907" xlink:to="loc_ifrs-full_PastDueStatusMember_1307908" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:label="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307910" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307912" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanThirtyYearsMember_1307915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MoreThanThirtyYearsMember_1307915" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MaturedInThePastPeriodMember" xlink:label="loc_gsk_MaturedInThePastPeriodMember_1307947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PastDueStatusMember_1307908" xlink:to="loc_gsk_MaturedInThePastPeriodMember_1307947" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable_2569" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments_2576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments_2576" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss_2577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss_2577" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness_2578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness_2578" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax_2579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax_2579" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax_2580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax_2580" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments_2581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments_2581" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets" xlink:label="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets_2146643168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets_2146643168" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem" xlink:label="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem_2146643167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2568" xlink:to="loc_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem_2146643167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract_2590" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract_2590" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2596" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2596" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2597" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2597" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_MaturityAxis_2598" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2598" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2591" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanFiveYearsNotLaterThanTenYearsMember" xlink:label="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanFiveYearsNotLaterThanTenYearsMember_1307918" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember_1307920" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MoreThanThirtyYearsMember" xlink:label="loc_gsk_MoreThanThirtyYearsMember_1307921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2591" xlink:to="loc_gsk_MoreThanThirtyYearsMember_1307921" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsAxis" xlink:label="loc_ifrs-full_HedgedItemsAxis_2594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_HedgedItemsAxis_2594" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgedItemsMember" xlink:label="loc_ifrs-full_HedgedItemsMember_2595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_2594" xlink:to="loc_ifrs-full_HedgedItemsMember_2595" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PrehedgingOfLongtermInterestRatesMember" xlink:label="loc_gsk_PrehedgingOfLongtermInterestRatesMember_1307930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_2595" xlink:to="loc_gsk_PrehedgingOfLongtermInterestRatesMember_1307930" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable_2593" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AverageFixedInterestRateOfHedgingInstrument" xlink:label="loc_gsk_AverageFixedInterestRateOfHedgingInstrument_2603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_gsk_AverageFixedInterestRateOfHedgingInstrument_2603" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NominalAmountOfHedgingInstrument" xlink:label="loc_ifrs-full_NominalAmountOfHedgingInstrument_2604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_NominalAmountOfHedgingInstrument_2604" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness_2605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness_2605" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsLiabilities" xlink:label="loc_gsk_DerivativeFinancialAssetsLiabilities_2606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_gsk_DerivativeFinancialAssetsLiabilities_2606" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness" xlink:label="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness_2607" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfCashFlowHedgesContinuingHedges" xlink:label="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges_2608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems_2592" xlink:to="loc_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges_2608" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract_2612" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract_2612" xlink:to="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_2618" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradesAndOtherPayablesMember" xlink:label="loc_gsk_TradesAndOtherPayablesMember_2631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" xlink:to="loc_gsk_TradesAndOtherPayablesMember_2631" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialLiabilitiesMember" xlink:label="loc_gsk_DerivativeFinancialLiabilitiesMember_2632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_2616" xlink:to="loc_gsk_DerivativeFinancialLiabilitiesMember_2632" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_2615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_2617" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_2615" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TradeAndOtherReceivableMember" xlink:label="loc_gsk_TradeAndOtherReceivableMember_2629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_2615" xlink:to="loc_gsk_TradeAndOtherReceivableMember_2629" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DerivativeFinancialAssetsMember" xlink:label="loc_gsk_DerivativeFinancialAssetsMember_2630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_2615" xlink:to="loc_gsk_DerivativeFinancialAssetsMember_2630" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:label="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable_2614" xlink:to="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2619" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2620" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2622" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets_2624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets_2624" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2626" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2621" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2623" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition_2625" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities" xlink:label="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities_2627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities_2627" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements" xlink:label="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems_2613" xlink:to="loc_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements_2628" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingAbstract" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingAbstract_2634" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingTable" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingAbstract_2634" xlink:to="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2640" xlink:to="loc_ifrs-full_InterestRateTypesMember_2638" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FloatingAndFixedRateDebtMember" xlink:label="loc_gsk_FloatingAndFixedRateDebtMember_2651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_gsk_FloatingAndFixedRateDebtMember_2651" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FixedInterestRateMember" xlink:label="loc_ifrs-full_FixedInterestRateMember_2652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_ifrs-full_FixedInterestRateMember_2652" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_2653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_2638" xlink:to="loc_ifrs-full_FloatingInterestRateMember_2653" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xlink:to="loc_ifrs-full_MaturityAxis_2639" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2639" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2635" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_2641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanOneYearMember_2641" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2642" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2643" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2644" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2645" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2646" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_2647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2635" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_2647" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfDebtInterestRateRepricingLineItems" xlink:label="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingTable_2637" xlink:to="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_Debt" xlink:label="loc_gsk_Debt_2648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" xlink:to="loc_gsk_Debt_2648" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestBearingDebt" xlink:label="loc_gsk_InterestBearingDebt_2649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfDebtInterestRateRepricingLineItems_2636" xlink:to="loc_gsk_InterestBearingDebt_2649" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2655" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2655" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2658" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2658" xlink:to="loc_ifrs-full_TypesOfRisksMember_2659" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember_2662" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember_2146645317" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentAppreciationOfEuroMember_2663" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember_2146645319" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember_2664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenYenAppreciationOfYenMember_2664" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenAppreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember_2146645320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenYenAppreciationOfYenMember_2146645320" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember_2665" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember_2146645323" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenCentDepreciationOfEuroMember_2666" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember" xlink:label="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember_2146645324" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskTenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember_2668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskTenYenDepreciationOfYenMember_2668" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CurrencyRiskFifteenYenDepreciationOfYenMember" xlink:label="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember_2146645327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2659" xlink:to="loc_gsk_CurrencyRiskFifteenYenDepreciationOfYenMember_2146645327" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2657" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures_2660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures_2660" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures_513656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures_513656" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures" xlink:label="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures_2661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2656" xlink:to="loc_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures_2661" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2670" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2670" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2673" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_2674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2673" xlink:to="loc_ifrs-full_TypesOfRisksMember_2674" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember_2676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember_2676" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember_2146643164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember_2146643164" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember_2677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember_2677" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember_2146643163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember_2146643163" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember_2678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember_2678" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember" xlink:label="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember_2146643162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_2674" xlink:to="loc_gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember_2146643162" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_2672" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#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" xlink:label="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_2671" xlink:to="loc_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements_2675" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_2680" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_2680" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2684" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2684" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2685" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NonDerivativesFinancialLiabilitiesMember" xlink:label="loc_gsk_NonDerivativesFinancialLiabilitiesMember_2700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_2685" xlink:to="loc_gsk_NonDerivativesFinancialLiabilitiesMember_2700" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xlink:to="loc_ifrs-full_MaturityAxis_2686" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2686" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2681" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2687" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2688" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2689" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_2690" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_2691" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_2692" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanTenYearsMember_2693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2681" xlink:to="loc_ifrs-full_LaterThanTenYearsMember_2693" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_2683" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_2694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_2694" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_2695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_2695" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinanceLeaseLiability" xlink:label="loc_gsk_FinanceLeaseLiability_2696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_gsk_FinanceLeaseLiability_2696" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FutureFinanceChargeOnFinanceLeases" xlink:label="loc_gsk_FutureFinanceChargeOnFinanceLeases_2697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_gsk_FutureFinanceChargeOnFinanceLeases_2697" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_2698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_2698" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_2699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_2682" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_2699" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2702" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2702" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_2709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_2704" xlink:to="loc_ifrs-full_FinancialAssetsMember_2709" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember" xlink:label="loc_ifrs-full_DerivativesMember_2718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_2709" xlink:to="loc_ifrs-full_DerivativesMember_2718" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_ifrs-full_MaturityAxis_2710" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2710" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2703" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_2711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_2711" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2712" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2713" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1307547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1307547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1307548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_1307548" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1307549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2703" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1307549" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrument1Axis" xlink:label="loc_gsk_DebtInstrument1Axis_2705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_gsk_DebtInstrument1Axis_2705" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DebtInstrumentDomain" xlink:label="loc_gsk_DebtInstrumentDomain_2706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DebtInstrument1Axis_2705" xlink:to="loc_gsk_DebtInstrumentDomain_2706" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateSwapContractMember" xlink:label="loc_ifrs-full_InterestRateSwapContractMember_2714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DebtInstrumentDomain_2706" xlink:to="loc_ifrs-full_InterestRateSwapContractMember_2714" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ForeignExchangeForwardContractsAndSwapsMember" xlink:label="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_2715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DebtInstrumentDomain_2706" xlink:to="loc_gsk_ForeignExchangeForwardContractsAndSwapsMember_2715" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2708" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" xlink:to="loc_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2716" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows" xlink:label="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2707" xlink:to="loc_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows_2717" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2720" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesTable" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2720" xlink:to="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2726" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedShareOptionSchemesMember" xlink:label="loc_gsk_SavingsRelatedShareOptionSchemesMember_2737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_SavingsRelatedShareOptionSchemesMember_2737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_2738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_ShareValuePlanMember_2738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PerformanceSharePlansMember" xlink:label="loc_gsk_PerformanceSharePlansMember_2739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_PerformanceSharePlansMember_2739" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FreeCashFlowMember" xlink:label="loc_gsk_FreeCashFlowMember_831714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_FreeCashFlowMember_831714" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TsrMember" xlink:label="loc_gsk_TsrMember_846664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_TsrMember_846664" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_RAndDNewProductPerformanceMember" xlink:label="loc_gsk_RAndDNewProductPerformanceMember_831716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_RAndDNewProductPerformanceMember_831716" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PipelineProgressMember" xlink:label="loc_gsk_PipelineProgressMember_831717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_PipelineProgressMember_831717" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember" xlink:label="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember_1223852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2725" xlink:to="loc_gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember_1223852" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AwardType1Axis" xlink:label="loc_gsk_AwardType1Axis_2721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_gsk_AwardType1Axis_2721" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AwardType1Axis_2721" xlink:to="loc_gsk_EquityAwardDomain_2724" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_2736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EquityAwardDomain_2724" xlink:to="loc_gsk_AmericanDepositarySharesMember_2736" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember" xlink:label="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember_1192170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EquityAwardDomain_2724" xlink:to="loc_gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember_1192170" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1317301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1317300" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1317301" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfEmployeeShareSchemesLineItems" xlink:label="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesTable_2723" xlink:to="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AtPercentageBelowMarketPrice" xlink:label="loc_gsk_AtPercentageBelowMarketPrice_2727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_AtPercentageBelowMarketPrice_2727" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2728" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedFutureDividendYieldPercentageShareGranted" xlink:label="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted_2729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_ExpectedFutureDividendYieldPercentageShareGranted_2729" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2730" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:label="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2731" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingAwards" xlink:label="loc_gsk_NumberOfOutstandingAwards_2732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfOutstandingAwards_2732" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2733" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement_2734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement_2734" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement_2735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement_2735" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_PercentageOfPerformanceSharePlan" xlink:label="loc_gsk_PercentageOfPerformanceSharePlan_831713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_PercentageOfPerformanceSharePlan_831713" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquallyWeightedMeasuresOverPerformancePeriod" xlink:label="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod_1192169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfEmployeeShareSchemesLineItems_2722" xlink:to="loc_gsk_EquallyWeightedMeasuresOverPerformancePeriod_1192169" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2741" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2741" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AwardType1Axis" xlink:label="loc_gsk_AwardType1Axis_2742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xlink:to="loc_gsk_AwardType1Axis_2742" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EquityAwardDomain" xlink:label="loc_gsk_EquityAwardDomain_2745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_AwardType1Axis_2742" xlink:to="loc_gsk_EquityAwardDomain_2745" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AmericanDepositarySharesMember" xlink:label="loc_gsk_AmericanDepositarySharesMember_2754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_EquityAwardDomain_2745" xlink:to="loc_gsk_AmericanDepositarySharesMember_2754" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2747" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareValuePlanMember" xlink:label="loc_gsk_ShareValuePlanMember_2755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2746" xlink:to="loc_gsk_ShareValuePlanMember_2755" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2744" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingShareAwards" xlink:label="loc_gsk_NumberOfOutstandingShareAwards_2748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfOutstandingShareAwards_2748" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement_2749" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement_2750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement_2750" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement_2751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement_2751" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfOutstandingShareAwards" xlink:label="loc_gsk_NumberOfOutstandingShareAwards_2752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_NumberOfOutstandingShareAwards_2752" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare" xlink:label="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2743" xlink:to="loc_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare_2753" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2757" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2757" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2761" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:label="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2760" xlink:to="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2767" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2759" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2762" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DividendYieldShareOptionsGranted" xlink:label="loc_gsk_DividendYieldShareOptionsGranted_2763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_DividendYieldShareOptionsGranted_2763" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2764" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ExpectedLifeOfShareOptionsGranted" xlink:label="loc_gsk_ExpectedLifeOfShareOptionsGranted_2765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_ExpectedLifeOfShareOptionsGranted_2765" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPrice" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPrice_2766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2758" xlink:to="loc_gsk_SavingsRelatedOptionsGrantPrice_2766" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2769" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract_2769" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2773" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionsAndSavingsRelatedOptionsMember" xlink:label="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2772" xlink:to="loc_gsk_ShareOptionsAndSavingsRelatedOptionsMember_2775" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems" xlink:label="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable_2771" xlink:to="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedOptionsGrantPriceDiscount" xlink:label="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount_2774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems_2770" xlink:to="loc_gsk_SavingsRelatedOptionsGrantPriceDiscount_2774" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2777" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2777" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2783" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ShareOptionSchemesMember" xlink:label="loc_gsk_ShareOptionSchemesMember_2791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" xlink:to="loc_gsk_ShareOptionSchemesMember_2791" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SavingsRelatedShareOptionSchemesMember" xlink:label="loc_gsk_SavingsRelatedShareOptionSchemesMember_2793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2782" xlink:to="loc_gsk_SavingsRelatedShareOptionSchemesMember_2793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xlink:to="loc_ifrs-full_RangeAxis_2780" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2780" xlink:to="loc_ifrs-full_RangesMember_2781" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2781" xlink:to="loc_ifrs-full_TopOfRangeMember_2789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2781" xlink:to="loc_ifrs-full_BottomOfRangeMember_2790" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2779" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_2784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_2784" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement_2785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement_2785" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_2786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_2786" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:label="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_2787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_2787" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption" xlink:label="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption_2788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2778" xlink:to="loc_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption_2788" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2795" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2795" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2799" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_EmployeeShareOwnershipPlanMember" xlink:label="loc_gsk_EmployeeShareOwnershipPlanMember_2808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2798" xlink:to="loc_gsk_EmployeeShareOwnershipPlanMember_2808" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2797" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareAwardSchemes_2800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NumberOfSharesHeldForShareAwardSchemes_2800" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes_2801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NominalValueOfSharesHeldForShareAwardSchemes_2801" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes_2802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_CarryingValueOfSharesHeldForShareAwardSchemes_2802" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareAwardSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes_2803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_MarketValueOfSharesHeldForShareAwardSchemes_2803" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NumberOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NumberOfSharesHeldForShareOptionSchemes_2804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NumberOfSharesHeldForShareOptionSchemes_2804" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_NominalValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes_2805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_NominalValueOfSharesHeldForShareOptionSchemes_2805" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CarryingValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes_2806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_CarryingValueOfSharesHeldForShareOptionSchemes_2806" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_MarketValueOfSharesHeldForShareOptionSchemes" xlink:label="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes_2807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2796" xlink:to="loc_gsk_MarketValueOfSharesHeldForShareOptionSchemes_2807" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_2810" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_2810" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2816" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoGroupLimitedMember" xlink:label="loc_gsk_GlaxoGroupLimitedMember_2818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoGroupLimitedMember_2818" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoOperationsUkLimitedMember" xlink:label="loc_gsk_GlaxoOperationsUkLimitedMember_2819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoOperationsUkLimitedMember_2819" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeUkLimitedMember" xlink:label="loc_gsk_GlaxoWellcomeUkLimitedMember_1306965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoWellcomeUkLimitedMember_1306965" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalPLCMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalPLCMember_2820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineCapitalPLCMember_2820" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineExportLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineExportLimitedMember_2824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineExportLimitedMember_2824" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineFinancePLCMember" xlink:label="loc_gsk_GlaxoSmithKlineFinancePLCMember_2825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineFinancePLCMember_2825" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember_2826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineHoldingsLimitedMember_2826" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIhcLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIhcLimitedMember_2146643255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIhcLimitedMember_2146643255" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember_2146643254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember_2146643254" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember_2146643253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember_2146643253" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember_2146643252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember_2146643252" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember_2146643251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember_2146643251" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:label="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember_2146643250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIntellectualPropertyLimitedMember_2146643250" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember_2827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember_2827" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineServicesUnlimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember_2828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineServicesUnlimitedMember_2828" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineUnitedKingdomLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember_2829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineUnitedKingdomLimitedMember_2829" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineUsTradingLimitedMember" xlink:label="loc_gsk_GlaxosmithklineUsTradingLimitedMember_1306964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineUsTradingLimitedMember_1306964" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SetFirstLimitedMember" xlink:label="loc_gsk_SetFirstLimitedMember_2830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_SetFirstLimitedMember_2830" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SmithKlineBeechamLimitedMember" xlink:label="loc_gsk_SmithKlineBeechamLimitedMember_2831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_SmithKlineBeechamLimitedMember_2831" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareFinanceLimitedMember" xlink:label="loc_gsk_ViivHealthcareFinanceLimitedMember_590391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareFinanceLimitedMember_590391" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember" xlink:label="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember_2146643056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember_2146643056" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthCareUnitedKingdomLimitedMember" xlink:label="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember_2833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthCareUnitedKingdomLimitedMember_2833" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.1ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.1ScottishLimitedPartnershipMember_2146643200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.1ScottishLimitedPartnershipMember_2146643200" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.2ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.2ScottishLimitedPartnershipMember_2146643199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.2ScottishLimitedPartnershipMember_2146643199" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AffinivaxIncMember" xlink:label="loc_gsk_AffinivaxIncMember_2146643249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_AffinivaxIncMember_2146643249" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_CorixaCorporationMember" xlink:label="loc_gsk_CorixaCorporationMember_2835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_CorixaCorporationMember_2835" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineCapitalIncMember" xlink:label="loc_gsk_GlaxoSmithKlineCapitalIncMember_2836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineCapitalIncMember_2836" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineHoldingsIncMember" xlink:label="loc_gsk_GlaxoSmithKlineHoldingsIncMember_2839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineHoldingsIncMember_2839" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLLCMember" xlink:label="loc_gsk_GlaxoSmithKlineLLCMember_2840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineLLCMember_2840" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEquityInvestmentsLimitedMember" xlink:label="loc_gsk_GskEquityInvestmentsLimitedMember_831772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskEquityInvestmentsLimitedMember_831772" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_HumanGenomeSciencesIncMember" xlink:label="loc_gsk_HumanGenomeSciencesIncMember_2841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_HumanGenomeSciencesIncMember_2841" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_StiefelLaboratoriesIncMember" xlink:label="loc_gsk_StiefelLaboratoriesIncMember_2844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_StiefelLaboratoriesIncMember_2844" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_TesaroMember" xlink:label="loc_gsk_TesaroMember_587841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_TesaroMember_587841" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareCompanyMember" xlink:label="loc_gsk_ViiVHealthcareCompanyMember_2845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthcareCompanyMember_2845" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineAgMember" xlink:label="loc_gsk_GlaxosmithklineAgMember_2146643248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineAgMember_2146643248" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineB.v.Member" xlink:label="loc_gsk_GlaxosmithklineB.v.Member_2146643247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineB.v.Member_2146643247" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBiologicalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlineBiologicalsSAMember_2865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineBiologicalsSAMember_2865" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineGmbHAndCoKGMember" xlink:label="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember_2872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineGmbHAndCoKGMember_2872" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaGmbhMember" xlink:label="loc_gsk_GlaxosmithklinePharmaGmbhMember_2146643246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklinePharmaGmbhMember_2146643246" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePharmaceuticalsSAMember" xlink:label="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember_2146643240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlinePharmaceuticalsSAMember_2146643240" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSAMember" xlink:label="loc_gsk_GlaxoSmithKlineSAMember_2882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineSAMember_2882" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineSPAMember" xlink:label="loc_gsk_GlaxoSmithKlineSPAMember_2875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineSPAMember_2875" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineSingleMemberA.e.b.e.Member" xlink:label="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member_2146643239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineSingleMemberA.e.b.e.Member_2146643239" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineTradingServicesLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember_2880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineTradingServicesLimitedMember_2880" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskCapitalB.v.Member" xlink:label="loc_gsk_GskCapitalB.v.Member_2146643238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskCapitalB.v.Member_2146643238" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKServicesSPZOOMember" xlink:label="loc_gsk_GSKServicesSPZOOMember_2879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKServicesSPZOOMember_2879" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesGmbHMember" xlink:label="loc_gsk_GSKVaccinesGmbHMember_2873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKVaccinesGmbHMember_2873" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKVaccinesSRLMember" xlink:label="loc_gsk_GSKVaccinesSRLMember_2876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GSKVaccinesSRLMember_2876" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_JscGlaxosmithklineTradingMember" xlink:label="loc_gsk_JscGlaxosmithklineTradingMember_1306969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_JscGlaxosmithklineTradingMember_1306969" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoireGlaxoSmithKlineMember" xlink:label="loc_gsk_LaboratoireGlaxoSmithKlineMember_2869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_LaboratoireGlaxoSmithKlineMember_2869" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LaboratoriosViiVHealthCareSLMember" xlink:label="loc_gsk_LaboratoriosViiVHealthCareSLMember_2883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_LaboratoriosViiVHealthCareSLMember_2883" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareGmbhMember" xlink:label="loc_gsk_ViivHealthcareGmbhMember_2146643237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareGmbhMember_2146643237" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareSRLItalyMember" xlink:label="loc_gsk_ViivHealthcareSRLItalyMember_831808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareSRLItalyMember_831808" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViiVHealthcareSASMember" xlink:label="loc_gsk_ViiVHealthcareSASMember_2870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViiVHealthcareSASMember_2870" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSaudiArabiaLimitedMember" xlink:label="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSaudiArabiaLimitedMember_2146643236" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoWellcomeManufacturingPteLtdMember" xlink:label="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember_2862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoWellcomeManufacturingPteLtdMember_2862" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineThailandLimitedMember" xlink:label="loc_gsk_GlaxosmithklineThailandLimitedMember_2146643233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineThailandLimitedMember_2146643233" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineAustraliaPtyLtdMember" xlink:label="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember_2847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineAustraliaPtyLtdMember_2847" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineBrasilLimitadaMember" xlink:label="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember_2849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineBrasilLimitadaMember_2849" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineFarEastB.v.Member" xlink:label="loc_gsk_GlaxosmithklineFarEastB.v.Member_2146643232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineFarEastB.v.Member_2146643232" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKKMember" xlink:label="loc_gsk_GlaxoSmithKlineKKMember_2859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineKKMember_2859" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member" xlink:label="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member_2146643231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member_2146643231" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineIncMember" xlink:label="loc_gsk_GlaxoSmithKlineIncMember_2851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineIncMember_2851" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineKoreaLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineKoreaLimitedMember_2863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineKoreaLimitedMember_2863" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlineLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlineLimitedMember_2853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlineLimitedMember_2853" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklineMexicoS.a.DeC.v.Member" xlink:label="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member_2146643230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklineMexicoS.a.DeC.v.Member_2146643230" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxoSmithKlinePakistanLimitedMember" xlink:label="loc_gsk_GlaxoSmithKlinePakistanLimitedMember_2861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxoSmithKlinePakistanLimitedMember_2861" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember" xlink:label="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember_590513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember_590513" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskEnterpriseManagementCoLtdMember" xlink:label="loc_gsk_GskEnterpriseManagementCoLtdMember_2146643229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskEnterpriseManagementCoLtdMember_2146643229" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPharmaVietnamCompanyLimitedMember" xlink:label="loc_gsk_GskPharmaVietnamCompanyLimitedMember_2146643228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskPharmaVietnamCompanyLimitedMember_2146643228" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_IDBiomedicalCorporationOfQuebecMember" xlink:label="loc_gsk_IDBiomedicalCorporationOfQuebecMember_2852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_IDBiomedicalCorporationOfQuebecMember_2852" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareK.kMember" xlink:label="loc_gsk_ViivHealthcareK.kMember_2146643227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareK.kMember_2146643227" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ViivHealthcareUlcMember" xlink:label="loc_gsk_ViivHealthcareUlcMember_2146643226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_ViivHealthcareUlcMember_2146643226" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskNo.3ScottishLimitedPartnershipMember" xlink:label="loc_gsk_GskNo.3ScottishLimitedPartnershipMember_2146643198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2813" xlink:to="loc_gsk_GskNo.3ScottishLimitedPartnershipMember_2146643198" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2814" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2814" xlink:to="loc_ifrs-full_GeographicalAreasMember_2815" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_2885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_ifrs-full_CountryOfDomicileMember_2885" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_2886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_US_2886" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_BOFS" xlink:label="loc_exch_BOFS_2146643201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_exch_BOFS_2146643201" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="loc_country_CH_2908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CH_2908" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="loc_country_NL_2903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_NL_2903" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="loc_country_BE_2899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_BE_2899" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="loc_country_DE_2901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_DE_2901" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_AustriaMember" xlink:label="loc_gsk_AustriaMember_2146643223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_AustriaMember_2146643223" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES" xlink:label="loc_country_ES_2907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_ES_2907" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="loc_country_IT_2902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IT_2902" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GreeceMember" xlink:label="loc_gsk_GreeceMember_2146643220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_GreeceMember_2146643220" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="loc_country_IE_2905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IE_2905" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL" xlink:label="loc_country_PL_2904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_PL_2904" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU" xlink:label="loc_country_RU_2906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_RU_2906" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="loc_country_FR_2900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_FR_2900" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_SaudiArabiaMember" xlink:label="loc_gsk_SaudiArabiaMember_2146643224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_SaudiArabiaMember_2146643224" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="loc_country_SG_2896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_SG_2896" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_ThailandMember" xlink:label="loc_gsk_ThailandMember_2146643222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_ThailandMember_2146643222" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="loc_country_BR_2889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_BR_2889" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TW" xlink:label="loc_country_TW_2146643194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_TW_2146643194" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR" xlink:label="loc_country_TR_2898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_TR_2898" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="loc_country_CA_2890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CA_2890" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP_2894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_JP_2894" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="loc_country_KR_2897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_KR_2897" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_country_HK_2891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_HK_2891" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX" xlink:label="loc_country_MX_2146643192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_MX_2146643192" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PK" xlink:label="loc_country_PK_2895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_PK_2895" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN" xlink:label="loc_country_IN_2893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_IN_2893" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="loc_country_CN_2892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_CN_2892" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_VietnamMember" xlink:label="loc_gsk_VietnamMember_2146643191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_gsk_VietnamMember_2146643191" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="loc_country_AU_2888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2815" xlink:to="loc_country_AU_2888" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2812" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" use="optional" order="111" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="loc_ifrs-full_NameOfSubsidiary_2817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_NameOfSubsidiary_2817" use="optional" order="112" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_1223870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_1223870" use="optional" order="113" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_1247804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2811" xlink:to="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_1247804" use="optional" order="114" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_2910" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_2910" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2914" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_2915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2914" xlink:to="loc_ifrs-full_GeographicalAreasMember_2915" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2916" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp1LimitedsShareCapitalMember" xlink:label="loc_gsk_GskGp1LimitedsShareCapitalMember_2146643204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" xlink:to="loc_gsk_GskGp1LimitedsShareCapitalMember_2146643204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskGp2LimitedsShareCapital.Member" xlink:label="loc_gsk_GskGp2LimitedsShareCapital.Member_2146643203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2913" xlink:to="loc_gsk_GskGp2LimitedsShareCapital.Member_2146643203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146643207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_dei_LegalEntityAxis_2146643207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146643206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146643207" xlink:to="loc_dei_EntityDomain_2146643206" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember" xlink:label="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember_2146643202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146643206" xlink:to="loc_gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember_2146643202" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GskPlcMember" xlink:label="loc_gsk_GskPlcMember_2146643205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146643206" xlink:to="loc_gsk_GskPlcMember_2146643205" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_2912" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_2146643208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_2911" xlink:to="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_2146643208" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsAbstract" xlink:label="loc_gsk_DisclosureOfLegalProceedingsAbstract_3011" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsTable" xlink:label="loc_gsk_DisclosureOfLegalProceedingsTable_3015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsAbstract_3011" xlink:to="loc_gsk_DisclosureOfLegalProceedingsTable_3015" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_3013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_3012" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_3013" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_3016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_GeographicalAreasAxis_3016" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_3017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_3016" xlink:to="loc_ifrs-full_GeographicalAreasMember_3017" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1307791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_RangeAxis_1307791" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1307792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_1307791" xlink:to="loc_ifrs-full_RangesMember_1307792" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_2146643045" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_GSKKoreaMember" xlink:label="loc_gsk_GSKKoreaMember_2146643002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2146643044" xlink:to="loc_gsk_GSKKoreaMember_2146643002" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DisclosureOfLegalProceedingsLineItems" xlink:label="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsTable_3015" xlink:to="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvision" xlink:label="loc_ifrs-full_LegalProceedingsProvision_3020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_ifrs-full_LegalProceedingsProvision_3020" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_DamagesAwardedToGSK" xlink:label="loc_gsk_DamagesAwardedToGSK_1315692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_DamagesAwardedToGSK_1315692" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_FinePayable" xlink:label="loc_gsk_FinePayable_2146643046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_FinePayable_2146643046" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gsk-20221231.xsd#gsk_LossContingencyNumberOfPlaintiffs" xlink:label="loc_gsk_LossContingencyNumberOfPlaintiffs_2146643262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gsk_DisclosureOfLegalProceedingsLineItems_3014" xlink:to="loc_gsk_LossContingencyNumberOfPlaintiffs_2146643262" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g382677dsp001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677dsp001b.jpg
M_]C_X0/E17AI9@  24DJ  @    ,   ! P !    (P    $! P !    < ,
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ ?
M    M    #(! @ 4    TP   &F'!  !    Z    " !   (  @ " " _ H
M$"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I #(P
M,C(Z,3(Z,#8@,#@Z-3@Z,S@   0  ) '  0    P,C,Q : #  $   #__P
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M_]#U5)?*J22G_]G_[0NT4&AO=&]S:&]P(#,N,  X0DE-! 0       \< 5H
M QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':NKP7#3CA"24T$
M.@      [P   !     !       +<')I;G1/=71P=70    %     %!S=%-B
M;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT
M965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %  1  M #(
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ !(     0 " $@    !  (X0DE-!"8
M  X             /X   #A"24T#\@      "@  ________   X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!$0
M !     "   "0    D      .$))300>       $     #A"24T$&@     #
M0P    8              W     C    !P!D ', <  P #  ,0!B     0
M                       !               C   #<
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #<     !29VAT;&]N
M9P   ",    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   W      4F=H=&QO;F<    C     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    !.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M   !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H # ,!  (1 Q$ /P#U5))))3__T/54DDDE/__1]522224__]+U5)))
M)3__T_54DDDE/__4]522224__]7U5))))3__UO54DDDE/__7]522224__]#U
M5)?*J22G_]D .$))300A      !7     0$    / $$ 9 !O &( 90 @ %
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M(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9$
M   !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P/_P  1" -P ",# 1$  A$! Q$!_]T !  %_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__0W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U]_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]/?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_];?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T-_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__2W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]3?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MUM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]??X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__3W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]7?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__TM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__4W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_];?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MT-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T]_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__5W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]??X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MT=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__6W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MTM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U=_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_];?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__7W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]'?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MT]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__UM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__0W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U]_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]/?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_];?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T-_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__2W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]3?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MUM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]??X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__3W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]7?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__
MU]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__TM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__4W^/?NO=>]^Z]
0U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g382677f_01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_01a.jpg
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MQ #[    !@,! 0$              P8'" D"! 4* 0L!  $$ P$! 0
M       ! @,$!08'" D*$  ! P,"! ,$!@4%"0@($0T! @,$$04& "$Q$A,'
M05$(87$B%(&1H3(C%?"QT18)P>%"4B3Q8G*2TC-#4Q>"D[,T5)0E)K)C<T0U
M==4*HH/39'2$155EE;7%-E:65Q@9XJ/#X[341H8G1V>7$0 ! P($ P4$!P8#
M! 8&"@,!$0(#  0A,1(%05$&87$B$P>!D3(4\*&QP=%"4N%R(S,5"/%BDH)3
M)!:BLM)#D[3"8X,T= GB<[/35(0E-287E&5U_]H # ,!  (1 Q$ /P#V9]S,
M]OMVOUTL\>6_ LUMEO0$1(KBF3+7'7TW9$MUOE6]U'$GD17D2FFQ-3JG+(XN
M(R:*SEI;1LC#R%D<%_PIK@_)/_?#_#@77-OIYM0U=#1DE&I>D;_VAZG_ '9P
M_3]_0II0T$\*/0[( _XP_4> ><X5\N;2+2AC5X4<E]\_Z=__ 'U?^6-M)CG2
MHWD*/2[(%1UWM]Z]9S_*K70">-"-Y"LP](_U[Q_],7_E:52J4A#>RC$O/_Z]
M[_?%TX[?TM!)R6FH.0HQ+K_^O>_WQS_*V.D7MI"!R%9AYZO^?>K[75TWKQ^+
M2*1QII"X)1@=?\7W#_Z:YO\ ;H5<J1&C-*,#C_'KO#R_$<X<:5YJ#28F@@9X
M)1H=?X]9X'>OXB^'#^MY:4+00%P%'!Y\_P"F>IM_I%^/^ZX:532HWD*-2M[:
MKSO@#^(L'A4C8C;0M)@*.2X]_K7N) JXOAPJ/BJ=M(IH3B@HY+C]*%]W@/\
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MO]U X4_-)WU[2//4+[V<X,<X#O-9RSZ&M),9+>'_ ,-G_9I%S^[=[="@,@O
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M$&L^8?=)D&@_WP::B4TR'A1XD3R0/G9OTR9!]O\ K-&%("Y$K/J32*&9,/\
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M\F'@TGNIZA)<&3-C3)7;?%&[/C+:H$MR*\]'R7-9-G8GQUEL+;<89<0MM:%
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MZ'-:.TN< T#M6N<=6>OWHAZ>V#[_ *GZIV2(-!_AQW<-Q,XC\K(+=TLSW'(
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M([?*P4*0D 475]QM"0FO,Z2 ?#WU.O*?75TV]W$RKJ>B_A]5>P.C+1MCLXA
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M_ Z-)XFG!X=EE2#F2^1U::IH$U))H3XFOLH=*T$$T.!(44D9ZVYZRKEJ:!"
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M/5XAXP@PP!+V'GC]5,EGEX[Y8ABDW)NZG;?&L/R"\7Y_!!CLB_-Y!B>539[
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M&U#N3])V\-/)**30$X9USGY8'B-Q4&M1[]5'/"]M/#>=<IZXA(4 K:AW!*O
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M5N'0UQ<2N#;AK38.7,XM"%408E>T)PKFGJ;:V$=N[<&.<S=0A1H)#T<U _%
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M',<TL8]R:7#P?"7YC4C=6*BL%NGIW9;M;NW/;X8C,QA42M(+E)!8/$KE;BH
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MX\?)IBS]X*/*2?($[:5O2.RAP-KN]L]SBFES9&+[2W#O--?U1O):6WNTW#
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MN$B.LEYZ\2;A/DE;[H2%.W!UMQ"@I:TMMMM<P!VH#S$;?U?UEO/66[_UC?)
M9&QB-C&DZ8V DZ6@EQ1225))<5Y :QTOZ7W.R[4VUVJU<+4N+BXEI>]R8N<!
MIQ#1Q#0&@)P7I2LXF-I9D6VSY3.B272A*[=:);T.0XD*)I,"$PG$)*>7F4Z
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MB@*);<*:#BF@IJQ=;A;VU_*VV\=HV5P8<B6@^$GV4VUVJ>YLXC<)'=&,%PS
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MR@Y58[D8ID5\/_PK-V\_QU^/#CJ!_P ;N^MXB*PL_=%<G8CR/F?IH-M-I]'
M$TIXGQ]@/O\ $Z4G&F4:!X ?SBGZ]&&= HVA\/;3A4:;3@.)R2LTBF_L/U^?
MAXZ.ZG_Y:.2G;?Q'@:4X'R)TE(31H%/#;A]6PKX\=''&D6CD@ ;<?U:=PPI,
MZS \^'L\3Y<>.B@]E')\*5'#^3CQJ-+2(#5?_J_[!=KL<["=S\WP?MQB^/Y;
M$DVS*KG?[1:&&KS)B"\M,WIHS5!R1&@.LW!;SK#);9);"N7X13@_JQT+TY8=
M!WU[L5A;6UY'<17#W1Q@.($@;)CF&H\D@(W#*O3WH?ZG=9[SZE[1LG4^[WU[
MM+X)K6**:4NC8?)+HD;D7AT;6-<X%^)&K$UY@\VGIDWAQ;RTK4X$Q^90(-0L
MJYBX10KIY;?7KSSMH_@@C,!:]\7<>D>7PK6[9K@1\S7'DIZBS;W5QMZ-/MFJ
M5LR.5)Y^<+('[-3;I)(^V9(/A#T/8>"5K<T*:XA\1;]])CNUZ7NS[^9R^[-N
MP^W63.KW8W+-)S:PPT6^ZNPWW8,CHW9*&)%NN+[3MN9*)$J*\^A"0D**: ;]
MTOUIN8V]NSW$IDLF.4,<5 1<0<"!XC@' +CG7+-RZ,Z6N-X?O-]9@;D^/0Z:
M+^'*6J#B1X7G 8O:2@ 5,*5>+9)9&)2QG#W8;.EIF9=(-D[_ /:RU7(OR<KC
M18BQ SG#YMF?C1+=$A)89$BSKDA*@'7'2A"CTW:]XMV- $04@8ASAPY'5CQS
M0')*TW>?2[;;MKIMCW.[@=X4:0"1I)(" L*8\ >U::/N'Z9_2WE6+Q(\OT\]
MBL5G1[-^6JS#L_WJR&-+E76;=($QVX#'9&/6B1%6(5O<0PI3TAQLOK:! 5SC
M/NWAODZX'O$PYHX'OQ.7<E:[#Z8]:_-GRK^.6W)+D>)&D@#)I+4"E%\2X<:A
M%VH]&_K%L.=7N-:>Z<=CT[-9;:)6.8I=[@_?LJN]I:DL2"RV&4+B6"/!)6R9
M*Y"W'&$IJW51*6;SO73WR+9'Q$[P8RK@$:#V\US3ZZPUKM/6UEO,EMNMS:#9
M&O&EC5DER!(U!&M"\#J*8(,ZLERZ]VIF\P[!;@Q(5;PFW/?*N @K3RASKGD0
MXKINCEJ:BJ?=KG^V-E)\YZZ3B/V5M5XYK8RT9U?Q_"*A?+7O*XS=/[)B[LN8
ME-"EE3LZ''CI4H$T)^853;XJ'RUTWI N?<R..0;^%<-]5"UFV0-/QOF'U FK
MUT\?93CPIQ^GPKK?^ZN%DUF!QX"E*\OCOQV&U -*::2N65'"GAN01O\ 01[*
MT&DJ,A<*S'OV/L! H12F]3PTM,.2<:S\?[@\2. TG'&F]]9<-O/]7C3WZ2DX
M5]'Z</Y])25EL>->&W#CO6OTZ6B@#0^(/GL1HHK:BU,F/N/\^R?J<33:@H-*
MW COJ*?^2_\ =/V5Y'NWV(NY#WNSA0:*TCN)F*1\-?\ ^:+F=<%VRVUWLK4S
MG?[M9K[[]4[\S:O3C; 7([^D6G_EHJL#[IM1\4PWH !M2(9!X#<HH3X4UMFY
M);V;D10/L%>7NC7R[UOPDQ+3)]]5L6C)TQ?W@N1<^);SJ4*)W_I</9YZY7',
M#+)-VI7KN_V9TPM+,# -"_54:K_<W;S=9$A:RM(=52IV)J:D>S6NW=T72I^8
MY5V#:[)EA9-A: #II\.QX/[P0FJDUD,@;^!6G;RXZVW9LVD\Q7-?4I/Z7(__
M "G[#7H5OTZ1C?9C$9D<G^W9;BN-26OZ+L7(;;=+>M13XF*\IMX'@ @^&O2?
M3K2VV!/+[*^&WK;=^9O1B!SF<?<3^-/A<L*S=^-B$+M[F%MQ46"Q+M%S%QA/
MS4)0MMI3-PB1F5="7+8<;5S,/I#;@H0M)J#)N]C>WDD;[*9D3F@@Z@3GDX '
M$CD<#S%<BL+BU@!^;C>]I((TD#+@2<@>>*<JY]U,.^9C"M.3=H)-_D8D]RV_
M.+E:&W+:Q!5;A-:O@N+W);WV9UT;2%0VU.NL.GXD@\8'"2?<66EW:^;%&4$C
MFX :?B4\R,6\#C4\;?*L'W4%R(W/Q,8=B2J:4Q. .911QIZ+HAMT8=((YF6,
M@A\Q4*@%^V7&.A6W#\9U/N)UL58=% !RI1Y!88&362XV"Y(D?(W2.J,^Y#?<
MB3&!S(<9D1)+0+D:7&?;2XVL T6D5!%0:]Q!%=0.MYL8W!#P]H/,9BIHI'0R
M"6--0*XA1[1Q!IN<"[++PS)I&1SNX68YDV(]PC6BW9*[%<%L9NCS;TD2)45#
M*;DXR6PAA718+:#17.:'6)L=F%C=&Y\^:0 $-#B"@<<02/B3(%!A5VYO1<1"
M/RHV.P4MP4C!0."\<3C3'^K'OLC$K8[@%D>=C2;LT[%O-S1\*5,*:YI%C@OI
M)");L99+JC[&QQ41X#_O(]?-VMKAWHET"7LO+B--TNVHC896I\C"X'XY6N_X
MIV!8PB,!7.(]0_V[^D[=ZNF]:[RUKX+=P=;PG]0.%P\'-H<$C [7\&@U1XCV
M\9]26=W'"\8FQ,7P&T/QUY]W.N$.7,D17G5*6WC.,LEYB%)RB>RVXL<P#<=M
M"G7=DI0KC_HIZ,7?7=T+2$BUZ8MBPS7&C$G "*$)I<]P!0G( N*-0'UMZA^I
M=KZ.[!%O&\ W?4]R'-M+)CPUI &,\Y0O; PH,,7N(8SBX74=E/3CZ=NV#*)'
M;;";,N]6F*W8IF3W:E\RA:5QV9*V)=REA2&E2VW@\XEEMI*U.$D5)U]-.C/3
MOH/I&)K^FK&)EW&SRS,X:YB$!(+SAXOB.D *I2OG'UQZL>H7J Y[.J=PFDL7
MR^:+=G\.W:Y2A;&W](\(+BXAH 5*=RU]LNW%CLETQRUX)B4#'KT\\_=K(S8K
M?^57%V2@-/&7"=87'=ZJ!RE)'+3@-SK<?Z7M++1]E\M;BQD77&6,T.7,.:0A
M7B"$K1V;ON\=XS<8[NY;N$9!9*)7B1A;B"UX=J!!R(*BJ_O4K_#4[7=Q,:NT
MSLO9;#VXS3G7=(]L984SCMYF--K4+>PZIU9QCYU1">9D&(%4*FTCF.N%^H/]
MO_3'4.WRR]*V]O8;V?$T $1O<!@U5/E:LO""P8>$"O4WI+_=AUGTCO=NSKJY
MNMVZ='@<YSEFC:2/&B#S]'Q(_P#B'%'DH*HL[J=J>X'8RXPK?D]DN>/"]?,I
MBNSVDHE0+Q;04RL7NRX3[D036.0K8<0ZIN0P4.MJZ:CKPKUMZ6[OTI-&=XBD
M9;2M=H#D5KP?'&\@.:'M/$'3(PA[<,OI]Z<^IW2WJ3!+/LL\-S+:N;YH83I=
M%)\%Q$'@/,;A@X%H=&_5&X:@*9Y?<,W"=;GKA(>CIC1TPGU0W$LK<$=P])U3
M$=PI;=2TI(*UI"EBNZAOK2I=FEB@:^!K72- 11P&6)&)3##@!73K7:&-9=6D
M0;B_6T."IJ&(4XH2,@<%R&%/IC&;?DY+\.5)^5Z1"I<S()$J._!2\76VGV)$
MQ<9AZ,%GE3]U/%- 2-6=FZBW?8-T;?;1/+:W@:6C1X2YI.+7!#J[G K@46N9
M]5=!;+U7MSMHZEM8+JR<X.=&^$>&0#!S7-#7(?U @XH2:=[MWZHYG;[/;/F;
M,",JR1_GXULO72<F_/SGXI2Y(8=^7,>BEK"0XRXN0!7EY2:GJ?0?6IZ>ZVAZ
MLWYC[F0!_F.>WS)FN<$$@U$$/:0BX:6$AI&5<9]3O10]4^FUST3TD^*ROXS$
M^.$'R8 QCU,3PP.(8X$D@M0OTERUT^^_JON'>._1I#MQM\&X66PEF1%:MU^0
MN3$=>3(,=Z=<ENOV]-!S%3X?:0ZK=L? %7O6WJ^R]1=WM=RLX9/DH+4PND+0
MUY<Z34<"27-9AI!(Q+DP)K7O[>_1S>_3#8KRSZC,,M_=WXD8V*3S(HV,C# 1
MX6J]YU$Z0WP@>(H4CS-R^QOLM19[]SM]\90T[8C<7;>F%:'Y',MI46W)8DKN
MMV"EJ*WG5):25)Y>5)4O7#O)O(K33!&V1C7N;*,3J:#VD%H<%)XG+X@A]$#;
MY?F?-:8S;/'BT@ZG<"KE :P%!I )08J4%.GV3[EOY%EC-FE%4BX+1(MEP:D+
M@R%7!B0R^E<QE@N_*3"T\A#P:I17*J@--]L]-.C8+3JWYUK6R64F$<;FJ'@J
M[0YI&.ES6G'#!20A30O4V&VM.F96V[C$\-U>8Q6F$A "UV;26N(7,*G*O0WZ
M>[=W'GXOCV=]Q,J=DR+EC\BUQ\:1$Z#*BS<W&F+[.DF9(;DSYT>"EU ;;;Y4
M/<O 4U]5>E6[E)80[CNCM$TD2&+@#JP<7*A) 4(T8%#E7QIZMLMNVO>[G:]L
MD^8M(9/#*A;J4 D:2I!:26G$J03QJ1Y^KS]VML K5ZC1W?[-H[D6!W%Q?)V-
M%V[OW.R7BV$IN%FE+YI!<@N\Z5-OI==>*-^7D64$%-08IX&W,1B?BP^X]AIT
M<CH7ZV9U'+MS$R3TX]T,LO&<7AS(\'RZSXE9,FRPA]-UC7ZTRGH=KSO)(CJU
M11%7"G+C7%UA7X:2V]R!*5@$=K'% V&)=+!@N/UYT[S'22:W$*X]WT';4H;I
MF:YLUQ+;U&D+(:0A56TM\$$%)*5<R=^8;*K6NL%/>E[RT)IKT%M/2D-A8,&E
M7$*2F)/:>7+D*-@9:]"?0X7.=KF <:*OA6BOQ)WVYB.!\#I\=X6$8X4S<>FK
M>_MG0O: X@H4Q:>8P6GGBOM26H\EA7.R^AIUI7]9"P% ^_P/MUEFD. <,B%K
MA=W;265S):S!)8WEI[P4JJ/+4TS?,/;EF0?5^:R_HU2193WFF?E%914#X!X&
MGV[ZDX5*SC2HCH&P]U*>-?LU&#BM-I21&^6GV'?P^CA74V&=5\2>VE V-@/(
M$^SV?KU%4E.'AB?QT5_K#;?PKX\*4&LC:'/OJC.,7 9Z:?./0IV\AX?7J^*Q
MXK8TM+6G)>Y*)%=DG@#](\*UTB<LZ>V0M\*\,*UXKX2HDA8KPH #[?$>6E(X
M'*D:Y[79^+L-=Y*PM/,GQ'MKP]OGIHY'.K[L6J"<J2-T>?0Y\',#S<VU> -?
M(@C5Z%D9'B3*L0\N!45!WN_;$2LKO#CKTEA^4XESJL/J;W+#7(MQHI6P[\/#
MG0=>;.OIIK?JJ[:QQTE[<.":&\,J]3^F\4,O2MH]S6EP8Y>:ZW<<_KJ+F==Q
M,ML:';8JX6J[6=<8QW69D55NG,QB@(5R2(3R(KJPC@2TBIUJ[MYG#/*?I+43
M*MWCV6R>_P Z,/9)J7 @@^\+]==;"KU&E8M)O$E:&5R(JXL>+U/[0F+;^JAM
MQ06KG6%O/$[T^\#XZK"8RM5V>'L%-EM0R8-"IB5YD]U12SZVR;V[/"9+*&Y"
M5M(^:7TP21RA*%KY>(/#>IU8MWM9XW8)4TD!!$8Q/93%XG+OO;29%QZXN6^Z
M1UN.OVM"VE-3(,+F+A;ZK:R5QFUN (24@4KRFFPF??>>PR18N;4@VV-CPY^"
M\JDW9[GEF3PFWX5TB0K6E*DAR,PY,=7Y)_&?#*4H(X*22-8X[@23K:-57?D;
M=B%2?IW5IR<:D/25&1?+I<'E+^)+KC4>/4J!51F,TW05 H22=6(KR1[P&H*K
M7$,+(U+<!4M>P^&Q(*G+BXR&U1E-J'-NI*Y"^1*D$U4:+-37:FNA=,VY+C/)
M^5#[2:Y7U;>:@V!F17W 4_=RL43(;?.ASTMJASEL!YIP)("&I"7U!22*$<S0
MKMP)UN^AEP-,F#"6_40?NK0M;H#JCQ> 1[P1]]4P>JWM4O/^Z%FO&$XIDV49
M+V_@3+U'C6)*XK$;';7?UHM1ARBQ6[W9OH7#^RQU_,MV\-@U!33D'45RV^W8
M^0TOD$A0-_1&<^T_%A^FO0?044>U;&6WLT<-O*UH)>%\<K5+<\&_!B0FNK'/
M2=VFN#^;8=W)R+&84&[*[<6JUEN:D*ND9N.\MAQV8T\B4[)<B(CLH82'D--M
M27U%M3OQC>.B+0W7D75U T20,<V.0HNESC@A"X- 3' ..'+DWJ=?NLY+C;K"
M\+[6YF#I(FKI!8 =0(("N<2H+<V!"E7(7%@?E@20"&SS(!%.G3@4E.X  I[M
MM=E,?@&.6-<#+DX9U"W+WVV[Q*34  [BO$BOUZA)0D]M8^3!Y6F[FRDKKN.7
MP' GR-/9IM0DK27ER$CFWW-?+8>/NT\!<>%. 0+QKCN2:^/$4._OW\@:ZE!
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MT)^SSV\.-/*FEH%9IWI7W;?KT4X$K1J1N*^'NIP'APTE.6CZ"@_3Z](M)1@
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MG8=;5RUP7<('N;*[WFM2V>I>)<,=:6J:$N!H @N44E03N*5!XZYC_P P/=;
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MES@, %4H42]?YW9O.7[%?K5"#<639Y(GX_=HJX[CLM_J1),!V0]%GN7.,Z"
MM+227!0)(.I]@M.I?[<.O9]EZH;$]S(XK@MMGN=K823%-!(@5[?XC 3H>Q[-
M)!:=59>S9L_JWT>-VV.>1\;_ #HBR>(AS2QH$C)&M#F"-S2TD:B-!500E3TM
M'JDP>8];K5(N$)B_37;5#M]HD2@+S>Y,X)2G\OM;#)FF0M=?@4V@<W#;7U?Z
M0]1-NZOV.VWJP<US)P$"J]Q!(. 0@E%1./*OG_U;T?=]+;Y/M,^#(BH*8:2
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M?[VFO-/46Z%LTQ)Q\QP'^HBOT)>D72T=CTOMMTYN=A;.]\+#4.+S=6XK:B5
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MK&U<RZ!3LRQ2Y<5!\RJ5!0![3KIOI1=.@ZD9"\_S&/;[VG[Q7@[^^SII]WZ
M;K,&J^SFMK@=@9.QKC_H>:M3S%IQ&79:XG8_O-?:;>=TE;\1KT3*=#BX<S7P
MB:Q0">5-3?\ N5$Q<GYQU+03_36:)]N]#3AI!(X@%Q %./A"&DJCU(XVWM^9
M,4\3U$4J//QWTAD/ XTJ\Q719]3>,!2$BXLU*DIJ'1MS&FPYJCCI?,**2">X
MTFL \4J5&!99&R6"W,CK"T*;2JO&I*0:B@.VIXP2[MISG L[#2IN5R<0E0Z>
MU.7:OM^O618W2 .-8V1XU<C3:W",J7(#O0*CS!13^S4/RH>XEV.-3MW!T4>E
MF??2VQJ2MM:(M&XR5)-5+!Y0E(!43N#S#1<SLV^ S/'A%3[/MT_4&X-M(3XW
M9FA>NXT2QW-5LH)RPD+#S*N5JBN /-0A>W#?7+=V]3I;.]-M#'J:!F,O\:]+
M[!Z 6E]M8N[R5[9#@1V^SA70F9LNUVQF[72*[%B/A)10H=6E*_N%:4@<I5X<
M=3O]2;BTM6W=]!IA<F6)QR6J;/0C;+Z\?9;9=N,[>808<N=<EKN[C;M*W M&
ME0'&5BE?=PTL7J]LCB!("WV&H;C^VSJ&,$P3AU+-O(7GH;4]BKD9\5:710YT
M^?*17AK?=BZAM=^C\RU#@U,S7&^L^BMQZ,D#+Z1CU*>'G6*<ADFA#:M^!W_9
MMK8M)3.M#^9"X+2)RRV+OSC5QC1%_F3* V\E"36='0*I!2D55(8'W32JDBGE
MKG77728W6 [I: ?/Q-\8_P!XP?\ I-X<QX>#:Z!T-U>=MN1M=X3\C*[P'/RW
MD\OT..?)R'(FFEG18W-5P)4A21S!0)IM2M16M=<,,!A*' &O0-I*9QJ:BBD-
M>S8DQ'PT9"7DH(HE#12MRA)^Z$K"1R\=]/(81@2M61KUHX-T]E1PN@CJ="GP
MF0M+I^$)*0>91Y0X@U)HG:GGI=!=AQJXXB-I(R.5=BU68J'SD\?+-*)2PT!R
MK<"@4H!1L$H!X?7J];V32-3_ (?MK!7>X)_#AQ/$\J=_"\37)F-RWVN5E '(
MC^C2O])1!H$_6=9W;]M\Z02.:C!E6L;AN@@C+&N60U*NTA-KM+DA">"0AI.P
MYEF@K0[CE/ >6NBV,38+?6WA]M<_NI'33@..)S[J=2SMR8L*U+Z:DK3#ZW4"
M*N.*E*<6M--QNASB?'PUN%A"1;QNR("^^M&W6<?.2#'2H"=PKL?.7!M/X3+B
M$5X445;U551H22234ZR :6BL6V5SL@:U9%WFH2HD.53Q!W!IOP( KH!)Q- G
M\2<:8?N'GJT-NQ2HI4H*0HJ)*J< /?X<-M0S/T#'.E:'S.3E42;Q++SCKRS5
M:U<Q.X-""!MOP&JHP 6K3F:6HW*D'+?Y:G<'@!QX^/EH<<4&55'!05SI+39@
M)KS4I4GA4^SRJ-2,<@*XU4+DSK4L,TJNRTU-/"OMV\B/AIITCEB_S41:?,"<
M34FK"L*@M$<?JX 4VWX5UBIOBK.#.E:V?A\]N/'PU6IYPIR>;^].IJC]U6 9
M%_X?O/\ XSF_\.K5M_QGOK8(/Y3/W17) WW\MJ>>FU,E'-I!K4>&QK]?NXZ0
MTN6%')'E05VK[N'V:3LI#1B0-_$^ V/T^T#0GOI.%&@ ?3OXZ<M%9)^VF_V
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MP,3O,$CM(+BW!ITJK0BE%SYD"OM)TEL%S8=,V;+8-?)Y+3@\M!!"N0M!X.*
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MR 04PERNT65>WG39'[NFV71*;?<5M!_\E6TB,E#D..>1D32^7'"\I16@((0
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M@?8=9'H_58=06EP1@)V@]Q*'ZC7)?[G=JMNH_1[J+:6@%\^SW0 _S-A<]O\
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M/5L#(\07A5Q_-5>F19U=7775IER2_P RT%]_D=65(50*YS4BE-M>3;VZ+W%
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MV]^?&3*CWF7<5=-^3)$V.ZEQJ/\ $FC*E!H-H2.7EV.,N+&.]U-E8UT)!5I
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M >2P_P"45S0*) H:U(/'8FH/ ^8]VF<:D-&I \-Z[_H!328TE& 5XUX'A]'
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M#)9\PJ*E_*Q@E2BS'4H=0TJ$NR#1UP4X@<B3Y:WUQ<G - R%<&9$P'F]<S7
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ME#"B"HJ%0@$4%:$BGEK/63@Z,.-8:=K6DM %31P_*"]"98_+UD-@)"^1"PH
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M%PKV+YNW-C_I]@6VWE@:6QZ6 -1 U @ X>$(#@HIBQ?+M\V_9<@C!RY6[YJ
MVIX_,*<#4B.X'V9"UJ4M703U&U%)V*DUWJ=_M]DA<T7%F2(9"UQ3 8@X)R7
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MJ_$BE10BA/LW&Q\JTUYER%;"21A7SW;>?\WEHI"I*.RHZ.ODDL+5L$O-*)\
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M@?MRY5]R1Y4Z=$G'G"W%=);0;8CN%]L(:"T%"24"2T\%?"6W 4[I-=$1)&(
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M3U'(X<+G242V@\M=:W97>[><8T=*\O3(G .TN>KD  S(S3$!*EGAM-)(<&D
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MS?[)9,GMK$R-=H#%YML.[0FI\8.)BW!B/.9?91*82ZL)6$\R0HCQ.E?#!<L
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M.W&XW)V%$MMJ@M1W%/..K#:%*5S*)4 JCU#U/M/2&UG<]YE;':L:O$EQX-:
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M=6-W!DXRG"$#'S=^I&RA>26]=KEXF^PGKR# 80;HS?F7%*9;@*8*%$=5;P0
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MXU0@^!Y_=IT0_B#D<*ENI-;"GY:C)=);@Y(JRH&.XM*DD4(4EQ2%>ZE-129
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MPYC*+9 N=DMUWD/JE7*-<6+[C%U?8-WL]]MTQB?;YC42\L+ZK2^=I:&UBG*
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MB4]5U:+HS$*U$T*D<!M72O42R_J/2UR!B^%)1V&,@G_H%PJY8.$5VP\\/?\
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M=)4M'!) ]NWD!N -J:%IAHYOX5!2#0@U!IX@U! X$Z,001PH*$(<J\MG\2[
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MA[O#6.=N,"J=8/8":WJTZ1W1L8:YD!#N)D: ?84_"GK[=^I3&\I6+8EFX.7
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MI4@SPV8D\#@=0HEG *M* \*<O^&%#39<9[PW)CF'YYW><G<ZV@R% XACZE!
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MLTP-C U8%U-[VS]2([D0VY;+;L-MT$(2^X$*(K0$CB*G5"2]E:=.%6X8V2%
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M,XZ1_G/YS_LC 8TU2[E$CJ6I2^99))4L\RB?:2>-=>?9'22/U/<:^CL%E/*
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M-,,22 3@ %KOP.YG;:XEAC%>X^!62YA3:467N*P([+\M W4S<?S%Z.VA];2
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M;*I,>/?<K6L);)?DY3?W[G?0X0CXN1X5KX<->6]YWS>=R>3N%U-("<BXAO\
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MUQ&.\LQ<Q N) *\UXX<PB<$QK6_.=K5^#E1.ZG4S[O?CDW':7FPNY+8;U#5
MO*&KP["OW4EN?,,+@2X]MDMK?D%L)2T^&P2M/*H !1=##*V0:00[ZJD=(W2H
MKH=MLZ$/#UX1D2&\XQ&2ZM=M7=)PM^3VB(2%Q&WD-(?84Z00VXI#G(7$J4*
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M>3%^EON%9CL5V0'#LWVJ'N[>8B/_ )HT>?-^MWO-'E1?I;[A68['=E!P[/\
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EBBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHH:**&BBAHHK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g382677f_01b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_01b.jpg
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MQ "R  $  P$  P$!             P8(!P$%"00* 0$! 0$  P$! 0
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MX.DPKN9AJC & , L5Q^,+;\TV+WP;FGFO.;GBYNHXRL%Y'1\'!TF%=S,-48
MP!@%BN/QA;?FFQ>^#<T\UYS<\7-U'&5@O(Z/@X.DPKN9AJC & , L5Q^,+;\
MTV+WP;FGFO.;GBYNHXRL%Y'1\'!TF%=S,-48 P!@%BN/QA;?FFQ>^#<T\UYS
M<\7-U'&5@O(Z/@X.DPKGZ/IWF8:HP#S@# +%<?C"V_--B]\&YIYKSFYXN;J.
M,K!>1T?!P=)A9.'I"&B>6>-)2Q58N[P0%ZK)4M3H^.3,'68)J6&4[#!PSFMM
MS)1OT)0&O]@I70TK]E>\T]F6:5/=^+M9*H^_0COP.DK,9WCYVI(W6-L:]DCG
M<$C7LD7W%['&5OJK?N[*R]/%W&8_(RXZPV.T]_=,KO6-VDKI4[8FLXK*G;&G
MOIVM0V'SO3(CBKB$RK2/ MTBXJ<$C2:9S=>N(!^.;A9.77+Z3*W-V3TY+&RM
M(IP="9>BHBMN;6@OL=G);3KJN9[HW_A*6TMFOQ5G;]Z*I.QBULG:QS:=B;(+
M;62RK]9'25JS:B.KUZ3M4DY?B$:B:./1?IQGKV\]\1YBKN2A-=KOD;:Q-3)N
MO58,8E-L=5(](V1V[3KBMLV;S=%CYDKJY5U8?/;/G$^GA@%BN/QA;?FFQ>^#
M<T\UYS<\7-U'&5@O(Z/@X.DPL?$!-@#Y5XY)J</+V&T-7*!_#T% 31E;FY>8
M6<TT!'Q5AC];-@C27W-)06U^T/T]?IUK6]ZTMFRY&'=N-EP\,UG*I=B[F*&5
MT,LDBO1&,CF9[T3G*NB2-[6?6[--3+WQ%BY]F96'-SP5<.ZA-W\TT39XHHD8
MJO?) _W)F-1%58W=C_J]NNAWKU9!/0FN(H%NOR]5!9J=FD-1#?,/YX4,@TR[
MS"#)"BWT>8E0I%KMV%MR;'0T^%)Z>:5I2>HM7L/UAA=27#T&5YJE9*<S^[3(
M)DZCG.M2(Y]6TV21CTU14G;[KXY^=KM4T5?6WHK89D5SF2=:@NV'78&=ZN,_
M_)N-8VI$K67*;HHWL7146!_O,E@Y'HJ+S-3(&>ESWD, L5Q^,+;\TV+WP;FG
MFO.;GBYNHXRL%Y'1\'!TF%JX7E"X/E[C*9 G*[638N\5TX6QVY@\JK0;P\BR
MM$I8!(IUB2,BA-ZZSK#"T.O:UU-;UULUMCVYJ&\\5=KSUJL\5^%S9K"/=!$J
M/1>>9L:H]T;>+FM5'.^JG$Q]_4X<CL?+T+->U;KS8Z=CH*RL;8F1S%18X72(
ML;9'<&O>BM9]94[#37K <HA<'Q-J$M4"/98".LT2_P 5UK@:R<'@UB&D[5+S
M>YPR!L5HG38PN<-?T0VV\A+AS)&GT*TTA*->U?6I<!+2Q"4;E=N4K131K0AQ
M<N-9!%)/)+WKHI9Y7,=(Y4<C7(BR->CT5&M1IZC]#6;DAR.:7(4K+L39E@D3
M(SYB#+/L2QUXH>Y;-!7A9(V%C>1SF*K8G,6-R*]RN,,YZ!/HD8!T[FNFS?'G
M,')U)L8JPYJMWFR &LK3M.EI5)D%AEL[W_W!)  EHAE>NE*VG4JU]&\\JWSA
M+VV]YY7!9-JLO5K\S'(OM]]7-<GRM>Q6O:O!6N14XGB'I_GL?NC8V(W#BGH_
M'V\= ]BI[-(VM<U?D<Q[7,<G%'-5%X'OO3Y"\A&\KT2P<<5H.R3=3O=#+9;F
M7$C5H25F+,'$5K\2';=:5'1ITTZAK3Z=]=I?0M/[2=9H>G-'<<^[L?D=M566
M;U/(5'(DBZ0-DDG;'#WSM4Y&/D5&\R=K5[4[40SO4[(;7K[,R.,W5;DJ8^[C
M;C56).:=T<5=TL_<,T7G>R)%=R+V.3W5[%4[9ZVK;/7>Q\4V$^5IUIKKW'3L
M?5KU3K?9[NQ;WH6P&Q%P)D)>YP=;L83T?:@GVV@' T,#M+Z[+C^GE.J\[]=L
MMD<WD\1D;4M.UCG8SD@M5[$]E+"QRNCL.?)9BAF:K9VN1L3HD:QJ\S'2(]7K
MZ^_C[A,;M[%9K%UH;]/*-RJ/L5+5:O46LDL+):K6159IX'H^N]CG3-E5[W)R
MO9'W:,3$^>BCZ!& ?TR?_IG0O1(8#'VCG2S2=%Y@(B^PJYW&X@TQR%8XP1:F
MV&9FJN]6.F8(-W:D-%2#@6FMZVTT6CHVC?\ 4;^4FWO0N>"/*[^M2T-YNBT@
M?2:V2Y,QJZ(DE=?<DB:NJ-DF=%R]K&3-[6G\DOXC[E_D'!8EP_IU4AR.Q63<
MUAEYSHJ4$CDU58K">_%,Y-%='"V7F['O@=V./@_Z?+=<:?SA7 N(I:VN*MUE
MC*@T'&L4^+L-JA#9P-\ ,@.VB7&D14J@P5@MI\MLT>-)9T\E?_3ZV? 'ISF<
MUAM]U8-FS7%6Y:971K$KQS3Q.E:K&N;8;9JQO1S62-=(DK(7M1Z.]W4_H]ZG
M8/!9ST\MV-\0T42C4DLJYZV9(*\K(G(]S75G5;<D:M<^-S(W1/G8Y8U;[VAV
M[UES$7,R=7/F)6QW%LJBO(XJN,+:^'I^AF*'OQR+HQV_&_%_'*7Q8XI!C#@[
M@J#&Y1?;]JX,[KK^=>MMRK<M5+%V6S=:_'K\!9CGQTM1VEMWQ*:TJ-+5K'=X
MU6+&DB3KWG.Z)Z<WK[T&H7*%2Y6HPU*+F9%%R-66MDX;C.:FQ:JZ7LA>T<]J
MQ/:])%B=73N^1LK%Y<&Y\_'T@, [-ZB>2K#R]SAR?R#9RWBI*;M\RTPV\ZMU
M$9"Q9K\9!0H>EJ5V(,3%BMM-HU]'3I2O_DI6]^;^I&Y\EO+?F5W%E7N?9GNR
M(B*JJC(HW*R*)NO!L;&HU$3LXKQ557P+TNVGB]C^GF'VQB&-94KT8E541$62
M61B232NTXODD<YSE7MX)P1$2B40P^.NU2D(JWB<?R8%ABCHZ\R#D@R#43A"V
MR!;"8[$Q\M)H&C'F].K[ 4AS>M=&FU].];P-OS6*V=IV:EQF.M1V8W,M/5Z-
MKN:Y%;,Y8V2/T8J(J\K'K_ZKP/(]QP5K6W[M6[1?DZ<M61CZC$8K[+'-5KH&
MI(^.-72(JM3GD8FJ_6;Q.E\V5FQUL3C/4IRQ4>6JY)5JPDTF3I3\^N%@X[5S
MFG)^*V-8:S52P#R;4462ZCV=2E=KI6U=3;6L\GWSB\EC(L7\7EZ>8QDM69U5
M]99EBB9\3(LT?+-! YCUL.D>Y.1575%5>7E/$_3_ "^*RL^6^#PM["96*W"V
MW';2%)9G_"Q)#)S0V+#7L;7;'&U>=$3E5$3F1ZG"<\ /8PP"Q7'XPMOS38O?
M!N:>:\YN>+FZCC*P7D='P<'28=;]--,L]LY;J1U6K]-N!E/L5<LCU-NEVIU*
M$MB6)@= T#'.W(\029D3BM)2@5AHMSIZ-J96CI3OS#TPPF5R^\*=C$UJ5V:E
M9AF6M9M5ZS;&DB<L3%LO:V5[G:(C&MD7@JL<W5%\*]6<]B,+LF[7S%J_1@OU
M9X$M5:EJVZLJQ.5TSTJL<Z)C&ZJLCW1MXHDC7:*G;O7K*6B=O7&TU;:N#"RQ
MO'#3+]A8N_'-\.NI,9+$QLH>5+<9/DP;,="RXSX0+1#CAJ6T.:<5K24M->=_
MR"MY7(9_%WLQ4C@N28Q$69+5.V^RYDCF2/=)15T2,BD:^*)KU65$1R.5$1&,
M]>_QMIX?';=RU#"7)+%*/*JJ0+4O4V5&R1MDC8V*^C9E?+$YDLSF-2)55JM1
M557OPIGH$^C!@%BN/QA;?FFQ>^#<T\UYS<\7-U'&5@O(Z/@X.DPNO [$R3S?
MQ"Q7+''T^P/<CU!F%M4J(.?'5^1>FA&QY(P M2!CV&5*Z-CN*0@CK=FI2=*V
MK6YZ?QWI=]X:/&68Z61=DZZ13R-1[(7K*U&O<QVC7HB_^#E1'_5541=3 ]2)
M*$7I[G),K5EO8QN*LK+7C<YCYF)$Y71M>W5S%7[;456:<Z(JIHO?O6O&/1=A
MXM9%@2Z#5G:/.O5;B:7XX$XIL7'K>KY81Y]V:J(L]9%)U>)YAZ6$+=+4I\9U
M*$H0VRCK>Q/72O+6R6):R"3'XI:$JP4):;:$U-$M3-E66NDLZZ696K/'(Z15
M=&Y&HU&L;KZT_C_;9<Q>9DFLLR>9;D84L9**\[(P75^#@="D5ET,'_R0JVM)
M&V-$9(U7*YSGNTQ5GHP]_C +%<?C"V_--B]\&YIYKSFYXN;J.,K!>1T?!P=)
MA[3C6)EI_D*DP<#5XB[S<O9XB.B:?8''68&S'EEMLC0\T\Q*0CS$66XK6GW$
MF"[0WTJ[5&M=.?JVO3N9#<E"ACZD-^_-;C9'7F54BG>YR(V.14DB5&.7ZRI)
M'HFJ\Z<3\F[+M+&[7R&1R5R?'8^"G*^2U"B+- QK55TL2+'*BR-3ZB+%)J[1
M.1VNAJ'U7T B/K'$7)!$-P?7#[-&V6$L0?$7*FN0&9Z6A+/*@@S;#<C;+A+N
MQT?#@MA/O,FDB"E([)2FW%I:3[6]7-NR5\5AMS20X*M8M1313-Q]_P"+262*
M>1K941]BQ(K&1M2)SFR/C8].15:YR,3T_P"B^YHK67SFU(I]PVZU26"6!V3Q
MWP2PQRUXWOB565JT:/?*]TK&NB9))&O.B.:U7KBC/1A] # +%<?C"V_--B]\
M&YIYKSFYXN;J.,K!>1T?!P=)A7M;VG>E)4I*M?3I25;2K6_UZ4G>MZW_ .F9
MJ*J+JG8IJ*B*FBZ*@WM6])3M2MI;TK3:=JWM+>E*ZRM-IWOJHTI7T[Z.CIW]
M.-5T1.W1.']/]OD+HFJKV:KQ_K_O\IXR 8!8KC\86WYIL7O@W-/-><W/%S=1
MQE8+R.CX.#I,*[F8:HP!@# +%<?C"V_--B]\&YIYKSFYXN;J.,K!>1T?!P=)
MA7<S#5& , 8!8KC\86WYIL7O@W-/-><W/%S=1QE8+R.CX.#I,*[F8:HP!@#
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M^0>P<#_\:4__ &#7/\EC]G;3_2\=^6A_L'[VWE^KY/\ -3_Y![!P/_QI3_\
M8-<_R6/V=M/]+QWY:'^P?O;>7ZOD_P U/_D*,3XDGS#_ 'J\\E/&"' & , 8
M!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8
M!,3XDGS#_>KP"+6MJWK2=;WO>^C6M:Z=[WO]&M:U].]X!4*OR!Q_>'YD6D7V
MD70JNE>Q6$:H6ZO6<B ,VM;>A9MB#D3G8HC;C:DZ0_IO>U)5K7TZWK0NBENP
M08!,3XDGS#_>KP#CGJ BB9W@KF&'#L4747Y#CBVC[LDY++K\)%#?=!#A[DU/
MM:V]!0Y0#;HY1J-;<$'>6\G6U(UK8J<3-?!PZ.7BN*N4ZU6N)./RN,.2>4X"
M;AN/D;CYNI\+R5)DH_COAB6%:J=6)DOO%R7@YTA)8P@3*(T8H-#JG$.9#I>S
MY>TWCE.!@$Q/B2?,/]ZO .6\T0\-8.(N2X6PUVY6Z%D*9.-2%8XZ89*Y FVV
MQ%$,A4<8@D,8BV[*9;7'H==0THI"-+Z4]*=BIQ[#AWI'E96V \HW^USY5@OM
MLM%=8M*[+,1+G)D*-6:TB+KE;Y,I5>X]XVKO&L]& NNN(C!!#=O;)>(<.?[1
M"6XA7?\ !KW*<C )B?$D^8?[U> <MYH&ES.(N2A("?E*K-$4R<9CK%!Q5BFY
MB)(6(K7M$;%4\.1MI9:VNLTC[J8>DFMN=H,A3R$:P5.)EKT)"BQ,1S;70K%*
MDB0G*+VPJ+-"<V,2% B9U,I8JZLASGBK52VM.VZMR8;Z@@VB(<+8G2R^Z^\4
MK<0Z=[#>.4X& 3$^))\P_P!ZO *'R60V)QU>C'W?9V JI-FD$;OA7%NAQ@P7
M2225<E!)690VQV&E+5+-:VL)*=N:U]&"IQ,T^CAY4U'\L7,>VO3T+9;=6@XB
MN2G,U[YTLE%W6Z@&/(1\Y<N1J_5[/'MV)^13)A12Q-LC"OZ(:>=07K3<0KC9
MF4Y& 3$^))\P_P!ZO .2<Z57\<\,<H4[6GMN6.E348PH<ZOQA+1;K&EADC2-
MLWJK E"%MH=:=DND%+B-=MK;?6UL5.)P3TF2]KF[7ZC3.1YF?L7)Z+9QB-;9
MJ:-X8DA7XYKCEA53#A#>#EJK/L@@+C[C[)ND2;19+BE)T,X+D0KO8;0RG(P"
M8GQ)/F'^]7@'*N;&;"1P[R@S4H:NV&RN4:Q:AH2VA0TG6I(S4>ZOL)F-L;K%
M<DA$,I6YH>1<; ?<0E!*T,J6K0J<3D?I39A@83D&)X_M=4OW#$9;8Q'&5YK(
MO#03TX:76(TOD8*68X)B*]1W'*]:G-#-.N1XDEUNU8>TZR..0\*[7V\35>#D
M8!,3XDGS#_>KP#G'+%9K5SXPY JMSFOPW4IRI30=EL.S (]N"A$B+)D)8DR6
M0Y$M!1[ ^W2-%I4(X.E:'TJ:4O6Q471>PXCZ3ZCQ;!0O)=FXOY/CN4Q;WR+*
MR\Y)1$/&UH&ND:)D)>)JKE< :8(&D8V,L^E+.-0DN3$<&<UI(J!4(B%=K[35
M^4Y& 3$^))\P_P!ZO .1\Z5)=]X8Y1I;393C]FI4U$BI!?@!C4F/#]<)X-^U
MF 59HH8MM#C>Y)YL'KHUI_?9];6Q4[%13A/I1E;?,6[U'&<G2=BF.5-6KB]F
MX2$\QPXTPJ-;XW'W3QH5SA.Q6.M.B-1ZR''TF.-2;93[FE(T-L7(A7>SY#9F
M4Y& 3$^))\P_WJ\ X[S\_,C<'\MD5VL@W2=:H%C7%5.2JCM\"L!?L*])C7:.
MR,8NY..HVK;45MI:#WDH87T(6I6A4XH9V]*EMB:W+W+B.(JO*P-,18(Z3XTL
M=M])5@X#W+I/J TM>=VIRK<0\;<8"ICYUCV>/,?&!.+5M8BM$>SCOOQ#IWR_
M]FY<IP, F)\23YA_O5X!1>1[ /5*!<[*79T4L>"KLE)+MCD#NU?<"AV=[9D&
MJOIQI=D*2_M*&0$JTLQY:&D?M+UK!4XF?_2CRQ<.51.47K9;B[*BLVV-AX4"
MQ\1:X5O]<';#D(^9$MU4%G[3"28AUDA2U1<H >ZT0RT\.XVT^*[I40KDTTT-
M:93D8!,3XDGS#_>KP#G?*H 4IQG?HV1'&* .JDP*6.;2Y_D<5UAT5:5I>H-5
M+C[/<$Z_3H".?9-?5K6F7$.:2K0J<3+GHM4T,1Z@X0<$'LH[DV%EG;!^57+'
M#5AL<G=*LU;IIR<I7-MUN=^9!C).4<;C"$*"@W&''&X]GI:)5D0Z=[#<.4X&
M 3$^))\P_P!ZO ./\]2YE?X1Y8G(Z".LQ\30K$<)7XP^W1DA+/L@KV@40Z@*
M1>V'?IZ_1"J3*.:3M N]/*1O0J<3E7I,B*_&5NZD0EFAKD3*6.,)F+&#QYS]
M19@Q\>#9%!%L!GJ.O?(5\L^X\)&D!J;-;# 8WMG3*'-N;5$*[_7#_HU?E.1@
M$Q/B2?,/]ZO .;\ME187%O(1DXNO(AQ:A-D2:K;)6&'K/L;0;BWDSDI46"K6
M%'N)UU5*C&G3][WI+"%.J2G8J<3+?H<=KDG#<OV2NGA@)FKY%"2/&0+'-PK/
M&AU7@E5Q].Q^?V@+RARXE@O%K4P$'$;6/O3&G"$ENJB'3^)N;*<# )B?$D^8
M?[U> <YY8CHN7XPY CIQ%3<AB:C-[D_QY,2->I;00X;A;Y=GL$/K<O PX"&.
MW=.%Z"1.RTZWO2T:WH5.)FGT7.QI4=S(;% T-\0_D9J3W<Z+R)?[\W:C)V.?
MM$E'2PO)\+7+G0_PG)3[J0(=P%H'8![9HBW4EN+R(5QM;*<C )B?$D^8?[U>
M <4]14=#2_ W+T787+ S#'T.<'-?J4,#8K2QUF4[$?KD'*O#Q,I-,'I:6,T8
MXV%VJ=;(4EC3F]%*G$SWZ6K7?)#E;G43DB-Y%FK-8]<=3A?*-W(]-H$9-:A:
MHY"@TJO0_ U[LXASL (VZ82^G178K-7HEX?2Q&%1#IVFB:?]FZ<IP, F)\23
MYA_O5X!RGF[\0_DYRC^$H6 L=F_ UAU!P-J"AI.O2Q^P7--ARD78WAJ]*M+1
MUMMB'N-A%/Z0T^M#2UJT*G'M.%^DF%B PN0'*_7U)HP%HC/RXM=KXDXVXBY.
METR-5 3>TV.K\>4^CBC1P,\QH6/,(B@2S1TN-;]H%&&)>B%=_P FQ,IR, F)
M\23YA_O5X!5K?".6:JV*NLZKRG9R'-C&]6VLLW2K[66UMO6K#4")"(8LT1T[
M_P"L$LH=)"/V=N)Z>G!4.0\#<#A\*+Y$D4$49<QR9/5^;FPN,N*H7AJB JK%
M<8K$9N+I4/,V-6Y8P%GKR!Y)[[Q:]-ITEIMI*=BJNIH'!R, F)\23YA_O5X!
M#@# & , F)\23YA_O5X!#@# & , F)\23YA_O5X!#@# & , F)\23YA_O5X!
M#@# & , Z-)<<SR3B=@I&)%6\XXRZHA#+G4<7M>D.-KUKH6CIZ-]'3K?Z<YY
MD*?A_+NT_91?ZUG+S(!^7=I^RB_UK..9 /R[M/V47^M9QS(!^7=I^RB_UK..
M9 >QDN2)O9I*0$BCBMO.-LH<8[9W:6U[1I;BU+UKKKZ.GHUK6M?H_P#/'*@/
MP_F-9_WP7]&GZ^-$ _,:S_O@OZ-/U\:(!^8UG_?!?T:?KXT0#\QK/^^"_HT_
M7QH@*43XDGS#_>KRD(< 8 P!@$Q/B2?,/]ZO (< 8 P!@$Q/B2?,/]ZO (<
M8 P!@$Q/B2?,/]ZO (< 8 P!@$Q/B2?,/]ZO (< 8 P!@$Q/B2?,/]ZO (<
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M!H.Z4)SER9>8D1I)QM3.I)@-.D/,DL,/.M:4MR('<38^4Y& 3$^))\P_WJ\
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M0+B2S\I5@?<=&U?D.Y4(6*@]UF;EHX+L-#>PQK3PXK9K8(?MFV4B+Q-+8(,
MF)\23YA_O5X!ROF+\"?E],?F517>2*=[1$_>5/8IX]\=DGOO,;<<\FKE:4R?
M]WG:;?ZV]=+&F^TU]*<%377L*AZ?0^-86JF1'$W'%OXWITG/6.XMP4]3]4Z(
MBYB8DF!YF/AXK3G1%M%E,>VLB)1MO33RG$*TE24)%555>T[[@Y& 3$^))\P_
MWJ\ XOSX+(&<5V)B,HT#R09V\,ZFH67CD#EB%D&6)85X@DRC25QH(<IJ+80H
MA+JY4?V13>G]:<VCLU"IQ,\^C*TQ,2#<^*7>-+QQK.[Y#Y)NK0QO"\-Q'Q1)
M**52I&?"XHB:M<>0(F+@X?5MCU]@9)N%GO$$%M+=1VK0L0Z=\INC*<# )B?$
MD^8?[U> 9Y]3T&FP<.3(;B'#61+%19PBO.4NZ\A0ET&KURA9I^BW"H\=1$_<
M92DVYL+8<IL,(K3 [FW7F7V$.LN%.F\3T7I&^ZM<3RVX1X(4(CE'D0IZEPM.
MO'']7XMD'I9ITWC&IU+D:OU*VQL!6GUJ>2HB+CF2"SB'AAAQG&F4$#N)IW!R
M, F)\23YA_O5X!QCGDH4+BZ?)-.C(T=!4)I9DOSE,^G !O:Y<1*$N\OU]DB5
MK:G%;TE#+:-ZD%;T,KH2[O>"IQ_TIRCT6R)<KQ5;S"Y14NG?./*XT>6CD^<Y
MOC]1(4G'BQ@T+S384M2/*40.,UI+4GMIE#"^O'Z3M0*G%Q"NXFN,IR, F)\2
M3YA_O5X!GOU-HLR^'Y?\+QL],*19*(Y:8RJ2U0KMK-X\;N4,OD%BLV>]SM:K
M%6FE531/92+QPSPVNML=QLG;3J(ITWB5OTF6MRQ<?6:-(E)!W53Y,NL#7*U9
M[W1.0N0:9Q^R2&13(.]6&@V^[QYLGL0EU\9PD]X],>\PR2XZ^RX\X0.31346
M4Y& 3$^))\P_WJ\ SAZIA@#N(UQQ4:%.2<G?N,(RFUZ2J<->(ZQ\@'WJ%%I$
M(?6;+9Z?530S+ XSMQR5/1'BI1M]QM_;:65Q3IO$J/I+J,; 05[D6:_4:A;G
M^0+37^7JU6>*:3QRX/RA7G8Q@E9!=)LMKB9B.%K+@.@O9"_87&G^WTR*4LEA
M) XUOE.1@$Q/B2?,/]ZO .)>H,")E>(K7%SQ(XD/([AQ)!XOB2R<XL]BJ9!<
M;3^6]0=8LDJ_HEI"F2A'&W8MY*#-+3MG2M"IQ*AZ30Y2-XB5%G0@T-%QE[O(
M=.(&XNG>&=VBF?>R2HFY&\=VN7G+=#2=B,**<(?EB-R$DZC9BTI0^WTQ"NXF
MELIR, F)\23YA_O5X!%K>];Z=;WK?Z];Z-_^V >-[WO?3O?3O?Z=[^G> , 8
M!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8
M!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8!,3XDGS#_>KP"' & , 8
M![.5CC0) P8D9YMU!#V_^VO:5I4XI2'&U:3U5MK3OIUO73K> >O[-W]T[_"7
A]7 '9N_NG?X2_JX [-W]T[_"7]7 '9N_NG?X2_JX!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g382677f_02a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_02a.jpg
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M P,# P,# P,# P,# P,# P,# __" !$( S0"U ,!$0 "$0$#$0'_Q %9  $
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M(D6NTO+O>V-MM;NX7-KQ$_,3]3&F_%>[Z5\/[_Z5_3WR9G;?^<@
M 8@TS>8[C<IQ$_),\W@8;A,]<;FU[J_.PX_)<)K/;PGFP:W#\+G;%89&1Y/%
M"X7%M>K['9#V36              ,*Z-O]-Y^M/Y^OTBWV]S(<CC*KV\8MB<
MQ+LSA+/8W]%X>_537]U4UGMX27*8F(87.4?C[]M=$$P&QZ(\ ^C_ %!^J_C_
M #;O7/@           !0^%Q7>]N  !06]S7W%L*"WN*^XMX]C<I?+_'=M=
M                I/'VY*KV\0   !T^=?=Z4
M                                  6NTN]'.#?1%5[>.T_6>-ZX<RZM
M9+'(3#-8+/O0N:ZB\<[>-N.Q<1R+LNK:E\?[7!L#L<NS&#S%NFB5UQ;Y/VK4
M                                    !@S0NB<F;]\YY\4U8\UO:,D[
M/JFA?S[])=E5&]G?OG(:(\ ^C]\OH'YNQEJVW9-VG4=#?G[Z1SWT+FEOM[KL
MFG.N_<YCV.REAQ^1H+>ZRYN.D 8U,()MQEXU^3(#/JG*         ! )C7NN
MG%E4?)YHT5S,VGAZ 4SFP  '!X=U1OQ$YOB:]%:6TJR;%S        ->>;]0
MU1Y'V?;OL?$,\]!YN(+@-BU4Y)V>_9#&92VS3^48JU+<]R>U\'&K7)^QPW"9
MW,&Z:-K_ ,ZZ;M-UGC>J_)>RR[,X.>;!K< UW9L[;_SC+&WZ6(^0]-6B2GT0
M).6$?8       !;$:<^E. *Z>#@E4/+6GTCIR=AZ#TO72F;X #@\DZHWMB>8
MGO)$6(CIF-$R        .(:.\'^B-X^\_.]HL[VQ8_(Z8\1[YOW]#?-/;71K
MAS/JNJW)>S>D_P!._)URNK2#8#8IUG]=T/\ G_Z0SOT#F]QN+7-&\:#I!PCZ
M%N-S:[?]FX9"L%L&*M2W/9GJ7)!0D%/DOAU%N)F7$       %C1Y_P#M1 IB
M]FR_G5FZFJ91-"8.EHS,>==2R&Q$/>JB92 ##.D;[>K_ !\$U_8ZOV\;?;W.
M=]_YQ]3%;[V_=70       !J1Q[MN'=*WN>;!K<MS&$U&X[V_8?H_+JSW\-U
M>X_/\,PF?UPYGU79KJ7(X/@MBUDY7UV]7^/C^-R>R'3>4ZU<PZSD#8M8ZJ/3
MN]//;CL/$8;A,]BS5-QV3Z=R@8>3CDLB9"B@(8G.R,VH       ^#S^]?/%5
M497IG>?RKO:0 !B,\+:XPE+<"'NS1/T :T<OZUL!T3F6+=3W&.XW*PC!;#/-
M@UOLJHNUY90_>= KB(PF<L2)S@BW$5+$FY(L*=KU,I        !1>'O6^_@!
M3>7K4^OD             !KU73I7Z49 B?0SQ]*T   &/C\\M<8^E[=43O%
M#$^H;I),GBKA<VOU,"+8G,3'-8(4U]80U-^1R7PC1;CL+P<GR7 DH
M                  /-_P!O.#3'H?X^F2HD    :&R\5JXV-A^@ZB0
M                              !$9CS3]O/(D3Z+>/H    !1'YG:XB<
MOTO^<SPX/'_UHW3HJEE-4B+FB-IMIE1&LL3G>4,)(5!1&8D=@    -+XJOZ(
M1,[<*<=U4V]           '!B%5>T=YGJ)R/$@     85JIT0]:-DJ*MQ_.L
M     >#5<:DR][J)VM@-&ZZ=BZ9AD559,$1-,P1;4R)$+3V'>59'3-J+@
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M34    -'ZX\ZZZ=DHGUB\J@              !:T?              *I-:
M     8BJITA]*8S$^F7E5+T@  #$\QX]>M-I/8'RJSE$C@TP]*,W457V)[C[
M.XZ" )ER*9-\1TE224N8      !KGS7J=LM+P              ?,3S,#+&W
MZ7DC9M4    \ZO2G2"J,E'JEY598B0 !K],>6WK3%3=VB?1>BH#@TJ]*,U45
M1R*NLMI,"M)"C#J;X7DI2)F>D3      \V%5[A;#T/FGQ@^&?T"@6O[(
M         !S,9VW_ )S8,=DK!C\ENIW#@.[_ '?YZ    HSRP]*=9JHJ#:NF
M=GJ9R3#I,52U4JC6RJ/DV]IGTS\ZNT &.-9VKHH].ZOSH+>ZDF2Q/11Z3K/Z
MZ        !C IDTQEA&D7!/HF/8[)@             <EUO++H\_7H\_38CI
M/+L[[_S@    =1HY73H;7%E  !+#T&\ZMP:9Y  -:.7=:V*Z5RW4KCW;,O[G
MHT\V#6]<^:]4R+LFK6RUN\@;'K'&Q:S'DW1&/DWLFZ(BGH)$C&"=H$
M                      6,UDJC!E404Y)\9]IG9BF;@   8'Y_T><9[7H9
MA,]W^GG/-@UO'6M;5<[JSD^5Q'$,2[!KM*30L!%S+Z(,FSPS%,8^3DY$V  *
M4LY;#M)@ 4A5@I2J*(K3J(H5A5'2#O+R4IV'<"A(Z594EI) 18N)4%H)65P
M                         (0:ZII"W)GR+26XC*<WHQ=$U,KA"-2DB*LO
MI'"RF12B/H@"?LJCE%T/@L9E P.F3&441,MR;VBT$J-C4
M             "R%[   !1GP5X
M   +)89#@                    ')>[_'BB\/>UVEX
M    !R=_KY<1(            %KM+RS65_+<QA      .2\WU@*?S]*/PN
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MTFRN)FN<U\              4OC[57MX]=-7952 *;R]>RJGMKH '!R#@Y
M       !T>?IW^GF !UTU=E5( %)X^W?Z>?952!P<@X.0
M                                        "P8_):,<#^BKO>V6TG5^
M.9+VC4]&>"?1.\W>_G8 8HU#=-6^4=BVJZWQF.XS*YSW[G0
M  &LW+>MX[UO::3Q]]X>\?/'GY\Z_3=]R&-R[N.D;(=-Y3!<!L6EG#^_<FT/
M5N/XFU#==Q.T<*               P;H71.9C..^<\&$-$Z%KOS;J.V_8N)9
M V+619[*^TIX;] 5'IY;%]+Y9B73MV^(JV.Z7RJE\_;'^N;-$\1FMGNJ<A^I
M@ #$Q@=50&2T:\)FIM:IG0      !HYP;Z(WC[S\[BPX_):C<<[=N)VGA6E_
M$.^;Q]Y^>(WC,K>;VP[:Z-%^!_1=;[V\^V'6IIG,!F_>^>X:TG?,6ZGN.Q/2
M>6R[,X0 #H-&(JE2,B2PPG[A*9C;I'(     ,!<\Z5I_QGN>XG:>%9YZ!S?S
MP^;OJ+;#K_%=7>4=AW+[9P:;9W7]"_GWZ1W>[M\]Z7\0[YL7TOEFL?*^O;O=
MV^>M%>!_1>:=XT'LJIDV4P\2P^<V=ZIR$ "VD8*@DIC\E1R2$       \T/E
M[ZURGMFF[9=?XK(,AC//OYU^FZSW\,Z;[SK8[IG*@-)^&?0.Q72>6Z/\(^A?
M0'Z)^9L#\_Z1-\[KNH_'>W>A/T;\PZ1\*^A-^?H7YJ  H"VEC*DC:9BBG)>
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M'<_G[6'E?7MO.R</U$XWW#;OLG#P (R8^3@I.<48XA:YG(*-A4
M
M                             4QP@              "H3]      'P=
M"             .Q/<     #0Y5)(0HW'FF U4VY              Q$JX,E
MHS_3-^2   !C@U,57D[3;::,-S2           *1.,D]AL5#*D2     -=DV
MPNYG-&-*J:(             &.HGY,@3&6J9NZ0   ,;$'3\EU,HJ<950
M        *$AT3(YC(T3D")
M             UT3\E<9_1AVJFB         !$4U"*LS+3,E2       !"S#
M:;F3]$GF,7S            BJ;.9!1F>FJI     !HFJNA+T;4HP-53;D
M      #%BKI1*38V)EL2       !B9.O2>38-$TFG#<T@          # RKO
M,YJ<_4U5:0      !U!           'VGZ          /D^$
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MZP               DA\IW$[1PFJ]?(
M                                         #%A D_9,"M1V%48U3EI
M%M+(F0(A29&CN+"FT'R9*1AQ.546 O9;4UR).8;30F0D8D3=3+J,;IH">(Q.
MG/R)J                          "V&$4B3HQDG(A;2Y%$4Y<"D*@QR9P
M18D_)TE\19DW=$.35'651<R*DG.U'45!PFA.TD**@L*<J(
M                                  $-PF=ZJ/0
M   <S$VSNOBU6EY'<9E0                    $Q+LQA*CU\N3B',@
M   !Q#F0'514.VND        #B YD!Q#F0    XAS(#KIJ^ICB)^ZJ0
M    ,2Z?NO737:K2]N]W8WB]L;5:7G11Z1K%Y>79C!]E5-HL[V\WUA;[:ZZZ
M:J^XMJ?S]:7Q]JOW\)%DL7%\3F+;;7<_V'68#KVRWB]L:?R]*CU\Z3Q]JOV\
M9OG==DN4Q0       $7Q67PYI6^7"XM9GF\#"<'L%RN;027*8FT6=\.46BSO
MKQ>V-?<6W=7YP["YW(6QZQCO6]ID.1Q=/Y^M)X^\FRN'L./R4@R&-R)LNK
M        4OC[66ROZ;R];K=V=)X^_!<;FUMMK=W"YM;=;75RN;6"X#8Y9E\)
MT4>EVO++B!./]=V:<Y_7(UB\O>+RQO%[84%O<]-'I7W%M1^'O8,?D_J:9SG]
M=[JZ        */Q]^CS](9A,](,AC$J;R]JCT\KE=6EKM+RNN+?OK\^NFJ%X
M//R?*XBSV5]>;VPO5_C[!CLG=;NSM=K>=M5!%@Q^3D&1QDBR6+
M                                             &H7&NXUMQ;V>ROI
M%DL7LCTWE&CW!_H?IHKW'[5PB:YS 6>ROM)^&?0/"=T.W<"D.2Q@
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M^^[<]CXC5>OCI=P_OOW51N[W;Y\X-(N$_0F[W=OGL   <%K!6'P6TOP
M  -;N9=6F.:P61]FU6\WMAH3\^?2>[?=/GS4GC_;,!\\Z7ZB_5WQY4>GGB'3
M=X@6O;),,U@NFCTSCOG/-(N$_0F[G=?GOF0   H#I*PIRF+F=X      -$>
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MFM]_"G\_3[JII?'VN5U:X4T;?Z7Q]YMG=?GNPZU]3    %N.HN11%<4Q6
M          UWYMU'8CI/+@                     ,>ZYL_P 4U9%V75@
M                                                          -8
M4]I9C9-&.JJ:$             $-39"]%F,@HR3$S2)   A)@=-Y.XS?-.+9
M@          ""IC1)"0HEAF"FH     :1*JV(ZYG:93C6JFW(
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M:9&<J:@       (XCK         !1%<7=->          "D+&@
M <%(7(D*0       ,5:CN='X^X              R;M6H72ZM      !9+#(
M8YUK:@               .#+NXZ/VUT@ : *I*1<WS4^+_PS^@4"U_9
M       )CF\#*\MANFBOYBK'^N[-ZZ_8_P 09CW31    !C$U,57,R$B2<VZ
MAY-_(7VJ             !-L[KTTSN MMI=]'GZ8IU'=/=K[]_.2[WEB !@A
M-L*PSHCSN^:/JF+8K,            5?KXW&ZM>^OSNUY8P["Y[?OZ&^:,@[
M%K(    @!"4]I6E3I^Z:*\#^C              +A<6UQN;6C\?>^7V.AF%S
M_IO]2_(M?<6P
M                      $'(VGL+RB?@$>)""TEV+"7XB!8BZ%H)D8]3E-%
M.513ER! RU%X(ZF0H^"C*LL*>Q&5SD                          $:-:
M57:B?F!HF:S'T6Y,O1&2XQ/$Q0F.D[5HCY#BYPF,H&7H@!>"Q)JD9%,:0OTL
MBD2(\9-(#"32QK$R*8SJB8@                            X.0   <'(
M              (_CLG;;6[                    ',Q,<U@AU450["YX
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M&L]O"J]O&-8O+=M=%_R&,H_'WUCY9UV3Y7$9\Z%S6UVEY(LEB[M>60
M     AV%SL<QF5MMK=UGOX4_GZ=E5-=[VU#X7-YO;"*XG,]M5-TN[+'^N[/I
MQQ;N]ZO<?ZA_5GQ\                                     (]CLG$L
M-F[Y?X^Z7=G:K2\^ICMJH[:Z*?S];9:W=7[>%SNK2VVMWH5\^_26<M\YWMSV
M/B(
M                         %FLK_1K@GT3<+FUSYT/FN&=(WP8WUG;-F^I
M<BPCHG0K=;76\/>/GG6SF/5]MNP\3                 USYIU/%VJ;C2^7
MMNYW7Y[T(^?/I3B&RW4.39MWKGT7Q67T@X1]#4WEZ[I]PX#@7GW2MM^Q<1
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MTYXMW;<;M/"0                                     .(<R '!R
M
M                                            :6JI B#IVZ4XYJIM
MZ              +6G$R<CHV(IF2)   $&-5%4@.Q&S<TX>FD
M     =1C!-0G8&&48D:M)H"^&>T8TJIH0             "W$33/D96IF_I
M  &*4P(I2ZF9YIQ5,                "G( F2(RE$Y'B0
M                                ,()H"\F948IJIHP            "
M,D5B<FS&5:9N"0   !"S'":\FB+ZC'%4              #Y(6GDS+"91(
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M*Y$"N1 KD0*Y$"N1 KD0*Y$"N1 KD0*Y$"N1 KD0*Y$"N1 KD0*I!@TK\#
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M(X<S'I>:OC.90F+14#+4'E,5)#EX#FO)_GR;F<2\_OCJ.I.G4G/+6H"/L@&
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M\T0U-X<>0[ MR;45_D15TI1SB9 N)D"XF0+B9 N)D"XF0+B9 N)D"XF0+B9
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MF(]8O6C75Q9#D\1BX[;ECK=U+;K>C=WD>.0R/UI1+[0H_1=N_EO3[^^K-/\
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MOTZ_3K].OTZ_3K].OTZ_3K].OTZ_3K].OTZMU6@]QX'13A^K\7__V@ ( 0(
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MMI^2>BSUULLNN^5Z;:5_S-]YL=EDG(,D<(#R>&LB9*R5"DIV0,.K"999;!9
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MAEIA_C=;;>N RN RN RN RN RN RN RN RN RN RN RN RN RN RN RN RN
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MX$ZLE=L:A,4;N;@Y5@DF/!A,HC;--FJCFYV^7E*$6XWB3UCL(LVOHY9EU/3
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MK3B7[[I:Y<SO]))9[3>L=;5QQ#2<D"6K2W+G&6VJ7R+913-EQCU]3WGF(9P
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MQ'CK6N*A:MNA1=:Z;J#^Z\6+%U>'Y16TGDY=9(B&JV. #0Z^Z,?MIX<+.6A
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M-2SECLHU7R=S8P0T[Q8EN/ QNWL40>U,;K?)$W2;C^.98U9BD"'7)<A9/;A
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M]J/$IU/M1XE.I]J/O;X52QA1_CBTF]R5.?1->/I5Q;7>@5G"4GO0XVIP.6U
MU2P<)^6/H:82LNMI4/O)4(T9]'**,$&=<H\H&#:C_;7%V/\ _N,_O0]_*5ZC
M'E(NTMMLJS4/N1,RPR&#"8;6^]M[JXX$&:4I*2JA)%F5$Z"##]F\;)#=X6A,
MD))HQSP#.<<!QZ6W"E)5*J:%%)EPRG_E-R^M_#&8LIM6]%$YX!6328<7?7 I
MUS F=A E*0G3E)ABZ!8%\N]DI56+2?F(,C#:_,BREAI=L);M&TH5$E4I 5RA
M]IRQ94"$2G44];CQ8(N>P<2EZZHKI()L6<QPU498;/F&R3=VEVK*)FTH53)
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MS.8&(4PT3LE[8&0$Q+0*@)S,QC,A"DOG[],IBR4D3XU3R$&4(O;FSV*G+-D
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M=(AV\W?9J0+NVLUR/3.CBGC,^"&TL ;5TT6JA1:,Y5T"J"PM*=OM;,P%*$K
M7.R-+#5RPVVE"4NJ4L34% :/6"3)5.(YX#2$@/625:*UBA:D46!.DI)F:L1A
M3I;"6T-)409VIJGHY)&LG-"VE;+:?#N+"A.BS+!QT'DC8I"2ZA 4=!PSM3D!
M9G9JK,^"'=@E*4(12%3M3*+4OU9 UF=/!#0;EI;$&<Z02D8,>')."TA+<@XE
MI-?2LI5,XDBFBLT51\,0V;Q;2)TV9*"C.5<Q9-$^.F 70WLP_LC*<YU6AD_5
M[4"ZW:Q;L6B53E*<JA+UT<<!ID-I58),YFD+4@@2E,3%?)"4-) <L35HK6)V
MBB0L#&DZ1P2H,%>S 2$-T&=JTY0!D -9E5@AYE6SVHNZEA0G@R3S&<62$F\J
M2V!79FLKP4U <)JQ1\,0V;Q;0)TV9+M4RKF+)HG3C@S2FVAPI4H!2D@6;0-D
M:5,P/U8:V%E3KI !ZO1*IY1(48X4V-F'4/-"=,B%%.#!72,47A1L*2A*)"FL
M_I3%C1VX<8PD)I*L%,AZX%V?""Y;32)RDJW@ID9HQP$L64V;U8PT_=VL'#ZH
M^*2&_AMI9E3:Z=B>*OJ\LZ(6]H&[)?6,-J6U(GBH^C+CCX=KIJ<>5,I6N0#D
MJD4X> 0J\(&S?L&N=$LQX)PZL!JRQTJ](V0HV?HT&B<YG$(:1=Y;1VJU4!*9
MGCX(3=1LQ>2DJ)ILR! H%!F9XZ,9H@,LI;#EE<YS(FA=BB4J#CP8H<?T?AOA
M$KLZ4Z;>$'&*\4H6L!'P[;J4&NT9V*<0E:X\D6Y#Q.S[=F?# 1=DH$FK>D5'
MK*$L>"O!B,%5U" A+:5&U.FTFU(2JHZU-."B$/&M: <XG_@^+4RLN)2M5LJH
M,IX+9-/U82T4H#Q1;ZQ$C4*$FF@S-0RQ]TCHH!(-JU2)V1))IX<.>&T,";SM
M5J@"B9)YL<"[I0W\19M*TC9E.0E1/2Y,L-E2$MI43,J)E,+*;-H"4Z)TRG@A
M14 ;L;RI%>E2J0R2!HE/+ ;HV 8<56H4BS31BG1/+DA2F4)4VRD6IFDFR%&S
M1B.&LYX2+-;LC34@RDOMHSG%"KRWHJ)DGC582K^*&[F4.+N^R,M+K6M)9T@2
MJD4UXHO!: 6TVH=)5)^[10FOAIK)XX6ZTA)NS823,Z1"DA5 E@!PUQ>[I=Y[
MBVC(5!8D.-,QPXH8+2FPT%-[6J<[ D1^J*9C N=JL0GX?Q6V9D2 %J,UTR'"
MD<0G#X/3T#^S+O6H*GP4I(7]+2T^O.@%(Z-%(571*'RGHR0#];2_A*?E-EX3
M$YY0<8(I'%!19)F9SFJU,5&U.U1@IB20H3,YA2@292I,YU04)2+!0$_LB<AR
MF-F4SET:2*152*1PB%"\ 6E.6M$JT3("A?2GC5EQ0FR.A.5>&OAGEBE,I3J)
M!TC-5((H)P5019$E)"3P#!%H)F;-FDE6B<%)-&2 FR9 2Z2JL1II&0T1:<33
M*1I(F,2@#(\<!HC[M,I?LTC-*%W:RIZ:IJLU6A+#,4B0I3BB=RWB56B%3MSE
M*9F231161'1Z]O\ :QP"X#:%1!*3EI!!I@*E)E+02+)*2*3BE082FS()$A(E
M-&+1(HR0I)2+*D@'@%4$A,U*39,R53&+2)HC9V="0%9J!)%,YT$T8HH33:M3
M)),ZIS-)H@S!F3.A2DTR P$8 (#"D_="4L$I52E2)9(4W9T5]*DS)%1G.<\M
M<6E)ILA-9I JG33+&:8.U3.<NS5F@MV9A1!)F;4Q4;4[5&"FB"S9T"JU69VL
M<YSGEG%LIIM3K,K7TK,Y3RRG&TLTVK59E:KM69RGEE%(D9DS!(,U=*D&=.&/
MAY#8RE+)%*35])5,JK5.E^U.++HH!F,!!Q@BD0$63HSD9J"J:]*=JG#33 V:
M0))D."OUP!8H"+&'HXLHX84DIH6J9X:.81MBG3M6JS*U]*4Y3RRC03+1L\5)
M^<P!=T)M6;-*E 615,)Z<L2L\(9%(2D#,/\ !\,!]S(B7# .DE21*:5%)EBH
MP1:T@9 &2E"8%5J1I@!<Y@S!!D0<A$"5L*3/2"E6J:YF<S/_ *0&A:#(ZMI4
MC3.D3IIBS*BW;_:G:GGBTL4V"GB5*?JB9M2( ("B H"JT,/-15"EK3I+;L'Z
MOZ8:X-T.YLV?TX(#EZ4KXFS9FE2DS' #1/#EB@*"2 " I0! $@")TB0A:2-%
MSI9I>J%O/&;[AIE4 .BD<'*28+]S7LBHTIE-/%5*/BGE;6\BJB03P#'E@.(4
M47A-2OF(PC)FD8LE;21C"3/B!,ARQLT?ZDX2<I^4B[78)+I3:TC( 58,)@-,
M-I#EE4[2J 4KL$4"FD4'_I"4(2 ](E5J<A)11+129T@TXLT%W9R90TE9GTM*
MUHREC%9A:%I;#I96H$*-%F5%5=-=4::9W@H;EI&S-:E 8**IDRR8H4TXA)O(
M+=1T2'%60:IB1G.%)6A.U0N2CI% !3:"J!:_5R'#*&FT&6W6$DI."14;)R@2
M!RSAQE:%V6[%@A4@E,J*+4Z2%3HIPT0Z\4A5U0\N>EI2M8,&CBG3*%6FT_";
M79&FFDA,Y2E*9I$XO3222II=@'#958PXPE<IY)P6DI2;N$O&THJLS3/1,J0&
M\/6-=1$75^X5+O!0:Y$6&[0$Z;()41.FJ?\ DT*5:#B:BDD&FL48(!1-#*6K
M(LJ(/2F:<,\,\--<)"+2+ D+*B#+%/#CIPTUPH$3"D!)R@3YS%HVE*LE.DHJ
MT36*<%$6""19 I49R!FFF<Z":#7&%2BI)F229II33DQ50536E:C24J(P2P0E
MAG0V<K'ZI35PXCC$X+CUJVN5L!:K)XIU9(*M*15:(M&R55S(JA24"DJMX>E.
M8Y0(5=KQI[6=O*55\&(8@!!^#4'&"<*I'CP'APQ\9?5!5X'1 J3.LY3_ /2A
M=Y>W:$DGBA5X2\;MY<#(2_TD5923+%!OEPO:WDHI*3.K@)4#R'%!=NWW-[4F
M6&A6,9,4>/&=7=CQXSJ[L,^6KO:G72M-H F0%9G,?1A++ MWYSHC%E/S##&W
MOMZ+2CU9FCB3(" Y>5_$^7SQSY3I).*M,)O5W,VEC]!PB+U\2XI=AP2G@Z7Y
MD0Q=1._.]'#+++"9T"-M?K\XEXX!,R[21F$-W/S%1O%Q=,@JDD?/1A3315!<
M69(2)GBA7]O7\/Y:DRG5G(I)R"@0;W=+TIRS21-7J42#&U6 +P@R5SCA]"[V
M]NT#_H..#>MK\/<9Z($QFE2KA)X(^,:O!>NPZ59'&E4Z,H-$(OB*+58Q$5B%
MW,N*^%#?1P=%/Y@?LXA^\(N]GZ)SVC/_  +O3N[0F</^>WG>N*(3_%\R1P&%
M;:IL:/[*!+US]#K+N[4@^J'6ST$NT<8$XOSKI"6PX)DU=:+ 4M64)HY91:N;
M@5*L5$<1I@N+Z"1,\4?'[65VM69D$4X@*S%BTL#&4T?IQ0'6B%-JJ(^77(N=
M"29:ROGEZ57=X3:6)'@@7:ZB30)Y85>+P0&DB'[T1)IQ8L\4^>7H^&O0FT<I
M'JA-W9$FD)D.*'ML1IH*0,9(E"=K05J*AP&K/*<.?ROX$QLBX5K'T!/EJC9W
M=S[[Z*J#Q8^+T/-!R2F.G.@"F59HBP%+(QA-'/R1M[HL+;_2O%\J%W\L2A3"
MT*"[4L.*9X87<_*PV4-*I"I3!,\9&(PK^[I;#-FBS*N>0G!Z6?)+MOG5 G/H
MC/3Q0BZ-=!"9?Z\=<-^?W8311:X:J<BDT3QQ;#R$*PI4;)&?YH5=/+U;1Y8D
M5"I(PTX3P0AM=#R]-7'@XA*';HLD7!+MMR76I(0GUG]!&R;8:#?U1"?._*/N
MRA6DD54_,:E"J%7M'1<NZCV3'Q-]%MAI5E"35,TJ41AP""RZRB6,  C@(B]>
M2N&:6S,<1D<]!^7)O]]2A+33OW:A*=<Q.G)"7FT,%M0!'1J/[4(-^D+W+2E5
M/T_%.K%]0FFPHK]4_GBPRC9.-4%&+@R>E;32K#JD$!6(RKXH_N-[2B_M(KM%
M<QEE_P#Y#) O-WH%1'T3BAVZ78V7'4A)5B3925\@@-,M(X2 2>$PJ]7!(:OR
M-(6:+4N##B.. X[XA!LJRXCQCEB]79WP8=4M8^E)1LIX)F<;'8-;/%9$)NC$
M_@[P*N&<M50HR?*[]>6_#J71QJ4?5Z%79IQ*GT=)(-(X84ZX9-I$SP"'_/7Q
MH@R1^GZJ:./T%"P"@X#%O9E.0*($6+J@)\HNO:ECQE2L?5'HOC/M-I/BFH>A
M^WUA(<)(@!5>P6<]HB#_ #E>I/HOGU3_  ?+BE724XF7K]0B[MN=,,I]4%Y]
M02T*R:H_N"USNF,4Y,$(O3&Z6)CT7E+&Z-N?9_B] =OA("C(2$X"T]$Q(U1>
MT-^'F)9U2Y(6%]9$APV$GYO0IU?02"3Q1>'O9J=HS?ZQYA]8_OGT7#]G]X_*
MO@;BTLH<1I+2"<EF@43@76[>7.V<)TIDXSH199N"PX<86?X1ZX=\P\P\8^:L
M0KIRDX,$"XW-"UK>--D$R2.<\DX;N@Z213E4:^6%7BYM[1X$44F660IHAN\7
MI&S?4*1^F.N"W=$+5>'='1!,AA-&2@<,)0L?\A>DOAQ<0H]#U^N25(OK+M 4
M)!Q"IS33*=7Z41L[W<WDWG%_UIA"[Z@W?RE!G+"?G)..4A@AQIH4;%0 'U:!
M!0\E2%[55!$L"<?HO;RD+#)29&1D>AAJ^7)O-]N;R[NUT6Y* X2;-,_](_\
MCW>WW(%Q;NQ8NY.D3/E) HPR G']I52SL[/^O#.F#=G6B]<)T&F7$:;.5)C8
M>6750>.'I2X!*6>%7J^4WYVO#(5UX23288NEV8MW9<IF1QTTU"R*:85=54+K
M2<2A^DC'P/F%W4XRGHG)D5(@C%A$?!^67=2 N@FLR^M()3PQLE4WA9FH_,,@
MAX-A:- %#DC(+2E,J>2-AYQ='-N.LFI67%F,?!W)E3%Q/24K#Q_PB<X1=&>B
MD9SA/'%_<<0M+:E&1((!TS5Z+DZA"RTF4R 9#2-9_P#-17=W [;0HI.CBXXJ
M>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*GM
M4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:HYXJ>U1SQ4]JCGBI[5'
M/%3VJ.>*GM4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:HYXJ>U1SQ
M4]JCO14]JCGA2[K;D@R-H2^?\H;W>)[),JJZ3**GM4<\5/:HYXJ>U1SQ4]JC
MGBI[5'/%3VJ.>*GM4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:HYX
MJ>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*G
MM4<\5/:HYXJ>U1SQ4]JCGBI[5'/%3VJ.>*GM4<\5/:H[T5/:H[T+^%MZ$IVA
M*N>7)^3O/\]?[Q^7VTUB$LW@CX@-G2L#1<7(I! &!(E49*43@BQ07$I 610"
MO#S'*#%X_F)]7Y1WA1^\/S ME:= LJ4G1$C*M157,2DG+11A+"D_=+0Y+1H*
M@.LJL6:Q*H\,XO/['\7Y.\=+?K_>CK<D=;DCK<D=;DCK<D=;DCK<D=;DCK<D
M=;DCK<D=;DCK<D=;DCK<D=;DCK<D=;DCK<D=;DCK<D=;DCK<D=;DCK<D=;DC
MK<D=;DCK<D=;DCK<D'>SM4_6P3RURPQ3:G%XLSW@]7Y1V=4T?O".MR1UN2.M
MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN
M2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR1UN2.MR09;;X2=/T)^J%^(V77KE^
MU_K%YLSZG\7^/__:  @! P(&/P*IKW3?=BIKW3?=BIKW3?=BIKW3?=BIKW3?
M=BIKW3?=BIKW3?=BIKW3?=BIKW3?=BIKW3?=BIKW3?=BIKW3?=BIKW3?=BIK
MW3?=BIKW3?=BIKW3?=BTTVE2<C*#_!%37NF^[%37NF^[%37NF^[%37NF^[%3
M7NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^
M[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[%37
MNF^[%37NF^[%37NF^[%37NF^[%37NF^[%37NF^[Z;=W6I"I8*(W[NL8W[NL8
MW[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8W[NL8
MW[NL8W[NL8W[NL8W[NL8W[NL8VBW+P$8S:E&_=UC&_=UC&_=UC&_=UC&_=UC
M&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC
M&_=UC&_=UC&_=UC&_=UC&_=UC&_=UC%K;N6I?2,!UQ;;:%=&V96N"NC*9#+!
M093!X>4?X!;$IB?$?\1LR"4IFHFH#]*!C-$;5:F[5D*LVM.1J,LQE.<J90IE
MSII,CQ0&04A2JIT"?#EJQ8X<<O*:&!2DX53LA)XS3D!C;I=IM%*4VK-($Y(
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M@&%7AXS=6HD\)]#:[ZW8#D[-6#@X?1?+LY3=2!P4A0/)%WX5?N*B\V\*Y\1
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M139&$]92L9*IPWIJ-U4H!29T2.'A%<%;8DEY 7QT@YY3X_EA\N\O2X'G6OO
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M&';K=[8>:4G241(VE!)HD)2*L9HAX#;(V!3,F1F+8221(63B3,\-%*57<?\
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MF,%..C#EKA4G%:1F>'&,1RBF-FRXI*)SX.#%EE7&U:40Y!>#AVA$CP8I52&
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M!9]#3[.\2XGUPRX.FIJGB491Y>TR"IU31D!6>A%LH0G(54\DXLWULIG4:P>
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M0>AD]0.[PY%1SO\  )Y")G6\,R,Q/3$QF<MM,?7=?/R7Z9R_VW7S\E^F<O\
M;=?/R7Z9R_VW7S\E^F<O]MU\_)?IG+_;=?/R7Z9R_P!MU\_)?IG+_;=?/R7Z
M9R_VW7S\E^F<O]MU\_)?IG+_ &W7S\E^F<O]MU\_)?IG+_;=?/R7Z9R_VW7S
M\E^F<O\ ;=?/R7Z9R_VW7S\E^F<O]MU\_)?IG+_;=?/R7Z9R_P!MU\_)?IG+
M_;=?/R7Z9R_VW7S\E^F<O]MU\_)?IG+_ &W7S\E^F<O]MU\_)?IG+_;=?/R7
MZ9R_VW43QY'HF)^^,M/5^*;NT_A%5ZJBVL3Y@@]8L$3VD>*(+P[%K[EQWU57
MR:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)K[EQWU57R:^Y
M<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]5
M5\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)K[EQWU57R:E*:.$:X?G*
M6-4VQMU[@,R4;:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)
MK[EQWU57R:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)K[EQ
MWU57R:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)K[EQWU57
MR:^Y<=]55\FON7'?55?)K[EQWU57R:^Y<=]55\FON7'?55?)KE^Z,?R^/F<'
M9E\/'P\/'MM\[AZ--K)JWL@VOP]JBA7AHUI(8,0:PV*7SI7,%RQDF;3$[=,:
M6T(.!8 F,,6:F1!1O$&I@BQ9?#$Q$Q^P/E'!\III9M^:U4[,"?QC/[)4L%C6
M6'!6K5T#QOL./>>%8S(CL"QDR*9@1 9F9U-95>\2^>^K%Z*Q=A*S6XH>F'1/
M%'+-9#QR,+DQX8+?2+:-Y392MZI*.$N6P8,=QGIB=ITVT:GN!,<;!KAS6PO>
M.-@KW@CA0^-,#N6T=$3/1J@C'V($LPT5IN*X2Y53D';?:3O! 1S67LN>F.,X
MGIC4TSQQ$/(79N6NR1;@%/>:(L9"RR2L.DV!/$4\<[=,ZJ14^BQN2<=5E*/0
M5;DJ;818J!U(6[DD# '8)*1*(B>+?]V0=>H=T^*(Y2VH44#M.Y\5ABPVC;X=
M]!9[ ^G7<H6H8YU4Y;$SU<"',()'\>NDAC>=HZ8Z9ZMOR[Z*!(9D=N*(F)D=
MXWCBCP;QJ>$QGA+@+8HGA+^#/P%J9(A&!C<I*8B(CX9F>J-1/$.T[;3O&T[[
M1&WP[S.FTR\0U5ZMB6'(BN8MMM)6 S,[\SBJ3\>I_%U_B\/3^]J9(H&(C>9F
M8B(B.N9F?!&N+C'AF-X+BCAF)VVG?JVG?4AQ#QQ&\AO'%$3U3(]<1.JRI\<[
M-J*FP2,\HRKOLQ+8WW$9"O.OR]7X]6+3FC":@&;RB>.5PL>(HD1WGBV\'7KB
MXHX>OBWCAV^'?JU!"0D,QO!043$Q/5,3U;3H8@PW,>((XHW(?X0QOTCK@XQX
M]N+AXHXN'?;BX>O;?1]W\39BI6JU:EW,MYA(XD776%!SK$>AHU%UB8[I\;>(
MZ>J4W:.23#IBS:K<M5VNWLU._%$[86(7 )/F>.(20G(_CZ-6J^29#\EA,A8Q
M-JS']:[/MRK,]$>,P.B?AF-_#^Z,E2L^\JDV,C9OU,CCZ)WNTJMMY_*\2I>!
M=E,S*I%@1N Q(_B9:=%SWHKNY5FKN7)B+YV,I#I%2Y&E&2[(01TQXA3'5J^/
M=^OE5*G"78LA8B_7EN3XD31%/O"1;.0X1;##'HZ1XIF=MKEA"\RJE-?NXF)%
M%R@YCB[Q1VM-47BAG:>SG EMTSOM$ZMSC57$XCLJ(D;07%++(\UO,.HJ] O'
MZ#:&S$0!%M^=!:R$HIWP8GO(F]8Y2[K>?B66>.&5YCC"U "PI,%[GT3O'5KB
M8G)1CFY\CX6C<J"VF'=E8 1A/*8-,[\=4[01]<:1D!"]V[_$UP6'++)?^%-R
M5Q?+))%*XH=FD2'HX8Z"C5-'+RR\ZYQJSUDNW+3V5@."Z7:9VHG7+>)J0J9D
M)X-MMBT=AZ[*BK-H8JVK@MS-FK6,IRN02BHQ-AR+MB5^CGCE"YVZ]IJIYEH\
M<[.A/9TU\GCUIICC+7.&.UO.Y[O=9X>OA#BG:.B=8(VQL@JF4I5RGYB[S>PM
M2&\]1MJ570/Y)CPZM*VS[^U9>]V:M9Q[U5ZU9UHG'<:YM*JE8DV3/TDS(E$0
M.^L$%6KET9=4)'+3:7>!44AKLBPNP;=J3%SXO9P#<A+;;;8]8&V7:U<S#MG.
MNM.L&/,74JN%E_GG(*:ED'M,\,Q&\=6L)?3789T'V;JZ<#].>*N'<$4*7.WT
MRL?9 @#PRN!\.E9E%U)G754&L? +0KLJ676#BR@S#BYD.X#4R(()C>-BB-JB
MZDPZEC+!6[5P.E!VQ2U->DAD>*XURZ6-X=X#A$9Z9Z/W;W9>=&P_L%6W5NUZ
M_*.PF;0*Y;("6"+1$T;%M.\<6_5OI%F]C^ U4LS*H=*6S6M6\Y8M)X>$S'G]
MG.-BCJB>O6,'&UAHWB[MW:-RPN14?;64Z?9^U.">-K!M 6Q^-(3O,:Y='$-P
M"AQMBO9-@(3S+O'6;C>&*[6=K/'V4RWG3^2)GB+5;)VZDPQ]XG9'&BBOD22A
M-2:F/B*S7"BV%=O$WAWF8)_%$3(ZQ3+-9AHKIS+U!;357%%]J[C655JJH:Y2
M8@$F:XC?E;[>+U:;;N8-N7J'B:E54K57M0%@;60-J^S/:$1)K:/TGYO5O&^L
M9BF],9NHH,J/-EA5TX=HM*"9ON_GT7A2,_#L,ZP'.HED4B[(&RJ$ R2@:1;'
MR&$(6>64Q/!^_'3&J36XSD8T+N5MU:+^40T ;6H CBKP9J5+K:G.%<;PKC\$
M]5! 8QM;,UKLOO9^83RWANWM#NU0R7W(R E$0F8^CWZ8C@C6"6."=5NT'E[U
MR1<B!<18VZAKNT"V6Y*+5ID'O,;COO.T]&L7471M4+&-P.3QIW'&D4C?.E4K
M5CKFIS&-4;%24,X>B/Q]&LE2J=VIQSV8=M7>R%5:VVH'=">(&L[68.CBBP4=
M$]/%TSJB-?%L"JFW7?<PO!70QU1<LYM;D@SLI[.D6\OBX6\.WAUD>3AV4J%R
M_P!V6#59R4PU-.]S+[)JK9(UPY?S@Z)*.G;>=/62'#S,DBQ1O5,?0+LM%/(Y
M"UWVO6ZB%,%2N50'2._#!<<ZLH+".L94\R-V,O'(X#J>]EV%G%PFPX1KX_97
M9]OS=MN'IU_B#!([5S:]6KEZ\*FPSL])KW*+L_59J/"R:WAM/B[?CF*.+HH?
M"JU@V5\52[8P&L9>FZ(-K\PR;RF3PCOTP,=,[].K#,B(+R>8OV,M>2N=PK,L
MS'!5&=RWY(1T],],SU_NN%N'B 6H?$;R/TE9R["2\68GQ6JB?Q_M$HLJ!RID
M2X#C>.)90:SCPB8&,3$QTQ/X91:4#TE($2F1Q+.5F+!XQZB'C&.B>B?P<ZSC
M:+VSUL=50PR_SB()DOW]"M8"L CA$ &!$8CJ@1C:(B/^!>T\L>?"I1#=O'A4
ME!RN)\ R8Q/[VE.-8DU''R3F/&7S!X&<,^#B']KDQ ((OG% Q!%^6>N?^.EF
M]:/EUJB&6'G_  5J&3+\L[1T?#JS9Q%[_#6 2XE*8,D#3F-O$EJA[19L0,Q)
M[$"QWVT>7J=Y#S]6I$NN5+'.=/('I:?9[)-DEB/SI6P3B.G5;+)7*29Q*L(G
MIY-E70T!/:.-?3N,^$9TWNMW&5Q/01KN9*(64P:YX'\HV[HKUT'/"32WDBZ!
M_'VI?>V768CB[+&3N],]?!'.1V6?WX@='W6[U)Y&87Q@A\KA!.8D>,Z]E0_1
MPZ51Q 8>*R/WMV9*YNR=X55K!,0RW9*)D$A,_-C:-R+\T8U[Q3D0[O8MNY5!
M!C*8L7X)5R5LO/#^.<B)>#HU[Q?D [PXM6TVH-C+@K7X9;SEKO(#^.$D(^'2
M\E3W7._*M53F);4LC$2:CF/G1M.XE^<,_O?@5W3[II[1FW</:'\ M[+S Y@J
M4+/H8;"?',S\18_CZNU_XO\ Z5MQ]E]Y7HCBZ^7O".R_R>'3NZ?>M?!ET\R*
M]B0!1M- \QE>P*_H2.4^.M@=!C\<Y:_CWE6N5PKREXB!2$G<KK+:&"83N!S'
M5K"WKSIL6[-3F/<4 ,L/F,C>8 1".B/!'_$O.\O_ +&OQ[?]EVVMS?WN#_DU
M@N5$1NAY'MX6S<L<V9_'QZD2B"$HF)B8WB8GHF)B>N)U"U@*UC'"(+C@$8^
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MCNS?QDXNY88\*^098KOQ_..3).ZJ]@;"%R7B3T%P]$QX=3C8L1=O6WS<R5R
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MB,I<QU-S J8BI#ZZ!2#)CEDXJS)GG\.[#B.(^J-HVV6E/<G(*2H!6I2VF +
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M)YHVEV+*5\(^ @(X+>-M5N\3.T!3N+059'*YEU[;)<%>JFNHCYMEI]$#$_\
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M,.+HG]I;6LJ!]=ZR4Y+!@EM6<;&!C/00E&E5:==-6L@>!->NL$I4$?FK4N!
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MOSXY9Q/XM(O]GJO6D<O6E!6DU8J*O9AUZNY#7Q"(%B2$&CT3&P[;[;:RGB(
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MGPY"[O1Q\?G0YHSQV(CK_HRMR_SMOAUP93(1.<R1#9OIKI=;;4#;^BU'FD#
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M[;+J<=WHSG;.[_OW+90'K[LX.E2L9EZK[^W9FLC/WN$:Z9XFQ7<;8X(G8?\
M%_*K(MHOU<97K%E+I6<9FL%F[6.R&)PXUT#3R>/[PV42#7'R9&N1$P2@( <7
MB</G\Q@<G7FAWCN9&_4KN+O)C,A::]]JL W+/9:5RQ!\"3Y;D+X D0']N53[
MMOH+HV:MROE57>5]-#H  @)96>0_1R?5,:OXCNU?HUU8FS/::]T:\D#GFT3Y
M1-JO,@YE<M_!$_EU9GO9<Q]BE-;:L-2*\&-KFAXQ<JI7GAY6_A_ 6$2XDXO
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M'JT#QSJ^\15OI(QN4*^M+N'_ *L#FZR(DORK_P [3<%[L7@<IAXD'XE0\M/
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M:I<$&0[]&%OW;DT$=XK UL-VM+%LO,;,]FY2Q@R_I:]C7$^,0%'1U[?MH87
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MJV^7OQ<OM5=;^#BVCBX.9MOJM_F3_P!(OVISL=G<?W:[.46,AF\C3"ZJCBT
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M>S1X9Z=6>P-:X:CF5V-FK;37-JFMKMBM9>A=>Z*GH,")1&(D.TZ[WW_=P@.
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MO/;]ZXYM\PN^[<9RI3D$(0RJ-/D\ *#L\$,R1'Q3.Y;=$%EIMN]]%D:>2'*
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MTLF[&A%2MVI)@+91QLW87+XH'IWWU1/:D.];.W+TI!MCC##9%-6$T/IE^-9
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M=&[-03_SF(=&_P /#^"WR.+A"W0.SP__ (>+$;R7\6&R&L#V'AY78%\SA_\
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MG1/\+Z9K5'^^,QJOW3RMHKN!RA#&*LLZD$X^6D@WF>3'.^C<O?AB9@XZ.O\
M:+=,;#JDVJSZ\6J\C%BOSEDOGHDQ(8<KBW&9B>G0JQ5,,'/NK)81C<8M*F6<
M;DZ$TFUK,FL^="V"MX[_ /6J'P;Q-2,SFK&9&C>&Z@'T<967]W9#&MKN75K
M+D.5D)F=_",>#?5SN[0S65QR7 ZOC[]<T'D,-3:4<%.@]Z6_1U%[K21P3%KV
M\;<8G2^[UO+6+F+59QS%U1HXNBOL>/>NS[L(:514,J7&JCG<6YL'>-_&G5-=
MLV]EJW NLJ!,0JXQ 'V8+/1QRJM9(7C$3'TJPGP;:EQ9"SD#7C:6$I<]55$5
M,1CB<=2M,55*BPX9?/$TNF=NB!Z=_P!N[[_Z6W_ZN[\'?3_: _W_ ".L&S;Q
M0R%D2GX)*KN/QP$ZJ-">(&5:[ F/")J$AG]^)_!WUL+\96^1\>.KQLLN!Z?Q
M\N?P8'#@R55\I>,K11T045YK@H2^$1.SQ[?",:K8^DH4U:BA2H!C;Q1CKGX3
M.>DI\,SOIU2TH'UK"R2Y+(W!BSC8AF-=[.[PL)M*C<EM;>=X$@M6*9S'^F!0
M3/XQUCN=MM[N'E<7_;^[KO+_ .=\'X>^?(]B]X)Y.WS?:,CR^'_[.W[45A5R
MJQ %(&\+"C2!QMN),$I 2C?JU#.V5>7)2$,[0K@DXZ9&"X]N*(GJU!M:M8%,
M"),,0&2+YL1)3$3,Z&M+E18,)8")8$.-8]!&*M^,@&?#MJY"<C1;./+@OPNW
M7.:)QQ;C<@63V8O%GH/;J_<-[_:L=_OBM=WR*8$1Q:B(BG81&.*9F9GHB(C3
M&8^Y6NK4TD,95<#P!PB)$N37)#Q0)Q\?X.Z^2H1RGY J?;!7XO.X[DT&D41U
MR^JSAGX>'3J&1KKM5'CPL2R.B?#!#,;$!C/3!1M,3HFXSO#D\<HI]%P"TXC^
M##UMJD41_&B9U6[HXEEBVJJSF9_+6"AEAI*V*X,%$0*55PF%#$?]<?3,[1I:
M4A"U) %*6/0(+6," #'@@1C\%ZZ!0-MH]CH?#VNQ$B)Q_H @F?\ -T-YXS%[
M-D-UDE\\:NTQ2"=^GQ@*6?E9KO!_LB_]Z1K!<K;;D/YFW_;=KL<[B_C<S?\
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ME-L6K("5QL-XS". .$8VF]B<HVK$Y>7>^,MC,A>][WCLUI6^WSWT$ A\R *
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M,8VIM)H73;:1,\<<%?LVRN*#G3,38KIG$%D.]5MF09D.8NQ5[P8G(UZE.<?
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M_!G3&XU%-:JM&E<>%XFRQS+M0;HUE$F1&N"TE&[2@XDI^;T:HW"& *W3K62
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MW!;L^U5;Q>),D,['XNVLI<*NEV-IYC)P\CM,[;V<;I0;:R^42875&>A9%$E
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M;=A<>URRMNLA86$PLH,>?8LJKQR5E'%P $F4QH.ZS=SIQC@H$SJ/B 8_I(^
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MG^K+7LS_ %9:]F?ZLM>S/]66O9G^K+7LS_5EKV9_JRU[,_U9:]F?ZLM>S/\
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M&,W7@[0XST&7*6$"&JJ:F<&S2[&G<[F\O)QT!I%CIKM@T5E@T.=NA,(K#@1
MJH:P85)7'*"MW)K$K#R_S-.RO%QJ.+UR)"@ UPLJIAH=QJ T(#BS I["XJVR
ML%*W\0N?04\H5!*$5''&72AZ:D!A:!FLTZ2!935J69!/#XK1P,B 48JA@?>@
M8<+!U.:?%V@-"?W82L+4'^CN#+PR>11IN]$QA%#76J[S=M$XT?P40HZXU,E#
M;Y+M6;O"LF<4%.]9'>&%DH9ST++JPL&X5?/ #WH$BIPYDO$R85B<"=-&'-;Z
M2L16UQ=L+6VP)U#N)'27&A"X#%+&"8L]AM;B7),O85,7/CB$9%I$#ZK<$(B<
MIW460*;RX J9H:IYH&W+SP-[.R'A!!D++'H\>9OD72 F; ('*OT<:S2S"V0=
M(9=23FN\&P+->]A]^AT2\;<AM/<*AM0%>DB9U4ZK+[C!8..8345?6O3#U=ES
M+MR5A67G.R.$=2DZ^(>$BFXC8I^I&%K U*EU?!!1YYKIKKJP9-""7)BZ24E,
M ;!KW..BAL@ :EF8PJQ\@DK9C*-Q=%7AN? P;:QRI;1>FLZ&+L3T)(-S#@E!
M7XKB_3&O3@-<1&G["&WT0W.D9P(1'QB=+<"5UE-(1$\'L':TM >P.$X+"ND/
M"1W '\+4I&!ZC\$#JCL9?P.I_3$WT_;_ *A+/&'U/_: _:W=<A\E<K6'CI)
M*"A"\*Y/*D<VP/RT.!IQA0/&^) :#\&QH @U2JL<^!J7AROO9#GRS>ZGK4RD
MC-UV<M$@NBUD)]BJV@%5PB';!#W*'EUGHXYX. N1WV.L='/-!F;R3F4 @<3
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M(O$3$: O:0>7(BHF13:4*@;:HX'4 Z40J'8^9$KX^_)H82'7I=1\&$W=8W8
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MF]&11$+0M/%>DU?2=1-VH?\  B(F[>H34"M=[@6<HWO8E Y#<R=S>IW[OV+
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M#SU7X2'P(<18)/@E"^Q8459^#ZO"WX'N>!\U?=3N>S.:"\[QF"!Z%8= #PZ
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M,YI9-SMUL&\FA[N\>Y#=UEZ-]3N?-8)9OU OR]R@& -P;6)M*VO1SME %A"
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MZWY["/\ QM<L.(M*%]$0 2@6!W70,=;YR6A;*X7@Y[L U:;E3]3JD?J8LQ^
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MJ/3%L<("T086%D\+$\BPP[S6I@*Y%?S?GX$0:%Z#FJIG.Z7]0!F<K'@%I/\
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M>*(+G^WGC.6@51M5^/0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A#F(. <
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MC BMXG6YP'0?<S[(^^+ (5= !:O0QW0Y"^UL^83LX0:N!^H5^05Z>!3ZH0J
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M]\\^>^>?/?//GOGGSWSSY[YY\]\\^>^>?/?//GOGGSWSLV\G7//GOGGCWPE
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M@!6$Z-=W([\+.K-5^ )! =A ORQL2IKH+4' 7:0+C*X9!4D[X#7.L31QAP(
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MXE'W' 1@#1G-3H!/F.G#PD@$ [ :#.=OP!;MJ%=[\/Z;,!E6)1[HY+%W?_'
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MD'_,_(/^9^0?\S\@_P"9^0?\S\@_YGY!_P S\@_YGY!_S/R#_F?D'_,_(/\
MF?D'_,_(/^9^0?\ ,_(/^9^0?\S\@_YGY!_S/R#_ )GY!_S/R#_F?D'_ #/R
M#_F&5I4^3_"(+C-0.-+82":<LW10_.^(^]0ITR92)*0*2V1JJ(.A:O5*""@
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M^W!]Q'@M(-'8%?ZS6$']E/\ P>+_ /I?%,K=I'!5"@ARVQT=<D%VINN>Y].
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M98DG3A6#EN$?M!-$Z%!1;*3KB:/!@P4D,IH%0WA)K@I>A.R=^W3"Q;@:)?(
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M;-N,!W7098:*(,3L%#JGLU@VMY/)ZJ@.[CH8]"-=M*/J"%YE&RN;D!>AO/\
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M/QA_N?C#_<_&'^Y^,/\ <_&'^Y^,/]S\8?[GXP_W/QA_N?C#_<_&'^Y^,/\
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M1HP[2.7&Y%'I&^;7(2^%V*3X(\8.B8F<>5,B;!/4O4:Q2-S"C/46)1W;XP<
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M0G8(7<T<NK*_Z(^0/L+ZKEWL-D T=AW/R-IFE/%ANA2[*J33+D"(.6;IHO\
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MDDDDDDDDDDDDDDCB_9G#_ =EZ9J] 2:3I/2<9_7%?^OV/EF\WF\Z/[KCZ/\
M )))))))))))))))+[RZ=;Z'/'KZX\C^E?[SG[\_YHO_ '^O_]H # ,!  (1
M Q$  !!VVVVVVVUFVVVVVVVVVVVVL!;;;;;;;;;)[;;;;;;;;;;;/ #  !?I
M6@             $'PO2+**+)D@           )4W?PA20<
M *Q_'Q/$EO\ P             @    %"0                 '0    #
M                                                       ']K-&
M.!!:                                     .I(&) P%NVX !)$!
M      &@CYP   \EIL        "J (X< 3"*!7 ,ML         ^27)-\  A
M$@E(        X%^PHD( 02_X$--,        X1\ %)N  4^\)        $V8
MR^.B&1JB= A!L@       #78  &YL $I4UAG,DHHH        % !
M       00   &=0 ^<W),MA)MM                          BP    &)
M                                     J@     C* )D(EX($     &
M8N__ /\ _P#_ /\ _P#_ /\ \4X      =(     "F 4B$&&2"0    "DG?_
M /\ _P#_ /\ _P#_ /\ _(<      .B      S@(N1@
M               4@     *"!)4[900"):*8 !"*222222222222=L
M&O     $D@ 6)<G 819 10!=0O\ _P#_ /\ _P#_ /\ _P#_ /;^      -B
M    !%                '_ /\ _P#_ /\ _P#_ /\ _P#_ /H      57@
M   79@1(FV@BTP       5))))))))))))))+&@    56@  8K@"+ $0F $@
M     [A              "(_    "9:0_+8  #6AT         60.VVVVVVV
MVVVVVVVZC0    "')))70  <;,)TRB$"D
M 97(P   #PV@SPB6AD4  0D@" 0  V&@0  V$6DP
M       FRFP(*&RF6 0DD$0PV                             0    0
M                                     !$DDDDDDDDDDDDDDDDDDDDH
M#_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ =VVVVVVVVVVVVVQ.
MVVVVVVP%VVVVVVVVVVV[.VVVVVVVVW)C4S^CUNV&E[N$60       N/I+')1
MM7@+N6         &+LA8BCJA'OCJQ.N       $FM#<+V+;P@G^
M      "$  .  @$          P  @  T $ @
M                                O''  2R                '0R.'
MI                &($^ F\(<!(  ($,H        $\8/.5@;8  B\&H
M   Y UI%)B5 X  $-E%       &@1@ &6 ;8  $M,I      "@K!T%40-(P
M  !         XP@  @HJX8  %!L(      '00+ &2QQM   IGE       ;ZI
M'4%8,&   %$G!
M                                                    $MMMMMMM
MMMMMMMMMH      $MMMMMMMMMMMMMH      &U7_ /\ _P#_ /\ _P#_ /\
M_P#_ /@F    *(#_ /\ _P#_ /\ _P#_ /\ _P"EL      #022222222222
M2225BP    9(R222222222222J
M                 !"!4DDDDDDDDDH3P        ;+4DDDDDDDDDDD@-
M   )"%__ /\ _P#_ /\ _P#_ !\         20__ /\ _P#_ /\ _P#_ /\
M_3Z       !"22222222223          !"2222222222221      (  DDD
MDDDDDDDDDDDE72   !  DDDDDDDDDDDDDDD@*@ !,R@              &!@
M  !- P              !CP    (DDDDDDDDDDDDDDD,@     (DDDDDDDDD
MDDDDDD@I0
M                   !09;1:#"8 2:13*;3!;0
M     ()2()  2)*"  )": *8
M            !TDDDDDDDDDDDDDDDDDDDDL 4DDDDDDDDDDDDDDDDDDDDE3
MP        & /P         V .     P!"@         !0$M0DXF2[#*Q]9P
M      !9U?Z0^(;BT+4          $;D3C4GS]J5VBQZ        (:RC#$<&
MZ0-Z
M%*)*1K.                +65WC+E@               &*U\#$E\    +:
M*2       "*([$ X<0    3"*       Q>A #)$T    93+0      !0'^=
M/@\    (:"0      &*@*# N(0   ) )0       +@"ZR Z0F    (
M   0SRT$>/D   !%+80       C\!ZE27J   !32%0        +@A&!@
M!((        /E6&O6*E     !(             !@
M   <
M    +;2DDDDDDDDDDDDDE( :   *2:DDDDDDDDDDDH1:     !."O_\ _P#_
M /\ _P#_ /\ _P#_ /W)?@    +?_P#_ /\ _P#_ /\ _P#_ *M,
MEMMMMMMMMMMMMMMME      EMMMMMMMMMMMML      !M"__ /\ _P#_ /\
M_P#RW8         IG_\ _P#_ /\ _P#_ /\ _P"[>      !<!?_ /\ _P#_
M /\ _P#RA@        "96_\ _P#_ /\ _P#_ /\ _P"12@       !VVVVVV
MVVV_V\           FVVVVVVVVVVW_\ @       !$DDDDDDDDDDDDDDT
M   !$DDDDDDDDDDDDDDDD\  2 (            5="     6"L
M    :WH   6 VVVVVVVVVVVVUQV4     P3VVVVVVVVVVVVVVW:L
M
M    62@ @ $4VF22 $F$DR@                            Q6RG$P N&
M6@AT6C16@                                                0
M                    <R22222222222222222222(0
M             "]4            $S#PD;QUV=7^V<EB.H9Q;T@!W=+?ABQ5
M5H           "Q_(;#?Q>9M=(LCAA&D445P )=%NY8!WT_
MD&>:B 8                                     "_ ER2G'@
M
M               "(G^--,                 ?;#@4G(
M 4]B0#'[2]@             !B;R"%$: :@           #W@#"E$$\\
M          " !4!3N.J\            0B!A2A"@@               R=AB
M8P#&"@           !K4DG<)H$$             !QW[D#%N\X0
M                             < "
M
M                   "&%-MMMMMMMMMMMMMM#<   "B4MMMMMMMMMMMMMMM
MMMMK &FS;;;;;;;;;;;;;;49@   2T7;;;;;;;;;;;;;;;;92X
M                                    "0$             %1@    6
M0L               "0  "*C-MMMMMMMMMMMMO1\    "0BMMMMMMMMMMMMM
MMML;@    ;;;;;;;;;;;;;;;8       #;;;;;;;;;;;;;;;;     #)))))
M))))))))))32@    #I))))))))))))))(G   ;J(              "88
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M-9*#U_54Y<*P[%5MIN)?$;N\DRPXB4UM@Y5A;.Y:PB)+2@T_:*O!P@&BOS9
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M;*5$?UR[Z]$#1X1M@?$2OP4)S%%;1"( 0T&@. S3N8O$$VP #H85(EU4#D0
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MU,&@ X5WT,L5B1.KL_C6Z1H- T0L . $\6^L"?*SH58D!4(@)S(.+CH6WH"
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M._[VQ>9@ =8#Z0]"XC@(J(@06)N:%<:IHY76?Q(*/,KZW^V/.N55^R'QUZR
MV(J<-),X8<'HPP&+TQ]L&#\GA#8 \Y0!MQ9./(;2" X*WH>)0%4 *KH Y5Z!
MCK&QE<8LB4"@FR E!C8)$W4ZQN&VABDS!>)DX.)_95%-U&)F"?Y,-55 3HH4
MHC]0_$I0=T%F+-[0@<+9@5ZL7^WPK"*XU-X1HUN4@I*:"$3Y-:WT@Z3+&P,[
M&[/XEGB*'9D*TQH=JQ E\RJI6[Y4*@(:^=V>'$,4%H0/WRF>.>\;20$'X^!
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M,CWR%H2I8@I&=)1<R&GH."MPN+588B6R0$$A''7D&<4FG)T"4!<@N"F!^$0
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M"GA(@=L#]Y;LNX][VN'V3E >6V=#FSR0LF=K4 =VV.HIZ<AK>1*JAU<!R=1
MJ-%&(/QO[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_2)%'"?:\%N,"Y'G"OC%
MSH)F,2K"6-U6%7%SO2*A6G!TO[5NU>]H\>0*$T5NUA[R8LBBL-_2%!6NN/=Q
M2.,3]SJUQOCQ%K39> E+MZ?$_OW[]^_?OW[]^_?OW[]^_?OW[]^_<6U:0_4K
MMH 1*%4M^0HE?@&#,Z$D?D4H C >$>L$CFS4#7_J" ,U'])T$1["ZM;AT#&(
MPAY3Y%BH<0\4UV/ .]D[:0V("J_#333333333333333333334?(#WB*R'JM?
M&J0J\S.CU(!7.I!XCZ:7F*XROW8?"P=:^"*S1GB.VYDBR#&)/84TGR]21]S9
MS9X$HI=F>.I2/?=Q4CKC->[4*0.:@ZX?B9IIIIIIIIIIIIIIIIIIIIIIIDGH
M6A!D#LJ&+P,Y(Z28^]\'D&)>$,-@QWA6L%E3\ J+^Z38K$<_!39*WNK0(3I1
MQ"0#Q ]0Y%B!]ZIW"?> Q_&/]S\8_P!S\8_W/QC_ '/QC_<_&/\ <_&/]S\8
M_P!S\8_W/QC_ '/QC_<_&/\ <_&/]S\8_P!S\8_W/QC_ '/QC_<_&/\ <_&/
M]S\8_P!Q'^0/TU'%V5<WBNV*.HU(K=GHR!F$@P=X#D*B)TM_!&G&K,&YP&*:
M>&N8HFXUQ#Z$$8L\!@"7SZ'.;U_5H3B@I&00*L.=UG^,?[GXQ_N?C'^Y^,?[
MGXQ_N?C'^Y^,?[GXQ_N?C'^Y^,?[GXQ_N?C'^Y^,?[GXQ_N?C'^Y^,?[GXQ_
MN?C'^Y^,?[GXQ_N?C'^Y^,?[GXQ_N?C'^X0ZLMG5JEM,Y@'U!UT<@0J?N"7D
M(-$I8H!2] ^".*$PH:-JK:K\0A0H4*%"A0H4*%"A0H4*%"A0H4*':-UV4\L
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MGP7U#+^XUG+*Q@T07.*DZ&B89$%)<N-MC]>!G=2 9FXG.B#0%-15*!!?F#N
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MB@+T@=*Z2/3"6T'I4MY3U2LJVLV[^QDN5JT3R:/6&[)%:I)AI2UC:3H["US
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M?P\B.,F.]H10"*+*!\$'"=9G,N8FY +H=:>AGE?DHR"PK!+-)%+!W %XK0S
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M+'.>0>+TTW&67NAP6ID(H!!12MVP$D+HJV[*C-!&N!JZB GN]+SD8X/ROY0
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M"^7A=VQ]-<FW::62;%41M"WW1K7(EBE<.]"BPRQ8>XN@O,F6,M 68\=B[ 6
M8F0T?!"[\,H?0IT4Y3XQ(!42'="A]<>,P=''#U*=!A# " @ @' ' ,O4I-@
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M_G >8WFSXIGL@%_\C'NE_ 33+<U6_JBP"H:9 2+S@E/W +"4&L B;"TZ/?\
M7Y" >?:3T;GO%<OK)]:UGJF[B^>7^-6>1T3_ /\ $,9YU-C>DY3GX_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ #_USS-TY_V[L^8]%O\ :1U,\@G"9W+N_L>0
MS0/I?*/,;['_ *RL/))F#[0,/FGN+_\ %W9_VD[\M]+>G&_X#_\ _P#_ /\
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MQ8)98@6%5FOL2P%*AT(*Q)A8C%5/0]H>NG.XX8QGA'5V_P!NMQU6GH2$(4$
MB! <@:,.F>'@;H0Y>@HIRU+[3%YW-_2?6F\D=)3DRQ.L!EBN!?Q0D<4,4&US
MWRV5'$EU"&@- ?\ BR]KHG9]IM?2W60> N>JL?7;^L?F 1$HCI$=(FD><,P@
M" [" =I)TQR>6B-5\6(I170&"2%^HQV>L->ATQE"Q:"E]5"^04YP)3@  @ T
M $ T&L2LX 4$4.D1B.DTX[?84L'ZU#RP[>"Z0*V))H* 8( \*O5-H@0:HO\
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M0'KDQFY&G U]'JF<A1>2$T=P(OLV6#T@4 P-M!.1-$024!6 =$.T(8)X1*V
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M?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSX,Q2Z%G$><XAR7F/JZ8@%N4G*;@
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MPPL!BF!'F@J-*.V,-!0>0(HP#,%%#"@R>??/%!2(8BHL4JNJ-O<%"4QAK.R
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MLI6P;#$!MLT^@ N7O]H(/; QP<>1JL,@=94_:3X>@:B0H2]E4/J?:P!B:.%
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MI8CAO1"#M   X  RV$=S[1E-E6NW?CF.1D,!N 1'LDS<9Z"H]PU'L@3 1@2
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M,VVD6M"$H47D$.Q/'18A(15%]\A&U0'<! W;!XE7)4(<%HR8M'_\H7(X.M"
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M9) ,*74M,6DT65ZE,>HJ<8(2Z*G*2@INI(A$?BC"\J2 ::- $ \S-<6 ZDE
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M*4(VDD+IND*[X_@")$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2._E8$6-G
MDW=>GJ9ZEDUS?XJ)%0[0A*,"HG 1ZB9OM"TG!K,.4)O#4595QU*I1=Z$SS[O
M_C-6ZX4T9_MA/9.DS3V!KTD3)*+8,VZO<_;OFM9K=LNY\_X#;;;;;;;;;;;;
M;;;/UJ]Y/6;^H=;'K?>I'DWM=MVW>=FMNG?Q/W/ZQ2_6U_ ;;;;;;;;;;;;;
M;;;T^_4A->OZE[IGX8_^REYS;4SY25_R?Z_7_]H " $# P$_$ 1B ;1UK:M7
MU=O7X!&C1HT:-&C1HT:-&C1MK<IS.:L)UKB8\L1)$Y$XI\4C1HT:-&C1HT:-
M&C1HT:-&C1HT:-&C1.*)H'9-)8^ILY/&HQU0HDH4H9W#X3QX\>/'CQX\>/'C
MQX\>/'AQ/#=37B$*]([^(\>/'CQX\>/'CQX\>/'CQX\>/'CQ^33$6]2=]XI1
M**!"NDM@(2>$E2$]5%8::8;%']#:13]!3]!L_4APBC8A%';+H,+*R&%,K!2A
M&ZH \'B 8 -)1B<X\9E&0ZQ6$$!KD\3F:%@02,B? "P>Q;=CAAN9 JF;*D T
M.0^GBQ>_&D)(T4@DW:BM83:*8'$PZ@$4H>"EUVRK="L%@%5] W>V\KSFD0AC
M%TQTSAUE45N$>@IOU&L=BL 57L!M?0P<;M2-(*TZ0%>P-XP/ ,D!-00U;=-
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MOIWO$5<D0YP >3X_HK.A,C9UR,O3(_!*!7$7IX O&'=@'3]$_95K8!QLJ4H
M70-C*';1$CR-W3Q!8_-JT/\ VB[ TPYQ,>6A'%3-(MC>$LP?6%=0-7%0@*/;
M 4G5-E.MYIF_,:-+.TYMBRF-L N$Y "CJ()\$:R;8#LNR:N,*TV&84E11*E!
M<@P,"NZS<B[SH)S7&0?E55AN:LBA24F7:^-V4S8F7<7AI*DKE(U"JK5:X1'3
M.2%GS28D9A>$\FG%*"*\)MP.-D D3H@VT4;<)95STIV4Z04*"N!6L[LLM;J
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MN/2%:;).FXD;S?W'LR3]87C#N_6DDBGHP0")0]2J,"!"A,964W*SBYT_(DY
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M^.9=OK>4@JQ,0'P:21?^I#XQJ72((OI;< 4)K'P<DD),EPW VI-XE/W3857
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MHK&KR0LU!'+*!F\Y0 =L )L4%+NK!4( [A#Y!_ 2?N#T^HR0]4P#K9'<9]"
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MY%2HH,MN%C=-9D "AM7>,DIKPQP(),$EX-.2'2 7P6>:$AQG.<..V7".BM!
MY@.1;]BNG0""@   \(GDWKBXG[CH*2@;@,RLH'5Q9%?7>;52B)98 ($!SD0!
M\#[U8T/9*6D%(M@1 3B>'MQ=B37,512(5@DE2 :(>\SK^L4XRO/A7?*XJ\_
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M^W"=_P!N$[_MPG?]N$[_ +<)W_;A._[<)W_;A._[<)W_ &X3O^W"=_VX3O\
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M;"[@FI I@0H8ZEK)>]# COV,9VB6ES\C1(&7.:\TZ42X:CU .LJB#9 FQ#Z
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MD(*7:@*)Q<7''[BSNA65F1 C*0@\BG.0>#$T,0JBJKM555Y? 8KR:=5'*DN
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M)T7]!&.^I NUMW#Q*./$H"(^NX586%/[+$E3W)56:&A6P$S6LRK(0;,2%C-
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MM*!L7-C#ZH,)$>PPAMB6G (/(B\#2LNIOQ+"0CIV'E*SDC9BBUT6C)Z!>@,
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MS Y5Y#[W=*U9]J(2?Q-_*$T<#2R\Y;;PRGJ--2:Q%UQ"6D" 10F  ?$@C5L
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M?CQ@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!&%\B:#1PIL3<DI/MO+D#>
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g382677f_03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_03a.jpg
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MH/BB=-K4K,,=CG*;'S>W#*_ I4)\IM?/6I46J-Y?A&V/ "%(PGT),*#./?\
M,A;5I<_AS<BR8M68DSG5E V2JXIR5DPVWNZ$_!E@HFJ!8K,A&W21Q ($J#QS
M!G;PJU.YPVND672)$6GM#$<<%$;1N(D2<ZRO=(]0AN"K8W[1D15<9%6U<$UA
MB;N?A:"YL47ML<2L<**#:=RN)*R2I NELL=;:V9%!F\L]K<'0]H:FYD>7)8
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LY3O?PL7X>@.[+_\ SYW+X&CYYC"T>YIEMQR]J.-_9YSPRN=]FYBX7Q=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g382677f_03b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_03b.jpg
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4VC_ _ _7]7C"O^C_ +']?V^/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g382677f_03c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_03c.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.D-"1D$Y-D8W0C<X0C$Q140X-$(R.30R
M1$1$-D0Q0S0P(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.D-"1D$Y-D8V
M0C<X0C$Q140X-$(R.30R1$1$-D0Q0S0P(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !$ $0,!$0 "$0$#$0'_
MQ !]  $!                   )!P$  P$                 !@@)!Q
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+?C'"]=.5PCW'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g382677f_04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_04.jpg
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MQ #J   ! P4! 0$            &!0<(  ,$"0H" 0L!  (# 0$! 0$
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MXH2Y!+<(6/<*ZM;EHVKJ![5RD&F.+@."56= 4TEUO]TB:8_WE<07%216U((
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MVQCFJG%8#;&X'X1D<\B4_#+'"#*'=*<%KV(0T=,D73[/$8N(*P2Y3VUQ(\I
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M14I!:UHH*:HHZ>YW&<-W>M53P1LZ-#@&FN@1B!:!?BU>_!4LV8F1N[DB4R<
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M=975O ^0S?.T]53T=^[?\C8V!U+=K5-!":BD,]-)+"*J-[W%[6DL<YP>QSF
MD9'J2M7],F].6!6=U#:6[EG7#^8,OQ4GK?5G=$ 0C8CU4[B\ A--H'4=</RH
MO,1 )<XHJBJ0(P"1FOB5'B>F> 2)U&,<2GHZ1:>6#53=\GJ6NJ9'*&AH R\-
MHS\?\&+R(%O2?,4K>;1!N!3:35(-2"'=5.9"H4T7+ JZ62O+-$UMJ 96=?*>
MIR^SPP,G#BK1H:\$L2S^<'('Q"Y(NF+$TI@IM4D2K7S W:ZZ#/IK^&#V"ZFY
MYW",[=4 L9ID1DNGE3&GMWU]R7D$544X\Q4:$:^_\V&IDM1#HK=1.KW9]!XH
M3A2Y0,>*8 _30M=9DIW]/*?'12A_#"TS5E6T,4%S3CY=^?\ 2]QR/Y\4)JJ3
M=N] \\^;B24W$G/VZY^S'#$*X'%8'S0)R=H?Y:)AR!.I&:J6HZD?+-.X*,NO
MA@]OS*EP>)(%SJ=L+O-U.I.J:IK@N)8)>8PY*.7.*K-Y7Q(S08-FEKHJ4TM+
M5@SLT)\NISR_PX1W/#M2\8^()]/6]H_V4^W7[],8U/\ B6S_ /"NDS!U](58
MY<HT=Y_J1XUVT=46"TRTE[YDUB2TAF!M]D+FJU]VEC<'/JMI#FTK")",WN8"
M-P+E^$#IQE\D&Y>A"CC4M;'->\59RJY.NO*.1276K\QA$TH934C7%?1H**(B
MFHX0J;6-!.I).> &Z)5D:I&[>C*N*5N#W.:[RLDIYI! XA[6L4!^NT$+_AQ8
MRP+JMLDEX8*25OIIQ2-+I9"4\Q!<X9CRM*D@$#+$W+KP:+BO>GXTHFMYYRHV
M&&9\N](P4:OE* DN=H4=A2<S Z "7&*%<N:,<%!3FGU#OHJ\04K@TOF+&F1[
MMSE<GE!(*#7KB8RE(Z3)NQ9=_>F,';$X*0?9_FEQY*RFF=(X"1"BEPS\"I*$
M'WXZ4I1D(8U1-K>G=AJ%*J?_  VU5L\#  \F4,*J=K6 $.D<""4).2:IB='J
MW !EBM41,F?@C6NXY5LA=O E8YIW-;N+B#H0" %RP66TD*QQ5C;_ *I8IC>:
M<9F;$\M]1K$<T9>9"I+"T #=[<4E&8!MS#2]L"AR#CFH-=RZ&LH14D;@T;G$
M^9=JD'4Z G/"YA('014)"\)#M4+[R:O]Z DN+7.<0,W$-4H!C/W%N<I Q01<
M,I5X)_\ MS2SS&(N:X'(G)Q\ @T)4G3!(^&+"M $W$.0I;<>LSGQL!#@ %)\
M7)_+WG!H^"+9IA_<EV:QC/+>B>5%T/3P(Q(E6A95T4<XI'J;0&DC:AR^']'[
M,B F""4L3548B@*1)+>^)[_+^@NX-*(?R#+%Q(98KM0S2'<"Z.#P1X5=R;0U
MR]?'%B^2BY+3#6]!7N3K]D7N?=B3HZ6!R IM) _2]F.CYB.Y=:EJT3.<13@2
MMD_&6$14:C]&,CP4@*<NA#L; S9.FFD<TX6*H@58Y<JQRY5CERK'+E6.7+G(
M_B><[MG*/J0=Q6"XU==<.(\4MG$J>UV^2EFJK?\ O6 \@OU7:*.5I;^^JZ.[
M049J9'-IZ,#U9D;"5'NYFW:A$>8U]_\  42=L>INIRQ :/N#^YR7[%KWN?;^
MV]LN*UI]*U15%1<ZGE3J.$2R68R4D>Q][K62/F-5:+%"PLMHJ"'UM0QU4YI)
M:UN<+?C]2?N^7\5Z':^(:8Y8GG1:_+9Q&;NUW-J;+;8ZK_.E\EKKQR"_;:Z[
MU;:F*.6G?6[2(&%#ZOI[2QL5/#&Y2TN/G.N]0&TL&<,<OZ."^C_:72?\PW8M
MR;0*FC^Q6SOMM]'79ZP4M VKLC;I60QME=)*&MEDE <UK7@-V[&;E0GKD,?,
M[_4=Q=)E(G21@OOW3^D[/:B(M6XT:I"E#QWL7VYM[71V^T4=%2R1-$L$;6Q&
M5KFRR-,DK'-_H@9Y>9$\5(WS,G%FJYQ]F6O.$8>2(U9,&K3+O3D4G8OM\8F1
M06F-Q4L;&0*AT52Y@1&%IE\S2ISVGWY8<MV"3X#( C >SI"]NYQI,1TC,C(?
M!"MT^DOB%=4?--CC;6TY]6.>DVQR,86._5/9('1$24Q(("M*H%5,.RVV[CY9
M'M!2=KJ73I>>U%Y?UA^67X)KN<?1+PJ^6B>-]BH:RDEV;YFP,AGCD>0Z*9S:
M8'T9@&@ ;$<47/+%XG=V8>KJ);V[D"<>F[F[Z%R,8F6 (SY'/M3',^@2ZV*3
MT^/W>!]H<L4E'*UX<RB!CF@A&XN8ZHAW*"0&$E_1Q4W[W<$/5F24ND]+$FJ+
MG91.M8_I8K[5ZU36U?K2,# V:29YDB> &,]1I(#R&'=N!&15,L"&\F"9REX>
MU7ETO:AH6HU[,403=L8J:%E%4T3*S;'Z+IX]L9D<Q(B[U6B9"(T:0<]H3QPO
M?ZO*/@%>:>VOV_:;U)>$DX$9) JN%T%KW>C3O8UA>) W8Z)I0D$/#6D,W!-O
M5<9=SJ%^1)CAVK2_RO;0&FA.2;_EG'>/WJ,076VVVY1,):QTL$3YHRYP>Y&$
M*R5IS!R <OV'VV\NQ\4:9K-W?3;<H&W<#@\0&[E"7N-VWX]Q)];<;?3/J+30
MP25COF'B<&!]5"RJMP?52O8'NIZV4[2-I !>/*PCV72-[*^:DTJOE_W!TNUM
MB= H0W,9J8OT\2_WKX#2U#XVU5TXW7-LM9!5NDJ7W&TUU)"VUUTP,T)]6Y6L
MSVZ=SEC'H:@R)CW^PW$I0TU<8=_S8O\ !?'>J[:%JZ9#RR?WC'WT/O11RB3B
MG*6N[;\DO]2RGK+,.1\#Y!.\1SUEDMB^G35LT["8N5<+N,BNDJ(R)J7>R=KV
M_,)I2N0(J7MD>XC$'L7G+L#$T%0?>^8Y%1SX/W2Y1V0O,?"N55 MMEL]3576
MUUE.V>?BUPIHI7TM4VVQ2CUJ>CKY)F/:R-[9K372A@=) A?F[G5&E-)J_/NS
MXH)AZT"W#W+>!Q+EPO\ Q_CM_AVOAOMHH+G"Y1E'<*>.J826@#X9/ 8T;$]=
MB$CB8@_!>-W=KT;]R H8S(]R<F"N<8P=V60"E0ASUSR*#%)4NNN@YLZ.*;_D
MM<X5$WFW-*G3-"<\\QENQ>Z 0.+H!,I0 +>%-X:H?,-4YJFN7X!,")=+L<45
M6RJ_6L\WZ)^SW??^&!R1 >"69JOS!"<ES4#3_!B,ET!4JT*L[@20GO.GOTRP
MUM\U,A7DC&V5?E0E=,QFB?=C2LG]0'D@S&2+Z"I#ESU#E4KI_@PS<-:*FEH]
MZJ:?-Q714S/@>N%;A^*9@/ _)"]UG_42*<MOX%5'M(P"Y2JI9'B;B4"S3_J'
M'V.T/L.!G%")R/%!55.JHBEQ"KTUQT?,R)C(LDHU"/R/5RY^'V8<MO5$&(?!
M*L=3^I:U<_?_ ".#VCXG4R%0_%(UUJ (7G<I^_H1^?!0?$$M=#E@HV\XJ\GY
MZ*#GIGE@N:4N@L733T52LS JY@JOYL);D4]Z$ ,4_OJCQ_[IO;]_OQD_FM3_
M .%=,N"KZ0M:/U\?71:?IUHH.V7"Z^FG[M\EMXK*J9CXY6\%X]4[XX;I5,.Y
M@OEUVN%!"[X&-=4/&T1"3,W^_&V_2A6\1[A^:2W>Z]$:(-K/P_BM 5\^I6ZS
MOJ*B>Y22332RS33S3R2S3S2ESY)YYY'N?--,]VYSG$EQ)).>,<;R9QQ6,#*<
MB"03^:%>/]ZKAR7D%LMQK7O;5UL4) <4)<X:$%/LP:S.Y.Z(R)8E=.<;<#+$
M@K>YV#XF9;-;9)&$ET$1)0N<FP*FBE<;$+4I!A@ZUMK&)@)1S'PR4X:+B#6V
MT$!D3@P;6%BG3,/\20<->E;((8,G=/'$J(OU"\4?266JE; A,4H  R\0YB(H
M<-/#/"=[;D !_ ].+\^U+;F -L@Y!:!>YU?/1\J9&\N BN&QH4H@>0@7]$:X
M'"!E6-*5*\7O[ER&HG T&5.*VL_232"X6FWS AQD;$I#E.K0AZ!%UQ:<2)ZL
M2V"V^C^*T)'$M\ /Q=;B.)6N.FHH2&!LDC&^&48#=C0@R;MSPY8MB$!3QY_-
M>BP"+)Z4)F&IKDJ9?GP8A0#P3:\RM-+)3;G,:CW%KPH5Q<KFN']9C@/LQ25L
M3 B:5_I]ZM)CVA0;[F\:AG%4D0>2QX.YBJA*_9E[\(7A&+BM#_0DKT 8ZE"&
M[\$2YKZ3B'O<0H4A"A"IEGIA.4GH13V]RS)"5LX$Y@XOVI\N"<:;3BF&P D-
M4AI5<B7=,F_EP*,&DX8#):5N@Y^Q4G;3:A%!&2$"-'4+^3XC[SB['A4HAP')
M9CK>2\@#+-"2 B99@Y8BG>I 5I]K+@"(UU*Y'V$^541,6';131\G2'765"7!
MB$LSU"]<B4Z'$XTJJ$?4$!76PN>Q&L+//D'!Q"H<VY:'!(REGBAD 4&"=/LM
MQN:&Y.E>"%D;HHW!H 5$7,N&"P$C0YF@Q5[,09T%%L,L$+8C"T@!K8T850*U
MH ]YRQJ@:8T3>,JHOQ"NJQRY5CER^$@:D#WXY<O)D8U5<U1J%"_B<<H<+'EK
M8(HY)7N\D<3Y7Y$G8QKG.0:$[6G+$M5LUTBP?)<F<UVCYAW)[H]P;Q2SU').
M==Q.0\@NU+#/%53T-L%TN3[+9'W,-D;\O;K:SU9(X!YBX;AY0@MS$2NF1Q!H
M.0H/@D]H)&T"2S@D]IK^+)B>_-:9+1R"YW"IIJ\QO@H64]#5.:V":285%/;S
M4P%\#:2..CAB#6.<2"[<4S<E<<._E9>FZ: PTX\TQGTNVR6FOHNUPMQ97W!T
MM4^I<V=AE,S@LT-.YK!%2Q^F&-E?N+F (?'YQ]TW-7A'E=?;_L.T+9,SYB[_
M "6UZPU\#GQ.B>'2-8YP0DB1S3YBPO\ *20",LR <?/[ES2=,<5]HL F.JYY
M)(WBNE3$:>":(,#@YY?% (W!K2X;'NR9,TDY$($'5<!,Y8$4/!/0M67)A(]A
M/Q R3C\7Y$8G^K50N=%%ZL)#7!CW+-(2_P!0*DD9>-OE)\Q S&-OIVXFSSJW
MQKQY+*ZKT\7(Z;19V.-!09<#5\L$15_((S) ))O3B9ZT3V O8TQN#I8R[:6A
M&-<- OE"'-3J7MS41PC4'O%/FL?;]/E$$@/*A!X&@+=K5',KS2WT53';8PUL
MX$SVQN]..IW-".E+BTN8"%+R%!&[<A(P"&X%QQIQJPS[42]L/1()+Z1I!.,>
MSY,*%6[Q='4S72L<^)S7- W$.=M>TREKB7ALGI$G,'S#,> KN)3@'C@%?I^W
MC>+28OG48?+AVT09)R27UHVQQ[8YG!C_ %%=&6AKV.59F-58T 5-<\DQFSN'
M4"0[^Y;/[*/IDDG4*N#5-K=;@VFFB=$\RR-E/S<H8V,2>4.!+07M5I"*4)3J
MN,^98N[\UK1L&<7  !% Z:+D/(WR>O$K'1/?*V7>XMD?,W:5#2%>P9ZD#,$+
MGA?55LBHGMXPJ?, F;J*BGFA#H=[(VS)&T;E#MQ)>7.)WMW+XK[,\.VI>%@,
M%D;Z,]1#@T41^\ESDFJ#0/EEGI:J2E=-##YVRN]65/6C +9&QQ[D!!\Q'LQZ
MKHQTR<8$,OEOW'(&6G(?D5+OZ<88N*V*Y7%[F?*ML;Z*6-H)%R;37ME90NDI
M]YG%;04,GIAI:8T$C6E"!CZ;LHZ(1F,A^1_-?$>LO.>DXF2Q.]]N9<Z""Y6^
MY/M1I+HV;CG([?!#<9./7JJ+*Z@JGP [+O9[@^*6.IC#VMGB<]H\[V NRN"[
M%QECRY]J\O.&DF)Q(#/\O;\%'.MK/_BIQ>]\*Y(RBXUR.."DH;)>:Q\LDO#.
M2@R?+45;=&O;2W3M]=C*Z*DN%0Q\M#35C:>9&,AGB4-TP\)K$Y>^H_'A7BEI
MP$91/-^?8?:JVW?3;>JNZ]DN BXQOI[M9[;_ '=O%/(US)*2[6.0T5?22,<U
MOGHZAAB=J%;D2$.']B=6UB#B*'N/Y+RG4P([Z3?4Y]]?FI.TM611M>=H0(?T
MM$S&;47\N&<?>LYR*5X(#Y)7-=(YY>5>UR $%/,W+Q0 8F8U!49XLF[^:_7@
MJ<R"/;EFA]IP%PAD,*8(PM563(P*?A*YCJ,_<F!2=< Y[DMRU.8R7(IFO3\,
MSBJEE:%4-XS0_9AJQ@B,XYHNM=4H^+H,ESQHVCXT&0HC.VU))1>CNO\ +7#$
MS55T^%N:R9I_BS.2G\N77IA>:-I:#(9NLW]FDS.GLS5.F 7%6R/$@:HD(IGD
M'/:[K[_?@1Q)2P#D.@.HJ$)S)0K^'3$P\R."Q20Z?S:]2N>@'CIARWF<U,7U
M!*D52L(*^Q5SP:WBV;(D^.21;K4GTY!H$R*^PG!@6*6D'DHU\YF*2D%0AZ^_
M!'2ES"N":ZBE)J(\]"WKJ%7\,)[C H$#6JD1N'C_ -T:Z_AKC(K\5J.?^DNA
M;OSW?L?8?M)S;NG?FMGI^+VB:HM]M]01RWN^U);26*R0$G=ZETNLT41< 3'&
M7/(1IQ3>[JWLMM/<W/+$>\F@'>5]$NW!:MF9R"XA.\?<+F?<'GW*>X',[K/=
M>4\PO-7>[S6/)V&KJG#934L9*4UNH*=K*>FA;Y8:>)C!DW'SX;V6XF;LI/<,
MB_\ #EP7F;LYRD?5((-<./Y9*-7).37&&*9OJO#6AZG4(A]N:8U]OXP%$#"%
M8TEQ_@B+L'R.LKN?\19)([;)>Z0$N)T,FCNF?MQZ#:6 91)=P4/J%V(LG(!J
M]X==I?TZ4,%1QFSOV-*T5.3_ $=WIA-$*;OR8U -(;)UZ+8L; ;!A\@IBPT0
M?3/1I+&C:4Z$A,^ITQ9DP3[U'?OU88ZWBM3N:I9'("=H0AS<R"WH=N!W8ZHZ
M1BNF#*%,5S"?4W0NLW)Y#&W9_G-@WENTD/>%]V0Z8-L[!TL1Q7S_ *T")."S
MFJV?_0W4R2\?MFXJ4@4G1'(4 77 MQ;$;L9-[!;G0)"=@#ZAG[_R6ZJP2@T=
M*&%4C8PKH4 ;^?%HKTQP8XHCFSC<0%"!/9FA_#%BJ#%!G)*4U%$YK 7.;M>
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M.4*-D\C(2KM3Y@/>#Y<+;Z,8WVC@MC[:D9;8$\?X_BMQ7% 74-.7:."^"9E
M?:$PJ*+UIP1L^-P WM<U5100H/4*-,6?)#8XI"JX=X(_QD=GU"+XG7%2$2)8
MIKN2V=@<[;$/1D;Y@T'R.4#<@T+B?<N,[<P\>J/F43B]1BF0N7%G.JU$3I
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M?&.KX( ZF"''XH?N??JIN32VF;,[4;F[T.1V] -=<S@7[D,^)5+F\N7, 0$
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MU4U<5LN5'64U!/2QU?H3,K'N,L#:B-I?&_<U[(B5:XCS-S0[L)SV>XVLH>K
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MG<F0XA $ ELR7:(>IY!:S).:5U9>Z[DW&'4,-MO=JI9S5PCT7"HO#ZFZ24]
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M1>O(^2HKXYWLAGJ&LACD<Z2I8USP^1[7-IRP -#A'A[[JN'_ "XC")D O/\
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MGA8^W8ZV)\5[8Q7KC5M?=+O66NY4,<<;;=9*ML=/424LDCHX*ROGB=LC8UH
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M2&_I!I ]HNEST]0B_E)9,]8MRET>5*@*?/\ <VDO'#'54VR1MNXP]U5)%(P
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M_P"G U./(9=Z3NQG"[A5V_MWQT4SW7&LN\]5'3.<=T?S[6V:WL>PH6F:MN;
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M6Q/Z.+6*VDJ)"T$MO$@T7_HH#A:\=-0LS=%IE\&^)6\OM580R"C_ %2AH )
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MH[8*09D(- G1JY83CB>U5LDZCJH#@.P!U(A\KVVFH;FCHW@-7QC.::].N)B
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M+#&Y2TPL@ND8:A.GN)]I]LP_[K=7?I MP'8-1Q[POB7WC(1AL[ \PA.9_O$
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MQ26EQH7MVJXQC, N5 /ZH\,&J[Q<Q'%6].1U"()8.2V"A!WRX\=U22S;G-N
M"^5V>8U4#_!@\91+:FQ2%R!=A5Z+2/\ 4?97Q?/?JW:2IM;_ (S02$R4X;@1
MI#)[I\S35QXK6);K1.V]7!(9%]5RG8[:,\DR7,8:UC#)>IC(:73@1T,L:;XW
M@#Q8[/3[<%A+53-$$@0MDOT3T[V4=0'QNSNTJG:5^"$^7)-1@=\$QU#'AR6;
MNAJG-L0(GYK=WV]A=Z-*2T@!HU&>:9>&$ ,7S0MN[2(\C?%/K41DVRJ< B1O
MT!/Z/7$P+4XK/OC](M@R @PB(JNH!R'A^&"C%EY_21#4>*RH=L3F.17NS;U"
M=0GB,22<J,C6)>G/4SHDI)P"AT0GKF0?MQTKAE#25JT=.%;)6NIV.)S:0H3[
M%"^[%7)Q7&C')7:ZMB9Z@!R#20H 50-"/$X8$HQBQ+24C!Y8)I[Y=6O>]7>*
MGH%"$CP\,%UB$'&:5N'421W)O:B=LV?0E$(/0Y9ZIGB@G*9U3\J5N#2PSS7N
MCHZ2O;66FYTD%?;+G!44%QH*N,2TE=0UD3H*NDJ(G*'P5$#RUP\#EB?"8M)B
M",.*)M[MRQ>C=LRE&[&0(()!!!<$'(C(K63W@XM+]//<)G;JOK:BMX9?**/D
M_;>X51J)Y*2SOFFAJK!<:DQD27&VRT<E,[<X_,4H9-\>\-^2_='V_'9[DW=L
MQM3JPR?\BOV__IC]^RZ_T6,NH.-[:.B4C@9  N&PU1(+<7& 3Q]M.3T5SH*F
M!GS$U)\H]K74K@V-KY&N<9&/CD,H='$X1A^;FJH!QXZYM]( E1?:NG=0%Z1,
M:D*0UKY376ZACM[FL+&_*R6]\\GK>A3_ "[#(L8:Z.6=CV-8\N+BKTV@M*@%
MDR80)U+>MFU=CZL@!'/M'%6(KC=;E=JRENE53?)6PQ236RDFV2.?51N=&^HD
M#QZ3*=27AI"@ %#C7Z?M81D)73,EVK@/=[<%V[W=B%C1M8QU$8LY]W'N5OF<
MEICLM;)0LBH7T-) R64T]/45K[E4^E"T,8)A)+ V11Z@FDW%OD:X.S]#>VU@
MVZQU2 R>IX=B\[M-]=A=\4FC*3-DPSYG)FS4:JOEG-+%,Z(7H5E/'+(12S1Q
MAS&Q0M]6&J =\P 6QN:_)V;F%3GC'W/3MM<8L8'-BO16.HF43X0010D,V8JB
M:W<WNUQI(9:HV]M(!ON5172,I12-^4#H&Q LD,CX6$H'/,1"%053 N;/1=-H
MDF;T &27N[JT#ZHC$1:M3\OQ47.['.+0&^N*JGJ@"6SLDC943RS/+Y(WNVOC
M+JML+%!#5 .3OB)W]EM+@C4?@OGOW!U2R;I%MG9FQ]BF&X#R>VPR5O*ZZ<4=
M% 8Z>V0NGIXJB>K+'&IF\P=&*>F#_280P[3*[,;4%]W8,KOHPJ<Z8)#I.]A:
M@;]YA 4#G'L3.]Q^\=;RR]Q-'I-M5+5,<V"F :RJ?(TF&CEC8P-1K6!\A>5:
MT*4) QK;+9V[,1+Z\TCU3JUS=GTXD:"<DEWFZ/I.(_O"Z22//)*\OK'O#Q*V
MPV;9/<VQJ<_WE7FGI*<(%;&T   88/ZDR(4,0P[\^X+#D(P$8YX\SR75O_!>
M^M?Z>:[L[QSZ.[ESVDX]]1=@GO7+7<!Y!&+6>0VSFM0[DEN@X;<IGBCO]PM]
MLF;\U1M<RLC?N+8W1@/Q[K[=VL['2_7)'IW+DI#B(N(A^W22OCWW7OK5SK\]
MLTA.W"$=1;3*6ERQXAP&+5=G6VKN(0ZDGZ!"0FH4G+VC&P*%>7W6?8H(<U#?
MF)O%)"[V#>Y/MUQ-QF?->1NDDR&2BORN /G( 0DG0:Y]<(SQ99Q+2JFTKJ!V
MR1Q1#^*?ETPO.[$-H/:JRC AHIA.74C6U4A(!!! *(B(?=J<$A<\3940-(/;
MQ2?Q^G2=F>2A0="N73K@NH$U0""),%(_BL63?8U#^49]<3-J,F8.!I'!$ET8
M0%:NY/'VG[%3%10(H+2"1K='5&7RD@:ZIKEJFF":@S%7,@3@Q=/CQ1E7&(B2
M H"*[JN0S09@X9M2:+23%MW;-/O91.8G>8 !H (S3+((HR7!7#.K2#E)M;%)
M&\ASVJ-6YHJG75,=*01KLA.6K-(DS4!\5Z%1FBI]F NU3@A7,%<B=_9) F>H
M]RD_DP$2+$QQ)2Y\U$,20^L_,[0NOB/M]F+QN,P(JBRLZI/@%DP6BF>YIDDD
M\?*@&O7+/!HW-*Z-H!QDB9EDHW0M<9G!R)L<X;CIYAEF,\3Z@%04V;$PW A"
MEZL] Z%ZR2J6O'Q:9Y:Y#%Q=<Z2:J;U@PMB6-5$KN18Z3TYG"=ZM)<U7A"IT
M1%U.&K-Z!-%B[@%WP4;H*6.&M :XKOU7P.B:+A?<3#42M:/BI!*[V?['-N@^
M_P!^$-0_%--_[2X;.X]RJF]S>>!KR@YWRW4E$_O#<0N1&BXM*(.55[J40 3'
M%.OV[KJBH;&LCLRP#W#/\0,*7(9M59UR1,?%BI><3BW!JG5':KX:].F*0&62
MQ=R02RDSPBGW5MM<1F9XE&B>?P]B8?LQ!N 9+S6^.F,HG%;NOINIVBCH<@0&
MQ'[@#G[\L>E.HV8\'65TXGS' K9';[4V>W@;5'I@9)KL733+IA(GQ%N*]=*W
MX(2#O& /Q4=N]%I#+7(H)'IRA2JJ&D'(*H(&*R+@ )3?VS&Z99&+K27WOM@-
MR>=@(,J[4/5Q3V*,4A'W++MR'JR+M@?@$A=IK6S]YP>5"7MZ?:#GU7'3!>F"
M/<N-I>H)6U[@E'LM%(@S]%IT]F(EP4P\CI;OL1;LW-1.C>J.'NTPJ8D(ERMD
M@8._N7F93;8PJ(X: Y %N9!(&[//&;N9"$B9.P _H6QLA5^,?FCZTAYH6C]$
M1 ,&AZ%1TR SUSQDS$-&JOJ$E_;Y<DW-I 2^HH9J[<:ZYT[0U?.2&H%U&0'4
MX!&$91!D]$COHF4@3A_!2FXGQ;TJ"BC+%3;NR'F+@'%7#-%.F"VXRE/6WAYJ
M=O9BPE+N'%/93\82F.YH^! &Y@')02A &6&QJ!88#)/&U<G%R6' 8 <#Q4*.
M^5@WU=3$&(2)<F^Q @5 <\!F2"XR]]5Y^_!IR,10'#+N6I3O3VO-V^9'H!V[
M<JMS.9ZID3AB%_2-/+XI7;S].3DT=0LI^P[&5E;)\B&N+W>;:,T.I):<D]V+
M#<U;-;D-V1 $&A0;R#ME^[R]($#"5) 7(^[&EMR)FOF*;M7I2I'S*7/TA6GY
M2"JC:UH+;I)DF[_HX2H'BH^Q</7++V^91!",YGU0]/;W+<_P"VEU-2! 26-)
M 4Y+U\"5QE7+9C+2IC:C&V8_0?DG[FLCC9ZI(QN]!Q**I\N6?LZX"/-7!9FX
M@ 6CY"FWDLD@C(V]=.OW:9G+'";=J3-F,HD$!D@U,3X7M4$!I]A(3IJB'!(E
M#E9A&0D KE/4(4/E15S7)?RXDQ*M&3&N"/+96!E, NH'5.@R7QQ%7=%8,.*2
M[M<]AD\PS:1FXZ 9)T5/LP2H#U2URX=7ITTY\OXIF[O<7.>\EQ!"KEE^&9UQ
MVLD!T-)%%,9W[<R%55(3/0C-<03(!GIP4Z(ZM6:/K#1%]=$Y,MX<==0$]OC@
MEIS+%<SEHA1A_B4=M3=NWW;/EC8'@QGD/&I9VM(].0_(7JW2%["'LF:65)C(
M(0CP7&!]T-&%F^U 3$\WJ/D5]W_TANFY^^Z<:$QA<CVCPEO@M,O;#O?R#MW=
MWV7D$]1+8JR=U+\^\%\U!5PODA,E0K6I ]\C7D'X01Y<R,>/WO3;&YAZMH 7
M&PXK[;T?KV[Z;N?2W))LDL3F.96QFT_4'QFZT5-!)61B@@,%73U\513$0U0C
M]*6*=@(D; &M+T:2-K\\VE/-PV,[4O&#K)7UG9=:VM^UX9QJ&QSYH7J>ZT5C
MNDM=2<CIWU4;*AD4;IY9J]K98P^=C]L;8ZH/G>_<';XRT $'<YS=BVT;>F,3
MI=WP5Q.S.9%V47 9G?O2O!WOCAA=!?Y;364.Y"VF@CMK))ML52(61VZNA:2R
M* ;(PFY[B22"F"#7C%V.0IR_I0?5V@EXF%P9DN_><^2;>^]WK145$W(:ROM]
M#3T<D<1I8:=[+BR.:(3M;3%U*QDDT]5(-SS*7D DJUI!$;,K\],8U(YLZK<Z
MG;VMOU;DI"'(N3RPHHW\D[^_NNY5;*(PSMDAFH8:**JJYJ=CZB83&KDA*?.2
M-I -KG-C82]26KAD=.C<$007=W7C][]P^G(^F0<FJ<5%;G'-KA>*NHFJ"YDD
M[G"EIFEH?20*@CE<T@ATDKG. &W:KAF-N-*W8].(B%XG=;J>ZORO2]@@&GY%
M6U%*:1U;+'0T;)!-4;@=H+W>K%2L) ,U5*YQ>=2$ ( *5_;VX'6WB*,+\R/2
MCY0KM@BGO=9'#$US&23+"W<]TD<:DNEDG"F:4AQ+W9J2@R"8XG),0@! 2.*=
M2@J'\^YI;;'24LU3QVSUE'8J&G:QYEO%TAF>PB#:7;V&X2H$RE>-R;=AQ0C3
M#0*RS[\D&[,0!OW&$14/P&:/_P"*%V?NGTP=R?I)[^<&N$W&[]>N!0<2Y)76
M.:2WW&V]S.V-PI;_ &'DM)54SF3-KI;1?WTPE'F_S6S54Q]=Z5LCM^BV+-P>
M.#QD#PF\Q[CJ'N7Y[ZCO1U'K.ZN8PN2UQ_NM'X@ ]ZZUOH%^N*A^MWZ8K)R^
M\5M(.[O$*:W\>[L6N$LA?47;Y0&W\PI:1@'HVWED$+I2&@,BK631! &C",H&
MS=-B50*Q)S&7>,#[T&],SAJ/F KV\?;-&7.9/[3*F1()^S<[3WXK<;->6F:R
M[5%GD]7*RJ<6AKMI=JI^PH<9UYF(.:S)RD"Z *RJJ98O@:BD( 2@\<(7&B6&
M"@:M.H8ICN6F=\[PYK1D1FU$&2(-1D,="1B7%2A GZL0DBR%_JL!: ,CD@ S
MR]N>'ABRI)G?-23XDSRQJ!FUH0^(0%3[2<$3$&TO]6:,ZZFWC=DO@ $&J9X@
M$#L4BN"Q+?1H\!P.I1/'++3,98I*['Z4:$2[E.QQMNPQM)*!?B4H,AD,DVX.
M+A <(]MQ)T\-JG,4$Q"$;2A)3-N0RUS_ #8*+P3-N,)D/BDFHF<YQ))<XN*J
M#US0#V?EP0W('-3=@('42 3DDZ1Z@^T)]J99?9BLY 1*!-C'FX7P.VTSO<IS
MZ9_SX$/*@-XF*&9ZIK"<T0DYH.NB] N.);%%,VI&J2SR"*G>AET/CD?!.B8%
M*<'KBN$B<$KNY7$R$/,N>W50%\/8F*"8-%J"Y",?,4W/).;L9'*WU6@9J5'4
M*H^[$QNN:&J#=E&Y'L41^X?.8G-D!G;M4[2"#F3DH/M^_#%J]5H=ZR[T-0#"
MJ9*V7UM96-+9&N.X$>)S4E,\%E,$,4A* D7'F4F/FAXC_8QO^WP]WXX4?Y,F
M=!Y_R5P\=S:>8=S>>K$_:>><M4@>/(KCEEADRCQ7M;A&DIV^V,!:V'<QP"MU
M&>2IY0, G(%9ETN%-;B,+-D(3^B1K[#XKF,4BV2P=S(ZB^2E)P:F:ZOMX R$
MS"1E\6XH![ W#MC$-B2O+[^9T2.:W9_3A3@4-"4_ZHZ9ENP9_?CT1E^G&(YI
M?IIB;8&86S"RQ!MN9HI8@R!T:WX2N61]F,ZX1&7>O=[.V;D2,0(CXATP?>BF
M:;7(2KD8Y5&?Z1Z>W+'2(UF)R*RNH B4'#%EI7[VQ4HN#M\;?VKEZ%-Q3K@%
MN]1AYG*Q/2,CA1(?::FIG72'8QJ[VKD2F>IZ9@XBY>(KP5Y"8+M0+:1PVD:R
MUTI8&E(VC[=J#4A5Q?6#'5R3$($@1%'5SD$6X1J$)*;@%) SR]A(P&1)+JTA
M^E))M2PBW^P$)EXD=$TRPA?K</)EM;$/IU8M5.%9F%]MC']4;2OP@ 9J3D%]
MF,>\(BH\Q#GV_BF).6)Q8)9XO:!67R%[@K6NR" @'<P!4R/BFN!V8@@@X)7=
M0$[\8AW.7<IL\7LGZJG>&M#&ABAH&Y$0LS"@C\^&XQ +#$4JM7;VHR@)&-3G
MRR3IFWM;2E&.VAAS#7(-0G]'=@FKZ4V-(\-.Q0F[P6ATUTJ"R,':^4%0I+22
MJDE%TPM< ,FXA>:W4 ;CY2#_ (*%W+N$-KS)_9VN)7+9FI*@@>)& 7? 6Y)&
M5H:J)E#VMB=-5)2@J7 ("J@YZ998#&4G<J]N&D?V5&3NKV^;1?,.$ :?,GD0
MIF$(TQZGIHU$&IBF]M*49:3@,%D_3%;&TE;5Q-R#KE*=FU%\L &JX]9>VP%A
MR%IVI:KG]EJK<EV\H1Z5&"W-K&ER!?A&73)2,>8W4-+]J=G & #-$A23CMP_
M=4KMK23"\D9D9-'EST.,MR*#!9MZP=$I3\P" KA;@87;8V[LSHA(7,+D0<"B
M[L5GB >E FCOM,8YI"&D#,H,U)\,D.#Q+ *ERVX8H-DJ/3=FTK[PF1RZ>S!M
M1(KB$OH8U19:Y7OC.[7;DFBZ#W)CL B0+ABA7D-3/%ZI9FHS7V#)?#$3('AS
M9(@F4GS)^28^ONM<^9S &-C4J4)**?*"2JXX4%<5Q+415QQCY-KG:E"@T*(J
MY$],1*;$<$4.0Y3X\?AC;-3D@ +GI\6775<7B6&H*\(DW(B6!5WZM.*4_.?I
M=Y& UYFX?=+%RC]27[VTD%0^T7-Y;$1(YL5#=G2%"$#%Z8S/N"T=QTJXU9P:
M7NQ^!*^I?Z9=0'3_ +ML1G_*OQE:/:0\?^(!<V?<'MTY];='Q1L>V>GE^8@
M<]KIH1Z@F8]^Q^V:!SD<&HI17#/'@MKN@WIS.!H5^D^J[ VKHOP#QD*J'7(:
MSF/;6O8^BJ:VJLOS!:96.#9*69I<UCCZT4E*]X+LMS7%H5'(B:0N6+ITW #/
MXK)T[K9O<V\CZ6(&06;/WLO4U&V6HK:LL-,:4N>6OC#6.+DFADE,@G;(Y0^-
MPW9 J%!:M[?9TXNB'K74#34<&]@LIG=6IN%"ZCJG5-2TLAWR;ZEKWN9DZ0;*
MH-A:[0[22J998)Z.VC(Z9$#L7'JN]N0].;RYN4@U?,F2"GBJZFK<*8>K%!+5
MS10@L+A#(8'33*^%A1JC:HT4X(([>()%2E9;K=7!I,B&YE(SN4TU+YZ;T@Z0
M.]26%KY*@AY,I<ZJJBXF17G<&@XK.=MO $LUX_S"2D)]T==/4?*Y]);&D/JZ
MJ60;W1>9[A"2&ND=(A&1">*9X7F2U,4Q"V(^9(]+<)KQ64<%OIS!2L<8Z2CI
MRP[86- ,]1(]K1--4,!+G=-K0,LL"D2,:E/6;;E/3;:>:U4WZIK?WC4!M/"?
M3;)Z$(=&=\+""!)O>$0;M^T!?,G1B34J+]X0B0&$0MOGT/?1Y?>-SVCNWW$L
MDMJ-.EQXAQJXTYCJX)98TBOUUIWLW15/I(:>)P#V@[WHX-#?6=#Z%.4X[W=1
M: K$',\3R&2^6?=OW3*_;ET[92\#:92!Q&<1^)[EK2_CD]X9.2=\NTO:FAJG
MS4?;_C=PY'=*=DGDCNG)*F.GI=P!.V2.@H"G7:[VC'O[VJUL[=L>:<C(]@H/
MQ7SOI\#*_<OG  1'S^"9?Z$/K1YS]*'<2Q\ZXA6>K!%$RU<JXQ63R1VKF'%I
MI&/N%AN#6DM:XD-FI9PTR4U4QDC51S7(3LC<1:7F!H>?Y<4UN8'&&*[-."][
M> _4-V[L/=?MI=&W3C7(Z1KGQ/=&+E8KM$UO[SX[?*=CG&CN]JF?LD;H]NV1
MA=&]KCDW1*),;@:0I^+]B\W>B8&0EV)N>2- J20,@2'#50??X8SKVD@OE595
MPL2AI].U[$#?MZ#+""J#[DT?,+:DTC@T$.:GPH<C]ZD8O$.TABAR $^10I:Z
M0LJ8QM52-0 B=$]N#VR=2B<02. 4@^)-"QCPVA$)]XR)S).&#@B1#1?(U3D2
M0 QJFU 47//-3FN28!=D(P1[4:ZEZHJ(N<"$5=?8=/MPC*Y(X8)H 8)P[11.
M8&EK2 $0C,DIH %RRPQ;O"@):2L ^&*/*960ORS,9S()S4 =0/9AL.S*]B4Q
M<&G!Z^^J1)YR"]?'/[<D3$XJ+DC.9*2YJS+:-JYHAS3,=#D<$C&KH;@,ZN^J
M11.(.:)^(UQ.;9*A\SIJ>17T4CW-+@$<5+OAURS'4' IR85+!+:]/>F.O_<.
MW4,KGU%?31;"22^1K4/M5P TRUQG7KA%(X)JT7%*E-7R'Z@K#0,>M\H6AC=#
M.U-,^H.%97C@ZT[-IQ4'5V?@H\\H^IKCKV2IR&@52K34M0E"@R=EGGB(WZNZ
M<.TD8T?W-_!1:Y3]0-JN=8(H+M33/>Y&ADA<T%2AR*?CC0LWZ-(K-O[6Y$&A
MT]B<#MWRP5SHYC41O!<U"URJ"=3J.OX8>C<C*@Q(67>@ Q8T*G-^]6^ _P!A
MGJ]=/Z6F+:0HT2Y_RN2Y-NXO"S)W"YR_TE7FG*SID-U^N&9;UUQDRWPU&()Q
M7O+EBCE%?"^."D=& PM1K3D#M/B2#[<=^YUEW6+N8FV"#@I-\:HO3$30W4M3
MW]0#ED0,,V;H)KBO.;D2+\%)_M["36T(3/UV^7_G!$/OQIVB=0;BO+[]A$CD
MMW7TZP$45"GZ3&?^8".@T)3'H(D:0E>F19Y#!ODMD]HA)ML)09,S4 #1H]@]
M^,V]YO?\U],Z>PMDYG3\DP/>L%MIG)3)LC'$+F!F"A&F*OX3Q*R>IV "PRB?
MB?S*T5]_JPQ7!X#BOKN"K_6=]^$87&D2?+^:PC$REICB$D=CZOUKG%N<I]0?
MI>4$^/7/\V(G<U"E$2Y AB<%MZX) :BWT0 #FMA8]X+5!1N94$:>_#0/@ 5K
M8(BXJ5<Y+2['N8W,-<@]QST!*$+ICJFN:O.L3D\?P2#5PDT#=?,4'7373)0<
M(7SID2< %H[4ARV(3A6>$FWPA,@T9IM:>I*]<\NA7&1.KDX-\L^]-D8#DG*[
M<4#9KB7D$EK\LPNXD#-.JG'6!2F#I>4_UQJ#EE-[CU#MIZ9K6EI<6D+T=(B.
M("Y!<.,(BN*W(CT[8' )RYJ1C;?*P[O+$6AI3:K6@[D'Q'+/WX'$$RI1#B-,
M#=(>X2.X/DH/]R(FNN\P(!5\@]@\X\5"H5P*\/$_MFL??!KH';\RF.KK+').
M@9N:]VT:E'%"N2986N%X/]026EZY(>_NU2I4.,8:I<43)0 $:BKG@-H/(<$T
M-LUOU":J$_?JT0TM/6.;&B-*!?AR/4@ZX]ETJ($]'MVH=FLJ\5'[Z=JAL=XK
MF[2!^\)M4&;3 @!&9;ECV^YMC]K$]GR*T[ ,=1&:W&]NI6.CINFZ-JJ5\Q0J
M<>,WS5"TBWH@YO\ TJ3=*&FVS9?]&]/8"T?E3&),X\$ONM)MDG#2A:M@C# 0
M=0X@$#\Z*4P($R#RXK$PJ$RO)VL%1(P(/,XY)^)!(.9TP6)!\*Z4::DU=6T-
M?GIN0:'WY?C@QD'YI:<0!J")[3FQ1J6H3F@R1?9@F05(@UB$@WZ+>V70Y%0$
MT0A?OP.[4AA5)Q# %\"4RU;2-$Q*%OF.HZ9CWYXBI"-I#A$5AJ&1O:U1KM'C
MD0.N()U#DKD#2V2>:Q3NDVN!&1;T4IXG,JIQ,20&3%O20"]5G\6[D6?N)]37
M&?HRI9::JFYAV7[J]Q^Y;BYLK;3QVGLS.)\'LCXP[<RLY!R[DD=>]<VTEL_[
M=IQL[?8QO[0SOAX7"8!^#'5+G_5'][@O1?;VN/58;N'DV\A)^,WH.[S'^[Q*
MU<\C[:LIJFZ6RKI9_P!_6F>6EFIWM$<4LE-42PUT)CE+H'[RW<T!"7-]N7P3
M=6[FSWT]O,D:)F)' @LOV[",-_T>-^+$F((["'48>9]GK'?J.2S54<8CJH)G
MT\H<*=DQW.B9FV29CFQO<=AR)/L(&+'=783>)P-0E+&SLSMFW+RSC3M4'^??
M3?6<?J)'4;I)H('*YQ)?&1"QCA)%&&9S'<'."KG[ NI8ZE&8 EBLN]T.5J9,
M<$R518*JT3L9%2N:QKC#+Z43_5EE:CY?3#WD!D3!GDNYV:8TX[B)!JLV[M96
MC@F^O='//5.V^JQ[WD%KXI$?M]38T':"UNX$NS.@&+BY(UQ2I@U"E"EL,-MI
MF7.\S&*.GB.R)P!:_P!-"X"-VZ-KRU40%5)=[+"3]JB31J2ARHJZ[DL\9HQ#
M3TS6EL<+ X-A=& \ESB[<9-C4<@)S0#$2E'-#C)S4,4_W;'@=\O-XL5CXW9+
MIROFG+JNGM_%N*<<H);A?K]<I'-'HTM&U@+88(09))7NCIZ:)IDF>QH7%K-B
MYN;@MVP9'#G[%-7]W8Z=8]:_("F"Z:?HZ_AD<9[,T5N[H_4#':.7=X96QUMJ
MXG3/CN?$.V\@26GCC>6^AR3E--EOJBTTM-(#Z#7N_7N^A]%^VHV6W&_#WJ$0
MRCS/$\L OE/7ON>[O=6WVA,;!=SG+LY<\^Q33Y]%0VBSWB\ULT5'0VRAK:ZI
MED(BB@IJ.GDGFFDD7]6R.)A<XG0 X]K8VLMQ<C9M#Q&0 [RR\!N T3*1HQ*_
M/'^J_O [O5]17<[N>9)*BBO_ ">M98=WF+.-VUXMUC8U5+!-;Z9LI'Z+I#@'
M43">\G&VWIP\$>P4)[RY[TWL[?I[>(/F(<]I_+!-O:[[)2/C,;P"TJ4.8S+2
M".B(B^.,Z/@+%,2BZVL?P^?K[Y'],O./EK@:B]]L>65%'3<\XIZQ<9(HW&*G
MY%90]WIT_(;.V0F,Y,J(EAD\I:Y@=YM!N(/&ET8'\#R69N]IZL:8C-=7$%_X
M[SOCU@YMQ&ZTU\XIRBVTMXL=WHR705M#6QB2)QZPU,9)9+"[]9#*US' .:<>
M4W&H>"0(D]>Y>4O0,+AMR%0O+80&)F,T/CTR0Z:84P0J8)N>6P@N>2<MH3^9
M-,Q@UIC0XH<P17)!5!!^O81H'*>IU]I]F#!HU5,:)[^)0C<TNUU3Q*@*/LP.
M=V6IAP3$ 9@1R 3GOIRZ %HU*$9],NH'W86N2+%RFHL*)3ME#*=K6@DE/LS5
M"3A61K1'B'<#%.IQ^Q554YK 7ANA(7+(#+/(C$QD[<<486](?"?(IQG<3V4[
MFC<?*HS._<1GU.-&W(D#\4:W;N1!F!7/L387ZPSTN]WZS:I(U R4HX89C+WI
M:Y&( E N^/:@52UQ#B5&6GAKI@XJD[A.I9Y?_8W!?8,]  I49DXJ:FBM(@V^
M3)B.;%WZY ,PX9@C).B]<L+W& D_L4II<=BU^]TF++,Y"%W-!4E<U4@',XS;
MQ\/>GMD?"7XJ$O,H'5#ZAH7,/!*N5$T&9*G&?=EF,5ZO:^4<V4<[AQ6IJI)2
M&.(+W%4<5!]BG(8&[BIJM8R BR1:/MU5&LAE])X.\:-* +GEIA^SY6R6)O+P
MC$YE31[2V&6BC@88WIY-6DE00#KT&-"V9/$T=W7F-R?%JXE;"ODW^'_</L^$
MZ^.&?4ARP?$JNL?]-<^/->(B3G'-'F)5Y=R8DHJ[KY7', #'@;N]D+A#_45]
M1-@&'-EBVSC[:=Q'IH&C,Y@G3((,A[,.;?=:ZGS+R_4K9 8)SK#2!KVAP'E
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M[8*6MCBKME:9I'N&T2/I9)HS' UVV-&.#2J$DG3&:=YH#,=8?X+T,M@\=0K
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M0M6Q5PMLG;\F.FH7#38Q-N6FWQ]OCCQ>\(UD)J0 #"K!2,CE=\I,A&<3M?\
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M. &[_O)F-EC6@0K/=WG=^M.XDY[CD002NH:/,,4U3)?-'C:@[*Q%=7-)<Z1
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MF3]RI.8(TC!.&VG8T-8-K0#(0J(3H6!4*-]X(P8 FF2'4I3B+(V@!P&V-GP
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MP;]30U%WN5XNE6^JK76V-XDBLUN%3)LIX(5<V(-#G/=GA7TM=PW;@>Z3[N
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M\A!P7YK9UV[F/RE*T@A$ZK_1/Y\/"@#X)VU*49O$U4AJJJVT#5R1@34*XM*
M@9@9ZX,&TMDM#<7Q".FW4D>Y-#R"J#]S="OV(%S7/ )T[%FFY$AQ7+O22K?
M?ZI+]GA[L"U'\59S_P!-19N7;US[O<W"F^.Z7!^[:W(NK)BNJYXO*Z2:,_%8
M4MJ(W)''Q'YK!=P:H:X,;3[0XH"C2![?=E@$I:09&I5A8B/+@LRGX1,T NA*
MCW9A 1T_D<+7+L@/#BBPMC'-%=#P\R>G&^)Q!*Y #H$ ]J:X7C=D9,6+JQM\
M$^O#^'BF9&YL(:B >33S9DDCXL\'BYCXDQ9VYD7^D'WI\*2WMIX&-#>HW. )
M1 <FID4Q<1!J5NVK'AU2'8$/\BM?J0.EC\R*7 #//5PU)TQQA)F8K/W43&%!
MX=3]B9R:6HHIG.>'('.11F<UR&A:<-6;;C4U/DL6[<T8E$5%R(B-""W+4 @:
M9_"%3+!9DP#LZ8L[RYHT1/A5FXWI\S';)"XY$!N6T!.A7/\ FQG3D0YDF#N)
MR P(^"C]S/D%3$U\8+BTJ222#L)(('O3/KA:4O"2,A[RA2\52F.J.3/:]T;B
M=I* IT]ONP#U'I5D'2^"QI+]&\-8YYTU*=$R]N+F9B&.>2[3(BJLBN?ZS)(2
M=F1> $!\"1DFN73$ RU C!"N0#/FB^DO3I/3!<X9 $ EA.2YJ0<_NP2,F-0"
M$(P$*%BEJJNADC?%&2Y0,\U!0>!4Y8JR%&#EC@@:MH&5,I>1YBY!EX^(STP%
MO'5.>@.Y8HXZQR* Y<U^T% "@PP(Y1=U66WC(T"7[?8HXW>FV-240 9E=,^J
M?DP6$9 L13-U:W8 Q]RYFOXVG=*FN7>;CG:FW5H?1]L^*0ON\$+Q)#'RSECA
M<ZN-X!VBJI+4VDC>"I:I'LQZOI6WE9V8,O-<.KN%(_(GO7H^@V09W+QP#1'=
M67Q+=RYT^;#U*.,L()CN%#(\(IVLJXB?ZH UUZ>&-4_RB.87IV(N!L&6?2;B
MQ2X@1@@JU&@E<PN:H?;EB+88*YPHO;IO*YXS']$(]=JCR@A6@X+$.60)$LZH
MS A 1N0 D)M(!4GKFHU\,$T#+!#IWLK+W$ARA6N0[5!+LRY%<5<2?#$CPTR5
M: 56+,0QH>Z0/>]S'"+>CO3!<"7N<[X3M+=OQ$X@BJ-"56"399O4>X OU)C8
M$'E(#0&G,E"T999^)QW8K%A)Y+"+OUC2KBA7S9 [2%Z>!^\86O$F3/1E>."+
M+<T.3)<E<I^)Q(4A0NT $_\ -Q:!:+54MFE:D!DKV_"XA0/%0<AM(&;@?9AB
MV 9559G !;5OX.-@;R7ZZ+'') R86SCLTI;Y7;/5OEF:7("1Y8X':>W!Z&[#
M@Y^2/MGU2)X+] NWTT;WT<A<7.9ZTD+"#Y'"CGC:Y?Z6USO;GAPGPL/:J,(X
M'VP3*?4MW"?VP^FSN7SNEF9#<[1Q:HM]L>Z:D@+.2<BKJ;BMDD;)<)J>B$L%
MPO$<K!*]C#L0D*H!O-Q^WV]R^,80D1V@4^+4SPS6W]M=/CU/KFTV5QC:N7HZ
M@: PCXI@D.0# %R 2 Y:BYA>;4E)4\K93-B%=>*KB=59+555KI&525=CK;'7
M4<_)>&%[;_47*.D>*QM?' R&H^8CDDCGEFDC^*VS*=H7I:B2(S(Q.N5F0E(R
M9YW3.V7(\%L$P\PI^^)SVVWF;/@$K!N1@9,0(V]S"=H:92C^WV\+6X>S8<SF
MT+L_ /%8O''X:GMK:^,3-IJZ7Y.FI&MEH^2WUK#=8745%4QLL3AQR"BK[='Z
M4T-.:F1LNUH,[VB*,5F9,R(,22^--=X>C8D.%N]#U)7 _AF02V$@7;!L;*)N
M1DT1(%H1,_3V4O7W-J1F=4KVWW4[?H2:(N682C%HO)'W\/ON6>QOU$<6J15,
MBLO-I:_A7(:$/Y1$RJCO\M77T4\E)>H:N'YN*IL%,DOS>;C*-]0\D0^P^WMU
M&'4X5(A>! !SU&6@D8.(VC_>UC.,1\7_ -3/M^<_M:YX(F]L;L9R(B PMBW9
MN:9"7DE<O&6%;9M$!A*1ZA*>H_?L<LL]'&^.+]9%4N#9&3M)!9DY<I(R",?1
MWTRH2OS)=&B(TLZR)K)07"DFH):6,0S,+)/29Z;PI!8Z.1FU\<D;T<Q[3N:X
M C,+B#(NY+E3;EJ&IV*T-_\ $(_5/<.V?TG\2^FBEJGUG+?J!OL$7(+[#5TK
M9:CMSV[KJ&\W)E910S&L;7WJ_FVPU,IC93S"*;:KG.:R[>CM9W\)3)MP[ZS/
M^[X?[V*SMVQN"W!F\Q'R[G^2XMF-_5^5H.1"ER,&W<CW.:20,UZH/;C/A $:
MCBZ4R98KI]Q$;BV4J&[(?+$FUV4KRT D#,: ZX)X@?$*>WN4#@5AU)+6^HQ7
M)((Y-K$8U\C7[(6N<$+BA* EQ 71,3+P#M48!\TFU1!9F"T! T%&M>YQ"EP*
MD!,@,"PH%#T;)>O+#%'Y5<YCDW;7><. =Y5"M"  (<EQ&*C *PH!,FYS=B/E
M9L\SG *,SYP=S J%I3\;8"F)78@%7W7JGI#1MN%1%1_/5+:6WM>X.EGG>V6=
MD0: PN<YD)4M1J] N*$Q!X/3O5VEA0I1DK$1H+04+BI<07% UH .I T/7WXL
M8L>:BI6.)WO$9<0P;B7L!.14G:\Y%I(*)[,0[&G!5"Q7R(Y<@7*UJAOF))84
M!R80OW8D#)0OC&DEQ5[O*7!P+?*YP:NYK50*$ T]N.)HRELEE1,! V*2[],Y
M EVW<GPAR.7HB_9B,UR5Z=LB-"%"[)=H*I\3M"CG ^TGQQ&8S/X*P8X)0])L
M8D<4#&M<]1Y6;6*XN+AF$4!<"C&4AR5\Z+$M;OFGU-T.0FW14N9:64T9VJW?
M^E,]7%,@"%TP2&D?J#R-15QHU5\JY=Q#W9;<@ 2$>1D=P4(U$0C F1H%Z+%I
M9'-E;N4A%V-< @<%)0GS%3^&%" Y!HK9T193R_J\]P :"J(XN(:C7#H%'CUQ
M83BPAB5<< B^V.9-&WX25*9 CJ-OFUT\-<<)"6"%*+88(SX?=*OCW);==Z.=
MT%9;+K1W"DG;DZ.III&24\S2,P8I6-<$.1&*SA&Y PD/#($'O0Y5%<%V[?35
M=J?G/"N%<RI@'0<JX[9>0,0*&/N=#!4S1HI015$CV?\ -QX^P-+VR*P)B>XL
MO$WK?I;B5C^K,^[+X+9_P>WF&FI\M&-.2=<R5]J#[,.$O@CPB9853N74N901
M[5^!?!/($:3IK@T?$0ZBZ1&+-6(][IB+_<#"]P<5)): 5"^)R]N!78G44I;/
M@!6+\_)[/]3?4U.OA[L"TQXIK4/^FGIN7"J/YVL<V&,[JNH<XZ)NF>3DOMQ$
MX.&&*++82,B1I%3WH>K>'4WJ-:(XW*<BTD J"0NX%-%PJ\AB:\V2D]N8$"08
MDMWK[!P^G0;HHFA2W-"2<DT_+BLHU?\ !$&UN.Q89X_DE6FXG R1GEC )"H,
MU'@2-$&!Z ,%'H5:)&H]J<ZQ66$^1H:V-H:"@^(C(H>A(ZX9,1&V#*LEHVH"
MU  U(3A1<98^G&R)A50"?B("$$%-QW)B=,C6CK0CM+TX"X"!RJAB\V&-D+@&
M-#@NX$$#;H0#XYX+;U&6F6'XA(W@3"5N8/#V[TS%^XW&]R")B#)!T]V&[<(Q
M+YKR^YM4>7F=>;=Q&,0A8FZ!3L!0%"<S[,5N0AB"?>K[:T6 D#W*[4\3B,3@
M&M)"*K0!J,QH=,9UVV($4H5IQVTR'D&&3^SIC.=\)B?&]XA8%+LRS(9'V'(D
M#"LH-X1FE[\+ELEV_!1"Y+83232-,2'>H4$ $$J4]H_#$QVH,0S:EG7KDH5)
M.DH'DIG1R-"-0=24&>@]V6*3L.6X);U2".!2M3U4;1L5C40 9GI[$TQ L2>I
M#*QO"1JE^G]-SXG*U4!3Q4>*IE^3!AM"2/$&4>L!YG")Z=T2A0WW>/N(U(."
M_M RM&_;)9R)*ZZ*-TS7.8T!40$)DJ$Y]<".W8T-$W$R;5&3A+$(IPB%BA-?
M#VY=2,'$!'R"O'-'$M3!(W/.7V'MAP;FO<N^/C%EX'Q.^\KN#2YK?5AL=OGK
M64S27-&^LGC9$T+FYX'7%[$9;B]"QAKD _#FK2)$285EEVG#XY+@9[]=RN0=
MU.;<NY_RJL?6\CYAR&[<ANTKG.>E1=:I]7Z#2\D^E3,D$48T;'&T:#'L28BD
M T(A@. % O:=.VL=KMXV(^8"IXG$GO+J'O,GD66O>'!WR_IS%KV[@]D<L<IW
M )T:?9@E#;)R9UH$O<CP6=1.::82EKE<!YBA'F:W:UP"-4]#BELEJ*W,+S(H
M>  #DU1M*-31RY [CJ<%PJA2()7IB!H"'R=,AZ;B@4N 4* ,D3!7)#C% (7E
MS7M#RXZ#(N4@-)1,PT$;M,6$AAFJTS2/4/5VC2_SA=Q S*@%I"M#2XH0?9TQ
M4N35$BYH%AR/ +41Q1"=S0P)D&E3DJ9:X[ '@K&-7)5MKW*UNKE.[+1RE7$:
M)FF$R(ZR](HKEN:*;>XGS-) <K24+2200 21UQ># <5Q^*7+.2^KF5R.#2A+
M2J 'JA37QZX:L^9SW*DGB76\[_A]N._W@^K_ )W=R'./'^$1SN<]NXB,5=4C
M@X! '3^F/:<&B'OQ & /X)S;?R[AR8#XKN?I"V*:F>]0R&$R//0CTMONS]3#
M<G11@&Q6H#^+SW7MM%VNX1V/LM3)'R'N;RNGY/<::&AH+B*'C/$(ZR:BNDD=
MSJJ.WTH_O-)!+')421Q@TCD*HGG_ +DW'H],-H%IW9@"K, 03+$4!T]SKZA_
MI=TJ5_KTNH3B]NS;D!5M4Y#R EZF(,:5>0;B-.UBNIEJJ>W\FLEOCKJ*VN@I
M+G=KYQVUW*W^BYD\;7-LECJ[C-/9[A*RA,'I25=-%&2T1MW,I_E4C!@92-N&
MF+R%#;C&7J"38_ISF-M(?3JU>8LOUGLWN3C;$+>YW)D1;!]2<;T[ML6Y EQ%
MKNVMGJ,987+@ D[ EQ+O<H[U))'<+A9@[UK_ !&G;W#OXIJ5L]+2TE?0T9I:
M22B9;Q8FMCIVPNE@GD:&0RW1?DVQ;D3$F41;N_J/ 'R7)#_N;46;P;6RURU@
M!(L"YTK1TVBTK -VVVV-N<K))NVHR_\ [1?GJ.KU=WN]4-W]6@ SC: ]1,CR
M>6:SP5-ZLM^I:&ZVNDGN-HE@[B7*?;<*$0UU)4,AK;;(WU*2V6=DDS7.>[>'
MT\FV5\=N;K;+<:=S"Y; $M89N$A&,"'JYV\#N *-(W =+D'R?7>EV=QTJ_8N
M1,K/HW!_+D UKU(2B2*?_M&]/;$L7MQLW/$("ZNK7Z<.8VKF_P!/O9_G9N4$
MS.:=N>)\CEGB<^:-TMPL]---!$0W>3!.Y[""CP6HX J,?6-I=_=[>&X@Q$XN
M#VK\4]7VT]EU"[LK@,9VIF)',<4ZDM;55?\ 9[5 ^CIUVRW&JC+9I'.(#(Z.
MF/F]1Y( <]$_##(TP\QU'E@/S6?$B(<47 +_ !AOJ,IOJ/\ KJ[CGCUP?<>"
M]G/1[,<-F;,:B&L=P^HK&\OO$+@L>V\\TJ:YX>/C@CB7(!)W\Y1E#;&HM18_
M[<B\O=2/]U9I,9W)7<'/P%!^:UBO(1KFQM>]AVJ2D(<T*XJ A(S.9S\< BS,
M,4.1<I/F<5D8#O.U#%#Y=R@!Q#W*UN:YH%.)\6G)U580$D#S)$&%SCLE@E)?
M3%@#=Y:$=MF+&!7 ^;: X$- Q331YL2HP6+4.I7),QSS$Z5S7-E:DM/(6A_I
M2,)<-C55KLRYH)0[2[ ZF@#* \>:PZNHWRAC7B1J'SAK=A 8WTVL<-S"'M"C
M/,'',V"@G+-7A'&89:JJGCAIX(C4/DE?L:(6@OE<7^?:R-C5*Z=<=@>:F)(/
M)-IQTOY=?9.:U,?IV:VF6BXE1O:6^H%]*KO<S'-+3+4>GMC!S#5/12O2_=]3
M_"C0<SG+\D67@CI^LX_DG(=4@M5VQOADI.\!S6N0+TZ>&&<V0XZB>"O-E#FM
M8JQM#2%( 9FK53S$J21FI.(/%<7[E<+R2YH:%+ 6J#YB0I<B([JN8^W$<U&%
M%Z87%P1Q,;43-&M:#N!T!W: D]#[,=S78=B4:=H* A0KUS)+2="6J-H7W*,5
MP#A3G5*\+5VM+5'1P8JJFV)S2 A3/%&?#%6#]R1KU7DOBLL!(FK)6M>&!I,=
M*/-42+NR)!V=5+CX8K.$H!@?$?@K@@R8X)?+?E8&0L.STXV-+05;N/Z0#?*
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MH7U$()+G %5)]Z$X%,2C)P5Q-4F2-]57MD,9$;V"2*-K]Q#4C8_<1&Z,.8'
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M'1SD+D!((:$4=3B#;D7:BE@KU7*((I'.\OI,):3N+D;M)"AH ;EJ1KB;D26
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MEKP]X$GEVL!> J;VD@?9TS7$M@% -:*PX.:&ADFUX:3(\DDHP!WI-78DDCB
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M)%8'>E4,:Y^V"5L[@ /3V3-])Q 'PN,C!GIXXK=C1Q4CX(MLU5N%Q=M:JAQ
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MUV\36X..@)$%2#YLPX(]_4($P.^10FDE,&JWE=%=07!P(1NQ=OE:CN@:?,0
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M'.+V[@"0':!PW@N<-6AP)U3ICI6XR#8%6$N*1ZR1U,\/4>G(6A%+7%';BO\
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M)1'I6_YLL#P'%3$.\CY(X_@/S199+;#;Z6GI:6...EIJ>.F@CWN+=C6 ,WN
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MQKT7"]RYIP4B+HR_>H_I?_<G=\1_GP'U.9P1- 4/N144T5WO#@S+]Z7$Y_\
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M(Y@<YM',][7-+KACY%N=+&1#@%ZAW% 15A6U=MORM7#3$_O7;2G;M"T)$W1
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M&TY GS$A5<,?6HN _-?AV5 PP6 UQ<USF-: C6DD-._:XKN_ZR,(I4DC[<2
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MV&=$ 7CBE/5N/4HGI;93,<UIC((VN3-QVIN) W-RRS1?'%@&J,%0L]%D/?%
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M7B6D"H."EW8)7/>CAK"2X%%3:I#GA"JC/IAT.2,:H6:**EBEWQ*"QWPM*NS
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M&0Z0"YB)H0<SF%'F0@@A#[UPM<?!'%8AN"OB(M?O+M<@X %J Y>7, J5&2C
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MX3*5<EA%^HZ>W^7A@9*H O&.4KX[,$?R^W$.584*DWQR9M;:(/4F+6RTT <
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M,O(F<YI_DC_]2M)/VVGP_DP99D<_Y:@;SK_*JC_93^T/^4Z]?B]N"!)7L/\
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MA6Y_.'F\W?@BQ_DGL[DM3?Z'G_W(]?T_@^'_ ,W\^'?\/_$S0H>;)/C].?\
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(DIN8A;J__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g382677f_05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_05.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C4T-CA",D-%0C<X0S$Q140X-C!!03$P
M-$)#,#!%0D1$(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C4T-CA",D-$
M0C<X0S$Q140X-C!!03$P-$)#,#!%0D1$(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( $0 T0,!$0 "$0$#$0'_
MQ "3  $  @(# 0$!            " D&!P0%"@$" P$! 0$!
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MMS64Z=/X[R&7'E8I5+DEX>S8G<24*\:1+)8T7)_#. 5,T*NJ9<8S%@'"3@.
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M0/X2%HCS*.(<>+M&N8:IEF#A$H^GQ^7\(FEXUZ]>PS=E&SM?DT7Q&3)5L]2
M62SNU]G>>DFPDV7IRZINI1@ZBU+-CY[?HU@]0.U=-JWDBWV6_P!2*LV5*51N
M8U6LK,W88 $@" " =.#?YU8MP@X#@. X#@. X#@8/D;)N.</U"7R!E>^4_&M
M%@41<35PO=CB*K6XQ("F, O9F;=LF"!E.T0(4RG<<?84!'V<$EO2/,AJ9F;,
ME']$^O3.!'B=4S=OCNWF;&6NE\<H]"UYSMGN!D5C&9F,BH4BBZE1Q\K)V%EW
M]!5.Q0$>I1Z#CMM)_)UXD_"+L, >G9@?6>CZTX[Q2T=Q==UUN-HR@X<R"2,K
M9\OYAN..K9CRP9<RE:'1C2EAOLLWO,J\</53*',LX*F3QH(I)EUSNUN;4]^$
MH'7)D&T^RKG%,@4SO &J[^G6S*42?O&+RIL5+,F-UQGC^:(!/#)5+#-9<1UN
MDF1S"D]G):"$Y1(P<)*E<3/C4\>$G <"J3-S4<^^JIJ-B9,I7E/TQQ!DS<;(
M*8F%9F3)>54I'7K7J.>$)U*C)M856^2Z!5.A@^$34 /T\+G32WSZ.DU/F QE
MZJ'J<8$F$EF"N8(;6;<_&OQ"8IDL-:E<:M-?LG.F"A@*#DE<O>+&*:_9W>+Y
M@D!N@F+W#;KI+]'6P=B'89_ZKV?\)1BMYA7F'&^I6'YZO$&11RK=M?,>9FF+
MF-&60ZDGXMKEK-+BKI.6YE&[F5@W1$3F[!$1QB7[6#Z9ZH95V8UXP7'[SXWL
M.+\!8RP9A[%>+=$K%-('2L"./JG36CO*VVK&ON#,;5;92?JZ1H*EJ.%H>O1B
M7=(I.I)VL1D;MM);V\YY_)/S$.H\)K7DB:F-<I.+QK@^\BD]NVM#2OI)8O@[
M>@F"!L@X69Q3N.;XGEYQJ0B<[%-FKB#EU$DW96[-\+IT[)NV9UY3$X2@5ZF>
MOEWV;TTR9B_&[!&<O#>>Q/DNNU%Q)MX5M?GF%\N4;+BF.U99X)6$:>^-*4I%
M(KN3$:HN':9USD2*<P%:63;-<5UZBF-4ZT>2C\ [P3MS1!!)WB2+TSSVG?&<
MBHW*LXCEI*8I\3C$P,51%%5\G8SQ1E ZINE$^AQ';?3W4Z>I=5MCMQ&^G>9=
MAL DU3U8QAN?@FE63&EQOT?9=D\TXVV4OD!@N_P=^)BR8>4'$^,9RO6Y-K*U
MX9JPO9U)4R3OX(B8)K9733&N9+FX7LYWV6K> I7&.&:%09/*N<\H)/&6(\$T
M4\;!F)5JHDR;V"]W*=<I#!8NPW1$7C5%],NDE !=PW9,&KU\N@T4URDSUO#5
ME<WD2QU:+CC7>*OX_P!7<@P%3')=0D8S)K[(6*LNXV"41@7[O&UTF:)CF<F<
MA5&Q/6<?-57Y,$JDK*1JK,'J+],Q3>W/QZLQ)G#9K*T:=]@77%M3()VD8\->
M]L;)*8O4D414,1&3CL,U& N63@:+)@"A6UC&H/\ M$ ,D3KUX,2<WV8(G7/5
M;;N#/5,NZ 2B!A$WT\. =A88B8"/4$"6<FQ4RL(@'L\IHPWX^/\ LX/T>KO5
MKWZDE;\ O]<-2<F(%]CI6D[0Y,HDFJ >]1M"W76Z8C43C[RIGESE'W"H'OX,
M:^=]FVJOF3-SY%,+AJ)DVN/.G1P6#R7K_:H\J@!^86SQUE*KO5T.OZ3':(G$
M/>0/=P63PK,W63+RFU.JSUYRP[<@ ^-JI/X+:=3?@HN?,BA"$'\2@?\ NX9C
MU:8F,O[FKO 2INF=1^ $_:+W).TE;J3DI.O^($=1,:9:3/U#W!\24>&XU\V%
M3$OZI4X?^6J%H9C=N?\ 2K:,HY_RZ^0 1_4M&PF*<.LU3E#^ C_H/_6'!^CU
M<>)P7Z@MM4*KEC>JC49DL!B.H'5W5RLU=VDD;V"#2Z9^NNP2GF$HB *!$)"4
M0[@#K[ &=?"?>V PT,UM<+(3.2JE(; WEO'N&"61]BIMYF6W,#.TE47+VLIW
M+XZJX_<JE6-^6MQD.W+_  I 'LX.Z^'16_N/BF=TR]+/7VM1%0E,@Y&T<R?K
MG9L%P^$,>7FY-;S8<(7% M2C+!5:]$3=@K 9=HZ3R"DWG8\81<W.E74<B@'E
M!PK6]V]\JMPUZV3Q'L]@JE[%8ILR$CC2Z0"\VF_DP")?5IQ%JN65JK=Q8O#)
MJUJSTB:CW4?,,W/8HP>M%DU/T=>$667%Y?/NHU@_Y'X&_P#;^/?]0\&+Y5I+
MT[?B9S6UOE>5022L>?\ *6:<YV Z2GF%3Z\RA9U*FV.IW&'_ "3'<?#1I""/
M5%%D1,?T<-VYQY)S<).!@^3,CTO#V.KUE?(\\RJ] QM4K!>+G8Y%0J3*%K-7
MBW4S-23@YA#J1JP9G,!0ZF.( 4H"(@'#9,W$Y5X>EK5+[;L=93W?S- /ZOEW
M?B_-LTHU&73.E+XTU\A(9&J:OXLD$3E(+9_ XL;)S$BEVE$LW8'_ ' !Q-PK
M?&>V<1+?-VHNNNQ=DH]QS#C5E:;=CE":85&T-)VUU*PL(.R_!_4U3?3-+GJ[
M(V"CV48Y 9&!D5'<,_%$@KME!*'"9M9PW32Z33,;U:$HV/*E6:'2:RR+&URG
MTV!BZQ5X".(<ZA&$+ 0K5E%1;,BBAC D@D0@&,(].HCPQD_ <!P' <"L;UC"
MMV?IVYVN3L%P:8DEL)YT?KMFZKMPRB<&9]Q?EJ<D$6R!3+KGCX.GN5NP@"8P
M$Z  ]>%Z?*,VT9H%CLO[C[J9:B7D=E[;%Y&3-;@)MOXI;$&L5<._#7S#Q&ZH
MF4AY'Z;DE+19FY03,:UV%\14H@V0[#-K^V<1#_=W$>9<Z^ICH2A$XAOD[3=<
MK[1,ZU;*WR-J&#Z1".V&:(+8P]UM#CK\9EB381U&BZC"E*HNB$B\D4P*5)55
M,K6R:7KRO#X<S@. X#@. X#@. X&B,SZVXESI@_*NO%O@5X?&6:8FRP^0HZ@
M2#F@2DRWN3H[RVN?G56-'/T)&S+K*C(. -Y7H+J@L)P4. FRV7,Y04_H:>E#
M_P +<6_^6T?Z@YF%?R;^;,]%9XN%\@[ Z$VX_P JG\07ZWYFP"@\'Q!?-4,X
M6^3N];F:ZLL)#2_[39%L$S3)<B11&/-'QYU *1\V[]9MUQM/\JR_A+$;W?Z-
MBZI3E^R5<JOC^CUABK)V*X7.>C*S68*/0+W*O9:;F73.-8-B![SJJ%#K[/?P
M<](JM4)(^K-)02BT+8ZMZ:53L\/:@"S14C6K%OW9:I*-IFL%+6I=LSF8+4&!
MG6"$@)WZ"+O(+QNB!$4H1(RDH7\/^OP6_$(1,A4TRE(F0I2$(0H%(0A0 I2E
M*4 *4I2AT  ]@!PA^N X#@. X#@.!P9.,C9J.?0\S'L9:)E&CB/DXN3:(/XZ
M18.TC(.V3YDZ35;.VCE YB*)J%,0Y!$! 0'@<TI2E*!2@!2E "E*4  I2@'0
M   ]@  <#[P' <!P' <!P' <!P' <!P*O?4N^W3Y9A#Z\_?#[I/K>4^SS[2/
MAONU^M/E:?UG^WOQW\L?MK]/^/ZT^KOY$^7>'YQ[?A.%Z9\,8\<\(6S/_P!%
MOR-'Z4^U3Y+T'Q_6?TC]P_P/L\?SOZ9_V\?4OB_Q/@O\N\W7M_[?3A7]7JUY
M4?M _?;'G]7O[G_N9^;LOVD_J'_0?V;_ %GY">'[??V*_P!DGU+YO%\-\[_F
M[O\ 'V_G[>&_JQ_7C'IS]_5Z4T?%XDOA_'X/&3P^'M\7B[0\?B[/R>/LZ=O3
EV=/=PXOZ<!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g382677f_06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_06.jpg
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MQ #Q    !04!               $!08'"  " PD* 0$   <! 0$
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M>_O3"G!39'-8'1$YJ.\>SV8/%^A!N2Q&(]%->S!F0&:00.(5GENZ)7^DJ^S
M<<T6D=*H1$U\0'85KW*:C!B8R;U(:8]+J[R2>B9=I.?:4Z8!DZ,1Q!8K-Y))
M\(=GV(G_ *.$C(.CTYX#-9F09T/<N0I4)T7!._)*$<7X(=% GY/95,NH3WX2
M2>"=C'!&T<?A%,P%^)O2M.PX;<IX1="A'J&5.N$2Z$]&("QRQH,^GO[S[UPA
MRV*!$3UHDNE;U"$)G]X[!@.W#BFI ' YHCN'M /=^&GOPF1!."27 QR1%/)0
MIET3^6>")YY).#(ID?F:DYUS [3VX(G@$@H"^74E3U]GW802DNR"/D/0_>1[
MAA.:22Z!O<:FA'0?R'3 =PP2F8MQ*#N<!GETZGV8&>/%#/NPR5-<%4'VCKWT
M]F#'2C#_  EW1E:/*CW9Y)3.N=<*ZT82GM'H1U (5<Q_-@=2?BR/XI50+3MH
MGM7"P4Z,D/9-331.ZJY"O;A6&:43ABK7RM2I3VY(*=JX-P,43X)';I<,<YZD
M(O:*A$[Q7"G?+FHU60R3=;M<Q".1"KW M#5\5'(B@$$$+A9D"&4;(]";^\A)
M?YE2"XA@J=((U%.AU9]V"S1.V2$1V7F-8_34H*T3, D9D*VM,S@.BZ$'FA<P
M%6UJ*9%"*Y4%%P18YH@#D@R,;JU :SI:4-21D="T:@&&"7+M@EH,UKC*\50J
M6 H@_*"]"@I7/!(D9VC](<7*X:D]M&]Z!5]V"XMP1\$>6]^U0I;'J:&N0D@@
M$$%!V-^W ]J(N.*<+]J=TG[D^3\3?U'YN?P]V6&M,?[:D^)_X*VZXSZZ:JP$
M%6 @JP$%6 @JP$%6 @JP$%6 @JP$%6 @BS>-VM-DL)K^\<D<8TLC:GF3S.7R
MX8@<WO(]@"DT!PNG"526F*;JU8TH&<LO:HV;_O=]OMVZ\O74!+;>W:3Y-M$<
MHX@<RB:G9N-3T MJ5*-..F*HJM6=>>J78.23SW*0<D ;G[,.,DA%\R:5)1#3
MO[<)*2,T172Z0*US-:(#@I'!/T/AER7*?_&9_P =O3O4M=EWM$0(?,@#7$EI
MH">VF)OEYA>W!&>B'M5)N6H[I+5EX4&])7++]6VES=Y)>U#9REP"^%HB&H@
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M)8L4=0SH![$%:=N!EAP3P/'BAOS>D?90&B_;A8("49<46W6XD,<">G_(E>W
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MK:.[1A407X)N8#.D_>4(H3FJ5*#++"W ZU%ECB<W6&%I+@.A!S3JGXA@W*2
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M?U<8)R:WIV-Z=_MQ(AZT]3&>K-D*(HJ=!IKT]W=@\#@B(TYH%-^4G9V?>F%
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M6S;C:;*T=&(I9&[U#\P/*(/R\3K6]-XQ[M-0&@]*X>\>O*.B<R B%O1I]Z
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MGK5?MC<O]2/W"_.?GVY_J^_#_@T_6AXQ_P"[70)BG7156 @JP$%6 @JP$%6
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M%O?7$\CJ]ZWI^G&_27?&-NG)J^%CD!K\(/4=<8RK3:H0>!/M6QM)"5K3GP,
MG*AW<. #GUZ@@J!W$ C!&,3UJ0_H1];[JP-:-29%>U:=YH<-RI8.,T_3KRIC
M2 "'1FS<PX>$M)R)R7NSSPUH(+%.2N7#B.*PFY!*ZJ]E"IJM4P^Y,6T]JAF0
M,G+A^2M=>AH*DY)44!S4 X?'+,H3K@C2,@M;G\4/FUSQ[Z5N465G=NL9>7[_
M ,=XS+=,.E\>VR79W'=FQFJ23V5BY@H?$X4QEO.%<T=I\,'[2<1V<>S)7WE*
MW%SOD)D80A*1]#1[025QW\@]6]IWKF[]I_:K60P,GV_YMURR%]GMUC(V&:&U
MDN'^4^\W*XC#;F1M;>SB8QIU/..;4J<@ W'/W+JU6DU-_IP2NXEMNR[]NEWN
M^VO?<VC;J']K<HW9L%K)/$7!L&W[/;6[6LL[*3S!&S46@0N+AJ<IQ)\+O $*
MLG6,,6 4=_X@GJ]'SG9>$>CG ));V)L$$SX=L$EW/>37,L\YN6V\#73B!]M9
MQOC+F ETP=I0IBXH4/!!N9C(<5%LR:]<0!!G*6/TY .G_P#I29L'#O3C8^+V
MVZ;:[>9X#,+"&\BFW6XN8H'3W#19QODN7011LU.>6C0&DE ,8??+:]KWAJBE
M5-,L =)9^ ZUV3R]7VZVLA0J5J,:@YS +=*6=I]9'TQ_M2;8[SUUX);7L'G,
MNH9[R^@=:MMG>7<.\V7;A:>%SM(?YA8"0AQ6'8-YJ1\86U4TWS;W.ZTQO+:G
M6%L:D?'D' =R1T8*5_I;]5/H5N$45KPKD>S\WFC(,C]BW?;=TN#H+(W.DAM;
MEUW#YC7BA8.A[L1Y[5?6\A*XIRIQZ01[0IT;V&GPHR[W4I*'ZG>+[7+#:[UL
M5Y%:W TQRW$<5N(M2M@#T#"U7D5+@O7"XVDI@Z0HU6HTWB3ZDXG&O6KTNY')
M#=P7<=C,$BU.)C+)0E"Q@>YP(*J3I *G$2=C<TI$Z<$_"XA(!I..E/ULFY[;
MN1%S87<5U'H):8WM:[PL:&G0'>(,%%Z]IQ$E"I3D),7=/3GJ@8="4MMO+YMQ
MA@>WS611@2-<7-5Q+6H2VBG43VD#$ZE4E*8$BX4"M:TA0)A\92NWJ_C@:&^4
M]K8X&Z!J#PUH:KP6O:A!["0<6-S5$!I;NA5=E0-66IV+Y)/,N'/MY'Z YK@T
M,!<-.IP^(M)+P":9X:I2<89E3:L1"HP.13:\WXJR\LI+@1G7I23RSI'B!! "
MZE;T]F(.XV4O#\1L@ZM]IW2G2J>$20YP6K7U<X5+8;Y<7C(6A[YB^5S*#4I8
MXJT*3I(5>W&7-8Z6.!"ULR=7BQQ=;*/HG]8[OE&Q0<=WJ\<.?>F8CFLKB21[
M;SD7")@RU$CBYVM]QM,SFMF1:B*3_2%-;Y>W UB"X%W0.#9R@1[77#?F#L,=
MOK?>J4"=MO'!!Q%.J,7;A&3DCJ/0IV?41L'[4VO:/4?C\WEWGRD=]+'7Y/<;
M8PNAW*PN8&N:VX=+ V35$:/:T(0X#&L\R4C*UANMJ>\P)Y$?6'7S]6*YCY;K
M1C7GM-Q%X%QTQY-[4I/3WD>W<C]*(+ML6BVCFO-MO(IE>ZR?+<1*2%#W-MKD
MMF:55S0I(=E8;/?T-QV85H]V+F)'(C,=G#L4#>+&MM^\RHR>4FC($\07^A3X
MVN\";AUG<3:'S[?>;8R9[@)1*67+MNFDU @_I8I0_52M>[&CJ5=5C&<LX2 /
MJ"S?A:;N4( B,X2,?:?Q(4=T==; ;(N66QW:Y!"@?HY'.?$UH+BXZ6D$N.9*
M=#C2^7ZWB0F/R3Z%F/,4!2$)',AQV)+WDI/B0@@C4 @U+0I4YG&D;@L;*;ET
M$;,]=(!1:%*]@ZU&# 2=0.+)1;?9/D+7.:4*@T[B"O9@1.(ZU(I0).H%L4=R
M[="U$7P !511G\/?B<8XL%.<<60!]H/,1M&U):IZ$#L2HP0!&(S3( \;\U&4
M-E"P N8*!5*J57[E7"F<OQ2YQ<-@L=ULT-PI\E7.:H-5!1,STP@PB4U*VC(=
M*2U]Q^6W:YXC.DDHT5("FE<$*4<PZB2I<BD7N5FZ-DCS&FDK5JT_-(':4P;
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M%V?CFPV7%9+S=>-3;3N>\7UCN\VY64&Z6C[*ZFV^[AWFWC^:&W+()M/A=<O
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M=N$G)^A2;;")Y.%R-_QNVAWKOP$ G4=@W4 +U%Q&1[ZKB1L3F[N.J/O5'O(
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MP-6HOM4=M<'"+%R%+.6)3;<CMV_*7(&8;J:N81S22*IAPY8JLN8.#IQQ4?\
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M_P#HW1A\9D<YS'.J%+B</^5J NK>A:1.-29)[29>Q->:*OW6ZN+J8:-*##L
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M_P#7[X'_ &VZ7_XB3'9X_".H+E]61E,D\TT?-GI&3T*Y=@4G[#B12#E0+B0
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M:6<W9,U]T B8QDR5O$^-[?L$%SN5RTW^YW<;GSWEP7&ZE):1Y8D(U0QEV3:
M!*841B&58)>+C+BD1M?JOSKA%_';V6WLN=I;<W,CKB"XG9?1PON'3Q^6SRWV
MTY:UY&DEH(H'!<6OW.TKQU3D1450;JXI/"<1* );FI?>E'JHZ_O[7=;AJ07[
MH[NWGA&B*4AP>[6V0AT;V%I:6D M=F,-SI?=L8DF03U)KJ) BP(9NA;3/2_U
MMVC<;RWL+N1D;8[1K7S%H+%< 0UST#02@R(.+W;?,=,$4KKNTQ%GP6(WKRC7
MITIW-L"9RE\//J3=?6/Z<'F_I9OO...3,DW#CMN_<I=O=IEBW+9VNB9N$(87
M@LE@81(TA:,/4#%+YGLJ%[$[I;2>498CF.;=;*?Y*W*IMU_':;N!$:N .'=E
M$$@<VEB.L.M#&X^@EAZIS_W\XI>7_'N<1QNVRWYSQ3>KOBGJ)L@9IBBVN;D&
MU/A=O%E9DD-MK]EU;@!/+ SS>W[G>V<13C(2M1('PY@3IG^B<GXL0>E=:N+"
MVNJ4O&C\0;4,)#JEP(S"<CT\W+Z__2';';7#ZD[7ZT[1!)&+5GJCQ*)^\V=J
MQND02[_Q>ZL)KE[#4N^5CU+\*YZ:>\;?=3\:=F*,FQ\";1/3HF) =A94-/RO
M1IT='WLS9R)5FU=6J(#]!(?I4D>/\[^O#E6Q7%W/Z)_3M?[E!.]EA?1>K'+N
M.6SP8@Z&7<-HO>&7]Y;O=,2',BD?I[<0=QM["Z K6\[B%.,>\#3C*0ZB)@'T
M8I=I3M]N,[>[J0E5U=S23I(;,]UP7<-C@F;LOI5]5/5+U"'K)]:O..%\ML?3
M;;[_ )-Z:_3[Z9VN\'T>XSONU;;>7<'(>3[IR*&SW;G.ZP743)6POMHK9TD;
M=;I(V^4:"[\R;=96\ML\OTJT:LX$5+BJ8BI('ZL(1<4XG+,R9V8XJ54VRI-K
MFZG#P_$B(PI@L'(#RE+&4AGDQ6T;T_\ 3F+9=BVOD5O;1Q;5L_I;QMT.B+RS
M?<JWC9@_<KVZT:62W#[^X*$HX.S4 +14MNK5=TK;E1BVRV]C3D[?%5G$MB>D
M];*%OF][=2\KT=GD(GS'=;C7B^/=H4YQ;2Q&.8).6(4M_2/:2=AVFRC;IDL[
M2>)LA </+?;""8.;DYLI?X6N"$GWCHWEBD:MK1$0YC$^N++@OF:H(7U:I,G2
M9!VZ"2G+NPQD@LX&&*&RB9:,:UQ<W7%^M<$H&F4N3.@SQZ&V2P&W[=3M_K,Y
MZUYE\S;B=TWFK<OW 3&/Z(_&BBYTQ$  J>TDTZCM)7IV8N0V2H61;-(I0"H]
MATE:@($PH-S0/-#; $'625'ATE5[B#F@PU,.$91]#,ZI#E:"%*A .B#VXC$-
MUH.L<\K7K4I7-#0=3D,L.TQ@BXI//9XG)D5TYH2ZGQ=V'NM&O(6/:]<BBE0J
MIF4&?V8(RCQ00B2ZE:B M " II+B<U5:]F6##%#!%SYY%JYW>KCEU]N 0$6!
MP0.>0O0+\)^, H0G8<@/Q8,>I*1/(7$EU.IS  /;DJX<!P1:<77K9'*%>J:1
MVG/)#3+!$(U:^100%!!RZ>PI]N$:.*-!3XW MJAZ J@JAI4^[#B(KPH"O3L0
M^RF77 X(B,&&"S1@ZD_*#:'LHJ#V8:E@>8281(#/WLUY+;POW';A<(RS,C9@
M2\1-\T$*Z5R58$RQF;NTA1J%AW3B/>M):UC6IP\0@L<6Z\$YF]6XW.&.QL&P
MAOR[76Y""WG+!I+&R*0US>_%-6HFIB6"TM.I&G\/!%']R^0?F1?N7Y'ZZ/\
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MA#54(X!STJ!=5*U*9I'!LNE/EPKFGIK-8VD.R;GL0L 2^,6%W%H8-0+RSR9
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M="H6!02,JJI[4K[,,RP+#)+ 0K<-O-]M_@/Z>$>;$Y"CM+3K:%R 3$*\I>)
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M(EDG9V@=$4A.GP^VH3$FF2R7Q13,H TT*($*995]HP]'!*0$1DN+G%"WV5)
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M;:IU(PJ-XTM31J$AF8!]+,#CCQ=>4Z_GBTI>8JN[;Q&D9T'\&+"4J8B207.
M.+C,@Y,C/;MNL]HLHMML&-;%"W0]S0&:TH=.8TD.RSICHOE/RI9^5]NIVU)C
M5$0Y;+H'0,5Q/SOYUO?-VX2JU 8V0FXB^,ND]>90UV7A")E6H_%C5'/#)8G'
M(JU*.+@*(E3]@0G/!(*[4C:$40%"BIT0J3GGE@(*TO!Z'W)3V8"#H'.M ":T
M:: Z7&I![,*C$G)$JC!:X:BI5.G5:9"M<*,"[=""$R-"*$1 C5S.I.WNP@AL
M"@ZN@0M:X>%#6HIXNJXCU,)E-R^+L0]C:]M5(]N9PDJ3#X0BS<(@@7Q#N^(=
MA0=]<.4IC)(D!'$))W@)<\D"B A4JB%:XF4R=1'!)9$DZ  5-4 -7 D)4^):
MBF'HD9(\4$*@ @*N78:]#5,\+05PC_*(=5%.H$]IZ=1@.C6-\;30AV5:C[<C
M@=:(A8BS0#I7JB_Y$[<'F@L84E2@<"!V ]<D0K@,ATH="U2TY$T6@%"3["I[
ML-2'>8(^"/(6@G4<@T$(<R,N\D%,(D3\,?B3T#W&&:R[C8Q;AM\]E*/T4\;F
MZL]#W(6/"Y(\*3V8;J4_%I&$ABG!*<2#'-('^Z&Y?ZF/]S/V?_SO];_ZKOQ4
M?=:G+ZS*=XX_L.IY7MJMW=:0S^TW!(!7_2OJ*#&@B& 2*]" ,I1=WR3;<FVU
MLC#J9'U!+LZY]H(IA6LQ*K:M(28L2F8O>/0O;(YT<;D#W A!^23DT=$Q*A6+
M)C[O3EF,E'/=HA!NMU$P!&S'2@H 34*>_$<EY.EP!C@,@FO<W_Q5=D')K%/:
M TY=Y&(%JWBR'2IMP#XYY:0IF_2X?_'%PG^PM/VO_%B35'=^G2G]K#7S?F'W
M+8RZBCJJKW)DN>*]B_0M8K0%]G;^# *"N_)R5%\2>WKGAV  Q?-)+E6C#CHA
MDY5*>VG9A$R!@C#DN,E8^C3_ "ZX99*=L4'*D'MPI-H.XT/4=I^+[<*IYLCP
MXHLER>G5U.ZJX>/-,4,-0YHFND1RI\)[*T.&9AR I R7(A_';.CUB]-B /#M
M&] ."J2'VYIU1#B3LS_?JWZ$?:50[H-6XB/.@/[Y7+]ZZ:1#+\+@+61S6CPZ
M:.!"AK0M2J("G=BYNB]2"E;=!J=2)S39_P *,@?7!Q0!S0#^VD!4:OT4I4!W
MB+3FI[<)ML;N(_WD?:F-Z;PK4<?'C[0NIZ_5OJ7RD>(_IV(UFE4=;1%*50 H
MHS7&MHAI#Z9K%;B/\35_XA]2Z$OI(?J](N.J'*;=GQYT+U![,\8?=1IO9]96
MA\N@_NFGSU24L(G?%T'8/=VGLQ 5S,889H?&0,S4)I]E1A0("8D.2S!2XJ@I
MV]/PX-G.*2>A"(W&H7)!^/ * Z<UE;U/0"H[L!W"-"8ZD)^<.SH4.(U4=[L2
M#T9(SC:15U0B"J$]^&B6&*?H@&+\4C?4^W^<]*_4ZV<T/%SZ>\VCTG+]V-T
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MD!=!<,U*X/8H\3%5CAXF.JW \33C+X5*,=0)<.$X5Q(8+J+<MMD>8RUP<'/
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M3+VC!?60)8+"X**U7/OPH<D4@&!XH(1X3W)A5/,I*+YU5WL*?:</\$91)<H
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M50M)! !)AF#FD.!C;I< 5!'BU)[S[<6]T6K14_;@)0(ED24TO\-)S&_77P5
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MZR7KK>XNU%Q+E<XC/J34X\WQ)K2\2H3*4BY)+DGF_->H*.T48D4Z4(B(P
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M^TH_JYDCI($OZ02TX_ZBSV^B.=X>S2T%7DAKR&:D!(<T]PZU3KC4[)Y]KT)
M59&47 X$-^%EG]T\IPJ'5".DI8NY!MNX.^;M;KY>[!)*NTEX;J< 2H=4!?\
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M[91C3K2R;VE^73FL/(YH[>S,$#6F$%P(:%:UVD@T%06@BK@0F6$2N-,?#I_
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MV7C&QW_J!#82[99\_P!TM+;<-WV7;;@B2XV[CEX\.=M%O=$?I_EC&Z<!)'N
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M;&,0-;I! :UK  T!$ QX:W"ZE<W!U#N.6'L7L[;Z$:%N(C,Y]ON1:X-:TM0
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MC61:G!U"P]*I\)T]F6&XQ,Y"(#DE6ME UJ@I0^+Z/Z%AX;M<T#I]^O@_YS<
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MZ[;\I;0[GYXVNT(> N(R/5!YGL[H?H47.,6[K81D/!U:7D."Q/8VC0[511J
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MR"[X/T,I0O:I+L=,\S;-L/G2V%2N!"_$>[7@!JQR$QE.(PP.(Q8\%.O+&A>
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MS\5F;_5,'!R.62>A_'8.4\3Y=QF5ZMWWBW(=H>XZ0YK[S;9XF2QN"(Z)[FO
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MKF.H2^@0HVX:UY)0J\!KF%[JZA1VLE"05'4>\87X4'&/>)3)K2?')O2@4\;
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M5$,X?$HIF?K<'>,EJ$T!J&HW+7X2$/Y1&&27)EGZD_I8")R?//THG>UK)2X
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M27'\H H,JIB!2C.99DR;3[Q,Q/ X)KI-WOM_W'R('2%C?%*6N( &KX,P=:%
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M8'=;!66DYG-)NYE0N^$YHXJ2P@($TD#,9&@7+ $FS*3,,D_=RM?DP4)U%'$
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M0",N X7D2@D^S\>#DW%)B"M?7\03?GVO%?3K8HJF[Y!N^\W$?4Q;=8V]G$2
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M6E7^)GQ^4^HW =SMHO'NO ;FREE'A#QLO)+R41AQ-=(W1K4:CE*DICSQ\Z:
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MJE;>-1D$5,P5SQ74'\21_.*L;H S@/\ =Q]_X%)_Z;D/J=M3:C^KS.!R4K&
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M+G Z6DEQ&ERZB*H<^S%+"IJJ^)+GDN>;WXU?@6#_ .E.Y=;J)XF6\+F>4-*
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M02\$ +X?OQTGRY2F*H%0X$8<&=E@MZJB<3*.)!](Z5(C962FU0N\#4:T%25
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MXAROS6G=B?M5*5"YC*/Y05A)B"%&>U<V+A&U1LU!EK+O-GI<'-<&VV^;BUK
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MZCP?D50W43*)!&)B0W)TX$UZ'%3X:.(=D"5* *00H]ZXZ[][<ZC@^*S4K(Y
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M<@"F*JC^TS/#7[E/NBU2F^>CWJ4OT^*WU(V&F0N/=X6@IW'$FZ+4B&X([?\
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M5-RN#V>(8@=@"^E/D^C]V\H[=2'"RI'TQU>]..)=#%!/=3QBFD]0H3L-,8H
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MEKN7RG2.#=):"X.8#H4*"'!7:%UY(G>%PT^#%6%&G(G#(H)%N3;?2XZ=8*
MBK5:&@JX_I-0J%5"F$@M@GIT)3) "-Q?E[6I*-*A=):T$L76" "=)"99GV8<
M,\.A1943 M(9ED3WER!*&.17&-N@DM:Y@*-+E4@ U]B=^&C-BPS4FG'!I%P$
M]_II>_+W^P/#DU;QMX<A4++>QL.HJ3I3.B ]<;_Y=70M/.NRUCE'=;5^HUH
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M%TA-S'B<45KCIT]KA^4I)H-'1<O?B13.1XJTIGN= 2-N06N4.2I(0="25=J
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M2#D.6*7VS79!9&7- <6G4''](W4 PDG42T.S)"^P8T6V71UBF< 3F%GMPM@
M9Q&"4.X7)U%HD4@'2$< B#-QZ]YQU6E4B:4>]B0/8F[6B-#D,$G[B7PES?$"
M*NU:07.4U!4T3(C/VXF0,6;-/&)B69)RXF#ERTA=0\)5P#G-!R0.0J30IB52
M+2Q3W@ Q!!29N;H!0XM.EH+&*I!=X0TU^$E3[L6U(EG*:J0\-GXA%TUTS3VD
MA26D-#7(- U$ JGMSRKB4,L%6U(R*".N@ZC%U%54] !J0J"74Z4IW8<@1Q3,
MHD,ZK;;#>-_W?;]CV*PGW3=]UN(K/;]OLV.?=7=U*X,9&(P"C&@J]Q(:Q@+G
M$ $XMMOH7.X75.QLZ<JMW4D(PA$.23P'O.0&)P55N%6ULK:=[=S%.UIQ)G(E
M@ .)]PS)P&)6QO\ ^\TW#_YK:?X,?W>^,_XB_P"M_P#\-_3^+NQZ._\ ^25O
M]K'^$>%G_P":Y_\ #Z<UY[__ .HT/]G+^*^)_P#VW+]/HRZ5+OU;_="Z_<[X
MV_OI_8/A=_8__P!H?F>_'H&S^V'Q_P!'/MZ%P/<_V4_99C[3+LZ>2U?\X_5S
M_N/^7\?ZK/\ )_H=G=C2TOB^NL'<_#_JLSU)C[7,?X<9NSS^+$D_#_K%7#_]
M#/M27O/[=)_AO\9SS^)^>(53C\>2OJ'PC[)-Q?\ [V6O^%WZKK^OS_)Q6Q^W
ME\7Q*75^*C]G]D,_<I1>BG[_ &P?N)^LG_L7]H^%OP=_;B5<?9'XE(A^V4O@
M^(?0+94W(?[JR&*F&2T/H5W_ .ZL*0]"PNS_ /U1@AEQ2)Y]BM__ '/@_2D+
M"[XC_N?^0PV<^*4,N"R6_P"OA_W1^N@^'/\ 71Y8./Q#/,)JO]D?AS']X+1#
MZI_OMS;_  N_>OD/]O\ [9_OF^_M/_6_G?TEQ\O?//\ _L>X?PS]MK?'\7VD
MOB_.Y]*][^3OX/:_MW[-1^#X?@^KT<DUEW\!_P (<_ROB_TOQ_T?QXYO5^(_
MP5=+M?A'\30*/,_X.=/@R^#_ $O]'MQ3W?PC^"=JT5C\7^;()-\;O\'.O^9\
M(R_I=ONQ6</\C6JI_ /XRB*_S/\ @QDS//X>O=V]V)M#(?P16%#_ -Z2$WS]
M2/\  WXW_KOB^%O_ .4_^SB]L/M1_!^SZ?0IRIE_G6:B'RC]\-D__P"=_P"W
M7'_:?]VWN7=_K/Z&.J;=_#:W\+^S'5\0^@6=NOMX_P 7^).1Z?\ ^Z-X_P
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L_DS]M5_@WP_ZK]K[?]WSZ67!?FY]C2_B_P 7^M_9>S_><NU;#,>@UPA?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g382677f_07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_07.jpg
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MQ "$  $  @,  P              !PD%!@@" PH! 0$! 0
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M,LHZE73J0%T\757,+OKMSEV;9^$-CW*&,?ION/<I.VQ9/Y#/5>5P4Y+I687
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M;^H5T:W?)/2UR_9_QE32H@G-_<!2B/C>G?\ JK7O&#P/ \#P/ \#P/ \#P/
M\#P/ \#P/ \#P/ \#P/!JUE_S%5_TM_J=I_J7_,?]OD_]*_^S_\ *_Z?\WBQ
%M/B/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g382677f_08a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_08a.jpg
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MQ #$   ! P4! 0             ' P4&  $"! @)"@$   <! 0
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MN1XCTYQM7"; B$2)415U>+"T?;[""PDFDN'@A2,RR4,DNA0O,D*@*7>FIR
M6)-!BDWUU%?7LU[#"EO#-*\BQ(24B#L6$:EO,52NE:YT P*?,6*YYF4OQK68
M%Y M/'KE=F\+(,KGUD0)GXAB%*Y%FVE8\RZ;;3KMJ38U[(NJ3"?/&Z8'V1%<
M^Z]Z<Z@ZCW[II=EW*\V^QL=U>[O5@<H+BWB@<)#+2FM6G:)>6U496D9E)04O
M70>_].=/;?OEQO\ M=KNDMQMIM[435_1N96*B5.[EIJE+"C!HD0,H<X.7(25
M5%$1-U5!3?845>@HJ]51$UIAS-<9T!0 '/%:&#QSC0^<\CL/S#^1_$UKXTRW
M&,$\=X9 O7O*MO'J5P:XGV0P)T,V\DAW4D*Q9->_(%F!,8CS5^4=?,1;)I2R
MZ/J[JB/U)W/;-RMK*V],]MVE9'O6F D6[8I*3/JTI%!\N7T@,Q!7F2%0ZJ-2
MO.@]DB],=JZKLMRCNNL=UW.2%=OC#F988]4;:8N760B4)616*'6(TU,KG'2,
M&=#LX42RKI3$V!/C,3(4R,XCL>5%DMB\Q(8='X7&GFC0A5/5%UHVW;C8;QM\
M&[;5-%<[7<Q++#+&P>.6-P&1T89,K*001Q&,QN[2ZL+J6QOHWAO89&21'%&1
MU-&5@<PP.1&-Q%V7?3S#?"HEO]"_V>_0P,9:&!B>X@2K%F"J]!DBJ)[E)H=_
MMVTHG#"4G'$OUWA/%:&!BM# QSR[_FN?\P_^)=('CAX. QCMKG'8&*VT,'08
MK0P*8K0P,6T>.>VO9@1!Y,\99OG>;^!'[&/.RZIQ9V=E.)S!1DYF+VK<.OG.
ML#WADOPQ:O8H..B((/S;9 2[[IGUCUMTKU?U1OOIF8;E[_:[>-;Q)X&2WFBN
MT/EAD8TG700)"H &L!2:-2]S=(=7=+=-;1ZG)2+:;R\(M)XWJZ3V[:QJ%*(R
MLC%02QJA# 9 QK\OWCBJ\#8FOA&NDVLFGQ^[RF\PFRO;"1:6-SB^3WLS(UC2
M+.49O3;;%IMH["DB2]Q8[;#^W%U51ST-L4/1NV'HRW0)MMI+(;0@ ![:1S(J
MY9<V!G:*09%E5)<Q(:/_ %-ZJNO4;?/_ +#NN6-RO((([Q$ 58KJ")8"P0?#
M#<I&LT5/*':2*M8Q4_\ ,??_ $+J\8S3#;,91R17RT3[R)*5$]OW,UHH;X_I
M)P"^L$TVGMTDGAN:#G0LU#_"ZZ6'L.1]H&'4$[1PS0?\.5!7VHP93]X]A.$5
M>A0[20^_*CL'(@16W$=?; R6))E*VJ@I(2J@RE1.GIKL1*L[3CXG55/\I8C_
M 'CCI4N9[5(41V1'8B@)'F"US_D&-2UMJ.57SX#TULPF0Y44A!B4^)=]AQK;
M=EAP53<M=31K-"\3YHRD'WBF%[6SW"&XCG2,AD<,*LHX&O:PQOL7E4Z#?^O9
M$R$=Q>1UA4)1151>^VWMLJ[:4S[<-GLKJ/BAIX4/^Z3C=:-IZ0XXR;;NT9D>
M;1BX/$G7RVY I(B;C_1KG2->OMI3"#:E7EL",ZYY8W07JJ>U?[-]=8XQD9@V
M!N.%P;;$G'#7^ZV J1E_NBBKH5 S.0&  2:+FQR'MQSSYA\+8OYF\1YGXSS>
M#,E1/+=Y52[AB#:6-1):D1;2GGTYNRZV3%D.Q<7J<<C.''<(XT@HJMN@;;A
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MB&YU1Q;/#:^P(=MD12E1:ZGDANB;KLZBZ?QVEY;#3;W,+=HT3RQ<>P!F=<N
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MQJ 36@Y096I7\(H?#AAAU%O-K/&ES>76S6MTD$:M&MM!<.SJ-.LF\D@D34%
M DS!KFV9Q:-G=B\$>.;F /N*XHK%;@8PDTN\XW\ K"E*?,-NG%55=^FNYM@:
M)GG"7JK3B9;C3Y0?SQT%?&@[\1MGU+LU[%;;>+W;WFYA6B[=MVLF1E[8KS5Y
M:9:22>P5%,;G\W,3N7SF-E(B I(3L,YH"(H9B*HU:L3J=2[:(6X;)UZ+II_H
MMQ$ P?1<'L/+8UH*T,;)*<\LQ7PQ(OU%;RR-;6=U'<;8"1\5U M*D#4EPEU8
M@T /QA<P*YXTF[FH.4,3'[&PH+60ZV<?ND=;*5 ]0AM3I)4\\'?[PLOQ5)/V
M4URUA<.IDNM$L"*=24$B^U@%$Z4["5<#MQRU[9V*A'L);6:>13'=P/\ *R9<
M!%*DDFVSZOQ+6!V_"H(K@I0+N5!;(<DB#*>%GB%Y6Q5J[B,9_"#\X%:;>"+\
M6Y*]\TPXB*G>3=-JO=62L0;!M$1;-';F1$=H4U(U=P&AA^0TSN5G<2:7DNM5
MW=10DK+%%\KN,;D^5Y4 &N)1FS SHX%-:ZLGIFL;?CA;U7RT6:BJ3%G!%6:V
M8:[[!9PFT(*>6[OMS%%C.[]47?=$#=R0L;2YU/;$9QMFRCOC8_&H[JAU[*<,
M.[:,;O"-Q5TCW &B7D8HC-P"7<0_IL>!>A5N\C+&QC=Q-QVY_':R.C5PR[V\
MBQLRX5]VQQ07GH0$I#76C+*JK1COMNO%5:(@6N=4[!8]06 MYR"H'Z%Q3SQ'
ML23\\9.1KF./Q#&O>F?6>^]%WIA(>.U=P;JT#5BD%?\ J+6N2-^(H/(^>0(%
M.U/&V=PVH#%U9RN6-SN95K:(3I8O)<,@>AO,BBN.3I3Q<'T%%[+BHC7W9&9^
M8MRV^XVJ]DL;P:9HFI3L_O*>!5N(/=V<<>[EFL^K+*&ZV+]2X:(-KX&=*5JP
M)HA09 $U(%');2 =Y3TIL6IWR@RK=T3:IJLWT:8C$ZVO-V5) 7A:XLEO)?%'
M.VVO;:0E+[R(N6D0<V)!)=YB-2:"I'%FH=(_.P!.GRJ"2 8>W6-R8)',=F*&
M5P*D@'@JU%23DBD@%O,Q !*ACQQ^7'#/'7E;R+YS9G6]GY(\IP8X9HX7RL?%
M&I<9QMV38XMC<6$LJIESX,&'%E.')E/2V8#)N*3RN&=,V+T[V/9NI[GKNX'S
M'6UY;F*>Z("CE:E<QQ1BHCB30BJ"6?2M7=F9R;_U/ZJ]1=2=%[;Z<:8K?HK:
M9BUK$ 6FJVH#YB=F_5.J21P-*1QM(RQJL:JHW_ ?YF?&?YD8686/C5<C.'@^
M0)C-Z>0T:T;S5L0R'0C#$<F2);+RQ6$>)J0VP^TV\WW $E44+H3U+Z<]1C?M
MTVMV;:PF6-I98A''*7U%6@;4W,0A"22%(J*C/"GJAZ.=8^D,NVP=8&RY^ZVG
MS,*V\W.I$-()<Z%449M%5+J65]+$"IZ $Q)=D]V_IK0,9813&>A@L9-O%'?C
MO!T)M]HT7Z0,2_LT*TP*5!Q&'=DD.EUW1YQ?H_;+7&?9A4#+%E=7Z-NN_3_M
MT,\'0XN#A*J)TV541%VZ)]*[>Q-= 5(%:"N"((!..*0\N^(?S=Y;Y\_*H]6^
M1ZFP\4)4P,XR.!(KZ&'#R2:3S@T6.7L6QL7I&544,F)DJ))@.Q4B3&B+FNXC
M@YW'H?U\VW<>@>L=IOK:*UO6K:WC+#+*UG.T:W4(AE):-95+)4L"I21D"LA.
M_KTQUWZ#V_3_ *N;7=;9<1;I&[V^E&G B*J?^8CDC4*DN:(RNKZT<*10XZ<Q
M^D8\=8M64$.PL;7'<=J8-9 &X>9DWC46 PW%BM)8M,Q6[$W> B@.-B2$70^.
MPIK/3NQ)TUMD.RV4]Q/M=O&L<0N',LL:***G.-'E510+S=4@% 9&H ,DWC=9
M.K=YFW2ZAAAW>[G>20PJ4A9G)9W,56Y?$DZ#I/Y <R ?+ODI['86T-Z$>4Y
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M6S.K, 4U:*B*(%SGC^YWTO5=Y/;6KRITL08'GMM(FN6)(CV_;UI185TDRN=
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MAEED@*AA%+,O+8.Z.JO&PT@2LZZUL75?IVGIS>=);_LU>L)[A?E]UC2-GMH
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M:./;=SB^8V]#5689@T&K25IH&50T1!'XE/#!'QZ1*?L&6)\A*^Y!$?@60_\
MMK)GCNV##S:)W >--RV(FSVW(4,/A87<XSDC U?"0/MU ^'8<Q^$T.#@V:*&
MW%NQ:7:B=1#FLD1RTLC  \?^(G'(2)EF9ZIMYXW)0,HU*;(1LZQ"3L2T'B?S
M#:?W3^%2 T_97WBJZAIKC*H/]G9E],QD<Z847:(@1;S$%#_3DH 0..ENX5XK
MP4_J)D2"4:-UEK='S<<:G.BJN\%^7^]4B0P 156W1Z"30HG AZ)U75<N_*H$
M1^$$C/S5[O$>)X]IQ)_(M=L9)ETW2T5J"B,@''M\R\:#L!H* 8FD8>,O@H"\
M:)V77#'@LF*>P-.FVBDB.<-D+JJIT]J+J(:77%^6N8%?A;M'T\<2-O;AB8CY
MF49'\R_V8)6*F]$=&+\TX<JJ(;/'G25.W'X'R=$004[I,FXFR$I;-.$(HB(N
M^8=6V*\\;G$  YH_<'' _P P%*]X\<;#T7O+BS.V3T* :'[WC.0!/<O"@IGI
M)J0*=94MJS=5<.R93@DAO[UK?=8\EHE:DQU^EE\"1/>FR^W5./'#^\MFL[EK
M=LP.!_,I%5;W@CWU&'A#]_\ 1_WZ&&V+H:>W??Z/^_0P,5S3Z?Z/UZ&!BZ'U
M3;WIZ_\ ?H8&(^Z2*\]]#I_\9:+'>,-]%@98K1X&->2D;LF[*$>U'!Q\G%1>
M;(-BIN&V8JCC9((_W51=$0#Q[,*1"1G"15UN0*=Y.0!QQ3^87+2B8P]5).?8
ME94W/D62FXCC]?B58S\U</HZ2=X2&(#<5KXMC><1.NZZT;TXVKYS>1?2H&AM
M2"M>V5C2->XTS8Y&@%<,.M[U;3:7V^W-"R\L$<:4K(P]HJ!_>ICA3Q=7Q6:G
M)?)^21FT=OP?LEC$J(D7#::6$6BHHN_['\P6L=L%]\6.VOHJZ]&7]U)-<P[5
M9MY8CH4]\KBLDA_N*33^(G'G&?;(+"TEN;E:LXYL@_@7^C"/!C0D>)QKULAN
MIH+G/;T$F7F2I^-RV'0526#(EN/XEC<8$5$-;N<PMA+;5%WAML-KMS'=U/<_
M-7L=E =&W6RF-".P**2RGQ5?(A_.S'L-(:WZ?>QV]HV02;[>RK-,#^*9S6*+
M++0IIK!RT)3M& G>/WAJD)B<ZWD%L3MM;VC3QH_71Y*\WW6)+>SC4JQ)C8'-
MT)FOBJZ/Q&:'*K>1']8H*$!$6@("KD!0Y$(#0#@97-> HK;=+Q*HM]3';K1C
M([ D-/<.=98L#J_4=>8Y&:P1QH*5-1'(?264BPL%?3&,?,8L9MHU;D6D@R0A
M8!P-U6XOGFE,S'DL:,*N)U6*FGGS&A?EH2 ["K'B!3_R1UH!^)\OSXF(]A=Y
M%O[E3)?2? O J&[?"23B6_X<?"ATTZ*\3>&8>4?(9QF<1Y^M^51BJQ1&_D'8
M;\1EJ:Y$C5LF*ZLC'W*F2Z<4P=!V20JZ;G;)5<I&_P#5$T6K;; Z7U5,G&H)
MI4L#_4J!JJ"$^%1497_8.CK.T<;A=>>;2!2E%H?PJ.(B!X#C+\3$J0N.[<<@
MDK0K^%QZ:.;C+3HLJU*>F_+Q:P&XEN]$5( S:MF$ A(:E&XJ-\-DV4=9M<L*
M_$SO0G.HI4MFH/FHQ.8*TSKB[--I&D4"#(4X =P[AX#!-BXQ'CQ3<B]L2=+N
M2ID\W7"?ENBJM)(%L6G22,2KQ'ER!%X)LF^HYK@L]).S@%IP'&GM]E#QP@9<
MLLAWXB:8FU'&W.&,2O>D/0Y_S3AH\U*EMLO1CF2&X^Z-RGK(R?/B[WGA94.X
M'<7=Z+HOH#DL "*#*@.8 KQ 7+A0$UH:8;\TK6E!]/W_ %X#.58ZW&DVSSC4
M*Q=GSZ^99NW.1R:83)J<KD*A*HA07ZV; 9IX$A?PTFI+I/2&4=;X*I)+VMQK
M1 I*HH95"('SIYFU$A@2Q UU4#2U#7+"BS%:ZN/$U-,O9]M...8<LK7J^3<R
M+:WRZXCTMPMOD]C8TM?,5DV\BN7K9M@93\6+0TUL7^A>=>[!/J#)1HWW1"Y8
MK2;RIR%B1G32@5B*^1=)-*EV'Q "H%3K;/);3%<@Q2C4M>!%:&OV>T9Y982P
MV_A63<>BL4"I=E*])JZN9:1I5S7@T7;<5QA&X-@S(8,.*NK&89DH*JWNHKPE
M)F<@R#S,H 9@"%;NIQ%/#42O;QSK5WM#6<O.A_Z=FX9&A/$'LS'$4H1[\'>F
MNI+3K4-6N=E6H).&)?%;0"3]MI=N".-(G5/:JHO1%1$AY?,2Y.1^SV_3+"+[
M7&L8:,$6DA_P.. &7#M![5)7LP8ZIF3:=@4<5JM-"G0F$5>#;IB(RV^WOL*O
MH*<D3JA)J%F:&!C(H!D84)[:=GU=F$V@GT ,2)86X=E._P >[V$8)L%@D8 D
M;4W !&C-$W)UHE)!<5>G%=NA?3OJ N9*,0#D<_?VX4%J(V$T>0XCP[Q].S$H
MB=V(_$G*1*4)P#,11![D0^0/IQ%$'JP1IM[]M5_<HUN[62 _C7+P89C[?LQ8
MMM/R]ZDRY(_E/<*\/J-#[L'?Q[;*Q,NZAN-.D,%V+:*0Q^TVA._Z67Q.8Y%3
M8^VR?1%3XM]UWUE;'2<E;Z>W&F;E")K"WNWDBYRDQ, VH@#S+72#WL.)X8(4
MJXLHP$;.,7%@HHO$(DO'P,U]B)\[=1 3?Z2349>WU[;(6M[&XN6[%1[=2?\
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M)^/*L3K#G,3;5P1?L;2RKFY45%"XLR:;4.^A+#=$1) 9W0KR]FM;(F)2+V0
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MN114ECF<&HBV3D.^<I(L2DL[+Y:+"E+"BUN!18CL"JJ(URZ4^QF7;M<$QD7
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MCF1@:)*J:+(7L;DXE1Y ZU'^?F6.409MK5A$D7D"-64S4.JA)83V*=H[2P.
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M4,'5%N-SV(A]A:O*N3\%R :&2W7(O#4$+.U$EXQ!XZ.9#==D?IZ3Y+>@5WH
M%[89-!45"W#9Z)2""85\Z CF%&\F-N^A%+IIH_,R>ZRVDL.)-)N<0AD+L*,\
M4Y@!#Z>W5B7(@DD_3PPPVZ<17J'2FEJH002/."O?V$@YX\Y_S%8RVUGU/=$+
MKL;+<2D0%,B4T6VHU5 4B7=$4XQ1D1/:F^VM(Z6NZV+VU<XWK[F_MKC:.@;M
MKC8);;(3V%^#0 #]*;/@.YN9@ JY*LX$N.ZC?(ZV!*!M'^3A.UI.,2&D/=Y8
MY$(JO%!3AZ\47UM4<H,7O.+3<[9'MN]"6+)3.P)(RI( P)&6H"H%:T/"N-Y'
M_EV*NT89,FX\AJ-+44W1R.^V3L<TWZKMWG 5%]BZ'-X,3X81&T&1KS:'H'93
M)'_?C-&'O4 CV8&^08F_8'<US;0,BT97,,A!2.1#D"H31'KONVCG/IUV1=.4
MN0H!_$I_V?NQ,;?+# 8+V0UCN8^1(2<ED7):^V@]^ +Y(8R(8*Y12_B<&XBU
M)XW?1\=M6<>N+6MGM-P9#$>R?KK$([,\XC?S"HT0N!N);B2ZL>T7ENDRQW&@
MVCN""X+*K#,$@,I-*]^1SQ%[OTVE[:3;9 6?<8-<T-%5_**L5&H%:T)T*14@
M$"E!@84%U7R7HV0Y+-LI=5CL,6;%C(<LG31'&:FQ4&&*/([>#7,U<O+79*PV
MOEH,17Z])3WW $VI6JY?Y9&CM$B%S*:KI2@>5ER#JNMCHH')J^EM ()QA%]L
M]Y<NMM^MHU< JJ8\R)'%#&A4"J$.15FH&-",32IS61+@NR<YC79WDF]JK$<>
M@5F,TF/S:Z]G6%NY*GP'84^'(#Y5^,[7J[$EQ6@!!5'.++0Q5Z]S9(@CC>12
MC)K$A<QLJ 9LH0D!@58K1R2" "6;#./IG;+Z\D3:[JVBM$35YXV61P#0!59S
M0G,D!@ISJ=( PO9VE,E6MW,M%?8HV*9N8W&PJPD0*U(E(Y;&CF37(+&A.3<A
M0Z<T)CM39)DZ#79^%(Z7=[:W4[A()XX%+%I#I4!6TQTH*RT8.LJLA!4)1J,*
MM*VG1^Z&Y&SA;4O<*VA><S.S"0G68UTQ$QHI)5ZY/0/G166YS6BC7+%IBLC'
M&<I:RI^/5Y7EF0A=5]#,IY4Z9';IHEBLL\KQ),0%EJ18VL-I6)CC(10'B*#4
MI>K+>2W%I82V]O#)KYDBQN9*@ S2HJJ3"220A)/-))84XW&Q]/[LCF]0M>W>
MWQQ(4M%(1&C:@1)J,B&1)"6Y<9THB\2>(KN,RQ.?,%^376;L0HE5:O-53E3/
MLBIY#F/1;:1:Y:]1A9T5W$DUA]A1E$4,IS+#2MM*Z&J)OO5XOD< 2RH#J(B=
MD158S +*2FK60ZAPK%7)<5QKG3W1TVW1JEO)$E&9 9$I6102O*C63EF.G\"U
M"%C5J' _EY/95\2J*PANY17,1\?<IK:3,;B7%Q07DIW')F*91=,.RV,7QJ;"
MYQ.#S2,"#3:@RWWR=6C'<[D%#<%)HB^NCFIS8U61E(<@T!8$DT"CAEC0X]JL
MB9!;EH9SS%=54E Z*)%EA1P%:13Y@:BI+&K$#$;@=C(KR;2UM;=,1;F=-_ \
M63*8MJ%%E3,VO9"*KKT6=/<L&()+%22!DR^U $C-Q%Z6SI2VY]VS\@?+LYJ*
MN4CH=50M1E^&NH$!AQ.&\S7!CCEYBM+'&NJ3E!=:%3F:$"E:/I-2"QIIQ[4^
M&L.9QNCQO$5,9,^ C5UDSR" =RRD_P"H>=E*VV#?(W",RV047UV3KJ^7-P#5
MDRB50B<30 4%*YT &5?MQDF]QDK)=?\ #>JI3M .9'&FILN)X'':=$KDH69+
M1=EM][@(**JKL-G8-]T(4$3%%)>A>OLU"S2%!QX"IQF5_;HC:"*E,_YC_;]V
M"U%>;-_UW!M"4NJ; C8?$J]?3FJHGU:@I;A2K-V_L&*S/$4'B3]^'&.J"+KZ
MCNKJH*^B="7N.>ST0!X_[VHMW(2GXCGABX\P'=_LPFVR=C*J8;8?';6\;DB(
MFZ1&'Q-YQ4]@C&C.']1:BKI]1IXXDMJ*V\T]X_\ 3M;9S_.0=(][LJ^W'0AK
MSWY(A(JJO$D0DZK[EW32956%& (Q1U++\)(/AABN<7QC(XA0,AQO'[V"1BX4
M2XI:VRCJX"[BXC4R,\(N"OH2;+J,W#8]DW>V:RW:RM+JS8@E)H8Y$)&8)5U(
M)!SK3$OMG4&_[+<B\V:^O;2[ (#PSRQ-0\15&!IX<,.T6-&@QHT*#&CPH4..
MS$B0XC+<:+%BQVQ:8C1H[(@TQ'8:!! !1!$41$3;3^"""U@2VMD2.VC4*B*
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8J ";KNNZ]$5=+1QES0<,)22+&I).>/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g382677f_08b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_08b.jpg
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MQ "]   !! ,! 0$            ' @,&" $%"00 "@$   <! 0
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MH(<&!-J("2%%R;7))-R222222:R'FY\[G^3GYGD93+R60^^1B -QL!T4 *
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M,4CF,<O5LQ55$U>\7FN+SN2RN'PYTDY7!$7U$0N6A]Y2\0DTL&= 6VW+ 6+
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MVU#[VS87R=QGEW+=!EDKKJ;B159(R935K(^#Y?DM@^0*QY$QH@I+AT%UE$(
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M6(Q/%7JT+?'NJWAEXL&= 8,I0R'^8/F#U!'6_P"9Z@%O_C$4W33_ %_BWCX
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M\@U( *BLI?9*LB7TVR%@=%"E"LF2\S^G_P!O+Z%,F-'&=!<C5U?(>1P^2[+
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MK2T880E%99;%EVF.L8K7LM:=XUSCE)\@.8XI!&+?+'8'H.OM*\ATL#=U)6S
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M)V0##"QS(9$"][1]('-5B>2LV5-1/)<;G<7.(L^-DD==PN+;@3\P\Q>_YU'
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M+SWECBQX5!VA8 PB].FY0Q9O5UU(OUL.E*Y!]K_!7N$P>AIN:^,Z'-&Q0%/
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M9SV2/E(E )1R8XGRE.UEF.0>A*T5<;YGQ'/:TUCC-HV:$ JXYT1-FL2SA-F
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M^NUN6RZVBF-A+<TMV.NK^_2SYZ&:!"@8]'"?XJFRZT7E.*7MS)7A'4#Z>*-
MJCY%50$4BYL0@7^E9AR'-'DLV3-SO7E3,7=Q^IW)9B1YDF]$?D;*\KXW-!I
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&[A!\:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g382677f_08c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_08c.jpg
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MQ #'    !@,! 0               P0%!@<! @@)"@$  04! 0$
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M?DL,<;C6OOSYH<%;>-LJ2)S^ZC'RHX<Q]R,^RIQ3VKL8.K(!MGO=;.T.-Q1
M_P#DCXCQE^4\HM.%.XBL_NPGP+KKHO*>X\W3C^-&-"?]3-E5"/ACX_K2-_A>
M2$^8[1C[?]I<:-W,<R,J8'_)XV!YK_'*R1CP*/VHUR!W"MW.B]M;&<GBO>YO
M(YN>M#+'9J\83'1<?]N,?9B8212KQ"&S?FY%9K2#>.7-W<F(V >*.)@".\7
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ML+W*ZE=Q5K!K$ZVJ/*MU((NNHM7DK@LA4OL^5H)F\H:KPUH\UEXLCC:-6.@
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M0%BD9S&!\Z]0=+?&]K?;1+9'M'R4\C8!Z_LJ3K]W_N&@Z'7(Y 475)6^"_\
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M=% '35/A8.#QQ8XD861S=GU:1SXO(Q,C_O,;=!85=<GS'*\N%3DIF?'CT2,
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M<B.'/A'WXB()OBT3DPL?$I+$">D8I[Q^U>0NV)+D<;.?].8')@OX+/$JSJ/
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M^UD!%;KWUP>?R?,YON[B(SD\#E2F>\>LN.'L3%EP?YT#Q&Z.[IZ4A'J1RNK
MUT 74>)&_P /'\'3P.M'7F@%Z+,Q\@/P_P!6VB].V^-4C[P9'$\$CPGO):DG
MKW.(WL9QG+1T(#:R/+>*<SS='!_P=6H1LDF7RW\29&I;Q,._>MU&1"JSRDXC
MWBHXQL3W?C@C-P)DCD L#/B9$B130&Y4,59DGA!.DL5A;>U_3/Z>QY?N,9G]
M.CM;"Y&&3(B+DB/%S,.%YERRUCZ<9@CE@RF LT+AF#&*,">XGD.5LRUX>0<0
MRO$WO.8Z'UV3P.65YO3:5:.0?!9"]%C<D\:,5C[I869659F;8-?Q<EDKDIC\
MABR8RRMMC8O'(I:Q(1]C$QNP!*@W5K$!RU@<IF\/@1PO-Q'(09_HK>0)%/"0
MMPIDC]9$]6,$@%K(X!#&,+<B4,X'AU.K>L_6J$F2/<_VT_[AH_OI:JL2;.X/
MZI=A_P#$>OPUSJ:5*Z&ED;[=#X>1^']6E!H!I;')M\I(V^/P_J.VD*WIU*U;
M;8>6FC2EI0K%=MCT)Z^)TO>]<I(PP\Z4JW@RG2@D:U#8;3;O2E7##[?,:[!K
MCSHH]'[>A\/S?;I2+TA%*/$:9;2U-JF?=W,<JJTQ_ ^%/)>1<5QEKF\6#6*2
MU]9=BD&$X_')1@GJSY(UK%VWD5IQRQ37/W;Z,;*\BL,1[C?(S>;P>/PU]3\$
M&SY%\2MX,52-+WD>68*-6_#V&MJ])]D8O&)AY&3S<XQ,//D7 64Z;58>ODD,
M00ETCBQS(P*Q_B=[ J"*\_OYD?8W(Y_@7(O?W)X;F/-N7<;L\;-#(>Z>-AQF
M6I<?Q<.6DSO+:WMMCI:%7B7',3D,A!+3Q<A:^T%'NF)]9BWK_P#2_P!PYV#F
MYF)FF3'XK* VW54FGD1;?-8,8T<'TX5/S*-[-8LH'3E<CC<>?!XGC&QFR(Q*
M77'D>6"(RNGIQ+D/_GS64M/,EHBTBK'_ )9->:V+OX;*5LPD*24LC1O8Q*,%
M6I0QE-XTIR<@R=R_ET9D@S)QL$4<$:>ECX);G<I"P*#[?QT4F)&C9<4<:LC$
MFX+'4JHV@#Y;ZFUV.WONJX;$#2!BH,174WUN.@ %R;].M]-;WJV:7,DEXWQ'
M!VHXL7#CX#1N-;AGKQ76^ILVU:19LMR.>[DK3W1]78[O3FWC,<H39 LV+OFE
MRHV]1"-R@6-M/)4 4 ?*+7Z[@3K57-@%96F!9P!=0#>YMIU"[5[C4][W-C4^
MP7)8$BQM6:RBS5XA7IU):R)7EKPS/ZL;M:L-O]%N0/3D9T\3L"RC+<LOI7VG
MZO ZV:VEK :C6^G]]+/$!']:B5B6OX"P(%^FYK^&GA>QJ:W^6QY/U()YXWMK
M*P=+;M66PRU-HTM5WB=:LDT($BLNZ'=NW<[[1>.QW+E8[E18>)!!ZCL;?&]8
MO+B".IB'R]3W!N?/K;P(\-#U-?8F?W2'-(,IAIL/P2:DD6*P><S6(K\C18LD
M);61OQX^>*WB[L-''57([.\_*067HK>ER0\$.,./.&RD:[2(K>GJ+  FX92S
M$=?]T$ODM(&!"-T!)-SUOI<#IT_M?V9]K;V.RN!HR9-<3GVR"P2T\[C^/8V#
M!Y:-XXE]>G%::ZU(32$L((R%^;=>[??7SS[BX^%)V,42QA+[D8EI$/@;*-UA
M]X_;:K!9\E#\LD@/DQ'^W2K<GXOQ:QN+'%N,3[]#ZW'L-*3Y$$R4F\=9$PPM
M]2(?W1_=4E,_D$U3(G7X2./T-41ROL_[99>*>.3AN'QLEA0LEOCD+<8N!E(:
M.3UL"U!99(G 9?56101U4Z@Y/#\7E(8YH(]K=;#:?RK8_"]76![P]S\=*LN/
MFSL5.@D/JKYC;)N !&AM;3O4<KY_E?MO/<@YODOXIX'4OPUH>:R5H:O(^*8Z
M^(_W3:YK7I1Q4,M@O49JTV6K15WJRQ=]F'TF,ZU,F;G<!NDY%S/PBM8RD?Q8
M%-MK2V%I(AT>0 -';<X9;L+\<7P_O%4'M^(8?NIXRPQ0Q./ENM_43%+$M#D$
M#?'CNS)*&V1,)+(UV=" 000P#*RD,K*PW5E92596'4$="-:@$, RD%2+@C4$
M=B#W!['O7GA!!*L"&!L0="".H([$=Q3+GN/8#DU*#'<CQ&/S="KE</GJU/)5
MTLP09KCN2K9G!92*-]PEW$9:G%8@D\4EC!&H^5B8F=#^'S8TE@W*VUU#+N1@
MR&QN+JP##P(!J;Q_)\CQ,[97%SRX^2T4D1:-BK&.9#'*A(^[)&S(P[J2*UR,
MQMW*..BW>5+=7*767J*E6G+]1"TS;_)+>M(J1K^LR=[>"DZAYS?B<F'"35UE
M25S^HD;;UOX-(ZA5'4C>W137? 3\+BS9\FD;1/#&/UWD&QK#NL:$LQZ!MB]6
M ITU:55ULA_:1_YT_P"X:*:351%MI)!Y%F_'W:9Y5;L-RVI7%)_9;H?(GX?#
M\&D.E1B+&U+8V_LG\'Z-**<#VI=%)X*?P'[AX:0CO2TJ1MNA\/+3>GPI:4J^
MQZ^&_7\V_P!^BWY*XR1W%QUH]3X$?@TH-JAD%3KUI2C]P^!\QKN&O2UF6U#3
MAGM6I4@J5H9;%J>4]L4%>!&EFGD/@$BC4L3\!KGD2PX\#Y.0P3'C4LS$V"JH
M+,Q/@ "372&";*F3&QD+Y,CJB*!<LS$*J@>)) I@XE7EFAR')+L+P9'E5F'(
M&"8=LU##5H?IN/8R12-XY(,?^VF7^S9LRC6>]O8\KQ3<WEJR9W(R"4JWU1PJ
MNW&A/@4C^=QVEEEK0>YLF%)8>!PW5\#C4:+<OTR3LV_)F![AI?D0]XHHJC'O
MGAI>1^S/NA@H;V/QDF4X7FJJY'+!OW71!@$LEK(E&65:4,<9,K1D2JFYC^<+
MK;\'.N+S.+.ZLZI,IVK]1UZ+>XOX7TOUTJJX<_\ W3'%BQ]9; "Y8DZ #O<V
M%NAZ'2OF!M(OMYS?-W6X9R7!X/V]Q]+,YG,9>]=HXW)193'SU,3+4J&5S>/*
M*J"9)(FGA$49B0;?(?I'F\D9/ PYD>1#-ES2%4B50SMM^K7JOI'K< VNQUL:
M]=CS$3DSQ4\2R2.NKZ;8Y+W*GH !8"WW?EU!O:;9'F61Y7FZU_#U(.07UXS3
MY!:P")7FKU8<]'#D,=0%.Q+5>7'4<)2AKS2K(LL5ZNS[KN2N>6?TL41 21YC
M  #IH 26ZZ'=\AOXV/GVRH\4+);YDMM^7NP-CJ+B[&Y7]FP%.M/W.P>.R.-L
MK2M6:LT%.]F:U&S#-F\2[Q7*^9QT4%B*]:K]YJQ.AFD55=55K!'J 0WQGEB
MF4O*Q 1@55-;$78@:B_AY"QK$Y,;(A]16)'TA2+D:_,0+FPL0=*:?</W/QV7
MY3B).#U,U!D<K4:*OPDUEL942U8YPL. C6VD<E6U&OJB&(M)$6>(AO34F_\
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MU9UBA5Y=I(5I OU!@+,UN*P)-JU)TEZ:3>L:2DK'?VN@'ZQ=/P?,.ND\O.E
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FMLC+#'"C!G17("O-(!VJHW.YW.P!UUBB:1AI\O<USED"*?UJ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g382677f_100a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_100a.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C,R049!,D,X0C<Y1C$Q140Y-C)!1CE&
M-S@U,38P,C8R(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C,R049!,D,W
M0C<Y1C$Q140Y-C)!1CE&-S@U,38P,C8R(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !  -0,!$0 "$0$#$0'_
MQ !P   # 0$                &!PH%"0$! 0$!                !@D%
M!!   @,! 0 " @,!        ! 4" P8!!Q((%!41$Q8C$0 " @$%  (" P$
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7":DTP=KPS9,;#VLB60$;%H@YL%*X_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g382677f_100b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_100b.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C0V,49%,# U0C<Y1C$Q140Y-40Y.# P
M1C(Y,#E%1#0Q(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C0V,49%,# T
M0C<Y1C$Q140Y-40Y.# P1C(Y,#E%1#0Q(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$(  \ #P,!$0 "$0$#$0'_
MQ !D  $! 0                 %! H!  ,!                  ,$!P40
M  (# 0$  @,           0% @,&!P$2$R$4%1$  P$!  ,! 0$
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5FDZF4XKG^@]3<T'LUK/)9EG_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g382677f_103b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_103b.jpg
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MQ #G  $  @(#  ,             !P@%!@,$"0$""@$!  ,  P$! 0
M      $&!P(#!0D(!!    8" 0$"!@P'#08%!0$  @,$!08'  $($1(3(107
MUQA8,2(5U1:6MM9WE[>H05.4-E8W.%%A([,D-'0UM797> EQD;1&QXDR0E(S
M)H&A0V0E&1$  0," P$'#@@*!P8$!P    $" P0%$08'$B$Q0=1U5A>1$Y2T
M596EM=46-G8W&%%A<2+24],5@;$RLC-SLQ1%"/#!(S1TQ8>AT>&#A#5B<D.D
M\4)2@J(D5/_:  P# 0 "$0,1 #\ _?Q@# & , 8 P!@# & , 8 P!@# & ,
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MIU*^=I_D&1VZ_P W:EN/#LMN]PV4^1N.XG 7<S7C%Q@# & , 8 P!@# & ,
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M[%JXS'=/O3W//+M-XJH3:-2/9[D'U?JO&]P+NYKQC P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /,N@?"R6IT]93D5]J3
M[F1Z)^C-T]:[YXQF-GUT]*;3ZH6'Q;"8>7UO<379DHLZCIC6C*X6'$(?%)HT
MVK%)1(F]N<Z_/D_P0G<3-B4A8%1[DE;I:H3+FA=O2->%,F&!2E$$[OM@,9Q3
M#!2L3)QGLB)S>S*WK-;" 0A9Q X^\?G&<7#7CK(S9$C3K^09<Q>6 Y@<V=K=
MGQ(.1A6N$=4BTTB.<$HAF%  $)T8$XXX*OPJ;D\<1)RD;%-?0F<UZ*L':X>/
MES.SG8<.?)/;H'FBE-0%B8T<B1O*-B5E2!LI]+I&ZJ$_CK+M:H3E%'$C+&2P
M&UP\)FX?Q?G\9F5 E*)C6BFJ^.<XM^5Q'2.%/2>WY0DMF*6)'AI91*%#R?'V
M]X:5,]V>X+4286Y(<F I4A3G![ V 5V./PJ1$/@5,UC3'FI\GL-D!)%&Q#C#
M*B3';D#$V=ZI^N'*1AB+K[@UU;$.3O$I?(W*UB=_9G,X]F-7!)4I%!  FD',
M!M(>FB=.0C3)D:4 BTJ),G1I2QFF'C+2I"0)TY8SS1"-/& DL.MC'O8Q[UU%
MO>][WDG YL 8 P!@# ,#Q)_6)R\^FF*_8M7&8[I]Z>YYY=IO%5";1J1[/<@^
MK]5XWN!=W->,8& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!XO55*YE5"VZGZ6120R"DY3R-OE>T32$,#K*EE;/R&R'MG?
M6:=QQD2K'TJ.O)J$M<C=$A"@D@TTTI1HOJ 6_P DZ89SNF0G7Z7,=)53Z?U>
M:+M)#5TL,E2ZAF;6RQS15D$373)!*K&RQ5$;)&L<Y[)4;BU3]E:JY(M&H3,O
M199K*2GU'HLIV>.>CJYXZ9MP@=0Q2P344\SF0K41(]T,U-*^-SVMC?$K\'-)
M<]*_CW_B.3K][<4GFMZ_>WK<5UO6]?AUOPZS6^GS2#NW%V/6<6,;]WG6?N%+
MV31<:'I7\>_\2"/BK._FMCI\T@[MQ=CUG%A[O.L_<*7LFBXR/2OX]_XCD?%6
M=_-;'3YI!W;B['K.+#W>=9^X4O9-%QD>E?Q[_P 1R/BK._FMCI\T@[MQ=CUG
M%A[O.L_<*7LFBXR/2OX]_P"(Y'Q5G?S6QT^:0=VXNQZSBP]WG6?N%+V31<9'
MI7\>_P#$<CXJSOYK8Z?-(.[<78]9Q8>[SK/W"E[)HN,CTK^/?^(Y'Q5G?S6Q
MT^:0=VXNQZSBP]WG6?N%+V31<9'I7\>_\1R/BK._FMCI\T@[MQ=CUG%A[O.L
M_<*7LFBXR/2OX]_XCD?%6=_-;'3YI!W;B['K.+#W>=9^X4O9-%QD>E?Q[_Q'
M(^*L[^:V.GS2#NW%V/6<6'N\ZS]PI>R:+C)\;Y/5BZ?R&O2II;4J4:V!JAL
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MN9>3.Q:WCX\ED_\ 6IY+_&:!>;K'1+7\\,W]DT?$1TP6[F7DSL6MX^/)9/\
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M@BUOKK>O!O6;JUR.1'-5%:J8HJ<)^?'-<URM<BHY%P5%WT4^V20, 8 P!@#
M& 58YO"$'B/R%[.]A[5820L73?3J U-HLP&_W0C+%L.]?AUOIF2Z\*J:.9CP
MX;5,GX%3!4_"FXIL?\OB(NMN6,>"[P+^%%Q1?P*F*& 0%[VD;RBP^':-"66
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M@=Q*6\1J'J, "PF[%!**F&[N;I$2&*V6]V>D31%GY?N]0MTBX4R@DKDP9*W
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MO\R_)'[7I1F/:*>CUU]:;UXQG-KUU])+1ZI6+Q93ELLV$Q08 P!@# & , 8
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MUE#IQ7:ZX<FIKGA5[KGB+'OH3]LBMTC]36*^A9'@:4(U*=LD1#>- << (Q$
M4[,T$79Z;_/6N]+F&KN>3VY3EAAS''F)TM.LR+UI[X;?62]9E5N+DCG:Q87N
M1%5J/VL%PP/TG_+Y69<H[5G5V;XIYLL2Y:;#4I#L]>9'/<:&'KT2.P:Z2G<]
ML[&N5$>L>RJICB:+OD(U,>M-]EUK=%:2PC^"<XZNJF<S! 6I+]J<-CE\$8I'
M&9*T",UON51!X=F Z;$6 74.K)#K=E^DC2#-MMOUGO;=R2G?;JRI8CDW^LU-
M'#/!/%C^1(UZ8IABUJXHE9GT(S'5R+49.NF7KW87+C%41W.BI7JU?R>O4M;-
M3U%/+A^7&]BHUV*->Y,'+\>DW5?XFT_J)NGYB9V=.^G7UEW[SW;B9U>[_J9]
M79N_5GXZ/2;JO\3:?U$W3\Q,=.^G7UEW[SW;B8]W_4SZNS=^K/QT>DW5?XFT
M_J)NGYB8Z=].OK+OWGNW$Q[O^IGU=F[]6?CH])NJ_P 3:?U$W3\Q,=.^G7UE
MW[SW;B8]W_4SZNS=^K/QTX@<E*C+-/4%H;,+4*@E 5*"Z#N0"A2!/K>DX%)X
M8#HT\!&A;[&A[WH'7?3IUQT[Z=?67?O/=N)CW?\ 4SZNS=^K/QTY?2;JO\3:
M?U$W3\Q,=.^G7UEW[SW;B8]W_4SZNS=^K/QT>DW57XFT_J)NGYB8Z=].?K+O
MWGNW$Q[O^IGU=F[]6?CIT'0N7<J$>ZL@$*GL:K&3&ID=JVW/(H\P%"7!]*"S
M7V*5^RRA*W2222>5I"A(-J])"T#<0<8:,P9F@%[KV9,P5^L5N?D?)]%<J?*U
M=@RXW.KII:-B4FTBS4]%%4-CGGJ*EB+"LG6FPPL>YRN<_9:67+&7;;HK<69]
MSK7VNIS;0(Z2VVNCJH:Z1U;LJD-3734SI*>GIJ5ZI,D7773SR,8Q&-9M./4=
M,F(1IDZ-*4 A*E(*3)B"]=DLD@@L)1)18?\ R@++#K6M?@UK-ZBBC@B;#$B-
MB8U&M1-Y$1,$1/B1-P_.TTLD\KIYG*Z9[E<Y5WU55Q55^-5W3GSL.L8 P!@#
M & , JQS=_9)Y _1J_?Q0,R37CV.9CY+E_$AL?\ +Y[;,L\K0_C4LVW?U>A_
MH:7^(!FJ4W]VC_\ (W\2&1U7]YD_6._&IW,[SH& , 8 P!@# & , 8 P"AMK
M\K[5ISD96E>2^E8D"D;7FKI74/GC?;X'"X7-S8*?DMP2>PR:42P@U""I8DGB
MJEH<U9LC+=$JL92D2+Q8TG9HY(B*F/"0G3G/?D5=+;IHC?%>$)K-L>BZ=Y0\
M?X^MY C+BCM0]RRA='D[Q<DIW585T"FM?($Z=S=FAD;I06L*6@3H%1QI1P@"
M5:B<.X:^M_U(;L)H2O>22#C+ G.KSY>J@5E.*/D.4I6R.7D<B'+CLW-'%9$E
MK \=[ F#@@!((^I</@NG>FM8F3IQ;4FC[D-E,<,=W^F^>OV#@, 8!4WAW^8=
MG?YE^2/VO2C,>T4]'KKZTWKQC.;7KKZ26CU2L7BRG+99L)B@P!@# & , 8 P
M!@%3.0_ZWN&?T[R3["[7S'M2?3/)'K!/XJN!M6E_H/GWU<@\;VXMGFPF*C &
M , 8 P!@# & , 8 P#XV(.MA#L6M"%U[.M[UK8NFNN^SKV=]-9&*(N"[ZDX*
MJ8IO(?.20, 8 P"K'-W]DGD#]&K]_% S)->/8YF/DN7\2&Q_R^>VS+/*T/XU
M+-MW]7H?Z&E_B 9JE-_=H_\ R-_$AD=5_>9/UCOQJ=S.\Z!@# & , 8 P!@#
M & , HNZ\+%[KRV>^59_(&PU(G^+-->*:F>(;3\AAK/6"1 $$@KN%O[U 5E@
M0>/SZ0!T[OYC8ZIUKJN*3Z//$0C1DD#EM?-V<""#/]*6,EU5/:O;>4G)%#\*
M*KKOCG$YAXW5WPGK#BY6LC6R!MX_QA0AK=M3NL:DA#D:UOKL[@7R)T:0E)Q+
M@=WVQ"=O=QP3_B;6]_Z>$K>WCC@_CY>V@A6<8&EV;:V9D%.\7TT ;5;@HVA;
M9*VUH530(/')9$H'_P#&&9>VHDQK6RFJ )NZ-5J330VM_<W_ )3TTP<!@# *
MF\._S#L[_,OR1^UZ49CVBGH]=?6F]>,9S:]=?22T>J5B\64Y;+-A,4& , 8
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M('WER>I=*XD2N51,XJAZ_3%HGI;'7J*J#U));IV%Q(F60*@:+,ZAT,81Z]L
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MNNGN7<IT[)FW&T3W)\SG(WK;DK)*=\76U1RN56I$[;VFMP54PQW<)OR^&>C
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MK<&2EL#JX('9S9 O@4VG+32X.C6F4G)^][HP\@LP0=B '>@QX. V()8 ;'L
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MR]V"XPC4_B9%/F7;,.0S41N&NAELD3Z5N<EE &%SF&Y'I@61EOE\G.&-Q W
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M7'RG:-TT)&P:$0C*G?)FZE/@3M'C) @6)I;W"9)W?:2Z*%[?81]-2<<=S\)
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MGD6KV D]\,^22]VBDM(<A(R][*;4!*@Y<H(+3C,W.(V5,N/DW6:5BFKZ\H[
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M+.?E<\G-C2>WI R2692&<&QH!_CS!#6F"MJ)@:XE'(NQ1YB3L3*1H"-.FT6
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M92I>ZQ>'1LT(MG;E+6B3J!+"AK""-L1LX+NKPEQ:O<%KM5U8.SFM-<W-VK6
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=S/>D[/../WA+C]_??/!_W+>_>M[\O#@_)^(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g382677f_105.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_105.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C8P.$,P-3DV0C1"0C$Q141"13DX035&
M-#8T.3@S-3DU(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C8P.$,P-3DU
M0C1"0C$Q141"13DX035&-#8T.3@S-3DU(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z,#=B,&8Y,F4M-S,W92TT-S1D
M+6(Q-V8M8S8T-#!B,39C-#0R(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C,Y
M-C@U,F8X+3AC8S8M-&,R8RTY83)A+3%F831B-C<U-C9D.2(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( % !)@,!$0 "$0$#$0'_
MQ "U  $!  (# 0$!            " 8'! 4) PH! 0$  @$% 0
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M',;J3$3766 76@D2&DJZZ6=9T$N14P#)@HBIP1[!+S$+FC">9P-6OB7OB)D
MDF9&?P%J4%0H 4 * % "@!0 H @!VZ$ E.17C*['G-_1V^%.; -04?J!5NL-
MTD8UD98A6VG^3 RZ8YT \7=31DB."I3 8@H7R,)1\O\ 4$#0%A,@J"Q*T66#
M&Y4]NPF]],$8Z5V=/#[8;%93Z'?K^&/M5A/L*?#RDXW&_G$@RZW%E%)-M49;
MIDMRBKBDB$BY))-Y!!D1"UTSKD\P$JP[?B/ZO^W@&\'TFO%VZA)%/)KGST_K
M&HQBH[3C-!:>H1YZ8G 4=,2NA1L&USBY&@8"NED,%=/;ATD452*<7+WL%:PV
M8P"585E@PQ"]LY;#*3R5?&JR0GR=G&0FY,XST%C2)D:2VS,D;R2UY(A5WV>(
M+>/8.ANPT*SR*2AM=1)"MT%&#N!<KUA!1!($[?[!9FFK3V5T[M)VI1A\N.3W
MM)<CN.793D9T$&ZBJ+RD)T$D5)/J8#<:*4BM=LI11#;:>1*$B1;' , ICF+F
M,8S&'%D5,[11-! 4 * )D@?^ZFLO_(MK_P"J>FF@D^POR_>8IN@@* % 'GTH
MZ&UU=U3R/J+<NH!?=3<DYG9Q:K1$Y(VCY2)-N'#+;&2E:*H]?UB0#R8S9<[D
M'NO+(A(3$ZKJ6 /U8PH10G@7"^UHLL&E3WM7'S,0OR,0M8<X_C#T8<,P,#(!
MIM1;@N)&E>#%%T*#8T^9DV\U&V45DAU_K%0+NE<%RQ6UPH/<"XX(5[X7!MZ;
M;/\ 6,F<GMEEGL12DUTZB'R D+\;QU#4^-EC1S#[%:$V1-#+Y=;UB)E%$!/9
MYRT-%F:$\3J/D,TAD[,VD"=3H",!@&00;5@H:1]'C95$=VYP&[#>EI^/U]6?
MT@/J-F5';DPDY2,$'*FJZ;*C/D1LN=KOM&5 '<<,7P, AC@J%@3(8MKAWPS"
M"4?QTD/E NBQA:>7='CF9KK>2H6C;2TT=*R*EN<TGJ8AUKM!W'7@6=2JJ DB
M9@1QGCI[,,0(# !/""M;$  +#''#$!J,]8LB@J% "@"2X;_D_K(_,8$_:O"@
ML?Z2%:4%0H PV16VNO%@O1I-A[+$;.-S-9>04*0F\225)?9"JK)ADB1=:(07
MBA]$-JR 9'Q-%@S8 Q?(8+&PF&6/3C<!=H\MXPT(IS>9R%!#)UDKX$T:3I!(
M2BQ7\U8OAXJ^(T5);8+W:[K,2:VU5ON%"E-2G%#=BZIJBLNAC*QU7%^O^H[X
M/IR"YJ^-F@QM6WMOMXD0T^,-"GN84N"X(+PP9RAPT4CE:)O)WP0],9$:+^_7
M:BR<WZPG2Z7@&&,[!&\>3@5XH%B4[LL!D+B*$;7;HTF-B*6AYKFX9&BM-D5Y
M(2VF:F'UJQ84CD"+9,K;'EAW3>\9R(B!("JD*#5<3=0EAZ&DRY(^5%^J3;_'
M,,UU#(8-K3;^P:K1_;0:Q6SY.N.:) >#BD9)U@$G6X5-!8J<,<4=937AYMOI
M4+)B&@IJ01Q:^,/EA$DN&#8/JG! S-Q^KCG<)V_W?U#JFKHCCPW+>))CZEWD
M,APC.L-3=)4'%4>.E(KA.[3A)J-%$5G$XQVSD^$)/>T:%$A4$2@#V(.!K*PX
M&09<6Y6@;1V=GP'J504"@!0 H 4 * % "@!0 H 4 * % "@#K%I92VZCJK@7
M#Y9+14-..JZNIG!+!%$Y,32PAP^>-"W^ 18H5!S$$RO\,<<;WO7ROGK26,HT
MQ?Q$PF+>$J)$6H[$H0A)J6M1_!*4D9F?P(K1];!@\FCZ#+)=#7&F#B*B%"AI
M*U2XBU$E"$E\5*49$1?$SL'U3%1,6TXDKHRB15TE3*@G4Y43#9<^G*!(SA84
MN;)'2H@I8T6'#RME@('EEAEC?IM>]JLU=M7S:&]8Q(<9G%02D1$*):%I,K24
ME23-*DF6DC(S(R[!5XS=R]U$8OX42 ]@K-"X<1)H6A23L4E:%$2DJ(]!D9$9
M'H,A.4#_ -U-9?\ D6U_]4]--?0/G/L+\OWF*;H("@!0 H 4 * % "@!0 H
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D>KCZH+K8YD]_FXHW>D[[U??E$_M=Y;M=AFG9MV=CY+-G0/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g382677f_107.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_107.jpg
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M<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M#QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'6'?K
M_^X )D%D;V)E &3      0, %00#!@H-   ;<0  7D@  ':W  "1"__; (0
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0("
M @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@
MG0+: P$1  (1 0,1 ?_$ 0T  0 " @,! 0             &!P(% P0( 0D!
M 0$! 0$! 0$            ! @<(!@4$$   ! 0& 00" @,! 0$     ! 4&
M 0,'%Q$A A05%C00,#(S(!)0,9 3-F!P)1$   4" @4&"@8'!04%"0   0(#
M! 4 !A$2(3&1$Q1!(C,TU):QX7*R<Y05-975$# R(Q8'(%%A@4*2)%!QP8*U
M4F(E=M9#4T1U)F"#HU1D=.0V%Q(   4$ 0,#! ,! 0       #'B Y,!$0(2
M(4$4!7$3!)!1(S,B,D)R-!,  P ! 0<$ @(# 0$!      $1(3$P\$%1D<'Q
M$"!A<5"!0*%@L='A<(#_V@ , P$  A$#$0   ?VPK76
M                           <L226+ZG&      5>4!0
M                       M"+_,C(XP  0B73@ $87RQ9^<.H
M      /0\=@@Q("-EFGF"@               ![=C]7HR,CC  !6<U9MR !%
ME\B)^4^@                ]'Q;\1"I7$3KH'E"@               ![=C
M]7HR,CC  !6<U9ER  *]*7                 !4*S(EB
M   "PBZ#(R.,  %9S5F7(     ^@              %1+9QWT
M    ^   &1D<8  *SFK,N0    !1DU)D     @2V"G&     099R@ '4.V
M""K.D     BR[H[Z     1!;PL[B  #(R.,  %9S5F7(    $=7SM+ZLN?@
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MN*ZU+6S0    (I6N*-EHE>T0=;$3B-%+N;(,OZC,=HKNI9&X    !UBM:M.
M    (C4-LR,C?2Z^($O*7*DA   *]K;DK@    "JJL2.Z?3$&)R&!F9@UQ76
MI:V:    !%*UQSQK"PS(Q(D;HV1F9@KNI9&X    !UBM:M.     (C4-LR,C
M?2P.7S*MV)ZH0   5[6W)7     %558D;$    &N*ZU+6S0    (I6N*CEAQ
M5*QJ7L'VSMK%H]G,^B[!7=2R-P    #K%:U:<     1&H;9D9&YEFL     0
M>MF26     *VJ<1W@    =$@VI8^:    !'*Z),8     @]DEEV8    . @-
MEBR@    1JHK9D#$
M'PWTNDL                                            YB8YO_]H
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M\125X,)Q_<+:()'MXQM)@V,FPE47(JNU'35$B<B=$QAR?P%*/.$1 /[#E?\
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M+*6*6%.V2S C.ME%BD)B()N4Q!0! 2J@7>S/#IO7"IU^#:\Y*-0/AN(\7/\
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MF!A$N3*=D]E+56BXZX(&5G[4<^UVKQ620BXL9KA91L@W 89V\BPWQ  SD@
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MC-T@\3EPB$GA8PL@HLW+O% 2Q4TYL<PXGER-%RN5)LMQF2"0?\#[;!@]C%)
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MUE+H(.NBAVIY14IT%%DU5?:"BDPL918XG$YAQ'3CB:17._!P?\(X@FX(5/\
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M)%P\>1HR9&/G.9=3B#KJF/HQWH%PP*%+>C-27I4_."A*8 ,4P"!BB&(" Z!
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MO5R-CPK.2_"CINR(W3)%21C,4@353*0[HR@B.<Q@&GN[N7\QA%'\J&]VH?\
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M;;;;:O;;;;VVV&VW^DDDDD>P    +"    !.     %0    .L    !;:@
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M+( %@    ,@    !+:A:   !@     %@    -0    !-2<B$@%@    ,@
M !+:DDDDDDHDDDDDMDDDDDM4DDDDE$DDDDDFDDDDDETDDDDD+;;;;;;;;;;;
M;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;:5;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;;;;;;;;;;;;;;3O_:  @! 0,!/Q"\T @M*V(C(BK_ 'NZS>7N;R]S
M>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;
MR]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>
M7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R
M]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7
MN;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]S>7N;R]
MQ\.0G]*8$2<PYZ>GAVW/+;&WJWMA5P_VV?U5V%,&VOPNK5JU:M6K5JU:M6K5
MJU:M6K5JU:M6K5JU:M6K5JU:M6K\+JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:
MM6K5JU:M6K5J;]-?A^X=3@K9))[%0T&Z:G2G)8:TS]Q<N7+EWG,Y2B).Q(F#
MVT1G&KQ0P1^#PA,B(E$J1#QPV:C:E5&=<=&M<A&VMW"J#E8,ZST"M[CU(N$4
M>1V=RDC9<MTBK*7O!UYL]6*I&?C6-09J3:Y3@><?]/./^GG'_3SC_IYQ_P!)
M3##//OK/,:4>-/<5T?OQ!)+\&D'23P%E>CF:FNJ\/6QT$54L;42F'4"6(W43
MR*\:60+1>'(66724_JFRQ#323,"WV8,TA_E-/#&H.&;#A5>J2:9B-2?A7+ER
MY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7 C-JK:V4>H2COEH]VA9TA
MW_"G+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N69;ETZIY-B,T-_'
M4'$?)]"/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY
M/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/
MD^C(^3Z,CY/HR/D^C(^3Z,CY/HR$P]#!QMT$<L$%1'TNZ%4!,MT3CY/HR/D^
MC(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3
MZ,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY/HR/D^C(^3Z,CY
M/HR/D^C(^3Z,CY/H_P":H.'=L*ME4VV;G139A @0($"! @0($2*!&D4A9V<T
MJ$!FH=)/2IDX;0($"! @0($"! B969I.FF\)>I$A^T($"! CZ*.4S0CDS0X_
M>D"! @0)DR+,R_WIA2-;0($"! @0($"! GUSD]^>"#IC-'+W%:LU,!)8DEM
M@0($"! @0($"/ZTA5ABL:E=2&FY<>M<:XK]GQ;_EJ#AYRLFM6NS<!,X:;=4I
MU>*&T(>9-E!MJFX;Q3RXMF_([EPFK\T#)TOYB59D79U$+11--JI-565<55E7
MTBLI[R<Y#9HWE =:@5FNC0HE8V2:=FZM[()<.Q)S\_1['7GBQ?"B2B222L$E
M$FTHM6;:MM[-GQ,#@SS82;&6S_F9E;S!.QM.G+^A2EB O**42QS5*>R65JNV
M.2@Y<'ROGRF=HJU>V5*E2I2!Z\2*%BZVZF"7NE2I4J4[M'Q!+3V'DU5P4 4
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MB=H2:7IO_E]5QV+(S0:23Q(DRWG_ ,.WGYJ%X//:=<L,.';B2-B?525$2'\
M8&UM!FR.Y/&=2_+T%.'N"UR-:)31ANM8,7TYRVHMHKJ",).I.-5)QJ-7,:>4
M_9/W1V8I)MA >YX[ H#XY@VJ:4._Y)(Z=T@2*P)6I)P[3[_AE3XZ\GEK5=UQ
M6#RD,JFZT\G8C2#3;':&H*,")FJZ0G&',1;&IT.(#5I3)Y0Z4#CQ2+/Y[.,X
M@F]A<N7&S3^^GK<9SB@B$U8Y>.)_^"-DYT@T3>/2+,O^MRY<5@!_O5L"2*B
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M?V3E:M#2XFO84.?+_P!$4=UB&B5X8GJM1%S.9+>+K!,2UR*&;92$F^&!JL.
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()N/_ ,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g382677f_108.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_108.jpg
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MQ "3  $!  ,! 0$! 0           P(%!@@$ 0<* 0$! 0
M     0(0 0 ! 0(&#@8(!0,$ @,    #! $"$=&R$W,&P4*"4Y,D-%1DE*0%
M!Q<A49$2M#8Q07&!H3,4=&$B,I(5L7*B8B.S%F.#HT0F$0$! 0$!  ,
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M:]S-YS_(9K^GWO<_E]S^G.>G^GT,^?G\5_*:CE$^FER[S2(@
M
M                      RVFZV 4J.43Z:7+O B
M
M              #+:;K8!2HY1/II<N\"(
M
M       ,MINM@%*CE$^FER[P(@
M
MRVFZV 4J.43Z:7+O B
M                                                    #+:;K8!2
MHY1/II<N\"(
M                                             ,MINM@%*CE$^FER
M[P(@
M                                      RVFZV 4J.43Z:7+O B
M
M                              #+:;K8!2HY1/II<N\"(
M
M                       ,MINM@%*CE$^FER[P(@
M
M                RVFZV 4J.43Z:7+O B
M
M        #+:;K8!2HY1/II<N\"(
M
M ,MINM@%*CE$^FER[P(@
M                                                      RVFZV
M4J.43Z:7+O B
M                                              #+:;K8!2HY1/II
M<N\"(
M                                       ,MINM@%*CE$^FER[P(@
M
M                                RVFZV 4J.43Z:7+O B
M
M                        #+:;K8!2HY1/II<N\"(
M
M                 ,MINM@%*CE$^FER[P(@
M
M          RVFZV 4J.43Z:7+O B
M
M  #+:;K8!2HY1/II<N\"(
M                                                       ,MINM
M@%*CE$^FER[P(@
M                                                RVFZV 4J.43Z
M:7+O B
M                                        #+:;K8!2HY1/II<N\"(
M
M                                 ,MINM@%*CE$^FER[P(@
M
M                          RVFZV 4J.43Z:7+O B
M
M                  #+:;K8!2HY1/II<N\"(
M
M           ,MINM@%*CE$^FER[P(@
M
M    RVFZV 4J.43Z:7+O B
M                                                        #+:;
MK8!2HY1/II<N\"(
M                                                 ,MINM@%*CE$
M^FER[P(@
M                                          RVFZV 4J.43Z:7+O B
M
M                                  #+:;K8!2HY1/II<N\"(
M
M                           ,MINM@%*CE$^FER[P(@
M
M                    RVFZV 4J.43Z:7+O B
M
M            #+:;K8!2HY1/II<N\"(
M
M     ,MINM@%*CE$^FER[P(@
M                                                          RV
MFZV 4J.43Z:7+O B
M                                                  #+:;K8!2HY
M1/II<N\"(
M                                           ,MINM@%*CE$^FER[P
M(@
M                                    RVFZV 4J.43Z:7+O B
M
M                            #+:;K8!2HY1/II<N\"(
M
M                     ,MINM@%*CE$^FER[P(@
M
M              RVFZV 4J.43Z:7+O B
M
M      #+:;K8!2HY1/II<N\"(
M                                                           ,
MMINM@%*CE$^FER[P(@
M                                                    RVFZV 4J
M.43Z:7+O B
M                                            #+:;K8!2HY1/II<N
M\"(
M                                     ,MINM@%*CE$^FER[P(@
M
M                              RVFZV 4J.43Z:7+O B
M
M                      #+:;K8!2HY1/II<N\"(
M
M               ,MINM@%*CE$^FER[P(@
M
M        RVFZV 4J.43Z:7+O B
M
M#+:;K8!2HY1/II<N\"(
M                                                     ,MINM@%
M*CE$^FER[P(@
M                                              RVFZV 4J.43Z:7
M+O B
M                                      #+:;K8!2HY1/II<N\"(
M
M                               ,MINM@%*CE$^FER[P(@
M
M                        RVFZV 4J.43Z:7+O B
M
M                #+:;K8!2HY1/II<N\"(
M
M         ,MINM@%*CE$^FER[P(@
M
M  RVFZV 4J.43Z:7+O B
M                                                      #+:;K8
M!2HY1/II<N\"(
M                                               ,MINM@%*CE$^F
MER[P(@
M                                        RVFZV 4J.43Z:7+O B
M
M                                #+:;K8!2HY1/II<N\"(
M
M                         ,MINM@%*CE$^FER[P(@
M
M                  RVFZV 4J.43Z:7+O B
M
M          #+:;K8!2HY1/II<N\"(
M
M   ,MINM@%*CE$^FER[P(@
M                                                        RVFZ
MV 4J.43Z:7+O B
M                                                #+:;K8!2HY1/
MII<N\"(
M                                         ,MINM@%*CE$^FER[P(@
M
M                                  RVFZV 4J.43Z:7+O B
M
M                          #+:;K8!2HY1/II<N\"(
M
M                   ,MINM@%*CE$^FER[P(@
M
M            RVFZV 4J.43Z:7+O B
M
M    #+:;K8!2HY1/II<N\"(
M                                                         ,MI
MNM@%*CE$^FER[P(@
M                                                  RVFZV 4J.4
M3Z:7+O B
M                                          #+:;K8!2HY1/II<N\"
M(
M                                   ,MINM@%*CE$^FER[P(@
M
M                            RVFZV 4J.43Z:7+O B
M
M                    #+:;K8!2HY1/II<N\"(
M
M             ,MINM@%*CE$^FER[P(@
M
M      RVFZV 4J.43Z:7+O B
M                                                          #+
M:;K8!2HY1/II<N\"(
M                                                   ,MINM@%*C
ME$^FER[P(@
M                                            RVFZV 4J.43Z:7+O
M B
M                                    #+:;K8!2HY1/II<N\"(
M
M                             ,MINM@%*CE$^FER[P(@
M
M                      RVFZV 4J.43Z:7+O B
M
M              #+:;K8!2HY1/II<N\"(
M
M       ,MINM@%*CE$^FER[P(@
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M,L>#[??NV AAL]=GM!^@
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M5$>#^Z.Q1\EO\OHO?RV^J]Z+?9;@M PX?H
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M_DP0Q8/HS<5RY@_MNV(+
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MO[FN^)D8O5=R@
M                                           \Z>(/S77Z&A^$B;G!
MQ:HRVFZV 4J.43Z:7+O B#T-X=?*]+^YKOB9&+U7<H
M
M            /.GB#\UU^AH?A(FYP<6J,MINM@%*CE$^FER[P(@]#>'7RO2_
MN:[XF1B]5W*
M                                         #SIX@_-=?H:'X2)N<'%
MJC+:;K8!2HY1/II<N\"(/0WAU\KTO[FN^)D8O5=R@
M
M           \Z>(/S77Z&A^$B;G!Q:HRVFZV 4J.43Z:7+O B#T-X=?*]+^Y
MKOB9&+U7<H
M                                        /.GB#\UU^AH?A(FYP<6J
M,MINM@%*CE$^FER[P(@]#>'7RO2_N:[XF1B]5W*
M
M         #SIX@_-=?H:'X2)N<'%JC+:;K8!2HY1/II<N\"(/0WAU\KTO[FN
M^)D8O5=R@
M                                       \Z>(/S77Z&A^$B;G!Q:HR
MVFZV 4J.43Z:7+O B#T-X=?*]+^YKOB9&+U7<H
M
M        /.GB#\UU^AH?A(FYP<6J,MINM@%*CE$^FER[P(@]#>'7RO2_N:[X
MF1B]5W*
M                                     #SIX@_-=?H:'X2)N<'%JC+:
M;K8!2HY1/II<N\"(/0WAU\KTO[FN^)D8O5=R@
M
M       \Z>(/S77Z&A^$B;G!Q:HRVFZV 4J.43Z:7+O B#T-X=?*]+^YKOB9
M&+U7<H
M                                    /.GB#\UU^AH?A(FYP<6J,MIN
MM@%*CE$^FER[P(@]#>'7RO2_N:[XF1B]5W*
M
M     #SIX@_-=?H:'X2)N<'%JC+:;K8!2HY1/II<N\"(/0WAU\KTO[FN^)D8
MO5=R@
M                                   \Z>(/S77Z&A^$B;G!Q:HRVFZV
M 4J.43Z:7+O B#T-X=?*]+^YKOB9&+U7<H
M
M    /.GB#\UU^AH?A(FYP<6J,MINM@%*CE$^FER[P(@]#>'7RO2_N:[XF1B]
M5W*
M                                 #SIX@_-=?H:'X2)N<'%JC+:;K8!
M2HY1/II<N\"(/0WAU\KTO[FN^)D8O5=R@
M
M   \Z>(/S77Z&A^$B;G!Q:HRVFZV 4J.43Z:7+O B#T-X=?*]+^YKOB9&+U7
M<H
M                                /.GB#\UU^AH?A(FYP<6J,MINM@%*
MCE$^FER[P(@]#>'7RO2_N:[XF1B]5W*
M
M #SIX@_-=?H:'X2)N<'%JC+:;K8!2HY1/II<N\"(/0WAU\KTO[FN^)D8O5=R
M@
M                               \Z>(/S77Z&A^$B;G!Q:HRVFZV 4J.
M43Z:7+O B#T-X=?*]+^YKOB9&+U7<H
M
M/.GB#\UU^AH?A(FYP<6J,MINM@%*CE$^FER[P(@]#>'7RO2_N:[XF1B]5W*
M
M                             #SIX@_-=?H:'X2)N<'%JC+:;K8!2HY1
M/II<N\"(/0WAU\KTO[FN^)D8O5=R@
M                                                           \
MZ>(/S77Z&A^$B;G!Q:HRVFZV 4J.43Z:7+O B#T-X=?*]+^YKOB9&+U7<H
M
M                            /.GB#\UU^AH?A(FYP<6J,MINM@%*CE$^
MFER[P(@]#>'7RO2_N:[XF1B]5W*
M                                                         #SI
MX@_-=?H:'X2)N<'%JC+:;K8!2HY1/II<N\"(/0WAU\KTO[FN^)D8O5=R@
M
M                           \Z>(/S77Z&A^$B;G!Q:HRVFZV 4J.43Z:
M7+O B#T-X=?*]+^YKOB9&+U7<H
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M:#X
M                                      ?=^@J?\;_D\U?_ $?ZW]%G
M<'\N?S.=]W#_ +?1]OH!_6O$+_U;.1_K?U'^:S5WW/\ '9K.YG#;F_UV=_[.
M;^GW,/\ W,'T>AF;]*_C_$^F=G:0XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX
M'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G X
MGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^
MF=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTS
MLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G
M XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'
M$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XG
MTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F
M=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSL
MX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G XGTSLX'$^F=G
MXGTSLX'$^F=G XGTSLX'$^F=G XGTSLX/MH/\)^IC_R7^4_2X;/?_3?I<Y@P
MV8</O>GW<'TX/YO4#T#_ /RW_K'_ .K_ .N?I_\ J]SW??X?]5G_ /[,Y_U,
&?._JO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g382677f_122a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_122a.jpg
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MQ #L  $  00# 0$!            !P8("0H#! 4+ 0(! 0 " @(# 0
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M3*J0@]$%U^B("H=00X@ B(%#@ >'B(W2T!277*^RJ>O-ZN20.N5]E4]>;U<
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M =<K[*IZ\WJX ZY7V53UYO5P!UROLJGKS>K@#KE?95/7F]7 '7*^RJ>O-ZN
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MAPA-1LA*$G"R*G7/;))[9PE&<)::2C)2BVFF>CFT:HP!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# (;VJBF"T,N!0ZTZ3U$QOPBFF9N<A1
M\T"F4-P\\<M$$2AXP\\/3RQ 'QCYX^G@$D:O^'7OR4?\[;9$NA)2G.)%,YW1
MSR$DHU.8C)?9.C(R5BEVXNVTA%/MW:^;2C-VW INM9N&"JA5@$.'5B;CP#/4
MOG5AT<AV%/!RJE=B7<IQ4+*VMT9URY3#C.,EZ8N+:E\FNI[@\B\V_CO,.'(8
MEKHS*.)Y>RNQ2VRA9#B<V5<HR]$HS47'_BTT+07+_;&F]MR]$C*]+W&:T9RM
M<PLQHV?>(/)=.\4N4L.JWNOZY)K)"#B4MM"7@UXAXV*8CF3;-&JQ?X1T(AZ9
MNR.[^R>\;N Q,:[-SN [2YBSB[9*5BRL:R[ EB4S:^=9D8CJECV034[X5U37
MSKFSWA5C=E]^=DT=QY>51@X'<7>/"U<O3%QJ>)E5T<C#,OK3^;7C9BNADU3:
M==%EEU<OF4I-)[VV$SJNS4M3\PSS><<TU+3[<KLD*K3EUM;[+FMAUF )64DZ
MQ7HJ$%"S5Z3?.Q@9!%>4AR1P@JL +E$(RO,#N2GB.5AV?W)/G\:'#XV0\W[O
MC-X6;;F44JA*BFNK2^F=MGW2Z,[\=4_/G_*(G$\N>V+^9XB?>G:]?;N5/F\G
M&6#]XRDL[ JPLBYWMY%]ENN/?737]\IE#'R7>MD&ZWK<M4Y_?D%<-X:Y@YB,
MW%(TU[K">JTGM9ZUH1DHB_1%A7L40O-:_H#UD_2A9.O@HQ*$6"I4G0I++&ZL
MAC>T>'Y'S#X_FN>[9P+JN;R<&>#;19R$XXFE>77<[JW;AXDHS54Z=:E[C<HV
M.$YO;%OU-S7&^6O)<%V]W5R-%W!8N?7R%.17QT)9FMN';0J+55FYD)0=M=SC
M<_O&URK4X5K?)*&-KWM[2.9U*5MFX-=:*=R?+EJ\M@"RU1?8,'/R+/8&QG4U
M!5B3>2],61)$G7,'E1VYE%4ETE#()B7HCP?N_N"_@?-6.7S'-<9V_=;VS@J[
MW^.\RJZ<<S-E;51.5F,U[MM_/<'*49QDZXZ:/GG9?;F/W!Y12P^%X+E>XZ*>
MZN0=/N,A85U,)86#&J[(KC7E)NQ)?R:FHQE"<59-/55!;]R[-8<P+^O5*R2D
MWJ87""\6\+ QY&#C=8ZQDYNM\O!+*+8H)U6WM2LIM5\8HN4)0Y(LKD@N2I$\
MES7>W=./YC6<=P^5;?V?NBZY*J"@^3^XSMIX=7[?#'R8^ZRI6Z;XWM8BMC[U
M0CXS@^P^T<GRRJY/FL6G'[UVM61=TW./%?I"NJ_FW1N\<C&E[W%C3K[N>.I9
MCJE[ISE!-!YC>8AU1;G;6>S*G>YAOJ-"SW.MI*1]KL^H+8^M-=B9*::Z]K.K
MJ;)UV/H\*ZF5G=:G9"2E%5(M(Q%%2]>93U]V]YF^9-O 9W,4<IA\AFQX97Y-
M*<,B_CLB>137.V.'1@8TZ88M4LF5F%E777R=$'&4U[QR]C]R^5GE=3W%@<+?
MQ.;QV#+FWCXM[4\;'Y/&ACWV5U2S<CD,JN^>7;'%C5GX=-&/&.1-2C!^[4)Q
M'=K2HQ50GX3FE';^N6.^J'";%O\ *1-)3BJG4K/1;9Y1$V"]56OPM/<0SRXG
MB53+II(.(@ZR:#E<"G#.>_MW3PV)A<C@=V_IKMFON'$JS<NRO%5>/CWXF1NK
MNRL>FK&=<LG[O)RC&$\=RC7;9I(]>?Y?7<WF9W&\AV=^@^ZK.V\RW!PZ[,MV
M9.3CY>-MLIQ,BZW*C;'%63%0E*<,E1E957K$CEW<978EKT#MJ>VG<(>CQ'-?
MS 4N)LT+&5UO!(5UY].(368.G#ZG22B3&SH-V\$@]5,5)PT?\2J%<*I.0XU=
MS67W+R_;O>/(<MFT<#3W?R^-7?5"E5*F7WJK!W2EC3:C>E#%C9)J,Z[?"2ME
M"U<IIX+#[6X;N;LKC>&P;^X;^R^&RK*+;+Y7.^/W2W/VQAE5ISQW*>7.J*<H
M64Z.+JA.I]EEMO>-6U_K1U#+KKJ[OB-F:@J#-C48=A&T?> ;AGVM+M[QG&P[
M1LUBUJ2\D7+P%B>2J# )G,45'"IU<M'>/?W$]N\7;@RE*?/4YW'8\8X]<(8O
M*?I*Z.-D2C"N,8P>+*Z=FY;&\2+:<K)RGBR.R?+SF.YN6ISXQC#MZ_ Y/)E/
M)MG9E\3^C*996-&5ELI2L67&BNK:_>)9DXIJ%4(P]#6^X=[2N_F]1F=F59"1
MCMN6NB3.G['.PK67=:OK#:3*PMC"EQ^K2W+Z034(R;3R4^>Q>\#TSDS8B20&
M323V.V.]/,#+\Q8\-F\KB1R:^9R,2WCKK:HV2P:(V;,B&-# ^\^^MJC#+CEO
M,^Z6N;JC&"<81UNZ^QO+C"\M)<W@<3F2Q;>$Q\RKDZ*;951Y#(E7OQIY4^0^
MZ^YJMG/#EAK"^^5*"ME.;4IRJ7>SRXZ]YG)W8%8GK8\L\GRLV[NJHRC&(7J=
MYOE.=R\L;7Z9T:PI,O3$042FC,4I%&1<K%$$E10 4 \KY@7\UVWYJY'<7%9&
M9/E;>TLC[ABN%;Q\K+QI66?<TU0[9:)QR75&Z-TY)[)^[UK7B/+FC@NY_*/&
M[9Y?&PH<13WCC?I'+4[%DXF'E1JK^^M/(54-6I8JME1*BN+3G#WC5CBNH[JW
MK.4V;<0&]JW<D'TURX,%+%"2-5O5JI%EV/MR KME9+1D+J>AUV'@I*JNG?3A
MI(KN8AUVX JH4BG2#B/#=\^8&?PE]G'=P8N=79?PL'=5/'R\C%OS>1IIOBX5
M<?B4UU3QY6:XUZLR,></G249:G,N;[ \N>/YW'KY+MS+P+*\?G)JBV&1AX^7
M1@\;=?1)66\CF7VW0R(UZ95#JQLF$_F1<H:$OJ[>OFJK<6O[!VD^?4"A\T,3
M1K)LBYQM6A#.->WGEX>7: 8W65BH.$KS-K&[+F&;-.4008E,8$$EC (FZSF<
M^\^X.T>97'=Q\M99VYQ_=E>+?FY,**MV'E</+*ICE65U54QC#-LKKC?&-2;]
MW";\7NX/#L?MSO/A'R?;'#5U]S<EV?9ET8.+9D6J.;B<W'$NGB5V76WRE9@5
M6VRQYSN:7O)UK1+;^ZLVCM/:%PU(#*_3:=7F7G-G:GQ&D# MOIC!:TWQ7('6
M< L]E(%08B)=5:2ZCRA(B;IRR,8Y5 5,"Y9[2[L[M[KYKAE1R-ZXF^?<%\]M
M54?O-6#RU-6#2Y3J?NZY43V;XI63J;:EN?O$[Q[/[.[0X/FW?QF.^8QX=N8\
M-UUTONMV?P]]V?<H5W+WMD<BO?LDY5UVI1<-B=;ISE3W/N[8FR(!*X[%J$HX
MEH&Z2.U=2+346>QZSDXF0091;&'IT5K&OV.C*0<LL6/<HV&<DQDT%/*FZB@D
MZ0^+\HN^.^^Y>Z,>'-\GA76W8^3//X]VUN[!G7-1KA7C5X--V*ZK&J9QS,J]
MWPE[VJ4G'5^4\YNPO+[M;M3)GP7%YU-5&3BPX[DE58J,^NR#G9.W*LS[J,M7
M5IW5SPL2A8\X^YMC%2T633/J@^2!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , @G:'PZR^2B?G;G+QZ C4?$/G#Z6207:1WP>Q_D;;^))F,DQQ,7=_
M/MBQTFHW*PZ^8[#YR=GQMHG(&&@G\FI Q/*S5+"V"/5L\)-Q;%8TQ#H]4Z,@
MJ0JA> E/^]SY>HM[BEWAD\%PV=D\;C\EWMG0OMJKJG8ZJ^!Q[H['?5;7%^\K
MCMFX22DM-)=#ZQR*>VH]EXO<'-X&+R>3Q?8?'V8]-UMT*U=9W#D4RWK'MJLF
MO=6RW5J<6XO76/4ZQ-T; -#Z>@MF[O<:@KJ\OS!5ZU;L]X:7%/+A;-0[*7IM
M#K3QS:8"5I%2=6ZM-',PY &1??55D=!D*11.0<*[Y[BEA<+Q_=//2X7C)7<Q
M3D<I[K&KEDY''9KQL2B4KZ;,7'ED41GDS_DE[^53KHV)M&678/;*SN=Y+M+M
MZ/.<K&CA;\?B??95D<7&Y/ 65F7QCCW5Y>3'&OE#&A_*O[O&V-F1O:4B*]6;
MWF-5:T02L%^]XH2PZ0YG+/0'TI H0);?M^+Y@-BN&SJ C)%@H_5M+Z)DFCE"
M$ 5#'26#H(' IA#B7:7F#F]H]KQAR7(_=\#)X'G+\2=E2J^\\C7R^:U*JN<'
M-WSKG7..+\YN,OFURT;7,>\?+C![S[LE/C.,^\<AB]P\!CYD*[G=]VXRSAL%
M2C=9":@L>%D+:YY?S4I1^=9'6*<O%W5>V^VM%P-DVF]/&[ H&J8D:91)'7*=
MWCKO<JM+.YVU7^AV>HO[-+5=XX,W<(RD&[0;PQFJGE30Z1CF'F:[Y[@K[QX#
MC^3Y>QXO(\=Q]?W;$GA+*AE9-%DK<C+Q+\>=]E$GLG&_%LC#&=<O>TN#DSA+
M[ [<M[)[CY+BN&K67QG)\C;]ZS(9SQ)XF+D5QIQ\/,Q\F%%>1&.^$\?+KG/*
M5D?<W1FHHH;EY=WJ&2TAJ&#VW>V:QMO<P\7MV+D8.HJS-=5J,A*6>*K)0<TM
MH2(;VU%=*3.Z.1P=<DFJ9JH1,R (> \MKN?PH<#V9@<SR$)_IKF*^1KG5CNV
MEX\[+ZZ/'&BJUD)QO=C4W)7S=4HQ=:KY#YH4]NY\^X>^.0X3C;(?H/A+.-LA
M;DJJ]9,*\>S(^;E2=DL9J5"K3@H.B"NA*2L=D_::V#MNS[HDM0V.:E%2:#<;
M 6V9.+Q46W3O[2ZS"2W+ZD=1%@DDW$M <.WKT6?5"9\Q3 W$ICE-[%[([D[Q
MY7OFWLSD[[6NW99;SK776EEQRK$^(3:@E'_XCLMM]WMUMJBGX-I^M._.V.R>
M([!J[XXK'I4NY8X2P*599)X4L2IKFFDYMR_^8JJJO>[M*KI./BHM1-+[KWBM
MS*3]3[P*A3U(;<=9J%6U'8Y^)BBW+5SUE#/9&R(5KNPG;Q9)"?C5I!PUFH^P
M-HN+=-2MW21 37ZSA^;WUW[/S0R.'7(X6%*CFZ,>CC[KJZ_O.!*-<IW*C[C;
ME7SN@[IUY-.7"BBR"KMA%1LW<UP>P/+NORGQN:_1F=G1OX+(R<CDJ*;+/NO(
M0G;"%$K_ -(4XE$*9JF%F+=AV9&178[:9R<Z]M 2G,5N.-I6Y)=QLV<CT:TU
MJ*VB+*^H\:H&R-9R?,&PJ\]MN1CT8DHS<U$Q+E&'".;D9>41AT9(B'3E$3(<
M=R_,KO3%X'FLVSE<BN.+#'?%7SQ:W]]PI\Q"BWD)P4/Y6RNN4,?W,%5OI<,E
M5ZY4)0Y-A^5O8F7S_ X-7$8]MF7/)7,40RYK[CGU\+/(IXV$W9_)5661EE>_
MF[=EZLQ)6;<.Q65+9M^[.@*UMU'5.Y2[II,!(:3!QO.1CJET-9FO5DF8[9\8
M:;J5-5I\FG4Z^S82/E"D.]^CA),1D"+II 4OD^4\Q.ZN.XOF8=H<Y^G>"Q[.
M,UY6<,?3!>7?9#.A[W'QGC36/3&J[?+&M^YJ_7(C9&"2\1Q'EKVAR7+<'/O3
M@?T!W!DU<KMXB$\G7/6'15/ L]UDY2R:WDW2NHV1R:OOSHTQI5RFVZGI.P=U
M6UCJB!;[JCY6&M?,/:*8AL6B/*I?Y5_0(/3EIM;V'F+,GK:K421F&5OAQ00E
M(Z+\F,B*93]-=-0#^5X+N3OKF<?B..KYVNW"S.Y;\99F)+'S+)XE7&WY$J[+
MUA48D[(Y%>R%]-&QQVJ6ZR,M?$=P=L=@<)D\UR5O 6TY^%VOCY3P<R.3AUPS
M+>4Q\>-M5#S\C,A5/&MWSQ[\CWBEO<=M<H;8XM6[MMP4;3(HMZA=14Z8L?-*
M_?7UXZI6N&TC:*9O2S0U4J S,_K"\U=$Z543\O,T%@A)6(2&,FZ.H1;K.,\O
MWYWCQ^+@XBY"CAN%NR>>G/+E+%PHSOQN5OJQ\;WMV#E4)K'7OG6ZH7YFC<;9
M2C/=ROAO+[LGD<O/S'QV1SG.T8O;T(8<8Y6=*&/E<1CVY.3[JGD,3(:>0_<J
MQ73HPM4I4QC*O95D[LGF.-7-M7I?:*T3+Z<U!H382-7J%6AG]#NEGGH"9EKH
MS75LU22MZM:L:# I2-VYV#UBJL!NGQ(!!\QR'='F:^,YCN"SEG3F<)PO$YBH
MQZ*IXF3?=399DQ;OQUDNBY06D(.FVJ4D]WS5%^$X[M3RJ7*\)VY7P\;L'G><
MYC">1DY%L,S%QZ;JJ\625&2\97T.;;G-756QBUM^<Y*3HO;4Y(;OM$3:=\K4
M2V0FWEZ53N6\*S6EV]VH2<4DX@)D_E<(XO+L]X1.:0^D35^G$1 !Y.JE_ K
M;E6)WCR&3WYEX?+=POC^8HYIXV-PON*&LK$5:E3;\ZIY4GE+6[[Y7:L?'_\
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MMLX1KE*3KCKM3;T6O71=%KZ=.IS9<QC & , 8 P!@# & , 8 P!@# & , 8
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MTZ:OTZ>C42MMG"-<Y2=<-=J;;2U\7HNBU].G4YLN8Q@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P"']J_T)_6'\SRT01"'C#SP]/+$ ?&/GCZ>
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M(\! ZB""R("'@.(>'*--=22[W( P!@# & , 8 P!@# & , 8 P!@# & , 8
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M!<8!_:*BK=PW=ME56SMFL1PT=ME5&[MHX3,!DW#5RB8B[9=,P )3D,4Q1#B
MX!F2Y.?OM>:WEK7BZQL^2<\R&I6PHME82\RB@;&@V!.@01JVQEB.9!X9!(@
M1K,E?HB = BC<!Z85<$_:#;MY2N=OEZYU*6:W:1N24@_CDD!ME#FR)Q-_I#I
M?P$;V2NG6553;J'X@B];'<Q[G@/4KG$# &)IKJ27:9 & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@$$[0^'67R43\[<Y>/0$:CXA\X?2R2"[2.^#
MV/\ (VW\23,9):7S;;FO^A8ZDWZK.(&1KI4MQH6FF3$,LHXGW%2Y=MO[@K+F
M/L[:4;K5\&L[J])LY)Y([!PU>J<.K.0AL$I:^!4NE=B[#=2.YJ3LY["W2Q:D
MEZKU5DHU5>UDMCC+C082YI,4ZBZL-G40DXE\^<M4S$?'!TW! 3$(J"AC@T2=
MWFI_H'LWZG.NT8 [S4_T#V;]3G7:, =YJ?Z![-^ISKM& .\U/] ]F_4YUVC
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M=-5DG+9RDFNW<(*$60706("B2R*J8F35253,!BF*(@8!XAX,$'+@# & , 8
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M*/2_@RB"F*R>GS5U+1CKXOH9."E*0I2$*4A"% I"% "E*4H<"E*4. %*4 X
M >+-<R']8 P!@# & , 8!U'[!C*L7L9)LFDE&R31PPD(]^W1>,7[%XB=N[9/
M6C@BC=TT=-U#$43.4Q#D,)3 ("(8!I9??"?=8I\J<TOS$Z$AUS<NMLF"(6BJ
MM"J+]RUIEG'1:(M_WZ@:XL+Q7JV)S"/O6[,5H8>J4:YEC+7P?4@P0Y<%UW)1
MS87#DOYB*1O"KF=NXN-<A"[$J[982)W37,JN@6RP"J8\43ODD4BO(\YP$$9%
MLB?][T@&&M5H#Z+M%NU8V52ZIL*E2S:=J-VKT1::U,-# =O)0DXQ0D8YVG^$
M@JM7!1,0>!B&XE, " AF DJO & 8'N:_[^G17+IN6Q:;I>J+;N][1)=Q7;Y:
M8BS0U2KD98H]84)B#KRLA'S#FSO(1P4R#E02,VH.DSIIK*=$3!=0;6H,J'*A
MS4:JYQ],0.[=1/)!2O2KI[$2L--MDV5BJ=GBA2"7K-A9H+NFZ,DQ\H34 R2J
MJ"[=9)9(YDU"CE6M'H"JG?,!JQE2-F[%<3[@E2T_8[14[_(A"S)U(><IKENT
ML+5%B1B+Z3(R7<D %&J:R:H#Q(8P .03HR9\$'CQM@@YA]/QD5+1\C(U64;P
MME9,W:+AU R[N%B;&VC99!,YE&+UQ 3S)Z1-0"F,V=)* '1.41 H_:>UJCIZ
MM(VBWC/KMWTQ'5R%AJG5K%=K79+%+F5".@ZY5:I&RT[,R+A-NJJ8J*!BHMT5
M5E3$124.42EJ>CK?8M/VU2*]L2A2IIFJ6=HJZBWJK"1B793-7;B.D(^3AYAH
MPF(69B)1FNT>LG:"#MF[04163(H0Q0$-:>#*WP!@# +:-6<V6IMQ6+9$)34-
MCIQ&JY&[Q-FV1:=3[$I>GG<CKBVR='O#6J[:M5<B:#<#UJRPCU!R,:_<E(5H
MLIQ%-,QP$M-% 2_W@?+/"U?3=T=V*WGK.\:@ALFHRC;6UZ6+$:J=S-;KS/;%
M^;>\17M!UR\F;E$))2<HFW24+(I+ '4$752$[7T+E=;;1IFVX25LM"D5YFOQ
M-QN5&-,FCI!C'24[0;'(5&TF@G3YNW3G8=A98AVS(_:BJS<*ME.I44*7I"(:
MTZD@X(& , 8 P!@$$[0^'67R43\[<Y>/0$:CXA\X?2R2"[2.^#V/\C;?Q),Q
MDEGG.#R]7??D?5F=1<5\4HJ"V9!NVLS>+SKA=A)WVOQ]?B+@C8=?14I+VJ)K
M+1-\G(4U^",#:$'X$?J #5$!%D]"[9O$<*^V@GSI1821+>+=O(P5J\JL9-H1
MLLY8A#N&ZT**@E$R96RI!0X@!#!P <%2EN[*N?&-^_:GLW];L$ZCNRKGQC?O
MVI[-_6[ U'=E7/C&_?M3V;^MV!J.[*N?&-^_:GLW];L#4=V5<^,;]^U/9OZW
M8&I^&UG70*80D;]Q IN'_P#:>S?'P'P_];OP9$O"+?R$Q\9)?*:?TISA\V"$
MI*H)<Q^Y2)(2DB@B0+U-"!$D7JZ21 $S@1$"$( >$>.=(V9Y[^<T,RZ$.YN7
M4(W322NZ)2:7H.^/#^'WR.GATSGVIPKG*FMM^XZMP3;^EZ6='_VR.;/_ -Y'
M<WUZF?R^:W^?'G1_B?E_Y[_TFQ_T]^1G^%.%_F/_ %&93[IZ];%WY';R6W!L
M_:-Y5J\C048 \EL>Z-!C$I9I:%9$J(1$W' ?RH[%$3=9T^'0#AP\/'[H^#7O
MOO+O;%[AEW=R>7R,L:W#53OGO]VIQR'/;X+3=MCK_P#RCX"^-[R_['[$RNVX
M]E\5A<9')JS7<L>&SWCA+'4'/Q>NU2EIZM69?.[*N?&-^_:GLW];L^VSX0U'
M=E7/C&_?M3V;^MV!J.[*N?&-^_:GLW];L#4=V5<^,;]^U/9OZW8&H[LJY\8W
M[]J>S?UNP-1W95SXQOW[4]F_K=@:CNRKGQC?OVI[-_6[ U'=E7/C&_?M3V;^
MMV!J.[*N?&-^_:GLW];L#4=V5<^,;]^U/9OZW8&H[LJY\8W[]J>S?UNP-1W9
M5SXQOW[4]F_K=@:CNRKGQC?OVI[-_6[ U'=E7/C&_?M3V;^MV!J.[*N?&-^_
M:GLW];L#4=V5<^,;]^U/9OZW8&H[LJY\8W[]J>S?UNP-1W95SXQOW[4]F_K=
M@:CNRKGQC?OVI[-_6[ U'=E7/C&_?M3V;^MV!J.[*N?&-^_:GLW];L#4=V5<
M^,;]^U/9OZW8&H[LJY\8W[]J>S?UNP-1W95SXQOW[4]F_K=@:CNRKGQC?OVI
M[-_6[ U'=E7/C&_?M3V;^MV!J.[*N?&-^_:ILW];L#4D A 3(0A1,)2%*0!.
M<RAQ H  "8YQ,<YN >$1$1$?'@@B':O]"?UA_,\M$$0AXP\\/3RQ 'QCYX^G
M@$D:O^'7OR4?\[;9$NA).V4!9_SC[!/6=?M:>P7ZN3O3E1JY$A@!1*O1W5+2
MGB'I%!ZLHBW\PR9U S+5'66OH163\-#%?FP8R7M(:P6VQ?XZNG!4D(T+[[69
MTGQ**,,V4(!VZ:@ /0<R:QBMTQ\9>F8_]P.5G+:M?22EJS-0Q9-(UDTCH]NB
MS8L6R+-FT;D!-!LU;)E10013+X")I)$ H 'B ,U.IE.U@# & , 8 P!@# &
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M!^IDG6?_ *A/XSM3['/^OBF>3.P8ZX!@# & , 8 P!@# & , 8 P!@# & ,
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MAXP6922B2R8AX043 ?P9*>CU!\S 4G#<3-W9!3=MSG;NTQ#@*;I PHN$Q#\
MD6(8/^#,Y!Z<'/O:I.0=KC53H256FXBS1RZ8B4Z+^OR+:79JD,7PE,1RS*("
M'X0P#Z@51L+:W5.L6MEP\CL]>A;"TZ(\2^334:VDD. \1XAU3D/PCFN25#@&
MHYS)7B[;#W=LJ7V"Z?K34?=+)!MXM\HL*-;C869>1\?!QK14PD8-635N4.!
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M_P!M@_4R3K/_ -0G\9VI]CG_ %\4SR9V#'7 , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P"']J_T)_6'\SRT01"'C#SP]/+$ ?&/GCZ>
M21J_X=>_)1_SMMD2Z$DB[%8GD]?7J-3 3*2%.L[%,H>,QW<(^0* ?NB93*KJ
MB'T--EN @@B ^ 023 0\P0( "'_ .;QK$Q\ODLE [ZTK,KF B$=M6@N%CF$
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MU"NB=0U=BA,<?>1F F,/DWXQA_"(^$1\(^'-:7T7[&7C])>U&D]+E*68F"E
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MX7&Z5B2C]I'D:W;;98K' /SLM6VYZS,]AYB3>1SLS1X@FLD*B9N@J0IB\#
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MFE_5R+[-@:L=SNJ?LYI?U<B^S8&K)&(0B9")IE*1-,I2$(4  I"$ "E*4 \
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MM+8(IE$QU'=IGF$&B!2@ B/ [X!'P>(, ^GQ"Q32!AXF#CR DPAHUA%,DP
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MRM-0FXI-RBI:22\=/G)/P)&]^MM_9]1_VH2_^S#.5'$/ >_6V_L^H_[4)?\
MV88'@:-7WUBTPX^\:W,M/1S"*E#5C4(.&,9*K3;-(A=:5T$3)2+B*A%5C*)
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M98QK+P\BV,!DW+-VF!R=(/WR2Z1N)%4S<#I*E,0P 8H@&FTT]'U-E/5:E29
M& , 8 P!@# & , BO=NYM?\ +WJJ[[EVA-)0-(H4&YFYEX;HG<N.JX)LHF+;
M"8AGTU-/U$FC-N4>DNY6(0/'QR4M7H#YT/-5S'7/FSW[L7?=YZ3:3NTOTHB#
M!85VU2J$:3R*J5)D?P%,C"1"9"J'  \H=&67$.DJ;,R6BT(+>A$  1$> !X1
M$?   'C$1R0;MOW#G*>XT9RK.MSVN+,QOO,H^86Q!-TAU;V-U=#(N6VOF9BJ
MIE60";*]=S @ \#HOT.(<4PX8IO5Z>@DSE90# & , 8 P!@# & , 8 P!@#
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MS%*(&C%]ZC]YK/\ /1>T*30CRE=Y:-?RZKFH0;HJC*1V%8$ 5:AL2W,A$#(
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M3%?;KS44Y.WUI7D'!&\C&)NF:QVZQ!(<"G$2' 0'@(<,S0^B1H_48K/>&?\
MT>L/S%+=CRPT?J9E#^YGZ=:^\9T/,V1%Q789I';6!U+S[9Q#134SC5-P;MRN
M9*22:LD#+N%2ID YP$YS 4.(B 92?T1H_4;3OWH-\H]@Y--BQD#<JK.22TW0
M#(QT/8(F4?K%1N\&JL9)FQ=KN5"I)$,<PE*/1*41'P .?-?Q88>9G>1_)XV#
M3;?DN_#TA7"5DWIE5-Z1@G)Z)-O1>"\3Z=^#[,P\#SZXK)S[J:,98^;K.V<:
MX+7$N2UE-QBM6TEJ_%M)>)JP=4M[G<_]&7_)YU'_ ++]T?JOD_S3(_)G<G^U
M?:GZUXO\[QORHZI;W.Y_Z,O^3Q^R_='ZKY/\TR/R8_:OM3]:\7^=XWY4VZ>0
MK8=!AN3S0$9,7BH1,DSHB"3N.D[+#,'S54)*1$4G+1T]2<(*  _O3% <[FOA
M[QLC#\ENW<;+KG5D0P$I0G%QDG[R?@XR2:_VHZ/_ (D\G&S//7N;)P[*[L:?
M)2<9URC.$E[N'C&46XM?*FR[KO6U=]I-!^N%>_SCGN4](:,_0VKJ\? &R*$(
MCX  +A7O#_\ R.!HSYSW-K%RTCS5\S4A'1$Q(1[_ )@-PO&+]C$R+QD]9N=@
M3ZS9VS=MVRC=TU<(G Z:A#&(<H@("(#F=-:%=&6^_1^Q?HY8OF&7['C5#1FP
M5_9X)!E3>8?F#>W%RE463O2\ V:/+2;Z.M'3DEY;J';MG,QY$BX7*G^,)"&$
MP%\/#AE)M:$I,VV.];5WVDT'ZX5[_..8R=&.];5WVDT'ZX5[_..!HQWK:N^T
MF@_7"O?YQP-&.];5WVDT'ZXU[_..!HRO"'(H0JB9BG(<I3D.0P&(<A@ Q3%,
M41 Q3 /$!#P"&""(=J_T)_6'\SRT01"'C#SP]/+$ ?&/GCZ> 21J_P"'7OR4
M?\[;9$NA).V4 P"%=_Z+I_,-K>7UY;DA1!R'ET!.MTB*2-8L39-0(Z;CQ/P
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M+#9(;<.K9>"JB<&K8)2*LD+(M(XEF749U[IJ,UENN/,OT%&K8J0',J\24;E
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MAZKC^YCW?RC4AB^?VDW83M%1+5_*Q4(%80$$GM_V1,6@I!$/Q3GBJY7*IUG
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M3;URKE/WA!1$)L6AQL#1WC.0]Y:NM5&CZ)L$K7WEAAG!F(H*'*18Z8JH (%
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M=JS9IF$I0XB!.(_ARH*JP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MH!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g382677f_122b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_122b.jpg
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MQ #R  $  00" P$             !P8("0H$!0$#"P(! 0 " @(# 0
M       ! @,$!0D&" H'$   !@(  00)# L,!@<%"0$! @,$!08 !Q'1$A,(
M(3%A%%65%A<)<9&QDE.3M-05-=9705$B([-UU99WESDR)'3$1856=K:WUSA"
M<S2U-PI2LC,V6'@9H<%B)AB!\4-CTV2$)2<I$0 " 0," P((!PD.! 8#
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M7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX
MZ97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*
M^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W5
M3VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W
M-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7
M '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z
M97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^
MZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53
MVYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 '3*^ZJ>W-
MRX Z97W53VYN7 '3*^ZJ>W-RX Z97W53VYN7 *HK5JD81Z@!G"J\<=4A'314
MXJ$!,Y@*95'G"(I*I\>=V. &X<!R&JDE*#VQ]4?9R2#W-6R[UPBT:I&6<.#@
MFDD3]T<YOL=G@   =D1'L  <1[& 2:VU8^.D4SJ5;-UC  F22;*."DXA^Y%4
M5D.<8/L\ X9742>_S5*^&T_%YOCF-0'FJ5\-I^+S?',:@/-4KX;3\7F^.8U
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M!YJE?#:?B\WQS&H#S5*^&T_%YOCF-0'FJ5\-I^+S?',:@/-4KX;3\7F^.8U
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M-2A)<)1:E%M.IRUED6R*KAPJF@W03.LNNL<J2***11.JJJJ<2D333(41,81
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MC='"5%)2HU5.E&FZ@SDCC!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MS+;+,KEY4O:O5\*Y<5Q*G=V[=R-N[^(A",;@-![;VML'9+O7%H?I=]Z*A[;
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M^]:-FSNNZ8V/>Q,?)R+>+D_+0C<G&%VG%=Y%-*?'C\9,[ 6+(R9$3,VID4W
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MX6YR\>0(U'M#Z@^QDD%VD=\WL?X&V_ DS&2<S & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , A_:O\B?SA_$\
MM$$0AVP]4/9RQ 'MCZH^S@$D:O\ GU[^*C_"VV1+D23ME , 8 P"W#K!]:?4
MO5NABN[S,&=V)\W46@:/!]"\M,US1$A52M#*II1L9TO8.\='20#@(%$YP @W
MC"4N7(JY*/,P.;\Z_F]=W*O8J/EE=8T5<5$DZM3GKAO(/6AN<4"6&TD*VE9(
MRB8\#I(=Z-#=H4C=L=B-N,?*S%*;?F+'N <3#_I',)SF[9CG,/$QS#VS&,(\
M1$>R(YD*'G & 0UZ1/\ RN]2O](/6N^%:=S!+MO[AFAV3$!@N, \D,=)9!RB
M<Z+ELJ1=LY1.=%PV73$#)KMETQ*J@NF8.)3D$#%'L@. 9CNIKZ:[K5=65Q%5
MC94F[ZQNH6PHME:_>I54VP8%@3F$XU+8C@CJ2<"W1( )M)@'[<2@!$SM@'GA
M5P3Y<P;?/5,ZZ?5^ZZ5%&[:0N*4FNP*@2V4F8(G%7RCOERB)&5HKIUE5FQ%3
M%,"#Q R[!WS1%!=3FFX8FFN9)==D 8 P!@# & , 8 P!@# & , 8 P!@# &
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MB9E#*RLFS19H'38MCB0IC *A@YH=D<AP:56#)3E0, 8 P!@# & , 8 P!@#
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MU:MW>N3=0N$%%6:K66,>0M@KTXQ;R41,13]$S=['R+%T11NZ:N$3B4Q3%$!
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MJRD+4Z91Y^D_<&;II&3+]R02E[&/_P!Z^C/]BW7^DQ_XY7_^?G6W_P"0[/\
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M"]DIB&$H_;RO+F2=A@# & , 8 XAQX<>R/:#[(\.WZW' & , 8 P!@# & ,
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MF"/W/'CV> 98<BK,%>7!>'Z/55XAUZNJ0M'LR2#Y+?%$.T8J.BL4W:X2(\Q
M[PR+@K8IQ[9Q(?A]K(ER8/H1>4VT_JMB_P!8C/Z.Y@+<!Y3;3^JV+_6(R^CN
M!P*&V?8]F*:TV*FYUG&-FYZ);RK+EO[18R*0UZ1YZA40KQ!4,4O9 O$./VPS
MQ[J])]);I5T_Z;D^@F>2]&<.L=IIQ?UGB^GM_ :3[;AWNAP'B'0I<![7$.87
ML\/L9T!6^Q'S(^BV]\M+\)_">[+&,V'?0ZRUPC]'[23KE09V-L?;)CKN'-G0
M@CHKC3JT44"H*Q;\5BE3*4W/YQ>(GX<.QQSM ]Q=+_M[O+KQ^NOHM@ZHO?\
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MVINJ%5+L285V=%M6;.RWY$EK!O<6XD%Q%6I-\U546$@+*24DJ,R!8*C & ,
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MD]1SM D&% -!P>MYBMKPDI4:38D:8C?JI%RLLY/-O>]I8%G\J"1G)U4&K1!
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MJ*7?\;SCMV#C740BY4 .T4SE(!_Z09:/:1#I0T LS$# -XGT(;V^(>CLU4G
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ML=+;=JCS'UYK&21<1I'*/%K9KZW!-S&LTP4#F.&5: Y'CD0YQ>^.]TQ 0%0
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M5/A9^]4^"FHO1.O64G#S5EAHJ6C7K> :IN&<A&OWK=ZR=H*%$ITU2$.0P<!
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MBB E5:O6BB+ENH A^Z(8HY +UM<>D/ZT>O$F[-:Y,M@1;?@!6.PHLLTY$@<
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MRUV@K[JN;#8&SU8AW&5^/LDN-AM4<19 )5\^+'(F.BW B9N "*\*%Q>"!@'
ME6CE_%R3%E)NH5X]8/&C298I,5WL2Y<MU$4)-FA)M7T:LZ8*G!5,CA!9 QR
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M(:]AHRP=:VV5&5I\K*0X[.<IZDC[L[9]8V6K%8L\?=>-'<QM@FMK7YJPDE+
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M[(C5YL7\=KRL4C3#58KCO-2.92!FC6-!%=TLD"H57W#+-@H, 8 P!@# & ,
MA_:O\B?SA_$\M$$0AVP]4/9RQ 'MCZH^S@$D:O\ GU[^*C_"VV1+D23ME ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8!!.T/GUE^*B?"W.7CR!&H]H?4'V,D@NTCOF]C_ VWX$F8R2-=N:,T
MWORO(U/=.L:1M"O-G/?K.+NM=C9Y"/>B4"&>QAWR"J\:\,F'-%5N=-0Q/N1'
MAV,)M<@=MK/5&LM,55K1]2T&I:XJ#)51=O7:9 QU?B@=+ 0%WBK6-;H$</G
M)EZ1=3GK*<T.<8>&2VWS!(&0!@# & =9-0L-8XI_!6&)C9V$E6RC.3AYABVD
MHR1:+!P5:OF#Q)9JZ;J!VR'*8H_:S5SL'"W/$N;?N5FUD8%Z+C.W<C&<)Q?.
M,H23C)/PIIHV\#<,_:LVUN.V7KN/N%F:E;NVIRMW(27*4)Q:E&2\#33(UUMH
M+2>GG,B^U;JRC4-]+EZ.2?UJNQT:_=H<\%.]57R*(.N\P4*!@1 X) 8 $"\0
MSQ?ICV=]"]%7;M_I/:<#;\B\J3G8LPA.2K72Y):M->.FNFO&AY9U7[2O:!UU
M9M8_6&\[CN6-8=;<+]^=R$72FI0;TZJ<-=-5.%27<\R/"#JE(*%6G&=F5BH]
M2Q1\5(P3&<.T1-*M(68>14A*Q3=\)!<(Q\B^@V:RR13 111JD8P")"B ':X
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M0U5$EQ>4 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M1 >55D\-R/OX\F*(#RJLGAN1]_'DQ1 >55D\-R/OX\F*(#RJLGAN1]_'DQ1
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M]<.7 ' >YZX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 '
M>YZX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N
M. ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N . ]SUPY
M< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N . ]SUPY< <![GK
MARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N . ]SUPY< <![GKARX X#W
M/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N . ]SUPY< <![GKARX X#W/7#EP!P
M'N>N'+@#@/<]<.7 ' >YZX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@
M#@/<]<.7 ' >YZX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.
M7 ' >YZX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZ
MX<N . ]SUPY< <![GKARX X#W/7#EP!P'N>N'+@#@/<]<.7 ' >YZX<N 5%7
L(AO(/T#R$A',&"*I%'!G3]HBLL4A@-T"*)U@5$5>' 3" % ./;'@&0P?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g382677f_129.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_129.jpg
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MQ "_  $  00# 0$!            !P,%!@@$"0H" 0L! 0$! 0
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M.W:NN@KISJ%UD.NWC1T%NI542ZY!1I/"H@KT#%ZQ$XE#B4W$H\ XAA8G'"&
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MM+UG6T97Z5M;97,+KVC6B(T8LRJB<:8NN-8V9\WF5)49Z/C9T\<F*R[]O,(
M;Q/AQ)K9^W'%090E<W]>9+;<5NO<&FM)5.$KVM7KW<\E1+X+-I=]SO%*>NW#
M6VM*P@JVMCZ+)!H D10P*C,N(] PQ/CPV;T[/7N5YA]JQK#:UAVMJ^NQDO'W
M!Y+Q--CJG4-P+VMN[@M;:O<5N#CI5X6A:_44:VGMSR3!-^JP 5RO_A)%,EQC
M[;D89>(+_F _T_D_F(UM_*]USK_KX_)>(Z1LVA@,!@;6<BGZ9W*_\\]/_C1\
M)>'K)W/O*SZ[V=!,8NMR<MK+7% >[6YA9>*<5=.1AZM:)AW1=>%8,;"\:2$N
MT92T5-3,DG%<7QDHIN@F)C..H6QDDEGW>%.SW?9E:YC52S[FU--'(V35.K80
M*Q(:;?5]78VP(B4/U>P860CW^Y6A9">E(ULV.Q<QZ38A$G HKM%5UB3W]$DO
M7Q_DVTRL& P& P& P& P& P& P& P)'U+Y>PW^"D_P"37.3MPU.6F&VMPQZ>
MT][,=-<P]X<M-?-W5>YAY)[N1I.# O;9M_53*UQ>J-=@^7)KTO+5JB0FEI>R
MQ<2Q1BA=((NG$C)HOEF'-VD\3,2-)[EE*ORZ<S;+4.X$+ R)MM'6G+_MN^;$
M?W.-J-.NL%HNLV[9[[9<B[FY^V4'1.R]H3"SJ7<.9 D>+$C)PZ*FCTB#&;,I
M=Y6]C.]G[">S3PL4NM7M5%UZ%@KMGD;M5;LE0]HW"!2N]5N$NBA*66&L!4>D
M=RX!10'Z;E(5G() Y5)8WVPR8# 8# 8# 8$-PG+IR^UDEE3KFB].U]*Z1SZ(
MN"4)K*EQ25KB9-X>1DHNR)L81 DY'R,@J9==%T"J:RQA.<!,(CA<U\2O+CR]
M3J%5:S6B--2[:BQZT326\GK&DOD:?%.'S:3<1E62=0BI*_'KR3-%P=!H"*1U
MTB*"43E*(#-9!5-.:BH=BGK?1]6:YIELM*D@K9K/5*36J[8+$K+2AYR55G9F
M(C&<C+*2<VH9XX,X44%9T853])01-@S:D?"/$%_S ?Z?R?S$:V_E>ZYU_P!?
M'Y+Q'2-FT,!@,#:SD4_3.Y7_ )YZ?_&CX2\/:#9]9ZZNLS7+#<*-5;1.U!P5
MU6)>=A64D_A%R.V\@F+)=RD<P)I2+1)R1,_32(Y2(L4H*$*8,,RV<+>AI[5#
M6UQ-[;ZXIJ5U@FIF4/:BP+(9V.;F!^4 ;R!DQ6ZY%.4<D25,)ED4G"A$SE(<
MQ1&;C'I)&$,!@,!@,!@,!@,!@,!@,!@2/J7R]AO\%)_R:YR=N&IRVR2KT @_
M7E$(.'1DW15B.9%*,9)OW)')@.X(N[(@#A8JYP 3@8P@8>Z/'.;;DI146BU3
M8HQK!)DBU58I,TF;=-JDR< 0%V:;<B8(D:K F7II@ $-T0X@/# A*.;H-.92
M5:M4$6S9MH.I(-V[=,B*"""5^MZ:2***92II))$*!2E*  4 X!A?2?,(8# 8
M# 8# 8# 8# 8'4WO#Z./E>YUN9;;=VWQ7[9,6"F0FL:?!KUZ[SE7;)09Z\]G
M>I7:1*R23EQ\(RBYNM/Q-T#%+W +W;.UG"WB,*_L%?HZ_,G9G^UVY>_,N_9/
M"L3Z!KZ.DA> T'8R@\1^J/MV\=+]KZB1(7@'[6-^P^_[!SZ.?_R^V'_M=O?_
M (IEW[!_8.?1S_\ E]L/_:[>_P#Q3&_89GKCZ%OD,U5?J?LNG4:]-+719]C9
M:\Z>;1N<BU;RL<<5&JKABZDE&SM(IA[J9RB4WZN3?LF'89Z':-[1>_&;SOF-
MJ:P]#M&]HO?C-YWS&U-8>AVC>T7OQF\[[C:FL1=I2C5Z[ZHHMLL#==Q-3L"W
M?R2[=TNT15<J**E.=-L@<J2)1 H?4E  #&U+UF4H^AVC>T7OQF\[YC:FL/0[
M1O:+WXS>=\QM36'H=HWM%[\9O.^8VIK#T.T;VB]^,WG?,;4UAZ':-[1>_&;S
MOF-J:P]#M&]HO?C-YWS&U-8>AVC>T7OQF\[YC:FL19M"D5^K'UL6';KI!9=J
M56JRW7.EW'70TJWEU'J"76''J%5#-"<%"\#EX=P>Z.-J3K$I^AVC>T7OQF\[
MYC:FL/0[1O:+WXS>=\QM36'H=HWM%[\9O.^8VIK#T.T;VB]^,WG?,;4UAZ':
M-[1>_&;SOF-J:Q=836]5K\DA+1C1RF]; L5(ZCYRL0 72.BIQ34.)#<4SCZH
M=S)>UIB,\R*8$$-?TFYOYB*M_2!<,+Z3OA# 8# 8# 8# 8# 8# @C7ORU<PO
M\,U=_H,3"WB)WPA@,!@,!@,!@09RS_()JW^:K3]]7PMY3GA# 8# 8# 8$$[R
M]=TQ\^U%_B=@PL3MA# 8# 8# 8# @AK^DW-_,15OZ0+AA?2=\(8# 8# 8# 8
M# 8# 8$$:]^6KF%_AFKO]!B86\1.^$,!@,!@,!@,"#.6?Y!-6_S5:?OJ^%O*
M<\(8# 8# 8# @G>7KNF/GVHO\3L&%B=L(8# 8# 8# 8$$-?TFYOYB*M_2!<,
M+Z3OA# 8# 8# 8# 8# 8# ZQ]G<^O*CRC\QVY*AS!;41H%BM<7J^TP,<I5;I
M/B^@2UIW#"_!Q6*[--4 ^$HU=/JU3D4^HX]'HB C9UM\Q;PIQ'TR/T<\_+14
M#"<P02DU.R<="PT6TUKMD[N3EY9XA'1D<T(-&*4[I\^<II)@(@ G.'=#+IV1
MO&3<,*<O2"G[9+W1#@?4U_(;N?L# ^H.3 H/-U5R/:.G[ZL;3:LF+9=X\<JZ
MHO\ U;=JV2,LX74Z, 8W022()AX (\ Q@79MM[7CQLV>-["FJW=MT'3=4&$F
M *-W*1%T%  S(# "B1P'@( (<>[C6IF*_I6H7Y>)[ADO>>-:9AZ5J%^7B>X9
M+WGC6F8>E:A?EXGN&2]YXUIF'I6H7Y>)[ADO>>-:9B*-&7*N4_45!K%BDBQT
MY"U]NRDV(MW3@6SDBBICI"LU06;J< ,'=(<P?LXUJWM,I7]*U"_+Q/<,E[SQ
MK4S#TK4+\O$]PR7O/&M,P]*U"_+Q/<,E[SQK3,/2M0OR\3W#)>\\:TS#TK4+
M\O$]PR7O/&M,P]*U"_+Q/<,E[SQK3,/2M0OR\3W#)>\\:TS$3;6N-<LBFL30
MLB5Z%>VS4[++\&[I'LD)&MIA-Z]'M""76@@=TF'0)TE!Z7<*/ <:U9VB6?2M
M0OR\3W#)>\\:U,P]*U"_+Q/<,E[SQK3,/2M0OR\3W#)>\\:TS#TK4+\O$]PR
M7O/&M,P]*U"_+Q/<,E[SQK3,/2M0OR\3W#)>\\:TS#TK4+\O$]PR7O/&M,P]
M*U"_+Q/<,E[SQK3,1*A<:X3>LK<32)0KCG4T!6D9'J'0@>;97"RRCEEV<$.U
M *3%^BITQ("8]/@!A$! &M-IALDP?-9-DUD&2O7M'B*;ALL!3D!1%4H&(?H*
M%(<O2*/J" #D5R\!@,!@,!@,"!8_FCY=Y5O>WD=N.ANVFM&W;;H[1G6PMHAD
M,DO"D>I.!$$9=FK/-E(XBK(7*:DD46A1%S_>L+K5-YS3\NL>PH\F]W#1VK'8
MZCI.G.%Y=-,)/L$PA7)-1R0Q04A&\19'2<8]5?@U39R2A6BYDW!@3$8J0Z!L
MRB;2CIB5H-C9V1C7K-,4V<4:INVZL3:( Z))>$D&C]LT=M7S/M"9Q*=, .FJ
M10@F(<IA)9AG>!X@/^8"_P"("7YB-:?RO=LZ]."NJ+0'R^Z'^>[4?](=<S5X
MJ/Z;F<%87LCY.[[_ #+M/\AOLLY'7W$R#")I,3+2KUI&1453HV4E))^X2:,(
MV,CH!!Y(2#YVN8B#1DQ:('555.8I$TR"8P@ ".=')BM@W;J"JU&K7VQ['JD/
M2[PR8R5.LKJ0$8RRQDC#%L365B#H)++.HGQ>.#]9V! ;-67]_7.FD G N+G'
MM)Q#IJIIJI*)K)*ID5162.15)9)4H'25253$R:J2J9@,4Q1$IBB @/#"/O 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8&VGC?XBZFA;&2KV^Z.&\;7F3.KT2')-V:
M8?2SME%LV[%JX=QL:U0(X>%.Y>/G;./8MB*+N5T44SJ%YWETZ\(9D.<B 8P=
M6LR6F-WR5>L-ZBM6R,DR8ZM35INSI#:2FGGE#L<));5CK*]FH&Y)\':L*REX
M\S(>U-W+A$#&+&]4A*[^*RW76M)3&I-KPK^Y!=%ZM>7:6MWM%F(NAQC"1G9W
MC!;(E[M%0H*R[)FDN_A&@"^?-T3@0RQ.),>,M@<(8# 8# ZM'6L^8[95AO\
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MI$"Z26<).1BVZ!4.L*HH53J^D!S /2&LU=,(8# 8# 8# 8# 8# 8# 8# 8#
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MR]=TQ\^U%_B=@PL3MA# 8# 8# 8# @AK^DW-_,15OZ0+AA?2=\(8# 8# 8#
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M$>0-NDJR\OUJJUPFMG1\X=S'6FP1##65IA[=7M9M6S>3@(09:*0>V+H.GRP
MQ9]'FZRS'VB3ESY7=T:*FKC.,WVL&\I8*3'T]X_\:=DW)C=+3'2=MGT]Q2U;
ML,9&(:U*K.6 YS4*KO$($H2+LR;],46H +94Z\M^J-A:[?[ALNPC5",DMLWQ
MI>EJE2+/;[U!Q$X-;BX>R3:5POD/ V57QI>QQ%$H@K5.-@VK=%NT$Q>F826S
MTV?PA@,!@,!@,!@,#QO_ $W?+WOK<?/=(36I-*[3V?#Q&F=9Q$K*T&C6*UQ\
M;*B\M[X(U\[AF#M%J^%DY35ZHX@?JU"FX<! <Z=+)/*5U&_U'>=+_=*YCO\
M8[>O_!<WF?(]/7T3FE]P:ZY/HNM7_5FP:18R;.V,_4@;74IJ!F",7KN+,S>'
MCY)FW=%;.RIF%,_1Z)P*/ >YF;9EFRY=E'BA:_-J=^*W?>L)BGBA:_-J=^*W
M?>L&*>*%K\VIWXK=]ZP8IXH6OS:G?BMWWK!BGBA:_-J=^*W?>L&*_0J%L$0
M*U.\1[G@MWWK!BN!&0DS-,&DK#Q,C*Q;]('#*1CVBSMD[0,(@59LY0(=)9(1
M >!BB(=S&88KG>*%K\VIWXK=]ZP8IXH6OS:G?BMWWK!BGBA:_-J=^*W?>L&*
M>*%K\VIWXK=]ZP8IXH6OS:G?BMWWK!BGBA:_-J=^*W?>L&*>*%K\VIWXK=]Z
MP8K@O829C!9!)14@P&2?MXJ.!XT6;B^E'953-8YH"I"]H>N"HG$B9>)C 4>
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M$U:WUBR2E0D?@BUQL#/1<N_K4KTER#&SS1@Z<+Q#X%&JI.J7*F?II'+PXD,
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MJL"SQG_XC\GGA*Q^#/VW_DC^<ORC_C<"\V/P+.^2OKK?RC\"^HP\._??N?\
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M?);P27R8\&^OCX)_-/ZWWS"KK_U2?@OPHI_@O9JOK?YT_NOO_2PC%#^!I?R
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MB?' N37PE.^2WAF*]B^$O83+P[^>?:GWCJ\(O[/UD?8OK[KV'ZS[*6]7[_\
*=?OO2P.5@,#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g382677f_12a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_12a.jpg
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MQ #"  $  00# 0$             !P$&" D"! 4#"@$! 0 " @,!
M      $'" (& P4)!!    8! @,#"04#" L!     0(#! 4&!P ($1(3(3$4
MHM)38Y,D%18)06&!L2)Q4A=1D=$R8I(C-$*R<Y34)86UU5<8EA$  0,"!0(#
M P4-!@<!     0 " Q$$(1(%!@<Q"$%1$V$B%'&!D3)"H;%BDB,S0Y/3%587
M&'+2E+34E?#14K*#)%46_]H # ,!  (1 Q$ /P#]M5HMDA,OER(N54(Q)0Q&
MS9(YDRJ$(/*"Z_(("HHIW@ B(% > ?:(\P*(K4\0X].M[4_G:M HGB''IUO:
MG\[2@1/$./3K>U/YVE B>(<>G6]J?SM*!$\0X].M[4_G:4")XAQZ=;VI_.TH
M$3Q#CTZWM3^=I0(GB''IUO:G\[2@1/$./3K>U/YVE B>(<>G6]J?SM*!$\0X
M].M[4_G:4")XAQZ=;VI_.TH$3Q#CTZWM3^=I0(GB''IUO:G\[2@1/$./3K>U
M/YVE B>(<>G6]J?SM*!$\0X].M[4_G:4")XAQZ=;VI_.TH$3Q#CTZWM3^=I0
M(GB''IUO:G\[2@1=AO)R+0X*-7SM X#Q R:Z@?SAS"4P?M =$4HU2_*+N$HV
M>Z1A6,5-O(@0B7!0W81-V4H%3X''L!0H!P'^L'VAQ(\E5+W(3]TO]T/Z-<43
MD)^Z7^Z']&B+EHBQ UY%$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T19,T^3/*UZ/<JG$[@A#-7!A[3&5;'%+G,/VF4(4IA^\=<#U55
MS:B*@]WXA^8:(L0=>11-$4591SAB?"S%L_R=>(>K>.*<\;'N#+O9N4(F/*<\
M;!QJ+N5=HD-V"J5+I%-V"8!UT;>W)6Q..;9ESO34[>Q]4$QQNS/FD ZF.&,/
ME< <"X-R@X%P*[_L/BSD'DZZ?:;%TJYO_2($DC0UD$1/023R.9$PD8AI?G(Q
M#2%!]8W\[5+5)I1+;)8PKA=4J*#BU5V>KL8HJ8>4A32SQD,>U QA[#+J)%_E
M$-8UT7NEX-UN];80ZS\-,]U&NN8)H(R3T_*O9D;\KW-'M65-=[1N?] L7:A-
MH?Q4+&YG-M;B"XE '7\DQ_J.IY,:\^065LI/PL+ 2%JDY-HVKD7#N; ^F2J"
MY8HPC1H=^XDR*M <"Y:$9$%4#) ?G)VEX\0UG.^U73=-TJ77+V:-FCP6[IWS
M5S,$+&%[I 69LS0P%U6UJ.E5K]8:1JFJ:Q#H%C!(_6KBY;;QPD99#.]XC;$0
M_+E>7D-H[+0X.HL;@WO[3A !#-]6X"'$/<;/W#_T#6'_ .I3@K^)++\2Y_8+
M-A[6NX,&AVM?_K+7_4*O_P!O;3__ '=5O]QL_P#X'3^I3@K^)++\2Y_8*?TM
M=P7\+7_ZRU_U"O7'^Y? ^5+&G4,>9+@[595F+V23B(]K-I.#L8XA%'SD#OXI
MHW C<AP$0$_,/'L ==DVIS)QAOC5QH.T]9MK[6'1OD$3&3!V1@J]U7Q,;1HQ
M^M7R!76-W\'<L[!T5VX]Y:'=:?HC961F:1\!:'R$AC:1RO=5Q! ]VGF0I'NM
M\I>-X!S:;[9X:I5YJ8J:LI-O"-$#KG 13:M4_P!3A\]5 !Y$4"**FX=A1UV_
M<FZ-N[/TI^M[IO;>PTEAH9)GAH+CT:T?6>\^#&!SCX!=*VOM/<V]=79H&T;"
MYU'6)!410,+W!HZO><&QL'B][FL'B5BNU^H5M-=281G\19!MQ5!()-[3+6WA
M^T>4%#/!BS*)H?VS)%  [1X!K!\/=CP3/>_!?O>5F-/4?:7+8OES^F2![2T#
MS6?9^SKN$@L?COW+"^C:^DR]M'3?)D]4 N]@<3X!9>P%@@;7#1]BK$U%V* E
M40<1LS"OF\C&O41'@)V[ML=1(XD,'*8O$#$, E, " AK/NE:MI>NZ=%J^BW,
M%WI<[<T<T+VR1O'FUS20:=".H.! ."USU?1]6V_J4VC:[:SV>KV[LLD,S'1R
M,/DYC@"*]0>A&()&*]?7L%ZU-$31$T1-$31$T1-$31$T1-$31%?%;N[BNL#L
M$X])V0SE1R"AW!T3%%4J93$Y2I* ( *?'CV=^H15576TRHF90I7\0=)(1#BJ
MU<@L<@<>T>DJDCS\ _D,&IE12,C-1KJ+4EV[DJS%%%5=90@&$Z16Y.JL0Z7#
MJ%53(':40X_SAKBBQ6UY%%UWBKANS>+LVGQ!X@T=+LV KIM@?NTD%%&K(7*H
ME2; [7*5/J&$"DYN8>P->&XDEBMY);>/U;AL;BQE0W.X-):S,<&YG4;F.#:U
M. 7GMHX9KF.&YD]&V?(UKY,I=Z;"X!S\HQ=D:2[*,74H,2M7V!-H-@R==;UG
M+>57'$O=9.RNF=?Q_,O2.(%C',P(9)^LG&/%6LA MBJ@UBFA%?"@BB950IS'
M#AI7Q=P#JN\]R:GR9W#6;[C<<]XYD%C,\.@9&RA#R(WEKX6U$5M$'>EE8Y[P
MYSA3>[EON-T?8NV-*XK[:;UEMMB"Q:^XU"%A;.^1]:Q@RL#HYW4,MU*6^KG>
MV-CFM::Y2Y'V8;<\DUUW GQK6*=(*ME$8JTTN):UZ9A'8D$K9V7X<1!M)MT5
M! 5&[HBJ:I.)?TB(&#-F[^W7B+>&D2:6[1K+3[MS"(KFSB;!-"ZGNN_)AK9&
M@TS1R!S7"HP.(P+LON:YHV3K4>K-UR_U*S:\&6UO9GW$,[*^\P^H7.B<14-D
MB<US#0X@93BK]/J;G%V6>=JN2A2LL;C"0>1;9F^%1RR& D)*6K%GKI 4,)_@
M3EXU*N@CQX)$=J%+P 0 ,'=J6I:E+;;HX-WC2\LM%E?$UCZN9Z$DDMM<P"IK
MZ#GM#V,K[HE>!08#/W>#I>E17.TN?MD9K*^UV%DKGLHU_P 1''#=6MP:"GKM
M8XQO?3WC$QQJ:US##:)M> . 8(QSP#L#_DQ_^)UL'_(/A08#:^D?J3_>6MO]
M1?.YQ_\ UFM?KA_=72D]K&TZ$C)*:E\)XU81,-'O9:5?+1!BI,XV.;*O'SI0
MPN@ "(-D3&']FOSWO"'!.FV<VHZAMO1HK"WB?+*\Q8,CC:7O<?>Z-:"5^JQY
M\[@]4OH-+T[=&MS:C<S,BB8V8$ODD<&,:/=ZN<X#YUA5]/FB1M^RQE?<C$U2
M,I5,0>R5 Q9681@G&1S5I)*HNI%0R:0<7KAA!D:(K*J&.8[IVKV_H "ZW]J.
MV+/=.^]=Y@L;&'3=NLDDL=-MX6".-K9"'2$@?7='"(F/<XDF25^/N@#9_O"W
M9>[1X^V_PGJ&H3ZIN9\45_JMS/(99'/C!;& 3]1LDYE>QC0T"*)F'ODFV&-9
M5WY;N\@%NDC)#@[!*[B(C:^P=JM$Y(6\FXAFS5)9(P"U=6N3C73Q\Z)P<>#0
M(@F8H<IB^FM=%?W0<^ZL-Q33'C3;#G11P,>6B3+(Z)K01]5UU)'++-(WW_28
MV-KF^Z1[RZUUG:9VZ:.[;,,(Y4W8QLTEQ(P/,>:)LSG$'ZS;2*6*&")WY/UG
MNE>UWO [$)#:;MHDH$U;7PCC]&,,@+<BD?"IQTNW 2\H+MK S.E.)O"=X*BX
M,?F[1$>W6VMUP3PW>:6='EVWI3;++E!CA$<K<*9FSL(F#QUS9R:XFJTVL^X3
MG"RU8:W%NG6'7P?F(DF,D+L:Y76[P8"P]"STP*8"BP)P,WG=H6\E[MJ&:?RV
M)LLM/B]-))*=0[1^\8OGU?D.!0*@G*D7B7,2^.F4A7?*DJ8H"4H!JWQ?%J?
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MB/[1UJ;V9 ?O#>[OM?O>+_OO%N1WR$_NW83?L_N67#_QV2VLZWD7S_6JS<Z
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M1,81[  ..O.2UH+GD-8!4DX  8DD^  Q)\ OS!KG$,8"Z0D  "I).  'B2<
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M&IV)Y'2%AJU;GY"'/U(A]-P45+/(E3K).>>,=2#1PNP/XA$BG%(Q!YR%-W@
MA^G4- T'5[B&[U:QL[JZMS6)\T,4KXC4.K&Y[7%AS .JTC$ ]0%^73=Q;AT:
MVFL]'O[VTL[D4F9!/+$R492VDK8WM;(,KG-H\'W21T)5Q"(B(B(B(B/$1'M$
M1'O$1^T1U[8FN)ZKTP  H.BIHBZ<A'Q\LQ=1<LP8RL8^2%![&R;1N_CWB)N]
M%TR=IK-G"8_NG*(<=?GN[2TO[9]E?Q13V4K<KXY&->QX\G,<"UP]A!7Z;.\O
M-.NH[_3YI;>^B=F9)$]T<C'>;'L(<T^T$*%6NU[;@RDRS+7!N,4I(BO7(O\
M*L>HF14#<P*$9+$4CR"!NT."0 'V:QQ!PGP_;7HU&#;.BMO [,'?#,(!ZU#"
M#&/Q5D^?GCFJZL3IL^ZM==9%N4M^*D!(Z4+P1(?G>IS33312201330003(B@
M@BF1%!!%,H%31113*5-%),H<"E* %*'8 :R:QC(V-BC:UL30 UH  :!@  *
M #  "@\%BI[WRR.EE<YTKW$N<XDN<3B2XFI))Q))))ZKGKDN":(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(JAW_@/Y#HBIHBJ4ICF*4H")C"!2@'>)A'@ !]XB.B
M+'N'W5[?ISYE69Y'9MHBJ5ZS6Z0MDU 6ZN422J=*>$CKA9JA?;!7XRFWR"K$
M@J1%XYA'T@FFHH3@)@.03*KEE*\X=WNWQ* D;$]NDQ#H1-CH]3?P=@QOE"NW
ME.;R<X=,\:HHXZG*8POKYE?WC)9"'=MXY5H^<)'234%4AR%E4RE=BC;L]O\
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M0%18-U4*JE&H-Y)!.11$ 0;LDU%2ZOFLB:E@"12VU3FW_)5V=716R0]_AU[
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MPF]R/(Y,I=H:1T%.RECD&;)TD\9*QKM@O'H BKX?K-UI17,5?+7:32&U4O\
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-N;]?+W?IXZF/S*K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g382677f_12b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_12b.jpg
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MQ #%  $  @(# 0$!            !@<%" $#"00""@$! 0 " P$! 0
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MY;J%'J!DEE"#U_KZ&Z#]/LX16E5+\JJX2CI\4U/6,5-"2[")F*H80*1-V4H
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M^2C3.X276REU2Z?3_'/0E*$\AHE>@2<E8/B#)/6B;YS,KOG#^70=*MA18"W
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M8O6_IJ.3LB'.*2J91XE26B^7,5HNN4K/(.JL86O7W+Z%J=6L-\NJ=/M]S@]
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M>7OD5:,=N]>KU!@46\J?*D)N&T)&VZ_!P%>J\L^O]+NJD=_*2PQ*#B7=HR$
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='Q/I^CZ/P*_J_!=GL]?LZ]W=^]V]>GL[N0JK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g382677f_132.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_132.jpg
M_]C_X0"B17AI9@  24DJ  @    # #$! @ >    ,@   #(! @ :    4
M &F'!  !    :@        !!9&]B92!);D1E<VEG;B Q."XQ("A7:6YD;W=S
M*0 R,#(S+3 S+3 Q5# Y.C(Y.C R*S U.C,P  ,  ) '  0    P,C(P J $
M  $    * P   Z $  $   !,!        $P$     /_L !%$=6-K>0 !  0
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M\5FV4NIM&*AL:7<_0WC&_P"U9MFF"P1M$ U63Q9)M$:M&6=WH4HCU-%D S&
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M'47><@( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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MHK)!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
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M?H;C<K9Y6VMW::=6C\V[_'W>-N/;W4U9.!I=)B" !  @ 0 ( $ " !  @ 0
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M1_.+W/[2\A[>Y=]G?I953Z'ZA:'%F-R^9'Q $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " /YP4 6"_!-C_ $"56)N &"S9T4C)
MYC$(FP;7]EG9K,>%F-PNT]5F_P!4WJI&HA9LWJL<#: T\5%C1]!S*#"RT!87
M8+\HU &T;%C9HTQ>"&8AVL=ZW"U+)%8H9@-5<;CLV+)N2JF\1XJ&;T&X!A&E
MU5A;-FJR-@"5#<"&8"H>T6^*RLS58*-#<!RRS> QF(9@+EDV:U6)O$!@;UFV
M:&L&PJ]%#&IC 8B LVRGAD,1%FWYK)LM*%ZF\0]<"%BW(L3>(JZSN\(*@V@
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M?'L#R?MCFWVMVC5$WH?O$9"41*)>) (.U?9*:LI61]:M-.'F63 $ " !  @
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M</F['-VEN[-DTS\G\OA[W#W7M;U6K+J=%=AR@@ 0 ( $ " !  @ 0 ( $ "
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MD/&\GQV_;9WZM-,[B](\\$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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MA$*786+9?AU>"AVZ#2ZDB/V*'9A@BPCO2[@Q9/"$I'B69*0[09$AV@R)" 9
M)(&" A$L@<(AD!"(X0G)/8B>%*0[$5,0J5FLB77H4X057>R8;*F&!\52W.I+
M1!B1KW*JVD14@JI#T*F+ZU29#J9G+&'JJ[C)T90P"I69#4 0J5O0S=/4I*/@
M5HF86K!C*/@K3):P]3.4&9E2M)BZF1B-AQ6JNT9NNCR.MT;K//=#YS+YSDLZ
M>7/+F)CAD8D$%W#$5==7'Y.[QMU;VRVKIGD^3\5Q?)\>W'Y-4TUT/JI^EO\
M5OS'3,[D^D=;YT\#PA&69F,#8&J:'5>OT9]-OJEO<'=IQN3=PFEB?A[ZT?0J
MG(IN<[Q^WCB\%_P/M=V/WWTKN[IO+\SRG,Y69+,A$_<D"[Q%@<WK]L^W?<O$
M\UQJWV[)W:1_/#W'[:YW@N7?9Y%&DF\_0_05\J/C ( $ " !  @ 0 ( $ "
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M:56!L S!0P>)M&+%GMU+&UI#(UB&638+'$9A%OBLFY-*^HQ$!@6K7U6;S+-
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M Q$4 U+)N%(#$(N1'5Z!<]GJ/X#H7.4LRXJD6,988;;/$K*S)]3<!9MD9C$
M0&W^2S;DT28S$>*R;*S-8C4Q/R?S65[:"-@+ L6+61F(;W639JL?@,1B  6J
MLV_N+-8@OHZAL3-HQL*S;#!8(V --JSL75.)-0+ L6Y<C9J R@AN2P"39+>B
MS-1$E0V&69N LVQI/,UC$,"17?BH;^XHT =3(-P6 :B39+9<1)^:F4A&P%@
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M]5#9#L7 P 2DALMPE3(I-.#9953W$=Q?@L+;J*>XGN+".[8DV)V+MX8,D2"
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M7MIL2[AAP#7IN1W,"1 :S=I1+N%D B!KVLB6P)88#P1+&2PTL\+$@!J6!D2
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M;0S$.VOX+)LT&8165F5+S&H#X?-8V9:R&8#S^*QMG.@QF,:-A@N>SQD?H.0
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M,0;U^UO;WN+B>:XM;[=D[M+4_GY[@]N\SPG*ML[]6DF_SGGB^39XGQL$P!
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MU#,UB'.KY+%O[Q^AO&+[/-9M@L,!B,6VXK)N1-C$(?'P63L96L;@,LVS)LU
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M67H-9>@\%SVR^TJHYE!SA[AQ1<]QZC(63-*C.6'N:S=:LK"&0+ LF2HD:@*
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M"IAO1H-6*2CJ9$%*Q3A/S4O KN((*6#')#*'2<AR0H::&5(="8TX*\)3E#E
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MF:U@8R_>V[0+.QHAW+%:U8+"S+6<C<!8N>V/P*6<C4;=RYK=1V'@L+.32AM
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ME5KJT\%SWZ&]<QV%FF*PL:4260S !AK]5E8T0[EVE<]BZCD+1<N>SP951O+
M)J+O%<[!C8N6#-ED,Y08Z8K*^(GBF-1#D+%X(FJEC>6+:8;UC9EK :@]%SV;
M3]!O(8RP#:L+. KBQV-U-WLN=FJ-XW;EFQ:C4 L;."U*R-XC3V6#Q&\L3:(\
M5F_R&;&8AR-:R9-5@,1"R;+7J,1'R6;9+8S&P;%D\Q&D0<"H;1+&8BS4 N>S
MQ8#,(ZKZ+&S!MYC>7'RL^"QLS.[&8CR639E9C$8MM^5BR;^XDV8"Q9MD9EHA
MR/7>LFQ-F\8K-LR;-@%#9DV: .5!#-8Q^U.2+6-HQLT='KJ9-C$8#1Z*HU9F
MVVX-HQ=5#?P%@OB:"+*U4EMEQ%/X$MFHCN"&B&RX "23(;DNUBI*<Q26C&]#
MC(EV-!#Q.E5$$.Q80N8F]2X7Q%W&@AJT\E#9'<6$-3*6)V)X0H:D7<PX0I:>
MN02P4O!"+,<#X("2&\TP!M6]$H)!FTW(E 0P*<CD.$(EA+(X="FFQ]Q0QU>"
MJ8&K$<.HHG$?<084+NFGCZ#5L2ICBJ]4-,KPA&)4LCAUIR'<0Q32D<D&&H^:
M>0U8H01KW(*3*IC! $,$Y8Y(X=:)')!#:TY0TR$#(8)R$LCA3D<E>&F]DL&.
M2IB]H\DY:6#'**F -E$I8RG"7:NUDYP$!!!9B=R32>)2<%<4FHR!0R#%Z)2.
M,2G!K0_0.X.!2TI#N*&&KPTHH:@I6*&(4P4K%&9)(J9#AU+6EG. 2'#\5UUL
MP[B>#738MZOH0R>&[3<MJVC,PM5$$'3VQ7H;-T<MZR0Q]MZZN]?D,NT^1^6
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MO-$&+8Q&-Y5I,R;T-HQ?8]5:KU%*2P-1%G962:1C9Z(_,2V;".+%/%Y&;9<
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MK1@.408XBB48X#3Z%#%/$J2.$I2.40Q1(2@8X%& Y(4P]!D(QS"01BL0!DI
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M1IPE3!,HMP:B?%)R3W%N$T4P*43PE$"[B.$ZD#[D3PTUI?F%/W!PB_W4-.<
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M!M&-FEREF;9<![$8(@L(_8E(I+,, EF3)+*8'F2R36&&8TL<2&2AC21+)/#
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M% T4X2JDJ401<@$9D,52+1"(0P2Q7P $YZ@"(3 &"("2IC@ED4GU*D%Z.G.
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MDS,=3*DRTRC%45(( J0^U/(:<%>$IR5*(X=6W2Y.1R4X:IR5)!HF,$("$>H
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M;?ZL'0A:RY;9&BSQ'<OPTL6%CJI^KZ'1RZLPM8LN:V!T4^X:A.,36407%#(
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MJ!1;(I,SD /%9ZP6G)1#4E$+-H94Q>RU0RDRA#*<RD9F."BQ2?4H0H:DLA3
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M>5_U)V_^ZE7^O>57_N4_L['RR'X'Q/\ 3O\ WM_YIH.[NX0Q_EO*4_YC[?\
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M"B0,5H ( @AR-[II]03*$&UDRI*$5VU53@7.!5,8( $ " !  @ 0 ( $ "
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M7RC:':/4:?Y2[2_IMVE^^4?Z/R(QW>'^*X_S3.WG>)_2YWX3E?*&\OM'J/\
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MA)K4 4C! &9H5:92R(3[1@R0%"WR5(I%4QD$.&0GC(&9B;J^2J0*J@!  D!
M%NM5(206LH-R%BQJ09]6I.<0F  >GGBD\P)  UHQ8I)9( 0 ( TC&PZ6J&]
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MODLF)Y#$ Y=<UAK%#>6'W+&PWA@/9=FY<UCFN-0#MIL65C%YC0%-JPL2\S6
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M+>#3-,>R_P (\/!<MLS:OZJ',L-$:Z^*QMF(=R7$AI>%SWR'7,Z$;=X7)?\
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M@2&9&T[4FRUD9RQ6;>FI=2BCXE$*!@FDP*.3:M8C(I*"$QF9#*BDY(2>0P4
M"!D&M/L374%U*'6J66!2!7($*!E#0G6FBD53&" *R) %CZ7,J23 R5@"0 @
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MD52*2*H&"8%)W;_953%@9I@"8%"0523*2@J39M9,:*DVA"126I54,$2 ( $
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M!N"X=)= +QM5"L:"Y!!HI()L0!<2Q1)+70N):Z)-HB"W$'2D7:R74SUR$"0
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M"I-=GFJ_.-+ H3[T32DHH^LJBX(1  @""0$0."CJBH(0!0R?4J@M(JF,$ "
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M(6[5R[ALLI'(6:_=<]C6@_E <+M:UVC+FOF4QP6#8N6V8&L+-ZSL$XP=++B
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M1%P5$1\"6C4%]J4&;4%XR;8I:^\"XD"6JE$ :"6*B!-="[A(D$ " !  @ 0
M( $ 0XQ",0A@X1 0RIE@G!274A,9"8$&3:W0E(&1+E6E $)@",\@()\?@G T
MBB914G#34J2E#2*)E0" ! $.$0.&4)=45!4EL4T-(J35PG!48$>28P0!" !
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MV]+M LX-Z4, <"VB(&2D(@^ENJ], X@: HA@1Q %O-.-0*B5H-1K3@"B8 F
M( @R"(8X94G1U4#2*<0VIP5!!DG TBJ8P0 ( JY-@\TX'$9E22G!4$/Y)C@H
M3@FD4D0F,$ 0@ 0 ( @D6.R<#290[73*!, 0!7B3@J"B8P2D9CGY^3RV5F9_
M,9L,G)RH2S,W-S)"$(0B'E*4BP  3K6^Y95HF[/!):R52EMRZVZ)N[>"1\^/
MKY^IG,Y^?.]F?3_FI9?*@SY;JO<&46EFD$PS.7Z?($?=M$LRP75J/T'[ ^F-
M=E4\U[BI.Y"MM[+TU5MSUZ5^\Z-S?IP%V;#5N9D[9JG55ZVZVTT/2($R,IR)
ME.<C*<B292E(F4I2)))D2:DU7WD\%"P2/,K+Q>8P,P;--2F#2?3 U&8"!A?M
M4P$J,0.: &?=9;XX(C4)48$?G/1W J "6]6-J.V,1.Q4Y], :W_!':Y)[C*6
M?K;91_-U2HR78R.>,2^\_!5V:,AW*_RC;C?;\4=B%W_G/8$Y36AR+#71EW;]
M$TS\U\;<B"ARP:@$@@V8[QBO%WJ-'O<?=ZFL86C5;4^M%YNZH9[>QN06_+JX
MV[%P[M91Z^SN+7,:RPS4^>\ZEYVXLSU=B^IT,L4%*C5M9<&XH<K(];:O,-#^
M3$ 6,;?1<]VV>ELWU.CE@L[65\/BN:V9Z6VT\LSI9=0-+URVP9UU>,CF4]UM
MJPN=.T\9T.CENP)P%;URWAX'71X2-PJVI<]\#IJTT.Y=F]<ULS>H]&[W7.SI
MI@.0%GDN2V#.A.<=1N L;4L+'11J/B-1LKNWVK"^0T;PHVU86$\SI0JVE5RV
MP-4,QN63)U&LL'3!<U\ROAF/98]ES6(L,Q%ZQ9BV-P:[!UBR7D7%HVK)DZ#$
M=-:R9E88BUPP63,+&L;0M5A7 AY#67[>5$]<#GL,QN29EJ;1OW)8_8#-HW[D
M\L&18V%@63S,B52R$;![E+,WZC$; RS>9D\S8/?:@S<&L;E#C&#.QJ'<-:I,
MV;1(>H#:PI<D&R0%@:[4,3- 64,AJ2ZDDE C2-@TO3(>9H#C\TF2T62) 42
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MA$PL1D)2P/"^^N_>W/IYT'FNO]Q\_D\IRG+P)A"4A^=S.;_ R<C+?CS,R<J
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M+4 64@2"R :DT4D$@LDT)J2ZDDE  @ 0 /Y($6$K73$UT+<0Q]4"AD@N@3!
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MO>V%:K_CT1\4_P!1'ZENO_6+J?,=+Z7G9_3>RN6SI1Y?E(REEYO5!&30S^;
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M.SV(B!!_NQB?Q2+"(7SSV3[$\E[OYJKM)[?CZM=^X\DNBZL7,Y7"\/Q/^_\
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MHI[ON L(@8HEL"R0 D ( $ 5DQH7N]U2G,!?/YC)Y?*GG9^9'*R<J)E.<R
M ":FQ:5J[VBJF[*V]N^[9;>VINSYW?J:_5CD=!AS?9W8G,0YCJ\XSR>;Y[*F
M)Y/("3P,I2B6EGAGC'Q7W]]./I9;FNGF//U=>*L:;;SMJF_0\;S_ +EX_@*/
MB<%UW/,66-L'7:_XV/E=S?-<[U?GN9ZCU'FL[F^=YO,EG<QS.?.69F9N9,N9
M&4J_ +],[>WM<?:KL[-57:JH2622/J+<W-WD;MM_?L[[UW+L\6V3EY!-@?WU
M[$6LD/ ?R^7 M&HB[;2KK)W8NYZ#,,D#%SX>BAV%BW@:QA7>I=BDG#D8AERK
M2]O50\0=<)9J,FQZ2.^E6WHC[A81@;C*8"]KQ;O3CJ)MQZ&T<A[MM->*,LR'
M&N1O')O-&8>5G@B2.]+(WCDZG\?1*60[O(WCDO8*MYW^"669E:S8S#EI28-J
M=K]5E$O@1W?>.Y?(Q%20=+"B6R6XSS'<OEA&R) V4&%$9F;8P.6):A\$TB79
M#D.3)-1<&-?%$I&;L^AT,OD&^]PGBP I=L=+N>1#MJWB=+*Y$T^ZQQ(??XI0
MY,K;M5D=')Y")(^Z3N887%TU5Z&%MYO(ZF3TZ19@=C59[%:HLV86W,<SK9'2
MJDRCZT?4K2Z&%MZJP.OD=+%&#@'"P8/:RI+[S"VZWAH=KE^F6-!\7!T*%5LP
MONJ)D[/+]+- ($C82][^*M4EG-?D)3!V^7Z02&X;2XI81CL*U6WZ'+N<C[$=
M_ENADM]REEENH+5;;U.3<Y*T/).4Z"2WW&U-MMUE:+;9QWY*B6\#M?\ 5V7]
MJ/X.+\"O^6OR'/\ ]TNNO4_VUK]A'\[ 0 ( $".-UKIN5U'D\W*G")XHD6/4
M@LV"YN3LK>VVF;;&X]FZM4^;/Z@OIDXYKFLGEOO0X^(B-N!&UE]5^X?&1-DC
M[D]G^<[;5I9X'S#[JZ)F<ES6;&4&'%(,;JEWWKZNYFQV6:/T5X;G5WMM8GY9
MS_*<!E%J5(MLJOC^_3T/G'#W9JCQ?FN7M( >K6[]J\3?IF?(^-NRH9Q\W))!
MI5_+XKP^12'/H>[Q]QRA#,RR]C$5UWOO7D;],#Y#Q]R89CP/;LLP%R\+DUC(
M]SCWU*&%S5'F7PP7A<FFJ/=X]^IF(D4(T=>5N+$]/;LLBW#85P[BAGH[%X18
M1=@WV%>;OTE2CT=JYJ!8 -3[A>O.MD=U+8&P%&TL7)N),[-JWZ)H(U%"Q]5Y
M6ZCOH\/48B+ QHWP*XF=%7AB,1!=PN:QHAB%JRL,V \[/%8VS-$\#1F69)*
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MZ=KBVOA5-L\/F>;X^PIO9(_6/_R^=Q?WCF?\4_._L1\+/-=W^F;_ .R?'_\
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MK:X6WMK)'FVO:_ZS<G4 A"D8@#4WP78J5JL$2D6XM7G\E0^TH@H$ " !  @
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M-\SP;;.X\#]4^T_,UY.S7'-(]<N?Y4N:,0[XVVKX?R*8-'VKP]V4CQ;/Y?\
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MJ1#)5"+C:2D0S0.UR'&I#@LLQ @"5:Q0B0[H:E8@S1206!NLP2:):+N;RD+
MM$VNGF2S0%M*),AXEQ=K2))2$" +#%VKXI,3+I$EP&4MDMR62$7BS4Q3(99
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M&7DY5(0B!_4@47;7:I58)&:3U+F6'LM!I%27M0/($#!  @ 0 ( $ " !  @
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ME VFQ:I)9#[2I)-J8X@$#!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0!P.O\ 2LKJ?)9N5. D3$\+@6L;=JXN9QER-IJ%,'5Q.1;C[JNI/F#^
MH3Z7F$N9Y[(Y=C'B,N&)J;2!8SNOI7W3X>&[U1^AO87N7MM7:O8^;W7.E9G*
M<UFY4HR'WI7,Q!LJS,OI_F;+V[-:'ZA\3S*\C9K=/$\/YC)DYI4!B!CJ-Z^/
M\G;P/F''O,0<?/R6+L&(KJ/O1>#OT/>XV[#AG+S,MB=?P:[6O%Y&W]Y[6Q>'
MZ,4E"ROEM^*\3D;>:/8V-S%08RA=\=R\/>I#Q/9V+MJ-# Q H;34;,/)>=N5
M;9Z-+1CH #AKZ:.O)WJ1)Z.S=1)!!.IM5<=J\^RAM,]*ELF:"@%7=\:KCWJ2
ML#LVW@6%%YF[6/@=5&7:CBSW7%?,Z:O# "'I8%B\,3H3+ ;%C;/T+61<,L-R
MNN@F3Y+"R>@%XQ:NFWP4=W^$#1:)8$O,O%G5K* >1<()+"_6I9++IIDD@&Y,
M3C4T4D @ 0!>(+NR"6T: >=[((;+C5Z)$EQ:[W*?0EY07V'3%(DL#KQ)\D/$
MEHNFA @0( EDI6026 4MS\"6S0$6,E!#6I;T2$7CBZ))?0L2++$Q1J&L'9[^
M*!?$LQ9T3H!;@Q.FU3W= (^Z+WJ+OBGB!+R-@8:7HA(#QON+N7IO;W)YO,\Y
MS&5 P@9'CD S VO(+U/%>)YGE^2N-PZ.UV]%@OB:=NWM[;W^194V%J\)/G/]
M8OKIU+NKF.9Z/V]S$LGD1*65G\[&0 G&L90Y<@ER6J;E^I/9'TZX7@MJO,Y]
M5?FM3#67Q/K/W)[PW.9/ \6W3BK!V6;^!ZS9?) SXIDYDI$RD2\C*1J296F1
M*^U)<88(^!),ZF3RAH!%F8 ,1LLHH:9:RQ>!T<OD9&IA>/#&MH1 .Z.EE<@0
MQ:_!JW[V1"R,K;L'1R^1+AHWV$6^R$L#&V[#@Z>3TZ5\6?\ 9=_$V)QT,+;R
MDZ63R#?P2^L5\2RKM.:W(S.EE=/D787/9>-RM5ZG)?>;R.GD]-):A/B2-6Q6
MJX'-?=U;.OR_2R:GR#E:K;9SVWE7I!V,CI51'@MO,7/RJM5MK-9G)?DI9L[?
M+](/[-]*>UX6BIU.._)PP.WRW13*G#2EQ\UM7;>B./<W^K/(N4Z%,R &633]
MD@5\UM79U9PWY26&AY;R/:V;+A_BV-+B[4>ZU;5VSBW.9&*>!^@]&[#YSFYQ
MCD<GF3<"S+D;:8+HKL-Y8L\KD>4V]O\ S+)?<?O7:/T Z]UB64!R.:!,BOY4
MW#EZ%EZ7'\;R-YPJN#XGY'W=PN-5_I)M'N)V!^D7/S1D9G.\LX^[(@P/%K#&
M@=?).%[8WMUIW6!]<>7^H:JFMJWW'NIV1^F;H_2XY,I\CE<4.$@RRXD/>7((
M=E\RX/M?:I#LL3ZT\E[SY?*;5;.#V4Z#],^C]*RX"/+908#^"+0*&RFY?*>-
MXC:VL%4^)<CR/)Y#??9GZ#RW2^2Y2,1#*@&L/",!J7J[?&I1'$W:V8^\8@"(
MIX>RZ$DLA)=2#(G5O3*2(0,$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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MQ$9< !$ -@%U5I19(F&!D3\E94(A  @8( $ " !  @ 0 ( $ " !  @ 0 (
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M6YR-[=?Z=FV>2PR,G( C#+ %S 47=7:I7)&4-_$TXL &6F60^TJ@8(&" !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M\>E#E<O,9X@U*;@MDDLD-+J5))M3&"!@@ 0 ( $ " !  @ 0 ( $ " !  @
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M6."J"@0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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ME X! P0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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M/$&84PL6R260XZD.2F.$0@8( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @#F=0Z=D\[E2R\R(D"]KT)OW+FY''V^11TNCIX
M_)W-C<5Z/(]4?JO]'.2ZYRW,$<K F<9D$0MHV!J OJSW1[2V^52T54GW/[)]
M^<CQN]1.[236I\L?J?\ 1OJG;7-\QG<KRT_R1*4B!"3,Y/[-&9?FCW)[3Y'
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MG%!0( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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MQLVSJQCEPI&(#4H %UUVZ5R1/:3Q'4KRR'VE4% @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " ! &.9DPS(D$"KW"JFU:W46R*K>U7*S/ NXNS>1ZIE9D9Y,7E
M$T,15PUI*^/^2\)L<NC_ $4Y/DOB?<')X.XG6S7VGI]]2?H!R'4HY\\KE(QS
M3QD$1!+G @,5].^X_8.UR%:U:)/X'W_[.^JW*X-JUON/M75L]$N^/H-U3I&;
MG3R.7G.,3(@Q@00!97A#KZ*\W['Y?%M9TJW4_4OMCZI\#R%*UW;I7PU/P#J7
M:75.GSE#,R,P<+TE @E?77,\3O[#:O5GV[P?.\/ET5J63D\=GR6?E$_F94XM
M_4TWT++PM_C6KA![NSR:7QK9&1RK:-M"\V^TZYH[:;RL4_+;4*[?@N:VU5YG
M0KIY!P@VBFMO9<FYL)Y&JO&N(< =R/#36N*^P\X-EN:(!E W'4;&ONHN:^PV
M:+=T-!D$X^#OZ+"VR]$-;N)K'E9%F'E7S=EF]BW0I[Z6J&8\E(M]T[/E@L_^
MUM;%(A\FJU.ERO0^=YJ0AR_+9V:20!P99OULS+JV?"\SEVC9VK6?PP^\X]_R
MG%XZ[MZ]:KU9^B]!^D/<O5YP$>5S,J$FMRY2E7< %\K\;]./*<ZR_FKMJ]$I
M?WGPWR_U'\#XNK=MQ6LO5)'L;V=^EWF>:EE9G/Y.9,EB>.,B&=S1@+-:^W?;
MOT83=;7VNZW6REGT?[H__('C<96V^)9+X'MOV;^FOIO(C*X^2A]UB28"IH:?
M=;U7WQX#Z2<?957N4_(C\T>Z?KMY'G.U=O=</HSV1Z#]*>C]-C!^6RAPM<'N
MU"G@OMSQ7LK@<*J[:5E>B/HSR_OCR_D[MVO:'U9^C\GT+I_)1 R\B 9K0&IN
M7R_8\=L;"BB2^P^([O(W]]]V[:UG\3K1CEY?X81#8 +N6W2N2,88<1V:;%8X
MZD(*!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( K*(D&(=(#F\
MUTW)YB$HSA&0-W"/@N?>XVUO*+(ZMGE[NS::MGYIW#]/.G]2C/BY?+(D"XD'
MMM;!?%O)>V]CDU<U3D^8>)]V<OA67;=X/U/6_N_Z =,Y[\V4.3@">*S+?>2'
MP7UGYCZ?<??3:IB?<GM[ZL<WANJMN.%\3UI[E_3?G94IRY;)(M+<!(M<6O@O
MJSRGTTO5M[29]V^$^L^W=);]D?B_5?H5UCEC)N4E(:H2VN" 15E\#YWL#F[;
M<4;1]G>.^J?C=^JG<29X9S/TFZQDT/)9HK5H2KA1E\:W_9W/I,[;/E?']_>-
MW?U=VIQ<WZ;=5@3_ '%G/_\ LSMMHO-O[7YRP>U8]6GO+@64K=K]Z,?_ )>=
M5=AR&>?_ $#;N"Y[>U^=;+;9NO>'!6>[4<ROIKUR=(\AF#68'7J4KVAY#<RV
MVE\2;^]_%[:FV]63N<I](>NYY']S\+TK$DX&E,5U;7L'R&Z\4E^4\SD?4?Q&
MRO\ ,G\AYSTKZ ]5YLP_,CF,2'$,N0MQ-/5>[P_I?O;S3NKOX(^+<_ZQ^-X]
M7V.L_$_9NV_TR2F<N6?R69.H?C@?4KYUXGZ1IM/^5CZXGUGYSZ]K;K:NSN)8
M:'L7VK^F_IW+#+EF<EECAX01^7Q67B@"^T?$?2C9I'\RB/I3W!]<N;R)5-UX
M^K/8+M_Z0])Z='+!Y;* BQ_"![;E]G>+]@^/XB7Z"G[#Z9\O]1O+>1;_ $[0
M_5GZAR/;73.1B!#(@PL8 ,VH, OFW%\-Q>,HK5+[#X/R?*<WEV;W;V<^K.[&
M&7EAH  "P!EZE-K;I^JC@<MXD\6IEH':023:@<)$(&" !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M2&7DY8 C&(;5\J+MKM;=,D<K[K8O%EC,LWOZ*P[2KG$ICA @8( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
D " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " ! '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g382677f_134.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_134.jpg
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MQ #"  $  00# 0$!            !P0%!@@!"0H# @L! 0 " P$! 0
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M/ 0$!]80X#[63HJ=%[A%14U3L! 0'@(" ^L(" ^UC1471>X145-4[ 0$!X"
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MX25.Y.FLJ*IR%11(<QP,&VI^^,9G<MAL7Q'$Y#*IFL4W(1OC=$SP0_*^+/\
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MV0I.R3AB+SBA 4( +B4A1X\1'.DA]-8B'#X[#)>M+%CN4.SC';(]SYW2RRK
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MD3(77;=YRKN5SI9)[;W.=*_5&N5C8VJUC$5JJFI*F=P<", 8 P!@# & , 8
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MJ@'JB*2@ 'LB)>X& ?/ & 5#OZTY^T+?.&P"5=5?'F_Y8_W7F5<23%E0, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , MTO\ A,I_;GO],KDIW!J@'>#V ]S+D'. 5#OZTY^T+?.&
MP"5=5?'F_P"6/]UYE7$DQ94# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M1,%K$["5V(6*4UILB;HT-LNZM&C923<UI5RJG'D75*W!\5QGR[.9/EN.GO\
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MJ:@U(U%&B0.F2;)J&FJ$A1;)7I>U3\VGR[%O\PX&N,J_7ZF9I&K)0T?VY5Y
MZBK]P!3F;)!U7%.1\9YA[3KNK(W'X_!I=KXVHVK-%)/+*G]Y;D=X6PPP;6.;
M7AWH^5ROGE1'+$Q.2YAQCE7"?4=AMMSLCDL\M&SE+BW()HJ\,2_V-.)/.^::
MSND:ZU-L5D*-96B56I*]>QW/TR?E48 P!@# & , 8 P!@# & , 8!;I?\)E/
M[<]_IE<E.X-4 [P>P'N9<@YP"H=_6G/VA;YPV 2KJKX\W_+'^Z\RKB3-"4>N
M)WQSLDK18+:[J+*CK/O+'0MS5R/F7\\U: P%7R(JQ).36.*P$[4Q3 43<H
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MW9+.>T>O))!,@E3,7BH'$0#B(-KD714ZA%1>Q#=;])3T#6Q9-O#=7&BS+JB
M$2E+Y$U\XB/<#B%@5B^4/XCP#(VK^!)M13]EZXV$AY50=@4F\->4#^4T^UP5
ME0Y1#B!NVA7[U/E$/5X\,CL#-L 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MY9XDU:-R"*KAPJ1-,ICF !$%XP#Y%71.JHW*LD9=$B2BR)5""JDFL*@(G43
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M:T-C&1?3P=TBS:(5#E591!NZ!E@Y57 ?%$J8_#]#(].KNYC5WX&D(  !P .
M9E*C & , 8 P"/>N_P#^)WJ-_P#=_3W_ *YU[F)_[T_0NWL>1O!88 P!@# .
M! ! 0$ $!#@(#W0$![X"'J@. =T7HS/2Z["Z.I*%U-N%W-;%Z8W+E-HDR.=6
M3MFGB+J\#RE(.L<R\E543'%1S!&-RD+S*,134YT7%'-UZIW![::)>Z=LZG5S
M8.OK)$V^E6Z*:SE:LL$[3?14O%O"<Z#IJX3'AZY3D,!5$E"F(<I3E,4,1)EF
M , Z1NMR.W+U&;XV!7]-Z0N>TC=)NK& ZFN%?LNKZK%4;K:M<E5-PUFP.E=C
M7:JN),U#I52K#956-2=&)'7&4:'X&5$HC(W1$ZKW_P#8A3JIZP)+>?3+U4V!
M[U )Z(9SO3I'K:7Z9Y+7]8EYS>%7V#I*)E;O)R'GJ&=[)MDO';&F[!3%DZB\
MC$JD]K"KB637*8Y,!&Z*G3ZD[LNKR:T_=-\_N^V4G75*D!Z]U*.[_9U5K[>W
M[TT_M.NQ-)B2/F$0BYNFSG-!6YRQZIG4I82('5!-T=NH*8;==/\ 0@3>N_\
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M-9>TU:&9Z'W6Y(LY;[ H42V;0<](B &(%^H[8S*&L*2YP'M':'D<IQ-S"Y.
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M'X^8531="3;#( P!@# & , 8 P!@# & , MTO^$RG]N>_P!,KDIW!J@'>#V
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M>A"]CI7SU&(8 P!@'8[T,09$X.^V4Z8=J]EXR#15]4$8UD9\L0O\#JRA>/\
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MT.E.H14)"14!?G,75X;2=8JS:>VQL*RGK=0Z=-]+=1^EJ;#O9^P2,@VJNO\
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M,=5ZMM[FJ1>V4+M;KB@1DNQB&/)6V[B&3=OR@E()B[04>"F94A/^I$3@/#D
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MJ:IH.QWD:[N\7L6G0=OB3%["5:$.X;<X&4CY!+_*D(Y?@(B55FZ*8G=X<Q0
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M.5B)>+=H/XV4C)!NF[8R$>^:G5;/&3QJJ51)5,QB*$,!BB(#GF+EQP!@# &
M, 8 P"WR\O%0$5)3L[),(:%AF#N4EY>4=H,(R+C&""CI](2#YTHDV9LF;9(R
MBJJABD3(43&$  1P#PL^ER](\KUM;3:T/6D@Z3Z;=42CS]H?!6:?[D6WD48/
M]D2+50$U?-I&QE&T&BL4#I,U%7!BD4=&33S-;IW[D'3_ )8# & , [#?15:S
MV#M;KFTA3M?VFXTMDWLA+UL66I-CFJLZ-KZC"G.SS*1>P;IH=5I8546\5R*\
MQ#G?@ @/'AE7=$U!_0IS"2, 8 P!@# & , 8 P!@# +=+_A,I_;GO],KDIW!
MJ@'>#V ]S+D'. 5#OZTY^T+?.&P"5=5?'F_Y8_W7F5<23%E0, 8 P!@$>5S;
MFJ+A99NEU'9VO+3<:THZ2L=3KETK<W9:^JQ<^1/4IN"C))U*12C-Y_DJE723
M%-7X)N!NY@G120\$%#)RD9"1[R6F9%C$14>@=T_DY-VW81[%LD',JX>/72B3
M9L@F'=,<YBE .^. 5V , 8!KOU-ZT/L;6CX8YN*]CJICV&#*0O%9R#=(Q92,
M3[H"(OV'-R%#B)ETT\R1NVN_)2KDU0Z=P$! !#O#_P#;U>Z&>DQC & :"]77
M7)5]!H/J11QCK=N%5$4SLC'!S T3M2<4WMH,B< =2H%,!T8PA@./<,N*9.!3
MPKM/U)1-?T//K;;=9[[9):WW.<D+)9IQR9U*3$FL*SIRH/<(0O "I-VK<GP$
M44BD113 "D*4H<,QF0[=_1H>EVV!T6J1VIMJ-YG9G32L\'R:);*E<W+4XNUA
M4=OJ&9XLDC)UTZJAE7$&LJFF!Q,HT41.91->KFZ]?J#V?:1WYI[J/HD=LG2=
M_KVPJA)%* 2$&[ [F-=\O,I%3T4L5&5KTRV__59O44'"??$G 0$<2HJ=R27\
M@# & , 8!C5KN%9H\0O.VN990L8@ \5W:H%.LIPXE;M&Y>9P]='_ ,*213G-
MZ@9*(J]$'8ZJ^HGJ#<;J82U$:1I6NKI)!Q'R\+)HI+K7-@N0R*Z%C;B*B'FA
M=,P_]#Q,4W'BJ)A I2>AD:-ZKU4QJY5/*#UK=&3_ $%+K7RAMG<EIN;>@4G$
M5'3S7\F[4'LH*76'F45A7"AN6/>G'N]Q!4>U IE95-/T)1=?U- ,J6& , 8!
M[$_^/ITDK:WTM;>JFW1AFUIWL=.!H .4A(Y9:FK;U0PR*0&'F(G=K2D=P'$
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M!NK74L2VIT(74%'U7:6-26V,U3L3U(L14WSK2ZS2K[,=ZPDXAQNQ63;,(V[
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MW8H6=D4)N1DI0+DWF%EV342-_)&RP(B?3333_4M-Q6ZP*]6]0RUHMG40&O\
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M%L4A6A7N.T[JLN6P[#GDFZLI'5P70NHRB5TY$R>0U^, I!<*E B\JZ3!PXX
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MZTQ<^;F3=53@TC]BPB*CI2DS(E,4HJ*&4C')_P#0<"<11)E:Y%_4@ZT"@!>
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MC*TUEI)-H1-HG(2*$8598$BE3!0X\H 7@&"%75=23L$# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , MTO\ A,I_;GO],KDIW!J@'>#V ]S+D'.
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MI< >>H;\VC/O[7Z7 'GJ&_-HS[^U^EP!YZAOS:,^_M?I< >>H;\VC/O[7Z7
M'GJ&_-HS[^U^EP!YZAOS:,^_M?I< >>H;\VC/O[7Z7 'GJ&_-HS[^U^EP!YZ
MAOS:,^_M?I< >>H;\VC/O[7Z7 'GJ&_-HS[^U^EP!YZAOS:,^_M?I< >>H;\
MVC/O[7Z7 'GJ&_-HS[^U^EP!YZAOS:,^_M?I< >>H;\VC/O[7Z7 'GJ&_-HS
M[^U^EP!YZAOS:,^_M?I< >>H;\VC/O[7Z7 'GJ&_-HS[^U^EP!YZAOS:,^_M
M?I< >>H;\VC/O[7Z7 'GJ&_-HS[^U^EP!YZAOS:,^_M?I< >>H;\VC/O[7Z7
M *"5F(@\7)$)*1QSG8/"E*5\V,8QC-U *4I05$3&,(\  ._DIW!K"'>#V RY
M!S@&0VB(7AIEVW5(8$55E'#-40'E6;JF$Y1*;O"9,3<I@]00_B&0BZH#'> #
MWP <D#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K!
M[08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T
M& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@
M#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X
M!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >
ML'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K![08 X!ZP>T& . >L'M!@#@'K!
M[08 X!ZP>T& . >L'M8!4M&CA\Y19M$C+.'!P323* B(F$>^;A\4A [IA'N
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&2OE0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g382677f_135.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_135.jpg
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MQ #5  $  @$% 0$             !@<( @,$!0D* 0$! 0$  P$! 0
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M7^&@&^/IA?*O\- -\?3"^5?X: ;X^F%\J_PT WQ],+Y5_AH!OCZ87RK_  T
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MCZ87RK_#0#?'TPOE7^&@&^/IA?*O\- -\?3"^5?X: W252E,8$Y.H.(.!?:
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M3?%J*2;X\SKQL# 8\$R(QA9#)$G3W2$2 QH;AOI"6X;ANF)>!)KN12?=OLW
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M+>;GW]?XX5_'9@HQA:LVZ\?QV;486H5XZ8JO$G5>G/*"@% * 4 H!0"@% *
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MNX'DWD_S;?U[?J%-2[@>3>3_ #;?U[?J%-2[@>3>3_-M_7M^H4U+N!Y-Y/\
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MNLF7%!*:&QC8&=J3.#P:6A;6Q @:VQ$ I*D3$)RBRPB-U=67'0@H!0"@% *
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MO\<;@-K>!*4#<%U<TNAZ]T,"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M)X:XA -#8#GP8/O_ "QV,++,M80;& ".P1VV"#88;"V"M^(5MO1M_C7"4UT
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M0%*V,S<B:FY,&][A3H6],4D2$VO?HWL402$.W\>RNKSXG/R.RH!0"@% * 4
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MA[O=IM_\9,K_ (?M1!7'/_(I[95@"@% * @>4_\ ACD?_P !R_\ W><:L?\
M)?$CY'SF028L$79GQ(NCCLM=GY.4WAD3+)D["YMK":G&6Z,R&ZJ-OX$]GNX[
M!5*"N#/&GM<BPK%F&V,[C39UTZ?$YBC(B4UA/1%QL)4C50U'CP^1">#C4HHB
M@5)#$Q86#B)907P2!O(1F*N,<"(D%Q!(":*X[*<>U17AW.VCF7C(VA0-25@W
M6MH3M0D"-$\FMUEK@C[8'O%I,,#>?W01^5.+D(U>WWL2$99"<JQM@DVO>.->
M/J5.AZ">[)Z+3F6^P-MKQ#+[ VW0VVH'^^P(;= (;?BM^*U<=_T_N;M\F>I-
M=<Y10"@% * 4!0>3/[B*^S$W\956X\@5]^9^E^2J0U'?M3?W@_UKT!>.+_Z&
MM^U#?Y5)69<RG?SB)$3J*O$34/LKC)+P2028^P>1.$3E3?8A6G66,9Y"UC+7
MMAQHD]BQB+%:XR1C!?H"O61R,;>1VQ<X#5[[2N1>SZ&M79?(<CMBYP&KWVE<
MB]GT&KLOD.1VQ<X#5[[2N1>SZ#5V7R'([8N<!J]]I7(O9]!J[+Y#D=L7. U>
M^TKD7L^@U=E\AR.V+G :O?:5R+V?0:NR^0Y';%S@-7OM*Y%[/H-79?(<CMBY
MP&KWVE<B]GT&KLOD.1VQ<X#5[[2N1>SZ#5V7R'([8N<!J]]I7(O9]!J[+Y#D
M=L7. U>^TKD7L^@U=E\AR.V+G :O?:5R+V?0:NR^0Y';%S@-7OM*Y%[/H-79
M?(<CMBYP&KWVE<B]GT&KLOD.1VQ<X#5[[2N1>SZ#5V7R'([8N<!J]]I7(O9]
M!J[+Y#D=L7. U>^TKD7L^@U=E\AR.V+G :O?:5R+V?0:NR^0Y';%S@-7OM*Y
M%[/H-79?(<CMBYP&KWVE<B]GT&KLOD.1VQ<X#5[[2N1>SZ#5V7R%]'C'?_\
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M;6O944[HY!>K^'D[_ X+U:E<*8,XW@]*F8R^$.,OM,-'NQ:V^8.]NB*_1O\
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MQ7S(:N?98S-XKTJ-/P'+%BOF0U<^RQF;Q7I4:?@.6+%?,AJY]EC,WBO2HT_
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M5*A((IFAJ1%Q=*(FUB[[F_>U^C>]9<JNHT]T9=\L6*^9#5S[+&9O%>LU+I^
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MB0/LBCM^ 7J4_:A><!PBRKA24RDXY,7<H1X"N&*L,&J%J;;6V;;_ (;[+?\
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M>K>BGMJ=&!&E4&C>T"MS+1&N"1[#'SV(@MQ;T"XQWLY7%< ."L4:G+&<$=P
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MQ3C!9@Z#N.61(X6^.[!-)>\F3.$8]CJ9]R._QB"0)ARH\G/$>6&)'AT06D'
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MHG1O;R4IZ2,(#2R.*-*:Q5@%@ 644&P?\LLLO= &F'S+5H04 H!0"@% * 4
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M2DE\]GR(E&Y/C6H;YGD\F8$3J2-SBUNB-R;G1_+GSOO&$'%W($N&(G@Q!+N
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M/8\\7:"KZL<E32]S;L">A['GB[05?5FD>E?2V6 1AFG# 0  "(8QCQ!CL(
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M H!0'7('AI=#G1.V.C<XJ&-QNSO1"!:F6',[M9"A<[M;H4G-,&WN-FUS3*.
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MY3];F];H^QZ40'=O*?K<WK='V/2B [MY3];F];H^QZ40'=O*?K<WK='V/2B
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M/5* ;"^F']&'JE -A?3#^C#U2@&POIA_1AZI0#87TP_HP]4H!L+Z8?T8>J4
MV%],/Z,/5* ;"^F']&'JE -A?3#^C#U2@&POIA_1AZI0#87TP_HP]4H!L+Z8
M?T8>J4!N%!37&&QQIY9>VV^(I.6<.P?Q[I8U1 17_P"<5J MS9#.X;9O*N*<
@9V;^X3VW[;[O_6X+A.+\+P/1W=_@^!Z&W\=9XZBG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g382677f_136.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_136.jpg
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MQ #-  $  P # 0$! 0          !@<( @0%"0,!"@$! 0$  P$! 0
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MW(<?N<KI:]EO':$*Y[%D5F-,;;(TURF_HIVRC"/WDTB0YV1U8P!@# & , 8
MP"!V/\&#O=B+V7-1Z@K6NOA0G]R+?8M97T!H;, ROOF'4),K=8RY)K"9T#+8
M2NJW"P'.NY035Z:>)'4#%[PJ9Z2A/841JEX.+3%&J#"2!'&@#L>MB#T_)?\
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M'D)\)Y-RNAQU?Q_Y)R#U-/VK;7OTRFKGJV[*E%43C>J'WPJPZ.^&968ECO\
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M/A;C]+@?CW<V^7Y7P/4Y?;Y/D-F.K#6MNLMUZ::-2BB6Q*4:\416Q=*V,_\
M<DZDNV+<9:^.USDTVUQ-'!*ZBTUK2V:]O6-.2NU9!/%-SV%'I <]35;:,E4U
M[&5[4[RTKI !:64N 28:6 )12=. &=5J_&OG$?"JN'JX_C-3G.+YC3Y6B<M^
M[;ER6Y3<[=F6]?+3HG79L+T5L8VJ+E&*C"NN,3MMSY2\"L\[NYJ_DN5W. Y;
MA=WB+ZX\=3IQXO2NI56K#CZ([M\+*M9^KJE*IRC&4G.=MLI&A*(@5E)["N2Z
MK68H]#)':I5?,39!([(S9@7&XU7+:]ID1[O)MM3(E<7IZ<I(K-&!.F"200 H
M/7&/K[U]'^/_ ![RBOR3F_.?+M?6T>3Y=:=5>I3<]E4T:4+8Q=E_MU1G;;.Z
MR34(*,(*"S)Y/F/R-Y)XG9XQP7@'AFSM;_%\,]VZS<OH6L[[]ZRJ4E51[ELH
M555T5Q3G-RG-S?;&/:5PMXJ25QO><R$R1(&VFGU-,9_&FAM-4^4C%>]C0)-5
M4JDH4PTP$.FU)%4RE>E&$_M-NCJH%U0]'6WYB_XBY/:^0-_DI;-=7A.Q'9VZ
M*X.7O5<KNZD="^]1:[>R-$;+8/NS[]]CPNK]51\S<3J_'''<7'5MM\\UYZNG
M?;-1]B[B-'<ER.O1W*7?[DMB5=-B<.W^/KU+N?14I N(MA(XZBBME5XGG:.L
MJGDM=Q-.\\D)6;"YKM\9FV)*4+!%R(-WU7<>>8TC&:;WP<I4-RXM*%/HW1/?
M&O"^/?#7DE/&U\1Y1QL>0IXKA[]/75O-;#UMKW:H:\H4T+5[M.FRB+E+OE.=
M-L:57WJ'N'T#R3YO\8OY6SF?%.4EQU_+\U1N[,JN#UUM:OLVV;,9W;#V^W>N
MJODHQ[(UPOIE<[>QS]HG[11O(\^NVC;DY)W%_KGD!%K9JJ$6G9"R:.I$/8(T
M-D<X3*[<;(L-<J4KW)V<5;>J,0N)B0K9!)YIWU0@>CTO ?DVSQNE[5L;>1XS
MR.CD-#5W]V6S8M:FAU3U=CD:Z'*4ISLNLIFZKI5Q]N%DY^K7F=[Y$^*J_*+U
MJ52JXWE?&=CCN1V^/T8ZM;VKKU;7MZW&V;"A&,*ZZ*[ZU;1&R7N65PK]%*&Q
MWA[8J>4GPN3DO;K7!EL2NV4<V;KV?FE&U*Y ^O4R:SRJM*BIVU$\8I&[Z(&H
M]\"V]:F+$>(18S-I]=)QOPMY+7RTN#Y6-]OC+Y?8Y".U#E;:XURNMMV:VM!4
M/.W5=9VN?O*FV$78W&4O;.^Y3YS\6LX>//\ $2UZ?*EPNOQLM2?#TV2LC335
MJV)\@]A8T[J*N]0]EW53DJTI1BK7,X?2U_:(XMU_(8'4S%$^,,R9%A\[9Y4K
M6.4Y9(_!)3"6]PBL7#&$YD45.I+N2J=DZM6/M%.]A*&, >TWWG">#?(BK\3\
M<Y+C^(U^'\5W:I/;JV)2GM54ZM^K"=%'L)T.Q61LV(66/-G^B4DNY]!SGG_Q
MH[/,?)N+Y+FMGFO+]"V*T[=>,:]2V[<U]N<-C8_D-;$:W5*O6G76L0PYQC)]
MJNFRXA<S=?4=M^KXE!YHA35#(*V=&F5SUR@RA,K=)G'Y00X)#T,)F(%I&B67
M90@B"3O0A]/3OHSW'E'#>;ZWR%K>9^*:>AO41X:[2LKV-N>JXRLV:;U.+CJ[
M*DL5=K34?5Y^AX'Q/G/ ]KXWVO!_+]WD=#8GSE.]79K:=>W&4:]6[7<)*>WJ
MN#S;W)IR]%CT)15T"F[1:UMV;,$;"U><V*4LF*9F5Z5/FVE\A;)*4LH1#7*6
M=FTK0$KGPL*11HH U)81"&45OH#OM?$_'N>T_+^9\JYJ&O3_ '73XR*KJME;
M[=NM5?&^+E*NKN@I6Q5<^U.:3;A#H=/YAY)X]N^&<)XCP=FS=_:-WE9.VVJ-
M/N5;5NO+7FH1MM[9N%4G9#N:A)I1G->I4R2A;40<-&WCLVNC US)W;3(3*9
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M.M=.L!IKJ3G!!@# & 5Q+OA1"/=YOLR/-+HP6/F0, 8 P!@# & , 8 P!@#
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MTAJ6VWR+R=>PE-S8H6F1E3V3:H5]@CP,KN>/1FS>-[<@L#G!9/(.DZGFE2T
MOXZ,=:SI\EU62FBRK]NE'/BWZ(R9HK6:QZ(2US\ST#TZ-*F2.#4FTNV_%($Q
MRDIM%V C](X?7)]1<&!@# & 5Q+OA1"/=YOLR/-+HP6/F0, 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , AL^^"KEZI'^FI\JZ@SH#Z\/J@_3U
MFR&NP?6!]2'Z6LXRG+ & , 8 P!@# & , 8 P!@# ,W3KX5.OJDOZ$FS:Z B
M?V'^;_#*0YG_ .N=^-,^[W@%QU5_LWCW6F]@%F9=2EKYD# & , 8 P!@# &
M, 8 P!@$#L?X,'>[$7LN:CU!6U<_"<CW&M^X#E?0&A<P#*=CW3?,+E"UK9>.
M+)(XP8Z)6J,2QUY!0*$BE"A4F)- 2E87MI,6IEHE(C"@)]F&&F=EUM:Z-ZUH
M:27W/)\\G+?Y&"3^I&O_ -G,#$?N//)RW^1@D_J1K_\ 9S Q'[GXJ+LY7HTY
MZM7PW;DJ5*2:H4J5'):O"$Z=.0 1IQYYQL>"62226'8A"%O00AUO>]]&!B/W
M.IY_.4'8FJ/BB,?8$+"6X\[XS];=B2X*#$Y*= :9[P]0M8>:K*" K>]#$(T&
MM:WL6ND,1^YZ/GDY;_(P2?U(U_\ LY@8C]QYY.6_R,$G]2-?_LY@8C]QYY.6
M_P C!)_4C7_[.8&(_<>>3EO\C!)_4C7_ .SF!B/W'GDY;_(P2?U(U_\ LY@8
MC]QYY.6_R,$G]2-?_LY@8C]QYY.6_P C!)_4C7_[.8&(_<Y!N/EMO>M"X8I
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MA1"/=YOLR/-+HP6/F0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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ME$TM1S,F4NR= XIFX:E]C#),429(J7)4H%:@M@D:(Q2 OK"2&G=@=H!Y9A8
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M-5L;!89R]@<E#\P+7UC*5+(K&6^&1HQ6QM+LCCJLMABC4F;DA9B011"0@LL
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M:,]K2R_N:>P08 P!@# & , @=C_!@[W8B]ES4>H*VKGX3D>XUOW <KZ T+F
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M2H(S+FIO>I)7;-:;;'A3(R+-\;$Y.4'?"7-N*/-2JG-!UCB"-Z 8$MZ$_?\
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MA)LVN@(G]A_F_P ,I#F?_KG?C3/N]X!<=5?[-X]UIO8!9F74I:^9 P!@# &
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M$=JSD=/Y-./*=XC8GN-U#%:?=0$UVQH%4E?HK,]*K>TC4^^RK0$.TR=P(VH
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MGX_T.D;6%F2TG4:9GBS^9+(PU)ZWAI+;')2:,DPV2L*$MF"E:'\TQ.6(2Q.
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M@#,!H\C8NJ/H$+76UOHWO*<)VL 8 P!@&?K'0&)9")7L.^Q<4Y)I8^CZGM"
M!3G Z?H=8.@!WO7]PM9N/0&3+\XWTER2B@X[<E159:IK2U2DN#'6A!V&:IX9
M()&RC:Q/K(![;UXVE5VA:<1IJ;0#1A(#Z.]A#E";71F.?FS/FVZZX'4%5,9D
MD*H^3\FH:PS&/S/D7!( D:I9+FV42UV>@(!R]V:DDU5-Y;(H1(C2E)NPBTD"
M'6M@"#HB6/ZFIS<G]>T^J3"@,<WEM1%AWO9JLH1F]:Z>H02+1IX]_P!V@% W
M_P!\KZ&#SGNP[VL:V+0KNCU]7P=DI+R89Y9++.B4FGZJ76#*XFU3Y)$V*.QF
M=UYN.QMFB,@;#5CP>K7'*%+@(DA&#O0PT[C-X266-\S*@8I&QP68N;\1)%<I
M#6#E+&"N[(<:;'<#8R.CQ+H&SVD9& 18YPCA4?<1'A.4E[)$D-3&;TM*.3@$
M[7U*P<_G (&5(:A?&B/64Z5!9=877/"G-#2-LNTW<R*W=:'&R2R,QMK83W-;
M6JV)VFM<%#GI$<4/L2"BS *-#3C&NQ]/J;PCT@998P,<JC;DD>H[)6=LD# \
M(#-'(79E>41#BU.2,[6M:-2+T*DLTL7V0!ZW@P>Q@# & , 8 P!@# .FXN+>
MT-ZYV=ER-K:FM&J<7-S<51")O;F]$0-2L7+EBD929(C2)BA&&FF"" L =B%O
M6M;W@'RB0<[KKGLZET0A$'@D3:9[87'.)<993.4,H<EA\$N&/W7)'6W[.B*%
MXCZT].\,M(KUT:8$RIJ5C1KF\;@I3F'GE)1OM2]7_B>U(>6/)I'"X.XQF/57
M*+%1\BK[XNS.%)X_(T+39$XKZN;;EE?RB /:Z?%GP%"^N%=H=+&ER ]"Z7(U
M,!P!WN!8<"BL^O3&3UZBY=3Y5:#95=J26(QMH;GX+BNLFUH6MX\R*<1Z4Q9&
MDK^ L=53F2Z>6BQ7VS]OP$^Q]IWS'HJ(X*86W%&M.!Q],H^G&# WO6M;WO?1
MK7H[WOT-:UKZ.][P#YR,7/%(NN>U!O2".L?%6$T:NL6&6CVCFXRZS7Z,68HK
MN5.D;:48QI5L&=WHTAJBA:8E0XR9P*,/2=HD5-^U WV^GYR1F*\P>0<HK!>:
M[U_7M=7+*N9Y_&&%,KN)[E$<KF/N+4DFC2]V0E:GUM4S":QZ!Z4!<D+4X-K>
MH?M!3DJ2TH=JA!VK_#&2!.G,SDPQCD;M(XZPEL=&31\A5B/$(JF92.!6DKA%
MAJD-G.BN4CE*T7'A%&:8/;I W)W<US$XO"H]"F4N&T@2%8O;'Z'T%XZVJ=;5
M?EO[T_P)=,RW1U\KHC!G]K?C:O4+W)8O8ZWF9C:ZNO>\^B4=.2HWKK[)":Z$
MJ!DE )V6'0PUC^A?."'E/J$3DSN:$'^HI1GEE?\ 4WJ;V5K?3_9LS6L(&5_J
MRQ^CUBS"Q>CKT0C ,&_1U_9O0@BU_P!MYR$/C_RG^:.HF]^2'$BZ8?4'&:(Q
MJJKKG%G<GHVY5*S:<N2#++68LDMFD FIA&WRI<5(Q'.!VWP0R1'&B,UO9F][
MR-')&;2:R_5?H?4V 5Y *HB#-7U70F*5S XZ6J*C\+A#"VQB+,A2U:I<EI;4
MQ,Z=(VH *W%8<>9HHL.AG&C'OI$+>\IAMMY?4TU5J PM(Y.0P["!4<2F(WOT
M.N%+HP1HM?WA[0[J]/\ >'>9D"ULR!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , I*TDA@7%M6]&^Q.1C3=;^S1I!PS>KO^[8@'^A_?T;S408?Y31K
ME5+*K]Z>&]O5M2-R>5#&KW-[6@9UC13R/(+7ZD++J.$%F#]]7(PQ-LA1T=!.
MBAZZ?JLKS]"QQG]W0P3"Z9^?10S*(K9_\X#PWD<"1RB/JIQ'F3BTX-+T_P /
M3NR0Z3,K.ZB3:"UNKJR@/(3J=]&B#C C^QQ^XTW5CT3S_4^PYFP;&/98=A+V
M,6P!%OIV$&][ZH=[_MWH.4XS1L%2#1QAN"9K81GZ.5]7?T= 4G#,*_\ YBMA
MW_WS#ZE*Y<N-U0N5;,54^3JQNBD3>3))$!LTCD35)(C)!N;F[ZD$:EJ-T+DK
M0[EKGE5O1I2K7_B/&3O6R1;+W\_VOC'PS9\8U_$?XTZN'T[W?K.NZZN[7O<Y
MV>]1L1L5]=BE;9B4;/\ 3.4'F#<3Z+J?*WG&IY7L^9_RJ[>:W==4;*MHHLHV
M:%775[-^M*MT6U.%5>8RK_U0C-8FE(Z0.+E)>;@RK5445.$:42?RZ6KETGE)
MTR73W9X5(IVJGP7DN9BF.S@ZZ' *X*@)>M%!$$K6B]<"^)_!/^V7XG;ISLXN
M6U_*E.=][V9[><_RY;?N+9_DY_\ S*U34?V)J"43]#^8?D%>5+S&G=A5RT-/
M^)"$-?76K#3QV_PXZ?M/5_BX_P#PNEP<OWM.;<CP)MPZH>PGB0NTFC\C/3S%
M*@(FT<;9_.6.(S98TH"&MI?99&6:0(6I\D;8A2D@*7G%B4[V26(8AC+ (/7<
M]\*_'WDF[L[?*Z^U*O=A!;-,-O:JU]F5<%"NW8HKNA7;=",8J-LDYYC%R;E&
M+79>/_.OR/XQHZNEQ&SJQMT)S>I?/3U+=G4C9-V64ZVQ;3.RFBR<I.5,9*'[
MIJ*BI23O&,P**0]TF#U'6OWO<IZ]H9%*U'?BY3[Z.[;'6:)HE?9*U)Y*/L6"
M/I".H0$HL79=?8=C$(0O>\5X]Q'"[>[N\;5[>SR%\;MA]TI>Y9"FK7C+$I-1
MQ537'$5%/M[FNYMOY[R_DG,\[IZ.AREWNZG&Z\Z->/;"/MU3OMV91S&*<LW7
M63S-R:[NU-122F&=T=$, 8!YCL],S W+7=]=FQE:6TK1[BZ.R]*W-R G>PAT
M<M6K#24R4K8AZUUC!!UT[U_?GY=S>TN.UI[O(754:=2S.RR<80@OO*4FHQ7K
MU;1^O2X_?Y+:KT>.HNV-VUXA77"4YS?VA"*<I/T?HDSTM;T+6MZWK>MZUO6]
M;Z=;UOT=;UO7H;UO6?J3365T/R--/#ZG]P!@# ,W3KX5.OJDOZ$FS:Z B?V'
M^;_#*0YG_P"N=^-,^[W@%QU5_LWCW6F]@%F9=2EKYD# & , 8 P!@# & , 8
M P#Q'YB1R!")$KZ0"T+M$Z@&M;-3':UO6A@Z?K@[UOH$'?H"U_UZ-ZJ> 4"^
M1)X8.N:J)":BT/0 +B!A$2+K[Z :&#>]&E"%OT.C>NCI^AO>:33(>2V-:QX6
M%H4!835!FA"UH0PE@" &M;&,8Q;Z-!#K?_7>_P"S6\H+]B<1(CA0SC1A5.9X
M>H<H"'>BR2^G6^P3Z%]5H&]ZZ1"WT;%O6O0UK71F&\E,*7:HAR.WY;((H?S@
MJJ=N36T1*Q)1Q^H*23&(62U-"49K J.522G[,A2Q^CR-U.2I7YH+3.910N]C
M5!I:<@HB&EG'TP4N)DJ@+]%EB47SE"2(PRTSKN8:V#QZL19%06HXII!Y02IQ
M='2DU\\> 2!_E"]^4-ZEY,; OZD:TM. 75 $7+_!W:B9Z+J"2.4P;8/SH?I&
M\H+/;W50OXF3&-,QX+6(J=+(%2.&UO2$'A;&X )IMJ,[9 WI1+5AZQ6M[Z4'
MZ,+!MO[&DJVY"5S5U=0&LH_4?,%4PUU"HM!&12Z\6KL4.BAHB+&@C[:>Y'IH
M(C3'KS43> 1PRRB@",WO80!UO0=#+RWGT)K\;^(?N<Y8_P!*EY?L9@8'QOXA
M^YSEC_2I>7[&8&!\;^(?N<Y8_P!*EY?L9@8'QOXA^YSEC_2I>7[&8&!\;^(?
MN<Y8_P!*EY?L9@8'QOXA^YSEC_2I>7[&8&!\;^(?N<Y8_P!*EY?L9@8'QOXA
M^YSEC_2I>7[&8&#R)!R>K*7,3U%910?)R1QF2M+BPR&/OO$:YW1D?&1V2'('
M5G>&Q?"#D+BV.2$\9)Y!P!E'%#$ 0=AWO6!AF)3:DX<-4AF,RK#CORTHR9R=
M14SHT2>GN'T]B:V!R"FU4P41A]B: RGW%C-.=4\X7I'A(Z)7)N<T0]$F)^CI
MWL:S+H_5?U)_%MTW&-UX(45Y]2 =?6DXW?HY^XQV,:IE]OOZ6T$<KGLN4MM.
M-AZA?)DMJ*BCD2(2%J1DMZ$I"E2EDC :&7^".3F+4!/%TI=W"#\]$+[89MFH
M+.?4?&"Q5KI8,'M<4232&NG4Z04X]@9(XUQZ LC0T*F8+8]-;:V@"2NT<8><
M8P$VOL;1*Y=0P@HHDJF^602R2P%%AWQ6O075 6'0 :ZPX:(0N@.OH[WO>\&<
M WEO"E11B513'*TXA26-.<2=Q2O 1)I)P=EF%G!'#.H(H8!;T+6_0WK?HX&/
MZ&*$=3?-^M\Z/FR#@C:B(E37)%9*8.DX%S8BOCV-)+FJ:HEYL8*J@*<3V@>6
M-'M.=U^H2!,5U :$6 81K,L8S_F>:VUGQ<BC+)F*L*EYK4^D?[;4WP@W6?$B
M:1\<3ML HB5'I='2SJ37I>K%&F+GMJ5M6EK&E2VO;B0M3*@FD[3AE_7!9K.O
MI!NK]FKITKOG/+&HNV1W9/'&1\9[;,=K@L Q]52W:ZQ]M-7M+6I:2Y=M"X%-
MS8E;$).VA$F 6%$4),8)ZYSZ'?HF1T_0:MQ7,%?\X).J/AD(K)E,E?%BS ^2
M]95L=(SX-"6X,6J:,!=2&,V5KMB<W;3B^+.UUWRM.Z@>@'E_8TAOF!$-:WOS
M.<LM]&NGHUQ3O+>_^VO(ST=X)A_@U8F/"J3IU(2SB@J"2CPE*23$R@L)H F:
M+4)S@@-(.!H70, M:$$73K>NG6"%:2V B<3S7-FV46K-WL:E&9O192@S?T32
M3/K2CA_9:%T!%OT>G6^GITG] 5(J97=$H)2*FY42I4BV!,4(OK"4#UO6MA(V
M#8@G;UL6OK=[^CFLHA+F.O'=>: QS )L1:WK8]#V#:PT/]H"B=;%V6]_0ZP^
MCH_NWD;*7JD2)T"8A&D*"2G3EA**+#] (0_W[WZ(A"WZ.][]'>]]._1S .S@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!XK^R)G]N-0*-]3>]Z,3
MGZUUAIU -;ZAH==.NMKT=Z%K[(.]Z_ZY4\ SH\1]U8SA%+THPE];>BE981#2
M'ZZ?0$6=K71K>]?8BZ!:_MUF\Y(>+@%@16#K74\I6YDF)&L @F;";K99ZW6O
M1T467O6A@)']D/?1TZ^MZ?HZC93I<KY[+:MX^3Z:U^N1-$L9"XN0Q+ES<0Z(
M$9SO,HXPF#4-I_02J)TC<C-=3T-^CTAWK>M;U\Q^8/(N9\4^.>1Y_P >LA5S
M-"H54YP5D8NS9IJ;E"7I)=LWZ?HT\,^I?"WC7!^7_)G&>/>2567<)>]AVPA-
MUSE&K5ON2C./K%]U<?7]4UE&/K1L_DTRV/+JEATQGCNX4_4\;F@Y6R0RA]:G
M\IE:F4K0O%CI9W(X<FCU7- &8#<(,?* H#L)XSE@#"RM&?%O+/*_E/1\FW/#
M^%W>0NV.%X>C9>Q5K<3_ -7??*^?N;L=N[6C3H5JM4_]'%335DIW*48*7W3P
M_P 0^)-_Q71\UYW0XVC6YWFK]5:]NUS'_1:^O'7A[6C+3HVI7\A:[7>GNR<&
MG7&%$HRFX^+/[NY0>3/(^S44_15RLH#5.JDM3"A\2DS$K=Y?5M<RB;1V62(8
M#WER:TCQ*E($1K:M2F@V'K[.-!U A_!Y%YY\K_VOR?RJCD:^,N\<7&RCQ_\
M&U[ZI6;.AI7[5.Q<T[9PC9?-52HMKDFLN<X]J7[_ !KX^^(%RWBOB-_&6<K1
MY-_<XRY+^5LT71KUN0WM?4OUJ$U5"R56O6[8WU61:?:JX2[FY?8%OWE1:FYX
M6\6N"P5D4CW&BQ&2;R"&Q%B6LK;9]Z'5O8+ L;V% A8U+$4SM)RA&H-*[Y0@
M/%H9QNRPF:[GR/S3S[P"WG."W.77)7Z>MPFY5M7:VO5*J&]RKTMRF4*H1JE4
MJZY3KG*/?4I-2G/M4CI/&?!_COY%JX#G]'A7QE&[M<]I7:E.ULW0MGQ_$+>T
MKHSNG.Z-SMLC"V$9>W<X)QA#NE%R6[[_ +5CC_R;883)V5N.KU?PZ9H:>J86
MUX+CSA=5@*8[,ANI M@-<]J6DY.862:,(B0[T(O8-CT+.U\\^1?+N,Y'RKC^
M"VZ*I\;9XW5K.54+%3/D]N5.R[%Z.SNK<&HR:<5AQ:[LG4?'OQIX9RO&^(\E
MY!I[%M?)U>3V[2C=.IWPXK3C?JJM^JK[;%.,I134GE34NW!#++O"^:)\^\!,
MGAUHO3*3QR7P:=/43A#2\Q$B]IY)X$_>^+8W[B$*>2HZIC??#3M<-$1WPK*(
M5GB*#L>=)Y3Y[\@_'_\ W!X[+D)<MO41X:>KMVZ^K79KKE=N_4M[X0_CZUBI
ME3WZ_NNN'?9"NZQP3D=_XE\>_&_R/_VYY+'C8\/Q^Q+G(;>G5L[=E6R^(T]?
M<I[+)_R=JIWQO[-CVE;/LJG916IM1//.M/E<V#:*\6R2410,IOZKJ]CEF6/%
M*666.0PS6"S]ZF+(\1&O'U_AA+HQ+(ZB6-*PY,D$<G6 ":4< L6S?RV>7?+V
MK*GQN_9V]-;?D6AIT[V[K\9+=56UJ[=NS59KZ=MVLK*I4U6:]DH5N4+(J<)Q
MBW/],/#?AC;C?Y1KZNGNO3\:Y#=OT-'9Y6.B[M3;TZM6VK9W::=IUW1OMJV:
MHSL49U2<)PE)*'Z65;M])X+RJM=@OANA&N-#Z]P)BKQWAD+<4DG,B\9856Y/
M.EZYOT^ D5CKW?MV0IO$C0$A$G#V*G1AH<WY1YE\A5<!Y;Y?QWD%>@O%]BW4
MJT[-;6G&]T452]_:G.'N^]NSL[]6-+KJBG6NRU2FC/B?A'QO;Y%X;X9R?C=O
M(?\ =NM5N7;M6UM0EKK8ONC_ !]2$)^TZ-&%?9MRN5MTFK'[E3C!E?R]=.8L
MY_.,2YPL)KE1K)6L'E8('+8'!W9@>37"KDCI%EZUG7(5'?37#A)1H@@Z@DZ\
M9>QJ.L<'>\\[S.QSW$[?R9S.SR56Y*CB]78_B;&IJV56N>A&RB4JYPEW0UNU
MU)8<+6NZW,T>FX/7\=YG4^+.$U>,NTH;'+;>O_,UMS;KNJ4.0E7L0A;"<>VS
M:[E:WE3I3[:L5R2+>L:Y;H @Y.VM'[998*T\7'U,RM-/K8M&UR"P"&J&Q>6J
M5$V=EY Y2C,L\Y_$@CWO2>B 1L!0]:4F",!KV7DWF_G$=?RKR_CN8HX_3\3O
MC57QTJ*90W%7K4;$I;5DT[XO>=SIT_X\ZE#$7BV3DCP_BO@?@,MGQ#PSD^%V
M.1W?,->5MG)PV+X3TG9M;&M&.I7"2UYKCU2KMW^3"USS..:8J,CRK#N'D$G9
M^45OL=H>3C%QRL./)6&K#8/%%;?)&(R!5?+Y)'YH^*T)TAT>=J7J4Z8Y H1F
MI#P]<8C@]0 /R^2^:_(U6EY7YIH<M_&T/&>2IC5H/5UY0OJ>IH[%U.S;*#NR
MULSA"54ZY5S3E)S7;&/[/%_!?C&W>\/\'Y'A_P"5R/E7%WRNY!;>S&=%RW.0
MUJ+]6J,U1A?QJYV1NA;&R#[8JM]TI?4@.^L$(O\ [M:W_P#773G]8)Y63^/6
ML-K[']RD,W3KX5.OJDOZ$FS:Z B?V'^;_#*0YG_ZYWXTS[O> 7'57^S>/=:;
MV 69EU*6OF0, 8 P!@# & , 8 P!@# & 0.Q_@P=[L1>RYJ/4%;5S\)R/<:W
M[@.5] :%S ,22VY^2CC?-LUM2\%IR3,5-0:J96YM<[E<NBLKG3C9'G /$QQ^
M0M3$_P =B^TB:$A+(/6HE99BA1_Y>R+#U\&L+&62F'\V>/4N9:]<M2]4S.-B
MQ.+2A%'E\>D"Y?'U4O:C71CADL<F!L>(XP3]TVG-3H&4]:%P=E(- 0%*NT*[
M01Q:*VX^\^:MM*NX!-)Z_-,%=[7/(>HG%RXW:!0XM#90^;9*]%9+Q)H2Q)(N
MX2!>':(IS6 0L+HY@,(:E*P)7:C%<6GA?0L]!S?XJN2[3>CN)B&;M)-'+O@Y
MKDZ1L"TUTJVW3Q\,>5;$0T%,$1=M:0N"\1^D:5P$%(,W2D02MAVR/3'S$XYE
MQ\N1&V$,DHV4:AA<?.AL^)GXI+MF\I/>WS8FQ8%CZ_\ TSOWTV=MJ[WTU^W.
MOWM_Y<$[61>M>8M<2*@:[O:=NK='FJSI++8[#DD5222>G2DQBDLV1-AT5:HP
MR.LD?]+HA##WI1M.C, C0EGGFB"G(&;H5Q]<(\ZK^;U/R^26%"II+8U!9="K
M#NR,DHW,YX1,:R,T\YNAJUW43!X:F^(E2 $);O?UP:0+AK4+9UU0R])BQ&Z!
MQ?5=#W$_.KBFI3+#P6RE).0J(6E.:5L4GC=)#3K(/DZ:O H8LX19-)',$[.A
MCGIF&F2&@<])!;3[,UL&Q!VR/<4<R.-24<B =:+>'<:UOMA 8I8:5(C R=MA
M TU>'E, R;37$S1Y1LYB>,B=CRW580D$#2@XLL0G:R_XW(FF6L#1)F(Y0H9W
MQ G<FXY8W.30K&E4@T85WTU/*1 [-JG6M] R%)!)Y0M;", 1:WK0A[> , \Q
M[=T; S.[ZXCV6WLC8O=UQFOH@1MJ4U8I'KIZ-=(221;P#Y25#S\LJVX+6@XR
MLXRR2V[SD<$8H;$FF43]K8JF#*ZFGUQJS+>6.34J?GPX;! E;<S;9D1*5Z=R
M3BBSRRR3QDC;BE]\(_1!\XG9#TSSV8MM4URGBG&]0TM/)%*MLIU.?GYY6V?,
MZM<3N.1A$2);9K&R%L'4JV9<Z[;]R54;II**2*R3S0AVK]2117G!;3A. 0&0
MP6)-DAE+NE);4KBRSR%-U,E,DP5 LU@MF33$:9CF:Z'5@ET[EO# -(V*G-8W
MH-%A*=6Q:K#M1]1PB",(1!%H01:T((@[UL(@[UTZ$'>NG6];UOT-X,']P#Y8
M5!\XRQR6MKQNRPY;2Q4.K.&2^P6BLX"NEBRXPQEFESY'HR%X2OY:5LD3I+N]
M&]"4%F3FDEOSB6AZXC!%Z&-N/JDNI;HN7[M):7IY\K!L@<JNNU[(C]&.$:<W
M>61Z$UE< H(_6%/6R;:=(RDL)(AAT=BBX],E-:4B]WT8AV'2<A8%26)V^OKT
M11SIS_M)F-3+)'7D3BK; WY\BEI$%-MB39MG#[7MPRNM[G/JJP&EM9F&&,=6
M0B+ FJ@Z4(MGJVQR*3"*3=[J5NA>U'T*I*>/ME5XU3&3-+;&WMW5.JE1$D:W
M:QRB#<H<5"N-1N8A$8,3?/V^*J4.WQ'T!"C<QG$@UL  C$,M89;."# & 5Q+
MOA1"/=YOLR/-+HP6/F0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , AL^^"KEZI'^FI\JZ@SH#Z\/J@_3UFR&NP?6A]3KZ6LXRGBR2,QZ8,RR
M.RIE;)$PN&THES.\(R'!N5[1+$[@DVH2*0&$F[3+DI1P.G6^J86$6O1UK/P<
MGQ7&\UHSXSEZ*MGC[.WNKLBIPEVR4XYC)-/MG&,EGHTGU1V/%<MRG!;\.4X;
M8NU>2J[NRVJ3A./?&4)=LHM-=T)2B\/UBVNC('8M$TY;B]E=+,K:)39QCVAE
MM"U_:$ZU0F3&G%J3FX9HPZ$L:3U!03#$9_:)3!AT(1>]^CGGO)?C_P )\RV*
M-ORGB]/?V=;*KE=6I.,6U)P;_P":MM)NN7=6VLN+9Z/Q;Y&\[\(UMC3\2Y;=
MX_5VL.V%-DH1E))Q4TE_IL46U&V';8D\*21[ZZLJ[<T<M;W"$Q=8@GHV\R:H
MU+*@-32H;2WM[2UB?B!D[+<]M[6U)DY/:Z%V9*<L >@(=:UV-_BOC6U1N:VS
MH:D]?D7![4950<=AUPA77[JQB?977"$>[/;&$4O1(ZW7\N\HU+]':UN0W*]G
MC5-:DHVS4M=63G99[+3S7WV663EVX[I3E)^K9S?JVK^4F2,Z20R-/ITOC)$,
ME!KJSH5IC_$TJAP5I8ZZC4$C$M:$JMV4FED#WL!9AXQ!UH0M[S7(>,>.\M/9
MLY/1U=B>[JK6O=E<9.[7BYRC38VGW5QE9.48OT4IR:PV9XWROR;AX:M?%;^W
MK0T=M[6NJ[9P5.S*,(ROK2:[;)1KKC*:]7&$4\I8(A&>/%&PYC7QN-55"6ID
M=E4<7.Z$EC2&A=UT/=-O<57.QRD!ZET6QYVWWPC-/&88G-UH0-ZZ-='2\5\:
M^ \)H6<7Q?$:%.C=.B=D%5%^Y/6L]W7G8Y)RLE39^^N4VW"7K%K!WG+?*'R)
MSO(U\KRW,\A=R%,+X5S=TE[4-JOVMB%:BU&N-]?[+8P48SCZ23RR8/5<0"1F
M2<Z00R,O1LUCZ**2X;HS(%PI)&FTUR/;F)ZVI(,]\&M >\*ADDF]8!8U!@@Z
MUL6]YW>]XSX[R<MJ?(Z.K?+>UHZ^P[*H2]^B#FX56]R??"#LL<8RRHN<FO5G
M1<?Y5Y+Q4=.'&;^WKPX_:GLZRKMG#V+[%6IW5=K799-55J4HX<E"*>4D1>(T
M%2T#:FYEB-90]D;FF4D3=N)3,Z<PU-,$J%0V))-I8I">M,>T;8K,3$J1F"-)
M3BV4#80= <ZCAOCOP;Q_4JT>&XK2HUJ=M;4%&N+<=F,90C?W2S)VQA*4(S;<
MHP?;%J/H=SS?R5Y]Y)N6\AS?+[VQM7Z;U)N5LDI:LIQLEK]L<154K(QLE!14
M937?).7J=*9<<:'L.5#FTXJ6"RJ4G-NFA4\/; B7J%[> @U,02YEG%B3.@D:
M8X9:<Q0 TQ. 6PE"!KT,X>;^,OC[R3EGSO/\/Q^WRTJO;E9;3&;G!)Q2FFNV
M;C%M0E-2E!/$6D<_!?*GR/XQPR\?\>YOD=/AHV^Y&JJZ<(PFVI-UM/NK4I).
M<8.,9M9FI,D<@I^JI8XGN\FKF%OKLJBJZ#*G-TCC4L<%4,<NIW]%5*TY*)2H
M8%74UUD@Q;(WZ/U/H[Z>SY+PSQ'F-F6YRG&:.QMSU):LIV4URG+6G_KHE)QR
MZ9?6MMQ_'J=5QGG/F?"ZL='B.5W];2ANPVXUUWV1A':KSV;$8J7:KHY]+$E/
M\GD26@:5F,S9K#E%80Q]FK!IOTUR)Q9$BAP(]Z#-G,XCA"!V2X;,?OKHA* F
M[2#^J)V#?HY^+D_COP;FN;H\DY;BM+8YS7[/;NG5%S7MO->?I-U/UK<U)UOU
MAVL_=Q/R7Y_P7 W^+\/R^_K<!L]_N40ME&#]U8MQZY@K5Z6J#BK%Z3[D2A;6
MU?N+=,6A?#(TL:K"7;<ITWJ6=$<CESAM W->ULA3C)V6ZJ=MS0E(ZYVAB[).
M6'Z -:UVU_B_CFUJ[NELZ.K/4Y*SOVH2KBX[$^R%?=<FL62[*ZXYEE]L(KHD
M=/K^6>3:NUH;VMO[=>YQ=?MZDXVS4M:'?.SLHDGFN/?;9/$<+NG)]9,FVM:U
MK6M>AK7H:U_TSO3S_7U?48!FZ=?"IU]4E_0DV;70$3^P_P W^&4AS/\ ]<[\
M:9]WO +CJK_9O'NM-[ +,RZE+7S(& , 8 P!@# & , 8 P!@# ('8_P8.]V(
MO9<U'J"MJY^$Y'N-;]P'*^@-"Y@'RVN0],P\A;8D<8O/D15IE@1>N(/8[=7G
M">X;15Z+K\F6'-SK6]MI*PEL-;UZUNG9I1B@")Z*3GE:$#JF@$$(VNGT_4HR
M.U'PWA-LLL]A33>[;$$"NJ7E=7LAX%\B9P=N24K%XW$H&\1J<RBC5TBBX@M\
M*95#AT:5*E#DV%K4ZA&I-4FG"YEC#QG^J/&34MQ12O\ 6ST);R!?B8O65.U1
M/6Z;_-^WY-BK CE'JW)3$%C:-^HI0""/3BG>5*)U-3%JR52+979%)U9(%>!E
MX^GZHECG7?%*1P)?7$I=N6+M'G.CIQ2*P:?AWR;;G,*.96JGMLF5I5.Z+6)P
M/C!(D9.B"CB3T:@)6N^"C0[& 09?XZ_='YQ"-4W7QC/,X%,[OA%WM;H_:561
M%/FV;S9F-^ATD;(\U.,(?H"GI;8'-&3Y+I%Z1<8YB<$;GHS99ND!IC>(,M^C
MQC^IZSRU4LNXS0KCDBG')(P40?W^0:LJ4<!N1$AEQ[K)'B7/2R2,FV^EHT&"
MSMM6R\XYN>&0U":B.+U_XAIQFIAB>N<^GZH[,@C'%^75B34\H?.73Q'!6_:]
MMNKD;Q$Y/ER=X66S ;4@;L@5NX**V7WZWE6F>O+7=AL9ZU(7LTL11AA8@]<Y
M]/U1Q;-U^X6HQW':5Q<J+(F3 X5(<BT'@+?T.90MU/J+G4,Z3WM8J/$9W](3
M+H5FN:G9P@B/1E;2DI2=[(T+],+'ZE6Q"C^*L"89/&HWYU5K4)F<X[6@9M\V
M?=<U<(6PODL;I2[M<E>W&CR'N?%=BUDMB4[2AI5$H"BS##3W HM< ,O_ (9N
M^G.0=0U+6$+K<]UY63TZ(LI349+IAQ/Y:N$@>1@-./V:J4&TP<:%,F[;L$A0
MS#AIT9110C3=@V8(9:;>?3]467\<BF_$O(;^D+EE_)7!.U_C]4/CD4WXEY#?
MTA<LOY*X':_Q^J.@Z\MJ<>6IS:.\N2K;[Z-RUO\ ?%JXE\L$3H@TL3&I]K6U
M8*DC-)'!+HSM"3.J+J&!#OHWT=&!A_C]487.8J5F*&Q5%Z3SDA?,QE=7)*BB
M$HG7S>EUEHH''65V6R6-R040;>/Y,>E5CMLO4$NICJJ+*([Z1$Z2)$)8CP'C
M7K],8_J=T,%X4;'QZ1J8';JF/\89%$5U3HM\!N19;^VQ*O8LD206".4Q!1OO
MTXL[)92;RR-,Z0&*WL!6S-:+ 9HX7,O7\_DDEW*J&NR6KI\\/7(O4I0"B)%?
M(Y%P1Y'3B 1%FCI#Z)Z87: /U)>]<S;YN\2$3BXB4&D'Z7-+*<2868T)A[$6
M5]OU+_J"_:(IRL(+5K*1R<>6J"1MMC:%T?.(_*LUS6D-Y.BPG'A2T>F1)2][
MZ=%)DY125*3H!))8"BP T(TV\^GZHL?XXM.#^HTR\AM;']3K?Q1.6(.CK>AT
M]?=+!T#Z/T>G71@G:_Q^J/G\_P >J^>K27&TKUYHSUU@C0)IH)_/X.W<S2&J
M5!5B5K:+=)WQ<W<<N\+6EB"5T[&];.=4A;>I1H# 'HS#U1ZD0WZ_1+]3]#V^
M"K0+I,NN[E2=<*VRV*[O.81\W]?J0A+;47AR:JV!Q30L%)C9_(<FG2SXZI93
M#3#U(%IZWO\  MV4<4)Z_C']2QVMTX_D52Q5._/W*J2M2RV7.Y;A<U7#7DTV
MK;FE3Y+'FQ7EO>D[11:1!&XJNL)<C5[0-Y80^]K:4W#&,DT\9@>N<^GZH_O&
M1WH#C6JE"MM<N1\E.?H_"X:FT#@WR0B)6HS7XY&8P.<J)C=&D%S>T',4H4^_
M<G6:"K==%$:V43HK?7!Y?V_5&M=\R*;UKI]Y>0WH?W<0>66]_P#TU2G3O!GM
M?X_5&HDYY:I.0I*T;HI224>7H\@Y*=HLX 3 :.3*2RE"<W01:ZP# !&#?H"U
MK>MZP0_; *XEWPHA'N\WV9'FET8+'S(& , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & 0V??!5R]4C_ $U/E74&= ?7A]4'Z>LV0UV#ZP/J0_2U
MG&4Y8 P!@# & , 8 P!@# & , 8!FZ=?"IU]4E_0DV;70$3^P_S?X92',_\
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M , @=C_!@[W8B]ES4>H*VKGX3D>XUOW <KZ T+F , 8 P!@# & , 8 P!@#
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M^P*]W#(>947BL+O5QLAABT5BL64$/D7AJ!$C1M2%J1HR"Q=!0QC&,3!7-O\
MR_R(]#?FEJ*CZ%X:)I;W)R[F5/0EF\8ZC:;DM)NE*;CQ3%NQHB'SAAJ$Y%$6
M9:"1N<71IFW4AD!K^_!;D9*7:O9.C0F@YO\ "-6-/$>J&:<<8+!1F2O;_P 2
M*BFU*51HY\+,0&0R?L=;1]^%*TO> =OCSI!5;7V"@(R-%&;/%U!=IT!&>Y^J
M^YI_!!@# & , 8! ['^#!WNQ%[+FH]05M7/PG(]QK?N Y7T!H7, 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7$N^%$(]WF^S(\TNC!8^9
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M"80[.##(4\T4'H0)(\L2O+6>GT 1@]"WHLSK=BH3&' XM=3:F#(P!@# & ,
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MT< :S7"3.WFZFQC&B6FW=->.C!&0O@&7;29+YI;]>.[6RMO;:5.(4@U18>]
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M.A7%Y?J\'+Z4YS2M,EE;[J0 <)D[HGV$+4KY*A$2E<0!6H (0$QH"-:[%.F
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M3'K"U!2PDDY'L)ICH%'[FDYOR=JRO;+65=)%+\2\,5<*;;FCVG8U)\3@%>$
ME RI1,'O8RPH&M4*&.8-&D%J0)QI@Z4[([=-VPF'C)G:8<\XUI[A,;C;%-(*
M]*9I5;I-DMVUI*H"611\\?I*QGSAI4OFVM,4,0XX>9U31[5-Q90N_DI(MZ!@
MTHO&3U$GSD_&1P1Z,;7";.#PXJHH"&Q1/#U8)/8;5-Q.@8Q)(<@5*$Z<YD<M
M,BKIVN.0*DXP%%'D%GJT92@3L9H6QN0D,K99#V9<Q6+*97-FEPDC9"8% 9#+
MY@@B3()H+D4L?V)L2B4,;*P*G]$G/[?85)RQ2!,F)4*-[+T(DV4JS?.!T%)T
M*5?%$EJ2DMU8JT=H\2QU9+%*J4.EOP1ELZOH5'DYR).-?-GBOWD3NI0[ZGO0
MWH5:AQ&D*3B'L7M9Z)O/CCBC:%CN[OTH8/>R3U;"WEI?H1)6M_8Y7;-C2"J6
M=C=V12A"O0J8W,XFYEOPQ [!I1HAK33.\A%'F!VLHCD;\XGYNA2=KK*N)?(4
MS56ER3(JT5D76N$%;GJD+ECU12UL4-J-:C>GMKVZJUY92I'UA&J H]$%G@5Z
M& 51SU-S5'=D2N0F7 8&Z71Q]@4C#%IG#Y]%W*(2V/.:EH;I"TF+6AR!_P"9
MM?HZ\)5R)408<0<2=U=B"<6<46,M8+?P08 P!@# & 1*>>7?D=(M5CJ)^7XV
MTXN)F3H3OY'IW@WJEIEDA*8 ^_*MM1=;9PTZ89)JGJ=EHXCK]L %CZ]#YF5_
MR<Y)VA)6RB(O-JJ0S[=FWTQ*KHDE'3UD)4PJBXO3+B<%;QW?+*8Y5$Y1(IK<
M 4!)R][ D71]J]^$10R71"( WA+U^AN_C1;#A>E!U/;;NT(V%YG4,:GI[9VT
M\]4V('S8!)7DAJ4*M!5FM6G1,;M-L[6CNPV#M/J^M@RUAX+QP08 P!@# *XE
MWPHA'N\WV9'FET8+'S(& ?%NC?G%'A>\M[_95UTW-X>G+O%WON&PFOWUID_%
M",5X\3)#"I!,I(VS*8)7(F6ND=2Q].UKF]$[/3JXEFM@3 )E1&AR./X>318_
MG"JT<IW$BFE>I:82V,=L"N!DD$8<SK(CLECZ>I5-8M+,Q,*MU.=E,^U8FBVY
M.@*<3G14<4E)ZJLHX@(SVO![#CS_ (R=.X!747IB]W.52&W$%43QC>:[7QIZ
MK)2^TW/[=CKXYH'=2F(?VQP;(8$8C6]0>F AVK,[?:A&)*,.TED=YVT,95#)
M9DNEVF9O'MC02-?Y-21N;T2MPHM+R&525,VN:7W](@8ZO.$ZIUQQ>][*Z$^]
M;5]).!VO.$3.O.0T7Y*QVQF&EI4M@MD1%*S@7$SJ%;<'2(@E92Y3$)0OB/OX
MW)GMBD)#.MTFT!Q*%VR4\D[L5!!I(1&L=3&;9=G,A!57G%=[%B\G857(.Y*?
MF$KAG%>5RM;3,&IRQ[G@1=FF5M#;5>Y9/]RYTK]E2K0)=:)CX750M,*4)DPN
M@;Q'./Q]R$6ESRGD6EJYLB/([CO)7)MX[TU9=00%JJ]]>W/F=/YZY704XQ:J
M4[/:KC)F#WZ*K=$C1E(RGT;0I5'J5FSDZ<TL(*/W3Z_H?: @9AA!)AI(DYIA
M18S4XA@,$08,&A#)$,O>RQB*%O8=[#O>M]'H>A@XS]< 8 P!@# & , 8 P#)
M',2>W55M8.UD56_PJ-LD$CTFE,R5O]46-=LE>EC<4W AT0C%?UP\1YQ"W2)T
M4G!=W@:L>VE(4$P*?98SE2,:CAO#,[%<K+Z=5BRTT(ZB0U#!KDXMT9,:Z1M[
MK,)+*73D/'N/3D_SB*7"TRY)%T[;"G;D0A+:TY;*O3/"-H4&B5%[6I]I1>U=
M/K@^H&# P!@# & 0V??!5R]4C_34^5=09T!]>'U0?IZS9#78/K ^I#]+6<93
ME@# & , 8 P!@# & , 8 P!@&;IU\*G7U27]"39M= 1/[#_-_AE(<S_]<[\:
M9]WO +CJK_9O'NM-[ +,RZE+7S(& , 8 P!@# & , 8 P!@# ('8_P &#O=B
M+V7-1Z@K:N?A.1[C6_<!ROH#0N8!1ER\=JUOD^.&6,D=W!-&FBP6-*WM[L>U
M)52"RHJ;$)#WX:C"!P K3-IFC4*A,>G/1K  .+'UP!Z!4VNA68.&D,..(?GN
MSKHE-DHY;!I2@MJ12>,K)R@35XUS-@CL/3)4T,1P3R,%'K*DJ-8D,9!F+M2!
M:H/-&L&6I*%[G_@13?S?U3GBCJ5SGUVO4:@L;6PNM84[3EN41>MX6KEM>3 J
M+QI.7&2'-<B:UM7M*5&I>%;JY)6TL:4"G1(^KH.Y_@LNZ.)E9\@9A&9+:2Z4
M2!CC"1>G35WV\=31!8:Z,C_'7%4H<BHUJQ4&G-GD9Q"U*W/R%O<0%DZ5IS]%
M!P%)KH0/7!"LW20ER>PK"NNWG0ILA\>!NS9DSO2,46A#R^O3/&E"!LBC(D6H
MU9TC4E.2L\!CH[$[!WXK/&6$S0=SQA'0:. -6,%9/]3LDXLI!%GUO88YT#2U
M ZJD$$CB%Q;VR [(?:D=&:2,>B''0CEKZD=GY0H2I3S'$1Z8DP =SSGZGM7/
MQS6IH77:RB2IJ@L>I8:DJ>&J&.WBJ\<':L%H(\A=HQ-9S*(';1KBU@#&$*W:
MS36>_$JDVS42L@\TT1@)^OKT/ JO@G#H)3,'@2V8S5#/XNW4FYALN&/^T+S'
M+&INEF*CDDIA WYN>B=)7B%-BE$N2O)#J0Y)7!2%669VPM:!R]<_0]1RX!T.
M]AC1SZ=/'IV86.[6IUD#C*"S7F=N=^H%""<2^<GEM925VE+?I>J,8S2"4J5B
M$K, B3E$Z+*+#N9WY%P9I^00ZM(0%YL1D:*TK!QI\L]FD39ISFL&=UL1>G1'
M/%CK'W7WV=7"5P=N>3G)*%$X#<0&BV=V2A02:'<^IHN,UI'8G-K+GS6-R$^6
MLX1=RE %:L!Z M3$8PBB35IJ3!(+&B*$U("]G!$,SKG=(M=7IZ,$S]"P<$&
M, 8 P!@$,L*#M=E0J109Y<9(SM\B0;1C>(?(G6)2IG4%FE*D+O'I&R*4KDTN
M[6O3E'D&@'L/:%ZT8$PO8P"#H95^(I! E^_B:V[\16^=+G:7N/(-%,XT1;KN
M<^0YAK]TCZ\T,(W7ODBHB$5:TH&TF/DD)SFXA:3HMP#M6(:[OZ8-55W (K54
M$B%;0=NVTQ"#1YKC$=;QJ5*XY.U-"0M&ETJ7K33US@M- 5USU!YAAZ@X0C#!
M"&(6]C/7U)G@# & , 8!7$N^%$(]WF^S(\TNC!8^9 P#%CGP'X^O,+0P!R12
MQ3&P0>>5I(D_E(-.=.X)/7][EXX[-#TJ0C;H7"YH^F/$:5E:3N#"OT+:10 I
M2N*5#7<S\B^!M/'LZ!M?WZPI(X-I,KTBDYSC$HI($B^3&UXK0OB =;PR$-#2
M^PEVJ]H<&52C1IQIG$LU2=WP<>:,0=S.XT<*8>V/R^;*[<O:0V0X61!;1,L9
M_E<452)._0*"R:L4+8WM22"H8.W15ZKV9NK6X-Q#0!.<%><J+T2O%WWH.Y_X
M'7UP"XYGD$('ADD,A9@<84G$M6PO,A.-:'2L4C:6R%NJ],B(0F><3<?+][O?
MTD9*L"'?8E]0.M= =S_SR7/2%%1RBV5W:6-^DDI4/:],M<'V5D0U,[&%($!+
M<VMP28+$(2QZ2(2"A"T/:+:H\\XT]0<<<:,S8C>2.'<:F=%#4\/@UH7%5NTU
MDV9: )% Y0R$O)[Y;4TEL\E[:YH9-%I/$'R/"?9FJVC3+VI2)$ LG91@32^U
MV&?N05KX*T:S1M\C[:.<IE#RP5XWD2S4L/'-H[*ZRE]EV#'[6C<F,2B7-MG+
M)S;;VYN*_?:)UYBH2<U-M$,Y,:+W,V,4 19118S3#QEE@ (\W16C3A!#H(C3
M-$EDDZ,,WKIWU !#T[]#6M>A@R?I@# & , 8 P!@# & 4=<E')K@%'EA-H7%
M4S[&R'YO2R*GIJ5%W!>QR@E 2_,;PA=6B1QUQ3JA-28U.K&A]]&L\G1B!4E&
M,W9@J>"HFG@G2T<?HLIBSG8\8@,8650]&4DT3(S51R:5T:Q1F.51,)0S+V]=
M(US]$6N#,.M:)=4R)P.8D)R].K.(T/8O<S9V#(P!@# & 0V??!5R]4C_ $U/
ME74&= ?7A]4'Z>LV0UV#ZP/J0_2UG&4Y8 P!@# & , 8 P!@# & , 8!FZ=?
M"IU]4E_0DV;70$3^P_S?X92',_\ USOQIGW>\ N.JO\ 9O'NM-[ +,RZE+7S
M(& , 8 P!@# & , 8 P!@# ('8_P8.]V(O9<U'J"MJY^$Y'N-;]P'*^@-"Y@
M'S^Y.1KA-%[-J]5>E)Q^83_D+.VV!H)'J')7XYO,)2MD?02J>N1RQ+MDA21\
M<V&/=_\ 0=V;J^MI&R^H>(PL:7<UZ?0_*RN.7 NK38BFD/'.NUJZ:3./PAJ;
M6*)-KDZ$N,E+=1MJ]:W;6$+ - Q,QQ?:E -,$=U0%EC%OHTP%W/ZDY9>&/"E
M\:&EZ2\=*R2IWA&W*TZ5UB &IT3B=$)#BF0.34O"0N;78*92'9J4X #RA=(1
M!UO6\8)F7W9%EW&OYO!ME\.@2VIZ+)EU@)90LAC+IG1&GR B%GM*64=XG$]H
MDV<T*7Q*684,P)HAF;" (M@'H(N9=?4F&^%O" *)4Y"HFE]-R$XY.M7[:&O2
M)(H3G=[GD*E6SNP3G$'[Z@PC%H01^AO6M^A@F7]V1&O^+O!:QHLYS!GXXUPW
M,S1+K+ABXU]BK8@&2XU3/I17,G6"V6L5)PM(WN(JCDQPC [,1[+,&$L0M@"P
M5N2],DQ'PIX2%@2&CH:F@%KQ(PH3!LS8$"T3B+86\*0>S=!4B7BUT$Z!UNUW
M];TX)E_=GZ#X1\*2E0T)E 4\6M+1"<C$8V-N J W ,V2->-.(S1H403==79N
M]=30O0Z>G'H,R_)^6^%7"((DX!4/3(1J^_>]0;9VS0E/O:/LG'O<.SND[WO,
MWU3^KT]D+T!=&\#+^[(#$..WS>D_4;*A5*5))DA3C/65:\-40V>QM;]6LR+@
M$K8'9V$2!&VO)$I$80E(.$$3B6G-/2]L0#9F"ON74GFN%G"':1&OU1%+[0N)
MQ*9O6Z:&OO1<H4BV!.0C4]MV*HY0,.] "#8A#WKHUK>"9?W9Z)?!7AL:6 TK
MCK5!A1@ F%F%QM(,LPL>M" , P[V$8!AWTZWKT-ZP,O[LY_$1X=?)QJO]64O
MIX&7]V/B(\.ODXU7^K*7T\#+^['Q$>'7R<:K_5E+Z>!E_=CXB/#KY.-5_JRE
M]/ R_NQ\1'AU\G&J_P!64OIX&7]V1&><1>%U>0V235?Q<B+\ECS4H7F,4+KH
MZ4RQ[&#J@3,\>C[8 Q8Z.KDJ& DDO75+ZX]",&67H0PBIR^YE,*'@D<G3LZ/
M@-*'"WA3F5P-PH%'75:F6>SKX/#(?8<H>G!P,LLJJQ1=!#;#CZLM<1)C@*C'
MM&D)T-:8).6P7]WW]#45:<5N!]N5]#;.@] 5@Y1&=QUKD\?5J(=IO5C;79*6
MJ)+7-RP!2QM<4W7V4H3' ":G/ ,L>M"#O6"-R3PV3CXB/#KY.-5_JRE]/!,O
M[L?$1X=?)QJO]64OIX&7]V>Y&.''%J%R)EEL4HBN&"2QUP(=6-[;8^G3N#6Y
M)M[V0M1GAWUBE!6Q;ZHM?0P,LTM@@P"N)=\*(1[O-]F1YI=&"Q\R#KJTB5P2
M*D"Y.2K1+4YZ18D4%A.3JDJDL1*A.>4/0@&DG%#V$0=ZWH0=[UO /G#"*E^;
MMG=W6OQ_8N+%0E32GFV-+WM8NIN$)HL_EOJ,E2XHX6\%ISQ/JV"[7MY#^7V)
M/O:H=49>]C$;OJ3T-YDEG/H>JJH_YOM-99U6E<5JB='U/'XE(SW%CI>(OC G
M0S"4S&() JU[4@5GH-M#K!UFW(Y024E0DB+$8;K8MA#<(F98SDM=5PMX/HB#
M%2WC9QU2)BBTYQJA57,&3D%DK#N]TAIAQK< L!:H_P"H+%O?0,?H!Z=^AC [
MI$-C_&_YNN4JYZ@8:-XS."JKY-Y'3\H-=PLCR6DFVAE?--CH8J:2"@#VV2!(
M/1@!#)V,W9?7[4LP )Z#,CIVYQRX#4M"'J>2_B[2!K:R)BE9C8T57 E+\O),
M<FYK,$UMRQ.@"LTD/="A';T8'19>]BWOZ&ML()R9Y+M1' 1LNJ/4.7Q3I1RF
MKS#'&P78U'6M7)VF&Q-*M&T-3E)!.RAM=CC92^%&HV].V(W$\0R#33PD)R]F
M[80S+&<EK$<+.$"D\"5-QJX[*%)J$ES+3D5Q!S3S&U0/99#@ DMM$8-">/6]
M -UKLQ;UT:WO&$.Z1^B/A-PF<2-*F_C+QZ7)MF'%:4(ZUA*HC9J<T9!Y>CB&
MP9>S"#RQ 'KIZ0C#O6^C>MXPAW2.K\3/@SWB-S^+CQQ][2S]I3'#S>03O$M2
M%5I#M.-7[W]@$_2W>B=@V+K=K]1T=;T,N$.Z1![2XX\ ZC@$UL22\8J*6-<%
MA\@G#HU,=7P%=(EK'&4QJAT&T-AZ=&%8<7LKL]=8PLO1N]!$,/3DP@G)O!)W
MOB3P+CD7?YJ\<=N.:2*Q=K>7E_?/-M"SD#8W1XA2H>E"@XAK-UKWM+1F]J'7
M2,(@;#T=;71C"'=)^B*-H"N_F_N03#+I U\.*OK]+#WR-,ZHFPZTIE,8X)II
M"HI/XD\MZJ(OLP:@HWN.S-%T)U*A.XIE>QIU"8HT&P[8*W)?4T?KA'PI$((
M\8N/HAB/,3!#JLX7L0E)18S34X0Z:^G9Y918A"!]=H(=[WKHUC")W2/T*X/<
M+E!8#B.+U '$F:ZQ9I580PPL8?\ [@# U;"+7_76\80[I?<_3XC'#/Y+-"?P
MMA__ !.,(=TON/B,<,_DLT)_"V'_ /$XPAW2^X^(QPS^2S0G\+8?_P 3C"'=
M+[E"WK2?"JC6UO7&<"6&T1JFR42)>BJNB*W=O)R*PM"D<)/(Y"[2A=$8V@)1
MIEI6DJ$*XQW=31" @2*=E']E<%3D_J5IWE\W$HEC2SM'#&)OT&7/U40]WNQL
MH6 !JJ)3>\66)2"JXA(U3DH;YJ6YRAML&/;&H2,BMN;37Y"4N4IC#1A+GH/W
M8ZFQ?B,<,_DLT)_"V'_\3C")W2^X^(QPS^2S0G\+8?\ \3C"'=+[CXC'#/Y+
M-"?PMA__ !.,(=TON6=6=!4C3"EW65)4U>UJK?R$:9\4PB)LL:.=D[>8H-0D
M.)C4C2B5E(S%9HBPCWO0-F"WKHZ=Y2-M]2W,$(;/O@JY>J1_IJ?*NH,Z ^O#
MZH/T]9LAKL'U@?4A^EK.,IRP!@# & , 8 P!@# & , 8 P#-TZ^%3KZI+^A)
MLVN@(G]A_F_PRD.9_P#KG?C3/N]X!<=5?[-X]UIO8!9F74I:^9 P!@# & ,
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M@6^4L[-72*+KXL])[,D/'IN5D.1S\@$UD.RT!B1480G$>-977Z^I]1L&!@#
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M&JJN2+T@(<F?G.J>6X_M0$.391U+KD2@:8\Q*IT2J2)S4Y@B51 RQZ"+?4,
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M!N2;('VIY1(RB^H+K"UT;P,K[$I\RO*3Y:;S_ *H/ \#,?L/,KRD^6F\_P
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MWV9J;@-BX6F')&!@K^;EO+<N7MZHM2YJ"-I1">"PJH:_],/_ -S[K93C& ,
M8 P"&S[X*N7JD?Z:GRKJ#.@/KP^J#]/6;(:[!]8'U(?I:SC*<L 8 P!@# &
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MF!A?<>?7D'\B2U_XM<:_YN8&%]QY]>0?R)+7_BUQK_FY@87W'GUY!_(DM?\
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M8ZKRVIK N6)T@W)T-(4*BFU $\PL2Q>:F2&F!)+ZQ@BRABUKH#O>@._@# &
M4;<'&ZFKY<H4]6C%%;Z]5R.1&P=Y;)?-H:[QHR6H$K5)#&UTA,CCBXL;NV(P
M)S=B,%O9&Q UT!,,T(5-KH>?\5;CX*?1*T3ZQ9%D_A#;'FV/R9Q4O#FO#J(M
MAS-%'9Y X.:E+*)3&6M280WO+H6L=D8!BT4I!T[P,OH:"P08 P!@# (78'P5
M</QB+]-(RKJ#.P/KP^J#]/6;(:[!]8'U(?I:SC*<L 8 P!@# & , 8 P!@#
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M_-S!,?E#XU#_ /)'Y;_J36G\W,#'Y0^-0_\ R1^6_P"I-:?S<P,?E#XU#_\
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MI'./?E-8XI]M\]]6.0L<IOP)K:A(3;;?>YG[ \!IZSOA*-86,?7!]5\&!@#
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M=DRQP[:0)VDMXFNVMC H96CWP'KO-K6F]\=^K-%*RP[OK]2S/B_K7#FLIO\
M5)U#?#F&FV%G;F\+@A&URRX%;G,60V>&LR?>UZ*0P"JUQS$4M4;"%:ADAA(
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M;_#*0YG_ .N=^-,^[W@%QU5_LWCW6F]@%F9=2EKYD# & , 8 P!@# & , 8
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M_9W R_NQ\57B_P#)OH7^#]>_L[@9?W8^*KQ?^3?0O\'Z]_9W R_NQ\57B_\
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M_?+R*^,_S1;X/C# \O(KXS_-%O@^,,#R\BOC/\T6^#XPP/+R*^,_S1;X/C#
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MW"73!&6TOJ\U*WK$X3SCPH]%A":R.W\G6FO.-NK=RDC%.:8G#._5PS3M^N!
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M%RGQ,H[JE\(QE >1<I\3*.ZI?",90'D7*?$RCNJ7PC&4!Y%RGQ,H[JE\(QE
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M.-, F:8Y NVG$M-,VG./3%J$I)IX!>UFS=;UO6MZWTZWK6];U]#>M^CK>O\
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M<X!*&@$9%)U4H3PE+'-NYRHM&%]53%64U%I-BTH,<#0)P@V:((=BX><?4D,
MLNOK59%,DK:91V;L2-Y=(ZL=8TZ)75&C?F-1WJ\,RLU*8/29S;%'0 \@?5,+
MWO73K73K!.A., \AS?V-E4L:-W=VYL529W]X(ZG7*R$ISV^::G1\]Z&HLX8!
MKG'WF9%BKL2]"'WNE-'T=4 MZ KU'?-*KX_9$L36I MQBGE[TUVM(#I.TI6>
MN5\<0@='U--'!4I)2QP;4V&A4';5B*T @6C-[ZN];P7#.VBNNGW&Q#*B06?
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M+^A)LVN@(G]A_F_PRD.9_P#KG?C3/N]X!<=5?[-X]UIO8!9F74I:^9 P!@#
M& , 8 P!@# & , 8! ['^#!WNQ%[+FH]05E7OPJ1>YUWZ,/*^@-$Y@# & ,
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MPWVF /:_X;[3 'M?\-]I@#VO^&^TP![7_#?:8 ]K_AOM, >U_P -]I@#VO\
MAOM, >U_PWVF /:_X;[3 'M?\-]I@#VO^&^TP![7_#?:8 ]K_AOM, >U_P -
M]I@#VO\ AOM, >U_PWVF /:_X;[3 'M?\-]I@#VO^&^TP![7_#?:8 ]K_AOM
M, >U_P -]I@#VO\ AOM, >U_PWVF /:_X;[3 'M?\-]I@#VO^&^TP#]D_O?V
MQ????O>_6UVO>W8=MU?[>IVOU'3_ /. 7M_^CO([[#W@ZO\ _%WYWYUNZ^^7
,:_\ [=3,>N?R4__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g382677f_139.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_139.jpg
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MQ "Z  $  @(" P$!            !@<("00% 0,*"P(! 0$! 0$
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M--?*5FU0<95G./ G>3.<Y_\ A7.2[*UY]2TA]&\=@)0\ZE.)XOL2EQ:<8_\
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MM E]N2-/UBR%@Y2&^TK"T+;E0Y3:E)PK'E0OO-JQY%)SCR<#Z)__ #S]M?\
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M#@. X#@. X#@3;^S'^\K^I_)XC]$B5]DR/J[O\8KF!Z. X#@. X#@. X#@.
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M-G6OGLYL. X#@. X#@. X#@. X#@. X#@3;^S'^\K^I_)XC]$B5]DR/J[O\
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M_P!.E:>OY:\XMMV:A%MY4WJ.^(J7ZXNICMMU(#BM2CPQ]RNYM30^WB(T5).
MX2=BX>BI>BIC+=>RY3.CID=)6J7J/JW7!E5A/U#5>JMC:;&CB9&.VL_3]H@
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M%'<H<!P' <!P' <!P' <!P' <!P)M_9C_>5_4_D\1^B1*^R9'U=W^,5S ]'
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MD<G+ENMM95EB*UA*68D&-W\Y7YM!B-(:1V^7*4=N?+G//3)),39RMSJC'*'
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M[7&'22]!USS]\]7K5>J5;7+?L*W-6^L$0/IAC\J,H1-N=9<B6"N'Z\1JDZ:
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M3U%#IP]8BTP]83YLBIMG$LJ:,D'I#RD-M-)4ONMMMMI0A-DP6YUJ5<(<!P'
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(_P!!SAXJ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g382677f_13a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_13a.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.D8R04(X-D9#0C<X1#$Q141!-3,Y0S,W
M,#-#,S0X,CDP(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.D8R04(X-D9"
M0C<X1#$Q141!-3,Y0S,W,#-#,S0X,CDP(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( &P T ,!$0 "$0$#$0'_
MQ "[  $  @(# 0$!            !P@"!@,%"00!"@$!  (# 0$! 0
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MBQ%C@*5[)L$(]984&"#D_0XJ" BL4Y0_8$=<_P#%/DW%\L\<?E6LU^9@Z?\
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M>G'0LVV24,4BQB(IB1=$3%*N@JHGQ+Q Q;.\\\4<<Y]X\'CK9%DP88(4QYE
M,D$N/&(X9E!L#8 AT) =&9;BX(JAX\\P\G\=>2SY-U82383Y$[Y,#$B/(BR9
M#)- Q%R+L0R. 2DB(]C8@U+A7']1[$L:WH;2FXOSC%1*!(VNW^0G2,)+Y:W(
M"#$9M-U8*\^<JMT"E 1<HG5X!P,LKPYQX/KIOE]P/#7B\&NTG)L*!1'CYSS!
M)/;463W@T\#L54 ?S$+6%C(_ZJL-LX?A7Y#SGY;D;/?<5S\AC+D:^. R1>XQ
M[I/8*X^0BAF)/\MPES<11_I':4?$EEQ7,W3>;N_N$79,@UFKOE(:!@!*-<HL
M65NJU1BX<P)HMG$V_%V+%DDW**2*CLYQ4764%0OV\:X%N>$;'8_(GS_L(,SE
M>%A.8H(+?M\*/M*B.+H%:9^_V850=B-*S%Y)'+CX.5>1-)S[6:SXS_'+6SX7
M#\[/C$T^1?\ <9TO<&:687++!'V>_,\A#NL2J$BC0(?S8O1Y^W.\@[OLF( %
MTS*_?EJJ;CL3KV/FC@J8G9F5X V9/3,4FJ!NP.X,"&\"P\8^,O&=KOI]MY^Y
MFO\ _1\BE<8P;T@P4:UT)_2C]BQH>G\F!3Z2&\_*SE6HX[CZ?XY<':_&.-11
MG**^N1L'6]GM^IT#O*XZ_P ^=E]8Q:]D7?*).21X6$O%-F9E,QB'B(FU0,E*
M%.4>!B]P9OUG8F+]( 01#5G<+E/%]GF'7:W9Z[(V ]8HLF"23\_L1RW3Z]*J
M?G\2Y9JL$;/::K9XVM87$TN+/'%8^A]QXU2W]-;7X.P=>[6OTTI32E-*4TI3
M2E-*4TI32E-*4TI6:?VB?UR^D&E*S<?B%_OE?3-I2N'2E8@HF8ZJ95$SJ('!
M-=,BA#J(*"4#@FN0IA,BH)# 8"F !X" ^#6(9"S(I!=38@$$@^MB/H;=;'K;
MK611U5796".+J2" PO:ZGT(OTN+B_2O@F8>(LD6ZA+%%1L_"OD3MGD1-,6TG
M&NFZA1*=)9F\360.0Q1_1Q#P@(#VZ^;8Z_7[C"?6;>"'*UTJE7BF19(V4^H*
M.""/Z/X5]>LV6QTF?'M-+D3X>SB8,DT+M%(K#J"KH0P/]/7ZW%>5> 6O^W7?
MCD;;Q5G+H,7WV"5M,/7UG"KE""D0KR%JC#H"J<Y@59-@=L!4$>=5KT>H)C)E
M'5'/%<'^4GR@V_B;2.__ ,*VF,<F* L66&3V%R8RMR>J+[L!;U:/V^\DJ#5_
M/+T_^<WQ-TOF3?(G_P [U&6,6;("A6GC_<-B2AK =';VL@+^E)?<[  Y%>LN
MKW5_/:FE*H9NWW8OL;.F>%<+-5+9N!N1D(U@RBT"R1Z464+P:NEVP<R2]G=)
M&ZC1LI_#;)_$N."92E/5WSSYVR>'SQ^.?'*'/\J[ K&B1CW#A^X/M9EZALEA
M]T4;?;&O\Z6R!0UM?CO\?,3FV/)Y/\G2#7^(-:&ED>5C&,WVC]R*W0KBH1VS
M2K]TC?R(;N6*;)M&VH-<!Q3^X7-X2TYNNJ2CBWV9=<\A\G3?K ]=U^(?KB95
MTHL['J2+X1YWRX=G!(A0'V/ G@N#Q;@R\@Y%(,WR3LE+9606,GM!SWO!$[7+
M%F^Z>;UF<=/Y:J#XGR)^061Y<V$7&^,QG \7:M@N'C*HC]XQCL3(FC6P4*GV
MX\'Z8(SUO(S$7/U8JJRTTI7F+NQE)+<=G3'NSBH/5TZ]'/&E\SC*L3")8^,8
MIIO&T2LH0>4JT?&N 4*0WAD'[4!#BF/"EWG;.S/+WDW4_'K02,NJAD7-W,J'
M^SC0!UB)'2Z1L& /]_- /5#5Z?CY@87A;Q3N?DIR.)6W$T;X&CB<?VDKDHTH
M!ZVDE4J2/3'@R#Z.*XLP,IS<+N$8;-Z9-OL>80Q+2X>8R8%9.#1[+-DF<86*
MJZ)P\@S-HTD&35!)0#(=4ZRZI%133+K#R!C[/RQY8B^/7'<F74^-=#KHI=C^
MW/:\JA(_:QA].Q5DAC16!3N,DKJY1%K]/'&5JO#OAV;Y*\EQ8MSY3Y#LYH=9
M^Y'>D3%Y?=RF'J'=XYI7=2'[!%%&R!W:I$LW]-W;C(5T8^D1EAQ[;V://7[S
M'6B;?R+*62+S,WDDV>NSM7:'>  500*V5*7B*1R" :VW<_#[Q#E:C]KQJ'+U
M._C6\&;'DS/(DH_2\BNY5E[K%NP1L!U1E-JTS1_-?S3A[G]WRF?#W'')6MD8
M,F+!'&\1_6D3(@9&[;A?<,J$V$BL":[[9#F&[WZJ7S&^5')I#)F#+8>DSTRJ
M?J.)V.*H^;1D@]6X +I^W<Q+ENHN( 9PF1)0_%0QQ'U/C7Y!Y)RK1;3A_.',
MO,^,YYPYY2;M-'=UC=S_ %G5HI$9SUD54=ON9B?)^4GC?BW$>0:GFO 4$/!^
M5Z\9N/"!98)+1M+&@_JQLLL<BQCI&S.B_8J@7=U9.JMTTI32E-*4TI32E-*4
MTI32E-*5FG]HG]<OI!I2LW'XA?[Y7TS:4KAX%'R3EYR& 2G)Q$.<A@X'+Q#@
M(<Q1$.(=NG0]&%U/J/Q'U%+L.JFS#T/X'Z&O%ZI7NQ?T\\Y7^HY(B+'8,%Y2
MFC3];MS,BDB\2.FHL$?)-UG:Q4I&4CX]R#&58F6(Y,""2Z?,7E _\Z=#R?;_
M !,\F;70<PQ\S+\9;O)]_'RD!D<$$^W(I8VDECC;V<J$N)#V)(EQVAOZ;<BX
MIIOF/XKU'(N%9.%A^5=#B^QDXCD1H00/<B8("8XI)%]_%G"&(=[Q/VGN*6ZL
MG]1C:S!P2TO&VZ:M;\J!E&E<AZM.,Y-ROR\4V[AU.,HV*C2F-V'446,! XB
M&X<![YN/EWX0UFK;88>?DYV5VW7'BQIDD8VZ*S3)'''^;,YMZ@-Z5772?"_S
MWM=LNNSM=BZ_$+V?)FRH'B5;]65('DED-NH54!/H2OJ(,V84_(69<[WO>7D>
M$5KL;.,Y"(Q[&+D63*Z3?MVL05:+!P1)=Q!5ZML@:)NQ*4KQRL<Y.PIN',_C
MKQ_EGD/R?M/D/R_&;$P\F-XL"-@1W!U6*\7< 6A@QT$0E( ED=F7])KJOR9Y
M)P[QIXGU/QHX7E+FYN+)'-L)5(/88V:8B7M)59\C)?W6B!)AB15;JRU<RU[H
M\:T[/%1V\2J%D/=K@A&*,W[2-05K[%S.%='A63]T=XF]%5^5F;B=%!5)'F+U
M#!Y7+8C>^:^'<?\ )^!XGSES#R/8+&4=8U,"-,&,*.Q</=^T]41E2X[B.MJT
M<?\  W-^2>)MCYDU[X0XOK7E#QO(PR)%@*"=XU"%+1]X^UW5WL>Q3T[HNWO[
MIGNW"E0T=5FA3Y!R&67:UJ7>IIJ1-89Q0,DY6>714$W?Y-L,FD#-ORBF*@BH
MIQ*3D4TGY*>;LGQ!QS'P])&#RO;"5<>5P#%C)%V"6=@?UR+[BB*.W;W'O>ZK
MVMOGQ9\"8OFKD^3F[Z0CA^F,+Y,*$B7)>7O,4"D?V<3>TYFDN&[0$2S-W)1O
M:EG3:!@M.2O=[OEJO.<[:=VYLEQ6I,_()Q!)%05GL9 O'P$=KKOE#<SY^<A%
MG1O(*!$2@4U9_!GDWP#XR2;D_)]IG;/R9GEFR,LX<\@B$AN\<#O9F9SUFG(#
MRG[0%C%C:GY >*?D;Y6>'B?$]3@:KQ5K@BXV&N;CQF8QCM26=([HJH.D$ +)
M$/N):0W%T/\ Z4[3?_:KA_D28_\ /5BO_P!B^"?^.V'_ "4O^FJR_P#XC^0G
M_ :W_GX?]%7(HMUK^2*;6[[5'#EU6K9%HS,(Y>-%&+I9@N=0B9UV:PBJV4$R
M0\2F[0U8;C/(M7R[C^'R?2,[ZC.A$L+,I1BA) +(>JFX/0U6OE?%]QPKDN;Q
M+D")'N]?.89U1Q(JR* 2%<=&'4=16G9UR]!X)Q7;<FSID#E@6 IPT<LJ5(9N
MRON+:!AD^80$P.WQBF5$.TC<BA_ 4=:]Y-Y]K?&7!\_F6R[6&+%:&,FWO9#_
M &PQ#_:>Q;\(U=O1:V3Q1XYVOE?G^NX-J@P.7+>:103[&,GW3S'_ &([A+_J
MD9%]6JMFP_$DU6:).9KR%U7>5<^/S7":>O2"#UG6GCA60A6(@<.=N,LJY-(*
M)]@%3403X?P@ ..?%_@6QTW%\GR/RR\G..4RG+F=Q]Z8[L7A3KU7W2QG9?HK
M1+_=BNV_++R)K-YRS%\8<.[8^ <1A&'"B'['R441S/TZ-[048ZM]669_[PU&
M.7921VF[N76XN8AI25PIFBM1]1ODQ$-#O7%/L+%&,;H.G2).'D&/"MW"11$O
M>4E'":8BJF4IM,Y]FY?@GSV_EW88\\_CCD>''BYLL2EVQ)T$:AF ^EX8Y%!(
M]Q6E1"70*=Y\=8&%\A/CM'X8UN3!C^3^,9TF7@0S.$7,QW,K,JL?J!/)&Y /
MMLL+N!&[,)_N&^_;!4ZJO9V63(>Y.P:F6BJI62/G-@EG@DXMF"C5PS;EAP56
M$"J*NQ2*D B/ P@!1ZIR#Y/^%=%HVW6-N<?8S]EXL;'#M/*]OM0JR+[5S8,T
MO:%%SU-@>1<;^)WG;D._3196CR=9C^YVRY6247'A2_W2!E=O>L+E5A#ES8=
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MSL7<DNQ)))N22;DDGJ23U)/4FOF?L&$JR=1DHQ92<:_1,V?1TBT;OF#UN?\
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MTZRU3W =+=*MVD4Y$DB*JBNJ1)(BJXD(D*ZI$RE47%), 32%8X"82E "EX\
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JE*D*@?EKYFCWKO/S;F'N'>NEW+J<.SH]/M[UP_9Y_P#I\K6)O_14U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g382677f_13b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_13b.jpg
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MQ "[   !! ,! 0$             !08'" (#"00!"@$!  (" P$!
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M5_[P,FV3N TC(,HBV$O$X =R$WI-PC74>*)I1)5VKZ9ZQ,[]:8\9%L@(P\U
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MT3$4+U*8HC9+QAS/:N?\#VSDVT.KQ2XL:2J""8<B-%2:%Q_=9'!L#W4JPNK
MU5SRQP;=_'/D3=>*;S&Z2Q9<KQ,00LV/([/!-&>S*Z$7([.&0V92*?\ 9K3
M4:NS-RM4DWAZW66"\O,23I0J:+=HT(*AB@)A#S'+@P FBF7J=54Q2% 3" <R
MK>M[VKC.T9/(=\F3'V?#B:661C8*JB_]K-^E%'5F(4 DBL0V+8-WY5O.-QK8
M('R=ZSIEAAC0$EG<V].RJ/R=CT1 68@ FN9_Z:,7)6:Q=PVZNF:C",T2^)Q\
M.B<HE!0X3,Q:Y8"?]IPCQGFJ!A#V>9XP^4!Y33X;869O6[<M\G31M%A;ON@C
MB!]3[LN3+;Z^W[\:$C^]J'I5XOG!GX6Q[-PWQ1!(LN=LVTF29AZ#V8<2*_T]
MSV)7 /\ =TGU%5IPO5](I%Y[B<[Q*OM+'L>P;7+L*P:1!)2(J,'6).W+V*XS
M::H@W!LR"81*B*_N ,50QBJ"0J2FF_&7.N8<:Y-RWB7C?$CR_(7(.22IC&2Q
MBQ8<:3*:?+F!_'2GNH$U_A<.S!M(1]W^5?'W">4\4X9S+RCF287C;C?%X9,H
M1W$V7/E18BX^' 1^6I_9<OH_VEBBJ4U&1+;F[/.ZF50">F^]VZMKL<OJ!;1#
M:?2JC9V(>,&R96L_%%%HF?\ = 21Q"]/D2_PYOMOC[YQSH_ZIN7DK<4Y(1JT
MQ+.,96[Z1IGB&D'I<0*+=D]*KP/DCX!V^7^D[7XMVQ^+@Z=4S8YRV3MJ.K'E
M_,CK9LAC?N_K6[&^XK9LMV&-[:^[,&#^7L@)$S;5V!$4F5E4<*'0CFLBY0;L
MFD@A*N$Q;IN11;NVSWHBY(;QE4#L\>^7/(G"/(,/AWSO[4N?F6&W[FE@F06)
M6-9&546196&A9"B2QS6CF4Z@PZO)7ACQGSWQO/YN^/7NQ;=A7.Y;5(27Q@H#
M2-&K,[QM$I]QHP\D4D-Y8&&DH7W^H)IE^RK'JM/9Y<9*C3#_ $N'A'\U&%;&
M6"(<PL^NY16(Y:NRF0*LU35,!2>,13  '_ <F^5W,^5<&\?X.Y\2W";;=PEW
MF*%YHPI/M-#.S AE;\055B +_CT^E8G\/N#\1Y_Y(S]IYEML&Z[;#L<T\<,I
M8+[RSXZJP*NGY$,R@DV_(WJ/6--[K>Z^,:Z KLTCV[99,()K9_4*LS>*V^<@
M"E!-C;+8^8R$(NDYL!">I31,Y,4J:@>%$A>ACXIC<=\Y^=,).52<BFXCPC(4
M'!Q<9'.5-!V3*RG1X6#3@>XJF0@*PTQJ+%LQRN3?'_X^YTG$(^,P\SY[C.5W
M#,RG08<&1>[XF(DD<ZE<<GVF<1 EE.J1FN%BNRV[NB[$[;4971](>[O@MGER
M0\D_EO5N)6(4$HK.2)*RBSV5A)UNQ(=RV*#MRQ?$143,!3A^[@^\;]YL^,6_
M8&=R_>).3^+<V<12/+J:6(]V ,I>6&94#21CW9(9@C(0&[9_LG'? _ROX[N.
M!PK9(N)^6\#&,T<<.A8IAV4D1!(IX&D*Q2DPQSP%T<%E/7KRT=M7[1H_8KD=
M,7[5L^9.DAZIN6;Q$CEJX3'Z"[=4I@_R'E^X)X,J!,K&8/C2HKHP[,C@,K#[
M,I!'\:\Y\C'GQ,B3$RD,>5#(R.I[JZ,5=3]U8$'^%;^=M=-'%*.*5FG_ #$_
MXR_>#BE9N/[A?^LK]\W%*T\4HXI7)C1<SI6Q?J-V7/\ 08<LU6IO"F+MPD19
M5E(-9*.A&J\?+1DFV$KIC(LU1$2G 1*<HB10IR")>40Y=PSCGD'Y>9G%.5XX
MR=FR>,(S $I(LD<*F.6.1;,DB'L1<$75PRDBO0OA?..3^-_A=A<OX?DG%WO%
MY6Z*2H>-XY)V62*6)KJ\;CN" 5(#(RL U:.WLEN[3>[A;M5=61]:,JT2+<3]
M'"1,'FQ;I>.D9:+?(H%'R&#Y489W'R*: $0<J$37 A1]G.KQ.N_^"?/3>#Y\
MR7-X-NT#3X?N=XV:.26-PH_%'/LRP3JEDD8+*%!KM\Q-QWY"?'9?/V/A18'/
M]FG7'SO;[2JLD<,J,Q_*1![T61CLY,D:EX2Q%=:3+(%63;F70*Y63451;&62
M*Y622$ 552;B8%E$DA, &,4HE*(AU$.O+XF2-9!$S*)F!(4D:B!W(6]R!<7(
M%AZUYYB*5HVF5',*D L =()[ M:P)ZV!-S;I6_Q& IB>(? <.AR=>I#ATZ"!
MR#^Z8! >G00^3G9<Z2O]T]QZ'^(]:ZM(U!K?D.Q]1_ ^E<AN\JO17;3N^$]Q
M&7,FU6D;19GL%>82&2(PB;$DU6B5))5>.:@FV+\=A))9%V4I (HLDDMT\T!,
M-!?D-M.#X;\G\8\M\)C3!S,W->'-AA 2*<*8C(6C6R_[:&1TE  #.L<EM8+'
MT7^-.\[AYO\ $_+/#7/)7S\+ P4GP9YB9)<<NLHC"R-=O]A/&CQ$DE4:2*_M
MD*%G]1<WYJUSM0RJ2642IMFMAWLL4QA(DX/*6FN5E3S1]A?,0B'"Q"_1]2;]
MO/H?+DC?.>\%X-FL5X]F9Y>7K8,9,G'QS?[K$S@?3W#]:^;\,!_0/'?D#G^"
MJMR7!V\)%TN5$6+DY(M]FF5"?K[8^E=6TFS9DDDR9MTFC-DBDS9M$"%20:-&
MB96[5J@D0 (DBW03*0A0  *4H '+SI##C(N-CHL>/&H1$46544:550.@"J
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MF=LPA6#<(06(10GM/KMJ,<,\6FTH73%D1AG'Y"_S_COO7"O+OA[/^-7,<F/
MWLSMD;;.0H,C%_>31?2)9\>8O>(MKEQI65#^)M-4-^I!VKRD&G+O;/9H!Z*
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M<1>*O'F#Q$NDFXIJFRI%_2^3,0TFCU*( L2$]U0-TO:JI^<_*$OE_P EY_-
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M(IG+-1<VM7D;]L6&H.I5<](]>SF5-8.[KLQ8;1-5!NENJ#5'8(^(J4K,NZ_
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4[_J_H^/V=?\ ;^]TYQ-_[*FO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g382677f_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_14.jpg
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MQ "P  $  @(# 0$!            !@<%" $$"0,""@$! 0 " @,!
M      $'" (& P0%"1    <  0($ @8'!P0# 0   0(#! 4&!P 1""$2$Q0Q
M(J'18E.3%4&!L3(C%@E187%"4C,7DB35EO!R0U<1  $# P,# P("!P<$ P
M  $  @,1! 42!@<A,0A!(A-183(C<8&1H4(S%%+3))0551:QP=%#X7)C_]H
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M]_8[9$')%_C9H=D73FMANGOB:V4O<YC R,R?,[46.TD1T+6E_P"#W*T@ 1$
M .HCX  >(B(_H#G=N_0=UT+MU/9:/ZAWK1=>OC_)\8S.U[]H\,95*P,*D)T:
M_7W"!_3<,WLN@RDU'+IHK_#7%-(C=%4!3,MZ@&(&M6]O(^RQ.Z)=B<=8:^W5
MN^W)$[+6H@@<#1S'RM9(7.8?:_2T1L=[3)K!:-I]A^,%_F-IP\@\FYS'[0V7
M<@&WDNZ&XN&N%6O9"Y\0:UX]T>IQD>WWB+00XX>G=\J;2YQ&?]P^/V_MZGK$
MJ1O7YBQJ*/JC(.%5"(I(N)1=A&*,"*+*%)ZY0<-TSF %3I /FY\_;WDRV#<5
MOM3EK;^0VGE+MP;!+<$OM7N)  =(8XRP$D#6-<;21K<P=5]+<OBJ^XVS<;PX
M;W)CMXXFS:77$-N R[C: 22V)LDHD( +OC)CD< ?C:\BBWY$! 1 ?B'_ ,^(
M> \VE(H:%:C U%0M=6_<=7I7N'>=NM<K,[8IV"@QG+E;&+F-3K-/(#8K@S"3
M!507SB0*9TU1\B9?]]T4GQ(IY<20\O8F^Y9DXCQ%G<W>3M;;YKNZ8Z,6]H-.
MK1)4ZW/!=$RC1^.4-_A?3,TW"V8L.&X^9LU?6EGBKNZ^"SM'MD-S>'46B2*@
MT-CHV5^IQ_EQ%W9S*[$\RVL,IPB<(G")PB<(G")PB<(G")PBF]<N[JNL#L$F
M"#HAG*CD%%%E$C%%4B93$Z%(<! !3ZA\/CR$554J::H45 !_$"1(1#S*-'/J
M'('Z1])5-,#]/_N')I16.A.1CN+5F&S@%F*"*JZQR%,*B16Y/56(='IZA52$
M+^Z(=1_1\0YQ1:K\\BBZ[Q5R@S>+LV@/WB#1RLS8&7(U*^=I(**-61G2@@FV
M*[7*5,5#?*0#>8? .>&X?-%;R2V\?RW#8W%C-0;K>&DM9J/1NIU&ZCT;6I[+
MSVT<,MS'%<R?#;/D:U\FDN^-A< YX:.KBQM7:1U=2@ZE>86!]G\]HUTO6X]Y
M%<5F[S*V5TT@:',O4GM>8QS,$S)2*J<8\69R,(@54&L4T!06I$$#*J$.<X=-
M+>+. ,IN[<>3Y+\A;,W.YI[QS8+*9X? R-E*2$1O+)(6U$=M$'?$&,+W-<YP
MIO7RYY'8C9>V,3Q7XUWK;7:MO8L?/?PL++A\CZUC!E8U\<[J&6ZE+?E+WAC'
M-:TUVFT;LV[=M*KKN 7S2K5)\JV41BK13(=E79N#="02MW:1XQ)LA((HJ=!.
MW<D525* E$ $0,&;MW^//$F\<1)BY<-8V%TYA$5S:1,MYH74]KP8PUL@!H71
MR!S7"HH":C >R_)7F;9&:CR\6<O\C:-D#I;6]F?<03LK[F$2ESHW.%0V2(M>
MPT(J!0ZO?TY+?;89UM7;A;WQY(^-3YA@%C'.H1@S--2<#-Q;(RAC'3B32C%-
MVV2Z]$O<J '0!Z!A3Q#S^>QT^X^(,_*9G;=NS\!))#&&:2":-E:D1?(QLL;>
MS?D>!TZ#/'FEMW;N2M]L<U;<B$#=RV?^(  !D?\ #%/!*^G0R_$]T4KN[_C8
M3U%5N_OFO1>%9+<-+D?15<0K#V]>CU3 'YO:I(1:5^, !'J<BKXP*+=/W6R2
MAO\ +S93E/?]EQCL/(;RN]+I;:+3!&?_ &W,GM@C^X+_ '/^D;7GT6K7$7'-
M]RMR'C=D66IL-U-JN)!_Z;6/WW$OV(C!:SZR/8/5:I?T],?E*Y09S<[SZSO1
MMT>K3ZCY\41?(U-5\N^9J'%3YTU+1*+*2"@>'5'VP?Y>8,\3>/[W$;6NN3-S
M:I-W;FD,Y>\>\6I>7L)KU!N9"Z=P_L?#]%L!YC<CV&:W=:<5;5TQ[,VI$+<1
ML/Y9NPQL;P*="+6(-MVGT?\ .?5;LZ5)RT)G&AS, 4YIV(HMODX8$P$R@2K"
MO2+I@=,H>(J)NDBF+_>'-D=XWM_C=H9;(XH$Y.WQEU)#3O\ *R"1S"/N' $?
M=:O;(L<=E-ZX;&9<@8JYRUG%-7M\4EQ&V0'[%I(/V6GW]-ROUR.[9(2RQ((N
M+%=;#9Y&[RX^522>R[":=,&C)^Y'JL8C&-224(F8>GF<'4Z=5!$=?_#[%8BT
MX8MLS8:7Y?)7=S)>2]Y'RLF<QC'N[D,C#7!I]9'/I5Y)V/\ -?+YJ]YRNL)D
M-3,-B[.UCLH>T;(9(62/?&W\(+Y"]KG 5I&UE:, $_[ZJU5[)VM:JK:$&IAK
M,,E8ZV\<%)Z\=9FK]FWC18K&^=)64%R+-0I1#U4EQ*(#X=.T^3>&PF8X1SC\
MTUA-E;BXMWNI6.X:]C8]![@R:C$X#\37D&JZCXI9S/83GK 1X)\@%]<FVN6-
MKIDMG1O=)K'8B+2)FD_@<P$4ZJ)U[?ULF[%<_P!DNROO+*CF,&RA6K\X^XL=
MH<).(NII+"?^(L5TU:I.W)_$?;)J'Y\+$\J2;#\9,5R%N0_)F6X6%D+7GW7%
MRX.CM0:]3J:ULLA[_&U[EV#,<0Q<A>5V7XUVNWX\([.SOF=&/;;6K2V6[+:=
M&Z7/?#$.WRN8U=GL9QN6S[,WVC7KUW6K;B__ )[N#Y^4?S%M'2"B[Z"B5Q/_
M !$E5"/E'SA/P\JSH""'\(.GF\9N/+[:FS)=W[GU/WSN67^MNGO_ )C8Y"7P
MQ.KU!(>Z9[?1\ND_@%/#Y5\E8_>&^(ME[4TQ\?[5B_H+..,_ENDC#8YY6TZ$
M L;!&[U9%J'\PUW:YLBM7$X1.$3A$X1.$3A$X1.$3A$X1.$3A%G8275C0DVW
MF,+64BI!HNEU'R^J9FO[58 ^ '(J(%Z_Z3"'(46"Y43A$X15WJVI53%Z%/Z-
M<WA&T/ MA.BU Y0>3<LJ!@BX"+2,("XD99T )D*'7R%\RANA"&$.I;ZWO@N.
MMK76[MQ2!F/M65#:C7-*?Y<$8_BDE=[0!V%7FC6DCN?'^PMP<F[MM-E[9C+\
ME=OH74.B"(4^6XE/\,<3?<2>YTL;5SF@Z)?TYJ79I%EKO<9<&IF<EM]G76A4
M#%,0%X=K+RDM*22 ' #"P=3LB+=L;X*)LA,'@8!'6'Q$VYF;NWS_ "[N!ACO
M-RWI,(I35$V62621M>OQNFD^.,_Q-A)'0A;8>:.YL'9W.W>%]N2"6RVM8-;,
MZH.F9T,444;J=/D;!'\D@_A=,&GJ"%1'>U>K%OW<14.W+.J[(7V.SIZ9[8*U
M%N@9MI^Y*MR+2J4M)F,5O%P=:BCD9NG2AB@W,X<@4P*>3F+_ "1W/E^5.6\?
MQ#M&SEREIB)-<]O&[0V>[+091+)T;'#;Q$122$C09)J$/TK+'B[M3"\0\-9'
MFC>=[#B+W,Q:+>YE9K=;V8<1$8HA5TL]S*'311-!^01P5!9J5W2V=?U,D6A)
MV%U;)X]5DV1!AF58;1+*'8,VB14VL''GF*@I&KIMFZ942>L^$! H?Q?\W,E7
M^T?,QD R>.SF"B?&P:,=;-B9$QC0 V%AEM3&X-: QNN;J!_,]5B[';S\')+@
MXK)[?W!,R5Y^3)W3IGS2/>27SR"&\$C2YQ+W:(.A)_+]%8G:MW=3FHVF=Q#;
MZNC2-NK2;TJK$6:D?'6E"-3 99L:)=*+?ELVS;']<Z!%%6KMH(K("!"B7G;>
M#N?,GO;-W/&O)5BW&\DV;7U9H+([D1C\UOQ.+OCF8TZRP.='+$3)&0T$+IG/
MOCKBMAX&TY3XMOW93BZ^<RC]8DDM72'\EWS-#?D@>X:&O<ULL,H$<H+B'*'+
M]OO<AVU6^SS_ &DOJI;<SN,FI-RF,WER5F2"E%O]P]?>KNX](S<A !-)1-VW
M7! I$E2+ F0X=>EXIY@X<S][E.!I;&_V9D)C-)B+UV@0RGN8'N=&"T#VM<V6
M-^@-9(V30UR[+%S#PIS=MRQQ'D/%D,=OC&P""+,V+=9GB'87#&LD.HGW/:Z&
M2,O+I(WQ%[FKHRV(]VO=5(PL5W*.:ED^.1,HUEI'/* _+(3=M=-#"9%%X\0?
MS )E\1*19P[$K8#"=)N97RG+Z]]QMSSSC>6UCS&^PP7'T$S99+"Q>'S73FGH
MU[FOEIZ@.?+2.I<R$OHX>UC^4O'G@&RNLAPBS([AY)N('11Y"_C,<%HU_P")
MS&.CAKZ$LCBK)0-?,(ZM."M4>P[K.Z^LXU!-42]O7:HW:N[2T9!TA9>T1X(Q
MS6O) 0125;I+LDXM,O41!JT?&#]_J/R\Y:6O.7.MEQWC&-'$VQF-=<L9_)EN
M8Z1M@%.A:',;;-'7\N*Y(_$OK8"\N_'_ ,?;[DO+2./,>_WN9:O?_/AM9*R.
MN#7J'%KW73CT_-EM6G\-%Z1SVAY_5Y!.+LU[I-;E%O+Z,7.6F!AGQ@/T],",
M7S]NN0HAT\OR '3X<W"RF[-J82Z%EF<IC;.]=VCFN8(G]>U&/>UU/IT_0M)L
M3LW>&>LW7^#Q.4O;!M:RP6L\S.G>LD<;FD_7K^E2M%5%PBBY;K(N6SA,JS=R
MW537;N$3AU(L@ND8Z2R1P^!BB)1_MY]R.2.:-LT+FOA>*M<TAS7 ]BUPJ"#Z
M$$A=?DCDAE=!,US)V.(<UP+7-([AS2 6D>H(!"^G.:X)PB<(G")PB<(G")PB
M<(G")PB<(N0^/ZA_8/"+CA$X10^_7ZHY?49J]7F80@JS MO</GJWSJ**&^5L
MP8-BCZK^4D%NB;=NF G54'H'AU$.O[IW3@=E8"YW-N:X9:X:U9J>\]22>C6,
M;W?(\^V-C>KG&G:I'9-H[1W%OO<5KM3:ML^[SEV_3&QO0 #JZ21W:.*-ONDD
M=[6M%>] ?*FIU/0/ZB6D-]*T9K)T[MAI$FX0IU1*L=!Q;%T5/3<H)+IB4KI^
M]*0"RTF3J1LF/LV@^;SG+HW@L%NKRWW@S>.[F38_A;&S.%I:U(==.!HYH(Z.
M>^E+JY'2-O\ AX#74X;_ &X=P;0\--E/V3LN2#)<ZY2!KKR[TAS;1KA5KBTU
MTQLJ3:6Q]TCO\3<#3I:?7--!G7(,&\-'M6,?7X8Z<3$L4"-V35I$,#>PCFC9
M( (DW23;E3(0H= +X<WW9';XC&?%CHF16EI;D11,:&L:V)AT1M:.@: T- 'H
MOSL?+<YK*_-DII);R\N0997N+GO?-)^9(]QZEQ+BXD^J\N?Z7<<UG8G==6E1
M*\NUEOC>+D9!?HH]18N6I[0\2!0W51,DG,2ACJ=/ XMR=?W Z:3>$]I!D['<
MV^;ZDFY+S*-CD>[J\,<TW+Q7N!)+*2[ZF-O]E;X^>%Y<8G(;4X_L*Q;7L<2Z
M6.-O1AD:X6K#0="8H8@UOT$CO[17JSS>9?G^O)WO2:(4OO![1]%KI"MK5/SD
M5$3'M@\B\FSBK;$0S4[D"=#+"M$6-RS$P]?,B0I!\"@ :)^1D$6W?(#86[L0
M S.75S%%-IZ&1D=U%$TNIWK%<215/=@#>P"_0?QDN9=S>.'(FS,T2_ 6=K+-
M#JZMB?+:33.#:]M,UM', .SR7=W%>LJA0*H<H>(%.8H?X (@'-[G"CB!V!7Y
M[,)<P$]R M6^[W=@P/&9J?C% ->;,<:CGC(A?5<J6.31.4THDW#J=8E?9"9S
MT !\RX(I_%0.82Y^Y.'%O'=QE;)U=S7I_I;!@ZN-Q("#(&]R(&5D^[_C;_&%
MGGQSXH/+G)=MB+YM-JV(_J\@\]&BVB</RB[L#</I%]F?(_LPK3F79VGLC[0*
MS 5<HI]P6]VZ.CY*:.)%G\9:K.U,NY\BZI5 4?5B)%-D@<X&*20<J..@CUZZ
M]W]OF_&W@"RQ6%%.5MTW\<<DQH9([FY;J=1QK5]M%IA834">1\M#Z[*8ZYP/
ME'Y&WV7SQ!X?VECI)(H141RVMLX-;5HI2.ZEU3/ H3;QLAZ>EUT?^G1@T;7B
MEU2-E]2T*51]S;KA,V:P-U5YMR7SO_RA-C(-C)-T'!C%36<&<.%?+YSF\?*&
M1]L^(O%]GB0-\0W&;W9.W5=7<UQ.TF9W5_Q!DC:-:XD-?(7R.IJ<>M!B_=7F
M?RS?9DNV#/;8#9UN[3:6<-M;N#8&](_F,D;JN<T N9&(XVUTM;TU&M<[93_9
MKW14[!F=DF+)@FZM'B]%CI]T+Q[2;0@9=/VC5?RD3*4'R2;=;TR)IND':2AR
M LD8QNG;2M<KX\\V8_B^WO+B\XMW/&]UE'.[6^SN6U&EIZ"FL-8_2&MD9+&]
MS?D82>[[SNL1Y+<#Y+EJYLK:RY;VI(QM]);MT,O;5P:=;F]23\9=(S47.B?#
M(QKOC> WU&YNRM#4X1.$3A$X1.$3A$X1.$3A$X1.$7(?']0_L'A%QPB^#IRD
MR:NWK@3 W9-7+UP)"^<X(-$%'"PD)U#SG!),>@=0ZCX<\4\S+>"2YEK\4<;G
MNH*G2QI<:#U- :#U7FMX)+FXCM8:?-+(UC:F@U/<&MJ?05(J?1?SUZ%W09]W
M/Z_'2>Z6BPTSM^I[T[JLYQ6(UW,3=A*4?*5U,NF2R#)G*S"?@Z="<QV;81;M
M2]3&6'\G=V\U;5YIY AO.3KV[QW%6/E+K?'V\;Y9I_35,YA#&2RCI+)4F*,F
M* 5+I#^Q>SN"=X<$\<36/%-A9Y/E_)1!ESDKJ1D,%N>Y;"UX<]\4)ZQ1:0V:
M0":X- V(>AD1_4<[/*_%1L%!.K;#PD,R;QL3$QN?K-6$<P:I@DW:-&Z3\")(
MI$#P /$1ZB(B(B([96'E[X_8JQAQF+??V^-MXVQQ11V):R-C11K6M#Z  ?\
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M.I4 FAZE9UVT:/VKA@_:-7[!XD9!VQ?-D7C)VB;]Y%TT<D5;N$C?I*<H@/\
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MI'-6K1--%HU;,6Y4VK=JU01(1-(A"D3(0I2@   <JXJG#8+FA\\892I&2BE
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I?RV=\WN/SS\DEO0]SZ?H^C[%?U?8^3_]O)U\WF^;R_#P\W(:U^RJ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g382677f_142.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_142.jpg
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MQ #X  $  00# 0$             !P4&" D#! H" 0$!  $$ P$!
M      $" P0'!0@)!@H0   & 0$& @(%$@\*# 0' 0$" P0%!@< $1(3%!4(
M%A<A&#$B(U<)05&1T9+2))2T)=4F5I:V=Y<X83)24W-TU#5UM3;6-U@9<;$S
ML]-4E78G.8%"<K(T1$7&1X>WQZ%D2(C!8D-51F9G*!$  0,"! ,"" H$"0H&
M P$  0 " Q$$$A,%!B$Q!U$402(R4M-5%@AA<8&1H2.4M!4W0I(S=?#A8G*R
M%Q@X&;'!\7.S)'2&1PDT9,0EQ7:B4T14_]H # ,!  (1 Q$ /P#U]3..J=+]
MTM>>8H0FW&3*M="WK/&5%[%+OVT!39""DFD9A57CNS1SD]I%=LHUA4DP)$L&
MPO#@111 5NNM]MG1+WJS;3[0;.[=-I?=ZU6_,TCVPVSXGM9IAJ[ XSU866S6
MTMX6&9V%SH\?:/3]V;@L.BMW;[X=;-V=>Z<;/1M-;!$QT]VR:-TFKBC<QHML
M,C9+MSJW,\@@;B:V7+A7&]?CF++MMS\R5D$\UY=[D+A2<F6<)>15D+15GSS,
M#*2J\G&*.U&(1-7:U=B+- B) C#,2&)NB!Q-\/MC3K:W@VOU$@,@WUK.Y[FU
MOI\QY?/ ]VHM? ]A<6Y< @BRV!HR#$TMH<5=A[NU2[N+C=_2^X$1Z=:#M&UN
M]/M\J,1VURQFEOCN8Y T/S;EUS-FO+SW@3.#JC#23<781Q3:\JW5''M==R>$
M4*9:,<YCL%AG)>PQW<)DB1G(9VN9<\F^<!8E,?!&O$WLV3<*L^D3LT1,1NJ!
M/J=I[#VAK&[KYFV[9\NPVV,]EJ4TTLDS-8O7RQ.-3(\YQL\$C9;H4#I9G0,)
M;&_#\=O3J-O?0]DZ<_=5VR'J,[4+>_TJ""&*"30[!D,K0&B-C<@7V9$Z&T-2
MV&!MQ(&NE87=2*212^#!>-R)%!NE@6QMR-R$ 2@W3ZFD5N0@B "7A%W +MV;
M/1JS:,8SW4WQM%(F[>F  [!C% /BX *_>OD?[Y<<KG?6NW/ XN)_2.6<1/Q\
M2536F ;!/1>4(K$&,7O;GCNSU"FQ@T&[2[:!BLB76'O+.?F$7$+1[%9G-1@[
M%36BU?D'[=9)Z]3D $$% ; )\6'IWJ.HVFK6FS-*DVSMN[LK9G=+J1L4=Y<Q
MW39I 8K6:=UO%-;-=:2RL<V61LU<MPBXY<_5#2]+O=%O=^ZS'NW==E?W<G?;
M2)T\EC:2V;X(BV:\@MVW4T%VYE]!"]KH8G04S&F:C;.M<?BH],I&+3=N#R \
M)=T-;:Y.[?89>*N#&4D9S#UXG(AY4'#J9CJY)P4K&D;OD_;Q@E.W5%9NFOO
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MQ&79 E&O;6MXU1Q1D3-\;B>$9.I2?'(L=&GNTK37,_*)[$8)>4>KPBZ@1J(
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MHUM_;L<DV\KC4&2:7I,E]J,%LV)TWUFI'3[&"#&*1YC<-U/-*'MCBD9A87.
M/''Y_P U/W[*G!7,6DO"_<'9L*.'"<G8W-3185W#2&33V)-9(>J'>*N!.069
MB%,0H@W,8JA3+ZIM^HN^KBXCT06NDC7W;DGTQQ$DSK<,ATT7QF!'UF(FHRR
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MU4""*CDJ2"#0\U6=2H31%AOD?O$K^*<U6?%-QILNC$Q^/*-/TVY1LBV?FO\
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MWO\ ,I[I/VU(_@Q!:LN_:M5QOD%:[-7E;31$T1-$31$T129A7^F3$WXRJ/\
MA+&ZI?Y)^)2WRA\:E'O+_.9RG^WJ_P#@C :B/R I?Y16,6JU2NY'?OE&_P )
M1_U8CJ#R1>J0GZ0O_)+_ '@U@K*7UHB:(FB+S*9C_I?RM^,F\?A-)ZS6^2/B
M6,>:CC52A-$4F?\ @I_YP?\ </5/Z7R*?T?E7IFUA+)31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31%YN.Y+\X#,GXP;!]4ZS&>0/B6,[RC\:A35:A-$31
M$T1-$31%L7RK_N]L"_ZX-O\ '9 U9'[9W\.Q7#^S'QK71J\K::(FB)HB:(FB
M)HB:(FB+,#L0_.8I_P# =R_!YUJW+Y"K9Y06_+6(KZ:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+1W\(E_3Y'_B[K_P#&
MUAUDP^3\JL2>4L$=7E0FB)HB:(FB)HBV)]O?YE/=)^VI'\&(+5EW[5JN-\@K
M79J\K::(FB)HB:(FB*3,*_TR8F_&51_PEC=4O\D_$I;Y0^-2CWE_G,Y3_;U?
M_!& U$?D!2_RBL8M5JE=R._?*-_A*/\ JQ'4'DB]4A/TA?\ DE_O!K!64OK1
M$T1-$7F4S'_2_E;\9-X_":3UFM\D?$L8\U'&JE":(I,_\%/_ #@_[AZI_2^1
M3^C\J],VL)9*:(FB)HB:(FB)HBMRX6$E2J-IM:C87I*S7)NPG9@MRXNR0L8Z
MDC-@7X2_ %<&V[O[A]W;MW1V;-$6#6.N_P @\@2N J^.-Y"N3V0F\@3/+.9M
MD6FS[8IE#$EVRG#0MHE>GD:6U6X,:*\<1*R'().*X!9HXI-U6R+@JL/-3J/=
M[VY#7"6E/*,,>,6G KC=,6%@3E590T2,^F?H!H;Q 2%/7PZCU,6G30COHOC\
MO[IHHPE6A6>]O"#G%M8RAD"U0..FEBKM8L*T4M+J6AS#-YS$5 S%++R9H&,5
M<,H6J5K(;$[^2<-V[)!NLW<+'1(Z1*)3A-:*5JSW&X0N5X\N*QD:"F+F)7O#
MAFP/B@X<1T5&3TA&-)%9FE$O)ME 3+5^JP27.]38+%<F2!':<"BAI7P*;-%"
M:(FB)HB:(O-QW)?G 9D_&#8/JG68SR!\2QG>4?C4*:K4)HB:(FB)HB:(MB^5
M?]WM@7_7!M_CL@:LC]L[^'8KA_9CXUKHU>5M-$439COLAC^N03V++PWMCO-7
MI9),]2LUY;P1;$LY2"57K%2.A,2PBX03:HI%7;D,X=)[Q]@;AH)HJFC$?D^)
M6HQR5<(G(\G"Y'%I4J:T%.'B)M:AS;*L6:888[87*PR;/(\A:S-8UDV<)2PH
M-5XDQ3-HM0@O#."F+J*FO'DI(!;5O/X_\RC5IW!6V\U[*5IHDUCZ,85*6JJ%
M#B%8E6^SUU89 @X<F/FLPA%7BNIUF>MEK?@0B  N9JT<IIK%!P@N&HQ$UHJL
M ! ->/\ #L5UT_N0;>$J(KD"M6M*YV]\O68TM5IST:S>+BQLKJLOXW'RLC,*
MN%D4'*)5AY]5N7EN(NFJJ@DJH1BX<>:@Q\32E!_#BL@ZK9HNXUZ,LT-SA8Z4
M3<BFC(M%&$BT<,7SJ+DH^19*"8[20C)-BLW73VF JJ1MTQB[##4#455!!!H5
M<&I4)HBS [$/SF*?_ =R_!YUJW+Y"K9Y06_+6(KZ:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB+6[/?"(1L%&WEBIB29<Y)J^:;!0X/'Z=J8$\6X@K&
M8W^)YWN);V T.9*.I4*O"/R/&9FRSEO/I-X@3B=^S=*E5A65+GN?P&S=75D[
MR=7F[G'Q7(V8BP2!"D48SC>K/VT$J9D"5O?1]L>(1#AO$&?+MY=PBQ4(5VJF
MB8HH5&M"[UL0W&'NEGD9>.K-6J,Y:HM&4=/W;R1FFU>R$MC-FY:54D.VM)).
M<M:(L48TK15Z$C]!E(=<-W126E7A&]X';3,2D+"QF7JP^DI^3:0S!!N64.1&
M5?VZPX_8L)ESTX&M<</;[5)&#2+(':\28:G9%VN=U(2C"5DGHH31$T1-$31%
MH[^$2_I\C_Q=U_\ C:PZR8?)^56)/*6".KRH31$T1-$31$T1;$^WO\RGND_;
M4C^#$%JR[]JU7&^05KLU>5M-$31$T1-$31%)F%?Z9,3?C*H_X2QNJ7^2?B4M
M\H?&I1[R_P YG*?[>K_X(P&HC\@*7^45C%JM4KN1W[Y1O\)1_P!6(Z@\D7IH
MLN4<;TEXWB[A>ZE6))PS3?(,)Z?C8MVLS.HHB1TFW>.$53MS+('*!P#=$Q1#
MXFL(-<>0*R20.:M[U@L&>^_CC[\8+]W:G [L*8F]H3U@L&>^_CC[\8+]W:8'
M=A3$WM"J\#F+%%HE6L%6\D4F=FGW%!G%1-EB7\@Z%!%1RMR[1LZ475X3=$QS
M;H#L*41'T!J"UPXD&B5!Y%>=S,?]+^5OQDWC\)I/68WR1\2QSS4<:J4)HBDS
M_P %/_.#_N'JG]+Y%/Z/RK=A'=Y&/'=HL]6E*-FJJ+4Z>I]8LDQ:L9RL778R
M<R#/UZN4E@>6*NY36/9']H9G0,D4Y"H*"HJ9,"FV82R\)6695$S F8JA#%5
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M8N/IZHSU[L\C%LU<AT]M*+MY::>/V 'BUI4CY%PNU<$-PC$!0-NP0U4V:,
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M@JHS'\JFB&[K<\G?!)GN<>>4!4JX29Z-0#20+D*!2+A(&K O 6(4H 4^_O
M  #IE1\Z"J9C^531![K<\F?=3-<H\TH"H+A)FHU -) N4H$*OU :P+SC%*
M!]_>  V;=,J/L%4S'\JFB>M;GD7W4QN4>,IQ07ZF-&H'4N.!=P%^H>&.<XP$
M]&_O[VST;=,J/G053,?RJ:)ZUN>0?=3"Y1X2G%X_5 HU ZEQQ+N"OU#PQSG&
M$GHW]_>V>C;IE1]@JF8_E4T0.ZW/)7W4RW*/+*<45^IEHU "2XYBB0R_4 K
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M+</ F.O,_2C#,W;#%.C/HS(.'HYZ<JA#O&$O6&;HQ%3 =4AG#<Z:IBJ'* F
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M#9H#Z)8.P:M@W0!NV!PW4!!  *'M"["^@/1I0'FE2.11_6*U*\OU.O0<CRB
M-FO/Q+!YRS8-FQNWYANIP4 V![0NPOH]C2@/,)4CD5JH[W\RY#Q]F",K53E8
MIA")T6%>),7=1I\V"*[B1F45N O.P4DY01.DU3#AD."8;OH* [=9$<;'-JX
MFJM/>]KN!*Q'>]UN>9(R1Y*Y1\D=!($$#R-&H#\R" #M!! SNKK"B@ ^G<+L
M+^AJYE1^$!49C^TK]>]UN>9(Z:DG<H^2412!!%21HU ?G10 1,"")W=86,DB
M!A$0(40* C[&F5'X0$$CQR)1[W6YYDU$U9.Y1\FJBF"**LE1J _511*83%12
M4=UA8Z2)3&$0(40* B([/3IE1^$!,QXY$H][KL\R:A%I.YQ\FLDF"*2TE1J
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MB4=@@(:99\[Z F-OF_2OOS,S3[X-?_)PV_G3IEGSC\P3&WS?I3S,S3[X-?\
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M8Y.T?-_&II'V'YU\^IPQ]]>R_>G5_GM,<G:/F_C2D?8?G3U.&/OKV7[TZO\
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MCBD9,62-J*'":M/!P!X+8&Q/<]Z"=2]#&X=E;LUJ]TW'@?1EJR2*2E<N:)\
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M@M'P,:UOBA[6]YK6KS]8YY+G.)U)_P#TQ_\ W%?^U6NGG_2K_F3_ -"N[/\
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MS'R#^)?L96*?/(N4C';>0C9..=+,I"/?LU2+M'K%XV.FX:NVRY"G34(8IB&
M! ==/;:YN+.XCN[.1\5W$\/8]CBU['M-6N8YI#FN:0""""#R7=6YMK:]MI+*
M]CCFLYF.9)&]H>Q['"CF/:X%KFN!(+2"".:S0EOA&.\R;IQJ._S5*DBUFG(.
M96/@ZU%V]TS$G".FI;&$0A,$643$0,NFHFX-MVBH(^G6[[WWF.M]_HAT&;79
M1:N9@,C(H&7#FTI0W#(VRUIS<US7GPNJM"V/NL]!=/UX;A@V_";MLF,1OFGD
MMFNK6HMWR.BH#R8YKF#S:+58>VWWQ*I54[! RBLA9(&MO+.RJ[@K*HV640L<
MY*5UJ@YF%B6F0:0$0B<YEE2JM%G11< 85"HD^=&@[7=H_P"/2VMW"([2XN6V
M\ET#)>01NMX8[E[Q$'6['W$SQXK7"9L;LHC"9'?4'<&ZVZT=O0W=G,9+RWM7
M7,=J6QV=Q(VXFDMF,,I;<OCMX6$XG-,+I6YH.(1-MQWD[(;".BIQXC$ILI=T
M\K+%8&+;H:TJS5FH5Q.G33D'-K"0;3D2+LT:DBJV-&%%,JIG)R;>7@V3M&ZO
M)],MW7!N;=C+EXQNSA$\0S-@!,;;7+=#*(A<.>V07)#W1MA:ZG"W&^=XVEE;
MZI<MMVVUQ(^V8<#<@RL,T+IR!(ZZS&SPF8V[&/B-L"QLCIG,KLL[?>^/N'PE
M5 A\.95>-Z<Y6>&3@9R!C9N*CY(CE5"5,QA+1'.'58?A(I*<TU3! "N -Q$Q
M/M$;&U.LG5KI/')M_;VHOM;"N,6\C8;J%F8 ]KX2\2-#7M<'A\3L$@..AK57
MMX=$NCG6"6+<6Y--9=ZC3 ;F-TUI._*)C<R<1NC<71N:6%DS<R*F"HPT4990
MRSDC--K<7?*=PE[I9W")&H2$JHD5-DQ3.=1*.BH]HDVC8B-244,8J#9))/?,
M)A 3"(C\!NO>&Y]\ZP[7MVWLU]JKFAN.0BC6@DAD;&AK(V DD,8UK:DFE22M
MB[0V5M38.BLV]LZQ@L-(8XNP1@U<\@ OD>XN?)(0 "][G.H  0  KK_^F/\
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M-6=O5VLK,J+.J0LU:M1Y;B+LU3I 0&QETSD+BV.G]5-4F?J.DW5O-'<AH-Q
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M8XEIQ,;PPM=5HH* 47>(0B9")ID(FFF4I$TTRE(FF0@ 4A$R$ "D(0H
M  &P-8KG.>XO>27DU))J23S))XDGPD\UE-:UC0Q@ 8!0 "@ '( #@ / !P"^
MM4JI>I_M0_W>_;G^PR'X4777M+[L'Y$[=_X67[S.O#+WK?[P.YO^+B^ZP*]-
M;\77A-$5.?P\/+&8'EH>(ECQ+Y.3B5)6+821XF32 2I2<6=ZW7-'2*11V%71
M$BI0]@P:*52EJ52G'/\ ,4JFN.JO0DI7CU2OK=5D@6(X"1D^+'&ZC( X3*IQ
MUM]7B% V]O  Z)4JN)LF21TE$F+))1!1VL@HDT;)J-UI!059!9 Y$BF15D%1
M$[@Q1 RYQWCB8?3HH5.=5JLOF8Q[ZLUM]'"I'JC'O8"(=L!5B1,:)5%DX9J-
M14B3&$6IMS:V$1X>[M'12N^>/CE7 O%8Z.5>&<-79GBK%HH[,[8I+(,79G1T
M3+F=,4'*J:"@FWT4U3E()2F, D7<T4)HBDS$'\NXS]JR?U$KJ'<E4WFO,AWU
M_GB]Q?XR9#^+XW7A_P"\!^=6Y?WH_P#HL7O5[NGY%;6_=+/Z<BQ!DWK&-C)*
M2DURMHR.CGS^2<G XD;1S-JJY?.#@F4R@D1:I',.Z FV!Z $=:ILK:YO+V&S
MLFE][-,QD;12KI'N#6-%:"I<0!4TX\>"V]?7-K96,][?.#+&&%\DCC6C8V-+
MGN-*FC6@DT!/#AQ4#VI]B>UTIC1"SBL:@TC@AZN5]$VQ-6-:'J,I'HRQVSIH
MR>.Z_P"#P>FZBJ8&0I)**\<#)"8NT]"MM^Z%N67=+K5LTLDV=<X);4B1XNHI
M#$'->]C)^]Y([NT9V)S&96%]#J;7[GI]K^V(MJ-NG011PY-KF178,;#:2QMF
M+7,8]]OW3./>'')PM?)FAS"1]KEPHY(,NK(V=:24D#@9ZJYR0O>'312.1> T
M<)&0-:W--+"M2+%'A=.*B3BE.!Q,<:(CU)A=^'LALFV;811@;IS;)KA(68FG
M%W5MWG.<P^-W@O=@+2T!HKE;TQF;^(R37SKUTQJ\NU(WKF&,/P.&'O3K/):U
MX\7NX8W,#@XN<>2.G,%QRZ]IC'Z@J.3OT#/FK2W/4ES6:.<6B4!JW28KD6(2
M'FC/7)DB&*P;+$,H*0"35-YIG5"\B;H=[$,# QP8Y]HPM[M(VVCQ.+VD$RPB
M&,.(,\C'!@>0Y5V6J=*K*9VOV,QQO,C2]K+MX=WF-UU+A:&.#@(9C-(6 B"-
M[2\Q@M50K3[$%:?I*U=_)"*KD*M'-HX+C,P;I^BR(=\$&U0;/(F0>D9Q0*/W
M3;B\/<,HJ<IE#F/B:S;=0=:M71ZW%#1K.\R.D[I#,UA>0S.<YS)8V%\N&"*3
M#BJ&L:X,:&Y>B773G0[MLFA2S5<_NL;8^^30.D:P%^0UK7PR/#(L4\L>+#1S
MY'-+W%TWCZ!V?&_X?_B'H'6LEM+EP7KL^#$_,@PI^PW?_P!1;9KV5]U/\AM"
M^*Z^^7"\1/>\_O";@_G6GW*V6?&NPZZUIHB:(FB)HB:(FB*P\G_R#LG[32^K
M&VI;S4'DL*M7%;31$T1-$31$T1-$31$T1-$5P5/^5-<_AR*^KD-#R4CFM,GP
MQ?YVD5^)VG_Q_<=>3/OK?G##^Y+;_;7*]A_<5_)2;]^W7^QM5JGUU$7<Q6O<
M*C%7:&/!S "#8ZR:P+ILH5XZ0$I3IJ\F:<BIALR6704,F*Z217*93"*2A#;#
M:YS;^OW^VM1&IZ?^V#2,)?,QKN1&/)EB<\-< [ YQC<11['#@N!W'MZPW/II
MTO4>$!<'8@R%[V\"#@SXIFL+FDMQM:)&@U8]KN*[(U6L'BV<*M781U$QZC99
MG'OHMD_:H.6B144'@)/$5RF?D3( "N.U8P[1$PB(ZLC7=;;>R:E'>7++^4.#
MY&2/8YS7DES*L+?$)/D#Q!X *!7SH&A.L8M,DL[633X2TLC?$R1K7, #7T>U
MWU@ _:'QSQ)<22JB$7& Z!\$;'@]!X:0!Z#%J#L) [$(L[\'()<8'IXLH-A5
MWN(+< 3V[@;NL,WUZ8.ZF:;NV7EX,;L&6'YH9AK3 )"9,-,.9X],7%9@L;$3
M]Z$$/>LS,QX&X\PLRC)BIBQF("/'7%E^)7#P7 U@8)BFHBQA(=DBJ\2D54FD
M6Q;)*2""XN4'ZB:"!"'>H.1XA%1#B$4]L @/IU=GU35+IXDN;FXDD;&8P7R/
M<1&YN%S 2XD,<WQ2WR2W@116H-)TJU88[6UMHHW2"0AD3&@R-=B;(0UH!>UW
MC!WE!W$&O%576 N06XSM"_W97?=^W9G\!JKKNQT8_NL=0/\ 62?=;==%.N/]
M[?IQ_JXOO=PM&4OD)"'GI2)4K\RYCX E25L5C;K1 1L0G='SF-AC&9KR"4N_
M KQML< @@<4DS 8-_P!)0ZJZ?M*74=*@OV7=LR[NS="WMW"7,E-FQLDP#VQF
M)GB.^KQO;B<"TX>!7;K4=X1:=JT^G26=R^SM!:&XN6F++A%Z]T<)+'2":3QV
M_6".-V%I#ABXA14G-X_G6<')&Q.LA7X<S&>>QXL:.E!,U<G$- 5QY.PR;A4L
MD[FU$RCO()J*,2F(HL/LD+]R_3-V:9<7-F->:[5KC' R3'>F=XTTY]PR"8M!
MC9""11[FMF(<R/P./P3-4VCJMO:WIV^YND6Y9.^/+L1 PZF,BW?/"'$2/F('
M%C7.@!:^0\VBE8^NLG:)REMK#C>'>S=EBPZW-+L:6@Z@X)>J0]QB&D>NP=N5
M9*":HR0)D;G*5RD1 N^!U!W]9V[=MV6B:9J4^D:S<1Z993_4PM?>.;-.VZEM
M)7R->QHCG<8RXO!,;G/.$M8,*P-G[GOM=U33(-8T6VEU2^M_KYG1V3700&UA
MO(61NC>XR0-$@:(R!(UL8#@YYQ*\I[(=2BI0\VYQH[DE9>0GJ[%VE&/J!GEE
M?5AR:M2['C.WR4NW0(Z=*LTC/ 3361!3]*D(;WSVE;1U^^LAID.M1PQV\,%Q
M+;&2[#+9ERT7$3Z,88G$M:V5PBQ.8_!S>#A^DU7>.WK"^.J3:))-)<33V\5T
M([,ON7VKN[31U?()FM#WNA89L+7LQ^2PC%V$;U3(9)L@YH/AVN2KYU (2A&-
M7"$<#7+"A#6+FFD>Y,Y;1-7FG9U.(NB5-5--19(/8W[,FU]QZD]\L.J][UB"
M)L[HB^YSF]XMS-;X72-#72W,+ W"QY<USF1O//#>CW7MK38V13:3W/1KB5UN
MV4,M<EW=KAL-QB9&XN;%:S/+L3V!KFM?+&.6*,T;]%,GKNYX^I\HXE[8UED)
MLTFE5(-&F#X>OUK!F,;'I1ZDI,KOZ.21>F='?.56:B1>+M.F0/M)-J7UU;1[
M<W;J,#-/L)(G0B,W4QO/K[&UQYDAD$4+67KK>$1"&-LK9#@HU[C\1%NVPM;J
M3<NS]-G?J.H1RMGS!:P-LO\ =[^[P9<8C,LSGV+;B8RF>1T+HQF5<QHSR[++
M>M:NX' 9)"(?PDW%Y=P8M*,WRD:L"Q;!,UV782+56*>/6I4'J9S[41,"J!R"
M0P;-TQN VIM^/0NK&VG6EQ%<Z;/N* 1/8)!0P:@R)\;A*QCL3"&^. 6O!#@>
M8'/[PW')K_1_=#+NVFM=3@VW<&5DAC.(7&G/E9(PQ/>W"\%WBDAS"TM(I0GU
MN91_EY8/V9G_ !:RU[>MY+P8/-6#J52N5#_#H?LZ/^-+HBU,?#-?G.T?\2L%
M^&%SUY3^^_\ FM8?N*+[S<KUX]PO\H=0_?\ -]UM5J.]G739=W%#KRX8D!G9
MXE])K%825E=/)TIF%I3;R=GC9^'A)!I%/2QX)24BQG8]HBLUCSJF3'TB3<,8
MVMB6^W]_&XLK^VA:;J&R:R A]L71VTD$LT;I69E8XWP22O9).&APX!V(-"UM
M<;BZ>"VOK"ZG<+2>^<^<&.Z#9;F.XA@D;$\1TDDCGCB8^*!SRT\2W"7%61#P
MV'8B%90DU/2\E)UR+;1K6175O3<S20CY&.2D4L=HJ@L1G-#8%6Z3QC#F6=D<
M&*V6)L 4@^FU#4>H=_J4FIZ;:V\-E>3ND=&T63@Z.2.0QG4"*%\/=Q(Z*:[#
M(G1@S1NJ0\_+Z=IG3?3],BTO5+NXGOK*!L;9'&^:621R1B0:<TU#)^\&-LT%
MF7RMD(AD;0%@J;9]@@SQ.62>/%)" !@Z56<HW<[YFX@YR+AF*<D@[9BZ-+J6
M6G(-2-UBBZ>.T#)E(H8Y@-@S6O5$6YL'QQBTN\;0&FR#'MGAEF>8W,?ARA;W
M;Y3(PY<43P\N:&@C/ANNE!N1J#)93>6F6XN<V],C'03Q0L$C7LQ&8W-G'$(W
M@RS2L+ UY>0>ZA(X53E'5J92;Q)VP!>T3CEB:X)L2K/9^663):V;=N#3J2=C
M7>$:Q[PI7)%MY$J0@ $#'EM.I+[&/0[F"-T$N&V@:\6A?1D$0)M7N=CRS;B%
MTD\1,99AD=)4ERR8KSIBV_DUZVGD;<18KJ=S.^!F)]Q,0+IC6X,P7#IFQ6\P
M$H?BC;'0!JG%HZ2?-6[Q %RHN4BK)E=-'3%R4A_8!=D^1;O&JH?%(JF0Y?BA
MK6-Q!);3OMY<)D8X@X7->VH\U["YCAV%KB#X"MIV\\=U RYBQB-[01C8^-U#
MYS'AKVGM#F@CPA3O_P#3'_\ <5_[5:^Y_P"E7_,G_H5\)_U;_P"5O_D5[==>
M[J_/BFB)HB:(FB*$,Z$.> AMTAC;)GT[I1'9M8.]FW8 [-NS5;%2[DL8>"K^
MM*?,&^5JNA5"<%7]:4^8-\K2A1."K^M*?,&^5I0HG!5_6E/F#?*TH43@J_K2
MGS!OE:(G!5_6E/F#?*U")P5?UI3Y@WRM$3@J_K2GS!OE:(G!5_6E/F#?*T1.
M"K^M*?,&^5HBE+#B:A;PW$R9P (R2VB)3  >U1#TB(;/9'4.Y*IO->6_O2$
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MLFCF;.<3W_68H8@0/J@QN!D; 37YV'IUIAE;=:FZ^OKL6SK<NGDQ?4/@D@=
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M,#)60L.$M<]K@'-D#@'+M2.&Z?)KR2SA[-)A*DCD'*#5>#;(E9Q(K#'MD>'
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M_$0"/MU3*:^;OFCNN0B[:3E4YR01,U3*5Y,I,$HHDFN9,2',\",0(V$^WVR
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MXPN@;0V^SZ0UY2>_"]C>J]AB('_L47,_^9NEZ]^X3&]_2#42P$CV@FY"O_\
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MZGV4VKZKTW[+!Z-4^U^[O6VJ?;+CTB[/JJ]LG)].]7O"_3^;Y_D/+.G<ES_
MY7G>5Z/P.<Y;W/B[N_P_:[=GHU<]F=LY61^&Z?DXL6'NT&'%2F+#@IBIPK2M
M.')4>U6Z<W/_ !34L_#AQ=ZGQ8:UPXLRN&O'#6E>-*J:Y.8B(5 KJ9E(Z);'
M4*B5Q)OFS! RI_TB15G2J28J&V>@H#M'7)75[9V,>;>RQ0Q$TQ/<U@KV5<0*
M_ N+M+&]U"0PV$,L\P%<,;'/-.VC033X5WDU$U4R*I'(HDH0JB:B9@.FHF<
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M&'F9F/H+CJ[TB:X$:-0 %#@LHDDH0-)5KN_A .W!".96-G,7.<H<F@^&,R9
M8\MTICN0E8O'DYE.4K;:T(1?*#88VE5YRNNW,!0(Z(++>YXBK9,F$JK7ONZJ
M%&RZECY=M(RC!E&7V%EV<+7IR7NLIEB"4[=9*I4>EPS,@DL'7:IG3FUU2%%)
MORICJ+(HMW1RD#:BJM>&[]\:3-MLD"E0LQ-H."JT'(MK,[QW/ME9F^2V7<E8
M24Q&SJ[EJA9$[ZG>\:.VS=(R HNB@LMOIMFQW!B8317S7^\["5CL[.I,G%S:
MR1I"O05A<R]%LD1$4.UVF0M,)"TZ^2S]D@RK5H=6*F/X[EE3&W'942F,!'34
MZQ1A(7;MW=_A^G5"M7=Z6^2T'9L;R^8R!6<?6FPRD%B:$C4I1]D*SP\;'K24
M) "W<H@@55/G'1U=B*"G#7%(F$\E;+KOKP2P;N9"03R:Q@_$4C3H*PKXIO)H
M6[7"&OA<;S-5HCIO#KJ6N=C;,82BBU3/S#9)==L*Z;9R9$F$KN%[W<))2#F%
MEDLC5ZQQ$5.R]KK,YC6VL[!2D(12O((-K/')Q[@[:1M+JX0R,"W;BY5G%)9L
M#(%MJ@IE.$JJ,>\K!ZR=D3FY*S4F8IBU1;V^L7FH3E:LM;7N4FX81Y9&+>M=
M\Z,>Q1+*/W#<R[9G"KHOSJ<LJ102C"5;4%WA0-WR_C#%]0K%PB5K6[<N[,GD
MFAVVBRR-0E:#DVU42T55*;;,491E9)#&;M,^T#JMDBF(NF@OL(!3AX57V'?7
MA#KX02C#*J!#2UBCT[ XQ3<TJHK&4W()<57:W$L1HWIP4^G9!<-8Y^],8H$Y
MY!RF51F8S@A,)YJ.H3X1+$<8QGI3)LLPA&1K0FA4@KS"<=N'%!CL0X9R#;[[
M.MIA"-?LX:L365 :K&!NFY.CP02;*J@KL)A/@5S/._\ Q)U*C+P=>OEAQ]:[
M+E* F<HLH$Z=2I;'$M6>VFRVJ;WSFD25Y-HP6VF.DBY312,L*(D%/B$PGY5<
M<EWQX>AS*L9.O9F969C%V&QS5&6P]=PNU=J%81KCV5N<Y72QIG;*L!%6ELY1
M7]L=QN.&Z1#/6R[5,F$JE/\ X0OM=9OK+'M[J[EUJ^N1JR6AXE9XRMKI.U0-
M(EDJJ_%1)FZ1KUMLS%B^<NCLVB:B^^14Z)%%"$PE9GQKY.3CF$DBDY02D635
M\D@\0.U>(INT$W!$G393W1NY3*H *$-Z2& 0'V-%2N[HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB\R7PG_J@>?,UX<\P?./BMO-CP)X<\#]5Y1OPNH=<]U\:\CP
M^<Y+W#;N\?Z(XFO+#WK?ZF?ZP)_PW\2]M:M[_P!UR>ZYF%M,>;Q[SAIF97B5
MIF?6XUZX^Z%_7E_5O;_BOX9["87?AW?,_O>7B=7!D\.ZX\65F^/SR_JL"V/?
M!6>J[Y367R$\2^->?B_-KS Z?XZYWEW/0M_I/UG\);O,]/Y/W/?XW%]WW]=F
MO=(_JG]C[K^KWO7X[F,_$.]X.]8J.ROV?U?=_+R<OA7'C^LQ+JK[Y/\ 7#[:
MVG]9/=/9_*D_#>Y8^Z8,3<[]I];WG]GG9OC4P8/J\*N\OJ9<YD+C^;GE;TS)
M'6.+ZPGJK<;;.>8W@+E/]DO7.>ZAP.C_ /:G%Z5]';VNVBZ=>-\J_83U+_#V
M0^K^8_5O*+N*\W?-/SG\VO+OPMA7S@\=>,?MSY[P+X,Z1Q/HGI?"Z5[3CZE/
M&J%>%N]3KK6>_$W4.K>76<?.7A^/]G@;R][</-W@<G[AQ?!'@3<Z?]$[V_RO
MNO.:(*\%0KOZG'FL;G_'7FAYJ3WB/P)YN<[U;D\4^)O&_A+Z%\K^)X8XW-?6
MGF=_A?\ :&B>-3X%S27JC](PUX?\T_\  WKP7Y/^>'BCP)Y@-O,;QUY=_;!Y
M5>/>6YKJ_P!!<7<Y?VG$T08E9?\ _P *\YC?IGF1T?C8/Y+POYZ>7O6?..']
M7GS8Z)]JWB'S.X/1.O\ N_*[O&^@N7T3QJ*S)CU1NM]IWE]_(SUGL,<7FO&O
M4?%?JN6#R#X/B#V_2.F^'>>WO<^9Y;F/HC>T4^-QKSHLGNX3U8_,FF^L)XDX
MOAB[^&_$?CWR=X?E]D'QCO\ +?:-XK\L>O\ ,?\ 6>0V<3W3DM% K3@HUK_J
M=^!I[J?FITSR8[E?$'FGYW>+_*'I6)/.KB^,?K[RGA_PMR/ ^B>'O<I]$<[H
MG%=XWJ<^>DEXC\9^;'5ZYR?CSS0Y+I/AG*W0_#?7OK1Y;]*\4</=^MF]MX?N
M?+:)XU%9]2]0?H>+^7\5\KYR]OOEWXT\X>M>9'@5WY \SXA^NO1?+S<X'4?K
M=R?+<Y[IPM%/C<?B4^X%]7?S/R?Y.^,^L=1LG5N;\Q_*WG_&#[Q_Y9=>^T'>
M\?<?JG1_1SF]P_<=%!K3CR6*]N]0'P=)]5\Y?+_H62?$WA;UB_#GE)XFLG4O
M%OA7T>1GC7JWA3G?K3Q^=Z1]"\WHGC5^%4KO1\F/(B>\I^?\:\'NTX_(>?G,
M^"O']N]:KQ-Y8?1GA+S/W^6\1_:OU/E=SZ&V:*6UKQY*_8OU(.GY7YOS#\/>
M4TIYF<QYK^7O!\.USQIT+H'VC^<7 Y#G^@?7?JG$Y?Z,YO11Q^E<.?\ RP\[
M\*^8?GSX9]4C*>]X%\[?,OPUX_[?_$7F!Y:?;KTSIO!ZYU#W3C?_ #.S12*\
M:4YJVKW_ &<?B"[^(_&W0/ =[ZCX5\^/)7H_E#6_,7P!X,^T#QIY3=(YGH?U
MUW=SE_HOF=$\92!%^I-U!/KOF/XY\1GZWYJ^=/F;UCS-[8^C>,?&'VQ=/\3>
M771^9^A.F;>![AU+11XU/@7+7_4I\59/YGQ_X]Z3F'S(\?\ F[XO\.^7M5\;
M=2\1?7+D_+GIO3-_Z+Y?9P/==_13XWP+JL?45YK*?"\9^&/!2OB_>\Y?+#C[
MM4ZGX-Y7[7O.3J'2.)T3[8^M;>7^N7.:*/&5ZT;U4?(_/?%\TO!WF''>>GFY
MYW>;'FMX+Q-X:W/&G^TSQ?T'PET'H7MN>Y7IOT5LT0UJK<@?4L\)92YOQWQ/
M(_+OG;YA>;_F;Y?<:'\T/,'Q/]N'BWE>G<#B?7+I?*=/^@>7T4^,L@<L>KAY
MTX,\U.G^:O0<P^4O4.N=/Z!X2:>:/6.5^UCD_"VSA]8]&SC<I[?C:*D5IPY+
M%%#U)?*<.+Y[^3GC:L<SUSUB?"G2MR/\!<_UKW/REW.5Z1M]PXNS<]VXFBGQ
MJ_#\BOJO^I=YE#TWQ3XM\VG?0>I>:/0O''G/,]1\&]0^LOA;SOZMO\K]:N?Y
MO<]PT3QEB]W5>0?#K7E7XDY3SG@//_PUY_<?I'K@6#^4/AS_ &:=1\]O%'1O
M&?UOY/F^2^A.'J%4*^'^'!;KS;NZ;?W=S='>WMF[N[/;;VWT;NSV=2K:\]F<
M/5F\T9?R^\P?#G5G/6N@^'>@\WS1^H>"^K?1?3N)O<+C>X;?\#[ENZRVX\/&
ME5CNPUX+;%B/U=/5?E_#']"7A.X^/^N\WU7IW1W?CWQ?R'T?U3I7$X_+^G@[
MG+>Y\+6._%B\;FKS*4\51!%^IAX IO/>>GEMXVK/AWS8]=/PUUSFJ5X/Z_YM
M?0O@?K/1>G]7^USJ>[POHKBZH5SQOE^1752_4E\;Q_A+D?&'F+]K_,>9G \9
M^,<Q<#PEUOZQ^'O&GC/ENF_6/F.:X/HW-$\:BHLGZB/AN%X>[RWAO'/@[P/Y
MP^/^C^+\N^7_ )?>!/\ :1UCQ!XS_>;ZY<CS_,_0&]HGC*A0']GQX)@O"7$\
M(>4;7HOA7SPYCP!YPROA/?Z+]?/'7G;U+PEQ_MMZSU#HGMN<T3QOI7Y;O4%X
MV/\ QGXGYG=QCT_K'K)<QS'FZIY0^>'$]UZSYS<?H/F!]&=4YGE_3S&BGQED
M/EGU7?-"L><7@;S,\GLT^'O%/%XODWRU9\Y^:XGUEZ'T_D^8YSW;E>:Y;W+G
MM%2*TX<E#[?U._!]#ZCYJ^#O,N)Z%X_]:SDO'?6J!X4\PO'WN_1>O>'>@^*?
MK+Q^7Y#XNBDXE4L=^I-XUA? ?(^+O'+;PGQ_,O@>).H=Q'2O!O7_ *R>%.?\
MQ>G]-^L'_2N6]KR^B>,L3LS>KCYH]N'E7T7P3YL8I\S/#GG+U;K'K"1WDEQ-
MO^QGJ'G3SO,>)_MEZ%S'0O<]W12*\:\UF#F;U0_%%F\QNL>/^OUGK_@#SH\Q
M.H^!93IG*>3WVW]"\O\ F.J\E];.1W>I>CAZ*!B\')<MI]33Q!GSKG0_&/AC
M!OG9T;QMXUZ9S#WR!Z;X8^V7Q;U']Y/#_P!?.<Y3=]WY/1/&4G85\CNH2/E9
MU3Q'Y?T+Q!XG\Q?&?@OQ7EGP3XJ\S/MIZEXM\6;_ %#ZZ<?B\UZ.!HH-?#R7
MWG7A[:7X;ZWYP=2E/*_P[T[F]_D4O$_B/J_UH\NN1X'6.9]&]RW+?7#DM:YZ
M@8?]Q_"\_P!M,V3N&3@Q5PC/SLSZON>'!WG'X<K*_P!YR%LOISCI?_BO=_8;
M*C_$,_'AIC/=\C*^M[]CQ]UR_!G9O^Z]X4%K^9GA&J>:WE[ZN?(1O7?(CK7(
M]#XC;DO&?BSZZ^5F[N]2Z1[MRN]S7T!S.O@'^U/X-9^UWX;_ %9Y;,W\)S<&
M55N'O/>/K.X<L_N_C9=<[_=\U;%9[)?C=[[&?BG]:F;)D_C&5CSJ.Q]U[M]7
M^(<\CO/BYE,G_><I91/O+KSHJ'-<3S5\K<A>&-SJO+>77BO%_C;;POK%Q/$?
MA[<XOT5N[W!]SX^NP@I3AR76\XN->=>/QK"P/[/GJ3CG^4YWR S/S75_,;=\
MF?.>5\QMSB?]O>:W4.D\O]L&SF>E^X<34JKQJ*A+^HQR#?Q;YK]?W,J>-_,'
MS]\T^0\+XR\5>;_5_MTY3D? 7AKGO=.I] Z']%<#1/&^12-VW^JEYG6_R\\T
M?.7IMR\P_.KSG\<<#P_V_>*?$OFW[?;X<\#\#<]PY;9ROM>:T0XJ?!_I47Q'
M]GCY>%ZAUOR\WJ'P/,#S9Y+PYY:Y<\K>#XE^C_!?E/U[HVWW+IW*;ONG):>!
M/&JI$[>/50\XYGP)YR>?'(63Q'YU^?/CWD/#.)^H]1\V_=N!X4\+\KP_:[N]
MP_HGG=%!Q4X\E'(>H3S%GZ_YF>(.M95\SO&'GGXPY#R_QUXU\S.;^O?ACP_X
M)Z=SGNW7NB\I]=]S13XRJ]!]1SF,W<[YH>(_+3+GG[YZ^?/C+P#Y?X!\R_$W
MF/\ 7?<\O/!' Y+V_+_]!]TYO1#B4S8&\A?-V?\ #/G#YT>5T#SGGEYK^,/+
M+JB/"Y#S-^B>G>)]G-;/;\[O;OM-[10:T^!?5HZUYXO?(;PQXNW9#QUYA<;R
M]ZWTBM]4\,=)^VKQ]T#H_6.1^MG+<GS7T5K1^K=^]O7_ -7W=/QFC^]=\KW/
M-RX<S(R_K^]Y/=N\Y7U&#(S?K5OG1^X?U>1_UD=\_!/$[IW*G?<K-GR^\9G^
M[]SSN\]USOK\S/R?J54L3<UYP67S=Z7YP;C_ *)X7V>6G)]&J77/"W,?7GQW
MX<Z)U3JWT=TSE>4^A.8UD[/S?;6Z]LLKVTH_*R/_  .'*M\W(K]9WO)[KG]X
M^MR,K)^IS%B;UR?8:T]B,[V&JS-[Q_X_%FW.3WC#]5W//[WW?NWU/>,[/^NR
MU7G_ *O?E7W2\YS/ESU'+GK$[/%/%Y_P(R\S.5X?UVV>#^%N=*]KO?\ 1_==
MNMSK2'&H[5@1W7>K-R]N\(^._,/S!D>C\WYT>4?B_9)>L+Y8\3_8YYK>7W7N
M?W/<.O;W,?1?-Z#X%4,7R*=Z?ZDOFA6ND>.?%/F&7R@\2^<G@OJ?59?JWD/X
MD^T_R[\2\7J?0?K-Q^1XGT-TW1/&5WYM]5#F[]XU\:>,_.6N=3\N_,WS%\U_
M(R Y;P1X*^O.YY$\#J73OH#DN+S'T1MT4"O@6'68O5L]8'&/%ZEZMG.W_P U
MOSA?!/F-ZJ68^O=7ZC_L;ZEY+\;K/*_;KU?A?]:YW15"M/Y7\:E=IZB?)ONH
M^?'F#XGMO"\8>LCZPGF9R';'SWA[K?\ M"\=]*\ONG<G_P!G\?A_0?5-%'C?
M!3_2N['^HEX?:]'\Y][D;5S/+>L9X_\ %GK/73I_B#G?MT\Y?6<\4>%>9^O?
M-=6Y'ZW<QHGCJU<O^J5ZJG<WX"Z[T[I>*/6$\0^8GF%T[S<E.N]3\6_;)YY<
M_P"(]SB?77Q#R_,?_H:(*U%5DEW2>J?TR)\WO&/3O*:^]1\H/-3=]7KHB'CO
MQWY-^V\H.6Y;9S_T-S.YRGMN-HH%? M=LSZM_E#9.L^;/B'UI;1X9ZOYX> .
MD?VA*'BWR6__ (IYD>!>'SGAOZ^\+F>![?G]%5Q^C_,LT*]ZCO)9)ZSX[\1>
M!+!YN^;/G1YL=(Z[C[<\3^*OMY\8\_X8\,\M]<^7Y#HWN?"T4'$ORO\ J'^(
M\==?\0>87,9[X/G;YJ^..H^5]=\YO.+S"^B>)Y2=,Y3Q%]#]&X/2_<-W11XU
M/@7+@GU,_.6N^"?.3S@Y.N>$/.#UANI^$_!N:O WA_S:^@_!?@KQ9R'#]RV?
MX;Z+X>B'%3X%=TCZF7AU+GNH=#\'9[W/Z0=OA?UBZEYS;>']$<3SRZ9P]ONW
M"V\I]!\31.*BEIZ@'*U?PMX]YKQ*;E/ 7G;XHZ9Y<X1\0>(O#_U^\K_!7@OJ
MG,?6_F>%_P!;X^H4^-55"?\ 46\37;QMYA^-/'IO'7C+SC\0=*\NLA\WXEZI
M[MY&^5'B'F^>^L_2MG&]/):E/&^!7-CKU-^JV?E/-'Q[Y9Y<\9>;WGEYH^5W
M1\;^*NN^9/VT]"\-]"Z%M].YS/)?174M%!Q?(K;K?J9^'\A^77GMX3\,H<]X
M \_?!_1>J1/B_P #]/\ M7_?;A>*>#[GQ.:YGT<YH5/C>&E5GYB7P#Y68U\J
M>7\K_ 50\N.4ZARO@3P_'^$N6ZO]=>!T#E]SF?HC=V<3V^W14FM>/-2#HH31
6$T1-$31$T1-$31$T1-$31$T1-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g382677f_144.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_144.jpg
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MQ "\  $  00#  ,             !@0%!P@" PD!"@L! 0 " P$! 0
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MZM'&F+-;]8=0E7KD219JV/*3L_'W&*B(XCAZLV9(&?2#M-(#K*)I%$W$YBE
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M!37C.,0(XD8#M#E/+%(BU5[3G,( 4?CG#?(7*.5'_)S4,35XJ-BV!R/D3*T
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MG>[[KVA=25QK-+IM\NU=J]?90])6:0\+&6F7;,(]NJ^JSIXHBU0(!2BHH<_
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,$3")A$PB81,(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g382677f_146a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_146a.jpg
M_]C_X0"B17AI9@  24DJ  @    # #$! @ >    ,@   #(! @ :    4
M &F'!  !    :@        !!9&]B92!);D1E<VEG;B Q."XQ("A7:6YD;W=S
M*0 R,#(S+3 S+3 Q5#$S.C(Q.C4V*S U.C,P  ,  ) '  0    P,C(P J $
M  $   !# 0   Z $  $   !1 0       %$!     /_L !%$=6-K>0 !  0
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M Q$!_\0 O  !  (" P$! 0            <(!@D#! 4* @$! 0$!  (# 0$
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MXWB'S*S>^X%&.\&!?&\0^96;WW HQW@P+XWB'S*S>^X%&.\&!?&\0^96;WW
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M+E:!E='#;N4 SU=*[NJ=,,AU?&]JVG3KE01F:4K"C#.>9SN>+#I73H*LM1U
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_P WU7DZD]9_W/5/^1S_ .+F\OIP0R7 & , 8 P!@# & , 8 P!@# & , 8
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M$B.2JDBH BS1;T,(1&J$LX(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MD[JE"23M4%. !G0[/.&6UHET1++FGM :]4)F=X$0U[-Y4)+G'9"K7ED\T/\
M"J4I90B3G&\_E]("@:Y.3T?YX&AT?5;C_/*T^593]98&GN/5;C_/*T^593]9
M8&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5
M;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T
M^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]9
M8&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5
M;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T
M^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]9
M8&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5
M;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T^593]98&GN/5;C_/*T
M^593]98&GN/5;C_/*T^593]98&GN8C8 .(U- YLI@KE5ZZ;IXC)#X:B.C,@)
M)62HIF6F1Y*:<LEYB0HI0[A) (1H1%AUOE%K8>7 T/F(_9JE'[@EB\9EC6',
ME<YE$=>H+((C<]C7*SO+W'TKU#Y N[,1&./8CVPDMU89BL<R -3,J"B2DC5[
M,)UT9>P^27;33J1>Y]4OJMQ_GE:?*LI^LL\9=/<>JW'^>5I\JRGZRP-/<>JW
M'^>5I\JRGZRP-/<>JW'^>5I\JRGZRP-/<][H9WS/_48ETG9[H^7J5YYG:SUC
ME]<YO7W.[/>J_P /JW+ZSTG\73\G\.!H9;@@P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *5<<MMR^#U@QU94"P*?B#XF)
M2GI&F# :$8;&W%_1J54TM)227OI@L]1P)*X/AQO)L&E"9.4+TG!UNI>KZ(%A
MZ7J6(4/4]?4Y D8D41KF+-469@&[T-6J*;DX0*75R.UK6U3N]+A&K%A^_P"(
M]4>88+TBWANKJ"3L@& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , UN<-6O_)[B5M/C*7_ /6UI7FI%PT\* 3-
M;,0KF)B>P%WO<K7H6A$F;L.?LX&1O5E[UL;-'M;U_ IWRZ>BH#9'F0, 8 P!
M@# *+7O/;5K>[*AE#7:1VZD?[4C%536%$Q*"&P*(ER"-.!B<5B2U0I66>EL.
M>S%]84<8&@V@8T72EZ="ME*=*A#2I3W*F1?B!XEF&-06J+0E=E0[B"N>1<.I
MBZ42/?#?-XO#H/9\B<V6:OE,=UT5U&2UZ!\0B:4J>4[?RR@K$"PDQPUI25L:
MHNJZ(O[PJ3R:S.(V,SSV0;F+Y55Y6G41,V.:VEE<9BS0M[ 6RO;XV1Y&VQU/
M( -ZX"1<)O2I$9RI*,TM.GY^R"QAT]"S^"# & , 8 P!@# & , 8 P!@# &
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ML8M:$'>O\=;P#UL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MJ7UCU7I>9U3S_7NF]'J7)Z[S?XNBYOIP0R[ & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , IIQW\0__ (\<.T\=HM(V]NO"7QY\B7#S%_4%
M$BE$YMQR;32(PRQ"&MZ9P=9.YD+CBSA%EIC4Y 0Z,4[ 1H0LL5KKT!H"_:O=
M?W8KQL*V8?+K[OBK:Z2M6U<NL6ZZT'/WMJFB=U)2E1.M$]K$)&]B?W%(K5&K
M>B(6-Z(E*#G) F#)WFY=J(;Q4G[;](2(\ARX@Y?=G%D\%" =K_R"M.02"&DJ
M="T8,2"IXN.)50D3B,Y=A*VRFZ#K?)R[_P <QW/TT*72A%=P"LV4F-US"(C
M8\G" )#'#(XSQAI*T /-#S&]E1HDNA:U_GS.7(#,< 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4<O+B\7-$Z/X=N
M&"'I+ZXGS$I)[O'].!J"KZ.:EH>1+,N(&<(BU!46;^;O9J1C3=+(7CF\Q.0
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M%?4_'^X\19"1C_;ZK57?+DXI4@W:Z9^CD=;\.%7&+"RC#$\KD3FUII5.):U
M-UL^.QU&>J+'_ I4I-ZWO5[:?F!G=<\#+.KE[/<O%?.W'BMO%H.TOCZZ9-:9
MJIRJUH@^DJFZ5(.61:,FI>700.Z_;F_F[!HP2P.][#IW>BT0+[9D# & , 8
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MDN<^\6Y5S>> 0H[\914=PVMR_P"'N./"M()Z0S+7=C7:=;<OP%L<[@.E!@#
M(OMFXZ]I.,]J+"?0M:92I VL;2D3J'22RM\/]"*.Q&.("SW:1/R\S>@E)DQ0
MQ>GG#V$&A#UQ3F'-N-\%VO\ JO(\A6K<YJ%JW%.=_(NO\MG'LQK<O79NBC""
M?UEVQ3:YAPG@?*/(.[_T?B^,[UV$'<O7)25O'QK*_/?R;\VK=BS!:RG<DEZ1
M[I-1=.YJT2NW(A)[=XOEY]&\+L*8G&9+**)=# /+]&6%(8[J7[B"D3&8,XY,
M!*FZ4,3:AB(T/FEJS5)NNBSJR'%.7>7)QS?(\+NT\$[E*ULMNY2]DQT<9[M>
MMM:>OV-F7QQT5^<Y1<3MV?,.&>&8/ \7SM;QY#2<;V^W+=;&+*E)0V:Q<7YE
MJOZA?C\DM7CV[49*95W]OWB*_:UMEWNMIX<X$MA[VPQE9,YL@MB+N)ZMXK=G
M5[&N>(R%\>IB#<59E1Q0E" &TRHH1Q(C$V_X-AY7Q'P?XMX(\I\;V?%M/-TN
M_)WY%8UJK:^XE<[+:>O9&D6TJI]JIP[F?GCRUS^.)#D^]Y=V.#K95OLQZ3:[
M7<E]O&UWW6M.^59)52:JZS5*(=PMV[5\4NGAPX-TM\=M9AN.-BN!(T_#*YHF
M],H<2'*>.3[*#*S>R8LD&V[Z!2F3JCEVSR1IRS"C.E#X]S\%>(=UO/(O[!MU
MG*Z_)C0>)<K]5<Q79G7W[JGDVOS_ .9MHLK&L<BW*]B+3X\JXLRU3Z?'EQOP
MI[=IEY/!A<S/<*QQK_BJL^L*!31,"=E@37*)18,T.FIX@;.=7%[METFD901Q
MM++YA"%,WC-4:,WLPX&P!Y?G+PMB[?#_ ,7Y'RO;)IIQBMQEEV8T]/ASX946
MFJ)JO1:-'T9><LK<I_\ EG&>([K!IJ4GML<._*OK\VWSQ)*2=6G3J]4S1Y^X
M[^U7Q2/]AP9V99_>7%60I:%J$B?2IO+E\G95"][4K5,3=$K6H2$,+(C$:!0A
M.+*2M@>G.!S2M@WL7%>6\Z\V>-^3.$=DN<QXKG68?!+"M+$NX=^,IQE:O*"R
M.^U.+A-WKBC1U46E%Q.9<+X#X)\G<5C.>_6N$\MV^_/[B.==EEV<W'E&,HWK
M#F\=PNVY*Y#X+;FVNUM2<E)?2)P8TFIX<N%6B*37EZ*=:^KMD:7TL*H*W09$
MH 8ZR+D5 V(HW0GQP4;_ -O>RM<O(7O8-!SOKCU_?,K8\3)Y+9LX^_W,>$LB
MU:DY6[5V44YVX2=7)6V^SN_U4[EHS\[\DL;#B[_F8W%[U[(X[;R)QQ[MZ*A<
MNVHR:A=G!44'<2[^S_37M>J+.9]@^(, 8 P!@# & , 8 P!@# /%D4DCL09'
M&2RQ^98Q'&=,-:[O\A=$+*RM:,KTF*W%U<CTR%$F+U_J&:8$.O\ /> 4"6<=
MKW<2I1'>!>F'_B04!.,1'W9(E"NK^%M@4 %T1JCO.>6T]WLG:$S?*)-$VQU"
M:'7)ZR7R\[6J4Z@J3Q3?M(V_QQ,T?E/$CQ=Z!;\;4*PQ9JK^IFE%1T!CST-.
M=((RPQM<]$3^0K5ZA"E&)Z<WW9X_50A]5+!OFZJDET0-F/!YPO1+@XX?(+P_
MPUZ=I*VQ #LK7R5[+)3N,AD$B=UK\_.YB%,(:5L(5.;@9T"4H0PIR @!L9@M
M",%ENKJ"SF0# & , 8!C4OF<1KZ..DPGDHCT,B;&1I4\R:5/#>P,+6GV8 H)
MR]V=%"5"D ,XP( [&/7.&+0=<N]ZUCJ#AA,[A-E1IMF5=R^,SJ(O !F-4FB#
MXVR)A< E&"*.]4=FE2K0GB(. (!@0CV( P["+6A:WK%*=097@# /)6/[$W;7
MZ<'II0[:F\QV=-+'%&FVVM1(=C-<E^CS@>IMY0 [V(XSFEAUKEWO/3O[CM^-
M\BR;]FW\-MW+G=.,>RVM7.=6NV"764J17U/=L;9N.5\7VN/?N?-=5NWVVY2^
M2X]%;A1/NFWHHQK)_0IFKN:SN)-4IC?"V(,3K,!QB&1\4<D:-JFU5HLT1*U#
M1$6< E!G+F'81 Z]6!"QIAZWLK2P6@ZSI&_S?E?D^]/:_$__ -/BRDX7]]OV
MVX.CI*.U8\TONI]5]U<IBP:?;\K[3ORQP'B'B:S#=O,:>;RYQ4[''K%WMG&J
MK">\9$*_:6^C^SM-Y=Q-*?P)ME@*>HJOJ2:G!)$4*U:_2!5UE-)[)EQL@G\\
M>1:_W'>7RE;H3@ZJ=BWOHRN4"5,'?,(**!_#G8G"N <<X'AW+.S6[ES<,B7?
MDY=^;O9>7<];F1?E^.;K6D=+<*TMPBM#K'G7D?D_D+,M7M\N6[>VXL/CQ</'
M@K.%AVO2UC8\/P6X_P"Z6MRXUW7)SEJ0UQL7)8%=\,W$:]<.)C7+>(2MZ[(D
M#1#6H"&4R=@+>%H$Y<E50LDQ0O4[0L:=Q<$))Z<1:XQO$ (#=:&#?-TJO7H<
M$-/O[+'&UQ26:AXB7OBZL-:\4/7K.P/B2Z+73LT10167N+L<C<XL*7'(8\U*
MFLYM&!0:2=L?5I@"PZ$6%2$&]RBO3J0^@&>U[6UY08V,35G9IM#7TE*X)!Z.
M">6$T(='MC_'7IO."J;7-)L6C4B]$<6>4+D$69KESC7*.*<?YGL]S8>2XMO*
MVVY1]LJJ49+\MRW.+4[5R#UA<MRC.+Z-')N)<PY)P7>[?(>*Y=W#W6U5=T:.
M,X2TG:NPDG"[:FM)VKD90FM)195H,OMGA'$%#::R0W3PWD#T4WW$4D-=[6J-
M!O?-)36\TMQ&U$XB" O6M=I$).UR< =[7D#U_OYU MYYAX;:Q^6SR=\\8QTA
MN2B[F?M\?2.XVX*N5CQ7_6VH_+!)N_;=5,[JEL?"?-\7D<-MXO'_ "O)5GM;
MDK6W;E/UEMER;[<3)F_^@O2^&;:6-<B_Y9=6/R%AEC(UR6,/+9(8\]HR7%G>
MV9:G<6MS0J \\E6A7)##4ZD@P/\ @( MZSO/;=RV_>,"UNFTW[63MM^"G;NV
MY*=N<'TE&46U)/ZIGY_W3:]RV3<+VT[Q8O8NZ8]QPNVKL)6[EN<='&<))2BU
M]&BMMG<1ZA'*U5.4-&B+?O$LL&W=K+6C10"JTRC7^R^6]+TY9Y3$5H/*,EI3
M]*\K]!YI1( BT;KK#E?DZY9W>?"O'N+'>N>Q2^2VIN.)@*72[N.1%-6EZQQX
M=V3=I2,(IJ1VQQ#Q1:O[+#GGDG+EL7CMM_%<<%/-W&4>MG;,:33O/TEDS[<6
MS6L[DFG!^-&*BA5)EOW$EQ*V4U3*R&1B6+I/<,].0QV#UA'=:Z9>S5NRKE&V
M:NXJ1SNC&<$8G%?OTJ5!@A\S7GX?XRM[5NKYAR_*EO7D"Y%IY5V*C:Q8/K8V
M_'UABV5T<E6]=UE=N/N:7K\V\K7=XVG^R>$XD=A\;6YJ2P[4W*]ESCHLC<LF
MBGEWWU494L6=(V;4:5?%8B9]XK6>/0-@CD EW!??%,R0^RK+62I_;IT\M,V8
MU***,E9Q5.R%:0+!EK2',YU<S]%E%!V2!-T^M"SM;I^TZ@*T\ O[2E.\!=@S
M.T8]8$VL^9R5A40]F7RU(R-::+1%8Y(71>A3(F1.66XO#DI:TNE"TS8-;+(T
M$HDK0S.=92<@;7LR!@# & , UCWO.>* J\++JVEY9*GHE6/A:DJ!C:%E"1J3
MPF,RM/Q.BLU+ GJSXJ<T.13]NFF7I0.2>1.*("I:>D  H/(0-JE*OW_]"(Y!
MQ66\_P ,MJS*ZLN6QEDX6J&K&?+H3.8C5KK(+9L RPKHA5HQ2X75G8/4$>DC
ME2BIE2G0@]I2=8''K2#E9'JZ< 471^K-RF# P!@# & , 8!#]]W5#N'FH; N
M"<.;2@9H-%7^0%)75[;6#<A<VEI6N+;%FM:Z&E)S'R1*DH4B,D.AF&GFA"$
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MO1K6(QC"*A!)12HDM$DO1%E*4Y.<VW-NK;U;;ZMOZG[RF1@# & , 8 P!@#
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M+X16%^J51YFX [:R7PBL+]4JCS-P!VUDOA%87ZI5'F;@#MK)?"*POU2J/,W
M';62^$5A?JE4>9N -S63:UO?=#86_P#AITJCEW_PURV=K7+O ,NZQ6?D+K_Z
M3UC_ ,YC_P"\_(?_ %C_ -5_^/\ ['_^1@AZV , 8 P!@# & , 8 P!@# &
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M9& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M9GX-:>7& .P#_P"+]F?@UIY<8 [ /_B_9GX-:>7& .P#_P"+]F?@UIY<8 [
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MR\GHY<I@UA1F"WRHE3T\KT'$>EARBRG9D2,DBM%_+?$40E%!3QAE/2I&VUY
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M:;X8Z.4<;JD62*F9JA5$)74;PUR!V&WN* H*4HP(]GD\X."55:^ICK;PB\1
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G@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g382677f_146b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_146b.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.CDR-S0Q-D$Y0C=!-#$Q141"1D)$1C)!
M144Q.39",40U(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.CDR-S0Q-D$X
M0C=!-#$Q141"1D)$1C)!144Q.39",40U(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( ( !- ,!$0 "$0$#$0'_
MQ "S  $!  (#  ,! 0          !P8(! 4) 0,* @L! 0$! 0 # 0
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M@3 @C]L[D.H]/LP8CTZ^3KZUR(=>GR=>F%\%/PA@,!@377XB,SM?J(CTV4<
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MB J1903<G)BKBGYN;C(]IB*FN:FA,2$SKFLR&LS1]Y4O5]-8+!(UZ[[ UI(
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=%1:S8JR+@R9WZI4WCA/LE1,SCP;6X0P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g382677f_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_15.jpg
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MQ #H    !@,! 0$            $!08'" D" PH!  L!  (# 0$! 0$
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MB8N2_P 66%3=(*=I&X C0*$\="G3%-8CB6",9 49Z9)-U5_FE<6PD@*0-?N
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M37\0\,=JDV)^*L6X!:C/49_]14'-%]^5.I!_'Y8J\JU*JPX!8^_4:&HG\?\
M/E7_ -(98YY\2K.. 6IT]4%/YFIT1/>ETS)(1ZZ'/KB-4L7/Q74.("UF:JVJ
M:FH'_P!OE.7PWY8XF69/Q4C0*46/O561_,5*=%GE\<U(DS Q&J9%"5/@Q7WO
MU/6JJ0?*>4KX?QXC5(AG+=J&0.%>Q;HJBJ0?]149A2LTOW>O7':SF2R[2.%5
MN,]2<_S50 ,R#/+GY?C Q4REQ*L&X!:)*FH&0J9P,R4GEZ+KZ_$8C7+B5;2#
MBR^;-4'_ .;*@%&_^NE.6J?CSQ.N7$_%30' ,E/914R2*:BH.8'^?*1T3+=F
MHP:,C2IJA2D&=@GPX]#*QK'&27+,+(\@KIF3XX=@2(8U*S;A!D7:B<"'W&L4
MR/"HBN=YZ9C#UO4(UQ298H5O?_B=_P"<?[\$>1S4+8TO.KWY'Q/[5P6#MS7%
M;P7G(.?I_B/3YX**8E0MS!)KN<I'^(Y+\\09<Z+FJV:W-#^KW+U]1\/CBNI2
MS57OJ_Q.U3\3M/MTQ.H_)5\7!4N<T[*4??KMO%;;M+5,M[*)SVQQ/>UCY61.
M:USBU%#7YZZC'XD_OA_?"7]NO<>SZ9L(B>^$M4L#IBX%1S^:^U^U/:NUZULY
M7>H&8M3I%N)S[E1)VO[25_$N_G<OA%NNE13LXXPLB)<X.F@,LA:V4L59&[?2
M<\L?JGV_[@_^0^W-CUN<0)[BT)D"@=JMR7S;<=*CTWW#N^EVIG19D0#F1B'5
MJ_T@UUU%=?J"K<7B"4[I)%<\N #3ZQT\%\<;$V)!65NB8XX?Q5E/&V@2/F(!
M0AJ9G,$'PRR.>*&0IVI4'4GGMM4^G@:^-Q:J$)TU^2+AZW<(MH<P'.I*JT72
MI?41B9RM)R#@,AYD8-"3UP*@<4Y<%6P1Y'S4)T'C\L-1OQ XA$T))7;E\5#*
M^-A!(15(^[Q(PI/>7'I@ITC !Y(G_P!=.C;[TAVM0G4(B*OV8I^XN.[J[9)-
M5O?/CEL,C*VL@B>S4&HC:0$4;FJ4TQ:&^E,TJ!R4R@!YB D;>OJ@X;;H'2&X
MT:;05,P<BZJ-P&#_ +J6G!5-O;0CKN3 "8N^?7+PBURNW7ND:%.UOO0@>&CB
M4*G ?7NXAF[72QW&SCY9:OH@=I^OC@U:YK/ZW0.!R ?/!D/([@I^&2XM&_=P
M-%4[O;19R6*4LOU8\-NC0YEVI'MD;N;MDB_"5Z N*+X+B+ER<A2.'-&C=V<B
M^MW0JR]_;5<:^"GMESB,LT@#4D9M:I&J%.N$KDKD092P"8:Q,>$U/-3N[?7U
M];0Q33U(G+FJ<QX9(%*#]N&]I<E.TTL4#TYVYN4X%;>J>,>VQX+CU4$CR(\<
M,&Z 6)#\%:6D$L"\L4WG)KQ=12SOM["^1K"Y@()!(&GF%&$]S=N@-;59RDSQ
M"B76=W[I3W&>DNPDI)H)7,D9(=FAR<T(A:X9@]1A2%ZY*325H7+>$AXNU#Z;
MO;0P$!M2UYU]6WI\<U^&&A=B!A56-V!#(\@[Z4C@![T0\0=H/PR)SSP:.Y(&
M!0=00D]\*4$_S8UR'1,UZJ,3^[EC53JB*.LV]\*/3WHNA(4(>N?48X;LGBI$
MXG-9'OA2$'^=3H$3U*1UZ)TQ7]V1Q5Z,Y-$62=]J8:3L*:^G7X9YX[]Y+)U4
MFWFLX>^M.XC^='GXM(0@@#JF>+1WI4^#3X4;,[WT>Q730]<]Q;\<M<7&]5=+
MC)D!E[]4+')[L0"ZEW4_W)COW3XJA,8T#.M;N_E&T;C+$&IF2F?F,\1^Y?-6
M<,]%H_\ IB;4Q0:JG54S<A/EJB#$_NCS7/'B M\?U#VEZ@5=,2 I&X#+Y'SQ
MQW4AQ4$CB&61^H2UK_WF#J"C]-//++'#=RX%5U1/!"XN_P#;9"@J*?+_ (R$
MRRT*YXM^[;(KF@1DA[>_=J";JF$?_;40IH% 5$UQW[Q2(Q;DOO\ Z86Q!6FL
M@!!SVS?NT7$?NR,ODJZH@U^J&1]_;(X%WYJ!/\7O#R\L2-X'J"RD:3@ 5B?J
M$L,1]=9".G^>S]J99XX[L$X*PC'@$-C^H+C[T2LA)(Z3,/3YZC$_NP*LNT \
M$('?RQHOYN,Y@$>\S((3T*G$G>1[U4VP*G#M7G_C_8@2/S;%Z?SFY>>87%/W
MD53PY _%1XH>[E/S+Z[NQ/':2831P<#[AW-VUP<R/9':(%( S+G39?/"AD+V
M^A=_EH.\++O@7/<.RDP>WM]Q_P#6(O\ 0*VNL>6R>D*O4KC8NR>9C()T.  $
M7N5YW9]"0,LQ^[ FJP41F 'D:DKYP.UO34^"!1]^)RJA"MQ\G1I2WBKI=K7+
M4PJA8]R/8W+_ "Y"IR'0J/A@UO<3A0UBF= 9@E;2UD%9'[D#U1-['921D]'M
M4I\<P>F'H7(W \2AD$8H5BZA?8Y<OL<N7V.7+['+E]CER^QRY?8Y<OL<N22Y
MWSWA7;#B5\YYW$Y58N%<,XU1/N%]Y-R2Y4MIL]LI&$-]RIK*N2.(/ED<V.*,
M$R32N:QC7/<UIY2 26&*IPNOZKE+WH[AU7 /ISMDM!PJD!9/W.Y!2&.\\C4F
M,OXOQZI819+:X@EE37-=5R-((@IR%.5N]]./@M4/'\%I;?9#U8B]5P[(MY7=
M:^\T=UN%UK*RY5]12U#ZFMKJB6JJI7&-QW23SO?([/HJ#08SP3*8E)R76D(Q
MC$QBP#)INP*&:Z]$N+T)Z JX!5].F&H_U _#ZK"V;^A/_658UP]/R8 7\()^
M*=/#7#+G2CQ+R(Y)8"+=KFJY_N(SPOH)1<:HPLU$&5C7)^(C73KE\2N+"WI>
M2$9 $ 8DI\[:"*=!T8!Y Y+B12); H%^6J[S?[DG+\3M=_RN4_,'3Y8H35'@
M/ XXG[OP3)7>;8][O!R?,GPQG7JW$:/E<8I^^VG,:"6UTUFK*B."IIV[(/<<
M&MDC)]+6N)3<-$QM;#=VY0%B5)!9.XM2M3E,_P!.1?L3Q-]05OJ!"@MS!'B"
M,:GT0!6H7A<T$ N:"2@!(!)\ %S..90X%"O<<I6,DC(F%\C@UH"DG()\<=VX
M*<E'3O)^2O+:!L6Q]13-E5P(<0QR(TD+UQA]5].X8F.5'3>R$H7S,_RJ+5=1
MF%[FH->ODNF,24".Q;UNYK%<402-S^)_9XX&B]B#.82#ITS_ +:8H74FN"!O
MC1>N69\P<_BN*475[EH>Q/!!TUUS"XJ:(@))05S/$(%Z$8JB!LD'+451_O\
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M_GC9M=/M0BTGU+$O$SN28O!Z)A[OWH[AWLG\YR2Y;'DJVFDDCR(<C YKMV1
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MD6-B$0P63^P!G"/JJLE5*/< 44#P7+ S&8.")&Q:(J2_R1O;^P,42$OJ7Z%
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M9=2?MQ!D^04ZBCFS\FBHIQ[M.WVI2CMI (1,R$3K@EN[HD[40R[+9S=UIN%
MZ22..6&:,C-K2TCJ#JA^&.W'IS\349&MF0  8C%4.?6[QJ@CH[K3T<<;V/\
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M[FTY_#5*G@X+KGU\,<=Q'A]5#C%@C&#N*R1=M4X*--XS^"@D:8C]S#@K#3+
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M?F,-X@O@FHT  S2 M7< 2<PKZ#W1OAD8U["XZN)5I'PQB1N']R03X7*<MCU
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M'B<4'D4? YZ%0OEB8L0H[$%<,\0"ZUK4C* <52PXE=#'*^USN],I=+2*?PR
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M4@ P0V6PM(RC&0R]+=/D?#%)6U77$U9%\E@:%]!^ : $U7/+%!;DW-7B8,R
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MO#&#NY>I?!?PQ<=ZUNG6)&8N2;28EOC_  5@%(*&Z<@--2,#H:1 1&&HU#M
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M*,1FB1(^2%,;N=\4Z]/[\%E)A5*Z==QHX.C!K1D!_88I@%H>&W%_RA"6-5/
M??B:1J?,LV[=E<-?*MFS_A/WXC5)"7-WSZ-K^TW)RX [*2<MW$@ ACD7P4>.
M,FTYN1_U+>NL=F0>(5>GT(=P[S:.X7*;9%/(VD%RE:UFY[@S;.\ @ AJ.&>-
M[J=FW.W&8'C 7DNGSD)S!\CFG:KOK9?Z^Y5E))-4/(>0<B<]P:<PJ9@X\]<M
MQC$OBM 2)D'.:?:$DTC4)),8\RH/7Q3&5(.ZW84B.Q"X.2TUJIYC+(UAV.5I
M( "#,9_'[\=#>0V\#J-4P-MZQ#KG?_5&YY3WVZVNU1.9*YE;[P+7*?Y8<@(
M.BJ$\,>@Z1>_<3U1#1 KVG!9'6K7I[B/!F^7\5 SZ6:&&K[U\#;.0Z&FN@KY
MGD^@_E(GNCS ):FX?/#O4I2&UDV;!9]B(N7H1.!D/Q^Y7A?5OW,HK!V6-+25
M+6U=XJ[;:Z:-A!(%5*R-[DS_  ,)QD[:W*=R,&\(J>Y;WN.?I;(68GQ3([@/
MXI<?2Y(X\.HG!Q;LI80I_B (S \/GG@.[)B*8E+[8-M8\ I47*[4\(BA<_:0
MA+@JDIJ3T7RQG:I'#!+W;QEX G5X?4^_01O4]/BBZYKD@QIVBT ^**[P$N27
MT,GVJ? HBYG0(F&@>" 0R'->H^6@&GE\<<^:MI++9GET/VH57%PJ\DE.6@FU
M503<L$@ ^+3E]N 7ZA,;<54,>/=T7\9O=SMDLS/;#Y1$US@2X$E T*I .?EC
MX)_<?V1;Z[.WN8#]0&K8LOJ/M+J4=K;-J98<_MWJLCZ\>8Q\QJK='3HYU/5M
M?)[:.+#')N(+@@(+RH7'M?[2^WI= V]SU,917D/[B=1M[R_"%O\ *:E%/9^F
M_.\/FIW ./Y9  0<]CAIDB#'TW=3$)=ZSNFP$]J <PHH\]X?5T7.8:W\DYK&
MSN=O8UQ);O*M4CHTGX8):WMHPT"0=(;O9W8;R,])T4JNJ']/J1I[!\2;I_T#
M"FB!Q+@,_(X6Z9('<WA_F50&[=1^I1?];UP;2\<C:H#G/B  *;O6W)?-,\3N
MO%O(\0E;E;\8\2JDJNXMD(&U"XG0DM3,*,B2@'D.N# L>:T;89P@T.^1PV$N
M8@S"HF:J5".08L2K2"/K?62T;AF\9EV[=F0#X@YYCIIBI'%"G:$^U.5:N45$
M;6%DYR3,*0[SU3%3 (7ZD!7!+RW<K%0C)B5.2CJ2>A&GGB#%L%T;XD?$$I&U
MK3'O+QGH"X9:9J<BF.;/)6B02P29N-Y@@DW-D#7,)<X!W74Y^>GRQ80)&"BY
M<$.=4#AYTQH##*-^00$!V2C=JAUQ4V2R);O0F*BJ]',V/ESF RS.YI7-,ET3
M;BAM%D3U(QJE/1<G9(  Y?%Q(SR&G7+ M!>J*+\"*+&MY [?N#G'S&>1T 4A
M4Q+!GR0YW1AFO:3D<@+09"B@Y*"=2 /#$4*HX/E2C9R@M:"9.BGU9A<]H^>(
MT%UVH]RV-Y42I]Q1Y$%!HA U7'&*G64#J^0-F;D2#GET*^/P3$%D:!+U1%_4
MHPXO=ZCGEEH3IB3)E$C2N"&17MH:@(: $"-0C7SZ^&*ZP<5T2 0V*T2WXL<4
M*@ IEFAS)/@A&)U!3+F@1Y68CZ%*GJ1^Q5 Q<1U()NB)<"J;;A/)WU?U[_2A
M'*\%CY^9-(&69XW7@$G526CR0X)< AM@1CZL/_,%A]4GZG5.G2./K3'_ -!_
M%=*]5(V1X>,U#1YY ?W8TS*J)(-3-T'!!R0#SR_NZXJZJM+R00,QDOQ7^[$*
MT0]5@4\TZ9Y_;B,$Q#5KU1BX9:Y""0A4IF,2"!1-VB0&DP*#R$[4RS(5?#$D
MC 5*BX7@SBJ"O1=?#%K;MP2-UC*A=:O 9*/[E^S%M1"8%N,P&Q"UPW9UFK*2
MYJD=)4,?, ?Q4Q/MU+?BZ!SDQ6W<T3]0Y?1=..J&E2)8]LC&O8X.8]K7L<TJ
MUS7 %K@>H(.-G&JS45R;9Z\D[2**+:W0[99\WD>!V- QVD$B68^]#GP3/=W:
MYK*KB-MW>NHJ[A5[!U;!3LAW$>3ILL8W59C]SM[?$R/P 3.Q#WI'^6V3\2!]
MR1C6J!FA(T_L<#.*?2/YS$O'ZS3*-Y73^$]/,X!N/Z3H^V\Y[%7,Z8M'((#D
MES7:<P KG*ORPC;\A'%:&V),) _S(KI"TUC4_B+CH$R0HO48X ZFR5B"'=.C
M4N__ $;KM,Z"HT\V.\/B,:$*VTN8UIB0F([.O/Y6Z'3_ -Y2.R]13=J=!I\L
M'%9TQ"\YL:;>3_SE37XA)_(A)"@^VA\#N U\,UP>6#)F@B>"DA:9%HVNZ(F2
M'-4(^T8F&#*I.!&)"5EB<DP \?)/]N!W<%-L'U&3M0N/Y=FBD?8@*8()$0[$
M(UHD/R)Q$<A)S<#T'P3YX <04S9#6SVJ*?,)?^JE0]$R^)0C"-PT/:F;8JZ)
M[" ^:/+0Z]1F.GAA<(MS%T\]"U&-!&@"9?;]H.'+'E 2\\48NT_M]N&B[*AQ
M2!Y.Y&IF202A^X:>&%+G]1^"./*$C+"]*\>()Z99KDN6#6/,P43-.]/MVQY-
M3V?FDU!52".&[4@A!<0&B:%VZ-5/@XX>LW!;OART33\%G;VV0(W0*"3=Q_BI
M9 @@$%00H(Z@XU,,4DW!%=XNE-::&>JJ)&L:QCCFYHSVD@9D:IB)2$(ZSW*L
MB!0JM?N5S&BNO*JR6"9CRT['H1FXO<2A!SS*8\AO"97Y$>5:_2M/I2/&5'^"
M0AN[':. 0C)?L4Z#3":U2^"UONH<-<ATT7X?MQ4C@IK@Z#FY-5 1XY]?#X'
MR#F58,<5K-P4EJ]53JJ9_'+',KL,!CFL!7 @^K(D'XJORQ!X*6:HQ7WYWS*^
M9_9T*XX!5(:J\_-*I!"$$D)JBH%.J+CB:K@'J5D9R0,\DZKY+H<0]7"MI!J7
M=>"8*$R(ZGY@Z+CB5VD @57OO!1F"/NUU*8Y^*FI%%Y[X"JIU )(5/VG7$N5
MVD$NO?=!!!49C1%(1-#X8Z7!=I <C!"HY2@4IF#]J?LQ7)U6I+(5O":DJ/+^
M_'8JS4I@@<[_ %9^2(G4>/4''&BLU&1W:V;]KCXM4?+-#XC$Q%602&+!.G94
M_EA4T\E/G\\-PXI.Z7FE_3O  '50?EIKABV<D&5>Y&L4BHJ>&BC+Y]<-P-75
M"$:PR:'+3^WAIADBBH>.:-8SF-$=KX%0F?RQT:QYA6D?#2M$90N!:/+RRZ@#
M7IB&JQXJULDC_,R,*=OJ*C3/[=,7G4AN"%MXO<).2-(VJ@_\[^WABG$E3NI'
M5HX(6Q@'4;1Y#P\<6'$XI9GJLE\_X_'I_=BWX*6"YLNX\HB[2<K8TY_E9<SU
MW1N"(H4%?$8RML";L>U;6YIM)#B0JK/H^D-O[C\B?(X!U1<'$9(G\TC4G3]N
M-O?'],#FO);*+RN/Q=7P<2F;/);W @;A"=5S&1(/0$8P;V!"T85D.#J4M$P&
MD:>A8#JN70Y?'3&/(XK>B/ .Q(3F''IY:.IJ&ES8G12.!;N #G,)U&:^6,W>
M;&6XMG**T-K> F#G%<S/UV4PAYX8))Y99(YGO<)'$[8]SFAP:7 !-!USQ['V
M_;-O;:."P^N7(W+T9#G]5''L5<I+5W(X[)3G^<^:6%6C:%E9Z]H!W$N709YX
MT]W 3M%UD[>1A>@1E)6.=^>+<OYU8../@$SZ6WUU%5-C#7["6'(/3TG5/'&7
M;OPLDREF&HM+K$;EZU"9!(B59#],5I,'"Z.&JB=%-#211O!&T[FL 1$&AZZ8
M2W#7)BM&1MN1.SIR?[D]MVM<KYH^K&OW*050(BDZX5](]R#*VTR^#)X^'1M9
M0,#4R: @RT3#L0  %>WY $N6//WHO3/IIDN"JK ET812!!D57Q\D R7K^W$X
MX*LJ'M0MK]$"#^R9XO'CFJ@.4FN5YVNI/3V7C(I_">OFF(N!XE'LG3,*H;NO
M'-#RFHGAF?"YLSPUK7;"[7XHU?#&)N-I*Z=3.,%H6NHV[ ,3*N*BQW#XF_D@
M:YY?*]TC2[J005W.<2W4E,L,;&U=VKL&'8O/]9ZC:W! !<I[.RG"64D;:6=I
M;&8_4T^@.&B Z*<9/N;JE_8]/G?M_P!48+V?M.Q9W=RW:GY"*H_[Q=O./0T9
MJH:9@J&D'='F[,%Q.I]30/#'R7V_[GZMO>N"S>F]LXT9?6^K]#Z9MNCF]"($
MXFE>*M5^A&N;2]G;!3$&/8Q[&L=D0(Y7!H Z!#C[MTF>FX7Q/X?BOA>XA^I<
M,?+ZDF^+IN/KJO;I([=0Q*_>\.(&TY,1VBJ%PU<)EO#+@%ERA_S<)'&(/T58
M.]SGE?3H %&0US+D*)@@++0B6QQ1C22[  "B'-,G*?XBN1'48([]JM]%LDKV
MC;N)>%1,LMI52A7)?ACLUPE1TK[*7U ;_A.9:22 H4XGFAW*P?-DM0W\NS>1
MFT:-/IR!73++[L2SK/PQ6 Y1^5#XI)![9;J3^#( 9Z9>/GBWI$J\;LHX)!7W
MD3B7NCDW;E_"[/-/!>GAAFW$ ,<@H,W+G%(1]XK-SG;WM*';JT!"FU.I.N),
M8Y"BC7+)!F<CK8CFY[@ %])W = .G3PT.*T4:YMBEY8^6$F,ND< "A4$>H=<
MSF$^"8'* D&S1(70,4YE%?8:D@OD;H@&2#+/+J7)A6=J0#*T;H)K@ES0;:@-
M+=JE"#D<EZ^"C[,"9DQ&3BB.WVV3:"&A/'JB:G+%588K 6U_^#<2B@$J0"JA
M"<\\0ZOH&)6S^G$M.YKB %SS(.>6N2#%2!BCQ$61>^C)E9&6IO09 +F4&8&>
MN((^*I..:'MLCG JQP'4A4)R&@\C@9B1V*H(?FO)./EP!#4R**J$9$A4 R\\
M6@ :Y*Q(S\J#'B;Y#N:T%?PN:XD.R"Z>"X)Z@C3-1^W$JNFQX[8Q9OK@^DZI
MFB;[L]]Y+ V9P(#&GCE>4C"H7R[0"3F@*8Z[<$]N?Y1.!_\ J"Q>JVQ:ZATZ
M.,C?EW>$KI2>X($*IUT&?[<:LC5E8VYF9;B5JW+U0^7^_'-GDK&U<H-/>%X2
M/,D#S*>?F,\1VHD+4XD/0'$(%4U=+21F:KJ(8(V@DR3R,B8UHU+GR.:QH'Q3
M%9RA$&<B! 9E@/B4TP)$(!^02!E[H]OF59HARBROJFO#'1,N-.YP.W<%+9';
M0F:G),9'^_\ 11/1^ZLN2WF!#]KIZ71NIZ?4.VNZ>.DH92\YXC<)##1<CLE5
M('%KFT]QIIWM(7<'-BE>A:A7(89M]7Z7<DUK<V)$9"<7^J6GTS>1#W+%T#_1
M+\$>QU---G#-%*/^![7#[ 5&-*%^,QX2\>3)3T( U<%;MVITRZ^'3[,20&Y(
MS@!\T1WQP_(5.2_RGY=#D<^OCBDO)+L0Y$$T3Q=N+X+AP.U5U3(2^W4<M'5O
M.J6P.C:X^)=2L8X^*XT]G<U[:,CB Q[OX+.NQ:X0,UNX963W"CN%?4$F2IN,
MK\P0&M+6N:P ]&!R8)MY:M4N,ON0;P,9Z3@(A1I[P<IAD[RV/C[)0MIXW'+,
MP$>F6XU$DQ4+D[VF,QYOJ=[5U>$<H6Q\37Z,G>EP!G=.>D#X?XHR9<F!H]8S
M^?EXX<$P0"63?IR'8D;SJYL;Q^J/N!"UX/@B$9CQSPMNI@P8)K:6R\B?Y57:
MR9L]5?B"H?7DA>@&[,!.IPO;K'DR;VV$NU%]/,T5P:F;0XID<DS"(2-,<%>4
MP7 Q3L/D#N.5HU/Y.;PU$9  *)_=AZW2/)*GQ&F*8SM!_P!SNV7X;E( O4;S
MG\,L'M^=>>V=-O)L-94S^)O IX$/^#["01F/A\L&GP3)K!ABI(6)X=0,S4^H
MYY_QNZ_'$0)TJD(O <BC&._TUJE#II&LSSW. 'WI@-Z]"-)(\0T]<1XBEE3\
M_MCJ:-*R#0Y"2/XA<_'%/W$&TN&5I;>+OXF2'Y1W#M;(GC\S$2A"!S7.)*H@
M&%[FZA$4K(_)&MV92BT &?-1HNO)::Z54KF2LS) *J$RR& RN"0;-&%F4:T(
MY)1<:.^:,_\ %]ZY>>> DL>Y3*!T$Y IZZ(?RV^"_P"_[L/;?!)SK*B&2HW/
MP:?]V&I<%5-MRN1" 4S#E/B@"#[L*S!U$\$6)H D58IO^L !U=]_C\L7V_F7
M%B'/%$/<V^55BADN]#,Z"JH0)X96E"US5=F.H*:88NU(.:I>CJV\HY,F0L_Z
ML5@XI5-XERCCU?77>E!@_,4LL)A>6 -#B9'-<U=2,T\<>JZ=T7J^YL1G:T2M
MR%"27^GVX+Y+U#WA/I]Z5HVH2TG.34'<47\Q^ORM[CQR45DM\EOIZAAV22S-
M,C6$(=K8QMW(>IP[N?;.^MV]=^0 &/VI]%F;/WF>HWO3.F(? 5^)2$L7):NZ
MN-1+(YSWD.<\N<XN>XJN>>8./'=2V4-N"!YG7TSI>_EN("0##)+MMRE:F9T!
M +E+E7-#C , O21NS9WJ5N%SG3U.=N]/GG]@RQ!A%7%V696P7%Q5KP3FN[P7
MI\TP&<0*A3Z\Q\4*97/)0.4HI!_><UQ3"J+&X2'"V"J><U5 0 #D/GH,\5HB
M"9..*S%82!KGT\=V?@=,5(X(@G(K8VI<5#22@R/@J9:YXXC@B N:LMS:EQZE
M? _'+KX8J K AJXK8VH<3J>NO0JG3$%2!X<5N$^GB-<\E&?098@'-U( 7PG1
M57/+_=B1)E#A;FS+M)(\-"N9\>N*REDH) #(PCD0 +YKEXKUUQP^2J Z$>Z1
MF44^"YYYYXEP%+L6&"T.E5R'X* <OC]N*Z@2I!+TP2AME2&HWID%ZA/AK@P+
M5"%,-5+ZW5P;MS33X^(^W!X2RR2UR#EQBEI379A W."CY_V&#AL0EV(Q1S!<
MHLDDS.70?+K@D9R"BAQQ1O#7L*#=UU7+]^#PO@*LH\$;P7!JCU CJ%_8<,"[
M \BJ,0CB&O9D0Y%\4(_;K@F-5(;'-&T=;&4.Y/A^]#C@2*%=*,9%S0\0C**N
M8F;@N@(0Z??IBP96<2 %P"78AC*]@";D7Q"@XYFJ$ VH/0D=H_!;/SL7CY_V
M]/W8E^:IZ7^;Y%<WW<9OO\!Y+1@!VZ M(&29. Z>H82VT?UX\5K[FE@@_P P
M56O8FCEM7=FKIF9"2HW':@!!F3,Y$IT&N-+='5 %>:V\/3W$X<E>?P6)8[22
M2OH4H5\2<L\TQ@7R[IJ(:8'-2SMP2FC:>D8^1'^TXR9XE;D):H@C@G M'&O]
M04$\3VK%L<T C)[@%0#P!^_&EM;7JVM+.Z7G.4+QE L5SY?JH]C*#C$;>:PT
M@@JQ6QTX=&W:XQR/=N#R6@. 557#W2Y&SN/V[^$_8)'J42)0N"L9T^W!5 =K
M:V&T\UL%7(C1%<(=VC$;*\* 0NG[QC9W$";4FX)&V6N G $+II[463CG->#6
MV9T4$DD=/ ]ZAAW$1M.\MTZ=<>)N7IBX6HO;6XV[MFH!#!/G9;=9K+&(*(PP
M.3:Y@<UJE.C0@.F#6B2'*1NPA"D  'P"'U[XW,&U["5T!!*>7QPP >Y*70X/
M-.%Q1/RH '\/CUZ_<,%C54TB,1S2Q\ B9Y%<_/!%7L0B(H!J5USU37$A5D'(
M.:&LD*(47H,CDFA'EB\3P5&9$G)"'VV<)_ZIP ^3LLLCGB)R851;()FRIS[Y
MW"2CY4]K6ESG5$C0T H[U$(U/X@!DO7#VRA;T'5@Z\=U^>XA? LY NBOC7'A
M=J5L]5#,THV0 A-JN!#2"/5KHN6-"]:M>G0!UY3;SW4[X!<1?-+YD4EG3\HX
M;XR   CB$W ^G(H/ECPW5^G6]W"5BX'A+%?7/;W4;NTB+EHM< 3@\7[>WCN/
M;[A45$.Z&GD:P*PHY0=V8R)(UQY;I7M+8['>'=1B1,"AQ7KMQ[JZCO[1V1N
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MV8#<L"(P$7;(RE^)#JF7OA^I;]1W(J6X4_'KB>.2U$\C/Z3P+C=75O=#&2D
MDMU)1M?N+0U\M1/'O&0C<'9^_P"E^Q^@[("1@;LVJ9G'N^B\EO/='5)'] Z"
M]!&+L.14#H_K1^K*DO4UYAJ^Y5%4E[9(6W2.OM-66TXV%\5MBND D#<R'HF\
MHYQ.-0^W^DVY:K%L0/\ EI]%G2Z[U2\\=P92!RF"?D2K!^P_ZRGU;]O:VU47
M)^?4ERH&.C,W'N8 7RYU=/$Y@,$0?.74#G%07-JGN9X$98#/;]0VAU;*]<(I
M0UC\ZH,K'3=VPW-N$)\A6O+#\%T=_2/^KEVP[[P6NQ<WAH^)<LJI64\E-2U-
M1/1N?(&B"1KJF-IC;+F-KG!RCT@@C&AM?=4]M,6>IP C_.#\V(P&=:+&WGM*
MY.$KW39^I$5TM5NT*VF>[VZ[6$UMOJX:JDJZ;W:6IA<'Q31N:K9(W-+@YKP?
MNQ[(7;5[;^M:(E;D'!&!7CKEJY9F;=P$3!8@XK=P*[7!G&9;=!4;:6MF>*AF
MUIW,+MKBQQ]4?NL #DU;B^UN3%LVXGPF2#HB2)2\P3^\0D@CM,Q<YD;654SG
MG\(:  KBN@VM7&SMF](F@ *SMQ_5)GB652W*^Y(O_P!2/+[@R9:;\W^2H3O]
M(I:$,IX44JA;$OAGCQ&YE*]O9;C*5P_# ?1;G3MOZ=STI^?TR3WU^W8GI_UC
ML W3 '+4_LPSZL15,':G(E)#F?*GU5DFCB>)'DNVL8[,G:GWIEX8I<O1E Q!
MJ46U;-F,C5V42+-,^6.Y2O+MSJN3>' @A%0?;AD "+#@K;5]!)XHLM]6#>9&
MN=FT$Y:9J0?D!CFIS5!YI,GJ;)NX]<$"G\I. 1EF(RB X=!\%."7LAZG%RF;
M[1!*.ZA0HN4J?$D!3EEI@\2!<6%L@^V)S]0J8/%G%M-$F2!OEH0A7S3!I5JF
MP/"I'<:D#K?%GF6NR.:>L_:BXZ%07P=3:<%N2C!]37);SQ;CUPN5H>144]/[
MK&JFFX[4;U) SZ8SMW;UR$"6B^*+*&JS*Y!Q<&85)U/]<7=>*Z55%-51Q-@J
MIH<Y7D[62EH_A 3:-<)2V3!]<D:%B\6>Z6[ G0M_U4\OOP8*JO8CP!,&2/.T
MD G,Y*!GTPO^W,:NZ<C9DSZR>X*1W .ZSJ\1?F*@N<]WJ<OJ50$(T"_?@D8Z
M:OXF5#*8.EBRGWV\N3*^&CEW*7@'4=2$7JF6*1N:AS73CJ@99%2'I0&QMR7H
MO77,_'&M8I$+/G22V32  C,Y9?#/#!J>2@)L>8N3:XZ(\C-!TP">)'-7&+IM
M['6?]<F1 >A3X>>(L$&;!6CGV))]Z)-W'KF042G?KI^ IHJYX='BF.U4OG3M
M)DX:5R^=X*VXQ=X*GV97C94R;G$D:N</+(!R>>/TG["VEJ[T^WKB]2OQ1_<K
MJ%W:]2O&W,Q+?BIG]CZ2Y5]/2R/+I"0T(CE<T9>9"II^[#7O';PM6SI $62/
M]O=W/<7#.[+4<59QP#@7(*BCBEAL]?)&C7&44L^S0D^K9M*8_.G6YVY3(@7/
M*J_5_0+EGT8F4XZ>U.5/QBJB:X/B<QS0 6O86N!'B#GTQY,D"A!=>U@!*(,"
M""BX6:<$@L<JC12G7R3%-<<BB"W/-;FVEPR(4G,Y?<"<SG@,RZ.+&JA9;/Z?
M*"2&A==$5-%.!$A7C:D,%Z*&1,QGKH<UZ+\1B,<$31(KT43P-/(!?!3EY!,0
M5>-L@N<%M;2N&>U2=#UR^_+$.^=$0 8YK-M.5(0JU1JF8ZGQ&6*LITLMC87
MH1U^]"IRS3$XX*S,.2R]EZ9#KKIX+\<#-%%<L%G[3\D! !Z$9CYG$9-P5>2R
M;"X$*AS"@KDF*]B@C-&36N&WIT^_-0/(X( P5@,S@MA(3/IDI(Z_LQ7%505\
MC0Y2X#R)RR3(CQQ26*L.2&4]4UA#@>@T*CIJ=,%A( ,<5.EPQ2EI[FU@'K!
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MZZ8'!76\+I&-AM1"!P;'F 3X'/\ MEC'O$UX)G\XXJ4MCHGUIA@C4[@ 2BD
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M<)Y*Z64M>_C7;#C%2?ZE)QPO(;-52/@BJB/<J#4,#8V8N\W-W?7/&\-M ^&
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M?R!.O)>+@]N<CR@0>HJ$Z#SQ'(IX$<$_?T_=OZGN/R LN+GNM= Q]16N1R;
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M2SW^VU5=;:2.GN<,3Y![30WWMK2=I U)Z8S-_L8W+9NV@TQ4\T:%ZYMCJAY
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M,&^$2#TNDVN&,B_U3>;N1M6'A!G;,#C(Y#AAS7L=MT?8;*(N[EIW 6?\O^F
M'FD_;RHF4_\ $?GG(;M5U5MXC#8:B(R6VEJ>1UC[M<J1C1_/GOC:*I;!'72U
M,Q>ZTVZ2*.,HVLJ7^J.+$-FU;B]V9E(UIGV?B>X+?MWK]Z1-NV+89@]2.UJ
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MUNOG<&:&5[);CR:L?)&RW\,I8!(]\0>W\TQH>YQAV-=BQ@3/7?.J8+D_E@.
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M!\5+!^!0=UMA'\.A1$R\"->OABHM_%2YR7G].BR!8OA_;IB1!2"V*W-MD15
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ME_U%;.UE!40N=2T$=9=(J5O/N\?("HIV"!E);I"^5K(]A)3WO5)-&U%VDXA
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M8%J+0(-L@@9U[$OZ[C5/S2T,K+3,(JB6A;64-2Y&?F)*N#>&"8.#XVW**-S
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MR4_L>^R5M5 Z-\0:JM<)"H3S.-$[W:".H2'Q2,--P"49Q,3@QQ4"^[G.^/\
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M)H45_BB69KP?VCX9:8[LQ1(%R],$0U8<.B#KX+NUU)P&?$)@%$TCW*J:9#R
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M@JH.Y]R$%QK&HUH,CSFH**[4 9(1KC<M^+!9X( 4;I*TU5TBC8]TF][6!O0
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M*-IW<YIVNWE4ZJY$Z1Q+F[RCB3F<O-#KA^*RMO$^J2<T_//)!_1Y@2"M-(
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MM]N+^G\%4W !S1I!99D",/CUU773/%Q:*&;@1]3<?D):K$351_L73!!;0Y7
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M43<;<0#/$YDU/8. 2@NS<1 KD!A_BGJBY7'VDM;;IR>^,Y!SR]0FY_F:NO\
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M&/ A\.XY+LF^DGE%G[E]LN-<\M%4)F5-*R*H;&GM.D8T$3P@.=_(J8R'-!S
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M?I__ +:;<;G3(SD'\9^X*V_A]M BCR.T-:"?D/AKC\W;B/JW2.;K][[4"%H
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M]W7!!M8M4EU76]$;T]GC'\((4#S7S/7!Q8@, J:B3R1_36EB@;!\@/[=<%$
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MFJ>37VW15U]H:.EK;I[-/!'6"9U2:=I?+!1PT;9JFIED=(80^5S6R3.,GH8
MA*6[;@.60@3<N@&0 )^S*05\YM;^$\3I^+1W^GW/;75-13B)M5<:ZY55.^*6
MH]MY,=IM,%/4>S$^=WNF,>B)QD<]B4;)NWO4(R^7WE:5V]&Q8]",JU)&))^X
M#"OP2+MM]IYJ"S0/K)A5W%M(*B)Y:&4K&7.JFI7K"9&.JJEUS+<R@;&!DN3A
MMEB0LT7!0'$_;[TB?J0M]'1<=X]>ZR*3\UQNJN%',90-ALM54FY0U&\'W :>
M.L:"YKP-LA\$P/;2:1&1^N'W)C=!X1)'BBX[G?[U"&^<6M;*ZZW,558VUF&V
M.FI*6%QEEBNE5#'32A_OQQB@='.]\\QC=)$P9[002X)'#-(SBQY?BE[].%_M
MM3'R#MG>LI[M+?K-2BI>R2;\Y;*J2HXK=#&]I+7OD<8XPX$N8-RD.!*74K+Q
M%^&0!^.(3_2KT)2EMKGYM0[QY2G,X=)_1KP+56./]8LDH,$CG.%1/35E0][G
M-*(]@D!.29:Y$XQ[UO5$R_*5KVG%QCB%>=QVBHN_'T^?Z6HS#7]U>U?&X.>\
M"$Y:)+]988S#RWA$LS@2)JBDAB?3ZNCGBC3-SL?-;DY=)ZQZY#;'<3,+@RC+
M\L_J_)U]$%J/5NC^A "74-O#U+?&0_/#X8<" KJOT.OJ!BJK%5]GKI6/EHZM
MM9+QZ":1CYJ,T99/2N>C@Z-M3%5R0/!4MDB8#MW 8]E[:W9V77I[.=-MNH@C
M@+H?ZC[LU\W]U6!N^D6NHVF]7;G1(9F$B\2W(N#P<+H:OH+;55QN"EH()77+
M]^/I,Z0+\%\^<2BXS48KO5[>/WB$E"SW6A"=/4F6,B9_3DA ?ID<U5UQ?<_N
MSR=X4K42NTT4-"JN2@_/!=J1Z<1]L4/:1!@.0/U3^7AP=;JS)2::89Y9F,A?
M G&G/RGBBV2?5#IHNR[_ $W4Y97!S434%SBI^ &.C_5'8EMF/^5G_P"X5.3B
MTB4(\'1'3_E.>G3#$QFK0Q[T HYDKW*G^8?/,Z^ QD$_JEL'3?EE7!*JY66"
MZPB&5@>)&M&8!"."E=<LL%N6A<H40W-(J:(_XAVMLU+&^44T37.]0VL <NJ[
M@%Q2&T$L'[5(W$A'3!P"ER;!343P(8@#EID.@&H5,=.P840S/54DNC^&A!8%
M'1-$Z?'!HV8Z6XJ#=E@,$G+U88*N-'1C=OUZ..8\.@PI?LMC@BV+IC)PJE?K
MZ[:4MRX%?_\ IV[C1U <=H0M#7)\<\*[<FW?I]N*8WD1<LA\=0_BN43_ $8_
MC7=!88W-_P"O?&!F#L4$E.A4(IZ''K-K'U+L>97A^JW/1MW""S.0KH^PE#6N
MMM&^0.;N$;FG,D,3)"<@HT"'+&[N-E&%IV%0L?I_5+EQ]1+9*?\ VN)%\ =E
MZP"W,H0F>?QQYK?VA;B&7K^D797+\G.2D+S6!T]MF8T$K3/&B^HM^W(8;Z(&
MWUN1PU!7]T/_ +1='^0JNJY]O+S<^9_FH(C[3:AK@-CRO\Q2!D@_#X'+'[9]
MD^X-CL>DPLW3X]![J+^0W]Z_8?6^O^Z+F]V</THW1D2]<E:Y]*_&:VV4S151
M;2UY37-4T!S&?SQ\C_N;U3;[S<:K)HR_3W_;I[=WO2>G"UO8Z9N[=[X*UCBD
M!92-<1FB>?@-%7'PI@9$Y.OVA9#0#A+MOI  0Y:)K_=@\8 BJZ4R" ,5]M#B
M?X7?<?+RQ64-(<5BK0FY8^9!I&#-1\00N RCJ"*",T3U=("I 4'+S'7+RRPI
M<M/3\RZL,,$F*JB!4(,]#^\GQPG*!B>:9A=?S>7YA)ZIHB%4*%U^>67ABH'Q
M13(@/C'Y]Z*I:-3^$(0AZ=.F66.,:.5(.K!%LE TKZ1YG3RSQ0P!7 T?!D"?
M;F+H!^[X>6*FU$G!=JRR6HVYO3^QQ0V8DJSKS^G@="/($?NQ/HPX*'*R_I[4
M&0\=<6]*!4:CCDLVT+<LF_/^QQ/IP YK@>"WMHF :!?ABVB.04E\2MHHF#^$
M?N_9B3 *KRR6]M$!_"%3H=/%3B13@NJ5L%($ 1OW?W+B:KA4C@MS:8= $\<L
MO$)B0.*K)\@A4=./#Y^'VZ8MI4.V+(TIZ4Y'+/P'3KB:!5)SE@CZEIM  $R4
M_9EXXF()[50RSR2AIX&Y>E= ,^J9X?MVP!S0)$DHWC8&Y+H N2(G3[\&;(*7
M %4)8$]2]<AY?[<'C$8% E,U(-76]L;G([4'4:?OQQD<((=2=16?MCQ&J?Q:
MXK^JI>*Y[^,3_DN45C!EOHY,RX[B0Y4\#KCPVX<V01Q7LG(NEE!'ZW)A/!:G
M%PW1W2G+2@*%6GIIG]V"[ ?J$'@L?JH)F#R3G_3Q6G^@4FXN#@(@A*$@;2'#
M+JOSPU?BT .2S1YSW*S'BLWNVVGS/^6T K_L&//W<:K6VY>(R)"<"V$ NR1
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M#\MS0U5RQJV'9SBL;<Q:39*,]TY)_0JVHACDJ2VWU,GNTCY6L$M'*\2S>V
M]DT81S""I(<JY@[,!KB"<2O/7CZ4R ^/R2"O=ZXW>+95NHY8V2SR-J:)C:AC
M&05#F?S@ZD+&R0/>YH<YK-I545<.VP00#595\QD7CBH1]V[W<*.1T<'LLA)+
M',93A\$[6QE-L@<L%2\-.V1S79J"!IC3M%JYK%ON20J\>XM%R.]UKX:2IN=1
M;:K::F.K@=^5IE:PL97,I96.<QN@E8[V_3GF@QJ[>Y"'BEC\TE.)(TE!.$=M
MK-;GP7&HKFR23RPB@AJ ^6VR5(#'QQQPTS9'UYCD(+&R$QHA<B;L%O;NY<&D
M #Z_P2XL1C)Q7Z*7=#4T]AL[*":2X4GYTQ2W^JW0?UNZ1L#?:H1+'//;K+0.
M<X,;M<_J/6\^G.->U:,!&(9&%UH>2<SK+;P[C']5LEEDFI:GDE;;:&L]RKI]
ML\=-9:.X/B-:YM(&LD(8YLKAF!&"XXZ,H0><F):C\>*BY&5P>G%V/#/DG:BX
M!^5K**:ZL%CXKQVVTM,+73^R7W"H93FG;1MN<LTC7S"3VV3R!@@C+1[>]0YJ
M\KKCP^8J\=OID\@T /BBCF7<_C7'[=)8*6W272H>*6.X1/K9!0N6-PAM#?RC
MJ2KJXY6N:XP[FM+2Z23U.8W%[5J<O&2P^:'?NPA'0 YSX)&\:[J7=M2::EJ+
M;::ZHB-/1-M=MCAMUHMX9M=3L?2L;[,LK&['2-):T -4JYV#SMP+ U[4&S<D
M'TEB> 6JZ<HDEE=+1UUTK[A41RPPPLII;E&7S%TYKJNN]LF5K)7N>X-W!7JX
M@ 8)".62I<H7>I0_C]]O\]VM%O,K:JHEGA]V:HKH !$#[@?[P4!D=86!(V;1
MH,VI@DH@1*" 20,W^]._WYY-2\WXMR".B<)J1ELJX/<$1;'5PV]L9%1 T'W(
M:=SX'QN .XM )R<@S[-HVR'XK2W$_6!(P8_)0:H)ZWE7::AY+;ZF+^L6YU+%
M,PR-9[M7:*B6D9-N+@T.JFREKXW%'PN(/DW("W?,#A^*5_J6!<?Q?>*),PF\
M67N3QOEEKAJHY+JRDWP!K860U<;X*VEJ#NV/D8^%\1:YV;86("B8O,1GMC;D
MJVA*WN(W1BX4P.Y]2VFY;P_N):Z&2BM%XLMEBKVL871^[<??+ZELC4.^GK8Y
M(2TD(6M:5W9^;C&4;4K,JR!*]->N 78WH!HF,?GBK,?IFYY<['6\0O?$Y_=Y
M+QZJEN$-)/M N#7U#8:ZS%VS=/!<Z!A8#I[KRYN;1CQ?6ML+@G;O?TI#'AS[
MEZ[HNXN6IV[VW_ZB!<<ZU'>*=ZL5[2\[M7TY?5%QSN%QLUUG[>\Y=_XA6B2@
MH_S-)1U=RW1<NHG0P>T^E_+W":*62!"UC@X>DD8S-GN+UW;1D"#O-M,!S_E+
MQ/>/BIZQT^QZUZW&+;/=VY2B,G(\0Y-)BNRBBY;;.9<)M/*K14Q5=MY)9:*[
MT=1"5CF@K8(YF/C'^$M=\1C[58W=O?;*.ZM%X7(/^([BOAU^S+;3E8N!IQ+'
MX_8J.U^<117N$?\ 9RN3+3:[]^$)GP206\!59O%) .Z7(TU=(]-/\8!^S!=G
M6$2A;3R'L*?>ZG_W;7$9EM+.?_X9(7X^6-$R)+9(MIA,'FF>[-2A+L,LZXNZ
MY N('3P7%XQ'JATILZ[6?^M3?XI*#0C,?Y)4$Z9$*1XX9E2B- .!3-%M/(EP
M(&?\PE,M2<LD&1QC873VI@BB=>W/]V2)J*H;F3J,@@\!GAS  C@HN :$^M@I
M@80&MT:$0IT*^>OVX9@!& X(<23)ABL[A3(_,9D>6:8K.(F*9+I'Q=J$T\+0
MP9:M&2?[,5:6 4@!G0*MI06^6[7PZKXXB<-08XJ(R,2[45?GUD6@5/"+T/:W
M.-+,=% _EG+/+7]N,6[X+P/-.B1G:8\5RL7_ (7^?[P,A$2[KJ\%I&>9&@+?
M24S(QZ/8;B-HPG+)EY#J]CU3.$<"K7^UG'H[904K&MV^TQB:D% @^ RQZ+<]
M1%\#@LC:],-J6EF 4F>W\?M<C<W14>79*FYN2ZHF/.=1N1G$-E)>IZ19-N_(
M'^5U*J:W"XAL1ZQM1 NH/ET&)V5[TK@D.*=ZM8]?;RA+RD,M_'.U%-/6,G=3
MM)+E<0,\M"2%^?QQ]$Z?[GO6HMJI@OB>_P#8NTW.X,C;!+_8J4W;"GX[15D]
MMH[C;Y:^C<E51PU<,E339Y":%KC)&%\0,(=9WFZW0]2X#Z9P+4^*]![;Z-M-
MA.4+.G7'$!B1VC+O4T^/.B-+&(W-(0:$=4UQYNV''>O=$:<,&2I!1WP489N$
MB(9 ?Q.O//IT^'3!(R$HNJU!=92(0'@?'^VN 2B0=*9B7#\4#D:"H.AS']OG
M@,HN$6D@B6J@;GDH/GA6<-7:J@F)=$513A24R_8-,*D9(\)F/BCFBB:D:I(_
MMY9:'$/DF(:;A<4FBN6%#H4T^S$4*YR[201T#5)VZDGS7RS&6*DD*1%QR*U&
M!=$.>O0>.1U.(89A2YR6+HFC0:^>.#9J2L1$,LOLUUURZ8FCT4!UFV(*-=>O
MQQ%0NID%L$:'%@7[5&'8MS6#(ITS\SUZ*<075HGX+,,:.GPZ_:OEB6DH.@=B
MV-B!(R'R !!^.>+,0J&8=HA;1$"<A]IQ<#3BJ'5+L0N*G4@)D-<_[\<X)43@
M8C4<$:PQ!0T!-/M^:XY"?^9'=/$  $^SJ-<-6K8%2A2DYY(ZBB#6@CR( 0*1
MXY=4PS$ 'DI$<T,:TCIJ<\_@F+!1)W;(H26@N:T*3U!(Z^"8,20.TI>0JR$.
M< -K?@3H<L6C$YX*DB, O/3_ (CX]=?LQ:O!5HN=*]U;+-?9ZLY 43VK^$ G
M+/[,>$ UVV7M)RT$3'!5J?5ERQEVJ[/1QO\ <WUS97H[)@8 5*(H!1,/;.TT
MC(XLL3J%T7)B?%/%V(Y"RDM5$QTFW=[+44?A&T#4*J_+!=Q#5;?-EF7YF$P?
MRNK5^!5[:BUTX:Y4C:A55!'WZX\Q=9UO[4"5H2Q3L6PJ]QTR=\ -N>N>F&=E
MYBK;@  $(FNN=5GT0^:DZ9:)AF>+)?F>";+OI8&WOMU=8PQLA=0S-0C<"-A5
MI!RS!P<BL25$H>I9E$><!QW+D4[EVMM@[B<CMQC=$([M.(XT#0UCW[FH%&TC
M3&_MYF=D2.++)ML*<%.GL,Z:]]NZ. D;Z5LU*-Q.?LO>UBY:-:[3QQEWO#>D
M.:W=B?5L2@<!(CY _>F$X[9_Z)]3E.QC T5%7%.W53[KV-0 M!()7X##4B9;
M1N:P[C1WAMC 375;V:"\/M8Z_EH@$\=@U/77&7"I/:M:8\,>Q/$&_P"S+3,+
MKID<&94IFOG,!Z'-,M-/''8GFH0.6)%^*]?'/[\0W!2B.YQCV7 >!\LB,QGX
MG YX.C6CXN]1=Y_"L[B OJ!!\4)*%$\,)2\S)V?E#(FXH2'L)#5).: 9.*+Y
MY8%)E>SC52&XE>'T-6QFYS69)F,BHR/3,89MDBB%?C^8>9.QR9D5UM#I-NYT
MC'-)R.:'5,@J_=AR4=4$"32/)E"'D-EC9754">V^.5SF.(R(*]/$' H&B6.#
M!)Z**6F<6O5NWTJ0GR'V8(H9*NU7(Q-#2Y-/+P'7RP"Y&KA-6Y1;3)&LT\=0
M0YB;DS:"/'5/'"LP<4U; _X5[51>[02-#55A \1ED<_/%(N)41]3TR95Q_4-
M:S'%4.<T$M+G*1E^)>N:A<>@LGPQ[5@7@UPA5\W$EM7'N &V1%  73,IU"_9
MC3#,J-X0I$.FE_\ #6W/CDE8TN#"YH4./YB-D\(<T$?S(9 %/@=<>!Z_+3=D
M,G7T'VV =N.+?>JN.]4E4:&]7(Q,8^L%R;/0MV^Q#76.J+)#&\@)-74M69@T
M?X#GGC.V;"0'#[_\%I[R)$#+B_Q!^_%5K5CORENIJ&N#GG;MGI)S)$Z0U3H:
METS7L1'>]6N+BUV690J<;L:R=8@BPYI=]JOI8N7<N*Z7:RP/=4W.KB=5MJFB
M5S&12U _+-K*7;3P!\6;7O:P%VA:=V W]_:VLM-PU6CMNG;C>C]')6,1?2GP
M^KO''+17VN\TCJ.AM#IZ>GIYZR2IGIJ<--/!/3P0BFGD>(B9'2%2S,A2<8US
MJ=P0E<C*.)QIWKT=KH=F=R-NY&> <5+G@%8EPO@YLG'([3:Y:B&TT,S7F&O6
MHKH:=FX,I9:VH)JBYL$37-C1T(!#/PM!'E-WO ;NJ=9D98?!>SV.P,;7IVZ0
MB<\6[<4ZM*?RT,<<L56*6LHXJ>=D!$3Z9KCN8:5CQLFG]>\L)1REBYA,:[=U
M2)&17H+5DZ<#4(CY#+(;0^\4Y96B&2/\U-&TB2>@IUA'NA(WFIC;+MD>\ME:
M$+@Y,JPF=>@T_%%E::&H!QGV*)G.ZZ<U-1)&YSH/S51^6B)+I6-?.Z:$RO"[
MPQK TKFN>-;;'\N;+)W46\0XJ)UWY5.*RJA<]:NFJB7T\F3GTY>)V"-Y:09H
M7EP!:J%H.U 2=V$0(C@0O-WI$R+X@I@NZUUI[N&UH>*&Y4S2PUS)2S</22:D
MD@Q[MVIR&@5I0:>T-&QJL+J#2((Q904Y)R#DE!4U,U-)*Z,EP)I?<,4Q:C1)
MLB9')M:PA2U'@G3PTXD#%>>NF6(3/WB_W*2KFCJ*POBFDCC<9'GV6QS %LS9
M(XYYRSKOV.</XG##D9$4"2D'+%)Z&EJ731U4%TEJ+>9W10-JZR C<[8^.&-T
M[))7Q1RM.X$ENQWJ ZGC<D!7%!,61]8>,<)?=6\@K:.H%\.RD_J-!25U911Q
MAGMO90TL[Q24CYGDESJ8.'J'X1BXO3(T/X'=#-J(.IO$G7J[I9K%#+/:>/QW
MB]5E6)J>GND-6TU=QA6,7*[W&L_/14+*%L!,#?<;ZMKAMW,6H>>)HK2+,14H
M+4\VO%-;:BZ\^Y]Q_MS22[&NX_P5TMRYI/;X2U\<$MTF=+/;)ZUCB7B.IC&U
M%8YV.TF4],(F1XG!7A(Z";DA'E'S?P^*;2;NSS+NA?K3Q?MY9;[307VXTUBX
M_0.I:[D/..:WJKG_ "M-/%1P1R5E;4U-14".FHZ>-Q,C@^1P0G!IVK.UM&[N
M91$8AY%P(Q Q<FG:2C0%W<W(V-M&4KLR (@/*1- .->"O'[0_P#U.Q]9'/\
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M#6. .>B9!?CAF?$8IR 856B*7_KU4!9>A\,_MQBR+72>:9DWITQ9/#9'[IX
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M9C- #IU4KH>F.!^*N7B:8(*YH'4IJJ+B"ZN"P6O;EGF=/B/CB*A2!QJOMI"
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M (;ECS>YNQD92HR]OT^Q*W*$2*X*PFP6Z&EM$(]N)\H@:TAC ';FLW%QS7:
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M4%>)J,OM"Z%<\T^_$D* :56! ](/EUU \.J[1]N)Q!4HJNB>R]!DG7/0>*G
MYNS%7AYE&?F35J)-%W*3HIS &8QF7,5I'+L2,H&D2 '57.5 ,QF0=,\5((KD
MK0%:IP*("4Q(0<@IZ+IJ<\%B:,<4640,$OG57Y6U2>L ['#[&Y]/+$@M&BJQ
M:F2B=RBHEJKZYX7:W<3_ !!=WS *=<-6J0YKSVXBUT]J,:2$EC2 ,PI)!URU
MSS3%CBB6Q1\T9QL+3ZCF0 7 'U+IKD!BDDQ&A0R6)LL9:]#X*A1P"@MZZZX6
MG)EH0J $#HV21/>T*H!/@O@G7KGCA(&N2M( A,EW6WRTM3 C@]\;@[T$@*TG
MJ@<OQQH;7%9N[<!^:JHY]1_E[W4Q@*KB[U9'4@Z:YM\OGC7M2HW-+/JMIYOI
MD,5/?@^=K2XR.$8R1I5I/7-6CSRPONPXIP4V9Z9@9.IX\KX':6<RXOS:GI(W
M1W.WW*U5+FQM,4-0RBCK*,NT+2X4DS6Z!1ECP_N"V^UUC%V*^B^TMQ_SXLD^
M%B0BNN@M$50T"FC<20X-VM=[;M7/:"$;ZPIZX^?WJ \%]HVEF4XN *(9)=HX
M(W",EK2PH00T .&0:5 7/RQCS@92HO168-  XI&7&_,:PO>\N"C: J%Q<U,P
M%)V#0:XO';$]JT+5*E%]#>'S"1J[7*7-S0N71CF[E5&CS3!);8 .$.Y)Y]B,
M&[J@DO1X>&:$AH(! "]'?<$PI.VU#@F(FE<4-AME2]&3/#V-.YKHW-+T!#H\
MP7'TC7XX7N1 C16%V \N*-9;(R=)'1L$@&TE'!R  N>2 "YH<5VG),"!8KM9
MP=%#^$4<\A:]KBYP1&L8W,CU*'M+ QQ*/:A:AT323.66+J-41%S5)ZN[7VDN
MW2T=-#,P.8Q]5'#)$KLWQ.=M+(XGEH4?PD C%X;B]$L262\H;69U"()[/EV+
MX=N>/2(PT=*]T8:)J=[6,VY(5+?1(",P[\)&>1RPQ'<W0Y!*%.S8(\4*=B!7
M+MOPRBHYJJZT%!1T%,TRS3U'LL@C: C722/&UQ<7(& %SSDT$X,-_?C^<LNL
M=+L[RX+-BUKNR+"(#D]WV'%,7R7Z2^.=TI'72[T+N"]N6.,U?6&*&BY;RB%H
M$LD=)'+&\\8L\D2?SY&FND:?Y<<!1YW.G]4W%L@.\N.0_'Z=J/O?8FTC _NF
M]0MX(5+\#+"G ?Q42>]O*>$<&LC>U_9*QVWB7"+1&]LM1;(_R[:VJ>QYGE]Q
M'3UE5* XR5$CGRRDJ7%<>JV.YE=.N4B9E8?4?;_[2T 8"  I$##'YGXJGCG'
M'N3]\>74_#;'!6S\+MEQ8[D%3$Z5C;Y6PN<]T53.';WT%+H(P?YSW(=%&V=S
M&W;,I%B,%\MZM"Y*Z;%H8?7^"F[].'TUSU-[N='4T3Y+A<ZNC?<*AD$;H;9;
MJ*G=36^ACF,1BI+3;*1Q>\M87SRL!:AD&,+J?4M$-?Y(@MS)^]$Z+TBY>O&W
M(?J2(<\ .? "IXD*\7MU]--RI;-:[?Q*K?;Y+33TM/1LDC<1*R*&-K&R.!!)
M>8P2?$G'R[?;HW[LYW0-4G/WK[;TZ[L^G[:&W@2(0 "JV^L;Z:.SO(>^'([[
M?K_4]LN\]FBM<G-K-2444-#RYT\,)MG)7TR1S-N5;3;-U1$X-JFL#G@O#G%C
MI75-[8VHV\8>IM:B+DO'_*_ <#ADO11V.RW<!NK5R,3*+T8OD[<<NY2=^ECM
M5=.'U?&N567D4-TJ+?=+?+$]I$$]10OEBCDI9(VN<KI87D(5]6,OJFYC>D1*
M.DD? K>$;?[&6VNDF,HD84P5I'U-<=M?/OIU^J;B1A#Z>[\/GN<#&E@']:M5
MII;Q#*#D&O-7:&./37/&9[<W,.G^ZK5^+"!W$'_XAI.':Z\%[KVMWJ'M.S&X
M-5R.TO1#_P L)F4>X'#@N$GO1QG^@.J8*%D=)=+E24!K86LE9;YJ"GOMWH7T
MU8]#%$36F-TLK '112,*H <?J+;R,ZFH=?DS=Q,21^8BOQP4?N35=+S"'@'-
MFU#C&VOJK+RJHG<)GPUW';>7\5N%>\%_NUL#6QTQG9N,HI0X_P":4;C$VI2M
M"E''?BE+@E<$+KG@3V8'[E!:FM<IJ^03UU7!%)1VJDME7.RH9*^2Y7"IG?&:
MAX$@EC+MT;MV9:WX8>N'PQ !;43W,%7:GQ2D2'$0.]SBI5]C>04%SL]%;KE<
MJ.6W5E-<^.W:TASO>C_*NBA@JO3%[3*-E0Z'V]Y+F,E<.F,W=6I6[A(=W!'8
M5I;>8N\-))'PHAMMX:ZUUW)^-U.^M=3;&/J+C')'3S5=+&PT%PIU>YKX64-3
M$'$N)>6;BB[0.=W4!,9J)6S"<K<@Y"EK].5QEIZ:VVB[>ZRW<BL=2^Y1U,;9
M'T\T)FL]X$H +2R2G9)+&X9!^WQ3&+U*V"/4CY@5K](N:9>G/^G,%_H?DI ]
ME9[KQ6[0VFX.$53:773BM>^6'W@1:JBM;32-=D]AJ8S3!6I_)?F=IQY_?PA<
MMRD,ZKT/3S*Q,0=C'PG[?#N5MWTZ\^H+7RF;B?(W,DXUW"H[);XZAE1[;[7R
M*JLMN;&9 U^X1W&.9C2TM7W1N4AN?BNH6I^GZMNDX$OSBY^B]AT^Y'UO2NUM
MW&SPD0/JK.?I-[@57:OD5Z[?\@;)!525-VM5REED+&UM33 U?'KD8'!OM_G+
M8=KMNKEURP[[8W\;.]$H$&Q=BS?18?NGIL]STTB0?<698\1_$(PXI<1)W*Y)
M*O\ WB]5\K N>V:0O'W.Q]7L2<!LU\DWEMK(' J7=?,6VJ:4$^BAE.7C[;M.
MI*X>X=JR;8))CWJ,O:.4>Q>SK_UL[AU'^8<_MSPU<QYI;:1>$QDX3^<?K/;;
M,5U:5"H,AX^)P.1HFH-@$[=ID#Z:A=_B#2J:9_\ W6$)(DF,M)S*=^*L%-##
M*\AHV,0_$?'7#(+1$N27E"I&3J0G;2[&LA12X-< "N8"#(?/#=FX\6S0&&!X
MIYY 2#TW $$YJF2GI@TZQ!70!&J/-UB,@/A@8;4BAQ'N0:IRCRZN4KUTP27F
M0K?D#543/J/0\6N@U/Y:?/\ X=HRRZKC&ZAYZ)JS0DE<\_*HP>[M( %)N2C,
M(CXD1Q_$">N28I&MI+7*;RU(8.I-Q6QTE*-C/_5H3J=$'IS5%P2!R6E>&H$I
M"<9M57'S"L<R*0M]"$ @ J0 ?%?N&-*GI\UD",IW=(%72^[T]TYN(<(?QNEE
M>RLK(2Z9CGO:\,+0 $Z$ID,LTP.Q8]26K\KK1O2D=N;!X@G\%2O2>YW:^M7L
MMPTM-90\6?5\ON;1ZHF248]NE=)^( F650O48V8P%JP6I_@L*["5_KFUL@@V
M[43</:!_@NC^Q.8^JHX&9,C>QH:,LF$;<E.F6,#J=S1L[DACI/T7J]I$7-S'
M5_,ZDC2?Y4;CD-K="? )KUQ\X!8.O3FAIBCJ>=M+99I"2)*VKBIXG9 ED0+Y
M0O\ S$85<SW=,(QKWH^G3MW.,C]%)+Z<+4V:>MN18J/;&UQ_^1MW:GP+NF/:
M^TK.N_.]P++R'N&Z-4;?"+_'_!3"J*J.F87/< @S_P!F/H5R[&$?%@O* '_B
M2&NO.*"AW!\\;$57.>@*>"E,)SW1R8)B-D2'B+)(1=R[?65 A@JX9'$D;63-
M*IJ@4@Y87&XU%A(:G42C"%"/FE];KE^<C#FO!) ZYG+PZ)@\;LB=,E24=-1@
M48N'XAHHR\-,6D 8LU$,O$OFBVHB'XDS"@YY*=#A6H*,")!T >P;47JJ@^.2
M8K+B%-8EP@LC J(A^>?[QBM$U;O G3/$YH*Z)1D$*Z_;\L<"QK@KRLOY<4%<
MQ,D3[A@@.KL2MR!B66&W/''!Q@J#4#I7P:20->@_M\<0ZEB2A#(R'!1Y_P!C
M\3CG'>C0M2)0IC$S'R  0+T.*X]J8T"-2A#69I_8_P!CB8GCBE;LQ+PQP0J-
MA)^!_MIBW9B@@<<$9Q,(_?DF1'[\$@'JJS)PR*,H0=?L^.&C0(;-VHSC;M:!
MUZ_;_=@T69T2."WM" '_ '_[LL7Y*"*NMS#Z_!0GSZ8G&-,54EI.<%L<U4(R
M*?;B\)Z:'!#G;,_$&=:R"$Z?'!P0<$$B09Z+S^_$JOXKGXY[&W\G7L<%)@G&
M0&FTJF8 3'@+7G#<5[:_6S+_ $E4E=YX(HN15YVC.<N&@3UJ2@0+GXX]+'RT
M7C;UPQOD?E4H>R%IBJ;+12M:UQ=%$0=K1GM:]/C_ 'X5NYLA;F9T@!6I]IHA
M!1T["0HA8 1F-$R\ACRV[#W9/Q6OT>1T-R4A*)Y]T9JWJ,E)3H/#%MKYR<V6
MA=<H@O;A^8:20,]4\':+T_=AJX2Z#)F"7?'7DTK!T.W(]1MR'73#]D^$ ):\
M:<U6%^H_Q#^J]O;O.(C(^&GFD9M:'(]@+@43/3'6VCN032H/W(6\\5J,_P O
MWKFYXQ72VN]4U7%N;-1SQ21E T[VR]4(7-FISZ8UMS%X$(, )1(.!5K'">;S
M7>KX]!(&D5+(-^T9H'-(.X>9SUTQ@Z9BV=606MNI"=C4<65]79-V[B%KU(_*
MQ9)F,CG\,7V@_3<XH)_H1;@GK( 4>'4?[\'QQ0\,%]K^_)-?[QCB^*X<%@@.
MH0C[D\\LL6R49HHNB"!P'@<_M7KH5Q6YY71+>-5&CF!!JGA0I<T(,_#Q"%<9
M=W'FM(9=B1D?H<OS!&:#0J<]!E@8<]BN*%T.AY134E9!01OC=42J4):C&L!,
MCW+HUH7!2)".H*_J0]06SYS]R/>0<HI8;,Z85D3]C0)!&2Q-S@T$+F[,XK%R
MW!7W(-FS*Y()E6SPW&J=4,<';G@E0$37,^/EA^)HL"41,ZL72OA:QD81%#5)
M">2Z9:G'8HP9EL8CD))(*IXH3_?@<CFKQ#H:0=O0Y KDJ> .N>%+CE/VXG#-
MEOCC!+7@'(AJHHZG-04Q%L*\PP8IJ.Y]$'4;Y&M:2UI>'$ @ ] J]!C0VQ8I
M#=#])LW557=FF_+WVIF,>T2H@8 @]/J11Z4)4XV+9;%9M8Q2F^GB1O\ 78\R
M1^84$  G<T -0CH.O7%=P7!')4C*HXDJW6CXS47SA%72TP;)64I;6VY1G[L4
M;W-C49L+M[FMZ#<?$X\SU#;_ +G;7+0Q(IW5_AWKUO1]['8;ZSNI_P!,%I-P
M-">[%1"J[OM=.V9Q9/ ^1LK'D[FEKG-+'D([<"JC(Y8^8W;9E1?I39SMZ0Q\
M) (1'5WUTT3@#_+&T[FGU9:(2>A\,+_MP"^:UX7&')).6XNJ X.+0TA6N*M#
M@YKO20A)0M(7/[,6,-/:C6Y.4<\<,E2Y\48#7-1Q+ C7%FX[BH*.VA!HN*2
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MUVY4)( :C7'+:0?G@$HEUJV"'<XI2V2J;22P@O;$V0MC$I VN#W#<H.90C+
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MZIKC/2U%8:8'VI;G9#51PE@D?35UU925<+97@DQS4E>YI><HPXGR/Z!Z>=0
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MC;V</V^T$!AI_!84S*Y*.K^H0/B:E5Y?71W9BX7V_OU09]LGY.IV '-SRWT
M!<W E<96[N>M=_;# FO>NW+BR81I,D =G/N7'#W'Y1/=[W75DTIDEK:^61[2
MY"3-,7/_ (U)5RZ],>BM0$+<8XL$O?F2 'H KZ_TP[/OBH*G9DVGIPOF[7)
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MHQA:]Q!"G-2AS/E\\#)R5XN.Y!ZV1X)+3\B F:*FF6%YX)^V3@M])4'V'*X
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M,.U<Q6P  9E1EJ/]^(>M,59J50Z$ ,! UU^6GW8Y<A8R"?-<-0BP!2K5<(3
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MN^/NIM\4-'3$T\=4U[F.DB8X2U$_MH7&5P!V-)#AECSL^CVK^\-W4/3.>?\
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M9]Z<98NE6^6L:ZA;3N:V,3QNG<6D^[$CA)%FHB>YZ$.^W KAN/$P( U5YA+
MVR):W),:=J4[RW:PEKB4#B6H/X5W#/0(AP8$'!(EZIO>>6RMN]GJH+9/)17
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M(##)M )PW<(C;)/VR69*Q^ZWEFR['6_<*_<NG"]54/'^,U$@(CBM]L]M@)0
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MCA@_$+P'N63W-(RK\U CBW&W555=))9*B+WZ'V:9@5K7ON%''++(5]4<CS3
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M=NT02>"Y9/K=[ET' :2Z\GK]CF49<:7<[T,E=!L8^7<,VQE2@\,:NPM>JT,
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M*D@FO-0YA(%/5RVQE!;YG .'K;2S/]O+*1X./52O:=AJ%*M^*\M.R+O4].)
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M@^DKZ@K=W(XS::^EN#*J.JIJ:1KVR[@=T;7 A#U!3//&;L[\K%S1.@)PY/\
M8A:-R W%D[B%0]*<59C8Z\5,+,_Q-"E>O0_#'IK,V/)8>YA^<=Z5L,A0@G)<
MLOCAZ$M)'!*$F00D%"#@UR)D'&*H,5O!!"C0X5(/>C CN7H)&F)U&/:I'+!9
M*N77[L'MW''BQ4&M O<\M$3/_9B[QSQ75[E[CG'%2HS]Z.V;N26VH%H(I+A[
M4HIZAF18Y[$0]2TD8S]UM8SB8X4H?JM#8;PPGIN,;9H?Q4#.'_2;?[KRQU5S
M&3^HT%-,!&R5A<Q[U5SG1N<YKAGIIC%EM9#PP&FN.#K0C^TL'UWUD5$<!W_P
M963\([/\:XS10,IZ"",QQL:"UD>]&H@4!&CR&-;:[)AJE\>*R]QO[E^1?R_+
MNX?-.W34%'2-#88V-:$ 1H4)]_7&C"S;MX"J0,C.I*&;VC09>9P4$#@JU>@+
M<RL??B;F7M^!S'S3ICC*+.6 7!NU:7W.G8#NEC!\CG]F:8J;\(A@:*1"1."8
M'NM*VZVRN@AVN#X)&DGPVDH=0BX\_P!1ZC8V\9W;DFBRW^E],W&XG&-L/(GZ
MKDP_4QXC76B[UU34TS_8F+I:>0-_E%I)):'#TLS.>*=%ZCM=_'U-M,2#5Y(/
M7NA]0Z5/U=W B,I4.7!59=DJML?<CC _A9<X6 ',.:7Y'+0IT*HOB<:V]'_+
M2[%AV_.'XKL5^G=V[@]I)U_*0C_ZQHR\04QY_:$DK;O-Z04B%Z'Y?V7#AY!+
M!EGN33P *G+S*9X'I*[%8GKX: >2J/L&)C$FIP79,BZX)[#@,\LQ_?UU&(N$
M"/-7@/&HY<J:'5KPH50J]2"4^( QFW:]KK1C2('!)&JB .6;2A!ZIDJ_//$1
M >B) _!D%J-K:1RGTM!)7_E^.68P56XOBF Y#=8HJR5L1!.:G5J]2ITUPY '
M2L6_("9&:;:[W":1CRTDG--$"]2H3X#!0R1F\L4BZ3\Q4U1"/>TN3_" J-*Y
M! 3X9XM]%2( *?KA]GB<&&3UN:T$#P :%!&8PO=)6O8M@0!S3QTT,<<;&@;<
MP2 $0#).F%BM"R:L2CEE0R&,@$)M1%0Y#JF:E<4Q*).+CD@SZG^6YP*KF//S
M (0C/! ,DK/!U'GNO$9**K! 38Y1U VD9JN8&'MJ?%$9)3<^)AFH6=MMT'/Y
M0"0UT[2,R$ ?MVC,C/#<R6?M63,:9<G"N0[;/W6J(E<X6;<A^WIEC/'F/:M8
M!K8/%.4' E1J#^Q4)Q)5<$V'=[M=1=T..QP1R047)K',^Y\6N\K"?RE>(RV2
MCJ"PB0VZYQCVYV@Z(X>IHP>W<TD.VG/L_%-;7<&Q<>7D/R/'N4;NSEIH[IRF
MY4?)HW6?F'%(66OD?&I7QFOLC*I\T=NO%&7L>^"PW@2.(J:4?EJ@I[@CD#MQ
M(7]Q8F++OLY$D2^X]G/#L7K[L]ONMAZVW _?PB'B/S#'4.; T&/:$^/>;MY8
MKEP&EL-RL]+;Y/ZHRKH+U;*>GH*RYU50\3_F*VKIF-9=GP5$(G:)=SVS-R<&
MD@I=1M"[;D;T1ZD1)I9BA>O#B$KT?K^]V5^-O;W9_M;]RV)VR3I+2I0X$9$5
M%0DS2<:L4E'0T]13TKIFU%,9X7;623T]3$QLL@>0X;0T9^E2ORQ\'O7#&9\3
M>/Y.OUYMI738!%1H+=H% F![P\(K^VG-;E>.TUVEAM=KEHYC21W.I%%)'64C
M9*V..&-]/*"]KY&2,86M?&7,<4.&H[N6SWDAM)ZK8P(S!%0<.PH-F%KKG2;<
M.L62-Q,%P14&,BQ&+8 A-!R#F?#+Q!::7F7 J&EM<KIJ^X5]BK8HJQEZ:P0S
M!M#6T=1 VV55*!'(UQ<XD [CMSVH]:B;>CT])-28G'N-/L[I*/0=Q:N:H7_4
M8,!<#@#FQ<D<>YE /O3WCX[VBY[:KIVFX1:N/NY+=[?9IIGUCZDU;*J5L$$U
M+1TM/0P1S3R/5S0 W(J"@Q-O<1W42T2&K4O]RF_TW]F;<ISC.5R0=HZ0<N)4
MJZ;E-\KK=0W*NK9Y*JX11OF#R08WN8%C:0-C&-(&T  #&=("=9UDF)Q%DF%N
MD04M++."T.F!+Y&-)<Z1' G1SBA7U+@-Q@$,2.>*<&S3%NY9 %<C".H+6C\8
M<6JY%7"5P5JN-.U.%2JX,=O4>ES2"U7>D9DA-,*R&26G<.02FIJT-]O^8[TM
M:H=FU=SE(\'.:<*S!U%#9'%/.QP#5:0QWN-1Q4.(+@ I+2%/3),+2HN<@<UM
MEEDD:7;F@N!<"0 TDJH#3H J #/"\P25(D :X(12N,087%N[8Z1YR 4(@!73
MRP2W%AS2EZ0)?(H/75+W,<!N(VKM!ST:@_Y0,-Q#!TI1,!W1J'5%JEI8UW.8
MZ(L#MK5<2@<1_A)Z8;L>$J2/ >)4%.(<0G@[Z=S;U[ DI;?9.VMOI2&D/@GN
M!KI+O$XD!SI(XZ>G>"%_EE,LUT=QN1^QMP&),_EA]ZSK&W/^X7KA&$;8'S?[
MDJN]=GI[/SG@%[A?[,%XXYRGBM3*U&[9)(&WRCJ% 1S(ZREF8BDD$@!3E3I-
MZ5S;W8'&,XR^Y"ZC:$=Q;N<8RB?J%5OWXIH;/8:YE;3@4T%.Q[7O5L+))*:.
M1L1!V@>U^8DC: =I+!CV.TGK+A>-ZA;T THN>+N[4?DN2W&.V4\<51>[K&V:
M4OC/LPL:^2.VQ"-V3:UQ?)(J-$;'^./;]/'J6Q*6 'V*\9NFC(]J:3EUNHX>
M.6*A$VUUUY#<N05,C6#WZFF@D_H]LDEV9L:YD+Y1&-0_)=<;>WG(2D>$ .SB
ML2_#66+@..]OL%IY1/#QZ]4-OFGG@91V^"Z5]%%-'&R:OFB_,4\%4^=Z0TMI
MH#%MC+29)2FU'$XBW W;98/(T%,/XGCEBE;][1?B#("V 2W'GR IVDIP>"R/
MY-R'_45<(ZZJH(Z2"P4<NRDHZ66J@C%LC@C>5$E7-3@S5#VC\O2T\DVTNV83
MW'Z4/1% ]<WXUY<.*=LQ-RYZF-*<*_CGR"?SF7)WTW"H_P I+[DKS1V^B+HG
M!U+8*:\06JMY%)1M#(8HKS-23F%CW-=)^9#5_#C-M1$KU>?TP3EZ4H6?!6H
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MD=Y('*@[&4B.U5SJJ:DLM.V"4P5]6RDKZEC!)+34E=,*6>KFDS$+)X/:AB)
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MZ? WMS(QIXQ\B/N7=MVJI_8L%NC .5-#T\6C3&=8!],!;=PTG]LT^;2 P?\
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M;VX!T$4&?:3]P[U9OVM[8=NNWD5-;^,\9LUFDIP=YM].VE<US@[(- !B !#
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MIV-I >?V%LX>@K*0 EN30Z12 /XB$)/W8]+N)-9D1P6#$@2':NS7Z9\N"V8
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M^6],?E-CO]QT+>_M>HQ/[8R9\01_..?$8MS7JM_M-IU[8#=]/E_SD 'C@?\
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MT\,=+$X@#UR-:7:(J YE,8F_.O<_Z:I._$0AJSD /O/W*W/AUS@CWB69C<E
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MH3VI>ZT@.(=+**\6IV7YR$ E%W@?9YX)JBU4!JXA^T(=%>;42&?FXB7- "2
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M2NX%V@LSI"8JFZ0,K9VDD.1[=S5#M,CT./%;N>K<S,>+?!=NI$"-N-6#GO\
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M]-RR JN*&W=;RR^"9A'<,T0790A[N=B_J*Y37/C@X555=$\&.4LJZ.-5W .
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M54G&%[6V-K<[_P!2^/T+<3.3X ##YE^Y>X]T[^]M>D^EM_\ JKUV-N'::D_
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M:K)P-74?;!]0O<J[UKZ;_3_'2&2('LBJ%V @*2Y^2 :#%H[J_+$CX+K=[<W
M3K# < %+WA'->4UM&R2KAH:9[VM/MQ12EN@S1SSXX9M7;LO,7/8R7N:QXI'Q
M%.&SDU]7)U,?C"_+Y[S@HG<!Q03(\?HA#^47\-#0:5I<,OY+G$=?\>6)-Z[@
M2J^$YKX<COP9E^5)3/\ DN))'GO\1CA=N@,"J&9>A^025O\ W N]BH*JXULE
M+#!2Q/E<]T&UNUK2Y-Q>@TUP*=^Z,35%$W#B3?!<G7ZH'ZD5UO\ R&X\#LE[
M:V@M<TM-/!2O]MDD@#F/W)(CO<3;F,AKTQJ;7:R(]2Z3J(SYICU#;MZ82E(E
MJ8<:<67,_P VY)_XA<@=/<(I:J&L>]TAC#LA(0' N:"FP]!Y8T8O&.G,)><
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M-F9^3?>OR_\ ME7BXTG>[N5.09>4\TNU-!-F7R4M%*ZECV.( (&TD[2@UQZ
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M(2QAS7+5!H1\/'$M7PBC*IKCBO 3DWQ.::^?RQ9ACFN<]RV*B#H/[^IZXN(
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M<U];<:QT$_MD11[G.?Z6,1H0#+[MLMWL_;VTM],Z=8D;$12H<G,R+5)Q/PH
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M),R9J[QNCK'$^)'CXE/[>.';1_3#*P!-2<EHIR"1F2"-=%(^]%Q=R]<5;2&
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M)E;SR3 #40*OJW5;G/>Y9&(CE!+O2 KB&@:MZ8M".E!N$N.""4UWK('C9*Y
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M52U2PGJJX$*ALT0D@\DQG=+C8Y#QFL?[?_O6QAQWH"^6C:Y02GJ/L.R^#O+
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MA.:X*6B%0!R^2!2R@ NT3]VB>.N RD] B "/:D;=JIS]S6EPRS14 )3-.F)
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MCU<8K6\1R*J9Z9=?LRSP&8C(XU5]0(KBD9=**D]S>]H7X#Q/3SPJ0#C@C:Y
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MI&KFTLD < H4.:04ZY83MT(.;K3OQ!<#!E49W>MK;5WQ[P4;8]C8NX_*)HP
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M6TI#Q(Q6F5K5.U?2""=4R0Y:8K.WJJ,52V6H<%L?>)HXJ2[6]S&7"B1M9$U
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M]QO16"14\L.7Y2C'3#SDM\5E;<1E-Y^6(?X(?;.YMGXXZGM18UD-/&RF8]
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M,3\PT@ Y(H70X-"6F>I)2#@A$5X2CN\50T!)2R4'0;@A5=$)Q-UHS(&9=7M
M3MN148J'7)+(^P<MY-;HU%,+HZXT>I#**Z!MQIV-09MB%06!/\/EC-,3&[(9
M/1:@EKM1EFS'NHJH?J:I8J3ZANXOMM#!75EBN;@P(=]RXM9ZF1P&?K?,XG0*
MI."'S$\TO:PH,U"'N3:XVF26< &0'-,RK@,OXD+=0,1JTAQBB7;7J@$^4*.=
M;QV.2J>0T;)@U6[5R:"@:5!4@*<7%X@,<4$;:.+T9$EKXA3R78PR1@^X'$!S
M5<!FJ:Y'RZ8B=XD4HA_LH2FK#>U_#X[9::%T4>Q8VD!H(4*U"X9@G<-<>=W%
MP^I)SFMW86?3@+?!2_X,R2G<&JY-Y7,9= #H,9DZDGDF]R6BV04M^%S)%"%S
MW-)!4$9@A?!<6L2\0!P2<5)ZT3[J5O4HT^8"9+YH<:L319]ZDF*-O=.66GG\
MUZXL9/@@UQR6N25&.*: E2=>J8AS@N%:)C^87+V9),T'4Z$9JIPE>G7DM$1>
M(?%,[/R0"1S6/4*=7)I\79#"AD<<ET9,6 *WP79\\3B''\+B0/#7,CJN%;DB
M/"%LV6,-35*:ZXU<LMQ*!Q1P30]3D1J-,8%Z/ZI5A*,HN#1/+P2H<C6N5J%I
M(S"Y^'GCT'3P: I>\08%D_\ 37;VX&Q@KZ1HG]CKCTL6TLL2]'QN,&1?5RNJ
M ,_MT&:X)*HYH I*H=!:9I8Y3T.2_/71<= ,&4R()0Z68M80"A\BARS"'!8\
M2NB"3R27K93N<#EIKD?$8%.LD_:BT&25K9]K7 E#H/D?WC )IEF89I&U-2"\
ML4:I\QJ.HP-PZ*8L*U*RIW@Y+US _MH,7!HH'%&P/@1\O[>&)I@5!Q6<9S^&
M8&J^/3$T4%\T91.W#U=0 1TT&2(5TQ.;9J&U=J1%]L3;E)(PQJIU15.NB>.%
M-P)&;C!6GXH-@4W]Q[90F*2=U.Q^U22YKD&6H"$@_OPO+6.*K8,HS +$)FKW
MP"B:*F/\H![C'-"M*;D/4Y(F!1NS<)R^+?IEVP40N==G*)YFDDIMVYSGC<P
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MPF5U/;::*-S*A[6B)@8 F>2(0%\L7T>I"N:>N;B>MY'!";?RJ>HE8PO>=Y:
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M#M#2\J7[Y&/ !<"HZ:^(3'88(@1#<>V%5*V>6WAC_9'\LQ?YCW!Z$.9T50B
MY8CU&-<$30<63;2RWBS5#:>=DE.^%X>&O:@=(U6@C< 41JYA>N),(2#HD;D@
M0R<GB_,GD&CJY&&.1NT02ANTDH4:][D0H44:]<(W;)B7%4W;N!ZYIP;==XK7
M(VXTGN112.#Y:5KR:=\9:T/]H-*2$-)55*HFF IV)&ETL(9+->DJ[/5%D\[]
MDL( :[W"Y?;ECVN<YI=_$"N77 )B0\V*OK,:%.]P6\"V7"&!DA!86L>QX
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M>'-_,1E!^'W&^/Q0XXW)&I!4M &B:'EW<FC?.&_F&$;FJC@0!N1<G($5,4E
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M)4H",^F%96]1))HKR!..":[D%QLPH)*1LSB&-.A#0<M5 )_;B(P\0840A(#
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M+HXKUYW'S3$FJZ38!:L0A+[$+EL:4\\2$2,D(IYWT\C96$M<URJ-5&8(S&+
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M]S&AKB& N0#HW:0A^6.O3$X\TN+/IR$8_P P*N4[6W"6GLM )&2LD;D1M<U
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M=9.JU&1Q9?--Y#TMS.(9G<=Z*W:XOFD)U*^!R3'.N!II7IS*$_+'+C4L<%D
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MHM+:[F6,2Z(^3\(MLS'-+8"$(V(" H.AVD!<+G91E4A:T.J7HC2Y;M4#N]O
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MANYQAY04 13@B49RA4$9_%J>GPP2$<RN8^4(4X",#(.>1GU \QBY8#FNTL$
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M:HWJ$!@K-_IH[FW&YU-';:VK:/9<QT:R#>2W\):$"IJ3J IP"]$1.H)VQ=)
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M^H'<R:!H<4RD-1R;DUXBKKI7U,Q,K7>RY[FQ@*-0%W(,%$")4I'(*TI6XP<
M.GW9;X::V/DC8T/]HB10H<$!<T_\Q.!RI$]B!&+MQ*AW>.,6ZDYP;W8K)10S
M3DFOFCI85G#9#O#G;%))09G08\I?%DSE0.2O:6[FZEM(V+TI2MQ8@<$P'U36
M*QWGAT\MUX[;I96Q/#G_ )2(/*;@Y!M(.3E^ RPN-EMKL)&<(F3<$78;[>[3
M=B%BY.$"*@$L>Y<JWU:<2M-NN]70P4+:6AK@\,;!$/;!>7,(VAH)80T%?(:8
MP[NWA9I ,'7T79WY;F G<),P,<53)RGCDUAO%90S0R,8R9_L.>T@/81[@<US
MAM+2TC0E <*2 !P6O&>LN6=$<,4D+7U$C"&H?;S(W$@A6N12 %Q0L[ U3# 8
M+9;+K4VJOAKZ=VV:%X>TKU!R49??BLXB8TH9)<@U=*GD\U5RH17IH,DL<6RI
MR!+=NU" W,M).ISZ8#;(MDPEQ1HVR84Q2 <_:=B(Y<U^SY$8.[40F(0N@,;J
MF(%7-<]K7!%R<4(1,RG3$3/@)S1;;FF;J:/;!EJMMNI:.AI :RND+ 7EDC_=
M#6N?,I;Z6,30$%0%QYZ_*4IDS+K8V\?"X%%+:R6NVP"EHJJ6-[YG,DF$A&3'
MC=(-P'4J>F?Q&$\4Y !BIH=K.X$5@>YM!<9:"EMK8G,ABE?$R4Q@.&UK"TN]
M+1DF:)F<&U #FR$?4B0P>J=BZ?5QW7Y=!)PFQ7FLL=H>Y\4MR8V;\W[#C_,_
M+-#@P  Y%R $KGBAT8@53< =7JFLPEMV7[-=P>XE9+%Q'M[W![B54\A_,7R2
M&Y24)D5P)FN,GLTSQO5 Q6C3X+7;EN)\1 3]BUNI-.D;>5&^94A;M]"GU94Y
M:]O9RMAHGLW(RHD+HPY7 /:(V,:1NT4KA?\ =6 ',PR=&R,RT;D#+AJ3<7+Z
M8NYG&92>6=K;Y$8W J8GN9'M<U=KHP-Q!"KB/WEN1:$@J?L+X#Z7'(NAT'#*
M*T,_ZVS<AM$A88X@YE0&A1ZE+!DU79'+/SQ<7B11"GMKD#4$#F@#*_D7%J]M
M70^_7VXM]5/4M;42.8""-NYXEW'(#(]5&"ZXRCD"EIV7Q"7=37]K^>VLTW([
M/):+I(-HJ61S4<HE+';7(0YH.[Q'P.!:[D#X2X0SMY&3^:/ XJ,'+^RE^MM2
M^IX+RQM93%QD;25KGF5L>9VJW4CP*:DX8%\$!Z%"-@X 5YI-4O:WN#R\"VB6
MA9<X@W^0^2)T$SFM3;&X#:)7>!1,6]6(KD@SVM*4^:C7]1GTY\T?9JJWWGB%
M2*C:[95QPNV.<#Z"9&L>URH@.GSPUM=Q E@:(%W;3AXJ&*J8NW;VHL%Z-@Y%
M:ZJQU+9F-II9:5\9<]/2XR!Q:X.]*G+/PQI59T*VSO')%-_[>W2W4[JZB#JF
M(1O+F1?C#8SO#D!W(6DC7IB(SB2QQ1/4D<,$3</[P\GX'= TNE-.R1O\ISW>
MY&FP.+2YR*@ 0J!B+O3[=^.N!:2%#?2LW#"X/"I[=NOJ7CY8R&CG+&5 V-<#
MMAD( :22 4)"?#/&%N-H;,FD[+6V]\70\2ZE-8;]2\CIBP/9+*&[=A+5_P#+
M#CZAGEUPJQ!9'/B2=N'%IA5.DIBUL'J+F_PE7%&/;Y$9.&83KIBXD>]1@FJY
MI:G/I:B)I?N8/6P@![7M#D#-%#FE5R(7-<%BZXE1KM7/.0<-Y'&Z*>:HH757
MMNC.YP]LD',#U.:"$*C53AV%L3@QX(%V,2!(493;X/W#H+RZGD.R)Y]MQ<K=
MH+@-K23Z6O#B0!]F%;D3%VQ76;@E(/165_3)WU=VUY'25<[6U-LFDIRZ-VU[
M/\QI+T<7-(<TYY!1C+N$F6H8A:]L0G$QN>6072WV=[Q]N>5\=IN9<4LT5OGK
M31T]8^&K<32U:1B8&F;_ "_4YQ<@#01U4)@(NRCA60S2%[:3AX)2U1(<<U]S
MZ>*C[E5%V8YGY7D])2W4O8=H_.!GY2MR!R+Y:<//F_#HD908^8).,0(4R6'+
M&_\ 26FZ->'Q&:2AEVY[6U,(?'N=X&:( >;L4M'Q&.119P_3U9J=_P!%-D%I
M[5<@N9CV.Y#SBY3AR &6"UT-!00NTS:)A+]^/1=/+6#,YR(^ _BO.]7.K<0M
MC$1'S)_!2M$JR[2?2IR R7H5U/RQ<DO5   '-']/""T$=1D!X9$]/#'-Q5A0
M/Q1_#'M9GD4&6@0]/@.N.YJDI$RTM_BC[CM-^8N<9<W^72,-0Y<QO;Z80J9+
M*01\,%L1>X#D%3<R M,,31:^4UWO3>PTJ.O4$@YGIH<6N2U$R"7C%F!P29IO
M4H_XAXZ)GBF!'%7QB<JCZ(\IH-X#E.?D5( '4ZA<#(+(\):32K_/XHZAB)&>
MU-I\0<ODF.B%TCB0LI(BQ2WIU\,R.F.(8<U6)!+_ )5JJ?\ N@=DK)@AS'XV
MN^[+'/1L@K  7*8D+"F>"G7,','/YY8M'"N*F)\3/0H)?F(Z"=#M<UH=_$A'
MHS.N>6)EEP5+)))CP*H/^J?BU/;_ *E>Y8EAVQ7>Z6R]M:<FN_K5BM=;-(W:
MY"Q]3*]/-<9MZ1%P@9?>F : FA_!-U-POC$UO_F,IA,YA 7+(@@JA5-V%A.1
MJR;C<(CYJ\%&?EW;2WT]5-46Z*,.<[,1M W E01J1F,\&%V3<DO<G&9P *'\
M6LMTB+&1PO:UI;N7,HH!*=,!N3$:NRO9!K(X*2/';=51QQE^]0 C4S&:E3X$
MXS[]Z)+!,0&J3C!/;8[+25,;75?I) +E7:<^I&:'&?.9?2,%JP,8P!8$HTK>
M,4,[@&%I:T  %@<U/_-5<#<BJN;P(:404$BX/%,6LCA@<"=!$IZYJ0 !BPG+
MB4+U-L<8!^P(OO/:IE;"8W1A""-H:U"3JJ(%^6+1O3B15T*X;$\M)3)<B^G6
MDGAJ'FC9(]W7VLRNI4(2BX<COYC%P J_M(2CX3$.F*K?I#MMPG>^2W-.XE28
MD&?FBYCQPR.JL,T(]+L.YC$GX(IN_P!#O'GVQT@MC/=+'_CA!W9$,)( 0K^W
M$'JLRASZ79N1,1;!';55V]Y_T\+?R*>MC?9@Z,AZ,9"T!2"<P&-7U8T=OU(2
M H8RXK(W?0K<P(Q,HD</OP4(ZO\ 2HA@=-54UE>QNY[XPV)QV$.5H:F0!<!I
MYZXU1U*.<BLN71MQ# DMR3#\Q^D&]<!<]M7;JD-A<6T]5!"X  *C:A@&;>BC
M3#%K<PN4>JJ+5VU(PE0]B3O#>V-PK*ME' 2'ME+'L+27@M\'%H(:YIRZGXX-
M(B(=7![RI8T?TRW^NMK:B%DKG[!NWQNW$HC2A#D">.O7 _W#,)$!7.ROR#Z"
MQ3;WOZ>.44,RFEWH23OC>"2UQ0!!M&T^&JXX;B,N*7-B];+&@4IOIK[)W*.I
MI_ZK0 M=/HAR;NT74N"=, W&XH=-"R-LK<YWJ@T.*NS[?=C[$+1%[]% 7NC
M <P9A 0B'/,9^>,.=R>IBY7L+8!@/M@E-<.Q?'R"110@C+)@5I3/:==/'$QO
M25):!B'0NR\&I;$\,@CVM&:9Y@'[0!X+CC-T L[ ,$YE%3KM:T*6D!,B#F.@
M_9G@:A@:IS+!;B7-DS(09-ZE1GD-$P.6**!FGHLU*6,"Z>E/AD=$RS& D5?-
M&B'[$I7 ;1\$/B?N3%LJJQ!Q2,OMM95!VY@<"@4 [LP01MSW +A:Y)BQ4:C$
MIK*SA=/(\N]E22N8ZA5T&$C*0*M&<6R1/+PIB$",-:""!M\M-/ 8D3(5S)PU
M&?Z('_HIO_9#_P WKX:Z??BWJ'CDJ-%3/+=["!ZCJGBOA]N/6%B"%YR)JCFS
M\ N-X<)HX"8U3<4R0:!?+"IM %G<K2%T0 U43F6[MHRD+'U  (0N&P;LO,98
MKID'<40Y;DOX<$O;38+32REDM+#,'@M;[K&.0$%IR<"!N!P6R8N1<9E$;EQG
M$BZB']2OTXV^GLEU[@<,/Y.:DC?5W6TQ@F&>-=TDU.QH5KP5*#YXPNK=)M68
MG>[<Z8#S#+M'#FO3=)ZJ9D;:^:Y%5=W66K%/,X.D#@'@)D40E%T5?+'G8GQ,
MO2&H43^X5\J83,QSW C<"=WF1J/,?#KC<V\=0"SMQ.47;-0"[K<DFIHY'"5[
M3ZAD2 JD%3IM*H=<;^TB"&7GMX2SY*OCEW+JVENGY^"IFBE9*#[C7;2&L<I]
M7I+T'EF.JXW+,(Z-)JO,;B4C)XEBIV?3;W4GOU-1V^X5#S(P-+)MSD4. )<@
M!)4C7(XR.H;>,091 6]TG>7+I%JX2\0I_14%:V..H@E=(QXW*T[D5Q3<I7[
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MD,4,;Q&&M#@O4A%^(S.%XAI4P1)8)B*]1/)Z2GJ0A=0=#X880$6/E<T9 _A
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MF3*U(4"67%KC,ZI:X2.5KFY_B.Y0HR4$'+"\SX5< J0E%6RRTR2N9DQ0<B4
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ML$#EY!&?3OS<IR7+37':R5(@,T7S7@(XJIU'\QP\T3,8&Y1HP /$(K?R<0.
M<]K2",G%W7()XXALP5?1#,41Y;[RRO+0'M)<=5R(=D>O1?GBP.10)0TNR3S)
M/RU;*U0$E<U->I&:)D@Q#9(XD-.KDE?22?RP]I:7,=N(!.B!<BU0A.)!S"H!
M$ QE@3G\>[DJ]?U ^)5'(:;M=<J"5D/MW#DM,]SFDASJJFL\[6@ $AP-*3GK
MC-ZF!*,2*&KIG8QE/5"C!E"&S=MJVGC9++5 .V@OV1/<H()(<I"_;CSL[<IE
MW"U+9],,15+>BXB*9S72S2RN"9&(,'DF9=@1@W-7E>D2G/X_:V,<P"--O^)5
M3+(8"8N6*H)O)SBGHM5*!&Q!T\-/'+08;A%F"DD /+%#)*97.!&>XYIB=)$G
M5#(8T1U;;=%,HVA=OXD!3S3KE@\8!@J2N%E[569[%(&YOB$5?EUQ!MD*D;KX
M8HFDMKU)0C,99K\\"THOJ#,(,;4]Y3:7%4T.6673%?3K15U U=#(K2V!'$%?
M! @^S!-+!E83 1/>X@V(#Q.7CHGR/G@5T>%$!<.4T-[ND=J<7.=L 4DG)#F<
MSEK@%N->:MI!-$S7,>]ELX^UQEK(VAH*K(UJ(%)52J?#7&K8LSF=*6O[B%C$
MIKJ7ZI;#*[:ZZT_XR,YLP>A)!1,L.G9SBA0WD)&C%&[OJ8LTD+__ 'C 3M)S
ME &6A]))R^&*G;3P)3(W$"*XINK]]1-I>5=<8B';B V5OP3-P^[%H[<LN%QQ
MY0W:FLK>_MJ+G%U;$<BA<\-!/DOCE@HLCFZ&PD<4G*GO];"YK&5D;B]P8UH>
M';G$@!H#'.)4G$^B>"DQB Y-$Y-GY#/=K:VH#B1*TO4*J;2<QF  #@4B 5$8
MB7B \*B=WYY'7VBVUU0UQ:(FO34 #;NW$_C P>S'7,1S4]0EZ6V%V'F%5SC?
M4/\ J$TG >57#CCZZMGN5+(3+2TC72/C:[<(G2/!#!ID%!QZ"UM-4 X #8E>
M.EOMWN)R]/4 "Q.3J%/(_P!2[EM87-M5!7D:-DGG9$1FN2/>X )YYX8ALH<0
MJZM[(-.0[ZICK[]=_>2\A[89X*-F8:/?J)D:Y05!+ 21]F';.TM1#XJ!8N'S
M3+\A_BFGJOJ-[NWN:0U7*JB%K\]E.PMU<,@2]SR2B:X<M[>V<1\:JD]M:C66
MHGM72#^E9SR]7^T\>ENEPJZF5[8=YEE>YY>]6'> ]Y:KE*9C&)UK;PM"6@!G
M!^]5Z.?1WND>0D_/[479?V''O6BBZGVH_'HP:*OACP-X$WGS7OXR>T"5*IM(
MJ#H?MZG[L$("6+K8*3HA^*?O\\0S]JJ:#DLOR9\#^+PZXLP5=9X)OH" ]IR!
MS^2:'/1<;)E2BS!S6FZ)F<@FTIU"A=?CC/W%))W:EG9;*9Q?1A"OIRZE4\=2
MI& ?E=-XRYHH95^V]\;LD) 3K\5T&+1)S3,H.S)6<=?)47*&D1GLO1TDYTA"
M@ E#Z@789C(Q &28V<7D6&"5?([;5V&L@=),P/<!-33T\AT!#FO:YH!:X'/$
M7):9.0MW:VX[B!@SQ.*<#B_<]E2R*U<L/N,RC@NS0#(S0-_--&6T)^,?,=<$
MCNH^6]Y3FD-YT&[:_6V3R QCGW/CV)O/J-^F;M/]0O$Y;!W L]!<J>9A?:>1
M4[8Q<K54/8?9J:*M9_,8YA(R5#U7 [VV\/J0+'*0Q[#Q'(I3;;@7(_MK\21'
M*H,>)B<1S&!S7-?]0GTG<G^E'E]/;JZM_KW#;[-._B_)(XQ&Z9L)W.HK@&JR
M*NBC0JWTR-&0&F%)3F9:;P:;98$?;$?-:<+,8>*V7M$T/W'@1\\4S-RK&U%$
M6->-SF%WJR! !SS7_;TQ76P(3$;9)?),]7USJ"9\+D,DSO4\DD:A6M Z'QQG
M3N-)EH6MH9Q?).MV^ADK:B)L4,LDCPP"-C'2$[B@R#79E=>F$;VXC $R($1F
M:)BULY&>B()ER4Q;'VMY5=Z0/HZ!\(> T>^QS7D%OX@"U$3X:X\EU#WET;I]
MPV[UP&0&51V8K=VOM3J>\CJC$0_U.._!#*?Z>^<FJ,KH\E7;[3T <3J #F=,
MLLL>6WG]Q.A$$ R)/8MC:^R>I6I:I2@W>L;OV!YNYCH8XI)$/J=[)VD%,AN3
MT@8PKWO7H]Z+N0MB'0]W8.DZ3WI)L^FCGSW$EKD<5!$+B47,KM)) &>,^7O/
MH\!YG1ST?>&OA^*VN^F#GC6&1SG':#Z13..Y<V@$#,J!TPO_ /.>CNSE5'1=
MU^8Q1E;OICYY*_;-[K#M!:YD,B.ZN!"'4G0]<4/O7I&,2BPZ5N0<0G2X9V7[
MJ\*N#*^R5U0T!P+Z66*7\O,&H$(0>I_4IC9Z)_=>/0=U'<;&[*#&H?PGM#K&
MZ_[(V7N/9RVG4[<+D"*%B)#L+*5%NN%WEIVTO*+556RL+ QU2V&1U)-DFYK@
M 6D#4$ IC]?^PO[X^V?=.U%B]>MVNH ,0]"<N8?BS%?CKWO_ &4Z][?W<K^P
MA+<=/))<"L1WX_4(CNUC>-AA(J(YWAC2P;DW%-I"*GV)CZ2-U9ORUQ(TG,&C
M=J\$=I<M6],@1(48@BH1RWCSJ"EB5&DAI+0$.@))7KAD;B).D8)>5B<1J(8H
MMJ:$.VDL.[Y!$/7(Z],'C,<DO,$Q8XJ*7U6V>:\\&%,QJ;#N>J[5:N1\TZ8M
M*X(15MA8-R^8<0J6>2\V9V_XCRJGGJ2R9L<\=/$",WEKAMV;AD0!G]^,7?[@
M1B;G)>BV'3S<W$(M357N51%B;<[K=>1<AD83476JJZHS/R+:=KWAKRYQ=M$+
M $33KCRIK,R.)7OMSIA"-J/)5Y=\KNWD/<%]#%&V2CLJL> H:Z4$O(*(YTCB
M?5F=<5G(1P-4QMH:;6HYIM^+=L.:]Q^34=FXU8ZZNK[O6QTM!24]-)-/423/
M:R*&FIH&ODE>=P0 (4UP*>XMP &,P,!]J+0V^UO;BX(6HDD\ NYS]$S]"*@X
M'36'O]]2U@IZODP%-<^/<8KX&306@92Q5%6R=NV6M>4(:B1H@77&5=W%S<7#
M;LD>FU9#(YB/WE:^XO6>DVS9VS2ZA*DC_)Q Y\_@NH?NYS6V\(LM)P[BT$4,
MTK8Z&CH:)C6G=E&R-D<00-:#G\,(;B<;<?3MXY\TET[8SW5Z6XW'D!=T>=E>
MSE3[$5_Y0'U%?5!LWLR$EL8D]8 !.F?VXG;;82EKF&!-'7;[?^+T;'E J5([
M^FT='<VM$,<3(T:TAK6HU@0A4" )C0-N$2",5FZI2LG^9TU_=+E[I):7CEL>
M735<C'U#8R"YL+' ,CR)S>=?+&?N[U1;B:+4Z5MH5W%S"/V^2,I(YK'Q"13L
ME_*N<]VA]UX]+?M<!@!B8V=7$J@(W&[!&!E\O\$E.!6.7VGW:=?=DE:X.3,D
MNW$#JC<7V\'+C!,=1O"5WT84A'ZJ3UAG>RFC*G( $?8=,:8#ELRL4D"1U/IS
M2G%<20A3S*C]@Q/IF)>O<N M&@D1W?4H\H[N C9"$^1TR&6N>#0O&-)X(,[$
MHN1\JHT?(V8-<U,]4&0'C\L-"0E4(!!&*#2H4;D4 SU/G\,+7I$$(EM!#'&X
M[3D[PRS&?0KBH ,=6D,BD'%J(,^%D1]" DDN"!0%0'YXI*,-#@,5(P134TT<
MDS26C/5 !GH/A@8%,D2!CI+D@C+B@591@1':H)!ZKYC[\3I<*L9!G%*U38\C
MXY!=&20U43)&H[\302TIJ"1TP.[;$X,<TQ:N&,B8D@JHCZS?IKI>2V:\U=+0
MQRRMC?*U@8WU$!SBB@@AP.,6Y V+HB:0/V;DO2[/=>JW\XBWP7,/34UU['=[
M()(HI*6VU=T9#6L:'"-H,SF-D0 ?Q$+Y8:E&-R!CBF;@ \$O*4K_ *XNU<O*
MJ&R]QK!1,JFM@_,57LQ-=&@9&Z<M:UA(<]HT(S1?' ME-@;<C4%+SM_H 'S1
M+=RIV^I+Z8+'W:[=4W,^)Q1P\HLL3_<BA:UKI]C6^Y!*U@R>-N0.OEC9VM\V
MKI@V*R[EN$C*,\6IVJI[B55<N"\B?;[C35%/-!.(*F"5CP(V*&SM>" 4! =N
M"ITPWN(^K%T"S/1+2#1U8)VMO39[G15L,NZ!S08W-(#7-*%B:!Q>P$JG7&-.
M)9CBM(3(IFREM>K?%=[:+E1.+*BG_F LC<[<YK0H+0@<QY^PX'BB@C2BMW'K
M=S/C[J&I8QM:ST1N.3B0U'JH+B [KD1CA0NJ2B"?\V2BOS#@=QXO53T]= YT
M$>YU+5%A#?2YKQN.P(]O3Q&?D2:@SU9U:41IYJ-O<)YLEVLO(:6;V8Y'?E92
MTO;O9)(U\8<YA4$N4 _A'7!(>,$!=$: XXIW.,=SWV:OM52RO;%2R&G#GM>R
M0-D;F]KGDM5"2->AQGW($N,TQ9,XE=%7Z8_>ZDJ^YG#:.XUK'T]-<Z6XQDNR
M#J8/G$3E<0KYHPYGFOCC/G&X;@S8NM,R-S;3CC/0NN3A]^I[C0T]2QS#'4D2
M1['!S5< Y"05S!7YX-:W$9'25B7+4P:CQ!.(*L,VEIZ:]4S5"",RF&#/@A"U
MJ#E*7BU!+?[M#2%6T<(-5<9AD8J.(JX-=I[D[D8SS*]#@NW@;]T0_+F@;N4-
MK9-S\YH.U.'?KK&9]C &QQM$<4;%:V**-HCC8T @!K&- &-*[*K#RA9-N,F_
MS''O21-TD;*TM>]C0]7'>Y2HR]+M6H%. :BZ,(!DO;?RF-].UID(+6@N#B6C
M(9_N^>#1N.&0C:@[D+&HY.QKR-Y(R3:-S2NJG^%-#CC=XJT8-&B"'E 527 >
M#7%WS=ITQ7U0^2D1+-D@<G*%*!Y!.2$;FCTY!YR3/7$2NM17%LE%AKZFX3!O
M\QC7H[)2/PG7/\*=,"U&1I@KZ1&N:<_C39*<0K(YQ&W\3BA"K_$-,,P#1J@2
MJZ-[DL5RE< /45.2^?R&>+"BZ/E8XI36B;> QQ'K:1J"<VHA&1&)CF,U2YQ[
M_A_!1_\ J-MPN7$^-2/B]XV_E<D8:YNX-%9;:D*4"M!? /CC,ZK$RL0.8G]0
MF^GB!OD?Y4T-@XA'<*=@_I[1D&KM:@! T)&$(6XRB*53.Z,8E@3J2L9VM@>W
M=^78TD:;6I\P@7!_V+U9)^K(!A+!;(^W+:8C9"Q0@3T@(-,D.0^['?[?R4?N
M)C-TH:3B @8"X>.@&2+T3$_LS')3Z\IBI9$EUL[:9Y(:@4YZ>>?0X4NV2#05
M3,)O&N(^:T6IH9* J9[?%5"9ZYC [8:BBX?!1*K\ODIS!U/S3/!BEP4"EI8S
MJP=2" GQ7QRQ5@S\447'/ (&^!K!^$)XY*N?77KBIB,D2)D!XL#@425DL,.X
M$J? (=5\TP.1BR+&,I&B0EVD-021DU@R ^&9.%;A?L1VT@1S43^\-S?2TM06
MN3:UQ"%,PU0NG77XXMMHZKG>C0(@)/B0N:[]0'ZK.1]M*.]3V^H]TT@F8UK9
MBS<X!$:T!VKAXC3'N>E;".Z,3A(D57ANOWI"X!9EINYT<,50PS]5'G=JJ9!7
M6JND:)7-!@KV9LW9D,(#<D0?:N>-^YTR,"VH'N69:M[Z0$A*+=_\4X=J_5RD
MVL;707VE*@G:QTC&$(N4;G*T_#7"<NG,:,4?U.HVL!J'^H?>R5C?U5;%6-]=
MWK(7O.9FAJ8B<@3N]+@UI/P&!_L:L&1!O=^?-"0/=]Q*S;^ICQJ=ROY&UI+7
M[=SY0&[04+B6[5/3+/$GI\L6<JXWV['Y)]RG/]+G>2\=XKO172&>>>WRRQ&F
M<1(6O;O!W@9!)&A0=43&=NH"W$@ 8*-IOKV\N@1),"?H5T?]H>%5=VXW2!T1
M#_98"K7*6;0BE,LCU\,>6W&X$)-&J]SM+>N#3HR;/ZD.R]54\8N9%.09*:5#
MM*E6.+ET);KIX8G:;S]4$TD"NZCM@;#$O!J-DN&3]2/Z?[GP7GU3S:"C>*6K
MJ'TMU=L(<UP>!33ORS#0=I\OACW>RNQO0]-_$ _:^*\'%]KNY;>X[3)(?CR[
ME5UA^,0$VZV-_MTPQ%2C:WQ![P'$ .<$<0[:':M)<,PAU&J8;LA\<TMN),.:
MZ3OTC*T?E;5'N<6PUOMDDJYH9,Z- @"-!:H&8S7&1U^(:3?RA Z:YW4"?YEW
M(_3JS?9*%P4@PQHO4%@U\#_=CYM<#7FYKWD*VB,E,^*C!8P@!"!F,UR77+/!
M!$)*=PB1 ^"$"AZ@*OB$^X8D!\%'J2<%;/R/_#Y_V]7W8[2H]6?+%TQ+%4%5
MTZH0GGU)7&H8D!)!>75"PG4(,R? !5.N1'WX3W0>H3FVEXB%E:2'TQ:@(:TD
M^170?\.%HA.8EDDKY33Q5.X.< XEP )"A,LL@/CX8L06=."L0EAP^I]MCGE=
MS]H<5T:W09YHN+3DUM\UJ],MZKI",[G<9:J?_,+HV#9&"XNR!*[5) !\,(&\
M7=>^V_3[<+8<>(XHO;."054$[3F-?@H\<=*\&K@F8[(BE72OLU[K&VNII1/(
MZE?*SV&.>XMWQE7NC!S _NP,;\Q!@#X24/<>VK=^Y'<$ 7&KQ/:J_?U"+'<>
M?]MK!8;:^A?=K=R*GN['ULS(VT]+%%)'-ZRKFF2-_P UQ@];]V=,Z+HCOKC3
M+E@'(CAAVKU?MG^U/7_=D9VNA6HR(F*SEHB3FQ.>5%3->NS_ '%9[/Y-UHJ1
MZ62"FKV'/<$+0"T$D=,SECRM[^Y/MV7]+<-VQ7OMM_VX?W#LA]QLK<^R[%"I
M/IDY=_3!?N1/EH6,+7[(P (BX?QS.80[7ITQE[CW_&W-K5J4K5/&<"^#(=O^
MS^\MB0W<Q;N0=XC\K<\"I$?3O1\6XA7BENDU$^6.1H?-4.CWD-( _&&AH QY
MGW'UG==3V_J1D8AC0$HG3?:MGI=V4(0]0_S$?8*T3BW/^WH@C9%<;4X!&I"Z
M$[2@">DH,_AC\[>X8[_UVD9UXDU7L-OT3=W+9E8MC2$N9NY/ *=S0ZKH-Q1H
M]41\@!D=<5Z=TKJ.YB#")/Q6+O>G[RQ(BY1&-'RCC-XGBAHHH)A(YOK#6%B.
M&JH/''=4V6YV%HSW'A '%9T+-R1I5.926.T20L<*6',!/2U5(S^&/#7-]=,S
MHF=&2!<-RV=+(6;!:2-HI8,D(5C"A">73"\MYN'\Y0?4F<JK;#8K6Q"*:$$:
M(UN?EHH.>.CO;^&LNJRG/"(*&_TBW!OIIX^A4M;ET('1<6.[O_SU5(7+KZ2Z
MTS6BV/RD@IT)(1T;)&^'4'!;/4MY8N"Y9NRC<%7!(/Q#(TOU(:+D-46P-1\$
MW7+>)<<BC9/'3MAJ7%_M.B<6'W,BKD](:#FG3'WCV/\ WV]]>WH"S^Y&YVL=
M(T7 [ 9 XOD]2O#=8_M?[8]SS,]QMQ9OU\=OPFO'CV*M+OK]1U9VHY+4VB2U
MQU]%2P;WU!>T2.<W<9-H" -8&?$YX_6OM3^^NXZML(;C>[41NR/Y2&;OJOC7
MN+^P>UVMXG8;R4++82B_>ZKYY-^L-VMXG?(K#?\ C]T9--6&ECFIF.FB):4+
MW&.-^QK3EZB/''V#I_OG:[JT+ESP2(J"#3X+Y'U'^V&_VUZ5NU>A.(-#@Z7E
MK_4$^G#Z@[74V*V\HH[/=X08:J@O$C*.<2D%C6M9-L<0X_A*:8W[77-MO;>J
MW($<0_TQ7D=Q[?ZGT/<2&YMR-LQI*(U"O,8<W5-7UI5MKI^7T_&[!=Z.Y4EP
M>]SI:&=LL3Q(1N>\QDN!C&0":_'"^\W&N  -<UZ#HMH&W+<2#2'R4).;W:DX
M3PFO=#44T-36T[:6EIM\;9-A86(YH.X25,I*ZKEC,E<C"!D35:T+<MUN8P:@
MJ3R3,?37])G+^^W/[?Q;A'':[F_/>75K"V&GA?/#225;M\U54U"!E%04S7'?
M*]V36Y9E#EW+VMR3IM1Q)RYGXKU>SZ==W$M-L#2 Y)I&(XD_9UWA?IH?HA=I
M/I,L5O[A=U:.W<P[P5\%/455;-2QFW6%SF->ZALL,K28V1CTNF*/D\ ,L+1G
M<W$!$ V]N<0?-(\^ Y#D]47>=2L;.!V/2@Y'GND5EQTC\L<JXBJN^OEUM?$;
M'(VDCBIJ2DIRV..)H8QK&- :&IU&(FUF&FV&"Q[49;BX(BMXIENT?;N7GG+J
MGN'R&)\L$4KF6BFG!,;(@3_,VN7U. P.Q9]2?J3%%H]2W8VUF/3=O26,B/HI
MSPBDML3&!C V-H :@&0'@",ONQHG!LU@B-6&)3*=P>:TUL953!IC+&3EKG(W
MU!KD:W(;B3HF,_=7A&+56IL]G=N-&+.2HU]LH[OR?DT_*+I'+^6]XF!K@2!&
MQQ]MIR(:J!?/&-;%R5W4:K>ZB;.UV_[.WBGRYQ=W3MHK-31N+ZEP?(0"48W)
MO\/\3CXX>O2E.(@%E[&V(R-^6$0EK9[8^W6JEIG@JQ@<\]2\^HJO4:8=LVI6
M[8=9]V]&Y>D1F4YMBE88 U_@"!EFH^S# XC%+@QC=/J!XHX>X *  GGK^W!J
M]Z'(@FF"T&1PST^&6.;BN1G27.2)&N)(R"@J0$3X8@ Q+Q7'Q8A'T-8R9NY5
M\QTZ(1J,5\\F-)+M+%EA*Y9-P\ 1]_[\,,8 <0%8!JYK!Q*%VI/VJ4PI<U$N
M?*H)J@A!$FYW7^[%1@I=XZ6&.*^FCWL<2@].0/7KTU7%@:K@<N-$C;C'Z7.
M!R(3KYY^"8O/$$J8%GCQ3*\WXM2<@M5='*QKGF&4!0#N&T^D@J/AA'<V1<@G
M[%WTK@<^'-<H/ZA?9O\ TES:MND-(E-522U4?MM >R1KW.?M.@.6X81V]S5$
MQ&4L>*]'*7JV01B/IDB[Z7*JW=V+'6\#Y,^"J?!$^"%E1ZMPDI@QK@N1WM5<
MLS@-X&U+U8.[+I?TM3.7JH"?4AVCN'TU]Q:B*2WIP;DM>Z(OV_\ 3#\VK?:E
M#E:US"?20BKA_:S_ '%MSY@$MN81D6ABS_P57'U:?3/;*VADYQQ6GCDCJX75
M ?" TK(T%S)',:=K]R9H0[77/&A;O&3@XA9L3&4QK[."B=V9JY[10-H*OT5E
M'(8YVRO(D4(SW'L+B6M>P^*)@=R(D7&"9D-)&8935X/R,U43Z&:0I+&H:20"
MA+06M1'9-!\,*2BQY*^LB+# HUD?44$\KZ:4M+)1(P1J/,G8-00N2Z98H:*]
MLZR'3FT5':.X7'I::Z11^^(DW; YPVC:HU)((4C G+IHP$PQR4'N\79AC+7<
MZ6 .?%%N?'&Q5B>QSY87TY()VZ':=%3!K=UBHT"3P*@I?**[6NDV"64Q6^0A
MKVD^F!H !V_S$._\7@0FN#1,92KFBL81?@IP_1']2EQX/SBRLJJV2/V*FC:V
M<2F,G9*QJ%RC:C#EU!^6%MS9T4 H4?:7Q&Z"*2-"N^GZ-.[K>9\'M[YK@*QE
M7!355#-[F\;)8@5#B=R![43SSQ@R_3OT\M?B%>_;$@]O+Z*P>&I=.RG;$'RO
MD+(F1L:YSY7O<&L:QH"EQ<4 37#\3J $<2L^@<G!2:L=H;Q:PMI' &Z5@;4W
M1X();-L_ET;79?RJ1KB/-Y<>HQOV+/[>QI/GD'*\Y>OG=[@R_P#2A0?CWI)U
M@]3Y'A'/)(S.>B_B)*8%(!U$"<,DF*EXW%JDKH%5 NB]47%,T<8+!M2Z,;0X
MM* )F5^TY8JXS4F!*R_, H''+P/WYKKB"0[!2(%8?F0"/4 #DB99^:]%Q24@
M*(T84YK*-[G$ 9EQ&TH=RJAS_$F(U.:9JL@V. 3A\<HY)-A>PDH#O+2!D<O
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M^$<@OE. 7?F:6AE%*0UP4LJ)/;C<A\"<\2=S9LD>I(1#YG[L56=ZT2;<297
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M_(191^$;6N:,^H."7A&+C(J+EL1D)@> R(_@K0>YW$N+]]^TETM%UIX*BK-
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M&+$X$BCA6F=DOIA[2]J[%0<?HN+VN66BACA+_P M"&LVL:Q/;#"$498\/O\
MK6^W-PSUR$5[_8]/V/3[0L[6W  !G(!D>TERI'4W;#MT]S?=XG:'JBN_*L("
M'T@@#,%5\L9LM_O1A<DGM,#C&/P"<[CMGL_' !9:**WM 4"!NT#, (UH1<M=
M?' _WFYF293D5WH6)8PBQY)UZ#N3RNV-#:2YR,:T -!&66NA&(CN+\:QD7*$
M=CMG<1^92RM??_G-NE;[E0VI:TC<I>PD!V9&:+ABWU+>P(\9(?@@SZ78E5R!
MPI_C\TO?_IH^1?\ SH/\C;_FC_-\?P:X/_O>_P#\GS2O^Q6^7P*<]?/+]GVY
MYX^E:0%X5V7LC"^DE'^'Y9D'XXK,> @8(ML^,<723MCO;NC1JA15\5(\.N,\
MG):H#E/+3(Z-H.CFMU\$/Q&"QH%1L1P2>Y-212T-0@ (8X^*E%")J-<*[V9-
MB<<M*U^B3-CJ5F[F+@[JJJSOLUU)?(Y$3<UX*9*53,KEF/ECX!UV/I[J0YE?
MUX_L_=CN_;MMB_@"B[=[B[84>FT'(9C<,\U(RQY2]>.&2^[[#:#4\ABF?Y 9
MZZ*Z0T[29A:;F]K0"YP)@<T%  I >H'4Y8'T8?N?<NTMY>JY[@ZRO[M;C_;/
M[3=;W&<ME* [9M'[U'*R\FX-Q^N_I/*74M/,865$$E<QT4DS7C:XD/VJT.&1
MZ=<?HO;;+U(N8N%_(/?]2V]B?I3EIN,_<JWOJS^G"C[[\XH:[B=9NIZ>28_]
M+(UT1;,0T .8OAFI*^&/3;&S"S:\(TEL&7C]WO)SW<C:(G!@Q5CGT"_H.\3[
MM<5@Y=W"N=TF]Z7W(*$5,L-/&P.:""R-T9<2UO7+,H,5.X$KIA!@1B_V^"S=
MWN-P+8O3N^G!SX0,>\U^"N8X5^@9]*_'ZRGK:WC-ON$T+F.:ZK!J'!S41W\U
MT@+@GAAB%FY.ID7Y$M]5YR[O(3+RN791_EU2 ^2LD[2_0+V3[46I]GX]QNU4
MM)*%+8J2%OJ+=KB=K %Z>0&+PZ=ZDC<N3))24NHF),+ ,8\')3E0?3IQ3@E#
M6R\/IH;6^JD=-,VD8(@7N57!K?02>J 8S.J=&MC;2G;_ *F 3G1.H?M;_I>6
MS(N0]'Y<$;<6[7/:Z.NGJ9I3N$G\YR@$M4G;EE\<?,=Q_;>SUC>PWF\>6DNV
M1Y+Z%_\ .?V.S.UVU'SS_@GPD;%;;;[31N<QB>GQ0C0?#'NK?0]EL-D-M9A$
M-%G #KQ?^Z;C=[GU9R)>7'FF0K[77W"[LJ4<R"*4/5X5=KN@1<QCYY?]L;O<
M;[U[=O1:$G?CW+Z+8ZUM;&S]&4P;A&2<*A>ZE8Q-Q<-4'IR \ "%\UQ[&QL#
M$1C(/Q7CMUN_5F9?!'D=UG&6V3X@.!\NB8TAMP/RA9IB_P"9@@\]ZF9N#FN7
M+:#N+OCIIBERVP<!7MVM3#53,HAJJ^MVOEWS>XX(UBN+!N**&C0!<)2L2E^0
MOE2J?@+0H2"!C_BJ?_U(N3U-JX]5PO@G<^>SUXIJH"1[H)7Q2L+AZ4TD^W%-
MGT[U-R)28 2#@C'[,O1V+^GI]PQ-2P'S7#/W$HKOW"YO?K-2LEF_TU55U7,&
MQN+I-M1)(Y\N8<YL;7J3J.N/:BW& \(Q*\C?U&1D3BHQ?TVEK^XD.UGNP6Z-
MNZ17-<)6N +7M"#:"I3IK@D3I+!(WB1 DIQ^9UG)^Z_)^ =A>WT<SKQW!Y!;
MN,M%,KC##53MBN%0YK&@^W! YQ<X:-!/7&CLM$9&]+" =#VMGQ>I/ \5^CA^
MGI]+_'?I7^FW@';VS4,5));N/T$-4]L8:^:H%.PU$KRT*]TT[BY3F2<\"MW9
M;F9W$PP. X#\2O,[J[ZU^4@^D2("L6XU86LE_J%2P.E>"8@X%8VKT\WC#]BV
M#XR$O=N&,1 )TZ6F;&T33 % K6GP'[#GAA*L2S9H1'!7WB5L,#'B!4*-(!"J
M-<L5Y9E&CIA'4:R^GXE.K8[-';( #&WW2T$N+<U3QP>$=-98GY(,C*9K6*,Y
MVL4;]H0?)/'%Y,17!4P*)ZV>GBB=L:QQ#5")X9+XDX6NRMX1 =T6$9F531-W
M<I)ZHEH:Y,B /C]PPL V#XI@2&>#(+1V&>H0O! W=0H^WIB0V!JIG(D4H$I:
M?CL3-JM4CR:/F"<2'0R0!5W2FH(:>D:0C6D +X@=5/CABU$1+FIXH4M1# 46
MBY7RGI6D!P! )4'0#]YQ:=S4&@HC!CX\$T/(^8PQ![G3A,SM#LR%R & '3"A
MJ480E*N$?JF8N?-YI)$B(:TG(ERN0]5TTQ65QZQR")"+"JWVZ_RU.T.<5)RS
M^TY9)B 75I1+/ L4J:>L<]K0=3FI/WH/'$FE0APF9$1.)S*%.>YVB@C(IIH"
M$'DN*XH_EH6"VQ3U$9"%P0CR/A\$7%M<A3)080)J*LC!E;*05)R^WXX)&8D6
M8.E[EK1@MGYASQF3X%3G\?@F#!GHAU&"#2Q/(R*9JHZ]/MP.Y$M1%M7  Q3:
M<XH:B6D+FE6ECVIX.+4'R.6,[<!PR>LR:8S=0 [U\"CY!PGD=NGCWF:BGV@A
M<RQRCQ0KKC)+6I@K?C=C&49Y/3DJ*NP[+EVU[JWZWTC?;@?6R1RTA]$<D?NN
M8Z-!D) #EDF:88F!*(=.W 9P(XU5J?".Y$G%KT^GO#9&VFN9_+>[TQR0/:KH
MI 1M]R($H<EQ2=D3B\?-P2,HRE;U1J114O\ ZL/8'CW=VPW3E_&VQ3RTT4TK
M)H6@O&3G^W,$/AJOPQI[&XT18N4<X\$EN3<C&(.#EQRR[UQ-<YIKAQ7F-TH9
M'305%!620.<\H\['()&%3Z7:A<\;5N$)0TGBLZ[.5JX",$X?;[NC74EZM45=
M4-;2R5=*RHD>2K&F1K6N4N:T;=V9*H/CA2_MV#A/V-U"Z&)::MNY7QVGNG;V
MT\FL\@#124\DSH]K?3-"T.C)0[D7]F,QSJ;,(EF33(.:;FU6'F-MLM!?[O25
M$O&*E[(16^UNBI!52I3R5#P'"&G?MV@G($C3 )@NY6@)VS(VX_U $JZCCXIM
MU10O+8I0Y[0TY;)"'%KP'$'<S[,"(91"[J+3%4RW)*1L;)ZF(ASE5\>W:XM:
MX@@!HS))R3+-.N(")/)1IY=Q*:FJ)>1T5&\5+FD(6-;'O+5S.[85R)=F0J#&
MA;D3'2<$,OJYJUW]-ON1=9>7]O[+53LHJNCO$=33S!WM 55*0X(]Q&UKV':I
M"@C4X!*+2;$*+D@"9X2$5^A#V9Y++7\8X_7U>]U1^3IVS%S@KG-C:S<5U<N?
MG@5BZ -)R^BR]W9$3^G@0ZE]9Q^>BC?$PO#@"J!2JYHH0XT8$2"S)'3BEA3T
M8C1KXT)&2@*N6I&?3!.>80)2.!&*-HH"/X"/@GAJASZXAC1=%L^*%-1F1:O7
M(']V(DSJX?N0Z.-C@FQS20$]!"H.JIEB55M/Q6;XI THTJ%VANJDYJ%\\=7-
M6$H,B^>EGD!]#B2,T4E>@(0JN.(<J8D N$5_DJEKE<QX 50X(FN15,5(+J^J
M)&2,2 :$+M)!(<=0<B#IYX[B5+RDTLB:I(U# '%Z9 D%' '77XGPQU6JKLB;
ME%E9R;@_,^-/<Y@O?%[[;@YJ[F2U%MJ&T[VJ"S='-L</,8X2$:FH!=NRJ%<@
M]!0FGQ5/='V/Y?=*5M1:>40S,+6ECRP.82@.1]P$$$YH?+#L>K;:1\5BG:LP
M],WHK#< '@7^J(*WLMWKM[C+1U-+5-826AKY&%R :!7#/#L-[T:Z--V!B_)"
M.WZ[:K"Y&78?Q2;K*/O/:&^W7\?KI T9R4SW2M*=0-H.9."#:=#N'P7(@\Z*
MW[_KMK^I;F>P/]$"MG/N;V^I935-HOD2N&]QI*@C4>D(P^&O]^*7.A]/NQU1
MG#XA3;]P;VU)KEN9/85-CLKRNX5I/]1_,-;(QH_ZB.6,M=E_C8U,L>9ZAT^Q
MM:6Y!QWK=VW49;V+RB8CFI1PU=*6[OS$?3^(#49HN9(QCEL$R+9!>/V",(IZ
M?([FN<>H(T^WPQ!K1U$;9#F06=17MBAEFVC;&QSLDS0+B"&%:JUN.J8#,JM/
MJW_50[+?2U-46/D]9$.1&&1U+;Y96L=)LR+V[B&AFX:]2<%VMB]NZV@T.)^S
MI7>=0V.RN>C=,I7V=LOP5.7*/UEH?J;-VX%PZ>EMD'Y>>6Y/HZH3SSP(@BW1
M2'VFN4 ]<:]CI@C+7(N0D[?5[.ZF+%D$%B3W!17X5^JUV][15E9PGN/8;A10
MP5E0RGNX62&:.%SVJTAQ>KAFA!'QPU>Z>9G5;/:^7\%%KJT+<(PO6I::L8R'
M',%OD5)&R?JE_2+SRV5=-1<\HJ&JJ*29C(:N1D;C*6G:Q'%NCPA.A3"AV-^)
M(9.6NJ=,N2,)3E M^:! ^(<?-(WB7ZG/:>\W*R< C8R:1MY%#%<V.8*-T4DA
M#90Y[1&&$:E4Q>73[N,2&;-#CU:UX;/IST MK<-_JXLIU<K[D</X_-Q'FHOU
MJ_I\4D0K9F5D+V112-9,W<UKSM !*!-<)Z"9,,5I;AMO&-Z=+8ECDQX%.\WO
MYVIY#*1:^:\?J&UD32@KH@27L#2 KL4]"[$5B61?7M7)@0G;)/"0_%*7L)?8
M:JX\JXY#+%51-EEGI'LF9('QN<YP=$YI(+4(^&!WHM$$T"+M83C*5MBSD_<A
MW/I:FV,?61M=$ZV50ED#E0Q[T>,QGFX:XZVE]S*4-1SBGA H>0\3M=X-+2O?
M-21K(*>$Z,V.#CL! 0^>!D>)DS.YZL(SR,1]$VG;WCUCBYW76NX4<(;7L+J1
MR^TT[BYS1$UO7=X8O<.JW2E4E9A:.XE:O1C*!% <'_P2H[@]L:"R5+N3VICH
MKC;7^X\QN>"^ $$AXW;7%F?14P.V3Y)5BHW5FW:A*[8CI(+L,.:DQP*[U%YX
MG;;E332OF]EK)/67*YH4ARG,D8'.)-$S:N"[9C=BSD('S9DDUO)JV%S"=L[7
M-!+6O0!XU!:IS/087E;>03<9@QTG@RB?RX4$UQAL-KJ89ZRFB=.^",I-"UQ<
MT($S8XKY:IA/>[2Y.WX!X<EVVO6K.Z],%RV&;)C[M$ZU5K:HDQ,<XB5N;=LC
M' $%IS.94:8\Q.&F1B<5Z*!U $)6VV\T;X&/<]K6H5)<!F@4YE5.%9Q)[49+
M&FNM'+&TLF8B( "I*C+3R_9B@CDB1P1K%6PEFUJ;CF"=/!0,EQ+%67L]3$ "
M7M'3^$IU!ZIXKCC@I-4%_/1?XC_L_P >FN*.IKQ^WXJPL@Z:CQ_<O7'V1?)^
M2]:T&*8=-I4:9!%R.>6.(<-R5X'Q I&-=[=S80?XT)TS!RZ*,8\GU,MD2!H$
M\E&2:-CPJAC=/AH3Y#X8."\4*7AN4P.*3%ZGEDBDB_X'M53T'5,*;B)E BN!
M6EL_!>A<_P P^JK ^I5KHJF*4Y).YJ@%/Q!20#J2?NQ\$]U#T]S+M7]:/^WC
M<#=>W[;5_3'T4*[E4GVY"%=J@UT(.0&H7'@[TRR_5&TLC4 :%9]LH:"Y<YCA
MN4C64@IC%,]SL@)YHV;2JJ7!<:7LF'K>Z[4I&D(3/R(^]?)/^YS<RV']FMW"
M!TF_N;,!E^;53X)@_P!1?L[QVBLE!R#A'LS7"W0M+13-:))62(Y[#[8&AS*Y
M)C]*;&X!+030K^1O6K1N0CN"YNNQ[%5OVVY;R:R7.*EJ:*J806#(;_45)1H^
M!ZZ>>-R,O#0KS[:"X78E^EWR"MN?9:W3U(?&_-6R$@CUO!R/0'&#;N$[^Z.Q
M+[QKFT&O#40K7H:MSD*Y_'3R\L:<+D\'7G+FVB#JR1M%/)DCCG]A0^&';5R9
MQ)=9UR,1(QHRWUCHS0S/E< QK-Q)S R.7Q3#5PQE8/J8H-DD7:<4T\?/J2CW
MT_YI@$+G,:"X@C:43),8XN1BXU,5MFR9L613<.X]![:R5\3 3_C Z:'52,4)
MC+$A$MV=,J8I,M[CVMSRUMSB.>FX9^" +D5Q1[1IJJG@)YLC6/GU(&@FN &9
M7=EH%7+IBP%O(CXJIA/-:9^Y]GI(WNFNL+=O3W&@Z Y!0JX[]/,CZJ-$@<D"
MI.XMMKG.J/Z@U 48#(W:<@,LR,ET\<1$VI5!"K(&%'Q1;=NYUMI&R&2O9_+
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MG$+C4^N?A4_%.Z=0^2$1FJ,S)2&INDB>2I  'JW$_P"S&UM@1$CDZR-P1*U
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MNWT5=JC> @.V1KO-$<U=,=Z XEU'[G<Q_+ CO"%4WU6VASV_G[*&D?Q_EXY
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M((^8Q(OQ(J"%0DFDHOV'_!-S=.VO=^R%S:[C-PG9&BOA:VH&355B$%NUF2M
M.+&=LXE!/INQ!![$GV<CYYQY[]U+?+8UP+'L;'7TD;@URH\1AC'!>A4?9B?!
M+@2N-NV2[U^W%*"@[Z<QM[?;-RJWL0C;4N;,S:CFL],C7/.UI\<\\6,($5%4
M01EITB9^*D-0?J%=^J:V6&SLY150T7'A'';'VVIK;16T\4?^7'^:H:D&01M"
M#<#A>>SLR>F/%$OPNW;,-O>EZEBV/"#E\&*F#V2_6@[]]MN2V*X\AY1S3D5E
MMM9'+76J>]1US*RF82'0@UL;)2C/%_7KA&]TNQ<B1"$!,Y_P5;-W<69Q,)7/
M3C('3ZDV+9,26!P5X]#^M9VX^JSB]NXS'VAY9:+K'[+HK[=*6*.@AGB #I&5
M399&AP<A753C,M]-N0F7E%EZ"SUN&[EZ(L3A-W)U"0[!0?!$7-^_?,+Y99IK
M+>(Z[V("QM#<2VK#=@(:QC9=P+ 3FG@F#V]E8AB/%R3EV0N1(A1\<*_*JIU[
MS_J&=U.RG-8*.M[:<-OMJJ'S&=M51R6Z02L</1%- V1A]UA+@43&K#IUK<0<
MR-. "\Y/>;RQN968>GICE* +]X9+'@_ZQ/:FJAC@YK]/=115.UK9:RP7:*5@
M<Y Y[&2M9(T=<^N0Q!]O"Y2/I]X;Z*\.M[JT7O[:R0,#"<XGX$$?52C[=?7Q
M],_=:[45@LEKYA9+S<7AL-%71,="25]!G,C6JO37"M[VO.W'U)1CHXB7W(\?
M=.W9IV[L9'LD!WO]RLKX)]+G(^[=%!<..6H5M/5QM,(JZ:,A\93/>V-X0-*C
M3RQA;KINVL2_J&)6G9W]^_;$A:U.'H [?%.M_P#\UNZ7_P#2-#^'?^"'\'^+
M_*T^_"7[2U_]P_!3^[O?_L\__#G\5T.*$)\D4CKX_ 8V14+)?-9PKN74*5ZH
MHU\P1BRL DA=V&.H)\'APR.@=EXYG[L9E[S]ZT[+&V$ZW&WB6WLZ%,P/%/O.
M>"6>!5;E)#!![L8UE&62YKXG7#$C'25:&LD$8.JV_JGI=U#7/ R*.&61"'JN
M7J(Q\.]^6_US+(EE_2S_ +1=Z);86GJ"JV*R5&N"(-KLCU .1S0=,?);WA!X
M+^AVV@\G*EY]$G-^-<(FYI6W^Z4ELEN-PHX8)*F9D!D92P-<]K=SF*@D)ZXU
M?8]J4]_N;\8DP%L#XEU^-/\ O;D;O3^B;&W("3W) $XY$_%E9[3?47VBIJ0&
MHYI9&H!NW5U-N:>@/\P9E4ZX^EQUC",O@5_.\[&]^8Q'>$G+I]578*."5E=S
M?C[@ 3M-QI7C,%26AYZ#!Q:O3#"W,]Q9!-@1DYG;I_F"C[RWZLOIVA+_ .F\
MFM51(=Q]NEGCF<XA--A/J7H,\0=ENI^:! YT3<=QMK;2E>C$#@7/R23LWU&6
M>\2@<<%<]LKA[18'.;M.A"[D5<6CL90+ZF*8N7=GN+>N(UCBS):LY[WQO5=3
MT_&V.BHI7M_FU3"OMKD4553J4QZ3:]-NRMQD\B3S7@>K;F[#<&WM+=O2,7JI
M:6^'F-1Q-T=\KB*XTW\P-*A2P;BBJJZ8]'8V.YC8TD@$?'XK!E=\3S/CS;!0
MCO\ QN]?U:N.R><NJ'#<&/<I4YY 8F.WF*,/BKRW(9HB3]A1?_IZ\[2W\M4G
MT@'^4_TC/1 HP>-J0+T2<KPC4@_ K0[C%_.3*&J+<U(AD)SU(!TRZXM( "K*
M(7=9H)?!>'C-]8TK2SM ;K[<@T0D:+IC/N&(HX6K9C<(J"_8D\*&[LN3FBFJ
MGD=?;>,P/! =PPL2&34=43@0E*VGY ^6.)EOKCO(:/Y3AKD!ZDU'WX$=)S".
M)3!<@MV%,G]2%ZO'".W-WN]325-+[5'(QDE0?9&]S"!M<YP&>[[,,;6V+MX0
M#+M4I1,ZL!FN5+NK<JNNJ+O>*J=YN]_NM0ULSWN=*(W/>&AAW$AFW+-,DQZ*
M0998D9W"3S*C^ZE<)J*FG0S-E]R8N!.YY)<2KBNYQ(!Q7!$YIQ^VW#Y^ZO>?
M@7!J&)U13R7>BJ;@C'&)M'!4,>YKMH<%<]H"G)Q\<$MAY/D*_!5(T0URP7Z"
M'T9=OH++P_B?&XH1'2VRVT1F:&H"8HFC:B#\3L\QIKA;;6IW-U*1%3)8VYO"
M.W]4^:1+?%6ST+HZ*A;!$ ';0"FF0 )73+'HS!V.2\^TC(R.91#=.14EHBDF
MEE <T%0H.80HJKB9&.!P1(Q,BP3 \N[D5=;[L5+*Z.,KZE0D9Y-1Q084G?TN
M0P";MV-(JQ^J9JMNE34$@.<\O*G\3BKE\53/",[DI85*8C#^:D?FAELXW7W
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M.MV@YD,6!_%>K]O7S.S"-TDS;[S17T?U8?XF_P#P1N_\GPTUQ@ZY<_*O2?\
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MF&D99N+MN@0XU)2$0YP67$&=<(J-O*.03U<SW2R$-*HU?2,_CJ<(W9DA-VH
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M8F1S"F&T@8$@'5]ZYJ.\'>7D'U5_4NZ[2UTE?QG@<DC[912$RT[ZZ,N2J="
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M4%NLCIBTN:I7J!]V1ZXL! 50C.<CBP2LDH8K?3J_:,B453D,\_CCA+76*A@
MHZ]S><QVR*:FHY!^8<'-.T EH((1 0AP*Y(OI!HF+%DR)EP4%N3PW+E-6X32
MR/:]S4"D@#<2B:(F6%A*6MP%H^#14XA.3PO@-#0PPU!C8*IC0]K]N9</\3B,
MUQ66J<WF^KADJ3N:/*?"0RDAQKD%:XPV=[/;8@C8_P $T&9TP:,B QP0)VH
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M:5SIFTD&$IQ[W2,K?H?N#=YM'/*^$_P"=[WHX(J[@I#B1\,'CU08RA5+2Z/
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MMM%)*T.="T'0$A&$@$E'*7*="O7%'5Y,,,$(I[%3^\P-8YCMS'>DD*XD;6,
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M3"W\8_"<U&I S*']_P L20,E4:@:@KZBJ(J..<S2L:QH+O4YJ(T$E%(T\L5
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M20$TS^W$Z7%$ S,:'!.S9.8TDD?Y.1[!.T;=KG([+(HNH^_!H2%'*I.W(#5
M$@K"XUS92=I5=/ GIB\I4:*ZU:KJD$A[H'E2/Q$J,LP$SURP/\JNWZA;S).P
M3%LB.UR30!NO[,4KFHD3FCEU:UL1#GZ!O71!]B XMK+850P [FJ;+DE8"=V[
MJ5\ /$IBN*/;CJ+)E^3$U#&H1U&6IR.?Q&"QP1Y A'O;RD]J43.&7I_:"H^S
M%+A9@ARP4AJV[-I+<4(!$?S"-4GP.N.U>$ 8I:,/$ZK>^HCNE74WYFAHJAPR
M<"CB%]1!"J5*$G!8V]8\7%TP=+<VK]RB-V\YCRE_((IXJJ< 3#(/R0OTR4'%
M[EN)BQ1ISE&46-7"M*M=WJ+]PR2.KW.D=2%K@\*JQ]5()4X5(\(;@HD/3OB4
M<BJLN^G#Z>XTUZB?%ND::CTH2=X+VM*:H$ ^>%XEIN,5J6YZ9-Q2;^C[F%SX
MS4UG':V20P_FBR*-[7>@L< [9^)&H0G4IB=Q%XZQB$2X!)G5MMH<*Z**?<UQ
M>Q5R&7V_[\7MA_$^"S)@QHR<2VQM,:$*@ .>OQTP0I=SJ*,?Z7'+D6Y. 4'K
MIEX'+'-+'-1K:B.[9:Z6E(<V-H(*[D0^6GB<7#@N2H<FN2<2URI_$@.BY@GQ
M^[%L@0JQ/C9*Z"4JT@E-2NBG!X2< % NP8OQ2FHZDM(S/R33P^.((TEAFA,Q
MY#[,E/3U(8]CV]4!^&GS.*2B^*-K$@!DR&/BCJ9))6M!TW9+EIGKBH\.*LT"
MP!IV9H)+#MR1/ HBI\D QQ/!7B-)8LZ+9F9;=H)3_?X8HQ=LRI< .@SJ3>F0
M0 NRT77[4&)96<"7:@KJ'<JM 3H <UQU'Y*)(.ZV9$ID-,AXG+[<6;L9#E<(
M#H.;8W-8U)ZYH/),<(BKXJ/6>@X+*.ULW#^64*#3(?!<6$0JRNR- @W)&TMI
ML]3,@,GM$C0(YR-:$1=3B+A @< ILZY70'+).VWD<+(XG.F82UC-Y:?PD,1Q
M*Y(#\TPMK#,4T17!.);KG%<(!L<UVY@+2"$((U"+@@+QQHR7,6E6@2!ORT]6
MXN<&(YN91,R<]Q.YJ)GXK@<R00F[;&/)-SWDC;5=H^2/<UJTU1Q^L9F"08^0
M6QCB' @$F*9WCJF%][7:2XT^H1-LXW4>_P"B@N"X.4=%^&?EU!QYX&JWW!HA
M327 J UJ A/O .N:XY5.+(QH81/, 1DHZ'QZDKB"2N%*IVN*T3HZB(M":%4S
M&?B,&@&J@7Y"089)[V1,,3 YC'%!JUI49]"%SPP ZR[EV0GX20RT2VNW5 2:
M@I9=PS]R",Z9?X53$2 =U,=WN &U%DE[EP#AER#FUO&[14!ZJ)**!RYY'U,.
MAQ H:&J-'<RY$<P$U]\^G'LS? YMPX)8Y2]5=^2@4YGKM&BXX&4"X)^*D^A=
M(-RS:)_TM]$R'(/H)^G*];M_"J&E<Y0'TL3(2T^/H:,P3@G[G<QPN20CL^GS
M!>RQ.8D1^*AYWH_3<[-P6NL?9):RV2"-[F$5$NV,[2@3<  5S\\7CU7<VY#U
M&E$EL&5I]&V$X"<3=C+M!"Y[?JN[9VWL&ZY5C+M^:HZ/WGED@W.+8P3N8\>I
M'!AQZ':3.X 85-/C@O/;^W#93?5JC\U5M2?6_P!LA-)!5ULM-)%-)$YVZ7:K
M'F,D#U-S:$Z8USTZ_%Z!^Y)B_ A]$V[%(3M=WJX_W7J6T?#*Y]QJ6EK'M;*
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MW3O@I:>6=\;2P@MD>6  Z#&%?Z%N;5OU(2$F=PS,P7I=E[MZ??W M;BR80)
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M4*$>95.N*D U1",R@4LX]MWKS*KY*-!Y8HZ&!7DFZY+5$0R(?X2F>+QQ<H\
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M\PO3!7J4-#XR5Z#[_LS.)!4!&$11/-"I7,^'EBV'<I/BQP0^)V8)0G7/+)2
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MV#+S *>.F#6YY$H-R#QH^H?3^"4MGOI@JW4[9$><BI(TSU!4XJ9"62Z4)0#
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M%R&H$87L23DFG[Q<5JK]P^HD@IR9:!9OPNW!JEVB9H6]/ABUL/< &:#.Z"#
MG$* _=;NH^E[<NXU02!]YJ(I*&K@)<V1@BC<"H"$"1/LP[:LB-[5+N6=N=P1
M PS4ROT%_H5J:[F/*?J3YW;O>:^OJ:#AS:R/>(8OS!DN%QAWMR=5U/H:1_!'
MYX<N1E<F+,3X)5DW!Z#O-6[%Y[K.X.TV,1&EZ\"W$1%">_)=@4=$0(J>-H;'
M&QK6Y  !H R3RQIQ C$1 P"\:$I:>G%/%N+0-K=W74Y _:<5)!IS18 "N! )
M0>61Q))*E4T/7IEKCBP[%SF?BE4\T754A8"WQ_?@4JYJ81>YI;)%'MN=U))U
M^.6GPQ#C 8HLK;AR:?;Z(PH;3)42-1A*G7Q7[1B?$:<\$%K<<<1FG#H;736V
M+W)MH< "5 0)T4ZX8A:$!JN?!!N7C<+12.Y;SBCME/*T3LC:T$$DAKG9Y !0
M<\!O7J:C2"/9VTB<*E1 YIW%DN4LT4<^V-2 Q?QYJKG#+IC/N;ES0T6O:VH!
M#!-O%</S+]SB22BH>JYDZ9987UN>29E Q"/Z>:"-FXN;GF ?@5&F#QPHEI N
MO)KE   'A=/]NNF.) QHH,)&@0)U7[S2&%0-#EGXC+$@KC;8H1;J4ODW$:D9
M^(/WKBP5"'QP3BT9CIZ97$ H<SU(TP4XLD9L9T25O-]BI&OD<]K0%.9S'4#5
M<\163@8HHMB)K4J#G?GO544E#4VZWSEAV/!=&\M.:@^KQ37%MO:,IZB28<"B
M7"+0?"X<.2@)P^\5=SY'+<)ZB66628N<7/):"20"%R1/GAB\!&&D"B!>NSG
M"1JI=V.^U%IJJ.LAF>& L<YH<<]%&1S)QFD'_B46;I@0#Y5.GA]U_K]OI9F(
M\EC'9? 9=0"JZ88A+5&N*+>@(EQ@4H>05S:.AD;+DC7>2%#ET55RP0!\,4.
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M4"5YI6O(:%(:V-KB-C0#M/Q&%HA@9RQ*T3$:8B(8+?;*;\K"US5C<\MBC R
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MC_,55 <0&CP$Z*0X@8F-LL&'VHK>K_-BWW23_=CW-_IW(1F3_4:<G+)3"\H
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MA%G9$MRD),"5.3M?72RFF+E(<YBL("*2.FA!.F%;D0SYK4VTO$V2EBH_P_\
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M%]K[%>KA0N%!>6GWFT]RB!DHZA\+B"YD<X!(:6G;IGCX<;%IP9@4D"V="[+
ML=2E&;70]LAJ4(YCFZY:[_\ H[_7S27ZZTK/J9LD$,=;5>SOAN(,E.Z=[H9'
M;I5.YI"GQQDWI6+=TP-H,]"[4^"]%"SU"<!.WOGM'"LW;F!@>]:A^CM]>TP9
MN^J"RQN"KLI[@6^2K*@\C_>N!^KMWI9B?^)4GMMZ<=Z/C<^*'4_Z-_UU,/\
M,^J:VD$(\,IJX ZJ#_U!<OS(3$F=@X6(?^+^"6_:[T8[T?&XE)8/T7?K<NEQ
M@IJSZJZ&EHWRM_,U+*.X2&*)1O+(VU8WR$:#3![0B2#Z,!'M_@K:+MGQW-VX
MX S)/T^95PGTU_I&]O\ M3145;W&YURKNUR6)L<E3<>15M3';C4 #W/REJCF
M$$<*Z!P>[Q.'_3G>/A$86^$<.\XH=WW!.S'T]F")9RD=1[A@%:'QOMGQ'A='
M%1V2UT=+%"QL;(XH&L:&@  9*2 GCBPL1@2/HL:[NK^ZEKO3,B4JJB9E+$7(
MT!H(: @ /3+PP+Q=R$Q>B:'D_(AN=&'Z$Y!V>!W;FGPYLG;5IAJD D7!4?F'
M%[@?/RTT"^>$M3GDF@:(0]X+5Z:>>+4%2N1+5U# J$9%#T(/7[,=S?%#)\5<
M DG7US5(";0J!=?^$#/H,4)$1S186_4/>F^O%R<T.12#EX(H("9C FS.*?M1
M#L,$VM;42RE^9R<4ZJ#KGF<+SJ4P1X6"1M<QY>]WQ))S.OR\,4'S5 X1,ZG>
M575<E73/--/MQ=7YK9!$YAT)]2@9'=XKURQ!JJ7$J8)!'&/_ "1EIGXKXG'
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MUWO,>%4 AI&2D*BC$4U<T&V_J#@IV121WGMG<89D/Y:)M4PY.+'1 .*:@9C
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M* 8L2>-%6-MZ9J4O;?MA$]T!]@$^A4C&0!3IM7QPN;AU_P"56(]*+T=2L_\
M#*G_ .P/_P &[?P#3_'KKBGJ#@@ZY?RY.K(PP$!,T/0=  "/$J?CC7)9865%
MDB9Y9YH!F ="3IB!*JEE\A&0T!*=54(1YXO(N'4@,B#D4.^F:4=MVN'3(_%$
MPI>P"9LN"2BCAL@CFF"JA)3J,B B_# 78NFX>8@8E/#;J[:6A[CJ%7HI")FB
MX/"3XXJY%&."!]P*MDW&ZL$J&P2ZD _Y;U&>I./=^R[XCU>-O R#*-I POB7
M-4R\MO\ !37VYTP(]-3(TKT5SO//7IC]0[.Q*5B,SP6[/PDCFG3^GGL;?_J*
MYO3V"T^Y0\?MSX:CE'(!$YT5KHWN7V(24CDN-7F(F=,WG(8R/<GN#;>VM@=Q
M>8WY B$,Y'\!G\$KN+]O;6_5N\: 8D\!]YR72'V\X9QCM=Q*T<+XC;X;=:K1
M2QTT3(FM#Y7@#W:B>1-TU1/(KI'DJYQ)Q^9.I=6W?4]Y/>;F1E>F7+Y<AR&2
M\EN9WMS,[B^,?@!D ,@G$HXW2O#Y"3F  =/BFF$[0,CKEDE9'+) ^1\,M/(8
M]TL8@K&-(BJHP-WDV4?QL^_%[^UMWQX\>*8VVZN[4^ O#@F1O'$;G8I2V>$R
M4X_!4Q NB<U=2[^$IXXR[G3S;-"X6C#?>MX@6EP1/#1OEE9&T',II\%7SQT-
MN,\%TKV=4]?&;'!1T[9GQ@O*'\(71<\:&WLQE4^4?59>YW!EX0E@YZ:#:- !
M\,L.3D(128!D6"*ZJ5H!W$(W-W]W3"9EX2]24R/"&";/E%\;%$X,=M !1#T\
M]3H<!,M(=,V[6IB7;%,35U$E?4/?FA.2X3E(F3E-L"&S0R&3VFD9?#Q\UP)G
MJIJ$'J[B(V9$9>!.N>F@Q< <V75.&*2-=="=QW(J9 ]0?]F*RF(EHXHD+)D7
ME@DU/5NF)SZZ>/EY8%@:IL!A1)VL@,RCH4()TZ*?F,=(T97$B$G*NWD?A &1
MS \.A\\4,'J$2-P&AQ2=J*,-)W@:GS/CH4P,Q9$+).U$(W.3,J@(TU^[$8=B
M@AUHBB!>0%]*J4"Y:KG^S$$T0FKR1HXM; KFD'/7HU%&2C,C$X=B*DG<:H.*
M#30G+0:E,6 >@4$I-SUGL-)>Y03ET7(D9Y')/#!-!."J4C;C>]KBXDHU4 1$
MS4$^'WX*+8 0IS QP31\OYBV""5K)4*D#U'1,QK^)-,'L6R]4$W"8U"B9S&^
MNJ1-(7DAX+FM+CGT4:J>I&-, :&R4"0TJ-]WKGNJ"=Q0J7=$W9@!%77I@D13
MFE;DF-<$7"M>R,ASSD 0=Q 0+HFJ^/EB60O4<TR0 S&61,W>#LQD,SH"O[,6
M&"#*8..*>C@5.PR1':BN!SVG--$5"0W&=>/BJF0/"I3VV)C*9CCZ6[&Y'5!D
M"? CIT3'#()<ZA(XKVIJW/W,:Y&A3D<LAEH  <\$C%D2)S%4F;A4?EU5_GU(
MTS0J@0]-<$C4H4@QY(@ANS(IE<\.#B0%.0!S0DX+%3*#Q&GS)L+Y45%IY/3W
M.G);#+*P[@N>\[00X=%UQTHN*XHP+PTO5F4GK)=9*Z@AJB=S#&TM<"?4X-"M
M"Y=<_#"Q !2YQ;-,#WS[@4_&K%6U<DHB>(Y6,!<AW;2"5().W-4PQ;B=+1/;
MV9HIC*A! #%5[?3_ ,:N'>SO11U<[))[;!7QU,Y<QSHRQDY<,W-0;B%!0#%[
MLA"V9X "B3L7-,]<S6.',Y!="?*+Y2\/X72V&C:V(04;(]K &D.#0,T*$Y8R
M[(-V>HXIN -PD/XG<J(7]6,UR-0H.Z1SB_+_ !YIGX9?[L:1%&3E!V)PH[B)
M8V$%SG %%TT U\AX8HS8JC5<8(KJ6-EDW-U5-R:?XB? D_+%Q2F2!.3UH"C&
MB@:YK1D2TY'77PR3<<\02H)("7?'Z7^<T@Y*U-05.0!74:8J33FEV>09/O96
M ,C.WH--%&7[1IUPL2Y9,D4'!+0DN:$!)ZC-1EKXX[ 44T",:+3T%"B'(D$^
M97(?+!0H+)0TSP"CEZ9GK\EQ=5(HEIQZH#:IB$Z_/(Y>)R.*RP5H!R1R1_RP
M;3!)_B3-/,(GV8'%7@^@M@L+'5!WMM:=$&91Q.2DCJN*&0[T242PGD4K)O5'
M*"W)T1.6>:'SQ0EPJT!=0([N0[*JHA+1NDJ)=N>63B5*]0N!VBX+IS<5B"F=
MMTC&5D ,B/B1 -!GJ0,B?LQ8 I&%+@4P*"[1V[ME=WN>&B2@<QI_Q.D:,PHS
M/J.7CA2<C$2B,RM:(!OPD<OP45Z4Q>X"YNY']1F5*A7Y9$?[\4JK'YI0T]RB
MB8XDA@:UVH&8)S\=$\\59U(D(A,9WA[Y<3[5\8K^3\KNGY"W1^XRFIV-,]QN
M=4&.++?::)KFOJJV7;D%:R,'<]S6@G#VPZ;NNI;B.WVL=4R<<HCB3D!\3@*I
M7?;_ &W3]N=UNI:;4>\DY #,E59V[ZI+SWKY=#-61&R\>IJL.MO'V3NG$3=V
MV.>Z5/H;<+@YF9*"*,E(VC-SO<W_ &];Z3LSH.O<$>*3?(<!\SFO(;/W'/JN
M[C$C18U>&+_ R.9^F2LSX1=H*WCL+8D+O::A"?A#2"3YEV/"[F)%TNO:CR A
M(OFUK9705,;H]Q#) $;D6G7,=04^9PSM;LK9&E)7[<9NZK+[R<(CI1<"(MSB
M9'AX R(*D="?FFF/I'1.I2F8@]B\)UO8BW"0Q"-OHTD#.3-:PGU5.U -H:T$
MM(3HGAXX)[N'_+.<62_M(_\ ,%L5?AQQ1;J?,_Y<9!\D^TX^(;C^L>+KZM;8
MP#H_C!+W>#25 \?VH$P !JE$1E$?2JJ#D@^.N+8%6 I1;P&N?&'_ (2BKX=/
MA@D0#CBJ2+#FG M5 S8'A@(("=2HUTZ)CI 8(3DBJ4/Y&-X0L&7B/[L4*[&@
M0>2V,#E+!M7H!IBA9E-26&22MXL%//O2$:9': BCH.N?V8H ":J-1);\JB?]
M07,>+=D^W/*NXW*98J>W6"WRR0PR/;'+<;@]KFT-MI@X@R35=0C1X!3TP?;V
MYW]Q&Q!ZGX<^Y5N2C XT <_CW+DPNL?<_P"K[NM?^55/OMIJZY2&HN#@]]MM
M%N]Y_P"6H:5Y.UQIX0&M:TH3F<>[LV[.QLBV#3/F<SVE8&X]3=7#<F6MCY#@
M%*W_ $)P'LQ9Z>V0-@K+Z86[WN:Q]7-,,WS3DG^5$UP3HC4 P(3G=DXI )=X
M1R_$I SW2>[3%TK@&+Z8&^F.-2T#:"0"=<\_C@J$:ET?6VDI ?=F(W@C:U53
M+->FOW8B19<.:<"RLDG.V !L34W/)#6M:TDJ2 &C+S3%<>U$B""^ 6CEO?#B
M?:6U5577U5,VK9&_;N>SW"\%Q :J. <5.F*$:CI'QR3EN]^2V1JXY*F7Z@OK
M"Y9W4NE5;[+531VL/D:!'(2"QSW,#SM=M+4&2_B3QUN!&(#>9"O&,Y./,*.^
M*BO1TDE1.RJKY7SR2A7ETA<!(U'D@YJA(RTR0KB)%4"65%3ESFAIW$@-5$;M
M:I5C%#2B@$!,")8.$Q"+TS9.M9*9WMT[6 %[CL:S:=^]V348"I>2F2*N%W)*
M(PH NB[]*[Z%+E+>+7WV[CT,U'%1;9^-6FLAVEAD:"*R>(C_ +Q('( ?P-/B
M<LKJ6]%J!VT2/4D,15D[;L@ VB/U"*_Y1P_U' C$!=*;-FT!J;6- 8 - T;0
M T!!ECSWT3!88 #EP6X-!:3M*>?7^\XA\E<=J!5,,>PJ ,SEID<@!XC]V./%
M6P+!(2\T3'-+@/')-/ ?;CG.!5AB^*8WE=H9(Q_H!0.S.6:G74 @G!K9+$(C
M 0)S48.2<;;)-(X1KF6JF3@NB88@4"$Y?\* 6#B;??8/:#279;6EQ.B]#T&"
M"J*;BEKVWXHQCX/1D"TG<- HS7-<_LQ$Y"!;B@VSKE7!2A_TY3_X!_W%/P-T
M\< 9'TSX)XFZD(FF:D>K-=2B8V2O-!>_A'R3H?@JY=,_#$ 55C4,O,E7QRR.
M?G\=,7DH#HNO#-] X$!03U.B9IF5;A>Z"4U9(+@8LDIQQWMUT[51NUP9GU .
M7WX73<0TQ).';:DRS,B&8**%Z[O\66B:8O#'DF)@,^!7O/VOCXU6O(R;%(O7
M6-WP10N/5^V;OI=8LR=O$/JJ;>0]8$8./JJ)Q9N6]T.^+^W/#*&6X7R^7@PP
M,:'?EZ. 2;JJX5L@"04='$2][CTR&9"_LH[C9])Z!_N>^D(;>W"KYG(#F4[N
M9$;B6HM;B-1.0''\!F:+I]^GSM!Q[L1VWLO"K-'')71P,J;_ '<1AM1=[S,P
M&MKIW?YA#I/3&T_@C :-,?DGW/[AW/N'J=S?73^DY$(O2,1@!]L5YS=;@[R]
MZAU"U&D1P'$\"<3SHI!TE0S5[@=""JKGKGKCS<A4'-!U$P-N1:M#Q[THJ6M8
MQ3N*!".B==#XX);GHYQ2LX2!8CQ(T@N^\[7 9Y Y?V.#QOAV- AM+)&#S2UD
M3XIXVOCD:6O9(%:YNB(>N&'$HU8A0)-+4*2";BY\6HJ"I%;1RI&YQ<:9[@2P
MJ/P% K1A>5N,9 @N$Q&^;D3$T/%*:AG:(6L:0B!/#1$TZ8';G*!TYH,H XXK
M=/, "-V83X 8M.X7>7P4QB(X)&WJZMAC<T.Z%2?%,E*^. $2QPDCVX@EBF"Y
M'>#43.A8[-?40?CD%^&%;TR9:1@%H6H XT1-2,VM5R?XDU5 -%ZX">:EZT6J
ML>6M+@0-<ADOP"98@579I(5U6]"Q>N1_M\,#E(NX3<("J2T\LCWD9Y^.8U4(
MOF<!D231&@ SRH%J8UX5Q.1R!735<ERQ,2]5,S' +U[04R)R'WC3STP7%41%
M6OVA <E0C]B_'$54P!)HDK7R-).8;KIUS"JG1<#D04R R1]3*CW@(N:$(@S*
MH5\,4*[!?43'.#ES*]-?FF*D/@JFB$7-QCA W$N.IT"(J!.N>)%5PXILKI6M
M@+W%S3EIF"#X#X^."P%5!(%<DVMVY"TE[0[)"%W'IKD"J^>&!P"'.]'2P34<
MAY6R"-X;(A(*>HCIT(T5-<'A;<UP2)D92K@H\WV^NN-2Y'[F[\RIS)U=X*W1
M<-Q#*1$BLDU7,:MM/ ]H!4M.UPS3)=53K\4P<*I.:8BIJ#),2YZ,W$H%+0''
MTZJ5_;@H2MRN*"25#&;FN*J>BM 4^HM&2 D_;B4)R'P*&4 ;++$ !F[1WJ15
MS\2<O/%+A8*L5(GA%)M#'9$IO<C"434YH0<9TW)!3;AG3[LJ3#3HJ  %H&0
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MMO\ \^'_ -HW]V!# IB."=2D_ SX-Q*6EB>]0][X?_&";_V(_8,#EB.U-_\
MZN>U11K=8/\ Z)C_ &C%Q@EH8GL3B7[2U?\ T##_ .@,)9]ZTX>5)N3_ "I?
M^6?_ .5XDY*QQ2?[G_\ Q9['?^SY[_\ GFVX/=\D.S[T&/G*8ONE_P# \O\
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M;K^H>P*#?*O_ (6N/_T3-^T8TX^4=BS+_P#4/:D@S\;?^0?^DW$(0P*%4_\
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%*[\5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g382677f_165.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_165.jpg
M_]C_X0H117AI9@  24DJ  @    ,   ! P !    "@,   $! P !    3 0
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ ?
M    M    #(! @ 4    TP   &F'!  !    Z    " !   (  @ " " _ H
M$"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P(#(T+C @*%=I;F1O=W,I #(P
M,C,Z,#,Z,#<@,#4Z,CDZ,SD   0  ) '  0    P,C(P : #  $   #__P
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MJEP'_!<=H1 FVP5(!9&047;@;#(*040I)B2R"=13H+5Y2U2"R.H]5<^<?"=
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M))))2DDDDE*22224_P#_V?_M$;Q0:&]T;W-H;W @,RXP #A"24T$!
M#QP!6@ #&R5'' (   (    X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-.
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /
M<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R
M;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R
M:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,
M8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O
M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0%(            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      !  2     $  @!(     0 ".$))300F       .
M         #^    X0DE-! T       0    >.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!$0      !     "   "0    D      .$))300>
M   $     #A"24T$&@     #/P    8             !$P   ,*    !0!F
M %\ ,0 V #4    !                          $              PH
M  1,                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  1,     %)G:'1L;VYG   #"@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ S     0 X0DE-! 8
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MCCUD"W^@]LZV]>O5Z[51?@:O]C;_ (I_3W6O50H'#K,$OZB./]JO_L;^_=6
M)..N_$O^^_Y'[UGT/5]'SZR"->/2#_0V(_WUO=2X'#JN@?P?ZOV==^-?]2?^
M23_Q7WK6W5O#7^$_RZXZ ?HH_P!L3_Q/O?B?+KWAH/PUZ[\8_P!3_O!]^U?T
M_P"77M"'\%.N_&/]3_O!]ZU?T_Y=5T#^#_5^SKCI7Z6'^OS_ ,BO[WXGRZMX
M:_P_X.N_$O\ J%][\5OG^WKWA+_#_@Z]H3\A/];D_P"]"WNOB&N.O>&O\/\
M@ZZ\:G]*H?\ ;CWL2/YMU[PU_A_P=<A K<6"@?7G^O\ L>/?C*PX=4:&,#X>
MLHID M;5_0FX_P"31_K>Z^.]:^72!P:F@Z5FT=W9?9F3AR.'J9:>2*16(1C8
MZ6!-@21^/:BUO+FSG6XMIBLH/[>@OS!RW8<PV<EK?0AD((X=6V_'CY\RT"T6
M*W'*L>E8XVDE8:''Z1<GZ7'O(;D7WJNML\*UO9*4]>L#_=7[L0F:YOMKCU D
MG%<=6[=>=U[7WS105%+7TY:5$:RR(2-0!Y4&X^OO+/EKG_:]\A4F9=9'J.L&
M.:?;[>.7+B6.:U;2I/D?+H:8Y8Y5#Q.KJPU J;BQ_P"1>Y!1TD571JJ>H_9&
M0@.M&'63VYU7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[K_]"LV(<$_P"/^WX_XW[P(D^(]?0;'\/Y]20H_P!5
MS_A_R+GVT_PGISK/'^;?[&_^QM;W6/SZ\#@,.LZ@6;_>/\?]?C^GNF<^O3JD
MD&O632"M[\\V'^MR?]X]ZU9ITZI-<=2H@!]+:;6)_P")_P ?I[;ZV:'!ZSJE
M[?2QYXM_O7NM*CN'5Z&E?+J6H/\ M[6]MO\ $>E*#2H'6:,<_P"P_P")'NG3
M@ ZSK<D?X$7]LEJK3SZL14$=2P.!_OOKS[8D\NK#J2O-O]]_C[;X#J_QM\NI
M2@@$<7]UZ=-:&G'K(JW.H_2W_$^ZLVFF.O4J:^?6=/S_ +#_ (GVR.GD&">L
MT8NP-^!];6_WWX]Z?AU>A/#J;'^?]A_Q/MKJO7,<F]^"!_O?)]Z)I@<>O=91
MS:WY]M=*>LRD6XX'^/OW7NI48&D:?S_ON/:5BQ/=QZO$.+=9D'U_V((/^\<>
MZ/\ ">E- !0_%US _ '^P'MGJO4D _FW^PO[U_AZM0<?+K(HY%_Z7'NI/D.M
MX..LZ@D@_CG_ 'C_ (W[KU;K, ";'B_]..?;;G@.O#K,J_0 >VB0,GAUOK.B
M:?:9F+&IZKUF47(O_K\?7ZV]T8T4];'63VSU[K)'^?\ 8?\ $^_=*8_@'63W
M[J_65$Y!/^V_V!]M2'%.F VIQZ=90!^5//T_V'U_/'NG532N.'7,"W ]^ZUU
MFC2W)OQ8#W1SP'3B#SKU)478?X<_[[_8^V^G.&.LWOW7NL:K_:/^OS_O?OW7
MNLGOW7NO<GZ<^ZLVFF.M]<])M>YU?[Q_OK>V>M]<UM9;_P!![;=Z8'52PK3S
MZRJEC8_TO_K_ /$^V>M*   >LX0$W/(_Y"/^]CW[K?7+1_C_ +Q_QOW3O_AZ
MMI/IUV1P!]?Q[])Y=/#KFJ"W/JX^G^Q^M[^V^O=9??NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7)!^G^O'^\>ZDTZ98@]OX>I ]MGI#*
MM#UB=.-0_P!B/;E>XCINE:BF.NXGDA<212-$ZFZ,ITM?_"Q]V/2.>))E9'6J
MD9'1E.H_D/N_KW(T82OG>B21-2&20KI4@V7G@^Q3R_S;NFQ3QM%<,801BO#J
M&.?O:38>:+6X86JBY(/D./SZOE^./RGPN^L;14U971BJ*(KH\@#%K*#]>;@^
M\T?;?W4M=S@A@N91J(''KF7[L>S&Y<MWEQ+#;MX0)R!C_!T?&CJZ>N@2>GD6
M17 (T\_4 _\ $^\A;:>*YC66)JJ1UC9/!);R-'(I!'4KVIZ9Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T:S(EOK'
M] #_ +#\^\!CY'KZ#%'Q*>I:BP_U_P#>O=&;3]O3O69/I_L?^*>V>KKVH:?9
MU) X'^PO_KGWOJR"@KUFTD*/I<7M[J&[OET\AZD* %!_WP_'MLBN.MUR1UGC
M4D_ZWX^G^^^ONFK3VTZ<5-34/4L#@#^@'MKI4!7K.@  _P ;_P"]^ZLU*=7
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MP>?]\>/;18GB>M_;UG M?FY/_(_S[;)!%!QZN 5-3PZY>W.G.N/-O2+Z>/\
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MJ^?4B,&YM_3_ 'W^]>V_@^=>G8Q4U].IBBP_WO\ U_;1Z5*.I"\B_P"3]?\
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MXN>1;\>Q[R?SQN'+EU"K3,8*TX\.L>_=3V;VKFJRN)[:U47-"<#K8!Z-^0V
M["Q%'_ET+S21QBQE74"P%Q:]V]YS<A>Y%EO=O#'+,"Y \^N7GN+[6[GRM?3
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M;KZ==L +6-S_ +[\CW[KW6;W[KW6+0_]/]Y'_%?==:^O7J]=Z6_U/%[VN/\
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M2XQ<GG\?[U[3N>X].^'\^IB\<_X$6_J;-_MK>V^G.LZ VN1^!_7CVT_'AUL
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MH]V#&M>FNNM*_P!/]Y/_ !7W?6/GUZG7BB_T_P!Y/NX/52*]<&06/)^A_/\
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M@"_^\?X>VV>AIUN@\NN7MLY)/6^N83^O^V_WJ_\ 3WKKW67W[KW78 MP./\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]:N!%^G^!X_V_\
MQ-O> )^!?MZ^A48TCK-J-OR+\V'X/NG3J\13J1$A8^H#3]?]C8?\2/;;4![>
M/5V-/MZFH+_3CC^EP1_K\_7WKIV+XC]G4M%(X^OM,>E2BIIY]9T^EO\ 6Y_U
M_P"O^M[H_P )ZOU.C' _WO\ J!;_ 'CVED\NK+Q'V]28Q]3]/^*B]_;/RZ>
M!.H=3$Y(%C]?]A]?H/Z^]' )ZMUG/T]L=77XAU)B^HX_'^V]Z;AT\!7'4U/H
MO^LW_0P]M]:;XCUD7_4_@"_^]>VW\NG%%!3J4HX _P ?]Z;W3J_4P"WT%O\
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MI:J/2?Z_\3_Q3W1CGJP->I('T _UO;;\.MCJ5'^K_8'VG?X3UL]25^H_U_\
M>O:8F@KU7J0@LUOZ#_C7MDDDU/2A$ID\>LOO75V^%OLZDK^E?]8?[U[3-\3?
M;U[K)<&X_I]?>^D_4P @6_I?_>_;/'IX!M1)/;UF46'^O_O7O75NLX7C@_J
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MD7CDC>ZLRLH4@\$$7]F>W;G/MMPLT$A%#7CT&M\V"SWJTDM[F-2Q'IQZM_\
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M_P"P_P")]IV74.E:)B@X=94%VM[8ZV./4M/K_K#_ (I[HW5Z8IU*7@?[$_\
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MX_P'^^'N^I?7K=>NB-)]VZWPZXE;\_ZP_P /J#;W[KWSZZLIYM]>??NO=<6
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M\#VWTXS4P.I"#ZG_ &'NI/D.FNI2+]".2?;+M3[>G!2GRZRHM[W_ -;G^O\
MQ7VSULD 5/68"Q_Q)!_W@>Z,U/MZ;)U?9US52#<^V>M=9T6_/]#_ +Z_NK-I
M^WJP!ZSH/5_K?C_??T]L=;H1GK+_ (< ?[Q[WUHFO4A%!L3P/Z&_ZOQ?_#CV
MV20:#AU3AUD Y /%_P#>O]\/=">)/6NLW _I[;J *')ZWUS501<\W^@]MD@"
MIZWUF"WL3]/]]_MO;+-J^SK=*=9@A']D?[[_ %B/=>O=9@"0 ..>?S8?GW1F
M(P.J,VG[>LH6RV^G^M^1_3Z>VR2<GIDDL:GKFH)Y'XM_OA[J2 *GJC-3[>LB
M+:]QS>W_ "+W1W\AU4MZ<.LZI;Z@6_I_C_L./;75>N84?4#_ 'OC_BGOU:<>
MO=<@+_ZWNK-3[>M$]=Z1[KK/6J]<O=.M=<]!_P /]Y_XI[]U[KD$ ^O/OW7N
MN5@/P ?]:WNNM?7IKQ?Z/7K^Z^)\NJ:W]>N2J3]?I[KK;UZKUV4_H?\ ;^_:
MV]>O=<=#?T_WD?\ %?=>O=9-/^U-_M_?NO=>"V_Q_I_@/?NO=<_$UM-N/]A[
M]U74*5KU[Q'_ %(_Y-]^Z]J7UZ]X_P#!?]NOOU>M:QUWXC_J1_O'OU>O:QU[
MQ'_4C_>/?J]>UCKKQ_[2O^\>]T;^$];UCT/7>AOZ?[R/^*^]=>U+Z]=%"#]0
M#_R#_P 3[L%--0ZV&!ZXLA-KV'^V_P"*W][TM73UZH/76G_:F_V_NG6^N/C_
M ,?]X_XW[]U[KM@3]#Q_3W[KW7$@_P"I(_V-_=U;3]G6P2#4=<;^]^)\NMZW
M]>N^/ZC_ 'G_ (I[]XGRZ]K?UZZL+VL+W^O'U_U_>]8ZOXO]'KCH'/\ C]/\
M/=^G>NM%OS_R;?\ WCGW[KW6'2/=]9ZW7KVD>_:SUZO75OZ^[:J_#QZW7TZZ
M]VZWUU;D?['C^M_?NO==6'^H_P!X7_BOOW7NL;)_M/Y^E[_[U^/=@Q'#KW6
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MA?K_ %M_O'T]L#IY.'69>0/\>?\ 8GW[JK?$>I2*";?C_#VT3UX#K,!] /\
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M>M]<OK[T33)Z]US M[;9J_9U4FO7(*3]+6]U)\R>M=<U3_5?[;_BOOW7NN8
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M!_K?_>_:9VU-7JIZEK8:+?T'X_V_ ]IF-6/3Z?Z'^?6?W7IQOA;[.I(!)L.
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M,EBW'AUS"V_Q_I_@/;75>LBJ6_UO?NJLU/MZR>/_ !_WC_C?O7377+0O]/\
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M)7^G/NI4'CU8-UP,9/U'^\_\;]M,NG[.MAAY]8V4'Z6!]TZMU[0/\?\ >/\
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MQ]Z/3J</SZEQBP4WOP./]<#C_7]INGEH3PZG0_I/_!E_WL>V>K]25_5_L/\
MB1[;?C^73L>:]2H_[/\ K_\ $^VV^%OLZOU.3ZG_ %O^)'M(_P )Z4KQ;[?\
M@ZSH.;_T]L]6ZF(."?ZVM_L+^Z-Y=7''Y=2U'(MS8B_]?]?_ 'CVP^30=6ZF
M1?G_ &'M+)\0^SKQZEQC^R1;_'\GZV_VWM-(:GJT8JPZS@6 'NG3ST5*#J4@
ML!^;DG_>#_C[8;XSTW^!?MZDQ :O]8<?[Q[;?AUH*6QU,1?[7^V_XK[;Z?\
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M<M#?T_WD?\5]^4$+0\>K>(WKUU[OU?Q?Z/7 J#_A_K#W[JZN&X<>N&AO]?\
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M\@\?[S_OO]C[;,8I@9ZU3KD!_J0/Z?FW^QM[H5'\=>FC)Z#KF >+_P"V_/\
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MG@#W4D 5/33-7 ZS<'FW_%?>L,/EU7K*!I_U_P ^]T'ICJI/IUG46%_Z\_\
M%/>P*"@Z;:H':,]9E7ZG3_K#_D?NP4MPZ;'^_'_+K,JFQN.1S_2U^3_O?MX
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MM<GI,SDL#U(06Y*G\6M_O7^/MT #AU3K(!?_ (+^![WU[A]O695M]0/^*?\
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M?">I2#CZ?D6_V']#[3]4\OSZS+_7W1SP'5#UG46^FH?X'_>[>V^M=9D!-O\
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MSZXV/]#_ +8^]]>ZXV'OU>MZF]>O$>_=;5J?9UZW'//^N/?NJ]<- Y/]>?\
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M1^(_;U9.(ZG0_I^EN?I_3VU+^'IT]31<6-^1^?\ >?\ ;>VNE,6 O4R'E?\
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M]U5VTBOGU*1?\.3_ +Q[T2 *GI-U(5!]2;C\>Z#AJ/33-7'EUG5-7UXM^/\
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M0UZ9).H*!CK.JGZBU@WT^O\ A_O7M\4H*<.F)/C/4A0;?X ?[V?^(][ZIUG
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MO*_FPO\ [%;'VG=B 3Y].)Y]3XEL!<?0?["]_:9WS7UZ>0:F'4I/H?\ 7/\
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MY)_XW[IK'3?B+Z'KUA_0?[8>]>)\NM>+_1Z][;Z:Z[M[O1:5KCK77+0?\/\
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M6EIC^*G4Z(#_ &Y%_P#??ZWMB3\/3X^$=3%X7T@CCG_?<V/MKI5#\*UZGQ@
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MC9+\K_MO^*>]AM/:PZ]UUH;^G^\CW1M/X1UKKC[KU[KWUX^E_P ^_=>ZQ,A
MO>_^V_XK[H>/7NN)4GG])^@)'T_WCVT6"$*!CI2K5 -.N!4K_B?]AS_P;GFW
MNRL&'5^N!!8W'(/NW7NL31WY/'^/_%?>P2.MAB.L3IIY'T^G/NX->KJU>N'O
M?5^N3+^+"W^!O_O9]ZU+Z]:J.N-OZ^]];!\P>L906-OK[]U[KS"W/^\^_4_9
MU;5Y_BZ[]UZ>Z][]U[KWOW7NNM0_K[]0]5UKZ]>U#^OOU#U[6OKUP_X)_L?^
M(^OOW5NNM!_VG_8W_P"1>[(VFN.O#KV@&YY'^!6W_$^_,Y:E>MU(SUCL/=>O
M:F]>O:&_I_O(_P"*^U76^N!C!-QP/Z#VT)".(ZK7KB8S^#_M_=]:^O6Z]=>,
M\_[Q].??M:^O7J]>$;?GC_;>_:U]>O5Z\J'5R.!?^G^PX]Z=J+4>?7CUS5 /
MKS_KCWIWI@<>O$]=@:1;Z\W%_P >]?VGRIU[CUS]MU-*>76NN'O=#2M,=/\
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MS!MA&'N:?\\MW_UHZEQ[!W1=?V\!Q;5_O^=B#\\_3<WME]JO"/AA_P"<T/\
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MAA_YSP?];>MGF+:OXKG_ +);O_K1UG78VX[CTX#_ -#39%^?_)BO[9.S7_\
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M]_?L[_Z_\^VCLNX_PP?]E%M_UMZ8/,&UYH]S_P!DMU_UHZS?W,SUQZ,+]/\
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M"F*\.G6#Z-_K^T9XG[>G!_:-]G^;J= .&/\ 6W^\7]L,VH_+I\DGCU-C_/\
ML/\ B?;3>72F$BA7IPBY&H_ZW_%?:=^('2DM3[>IJV_M7O\ [3_QOVGD\NG5
M\^IL=AI;^H/_ !/M-)Y=*(QI!<]3(P+V_'U_VUS_ ,3[8?AT\>IZ &YL/Q^/
M]8^V' ITXE:?+J9&M@+@6L/\?Q_P4>TL@ ((X]6/4Q$ T@@<W^G^!/UX]I7^
M+JRLR@@=2XOU_CZ?T_I[8=5QCK99B*'AU,0>H<#_ &W^W]M$"AQUH$UJ./3E
M&H'%A>Q_'M,X''SZ4]9UM<6 ^OUL/Z?\3[2R?$/LZHY(X#'4U   2!>_/ _P
M]II*5QQZLM2*'CU*55-@ +'_  _'^^'MLT\^KEB>I<8%SP/I_3VQ)33GK:U)
MZF*HL.!]/Z#_ &'^V]IWIIZ\Q(I3K*BCG@?T^@]LL!6G$=4J:U\^I:*!;A?Z
M_3_>_;#@#AQZN"2>I* (> /K_3_6_%_\/;9 (SUIO3J6H  X'^M8?0?7_>O;
M9XXZIUG51_9 M^;CC^G(_P!A[:DH/MZ\.I* 7M8?U^G^P]I6 !QUNM 3U,1?
MH+*./RO^M_O-_:9M->WIJ0\!Y=2HU')L/^2?]Z/MF2F/7IAB<=3% ^EOI_@+
M_4_ZWMHT\^J$^O68 %KV'^V]L]4-:=9T5;_0?U^G^P_XGVRVG\/2=G9N/#J0
MBKSP/J/Q_P 2/I[H0#Q'3;$CAPZSH@N. 3?ZV'^O[KI%=7398GCU(5>;V''^
M%_\ >OK[V%7[>FR3P/4Q% 7Z#DG\?[#WN@)IYKTVHHH!X]9T47-P../I_7\^
MW@%"U/2<LS<3UG51;Z#FQ^@_LGW957[>FR37K,@Y4V'^MQ_3^GNU!2E,=49@
M*!CU,5!P"!<G^@_Y%[HP4+2O25F/$YZD(GJ_!_-K?2Q_WKVVU :#IIFJ.'4I
M$' L."!>W^ ]UZ9+$_+J6J V%A_KV]^^9X=4ZSJHX%A^!>WO5!Q]>FW>E5 S
MUFL/Z#_D@^_  <.FM3?Q'K,$TWX'^^_PM[WU1F)/SZYA1P;#DV^GO?5:GUZS
MZ1]+"_\ K>_=)S*3P%.LZ(!].2?S_K^]?/IMF)RQZD1_G_8?\3[UTGZY #2!
M:_ _WKWXL5%1QZW4DU/7?O18#CQZ]0\>N2\D7_U_>C0K4]>X''60 #@>VJFE
M*XZ]UST-_3_>1_Q7W[K?7+0!R6M_OO\ 8^]=:K\NLGOU//SZWUPTCCG]/U_W
MOG^G/O?7NO66^J_'U_PO_K^ZZU]>O=<0H;Z$_P"Q][ZT2!QZZT-_3_>1_P 5
M][ZWUQ(M[HRJ%..O=<2+^[]>ZX:!<V-A_O7MIN^FGJX;R/7#VV:5-.'5NO>Z
MMPZ]UQMS?_"W^\^Z=;ZX%...3_O?OW7NNA[3-\3?;TIZ][KU[K"X' 'TL/\
MB?=U8JQ/7@?/K@Z:>#]/]L+#_>K>WE8,.K==>[=>ZP6'/X_IQ]>/^)]^Z]UB
M\8_J?]X_XI[OJ^75]?RZP^[=.==DW-_?NO=> )^@]^Z]UQ(N+>_=>!X$=<2#
M<#ZKP/\ 6_Q/]??NMB@.1CKWNO3_ %[W[KW7O?LC[>O=>]^Z]U[W[KW7O?NO
M=>]^Z]UPLG^^O[]0]5UKZ]=Z?^"_\D_\;]^ZMUP87"J#_4\_\B][4@'N&.O
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MA?Z?]&\^V7X=/GJ>%X(_-@/]Y_XU[8?RZ<CX'J9'^D#^G'M)(>[JQZFJ+$$
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M[[_>H?\ H'I,?ZQC&O;_ />9_P#H/J0&V.3;P[R_\ZL!_P#4(]VIL?\ !?\
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MXT@V_/T/^M^![>%:=PSUOK@W]2O^QO[V#Y@]>ZXE?Z?[;\CWOB<]>ZQ,M]/
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M\V%>FRC_ ,)ZSADN/4OU_P!4O_%??BR^9ZH58<5/4A2O&DC_  -Q;_?7]Z#
M"K,.DS#/PG_5^WJ2FF]RR_\ %?\ BOO6L5IJ'31#$4T'K,"A_M+S:_T_'/T]
M^J?4=-D-Y@]<[J;^H7/T'^/XY^GNI84*ZJGK84\2IIUF4?X<_C^M@/>N"_,]
M4ZD*NG_'W4FO$]5)!%!QZ[][/$_;U;KDH_ '^\_T!_V_NG3)))J>LX 'T'OW
M6NN_?NO=>]^Z]U[W[KW76H?U][H>JZU]>N_]@?\ ;'_BGOU#U[6OKU[WKJW7
MO>B 10]>ZZ(!^HO_ +W[UW#YCK?6,K^KC_6_XGZ>ZLP*_;U[K"RWX/!'T/\
M3W3JZM3[.L6FW-_T_P"\_P!K_8?7WOIWK'[]U[K)]?;)-37JG7 K<W/TM]/>
MNMU/&N>L3*?P&_VW_%/?C6F#GJZMY$]8_;'3@((J.O>_<,];Z][]U[K$P*F_
MX)]^ZV"0:CKOW3I_K@5!'IL#_OOZ>]FM<]:!KGK%[UUOKI@I_ O?Z\V_V _'
MM0C,>(QUL=8W6P/X OP/]5_OC[VK!AUOKG[MU[K'X_\ '_>/^-^_=>ZQE?\
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M?U/^M_Q(]L2<!Z=67CU,0W _PX]L]6;X3UG0<7_K_P 1[3=-]2U%R!_A]?\
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M^M!_Q$O_ /LCNO\ K3U)79F2M_Q<]F ?C_?^[,-_]MG?;#;3/Y7%I_V40?\
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M /V1W7_6GJ1_<_(#E<GM'_8[XVA_Q&9]M/M%SP^JLZ_\]-O_ -;>J_OVT/\
MQ#O_ /LCNO\ K5UF7:.0 '^Y/:)'/TWOM+^O_:Y]L':+CRNK/_LJM_\ K;TT
M=^LVXVE_3_GCNO\ K3U(3:.1/(R6TK"W_,;;3_P_KF![;.T7 R;JS_[*K;_K
M;TPV^V8RUG??]D=U_P!:>LZ[1R-[G);3/%K#>^TK_P"\YGZ^Z?NB;_E+M/\
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M_7'_ !/MCJWE^?4N(7X_I;_DXWO[H_EU4]2E_2/]C_O9]LN:#K76=/HO^O\
M\3[3/P_/K8ZEQC\_TX _V'_&_;#_  GKS&@)ZEI;T_TM^?\ 6_/M.U:=O25J
MTQU-3Z'_ %S_ ,1[9/$_;TUUF'T]LM\1ZJ>/4A5^BW_KS_O/MMS04Z3R&K4]
M.I49MQ_K ?[>WMD],OPZSJWT8?[[^H]ZZ;ZE)S<_FP_V''T][ZH>/4A+V_PO
M_L;\>]]47X5^SJ2@XO\ D_[[_>_?NDO4A?[('_!C_O7O1ZH_EU)7@$_U-O\
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M6^IO;^E_3:W]1[2/6N>/2L4H*<.IZ?0?['_>_:7I4OE7CU.B%E!_V/\ OO\
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M>H/7J4AYY!^EOQ<_[S_A[3OQ&.MT^?4V+BP'^/\ 2P_P_P /:>3R/5)!P/\
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MO[T:8KU[K(GZA_L?]Z/M+U7K(O\ :_X,??NO=<O?NO=?_].N&$F]S]3>UO\
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MI?8_Y#E[_O5I_P!M74M=OXKC_?[;8XM?_)-Y_C_R4?;+6-H/^6W:_P"\W/\
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M'7NN_>^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP!LQ_KR6/\
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MK?U]LM\_BZLO'J7&.3:U@!]?I;_7]M-P'6FZDCZC_7'^]^V^J=24_/\ L/\
MB?:<F@)ZMU+C_'/^^_I[3];ZEK]#_K_\0/;!XG[>D[_$>ID7T^OXX_WW^'M.
M_P 1Z8;B>I*_GVT_EU0]9U%AS^3[:8T%>FW) !!\^I,?U3_8>V.DS?">I(%N
M>>+\_P!+F_O739-37K.@N /]O_K7Y]['39/4Q?H/^#'_ *%/NQX#JHSGK.HY
M'Y'_ !-OZ>]</MZ3N^K[.I"_H/\ K_\ %/>NFV^$]9T^J_ZW_$>V'^(]-=2D
M_/\ L/\ B?=<>?2>3XSU)7](_P!]^??JBM*YZ9/'J9"?TV_/!_V _P"->_-\
M)^SIE^/Y=2D_4+_X_P"]'W7\/9U3[.LONW2>3XSU(3^S_P @_P#$>_=4ZEK]
M?I^?^BO^)]ZZ8ZS#ZK^/KQ_3CWL=-R>764?7WOIEOA/4GW[IL<1UDC^A_P!A
M_P 3[]UYOB/4I?[/^LW^]CWJF:]:ZR#Z>]'IEOB/69/I_L?^('OW5>N1^H_X
M,/>QU1^'Y]<P+"W^O_O?O8% !TUUW[WU[KOW8,1PZ]UG0\?4?X#\@#W3IIOB
M/7/W[JO7O?NO=>]^Z]UX?7W1_A/6CUU)^D?Z_P#Q!]IQU9./6#WOISKWOQIG
MTZ]U[W4^7KUOK$_'_(7U_P!A]/=>KQ_&.L+_ *3_ +#_ 'L>_?;THZQCVU+^
M'K1Z\WU^EO\ #GC@?[W[NGPCK8ZQ'4/[7]GG_??XGVQT]UC]^Z]UQ]L$UZWU
M[WH8SU[K')^H?ZW_ !7VH\NMCX#UC][Z=Z[/U/\ KG_>_?NO==>_=>Z][]U[
MKWOW7NN'I_7_ +Z_^M_7W[KW77NHI45X=*.O>_'&.O=>]ZZ]UC(Y'^L#_O/N
MZ?&.M+P'6/W3K?7'VKZMUV?J>;_3G^OT]^Z]UBMP;\Z?H3_K7M_L/?NO=9/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UX&^JPTVM_0DVM<'\>
MZMIIW<.O=>]VZ]UF!# V6UK6_%_^1>V&71]G5&6O7+7_ +4/]X_Y)_U_=?\
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M7J\?QCK$_P"./S]?^(]U;X6^SI1UB][Z]US;]3?ZY]M!M*#UZV/A/6%OT_\
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M@\*?D/\ )_.M>J$"E?\ +_/B:#Y'K.GT_P!Y_P!['_$>ZXK\^J=9!]?]@?\
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M *'_ -]_L/I[]U[KC<W_ -JO]?\ >+6^GOW7OEY=>O;CZZ6O_MO?NO=<V:W
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M?,\.L7O?3O71_%_Z\7_K_A_C[]U[KOW[KW7O?NO=>]^Z]U[W[KW6'G5S]?\
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ME]J^K==,QXX8D&X^I_P_I^/>@ !0=>ZX$@C4W^/Y][Z]US]^Z]U[W[KW6(D
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M<7_XI[8?XCU[J6@-O^#6M[3O\1ZN104ZE1C]/^ O_M_^1^V9/+IF7\/4J/\
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MO>_=>Z][]U[K@S$$ #GW[K8!)H.L7NRBIIUKK)[;))-3THZ][UU[KAK7^O\
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M(O<?X7(]\^VX#TZ[OQO3)X=.T0.D?U/#7_K?_C?M.YJ>C!6K]O3M%^D?Z_\
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M][%!U1_A/63W>HI7RZ9ZD(US;^GX^HX_I[]7%/+IMQ0UZDJ0>;6]VUMZ],,
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M_7_8?\2?=>G.L?/ZO\?]Y^OM7U;KS%1] 2/];_?7]MTD_B'^K\NM9ZX<,/\
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M?D7]I,4->'2I#@UX].Z?V2!Q_O XM:_M,YX#I5$1I^?3M$%*+?\  M:_^O\
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MO5Z]I/OVL=>KURL?S[K4#X1GK5?3KOW7K77O?NO==>]5/H>O==^]]>ZZ]U+
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MJ8G_ (C_ &_'M[POZ76Z=8W8K8#^T+\'_?7]V1-/V]>ZQDW;5^!]3_CS^/\
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M@ZLCZ?LZE1W+6'Y^O^P_XW[;Z4=3E^BZK_X_U_P]HI1GMX=:ZDK>ZV^O^/\
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MUS]UZWU[W[KW7O?NO=90][W'T]0_V'OU.F]'SZS>]=-]>]^Z]UC4A0 >"/\
MBOOW5F^(]<M:_P!?]X/_ !3W[JO7 N#Z1R3Q?\<^Z?#_ *8]6H: ^77BX6UO
M^)XM]/;77@">'6#WOI_KWOW7NO>_=4 #"IX]=?4?X>_=6  X==^_=;Z][\#Y
M@]>Z][]U[KWOW7NN#,00 .??NM@$F@ZQ>_=:Z[]NGM7MZUUS]I^E/7#ZJ!^3
M]/\ 8&_O9X]53X1UB]ZZMUR:][_ZGG_;D?\ %?;W_"_Y_P ^M_+J.6%C:_\
ML>1_P4_[#V[UOK)[]U[KWO8^?7NL!/\ 3@?D?C_8#CWX<1U[KC_Q'O77NL7D
M/]![OI^?3F@>O6/W;J_7O?NO==\7X_WFW^\_CW[KW71//^)]^Z]UT3:W%[^]
M]> )-!UCN2;G@#WI@1@\>KA2IJ1CKE[KT[U[W[KW7O?NO=>]^Z]UPXM<^[JI
M8G..J*H85/'KLD_BU_\ '_??7W;POZ73E.NO;O6^O>_=>ZX,VG_DK_>+ G_;
MD^_=>X]8R;WO^?==(U:O/KPP:]=?7WO"CT'6NH_W=-_RLP_Y_P"W_P XG^?_
M ../_+3_  ^OOWA'^$\*_E_FZ=\*7_?)^&O \/7[/GU__]6O01W%^?ZV_P!:
MU_\ >_?/1\4'EUVLAES1NI42\!KV'Y_V'%O]C[2M\1Z-X7##IQ@M=?KQ]?\
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M_I[0R?+AUKK*+7Y^GMDUH:<>M]2HP2W'^'^]_7_8>V6I4TX=;ZG+^A?]=O\
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MWY=3A?\ %_\ 8?\ &O;'5.I"_5?Z?C_>Q;VW)Y=;'4N/Z+_K_P#$^T?5NI2
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MJ]9??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP9B" !S[]UL
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M$_;TL5@PJ.I<8'%K?6_^]>TA^?3J\.IL'#W_ -]S?VR_PGIQ31@>G"/](/\
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MQO[KU[K)_:'^M_Q7WORZH?C'7+WKJ_7('@<W_P!CS[L.F"*<.'7._''TO?\
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MC^O'X_U[_P"'M#*-1/1U;2=9HUTF_P"?KQ<<?GGV6RK0U\NC:-ZZ?3J;&/\
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MD>W=(U:O/K3\.I:_I'^^_/OS_">F3Q7[?\AZRQ_J'_!A_O3>V>O1_ .I$?\
M:_V'_$^[KP;I-UG3ZCFW/T_K_P 1[HW^EZJWPGK+[]U;KDIX7_"UO=>F.LWY
M/^P]TDX+TP_Q'K.#< ^VNJ=<T_(_V/O?5"*=9E9@>/\ ;>ZZ%].JTZS+QI%^
M+C_D?]/=^M]2P;W_ ,#P1_OOJ/:/I-UD4V(_QX_V_OW7NN:M<6_('OW7NN?O
MW7NNN;W'U][!ZHRUR.N:DVO_ %O_ +#WOIKKFWX]T3SZJ.O<J?\ ?<^[]6ZR
MAP3;_;>VZ'TZ9(IUS]ZZUUD\G^'^\_\ &O?NO=9/?NO=<0S 7/"_ZGF_^Q''
MO6E?X1U[KD)"?1]/\3Q^?=="^G6J==A@>!;_ &!/_%3[\Z:OMZ]U[4+M^1_6
M_P#3^OOVGLT]>\NN8*M^G@_@_4?X_D^Z_P!G\Z]>X==!@.2Q/^'-O]YM[=ZW
MU[6/K<6_Y-_VWMCPV]1UJG7F< WN#_@1_O7NWA?TNO4ZQEW%]/%_]=O^B?=M
M"^G7J=>O)_4?[=O=^M]<201J;_'\^_=>ZY^_=>ZQ$E38< >_=>ZXD_2U_H![
M]U[KB3^3^3_O?O=#Z=>&33KHD@<<GWL"O5E6OV=<-;?2P_WW^Q]V%/+K=-/=
M7K%[WTYU[W[KW7O?NO==DDFY-_?@*8'6NNO?NM]<"2&X_H+_ .]^_=> )-!U
MQ.H_7_;>_5'5M#>G7+W7I[KWOW7NO>_=>Z][]U[KJX]VT-Z=>IUP^@_K_MA_
MQ3VHZV %%!UW[]UOKWOW7NN+.1P/=="^G6J=8B2?K[MUOKKWHD 5/6NN_IS[
MIJ9NVE#U[HO_ '3WM@NK<<])3M%D]TU4+&BQ:.#X=0*BHK+7\42$WY^OT^OL
M?<E<AW_-5P97K%M*'OD(X_T4]3_(=+1%%!&MQ>? ?A3\3_/Y+ZGSX#JK'<NZ
ML[O+,U>>W!72UV0JF))9F\4$>JZP4\9],<,9^@ Y^IN?>5FV;38;)90[?MUN
M([=!^9/F6/F3YGHOFN9;J0R2-P% !@*/( >G30K:>/P>?:HU\^/5""O<OP]9
MQ(H^EO\ DK_?#WKJX=3Y]<O(O^/T^MN/]O>UO?NO,X7CQZZ\M[D6M_C[]UXR
M!>!J>NC+8\?CGG_>N3[]TT9">&.L35%OH1_C;T_T_J>/=Q&W6M3:=-<=8_,/
MZC^GU_Z2^OO?AMZCK6H_Q_SZ_]0KKP%1P. .#^/I^?K;CWA7,AIUU(MILTZC
M^'B]N+_IMS_L?9;(FH='MO)D$]<#%_9L3;Z?ZUOI_6X]DT\>D]']O+Y5Z[6(
M _0<_P!"?Z_[Q[*Y5I_INCV"3X6'P]9C&;_T^O((_P!B?9<ZD@$>71S Y';U
MS1?]8M_K_C_&W^M[0R#AZ=&D,F?ETX0#^HY_K_O:_0_CV62K_+HV@?R'3A&M
MF'I_XC_>.>/;!-1CHSA?'RZ<8K"_!_'']!_L/:>3B/LZ,XG XYZGQ<&QX.K_
M 'O@?T]HF^$_9TO4\#U/2_\ 3^G_ !)/^O;VGZ<1C@USTYP#BWY O_M@ /\
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MP'U_VWOW7NL9.K_ #WXFG5E75]G7+W7I[KWOW7NO>_=>Z][]U[KWOW7NN/\
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MMO\ C?M(_#KP;23IX=38_P"S_L?^)]II/P]6.C2-/'J5']3_ *W_ !(]LO\
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MZ]UBUFUC>_\ 7_#_ (K[KY=E.O?9UP]VZ]U[WIOA;[.M==,R*NMB$5;EBQL
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MB95'-N/Z_P#(@?>NM&8D4IGKB9QS;@_U_P"(^GOW53*=(&K/7 S?3G_>;?\
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M.YQD1^H7R+>K<%\L]$'#,[/)(Y>1V9W=W+L[O=G=W:[,[,;DGDGW/E ,8"C
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M716"35CI/34IO]#JO>UN/Z?B_P"1[+91P(X=']K)E?0]-S0V+7'X_P /]?\
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MZT3U!R&1HL525&0R%3%24=+%)+/42R+'&B(I9BS,P'T'MZWMY;F:."",O,Q
M"@5))\@.GHXGF?PHEJY_E\R?(#S)ZJS^0_RBK-Z3U>T-C54M'MF-GIZ_*P.T
M51E2+J\5,XLRT9-P7'+C@<<G*+V^]L8MF2#>-^0/NE*I&<K%\SZO_@^WHNO]
MVBMQ)9[;)JD-0\H\_58_1?5N)\L=$S0@7O\ 3@_[S;_>_<S]$$8H,]90PYMS
M<?[[_8\>Z,NK[>K_ #'63S7X6]O]58CFWNN@TK7NZ]J(%=77/R@"UF_V-O\
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M^ ZVIJP)ZD)]?]]_0^V'^$]7?RZF):W^/Y_XCVR>)^WJG60>VG-33JIZDIP
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M'_$^W.W3_1Z3]91]5_UQ[HWP#KQX'K-[IUOKE[KTQUX&XO[]U[K-_9_K]/\
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MT@BYL"/]>_\ Q6WM8_PGI(#4]<_H/K]3R/\ 6^G^]^V_Q_GU;KEK.GZ_VO\
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M3I' .H_[=?8#WS;:ACIST/>6]V:&5 3CJHGL+:,N/K)TDB*LC."/3?2#]/\
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M+47Y=9Q"+@?0&X^GU^O]#[J7-*D]5#5J:=9A"H4'_ ']-_\ >O;>HZJ4ZT9
M#0=9(XP3Q<D'D'C_ %K?3WIF:O3;,2>L@7\$'_8<_P"M]+>]T?UZUGK(%_5K
M ']D?XG_ &_X'O6GS4]>^=>N20D#4/K<?4G_  !(/Y]W-//K?4A:9FY(Y/\
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M?7KI4%VO]#^;7_V_/Y]E+>71K&Y(J./792_]. +?3Z&UKDVY!]HI!2HZ,X)
M>WKFOZ3P#_47/^^O[+)H\TKT91D4 '$=94 ^A4DV_KQPJ^RZ04/2I"3Y=9D
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M#C@?U)_XG_>?99)AC4]+ :=25N0/SQ^/:5A0TZ=ZS*. /Z_\3[:/$];ZD*+
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M95A@B+2,: #)/3\,+3&BX XD\!U6=\B?D_4Y"6LVILJITKJ>GKLC$04B_#)
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MC10+ 6']/\;7]FL=O&G!>DK NN?BZE:@O"CC_;?\1[?  X=;(!XCKC<_U/\
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M#[8<56OIU:M17KE_3G_8_P#$\>TKD@8Z]UDCU'C_ %@/]Z_UO;)^?6CI\^I
M'J8_Z_\ C8W_ !_C;WL,2-'377:K_C;\V/U_LC_>/;VI5 'EUOKFGZA_L?\
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MKWOW7NN+HKJ5(N#_ %_WCW4BO7NBX=P[#AR^/J76$-K0_B]FL;_0?X>P?O\
MMBRQO1:CH8\M[N]I.O=U3OVKLF;#Y"I0Q%0K.5.FVI=1'/T)M?W!6]V+0RR
M+PZROY1WI;F&/]3CT7*MIC<\7TWNI'/''U_VWL&W"5ZEFRE_9TFZF 7/]6!7
M@<_CZ?[?V1SH:="*VDRIZ:'C()_H1>_]/IQ_3\>R"[C^+H06TE6Z@R1@%AS8
MWM_L/\/ZBWLFF6M"./1Y ^DK\^HDB<7_ #;_ !/T_I_KGV27$8K0]'\#:@#Y
M]82I/U']!_MQ_P 4'LAG72?GT:PMK"UZQ.OJO_9N!]2;?3Z_[#V7RBJUZ,HV
MICKNQ/*FWY']/S?\?7V62J >EL+ ZO7KB!?CBYY(-_ZW_P!O;V@=:T]>C6$Y
MIU(0?7_8?\3[0RKFO2U#4=92O(/Y4GC_ %_]A[*I/+I5$^K!X]>MS?\ /M&X
M^(#I=$:J1UE YO?Z7'^VX_WKVE(I4'I0GGUS*_0\<?\ $^Z?Q=>5B6ZY*+\>
MTKMJ->K5\^LJKIN?Z^TS<3]O52010<>LJ$6L1P /][_XW[KU5A0U\NLX-[C^
MT"#_ +?_ 'CW;MU?T>J]</:GJ@_M&^S_ #=2/>OMX].]>%[?G\7_ .-^]]4D
M^ ]>]^Z3=<U^J_ZQ_P![;W[KW64>[IQZ\>LH8Z"3S8_\4_XK[H10TZK^+\NN
M?OW5NO>_=>ZY>Z],=<03]#]?^(_K[]UNAI7RZY>_=:ZR1_G_ &'_ !/OW7NN
MV_'OR:<Z>FY/+KDA^O\ K@?[P3[OTWUE46_V'^M_4_XG^OM)U7KE[]U[KWOW
M7NN80#ZF_P#O'NW'CU2I]>N7_$_[[G_;>_=:Z[]^Z]U[W[KW7+_'^U?_ 'G_
M %M-K^_=>ZYK)_JO]X]ZZH4].N6N_P!!_O7^]7!]^IUK1\^N/D'^/^\?\5]^
MZMI7TZY^]]6ZQZ&_VG_;#_BGO75=2^O66P]^Z;U-Z]=^]=:Z[L3]!?W[KW79
M%C9O]X_XW[T&!X'K77+@'TCFWT/^\_F]_?B 10CKW2$WMOO"[*Q5179*KAC\
M,;/9G0 $7_!*EC?_ &_L[V38;_?+N.UL(2SDY-,#[>GR8;>%KN]D$=JN<^?V
M=5.=S=XYWLBOJ*.BGGH\!&[!51V22K (_5:Q$3?T^I]Y;\F<B;?RM;1RR1B3
M<B,L<T^SJ*.9N;9MV9K2SK'MPQ0<6^9^7RZ **D+$!1R?]3]?]Z/L?D^9/0/
M0'4*=.,5(H(N?]A;\\_\5]T)/5P=#%0<=.4=(+ZD6Y(X^O'^"@?3D>Z$DXZO
MJQ6N.G&*A)TDW4_ZPM_06%O=20.)ZUBOE7IPCH0H'&KGZ$#ZD^ZZQ\^JZU'#
MJ5'2V)X%OQI_WG_6T^_?\T_]7[>O$L?CX=2TI6?BQ_-OZ_[S?W?2 VKSZ:8Y
MU'J9'0'\B]S^G_7O_MF]VKTV9%'3A#1:0 $Y_P ?^*"U[>]=,/,3A>'4Y:)B
M.1P/I:PM_7^MO>P">DSS4'<:CJ?%0 @<$GG_ &W^Q_Q]V /ITGDF X-GITAQ
MQ/ %CS< $$_U^ONP4#CTE><,V./3K#C#<>@?UM?Z#_7O;WL<0!PZ3O*RBH';
MT[0XP$@A5M]>?Q_0GZ<>W!$QZ2F>@J^1T[PXP?33_0?[V+_0_3V\L-.D\MQP
M"TZ>H,0SV"H0 QN +WX_3R/;RH*87I(UR:X/3[38.UBVH_2ZVMS_ %]N!&XC
M'222?XJMTHZ7!EM(2.P)_(_/^O;3[<6.G')Z1/<C^/I3T6W'8 :"UC^;\FPY
MY^GMX(2:#I')=FE"U.EECMHS2%0(6=@?[*7)XX''/NZQU^71=+?*O%L="YMO
MJ3,Y5U6GH9B2 0?$;7X)XL3JTGVLCM'<T6/HAO=]MK<5>85^WHTVQ/BSF,F8
M6J:*0*2I),9 _P!86^O'L\M-@N)S4J=/0%W3GJU@#".05^WH[6P/B50TBT\E
M52*2-)8%%%B/]5J!+6_P]BZPY4 ^->HRW;G^:4L(Y#^WHWNU.B\'B$CTT4*Z
M0MP44_3\V _!]C"SY?@A5 (QT KWF&\NV8F0TZ&K';4QF/15CIXAIM]5 ''Y
ML./9]#M\<8^$=$DD\DC4<D]*&..&$:40*./H%M_C]..?:]8D7@.J]9-9_H/]
MY_XK[OU[KA[WU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__4W8?:;HQZ
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFS*4$=?2R0NH.M2
M#<7_ !P?]A;VFN81-&R^?3L,AB=7'5=GR#ZP,T535PP>M-1N$N2 #R?\+>XF
MYHVC#.%ZFWD?F Q21QO)V]5<;IPSX^JD5E(56((('!%P1_9_LCW#5];F)V!Z
MRGV3<%NH(Z-D#H.:N#DBQO\ 6Y!'^%[?T'L/W$>*Z>AI:R@JM.F&:&US:US<
M_C]/^/TY]D5RA.!T(;1SV@\>F^6.Q(_PO_L#]?I[(+A*#H]@>J]0VCL.>..?
MS>_'LEG0]'MM)33Z]1=!Y/\ L+_U O;CGV1W46>CB"0:OEUA8"]C>W//UYM_
MMR>/9/(E!4<.C2)\**9ZXA2+7O<?[&X_IQ^?9=,*-7I=&^DUZ\$Y_!U6-_\
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M419C=+6M8@<<<7O[H6\QU= -6>/3G%0+INR@VMR0#_C]0+?GVV7:NE>/5RP
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ML#+_ + WY)'/TX]D<JA33HXC>OPGK$5_#< _UO\ Z_LND0G'GT8(?3KR"_\
M7CCZ#^U^/99,@)IT8Q-3KMD'##^S]?\ C?LN(TZT/1FDA(ZR* .?ZVX_I^1S
M_K>T$R'R]>E,9J.N?IO?\7^GYM[+ID/IGI9"U 1YCK(RK?Z$W_ M;VC(J".E
M438HWP]=Z/\ '_>/^-^TQ!!H>E/7(&XO_7_D7_$>Z,.M@$\.N[6-C[32A@"P
M/7NLBC\WM;_8?[S^/:3K77?T_P /];C_ *'_ .(]V5M)K3KW66W*G_6_Z&/N
M\;<%IUNO67V]UOKP^GT_'^V^G]/?NF9?P]<U/]D_VK_\4_XCW[IGK)^../\
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQR1K+&R,
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MY_K_ $_'U]E4H'1O$PH#3KAITGZ_JM_3^O'T_K[+9T-:]+8']>O6L2/ZF_\
ML?S[*YE_%T:PL ,]=(+7OS]+:OH;_G_;>TCBH^SI?&PX>?63_4?[#_B/9=.M
M1JZ4(P5@?(]9?Q[+90:GI8AK4]>%P/I] ;?U_P!]Q[2'I0A/#RZ[ M^2?]?W
M0\.G.N2_J'^Q_P!Z/MMA44ZWUE]LD4-.M]=VN18^G^H'&K^GTO\ I]I.&.J]
M>/\ 3V['YN3UL>O7./\ /^P_XGV]UOK):]O\3;W[IF7\/7:FQO[]U23XSUE!
MN+_[Q[T305ZT00:'KE[WU7K*O"$_X_\ %![UY]5/QCKG[WU;KWOW7NN(#'])
M 'X'U/\ C^#[UTV"!P'64?XV'^^_UC[UU3K* %_'^Q_WW/NK-I^WK1( J>N7
M^P'^OS_O5_;;_$>F7^(]>Y_XG^U_R7[KU3KD' -C_L#^+?CW?0]/EUNAZR>Z
M=:Z][]U[KWOW7NO>_=>ZY <7^O\ A[W2O52?(=<P+"WO?5>N_?NO=<E75^;>
M_=:)H*]9[!;#\_@7]MZJY_!U3X_D!UT&U7_U_K>]_P ^[]>TZ>ZO7,*2;?G_
M &''_(O>B:9/5.N8CN/]3_A;C_>_=6<+QX]:Z]I ^I''U'^^(]V!J*]>ZZU_
MX#CZ<?\ &^/?J5X];ZP5-3%30--42*B*-7)5;\?XV]VCC:1T2-27..G(XV=M
M*_\ %=%'[F[\I<#%/B<+(M1DI R1QQ/?06!7R2D$%5%O]C[FWD3VRDOV3<-W
M4K;BA /G_J_9T'=_YIM-EC:VM*27Y%/L_P W5?&7K,GN#(2Y',53U55*Q8EF
M+K&A/^;B4DA5%O\ 8^\E;2UMK&".VM8@D*B@ ZA^YNKF^GDN+J0M*Q_U4ZQ0
MT>FP5+7M<\WOQ_7_ !]J.FNG2.B;@%0RAOK_ $:U^>/J/=:<2./7@16O'ISA
MH&X_!YM_7_;_ .M[]CCU4R4P.G**@MI])_/'U'/^P]^^73+2BE<=.4= ?3Z1
M8VT_UX_P^A][Z8>?S!Z<HJ#Z7C-^/Q:_^%C_ *WOU.F))Z?$>I\="QMZ?\/I
M]+?ZW^'NX7UZ2O,2<8Z<X\<W]I?]8'^OY^GUM[MTF:11Q;IW@QC76Z@<#_7_
M ,+"W^'NX0GCTF>8#SJ>G>#%6LVGD6%R+<_\4X]NI&/SZ22W(\VZ>J?$D\Z;
M7^O%N.+<G_6]NA#YXZ1M<XP,]/=/AQ=?2;\&P'^P_''MY(ZY QTC>X/FW2AI
ML&QL EOK].3^1_3V\L2](I+I5P.E31;;D=@?%Z;<W!O_ +'TV_'MY4K@=(I+
MLTX=+7&;/FF**E.[DD6LAY!/^ ]OK#7SQT737X742U!T,FV.G,WE9$$5!+8A
M;?MM;Z_F_/T/M;#8R286//0=ON8[2V%6F%>C7;#^*.4KVB>KI&"MI-G1A_L>
M1^?\?9]9\NW$Q4LIZ &[>X$$.I8F%>CK;#^*.,H1&\]&CD!1=HU_WJUP![&%
MARLJZ3(.HQW7GVYN"RI(>C8[9Z9PF(2*U' NBW^ZU/Z;7_']/]?V+;78X(AB
M(= :\WR[NBQ,AT]"[0;;QM @6.%!;_:5 _VP M[.XK*-!\-.BAY7=JL6)Z>U
MCAB%D5;#Z 6_UN /:M8U7@.J]VKCV]=ER?IQ_OO]:_MSJW7'W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U_]?=A]INC'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NF3.XN+)T4L+J"2C$7' -C;_;^T5Y;K/$P/&G2FUG:
M&9&'KU65\A>K#>JJZ:GMH\A-E/T.HVMP2#[A;FK9<R2JN>LA>0>9C&\:/)BH
MZK6SF*>AJ)8V4@:F(!N+<C4/K]>/<,WUN8F84S7K*K9[U;F&-@>DA/%8G^HX
M])_/_&C[(+F/4*]"^"2JK\O]0Z99X;&]N/\ 7XU?CZ?[XCV03I0MZ]'=M+6@
M\NFJ2,GZ?@@'_7^GLFGCZ.H&XCRZCF,$%?R#_O?(_P +GV1W,=<GHY@>N?/K
M$R@$'^GIX_)YYX]DDBZ3IZ-H7X$]872Y(L?IQ^/]XOQ;V6S+Y=&4;4/6-E](
M!O>W'.K_  M_3V62H*?+HTA?/SZY:+_[#]7^M^/]Z]ES&A_H]+86';3KLJ/]
M?_;?TM_A[2.H89Z7*=0Z[%OQ^+ 'V62)7[.ED;@BH'7, $D_0_7C_>?P?9>P
M ITZC\,YZ["GD?[8_P!?\/=".GU;R)Z\%)^G^\^VJ8KTYUD7](_V/^]^VG6N
M?+K?7<=QP00/K?CZ_P!+?3VFE&0?+KQZDD@CWM596^77NNO;O6^N@;B_OW6B
M PH>N_?NM]<U_P /U<_\%^O^'O720TJ:<.LOOPKY\>M=<P;FUV/^M_R,^_-6
MFDJ.M-\)ZR^]];Z][]U[KL$#^@_/X'^Q]T[M7]'ID@CB.N0('U%_>R*BG6NN
M0:WXN?ZD^]:16M,]>ZY<D:C;_C7OS?">JE-1!\NN7T-_][]TD\NM,A;(.>NO
MR>/Z<\\>[E>RB]4?XCUD&JW-]7^PM;_>O^)]MMIQIZ;ZR"_Y^O\ A[IU[KWO
MW7NNC[V.JMY=9_>^J]=?3@>_=>ZY<?U/^V'_ !7W[KW78O\ 3\?\3;CG_7'O
MW7NN:H>2W_$'_>[^]=49O(<>L@4#Z#W[JFIO7KP:QNHN1P1]/\/S[]]O5O\
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M&U$<'\7_ .)_UO91/%T>0/3[1U@*'2"OT!'/Y_U_K[(;F/XNCB%QVD]8B >
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M4I:PT(+&P^E@+7]BZTV*"(+2,= :[WZ\NM3,YH?F>A:H=MXVB51'"BD6LP5
M./Z+8@?7V=QV4<>GM%.B=I9)0=3$=/J)%$ J( /]I M_O'T]JQ&B\!UI:@9.
M>N1<_CC_ &WMSKW7#W[K?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]/=A]INC'KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7N@M[!VE#F\?./&&+(P(L"2""+@6O<>PUO>V)<PL2N>A)L.ZR6-Q&0
MU!7JHCO;JZ;$UM550T[>,LS'2AL!<G5Q_O/O'3FG9&@DD8)V]9A^WG-:7,<,
M;OW=$YJJ9HF9'!5E/Y'UMJ ^OU''N+[F,]P/60=K,'167(/31-#>]@ 6%B?R
M0/T\^R*9*'H]MI/+IEF0@DZ>/QZ?P#_OO]?V37$=-0Z/(7JO 'J.PL?]Z]DM
MS'J#$]&T+Z3UB=2I]-K'@CZ_[S^.?9*RFM#QZ-4<C[>L95K7X*D?0CZ?Z_\
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MOS;\_3_'_#_#V72H?/I9&P(IUT8R.1S_ +#_ (GVBE3TZ4*WD>L317]0^O\
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M+/\ ,C/6/_-OO_8V@FCM9EJ/F.C7;.^,]-"L9FI@  I/H _%_P"GX_V/N?\
M8/:N"W6(RQC[*=8N\U^^FXW\DB0W)H:^?1DMN=)8/&+$?M8E9;79D4D'Z^JP
MO;_7M[E?;^4K*R5 L(_9U!NZ<X[IN3LTERU#\^A<QNT\70(JI3QC3;Z+;Z?3
M\7X/^/L40[9%&,* >@Q)=32M5RW2@C@@@&E$ '^T@6_UO:]8(U%*=4ZS%_P
M+?[;_>C[?ZJ%"\!UP)N;^_=6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z__U-V'VFZ,>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KBRAA8_3W[KW3%D\+35T962)#<<MP2 ?\ 'ZG@^T%U
M917(8,HKT86M_-;.I20\>B[[]Z=Q^8BF+4<;!@WK"@\G@$J1>X]QQO\ R=;W
M2OIB%?LZE?E;W!O-M>/_ !@BGSZ(;V+\<IH'GFH:?CU'0JD@"Q_%C_3W _,7
MMY)&Q>&,T^SK*?D[WBBE6.*ZF!/K7HIF>ZVS&)ED#4\BA2WZD8C@GGZ7'(_/
MN)=RY=O+5BK0D=3_ +1SAM^X(I6537I!3XFLIS9X3P2;V/\ K6M_A["UQ9R)
MJJG0PAOH),B0=0S$P)!4J?IZAS?_ *6]E$D!7++GHPCG!!.JO7 Q@\VM_7G_
M (I[2-"O \>E:2@X;KVBW]D_X?4GC^GY]I'MJ"E>G0X]>NB@;\ F_P!.;_XF
MW]?:22 C'3@<$5Z\$YX O_K\?[W;VD> G%>GA*WGUV(/I8&UN;&YX^E_:;Z=
MO)CU?Q?Z/6=:5OP#QS<@?[W?VT8&\CU[QDZS)1.W&@_ZUQ_Q!]U^F9OPCKQN
M5' ]3(<9/(0$B=F)XTJ6/^L+ \^[IM\TAI%"6?Y#IF2^B05:10/F>E=B.O=P
MY9T6"AF&HBS,A^EOZ 7^@]GUCR3NU\:B'0I\SQ_9T'=QYQV7;T8S72U'H>AT
MVI\<,SDWC>LCF*,1==#(+7_I;4>/<D;%[/37!#3PM(?GP_9U$O,7OEM.W)(M
MO(NH?.O1L=D_%ZAIO"\M(I*D?5%_%[7NI-S;\$>YWY=]G8X@FJV 'R '6-_-
MGW@[JX,B175!]O1I=M=)8?&I'_DD2E0OU51^G\D:;W'^/N:-E]NK"R5:PC4/
MEUCOO_NANNZ/)^LQ!^?0P8W:&+H%0)3IZ;?0 #_B?<@6NRVULM$C ZCRZW2^
MO'9II6-?GTI4@IX0 D:V L+*O_$ >S9((TX+T@H2*-3K)J_U("_[[_6]N@ <
M.K==$D_7WOKW77OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[K_U=V'VFZ,>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZCRTZ2 W'U_'X/^^/NCHKBC<.KI
M(T9J.DAE]IT5>CAXEY!%](YN/R?]A[);W:(+D?V8->CRPWNXM64K(01\^@(W
M7TQC,@LA-(AUJ;D*H)O]>0 ;<>X_W?DFVNM0\$5^P=2CL/N/?61C_P 8;'S/
M18]U_&Z"0NU-!H(O;2"!^2"; \B_N*]X]M(V+>''0=3AL'O/,@0335'0!9WX
M^Y.F+^.GU@ZFOH)/TNOT46O[CG</;JZ0L$C)'4N;5[NV$RKXDU#T'%;TWF("
MP-!)P?597XT_0_I'L(W7)%^AQ#CH<VGN-MDN1="O2=FZORT9_P" ,W' ]!L3
M_KV_/LGDY2OUX0'H\BYWVY_^)2]0CUUE@3_D4US^=#"X_P!X]I&Y6O2*?2MT
MK7G*P _W*2GV]98NM\S(>,?+8CZE"/;9Y2W!N%N:_EU=N=ML44>\7IVINI\]
M,UOM2BFYN5_P_P!;\>W4Y&W"3C$!TBF]P=HB%?J*_MZ5V.Z-S-44#JPO:Y2-
MB>?\=)O[-;;VUN9AWU_(=!^]]V]IMQVR#]O0I[>^-=34LC34\\A)!.I&MS;Z
MCV+]L]I=;*3;EOMZ .\>^MM &\&50?ET8':WQFHT\;24<8)M^I;F]N> MS;_
M %_<F;/[2JNDM;@?D.H;W_WYN9!(([HY^9Z,9MGHW%8\1N:.*Z@$^G3_ &0+
M_I!'N3]I]M;&V"ZH17[!U"F^>[&Z7[$+<,17U/0R8O9&*QZ@+31 K^5 ^G^P
MN?Q[D&RY;LK0+IA _+J-;_F/<KTL9+AJ?:>E9#1TU. $11;_ %N/]MSQ[/H[
M6*(T10/RZ(W=Y,R,2/F>L^O_  _WG_C7M0 !PZWUUK;^O^\#_BGO?7NN/OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[K_UMV'VFZ,>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH@'@\CW[KW6"2F206X_/
MU(M8C_6Y]MM&C<1U97=.#GIEJ\#2U%[IR?ZFX/\ MA_7VAEVZ*0?".E\6YS1
M$48])2MV-25&KT(?U?51?^@ /!_P]DUQR]!)_H?=T>6O,]S#II*:=)&MZLHY
MBY\"_P!?TJ+\?FUS[)9^4('X)_J_9T(+?GNZB_T8UZ3L_35))?\ :'%_H ?\
M3]5'ZO95)R/;D_V8_ET<Q^Y%XGXS^T]-YZ0HF8_L_D?V+?[VOM*_($#&A0=*
ME]T+U1B;_5^WJ;#T=C0PO &_VY^GYX-S[=3V]M5XQCI/+[HWS<)C_/I04G3>
M'CT@TD7]0'6YO^?S[,8.0[):5A'1+<^Y&XR+03'_ %?GTM,?UKB:8*130BP^
MGBM_O-OR/9W;<IV47^@CH/77.6YW&NLS4^T]*RCVMC:0>F!.+$64&QX_ M^/
M9W!LMK#D1BGV=$$^[W]QEYC4_,]/D5+30<1QHI']!_L?Z'\>U\=M"GPJ.D#O
M))EF)_/K/K X4"W^''_$>WQI\NM_;UQN?ZG_ &Y]VZ]UU[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z_]?=A]INC'KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z]P?J+@_P"-O]Y]^ZT0"*'AU[3'_J/^3F]^ZWUWHA_U-O\ 8M_Q!]ZH/3K1
MU4[>/712(\:/]O<_[Q?WZ@].M]<_0/HJ_P"VM_T3[WU[KP8#Z*!_K<?\1[]U
M[KHN3_A_K>_=>ZZN?ZG_ &Y]^Z]UU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z__0W8?:;HQZ][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__T=V'VFZ,>O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z__]+=A]INC'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO__3W8?:;HQZ][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__U-V'VFZ,
M>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z__]7=A]INC'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__6W8?:;HQZ][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__U]V'
MVFZ,>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z__]#=A]INC'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
>7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g382677f_167.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_167.jpg
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MQ #"   " P$  P              !@,("0<$!0H! 0$  P$! 0$
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MS)15!3XJ "(D4 !X#[!^'(J(4]#=O-,SUZ/<VV5-!!6P P P!BK?:)7TW/\
MAZN1=92>[>:9GKT>YMLJ:""M@!@!@#%6^T2OIN?\/5R+K*3W;S3,]>CW-ME3
M005L , , 8JWVB5]-S_AZN1=92>[>:9GKT>YMLJ:""M@!@!@#%6^T2OIN?\
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M\1C/HOY^^9[EOTW1@H.Z*8PW%-W!F9_#:C,@R7.Y;(**MTK%+23PBI*FP0<
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M4;=!;J>:X5D$ZT$Z3T[Y*J=K*FHKYG/AKI*MT:2PL5-NGZ9CZ5(XXE5<KP
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M>[>:9GKT>YMLJ:""M@!@!@#%6^T2OIN?\/5R+K*3W;S3,]>CW-ME3005L ,
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M9M.@@=1489*J88%Q<IB,5;[1*^FY_P /5R+K*3W;S3,]>CW-ME3005L , ,
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) /%_._5@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g382677f_273.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_273.jpg
M_]C_X0"B17AI9@  24DJ  @    # #$! @ >    ,@   #(! @ :    4
M &F'!  !    :@        !!9&]B92!);D1E<VEG;B Q."XQ("A7:6YD;W=S
M*0 R,#(S+3 S+3 Q5#$P.C U.C(U*S U.C,P  ,  ) '  0    P,C(P J $
M  $    * P   Z $  $   !,!        $P$     /_L !%$=6-K>0 !  0
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ME85#P\!LL%V#+!+:(#N"QEF5%>(9;"Y)EL8:(D=ZS>".@8"S+61O2!!)(MA
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MQP$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0!_-I8)CM<OPG(_OTE09;:%BS3@;-MX)(<,QJG 0\L.U
MZB1HJFPM,+)1.&Y9O+M-8K@:L^%VVJ)9&LLAEE^^2S>)<<4-L'D'BH9K#'P&
M[!/AZ%$LC9&X%@VP[UF^9;&V"  P"Q;%'%C#0)8[<5DV:8Y##6\-RDTP2[31
M EF--&%RQ;-8HV: 3 1.'<H;-4J*O$:8("R$@LI.K-."+J0&&C>LFS2,:XLV
M:!:H93? V8V\\%G)\"DN(PT+-FT%Q9L  H;&V:M;"V(W%0V"-0+E#9>2QS-V
MA9MC2KB; 0C@LVRF:M%ZR$C<-Q6;ER*6!HT1,%FW0&,MI@0C:-DEDY/AD.AH
M H&E4LD70N!&92;$V:AF,CPL4.7(1L!?W*&Q-EU))8-,;$JH=&:M:!>H;+4:
M^ U 4-EX)%PV"51-U)2$6:(E)Y 7#0#'W%G*5509HT<5DV2V3RC!%0JR0-B5
M0HV6@E4?3S+M;.8X32;*42X8,%'4/I?$@LPEXI]0499K +9X6CSI.0TN9;E!
MNCPBE4?2BII@7$=_G34A.+*\@VI]1-"[6 ;TFVRTD6Y=A\5-1T1<4XW]N]2Y
MT%1(W# V04=3>)QS_:E4"$U*AE*%1_*=0S'3ZS,UE*KJ-:F06O82#(Q$80)3
MC524HNDD\'R/+U6AM:NV[%^*E;:QJ?0OZ,?TQ^LZ,SV1Z/U_.5'945*=-E5]
M0P#8@ .YKX7K[<[C?,G<.[VHA8U,V[-<'5T/R7\Y/_Q_T.^Z>YN.U6U][2K2
M6)]Z?97[:].:_P"FY:KE<]0J5*C&'WM1A,2T&!@ZXE?N#NAW_P!OWZQ&+G'[
MQI<3^9G?/Y?[KW8U4[=ZW-03?#M/W5KFN:'-<' W@Q\B^R(RC.*E%U3/KEIQ
M='F65 " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M#VU&/$06D&1$;E]\V;]J_!7+33BSZ NVIV9N%Q4DC=;&8( $ " !  @ 0 (
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MBZ&XBLRC1K3+M<I;&LJ&[5DRF;-%D0H;*C&F9N!8.WE64F-FX%@4-T56!J!
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M9.LRJRHQKO>N#OA3%D5^IM!N.FW&RKVGDFFC\@ZW0ZC0WG9OQ:DF=9=YQ@@
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M>M@UNRZF5C4P:HZ9'F*^1'A @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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MFMWL[F;EW;UD[-^W)1C)\&?K8F 08@S$%\Z3355D?"'@Z/,E, 0 ( $ " !
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MC$&'I7VU"<9Q4H.J9]1RC*#Z99EU8@0 ( $ " !  @ 0 ( $ " !  @ 0 (
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M*0698-[TJFB@EGF7 BI;2*9/*%'6Q5)4B)2 GE.Q*I-46#45"H<HVI5%4E
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M:?,\^7R8^- F ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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MF;-:#,J&RS50!8"(GP2;H*CX&HF5#&S8-DLVQJ-54L!!(M)(T @LI2KX ;+
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M,C=@6;-ED-TQ9WD[5A-C&V+&17 :;#C?NBH-.T:IV0GV)6<EC4J)N%#-XC;
M( BRV'!82;J:UPH:A2']HW3$.XW0O6$G4TIA488 3.Z86<LBDAIHGA8L6S>*
MXFP%RAC69NT0"S;Q+0PT6+)LJ*=:C+!9;*'8[EC)\$-YC !-BSDTL&.@S3;S
M'MM7/)T0QH" @L6ZL="R1:5#:F,;I^*SDR7B\!EHO639+? T:(E2W1#BAAH@
M(+)NK-8JB-H04$FK1#>LI2KD,U:.]9-BS=#=K9VV>*S;*BN!NT1,%FV:)4-@
M+@LQEVA)L6>!LT=RAL;PR- ++5#8)5Q9J&\%FY)&F"R+K-YU$7 @H;J0W4M
MX)"+AO%*HJO@:M99ACP4.122K4U  "BHR4 7#+">Z"EL"X %BFM0) BD!8-B
M<."50+\HP\J56,M!(6")#2;BE4/ 7#,?(IJ <@15C+ )5%1$ANR'!*H.A;EM
M\J74#YARXHJ)MO(.1'4"#EQ1U<A.KR)Y0CJ#$"V-J$^0J%2T)U#% 6##RHJR
M:,KR0M,NY/J%0B %L,08W78(J^ $EF$O'SHZ@*&D(0[K9'O5*>-1-8&)I$8F
M& 5J9DT4+<>ZR&Q57D9O#(( JE*A)!;.,./F@K3P,G%T*%HA,*DS)QH8N9,6
MS5J1G*)F6VB^[:M%+GD925"L' \PB"#$&R!WW+1-&,H*2H\4S]\]COMLU![.
M^L99]+-UAEVU&Q9SNY2 1&48 P[U\M[M=ZM;L&JC.W-_<IKCD?4OS"^6VV=Z
MM#.MN/WS3X'WS^CK])WHVN.FY2AF,[3_ '06-:]CZC8AT VPDFU?N#Y<_,_3
M;G8A8U$U6B/Y@_-7Y/[AW<UER]:MO[JK/>7*YNAG*+:V7J-J,< 06[HK] V+
M]O46U<M.L6?G*]9N6+CMW%1H96QD" !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ ?S?&W;O,OP9P/] 7 9;&6*R9K#)5-VVV1\VU9O(Z'X:#C!"$^*Q>-
M2XJK&V1(!4-F\4,,Q[%9LV':-D(6=HK">8)8C3+=BQD:85&&@RA?*Q&2-,!U
MHA 8+!LJ*X&[($CM<LY9&\:#;1 !8O,IFC!$J).A<%Q'&V#M>L7F6QFF) P[
M164LRHH9:+;[%DS>E#9@GW<;_,LV-8##1LDLV4W@,L&SO64C3)<C=@OCP6+Q
M9(R! >58-U=2QFDUPF8@&[' K&;67$#<+-E1K]!HT$FR,E+=!L9 XF\P639.
M1J!&045)2;-V-@5G)FD>0PT7K-LIO@:M MMV+.3H(U O\RP;!O@;L:;?7'8H
MDT-(W:+ LFS5(V  45&:-$_6I;%G@:@*&PR-@V]0V4HUQ- #*2S<E])>2H7
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MG31N6I)R:1_/K?\ N]K=EU<K.H@U1M'G*^2GQT$ " !  @ 0 ( $ " !  @
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M=F:N6VU-'GZO26=7:=F_%.+/H/\ 1N^E#U+2N>R>0ZCG*AR_-28>>I#E /+
MDFP VQ7WI\O?F3J=JOPM79OH37,_)GS@^2NEW>Q<U6DMK[UIM42Q/N=[+_:M
MT?6W2\M6H9JD]]2FPR>"8D  &\&*_=/='OGH]\TL?VE]Y3GV'\UN^7<G<.[N
MMG;NPDH)OAVG[0"#,&(MCL*^P$TU59'U^TTZ/,E, 0 ( $ " !  @ 0 ( $
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M&N:]H<T@M-A"^SHR4EU1Q1]7M.+H\RRH0( $ " !  @ 0 ( $ " ! '\X:F
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M,4VU:3VO:YH<"TQ!!$9$+[RMW(78*<'6+/H6Y;G:FX35&C9:$ @ 0 ( $ "
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MQ2J(T#,8'O4N7("P:+AY4JL"T#@E4543RE*H51/*$JBJPY0CJ"K)4]2$".H
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M&QO\%+8\LS=K?<6;9#9L&1[YJ'(S<C<-6;9DY%QL4D%N7@E4534-CL"ALDT
M@%+=1EPVPJ:DMEI*:B!2Y "0$P*54*J)Y4JA4MRV2]<DJD]1/*<$JBJ6Y=J*
MBJ'*BH5) AM2;$W4F 2 (3LF45%4B P3JQU98-O 2J*O B P"*CJ'+L14*A
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M\NSR(Q?@%U$\EX]!3IX@ZN9(8+3:G075R#D;V@D'4PY9]K4^D.H.0>CMO13
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MFMG))LELMRJ:BJ3RB>U%15)@C%XBJ3!/H;$3!5&-,6 +00( F$HH $ 0@"4
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MTP'9 QW]I+";P'D;L$P,)KG;)S'&"SBL9&\5@D,M \5DP?(8:"! K)XL0RV
M P7/+%LU2HC9HLA9)9,ALV:(J&9OD,L%ZRDR\E3B;L%_!9R? !AHL!Q63(>+
M-P("5BSJ!JT6 X^=1U5R$UB,-$2-GD7.V"YC+6QA*]8M@ZU^@;:TQ[2]2R;,
M7+ W:)K)LS>1NUID=OG4-\"3<"_N639+? E9MMB-0+@H;(;YFP;9@LVS)LV
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MX!A@,N"QDT&2P&V-P':Q8MD2=&--$L;UBV8MF[ 97"U9M^,@W G';'MW+-O
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M8T^17E"*CJ1R[4ZAU%2W9%.I29'*,$=3"I4MMQCW(ZG7'(""V)E*275A5YU
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MB.4;4ZAU%"R?H"=:YE*1GR'!/ OJ*\L_0C$?5@1R\$5'5E8$(J54A, 0,(!
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ME5(Y=O;O0/J*P."*(=2.41LG@@?45Y>"*L=2"V&W@BHTR(' H=&.I"EH9"*
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M,Z=&1AL]"PN9'14Z-*P<?*N6>9I ?IV'AYUD\C19#3!(=ACWK)G5;7C'J32
M#C K";J;CM,7;5A)FMO'$=I0Y1#L8KGGF:K]X<99L'>L)?6="2X#E.9;VL6$
MN):S'F6CCYXKFEF4-ML7-+,ICK;MZYV;+(;I@6SCX+&3X$O(88(N%G'M:LY9
M"CF="G* V>M<TC09 D.UJYY9U)8W3'A+MW+GDRXK"HVVP"[Q6+S-'F--$2.W
MI6$FD@SP&F"[<N>3*:HC=MW:Q9,S8Q3'@LI,%B,LMX>A92R*&67;_*LI$O,8
M%JS>0GD,-L7//]XE#=,=WI6$F&8[3;9VO7/)F4F,L'B0%E(RD--&%RR;)9H)
ME8,EY&S!VW+.3,I,9:/0LI&$F:-M4LEY#+&^9!A*0TP2WK1*F)B\7088+3P\
MBU2HB7F:M%Z9#8P!VW)KF8LU8/%#(DQJFV&$)>0J9/@839NUL;%-:8F3=#<-
MO2Q9DV,-%W::,C)LT 0N;(;J;L;*5X%JF3%6AJ&J<62V6 BJI3$ELN&XIXB;
MY&G*4L$9MEH0L2:J26A%& >$D-Q2;)KR+AA"B5'D)R0<D.[@I;X"ZL">2S8E
M4.H.5+ .HCDW)9#ZBO)":74/JJ5Y4ZCKXR"W:IH/J*D>(045AL6<H\4%2O*%
MG0JK*%L+8%+(I.N13EP\52Q1?5S*PG! ZX5! P0!4MPQ3J-,H1:, G4JO$KR
MC:JJ.K((@G4:95 P0!4M!Q33H!7D.SO]2KJ J01:FG4"I&"M2IF-,B$D^K'L
M"I56,CEDBKJ.I0M/N*JE)E2V(W*6D4F4+2E_:54@B"5*C3(2 $ " ! !!*G
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M U#0DT9U9?E[04X$]1<-[_*DW7 ER+<LMJG 74'*$"JR>48>5 58<H2H%6$
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M-$;!C8$&$I,;:T"X=P545%S,DVW4W:! 2'=M6D8DMNHRP S@.X*J+(QDV;-
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M5*3*%L%29=2J8P0!!$H6('4KR\?!.HZE4RB.6:=1U*EJ=1U(@;4PJ0@8)40
MBG( 1CD@!)U  "44YA6A/*5(JHD-[>9 5+!EMZ>!+D6#2BHJEN7;X*<!5/@S
M0=%W")]*_?%Q8'2L/ =.D9CT^*Y)K VBZI'5H>6?B%SS-H.ITJ)NM!VV0EY5
MS3-JXUX'1IV@<?/!8/B;IU?8-M63.BV\1^D?>VQ@87KGGF=/:="F1*=JYI'1
M;P'J1C 0D+^-BYYJAM%8C3'L!@7-!!$BX ^)6$J'0HMI43'Z=6F!'XQGU[<!
MM7+-HUC&7)CM.K3('OV8_#;LE:N6;5<\2U&7)CS*E./[(R0_5M]*YI-&BC+D
MQRG5IPA\8RP_5-QWK"5 <7R=1NC4IDP#V$QC\)L82VK&;5,7@$8RY,Z3'L@/
M?-^N;Z5RRE'F:.,J9,9I/9$^_;]<-NU<LVJ9H(1EU9,>8YEO.V[ZH3CQ7/*2
MYHTZ9<F-,>PB'.WZX>F2QE**QJJ HOBF.->S]4VS]4)>*Y92B^*-'&5,F;M?
M3E![;<1Z5DVC*49\F-,>R/PF_7#TK*4ES'&$J9,:8]L(<S9_Y3?2L92CS'TR
MIDQECV1^$VS]4,1M64I*F9'3+DQAKV3]^WZX>E93E%<@Z9<F,,?3MYVCB%SR
M:6#:!1ER8Y2>S]6WZX>E<\Y1YH4HRIDQYCF2]^W;[X>E<\IQYHYI1ER8TQ[+
M>=N[F&S:L92CS1GTRY,8YV?JV_7#TK&4H\T1TRY,U8YD/AM^N'I64I1YHB49
M<F,M>R7OVBSZH>E9.4>:,91ER9LU[(_#;]</2I4H\T9.,J9,98]DO?M^N'I1
MU1YHQE&7)CC7LA\-OUP]*;:IFC%1E5X,W8]DO?M^N'IO3JN9,HRQP8RU[(?#
M;]</2K4EV&$HRY,V:YOZILX?5#TJG*/-&;C+DQQCV?JF_7!%53-'/.,N3&6/
M8?JF[^9OI6<I1YHPE&7)C+7LMYV_7#THC)<S&49<F,M>R+??MM'U0]*')<T8
M],JY,::]D_?M^N'I4MKFB91ER9LUS(?";L/,/2G&2KFC.49<F;AS)#F;'_I#
MTIN4>:,G&6=&,,+8?";=]4/2IZH\T8R3Y,8866<S8_\ 2"GK5<&J&,E+DS7F
M;^J;WA4FGQ1G27)FP 0W]1&;HS5HG9$**C>"-0(H;(;H72KP))":7$1H /=2
M;(;+@)-DMEH!*HJDH$"0 @"(7H=:4'4@B5BG'B.IF1B$\"D^10MP'D@EP*3Y
ME#)9LLA)Y 0LWE091PP"AO I/F9D!*I=:%'""EE)U*+)E H KRC:G5E5917@
M400D"9FJ+*EH/J5)L#,B!AW;E2=4!"8%2W!4F-/F4+;L$ZE)E(%54NJ(0 (
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M1R_FH+GEO6[>T7/J^PU7=?N]3\G9_P!;SAJG[0]<R_*?JG?0^P+">][M1_\
MN+GU?8-=U^[SRT=G_6\X:;[0M;S_ "FZEWY?[ N9[WN_M%SZOL+?=?N[['9_
MUO.&6^T+6_Z3]2/'+]_[ LGOF[^T7/J^PQ?=CN]7#1V?];[1EGM!UO#\YNI3
MVY?[ L9;YO'M%SZOL-/\K]WLOZ.S_K><-L]H.MX?G-U.Z_+_ &!8RWS>/:;G
MU?8*7=CN]['9_P!;[1AOM UK+\I>I77T//06;WW>/:;GU?82^['=[V.S_K><
M,-U_K4_WEZENYLO]@7,]]WE?\S<^K[ _RQW>]CL_ZWG#C-?ZU/\ >3J/?E\/
M^X6$M]WGVFY]7V#?=?NZO^4L_P"MYP[3U[K27Y2=1OOR_P!@6$M^WGVFY]7V
M'//NQW>]CL_ZWG##->:S,OQCZCOCE_L"R>_[U[3=^K[#)]V.[WLEG_6\X;;K
MS6?+^<?4>_+[OVA83W_>O:;OU?80^[/=ZOY.S_K?:7;KS69_O'U$\<O]@63W
M_>E_S-SZOL(?=GN_[)9_UOM&F:[UE^D?481%]#[ L7O^]>TW?J^PQEW9[O\
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MJ9#&!8$,R>994B03 N(RP@EPQS)P+)8"!  @"%,@*.A&9A+!04JE$B@4RK]
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M;P1+9LWR^M2V9,T;;P39#R-@;I<$E]9DU3$NFF(E6($ :$P6:;;)H%J;J(%
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MI(HJ*(4L 4@"!E2;9S32&D45I5*!-TI0"#(*4",U18)@$0!&Y &),5:5 (3
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MZ.]928*N0Y3O&%O'!8RYE2YC3+!O\ZQEQ)&6">[SKFD-#=.4=JPD-K =IW<
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MB?O%SS12T.^?XDO=;7GCS>K:3A^9-2$?TNZK]PKG>KVKV)^\7/-.66AWRO\
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MFCJM2.G2QV#S>A<DSNBZT'J9GVM(AW+GD=EICM.1[ESSQ5#H6#368Y37)/#
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MC[&HE8O_ (<_)?V&4M1IZ_S+?E1^TO\ N+._Q+.?:N8^QJ?N-1^'/R7]A/\
M4:?\2WY4?M-VY/.1'[RSGVKF(_\ X=J;L7Z?RY^2_L,I:C3T_F6_*C]HVW)Y
MV'\"SEO\5S'V-8NQJ/PY^2_L,):C3U_F6_*C]IJS)9V/\"SEW^BYC[&HE8O_
M (<_)?V&<M1IZ?S+?E1^T;9D\[ _O+.6_P 5S'V-8RT]_P##GY+^PS_J-/\
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M<2MGV?V32>AM^:<D.G&V,SM7G5KF=[1<&*3):H2@"4")B9[4!0L#%2T2U0E
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MS&E4I%,HH3=+BJ2&D5*92!-J@ EP H78)T*2*IE%70E&/!-#52JHHA  @ 0
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M!":IQ&2G5)"(2KRR&03!"0TJE>8^A.@Z$1BG0>"(2 H78=\H*TN(BD9QVQ3
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M4)Q5%)%2<$TAI<RBHH$ " *ET$Z#2*DQ3125"))C,XDJJ%4(0,$ " !  9(
MKS&Y50JA5,8( B*!E"8JBB$#(4U;P0'K1[;OI =*]GV7K=#Z#4H]3U97IEHI
ML>'T.F->("OFG-,GCZEMI/>OLON/\OM7WCN+7:U2M;1%_O9.=/[L.SG+)=IV
MQM6]+%7M6JW'C&WQ?_BGRCR6<O ?-CJ?6>J:AZGF>K]9SE7/]1SE0U:V8KN<
MXQ))Y6 D\E)@,&M$@%^F=)H=)MNEAH]#"-O2P5%%?Z>;?%\3FN7KFHN?>W76
M;^I<$EP2R2,FNA881O"MJN8)K(V%20 F<8Q6?3Q&GQ9;XXB(!$>\^A'17/(*
MU>9(KN@(P-FRSRI=(G*F"S#]T/[88;D?=HGK\)YG\2 8XSXRCODOEMV)^3K$
MZ.H"D";(1O[6+R;\,*H]_2WJJA(IF)G"'=P7FW%3#@>YIYU&&-M&,_(%Y]V"
M9[&GGAV#--L<8X[+?(O-N1:/2M2QP'&,C#=;MCP7')T/8M3KB="BW'M""YIO
M' ]2U.L:<3I4P3 @<.%BQE@>A9DD=&F)^'G\RY9/ [[;1T:4P !V]Q<T\SJM
MO >ICP*YI,Z+;7TG3I"0PQQX+EF\>TZH2P&V6%<\SJM.N8Y3'O1QN\5RRS.B
M+X#M.4#BL)&T7P'6B(';:N2>$F=2>&(Y3!@(':=]JYY-&J[!MBPED:<F;MLX
MK!C>8_0$SN]"YKF01S'&WK!EL:$(B%\+%A,2&Z?H\2N:0V/-LXKG9SO,9IVV
MW=ZRD9\1@6+&1#S+M[<?<63)8RP1@LI&,F,!*&=3%F].[<KXF4QIEW'SIO(P
MD,-M"D7 V;:$Z51#R-FPXJ))_09,NE$1HVY)F<AAM_!9LRD;BP;DD9,U%T?3
M%3A])F^PW;;P6>2H9RR-6VBZ8W[DB39 B[;TF)FK;%#,WF2D(T:;L+T$27$T
M:8QG%)Y]A$E0NE0DD&&Y#54)F@,H>*BF)#6)<D!*C)H6\$@)#B+9\4FJ@:@Q
ML-BF@4)B<4@)+H[$4$D1';% 4)))V(H%"(H'0$  *;09D( J7 ;\$TJ@5+HV
M1":5 *Q.)3H(A,8) 03#>FD-(I$XE50JA4F$$TAI%8Q5#2H0@8( @F%J,6.A
M!N@FNT:[2B8R">]-%)%%11" !  @ 0 ( H3'TJD4D0F,$ 5)@()H:*(2H6";
MR J2&B+B !$DDP  F229  *4G)X!V<3TR]O7TDLOIP9O2&A\Q3S?77!U'J'5
M6$5,OTH.;!U.F0>6IFX&SZF]?<W<+Y:W-UZ-WWR+AMJQA#*5WM?*']IVRZ-O
M5;B4M;PCFH=LN<N4>'$^>=?-YK/9FMG<[F*V:S69J.JU\Q7J&I5JU7DEU1[W
M$DDQ7Z+MVK5BW&Q8BH68JBBE1)<DCSI3G<N.Y<;E-YMFK:D++([C9Y$.-<QU
MIF;"N("4]]V]9]&(TRXK"<R(;HG<D[;#J?,K^Z)R!WD^5/[L3ER(.8@+3&_"
M*/N_$+J,_P!U[?!R?W2#J1^Q&C 3 %Y\LQP7RJ]"C/R-I[J:6)B:,R83@(C=
MYEYE^&![6FNT?-A\7"$R(PGLG:O&O1/D%BYA5&C&"P"=D[I8@+S[JYY'M:>Y
MQ9KR0G"$Y;^P7!=B>O:GDQNF!=$X;/!>=<B>K9GXAY@WKAFJ'KV)J@_2!$(1
MB8;XB*QDZH]&U)/$Z;)PEO\ (N61Z$)4H>8=(ZWD<EE:>5KZ3TWU6JQU1[L_
MU%^I1G*H>XN:RH.FZCZ=D^6DT\K>6BTP$R3-4M3:MV^F5BS<?.7WE?\ 5N17
MU&=W1ZB]==RWJ]3:@U^[#[GI5.*Z[,Y8YNLGV4.Y2U-TJ,]!:- -_P 9K/;_
M (Q6<]99I^5T_P#ZWK2H;;JJU_4-;XM/\.=.EJ7I1:/R#T=+_M-9>?5ZY)ZV
MS7\KI_\ UO7'5';=2O\ ^0UOBT_PXTS4G2YQT'H\8?KFL?G>L)ZZQ[+I_P#U
MO7'5;VW5U_ZAK?%IOAQNEJ3I<1^0FD(0_;-90A$?XO7-/76/9--_ZWKC>.V:
MO_$-;XM-\,/4]1],NT+I"'_>:P[OSN7/+76/9--_ZWKC>.V:O+]0UM?!IOAA
MMFI.E_H+I"7_ &FL-WZ7+FN:ZQ[)IO\ UO7'3';-8XT_4=;XM-\,.4]1],M_
M$;2.[XS6%ORN7/+7V/9--_ZWKC:&UZO_ !'6^+3?##3=1=,_0;2.[XS5^&/X
MW+)Z_3^R:;_UO7&CVO5_XCK?%IOAC=NH>F6?B/I+'X>K_G:N=[AI_8]+X[_K
M@>V:S_$==XM+\,/4=1=+A^9&DH_]/5WSK7/<U]BOY/2^._Z\<=KU?^(Z[Q:;
MX8<9J+IGZ$:2M_5ZM^=:PEN&G]CTOCO^O+EM>L_Q'7>+2_##+-0],E^1.D_K
M]6_.M83W#3^Q:7QW_7B6UZS#_P#V.N\6F^&&Z>H.FR_(K2D_\O5G=^=2YI;A
MI_8M+X[_ *\;VO64K^HZ[Q:7X8=&H>FP_,K2GU^K/G4L'N&F]BTOCO\ KS![
M7J_\1UWBTWPQNS4'38_F7I6S]7JO9_BE92W#3^Q:3QW_ %YG^EZO_$=;XM-\
M,,#4'30/S+TK_P"\U7\Z5C+<=-[%I/\ U_7D/:]77_J.N\6F^&-&:@Z;'\R]
M*_7ZKP_YI64MPTWL6D\=_P!>3+:M7_B.N\6F^&&6:@Z==HS2T?\ IZJ^="R>
MXZ;V+2>/4>O,9;5J_P#$-;_];X8V'7^G?H9I;Z_57SH3AN.GK^1TE/#J/7F3
MVO5_XAK?%IOAS>GU_IWZ&Z6^OU5C_P T*WN.F]BTGCU'KS*>UZO_ !#6_P#U
MOAQIG7NGP_,W2PQ]_JG;_BA#W'3>Q:3QZCUYA+;-5_B&M_\ K_#FXZ_TZ7Y'
M:7N^KU1\YU/ZCIO8=)X]1Z\/TO5T_P"H:WQ:;X<V;U[I\1^1VE_K]4?.=4MP
MTV/_ ++2>/4>O,WM>JI_U#6__6^'-1U[IWZ'Z8^OU1\YU$MQT]/R.DIX=1Z\
MS>UZO_$-;_\ 6^'+_P N]._0_3'U^J/G,E'<M-[%I/\ ['KQ?IFK_P 0UOBT
MWPYHWKO3X#\C],?7ZHQ_YF2>XZ;V+2?_ &/7D/;-77_J&M\6F^'-F]>Z>;-'
MZ8^OU1\YE#W'3>PZ3QZCUYD]LU7'7ZWQ:;X<8'7>GP'Y(:9L_5ZH^<R7ZCIO
M8=)_]CUYB]LU5?S^L\6G^'-&]=Z?^B&F?K]4?.90]RTR?Y'25_\ W'KR'MFJ
M]OUOBT_PYO\ R[T\?W0TS]?J?YS*?U'3>PZ3_P"QZ\S_ $S5>WZSQ:?X<T_E
MWI\C^*.FMGO]3_.5)[CIL_Z'1^/4?$$?IFJ]OUGBT_PYJSKN0(GI'37U^I_G
M*E^I:;V'2>/4>O#]-U7M^L\6G^'-!UW(1_-'37U^I_G*D]QTWL.C_P#L>O$]
MLU6?]?K/%I_AS0=<R%VD=-?7ZF^<BE[EI?8='X]1\00]MU/M^L\6G^'+_P N
M=//]TM-?7ZF^<BG]2TWL.C\>H^()_3-5[?K/_K_#DCKF0_1+3?!^IOG(C]2T
MWL.C\>H^(%^FZKV_6>+3_#FK>O9"[26FMW/J;YR)?J.E]AT?_P!CUY#VO4\=
M=K/%I_AR_P#+N0,OQ4TX"9?#U+*-\]1PDI_4=-E_0Z.O_P"X^((_3-5G_7:O
M_P"OZ@\?[;MB\L]4D&"30FC123D6!Q@E0EHL""D*A,2+"D!(<8QF>,DJ 6#\
M9(Z0)#Q>E0 #Q./"U% #F$1A?:BC CGD<8RW(Z0(+R4Z 07$[-R=$!5  F (
M KS6^"=!T()CLXIT0TBA=WII%)%224Z#H0G4= 0 ( J2,4Z#HRI,4RLB"<4#
M*%Q54*H0F,A  @ 0 ( @D<4TAI%8E.A5"$P! %"XS3IS+H530P2J@,JM6G0I
MOK5JC*5*DUSZE2HX-8QC1%SG.,@ $0C*<E"*;D^''Z"HPE.2A!-S;HDN)\_O
M;]])IU=V<T9[/<V6TQSY;JVH*+K71+*F5Z<YI^$#)U2,!.$[/T!W ^6*BH;U
MWCARE;LOQJ5Q?V1\9T7+]O;_ -BRU+7<9+&-OLCSGS>2RQ>)Z+M<Y[G/>]SZ
ME0N?4>]Q<YSW$%SG.=%SG.)B2225]\R22Z4DHK*G(\M/JE5XLWYH""SI4IM&
M@JF$/$P]02:*ZL"?CMHW]II=+%U$?&QO(AM]:=&)SKD5=6$XF&R,K+$*+)<C
M$U[IF%A]$2JZ!.17X[?C<GT(.H]DZE"^':&Y?*KT,#\<Z:[1BSJ/*<" (VS\
MZ\NY'#M/D&GNK R^+C$7&<;MT-J\G46Z.I[NFNDBF08[?=7D78^(]W3W%])H
M&1LOGNEQM7GS7!Y'LV)^(T8V D"(XWS7!=C0]6Q/&CR'Z;($Q,HCNEL7GW,G
M0]:S/*IT*33CM$,([EPR=,&>K9G0>I-@1; WK";/3MSP0_2MA='C*U<\SO@\
M!^F)A<TF=$'C0Z-$PE==ZURS7$ZU2M!QL(S7/)5.JVZ,=IVPX;URR.B+Q'Z=
MG?YUSRS.B. VP6\/(N:X\#H@\V-LC(7KFES-X.@Y3%D[%C)FM6Q@#O@N>68-
MC=(0AN/E7//$J.#J/,NV=O.N=E-IC+%A<!<!ZF+#CY%RR!X*@XT3\5@V828T
MRP=KUE(C@:K&1)JV[BLV9R&&7+*1C(W"<*_09F[;>"I9&,LAIFRQ' PEVF[8
M1"5:!PP-A:GA1UR(9LWQ426%5D9OZBZ4>9)HVP=KT/,AYF["!N6<C*1NVR[M
MBD9,NVU)NB(>1NVQ0S-FK8P'AC:@S>?:;,),8]NT%#5!%T@-!8-RDAYF@,5+
M(:H2D!8&"!-5-(^*>9!H#%20U0E @0!<$DJ6B6J%@8'M8DT2U4O'="[%305/
M&3$(%0$@!  @ 0 ( $P"(" H1$8HHPHR"[!.G,:7,J3>F45C*(3H.F)144!F
M@$" ! $$@(H.A7F.Q.@Z(JJ*(B,448Z,HJ*(0 ( $ " ! $$P[=Z=!I%%10(
M B,$#*DX)I#2YE4T4"EO@ EG^H9+I>3KY_J&9I93)Y:F^K7S%9X93ITV-+G.
M<YQ D M;&GNZJ[&QIXN=Z3226+;?!&EJU<O35NTJS?\ VJ^27%GS)]OOTF,[
MK&KFM)Z(S%7):;IO?1SG5*+W4\QU8M+F.90<"',R9_56ONE;^F>X'RTL[-&&
M[[[&,]S:3C;>,;?)O@Y_V$W]=;TR>FT+K=>$[B^N,.*7.6;X8'J+3@&SCC)?
M;[S/-@J(9:Z E> I='F.I<5#*]*B'7Q@:DO6BB#JP*_&'&2,!=2^@S^-A&=M
MN/8)T9'WB,S5&**$N;*.K2EVW)I&<KF!3X[TWIT(^]7:>X5;+<LX>$MD+XKY
MA=CA3B?CG37:T7$0JT1:9>0+R;UM\#W]-=R%C1,#*.V$H>ZO.NP4D>]IKE"@
MIP,(7V0O"\346Z,]ZQ<>'(L*=I ALW;(KRKL:,]W2W*E@TB4)2/&W<N&[%-'
MKV95'&"SAW>XO-N1HSU;4L$A^D!+9LQ7G74UD>K8G2B[!VF# QG?%<LFCU;,
MJ47 <IB,)2[>=82P/3M2JJ'19.!A&0L7+(ZH9C],S NM7/)<3KCF/, ,PN6>
M!NGAV#C!WFU<TF=47CV#M$0,OU,_!<\V;Q8_3%DIKEN?4=4)56 TP3CW!<\G
M@;Q=1IEEDUC(UKQ&@!"R_M>L)M@VZC5,62N*YI%1?#@/,[<%SLMC+19PQ6,\
M@=:XY#U(6'MAWKDF$G@-MMW+%F#R&6" ':]8LG@:K*1)LRSN64C.0PSMX+*1
MC(V"N&1FQAEJK@8RR&FH9A(V%HX*4J@W@;-M":(>1L!>ID\*&;9=3$DNV'%-
MDLV:;"-RC)F30PVW@HXF4LC06I2_=(>1LWQ4,R9JVW@A$2R-6D [X!3(DU4@
M6;:AY">1H##L?,H9#-%)(($2"8[[>"!-8&H.%Z>9#1<634DLE @0!(,/,DT)
MJI/-L2H*A:/;>E05"4 3'CZ44%0.8I4"B#FFB@4 N**!0B,!QBG0=*D1D+=R
M= IB1&4>[:B@Z8E8F>U.@Z$)C!  @ 0 ( J78)T*2*)C! RG,=BJA5"J8P0
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MWQV_;()17[TG^].7\4G_ &+)'PW<-SU&YWNJ[2%B.$(+]V*_TM\7FV>&TW
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MI"!ME$6FW$+GF=4&AUD+IKDG7B;1;3&67;[%BSHBW2O 98!VW+*6)JFZ5&F
M2/N+GG@J%QEB.,!LV^7W%S29I5#U,1@=G;O7+<!,:IV^;R+GD#RH-LL.]8R)
M-[EC(CB7;&8W+-DR-V>(63,I# L4<3%YFC;5HLB)#5/S'RJLS"8PVQ)F3S-0
M9C:A9#9LVU-9&;R-!'MVP4R2H0S19HDLVU4\B7D:"/DBI9#H;MMA'CYE+>'@
M,WD;-C">*DR99MJ4LB6;-MX*60\BX)!DI(9JF0:M),L![G@I: LI D&"&@:-
M%)!8':DQ,LI))0 ( $"+--L3WIB:Y%XV;;$$@@01VH"A,2B@401**!1$( $
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M2*9!.!V=\EY%Z/(]>Q.CQ- V'O8+SKJJZGKV+F%1FG DQP7'=6&!WVW1U'&
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M:(R-6N$ +U#3 LI $ " +@[8E)DM%DA!8@#0&*ED-4!("4 " !  @ 0 ( $
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MF/+(2AC;/SI5#J>1+8P,X"4TFR).A-D[1L2P(K3/(T(-H@T666J>K@2Y$D$
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M:DADH$7!%BEHEHL@1H(0DF0Z\2PVV)"+ V!#1+7$LI$:M(( P4M 64@" !
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MFI1/G#](#V8<[,UFJ5#WPYG&#9P@9@C8OK'?MMSDD?:_=3>G&482>!\M]7=
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MPXJ#-ED")%J&#R-%)!9I[D5H2UXRZ9)(0!<&*DAE@83"0&H,0)B*AH"4@!
M@ 0 ( $ 3'Q0% C9*S:B@J!&W:@= CLGC% 4\01P$.**"IS")" H$244'0A
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M=(DD2.VSS(>* TYA'A;YK%-&!8&,PD ) " !  @ 0 ( $P!( 0!7F;CX%.C
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MP.Q0Z;"'+3(G;"4HVWJU!\3"=]9(?_DQWZBZ/JM5?=HQ_J3_ 'OK]I'\Q00
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M'::6K5R]-0MJLF?-WZ2OTKCE3F]&Z$S#'YV%2AG.HTWQI90$EI#' PJ5S<+
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M3H0LRR2S++MA-55HEEU1)+;0AY">1HE&OT$%[SCX*<>E5R)X$J1$IK, 5B-
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MHDCQ+EZY<=9-GD3*5*B UC != 8+MC:A')&=*EN8X#MQ6@Z(J@H$ " !  @
M0 ( $ " !  @ 0 ( @@$$&PVI ?D'M*TA0ZSTZN[XD/)ID.'+$D",X\5\>WG
M01OVVTEBCY!LFXSTM]-.B3/CY[:?9]5Z1U#,EM$BFYSR#RD"UQ@)0@OHG?\
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M38 /\D1,/*O1AIX0\)S.K&"ZR$N 6U$LAI<RI)-J8Z @8( $ " !  @ 0 (
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MM/;5FTE&$51)'U/<N7+]R5V])RNMU;8Q2Z<! DFT2XSWR0YXT0E%I8'5IY,
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MVI84+-$)0$^Q7+)'=:FLN):"\V]#'%'7%X8%A!>=<B=<67A"5RYG]9O%U7:
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M&,KR2[3I4>G7D3C9.0\E@3HF82O.F!U*73X7-!OA'UF,TTCEN7^TZ5+IU\/
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MZ<-/"".-MRS&X@"#8;H>XMTDE@%/$07$[-R95$0@8( $ " !  @ 0 ( $ "
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M*Z!8#: 9#C.*^2:+NS>NT<T?7>[_ #$MP3C:DD_">Z6AOHN=)Z:VDZMD:;G
M-)C2 P-D(6A?,-#W5M6Z.2Q\!]9[IWYU>J;Z9.C[3V@T][*.C=)93Y<K186@
M6,' '<OE6FV6S:RBCX;J=WU>I?[4G3PGZ5D^B9')M IT62$/@@0&RV'!>Q;T
M=NW2E*GF2G.;K)MG4 8R36PA@ NE1BLD+I#F*H?2BJ"@0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( J]H>TM-
MA2:35'D':>O'M=T#0ZUT[,N;0#B]C_J1)TS&(N,5\)[Q;1'46Y-+@?.NZN^7
M-%J8IRI1GQV]K>@LQT#J>8/Q+FL-1[FF$ #&R,+"+%^==_VN6GNRPXG[*[D=
MXX:NQ"+EC1?V'KQF:4R(3!@1>-EUA7P:_#!GW%I[BG%/@<JM1:1#R8^M>!J+
M=&SV]-=R.)686NB)<+-_!>/>@J'N69O!\1=U,8&)OEW6+P]3:IX#V+,\F9<L
M=]^$L;5XEV%&SU;4U15,7-@;,(R[6+S;T*H[[4VGV&9;<+;O*9KRKT>)Z5FY
M1KD#0!O7G3BWP.^+XD.9>.*Y)<F=D)HI+CW3XS7!>MM/L.V$Z^$D+@FL3H@_
M&:"!]"QFFD;5P+K)KF!"QDJ,:)A@LI)K,O L!+;-9MXBKCV%VBR8XHS8FS5,
MS) VA";7@$S2133)R! @0!*J($@13J+(N!QO2;Q);+AN/@E4AOD7:WQ2S);-
M0 ,)\=M^Y%2&R1(I/$3Q+A22R4") BA@RX "EMLAMLM$"P02QXBQXEA$SCV\
MB:0G1&G*#?'R(J15E@()$MU+AI.S@E7@!<- P.]*C8JHQS&9HY6FZI5<&AH)
MF8"7F71I]-=U-Q6K*<KC? :QQ>$5QX'KC[3_ &Q93HE.KDLC4^.SKVN;2I4W
M#F!,@YQ$0Q@-Y7WIW'^65S4..NW)4@J/$^']X.]NFVVV]/I&I7VOK_T'I1UC
M/]3U)GGY[J==]>H]Q+&$GXJB"8@,:3[W?:5^B=%HM-M]A:?2Q48)<.)]/:O<
M-1K;SO:B3E)OQ> K0Z8.68A?(CM85TXO!'*YG9H=,=(-IPL,2 3+ODBF%3*5
MY([-'IDFDB8-L(SCA8G3$PGJ,*([%#ID;&PX#'8$Z,YI7F\6=BATNSF$ 82'
MJ5J#;.:6H@LV=G+]*F.5HX0C'<MHVN9QW-2W^[D=K+]'<8>]@<(1/JBNB-I'
M'.^^+P._E>@O<0>0PC#9';N6T8\#DGJ(K)GD^3TT]Q$61W"<9RXK:-IO)'%<
MUB7' \TZ9HZO5<P,R[B3"QL8G!=$;">>)Y=_<(QS9^PZ;]CW6^K/IBCD:L'$
M0/Q9B9"7P3<NZSH[T\(1/C6N[QZ/3)N<U5<F>TFA_HJ]5SSJ+\QE7 /@8.8X
M&P&R$;%[^C[O:B]3J3/@&[?,&Q9K&TU5'NEH3Z)_3<F*+\SE&N<($@TQ<!C.
M(@OEVA[J*-'-'UENO?\ U%^JMR?C/;#2_L6Z)T=E/ER=%A9_V;+KI0\Z^7:3
M8+%I?NKQ'P76;_J]4\9/'M/U[(::Z9D&M%.A3'+(>\;Z,5[EK0VX+*AXT[UR
MXZR;;.XRG2I"#&!H'ZD!=<;<(XI&=&7+C=9P6G@'3F504" !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ (Y_)T\YEZE*HT.#FPN\^"QO6HWH.$N)K9N2M34HL]$/;Y[*V9_*YJM2H
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M@.5H@T <%T*,5EF)+Q$$D^I451$( $#!  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M<K'0J23:F,$#!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @"+9%(#PW5.FLMUG*56/IM<7,<(%K9QA;)>1N>W6]7:=5B>Q
MM6YW=%=4HNE&?-CVZ^PP9AN:S65RT*C>=S7-9 @CF(F-R_/O?+NC7JN0B?JW
MY:_,5V90M79X=I\X^N=#SG1,Y5R>;IN86./*7 ^^ /E$%]!;CH;NDNN%Q.E>
M1^O-GW33[A8C>LM8K*IXQ5I")[3]2\*];3/D]FY7!B+V$';Q7DW[-<CTK<N1
MB6 V 1MA=<O'O6W$]&U<KGF90<#,';;;P!7!."9UPE3P 6XKS;]M5.R#=#!S
M"+)B?".^]>9=M8XG9;N1R(A*SCX+DE"G@.J,NT@,.$;YVQWE<TH<C53)A$@0
MA$=W%<L[:XG1&Y3$CDO$]OF@N2=NCH;QNI@ <!Q6$HFBDF'+;M\%#[1U)  6
M4HUQ$VR0P>XL)1JPZF7#9+FFJ9$]18""RQ%6I;E4U)J6#< EC4ELV#.Q3K0S
M<C5K.Q2(<C0,V#MY4TJY$MLU:S ;U72%<,34,O/C8JH0YC='*5:IDV#<3'L5
M[>V=W]PW2XE:@U;?%_Z$<6IU^GTT7*Y)(=J-H9"GS52 Z%QBXF\ +[O[K?+>
M%MQN78UN.F+S_P"[Z#ZV[P=^;&EC*-J2P/%,X[JG5G&CE*;Z=$DCFA[Y]T0&
M@F$U]Z[3W;TVA@J154CZ,WWOG?UDW&,_V>9W>@^R?J_5*C"S)5ZA?"9IN@8D
M3LC:5\LLZ.[-*,(X'UOK>\.DL-SNW*R\)[+Z+^C#UGJ)I.KY1U-KB"06NO,;
M(17OZ/NYJK[55@?!MT^86EL)JW+$]OM#_1.R66%)^:RHJ.'*3%E\;(07S#0=
MSU@[BJ?6.[?,;476U;DT>UVE_87T3I+*<,E1;R@6L;=C*/F7S#1]W-/92I%'
MU]KN\^NU<G63Q/V7IFC^E]/:T,H4QR@0@UNZ4&KY%9VRU;HDE0\"YJ[]UUG)
MGDU/+Y>@.5E-K88 0A# !>A"S"!SXO$VYMDMZU5%D/I*$DH'0$#!  @ 0 (
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MA9 >I>C"Q;@LCFQ>9OS 2:!#=#T+6B60TN9$3BF.E"$#!  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M+.S3)8FL;KKCD6^+,I&=FU<T[;1JKM213%ME]BPE!\<@Z\:%_BYPODLG .K
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MX 92:(0 @T7>*]*&GMP6"1S8MXC',!\$>'H*V225$-11!,4QI4(0,$ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M)!)-J8Z$(&" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ 1:@!3,Y2G7:6N:
MUP((((!M&VU97+4+L>F1K:O3M-.+/S#4^@,AU:D\?$,<7@@M+6@1O,5\5W7N
M[I]5%UBG4^8[-WIU6@FG"<D>G?M$^CODL_\ '5*.4#:C@\MY6SC.-R^F^\7R
M]M7NJ4(_M'Z%[G_-W4Z3IA=N5CVL]+-7^P7JO3:E5U+*O<UI,"&&( )P; ^"
M^E-Z[C:S3-N,:H_2O=WYI[?KH1C.:4F?AW4=$=4R+WAU&HTMN>QP%NZ:^ :S
M9=19?[46C[3T/>/1:I5A)-4X'CE3I&=HQ#Z+M\"(<(+P+VBN1PID>]9U]B>,
M98"KLK5$8TG;X6KSIZ>2>*/0AJ8-X-4,S0J#ZAT3?#S+GG8;5*8&ROPYH!1J
M'ZEVV2X[FD;X&T;\,JHL,M4C*F=Q$O0N6>DFS57XKB:#)5"?@>$%SRTL^0_Z
MF*XF[>GU(1Y#MM64M)/E@#U<%Q':/2:U4@,I/?@&M)*<-NOW72W%M]B9C<U]
MF"K.22[6>3].T+USJ#FMH9"L>:][7 3W17LZ7NANNK=(6G&+YGB:SO9M.BBW
M>O1PY,_7--_1]Z[U5[#7I/8UT(M:TC;")!/<OF^T_*G4ZMIWU.78L$?76^?.
M79MMB_NI1<E])[/Z*^BS18:53,9/F,B>:FXQ@1B#:;U]R]W?DW"%&[2BO!CX
MV?0/>K_\AKDE*&GN47_;D>UVE?8%TCIS&%V3HL+>7ZFR$,1S27W9L?RPT6D4
M93@O$C\Y=XOG#NNXSE&-R;KR;/W/I.@^D].8P-H4P6PL#0?)-?9FW]V=%I$E
M&"P[$?5&X=Y-SU\FYS:3?,\PH9'*Y<!M.FUO+"$ !VBOD-O26K6$4J'A2E.;
MK)ML9B!( 2L@NA1C'($B(DWICHB$#!  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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MW6Y)OZ1[F#9 "'=YEUJ,5DD8J/,J7$[.*921"!@@ 0 ( $ " !  @ 0 ( $
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M$H $#!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ B<2@5$$<9[YH"B+<QP'CZ4!1!S' >/I0%$',=GCZ4"HB"XG9
MN0.B(B<3WI "8 @8( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
G " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g382677f_275.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_275.jpg
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MQ "X  $  P # 0$!            !@@) P4'! $* 0$! 0 #  ,!
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M7/WZOQX!QX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MUR4Z(+5V(=KE?4NK1<M<P)<B0W,.$%@-BLO"-  C"J\%R#3::<.1=;*8& ,
MZF?BESL#.03<M+P#DW#2L.B=KY+84_"*E " =2\$:\P2T',QFR/7%>4VXEI]
M"%;2KP\-BGAE#]K''^:](UU2IAW5JTII0-'1\\ZETVW1GP A\V>]*/1]MMTX
MR;-R*IUU#SC_ *K2-(0MEMI[SN+:%EIF-"Q.#(P!@# & , 8 P!@# & , 8
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M1;:\AZI+%;M32YNO2,6ERL+.+ !38D**\0O6?89^)TCSN-I\5Z%CF4B]F-!
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M6"QS*=^VRCI;[3/V:TN=4CKS&\6YG(@Q9GNPZC[B><RM/O<K?RHR8F2;6]%
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MC+K!!]$VG[H>_GA/SC&L ?1-I^Z'OYX3\XQK 'T3:?NA[^>$_.,:P#'+H?\
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M2UBN^BS7$3+Q,K$3,Z%OO>9%T#3%#L57E.:R$V=9.G5M]7+.R6/L4 31:V;
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MPF]KY7B[?ME33N,;8C+MZ1DI@55+MEME3='3?W;K)BRQYC@L1"E%L\_GHH8
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$;I__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g382677f_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_29.jpg
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MQ $(   " 04! 0$!             0(#!08'" 0)"@L! 0 !!0$! 0$
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MIT1%$11%$7)Y6^V@4!2^G"WW44HHB8)N+7ORYT12&EE%6IOQ!/EXT15.6O\
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M7M^RB%%];6]]1PJB=JD!0I7/C5=$P400=1K8W\KCQN.%.*=R 5$BY(N3:UK
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MKK?4^[[*)BG:BFF*-*)0)#7@>?T%% 3HJD$7\1X'7[M*#'!$#PO<CCI;C55
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M2$NCSJ:*K4CH\_L_;2B:DPD<]:44:E*WV4H%"?A32$JCIX'74WL+ZVTX526
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MMC_^FKW_ -\B_P#4I_\ L^M__P#JFQ_]RF_]>@_YQNT#_P#Z"W6/9OW" _\
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M$4P-3<>8N==+<=3>H4I!2;FQN3P !'[+WYU/#L4<>U,J-[6N; \:4XI5 *M
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MZN1T-QIQ\/=K1$NO7AKPM?S]E$4Z(BXU/@;41&O'Z]=![-.=$7R]_P VD_\
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M/5;]=;/?;^_MCL]K-*RQV:]O7.$V[L;<^1+ !ML3=KNK9K+FX\PO9/.)G-
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MK<N!(^HZ:410'3QUTY::^[R%$3OP^#S^FE$4@J]^'/@=?:!:B(OY*T\AK?\
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M;J7XLV#,91(B2XS[9*'8\AAQ*T*&A2JOL*VN;>]MH[RT>V6TFC:]CVFK7L>
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MU/?A49UU*?XRUT\2*\-_,ITWN/5?HCO^T[6"ZZ;;-GT#.1EM(V>1G;5C":'
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MS<BB)WT\[_7_ $41305 D"P)MQL/$Z7%%!4D)5HJ]@=/'CR(Y7HH*J"R#:Y
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M][6\ >%$1XFWU\^/V5"G#-+JMQ!MS(U'E8\Z(!S4">-QH;D?7IRX44GV(U(
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MID'I/4;:\;<1[!09X*>"B > _>'$^WR.F@J:C/@HX47S'_S9_P#V9MMWU_\
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MP\JCO&(^A9=A,8+R.08#50]SL#\"KM&?$J-&DC028[$BWAZS2'"#Y@JJ^#J
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M[=^MR8S>?YP.X.+[7;!>EM2LGV6[>9#_ !'W"S&)2ZIQ>$SN^(KB=J[25.;
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MF4S&,8R3KLAX)2A"Y/H(ZDLA:_U$],VO_P"!-LG<6:)[5DS0T4:UDH$C6CL
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M3A 3\[Z,9S^9] ?94KS/;NR;^F+V^II!!Z9.=F(B#R(@PDS)"@1K92VS4X\
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M $\7_71_AO<O_P ;6X__ ##EO_?.I_I.[?\ LEW_ .AE_P"JG]8V?_VRS_\
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M3=B(Y^#P4JU2+,XTL.NMDJU2ZXXE7,&JA08&AJLJ.:VMG:K&WBB-/F/WC_\
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MK\!Y_2]$P4M!K?ZS^VB5Y)>R_N/[:*,47M8</"]K>/C13BBYY6.OOMIKQHF
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MG_B3O_"L56S-6Y,O:MEU<5I%$11$41%$7-8O86TX^[Z_&L99QI5!(/'7PX^
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M6=C)R4QLC"2D76IUE1(>93R=:*VC_6H"#WKA=QV>]VTATS0ZV<:-D9C&[N/
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M<O:61D+6E"<?(R;>'RBW%BZ6T8S-#'SG%*O;X$*%].-8'3'K-Z5=8T;T]O\
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M 6UUT<G5VV2.AD$S6,^T0YKAS&)I\.%%Z2=ZZ#W6UAOMLNK>43FFEA+9&DY
MMP-3RI44((7@'9';:)+,_!9_(-M1EIDHP<]U^7B\J+* A3'V)D#*1(R[@];+
MO5IX:5<?UENYC\D-:'' R-IJ9^\&N:YA(Y$+86_2/2$TGF;];"XCP+6/:YFH
M<B^,L> >>-%KS<7;GN#BWY<R+B<9E(#CSCS<+"2I"UPV%*^&,RC*.JF2 TG2
MZG7%JKK-JZNVR2%D%Z]WX@- +W -U'F0T:17D  O*^I?2BSGO)KOITNM;5SB
M60EQD:P?9#W$OIWDE:\;RS4.08TUJ;A)J20N-/8=CJ!!L?A<2E13?F 176-?
M;W;-43V2L/(_H%YS<=.]4=/OUOB<Z(?69B/@LC&9:6E*^H*MPD1UFX(UOUMG
MJ2=.=8K]N!P;QX$?J*B'J&-SPRY:6SCCBUP/?@5F&'WOF(:4):G_ #C!L#&F
MV6%)_J^H.1'B*YZ^Z<LY27/CT2?:9ACW+O\ :>L-UM0&07 FA_V<N-1V._:L
MC*]M;A-W&OP3)+M>P_NCJSQ^(#H'4?"M6UFZ[9@P_B+4?Z0_6MG.>G-\-96?
M@-R=_P"C<>_Y<?>L?R>W'\>O@6U<6GVB5-+3R(4-+*^JMG!N$%Y'I> YO$',
M+3.@W?IRZ;+"]S2""UP)TGEW*GMS>6[=B2@]@9B6&"YZDG!ST.R-N9%5[K4N
M,VM#V*E.?^$1%-DG5:5C2N2ZCZ$VG?8S,UE90,'-HV0=Q^L/W7U'*AQ7T/T#
MZXO8YFV]3U.0$G_6YCM&([5TYVD[G8;>:YT7*N-XCN%+==FY7#2%!"9,)A2T
M0#MV0H]&7P\"'T@K;L\A:E*=;055X'U5TQ?[)+YFDOVL4:V0#(\1*,V/)Y^$
MB@:2OJRVZ@MMX:RXM'-_#E@T .U"G$AU #7,\1E3!;P4A)OU"Q(()XA0/)7)
M0(KC:+<P79P ."\^-G9?:SRW\ IMR(ZLN3-OR5*&.E*)NMZ&M-U8Z61_$@="
MC^\DU013%N2W,QLMYC$.Z5$X%&S-'WC>0=PD;V'$<"%N;;>ZL9N=AQ<-3[$N
M. )V+E#TYT)=P#UH_=>8N?A=;)0JXU!TJ1CDN1W79KW:7-,X#K5Y\$K<6/[*
M\'4S8:$=HQ5#([D=7,=P>V(S.6S;01\ZZ\XMO"X!+@NA[-S&0I1?4G5N(SU2
M71K9"+K%B21]=$ !DYGY6]_[!B5C0VT8:)[PEEOP IK?V-!X<W'PCM."EAMH
M0X&0_'\K(7N+=*DJ0,[D66PK',K-U0]OP4E<? P=+$,DONV_FNN'6K<5G%'+
M^)?]Y=G#6[,#DT9-'8,^)*KN-QFF@_!0@0[?6OEM)HX_:D.<CNUV ^J LNK+
M6 L:W3NS$[1QZ)V2,A]^2\F'BL1CF%S<QF\BX#Z..Q./9"GY<ITCD.E"05*(
M2"1K=SW2#:X!)*'R3/-(XV#5)([@UC?I.0&)-%M-IVBZWBX,-N6,A8W5)*\A
ML43.+Y''  <!F3@ 25I5?9A/=#<D??G>C$XI98A,X_"]NHC<61!CXF--7DH4
M;?N;91\QNU;4]U4C\*#AP[+ZNI:9*P%)X-W0,75&\Q=2]>QPW%Q *6]F '00
M '4#*?\ \(EKXB'?=-=DUQ (] ;Z@OZ2V>3IKT^FFBAE<73WSBYLTCRW0XVS
M*TM6%@#/- %PYN&J,$M/1R4I0A#:$I0VTVAIIMM*4-M--I"&VFFT!*&VFT)"
M4I2 E(%@+5Z=V#)>5YDDXDFIXDDYDG,D\2<2O%D\E PV/FY;*2FH6.Q\=V7,
ME/K"&F6&4E:UJ4H@7L-/$U@[GN=CLVW3;KN<C8;"WC+WO.0:/I)R S)( 678
M6%YNE[%MVWQNEO9WAC&C,N.7]IX!<:3-D[M_-E(1F-VYG<&P_P O[4CJVYM7
M!2'L/NWNA';6H*S>4RR0F3MW:DU.D=; $^8W=;*XS10X[\R2>G>Y_F"W&+JC
MU,,]MZ8P2A^W;.UQ9^)T_+>WY%"=><4>8;BW0""_Z)@ZOV7T(@=M/2$-KN/J
M@YE+J_F:)8+%QSM[>,U;+,SZY?6)CL'-D>"UEJ_,G^03LMWE_*QW5_+KV_V1
MV^[69'>N(Q\C:^\H.UV%3L%OG;>8QFX]K;BS&7C-JW1F&6\OB&D3>N4X\_&<
M=22HJL?=Y^A>G(>G9NG]CLK.R@=%I9Y<36AK@/"20-1Y&I)()7-]&^O?7^Q^
MIFV>H?4VZ;KNWX.XK+#)<OI);O!9+%&PGR8ZL<= # UK@W  +<7Y7ORS['_*
MSVPQ_;_:3C^9R\A$6;O??&3;2G-;TW"TP6U3)"4J6G'8;'AQ;6-Q[:O1A1R0
M.IU;KKE?1/1.Q]![(W9=DC#07:YI* /GE(HZ20C,\&CZK0 %S_J]ZL]3>LO6
M4W5W4C@QA)9;6S"?*M8*U;&P<7.P=-*?%+)5QH UK>CKWT)L.('*]M.'.NO7
MER--+WX:VMQUM^BB)@CJOR%[7T]E[:<*)P3]0@Z!(UX@6N/ Z\#1**:5$C0*
M)!OY:^-U7TY4444A<(U^%7,JYZFVM[FPJ5'%-*@+ K!Y#0W/#G?C1".2?6+'
MEK8%7 D>PWHE%($&UCQO;SMQHHHG1$KC7CQYZ_KTHE$Z(LIVA_SJX/\ ZB=_
MX5BJV9JB3Y?:MEU<5E8;OGN+V^[885.X^Y6^MF]O=O+F,8]&>WQN?";3PRI\
ME+BHT%.4STZ!"5,D):64-!?6L)) -C1 "<ED6*RV*SV,@9K!Y/'YG#96(Q/Q
M>6Q4R-D<9DH,IM+T:; GPW'HLR)):6%-N-K4A:2""11%<*(BB+F<</&L7@MA
MP11$[\/+2I2B*A$];'P\>?+2I44%>U*BE.Q\*)4)G0$7^SV>=J*,\4?#;A<^
M\43%'5PL-+:_JHE$[DZ@?2]O*BB@2U//AQ Y6YT4B@2)'#][SN=/T43M02>'
MPZ^?+QYFB"G! /F;??\ ;SHIS3OX#[=/JHHHCXKW/#[OMO3%1AD$6Y$^SG_1
M137L2ND>9''RI@F)1UBV@^GU4JHHGU:>)TT /C[Z50A(D@CJ%KD :\SP.E,4
MX+5/=WMPG?\ @HCN.=$#>NU9@SVR<R@^D]#R\=3;QA+?L2F%DBPE*@=$.I;<
M_@L?-_4SH&#KG:(9+8B'JO;)Q=;?<#!T5PRATZO]G* &O&50UWU5Z%Z<];OZ
M-W>1EXWSNF-PB-O?0'%LD+JC6&Y:XJES3Q:7,^MA?M@;P&]-KPLN[','+L*<
MQFX\:X"AW%YZ 0SD8JV3\32%.CU&P;V0H"Y(-=)TGOSNH]CBW"=AAW$5CN(C
M@8YV82-IP&K%O[I"T?5_3_\ PSODNWPO\W;G4DMY0:B2"3&-P/$T\+OW@>86
M;!SIT/ "P4;_ !'EIJ172+F$O4)N1X:<N?GH:C(XHO!/@PLG',>=';?8"@XR
M%=0=9='^[QI""E^*^A6H6@I5YT<T/%'!7(Y)(7:XR0?I[#S'>K2'YF%(1-=<
MR&(T0C(*N9D&YLE&3Z0E+S/(2  .2PG]XF@@4K@JW%DN+123D,CW?L]RM.2W
M(Y-08^%?Z83B!ZV<;-PZD@CT,/>X<=)!"I'[J."+GXA66%N#L%M[?;FVM);]
MM9^$1X=LG(<FYGZU!@<64ZU$9#,= ;1<J],$J6XM7[SC[A)4ZZLZDG4FJL!@
MJIYW2OUO-7<\J=@X +&YD:6RN3E8+I#ZFE+>QCGIF#DU-)*D)6'%(^3EJ Z0
M^E0'#J"K5L;6YCTBWNVAUO7YOK,'$CF..GW46!+<R4$40U'@,_8%K7?/=O$[
M:QRG$!YF4I)2B'(1Z4M#A'^S+0<5\0)M<'4:W X]GT[T%>;W=!Q--MSU"M7#
ML) H.W,\%R?4W56T]*0%]TYLVY$81UJ&']^F;A]D8#B>"Y/3(W3W4S8*D.O-
MEX%MGXS"AI)T6^1_MWP#HD:#RKWZVL-HZ3L!'&&L:&\*5/=R',\5\V[IO^^]
M<;FXU+Q6G[C!VTXC@T9+8N5S&Q^R\8L%*-S;Z=8!1C&E(4894FZ'<H^GJ1C8
M@.H;'\Q0Y<ZUUO;[MU7)J%;?9@?FH?%V,'UW=N05=S=[-T<PMH+K?W-^6H\/
M:\Y,:/LC$_%<C;\[I9+<4Q>4W+DD37FB?E8+2BSBL6V;CTHL8%0ZNFUU:J5S
M)KTC:=@M=O@\BS9Y</UG'YG]KG<>[(<EY;N_4E[N-V)+EYGO3\K&_*RO!C16
M@[?F/$E:GQR=Z=T,PC"[/Q<F<XI00MY*%)B1$*-O4=<MZ4=(!YW4>0K.N[S;
MMG@,TSVL9]HYGL'$K/V_8+_<I&_U$.?(<1"WZ7G)JZLVOV([<=KFF,WW/R[>
MY=RI"7F\(PH.L-/6NE'H74IPA7-?U"N'?OF_]1R&WZ>B=':Y&9V&'.N0]BZ?
M=I^E.CK03=57$8<!X;:/&O(:1B\]^"VBUNS=N\0C#[0Q?^&L$/Y2$16?3D*:
M_=!6XD#I! JC^B;'L7^<WJ7\5N&>)\(/=Q7!S]<]:]:N_IO2%J=NV?+7II(6
M\\,&K9>VNTN*PK7XMN62VMZQ>=?FNI*4FUR5%RQ)(%<YNG65Y?._![6TMCR#
M6#]BZOI[TLVC9VG=^HI!-=_,Z24U YU+EZLMW0VOAF)#6VL:_N!S&Q[NOMI+
M>*@QTNAL..2""E+ >6!\(5J:Q;/I'<[J1LFZ2,M&SOH ?YCW4K0-S)ISHL_<
M_5#9K:WE@Z;MYMTDLXBYSF"D$+ ::G2' -KAX0Y:!W3WFW/D$N)>S8QD4DA,
M+#I$1 3PZ%RU%4APV&I3T7\*],VCH':;8@M@,TWVI/%[FB@'MJOF[JWUSZCN
M@]DEX+:V.4=O2,4Y&4U>X]K='<M)R]Y'K<?3=:B2I<I]:G'%$\2I]]94;V\;
M5W3-D9!&!(6QQ@98 #V"@7B/_%NZ[U=ENUPSW-RXYM:^1Q/:XU)]IHK&-X3\
MH[\MCF)N3D*-D,0&7Y;A)X"T="^=8\PVFT;6:1I Y9>\T'TKL]LZ"]1M](=-
M VSA=QF?XO\ T;-3O8:+(X';KO+N,@X[:DC&L.&_S.8>;A!()OU%#KBWK:_[
MW>M%==8].6. >PN'"NH^YH ^*]*V?\OMW<$/W.YN)B<Q&WRF_P"DXN=[<%FL
M'\LW<!^R\YO;!8I*R"MMGYB6XDJM=(*E1$$^ZU<_<>I%J01;0RN:.0#1^LKT
MS;/0SIZP()AMQ*<*R.,CB?;Q/8%=W/RU[*QZU(W%W,E&2A12^TPS"BK2M.BT
M*0Z'7$*!Y'45A,ZXWV]:'V-F]T1R.IQ!]HP6_FZ*Z*V.0P;E<6=O,W-I9$T@
M]SA54U=HNP6+3>9N[<$QP?Q-Y%IL\KV2S&3QJZW=>N[H_=6C&M/,']96OGW/
MTCVT?YC<82X?9,?T-:K4]LS\O*"0F=NV38$73EG$ ^_H&E9;&^H#\71V[!VC
M^U:&?U#]%X"0VYEE(^RT'Z6A6]S9787]YF1O5D\B,PE0\K>HV=!64P==@T<;
M;W.'T%:N7U%]&7XN9<'_ ,U$?I:O'_@KM*\;0]X[UQQ'!+JXLU"?"X"$*L:R
M/.ZTAQ=% \=CG-^FJP?^,/0S<SHEU,/)]M&[_FA5V^V>WUGKQ/=<(/\ "C+8
MQY /DI3;I2/JJD[YU%$:7-BYP_=>UWP(3^B>AVZC_+WEE$X\XY(#[V$*O_V;
M;P3_ ,T;NV?FBD? TC(JAO+\.E#Z$)ZC_I5;/4L+?^^V4\?;Y9(][3^I4?\
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MZ?H_U&WWHJX;$]QGV<NQ:2<.UI^JX<_>%OSM9WY?7+A;/[DR6OG)3S<+;^]
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M/AI,)K:Z,>Q@,OCVEN.8YKK5'RFO5*RL22\I;\R0^KXW_56M_J)45*3\0AM
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M;2&W5_&X@!1U)HJ5>:(BB+F'J-8M%GT"D2/Z/9RJ***))U/$Z<K^WC4E20I
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M;'>?A[^U$+Z Z72N)H<J^6QPR[53,3N*1\/;_>BP.:L=)^_K_35/_$/2P_\
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MLAO(A(T&M@Z-/&NIV[<K?<:!I\N\&;3D[N_8N2ZHZ*D:UUWM;1KS+!DX<V<
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MFYK=]B;GD)FCB!]L<1QS70&[=T.P)3>VMN1$YO>$]'7'@!73$Q$8J+:\QGI
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MP^!V_@<?%Q.%PN)@,ICPL;B\;!:8B0845E 2AMM"4@5E1QQPQMBA:UD310-
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M,#B!_/>BO3$M.*0+*+?4ZLI:) X"ZCX5DWW7VVV9&S=$6?XB]R#@VH[\!4_
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M_D[U'.)(6LF;'YL$C!2/6'@.!^\:#JQHW'"JY"R?<#$X-]R RMAI]#RHQ;;
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M.N-S6F!MO/@>VWE<ZE/W3S6*.YC!-*Z-T=GL[M-? 2<).SF,Z!P)2U/3(BJ
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M.D)?Z;O3'RP-P,<S233L)P/O*F[MO96Y"J7AU.;,SRKJ"HP"L7(<O?IDPO\
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M7L<;ER2#U)RW<.>),9*P+A4?:V!5'QZ %:I#TEX^-ZIN).K-WJR[OOPML?\
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MQ0T2"0>' >VOJ"&WVOI';FQQ-'G!M .-?TXKYRWG=MWZUW1SY7N\JN)X!HP
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M'XR9.9>?BX^,A:PX[*=894HE"5&PN; BO5MFLMJVV2+8K9S(GNC,FD_.]K"
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M/^RC\@N;V!K&$U'83WJWY*-(7U,O?FIW)E>D$%.)PF\939X_"@M-P(92>7Q
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MO$@YXK3]1,ZAVV_M[Z$-(8' S,)(FJZH<\&H!&5!_8O9D&\1O9A"YK#>-SK
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M6G7FH6#FR4N.ML-*??6(+;H9=#3*"I7PG0&M9ND'3DMN;C<WVX@J 72AN9-
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M3&B-.-K1!<E293C<=#"Y?IH5U*"OBLDW*:UVZ[K:6UIYVI@NR1I8XFKJ$:@
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M7YE^=(3'BAM3+##JW_56SZ:WEM,-AWTR +@=6G$B^1<75E;V?F3.TQ,;GB2
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M+TIFSBG%K6M:E$E1))HJ%D=$11%RQ6,MBBB(]]0H3!UYTHA" ;']%*)12O\
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M7N_=6]YV7W+DGG\L_B8 ?D.,MH9AX?$JEL0F(. Q*%)$:(9<IIIMF.A;[JE
MGJ-R.FL[79>F;6*UJR"*1]!J-72/H7%TC\W/H"278"E!3 +@;AW67J7NLTMI
M'/?WD<=7^6VC8HM0:&Q,J&Q1 D"C?$<W$T)&B<WG8;3JFMPQ7\Y+0H>CLB'-
M=CPT.DCTAO7+P%_,K7J.K$P%A[^&0^TJ[57'RW^[MI8N_"[:<YB/&\<?*8<
M/^T?@?JM<,5W6T[#TWZ?/;/NL3-UZQ: 6V[36WMG</->*ZY!Q:VI:>+3BMI1
MMB/O8S#[I_,)F9^%VZ64O;([,[69CXO-9>*FWHIQVVX_HX_:.!4+!<Z2@/.
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M^FX!'91ZX0N]A5IK7-=J>14CEE[5N>I38;]LL?\ 38'MW&RU%SRZIGA(&!C
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M]'X0=W/NA<^Z"XEZ%@UJQD1^"$)*E/*CJ82D&Z]*P[W?]LMM0W&_:-(\0C.
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M@RENQ^( (<'M&?BH#J)XURR6_8370VH8?THO1@7MO=Q,IN'>F\WIF5PF(L[
MVQ+=D1Y(4^T6GTR<C EQY3++BE!"8Z7 V[J5H4$BJ+AMU8Q1V-B&LF?@7BA
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MCNI'1$N>US@6-)\4CZ5K5V+6TJZ@&-!3T?9>IX]V#Y^I&0Q[%Y](P_26N?\
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M@: 7/<1QS QY4I3BH!;JI3!;#W:\SVYV7E-KY:3&G0\FTQ PL';TA^"SA\=
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M\R[O8FXG9Y<C#0G)KL:5:3VTJ*FE1PRX'=-AGVYQ-I66R<#5I&JE.#AD>QP
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M05>DD7))ZE<JV;MQO=ILX_P;(S,^3Q.=B"7&OAH1[_<%9+6R/\1. X+7VT\
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M/H=/!6BP'$KWQ;- $ZVXV\-/T5;E-?:KD;:8\576Y#1):DRYLF'!0MI<AJ!
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MI.TWI\E3<6#&B;E.1,B#)QK3+<9:F7S%=?9?86AQ"EA2%**N.@JJUN=T&W&
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M_3VA;-R$^5FV$F2XPGT8;$6 U$:+$#'LL%;C3$1DN.J0PXMU96I2E*4I=R;
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M[!9L#ZEK+664D UT%TUPZ@(P+@T.X@@Y?6>T_D^].F.#=QN=TGKA7S6,IPU
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MY4Q_/LP$Y-X3)Y>7DW4,I92TB-'#2?@2C47OJX)]SD$M]#*(FU+0_  ,KI!
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MVVVCM(&0,P8P8]KESE\V?=;X,%3+*X =C:X!:[VMZVW=EY#*.-J.Y>YDOU0
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M(<ER4NI D27G^E3OJO Z65IP%7=KLI9F'<=P>3&:D-J0T4. IE@ES-'$/(A
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M"T7BZ]FQ E2F"RYTCI0XW=-TK"C<:]UOTE;,?N$;[ILDKG.C\IKWL%2:8,J
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M@(X#FK]-<?MH==WKKJ3Y05G;HXL@T?XCR252RK9VMV]QV$00W-S5WIW3HM2
M [(OP/[RDHUY:5?MW?C=U=<G&./!OT#]JUMPS\+MS8!@Y^)YT7*NY(C^>R6,
MVVQI(S<]B" #HS&ZDKEOJM^ZAF.DW/A>NCN+H6]L7<&BOZ=ZR^D-H\Z^.XRC
MP1"H[\A^G8MF[2BP,EOF=N%UE"MM; QXEQF5I!:<1B&D8_;T/I/PDRI:$+(Y
MV-:J9TEOM;+-AI=W+J$_Q8O/L;@LJ]<VZW62[?C#$,.7AR][L5I+NEEY\I;M
MW%R,OFY2F0;E3CLN>Z5O%/,J+CG2/("M[ 8[:U#&X1M&'8 /V+#Z?VUVY;SY
M\V,<9U'OK7Z5G&(V9"D[@V?VXD*2G;7;S&*W3OV0G_9/9):49#)MN$?"I:E=
M$9 .O$5HV7<D5K-N3?\ O=P[RXAV9#_K+J]Y>VXN6P?X3,7=WZ?2O%O3<CF>
MR.6W#,*8S,A:G&V]$-0,5$06X,1M.@;:C1$#3@#>MK80-M(&6[<2T8GFXXD^
MTKCKADEY<5 JYQP'9D %S0_/R.1ZH+"Y >W1-A9:?$0M9"(#*'&MJ8TL@E/J
MHARES'-+^I,0DV+=9\38W3&\DIIC!:TG_7=7O&D=QYKL+J,[=8Q[/"<?FD_B
M(_3V +HG>+C7:_8.+[;8LAO.9U#67W;*;(#A6X@*:A*4-?3C-GIL=+W-:BRU
M;GN#MSE_D1^&,?2?:M;.T10B!N9S7-[*$YG<&#VRU?TYC_S67<2;"%MO&E,K
M.2UJN.DF&@M-ZB[SJ0-:WUW,Z"T?(PTF(HW^)V#?CC[%?V7;HY[G\5=-K8P4
M<[]X\&?WCGV56_.W>>[9;?WGC.ZO<?&8B1@96=?VYL'::HD2=A,!%Q0;+N3R
M>(<2['9@X^ %M0@\WZ7JMK<-UI;-<MNL.XR6#MDVQ[VSMC#Y9*D/>79 .S)+
ML74-:$#(E;NSA-]=OW2< DN.D<!3,\@!D!WKZ*P\QW*R3&ZCA\=M+);$=$AV
M+F9>69;?6PB&P\Q^"86"A:EXQEMY1)_DM7'P]1X>:OBVV)\0E=,V_&;0TTSQ
MU./UC3M*WH+-0)1N;<CK>U\7C-MQV9*<C QT:)EX2 Y^/..QVFV)7K-=3CJ5
M:EML*(:'P@ BJK6U'XATUR2"UQ):?J<Q3AVGCFJ!0X\%+9'==F#/B;.S&5:&
M8RFT\3$PGS#B%M1Y<>/_ 'QAQM1*42G'2$&Z0?@MXU1N&S/?'^.MV?Y=D[G2
M4&)!.![0,_:L=T@UEIXY+)\=N;&1(\]&Z<=&DY->1^3;7&;:BR6&$>F@%"6B
MAEYQV0L$%84+@6UJU-9W,DK'63RVW#*FN()^D #DK1D#11V=5?)6,S.S6\BS
M^*MQ(>07&DIQ[LE;^3CH;Z70!\L#'9>6GX2 X4\>'"K44MKN;V2AA<]E1J H
MT^_$CCDK4A=&"*TKP5A3E-]RLH,CC(&9E0@4E+R69 AK:L/A#JDAM2;>!K)%
MEM#+?\/.8Q*<\1JK]*QG37!?K;73\%N6!BX[K#60R+D1[)9.$7!@)+KB%QG%
MC^4Y\PVM3:I _>].P3J =;US[[\1R&VB#Q#&^AD J,,Q3EPJLCRBX:S3416B
MJ)R4.#$>ES(9ES\,TW'QV,>8].%'4XM05+5'7<.OEPZW!' F]7)(9I9&Q6[M
M,,Q)=(#5QI3 '@**VU[ TND%7,R'#O2;8R$R!+S.Z))G25-]6*P@>Z&VFG.$
MEY"2.AI">"18JMX<8\RVM[EEE8-TU/CDI7$<*\2?AWJ@B22,S3&O)OZU6.%Q
MQCX"%%@04KG-N3<A.6.MU"/74@-I43T(2E";\+_75P74S9+B:5[O+C(:UO"M
M*^TUP5LL86QL:!J=B3^F2M.5?QCV8,;:YDJDQ9#+?R8ZU=8!"3Z-@00L\CJ+
M\:N6@N);0NW-K1$YI.K]O*BHF+(Y@+<G4",$)@IA_C<N9D7L&A_U42@VVW*F
M1EJ"6U(825I:2IU:=2HFPO5NXG;%;0Q"/SW"FD9!U,03QH JHF.FF>X.\NN?
M,+7&-9;:FM1O\3.Y&*[)^8;+K*FY+99427$'K6VVOH.H!-ZV\,L=U&;AMMY,
M[6Z2,*&O#M'+!8MPR6W<(WR!\9-05M8[?P^WQ+W;'R"7IUBIHYID!"I"F[-*
M96TL$+;4;I"DD7XUHY]SD>UNW3,+83@?+-2!7'#M&:S(;2KOQ$9U/'VLO>L<
MQ\K9V+Q<_,[@6UE)V20\W),I"I$I3B@2KTDH)4VDE?[V@%9UV-PE++;:P6QM
M +=.#:=I/T*S!Y U27A&LD@ZLU@.U,;V]4I>7RVW6<OE%RNB&J4M:6Q'96H,
M69NGJ+:!QO8^%;?<)-W\L16\OE1:/%0<:8X]ZQK<6A>2\:W:L.[@K2K,;BE[
MKWTUV^Q;60F,M,,XM+0C0L=AGIL=I#BI+P]-M+<0(6H#0E2A5F&&V?L]M_69
M#&PN.LFI<\-<3AQ\6'L61(Z2&]?^%;K.D$ 9-)PQ6-[9V#NC;,G)9_N=+PC3
M$YQAMN=#"=R04S_2"')$EJ'*;,.8Y;_=06E6M<DUG2[GMT\;+#90\O:#1KJQ
MNTUK1NH>(#LQ"I+)O,-Q= -:0*D#4*Y5-#@>]>;<F[\[MK=*<#MK,1,HSDH$
M/+-R,9CFL0N5$<=5'=O$C%86]$6FR@DD$*2>-ZJL;:UW"S?+=QN8^)Y80]VN
MAI4>(\#^U7)72VSF%I#HY!4$"G8<.Q<EYW?&XNZ_=S(;5P0;EY1IN9B9DV0?
MDT2<9\C)C+3(E+2E*OEI3ET$ZV%A746>T6NR[.9[BHMW$/#<Z.J#@.T#WXJ]
M/>,F?'^''W[:AQYCM[EX>Z?_ &O_ ):.SV+QV1:VQE8>7:FXW)S<%N-[*YB.
MT_%4TA3F,?C1W!"6H]!<:+B4%0"AS-BU=LG5^[O@A,S)VT<T.9I::$'!P)Q&
M=#0G&BVFU..W4OKJ+S+1AHXC$ N!#0>\K1VW.X6<[$XZ/NB$K&;BS/<?8F"R
MARV-;$S-X&/CNO%2\7/2A9^6EM(82E3G3U%-AQ!KH;G;H-\E=:.#XX+:X<-+
ML&O+O$'#F*D]E59CN!)IEG(+BP#V-P%>Y6&5W[V'^9O<4C;/<7,[IV)'VWM9
M0:W%M?#MY&9$0PZIU^=G&'/3E&(TASX5!RP (5R(F+8-RZ9@==V#(I_.F!T/
M=I%:4HTY5/$46=-<6#V1PVVH7 #B\UP.(T]U,>]<^NSNZG9&9NB)V>[@-=S]
MH9/"2<PQO>"LX>8G;DAZ+#>3^#3)[DN+GX626E*VVRZ%I/J(-KVWC8]KWZ.-
M^[VYM+QKPQT1\0UBI'B H6%N1-*9%76SSVF@/H]E-;>( R]]<PMD?EYWQD=Z
M;CF[AR_>1C:.^8$R+AYN"W'C59#'9U^7CHY5.W-&CAC*C'R%%N,\_P#WJ.MQ
M(2ML%0*M=OFWLL+,6T5F9K$@N:YAH6@./A83X:C%P&! .!PPO7-Q'=7IDB#0
MXQM#FX %U,33GP/-=5/;MF;$W;(V/)D0&7,[BHFZ7\+ G-9C;B7F'A#.7VC)
M4M4B+CI"%A3+2PAZ,EUUA0]/I2GGK6"/<+7\4 XF)Y8'$:7T..F0<2#GF#0.
M&.)Q=RLC&UEQCY4M10BA!;0'OJ,CV%;HQN::?3&>CD>F\$E0%['JT4DVT/A6
M)+$15KLPM((M)-<E[)T$+*VB5!*K.,*'$7-T'VI.AJSJ#FT/<5DVTCK>82,X
M%7+:&4&.R9@.MMQXTPA*&FFTLLM2D:*Z&T@(0'CJ;<2;\ZPW-HW2*DCVX+<;
MW;?CK9NX,QDXY9>SDMFY9DN--/ ?S(Z@+_\ >EG37P2H_435IAH2W@5S$(QP
MX*_;9D]#J.HZ*"670>!L"67/"]KI/L%8$HT/+>!Q"VEY$+FT$H'C;^A6P72E
M^,7$?[2*JZO$LK/'_45K6,#HDH?E=]*TK65':%X8N5EM9!,1?HMXYYE:FPV7
M?4>G.N)+SSX<><;2OH0$ MH0%I(Z@2+U8EMVM<Z85+C3.E !P&%>W$GL6SD'
MXK;6BH\R%V7'2<:^_P"A7V:GI#,I LAP=#@&@2XD >P UBQ/H3"<QEW+7EFH
M!_->K%O?&M-[@Z@WT!'ZQ5N<9%9=L/J')9Q"<"TA7L)'F18_:*U<[:$A8SF%
MCZ',%>*2VIN2H@$@GJT^G,U#'AS%06 %>MD7/2;CJ%O'V58?7,*_%@5%UI:>
MA8XI5H1_:L0/^[0/KJ0ZK:']/T"V5 <>:];R0XAMP?Q65X:GB/<:Q?E<6K%>
MW2[N1C71#SF/>5TI1)#V/<-K:N@.L)!OQ+S  _TJU^[1F7;W$8NC<'>S(_ U
M]BWFUNU-D@^TW4.]O]A*S68BX)UN.%^1X:FN-?G7@MS9O-0.*MF!R4; [OQ$
MV;(;AQ91>QS[SSB&6DB8TI#1<6XI*0VF0$$F^G&L9SF-<*D+M1M][N.QW$<$
M3W.C:),!P9B:<?EJMT+WSMDEU$.<]EW&;!QK!8^?FEI4>"",=&?3U*' 7K'=
M?6S:AKB\C@P%_P#S05R;=HOR 9&-B:<C(]D8_P!<A4'MUY): <;L?=T[K'PE
M]O$8;GQ4G+Y2,\V"/ZR ?*L>2_N /N+2>0]NAG_/<"/<LF+:;,FEUN%G%3EY
MLON\N,@^^BL<_.]V5GIPW;G ("M$O9W?42.$ V^);>*QV26>GB0-=*TMY>]:
M.\.V[?9#DZ>Z-/:(HW%;NSVWH!HU;GNU\3Q;!95)[C+(P>TK"\SA/S-9QL-0
M=Y]J-CMNG^8[!PNX]T3XZ"=0RN2G!LO.)3PN4"_.N!WOIKUQWYI@M^HMJV:V
M=FZTLWSS-')KYRUM>VBZ_:][]#=H=YEQLN^[K,W(37,%O&X\W-C$I [*%:0W
MA^2;/]R5*=[@_F;[I9-U8*O3PF!VMBHC+JQ99C-90;B<:;%K!(4G2O*[O\GG
M3/45Z-U]0.H^HM_W4.+@^ZF!:QQS,<;O,9&.Q@:*8+T_8/S46_1C!!T7T5T]
M9P"G\R2YE<X#+48S;AQ[2#CBN..X/^4EO]R0F7VO_,XA[K2XF1![G;'7U_$H
M*;4QF=G9-L'IL;I7 U\>58NX_D[Z8:P-V*^<P _+/&#_ *T?_57OG2O_ /,(
MVN)GD=:]&Q%HR?M]V6XTXQ73'?";V+I7\E/^7M#_ "P;FR_=/?\ O\=T^[N4
MP\G;F-R&.QLG";0V5@)[[3V4B[>QTR1*R60RV:^6:1*G2E(*64>DRTVE;BE^
MR>E?HULWIHU]W&]L^\2,+"\-TM8PTJ& XDNH*DTP% !C7PC\R/YK=R]=+.WZ
M6V3;OZ-T);3"8PND$MQ<S-!#'SO:UK&LBU.\N*,$5<7O>XAH;]):]E7R,BB(
MHB*(CZ:419IL3_GE[_Q![_AHU5LS5J7Y?:MO5=6.N#?SI]L.YG<N/@XG;+;?
M=G);GQ^"SK^SMT;+WYV7VMM#8?<!82SM;=>Y,=W0Q^>S+\S#2W/7$O$8V8^U
M$2ZA+;CBT-J*II SI1=O8-C)1<+B(V9DLS<O'Q>/8RLR.'!'EY)F(TW.DL![
M^:&7Y25*3U?%TD7UHJ5=*(BB+D,UB+:(^^_&B)W\=?IPJ*(,,D[Z\_LM445-
M$[BE$HG>_A1$7M2J5HG>IJIJG>E5-47J:I5.B(HI11$44(HI110BB+%MZY%6
M,VOEY#94E]Z.($4I_>$G(K3#;4GS0'2KW46[Z<M6WF]01O ,3'>8[^&,:S[R
M /:L"@0Q#@18P%O1CMI(_M*'4K[35P"@H%L]UNC/<R3'-SB5H/\ -'N#\#[7
MY"(VKI?S+\/%H'5TDI6LS)'2 ;JLF.E)'#XJ[CH"R_%]21.(JR%KG^VFD?%U
M?8N><^EO<3<F:1WN/_5#EQ[VD=3AML;ES;FET^BA1T^&.R5G7_357NVZ-\VX
MA@'?[UYG*297R<5S1FY;\MO(3;*<7*D/2'% %1""M2U*/$V"0*Z./2QS69!H
M54-N?+H!B[#WK<O:;%OX#MM,R$B*_'R&XLF[+?2^VMEX1[@1@I"PE83Z !'D
M:T]S(VYW( $%C&]X4=1$1M_#1_(QH;[>/Q6X^UL7^\9',R.*2HB_)* 0D \>
M K%W=_A; WBN9LHM),AR6I]_YQ>7RN9R3BCT+5\C&!-[1V3\:D^'5;6MWMD0
MMH&1#,"I[RM3=L=<S%V9<: =@_:J7Y?=J?C&Y<KO2<@F/ ZF(76+I3TIXH)%
MOA;'EJ:UN_7U(_(9FX_!=U^#&WV$-B!X@-3N\XE;.D-G=F_X[:P7(L:07NGB
MD-L*!0G70=2D@5:C=^!VPG)Y'Q*YJ9GXF[Q^0'X!6ON;D_F,]+9:L8^)91CF
M@-4E;0ZY2T\OB?5;_4J_L[/+M@\_,\ZC^KX+$OX_.GT#Y6X?M^*TSMJ$L.[N
MWK)X8:"<#B5*T3^*YB[3[C?+JC1%+U'"KUY-Y]Q%9-R<[4[^%N/Q*[>VMV[5
ML8H*2/&K]35GT2"-O=O,?%(Z)N[9:MP30198Q<&\;$,+OKT//E3MCH:>9^)W
M-S_\.$:!_$<7'V#!<C/'Y5L&_6>:GN&7Q6A\2VQD.X,[/Y"SF&[=XQW.R$+U
M;?R382,?%-Q8J=FK;%O(UF;A,YT+;2+^9,X-'<<S[EV'3UB+#977L@I),X_Z
M(_;BLX@JDXG8;\^8M7X_W.RSF4R#BM'48*$ZIP-DFZ@W,F+&E[$)JFC);X1L
M_P"[VK-(_C(_4%H;MSG-<\_-(?@%I'>F0:EJC;?*BF-)2_/S2D$ M8#%H$G)
M)N""%3;(BH\5O"U;,N+&59_,<0UO\1P'NS]BV'3>WM=._<9Q]S W5WN^J/U^
MQ;/[%[*V'G6G>X>0W-)<SF$D?C&5V\[A%(Q3!6Y-6PVWFE3E-+^66VQT-%@=
M2"K4=(OJMYO;^V(VR.("V>-+7A_BX?5IQQJ:Y\ZJ7-$\CKMSB9"22VGZ_<M+
M]R,[(RVY,YG)KR7/6><+"D+ZD)CH!*2DC@ D7\K5T&W0L@M60MP &/>M=(QT
MK\ =9- L?V/BYK6U'MQ-QG'=T=ULJSMW:\4))D-[:C2TL1_11?J"<MD5%U9&
MA0A.MA6-<7#)KTZC2UM6ESCPU4_4,%U=[:_TZSBVF/\ G&A?VO=P_NC!?3#M
MYV][;1>R_P#AO,8[:^+QF4&0Q.?7(AIG9#><R ^Y\SD-TSHK'SZ8S4I2EQV&
MGT60JXZ$FQ\RW'<=REWLW,1E=,RCFT-!&",&L!-":8$D''F5F10MMV"%GB8W
M]#[RKILGL9@-LQI\3&SWMY93,QV\JQ 1D\KM[8VR\'^&Q8$1R+BXDA$M;DM@
M)=D&0XZ'GW"AIE( JS=[W/<%KI0(86.+:Z6NEE=4DU<:C U H!0"I*N.>#*9
M *5X88=V"M>%Q.TNV6W-S09<K.[AQ>U'(TS#P&ER$?**R4N3+SCT5+"E&# :
M4.B.%N%2 OI1=1-LB62\W*YB<P1QRR@ASC3&@ 8#S/$T'!6GNTBK0LV;VUVC
MWEEH$W;NS9C^17"1EL5EL?F75H8B,):D&3(>DJ4VPTT$@K5U(Z2/&L1MQO5C
M 6WL[0S5I<TLS)PH*9UX9K$<YDAP'M6?Y6%L:7$2_@F4Q9?RS;J%3GG,A(D!
M002ZQ*>64J=]1(-T@:BL"REW,$B\Q;J(\. %.!')69C'DS.BN4C,?/,P).?B
M/IF8B.TZMU]-F,@F.T%M(="K$^LI((%OB!M5,5F8 ^*T</+D<:4S;4XT[E:=
M+4ASQB/C17Z=NW*[U;QL>">J4^6FS%;>;99:0@767$J4VRTPVA.IT2D"L.TV
M^/:/-DNC]TW'4023^NM5$LIN UL7S'@O+*VIO:1.5(C/X^06WB64Q,G&>+2$
MVZ0HI='Q)MP L*O0;CL@B+"" [.K2*^\*S+%>:M0X=H6QX BQVU2MY2$F<M
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M5NE<W<NV=E-MG#3-N;KP^1B!J8^9T54N#(;?;?4HI0Z' X2GKG/OMK?'TFZ
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MM%Y>RP<WZG>]Q ^@+#M[I#&R]OP1:[KD>Z>1T4XH^ZU=I:/K=R2=BXBW@US
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MN 74]2AHOOP[,(XFAH[LOU!9COR29>56 ;L8>+&QD5OD/E64,V'+XG!RJNR
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M&1N<;SQ8Z-SOE'U<Z"CZ2WMV[;(63=&;B\RVLL9#XV"3Q>3J;4$-J?*=D^,
M8/:]HW/>Y%^%?0:\CIA@I7X:#Z_II2BBB=QXBHHHH47%$HM)RG.O=N['B?W)
ML>,+_P!6-!BH(N>5P:J8<UZ$]OE]/[?'SA<[_2>XJ8=!4X?%M0]M_P!IJ^VO
MQ7)7A]R^5_?>5Z_>?<RD_P $IB*.!MZ"&8YY<RU7T)T,S1T_".;2?>25E;[$
M6[1:M/\ L6_$5_6H;^-\;MMLVLAM;ATM_LXJC?ZS6_MW4,A'$_K7(;7#YEU3
MD*K4>#F[;E9_:N'3AIC&YL;E)F3=SPEQW,=D\5,1':8Q:X#JA*C3<;(:<<2X
MTDH=0X?4U0FKUQ^)$QD+VFU='330U:X5.JHP((PQ-00*9KJ&6SX^G;R>IH96
MMIAB./&N!IPIFM][@$-T19OXBVY+<R#\1S&!DA<9B.AI:);DDO6*))64I0&_
MX2>KE5NU?('.BT'0&@ZJYD\*4X<ZKS>6$_/P61=QK1]F[>80;'TBZH>)]%2K
MGS'55K;36\E<>=%CN96@6J=FM;;F=PMF-8J/E6\IC\#,?W.9ZVW,>_EOQ"48
M,G"645MQEXIQI+J% =+R"1>YJYN$EU243%IAU#RZ9AND5#N9U D$<"NNLH!!
MTO-,VM99@T_W5M+<\U61SZF4+Z@'T,!(-[:@<*HM&B.VU'E5<G+'5Y/)7/?D
M\0Y>*QH-D8S#M@I'PCUI"@5*M;C9)JG;V!['RG-[_H5J2.K@.06@,IGE?B[D
MPK/_ ),PV6DLB_"1*:1BHI']H*FJ(\+5F3QAQC@'UGBO<#4_0NRZ?MA#MEU=
MGD!7WN/T!9GLW<N7Q/;O)J@9G,8Q4S.,0V#C<K/@E)" J26Q&?;2GU6_A78#
MJ3H:7EI;3[DWS(XWZ65\30>[,+F'>8&Z?T[5C69W1,CQ\%MZ;(9E8.%N29OM
M;,F''>GIG8K#R'G/_*BT*G*BS)*8X6R5EM2PDVT%4RVD;BZ:($7#V-BP) H7
M?9RJ,:&E:56\Z?9]]+</'\N%QKRU4;AW@GW+$FWRWV\R.3>5:1NS="&U.$_&
M\QCT.2Y*E*XK2J0L$^ZMFT 7S(F_+%%]. ^"UUP#+.YYS.*YTWIU9*1BL.A1
M4,GEH,-:021Z'JI<D7\04@7]E;.67RH'/XZ2NIZ.L1)N)N7#PPQN=[:4'TE>
MS:"3E-XF<L=3?SDR2T"/A3'C%PLI X!*&FA;RJ7_ '-@V,9Z1[SG]*UFZDRW
MLTAQJ\CW8?J6/[HSR8T27.7\;BE29A'-3SKB_02;ZW"E7_U:RHVTPX +'L;)
MUW<L@9\TCPT>W/X+/>RD#!8:5VVQ^[9./CC<66R6^\HUEFU.0<HK#Q7LCCL;
ME;!7]Q4B)ZC@7=)0DIL2H Z&]DN)X;F>V#BYH$8+<QJ-"6]M30=O<NOZK,;+
MIEE'A%$P, _3V+?>Z^_'8+LQELOD>W^[,-)8WOD,1@=U[<V5MD[?Q.W$P$9>
M1CMR0H<8*=RK,C*3UMY%QT^JMM31 "6@FM;9[%ON[QL9N$+PZ%KG,=(_6YU=
M(<PD_*0T LIA6O-<FYP&#QB.-:K8>V\K^6S\V&*:V[M?-9O;V_<043,RQ*E.
M0\]M[)XUEN3_ (@?F)*1&QB24NQWV0D?$A*;+-JU]PWJ3I20W-Y''+8/P86B
MK7AQIH .;N!![2<%8+@X:*U;RY?IS6T<5@/^RG<LSYY^?FLEN&'!C?XS;],H
MSS9>:3.8C18ZGF<;'=E=,Q]Q3A]1?42 ; X3[@;K:@QAK(XR3Y?V,,*UH2:>
M$"F"LO[%M?<69V-N'%Q\;*Q&WI&/C9:!C<E(?B,O3Q#=D=*I"9#B2M4LMI40
MLW/5Y:5J;.WW*UE=.V27S71ES17PZ@,J<LL.2L2EIHTTSQ5WW--A]M<GCINT
M,3C6\%,81&@2,9CHZ8D!A?38AYE%VY&B4EPGK())/&K%HQ^_6ACN97BZ8ZK@
MYQJ2,P0>'&F2M/<+>2M!H(5DB.;<RT*3OC=>>R\?'*F2(<3"8J2H?//-CH=<
MF@*L6DJ78"UU'R%9LKKF&X9M=A#&ZX# XO>/E'"G::+#(:YCIY7.$=:4!S5S
MPR=JLP9<W)YC(920MA<[&[8:Z&6L7! /RKC\A0<D*E*:LM00!TI(%R15$KKW
M\4(;:!D<>K2^4XZW<0 ,*5PJ>*LTC,6N1Y=05#1P RQS5QS;&RX>/P[4_(YU
M^5(CLSXN,QLM6/B1')B0ZV'7[E:BD$%1M>HLY;^ZN9?(CB$;'ECGO&HNTY@#
M^U8]PR*"!CI'OJX5#6FF?:JV>VW@<OB,=!Q&^%8_(1&@78N0ER&?5GK_ )CJ
ME+476W%%2@FZQ>R>-6+?=7P7#S>69="30.:T$:,AW#L"J?92&-KK>;2\"IJ<
MW*P0=D[Q5+AQYK?KNQFUJ?GXV6T%RXEP$%LI</4>@ZGA?E6PBO=HCAD?;O M
MWG!CA@UW$8]O!8ERV_E>P2L/G-&+FG,<%FD=<; _^1\=L&;US 6$9[),HE/F
M6[\*4-O.("&D]7-(O6(]EW=O%Q)>1B%AJ8V&@TCB>:I$EM TQB"0RN% YPKC
MPI57+,YG=FT<-+C0,4Z9SJ$-)?\ 5"G/F"D)2E*"D$(2>!!-4"PL-XNF2/F'
MD-S:.2H;>3[= YKHG>9P)YK']E]M\]G7$9W?,_(OK4[\PELRW66XC=RHH;6I
M8XITTXWK*W3>=MVR!UGM[8FBE*4!J>T?M6+96-]N$PN;IS\ZBA(H.Q85E$[0
M.2S6WEQ\DTRF:IQ)@2NEV0E*B4)?X%U"E&_$ZUM;8WLUI#>Q^4XEF3A@.[DL
M.=\-M=RV[W2L.K,'$]A7DP.V,5BY\.>QM^.Q 3+02[*"2^^"L70XI5POX=2*
MRI[B>6!T3I29BPX-R'<L6L9G8_03%K&+CFKIW%B;3F=Q&=OY*$TK!2,=#?;Q
M,,F&Q(4\HI<_<'1ZA6L&]JP.GY[]^Q/NV.)O&2.&MV)%,O8LC>8[:+>([8C3
M;2,!TM.FM>Y:%[B0_P JVR<^B%%FY?$;C=:>0ZB)EOF(,)XHZ"F62 XELJ-E
MIOJ+BMKM=_UU?0ZY((I;(.&);I<17ZHY\LEE2[1L30[RKI\,^D^'745ID>SF
MNCMC[LV$SL;&SIV>V[%B)2D1I<B3'"WV2G1!(ZG5I\ K6M%O+-PCW5T<<4[G
M$8M:TFA^CW*[L\#)]O;J,8()%21B/V+EC\T>;[#[HQV,:Q^2A8K</041=PXZ
MR8+KB5 H8EM)*4D&YLM(!3SOPK8])W_5%MN+[::"67;SBYKA0MKQ:3GVCZ%T
MLW2$$FV?UB*:"VF94-JZGF$<"!EV$T7.^R-AM[DP+&Y=W[5R.[MDX"&YAY,/
M$9%4>?*C>J]+CY*>6EAU$=PJ4CATD"UQ>NWN96;==RVUA-'!N=T\2-UMJT$-
M#2&@X%U .-5RMWNTFZP6XN6R.MK.-T3W,=XB'.+@21CI!J.26]-^=A-L=O\
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ML7T78;S,V9T2G>N,ET%F&VVZ\XDE:0- #J>"36AW&[\H!C6O=)@X4%1G3$U
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MB-1XL5M'K%M\.J4XXJXU^_W/4<I_&73C R,TA8*B-VK3Y6HBFHNJ2XG"HI@
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MIT;1 \.!<0'8=QH.(K@."PI&OJ33%9YL2+N_"P2WN['9G*[<CN&5A\)#<?\
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M$<8#:\R.7LSX+SO=KVE39RLWGLXUD'71^'8Z+%#C<UU;B&T-A_U$A+KBE7
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M1/O6E([3ABYR>LD(3D8*"3?7XG+#W7%6XW@WK>=3]"]7W*(1]/Q6M,?PU?\
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M$Z?.0@/_ !N7?_D]-#D\UB/\ ;A_\-A?_94K_P!]Z:')YC%'_L^W!_X9"_\
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M(ORI>2GRWGE+DY^= EML?*Q$>FI+385=8)JU9[U%N[Y=NE@#97!VN=XH*@4
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MC5RTZ?W&^ZIOMQA<S\!"UK'%QIJH-1H>8JM/<W=E:]*6T-QJ%S*YSF 8FM2
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MBFD(D-K*RW+0HI44N"U=SN.PS69M=IA\F9VF5XYDU:_O\1P(S;0<%RL]SO\
M?79?O+?NFU#2!@!AI;[@:<:U)Q*^D';I*O\ #<!V0'$$QWEM^JD)'RR5.-M.
M-$#XV7"VJRO$$<JX><_?. (^;]>2T>\AOXFC!0!K*]ITC^Q;)S?;+=FU8,+/
M9K&,1\3EW641)D:?$F /2F%R6HLIIE1<CR@TDE:2"$G2]ZU]KNEG>2/@MWZI
M65J"", :$BN86"V^@G(A:#K XC T7MQ\J.SC5(DR6F6V5K0VX^X$?&TX5)2"
M;$_#I;D*K!=(XZ14XJW>6PMY6N(P<UI]X_:KGZK,A+3C3\<LNCX9)>:1'LLA
M(4N0M0;0A)XJ)L+5CL+FN>75J!R)/N5ZZ8&P0M:,=9)'%;2VVUTXN.";V"![
M!I>WB#6JF=C3O6MWD5O=3>("BTWT2GD^'JBW^L+??5XNK&#W*Q&, [G19A$"
MOEU)MJ0;#_22#X6O>M;,?$"L>[ \^O!3;"@!<ZWL+7'TM5IYXK&HO4VX1\*K
MW!%N?'33VWK&DQ]RR8FZF%>A5_37XW!^L'7VUB'-4.9E16X$FUQSM]MJJ*N-
M908YK(( ZD*3?E<>ZQ-8SOFP4M&FI5P0S_M4WX"X\R;>[A5#S4!7WD:6D*W%
MD!Q0/,$ ?;4\CQ2$ELHT\T\6TVG!PDH0W=LR(KQ"$ N*C2'V4ATA-UJ2E'.]
M<Y=MTSO%/K%;:ZK_ %*0GB0X?W@#\:K&,VVEL.J:0AI904J4A"4*(\.I*0JU
M8#PNUV!Y,K0ZI%0MN]O]O[;S.Q=OO9+;^#R#H9ELO/2L7">D..,9"6V%+?6P
M7E+ 2-2J]8KK.TN&UGBC>[F6@_&BU?6-_N-EU3="VGFC:3&X!KW >*)AR!IQ
M5^E]M]E2T)'X*J"1>R\/E,SA7 +_ -;%Y"*#K?B#6%-T_L\[=+H=/:Q[XS[V
M.:M1;]5]06SM3;C7V21Q2CW2,<K',[4PG$!.*WQW.VZH6LK&;P=F(TX7:ST/
M,(M[+5I;OHFSG86VM_NUJ[G%=OP]D@D"W-KU]>POU7NV[+>-Y2V;!\871%8?
ME>RF]9C?3C/S%=V,4HG1;L?;.1 '( (QV-5>_P#:KAMV](-XW!A;:=9]56E?
ML3PG_P#=-/Q77;?ZL[!:N#KWHSIJX _=N&?_ +UX^"TIN_\ *%W>WC&7CC^;
MK?"F)"@@1<UL]N;!5UGI_G,P-WX\+2 =?AKS#?/RJ[EO\#K;<^N^JKN!QQCN
M)WOC/\3&S,:1V47I_37YENA^G+AMW'Z=[&V9@^:"<QO]CGVTA'O7Y_>V&%[D
M]W.\'=7MSA=L9'=&]-G]R=S]O5,X2*7&\A_@3<^X-JN;BDN*7\I@L;D1C?F2
M93Z41VUA*W"H:_(N^^CV\V?4T70?1T4VYWD<LK*L86M&+:ND<3IC8WZSGN S
M%25^J%WZA]%[)Z7[3Z@;[/%L^P7=@RYTSR!SF^>R.41QAH#YGXZ6MCC+G''2
M,:?=G\K?Y$6NTF:Q'<GN1N-W*[]QG1)Q.WMKSID';F ?<00L93)L*BS-V26^
MHI+12UCKWNV_\*A]D>C'Y9K+H#<(.K>J+DW75D0K'' YS+> D8@N!:ZX<*D'
M52+]QV#E^9'KY^;2Y]2-MN.BNC+-MKT?,2V6:Y8R2YN&@X&.-P<RT:: @@NN
M,J21XM/T9ZSK[K>7V:WKZM7Q>CJN1H3J#Q N=!X&B()\--;\^.OCY411))XF
M]$6>]NO^?7_^C7_^'BU6S-69<AWK=E75811$41%$11%QG6#JYK;TIB$<?"I!
M4'V(!(''G<?5K555"F%BVM[^ZB*05<7'CS]U_LHBE?Z#7[J(BB(HB**$[T4H
MO8^=Z(GU'RJ***!&B@I*P"E:2E25 *0M"@4J2M*KI4E:200;@C2H+000:%I%
M"#C4' @CB",PHQ!#FFA!J",P1D0>!' \%A*-LO[=E/3MH^FW%D*+DW;+RPWC
MW%6U=Q;A-H+_ ((5_+Y I'PGB+?I0].7<E]TEIBMIG:I;,X0./%T7^Q>>0&@
M_NC!=G)U+'O]JRQZJ#I)XQ2.[:*S-'!LH_Q6]OS\<3BLFQ^6BY#J:3UQI;?_
M !B!+3Z,M@V%PII=BM'@I-TGE756FX177@HZ.X'S1O%'#]H[1@5SEYML]GXP
M6R6I^61AJT^W@>8-"%=+UG56OJG>E4JM/;A04[RR5K6=QN-<&EK_ ,I39/#4
M_P O[*J:<2NQMW!W3\/[LL@^-?UJ,8:D:_N\>0L0;^W2KXIDN7O<:U7R?[DX
MY$;>6]F$)L(W<+>24Z:@2<FN6+C_ .?WKW#IB4G;XB?]FS_FT7MN]?YC:-KG
M/U]GMO\ 58&_J5TB)]?MP4$$F%D0K_1"7$D^S0UOIC6?O:O++;_+[XUXRK5:
MAQ4?Y+>49=O@^:T/+XR%7]EEU;=)5C*YKU.Z@;<;!>L;]G4/=59UD\9(F;H8
MAP&%RIV0E1HT*,WT!R1)D.I:9807%(0%N.* %R!KJ:V4,S8[<OD-(V@DGD!F
M?8O')HQ^'\QV0::^Q;^W+L3=#&+VYB\A!CPLAEEI9B,.3HCY0MDLE\R_DG99
MCHCMN=:R?W4)4;?":U5ON5F^226)Q<QF= 16M:4J!6O[%S$9&LO ):,^Q:*W
M7MF7LC?$#&SGL>_(EXN<T)6,DF9 =#[0(2U(4TP5K8>2I#@Z1TJ%KGC5_P#%
MLNXV3QAP;4BCA0^T5.?!>D=. WO3][&&D:'Q/H<\"X$^T+U[:5 CY]P8XNI@
MN'HC^NL+>""VD$.+#+%U>K?^ >&O$YSG/?;CS/G_ $[2N/W"!X!U?,"K1NR.
M/FI*3;5QS732_0?MJXQ_W8[E=VJ.KVGM5G82PUV_6TV++_Q ^%<R>A"@.5ZP
M(23?U/ %=_O;'.<Q_P!5UM&O9FR)$'!.Z'TL5&0!H=4N/(/W5L6.H7#][]BX
M.WAI<2#M*T<XSZKTD*&J\S/(_P!5]@?<*6TE)Y/9^M>H[U"!LFW4R%LWXMJM
MX[WAIANXQ!L"YMW"*X :B$V#5-M)K:X_ON^E>:6+2XN(_P!H[Z5SKF&4KQKS
M'\/X[-D*')1..A-I)MPL :R+20B]<>.@?2O2+^#7LEJX<J>XN/ZUL7%.XO+]
MN-P1X<925JS>':#CV/QD=\L8S$IC1^J3 ;;6YZ0*T=!%G  ZLJ<4:J>9(KQC
MG.J-+N)XNJ<#^G 8+@WVICOVZ@ 2"<"2,3C[\_@L$>5&@N'H9*)0VGG,2ZXB
M/$99,<R&9T=9<90B1*EK<6XE:WNI01T)!(2 *GZI'AQ-6ZP<SW=P'=VKIK*,
MMM9(?J&:-X[P"#W"E,%X]B=\-T86/O)QW$2=X-]OMH;8QN4V;BICD>8]L[(Y
MF8U#W'A(S[BVG,S$=;2TE ^%UUMY Z0M-;.?9K>?R:/$7GRO(D<*@2-:*L=3
MZIS[ 0>"X;=*13D4^\+]0[=1_P"6O<MF=E=B=_-^S<ENF?EHVQ\9L;=(':[!
M9N+\YGMQ;AQ3#$IZ7+B>IZL+ 8))4'W5%%W.IM()02,'=[[8K)C;.-IGEGBK
M.YIHUC'$B@/%[N Y8G-:RYD)D/F"C:4PI3'F>/<LZB;=R^^9;>^_S$=S>V&U
M.Y.(G3&>V6'1,QV.R62QD&>T['G;NGE:(\B,_.A!<*,ZGK'[ZR+IK$-U!M[?
MZ;T_:W<NVN \YU'.:TD8A@Q-0#1Q&' <5KC&ZNLC#AC_ &XK/8L/OXQAAEML
M87962[8.8)N9E,5OZ4IOJGQ,:Z[G,[A5,OJF(AYJ<A2FQKUE06G0F^&__AXW
M0CN99X]W\RC3",VEW@8\4I5@P)X9%8\DCM!9H:YO.I!'[1[,%%G([.A;'8WK
MV1[@XC';AR;#6(R>PI$&0[)R^=<<0,GMO*QT%J5";5*"E,/HL?2"%CK2K6ZY
MMW=;@=LWZUD,,;M;9@0 UHKI>TY.PP+>=0:46$X&"/\ $1:2PU%#Q/$<P5O/
MM'L"1B<'C&]^J@8[=6UI+V=P^WA.8? G;LB(=3F'&7@A]V=@XK2HT<J "%+4
MX1U!/3H]ZWBV_'D6CZVMPW07D4J(3BP'*CB=3J<*#*M;,=K/+ 7:"2PU-,::
MLC\"!7O6L^YFP\%@\W$WH[/DQQ!SF*W#.Q[39FMR96$D)E19*TI0L-.-]'25
M=22I/PDD6%=+ME_+>VKK)@!UQ.8UV5 \4(_3O6CN&&V>'DD,U@D9Y&OT+$V=
M[[5[C]TX.6S>'RN4VBU.BR=P90R0SA\BW)Z7XV(EJ?:;$MKU"/5:2LDIND@*
MJ^;#<-GZ=?#;O8W<&Q$,;2K@1@7#D:9'GCDK#Y+6^W=C&ZC"]X#CP(/ _K5E
M_,IC.V>6S2,XYF<H<]D\C%@-2L  W'Q[,J0W&4EYTD%H-QR4A"0A!&AN-*R>
MB[[<9K(1,B;^$8PFDF;B!7 =_$XK'ZDVUVW3NDD+F71-/#D <,?9P73?<+;>
MTMN;8PFT-GXUJ-@=I8)J#A2TML-AM2"[)F.R_P#=ILR6MQUQ=[EQ9M;2N;Z;
MW&ZW">3<+U^JXGE)?WC -IP#10 <@K>_V#;:)MO"PM;$SP\.VI/$DXU5GV1^
M7; ;KQ+&X-P0)J("(>OIRW!+R$AY2@XAM\GK;A>GHK4]5R-:V6Z]82;=<&QM
MGQF<NX@4:!E4?:Y+3;?T_P#U"(7L_F"+3P/B<3GC]GZ5K;(O]J^R_=G+[HS^
M+7F-S0<$$;-&>R1<Q6+AX]I*D0X[+R.ED$)*RM/$I(XFLJ\=U!O73+8=F+&M
MDEI+H%'.+C\Q(X#EG196Q66SLZJ;:;[(Z.UC96-[S5K&M&( XNY5P!7+\_O5
MW&_,1W;B;2_Q(N!M_+2$/95$-]*L?C\$PLR)"FBV;)M'0;$&YT%=!M&Q6'2>
MQNW"XCU7D3<R*.?(< ,<<25F]7SV^YW;=KV=^JVE<*$T=1@Q+S3D!7#N796R
MORQ[%WC$S.33%W6SC9K#^/VY+7G9*Y<'&L!?IIC2C8L"2Z"LA%DI*NFY KG=
MUZRNMI8R!QM#<8.F;H%'..=1QH,,<3FN=VW8I-TN#=F2\9%$2V!VNCFM;VTX
MG&@P&2Y_[.;;[3=IMQ[[V=N[9;>Z,]FYL@G)[ED_B$F1$BN.I5CF/F$$LO)9
M7ZI4#=P7_JUO.IKC?=PVZTW+8[D6]DQF+8Q05(KJ-,QPIPSXJ-@M[._W6ZL.
MHXC<;B74:Z3Q'2,P <G?6)&?918HQW1VSV1WGW,RW;3:K6.D26XK>$,7$C(P
ML4M3;9?=A9,(=>ZG M14D$)%[<JO?TC<NK]ALF;K*\G43+1VC6*X M[#3'VC
M-7W2[/TCU-<6YT&-L;1&T^)S'$ FCC6@(.0*UCNKO!AN^RV9^]\=(Q6]\$VN
M5B=RXV+(MD$-V4N%-@M(3U2%E-VW-;*T.EQ61MFP;ITN3:6;_P 1LTIHZ)]-
M4=>+'\6CB",L5OKZ]Z:WJ-NY6[_P.]1 .#P:LETFM'#,.Y$$X\EGG:_<^/V0
MG+[BR> RFY]T[A97&?2O%(9QAQ"F4-)Q^0QZ4J8EESTDK)-[*'&]8]_L,[K2
M+:MK<RWVV%VH8DO#RXNU,=FT"I%.1RHL.ZZGL=[W:3>]]D$E[)&(R  &.8&A
MM'MR<30$GFL=W7BD=S,U$:ST'<&T-D9.<EO*[/QV15B(N;D.N-BT); 4J(VE
MK0)(58GP.FVM('V4 DF,5QN<+/!*]NLMIQ<.)[11::3?(K,26?3[YH-ONGTE
M:QVBH-/"P\ >2RK>&3[?-=S-L=F/RS;9F[6WCBX.,9W;N#"2U/PL= 8#;RV<
MS%4AV)F)3_0$J2[HKJ*EW%KZ+96[UN%A=;MUDZ.39/,=Y+7BCGG+5'Q8T<..
M&%%NM_M=LV!EI%LKG'J69C2YC22(XS0CSB:ASG#$M P%"<Z+)>[G:C=6%RNP
M?^TK<^R<]BLUF+8['0]EXC;><8GL,%16XY"*#*AN)20H])!<"=*QMBW/:I+F
MYBVK\6V>.&I:^9TL>DG,!U2' ]N2S+H;J=G$LUM:AIE:UT\4;F/J0? ZATD.
MIRK@ME=R8F\-D=MI7<3LWEV8FX=G8*0]E-GR@S)PVYL'"*IC[T.&\H-Q\W#;
MZR%)LIU' W%CK8KJPO-T;M>_-)M;B0!DH)#HY#@&DC-CC2G(YYK,VVSN61-G
MLVAV@'6PBH<W/4!]IN9[%\].^'=#\S'=G$[<WANG;.3V;V>1DMJ16XV?<9CO
M;^=ENK?E1X&&2^IY_!^M'Z7NK1;2D\B:S^G>CNE]JZCE==WHN]_^\?##&3Y=
ML&4TR.^U,*U#C@TG 857H>X=70.Z5DL>EK!T=J^-C;B[D \QPD-'QQ_883X:
MUU.;R%5M_OEVIW9V]P3'YC?RQ;TG;1;D-QLAOOMM"S*V8N,F+:ZW9>+@*?0B
M5BUJZAT!)=92>DA2 "+MAO&U[C<?\(]91QRS.JVWG< #*/LDYB0=GS9BAP6@
MVF+<;*0;EM\3WV;?%(S3J:VF))&(+*9UR"P#:WY6OS(]\]L3=_=NM^0>U;6_
MLZO.[EVUG<<B5-SS;OR[LO\ #YK"G8.,BY*5ZRE,E 6%*!)(TK(N]SZ4VB"+
M8>I(3N'X6(,:^N H3H+P<7.:W3XL<17-;6#J6_L=[GWCI9K;6UEDU-:YH) H
M-0;G1A=4T%#I(%5X(&Y]_P#Y,-VY+8.?W-%VLW#;8SKV87!449B))8*V4397
MH*5)6$LK;#741=*K::UB=17VS[IL1WPP2W%M&"-+!J+:&E0 13F7&E,R5U71
M73%SUANAMFR1,NWDFCG4+@ *Z16M&C"@X98!8-OS)=I?S=[QPT;9T'';"W]N
M1]$'>6X-K8P1,)O+#L>G,9F;GQ$%KTV)J,C#93\VGI6M"BAPKTMQ7I[UEN%[
M>W,=Y;R3[%ME)H'3.^\@F=6-K6DGQ:F.D(;CII7!>A===!W7I]LH.VW%)-S(
MB?$&ZBYC?&\M(%6 '2#CB'4Q6Y-M_ENWIVN[@[;R7YC)#/<#LK&B# ;;7@H$
M:7MV%D<B^5(8W)$C!+<+UFD):CNNM!*[=)4'./3WO4>RSVUWNG3I,6_.CK)K
M<=0CCJ3HK^\2YU#RX!<+;#<>H[2RZ8;%'#+ Z1P-"TRN=D3@/D8* 9U)/%<L
M]Y-AYCM7G,'NOMQ*GRMF9[<VX\-B,<U)D&)CI^"R[Q^60L];*860PTJ.OTK%
M/4'A8@4LK79^OMNCFO6-;>.MXIA( &R4< 0ZOS:FO!H>6FF:]DZ<ZO@Z<L+O
M:.HX_--N=(!%2=3<1D<,ZXG/%6IN5D.WLO&YR7LK,P&DP\@Y#@[?95E1E\B,
MFJ'(C0Y5@&W(^3C.I>;< ,5/2D)(*;[V:VNMRMY+2UGADN-31JD\ 8*5U/:,
M3X2"*?.:XC&FOM]\V&VG;=WCI&1-:7 'QN?EI#3E3A^Z MG=K^\F?WQNR)#G
M8F7"BOC+R\DN4X]>+F6X^/?B1.AY#:U*5BDA15T@'VUHW=,.V>%TTDXE>UC6
M-P )95Q<XT)&+S0#@!1;7?MVV;<K9L&V-+BYPD<ZF =BW0#05HVI.687U2[;
MA"-I1.I;JQ*:FH=ZN"&UNRE^FUX)L^H@\;D^%<?=.^_(%,'57FNZP"2YX8,8
M.^@ 5TQ6Z,I+_P#(F2S.3R.-9GQG\5'F.>I\L_"2]'05EDQVWE+C.J25.(7K
MJ +"V.8(XQY\3&-E((<1A4''MX]JBYVJ!LK98VAK@T5ID<,<\<^2VCC<7!R\
M)['Y&.B0S)0VX>M(ZT%:_B4RYHMI:@@"Z3>VE8#97L<7,)!K^E59W5OER1S,
MS94=X'!9*W B1T-Q6H[:8\=#(0T&T!'\M*2@E'3TDW )\3J=:C6XAQ).H^]:
MKQ2.C)YGXE;/V\+0$=7$ALC3FIM)TK62=O:M9O8_S;:9:?UE1M_Y0>TT]1SZ
MKITJMO\ )%5:8 (QS6;0VPKH MQ:'UI3?EYUK9W 8BO%8-S77CG1( %:TV&B
MS;P&NEQ5NM6@E60TH2W=VVNB>KAS!&ONJTXX*]": CF%<0U=#NG!(/#7]X"]
M83CB*J' X4YJV!GXK\;&X'"VM5D^%7.Q7: 5)<MR-P?>.'UUBOSJKX8"#7DK
MND_$K_1/OT-Q5!R5996(=ZMSE_4&G\5KGG<>- 5#6M!!1CA:!*1_4RTP^SU%
M(=/_ +DX:T5__P!Y=W+:7G_>V'G$SZ*?J6,YT? OE\!T\N/#W5K7X+K]@_F-
M[PMR=I H;%QG4+?WS,*0"/\ <SE))3]MZ,%&K4]>N:[J:4M_V,->_P IJV15
M2XY.B(N;6Y?K_IHB/#EYW(^WE:B+Q0<;C<7\S^%XS&XSYU]V3-.-Q\/'F;*?
M<4\_)F&&PR94E]Y96MQSJ6M1))))-4,BBBKY36MU&IH *GF:#$]IQ5Z:YN;G
M0+F6241MTMUO<[2T8!K=1.D 8 "@ P7LJM6441.B)41%$6?=NO\ GQ__ *-?
M_P"'BU6S-69<AWK=E75811$41%$11%QC6 MLF/I]+T4A%2"H*=_("E5/>BYX
M?6+\:D%11,*(\_;52A3ZM">-K>5[_=1%.B(HBT#W6[]8KMU-7A(,!G-YUB,W
M*G-R)AB0,8E]OU(K,A;3;K[TMYHAPMI"0EM22574!7QQ^8?\WFT>BF_1]&;%
MMHWGJ\Q-DG:Z8PV]JV05B;(YK7ODE>VC_+:&AL9:YSZN 7O/I9Z&;CZA6/\
M7-PN'66QND+(RV,22S%IH]S0XAK6--6ZCJ)<" VC25KSL_\ G$V5W'W4]L3<
M<-G9>Z5+;1AGW,@)6V]Q.NW"<?$R,AN.[ S2BDE$9\=+R?\ 9N*7\%;?T/\
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M;<2J9DITQ]@NE+DB9(>6VMS5PH4MP^F5E.MK7J!%#%+X&- /8,5SLUOY=WD
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MT-9I/9^M>F;K$'[#8OX>0T>X$?J6X]\RG<AD,8A-U].'QT='0"HE2(C:NE(
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M,A]*$J0+G732M"^.[WEUQ/L,[C!;M'F,D)!+C6C6$ "I .![%M;..SLHH_\
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MEHT1F+!H.DFLL-?"ZO$.()IX2<E3LCMHD)M^H)9+5\KJMD#=3!48-DIXF_Q
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MM-XZ!NIL+R6:JZL9)I#0N+@-3@<23A5=+LFXV/J)+=5+6&U-6QFA)CR!:.\
M$CB<5]!\'O;8&^NU>X-C=[\KB5[JWE&R<_"92'.A1\Y@<^MMZ9#SL2=)4@Q6
M\0]8K*^H+90I"KA1!Y.]ZPZ?M(K>SV*.:^VJ Q1O#XW&-X#A@_4,7/<-0%,3
M@!P7&1]"]4;9OXZEVAP@GCD)H&DM+#X2S33Q MPRP-'5!%5J'M)M-CMOAXO<
MB9@SN;MYN-;FS-W8'),/3XV0&0R+D;;4UN-);<3*PFYF%A"@XE2HTD!86GU
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MBSA6O6YIP3"C?77Z"E5!')2"KWX:>/#^FI5-**5QXBB411$41.B T0*FI 0
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MOHUAX>,T&5: UR7E:_.CVH[C[%8V;O/8&VYWS1;_ ,*?*Y)#>8BY>.I*HT^
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M(M.W;2/72XIW35?6@IU//][2K#LAR6GDB+K@#@"JT-1ZTI+SSW4\"/6<4X4
MGJ*$=1/2@$D](L!>H<R.)G@:&BG#!6_+U.+@ .X465-.$)ZO)P\M+A7E6!)2
MM"L*:V)=VX*+9L?/0Z>/G[ZHU8=BKN;<MTLY!1> 2Q)<(9NE+82E]20PI2GV
M[(?*RE :7:RKD"QXBK4CP !6F>/L5,,.D%S_ ) TUIRH5:Y>1Z(RWE0G/B/J
M+2R EAECU';K:<)6VXVE %OBL1;6L&20QM&K/V\EL(O+)C=4$$8=N"<5*'VF
MI#)*VGD!;:B%))"N%TJLH'VBJF//EUKFLJ0-."R''-I:47%WL@%1Z4E2CH=
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MA2"QQ(U\N?M]E$4@H&W+Q^K[J(F3;STOIX>/A1$G$(=06WD(=;4+*0ZA+B%
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M-D@VW<'O%S(]KXSJ\,88::B:#4"2&Z<\:X$57EU_<639H],+38 U>QKB ZF
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M(:%J0P>9J.>)^']J]>-3=])/\*5N>0L-/K-4SO\ #3BK?E5:LB2>EI:B; (
M/^LH<_,"M;*ZCB5;,32]K?WOH0E0-B.%K_L]M4M=6/4HGAU2(/0_'<:='PNN
MMI20;*!;NX%)(M92%!)!K&D<":')#&!@*@T_L4)JVXT1AOJ59#GPI!%EI;;]
M,!8L;I!5?2WQ"L:66E3[%#(QY@Y-"I,2$NVZ1X'3]7"I9)5@"N.;3'L61XX@
ME9-P.A6H)!2;6NE0((-SI:K3W9+#E&7>J6+;:8>RJFKA'6 2I142M6I )O87
M63[;GC6*9"YY)5<S0(V-YFJ;CWPJ-Q< GB..M4M?F0I8 33BL,1N=.)@H1D,
M=E&XTC*3GADF\?+DX\1E+5:0]*C(>;90%I*#U]-K>&IU%Q*X/)TDBJWS-FMM
MQNSY5S$RZ;&P:'$ EP P%2*U'*JLV4SN&G-/N1<I >0HH9*VY<=70I]2&D!:
M>L%*E*< %[7-8+[F&M":!=YL72F]P/:\PDM +JBM*-%2<N !.%5V6PR(S#$8
M7(CL-1QPM_(;2UY'7HK,RP7@TDGG2.F^VXN]Y)_6JOO'[/KHJ$M#SX'D?L-$
M3\KB]$2NGQ'+P^FE$2"DZ\M?K\Z(A1T.H'E?7CH>.E$42;:7O?C;EKP&NE$2
M)%K:DW/'73A1$=1MQM:UM./+V411O?B2?"B+8';?_GV1_P!&O_\ #Q:K9G[%
M:E^7VK>-75CHHB*(BB(HBXDX?HYUK*D=Q6Z4PKV6X ?5X"]2:'CBB85Q)\?.
MW#V4TG+BB8-^!]W[;5-**,5+3Z?3SH,JIV(L./#SXU*I-!EFI!8&G+Q_9:I"
M@YJ=]+\J)3@G10BB(N1P_HHIJBBA.@-%)'!%350BJZHF#J3?7V4JBJ!9/M\/
M'W\!841:M[B,.)R&VLFFZF&ES,>Y8:-NO^D^THJ.O\Q+*A[J<5V734L;]NO+
M(_SCHD':!5I'L)!]J\+2_B2?W1>_CSJ\,UH[UE"M*_F;QOS_ &R^>'' [EP&
M25<<8\MY_!2$^7P9@'_5KH^G9O+W)K>#V$>T>+]2ZWTFN!%U;)9'$7=A<1C^
M)K1,WXQ4]J^>$/(OM186-<4A+$&=*E@^CCRZ^^^L64[*;QS&1Z& "E+2Y#S:
M;E0M>P]5#@35HS ''A[:? %>G7FS@7,U^XDRR-#1B:!E,M-=-:\0 KAN9II.
M2CS$@6?C-K*K"_/^+^K>K6L_)VJYT_#KLY!]=CB%=^WKZ3,FL<O640/)P7 X
MC0WJV<'*GK& R6$,]/$&CX8+RYR.I&7?/ >H0/ 7((K-C?X5SEM&)+4'F%D&
M>CA[%8V3P(92"?&X -4M?B1VK5;:S3>OB[5C6W\9!5%W AG,=.480B<=O.8^
M25SX'J,QC.QF094ZP^[$"EKDLNH:+;2.M*E@GIQG2.9, YO@=]:HP/(C/'@1
M7'.B[;=I9Y+:TF,58&NT:P?EK4T<.5: 9UJJF'"436>0*U-J\.E8Z3S\2*SB
M^H7+[E ?*=3,8JQ.PTQ]R-)X?W@L.>14HI22;<"I(M[:Q9W'0'+M]BD\W;9(
M>!8'#W5^@K+(K?X?NF&ZK1"IC:%_^ZY*"RKRX+JN)^N&@7)[S;^;92-&>@GV
MM-5X-XX$MR)[(3\3+IDLW&BD$^H4@#^L@E/OH]VN.O8LOI#<&PS0RN.#O"?;
MA\,_8JG;3'=MT8]W)[NSF95D4F?&_P ,P4P8+$[Y1<9N*$99QZ1,;=DE[J*1
M&%@A5E&QO6^:[<QK;=K:&GB-21S\- /];CDM1UK'OT6]26UA$S\&UP<V0XD:
M\<>P=BU!ODL.;3G1E8Z&)+>2C9./D4+?<R#"&0MA[%J<*DQGL>IIP.]0;2[Z
MR+WZ3:LHXOJ":94PIW\Z\,Z4[5V?1C;B+?8+A\A$;H'1O9]4N-"'#MJ*=RP'
M#.18KT&1/B_B&-*D_,PP\Y'+Z$Z+;#[1"VE*;-TJ' @7N+BKD3CBT'Q<%TW5
M-E-<0/%J_P JY& =2M*\:=^"SC&SU9C;,:-%;;C2]GNRW6)L1*8V3>;DS53F
MI,F7&"'UR(1/2TL*NTE ";6JY(-,FHY.I@<1@*<>?'GQ7GYL&6>YR.E)?%>
M!S3\@.G20 >#N/>M0;\>R&38RTER4^<C+0])5/0OHE&9Z?2)8=3TJ^9L$GK_
M 'BH7-S>MC8.;'*PGY01APIR[ENG;? VQ-G"P-MO++0T9 &IH/:2M,?EVQF_
M>U^&[\?F#B9[&S,D_*V]M9>TV5LXZ=O#(2I.-;QTAQJ*S_*S<J-+DL(>"%?-
MN.J"M22.WWN:PW=UAL!:YK '/UGQ", &HQ/RB@-*^$#!>&[O;G;MQ>)8A);N
M;4< *\:Y5K[UM39X[R9'%;VP.+[.21C-J;DW7EL?OK/9I_;>Z=@9>?@8K^X4
MPPVU(Q^X,,9MD*2%H#KCCB0HDE*<.^CVBL,D]XW5-$QKHFMULE:''1C4.8ZF
M(PP ![5S]G>?@[[\7'42MDJPU'Q800X<#S"\>.__  @]K=E.S?;+MKOAO<,?
MO]->R3L>;!QS61VGNO<6YI"LRF/(?:6F3@$&,IU_K5ZB/34M*AHFKGE]/3;W
M=;G?PF,V#0W DMDC8P:30'!^-!PQHL._N'7;)I;I@-P]]1(,"#GI(R+>6%0K
M=^:[\SWYAL5N#,;#8=W$J1\RC#P,OC<(TWC]PK<*(C#S+B 50WISBP0TH*LI
M8'56-TCT-M1T[C/.U]L7%^ASM+HFYZ2!@X-&&JO"M%N(NJ>G;7:C;VNWB/>@
MS%[P)&/.56DXMYT+>S4L3>_*]W/WWW)Q79%CO3E<;O#!;!Q^\>XN2F..3(T%
M[JC.9_!X8OK+V1D8GY]EM*B0A2@LD!*:VEKOG2^V6,O4+-L@_#373HXM+6M+
MSB&2/( IKH3CCEQ*YV_WKK+\'%9_U":*(M#M+3\K3DT5&7>M^]D(>VORS]RL
M;MW*2#N/8N5W1#>S>8S;49^6P_,Q62VW,?F*],I5B)4/*#UV[]"5M(<M8*K"
MZC==;[LTM_:@QW\5N[2QE:$-<V0!HXO!;X>)!+>2YICG2WC+>[=K?)(!K?3
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MU29<YR4VF04N*ZVVU=2KA8K,MHM\ZPM8[6$L;';-T1- #!(6BI:S)NIHHXC
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M2WYL/,*>*EM8!63<4MC3I*&W+@J0!7I=E=[ANEO)N$7X?^NV =#-(_48PTD
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M&:DN[?H4<:V4E5]?I^VKS3A0\E5)DLPC)#45UP@@DCZDA2C;V6JW(0%AFIE
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MO() 41:X^$Z>=1];Q+U';X1=[5<VKA4!K9&][3C\"LG@I/4EW4*"P= 1S!!
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M PT>^1KA4!VH4:T5TT%20*UH51<MM]GA:_;9+@=3O=1[6DQMAH:&I!\;CPR
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MU=5_K.$U::ZKOBL"WC++1TSOGE=7V#)72.](@B&U&CE]<M:FC87]$J"0TXX
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M-KUQVR[3T9M,$U]OT[IK^05UDZ0T/:'![-.)=CF<CA0+N=SZL?MMZ.G[6$L
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M:VVIXY/F(-#VZ6M/]Y;HJZO+T41%$11$41%$11$41%042N#]=O?0TR1+JO\
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MXT[MY_V:+W3%;QVSW8T;)XO(8V*]D!D,E,99<FY2<VPEUR5/0\!'2VD? A
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MT3!,^YM'$:6S-()+2#];'V@GO70.R=I;@V!V<S&[-RPY68E]^_\ '>*W-/@
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M\]=UYU:T)5?I;;4 #7<;#LFX-M(IKOR-PVNU(#8W:7>,D/>WS7!S:M^4-8*
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M4ZX]T@K5H  0,S42< *<*8D]_;7DN/A@W/S;LWC&"T:X^3IJ7%@:"=0YEU:
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M/Z8K:7L]D&/AOAYEIK#6M>*NQH'%CJAP'(G/M52/W$Q>_=SQ=X[OW)C&-TP
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M(JW+IK0^WN_M6KNGND=Y0_O=W+VJ[-L@>K+=!4W&LH=6OK2%W+2">=U#J5Y
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MSJ,17V_6<?F'4]]7!N+<6ECG-%* D&BV6XW[Y1;WFT1GR(G:90YM'#A5PQ-
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M+BQN8;.V(K&!(\$5!<[$ _PMIRH25JZ9MCN%M5M:MH[JBYV&T+MX+<S)94L
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M?;F/=Q&WL#BGVH;#^,PV+Q[S..<F/8]EV%!8C.-07<BX]D'8;:VR&E/K4\I
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MDP]G;QPF?F1&U.R(420XU.2PDI"I*(,QJ++>BI*@"ZVA38OJJN<Z0]4?3KU
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MAV_K'9&[W8 ,EKIGBKC#+3%O,L=\T;N+<\00O7C)BR4659ULA2% \QP(-9)
MXJS>V[6U-*M.:N^2Q:,FA62A)Z9;0"I\9(U58:R6@.*3_$.1JR:M/8J-MO\
M\+2RN<8"? [E^Z>785A\R*%H <2$@:H<MHTHDDI5_P!X<)U_J'7@30.TFO!=
M3$1)@#5WQ/\ :/B.U65'4A:FR"AUHZH/$$?>#62'5"LRPX:OJ%9% F%?2A2B
MAQ!!2H&Q"A:Q%N=%I+JVTU<W%I61OP&<PRZ%-@RRDEYD"R98 OZS-K%,E(%R
M!J2+C7C:=5N(R6%:WLFWR-%2(:X'['8[]WMX9'!8=,B]1#,A0+X(1$FN&Q?
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MQ52-'<G*)*BU%;L77+</!#8TZG5< !]U7'%L(H,9#^GN6JEFDD(:W,Y#]:N
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MQKC]+@O='Q&+*AZ6(:<(-A\P_,EW)X73ZK31)_T;4+GTJYV'L"PI;JY'S3N
M[ UOZB?BLABP2U81_P ,QB0#U*;1%8<%O#Y9IZ7?[:MN>S,DGVK5S3AWSB64
M]NIP_P!8AJ]K<;$H4I4E[)Y1Q:D%:64_*M+* >CJD2U2'U!))M9""!5!EP\-
M!3V_1184AO'.#HXX8J"@)\1 /8V@Q[RO>,PW"%H,+'XNW^ZE!FSCX'YB3ZB@
MK_12FHI))P-.W >X*P;$S'_,2235X Z6^YM/BO$[DI,U76ZN5+5R=E+44Z<+
M)4;6'LJX(:?,?8, KPMXK<:8PQ@Y- K[U:<DGYU@1I*6WVRXTM;!!0TH(6%*
M25I^-)('$:BK\8$?R"A4M);J<QQ#RT@' FM.1P5S2ZPY+=3#AH9:6Z!%B1@Z
M[TMA"$  .*=='6H$V*E6OQ-2UKM UGQ<2M9&Z:*W O':IP#4FG/F*#X*_(B/
M)*1+<9Q_"R'CZDI05>UHS)4M)(&GJ%%Z>'AB?@L&2[:?Y57?1[S^JJN45M*G
M0SCXSDJ1J0Z\@/.Z6^)# !8CI!'$A1 YU%,*O-!R_M6!/*X-+YW!D?N'OS/P
M[E=S&8:7UY.<77M.J)"4)$@7_@=DJ)89MX#J(\*BIR8*#]."U_FRR#_+1^#[
M3_"/8,S\%,3PS=,-EN"V=.I"BY*<'@Y*7_,X\D= JKRR<78_IR5LQM)^^<9'
M]N#1W-'TFJ\CTD(:==T 0VM9*B0"4@GXE6) /,\:K#0,E-"\@.Q[OV*Q(GX;
MIC.NY=O+J:>F&8IV+*8Q3$EE9^32F-&4Y,DPUE(19U22I8)4A*;7M:YY X!A
M9B*4(K3CB< 1V>^JP#<W<KGL@B,8%  ""ZG'Q' 'C@#@<#5>V%\SDU(#,9!D
M.CU7&8S1:88"K$BRC9EM']HBWEPJ^2V)OB.',YK,T"!@,A.69Q)61I8@8=(=
M=+<R<+=*M%QV%G@&D$?SG ?XR.F_ 'C6!/=5&G)IX<2IC@EN#C5D7Q/?R'8O
M:Q#5(6F?EUN(:5_,:B]5Y4O6X(2;^FV?ZYT\+UA^*0T&7T?IR5V29L+?)M@"
M\<>#>_F>Q>Z9D"XA*%A#$9H6:B-:--^%_P#?%GF360QC6]IYK!;$02\5,AS)
MS_L"Q+*Y]B'Z#12\_*ENB/C\;$;5(GY&21\$>)%;NMUPVUT"4#51 !-4S7$<
M#"2<5LK:R<\&5Y#86"KG.-&M'-Q.0^). J5?,3M$L+9SN^FHTW*)'JXG:?4W
M*Q6$N/@E9,ZLY7+A)_>(++)T;"E?S*YF\OG3DM%0SXG^S]"M/N&^&<&PV;4R
MT.#Y?E?)S#>+(^SYG?6-/"M)[HGY[MCNV3NA#TW+[(W$^RWFHRE*><PKY/I1
M4LHN$L-Q@;1U@!+J"67#U]"CI)'NB=KQ,?'L79=/[;9=2;>W:W!D6]0@^4[(
M2#,AQXD\>1HX85"VC&DC-IA+Q!.2_%$(<QXB_'\TAP=25(ULE( /456Z+'JM
M8U7J:1J&((5^#;OZ>)#?TA;"3YA=AHIG7MY 9\*U"WSLW9K>W6S-F%N1FI+?
M0XZCXFH+*K%42(H_O%1_VCEAUD6%DC6C'YAFN$ZDZD=NY%G9@LVIAJ ?FD</
MKOY?NMR;F:NRSJ_.]4X'$G%<FL5W5MHY^,R]"EG$;AQ2E2<!G&TW<@RC8J8D
MI&LG%3 @(?9-PI)ZA\20:U^Y6(OH1Y+S#>QXQR#$M=VCBPY.;Q':MYL6\_TB
MX<VXC%SM4PTSP$T$C.8/U9&YQO&(.>!*LVR=]?X@?R&W,[%3A-\X"R,Y@EK!
M2\V4@M9C$.&PF8F:@A:%IOTA6OEI]BZF;N%Y+L6X 6_4EL*R1')[.$T)/SQN
M[,6UH<*%;OJKI#^CVL'4.SR&[Z0O3]Q/3%C_ *UO./J3,R(.#J5"V'ISX_3P
MKJ:"OB*XC%&GT_HJ/".U$J5Y"A1!]M023FB#X?041!L**4B; 'C<Z<N-*(D2
M>>GVVI0(HW_BO:_+QMI578H43J2:E$:G[A1$J(BB(HB**5LGM7?_ !'(OI_Y
M*D:?_7,36KL/S^Q6+FGE^U="UE+ 11$41%$11%\]*TRWZ8)'#Z>5%!"F#QO8
M45)')2%^?V5-2HXU4K_0U4%57DC6I3%3"K&YX> ]_P"FH(P2J8OP L;:DBH-
M.*E3OXD"_P!U1VA%,&W('VC[J#%$:Z6'#7AQJI%+K4? ?3WTR15$D\_IY^^B
M*5_&BBB8/D.'(??44447+G?/\MBN^F[MMY?*;T>V[M_;V D8Q.,QV)1.RC\^
M5DERY,MN3+E(@1F7& TC5IU=V_"OG;U@_+_;^L?4]AN^[[K-9[-8V9A$,,37
M2/>^4R/?YCW:&@MT-_EN-6\J+Z*]'O7YWHYTQ?[5M>TQWV]7UZV4S2S&.)L;
M(@QC"QC#(]P=K=\[11W-7':'Y1NP^T5,/KV>G=T^.\Q);F[WDJW A,F,0IIY
M&)6W'P*>ET=8!BJLH C@*V_1WY<_2+HF:.]V_;!=;I$0YL]V]UP\.I2H:=,+
M>>$6'N6NZK_,QZQ]61R6S]T.WV$C',=%8L%M5CLVF4%UP:CPG[T5&'$KI9.B
M4H 2E"$(0A( 0AMMM(0VVVE("4-H0 $I   %A7N(P7@M<:G,FI[2<SWGB>*J
M7 X'6W*U554YIWMRU^GLO1*5[DP2>(J0H-%*I4+&&GAGLLM39ZL-M^46^H&Z
M,EN!D#KM8_%&P85[%2E>+5::VG&Z7;IHS7;[=Y:T\'RC!Q'[L>0YOK]E='=0
M?T3;FP/PW6\C#G#C% [Y6]CILSQ$8I]=9/6Y7.(!M1%($D@ ZG0 #F;Z>-]:
MGBI^E8/E<)&W9D$Y!H(CG"QYV-QN62VE3TN7)>85/:Z[=:L1&=AH00#\;W44
M_N?%#75?J;\K:BO$GC3L'Q*Z2QW2?9K<V,E7VT[VOEBK@V@(:X#(2T<<?LT!
MS%,/"Y,.2Y G-%B7'("T&Y2L:]#K2]$N-.#5*AH?(@@937>]9EY90S1"[M#K
MM7Y'ES!' CB/U*]1Y2D$$'E>XX&W+C5]KERMS:$$\EBN_NWV([@Q6IP?;PN[
M,8PIO$[B2WU)+%^LXO,L@I^?Q#RSJ@GU&B>MHA5P<ZUO)+8T&,9.+?UCD?IX
MKJ^A.OMUZ'NS;Z3==/3O'G6Q-*G+S(B:^7,T9. HX#2\%N7)+3\Z%.7!EHEX
M'<$!;X/R[JVU.(;<>A.SL1-2$IG8Q]2%H#K>HU2H)4"*Z6"XCF8)(SJC//Z"
M.!7U2YFU;]MOXRQ<R[V:6@-:58Z@=Y<S*UCD;@=)P=\S2YJR>+*!2$R%*6HZ
MAQ:BI:CQZRXHE143J23>KA%3VK6.MF0#3;M B' "@'LRI\%='6V,BV$33T.I
M 2QD4IZE6&B6YC:=7$#DL?$D<;BK9%,LE:@DGLG:[7Q1'YH^'>S@#V9%6HQ9
MN)>4V4-EI]-UM.#U8,YL\%@CX#<<%)U%4=JW;+BSW2$/!.MO$8/C/Z<#@O,Y
MAF):O4Q5XLRQ*L9(<2.LCC\B^HAM\'DA5E^VJA)P<H-S-;"EY]Y;Y>8T9?QM
MS;WC!6-3ZXSJF7VEQWVS906A2;*')256*#?W5=S%0LP1LFCK&0Z(C C'#OXJ
M#F76%=#J5%.G2L"X]IL#I55*C!6V6+!B#BO?%#3X#J5W(-TK2>E23R*5"Q!%
M4#4W%8MR"P>61X3PX+W2)(F!+.28$] LEN2#Z.093RZ9("@\$@<' H>=/,:#
MR*P8;=]J3)9/,1.;2*QG^[P[VT5N.&()7C7_ )K0GT5?W>>D'BD,D]+^G'TU
M*OS%5$X5X+.CW1KO!?,\L\_FC/MIA_> IS7C0W'NI+S#C3H)"UQPAAP*Y^M&
M6CY9PCR2VKSH"1W+*D:]P#HG LX!U7#V.!U#WN'8O6S#*U?W9UE\\FU$0Y)M
MX-2%>@X?]!U7LJ=?/)84[S&/O6N Y_.WWM&H>UH[U0F(DQSZ<F.\P>0?96UI
MQN%*3TJ&O$$U<:X.R5$(BD&MC@[^$@_ 8KSA-AUI5TGCX</,54H>"1I(P7H;
MD/@B]E@'G8^/G?6H+&N-2%BNC8 0"05?(<STU)793)_KM++9MXW24FJ3&?J$
M_2M?/$U[2UX:[O *R)K.3TIZ6LM,"/\ >W'E/(]R7?43;W526O&0:5JI-NL7
MXN@97F!3Z*)_BDA[1Y<"4/\ ZHQL!PD^:OEPO7VT+7@8#XE4?@;>/&/S6']V
M1X_6J"EQ57*L?B;CFB(63_\ 07FQ>H'G98>_^Q5%LK1X9;BG(NK](*M,N0T@
MD);BMCP0'M+?Z3ZJD"X.6E9# ^@J9">W3_U5X69*22+I5_HMFWUJ)_34^7='
MYG #L"J>'4!%??\ V*Z,.*XI;U',@?8 *J$+R*/>[V4"PIJUTDBGM7M"I*K)
M38 $Z=*E >XDBI$$5/$"?:L,N8#4YKV):G%(LOI]B4I/ZZJT1@_*%CN? #C7
MWJ)C25Z+<<5_K](N.7PE-ZK!:,@K?G0M^4!>IF*E*@.GK638!*2M9/ <+J)H
ML66Y)')ON"O9Q,]3?4XAK',*L?5GNI9)&FJ& 52'+^2:!S>\]BUCKZ'51A,C
MOW<?><![RIMXS$L6+[C^1=!L0;P8H()!'2;REV/^A557'Y0 />5B.O+F4>"C
M&GEXC3OR^E7UAN<6#\A$3!C<%.,-)A,VX'KF/*2MP$<;K-Z@AM?%B>W%:V26
M$2?>OU2\L7'_ $0#3W*PSX\:+TR794F4I"E/_)PO4^4>EMH*8PDO*2I2NI9L
M5-I)";V.E'2.:, *=N=.-/[<RH>^X<X&&-H=\NIWS!ISHT'ES/L60B>\8R6T
MI1 CK0E3D6,%-@J(!(?<)+SRO'J41Y54&?6.:QS%$)-;JR3#B[&G<,A[%X#*
M3^ZTDGS^[3C5T,53@7-\?N55*EG5>G.WMU\Q4X*P6@#2%YY#ZW1\M'87*<>!
M;$=M"G%.@Z%!2BRB"/#A3 8N-!S538@!K>=+1QRI_:I8S:#<$%>4=CXF-ZBW
MU8V!TKE+4M16HO%*BTP5$ZE:BK6K$EVT#[NKCS=E_:J/.!&FS87N.;W8#OYE
M9",D7&C P,1#<=/^T*#9NR18N2Y2_P#;*'B3TCD*UDD[GNJ"7/Y\NX*MEHV(
M^?>.K)V_0 E'+,-WYB0Z)LWB@E/7&8)YH;4/YJQR*ATCP-5,MWN\4B2RND;H
MB!;'Q/$_L]F/<O09SSJU+(*E*/4MQQ5U*TXE1X_HJ_1K10G#L6.V$4  ]BL;
M4O+[CGO8?:45O)SHZ@B?DI#BVL#A"NQOD)J$K]22!JF*R%OK\$I^*L"ZOHH&
MZ6_,5E3?@]KA%SNCM+'#PQMH9)/X6\!^^ZC1PJ<%=]IJQFRLI,Q^5?9S6^GT
ME,_<[L4LQXS<JRV,7B$/+6(N,*39"F[>HM)#RE+L!R\]V^9_WAIRY?VK4;J;
M[?+9MU:M+-F:?#"#4BF!<^GS/XDG('P@!9).G+6I:RLK<625%5U*4>9)/.L8
ME6+"PK3#!6%>,=W&MS!MP4Y-619=8D0W!>.J*Z@H?5+<4"AE@(.JCJ#;IUM5
MMQ!%,ZKM+6.';(OZE<R>3#$0=?'5F T9N<> 'MPJKGVK[??]@;BL1E<Q)W'B
M-U9$&)NB:A+0VYEY1#;>VRP%N-P<-D"E):D7'KRKESI4M(&"'?AB(WG[IQH#
MR)X'D#P/-:CK/JZ?K^47$$+;86T8'DLQ\UK<YGGZ\HXMR8R@9D2>E2+7' \#
MXCQXUDD 9KS9+0?MI@#ABI145QJ,$6G^[?;S*;LA0MQ[+G)PG<O:?J2]K93U
M PSD4B[CVVLLZ00K'9$W#:E]2([RNH@MJ=2KS3U,Z*W'JK;&;ETO<?@NO-O)
MDL;C(%XQ,$W.&7Y36H:34@M+P?3?37KBQZ7O9=FZGA-YT%N5([V"FHLX-N81
MPEBS.FA>P:00YK"+7V6[VXKNI"E8G(LC;O<;;[TC'[JV?,!C38\V X8\R1"C
MO'U'&&WTD.M@J5&4;*)0I"U<QZ-^L]GZDPS]/;["-K]4-K<Z._V]_A<',.ET
M]N#C) XXD N,1.EU6ECW;/U7])=P]/+F/=MN?^/Z"OFMDL[UGB862#4QDKA@
MU^GY'&@E&(H\/8W9.V=][)WK^)_X.W;MS=1PLY[&9@;?S,#*JQF0CN+:>BS4
M0WW5QW$N(4D%0Z5%)Z2:]:VGJ'8-]=*W9+ZTNWV\A9((I62&-X-"'!I)&.%2
M*'@2O/\ ?NDNJ>EO(_XEVV^V\74+983<021"6-P!:]A>T!P((.!J*X@+*K\.
M0Y]6GU5N33O*Y]1ZN.HT)]MO+SI1$BKSU' V\>-_=4@*$NKR'U4HB74;W]WN
MI0(E4HBB(HB*(E?W^RBFB"?"QN;40#FHDVX6X<K<:A5 5S2O[[\>'+A1*+9?
M:G_K')_Z)D?\IAU>@^?V+'NOY7M_:NAZREKT41%$11$41?/2M,M\BBE%0H3!
M/C[]:E**H% <_OJ:JD J8-5!2C[*E1GBI \!J /#V^VHHJ@I_"==?#7Q^N]1
MB$4QIYU2B8T-_KMQ(JJH."*=T_98"W#S]M,40"18F_3?]%2BJ7%[7U]A]M2B
M=^7@>/V_IJ%"D.?C[^%0?@A^"D#>A5)%$ZA$ V\/IS]M$4^H6YW\?/GSJ0I"
MD%'V>VYJ4HL,WGN"3C6<=A,.4'<VZ)@Q6%"AU)B]3;CL[,/HN"8N)@M./J_K
M>GT@W(KB.L-_FM9;3I?:7#_B+='%D?'RH6BLUPX<&QL!TY5=@#5=MT;L5O=&
MYZBW<'_AW;(Q++_VLE0(H&G[4KRUO&@-2* K)\7C8N'QT/%P@H18+"6&U+/4
MZZ1=3LA]7%<B4\I3CBCJI:R>==?96<&WV<=C:BEO$P-;SPXGM)J2>))*Y/<;
MZYW.^FW&[-;F:0N=R%<FCDUHHUHX- "N%92PT416B>\Y(>&(B.*:?>:#L^4V
M?BQ^/62BZ%?PS9Q!0SS2.IS^$7LO?J?Y+#XJ>(\A^T\/:>"V-M&+>+^H3@%H
M=2-I^N\<?X69G@31O'"YLM-1V6H[#:66&&TM,M(%DMMH2$H0D>"0*O !H 'R
MA8+GO>\R2$E[C4GF2K3GL'&S<9*5'T)K(*H4Q(NIE1U+;@N"Y'</[R?>+&JP
MXM."V6V[G)MTN6NU?\[.?:.3AP/L."U>V[(ARW<=D6_EYD<@+0H]2' ;]#S2
MN#C+H%TJ''R((J^'C,+H[NPAG@%Y9G7:/R/T@C@X9$'+NH5C^]7WI4#'[?B/
M.LS-Q9.)!0IA:T/MQ$."1DY27&SUM(BXYM:NO2RRG4&U'O)HP9D_#BK>SV+;
M0S;Q,T&*WB<6UQ!>1I8*' DN(PY55^S^R-L;LV_%V_(B_APQ:2=NY2#89' 2
M.FR7XCSG4I]MU7^W:=*D21?KN2%#86UP^V?JCI3B.!';^W-:SIOK#?\ I#>#
MN]B_S1,:3Q/J8KAE<6R-&7[CVT=&<6D9'E?/XG.[,RC6%W6PTRN4HHP^>BI4
M,%N%*1>T9QR_X?E D=3D-T]:=2@K1\5=+;W,=PS4RN&8.8_L[<N[)?5G3N][
M)UKMSMSZ=<[S8VUGMG8SVYYD?XL5?EF8*?;#78+UQIBF/A6"1S!X@5D$554L
M )J/>%?H<P%'IV1(BK-UPWK]'4>*V57ZX[O]I/O!J@CFL":"CO-:2RX&3QGW
M$9.'857<Q+,H%>/47B/B,%_I3,:/'^2;A,E(Y%'Q>54'#N5V+=GP^&]&@Y:Q
MBP]_V?;AVJTRTHD(^7R3!E>G\"5N'TI\<#3H;D]*BM*;_N.A0]E0*C$+91-:
MUWFVKA&3G3&-W>WA_$T@]ZQJ3@E@%R"L2VD7*V5-]$II/$J<B74I0 _B:*T^
MRKHDYYK/;=MJ&W(T/.1K5I[G<.YP![U;$K#0L!Z)OQ!^ D<?B'#7QUJX"2KL
MD>JAI51$UQMS504+7N+$<=.%^5-+3F%;? US* 4*NS<YM8'J)&O,'AKQ'@15
M!9]@T6$ZV>VIS"]BY#;X <].2FW2!(!+B1H!T2$J2^FW(=1 \*I)>WYA[EB,
MB="ZL)=&:\,O:T^'X ]J]3,&,H'I6N/IHE\&0U<V%O692'  /%!J0\.R5M]Y
M.TUE:']K3I/N)I_K#N7O;B99A!^5ZI48:J;B+3.8Z0.+D0ATH!']=L55AQP*
MQ'W.WSO^^HR7AK!8[V.PJ>YQ7E7^'/$HEXED.<%+AJ<@/!7.[:?48N/] 54*
MC%IP5>BX;XH9G:. < \>\T/Q7G_!\4HW9R$R(H\$2H8D('D7HK@7:_/TZK$C
MAF 52Z>]I1T<;Q^Z[2?<X4^*J)P\FS?HSL3-]1)4EIK(QVI("2+AR-*+#K:]
M1H1STYVGS!Q!'L6'^,@<XL?'<1O:<2Z-Q'L<W4#WJD]#DQ7&#-AS84(NH$S(
MM07LDU$C%5G97I1'/YZ64GJ*4K!(&E5M<#D:NX#+V*W-<1&%[[=\;YFM)#"X
M,+B!E5PP).&2HSGX>/DOLJ>68[106ISL61!9EL.LMOLRD-RK+;:>:>!%U$>!
M(M53*N;6F/OIV*S8S&_MFSLTB1P-6:FN+2"01X<R"#P]BJL!I]/4EY)2NQ20
M4ZI/ @]5B"*C(J\\/9]4U"]2H<86*W$DG6UTG3SL;U(=P6*Z68_*PKTQXD>X
M]-'6;<$(4NWLL#>HU'C18DLLWUC0*\Q\?-6+LXZ:M)UNF(\ 1;3XB@ #SO4%
M[.)'O6OEGA;\\D8/\0_:KHWBL@+=<9MCG_/E16NGVH4]ZGV53YC<@:A83YX#
M\KB[N:X_JI\5ZCCPGX7LC%;-OB3&:?EK]ERF.V/^Z-2'$_*"5CNG/!CO[Q#1
M_P!(_!5V(V.;4$)9FY1]1T0M7H()\H\4.O$?Z]54><31OQ6)+<2TJ7,C8.6/
M^LZ@_P!59$U S26P4,0MOQB/]HZ6X*RD\[K+N0<T\Q>H^[XDN/Z>Q:A]U:N<
M:%]Q)R'C_8T+R*AX=I15)R$[*NG528;0BL%7G+E>H^L:<0FJ@\Y- 'Q4AU_)
M\C&11_O&I_T6X?%>>%D$1UK8Q^/CP2AEI;KS_K9"6B2I3@6D2YR @E: E8]-
M(2GJ(XB]0WS'$A]: X<!3N"PQ"]Y?^-D?)1]&Y,:6TSHWEB,<U*5*4Z?4ER'
M7U\;O.*61Y $V2/95UK>2O- C 9 P-'8*?\ *K0Y.-^EE/D#KJ*O!@ 5094U
MD-0H(2^\0I9/3YZ?3C56 5#BUN6:O$2*ZZ2W&86^X .KH&B;?Q+</2VA()XJ
M(%6W/:T5<:!8\A \3S0?IES5V3C&&]9\KK5<'Y2$0H_Z+DI04@?ZB5^VL5]T
MUN#1C^G#]M% $C_Y0H/M._ZO[:=RO4.'/>0IO$PD0(Y!#KZ1TJ*>9?EN*ZU#
MR*K>58<D[W&KL^W'X9*W)^%A.JY?KDX _J:%;)D/$1"?FY*\Q(%R66EEN"A0
MULX^0$KM;4(2?;1D$DAJZH';G[ KC;F>3^4T1MYG$GV?M/L5A<R3\@^A&2W'
MC(5=+;"/3:!&ETIU*R/ZRRH^%9S(HX65X_%5B&KM4I)?^GZ8*WY//X;;L;YO
M*S&F>H@-H<42X^ZH@(:9;%W7W7#^ZE())T K%GNF,!J0 LBWL9[M^F%M0!4\
M@.))R [3@LLQ>RL_N1M$W=;C^U-NGI<3@XSR4;ARC) 4E.1EL]:<)'<&OI-E
MR6I/$M'6M#<[DXC3%ES6AONH[.Q)@V@"XO,O-(^[8?W&G&0C[3J,KP<MB)D0
M<5!8P^!A1\1B8J%(9BQ&TLH 5^\;))5U.*U6M2E..*N5*)K3O>7&IQ/:N5#+
MF^G==7;W27#CBYQJ3_R<!D,@ %@>X\7$S;*$J48TV.%F'D&P"Y&*_P!]MQ)L
M),-TC^8TK0\190!&,]HD&*[/873[?+KC&J%U-3#D[]A' C+M&"Q#;.=F943<
M4^CT\AB)Z,5D<C(]9&+A/N$):3.R196RP%I*5ME9"W&5I-B;UC-GT@M?@YII
M4Y>]>@[ELVW;7'#NTCVLL+F,R,C!!E=3,,CJ'.QJ#3PAP()&"ZRVMMR+MS')
M9:<3*F2@EZ?D !>6X1\*6B">F&T#9M-^'Q'4FJJG->-;]O4V]7>LM,=I'5L<
M?V1Q+N;W?6/L& 5WR>.@Y?'3<5E(Z)>.R$9V),C.7Z767D]*@""%(<3^\A8L
MI"P% @@&J7QLF88I1J8X4(YK4032VTS;B!Q;,QP((X$?IEQ6NMF9^;B\W.[9
M[FDKDYK$04Y7;.9?T<W;M#U/1;F+/!69P3I$:<D&ZB$.VLN]:JRNGQ7CMGO#
M6Z8S7&X_XL5:5_CC-&O'<[(KH-VL(KG;V=2;:T"RDD\N:,?X%Q2NG_R<HJ^(
M\/$S,!;0)%AIH?$7' \JV]%S2+JTT'L\/MJ<$2!NH"_$6U-A<GQ)  \ZD-)P
M&=5!( J<@O@1^9GOCB-R_F%WQE]D;;S&W<+C,3&VMG<SFDS<#E-S[PQGSN/G
M9N%MMR-!RV,CJQ"V8B5/K0].::#KB6D*'7^4/YHMUZ<ZC]4&[OTH+RQZELVB
M&XE =;R2NCJP2#Y9(P6'RRYPK(P"@(-%^Q/Y>/3'>-C]'-NVSJR[M+V:YG==
M6T,)9<QVUK+HD;#)."^&1PF#I=,8<V![RQI>X'3<?\OC=+>#_,;BL)&CMQ,9
MNG:6Z<"F.U9/\^-#:W!$?>4 GUWNK"E N $)79( X[O\I^Y.V_U>CMYCJDW#
M;[F D_NM;.T <!6$X9FM34K%_.?L+MT]$+C=)G%]YM^Y6EQJ/V7O-NX#D*3@
M]I%225]XR2;>5?J)2B_(!*B(HB*(BB(HB*(BBE1OR''P^AHIIS2N/$7'#2W&
MB4*B#;Z<_&H51"*(BB+9G:G_ *QR/^B9'_*8=7H/G]BQKK^7[5T/64M>BB(H
MB*(BB+YY CC6F6\&!Q4J*H%%%***$Q]O+V\J(542?L^GVU(*IR4KU54I4*52
MI3!(T!XGRJ" I52]K!7'B?T<*IIR1 *> ]O/]-#7,HJ@)M;QY:<^5Z"B(L;V
MYU5VHF-.DVY\?&Q_11%,+%SX?T>5$4NK@..E_=;33044*7'Z>^B*0-]/*HI1
M013%2J%"*(H.NM1VG7WW$M,,-+??=60E#3+2"XXXI1( 2AM))]E8]W>6FW6<
MVX[A(R&PMXGRRR.(#61QM+WO<3@ UH))Y!78(9KF9EM;-+[F1X:QHQ+G.(#0
M.TD@+1?:C)J[B;GW?W1=2O\ "X<R7L+9+;B2$(Q^,=:>W)E6>H"[D_)AN*5"
MX_NC@!^(BOGKT'W:Z]3+O=/6S<&/99[C,ZTVN-XH8]N@=_, .3KB05=_ >:]
MP]5K*/H39-J]+[5S3=LA9?[@X9NN9@1!&[LBBK( :&DK#3 +?H/._MT^EJ^D
M%X61P4A]5%2K3E\J,8TREIKYO)3GA%Q< *Z52Y2@5?S%"_I1(Z 7'W#HVVDG
MC8' O[X6@9%&-=[,[3&SF>)/)K1BX\!VK:[7MOX]TDTSC'MT#=4LGV6\&MYO
M>?"QO$GDJ^-@_(1U(<=,F7(=5*GS%)Z52I;@2%J"?]S8:2D(:1P0VD#C<G)M
MX/(CTDZI2:N=]IQS/8. ' 4"Q;V[-Y/K#0R!HTL8,F,&0[3Q<>+B2KA5]8B*
M(L9W7MAK=&,=BHFNXG)H:<3C<S&9;>D0'5BXZF7;-RHJE?[1HE/4-4J2JRJJ
M#G-R6_Z>WUVQWK998FW6W%P,L#B0UX'$$8M>!\KL1P<"W!:)P6#F[:GJC[EG
M3LON2&PYCE9.>[&4U\LZZF03BF(K;;$6++1Z:K'J?#82'#>]ZHQI.IU?,XUH
MO0]_GAWRW_$[*V-FR.=J$<;2"TTIIEJ22]N(ST$U+*BBV&Q(%[I4;:6'VBQ]
MM9+7%>:W5D6DX*KD\?A]S8J5@MQX]C*XB<CI?AR1=(4#=M]AQ)2['E,*^)MU
M!2M"M0163%,^)X?&:/'Z4_L6)MU_NO3VY1[QLDTEON4)JU[#0CF#P<UPP<UP
M+7# @KE_=G;G<O;WKG8\2]Y;&1=0E)3ZNYMO,\0C)--@)R4)D:"0@!0 ^, Z
MGH+6^9.-+J-FY<#W<CV'V+Z?Z1]2]@ZWTV&[^5M?5IPY6MR[FTG^5([BPFA/
MRDY"RXZ9&FLHF8V0F0PK7K;(NDZ$I<1HI"AS!UK/U<#FNOOK">U>8;QA9)PY
M$<P<B.T+((\I"K!RP6#<'4$'Q!Y&]01R6G? 6=K2KFZ^B6$IF-"6D !#X7Z<
MU">5G[*2\D#DX%>T5;[\%8BC=;G79N\NN;2*L)_AX=[2.XKQ.XM0'J0EF2E'
MQ! !:F-$?]ZOU*('\394/945YK8P[BROEW3?+><.;'>W+'DX#VK')@:EHFN3
MF$!F(N*R]-2L1)SLF8>EMAB[:H^0=:2 IQ*QUI20;VN1<:'4J/=V!91N66MW
M#:6SCYLP<0VFI@#<R174P'($&A.%*X&R':AD*]3&S43$FY]%*DQYJ>/PF*M7
M2Z?-M1OX56):9K9.W0Q-T7D9C_>IJ9['#$?W@%;GHTF&[Z;B5]:392'4*9=!
M_P!%0!XU6#7%7&OAFCUL(TGB""/>%694I2M0I"AK97'3G?@:FJQI6482*$*_
M1Y+S0 )NGF#Q^L52YC7&G%:F2,'L5VB3&RX%GJ;<'!:24*'^BI)!JGRW-P!P
M6#/"2W2X!P_3@LA1E7G $O*8GM@:-Y!AJ40.-DO.)^81[EBHH1F/<M2^QA95
MT.J%W-CBWW@8'VA(O8M2OYN)4S?BK'SGD:^(:EIE(^H@5&NAH:CV*/+OVL^[
MN [LD8#\6Z3\%35$P,BX&0G1%'4)EXYN0E/'0NQ7;_\ N-5!^/ ^U4_B=UB%
M70QR#]R0CX.'ZU05B6H_IO,9S!.,E9;=]>3(Q:T%U)0TXI3L1=DMNJ!4!<D"
MPUJXUP<:$.KV8_K6/=;I/Y+M5O<M>!7!K9!AB1@X9C"O#-7>=M_.LRY#,+,0
MI;3266&W(NXE6>9^586>EN48CR6%*6KI;6V+(L-:H9)$X!Q:16O#M[%IK#==
MKN[%LE[ 6/<7$_<4IXCQ:""<!4@XFJHM8G>""$^B'T#1-I.,D"WA\2U?". '
MAY55JA[O>LS\?L+6Z0[2!S;(/U*ZL8O=(L3##.HX#%,Z>T%-KTU14S^E8DU]
ML_U7ZA_YPJZ(@;E L9;3"=-7<K#9 ]H:>!JD>5RK[%A.O-K)P82>R)Q^D(.-
MF*UF9O$I'.TUZ4H>YMITDCVU6"T9-*MF\CRA@F)_@#?I(51$3$MZ.920^?"%
MCU '3DY)=:'_ +C4^8:Y#WJP^6^=71$UH_?>/H:"I]>*CG^1C'9)'\62EJZ/
M&_H1$LIMKP*S50<\K%=%<R"LDK6]C&X^]Q/T+T?CDI"5-L.1\>V?]SQK#<4D
M:Z%Y(4^KWJJ?+)S_ &JQ^"MR=3PZ5W-Y)'NR^"LKTM"EE:RMUPDDK<47%'S*
MEDDU>#,%?#'-P9I:WD,/H7F<GJ ^%  !)O5QK!DK3HQCJ*H?-27N%P. L#I^
MJJ]("MN9&!0*L&%KU=6?9QUY"UKZVJ*@9*VYU>Y7>-A)SH"PRF(P=?F9RQ'3
M;^LEL@O.^72DU;=,QO&I[%BNFC^4$N=R;C_8/>K@F+CHA2%E_*/@_N)"H\2_
M(!"3Z[FIYJ1?PJPZ=QRP^G^Q2V&XD%32-GO/OR'N*R*+C<O,9"Y?H83&C5*5
M]+""GQ0RD)ZU$<PDJ/C6(Z2IH,7=G[5CR365L[3%66X[,3[3P5;YK"XP6@Q5
MY60.,F8"W&"AS0T/B<%_&C8GN)U>'XE6'?BY\97"*(\&Y^TJR9#-3)EA+D$-
M?P16/Y4=(Y -(*0K3QK(;%&W(8_%5Q6S(SJB'BXN.)]ZQR:\TVPY(F/-1(;*
M2XZX\XEMM*$_Q.+40D 6YVJ73,B%1B5GPPN<\,8"Z0Y4%2?8H87 [LWBE*MM
MPT8/!*_>W9N".^VR\W_$K"8@^E+RJK ]+BRU'X'K4*T]UN0R::N[/V\%B;AN
M^T[/5ET[S[X?X,1&!_[23%K.UHU/X4"V'"V#M/;<23\JDY[=#R"?\5[@;:GS
M&939]2.J*R$HC8V$V\!=F,ELK0/B6HZUHI[A\WSG#AR7'W?4&Y[G*WS3Y5@#
M_)BJUE.-<R]Q'UGUH<@!@K;@,WE)$<P,\^7<C$<>:4OI0VE"T'J=AI;;2AL)
M9"@IDV^-A23<D$UAB0_*?F69=;3%J%U9@_A7@>SO[^/)U5[Y$H $E?0GA?\
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ME:$TKC04;6I[ JJ%RPD+NH @:*Y7X@BYU!JKPUX*B1D?RY*LB8^G52!:WO\
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MEGXQMN\,G-N320Q.+7T<T'5335P!:""0X?E@F[^[NN=X-XY?NOZB9N3S+_\
MBDMX^!B9^,W% 4[!RL>7A,=%@1&"IZ,E*BTV2I8*U=145'\?O4F&;J6\N[[?
M 1UR+A[;AKXVQ5D:0T@M8UK YM"#@-5*DDFI_?;8>D^C[#HBQV_H0QOZ;9:1
MFRI)),#"\:V.;+(Z1[VN:[4 7'3\H  H-M]OL#,[R=P=J;$VY*"YV\,[&QOS
M#*[JQ>/0HRLKE%I *FQAL2P[(NH"RFP.)%<[Z=] 7W5W6.V](PM<R6ZN&M<[
M'P1M\<LM>&AC7.!Y@8XKENN>IK'TVZ'W+K#=&@P;=:N>&'_%E/@AB[Y97-81
MR).07Z98L=J%$B0FG'G68<6-#9=DN%V2ZU%8;CMN2'3JZ^XAL%:C^\HDU^V<
M,3((601DF.-C6@DU)#0&BIXF@Q/$XK\&IYI+FXDN9 T2R2.>X-%&@O<7$-'!
MH)HT<!0*OKK[[?HYU<5K!+775.O(T4^]+VJX>!HG<$'D?=KK[ZA2.2-.9X>'
M"B8\%'V\?;12GK?PHB#?G1!3@E1$J(BB(]_OJ%'!(FE4)4:I5**(MG=J/^LD
MCRQ,FW_V3#J_;_/[%CW/\OVKHFLQ8**(BB(HB*(OG76B6_11%)) .M2#BH(P
M50>!-SSXU7]*I/P4@:*0?>G15(HB8(Y_710:IA7[?;XT4$*H#P^FG[*JJH!4
MJJ4TQJGX>V_U412%S<WX"_#QJDT4_2I F_\ 6&FO"H(%$53W>ZH")BQYV]UZ
MJKR1'"_V'A]+U*)@Z\;"]_'R]O"B*IU7X:C@3]-=*E%@G<CMOMWNGMM6U]RJ
MRC$1,QG(19F%GG'Y&#/CMO,LR6'5-R([H#<A:5-O-.-+"M4WL1P/J/Z:]*>J
MG3O_  SUA%)+MS9FS,,;S')'*UKFMD8X5%0U[A1P<T@FH7:] ^H'4'IMOXZB
MZ<-N;LQ.B>R>,2121N+7.8YM6N&+6D.8YKVD8',+AK>?^73M_?#R<+N+NOG7
M>W#LIN3G,,W@\="W/D\?'(=<P[FY6Y9Q<6%*"2E]]./#H9)"0E7QCYKZ:_)?
MTETMU='U!;;M=R[/%5P@DC9Y@XXSAP;IYN\L&G+-?6VT_GCW[9MN?/M?3UFS
MK(Q%D4_GR/MHWNP\T6Q9YKI&YL9^(+=5"21X3C7?W\V4O(3AVS[%91>W-K;>
M$/&S-ZX/HC/Y3\*]..G![2?"3^&[<AQV S\VU9V24V:4E@=3O!_F"_-'=VT[
MND/2JY$5E!X)[Z+YG.;@([5V38F$ .E&,E*,(9B_J/0_\LEK:60Z\]7K87F^
MWFJ2*PG\38A+5QGO&_XER\N+_)=5L0-9 932/1?:+,K[^_F;V=VPWCG9N8AP
ML/FNXF[(V?F2IN0W1B-GJQR&,$?FG"MS&R\QE(GS2$_RE1DN(M\5>4?ERZ&W
M#U?]3XNL/42ZGW46;3.3<R.FUF,C1%XR0UFLM+F  :6D4Q7J_K&^U]%?0V\Z
M@Z2M8+*^O+AFWVGX=C8V6S[@/,MP P"DC(62"-Q\0D<UU?"ON!X  )   "0$
MI2D"R4I2D!*4I L - *_6)?DE^GZ<U(7.@]O[>%352I6MQJ:J:J8/$_9X5(H
MJ2."IOOLQ6'I,A8;8CM./O.*-@AII)6M1]B15$LL<$3II32-H)/<%=MX);F=
MEO"*RO< !VE6_$-/%AR=+06YF46F6\TK]Z,ST!,*$= 1\K&MU#DZI9YU:M&O
M\KS912:3Q$<N3?8*>VJRMQDB,XM[<UMH1H:?M$?,_P#O.J1^[I5VK)6O11,\
M%;',LP7%1X*59*6@E*VHJDEEA7 _.2U'Y>-8C4$E9Y)-6/Q4;G%D/WCQ]G$#
MO=D.[/L6>+&6-@EN_N8CEJ^8_P +/F/?0#M6.Y_9$#=T62WN"1+1*DQEQ&W\
M)*<QRX$=84%-1WPDKEW"SU%]*DG^%":J\MSP?-.)X# #]9[S[ %N]AZMW+IF
MY;+LXC, ?J,<S&R,>1Q+3\I-,V%IYDK#']NY;:L>/'0TO)XB$PS&8FQD*<DM
M1X[2&6_GXR>IQ*@VV.IQ/4@G4D7M64TB@;R"WK+[;.H)'2L(@W"1Q<Z-Y !<
MXDGRW9$5.#31P' YJ,6='DI"VW$J"AR/ _L-7 XCN6LO=IDB<6RL+7=RNJ)"
MDV)]Q\OMJXV1<]<;>6\%5E(@YB(8&7A1LG#7Q8F-ASTU&_QL.V#L=P#@IM25
M#QJ^R5S#5A((6);27VUW'XK;Y9(+@<6&E>PC(CL(([%IS<78S#SUN3-HYN3M
M^>;J$2>I<F"XK^%/S;:3(2D?]]1(K8Q;@1A,*CF,#^GN7K/3GK3O.V-;:;_
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MKY>//]JZ*K,6O11$41%$11%\XNJX_>^VU:44*WWB!PQ59*KCCP&O#CI[:A5
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M\+I \ZDO"T[I=GLQ][)YCQP8-7QP;\5<I':["9K'2<9NY1W! G->E,QG\R+
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MRR6SNTQ!W+*_Z(D?9)AU?M_G]BQKK^4.]=%UFK7HHB*(BB(HB^;X6?#[;5I
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M1<4ZX^XVCT0L7!UJR]PJ'=J[?8MLLV;5?0[A<10.,?@UN:UI-":8N!+J@
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MM9;'K],O%"/A2F:R X+?#U=0&@KG^A.I9.I-F>;[2W?+*XDM;M@^K/$:%U.
MD;1XX8FF 6_Z_P"F8.FM\']-J[8+Z!EU:.-<8)14-J<S&ZK#QH&UQ*S^_"NT
MJN'JM4G)(V_W;1BBXEN)OK!&8EI2EGJS6)$@=;:3\*5O18B[^)5XVOXK)O<?
M37KI'T^]P;9]1[2Z9K2<[JT+@2T95?$TUIGAQ7JPL';_ .DCMU#2Z[V/</++
M@!46UQI-#Q(;(\4Y8\%M>_L^NO:JKRFJ$V) *@D$_O'@!XFP)-J#DH<Z@)&)
M"^-/YC_S)[GWMOS+=O\ *; 7L";VOSV;C1\=N!PRLYEL9E6VHT'<+H8<_"W\
M+G(,5#\8QE/-#JL7%D5^47YP>MNH^LNH(NB^H-L;8;)M5U));GQ&XE+V!A?(
M^IBT/:T/8V)I%"#YCL:?J;^7;T9Z;Z8Z2BZSVO>/ZM_7+2$R.A ;!#)$7.?
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M-T[U7Z7[ [I6\;<[;NFX/GHW!P9;0EI9,RNJ.2.6=K7L=D\5!+:$_3>WG7Z
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M XUM)7N.ECF.KY#G$-+3Y1(+6:OL#\P_HGN&[7LOJ!T5 ^YN"!^-MHVETK@
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MGKPN; ^0\_&BBJ0TY&_TTU^^B=Z#XD6%]=?9II1!3AFC_6UM;0?JJ%/L2&G
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M>W]JZ3K8+7(HB*(BB(HB^89%@-;\>?GRK0@U*Z= /F01]5AR]M2459) X@\
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MH112I@_J!X^ZPHJ2I#Z'AX\O94J,%+C4XE#CW)VJ:X8)0)Z <-;\?T4.&:G
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M5KGDF:#?6HK0J/8D.5"16H4YXA/B:8@**'CDCV^/Z=*CNS4I7Y$:'ZZGA@I
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>3#VI::^T7^OX:I/9DB@/WOB]WUZ<*<,$52J47__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g382677f_297.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_297.jpg
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MQ #C  $  @,! 0$! 0          !P@%!@D$ P(!"@$!  ,  P$! 0
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MAN/=1*(E3=>0 2<<)+]=,X%ZGH.9Z/DNYVNDU$AEL::Q'!8</R"9[.\QM/\
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M!P5%<R.BD.PK6.:U OX9M7Y6*93<.U19H)L9Y$DZD<&!"$:JN1E@>'=N4^+
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M/LA7_9^B9*=UF,?#FA]D*_[/T3)3NLQCX<T/LA7_ &?HF2G=9C'PYH?9"O\
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M/(Q5.9JU9M6Y&Y$A;(&3*<E8W_9'W9/ S&W9EAYO1,GW*C2^[V]CI+O)*#?
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MZO!>D@X/^_\ QI7<YU;3[.%\1)))BN4:TQ=U_K6&V#]N1\,#\7G_ ']GGO\
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M42G Q#[#%$#  Z)DJER.XBV;P!XDF67KE\C5:OC"-?RV+,5S#%KB.G5FX5*
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MF*/\QHF2JE[Q-+QCC;)N[/DU]4ZM&U1A<\@42Y#]S1Q&9XFXXOLDW'KODS)
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MZK=&_0,;;T,T+I8F2L$C',[XY!EDC>X#N8\=6/&6N'4$A9'NCQ?X?U'F*/\
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ME)-596'<D*0@$$KD."7@[ UYUXWR.SQWP%N*MN0G;<6I[/7.)]2ZBR6.J?\
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MCB**3=))!!,B2*"9$44DR@5-)),H$33(4-@%(0A0  #X #7IEC&1L$<8 8T
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MRL1FZCA*FPMQQ=DBLV:Z*D3^ :O"/U7B/"^29TDD3RB8 '\?G34<KVD?'/\
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MO7-:KP$5"1D]OEK*.XY>)*X0A\QY8QM<:$W2;M"E7XB385YZX71+Y&JQ0!0
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MJ7#M."H!!&0I7Z'W+Q9M/9['_NEJJE5TK6696TYWL.&X[(EQ^[8:$D@CKNI
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M0Z);SJ)"S>UMO*97KF'PO)&Y#+J"A$/QD$MNW@F:.^.-P>" ENUH;U=ZC_\
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D.BM_1^]7.T54T1-$31$T1-$31$T1-$31$T1-$31$T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g382677f_30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_30.jpg
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MQ "=  $  @(" P$!            !PD("@0& 0(#!0L! 0$! 0$
M       ! @,$$   !@$# @0"!@<' P4    ! @,$!08' !$($@DA,1,4,C-!
M46$B-!5"4F(C-18*<8%#8R1D%Y%3&*'!<\-T$0$!  (! P,"!@,! 0
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MARL8@B7W!$TG90'[BI=2ZS;E9;.%T&'>^B4J+2.SYA9<5R]";FU8HDTE$E0
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M0[-Z1+\W2EHMW&M)$1(BFE[\CA1J@]$792%+U@?]Z !\0;AV70- T#0-!ZG
MPD,!#=!Q*8"G$O4!3" @4PEW#JZ1\=MPWT&@_G*C9$QSF+(-0RM'2S+(25RG
MUY@95)P9W8GDE+NG9+!'+JE$TTQL'K@X;N$14*N14-AWW /9++.G#C>6W9VS
M*-D;'?#'$E;R>UDHN>*E8I6-@9A-9"5KU5FK')RE9AW[9P +,EDHMT14&YP
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M<MA3(&6.8B.-<MUQ>)L=G3E+O#8;@H]4Z;]418MEV2BDD9PGUE"+XZSK/?\
M)T/$N9^8N.,/0CVPVV0L.9J!Q]RQ#VO+>:\3952E:A;F',[%M/L="F4H]M8H
M^7DPQTH[>P<D\CW3%54S)VJ[)"I.%#.I9KGV3!S7RG-92P/VTY_(C"/95;)V
M3F]NSG0>0W';*,I#2E<98%R*5U)Y/QIC"R2;&N(0EHF63N.BG[YTFI8%XIPW
M,869RBJ:SK</V</VC"/'_FGFGDLSQ_D'#^ LB<!^!?N)VR8RR6E/R-NL.?\
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>M!Y:^9/P/X5+\+Y_&K\'^U_4_:ZM!S= T#0-!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g382677f_317.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_317.jpg
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MQ ")   " P # 0$            ("0 &!P(%"@,$ 0$! 0$
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g382677f_318a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_318a.jpg
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MQ #%   " 00# 0             )"@8!!0<(  (#! $  @$$ P$
M    " D%  0&!P$#"@(0  $$ @$# 00$"0D)      (! P0%!@<1 !(($R$Q
M%@E!(A0546&1(]355I<8<:$R0D65AI97@;'3I"551A='$0 " 0," P0$!P@/
M"0     ! @,1! 4&!P A$C%!$P@BTA2446$RD],5%W%"(S-3-%16@;%2<I*R
M0[,D1'0E1546D6*B8W.#9#4F_]H # ,!  (1 Q$ /P!B/S<\M=CY5F>0:RUC
ME-EAN!8U+?I+2SQV4<"[R^UBJ3%H;EU%49L.BBR.]AIF,XW]H["<<(A( !6_
MF(\SFILGJV\T7HB[DL=,V$K022PMTRW4R>C*?%'I)"K51%0CKZ2[DAE565^7
M/8S2.$T_:ZQUE919#4]Y&LT<<ZAX;6)O2C B;T'F9:.SR*W14(@!#,PKY[V1
M 9JN8Y,I]RJ2EE5WW*7/MY[K'GE5Z%==>9VOIY&[K7\O)Z_!KVL6*=0!C[/I
M[OZ-%]'Q%9ECD8JO;F>3)[_Z.670K^3[QX7J\BUWF^_(W7S[^MQ,PV>)/(XZ
MS]VA^CXRYXS6V1N>2&A6W\NR.2RYM_7P/1G\FMGV9#99/6HXR\P[/-MYMP?8
M0D*H2+PJ=;$VIUAEKK<[3MM+?7#QR9JS4J9G((,Z"A!:A!^#OXP3>+'8I-H]
M3O'86B2# WQ#"WB4J?9Y*$,$!!':"#4<-Y].@X0_QSJN*X%W\RS>>:ZVHM?X
M)AMY+Q@,[^(IV0W%;)*%9R*RC^ZHS5-#G-D#\1B8_:J<DFE%PP;$.Y (T($?
M.]NCJG1N'Q.D],W4M@F5]H>XFB;HE:*'PE$*2 AD5VE+2%2&*JJU"LP)I>3W
M;33FL,GE=3:@MH[UL9X"012+UQK)-XC&9T-5<H(@(PP*@L6H652 OMY[DGTY
MA?K_ (BL_P OMF]*X?46=[LE>>\R^OPPU]+8C_+[7W>/U.+BSL#(D_\ +[Y?
M\167Z;^/JSDU%GCV9.]K_:9?I.+5]+8G] M?=X_4XREJ//+Z1M+6<=S*;IYM
M_8.%LN-.7U@X#H.Y)6MFV;93%%P7!)45%145%XZR7;K.YV7<?3T<F2O&C;.6
M (-S*00;N($$%R"".1!'/C"]=Z9QD6BLS*EE;JRXJ[((@0$$6\A!!"<B.X]W
M#0/7H<X2]PK5NG8N3P]P;ABL9)?,M1=E;!899:NK)MMEMC)K9MMMML)(@V#8
MBB(B(B(B<)T@/=F\SXW'U*L5_?)&,WD.D+/, ![3+0 !Z  <@!R X=;MWI3#
M3Z"P$TEI:M(^'L2288R23;Q$DDK4DUYD]O#*VJ'W).K=:R77#==D8!AS[CKA
MDXXXX[CM<X;AF2J1F9$JJJJJJO3RMN2[;>X$R$M(<-95))))]FBJ23S))YDG
MF3PGO7,:PZUS$* !$REV  *  3R   =@'P<>6T=I8;I_$+#-<WLPKZJ$GIQV
M [7+&WL7!)8M141%(3FV,L@5!!%01%%,U%L2)+?<;<;2NUFE;C5VK[@0XV$4
M510RSRD'H@@2H+RN10#D *NY5%9A]Z*T3J'7^?BT[IN$RWLG-F/*.*,$=4LK
M=B1I7F>TFBJ&8JI!1MCR5SS=&7G>R9UA1U33AP\9Q>GGRVV*N$\Z*-M&L16C
ML[>:0@K[RBJFYP#8B B/2'=\-^-Q-Y]7MG;NYNK'%QDQV5C;2R*D$;,**?#*
MF:XE(4R2$59J)&JHJJ&<Z#V?TMMU@!C((HKF^8![BYE12TC@&I'741Q(*]"5
MH%JSDL2>-Z-6^-6:5&I,]SS.GLEGY[9:ZS#X'P@;.S?DTLV9C-DW6R9D9)*J
M_E4MYT188]J0U).>7U_-&)M)Y3]:X7:+46X.X,N5N=PKK362&*Q8GG9K666Q
MG6&21/$]._D9E$47,6Q(K6<_@AJUQO-IW(:]Q>EM,+91:6AR]I[9>>'&JS(E
MS&9%1NGT;90"7?\ E0#_ "7RQ29\RV5[D2JJ*I7-NJK_ %N2GR.5[O?SROOZ
M"W-R,<W?$DU-Y/S_ .Z_!JZ9=QC;0#L%O%_$7AD7$]=8!78OCL"#A.*1X<2D
MJV8[ 4%6H@V$)E$12.*1F2^\B)5(B5555557I^FG-&Z1L=/V-I:8RP2VCM(E
M51!%R 1?]VI/>2223S))/"B<YJW5-WFKNZN<C?/</<R%B9Y.9+GX&H!\ % !
MR  XOIX-@HB1N8?B8@**1&>/TZ"(I[5(B*)PB(GTKU,MIK3* LV/L H',F"+
ME_P\1JZEU,Q"ID+XL>P">7UN/"/CFO(C[,J+0X9&E1G0?CR8]71LOL/M$AMO
M,O-L"XTZV:(HD*HJ+[4ZZXL5I2"19H;;'),A!5ECA!4CF""!4$'F".8X[)<O
MJR>)H)[K(O"ZD,K23%6!Y$$$T(([0>1XE 3X+ABVW,B.&:\" 2&2,E]_ B)J
MJKU-+=6KL$22,L>P!@3^WQ"M:W**6>.0*.TE2!^UQHA\P?R"R[1FK:&%@,LJ
MC*]AWDNDCY$VVVY(H:BM@+-MY5<CHFTW;2/6999<(2]$7#,4[Q!4%SS9[KZ@
MVRT/:VVE9#;YW+W+0K<  M!%&G7*T=00)6JB(Q!Z S,/2"D$WY5=J\#N5K6Z
MN=41B?!XFV69H"2%FED?HB62E"8EH[NH(ZBJJ?1+ ZK?+,O*S.KS=$C9EO&S
M+*29PV15OYW/'(KI*XW,C6W<K7,@=F26XA3%C_:/15!4_2[_ .IUHKR79"QU
M/D]22ZUN$R.<*VC1-?/[1-X9-QXIC,Y=@A?P_$Z*"O1U?>\;L\XV-O--8W3L
M6CH'Q^$#7:R+9)X$/B 6_A"00!%+='B>'UU-.OI^^X+;\,:X_9["?[IHOT?H
M^/J+1GZ'C/FH/5X!3ZYU=^E9'YV;UN*_#.N?V?PK^Z:+]'ZX^H=%_H6+^9@]
M7BOKC5OZ5D?G9O6X^V-B.%H34J'C&+H;3@NL2(U+5(3;K1(0.-/-1N0<;-$5
M%1>45.KF#3>EPRW%M86'4K JRP0U!!J""%Y$'F"#4'BUFSNH2&AN+R]Z6%"K
M32\P>1!!;F".X]O$HZG^(;A2KR2J;*@WUO"MM(SL2:WLO-Y:LNB0J46UNIMM
M720[D3O8F5TYIYLD]A :*GL7I$&\>.NL;N?J6ROD,=R,Q>-0BGHRS/+&P^$/
M&ZNI[P01P]3:&^M,IMCIN\LG$ENV'LUJ/W4<212*?@*2(RL.T$$<,=)N3!M&
M^->O,[SVS&%6Q-;X.S!@L]CEM?VKF*UQ1*:EAD8%+L):BO"<H#8(3CA V)$C
M=CN'IC;#9K$ZHU3-X=G'A[-41:&6>4VT?3#"E1UR-3X@HJ[E44L%'G;_ %+N
M3O!EM,Z8A\2[?+WA=S4101"YDZI9GH>E%K\98T5 SL 0(;S\C<X\B,W^(LB)
MR-7,/'"PW#(!NRH5!#E/"VS&C--BAV5Y8EV)(D]GJ2'.  1;%ML4^;R[J:MW
MLU5]<9PLMDC%+*RC):.W1B %4 5DGDY>)+T]4C450J!$#0MM-I--[3Z;^J,1
MTO=,H>[NW 5YW4$EF)-(X8^?AQUZ46K,2Y9B5KPP\-3P5BLVMMVN$\Y>;;F8
MMB,L1=:PMIP>YJRMFE[FWLL< N1!>1KT7CVO\JT=WE:\IEOHTV^Y.Y-NKZO(
M#V=FX#+8@\UFE',->$?)',6W=6:IC!_S#^81=2R3:'T%*1II24N;I20;LCMC
MB/:+8'M/;.>?XJ@<F'1_<!SPJ-FE^!W^1"BI]6[N!]Z?18R4]O*_BZ\[.;A_
MOJ^_MDW\ZW#O]/8UEQ=H?_&B_FUX:BQ]>:&D7\-16K^6&SUZ%,/RQ%K_ &:+
M^(O"3\KRR=R/^?)_'/$6VOB$G8&L-A8/"DMPYN789DF.PI3RDC,>9;5$N%$=
M>44(D9"0\*GPBKV\\>WJ%UWI^;5FBLMIFW<1W-_CKBW1CV*\L3(I-.= Q%:<
MZ5IQ-:'ST.EM9XK4ERADMK#(6\[J.UDBE5V [JE0:5Y5I7A5+,-1;<P2RM*C
M+M=YO2RZ17OO-U['[AZL:9C(2N3FKB-&=JI-8K8*8R0>)DF_K=W'2/,YM]KO
M2UY/89_$Y*VN+:OB$P3&,!>UQ*JF-HZ#J$@8H5YUIP[?!:[T+J:S@OL!EL;<
M6]S3PP)XA(2W8AB9A(LE30QLH8-RI7C)/AJ9+Y4Z+Y,^%S<$X[R5%_Z-;_1S
MPO6;^7LG[;=,\R?[R'>?R4O&'^8% -D]2\A_ZT]P_*Q<';\VO&VQ\C]6Q*W&
M)$6-G6&VIY#B@3WOL\&U)V(Y#M*"5*7D(?WI&(5:>)% )#+??P"F2,Q\R6SE
MWO!HB.SPKQIJ?'3F>U$AZ4EJA26!F^\\1:%7/)9$3JHI8A:/ERW>M-H]:R7F
M:1WTSD(!!<E!U/%1@\<ZK]_X;5#(.;(S]-6"@KSY-I#=&&63M7DVJ-AU<]@S
M;5/A*ZFQW.U>TCB659$F5\UD^.4-EXP)/:BKTIG,[8[BZ>O&LLQ@LM!=*2/S
M:9U/QK)&KQNI[BC$'X>&LX?<?;S4-FM[A\YB9[5P#^=0HP^)HY&21".\.@([
MQQ'?@/8_[ ;!_P G95^K.HH:/U<?\+RONMS]'Q*_ZGTC_FF*]ZMOI..JX-LA
M/=@&P?\ )V5+_NK.OK_1NKC_ (7E?=;GZ/CG_4ND#VY3%>]6WTG$AU_N?;>B
M<I;M</R/(\3N*V2U]X8_8E8LUDX&U!TJW(L9GJVS)C2 5.1<:%T4)";("[22
M=TAK/7VV.<6_T[>7EAD(7'B0/X@CD Y^'<6ST5E8=H90P!JC*:'B)U3M]H3<
MO"&QS]I:7V/F0^'/'X9D2M1XD%PE65E/858J2.EU85'#0NA=MUN\]1X3M&LC
MI!')ZM7+"M1SU?NJ[@2'ZV\K4<_I.-P[6&Z#9*B*;2"2HG/3I]LM<6NY&A<=
MK*U3PO;(*R1UKX<R,8YHZ]X616"D\RM#W\)AW/T+=[:Z[R.B[Q_$-G/1)*4\
M2%U$D,E.XO&RE@.0:H[N!N_,=N?$I; :_-:O(K;>4>F;1I_7$JOK;6NJW&C<
MK&LZL+./+IGHA YWQV'&'YXLKR'IM&)*'7F_R.P_M7LFHH;R?<Q+<4;'O''+
M'&03&+UY%:$J0:QHR/.%YKT(P)+ORCV.^@M?:M.SVD&VKW!J+]9)(I) 0)#9
MI&RS!@121U=(2W)NMU(&@GE34;\@EJFSV]);L</F:YQ1K5D^A;DMX=%I4QVK
M<<JV6'4YBY:TRC:V7K?G9"BAMJL=&Q 5=\\=NI <%>:^<38"3#VHQKPAA:+#
M[/&3$%/R;H#I-QU^E(0&0F(*%*'9/(;7W*YNST&AAST>7N3DDF*F[:;QY )"
MP^5:DU%OT>B@)5P)2Y;)/RZ\DT14;J!O:K7I9M+^R1]36URY'^$H%XXK@2&7
MFW11(V63.X!K9#Q*R*]P-]D@FU+./*)<;96.X8EUM'_]*W2,9+*5]ECF-0P(
M(]&Z:H%O(YZ1Z2ITRE"</\V.)W,O]NR^B#U:<3J;)Q1!O:GA%"I!'RK9.9N(
MT'6?19NJ(. QGTW/A2W'.JXKA-+,+YQK*<K9<[A<9R2_:-HDX<$V[:8)-J"\
M*A(0JG"_3T@'/8EUS5\"I#B[GY=]?$;E]WCT#8&QB;"V+K0JUI :]U#$G/[G
M#4V%^2OC[:8CC$^/NK6#;4JAJG1:G9OCE=-9583*&S+@3K&/-A26311<:= '
M )%1414Z==@-U=L[G!V<\>?Q"HUM'R>[@C<>@*AD=U96!Y%6 (/(CA)VH=H=
MTK/.WEM+I[,ETNI15+2>1#Z9H5=$9'4CFK*2".8/$G_B$T+_ *UZG_>'B7ZV
MZEOM0VU_6#">^VWTG$-]EFYOZO9OW&Y^BXQ+OO>&G+O26V*+']JZ_OK^_P!>
MY904-%C^7T=W>7=W>4DRJJ*>HJ*J=+L;*QM+"6VPRRRV9N&:)QU@FZ&XF@\E
MMSG<7B\UB[G*76*NH(88;F&6::::%XXHHHHW9Y'D=E155222!3C.ML=N=?8W
M<;!Y/*83*6V+M<K:SS33VLT,,,,,R22RRRR(L<<<:*SL[,  ":\"]\$_#W<W
M_N?#]IY]A]UK_$,!DR+IGXHBE4W606Q5TN#75]=2R4&R;B@[,]9^0\TTWV-]
M@*1%]4+O+1L!N NX6/UKJ>PN,7@<6[3#VA3'+/+X;)&D<3?A H+];NZJM%Z5
M)8\C/\R^_NWQV^R&B],7]OE,]E$6$^SL)88(O$5Y'DF7\&6(3H1$9FJW4P 7
MF>>[O:7&JJ9>9%;UE#2US8NV%O<SXM9606C<!D7)<Z:ZS%C-DZX(HIDB*1(G
MO5.F<Y')8[$64F2RT\-MCHA5Y976.- 2 "SN0JBI J2.9 X6/CL;D<Q>QXW$
MP3761E-$BB1I)'(!-%1 68T!- #R!/&-?X@]#?ZU:H_>%B?ZVZQ'[4=M/UAP
MGOUM]+QF'V5;G?J[G/<;GZ+BG\0FA4_^UZG_ 'AXE^MNN?M0VU_6'">_6WTO
M'/V5;G_J[G/<;GZ+BG\0NA/];-3?O#Q+];]5]J&VOZP83WVV^DXK[*=S_P!7
M,Y[C=?1<+U_,@SS",[\EIMO@-_29/61,'Q:ILKG'I4:PK9%U$=MW7V1LH1.1
M;!Z+!E1P,P,T#A&^>05$6+YJ<[IW4V[<F0TW<V]W:)CK>*26%E>-I5,I(\1:
MJY5&0$@FGR:U6@:MY1],:CTSL_'8:HM;FRO'R5S+'%.K)(L+"(*?#<!D#.LA
M (%?E4HP)+A\L-'/X1<0-P3%',JS\VU)%1#;^*[$.X.43D%,53G\*+T;GE'C
M:/9.Q!!H;R\(^,>T/S'[-> 2\Y10[[WX4BHLK('XC[-'R/QTIP";R.M95IO7
M>$^PDG)EN[/SYDWG24B5J#D%C B-)S[@C0HK;0"GL$ 1$]B=*SW=N+J^W-U+
M=7;%YVS5\"3VT2=T0?<5%50.X  <APRW:2RAL]M=-VUJ@2 8:R( ^%X(W8_=
M9V9B>\DD\,KU&L<+W#XV8#@6?4[-UCMUK'!D<:+\W+@RV\7K5AVU3,%%=KK:
MO=+O8?#ZPKRB\B1"KB[#1>G=?[/XO2VJ;=;C$W&%LJ@\F1A;1]$L3]L<L9YH
MXY@\C5205 WVLM1:!W=RFI]+W#6^5M\S>4(YJZFXDZHI4[)(G')T/(CF*, 0
MMMY@>,><>+N:#67*2;K!KUY]S",[:85J);M-<NK5V?I<M5F45S2(KS'*(Z*>
MLQR'* KW=39#/[19XV%]U7.GIW)M+L+02*.?AR4Y1W"#Y2]C?+CJM0K==AMY
M--[SZ=]LQ_1;ZEME O+,M5HB>7B1UYR6SGY+TJI/AR4:A8B'R^_F+M7+M)H?
M?MZ@W!K'J==[(M9""%ROU686*9=->)$"Y]S<*>XO$SV-/+Z_:;Q=>7CS"272
MP:"W!G_IG*.TO)#^,[E@N&/\IW1RD_A.2.?$HSB?YI?*>^/2YW,VPMJV ZI;
MZPB7G%WO<VJ <XNUIH5_%<WC'AU6,X'1P\+DX6$^8AH3$Z3:68;4T?M/3^5U
M>0V\Z=G>LH>T< A9QA68(^K>0+ Q^=D,1^UK;"Q$WG(K*?;H<HG0]$F^U06G
MOKMOHP:KO=2:6S6$DCN)W:YM/;[1)[>XK27IC:92RL]6*#\)&Y9>DK2C?_+#
MNAJ6[T78:.W P>>M+NU@1+._;'7KVMU:TK#US) P1T2BK(WX*6,(WB!JAAD,
M6MTA<.4TCN1>%^JP7UOY4=5%_P!G0U3X#%5-;JSK_P!>'U^"RDEBI52]/WDG
MJ\7UFULU1.:A]/P\@Q_Q/=U&28'%_I5E\_#Z_$=)*O=XG\"3U>-P?"?"'-@^
M0^L'KB_Q'"*+&<SQW(I\W*,LQFALK>556D:94XUBU/.M&;B^O+ZT99C-A&8<
M%L34B7E!$MG;*Z(Q.5W)Q$]QD\5;6EKD()B9+RV221HY%:.&",R^)+++(%10
MBFE23SH#H[?S5D^G]K\Q%96.1OK^[Q\\"K#:7$L<2R1LDD]Q*L9BAAAC+.QD
M9:T  I4AM3IPW"4.-.OF ..->'>]'&FE><'&JQ1:3MY-?BFA3A.Y4'Z>?;UI
M/S&01W.RFH()61(VM4JS$*H_#P]I8@#]D\;W\LC=&^^G&%>5W)V D_F\W<*G
M_9PJ$MI8?]G<_P"6Y_G<Z4*,!C?TNS^>A]?ATXN6_<S4_>2>KQY+96"_V2:?
MRI%X_F=Z^OJ''#^M6?ST7K\=ZW#?!+_ D]7CHLZ>O]E\?A[BB)^3\]U7U+CA
M_6;7YZ+UN+A9F/Y3^#)ZO&6=2:QN]KY)"I'<LUMK6D-YK[VR[8^?8?B]9402
M-$?D1JVSNXMO>2P#GTX\5DN\^$,VPY-,KTIH*WU/D4LCE<1CK(L/$N+N]M84
MC6O,A'F$DK ?)5%-3VLHJ1B.M=<6^B\3)D5QV8RV1"GP[:QL;NXDE>G)6DCA
M:*%2?E/(PH*]*NU%+:6@L8UWA>GL"Q35-]4Y3@E!2#64V24MK7W<"]=C29 6
M]LEI5/R:^5+GW?VER1Z1J(2",?9V\(X+;C$Z7P6B,=A]&W$-WIRV@\.*>*1)
M4E*LWB2>)&61F>7K9^DT#EARI3A'NZ&9U9J'7V4SFN+6>RU-=7/B2V\T3PO"
M&53%%X<BJZJD/AJG4 2@4\ZU*IOD,Y9)N[>/9&(@3:NRT!?483D4RVY[5X)Y
M%1%3\72:]S+*)MPM0L7B!.9OCSDC!_.9>T%JC[AX=QM2MI]G.F^IQU?4F/[F
M[?9HOBX;%TKW+IO4JFG!+K/ ^Y/8O!?"U5RG**J>Q>G/Z" 70N%44H,39_'_
M %>/O'".]Q*?:!G>GY/UQ>T]YDXL?D!0:5RK5V08YO\ GXC5:WN48KY]GF5[
M5XS7P+)\U&JF5]_;2H;-5?1Y7!0W0<%U'4^KRBJB]&OK#1>4TQ<8[7\EG%IR
M:BL]Q*D**Y_%LDLC*$E#<XV!#5[*\QQ([793</"ZSM<MM?%?3ZMM^ITCM(9+
MAWC45D5X(E<R0LO*564J5[:<B%%O)#2]-IG8<['L*VCK_<."SO5GXIF&%YKB
M60/%6*]VA793#I+>4M+D,%20#[A%B4G#K"\*0-JMU[HS&Z1SKV&'RF/RV$>K
M0SV]S!*>BO))ECD/ARKV'L5_E)WJKU]I-P;_ ' TK%E=0X;*8#4L=$N;6[M+
MF >)3G);--$OBP/S(H2\?R).8#.7GQ\W[Y9.^-&X=,;HTYOMNU;T3LP-.;E3
M7^;A(D2&]?W;F/T.0WK-9ZC=H#B-?=-PCB>L2 V\:.^FZX6>A=:[GMMUEM(:
MNQ6;%R,)=BPO_9K@$GV63PHY9 E>L&G@3U]+DK'JZ68$=T]L-CDW?P&X6WNH
D-,&R.I<><KBO;K,JJF^A$\T$)DH8R.KVFUIZ(ZGC7HZD3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g382677f_318b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_318b.jpg
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MQ "F   !! ,! 0$            (!08'"0 ! P0""@$  @(# 0$!
M    ! <&"  !!0(#"1    8!! $# P,# P4      0(#! 4&!Q$2$P@4 "$5
M,2(602,)43(S0B0E88%#-1<1  (! P,"! 4" @8* P    $" Q$$!1(&!P 3
M(3%!(E%A%!4(,B-Q<H'A0F(S8Y&A4L+#M"55%S<F5AC_V@ , P$  A$#$0 _
M /UV_P A%BDK!4\6]8*L[.WM?:+)$+1WBK< .XB\;PKMI.Y#FQ*751-%M&(I
M)&'30R:J@:^P^JY?D7DKG(X?%<5XIRN6W7DX[5B/U)91LLMY+\:*@53X>*LP
M^/5H/QAQ5IC,UF>7\P@;#;.Q4MVH;P62^E5H;*+X$M(68?!E4_#K/X\[1*1%
M*R3UGMSDRMRZN9%FJ 0R^H+R6/I)V[F,>S9=X\BC=S%**(IC[@"2"?O[^L_'
M+*W5E@\GQ=EV)S6U,E):"OF]H[-):2_'2R%E7^ZJ_'K/R@P]G?;@Q/+>$0#
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MS+D:2DT[VXQ]+C&T.1>,:S,$MK2CL7EFDDUO AXB;LKL&[%113E<<9S@F!
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LVGZZ>B1]/H--&C5X^5-51Y_.M/G6G0Q^IUC5K[FGP\ZZ:'R]:4K\J5Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g382677f_318c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_318c.jpg
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MQ "5   " 00# 0              " <$!08) 0(#"@$  @(" P$
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M+8G =('%)IY >;5EUMT2!T)"XHA")(QJWRA5+FMIVEW3#IU8<2T8%>T9,=M
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M0G&%=$S%UMI10-14U7&Q;1Q ]2M*2.)\%'-VZM,O];N;H4-R:];\M1:D(R0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g382677f_33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_33.jpg
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MQ $!   " 00# 0$              0($!0<( P8)"@L! 0$  04! 0$
M       ! @,$!08'" D*$  ! P," P4%!@,$!@,( B,! @,$ !$%(08Q$@=!
M46$3"/!Q@2(4D:&QP14)T>$R\4(C%E(S)+0V%V)#=7*"--0E5;4F5G<XDE.5
M=AECTT2$E*0U9=665QBBLE1D10J#D\-TA:5&9C=G*!$  0,"!0$& P0'!0((
M"P(/ 0 " Q$$(3$2!09!46%Q(A,'@9$RH;$4"/#!T4)2(Q7A8G(S%H(D\9*B
M0[.T=C>RTE-CD],T5)1U%\)S)296&!F#1(0GXL,U549F_]H # ,!  (1 Q$
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M)U,#BJH*-B.ZWL:R#1\41S#O/V#[>'"FGN19)M66%%IT3[*=%>BB;]E11%^
MXGM^SC60^Q$E$@Z5,"J H55DB_\ /\J4^:AKT2[@?[* #/JL4N!TJ^*B5ZFH
M5HB+UB3T*J*!$4ZHE3O10N=+G37AQJT62555'O[/"G@I7Y)7-^'#PJ4PI7%2
MM#3HHUEF,%$55$5AC7$!5%2J)41%$11$5$151%Q^5$H5QWXU:8]RR\$JJ?<D
M35QZ9J$UP13'HIW(J5P[TPKW)5 3\$[T5$15K\T141*B(J51!-K>-$HH\W'M
ML3;[Z566E0\:BRI@E?4CN%_;[*JB@I0TUN.X'7M[CPJ@?-8E0TU[#KQ/9PMX
MFE<>Y6E E8BUQQ%4D]$ [4:UC@<5<>J*BJ*J(J(BBB1XU5B204KWOV>W$45K
MVI$VXTZK'HHE0\=1V6_CQK*B**K'AV <?;C5&&:*.OM]M51%_ >PM6)H,D2I
MW]42J*IBHJT5*B>.M9!:N82HJBB)>W'\*JQK1(T4*1%^^JHH'0FWN_C62RK@
MH_AP^-*BM.JA/8E0T/BHB]#0X%3-2!N*TG>7!8D)UATJB*G1$41%$11$41(_
MCI09JA1/<#X<*#-7O4>%4XJYIC7V[--*Q=Y?,%"HG32PU[:R:=0JI6I0=;:Z
M#2_V4%0<LT2)T]W;[[6JBN92B1%]*J@PQ7'<ZZ\?OMPJ+,(\"=*J=_5*HJBB
MB**HHB79^=,LE$5$4;\>RQ]]_#AI>LN[K1%$DCW$$^Z_XTI7NH44>WW:?9I1
MN)JB*S19-O6-5A51N03K< $VT';5S"8_!0TL3R\2=;_E62=$DD@CQT-5124=
M:Q6>0Q4;_#QX_=0]V)4)2-2I(RHHE65<*J(J$JYHK'JB*51*I1$7%49)1<=^
M/N^SQK)9')%%4NRB@RJCNO0UI49K',*-,*U*B*$C-$5#V(BHJBB)41%$11$B
M;40"J+]W#OJT[5:*-_AW_P!E6BM$OP_&H3V9IX*)K)8G%*IW]JB*A.*(K$'Y
MJHJHE41%5$Z(HW\#V\!45HD5#X_=1*%1)O460%%$D $]@J]W5*C-0*] 1]AX
MU0WH5B7=BX[F][\?L_LK*B@[4SH=+>_^S2L1WK+/)+\?QJD]F2@';FBL21T6
M5#U14511$41*JL:TR2-%#]B+]M$KU4;WX'MMK;AX6JTIX)6OBH"]^PB]OF.G
MO^RJ2*=_<H,TC8GL%N[A\*9!#FHTK]RB* HBHJE4*)$VJA *I7N?"K19M%$4
M6HBB)55C5*BQHD?"U_'NJHHJ4= .T<1W^% .I5-**.G?<V!O?M[N!JXG Y*8
M*/C5PI@B52O0(BH:_:B8.M8NQ\5"I5I%8HHJG11*B(J5542?L]M*M.U4#YI7
M/#L_*F&)&851X6H,3JZT3O2]_#LH:D>7,%2I4>W3OK(95*E450H5$VX7\?A1
M D;:"_=8=AX<=*++%(\?LT[*%!DHFHJBBJ*(BBB*5")4.*)<PM_;KW6JT-44
M>;MXVUMPM\>VU#@$4.\CQJD@-JB+_#3[?&L023CV(EX^UZAIF<%44U(LF$Z$
M]A%@?'6M0 K37%\/QK)1 XW\>'\Z>*H[4[@D$"WQHF!0?;VU%3I@J5&KT6)Q
M14514IUZ(BI7Y(E1$N;V-6BM%&_A2BM$N)[JJJ/STHH4CVGA?L]U ,JYA8]*
MI>W\:JB1-34!@B*A[U45BB*I1*B)T1*B(HB1-A14"JB3P]_X5:*TQ2)[:J9(
MO1*I>[LIW=5*]BC3&M5$5@3JP1%6N%.B)41%$14^]#3IDBB)<PM>G16B@5$^
M'NHLJ!*HJD3QL1?QX?&K3%1<94>6^EK]E['C>X[165!6G58]*KCK+N6*?MX5
MB3T"RI7$H^S[+?A4)Q60"*B(J*HHB552J+T6).."C54038>';0"I2N%%!1TO
M<@]WAKV5D,Z*+CJU12[+W\..O]E3!7I51I7M41P^/M8UCX*HJ8HE1$B;6JH!
M51))K*BRH@468/1!HAS2!O?P]KT."5JBG53HHE0&AOJ.RJ!5105KJ.P"J,,#
MVHHZ_9P_&LD1?AH-/#\>\UB13)$J8HBIFB*(BHB/=6):BFDWX\:FD!8E!/"W
M;V^ZL</@@':HW-KGAW_R^-'?:4P2N>/'L^'=2F&"RIV)::WJFO1*I7]M:4H,
M,U*]B?8>WM^-8D8AQP.2G?T4;]O=6?<5/!1)[>_^%Z9"BM*H)T\"-#1 %#LX
M"BR2J*H[+>/&BB.ZB(HJBB(HB1-NVWWT )445$]VE^_B/YU<"<,U5"_=I?LX
MU:4Q.*BB?;\_LJ$U%>B)\>[3QJ X?%$JA_6JE4KT1.Y[SQ^_^-*=Z+)-K"X-
MP=+V]^G?6OU6FHFYM?NT]U*C)*$XHJJ(J=RO>E5411$5B15$JQI15%];?V41
M1)[/?QJT5HD?A\*#%5*JJ@]^E0&II0K&JCV>-_NK+&O<HE4J,D15KA@B*P.:
M(HB5.]$5$151%$1>B*-_$<+^VM*55422:R5R1_ G^%%":%+C:W=[=M/%*E /
M?5IV*$DI=_C3!$M-/OK%Q[$P141%$11$411) J% "HD_8?M%J+(!(]OY<*BH
M42; G7X4&*J@I5OZ3>_CPMW6X5DT=JQ)[%QDDZWX^/=WB]99&BQZ51K:US8=
ME7PS5 [<@CL\.ZL2<>]4#!%8U514511$41(U5B4J*?>E[?Q^ZF*@I\4$Z>/9
M?2KU3HH$@Z7[;G[S:J <T42?B#P)\/&K@HD;]W;W6J89HE0E$JQ..2J=$2JH
MHJM;C5"H4:JR11$45HBB52O>]N^W=;W:<:4HE5QZWUU%["Y^P_966%%$C8GL
M%ORI@!CBB5"?N1*B(J(BHB*J(J(E1$542)^[LI2N"H3'"WM;C6F00>Y3(ID]
M_M]E8 =6J8!1)TX<>!O60\5":I<P L=?#^RFGJ/J10"C?A[JR(%,5=*?-?CV
MTH ,%*%(D<./\:B %(D:?#7N_L-%E11[:B(HB**HHHD:(31*]6BQJ4BJK19X
M43XC3M_"_P#"IDBX['["1]E4&N!42(X'A?OU_ 5#3*N*(X>W?K\+U#E2O5$B
M2>_[;U/V*HH2B53$8HBJ#T1%*!%D>M=:2D3<<->_OJ9(E1$JJ(HB*(BX[Q42
MBB3W$=WXZU#BL@.U0N>^BRH$41*BA*7M\:JQ!*5,.Y1.E42K',X*HJ(E1$41
M%$3HB5$2)[!5HK3M43QJA4)451X<:A(&)R4)42:M1T6)*+ZWJIFE3N42K3&9
M*J=7!$JB)U42HB+_ ,?A4105W]]M*+(=BC462@HV20%$GWZ\;^!X5EU_2BG2
MB@5W([N[O!XWUM5TX=ZQU8]RAQTL/S-4FF*@%< G\!_'WTKU5HBL:]BRHBH2
M2J*(J(BB(HB*(HFJL#FE5442H6.I&G"W\J"IQ&2+C))XF]9 !H43%ON.O$<.
MZU"2B6HX>/V5*4%>JJ"2>)J(E>U_'\*'%$J>"(HB2C;XT"H"A62R11*(HKCD
MB]OSI2J5HH*)M?AK;WCOX=M9#.BG1<=6M<D4A>U_^]\>^H0*X9HH5:]J)ZCX
MC[N'Y5AX(E3$HBB(HB*(BB(HBB>&G"L@LAGCFHF@5" ;#XU'"OBH<4E+OX_=
M6FUHR6%$BLF_CQ^%-(!\%:!0H413N513%$5$11$41%$11$4)11JK3*55%$D<
M.WO-9#)45^"CKP%0Y+),]][_  ^XUAJ&28J-!09Y=%45">U$JB(H:#/-$ZN*
M(IE@B*M461ZU5I5Z)41%5$ZB)542YAXBHK0J!-S19#)*HJCW_A4H3AT42OQT
MX^VE"/F%*J-9+%%"B*PJ<C15%*HE1$5$151%$1[?C1$B;=]*)1*X[OX?'6K1
M6BCQJK)*JIDE>A6-47J4!S2N*5/!$5*G)1%"545!1$J(BHB*(@G2]$IBH$\#
M]M19@8*-%0H+-AH=??K6314K$Y+B!(-R+^_MTM61I2BQ%:U2H314"J=8DG,J
M@=B*BJ*BJ*(BB(HHBB)7JI6B5%@?M151<:_O[:HR10)%AWZW-4'M1*HB*B(I
MUJB5$03:B 52N+BE"K0J)U-9!4(]U%D.[-+O_L^^E:)XYI=E%%$G@-==3IV'
M^%4=J%0OVG4<!_#3PK+ !$C[K>W\*A[:HE0GL1%8GN1%$151%1$411YA5HK0
MIWTHHHW^!\;5:?)94^2C55030 *5 Q2O[=]$)4:Q(H5BE6FB**HJ(BH:DU1%
M$151%$11$C[K^ZI@2HD5 ?P[O?65$2JK!'M?Q]U1% ZG[O>?RO2I671+2WC>
ME<,5>O<E?P_&I44PR52K&M, BP]UVZV[2]/O3K(]1MXM9";"C386)QN'Q*65
M9/.9O)%WZ+&1%2%MQH_,W'<==><4$-,M*591LD] ]R_<78_:SB<O+=_;+);L
MD9''%%3U)II*Z(VZB&MP:YSG.-&M:3B: ^C>U7MAR#W>YC#PWCCH8KE\3Y9)
MI2?2@@CIKD>&@N=0N:UK&BKWN:,!4CSM_P#AM.T__L&[G_\ KWP__P!0^-?*
M'_Y\^R?_ )-WG_QD7_J5]B__ */O?_\ \J;'_P""F_\ 7H_^&T[4_P#L&[G_
M /KWP_\ ]0Z#\\^R#_\ UN]_^+B_]2G_ .C[W_\ _*FQ_P#@IO\ UZ/_ (;3
MM3_[!NY[6_\ 9OA_MO\ H=7_ //HV3_\F[S_ .,B_P#4J_\ Z/O?O_RIL?\
MX*;_ ->E_P##:-K=G0_<_P#]>V'X>/\ Y#U/C4__ #Y]EK7_ $W>?_%Q?^I5
M_P#T?F_4I_JBQ_\ @IO_ %ZC_P##9]K_ /V$-S?_ %ZX?_ZB5E_^?3L?_P"3
M5Y_\9%_ZE8?_ */K?_\ \J;'_P""F_\ 7KV]K[S7YX(JHG4Q5Z44? 6X7O1/
M%(J^/QH>Y4!1OK>HK3"B ;4(JA%5$_;3)0F@HCOO3'"F2F:C3 *(H2$14.."
MJ*F'Q1*B(HB*(BB(\*(HD]FH]OPJT5 4;GO-5941I]_W=],:]RA-$O[*)7!+
M\>'A:F/P6-4JJB*E414/<JBI4THB*(E1$41'\*B*)5;N)\.']M%E10)O45HE
M?6WA>_9]M5%QE9%P1IK:WW&][6K(-4U=N2X]3Q/VUEAT6.*D/Z= ?$_E?N\*
MQ-,UD$JQ514511$55$5$11*I54)1>BA/4)4R6.:1-A<WJ]:)BHE0%OO[Q5TU
M10*KWT'V:U:%10K'%5/\?;LHB51$541?LHBA<]]94"RH$KT511$454"1K\UO
M"W'CVU1CB$\5 J)XFL@ ,5$#7[_=PX]]"42_G[NZ_P!E2G6F*)7/M\?XUBB=
M[7^R_A_.AQ1*E*9(E>U5$<:(D2;:=]N%%1WJ-[CW5>JM,4ORJJIW\31$N-3I
MBB1_"JH>T)$6THW)8HJHE6!-42K3(5141%$11$JG<B=5$KBH2.J)TP.2+B*B
M? 7/"LQ3IFH4E$V T/;X_'QJ4(Q&:(!L=:$DBO50A/F'#7WTJI0H)'#CX\?8
MT5 *A4.2R14^Y$JG5%YN_NE?^XY[>_\ ;8VW_P"@-U5\B_G3_P"Z:T_^>6__
M $%ROM+\B/\ WR7G_9^Y_P"GM5\_U?ELOUQ11$41%$11%]M5?T%+^;=!MV^Q
MHKX*&FI\=/QHKCEW)$CAXWHKU^"515*JH2B]$JHT6"+UCJQHJBH>Q$41*E41
M4[T151*_AKW4I\E:?)*]SJ/Y5?!6G8F>\$44\5$F^M6BM$O?17)'=4"E:*)/
M]OMV50,:K$FJ* 4-5$J5[414.?<JBH42HB=$143I1*B)7U\.%_&BM.U0)/\
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MBWC^'"^E2@R.2B7V=FG?[7K+K@GBE?0COK$Y^")4.-5$5!@**HHB\WOW1_\
MW'7;W_ML;;_] ;JKY$_.I_W36G_SRW_Z"Y7VE^1'_ODO/^S]S_UBU7@)7Y:K
M]<5W7;W3G>VZ\2,WMO;\O,0'-Y;:Z>Q1#7&7-R.]=WLY"1M[;N*QJGDS\G/G
M,8MY:@PVM+"0DNE 6@GG=MXUON[V?X[;+9\UN;V"S;I+=3[FX#W0PQLKK>]P
MC<3I!#10O+=0KU_<^5<?V6]_I^ZW3(+D6$]Z[4'!C+2V+&SSR24T1L89&@:W
M O-0P.+74.H'3G>O2S<CNTM_8)W;^>:AQ,BF*J;C,G&E8Z>E:H>0Q^5PLW(X
MC)P9!:6D.QWW4!QM:"0M"DAR+C6^<3W,[/R&W-MN 8U^G4Q[7,?72]DD3GQO
M::$:F/<*AS2:M(#C/*N/\RVIN]\:N1=;:9',U:)(W->RFICXY6,EC>*@Z7L:
M=+FN TN!/2JX)=@11%]L-?T#9+^;A'=Q]N^JB1(_LI1 %&_'W$?VUE1942HJ
MBBE:*)JK$E*HB*QJB*"A1*HB*(BJB*(BI]R>*1-K]XHJ HWXC["**@*-19)$
M@7OV4&*B@5C4<1;NXGW7X5F&J$KCN+<-;_"W=5H:UZ46.%.] X<=;VMX4)5
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MBN"B?&]ZQ&7@JE0FJ(J(BB(HB\WOW1__ ''7;W_ML;;_ /0&ZJ^0_P Z9_\
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MU%%#6YOW>%94PP66!&"@2:H &2E:)50**52K&E2B*F(1%15%$11$41&G::R
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M2"7$.-7$@D$NS)!().!(Q7V#9N:^SA>UHC:88R&@$!H+ 0T @$!OT@$ @#$
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M4H2:DI@HU>N:B*Q*J*QIA1$5411$5 B1MV]G]M7[T42H7';X]U0J@%!-];7
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M8O9/8OVION<\NL-UWC;KBZ]N+?<617\K"&M8TMQKY@YS6%S'S!E2(Z]JZ/\
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MA=[ <MC\*[_L.]V%XQ\<TFF<4HTT%13$@G.F1&:]-XYN^T;D'7#IFB4FNAQ
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MNI=E^:'4H#7FM%*5*;!T0HJ2HD 'CQK-I-%H7%C'=$23$ZJ4P7?\;,D1666
M4AIAMMEM*4\@2V@!* E()39*0!66I;K2T  9 +M$;++L+FP/B0/:]75BM(Q@
MKP3_ 'I\\O*3=B[?"N9$/;#DDMW)^>=D9-U<O?:.GCV"OAG\R^Y>I[E[3M]?
M+;;67_&:9WZHPOT+_)SMHAX1O.YD>>>_:SQ$<3?UO*]%_P!KG9[.S_1#T<@N
MLI0YFF,_N=T% 2H_K&:E>6HIL/ZF(R?A7TE[,6AM_;RSE=]5Q)--\'2.:/\
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MV=W_ +PQ76WT^8W(28G6K&'#]4,%A)<3%9;&SLI!;8B]0<:S.<BLMN^2 F>
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M0*OB[ZM&#E]!+^0"D\R' M"DA25H4%-K0I(4A:% D*2M-B#P(K])=0(!!!!
MH1D:Y&O9V+\F0T@T(((PRQ!Z^"LDB>H@_,>'#L^SXUC6JR  5CD2EJN;GVX5
M@7 8+!\H:%9W5*6JYU\->ZWVU,UQDTY.15*620>8@DV[["LJ@9+CG.)-5U7<
M$1<2;"R[*2E(6B)**>-BJ\=Q5M".8E))[#7$;LQXC;=1_P"9&1\EWK@]U%--
M+LEY_P"S7+"!7MIC\>OB%;>J<O=D/I3O[+; B)G;RA;.S>1VU YTMKFY6%!=
ME-P6G570W)E!I3;1.@<4GWUQ',6[QN?"=Q9QJ8P;U+8R"&0?4QY;B6_WPW5H
M/1U"L^&V6S[5[D[;8\O;JV*/<HFW .1CUT!-<V$EKG?W:KQ;]!/[@'4GJ=UH
M&S.J>W<ELV!,D2<0N)FLDS(4[,<<+$:4$-N.^2J-)2+D\I*5$5\.^T=]N/ME
M[AV3+O>I[_8-T>;>X9(YY8R67"*8ZS@YDM 79Z7.!*_0KW\]JMBW[VPN]SV.
MP;#O>W@3Q.:UNIT;*F5@TBM'1UHW*H:0KU^X=T;<V+UI@=2L+%\G';V0,VAU
ME 0EC<>/4AG-,#DY4A4D%M^VG,5FLOS*<4/&.<'>X&%NT[RPO=V"X;1LP[B?
M+)_ME=U_*!SZ/GWLX_A=\\/WOCTGI-!Q<ZTDJZ!W>&T?%X,':%ZS>ECJ.WU-
MZ,;4RKKP>RF*AM8++?/S.%^"TA,=]R_S7D1"GXI-?4WL-R__ %A[<6<L[R[<
MK&MI-4U<3$ &//\ CC+3WD%?G]^8'ACN$>YM]:1-T6%V[\3%A0 2$ZVC_"^O
MP(6Q@M^0L?NXU[+5>*B0]2GS>QI@KK3)YOE[Q;OX^ZK@<%1*6$/&8-?DK;CG
M"5/-W_I/ \/E)3>N"VAVF6: YAU?MHO1N= 2V=A?C)["*^+6N_:KGS6[>/W7
MKG05YQK7!(;\]L(YBBR@KF !-QV6/9:MM=6L=W'Z;R1C7!<QLN^3[+=&ZA:U
MY<PM(=6F-#T["%S@\H !T  &NI'C;MK<, :T-&0'W+C)IW33/F?]3W%Q\2:H
MYCVZ_D.^K6BP#@K4TLG(N#P7V]MAI]@K@[<UWB0=:']2](W,Z."6I[7,^]Q5
MS*K<1X]G'O[:YLKSH.!ZKB)40>%O;QJX+,.Q7 MOF&J;CM_+P%8DM% 2*G+'
M-9:7R D EHSH#0>/8K,YA("YK.15#BJGQDJ1'FKCLJEL(5_4AF24%YI"NT)4
M :VS[&RENF7TL,3KZ-I:R4L:9&M.8;(1J:#U (!1DMS' ZSBFE;9O<'.C#W!
MCB,G.9722.A(JNP,.N(Y0%W'<2";5NZ88K/5VJY-RC;C;OU''[NRK4H<U5ID
MZZZ^[2P\*M4!IDJM$BUC>U@D^&OMK60)Z*U'57.*_P [B;_TI^91OI9/'X7T
MK":71&2,^BWVWVWXJY;&*Z1B? *M5.YW"0;VTT/8#I;PO640HP5S6>XN:;HM
M;]+<%4(F#M.FGOMW:5J!;$ Y%<.0GXF%C\AE,J\VSCL9"E9'(/+U\F%!87)E
M.E(^97EL-J.ESI6WN[JVL;26]O'AEI#&^21W1K&-+G$^#02MY96%QN%[#86C
M/4NYY61L;_$][@UHQPQ) Q7@'TEZ<O\ [@?K)WGUEW,U(C]%^B>:@3(,!M#;
MC.<W2J0D[9VTA:DAI;6.PL1R5.6DEQ+CC8XN CX=]L.-/]ZN;[M[B;NU\.RR
MW+',8* F%KAZ%L3_ 'XFZYG#S>:E?-5?HC[M\I;^77V@VKVSX[Z;^67=J\/=
MD(ZM(GN:#]X2NT0-/E\KC^[0^_"%MK2/*"$H2 D(0.4-A(LEODL.0)3H!V"O
MN+Y?!?E_H<PT=75W_IBI<PXJ(  .JK!*0.)4> 2!Q/92BP)[,UY/[T4YZRO5
M7BM@1%.2NCO2)2,UN]Q!5]%DV($P#].4+*;<<W5FV$QK<3 9=5PKXFG?_P#G
M >^S;6*LGMSQ<G5_Y.:9KO,>QWJRC0.OHQDX57Z#[0W_ /-D_+M+OTU(_=#E
M?\NW'_.0->SZQU'X:!Q?V"XD:%Z2]0]\8?IGLS+;JR?DLQ<3$#<"&CE:$F86
M_*Q^/CMIL$H*D@6 LAM)/ 5]0^X_/=H]M.&WO,-XH8+6/^7$,#-,[RPP,IU>
MZ@P^E@<[)J^*>!<,W3W!Y7:\7VS49KB2LDF?IQ UEE<>M!4BOU/('5>&FSMD
M9_UL>HQ>#SCLF1L/"36]X=7,BE2TM.8A$J^-VC'=0I!;D;C?9^G 2;M14.+_
M +HO^<_L9PG>?>?W*N>9\N+I8G3_ (J[><C4_P N!N5 X 1L ^F-I-,%^HWN
MCR_:/RX>S<6V<=#8N174'X3;X\-3#I_F7+AC_DAVLD_5*YHZE>_L6+%@QHT&
M%&9B0H49B'"B1FTLQHL6,TAB-&CLH"4-,,,MI2A(%@D 5^IC6L8T1Q@-C:
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M0%..%2^5(%[  <;LNQ;/QRQ&U[%:P6FW-<2(XFAC03F:#,GJ34TH,@%RV_\
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MR@=FE>JKR5<@22?S_F*H%5,L59-Q81>2A!V+9.2A%3T11TY[ E<96G]+P%O
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M554!(X6'V4J5%R!)_GK?X7%%*]BQ-O3%NX.:-QPDGZ&6XVC*MHT3%DZ):F@
M62AXBRSV*L>^O-^=;/)Z7];LP?4C_P P#.G1_P .OSZ+W#VIY.QSCQ7<G#1)
M4P$Y:CG'\<2WXA=[VUF&\M#2"L&0RE(6+ZK3P2L:?;7-<1Y#'OEAHD</QT(
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MI:RWOE_[VNJ>V]B6;2[=)1_,N'>7_ W#[37Y!<W[S;N)MYAV&$_RK1FIX_\
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M8E<P%$ 4@#?A>HK5<@3QT'9IQ[O"B8Y+E MV>/#A_*HL@ #4*82;Z]GM]E4
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M-3C*&/3D\3&A-ASRG0S!BSWTV24AY:UN'G)O9=S;LJD::>II<X_$@+"2!T=
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MH%IJ!DMR"UU6TJTBA![%40-Y8'R4Q963BIF15&*^VRE;J0IBR$J!CMK;0%)
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MY0#KH:W>TQRLN7-?(' 4H6BM?GD MK<'5C2A*I)\B4AM2TL+<; U(2DZ6_T
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MO:''(9S2,@J/&1$BYUII!2T$!I#C2DBUQ7#<AY%N-S=/W2^(?)*YH-, V@
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MHJ2QFW#968P9 ..->VG8L9HWV.EX!=9B@ <3F>M*=%18O/\ ^5%.8'=+3,'
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MEGBS#:2OD +KBUAMEH*U'.O74C@D D]U;6XNHK8#U#YCD!FM5K"_$9+N2<!
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M,VM\XW-HXVVX U#V95_O-%*^(H?%>D\9]R]SV>/^F[TP;CL9&DQRXO#>QCW
MX?W7@CL+<U9(/5;-;1FLX3JCAGL.XZI+43.-'ZC#Y W(!C9!"4M*4KCR.!#@
M[NVN!')=UX]*VVY3"3:DT;<,Q:?'I7N.EW<5VR?V_P",<WMG;E[<W3&WP;J?
M9RG2YO@"26CI4:X_[S5GK%Y/'Y>,B5CI;,MA8"@MI25$ B]E $E)MWUWFSOK
M/<(!<V4C)83U::_ ]A[BO&MUV7=-ENS8[M!)!<#]UXI7O:<G#O!(5U%A>XN
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M9SM=+&V:!VJX%  #04.?<I24+V3NEG-XO%)W4]DX:6BY.7)QT+]+R3:"5HL
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M$..K4ZOB59?\IXMYXY 1D!+B>80UNN-)(U(4"V>= 6#P/OJ':K:<B5I,<?\
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M"O2+[=62AL5B]KFO:#J::AP(J-)&%*8UJO%/P4T$SH+ICF7#'$%KA0M(-"'
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MUP( .9/;]RXY;+^\MJQ/J-S8B1E,&VMO<#6VD"!+@-,N^5C(3S<5* XIMAH
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M,8S\-(7LO+/R:6LS#><*OW-:14,?_-8>SS8/'S<MYMI=8^G&\4-*P^Y8(>=
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M3A\!U6YDC=>PMDL/3UPBH+Z-J/X0*5)/>M=/4=ZU?3KZ2.K^S^G.7W3CL!U
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M'.H*'FM%/#@H'C7+2M;';M8' M-0>\BA"T2_4: 'N7?H>VH<Z;FDJFH6[,8
MC((6T6V@K_&<"4JLE]MZUTV*;&^E;4Z#I'1IJ?'I\*+5,CF@8+K.3VY.P:$-
M/I^HC)2&TRFP5(4FW* \!_JE$::Z'L-=PL]P@N&AA.F484/7P7%2Q%I+ABU>
M5G6SHLC:6]<AFX$(?I6;D/3V%H0>1#CRBM]DE((2M+A/C8USK)W%H;7)=ZV3
M=OQ-JVW>?Y[!3Q':L/O04,-#E1R<E];"Z=!KI?F^8]E[5N(JDXY+LD)+LUD+
MIM)<C95EQHE/*H<Q3:Q5SCD%QK<G[*Y3TZQ4*V.\QM?:EKEZ8Q5J<B1'%Z+7
M&86L=RE-@D'QN:ZJ_!Q'>O*B*$^*BZ#<^/S6]VA-[T!45(KWWU.G=X5J=%%2
MK'$GB/QO^=3[UJ!4R[<3\/;XUF*JU5K?Y$7YU)2#QN1[^';0D-Q*U(H99C2)
MKG> _7T5"Q,2V\E39)Y2"%_TBXU^7B334#4!:[[:2,>?/L6GOJA]9.;Z+[JC
M[;=RF0;RN9@LR-L8G%07)N1S*)"5,>5A\1CXS\[+2TR$%.B7%)7P KX;]^N>
M>^6S>XW^D."NDBVV:UCE@DCB:XD2@LD;4M.I\<C7#422W @!?;_L![1^V',_
M;\\IY%':AUM</CNGSR$!CHR'M)+GAL;'L<T@ #5B'$K7?;?0/UO^J:4WFMQD
M>GG8614VZO</4-+F9ZE93'O J+F#V''D).*>4@CE.6?B%-_]4KA74N(?E5Y1
MRJ_')/=&^GDNY2'.]9[I9G#L.HDM'8"6@=B[YR?\R7M'[9VIV+VXLH]TOH@6
MM,31%:,<,/K &O'_ ,FUU?XEZI>FOTU[-],FRIVT]KYS=>[,AG<FG.;KW?O3
M)C(9S<&73'3%0\&6$,X[#XZ.PGE8AQ6T-- DGF45*/VMPO@O&^ ;6=IXW (8
M'N#I#AJD<!I#G4ID,!V+X8]R?<[E7NIOC=\Y3)&7Q1F.&*-NF.&,NU%K1B35
MV+G.))PZ !;$UW +SU%1$41*B(HB5];'3N\:M,$1?C;4CLX?>:41)1";$]I
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M%0VH.EW0TH3DI]/M\8['[D/3!KIK(E[5FS'?H,\_,^CRAR3J0UYOZ<EAUMF
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MUQ^,LXRR$G EIIW@$Y?!:+9HMDW-V\;9;RV]@]Y$;O3<^('"K0XU <*'%IJ
M2.A71=@[GZ)[;R)Z+Y49K)I?GJ<C;EQ>,^IVWC\J_:.8+*BZV\\A7*"IYI!:
M"C:YXUJ7,%[<,.XO#0.RM#3M_P"%<SN^U\CO[5W,7L@=;4!(+]$A:, ]K?J
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M)2E.MAQKZ#V^WVB&,65I-5S!4EQ\Q.52>T]E !V+K<KW/<9)6D-.6 HNY/\
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M*"4.6N%MO!2%G4$BQK6B#:^I&*M=UZ%<9ON\7AA&T;F\!T(TAH:212@!:[(
M]"VH(5)U#ZG]1]Q[_7BLS"Q^6Z;M QV,1CX#,:<$*(\K-PI:#Y;TA21S!*KM
MN(-OEN"(9)?6T!H]&F?4'[OA]JXVTL=G;MCIW2R#=-=0"?*6]!_%7L=6E>E%
MW;(9'I]LZ([M#9N]Y>.ZA[LQ\8,1HS<_$.)B+Y7_ *%^60B.SDY (2VV5E5[
M@'7623  P:P)3E3.G:,,_M/1<>^"6\'XMMM(ZTC(#GO.K'/2<?*.TTP-*KID
MWIAO^?B(8WCN+<&0V_C7&7V\2_*=>7*?C+5)1%=D/$K 6A*T* ^8H41<'4>7
M<KXM!RN-D\]Y>LLXY6E\+6M8V8L!I5]->.3A7S TP6,MS%:3F:V@B9,12M2Z
M@.!HW(=QK@>BR*YU03N?#S=CY[=FV]J8IR"U#;@8W'RIDG#QFN0Q?++98B(6
MT4!/(%6M?YKUP^Y7VW76WR;,R]MK"[=&61D2L+X#2@.DZ65 P+-7:*K@/P[X
M+D7 C?(TU)P-'?'KXT7<^GOIWPV.9?G;CWH[F&YK*CC1!;4R1%D)YV9+ZIBE
M@/.,KOY?(4I/]Y5<7Q3BFZV+9W;]N9N/4U-;H:6TC-14ZG'S.'94-Z$YJ7FX
MQEX,$ !&=>WX9K+N2+.S,+!Q&W,4[GD+<CXN.MITH=@1W"EOZIX- @MLW*EJ
M";7XVKM%U"RR:V*)IEM:!@TX%G0'$@4&9..62V<)_$/,CR&2 UH<CVA8QA=,
M-S9+<$K_ #6_)G891>4RPM7F0'KJO'=*5*+B5-@7L4@@\":XJ)VYNDE9?NCD
MV\-HUFAI:XX4<:MK44ZG/);Z26T $D1/JURRIV^*RUA-B/;7PXBX5S&PRE*U
MIBA#C*'%J)(YG4I5J;]H-<MM&W,M;1D5LV**W:,&L :!4U-  !CFMG=73)I3
MJ#J+2/K=FYKF3DEW (@;DQ"BUE'8C*"Z_CG$J6W*?=:2D2HZ7$@H=^;19UTK
MK_-KMMC:?BML9(_<(' RD-Q$+@:O=3]T.ICTJ>];K;V-DD].4@0N^FIS/8.^
MG1:S)W;DQ*',ESD2>92@%6"0NW,?ZK)':>RN@;5S:69VL.)H*]OZ>*YJ3;8P
M.@6;>GYRV_LLU%QQ"<;$>8_5<HM81'BLE0*T-*-_/EK0#RH3>UP385ZEL&_7
MN[$20@F",C4[I7, =KN[H,2N#NK*.W%'_4<@MK\FRC 91N?MB.[)<R,5K%/X
MYI?FN.J06_(?;&@YSR?/P!XUWECS=0'USIT.U5^_[2N/ #7 G'"BZID>DN0R
MD=N1&^GQ^7F25_78MUQ!;9+SBEM/LO-%25!39L4<0L$ UP6Y[=%.YYLJ!CZ$
MT'[U,3W^'R6ZAG;3^94.&77X%<N*V?#V'%D_5/*DY)YQ*UR7&_)2@-Z>0TT2
MHI0;FY))-ZYGC_J[?H@87.%:NKA7^P=%HW;&W#2[NP7:0M+J&W4&Z'$)6D^"
MA<:_&O0!CBN [EQN"X/N/X'0"JG>J(C36B%4ZAH16&15Z*C6D?:>'L:H-"BH
MU<#6?549JG7[_A0+-4+PL1K[:5D2F>*M4IY+#2W2E2@@ D)%SJ;=E[ $ZUG4
MK4BC]1XCK2JX($Y];B'&DK9((4VY8CD4/Z5@J%K@BF-/-DM66!C!0&I6L>Y?
M3'ZONKNYLN_O/U+8+8'3M[*33AL5LS 9/<F[I& <>4J J1)R,O![7Q,]R*H<
MX^FGI0KM57S5O7LER7EV\W-UR_E.Y2;$ZXD,-I;N,+&0.<2R-VG2"6L(:20?
M$KZIV/\ ,![;\&V.VMN$\+LW<D;;1B:ZNW-<'7 :!(]K0'2%I?4MJ]F>07;M
MI?MK>FG$+:F]0HV^>NV90\)!G=6=WY'(8KSDGF ;V?MO_+NTBP%?W'H;]QQ)
MKM_&?8WVPXJ _;]KAENQ_P Y/_->3VU=A]BZ5RG\SOO)RAKH/ZF-NL'"GI64
M;8!3_'YI3XZPMV-J;)V7L/&)PVQMH;7V9B4!(&-VIM_$[?AJY $I4N/BHD5M
MU8 _J4"?&O4X8(+>,0V[&1Q#(-:&CY  +PF\O[[<9S=;C/-<7)K5\KWR.-<_
M,\D_:L*=9.NK6T-P8[I?LR'(W+U/SD!&5=QF.;\]&U=NO/*C-Y[<#X(8Q3,Q
MY"D1B^I'F%"E $"MY#%J-78-'Z46G'%5ID>0V,?;X+H^,P6Z9H,C)Y#',S7O
MG?29#TQP.'57F.MH\LD$]A(KGK.RN)A6)OD^2VSO3>2&9CMP7'G<3N[&1G9,
M**SET-(4M2,>_P TNR0;^7$<2VZZJW8CF)KFH-ME:X>L-([<UI&+M6H.]?4=
M#P'UD>0\8LR(MQE]A\+8D1WF[AQMUEWE<0\@\4D BN_;+Q?\06N<XZ#V'"GS
M5]!E-3OI7?\ T/[^W'U?WWNW<G.^O:>V(ABMR2HEB3DY94TE@*'R**4E1L/]
M$ULO<^WV_:-LM]NBTF]D?J(!J0UO7XFBU(VQX%@Q'5>H5]+=U>)+5IC5+V\*
M*HHBROT=_P"*)7_8TK_>H-:D7U?!:,_T?%;,UN5M%Y@>NO<N-PV\HJ42)>"G
M8;H5OS?6Z\A*ZZY?H9 WOT^VQF(#61Z?;8=P^U]QC?6\WI&46M,>86H..3*8
M#B7/KPIHLV_K7HCL3'8_&[6Q*<6WGX^/G1D9>)C]S/RG,MB&,LE,]O"NQI;C
MJL2SB4/B.W!19F$AL,MI2A  +!=NHB*(M4ZT%N441%$11$<*(HD]W"W'Q[@>
M^J$4>;^&O=X^-73U44":M1DB":84S1*L2:JK#7J&W!U&VIT1ZE[FZ2[;G;PZ
MAX#;$O+;<VOBDMN9G.O0EM/S<=A&72$2<V]C4/?2-<79 2A/S$5U3G$/)KCB
M5_;\-E9!R9\!;!(X5#'$C4X#+6&:M%:C70T*[?P#_2O^L]N_UOK/%?Q _$!O
M5M#I#NN@OTZZ?N:E\\. ]??JLW=#$E/I]]3^/FJ??8?Q<[IKO=B9'?8<*'4/
MM.8E*FUI6#H:_.S<^!_F$_&/@?O6[SN!Q+7W!%3GEA\E^G&W;=^7)UG'=-EV
M6*)S:@.=;--.F!-0NT-^I'UK9<CZ3TX^I1T+("2YL3=;0-[6)+T!L 6-<6?:
MGWXN15]]O;J]]RM^+W\M=I]5_L(I_P"<MOU%7)G?OKXS%C']-77Q(7P^KP62
MB"YT%S)+-@0>WA6F?8WWKN#227>7^)F_65F.9_EHM,3N>RBG8^(_<"NV[>Q/
M[@F5RV,<?Z*[]VI%3,8>DY_<F7@XC'X9AIQ*W9TMYW(ETH:0+A"&UK6?E";F
MN0VC\NOO7_4H;JSEW"VO(Y&O9-),8PQS2"'$F2N%,10URH:KC=W]W/RPVFVS
MQSWEG>1NC<TPQ1&5TE130&AE/-7,D 9DBB]7HDN8XAH3E%4I+38D+".4+?"$
M^<L)T"0IRY&G U^H=O'+%"QDSM<H8 YV57  %U.E34T7Y=;G/:W$[WVK!'"7
MNTM'1I)TCX"@JKNRH$"YU[K\?AX7K7*X=5R!I[ZB*K;[: =5ITQJKHWJD'7N
M^ZL3G18U5:UQ3\?SJ%3HK@GB/;A6*')5;8N1J!KP[>'9WU1VJ%5:1K[AI56!
MR7.GQ/Y?G4*K:'-#[BF(TA\"ZF6'G4CO+;:EC3MU34)HTE9D5=0K7C;W3N3O
MG<;^9_4EXK;K[JW9LQ49;RD22=8T,?(RXXZN^I59 [Z\/Y#M-UNF\"]M[KT[
M%PJ\ '7J&%&]*.ZGIV&J[9;31PVWIN95XRQZ=_A]JSXSTPSNW(DJ/@=^.)Q4
MCR'%1Y7DB3$B,\S\EU'*YY1:6\/F;Y1=-^8D5J65GN5B! V8RVYD%"^A=&S'
M4T.'U:B?*'5+>TX+%T]O("Y["'AN%,M73PPZ_8NJ]:=P2(VQ8F+3D\5F]U-'
M'YI:9C*(>&FHQ60BK5D\FTRH,M8C&N.I>6"H\X;'O'KWMW9-DO9;F7$,9HU
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MI;V@OO9G/NJCIS&Z\@K-;AR 4E4S)SUI2TV9D@GS7&,?$;1'C-7\MAAM*$
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MQK"ZAW*]A_K-6-TMR#CJ+1UR^SL7(;IMW*=]V]_N%2W]** 5#)'-G=%'7^8
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M.(8T#-KPT4<X5_<+0ZHJ!BNH[?RG33KYC9N_M[-0^D&8V^@/[DB[@EG(8+Z
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M.8 D&U>NQVLEU+M\;82ZYE<QE'8N:)"*MJ,BVOA48K8[;;/O+_\ !M)+'/&
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M%L#H#"@R-M]4MNQNI^[\4_$V3"A;CA,9?.&3&6ZCRHJ'6G)24I3S(;6FZG
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MI*^.9CZMP #M((.EH.':!F0MFS:.1<+T<GG$$K)&4>&DUC#B#YG$5.(HYP%
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MB3VJ(';6UY!R/;M@V<;S?S'^F-D#7/C!> 36E:4H*X$G '-:]M;37<HMHO\
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M2,3OK><+JEU+_0NB'4YB7CTX3<&5:P^UL;E9CD=> Q^*;DNMQX)D--J;+:%
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MC064?04 ->F&!(S'5:M_RO8MAY/#R3@EK'';?A--RW0\,:_7@6D@MC<YOU#
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MO<"X]F ^ &0[E8][[GZ<;]@LQ-QX_%9941WS\?(E0V7I6.E<MA)@R'6R[&>
MT)21<:&XK1O]CM-W:UFY6]O,UCM3=;6NTN[6DXM/>*%;>&62V),3RT$8T)%1
MV%8@RN8]/L(2L7&4V-Q2&#!9S+3_ /MKDIL%"&EM*< =;0_\JD!.EM#>NG6<
MG"W74\X?81[GYH)'- ]0!CBTL+@VOE<#A7-<A(R^#6M >8/J QICC5:6[JZ(
M[FR6=D2,5)QDS!R75R?TO+8=<V1!E.%2EKQDMJ3'/T[ZS?RGDN(0HDIM>U?/
M7*O9G?6;U-N6QND;!(\O+6XU)-?+4@ N^\Y+M.W[_!^';#.T^H!2HPJ._#IV
MK:OH#Z:Y&#PGU&[W,:[E,BH2,@^(+#\R;\O(TV^ZZTE#3,=@);::2GD;0+ "
MO7_:S@MUQ+:''D3;>ZWN<ZG%P]30#DTN<*&@H*-&D4S*X7?=S9>7(-MJ9;M%
M VM/C@<ZX]JOV^O1Y@HN'RTGIB]$PV0>4_.:P1CQX>+<D.$N2$05Q&FQCW'R
MI2DCE4UYA_N@DUP_*/9>&6>ZW[A<PLMWF)D_#FGX5\G4-H-4&KL&I@=^Z <+
M:\BD)9#N +X6BFK-P'2O\5/G1>=>_(>ZMO)>QD3#9U,W'+5#E1_H)DB2Q(8/
M(\A]4=IY*G NY)!*3>X-K5Y!LU_R*VOI;&_M+MM[#(62M,;B6O!\PJT%I[B"
M010@T*[,T6DC!)KC]-PJ/,,OC1;&>D7IEN?+9-.[=]PGF<8A#@A8V>EQ"Y9=
M:4VEUQASD=0V@JN.8))(! KZ,X38[C=0'<[^)T5D648'@A\A.9TG$-'::5.0
MH*KK>\7%NP^C;D%X.)%"!W5R*V<ZH]),DUYF0V0IEYE;2UN8R7+#+B'4B_EQ
M'W1R.)6G@%J20=+FNP[ILNXR2"YVAS2[]YCC2O\ A.(KW&@RQ7$P7$1\LXIW
M@+!W2?;.\MRYN>O,1)>V(6)<<94_DXZ@\_-05)\F*SS)\YMM0NIP'DM_22=*
MWW'6;JQ[I;QDD09A1PQ+NX',#M%0>A6I>BVT!L+@XGLZ>/?W+O64R60P&7?Q
MV3<"'XS+KR'4KYF7F$I41(85H2VJUM=000:[HS<7L>^.4  1N=E@0 <?F/FN
M*,3C1P)KJHKGM_<"W,C@G2Y_@37E +)NDE"RAT? *!KE[&[+Y8'TH)6G'P_L
MHMO-&[2]I/TFOS6=#;7NUXUV1<>50KMS&W"^E$&6*IU\:Q<@5$[Q^)J'HJJ1
M8/9W7^_A0$##JLACX*E7P[/=_#MK(+(9*B>(U[[VU^^LADKT[U;UVX#[_=63
M5?O5JE</;O[*U&K7&:LR\AD<6E_(X>/];/Q;:LBW!*RVF:8J52/H_-Y5<ADA
MOD!L;$WM6$^KT7&,5D#305I4TP%>E3A7I5<A:Q6TL\<5Z[T[61X:YX%2T$@%
MU*XZ:UI45I1>>LGU[>LSK8Y+@^F7TE=1LE$;EO0%;FRFVT;2VTQ(:=4PLJW7
MU'DX3'2&6'$D*7%9>! N+Z7^4?\ 5/YC>8N+=FV[;MAL=1&MS77,U*T^J;1$
M#3'",K[-9[5?E7]OF"3F_))]YW#2'>C"_0W(&FBVU/QRHZ3Q7"UZ/OW)^O,G
MZCKMZD=B=$]M2;..[?V",OU2W:E*QS>079Z-M;*QCK?-8J;$Q-QH"-:UF>PG
M(>2N];W(Y%N6X!QJ81,]L/>!#'Z<5.ZA6E)^93VFX.ST/:7B%LRX;@)[B-C'
M$=NH^K,[XEI6?>DO[4?IVZ>Y_"[VWMNWK1UPWYA9!F1\WU!ZAY3&X(25MJ;=
M"=C[,.W]N.0W4+4E3$E$IM:%%*^8:5ZGQ3VAX'PQ\=QLEDQEY&:B3 .KXMI\
M:DUZKQOG7YE?=+GMG-M6XW%O;[),*.@AB;I(K4 NDUNJ#0@BA!Q%%J;ZQ_VH
M<UGW\CNOT]O#*091>DRNGLZ?'B9B"XI07Y6VLE/4W"R,5)N4L2'6G4BP"E5[
M#M^XBU<&RBL7W?I_P+R.#=(;AOIWM&3_ ,8%6G_$!B#W@$'J%\[/6CT.^HO9
M^0R<6?T@WI#F0EN)=\_:^9A2&E+4HM+3)3'7 F,FQ(<9><18:&U>D;3N5C(
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M.'#RXBVIC:3R\X^9*F[E)2JL.0>SGY:HMEC_ *7NVS[;R)KCK;<W,4K'M/\
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M3D)[',[+4F:T\MMV4A!:2EL"P)(KV^.CYS:1O.B_8#(\BH8_$N Z88$!>H0
MW-X;"*1KH=Y@C,TI%1%*7/>YK2* TI]).K',I9S]/P^83UHZKYS*;3]//5[:
M6'@_Y+;^NR.+P^5RL2#-Q2W,)#0XAV7CGFI"I,IMOF_J4=+"M)ADGC_IM@UL
MF\VTCCKP!< 2#YCT((H"5O+*&>Z@9L6S0^IRJRO'N]44J]D9>UVESCBVA: Q
MQPR"J]N[MW9LK=K/0[IWL[!9?I'NW'Y!O8V^G(<AS-8G,9O&R\TSG(Y*S"E0
M)4I\>2TMM*T72N][IK;W$-M<VIW:[D>W<8W#U(Q2A:TANGM! SQ*QNK';]TV
MR?E>Z3._KL,K1-!0>9D;VPEG\3'Z1CB16HIU5HP_1'=&]MNSNC?J'ZH-Y')X
M_).9KIE%WKN1A.9E8M,1;&67";R#R).11"?L ;.*:2M24FV@PEW:WM;ENX;-
M#1A9272T@ UPZ85'A5<O+RK;]GWB'?\ A=D(K=MMIN@&/#&N#P6="V-SFYY!
MU 3BK/"ZE=$<OLW,8/8F S>[^M70_'08V$B9W%+@8O<;FVY4;'0-R1<CYJI,
MS QI2$%:0&Y#B0+)"5!58OM-T;*);EPBVZ[>ZM"#IU5):1T)'P6H[8N71W++
MK<I38\>WRXDU$.8YL8F#GNC+* MD<RM,VZJU.%%P9KJ'ZAO4%TRPFZ>G^*3T
M5W[M#<TB+N=S9B9+,K-S(#$63#<1*F"3*8PDEN7=R*24K<20LJ2 *VDEGM6U
M7YMKM_K6SV!S:X 5)&('7#Y+D8..\#X7R[^D<GF%_M$UHR6$D%K6ZR]KM88:
M>H-/E<"/*<*&JK]^^G;,]5<9MOU!=0MX1<3OK9F!Q4O>V=DYAAG_ "Q*P#:9
M<Q#L?F"L0R?*4\&$MH*BX;))56TBW2VLGRVD<6NV<YP:<,0<L\_'N6GL7/=L
MXS-N7%]LLOQNQ7%Q,R#)SYF25:P'50OI72'5. 5HW5U$]*R=H+]2O2MQSJKN
MO:>6AJ9VGA,7.P^2:SSZ7%H_7EY""RK%XI;2'5&0$.%Q%PA*C<#B3=7[8'6<
MM!$X9]:=QZK1VZU]RYK9GMMN9-K9WUO35.T4]$%NK0YKJ/(-!3/$$@*Q[U]2
MN]>I'2C;O5?TI=.8NP]WQ\[,@[TE9R+!W+E\;(Q3<=Y[$8B-(BIQ[V/R:92%
M*?=;+A:'*$I43;9>F6DQ2N)93*OZ?!;S;_;ZRVWE)XESS<#^!9$R:!L<KVQR
M:BX!_F/E=&01I[36I%%2]3=F>IGU<],^EV_U9/,['W5MX3!D-L[7$G:V+;W+
M#F/Q%YX,XEYF0J3,BH0ZSYJUEE*RE %S6U>Z&!Q8V@KUHMQL=W[><$Y5N>R[
MK&-PLJL]*=[!,/3>QK_3=04JTDAQ JZ@)R7;=Q^DS;G7O;F*R/4;J3MQ_JIL
M3;6.Q74R9(W=C9.<Q[^'B!,B3FX\B:[-B(=90'%%U*?F4>VMC.03@#\%Q>P>
MY\W#=PO8>/V;7<;N+V1UJ'-=&[2YU0UM6T>*U:T"IH .Q4.U-_\ H;ZRXJ;M
M1[,Y?>>\>E.WWHHQ_P#E:>W/WG VE#:A+R.VI4IMEG((?2PG5TM*L>?EY-:X
MJ<V=R[2[0]S6U.=: 8]Q^"TF1^ZG%Z[E"R6QV[=+QSFBL;H8GSR%S6.KYHZ5
MZBF%!4X+KW0SUR1NJV2W9TE<]/>"PN]]M8#-/],7<IEYN0B/PL UR0<9N>*8
M+!_48L)*%GZ9T-.I04BW$\=%ND-R]\43':VL)8*@@Z1EVA:W)O:G<.([?#R"
M_P!R8^PN+M@NWLU->QT[R3( UP:YNHTQ%6U!((5J]-W6#UP[DWAOOI/U!RN2
MC8#.XC<8P&XF]K[?AN[6S=P[":VQD8F-9=B0G4.J::;4IU3:@"E04":X2QW/
M=+^Z?9S-#6F-]'Z*>F6C#'(@_9@MWSCC'MSQS8[3>=BE,LD=S")(1,7>O'([
MS^6M0ZIJ=- <:JU=&/2WU3Z)[ZWON'JOOI&%Z0[H@9G$[LE[EW1+QF-R4C..
M(1#G9I[)3&H4G(F4LV<6I3I25:VK9[3M^\6]](=QFU;>Z-X=5]:U'E(QP-5>
M;<SX=O&PVT7&;,CD5O<0OATVY!8&.!>TT;4LTXD"N(!7:<AT#Z">CO-Q?4-N
MOJ3"FX+(_51]M[?VS,@[E?W.UE6/)=B8&)BG'6WXR8[BEK=6XEA!L"L$@'90
M[3M?&KH;Q=W!;;MU4!'U:@1I[QC7#L6&Z<XY3[C[0_AVVV#/QSC&7O#B/3]-
MS7:L6C03IH*FN. *J]Z=3O21L+I^/4ST.VS/ZA[KG3)$/&,2<1,V[%V]FV64
MKDN;OD.M*?CLP&G=&XR7B\I0"5!-U#:76X\6V6U;R:SB$Q]0AF@GZSG4&FF@
M/CV#&JVD5C[B\DN9. [Y=26UKZ(,NL,)=#7#26UUU([AAYCT-1"]7FYNLWIX
MW'U"Z2=&-M[:ZLXN8<)ELS$<<W$S$0_#4XK.;3@9"(R%9!]!Y$)EAQ#"R3\]
MA6PGYI-?<?FWG:+:FY0R-8X. =HU"H>"!4]U<CG5;4\!M=HY5;\<Y%?5V&XA
M=(S2XL$FD@&)P+BUN=:@5(RHN/H;OSUE]<>@_4+8>ZL]N/%9]E+43;N:D87&
MX;=LO%EA8R&)=S6*A1)BXZP0"XWR.ANZ><IKCMIW7EW(]AOHFTBW%FC1*&AF
MH.^IM3@'9>8"N.:W'(]JX#Q'E.VSQ#UMJE#_ %(-9D:PL T/TDDEN=6DD894
M77_3IZ:=Y]*MK;UVOU\WIBME[1ZDR6\)C8>:W.,'@)N>4Z9+;S,7+3(L5^:X
M0 ZX$$GBHULN/\<WJ.QO]OY'<NAV^YB#&ZI029":U;5V-1F*XK/FG,-@N]QV
MW<>)6HGW.TF+WEL)H(M)%'4;6@.1I1JO3W2GH#Z&);^8ZF[^>W%D]Z(,&!@,
M&IO=>;7M_(N>7/R;C,1P1(6(8CK)1YCJ2\ 0VE9O7%;?L/&/;RY=?<@O01<0
MNB9&UI!<UXHYQ&= .N5<B3@M/=.1\K]S;..RX_:!HMIV2OD<<&N8:M:'$ :J
M],^V@Q53N/%^E/H%CX/7K [FF=0W=ULKR.R=M;5BRS.E2+H'GSU9M,#';>BX
M]Q5G?-4'>9-D(41>N,_IOM_PFY@Y=)=/FMWNUV[&T)>[MJ,:-.>K3CA0G!9O
MW;G_ #6VN.&FW9!.QNBX>X4#13*F1+A_#JKV@8JFGXST=;DQ>W?4'F][3]FQ
M<M(D!_9&2P67E[E<S41*)F1Q\;%8:/-QN2+9<N)*'@PH*%U7TKC-UVGVSW9\
M?,Y;]UM83S5+""7F0&KF "KJBN)H10YK5V_>?<;:6/X:RT;<7D$0 D%-(C((
M:ZI(;3# &APR53C/2UA/4-N6?UWZ<;N8W#L1P+S;S$?RH>X,1)Q,/SD8S(,3
M/)RN"R<$1^1D*" =%-J(L:T+_@-QRC?)N7['N+)MJ<3)$0]_J-T-J(: >5P+
M=(Q':EESD<:V:'BF]67I;DT".34&^F=;J&3L<"'$F@/8M?X7[O/3KJ%NK&]!
M<+U"R#F\7<G#V[BL5(1-E2HN7QRA%C#-MRDK.0CLNM_[:)04'6^<J(590\TV
MG>/S'V^\LWJ^_F;,]P#X7Z?2],X4(IV?4<W8ZB:E>H[O[:>SXVJ:"*ZM_P <
MR-SFEA.LO )&GOK](R!I04"W!W'UU]/'1)6V9&]=C[ZB=4]W8YF1D\9MC%PL
MSMS:BYKJHSN9>R+\Z-.>QS2BI]B.EMZ5Y8 (-KGUFSO_ &VXM?6N\W]N;/?+
MF+U-!J_T-=?, 2!2M2RM3IHO 9[+FG)K.YVZQF%SM%N\L#B[3ZFD#"@%:TH'
M8TU5Z*IZ:^DD8W=$3K9A<I%5A%O*W/@MV8;),QW<DN25R6A$DM+1)=DY'S>1
MR.I(<NM2'$7N*XGAWMER*TY3'R.6_8_;-9E:^-Q<Z4$D@-Z><&A![=-*X+>\
MC]P+&?CS]B%L([T1^FYKP!H+0 >\%I&![JU73=K=1/4QOKK+*;ZFY-W=_3-^
M7)ARMC2\9C,1CL+B!(*F<CA)<'',/1\O ;0"7'5.)?"2ERX.FUX[S[D7,>3O
MX[OED)MBGD.J(LT^FUKCI?44(<RE22<14'!-XXWQO8=@;N^VW+F;Q'&-,@>7
M%[B!5I%3@[*@&&!"[)-ZJ] NN^4F>G?I_M[=FU$OY%*HFX]XL8N)@]XY/'O.
M(3BHCT27(,)',%.,&2EM+Z@!<*Y0>S27?#.5;7-P/B4HLYW7#7AU*,E,>JK=
M57.)-06USI09KAVV7*>.W<7,=[C;,QD1!&HN?&) *$U % ,'4RK7)=YS'3S?
M_IKZ=9;#=&]R_H>\MR9".G-JVYD(.27A(R&7E)E2(:#+CPLE,"0AMQ: YR V
M[*WSMKW[VZX=Z.S2/N=WFNFAY#=38FAKC4-<"0YU -1:.[); ;GM7,^3,EWK
M3%MD<#BT5+2\D@ %PI4"I- 2I[0ZEM=,>G,+<GJ#VQD^H&^')CS. R<"1#A9
MC/M-H#JGMQ>>TAEQR&HI09#8YG 4A0)^:N>MN5Q[/L%IOW,;;7O4TA9&6L;Z
MKVL .MVK2&AH(&JA)J*!<?=;(-SWF?:>*2TVQC Y^ISO3:7$C2VE:ZC4TZ&O
M13QNR=J[M7(]0:,Q%Q\:2J7G8^/RDV+&S$+(-,..*P36.=>#TF8SR^4T&.=+
MGRE)(-+GBVU;_P"ORV.]]-EX'21E^#FR#$,-2 2" R@.(RS6SN-[W#;[#_24
MENW7$!&[3B"TGZA05HZM:D=M5C&=U[=S.U\5O'93ZLWM_.P&LCC)D8*7YC+B
M3SM/(3\S$J(ZE33S2[+9>0I"P%)(KPX>YEQ#.8+F1\<C3I<UU06N&8(.1^]<
M._CD52' 5[LB.T+K_3WK?OK=6XF,7^FRT)\](<6MHI"6RH!2@2.4V![[]U<I
M_P#4@@-;;SE\[R &@U))Z +C+G8X86ES@  MJNFOISQ(ZBQ=_9K<3LF#E<E*
MS"($EW&384&7*D.29?T3[;9GPG5/*59IQPA!-P *YWC'M5!=;O'RM]TXB:4W
M+HHWA[)'DZJNH2,'_4.T$46QN=ZF-H;(1@-8T-U9&@& ^75>E4;!;$2&Q$=:
M:6I*4I6E;:R%6T.MR03W]M>[2VTKJ.<Y]1F"%UD7,PJ*9K'.Y-])VIE7<8X4
MN)2A#T9U!'(]'7S!"P+FQ!24J'816]B9;!@,SVM<>W!8N+78X_)6)761DIMR
MVO<6YOYUN1%9?^6;\UHF@Z.^2Z1E'(N\5Y#*PI;./GQEQ79"'=&IL3YTRB@H
M%_K4)0GEOHH:&VE8WD+WLC?MTC=0<-9I6K12M>M0,CEA0X+*,L<2V0$!5V+W
MI'Q2$M1PE*$Z #0$=M^PWK=UMI\Y&_-9%S *4-/!7"?U&$UA<;2S@Y>/#70@
MCA8UKV\5I'('%X(^]:+GX>4'4L91][.-!]OS^534IYM5R";H7R'CJ"% \:V@
MWBU,CV2@:V.+>S(K,,F:T4Q!Q^:QSU2R<[+;9?R..;5(G19#$23,2=(&(FN7
MF27DI^9QM"VD 6_I*[\+UH;S=13;2^>!M-+@QSQ^Y&[%[CVC #Q*W-@UWXL-
MF.!%0.UPR ^9^2Y-L91M6,P<[SRIG'.R(+!_]ZR5QV"I2E"Z;I2";=I/A6[V
M_<(C9PW>(8'F.,=U!B?@/B2M*YA/JR1_O$5/S*W BN^=!BO*U+L9E9MJ;J:2
M3\:]#:?*#V@+KY;F.Q<:K7-KV\>-5.BX%\=./;[=]JQ=FC51.\;=MS[&H>BJ
MI%]O'@>/MPJ#-9]%2KX>)X5F*JJA=UN2!I]_#AWUFK]ZMSAXV[KZ5D,ED,U;
MGP"FQ]^O'B:R;AX+5:237JJO!%"<C$)2D_[0R-0#<>8.-]"-:2?2D@.E;!+6
MM1LI2E!.B05$A(&@ !-@ !6TJ3FML&M;D %"HJE508*00LCY4J4.\ G[P*:7
M.^D%8ES6_40/$I**U)Y%DE(N"A5U)%_^BJXJ85KU2ASP4$!+5PRA+05<*+2$
MMW'<HH";CWU,\>Q9'$)\*QS52YAWCM]W;5HHHZZZ@_&]N/#NJX)51X$<.^_\
M:J9K)_22=%A[K*)+S;/UF.E18ZG%!"7)"GHKR6@I1 YUH95RCM(L-:U(J!^/
M8M&9M68=%M16Z6T11$41%$11%J81;[_NK0%>];E*A1%,T13JB5[T(HE$B;?S
MH#4TZJT43K^%45&"N2.[V]C05J2@JEW^[V^-0@X>/3],DZK#7J#P/4_<_1?J
M%A.C&0Q&-ZHS,$L[,>S\N3C\-)RL9]B3^EY#)1&GY&-8RT=E<;ZA*%>2IT*(
MY0:ZMSK8+_E/$;[CVV7<MC>W<.AL\9(>P:@74(Q&MH+"1B XKM_M_ONS<9YG
MM^_<@M!?;/;3ZY(33S#2X T.!+'$/ .!+:+P68Z)_O%91*?J^BO3'%NJ YU3
M.NVVWF@O4+*3%>D+4D_W3RZCC7PZ[\G^_22'U;^=[:G$S#'O^HE??C/S0^R<
M,8++&8.H,!"_#N^D9*\L^E']VW(6,G"] \0%<?JNK<N64'Q^BP<D$>XUJ-_)
MG>.H9KKYR_L!6+OS;>T4>$.VW3J=D/[7A7F/Z'_W19:>:?O/TW8AL)YG"=Z;
MQE\@U))+6T^2R>^];R/\EXIC=QU[Y'?J8ML_\XOMFP_R]EO'?_JXQ]\JU!Z^
M;<]:W0'.XS&;@SFTNIT=YMN1E)71^-F\_&Q24O(;>A9"3F&,*F/-4E7,CE#@
ML"3:MT[\DVN(EMS  X4#B^3#OIH!/=3-;FW_ #D<"<PRQ[)>!X.#2V+'X^H0
M*_&B]J,-@]Q;?Q>%9S3K<E]6%Q:G7F75.H*UPF5J^=:4**N8F]P-:^Z-@VIF
MS[3;;4QQ<+:WCBJ<SZ; RN/;2N*^*-_WZPY%N=SN5K&8VS7$DFD@ C6XNIAV
M5I@KWB\K(Q^1YVEH0EQ"T.^;_J^7BE2A>UTJX5SCHO590?4%UZ:"*6+S D ]
M,U?7]RYJW-'R6/01_HL D#P)3K>M@^VG&&L ^"PCBVMA_F6\SO\ :'ZE;(+W
M43<S\]G$9_',I@J90^I]<AI2//25-*2AEA?.E021QXBMI-9W0 K,:'LH%S;+
MSB=A&Q]U8R.>ZN&!&&&9(^Y5J>FO42>ZVJ?U#3$;YTJ7^GQY;KP2%746UONM
M("Q;0D$7[#7'R;3+)BZYF![C]H6\;SGC5JPMMMFB>:?\X6T/<0T5([<0>];&
M1T>6VTV5%PH;0A3BK<[A2D)+B^4 <RSJ?$URU:89KRUYU$N  !)-.@QR'<,@
MKDQQ5\/SHL3F%6H^^B8U52U_5[OYU0HY5:?=Q!M18]G8K/N*:N#BG%M!2G7G
M&8K:4_U%3RK<H\2!:M&X?HA)ZG#YK5B&J085"PIO;9#>5F85W.9IS - !^7/
MC<CP?0VT4N8M,=2D%Q]7RJ\PV0D]]>3<TV&/DVW_ (3\4^UTOJ9&EOTG#2 X
M@5.=3E3(Y+LUA<&UDUE@<'-ICV]O]BY,5!V!%:G-R]T.QUAE#&%8$=M4V4XA
ME*6Y<T)^0-*>'*$IU(%^ZM;:Q:[3M5K:V\T;V10M9J<]H+@WRZCB,32N I58
MOB?=7#R0:$GH<*X]BPWO[;J<OA,CL'<CB-O87>,.0QFLAD&4PY<LGDDX]4:2
MM+*5/9"9'0UP*G^<(&MJ[][?[LZPWQMK%'J<]KG:NTLQJZ@Q)!..8H"NZ\*N
M[BPW/^HQ-+[B.A:VA+0&UU5 !(:!4U% TXG!:MY'?SF)B[;]4.Z]J1\QN*##
ME='\_P!+(;YC/,X1W,/LM[A?86F1)C(>AP!+!=1R.O*Y4JL-/>6VGJ%^PV\F
MF(GUFRGM ^GOQ.G#(+VJVVC\1-)PRTE:VV<\745P1FX1#R>736A=IU-->I"X
M,KM/:?3[<&XMO^I/=^11L7K-N&/E.ET4M3\IB<!D5KD<[<2*A3Z,%C'8V2C,
M!20EKG"0JVI&FVYN;V%D^R1#\5;1D2Y N&&9PU&H)[5O;"\O]SMK6_XA;Z=T
MV^V?^*(#0^1I#2"22/4-6/.!U4KGDHL[CZW[ZQV^?3YB-M1=EC 8]#W37J'M
M]J7#W4UMW;V0APV<1*E!UQMK(NQ2VKZIA25!"5HM8WK1?;[5:.BW>9YE$C_Y
MD9Q;J<":CM%:X'N*?T_BNV,LN67DWXMEU<$W$! <WU)6NDU"GF+ X&K7 XT(
M( HK7ENCIWAMO#]1.M74F _U9Z)06,AO)^=F(SNZHN%P.2<R.)=?P[#WUS3N
M5QJ&DHY6D_5.+!LI2[G3&[-MIY;3;(/_ ,'W&#*#"KA0BIZ UZX!<C;<N9M5
M[?[1Q>QU<>W(F.$4-#)+$&N:'/!U!CR<-7D (P 5KW'Z@.CFV</ANO7IUZ=R
MNJN6R&3E;<WQA<U%E[:&WL>\U'GY2'D&VT.NKRTC_"5&"4J9Y?F*C;EK;?@-
MUG(VK=)!&P /:<#6E0"*'(=>JW>W\+YAO4\7".77GX6VB8R>,NT/UD!S&%A:
MX5:#JU5TN!H%497J=ZF9'4G875+HRAK:G1K>\#:WZGTZ8Q41\-P<HXTG-S\M
M(EP7'W-Q1/.<"74*0EL,I 3:]^._"6#8Y;>\?JO(]0J7=E:4[NX]JEGQOA$&
MU;KM7)+L'EUEZ[&R>JYH!B!,38P7&L;L#I-3YW9%6=[TR0NA'4?<757JKU'3
M@>D?4#]5QV\Y&]<NXK&9O*;H6%XN5,^H6[^HRVIJ0INR5*;0%6L@&N,GW*"X
MM!#%'2X;2F&0'3P6,_/;/?N)V>S\>VQS>66\L,D!9$#H:PCU*.%2&EA((KB2
M,S16?/[T](GHIW+&CS%97?\ MKK/ A9#*3NGC,+-[?P6%@NR!C,P_-D2F(4S
MSE37N6/%6X]Y:22!\H/%RNN+AH)&DCXU6X<WW']U'6[K:-EM=;2Z1H=J=$]T
MCPT.91S?*1I%=0H21V*EWEZP,QT!ZJX;"]+N@>%SWI_W9^@RCE9\:8]F,X<Z
MF,XYNB$O%O)A06VH+Z"U'6AQ3J4$K4#:VT>W4:2&KNU:NV>V]US7:9][W[='
M_P"H[=KXVQR!CA'Z1=_*?@#76#5S<J]1BH/J]<NW/5!_F+&;OSDOI-O#/1X>
M:V[@G4XW;.*V?()B);QN*+1;AR,;$=#R9+?^TN+02M9N:V$LTS9A&&DQ5 ^'
MWK9V\/M-<>WLDFN)G)8[=SVN<XMD,[1JTNH1J:XC1IQ%"*9*A9]$R?3OU<E>
MHW>74.'MGI>VYE7=WRMSS;1\U"W0S(A2F9<V0ZMW*R9LB6AQM #CSCJ;B]<<
MV-[;GUB\"(5KGE0UK7!;C<_<NSY-PEG%MLVR4;\61^AH8TADD;FO:YA!\H :
M:TIY255;R@>C+TNHQ7JKVSN./U*<S4R3CL#ANF\R/D4Y).3CJAYIJ6Z\XQCL
M*U%@RE*>$M2'.?E2E!5:MA*;+;O]_>7%N(&(=4D4(%,Z+;R[Q[E>X5B[@$T,
M43FB-TKWMDB<P1O#V$ZJ8N+: M!P).2H>I'J\Z9X_I)A>OOI'Z0?JVX\CG96
M-W%F]W8J*L[+>QZ([N5QLO&8.8X_E)DV.^E*5A]#'D+Y]39(X6[WJVM+07]E
M$USW.(RTT<<Z]Y!6I8\$Y-O.[R<.YGN,\=E!&R5L8E$GJMJ?3<RK0"UKFXZJ
MFHI3,JQ[[]07J9]6?IEPF[^D>W6NE>XX.XY^-WMB-D-93!YK.3,1]))QK^/S
M,Q:<KCL9*;D)=\MAU/.Z"DK4D6K87FZ[I?;6VXVQKVO]0M?I\Q% #AG@:^/0
MK/;N'<)XKS63:>5313P&V;+;F4-8PAQ<UVL# O:6D#'2!B!4J[M^G[U2^KWT
MV;>VUUGW#N=7479F;R9QR<W-7D&9>((C#%97)164M,SID8>8SYSJ5N@)U7<D
MGCKS;MYWK96B=Y9.R4@AU&:Q04)IA48BOQ6,7)>#\&YQ,[98FS[9/:L=6,^H
M89-3@YC22:-=1KJ-/7P5WV-Z7^D>S^GN/]+'J'ZQ[$Q6^W\A.W!MZ%E\Y"PV
M4C0,RIA"(#7G/ 8M<B0T7&4.*:+O-="3:MI_I^SDVENS;Q<M;=>J7Q .!<&D
M"K?-2HJ,A\%LMPY]NC^32\IXG8RG:S;-CG+HW:'2-+CJJRI!#30D_&A7 CJE
MZ+/2'G7/39N"-NC?N R$X2MUYS"1X63PVW,U*++#+!1E9L63FT^3_P"$&&E:
M&R+74H%-<6^\X;QEC^/WSG3^I*'OU-JUCJ:172<#3.E>]:,UK[B<VN(^86(C
MM3% 8X@UY8^1I=J)\P-03@W4!7,*T=<?6PQZ6.IF#VET7Z)[>'3^7':ES3NK
M%3WY&_$3D1W$OPF\$\VSA(L5E:?*44OO*-^9*1I7$;KSFVXS>NVG8[%AM0 ^
M1U2W745!;F:4R)SKE1:FT<$NN:6+=[Y#N,OX\:F1M\KQ%0^8/!%*EPQ#0*4S
M7%ZM=_\ K'W1N[ISN7H=!S>UMK*QN-SV#P_3::K;Z,3DYT1EZ2_N"65-OYMZ
M[JF^21SL)2 /+%R3L.4;_P OFOH';/ZL6V/@9+'H:7:RYH/G-,P<*8#N6?#M
MDX+'8W,?(3!-NL<\D4GJN#= 8XM&@5% 0*ZL75ZTH%W+U#^D'U%^JV+TZWD]
MNO)/9R'M^#C-R,9UER?&B9!N,TB<G'P6@U%@.2I%W'2VA <*KGL%:?*.*<IY
M-^#W!Y%'6K=43GB/TY/WCIRQ.-:56AQ+FW%.*NO=NB87,;=OT2L;K]2/-H+B
M:^4&@KAU60Y_I,Z"]2<3M'I3U$ZN;#Q_47I9BHN/R6"_SIBX.X'XT:-YJ7'<
M>W.,QY##2U7;Y5*;MP%;R^X#8[G:V<.[7H&]6UOZ<A:6N!%21746D$ T)^:X
M:T]Q=TVJ^O[O:[1PV:ZN?4C#FN !T@&CF M()!P[5U6%U ]$&]\W%],YS.[7
MV=N+3C-N;IC;0ES=L9S(Q&U_58N)(3)3DT.*=8LR\XPB.\H@>9J+]>N[+VSW
M:"WXB+F3\1:%VF4?O$XO:,"#B,,/ K=0W7N+M=S<\Q?$P17(:7QX#2T8-<16
MHI7'&H&874,!NSTI^H7.'H7+VING9&T=CHR$W#[QR:F)"DO8X*3F'-TXS"%<
MW;3#[3 4TH.R GD*7>4D&NH6EU[:\K?;\2LFWEFVU,KXIWAI$U0#*7BOEP8"
MUQI3&M%S=Y!S[B_J\LN);>Y?=-C8^%M:LQ/IZ,M6+J$#NI55FZCT7ZL=,-W=
M'?25O+*9-S H@/[OF8R%G-L2-Q8M+CL9E6.7+3#G9C"1Y2>5]S@"M/, E0)Y
M#>9]OM.)2;3[9R/N;N*5IN=!=ZCF&H#@!2K&NP<6B@J%Q%G_ %)W)XMW]P8O
M3M9(W"#4&EC'BA(-*Z7$"HJ>AR7CYUWZ)9#HOUGVYO&9MB+A-RSXN$R\[()Q
MT>/D9REH;0])7D&VD/2C(D1EE2BH\R@03<5W;A.Y7]_Q^&UWEDD5]Z7IR->"
M#45 ?0C)P -?%;_=Q8RW3[[:7,DMVR:FN;3IB6^(^Y>Y.&@]%NKFTL#U1ZH[
MWP_3PX/:^VEY3/;O=<8PF5B_3?2LKQTYEMY+DU#L=;+L-0\XJ2%H"DJN.@\D
MX'L'+-T=?;O?OLKNT9'%*'@%KV,PB>QQ(%2T!KFXFK=5*%<+#R/>>,N?MVU0
M^O;7,LDD8:"7-+Z.<UP )H":@Y4-*U"QWU=Z+Y#KAN#9.YNCVY)F=Z508V/;
MV-FMH9B:UAOJ(4E:Y>689Q[S0C949!)*^9*9#=@%<M=?YO9<RCWFTM.#MN)>
M,100LMWQ$N:2!_,>ZF#7^IJJ#0C Y46YXQN?'X-MNG\F:!OTDTAE$C/-0_0T
M?W=%*4P*R3U2]5/53I3F\'TEQ'3#9N]I\7&XJ!U!WI/CY"#NG-&6ALY*!CU8
M]:,?$R8@.!*Y2FEE;RB5#B3VW=_=C_2FZ-XWN-K#-NK88V7<C?(YSY& N:--
M!JTN&HU(U8@+@=KX..0[?)O,%P^WL72/,$9H0UK'$ N)J::@:#^$4JN[-O>E
M[I]-Q\9G?^,PW5?>^,:.T]F9S%3X^3Q&8S49:,:WGL@8SN'Q:VY*AR*6^D.K
M *38UOMBXUP7C=T;O:[JO()[4NMHYB&Z)'L/I%]!@=1&+B!^]D5Q^Y[SRG>[
M3\/>Q2/V>&8-F?$ 0YC'#U-)K5PT@Y#N76.D/0??_IZS>\.LV17E%?30)SV7
MQV09=F8[=;KW,Y'@Y)B7=F4M<Q8+:P/,:%RE0UK0X;M',^'-W#DG(7._"6]L
M][HR^IF=^ZV@)/U$>;IT6ZY/O.P\CCM=EVF-HGEF8ULFFGI#J1T/E!J,C]J[
MYTZZAY+K[E\N_P!>MKP=OX3!LJ?VWFMM89;$/'1RXD/XB3BA(=7(^H4E*VWD
M$KY@0H6L1RNQ\LL.<6%Q?<WMHX+/;VF1LS2\,8UQ <QU=3BYQ#=- 22"*"JX
MG>-KGXA-$S8+I\DUS1KF'27.(!(<W(  $U'3 ]J[GN;IK&ZF97%HZ=I?D;.P
M+"<<AA4/Z>:U+2ZIUZ1*B *$</ !3:KFZ1QN#;D;[9MO]R7V=_Q:XB=QVS9Z
M0 U,+) XN<7,?1VIPTD.IB!@N'LMU?Q\7+=TBD.[3NUZC1U6Z0  X89UJ*X+
M77$>F7?4'J)U"@]*$L],MD*W J7F'$PVLU!W/NJ;&9D[DSF/VO,0O$X560R+
MR_J'V?*7,D)4ZM)4LJ5Y'S#VVWGFW.+ZRV:'T]OL"RW==/JWU)&L:7TK]>FM
M 2#0  'LT7[_ +=;;7#)=L]6_EU/T-J QI<: D=2,:+97I-Z?]Z;/W+CLVR[
MENH6XFTN-_4386,QD*,HN(<') B-P\7%:"1;F4"I1M<FN6XY[3[KP#D%EO<=
MK_4I6:P1J9Y7%M [S.H /-0_Q$'L76+_ 'R/<[5\%/P\=01F:T[\RLY]2-I[
MXV[*.YYNST8![-AIJ2K"*1+QSN2:;"&2^W =>8A2I+=N"4)<4+ZJ)KD>;3;[
MP[>X>4[/M<]K;7H$4S8'&8>K6L;G1Q5#-=2VK6@.<*DZC4\98FWO8C:RRA[F
M8BN!IUSQ-/TP71^FT7JQN?<2AGFF-I;6C*4H9'(ST)R4P)%PF#C6RMU"EWL%
MO<B4]QX5Z=Q6]Y[O4$=YN$<MI9.H3ZH D</[L>)%>UX;X');2]@VRW\L)+YN
MZM!\?V56UKL+IID<7'QF6AMY!;*%).2DS)(RI<4 %K^N8<:<2.87"$V;!_NU
MW^ZVR2\:&W+=>G(Y$?$4^/:N+:Y['580M'NM6TMX;$3)W%L'(+WCMIA$B7-Q
MJEM-[@Q$1E"WW'4-W2UF(S;22/\ ""7]/Z%<:Z?NG'-WV]KKJT>Z2R&+@?K8
M/_M#O'F'4=5RMK<6DU(K@!LIP!Z$_J^Y=QZ+8[*[_P"F4S='ZB<;F)B$2L''
ME?+$EQ/+65IE?+YC8?/^K6FX%M00:WUC;;G=[&^2PETW;P]K*GR.-,G'$TJ:
M5&1Z%;>Z$$5WH<*L;2M,UB_=^^96SY3T#+7C3(P!<0I0LI)!4EUM8NAQEQ(N
M% V(KS%F^[KM=Z[:=S8Z&_CH"TGH<B#DYIZ.%05RT=C%<Q^K#C&?THNH[<ZP
MM9_,1<9$>+CS[Z6[)5?E%^92B!P2E )N> %=[V7<+N[NHVEQT5!)[ ,2?@%M
MKJP;#&YYI@%9.J6]GNGNXX^/3,<DP,\PO+0'EK!=+CKZDSH[AL$E3,I=Q_\
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MG15R.)HAS52V;&_MV]O95"CE5I/ ^W"F2QI7!6/*9?'PI49F9R*+7^V(2NQ
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M2U< HBN*N;F*H?;X]#0?$56ZW?W XWM.]V?(.%6;'N]!S+MK6>F  6F-SSI
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M(LYI<@V\YIU3;8(*PGA6AM_%^$W&\2\FVO=9#8VCS<>AH(G!;Y](#L'"HH'
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MV+I?J5B;KZ<Y/$RMI1I>X,7N/(B'$>CM..*QCX27'T9/R4K##+3"2XET@)6
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MLFUW]SMQDCQDGE8#4Y,U:G.';C3X)?36D4X;4%C&DU&5:4 ^*] H,-.-QL.
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M]X6U.DN6P.;VUN##;KR,.-MMR%NM3+<-YZ7/=0@*B36FG6A<D*N17$3S!_\
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M$WYM[T^9[HQZVNL.-P6U-T9YG_(F0S^Z5X?$;6RZ6'+P,5(S4M$9I<Q*2L!
M"0I/ 7-;>+CNYW-@^QWF5]G9->U\)E=4:Q74T@GZ2#\#XK1ON7[5!N\6Y\;@
M;=WY8YLXC86UC=32ZH;]32.S&N.2["UL?T>_MP]/SA]\;LD]6ML]6'S^K8O
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MII>T&@SJ'+)N\\;XA>26UL V*=H<71?S-#Q6K'&I-*4+17#%767Z=O2;Z?\
MI1M7TO\ K9ZKQ).37/?W7B,N]#R#^0Q#TU[RUIR8PK4A_$0I5K,E?]82;BVM
M;0\?L[(-M>2W(L[P$OB$1]30QU 6O&.!IJ'8MO\ ZAW?<[E^X<7MG3V>G1+Z
M@T:W#$.;B,16AQ7'U3]6?IG_ &_]O;$V;T4Z88_J_P!*]YXY>5<R4E[(8_;6
M7<2^$).WY'T;\B5E&RM1>6X@)"OEY"02,9)]DV2<[=91-W6*5HDE,V#:Y-+#
M2HP%"5MXK#?>2'^I;G.=ND@<8XVQ ZJ'%P>*]N(%:]5Q]<O4)ZL>M72;I5U>
M]%6R,STSPRI,YG,;:VG/=;W-%E+*&X\S(Y!Z+CW)^)<8-VV0TA"=2H+(%</N
M7(IWOC?L$3]OVYH<UQ@;J=ZH(JU[P#A2A;T*UK#8]LM+F>#D4S+S<':2SUG4
M:6&OF:":UKGC7X*OW?Z<NMGJVZ%[+PGJSZWL=.^L.-R\F?MK+[TS^*@1,EBY
M#:$2,%Y<MW$19<V/9*RM \X<P"E*M6T?;[_RF*.YOYHQ- 7-C%V[TFRL=3S-
M-*!S3GAB%BS<]EXY?21[1"Z2UF8"\P><QO!- 3_"X98X%=WA;*Z._MM=&G9>
M^WW^M>/W.IB)N#'X'+8V<O(1W;(_4',FV9\&##B$V2E25J4%$ <36F=BMN-Q
M.'*!!=P7?TP028 C)P<, :_-;2;=;[E=\S^CB2T=:XF608XYM(Z_J6,,-U<V
M?Z@>CN^,)^W9TI?Z7;]QN3Q.1W@E^?#1N?*8"2Z_YIVUE,.B(N'Y4UM'U*OE
M>"%#E(255PMW^ 8S3Q.QNXMS!K*\O,T[(NAB P#-5-;@"1AD%O\ T;B*[9)R
MZ[BFVX@B(4TPF3#_ #!0>;34M!P)JNP;>R/4+TO](\SOKUT3L]U-VUO*=C\!
M"Z;;AS\K(9!,Y3;ST>7A\EG5Y%O%JCH0OSR$EMQ*@+%7*:TV?C7V7_XZVUW-
MM3W?R6R.<V=SVU.N(D5&D?544H:'HMO<?@;S<FQ<1DBAOXVUDDC:!&&&@TN[
M=1R[PNSXS<6PO7-TAW!T:],^ULCT'=QT_$Y=P9J7C9\3=\#'N../8R-DXT?'
MLL_3.K0MUE:>=:4\R20DUA/9;;N^U_TCA%F(KX/US,FF'JS, . <2&^4T=I_
M>IW46VEDO]AW9N[<DG-Q"6ED;F-PC<:&ND]H!;7I\5;9NR=X?MI]-U[[Q'_K
MWU1WSE8>W9..^@1N/;+&.\E<QZ;G\?'=Y768WTH$:ZT+#JQKRW!V=M!R/V_8
MV[W'\,VZN@6LMW.;)&&#$F08BM::0"#7&N"QFN=NYO?_ (2)LC;2!NMTE*/+
MCY0&=Q!-:].]=FVYU6P_J7Z?*W/ZZ\/A^G.T,1F4KZ=;BPF F8B&)DN.&I.)
M=V]!>ER'YDEE)6W):23R)4E:0/FK=76Z[=SRT8_DUS^ CM*MCD@C_E$NIJ9Z
M8Q)- 014BE#AEMCMUWQ>_+>.-_$33-_F1O(+@UN+75%*"M00:="I]4>D47U#
M[ V;MST:Y;$Y?I-MC,SH^[9C4*;B\O*W,I,=N.G)XZ4PF:W#@P5J<:YTW>6Y
M<&R:XS=^-S"R@M.#QW5_M;?-)*!YG3'(.;FUH'TUS)<>B;=O(M=PGN>5N$-^
M\ ,:15K8^NDBHJ78'N [5<<3U*ZJ>@K XCHWT_S$K<NX\U'&XL_C,SAAF\+B
MI\U2V8\+"P'B%1)4AMHN/!*[!'*2 3>K<\^Y5[<OAV"/0+]S1).R4:A%K^AH
M%11Y J[NTBBPAV':N9.EW4ZH[1KBQA8=)?IQ+CA2@)H.N>*]/?3XQ,Z@[4A;
MMW1A<#TRW[O2$W.WE+GR RUF)4%*HT"8D(:5*9^HCJNEE966KFQ KW'VZMX=
MPL[OEQ@%KR'=W,]=]:^IZ3=+7L:3Y&NJ2X-PU"O7#QSF#FV]XW9X)G3V%G4-
M[BXU+>PD',]5JCZO=RS\3%E;(Z7YW)9'K8T^%Q\ V),;9^5VVJ0VS,>;W=%C
M/G%9="B'8SI:>1RI4A;1YN9/2^6.M9-R,45U<1[S:SZ7 1AT#F$5/GU#4:TJ
M,*9*;.TLB]:5D;K1S3B31P([NQ=!]/>/]1^WY,.3O'>IA[:R>,6SN;9LM2]P
MS)D[S5/1EC<CS<))88)'RIBM:ITM<UH[;=;G%,7MN'>A(W0]@: QS:U'E-2#
M7K6M%;TV4D9:V,>H#4&N(_:MNU=0>F&S\C%3U%E.+1-CR'X>*C?5(ER66"A,
MB2TXQ&>2X(ZG4@M@^82H'EY;D<T_?>,[;<1MY&]S8)*ANFHQ[7' 4_V@:T-"
M*KC8[*]N&N-HVI;GB/T^RBQ)U;ZNL]-V86YMN0,W)VUD'G@)43#93+S\='?;
M#N.?R&*Q$*7E%Q].1U3;"E-DA12!>W1>2[[=;=?Q7_&"Z2W;*[36C7.8<B.E
M1XXC%<IMMC'<M?#>D-?3MPJ,\5UOTU^JG(=;IVX9;@C2=O[?E2,:UF&(F2A)
M5E([I9DP1'S$+'3V7XH22[S-)%R +V-=AVGW"W3<-ZAAW8/8+=FHA]"0YP%*
M$$TP[ZY+3O\ 8[>UMM=N:F0TP[ MV875:-CDA*,@VW;4@K2#K;QKVVVYO92L
M F#7&F:ZP=ON&8,K1<L_JG'S,61%>GM.MK9=*T%:.4!+:U%1[ $C4FM>?DNW
M7MK-:!K0R2)[37L+35:8M;EC@XYAP6GK75>!U&BRML8W:N0WA'GH5$?@1L*_
MDH;J5<R"EU?D+BM"Q)YE*3R\;BO%..;A=[Q9LMH8G35  #6EWW T_3%=IN+(
M6;_6?(&4ZDT6D>]/03UEA9K*[GV_ QLO::V)67@;7<W(EK=6.*$./IP1;>B.
M0'RHHY4.?4J6FX2H$@D^@Q;'N^V0?B9K9WI!M=((+A3'*O9T6F-ZLIB(B_\
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M=M3;64=DXR,X]E%8&)BT9&8]]1(1!@..*=::%@ADR77RX[R <RJ]+X]#9PQ
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M405$"VW]NOZKRNU=N7(B^38'!\5O&[Z) 26N>_M%/*PUS!(QRVF^"UL)1;6
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MG_W.*)WKL\S210$=,?[RS@Y3N=^W_36U;=,=XBI/ Z0!D;XP?*[4<A(PZ?\
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MV%"@9;.PLP,9D(F)QCTP1).[<8N!]-+W"6) #0C*#'EN/)*R4\>*EN+&"/\
M$Q0!LM:@D9'MKC]RUH>)\KDOX]IWK=#+LKP06M.+@!_ED4PH,:ZC6F%%BW&>
MN+UE>NSH%OG;G3W93'2?J/TYS6(ESWMOX7*;6G=1L.LO&&N!DERW)&'=QF4A
M_P"U-1E .%3:KA)*:X[=-UO9;0"'"34"=&)IT(\.Y9V7!N,;#NC;BX<]]JYK
MFL$Y% ZF()P#B6G GI55FS?2_P"N+UI=!I&QO5!O/<6'ZH;1W%*?Z8Y;*95W
M+%_;,S'L(R$6?'5Y29&0@3$E/G *=5'6E)58&N O8=UW=K(82Z0QFI#_ "ZN
MVA.9'ZUJ2[GQ?B%VZ>)D,45PVA,(UZ' X88T:X9#*H/:NZ[=]$WIUZ*]),7Z
M8?6YUTV\WELQF<AO':V3STU_&3\-$G_2PGL<)4-I]>'Q<G(1UN,*D*;0I:W
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MHK2OTL>I/=C73_<&_>LN>QV\>B,>4S#RZLR((<Z7?5N2)4;,L><A2HLW&&1
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MCLKTO>H7,S=YYKI$Q V3MSJ'+PB<_BI,AA02G$S<LW*&0=,"4[]/]065QC8
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M'U)(74QJ0YOF81EB' $+3M(+BWNXYG@!C7BOAU^%%XT[<_;^]2>Z!)RN^?\
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MRV.7;&PWOJW!]*!A8V5L6%72S5:6E]:ESM0:&@ 8FJZ3R#=^3[!?-EEEA>
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MBV;BX[_M[/NK%8.5>RHBWMP%1Q%5@KDV?'3X6[>WC4'8I@%6M+.O,JP O<V
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M*>8@5M)[*&.PK-<7GH-&IL1:T--,::P:T[ 14K 7>]FXT.BM USJ.D#G$@'
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MI+E<%DM]=%MP;,BYLN[JGIAS%,0):5,_J>)=$B)MZ6XV5LRDN2$7>0"4I=Y
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M8@45(XH::=E@/MU^^J<$5,H]E8+(#JJ9Q7QTO;P[_OHL@J)Q5A<GCI?X>ZJ
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M*ZH_;>360FW3D4]BZ2WN0(XF/<]SBVA,[21@=1\K7=E:#!<G#N%C*UEE:0R
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M41%$11$KW%QWC\JJJ15K;M[N^HJ HDZV\!\/"J*YJ@?-(\;\/;2E31**)5J
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M_:N:R&Z,^ZXU)R4O*SWF,&RH>6](3 C,-QX\-LJ/+)D)YE<X 1S\.1W%\$,
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M#35=<MA;9Z5=)>I\W!9'#-1_IW<P^O%/JDQXC428RIM[S"S;E3'->EW1[>6
MZA=+=@;SVOE\OG\!N#:V(FXS.9[&9K#YC+L"(W'.2R./W#B<%F6I,UUE3BE/
MQ&"[S>8E/(I))8G T62**(HBTZK:U^:W**(BHB*(BB)7[/"]55(G0:VU&MJG
M<BCK8V/X7JC[5DHWMK<6X:<;_93$X4Q11*AI8]HO[NVAKU56*^L?4_#])=FK
MW1F93<..]D(N(CRG_P#4L2IP<\E2R3R<Q#1Y>;BJU<]QK9G[]NK;&,$C27.
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M024^0T2I$5 3=+8LTRD$]ZJ_,KFONO[G>_6X'9MJ9)8\6=)1MO%J&L' >J\
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M=YCG 95'D(=CR8LEMZSB%6(T4A0(KYI]U/;SC?N/;06^_0M>^V>YT3B*Z2\
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MW))KG)X7,-1T'Z?IT7I;(,!X+4#.]/\ '[AR$>-](VXM]]')SM"Z2IQ1-N4
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M_--UQ"ZFL92,&L>)HJ]*LE)>!_AD"]$]F>JKI5N]IHJR+F$?=";)E\LJ*HJ
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MHN_8V:Z4=+<HU'R6V-NORDR]Z[APTQM#\*=*E+BQAA,?.BE*VQY8D.-*2OY
M1769H'2-+Y3Y.@'6BW44A(K(2!T"]7,CZ-^B^Q<%])C]J09$AMI0\YYGZN4X
MH(5_BNR9!<=6Z2-5*4=3I7%2VSJ$L7)6S&2_2T47E/M;TU83:W[C?I1ZBX:
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ML#A4=@K]RI.LO3UJ4WY$/)N0OH&GHT5MZ+&FLL-)T0VVB4TXXA+-_E2E00.
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M=5*-=LAABMXVPPC3$T4 77))'RR&60U><RKPXY_=&GY^ZU:N2TP:JF)[345
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MY4W)#F;DX1V6,GG'W(J5-.KBRU1&X;8YD\J%BW-R*KYT]Y>;NN=O.S DSSD
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MS.!S\I 8.\.>X$@] 5Q^\7QMMO?.S"2FD>)P^P+ZJ6'Q%C(0VI(2E( 2 $W
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M'CV>_N%ZQ(JMO)'FKPG&X:;.B927BL;*R<%)$+(2(<=Z;$"C<B/*6@NM7)T
M(K1(QJ>BT1<7443K>.1[8'?4T.(:?$# KN4>5>P5]HXCQ-ZQ+:8A;(CHKRP]
MP&FO#W'A\36*TG-IDKBTY8C733@?;C6)6&.2N3;M[$?P[OOK'Q4HJQ"_$<+\
M?;6HL3ADJA*K]ON-50CJ%4(<Y>))_#LUX\:M:C'-8JI2H'5)^_7[J9(N4+L
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MKV+73U!]"3U>P2G=OY.#@MV1V^5MW(P(V2PN99;2KR8>8@R6WD%;1/\ A2$
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M/4X-'2N:Z/$Z>Q>D_7G/3(F,;P<-Y6,RDK"+'D'&IR+ 6E#+)#21&CGY"E(
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MSG.( %2!WD@!5.U]Y[=WS@X>Y-K9>-F</-05,2HRP0A8T4P^T;.1Y#9%E(6
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M(D3K[A]O'[:=$45'7L/L:+(!0J+)%Q[J**!XWN;7/$Z$#L'C62>.:S'T.O\
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M]/O50>S\N'A5%:DX54R\%$JXBVOW'Q\;UB 2:U11N#8 :GB;?A61.'>IDD?
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M<[$B;3>DYB6RE><G\S:7E"YAPU*NEAI1'R+>(NX1QX<!6H(FM'E7,[UO4NY
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M_40H9C-SU*4@$F27236]AV3;8""QE0.A)I\AG\:K1DW.\D%"X"O4#'Y]/@O
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M)0DJ6ZI:_E2VE )5<VM5UA@+G$!@Q).  &9).0 S/0+)@<7 ,!+R0 !F2<
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M<E)*CSQTN[<06HI ORE3VY\@5WUOY7A77(XQ>[R^X=C'%Y1_LY_\I>]73_\
M2/M%'9-\NX;D=3NW^<0?LA:!\5ZM(D$_U'4GCQOP-[\+DUV'HOGXL52EP]A^
MX5BL:8=RJ4OJT 5[M/Y4H%,>JJ!(UUL/@?[:E/DH1AAFJE+P) !XWMI]M3Q4
M(7,'3I]]OL%J*47('.'S7^W[Z(M)/6;UTV!T[Q.U]A[NR Q60W8\]N6)DY3C
M$;$8_'[8?89D_727W$<K\U[(I;92GB02;"OG[\R=XUGMT^P9%-+<R7,$@$;=
M1 BE;7 8FNJ@IWKZE_*AQN_O^?/Y#"^)ME:V\L+@YU'.=/&2W3THT,JXDC,
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M_B29H?#2M;TI>W[5H^I%^@4?^5?5+_S@/_KDF?PIZ4O;]JOJQ?H$'I7U3_\
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MT\G]DO<5F];>"R^L[C4,],C:U(-*59*TX]QKFOUPMKKCGO!P 31:9-JO[:A
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M2PN;_F:Z\L4OE-C[@./PIBBEX=MJB?<H7-M>^U]/LM460"5SV'@=#PM;A1*
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M$F][=]B+VT[>.E*41(FUM.S37W=HI6@PS11*B>WL%_?]E04ZHHFVEA[]>/\
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M$P'=H&NE@/4N:*F/_;&0_B 7V5[.^Z!X;+M>[7KO_P "3EEK=_W&N/ILE_\
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M*UMGN.<T('\LGZXVTJ7-&KVO\R/M+MES9,][/;H,EXKN ;)>1Q?3%)+2ERP
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M%5&_A?XU*J52/#3C[:44PIWI7X7XGL_&HHD=0=+^'#N- B.'@!_#\J*_>EV
MW^/=\.V],DPZ*.EO'MJ++JE>Y'>>_ML.&EO"B)$@?E0"J&O10-K <!K?M\:R
M':G51O?W]_N!^^K1$J(F;:6HF*5[_A1$41%":(BG<BS7T&_XRF?]@3/]]QU:
ML.#O@M&?Z/BMO:W*VB*(BB(HB*(M([@Z]E;(GH,UOD?'C[6J4H>^BJ1%AIWW
M/N[^_LJU=FHN,D&_??0]ENRIUQ[44:&GQ1%2F%>B(IX(BHB5$11$41.J:YE$
MKZD=U1$41+F%KGAWVTHBBJZ4E0XZ:V\>[W5<_! H<P1V'P3_ */QO_>O3-94
MJN,D$'6P' 6XW.NOA5ZIXI"VMZJ&O1!%NRPHJ/M0> UO\/S[:B=4J(BJB*(B
MB=4JB=:HJ' 54ZXHJ*I5$2)M;7M'Q\*!.B@>[O5>WA67[%*_) U]PX4^]#]J
M\[_W&>CGJ0ZL=,]IK],T;;>>WCMO/S'<KM#<N:B;=8S.(RT)$4SL9E\@48YK
M(XEYH$M/+0'67%<IYD@*\7]Z?;*?W,VJQM87G_<KA\GIZ@T/UL#:U.%6TZD8
M$KZ"_+W[J;'[6[[?W6^0E\%[;,C;( 7&,QO+Z%K:DM?7H#0M%<%DCT(] =X^
MG7T^X;:/4N9B)W4_<6<S&^>H*\$[]3B(6>SOTK+6%@3BEO\ 4&L+BX##"GPD
M(<=2LH')8GMOMOPUG!>*Q;$T@RA[I'TQ <Z@I7KI: *]M:8474/>3W";[F<X
MGY) QS+%L3(80[ ^G'4ZB.FISG.IT%*XK<<WX'L]U=\7EN&:7Q%50GY)7'MV
MT2H*-;<:)C3%*_C]W"GW*5(PJF?#CI]]0]ZI[LUY)>MKJ8K%;ORV.5("&X3<
M'%-)*K<J$Q4R9 %CQ4MU5_?7KO!MF$]@+DBH)<?U!:S2&1@KRIC];H$'JKTV
M5-G-QX8W]MAB0I:OD2T]F(K"E.$J)Y$!T%1[$^ZN>W3;OY#V@>8M/Q6'K4<*
MY57JI(WPS#SBX3KEN1#@6G4GG\YP<UAK<% %;NRV,3;>V0?4:4\**.BKB5:M
MP]3(D-A9-OZ3;S%<M[<=!XUO[;CFH^8_)2. #%:J9_J<K-;GQ\*.\"5RTGE0
MJZ4-M!2E&U_Z4@:DZ7-<QN&SPV.TR3.&3<SU)6Y:\#R!>;&]^N6/W!U\WT[!
MFH<A8O*M;?COMN<Z'OT.*W!?4CE!)0N2TNUM/NKR>.R:^8X>;]?>M-TP]0K9
M_:_47ZJ&T1) 4E*5I2'"L)6/ &R;$7]_&]<[!MH=0TQ6NV8XT7M-Z!=[?KVV
MMV87S.=D.P-QQ6@5%$9UY/Z5E64<QMRKD1VG-+#YJZ!S2P-I=1NI0D%I[Z8C
M["L;KSM;+U&'ZQ^M>@QO]_AKX5TI;)%$7GQ^Y;T\5N_TW3=WPHX>R_2?<.+W
MHTZE/^,C!.K_ $?<;:"+'D^DFMO*'<Q?LKQKWXXX-_\ ;Z>5C0;FQ>V9IZZ?
MHD'R<"?\*^B_RN\K/&_=2WLI7EMEND3[9PZ:_P#,A)_VFEH/][O7SP=0W1/V
MUB,ZVLE[;^6:YB$BZL5N!"8\@E1YOD8R45@^][CK7PIL0-QLMQMS\7V\@>T=
MC7X._P"4&_-?IK<$6?(HIQ01W<)8X]LD7F9\2QSQ_LKZ%OVR.J*-_P#IIQ^V
MY$I3^9Z79S(;3EH=5S.MX>8M6:VVHWN0TF#+6RC7@P1V5]T^PV_?UC@$5E([
M5=;?*Z!U<]!.N+X:26C_  K\T/S4<5/'?=:?<HF:;'=H&7+:# R >G/\=;0X
M_P"->A]^_3L]]>SKYN2)3KV'A\.T?&KW(HD"UQW_ &:<.-,:]Z+Y=/W0=FS.
MCWK88ZB8%M['L]2L#MGJ/C9K=T-C>&VI"<1EEQU((_VA$K%1'UB][O ]M?'/
MO?MDNS<S9O=I5KIV1SM</_*QG2XU[:L:?BOTJ_*[O4'*?:J3C&XELC;*6:U>
MTX_R)FZV CL(D>T=S>Y>U7J.ZH[:W=Z%-V[\E,L9';_5?I'$AKCNH2MM:-\X
ME$2<T6R" ]#6^\ +$I<;':*^L-M-OR_8(I(_-;7]F'?"1F/R)^87P;#9[CP?
MW#_"BK-PVC=#W8V\N&/8X ? KX\^F&5_392L/E'R[^BR).%= 6FRW8KQ,22"
MJX0)$9)-QQT&E>2>S$LNW<FW'A5[Y7$F:,'H^,Z)FCQ&EV'\)*^VOS&;/:\D
MXOM?N)MP#FNC;%(X#-DC?4B)I_"[4T>("V$R&2C/LO\ TC;*?J&?* ^513S)
M0E7EG3B +A0-Z^IV[4X-RP/<OA2]#!@*4%5JON7I/NW*;J?WOL[ N9/#;6PI
M5NH1&UN2&8DJ:WY$MMA*5B0Q#6@J>L;MM+YR+7K;2V+:&*1H,;J@@Y$' @]Q
MR7"^I)!<LG@);(PAP(S!!J"/ XA=HV-N*/@X62V9DY8C-34N[BV,_(#P2J5%
M#C^2Q310E8NA"'&E FR04*-A8U\M;-M6Y>VGO?'96<,DFQ;JX1/#03_+>:PR
MT[87U:ZF.FM5]][]O&S^\GY>QO%]-#%R?9F^I5[@#ZD8TS1XXTG9YF_WBVF(
M7=#N)S,L8W*XIU+>Z=LN_J6$4IU#"IZ#8S<(\\5)0D9-E%FN<A"9"4\ HFO?
M/?#V@/N1PI[=NA]3?K1I,8 &J1A^N,=21@]@KB00/J7AOL![L#VXY>&;E)HX
MW>D-FKE&\?1+3L_=?W4KDOH;_:TZ^3-^-97:N8Q\_!R\AA4Y483)NMF9%E8]
M2FRZZTTLH9=F1@5J1<D:7[JG$N-<WVSVDV:YYY$YF_6Q?;%SP1(^!AI;OE!Q
M#] #37$AH<<2ND>^,_#;WW&O[_@LC7[+<.;*=/T-F>*S-CI@6:O,*85<0,E[
M+5IKR!0!)UO[SIXT61 "6E]=1[K5$Q(2T[.%%5%1M^)]VM4!#V*&H-^P\.';
MPJ]RA&"6NHOI^)[/MJJ]Z?=<=WNM^%%/!(G^/#A4R3)1_ML+55>JCH">\W-3
MO4K\T>\]M^%13-1O_(6X^-*)T3HHH7O_ 'ONHLJ=R"1:U[WM;PMWU$&:CX7L
M#QM;\[T5(ZC-*^ONHE1DD5 ?#[J (N,^^]_[*S"! ]]O;\:(E_&B)W%J)BE1
M$41%$12G5$J=Z+-?0;_C*9_V!,_WW'5JPFKEHS_0/%;?5N5M%1OY''QE^5)G
M0X[O*%>6_)9:7RF]E<CBTJY3;0T15#3S3[:7F'6WFE@E#K2TN-K )!*5H)2H
M BVAXT1<E$11%I&#>MA3'!;Y(G2]^'W\=*I1<?-H>.I/;PI2@JBC[&IGX(BF
M'1$5$11$41*B)TR1*_\ &B)=H[N^_P"7;51/@.\_ 7J(E>][Z#36_&B*'F6!
MLDV''7OK(@UQS0"JXU$%-^;AP3Q/'M-]:++%0-^WB>V]56M<D%1/'X^-%*8U
M2[J*H^VB(HB79I2BA.&"*)CGT1?N^RBE:Y)6_C6))"!N-4]?;VTH#CW++%+Q
M]OMJ$U^:8YI%7N-SW\*43HH<QO\ &WPK+-3H@WN.ZX[?OJ?>@[$=E[^([=>Z
MB )7/WWJT52JHBHB6M53%*^OAV&E%-6..2>EO"BII3N4;C2WCI?\:%8@C"B.
MWM]]ZA)& 04.*6HMXV_G]E0T*F+33HOFU_=$S^3VUU<SD?YD-2<FU+0\NZ6D
MQY.(CO-+4;:C4@"_S$6KZ9]M8X)N+M>*&1K7#XAY']JD[R&MIDO /JAO21/E
M.?2YF4A2'4K9<C\B76G4K"FW$.W/(MM:0M)MQ%:FZC34 +:/?7JO<#IOZB8F
M_NEG3GJU)*6968@_Y=W>VM+B$8[>>%:8CY2.2Z$GRIZPF8TK5*FY2;$D&N5X
MOIW"U=8-_P#:8>G4MZ'O[/@N2;.TQ!S\C]ZL?4KKUBY$1<=B0AQQ:#\K2N==
MK6N$HN;7-=WL=E?&?4E\K1VX+%]RQHTLHL![K5U;VKT.WOUIP^T\Z^)BGMJ;
M>S7T3YQV&?FQW')$MZ26U,KR*8B2IIG^H+";\"*Z%SSD=AZS=EM'M<]HU$ U
M+CE7N:/M*TV%X89/WEXQ;2W'DMOY-;LA^1)"Y"GWYCB@J0Y)=65+<E=H=<<4
M;D_U6KHMC%Y@3BZN*V9>0<%O1T_ZKJ=98"I*5!24WLON '&Y%TB]=XV^T#R#
M2JW#)>U?1E^TSF7<]!WO+YU*:C8KR!<FW^-FFEI': ;MFPO7FWNO;"VDMV_O
M.)/_ "5N=>J$#O\ VKV8N-;Z:D<:\>HM-''@>SA:]Q^-$77-X;7QN]]I;GV9
MF&D2,5NO 9?;N096!R*BY>"_"<N-?]7YP4.T$ UM;ZS@W&RFV^Y -O/$Z-P/
M4/!!^];[:]RN=FW.WW>S<6W=K.R5A&8=&X.'W47R(O;;R.-E[WZ69X!G+8:=
MN38>3"S\S62Q<QZ+#< .FF4@LK2KN]]?F<;"3C?,YMHN_*#+);OKXEH/_& (
M7[,?U6#D7$K3E%AYV&*&[CIU&D.</BQSFE;H_M!]75X/K9N+IMD9/T\/J5L]
MXQXCQY/_ %MV4Z9K+24FW(^O#OS4D'4\G?7O/L!NCMJY7=\>F=2*\A+F@]98
M22*=Y89/DOG7\WO&V;QP.QY;;-U3;==!KG#I!<@-)/<)&Q?,KZ/>?P^^OL(8
MK\XU'F.OCI\/?\: =41V<?AV'[Z=47C=^]!TR&<Z$["ZP1&_]NZ2[Y:@9)P)
M-O\ +6_$Q\8^MU?]QJ+FX,-5SH/,/?7B'OML@W#C,6Z,%9+2:A_P2@ _)S6_
M-?5GY2N4?TKG5SQV4T@W*UU-KEZMN2X?-CG_ ""UTZ<=2'^H_P"U7FL>F0<A
M_P K>I3^T%/H/F,G$.<N>QD<._,A9A'-EL@?T )!KN/Y:KN?=..0;?=AWJ6L
MTT+:X>3"1H%>P/(^"V'YD=GM=G]X9;^T+?3W&SBN' $828Q2$TR+C&'=]25\
MXP8W,G>RLNSE68F"2^')D%+9^IR+K!4(Z7%D<K26DK^90/S63W5[C;^RFV6_
MN .>:Y!<MU$1B@;ZCFZ'.)Z@C$MI35C7HMA>^\6]R>WKO;_1$=O) ]0XO]-K
MM88*X @X!W9A3JL]P-Q2I)B1&$.NR)CB(T)EM-S(==4$)0CE!YEWTN+@?;7J
M,VVMCC+B*- _4O!;FX+GU7UD>@;TM[8Z6] 8,C=.UL?,W;U-A/Y7<ZLQ%:F/
MKPN6A,Q(V((?02Q#D0&PXIL &[NNM>+;U?NN+YPB-(6&@IVCK\UL)'FM!DO.
M;UH_M8;OP\_*;[].L5_/[<DN/3I6RV;.YC#+5JMF'&\Q*\G#L+)6VDNI0 E:
M56YJY_8MYVV65C=T:QMRS!LA:.O8XBK:]<:+<1WD[(70,>]L3OJ:'$-=3*HK
M0T[P5XBY_![MV-E'L5N_:N8P>1B.K8>1+QTF$\VI*K**@IM "DJ["+WKV_8X
MHI=,D#FN8>HH5H/F(S"]=OV@&]Q9CU 3)3#$I_#X;9^6DY3();<,2,AY)C06
M)#_*$)DOONV2DZFQM>U:7N]=V,?"X[0D?BWW#-(ZFF+CX ?):$;BXFJ^FFY^
MVOEE:E E[M/C>B42)-M./ 4'>BB38#M-K<?Q^(J@(HWO<DZ_VFLD2N3I?Q%,
MDR1P]_=X]_PHIFD3WG[Z9*J/'\./CQHH@GX?'L&E10GL4;D\?85%$?&B*-S;
M0??P-16B1.FNI]_#WVHJ!V*.ONT]A0*E*YM>W=I>K1*I&]C;B"/'VXT%.J)<
MVG,=2.P?9K5(QHBC\PN>WM\.ZF&25Q2-[Z\:H[D2)OQHB*(BB(JHBHB*(E1$
M5*JK-?0;_C*9_P!@3/\ ?<=6I#]=%H3_ $?%;?5NUM%Y1^M+8>U,KU9PNXG]
ME;4WCN>1,Z2[?_2M^^BK:_4+9^7P>1WS&QF8QV5]3^]MI':NSTC!Y"6MMF3F
M0O'O!/DQGGI#;#Q9M.']J].MI[0VGL+;V,VCL;:^WMF;4PK3K.'VQM3"XW;N
MW\2R_)>F/M8W#8B-#QT%MZ9)<=6EIM(4XXI1^91)+#/$KL5$11%I HGAQ]P\
M?>>ZMAX9K?+C[;]],L40:''%$5,$2HB*(BKDB*B(HB*(BJ*(E< ^_C;X4\,D
M1VG4:6^&G;41<;A^46(L?OX</=5"R"X223<]OV:55<$>'8+Z_?54"+\+\!>B
MM.S-&@L1]G=13/ I5%45411$5312OS2K$THF-45"<,%0$JQ*(_&WQHBB3H>S
MLL1KP]]4#%%"_P"%JR4HCNMKVT53OX#7C\?&_"HIT2-NRKB@2JJHJ(D?LUJJ
M'Y(X>ZB9'N2OX:44KW8)<+6T]_;44RPR2TX Z]G?XUCU4IA09J-S8V&I[+<-
M>VA[4'9U*17P'VGC[NVG57-M"M$O6/Z%]G>K=B#,E[DD;/W+!AC'N9!&/&3Q
MV5@M*6N(B;%1)A269D)QU0;?;<)Y#RE) !'<^,<SO^-,=;Q-$EJ]VJE:$'(T
M.(H1F",\5'!KQ1^2T4Z>_L5=%<%E6,CO[J'F-VLLNEU6-QN'3##HYDDI^MR4
MZ>&^:P^;Z=2AV&N5W'W%N[L$00-8X]2ZOV "OS6#88FXT)6Q6>_; VG,WWAF
M]L=4<KM/T[HP+.-W3T(9VQC)KV;S###S/^9\?OTR(V4Q6=<6I"TR5,2'(W(I
MMO\ PEEL><1;KS.SYA%RK;]XGAMV1Z'6NAIA<#G@*4J:'407"F!H:+O%OR+C
MK.&3<;N=EMY-Z?+K9?B1[9F=C2W$.:!4:06M=4%PU %4G3;]H#TO[ W4K<V4
MSG4_J(AN6)<'!;NW#"&*CE*RM#4@8G'PY$YM/ W6@D5Z3N/NMRS<;?\ #ND9
M&"*$M!K\*D@+H[8HVFH&/>O1O+],NG^;V%+Z7S]I84[ F8M6'<VNQ":CXQJ"
M1\@BM- &/(96 M#J3YB7 %7)X^>_B[G\1^++W&YK4N)J2>_M6K4UJOEH]=_[
M.?4'IWF,QU*]/<&9OG9#KCTZ1A8<?SMP8-LK4\ZU.@Q@IV0VR@?^%M(+:P+K
M2V;UZ;QWDMG<N;!>N;%<98_2? G[C\"5MY8=7F9GV+R-VWC]W;7RRL/G-MY#
M$S \IAUB9CGF775%PMJ;0D- . @]YKVO:3 &B1SFZ1CFMOYVNI0A?7'^T_TO
MW/T_Z09'*9K;<S%XK=D7&9#"YC(K\J3E>:?E5O1X<)24OC&Q00OSU62X7$A'
M-RJ->%>Z>]MW7D@M[8AUI;P@%P/_ #A.+:?W6@$GM=3H5RXCMV6#':R;PRNJ
MRF 8 *.)[7.)  Z-J<PO5P@7)L;]WCW\>%>;=RVZ=[C7B-0#H;^&O"HB+BUR
M1S#4>!]UZ#/!%\UG[AW3]WICZO<IGHD?Z7!=7\%C-[8UQ">5I>X8:48G<P3;
MY?-_4(C<A8T/^T ]M?"_YB>.G:^6?UFW;IBNV-E!'\;?*_XZAJ^-5^G/Y5.4
MMY![:?T&Y?KN=LF? 0<_2?5\7PTDL'^%8K]*WIW]3KOJXZ2=2.G?37*CI).W
MW%W[(ZLNN0_\H8K -O/HWIAWG$2@_P#JZ'URX#<,H+JU.)4$\GS#G_;CB6_;
MMONU<RV]CFV#GME=+AHPJV9I-:U)U-TTJ:]BX[W=]R>&;5P7>_;S>IFOWQEN
MZW;;X^H7&CK9XJ/I#?3DUUH*$9X+ZHU6YCR_TW-O=?3[J^RL OS62J=ZJ*$U
M1=?W7M3;.^MMYK9V\\#BMT;5W' >Q>>V]G(;4_$Y;'R!9Z)-B/!3;K2[ ]A2
M0""" :T+FVM[RW=:W;&2VTC:.:X5:X'H0MU8WU[MMW'?[=+)!>Q.#F2,):YK
MAD01D?\ @."P-NGTR=,X7IRWGT Z4;'VUL#:V3PF7."V]MV WCL6QN)\B='G
M.I!4X]+EY!A <>=6MP@ZFP &]XP+'C5Y;/L(F0V4,NHL8*#2?K\21U.*WFX;
MWNN\[B=TWFXEN;YP =)([4X@8 5Z = * +XM-\;&D;0W?E=FSL++C;BPV7EX
MB9B9<=\Y).08E.-+CJC\H<4YYB0$CE.EK7K[08RQN[9EY 6FW>P.#@<"",P>
MRBT)[LTH#5>UW[=7[;FY\]E\%UN]06WWL#MW%NL9/9^R<DSY&3SSR>5R)/R4
M-?*[C\2D *LI*5O_ -( 22H^'<[Y?9QAVU;*\22FH>\8M;V@'(GPR\5LM3CY
MG?5T7T9A*$)2E*4H0VE*$(0 E+:  E*$I%DI2E(  X 5XR>U8IW LJ^HX6.O
MC:GW(NG;FZ?["WHGR]X;*VIN<:ZY[ 8O)K%QV.2XSCHN/^E6YM[Z]M#6UEEB
M/]UQ;]Q6677!<NU=D;+V+#>QNRMI;;VG >6EQ^+MS#0,.Q(< T<?3!99+ZT]
MA5<BI<W=W>/]6[EDE?VO<7'[2:)G@NSWUMWWK;+)1)387![;?GVU17HHH_+V
MW OQM?373C66*()N!I;L\+:TZIU2'XFWC:A0H)]O"@3Q42>S2U11*X'OM3!
ME>_V5%"E?X6[_P ?=11($=G?K_'W451J>[CW<1]M$4+ZBU@!P%1941Q/B?;O
M\*H2B1^_PX? U$4=$VM<W[M>'QJXE50!( TTK+[U*=4AKH?@>[B:(EV#OU_E
M3JB9-^RUJ(E1$4JB*(C^'WU*UR1*K5$5"414K\E4JBF2S9T&_P",IG_8$S_?
M<=6M!]?P6C/] \5M]6[6T7CCZM-\;6VUZSNG&?8VEN?*Y+::^FV WAO#=&?V
MAO'I_M'_ #+E<ID]O-; Z&;^@9')_P";YT%I_P"MW!M#(;6R3G,RP'<R]&5
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MBHHDZZD_U7[Q;XU42T)/\O[*J( O[<*50X):?&B(]]"B*$51*A1.B)5 "B*
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M"G>B6I\?C?[N-$2]M*=*HBHB5$11$7U'L??[J(D#WVXVT_#7MJ^")\+Z^/\
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M*E;XV5]P_"L*J&@/<EWZW)TM:B("B/NMX5:*D I$WI12E$JJJ7=09*',(I@
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M^I19=Q2]O;[*BJ1/'2]NZE$KC1(DFXX<.WVM5"E2@DFXX<.WVM0)4J"K]O\
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C05S6%[<=+7O>B*&O;W'C\?OO]]$3U_\ N?\ I</;X41?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g382677f_34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_34.jpg
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MQ "1  $  @(" P$!            " D'"@4& P0+ 0(! 0$! 0$
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M!5.80\ /CF/GMC$O#7$9280D+%)E2BXB+C4BAX*DPCVC-,H!^ %(W23* ?\
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M(B,L$3*0,TQ;R<--QSV)EHUVF"K20C))LJS?LG*0_11NZ:K'3.4?Q*80Y!I
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M5+L/<D] TW,DGMQ,5LE)SL%/6&JN[ @S3(BU2L05Z3CT9<R#=,$BK*E%P"0
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M2COB/-"41A6*]<LLA90<9;TRYJAE1W58UR^USMC4^SU8?:_7&T[$JW[/Y5.
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1BF0W*SVN;[IR<.3@. X'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>g382677f_38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_38.jpg
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MQ #S  $  00# 0$              0(#!@<$!0@)"@$!  $% 0$!
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M\+54%4,E=HB41*(E$2B)1$HBD&UQY^WE[:@CBB'GQ-_;4HHHB>[\:*0KR3<
MVM[/*J#FBFH1*(E$2B)1$HB41*(E$2B)1$J<T2H1*E$HBLF_CX56H4'[_O/[
M/(44I10E$6-5BK*2B)1$J$[DJ42B)1$HB41*(E$2B)1$HB41*(HHBFB)4')
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M:G!6WXJ[16THB41*(E$2B)1%4"1>WB+'W42JOLJ)42>03:]N  Y<JD*H&JY
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M4%N&&*N)-B$V!]H!ZOX5<\MVG$B@3&O8KOCP^^_W<JD&K '?#V?K4\5(MP/
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MZ79U;Z8[IM^G5<10F>/^*($D>UFL+Z0_*9UG_DSURVEL[PW:MXU[9<5R+;L
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MB<+'S\/WT1.(/D:9HHHB41*(M;=YMYQ';'M!W3[AY^6S!Q.F=OMNS\N1(/\
M:ZH6#FF''(!!6Y.R"FF&T#BMQQ*1Q(K W6\CV_;+B]E(#(H7.QYTHT=[G$-
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M\=$U_P"\RD;^_ :''^)OM5@[.]BR&]EQC^-0!8Y6+U3L.2+ J=D-I#T(&_\
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M/4/_ *U%0?=7DW5;/F^N["#_ )J!I_OS?Z%]:>D3OZ9Z']1[@</F)YP.Z*T
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M^1<,Q\J=HS:26O'BC<YN*S4^ZWG70+G%%$2B)1%()'*F:**(OEAL+?\ J?\
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M#G8\+<;<:**88*0L%?/QX'V<#T^RY%$(P595TGB?A))OP^Y-A<V \:**5&"
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MN0E742H<.75<\!SM;AQ)J521P5VI4)1$HB41*(GV\ZH(QJJ7#BW!W-/'\:'
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M@*:5<<[I5:_LK,MW^9$'<:+2;E ;>\>PBE23^U9A5Y8*41*(E$4CC_.B(.)
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MIRP#S#J% *;<;<N"D\4D$'E5;#5N&2QK^V?:7!8\<?9W]Q6SB;#V>-5K#47
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M.:[=9+&;YBULI)? PLE'ZHTW;XK/XEUX&WE7D?KELMQN_IO?7%B#_5=M,=_
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M+4$-MH2+J42 !Q-'2-:TEQ 8 222  !B<3@*#$DX *0'.<&M!+R:  $DDX
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M]I8\L.8)'N6;&\2,#VY$5]ZO52JTHBH<<0RVMUU8;:;'4M:N21^TDGD.9-2
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MDV79=>TW 93:-KS&.U[7<'$<G9;,Y60B)!@Q6P>IQYYP\U'X4I2"M:B$I!)
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M>>=22ZLN%7&R?%K?<=__ *Q+O._ .NI&%KY6%C])=0.+@R0D-:T!H8UI\(#
M.?M#^E^DK3IBVZ3Z3C+-LMGL=%;O$C"X1U<T,=+&*R/>3(Z5[@3(XR.=CAU^
MNR7X>W36Y.%;GYQ2XV$@1RPAW&8AJ,CTY*&8LAISYA#;:>AM5DIZ25FW7:L[
M<V-GV:/Y:X=%8,!ED>'$/D+C45<#@2<2 3B T?"L#9(F0]03'=;1D^Y3.;%%
M$6!T<08VA#6N!JQ@P:\@9EYH7@+E;-W/@86-)=VKY]S68F8;:. A+#&3VC/Q
MW?1BX5IIA2Y#S*W_ (G4,H<6EA)L$@DU78],^8Z-NV/C9NDD'\YP+FPQ.%2\
M<-5,&DEK2\XDTHM9NW6<DC9I=SM9I=F@NZ1VH<V.2:>-Q:UKG$U:TNJYP:'O
M$8&EN*N;CW6S<J'C\QO&"V36V)T1U_0(DG,0]7Q6/FM(3$*UX[#9B1DL;CL=
M"?NDN@O/*N#Z?45IM;%TO8M?)9=.O@F,3P+QXC,\KV.J[XY&-:^1[@06M\+!
MD'4 .NZ[ZNN8;>'<.N726UQ<,<[;6273K&WBN&@,=1L$CGQPPQO#@^0E\AJ"
M8P2X:6QD'-:ML.LY6#WFVK2-7AKDY[;]CVC(2E0&I$KICIDZ[%]%_#;#G-AC
M%Q4=B.9<AIIL*<7UDI';3G:]SVRZMI-FM[_=' 16\,#6AY Q(F<2)(8HC3S'
MO$;'.-&MH*GYVCVC?^D.IMMW"#J[<]BZ:@UW-_>7TKC"7/&EKK)K6NMKNXO&
ME_DQPNN)8XVA\C]1+!Z?U'1V,S@X^<[6Y7_6L$Y#(;*]E=X[?ZSF\YM&<2'W
MHAS&RY5F!DE8]4IQ/PR'U*2$(2E24H*:\HWG?G6.XFPZLB%E-Y380RTO)XHH
M(L ?+@C+F:Z#-C #5Q()-5],=+=!66[=-MZA]-+T;M9NGFNO,W/:[.YNKVX\
M3F^=>3-BF,1>0!YCR6Z6-:]K6%JZK"X_-;&IB1N>;QV,S[D%Y@:GV%9:U;8&
M,L\J3'R,?.R-4<G1G8+*4)0E>1<CQEJ"E^H$V)S;V6PVR(Q;);RRV8D#OF-U
MU3PF,!KF.A$^@ZSF1"'O H--<%JMFVC==\DCDZTOX+7?#;T^1Z9:VTNH[A^M
MLT=R^S=*TQL:&M#KM\4)?J=K#:$[[[<]O^ZV/PL"+.WK4&HF.?>&(U;):YC]
MAE-8X%#D%6QY77LUA(DS,1W2I1;8;5%0;7+BAUUYQU/U!TA<[A)/!87CII6#
MS+ADSX6E]*/\F.:.1S8R*#4XAYQP:,%[9T+TGZH[=M4=K=;UMK;.%[FP6LUI
M%<R,@P\KYJ>TN+:-]P#J+FQ,,3:@:I' O.2X36=TS>U;<,GW%D8Y32\?%F.:
M9KN.P[\I*8ZG$-MR\P]LC\+TDNV*F@E1)N%#A7E^V;]T;'O>X':=EKN,7DLE
MENKF25KSH+F 11B%H#0[&M02<E[7O'3'7]UTWM<.]=2>782^=(R.PL(K61HU
MT-9YY+QQU%N!8UA;P*VG@M&UC7I1R,/'*EYI14I>PYR5*SVQ*4XD(=Z<QEG9
M4R,AU(L6V%--6_RVK/W#?]UW*+Y:>0,L<*0Q-;%"*8C\.,-:XC@7!SNU8.S]
M']/;)<?/VD!EW;&MS.]]Q<DN%'4GF<^1@<,"R,L9PTTP66\S;SK3KIUU/ZM'
M?EO8_'*3.EQU=$Q3)ZXN/5?BB7(3=M$D>#()<\P!QK-^2DCA;<W=8X78M!^)
M_P#"W/3^\?#R)*UQW"*:=UI9D23M^,C%L?8YV6K]SXN8 7:H'0$I/Q62!>UK
MGQ-O?6&XEQ)RJ5G,:&-#1P"D<?NN?V5"K4415)/2;D7'M\^?XT4*\A?42".
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M V&ZN6#[[HJ"WC<<3#$=1_XDA!+!]9$N?TH"0 D)0@ !*4(0D(;0A( "4(0
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M#A)DZ?ECKNX=SLI)_2L7@L'TY9G5_P"M#^-PLM.1.,Q_00/F);GJN/+_ *>
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MD-AQT6%#FY9#JK+C+RBW(S80D-H^ 6\SZ_ZMBZ<N@_888++J-EHV*)UMXC#
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M[Z]OOIYT*=O_ '"R*F8K2Q"P6!@#YC8=NSS]DP->US&MI<D3\C->4E("$*"
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MH!*BH))&WMF_+0>9/*'338MCKIKRJ,7.#<];AAB0 2%J9XQ<W(9#"YL46!D
MJ1STFNEI=6FEIJ< 2:+&LKHNVXCIR>-R"Y66;R%F\:B,EG(8['32#'==<R+"
M(S&92T4*>5')0RUU66I1%]G8[YMEP[Y>YC#+8LQ?4D.<W,>$U,=:AH=BXTJ
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M>3Q^(AH25+E9.8Q"82E(N3ZLAQM)L :P]QW/;-GM3>;Q<P6MH/MS2,C;[WD
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MAQ70RS&QN';GY*0MURP2D("B:\IOOS+;=?R&SZ!V3=-WNZT:\L,4)[?M//\
MLKZ'Z=_)1ZCW-LW=.LKJQV/: TN=)/(U@:!F2Z4QL  S.*UTCOE_N.]_DK;[
M0_3LYV<UJ2^&6]O[SRFNW/I,+O>6S@\B)V]3V&1\7]G'?'R!\L4'\RW79H76
M73>UN/V168#^)VJ2O=1;]_1WY/?3#Q]4;[-U1O3&U,&W--Q&7#[)F_#M6U_C
M=0+OL)_MR;YW(=:S7U;?4]O._2'O4<F:%VE<EZ)J#:G%A08=VO)KR&WY-I*0
M0HL-8PK)X6 X[C:ORW]/S7#=RZ]W&_WW=*U/G2N\H'L:233V-6GW/\WMKT[
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MD,>YA&<@A3KZ5QCGI"F&5R'D8[&LE3#K,= *UJ=-O1!203U*X5Z#=B4W1C(
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MD]X;$.^M&N^E=*[TQ_*_T(YSNL.HK"XO69PPO==R5^Z&1>8*]X':N<[]-?\
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M^A4]<N!$??D%XQWE/-^AB8^*R,=#2%*0AL%^1_:4$+*.KSZZ>VXD;\PWRIM
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MNXM"+6*W=)"ZI-&YDYZA4&I^E6)61/\ &26D<B,%3E.XF9VO#Y_";!GW=BP
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M#:CU'Q%UDG:Q;E;T;)+)&R<_;;$!Y=*!P(;@=5,_V+436<Q+F1L>^(#%I?\
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M=2LCG2/!.04V72T#J/WB.WETO+\&C4<<!))0 A@R:T,::57I7%X?M7KBG?\
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MTN,%MI).!+]>GN!P6[$-U(UNN:N&( TU]V-/:LHCM>@REKI93TWX,I6E'O\
M[BEK)/B236N>\O=J))/:LZ-@8W2 !W*]5"K2B*?MR^QHBZO+9K%8&,J9F)S$
M%A()'K+ <<L";--?UN'W"P\35N6:*!NN5P:W],ED6MI<WLODVK'/D[!@.\Y#
MZUXK[P_6QI.A-NP\7,:7/<5Z$=""F5D9,A9Z&F8D9KU1Z[B[!*$AQ:B>'&N4
MW#J5PK%8-+G\#^F 7K/3'I1>;F1/N6$(%7#X6 #,EV9',X!: QNJ_6#]3#WS
MXB+[*Z),Z5IV;N&U-&Q3X;W4?5P6DLK:R[MT %*IJL>T;@A2A6D&P;YO;O-O
MY#% >=:D=C<_?0+NI>I_33H"/Y>Q:-TW9F&B#2(FN'WYR"S/[@D/8O3';[Z#
M^PVI.1LMN6.R?>C;&ULR',[W-D_J>+;F-6*G,9IT?T=;A,>K<I0^U,<2+ N*
MM>NCV_I#9+ !QB$TP^U)C[FY?6O.^H/6?KG>M5O97#=LVTU'E6HT.+3D'38R
MN-,*M+!^Z%[+QT.!B8$7%8F#!Q6+AH"(>+Q<2/C\;$0!P;BP(;;,2,@?\*$)
M%=*UK6-#& !@R P [@, O*Y9)9Y77$[G27#S5SG$N<X\RYQ)/M*Y?._$</NJ
MI4)1%)\.%N'V-$3P]OE1$%K'Q/*W[Z(HHB41*(E$2B*1Q_G1$' \KT111$HB
M41*(E$2B)1$HB412.!Y7HB'B>5J(HHBZ!*B+#J*4^S^%25;HKB7K6!XCC\7C
M[.%2H5\+21<'GY\**5-QYT131$HB41*(E$2B)1%PYV0Q^,95(R4Z'CHZ 5*?
MG2F(C*4CF2Y(<;0 +>=6IIX;9GFW#V1QCBXAH]Y("O6UM<WDH@LXY)9B:!K&
MN>X^QH)6#/=V>WR%*;B;&SFG4GI]'6H62V5PKY!(&"ASTW)]HK4'J392/P9_
M.)-/P6OFQ_[)KQ[RND;T1U1_XFU-JVE:W+XK84Y_XA\9]P*ZN9W1G\L%VK[H
M;"2 4N-X3&X&.2>5W=HS&&6D$6_R$CRK#GZBNVFEEM6Y7%<B&11-]IGEB(_N
ME9MMT;9&IW+?=DM*<#+-<.]@M8)P?[RXJ-V[L2__ (D[)OP0?Z3GM_UB(JPM
MQ6C%)S)23X 7]M4MW;JF4?A[.V,G_G;R(>_RV2_6KK^G^A;<TFZB,I_Z#;[A
MP]AF?!]076RMF^HCJ5\CVE[>*1?X1+[JS$.=/F?0TM: ;>VL":^]1_\ PVV;
M13]^_FK_ +-D0L^#:O2(C_%;UONO]S;(*?[6X KAIW3ZC(Q)D=CM/FI%S_Z3
MW:8]0@7X!.3UF"CJ]Z@*L?U3U+C-9=GVN0?]'N+P?_JEF!]*R!L7H]*-,/46
M[Q$\9=I:0/\ Z*]>?<%UDCOCW+Q2E?Z@^F+NLAE )<F:OE-(VYD!/-26,?L#
M,]P6Y ,W/E6)-UIUA9'_ !G2FY2,&;K6YLK@>QKIHGGNTU6?%Z<="WX']+ZW
MV42')EW;W]H?:YUO)&/[]%:C_5SV=C*2UM\G;^V4A2TMJ:[DZ/LVJ,H6?\JL
ME-QRL5P/B'[>VL9OK!TI;"G4,6Z;0^N/SME<1,'_ &K620^WS*=JOO\ 03KV
MZJ>F';5OL8%1_3K^UN7D?]4)&S>S17L6\M9WS3-TBHF:CMFN[+%6 H/83,0,
MBDI(OQ$9YQ2>'F!7;[-U/TWU%'YNP7]G>L_Z&:.0CO#7$CVA>:[YTIU1TS,8
M.H]NO;&8<)X9(_I<T ^PK*NNQM:W"UO+V\JWBT%0IZ_9?[_Y413UCVT1.L7'
M[3X41"L7L!?[["I12""/#VW-0E%-Q1% 4#X_C:]$4U*)1$^U_"H1.!HBXRY3
M3<EF,Z?35(N(ZEV"'W$@J4RVKD7P@=03P)3<B]C9C[ E0,SFN31%QIC4EZ,Z
MW#E_(R5I*6I7R[<KT5?\88=4AMPCP!-KU(H""14<LJ^U%XN[H]FN^</$;G+[
M>[U#V&+L"I$_,Z1,P\&#*V1YYH"7*A2'E+Q,+8;MH6TX@,>HZVA74'!>N[V;
M?>G]=O%N=L]DT5 R<2.<& ' .&#C'B:M\6!(I10Q@K1Y\'<ODUG1MN8QFSZ!
MW9[H;Y@(D1,G8%=KMA;F:TYOF=F9</D;5.C_ />SY[#X<>DR9SGQMH:2PI2
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M.=[%O+6<M+S.'9GSVV42EO2F7?EUJ<CJ5'?6R7&5K 4M"^F]S4[==F]M1<.
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M)WDM']F+0/H68L,,16PU%89C-)'2EJ.TVPTE(\$MM)0D#[JV;6A@TM #1P&
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M,2M:KA+3A0E"@OTGI/J+;>GW1;3M_F/N7N+KB0-+O,+:D001D@ N^#S#3BX
MU!%#@1XLBOGUWRT!WLWE.UVF]V^_4'.0L.RR8R)\?);3%PD?UY#S.3UO6,',
MG'8='R2DA!:^7;?:6I2'6 DIZO5NG=T;OL%YN&R[<Z-[R:Z2V,O-!5KY' :)
M6\]1:<"UU:TL/?&VGG$:N>1^C/W+R;#F;-.;SN1T/2,3,&2GSI4^,YVSQ<_Y
MEJ-*D_)Y-<?)8D?H:7V72MMAMUI:&E)"A<<.FNKFVMKB&TW"6Y#PP!I$HIB!
MJ;\8+Z$4+M+A7(K&?;QF'YB 0:B<*ZM5>!( S[ULJ%MN<S>J8S79+>LX22J*
M[+R>NJGXK&Q426GPTX]\A,^1AQ%O&SGRX6ZH$W23QK&=!9P74D[F3N!- \QN
M)(IE4:JCA7 =BM,DD:RATAU*D U_U+$5;= Q<-O&2L)$VN+%DEAN!C\O*CV>
M5(7Z[,?)8]\(0AUQWXE*6ME(2.20:RF64+7@P3FV<145 (I3#P/%<*84 *QI
M72Z=>ESFD\.?>MIR=L[H3H3LC6^X$S7&L6Y%C+PN]8G2M]BI2E"4_)8[9G&Y
MCTMB.E 0H.I26^I(O8@UBQ6FR12!L]NV1T@)U1&6(_Q%@H 3PIGBK$C9G#5&
M[10BM0#]/Z46QM-5K32)<38\'B,%W&V!R7\S.[<Y60C"26V&5I<DP<"B=D]>
MB9>1'<4J8R8R/5X@I4$DUI[BX==RD6DSY=JA#<)F^($G#4\M:\M! #"'*Y"V
M@T/HV0\ <#W#('FMP86/FI,7Y#YJ+._0HV,DNSXT=</,SI+3K3465*PS>,=>
MP<B*PTV ^E:V$)(4WRZ1JYQ;6\OF4<V.=SFT)K&*@U&HNH\$D\ XG!W-5::
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M7$;".7"BR#"Z[#UN9%0)#K>.B+5(?:QK16I+2U=)E)CEMP2!&7_>Z2VXCK"
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M62+%UU0'4\^ZJZEK5=2U$DFYKZBV79-HZ<VJ#8]BMXK7:+:,,BBC:&M8T94
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MEW<5N;;Y6)WVG<A\(IVXEQ*[+#]KLPPI,G*Y'$[,TE"C'QLA.:B8Z%UI*?\
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M%(>M>X)N;CCR'E1%<#R2"3PMX>)]U$506D\ 1<^%$55[<3P%$4T14J2% I4
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M %]R9F(LE42"N&Q\;RG"\O@;#G;D)>F=J?=:;FSL(K-]<6.>'AW"C2T$@G
M4]JR?-W#R:M)8X$?$VHI['5KVK<^K][N\7<'7<>O6H$XY)N8E.2EX#37\QC)
M>,<Z EYG;\RC&Z\U,;4E84(S$P$\C7-WG2_3&UW[_G7L%OI\(?-I+7<C$VKR
M.1<YO<KXN[MT0TM)?7'PD>T9_3BO1V'9WY_I5'S^0;?;1U.,;0QB\C <-@?2
M6G&8G!SFEA1MUH60!X*KC+J796'0Z%CHB<XB]CAV@N?(T]Q69&^X>:8@]O\
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MZ,MH_P!0^+C-K=)96LNUO\US(KEWEUI6,'Q-KB"0]A!IP=JX'"=RB;+,R[\
M>Z(!U,G<SQH001VMIR5^#@ALD"./U%*A@WG5XT*#DM6.AN,(2[(;?RC"U2(+
M@>64H<ZBSTW"0+5AON&V,LI>TM,]-5/"'$&H&EAP>*#$4)KF5<?#\PR+RR"(
MFX5\1%<S4CX37 '*F2[EJ$_"F1\@B'*G/1B[#R,:2IQ,C(QUM)"7(D=U(CH=
MC(21U=)*^FX"> J@OU0ECG-C;@6$9-_B.?B/#AVJWI'FA]'/<:AP.%>5!E@/
M?2H70!6$S/S;<*4\F!-=M<]6.C*("4=;S3;@?>=1=:#U"RDDW',5M"R:W:R2
MX8//:,OB/=6E ,CS&55A1^7(YS(GGRR<3\(_;V=O)=B-5:D1HP&-$Y$20I>-
M=6\Y'N]Z26T*0 6U(8++12A2DA*K&Y/&V#+>/\YX;,V(Z!J  =05KQPSQ.96
MPBMV>6VL3G^(T))%3[,<LN"T]W &#P"G,SD,+B].VM;<\ZW/8F,/-S#)4S F
M3\A%@,F/)AQ/1*D>J&G77!Z39*5DCH^G?ZG?O^3CN'W6T-+3+4$::>)K6N)&
M+JT-*@#Q. ("U^Y?*6K1</A;%>FH93'56@)( .5*BM*Y<5KQ$S+[%*@RX4AU
M3F1<^::R4TQH#^44EDMJRBHCO2ZQ">#14VM#?00!T$GC77!VW64+H  6LP+6
M N#<?AU"H+L<037G@M7'!?W4C9C45R<X@5[:<!RP^E;UT33<1A6UR6MMB#(K
M+/JOQ8*)(<9<2DB,GKEI;3']7XDGJ5U%NZD@!-<+OV^RW1\M]L_R&UP+B*$'
M,T!Q(PX8&@-:KLMIV^*U;4.!E.9'U#L_8L/[I8# 8G8<?&R.]2($G9C'EQ8(
MC,2TJ3(6XU+7C(.+:_4IX<>2DI3$92TW92%+*@+9>Q7EW=V3I8K=KHXJMJ'&
MM1D'%V PK4N-3G0!;LR,B-*8Y]G>M&S-$VO*P!A]NVY[3X[K2\D[K>NB6K%1
M<'\VI*<AN>WS3$@1'WRV5(@QS)?4Z;+"0DJ'1,OX(I]=G )6M-/,DH'%]/AB
MB%7.IQ>[2VF53@J6R-E\3NW+B.]8"]W0TS0TO:GVLUG%9: S-B2<EL,Y+N2R
M^T9+'N!3#[Z9(0ZQBX,EOU&&_3]$JZ7.)L:V']*O-P<+S=)7L?I(:P>%L;3G
M2GVB,":UX*ICXQ@&ESN7Z8_J6::AW!D3)[F5S/:_46G,@9!,]J0_B9BI4@?%
M)4&7_DI:PXJY0ZTM)Y6%8=WMP;&(H+F8AM,*:A0<,JCV$+*:\4_$(97M"]*-
M0#M,G$[)D,5G-:FQ8;.-9S&,9=3@I<=A'I(1)@1TM8=]]H</4#:5D?U7MPYK
MSFV@?:L='*PN+BQQ\8)Y$U<!V5[D,(<-4;W-)XA>O=6[AYO1M<Q42/ND#9(*
MI$:(TSF==EM+PT0@=;45R#EU,N!L"X;4ZVDBQ0D6('!W^PVN[7LDK[5\4H:3
M6.0>,\-6IE1WT)YG)7_F76[0R1XJ< 2,/H/[%Z!C]P(J64+>V#4\@[Z2'3&@
M*FPY"4. *27&)<AYQBZ3>RA7G]_MTEK71;7@%3FT/&'(L: MK:1RW;]+7Q4%
M*XTI[":K5NZ=Q</MK\;56D19+DB2E3+OS"(K>.D-I*A-.66ME<1UA()"D*3P
M%C>]BV?;>J)+GYVWC?:[>P>-SV$ZV\6"(BLE<@*4XU%%O)AL&TP%U_*R>]</
M#&UPU5X&H)$8&>IQKR%5E>NX3.P'FF\;L6-VA2V51XN9DXY_YW64OF\U^)):
M;&-RKCZ$A(6YZ3HZ1?J3<5LKF'9VELDMHZU;$7%L8+:/U'&K:ZV$\:5%,!1<
M[)N5W=:M4AED?34<:>'X<:4(;P[23GBMT8W'1<5#:A1$J#3?4I;CBBX_(?<)
M6]*DNJ^)Z0^X2I2CS)\JY^>>2YE,TIJX^X#@ . &0"K:T,&EJYU6E4E$2H1*
M)52#QX\OM[:*:J>KEP^W#PI13J2_EX?85"E+W'N^WY44I1%-C]OMQHBBB)1$
MHB41*(IX>?#W?S%$441*(E$4GPXW]GE1$OQ!\K?E1$X?;G_"B**(E$4WYBYL
M?Q\?;1$]]$2W,^7.B)?A;V6_.]$3GR_P^^B)<^9_$T18HE?#CX>/'C5 =3 J
MXJPI)]@%KD^VJM8*455_(W'LY54,J\%"4J3DB4JBGB/O'L/#]U,RBBIQXH@]
M]OX?OJ*\>*)^VF/%%42?,^?W^?,U"*0M0\;\.1^^IH%-5<#G($\^9'+W>=4T
M]R&AI55A8/(WY\/(_OIW*FCG'],E-_/V\_SY&I!&2MN:1WA.)^WX5.*8$8<%
M'G?A;]E1F%-/$-.2G\;>VI5+L\PE17W)0T[4J?J4?6E*A*&M.*404XI4HE$2
MB)1$HB41*(I2I23=*B#RN#:H4$ BAR70Y75M6SIOG-6UK-*L1U9; 8G)+X\[
MKF0WEF_OJU)!#+C(QCCVM!^L+,M]PO[,4M)YXA^Y(]G^ZX+I8_:[M;%5ZS';
M7M\RX#8*9TO6FW .=^M.,"K7JVVRM&&K8HQ_9;^Q9;]_WZ44EOKQPY&>4C_?
M68PH&+Q:4HQ6,QF,0$\$8^!#A) Y!(3%992#85D!K6BC0 .P46MEFFG.J=[Y
M#^\XN^LE=H'2Z#U%1 X?$HGG]]2<<U:  4!:;V!%_*I4K"^X>27AM6E9CTEO
M1,3.Q&2RS;22M[]$B92([EW6D W6J-""G2!<E"#PO6RV>-LVX-@K221DC6'A
MK<QP97O.'>0J'@D4&51^U:4W/+LZ?EF>XNI97%Y#5-DGH<DS8,F-)QN.VJ6E
MN*$9%R*\4M:[O;;3<=YXV^1RZ&7UD)><(Z';(77\!V7<(Y&7<3* .!#C&"35
MM1\<!)('VX2Y@^%J.;CK;\7U\Q^M<"?W"D*WVV)G3YN$QVCXK>9L@ZN<YBL0
MC?Y.4Q[?ZEC<9-1FE1$C6G@^[':?,-2U=:;+)%,6S ;48IQ&V]==NB UZ'/\
MD--&.<- ),@(#B-8 IB%; <7ZP:-()]Z\(?4!MF*PD;8$]L'M<8W1Y>/VC#G
M7L]&V#19+3$R4WDM?0PVWC\W%Q\IIYYT8'(1'F(;I6MDA+MD^G=+[=+<",[R
MV4V;:QN\QA9,#04?FYA<* >?&X.>  [$*F2%Y/X5-?;6E>8_T+Y6]U]>SFTY
MES:-7G1-55FUJDY35<IE(3+&"R!0?F6,.9R(_P ]B9$@>HTGK06@LIZ18"O8
M]IN;>U@^5NVF41X-D:TU<W@74K1P&!P->:UUS;71(=#)1Q&(<6D ^VE05K5S
M=N\^JM8F%E=?[/[;C,0EL(=RF@X5.1++*P0E.S827%R'S: 3Z;JE+7?XC>U;
M$;9L-VZ22*2^BFD)J!,\MK_U;P6@<P  M9++ND#VD"%S!3'2!EVM<<>T^Y;=
MU+OGL>>E_I,;6-L@X9J:K]49P^S/[/J+3DKT6 MUUF9C)^/GQFW$.):2\@NA
M(ZRI )',;STU9VMHZ<7,;;ES1I):8Y#IJ:4HX%I-032@X4*S+?<C<3^6Z$CF
M001]&-<<J8K;$2!G]2V6-GM<8[G2,G-1D$NQX6ZYG&84N04];T&-/P*LVN<E
M73Z[B3*2AM)]%0(N3RL%X-RLOD=RDVYEM%IH]\;7R8G!Q;)HH> .FI^*JS)8
MHX'%T9D+G9C'"GL/'V+K6^Y,Q<P;'M7SB<W"E28TO%1'.X;&4Q!<?<;0,UF8
M[2<.PS+::+B4J;7;J'!1N!OI;$L9\MMD;##( 6OK;Z7T%26,)UFAP.(KCB!0
MG$$K2=3R6D<!JJ._"BWAK.X9#'PL1L\W+;7&"6GLPTO6.W\W9(?RLUN^/.<=
M:>UZ4Y$4EU1<]<KZW6@L H-<U?1"1SK"6*+YASM ,DC8\L]! E:#D!E@:8%9
MD<LK )V.TO)X G#MRJMVL8O&[/@<E@,A&S.'CY-D92?JL)$C$9S$9!U*71N>
MFQ?G'58\3$**LAB XZT[==A<_'K!(ZVF9<,,4FDZ6R&CV.&1BE-*'3]B2@(P
MKV;R$Q7<)%.%7-' \7,^LM6!87M7BL+DI&%5+$[%3\:K*X//9?'(V-<ER"H+
M,:)G'Y\>5K?0VLJ+3J+%=D)2HCAG7>^.>(Y6M+9&NTO8QWE@ YDL#2),LP<!
MB:!84T#[9XH"6'$'@1^F:[3(ZUEH,]P084B5"R4%MR5DHTP9G'XV<RR%(;>?
M: 3CWS(!NV1<WLE2B+5C07\-V!*\AMS ]P +=)<QQS ^T"*$'F,0%M;)L;XW
M0RD:)!0=CAD?IH3R*Q[&ZS@48R+EX\7Y_/\ K9AK+;''R4C*09*79BTF&S-#
MC4*&PREYOJ#R4JNE9!)"JW/SMR9G1.-+>C=#"T-(PSIB2<#2G,!:6\LPRCFG
M&APXX'],N2Z7#:[FL!(R$_7MD@2'9653F<9CVD2&7777&&\?E9+!?]-991'B
M(2^E*@EQ)"A?K-9SKNWO0([J%[0&ECB:' '4VM,C4DMKB,1A1:"[M7P^/A(T
M.]_#Z*%;#$78D9[,1L]C8C$/*X2$]$9F1NN)DLM.6XDB0R\E=X4B L*4V"I"
MD)-P"0*UYN+!]NP1R%S6.>':3XFM8 3B/M B@.!KS6C,$SB^!C:2$ "N3B3A
MGPY^U; [9Y:+E\7C8.!R6*R;F';1 +#;Q9QZ'I*"/E&!_<]!AJ6V6TE-T_"+
M$UHMS+(I'74@>V&5H[7C02 3VD$$K"A#YH6P#29XG&O '53 =Q%%M'%XO*9"
M%D',W#$.:Q.=EP)*5/R1 BL)7\:U(4F0Y\I&"4+/$J2V3;RT=U-!;:3&[7%I
MH10#4X\!7#$XCE57(XIKAU"-,FK"F-!VK(L3L\#=968Q.0;R+3\)$22O)28*
MH[3D="&(X=>FM**#\]*4I38 4YTD!9N;UAB-]A'"YM'1O! %:T))( ;G@VE:
MX9D9*[*T7#Y6.JV5IQPI4#,DY8FO:N/!89D2ITIM,=F)C93;2?6DMQT])/3\
M3*VBA8>4H!=[$ V%C<UL[UWEP,M\Y'LU$T)Q[#V#*G)85F ][I69-=33AEV]
MZ[.-\UU3,=/R$3,XV2E!;:@10P,87'.I(#TXIC,I3U%".E8"NFUB.)TLH9;?
MXIK9&S8@AQ'C]V/;B,,,EM8Q),/(<6>5G4 X>_W=JL3<!#=+4V,XS/R.">7"
M:ZHL=<2 DH1_>A!MU:6&HR7A\2 &^H73?C67;WNJ-]H0Z.WEH<SJD.9!PQK3
MOIFK;X"V1LP(=*RHR%&C*HY*Y)AS8CL93L/&9EKH0RO,N8=J0MIL(!# >4PI
M]2&%*(Z20GAPX<:R ()+9YA>^"0>+R_-+?;0&@JKGC8\!P#V_>TU]E>Q<+)X
MF*PV]F<;#P3:D17EM(;AQH(<FL-)0P[*DAM:8S7J-$A+32E K(*@>%4VSY9F
M-L9W3.)<*U<78$XAK3\7>YU,*@%; EL?XPH&TY4R_3@M29N-&A2U;#+B-C.Y
MY+2G4Q'?U3-R'G%K=$&('3)F08:0XIQ+06&FD<>!5766KA'$+**OD1&E2-+
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M.TBN@%W:</<%Y@[:=I^^_=S;<Z]V_P!9C#";3)7B]HSNRX>+%TG$*GOAQ3F
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MF,X]<N(XZVM2 ?5="%=)*:U5W=SV+)3=3^<[7I9$Y[G/<)'48PM(H7 $ XG
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M6VX6;@_;KVR=$16AF:&GOCET_2%7I;7A]"U7D])^GW)R"_+[3]]<V^I/2?\
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MR3?!L\A'\7^A=5_].?\ 3;_]TS#?U]'_ %F?ZO+_ *U6O_F9](/_ 'ZYS_\
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M"'&05! 4TSU+(7_EK%GW29MJ+>TLFQAI\4H.MV&)!U!KFDX9$T&'%9(BF;B
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M2?B0II24CIO8F^%/;QWT(EMW,&KX,7!V'V@"17M)![ ME'^&SR / 35QPQ/
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M]G\@L^)7W2[M$G_^>*OCT9],&_#LUF/8[_VD_P#F]_,7_P#K+-3_ .QK+_\
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ML@VTGF](TG._+992R@7Z(CLHWX"]8$N^^I_3V.[[3;;S9-SEVZ7RIZ<S:7)
M)IPBF<>06PM^F/1_JS#I_?KC8MQ<0&V^[1:H23P;?6VI@%>,T<0IB>*RW0_J
M+[0=PYKF&P>VQ\?LS"@B;J&SLR-9VJ"Z1<LR,+F6X<SK3;_*E0/A6RV/U2Z+
MWR[_ *4VY-IOE:&UNV.M;@'D(Y@W7WL+AR*T_4WHSZA=+6;=WNK(W>P.%67E
MF]MW:N',30E[1_:TD<5O!*B #:Z;W!'*W@;\K&O0CE]2\N%0[MICS586#[/'
MC^ZI5)%%5<6'MM:_MHE/<IX?MY>= :HX4_3@O%/=6:-(^L+L3O.81Z&K[/HF
MS]MOU5U?3$A;!*G2)4-M]1NEGU3.92%&P*5D_P"4V]"V2/\ J70FY[;;XWD-
MS'<:1FY@ !IS^%V7+M4Z334LY[H9R+V][CXG/18.1RB$:GN6XY[7V)D2/ :D
MM(Q6HQLXQ'E%/5E<B]F$1W&TD)=0A2R.L&^)L4$F\;+)92.:QQGBBCD()<15
MTQC)'V6AA<"<B0,E:#09!3]#^U<?MOM3/;SMWV]DY_=<=)S67U3$9S;-9R&8
M@M9QI[(QV9LK*8F!Z_S*3ATRTM2&RGTW4MERZ5 WIW>T=O&ZW<<%L]L$<[F0
MRACM!#26ACW4H=5*M.8)IB*+)8YLH$4SM,V0/;P:>_FO-W=[O+](K^V*UR-]
M.VS?4#W-Q#JHKV.UOME-<R0?3=U*\KG,FUCS.;=4[UATMRD*"NI)M:NHV'I[
MKJ*P^8=NL.U[.X5#I+@::<=+&ZM.656XYK!G>('F-S'F49BGZUXU^J":YW0T
M#%L[QV6[=?23C=8E9%[ .3LMBLQW%>Q;327LCC<3J&O36,OZZ(TE,J5&5@WE
MI;^(* ()[KI"W@VK=7OL=QN][FF#=8:US8-1P:YTCP6TJ-+7"88X4PHK!O;F
M*(D:8*US <33D.=.Q>.] G?2GV[;SFO14/=S9L94<L[CF=<[P:U@<JM]XN34
MNXMC6&&(V)Q#:N@*$&$77% K6M-U5V>[V75>\S0W<[/EK:AK$);:1S:##'S"
M7.<<:%[Z#( X+#MKNWA)C+I"_F8W &O<T- '.G?S6_,T] W7#8V3K<5>%[=I
M*DX@PU?H.G1'(J?EF'H<>+'QN1R$R>I]3*VFS(6L@@D=5ZTD$,MDY]O>"-U\
M1XA\;R#B6FM0T-IJ!-!V+;%WS#/"[\&F;<![L#5=GI?:K;VGIT3";F-)@8Z/
MC<YLT&(,CC-?QVOXQZ0X/UQK)RYL/"PVF7%KO+)<?6I(0T5 @:RXDVZV/G/8
M^:XF!C8XEI<7N ^   EV IH #0,317XH-!;1[FXX$8>S/&O:L.RVO:%,V.*]
MBMP;W3)-Y-G(PLF-RBR6X[K*&'B]"C11.C_,Q&5!Q#90DH6?C*3RS8!>16IB
MN8Y&,T^(/8<<P-5=.%<,,#R*W-O:VTHUB5TLH.1?45'[HY=@]JRJ!O\ .Q[K
MT/-Y)66R.%+TU7RF1=&?=QGS+*4N2#A8K49I:D*LXXZ6T/?""E2BJL"[L(8X
MO,CB:()"&@:1I#J'@\U..0%2,<0%G-="QGESL8X@9MS]HX]ZRC+M87:UZKD\
M-L"=-R.0>QR\5#DZXW*W%X2PAT,8J! 6T[(@S675!:'4.-+:*DKNF]:=UY:[
M/%=.OA$^SCC>9'!VF-H;F9'&H!'/ @TIC19MI$[<)VV5DQDES,[2UOEZ7%SL
MA4F@/,Y#,FB]W:WBX/8S1GF8ZE9K>]K=6ZZZ(>.@3\C/<;):;$+'HCP8C41L
M7]-L!"3?B3Q/QGU1U9?>H_5\.V[4"R)](K=I+B(+=I\<[RZIR)<XDUKI;P7N
M.T[)9['LADW-[6;38L\R=XK224Y,:34N+C2-G[HK3$KQEL>Q[U&RK[T_2]?R
M\V)FF)$O*9%62BY*-,:=6[$]/].R4&29C;:U,*4U_4V++!-?6NR])]/[?MMO
MMUK-*+:&(!E""'$CQOH015[O&:\3A@O)MY9#U'=.WJ9\FN4DM:'#1&P8-:T$
M' #V5J>*V7E4XPXN!DHFF2LDQ/3&,] 8G:_\G(*U-9-W'*R?KY66S!?*T(]0
MCU'D\>I)L:WP27L3[.66-I83IJ6OK0>#X*-878' 8!<]:7%W9R.-O(&2--,P
M[4W@' >''_50K)] [AHP'R6$S:HJXN1,E['8W)2(CDQ@Q'E,J6&G!=,AA-E$
MI2+!7#X;UR%]M;89G-B=21N=*@&H!-.Q:W>3!>ZIH_!<#XF_K',?H5W^2]+)
MY>$QALE\I.RD&9-0PPTDXK*EJ2EAQ4>$PUZ.+EN-K]/TRDMOK2KI(<L3D;9>
M:&F"\&I@( =7%O+&H)YYX=RY3Q4.JIH/T[UB;6!VG%9)IV&B.PU^H(]=O(F;
M(BX[%F:Y*>QV/9=0N0(9><6?3*^I*B;F]Z["*XM'1N,E3(68%M 7.I0.)&%:
M<0."M21D#P'$K;2)N-9P^$BRH[JI<U>6R<1T1I#L,8G$RYTIUHN@$M,*0VE*
M+W%K@$D6K21Z[:9[(<6, ;F*ASP #3VDX9+%O6!UQ6N.%?<*KCF89\;5GYJT
M/2(\0HE];8*7$/ROF5I=!-U@]*PH*/\ 3P%@ *S[6U?;Q3Q-/B)P-<:T6#>N
M89',:*1"7(94I0?0KDHIGLR3!Q,B+,ENP\<SLDEM3&,<BA;L?'0G4Q79:X;#
MK2@XLKX W2D6O6MM)G0.#+MP="QKG%E:NU$XG&E3^K$K!N( V1WE#\8$ .I0
M## <: *TB<8#$=Y#D9B7!82VS"+D=UN,L!P3EON^HA*ILYT MDD]25!-K<LV
MX>^=E':O(.+B :N^ZUHIDT9]M25BP,$;JBFOA7A]XGM/^A=-N.<.2D)QD'$R
M9TW',B4[DX+#D>-(&00A4@O0&D"/:%)=4E+IM<<?'AM]AC\AANKV5K(7F@:X
MU<-.0U=H J!Q47KP]_E0,)>!B1@,>SO7 PF S4MQUJRH37H^FZ[TI^9D$J:1
M^DXQE%W>MM*D^JM)_H)MXVV-YN]@QHD#@]YQ#0< ,3K<<NX'BEM:S&H<#3B>
M9Y#]960G)2)/S'6E]G&X3Y=G">M QS; S#9(?<3B5/%V9"BEA:&W75*2VHA?
M2YQ%:2&?4\1#&66KI7ZS4,.0! HTD$5  )R!"VH;A^Z/A;3C^NBXN.?4_->G
M*=#\J1ZGS>1D'K3&2YU!]\J"V8[#3!4>E(N 1P%ZR9W3LB$4#&MMFTTM-6UI
MD*4<]Q/.@[Z*_&UI.J2I><_TR7>2<XSG(.9U_%Y%F9G(T$3,9D&XT.4]L&-B
M@JG1(#927V\HQ'=+C3]@LE"D \C5AL'R;X;NX9HMG.H]M7 1O=DXX_"3@6Y"
MH*RF-/'%:<CR\B_(DQ(CKL!]EQ^(^YQ?FHF-E32VG75!30>9>39;:2I0L0;6
MKI2V,-#G"K2 1P%.?<1Q5ZF%25RL9VAU]M,;/]RYQV3*)/J,3LY)F);0E:5!
M4+!ZSCI2&DQB5]2@M22I0!6OA:L.XWR=SG6>TM+6\0P"@[7R.&?<">01IJ=0
MS6=:A)[?*SBX>KZ- GY7I=]".WBX\W(Y#T4I=?=;0^M4#&Q&4M\NNRB; J-:
MO<V[FVU#KJ=X9S#RUK:X"I'B<3W>P*[I<<*X=Z].835=XVB%'=D[/J6@8J2D
MJ$-N2SE\ZTGD&W833L+&Q'@>:5/K*+<J\ZO);6TE<T07-U..-'-8>YU"YP[:
M"JRHHX:5>X&OL^O]BVI@NP_;ML-S,RJ=O\P!"E2]CR(F8XNI5U%QG"P#'Q#8
M*O!:'> M<UH[C>MP),<8;;MY,;I=[7.J[Z0LYD@8/P@ .S]JW5%C1H,=$.#&
MC0HC8 ;BPV&HL9L#@ AAA#;2!;R%:<DN.IQ)<>)-3[RJ2234YJ_10E$2B)1$
M''EQ]W&HJ$2B*;GSYVO]U$2]KV\K<1QHB=1Y7X415]?+W<?.]$P4=9]GY_QH
MF%.U2%GQM;[?E1%5U"]OS\/VT1.H7YBWO\?X5*(% _SJ$HHZA[;#G?F?=131
M5>WP/G^ZBCLXI<>8_&B)<7MY6^WW4105 >WSMX>_RJ45/6/;SX?:]0I"JZA[
MO?X^ZBBB=0O:B44=8_QHBCK'MO1%3U'C<GV6\_X411U'CQY_;A4HHOPMX'G[
M:A*ISJ42B)1%AE82J4W^ZBFJF_*_+[<JFJFN"J'$>'#\3?\ ;4U"E.=S?\>9
MJ44@#F3]PYU![$4#AY\O#[<JE$O]]_M^-$4WX6^\>=_"HHBJ2XH6\0/"E BO
M)=!X'@?R_;5)%$5VE2,E*?;_  J1@*\$2I:XY#_4BBWV\_?4ZQDIJH/AX>[A
M5P$8Z35 K$J%$R,9R'D(L2?#?24/1)T=J5&=0>:7&'T.-K2?(BJ'M9(PQ2AK
MHW#$$ @CM!P/M5<4DD$PG@<Z.=IJ'-):X'F' @@]Q7G_ "OTQ]M52G\MHSFR
M=H<^^XMU66[8YR3KS#KZ^/JS==)D:U/3U\2'(O'CQKSN_P#2KI">X=N&T1W&
MT;LZI,^WS/M7$GB^-A\F3^W&:KUK;O6WKJ*V9MO4;[3J#9F #R-T@9=T:.#)
MW4N8\,/!,*<ECZ\3]6/;]*EX79-#[[8AD?#C]GA_^WNZ.(3_ )49;'"9KLQ\
MI\7&XX41QM6K.U^K_3_CVO<K#?K,917L7REP0.'S%N#$X]KXA7B5NF;IZ!=6
M$,W;;=UZ5OW9RV4GS]F.TV\^BX8WL8^0A2S]5>*UI0B]Y^W/<+LY(]1#3F3S
MN&=SNHE:A8J:VO7A/QJ6">2G"@5 ]6'[/X.O=EW39J9S:/F[3O\ /MM>D?QM
M;VJO_P!"Y]^_$],=^V;J,$$B&.7Y6]H.=I=>6\N[&ZEO[5>X.C[Q$;GZ?MFO
M[)$<3<.XC)Q)A' &RFVW2X@@<P0"*] V3JSIGJ:'S^G[^TO(J?\ "D:XCO;7
M4/:%Y5U#T;U9TG<&UZFVV]L9QPFB>P>QQ&D^PK,/R_*N@'(KFL."54B4/8B5
M''M1* HE.THE*UPX)13S\1P_&F2$889J>H\"/#\O=;C2E52&X4*UIW#[.=K^
MZ\5,;N#I6%V%;)"HF2=CF)G<>Z+=#^.SL%4;*P74<+%MY-:#J'I;ISJJU^1Z
MCL;:\MN E8"6GFQXH]AY%K@NMZ4ZZZQZ&NS>](;E=6$I^)L;SY;QRDA=JBD:
M<B'L<"M#+[+=].UA,GL9W<>VO 1PE3?:_O0IW,1O11<F)AM^BH.<@%0^%'S3
M<E(\56KS@^GG5O2WXOIQO<K+1N5AN.J[M:?=CFK\Q#R%'/ Y47JK?5+T^ZW
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M*=YGB;7$L>, _##4M:RDCJ2-T,(IJS_;^G!:XTKL%$P.6R#^$S^9W+"[7A!
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MHZHH6.GJ! M7N/H]Z2?Y+VN3<.I)6NZJO8VF8!NID(P>VW8\'#R_M.'QOKP
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MMQ) \*4"*ZEX$_$+>ZJ2WDBNA:2+@_N-011%/&J@T%N!\14I4-(%:DHGW54
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MX(/&JN6-[\C<B9[#Y)P=SS^+O&=.(J%Y1/9W2.XDI6S.Y7<]KU%;"E'0]&3
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MTN.9'1-Q:W%J^8<']P=0/'INFOJ6#;[K7\K<.TL+0& -:2VG TP=R&7ZUYG
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MUM?'>_6O?3:2R$/=!!*ZZNI*XELEV\F.(D9^6'D=E%K]X]:O1GHN#R>BH_\
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M-KW/&MI+:37;-+!Y,.!).FN'(YBN?Q*YHC;B\ZG<A@/>L3S\F5EIX5L^>S#
M>;+<;5M3:D_K$B(2%!J3)QS;TK&L.*XEJ.(J3_G4;5DV-G%9L)MFA\O&64@C
M"N0-![ZJZ9'.:&- ;&. RK^M=7'?U;7O2Q^![3--2GG Z]E]LG:1B'V'5K"5
MNJ.T9#+YJ=)4A%[J2A'$>ZLM[;RXK)-=U8,-+!*ZH_[,-: K-0#0TI[/H7HK
M&Z9MO<.)A(B<5J&I8?YR''8R&-V7-9?+Y5Y;A2PF;"QTK%8"4%I!4I,>,ME
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MYD'VY? S^XWQ'LJ]O<MN:A].G9_39#61C:C'V#.-I 5L.YOO;9EEKN"IUO\
M5B]CH+BU"Y^6CLV\.%0^:9PH7$-Y# ?0L6XWS=)V&)LGDV_W(@(Q[2WQ.'\3
MBMLY@9%./2YAV&I,['*;D0L>Z\F''EH:"DNXY+_0MN()+*BE"NGH2NU["EN(
M3+IN"6PNJ"X"I%<G4XT.)&9&2T[F!S@2:&N>:Q)O9NXTA/5$[:,P.%[9O>,2
MPH<OA4C$0\MP/OK8&TVEA\=Z7']R%_\ RRU7_)MBW2]]6]C2?K(6@^]W:D=U
MM8RF/WGL5I>0;>BOE[,XO)Z-E<TAA+:E.(6]LNFF8ELE-R8[B7A;X3?A5O\
MHO2%_,!N7R]RPX%ES:%S37M:\GZ0NEZ?ZKZCZ4N&7/36[[A82L=4>5+-&VHX
MEK'Z3W$47R [L]C?I UG7MF@X#MEW*T[>X<3TV]ES.[9W_3V#R;P;^66_KN&
MQ^$Q[V.Y]*&TLO.!0/5PX[ZS_+[Z<;W=17%_L/3\]@XU+(K?0]PXT>)20[OJ
M!R7M-A^:;UXLF!@ZHGEB'"2&.4GO<]A=]*\1['VMP\[/IQL+9<+K"LGC(^4P
MF*R^Z[!KD>5%FQQ)QLM;VV3DN?(Y%H%3+H*TN@CIX&]=A8_EI_+U;0B63H^Q
MF<QY:YWENE((-'"C)"*M.8H*8]ROS?FL_,3+$9+3J(:&X$MM[<&O]J##WDK7
M3/9G-1LO.;V?"9!["L-!AC-:GM&$VAEN<JSB3,Z);SKT=;(^%+*PL]?419-C
MZ%MGIIZ.].QQCI+IW8[:[KB9+%FIH%<C(":UXFO[.5W/UR]?NH8GC?NI]W-N
MX8,MYFPAP/,0",@=QQ7.A2W$S8FEX_7W-:CY_,P(KV8S;<S#X3%J<Z(9FY3(
MX^ ZXC',)65N+4I?2GPO<UZ(RQ;%;NN?/:Z*)E6Q0-8,!CI8RM-1X  +QK<-
MQW2^N?.O_FIKQSOYD[Y)'"N&+WZC2G:O?W;KL;LNF19&<PF6@;HUE<(<+.DZ
MYA-=CRW,0RM+[C&$S4B5*;R8?ELH4E4N/U++5RH*M7G.\[O'NL@M'L-NUDFH
MZWO<-1% 71Z1I(!QTF@J0J[>R>R4^>Z-YTTRII/>*57#C:%NOSN7EP=MW'5\
M= 8@)?QW<#7X,>$<>^B6Y\MCF=>E3VILA'I)+C:2TEL&R_B K73[G#:VC+:>
MT@GD<]P#V/=GA0D.:/#G0G/@5L;:ZN[;\(:7P./P.8',KWNR]AQ6=8_=SK>N
MZL\A[8'\)CU/M9[-ZMC,UI>&R(,I+L=3>->.6A3%?+)#3TMEEIIT"W6%I*JL
M"R^?GEUMB;<$#0U[F2N;ACXAI<!7%K'&HSI0K:VUC:WC96S&&*=Q&@-;J PQ
M[JGA6HSR5S*:F=WFQ]BU+:<1C,;MBEJ@RG\W"]=+LIAUL+C0<CEX$B1"AY)'
MRLD^LM;3Z5)2TLV2<IE['9M-M=1/?-#\0#7<*'$M:X EIU-P%10U&:V4>X26
M,1M27/DCPP:2 !V@8&GB Y4Q78Z3KO=J,B%I6RRE;=B<-/1%A141C+S>(<A2
M%NRV,#FHB@^QCUAPW2ZIQI-Q8) L*+N?9S(Z]M&^3<2-JXUHUP.1>TX$]HH5
M=;;VCI#>,-)GMU'@'5P!<W $_2NZWYG NMY2'.3F&UQH@5".3EXC#RF9,:4V
MV^ZIUIQYJ7'CM*L6D=+G4GJ\;&BRDG#FN9H()QH'.J",.5">>7!9$4,C0'@M
MH:5%"<*<#P->)KR6;8KN-K8U")AYC^1>P:L-D4(RF=R"LWF(>?@I8$;#Y&&X
MT94C#3T\8TE2$-H"@D*!0I1U\EC>B\=*P,$H>/"T:6EKJU<#D'M^TW&N?$!:
M4VU['>NEA:QS01@!1I::^('+4.(XYJ=;C:LXTW*FX_)Q=AE(=AF J'%D:WEQ
M&^.8=?S.,D26YS>*#K3;P4"OU'$W)*N%R:6Z$FB,M=:MQU5(>WEK:X C5B13
M"@*E]Q-)/Y+=/ETKJQ#F_P 32!2IK3A@LI?P[+C4/HQ,%"&)'2Q+>]24]BY3
MKBGH;C$1,AB.07HY)<<42A*B>DE(K#FD?K#1(=3A\-  X#XO%0G(Y#/N6IO6
MNEE#6NQ/92H&9KSIP7*<P"L\B+DHF0EP'L4'4QGHR$)47%R&WGWVS8K05EA!
M19/Q!('^87HBN!::HRT.;)F#RRH??[%J;DCS"QH\&7L6<X)AM63:R,J?&A18
MCS<F5)D*7#@XR,V\VE#KZ)B>LNS9 !<;-@$E04?*S=/:RR\I@=4MX8DGO' <
M^*Q)"V&S+&  N'>7$YG/ #A]"WAL<S&*BQHZ1#ER9[)FP405?-1WT=7PS&7&
M?[:&U6*DJY6!-^%:&RC>]WFXB(8$G"G8>U:#R'2-)&# >//]:PD8_)9N&^(+
MB&U.DP91CK#C]G;.'YE2G2EJ*EMLW*0D$7"E$7K)N;FWM)0'T) J <@>P 9]
M^/)1(X6^GR0'2\SDW^S^U=_)R<YQ$+#Q9"%/07T.277.@QX2(CB#)?"D%,9Q
M*PUTA"4EM8/+Q.!%:Q ^8\"CB>\D\N(Q*L,D.,CL10Y\3^SM76;! B6B-PG6
MEO[!(#R4,".B*U&6MPSW'0A"Y+'6"4D*2/A X<JSX-<E7FH$%*8FI<,1R!IQ
M[U3&W375306GZ5C66UZ> C&896'5@"66W!(<GNY!YUM8>;>6AUY?K^@X2D)2
ME(4D#AQK;V4P;*;N],QNZ&A&D, .!&6&"LM8 W2P"BYWH0H<3T&&U2Y[R50F
M5H4B*ZIYRR/20M8*68X6 5"X'A<5=<^64^87!L(.HUQP'&G'OQ]JR(V-XK#M
MAQT>=%>@O!]<N$DR\FZIX@&/!3Z9:2YCLDVRY%2RD!E!6"DBYO8"KEA<,BO
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MXM@;R/BE_?;DM@,,,QF6V([3;#+20AMII"6VT)  "4H0$I2![!72L8R-@8P
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MD>T(GF#;C4ZJ8C.JA/=S%58$AU2 5*BU_#G^7W>-ZJU "A-2%-5(YD\JD:2
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M2E$)3?[J<>Q"0,UTV9Q;N2:9D8^6F!EH)6[CIRFOF(Z@XD!^%/8"D_-XR<@
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M6@M=NK(V<@.#Q.:8^)XU@,:&DBA)&=*X4-U\;+;3"UA,,K@'A[9#1FH:W@'
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M=#]HC_0LXDP845]+3T;YA;DU+\M@F3.C@S #,E8^1%06'EN^GP'J,!7J ^H
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M2@;7B=-*.(X&A-<L520*5(-%JN/C\JN''^;BW4\Z5.XW$X5_*-F<]*=>;88
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M(P?,1A\$0 !*^S^J^MN@ORA]/3>GGI*^'<_6BZC#=QW5S6O;:5SCC!J ]O\
MP[<5#/YD]7T8ONAJ>MZ[HVNX34-.PF,U?5=;QT?$X# 82(W QN)QL1H-1X4*
M-'2E#324)XGBI1)*B223]#P00VL++>W:UD+&@-:T4  R '!?GKN6X7^\7\^Z
M;M-+<[E<RNDEEE<7OD>XU<Y[C4DD_L& "\N=Z_HE[(]XYDO9X6.F=K.YCO\
M=8[C]N"SA<F[,2E*6G=APK:48+9V4](ZO7:1(4.3Z3QKA>L_3/I#KJ(_UJU:
M+\?!<1_AS,/ ZVTU4Y.JO9O3?\PWJ/Z;-9MUK<MW+I88.L+VLT!;Q$;C^)"3
MP+':1Q8<EY&E;%]6GT6K=G=PX0[N=GH[H0[W-T:'(FKQL%*EAJ1O6GK"\I@N
MEL#U)+9?AH/_ ,\\A7SA?=*^K_HQ<2;GTK,_>>EJU>QK:RM:/^=@KXZ??C(<
M*5)"^F;.;T$_,C$S;[2G3WJ"YOAM+EX;'(\YML[O!KR3\,4@8]V0C.:]X]F/
MJA[9=Y\5"G8/.X]N1+;1TM?,MJC.N+!*4-OJ5U,.JMP0Z$D\DE5>M>GOKUTC
MUJ&V-Z]MAOA-/+D-(W.Y->ZA:[]R0-<3@TO7S1ZF^@/7/IO>2-N;>6>P8?B#
M3YC1S+1@YH^_'44Q(:O1I<LH\+( XJ/ #QZB3R3:O="",3D%X74' 9E:WV3N
M+!BNNX;6WH68SZDJ;)$II.(PW"RI>;R77\O&;9!OZ(47G+6">9'#;SUE;,+]
MMZ=?!=;SB"XO MK;]^YFKI:&UJ(FDROR#0*D=YL?15W*UFZ]0,FMMEK4-#'&
MXN?W+:&FMQ.1D($;!B7<%K:'W?[3]M(:\._N;&U[5.D/Y#*1=;8=V'-93+23
MU/J1!PZ);C3:560VDV"$ "N'V[U"].>B;;^BVVXNW?J&:5\LXLHW7EQ/<2&L
MCRV /:P$^%H<YK6-#6UP7;7OIUZC]<W7]8?MO]*Z<AC;%"Z[>VUMX(&"C&ZY
MBW4:>)S@#J<2>Q=JQMO=_? G_3.IM=N<&^DVV#>.F1G5M*'!V!JL)Q7I.=)N
M/FWF[>*36\BW;U)ZI:/Z98Q[!M;LIKPMGO"#Q9:1N\N,_P#72U!SC*U,NS>F
M723J;O?R;_NS?^!95BM0X9A]Y(*O'/R8W5X.62X#M3@<7D&MAS\N?O&UMW*,
M]LSB92HBC8J&*QB$HQN*;ZOZ0TV%CQ4:WVS=!;/MEX-XOG3;CU"!3YJZ<))&
MUS$3:"*!O[L3&]I*T&]^H6\[G8NV7;60[7TX?_"VC?+8[EYTF,LYIF9'D',-
M"VKZOP#I(!'#I(YCAR\*[=<'V<$+P(L0KVD$"B*"[<*(-CPZ1;PX7X^=$5OU
M%V OR_'\:A% 6H*ZK\3^'X5*(I:E<2?PX414W/F?*B)>B)1$HB41*(E$2B)1
M%A)/@#<>[S_QK$IS5U2E=K#P_/\ ;4HKG4/,?C45"*:E$HBFB**(JPM8\?QX
M_MXU% HH%>2X"+JX'EXG]U11117!Q%QR-%"FH4J**.Y*E$HBD'^=0I!4]5^?
M/S_9PM50* JK[>ZI52BB*;V_91$%O'R_.AKP1.1_,?N-,T3P]OG1$N1R-$5:
M5E/"_/QM?S^\U!"*\'02!8^_]]01Q1429<6''<ERY#,:*RDJ=D/N):9;2/%3
MBR$C]]4N(8TN>0&CB<E7'')*\1Q-+I#D *D]P"\J=UOJGU/26'H^.E-.R5GT
M&'UI]60^^L]"&<?CP%.NNNK/2CJ25*/]*#PK17>_00^&#Q/Y]O8/T[EZ-T]Z
M=;GNKPZX80S,@8 #B7NR  Q-,N)6IL'VR[[=^5(SFYY2?VETR<4NMLRF$R>X
M6:AKNI*VL3)M&UIEQ-NE4R[X2;B/:U6X+._OSYMTXPQ'&A^,^S)OM]RW5[O?
M2'27^$VQD>Y;HS Z3IM8W#F\8S'^#P_](O7?;?LQVW[3L.#2]<8BY.4V$9+9
MLBZYE=IRMKDF?G9I7++942?2:+3 \$"MU;VMO:BD#:./$XN/M./U+SK>^I=[
MZA</ZI,70-^&)H#(F?PQMHWVG4[FY8?]1G8V#WOT?Y",ZQB]YUEUS.=OMD6B
MZ\5G&V[*A25"RUX;.,I^6EM\NA06/C0DUR_7'1]IUGLC]LN*,OXSKMY<S%*!
MA_8=\+QQ:>8"[/TD]3=P]+NJF[O&'3;%<-$-];UPGMR:FG 2Q'\2)W!PI\+B
M#@?TG]W,CN&NR]%W%A[&;OI#S^'R&-G+)G,JQCRHDW'OWXN/8UY("5@D.,*0
ML$CB>9]+.I;^[M).EM^#F[[MY+"''Q.:TZ:5^UHP%<=3"UW-=QZ^]!;;LVYP
M];]*N;-TGO#1,QS!X Z0:FN'W1*"26FFF1KVTX+UX18"PM?[^'G[+UZV74(K
MR^E?/'>EATGSO4U)R[TJ@)M<>5CR\*8# G$E,BI"C?BH&W$VXVOQ%QP(O4T4
MU%:*HJ'(I'0H$*"P"%<[@I\CY5.KAP18XS+.'SC&%>/3C<RT^]A'5*X1\A$3
MZL["CJX!+D8_,1A>]DN( LD5DMB\V SL^.,C4/W3@'>_ ]XYJ@#2>PK7G?+"
M/+U:-ON%;CHV_M=.9VO"27W&HS$W#(>9C;MJN6D/*;:5KNSZJ[):DMN*#0=0
MR\?B921MNGIV"\=MTY<;*\9Y;P*DM=G#(T"IUQR!I! K0N;D2KK7D5;]DY_J
M/>"NN[;0=<V_M0>V^<DQLE#0UM6MR<0); R+FHP]ERV/P3OIJZWV4_Z>$4-O
MI2%M'I4E25@$9&[OO+'>?ZO;!S'$QR!]#I\TQM<\5R^/55IS%000J'.J=3/B
M%#[>*T1@<WV:U&$C4^^F\Y5&_:9-RN-CY;N;M.PQ,C/P<.9(_P!,[GA\-GI;
M>%E-R,(MI#LAAET-R&E]?.N@NX>H+UPONF[9O]+N&M<6V\<9#7D#S(GN:-8H
M^M 2*M(HJGZVC4RI816HI4<ZKQ+WLV#O'(<PA[):#W"V/7,+G<LK_7V-V_3-
MBC]PL<\ZM.,2_C8S>3CXJ*PRI*_3<6XM*R24('PCT3IZ'9*/_P Q75M'=R1L
M_!=%+$8"!XJ..DN)-144!YG-7H[J_8PB(N)(& ('UX]Z\9[5V1[[;=LDO.=Q
M]/P,-.0'K-:NQK^Z;KD8B@PE/_<Y9#S&#+RWTEU:4-AOJ/2E*4@ =[;;YT]:
M6H@VJYDP^WKCC:>YE-5*8"IKQ-5=BAW"XD\VZMHGCAX'5_O$T^A;O3VH[@XG
M5L=B-E[>]M<QJ_H,/NQMBVW6.WKN/E="6U9S]25EXTW$39<<-MR$J+_J(0A"
MD I%N3?N^VR;@^>VN[EMSB 60R2U&>F@!#P#4MRI4D%;>,F :[F-PJ?A$;A0
M']ZE/=[UE<+Z4_IWV?#L*V5K%NR,G'>F_I/;_>MAW2&S%OZ;P8S#$9B"AE#M
MS<(^-5R%+%69.K>I+.8_+.(:T@:I8F1DG,>$FN7Z!;.*TVV]C#HV2%I_>=3Z
M/KR67S<SVH[:X2-K^%3)RJM>C,85F5G\^O9-B2%-+;BQ)SKK\[)!3D9);;0X
M& 6T!(385JRW=-QG-S<:8_-<74:WRV9XD"@;GB:5Q-5N[6"UM6"!\C !D'.#
MCA_$>"\G[%WCSL[:H^'U9S(XG,3'S'Q/I8MN$Q\TMM05CS+D-3%1U^F%)47;
M)L#Q3P-=5:[-"RU,]UI?"T5=XJFG.@I7V++N+J(QF(QO<RG91W$95XKH%)R"
M-@GR-FRDS(-_I;DF+E(NSX+5\5$GA 7)?FY+(PW Q#4VHH0R%-R%+)%CQ%77
M%AMPRS8QL@=\)8]Y(R  :<^).(^M8DUU?& O8Q[2#DYM11=HJ+#Q2L+FQ!=P
M62S4O$OZQGE07IF-<:5'<$W+JRL::\<G E,N=7KHB*6ZWU%"2%"]L.DGC? 7
M"2.-KA(P&CJ\&AI TN!&1<*&E3@L5DKKMA!+79ZVTIW4KE[2%LW)8? JA9J'
MM?\ IC [CFLI <8A8YM0;$14/YB#-2IF5$V+%/9&,Z2^F3#;8:4D6'5>M7:W
M$[GM=:NFEM(FD$N'&N(.!8ZARTO)-3PHL2QE=)+I8YWEL!&/U$Y$C@0:JO7Y
M.G0YSV Q^(S>*RRH3[KLJ"^U+@85N-*9D28,;,SY\9[,1<MCSTO.A"9+2ECT
MN("JKNVWSHQ<R2,,(=D1B^H(!+0"&EKLL:$9\EF26MY=&.VU@-KB:5+L#B12
MC=)QK6F"R3":_B-M9R):U>7FIK;_ ,^O+M[&X]_ZC\X&W76V9:9$J6QD'IEA
M%2XIX+1U!:[JK ==W=K<ELLC8K70T-9H PH:U(P!;08T#:< KDL(L8XR)8Q$
M7D'PYX"F(RH 3J(H:\,%M/ :K(@.Y>3C$Q]?Q$*<QD\G%;SL@M')0< 8V*]2
M$VI^ XRE^<)#TD*+P2GI59*5)K7WTT=R&ME+GRNC+6G1]ESP7XX&I#=+6Y8U
M&=5HKK1<N:]VIQ#'8Z<*5J['#A@!DL^P>1&.QV%B$QY.-EXK'MIFC*8=N%-R
M2)1BOSH9R..4<Q">F<"ADI;0V?B4>!&LORYTCY 2US7FHTNJUM*@'2?"X#B<
M2< M/=N+I"\.-:G@:AM*@'D0.:R^#+Q:VM?D0TP\Q =;@J?FL/O1,?D&)[Q1
M&>:7.])T1I4LH/200"W_ ,)O6!)KN8RV9Q;B2*BI&G&E!A@%8^*-SWN()P;A
MCAG[AQ[5L37)J QE7\_(4\WC7!C,0PW)C".S&BP)#BGY+!6F=(:#\<@.64E(
ML$^ K"E:X2M9 T>6XU)Q!QH,.&/)8=RQNID-NWXL236I)/N&"[+7LIAULR<E
MM"5PI[9:DM*6AI:41)CBDQ&X\ %,KUF8_2IQPMA)"N? VKG%TTB"V ,1KD:8
MC@3E]*Q+N)X>8+;Q1C TXGCCQ%:K&<UD4*R3(C_,25,RI2,2VVW\[D29:D^N
MQB8O0E,83$M)]51 (2 "1:MC#;"WA\QQ#'D N/Z<LJ_M5VVL&,!?)2H&))HU
MH[_U+D-Y20'%IE,IAOM/(6\ZW),U]!:39MJ06(ZFG7$IO\*"I#8X W%8\D+I
M Z2C1"X89ZG=O<K%PZ%K,'N$/8*:OUT^M9%9N<N+(EH8>A07'',=E<F[(+S:
MY+3:7U8S'J91*84ZA("E.=/5:XN#>M8YKH6.TN?YCABT <,M3JT]WT+6'035
MC*-[3^I1EYZL8(L8&.TP77(H?=4I$=4F1T%I*G6W+.NMM"Z4>%R;$UG;=:Q2
M R2ESI&C46@5-.0[.9&/<%9D<-6 PX+J4K6AQ>-2M#R9"$*R&3:2\F00%E:@
MM3SJA%C1PH)6HV]0#B ;"KEQ< 6S]PF#6VK!2-A(#>521GV <<L,5=BAEED;
M#$'.N''!H%37A[>?):%[P_5IK7;""G6-.CM9G9&FU1$,X]U<IDR2I0#ZU!KK
M6ZXI0)2 4@\ :\BWWJ:XEE=!M;2ZX<: TRX  #Z.*]ZZ%]'Y-P+=RZB=HM!X
MM!P[?$?U9+P[D=;[M][G,CG>Y6UY/7\:VTF3%U;&Q9;^3EB0"8D>=(26<?@(
MTE1"0Y(<"^/!!K,Z<]&-SW^YCW/J^1\-I(ZNBH$CAF<#4MP["[L&:]!WOU@Z
M2Z$A_HW1EO%>;DP:2\4$,9'-P_F'L9AS<%F&L]ML#V\Q;^1:T&')#<14D8J?
M*GH1L:XBV5K@9/9A&<AQG)/J$I2DO..* 0A!)%?1W3_2?3'3;!:=.0Q6K\C,
M&M?,*@^(EQ,CO>UO'!?.W5?J'U?UC(7;W>2RQU\,+7%D+>0$;</:[4>U;BTO
M<MDP&9_U7OFLZ'B=-R+0AZSV[EN91EOYLK:#3V+F%YW;=AFM6-PR T%*N4I
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MVFQD0]3U; Z['0D)",3C(D11 ! ZG6V@ZL\>:E$U]"[3L>S;#;BTV2TMK.U
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MIM2"TISTQ7HNU;!NW46Z0W.V^5)M4]N&70D< QHB<6/!;77K #7QN: 02#J
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M1P]';SK#@1&+DF2AZ0W"?"BPIUXHL5!/40X2"16DBMW/:]D@UY AW&C:5/'
M4'>%C7436->TBK)&UTD=F%0L\^1E+2O(85,38E_,1LD]!D,!+[$QMMJ0$>K&
M47H+;;;@5'7'<;4X4!:@%WK5.=!,&PS:H6C4RH.! J#G\6(H01A7#@N.?Y;B
M62-,=:@$9$9<?IKEP7.86K)PV$-X\P<UDO7C9.%-A0'S'5.?D"5EHDD,I>BH
M3%4I9Z0@!:K_ !&QK'N(]#BS4#",&EI(\( P(XFJMC2V05/X;/AH3P P([\U
ME67GXZ"Y!_28\:8TIL,18\QDM2"AM'29,I"VNA^*%)78]25]:4V38FU-L99"
M(J$&OBH<AV'@<O>K,;9)":'2>)_4.2QR;)R&9E)5/DN?*LF,RV^^ZI3,EULA
M;#,F0I+SH;"4 );Y\KFMJ?E+>'2*4K72!CGG3#CB2I?/;VL19#\9S(S_ +/:
M?O<LEEV-49*H:<"U)_425IFY MN-R8Z7 $A!DJ=0W':Y_"DCS*CSK$DD!#I;
MX59]AE10]M./>?<M1*][VZYR&0CX6US[:<3VE94[)BXJ*C'8D(F)"E'**7"2
M],];J4EST7^OTQ92N LH<.?C6(]LL[_F+@EM!X6@T&6%?UK5/E,K]3\0%C>0
ME9-<Z&#%EJQ2"3(?3':$J4MKI2TP2$%B.VTV1U.=*U%=KBK<<#7L)#F^<3Q.
M _;V9*RYSB<<C^E%U;JF8#4K9-CRDN!AV5H?B0,U*:E1H,N.VXV)>/BI9C>I
M/<ZU%' )92KB;F]6]PW.RV^,1-#72Z:.+!1SP?L$U-&\''-U.6"VFT[1>;I,
M&6[3J.1.0[>]>7MN[E;WW.DR-([309D+#N.6RF<6HI6^CJ],R9LTA+;;=U$I
M%^D$FP)KB+R3=NJ+D0L $#< !A'&WZJT]IX+W/9=GZ9Z$LAN^^O:;JF .+W.
MSHUN9/T#BME]J_IVTW09>(RN:6QL>Z2G',CD,UD765Q,9%2KI"(D>0ZQZ$KU
M 27G' X$C@$\:W^T].V6VLDGC;YEPP :RVM7UR:*&@Y8$GGBN%ZP]4-ZZF:Z
MPM2;39,1Y;31SQ_TCA3 _=&'.JWGDH^+@0FL8PTQ/A29R')/RK\>1#:8CH2^
MAV<J6I3DUI3R 4F.WTH>;%U@<^NCGN[F1]Y*[1*R,@5!!J<#IIEGCJ-2#@%Y
MB!A0?0M Y#'2,WD)^SYV7#Q(8+T7!E42(1@,*V^\XPIU$EY^!-RH6\I?J/%Q
MMLJ "2D!-=K:^7:6K+6WU28 O-3XW4%> (;AD*$YYXJXQKB"QHHXGVKL\!-P
MT2)F<_@(CS&3#3:#N6W0ITE[--I4H\,D\Z,XK'-==FD,--1;D!I %JM7'G.=
M';R$&$GX(R &_P!FFG4>))+N95X0")Y;("V3MS*V%VWWOYV=*E9%,K86PPTW
M&;BX#-8;#H=O9Z3%?G+,[*NNE-DI"TMH'&QX$:;>[!Y@$<$K;<U))+V/>1RH
M/"T<S2O"JN-#6CQ-)*WMCHF5V68A_'Y08#I2XES7<SD<5'ZND)*75PW6969:
M:(Y*"RD@WX5Q5S>VFWM,5RSYJO\ Q6!X [*AS6D]PP5?E1O%6T8X<,23]%%F
M431.XF0>7#R<YN%KK@ ANX1$R/C?5NDJ4[C8N/9D24&X_O/_  +L;<.-<W=R
M[6^(2;>?QC\7F'\0<?"7:FD=Q!"V#+AL8HX$T.5/"1VT(<#["N8.P?< 27BQ
MW>B8:"M7]EG$:+"^>0V0.#LR1DDMN. WX^F![*Y>6.:8FLCM/O/[/H71V^^[
M7;Q@';VOF Q)E<&D]@#:_P"TN6U]-\M\*_6N]'<K(%9NH0$:[AF_:$AK%RG1
M]ZZQ7;<Q_P 3WGW#]2S!UD8C6UV^R9WB1_UO'U*\/I7T%W_[([3W2RAX]0?W
MN?$2JYXDIQC,*W#RJP[9+)_Q^8[^V?U45P>H.^L_D1V,?=;L/^_J791/I8['
M1A_W.IS\VHD$JV#;-KS'5_XD2\RIH_<D5 Z>V<?% UW\1<?K*B3U'ZS=_+O3
M$/\ HHXH_P#=8#]*[ECZ;^P4=86CL_H;BP4GJEX*//-T^),WYCJ)/G5;=AV5
MN5I;U_@:?K"QI.O^N)11^[[AIY"9[?\ =(6P,-H>BZZD(P&E:GA$I  &)UW$
M0.7+C'AH)/#SK/BM+6 4ACC8/W6M'U!<_=[KNNX.UWUU<3N/_.2R/_WG%98E
M10 E%D <@@!(Y6Y) '*LA:_2WD$*E'F2:@@'-3EDNFCZ_A8KZY;.-B_-N+4X
MN4ZCUWRI:BHV=>ZUI%SR! K%CL;.*4SQQL$[C4NIXO><5GS;GN,\#;:6:0VS
M10,U$, '[HH/H7<7/+P\O#RY<JRN->*P* +%=VT;3>Y6L9'2^X&L87<=4RR
MF?@=@@M3X#RDD*:?0AP>I%F1U@*:?94V\TH!2%I/&L2_L++=+.2PW&&.>RE;
M1S)&AS7#M!P_6%N=@ZAWWI3=X=_Z9O+BPWNW=6.>!YCD:>-'#-IR<TU:X5#@
M05\UMG^F#OS],63>W;Z4\]E^Y.@1G%RIO938\H%[K@(20IUYK0MDFK]/;(J
MFR,=.Z9:@>E+D@V37ROU/Z#;WTGN3NK?1B\DM+UAU&S<_P #AF6Q.-06NXQO
M!:<L<%]J=.?F ].?5W;F]*?F LX++>G@-9O$$7X$KL@Z^MV"L+N=Q!X1346,
M%2O0'8'ZT^WO=Q3FN; ZYI>^XMSY'-ZYL,5_"9;'Y)HE#\7+8?((8FXN4EQ)
M!*D>D?#I'"M_T'^8"UN[T=+>I,!V;JAA#"Z0&.&1PPQU#\(D\:F,G(LR7F_J
MM^63J/HZ =1])N;NW2$XUQ2V[Q.QS#B#%*PELHH<J^8.(<5[224J2E:%)6A:
M0I"T*"T+2H72I"TDI4E0Y$&QKZ38]DC0^,AS'"H(-00<B",".T8%?+CFN:XL
M>"'@T((H01F"#B".(*FJE"41*(E$2B)1$HB41*(E$2B)1%%0H4U*E*(E$6HM
MLW/4]$PDK8]SV+$:Q@X:%N/Y+,S&H4<!L=2D->H0Y(=MR0VE:SX"N<WWJ'8^
MF-N?NW4-W!9[>P8OE<&@]C1\3W<FL#G'@%TG3?2W4?6&ZQ['TO97-_NTI ;%
M PO=CQ=3!C?WGEH'->25?4[W&[MN.P?I8[13=NQ?JN15=W.Y+K^E]M([J."W
M<6V^U^L[,E (4DQ6UA7(I%>2_P#J/UEUH3'Z7;.3MIP_J6Y!UO;_ ,4-N*33
M4P()+0>+5]$#T,Z$]. VY]?.HX[/<Z!W]'VL-O=R(X-F>#Y%K6A#A(X$<"N*
MKZ1=U[FO-Y'ZF>_VZ;ZT5^JYV\[>J7V\[=L$BZ(SBH:G,]DD1U*(]1*XBE@"
MXJAOHO+U&]MSZG[S?;Y)4.^6:?EK%I&0;!%I#@#6A=1W,J\?S(;#T3&ZS]#N
MD]KV,Z=(W"] W'<G#[VJ4>1&30$MTR@' 'BO0G;SZ>^QO:<M.]O>U6EZY/:;
M],9MK#L3]C<' J+^R9;Y_.O*61<E4@DFO4=CZ.Z6Z:B;#L&WVEHUHH#'&T._
MOD%Y]Z\6ZP]6_4[K]SO\X[[N=] YU?*?,YL /[MO&60- X 1@!;E4ZXO^MQ2
MO =2B;6Y6ORM:NE..:\Y:UK11H '9@@6?PYWX^0J,E4K@(/*I1*(J@M0-PH@
MCQ' \K4HA%10Y+'=IU'4]ZQKN&W?5M<W'$O(*',;M.#QF?A*2H6(^7RL:4VG
MW@ BL>ZM+6]B,%[%'- <VO:U[3[' A;/9]ZWGIV[%_T_=W5C?--1);ROA>/[
M4;FN^E>/]M_V]?ISS+C^0T7'[7V.S[JO51E^TFSY#"PFWAQ"EZEE%9C4G&BK
MBI"(;5^5Q7E?47H;Z:=15EEVYEM>'_B6Y,3A[!X?H7T/TU^;GUJV-C+3>[VV
MZAVIN!AW2".X)'(7#1'= \CYQIR6OAV5^N/LJ?6[4=W-4[ZZXPM71J^]M*T3
M:TPT_$EMJ=U9?4\G+-K75^GA1-^%<#_Z2^IG1GXGISU)++:-RM;WQ,IG0$ZF
MXY5HWO7?_P#K#^6WU,_!]3.E[G8-V>!6[V\_-0ZCA5T9\JY8WC0.FIR*N8__
M '!%:#EXFJ_4UVHV_LMGW_2;1+SN->8P,TJ5Z1?QN?8,[6LFVMP</0F?<+BJ
M!ZV];=(R"V]3^G)H8@0#<VE7QD<7Z3J!YT#FI/\ E-V+K:QDWCT.ZFL-]M&U
M/DZQY[*"NE\+O+N&&F9=$[O*]L:1WJ[8=Q(K$K5=OQ,X2$!QIER2VP\I) (Z
M2M?HN$@\.E:J]7Z7]5N@.L UNR[C#\TX?RI3Y4O=I?0$]C7.7S;U;Z0^HG1,
MSXM^VRX8QAH7L:7L'>1X@/XFA;2\ >84+@CQ!Y$>8->B4*\UXTX@I4(E$HE2
MB5"*L&Y\JJJJJJ?Y_E4J4!(Y?;[7HBXT^;#Q<1^?DYD:!!C(4[(F3'D1X[2$
M@DE;KA2F]AP N3X"K4L\-O$9IW-9"T8N<: #O*OVUK<WD[;6TC?+<O-&M8"Y
MQ/8!]>0XKP-WS^NC4]+Z]>T +S^PRU_)0Y3$9V7)?F.J+33&%Q#3;LB9(=78
M-E2"5$\&SSKSO=^O8M?RFR-,DA-!)0Y_N-S)Y$X=A7T'T/Z#[GN0&Y=3D063
M1K='J  :,29I*Z6 <0#AQ<,EKKMW]*G=3O=DFM[^I3*Y?5-;F/HGQNV\*>4[
M;G65E+J#MF596LZ[$>2;+BLE4XI-BM@\*;5TK?;A)\_O[W#5CY=:O=_&:^$=
M@Q_A6UZE]5>F>CX';%Z=10W-\P:3=EOX$1R_ 80/.<,Q(ZD5?LR5JOI5K.L:
MWI6!Q^KZA@L9K6NXMLM0,/B(K<2%'!-UK#;8N[(=5\3CKA6ZZHE2U*))KT."
MWAM8FP6[6LA;D * ?ISS*^;MRW/<=YO9-RW:>2XOY35TDCM3C^P#(-% !@
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MMWB,7-P>&Q&M=K)^];3L<9QIZ7D=AF87,[!.&N1,TR_C'7G8V-++13&*F6$
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MKNFUWP#K*ZMI@<O+E8__ '7%>97FS;O8$MOK6YA(SUQ/;3^\T+M0E1M9)/M
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M$2%0=8A*45 )C@R%)-G'G!7J6Q=+;7L;0^!OF7HSE?0N_LC)@[L>9*^:^O\
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M<Q(V5C.8C<WY6S#XY$R8Z,DE:BE:ED7K82=-[GNF]B_NY_.A)'AD(9)&W[+
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M?0X[ZX9==6J,"E".LULYOD*MM[:3\,LK1\;I3(X&M*.I&!E2H%#F:+#O?F2
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M1,4Z^F/#D,QNIAV5ZD9U0+SW7T*'#AH[Z 7K7OCC:"Z2M6G$UIF2":&E'-&
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M,*Y"M:$8-S ^X:9"X-D T]G<!D/=^I9WE,^UDVX\9[/:RU%UIE$G,9?$1<K
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M+-F=(A9 E;&P=P%A!<"%Q\<2GJ55KJWJV&PMF6LT#61-#3:[>12A'P7%^&X
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M@)Q4UUU^"ZL9EAYE14^%XO%P<BF46TO(D*0KU@.L(*DJ!5PR@Z4QQMN6.\\
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M#FXG$E;-D;'EHT1"==,A&%Q4!IAW-R0J3CI0;!6X[&=3%7*ENJ<=LMP_#PL
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M5+&_+_#SIBJ@&TJ2$LKR/YU-"J01QR0BWLJ#49Y*?"6X9IY5%>24/%14E2T
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M7_4#VX[J8^-,P&>QRW)"&U)2B4VMEU2T@@-K)"FR;\$N 7\":]+Z8]2^G>I
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M6AU:,1V5<,#B0MI'H!U^3_=Q/T\.VM/<O-KV%SD+:CD_5U7(G-9%,?8<EM6
M,G#QI#'6_(D#U9+^:+$!*U%70$=92D )' =.VY@DL_*<9HW1LJQL<@#C7(8
M,J?T)5B=@F/EN8TW%:X$ZJY@$TR]ZS/'X"!E)4!UW(['-UXRHL7*97$QY\:"
MXGJ0VMUQ D(?>QKBU@\>I:D*%A8UK[B_?:P2!C88[H,<X"0@D<>&;NP+,F:9
MFM=>.=\W)X8H6$:G'@,?"UM<ZA;(U+-XIQ_.8?"-S9>/3U+?R09EPG<5)DNM
MPL@J>PN8LQ<?-@,)1&6I!9"R?Z5 &L+<+9SH8S<EH?(*4P(<VA(H:"I!)J*Z
MJ<UC0[A'%=1ON<#K.!^^!@#PH"![EMB=G8#V-Q&BL1-L4]@GXQ=?SV"AJQ$S
MI4A469&RTE*WVYJUKLMV(0V\GF+<L".S,<SKX^0(W,(;H<0]HIBW2,--,@[$
M<%I8[=[K\[A,6.H":XZ@>W@1F:$5"R2- WN8J3F48:,<9"C,:]!QTO-3&,/C
M2MIWT)S33DY/6\HH<=6DE+"73U*L1:L5TVV6X%JZ73,\F0D-!>X5RP;EDT&A
M=3*N:QI9[.*0_C_CR.\QSJ5)%<1EA7(<<*+&M@RNP-P/U& P]AY6.4["6Z9K
M/RTQQ9^58<QKC3WJY'&RV8ZDN+0"@@D<4<3<:RSGF^5D<U\3@#0#Q ?O"GA(
MK@#C[5T.T2PNMYFU8^YD:=(IE05JX<""X4[0#FKPV9[:LMC\AZ&N8C8<A)]#
M,386+.)&4Z%PV8D_+O/O-XGYV0$D&4REH^F"'2214V]DVQA+-4K[9HJP.<':
M<R0P :J<=)KC\*P)K-FW"Y@B,GRH<TXG4<&XBM-1%>!)[%G&$W]S5]LQ<B+,
M_P#3\9E$IELY"'BYN!<ALA:,VN#+QS<R;*AY!9<0EUM2BME=TI*CTUK]RLFW
M%B^61M'N94$%P>/N5!H&D8&AR.96I;:VUS87=Y<-Q;#X*$@AQ/@=C0 C##FL
M5E2\KCLAE%O:Q&FXF2X^,2].!,O&!2W48Y4^>XPTEU?6Y_?0XAOK4A-[%-9-
MNR*2"*LY$[<74R=7%U&@U[B*T"U;GNEC9YLA,HJ2?O5Q/^A=_P!NH/<G-3?2
MFP8,"5AWI+&,6A!0EEE4OYQ3L\O)<8DN%Y?]KI"PI'21PM3<;C;(H3(UY='*
M!D<<J8<1VY8K--Y;"V>ZX=A)3!N+J :<C\.6?->E,/K:I>2<G[%FQ+R$=YF,
MF3,>:A,Q9S[1*Q"AA?RK:7$M!#CBD^HM9N3QO7$7$\+/P[>(-B )R+B1S)S)
MQ]BYZXOPUGRUI$V*VS( JYW:YV9SJ!D.2YF:4[BX2=43(:F3,I/9B0(F+2UU
ME<F6VX92W6@5EMMM)6LH4I)Z3RN0;,;(\;P Z6BIK^GUXK!9 V1QG.#&-U$G
MD.'MR"ZS*:YDL-,DQ,?*A-99N(TUC'Y+']EI\]7RK]G6G'!U.,]2>M' K /P
MFL66:.>6.20.\D9TY',?M6JGU2QOE=F37'L_UKC:["R+<&,C:WL\91,:.\[E
M)"%)AOK'I-IF+Z&T1FECI2CH0D=*A\0K+;<0B1S+-D8HXC#$D<P!].*U[@&
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M"H!JHZ_(?G_*J45N]CPX^1_D:G"AYHNNS&(Q.PXN;@\_BL9G,)DV5QLCALS
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M3[/;^U?+"&/J'^JCZ@9$I?;_ '[L'V&P^)6VC<-NU_$KV7/2L-.6]B48?#;
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MX'/]EMV[F8K*;IEMDQ6B:[*S.87D-@G/IE;!E82)[JYTS"NAB-A<+@)#J?\
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MAA<IJ7$+WRSB&9;S"D-14,-M(0;W40#6FE=?-VYM_%#"^0Z::27/=J--)',
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MO4:?Z^A5]G-%\A-!>6CG&W?1\9(%1I-"UW#4TBAIG@X4JMK<'^FWD6Y6+_\
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M[BY&.K!P)<)ME):B0IRVE)Q\B.XI4_)Y5F,I;+"6.#<5)L5JLL@@ '$:P6L
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M3]UQ=0Y$#!85.TKZQ-)0N1@LOV_[G1&$E8BQ)N0TW.O!(N$-1<JB7BUNJ X
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M0#^'B*(G"_#W\?'V411X^7[J(IN>%OL?V417@X;@>(X7\SYU" T5WP\_S/\
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MZ)E!QB=RM_C*XV]27@)R ;$#X)> <N!Y7K'=MTQ^&\NVGOC/^]&5FLZBM/\
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MS^O=HLB;:5[OQ;^P9D-1Q-W94;X\7.C#)34LDK]8]*W/&;[JV*VC$.),?(,
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M5UHNJ'/9TW?NC^(6DG^[C]%5Z5Z-1P2^K73<=S_)=O-L#W^8-/\ M47GS_;
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M?RMQX^=0BK2L(3RN>-_/@>1X\*E0KH(4 1]K<ZA5MR4^?/[>=$QXT3D>'&B
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M@W7VT^HWEF,3#GS7&LWD8W4Y%?,/T4PXV0B1704H*U%T)/1\5Q5EFX-LO#=
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MI4DA25 *2I)"DJ21<%*DD@@@\QPKV[ZE\(=G$&A[#R/:IJ%*41*(E$2B*"H
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MI<21VAWEKMK\S*D]O]G8DY305SGUR7<%*84G]1U54MXEQV/%4XA4;J4I?HN
M$DH43XQL<$GIGUM%T?$2>B-Y$C[(.-?E;IOBDMFDXB.0>*)O X#(E>V]2W$7
MJCT2[KA[&-ZXVES(MPT-#1<PN!\J[+6T ?@1*0*:FDT > /0X'&Q-O?7MI*\
M)4V3_P 7Y&HJBU&DD6XFP/&QX6_;5DK..=%R ;B]0H4T1*(JDJ*#<'^%$7,;
M<"P+D=7B*A5@U5RBE*(E$5Q"O#Q_=Y417>)^^]OV_OHBBB*JY))L#YU& P17
M L)%QQ'E:Y%_'G[*<45[AS\/ ?8\"*=JD94&:@#VV^WOHJB5(_'R]P/'QHH-
M,E4/9P\_X<Z=RMN%31U3]2J2;<+\/"Q\?QJ<\59<PL9H.?8KP)5XCASL>'W\
M:CL5GPN.% !^GO452H4\"1S/"I-%&-%5P\K??[_;YU4-6848J.(/#[B*N-:Z
MM"BO@@_O]GOJLD- "*H?CY>__"I[40?;[7%2B<3YFB)Y?A]KFB)^RB*M*N0/
ML ^UZ(KE$4T1/O\ X_A1%%$2B)1%6E93R_.A%5%*KDI4%"X/\:I5-**JH4@8
M=JUSW9V ZUV^V3(-*"9DB%^DXX$VZLAEUIQ\8)\;H+Y7[DUPWJ7U#_E?H7<M
MX80+EML8XJ\99OPHQ_>=7V+N_3'81U)UUMVVR"MJ)O.E[(H!YK_>&AOM6M/I
MMP2(FN9G/](ME,DG$P%VX_I>O-F%P-AP<R*GU&W V%>9?EOV$6'1LV]O;22_
MN2&'CY-O6)OL,GF.]J]*_,3OKKOJ:VV($Z;.W\R0</.N3YAPYB(1A>D;$FP!
M)/@!7T,OGDKYB_7CW"[<8C)]JMEP/<'!8_O#VSV]<F'&@NG(36=>R<17ZC#R
M*H:78\=#62AQ)"&GE?$6U)*;*-<'UATC;]3[KLMX+@6UYMVZ1RF05U^0<)HV
MTKXGT:&U!%<P<E]"^BG56X]-;5U'LEYM\M]T[OFSOA\HX,-TP_X>4UIX6M=*
MU[FXZ2*$$ CXE2I&5[A[;W/W23\QEY&.QN5S#^;G*>=>DYO)/NS/5=]19_[F
M<F*LE*1U>DVGE<W_ $3B$=IM=C9D>0'EH\L4%&  4(I]D$=SB>2\@?"VWD+6
MD$_"",L,#3LKA7C2O%:M[<=O<[CLU_JK;8GR;>#'ZKC\,Z'$93*YI^4PQ%D3
M6T@*'RP>7)*72XH>F!T)\<W?+ZU>QEE9!SQ.[0Y^<<4;&EQIP!) :",R<UT^
MR0N@F-S*-4D<;BQH&+WNP;J/!K:UIR JO:>Y]L>X4[;>X>4EP-9FZ3 RD@:Q
MFLK*G2<C,TV,6&\=FFH"G'8<_P"8@NI]%:PE0<4NZ%) (\+N+6WO+J*2S=.=
MQDC'F"K QK_N-IBW01C6I.=025L;;=9+P,8&EMTX8AO!V-=1R'<#2G:M;ZUV
MTE;OF)4'5<-'S+F.8BG)YB=),[$8=$AA329<Y,[T?GLM(;9<9C1&6@Q&2.KJ
M!2+9+K2^VQC)KH2LG!.@#XG$$5+"*AHR)<34\E:OII;:'3('A[C4-&)//(4
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MI2@ DUT4L9EVN5D]S;FSB<V@:"X-H:U!;I89#DUOB .+B<E;MHO,)CUMT4S
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MW$LU=!CETL<2,7.:YI<&M&9Q [:A:N>XO8X6PRVC)G.)#*2 -/:6D:@ ,>/
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M3T23_K;NBY(8Z7==[9L/P_6!*FI>YY1H)=2V1\"OT?'*(4;FSC@\:\LM)?\
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M[O"W4IA9-S6LC:+7<WMRCN6ZO^T8 UW]YFD_V2NIN9'[KTO!*XEUUMDAA/\
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M2.ZR]',3+0<R[%>9=39:&K<02*AD[KJU>QW\D/:">&(-".XBN'ZUSI+HW"0
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M+Y&BK?$&F.K26 >$N I6E2:K1[D-Y9927K;D1/:YK=.! U&F#JD!QS#<32N
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M%&242JTS5I;M 2+^VB*\A?@>?@?/W_=1"2?"<BKO,\+_ &^ZBI=707.&')5
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MP[5C4C_T3)?/#X<7E7$-ST ?!#GJLEF:!?X6I'!#GML:QW'RGZ_^&[/L//\
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M,:'O6H9-B1D-/SLU$7 0-8"52L-L>3W:3EGV(>1R.4#D9N"J(ILEE;BW6DJ
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M^;>'(\1[KT1 +T1/8387\O']M$4417TJ/Q7%K 7MY>%1P3C57#]C_*F:D85
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M<^7C0D-:7.^$"I1K2]PC'Q$T'><%U^&A%)EY)Y/_ '>1<#AO>Z8[?P1V@3R
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M<20%M=CV:]ZAW>WV;;FUN[B0-%< T?:>X\&L;5SCP:"3@%B';#!Y&#B)VR;
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M:415I58@<+<R?/AR/XU':I5_[<**H<^*43O3[>VJ@"Y**1;V$<+CPOYU<J0
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M*(E$2A1*(E$2B)1$-17FBA1L+_;[ZIJ2:8(J+W'A8_Q_.K8454#@!P/[?X5
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MUK_MJ58=J)J1BG#W^7VO14*I)Z3Y>?NO^^B*^./&H131$HB D&XX&B+GH5U
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>g382677f_39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_39.jpg
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MQ ":  $  @,!  ,! 0          "0H&!P@% P0+ @$! 0$! 0$
M       ! P($$   !P " 0,"! 4# @,)   ! @,$!08'  @1$A,)(10Q0146
M46$B%PHR0AAQ(U(S&8&A8G*"HE,D-!$! 0 " 0,# @0& P        $1 C$A
M01)180-Q,H&AX2+PD;'10A/!\6+_V@ , P$  A$#$0 _ +_' <!P' PZ\:%2
M,UA%;'?;3#52&1]0?>S#U)L"ZA0 ?MV2 B+J0=B _1% BBIOR*/+);<1+9.4
M;&H?*%48M1S'Y'2']M63$Q$[':UE*_!F,41#W6L2B1:<?(F^@A[HL3"'-9\-
M_P JXOR3LX<N/?;L[;SK%2O+6GLE#&$C&F0<=&^T4?\ 862?I2LR/@/S^X#F
ML^+2=G%WVKG^;V'6K*<RE@TZ_3!SCY-]];9Q4@B/T^B7WI42_3^!0YU-=9Q(
MYS7$OR9W>ZPV?]'7</<K9$NW%+["*.'479)J/<.%$-?9)H'<+M'J*JYT$_Z2
M"81$I?H'@.9;2>5:Z?:X'I'>?N;FXI?LGM'N,(BD)1(R-H$Y,Q@^@?)2J1-A
M<2T8J0/_  F1$O\ +DQ':0O'/GS[TYTLU;Z"MG&ZPB7MIKHVZKHU*R'1*(>O
M[>R40(=F1P8OG_N.(UW]?Q ><W2";_K)\]'4':5X^NZVE.=;+B].FW*>[JHS
M><.72@D(4C;0HE!)&-(=0P_UR[*,2*'CRH/.;I8J;&'F8>Q13"<K\K&SL)*M
M4GT7,0[YK)Q4DR7*!T';"09*KM'C58@^2*)G,0P?4!YP/2X#@. X#@. X#@.
M X#@.!'%V@[^UG+%I&C922.NN@-_=:24NH<7%2J3H/)#I+J-U"&GIIN;\6R)
MRHHG#PLIZ@,D.NGQ7;K>D9[;R=)RA-OFB7C4+ O:- LTI:9M83@5U)+^I%DD
M<PF^TBV*8)L8ID3S_2BW333#^ CY'GIDFLQ.&5MO+#.5#@?XF8%3>A(?>/Y\
M>A(!5/Y_AZ2>HWG@<G_*,R?!FO1Q06#\$T:3V']]063KT(>O8&1R>\?V?2B)
MR?4OJ$/(?4/IS';[JVT^U#N5=$YA(19(QRCX,0JA1.4?X&* ^H!Y';Y> X';
M?3WY!^S/26=0<9)<U9&AJO"N)_'[>J[E\YG2&.0SDS:-%8KBJ2RY2^ ?Q9VR
MWJ\>Z"Q %,9=9>1=+Z'?)1@O>^M&3J+LU(UV$8D=7/&[(];FL<6F'H36F:X\
M(1NWN-3,N;TE?-B%41$2E=(-SF(4V5UL^BI$.<AP' <!P' <!P' <"'+NYW=
M<JN9C&,8F#-V[<R\9?+Y&+B5==<HF1>5>KO$C>44D1\IOGR8^HQO**(@ '.;
MT?'\?^6S+??M$1(  !X / ?RYNR?(DDJX61;MTE7#APJF@W;MTE%W#A=4P$2
M0002*=5994X@!2% 3&$? !YX$A6)_'1K&AHM)S1'9,JK;@"*ILGK4)&[/$#
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M@:Y.GM&JZ58U#>L\W>[7(^H?KY(XFWID@_Z%1 H!_(.>W7IK)[/->MRQBKQ
MV"SUF  //Z[8X*%\?CY"5E6C W_VN.6W$RDZW"W W;HM&Z#5N0J2#9%)N@F4
M/!4T42%33(4/R*0A0 .>%ZGS<!P' <!P' <!P' <!P(/?\@:E(63H3^YA;D.
M\SG9LXL3=P)0%1!M,J2U(>D*;_:FL6TD]7\1('.]/N%(OFJ)V/\ 'HM:L)WD
MM5; _A"[8#<VBB?GZ'<5^U4B;;'\?F=-$JX!^?@P\XWX(NO<R4X#@. X%1.?
M(=.>G$U?/NIS,JFKY_'W"/W!5//\_6 \]SRLRQHZ:>PY.=;Q[1-,H@J>?'CT
M?NB+\^?/T\<FWVWZ+.8M=<\3TG <!P' <!P' <!P' <");YP56Z?QL[B"_CR
MK,9.DW\_B+D=7IID_3_\0%((_P#3G6GW"AES9$RWP+)*J?(I4S)@/H1R3655
M_ ?0$1CX=$/5_ /?63_]OCG._P!HO0<Q4X#@. X%53=Z\-4VO6*X)?06)T"T
M(HAX]("U6E7#QF8H?^$[1R00_D//;K<ZR^SS;=+6NH:44@YF&G$A$%828BYE
M,0_'W(I^W?D\?S]3<.7GHBW%&2#:7C8^59* JSDV+20:*E$!*HV>H)N4% $/
MH('24 >>'CH]3[W <!P' <!P' <!P' <"!W_ "&+^VK?22LT<'()R6F[=3(]
M)L!O!UXJIQT[;Y)7T^?)DT'D6S*/T\ *I?Y<[TY%*OFJ)^/\=>FGFNXVGW(R
M0F;4;!)5L"WI\E3D;C<ZJT:)B;\"F58PCP0#\P(/\.<;\$7/N9*<!P' <"O7
M\BU&/4^QTE.IH^W'Z%7(2RMSE#P0S]BA^W)9/S^ J@>*15.'X_\ ? ?SYZOB
MN=/HPWF-G" @ @(#]0'Z"'\AYJX61NC6EIZ3USI)EG/OS5)1/09PIC *I%JX
M1)&*5.'D3^'=>5:*>H?Q,8P?D//)\LQO?1OI<Z^[KWF;LX#@. X#@. X#@.
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M-U57S@I//V<LBS6\^?;]TH <=9M+PCB(! 0 0$! 0\@(?4! ?P$!_,!Y1_O
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8/,Y")D&!EEG[UF]*"!I_9?W9[<S^C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>g382677f_41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_41.jpg
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MQ #U   ! P4! 0$            # @0' 04&" D "@L!  (" P$! 0$
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MH"#7ASX5)[^.) \%0P74/^GYL\)B[FW4\V?XKZ(;#A21\+23J //XCC&N",
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MA]@KQP@ZN8<4OX>^F0]IP!(B7-!4H@U':?U88;BJJADX9(4L<>%,\ZG[, '
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MXDX/4/B%$1EJ8X(Z6>!X>O(T]?;B,I.7*F('20<RB>4!EEZ^?#W5Q%VR4A$
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MC'X0R(&"!P)KV"OJXG!ZF.&:KJ0]08$,B!H_AH:#F?LY81F1GFF(4S#26/\
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MG[\L+%-@J%%*4J:>'ZL/%T-Q0CD2._QI@X*/% 402I)J:4SY4X\*]IPOL3+
M/Q0*U'AW#G3#0"'9>4JM.W@.T>)YX.*B7'O0"$GE49D^&?;WC"Q0P3-8%304
MSKZ>W%@)!?-EC?B)X.A@<\\S2OIPQ:6;J ZD<<DUFRF8$.5->6$-1F'7W5$T
M 2TC74FM.6%&1D6XJ0EY=:^?;KCO9_J!U0W+?EN*=BIG.0H(*E%(CQ5%H% /
M +4DG&WC!XQC' @+GJDO4J&0S)^A4/._$345ID.X'WXBVG#@H+87Z5]I_P":
MNLVV62T'&;<ZJYO?#5(^7*?+)Y :SBFM+3#JLFS@)UG;+%=[4LA #: :( 2
M!04 H/'&NU@8A;X0"(ELDT(*1SIRR[<1E4<*0B B% %2#P' \_'%;N>J>&2J
M$$9BE>ST.>'F&2.?1'2@&AY=F?CA'HFB! %<L+%#>]$ &1/?RX8?1#<>*\0:
MCCGR_0:\,#)#')(T5(!!RY>/OPF(350U4@4Y>HT&']B&22W7T%/3+ @X9JM
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M,BRX7C40HJ.I2BHE1%5$DU4:YFI)QMP.:U0 &"#IKR/NQCU&U>51EG@NCO\
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M3T[<0\,UDQ)(<\40 G@,#>]6.!X)0-":9\*>K DV3Y)814D#CE0@Y \Z]N6
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MX*$HM$ \%+/0G:IW7U8V9:RWYC(NS,R1E4!F$?/4I65*50,8=:6F!5UI#77
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MC!BFO>7Q(^RG'U\*8D)MAP3$B,\D9":#TR]*XA.6HA!+ET2F$ DBHY\Z<./
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M*#GWX!EB@YX)"UYT KII7,C]N!T]*3JU)I7AP',^_E@1B/8D*)*@:G(#AS\
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MS]=,)28L_ HS;%>)IP[_  [*8C*6D*X4HL)'!&#.>? ^F79B)F /*IBD"?\
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MUEW#(V3N+9>X'6[C9-F[Z7&'^7;Q9PM"/D8D^44(=0O6 :D4S&*JT9B4)1+
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M"*D"O']?'#""4[;8!'Q<0?53EE@P"@3R1 RD&O"M12E0._CW8>"3E/F4I&9
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M4?)9%&GCJ(3T-9@9\<Z<*']N*G)*R)1!BW#CU3I*:T2?#QH,)L7"8P 3I+!
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M;EFI/(G,\_#/PQ>%2<7*;%/9AYJ#\U0BE.W[,#>Y,8I/#[<)#)/=7/D3Z '
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MVG(1(U%@,D9;P2DD&I\?M\,0C%RV2LJ58F+1R*MJG5J42":<AV=V8IPQD"(
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MU.0/:#R]N*YR.(')7TXC.1PX!%"0I=<A2H'/,81(C$ *V/FD9-E@@2 .X%(
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M&8(BD=(6/,:VE+/ZE986V(G4%NYO6*%/93%==;\UX,28<D@*+18D-*;>::<
MI_$;&E1H3Q.'&J0?,[*J5&)&K+#ZU!>ZMHW:QR7(\Z#)BK3FE+[*FRM(K0H)
M&EQ'>DD8MU1GB,5CFG*.!49R"\THI4".S+WU[!B!S)5D*@$=,Q@F1E$Y&HS]
M5:T)PE93G%C&&'[%G&T8S#KK]WN1 M5H0)$@J&3SHJ68X_MJ4JF7,4'/ &&,
MLDA#0'=Y\D"[[KDWF>Y,D:M)_AQV@HE$=A)/EM(3P'PC,T%3B&H.SXJ3AVF
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MN-!QB*K^8ZHA*<DBJL@IO*.D*R,@^J9SP'TY**MU;;W1M=\+EI1+M:U4C7:
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M#-"<H509FE,^T9]N?'".:17C0\*'N!R]?$C!EFFHBZQ]&>GO7+95WV#U'V[
MW'MR\1UL/1Y;"%.QW%)/E2HCQ27(TEARBD.)(4E0!!&)PD8?Y2JZE,5 QS7S
ME=5.A_5G^G?O+S'UW??OTS7JX!-IW4E#LNY;%\Y56X6Y A-&XJ"O2W*'P* ^
M.AXYE.H8##&E]8_L6GNK>49/D?M_85NYTIZHV^]6VW7>S71J9$E-M/QI##J5
MH4EQ*5)S0HT("L9>@2&*Q:=8Q.+B3Y<EOCT\ZDNI+3C3O\;2!)C%1\N4D4J4
MIK0.4.,6I1X+94;@$/$O);76>]0[Y&;EQ' K+^(W6BVE4%4J34D$'&#.!@X*
MV%.<9Q>*NP6.0]I[.-<1;FII)":C[!7.OKRP\4):4C/3Q&1K^C"QXH)9>H4@
M"M"<@/#B<C@/-#ND^92N7(^E:BF&R,T&FH=V1KSX]^ XIH!RJ,CRQ'HA';;J
M,QQX<#]N&&'BA/&T  =M>/?@=TL?8G(13,4';3[^_ Z6>2<-IJ.TU%!6F>7/
M$3AB<DPP#E.VV$FA/NR\?=BJ50Y!6PI&4=;L$X*$C[*??BK-93"46.,2$DMI
MYCT\<2$B"_%4>G3$C(_ F+R4)%0/9R\:TQ="1EGFJ982\OPIF5GEBS!1;!DG
MS#PKEEX'OXX75#\%2IXUS.&_-&"]6N!TTH#//LKAI$JI(Y=AK3+LP<$L4C$5
M)(KX=GW>VN!1X>Q8AYX.>JGIW8O]/'HHZE7YD=WMR/CGB0A$8,C47Z))D!66
M7AA".DN,D:P1@JI=%>=*UXUIVD>K$B ?%$3@B%T UK4=@I]OCB,H/YAFF#[D
M4*"DA7 9]_/GB,\) D.$QDP1$'/ 9"0P&*8!&:+BL#W)JJ454#3]?+ X 9"N
M#2=0H>_+AEG7GE3"R#(1?*(/=7]G/!P2<(J4 &HX\^)J>WC@2=T49X04D?\
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M:HA0"5JE.N17893^(^:ALC'S1OGR;^9-A?BTM]NE=/+RU:$XRI^)D3$P;CJ
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MQ%#)F\]J--7"G/NQ( ^Q)-%ND#(G+CZZ?IQ;&F^)2,FP0%O4-"3ZLQ[!BP1
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M<*<,^6%IP=-*!S!]M#Q[\)D(H<IG2I'"I/Z<"$):U'CX<:5KRXTPP.J$!1/
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MDJJ*8[G;_F1N%LU/<(1K0''X9>\8?45Y%O?R*V2]UU=DJU+2L2XB?/3\-)Q
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M>%]B.&&:KY8I0Y]XJ#]N)(2/*^($4IV5-1RXXCEFF<1AFB42* "M*T/97].
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M'78;M9RKV,1$LTA(]6X+F;U9V++A7#\U8:^96I:EQU(:U):4\E1<T+3I!10
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MST7V1;+HZS!W+YT:;>)#$*&$I#3\)EU:M3K*W1HIY/PA*TJ2JOABRSN82N3
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M3HY\Z^OVX1+X*>6*H54KV]G#O^S$E$JE?[(KZZ?;AI)21P!/B>?/OQ$G2'3
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M\#J,B0H5SJ/9BFI3<L%F4:L0<3A]ZWEV'ORW[Q@I25H:N;24ID1R0%%5#\2
M3\0/'&OJ4S'/);.G5$L"<5(7E&M./@#[QV8J97):6LP:D99U''#P"2<H!33U
M_;4XCQ0611X8,4AT2L"DB) X\?N.'E@D^*,*A)ISR.51RSKXX6"F"8CQ234
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MY\C[<,LH\$Z0<\SW#]HQ$!LDG5U:H0*UH>>7Z<4'-13U%..7&@S].W$#R0C
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M:B?C10YA25>/#%4S[DR=1<+JW].CY7LR4@_N3TY<_B81G7AF1C"Q<\UM:9>
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MA>&:JJ$ZM 0]0S-#V^W@<SSKAX\%7*1+1)=DG402:\#Z<.6'P5\0(Q2%.$Y
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M\!@$)22K57,#CPI4=F$A$"SV'GQ[^'LP(5=9&5:UIQXY8$DG63F"<\^[M^W
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MK2/U).GL.7;Z'/$B<$@?,0JD995KV^NN(_8F,$5H$D::CCW^W.N>!#A7)I-
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MCKQ$[>O1U,1JB3 C,%QE(\W6FKG1Z'=7C(LEQDV64!J;?BM+DQ00,REIA:'
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M+2F-=B3QC1^6?\U1KX8PR":A#8LMM2'\-^I6TWG)\>8S]6)D:<\E,!T-<C(
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M?TJGI[9W*84;N)$16_\ +J##^9$?#+J Q/)?BG^J_P#Z=UUVY.OW=\HA5O\
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M;.E<S/E)P. \%L:-W4/E,G!P&>06(W=MA,9;/F.1_*0MY=2IM)6K60?XE6U
M'4:=PQM[.4S4$V$@3@MY8FI*L*A FY '')N6/()'1YY3D23&DK!ELW2>F*H(
M#0:9>6F2V-0)"EAMZA'[W9B'>4#&4*D U,TXZN+D8?3DI=\TQ&XA5HC^%*C
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MJ1,3I9HI%.T.4H2>0[?U8K!/L0P.6:<)=J/'C0]^6) NHLE>8GO]WZ<-"47
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M4>2EM.:"Q1M:DJ0,P2<DGOQA5+2[I3%2O2G&,B\7!#]<OJ6!5L;JG,3N*52
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M]J__ "R;TVA>-NW6S7.Q1I<?\MM)N,Q<9W;\Q1DRU )BS'U:D:J!-3C\^O\
MJ,]WPVCY)6?;%&4/S.\;U0! )_E6L)W$L" ?C](+[A_0QVG7_P#O-W'N*O&1
MH;?M,H0G@WJW-2$"!Q_EPGCU1GXB-/PG0EQ: HJX!:U!.HFM--34URQ^)=&M
M4,FSD 0/N7ZM4:I-2(EX>Q?/1U<_K*WFXSNK72GI_P#3_:KMLF[W+>'1F?=[
MOO6\7W_--MG/3]JW'<-HVM#MMOMZ3.B1S)894Z_I)35>E)./Z5ODI>P[-^3'
M;7:<;00K66SV\9XA_5G2$JN#$XU)RXYGJOP[^=/:LN\?FMOG=E]>DPN]PJ5(
M1$3Y:<)M2 D3@T(1'PD<0ZMWTUV;8>V93=Z:VF[:+U>MHM[4G1IM^=M,!,1E
M"%6XSYL&W[H^>N4/26];B&0&4I;*W $E/JFPG>S6C6M!"C1E!@*CEQU.)#\B
M%Y)W#^2NJ4J%0RG,3<2 P!#Y!QTQ^KEL/?\ H=>YJ[5N+94MB!N!B/'6_?5;
MI0ZU&N#<M#BA;$0K=:EF&(P4$?,/)42NBD*;U)7U%QMG<%U7U>K1IX /!\^6
MKCAR9CS7-6VY;1:_P13J2EC\?'J ,.?T=:E?63])'5+=O3FS]1MH#;=YZI]%
M[FC>FV(]IV?9HNY;W#M%P8W'(M;-[MIAS[U=&YT5QYL/*D^?JT(:"Z*.IO.S
MKRA;RNK>N9WP.ICQ+@Y\3A@?H=I9]T6U*ZC3JP:UF! G(1CBQ;'#$N%MW9M[
MQ=X;4VGN*8TC<&PNH6WK3NO;SL]I;3MN3>X+4UV&VM01(B.P)+BVE()!0MLI
M4 1CM8UA<4*<Y SHU(@N>!8/[07"XVO:&UO:M('16I3(#8ZH_A/)C$A;\?0M
M]6JOIMWF-G;GN=P=^G[>]];;O\6<^9$?I;N:[+8BL]1[.XZHO1MO2G_+3N..
MBK;C!^?2GSV'/.\][S[9I7%&>[;?$_G(!YC]^$1B6_>B,>H#9LNI[?W+5..V
M7A C(-2D<!&68C+_  RR!_"2.#KZ7HZL]-4J^$%*D+2XVM"@%(<;<02AQMQ!
M"DK22E22""00<>1#IDNG(()!!$A@1R/$)^!PY\<23=*H,N[EZ=^!N2BZ10X%
M)^*I2I!/M\.'OPDBJZ:9X: RH33CVY]],"' 50OB/9W8$'-(+M"*D822IYE3
MQ^[ A>\P#GQP)X\5[77]=,!0Y94UC@3[Z_?QPW2*IYJ1S\>["=&KAQ3<NE2B
M0<LQ3M%>\\<&?BHDXXY)PA67KIXY5P*0*.%_MP\4%O>DA8%<LO'A@0<54+S
M.=3Z=F!T\ 5P1^I/XNM?47_\IYM"#09ANE:]N-C2_E@\&7.W+^O/EJ*B2WHS
M'"M=.?'( XE++V+'CB3R4CV@9(\<CW8QC@59'X@IHVJGXFAP^+EQSYC/L&*I
M\5?G+HN@?0A?EQYG#^[) ''(N@Y^O&&#_$)Z+;T/@8\%L47P<LZG[N.+G"NQ
M=W5"^!4DY<3W=F$2FAF0@Y@U/?EAOR0Q0U2*U S-<N_NKW86*8#%"+BLCS)[
MB"*C*O=3 R;!4#JJY\.SQX?;A')#(J'%$Y]J@.T>_/+!BD>2,%JRSK7P]^&Y
M21D.%67IX8!BA$2>.67CZOOPRF7**E5#48?!+CBG"'>1X'[?'QP##!!CQ3E#
MQ))IF!Q)K0<LL1E&)89!U60G27*Y?93B.ZO/%$HF!(&21R2FW *@#M]N=>WL
MQ.JV'-!^M.4J/ \2:>GLQ2Z:,%T_3WY4PQ)LTB.26E5,\ARXXDXS2(52[4?M
M[N6%J"-)3=;O$<_0UPB73R3=;AI0&GW=^?AB4 "<?<A>;22JI->%3P^_GA2(
M. PB@)QY05F./N^W"9TC@4@M]F1'CZ^["RQ3Q2 A79GR_1QP\#B!@AN:J&E<
M:>/J^W 26;@CH57Y<G,@BF7'UCF#@8\$8<4VDVN/-9<CR6DN-.I*5!0!.?$C
MC2@PP9#$(#+3/JUTCE6:2[?+$T5MJJMYEM/PO(J30T) =2*T.,J$Q( '-8=>
M@_GAX^"9])NJ,BRS&;;/=66"ORQYI-6U:@"TY4BB@!A2A$XG-%&M)_3.75;T
MVR=%ND5J7&<2XVM(- 02"1F*@XQRX)'$+*^Q/2@\.(]7Z<-"2IDD\1WX3@H0
M_*H..5:<.?MPV9"]Y8].WD<"$-*\B*9Y5RRYUYXB"F0R(DDGN'JX\,N[$DD<
M"M.?;F/5SJ,!R0EZ,B.S,'B./CV86*8!E@,TL-Z1J/V\OLP>*D7IEQFE:T#@
M1PX>AXX,5/U!(")&*\%!?"E!7(>G;ANKFYYIXRG@!F:YC+C3LKX8B2C$E<M?
MK<ZR?YBW UTIL<LFQ;-EIE[G6TL>3=-XZ"(]O44D^='VTR[I4.'S;BP15L''
MY:_K&^;A[E[FA\MMDJD[+ML]5V8GRU;KA$GB*$2V?\R4GQB%^J'Z._E%_P"U
M>V#\PMYI-O\ O%-K<2'FHV3YXY2N"-1_^6(?O%:'PHZUAW5I47)"4ZG":J0R
MD*40FE$@K0<LN./B>O, @QX1R'7Z!?:%>J(LSL(\.O\ 80KJK^&B2I/DK*Z-
M(S/$ (!J$J%/,<.,-M9@/,&Q/T]BPAYY1!U #$_;]@5[MDY<:6S1L!##/%MP
M)(*B *5"""$H.*B (ZI8R)Y+ O+<5:,G)>4N(_OYH6Y[2J5"9NL- TNZGKA'
M6"A:5 ZP\E20I"D*)&OLIV'&18U8V]71,D./*> Z?L4MIO11KRLJYQCA C%^
M#<P>2AF6VVX#YT9:%/K("@@+/DH_>JW58JCM S5CL*1D/@D"(CZ_:NZHRE$C
M1)](YMC[?I@K!/HIM]3+Y"U),=A)7JS&H5T. D@J]R<;&W<$"4>I6RMO+.(G
M'RC$X?>/IBHOVW<'K7O[Y;^"Y%=MB_-(*FW52(SB'F4I!!1_*UJ5\694,=/N
M-O&ZV$SQ%43#<0QP/W+L=UMJ=YVUZOF%:-8-Q&F0(/7-@,."F>^WZ')CHM,-
MQQIRX.ICRG"2TX^%I)?2 !I+2&ZC+LQPUAMU6E4-U< $4P\1F V1\5P.W;=6
MI5#>5P#&D-41F(ME[7Q6AVW;O,Z=]=MP;5^8?9AS=<NR1&W5AAY%/,?;=94H
MA54A1&>E(37C3'N=]8T-^['H;K&(E6IG35)&(/X2#RRZN5]!;G&CW/V5;7=<
M4C<"F"9-YFCY9.6=P3$X/@0"MS1=G9COG:Z.3+?4H0D+6R_!<!#:U*H#5,@$
M*R!TY8\A_*0I0T,XA/WB0_:/K7B1LH4(^FWEIU6?($3'_P"R<.J!-D7"093*
MW$);E0'&SJJXK-"VS5*=** +'[V=,%.G0A$&(\PD^"OM:-K"4) %XU1TP<<<
M>O!<Y[S>Y[MSN$-3F3<ACS5CX2XHPHP6X0!34M:#7+B?6?V?[0W.I?\ :FVW
MA/GK6-"1\33B_P!:_#/YE;#2V7YA[YM,01&VW>[ICPC7FP]S+,NF%I-]ZG=-
M+ 2M7YAN>-.>2$U)8L[;DVA33-)>""3CHZ!!JL.,@!]ZXN=,PIF0?1"$I'V#
M#ZUW+WC!#.T;.I6A: MY*BH$#25Q/Q<*!5.7/'SC^L:D:WRENJE,%Z=2E+#A
MYXKZ-_1K<:.\[VF"1*=J2/$.<%@MMC1'&0V[\HXCXHLA)3\+C+X*1J%35*@H
M5\3C\<ZLJAJ @D%P0^8/]Z_0ZZJUHSU4]8EA*)Y$8_3V*TW"P=18D!$/:N[=
MK-F++"([6X]NOS$?+ @QF77XEPC/%0:HCS014YE)SQN;2_[?G6,]VM:\A+/T
MJL8G5QD!.$@Q..G'DXS613W#MVXK&KN-G<ZYP<FE6;'\1$3%L3CIX<"L/<E=
M>;:E2I6R>F6XM"UK";/N2^V:0\XV*NM--S[++CM*> - 7*"O'&T%'Y?W0TQN
M=RMG/_F4:50#VTZD20.D? +9QAV7<-Z=[N% D-YZ=.8 .3Z9 EL,4RM^Z]XS
MBMF]]$]Q0DIUD"'N?:=T0[&5DM+2'ID)QPM5J 0"1EQ.%<;/L%$">W[W0F20
M<:->#'@[1FW4N>JS9[7M-*'J6V]VVM\I4:\<>!)C&0#\?%64)V7N:=-M<-PV
MS<$9*7).W+NP;/?F="U@.BVRPDRXRPFJ'XY<96."CC.,M]VJWA=5AZVVS+1K
M4SZM(]-<?A(XQGID.(6RC<;SME&-S5:M8$L*M,^I2Q_QQ^$_X9Z9#DH%ZK]$
MXMT9EN(BE+JVRE+S +3N9\QLH6!H51].5>!..\[4[TE2E")F,\CB.7V+T[LS
MY@5K24*<YO3?$'$<CUR^Q8'T[?E[8G(L[Z9+J%J;+*Y>M*FG"KREM%Q:4H2@
M@\!SQT>]PI[E1-Q Q$@,=/$+I.Z:=#>+>5]2,(R#OI9B,P6&)/BMHXH44>4X
M\FJ'?-0RV@*HD@ZD+4?Q5)4.-*''F-8Z9ZXQP(8DKQNLSZHQ.(9R?K'U+DY_
M5*Z<WJR;=Z5_5!L1/Y5O#HAOB"W.N<-I DM[:W+-8$)YTI!\YBV;KCL A=4I
M1.<-*$X^R/T;?,&IL/?%7M>I5EHOZ7J47. N*'F+=9TM7B8#BOG+]3_:=#NO
ML"%Y5CZE2SD:<^)-"NT3_N5/3ECD#+'%;H7?H_L[ZP>D^T/J^V3:XETB=0]E
MVF;O+9T!,<3=G[SL-KC[:W%;F%M &5$1<[*LA- M@$ U311_:'8[+9KO;281
M\U02G#'!Y'40.1!.7N7X5;Y2W3M7N"MMER3^7A59Y9Z3D3AD!Q?!BZ5_3_Z:
MIV?!ZV;F=C%MS<V_HELB274GSG+=8;7\PXP2:_R)UY4DT-"I'*F/Q2_ZE/</
MYCYD;'VA2D=-AM=2O.)X5+FL8Q)' ^G1'L(ZK]7OT7[.;/Y<7V]G23?[DT)#
MC"WIQ&?+74FS<0>2V8^I[J8CHU]/'6;J@6_.D;-Z=[FNEKC@C7,OKL!RV[;@
MM)H?,>E;@G1FTH )4I0 %3CX?^4_;,^\_F5LG;,03"[W*A&8 <^G&8G5.'#T
MXR7T]WAO<>W>U-QWN1:5O:5#'_.1IA_VB%\C_0W9439NWHDV]1$3]Y32E<F4
M\L!NW"0E*GXL1"24I<#N4AZI4ZL$ @ )3_2GV]M@A 75P&GE&/"(\.;8=%^*
MG=^\3OKVH+>7_#OB1^+@?9R70[I?<%P+1<;F_<[=#<:;#DB-=G4LP%QV2%%(
M513<;RTFNM2:9\<>E6,_3@9RE&,(\\F7EE[2,Y1C$2,C+@'(4X6GJ1>+?'7-
M@VFX+LMS4&:R%6V%;ROR3G:[Y?9MALUQ0S( 4C0XXM32EH-<E8<NYK.WDT9&
M0/(&0'A+ 9]51_0ZU5A/"8RX%N;8G)%O>\]SGR;I8F3M:ZMI:>;7<=X;!:LU
MP\H)+;,E+N[U@:0G^&^BJT@A)"Z"F#+O7;:TB+.H)7(SC&4"W/4-3Q\2/%9/
M_M>XA+3<Q:,CAJ$HN_)X@%QR6&;<ZAN67:KFU[ILMLV]N[;BELVZV[YZ3.1(
M+5UW#=+S&<M4AW?T1N(N(JXDH" $+;R*12F,NCW58TZ?H5J<P\I.!H(\Q? Z
MAD3X+#O>W;R=:-2$X^I"$8Y2_"  "-+NP1875>!#*XS]CO"VW$44AS<O22YI
M>:6TH!L,0.I#BW5\:-A*]7X2,5'NBQ]0T81K&H<6(B</9)1/;FX&(J3$- !Q
M&H9>,1@OHD_I(?5I<>MNRK[T3OMLW3\]T@VY9[MM:^WW;M[M).P;A=9%AM^V
MI4^Y-*A71&W[I%<CVJ1'?=U6]I49><,..^3=PQVT7PN=OD=%<R)AI(T2#:B"
MVG27P#X%QDRZJWH74]N%S<B.NF8P,A('7JU&,FS<")$N>$LW79A+*LB!GXXT
MK*O4,D5#5"*BM:@#ER[:8%$E*\H#@*US&>?J/+/#0"AZ$FNE.D@9@\,^'NPD
MW/%!4:=_+NP*0#H9IQ'L]7CB*;D(*LN5??[,/!(=4!5.?#"*.*"I2J<?3T&(
MN0@=4$/*&7#.G<,/'FF1[E7SCS.9[.0R]YPCJX(94+YX=^?+W8,489*NHD"N
M1-<Z99<^P811GBO>8$TIEGP]^=>TC '0V.*7Y]$5-"??[/7B6.2&Q1$OU%>S
MO-!^S _!(X)*G0.?#OKGGPPG* $-,A=0.'ZLAAAWQR49, \<UPG^H]5>M'4$
M\:[CE5[ZI:.7LQM*7\F/-<_<?S9/^\5%,)5%-HJ 5< 3FK3FJG;IK@)S5(4B
MV?/1R^_AC'(5D/B"FC:P.IH@BE1ZSD/;EB$V;JK8^:0)_>6_?0^A8E)I_P#0
MR?$D.BM<8(<5"5N+<^4%;"!M9.KCRRRX9CAD>&+/9@LAQDD>6K50@GEW>O.N
M6!TW",&"#D/ DC+W\\&)\$G2PP,J@ $Y]_MPP#QS2<I2FDTHD4KZJ86E#JGD
M#@!EGZ5Y\<-N>:'*(EJA[AQKR'+QP,GPZJOE\CG@9&/L50D#W5[<L2&"3<TH
M95[QEXC 4!$3ZNSV4[>6#(H+<$08$QDBAV@/?QI^W"(?Q42.24E9R()'8/MP
MW.1R00G2',J'\0(.67'A2M.1Q7*!E)^"@1[D[2\D"G$GNY^W%4J<@'X),O"3
MRRJ./I7#G3TAQDAFR2@]7L\33].*V2ZKQ> !Y5-#ZA3U89B1FFA^8"?M&7;A
MZ<'053545/+(GLSXY>&$ 3@,T8I7F#+LYDCWX>@E =.DO95IZNWEXX6(1GFE
MAQ)R)X_;]V#-'@B!0^SAX#CGA@A#*NH8;C))BJA8&8RY=_+MP."ABO!=.'W9
M^_!J"&*#-B1KE'7%DMI<:=24J! (KR(\,-^(S2\0M)NKW2>59)3M^L;)**EU
MQMH4#P2*U&9"744X\\7TYZAIEFL6XI&7FIX 8JX]&.JZH*VK5=75CX@TD.Y&
MH--*J\%)/'$9Q./-3IU'\DL</[UNA%FL36$/QUI<:<&H4.8KG0T/*N*F8XYJ
M\@A/!18J1F,LJ\O7@\$(^@4X5IP\._$1FG".HYXJF@5X94]7I7#^U3].3?XD
MP#??0TJ?3MPP %6Z.A":<:>'IG7!DC/ (N7("G+ES\<+[5=&D&\V:6%<\OT'
MMP8*<!"):.:&\XI2J#A3EQ. !E14.J?@J(14BH/'CR[O5@3A R&K@GB&:"G'
MP[/5VG 5E.HKZW]3HW1_IQ>MU%;9O#B/RC:L18"C+W'/:=3#6I&I*E1[:A"Y
M+I%?@:IQ4,>,_/?YFT?E7\N[S?X&)WFK$T+2!_%<5 1$MQC3#U)=(MQ7LWR%
M^65;YJ_,2UV2K&7]#MR+B\D.%"G(/!V^*K)J<1U)X+@K=+G)G39$N5(?E2Y,
MQZ3,FR%J?DS);JERY<EQ2ZJ6\_(<*E*.9./Q1,[B\KU+V^G*K>5Y2J3E(XRG
M.1,I2/$R))/4K]O+.SHVMO&A0C&G;PIB,(1#1C  1C$ 9",0P"NMN:5_!7Y:
M#H9+KGF+J:NG42<EY@)/MQJ;F0>47(<L&')8MU,>:()QDP8<O<O28RJ1PMBI
M4X75*%.%%.U%"E7XU)Y8*=7&32R#?=^U%*J"9:98 -]WV.F8DH09-?F&U*=#
M"" ]G0):!!%4Y+6<7FG*6GX2-+G+Q\>2O-,G3\) #\.I^Q9_8[LRESR'G@Y'
M1'+;S4E(6VM#QTJ2K6$Z@4-T.9R.-?*$OBED3A[%S.XV4S'U(1:J9.#$XX<<
M.I6#[QVU(M2FKG%+3T"X-($04-(SSE%JC..(X4U I)%2E/:#C>;7=B<1;5L*
MHQ)Y@?>%T&Q[K3O ;2JXN:1\W^(#\0!^OJHJNZPVTH+9U-QF5ZB@!VJRW_9H
ME94$9\*FN.FLHZIN)8R/'#!=E9 RF#$M*4ATP?\ ;]B@)-JF)W1:+M'D&.VU
M<//G)<JI/R[S;C+C7E.46A?\9"10C(8[X7-'^FU;68<F#1;F,07]A7I9O;<[
M-7L:D=4Y4F@1GJ!!!<8-@3Q4MI)3*CEYDK0PG65( <1K<45&J#1S50<ASQR$
MP#3D(28E<21JHST'&1;' L/J_N6D_P!5$1_9753I[ON$@^5.1%9DK! 4V(TH
M&:A.J@45192AI/'+LQ[-\JZL-Z[8W'8JQ\T'E'J\6B?]Z(Q7I'8VYFX[<J66
MB,ZL;@TB^!%.J'$AT$HNP9RQX+;:P2 ]'MLF*HF,5$//.A:ER6GHSB4*1JH2
M4N!.9H",@.&/*+R&BK5IS^-L .!!&?L=<9NE(TZ]6C6'\7@!E$B0P]SY>)5+
MG.:\Q@><XL>2ZVIL'CH**@M,@<0FN>*Z%&6)( Q#?0IV=O/3(D '4"_]I^Y:
M"2V ]N>]%319TS'2EM0/PM,SY\5(TYI3I1' H,?J[\I[PW7RWV:KJ>4;.,"<
MW,'C]R_&?]1VSSVSYX]S6Q=Y;G.K[*\8U01XZW6S_P!*>WS=^O4*6MM2V-M[
M6DO)6G)+,J[/):002*)<+47Q .6/3["9J7U*F>LC[,%X=N=/\MV_=5SG/13!
MZR+GZ@NP_4*-38R<B3'0\[7-2:I\E:2 *)"=20<O''C'ZHK3\W\HMX/X86^O
MW3@O7_TD7?Y7YEV]$EC7C*'B/3F?N4.0;BIQ(T.M(^9CT)":44A([5\0%GV8
M_%>O2,'\IP*_32XM1$^8$Z9_3[%D%JW$V^ZTQ.?0//08SA2T@_&W4MKHD'XD
MJ"L^_%1HR#_N-Q6MO-LE3@:EO$^4ZAB<CG]3++W(:7VC)9#:RK2Y1DJ9<#C'
MPO )5347&Q44.,60#G@ZT<:YIR]*;@98XACE[C@L?<@J9=4O3)_@K#R<T?W9
MRNJE":T 5[!AZ , [!;*-P)P$?)B&X_$,ON5FW#LNRWY#:;M:X-Q\HI^77/B
MM*=CJ2KSXZHTI*?,85J32J5))(&+[3<-RVNH9;?7JT8R<$ D1((XC(\L0L[;
M=\OMNF39U:E)\]$BQX%XY'GB"L;_ ,IP(49R*S'>3&<(6I#CSLQ(;>0&U &0
MXZM(;*!D#04Q?+=[ZK5%>J8RJ < (Y'_  @9\<%MOZU<5ZPK5) U1@X CB,?
MP@#%_K6L7438JK9<//:ULLGSDEPM"I4O2XA0) *"-!I[L>M]L]P1O+80GC4P
MP^U>N=K]QQN[;TIM*I@<^ P/CFGNW+IY\6.XI06XA"6'U _C<;2$*42 :\ 2
M>TX-TM!&I(1PB2X]JQMUL_2K2C'"!+@<@<4RZM=/[1U;Z8;YZ;7CREV_>^UK
MQMQ8=;\YN+(N4-QNVW (*@/,MMS\B2DU%%M \0#B?:6_W?:?<MCW'9N+FQNJ
M=88LXA(&4?\ ;AJ@>A*X_=MJI[SM5WLUP!Z%U;SI$D MKB0[?X3B.H6A']$'
MKI=-H7GJY]*.\Y0;F0)]QOMDM%S.E<:[[?>_(>H%LA172E49R1%;BW#2H5/D
M/JI^(X_H9^5W<5KONS4S;U!*WJTH5Z!<8PJ1$P W#'''DOPA_49V7=[;?G<Y
MTS&YM:DK>XBQ##48O(=*@;FT^2ZS].+-"L]EN"8##3$2\[NWAN1MMHI#81<K
M]*3&"-!TT5#CMG(D GB<?A#^NKN.'<7ZH.YJE(O2L:E"QCXV]& J?_A93?+%
M\ OT[_3%L53M[Y#=N6]9_P Q<6(N)<?]1*549APT)1PX'!USR_JN=0X]KZ+;
M.Z5I=2)O4_?$.=<FVG4)DM;9V$&+W(4ELJU:)FX9-O;"BDI 0O\ > QW7_3]
M[!COWS3O.]+N)_I^R6.F!9P;BZ)A$/D\:4:DN>(++FOU4]Q2VOL6AV_;2:[W
M*YQQQ]&CYI89L9F ]ZXQVYBVVIKYFX-"4Q,C>2PVAQ,93;@"4-N(4 0RVSJ3
M\2J "G/'[@1N:%M2%6JPCIP#LOR\JV%>YKRH40\@5M%T0Z$=1^IER@/0F'X%
MI;6V7[Y=XJ76[8TS_#68L&8T['8N;;5:*?9DS@LBK40 G'RA\Z/U2]J_+N%2
MQM:@OM]C$Z:$)/&,FP]26(!!8G/(A@6*^QODI^C/NCO6TI=U=Y2_HO9=5C&4
M@/S=S$C'\O1.(C+(5:C4\0099+M7T;^FWH+LF(B1?;&=_P"Y9L1#,^Z[RER[
MD].T^2IQQR/)>=4(ZG&4G0XIRB0$@A-$X_+#YA?J8^<W>NXRK76YW-CMD*NJ
MG1LY&C&!&K234C_$E("1#B8?B"0&^U=G^278W8UM^2[4VFUIL&G<5J<+FXGA
M%P:E6,A$2E 3].$8PC(G2&4H;U^DKZ9^J6B<WMJU[,OBDZ%*M#$B+MZYK*"@
M)D6)I]45+E<B]'#:B!\05QQR&R?./OG;XRC2W>]]0\9U:AECF-9D9D?YB0NY
MVON/>.WXFSW';=MW;:@21&XM+:K5I\]%2=+ -^&0('X2%!%U_IS])[03-F;"
MLU]@)*@Y.LR7)@":53(DH2H3HE /Q.(2!VXZ"O\ /3YF1@]/<[QFPD*TB &9
ML\ Q8 \'"W]+NGL#=ZND[!L%&_)=JVW6D23A@)>EIF7;*1)888(5G^BSZ<+:
M\S.8V3;8DM+JELN7&ETB!YLZRER#<!-AK8</[I17&FN/GO\ -2Y\E3=[PP&+
MQJ5(R\=42).#B[YXE9%6KLHC*C#8-@E1D&D([?; L7&!],,<3B%VJ^B&R]#K
M#:;C9MG=-.FO37J'.AL-WJX[%L%IV['ZB6Z(^_*:EH8MJ6H[=RA27ENS(;*&
MT*6KYA+="H-_HM^F7]0%I\RMO_\ ;?=$Z=+OVT@ "9-^<I #^)3!+"M%@*T(
ML9,*@#.!^4?ZI/DM>]G;G/NKM:%>?9-Q4,JE%B38U23@<'_+S,CZ4Y.($FD9
M?"3OLY%#9R%?#B*9$</08^OA-PW%?&K$9H7E=N0!/NS&7:,.<FP'Q(0EH33*
ME3SYBAX]]1B())')":+000:)J 2:\#V<.RF+4QR318I49>APE8,T*E#X<<),
M)!!]>#[$O%-EI41PIQ[<(XH";:%TI3@>TUR]7.N()X)"6E^JO#,GP[ 1AI%]
M.&:66: =G,5//].#%-TD-A)/Z<\Z$9=V$22$.O*!I\(S[:\.6'QQR0$/2HD5
M]?APPST406ET55I%*_A)IQSX"E,JTIA EU,*G[M*\._+LY'V8.*" 0QXH%.\
MY=^0%#PQ)(A\.'%5!)4/$9_H.%QP491&GH%PR^HT4ZS]0*9C_,4SX0,A1+5.
M'CC94?Y<?!<]7PKS'^)11"8"GF7@DZVDE":D@4<"=65>>G"FY8JK@I(M"%_
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M13('VG >2810H #/QX^O"1U2@L'G[<-#E5K\0]^?A3"3Q*4"#V>/;3+M[L-
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M:TQY3;U:E,AWREJ!]H+K\KOUB[+*V^>]U<1B=%]M]E7&'*@*);GC2..96_\
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M+;)8=2ZR]$4&%H=0?YS1"0IIY%:H- 0HGM(/BNP=Q;ML-U"^VFN;>\IEXRB
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MD&@_$*ZL>M;U<0O.X+C<(AXW!E4Z#U(ZL/\ >7K?HT*%V#1!E0_+@ \AZ0
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MI<44%%$U/  5KQKCI:&YW%& -<0E;Y9 Z@<&8NY/3W<5S-7;!6K:;<R%TX8
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M$XJ+.G/:3Q^VO;A*T"4H@#X5;+M:XEVBKB2T)6AP$ E()02*?#D3SP D9*L
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MNJ%4QF)&)((.!;CU5SB/NEIQ*XC[2F)K!*F\BE+R$H)*6UZDA1)X"F+(PPU
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MCC*=21E.1ZDG[E^Z$+.VVVRI6%C"-*SHTXTZ<1A&$(@1C$#D(@!,7XVA.DI
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M5/J96IME57#J6V^%.M'CPJ,L3,9Q#AC@^;'#Q=0IW%.G,1JQG%I$'!PY'0C
MK&KOM==]@OP+E'80E;OS#2@^TXME2D@-2H[[2E!0\T5*2D<P>.(TJ]6G4]2
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M\?<98+]&_P!#D:U[V3NNV-JB-PG%CRK6T<O]J ]H4NBUN3OE[@U)><0Z7 I
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M6]I^6J ER)V\I47]L8"7M7Y ?J;V:YVKYK[I*X!(NJWYB,C^(58QG]1)'L3
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M'GF,9!D0Q!/+K] LW8KF5*[G2+B,H\.)X%N#E*VNPIA!:2 E2*>6IAQ*E!2
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M\N[WUK7,X,4LRQ50,\R:@\!P_7A )HH":"O'/F?LKB1 "'=4.F@[:$^[*O/
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MI2I.D!9J:TIRQ\&=VBK6M;71KF8RD&CJ) T@\/!U];_,.VK7NV6AIO5G3E(
M")F1$QB^#'EPR6T"=\W*THUR(#S\(SCI,I#Z0M"@ JCBVEMKJAT_$"1GC@J5
MUCHB(R&)9_J\5Y'/MRWNI-"8A7]/@V?@X.8Y*SO7NW7E$Q+%M+"/G4/)&ED_
MC<:+B03HK12S[<5S(.#,Y?AEU6;#;[JP,#4JZI>F1Q&0+?8%9%?*Q79*/E2
M'&W>#"0?@:6/WR.*<5', YC[%L!ZU6,3KQ8CCU"(9;*G9C)C*HMIM224,&M
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M_,3OF^[OJZAMVJ-.W!S%*F--*/C(#7(<#(KV/Y5=@67RY[(L^W:3$6D-560
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M_=:Q!E7O*U1^'FJ2(;HS-T4^;=MBG(46/H /E(!.8!J!JIE4D^./2;2 ].,
MO M^,I7$JDL7+J06-H(#*G4MMNJT@@:M!&5? YGAC:"E$#JN3-Q+6P+1=1=N
MAI]I:&92O+89NEQ2RD*4"5+A6IQ7Q:4"B10:14#///'PI^LR-71L-4-Z8E<1
M]I%,_<OT(_176A*P[@ITP3,SM).W#_B(M[US;^N'IQU>ZD;-VC;>E$>%<KE8
MMZC<EQLTZ^-[>CW2)%M<^)%4N3,4J'+=AR9H6AMW2FOQ U QYQ^F3O\ [*^7
M/>5?N#O2E*I:SL94:9C1%8PJ2G DZ3D#&)!(!.+,OI;YY?+SN[YF_+^GL'8M
MW3L][A?TJLY3K3HB5*-.J# 3IQ)?U)0DQ('E=W "T%L/5#ZL>BDA36X]A]:M
MJHE+,9Z]]/M^1[G%2AM24><W L^Y)D!UQLM#27(A)2 *4-,?<]7?_P!'_P S
MPW<&W;/5K$N34LY4*@)?$RA")=R27D0^*^-Q\DOUS=KTY4^WCN&XV0)<4ZUO
M?1\1&M*I*(( Q BLWMWU_P#U V"68LKJO]0-R;2^FLM6UOG4J3\!:,J%=-E2
M4I>0$)#B*BJJT.>,.O\ I^_13?0PM-O@9#XZ=W7@6YC^*S^Q<['<OUG6,C3K
M]NW4ZU,F,HUMLIG'D\81S?#'B&X+*'OZDO7B,ZYKWGU1NZ:@ZV.FMF6O1^ZE
MV.O8>II^E-22>66--4_2_P#HO$,<CD1N59_<9K.M.\_U@FI*/_M$F<,");54
M 'MC./V\5?6OZI'6<ZE2+GN^"4A*%NW_ *%6V<WI*54*W(EA@+0*+[2>&6-)
M5_2/^C:^&FUW"]H3/[NY:G_WXR6=4[W_ %9V(,[KLP^E%G:QNX '/%JN#K)&
M?ZH'5YY2K@K?_33Y5A"$S;=>^C5TL4\,$J <;>_S)$#X34Z] 2I(Y8P1^A/]
M-&X0D=N[DOQ+A_Q=M(Q]DJ8!6#/Y[_//:2([OV'7$0Y_DW\1XD^;3EQP999;
MOZKMZF(;AQYG1&]7-3)::CS#N7;1FK30^2RI6X[BTR\X11((H598T]?_ *<W
MROO9F&T=X7P)QB)4[:H??$Q?ZO8I1_5AW%:'U-V[*NJ-..,B+BM%FS/GM9,.
M;DMSP696'^JU,?;:M\W;'21J:EE33D)_?NX;9)!U(JE*ORNYC().>>8[,:>Y
M_P"FEM<YD6'>%0'_ .991/\ W:X5X_5WM52?K5^W+Z,27>%S3F/^U;QYJ287
M]1I:EQ?G^F%H65Q@(TJT]6FW84Y*BV4AAV;LUMMLT;.H+*2DG/MQS-W_ -,S
MNJ,C&T[JVR=,EXZ[6K'ZXU)>Y;NG^L7Y=3@(5-JWB%0EY!K:0B<<CZD"<^("
MR^W_ -1JQMH:4]TOW8A;324+7:-Z[)N[:G: +CI5-D630M2D_"5%*#D*C',7
M_P#TW/FO;$G;MZV*X#EG-Q2/3.G(8\OK6=#]6GRDN,+FWW:EJED;>D6ZG1<%
MVQX/TX)_-^N#:O7ZU?Y$MVT]\;?W+MF'*OJ8^ZXMDCO2H+3)@3X<9NV7:Y+F
MK:$MI:7&RMEQ JE6/.>ZOTH?,OY*VU+NGO&MMU79ZU86O_#U*DY0G+STY3UT
MX 0EID 02QSS=?0'Z??FC\M_F!WU=[7VC<UC="R%:<:M(T@0*L =#REJ,"1J
M#!@7!.*E/^G'#NEFV-U5NL@S)$+=74ZYW^VV^8TH+LD);%OM:8(86AMR,ANY
MVI]S2!5/F9C'E7SKNZ4M[V^VIB!JVVUTJ5242XG(2E,2<$OY9Q#OP7J'SOM(
MGN02_,FM3JSG4IDGX(&%.)IQ_P (E&4@/\18KHO<TN.!*/,94L50XRZ"G2'6
M$*^#XDU^)' @C'C<O-#3AC^Q>)VDHP.H"0CF".AX^]/1YGY7YJF5%O0VXMQ@
ME02KRBA9T  C^6<Z<N.+81)@S'V<.;^Y4'3^;TB0UN0 <'QPQ]O]BQ\OE\MJ
M 9EA26E%627"1YD1P<5)UF@.93AQEJ+EB6'[%L13%,$'5!B</=(<D)QSS4@)
M<+6M(04/IU(_B,E(2EPD<760/Q'/EANX88'KX*<8:9.0[',9X']AY)J@>6^5
MEDC65J\R,JH3YK:'TZD@ J2%MG]TX XQ9B>(ZJXG53TZG ; ]"1]A5'BWYFN
MFL J =:^%U 'F :T\2D#3^C$SYCJ+(IQEITY'D<CE_;^U8'U"?CQMJ76;-=;
MCQF8[:GY*E:6E,!UO4IP5XA-12OQ5IG6F+[#\Q+<*5.UU>K4)B!'CJ!!'NSZ
M=%T?;,*E7>:-"A$RJRD6CQ=BS?MX9K5.LI4.5=)<=35POZ&X=O:*B'8=N1J=
M2TI5$EMTLK2IP<G'",P,=Q&%(5X6E&0-"W>4SPE/)^H!P'0+V5J0KPLZ,WM;
M8F4SPE/(GJ'! Z1!XKI?]!<8Q-R[J6E"4I5L>,MSRR2-:[W;="5<*$!-,?4?
MZ))2N/FYO$PYA'9)AR.=S1;WL5^?'Z\ZXJ_+NQB2\OZY !^0H5W71]]VA421
M7/[_ 'X_4O !?E/X*UNO Y$@UY<LOL[L1Q)=2 ]Z:*5P(/&M3EACJFAE5,R?
M2G#WX:@^+)!6*<?3A@)&83<I!<ID/OR\<(E1=\\E7S0""*X"C43DO!P\30X
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M;GO589!3^</+(+B-7\:V6Y(6JM5#4&OW@%4 Y4Q\/?K4JP&R[)7!8?FJX_\
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M:1ESF=%$-IJD Z:Y=F-[:?-3>X:(FOJ(?XM)?/HZV=OWEM]81C7M;:>L>8G
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ML)\DLGOR/'E7OPAABI5)2D?3 +#-4*J@5-"#X#/UX%8"(?%@"5[4/6.VOI7
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MQB):3I!Q7UG*Z\TX0$@!+'+^U-1;EN(;4E;/]\H!Y9R_C+R'\3"_.TA(@O\
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MC\Q(8(30GD"<>C[5^FKYY;L0;;MO<H!P0:HA1BQ_^I./V>*\HW?YT?+&S/\
M'W[:M7ID$0JQJ%V9OX8ET6(_47LV>QTO<>EQ5"+&OL12)+4MF8RE;]OD-)U*
M8>?4V5NITU4 "<L9&\_)?YH_+"5'>>[]JK6FU2J"F:NNG4@)3'EC(TYRTF1!
M$79V76_)/YG=F]S]Z?E>V]QMKN]-K,FG!XSTQJ1>6F48D@.,0[.H<^AYEH6O
M?<%T!09NRG6JT"DJ3,>T.H%:D(\[/+@3CE.\:1K;C3FQ(_+1QS +X8Y \N:]
M>_4)5G^=VZXCAJH@'KY X/N6VE]AK$AM2H2'_P".E(<;* K3(9&8J$T^,99X
MX"XA(%S$$@_:%XIMU>)IF(J&/ER+_A/[%B;49Y+Y4N4ZP4*C.H*T++80A2V7
MJZJIJD+%:$8QH@D@ZB"&/W+=5*D#3TP@).) XX\Q]G)"E.R ^XE<9"U%!4W+
MB.4+ODN)'[NE7F>6M66HXD9U'\P?PZ?M"G1A2-,2C(@/C&0R<?M 6A_U6_7-
MTY^F6,FPK6C>_52:'&K9LN&#)5 ?8CK=;DWOR-#JB(K@68R%)*6QK><8:_B8
M]V^4GR)[I^:5Q&ZCJM.UHR\]S.#ZF)!A0B6USX$GR1XDG!:KN/N79^UK3\S?
MR_XFI$2IT(2:I4!QU2./I4G'QD:I/_#B<2/G"^H;ZE[]OB\2NI/7;=S:)%WC
M!NP;1@/_ #<Q-F\X_+VVSPV%QVC;%I!+A8^5LZE&I<N"AJ/Z@?+OY:=N?+S:
MOZ1VY;QI4P :E23&K5FP>52IG(EL(_#$81B OE/N_O\ WKNZ[:N=%K2)%.E
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M9XPKRE0C2E7F8PA&),I2($0 ,22< !F2LO:YW\KJ%M9QG4KSD!"$092E(G
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MXARJ75:0]QJ-]2S2)9[>AD!+3CB#159$F4_Q%%9R'W%*[,SPQT\(Q@-, (Q
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M 0/5BJ'(!W4=9CB6;ZE/_3O8S;#D:V0D:9#GE+GS*$F.V[P3K*:?,&N0([^
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MLR[,L6!(XY*JE$FH3VT(X\,\&* J'5VUY#N%/'!B@,D?&?08CYB73\H1@E5
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M'(DJ^((J"D9GCEF<;6G2Q<K25)MQ5VBS%D)!752:@C210<SK H2FI]GKQFQ
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M(>\>_OP#JJ)&5/ !QCB_-*"37EF?#]G'#</U3E"<H8ER?J5144Y=O;B)YJR
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M4T./#'W1_P!/+M26^_-[<.Z:\'I[1M1$"<=-6[F*>!X'TZ=098@G)?'/ZO\
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MT+M3MGM?<+6GN5.U!J1GE(RE 3B<Q$ECCB'&"\>[P[C[FL=QK[36NOX8 8Q
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MMOSG.4')]S^/#JLFBAW4](?=DS'4IT>;*=4\XLI!6X5..E*:E2J5 /#&!+2
M(P C'D P]RQ*Q@T:=.,*<.40P' 8!7N):I<^*TGY4.A\,E6M]2A5Q:%$%(9*
M>*L8M6ZIT9'S,0_#^U:^M>4+:L9";&+Y1Y ]74PV#9[:GH8?MB"0I;FH)86
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M61("M 25DBH'P)2>T??E@]/41T5$VU.3Q5P8NZ:I3I!(J$T6E220 D$*J"D
MY\.W$O3*6N.2OK-U*DBBA0*2G3F?+*S\824FB30UX$4.*Y @LV*Q*K1J@@<1
MBGKLC6A2]1*B@5U9N$UXG4"I.I(^SEC(HP("R7P4M=+FC=[BB&WFNH)5J"$!
M*:?$XM1T)&G-14:=^*;J@PUC'!T>D:C+M3]+7]+KZF_J:9BWO:.QSM?83ZVE
M#J9U!7+VKL9V,LBLJPONQ';WO1 ;J4_E$24THBBG4<<56ME7K#U),(=?N&9\
M<NJT&X7MK:5#'XZH+:8\^I. \,^B^BGZ:?Z/OTP]#T6N]=2FWOJ$WS"0V\?\
MW0&[;TOMDX:%DVKI\PZ_^<_)R$U9D7B3+*A0F.@Y#=6]I2MP6\TN9^X8@?6N
M8K7]W7>,I"-,\(N/?+,_4NJ)AMLQXT2*Q'BPH3*(T&!#88AP8$9L!+<6#"BM
MM18<=M(HEMI"$)' 8ROM6#I; 9(C,=0.8R]..']J8"O4=L5 IP^W/F.-*8 %
M++P5]89! -* =GIW8'XE&7BKRPR,B /3+].*C)_!.(<@?B)5S0UE7+[Z<,O#
M$' PXK(%O(3<$,GJ-(^&HY\,N[ASX8BY97&,7Y#[^J=(2*5"<^'*E/;B1Q1
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M@!R4W6/946*F*PB$^R$Z%$(#GX64C+^&M0(K0>&.1O=YG+5,SB3^U>>[AO\
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M/,GM]F6)T\2!P6'(,#,_$5-5L$6$RXA*%^<&::R%!*0"X4T X$%6GAQQEZA
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M+N#BN9R]1''U80B &X)>.:$9B@:FIISS_2<L2P P2 ?%4$U2@>(KSS.?=D,
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MUJIUW\BN<ATF'-/P,OJ4R]3S6U'X%V[<-M^:=YZ=Y*G;]Z&FU81&F%R8C^=
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M2DD@TS-. &5.SD*XKD,<%+$X]%+EA2:M'PSY\LLL4U,,LUD4')U+9+8B:K0
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M]LNZA 81N*6O(AM$I1F[\-+K$=S.+N-N0[%<(EQWRK0%"BBA)**T-$.*T\P
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MWD?8J[FD:9%6)B:,C@1]BS^Z[5V[OO:[^W-YVR/?K+<&A#NMGENR! F)AO\
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MRBW[A<KW/#;:E'S[O-0E9<I1 ;BN1FR"?W=-*5QT="QMK6,8V=*E2@, (0C
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M04:E-+7Y=6C2M",9%/Y)]Z0/GD:<)#S $GQP)#XXK'K?K,^1E(D4;[<:D_\
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M+O9;C/""0'+DNQ7&VMW)\I_[Q]*W. K3+'6=M[=W)VY 6FV[G=4]O!<43HE
M=(ZXR,1TB0%\T_-'YF6'S6OI;QW7LFR2WR88W-.W-&M+EKG3G'U3UJ"9;!T3
M;G].?Z9+$H.Q.C&TGW&Z!I5UMCMY.5"2H7IVX GOH3CM3=]P5L:]Y7(_PG3_
M -T!>&RMMAMYO;6EN#UB)?:Y4YV?Z9.F>W4-MV+IQM2V: "DVW:]E@$)204Z
M##@LJ!2KM.'&UNJWFN*U:;\#.1'M!*JE?T*+PH4Z4!D=,(C[E*MLZ?I:2&X]
MJ2HHR_BMI)2*?@2%)I5)'JRQET=O@"(:0RP+F_J2&L%V]ZR0[*F!L 6PI!%
M2DZ>0U\. [L9HV\< M:=PB<7:24QLF8%I)MJ4I2:UTJ34@Y#--*4/#&52L S
M:7556_(C\2RQ.Q)= O\ +FQ^$4H/544H,N.,N.VQCYF6O_JAF=.I76W;3FQE
M)*(#6@J332"HA15F31.0[<L9%*B!, ##P^U5UKK5 XAF?@I\VG;7DM(;6PVC
M)(IDK(43III^(4IR&?97&[HT1%Q$,N<N*K@2&(XJ^[CMZF5?P&&R5@40G4I
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M+#4AT*\''5Y:E"I\!Q&7/ D<$LE=*DJR':?OP>"00U+< %"36IX&H.7'B,-
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MK^M;]!)4F2KJWUL2HH2AQASHI57#/S/ET^4DCA\*JFN('LR\?7ZMJ1_FJ?\
MPJ7YRB<''UKS/];#Z%([P!ZB=>WDOJ4E"V^C4 H*14(* X\V0"KB:8MAV;?!
M_/;-_FG^Q0-]0'XX-[?H_17%C^M=]"LM\VYC?_7R6\\:H8:Z.0/X;@HL*2 ^
MTA1HDY%1&>)Q[0OS+2)6W^]+]BJ-[;OK%2(;Q6:Q_P"L]]%$1O7,W+]0A2O2
M@.2^CD13""D*J"8<TN)4:"ATG/EF<6GM'<9Y2M@/\TO_ (51*^M=3>K$=,?O
M"O$7^LW]#\>(X^]O;KDS&61J2]T;.A/FIT@ LK+@2,SF<N>(3[.W)F]2W_WI
M?_"H?GK4Y5(D^UG5I8_K<_03%\V+$ZA]=+JL!3CD.+T?=U(32IJ[+^492**R
M.NN7'CBR':=^&C.I0/5Y?_"ZE^=MICS5(CWHJ?ZUWT)SV$Q(E^^I+7*9+JHS
MW2.RJ4P^E"0[Y#[%Q6P$*4*A*U5SIV4N/:5Z)/ZMN8\WG]FAU4;NTE-A6IB?
MM^\)-J_K6_13-OS%LMROJ@O$UM80II'3O:%H*M(T:/G+EN:W-N+;*@-((J
M>=90[1O3@:M  \1K/_A"C/<+2 TRJ GF 3[,E<[W_6?^DFQJDMRMH_5N%ZZ$
M-[ Z=$J6@I6V4+3O5ULI6D$:@H@@GQ#_ /:-Y"?FJTF?E/\ 8%&&XVDIB(J1
MEAR/UX)W8_ZT7TMWE]B=$VE]3;;NBI5-MW3>',.I"D?Q(YW:\TA96H?"J@RK
MPQ:.T[AV]:DW^66*KK;I:4P022>@?]BD!W^L;]*3413LQGZB[,R$A3YE[/Z?
MS662@:U*<7$W)(<<;SI1&9RR[:I]I;AJ\DZ#/F\A]RLH7EC( RJ8\C"7VA0%
M?_ZK'T)]0YTNX._4];[#(>JRFT;ZZ7=1+))B!I12@+N$*S/VA8T\2A:DGB%8
MUUUVYNE$&6F$X9^60^]EVFU5[>G &%6F02XQ(?\ W@%&>X_ZC_TF]*[>>JFS
MNM?3OJENBPR+6_M3I[T[W)Y>Z]QWA$LKA0I+5XA1)5K@O2%H;??:9?7&96M>
MA930^!_,'L[O#>^^NU*_;U"A4M+#<YUKJI.M&.BE.D:4A&(<SE*,I%LW &#N
MOI+Y:=\=E;#V!WEM'<M]*C=[QLXM[:%*!JF56-3U82.GX=$XQQDT=)D27 6_
M>WOZPG1VXWNX6_J#L3>%A=:>B-JW'L>3:>I.UIJG8S+TMYEA9V7N:(U"?=4T
MH!J<L.-J K0#'M_;O:.Z5-@M9"$J584V-*KY*D-)( DQE'@"&S!"^7N_;_8Q
MW;?2L[N%:WE6$A5C$FG/5",C($$GXB1)Q\0*W%V1]9WTN=7U1;;MKK/T^^=*
MVU-6?<MUE; OBU+:>=#35MZ@V[;34A[RVE:O(?> 4*5S%2ZV/=+.7\>C4 Y@
M:A[XO['7*TO2N8_\/4A4/^&0/U%I?4MEX"K>U#;FMNARV38_FPYD=/S4&;&=
M0LA<:= ,N%+;\M!-6EN#OYXY2]KT[7=;$503.I5J4QAD32G+'D&@1XKL=DLJ
M];8MXC%HBE:4:TA+ RC&YIP\KYD>H_@GM^VS!W!;X[4F,EM;D6.AA]25U*4(
M2II=2 -3:A5)[^.-Q(8F2XVI%R2V"Y,_U.NG.Z972OIQNC:EMN][D=+M\/W;
M<DJTVZ;,38]MWBQ76!(N%U,)M2H=G5<F8S#CZRAM"WD@FI3CQ'YUV(OMBI:J
M<IT83D)D1U"(D/B.!81(!<X/G@OO_P#Z='<5ELGSBOK"_O+>TE?[9HI>K.,/
M4JPJP,:4-9 G.8,FB"9$.P)7-A+.TNJ.UXD#J)M';6_MM/HCM1(FY[1#N4ZU
MN.^4)D9N:Y'\YAUMP %QA3*UA*5%1J,?GU5_JO:N[2N.V[NXL-S@9$RH5)0A
M,!],M(.1'"6H DAL%^X'=?8G:O>-@;'N7;K:YHZ2]*XI0JQ!.9&H$Q)+%XD,
MLHZ+?TJND'6^]RKATVZ$.VZQM36D77=4K=>Z;#T_@4J5M?-2)\I5RDMJ0JL6
M )$@*R*4C,>W]B=R?J=[_,+38K^4K"(:5S<4:(IPX.:AI^>7^& G+FR_.WYY
M=D_H=^2\)77>EA1._P @3#;K.O<3N)RS ]&-<1HP. UU#3B!DZ[J_3?_ $Z_
MI>^FD1[IMOIOM;<^^T>2XK=][LAG-6U]H* _R[;+Y)O"XH05?SY#CSRR H!H
M_"/L'M#Y85]KC&^[UW6\W[?&<^L1"TIGB*-K3$8?[=77/EIR7Y=_,#YYT][J
MU=M^6FQV':?:TB0(VP]2_JQR'YB^J:JH<9PH>E#A(SS6\SC;\ATNO*<==41J
M6X2M9 &E(*B22$I&0Y#(8]9C&,(B,0!$9 8 >"\ EJG(RD29'$DXGQ+YNG4=
MEQ.:6^?$Y5X\B!PIAH&&2N0,A5!3@!4"@KQ^$<P,)@"X027<DIRCSJ?@]_B,
M#!W2# Z@C)9?76B%9<,E9>W [9YH<8E\TX3$> JJB>XG/V9FOKPG'M3B\L1B
MC(C$\>SCV8"0H2D8GVIRVT$CX$5-1G3/.G"N(DN7*8GIP;%(87(=;"PC)96H
M$ CX2M6G*G-(&(4R)0U<_P!JOJZHS, ,0 /J12F5^(C(=JJ5_2<6>1^BB28@
M-B41*%<5D=]"<LN0YX7'#)$9<SBGC"VO+23GE7[NWEA8*3XL^*=?,M42,A3L
MP()9*,M/ '.G+F>?;2F$WBD91 =PEI=2I533OR]WJIAI"<6S3AQX-,N.( 4I
M"2L) KJ"14IXU%0,1DX#C,*<6,@.:T)ZK>7+WQ?)#1"FWI27$%-,TK8:(H1W
M8L@?*"%K[@:*\HR^)UBMN9&I)IPH*'L[10]V6&<D1#0_Q'%2%:F?PY9GCZJT
MQ!\%9 $ D9LI6LK(JV*5K04IWC&%5.&"S8C(*?\ :35"A(%/A/MI0XP:CN.:
MSX-I CD5CC[#7FNYY^8YEPSUJK3.G/&^B[ -P6KF&)D<GPZIDIE Y@'OIB3!
M*(B<R@G2DU!&5,P.& MDD0/8@J<(&1!X4]?VX'<,D$V4H\1Q[.&$F@_,J%:H
MSIZCX94K0XE&.K$(."H9BP/A13_VN&$<$*.>JNW+MOSI]NK9UM<L33VY+:JT
MRFMRVIR\V*X6B8^PW?;1<H3,F)(#5YLQ?C(?:<2[%==2^D*4V$F-Q;^M0E2P
M:08N,&.8]SJRE7-"K&JY\I!P.+\/K967:V]ME;3W%M3Z?;1<;Q,W18^F$'<4
M2!(CW2ZN6_8]D?B[4MUQW)N1;"H3-PN4UHM1TONB1-6R\M*2&UD0IBE2$;>#
M^6(;P& Q3D*E42N2&!GB<L3BI:^<>H?BX@T%#QSX>K%^@,[JG!\E03':GX^Z
MIS] *X# AFXHP5?G'5?O<#GP&5.'MPA#CP3?EFF-X0[=+7.MK%TN=F?F1ELM
M7:S/,L72VNJH6YD%R5&EQ1(84*@.M.MJS"DE)(P2I2D&Q'7]BG"II.H@&(S'
M]RT)ZE/]9^A6XMM;P7U/VU#V%/W!/<WKNZ\0[M8]FLL*M[YM,7?&SXOYW:;)
M,N$Y"$*O5KDVR.^XX?-BI<2@KYJ^I7UA<1N85 *$I-(EQ'IJ&(_V@W@NDL*V
MW[A0G;U:)-81\@!#]2)8' <"ZW"M]XVCNJ18G]U6G9KN_++:K!<C$?3:MPR=
MNR=R#5#?VY>9</S'(-PFQ%"-,C:"]Y::D*R&_I3$XC5I]5@2 7'B.8Y%<_6I
M2H2/IZA1,B 2X.' ]>86/];;?N6%M2V[HV#'@C<.QKC%N<"RK@ER#>K0AQ0N
M^VA'@PI4F,;E!<=$9<=HJ;F%I12I&M)Q[TSITOS%( U($%N8XC]BMLR)5/0G
M\,P0_(\"M7(_23I#OVWW#J+L6_W!QG:TV]7[:,&P;INFW[%%-U^6NF]+&U,L
M4Z%<+; OZXZ')C49]E4*Z1'G60VI^0T=;.QL;H"YMSYZ4C*.)8%L1SQXCFMI
M"]O;8FWN@"*D0)8 G2_E/(MA[%.M@W"YU Z?;;W3LW:?R>]NE]ZF0']@7.]_
M.O-7FT6]ZT7.W,;BE.NJNC-ZVS-6_:9\DTFQWD%P)*U:,H5IW%N*MJ/XT#B#
MT&3]1D50:<+:X-&Y)]*0^(<'XMT.84A[E?LW4CI;=FT;.A]1]N;C@LRKCL*[
M7!%GE3K1,/D;@VZN8\ B%N6SW)I7EMNN15-2D)!>94D.#(>E=6IU1,H2#&/'
MJ#U^CK&:K:W.$M,HXB7V'P*UV3>]H;YZ30[)M9_J+>=]_3SO*SO?D.ZX\9CK
M7L123.ML)J_6VY,K9W5^662?Y8*'GF;_  XX");DA0<.#KM[FB:=$R->WD,"
M^N.8Q!SP]XXK/TW%O5%2II%&YB<1\$N;$=1["IH<ZZ=&D;2M\W=V^;6S.VUN
M*) 0([,YV_3-TV%]$)X6O;$"-<]RRV7GGEH4&XSFJ&Z%K(0O5C8TZL*E/5J$
MM.?-QT6#4H585-&D@$>P \SE]:DV]V/;W5/:KS<>Y;DL*+FTFXV'<MG;EV2^
M6P3X10U*;AW.)I?C26W%I>A3XKD>2THI=:.1$Y1-6+.0_'DJHDTJCD @9C@5
MK->K=N-SJ'MYB\0G[MM.UP=G18.\H4*VN7;;6Z-O7IM=TL5QEMMM7*U[6WHS
M!:F*;<,B.9T=U*%LK*6W-57I5IUXQJXT@S2&8+Y'H5L:%2C&A(0PG)_*<B.G
M,CV8*YV#J!TYL&^^JEJV%-(F6K<>T]XWVR"W7MA>VW;NF?;=P7!JS2K>Q/59
MW9Q;E.N1D.1G4K4M"J5(I$Z-K=W$:)_B'1.08^!/7JL@TJM>VHU*P,:<HRB"
MXQ;$#H>BV-Z7[S:WGL^%?$07;2].=E+FVEV.[$=MES2\IFZQ?(?;9=$=-P;6
MXTHH'F,N(7P5C:6-7\S2-3(ZB",L?IB%J[^B+:XT.)088C%WQ&/V]4QZC]0H
M>PHK$Z_6*^/[1F1K@S>]V6>&NZ0=GJ2P0Q*W1 A:[S$L4Q*U)-PCLR&XJQ5\
M--GS,9AD(1<_#]BHIM4.F!\_V^"UBN73:P6;JWT1ZC]+(6W+)TCA=(.H]JW'
M,VY+;9L%UMUU;A;FV7^7"&Z[;)Z%W=4V=YP":*?6Z5K+B@=1<6THW5O7MSIM
M:8F9-D7&#^W%;2C=Q-G7H509W=6I%G&(9W/V#@I$Z$0+;M*Q[RWKNR]P?\S[
M_P!P.;OO-TO=V"YUMVK/>?&Q[!)ESI3B8%IM4!2VX4=M8CG4IQ )<)Q?MOK5
M!.M5D\IR>(_=BP 'W^U8VX3@*L*=*+4J4-+\SF3XJ]7IQ=J^H;I]N5M]3%JW
M1L7=>Q)3GEI=:N-]BOP-U[9MH/EEZ$Z+?%NLA+NL(=2VILBI1B^I"7YJ$_P:
M3'VY_<50)@V<Z9!>,A+P#:3XN63J-N:#:NH'4W=LYYJ0J!(Z>["CVXI\J?:H
MT^4W68IQQ8;5:[K<KZAQLA.I9CK%3I $(,+JH9'RQ$0W)\7]JNJN;6C2&1$Y
M/P^@"E:U[D9OTF4[:WTJ@6F9+M<X%LH>7=V-*9$1]IP!V/\ (ZP5 @*4I0IE
MF<J.DX N L"8E#,^8_8H!ZE;VOFP=_N7NWA+=I+.QKKN2(ZEQS\WVZ[>I>T]
MQ2X@:KH>VXS<X<I51D&ZDA)J**\Y4Y>H/A QZAV/N5]-JT=,AYF+>+./>RV$
M>OT!%TCV9<V,BZ3(DB?!A+>2F3-A1%M-RI,1E9K(;C%]'F%&K0%@F@-<9?!^
M!5$9S9V\H5CE,N[8@7*;;F7UVUN.](:LT=I"V($G2ZZN3;VVT_,-0GG5 O1T
M:T(J5MI3\25:NI ;;&=Q0$C;9RIQ#MSE #WF(SS&*SJ53\].-"J8QKG 2D6?
M_#(_8?>M;T[QZ[?\KG=U*;V-^;_F<>YLL S//_(C#DR)%I7#*OECNK\U#41*
M OR=.ITG51.*OSUS^1_.>30VK(_#B<N?!9?Y:W_J7Y/^)H^'A\3ACX9XY+8V
M@%2"*'C45'/OQN7'M7.Y)&JE0#X4'Z^&!->UJ R4?# A+2\O/XC^OQK3E@2=
MT</E.>L^K/!XJ1/O1TR5 ?CR\1@3=/X\Y:3FI5/&I/?F>W"8(+'-.+]N$6K:
MFZKF'!J@[<O,A.M5!YJ;?(#-:5.;RDC+F<8MU_(D#QP]ZB-;B .!*XT7CKI]
M/_3AY<'??5;I_9)UF6!<[5<-UVQ5Y;NBTA:V9.W[6NZ7YIUAM(HVN,E8!J0*
MC&1:;;>W47H4IR',##WE@MB(QI@RJD0)PQ("P"9]??TAR)+DASKCLV.TPI"(
M*W;1U'+"M"M2G%+3L6B0HGF>&-O3[8W81'\,/_G@/M*KA<VVDF$X8?XG"N\7
M^H/]'37\=SKML"2"O4$QF-\/O*/XB&8;>RE2*M\:!-<6R[8WGA2&G+XZ9^H2
M4I;A;Q@]2=,?[0_M/U+AE]8OU';O^IOJEU2:F[[OT[Z?K!?EV?ISLEML63:K
MMJ3(:2S?;S86F(CM]ODM%O4XF3<P_+CBF@,&J!TFT;#"SM8RN81_.YR.;'H>
M@Y+07NZRJ#1$CTBY#?>?N7-G?=S8 ?B6QE,>*&T1F6V6@TTVTA*4H"&Q0-H"
M4_"*9 \^.-J*,?,"&!+J5"IY8RC[U!\)A32G74) <4KXU%2@XHK )^(G4-0!
MH"<5^BP99OY@9E,[DAY37\76O\:EJ63I)J0H535%2H@5XT';B.@@MP4XW40[
M'%8U+)<:0W_W8"QI05)R )0" DE0344' ^(Q(!I.K(5R^;A83(M[RY&LZ4_&
M4ITJ4:I"<@K(@JID234G%A#EUM:=X)1YGJK2];WUN!9 ""4C355$I5D-1(HK
MAQ%:$TJ,2]*,L\V4(71]1]7%V2%0% Z:#XBA*E*&2=9T@*)"B"-65./+%8I#
MBKZEX 'Q<?8B,0=861Q34E2$<*#2?A"J9:JBN)>EB&1^:B8XX2]Z,;<\$I2J
MBE'4"2A*&R#32HC-)U$<./;BT"/%1I7,8.)$E(:@^6I>D,9%-4$:C7EFD\@K
MU4YUP$ K&NKXBF:8<.$_EP7),4(H@!(U&H< ("$KUZ*&M": C(5Y8B*+ABM3
M1J2$R0?#@L*DV"2I8\EG5J&="1I3G4D&N=0: 5Q3^7Y +*A<2B022!U040[G
M&=;+J"VEL@@*!"=-=0"E5RIIX5]6&*,@<<D$N1,2!Q67VEASSVW5J:U+(=4M
MI%*I)"4I"Q4D#+AEQQDB('!8U>L(R,CP4LPKU)8AF-YA<:6 5-K5J4.!-%G5
MEJ' 9C+CAF(;!8%:IZKR#)Q'6])IY[I2A0!"%-DA1Y(J""M"LCG3$33/ %5^
MJ6 "]8X+;LM_R&@4A:FU$MDZU%(%:&ITI!)36N9IAQ@&PP4J=2=0>8X K.K3
M8)*9J"E)2WJ!" VD?$KB2JI4@!!KVYT.&(.0R1B!+U7P3^Y;8DQ;U%N,8"K"
MT+U4HK6%I7K5H( 309\.-3B[08D<4?$=06R\*[P+U:([<\M*D);\DK4$#X]/
MPZDZE5 *SPX^.,N.F8QX*J1D"& 91O+@P;1-<?9<3_$<6I-"K2BA)"DA.G3G
M7.M">[&-.G&!<'!2URG\:L&[GTWBT2&([NH+;*%I0ZI2R%) 4A2TE(5Q50BI
M[,4DC4RR8$Q8N66JG42R6K;NWVPAIKYAY5:TJL$'44FH.2T<37]&**L0(E_A
M9;>C=52(B4B>CK4./<56B_VZZLA"%0+HQ*!IK0E+;R5$$4-4A%>6/,K^K"RW
MNG=1B&IU8D\F</\ 4ZZVD35MA^\8D+O_ +@<:M$;IQU&LS]-N;TVY8KHXM#A
M>C">[#:%T05?&A(3,0M-.WLX8]EK4/R\J=Q#"A5B)#[UY69>I4G;U)$3IR+]
M0^'TZ+8-.W8%_L2KE!:0^7XP=(>9\]ORW "XFJ%)!*2"2*YBF,ZK;PJPUT_B
M9UIYUZM*J0>!_N5IC[TZS]+;*\>E74+>FQX-P^7@7;_)VX;K9'/E/S!IU#<-
M,&4E%N<"]14MD(=4/@)*"L'E]Q[7VS=*U"^OK>G5KVTY2IR(QC*43 EA\1TD
MCS.SX8KL-A[VW[9K6ZVRPNIT[6^I0IU8$1GKA"8J"(,XR,!JC$G08DLQ<8+I
M[T6_K$=1RW^5;MZ%[(OZK6'+<;CM??._MG79]4):8*IL\3G=YP9LN46_-><4
MPWYCBB:9TQH+GLJWK FWK3@1PE$2&?\ LEOL6;_[@LR=-6C4B7Q,:@XCA&4?
M_$NU/]//ZM=A_4COCJ-#M5KW-MO<=KZ?)&XMH[S3:+J7HDR\VE+TNS[@M!%N
MW-8'/.2T\F3%B2DE:/,8*55'$;GL-QM584KL1G;U 0)#X9<XD'$%CEB&?$K8
M4;JVJTOS.WUI>I3E$\85(2SB<#P(PE&68X*==P?0A]*ERW>=Y#I#9X,Q4U^Y
MS['9[C=K1LN\W%TK/SETVE!FM6HE"E$AF,F-%4<EM+3ECR:_^2WRTW;>([W>
M[93-Y$DF(E.-*3ER9T@1 XXY8G-U]$;9^L3]2&U=I'LRU[GNY;48"G"I4C3J
M7=*F,-%.ZG$UHQ;#&4B!\)"V$3:8<2+%M\2+$@VZ T(T"VVZ+'@6Z!&3^&/!
M@1&V8D1@<D-H2FO+'J-M;6]E;PM+.$*5M"+1A ",8@9 1# #P7S;N%Y=[G>5
M-PW*O5KW]:6J=2I.4ZDY'$RE.9,I$GB2O(@QTC)*=6>92.'.N+W*P)"0)&+(
M;C4=L!2R$H'%>0">0U< !7 21X)PB9.'QX!)4AA(R(KRX<#ER/KPP)(,91+!
M(^!.8IQ[N%:\>-:XDF1Q5%/MM%%0-)6$DDI30JX4U*&JJJ  9YX1DPZ) &6"
M<ID@<!2G'.G' 8J46B&*7\VV<SE0$DDT2 !F22:"@'/"TGV(!(Q*''N4=]*E
M,.LO)2K2HM+2X$G^R2@J .!AP*C-Y#HG#D]*&W"D@$-K*2<@%!)TFO<<0J/&
MF9<0#]BNI8D1/$I34U*&FD%6:6T)43GFE(!J<\R1ATX'TP.+!.=0ZY'@Z.)2
M%4S' ^JO"N=,2$2%'5&6)=PJ^:T<BK+V5\,\L,!AU3>GF 7*"TME" BI.E2D
MU)K\.HD<",P"/5B(B6;DJYAYN^#!4#C0J HDCCEV]Y]^)!\N*)YN,BJ"2T-0
M'KH1E45SSKPPS%TBVL2;^U*$Q(%:9=OISP:>"C*#E^*J;CQ%2.(!!S%>>7,'
M!H4Q*0\%I?OIIU>Y+HMX)0[\TX%( KD*:2: )!4D@D#(5Q7#)CF"JJVDU#*6
M+A_:K9;8P*DDD>RN7$&M<2)X*J( QX*0K2P"I)IEPX<@:'GF<5SPBKZ8.+<E
M*%E9JM IQ/$>[&'5R!6=$8]5/>U62%- 9D@UKV:37.N,*1>6*SH   <5'4R<
MCYB0FM"F0\D\:5#BQGCH(B0 '1::1BYQP=89O2[;F@[6ODW9%OM-YW9%@.OV
M*T7V>_:K3<9K92L0YERCL2G8*7VPH)<#:PE=-0I7"G&KI\C:^#Y>UDXFF)?Q
M']/BS(\G<3<0VU+D.?)5.=;CR78#(E1[2IV*J2)-S4'4N,0-:2V'$I7\134
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M4K2IZRT1 19_W28Y9>W-;%0)0<=2I"RXEV,=+E:ZT,/5;56M:EJ2FO,<\;7
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M3<HS4*3')8+PT^6ML>8-+*TL!:U:5,S%F01(.6B^+Q'5UN(W.X1N*,JGI_G
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M7@]&G5,+N!U1,3Q'U$<PJ;07=BTJT!*UJ2TS!R .'L/59[]$GU#N=6=LO_\
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M5>8-@@PPEQELC,E0!JDDU43I4:@I*:XN  Q"(V\:7P.KRW"R!6L:2Y11%<B
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M8*D+JI0QR=_N]_7:A83&J-+22,7(+X\SAARXKK!MEM1IU*U6 ,YU-40<!DV
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M//\ $E_\O7^J]KV(Y=F[I(C77=5]N;UZ%@:A';VPD6%F7?-FW>;(1!<AP[7
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M_P"JSJ/:>G/^;;3 V\\[&=GOR)KJY4U#T/Y23)9UL":E+3<IAX,*10!#I '
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M,M)C-Y-Q=@.0\%EN[;=*WD[U69W39X&Q-[.;KL^W;%;?SM%_7/NVQ$R(Z_\
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MEQYK#K+14E24G&CN[B-.Y%$@QI4Y1E$Y!IR:1 Z%CTS6[MZ J0E*/Q2B7?\
MPAXN?!P/8%CFV^FEQ@IV6]N(6^5<HEIO>Q]R0$&$_;P;GMU<""Y#BR%%+D13
MT=M@HJX L-DBE3C/J7,3.H*;Z"TA["Y_:L441*E$S ,@"#RQ#(-BZHL7;J))
M^FGKI8=P7CI/O6%9-R=/]V2THF;BZ-;DNDUBRWC=6R'HZ'7'MMPI8AKO%K75
MN4R9* $J;84C-V^C&-"5:&C5K(DW$,3%WR.8ZAN*PA.>N5O5),(?#X$AQX?3
M):0]7M@V?H3TUZC;4ZM7%^S[KVE?[;LV]W4R?+M-YL[=ZOI@;ED[A?8><D6Z
M^6B5#FVU:EZ783K#R"C4JFTMQ*=]"A0$?2() &.) R^\JN(ITK:>D,(_M+?W
M*>-[S-OL[LZ30)CTV\1U;%Z80MG[ZN[J+O"A1YFT&57BR1T,QX*Y<F]0$+9K
M(=<=<E+("A5)&EE<B5*M4HP)EJF)1CAC&3.<\CCX+(]*(N:,34\VD$/B[A_K
M'UK(I6_8D7<FR;TY$WHG8>_.BV\[%;5-WN9885LWC;3+G-0X+,I2X;-X?AV?
MY-2"0IU2V]7Q$5C0I3%*<-4?5C5?FX//HY=9%:XC.I3(!$='NS]V2ASIQ?5W
MKIWNC>]H@W&'?G+AMZ%=%OW!Z"_'G/W6[0XLEEN06H2TNV[3J;:;29#JB118
M"L1JU:]*X%*I(^F'8YC(%EBVDQ.M5E$DDQ!SRS'TYJ_[!W-:[S(W%!_.[O;-
MK=3;U>]JSIMQFM?-1K].8G6:#?I7D-(=-FA7*&T^67%*4$-ZJFM,8U2I5A4$
M2'J1B).!@P()'B1@E=.9- D4YN)<PXS\ L1W=%FOWC9^W'K9&C;HWKMJ--<G
MJ;4W)D=6]JWI-KO;\*5*C^>TU>9=O*DH)2T/FP2/B..AHW%/\K.$A_#@Y?\
MP$.';I]BUE01IU01'54D'D?\61^F2O%RC=0MV[<OUX?V/#W(+&[+7LR.PJ+
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M\LF'(O,)I_Y@?B;<0IT>44DYZL9%2\M*52-&K5IQK2R!D 3]:LC9UY RA$F
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M6I+B6-?EMU;8=(^%:J5(*E9:DT'#/U8*EV3$C\(6^M-CJ5M,8Q,JI;  DOR
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M>4PRB*B2HU)0X#0<1CT39Y5_Z).%I5E !Q(#"19G'AP7F-256VW.-&K 3H8
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M$?4LVZEWGHQOG;".K.S.FHL>_P"=NF_;EW9 <OL&Y;=L%J#>W=K7!BSP7?\
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M*N&>/7]F_0=\G=KE"=:PJW<HAGKU:LG\8QG&)]WL7G^Z_K=[\NP8[=#:[*'
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MMJ)KR&HCAR6R&R>C]BM+:5/)<DS'2$O2EA"J$)&I+2:&@UY:AGEPQMK;;*%
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M98N^XEJA2&$);2PXIG3JH3C/W+T191K#29Z)-'@PBV?M;GFJZ4"*4A"+R_Q
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MW#;EMQ;:&7IL:H8@3PVD:OEDMEQU]6LDUHGM[\4T3"5U",3Y9'Z/R61"$3(
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M1#D"YWEYAAIYTK89<2&OA30='<3NX6\?Z=_%GICD6P<%\WP&/BKZ=:WE2 )
M DQ)RXAOK8.MMML18#@-PN35C>DVZVH7.4IY*7C>40A,NR8LABD=MYZX0U(=
M<*2I0<^,?#7&LC=UH5S"HYQ9R^1!8_<ME4],DZ"U-@V/'!Q[%'FR.GTK;-MW
M'(5';7:I5\1<H-TB)B/M7"3=[TB8[<+QJ2/,+VW9<!*U)6M2%PPE(3I4,;8Q
M,:>N6K1&  ^SW9^]:Z5*4Z;'XQ(Y<0<1[E>?JAMBF>DO26[QG&(>Y]H79NX,
M>?,,9FXW;:5KBS;-<)<QMEV4S!?9:4TKR05$2BHI42*9%Y4E2N*1C$1C4I'6
M^)/PLW 8'ZEJ=PM;XV8NK:<(U*4A\0)Y\O#KFH2^O3:,*9TDZ"WF!<(=@LET
M=@[GWI=;;^;(G+G;;M$Q>V&'6;2I)N5OC'<B4,)D("6E:!\(%,9T*]&UM*->
M/QUJ<O-@X+L2YRP4=RNH4:L3<_C$1J );##P&.9Z+7RP3K):NEEB\YUR!=>F
M'4\;)O$>085LEM[8EM/;KAW2%';=:7(A!E%9;6I9-"H@Y8TE/\U9UA"U/K4:
MM,D@DDYL9.>(_N5EM<5(V J1,B14TR!S88ZA[,PMB'.G^W]BQ-B[TW!)%Z9L
M<:R/6"QV^WW&>R+O<?)5MG<;"3',J,Y9UEZ9.>_E2%MH2EPH*TBRXJ7(C3@2
M-39Y%\7]PP'BK;NE0IP%6J?X<&\N)\W!FQ#9E6#ZA]DWW? Z*779&Z;DA5IA
ML;9ND1?F6<N6:;N)F_6Z]L[1MK4XEJPWE]:@4),R,%)HH + A2OHB4+0 D#(
M<0>)YL_'):^\@+@6U"$FGIP?XCCG[%B%LCWG>S_7^S;<W,N1U+W3NS<F[[Y,
MAR)=HM=YA[?NLG;Q%Z8>8<K?(D*\MM(;0TVLOQU52%K2<8U"[N:=U7_/-K,C
M&G$@' @%PW,O["LBT%(3E2'FDTC(AR?+)F /BL<Z7QM^;6L45R?;XFY(NRNE
M>Z;A:]QE"+=NNZ=1'.H+\6V[%EVJ<\8;UH;M=Y+CNM310\$:C50I$PMKNI#U
M7IW<YD3;&&D 8NP+OE[5==U"+65>C4J0M*<#/2<&()SQ+>&8P6Q5RW64"[OS
M_DXDZZVNT;.B;?M=H81NZS!&V=QN7Q?S-P6RF\6O<E[4AIT>:XRT[;RDN%1R
MVE&C&C:0H1^*)EB[ 1! !Z,.CL<E@5KN=W6I"#2HU* U$9AP<0^;_:,UH7UP
MLK(L-OB3X=ZM5LB;;O$S<&UY3(5MP,6;;UTD;9O#J&Q(DQG;@\J$B;\J\A+F
MEU025#/D*.^[I:WEQM%_5T6;QE2K"8E.9JS8QC @-H((#@X$%UFU!3IVIE9Q
M^"+3B(LQC'"6KBXY<5K1O;>_YIT/B7#;V]=RW!-Z>EQMJV:+#1+;C2YBK8NX
MN/W61$-TC6",^XU':COE*$>6="P5D8ZG2!=4#*,*D+:0]:4F,C @XL"QD<W#
MX<%S>W"5:H:E:&B4:A./$'CU=3W9;];+QTRM5FJEK?FR=GJW-6.PIV,Y9KKN
M"W6J9 AO25KC0%.7!U*TML D(>6M!"5$G63N!4N2(@&QJ:@'Z.06X^U=/1,#
M;RD9:I '2#EI)8LL4CVR-#M-WG;;W$^XJXV>58-SID(-OEPKVA";KLX1%6\I
ME.QV;6)4)*VE(4/EAI633"W&0JT:)K4XFI)I"8#LV!P+@\,"ZTOKU*%*5:EG
M/R^!S#=&<>Q9M;;]"L]@B;UNV]A,MUAM+5RM+<BUO3[NJZLP$6S<FVTV^&W-
M5.7?6E.3&I$ATQVY$1PN?S36=[97%W3A4I>0U#$S. ,B)=2 & ;)V*R+>=65
M(50Q$'(#.7.! \<^7O6V'2*7M+IK?]G[GOEZM/\ EJ98K@+O)L,/\\=M<^99
MI,J%#N&W;(N2ZS-N+S^AUD,A;;ZRI+8;IC+KTHPW 6=81%.5&0CK9G.3D\,P
M"KA;6OJQK#RP_$&Q!/3K]JA+K':>H.X]S;#WATPBVN!T\Z?;XW#M_<.V B&E
MZ-$?VS=[A;-\PK;<(SJKON"U.W9YLQ4:6UI<5J&I(*=):W=OM\S2F\:LYQ]'
M428B1(A*$I_AC+ @\_%%E4KQ_,[;; 2M9"6$BVG0TC+JV&"FG>,R\V7IY?\
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M5+ANA)1'F,A0%:@]!N-4U]VITH!IBGQXEQAX%\?9R6YV:[/]/G5D6F-!D/\
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M>VZ[H6MB2Q\3?F*<4I*2D)/PJTHT'2I:=-1P&(U*D9428Y,?L50C5IS$3F)
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M/ 9AE8HEFNB+/T7W_)NX5>)4VW.1FUR46R3?;7<9B'%V]+Z*$R5;1NT/Y=M
M0TI3#@"B/B.^G.G=T)6M$L8P+'-RW _Y@5C4*52G.C5KR_B:@'Y^[F"ZWAW5
MMXVNT3E-W.6Y9RJR7BT-F.Y*?9<NMA1$#KI86$OQ$S5I+C:!4.I^(FM<7FC5
M_H=04W>F1+'DV*V)K"5Y+7Y1B/=@#[5I1M>]7#J5LCK,C<$=<5NSWW9=WN&X
M+.F9;K!N^%9EQU(1.LLUQ<BU3+(X5-2&N#:-*DT"JXQ(>K6VBI7A)S+3@!B
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M'35;FC4W<VIEA*C3D"1E#.)ER? .6>6"OVVSITI0J61&B=,RG3?'4X8CZ\N
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M*=DMM><PXI6MK&7NU*=*\G:U)F%3/Q,N&&;]<CFM7*WG.<)$M4$OB'7$ @\
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M3=7)$3<NWK!O:S]0]G[DFN-"\;C:V^T]$O$5ASY]MMDEYHEXJ&QW#;9FI.1
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M14 $T)0G4. X5%.VN+!2#-Q6/&IJ?$JU7:"J9(\U(\B A:RE@$^8?A 6M9R
MSS X 4&*C2+]%DQJPE 4\7S/3P5LAII(2V2VMIGXDD)H5$F@"OQ*!R''#A$B
M?@JC$/@ZR6.I3@2 E9_" H%2DBG8LE()HKQH,9@=E'2V9Q?)79@A"M00A&@@
M$<5'X"K54\O#GB3/%-DY#RE"JJ*^,9))*AE7,&E>%#7C@RP1B^"N;$5QW0XA
M!<!'Q*4O2I("S2F2N)//++"$)''@IAM)X.5=%S41FSH512AHUYT(T&J:J72E
M!\/?BP'02RC4B K1-O#A2MJ.$EU2*%QY'P#B*%'PH*B/61BNL7(*RK6,*D#
MOZFGV+#;E;6W4H5*:9DTJ::$D)*B22.9 (H #EC E1!+R8A9P$Z1U L 1D<U
MBBK:VEQ2VD-- $JHD:":ZCK2*::Z0:5_%BOTH@^5E=2N9B7G),%F5L>>\H*4
MH@H0D("@H*&INA !5F5@#@>&,RE,@:5CUHQN 2S3Q5Q:NTZ,&U)*PV%ZE-I^
M%1J 0<C0@4R RQD0JRAYHY+61AYC3+:GXJ0+5N53WF56$+&A(%30*62%"I"1
M50%3D1C,%S*;,E4I:'  $@LIC3&WU)6XNI4HJH0I94D@5RRR<TF@H>''$=1)
M+YJAV..:=)EE!2I!T@NK!2GXM"0,E423K2D$ "H4!D:89)AD58';I]B<KN3@
M6E964! I4@)40HT0.*172<QS!&>(&M,C%1.!ZIH_<GC("6ZH2I(2A*6UK'X@
M<E*ID2:D@Y5Q*,Y$XY)<=1P=-I[[H:2I+H0XLUR!.K0D"M">!"J&N5!EB,Y]
M5.,(S!.2C/<$T@!&O,I0$%5"55U%2JA52% URH ?'%$B3X*0BT@.#K VVW)\
MM3:ZN%.22G4#10"24FA*M)KF?9C%:4YZ7P6P%>,:>F08 %E*5NMSC$8M !(0
MV#\8"AI )2"G2#4I.7;C)A3T1987K:IO^++^U.D>4PA*WUH'P (2?A2LE1'X
M 0&ZJ SRIE7$I#RL%.)IXREB/O6H_P!1][>'3N^T"U-R[K:[0E=0J.V2\N6Z
MV"LJ6AY3;)HD9%-22:#' =^7?H]N7$<-4S& _P!J0?ZG78=D6WJ[U2J$,(QE
M+Q8-[G.:YSX^>E[<O8$++MBIDKW7941''&GUR7$A3:U(66U1GP^WJ0"HI>8*
MD$?O!1'/'1=M1']7MGP>K]Q6LW<C^FUG#^0_3V9K?GZ3;N_9?J0V+?XX6PF!
MOG:L99K4.,OW-"76@156E;9((IQ)Y8^@-@D:>\0GE'7$%>7[P8QV6=!P:LHR
M;H[8KO--G-L=:MX1990W9]R%=G>\S04-MOQFFXDI 50I$>0E#@/'X:\\=^)B
M%_4A+X)N/V?M7FXC/\K'C4B,N!YA2!)M3UPVG+LTC0)02[%JLT'S*$Z@V."2
MEQULD*&79BVI3E4MC _S&(]JQX$"Y]7@ZZR?TE+9*3TGOERAP(L>[C>6Y&KY
M-G+^85=+);XUK@Q[;#A/(+#;L5]QTJ*EMDE842K+'Y;?J<NY1^<M(TF]6GMM
M$2!8C23/!CF<77US\K)Q_P#:D:="&JL:E5_!PS)_<)4&[?4%TX9M;>Z[]N"X
M[EVQM.UVFX0$,07KA;KU)O&ZY[EEB6YF)8+'&CQW@S(+JW%+2%J5I(*?F_MR
MSHWFX?D91E"G3G*9+LY&41S,I,&Y+HJE&%2\C&N"(@'/#$.<&P )R6M%WWJ6
M;C?1<NGE^DW+H\J?;]IV>1?FY;=JO>]=SAM>XGD6UU]F1<;4W=@Q;VD-R'74
MA20BJE''&;M1M(W7]-%.,(UH5=1!Q!!,M.K!XN'.+ L3DLNUNJ<K,4YTY3A1
M@-,7?3(R9SS(?#-UCFY++U V+LOJ/N>1(_-9]X1#W#NRT[VO,UV-*7<EO?Y0
M$Z6FX1G9MTNZUI$B2A*I$1U0 1Y:"!=3IPO:MI=WT*E2WK%CZ7E,1%@2V(8<
M(E@PS>2QJ>]W,Y7%*]IRJ6M,QU/(Z=)!,6&&+XDC)9WTDVS%G],H=GOR+Q!W
M-U:W=<;9MZVV]QI^)8K:[LNY&7N%RYR5L+E6?;[$%29;K_E.*<2R@!1(!SML
MC;0WNG>T9#\M0%01<YD@C2!CC(R=AA@76SVJVJSLS=R?1ZDS %R(QTDY\N?5
M6JX;]N.U69]@VA<[E%M6[QL:6VVN.B+!W+LO:I>L,R!&N]S+:#"N%T:2X\^T
MH*=:"D)J%J../A*%S4]>_ ]&@)Q9WD:A:3R$<FC@ 1GB<E3O%S1OK0W5(S%Q
M.8/PL!$8:H\P2"W A;B;"OEJ38.HCKUKN5BG2W[=;OGW(RHJK?$AW^!?X-NC
M(2G6^]*;?:;;2T2AQI%%9C'8;;;PW6SK3H1B;TTQ*(C.. !!Q;(EL.JV%*PI
MPI_F15,ZAC$Z8@ @ N"XX\QQ4K7ZW*CCI-=G7&IUMF[I6ZJ<J5%99>DW1MQ]
MYN';W"T^IZ4R VXINH1IT$ YX[NO3E1IV)C(:A2(+'-CE['XK:6M&4*E,";Z
MJ@D3@Y!&(^PI_P#Y_L]VME_E6>!&7,E[4O=I@/.P6F=M6^=M&7.N\ZWW-:2V
MY;V1#G%X N*\Y84 -2:G&N+8BJ#.0!TAXC,DEP1SPS707$_RP-P1JC&+_P"Z
M"[MCARXJ$>HNY;_O;JKN:/&W4N/8XO3UBTV5FUL6UI+5U59[I_F)]B>?+CM2
M85S:;82V\%A(4M>I.D XG<5S>PVCU;>)-[ "46P?2'$2,,)$8\QXKF;J48UH
MWEG)]4HZ3@7!=\^>2YZPFC/L.](UBLL%]<*3>?RJ3:'V[= Z@;@M>W(]FN.Y
M+C: ZTE4Q"H:U.ZG4J+R:-MGS*8UUOW?7E*WEN$XQC7IPE5I5!_+C+S& D0\
M8A\,,0,2J[^L:%R*-.4', 91)S!SQX<_%;[]'1M38VW]MS7WYDUJW6FP[)M-
MTE,QG8TV/;9<3=MRN;HCO+EPH[$HOQ%)*E/:WE420:8WM/NRAN&XBI;P,K6I
MCJ#Z=0&@#$#@.2UUC7TU*GIQ(H3EY#FQXX\LU,8_SNSO2UQK',8BV&Y1E#>V
MW42&[A;[I<)?ERQ>9$.9Y$FP742 VTW(C!0?*0TM02DA/0PW.,#"G/\ $PB/
MJ<+(O*=<WU,3&J)C,GDPQ!Z%\!Q6$]11:]I;ELVR+)N&>S)WQ%O<)Q^-'C,.
MPFC>)EL8\ULR"F>];I,!+#JFR%H1(2G+CC7W-&5&O'U)/ U7#\"YP^_DLZSO
M[>C;QTZG(,<!@'+?;@@;SL;-ZMOS<-<Z]VV7:(#\BZQ'I5MF2=P[>A(M35LD
M,Z6_GJVZ/&ENQWZ,A39U9YI=330_XDG&<B,G =A["_$8XJJ^J?Q?4IEZ,Z0+
MY>;$?8'\4'H)YLJV;LO=UO46_0['NN^VYIF):;A:U[7ANVN=>8\*XF7(E-SI
M"7KQ(")<9+3"DJ  .>,NWL:-O;FG3E*9C\9P\DI$D9< .!Q=8EA*I"M*E3D\
MP29%O:/!0)M9J^[+W)U4W/=9=WV_+@;EZ61;-:XKC=]=WC W<[:[F[$9@N34
M1K/#BO1'[C/>#:9+ :&2_. --N;+<S0C<P,:UM.6DD&,C+'3E^&47.)8X+-M
M-RI5Q*C"7J::H@3'$$GXB_0X$<UGD+<)W!U6ZI.Q;0TQMJ??[(K:M\^<D6ER
M[.;7W,H0;/:W(:U,KM"W7G)"4I+;CBT)0XC2HUQS0H;3<5;2VE*-*J=0@ -,
M 7( .;X.1B!P5].YHT[Z-M4B(T\")AP"06$>7L4P=1MVS+[T7WS^7RS =F[T
MF;<M3UGB.2[TVF]7RV7&*RFW,%"I+/R-Q6B0M2PVTD!2C1)QE7UP:MD*=$>?
M6"0"QTZL0^>*U^\&E/;:]6X_DBJ8$Q?X7&.'UKGA8-P[+Z3;B<L_4)Z7:Y5N
MVJF+<K[<4NLQ;:VC?#-FBVR-;H?\%*I%PN+:6Y*DE:UIU9#2!HK*VE3OJE.S
M&D&)#$OU.J1SRR7']NU]LH7L*MK*?IZ6+DEC*0'L',E2!TX;VG9K9UOZ;;;9
M1$C[6MJ7+/.9GO7&XJ<JQ>YQO;$IHJM]QBWN[27F@#\;"VU  4QM;^E7N=HI
M4[B7_$"$@=(:+F3C2V?E !ZKHNX)2I0N)64F%*F#ARPR^OWK*-][,V7NC<D=
MC;ZC;^JEH:VI 8OKD."Y=&MJR!$G3DV.%\NN+*OD)-S<:<<<*)$>%*)34(&-
M-8;I*GOD;&K ^E*$1I#D2<'S$X$ $8YNWBN9OKZK;7M&5A ^K.-,&/,2 =N3
M#$K.]LW&YW#JQU?N-O=N<Z!MWJ=9]Q;05"<9>NGE*V9!_+V0U<5(C3'=)2CR
M7'$)4@G64@5._-S2O+F88>288DEG!XD< QYJ[:[&5:G?U#JC5-YF#C$"(D"'
M\<0M?_JAB2(FZMO[BV=9FK/TVW-O3IQN.\V^ZQ2VTBY*ZE[W7O2+.NB&UR;@
MZBZR'41O,4[$2S,;+9(="CT-_(3V>XL[64H752A(PE!M4"1$B0!S 9R#B1@5
MUT;RC:UJ,Y4QZ$)P$M0^)Y2=_?AXI/7 6^-9>CZMA,QK+>-Y=5).YKG9B\B_
M,,WFR=(K'M:*M*Y3S\B1#>B75+DF,II"E,-J2BI)5CRJVC"W[<W;\[ZDJ@KD
M8M S$I0(C'2!Q?3+KBX71[U>T+>D+^+"UIP?3F-4<CCF"^(6I^X!LZQ7;:G5
M/<5@N W1MV)>]M[=?LC#CDV4[NRX.IVWNNXK4RW B6:U2H$4(;#" TZXPVHE
M"B,=SV_>QI[<;*ZT4ZUW2U@9X0#&GQ))Q.HG'$C%><;5=0N+GUKN9UU',3$:
M0,< ?#@%?[IO:7O;I!L/KI.G[:@[0ZTMWJ=O*XP;TBTTZE)9M.VMZ1[L^(S$
M:=>?\QV9Z:H,I"D2)BVE'S$I<7J=QJW(J5]HE&O*ZC\!G%]46)>(XQ'7,,1@
M5M]PNHSI>O0B]&8TC/XF )][^!6"0-F(B2K?>MU[C@7&S&>&8VW+% F6>*[8
MH@6EV_,W5:8S6YE*O[02L.!I3>LU"@H@<Y8[G&-&-U9TQ&ZM)EYR E,ZSA_D
M#. ,<ADJJU3\GM%46T1*K!M4>,A+$?L627+JA;]W;/=Z@75],J^QKS<;4);%
MNCQ]O#:O3ZR16&T;?VHU&C66))D1+HCYM082');KDEPK45*/8&.Z=P2G3W*J
M6]6.B,0!*+QQ&H9X\7.0&"T5:A/<K$1AJA*I/B[LSM[';HM&=^[:N_6>;T0^
MH';FWWKAN!G?'5+8\"$[!B6Z':X-FMEJW+#D+M9FK0W?V'F;B7UMK\MU25*2
ME! 2.AH@;397FT5"11,8SD2<9-@>&6(]O-9-OKM+4[=5( I1D3I!<X"1(/(C
MAFZD3:WU$[SN.[;YT]GV&UWL2KY>-P-6&X[CA;7@6^QS(T1$2%;=QW)F1:8+
MD:=:UJ6IS_AG9#M"X"<:NEM6W1MZ5W6U4Z,8D8@R!)=B1F1CA@[!8\=OIQI4
MKFM.6B, ,1^]YG?P^M3;<9KFZ[GM.Z;;V5^2;RLEVO5CN]VNJ+0\K=.VM[S=
MOV%V->8C$AYBT2[$J2ALN@)1)96ET+.E5.1C7IV="5F:G_"7%4Z )$")C$S
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MSK3IO:48&$:A,93=HF1/T?D5D6DXD0N1..N+2 &88!Q[\/!::[*B;V^@7?\
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MU>&&P([-3I3H1J)HM=4G5E4 'O-,\53(B<<U91I3E,3R@H^GW5U(\M"C7AI
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M-2M(2+$/@.?(,MANE>O2A/T(F<#+"+L[@G/(?3FH#OFZ+=:HNU7-YP8.\?\
MF9>KS9T-6VWO;4NMOO$*VJOC4)3S/RZ8,R[/7 %2=!0I:BXH@)RWEP:%:QC6
M $"Y,R#JTL. X@<N2X:KN-M<6=O*(G"I3F(Z<BYD2V&;8L>86AUM>@[VEW/K
MIN&!>>GSZK=/&\MLL6ZY?.V^9N^-=(ELB2;'=[BTRZG\S;8*9^ED2]*U-)^-
M(QR&Z3M*DSMT8:Q&M!J@8FH(AQI(& +-(!]+C%4[G=QNX5J@IYF.J1^+'(=
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M?RB_QD2(\>]VRVRRR7%?PY4JWL3B6Z_]P\7=;9)_"H8]%W&C&,O4B^B7]_\
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M "_],VK_  ?_ -9_]U_V*XYNC_HY?#_J#\67TY^Q9.X?%;YY2\./Q+6'I?\
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MZG_\A_XO^_KC"W[_ $E3_3_##X_BR_#_ (ON7-'X1\.5+/XLOLY^U:9]3?\
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M[Y6-=/\ U<L_A.7^7Z>QUR=+_F%7XOYLO^\?AZ)MOS^\[D_O7^,,?WG^]?\
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M^;_CZ_YG_P +O_OG^YQQ^R_\QK_SOY$?A^'/\7^/DN3[5_YC'X_CCE_F.?\
MB3?I%_T.1_KK_5MJ_!^#_&^L/^.__"7_ &O_ -VQN>_O]''^5\,?YGA#X/\
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M5'_)Y_YC\.6<<^O+HES_ /%-Q?ZH_P"O.]?]/?X#_P!$+G_+_P#4O_&_]/\
MF,9&V?\ XHP_^C'^9E\8^G^;2I#_ )4,OYDO#X3\*Z/;$_Z)]*_\=_TEM+_$
MO\5_Q&%_?N[^Q_O=>.+_ /\ *2^'.67PYGX>GW+M=H_Y#_YG\F.?^8?0=5C6
MX_\ $/J1_P "_P! ;N_UG_H;_6M@_P!8_P#PP_\ U/\ _._(8[#:_P#36_P_
MZ@_#\>4OAZ<_:M1MG_,:N>=7+/A\7W=64>[)_P#BC_H:_NG_ $3WW_=O\;_D
M[Y_#_P#"]_[K_M_,8RJ_^AN?C_U,?#\/Q=>?1E/=?_Q@LL_Y$O'(Y_X>2OG4
MS_\ N_\ Z4_T7LC_  ?_ *@_Z3:_E_\ PW?^!_Z3\IB&X_Z2SR_F?B_S'X>O
M]JUU[\-A\7QRSS^"6?7[F6LE[_T-$_U-_P!&-P?W'_'/\4VQ_<O]U_[C_O-.
M-G;_ ,^>7\WAX'_M<^KK*[9^"[^'^</B_P#%]RB[J#_UUO?^A_\ &FO]?_Z6
M_P!'7W_6_P#Y/^U_YSS,44OCG\?PSR\8_#_B_P#V5I:G_.[S^3_IS\>68^/H
MMTMZ?Z1^E/\ O'^I)G^"?]'/\1ZB_P!R_P#4O[/^S\SCE+K_ %%?^9D<OB^&
M&?W]&745_P#34?\ P_R\Y9=?[5$\7_&>C'^*?Z[W%_-_!_CFU?Y/_J/_ +Q_
ML^1A6_\ RVU^',_Y?B.?3DN:K?S:?P_Z@99YC/KSZJ 7_P#XHC;W\S_6%F_D
M?Z9_ZI77^Y_^J_\ A_[JF-W;_P#*I?R\ZF>?\L9_X%?:_P ^A\'^L/C_ #/P
M]>75EC]O_P "W'_<?]7]6?\ 5/\ <OQ0_P#II_OO_&_WM,$O]%#_ .A#X/\
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MW?XM2C3ZV/\ 3_3W_J7_ *:W/_-_Q/\ O=G_ ,2_^%?_ ,7_ ,UYN/1]G_\
M._E9#++(_7]RPKS_ $$<\JF?L^GO6R$;_P#T:_O7_P 3G8_[K_C?"-_AO_HG
M_C_^>_,\<C<_ZZX^/_4#X,_B&7T^%EJ[S_EEOEF/'(9=/O=3C=/_ (@[KQ_H
M'_4FV?Q?Z9_Z8W[_ $K_ +S_ .I7_D?D\<;M_P#JI_ZC_71^#_/4^+_!_P"I
M_B=:#M[_ %-;_P#J8Y99'+Z9,LE_I^_]6.G7]T_U!>?]0_X7_P#6A_H;_?\
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(_.M_H?8O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>g382677f_53a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_53a.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2XQ8C8U83<Y8C0L(#(P,C(O,#8O
M,3,M,C(Z,#$Z,#$@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.D,Y.$8U,C-"-S4Q13$Q141!13DU.$,R
M131$0S)&140X(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.D,Y.$8U,C-!
M-S4Q13$Q141!13DU.$,R131$0S)&140X(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C @*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z93@T-V8W8V8M-&8Q.2TT.34R
M+3DS8V8M-S<R.&8Q.3 Y-S8P(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C-B
M83<W83@X+3-C8F4M-&8V.2UA-6$V+6(W,F8X9&(T.3-C-"(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !  $ ,!$0 "$0$#$0'_
MQ !>  $! 0                 )" H! 0$!                   " 1
M 00# 0$!             P($!08!!P@1$Q41 0 " P$               $
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%*&V?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>g382677f_53b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_53b.jpg
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MQ !@  $! 0                 %"0H! 0$!                   ! A
M 00# 0$!            !0,$!@@! @<3$A<1 0$  04!              $
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*E337.%<O3W?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>g382677f_65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_65.jpg
M_]C_X0"B17AI9@  24DJ  @    # #$! @ >    ,@   #(! @ :    4
M &F'!  !    :@        !!9&]B92!);D1E<VEG;B Q."XQ("A7:6YD;W=S
M*0 R,#(S+3 S+3 Q5#$P.C T.C(R*S U.C,P  ,  ) '  0    P,C(P J $
M  $    * P   Z $  $   !,!        $P$     /_L !%$=6-K>0 !  0
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M!0V&1<!E)#<E@'0"7F-!"Q0[%I/)&H&M0WR+5$LS014R-LLR1)8!]VM)N -
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M9]5T*ZVA9.4GFC\3]2Z5N^F:]M#<4M6R;6*9Y O7/+! P0 ( $ " !  @ 0
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MQ\ET+N?.3BTH84<3%G]&0) )K(-0+[R^'OQ6WO1]>FTWUWW92G@S\,_&K_\
M'70W5-3J?1M.5B\%E+[#[B]@_$KH7>W3<MF\CG,'$EBX0DT91D[A];@K]L>&
M?%VQZ]MJWI>O?:YKD?SF\2^$^H^'MW;0W&G9*KC)GZ6OF*::E9'Q(E, 0 (
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MZKE,^JK5=7W;9EU0@0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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MS($ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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MV!-FI3)*DD19*1PV6 =*0A(MR:51WA8<".0ZQX.CO(,"_*+6]JF6(LUB4E0
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M73^I;;J.@M;;V331^.]]L=QL-9Z.O5ULF=9>B<0( $ " !  @ 0 ( $ " !
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MY9-L;P- !10V2G+-8Q)V*6X-.ZS41 N6;;927,T$3NT]%+940:@-X >"D 2
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MWO1MS;1W-+*'Q3/,%\@/#!, 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M61\,["4P!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M5?(]B83CB1$HD2!#@@N*K[2K:MZ]ZKE,^K+5=7%E#+JA @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @#^;I%?@QG]_7(S"V/#R2>1
MLEA P&N69=<C: J+*%Z[U%F;Y5@<CZMIXK%\BJ+ :P[^%V_:5#9TU4(W@'(:
MY0\C2J68S"WA[EE;(H<@&I?\JPL^)=?G&849]&L6;S*0Q$$D#7:D\$5A(R!8
M-C+%OB:)<#6(>BEN#:N0Y$46#9H^1I%G#ZPI>0)2-Q%/_*?V>Y8MFJP4&T/K
M!0\@0R LF;51O$,%FW)?D-8QOT=0V..'$WB%FV/+ 8B/1UDV:+!#$!?P65L6
M(W@+^"QOF4LC6 ,BP;:^J]9-PI#,< :BQ;XE(L$BTH+Q#G34I;%9PAE9$I0:
M 490R<V:P#D;%-G@6E@;@+.32(Q-0H)-86/XZ<5%F!<5*Q;!Y&C*1)&T(AM-
M96=GB6JR;1B[LH;@T2-A0#<H&2WM9()+\HVJ9$FV: >2D>1H(ZE+8L;."XBR
MF3142QXEP'4.R6#*P1("EWY"DM<Z@DD E$A)<7*200(D!T@;@L(ZVU)2)O"2
M1$)2&+Q+\I2D.Z_D)$;DI*[F!(BAL37=\I/+P&I*13@'*-J)"21$!$DM2#(D
MGNLKRLG,@YR8->A."7BH!D^\Q=U$&(;<J5\<0:C%&9C1:)DN+8&1BRM,RM2"
M "B3&U>86IK SM3S$$<P9Z%4KQY3-TX&33PY<\9<IB7C(4(VC:MDU8PO1-.E
ML:L]G?@;]X3N+X;=6RD99W'.2&+!X'$ERB(D 6K2ER^9>%O&&_\ #NZJZWL]
M"5QR/I#XE_"?I/BW8ZE]/3JMSW7P69_H"^ 'WE.A?$'I64A/.X4LQ/#PQ*)Q
M8\W-RBP$NOW'\/?B9M.L;>FEK77>:7$_EW\3_A+U+PMO=2U=-K35GP@]Q\#'
MPLSA1Q<&<<2$@"#$N*AU]XZ6K36HM33<U9]#:FG?2NZ74-&RU(!  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " /YNL2;^"_!O$_O]@F,
MP#L7:G&]39X&J&3;P67 UH:P%:W5:]1;(V;P\HY #Q99>4NBA1Q&X#S99MR;
MU6)O&T,H9NLAG#B#<_N65G AR-V_U6#-%D,Q'M4(NJBHU"-7UM[%D[?X5D-8
MO$W 4LUJFV;X8KL8K.V1O58]@TL0-L,7OP469=9^0:C8L7F6\S>$?-F6=F55
M2,1%1I<LVS=)I2;!0-9F\1[5DV5PGB,1&I9MCKG)N!JO65FT4V;Q%@63P4@N
MTWL6.8QK#!$:VV<%C9R\,AHU"@I(O$.5+<%-P,1##34LVY9)K$*&2S6,74-P
M-+ WC$!9MR:I1GF: :U+8F^1H(FAN4.R7E$:@.L6^8\C6,7H%#?,G%XF\8T%
M-JS;-$C4 FQ0W!9J WJH;D99CJ*02:1BUM=REN0- -:AL&S2,=GRJ6P2=L7D
M7 U*9-$DLBX"AVY9A)99L1(B4I%)< !(F26V($2 2E(%HQUJ6PAOR%^2YM."
M4@JXEA$_)>I;*22\A<1UA)L,)P+,$I"00!/*=1\"E(HD&-K'>B0CB'*;61*&
M#/<^ZOL1(HDDP+/Y([PG7D5Y3IZ)RA1P(,: ^3)R1&)'*;@42#2X%2&H4R2&
M5]XCNE3'2Y6F+L94Q:Q5/,B'&)0C8FF<]JM>0JR9FUR*R#AB%='#,[U;1G*%
M'B""&LUZ]ZU5N9@ZX0S]F^$_QB[A^'/6,KFLIG<:.7ABPYX?:2B#$,X9V!8+
MY!T+Q#ON@[JNMM[/[I/+D?6GCKX>]+\6;&^GJZ=?OW5XP?>[[M7WK^C]Z=/R
M>2S^=PQFC"(G#$Q8\W.0 S$N[K]I_#7XK:'4-*FWW-UWH2Q/YB_%SX)[_P .
M[K4W&WT[?<RW,8'T(R/4,MU' AF,MB1Q,.8!!B0;0YL=E^D=KNM'>:2U=%IU
M:/R[N=MJ[74>EJIJR8\NDYP0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M%)>,5+88M]AH(V;K5+9<8%Q$:/I53+#(LS) 2@ %2 D!8Q9K^"28 (OLX(;
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MQJ,20"U]M-RAV2<24WP&HB@W+-YR71&T038+J;6HH;@VKC@AN(8:E@W)HS:
M((.NGFH;&ECVC48[%DV:<.TW@+R-3>:RL^ TL1F(=9-F]>9L!<H'FS>((T\N
M"S9:YC$!<LK,=<7)N*!9693&(QLVK)O!L%S-P+!P6+?$H:PXF((-KOY!8V<L
M$:A06D:1CS'P4MP@;@9 L"R8C4"Q0R<V:QC\RALJ.'$W \EFV:MP:@/9IM4-
MP0:MJ6-NT9K$,LVQ9F\8./59NQ=4\^!L _S'T=0V6C8!@VFM0WQ&6 M4L3-0
M*J&PB,30!2V&+- &43)I6L8EP%#LHP')<#4LYYB+"/S)22V72))Y2E(I-(Q]
MQ*EL%+9<0L^=1WBDN9J !</!3(P0!(#T"0%N4ZO,)2@1:,=?@DWR'P+,-0\$
MI8B4 " )Y9:O,)2AARFE$2@+<FWR^5+O"#E:KOP1(/("'2DE, &3;!N26&H>
M"4B*&-& JZI/$&5,2 _CL3D4%3 L_%/O+(EU*,JDCNE2'M":<9$OM(8,S FJ
MOO2Q%#%VNMHZM61#7,KR[G528V4E2$T86J4(5)P9.I0Q<7+56A]IBZO-'DO;
M'='5>U>H8&=Z?F<7".%B1F/LYF+<I!< $.'N79L][K['76XVUG6Z/C_7>@;'
MKFUMMMW2MI7$^Q_W5OOAQQADNC=>SPCBCDP^;$G]84!^M(!?J/X9?%C4T;4V
MN[MCEB?S[^-7P&MH6U-]T[3_ ',\$?8;MCNOIO<N1P,UD\?#G]IAB31E$V@&
MZYE^QNC=<VG5]NM71LG9KFC\'=8Z)O.D;FVCN*--/D>5+W#Q@0 ( $ " !
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M7,_G=XC\,[_H.[MH[BEDDXR/T+;K7RH^+DI@" !  @ 0 ( $ " !  @ 0 (
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M>!! (((-00OG1\%:APR4P!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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MDNQ8 !3),LE $L]R4BF 8ZD2@E$\J)%(<NU*0DD1XHD4DL-02"62(O8!Y(F
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M\,>*]GUS;5M6Z=FN9_.?Q1X4W_0-W?2U:-)-\&?I@+U%05\Q/AY*8 @ 0 (
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MPA]$-I6Y87S&I;'8 WGWK!FU%YQJ(=AN2R&\QN*Q9O18CF$& W'VK"^9NGA
MQ$$EQHZS;'7/M&XW\%@S5C<!0::46-LS2BG(; U!8SS-1B(U-59-E+F-0% L
MK,NN4C,!??<L&^+'Q&8@L'6%HEP,=@&BW$;F"Y[.6-2:@.H-&X&X"@V5\UC;
M,C@;"WB%FQ)2-0%BR;-%E(Q$&[8-*+&S20&T1>L&#Y#$ ?3WK.S*2X#<1?K
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M.[BL60S: ?@WJL[,I(:B-BR9;R&(6!J>=EZPN\8%P-XQX:.L6Q)XXC419O\
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MZ?=0FX+\K*A=XD!D"F2PB;=:)$[$\M4I)GSEN1KBG#%WN1(A8?<J60G8ORE
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M;);++-N1%HBFMU#9+9K&/R*&R&S41^92V9MF@CK\%$D-ETA%A%[:)I-DMP7
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M=&(X;--ZQ;.FN0WA6AK3IY+&^1;;\ATL,6\-/)<SYFBD9@'D!;\REO"35#T
MS:7+GL:TS&<,4?65E;,WKD,X?S:;5E8UIF.X<7:YF*Y[,T6+'8!JZP/8L+,V
M6(S 4WE96S*0WACC30K&S*2^0;@*AJO[USV>)<XP-P%VSS*Y[/&2F.Q# +GM
MF6HDV@'-JSLX0V-P%-U/)8O,AF^&#59V954QR()87K!N,2C>,?;8N>TK,&^
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M&Q>GFQK#!<&Z_P %C9X1Q.JHY"X!8V+K_%B-X8^J-OJL;<38?A9I<N:QK6.
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MRK%Y&K'(AAO 6#>)#<C6$+-MJRNRJX#D!3BRY[LH9#O186)\HYAA<UC:N27
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M5*Q2L4,54E20QU(D<D$#4G(Y*\NU& ^\59#4>4<\B&I91*?..<>T@PL^4HE
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MS,<8S/+(2^&[-]A\0M_\-[5_!R+OI4Y;KSZ?V3ACQ-'\73?JZ_VQZ$OAR_\
MB/B#9_GG:WX/*YK/I/+=>?3^R:)>)H_BZ;]77^V-X<OATS_8?$#5_P"^=K?@
MY8V?2)RW7GT_L@UXF_FZ;]77^V-81^';N,'X@6L?^>=K'_\ AZQN^CQBMWY]
M/[(57B;GT[ZNO]LZ$)?#H@?N/?\ _'.U_P 'KFL^D+&-WY]/[)<>)OYNF_5U
M_MC$)?#M_P#$=_/MSG;%G#IX7/9]&Y;OSZ7V28\33_%T[ZNO]L<PY?#WZ/[A
MW[_'.V?Y L+/HN.&\\^E]DV[OB?^;IWU=?[8W"7P\<_N'?O\<[9]G\ 6-GT7
MEO//I?9#N^)_YNF_5U_MC<3\/A9@=^?QOMJW^(+EO;HLXK>?6TOLFB7B:/XN
MF_5W'VS>,OA__D.^[O\ IG;7\@63?1.6]^MI?9,[+Q/_ #=-^KN/MC,9?#]Q
M^X]]VC_IG;7\@63?1/Y=[];2^R36OB?^;IOU=Q]L:B>P+?L>^J4_][[:U?\
MP*Q=NB9=W>_6T?LEJOB:/XNF_5W'VQJ![ !I@]];?^=]M_R%8V?0XQKO?K:/
MV28\3\;=-^KN/MFT9=@O_B.^?XWVW_(5FWT./X=[];1^R)U\3?S=-^KN/MC$
M)=@L&P.^:?\ 6^VV_P#T%87?0Y?[N]^MH_9!5\3?S=-^KN/MCD#V%_D>^/XW
MVW_(5SV?0OY=[];1^R#7B9+^+IOU=Q]L=A+L/_(][_QOMRS^(K"SZ%_+OOK:
M/V3GLO$W\W3?J[C[8U ]B78/>[-_G7;G\B6-GT'^7??6T?LF<>)N-NF_5W'V
MS<2[$8?N/>W\:[<_D2RL^@_R[[ZVC]DEKQ+/\73?J[C[9K&78E/W'O?^-=N?
MR)8M] _EWWUM'[)G9>)?YNF_5W'VQB![%_R/>W\;[=N__ 5G:W0/Y=]];1^R
M967B7^;IWU=?[9N#V,3_ (KO4;?X5V[_ ")1/A_^7??6T?LF37B1+^+IWU=?
M[8Q ]C4?![UMM_A7;O\ (D3T#^7??6T?LF-EXD_FZ=]77^V-Q/8_^1[TXYKM
M[^1*IZ!'\.^^MH_9,8\1S_%T[ZNO]L8A_8?_ "7>=?\ K7;_ /(D)] G^'??
M6T?LBM_N/^;I_P!77^V,Q/8_^2[SHW_2NW_Y$K3Z!_+OOK:/V3"W^X_YNG_5
MU_MFL3V0],'O+^-=O_R)-_V'EOOK:/V3-KQ'_-T_ZNO]L:P_[$T_<>\3_P#A
M70-?_P &G/0>6^^MH_9,+_[C_FZ?]77^V-1/9/\ DN\:?]9Z!_(U#?0.6^^M
MH_9,&O$7\W3_ *NO]L8A_8J@^Q[Q_C/0?Y&DGT#EOOK:/V#&W^X?YNG_ %=?
M[8Q$]E?Y+O#^,]!_D:&^@\M]];1^P8O_ '#_ #=/^KK_ &QF']B_\EW?N_A/
M0OY&HGH/\N_^MH_8$_\ <*_Q;#ZNO]LU![,_R7=_\9Z#_(U2_L"66^^MH_9,
MX\0_S;#ZNO\ ;&(_V+#_ +EW?_&>A?R--OH'+??6T?LF5O\ <+_Q;#ZNM]LU
MC_8TD?N7=_\ &>@_R1*>@<M]];1^R0_]P1_%L/JZ_P!L8C_8W_)]W4_ZQT+^
M2).WA_EO_K:/V#%_[@_FV'U=;[9N/[&L/W+N[^,]"_DB7>Z#E&^^MH_8,G_N
M#^;8?5UOMEG[._R7=W\9Z%_(TU_8.*WWUM'[),=?_FV'U=;[9S,[_H[[8?Z+
MCU".6^S@XZE/*XF9^UK]H>;*8>%A?9LS!GM=<&Y>T^]G9K56C'_4=7:>/\*2
MCEQ.S;_ZO[O_ ,8])ZTO^FK*L</XFW//&#"(=<N/',Z7AD:@.DR&X+V),D$@
M) =''$4EP!J;BEB3)+.;$0^(I)(T^=$!(,=12@)*F/BC%#3(Y=ODG(^\44%$
M)-+,"" 5$CDJ8TI\Z3*3YF9"EKB4BACJ\%!:?,HI>11!6%E+&5(!49#DJ8M5
M-,:95,HS(946G)4Q!3F *2BUE>%BI,"C7%4!4QU*DYS')F8\."<EIE&.I5@5
M(( @AT#3@@B]-,:91,9! *<CDJQ3DJ2&3"2$#!': ) ",4 )3@ (7;F )0,$
MA$B+H$W!/*:[-EJ [Q81%P3)EEV.NYK+O>HQ)E'P;P95 >WW.5^^-18'2FLN
MTZ6&:O0FC?(N6QNG)UL&P;O=[USV-JXKY3HX)LNL V[?)<US5'2PI&PCCXKG
M9T+LR&X':LV;Z;@Z&$?HC6/)K%S76)U+,>P[AYKGL;Z;'\(AA8[<;5SW-Z3,
M#F&;";BWB]>"PL;#^&6JUC<:57-<TJ.PLXKEOF6A^%O!<MC4;PS1GV[JK&^<
MB8W@D\S!8WB!U.E 4!L]5R6QP+;&,.WP]5SVR"O\0]ACRNTU+GL:3YAJ <<?
M<L;. 0Y&W@N6V)IP-XT-KU"Q9FQJ J]%E9BJAJ IQ6-LRLAF%NE5E;(@W@'.
MEZRLX0,9@X\J::USWB060[A7[ESW%;)#L!0#=586.>PW"SCZ!8VS,S=869!K
M"SUU7+*QG;,9B+&N63,7VFPM"DS>0S"[BF86' C@8U-XW<$T\26-1L6B9A8U
MA4IMD6'(7;T<#FL,Q^33Q4,Q8S"]",+#,;N"3,N(U&]2R;&L1>FL<&9V-Q8$
MWF8O,8@*.D96? W@**9Q,K,W":4F1>(0\87(EF@#TLHIE_(#B#<1X!2V2W!=
M++'B22EF(L(ZU7D);+B.H6[5+QP);+\M$2*26&I(4L$IQ E$B(8:D.8')0AE
M*9290A)R44,6\605)51F40D\@(8;%FY')F0RELM.3,Q=U,X%IE"&467$I%5B
MU P2&9D->ZI/F5)#*HXH9!'EYHD:9FF44,+2/!6K 9J@!@4TPDH8Z:E4\BDS
M,QU)IE)\RJ90( AD 01IL3DI,J00G(Y(0,@@)R$D<NU.1]X.7:B0D.7:B0DA
MCNWHD<D)C+,'NLT*G@3.!9(1(BDX$V78)23(,@))0(^"V"_,+Z7MJN-UJ_?%
M_P"$ZL#I8=@IQ=<MC:L'6P#8=8=<ULH-:8'2P6>.C7KFOQ-T=+#M&\!<_!F]
M<AN-JAY&^G_$/8- YU^.M<U\SJX'0A=YKFL=&EV#N#85AJ'17,?P[GJ-7BN>
MQL/1(C$<Q$030D@"SY%RW-:IO!#<,3";_&0_91]ZY;O&#3NV7!C\,3"K].&S
MZ4?>N:S-%6W)C>'B8;/SPOKS1UV6K"SQ$ZVY,=P,3#/ZN#V?6B^O6L-1KF.M
M;<F=&$X,/IQL'ZH>]<EVN9;K;DQC"E$FDX_LA[USWM5+-!6MIF&/PE!OKQ_9
M#5OO7/:RYHT[MN3&X2@P:4;/UT1JVK&UJ\64JV7!C49P/ZJ/[(;=JY;6KP:@
MKNWC%,8A*'Z^.OZP]ZRM9<S.RMR8U"<*_2C=^J%/-8VLN8U6W)C,)1I^Z1'_
M )0U;UE:U>P;JXR8U"4*GFC^R'O6-K+F1W;<F;PG"OTXW?JA[UE=UYH.[:,F
M,0G#]?']D/>L+7K.:!4LN#'L.4/UT3_Y0X7KFM>O-"M6RX,=A. ;Z<:_X0]Z
MPM:KXHYK5L^#&H3@WUXV_KALVK&UJSFC/NVY,WYX./IQM_7#WK&UJ\T1W;<F
M;PG"SGC=^J'O6-K5YHSM6W)C$9P_7QI_A"OFLG:O-&-JVY,UC.!/UH_LA[TN
M]7FC.U;)9,;A/#_71V?2'%#:SE&%JWY,:C.#?7C^R'O5MU>$HR5;<F,1G"GT
MHT&L:MZF:\T0ZVY,8C.#?7C^R'O5JU9B48VK;DQB,X4^G'Q'O5.R>$F-JVY,
M;PY0;ZT?V0KYINRC-&%JVY,:A*'ZZ/[(>]96LN9A:MN3&82A?*/[(>]%;+F8
M6K;@F,1G!Q]./[(:MZ'91FC/NVY,:$X-]:'[()-KF2ZVY,VA*%/I1_9#WZDT
MUG)E96Y,W$H./I1_9#WH=ES,G6W)C,91#?2CXA3->:,&K<F,QE%OK1\0EWJS
MFC&RMR9IS0I]*.VH5)J'BB(MR9H)1_71\0H=DN*Q!5;QAF\ #4,=M-2)P)M@
M\38!DL\69MR2AXO 1:,2^F].80FT; ;W4MF399(0( &*0$L42$H&.I$BE$(&
M0AJ0(8:E+D<LJ8BOEO2;P*3,Y1\5!:?F,T%D*'F!4A9-<!E&;=I53^TN?.4(
M=)S&!29F0RRS+3DJDUB,A2,K(-54FQIE53QQ**F/BB1IE69,HH15V%E7L]AJ
MJ64 4E%K+/54FP*I@1RA$CEE#'2ERJ2DRACJ"J2D^95,8( $ 1RA.1RR"*T"
M$QIX%>4IRAR@Y3J1*"4#%$A*#E.KV(D)0<FP:;D=X.\3RGCP1(I+-L"F122@
M0( D!RDP>!IRC_Z*F7\Y'>?SGP0P'>/%_!?OR^1VY'3PW8>?B5R6B36F1U\&
MMS4 #KEL;5>/8='! >+WV:JC4N>^3@V4M8G2P[1P\ES\SHKD.88>0TN*SL\#
M?33DZ&"+!O\ 5US7.I98YCV'[ESV.G2'\( "E]5SW>)O5CV&#39;YKGM!LCR
M3HG6NI="S$LWTO'P<OF,3 .7G/&R'3NHQ.%*4)RB,'J>4SN!$F4 >81$@S L
M2#&GN-;;7=]%I6:C%5MAY+)HQW6RVV_TEH[NKMIJTPKWICBLZ6J^.4QV'ED/
MB'W@6_UED?S8[2'_ / =2=^K;^?XZ^CTOL' O#?15_TM3T^X]:/0^(7>%?\
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M][]T?Y_DP6N[?[:X_P"QED^N]4_$IZ'1]60_#G1OPKQ_W^X]:7'>_<Y/_O\
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MP%--RJ%!C_B-XV<4,3S&H@VI98&%C: 6B4(SL-X8TW)3#.:[&X18A)LPLQJ
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MA91_9MS^+LO>MOZPBW6=O^%O/==QZHYF=R6+D,;[#%Q<EC3Y(XG/D.H9+J6
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M401>KJQI\"BLHH;4T4LBJ&A@H $#*R%Z:8T^!17G@B@2 K(#=PM30U)1,H$
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M=+Y_I-QWEW4P_P!>YZS7@_O*/]P=;<?^*U?F^@R?A[H<_EM+Y_I+1[Q[I/\
MMW/>.#^])_[@ZVL%N=7YOH)?A_HB_P#+:7S_ $G-SG4<]U/&_A/4,UBYO,"$
M<(8N+R\_V<',(?1C$-$R/BO.W6[W6]UOOMW>VIK1$O.%DL(.S;[3;;+3^YVE
M*Z>E,PLI>;Q%HVKG>1J\C<7::T=ADRR=2258&@L4OYB'F2DIX " ! $%2P*2
M?AN4,M1\I1(8*;#(*BPS.1LVW*&4D82#:6*&WQ-5B54,966@]4T4C*7R?*H9
MHC)9O,LA9MR,$EF!65O!;(:R*IE%#:J612R*J;#!+".T 2&5DFAHHJ10)O
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MB7,JH&0H>(P5)/@!0VE:+(HA,90E]R:124%4/(8*9P@ 2&0;$T"S,U2+!&*
M$ 4E<FBD04QD)@9RD]&:KU5) 43 $P! $$H0(J]U@U*RH\Y"0R'&M %>;C6B
MJ"H)?BB!01S:K*?,B!P2)6^Q$8":)!!2AA!/-<_L2@4<0YCJ_P 'AK1""$?
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MU\46:*1F2Y]BS;-$56<I#(49L9*I+S@9DK0I%263@:4E275(I*"J3<#!0 (
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M5M..4K@1N-ELM_IK1WVCIZVBG*K>JLD\IAIJ8;Q[3RW#^(O?WY;=UO\ ]O\
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MH&(=Y=V_E/U_7_.^?_?U']_Z[[9NO2W^DRMT#H?L>U]%3Z#6/>/=CU[FZ_\
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M734E*?D(3&0HD 2&0@"A)5(I(A6I6'$8*0*R-R:&D43*!,#.3NSZ.52@"B8
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M=3#+@%J7757);..)V4Q<'2P:FUQJN:U^*Y;X'74>A:N>QTZ3QC@/81N;4'W
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M65B3:%@H7XK%F=LQJ 8+&V9A;,VBM$YJ9V&L.Q-'/<9C0),S3Q-Q8-P02,1
M8:7*;-K!&5LRZC'Y"3: ]C<4/$Q8W![]+5DXDQMV&L;U%C.PU CB?<LK+B9C
M V6)$/MS-(FY+)R0UQ-A8AYF;S-(WJ60S:-BAHS>9>)9W2(:-XF@1+X&31M&
M7DWBJF/(9M&\9 [^%4Y$7C0^U#::):Y&BD0( E BPE:Z&)KD6<%2* 0(LXNI
MIQ2\HH?$.8HA!"*DI2D. ,J+-_.$$.Z@9"8P):J(""I+V:TTAI%71@BB$FP!
M+R 0D,@D)P"16U6EYBB$\(P&"D"LC<FBDBJ8R'%]-Z>/ #(R-0]."I) 0[\$
MP(30BLCX,J*10ED\RTC-U4% @ 1@!4G40G TN94Z7IE$.$QP4<O[$X*@JF,$
M " !  @"I-HVJH*2*IC! %2;&-_DD4D5)?<B)&E!5& S#^%9?_+X/^._@_\
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M ED0"Q*2.VBKL*11PZ:14%'=44" ! %22$TBDBB914G44TAI%;511" !  @
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MY&GF%R7^<[*N5' Z.%8"=:Y;G3IM\<AW#M"Y[9'95I(Z6&"T>'N7+?&3JHU
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M"=QI5V=<USHJQZ LV+GL;T:0[!J#@N2^+.I?PCF$+"[;-=%SW9KIQQ&H4\=
ML;8FK-H@^JYV%FCH8,2*O:- N:[605YCD5BRV-1!I[>"Y[B',,;-*+FL.SP'
M8V+!F#S&(6\/<LK&8P+%C8EYFD Y;2]96(M@AF%@V6+)YF-LS<)4S,6,8?IZ
MK0RN-0LTVH>1A8V'AM4Y8BX&\;MGS>U/R$/(VCOX*;99&;+J:DFD;D,SL,1]
MRS9DS<:ZU\DC)\C2-@6;_BAD,W2A&9J#4;P5/ S-@7=M:0%P6]Z30FI-(GYU
M+1#1HI))!8H$U)K$VM5[-ER&9M<S1(@$@+"6FFU*"8+\SV>5$H%$9EP74P1#
M)2 L)$7^*(0%N?9YI=T"1(&VB4, YAL;6_I:B + @V)0 ( CF&M$,9',-_B/
M>G B#.M*H@"CDWE4!"8 @"#((@<$$ZDT@2YE3)ZW)P4EPXE3(>2<#AE%10(
M$ 02R!HJ2=W'<FH&H*DZTRH*\VQ5 X*DNG TH(0,$ " !  2 G XDJ3J-R:&
MD53&" ()9 TI*$NGD4E!":[!D*6^" _ _C1\=>A?"SIT\K@SP^I=TYO"D.G]
M+P\2)^R,@PS.<(?[+!@:UJ;JKYYX+\"[_P 5[C[QSI]*H_W]1K_+3G9^9<3J
MKI:>CIK<[O\ @?\ #3)W^BO-\<D?+#N;NKKO>G6LUU[N+/8F=ZAFI$O(G[+
MPG'+@9?#<C"PH"C"IM-5^K.E])V'1-C7I_3=-4V]/.WQ=GQ;YG#K[G5W6IW]
M2(2A)8*JX)+A_P ^.)QHRY:>:[6N).*R-HXHO]?<E UCV$G% %[I1(=Y)X ,
M4BPT-#6K;[T-"=N)!Q:EKJFU$"[S,SCVW>WVI]UDNQ3[7_"E;Y:K;%4,.^CV
M$Q, BMQT;P7RG6IYS\>[76X"_P!BVXVA>9JT3/>V^HIGB4.'<QI9K;WKQ]?3
MA]A[^VU<(DF, #?NO%-0L"\G5KYSW-#4P6.!K]G6SP\UPW2?E/8T=3AP-818
MV.:#6WRKS]5'JZ&ID=#!B-1<:]J\_51ZVCJ<$Q_"B'!(H/!M6Y<MFX/4TKX'
M1PA6QPU!J\5S7>!Z6E;F/X+!W^M[US7GY#NH/8;TX+GL=%'YSI8-X-RY;G75
MX#D!6GN7/;/'*#JTQS"H0]OR_(N:YT5?(?PV8%J_*N:V9T5@;A?P\&=<VIP.
MBC?$<AY+GL;TPMB.88#5%76%FS5N6;@,>"Y[";'<%P&.E?<N>\9EU'8-3:L&
M589A[ESW#D.8;_1/BN:P.$AV(N\5@V8-C,!8;[&NM6-GP,S>[4LK9DFD!73:
MLK$6R&8463,;&X3H\(,F;PMII55PQ,K=HW#ST=-G/8VC:**0X&\;52R(>1J
MHLU$<3-EU-?F)-(V!#S(>9O"RWU6=C*W8;QO2,K&@-@4M<60T; NI9DU!M%V
M2@AYF\;/<U=M%+S$2D!J+E+(9>-G%2R662$2"13:@EI9FKG7XE,B$7>Q[U))
M*!$\Q2@4(N[Z:!3!,%HF[P29+19[DH%VDI " !  @"7.M $( FU $( $ 02
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M"4,4,CF'!.!PR>8)0$,CF3@(*DNG@AI00]Z!D<UODG X()<>U-+$:6)5,8(
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MDNFD."*;D#!, 0 ( $ " *N&=.!P03YV(@<%4RB"6WIP"14ETX*2@JF,$ "
M!  @ 0!61N5(I<RJ8P0!"!E>;4B,1P5589E I;X 98V-A9?"Q,?'Q(86#A1,
M\3$Q)"$(0B',I2D0  $5K:]E6J;LWP*I2VI94HF[MPDCYT?>*^]++'EG>Q_A
MQG&@#B97K'<6 2""'CB97ITP2#B"H,_JQN<V?HGX=_"Y45.N>)*8X6T]%_-;
M47SJOG,]WU#3Z;.AM6K]0RM=8UT^:KSOSME7AB>@@E*<IXF)*4\3$D9XF).1
MG.<Y'FE.<B292D2Y)J2OOU))0HA8+L1\=JW9N]W-GF^;-HRE8&;7NN=2TC7O
M0:C%:UR3;:=RGN<L@[SS+?:C6EW2>^^94XNSS3[HG<I+%U,/-"JD2]1&9Q:V
M^:<=A#U.1E+%MX,J29#U'Q,SB[D^Z9NZ,OM[;?&G#6GW3&VMPDC[;:-=MWO1
MW3+[WRYGTBSF3'TB 7&SVKYKJUXGXZV^I.69X_C96A#%QY;%YFM6,>![^UU(
MB<CFXF 0[OI\J\K7IQ/D6VU%@T+2PA)QI[77F:M84,]O;ZKE<C$X9B>5J,&V
M@>XKQ-QIPSY#M]0G[,'2_6O*U*M'MZ&IE)I'#+"EC<:+S]1<#V]&_>2&L.-@
MO%."\W6I!ZVA9P-P#:]A;4#[5YNI64>KHVB&.8<7J[64OJ]+5Q6;1Z>E;S#>
M&]FJ@#+&QZ-;)XC^'%FONX+FLSLJW&)TL$OP=O)<M\#9.4.88H";*T7+9K)9
MFVFX\@WABHU+GMD=='B/85IX>JPOD=%'#&X"QZ;&V47)8ZJWY#<0S:7+%LTG
M&6,P% X)V +"_86AK#HVRG$WKGL:)CD+!X_(L+9E#< 7'M&FI<^ID' =PP&%
M-/F7+8D<@ =GJL+&;S&8V\%D\A/(N+1O6+)>1O$<5FS)F\+MRS;,;&H5TRDA
MC4&OTJJ1SV[!F-_!)F+-1:-Z$L!MF\6="R,V:AE-IR64$.2ZFN9)>-EO!#(9
MK'W*6188@[VVJ7">!E8T2,S0;UGAPR(9L#84B&C0$%,S:@U@7MNH-."FP%U(
M%XFY)DOF7!--2EHEHNI))0  D6(%$F@(:U,EHD$A!+@N"$H8FF2/*Y(1*! @
M 0 ( $ " !  @ 0 ( $ " () 1 X*.54(J$0@8.-:8%"7L32*2(3&0@ 0 (
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MP/O+PSUE:BK5L]#^X.CRR^-B1,#0D<0[A?$M;3B5;-'VQL]Q6U599'YKG\D
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MSD&3[$X*2*N=93A#!- 2J0BA/TK:7^:"HP*DN@:4$)#!, 0!!D'3[K>(%)3
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M^&WPIOOW3KGB*CKLE#T])X._;;_L]G$\SK?7]#H%7M=FZZG6FH;SKHI_MO\
ML/E1F<SF<_FL?/Y_,8V<SN9Q9X^9S.8Q#BX^/C8A,I8F)B2>4I2-5^G*4II:
M:TM*JKI54)+!)+@D?56IJZNOJ6U]:SOJV<MO%MOBR^&S4:X.18=B&";@9@:$
M4IJL*AEIX%Q-J-PUHS!W\YH[UH_"FQ(GO,CF%]#>$@[RS*-(R#M7B+KDY)[7
MDRY-"+35*1NU8A *Q8V7-YON4R9-DL-+#[RD3)?E'ZU];4]F]#:YDV=2QC$-
M>19NL(-%";^0S=@>C<H\->I$8R2W),8DO2YM-R3:)=H9M'!-+-NO:H=S)ZG!
M&T<* M#G8?>%#N^!#OP69I& J!0/9=YJ'9_*)SQ980(I<FI9."1<8;D5-+1=
MZ)P)O'L-XX.X)PA3SR+_ & ];;]=J6 H?,_IQK]MG\@B" 00;T@/Q;XG]FX/
M6>G9@_9"4I0(E1[:N=R\'JVQ6K1V2P/9Z5O;;;52F$?'CXU_#G$Z3GLU(8!C
MARG,@B-'J?-E]2=7V-M.[PP/OWPOUE:M*IO$]*>N=+E@8F(#%C$EZ-5S74:!
M?$=:G#B?;.QW'>2Y,_/,[E+V;53S7DZ](S/D^TU>!XOFLJQH'NI93A5>/K5A
MOD?(=KJ1#XG(Q<NQ<7V^8LXKR=>DH^0[>Z<-">)@UK?5[UX.XTX\I[VVU)_=
M%)X53H')9>/K5C/(][;WQ[3.6'LL]FRQ>3KTA,][0U8R*'#L8,[[WOUKQ]6O
MG/9TK)PUF5$""=+Z%>9J5Q/5T-2<.)O"-=3MNN7'JK ]/3M,#, 0*OLU-[UY
MNJL6>E6V"9ORN UK+SM0[J6> U!J,]!Z-Z+CNH.JKDUC]8+FMQ-$/83&E;ZW
M7+GN;IX0.80#KEU'B:T<CD!?K]ZY[/@6LQF-BY[YFBSDWA9XK&V9:Q8Q'99M
MM6%YXFG[3>(L"Q;XDM\3:(\F4-F39HI)-(V*ZN49VS-8V<4WS(>8S&[9;P53
M@8LU"3%4TA?P1'$5C6-J&B7D:!#4J#-EUD22K60%X^U)D,O&T)/(EY&H]WM0
MLB&;#CPTVJ69LNI()'M(0P9HI(+@W:>U!+7$LF26!8I,3- Q?BW![5+)-(W#
M8"I8%E( @ 0!+V;$0$%GUWZDH)CD62$" !  @ 0 >J0$O1D"CB!+H!* >C("
M.)"8P0 ( "6"<S@$$$@*@2DJ23J1F4E!5 P3X 4,B";+57=42P*$DJE"P60B
M$N(R'HZ<*88"^:S.7R67Q<UFL:&!E\*)Q,7%Q)",81B')<[%KITMJW6GIIN\
MPDL6S72T[ZUUIZ:F[/EM]Z'[W>+F<3/=A?#7.<D8G$RO5>X,O,'[(D&&)@9.
M8<3QGH9!Q#>OTM\-OA3716GU[Q+2=3/3T7PY6NN?8?'>O^)]+I5;=/Z197Z@
MU&IJK%4YUI_VN=N' ^:_-.>)/%Q<6>-B8LY8F)B8DC/$Q,29,ISG.1,ISD:D
MDDE?H6$E"227(^L.\[6=KN;O-OB^WM-H.#82""D:+,8B'?81;J4L9I52!<1V
MT(KLL-%,B;+RB& !<:[WH2Z)#O/(FG(UI#5U6TNN2DF66Y79PQ%I-A'! -P@
M,:AK-+4I@EV2+"#/5MHN4]XAV;R+F!,0+3<;#N\$N]B0[27Y'H2=>S4HF"6^
M>1<0,A96RB3LD9N]8-X8(H"YL&IEF[O@1][.2-HX3;."AMLS;=GB:&(-&.]"
M3)9>.$:FOA\J?=D)DT^R-">*I*ORD-F\<%ZTHV^S<B1/F\AF&5)8M;9K&_>D
M[$NT9)0-0R9ON:ZS7XJ9? SL^0S_  .'ZT?5?Y=Z4V _IA+]O'\B 0 KF\M#
M-8$\*8<2B01K4:E%>O=8ZV=;2CTD^._PTP^H97-8N'@ R$)2C(1!<'F.HV+X
M%UWIO>3<'SWPUU=Z.I5-\CY$?$+M/%Z?G<QASPS$PG)_HAB'7U7O]N]*[P/T
M/T+J-=?32;/7WJF0^SD?HN*C4QU!>!K4/GNUU92C,\+S>6 ,J&U]*E>/KZ>&
M!\FVNM,/B<#,8#$AK:\-J\?5J?(MKJ]Y(YF)A6AJ:>:\;<:>9[NAJ--0*SPK
MM!Q7AZ].#/D6WODY%YX8!<:Z@;0Q7D:M&ZQQ/;V]\8X&9P]37>ZRU>-KT:9[
M>AJ++M*_9!JU<$$Z;EY.M5I]IZVC?BBT(5V-5];U:Y<5U*@]71U%,FX@&I;I
ML7GZJ<XGJ:=L,1G#BX;46.NQ_5>9JJ&=NG:5VF\8&O!K*A<5TGY3NTKRH;Q-
M81#BGO?V,N*\ILW30[A@ .!>N:[<FM<AK#!,AL8Z;USZD=TU6(]AVE<EC6IL
M%@S6HQ"[>/-96&F,Q8K"[X%J<T:BU9,&;1'O6;,F72$:1%/-.KQ,[&X54,V,
M1:F[S5K(Q<F@285-(WZ:.@+&@M"&B'D:BT)/^$S9=9DDJUD(O&]#%8O&U0\B
M&:Z;$U!!J-[44OF9OM-%)(($:!J54DLMJ;0A+RD^4T5$$C:@&7YAM4P3!*0C
M8%P-P4/,"4@!, 2 $ 2#XW( GFL\TH%!=(D$ " !  @ 0 ( AT #A$#AE2;W
MW;-ZK$<$$N@>1"8$./-J(QXA@5D:C9\BNJP\H%"JR4,1"3&" !(#G]4ZID.C
M9',=1ZEF<+*Y3+8<L3%Q<6<81$8Q,C61 L"Z-MMM?=Z]=OMZN^M9I))2VS71
MT=37OW*>5MY)<V^"/D/]YW[VN>[QS&=[+^'^<Q<IT#"E/+=1ZQEYRAB9YB88
MF!D\2)!&$;)8@ML&M?JWX<?"W1Z-2G6>O55^IM333>*T^U\['P[Q%XKIHTMT
MKH=I3PU-99VYUIR7-\>!Z#PC(_2=R2227))/UB35R2ONYL^NZK ;A ERP:]Z
M<5#9HD,1PV9R[$,WJ-Z394R;<NAN42/ TC&E'?6+M2383YC3[,D!JE(6!/+0
M"V0?:-&0*4:B &ZU3),E^3UO+I3P%WI9:.$_SEN*EV1%K)8FGV;T=CK9PLW=
M&3NHP-1@C>=?R*7; AV-1A"^M3K4=YY\#/OIXO(T$1JHR(;?83WF\LBXAJ%G
ML/M3[HDS089U%VU74>Y.(%,LVC@R);;9:$W FUQ&H98ZF\R5+L1W^60W#)ZQ
MM#VC995U,MLS=N ['*@#ZH9P-R,S-VYC<,L0"-E@M\DOV"=^0Q#+O2I%*$7*
MH;\IGWI&OX/_ (-SV?J=2?=83VG])]?ML_D>" ! 'B/=?0\+JW3\?#,!*1B6
M! U&CMJ7!O=LM;2>&)U;37MH:JM)\K/C]\,#E\;,YO!R_P!%Y&3#C<#1?5'7
M>G.EFX/NOPGUI/NTLSYR]R]$EEL?&A*#5(8;RQ7U[N--TLZGWKTW=5U:JR>,
M'Y9G\FQF.7?O^9>/K4/ENUU8:Y'B^9R['7Z+QM?3<RCY'M]2/(<7&P:TVOP.
MY>1N*J#Y!H7;AH2GA:KJZ:UX6O0^0[74X"DL.VFGLHO&UJ8X'N:&HUY3&6'R
MWCP^:Q>1N*3EF>YH:DY%1AFRVW=0KQ-:J/9T+S666C!C99Y;UYVHL89Z>A=F
M@@ Q.M<6M64>II7>">1O&%35>7JH]+2N;0#BNJBX+H[-)Q9\C01 MMIYW[ER
M:JPP.JKD;PQX-1<%OG-ZMQ(UA>@]%RW_ .9O5C>':5C;(UKF;KG-TH-\,V:6
M6+*P#<1XKGN4FY[#6(HZQ8F:QL4LAEA:I9+R-HVC2Y"RDS>1M /;575\C.S&
M(M36K3?R&+^8T"0UD7A?P3X">9H*D(;P)9J$GBNPS9=9DDJJS\@%HWILEF@4
MDF@JWJI(9H+/)#[<B'F:O79K2,X)2$2+4/('D: M500RX(;576GDB6F63))?
MWH N"ZDAJ"X)%G';[5+0&CDMJ(4X?*!*0 @ 0 ( $ 6<ZT0A0@<Z_)$((1+T
MM^5*!1B0)6^01 X)>]QN0*. <VQ$#@A_'T3@(\Q!+H2@:4$)H 0 ( K(L*&K
MII 9U%-1?BKA !J4XAPA QU%*9 $TL,0 #:R(@&<'N3N7HW:?2LUUCK><P<G
MD\I@SQL3$QL2, T 9&TBC!=W3^G;OJF[ILMC2VIN+N$D;:.C;5FS:IHU4VL\
M%5<6V?&'[R7WI>L_%+/9KMOM?,8W3^S\&4L'%Q<*4L'&ZORR,95#2ADRV^;Z
ME^O?A[\--GX7T:[_ *BJZO6;*<8:TYX+MYL^ ^)/%:W5;=*Z,[4Z?E>^5M5_
M\J]G$].H81(%P=J"C;U]K-GP>JA#L<(M$AO=P6;L:0WY!J.&VTBVK<-RF2EC
MY340<L S&T5]ZF6-&PB'%[$$TNO"ELGO(VY8\WT10V!3+$V6$:WA^.CH;P$[
M&L<-@W+:;3\JAV1+NH[2_P!B/FJ?F4]\S>HS6&'RUJ2#50[3@9NS>9H<,$A^
M''VJ9([Q>, #99Q=$-DNQJ($U]&".[CB3GCQ+QPR;:"^]4DD+,8C@.S"FLCV
M^*)2!\S>.7-MHU *9(=N*&,/+5</J8APWL0Y?D)M:!["REFW4&?W%E)D[)/%
MCV'E@+J[DC/[Q#4,!V+%P!M\DU5D.\Y#>%E)2!:-=U-M; R<)9DOM'L+(2<$
MN +&KYM8Z.]58(EV2\AT\').PC"ONN9KE#LS.VLFG ]_HXZA9J'BEWGS9E]X
M_G/Z-B_<!_)L$ " *RB)1,3>$FDU#$>OOQ<['P.K]/S$Q@B7/"0)8?6(.RB^
M+]9Z>M2C:6#/DW0^HVVVLE.1\=_B[V'C=*S^:C]C(1$Y&+Q.LWKZ>ZMLGIW>
M!^BO#'6%JZ=4V>IG6,@8&?T2\27I92RJ^*:],S[6V>NK)/@SP;.99CS7,2_O
M7CZ],&EF?)MKJ<'D<#,9=C4;/&U>+K4S/D>UU,$<O$PB+M?R;5XNXH>_MM3)
MB.)A-5J7UO7BZU.![VA>4+SPJ4LTH&7CZM,75GM;?4B#(0;Z.VT7:_)>+N-,
M]S0U(\C+"-EUQ%6^1UX^K5IGK:%N9<1I<;BW'8N*Z/3TKY,UB*C51A\J\W<4
MP[3TM*V*@U :3V>PKS;J5@=VF\1@1$@_AL7'=/%'6K27P[UY^HFF==+)X#4
MWN\"N.[EG17(9P]UZQN:U>(P-SO8N=\N1N:Q#[&;3@LVP6?8-P7/<M8,WC8%
MB\Q/,T%BAD/,O$529+-HB]*>!FWP-HZN._8M%S1DQ@"E;0K,F7"12R-(Z;?F
M3)>9>-H2>1+R-1:C%5,V769)*M9 2$Q/(T4D&@J V[BHXD,T&JU$-YD,UB:
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ME>*3(99( ! U>/RII,()=Q1O;543!"8R57 0)-R,G4U-9N4^47E+ ^*1,$I
M" ! $L38$ 2Q+ T'L^=*4!H !8IF4!( %B); $@!  @ 0!#_ $FV>;I\ ,S(
ML7(:_8-9-BN%('J_\>OO%=O?"SI&-ELMCPSO7LQASP\IDL&8.+/$J'+.88<'
MK(BY?9/@7X?;_P 4[E:VJGI],J_WKM9]B,NI=1V/A[;?ZO?_ +^Y?]/2XM\W
MV'QG[V[S[D^(O7,QU[N+.XN8QL6<SE\ SF<#*X1D3'"P,,AH@"A-I7Z[Z1TG
MI_0=E78].HJ:-5PXOFSZ;ZMU;?=;W;W>]LW;_#7_  U7)+]KXGC6'EPX C5G
M>[QKJ7HNYYZ<X#L, \H;Z,KR]&U+-VYE3C S##<W/YOOUJ&W U1O(W&#8^GJ
MEB55)9N6,#"=OHW!. M:1B&!< WMKN2<(GRY#$,O(VCR\TG9<!.Z66)O# &Q
MVL:WP!2;9#U)_A&(X%3RZKA=?4A+RD-MYLVCE]FH^'%TYY9F;LLD.PR;@%AJ
MKM\Z)2V9VMQ&L/)LSQ>NEB420[#L<M0@#999N3@S=GS&H9>[EW4OM3@AZBRX
MC>'DB;(AB]CT1*^4EV;P9T<+(AJQJ=8>S4%,O+@9O42S.EA9*GU7U "F^EZ4
M-F+UUP'\+)DFD'84WO?>K6FWY#GMK6@ZF#TR<S4,PTOL5JB2,+:JXG8P>F6?
M18V!A35MO5)&%M>,%R.QA=,<AHTHQ(L(9PRJ#GOJMO$[.!TPD@&)/"V^FXJD
MFUV&-M1+RG:R_2O\  :FTJK6F_*SFON$LCN9;HW-R_0U&H:W5K6M=,XM3<]I
MY#E>B.P,;Z4;V+2NEQ@Y;[F<3R3*= D>5H$O2RU]2VKI<SCU=TE+D\OR/;&)
M(Q'V5;2P?@MJZ,G!J[U)9GD?]D<3_)3_ ,7S?4NUV+3[DY/[@N?$_P!DJ_7!
M^ @0 ( $ " "Q CA=>Z7A=3R6-A3AS&4"WT06DQ%^MUR[K06MIM1C!OMM6VC
MJ*TX2?,_[P7PS,3F<WA8#RC]H9-%J6UV2M7U-XBZ7#=DC[K\&]=:M6EK88'S
M,[EZ//)9G$@8&(,I#4S>2^KMYHO3LT\C]%]'WE=;24'YGGLL(2D&+&R^]>!N
M-.4?--KJY'C68P&>520=VM>-KTE0?)-KJ2TGF<O&PK/8W%>!KTQ/;VVI#$)X
M5KW.Q%1KN7D:])1\BVVHFTS'DHWAOVKPMS2'WCWMO? S,"Q#%WU:7KPMQ3'#
MB>UH7P*<A!/S+S;U2/1TK-!R@.'W"G%KUY^K4]'2O@DR\8T)OI33>O.W%9Q/
M0TGAB;0#VZ;5YMT=U+*?D-8AY64]'UKBUJ_NXYG=IVR-Q%@UQX^8HO,U5Q.S
M3<FD14;W7'9/(Z4TO*;[5DZXEYF\'>G%<UXC$*FRQ+! %XAN*EDLUC\R$9LU
MCYIK(S9O$7Z6K1<D9MF@1.,#61I$T;4J1-BXMJADLT"*D&BS@@$@)5K+ "P-
M@L"37$EHNXUI$EP=:4$M<BXT*:<DEP:6J&N61+-(M8/GX)$,L@D$ 7! V*7,
MP2TRPD_&U)H34$\Q1 H1"8R02+$"A,T?BF1 ( $ 3K0 ![4IQ@78:,R1)+'4
M4@+B(:HKQ4MN< +  6)3($I " !  @"'&L>*< !D!>#L=-*< *&9NHGW4!G.
M<<.,L2<A",0\I$L +22524X#K6UK*M5-F>F7WB/O-=+[!R>/T+M_%P\]W#F(
M2A##PL0$8!/T?ML>43]"$7LM-R^X?A_\-MSU_5KU'J2>GTRKG'._8CBZUUS9
M^&M']Z-7JME^[3A7MMR@^1_<'7.L]U=6S/6NNYS&SN?S6)*>)BXDC(1$I$C#
MPXDD0PXNP 8+]4;/9[7IVVKM-G14V]%"2[#Z8WV^W74MU;>;V[OKV>;X=BY+
ML$(8(L.H67+?%Y&$8#4,(\K "^M_RJ8X\2DF\LAF.7-*$[@40BE59\1J&!6@
M:EPI=O2;4%8F\<L3\ORI=^"':LYCD,N-5;=-JF7P)=WD,PP11@-BF.;(;?E&
M(9<DFAC2GC;6B)21$H9P\J*_1>3[0/)&/R$NR7E'(906L-5NL^".QF;M.68S
M'+1# !R;@'9-)YHAVAXC<,N: @:Z^S4C EN!W#RCL1$D;13R09NW(Z.'DB6#
M6U8-7Y5,QB9NRB,D="&1;]2'(MI[3J",S&VLEEF.X61J*-90-[U2JV<UM:SS
MP1U,+ITI4$:?X5P?P5JO/,QMJK@=;!Z6& 8W4IY4551A;6X(ZN!TR(%(%SYW
M4O5I>8PMK><[.!TTEN8, S"(#W6T>B?=;>!S6UE&+.SE^EDD-"A-7T <K1:?
MG.>VXAG<R_2"2&#7L6%F]:UTSEU-R>097HAI]'?2R]]:U6F<>IN,)D\ERG0)
M$1:#D$74W[%K727'(X[[GA)Y3DNVYSY?W,M:[:]RVKI2<6INU5'G/2^S,QF)
M1CAX$IDF/U8DOY%EO71/,UNHUHFVTC]I[6^"O7.L3PQ@Y'%C&1:).&3J_P '
M4NW1V6KJ.*U/C>_\2;/;)]ZZGRGMUV#]TKJ.=.#/-Y6=3&4A.%EC_19>_M/#
MNXUVG9.#Z_ZM\0-'33KI/$]B_P#_ (_RO^;#_P!SY?\ %?JM6_8O=_VG?E_A
M/AO_ -P]7^=_Q<V?6]?=A]-@@ 0 ( $ " ((<$&](#\:^)_9^#UGIN.?L8S)
MPY1F&#6"KLOCW6=@M;3;2S/>Z+U"VUUZP\)/CY\9OA_B](S^:;":)E.42!0?
M6.IJKZ2ZYT]Z6H\,)/TSX0ZW76TZIO\ >A'J'U/)&,L2$HM*)(LM8[MB^$;B
MD-GW-L==7HGS/#<S@'Z0(]E36IW+P]Q2&?*-KJP<'&PB#6T@:;V7B;G36+X'
MR#0O*P$<7"L-XT:E[+P]:N:X'N;34$SAL3;\MQXKQMQ3L/D&VU&\&4Y'!:T7
MTLO7Q_<:<..![NWU.#,I0KO]-:\?4J>KIVR*&!-;N&I<6I4[M*T.40 7%UO%
M>=J5P<GJ:5YA<&:BQ>9J5Q@[J,8 -6 MV6+BU:SF=NG9*#8 -NU%>9JTAG;2
MS6*-(C4N"ZC ZJN<301+5TX+&V+-DU!O#4V_3BN74K..1=358%$@/I:DQ-FD
M152R'D:H1!J%57&",V:Q% %I7,S>++A)M24DX+Q+<65)@T:)D&@L"4XD/,TB
ME>?D(9*@1*:< "L18'W ZDF)HNI)-!O!TWJ2"X>F]-/AQ)9<'QK[%!+-14((
M! @0!()IJ0T)HNXUJ8)ADH $ 7I$7%!.++ [702"8%F>ZQ(618!Z&F_4R38F
M:1:TMQ92YX"+ZFLV*?*!*0!ZI@".$@&Q %3(,XKL3AS %#(W4V43A 02]2F
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M3M/3X*$>#J;C5U,;-GD'^CLG_D<.SE^K'PL7;_IM/D92QE=!8( $ " !  @
M0 MF\".9P9X<QS"42&-5GJ46I1UL52SHYJ>C?Q\^&T,]E,SBX6 \A&4H2 -1
M](C6:+ZX\1]*[U;-(^S_  ?UMZ&K6K>!\EN^NW,3IN>Q@<.0Y)RC(&)NDSE?
M3/4=J]*[3/U'X>ZC7<:56GFC\;S^5Y9$MKW;5\;UZ2CY_M-68/&<U@&T"RWP
M7BZU$U!\DVVID<Z6&#"RM]P.HKX]N=-IGO;>T8H0GA&X$N;7:GE8Z\?6KA#/
M>V^I,,7Y&)##Y+EX6ZTSY!M[RNTS,*C0^-R\'7IQ/8T+O(P,6DUQ]%P64H[]
M-XP'("06U[!91>=JUX'HZ-R8Q8F@I8*+SM:O+,]+3L;Q#ARU]CW+@U*G76R-
M6V,O-U5WCTM-RD:0MKXZOG7GZE3HJWD\C867KF:Q-ZO TB*4;5LW7%UA=&B9
M=<MJ]TT3DO%N*S8F:Q'FIXF;9K%N*<<"'/R%XBY_+W*NU$LW"U61GQ)4<8>9
M:^8L YHK$S5,@O$CCIZ)<<<B67'@G,K(AEUD22A "M 2-MB8C2Q1Q(+1/N?>
MDQ,OY)$&CBS7L1W28+@L/E2CD0U)=(D$ " ! %QO4LEED" ![$!D:#<Q1*6'
M$A_,7Y2B291=DB02 *7:% %@6+58^3WT2C#M L9 ,*VU)=[7U)1.($<]M']R
M.Z <^SS^1'= JY>T[WTHJ A  @"XB6L=["]B4KF!S^I=1R?2<KBYO.XT,'!P
MXRD3.0%(ASP6^AH:NXU*Z6A5VU+.%!KHZ-]>W=IDLWP7:?-+[Q/WH<QG,3-]
MJ=E9AF,\#-]1PI/#!!#&&#*-)8I%NI?I+X>?"^FVK3K'7JSJ8.E'^UGQ+Q)X
MMTNGUMTSHSG<97U,X[%V_L/G_*&-FL7%Q\?$GCX^+,XF+BXA,IXDYEY2G*52
M3:OOM*M*JM5%4H2Y'U6W;4L[V;=VY;>;[6,X>4L)BYMYJZ42=BDHS'X98 .0
M;0=9\@LW;D-V2R'89>(J UEMOL=0WS%_%F-PRI/ZD/MHW%KU,I!A UA91R#(
M5)L&JX&CI-\!3CVCT,J0&$3:[5]W%+-R)NT=@WAY,?1Y@7HX&JT [TY(;'</
M*!JAJ"C?(Z7>Q)=N>0W#*Q9ZO\NJQT?O/R&3LN>(Y')F5.7EWV^=:II1BS.U
MTNP;PLB"0];*,P">/ QMJI+$Z.%D6^CRM0U N+WVIPWB86UHP9T,+($BD;=Q
M.ISJ=-54G-;6PS.IA=.)B"Q#L]"^XM<%JJG/?71U<'IL0 #$%V]+K+D)'/?6
M;.Q@=. 81PS6PD66VT5]ULY[:TX'6P>FDL);F (&JC!:5T\>PYKZZS.SE^E
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M !  @#F=5R&'G\KBX6)$$2B14 W4(?:%S[C1KKZ;H\S;0U7HZBLCYU?>"^&
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M>RG%6.$5<ZT#! P0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M34+&U%F*81=9)0RR50B1[=20F:#R ^1"9#-!P:[Y56>)#+@.4YC(3+J<R 0
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MXNM2)1[NWOWJR(&-336_EXKQ=SIRCU]"[2@Q,&)+VBQ>#N-,]C0NGY3&4*N
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M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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MO.3HY?I)#?1?4+!N5P<UM;$[F7Z3(,.4 :FKO.P)YF%M93B=S+=(! ^@2=Q
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MLLAP5<ZRD,$Q@@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " .=U+(86?RT\'$B) @T.XU7-N="NOINC-MOK6T-17JX/
M0SX\_"/#ZCELWC8>7!FTY<PAX2!8KZ:\7^'%J5M>M<3[_P#A[XROM-:E+6BN
M'$^4G>';6:Z!U',9?&PI0$9D'Z) M+2U&@KM7YXZKL+[;5=6N)^TO#_5]+J>
MTKJ4LG:#P7$@).&J'9O9M7Q;7TX?8?,-MJNK./CX-32_36O*UZ=X][1NG#0F
M8AF-FVS<O#W&DZRUD>KI737:9F#6LVK5N7CZM(<GH:5\EP,N4.QOJ'V;5Y^M
MI]Y8+$]#3MA)E*!B32I'!EX^MIP^P[Z.<3(Q!?U&EB\^]3JIJ=W%Y%.1G/IX
M^%ZYM2BLCKIJ(J1I5<&KIPSJI;D#$,0%QW4-R=5;2H+,]6(K7WKGLO,;IL*O
M4.::R6\;5FUYBDY+BM=:RM7SE$B+K*R@))Y5C9SY!22H@0)@2U'0$\"0'\40
M)N#01\J5TV(R(;-!&^_4/F5=YD.QK&)N\3\A4X(S=C3EVI23)(#)9BDLR<-B
M+Q!.E54$N"\8IS!-F: 6,I(DUC'Y4F9MFHAKTW)"S+LKC@$><B4A$$R(  ))
M-B[-GL-UO]5:6VJ[.8G@C/4U=/2KW]1I(\ [I[UR71L&<1B@XS$1A#Z6)(ZH
M@"]?>'@_X:NUJ[C>5FW:?7_B'QIMMA2VGH63N>M?7>K]5[EQC+,2G#+<Q,,N
M)'E,7<'$K]*7DOT#TSHVUZ;I+3T*I..1])=3Z]NNIZKOK6?<G(1RO13)CR%P
M+AM\RO65#QGJGD>5Z&2!RPIN:RS6J[G,QMK*#R?)=MRD8DP)+BYO'75:K3G@
M<M]U6O$\OR/:TY&+8)JS@0)?S6M=*3AU=\J\C] Z/V!GL[. PLKB2)9C'#)=
M[M0*Z=/;WLXHFV>-N^L:.BIU+I?*?O/:7W?^N]7EA'^ 8O+*47)A1J5L9>OM
MNC[G6:BK/AW4O&NQVLQ9-^4]N>Q?ND8D_L9Y[+FV),3AO2AH2+5\IV/A34U&
MGJ(^M>L?$G.NC;S,]Q.R_NU=$Z7#",LAAGE ^MA DU%Y"^9;+PMI::7>4GUI
MU/QKO=U9JMGB>Q?1/AMT?I<("&6PHF( #0B+#L#LOE&VZ/I::454'Q'7ZENM
MPV[V9YYENEY/*@##P8!KV'SKU=/:Z=.!PNUK8V;8\#$6!N 70JU62#NE224R
MDH! P0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0!XKW+T' ZO
MD\7#G 2D82 </5K+0O+ZEL:;O1::Q@]/IF^U-GKJ]6TDSYH?'[X,G$CFLWEL
MMRSC]I(&, X-2Q8.05] >,?##3MJ4KS/U1\-?'?W=J:&K;#!9GS;ZOTG,=*S
MF+ELQ"4# RB.8$,Q8!CL\5]%=0VMM&[I=82?K;IF^TM[HUUM)IIH\?Q\(&MM
MW!E\?UJ-'R7:ZL-3D<W%PB'H&N'M]J\G7HGFCV=*V(F8L:V:F7B[C2C(]/2O
M.9F8"0V&W9>^Q>5J4>)WZ5L"O);$W%]OG<O.U]-64G?IZD9&1PV)\/9M7CZV
MFZ^0[=.R9E*)IZ\."X[(Z:N/(9<IKZ^Q87K.9U4OD B=-S^:X-71EG534X<2
MQ%ILWKAM2,SHI><  JQKL=8QS-)XHL -1J1M99NI2999VK/D&00L;4GR#(8Z
MEBU 2B12XJ6#[#0"HIP4D<#0#4%)#?,T :N@XIX$-R65*1%_I'8C"2<"0#>G
M"8G' ORE.$3*+B/%5P)=C6,?%)LS;\QJ('5Z*99#L:B#-H$I9,MEQ&X!5&!/
MES-!'36FI>%<6QMP9X^-A9;#EB8LA%@36X#6]B^9= \&]0ZOJ5>I5UT7PXL\
MCJ'6-KL*.VI92D?D/=??$@9Y/IO[IB_2CSQ?[.!(OL!-5^D?"O@#:=.TZWU*
MI1V'TSXE\=7UK/1VSPRP9^22R&;ZCCRS&;G/&Q)2))DY !K]$$V+[0T=#2T*
MJFE5)0?5VXWFIKW^\UK39]IW<GVW.0'T7J+A>RW599R7W"KY#R_(=JRF0(X4
MC98//8%I72;.34WJ6,PCSWI'8N;S4HQP<K.3T889)?5<+5O30;P2Q/*W/5M'
M24VLH\I^W]J_ KK_ %>>&,/(8O++EMPS83=2B]/;]*W.LXK4^)=1\8;';5?[
MZ;1[8]C_ '3<WF?LL3/8$Q6%##FWVA@OD^R\*:VJT[IGUOU?XDZ=$ZZ34QP/
M<3LK[L/1NFQPI8F2A*08\TL,4HYNY77S/8^%=*D=Y'UEU/QUO-RWW;/'M/93
MH/PJZ+TN&'RY;!CR@68<;1976%\KVO1-#16%4?#=SUC>;FTVNX9^CY3HW3\G
M$1P\&#BPL-3+U]+9Z=."/,M>]W-FV=.(A"D8MN 74J5KDB88<QT 5%0B$#!
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MZC_>;.Y#"PL*+0C$-8 R[*Z=*Y&</B7,J6-Q6@X*N=:!@@8( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M$1N'S+NII4JLC*&S4RN'BM,L%D..95SK/B@8(&" !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @"LHB08I <'JG1<MGH2AB8<2X^L!%Z[5P[O8Z.YHU9*3T=IO];;75
MJ-GKKW[\'.G=9PL9\K"?,)$2$(O4VD5(JOK;K_@W0W5;/N+S'VSX6^(6\Z=J
M52U'"?,]"_B)]W+'R\\?&R67/*#*3"!+T+7;%]#^(?AYJZ=K7T*_(?J?P?\
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M9SPD\FPLME\$ 8<(1 %  %ZU-#3IDCSW+S-N87"[4%LDED.'Q*N2F.$0@8(
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MNJ9:4SAY8S =FA(FPD5%B^NNH?#K=Z;?<K*/MSI?Q<V&O5?>7AGYOG/@[UC
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MW[+O:;L^T^!=8^.NWT*M:-JI]A[ =K?=FRN$<*6)D8BQS+#<V5H(DK[,Z/\
M"55CO::2\B/ISQ!\>MQJ*RT]5_/])[&=M? OI73^0RRF%1C]0"P-812S6OM'
MI/PUV6V2=J)OY#Z2ZY\6NJ;^S2U+.>UG[/TKL;I73HQ$<##!B#8!1E]@[+PS
MLMJDE1>8^M-]XEZGOF_O+VA]K/+<'*9;+CEP\.,6LH!Z+Y!I;31TE%4CP;ZF
MIJ/O7;;-^9@P%--BZ$DLD+ND<QL= X(3&" !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M^VIJ:F-FV,\P#<MVJC+=)+(B"ID^SBF-*"$#! P0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0("Q#$ OKM\15 -20(0
MOCYR]Z!-$\F%J\Y>]+NUY()N'V>%J_\ .1W:\A0R0,,&D;;S7VN4\ :;S!VL
M \$#[J)YCLTXH#NHJYUGQ2&"8P0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
: 0 ( $ " !  @ 0 ( $ " !  @ 0 ( __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>g382677f_73a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_73a.jpg
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MQ "T  $  @(# 0$! 0          !P@&"00%"@,""P$! 0 #  ,! 0
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M=/,TW;!L%CU^Q&E)0YV4(R45)7:ZFJ)VL4U,/I]Y;T^".I5R0 %=<0_[!/!
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MJB2R1RJ)G* E$!#B)[3_ +0/W40[7PJ'7S>)5HV['5.(.O!6%7V&2&T5>+1
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M+3%N*_?0O\O: *F]5   &GH )^C\+N/:,'_E0W7L3.R*^$Y1\)\ND-I7D/\
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MB(XB.(CB(XB.(CB(XB?DY"*D.FH0JB:A3$43.4#D.0X"4Q#E, E,4Q1\" _
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MX\@G0:Q/Z751J\-1ZI6:77&A6%>J%?AJO!,2>/2SAH".;148U+X  \-V30A
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M]]+2SYG%Q<6S<R,E)2+E%E'QT>R1.Y>/GSQR=)NT9M&Z1E%55#%(F0HF,(
MCQ$\,_W??N0AW1TYKF>52C@>MF3R[I2ONB>ZW3U*[)$6CWFA.6QP34&!8-E%
M6L$FJ4#_ "ZJSHP%,Y*FEJJZ#4^LB:;>7B>J?_#Y=*7;%&Q]W;_$&0&692E
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MLJ8:A+02Z*;V+;E,JFHND!7WN)*&1)R%JT'G^J9&PZ^/2>8OM3UAL'6:[Q[
MLJ%WRF^,G-CQC6&;,S2,OU32< @NW?M0$Y8&^55P<K.?AU#>\Q>!ZB^INJ@H
M>/R/K- 01J/26 ^VK]OFX=\ME0C7*,G!X11'S%]L-[;E.W\M!$KEO0:R],7V
MU+A9T2^GU%]7TUD8[I0/5[":U6;0?G)GOVJ53K=#J]>I-.A6%<J=3A8VNUN
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M5T9FLY2K\F[;M"'(9)F#I4R)2'-Z@1J9Q[QU]SK0+$\N,VG8VES6;UAK%6^
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M1'$1Q$<1*D]C^F>0]D6YY"=8J5>^I-RH1^@UU%!*8 B11*@VG&IP*TLD<G\
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M5@ 023ZF=%;VSL]_)YG,WY^79RW(5659-S6NUE]=P"VI:Y)9U=0%96)!  ]
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>g382677f_73b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_73b.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C5!0S$S,3DT0C<Y-S$Q141"-$(Y.$,P
M-S S-#4Q-3%"(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C5!0S$S,3DS
M0C<Y-S$Q141"-$(Y.$,P-S S-#4Q-3%"(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( 'T! P,!$0 "$0$#$0'_
MQ #9  $  @,  P$!            !P@%!@D" P0* 0$!   ' 0$!
M      $" P4&!P@$"0H0   & @ # @D) @8."P    (#! 4&!P !$1(($Q<A
M%%24U!55E0DBD]/55M:76!DQ%D%1,B,D&&&!L5(S<[,T=#6V-W@YD4-$9+1U
MM28V=B<1  (! P,! @H$!@T+!0    $" P $!1$2!@<A$S$B4I+2%)345@A!
M%1@946%QL3(C\(&10F)RLR0TM'8W.*'APW0E-55U%C87P;)390G_V@ , P$
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MF X0ZF<KY5RS,VG$^MMA-Q3I8^0C+2QKZVE\T<FL4-Q>1MW=I$Y <ZQEOI)
M0LOT.Z4\.X?P[!WG,N@>1AYCU>3&2!896%D^/22/2>>VL9$[V]F0,4!$H7Z
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M129(S)7 )B-"[IE!:FT5:SIGZDV>\HU(I&Z2:OVYT <*2I(&SR%$MD4)K<U
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MG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG
M?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_E
MYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#
MEI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y
M[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_X
MC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9
M)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[
MU3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW
M/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3
M[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];
M::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]N
MG.?#EI[9)[O3[OG ?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG
M?%%Y[#'[U3];::_EYB_XC.WW/Q]NG.?#EI[9)[O3[OG ?%%Y[#'[U4KT5\6^
M67!<U958LH^.L*6?RYLC)[RFG;DX*&PM?LS0EA*(V+I"U0RN3P $:#6_X]9E
M_ /G#R_,^;8OB<^!MK>+(WB0&1;IW*!]?&"F!0VFG@U&OX:POJ-\DF%X+P++
M\R@Y#=7,V,L9+@1-9QHLA33Q2XN&*@Z^$*?R5V^SNVOGK3%*8I3%*8I3%*XH
M6;;[6?;-L)JRZH9W^XL3F<6@W4NO<+H1*5[1^\5_5@WS995T40J4ZVE8504
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; 'Q/D_P!^>OV9Y]M*^"U,4IBE,4IBE,4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>74
<FILENAME>g382677f_73c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_73c.jpg
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MQ "E  $  @(#  ,!            !P@&"00%"@(#"P$! 0 #  ,! 0$
M       ! @,$!0<&" D0   '  (! P(% @4"!04!  $" P0%!@< "!$A$A,4
M"3%!(A4640IA,D(C%S-3<5)#)#2!H7)$&!D1  (" @(! P,$ 0,$ @,!  $"
M  ,$!1$&$B$3!S%!%%%A<14B@3((L2,D%I&A0E(E%__:  P# 0 "$0,1 #\
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MYYN-GH^V]UVW8^@V59&GQ^G["C8YE YQK[W\'PJ!:H]N^^A5R'9D+FJNP(S
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M3P/Z@$ YJGR'(G'(X/$X.?WRT9?=*YH%,D#1EEJTDC)QCGP)D5!(!DW+%\B
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M_K!9PY8LW#QF>.=N&C=9U'JK(.5&#A5$AUV:CAJ=1LN=JJ82"=,QDS"7R41
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M@K)XX=?B+GXQW_Q?E+"%"'AU]-ZU\O=7_P#2NU8F7U[K&%GY.NQDHI2O/_\
M+?\ .H+J_EG6>1H3RR4(:LBRL%BZ\HV05"T:#BFD]CGUEQ31K+1= V(+13+'
MG4"TM<NZ4)FV?0;Q*8K[611F$8ETYAQ(Q?%3.@"J3A-?X *D=;L=-M>Q=&[/
MV;(VFCV>5H-CNO?QKL.I<BQB,+$J864JXL%;&OBJT J&6Q;/;X4OUN\T_6/D
M#J?5,;4]@U6)V+6:+\?*HSKFQJE!SLVY35<U9J-BK;S=26#E6J:OW"SJF)*9
M7J=@)'Z5+T=]!SND=S<@UM_1".XQY(T/-Z3#PM/8/[2LR>+1?\@4B*Z20DR-
M%W)6ZCDJ!3JF2,8>G?J7;-B*^SYF!91L-GW?7;!\4,C/B86+75C*]Y5C7[QK
MI%UXK9PA<5@L4)G=IW+INL:WJ>#L:\C6ZGH6SUJ9A6Q4S,[+MMRG3'#J+/9%
MMYIQS8E9<5FPJ@< 60TFJ6.7[ ]:+1&0[MY7ZB79@LTNC\/TT*%@I<<PA@>>
M]4BWB2?(BFG["G_47]7@/7GIO9]1L\SY%ZOM<6EWUV'_ &7OV#CQJ][&1*_+
MD\_YN.!P#ZCUXGE'4]UJL+XR[;I\N]*]GG'5_CU'GRM]G*=[?'@$?]M"&/)'
MH?3F6+YZ5/+(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB
M(XB.(CB(XB.(F$W?2*'FR-9<7VUPM30N=TKF=556:>$9DGKS;G1V59J\:)__
M )$O-.DS$02#U,)1_(!XD@$_28;)=A,ABM"?Y8\M2PW>)-'EFHMG6;;),8$T
MK#C8(\M@L<; NZS &<08 [ 'CQ 2MS%.;P4Q1%'!^L^66=A,<VI19OFEW9V)
MVC!Q5H"/5CIR DW56G?>$-:8Z+LL7#R$I6)0R8E0D6R2K)0WZ2JB(@'$$$?6
M3-Q(CB)PY&1CXA@\E99^SBXN.;+/)"2D72#)@Q9MTS*N';QXY.DW:MD$BB8Z
MAS%*4H"(B <1.MAK17K$\LL?"2S.3>TZ>"KVALU4]ZL'8304)9@B7Y? ?$\&
M LC!W[?7_9=)C^?$3$X;8<UGC:25A;&"8Y!)/(K3!E47\ 2G.6,46<<+RZD\
MTC4R17[*<':;X@G9+-O]Q-4Q $>(X,CN+[<]<IID65BM3A7T K4S79K:T&,\
M:F2,"G2X[1EOVBZ#$A59B;;T*6;3"L4U>+2J4<L5<[<J?D02?$RQ::A54TU2
M@<"J$*H4%$U$5 *<H& %$E2D52. #ZE,4#%'T$ 'B1( <=J^O#1[:F+C5ZPF
M>EQ5PF;"\][X\,W9Y\Q>25[(PGR,C0<[)4YC'N%)-DP<.7C$$%/F2(*9P!)X
M,X#GMQ@3*,B)9[<9=FVGY67A85N[SK36TO*/:_$L9R=.R@%Z:G.KQL/%2;=9
MT]*V%F@"I2G5 P^WB.#)WK=D@+A7X6UU69C;%6K'&,IJ!GH9XA(14O$R+=-T
MPD8]ZV.H@Z:.VZI3D.0PE,4>)$[KB(XB8A:[_2:,QD)*WVF$K[2*CDI>1/)/
MT$56<4M(MHA*26:^XSH&!Y1XDW^;V"G\RA2^?(^.(XY^DXVC:12\EJ$M?="F
M?X]4(%-->:G#QTK)-HIJ=0J9WS]*'8R+IM'-0'WN')TP0;)%,HJ<B93&! '/
MTG0Z#N6194[@8[0M KE6E+5%V6:JT1(/!--66-I[-B]LCBO0[4CB3FC1B4JT
M*9-LDJJHN[;HIE.LND0Z2 3])],!NN76A!PI7K$[EGS* M5D?5QI6+:>ZL(Z
MDRY("RMY"AF@BW1A/L)L_P!(2*68$E'3@!30;JF*8 1P9+G$B.(CB(XB.(CB
M(XB.(CB(XB.(CB(XB.(CB(XB:_\ MEUQV3LK=VT)!3M#I6;U3'KNQ@9ZWUV:
MNCYSLFFJ#!,[C7X>NWZD.*].XU68 5HV0=&<%5<V-0$D_<V,<$L" )@&?YQV
M.2U+2KGHE$U-I);!3LY&98TF^8DMAC6Y(=>HJ@70;=$2MI8Z4X+%WEFO](M%
MMUDU6A&:H$$2K)@DGCCTF;=1.O6O8_9*TYU^<G-(4A>M^;4"BVR8E*&V4R5.
M.B*@AI6+J5^C5RI,+"A)6^NMY9C9A2?.G;)L5BZ53%D@O(I#$'Z?K*=EIG8.
MQ:9*8E'V'56VI%Z_6$-SLD7VA=/X>T7=UV-ZWO$;[3Z["7%V[P\)[*F]H-!D
M5:U=^5BLO'M&:J3/ZDR6]..?MS+'GZ^]B'UDL-=BY?3*:X7D]P;/MD6W*7FJ
M3.9I+PMI0ZZ5.F9TM:I2:KMQS:7>5E60?+Q<<<Y8"0$\C*#,./D2.1]Y&LOU
MB[>[!G.YU'7Y%Z1CJN+ZI>HNGEUV74AX7>MIBVL(TP\'L+)$7+F.(QU0(I'N
M $8]T[LJJI2J?3G+Q'(!Y'ZR8<WZ[ZA4M-#5ZY%7VE'LG9*N3LY4;#L4E8F;
M?K^/5"G9[,1-GK:-YM%*G[0SU&M(&4> =_+JN&23DCP[?_,@GTX_:=_IG636
MM)ONV*QECIM5HMYTS'K=(Q%OK,A>8/6ZK0,K2A5J/8HVNWRC2T+ %T!LS=OT
M5%E4YAHQ^C53%FY<%42 0 /UE>DNENN,L:ZTPK6H5]MIV<42@7#6Y"&L'BO3
MFF4.*H-0;5JET*U6VR9LA>7U78.G3FR/&8M))] ,&CQ4\;(/42)/D.3^DV7Y
MA'Z5(9.VC-3?O6%Y?IVYDM(I*U\MDCX1W/3B-)=33BJ))U+^=LJ:I'FE5(H@
M1?[P5<6H?3_'Q*GCGTE.)&A;ZIU MW4EMA9&TQ&=:= Q^+T6$OU!942T2K',
MI.I4N3J$>[E N+"8N\F+=5RA,QL:TB%EUA.^>%2*HX2?3RYY^\Z2TX7V3T1;
M+)*AW+<\2MN?L-V1;:+L,KUTT*V-Y6Y5BAHU)D\BZNAHU6E,_D9.(<H.2(HM
M)IJ9$RB:J93)F42>0/T,SJY9_8J7UNP.(:5.RTK/LT<,7NZY5$;=&5.VO:RC
M4+0R>)-]Q4N-!BY)"+T>18SCU9>8@@FFB)Q6,B83QZR1SR3*L8AE79/1L;I>
MG+SVM3:*N<Y<SCZTKV#LY)BZU%'LGV L>KPT3:#V.OQ[JYVW%92H-8VX//I%
M)&/3*@VD&)%3ND4L2 >)(<MB'=,C%B-%G;M7X&5F[#<&=1L6PEF[;GL5C%D>
MZ1U^RZ9M*]@F4K$78+/)KPEN51D)%NWK9&T>N\?(MBJG2.5F.Z[TXVR\L6$[
M),+-;=$T#JY:<XNTXRUIW%)4;0K5L<7K\I# V>6R+C'=5BT9V5BJ^\CVSQ>.
M-&,O":"9$%D4!@/XYEKYG%-+# .Z>/QRLU.M;VRU6%Z_,[=?)"V2(P%YPBL1
MZ40\M5LEI:;9L#; _GP1))NCBT;*% HE:@B4J1R.09$5RZ<:I<.S%)TRZ3><
MZ-G4I:;>UMC-[3[#"73/,C+D,_7:%G=7LB6JJMS$B[\__=CR49&,GQIMT,B/
ML%LT(V2?(<<?>8U2,'[+9K<+E8ZQ57[:&UN1).VJL1F@5\[YM5FKO1F<I2+?
BJL]/.-B7TQU67<5(0,] S!&R-PFI9Q(.0:)-3<02")__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>75
<FILENAME>g382677f_73d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_73d.jpg
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MQ "W  $  @(# 0$!            !P@&"00%"@," 0$!  ,! 0$! 0
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MS\?>&N:%\5XY;&>-<WP;EQRP%^HMEC6YWQDX..<DBT7"+99X>0*LU)@;Z>'
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M)''M''(H-_*!?AJ<"-U!IY?R?E0M/D/70;^4^5R=?EZ?Y>'+X:"J\NAD):]
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M!\N5B'""X?L%02_AKL:NI$4YE2BT(W$.("'$Q1_ Q1$IBC^!BF#Q*8H^(#^
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M@CXUCC:HK13:2:M)F&96,$9E%JA,)FL#=.6!&619+.&B<@U2=%14!,YR *?
M!$ US.6KEJ;)R)*U4D: : : : : : : : : : T1_=IQJC%7G&F5V3<J9;;#
M2%.G5$R\.K)UI0DC#.%S? 5G$7)KI /QY&A0_#71"O!4,9$XU-1.MS,W?_:+
MNZB\#F'&[A<QB1<O7[K%MQ'B!$YQFYA9@Q $?R@"T&U$>'XJ:YYDXHIK&O-#
M<GK U&@&@&@/YP#CQX!QX<./#QX?'AQ_9I1*UZCY=#^Z _@  !P   /'P .
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MCZOP,H=RK)PD1(J/6*48\4?1K)V=W&H.3O$8]R=PBH9=BB[4,J5(_%,JAA,
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M: [30#0#0'D?W-UL:CN(S57N04TV.1[,LV*)>7BRE7QYEB8"_ "G9R)!#\.
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M/B55-0H_#75"VC:]5,)%JM/@:VM:E#T#_:CQ\I7\*6Z_NT3).,B7-1)@8Y.
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MH78ZB_(].Q3%.4IBF Q3 !BF*("4Q1#B!BB'$! 0'P'7(;G]T T T T T T
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M, " @(:D@W+[2_N7!&MHS'FY!VY7;H%190V6")*.ER)%X)HM[VT;D.X6$A>
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MI6<E%2$!Y-S;T"$,^DWIB!S&$ (0H%33*1,A"%Y'.5RU7F;HB(E$)2U!(T!
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M=2VWU>;>O_C4^_V?LW_@>R?]0_\ V6_X&_ZU?^YG^^__ $7J"**6ZU)4: :
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M:/*E_P!/?1O)]3D'D]2]*^=Y[EX\WFOG\>/-XZYW:J^KF;)2G#D3!JI(T T
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0]Y?_ .R/_J[4?O)]7R/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>76
<FILENAME>g382677f_74a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_74a.jpg
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MQ "\  $  @(" P$             !P@&"00% 0(* P$!  $% 0$!
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M*.=G)SB*24R8W",#U#&-6-M-7=V9>W5CH;L+$;>VK?=*Y<[=Y_=5T[6MK?-
M,LEO01CF&.*,7C&20PTE(='!]=&9G=L6@>2G._DJW6N_&'36LJ'IM9RY)4K7
MO-_+!8;TS:K'0&48Q$,[2!@P=*)CV/\ 952*/4"N5!*;IB<?U/Z_]3XRSO2O
M"8O'[*<B\O<90Y.=="+NW,&.,FT 3MP]TA[FE*CTS&2Z3>G#I+*.WNKV>R^2
MWX("]S;8@(^1:$3,7+.647UF+/Q]X2?@[Q SM63])\P]CI;=C^-_+76$?J/;
MEA9KOM?V.N2)Y+6^RT6J9SKM8-ZNX>'8RP$1.)$C.5@4.44S BL*:2DIV+UH
MW,&\H^F76'%1X?>-R#G:30FYV5ZPMQ&(G<G&3@[L+F57;2[ >D"B'4'H7M4]
MCR]5NB67ESFR+61@O8)P:.^L')V9BF!A%CCJ[,Y, :6=C9Y U&$L0V_;9(\U
MK?QM6BZ^2EU_141M!G,)H2(696<?V9E"K,G#@T@:+-%%;.3&*4K4JO; .J@A
MY,F-EU"R]SUPO.F1Q6[82WP,=\,C,?/>4Y@C<7?7HY>DG=F:-BK3WG;@H5?]
M-<):^G^QZKQS73Y^ZW'+CRB=P\NT(6YRL8MHYG,<A9G=Y'&G[M>*MOFX%I),
M(F$3")A$PB81,(F$3"+1E>('E ^YS6/EJTT7=5=8,;4]X6-Y)K/2!;@ZXWR=
M==P\O;V>E24Y5\_@S<MG[.PELI)/RTV-%R5 6H]Z)>C4TZ>_M5(M=\1Y*Q\(
M- :MUIQ)T%8-N,]O<?9S;6NMF\"MX\;M7V.5J'&'<K5NUY)O;E[W5W(\B-@+
M*M7%QBRDBV<S(M5E&H%7(1:BN<O>=W?A_'[5LFJ#_?FC^#'$6KZX:[3IXK6H
MU=W=.M>.EGV)L[056<$V'8!J-.X^E?VZ:=5"J[";Q5(CG::UD;1E3[E^DH\;
M 213JK'HY/50QJ/E'\P;96BWNV57$HO N8/1<8M9:;QO-9)R)B[;L2_Q6Z-Q
M46@14K./=CV"A5RLQB"=8CSRI8XT@L\4)*]RFU6HJNPL]%V,WR@^9I4(JC6%
MOINY;+K2B+_:$LK'Z%DZ[>+1I;1NQ]B0%XK<C1#*.9*@[YY)ZVG:--UBON *
M[;/&TPF1JCV#,VA* L>V]KOG):-NZG87:][0?3-HKORY[DX3K&DF5DTKK[:=
M*W??G7(*?9R<9&JQL!)ZX;3\8]*A*OD!EV#PAUBO&T5V&]49Q[O:MO'%R?VY
M8M+03G>:*@;-B+3M*G3DFK5%:.I:XV@[6NU'J%^&J*+N4H7Q$I=>CYT$FYS,
MQ]X]IM_QS)!A6/2O#L5@\*BT^;OUEJ:6Y2;5L/+CC%M[D&J^>:R<<0;?2M67
MW:\%0:NPJE=;V*L4^:HJ*K?0>T&>W6,Q-2<]).H$9"*>QXDDE$6)D&A7L[Z?
M=>GBJ+SW' \S5?F<PK/CW67V\]J6_E V@7BO!7<T+L*[T:W<GT):/:6OE*Y<
M+4#>&O;545(]RE7X9!L]-$)%*"BOJ2IL*^O[/'AP[U<GCQ4>0G&3AQRE:T/4
M,'KG=T9O22<L=+:?U#8EM'ZTK2ZVMZC,W7BU0W]A(XV_7Y/6C!YL)".:.V!Y
M:X/7D0JR9O"KML*UZ.3>%/X54=:]Y/?,#NJNZBZW?2^U8[3*'(]"">6WC0?6
M]DO]AIM#XB26K*G:ZB[EJ^\JEU.?;]OF2PIQAY*QC#D:E1BP[P$*([#^/_JN
MQF=\_,U&H+)ZAA;3LM"UW&R:GU1LS9G&.6U#9O>AJYK+9;#;>V=4RK6'E:?K
M^ )!WZF)/'#&*;RDBXAE"HB82.7SBE![UAG(U;FGNW44'?YUAO6M0^^.(?S%
M(9/CE":4-+^X)F[LZU-<8]9;B8QL0^L]7ODAK>(<$5DG0LSMI]HM&(JH*R0H
MN"#I9Z>UE:/W;\PCQ _A7C@/\9\>_#+^=_\ 5>M][X4?]9/^P/\ ..\]_P#N
M'W=XM_\ ZW[SNO5NY_L[[WQ_R,JJ>[2M.[Q]JZGEGM;5]$Y_<0;A.; J22-)
M;[$IVPXMQ-,@>:__ );6$UJ[/61H93MP\?)$FRF(NJ!2]A,#=0#H.<:]7]W;
M4P'J'V;FK_(V;!8#>6]Y&4HZK3S$#/#+,-?RP-I6=B*C4:O8NX>BFR]X;C],
M^^<%CL9?%)D"LKJRD&(]-[Y:X=IX8"9OS3!XG9P&KU>E*K8?1N26@-F6!&IZ
M]W'KJZ69PU=/4(*MVJ)EI55FQ(4[QRFR9N55S(MB' 3F .A0'RYTC@>IW3S=
M.1;$;<S6-OLH0D310SQR&XBU2=A$G>@MVOW+ES<72CJ7M+&%FMSX'*V&($Q!
MYI[>2.-B-Z"+F0LU2=N#5XJ;<G*U\JY\L=ZLN.6@]@[36,D>7BHDT;3V"G0X
MRMUFQ]W5EB1$0$7!"R*Q5UB  CZLBH/^&:TZO;^@Z:]/<CNLZ/>Q0Z+8'_O+
MF7W(!9N]F-V,F;]P2?N6U.BO3FXZJ=2\7LX&=K&:?F71M_=VD7OW!N_[KZ&<
M!=^',,&[UK+VCQ]M>E_E.;!AE2/%]DW)."VSN9V/;/*OY2QW&NS5D;/U>@+*
M# PZ:*#CJ(E_XJQ_Z&-G+FZ^G>7V1Z0\C9$QEN>]:+(9(O[PCFN(9)A-^U^5
M&P@?=[AEWNNN-G=3<+O[UJ8R_!P':=@\V-Q8\&C"."UGB@(&[&YTKD84X_F
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M&>=B "@$AH0SB4D;/%(('20"87 Q)^QT=5-44_5U2C])T.#UOK:1C4K'7:O
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M/>P6W "_N_YIWTS$&/@+Q>&/G7A-QH;VI/W+VPC-L?I/>[F/W=P;GD/'6?\
M.#'P.!Y*<?!IY>39"_"H->!7M4/['US>-1:G+3I*TUFPZ-IMKK4I2ZFPKTFC
MN"^2S:_1UAUAI;WN:64KQ DKY[NCSRZ#3UQ:/)_>DDH*KK(9N;;6>V;M!L+=
M7=K<[#LKR [:W"$VR-W(-V$UCC.9S'A;7=\F%[@8^84+>\ %KE4YVKNK;V^-
MZOG;2SN[7J)?V5Q'=7)SQOC+.,K,X,AE>5RVG?19\^9K8Y.4$S^Z9BP0KO\
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/$3")A$PB81,(F$3"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>77
<FILENAME>g382677f_74b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_74b.jpg
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MQ "]  $  04  P$             !P4&" D* @,$ 0$!  ,! 0$! 0
M      $#! (&!P4($   !@$# @($" H( @D%   ! @,$!08' !$($A,A%#$5
M%@E!42(S-38W.&%Q,B-C)#1E9A=28E-49%5G&$(F@9&QP7)#PR6UQ4=(&7D1
M  $#! $# @0% @0%!0    $  @,1$@0%!B$Q$T$'82(R%%%Q@2,5D33PH4(S
MX6*S)!:QT7(E=__:  P# 0 "$0,1 #\ [^-$31$T1?AC 4!,80*4H"8QC"
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MT7'2,HW?O59:0;I&2,[281\8L9-'N$!5<4P,/1U:[C;<ZA[+ESK15:V^(7O
M\WVG-M2QWEB5C[I7<A2HP#5TE 1,+*UV8=HKJQCEFI"-6*#N-4<I%17273.<
MA#]PAPZ!*>U\;0VK>X5;7FM#V6?DIR@LL%,3%$G(ZH1=Z@.1;ZCS#AXX>MZY
M&X%CZBIG)YEAX"C\'*/E<(HFCU%Q6\F6W%$G1V0\OK.M%OKZ454C^<&*9!\X
MA253,+2T.(JBSE/J,GC:4C+'DB*R8ZM:%'>45F]710D"RS6CRKQR1VJR5AV+
M)5>3*R(41 EI5XH<H:C)2OJ&(IV5EY)I$Q[NV.7.-K&A&8NEIN&=3D'7LGB*
M(25>E7<>W*X6*BW=(LVCALY<JHMG;198HHK$K7.?#DJM#MY<MMB(]>)I"TYD
M1S4)=ABN&GKWAN.SG!P;BS278=-W#^AO_,%%1MVVZW0U<J).EFZ2Q26E?"P]
MX)@&6;1?JLUP?3LY8JQ!0U22AXM*P2+>Z0-DLU3L!!=3S>#:15@A:?)G;-W+
MU"64<LSLO)^>$K8Q+2KPR]RMA<+Y:B,?VJBW!U5'>(;)E:8R1"HL'T3 $@[S
M3*.WA'40=ZA,.EG;RXHF44034%$5$ Z#E.J= @%17U52N7+;%E)N\MC^09W>
M3L%?5O8V$8*J.Y"+@(S&V-L:Y6N$]+2IEF[)M#1U3RS"=M3J,HZ>N#-4$U%R
M] D#2>JMB&YMXMGV;)**J.87-SERPK^"Q8;'CQODF<J]AJZERBKNQ@7+U%HE
M4%8!!4RKIRZ;G;/4ACUDTY$Z310EI555YL<>4*RXN*]N>(5MHN@+F1<0,JW.
MA#KXD?9J/9UHY=NG*)5YG2XIX1PL9 %$)9FM''3!ZF*.B6E?+3N:>([W9J?2
M:Y'7M_=;;:9BJJU=O7FCU]45H*N5VX/YFZOHR8?P,'7?9>U,7:;H'BP*F5,U
M(47R:C4I+2JA;>9&%Z?D:9Q:[=V&7M4&]&O.4*Y$)S)75^/2CY#88SBFC=\$
MS*WF7J!2.&K=!H=JJNNBS\P#Y9)L8HM-*KUUOF1B.\JU\<<L<@Y+C;&DG+M)
MRA4>5L<0WI#JQ+5&.R2Z5:[.ST>:LK!\U8+MT5W3\L6]<MVZC-JJX*2A'=43
M%_+RLS^/96R7Y/U98JR]@2V9E6HB3=13=AD+/&0\(XV48*N7#I1VXD9*B'._
MZ53%:@;NCTIF*4I26]>BLV:YQPJE_K,/6*Y.(X^FJ#<;FWR!;:?98^#N2$3F
M+ F**[*XYE&!G 3->D7F5GACF6:IK*D!B\2 (Y8'*Q+5?$'SAPQ-Q\M)"PR5
M$(-X]62JJ4QCZ:;O,GH)Y):X?!+&K%L#MW8WJ^3)1A$I('(V664E&;@A3,W*
M;D26E3/A_,]9S3&6U]7XBWUY[1+M(X[M]>O%>7K<_!VV*AX&=>QZS119RV>M
MBQMD:*)/&JSADZ(IUH*JIB4YB@BBES10FB)HB:(FB*,,N9BQ]@ZFO;SD:=1A
M89KNBU1*'F)6:D#$,="(@HTA@7DI-ST#TIEV*0H"=0Q$RF.66M+C0*"0!4KG
M?Y-\[\K<@7#^ B'+S'>+CG.BC4H=Z=.4G6O4/2K<9IJ9-5^*Q=A,Q0$C$G@!
M@6,'<'4R,-Z]RJ7/+OR6#92@4 *4 *4 V I0   /B  \ #5BX0QBD 3&,!2A
MZ1,(  ?C$=@T17U6<491OZ)PH^.+U;2JIG*1>OU2<E&AA,40#]=:LCLP#<?2
M*@!J"X#N5-">RWJ9@Q5E*VX-R8QC*+8'MBM>$\:LVL.5!!*1<61 ^-G4U$=E
M=PD)9!BI&.A6*82[&2,'I#QH#F@CKZ_^ZL()'Z+2Q8^.>?ZB@=U9,+9-BVB0
M"*CP]/F7;-,"AN)CNXYL\;%* ?")MM77-/8A5VD=PH:.4R2JB"I3)+I&$JJ"
MI3)KI& =A*JB<"J)F ?2!@ 0UTH7YHBDW%.8\E82LB=JQE:I"M274GYYLD?S
M$+.()F ?)S\*L)F$LU'T!W"]Q/TIG(;8P<N:'"A4@D=0N@_B3SLI'(I-M4;*
MDSH^7$FXF4KQW C#6HJ"?4X?4]XY-W5CD*43JQZPBZ0)N)163*90,SXRSJ/I
M5S7AW0]UGMJM=IHB:(HIS3AJE9YQ]+XXOC9RM#29VSM!W'K%;2D/*L3BK'S$
M4Y.FLFB^9G$0#K(=-1,QDSE,0YBCTUQ::A00"*%8G<=_=VXPP)?&^1UK/8;_
M &2(!R%6"<:1L=&P"KM!5HK(E9,"'%_+E:+'3364.":0',8B0'Z3%[=*7"G8
M+EK #7U61]BQ7@Q?,7\QK4VKYLFW7&+[#)&,Y.D*C:*(M*K3,E#MZ>]>ECI=
MVJLZ.DLY(V4="T/V#'[/R-5*RII\%#3+B-QQB;!*,@N5Y5R VK5(1A'\KF^S
MR5\QO5,9O;2\HJM(-)3KB1JT77R765;'< D8))D]5;R)WB1S%$IN/Z*_TN/&
M(H:5B[42WWYB9]#QS:<,MF.WA&91-!PKIG$V'( N9\WMQ,1T*Y,47*ZABKLT
M6Z+@%6K1HD@45/946$X^\7A0<8HC5(694AYV@626I"MX--2B3W%^-*WB6L)S
ML*I*.'YHU*AUQDU=MW"?9=CU*K%,=4QA*:GNJ;*\3\#)T]7"DO;[PVAK^LJ@
M:L/\L2R4I;ZO#P*D(O1$6;QZ+B8J47 O!!0B:9WJ1S@Z,Y!R!5P)4]U(-YP=
MA'/*C=Q+J#.IUFLW?$<DG5+B]:(J5RU(PQ;'3;&>"D2J^:C)2 C)%H8QTI&+
MDF**Z"J1^OK**D*DPG$3$$.K9GSCVVLDW<XG(4-:[';+W9)Z=G6V4*=C"AW!
M1V]=O>E%=Y6,/0+=#L$1(S\J<R!4S+*B8EQ7E,\6,.V271L$>XME=N-?A*?2
MH^XTB^3D#;*Y$4F&GXN.@VLI'O14:I2$'<G!9!%4I@>]39=0O?:M%DB5*^C_
M &A\?!=-US4% [=M@]WQV)%J2TTI%'Q:]=F>.8Q=HI(&\Q/**JK!ZY.89?9P
MM^L[K*"8E3_FJY1N.>/:%*UFP,%[;-V&IJW-6*G+3:Y:=?\ _/C*KQDZDY!=
M4C-9'U=38]) @)%*D*1U?%===50E2J=8N+V+['<[3>3GN,'+71F_3LS:JW.>
MK47)R\C5"49>V"TB73<[6U$J*2;(CM!1/I[*3CH\VBBX(2XJCQ7#_#59DHV0
MHZ-SQRE&.C@E#X[OEHID$M73S@VDE$5BH*1:-DJ(SM3AY(M(U $4V2\I($;B
MD@^=(JE-Q/=4][PLP>\5C#)M[O%M&)X,\A$PV0;7%PUH&J97F,V5$MLC6LD1
MO.$JN1K%(/&15   2>*ME.XV$$0)<5ZVO"C!S:8&5,C?'C=I"/:O6JX_R-;W
M=2HU7D,AT+*;JN4BMJR8Q=>B373&L0NF1,@G0:-2L4C$8E(W(2XJOR/$[#;N
MO0T$G R_;JM1L%4JBJ-QLD5(0J,Y?ZGE4LE'SK!T:3C+!%9"HL5(L)-/K=,%
M6H=KY(F(8EQ7KXM8/G,'U2^HVF8&8M.3LJV3*EA_YJLEZ+&/IF'K5;;19;I;
M6D5.6<Z,14VRBKD\?%MP75.DU9-6J:*)2@FJR;T4)HB:(FB*+\QY=IN#<?3N
M1KP]%K#PR(%0:H]!I&;EG &+&P40@<Q?,R<DN7I(7<"D*!E#B5,AS%EK2XT"
M@D 5*Y;^0/(&^<C+XZNMU=&1:HF7;5:K-EU#PU2ACJ=2;!@F;I*L]6*4IG;L
MQ05=*AN/20J:9-C6AHH%G<2XU*@P1  $1'8 \1$?   /2(CKI0LY>-/ O+7(
M))E9GX?RYQHX$JJ5LG&*JLE/-NH ,>IU\QVRT@B<-^EXN=!F/I3,L("75;Y&
MMZ=RNVL+OR6[##W!CCEAQ)JXCJ.TN%D;E*)[9?B(6:5,N %W69M'2 0D1L<!
M$GE&J)R_"8PAOK.Z1SO7HK0QH_-9=I))HID113(DDF4I$TDB%333(4-BD(0H
M 4A2@&P  ;!KA=+ST1-$4/9-X_X8S$U5;9&QS6+(LH42EEEH]-G8&PB42@=G
M8HX6DVU,7?<.A< $?2 ZZ#G-[%06@]UJ,Y"^ZSG8!!]9^/DTZM3! JKE;'EF
M<-D[&DD0O69.NV#I:L9@Q0 >AL[*@L(!L"ZIQ HW-F'9RK='^"U'24;(PTB^
MAYB/?1,O%NE6,G%R;5=C(Q[U W0LT>LG1$G#5PD8-C$.4#!J[OV52];-X\C7
MC.2CGCJ/D8]T@^CY!BX5:/6+UJH59L\9ND#$6;.FZQ ,0Y# 8I@ 0'4HNB3@
M;S3+G:*+C+)#QNAEVOQXK-) 03;)9!A&9 !:5;HE B2=ACD]A?H$ "J$_6$R
M@3ND2RR1V]1]*O8ZO0]ULEU4NTT1-$31%KVCJ[4:QE+,B6<\$67*%WO&78JP
M8]OC3#LAE2&F\?F2KJ6/H9A;FT+*PN,4,3.V:Q';*8=PR*;Q%:6;BL9\=4Q=
M>@HH88XS<'QS7<6J8/M \NF6:(F>L.:'6-Y$81]*H9-1G[CG%YG=:*2KDO2K
M9CX':/L_ZT5E5HQX6N*QI$0.BF4UZ_\ *K8LV$,MRN,\VX]D:%:WD/QBQ;;<
M#<=DC10R:N282_VF&LT58ZL=(AG$N-+PG"5:JJ."%ZPE"3B/@'6 DJ*U_%5Q
MU0B3,9F*B0&%+FVY&RG+?(%SQOE%3#]FK;"BM9#)[6P0F6 S?*5J-K#FM,:H
MF91=I'R[MU,LQ/%>66!=5'1/UZ462>>,>Y5R-*8>)9:Y M5X;D6_)7K?BU>;
ME[/1\<SV'\OUI2X2TM+P$<>K33-]+L>L[4RK,KP40ZS?)#10".OY*-.*V%,F
MXOF,\2KNN47&K6EXQI&!Z&[QGCFPQ,3E6;QQ7IBP2&<YG'SXS)]9'8RUN2B8
M]!%RNHX/'OTTWSE%=NL *7$&BL&(RARM7I$$E9)'D9"MXR-R@U-D:JX18V^U
M9)RQ$1]!>8[8I4">X_TJPTG#M@5EYM( F*U$K%DHX[9:?*R*T?2$)0>E%\A+
MERHQ(XY&SRN-KXSFLD5++-JK\3CO&<KD:-5Y/-./G%]M32QCMC#3:H5=6?C[
M#'1SU^J2!=+1:R3E?O B"DIT-%\ QW*R@6[+#BFL<H7>V'RGGF[P1KK0H.:K
M\#"6O"]8E*.KCFR%J<!'JHN9M)XU3B E3 :4C48]YY;OJ'6)\I JI6B9+E)>
M+57:C5LD9YA<1O,B6)!#,5KPU2:GE=]7&F#9&8.QL5=N>((6)@Z]'9A,U0CI
M%>L1CJ3 %F9051(D]7)\H_-75QHR3R1LN5(QKF.*R$9A:,,5&SRD8&/7E!Q_
MBBY$I&,5+#59@]FQLS<6FS3-QD9M=H\AKI*D01!9D]AV1F:;E0H(%.BV%Z+E
M-$31$T1-$31$T1-$7B8Q2%,<YBD(0HF,8P@4I2E#<QC&'8 * !XCHBYC^=G)
MMQR#RLYBX%\<^+L>NWL/4$$CF!K-R*9S-IFXJD\ 5-)*)BDR$0^0Q(40V,LI
MOKC9:WXE4/=<?@L'A$  1$0  #<1'P  #TB(_  :L7"W&\$.!+2R,X?-V<X;
MOPKD$).@8\DD1!*60^2JSM5N:*ANK&K>"C&/4#I7)LLN IB1,U$DE/E:K6,]
M2MX::::*::229$DDB%3223*4B::9"@4B:9"@!2$(4    -@#6=6KST1-$31$
MT1-$31%@]R_X75#DC!N)^&28UG+\6R$(.TD2!)M/$;D$4*_;@1()WL>IMT(N
M=C.&0B DZD^M(]C)"S_XKAS;OS7-9:*O8:58IJHVR)=P5DKL@O%S,2])T.&3
MUN.QR"(")%4E"B!TE2"9-9(Q3D$2F 1U @BH[*CLO&L6:?I=BA+=5I-Q#6.M
MR;68A91J;99F_9J HBIM^2JB?Q(JF;<BJ1C$, E,("(!%#V3MU75IQBSS#\B
M\15_(3 J#.8$IH>XPB)Q-ZCM<<FD649E XBIY-SW".6IAW$S5=,1'JZ@#&]M
MKJ+0UUPJL@M<KI>I99%LBJX<*I(-T$E%EUUE"I(HHI%$ZJJJIQ*1-),A1$QA
M$   W'7+WLB89)"&QM!))-  .I))Z  =23V7<<<DLC8HFETKB  !4DGH  .I
M)/0 =UCG5.6.%+E/P$%#S-C2;W!^I%4:VS-#NU?Q_?)4A'"I8VEWR:@6-6L+
MMTDT5,U*@Z,#TJ8BV%4-?--1[O<'W>QQ]?A3Y0CS9#'BY$N)E0XF7( 39C9<
ML38)G.#7&,,>?* ?%>OJFZ]E?<#0ZS)V6=CXKI<&(29>-%F8DV;AQDM%^5AQ
M3/R(&M+FB0OC'B) EL7PNN8&%F;ATV7'*I5&:[ANN8F <ZJHE4:J'26,1PEC
MHZ"J)3)B(*$,*9B_* 1*(#K/+[S<'AD?%)_+W,<0::C:D5:2#U&&01T[@D$=
M0:+3#[&<_GB9+'_"ELC6N;_]SJ :. (^4YP<#U'RD @]"*]%6)/E/A2.IU#N
MJ5CE9QCE%FL_QU"5FH6ZPW6XLVI0.\=PU&BH1S:SLV*8E,X75:)(H <G<.7K
M)U;<KW9X-BZ77[UF3-/C[5A?AQ08^1-DY+6_4Z/%CB=D%K!U>YT;6L!%Q%PK
M@Q/9OW RM[LN/OQ(<?)T[PS.FGR<:#$Q7.Z-;+ER2MQ@YYJ&,;(Y[Z.M:;74
MJ<-R2PW.T6<R(SMAT*]5IR,K-L;R<%88JRU.QS$I%PT?!V:GR$4WM,)(N9"9
M;%*1PT(!DU05 12^7K5A>YW"L_03\DARRW78D[(,@/BFCGQYI)(XV13X[XVS
MQ/+Y6 !\8Z.#P;/F63/]I^>:[D>/Q:?"#MIF8\F1C.CF@D@R8(HY)7S8^4R1
MV/*QK(I"2R4T<TL(O^53IKWR^<IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB+ SWB6;UL0<?Y*)A7@M+=E)RI2(11(XD<LXMPV.M:Y5 0\2F:PV[<AP$!(N
M[2,'B&K(FW.^ 7#S1OQ7,^4 * %*  4H   'H  #8 #\ !K6J%GSP XQHY\R
M@I8[8Q\SC+&JS*2G6ZQ?U:R6)417@ZN?<!*LS 4A=OB^("W(1(VP+@.JI'VB
M@[E=L;4]>RZ6"$(F0J:92D(0I2$(0H%(0A0 "E*4  "E* ;  > !K*KUY:(F
MB)HB:(FB)HB:(FB+59[R[C WO=*5SO3XTOMM0& !;T&B(=ZRT5MU'6=K%3#J
M7DJD!Q7(<0$QF/>((CT) %T3Z&T]BJY&U%1W6@ !W\0\0'Q 0^'6E4K8I[M7
M-ZV,\ZHT"3=F3J>8$T8!1)0X]AI<F15EJL_*7?I*J_$ZT>;^F9REO^0&JI6U
M;7U"[8:&GH5T?:RJ]1;F^$L-GP[DZK52*)-6&TT>RU>+CCS25>*JO8XIS"F6
M]=+M7B3 S-%\9<IA2-N9,"^ CN'D^=X&QVO"]KJ=1")]CEX$\$;#((:F:-T5
M?(6N#+0XN!+34BGK5>Q]O-AJ]1SK4;C=3''U>'L8,B1XB,]!!(V6GB#F%]Q8
M&$!PH'5]**#>(=ZNN2\18V6MF)(*J5.*H553K4\A<8RR#)3-912@%NU6$H!B
MK63-%XU15$WF%A2V @#N'5KP7LWO][RCANK?N-/CXFGAU\ @E&2R:^2 "$T@
M$3#!:6%S3>ZWZ0:]5]$]\>.<?XESC;,TF[R<W=3;+(,\)Q9(/'%D$S"N09GC
M(N$C6N%C0[ZB*=%7N5EAF7-2KF%*:^687SD-8?Y;1C]F80>URF&9JR>5+LET
MAU)>S-$;NBH*;EZ9%VT* [F#7Z'NYLLV73XW!M+(Z/D'),G[)CV_5#C6E^?E
M#\/!BAX:>E)I(1W*_.]F-7@1;O*]P-]&V3C?%\7[^1COHGRKA'KL0_CY\QT9
M>VAK!',>P*CBQ1S;CGR KF03T.U2^&GF JWA*%DZ'5)J[N\3/:59I*6:,']:
MK3.3L:56N,5(MDQ>-&K@J;N*2(X I3)G#S6SQHO;3W$QN1NU^7-PE_'H=9$_
M$QY<IVO=C3OD:Q\$+7S"#)C>P&2-CP)(&-DH"UR]5JLJ7W4]L\OC#=EA0<\9
MR6?;2QYF3%B-V3,K'CC<]D\[HX#D8LD<A$4DC"8LA[HB2'-6+N5K$ME:%Y@9
MSI5;FHVJ$5XXX;A(^>8K5E_D'(&-LRQLO-R\C&O2%?118MS:FD$FHZ2*Y3%!
M8BB9#(]L/E/+MD_EN%S/GVBQ9XM2#IM;$R5A@?EY>%LF22R/8X71V&>/%!D:
M'BUX<T%E@^P\+U<?"\_@WMUR#+QY=R1O-I*^%XR&86%GZN2**)DC#9)Y&X\F
M8YL;C&Z^-S'.#[SESD"9Y"X*@B9EMN4:[D.J14O!FR;C9O0(ZMQL)5YV;8Q,
ME)8UL;5XK9%'M/"1*X!*:5?A)MD%"[ME3DZ?L7(LWW'X#KQS;<;;&V6HAFB^
M^PAB,A9%!+*V-[\*9KC-=C7A]N2Z43L8X?M/(I\1XS@>U_N-LCP/2:?*U>ZF
M@E^PSW9KYY)<B&)\D<>? Y@@#,JPLNQ6P_;R/:?W6-=7\927(3+.1\_UFK9;
MAL65G%60HBLU=XQQY!V^;EU9'&=(M;AG.^T#KR)(2/?SQC?JZ:;YSWS%!P@5
M$O<B#*]QN8<FY%J]3N(=3J]1LHX(',PXLB60OP<7(+9?,ZT1,?*3\C1*^\@2
M1A@N9&)[8<)XIQG;[C23[G;[G5RY&0U^;-C11!F?EXS70^%MYE>R$#YW.BCL
M!,4AD-LU\=\C3V4\1UNVVMG&L+:5[::M;&\-W_4YK/1+;.4B>>1!7)U7"<7(
MR=?4<MTSG.=))4I#&,)1,/N?;?DNPY9P[&W&WCBCW DG@R!'7Q^?%R)<65T=
MQ)$;WPN>P$DM:X DD57S_P!T>*ZWAO-\O2:62672&/'R,9TM/+]OF8T.7"V6
MT!ID9',UCR  YS2X  T$V:]TOGR:(FB)HB:(FB)HB:(FB)HB:(FB)HBYT?>B
MY'4MO(AK24%Q/%XOJD=&]HJ@F2"?LY4[!+K=.XE!7U<I'I&^$.UMK5"*-K^*
MHD/S46MHP[%$0 3" "(%*&YC#\!2@'B)A'P /CU:N%U<</\ #:&#\ 42HJ-B
M(6!_')VJXJ 42JK6FQ))/I!)81\3#%HF28D_1M2ZQO=<XE:&B@63>N%TFB)H
MB:(FB)HB:(FB)HB]#IJV?-7+)X@DZ:/$%FKILNF55!PV<)F27062. D4262.
M)3%$! 0'8=$7)/R5Q,;"&<<AXW3(<D5#S1GM:,H(F%6JS:1):O\ RQ_+,U8.
MRMSC_:H&UM:;F@K,X4-%#$;)OX21CIJ)7.UE8:092\8Y3,)5&\C&.DGS%<A@
MV$#).D"&#\6NE"[#<8W5ID?'-&OS$2>6N-4@;$4B8[E14E8UN[7;;_TFKA4R
M9OB,0=82*&BT@U%4R5!7&ST6R5^@7%O0+;+L!8Q-R<P7M*$ 9=5,KI\A##)Q
M!'+XK(5"MS&7*5%<Q%!*<"=!OP.48&ZVN@RM=QW-;KMQ-';'DNB\_A)(N>([
MX[G6W!A+P&N(<0ZEI]'Q+8Z'4<CQ-GR; =L])!+?)BMF\'FH#:PR^.4M9?:7
M@,)<P%@+2ZX8P5GCGG**J=-QB[S[68/%U4-5FRD3C+%,K2[C)0=5>L7R<$G=
MY'*%I<1J4\HP*22=$:G=N4E5B@<@JF-KY5J_;3GN)J,+BLW(<6#BF&8 8\'
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M:%*U\NC"A5UQ//D5'0E52:,V2)@34>/5^L4D 5,4Q42 1,QSG$!Z2%$0 1V
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MW&<MN6KG8+3%65 T@QF,=IS^+:OBTQZEYB3DHF-M4?&02ZC>:;-&SQ,'@D]
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M9]LWXV?[G\IEX5C\?S'9?\]-ML_69>UP\/(G9#!KYC%-F1Q8T4Q9DY+"QD#
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M"OHUNJBR.KY03($ZTSE* :^=X_LOIFQXV'L=MO\ /TF*^%S,.?*;]H?MW-=
MU\44,5T<3F,<V,N\=6-N:0*+Z9D^^N\=)E9VKT_'==O\N.=C\['PWC,'W+7,
MR'1S33S622L>]KI0WR4>ZU[2:JXK;QBK\[;;'<JAD?+>'I.[G;+7]KBJU1\'
M$W-ZU9I1R<U(QLQ!3[>*LQHYNDW/*18,'ZJ21.XJ8Q"F+^EN/:O79^XR=WIM
MGN-+E9Y:<MN!.R*/)<UH8)7LDBF$<]C6L,\'BE<UK;G$@$?EZ3W>V>NTF+H=
MYJM)O</7!PPW;''?-)BL<XO,3)(IH720>1SGC'R/-"USG6L <09EQ]0*GBZG
MPE$I$46'K5?;J(,&??<O%SJ.'"SU\_?OWJKA])2DI(.57+ITNHHNX<*G44,8
MQA'7M>.\=U'%-+!H-%$(=7CM(8VKG&I)<][WN)<^1[W.?(]Y+GO<YSB225X/
MD_)MUS'>Y'(^0S&?;9+@7NHUH :T,8QC& ,CCC8UK(XV-#&,:UK0  %\K/'=
M?8Y*G\JH'D?:>QTZM4:0(=T0T4$+59>R3469NR! #I/A>6EUW5!4,!R 0 *'
M2(C5!QK78_*,CET9D_E<K"@Q7@N_;\6/)-+':VE0ZZ=]SJFHM%!3K=/RG9Y'
M$\;AD@B_A\3/GRV$-/D\N1%!%)<ZM"RW'CM;:*&XU-:#SM6/8&X6''EFEC2!
M9+&-DD;56P9NBH-CR<G59^G.2R:)D51=M0B+&X$I ,F(+ 0VX@7I&=MQS7[K
M9:W:9AD^YU64^>&UU&WO@EQG7BAN;XYGT%11UIKTH>=-R?9:+5[3480B.)M\
M1F//<VKA''D0Y3?&:BUWE@94D&K;A3K4&^/8!MDF6RHF:0]IYFDP-!>$,Z*,
M6$%79RP6"/,BS[('3?B_LKD%%>X(&3 A>D.G<9CXYKXN3S<M:9/Y6?!BQ'"[
M]OQ0RS3,HVE0^^=]SJ]1:*"E2EY/LIN)P\->(OXB#839C3:?)YIX887U=6A9
M9 RUMHHZXU-:"PT^/-!25;+%5L'6USJ^Y#);RB0A[?2+*08.$CAY+QKX(2:G
M2U_+ W2/<';8?/M]M^/->UX.3<S?NW _<']V]KV$?3_LT>:1]ZT^9>D?[H\E
M>Q\9;BVOXXS2']L_V;'L>T_7_OUC;63M2OR=5YLN/E"8.(%R@K8.Y7,TW#/,
M?W)-(Q1O%X;VUM-)N !D'=@BIW-YV&P=)DQ!/=0W2/5,'MSQ['DQY8SD78V\
MR=JRKQ_=90R&R@_+UBIDR6LZ%OR_,:=><CW/Y+DQY,4@QK<K08NG?2,_VF([
M&=$6_/TFKBQ7OZAWS?**]/AD^->.)6K3E75/9FHRV4;!F:.LD9.JQMLI^1;%
M+/)AQ8*?.,T$58A1HN_6222,59([551!<JR*BA#497MAQG+U,^J><IGFVTVR
M9,R4LR,?,FD=(Z;&E: 8RTO<UK2'-,;G1R!['.!TXGNSRK#W&/N&#$?X-/#J
MWP20B3&R<&"-L38<J%Q(E#@QCG.!:X2-;)&8WM:X?70\#0]1MJF0+%=+[E:^
M$AG%<B+3D:2A7:]8K[U=NXDHNKPU9@*Q6H7UPLS0,^=)LO.O.PF558Q"%(%W
M'_;_  ]/N#R+99VPV_(! Z&.?,?$XP0N(+XX(X(8((O(6L,KVQ>62QH>\M "
MHY'[D9V[T@XSJ]?K=+QLY#9Y<?!9*T9$S YL<F1+D39$\OB#GB*-TOBBO<61
MASBY?>SP526."EN/**DY[ KT.4QV=4\BF:P^S\M'NXUT<LH#0$@D0;/#]"O9
MV*;8>D=MM:(> :*#@+O;=AR/_'G:]^&27CS>&1CF._<MI?:XT=;T-.BS3^XW
M(<CW&;[HR#&_\E;LH\X ,/A\T;VR-_;NK9<T5;?4BHJI;CV2,:P91S<3BW8-
M&S) 5# =046J)$$A4, % Q^A,-QV#<=>PQX&8N/'C15\<;&M%>]&@ 5^- O$
MY61)EY,F5+3RRO<\TZ"KB2:#\*GHOKU<J$T1-$31$T1-$31$T1-$31$T18_Y
MXXR8CY%0Y(_(=>*>69HG2A;A$&)'6R"ZA$W2RE2I*>89]8B)FKDB[4XB(BGU
M;&#IKW-[+DM#NZTB9O\ =IYSQHJ[D\?)IY@J:8G42-!I$8W1H@ _)*^JZZQB
MR"A0';JCUG!C[;]DGHUH;*T]^A51C([=5KUE(R3@Y!>)G(V0A95J<R;F+F&+
MJ+D6ZA1V,1=B^20=)& ?Z1 U9W7"^+4HFB)HB\3'*0-SF*4/1N80*'_6(AHB
MR(Q%Q5SUF]9N:BX]EQA5S@!K;84E*Y4T4]P ZQ9>233]8@0!W$C)-TJ/P%UP
MY[6]RI#7'LMR_'3W:&,\7KL+3E=VVRM=&IDG+>,79BA085VF('*="&<B=>Q+
MHG+N59_^9^$&Q# !M4/E)Z#H%:V,#J>ZV9D(1,A$TR%333*4A"$*!2$(4 *4
MA"E "E*4H;  > !JI6+RT1-$31%C!S RK)8GP?.NZPI+AD"^2L#BC&R==AIB
MQV-.XY#D4X%*=A*]7V$I-33FAP:KZR+H-FZJ@LH=<W2(%'12T5/P6N.'S%=K
MK-8&Q'+3V5I^4Q<SY1XVR,2VYHR'Q%N]R+CB>X\#B#+5Y4(E5K;,6&T8?OS.
M7.T=-VZ2[R9=K$+LF4P%W0=3_P 5>N/[]DQ[RI3KA)C*=?:.^5>88)ID.ZYB
M>S.%KICK'M<2;.\"UC%SNSSC9GD[M/$I"/%6)AG*[:-D))&0>>5=M52$"W]%
M)V?N4EY:97K-!K3RGU"OUSEQ@/#\^R<7AY&YGNQ;$PK61)->M48L3Y.6HU@A
M)08P$1==]\BW?.2F(1MV52@ 4^-%2*-S\R)>V563)C"EU-SE%Q0STFV6ZY.X
M[']%+>H7(%A1K.5G9F1)L+>VCZ"9JP\@W3CYN9>>137;*-S'5):%:5MYC9$Q
MQ<,IV4BM=OQB5B'L5>JD#DKSV)DY6-X]QUO78P%K&G.I*1JL_9'7<"0;MFAR
M )EC(.! $M$#:J3+YS:RE0'4C19/&=*=Y)K5[R-6K#+,K'838T7CJ%BW%67V
M16#]>#0FHZ?M=;R^P;@DY(9".&-D7ASKH()IJD#0>OHLSS96DD8#&TXMBK)#
MD+[ ,YR90@VU7F@QKYB'CY9PSN1T[0U6=K-!>G0#U,E*&75;J D4P"GUES1:
M9Z5G[.+BG(TUKF2/9V+/]6XW*1>3+#F24N59I"%^G,IRM]R7:)OU$P+Q^O\
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0JU?3'Z#_ "W]V>>T3T7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>78
<FILENAME>g382677f_75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_75.jpg
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MQ #1  $  @(# 0$!            !P@&"0,$!0(* 0$!  $% 0$! 0
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M:,.Q+UY&2F6,:1LC'.5V4A'R%[J[-ZP>-5#).6CQJXE4UVKENJ02G3.4IB&
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M<M:T5)/ #M)))J3Q*[5\4^:RVX^GO3/.YVXDNLO>8"XFFE>07/DD?;.<XT
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MW5DJ')SVY9.0*!TL+W0O?3L',='KH. U4' +E?7S8EETUZNYO9^+J,3;W0?
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M1_LV\*DA>0\Q;7-UN"^9;1ODD[W,:-:7&G,=QH 2LO(<BA"J)F*<AR@<AR&
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MP34#M+)@QCW1ZB USFM>W7H+M#CI=1P($4RF!RV%@L[G*0F&._MA<0:BW4^
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M;6RG0;I;N;J9U B?CLUG</+BL393#1<SFZISIW0NH]D40#7>>&FC75 U1ZY
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M=FMD88V2G:-8=QX]JE'(N-:'ENJ/Z-DJJQ%SJ4FHT6?04VV[2R678.4WC-<
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MRV=^@8>T--*:@G/.K_EL[] P]H::4U!.>=7_ "V=^@8>T--*:@G/.K_EL[]
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M2WQ2]G,)+2T)(7:T)R$+*2,/()DQ];U2)OXIXNP>)D53BS)JD3<MS !BB)3
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: -.NNUKF_P ^W^,!_D6[W7NQ?GJFB)HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>79
<FILENAME>g382677f_89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_89.jpg
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MQ #!  $  00# 0$!            "08'" H$!0L# @$! 0 # 0
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ML):Y7)<(7/?Z25#-B"U+:I9Z*% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M:[A4N#IW/*10'.8)",M5X:!HZ/.MNIK8,H>2BY07*/&98)%-X"EL,-HCYF\
M.;X8F1[1-_FZ1QTE7\8R)>92XT$?##$?:-G2U5IR9&,KW"YM<EDDO)J6*8AV
MMGREL[#Z^G'1?'1?6**3V9.W3:)-USQ[WZ)L;,G;IM$FZYX][]"QLR=NFT2;
MKGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;
M1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G
M;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"Q
MLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWO
MT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>
M/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$F
MZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NF
MT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)
MVZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L
M;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][
M]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KG
MCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)
MNN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;I
MM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR
M=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+
M&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>
M_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZY
MX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2
M;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ
M;1)NN>/>_0L;,G;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,
MG;IM$FZYX][]"QLR=NFT2;KGCWOT+&S)VZ;1)NN>/>_0L;,G;IM$FZYX][]"
MS][-G34T>>L3\IKZ=;U8/#4Y/5_:ZGK=UM?6\.G6T:/!H_#0LNQ1!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*"/9U>U9]GNR7.Y&8Z>)MFH[G:*\KMAR)!A%? @Z4O
M()\PEJZ:.(6:PY<08B?*B!Y7#SSPO?'3CE>VB]3ZR.A_YO\ [-K_ /:QD>\3
M^ZHU/KEL,L(!XFX(XI&TLO" 9&29*;3>7LVPLJR.3628!!>P3B*MFG"AK:8E
MF,QL4]3 %TX898:!+6UM-KVM$Q,:B^]0% H% H% H% H% H% H% H% H% H%
M H% H% H%!;MFR[%DB+#E;["D5E/-<9IC$JZDEL.5(6U!OCYF#9/'!4*IYLP
M*4M<ZGF -;*UL;&"XH6GE \\<29B8U4V7XC8!-M5RODI,\9&F<SE4!#=+F+/
M5OCHJ$LFQ00"*6I* 1[,N7/*(QD/$J%?+7,Y"8V"MGK6TBDNS%G.%P3; ("R
MO'F)R52Y8W&A?SO0KB/PJ=R+ADC34MB>OMPN>&-A!@9E]?$847 /"^6>6.-Q
M25U:(*!0<4\< 3B1Q0-97P*D"I@X9SQQRSRP *@YCC98X86OEG?$/"][6M;3
M>@P1Q]I=PDYXXYXO1Q:N6-LK?\!NVW@RMIMX-E_L7K3^K-3^S%_?^99PE=-'
M%Z".S_==/ZLS^S%ES&$F-&8&0BR&Q3IE1:Z_S[9APV0-IA@79RB;2C7*$CP0
M)H'4.$A,;:V-M:UK7MX+VJDQ.,TG5:)B8K"OJA)0*!0*!0*!0*!0*!0*!084
MS[,<A,5^XH;96"Q%,N@IIZX J2FG<N<F!S^ N?+&BXHNC+$#'P:=%M%:8XQ,
M5E3*9B5D_P"LK,720EZ/HGB57],4>TKZ</DP/]^O8\C.A7+GTX%NG% ,$)*3
MB66)H$\G X"7%*%PA;VL&8SMJWOHOI_L53/&(BL+8S,RS.K-8H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H/-0XO/K9\47VB9I^D9Q5O&D(8
M\5(W&?NX7U5IS^T0<^C2/JRSU3#8=J@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4$;S):\K+[XE-P/KA_>458K#56^'V#4I %ADZQX^BU=4CI@P[%H=B
M2>K+YQ<=RZG$UA5M=-*E$5/ )DB6 YNQXP;+33=0+7A.<R"C%4CG81,E!X/1
M.%9G&XV"=\:CN&0?4JQ>)-F.UT,DX&Z<66&F$#D[$#B#@N**.>-A(XW+ D!;
ME\,B:QI7=U8'#5.9-$7VY>,2>6<WIC N;44]UL[-+@LR@\8TV<12DE.JQI53
MU%6+I#-ETJ6)B-DNK8#+*1F%J@EL@#E"L?YX2A.HK(!C,E=D+;.2 \,1]HXN
MIK+;CS'RO<+FMR620\&M8IB':V?*6$L-?/3CHOCHOK%%);-GKII$.[)Y][=$
MV-FSUTTB'=D\^]NA9T+J3ITLUW+<P\HFS LWUJXV ,:/$,7,.R:9OG@&)G+
MF >>5O!;*^.5L?=T7]R\QK")I1J2 :.0!T:;6Y(/1:]]-]&I;1IO:UK7OHKN
MEROK0;&W :2EL;A5C 1KN:.4Y$RL[.9DUYBN9950K6>KAL-SI23Y$0BAB^9F
MV>6.H5"U<+XXWUKVOE?C[.<NCKIZLOMFSUTTB'=D\^]NJ+V-FSUTTB'=D\^]
MNA8V;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3
MS[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[VZ%C9L]=-(A
MW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FSUT
MTB'=D\^]NA9@SQ#@ND"0<,'>I("HK^;Z9E8TVT510$WFES"AR 5R"HON0U<S
MAG;/7$YSJY6OCHPQT7T[=?%GEJL55U5_N'(!V#OL_@S5-NI2K9MG<A3+F0U-
MP$,B5CZ;84(,DE.%M&,#60M\+XB7,988XVRM?"][VO:G9Q6QU9N[-GKII$.[
M)Y][=8M+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ
M:1#NR>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-
MGKII$.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="
MQLV>NFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGW
MMT+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ:1#NR
M>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-GKII$
M.[)Y][="QLV>NFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="QLV>N
MFD0[LGGWMT+&S9ZZ:1#NR>?>W0L;-GKII$.[)Y][="QLV>NFD0[LGGWMT+/[
M9-GG3;6>D1:NFVMHC%Y:=&GPZ-,MZ-.BA9YTG%?B<QXI^)?%1%+#J&,_S#B?
M')%Q2A(8[:07!8T*3*CF3HY8J(-K7##S&&SPQO:U\\KVUK[QI"JP-2-N+[O4
M4D<QPP39DRU]DI)'&?S6)D!T-%=<)H4WZN6)?,4 TDO=L @%^1N'C8/($3+6
MMEEKZ+VQMEGK^)A/MLV>NFD0[LGGWMU1-C9L]=-(AW9//O;H6-FSUTTB'=D\
M^]NA8V;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=
MV3S[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[VZ%C9L]=-
M(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FS
MUTTB'=D\^]NA8V;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8
MV;/732(=V3S[VZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[V
MZ%C9L]=-(AW9//O;H6-FSUTTB'=D\^]NA8V;/732(=V3S[VZ%G[V;.^IH\\H
MDY77TZWJT>.IR>K^UU/6SK:^MX=.G1H_!^&A9=NB"@4"@4"@IQX_T1=/Z.+G
MP8:J8U1.C3*+_FX'^9"_(QKNG5S/M0;/?L[_ *H,3?N7C\>W-7'V<Y;X<6:]
M47*!0*!0*!0*!0*!0*!0*"-KBK^5/#]%D;^5*M;=?%3+5C75U63_  F?*6I?
MHBH_":15.SBMCJD:K%<H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H/-0XO/K9\47VB9I^D9Q5O&D(8\5(W&?NX7U5IS^T0<^C2/JRSU3#8=J
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%C@N(^'1HW5)8Q<REBRT9U
M^8BD,,RGX7<I9ZW=9-CAM+S!';(;]&<AAV* !($D&F9F!A1L+AX98Y6RN32:
MT?T3B/AHNNLEL'G<.E."0": >;J0MM9XH9X(%V*!M(:03H!5V^2NPSSN62 Y
M%)++NS3*F>!S+E0Q1L,@["DNT8<\1+)KD7VBQGF27E]MX'!SY,(DKD@3I%.6
M3+<4U9M**DG$DQY(:6XB8B>:/I QXF6/8\@*+@+>V%Q,3&J[E$% H*<>/]$7
M3^CBY\&&JF-43HTRB_YN!_F0OR,:[IU<S[4&SW[._P"J#$W[EX_'MS5Q]G.6
M^'%A;[425I/CZ1XK(L.0WHS"2BR5LVH%&PXU1%+'30*Z""$9- D# . XX865
M\<<LK7O;&^BM.F(F)K$:J]DS$V1A?UE>(KMVEKT]<7CU;>F.T,_;+>69/ )-
MLRO+BF83==\K2$Z$ XDO<0VBK[L655+,B%&DJF2H@Y(X;%+BYEC >(F%[XWU
M<\;7MX;5GV8XQA6(A?"9G*\MAVN9L4"@4"@4"@4"@4"@C:XJ_E3P_19&_E2K
M6W7Q4RU8UU=5D_PF?*6I?HBH_":15.SBMCJD:K%<H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H/-0XO/K9\47VB9I^D9Q5O&D(8\5(W&?NX7
MU5IS^T0<^C2/JRSU3#8=J@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$
M?;J@Q_F&D_&2<C%$DE/<'$$YN( B#ZV'+&9?,$K)#>7VLA N1K8%'"FO'FV(
MBF#;(,9(R%3^:FA,<3&(N!:)C50#:X9>(9+,$TE9Q:ZZDR K</"T[7"JR0OK
MJ_%"1P_<03EEU(8X9Y:;)A;E\;%B'TQN$UDT9(FACA,4T<M?&^-Q!6/A=KAT
MA"66(ZXU ?:6T$QL0##<@PPTUU!<AI94I-">SSC=<*.LXBC(29BS@4U!C K8
MP4$,G1!%%0&QPSN 7P&,"9B=/EEH[4-XK&9')JOFS.P+XF+'<+MA,<//\A+@
MW SUE$<&Y7FUL,[:,-.OK^'W+454?YE2]VW8[M&UX[1-8V/,J7NV['=HVO':
M%8V="Z69+0;7<F8TT8C@X("SD*#ZMVV'RN%DTS?(/7Q.WOAK6\&FWN4C5$S%
M-&I6!HN #HMHMR0>BVG3HMJ6T6T_AT5WRY7UH-C#@0;$C*/"O&!Q E+%N)0N
M+KYLCW8Z&K\TU'HX0Q;;1-F@S!CEA\<A-.5K:NOJV\%K5Q]O.71UT]6"'M2$
MET)$CQ2$Z7=9WF160N"%3=F^GM_F@.*\#CF!R">,-@8Y3.]LM;*]KXZ-%O=K
M7IXSY4[=81?5NR9E< )%94N*A@DV^NV;2J(DO?(NL72RJS8M@&TE7,?#9QP0
M(N-S@'&^&F^5KX:VM;PVK+MX2OU\X3[/Y/F5EL1ZO$M,150,--I.-RER!N-T
M ,J='0D<XJ!%#.9=0#,8%S(A6V&=P\L<[8Y7U;VOHO7-$5F(^V\S$1,T0N8>
MU/XH,\,,N:15;6QQRT69ZSHMIM:^C^EW]FNG^G#[8_V9?3]?\TWB@_U2*_0]
M9ZW4_IP^S^S+Z2S</#AFV<(98DJJ<II;</O%/.GC"*CQTD&$U/R*+*DEXA%!
ME)4,GA,,PR%L[W$$ROK97T>#1:W/GCZY3$:-<9KC$RP>XX^)+B8X=Y/;#0:T
MO8&B*PQ2SC,9W83.+:IL5>6TW+&V!@@J9Y?O2?C?3;/&WAT:O@TWTZL,<L:S
MK53/*8FD,,/^8=Q>]JH?H6Q^KU:_U8;*?V9,I^#?BKXGYXFXG'KDES NEF&J
MY%C(6S$9IC082L2'(6Y,!,3A/=,WOIY71X/#:^GP9]F&..-8U6PSF<J3HEQ\
MRI>[;L=VC:\=K!M6-CS*E[MNQW:-KQVA6-CS*E[MNQW:-KQVA6-CS*E[MNQW
M:-KQVA6-D*7'UQM19PPST%&4T+[[=SSS8;;<V*LVV D@)UD96/KQ8@4O@67R
MH?.0!DT:^=]73>V=O#>MNOBSRB9FS"G_ )L7"G_J\M>@I#K15[*TR9T>SYXS
MHSXIIL7([A-Q/AGNU.CQ8=1M4<L?HXY 5#(+C=3C1,/ RO&\+&1#:L!GC>V.
MG5PR\-4[.*V,3$W3-^94O=MV.[1M>.UBTK&QYE2]VW8[M&UX[0K&QYE2]VW8
M[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&
MQYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[
MM&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&Q
MYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M
M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QY
ME2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&
MUX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE
M2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&U
MX[0K&S^V94O6O:]YLQRM:]KWMZM6U;3;3X;:;'?!IH5C9YU7%>$9 XIN)8 Z
M;V@<!GZ80CA_FX9/GQH.0'!@8.<T!RR!*\Y%M?/D\+WQPTZ+7T6K>-(56"J1
MMO?=[D![J_##-@S7D"S0*!S\9"')W:B2X.<&;1RQ<\S7.% P"(#KAYX8:EK7
MQMR>GW<KUEV:IBB?/S*E[MNQW:-KQVJ)K&QYE2]VW8[M&UX[0K&QYE2]VW8[
MM&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&Q
MYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M
M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QY
ME2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&
MUX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE
M2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&UX[0K&QYE2]VW8[M&U
MX[0K&QYE2]VW8[M&UX[0K&S]>9<N<GJ^NO'7U];E/5LV_P!IJZ.3U.>Z/VWA
MT^[^"A9>.B"@4"@4"@IQX_T1=/Z.+GP8:J8U1.C3*+_FX'^9"_(QKNG5S/M0
M;/?L[_J@Q-^Y>/Q[<U<?9SEOAQ1W^US^5&'_ - 5_P",0%;=/&?*G9K")2MF
M;.7V;_UOHY_F9_\ Q+6*S[>"^'*&PW.7R)S#\UL@_%)7KEQY1Y;9<9\-/L'_
M !07^;P_)M7<YGTH-I/@(^J'"?\ ,"Q\;7!7)V_^DNC#A'A%I[6;Y?6#\TA'
MXWNJM>GC/EGV<OQ%O6S-(1[,/ZUR5\WSX_)1ZR[>'ZOU\FR57*W*!0*#2%^\
M#_7]+?,%&OP\_*VPXH0AU83Q?=X/KP/C[.CR^/4<53/3](;H2PLI#>3#JVO*
MB<B(R:!D:4596.ETY-(%L-&N8.'C8@)8L!AI\.>>6.-OV:RUM&J5LOZP<#=M
M44;PFG_O:K>N6THK!?B#@:WAO-446M;PWO>0FGX/_P"6IZY;25A=4B>)*9(F
MI)ILLH)R@5+GB!\D.$:)G21L+ <J;*&0,LP3!8R )CF'GAE?'/&]KVO>UZJE
MRJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>:AQ>?6SXHOM$S3](
MSBK>-(0QXJ1N,_=POJK3G]H@Y]&D?5EGJF&P[5 H% H% H% H% H% H% H%
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MPF6F]_#HT6MCERE+#/VGR.MHDW,@JO.Y3>1L2+B0X2DJIC?2ARP%W4YL+$L
M&XEI),0+$3#+.V>8>0NG.]M;5M:UM^GC/ECV<OQ&Y6S-G7[.9,55?B:3B2,Y
M#[3/9,1YB8K":015$U@&'BE:Y>Q9?3E1.N&/?*VME<*^=M71CE;3>LN[A^K]
M?)./*S;>#9C-_.)?FQUJ"(B-%?5%8B.T8\P -IY%-,&#9<7-+: "EB&, 'EC
M>X&> UK7_$O:^BN;'E#>9LAZMQ$Q%HM_Q(:]RW_H*WXC75ZRQK!_6)B+I*:]
MX%OQ&GK)6$O<.H#L=D5Q^YFW-3K34%=:B.II! NTH^$ )D#90,4L7!S5VB85
M,@PP\K6M<P)F+?\ PKWO7+ERGRUQFS41]O&EJR/QV%B:TYE%VG?45' NUE,@
MB)QFP62T]\,2O-F^FI1#D@Q,,LL<N2Y3\>]KY7M:VC3#B2AAJXG ]@,DK*SQ
MH/4HANI29YO'A^=XV:FEIR"IF!0,7I'V&13(!PIBL2Q"S$$QSOEB%832':UL
MK6O>UZ9Z$-BWVFK,?"=P!<6!U3E]T+Y(O#Z^(.D'&S'I(J>#L*3OD .92VH2
M4 @\\=-KW"%#SMITVR\%9X\H2T$JW0^0W^)%_#^]">#]G\2]!Z*W".QW^:X4
M^&4R4FMUII4QP^PT.63@&G&HP!  6.FX("3!&-M P;%"*AY6#QR%$S$RMCIR
MROE>]ZPG64H;/:%IJHD\43J(K#B/.H^&V&3F(LJ)%'3C8^ B+CD&#F50B"8F
MX8E\?Q<;X@VRO;]M>]_#73U</UAV<V$M:J),_9=(JXMRW))=!>"HS#(,<%QA
MCZ4F-U4&-@^<Z=A8H*"XTE7*AA6SOKZP>& FFUK:VC3:^/=QCRTZ]93?>K^1
M^WAX^A\6]2ZYFYZOY'[>'CZ'Q;U+H'J_D?MX>/H?%O4N@>K^1^WAX^A\6]2Z
M#7&X[""BE\5,H$59=..4^!=I<NM'R:60-G.49;?$"Y4HBDDY-"Y +.P=N3!P
MUL<+7RTY7O>_7U<(<^?*6(]:*)5?98(:^N.^90D!ZJS+%+MIFYF#"2DMI5S/
MX"*J_8((?!R(ZP$#@7OAE>UP;!Y97S_&O>UK6K#OTCRUZM92>SLT7FDQJLGE
MB5G&Z2 9I(Q%15%N,-/*&<A%0K@$((:0VRFJ0>1<3*V>-L!L;97QT96OC>]J
MRPY-,M& U;,W]M[MO[=O[]!*@58,BY%2V6,ZO /'(N#ECA9H1=>V&-P\;VPM
M?)F7RO;&W@MIO>_[-<S5;%;>[6;2L>07'QN-IOKJ6-8NIHJVI\/Z4K)QBX>
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M.^.8.O="LJ$+</"(([WV.OJ3W/1^LMEJ)J(AF)GEX<(L; L[0GKF<)BO+$'
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M&GM.XOI%G _PDPB974^&8P3HK.+X*6=<I&/'H^F@862Y$0^ C&EHJ@.PB(>
M*BBFL"^8V.6..60ML+Z=:U)F9*RYK<@UAMJ/T0I-RZI*JGM R4.GW=,LBJ"*
M?4#ZXH9MXN'YQNX$B94K$!P00+<ERVMC?'#3[MT3,$W\*DQX?^'+)9$;N+=1
MLG $0Q514+%X+]UD-+S&YM@I")EG%SW AF8_>[#7PY.^?XNG3X*GVRW13Z=
M/%G"422"[C,"L@FA&%(1)*+PLE'RR4,L%\Q<14TLJY.S IFJ%Q"^=KA8"<MA
MD'EX+7QOHCVRW*?3NE?A_3C#W9*DDK+] 9Y!.=X;M3;S5,.(BH=4 43%L#X
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M^0H*C9+9D=(<N'SRZ[Q49N(9P9U2W(*P"OOD)$+A+ J&&XG;H.J2B< '$M<
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MG#5N5"(@"F\2N/AQ"PR$\&-KV5F"LRM00]EE[,A5,*91+X7H84C:*;L062I
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M2[EF6H8G="9+>18?7FXVH2XE)+>^*]@5:K:?*:AJD8LTOB(D"%GF*7(%SIA
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M0LT521[OR1U.3V6UVB? XFWP\G*ORFF1XI-I,3!'W&U\#P5RB@9S50BQ8(H
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MJJ,>+21,7M:&3<2,HC-0DF9,P D;EQ2 BK-N^J4I,H:[G('JO$</G".WQQ2
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>80
<FILENAME>g382677f_96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_96.jpg
M_]C_X0"B17AI9@  24DJ  @    # #$! @ >    ,@   #(! @ :    4
M &F'!  !    :@        !!9&]B92!);D1E<VEG;B Q."XQ("A7:6YD;W=S
M*0 R,#(S+3 S+3 Q5#$P.C T.C0U*S U.C,P  ,  ) '  0    P,C(P J $
M  $    * P   Z $  $   !,!        $P$     /_L !%$=6-K>0 !  0
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MR<H_$G<NV;KMFO;0W%6FF=Y>J><" !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( _FZQ8MYK\&\3^_P!C
M(Q$/N'P2;-.$#,69CI8L7,RC2J+AV&*3.BN%1F+ ,:;-#BLG.:$DFYXC< Y&
M%++7HHQ2-DN#XC %P4&R4*#> 8+-FL0AG*C^JVA97? 6,QP&H!8V+6"&("K7
M+-YEUPQXFPH@8Q") )O]A99V<EI1Z38>&Q9LWJAK* 9_#Q65VRTL)-K5 S:$
M6WLZS;*JI9O$"U9MFKPP-H1>UVU8J&X$LQB(>U9-FU4VS:(IIBH9;Y%XVV.I
M>0+YC>(\<%FV6L#>,0LVQU2>9N!33R6;9;S-(Q!K59S+)XF\07!TL6=VLBED
M:"JR :A!JD5LW6K*UN"!*#104E)9(M*"P%AUI2#8Q$4L P6;)- +*44MB;+J
M2<RPB2DVBDGF;QC<VN_4LVRZUE?I&@'@H;*F,BZ1)<1+@D4MN4M@:>Q9-C!C
M@5,A)H([U,DXLN(^B3927%FL8TJ/10V4DWB!RWU>".H.EDQBS. ^Y)L:4&@#
MZ6J2H-!$-4#P4-C+) " !  @ 0 ( O"A?4D\B;8J#908M8RRAJFC*T/(HWN5
M]1DZN2K,7%HP5JTJ&97I@>2]N]R=1[?YW)Y[IW,YO+YV3F1G]29@28FYC?@J
MT=76VFLM?;V==1.<#X]WGLNS[OM;;7>45J636*/KU^%?\9F9DSY+HG<7.F,P
M890GF9@'%7AJYM#V+]%_#7XL:VRU:;3>W:R6+9^"/C7_ /K^K?2;_M>G-<7@
MD?:CLWO3I7=O3<CG>3YC*S!FY<91X)B3N!96MJ_:G8/,.T[UM:ZVE9.S1_/G
MOWE_>]CW=MON*M.KC$\T7R,\ E  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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M=P[#N[Z.YT[52;S3YGZ*OEI\6!, 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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MC_0!3B-PH ;\/)9VS@T69H !:*J&SHK52,0 9[\5#S&\XB4,BVJR-JPV-PJ
M^E5#YFR7 WB&)K\;5#<FB7@-90OUUV+&X-XP-1%0L6:)0I&("HVCU6;+JL)&
M '("&X0#$0S!9,UJC0*#:J'8Q %/#>L&Y-'R+BT;4A#,0!8LFS6JYF\0*7/:
MLVQLWC%AC>LFY+53>(W*&S98&PJ5 +,VB*"FCK-LI(WC%9MCS-XB]9MFCR@U
M@'KN63<LGP&(B_RP65WPX%+ UB'/@LVX :B&&M@ZP;D9<!(I*2WFD4;0CJ+"
MH\5G9DFP#E0Q,T"DG,TC&M?I4M\BDH-@ UGT+-LT2X\34!JZE+8-EA4A2(U
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MK46IIM.K/H?4T[Z5G2ZBR-EJ0" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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MT <@*7@B39FHLK-C+Q#;UFW).9I&+E2V-*#:(99MEI8R:@/9;>_DRAN#0U%
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MI&C^:/G#R3W'RUO;Z6MIV5$^*/V4$$.*@WKY]GBCX$2F ( $ " !  @ 0 (
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MT6IIM.K1^?\ 5T[Z-W3435DS=:D @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " /YPL;:DLOP.S_0-5&JDZ4H0YECZM&'T!86S"F6/,:@"
M*W,H;Q.FL1@,QN4,VK,2-Y0. :F&M878?E&HC5>LF6LAB *CQ+KS',MGI:QI
MJ?8LK3QR*69N%#-:YC&4'EL6=W"-US&;%B!ME@N]P\#M469I5<AJ(L#56+97
M'P&HA@V"R;DTJF;Q]RS9L\C> 6;81R-HQ\-"LVRIA>(S$:G639HE"Q-H!SN6
M3;R$,Q#:.L+N7@4;Y<.(O5@;EE9P T!<LAEE)H;9<78^>MU%GP)>8Q$/N6;)
M;-8ARQ4-PA54C$8@!@LFS6J4&H#*&P;DVB SVZ74468BX#VK%L&S4"Q@H;!*
M1B,6K>LVY-4N)M&-Y^"S;X%%U(&D0/)[/:I;%#;Q- #3!2V/+ U L6;?(*J7
MB: 7!2W&+-<$B[!9NS9,EF)4R*47 922R0'*0F7$;TI%+@N(O8-/12V-+#$U
M$!>H;96"R+ -ANHD!+'34D  $V(E("XABX\$G;D!81 U[:J98$H E $@$V)3
M !PRP\PB4,D0-]/!)OD!;@%Y*74Q P%B)D5B&%J<BEDI"(8$NB0(X!KTW)]3
M SX36EEME%<B@J0G)#K!0ADY(:XD$ VA4FUD20P>P,RM-P#1F88;[%:L9LJ8
ML]$Y,;+P*D$7-Y)IF#14A76WJ,K5]93AJXH=*V+6<(9A=*(>1^R?*SYN=?\
ME[U?E>8Y;G,Z.3#-RS./&1&0B;" :%KU\A[#YBWO8MS76T+/Z)/(^M?//D#M
M?FK87T]73K],T?>K\-/XJND]Y]/Y3DN?YS+'-&,,N<9SCQ$L 0'D\67[5^&W
MQ4T-_I4V^YNIA+%KD?S'^+GP6WW8-WJ:^VTW]'+>"?,^A/(=0Y;J/+Y?,<MF
M1G#,#AB#<]UZ_2.UW>CO-):NBTZM'Y=W.UUMKJO2U4TT.KI.<$ " !  @ 0
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M^L]'7JU9,["]$X00 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M.M2RJF^#/U+7BOF?B?#.,<24P!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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MXD) 2B7!L*^PTTU*R/KMIIP\R4P!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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M"(-HCV'<LVRE\PS 5L65A^@:C9H5C8MC$0X U+)N%(U\PS"+D#5[%SV?$8X
M!8L&Y&BX#D*66QF 86+*SED^DV 6;)S8Q ,,5G9EU0P RR;*;DV@/$^BRN^
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M<R,XB7U2[. :^*_4NQ[AM]_HK6T;)I^)^0M[L=?8ZST=:K5DSJ+O.,$ " !
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M1U ' ->FY'4P+"(>S=1DIP$'"*T")8P  L2 DC% !PZO)D2*4# >]F^*);!
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M"R;EFM>8U'[0VA2\F-9C<;5DS>F8[EAHZ:6+GMF;#$!4&E_NL6=F77YQN(L
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MUGO65F_% : 6#Q6;?$?I-0&L6;8TIQ-HQLIL^*AL;9L(ZEFV2V;"#UNP4.W
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MRN7YG*YK*CG9,XSA( @Q+AB'7WQHZVGKT6IIN:L^@-72OHW=+J+(W6IF" !
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M+:O/(RX=1MV-K#+T-.\G)J5C'@>>=G=Z=1[:Y[(SLGF,R RI@QD)$<+$4I:
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MIM 5!:\/L=9V8V.!8,GCB,Y8K5[%E9EUXC<!??<L+-\!C$032]<[?$D;A&S
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M>OP59C5L"IC:;D04F52*! %6#,G(Y(X3J3D<HJ1<F-%3'!-/F5)4ADQIR0@
M3 KPAMAO]J<@5,34T]/)-,"B8$$.J5FL DCA5=8Y*2'DKJY]!291460H J0"
MB8'(<(UHS'U,CA"B6@EAPA$A)'"B1R'"E+^4) QP2;YY@F1PG%3(Y) 9(3<E
MP'1,$ME@'<+>EA-P3P>C;O&U:2+J/BQE>?N7[7MD=%,CI9+-%J5K[?%<U\\3
M4Z.6*;W7,\6:U6 \*K*V1M7%C8KP[1]&U9,ZM/(=@*UV,N>QJLU(]!BP J/@
M"L+2=%<AW+%QP]RY[&U,%@.9>A6-C59#N5]G3$KFOF7P'<NY]- N:XU,#F59
MO]BYKFE!R !-ESZ[EC9E9YC5JQ('<H,*8T]?5<]W+Q-%D.QO7-9@QC+ IK98
M68Z9^([ 7Z_8L+&DX0,PLW^Y96S ;B-,/H7+9RS3)8F\0LF0V,0%ALL>FNTK
M*Q*6/@-1H10E9,H<@ _GZ+"S9!L+0H>0,W@-/587^<G/T#D [:O%<]F/#)CN
M70!]?HN>V)E?$9B-2R;,6-1%5BR6: /N6+9#<&\193;XK-LRLQF(O\%DS%FL
M1J4\? AL9B!N34F%F-1%C:EHL#'%XF\0PUE:+YB6,0#'=IZIF=F; .JR1FV,
M1B]RGTY&-F-1%@4N68-F\(Z:U+,;,8C$VZD9&5FC8!D1./ S;DVC%MOL2;GT
M"-QJ4Q/I(+Q#W)^");-A''<GZ#-V+@8)$MEQ$_1]"/20V:L,%$<R)981)-B6
M!,HOP:M]5+?(GJ+<!U)8BZD2(XI0)VY$<)U('U(L8X)8B3Y@UCW*&G,A(<(2
MAA+*F.",1I\RO!>WM3;X#ZBACN2;7RE*Q5BE)4HJ0]J3\!IE# -Z+*TE*QD8
ME\ LW9K T5O65(*<K-8%2B%8%#'!.2D^9!&*8TS,Q*"TRK'!(8(&0@".'"BI
M/F.2K%$CE$$8A.1R5,<$Y*3YE6.!3'*(0 )@1PBUD2P*<%+G?78JZL0(,3@^
MQ-- 4,:6,ZM7&F495">14D<-71& YP@CA&'JI?B$L@QP1P!/F'#36E ^H@1Q
M2822  E(I#A&'JE+D)9!CJ;Q4C5@$4FQMEQ"VC;O0*9$7$7%E5M2T>@S;<D\
M!\V6G6OF"3XI95U-2_;CR.JK<P=+*L#4K[ES7S-D=++- YN7-Q-:#L;5E;(W
MJX8Y"T:I#3S6-O\ @=5,$.PQ6%C59ICV7=M]?H7/8Z%D/9>GDN>QM5?HC>7H
M-,5C8T4Y#V6&#>6FU<U\2U,0QR LU!<^H4LAV   I;ZD+EMF:5',L'BW6K&V
M0QF-HVCU6+R)'\L?9H="N>QK$#<19K7/<EC66!X>JYK-ET^<<C9O6+S+:@:R
MXV@^6[4L;OD4L,1J.FM<K93R@WC=3:LV96&86[EE8%D-0#^/DL;%2X&X"_=Z
M+&W(@UBH8F,P%EVGM7-?-B',L5=868G\X[$8X7K!F5AK+'I[5C8RXC H%C9D
M/,UB+-;+%D68Q 7746=F969LLS(VC<A9&=AN$?#X)I8X'/9C,1446E<62\$;
MQ#[F6G@9MC$0VU-&+9M >:&9V8W 8_2I;A086?(8@'/@IR])C9X#$19@/I27
MB8MC %Z3,6S:$;#Y-J1P@1N RA8DMEP'V*R&S:(U4NJC+TF;9H 2D0W!M&#6
MX!(S=N1H!HR4D-F@@+-/8IE\"'8TX0E#9$LLAK  8X%2$H -1VI2*2_",$I9
M,LCA")8Y8&*,\PZBC' ^"3P*3!C@4AD)-2!4@&U1 Y9!B-B3'+*RCO23*5C(
MQ9)EIE",0L'@_$M,H8A$\\AR9F.HA7U%JQ4ADTY*3DA,"" B1R4,1M'M5%)E
M#$7(*3*)% @8( A/Q J0PUISB-/$JQP*"I((>OBJF!IE3'#P3D:9#'! R$ "
M ((!M3F ,Y1;2S>KK9@4(5JSXCDCAUH=IX!)#%V\TI')/#K1(I#AMT9*0DGA
M%A'DD$L!&X"W3&BEX!+),2U0=/-3, 1PL;*N,4GCQ*3?$OPG9I@LPDN(@59:
M5? DLP]N]5+$?$S)NWK]PVR.JF9T,H$W7T&.(6%S:N1T8V86:;ERO,UID/99
MLV>-RBW@;9/$=R[133X+"V1UTD<@RPL;83CD=#+8MLPP7-:3H60YEBCK"V9M
M7]6!W+NTI:L+&B>(]"K;5S7->(Y $V7V+FNP0[ 67D"Q<UF:I8#>4*N^-/!8
MW!Y#,/M#S65LB5F='+%C&SS=[\%RV-AF(L\=ZY[YD-CF4%SW9K10AL776+%C
M>8WEWKGU&749B*#7[5SL&;P6=C*V+&H!AN"Q92?#D-0% =7G18V!C,00*XK)
MXDF\;GL6=GG&9+6(U"+GP7-9E9#N6'\ESV9G>(P&XBS3<L6S&S&H"FTK&QF;
MBT7K&Q+-8QLU>:R;,VQF(\EDV869K$54^!#R&8"GFC\AA9C<0R:P,<V;PL6M
M4A6S&("RFWQ5&-F;@55\#-C,(GS]U%!A=C,12BEF#8S"--J6;DQLY&(Q+(F#
M)M2;P%12GP2R4\3,8B*>FQ0\62V: .J2);@VB/!/+TF5F: $^*DB8-HQ;5[4
M3@9NQK&+I>+(;@V$?H2>.1DV7 >Q&1)81^A*12688!+%DR#*80\62R&L,,QI
M.<2648LJ$" @AD"@&1F$1B#7J&F408@BX;D8K%@4X-=,?9:DVH H0U"EF!"A
MYC(X019[_%)EK(S,2"VUJW+*U4\2TX,S!S:VIEGU%E""+0J3 H8O]"<C3,C'
MUL5IEIE;%11!#H&G!4Q-R:8TRI&(3*GD4,;?1!4D,;40.40B&A@G,B!G3@94
MQ2AC3(,6OJCTCDJ0UMJ<CD&& \%4H,2IB_N1*&F5X3@C,<H",1Z)XC4<#/@%
M:^Y/J8$<%;:8I]0$<,L/,(E ' ?@B4!(@;Z>?M1U 7$6UG%2W($L, @ 4/,9
M"(8 E $@)I1B(MPZTY%)\2<EZ./B;5^Y+1&!UTS.ED_J;?M#UN7-?B;+(Z,;
M-+5S/,UID/P 8:7K-FG'$;RRQ&T>!6-LCMIDA[+#E<]C7&1^#!KO>N:QTI80
M.9=FFI86S-EAAP/+NC=J]9ZURQYSD(]).1'-ED?\^[F[7Z/G<<(PE)N4ZSUG
MI_-R@TPTQ#@E8"2"UZ>SW&XIUZ71TS&.IIU<^BUJOY8@X=UW78['56CN'K?2
M-)_HZ&OJ*'_S:>G>LX93*XH\@A\O^Y_J_4[=_/KL+])\%%^V;SEI?;:/M#+_
M '%VOGN?==W[ =RNP.YG'U.WK_\ ?KL/#_S,N:_:]Y_]K[;1]H5_N+M>"G<^
MZ[OV Y'L'N9_L=O_ )\]B?I,N=]KWG+2^VT?:&G^XNU1GN9_]KN_8#65V#W,
MQ/!V_;_;CL35_P 2K&_:M[.6E]MH^T$_,7:N>Y]UW?L!G*[![E,OL=OV?VX[
M%U?\2K&_:M['_2^VT/:!7S%VJ<]S[KN_8'1AV%W*W^#Z!;_;?L;])%S6[5O9
M_P"C]OH>T-/]Q=JY[GW7=^P&(=A]RF0_<^@_GMV-Y_TDL7/;M6]C_H_;Z'M"
M5YA[5.>Y]UW?L!W+[$[DI^Y] N=^]>Q_TC7/;M.^_P#L_;Z'M37_ ''VOGN?
M==W[ 9CV'W(]8= 8._\ 37LAKV_WC63[3ON6C/\ W]#VH_\ <7:N>Y]UW?L!
MN'8G<8?ZO0/SU[(_2)<]^T[Y\-'[?0]J6O,7:N#W,?\ M=W[ WCV+W%3ZO0/
MSU[)_2)8/M&_Y:/V^W]J)^8^U<]S[KN_8#$>QNXOUO0/ST[)_2)9OL^_Y:/V
M^W]J9_[B[5.>Y]UW?L!F'8_<0 >/0?SS[*L_.%9/L^_Y:/V^W]J4O,7:EC.Y
M]UW?L!J'8W<34CT+\\^RL/\ S"L;=GW_ "T?M]O[43\Q=JY[GW7=^P&1V1W#
M^MZ%^>79?Z0K+^S;_EH>\;?VHO\ <7:N>Y]UW?L#>'8_</ZSH3-_;+LN[_U"
ML;]GW_#Z&?\ W&W]J2O,7:WQW/NN[]@,P['[AI]3H>O^F/9GK_M N>W9M_RT
M/>-O[4;\Q=KY[GW7=^P'<OLCN#]9T/\ /#LW](%A;LW<.6A[QM_:F5_,?:^>
MYC_VN[]@-P[*Z_?'H8J?]\.S?R^L;=E[CP6A[QM_:F-O,7:YSW/NN[]@,P[*
MZ^/U/0_SP[-?_P"_UD^R]Q?#0]XV_M27YA[7SW/NN[]@:#LOKY/V>B?GAV=^
M7UC;LO<,XT/>-M[4E^8>UKCN?==W[ 8AV7U]A]7HE/\ B_L['_W^LGV3N'+0
M]XVWM3*WF'M?/<^Z[KV!O'LOK[?9Z)7_ (O[._+ZS?9.X\M#WC;>U,7Y@[7S
MW'NNZ]@;0[+Z]^LZ+7_B[L_7_P"/J?[)W'EH>\;;VIG;S#VSGN/==U[ 9AV9
MU[];T7#^MW9_Y>3_ +'W'EH>\;;VQA;S!VSGN/==U[$9CV9UZCPZ+=_O=V?^
M7E7]C[A.6A[QMO:D+O\ VSGN/==U[ 8CV;UYQ]3HOYV=H?EU:KLG<$LM"?\
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M (DK3[#RWW[VC_"8V7F.?UNW_NZ_\9M ]D4_<>\K?^M= _B::?87PWW[VC_
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M_M1F'=W</_7>5_U)V_\ DI)]][JW'TE/L=#V9C;L7:?J[_;:_M32/=_<)/\
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MI,I.2J3Q&"@"&MUA.1R4LHK5L"LR$/F,K)VU(0T43*((>U-. ,B&+*\P(3]
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MY]D;#M;GG'\H]K_GAVM^5TUV;<Q_-V?O6W]H9OO>VC^3O?==S[(WCVMSUO\
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M$->H9:9F0Q\TT6BJFV91!6-QHJ0X4)C1FJ**&U4BT50U(P4Y@"0%2+U292?
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MQ%=E4QO(WBL^)%BZH@U@#MLW(E$69JD9EXCQ4LELV&Q!FRRNI(*@+")V(R]
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MY#CW.GW:VKU;'5VM-'IRU-+4U+3QQKKZ:C+#IG/%G?R^:^7?^@>^+?[7]O\
MZ#+*]^U?5;G[6GL3/Z+S)']1L/=];\4/9?-?+QOYB[W;_P W]OZO^!ES7OVF
M?Y6Y^UI[$TKI>9(PW&P]WUOQ0WE\U\O>&G0^]ZDN_=W;]OYCK"U^TS_*W/VM
M/8@]+S)]XV'N^M^*',GF?E\_\Q=[,SO_ +6] O/_ )(6.IJ=H^JW/VM/8CKI
M>9?O&P]WUOQ1T(\S\O\ _0?>NL?[6= _0A<E]3M&7T6Y^UT_8E/2\R_>.W^[
MZWXH:R^9^7_^@N]/SLZ ?_R0N>^IV?ZK=?;:?L KH^9(PW&P]WUOQ0Y'F>P&
M_F/O39_M9T&W'^I*P>IV?ZK=?;:?L#7Z'S)]XV'NVM^+&X<SV"X_D/O-F_M7
MT']"EA?4[-'\K=3_ -[3]@4M+S)/]1L/=M;\6-1YGL+_ $)WG;_:SH/Z%+F>
MIV7ZG=?;:?L"K:7F3[QL/=M;\6,1YGL)OYD[R_.OH7Z%K)ZG9?JMU]MI^P,?
MHO,DX;C8>[ZWXL:AS'8?U?Y%[R_.KH5Y_P#)BRMJ=E^IW7VVG[ M:7F3[QL/
M=];\4-QYCL-OYE[QK_Q5T+]#%B]3LOU.[^VT_8$O2\R?>-A[MK?BAB',]A_5
M_D3O"S^U/0\/_)JR>IV7ZG=_;:?L"7H^98_J-A[MK?BQF',=B?Z%[PU?TIZ'
M^ARYK:G9)_D[O[;3_#E+1\R8?_D;#W;6_%#4.9[%/_<O>%/^*.B?H<L;:G9/
MJ=W]MI_AP>CYE7_J-A[MK?BQ[+YGL;_0O=]E/Z3]$_0]<]M3L?U.[^VT_P .
M<]M'S)]XV'N^M^*&8<QV-3^1N[[?[3]$_1!96U.Q_4[O[?3_  YD]'S)/]1L
M/=];\4-#F.QV_F;N[\YNB?H@L+:G8W_T=Y]OI_AR'I>9)_J-A[OK?BC2',=C
M_P"AN[OSFZ)^B"RMJ]B^IWGV^G^'(MI>8_O&Q]WUOQ0U#F.R/]#=VX_UGZ+L
M_L@LK:O8?J=Y]OI?AS&VEYC^\;'W?6_%&T>8[(<?R-W;^<W1?T04?2=AG^1O
M/M]+\.9/2\Q1_4;'W?6_%#,,_LFW_,_=MO\ :;HOZ(JWJ]BG^3O/M]+\.8VT
MO,7WC8^[ZWXH:CS'9+?S/W9^<O1?T12>IV++Z'>?;Z7X<R6EYBG^HV/N^K^*
M&(\QV4X_D?NS\Y>C8?\ E)'TG8OJ-Y]OI?AR'I>88_J-C[OJ_BAB/,=EM_-'
M=?YR=&_1-)ZG8?J=Y]OI?AS)Z7F'[QL?=]7\4:PYCLO_ $1W7K_I)T;]$U%M
M7L/U.\^WTOPYG?2\P_7[+W?5_$CL.8[+:G2.Z[/[2=&_11-ZO88_D;S[?2_#
MG-;2\P?7[+W?5_$C67S'9C?S1W5^<?1_T42^D[$WAH[S[?2_#F%]+S!]?LO=
M]7\2,QSNS7_FGNK\X^C_ **I/6[%G]!O/M]+\,8VT^_Q_/V7V&K^)&(9_9MO
M^:>Z:?\ $71_T52^E[%]1O/M]/\ #$_1]_C^?LOL-7\2,#/[-%/\T]T_G%T?
M]%D?2]BG^1O/M]+\,9?1]_\ K]E]AJ_B3>&=V<_\U=T_G%T?]%E7TO8OJ-Y]
MOI?AC.VGW[Z_9?8:OXDWCG]G&SI/=#Z^X>C_ *+(>KV+ZC>?;Z7X8RMI]^XZ
M^R^PU?Q(Q'/[/?\ FGN?\XND?HLD]7L7U.\^WTOPYB]/OL?S]G]AJ_B3>.?V
M@W\U=S_G#TC]%TEJ=A^HWGV^E^',GI]]G^?L_L-7\2;#.[0'_=7<_P"</2/T
M70M7L/U&\^WTOPQF]/OK_P"OL_L-7\2:QSNT;?\ -7<WYP])_1=#U>PK_H[S
M[?2_#@]/OV7T^S^PU?Q)O'/[18?R5W/;_:'I'Z+J?I.P_4;S[?2_#&;T^_3_
M #]E]AJ_B3@RX#F2.6)QRS.1RXYDHSS(Y9D>",YQAEQG,18$B,035A8O+MT]
M3Z95)<3BXX2X4N,W"]"/375TKKAWC&,%/&%+A<E+]+-8W[E+,[%TB3:(JC@9
MVR- CB02K$2 Z:CB#<%P+*GQ1Q\"&R5'H KC1AHZ!E6K1-M1B/TE3>H>"P*1
M"S&"FP&<K=WM4O(I9&<AY*32K,EG8L@U68S*3U:M51:\3)2W!H5*PN,A9C(E
M<M:C11444(94BDY*I/(8*!@@"I;>FI&OF*K1,9"D9!L]-J$"**BR$P"WW% &
M4@QM>BM 00U$ 0F ) "8 @ 0($#!  @0(&;1H "LWB\ +) 7%VQ(AEA:I8GD
M:)8DGP3R;5^^KGK+*3K\O0#?Y_2N2^)K7_@=+*T\5SW.G3CYSHY9IL6)UTP9
MT,HN=P\V7-<Z=++#,Z&3[O7X+GN;I_I'0R_M1Q=<U\F=J.EECS7+8T3'\L5?
M#VKEOE!O0=RQ9I:N:YIFAZ'V1JHN6V9M50AV'V1L]5A;,0YDVL;; UC4\UA?
MFLBJG0BN2_S%,;R[5SW"N0[EW:RN>QMQ',NTKGU,AUS&87::USV'89B&63,D
MY8Y%G&JQ8,M#,?6U9,EYC,:$>"QMBF(:A<=?FN:PX;8WET'@L+!8>RP67/8Y
MKL;RZ [O:L;&1N+ L;$<3:'IH?596(L-0#+&QSV<FT+=WN17,SMD-9==-;(A
M3)A<;";,EE(Q"W<EQ(L,"P;%/$R>9M'V+-F5AR I738FL4<ULQK+KI@[I+!F
M%\!N'N4SQ,+9C$;-Z;$QA,R-XV[E1C;(8A\4GS,;X#$;4GD9/(8%@V!!B\S8
M*4TB(DWB/-/'(&S4!J*.)#Q-(WJF18V  JCP,FS2(O29+? VC8AF3S+)I<22
M58%XBI1E'B2\BRE\A D!"33 "I?(#,TO%<"AX*"T54% IMF!0AUFWB-.#*0\
MJH-$S)9V-""LQF1O95P+7B9RPWK-N2US*%96*(68P-BT2Q0+,S5EE98IH:*I
ME$*) $@(-$#,RK+!5FH0 I I*U4BED50,$ 4F+#N55Y 4V*@(3 $ " !( 3
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MU,:WY?'_ +.L+]Z[M]XU/F_,:4\L>7NG^DT?\W\0]#YA]\U_I/U.QK>7O_\
MD%SV[WW?[QJ?-^8K_:_EW[GH_P";^(9A\P^^"*]S]3\>7_Q"Y[][[O/]1J1\
MGYBZ^5_+WW/1C_ZOXAF/S![XI_2?J5*6\O\ XA8OOG=_O&I\WYB;>6/+WW/1
M_P WYQF'S"[W?^LW4O'E_P"+K&W?.[Q_4:GS?F(KY7\N\=GH_P";^(:C\P>]
MBW])NI OCR]G_P PL7WSO"_]1J1\GYC3_;'E[[GH_P";^(:A\P.]O[3=2-,>
M7\?\ LK=][Q]XU/F_,1_MCR\_P#T>C_F_.;P[_[V_M+U+QY?_$+&_?>\1_4Z
MGS?F#_:_EV?Z/1_S?Q#4._\ O6G]).I>/+W_ /R"Y[=][Q]YU/F_,->5_+WW
M31_S?Q#D._N]+3W)U'QY?_$:EA;OW>?O.I\WYB+>6/+N2V>C_F_B'(]^]YT_
MI'U'QY?_ !"P??N]?>=3YOS'._+'E[[GH_YOSC4._.\V_K)U$UL?E_\ $+*W
M?N]?>=7YOS$?[8\O?=-'_-_$;COSO,EO]H^H^/+_ .(7.^_]Z^\ZOS?F(_VS
MY>2_H]'_ #?Q&\.^^\J/W'U'QY?_ !"SMW_O7WG5^;\QE;RUY?\ NFC_ )OS
MC$>^^\6_K%U'QR/\0LGW_O<_U6K\WYC%^6O+_P!TT?\ -^<VAWUWC3^D?4#9
M?R]__P @K7?^]I?U.K/R?F,[>6NP?=-+_-^<<AWUWA1^XNH7W\O_ (A"[_WO
M[SJ_-^8YK>6NP?=-+_-^<8CWSWA_:+J'CR_^(4_[@[W/]3J_-^87^V^PQ_2:
M7^;\XQ#OCO"G](NH#?D4_P#Y"?\ N#O4?U.I_E_,9V\M]@^Z:7^;\YL.^>\*
M?TBZA=5\C_$*'Y@[W]YU/\OYC)^6^P?=-+_-^<8AWQW>3_6'J'CD?XBBSMY@
M[W]YU?\ +^8QOY<[#]TTO\WYQN/?'=[C^D/4/'(_Q"S7F'O?WG5^;\QA;RYV
M&/Z32^?\XS#O?NXM_2#J'CD?XA/_ '!WO[SJ?-^8QMY=[$O_ $NE\_YQJ'>O
M=K#^D'4*Z\C7_P#P4?[A[W/]3J?-^8S_ -N]B^ZZ7S_G&(=[=VT_E_G_ !R,
M/_B4_P#</>X_J=7YOS&=O+O8_NNE\_YS;_;7NW_3_/\ CD?XA4O,'>OO.I\W
MYC/_ &]V/[KI?/\ G&(]Z]V-_/\ S_CD?XE'^X.]_>=3YOS&+\O=CG^ETOG_
M #C$.].[/]/<_P".3_B46\P=[^\ZOS?F,K>7NQ_==+Y_SC$>].["/Y^Y[QR?
M\2E_N#O7WG4^;\QC;R]V-/\ I=+Y_P YO'O/NIQ_+O/>.3A_\2G_ +@[W']3
MJ_-^8R?E_LGW;2^?\YJ.\^ZO].\]XY/^)4KS!WO[UJ?-^8E>7^R/_P!-I_/^
M<W'>7=3C^7>>-E^3_B4?[A[W]YU?F_,2_+W8_NNE\_YS4=Y]U._^?>>\<G_$
MH7F'ODS_ *G5^;\QG_M[L?W72^?\YP)3EFSGF9DC+,S)2S)R-L\R<C*<C964
MB2O(O:UKN]W-FVV_%YL]15K2JI515))+DE@BZ29!I&S>CB38V&U_)#,V65DE
M@;L?)-XH31;>I<Y<"24@!( 0!"E\@,Y"^WV*66BJ3*(46]8$+,9C)J^6Y2W!
MI63)19FA"D#.5=?TI\"ZF4K=WM6;-*Y%%DRB%+SP&"=0*%:%%966ZTT4BBHH
MA1B ) "!E"!\%2D:954I;*!)X 0?1"!%')5%X(A  @"DF  %QL?:J4R!0ZJ*
M@(3 $"! P0 ) "8 @"PDUWFD\<. &CT%]CM<IC'$"4@+Q\/:I8F62))?T9$"
M@^"'*D';LU+]]ZQZ".UR]HI^I]RX=3(UIX'5RS\=KEJKGL=5'P9TX5V+G.RF
M>!TL@4L#/Y_%<^I\YO3]8?ROM5O'G3V+FOD=".CEAVW47-<[-/\ 5.AE!O/T
M7-<W3E'0RA8=N]ES7-J+&1W+]RY;YFWYQ^+.%RN3;A@-QL&P+%YDC^19K)VX
M+FU"UD/QNV+CMQ](6',O[.F)7/;,TJ.PO6%BQO+NOTM7+?,NJA#,5BR+#,+5
ME;(51N KIJ6-F4\%XC<+=RQMD0,0]JPU,@X_(-PJ018N>Q2'<O7[W7/8SOX#
MD;E@SF8U"P;?:LK$<#86K!D,8@+/%8V,K#$;%GQ,7F,0%FEZMN%B96&\OXI'
M-;,9C?N0OG%88A6]#,K&PM"S9F\AG+'FLK&%QN-JR1@\AF%SZ.J3,+#D;!IH
MR4XR9C$;@K3P,[&HJJ61FQF-B4\#%YC&78AN3"^8U"[95*<#&QM&T:7*N!D\
MC4*6"R-XW-[DN!%C4)H@U%PO#429#-0A&9I%/B18V#7(,V65D@+4 :*2"4<
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M[>HUWRGW/N7NU_SC,.TLT,/]I>Q_SKY#]JN>W:K?>=E]O4O^^4C^C[E[M?\
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MQ_2=P]WN,P[7S/[1=FV?VFY(_P#[JRMVFWWK8_;U,;=YK]T[A[O<:CVOF/\
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M9"@8&PJZ@LS-645E8J12*IE$*) $A@@"DK=RI%+(A:("%+Y#(-Z0&:HL$P!
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M6^1A;(=C8$N)@\S:-_FGB%AF!LU^Q39&-C6-H4/(S>0S 5;2Y969A=C< Y\
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M"LF8L;C0>"PL0S2-ZQ9+&8B^OTK)F%N0R Y4US,6X&(>C*S&PY"Q)HQXC$;
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MF44V*O27Z2$P!&  @"G%A1."HYD:.GQ&0Z8RIEA1.!P53*(0 ( $L8\0!&(
MB !*/R@?##*J:BSS9JK]T7/C]'C*.KE5 \%A?,[=-R=?(%+;&+8647);,[:8
M(ZV0?JU%A\:!ERZF9TU.EDEB ]'IK*Y['11XR=7(%?!_%<NH==7B=3)MTU+D
MN=6F\/$Z&75J?1H5S6.NCC'B=#+NN;WKFL==;2AS+&Y<VH^!T:>0YEV[M/1<
MULCKJ.PM%-"N>PSJ0L"Y+9EU&(4(H^^]USVQ6>)53HY8Q7+9F@Y"H"Y[9EU&
MX+FMCZ08Q 5%VEBQMD9\1N !E72H65LC0<A;97'!8,D8A8L+C0W"W=[ES6&L
MAW+NW+"QG<=C;N]RP9RV&86#;[5E8G@:K%O@2;Q63,K#,++,%B\S"V9O'!:<
M#.PYENFLCFN,1NVJ25D,1MM^*;(9L%%F9,O&T*27D-Y9J^+>U9/D<UAB-JAF
M3R&8%F\-SK-F3S&@:;EEDR'F:QV[DVB&;1L4K S9M V765TP5IF5D;OO6DX8
M&3&(&U!E8WB;\*>2EF5D;))HS-8&[2U'&4!=4(TB:;$\$0UB:1-R3@AHND($
M #WH N"ZEDM06!(2)@'*(00B'(L4-R.""H>0 [7VJ8'$E26UIP-(H2Z;P121
M"S;@959-\AD+'%C!-5D"I+K1*!I%5113B*<%002C(9"F6 (; $AE.(JU665"
M(59("%(RIE]*<%043&"8%)2L;:Z:0%"7J50$)@5,OI3@<%"2]?%."DL"I+VT
MKA]"M*"HC(J@8( @ED9C2DJYNIYJH'!5!17BJWFG X(-3J360UD53&" !  @
M 0 ( %+?("O%ZM\48C@^&>5;N7[HOD?&]-G3R+AK]CK#4.W3>$'7R*Z6VA<=
M\&=M'B=G(#1:VCM[%RZF<G4N$#^5]H.-WA8N=G13#UG7RJ6W[[;]SKFOB==+
M2_$Z>4&.IO<N2YUZ;1TLH4W6KEN=-,1V%VWVK"QVZ;E'0A8-2X[_ *QT:;E#
M,'\0L+'56WK.AEV85]WHN:Q7 Z,;%RO,NF0S /?95]ZY[LNIT<NQ]WD"N2QH
MG@.9=&W>:PMBV4N(Y"Y<MLV#-H_:"R>1 WEV[O<L;9&BR'8"_%86? DW@*;U
MCJ .98JVJU<UBEE([EBS2Y86,KCD?98L&<S&<NP;UC8EY&UX6-B>!M .LF96
M8U%V63S,+9FT/@M.!G8<R[DUD<UQB-R7$E9&XTU:T,AC L6;<LR9:-HTN2)>
M0U&U9\#GL,QM"AY&+R&(BS6LVXQ,GF-1OW+%DLUBV]-F;-HV;U/H,WF;1-R<
MP9M<3:-@WJU;$SMF;P.G@JGD8V1O&U&:DS>1N"ZAX&34&D2*"S7C6Q$B-42P
M+ LJS0FI- =R1#1H"^U$D-$HE"!+J ET2@@'/BDW(02)"\^JAL37(.(;%,AT
MD<24#@@ER@:1"8$+-L9"SM89"Q;Y 02SIK,:*$NK2@HJX3@<,J2Z:124$)Y#
M(4/, 2&0[6IP$%"=;IHI$*UAF,$FY K)]+T(I%4QE20 Y36(%9$$&NCII.0,
MU8 B) KQ6WNJ0X*&Q,HS5%@@ 0!!("('!0EU11"!E7(M]542.)R*IE$( $ "
M !  @""==4TAI%7;7[$FFQQ($NA5C$:4%4X_*,^&N4:#50[F7[DL?$M*T,Z>
M2;-=GMIO6-L4=^G8[&174:4"X[G:K<4=?(=AKM\SM7+?$Z:-QX'3RA48X[\5
MS6>)U49ULL6:O*NM<UCII:%+S.IEUX6W>"Y+';IN8? Z&58-^[4N:^9TT>,#
MN6*+"QVUPJ/99HN747$Z=-K%#D+M@]%RV-TX.AEV#7[ES7-^ ]E6';[EA?,K
M3',JA&+>=%R7Q]!KD="%F]<MLQJ1V#/J7.^)HO$;A<N6P6R-X6^BS>1"',H7
M[O1879H\AR/V1O\ 58/,DWA=M]JQU YCF7:RYK9%_P"$=R]/!86,+C<?18LY
MV-0NNU!8V)>1I>L;9D\!F-UVQ8LQ8Q&RBSXF+S-X>U:LRL.0%GBGP.:PQ&Y3
MQ%_A-XW[$F9LW%@4/,R>9:+/IO2$\AJ!TTVJ&HP,+(9%H6;,6,0NVCU65C%Y
MC4;]RS:E>)-C06A/@0\C>)NWJ7ACQ,V:1MW(>1F\C>-B2<,SL:Q-NY7./B9V
M0P-IVZE29BS>)&-$GB9-&E0I%#1K N+23>Z!%D3 %A)D/$31<%)/@R&C3B#/
M8B43!*F4(E.4!"3?( 4@0I;Y "4L8)SZQ H=AD+-V]8RI+*'+R&D1Q#:CIQ"
M&5)=4D4E!4D!.!P45%D)-QZ0!2YX@"0$$@('!0U5I8%(A/"/$8) 5XM7FG!4
M%4QD)@9F3AF5)0!1, 3 J9*LLAI,H2+'JFD6D_D*.6;S=4."$^'B,$@*D^&*
M<#CUE4RB"0+4QP9DG$JH*@$#(0 ( $ " ()&+(QX#14EU121"8$) 4,L$%I$
M.<3XH'"/AYE1.%P7[@=IP/@VG>'#R.EE!N'%Z"\:!9/(]*C7 ['+U'EO=<E\
M&=]'AXG7RK+3=Z?!<USLT_U3J93AO+U#^*Y+&U7#GP.EEWG9IYK&YTTS.KDV
M WBFHM1<=\SNHX.CDUI@Q'B5RW.NC4CT+-Y]5SVS.ZN*',D&A%WQ6&IDS:OZ
MX]"W8N.QU#^50 /<^^BY[\S192/Q!U5++F9K24-0!)#7-ZLN:\(U6*.C"Q<C
MS*6<#N7:=RYKX8FE<6-0'H_T>*Y[!9F\!5\/:ZSMD0.Y8<::EA8T>"&X_9&_
MU6#S)&(&@\/-8:F8<!S+%AO]RY[%/!#V6':MS:USV,+C,;UBS!C<:ML]BQMR
M)>1H+1M63)X#,;MZQ9A88C8%GQ,7F;0N:U:O RL.0NWHP@Y[#$;G2%P-XWH,
M[&XL"S_Q&3+Q\REC)-AB (TN4VS,;?,-"T;5EP,7D;Q-V%BS:DR?,9B]'('H
MLN)+R-A:$R&;1M2LC)F@M00S>+ZJ+-P9N#2-NC)IX$,WB:5-<-*JDWP,;+$U
MB;E4\B&AD2!VM5226!X=A9#Q(:@T4 2J3YB+ XG3P=#:):+I$EA+%DH$T3Q5
M+^]((Y X*4L4,E)O@ *0! $.I;C "#J6;? :(<)0."A+IE)00F,J32GM3@:7
M,JGD40E.,( 4L 2 @Z;$#*'42=JM)E(A-\AD&@20(HY505"(0,CBCBG# H9$
MN*,J2 HJ$&U-8C*$NFDBH@J]'#;TTBHQ*$NJ*2@A !8@"I+)I%)243&02*XI
MI#2*;_-5D40@8( $ " ()9-#2D@RP32&D53&" ()8(&E)F22EF4DD5)$03(@
M !R30 "TDW (2;<+,>+P69XI_MUVC_I[D/YQ_P U?X>'_3_WBWSL7I_V7NGW
M?5_E?2?JO]3]KT'H?VO?_5O]6<UZO_%X9GQMROU(T=O:OV4V?5FC?@=++#-9
M6^^Y93P/4T[1!U,D$ABU/.P^-5S7:3D]'3LFI.KR_P!F)Q'HN>YW:+.OE"P[
M'\/@N.SQ.FK.EE,[7O7!EC?GP.JDG4R10FZBY+\CKH_7!T<K580ZY;^)U5>(
M] U&EZPL=VFVU\@[E6Z7KFU,CHT\&I'XAO"NF]<;9U)XC^4WF/8N>YK7(<AI
MY+"QKI9#F6SAWM#-CK7-J&B6$\#H0L7';,UXCN4;]06%^0_ <C?N7);,&;Y=
MZSL"S'<LDZ;%A906\AH%PL62,PH=RYKN1Y#>7=9?H5A8;'LI<]SGN,QL63,'
MF-QO6+)?(TB5C;F2QF(KL6+,&;BY0L69,V@']?8MN)E9XCD+MZ.!SV&(VA2A
M/(WC>CB9V-Q8%F\S(M$5=+B)O@,P.%@#*;&%E R%GP,3:)\\%FT9V0U#]3X>
MQ9O!D/(W%J1!J"R%BC-HU2(-(V!2R&:J>)F:P-G@E)G8W!9-.<#-J3>,FNVG
M5L33EF9J"X=.<8 TB?)DF0U!*0 @"P+750)J2P+[4GS):@E(0( L[6!*!0'$
M=2("$0]7.Y0WA"''!$&1680504#U9 1Q(XAK3@<,H2Z8TH(0W P4]7J %( @
M95[Q8G X**T42FW B%(S,VJD4L@-4#*2(&T:5U*DO4!F2Y=5$ 0F )I2A%";
M1HZ?B6EQ,^+1OBJ@J""70E TH(3&" *R]4T4BB8RI-H32*2XE?8J*(0 ( $
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M $.,0@(94E]BI(I(JJ:CTC!#<@1Q!$#AE'MUIP40F!4R U[$X8&9+U*N( A
M$$W.Q]$T@\3-Q>4X+*DUI<J2*2YE4Q@B ! &9+JD6B$QE"732*2@JF,$ " !
M  X3@"O%;Y)P5!5,8( A RA+[$)E)00B$EB,Y?5^L=-Z%T_F.J=6YO)Y+DN5
MRY9F;GYTQ&($0_#%R.*4K@NC9[3<;[7KM=K1WW%G%:K-FNCH:NYU/H])2^/)
M+FWP1Z!?-;YU=2[YS\[I71IYW3^V<N9B(Q,H<QU-G S.8D"#')-T+[\%^A/*
M'D;;=BK7?;]+4[HUAQKI^"YVYV]1[>G73VE'I[?'4?ZU^+\*\J_.S\0A8 OG
MKS-]-_HP\S;C'_P6WJ.E_.;=:/ XY=@(LUM38O3MSXGY^T=25Z1W*@S4-+*V
MZ!8VL>KHW61T<D5I3=LQ6.ID>IHWX,ZV2S8TL?;3>N>QWTMP.IDFHI1GWX.N
M6_/B=];G4RF$H[_0K"^3.E8HZV50#Q]RXKG51\.(_"Q<]LSLTGAB=#*J!0X:
M;5S7.VMHQ'<L6,+]/5<]\G)UZ=Y])T(BS"BXF=$\1[*L N=<]S2CD<RQ0[?<
ML+'33$<@[TO(]GN7-?#$U64#T5RLTH.91%PM9M5JPO);'8BFU<ELPF4;0O.O
M3U6=@0]ET&-?8N>V90V+5B#&(>Y<]PD=RQ751USV!Y2.P7/8PL-95^_V+&YD
M\QF-F]96(>9I%8V(L,1M63,6,!*CQ\3%C$*&FEBLRMBAN&)]+TV<[-X*.(GD
M;QL0\R&;"Q1;,S>9:-H0VR7D,0\/:%-C&V(R+%EQ,7F:QNVJ;*&9V&(FJB)3
M,GAB,@T&Y1!)H#J3\62T;1-V"EHS>986C:D2S4%MBAD-&BD@UA+%2_ BR-0:
M@J>)F;1D#[=*)- ; J<40R52<B+"1VZDY$TB[I=49DP#HZ@!T=2 $G8 2D"$
M2@!$H 2D 2D 28 C  0!!HD,KQ:O-5 X(5)+B,A#Y+(9#[/%&+S""IDZ(*@J
MJ&0XQ'BB *RE=:][ZTTN(&:L );Q3S!%2?5-*!I%"4TI*@H2^G@F5!"8P0!!
M+!"Y#6)5\**H*@JF,H2FD4D53&" !  @ = %"7N5)04E!"8P0!4EM:%B-*2K
MVX%.)*@A+"!GBW=O>'0^RND9_6.N\W#E\C*C+[O*XA]_S.: \<G(R_M9DY&E
M%Z?:>S[_ +WO*[+84=]:S^1+BV^"7-G3MMM?<MPU72K^M9Y)?GY+-GSD^97S
M7ZY\Q^H2.=+,Y+H>1F$\CTF$R(&(/U,[FF/#FYY%U1':OTEY8\H['RUMYK&I
MW&R_3U(RYUKR7SL]-7TZ4^@VZ==+B^-GSM_P62])^<PH+:DOKJOE+%ED;";7
M.H=33Z2R6 <1]NFI$#^E9XMEQL-N.S>R]+5J?G[2MCX#<(_5V,;,2N*^#\#U
MM&X]E,&;;J63Q1ZNE?UG3R &#;7O>QESV9Z>E:6CJ95L=+?BN:^1Z.FY.GDV
M@L^GL6%LCKJ\(.KE58+DN=5'B='+% 7=<MF=FG:,#HY1! N(PU;ES7E'8GA@
M/9=HW+FOD=.DQ_+JXWBCOJ7'; ZT.90+@;'\%A<NKAP.P&"PL==,,1R%[:ES
M:G U0Y"RMK!<UC:AT,IF!878+EOG!3&Q8N:V8&L+%G;,:.EEBM@#747+9E&\
M;5F\A/(9@/%PN:[G+($A[+!IXKGLP>0Y!V6%C"PSEBNG@L;,RS&18%C8EYFD
M+=X65B+#,0LF8V-PE3YS%C$*:UIF96&XZ5=DF<]AB'N4\1/)&L;2J_*18W%B
MR>9DRPM";7$3R-X>2E^&9C;P&HV++C)B\S6/IYJ+9F;-XVJ#*V1O&VW=<DR?
MRFH24/!B-HG!)F;-%)):-B3(9L+ I:XF;S+ LI@34F\2"-,5+4>@R::9>)8Z
MCHZEH1O&6]U+7!B:DN""I$U!*!%N+5N2@4%G"1,$I"!,8) " !,0)#(0 66H
M '8IP$%3)]2:14$5Q5=($(> P2 J9#:G X*)E F!64FI?Z8)I 9*@! $$LFD
M"4E'*HLH3@527,I+F53&" ! %9%-%(JYQ3&5)9-(I*2A+JBB$ " !  @ )8(
M!%"75+ M*"$P! %.(5KL05!544"3<>D#\W^8_P S.W_EOTF?/=5SHYO/9D)#
MI_3,J8/,\WG,>$"#O'+$F>1H OD7EORSW'S)O%MMG6-)1UW:_1HN;?/DN)U[
M;:_2KZ;6;IMDX;XM\JKB_')9L^:W>_S [@^8?6<SJG6^8E]S&4OX!T^$C_!>
M2R26$<N% <TQ;BF:E?IKL/ESMWEO9+:[*LZK_7U'^M=^/)<D=>IK5O5:6G7I
MT*Y5_P"+YM\7ZCQ;++ 5O\G7K6S)JTLQGBUK/$M6P+C,((<O]&M(?7@3]Z<;
M]5F"(%U>@Y$(![PUFL8[EZVM2#\^Z5W&(S")8TLU6BEFI>;J+$];1O#\!N$;
M'&KV^I7++6!Z^C<?R:,UE_BL;<3U=*R:DZN2*@V@,?:N:_SGHZ5LCIY=V+.V
MT4\5@\COHYR.IE6!L N6YU4?,Z.50:7N_HN6YUZ>#.CE"N[S=<USKHVQ_*HU
MOQ7-<ZM.T8#^5]K3 KCU#M7 =@[^:Y[%U?Z2'<OV>U86.JKP'("QK?<N;4RQ
M-:.1J&NWX6>*Y[&U7!T\H#AB-+UR7S9;R&!8N9YC61MEVC!UG8:S.G 6^&G@
MN6Q1M'%9L3&8!K;77-=IY9 AV%6TLJN>P,=C8%@\SGMF-0!=[O:L;&0P+ LK
M$\2\*'P6-B;#4+5E8PMD;A53(R9O#U#JLD8V&X8W$),PM$P,04\1/(VBJ:>#
M(L;"P+)YF1:-H5<"7D;Q]JAYF=AF/FL\#&QK&]3<S9O$V%9<8,K(VB0X-WP0
MR#=)1P TB;-+TF19&J@S+ L4F)FH+;$C-J?274Y$FD38$FB&C4%U/Y"&H+ D
M7^Y*)] C:)-#J4-!F: NI(>!* ! $N<4H%")$JW(@31)D+DH" ,L$0"7,GB&
M*(8H94RP3@<!Q'4B!P0Y*:7(, 50D!"6"R&"); J38R(YE)<RI)*< E!"8RO
M$';1\$X8%":T):GHJ2Y@50 .F!0DV)PBH14FS3%5'(:7(J98(2&ES*JB@0!#
MW(&03<FD-(HF,J20521214U3*(0 ( $ " ()9-#2DJ^ER<%00F ( S)K;1.,
M"TB$+Q&0E('XC\W?G3T/Y9\A/E\N>5U'N7F<N7\"Z7"8)RB13/YL@OE943C4
MW+YMY0\E;_S1N5?'3[91_IZC6'_AKSL_4N)VZ.VI336XW<K2?ZM<K7]'*O-^
MH^:G<7=/7.\>K\QUOK_.9G.<YS$S(/(_<\MEDELCELLD_=Y<&I>;U^G.V=JV
M'9-G78=NHJ:%5\MGSL^+96IKWU[IVA52A)957)+_ (YOB<_+D / ;!>NJRD)
M@VXQ=7V*(&[0L309C ,23M]ZAUD4K@6&:;2=Q0Z(5K0'WVRW3<ET$]?@:QC4
M/6MR]:]<&C\_Z5IP&8QL.P%MJ\W5H>II740,1@P.'T57GWD]?1OP',J)>K-=
M[URV</Q/6V]Y6!T<H$$&VS:L;M0>GI6AR=3*%,;R^Q<S9Z.FY:YG2R10;#Y$
M+GOF=U,3IY18:7KDNL3IZH<^!T<LV;/BN:QUZ=OTA_)#@:G'L7-? ZJ/&#H9
M0+AFQ]5R:D/,ZZN1L7/O;V+F?@:K!CL [:UA8Z:?JSP'(!US7<(Z:O$;@+[C
M[%S6-3H91H!@RYK\RTY0TN9YEK(UA<L[!,,Z<+]-+%RV+-XV+-YDO,:C[ERV
M&IX#V6';8N>PKY?*.1!/@L&<[<#,+\-/<LK$&]E%C9R0:1NVK)D6&H#WK*QA
M9FP3ID9L8C:=-+%>1C;D-Q?<DS!Y^)O"_<I06-HW[O:J,[&PL"R>+,F6C:$W
MC43R-HX7E2\3*PS"U]7N69C8U!\TK*5)FS:+++B9LW"#,82:D1>)N2?,37$U
MCZ*&9LLD26!NM*30FC:-B42C-YE@C')DF@/L41&' AHT!=*((:@N)$4#*80%
MQ(%A>DU &O%BH@4%A5(D$ " !  @ 0 (D 0 $LC,""61 TI*\57."<#@@UJF
M,A %9%MMRI*?0!F2YW*DH A, 0!!+,G )243_*64D;DTN)27$JJ&" ! %7MU
M)P."I+IP4E!4EDX&E)'%@G X*)E @ 0 ( $ 5)N^A-%)%50P0!!L*0UF4)=4
MBDH(38R%+<L#U@^=WX@^F]AY.?T#MS-R>I=U9T#"7#(3Y?I0F"!F\S*#@YH_
M4P<$E?9_D?X>[GS#=;_N"MI=G3SRMJ1PKX<[9<CNKI:>UJM7=KJU6IKI_DM?
MDN2S?H/G)U'JO4NN=0YGJW5N<SN>ZASF9+,YCF<^9G.<I%V#_9A&R,10!?I/
M;;3;;#;4V>SI73VVFHK5*(_^?-G-J:VKKZGTFJYN_F\$N"Y(IEY@ 8"S7K?V
MJFG,CF,3>.<!9)]-BAU?%%*S+#/ #"N._=8ETMYB^D;)_A !W4]R71(.[R16
M7,DV"Q[[$U2"9?,K_")>>)M3Z ZO$\J&4U14>[8N_5JU@?GK0U91M&#>@P7!
MJ)L]?1U%\HW$"GI?:O,U:0Y/7TKX#,(BE+]3:EP:BAR>GMKXQP'<L,0=,-MH
M7-9X0>MHW2:.IDT M.GHN>V)Z6G;#Q'\H$4T ;R6%V>AI6XG1R;1:Q;V7KEO
M\YV4:B3I98'@N6QU)G0R144IAM7-=^LZJ/+F=& 7+=\3JI:&H&15<[S.E9#V
M6+"ST]JYK,WHX0[EBS'XKFU,O Z:6D;@*@"S:N:QKB/99/HVY<]H-J\AD+"P
MZF\+1I<L;"XG3RVX: @:_-<EL\35,8A=X_'Q65A/,:A;I:N>XT.Y2YKDW'(W
M+!G.QF%!K?;<LK$>DV6-LR3:%C+*QG<8@=MBRL8V-HZU=)Z3)C,-6+JH@QL-
MQNTO29AQ-H7[E/$=C:*K(SL;"P+)YF3+"VBK@)FT?@H9DQB-H4<3&V1L+4GD
M0S:*S;1G8UC9O4LS>9O O:[XZA=MJD2:"T;4< 9H+1M4LAFB@@D($:@M4,E#
M(:YF@J@@D$A*.8H- ;,5+(:- 74M$-%@6J$@+B>+DI-<@+"3BV\G6*J6@+<1
MQ2A"A%N*FM*!0 D$0$!Q#6B A@34^2('!'%:^Y$!!#NF,A  @ 3 IQC7Y)]+
M J9$NUFY-+U@53 $P(<)I-A#*DG<G$%)%"63@I(JY.Y4.$0Z!@@ 0!0EW\O:
MJ124$:'6@94E-(I(HY3@<(-'3&0@ 0 ( $ 5,L%4%)<RJ8P0!4D#7L0.&5)=
M/P*6!">$8 5,A$&4B(QB"92D1&,0*DF18  *<6-8N%BSTJ^?/XD\CHHYSM#L
M/F<OF.K$2R.I=9RR)Y/3W^K/)Y:0<9G- />T;\%]U>0OAIJ;_H[QWZKIL<Z:
M3P>IR=EFJ_._0=S^CV&-XMON"S6GXO@[<EPX\CY_SYCF.;S\WFN;SLWF>9S\
MR6;GY^=.69G9V;,O.<\R1,I2D2OT-72T]'3KI:-:UTZJ$DH22R21Y]M2][/4
MU&[7;EMYL8AF1%'8:Z7;66=JMXC3A2;<8Q]BCI&[%OO18*#7;YI='K%U<RD<
MV+T+Z\,53HP=P.?$$U&RINU(6FV+J,I<P3I16M(744^_.K3>G]&B>I\S]4CE
M%B/)O-=>XI&9^<MKJ)HL,MKAMTM7E:BC$]W0U.!L,L "]_'8ZX=12>SH:B?'
M$8RQ5JV6LU;[UYNK58GIZ-\8'81!LPT\5PW4'K:-\I'\MZ>0M;VU7*\SU=.S
M^4Z.4QVD>=ZPN>EI6X'1RQ2(LJ*X:US6>)W4:Z3HPBVF#KELSJK; Z&34;6\
M;%S:F9TT<^DZ$=BYK1QR.JK]8U$4B?'34N:[QP.JEL!_+QQ'M7-;D;5>'B.P
M%1L\US7RYXG1IOQ&H"P^6FI<UF=,XCT* 4P7/8WKB,1#ZK&]?)8W< ,0!)MO
M]BPL)YG1@" '+TV6KEMF:U&H86T;3P65A<1F'M7->)P&L1_+&[6N:S)NQF-H
M6+R,'D,P&-*W[%E8@VO6#)-XK-F5AB-VSV+)F5C8!V6BPJ9,9R]E_NJF87&H
MV!2S'B;0OW("QO&Q5XF=C46!8O-F9877JN F;1MW*&9O(8B33%1Q,;&P2>1F
M:Q]BAI&=C:)N4M&;YFL"S@V6[U))J@#2-BEYDO,T!?<I9#19(1:)NWIDM&HE
M8%,09M<2Z"2062")+@V5^E20T7$L?%)HEKD62$2"18EF!83-X=+I D3<X!*
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M%$("$ " !  F ./! $&0VIP."I+[O:FE TH*DLFL<"DI*O7#5:/5.!P53&"
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MU*Q)HH M&W:DQ,T!92T0U)HI)! $@L@34FB9!8''59J2@F"P+I":@E @0 (
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MFPK\5  D!H+%+)>9>)N2:(:+J1 @"1(TP0*$: NF02"R($U)=QBI@F&2@0(
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M/P39+1I$@$/K]%#$:N,0I $@! %P=-,4FB6BR0@>Y("PEBE!+7(ND($ " !
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M0$IIB!#8$*<QD$LR:0TBO$=B<#@A/A(P32X@!VLJ J97>:"H*)#!  F (SR
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M6Y*).7F=4$)_5S^<9OW(L\<N^V6"_8OD+X>;#R?M5KZRKJ]YNOTK_L_\M/\
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M060U(-27!=2U!+4!?=[4")0 ( $ " !  @"!5 $<0UIPQPR#)T\QI%4#!/
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M.[3L,1N%RX;'55X2-0\[1NM"YK9EJ'B;P%ZRL/B;@/IZK"V#+3P+@,H$W)*
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M]W5FNIQZ3]F__2'HO_4\G_ ?<_8N\5[G]CT/V5^J>#_=]W^T\Y/V=?*3S00
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M):DN'O2P(<$I"! %@'?4DQ-E@Z1+- &M4MDMDI"-(TIOTU)D,F_5[4"_*2@
M0 ( CB&/JG X8./<B @G:@1)H:6W[;TL\P(=T 6#,;S@SBY)_,!I2-2P M-
M&UE)<@B3\(^;WSL[?^7/2.8S,WFH2YTPE#)R(3C+.S,PAA'+@[DDKYQY/\D]
MQ\T;RM-*KKM4_P!*[6"7I#>;O9]EVW^L[BU/^&G&SX8'R$^8OS&[C^9?6<WJ
M'5<_,'*1S)'E.0$_W')@\N&4Q9/,(-MR_7WE[RYVWRUL:[3952M'Z5N+?'Y#
MZ;[YWW>]]W'TNX?3H5?Z-%DEP^4\$R^4#AHU.VH&VB]UV9XN'#,Z&5RUQ<&X
M*&RIG!G0R^3>R)%]<*+.1N. ]E\J(@ AVM-*#U4MM^@:8YE<J201$M74#[;
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M_IMGFF1R7*\L (9<8C9@&\EZ5-#3HE@<N-LQDR;[*V22R'',JYQ*8X1"!@@
M0 ( $ " !  @ 0 ( $ " .7U7D,KG^5S,G,B)<<>&JY]QHUUM-U?(UT=5Z5U
M9'SJ_$#\L?O<OF>9RN7><1.3B%L0"3XLOJ?S-VE_I72Q1]U>2/,'T6I73O;
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M8\"(T$0!J^A="JJY!TD<1Q3'&$$(&" !  @ 0 ( $ " !  @ 0 ( $ " !
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M-J!@@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
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M/'Q)+<1U)P*"X>]E)+- &KJ3(;X 3@FD"1(<ZM+T. P)I@D(TC$N#3SHI;X
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M-REQ1U^7Z42:Q8;/?@5M72Y(XM3=/F=GENDN:0K<T7 MK5[ENM)\SDON#O\
M+=#S)?J"QK8:Z.M:Z:1QZFX2S9Y-R?;<I-^YD[KCY47172;.'5WE<8/,^G=H
M9V<8B.3.1I9$U]C+>NBCS=;?Q,V/UGMWY3=7ZI/+&1R.9+C8?X(F\,]C+KTM
MKJZF&G5GQ_>]^VFV4ZEUZSVA[(_"YUCJ4LF7,\GF1$C$L8$  FP6FQ>WM.P;
MG7>*<>@^"]T\_;;;RM-J3W2["_"9R/*QR9\WR<9$,[Y=EE: E?+MAY3B'='U
MCW;X@:^LVJ6<>![<=J?(SH?2(99CR63#A$:'+%PQJOEVT\OZ.C'Z.)\!WOF+
M>[I_K.#]GZ;VETOI\8B'+Y;QPA$4L:EB^0:/;]/3R1X>IKZNJYNVV>1Y>3D9
M0X80C%J4C@NVNE2N2,H;QXFG%@ URT] X15R4#@$#!  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " ! 'C/<O1<GJW(Y
MF7/+!/#+AH]6]J\_N&TKN=)J,8.[8;JVUUE9/"3Y=_B"^54LN?,\YR_+GB><
MJ1\7(!8,OHGS;V-T=M2M3],?#SS5%J:-[88<3YU=7Z?F<GS&9E3B0!(BH;:/
M%?3>\T'I7=7@?JCM.]KN=%73EP>+YV54[Q2TKP-UI'R30NT_!G)YG)9Y-< P
MV5\EX>M3$][;7G(Y<HVAK%XVYTIR/9T+O(SD&7@;C3S/7T;Y<S*<*FES:GV.
MO+O7 ]*EN*R,91MI5>7K4Q/0TKNRQ,S%MZ\S4KB>EI.:FG#Q /:RXM11Z#MT
MKQ@9D,6-OKAYKCU:]2P.W3NOD "J\V]8?B="LEB7%M?@N;@=-7)=@:V+&V<%
MS <(N6=E@$@!:L&/,E9EFD;%+)>9J& ?Q1!#S+)DDBJJ1/ T"1+! B4US %2
MY@2*IBX%Q122RX'@IDEOUEXQ%-;)D-R:@-9X*>+(+@D[DFH):19(D$ 6 ):F
MOSJE@A.$: >K*$H])#9)87(4L2EEHUL%R<(3P+\)O3DF42!BDV)LN 2DW H-
M!$7VJ9;R 7YKG,CD\J69G3$1$$L2U@]%T[;:Z^ZU5I:%7:[? <8=3PJN)ZQ_
M-/YS9'289O3^ES&?SLXR$,K+G]FA E-@\8@VXK[\\C?#%ZCKO^YU_14/%?D/
MA7F'S?H=NJ]KLFK;AYM?\3TLZIS74>O\_F=0ZIS&9S&?F$R$2_W>4#^IRXD\
M,0!?:5^@]KM=OL=!;?:UK722X?\ $^H]SOM;=ZSU]>SMJ/F:9/3+':-,')OO
M6\R<]M1_(=?(Z:*$PXM9&&&"4&3U5DW@=C)Z95I1IA<#L>U5',PON(P1U\CI
MC #[M[WNVXIQR.:VM9K$[&1THEOJL/$U5*K;R.:^LJ\3LY/2P6> )%7(OV6&
MJUKI,X[[K' [/+](D6^HP=[*O998NA:2.2^XL\6X1W.5Z+.=>!__ &</@MEI
MI''?7269Y'RG;LI,>"VYJTWT6U=-LX]3=)+ \OZ?VI/,X ,DR-*"+FOBMZ:#
MXGG:V_2G$_3.@_+7J?4)1CD<EFRXF8_=FCW6+KT]N[N*5Q/#W?>=OH5;U+I?
M*>QG9?X;>O=6EE&?)9HC(Q_Y.E1KI1U[&V[+N==Y.#X3W/SQL]LGTV3?I_X'
MN3V'^$;+A]SF<YRP)#$OE@UHX)(O7RG8^5+6AZB/K7NWQ%U+-K3MZF>XW9WX
M>>A])AE/R.4#$6\$7QM;%?,=EY;T=))]*/KG?^:][NFXL\3]\Z1V)TCID("'
M+Y0X0 &A&[%F7R/0[9I::A)(^-ZV\U]9S>SD\PRN3Y;EX@9>5&(% T1\%Z%=
M#3J<V+&.(7!;))9#Z?402Z8TH(0,$ " !  @ 0 ( $ " !  @ 0 ( $ " !
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MBVH>Y>I3:Z=.!PMVMB\1_P"K$-$-L 9;JM5D@2(<E4.$0@8( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ 8<SDQYC+E"8$N(,7 J#3T6=].NI7HMD52]J6ZJYGI]\\/EAD]7Y
M+FIPR!*1RYR@8QJPXG%,%]8^:^Q+6T[62/MOR/YFOL]Q2K?%2?(3Y@]G\ST#
MJ7,9<\N<8B9$21]H T- '(9?G7O7;[[;5LFLF?M3REWS2W^UJU;&$?E&;E5K
MX:&TKX?KZ9]BZ-YQX')YC*)!+. XT%K+Q=QIYP>YMM65B<J4&+,:N7N!P=>+
MKTX\#VM*TJ3+A<,;7=>'N=*,>!ZNAJ81Q,3:S-=YX+R]6DIGHZ5G\AF8F_5J
MV4UKR=:CXG=IV9G.+L<-QJO+U*]+@]#3N\RC-0KDNI]!WZ=I4D2@]F._;1EP
MZE(]$'52Y4.X&J^BX-6L'92W(L(O7VKF:YG16SCP)4/T% U'6;4(<EHX'Z&^
ME87JLQEL%SVK"P&78#R;4I_(3).ENCIB+55*RXB)X42*2Z1)*I+B!*H1>(/B
MI;);+B.F*4^LALT ='BR&X+@6:;$-Q@)LT &]0V0V62))9. DN(C:B5),LN(
MW,1MT""&RX NO4P2V:<.(T]Z1,EQ&SW>&U&9#9<18_!..' 4M^DL6C4D )]#
M;A9L:1X?W+W9R'0^4S<[.SX0$(DF1D  U&M!)U!?/_*_D;?]ZUJVU*-:,_\
MQ)Y'=.];/M>D[ZMD[K@>FW>_S!ZIW3GYO+<E+-Y?I_$QF#*.9G@.'H?JY9?>
MOU%Y<\I;'L6A55K5Z\9PL#Z6[[YIW7==1TI9K0GUGY]R_23(AXL34XWE]Y7R
MO(^)VUL,'B=SE^DDL!"RMA-3Y6IHQMK';Y;I!_51U&GH$^EO%'/?72\3N\OT
MD4:%UX+UW*ZZ=GZ#FU-SRS.[RW1I2X7AA8^ >Y;UT8SR.6^N^.9Y#RG;\I$
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MR<92B8EC &M]&JOF&P\IT4.Z/J_NWQ W6XLU2V#\3VJ[9^2W1.DPR^'D\F/
M WU(BP-8!;5?+-IV'1TDHJCX+O._[S=-]5G!^M\AVSTSD( 9?+Y88"R(:@N#
M!>]I;#2HLL#QKZVIJ/\ 2;.]"&5E@"$8Q84 #>Q=E=.E<$C.&6,J6-O5K# <
M%7.)0,$#!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M$"QA[@NZNC2F"1CBS8RPLWK7!9#2YE224#A$(&" !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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M :M"M4DLAJO,@ETQI00@8( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " ! &',9$.8RY9<P"""&(M<$-L47I74JZVR95+O3MU5S/6#YN_*
M_ENM<ES)AD"7%"8'U0]CL]B^M_-/ERFYTK-+$^U?)7FW7[;N*?I-)-<?$^0W
MS6^6O.]K]1S\W+R)CE_O)D@1/U:EM5%^9/,?8M78ZUFDX/W+Y(\W;?N^TI2U
ME])!^$YN7B+Z@L]5\#U].9P_2/M;;W.?F9=3IH5X^OIGLZ6I.>8AF93'7XKR
M-;348YGHZ6IZC( M5O;A5>5K:4,]'2MZB#' ;EYVMI'=I7X&4H$$4]X\%Y&O
MI+&$=M+0O$Q,<0Q\G7G7JZ^@ZJWG S,#MPTL6-DGF=5;+)&9@;*OACCJ7'>A
MTTMSR)&QKWU:RN34TT\C>K)"Y+4@VJYSR+!9]'$T3)X2LG1#ZD69J+&U&*9)
M(&M_)86TW\@2RPB%DZ>HEV+B-E*:[U+48<29]98!KO1'Y!-EP!1P[^2:\"6V
M7 P\D>DB2XB&J/5!+;- '34<29-!%ZFWR0[0L,B':#01J-RF;-^!#9J +AIJ
M37SD8F@C]*8+!&@@]+2JJFWTU6+$[1B\A@97#'BFPB [$W?2OE_8O)^_[KJ*
MVI6U=)O+B_S'D;_N^UV-';4LI/#>O]SY/)1.1RG[MGD%HY=0#6T@BQU^B/*W
MP]VVSI6UZ)1S1]/^9//T3IZ%O4?E?,<GU'K.><[G)YDG/U8!^",7< "Q?;>U
MV.WVE%31JE!]0[WN^XWMW?6LXG*<#N].[0S<QA'))=F^J+?!=BI+/*ONTEBS
M]+Z)\MNH\]*$<CD\W,,N$/'*)%38_"NG3V]KN*IL\;=]ZV^@OT[I'L'VA^'3
MKW53DG^ YF7&35&67)VD8+V=KV/=:[257!\*[IYYV6V3Z;)OTGMOV/\ A(#9
M$^=Y<_J27A4$C^ZM*^6;'RA>S3U$?6G=_B3=IUTK?.>WO9_X=.B=*AE&7(Y3
MQ <G+B] ,0Y=L%\RV7E;0TH;JI]!];]Q\Y;[=.%9^L_?>C_+[H_38P$.6R8\
M( #0B-VL>"^3[?M.EIK"J/BVOW#<Z[F]GZSS7E^G\IRP R\J$6U!>G3;:=>!
MQ-VLY<L;!B* -L "W22X!TD<1Q3*A$(&" !  @ 0 ( $ " !  @ 0 ( $ "
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M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
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M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
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M'#RF3#A84@ : >07RW:=CT-)85/AVY[ON]PV[6>)^A<IT7D.3C$963"@PO\
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M0!=:I2N2)AD\1U*Q])5!0( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
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MU+-OTG4 A"D8@ ,S 7+M6G2N2,DF29&ZS<K*2*H&" !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
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M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
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M<SZGF7,Z,UCMJ?<M,L$'24<XE X0(&" !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !SB4"@"(EGC9K(]&0+I(X<O]9_
M\*7O0$>)/!E8><O>E%>2%^D2(Y8_4C>'\RY3A!##ZHLB/ #V(] =)/%J0/I(
M,GU;T E!"!@@8( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M$ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
M( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @
M0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ "
M!  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 (
M $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !
M@ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $
M" !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0 ( $ " !  @ 0
2 ( $ " !  @ 0 ( $ " /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>81
<FILENAME>g382677f_97a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97a.jpg
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M!@@0  $$ @$!! L           ,"! 4& 0<( !$3=5:RLY34Y)46-C@)&1$
M @( ! ($#04          @,!!  %!@<2$Q&2"!BQX2(RTG,45'15%C8W,4'!
MPA7_V@ , P$  A$#$0 _ &K\J^6>^.8>\9O4FFI>?#KMK)ST/2*-6)5$"6[
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MPI]XZWWW/--?,'=2/2PNKOJ:I^7)Z\^C@Q?LW_&65\;C_5N.KMVJ/Q8WX@/
M6*+V1_RVGX<_".*^_J!^PMA^)QOHN>AQV,/M[,O6A_."=VX_N3*_5,_KAR'6
&V<81Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>82
<FILENAME>g382677f_97b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97b.jpg
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MVNUJ]PS8V)A5?GJ>H<06)L#XJ7&&"NU'D8X_!*7<5-)?'<BK;=L@<?7S7TV
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MA/9;]0-J/1C!\EJW+3]./F;Z]HX<>0/M8==L')K&)82FP8C(J9,1^C[7;?;
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/VN_D7^,>+J^-S>,!>/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>83
<FILENAME>g382677f_97c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97c.jpg
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M @<!          (# 002$Q0'$04&,Q< (2(C%18(-/_:  P# 0 "$0,1 #\
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L\_@K-CF'WMI$RGVC] _"71 1N6,\MSV_5:P]CTW?HZ",-#0W$[G4^7Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>84
<FILENAME>g382677f_97d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97d.jpg
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M  (" P !!0$           0% P8! @<4$1(3%0@6$0 " P # 0$! 0$
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+3(DSLV&H!4D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>85
<FILENAME>g382677f_97e.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97e.jpg
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M  (# 0$  @,           0% @,&!P$1%!,5"!$  @,!  (" P
M @,!! 4&$A,A!Q$C%/_:  P# 0 "$0,1 #\ V :5UE]AS5-W;KR4K<YK?.U5
M7.^?-G@V<YKB\J[L*\RKS9W&F#9_]DZ74Q*-:M?"8C%FT@B0KC\2MSQJ7LK:
MY='V!V:#T,O1L+BG38T4TJU=LE_.VS)$*?-H1#&OL>< QJZZ8&/D]*9-#8PN
ML?\ 7/#V SM;-KLF]=6HGW[5A4#_ $)JP D[UJ.96JO6]<L6IEAQ'/P#W19%
M;RA E:Y9-?+ENU]68GH?&#G5+/+U4]#\CGU3#+%,&!"[.WUZ)N, ?2,1!,6
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..JH0+"A0FQUDDBJ(9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>86
<FILENAME>g382677f_97f.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97f.jpg
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M"!   @,! 0 # 0          ! 8" P4' 0 3%0@1  (" P$  P$
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MUW77UV57U_)DYKG@J4.B@K'').XW76:\?TH97<A\/K65IAK9BNECHA@A*20
MF;!(&#\MCZGI&7-CS,C6[9RZ2MG5LS_+87918KS7M56NE2HFR]:))9F+QL&0
M L@-9_)<C)YBV<+R.?A:#2N?R4F8Y]S%T]LT3\AC=:*/THXN"F3*'H:S"!6(
MV!4].P2H@@L.@4.!=UULZE#*?*;C@$\XAENM^.44'+KU@S6ZU$>\2JTE$6"D
M7%#)?*Q,V+6I(N,S('"KO7:7]%?TUA5.U^UWWA"-?6 &HJ3./*ZUY*:XP2 E
/<(%A "VL<\DK6 G_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>87
<FILENAME>g382677f_97g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97g.jpg
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M"!   @,! 0 " P$         ! 8" P4' 105 !,6"!$  @(# 0$  P$
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MEP2F *R(H:LA_+NN9V.[V-[;<7C6^CNUPHVE2R,)LK%,I];58K&"(59A2IM
MV1:LS8(C*F"7X)EO,&7BP"AF0T\7_(*T/_3N'0GOP[)S-]'#UYL:_P ^0!#Q
MPVC5P;=.P4:!DJ(1^L'K"$F821Y.H./E=IPR]-5AJ/C-4?>S<MYK!U462]-.
MH)P+V*DY6$,D(CP 4))S69 4!U^I[YN\MRFQ]PME_GJTJ>#&)MDJ$.NW" BK
3K="X8R50<S_H,K#A0I6)_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>88
<FILENAME>g382677f_97h.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_97h.jpg
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M"!   @,! 0 #            ! 4" P8' 0 2"!$  @,!  (" P
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..E NE:5M<UY5UJ "__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>89
<FILENAME>g382677f_98a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_98a.jpg
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MPKL#YSQ/QL>OA@7<7Y'S'P$^S'#T>-^<+JX3/U:_/&[^Q0WN]GC$7>+Y]O\
EN%>Q'&\^RG\>8[W[?;GB<?\ CK^,?N<7S_27Z5QGC^]?U?C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>90
<FILENAME>g382677f_98b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_98b.jpg
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%_M<?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>91
<FILENAME>g382677f_98c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_98c.jpg
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M)C/D>:$EV?CZ04R7/:^,:>51E ;M!N*Q&D12(D];F-S*Q@V@P-&"("'S6M&
MT_JV=D;!KVX$;$L5@HU)IK%&J4E#V-V3/I8QHC=B9$A^(>O&V1HAG$H84Z-&
M)6.E]Q3:U.K6K<!7Z7U+D&\CUNZ7)<E9X^K6BK7-;I8=82&'0*_HDG00Z[&$
M"(D(84C,F1-G8K/>>X\<KC.ST1XOBZW(V[4V[*VHA86B I1)-_DX42);=2Q9
M8F#E8P0P B[8JEJHX-/NN \V&P11-U+V'"0+>7WS@-ES(UFL?B[3N&W9(BIS
M@ ?2,YPAXV/'=0A&27&VU,"^(Y?@*]+G8#<\DDK17%*C&3"ZR'NT(G"3FNT%
MZ8_0FI X&-0A&5QG,\-V*Q>X"6;7C'!5&DUTX0!T%$A&XF,86-E1MU"^HJ<8
M$4Z0D4"1@M ![5,WL+L6&;NDD04W(QCY(!$P1&D5*NU5%:;J)#"K0!+AD5ID
MEK+ S<IA;Y R^-A[+6 2D>ND=N/V KDT1SK2*#"9"62$UTU]"*\QKBP90)C(
MA#\28J<RSD(8&V/9C^FK]<.XI\\ H1D&0)PH6#9?8E\V1+;FHA>2R@V%7P!3
MARL"#E!T-T\R_>O'Y?D=#X;X%TN/*?R[F]Q\@[;Q<SR[R7^_MGWU/:OY^'KO
MY_A'0YS]W_H>V=IZ>VVF7_HV&.?6R??<:_RZ']]O\>&X^/P9N. _1?YMND:F
:INMYF_Y_V&&31U/MMM#X=Q^/<?+CM_E\_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>92
<FILENAME>g382677f_99a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_99a.jpg
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M"!   00! @((!P          ! (#!08' 0@ $1(3LQ34=196E!65-S@)&1$
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>QKOV;_C>H^LG<W6RO>W^4Z;Z+]Z]-^X[/ZX=Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>93
<FILENAME>g382677f_99b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_99b.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,P:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.D8U,$-&03@U0C<Y13$Q141!,S8X1$8W
M,3)&-S<W0S!&(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.D8U,$-&03@T
M0C<Y13$Q141!,S8X1$8W,3)&-S<W0S!&(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EN1&5S:6=N(#$X+C$@*%=I;F1O=W,I(CX@/'AM<$U-.D1E<FEV961&
M<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z-C<Y8S8Q-#<M,S=D-RTT86,P
M+3AF,S4M9&4T,V0U9#<X96(Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.C=E
M-6,X-#8W+35C.34M-#DS,RTY-#5E+3!D-3,T-3 S-F0R82(O/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !$ (P,!$0 "$0$#$0'_
MQ "1   " P$!               %!@,$"0@* 0 !!0$                %
M @,$!P@&$  !! $"! (&"P         $ @,%!@$5!P 3%A<1"!*S%'4V-R$R
M(R0T=+0UM29V$0 " @ % @('"0$        " P$$$A,4!081%0 ',3*R(S-T
M-2&Q(G,D1!8V"#?_V@ , P$  A$#$0 _ /:L[BFW2DG;U;R9U6@N"JL%6J,F
M,1(5F&J/IY;@),VKBMD-VBVV8=QLK.2625#Y*;%%;1E#CC]3G&R;YL3.=<V]
M]QZ0SJ]<Q(T+K^A3"0,%#[#QF#_&)R&8*5",P1,N )W[8.0+X!P3W/)8/)L6
M5D(6&V>G5RPL%(S7K5Y@E] )<'EDYQ%!"*R>*="0%55N5LQ6S=OY,01^;+H^
M((VEQ=N"B\OYD*[8J,6*$-&2YH[#B 9% S)3#ZFG.8Z*IQIZ5V2AMVT3RC@U
M4]NM $M*KE%678%?7&EU4A& 8404*= "P#D"Q&F2 XD[[N&Y;S'$^?6U[G4,
MX4-O."TRL;.F!Z+8D9,4!2,N1+"680880= F!XR05NS/#UV*ESX^@A5>OVFS
M$1)9,7+6A=O;*(KM81)B*9/B8EJ*"69)9&=:)(P0,REQ+62$N$'69YCN [;4
M<Q?'5U$O?*R);'S9@B2B#'H:UPL98[ 0F>-004!F00U%6.%;:6Z7$*;R5EQU
M>N+!%BZ\5I$7V)674&,EAPI&,26&!QR$G"I%(KU5\N]IF'X6BT=ZMRL=JJ(K
M<:F4>>IS+IT.4N-E5U_<X"'"C9TJ-D,*0XA99(Y:T+3E!"$NXP"VW:/+7=KI
M4>/T"JW%9D+NUJK:T2:RP,E-X%B#2 ^L%$L,&3!1,,&#B.AW3>?-'9Z [AR/
M<1MTFY<LHVK:;4P#1S%PZ@;38D3#I(S"UFN)&8)12$^+>O[J^T:)U6SU#U'V
M<\.FHC2]7TSN#W=YOCSM2[7?3I'[=K'V?ARN'>X\NS-!K([EJ>V_ 7EYF#6=
MQZ^G'H/V_P '4_AZ8/#';>&Y7<-$7:]+W3X[<S*S-%VSIZ,ON'[GX^E_%UQ^
M+E7;9&HSWE]F96(A+= P/2<%U1"!3<1<:<"VD&#G0H*1)%!ML<7!-MC2P3;R
M712L.MN>@A3#KC^TBM6P%Y<7G)1O->OIU9ZA:NS6",*FBHR$+ $J("PJ"@EL
MQB6&)69,[P3&\B'S-H)?8V2S9U+M.TU-JVCG&Y)N 2.L8NDF5FR,BQ> AQ3#
M ",1I.TVW@VT,#847/<>5;GQZQ$L-.,HBL6&3/*9*S$*D)DJJ[:T5F12VS@D
MI[#((K8K3KQ"V6UI2$</XV/#-OLQ>Y.Z'0A<1,9><9E!9>-I5Z56#B!QL+"I
M8J$S80"2GG/->4'SC<JLT.*)E)6&3,3+,A8#(YN!0V+]R0F2RUCC:PW& +$R
M$H(S&[)V,14F\H:@6"J4ZKYLQ:O0!KMFI@C\)']1D>')BXZTPKX[;!;JDC-&
M!9:<6E9+&%2TA5X)N83:*1X[9IUD9Y?8"7UAE09T^A8/5(0+"F %BI B@FKB
M8;V6O,#:CBH,'R6M=M6-./VF]%HH:>0/I8==L&1K&)82FP8C(J9,25J(3LW&
MH?E]V(K&T<0(>U5H*0@XX:1$'.)25&QJ[8W)D/69N+;4H:.8&!9,?0I"7%E.
MXPI2MKIQPBK#+F\)_AJ0.$*-0"8P18@#40R9?"XZ@D 4+#B1@B:<1,IW:]//
M+<JH[*[^;O,)L.!ID!$ X6,BM*QBO+)Z,>;'$H)@I 4A,Q"?JEMU#J?HFXZC
MUEWHT70".7T/TOVBZ;]LYO+[D=+_ -@T7\1S/NOU^ NKWC4]UT-W4Z[N>5DS
MTTN1V[(Q=>FMR/U>F]?%[KUO!S1[)I>T=PHZ70=JS<Z.NKU'<L_#TZZ'4?H]
M5ZF'WWJ^ 7GA^48?^GC_ %!7 _SZ_IJ_FP]DO!'_ #U_=V?)G[0^$KR$?#=_
M]]17Z4S@%_GGZ9N/YZ_9+QT'^D_JFV?+L]H?'<%K^%[)[@F/XXCB^MX^DVOE
MF>P7C/.S?6*GS*O;'QCEY7?GU4OSLKZHCC%/E1_T*G^8S[I\;L\X/^;W?RU_
+>/C:SC<_C /C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>94
<FILENAME>g382677f_99c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_99c.jpg
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MQ "T  $  @,!  ,!            " D$!@<# 0(%"@$!  ,! 0 # 0$
M      $"" ,'! 4)!@H0   & @ $ P('#P0#      $" P0%!@ '$1(3""$4
M%2(6,=)3D]-5%Y'1DB.C5)34U5:6UE>7&4$D& F!,C,1  (" 0," P,)!@0'
M       ! @,$$1(%(08Q$P=!(A11D5+35)34%19Q@3)5"!AAH2.3\+'!X4(S
M)/_:  P# 0 "$0,1 #\ _M(?2;Z1=+/';E51=<XG,(G,!2@(^R1,H#P(F0/
MH!X &="#$ZRORJGX9OOX ZRORJGX9OOX ZRORJGX9OOX ZRORJGX9OOX!YX
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & 8<B^1BXZ1E')5SMHN/?2;DC9(5W)VT>T6>+D;(%$#+N3I("
M"9 \3G$ _P!< B6S[NXM]]FRK+7\C+QMHJVBK1LB;@[E5Y"-T_\ \DIUG6]1
MP+L#"W=7NPR\F\ZSUK&D34819/.<%2JH)JQJ6VDP1#@(@/P@(@/_ (R2I\8
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M'438I:1:]P#LUZJ52Z4%:%VKM!@ZC33"#]95R5:16*T:@$(O-OV_*6;9)S&
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M@64YHT+.3:T?@2)R2HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , WIYKRR(.5DVK9)XV*<>BX*Z;I=1
M,1]D3IJG(<B@!_[!PX<?@$0R-428WN#:_JTGZ:R^FQJ@/<&U_5I/TUE]-C5
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M'%8>71QN#/$;X&>!*_A)7STLQ9+DLG6JY1E"EV*JZF4HSMJG":B5QYF$U0,
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MY5\X\FWZ,OF9_<19VNF9B77=6>H5&R2Y *V7DI.GQ,VZ$J <A$!D'D>NJH1
M Y0 #B4O#@&?Z!,[MCMSE,AY?)\?@Y.4TDYVT563T7@MTXMZ+V+7H?YRN/[J
M[GXG'6'Q7)9^-B)MJ%61;7#5]6]L)J.K]KTZFO\ H';S_3&@_P!N:]^RL^%^
MA^S/Y/Q?W6CZL^;^O.^/YSRWWO(^L'H';S_3&@_VYKW[*Q^A^S/Y/Q?W6CZL
M?KSOC^<\M][R/K!Z!V\_TQH/]N:]^RL?H?LS^3\7]UH^K'Z\[X_G/+?>\CZP
M>@=O/],:#_;FO?LK'Z'[,_D_%_=:/JQ^O.^/YSRWWO(^L-#S^K/Y,8 P!@#
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MF:FIE.)@X=W1^X!#<=S9P&Q=E3;YIL27TT>CP*LC";)T5JIZC&R]3<!_M$2
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M24& , T7:$J^@M;7R:C"V8\E%5.;?,"TR2K\+;/.-V2IVPUZ:MB#JKPTF14
M$CN1259-0 552'(02B)7B1J[:T-MQNS=SL=@4\[Q)="B#-;?G.XN&W3:9JS1
M49+-&NNUHFMZFUC P#*EQ#@JXI)LV3A$TF"BY79G15481:6FG_8F?DE!@# -
M2OM+AMCTFUT&Q&>D@[C!/Z_**1JZ;610:OT13%RP760=()O&JG*HGU4E41.0
M 43.03$,)3T>J--U-I&EZ:)8E*LI,OI:Y*1;ZZ6"><L',Q;K%'KS[YY;9T\7
M%Q#%Q9K#*6=ZY?N"($!0RA$DR)-T$$4P;U.OX(& , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .]O=:P;IRJX37>M
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B'RJ7Y;Z' '('RJ7Y;Z' '('RJ7Y;Z' '('RJ7Y;Z' /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>95
<FILENAME>g382677f_cov.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_cov.jpg
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MQ $>  $   8# 0$              04&!P@) @0* PL! 0 !!0$! 0$
M       ! P0%!@<"" D*$  ! P0  P4#!@<("0T( R$! @,$ !$%!B$2!S%!
M41,(82(4<8&1H3()\+'10E(C%<'A8I+2,Q87LK/3)'24-5:6\7*"0U-S-+0E
M=39'&**35-35)H;68X-$9%6V-U=8&0K"HT6%E;7%=G>W.#GBPZ2E1F:F)V>'
MERA($0 ! P($! (%!@<%$@P"!PD!  (#$00A$@4&,4%1$V$'<8$B,A21H;%"
M(PC!T5)B<C,5\((DE!;A\9*BLM)#4V-SD[/3-"56%QC"@W2TU$55974V1@E$
M9,-4A,0UM28W.!F%XJ/%9B?_V@ , P$  A$#$0 _ /?Q1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1%UG93+1Y5*NH=J4BY'R]P-30TKR45'!?+]H,>#G\4?RJA2G[08\'/XH_E
M5-*J*I^T&/!S^*/Y5 *H31/V@QX.?Q1_*J%*?M!CP<_BC^54@545HG[08\'/
MXH_E5"E/V@QX.?Q1_*J2"% (*?M!CP<_BC^54*4_:#'@Y_%'\JIHHJG[08\'
M/XH_E5"E/V@QX.?Q1_*J:=%%4_:#'@Y_%'\JE$JG[08\'/XH_E4 )0FB?M!C
MP<_BC^52B53]H,>#G\4?RJA2G[08\'/XH_E5-%%4_:#'@Y_%'\JA%$!JG[08
M\'/XH_E4I52G[08\'/XH_E4HHJG[08\'/XH_E5'%2G[08\'/XH_E5-"HJ$_:
M#'@Y_%'\JE#P2H3]H,>#G\4?RJA2G[08\'/XH_E41/V@QX.?Q1_*HB?M!CP<
M_BC^54T453]H,>#G\4?RJ $H31/V@QX.?Q1_*J.*E/V@QX.?Q1_*J:8T45PJ
M@R#!(%G!>PXI%N/C[U""$!!5*ZQO^#VQS9&,<UD6)6I[',UC,Q9\9IA]C(PV
MH\E+B$MR'TN0YD64VZPY<%;:KD W%6EM=Q71E;'4.AE,;@<#F !PXU!!!!Y@
MJ_OM/N+!L#YLICN;=LS"TU!:XN;0X"CFN:YKAR(XE55^T&/!S^*/Y57=.?)6
M%4_:#'@Y_%'\JA%.*5JG[08\'/XH_E4HE4_:#'@Y_%'\JH2J?M!CP<_BC^51
M2G[08\'/XH_E5-,*J*XT5.[#OFL:LW%7G,@(:YSBVH,<-+?ES%MI"G?AHL<.
MONI:2H%:@GE3<7(N*U+=>^=K;)B@DW)=M@DNY#'!$&OEFG>T9G"*&)KY9,C3
MF>6L(8*%Q%17+:5HFJ:T][=-A=((FYGNP:U@/#,YQ#14X $U.-.!4JQ?5+4,
MSD8&.QDQV7^U&)#L&<TV@P'GHB@F5 +I>#K.1CDCG:6A) (/>*K[>WAMO=EG
M'J.W+N*\T^4O:V2,@M#XS22)WUF2L.#XWM:]O,+W?Z%JFEB3]H1.BEB+<S78
M. ?[KQR+'<G D5P5;_M!CP<_BC^56S4-:+#5'%/V@QX.?Q1_*H11 :I^T&/!
MS^*/Y5112G[08\'/XH_E5(%5!-$_:#'@Y_%'\JIRE,P3]H,>#G\4?RJBF-$K
MA5/V@QX.?Q1_*I3&BGE5/V@QX.?Q1_*J$3]H,>#G\4?RJFBBJ?M!CP<_BC^5
M1*I^T&/!S^*/Y50I3]H,>#G\4?RJDBB@&JX.92*TVXZX5H;:2I;BU) 2E*1<
MDGF[*@T J3@G$T'%2#%;MB<Q)<C0F<@2T"IQYR.VVPE([ROSR0#W<*H1W#)'
M%K*X<^2N);=\30YY&/+FN!WK"_&? MMSWWO-\H%F.A3:E7Y?=47TDB_LI\0S
M-E%:J.P_)G- %4O[08\'/XJ?H^UW5<4IQXJA6JE>7VC%82(N9/6\AE )(0A*
MED)%SRI+B;V^6J<DC(F%[S[(7MC'2/$;!5Q6)VV>O/H;IV8>PF38W:1*CE(>
M>Q^"@2(B%*)L@O.9MA7,+<1R\*X#NK[ROEQM'6WZ!J U"6]CIF,,+'L!/(N,
MK,?"B[YM?[MOF-NW2&:SIQL([62N42S/8\@<\HB<*>M29W[P_H"TT'?AM]<2
M1?E:U_&+4.%^(_;X /SU9L^]#Y;2-#VQ:I0_W"/_ "RS3/NH>:+WY,^E@^,\
M@'^(5&S?O1?3A =6U(PW58<E^9Q.IX<M6'>%':4W'S50D^]3Y:QFCH=7_B\?
M^769M_N:^;-RT.BN-$QY?$RU_P";*RN[_?A^BW0@X,S ZSR5M@\S6*T?!RW;
MCM 2YN<<7^>LYHWWA]CZ[)DLK?5 /RGP1M;\O>*V6Q^X5YWZ@ 89M! /Y5W,
M/_NI5_N@GWE/0WU$XUK+Z5IO6?$0'TH<CO;AIN&P_GM."Z76T1-LRBB@IX\0
M.!K?=(\PM$UN9T5E'=T9]9T;0T^@YS7Y%QSS$\@-W>6=U\%KM[H\]SC46UQ)
M+EIQKF@C_"LQ8G533),,S7LE^SFQRD-Y --/JYA?W&FGGRJW?6W#4;/)G>]K
M1XD5^2JXX[2[[N=ID;GGJT$CY:!2176[3%OJCX]G/YA:5<O-B\0M]LF]KA;K
MS";7JU_;=FY^2$2R'JUI(^4T"O/Y/WS69YS%$.CW@'Y!4JKHVY-28:IW]']C
M882WYO\ ?,7'M.*1XI;_ &FI2JR$<YD;G[;VCQI^,K%S0-A=E[D;C^;F/_!"
MP?ZZ?>7]$?3WLV*UC>=!ZY3)&8#GPF3UK2L#E,*A;1 6W)FR-RQZXR@#?WVP
M".PD\*T#>/FCMK8H#MP"Y9&X8.:QK@X]![8)/A1=I\K_ "!WCYN6\T^U+K2@
M^"F>.>:6-X!X$!L#P1Z\.:H]/WNGI.*&2XUU-8>> *(CNKX7XNY'V2RWM3AN
M.^Q(KE1^]AY:XD6VM%@YBVCI\O?751]QOSI)-)-%+1S^*EI\IME7F&^\L].V
M>0E6-@]2'EJ3S^0=9Q0=0CA[[G_G(6VDB_YRA5.3[V_E5%$99&:J .78CKZA
MWU@+[[H'FOIQ/Q4ND-8#3-\1)2O0?P>I]05<:EZ[^A>XYDX/'?TOB2P!RN9/
M"P8\1Q=R%,M2&<S)2XZ@_: [*SNSOO,>6F]=1&E6+KZUNW>Z+F)D0?\ HD2O
MQ]-%J>Z/NX>9&T]*_;%\RSFM>8@E<][1U<UT;" >164F$W/![ P'\8^XZDI"
M@E2$!?*1>]DN*'#OX\*[Y#/%<,$D1JTKA$T,EO(8I@6O!Q5(;MUFU/08TF7G
M(^;<:BI<4Z,?!CR%V;!*N4.36 3PX<15IJ.IV^F6[[JX#S&QI)RBIPZ8A7%A
M8S:A<MM8"T2/( S&@Q]16-6'^\1Z"9N4Y$BP.H;3C;ZXY5)US&-M%UM12I(6
MC87+<1PN!>OGR;[U/EI!>R6$D.K":-Y:3\/'EJ#0T/?_  +L[/N^;ZDMA<LE
MTXM+0ZG>?FH16M.U\N*K=SUI=(&6_-<B;FE-K\<+C[V'_P!.K5=2?>>\MXH^
MZZ/4RRG*"/\ RRQ'^Q;>'<[1=9Y_[X__ ":HO*_>'= </S&7'WT\O;Y.O8Y=
MO;QSR*P$OWPO*B)_;,.L%WA;Q?\ 2%E[;[O>_;H5C=8 >,KQ_P#1*W.:^]>]
M+V#9>?EPNJ3J&4E2Q%U3$.JL!?W0O:6@3\]7NG_>R\L=2G%O;P:P'GFZWC ^
M7OE95GW8_,=XJ)-,'IFD_P BK-1OOS?1O+EO1&-8Z_K6PZIE;G]7VO>25)/*
M2E?].^8IOWVK;+K[P.P[1H=*V^Q%<(F?Y5;'IOW//-?5(A+;S:,UI_*N9 ?F
MMRJUA_?)>DZ:E"F\#UJ1SVL'=)P2%"_B!N2JUJ?[U7EG;N+7Q:J2.D$9_P#I
MUEA]R/SA=B+C0J?\JE_Z,KM=+_O*N@/5[8'M:U# ]5%Y&.VVZZ<AJV%C1TH=
M)2@^8UM,E?$C]&MSV1YW;1\P+E]KH$.H=R, GNQ,8,:])7=.BY[YA_=QWSY8
MZ='JFY[K21;RN(:(II7NJ..!MV#YU<?JAZV.E'2& O)[C@NHC,%LH"WX6OXN
M0A/F6Y+EW8(W:36P;P\R=%V18'4M9M[YUHWB8HV/I\LC5IFR/*S6]_Z@-+T*
M[TX7CN#997LK\D3EC7)^^#]*D:__ "+UB?M_X/J&NKYO8.;=$"]<EC^]EY82
M&AAUAOZ5LP?_ $Y7;H_N5^;\OZN?1#_]JE_Z.J2E_?7>E>*^EA/3WU&3"I:6
MTN0M"T]YLJ6H)3]KJ.VX 2>WEK.VOWEO+"[H&2WC7G@'0@&O]&1\ZO6?<<\Y
M',,CKC0F-:"36ZFX#$\+4K8#TI]2&A]8,3 R^M8_9X#.09;>:C;! QD&8TET
M A#[43,Y!"%I!X@*4!XUV;1]=L=;M67ED7=IXJ,V6N/4!Q^E?+>YMKZEM34Y
M=*U(L=/$\M+H\Y82/R2YC"1Z@KY#(,'L#A'B DCZ0JU9G#JM;JG[08\'/XH_
ME5-$JG[08 )(<  N24I  ]IYK"H4J62=HQ$6X6\M:A^:T@.'Z0KE'TUX,C!S
M7H-<> 759W/!NN!M3ST?F[%OLE+?^R6A3@2/:;"H$K"O1B>%5*%H<2E:%)6A
M8"D+0H*2I)%PI*@2% CO%5%37*B)1$HB41*(E$2B)1$HBZ\ITM,J4G@HV2D^
M!5WCV@414_\ CKUR48)45PHI2O0J.2\X%*@BA\$&(\4IA4=$^E*85PX*<:)2
MF&*BO1*C$J<$J>'%./!*4:E3T2E*<4K5*@<4*4PIXIC7P2IPKX)C1*C!$J?&
MF"C#@H4PIBF-<%&E03BII08)4<,$\4I6F 2E>*@:EO%0[@HT(-:*12E4IPX\
M5&!]"5Y7I*G!$J12JA*&GK0)4\J#BHYU/!*\U7I*] UY+S2B4(KB@.-%8AH_
MT/\ 4&]')\O%=9-,^-9[0W_33IVI#$M _-^(R>K9)M=NU0A&W 5KP/P>XLO"
M&]@J/[[!@?6Z-P/H9X+;R/VELL2#&YTJ\RGK\/=XM/H9<1D>!F'57VK8<"/!
M:AC5*@XXA!AQ4:BN%%-$J%*5ZZ5X*/0E,0/!1@3XK3/]Y5JG7'<M]Q#O0J;F
MMHE:OTQOL&@Z9BLCE]JA9F3MK"\7+;$!;;<.-D\-E7'Y"E%3K+<)G]6H26R/
M@3[TVSHM_P#F3I%IMZ.YU/<^G:9(Z>VM\SC9V[Y0YL\H;[KYWN:QD8(E>UH=
MER %??\ ]SW<GEYM30KH^9L5M::;?ZJ!!>W3V1P.:RW>)64>"7]N2-K&THPO
ME>"\&-X-UO11T5Z_:ET(SN=ZTQY&#W^?M,';-.U26ZA[,8/$87%HBN_MLM//
M)CY+9%*6I<:Y6TTRUYG*M12GJGW</*/5?+39-\R^CDMK^_U 7;('D%T62-L=
M7 $AKY0/:;6M S/1V YS]Y_S"\M-U^9-M#Y<EL^VK:R=;SW+6EL<\DDA>>T'
M %T< RALE '.+\M6@..R;6,Y&V7"X[,QU!*);2?B$<"J/*19$IE:/S5-.@\#
MW5]06MRRZMVS-^L,? \QZBODZ]M)+*Y?;/Q+#ZB.((\"%A%TQ]4G5?=O5CN_
M0;,]'-GP.L:B]L)G;5.Q$J-A8F)@ATZWF8^96PF'.8V8I;^'Y'7?B/-5RI3Y
M*[?/.U=^^;6I^=FH[.UO2[6'8UM\0YLK6R=QD0I\%*9#[#C<D/#FXC\@-[3R
M[Z-W;Y0;#T'R+TOS/TW<-I=;AU PM%FV1AF[KC_"8G1 E[/AN+B6M#0&U<[N
MLKGS7T:,<"OFLX8I4G *!B?!*@&@0BI2IK3%*52HP)JIY)0@@UY* 011*C$X
M\E. P2I (Y*"0E1AZU*5. .*<5;/<,R[,D-Z[C+N...(3)+9!*W";)9!2#P0
M2"?;6.NI7.=V(^)XK(VD0:WXF7W!P78E!G5<*C&QR#D9J>:4ZFW,D*!"O: +
M\J?9<]]>W 6T/;9[Y5(.==3F1]<H7VT_#\J3E9";K7=,8*'<;A;MC\X!XU[M
MHZ?:.XE>;J7-]FWW0J^X#B38#B2>P =I/@ *NE;8#T+"KU)]2CB<=+B07TA]
MQ"HT5',.*U#D2JP-S;BHUQ;SFWQ_)';$T]NX?'R#)$.>9V%?5Q*[%Y.;*_E3
MN.,W+2;&(YGFF&4<O7P6I;8,?&RQE":5O2W7''''BE1<6XH\REW *NWZ!7YH
M36_QMQ)>:@XR7+WESG.XDDU)JOTKTN=VG1QQVH:RV:T-#1@ !@ K23,>YCWE
M!ICRF&C9R3-D,Q8Q2!VK<?<0+#V U9RZEIUI)D9(USQR:<WJPJMUM[AERP5=
M61WU6M+G?( 58GJEMVDX_'2$YO><-BD>6M+@Q4=_,2TBWO!LL)0P%_*2*IQW
M&HZM.(=-M))75YT8/#CBMZVUI>KF426]E,_$8R$1CY#5U/4K6>E/TU='_5;N
MF8F8F+O.TX379[,?(YW87VL9BG<B[RNIA8W&0V^:2&VB%+\XE(N ;U]*^7'E
MUOS<!^&OI[;3-*C:*_#L$DSB>1?('-::= 5I7G_YYZIY.:9!8R"V.M7<;BR&
M,N.6,89Y'D@BIP:&T.!-5Z1>G/I:U31\3C\9'D9<MM1F4-1!-5$BMM(2FR"Q
M!1&;X  #@+"OK71?+;3=*B8R:YO;EX _62D-_H(PQH^1?E1N7S?UO<5W+=O@
MM(GO>22V(.=B:^_(7N/RK(+':QKFOQ@IC#Q$R&E%*'9*#)='\/GD%RQ]M;W;
MZ?864=(HF CKB?E-5S2ZU74M0D/>F>0>0-!\C:*;P]EPC+B4O.(<6W8F+!""
MI=CP1^K]QLK[*N&WENTT<<>@5N_3KMXJ&D-ZG^:JK&9W79$^3AL<G"X\@($E
MY)0?+/N\''0;V'Z":K]Z]N32%N2/J>*H&#3K4?PAYEDZ-X*R?4WTC:?U(QDS
M^DS;><GRF74N*<;'.A3@/,8[JKO7%S8@I([JP&L;&T/7HRW6H67+B/K"OR5J
MMLVYYG[JVC.V;;$[K,-(/L&E:=:4!\:A><+U$_=R9/HSU7=V[5]OFQ]"5\3D
M]CQ\L3LUE\/'CA3RTXY*4NK?0\A)"4N<6^T!7V:^2?.;8#=O:?\ ![:LW7MQ
M+7MV\;<8QS<X@>RQOCB> 7Z1>1GWHKW>&D'3]X,C;J,8#8YW.;''*XD  UIC
MU+<,.15(ZGU5PF<BIP>B,/0,(VX6%NO<PS&66A1;6_/6?UC"7"/YO@H#@;#W
M:^)=0V_?:=.7:N/X::>R/=;X#J1U7U [1>[_ *4U.1L]R144_51BE0&#G^D>
M/'Q6=G335%?LAF<^^AI[RTN-^]R+1WIY"+%)'=;OK:-)VZ76_P 7FRS#$&M"
M#Q!!\%PK=^NL;?NM&-+F$T.%01XK.7T[=;9F*SO]&,S.#BHZTF%)<7_/L@@%
M"B3REQKL/Z0-?8OW?O-VXN;AVSMR39KR,#LR.(J]G#*2>+A\XHOC?SV\IX6V
M;=V:!"6Q._6L:,&N_* Y _,:K)GKMY.?UJ?*BE*T2HSC@Y2#REQM1M\Q-J^K
M=Q-%SI<O;((=&?H7RKH)-OJL9E%"'CZ5HWUJ/+Q6R9V$ZT5!O*2DJ"@;%*WU
MJ!MV]BN''MK\B->CEL-VWUI,*N%T_P"0FH^8K]&;>:.ZT.UNXG$'L-((Y$"G
MX%>/+S)B,>F.7E)#B"8CJS^>4^ZP\K@+D]AOQ^7MIZ@V5L%&DY"/D4Z=';:G
M-24!MRWC3F.H'TA:\>K'4O(ZUDI^/S"G(KJ%*4E#I*4K0?LN-J-@ML]Q'XZU
M_2MN3:A*7,!/M8KKNF: PQ-=&*BGJ5AL$QU ZP?',ZCAYDB$TA8=R"D._"+(
MX%+:PD^:>/=P'C7;-I>6NHWDX?9QDY<2:&@IRKU5#<>MZ#M2)IU69C9G'!M1
M7U@E45C4X_IUFI6 WF&G'91E96XU)]SS$N*5RO-E8',VLCM[B+52WOMG<,-T
M;=C7A[1RKB%T/8^IVFO::V[TIXDAX8'@>A\55K.6QVP3DHP)3Y*1]MM5T 'V
MCOKG,MA<Z;$7:@"'GD>*ZE QUO%6;BLG_2YU-C]%^J"LQE)%V,Q%3!=*ECE9
M6TYYC2^) %PLB]=<\F-]MVGN'/*W^!SL#2>C@<"?55<%^\9Y?R>8.QQ%:87-
MI+W .H(HX?,%<SU\>JYC96,+@H4D_ R(J,E-<2O]6L-*4AAO@>4W4BY^2NM^
M<V[9=W"WT*PK\.X"1_RX#Y17U+Y;\AO+D[<N[C5+]O\ "P\QL',=3\F"T5]0
M^K\B9*6SCE. \U@XPXI"N:Y'VD$$6K3MM[-CAB#[FE*<"*_2OO#;FE7#BV1K
MG-'I*V0_=>= ]CZ[;D[M^U93,S=5P$U$:+BGI3SL*9D!RJ<4]YO.'$1@H #L
M![>ZNJ;*\N]#U_61<3VD)MK=P-0P#,[U#D/G7&/O3^<]WY=[=9MK0WAFLW<9
M+GX9F,Z#F"[F>B]>^B]!-;P6!C-152\6Z&4!L1E-I2A'* 5<I0@CF\+]@KZI
MLMOZ?9P"*V:8V@847Y+ZANW5]4N'7%\\2O<:DD<5/).FY+#DJQ>[/@IXI9<4
MZ5#NL?+6M/UBKEUG+'^KF(].*LFZA#-^NMVFO,8*7*S/4O&D^1-AY5L=OG%L
MK('^^!*K_/5,OU*+W2UX59K-'E]\21N\/W%="3N^Y*-LE@GW!W^07 CP]U+1
M<;_%7@WMZ,)(CZE4&G:<16*<'TKIHWF.%!$_%Y*&HFW,6O,1?^*@\.^O(U!M
M:2,>T^A2=)?2L,L;QZ:%5/C<YK<XI\W+L1+]HE-O)4/H20/G-7<=S;OXO ].
M"LI+.\C^H2/#%7JU*;BE,*@X[*L9!* 7TH;?;<4TDD!?*V/?0V5*!MV GVU?
MQOC<*1N#EC9&2M-9&EI]"K*JJII1$HB41*(E$2B)1$HBZ.0_F!_OB?Q*J0H*
MDM2*'!#4!*BM"I2@\5!KR2A.* 842E>?-*<D^>O0-?2H(IZ$KR 2IJ E0I2G
M%$J>''BH^A*FF%2E<:)7E2E3A7!/2E37Y5%$J*T4I05."@]4IP*GBE17"B)7
MNG,+S7&A2O!-5Z2O5<%YYI05ICP4GCXI0@@8H""4H /6H)/J2A'/FE4H#Q4I
M4"IP0]4KU2@QX**UX<4KR:<EZ]*5+150310J30!0*DJP_J':?Q>E8SJ3 ;4Y
MDNCNU8;J*$M@EU[78#B\;O,1/*.8ID:;DIJN7O6TGPK6]RM=#I[=5C!,EC,V
M?#FQOLS#UPN?ZP%NNQ"RZUI^WIB!!J]M):8\!,\!]J[U73(?42KZLO,26694
M9U#\64RU(C/MGF;>COMI>8=0H7"D.-+"@1W&MB:X2-#F$%A%0>H/ ^M:66NC
M<62 MD::$'B","#X@X%?2A<2E$J3\Z#YDJ.2E*G*2HJ%8[K;U</3?$L8K7F8
M>6ZC;)%F.:OB)?FK@8N!"4PUE-VV=$<B0UJVO*E-A2$6>R,UUB%'N\^"GF?F
M5OUFSM--O899-Q31.?&T@O;#$TAC[J9K?:<QKW,CAB%'W5R^*VB]I[G,Z'Y?
M;(&Z[U]]JSGP;3LWL%Q*V@?(]]71V=N7>R;B<-<<QJRWA;+<RTCB(=#H-TN>
MZ<ZO)FYV7.S&^;G-<V/=,_EU-.9B;D9JU/ICS5, ,,KCASWV6;,,+/DM#R6F
M@,=Y0>7IV3HUQJ>JF27>>M7'Q=_+(X/E+W#[.!SQ@1 PY2&4C[KI3&!&6-;/
MF3O-N[]99%I\<5OMG3XA;V<$0(BCC9AF8#5QSTKG?61XH^0F1[R;Y7XFNN\A
M3JN=<S7@K38C_P R]XFX!9*,#MZG,MA5*-FHV72/[^@IXV3YU^9(OX5B(JV&
MH&W_ /AYO:9X/^LWU\5G)_\ 2.EMN^-U;48_J6?4<?1[I*FF"6I74[J/[Q*6
M\#T\:L2>!\G8W;6[B/-K#:4<V]=9KP%KIP_YX?PJYOP!M72R *FXO?IMQ^!7
M%K;ZT."UOB,4J:UXI2@P2HKC5*)4BE$-?4E3QX\5'!*@U H5.!Q2E",4J#@H
M5(H,5!J<%&O(7I4QM&>3AH12TH&=)241T_G-I-TJ>(L>SN]M6UQ/VF8>\5<6
MT!N'T^H.)_ J?UC%HQ4-[8LK_P (<0I;"7/M!*K^_P >(<>(L/ <:I6T0C:9
MY/?*JW4W=<((O<"I]3[.3R2YF6FQL?#"PX_(FR&H[+32>Q(6\I">P6 [ZHOD
M9F,MPYK(QS<0T?*:!5FQR!@AMV.?,> :"X_( 2IZ[U5T.,1"QN2>SK[*0AN'
MK./FYI8Y0 $>9#97'!^58'MJA_*#2@[MVLAGDZ1-=)\[06_*5<C;>LEO<N8Q
M;QGZTSVQ#Y'D.^96UW_K1L.)Q,E6*Z?92.E32[R]CRN.PB4I )N6>>1);N+7
M'+<"L%KNZ=2TVR?=6U@2UK2:SS1PM ZGWW ?O5GM VEI>J7S+.[U*,.<X#+!
M#).X^C!C?G6I3=.HVY=1=P=<DLXV(S&=<;CB*_)R3(/,0IULNMQ&G%6X!121
M;LK\V_,O?VX?,C<O:FEC@T^W<YK&P5>TFM"[.]K:] 0T#HOT1V%Y>;<V!MH?
M#.GEN9VM<\R-;$_A4-(!>6CF16O54!N,3(XR,N1*G3G$@%2D(6B*VJW&Q3';
M0OE^<UH]YMZWM6B6[[DV%3G>XCY 0WYET+0;BTO9>U#'&#U(+C_3$_0L&NKW
M49B#"D./14V:2JQ6M2_D/OE1*O;6/@:R]G;;6D;8\:#* /H7?]I[<>*/:\XG
MEA]"UVAO;/41U PW3#1(ZW\MGYGD*4D*6S!A)4/BITFUREB.A5_X2K =M=\V
M%LFY9=1Y69[J0@-'CU] XKH6Z-QZ'Y8;3N=V[A>&6ENRH%?:>\^ZQOYSC\@J
M>2]:GHG]*6K>F'I7KNM1TMMNLL_M+,3Y"4-R,GEI0"Y,N04CF6XZY>P ]U-N
MZU?=.V- AV]IK('D=TC,]W EQ_%R'1?A%YQ>:>M>;V];O<M]4MD?DBC&+8XF
MX-:WP X]3BLUY&S-N)5^RH3\]] * KE*6O>XW%AS*'N^RMA==AWZAI<X<^2Y
M<S3BT_PI[6-/C4JFD8[8-G?4WE)*($=7!J-&N5J%P ' @6N;]Y-6HAN[MU)W
M!K.@5^ZXT_3V!UHTOEYN=^!5MC]2@Z[R($("4@!2WGT\[A4KB% J%OG K(0V
M<5K[K1FZK$W.I7%\3W'')T'!7/Q&>;6A+$UQ+90BR9"R$HY4C[+I[$V2.WZ:
MR#)</:."Q;HZ'V1Q_=ZU3$[:\ML\M[#:$E*F6EEC);8^#^SH)XI<1CR0/BY2
M1V6N :QLE_/?/-OI=.V#[4Q'LCP9^4[Q& ZK*LL(+!@N=7J'D59"#[;NA?\
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M>PGLX7XU;.B,EO0XX*+2;X:Z$C31P/'UK#WK'T_UK:XB,!N:0PH+MAMF N[
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M?1F]N2GCG!5O!JFCVC>Y8Z9#GY.GD?,?Z'[./^E5=:_T>T?&LLR,A@D9K**
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MVJ.H1;,;'55S,:B8S"-XV''99<>3\0^6D)"@DB[+?/;F^R.8B_?5^6LCBR,
M HL6'OEF[DA)->:DFMI#609E.)NA#R1[P!!)4+\#V@"J%L*/S'A57%V:LRCB
MKC[;.P>,Q:\AG9;4)IL*3'=(YI#SINI$>.RG]9)6XHV"4@FY[JN[VZM;2 S7
M3@UG+J3R#1Q)/(#$JTLK6ZO+@06K"^0\AP YDG@T#F3@%9-[%Y[95I=R[,K
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M3Q4T 2@%4JE*)5*5*FB5- ?2HX)4'C@GI2GAS3Z$J?#FGBH5ZX>E>:5]"5'
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M!\1&\#Q49]C65,L>I:C(!CG=%9Q5\ P7$I'I<P^A?4=+W,AS*V[J!OVT\_\
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M0.4&Z38W62:^HI3E8&@K\O(<79E0JGT\SI*TH:82I3CBU)2A-@2M2UJ(2E"
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M6"U'<: V4"VH]H#7Y@ KVPNAO2F,\U+GZ?$VK)-*#B,QOTW)]0,OYR5<P?\
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MQDD^04-SI#ZV4H4ADH^8M/\ +X7VIQR7S(X=YLT$:Y#-<5<Z"^=?E]LV:N!
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MXGYS48H8F5PJGFJ' '\/IJ?I4Y&\ GFK\?QT49&CDGFK\?QU*9&KF'U#LO\
M2:\X^"=MOBH_$&WV1?QX_BIBG;;XI\0?T!]?[]*%.VWQ02#WI'TFF*=MJC\1
M_!'R7I0ID:HA\7XIL/8;TQ"@Q]"N1>1W U KS4"-RB'D&_=;ZZE.V>2AYR+\
M;V^3C4IVRHAYL_I6^2O)S<E(C"^@4A0N%#Y"0#49B.(0QJ'.V.U1'S$?C%,Q
M/!!'U4 XV38*^FE2.*&/HH\Z >4GB?J^>]J5-*T4=O'BN5T]Q_[I/&HJY>NV
M/%0YD#@I0![@#S</;8=M34\D[84;I/>!\X_+3-1>2RF%<4/"O0->"\$4-"E%
M"41*(E$2B)1$HBH#J9U%PO2W4)^V9B/-R;J'X>)U[6L0VF1L.Y[;F7TP=;T[
M6XA(^+SFP9)Q++0)#;*.=YU2&6G%IQNK:G#I%DZ\F#GNJ&LC;B^61QHR)@YO
M>[ <@*N<0T$C/;;V_>;GU=FE6CHXFEKI)9I"1#;P1C--<3.'NQ0L!<[ZSC1C
M Z1[&G$#(Z.^SF,+A.J^3Q,KJ=UTR6/W[U YEB05X#4ND?3R6S+UGHCJDAX(
M6WIO]))D?%(-D.9A;F6R#J0MXH;XQN:SBO-9LMK:W-#\=J+VZAJKBX"./3[.
M1OP]DPNI2&:[='$*T,S&7;W"KB!W+2M>9#IMUKFU8IF[:T")]EHL9;]M<:G?
ML<V?5)VMK6Y9;,DN32K;:EA;,.6,%UY9K6*ZD]<9",;E&IN%QG3[!(V%,984
MS,8;VK,9&'$0M/!3,B8L!8[+-&KJMIN7SKN8[:>.73K?;-IW@TY@]QU"Z?&R
MHP+3DJ\?F@=5HS'7NW/+6,7,+H[N;6)S"7 @M/PD,;W4.((;@T_G$]%8WU1>
MC'I]Z@=ZTIO:MJWC1H,B;DI6$R6CSX,5 SK[<&3L.M3X>3A3H*6=FB8EJ;#D
M-H0_'FQY'*5!TIK4_,GR?VKNG>EO!N$21Z1JTKWQ21AOV6H"-IN(?;:YH;J-
MO")13'XBUD.+IJ'I/DM]X'=WE/H6H3;<MM/OKEL#(YHKN-SP8 7B"=A8]C\U
MJ^5T3VDECX98P0.W59X:UKV+U'7,!JF#9=8PNL87%Z_B67Y#LN0UC</"9Q\)
M,B6^5/2I CQT\[BR5+7=1XFOHW2]-L]&TRWT?3F"/3[2".&)@X-CC:&,;ZF@
M!?-^K:I>ZYJMUK6HN#]0O+B2>5P :#)*\O>0T4#1F<:-& % ."G=7RQZ41*(
ME$2B)1$HB^$B5'B-J=DOML-IXE3BPF]NX GF4?D!J'.:P5<:!>FM<\T:*E6I
MW7J!'C8N6QBN93[B2VE]V[:5>(;0+J4#[;5B;_4&QPN$7O=5FM-TI\]PWO"C
M*XK"-6FS,S/R.R;'F)*T)+RF(S+BT(CH5]@E /OK%KW[JX^W:;[S4I==UBZE
M?QR1M)#&#EA7$^)7<#NJ"QL(=#T6UC:XTSO< 7//IY#H JDZ(1M8E3\G/A!$
M[X!R4P_)= 47)31*1S\2"4*/$>R]9W8YT:=LTNG .$<CFN<<27#B">H6#\PC
MKL#(+>_+HQ(QKFL& #3B"/ JJF%1LKO\)Y_D(5*88:!Y0 PT]P"4\!97"MC
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M2E,9F>V0"(S9,%A8O9\\K@M+;:FJ;GN8M9\Q.T88G!]OI4;NY9V[@:LDNGT
MO[IM 07-%I _]3%(X"<T)M6M](B=;;>SR3O!$EXX%DCN1; P^U!&?[8?MY <
M3$*L7;RV>ARA(0^M3>/B@KD'E)4ZEHWY4(L"I"0. [21:NB2'-4G'JL):VTS
M'-R#[5QH,>JI*5UCZ?8J 9+F1\EEMQ#*@AE?ZM:G0R+ME/,GD<4D*N.!/A5$
MR1 +.1[6W!=3=ID=7$$\1B*5X_0I@.HN'>:;EP9D><AWRUMJ94%#D<4$I4H@
MW%@KY;WKPZ1O+BK<Z#>1N,<S',I4&O4!='9.IN/@M_!A32Y3X2&TI6DD<_$&
MP[1;Z:I33 -('%5]+V[<3RB4@]EO%23'[(M:%R)#;P:"5!2P"E/, OW>\G[)
M/"X[!5F#7BLO<V 80R,M+OGHJJ&V0)N/96E7,EH>8GRE^9<H 60#X'L[".(]
MM5.X"U85VF7$-P1UPQP5"+WK 3,EY;$]I2V5*#K)4E+S3@-N13=PL*OV"WA5
MA)+&Z3 K:(=&U""SK(PT=SY$<B"JO7MF"CIA252V0^M2& W=/F+["$$W[.P
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M02 7&A ]:V-VE76TKYE_HDKK:9Q [D8#7 ^D"JQ\1Z&_3QM#LF=B-1GZ._\
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M\W&@X_'P65R)DV7(=(0S&C,-J6M1-@D&J<LD4$3IIW!D+&ESG.( :T"I))P
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MM/<,N33"#V@*=VX -*P1G$LK@9GTB;PJ]]&&@)AR^%R#LO(SY<_/F.J+(EO
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MG_@B?]^1\_NKJ0O+N"I:YX]W'M\/9;OI0*G0(+\3V^RE AHH\+]OS5- HY*
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M59NA-,.*R)LH;/[."@X?NIR4ZZP;YI>$U"<XG,8U]QUM(:Q33Z!,D.7"BZE
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M&JHNK=G/V5;2P22,'UC7I^)/V>C%LH:>RJ%REN!(CXH?$.*4"+%U94EH$@\
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M>XI;!/,+^)-;Q'9PQXN]IWBM/FOKB7!OLL\%5B76DI"$I\M"?LI0D)3P'8
M FKO #P5CE<36A4?-0">!M;\.-*A"UW0J >2 >!-^[L^NU3453*XXT*><DD"
MRK<>SM_?J*H&FO!45M/475M2;_Y1F^=-5_-8V& _*</=SA)Y&$W[2HBU,78,
M%2LKINBZCJK\MHPE@XN.#1ZSQ] 5ALIU=V7///-PY+.!QG*H_P!ZE)E^6K@D
M.RED\A*>WEM;QKT8S3VC\F 6\VNT-/LHP^]K/<<QP;7T<3ZU0<+(-O>>^A],
MIYY;QE/R'B])<6%6"7%+"E*2"FX-[4R@8< L[+%V0V)C R(4RM:*-'CZ52>:
MVDMH?$ <TH+#2T+LE"BD\ FY25A-N(22/;7IK ?0LI:60S-[Y]BBMSG=XV13
M:_@IC&*6S9<D.1V9GF!*??;80I*5MJ5XI-P/"]>Q&VOM"JS%KI5C4"1ID#N%
M#E^7JL9>I'6+.:Q&DY+&RE.)2%N%*2YY7,RD\SKX)) ?*2.6PL!V W-5VP-.
M!&*W?1MNVET VY:,/H\/1UXJUF.];V R$!<!@+B[0S&M(CY.2S&@AP\Z0\VK
MF#LL-V 2WP*S?BD<"=:.;B?<5X-B1&YS%X^%K7 '-3ITQZCAT*Q!Z]=0F)C;
MN4V7,-93 ; (B'X#3J593&S%N!M\M,M@<_F1U(#02VH J4 22 /;(^3<*8^%
M!S/0#F>BWK3[..TC$$#,K68>G\)\5:'9MNU+HSAF'=\R69?=>QWQ^K]'TON0
M=OR*)30,3(;I*3S2>GVNO-*NF,H#+2VU_JT,((<KBEYOS7=^7TVW_)X0OMX)
M3%=ZY,WN:?:N!H^.R94#4[QN(HQPM878S2.([9V.VTUSPV:ZJR%W #WY/T01
M0-_NCAEXY0\BBPHZR>H/<^N,=M.\N-,)@N+.$QN* CXO$1[_ -[X^!!+BQ'C
M-)[5$K==62MQ2E&];QM#8&C;($LNF&>[U>[(=>7UR_NWEY(/K33$#V&_V.",
M,@A;1L4;0%G#8OM[8,#8XH026QC@*_6/-[R.+W>T> H,%CU$R^8B**8>2F-J
M:00IM#RW !=)*%-J  "C8\.RU;VY\9%:8A4XM,AG;7FNO+6_+E_%2)+[[O(A
M)#@YG+-@A "OS$@< !V 6JU+<S37W5E&6<%N0(ZU(]?I7=@2=@;2A<;(3X@M
M8(9?6CD%_L)L1<'ZZM7.BC&/%58M%==/[KVT9Q*^<PK*BN?,DOOWL7)#BG70
ME/#D2%$E(X=@JS+NY[H]"V6UT2VA904:RH))/+UJ3N^5-6E:"MN.FXY2%#S"
M 0;@VX@_55(T@;0XR*Z?IS+F0!KV,MAPQQ/J5Q>CW36)U<ZJ].^EB,Y$P$SJ
M#NFNZ;'RTU//"Q:]@R;&.3.E-I4@N(C^=S! (4M0";@F]6,U[D(#0/:(&)YD
MT6,W$RVV]MR_W"X.G%A9RSF-N#GB-A=E!Y5I0D\!CR7JYZ7_ ' /I@U$.*ZB
M=1^I_45SR$LICXM_&Z-#1('\[**X#&2R+Q62.5/GI2D#L)-7)T\RG[>0GP H
M!]*^%]2^]3OB5@BT&STZP96I):ZX<?"KRUOKRDGP66&K_<_^@'5)$&5%Z.9'
M+OP@D.JV+?-PRS>44F_O9=A>4:8F!9/% 2AL]G+;A7LZ9:NIGS$#D7&GR+2+
M[[PGFW?L>Q^J",/_ +5!!&6_H$1U;Z0:^*R?Q7H[])^"9C1\/Z<NCF/9B<OD
M)8T3!\R>2W*5N+C*<?4+=KA42>VO9T^R-,T3#3J*_2M(G\P-]W+G/N-8U-[W
M<:W,N/JS4^1=K8_39T%<A/J9Z*=*D1Y"/*GQV]!UE*)+9!2DNI3CA< &Q]E4
MI[&T(J(F4_1'XE;VV[MT,D!_:5_F;B#\1+@?#VU:O#>C;T@2'I,2?Z:NC+B9
MZ%,N*.D8=L@JX\J5-,I4V%GO24F]6T-C8DY71,(/@L[+YD>8;<LD>MZH"TU%
M+B3^NQ]:NG@/2/Z6-78;C8/T[=&X#3(4E _J_P!<EK"5<%!3TV#)=7<<#=1O
M5\S3["/W(6#U _2L/>;\WQJ#R^\UC4I''C6YF^@/ 5!9WT7^DK&9 9S'>FOH
MI#R$M;KTB4QTZUM"ER2H++O*(/E)<5?\U(JVN=/LC1QB8:^"R%MYC[_=%\,[
M6M4[+< /B9<!_1U^=7/Z<=,^CO3F)-RVK=-NG6FOP4N27,G@=1U[#S4MK0KS
MK3HD%B3=9'Z8^BJEK#:6\9<UC&-;C4 "GK6&U?7=PZT\1ZG>WEWF( ;+-)("
M> ]ESB/F6E'[RKUNM2-:SNEHE)&L.!:G&3&1*9>0RXM,=UP.I<2I7FIYD^-@
M:XSN/<M[N"]=IMB<NFM?3#B\@\2>E>%%]S^0_DW:[<9!NK6&..X7,JVI([(>
M/= 'ULIHXGG4+QP;3U$VN3L>9=Q67?:B/3I#D:.F/&+"6E.*Y"EDM%#8([NZ
MMDLK.,6K1**R 8FI7URRWA;#D>*R8X\_W!5GKW4+)LPVQE\+A\@HI3S/!DM/
M+X>\HALEL+]MJ\36+7&K'N'T*I!:/D80Z1[%<#$Y;5-B2M&1PTW%0"1Y\C&R
MT(D+43R\B6U,K4\"H^Z$VX_+6,N3+9N!<X.=R!5Q#IVKO!%C,Q\A'UQAZS7!
M9 R_2UF\#K$';3HW4?!X+/PDS<9F=AP2I"51E'F:F*ALEB5"C/-\4E] YAQ'
M"K.ZO)W99+CV8_00#ZUI-CYA64>H3Z,VYL;G4H9,KVQ2_6YMJ:AQ!_)."L=%
MZ<0\ADY./8V?7\HMO@(\7*11/6YQ4IDP@>5A0M8A:[@\+5CY];LXB&]R-KCU
M( ^4X+HUOJ%U)9BYFLKR-M*U[3G-IUJT&H] 4GR^OP\,Z]'7 R#"F;H6%*25
M.E/:D+;'*$GV54$SY@'!S7 ]."O;.]9,,[7M[9\"#\AH52!=2"IU,1V.TV"$
MI 4.P6XFUS>H>,,M07+/0&)PS']6 J0DM2GWERBWY,;GX*='*5@6) OQ*;55
M]AK<E:OHL=/ ;FI I%5=ELPUM&.ASREA1?5R$#F4D<!?V7X"K1XD#LY&'!8^
M:*2%H@B ()QYJ_W3+J3K>KXJ4)FMR<ID^1<9!6LQVD\Z"DNETD*6N_8 #6M:
MGIEQ<S59(!$<5-IH.JWDYJW)#FQ)P'J5H=DR33,B7(9;#*)#[D@(0>#2W25*
M22>*DA7>;U?0QG(&'$@46ZSQR:=:M@87 M'$88K,3H-MFF:YK[&:>C,3YR$<
MTB*I"7%N.J]T^Z>ZYK0-PVM[<71BJ0SD5I1CN)G$.)S$XE9<ZCUW==F0HDM.
M U_".R%N25S'0W\##2HCF0@E-G%I7[.RM'O]% :YS<\DM*"@XE7,EF W,W,Z
M0!79W_KMCID5B+TXV2++QC"$(ERHCG,R[)64CE4Z;A7'MM>L!'HTS7TO&.:T
M\B*%>-.T<L_A&H1_;N.%>0\%W]YW3"Q=3TB/&SC4O<9B?B)S;%KI#B &VRH<
M??=4.%8%FF.EDDD##\,VM:\L</F63T>"YDU"Z<^,-L &AGCU*R'T;=\JSC<C
MKV2EJ#2\/"E,.*64*CS%,746E"RA9:;@BUC6FW-6 Y*Y233P(.!'BM4UW0+2
M6XAU.WC'=[SFN%/>;7G7PKZEL.]-'J]SNK:U%P^VOKSV+BK2V,@XLO2FHR?<
M2'>8A;I; MS \UNV]J^B/*_[QFI;9LV:'O!DMYI\9HV<&LS&='@XR!O(US4Z
MKXY\Y_NVZ?K.M2ZOM#)97THJZ#+2)[^K:?JR>8IEKT6T#&[+K_4?6XFQZW+9
ME)4R'N1MQ*W/**>90 !!(1V^SB#7W!H^LZ7N72HM8T>9DUE,P.:YIP(_ 1S!
MQ!XA?"6K:-JFVM4ET?6(GPWL+BUS7"F/4=0>1&!5L7<7G-9SCVWZ$&!E92FS
MLNJR7DQL)N;#8"2YSJ_58C9VFQ^IF !#M@A\$66G 7^DWUE?/U[;60:B^G?M
MWG+#>-& S'A%<@81W P- R8.90LV&QU:PO[%FA;FS&P8"+>X:,TUH3C2G&6V
M)Q?!6K:E\):ZK77WU+;L1NF*.5Q"GVE,2'(&5Q<YHQ<M@\JP 96*RT)7ZR+,
M8Y@?T'$$+02D@ULVCZS9:Y:&ZM,[7,>8Y(WC++#*VF:*5AQ:\5!YAS2',+FD
M$ZQJ^CWNBW8MKO(0]@?'(PYHYHW>[)$\8.8ZGI!!:X!P(%?8/_AB_P#!U_V;
M598K#G@JLKRO*41*(E$2B)1$HB41*(I)G_\ @*?\(;_L'*IR$M;4)4C@J,JA
MW')F*4[CN:9BE.X],SD[:"1W5,SDIG<.)3,4J>XZG%,Q2H[CTS%*9W]4S%*9
MW<TS%1X>%2'FM"IS*'&JH<O=04X&O68<TJ$IF;U45"4S-ZI4)3,WJIJ$IF;U
M45"4S-ZI4)3,WJE0E,S>J5"4S-ZI4)3,WJE0E,S>J5"4S-ZI4)3,WJE0E,S>
MJ5"4S-ZI4)3,WJE0I+L&>Q^M8J5E\DLI8CI]QM(*G9,A7NL16$#BMY]P@ #L
M[:IS3QP1F5Y]D?/X#Q5Q;6\EW,((<7GY .9/@%1^DZ_D'IDK>=I;OL>9:#<&
M(JY1KV$59<?'1APY'GDV6^H<5*X'LJTM(B7F\N/\X>* ?D-_)'X5?ZA=Q-C;
MIUF?X)&:D\Y'\W'P'!HY*Y?;P';5_F;U6(J/!6(U4?T_ZO[9O2SYVM]+VIW2
MK2#]IB5M4I<2=U6V*/\ FJ5%?8@X%MP D&',2#91OS/;[ANC?.H;K?[6DZ4'
MZ78]'2AS7ZG<-],K8[-KARMI:8.*Z=KM-K;!L-L#V=8UIS-3O.1;;-#V:9;N
M_2:9KUS3Q[UN[ZH5]JZ9F;U7,:A?&1)CQ6R[)>0RV/SW%<H^;O)^2H+V-%7$
M +VUKGG*W$K'O7=L;9ZA]9UXQA4YR7GM'88<Y5! 3$T+%)(Y;<ROUKY(\:Y9
MM6\8=^;ODB&9WQVG,'[W2[<_2]='UZQ/\D-MMG.1HM+UQ_?7\P_X*KY&$V3/
MJ#V5E+B12;ADGWN4\0$LH( X^-=#[4\_M3.RMZ+3#<VEL,MNT.?U*Z&S:$F&
MQ%V'66__ #FP-WVENV4<G#39<G'/)L$<BTINC@;*%6M]IC?9O;$#]H0^Z3]9
MO-A\#RZ'%7NG:QF+]/U!Q_9<_O#\AW)X\1SZA57C9^'ZA:J\EQ'/#R<1Z!DH
M:Q9V&^I'(^RI/VFWH[@N@]H*015TTV>NZ8^&9N:UGC<R1AY5!:YI\1^(JPFC
MO-!U-KHW4N(7M>QPX&AJUP\"./K"Z>AY.8N%,US,.%>>U20,7-6K[4V&$\V*
MRB> YD38?*2>P+"A5AMVZN#;R:3?N+M3L7"-[CQD92L,W_&,IFZ/#PKK7K:
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M]KNVA>"DXS'(^+NPYS-M$,H(Y>5*0CD  -:IN'SRO=7KIVGV[(2^H+B:Y?0
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MIFPV[Z\)"X5_1/ ^CBL(MV]*_5'ISB7)"^F.P0'>UW)YQ275I0>"2"TD16;
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M7VP+">,Q!@S<0317C:]6&H/8_DB[%%?6L6>2B0VHM\+$DA7"LP-1O(X<CV2
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M3SF5UG))B1L2^PZB)-?=0VGE:0I*G@HVXJ(O[*Z/8Z?':VC8+44C&% %Q+X
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M,0XXT?R]7)7RV+:,=%UR!N>8R'(UCD(@YQ;?)Y;4I*/[VG.&XY$S&P 2> )
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MG2A:DIORDW!-?G7>[KTUE])':PWDN5Y'LP/QH3U X^(7ZXR32W-DP&VN,[F
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MRI:'6[@)=YA\E[V^85>!^5]>2U\M!CRGC17,+@+?G<WN<GF^SEMS"WA63;(
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M1JZ_L75=<@N:0/MI'NP]M[VC'T-*U3]5(/I9GY=J)M.]]78^3Q45MM(@:AA
ML15@)2P7'GEH<"%)X>%?9FT=U^>UYH=M<:/H.A/LWQ-#727T@K0<2&MJ"N*:
MCMS1M&W-?1WM[DNYYW/?&&/<UKB:U:X-Q'TJU*->]&UA_P"=7J F@F_NX;3X
MR3W<.=M7+?VUM)U7[Q\F(TC:T8\;NY=]#54&CZ,[$7<I!Z1._$%4>,P_I#@)
M5\.GKT]S_:6](TN,I0]G+ <Y16"U"Z^\3+C);[4CITDNW?B6WZ)HMO:-[EO,
M1F'%T9K_ %07JC^Z4P:<1Z48$_H5 Q+.J[#MVS9*6_U"RDZ9L\C*-SUXZ0N<
M,+!C0&VT" E#2&Q8-)23[Q-;YL]OF!)I DUG]CC4B]V?M?$9,,!0''A3FOS^
M^\S<:#/YJW%OK<FH/N;>UMXQVV1-C#"S.,N=Q<<7DDGZU<*46SEU/6<MN*<E
M=,&&TI)7SP]CD )':3=]L$"MH=;[N(QETT?\7,?^&U< :_9+2*1ZJ[_C(&_\
M!RU=^M'U#YW3H3^NS\KK&06ME9R./U:/E,3*:8L;GXN1,FI"WB+!(0%6OQM7
M'O,'4-]%O[+TC4=+BG=[_P#!)74;^E\32IZ95]3^0WE[MC69AN*>SU%D$+@8
MGRS1/8YXZ1B)E0WC7,16@H5YXNI?J4Z)9[:%-[5H.6E20A3(7(WW)Q(X"#]E
M46-'0 3R_I<:YG;;5\V'1YXM<TYK?S=/K\[IBON"QM+:)OV3K@?O8_YJQ1V7
MJ5Z:)^:<>B^FR/EW>;WIC_53=8S2@#]KR8C[:3<\?&LY%M7S;9#[>[(HF]&:
M9 ?G<\K<M-TN:5P9').&GG2/^L*S"]&_2SI5ZE>J&'T/7_3KJ^NP7 J;F]BE
M[#U"V6/AH#)]QQZ*YL<%J0[*> ;;0I:0JY/8*BPVCYCWVIQVMUNR=\1-79;"
MU:,HQ/ 5H>'&JT?S@WDSRNVK-KD\TT]W@R*(211.D>[HX0N(#![1-#3TE>P7
MI5T D]+=2P^KZ'O6.U;$8Z$U'9@:QT]UF##82$"Z&FY+L]U/'BHJ6I2C<J)-
M?0%CMW6+2V;;QZO+0#BVVMFU\<6.^E?DSN#>^G;AU:;5M4TGOWLSR7.FO+J1
MY]+@YE?4 .@ 599GI]NCS"I#G5S8WW&A[WE:SIC!#?#[/_)+I]WYZ]3Z!K+V
MU.LWP/YL5F/IMRL?;;CT&-^4:%94/6>\/_TX5!KU#8P^&WNJ^\ .\0IJ'I;)
M*Q<$7.L.<HX5BW[<U)SZ/US5Q7I\&W_[H5F6[DTD1ES-!TDD=77KO_O853OZ
M+EE8EEUSK%U74IPJ:4RWD=3CMA+?$V\K4 H"UN^KD[6NBP%^N:X?^.MA_4VH
M*L6[KLFS$,T#0:#'&*Z<?Z:[*MCCNB+W4;1-J@O;[U":_I)B]E@LP4YC%'#2
M\@^B5%QLO(P',$L32_,:;=D)*@EQ0-@D<*TC;FP&ZSM*YM9]5UI[=0DO":W0
M )EED#2<D33P#2:$5X\UNUWYC-VMNRRO(M*T8_ 26KR[L/[H8P,<]C'][V0&
MES&&A+12I-%:-S'KQ.B]%_4\]N_4L8'.XC5M5]2;B-L<CY?':_++N!8VE63A
M0(\YG&=(NI4I]4R,M2FFL3-FN626 :M3H=O;V.F[_DO=8,<MO%!J/\.G!$52
MWNG*YM/A+ESB_"HADEJ?9%-Z9=&^W%K_ ).Q:?H_[0M[FYN-"'PC'1OG;27X
M<1O<YA?JFGM8(GTS.N8K9H)$A"S15T9U]5P]MW5>3XE75/;0A0[00J)D&4*2
M0;@C@1Q%=)=L?2'_ *RXU9X_\2OA_4SA<";OW5FC[.ST9G_\ML_^%"5\CT.T
ME?\ /9#J+)OV^?U6ZC$'Q)\K96N)JB?+S;#O?_:3O3J6HG_[TJH\Q=QL_5LT
MMOHTS3OPVQ7R/0+IDO\ G86VR/'S^IW4UV_C>^W\;T'EUM#ZT%R[]*]OW?U5
MR54'F=O)OZN:R9^CI^G#Z+1<?^SWT@/\YJTU_C?^^=TWZ3?Y?B-I<YOGI_LW
MV035^GM<?SI;AW]5,5)\TM^?5OFM_1M;-G]3;A?5/I^Z,#[73[$O?X5-SLSZ
M?B\L]>O7^SC81%'Z18N'YT>?^J)5,^9_F$>&K7;?T<C/ZA@7W3T$Z)IM_P#R
MLTERW^[X5F3?Y?B2[?YZ#RW\O :_L+2"?&T@/TL*\'S-\Q3_ ->:H/1<2-_J
M2%]AT*Z)#_JAZ:K_ -]TO7WO'O=@K\:KLV!L./\ 5Z'H[?196W^37G_:5YC4
MI^W]9 \+VX'T2+L(Z*=&6^+?2'I<GL/_ ,+[4B;CLXJQ!-7;-G;/C_5Z1I8]
M%I;_ .35%_F'Y@R>_KVMG_[?=?Y53)CI9TNC$&/TRZ<QR.PLZ+JK1^E&)2:N
MF;=V[%C%I]@WT6\(^ABLI=X[QG_7:OJK_P!*\N3],JFJ-*TMM!;:TS4&4$6Y
M6M7P30L?][@)M5\RPL(_U=O WT1L'T-6/?K>MRFLM[>N/C/*?I>K2=2.@6C;
MEB)T1>L8)2)+3C:V$X?')NA:2%)2$1DFQOVCLKQ<6%K/&6.C9E(_) ^@*O9[
M@UBSF;/%=7.=IK^MD_"Y:".NOW4F1B;9/V3I=,3CX\J4Y)7@YS"G(+:W#=?P
MCK0#D=*CQY?>%^X5S#6-B/DG,]F<*\%]*;1\^S!8#3]?#WN  [@)KAUKQ6%O
M4[T]];NF<=,3*:UE9<1*2@3L+&D38Z2GL*T-H\UOV&Q%:7J&V[BR?GEB<2.8
M78]L^8.B:Z"VWNF-<?JR$-/HQ-%B5E&9T<249*)*B9!!4"U/BO1EJ4GMY"^V
MBZC;LK#W3CDI)F%.JZWMQI;>-=:N8YA-:M(-*]:<EU(FOX_8\2L+<Y)B00L(
M*4$$\ "@V2#QK69PPC-&:$+ONB:KJFEWS/B!FA-/'#U*J.FO1S/[!DV<'KF'
MD9";-?2RB2&U*9:YU<I<?DA!;0AN]S;CX"]8<Q7E_<"VA:72.(  X?S NN:Y
MOW1-"TLZWJMRR"UA9F+2?:-!P:VM22M]_IK]%,WHMI$K88CJ\AM.69$S*S'4
M%"420RD-1XS8)*8S!3[O$FYN>)KKFF^7%SI^EF[@D_TDZ.O@#Q 'A]*_,GS@
M^\__ +4=SQZ;=Q"';=K)DA8,265-7.)I[;N?08#@L]O0=OFS9;J+MFI;>CR\
MQC<%E)2%)YPAZ(UE<4RTXE*^*>#PO[:GR1W/K]SK-]MC=.7]KVX>\$5HZ,/:
MUIQ\'"OBN1?>#VAMVPT+3MT[3<7:/<O8P@TJV0L<YS33]$T6UJOI1?)Z41*(
ME$2B)1$HB41*(J<VC_)J?\*:_L':IR^[ZU!5O:H*$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(G93@BZ&5EI@8V=,40!'C/+N?'D4$_]T15*
M>00PNE/!K257MH73W#(6^\YP"M-T<BJ7!S&:=!\W*Y!U[F/:4J<64]HOP0E-
M:[M6,FR?=O\ ?GE<_P!1.'S +;-YS-%[%8Q_J[>)K*>(&/SDJ]%;.M,4LS*,
M8K%SW,RZS'Q46)(FSY<A00S"AQ&5R),UUP\&VXL=M2U*[D@U;WDUI:VDMW?O
M;'90QNDD>[ ,8QI<]Y/1K07'P"N;-EU+=1P6+727DDC6,8T5+WO(:U@',N<0
MT#F2%C+T1?GXMG)]0L_"?C?UP38VPX[XIOEF8G1H+2X/3G$O(/O1UMZ\Y^T'
MV>'++R;UQ>N;>74-T;&?=VJ1NCU#7IA=4=[T5J&Y+"W/3MVP;(]O]NFE)Q*Z
MOYENMOB[?9>F2-?;;>B=;/+3[$M\]P?J,XI[V:Y^P8[G#;14P65:%H<0EQM0
M6A:0I"DFZ5)(N"".XBNH@@BHX+D!!::'BHV'A4U(4*-3F=U2I2F9W5$_#LIF
M=U2I"LUUQZMX'I!I4C/Y?*0L8_)>:@8Y<M0L9,A10%I: *W"V 38"_"KJRMY
M;VY;!'4UXTY <5GMN:'<[@U5FG6[7.K5SJ<FC$FO 5X"O,K4CU%VV3NDUK*Q
M&YVVS9JPYCT^8J+\3+\SS64I>(M'0M/ 7 '=6\VMNVV9V\&-'']W-?2&C:;%
MI%L;:C((F#'G0<*GKU)*M%L?7?9^F>'=G=1-05K<Z!+YL9'4#-\^ OW.=R2R
ME20^+^_5TRQAN#6%^9A^E9.+1-.U"KK.;/ X4<0>!'A@L3NJOK PV[X]]M./
M>8R'DJ,22'%MASE]X)24_:L?G%9"VTTP&@-6K8M(T)MA5D#G%IZK";9^O&U9
MR*[C 5L^:T6)#BW%O/*9/.D**[)LM(40%=H%91EHQOM$U6U-T^.-PSFIZ!4M
MK'4'-ZD@JP+H;F2CR2Y$QE,U4DJ(2VAIIP+5S<UK$<2:B6*,@NE(#6@GH!3$
MDGD!\RR[=,-Y('2D9!P 6:?IU](NZ]9-OQ&>V[$YB7ELM(1D,+JD9PP\KDVV
MU!S]IYER[:,!@8_.%+4ZI"R.!L2$J^3/,CS?EW'>7'EMY81QZAJTK'1W-SQM
MK9CL''-P<[QX?D@E7&JZII>T-,.LZS.VVTR(BA(JY[N(8QO%[SR:WTD@ E;*
M,Y]U-U6R>V8_)Q]_U7&81YR*Y/QN/ASWAC&T%)>BPY;\AA4M2DCE4XI#8)XA
M-?+X^Z ]N6-VK-,<A+ICVL0YQJ1'[5*"N!</&E,%<Z1]_G1M-T"337Z%-->L
M:6PR/F:,PI1KI&AA IQR@GI7FMJ/1W2=9Z1:]A^E^1P>/CJQ;"6\?EGHK3S>
M5) YW5R'$%1==<*B23<DU]5;.T6PV;H]KM01L$%K$V.-^4 / %*G\X\3U*^&
M-];CU7?>N7>].](Z6ZE+Y(PXUC)X #\D# = %D(C$XU%N3&8]'ARPXXX=WYG
M9PK>P(1P:WY%SDW$CN+W_*?QK4#]ZIZ -D]2^N8'J9T5C16NJNC1Y$>9@V7V
M\4G=, ?UZ8:7TJ98_;./>251E.GE6E:D%0!!%_ILVG6EV9;J&*2)XH26-<6T
MX$5%?2 NN>5/F5)LZ]?8:E-.-"N.-'.(B?\ EY0>!'O4%< 5Y?SC<A@-J_HQ
MO&"RFN;AKF41!S>(SC;\.2QD(KB>9J9&=(+:K@'L*5I(*24D&NA16VGRPB:V
MC@=$X8%K&_B7U[;:B=0M&WME<NFLY6@M<UY+7 ]"#\HX@X%9]ZQE(^6QL43\
MHR,O'\I;&,9_5-*82FXYT(2$+Y;6(X\:Q=Q;L8/98 ST!4&9P^HK2F)J5U>H
M[6<VC'L8.*VS&A$I4OX1 0\M2"2%*<;3=)2KB+=]8*\C!9VZ8'P66TML$#W7
M$E7/QXG\"]!?W>_J4R75;IQ!Z<]0'DL=3] QK$%UQSW5;/K<1*(N/S[0/VI/
M($MR4WN'1S< I-8%K76_V<G <#X=/2%\5>;6R6;7UU]_IS2= O'ES#RC>:N=
M$? &I9U;X@K8L%K'YU_H/[M>L[>JY/5JB5J/>1\G#]VF<=5(<T=5#F7PX@@<
M1<\;TS-ZXJ<PHK#>H"0MK2\DI*@E0@R+GP ;<-ZQ.M/;^SY23]0_0LUMZK]:
MMPW'[1OTK3+TV?QRBMR2L%]4V5=7ND'^^%V4>\@DBOAED,+=0E)./<=_5%?J
MCJGQ9TN!L0HP0,PZ>P%D<\YC7X884E*@M'+Q Y2"+<*STYMW0]OG1<\M8KZ.
MY[S:X%8Z=7M=QB,)*\EI)4ZRYPX'[0(''MK1-=M(FPD@8D+LNQ=5O':@SN$T
M:X+SG^KK3<_AMSBYUJ.T,+*BIA!24 *:>CJ/F)=L+GGY@03V<:^M?(O6+34=
MF16;,+FW<6N'X59>85D+?>LDCW5^,8V1AY8"A 6,>,5<_K%)OW6'AW$VX^RN
MW/=1E*+WIMK.YH<7!K0JPBH;X*45*/8+GW1?V5K.HM< 0WB0MVL8@TA\CG/(
M^1>L7[A??<EE.@O430YB4_L[2MXE/X]\#L;ST2/E'V5J)Y?U4E:SP[E"J.@R
M.:983[H<"/6/YB_/S[X6D6]GORRUB(_;WVGCN#QA<8VD>EM/6%LU]2/J)UKI
M?K,]"L@S^T'&'D,,I<2'7G4MJ/*D7X-H(]X]@'RU;[FW);Z/:&AK<NP:WF3^
M)<7\LO+G4]]ZRV"%KFZ=&099#@&M_"3P '->3'U,^IIO.9+9,I-S#1GJE2"G
MS5<WFN+6>4(22 4)20 !V 5QB"VN;^Z-Q-5TLAJX_NY+]/=J;?L]'L(-)TYF
M6WA8&M'@.9\3Q*TM;?-EY[.R\Q,D^<9#ZG$ELE*4I*R4\H!]O&M\MFMMXA$P
M< NM6^G,;;@4 _&KW]$>F&R]7-PUW0M"U^7G]JV"8W%B1V6W%-1FBI"7\CD'
MD@IB8^&@\SCBK  6%R0#87!GFE$,52]QH .95?6MP:5LK;T^XMP7#+;2K=A<
M2>+CR8P<7/<< !Z\%[A_0IZ%<!Z7^F&-BA$6=NF3CLS=ES2V0A_(Y-20I9:4
M02S"BWY&&SV)%SQ)K>=$T%FG0YWT-V[%Q_ / +\@/.#SEU3S2W-)?W&:/1HW
M%MO#6H9'R)ZN=Q<>9\%G.I&1QB^8^8T0;@B]C\A%TD6^BLU5T?.BY,'0S=%-
M8NRJ \N8TEP$6*D@)600>;F'%*K_ ""JS;EO!X5%]J.,9Q5'[%Y"+2(KOZL.
MA: H\BPE?YJ@3VI4*L[D,]YG59"R<?<?T71.?9?Q<XH?2HPX<EQ20H72I+"E
M*4./9[HJSN;V..PGGJ*10O<?WK2?P*ZBL'F^ACH?M)&@8=7!7!Z<P_V9I>N(
M(L\YCH\QWQ\R2/B+<;$6+EZ];3LC:;9L(GX/%K&3^DYH<?G*L=SS"[W!>2<6
M&=[1Z&G*/F"M'TCQ6(!]0717/8Z-DL!ANI&ROIP4Q <A3^GG6[$-[PB XPJZ
M5XYS)9W,0B!P 9(X$5C] M(,^K[;NF!]K%>R'(<0ZWO6"?*1^27R3LZ>R0MW
MWK>7I;MC?VG2OBU*XTFW;WFFCV7ND2FRS@C@\106DW6KP>:Y>GO*Y76V-GZ
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M#Q,93A0#!8H^8F[-=@(U6[FN*DYLSG.K57N6PG':XRT[Y32505^2>9'(LV4
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M%K>XQ'!C_P !\5F+BRM]3A-]IHRS#%\?,=2T=%<]*PL IL4D!25 @@@]A!'
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MMUL90V+M,Q)PH%E#T@F8S":OL+;F2=Q3^20TU,DM/*:*V&7 \EE92H I+@'
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M<MQ=6+K_ -CW(^:KQD43!AQ5B^9TG&M%)MGD6:CM WYE+6H>P!*1^[5&YR4
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M\5*2H'B".-4MJ7YU?;5CJ%Q_G3[=HE'2:/[*8>J5CPKSS'T&WVSO_6-"L_\
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M=A\EON_:'Y9-.X=;>-3\P9V_:W;V^S%7$Q6S37M1M/3VCQ))Q6UZAJC);?\
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M>3,3>Z(VSG/_ ,SI$CK(DGF76@LGFN/M+)T$@@]X((^45NW!<A./%69U9O\
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M7"A(HM_TW:T^HZ?)'&TESF&E/17YU+]I7+P&>4U):+HD$/LO\ILI"KW%[6)
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M'Z:M7W3G81A7\>GL:,T[O4JZZ6,9QS9)$_*%[RE8F2A >4;\RY,-22ELV(2
MD]U5[03=S-)PHJ=TZW$?;AIFKR60M9)8]*(E$2B)1$HB41*(E$5'[M_D=O\
MPZ/_ &#U4Y/=]:'@K5W/C5%1F*<Q\32J9G<BG,K](T4YW]2H\RO$FE4#W<R2
M$YCXT53O>"@23WGY>\5->B=X]$N?'YJ53O'HN7F*\2?E)/[M"05/>\%'S#X#
MZ_RU%!XIWST3S3X"HH$[YY )YI\!]=**.^[H$\P^ I1.\>BCYGX?ZE>O9Z(9
M:\4\WV5&!X*1-U3S1^B?I'Y:9?$+UWQT3S?X)^D?EIE'4*.^.BB' >T6^BF5
M2)FUH5RYTU%%Z[K$YTTHG=8G.FE$[K$YTTHG=8J9W'(G'ZSEGV2?B'8XA1 /
MM*E3UIB,!/;<\[M_FK%:W</M-*GEC_7%F1GZ;R&-_IG!931(HKS5887_ *H/
MSN\&,!>X_(TJDDPD-[%JV";%V<%C&/, [/,;:"W%$'\Y3@O>O,-NRW?;V3/<
MAB:/D%/P*YDNS-:W-^_WYY3\YJI)DB-]ZSXG#@AW6>BL2-MN9[V9G4_:8,F)
MIV.<(]UQ>I:F]+RBTG[$C(PE\"D5I]Q7<_F+%:>]HVVXQ-)^2_4[J,M@8>1-
MI9N?,1]5]U$>+5M]FYNU_+B?4?=UK<TCK6'JS3+61KKN0=!=W;8K9I'O1VUR
MVM'%7ON/$?371J%<W3F'B*FA2H3F3XBE"HJ$YAXBE"IJI!L>R8W6<7,R<]U/
M+&CNO)82H>:\I*"4(2GM]Y5A\]4)YX[=A?(> 5U9V<]_.VWMQ5[B!7D/2M4&
M\[3A]W=RF2"D97:L]/D!C PTI?GE;%DM-<JSY<6%"9Y2X\X4MHO<FY /-]Q;
MA=K$4>B6C);K4I\W8LHB!)( :&60G"&!I_67$E&-&#<SRUI^KMG;7FT"U9W'
M-M]'MF@S7<F$;2_'#F^1QPCB95SJ<* D8C]5=2R$#6YDI^=Y&SL-..Q8<=:W
M<?"400EEDK2E<J3R*LIY5N-PA*4\#TSRR\I[+0;^/<^YNS?;P#"UCF@_#637
M<8[-C\<W*2Y?]M+U8VC!MT^\3J3':1H;70Z XC,]U.]<$?6F+<&LKBV%IRMP
MS%[L5JXV?=NL$-J1@-CFY;*:XZZLHQLY*W(['.2#Y!(NA(MPXD"OHN*"UKF;
M02]>J\V\%I7, T3=:8E6'R8DP75NP ]&1)%W+)4#<CWD*N.ZKUN4X/Q*S$36
M.:,Y&"KCT^^G?J/ZG^H\#IYH4*0IYU]J3F]B4TLX[6\;YP0[DYS@MS%)N&FT
MGG=7[H[R,/KFOV>BVI?)1TQ]U@XD_BZE83=FY-+VKI;K_4""\X1L'O/=R:.G
MB> "V"]</NR_5SZ>\)D]ET#8$=5=1@1?CLA'UT2(6QL-,,\\EY6OO.2&IWE)
M22?AGBXH"_EDUKFF[TTJ]<(=0C-O,30.KF9ZS@6^L4\5S;0?-3;FJRMM=38^
MQN7&@+CFB)/#VP 6_OA3Q5O_ $C[KO\ O:GG<?MRL7,UQ]IIV)D)"FPM1)"D
M+9=6E?*E22E2; @\#6=U%ELQGVC,['#D*^O^:MYU..U9&6W#.Y&[H*_)^-;G
M]+W'.HQA9RBQ+RL=+:_B(JTN1R !S<K(*E$*'CV"M(N;:$OK'A'X\5R74].M
M6SY[?V8'<C@0KKP=U0MOS,BAB&2I-E.*Y''56-SY0'NVJP?;&M&5*P;[%V8M
MB)('3%3F-.;E.KR.+=,9Q%GE2&'$CE=0+MK-K*)O]-6\D7L]N45!PHO+XV.A
M^&NVYXSA0]"LB=$ZE#,*8Q.>#<;)*; CS >6/-*0  ;_ ,V\?#LX]M8*YM'0
M>T,8J\>G[NJY_K.W76!-Q;N+[,G]\WIF\/$*\%JL\%KW8\4M2H3L'JEC2JCL
M.ZA67W)XR<Y&BI/,#*XCM]UOE; MWWL:P=\>Y=-CZN6TZ3&8K*27\RGRJ\,5
MH,Q8[0%O+9;1:_>$"_UFLV!E '@M9?'G>75XE?>WX?@*FJCL>*6_#\!2J=CQ
M2WX7_>I5.QXK@ZRT^TXP^VAUEYM;3K3@"D.-N)*5H6D@A25)-B#2J=GQQ6@#
MUO=&5>G#97ME3BDY#T]]0,@J-*68XD,]--BR3AM$FIY5!&I9>0Y9A? 0GSY9
M_5J1R\DW9L:^CN_Y3[,)BUN(YW1LPSTQ+HZ?7 Q<WZW)?9_DKYE1[DMF[1W)
M+76H64AD<?U\;13*XGC*P<S[[<>(*P+V?'[#AHL/':?CS(P^64V&,YC'E*5!
M:=L6Q*#94?)6@@)=%QX^)Z-Y;>:-KO",:5K5(-R1"A:11LM.):.3NK?DZ+M5
MWI[+9_><08AUY*]73QA>#9@XQZZI2^0Y!<I]:R\Z+>8L*</,0174+F/,,.*U
MB]?W<SQ[E,**[6UZY!GXQ].+<.->N)B9\99;>C364\S<F.\D\R7$+M8CM[#6
MO7]G'<0NAE'LN'\Y8VPN3.PV]\.Y&X%A:>;3U"LWTX&2UO)3<9G7EJ>EO*D,
M/6*&7@\X5J>:3]E"5N$DI'838<*^<MQZ/)I>HNB>VD;C5IY$+J&CR$V#;<.S
M"(4!/&@X ^(&%>=%>K>.DD3?=8?$F'\2'6%$#D"NQ)L>PWK$,M7Y>XWBO5IN
M-EA>"!S@!6BT(>IKH9DNG6=7(AX]YC'O3$(>4EHI0VVMY*2YP M8&KVUF+SV
M931W)?4WE_N2S-DZA:9 PD>D!8T=9WL4X,*(W+YK,1I)7V*)["">\^[79MNQ
M.MK1C0:MHOD2[N+F3>E[<']2^4U'K5':R&Y0;N 2@B_LM;C]59J[DR,)76=!
MLFSN:XBJR9Z09I.#ZF].<VAI<A>'W?5IC49/VGU,9J&0VD_I+/ >VM%O6D5?
MXU_"M[W!9QZAM'4M,!#!)83M+N3:Q.Q/H7Z#NBS#/U# 2E(+:G<=')0J]Q=I
M"N-^_P!ZMSB=FC:[J OPMNF=JYDCK7*\CY"JLJHJ"41*(E$2B*E]H=Y6(S-_
MM*6X?J0+^RK>=U  KVR;5Q=T4GFGX/3LBYP"I(Y >^RE)0!]1JTO'=O3I'=1
M]*OK-O=U:)O(&OR*>ZDR&-=QJ FQ4T7#\JUJ/XJK:<S)91M_-5KJTG<U&5WY
MWT8*HZO5CDHB D$$&Q!N#X'QJ4XX+'?HI_YN;QZA^F2OU;.!ZH-]2M>8[$IU
MCK7A8^V.^0D]C#.^0L\WPX!0([:TC:O\!UK7- .#8[\7<8_N5]&)#3P%RRX'
M@5UOS(_TQMC:.\VXR7.B.TZ=W_S.CS&V&;\XV$E@['B*%7_EQ&9L=<9]/,VL
M=OYR#W*2>XCZZW1S0\97<%R>.1T;L[.*MT%S-5R-E\SD1TBX'!#K1/$I[@M/
M'VBK#VK:3\Q9BD=_#TE"ZF1?:UO9X>SPU7P>QA,7+!(]UJ4#P>('!*Q<$W%[
M@T<YL$XG;^J?@?3U56)KKVQ=82?YU![3.I;S"NP%)4E*TD*2M(4E0-TJ2H72
MH'L((-9%:^>*C1$HB414YL.S8[76 9"O/F.#^]X#1N^Z2/=*@$J+;?-WGM[J
MHS3LA;CB_D%>6=E->/HS",<7'@ J1QNMY3:)3><VXJ3&20Y PJ;H;0BX*5/I
M[DD6X'WE=]6K('W#A-<^[R:LC->P6##:Z=[Q%'285/H*N>A"&T(;;0EMMM(0
MA"$A*$(3P"4I%@E('<*R& P'!8,DDU.)*^;\AB,@N2'FV$ 7YG5A%_\ 6@FZ
MOFJ"YK15Q "EK'/.5@)*I.?ND!BZ(;:YCGZ7%#0/9_KE?55L^ZC;@W$J^CTZ
M5V,GLM^=2!4S:,\>5A#C$=1X\@\EH#^$LV[NVY-4<\\V %&J[[=E:^\07CUE
M3.%I*;AS)2E.+-BIIDW3VWL7%7''V"JC;3^V%4)-1Y0M 'BJPAXR# 2$Q8S;
M9 MSD<[A]I<5=5_DM5RV-C!1H5A)-+*:O)*KO3/\K._X$]_;H]5X_>5,*Z%5
MU*41*(E$2B)1$HB41*(J/W;_ ".W_AT?^P>JG)[OK0\%:JJ"\I4HE0B410-^
MZI4&O)./C]?[],%'M_N*<?'Z_P!^F">W^XIQ_ _OTP3VOW%./L^D4P3VDX^S
MZJ8)[2<?$_-3! '<R5'_ &1HIIXE*A2E$2B)1$HB41*(E$2B*BME'[0SNH8$
M<4.Y%_.S4CC_ 'IA6@IGF'$%*YTAL?**P&JGXC4[#31P,KKA_P"A WV?EE?'
M\BV#21\-IE_J1P<(FP,_3G./R1M?\JI.=M.*U8=0NH>;*SB=5Q<R8\AH<STH
M1TV8Q\-'%3LW)/H1&80 2MYU*1Q-6NLZ[9[<TW4-RW]76MG"YY:/>D<,&1-Z
MOE>6QL&)+WM'-9/2M!O]Q7VF;5TR@O[^=C&DX-9G/M2// ,C;FD>3@UC''@%
M-ND^K935].85L@0K==KR&0W??G4GF3_2_9W$3,ACVUBY5$UR*EC%1N-A&@MV
MJGL;0KO0=NQQZL0[<-W(^[O7#'-=W+NY, ?R(JM@CZ11,')5M_;BL=<W&\:*
M#_)FPBCLK ' _!VH+(GD?EW#L]U)UEG>5<GE -_P_'6WDK3.[X+E[3VCL]GY
M:A#,5 )X\PO?M[/'YZ5PHG>YT5*YW:(^-"F(I$F<?="4CF0T2FX*K?:5?N!J
MRN;QD/L,%9"LI964MS]I)[,/5:_O4WUV1K&-R^#@+7E]E;::5GG6FWG\;J<1
M_D(.6=CW/QZV5A28C9\U+9YE\@(56EW$VN[CU1VW-H1QSZTT@3SRU-G8-=CF
MG((,UP6XQV<;LYJ'3.BC(+N]>7>RK5T<>Y=P.=:[=Q,+&T%Q>N;R@:0<L((H
M^Y>.V*$1]QP(6%V4ZI:#TNGXO;<1GH.>D;#"93FYKS[ D/*N'0F-'9 :@PDK
M6>5A "4VXE2KJ/9=E>7&F;5MY_AP^76[IP=<WDM#/<. H,Q  9$SA%!&&Q1-
MP:VM2=ZU:\U7=<'P-^P6NEVSS\/!'7MQ@\ZDDR2.'OROJYQZ"@%Q,M/U;JAB
M&,_'?BA2F@XRWSMV5[O-[R> -_'C6WQBXL9.WB05K5I%>:+)\,:NC)XK#[J6
M]JSGFX;)0H+<A(4@/A*#RIM;G%A;A>XK8+9DA&<$T6[V,4C@)0205KMZOXW&
M8>(\W@'VYKDAT O$C]4CO2.^]7%W=.M[8RG!P6U6<9/VDPH O0Y]T%T:;T;H
M"OJ+-Q[+&;ZC9!S(MOJ:2'QA8BE1,6V%%/.&G$M./ 7[7:XMJ]Z^^U!\CR2U
MOLC'Y5\G>;VN'4-U.LF.+K>T;D&.&8XN/T#U+;BL^8A;;B4+;6DH6A224J2H
M6*5#FX@BL8N6=XGB,%HK]97W4LG/[)M'6CTR[4K2-IS;[^7V'17G'H6N9?)+
MN[(E8N;#LYA)DYVZEA:'(RW3S$-DDG==$WB_3HFV>I,[MDW!KA[[!Z_>:.7
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MN<WM;LI2H6(NE!2OSI1(3^K2DEQ?.5!#32$@E2B18<385B[B\+B8X*4 Q)P
M XDG@ .-5G[/3&QM$]WQ)P;QJ>0IS).%.N"L[B4YOJ8ZXG3<@]AM'9<?3G.J
M;:&S+S?D%:)6'Z7HDMK:D#F04/[ XA45GB(:7W/UK6FV\M]NEV30Y'P:!6C[
MX>_/0T='8U!&3B'7CAEIA;!Y^U9T"\AT[9<?=W+"VXW*6@Q::2<D%0"V74RT
M@AW LL&D2.XW1B9]E)@?U?PTB9FMCC:2PU'U3&Q7\%$P,=!EN2W&E/.39TV;
M)4Y+GY'(RG5+?D/+6\ZY=2U%1)KO&SM)TS;^CPV%C$V&V!+P!7B<2YSC5SGN
M-7/>\ESW$N<XDU6\;<U"YN[=FIZ_*Z;5[IPD=(ZC0UM,K(V- #61L8 UD;&M
M8QM&M: *+ .-T7S&0$MG8]*EXB&L.?#O+0/)<0X2 4<I(94/FK?VW4#?<>TG
MTK?F7MJ?99(USAT(JI(WTXW?INLR,1FLD_KR;K;BNK<6TRCBHM)657Y4D6XU
M<1S0S^RX#,KR*X@G&3 R#DJ'V?0-AV_S=FR.5=Q.*;;6>93Z05*0"5%*BK[-
MZN6S1QGM@>U19>&>**D+!60TY+""/A\IL74>'I[#[F0&2ST#"XY:7"X7W\E-
M9AQPE*>!)4[<^ %:[N2]:S3R>!Q/R!9K59&:?I+[QV 9&YY]#14_0O;YT:T>
M!TWZ7Z3I>-92Q%P&O8R A"0!_P &B-,E1M^<HHN?;7'A4BI]XXE?GUJ=[)J.
MH37TQK)+*YY_?&JN;4JQ4" H%*@%)4"E23V*2>T'V&B<ZCBM<WK(]!G3?U'1
MXF6F>9K6R0+H@[3BX[2YL=I9YW84QM0")4%P\0E5PE7%-E7O7T[6M5V]*9=-
M>#;O/M1N%6$]<*$'Q'KJNG;)WW>:!(Z)P[D+ABVM*]#SQ'T+51U&^[)ZD>G_
M  LOJQTVV!GJOK^#BKD[)K@Q_P #LL2 R/,D3(4=IUYG)JBMI4M2$>6XI /*
M%*X'H6D;[CU"5L&H-$0=@' ^R#XUQ \5TW1_-2UU'46Z9K$7PID=E9)6K*DX
M9B:%M>', \:!4=TVZ_C"PD3\;@(<YN&&IS3?GI;D(*.*_**P5BW@;UMEU8B<
MY"X@G!="OM.;>M,,CG-#A3!;!>C/J.A;\XV,KA9<$RE(#+B_+4&EV"/>6@6[
M:U?4=%?;,S1N!HM#US:C["'NVL@<P<0>/J6<F/!6R'>8%#B4*21QN.7V>(K5
MWBAIS7-IGECJ?6"F<25D,3(1-P\EUAQM04XSSW9? [4K;/ \W9<6-49(8Y6Y
M9!CR/-4IK:TU&+M7;074P<,'#T']P5V8/4;'RHCC>2:<QTOR%CG"5+C+64E-
MPH7*+DWXUB+BTEB:2WVF@<N/R+3[G;=[;R@PTE@KQ''UA2C14IG;!D9Z5!;;
M864+3Q2;GE20? UK>FC/=22'JKK7:P6$-L:AU,1ZE>2LXM22B)1$HB41*(M2
M/WOWIES'7;T^Q=KTW"JS.[=+,J-DC18S:%9"=@2PMC/P8U[%UPPK/);O=:V
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MK<&$XZ?F\YDXVOZQBD!Z;D)KGE16$*<#;*.QQZ3-ENJ#;+#:5O/NJ2AM*E$
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MP^:A/R* /E7(&Y(\+5%%->*^2DGB>Z_XS7H$<%Y(*I;:'N5B,S<74I2R+]P
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M=\%[^W1_R54CKFIX*E(/9KR5UZK*@E$2B)1$HB41*(E$2B*C-Z_R*W_A\?\
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M##C(;CQ8L=I(2AM"4I2!P%=7AAAMH66]NQL=M&P-8QH#6L:T4:UK0 &M:!0
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M"_\ K0>)->72-:/:P"]M8YYHP$E64ZHYM[*Z[-CX",IZ9';><8D$%*@X&E!
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M6G+\B[6[.VK:>VF@Q>*MZC]V"L+W2+NR&9X#HORFXC^8JI0I+@N@A2>Y22%
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MAP[+V_#A3*TJ*D<5SYCXGZ:\&/I1>LRAS*N/>-OEJ<AI1,ZDV>S Q$%;W/\
MWPY=N.@GB7"/M6\$?CJA,[M,J:5Y*ZM('7,H;CE''T*GM1Q3OOYN;S&3)*BQ
MS_;2E1)4\;\;N$V'LJE;0.IW7>\5=ZC<MPMH_<;Q5=%2^%E'V\:O,AZK%9EU
M9T"-EX.0Q.10E['Y:#,Q<YE?%#L+(QG8<MM8/ I7'?4#\M>);>.>-T,H!B>T
MM<.K7"A'K!*K6UW/9W$=Y:DMNH9&R,/1['!S3ZG %6IZ!Y&9)Z3ZKC,DZMS,
M:8G)].LTI9)<.3Z?969J3CCE['FE1L4T^">)2Z#WU@-JNE?H,$$QK<VV:W?U
MS6[W0U_?!@=ZUNGF7!;Q;UO;VT;2PU QW\0' 1WT3+H ?H.E<STM(Y*\/,?$
M_36Q9'=5HN8*W\8E/429Q/OXT'_YTW]7"L8QO^E7-_N:STA_T"P_W97##MNT
M?163R4X%8'/RY+GYJ? _A\],A7K.%#S1X'VTR%1W GFI\#]7Y:9"G<">:/ _
MA]-,A3N!/-'@?JID4=Q/-'@?JID*GN=4\T>!^JF0IW$\T>!^JF11G*>:.\'Z
MC3(ISCU*M-#6%9ET?^\#_P#;HU5(FT=ZEX+JMHKOU<+PE$2B)1$HB41*(E$2
MB*@^HG^06O\ G*-_:I%4I7%K*CJO3>*LG>K?N.I15*)>G==RHE$O4=QQ2B7I
MW')1+T[CO!*)>G<<E$O3N.*42]3W#6N"42].X[PHE$O02'@E%R!([":J%H.)
M)4*)4H\.8_34"-O)*KIS)S$%LNR'"FPNE MS+X]@%Q;Y:IR9(QF<55BB?,[*
MP*V&P;45LO/R93<#&QDJ6Z\\XEEEM -^9QQ2@DDCN[2> K6];US3=&TZ;5M8
MN(K328&YI)97!C&CE4GB2<&M%7.) :"31;/I6CSW-PRTLXGSWTAHUC1F<3X
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M $GMM?A4Y'42JT[^H/$-;_U<V7-:_CU9G]F?"X23R(+C0D1_,>=:X @J;$@
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M1<?:4;)L D "U=$VGLK0]H69MM+BI-([/+(]QDFFD/O2S2O)?+([F]Y)Y"@
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M=7.A6V7N-<J[K2/+GJ,5D'C-Z=G1DJ6HH=4+E)(!!MX<#8UKTM@UCJ#@K4Q
M%26;N,UJ;R/QEN1R;%P*[.'A;LX>-5FV4>2K2*JNR,4PP4Y@;2SYUFB4\UK"
MXN+U2?:DLQXA>C'A0J?HV932@5+L#VF]OKJS-KR"\=MIX*6Y#;D)L4NA1)'N
MI4"?JJI':$\5<0Q?(HQ,VN:M*'%>Y;O/9V5YD@#!4<54+ S%31[(Q8%DMNCG
M5PY2KCQX]_MJBV-\@0-,@X*#>8=+B7.;F"2#^_>O+H0!1>LH&"^F4V9NR$*<
M0E1'<0.SA>WC7F.W)-54AC<?0N@WLS 4D./)4FW9S ?3:O3K9P%1Q5<Q.Y*5
MJW_ P9;K#DA*"JUC?M)%^V]>O@9GMK173+>61M>*K;#YF%,;2]YC;J7!S)-Q
MV'VU9S0N9@J$C'QGHIL[)BEM21RV-[&_9Q\>^J :^M53#W U5.HR ;EJ962$
MGBT2;#@;6!O55T56UXK)-I+$'8553,S7HT94EJ4XA2!<<J[@>VW?:K&6VAE.
M5[0K9\44SLDC6GU+AA.IN46^N)+2TX&E\J5G@2GNO>X)X=U6<^B,:,T;W *)
MMO0%N>)SAX<5<!.\M(03)B%QL\"6K%*@1Q"DD$*38UCGZ5-6C7 CQP6*=HLQ
M-(W#UX+6-ZQON\.A7J30UN&B0\9T8ZLQG_/7LN'U]M6N[.A2N9QC;,%CEP$2
M)!_,F-%,A)^USI/+67TB[U32I@T_:6AXM+OZDGA]!Z+I>QM[[GVE<B"=QO-'
M(H8WOQ9XQN-<OZ)]GT'%:[YWHFZY]*9N,7F<%K6XZE!*!D=BTF=D#DX[#7O"
M0K!3&!(6@@7/EN*4!W5O$.J6EP:-.63H[#Y^"^@=,\Q-OZM[#7O@NG<&R  5
MZ9A@LN-)Z@X5_7DX/ R?*^"08SC1"VYD=: $E,EM?*^T^%@DH4 I-6EQ:N,O
M==BL5?Z3-+=_&ST<'8UP(/X**_6B3M8S"U+R<=R5^SE,*2)+A?22YS(*$!Q1
M(2VX@N#A>RK'LK%W;+B+!F (Y8+4M9AU&U %N[+GK[HIP_'6GJ5[X6=Q>2E)
MC,/I;C_9"&TCE;2R5M<XL0GE6$CV<!\M8E[>TVKB,WB0M4DLKN",RN:2ZORD
MXJ'4;!Z)U!TZ=H>R8+%;5KF8A.PLM"RL-N6T\PX"VM;86;LR&E*);=39;:@"
MD@BK-L\+79I)&CUII3=3M[L7;<S'@U _'U'@M$?6/[NCJ#TIBY'/]%]ED=0-
M#;FN29.D91/E;CK./<4IPN09#:EQ=G@PD&Q 2S*"$WY7%7)KG<>GV4+I)W.>
M&"OLC,</# KZ+V/OFV?,VPU9G9G=@R0D9''D">+2>5</%5MZ:NGO4'(+CQ&-
ME1"Q(39]HLK5Y:NQ;0*@@I4@BQ!L1:L&W?\ H%Z2;-DC\>)%!5= W1>V=A;F
M>ZA#YZ84*V?X/IYKN+Q[<>4\YE)J;+=?6E('F6%RFY5:_;V5CKG<\<F+(\/2
MN(7VNZQ>7)DCRPVYP YT57#%IC-(;:1^J '*A0O9([N %A:L3+KMP[W&-'SK
M"DMD>7/)+^JFFD;=D]'V08YA_P"'PV=:D%;9 LS+2!S\H/YKR3](]M8637[I
MESDEH&N!I0+7=W[4L-8TT:JQI_:$#FM<:GVF&M*^BG'HL6/4AUWG:=L3"Q'=
M:BV=#;RTD,+>N+))^QSA(-NRO@G[U7\I-5N+6*Q$C--$A,CA4 X8 TY$\?0O
MJ+[MWEUI6X=*FC?(QUZ,M&5]H-YD<SC\RL7HOJ@RVS;EK\%E:B\YD6&RECF6
MH1RK]<I83<^6!X\+VKA_D]IFYK+S&L)[*206V<B5HKE+:'WAPX\"?%=H\S?*
M+1MO;(O[NY#6T@);F-*N'"E>?HY+>_TNRW[0UYIP/<R^5E2D$@+25()-TGCQ
M-?L+I$V:T;F-791]"_'O<4/:U!X HW,?I5R_,7^D:RN8$U"P%%*LSEQBH+D@
MK_6F[<='"ZG2#8VX<$=IKQ/,(F$GB>"N+6W-Q*&#W1B?0J9U3&O+<<S<TE;[
MREF/S\574??>-QPOV"K2TC)/?DQ<>"OM0G#0+6+!HXJN_,7^D:R-5B*!/,7^
MD: \DH$\Q?Z7XJ5*4">8KO-_EKR[%2K3=<X[[W33,9B$V5Y/2)N#ZA8SD!Y_
MB=(RT3/2&T6/->5C(LADV[4N$=AK7=S0/.BRW46,]LYEPWTPO;(1ZVM<WUK=
M/+Z>)NZ[>QN"!::@R6RDZ9;R)\ )_1D>Q_I:%=:-D&)\:-.B*2Y%G1V)L5Q-
ME)<C2VD2&%I(-B%M. UFF 2L$L1';< 0>H(J/F*T^2.2WE=;S B:-Q:X='-)
M#AZB"%13Z_\ ^84%1!!7AG0 ._E"Q6,+2-98WK"?I6:9CMV0]+@?0%7H=%C?
MYN'XZRW;-5@JJ'F#]ZQX?)3MI5/-_"W[].TE4+O#M^@&].W3%*H'0#WJX>/?
M\],E< E5$.I[3P^0<:=MU,$JH^8GCQ/SCA4=MW-*J/.DCM3W7!_#NJ1&4JHA
M8MQ(%#$_DE5$$=RK\?&]>2QR55<:#_EM[L_R>_\ +_/1JK1,H:^"\NX*\=7"
MII1$HB41*(E$2B)1$HBM_P!2?^CS7_.<7^U2:\2&C:KTWBK$52S%>TIF*)3,
M42I!JBYA:AV=U31,>2%:C^!O442I7$DGM-30!*E1"B._LI1*E?"3-:AMEY]Q
M*4GL%_>)\$B]4Y'LC;5W)5(HY)G96 JT.X=0(T (:=6ZX](N(.)A /9">M/^
MYLW!2V#]IQ92V@=I%:#NO>^G;>#+>;N7&K3U[%I  ^XF/4-J R,'WYI2R)@X
MNK0'?=M[0O=7+I(LL=E'C+<2'+%&/%W-W1C YYZ<U1V(T_/;Q(;F;)RQ\6TM
M+K&$94M6.9((*5SUD Y:8BU[$>0@]B3]JM.LMFZYO:YCU3?SF? L<'PZ=&2Z
MTB(-6OG<0#>3MP.:0"!COU45?;.T7VYM&VC"^RVN"^^<W*^[>*3.KQ$0_L$9
MZ-)D</><*T60>*Q,+#,)8@MI19(2IT)2%KL+=W8FW<.%=IMK*"UC$<30&A<A
MO+VXOI3+<.))*FA79)45\H'$E1 2!\M5\C5:*09#:L? ')YK;KO&P2KA<&W9
MWU>VND75XX=MKLG4A4W3,8,2K5;+D4;--Q,C)LHEP==R+.;Q>)=XPG,]$N<?
MEY[/%N6]AUJ*XC:PIMI^SUO,2@IRLVP-,U*6WEU9O>^%F;-$TXM;,T$,E+>#
MGQU)C+@<CCG: \-(R6G[GO='LKF#23VKJ]A=!-*/?%N[]9#&[BQLP%)B*.>S
M[.N1SP[[?M[(Y%*GI+ZTD7/+S$DD=Y)-[FMIAT6QM#1C<SNI6NNF>_T*FGL@
MXI3Y=DA03>R$KN?D-[GC679!$T#*T ^A4R7$X+H0-AA.2?A7[-E/#WC8'N[^
M/;562VD#<[<5->05<166)*3Y2DJ21>XL1QMWC@:QSLS3[7%>2<,5T7XB89*@
MK@3<@?*:]AY?@5Z5)9F>@-E#9!/'F -P ?W35[;QXXJ5;[]L_LZ3YKA*&[@J
M)-AXDWX7K)=CNLRCBE5.W>H^ 82UYTYA!5P',YQN3;CX5:MTNX)-&FBD8\%4
M<#;\5DD<L>:TYS#A9Q!(N/E]M6<ME+$:N::KU1?!W(28[U@Z/)7>R@00.\=E
MZ]B)CF^**G\IEIN,6) 6MYA1'/RF_+?OL/EJXAMXY1EX.7H8^E3+$[3!EM<P
M(#GYP)LH>((/9QJC-9R,-.2D@^I?:9LD9(*26P>/:KC>O#+1W'%>Q7U*DIF]
M0X:R'BE*03Q*P. ^7NJ\98/>,%4#312M?47!D*6Y+9">' N)!'<>U55/V=.,
M "J@8[HI+)ZEZLKF;;DQUN$?9+B;=GRFJS=-NN)&"J")_&AHJ*R^RX[(()CN
M,-.I-T*0H"Y'?>_;5[#;21^]B%4:T@XJF'^L>5U9GRD,_$I^R%7!)_'XU7.D
M0W)J315X[?N<Z*E,KU@F26%3EQ7?,6"2$&]N_AR]G#NJXCTJ-IR BBN8[;VJ
M5"I3#]9OBIXBR%*2%*L4/GE]TD#C<D"J\FEAK<S0KEUFX,J,5?&!F=82TB?Y
ML0/*0%*L4!0N+]O"L1)#<DEAKE5IEE]T55-;1UJU77&%O?M&.EQO_:P^@*-A
M>P2/DJI;Z3/.ZA:2/0KB*SFD(J" K23_ %?8M>.D-PV/B'T(4&U#QL>/,02>
MRLBS:[\X+C[*OF:8\.]HX*WW3SU/9S*;"XG+QRQ"6\0VH&P2DJ-NT\:N[S08
M60?9GV@KV73HPRL1Q6=+?4/ S\ 7V9[!D%GGY?.1S7Y20"+W!O6FNL)VSY2T
MY:K$]F1K\00L,=B]1^4U[978LA)5!0Z4H620" 2!;N(%ZVJ'0H98 X4#EG(M
M/8^(&OME7OTKU$8S(H2ZMQ+=TBY*AX?PC[:PUWH3V&@5"73I!PQ"J67UFQL_
M)1_)D!P\]CRJ'*.P=G-V5;,TA[(SF",LY&-.%%<QGJ0TY#"6DE:U)38H!40"
MG@3:_A6,?IY#L<%0^&JZI7P>E/9*.)++ZPZ02;KN03Q[":AK!&[*X"E559[)
MH>"Y0F)C,%^7,?*^0$CW@ /;>X[*B0L+PQ@HJN8%U K7XZ+)V+:_-?</P##A
M 3S$@JN1?W>!J]D+;>WH/?*R9D$-M1OOE980X$/'P&U,/!/EMVL%]I OV7XW
MK67/?+)0CB5A#(][S7@I!.VT04%+CHYB2E XW)[.[PJH+8'%7,=MW#@%U1LY
M?8#I1=:"%)5V=G'YN)JF6PQNRN>T#TA7<=K)FRM:ZA\"JH@[,B5&"''$M I'
M,"L>\;>%8^::TC=7N-*J'3;H.S-C=54S,V6!%R#;;+C163[UE<2#[!QN"*HO
MU2P:VCGU*SMIHNI319BPAHYJY<#8H#T-"EKX!-U"_98#C\]8N34X!BP$JTDT
M2Z$N6H!77R.YXZ/"< )<1RJ' BZ;< >''A5H_5VM)(:KJVV[</E +O;]"I2#
MN<;)8]U;*0M;)4@7-RM()L./;8>RK;]L325,8 6:EVZ+69HE)]JBH&9I?379
MLBO+9#4L4<R^.5W(1V1%E.$"P\]R/Y?G*'<57->1K>JN;D9*\,Z K8;>XU72
MX^S;S/$'0G,/4#^!4GD>A;2WA.U#.SL"ZA2PXP^@SHK@5?\ 5GWFW4H(\#6,
MN7:Q<BK)Y?022%L5KO.*)G9U6VAF;R(HUP^E5-KFC[U!*WUJPV7"0$N%AUR,
M\JUDA0;=04E*3^:%=E6S++578R&I]:L]1U_;ERP1M[L/, @.'HJ%<B!CLI&N
M)^';*% J#D.0V\II:K<Z7&R$+L;=H![*NF:5>N]X#Y5K,]]8.-;>>I')P(P\
M%,TQ([3:WGD-QN<'DNE7FE()2+^U9O;N -7#=#F)Q(JK4ZEF<&1YG4^16YD=
M+,1(F2\Q@8<;#Y.:X79$B!'Y&9;A/O/2HR>5I3RN]2;$]]4/Y)639#)4,D<:
MNH*5/CXK9H-ZWD,+;2[+I[=@H&O/NCH#QIX'#HOG$Q"L?S,Y!U9#)"5.MI4D
M.FWVKK!4GY/KKU+HVEV;<TSR5<NU>6]]JU8,> )X?)Q4\4_CPD(A-*<) !=<
MN?F3X"_?6'FDM?<MH\.IQ*MQ'= YKDAN/ *3SM?7DDHD")9R.KS8[Z0$.-.I
MORJ;*K7/L["*HQ:1)=/$G; \2%<MU6WAB=;3.K$\4<WK^[ET5$9KIWJW6Z&_
MK>PXUIS*Q'/(=9<:0%2T)59,EJPN5+[R.-ZUK<&U-+UQCK2[C;)%6AJ,/D6/
MM-R[D\KM09K&AW#X[:09F/:2*?FGQ'17&Z9>B30=&=1)QV!C0I*@A3DM3:5/
M)6+&X4NZP/95KH7EMMS0CFL;:.-YIB&@8K7-Z^?^^=Y-[>LWTTT(K1I<:4]
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M>;0XYC7*,I5Q\"'X@8+(G ^J]W(X@>=*0Z^E%AR.7)(2+>[S=OLK!S;:8R7
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M/="C]5CW7KR+N5SN5%=_R7MA'[7O+LO]1-C>0DM3WF1;\U2CP^FJ,MS/7V
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MJ,=$6$64]E7_ /VMMM %^/:0HBM/O?/.3'X.TC'Z1)_$MHM/+5HPNKA[QT
M4YA](, RXER3(ER%)L;+D6!M[$%'"M9N/.S<LCJP,B9Z&5^FJS<7EWHC&Y7A
MY]+OQ456OZ'HWD-H<Q[*EH%BIQ97V7[>=2@0:Q%WYJ;POFY1-(W]$ ?117$&
MPM&MGYXX6GQ-3])7P:Q.DXI(\MC'1RGL59A!%N^_ UKD^Y-XWU6F6Y=7Q=^-
M9^/1-+MZ?91C]Z%5$;K'"UV((4;9(C$=L$!M,E *4CA:R%#LJO;_ ,O[IO;B
M;=.;^BX_.DNC:%F[DC(@[]Z%3V4]1&O+96S(R1F+5]I2$.ND]O?8#Y*R;-F[
M]U)F66";'F[#Z58EVC6KZMDB '($?@5MI77_  D915"C3WU@FQ2V&Q[+%QQ-
MJNK?R=W7*:S.9'Z7?B27<.CM]FN9W@TE=!?J3RCB%(:AN!%B$_$2$W'LLA*J
MV:U\E]0RTO;Q@'@"5B;S<UG"W/;02/(] 5%9#K=LSKOF1A!9YU7N0ZX1QXGB
MM*:R=OY):*QV:ZN)7.KR "P<6^[V4NCCM<M.%3^(*OL)U@GB '<AF&VG$)"C
MY*$)43VV',2;UN5EY8;/LVC.R21PZN_$M<O]V;C=*1"V-C2?R2?I*K/6_4A,
M3*0PG/R8K2%6+BW.4*2.WL(K9[+;NVK4AL5LP =:GZ5A+ZZW).,\LI(/0 *J
MMC]0VI9@MPYTH37$6+DA3BU!1';>QM65$&CPNI'#&/WH6#=#K;O>?+0_G%3G
M&>N%O0,8,3JF-85R@IYAW_);C>J5S\!(:Y:D<A0!>7;=GO#W+K-ZR2K,[SZF
M][ZHN)Q[TE6*Q\M8,SW_ 'EH*KJ0D7L 1XU1[P/V4+0R/GU5Q'IT%DW*P9G!
M3#7NH^%T)+#F-Y7YK20K]+S'>TD^\>)-5Q-%$V@Q)3L22FKO=63'37U/9)QF
M?E-TCM1(/EJ3";-@MRP(2"".T_NU0>V.2,N<,B\26##1D9KBJ*EY;7]NW-O;
M\K/,6 7/B&(!?Y&;(4%)4IOF";^%Q?C7EHCD]LGV0%>#-&.VQ9"1?51A]7AJ
MBX=3<AUM CQ4-D+YN063PO<"]64T,#S5QJ5;R6#+@_:U5E\AZA>JF_[:RU)G
M/G'QU?WKB894$ K/NK="3[Z@GL[A5&)@:^D;0&J]@M+6V;DB: X\2LN,!M&8
MQV!@_MIA;$F6^E3;CJOUA;"4GE%R#7F>)I?5JN;>!DLCFC@&G@KV8)S,;+ 3
M(QDU:&6R"MM"N6Y3P/F@GL-JL) R(T<*E8BY-M;2Y9&U)5.Q-CRD+?93<B4D
M1\3C4<ZE/<S7FN**G 5$BQ"1V=U8K4M1TZPBK<R-:ZE:?6^3\:V.PTUU[IF2
M",GN/P-.BO)"V63F(KF0QLX72PM7E<R?* 0DGF))[%6X>RM"O-SNN6%FG@"/
MKS*],VU!9S-;>MS.S#!2K4-X_OX_%S" DNEUPD*0IQ-QP-P$@#Y>RL7IVFZK
MJ;^\]KLM>)X+/:U:6MK:Y8PW-R:.-%#8-WCY!'GL.N!IC+PD\"$%\*=+96!<
M) '/PX\;5N$&W+:V ?*.Y+QQX+$V1FS=B@;FB=_.5S(_45B+B%1LLI0880VM
MF7#!>4ETCF8<84T>4K2X >'MK(BV!PCP\."UJYTF1UR)8,23B'=.=56.*W5K
M/8EF>MY;;SC"V_/5=)*VTE*VY(O[I"D$$=M470%IH.-5C;S3'6-R8@*LJ"/0
M>'TJBI6]-/M+QBY04TEM;S+JPE;2 DCS6%.)/F+0$W()!*>/A6G:K.+B[^&C
MX##U\UNFG;?,,(OG,H\D5Y8'@>GXUU<YF%X[ 2$LN1Y!A.#D3S)4N27F_.2&
MU%2+<S5_%7,D]O"L]96GPUN(S[W$^E6UM%\5JHD>"UKOZ6AH:\:X_,LE?2UG
MI,S6<OBERS*B1)3.2Q96Z%OLQ,FDNN1%HXJ2(LD+2.ZP%8N^8&7)(X/%?7P*
MY%YM6#+3<$=Y&W(^>'VP!@7L.4N'Z3<I/BLE<IE$XR&Y(6JZ[%#"#VK=5]GN
MO9/::Q\\HBCJ?D7,K:)]Q*(Q[O-4OK$%Y]US-S"2ZZI9C\W$<Q(*G;'PO8>V
MK*TASN,TG&JO]1N QHM8L !C15PX4O-K:?;;?;6+*;=0%H5P(]Y)X&]ZOG1,
M=@>"Q+7N8<S30JW.4TA;+YRFJRU8K(()6(Y7>*Z1Q*>-B@*\#<5CY=/(/<M7
M%L@^0K-6^KAS?A]18)(#S^L%RQ74'X64C"[E$5@LH2$1Y;J>3'3CV#D>/N(6
ML=U[$U2BO0QX@O1VY>1^J?7P7NXT;NQ&[TEW>M^):,7M](X_(KCA_F"5)"%)
M4 I*DDE*DGL*2"00?&LIVFG@<%@,>!XJ/G'] ?2?RU/:"8KDEX$^\+>%KGZ;
MUZ:P--4Q7UYV^Y8KTBM-N*TX?J1TNVA) 9R+V>Z?Y5?8DM9V(C+X8N'LLC+X
M7D3?O>X=M8'41\/J]E>C!KR^!WHD&=G]/'0>E;=HI-[MO5=*.+XFPWD8\87F
M*6G_ !4Q)\&^"J'*K WG5U BQ@9))-^' */T\:J75!K5KXQR?0%869KMZ\ Y
M2Q'YU7'.C](?369H%@$YT?I#Z:GFBAYB3PO^+]PT(Z(N5P>P@_/44%>"*-*!
M$IX%$H2B4P(1*4%*(E>7T(J>**NNG?\ EU[_ )MD?V^+7F#W_4H?P5[:NU32
MB)1$HB41*(E$2B)1%;SJ:2-=:M_[\XO]JDU2E]WUKTWBK!!Q5^T=_"W[M6Y&
M"JT40I7C;C^';V5%%"B5J]G;^'?2B)SGV?A\]*(OA(F-Q&BX\L)3;O[5=XL+
M\:\O+6#,XKW'&^5V5@J58S;.ILB7*>P>JLIRF1:5R25!91BL457 7E9C:3=Z
MW$1VN9Y7>$CC7+]=WU-<7<F@[.B9?:S&[++(XD6EH3_;Y&XOD'*WAK(3[YB'
MM+J>@;%CAMF:UNA[K32WBK&@ W%P!RAC/NL/ S24C'+,<%*-:T:3.F'-YJ6Y
MD)_(0_EI@2TU%:(YE1L7$!4W C'LY4DN+_/6JFW=C%EZ=;U>62^W!(VCKB0"
MK6UKVH&#V8(1_:V"KN,CI'>TKC<&](H+/]D:1&RUTIAJV%AKF/Y<S_>FD\7>
MR/J-:%<&;MN"U2*IG'-AYU*;+=L"I2@ #:QN!7<-&VG=3M :T,BZE<?OM5?<
M/,DKJGYE0[6W/Y]3K\QQ3;?,0VUS%/ =ER3VUOEMH-MIK0(P'2\S18=]P^7'
MDI'D )/F(0H *!M97'Y1X5<S7\5F/:Q<%>V>G2W1KP:51,?7!&7(<>6I27"H
MI]ZU@>-8N3=[,X82!1;$S:[2RK025U<Q/CP\4[%95=82003[W8>\<>!K,Z9K
M%O>S@DBI6+O] NK5I<T>RK'HWZ!@)+WQ\_X8<RK!Q9 \;BYX$7K=C8NG8#&*
MK7PUY- #4+'WJMUERV.<:SV"E?'P(;H<EQPXHE;0-U<H/!7NW[*SFF:5$\&"
M897G@57$7LU=Q4AF^I_6-EPD>1AIXB9)M"?/8YN125)'O)4#;L(JJS;]Q;S%
MLHJSD54CM7>\?=4[P?J$U&=C@WE\ZPB4TFRTK=!-P.ZZCQX51FT6X9)6)ARE
M2;24XL'LJ2-^I_58^55A6,@TIIU7(A2B.0W!X\?M&JCM G<SNN;[2JMLI<N8
MJB>JN8P6U8>8)&2BI2\PMQ%EI!/,F_ 'C5[IL<UM**--05(B>&Y:%:L\X_D<
M)D)O[&S\MH,OK*$-25AL6)(Y4A5@/96V7%7^W7$C@<5N&CM#XA%-$'-/.BIA
M[JMO?!HYV4HMD)]YQ:KVX?I58YPT^XWY%G?V/ISB!D(4KG[#E\Z$N97(29*A
M_NCJRD?(DD@5Y(D>: >RLK'9Q6\8;:- /7FI4'1'<2H)YTBW,/$=_$T;&0[A
MS55UG-+'[1QHIV=A\GR7(* EQ-@NW:?E%798]N+118QFC22$B4KN.S\KEU(_
MO:0XI5A^K8=([/X*2*QEY<P,%;B:)GI>T?-59[3]!?%3LQO<?!I/X%'^B6Q2
MU#R,/.63W^24<?\ 9\IK7Y=Q;=M16:^MP1^=7Z*K;[;0M8D:!';2D>(I]-%-
M(G2_>)+B4,X9Y*E]B7%<;=I-D!9[*PUUYB;.MVT-UG</R6D_3196+:6NR>T^
M$-9^<YH_"JH8Z+;6]8/ICQU'@;AQP@CAQ/*@</EK6YO-_:T!(B9/+\C?QK,P
M;#U>1HS/B9ZR?P*N,/Z7-NS;1>9===90"M:X["2!87(%U.7-AW5B9?.2!U76
M%B7#JYQ_  KW^0S(@&WEXUIZ ?C725T4Q$!]43(3IOG,J*'6U+;9((X$$!L*
M[:U2Y\ZM8S.%O;0L](<?I*SEMY?Z=D#I)I'M\" /H4U:Z3ZBA(YVE/6':Z^X
MN_RCF XUK-YYM;MG_5/$=?R6@?@6<M]DZ+$,8R[TN)4XA:%ID#C\#!'?=325
M?/=5ZUJ[WUO*\-)+J>G@2/H63AVUHUO[3((Z^BOTJHHL+34N-QPF$R"M()'D
MI[5 > /?6.BGW/?R8ON'@_I%7)@L;-N8-C:/0 MN&C^@'0,_K&#S*OVPE[)8
MZ-*<<8EHY2MUI*R4H4URA/O=E>)+*XF<>Z7%U>9/XU\XZCYSZK:7\T$#;?M,
MD+1['(&G&JG<K[MS$/24J@9W+QHWY[3J(+BQ\CBFTD?0:MCH;GG%SJ>E>6>?
ME_'&6S6T#Y.HS#YJJI8GW;FFI9L_F<NI[E^V)D9 O;MY4,6JLW;\?UJ^LE8^
M7S^UXNK'#;AO3*?ZY=1G[M/6?-67=JRY;*O<;#\;@#W73&N:J-V_;<7U^=>9
M/O!:^6@1VML'4XT=_7*D]@]"O2#!2U0).V9_(3F21)B1I[#+$8I3SJ3,E&.K
MRW CCY: I8[%!/;6QZ9LJ*[ E=&&P'F:FOZ(KB/$D#TJ8?.O>MVW.R.UBC/
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MIKJLA!C->:_)D2XS#*2HK6Z\^^AMEL<Q))6XL ?+56.RLK=^<1QM@:"31H%
M!4GAT6L:E?7<C'/GED=@>+B?PKVP]*69L+IQI<2<D(F1]=Q;<A(%K.IALI<
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MJD*&2;>>6%Q5H0M0)2@BZ2GA8V[JW9VW&MDANXR ,H.6F&'%91D+"]SZ$%F
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MZGUK;5]UGD)F7U[KALODN+&7VK :[CIR$DQDPX,6;D9>+QZQ9!1'EY$<X3V
MI'LK3779EGE:VM:CT $D@?)BN _>,B;%?Z+:/< V*UED+.>9SF-#W#Q#*"OC
MXK=#@\8G%PDMD#XAT!Q]0\2.#?9V)!^FLI;PB)GB5\H7EP;B7-]08!3FKA6B
M41*(E$2B*@MPZ<:[N3\3*/G(8#:\6A2<)N^L2OV5M6(*N/EHG);<8R>.6H#S
M(4UJ3#> LML]M8G4='M-2+9I,\5['[DT1R2L]#L:M/-CPZ-WUFE;#HFYM2T)
MC[6(17&D3'[6UG;W+>7Q+*@L>![LT3F3,XL>.= KZA[?TN!8ZT0FLGJ+%DL=
M;-1QD@X6,US)0V>INH1!+R6D/CF'F9.)\7A%&ZW%0D^Y6"DUS4]NU&YV=[2F
MC_/H&$M:.MW;MS/A\9H@^#FX0A;7'M70]YT?L"4PZ^[CI-U(T2O.)_T==OR1
MW8_)MYNU=C!K/B78J^4.9#R4*'DL;,AY+&Y&,U,Q^2QTIB=C\A#?3SL2X,V*
MX[&EQ7DFZ7&U*0H=AK;;>XM[N!EU:2,EM9&AS'L<',<T\"US26N!Z@D+G5S;
M7-E<R65[')#>PO+)(Y&N9(Q[30M>QP#F.!XM< 1S"^CT=J6P_$?2%L2V'HKR
M%"X4U(;4RXDCO!0LU4>T/:6.]TBA]!5)KWQO$L9I(T@@^(Q"L%T_D.IC:!AI
M2B9FI93:]-E<WVK8%YR/"*NTW<QQ94/8:TVP<6S6%N_]9 ^>$_O 0WY6Y2NC
MZ\QK_P!J7T7ZB\AM;IO3[:A?\DF<>I9!5NBYLE$2B)1$HB41*(E$2B)1%<'I
MK_T@>_YLD?\ &(E>X_>4.X*^U5E32B)1$HB41*(E$2B)1%;OJ=_T<:[!;)Q3
M<\!P:DU2E]SUKTSBL9)^PP82B@*#JAVV4 GZ>_LK%7%_;V_OD++6NF7%S[H(
M4L:V^,I5E)2$]]E=GM[ZLH]<M)'9<S?E5_)MZ[C;6COD5+;5U2@XU2,3@8LC
M.;));*V,5$*4EAH^Z)>3F*!8Q<!*NUUP\RNQ"5'A6%UG>5M9SC2M(B=?;@<V
MH@80 P'@^XD(+8(_%U7NX1L><%G="V-=7T1U35Y66.@,=1T\@KF/Y$$8]N>7
M\UM&MXO>T8JVD;7<EFIK><W"8C,Y-E?GQ(325C7\ >T?LV&[QDRT V,M\%TG
M[ ;!M6$L-KW6H7[-8W/*V]UAIK$P BVMCTMXG5J\<#/)65WU<@]E;-?;FL=*
ML7Z3M>-UGI3FTDD<0;FY']VD;3*P\1!'2,?6,AQ57,;1K^")*@B;D+J#8)2M
M#:QQ',!<*6%=QKM6D[(U"5@E>W(TXU*Y%J>X6RN,;#[(P5HMOZA/Y',(@RW5
M,H=25);Y[ CA8* X'AV"UJZQHNW8-.M>Y& Z7F5J-S>.FDRXT5AMFZCN:9F8
MTI41V3#+H2?)2IP@7'&P%N^MKAL8KJW+7/:U].9 5"*.>24")CG'P!_$K=]2
MNJN>VME"M3QCRI"$CF*P&@D6!)]\W/;5:PATNP)%Y/'3TU^A91FDZI,X$02T
M\0?PJT$7;.I;,4O.$L/L_:;<=)%@>P)3?A5#6=4VXVU=EDS'P!6VZ!M+5Y+Y
MF>&D9ZD*4Y+JKM<H)9EK2VXD>\M(6I)([KBPO:OA+SGU>2_MIK'2XY3F!QIX
M%?<OEKM"QL6Q/O P' D55N9'5K,0YODO3%)YU]O$7N>Z]Z_*#7/+'<<FNS3&
M!Y+YLU2/%?:%AI&VIM,:\%E0Q3/)[Y&RD,>?(<#B@05^84\2.VP !K[6\H;3
M4=$LH6NB+9P!B:\EPS=^DVIN'-A<WM G *R&Q:S@9SAR[W+*>%U)#KBU>]W?
MG6M7WGMKS#W)I.FTMY SV1@ /Q+@&M[!T'6+L&\B+S4\2:?)54ID9,.=';AN
MM1V&&@ &T6Y5V'+8WN+5-_YE;OOQD[\K0?R33Z%<:9Y;;0TH]QEK$Y_YPK]*
MI]K'X".2KRHC8O<GD0F_C<A('&M>.H;DOWU<^=Q]+BML@T[2X12.*)H'YH"Y
MO9[6H:0V94%">\%QD>'=>_"KF/1=RWA CAG<3X.5R^ZTRW'M/B:/2!^%?3';
M!B<C-BXK"-NYC*SW4L0L;BHKLZ9)>419#3,=M:U'CV]@';PK-Q^7^Y^P;FZA
M?%;M%2Y_LM \22%C+C=NV[1I,US"UH&/M?B6?72KT/=6]SCQ<KG(3.L0Y/EK
M$>8A3V00TOE-UM!26FG.4]A)L:UJ;38H7EC7]QP/$</E*YSK/G?MNR<Z+3FO
MN91S&#?QE958#T+ZQ ?G3LAF<CEHF#=C+F8PHCM)F*2;2&U266O/2RW8DI00
M2+W-:M<V-Y<7;YXYY&VL)'V;: ./.IIFIX5H5@)?.J_?9Q6S;6".[N6N EJX
ME@Y4:3ES'J0:<@LWM'Z1:+@L3%5KF,@P(CK86&H\5I-E@64EVPYE.)4+$DWK
M/Q6\<T;9 :M(7$-8W%K%Q=O&HR223@TJXUPY'\*N,UJF(; NR"1X-MI']C>K
M@6L8-5A':E<'FI@WA<<T+(C(('8#>WS@6JH((AR5!UY.XU)7;1"B(^S&9'^P
M%>NVP<@J1FE/%Q7W2A"19*$)^1(!^2O0 Y*F7./$E<NP?-4J%&AXT1>=KUM3
M>HNL>JW/8^3J[LG1M@Q."R4'8$HNPE?(N%,BN*L>5QA]H$C]%8KO'EQ/#<Z
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M%]!6'F4QEL&B2C:<*JBYW4G*QVU)^**TI!Y$DGZN-ZZ%M7R/M9'-$C"WAP&
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MZ!;21"0N+A3DOC*;=-]!(6-8&NKSX_S5CKN6/RS+$R>TY9*&E.)+0]ZP!4>
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M\2\X"O@.]5Q6&U681Q.(X@+;-MV9GG8*&A<"59G3^J6(T[4,CN69C*AM(<=
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M#4(@]M.:)V?O?AQHBCP[N[A1%"B)1%&B*%O'C3T(E$5Q>F7_ $B>_P":Y/\
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MN#CC;+;CSSB&F6D*<===6EMMMM(NI;CBRE"$) N22 *\N<UC2]Y#6-!))-
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M_IBAS<0WYTQ'4_44I;_2;..V-2Q]":ZMY.11R[M<R7W?@Y?ZJ-:EO,TTEO\
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M_'B*FA3(WUJ@MNTO'9N%)>89;CY LK4'T'RR;()40HFR%#M'<:Q][8QW$9-
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M^W-":5!6MR,<YA<Y;A?3%ZA(65BL:)LF89>F0@EG&3WG/><:(LW&?4KM<0
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MW0S.;B"& .%'8WJAZ?,QT.)CH$F/#@0(T>%"AL*<0Q&BQ6D,QV&4!-DMM-(
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M'M<593V5J#0FCNBRVZ0;A(8R+"TR5KR4DH%D*/-S< DCE/#RR+UKVI6P<VA
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M.RV.]2U$74H\$I%U+40$@D@5:WM]9:=:27U_(R&SB;F>]Y :T>)/,G  8DD
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MQ09DRIP9 ,B1@EK#Z7% J#7.F]K6[?Y+[PFTS7&[:O9"=+O3E8"<(YN+2VO
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M?JU'3%=#75B7*3(=>\QJRG'7+DNEI!)64KN?>=^R#XJ%;CN!HMM/[4+0T!P
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M0?Z;=3VH*?UNO]-6VYDWCS,2]QR3/-#CGM0M6'QQ\Q0_-6\GPK#./QVJB/\
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M LKH6BWFX=9MM#T^GQ5U,V,$\& XND<>3(V!TCSR8UQY*T.D:WEX>#@ZIEU
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MVO;N#3K.6_NCEMH8W/<>=&BI ZD\ .9("R6BZ/J.XM8M=!TEG<U.\G9#$TX
MOD<&M+CR:VN9[C@UH+C@%COT(UK-9D2MTW",&LSD]CR.[;-'*O,0YU%S49F*
MUAFU\0_B^D6I,P]?C6_5F;'D.#WA>N?;5AN-;OY-6O!]A;W#W'F)+\C)(0><
M=A$&V<1X&83N&+&E=9\RM4T[2V1[>T%Q=9LM([6 \"-.B<7B0CZLFK71EU"4
M8.$+[=AP)"OEN6]XG3ACX;C$W.[/GE.LZOIF#0W)V+8I#(!>,9EQQMC'XN)<
M&5D92VH4-'O.N#@#L^O[ELM!=%:=N6ZUVZ!^'M(:&>?+[SL2&Q0LP[MQ,60Q
M\W%Q:UW/]L[1U'<QFN620V>W[,--U>W!+;:V:[W0X@%TLS\>S;0A\\Q%&,I5
MPIO Z'E<SEH.Z]5'X.8V2 _\;K&I8]QR1I/3IPI4E#N+;?;;5LNW):5RNYJ6
MV%-JNF$U'1=2\=I>VKZZOHMP[Q?'<ZW$[-!!'4VEB2*?8-< 9KBF#[R5O<.(
M@9!&2UV9U?=VG:=ILVUO+]DUKH,S<EU=RT;?:D*U(F+21;6A.++&%V4BAN9)
MWTR7:)N23<DF]SQ/'MN3Q-;I0KG=1ZE"E"I-**(I0H"/4H5Z /)>5'\=1F<.
MJ]4'K4+FISNZJ.!Q2],[^J4%?!1XT[C^J$#B@-"]_5!10OQIG?U2@)\$IG?U
M0@52YIG=U443C4A[NN"47(*Y3<7\/#ZZC.\\U/ X*/F'NX>RU1F/-3@5'S%<
M.SV^W\E3G<."54?-/A]?[U,[^J53S%<.SVC\7&U,[^J53S3[/P]M,[^J54"Z
M?#Z_WJ9W]5!3S3X?A]%,[^J#@H^8? ?349G#FO2AYA[?JKT'FO$J*#B5$.>(
M^NO8<>94>ST7(.#VGZ*] UYA*E1\Q/@?J_+7M17Y4\P>!^K\M%-<,4\P>WZO
MRT453S!X'\/GHE5$.))MV?EKSF!X+WAR5U.D?_2>1Q!_Y'E=G^%0:JQ$%WJ5
M&6H;CQJLDJN5;I1$HB41*(E$2B)1$HBM+UG_ .B+/_/4'^T3*HS^YZU[C]Y8
MM59*X2B)10E$2B*(OX?+P'S]M0:)4+YK?:;%UNMH[?M%([+=W;QJ#E'$_.O0
M#CP!*Z;N5@M=KZ5'CP0GF[/;853,L8Y_.JS;:=_!JMKU*UK0NJFI9?2-XU^'
MLFO9J(Y%EP<BRVXT0H>ZXV5!2FGFE64A:2%(4+@@U<66LW&EW<=]I\CXKN)P
M+7--"#^[CU"JNT=]S&Z*=H,3A0@XU"\R_7+T1)Z.]0)\.2_EEZI,FO/ZMD@L
M):<Q[CA5'QTF6A%U38B"$74>9:0%=MZ[0[[Q.NR6S(8[:!EXUH#G4)S$#%P%
M:"O&G <ENVSO);:^I0&[DNIY' G-%4-+?#A4CQ^57(Z4].=>P*F?BN=Y'N\I
ME/NR" >^[JU#A5E'YI;TU8D33%K2, QH;] JMQOO*W8^GMS06K'R#F\EW#TF
MGS+.+3X&JLM(*UQ6F6[66GRT&]^!/'MM5O+=;AU%U7NFD)\7%:Q>PZ#H_LPL
M@BPZ-"N"K;,-C^:/CWVY*$)ND(]_L\+6X\:KP;7UZ[]HQO /-V'TK6[C=FW+
M05EECS=&X_0I/D=M1.;3_P GOE0X"Z.4'P(!/ 5G;38%VX_PJ5C1Z:K#.\SK
M"V)^!C>\]:!OTJNNA/4R5C>H#.I['SQ==SK9:QSJE?JXV4N"TVM2S9M,A!(!
M'#F \:Q.\O+6VMM'.KZ<XR7,1^T;3BSJ*?DGCX8JT=O^769!')"R.3DZN)\#
MR6>&JXR!)S>Z9'RDO-)S$3#QED\UVL3CF"X1V WE2W+^VOG?1X8Y=2U&\I_\
M0R$>B&)M1_1O?ZUMFX+NXBTC2;',0?A7SN_2GE=3^D8U5^AAEJWE--HMV60D
M'Z;7O6R  <%J#GO=BXD^M?6_R_/7JI7D+ES'AQ)'?Q/Y?"E2BA<]MS]/X=U$
M2Y\3])I4HI1EL8C(,E2;"0V#R*)L%)'YAX&Y\*H3Q=QM?K!7EG=.M9,/U9XA
M4AC<@]BI10YS<A(0X@W["1>W@H5CXI'P/RN]WFLY=VS+V'N1^_3!7'8D-OH;
M5=+T=P +"DA25MK%EH6#<&Z5$$=A%90',VHYK67-<PEKQB%XKNNN@=6_35U^
MZBX#8].S.K:Q/ZB;;D-2GR<=*8U[.:S-SLV=C)F R:4?L^8Q^S9#9*&UE;)]
MQ:4D6KZ]AV]LGS2V=;LN9(9]8;91M=B.XR5K "V1I]KWA@[@X8@E=,\N-^;C
MV??Q-LY,VGNE]MM:T:3CZ#3@%>+$;9,EXV)/B24/\J&I/*M(/,T$A2@E2?SK
M7^<5\P6VR]+T_6+C0)V&VF?FCJW 9^ )"^W=0UI]YI4>KP 3QT$GB6\74(YT
M646K]9'1@ 'TMLQA''-)4I/*D<ME&Y' #O\ ;7Q#KOW=-\.\V9'6MW*;$24[
M0KBZM<!^!=#;KVU;G:D=^&CNF/-4T I3B3X+Z:QL!RKLJ;C)+00Y(4?,XO!S
MFOQ^T.4*[>'97U_LO3H]K.^'W/!+,V/V:4[= !3UKB>Y8I]2M2-%FCCE=B''
MVQ\W\U9U=)\N,ST[WCI9M^697ANH>+F1L+D@DM.ZKGI48L,K9<4?=B2I26U\
M1^K>3S7LM1%/4?-ORXEWQ:6FVS''K,+VN=$2"Z3MN!J6UXD5;^<*#ECP7=WE
M?O4Z4=<N)'RS1 YG,&4&,]"*$EE33GEJ.06L3J8Y*E8YN \IY63@F3!FJ>26
MRJ3$4N)*24GE(5YK*N!XU]Z:--#<L9=0T-O*QKV\_9< X?,5\WW,;[=SFRU$
MC'$''F#U\5@OE,),9D2' X\V4N+45)<6F]R3W*'8*VTV.GS@=Z"%]?RF-/TA
M5+77[RW</A9YV4_)>\?05='HQA\ZYDVG?VIDTI>?'(!,D<H3S<+CS""+>RM:
MUO;FULE7:=9%],3V65^A;':;UW7P9J-XUG3NN/TDK;!I/[?8QK$=Q]Q^(EI)
M4OS5&02 > *@00!W&N3ZCM?;,CS2R@;CP#:#YEL=OO/<49$CKR5TGYU'?2%D
M3T0S>+_K)P;.6?DQXLI<C'@2"&E>9,0IED<QN"E4E"0/:1XUSS=FQM#;I,MU
M8VP;<QT=[)/N@^UA4\L?4KW5]W;CN]-=#/*R2,$.]T5%.=13Q6QYS3,22?+D
M3&CQ["%?)QLFN+NTJT/#,/05I[-Q7H][([TM755IW+_P;-3&CW$@@CYPKC7C
M]E-'N32-]:JC<(=^NMXG>I23/8788&)F+C[*X0IORDAU!4.9S@.9)!"@.^K2
M]L[Z.U?VKDAV6@J <2LAIFI:3<7\39K($!U3E-,!BOIAH6^P<5!1'R>,?3Y"
M'"EUD(N5CF)L$CBI1J;6WUF&W8WNQ.(;C44J?4O-_>[9N+V5[H)F#.1[)K13
M3]I]06.*\5BIH'>V^6R?'A:UZN>]K3.+(7#P)"LC#M>7W9KB/TM!0;=M+'"7
MI<IRPXJA26G ?: I2:?M#4&?K+1Q_1<#]*C]DZ-)A#J# ?SV$?0G]8K;)'QV
ML;+$_2*8/Q*1\[)5V5Y_;63]=;W#1^C7Z"O?\F^YC;7EF\^+\OTA?1/5'4@;
M2GLC )[1,Q4QGE^57EE-3_*'36FDAD9^DQX_ H.TM:(^R;%(/S)&'_A54P9Z
MAZ1((#>S8H*/8AZ2AA7SI>Y"#55FNZ/)@VYAKXN ^E6LNV-PQ"K[.X(ZAA(^
M:JGT?.X:6 8N4@20>SR)<=PGYDN$U?LN;:7&*2-P\' _05C)+*\@_7PRL]+'
M#Z0IBEYM0NDE0/84CF'T@D57Q/!6U6CBGFI_A?Q3114=5R"DGL4#]1^BB+E1
M$HI2B?2E%%$M3Y%( *6I\BBBQ#Z_Y6?OW47IOZ=]:="GISL3JGU%="0ZSCM:
MU[(K_H5"R*.(+.0VN"K**95P?1A4,J!3)%^1^8VK7NH:MIWE[H+LNM7[N](\
M $6]O$:FX>.%(W?:,:<))VP1'V9#3OOE3IEGMC:>L>;>N-_@L#7:=8MK1TMS
M<1_PKMGC5ML\6^<8QB[DE'M0JZTG9G(#@Z7]'\=#S.P8".Q!R^:R:GWM.Z?)
M=0'?B=KGQUA_.;7*\TR$8B,OXM]Q?/)7&:5YAR1U<VX&Q?+>&*6ZL6-AEN):
MOL[  <)W-(==7A]\VL;@\O)?<R0AU7ZG!M]EPS^7WF9-+;Z5>O=+#;Q4;>ZE
MC2EK&X%MM9M($9O96]IC1DMX[B1I8*NT[0L9J*Y^3<F3MDW#.(:&S;OG/)7G
M<X625LQ&TL)1$PF AK)^%QD-+41@<>5;I6ZK9MO;7L=O]VY#Y;K6[JAN;R<A
MT]P6\ X@!L<3/[%;Q-9#$/<94EQUK<^[[_<C8;%L<5EMRT+OA;&WJ+>W#O>=
M[1+YKAX [UU.Y\\IP+@P-8VN*V3Y%J=$M3Y$HEJ?(E$I12:<DJ".BA0M5+ME
M35+5':=R4UQQ2U>3&X+U4<0G'OJ1$Y1FZ\$M3M.4 CFEJ=IR5%4M4]IR$BJ6
M_>J.TY34*%JGM%151MXU':<IKCBEC3M.452U.VY34<E"U.TY151M3M.4UPHH
M6IVW4454;?A>G:<IJ$L:=IRC-\B5';<O69JA49#RXJ*BB'MJ"".*85\$J$K0
M)2I4\\$[K4\4KA10M\OTG\M*E%'Y;_2?RTQ2HYH*5/)0*<U=;H^?_.F1_P S
M2_\ C4&KFV_6'T?B7B7%GK63-7RMDHB41*(E$2B)1$HB416EZS_]$6?^>H/]
MHF51G]SUKW'[RQ:)L+D@?*0/QU95'-5ZKX+EQF[\[[:;?P@3] O7DO8.)"]B
M.1WNM)4O<S<!L?SBEGP2G]^J9N(PKAEE<N^K1=!W9&A?RF2K^$M79;^".^J3
MKMHX*Y9I<KC[1 4M=V.4O@V$(^1/U]A-4C=N/!7+-*8/?)*E[N5G/7YGG"+6
MM<@>'"J)FD=U5VRRMF#@*KK$RG;$%:C["H_EXUY'==U57^#1]/F799Q4]X@I
M97RGM-B!])L*]""1V&*I/OK9G,*9-:Y*78N*;;'M5<CYO>JL+1W-6K]68/<!
M)5-[UT;U'J1K4_5]NBMY&!.CK:!+2?.C.E)#<F,\1YC+[2B%)4+$$"JS+5C7
M!YQ<"O5GN74M-G%S8.,<@^?P(Y@\UYV?5%T5ZJ^E[=$P,MG<EE^FN<DK3I^W
MH!:2RLW6C!9Y3(0TQDFT#]6O@B2D<+*!%?8'E,_8>Y+#X=EG%'N"%M9&.QS@
M8=R.O$?E-XM\1BN;;WWCOWO]U][)^SI#AVQERD_5=3YCSX<5;O1-OV_,2SCH
MV3:\HI"BX[+LM0' DW7Q)M78I],TZUCS1PL:!^2T#\"YA-?W4YSW<TTDI_*<
M3])68/3[)_"LJ_:DA*GFE)"CY@Y2!V\3;MK5]5MW/_5# KQ%<@OHKBY#J+%<
M>;C0DI66B+J;0"% <.V_&L-#I+F@NE/%9ICR14X+X97;PMAMT1U(D-%"VW$7
M0XVX@A2%H7P4A25@$$=AKW%84JQQ!C(H0>!!Y$<PKN!U7!P-#59]^E'K9BMS
MPT[5,O)^'VV'D)F0=3(*4G*LS%-J^+C*)'FJ!398[4GV$5\S[ZV([:U\^]L&
M?Z(N972 CZCW8N:[\!YCQ74&:X[6&0&?":"VCA]+8QE!]?,=5F57/56]"44I
M1$HB44)V^'S]E$5.9W$B2A4IA(#R02XD#BM(_.X"Q([ZM;F#N#,WW@LGI]Z8
M']I_ZL_,I+A<JJ&Z8SY/DJ-C>Y*%6 !%_K\:MK><QG(_W5D-0LQ.SO0^^/G5
M">I3H'JGJ;Z.;5TGVA2(R<U#^(UO84L(D2]5V>*DN8;/0N;W[1Y%DOMI(\^,
MM;9^U6V[=UV[VWK$.LV)K+$[%M:![#[S#X$<.AH>2U]CWQ.S,):[G1>2R!CM
MFZ%]2=UZ#]1T,)VC1LY+PTD,.J=BO%GD=;?@NN)0N1 GPWFY#"B 2TX+B]Z[
M)YEV]OK>EVGF%HK#\/,T=S#$.&%7 <"""'<JCQ7UCY(;E_:-D_;-[*7R-:71
MUXEAXM]+?H*R'D1HATQQ<=M0;D07?+0D$E2R%70$I]XJ/<.^N+;5W,-8\P87
MO>/B(KI@>20,,,3^$KNVLZ0-/VG<6D+?L3;/H *\030?B5<=%](R&*:8S.>=
M?A,*1SQ<9YJD!*5)!$B:GARDCB$]P[:Z'YI>9>CZC._;.@0Q7-VXECYLH-"<
M"(R/DS?(N+;7VKJ5F6ZKJ$LD30 X1 D"G(R?3EY<UD:K:<#AXKN73F>?X=2(
MZ8?F )D.*('*VDJ 6$7N3P[*X[LC[I.CV6\H_,;4V$:Z]M15Q]EIQH1U/193
M<7G]$[2I-G6<?=RU!>&BE0*8.YA8T=3=@&6@/YUPV+V;<1+YDI2X53UWBR0X
M.*RZ20OOYB#<W-ON_;L#+1C;!@HR..C?0WEZN7AAR7QQN>QD[AO&4I*[VN@)
MZ= L=LYBUS5LM-L!LOK 1:_%-S=5P3>XK<()2 7.. 6I.,4)R,Q5[NC^OS(T
MQ:FX!>3'+;;/:D<ZC8K( )-B#PK!:S.TQ@5Q*RFGM#GESS1@6PW5X.41CDH4
MVA"U(/-P[.!  %C7/;HL+BLOWHC(#C0+N3&A_>Z@I34YGF+$IHE"H\A!"FG$
M$<>=#B00>XBK(M:ZK78L/$=0>7K6=MI'8TQB/+J%MLT/*2<WI6JY6:ZT_-G8
M'&OS765A:')ABM_%*"@3<EX*OWWKYCU* 6NHSVS06M9,\ 'D XT^:BUJ5K63
M/8W !QIZ*X*K*LEX5)[<X?@XD9/VI,Q";<.(3P_&H58WYK&UG-SPLSH;:7$D
MYX1Q$JJ6T!MMMH=C;:&Q\B$A/[E7H%!0+#$ESBX\2:KZ7X6MWWO^Y4HER.\C
MYZ*$N?&I2@Z!?-3;2^"VFE]WOMH5_9)-10'BO0<YN+20? T4O?P6%E"TK#XN
M0#VAZ#%<'9_";-JHOM[:3"6-CAXM!_ KJ+4+^ U@GF8?![A^%4])Z<:'+)4_
MJ6$YB;\S41,=0/>0N.6E#Z:L9-#T64U?:05\& 'Y0 LI#NS<\&$=_=4Z%Y</
MD=52]SI5IYXQ&LWBU=RL5L^=@<O^M2SD @6^2U43M[2!^J9-$?[G-*S^I?\
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M&1Q@-:WF<.9<:ESC5SG$N<222OSIUC6=6W!J4NL:W<2W6J3$%\DAJXT%&M'
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M2EJC(TI50M7GM-*52U.TU3F*6IVFJ*D):G::E4M3M-2JNKT?X;3(_P"9I?\
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M<]E_D%3F48J/GK]GT4)JIY)Y[G\'^+4 T0U5V.C3BE[7(!M;]BRSP%O_ '5
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MFF%>:PJUS/K8DL.2W_,?4L.^>X02XM5_>4#QXGO[J^NC906MN+>V&6WC:&M
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M3(8K*P'E,2X<AEP M.L/-D6^R1Q22""?K2WN[35+*+4+*1LMI*P/8YIJ'-/
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MUS;>IZ!-V[QM8SP>,6GU_@7T/H>YM,U^W[UF_P!L<6G!P/B/W!5S8GOX_+6
MJ>*SP>/%.)[3]9J:E1G"<;^SQO\ O4J5.=O4I8\>/R<?WJ5*9V^*"_C;Y":5
M*9QXKES+ 'O#Z*BI7KN- YIS+\1] I7Y4$C>:%:[\"+?A[*8H)&\U$+4DA2E
M#D3[RC;L2GBHGV "I:6UJ[!O/T*"^HHT&IX>E4-TY\U6H8^>JWF9R9F=A<OV
MG]N9B;D&5&_'_@KK8^05INP*R;4M[]X^TO9)[H__ &FXEF;_ $CV@> 6Z>8#
MV1;LN+!OZNRBM[4>'PUO'$[^G:Y5D^TW+CO1);3;\:0VMI]EQ"5MNMN)*%H6
ME0*5)4E5B#6XFM016JTITC2*!>8#[R?[N^=T?S^8ZY=&\))G]+,Y)D9#<M8Q
MC"WW=&R4A:G9&7@QF@5G79;BBIU"1_>JS<>X3R_6GD]YK17D+-J[ED#;]@#8
M)G&@D:,!&\GZX^J3[PP.(%>=[FVY-/.+[3_<K[;.GYS?#J/6%JYZ6]2\KT\S
M\)R+.7^R9#[9<9*BI'(3?F0>*0+'YZ^@)&1W(,;Z9?H6O7-NZ&(!X)?3!;C^
MGGJ"PN0@8V:G((#B6T)7R*3<>Z+W 5W5I]_H+B7-I[)6"#I8Y02#4%9A8':X
MNS8X2HTM"TK0#]L$GAX WO>M'NK%]G+E(*S3)<XH>*Y_ "7YH?<3Y=B L\2"
M0>/'LM>H[H90 8J]@FR*<:6<[J;<J5JV4EP'T.J?/PSBC&=4FZK/1E%3+J2>
MVXO[:L-6L-,U=@@U.%DC"*8CVAZ'<1\JRC+ZXAD#XG$#]W%9Z]%.KD;J3AGH
M\[RXNT8<AC+0P>7S>Y$V.E7$L/@?[%0(KYUWEM67;5_2.KM-EJ8W>'-I\1\X
MQ6]:??"ZA#G?K.:OB+*O8@6\36FJ_+VA<N7^$GZ?WJBH3N-\4Y1^DGZ?WJ53
MN-\4Y1^DGZ?WJ53N,\5)LOBTRVBZWR>>V">VW. .P\.)\*M[B$2MK]97]C?B
MW?E->V3\BMKD<S(@%O!LJ5\3E5^24)/%IB_*ZZ>/NI'9\EZP<MXZ!S;,5[DA
MIZ!X]%N%OIT5VTZDZG:A%:]3R ZK4!]Z]Z-HLG6T^J[IPU';RFJX_$XSK#BF
MP6UY["_$Q,3AMX@A*2E>5PSLEN+D$*(+T,M.@\S"POZ-\GMZ'196[9NW$V,I
MK"2<&O-2YG@'\6\@ZH/O5$;>W#(R\?9WE<DCB6?FG\GUCAXX<UI8T[+?&-MH
M\X.N 6*5J!6CE/S7'"OIYYCEB$T?N.%0MUG>)6]T"C5?/5D3$ST?"/".74*1
M(E)/*ZW&6"'T-+/\VIU%Q<<1W5C+D,R>T/YZQMQ*P-&<5 . _&LH]0S0Q82\
MP$-0X##9:9;20AME@W2ZH@CF6XXL6':J_A<UKEU$7FA]\GYUAKAHDP.+G<?6
MMBO2[K+C=QU5O'R'UISL(&)SDCFE,M\Z6'E!1YG%AELA5B24IYC6J7>GNMY\
MP_5G%:!JFE265UW&#^#.Q]'@KC2TL,X9YE;JBI]!^(2V4E);<2HEU)X76$N
M]_95H*F2H5C&XNF!Y!3?TT,YR-_6/@,N\B2VK==7D8>2RX%-3,*]AY7DOA*5
M<S;B7D+0XE0!2M-N(L:Y#YNF.2]T]L>!?$ZHZ%K\?I6[VCH7,^.C&7);/#AT
M=7\5*+/^UAR@\  D>%AP'U"M#I3!:A6N)2BB@2B4'1*)0=$J4H.B5"4'1=6=
M/A8R(_/R4R- @QD%R1+F/MQX[*$\2I;KA2D?)VFJ<TT-O$Z>X<UD+14N<0 /
M23@J]M:7%Y.VULXWRW+S1K6-+G./0 8E6]5L.T;C^ITJ,<%@E\'-WST(EV2V
M1Q.L:](Y'9A4#[LJ7Y<<=H0X+5@C>ZEJOLZ0WL61_P#B)6XN']QB-"?!\E&]
M&N6UC2=#V_[>XW"ZU0<+.!XHT_\ S-PVH;3G'"7/Y%\951:[IV%UMZ3.C)DY
M#.3P!D]DS#YR&>R':?+=G.@&/#3?W(S"6H[8X)0*O]/TBRTYSIH@Y]Y)[\TA
MSRO_ $GG@WHQN5@Y-"Q6K[BU+6F,MK@LBTR(_96\3>W!'XMC'%Y^M(\ND<<7
M.*JJLDL%0)1*!*)0=$HE!T2I2@/%4&H?M_>&P??QNE,*= [6W=CR;10D^"E8
M_'*5;P4]?@16JD?M;<X/&RTMGJ-S,VGRQ0D^@R^"VX?Z'VH0,+[57@>(M8G5
M]0EEIZ1'XJO.-;4M1H$J$H.B42@2B4'1*)0=$HE!T2B4'1*)0)<^-2E HWXB
MY-0IY8+Z\R?TNVPXGO\ GJ%0+'E0YD^/X_R4Y^"\]MZ<R?'\?Y*E.T].9/C^
M/\E/E3MOZ!.9/C]1_)4#!28WJ/,GQ_'^2E/2G;>H<R?'\?Y*<$[;_!.9/C^/
M\E*>"=MZ<R?'\?Y*!08GIS)\?J/Y*"O.JGMN\$YD^/X_R4HG;>G,GQ_'^2E,
M/%.V^J<R?'ZC^2E#XJ.V[HG,GQ^H_DICXT4]MW0)S)\?Q_DJ>=:*.V].8>/X
M_P E*^"CM/JG,GQ^H_DJ.6(Q4]I]<."<R?'\?Y*4]*GMO\$YD^/U'\E*)VW]
M%R_"]1A3Q7@AS30J%3@?!10CQ2H/&B#A51I0_(IXI3UHE :%015*DGJ$YJ[W
M1/\ Z72?^8YG_&\?5>#%]?!>78"BRLJ\5-*(E$2B)1$HB41*(E$6D+[_ +VC
M^B'HAU?+$**/^T3TWBN<A]Y*'==WY94+<38M"NR^1=R+7>KY'<#8RCY71KE'
MG)I+M8V@+5A >V[C>/4V3\:\NNB=;\?-5C%P,DZR\M2$E"UGRR;@V)) _=K[
M,#[>Y;2H-0OAN]T6^LI"Y["T-/3!;4.DN_.YG570O)H<6$I24)6%<IMPO8FQ
MKGFO:4R&^:YC/96Q:#J\CK)\4KZ4X!7 P^]YO&SEJ<49L9) '.GF#:/G'"U8
MRYTFUGB#64:^GRK(V.NW=M.7R'/'R\%=W6=S@[#)<0MR.RI%D*2+ E5N/"W=
M6NW^F36$8=0FJVW2]9M]3F+6Y6TP5?-09$&2UD\)-=CRF[*2\RLH/;S6X<%I
M)'$$6K W'PU_ ;34(VOA/(CA^);;:.O-+G;>:;*YDO&H/'P/4>"R#T#JTY+D
MQ\!M1:CY!T\D.9<(:E+[ V;_ ,VZ1V#L-<=W7L4Z?$[4])J^Q'O-XE@_"%VS
M:6^X]5>W3M3 CU$C \ _T>/@K_@A0"DD$$ @CL(/$$5S3FNDJ-2B411X5&-<
M>"!0HE4HB42JIK<\@K%:AL^10;.Q,#E%L6-C\2N&ZU%">^ZI+B +=YK7=WZ@
M[2MIZGJ,>$L-A.YOZ?;<&#TEY:!XK9-G6#=5W9IFG/QCEOX [] 2-<\^@,!)
M4RPF/&)PN'Q2188W%8Z!;LXQ(;+"O^Z0:R6D6#=*TFTTM@HVUM8H1_Q<;6?\
M%8W6M0?JNLWFJ/-77-U-+_A)'/\ PJ9U?XUQ6--.2ZLZ##R<.1 R$5B;"EM.
M,28LEM#S#[+J2AQMUI8*%H6DV((((KT"0[,TD.!XCP2AXKSX?>"?=508N*SW
M6?TT8UR/)A*D9G9^E\8<\28P"I^;.U)K@J'-;3=9AINV[Q" E7 _0_EOYQ7-
MK-%H>ZWY[,T:RX/O,/ "0_69RS'%O.H6!U;26W41DMQ2<&M!P=^(_2M%NO9_
M/X4)5$ERF0A10]%65H4P\TKD=:<:7RJ;=;6"E22 018V(KZB;)(]H>QP=$14
M<P0>!"P;6Z:]G;GC^U'$\*=5GYZ?^N[L%:(>6S#[3A4E*6U.V0>P<$DU9:CI
M\=S'F8!GIB%K-U;O9,70L/8KQ6R+7M[9V",VF'(\Q2D ^ZH*YN \+=M:3<:>
M('9G#!>(WG-0JN\1EL_&YF8\=99<'(5*'Z1M< ]W&L;/#;/]IY&8*_#P%W6,
M]LVA9N#L>MR%,9L+!6W8J8F-+4DNQ935P'&7 /E2>(XBL5J6E:?KMD^PU!N:
MV/ \VGDYIY$?/P*SVG798[,TT 6Q;H]UFQW4Z 8\J*</LT)ILY#%NK"@NXLJ
M1#<[76"L=]E)[#7SCNS9UYMB8/KWM.>3ED ^9W0_,>2VFUO8KD$-P>.7XNJO
M?6FJ]2B8)2@12;8I4Z#A,G+QC/Q,^/$>=BL7MYKJ$$H0#PL5* %^Z]6E\^>.
MSDDMFYK@,):.IY!9+2(;2XU.""]=DLW2 /=T:3B?&@QHL4NAN9ZB[T]MF?WS
M5YF D1)IB8M$U@,/*C-BSY:;YE<S/.+)7^>./97&_*^]W_KEI>:AY@V4=GJ3
M;ES8FL-081P/$X\J\^( JOHSSATWRZVG)IVD>7^I-O[&2V#YG-)($KC@":-H
M:4);3V3A57=WG5X'4OIOO_2W.)Y\7ONH;#JKG-[WDO9G%R8<.2D&_OQ)JVGD
M_P )L6KL>EZA)87D5P#1\4C7#U&OS\%PJ\MB'"[M_P!8T@X<Z8KQ*X9K+:]G
M\IB):%,93!9"9CI\1U*D.I?QTQV#,0$J 4/*D,*20>*>PU^@FWYX[O3V/::P
MR1M>TUJ"' $$>FJZ'8W!DBQ&!%?W=%D9@MG>>:;#"5)4I()"@$D'BDCNL1^2
MKN6U;7VE:71$;^%0KWZAF\CD9,?".N!F!(E-R<G,>-G%1V;+3$9Y;)::60$V
M[2/FK#W5O'&TS#WP* #KU5@^5C27TQI@%E[K4U4$8>1BGT-!C87,HZ8X <5Y
M$)]$.,D@*)8!4.=/ * K6)V5+@\8Y*8^G$_B6+N(V39A+B"RGSX^M9IZSL+$
M]]M4F.XW E06W$A204)>6.:3'YR![G>D=@'96OS0EH.7WP?YRTVY@,(HT@O#
MJ>KD5=GT\8N.SU8VQ_'/.*QTS!8J8_'4[S-L2XDZ>EA32+W2%,25 BW BW?7
M(_-"!TDNF7#N+3,WYF''U\%L$5\]FWIH)![>9M#X' CZ/D6>',>/%7TUS?%:
MOW3T4+=]S^[]-1CP4]RHJHA2K\233@H#R3S7+S#WBIQ4B4\^*CSW[J5HI[G@
MJ'R&[!V4[B-2@G9LTT>1]3+ODX/$KO;FRN7*5LH4CM\EKS'C:W+6(FU7-(;7
M3&?$78XXTC9^F_A7\UN9QZ!;-::%VX&ZAKTGP6GNQ;49II/[U%Q(/Y;LK!U*
M^$/3#.EL9?=IHV;*L+#T."6O)UK#N@\R?V;B5%:7Y#)-A(D^8[PN.7LKS%I'
M=D;=:L_XFY::M;2D49_,CX$_GNJ[I3@IN-SBW@=8;=B-E8N%'/K6XE']TEXA
MI_M<>5O7-Q5?^8?#A]0MV #N %9GZ5K'<\,$"_92JD2540OQ%,4$@YKGS-^*
MOHM3'DH,F. 4"INW GY_RVICS02XXJ'.GQI55 X%2S,99C$8N;D722(K"EH0
M!Q<>-@TT!WE;A  JSU&]CTVQEOI,6QL)IU/)H\2: >E7^EV+]4U"*PBP=(\
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MP-JL.8]O$$?56)GGOYFF.8'V1A59^UM],M7B:W</;.-%>49_&0FX,)+[?GR
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M#,?R3S'P*FW$V<4+D6-CQL16$O-.M[*W?&U@.<'DJL&JSW%VR0O=[%*8K-7
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M(3*F1XSY<D)]Y2>6R3V$U]:>3OF%=>9VRH]U7=O':S/N9HNVQSGMI$[*#F<
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MO!_]P;> _P#3>F_QJ?\ R2\'[E.V1_U[?_Q>+_*+[)^]'WE7_5-J7^DN8_\
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M\U]Q:Q2EHMXB 9(VO(![F(!=0'FNA_\ )/\ <PA:STKU3W4*5;^DF7XV!/\
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MGZ%G&1#NM_2'TKV!]/>.@Z.?'4-:_P#K+"K^@S:6&U-,'_=]M_B6+\#]U?\
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6H;[V&7\+B.AG&WF9;?A\O+
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MKA^L3_&JU=H3NGS*U<U=Q&RM</UJ>[\X=GTU1.A.Z*V>%6FC8G:NINTXG2-
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M>NG1*%)D0YG6/I7$F0Y#T27%D]0M28DQ949U3,B-(8=RZ76)$=Y"D+0H!2%
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M9T+&R-DQZ,EF\>#L;F'85-DPL;D=>Q.OS\%EI+3*_ACS/QG'>5IQOD65IO\
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MQC]IF9@<_JWW:O.#0_.W5KW<&HZ;:Z=YF6-D(;IUNVD=]9R/:Z.0AU7AT$S
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M_1].\D=_;8^\'Y;Z=#;0:DR5[[*>)\<4=T^WQ+X&F-T+I(KAW<B:6!D\3B
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MY*GV>Y9W+GLJ*'V35M?"JY+]T+:=ULK[QVY=G7#@ZZT[3KRW#Z#VNW>VK62
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M8!I.X+JVGJ/=^)BFBCN *8>W]G-XF4E0^Y3_ /P;=_\ _NNS/_@)TRGW&_\
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+)1$HB41*(E$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>96
<FILENAME>g382677f_toc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677f_toc.jpg
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MQ "-   # 0$! 0$!             0(#! 4&" <! 0$! 0$! 0$! 0$
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MN]$O>"7]OZ9OZK__ ")<<O9_*,_[)_I5+]54?Q\(E_:LW]*O_P#*N+MNCO\
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M"::N$36=ID  2%VG(Q>PD8G;Z$C#L<D:V"8&);!DQD39]']EPZQFR4?8]O\
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M8HNKJ<675V$%$(HG%%U=+%C5TH=&5=(!8HNKJ<675V$50
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M5J66M(.>IUAK=0GLO&5HG)E+,5;Q)?3-]-$X,V,6:T6YF&&IE@)2R%\-#+
MJU<R6LV_"R,J5M2:EJH1-J;3(@ :3)L38>)B\_H\U278S>5IEOM4&=7)%*U]
M"::>*)J;5$0 /%C4V*Q1-33B"( &0?AJ'0_J'7] ; %(!8JA=IM&*&TVECJ7
M5T8L;%V)*I0BZNU.(U=&++IL3!=,E3CT+J92Q0U?*7;0LJ;]I-- !8H;5VH:
M@UJRZ34E7<0[7R+K6D50 H3"Z6*+J[2QU&FE#+J["  H
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M4R,W;0U*SMGM,,NQ=@AT8TV):G0NM2H:@TT4("7;0NM2_90Z%U=A%
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M+JZ4.A=AL 4@               I*25+<7$$9-+0FIK?Q\=M3GR].7/T]?\
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MDRZNEB732::*T0":D&XG&A=:TH95(H&I"[B7;0NKJ2J I 2[:%U=^TQ!IH
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M "7;0NM2I*T $!+MH:E:E250!+MH659?M!IH  "A#5VECJ75TL675V%#HP;
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M7+PUA(QKGI@:6J./,S:Q:U32X;_DQ6>U^523#LM7+H9RHJ9(&N*ZDJ7TT,L
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MBSZ41#382XU4<_4Q6+JTTS+!@4E'4S:S;JB)M4KFJDL2ZM,SB;8<C#L9&MT
M:)R9L9LPTX(C1.3+&881:<F<9LPR(M.3'*,V89S%ISU,V,68H(T3YF&+_*U=
M)FQFQ:<$QFS5IIF<9Q2;1,9R&KJDQ,5*J,3*I-KH8O&4VM$SG>-^$[?:LF3K
M3_Y*=1UJ[#R>A.J>#5R)989]*E$3#ED3#R8R&1^4#]]?K0 EVT-:U*DJD
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M   4)VH:NU#31IK=(   $USYEE:E0::  !+4]2RK+B"M   .)1FU!J-RZ04
M ":GAQ+*LJ#30   ! +%%U=I8OJ-72Q="[#84,+H        !4&G,S78!=@
M H:XDOI+Z>A^OR['E_;U7FY^Z]S];=[/;N?(_P#1Y>?D]OP_V?&_3V\GZO1L
MX;41YN7MX^7M1$-*26I;BUN,L^UIR9L8LQTV/=2GP<^4<N4:*Y]3&.>+3DB>
MFJNI)SO&?+'F-K;H76#E>$OIBU:N70S>%#E&,P:F'-:C_274NJ(R *5S)B9#
M5R9,2Q1$6E&\EK-JC+(D+M4KH_LEB75R9Q.WV<C#LM.49QSMJU<UQX$L2ZTM
MALQ=D\)O_;0XH""[7NZ$K%41%IIF<9PR( +5U26,V?2B(I75,XS8J41#"'+J
M3(F09,88K)$Q,.548F4$#EC(F0\F3$Q^6S]S?K(      (:H:E:E250  )J>
MI96I4&F@  2U/4LJRH*T    S:@U+K<ND50  )J2RDN(X%;!0        H5$
M#1"H-J[2Q0VFT8K4NFT8K4::6.HU=&+T&G:(Q>AK7/8,7H--AXDU--6HUQM-
MHQ6IK4VFDD-+==O@W;;4/-^OIPY5[OZRX:P?&_>^WFYWQKV_"HC;E^#Y/Z[K
MQ\[,>A;P1Y+[>6^U!&BX&*Q?8 I-DJ5LFH@Q8Y6-;7*,5BSRM-HSC-FM+;D9
ML<^4K1.C,XS9]K3;,V,V8M+>9OIG<;*Z#C>%395RGS,99[#EHB8K*I,3%2JD
MQ,IK<R5F^FAED!%*ZI,3%3)$,B&G PLU2:9G&;,4G!$]K33)C%F*3CH9L2S6
MB=&9L^V%*ZIF\8GGX6G1F;PB;?E63,WA/@V*5RZ&;PHI.C,V?8M.3-C-AD0T
MVAB6:M7(SB93""8(BLF3$P\M!AARJDRIE,( 'DR8F0\M"8F/S&TF?M[]3W$.
MV#6M2D%     $NVAJ5J7[050  )J2RXLN(--@  EJ2RK*@K0  #B49M076Y=
M(J@  &I AJ#4K4I%4              ""7TDK    LM@9K8AK>RTOIV^'BCS
M?KZKAR]W^GN?K<MD?'_]'R\_/_\ E[7A:C:I\SG'S_TGEV)T9PLE]O/YAY,S
MTXFM[&VMYQY22^$JC*&$-7,F)8Z+>1SKER:F'-::Z&;&;*I<42LWTU3@Q9K%
MFJ5RZ$QG%JY]3.)BLNQ,3+\*5SY,S>,3;\JSJC-X?1JE<F8O&P4F^1DQHF^Y
MFL612NJ3$Q2:9G&<,"E<^9,9Q1&3(+3G=S)8S89$6G/4S8S8M.#-FLV:K)$R
MLY5$0\F,B9#RJ3$Q:?H9LWVE:)F.L9VPY9.L.QJYDZ0U2O7,S>%^#PI.>#,V
M6>Q63ZF<3(>2U&)ARJDRIE, (AY,9#(>6A,3#R0RIE?F@_;'Z@ ):3&K*EIH
MUJ[I!0   ":DLJRXAJ#31  ":GJ659<0:;  !+4EE67$%:    0U!J5J5)6@
M   ":GJ6594%:!0            @E])*P    9J3Y#7$M2^G9X7PZG#]9XKA
MR^7N?KO<MMN!\?\ ]$\UY^?IZ_AN>[H?-YQXOTCJ3E')Y[X:V)OH<^=R?RGA
MT)P>>QFS5IR99S !:MF#-K%K9*$8<ZI-\B7$LC1.&98K254RQBE<^I,3%)HS
MB93(RI75)B8O4C)Y,F)D6G)&?32W=O,<I*EM:*^IRO"_">%2JF;+ R!RR8F1
M2N70F)C17>AFQBQ2:9,3#(BE=4EB6?2B,JR9,3#R1,3*::Y,F)BLF3(F12<D
ML9LQ2;1$Q:N70F,XJ75D3#5SZDQ,/(F)BD^:)9\5/2U?7>8O"?!IY+4STIII
MI\#-XV>U40$LF1,BLJC$P\D3*F42JC*97YL/VI^F@   $TF-)<0TT:UJ72"@
M  34E67$-0::W2  $U)95EQ!IL  ":D"&H-2ZU+I!0  0US1J5J5)6@    U
M($.UFM:E(J@           (*Y@    !HU+,1V^#BMJG']/5<.;V?!RZ?"1\G
M]_EQY/6\+>Y'S><>+]([;5S.%>:UNG'!G.\=]N?E6>AB\/I=C6V[<<N7&RLV
M;Z7*J9RIE:6M^AFR,61:NJ9QG%VW(EC-BU<C.,93(*3:)B6:I7+H3&<JI9$4
MG)+&;&BN@SC%BDTR8F52N@SC-FJ31,2Q>1G&<5DAB95)ODS%XR^S:K-F;PGP
M::N3,WC8>&THY,>3 :;1,3(I75&)BDZ,SC-GV>3)B8K)#$PY3(F&FT3$S5*X
MF)BU<^IG&<4KET)C.*3HR8F'DQD3(>6A,,4KJ,F,V*R9,3#RT)B8::J,3*O)
MU,=>(>;HB=(:,]/<G^?\FGDB=*:>2J3IR-?G$_9GZ6      "';0LK4OVDJ@
M  .)1#4="RMRZDH $U)96I<0::    0U0LK4J2J  "7;0U*U+]H*H"@   "$
M#4NVA=72::+J["*H       ""N8      .OQN(.?*RS*\_*/:_5<QT/E_P#H
MCCR]5[?AMF&?*_2O#^MQV'!YE6\25*LC*E<9QG%)R2S[3S&MMT*ISY<)6;;\
MK5]4<[POPGA::Y,S9?DQHG*,5FG,$95E4F)BB(:;0Q,:IQW,6,6+E&<9RF$5
ME4F,XI-,SB8I-HF)D-75)C.*Z$1IDC.5G*I."5FS5Y*IG$RQ2N=3-X1-5G5&
M;P^EV*E5,]>4^$$JI,JJEF<3(M$9,B&FT,+%IR98S#3:(F:I75)B8I-<F3$P
MY=1D3(>3)B9#33)B952ZDQ,5EH3$PU<N@Q,4G1DQ+/L\F3$R'EH,3!DB88>2
MJ,J97YW/U]^E@       $TF-)<0U!IN72   "&HZ&HW*DH $U)95EQ' TV
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M3#RT]QAU?PT_4GZ DTY@    !< (;DU(U)A!0    !+<=2R+)J6Y--$
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M=_ODFG.^P FX$FK)J<BXN)*H       "&HZ&I6I4E4    FXX<2R-2(--
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M51AE$T9$Q63&1,AY5)B8<JI,J95)T(F#)C(9'\>/T1_NDFG.^R;@#-N338
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MF5,IS1@.63(F0\M"8F'DAE3*<T9##EU83(_E!_OW^S8MR;23"
M   $W!9%DU!IH@    J7=0LBR)--       AODBR-2)*I-P41Q--D%
M     F(SR]$5D     59_P"6U43EZ9Y>GL?J\+:[CY_[O+S^7KV\-J'@OMX^
M7M1$     %I0C-8ID1=K7 E2RK1$ERK5T<C'6-8>2H3K$PTTR7BGF*7$S>/A
M+Z68RLFFUT)8EBS+*[?Y,UFJ(R     ', 5E4SC.*(@  &FT,3#RT)B8LB&F
MT3$Q2N70F,X9$4KGU)B8M7&<-L]JDF'82%V'+J,,AY5)U2R0\T3JSM+)5^2]
M?X9_^CG4SUAM/)DZ0W^%9F>E/!Y(G6ARJF<IA@?RNY[H/]['^O\ Y9&D
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MW)IJ3 50      2W'42+)J#30 FY\C4C4GR@K0  !N 9K-N36-28"J
M  @KF    "R:+LY]A>+')Z_ZKB-MQX/WX^X\?Z?;U[>!\[E,KS5JGP1SL8L^
M5$0  %I0C-8MTR(  !@/)C$Q2NV9G#S%R3%V"4#8TE,QC&PP'DR9#(>542\4
MQI:U!B\/+-BI53/5G*?0G5#EU)>)D$LF&0\M"8F'DAE3*9$    --HF&*RT&
M,XHR@ K)DQ,AY(F)E4$.74F1,AY,8F#+0F&'DAB93E5)E,HE50,H3H_0)ARZ
MDR)D/)C##R)B8<H93*<JJ"97\R9_M(_UW(@R         !N"C-N36-R80
M ";CJ61J1!IH        FX$FK)K/B::   FI*):CH76Y4E4 9MR::@*H
M     @KG0    SI)C'([>(OICEZ>M^M_"/!^_MY^?IZ_C;BIX.4\O-8V3C><
M>485DC&)E,B&$5EH3$Q4JI,J901      TVAAD5DB8SBDZ,EGVEGV>3)D3(M
M7:^I,3S%29Q>QA?:E<^I,,-7+H3&<JTW7^28F'DR8F0\ESW$O'4P]U49ZGD=
MQU0;R7C0\F9Q,AY:$PPY1,3*80 5DR8F0\M!AAY(F)E,B'+J,B9#R>A,,@RT
M&)U/)###R5294RB55##* '+J3$R'DQD3(>6A,,/)#*F4Y5293*_FQ_LG^H
M       ";2+BR:AN334F$      )J2ZLN(:@K6Z"J     );C4N+(@K0
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M*I          5+NIZEQ9/M)IH    FI&XLU#4&M672"@  3<%DU9-9FF@%
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M,5+J3$R$ Y=1AD&3)D3(>6@PP\D,3!DM1AE?$G^B?; $NZA<61/$TT0
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M&0 $P!63)B8>2&)E41!P"*RJ9Q,4FF,3,,B*RJ3$PU<JDQ/,6G)*U-^3(H
M  EU&1,AY/J3#(>2)B8J54("  K)C$R'DJ&;Q3#E5)U3R-U2=0=T.M 3K0]X
MZT$NI+,3(>6A,,/)$RIE/)5&4RB548F42JC*92R0RKE/)5&4RC)5&4RB5494
MRB55$,HE50,ISK[C#!+JPF1Y!]%]$FX+A)J&VS3>80    $NVAJ5J7[250
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M2RWS\,S804 0WRY&I&I"*I 0W)J1J3"+/:LKG+.T](10 2W!9-634<330
M!,L9Y$&4LL9Y>R*R +MY]B9K/)W?K\MJ'G_68YUVY,\^.>*5W8EAEWPLRT8
M     \F3(F0\M"88<JHRIE.2(AN>AJ-2"6,AD-75)89]'*J3JF4S/7Z02T9Z
MF0\F3$P\D3$Q4T"'DR8F12NJ3$PTZ,F)9]J5S)B9%*[L3$RSTI7)T)C4VG*J
MB+E, "       <NI,AD(H              #E.KN   ;2+BYJ'=3<7%D(J@
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M@R=1D,@R=1D,@R=1D,@R=1D,@R=1D,A%           2U)96I4%:
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M3*F4PA@                       I )54%RB55 RMSS@
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M*<ID, 0     , EU)D,AY,9$R'EH3#!DM1B91DM1AE/)#*91*J,IE,B"4#
M            2JH&4I51E,HR52Y5REDM1AE&2U&&49:#%ZNPXO,
M ! 2[J%QJ1)6@  *8*);DLC4B2J   ;@#-N339% !FW)IN3 %0WR-2-2)*H
M'/(#,TVBYP:D2^63?,T>HF33%NLVY9J-1-SA';C"LC8 (;@L8]UF;:)L,VX4
ME3S6;<]#4C4F$4   $'?X+WPY'G_ $XK8[E=OWGFY<=G\N=X^%Y(Y=;&.M&2
M&&'DM1AE&2J3*95IJI&Y+AD  2ZC$R'DQD,@EU&0R#)DR&0\M!B=35R)AEGI
M4DPV_)R,7L)078<T9#Q3EU&0R#)C(9#RT)B8,M/<8=3R0Q,.55$, 0
M       , EU9#("A             =YYWE         " AN>AJ1J0@T  !-Q
MU+(2:AN331!0  )N 2:AN33?HB@ AN>AJ1N3""DW!82:S--@  3<(09R;;V,
M[^.AKB;$/@:B7TR=U#<B2)-<8K)N7\':3$3)4MPI+C/:LVY-28LF$54OB5B^
MTW<"PB#30    +)HZ_ H:7J<?UF34[>'=)Y4ET&.4\J>3,X9%F6# <D;V'-
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M78)&)V@E!=@E V &PR*           EH(<L89""@   %*JBF"54897J'D>$
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M)=29#()=2Y#()=1AD$NHPR"75@R$%.74F1,AY/089"R8R&02ZER&02ZL+A
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M  &1MOTB]\C7&+\,S2 3V,[GO.\A?ISOB^ITC-(HEW0619$E:(!,J6:16
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M&)BE<JDQ/,.2&T2,7L<C%[')%V55KWF>4\)6ASZM =0&5 !();#DF-=CD+L
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M )HP>*)=0           4JHQ<HR1<IE++08N#+08=7T9\M\8%R@&4!>M .J
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MCJT>:'4\GE0YWCE3?N'D]F3#8I7:$PDT9,8N'DB8F49+4891*&&4YU]R8F&
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M"EU&+D(  ^O/BO\ /'+J,3(,F3(9#R&)A9,9%R$50      2[J%D63[0::
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M>*^%*^J,=6I_*\D3*N?2E<3%V_*Y:YF<C2[;]^IRYQ<EC17LY]8+5R9G*O\
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M>)]A_LO\X_.?^%9]/4G^<#SZ^I/\XR?V=1_G#_@_LVV0_P XG_!_8M/6#/\
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MCDM3<X+J'>JR;_S-+)5'2IHR5?8=*:,E7V'2FC)5]ATIJ+G/#@7K@D EU8,
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M=?<O6_2>!.ON.M-@G7W'6FP2Z^XZWZ3P)U]QUJ^!.ON.M/!#K38!UIL ZTV
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M[C-BQ1FS?[7T:9S;ETTVB8K17U,V+/*IH0]*XF;&Y=$P<U:*^IFQJ>?[4G/
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MP,V8T9FS0T<W275)M$LTQHKD^IFS%40.28WV?F<_?GYN8
M                   U/*1<^4:J8W\3%_A3(LWX4IU[$\-_VM9?Z9N,W%J2
M+-,C0 I9<I_C^B>!:RYQ_/\ 1FY\*HS<^0C-SX#WF?#4[&&O[5OU]R>#PI9:
M=_P3PSX4I_PG@\_![R-3?DPJK<N4F;C4_EIOYF46B-S?D;^4]CGRQ6JF-YSN
M?"J(3?A1'3^UVY=C-Q/GPT,M!&.6?\M<=_X:++_3G<6XT1DF_P#!AI=N7^F;
MC7]M#*'U,<L;F_)J>4]C"M5,;]NIBY\*9!2(W-SRI3R_!+A<:J8WF%@,7-52
MDS6YZ\K4\_R9N)<^&B,M3?D$5=N6I+C4_EH80T<[F^&YOR9%:6Y<^&O$S<7X
M69%(C<]>09Y8K2V>?Y.5SX7X_E9 R-ST9%:J>9RYYOAK_P#9F!1&S"_TU4\S
:%Q;GP9SY$49= B$W?#53SX:\3-QJXHC+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>97
<FILENAME>g382677g0224043354317.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677g0224043354317.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G '$# 2(  A$! Q$!_\0
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M5')^'=>O[[6H;>>X+QMNR,#G"DUV]>9>$,CQ+;@^C_\ H)KI/$OB9;(-96;
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MFBI]FN&#_P"D'[K':?X>WU_2N9NH9K.]:.\C;S%;YP3R?QK2\'-GQ/;?1_\
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$PG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>98
<FILENAME>g382677g0309011809629.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382677g0309011809629.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < ) # 2(  A$! Q$!_\0
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M'_K_ (?_ $,5],_%"TAO/AOK2S*&\N#S4)[,I!!I 8?PF^(LWB^TFT[5"O\
M:EJ@?S ,><G3./4'&?J*[_4=6T_28/.U"]@M8ST:5PN?IZU\T?!29HOB5: '
M"O!,'^FPG^8%9/B+7;KQSXW9[N\$%M-<^5$9&^2"+=@'\!R:8'U#IWBO0-6G
M\BPU>TGF/1%D&X_0=Z\_^/\ _P B58_]?Z_^@/7D?C#P]IGA:>QN-!\0)?[\
M[FC;#QL,<\=C_2NQ\;Z_/XE^!^@:A=-NN?MWE2M_>95D&?Q !_&@#=_9Y_Y
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C=ZZ6?2+4^,!:D-Y3_O",_CCZ5Y^/K5:2A[)VN[$3;5K'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366597520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GSK plc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001131399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-15170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">980 Great West Road, Brentford<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middlesex<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">TW8 9GS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">4,311,343,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">London, United Kingdom<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">980 Great West Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">TW8 9GS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Victoria Whyte<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">company.secretary@gsk.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">8047 5000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_AmericanDepositarySharesMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_ZeroPointFiveThreeFourNotesDue2023Member', window );">0.534% Notes due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/23C<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.534% Notes due 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_ThreePointZeroNotesDue2024Member', window );">3.000% Notes due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.000% Notes due 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_ThreePointSixTwoFiveNotesDue2025Member', window );">3.625% Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.625% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_ThreePointEightSevenFiveNotesDue2028Member', window );">3.875% Notes due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.875% Notes due 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_ThreePointThreeSevenFiveNotesDue2029Member', window );">3.375% Notes due 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.375% Notes due 2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_SixPointThreeSevenFiveNotesDue2038Member', window );">6.375% Notes due 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.375% Notes due 2038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfEachClassAxis=gsk_FourPointTwoZeroZeroNotesDue2043Member', window );">4.200% Notes due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GSK/43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">4.200% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_ZeroPointFiveThreeFourNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_ZeroPointFiveThreeFourNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_ThreePointZeroNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_ThreePointZeroNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_ThreePointSixTwoFiveNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_ThreePointSixTwoFiveNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_ThreePointEightSevenFiveNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_ThreePointEightSevenFiveNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_ThreePointThreeSevenFiveNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_ThreePointThreeSevenFiveNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_SixPointThreeSevenFiveNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_SixPointThreeSevenFiveNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfEachClassAxis=gsk_FourPointTwoZeroZeroNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfEachClassAxis=gsk_FourPointTwoZeroZeroNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367385136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statement - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 24,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(9,554)<span></span>
</td>
<td class="num">(8,163)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,929)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">19,770<span></span>
</td>
<td class="nump">16,533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(8,372)<span></span>
</td>
<td class="num">(7,070)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,437)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(5,488)<span></span>
</td>
<td class="num">(5,019)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,793)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">321<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating (expense)/income</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">6,433<span></span>
</td>
<td class="nump">4,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,979<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expense</a></td>
<td class="num">(879)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(874)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalOfInterestInAssociate', window );">Loss on disposal of interest in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after tax (loss)/profits of associates and joint ventures</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before taxation</a></td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">3,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxation</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(67)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Profit after taxation from continuing operations</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger', window );">Profit after taxation from discontinued operations and other gains/(losses) from the demerger</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger', window );">Re-measurement&#160;of discontinued operations distributed to shareholders on demerger</a></td>
<td class="nump">7,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Profit after taxation from discontinued operations</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total profit after taxation for the year</a></td>
<td class="nump">15,621<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,388<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests', window );">Profit attributable to non-controlling interests from continuing operations</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent', window );">Profit attributable to shareholders from continuing operations</a></td>
<td class="nump">4,461<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,873<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests', window );">Profit attributable to&#160;non-controlling&#160;interests from discontinued operations</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">409<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent', window );">Profit attributable to shareholders from discontinued operations</a></td>
<td class="nump">10,495<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Total profit attributable to&#160;non-controlling&#160;interests</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Total profit attributable to shareholders</a></td>
<td class="nump">14,956<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total profit after taxation for the year</a></td>
<td class="nump">&#163; 15,621<span></span>
</td>
<td class="nump">&#163; 5,096<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 6,388<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share (pence) from continuing operations</a></td>
<td class="nump">&#163; 1.108<span></span>
</td>
<td class="nump">&#163; 0.829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 1.224<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share (pence) from discontinued operations</a></td>
<td class="nump">2.606<span></span>
</td>
<td class="nump">0.267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total Basic earnings per share (pence)</a></td>
<td class="nump">3.714<span></span>
</td>
<td class="nump">1.096<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share (pence) from continued operations</a></td>
<td class="nump">1.092<span></span>
</td>
<td class="nump">0.818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share (pence) from discontinued operations</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">0.264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted earnings per share (pence)</a></td>
<td class="nump">&#163; 3.662<span></span>
</td>
<td class="nump">&#163; 1.082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 1.426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalOfInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on disposal of Interest in associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalOfInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss from discontinued operations and other gains losses from demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-measurement of discontinued operations distributed to shareholders on demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from continuing operations attributable to owners of the parent. [Refer: Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from discontinued operations attributable to owners of the parent. [Refer: Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Example 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Implementation%20Guidance&amp;dita_xref=IFRS05_ex11__IFRS05_ex11_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations attributable to non-controlling interests. [Refer: Profit (loss) from discontinued operations; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Example 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Implementation%20Guidance&amp;dita_xref=IFRS05_ex11__IFRS05_ex11_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367625072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statement of comprehensive income - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total profit for the year</a></td>
<td class="nump">&#163; 15,621<span></span>
</td>
<td class="nump">&#163; 5,096<span></span>
</td>
<td class="nump">&#163; 6,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be subsequently reclassified to continuing operations income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">113<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax', window );">Reclassification of cash flow hedges to income statement</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Deferred tax on fair value movements on cash flow hedges</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items that may be subsequently reclassified to continuing operations income statement</a></td>
<td class="nump">120<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to continuing operations income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated', window );">Exchange movements on overseas net assets of non-controlling interests</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value movements on equity investments</a></td>
<td class="num">(754)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome', window );">Tax on fair value movements on equity investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated', window );">Remeasurement (losses)/gains on defined benefit plans</a></td>
<td class="num">(786)<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated', window );">Tax on remeasurement losses/(gains) on defined benefit plans</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will not be reclassified to continuing operations income statement</a></td>
<td class="num">(1,307)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations', window );">Other comprehensive expense for the year from continuing operations</a></td>
<td class="num">(1,187)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations', window );">Other comprehensive income for the year from discontinued operations</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="nump">14,790<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">7,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Total comprehensive income for the year attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders</a></td>
<td class="nump">14,153<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">6,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="nump">&#163; 14,790<span></span>
</td>
<td class="nump">&#163; 4,759<span></span>
</td>
<td class="nump">&#163; 7,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange movements on overseas net assets of non controlling interests restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueMovementsOnCashFlowHedgesNotReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value movements on cash flow hedges not reclassified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueMovementsOnCashFlowHedgesNotReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax relating to remeasurements of defined benefit plans of other comprehensive income restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive expense income for the year from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive expense income for the year from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income before tax gains losses on remeasurements of defined benefit plans restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income; Reserve of gains and losses from investments in equity instruments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income, before tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to cash flow hedges, before tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368613328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheet - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">&#163; 8,933<span></span>
</td>
<td class="nump">&#163; 9,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">14,318<span></span>
</td>
<td class="nump">30,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associates and joint ventures</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">5,658<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">39,377<span></span>
</td>
<td class="nump">60,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssets', window );">Current tax recoverable</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,053<span></span>
</td>
<td class="nump">7,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">Current equity investments</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Liquid investments</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Assets held for sale</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">20,769<span></span>
</td>
<td class="nump">18,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">60,146<span></span>
</td>
<td class="nump">79,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="num">(3,952)<span></span>
</td>
<td class="num">(3,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="num">(16,263)<span></span>
</td>
<td class="num">(17,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative financial instruments</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Current tax payable</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Short-term provisions</a></td>
<td class="num">(652)<span></span>
</td>
<td class="num">(841)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="num">(22,810)<span></span>
</td>
<td class="num">(23,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(17,035)<span></span>
</td>
<td class="num">(20,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Corporation tax payable</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Pensions and other post-employment benefits</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="num">(3,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">Other provisions</a></td>
<td class="num">(532)<span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(5,779)<span></span>
</td>
<td class="num">(5,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(899)<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="num">(27,240)<span></span>
</td>
<td class="num">(34,091)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(50,050)<span></span>
</td>
<td class="num">(57,761)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">21,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium account</a></td>
<td class="nump">3,440<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="nump">4,363<span></span>
</td>
<td class="nump">7,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Shareholders' equity</a></td>
<td class="nump">10,598<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="num">(502)<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">&#163; 10,096<span></span>
</td>
<td class="nump">&#163; 21,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at fair value through profit or loss classified as held for trading. [Refer: Financial assets at fair value through profit or loss, classified as held for trading]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365894512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statement of changes in equity - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital [member]</div></th>
<th class="th"><div>Share premium [member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Other reserves [member]</div></th>
<th class="th"><div>Total [member]</div></th>
<th class="th"><div>Non- controlling interests [member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">&#163; 18,357<span></span>
</td>
<td class="nump">&#163; 1,346<span></span>
</td>
<td class="nump">&#163; 3,174<span></span>
</td>
<td class="nump">&#163; 4,530<span></span>
</td>
<td class="nump">&#163; 2,355<span></span>
</td>
<td class="nump">&#163; 11,405<span></span>
</td>
<td class="nump">&#163; 6,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit after taxation for the year</a></td>
<td class="nump">6,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (expense)/income for the year</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="nump">7,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">6,753<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Distributions to non-controlling interests</a></td>
<td class="num">(1,208)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity', window );">Contributions from non-controlling interests</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Changes to non-controlling interests</a></td>
<td class="num">(131)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends to shareholders</a></td>
<td class="num">(3,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments', window );">Realised after tax losses on disposal or liquidation of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments', window );">Share of associates and joint ventures realised profits on disposal of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(529)<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SharesAcquiredByEsopTrusts', window );">Shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="num">(609)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based incentive plans</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax on share-based incentive plans</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="nump">20,808<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">14,587<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit after taxation for the year</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (expense)/income for the year</a></td>
<td class="num">(337)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Distributions to non-controlling interests</a></td>
<td class="num">(642)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity', window );">Contributions from non-controlling interests</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends to shareholders</a></td>
<td class="num">(3,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments', window );">Realised after tax losses on disposal or liquidation of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments', window );">Share of associates and joint ventures realised profits on disposal of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based incentive plans</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionsWithNoncontoliingInterests', window );">Transactions with non-controlling interests</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax on share-based incentive plans</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="nump">21,342<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">7,944<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit after taxation for the year</a></td>
<td class="nump">15,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,956<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,956<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (expense)/income for the year</a></td>
<td class="num">(831)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="nump">14,790<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,867<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="nump">14,153<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Distributions to non-controlling interests</a></td>
<td class="num">(1,409)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NoncashDistributionsToNoncontrollingInterests', window );">Non-cash distribution to non-controlling interests</a></td>
<td class="num">(2,960)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity', window );">Contributions from non-controlling interests</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Changes to non-controlling interests</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary', window );">Deconsolidation of former subsidiaries</a></td>
<td class="num">(3,045)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends to shareholders</a></td>
<td class="num">(3,467)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments', window );">Realised after tax losses on disposal or liquidation of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonCashDividendToShareholders', window );">Non-cash dividend to shareholders</a></td>
<td class="num">(15,526)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,526)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,526)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments', window );">Share of associates and joint ventures realised profits on disposal of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SharesAcquiredByEsopTrusts', window );">Shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based incentive plans</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax on share-based incentive plans</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingGainLossTransferredToNonFinancialAssets', window );">Hedging gain after taxation transferred to non-financial assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2022</a></td>
<td class="nump">&#163; 10,096<span></span>
</td>
<td class="nump">&#163; 1,347<span></span>
</td>
<td class="nump">&#163; 3,440<span></span>
</td>
<td class="nump">&#163; 4,363<span></span>
</td>
<td class="nump">&#163; 1,448<span></span>
</td>
<td class="nump">&#163; 10,598<span></span>
</td>
<td class="num">&#163; (502)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingGainLossTransferredToNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging gain loss transferred to non financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingGainLossTransferredToNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NonCashDividendToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash dividend to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NonCashDividendToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NoncashDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash distributions to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NoncashDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of associates and joint ventures realised profits on disposal of equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SharesAcquiredByEsopTrusts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares acquired by ESOP trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SharesAcquiredByEsopTrusts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransactionsWithNoncontoliingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transactions with non-contoliing interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransactionsWithNoncontoliingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-down of shares held by ESOP trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the disposal of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_ix&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368631920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated cash flow statement - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Profit after taxation from continuing operations</a></td>
<td class="nump">&#163; 4,921<span></span>
</td>
<td class="nump">&#163; 3,516<span></span>
</td>
<td class="nump">&#163; 5,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Adjustments reconciling profit after tax to operating cash flows</a></td>
<td class="nump">3,023<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">2,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations', window );">Cash generated from operations attributable to continuing operations</a></td>
<td class="nump">7,944<span></span>
</td>
<td class="nump">7,249<span></span>
</td>
<td class="nump">7,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations', window );">Taxation paid</a></td>
<td class="num">(1,310)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax', window );">Net cash inflow from continuing operating activities</a></td>
<td class="nump">6,634<span></span>
</td>
<td class="nump">6,277<span></span>
</td>
<td class="nump">6,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations', window );">Cash generated from operations attributable to discontinued operations</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations', window );">Taxation paid from discontinued operations</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="num">(569)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax', window );">Net operating cash flows attributable to discontinued operations</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Total net cash inflows from operating activities</a></td>
<td class="nump">7,403<span></span>
</td>
<td class="nump">7,952<span></span>
</td>
<td class="nump">8,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(1,143)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="num">(989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(1,115)<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Purchase of equity investments</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Purchase of businesses, net of cash acquired</a></td>
<td class="num">(3,108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Proceeds from sale of equity investments</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">3,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities', window );">Contingent consideration paid</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of businesses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures', window );">Investments in associates and joint ventures</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures', window );">Proceeds from disposal of associates and joint ventures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInLiquidInvestments', window );">Decrease/(increase) in liquid investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities', window );">Dividends from associates and joint ventures</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations', window );">Net cash outflow from continuing investing activities</a></td>
<td class="num">(4,981)<span></span>
</td>
<td class="num">(1,655)<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash investing cash flows attributable to discontinued operations</a></td>
<td class="num">(3,791)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="num">(8,772)<span></span>
</td>
<td class="num">(1,777)<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issue of share capital</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayment of long-term loans</a></td>
<td class="num">(1,594)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Issue of long-term notes</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Repayment of short-term loans</a></td>
<td class="num">(5,074)<span></span>
</td>
<td class="num">(2,304)<span></span>
</td>
<td class="num">(3,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings', window );">Increase in/(repayment of) other short-term loans</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="num">(3,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="num">(851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to shareholders</a></td>
<td class="num">(3,467)<span></span>
</td>
<td class="num">(3,999)<span></span>
</td>
<td class="num">(3,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities', window );">Distributions to non-controlling interests</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Contributions from non-controlling interests</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other financing items</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash outflow from continuing financing activities</a></td>
<td class="num">(9,251)<span></span>
</td>
<td class="num">(7,126)<span></span>
</td>
<td class="num">(9,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net financing cash flows attributable to discontinued operations</a></td>
<td class="nump">10,074<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Total net cash inflow/(outflow) from financing activities</a></td>
<td class="nump">823<span></span>
</td>
<td class="num">(7,589)<span></span>
</td>
<td class="num">(10,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">(Increase)/decrease in cash and bank overdrafts</a></td>
<td class="num">(546)<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and bank overdrafts at the beginning of year</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
<td class="nump">4,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange adjustments</a></td>
<td class="nump">152<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase/(Decrease) in cash and bank overdrafts in the year</a></td>
<td class="num">(546)<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and bank overdrafts at the end of year</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract', window );"><strong>Cash and bank overdrafts at end of year comprise:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Overdrafts</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and bank overdrafts at the end of year</a></td>
<td class="nump">&#163; 3,425<span></span>
</td>
<td class="nump">&#163; 3,819<span></span>
</td>
<td class="nump">&#163; 5,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flows from used in operating activities continuing operations net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flows from used in operating activities discontinued operations net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash from used in operations before tax discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash from used in operations before taxes continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes paid refund classified as operating activities continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes paid refund classified as operating activities discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInLiquidInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in liquid investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInLiquidInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProceedsFromDisposalOfAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from disposal of associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProceedsFromDisposalOfAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (repayments of) other current borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PurchaseOfInvestmentInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of investment in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PurchaseOfInvestmentInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from dividends received, classified as investing activities. [Refer: Dividends received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428696832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Presentation of the financial statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Presentation of the financial statements</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">1. Presentation of the financial statements </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of business </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK is a global biopharma group which makes innovative vaccines and specialty medicines to prevent and treat disease. GSK&#8217;s R&amp;D focuses on the science of the immune system, human genetics and advanced technologies primarily in the following four therapeutic areas: infectious diseases, HIV, oncology and immunology/respiratory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance with applicable law and IFRS </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards as issued by the IASB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Composition of financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consolidated financial statements are drawn up in Sterling, the functional currency of GSK plc, and in accordance with IFRS accounting presentation. The financial statements comprise: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated income statement </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated statement of comprehensive income </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated balance sheet </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated statement of changes in equity </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Consolidated cash flow statement </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Notes to the financial statements. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Composition of the Group </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A list of the subsidiaries and associates which, in the opinion of the Directors, principally affected the amount of profit or net assets of the Group is given in Note 46, &#8216;Principal Group companies&#8217;. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial period </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These financial statements cover the financial year from 1 January to 31 December 2022, with comparative figures for the financial years from 1 January to 31 December 2021 and, where appropriate, from 1 January to 31 December 2020. Income statement and cash flow comparatives have been restated on a consistent basis from those previously published to reflect the classification of the Consumer Healthcare business as a discontinued operation (see Note&#160;41). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting principles and policies </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared using the historical cost convention modified by the revaluation of certain items, as stated in the accounting policies, and on a going concern basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements have been prepared in accordance with the Group&#8217;s accounting policies approved by the Board and described in Note 2, &#8216;Accounting principles and policies&#8217;. Information on the application of these accounting policies, including areas of estimation and judgement is given in Note 3, &#8216;Critical accounting judgements and key sources of estimation uncertainty&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent company financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of the parent company, GSK plc, have been prepared in accordance with UK&#160;GAAP and with UK accounting presentation. The company balance sheet is presented on page 268 and the accounting policies are given on pages 269 to 272. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428716416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles and policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Accounting principles and policies</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">2. Accounting principles and policies </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consolidated financial statements include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the assets and liabilities, and the results and cash flows, of the company and its subsidiaries, including ESOP Trusts </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of the results and net assets of associates and joint ventures </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of assets, liabilities, revenue and expenses of joint operations. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of entities consolidated are made up to 31&#160;December each year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Entities over which the Group has the power to direct the relevant activities so as to affect the returns to the Group, generally through control over the financial and operating policies, are accounted for as subsidiaries. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the Group has the ability to exercise joint control over, and rights to, the net assets of entities, the entities are accounted for as joint ventures. Where the Group has the ability to exercise joint control over an arrangement, but has rights to specified assets and obligations for specified liabilities of the arrangement, the arrangement is accounted for as a joint operation. Where the Group has the ability to exercise significant influence over entities, they are accounted for as associates. The results and assets and liabilities of associates and joint ventures are incorporated into the consolidated financial statements using the equity method of accounting. The assets, liabilities, revenue and expenses of joint operations are included in the consolidated financial statements in accordance with the Group&#8217;s rights and obligations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Interests acquired in entities are consolidated from the date the Group acquires control and interests sold are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date control ceases. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Transactions and balances between subsidiaries are eliminated and no profit before tax is taken on sales between subsidiaries until the products are sold to customers outside the Group. The relevant proportion of profits on transactions with joint ventures, joint operations and associates is also deferred until the products are sold to third parties. Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests are recorded directly in equity. Deferred tax relief on unrealised intra-Group profit is accounted for only to the extent that it is considered recoverable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business combinations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognised in the income statement. Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition date is reported within operating cash flows. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the consideration transferred, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in the period in which they are incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is capitalised as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and associates. Goodwill is denominated in the currency of the operation acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognised directly in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where not all of the equity of a subsidiary is acquired the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest is recognised either at fair value or at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of the net assets of the subsidiary, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis. Changes in the Group&#8217;s ownership percentage of subsidiaries are accounted for within equity. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign currency translation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Foreign currency transactions are booked in the functional currency of the Group company at the exchange rate ruling on the date of transaction. Foreign currency monetary assets and liabilities are retranslated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On consolidation, assets and liabilities, including related goodwill, of overseas subsidiaries, associates and joint ventures, are translated into Sterling at rates of exchange ruling at the balance sheet date. The results and cash flows of overseas subsidiaries, associates and joint ventures are translated into Sterling using average rates of exchange. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Exchange adjustments arising when the opening net assets and the profits for the year retained by overseas subsidiaries, associates and joint ventures are translated into Sterling, less exchange differences arising on related foreign currency borrowings which hedge the Group&#8217;s net investment in these operations, are taken to a separate component of equity within Retained Earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When translating into Sterling the assets, liabilities, results and cash flows of overseas subsidiaries, associates and joint ventures which are reported in currencies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hyper-inflationary</div> economies, adjustments are made where material to reflect current price levels. Any loss on net monetary assets is charged to the consolidated income statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that GSK enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, vaccine and (prior to the demerger of the Consumer Healthcare business) consumer healthcare products. The average duration of a sales order is less than 12 months. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue is recognised when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Estimates associated with returns and rebates are revisited at each reporting date or when they are resolved and revenue is adjusted accordingly. Please refer to Note 3 for the details on rebates, discounts and allowances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has entered into collaborative agreements, typically with other pharmaceutical or biotechnology companies to develop, produce and market drug candidates and vaccines that do not qualify as joint arrangements. When GSK has control over the commercialisation activities, the Group recognises turnover and cost of sales on a gross basis. Profit sharing amounts and royalties due to the counterparty are recorded within cost of sales. Cost of sales includes profit sharing costs and royalties due to the counterparty of &#163;1,635&#160;million (2021: &#163;640&#160;million; 2020: &#163;4 million). When the counterparty controls the commercialisation activities and records the sale, the Group is not deemed principal in the customer contract and instead records its share of gross profit as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> income, on a net basis, within turnover. The nature of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> activities is such that the Group records no costs of sales. Commercial Operations turnover includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> revenue of &#163;3 million (2021: &#163;7 million; 2020: &#163;12 million). Reimbursements to and from the counterparty under collaboration agreements for &#8216;selling, general and administration&#8217; and &#8216;research and development&#8217; costs are recorded net in the respective lines in the Consolidated income statement. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other operating income and royalty income </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK enters into development and marketing collaborations and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licences</div> of the Group&#8217;s compounds or products to other parties. These contracts give rise to fixed and variable consideration from upfront payments, development milestones, sales-based milestones and royalties. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Income dependent on the achievement of a development milestone is recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, which is usually when the related event occurs. Sales-based milestone income is recognised when it is highly probable that the sales threshold will be reached. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occurs. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For all revenue, if the time between the recognition of revenue and payment from the customer is expected to be more than one year and the impact is material, the amount of consideration is discounted using appropriate discount rates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Value added tax and other sales taxes are excluded from revenue. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. Manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs between validation and the achievement of normal production are expensed as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Advertising and promotion expenditure is charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shipment costs on inter-company transfers are charged to cost of sales; distribution costs on sales to customers are included in selling, general and administration expenditure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Restructuring costs are recognised and provided for, where appropriate, in respect of the direct expenditure of a business reorganisation where the plans are sufficiently detailed and well advanced, and where appropriate communication to those affected has been undertaken. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Software as a service (SaaS) configuration costs are expensed as they are incurred where the software being configured is controlled by the SaaS provider. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and development </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group&#8217;s policy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Environmental expenditure related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible is charged to the income statement. The Group recognises its liability on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">site-by-site</div></div> basis when it can be reliably estimated. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This liability includes the Group&#8217;s portion of the total costs and also a portion of other potentially responsible parties&#8217; costs when it is probable that they will not be able to satisfy their respective shares of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> obligation. Recoveries of reimbursements are recorded as assets when virtually certain. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Provision is made for the anticipated settlement costs of legal or other disputes against the Group where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome. In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover asserted and unasserted claims. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In certain cases, an incurred but not reported (IBNR) actuarial technique is used to determine this estimate. In addition, provision is made for legal or other expenses arising from claims received or other disputes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases is included but no provision is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Costs associated with claims made by the Group against third parties are charged to the income statement as they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of providing pensions under defined benefit schemes are calculated using the projected unit credit method and spread over the period during which benefit is expected to be derived from the employees&#8217; services, consistent with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension obligations are measured as the present value of estimated future cash flows discounted at rates reflecting the yields of high-quality corporate bonds. Pension scheme assets are measured at fair value at the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of other post-employment liabilities are calculated in<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>a similar way to defined benefit pension schemes and spread over the period during which benefit is expected to be derived from the employees&#8217; services, in accordance with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The service cost of providing retirement benefits to employees during the year, together with the cost of any curtailment, is charged to operating profit in the year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Actuarial gains and losses and the effect of changes in actuarial assumptions are recognised in the statement of comprehensive income in the year in which they arise. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s contributions to defined contribution plans are charged to the income statement as incurred. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee share plans </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Incentives in the form of shares are provided to employees under share option and share award schemes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair values of these options and awards are calculated at their grant dates using a Black-Scholes option pricing model and charged to the income statement over the relevant vesting periods. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group provides finance to ESOP Trusts to purchase company shares to meet the obligation to provide shares when employees exercise their options or awards. Costs of running the ESOP Trusts are charged to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shares held by the ESOP Trusts are deducted from other reserves. A transfer is made between other reserves and retained earnings over the vesting periods of the related share options or awards to reflect the ultimate proceeds receivable from employees on exercise. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Property, plant and equipment (PP&amp;E) is stated at the cost of purchase or construction, less provisions for depreciation and impairment. Financing costs are capitalised within the cost of qualifying assets in construction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Depreciation is calculated to write off the cost less residual value of PP&amp;E, excluding freehold land, using the straight-line basis over the expected useful life. Residual values and lives are reviewed, and where appropriate adjusted annually. The normal expected useful lives of the major categories of PP&amp;E are: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:45%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Freehold buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Leasehold land and buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Lease term or 20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Plant and machinery</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">10 to 20 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equipment and vehicles</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">3 to 10 years</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On disposal of PP&amp;E, the cost and related accumulated depreciation and impairments are removed from the financial statements and the net amount, less any proceeds, is taken to the income statement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group recognises right of use assets under lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. Rights to use assets owned by third parties under lease agreements are capitalised at the inception of the lease and recognised on the consolidated balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The corresponding liability to the lessor is recognised as a lease obligation within short and long-term borrowings. The carrying amount is subsequently increased to reflect interest on the lease liability and reduced by lease payments made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For calculating the discounted lease liability on leases with annual payments of &#163;2 million or more, the implicit rate in the lease is used. If this is not available, the incremental borrowing rate with a lease specific adjustment is used. If neither of these is available, and for leases with annual payments of less than &#163;2 million, the incremental borrowing rate is used. The incremental borrowing rate is calculated at the rate of interest at which GSK would have been able to borrow for a similar term and with a similar security the funds necessary to obtain a similar asset in a similar market. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Finance costs are charged to the income statement so as to produce a constant periodic rate of charge on the remaining balance of the obligations for each accounting period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Variable rents are not part of the lease liability and the right of use asset. These payments are charged to the income statement as incurred. Lease rental costs for short-term and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> leases which are not capitalised are also charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-lease</div> components are accounted for separately from the lease components in plant and equipment leases but are not separately accounted for in land and buildings or vehicle leases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If modifications or reassessments of lease obligations occur, the lease liability and right of use asset are remeasured. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Right of use assets where title is expected to pass to GSK at a point in the future are depreciated on a basis consistent with similar owned assets. In other cases, right of use assets are depreciated over the shorter of the useful life of the asset or the lease term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is stated at cost less impairments. Goodwill is deemed to have an indefinite useful life and is tested for impairment at least annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the fair value of the interest acquired in an entity&#8217;s assets, liabilities and contingent liabilities exceeds the consideration paid, this excess is recognised immediately as a gain in the income statement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other intangible assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Intangible assets are stated at cost less provisions for amortisation and impairments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and marketing rights separately acquired or acquired as part of a business combination are amortised over their estimated useful lives, generally not exceeding 30 years, using the straight-line basis, from the time they are available for use. The estimated useful lives for determining the amortisation charge take into account patent lives (exclusivity period), where applicable, as well as the value obtained from periods of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity.</div> For Pharmaceutical intangible assets, depending on the characteristics, competitive environment and estimated long-term profits of the asset, between 80% to 90% of the book value is amortised over the exclusivity period on a straight-line basis and the remaining book value is amortised over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity</div> period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-15</div> years on a straight-line basis. For Vaccines intangible assets, cost is usually amortised over the exclusivity period plus 10 years, or 30 years if no exclusivity period is granted, on a straight-line basis. Asset lives are reviewed, and where appropriate adjusted, annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Contingent milestone payments are recognised at the point that the contingent event becomes probable. Any development costs incurred by the Group and associated with acquired licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> or marketing rights are written off to the income statement when incurred, unless the criteria for recognition of an internally generated intangible asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Acquired in process R&amp;D and marketed products are valued independently as part of the fair value of businesses acquired from third parties where they have a value which is substantial and long term and where the brands either are contractual or legal in nature or can be sold separately from the rest of the businesses acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of acquiring and developing computer software for internal use and internet sites for external use are capitalised as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset controlled by the Group. ERP systems software is amortised over <span style="-sec-ix-hidden:hidden69044974">seven</span> to ten years and other computer software over <span style="-sec-ix-hidden:hidden69044975">three</span> to five years using the straight-line basis. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying values of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available for use are tested for impairment annually. Any provision for impairment is charged to the income statement in the year concerned. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Impairments of goodwill are not reversed. Impairment losses on other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investments in associates, joint ventures and joint operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in associates and joint ventures are carried in the consolidated balance sheet at the Group&#8217;s share of their net assets at date of acquisition and of their post-acquisition retained profits or losses and other comprehensive income together with any goodwill arising on the acquisition. The Group recognises the assets, liabilities, revenue and expenses of joint operations in accordance with its rights and obligations. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventories </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realisable value. Cost is generally determined on a first in, first out basis. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-launch</div> inventory is held as an asset when there is a high probability of regulatory approval for the product. Before that point a provision is made against the carrying value to reduce it to its recoverable amount; the provision is then reversed at the point when a high probability of regulatory approval is determined. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial assets are measured at amortised cost, fair value through other comprehensive income (FVTOCI) or fair value through profit or loss (FVTPL). The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. For financial assets other than trade receivables a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> expected credit loss (ECL) allowance is recorded on initial recognition. If there is subsequent evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are recognised in the income statement on financial assets measured at amortised cost and at fair value through other comprehensive income apart from equity investments. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current equity investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. Dividend income is recognised in the income statement when the Group&#8217;s right to receive payment is established. Purchases and sales of Current equity investments are accounted for on the trade date. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other investments comprise equity investments and investments in limited life funds. The Group has elected to designate the majority of its equity investments as measured at FVTOCI. They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in limited life funds are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends on equity investments and distributions from funds are recognised in the income statement when the Group&#8217;s right to receive payment is established. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Purchases and sales of Other investments are accounted for on the trade date. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trade receivables </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables are measured in accordance with the business model under which each portfolio of trade receivables is held. The Group has portfolios in each of the three business models under IFRS 9: to collect the contractual cash flows where there is no factoring agreement in place (measured at amortised cost), to sell the contractual cash flows where the trade receivables will be sold under a factoring agreement (measured at FVTPL), and both to collect and to sell the contractual cash flows where the trade receivables may be sold under a factoring arrangement (measured at FVTOCI). Trade receivables measured at amortised cost are carried at the original invoice amount less allowances for expected credit losses. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether, and the extent to which, settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Subsequent recoveries of amounts previously provided for or written off are credited to the income statement. Long-term receivables are discounted where the effect is material. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash held in deposit accounts is measured at amortised cost. Investments in money market funds are held at fair value through profit or loss because the funds fail the solely payments of principal and interest (SPPI) test. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative financial instruments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by GSK are foreign currency swaps, interest rate swaps, foreign exchange forward contracts and options. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial assets and liabilities, including derivatives embedded in host contracts which have been separated from the host contract, are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading</div></div> and are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedge accounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives designated as hedging instruments are classified at inception of hedge relationship as cash flow hedges, net investment hedges or fair value hedges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective and accumulated in the cash flow hedge reserve. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in the cash flow hedge reserve are reclassified to the income statement when the hedged item affects profit or loss, or if the hedged forecast transaction is to purchase a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset, the amount deferred in the cash flow hedge reserve is transferred directly from equity and included in the carrying value of the recognised <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net investment hedges are accounted for in a similar way to cash flow hedges which are reclassified to the income statement when the hedged item affects profit or loss. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current tax is provided at the amounts expected to be paid, applying tax rates that have been enacted or substantively enacted by the balance sheet date. The tax charge for the period is recognised in the income statement, the statement of comprehensive income or directly in equity, according to the accounting treatment of the related transaction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company and its subsidiaries intend to settle their current tax assets and liabilities on a net basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are not recognised if the temporary differences arise from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction (other than a business combination) that affects neither the accounting nor the taxable profit or loss. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where an uncertain tax position is identified, management will make a judgement as to what the probable outcome will be, assuming the relevant tax authority has full knowledge of the situation. Where it is assessed that an economic outflow is probable to arise, a provision is made for the best estimate of the liability. In estimating any such liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the time value of money is material, balances are discounted to current values using appropriate discount rates. The unwinding of the discounts is recorded in finance income and finance expense. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets and liabilities held for sale or distribution and discontinued operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal groups are classified as held for sale or distribution if their carrying amount will be recovered principally through sale or a distribution to shareholders rather than through continuing use, they are available for sale or distribution in their present condition and the sale or distribution is considered highly probable. Assets held in Assets held for sale or distribution are measured at the lower of their carrying amount and fair value less costs to sell or distribute. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets included in Assets held for sale or distribution are not depreciated or amortised. Assets and liabilities classified as held for sale or distribution are presented in current assets and current liabilities separately from the other assets and liabilities in the balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A discontinued operation is a component of the Group that has been disposed of, distributed or is classified as held for sale or distribution and that represents a separate major line of business. The results of discontinued operations are presented separately in the Consolidated income statement, the Consolidated statement of other comprehensive income and the Consolidated statement of cash flows and comparatives are restated on a consistent basis. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428844672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical accounting judgements and key sources of estimation uncertainty<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical accounting judgements and key sources of estimation uncertainty</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">3. Critical accounting judgements and key sources of<br/> estimation uncertainty </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In preparing the financial statements, management is required to make judgements about when or how items should be recognised in the financial statements and estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. The following are considered to be the critical accounting judgements and key sources of estimation uncertainty. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Reported Group turnover for 2022 was &#163;29,324&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;24,696 million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Gross turnover is reduced by rebates, discounts, allowances and product returns given or expected to be given, which vary by product arrangements and buying groups. These arrangements with purchasing organisations are dependent upon the submission of claims some time after the initial recognition of the sale. Accruals are made at the time of sale for the estimated rebates, discounts or allowances payable or returns to be made, based on available market information and historical experience. </div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales of pharmaceutical and vaccine products in the US have complex arrangements for rebates, discounts and allowances. Turnover of Commercial Operations products in the US for 2022 of &#163;14,542&#160;million (2021: &#163;11,914 million) was after recording deductions of &#163;15,272&#160;million (2021: &#163;12,518 million) for rebates, allowances, returns and other discounts. At 31&#160;December 2022, the total accrual amounted to &#163;5,855&#160;million (2021: &#163;5,044 million). Due to the nature of these accruals it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, returns and other revenue accruals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As there can be significant variability in final outcomes, the Group applies a constraint when measuring the variable element within revenue, so that revenue is recognised at a suitably cautious amount. The objective of the constraint is to ensure that it is highly probable that a significant reversal of revenue will not occur when the uncertainties are resolved. The constraint is applied by making suitably cautious estimates of the inputs and assumptions used in estimating the variable consideration. Because the amounts are estimated they may not fully reflect the final outcome, and the amounts are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The constraints applied in recognising revenue mean that the risk of a material downward adjustment to revenue in the next financial year is low. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The level of accrual for rebates and returns is reviewed and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Market conditions are evaluated using wholesaler and other third-party analyses, market research data and internally generated information. It is reasonably possible that there could be a significant adjustment within the next 12 months to recognise additional revenue, if actual outcomes are better than the cautious constrained estimates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The amount of turnover recognised in the year from performance obligations satisfied in previous periods is set out in Note&#160;6, &#8216;Turnover and segment information&#8217;, and is an indication of the level of sensitivity in the estimate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Future events could cause the assumptions on which the accruals are based to change, which could materially affect the future results of the Group. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tax charge for the year was &#163;707&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;83 million). At December 2022, current tax payable was &#163;471&#160;million (2021: &#163;489 million), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> corporation tax payable was &#163;127&#160;million (2021: &#163;180 million) and current tax recoverable was &#163;405&#160;million (2021: &#163;486&#160;million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has open tax issues with a number of revenue authorities. Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the outcome of the dispute. If insufficient information is available, no provision is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If sufficient information is available, in estimating a potential tax liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group had recognised provisions of &#163;551&#160;million in respect of uncertain tax positions (2021: &#163;858 million). Due to the number of uncertain tax positions held and the number of jurisdictions to which these relate, it is not practicable to give meaningful sensitivity estimates. No uncertain tax position is individually significant to the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Factors affecting the tax charge in future years are set out in Note 14, &#8216;Taxation&#8217;. GSK continues to believe that it has made adequate provision for the liabilities likely to arise from open assessments. Where open issues exist, the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of negotiations with the relevant tax authorities or, if necessary, litigation proceedings. </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10.5pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). </div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Legal costs for the year were &#163;144&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;50 million). At 31&#160;December 2022 provisions for legal and other disputes amounted to &#163;218&#160;million (2021: &#163;196 million). </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the likely outcome of the dispute and the legal and other expenses arising from claims against the Group. If insufficient information is available, no provision is made and disclosure of the claim is given. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The estimated provisions take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. Details of the status and various uncertainties involved in the significant unresolved disputes are set out in Note 47, &#8216;Legal proceedings&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The company&#8217;s Directors, having taken legal advice, have established provisions after taking into account the relevant facts and circumstances of each matter and in accordance with accounting requirements. In respect of product liability claims related to certain products, there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases would be provided, but no provision would be made and no contingent liability can be quantified. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. The position could change over time and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions reported in the Group&#8217;s financial statements by a material amount. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contingent consideration </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The 2022 income statement charge for contingent consideration was &#163;1,645&#160;million (2021: &#163;1,063 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the liability for contingent consideration amounted to &#163;7,068&#160;million (2021: &#163;6,076 million). Of this amount, &#163;5,890&#160;million (2021: &#163;5,559 million) related to the acquisition of the former Shionogi-ViiV Healthcare joint venture in 2012. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Any contingent consideration included in the consideration payable for a business combination is recorded at fair value at the date of acquisition. These fair values are generally based on risk-adjusted future cash flows discounted using appropriate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> discount rates. The fair values are reviewed on a regular basis, at least annually, and any changes are reflected in the income statement. See Note 33, &#8216;Contingent consideration liabilities&#8217;. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Judgement </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where a surplus on a defined benefit scheme arises, or there is potential for a surplus to arise from committed future contributions, the rights of the Trustees to prevent the Group obtaining a refund of that surplus in the future are considered in determining whether it is necessary to restrict the amount of the surplus that is recognised. Two UK schemes are in surplus (2021: three UK schemes), with a combined surplus of &#163;109&#160;million at 31&#160;December 2022 (2021: &#163;606 million). There are further recognised pension surpluses totalling &#163;120&#160;million spread across five countries (2021: &#163;135&#160;million across six countries). GSK has made the judgement that these amounts meet the requirements of recoverability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimates </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of providing pensions and other post-employment benefits are assessed on the basis of assumptions selected by management. These assumptions include future earnings and pension increases, discount rates, expected long-term rates of return on assets and mortality rates, and are disclosed in Note 31, &#8216;Pensions and other post-employment benefits&#8217;. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. A sensitivity analysis is provided in Note 31, &#8216;Pensions and other post-employment benefits&#8217;, a 0.25% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#163;424&#160;million and an increase in the annual pension cost of approximately &#163;19&#160;million. Similarly, a 0.25% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#163;400&#160;million and a decrease in the annual pension cost of approximately &#163;19&#160;million. A 0.75% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#163;1,341&#160;million and an increase in the annual pension cost of approximately &#163;52&#160;million. Similarly, a 0.75% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#163;1,147&#160;million and a decrease in the annual pension cost of approximately &#163;60&#160;million. The selection of different assumptions could affect the future results of the Group. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428815952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New accounting requirements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New accounting requirements</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">4. New accounting requirements</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amendments to accounting standards issued by the IASB and adopted in the year ended 31&#160;December 2022 did not have a material impact on the results or financial position of the Group.</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 31&#160;December 2022 reporting periods and have not been adopted early by the Group. These standards, amendments and interpretations are not expected to have a material impact on the results or financial position of the Group in future reporting periods.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428844800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exchange rates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Exchange rates</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">5. Exchange rates </div></div><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group uses the average of exchange rates prevailing during the period to translate the results and cash flows of overseas subsidiaries, joint ventures and associates into Sterling and period end rates to translate the net assets of those entities. The currencies which most influence these translations and the relevant exchange rates were: </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Average rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">161</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">137</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Period end rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">155</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57__IAS21_g51-57_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377051776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and segment information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Turnover and segment information</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">6. Turnover and segment information </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the GSK Leadership Team (GLT). GSK has revised its operating segments from Q1 2022 and from Q2 2022. Previously GSK reported results under four segments: Pharmaceuticals, Pharmaceuticals R&amp;D, Vaccines and Consumer Healthcare. For the first quarter 2022, GSK reported results under three segments: Commercial Operations, Total R&amp;D and Consumer Healthcare. From Q2 2022, GSK reports under two segments from continuing operations as the demerger of the Consumer Healthcare segment was completed on 18&#160;July 2022. Members of the GLT are responsible for each segment. Comparative information has been retrospectively revised on a consistent basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">R&amp;D investment is essential for the sustainability of the business. However for segment reporting the Commercial Operating profits exclude allocations of globally funded R&amp;D. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Total R&amp;D segment is the responsibility of the Chief Scientific Officer and is reported as a separate segment. The operating costs of this segment includes R&amp;D activities across Specialty Medicines, including HIV and Vaccines. It includes R&amp;D and some SG&amp;A costs relating to regulatory and other functions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s management reporting process allocates intra-Group profit on a product sale to the segment in which that sale is recorded, and the profit analyses below have been presented on that basis. </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by segment</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,232</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This business was excluded from the Consumer Healthcare Joint Venture but was included in the Consumer Healthcare segment performance in 2020. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For 2022, product sales are reported within three product groups: Specialty Medicines, Vaccines and General Medicines. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercial Operations:</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,749</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,777</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,876</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Oncology</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">489</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">372</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflammation,</div> respiratory and other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,609</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,027</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,960</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,293</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,309</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">958</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Specialty Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,251</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,116</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">961</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,029</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Influenza</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">714</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">679</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">733</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shingles</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,958</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,989</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Established Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,085</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,970</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,231</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,873</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,331</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">64</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">447</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,778</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,548</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,048</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,006</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,570</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,619</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,275</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,667</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10,281</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Commercial Operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,232</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the Commercial Operations segment.</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">During 2022, sales were made to three US wholesalers of &#163;4,045&#160;million (2021: &#163;3,159&#160;million; 2020: &#163;2,928 million), &#163;4,161&#160;million (2021: &#163;3,081&#160;million; 2020: &#163;3,085 million) and &#163;3,227&#160;million (2021: &#163;2,670&#160;million; 2020: &#163;2,795 million) respectively, after allocating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">final-customer</div> discounts to the wholesalers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Revenue recognised in the year from performance obligations satisfied in previous periods totalled &#163;1,601&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(1)</div>: &#163;1,438 million) including &#163;898&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">(1)</div>: &#163;949 million) impacting turnover arising from changes to prior year estimates of RAR (returns and rebates) accruals, &#163;115&#160;million (2021: &#163;61 million) of milestone income and &#163;588&#160;million (2021: &#163;428 million) of royalty income recognised in the current year. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment profit<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,590</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,060</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,567</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,397</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#8211;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">55</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(379</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(407</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment profit and operating profit</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,718</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(2,136</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(677</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Operating profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(879</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(769</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits/(losses) of associates and joint ventures</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">33</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">33</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,628</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(707</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(83</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(67</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation for the year from continuing operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">3,516</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">5,103</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other reconciling items between segment profit and operating profit comprise items not specifically allocated to segment profit. These include impairment and amortisation of intangible assets; major restructuring costs, which include impairments of tangible assets and computer software; transaction-related adjustments related to significant acquisitions; proceeds and costs of disposals of products and businesses, significant legal charges and expenses on the settlement of litigation and government investigations, other operating income other than royalty income and other items. Please refer to the detail of Other reconciling items between segment profit and operating profit in the analysis of adjusting items (Group financial review). </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td colspan="4" style="height:3pt"/>
<td colspan="4" style="height:3pt"/>
<td colspan="4" style="height:3pt"/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation and amortisation by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">829</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">467</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">378</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">355</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,296</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">112</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">739</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">761</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">724</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,147</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">2,122</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">2,050</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E, intangible asset and goodwill impairment by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">55</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">85</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">124</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">63</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment and total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">420</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">392</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">583</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">501</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">540</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">712</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E and intangible asset impairment reversals by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment reversals and total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(35</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(26</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(12</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(54</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 7.5pt; width: 742.547px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility: hidden; line-height: 0pt; color: white;">
<td style="width: 542.188px;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.875px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.3125px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.32812px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td> </tr>
<tr style="break-inside: avoid; font-size: 6.5pt;">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating assets by segment</div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(revised)<div style="font-size: 6.5px; vertical-align: top;;display:inline;">(2)</div></div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,288</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,440</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,299</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,461</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,587</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,901</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">264</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,504</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25,208</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,851</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">39,613</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="1" style="height:9.75pt">&#160;</td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19,838</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current Equity Investment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,087</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(22</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current and deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,176</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,479</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale (excluding cash and cash equivalents)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,342</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Commercial Operations segment includes the Shionogi-ViiV Healthcare contingent consideration liability of &#163;5,890&#160;million (2021: &#163;5,559 million) and the Pfizer put option of &#163;1,093&#160;million (2021: &#163;1,008 million). </div>  <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Geographical information </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK is regarded as being the Group&#8217;s country of domicile. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by location of customer</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">695</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">656</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">659</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,542</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,914</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,148</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,087</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,126</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,547</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External turnover</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location of subsidiary</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,134</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,618</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,024</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17,852</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Belgium</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,415</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,065</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Switzerland</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,552</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,559</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15,390</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,166</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">51,477</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables. There are no other countries with individually material external revenue or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the new segments. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377393616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income/(expense)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Other operating income/(expense)</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">7. Other operating income/(expense) </div></div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Upfront settlement income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">922</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">256</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposal of businesses and assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">215</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements on contingent consideration recognised in business combinations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,607</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of ViiV Healthcare put option liabilities and preferential dividends</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments on derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(235</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(504</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,463</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy concerning ViiV Healthcare&#8217;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#163;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fair value remeasurement on equity investments in 2022 included a gain/loss of &#163;229&#160;million from the remeasurement of the Group&#8217;s retained investment in Haleon plc to fair value at 31&#160;December 2022 from the initial recognition fair value <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(five-day</div> average share price after the demerger). See details in Note 22. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2022 includes milestone income and the reversal of provisions no longer required. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2021 included a net gain on disposal of the rights to the royalty stream for cabozantinib and a net gain on disposal of the cephalosporin antibiotic brands to Sandoz. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal of businesses and assets in 2020 included a net profit on disposal of the Horlicks and other Consumer Healthcare nutritional brands and two subsidiaries in India and Bangladesh of &#163;2,815&#160;million, which reflected reversal of &#163;240&#160;million of embedded derivative gains on the value of the shares taken in prior years. This was partly offset by the related &#163;476&#160;million loss on the shares in Hindustan Unilever Limited, including fair value remeasurement losses between their acquisition as consideration for the divestment of GSK Consumer Healthcare Limited in India and their subsequent disposal. Other operating income also included an increase in profit and milestone income from a number of asset disposals. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Fair value remeasurements on contingent consideration recognised as business combinations included &#163;1,431&#160;million related to the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#163;193&#160;million payable to Novartis related to the Vaccines acquisition, together with fair value movements on related hedging contracts. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377530944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating profit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory', window );">Operating profit</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">8. Operating profit </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The following items have been included in operating profit:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee costs (Note 9)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,693</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,680</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,555</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Advertising</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">735</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">433</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">361</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distribution costs</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">192</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">169</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">885</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">855</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">822</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of property, plant and equipment, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">176</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">179</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">182</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,088</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,046</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">435</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">230</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets held for sale, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of goodwill allocated to a disposal group, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net foreign exchange (gains)/losses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">99</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventories:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of inventories included in cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,137</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,885</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,934</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">687</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">800</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">607</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of prior year write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(483</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(325</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(250</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variable lease payments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fees payable to the company&#8217;s auditor and its associates in relation to the Group (see below)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.9</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">31.7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The reversals of prior year write-downs of inventories principally arise from the reassessment of usage or demand expectations prior to inventory expiration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net foreign exchange (gains)/losses include a net loss of &#163;2&#160;million (2021: &#163;35&#160;million gain; 2020: &#163;36&#160;million loss) arising from the recycling of exchange on liquidation or disposal of overseas subsidiaries. The recycling of exchange on disposal of overseas associates of a loss of &#163;nil (2021: &#163;10 million) is reported through loss on disposal of interest in associates. The recycling of exchange on disposal of overseas subsidiaries does not include recycling of exchange on disposal of Consumer Healthcare subsidiaries as this is reported as Profit after taxation on demerger of discontinued operations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Included within operating profit are Major restructuring charges of &#163;321&#160;million (2021: &#163;424&#160;million; 2020: &#163;1,178 million), see Note 10, &#8216;Major restructuring costs&#8217;. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Fees payable to the company&#8217;s auditor and its associates:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of the company&#8217;s subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.7</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">27.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28.3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.3</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4.0</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.6</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services, audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.9</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">31.7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The other assurance services provided by the auditor related to agreed upon procedures and other assurance services outside of statutory audit requirements. In addition to the above, fees paid to the auditor in respect of the GSK pension schemes were: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.2</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were immaterial fees of &#163;0.1&#160;million paid in 2022 (versus 2021: &#163;nil; 2020 &#163;0.2 million) to other auditors in respect of audits of certain of the company&#8217;s subsidiaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Audit related and other assurance services include &#163;4.4&#160;million (2021: &#163;2.4 million) due to reporting accountant work performed in preparation for the Consumer Healthcare demerger. </div><div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367622288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeCostsExplanatory', window );">Employee costs</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">9. Employee costs </div></div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,110</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">763</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">775</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs, including augmentations (Note 31)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">314</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Severance and other costs from integration and restructuring activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">137</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,693</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">7,680</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">8,555</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group provides benefits to employees, commensurate with local practice in individual countries, including in some markets, healthcare insurance, subsidised car schemes and personal life assurance. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cost of share-based incentive plans is analysed as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share Value Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">243</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Performance Share Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share option plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash settled and other plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">314</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">345</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">330</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average number of persons employed by the Group (including Directors) during the year: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> Number</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Manufacturing</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,946</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,642</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,542</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,874</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,744</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total Continuing Operations</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,130</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">71,345</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">73,257</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued Operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,292</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20,616</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22,628</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90,422</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">91,961</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">95,885</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Note: Consumer Healthcare divested on 18 July 2022 is shown as Discontinued Operations in the above table. </div>  <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average monthly number of Group employees excludes temporary and contract staff. The numbers of Group employees at the end of each financial year are given in the financial record on page 277. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The compensation of the Directors and senior management (members of the GLT) in aggregate, was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">60</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">51</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Further information on the remuneration of the Directors is given in the sections of the Annual Report on remuneration labelled as audited within pages 133 to 164. </div> <div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfEmployeeCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfEmployeeCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348379434064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major restructuring costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMajorRestructuringCostsExplanatory', window );">Major restructuring costs</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">10. Major restructuring costs </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;D sites, are likely to take several years to complete. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Major restructuring costs are those related to specific Board-approved Major restructuring programmes, including integration costs following material acquisitions, which are structural and are of a significant scale where the costs of individual or related projects exceed &#163;25&#160;million. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In January 2020, the Board approved a Separation Preparation programme to prepare for the separation of GSK into two companies. Materially all of the Separation Preparation restructuring programme has been included as part of continuing operations. The legacy Consumer Healthcare Joint Venture integration programme is now included as part of discontinued operations. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">After the acquisition of Sierra Oncology (July 2022) and Affinivax (August 2022), the Board approved a Major restructuring programme for the Integration of significant acquisitions designed to integrate and achieve synergies. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The total restructuring costs of &#163;321&#160;million in 2022 were incurred in the following areas: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Restructuring costs to prepare for separation of GSK into two companies </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Continued transformation of central functions, including GSK technology platforms and interfaces, to deliver greater digital synergies, simplification of applications and staff reductions </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:8.25pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The integration of acquisitions. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of the costs charged to operating profit from continuing operations under these programmes was as follows:</div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in provision for Major restructuring programmes (see Note <div style="display:inline;">32</div>)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">138</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">321</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">606</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amount of provision reversed unused (see Note 32)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(111</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(140</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(71</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses recognised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges/(credit)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">62</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other cash costs</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">179</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">204</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">234</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Provision reversals of &#163;111&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;140&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;71 million) reflected provision releases mainly related to the Separation Preparation programme. Asset impairments of &#163;122&#160;million and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> credit of &#163;7&#160;million principally comprised fixed asset write-downs of manufacturing facilities and accelerated depreciation where asset lives have been shortened in the supply chain manufacturing network as a result of the Major restructuring programmes, offset by profit on disposals. All other charges have been or will be settled in cash and include site closure costs, consultancy and project management costs. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of Major restructuring charges from continuing operations by programme was as follows:</div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:84%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">177</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">287</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Significant acquisitions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">206</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">353</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">412</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">385</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">39</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of Major restructuring charges from continuing operations by income statement line was as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">102</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">102</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">585</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">180</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">277</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">45</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">198</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMajorRestructuringCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of major restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfMajorRestructuringCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348379902720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory', window );">Finance income</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">11. Finance income </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains arising from the forward element of forward contracts in net investment hedge relationships</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348380006496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Finance expense</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">12. Finance expense </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(789</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(735</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(811</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial instruments mandatorily measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">743</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(565</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">382</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retranslation of loans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(761</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">565</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(384</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of hedges from other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discounts on provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on lease liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(33</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(23</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(879</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(769</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(874</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428673840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and joint ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory', window );">Associates and joint ventures</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">13. Associates and joint ventures </div></div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits and losses of associates and joint ventures is set out below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses of joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">2021 and 2020 comparatives have not been restated, as the demerged Consumer Healthcare business contained no associates or joint ventures. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following the disposal of Innoviva, Inc in May 2021 (see details in Note 41), at 31&#160;December 2022 and 31&#160;December 2021 the Group held no significant individual associates. At 31&#160;December 2020, the Group held one significant associate, Innoviva, Inc. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Summarised income statement information in respect of Innoviva until May 2021 is set out below. The Group&#8217;s 2021 share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates and other comprehensive income included a profit of &#163;33&#160;million and other comprehensive income of &#163;nil in respect of Innoviva. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The results of Innoviva included in the summarised income statement information below represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information at the balance sheet date. Figures for 2021 include share of Innoviva&#8217;s turnover, profit and total comprehensive income until the date of the disposal. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">108</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">253</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Aggregated financial information in respect of GSK&#8217;s share of other associated undertakings and joint ventures is set out below: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">53</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of total comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">45</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s sales to associates and joint ventures were &#163;nil in 2022 (2021: &#163;nil; 2020: &#163;nil). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Please refer to the Balance sheet information on associates and joint ventures in Note 21. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Associates and Joint Ventures Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377634448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL;text-indent: 0px;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">14. Taxation </div></div>  <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group&#8217;s tax charge is the sum of the total current and deferred tax expense. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Taxation charge based on profits for the year</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">200</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(45</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,351</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">593</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">745</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge/(credit) in respect of prior periods</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,491</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">931</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">711</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(784</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(848</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(644</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In 2022, GSK made corporate income tax payments globally of &#163;1.5&#160;billion for continuing and discontinued operations, of which &#163;48&#160;million was UK corporation tax paid to HMRC. These amounts are for corporate income tax only, and do not include the various other business taxes borne by GSK each year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The deferred tax credits in each period reflect current year losses where offset against taxable profits in future periods is probable and the release of deferred tax liabilities. The latter relates primarily to the unwind of deferred tax liabilities on intangible assets. The deferred tax credit in 2021 also reflected the impact of the remeasurement of deferred tax assets and liabilities following enactment of the increase in the headline rate of UK corporation tax from 19% to 25%. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for the year. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 59%;"><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td> </tr>
<tr style="font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 7.5pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of taxation on Group profits</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>%</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,628</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,599</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,170</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK statutory rate of taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,069</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.0</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">685</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">984</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Differences in overseas taxation rates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">318</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">302</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8.4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">363</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefit of intellectual property incentives</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(600</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10.7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(382</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(10.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(516</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9.9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(119</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(103</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Permanent differences on disposals, acquisitions and transfers</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">275</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(316</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.5</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">90</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year current tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year deferred tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(233</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(281</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(283</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in Tax Rates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.4</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(353</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9.8</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(163</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3.1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax charge/tax rate</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.6</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2.3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"/>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">As a global biopharmaceutical company, we have a substantial business and employment presence in many countries around the world. The impact of differences in overseas taxation rates arose from profits being earned in countries with tax rates higher than the UK statutory rate, the most significant of which in 2022 were the US, Belgium, Germany and Japan. This adverse impact was offset by the benefit of intellectual property incentives such as the UK Patent Box and Belgian Innovation Income Deduction regimes, which provide a reduced rate of corporation tax on profits earned from qualifying patents. We claim these incentives in the manner intended by the relevant statutory or regulatory framework. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In 2021, &#8216;Changes in tax rates&#8217; included credits in relation to the enactment of the increase in the headline rate of UK corporate income tax from 19% to 25% (effective 2023). In 2020, &#8216;Changes in tax rates&#8217; included credits in relation to the UK, where a reduction in the corporate income tax rate from 19% to 17% was cancelled, and India, where the tax treatment of dividends changed with effect from 1&#160;April 2020. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Permanent differences on disposals, acquisitions and transfers in 2022 includes tax on internal restructuring to simplify the group structure. The tax credit in 2020 reflected the tax impact of the disposal of Horlicks and other Consumer Healthcare brands to, and subsequent disposal of shares received in, Hindustan Unilever. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group&#8217;s 2022 tax rate has also been influenced by updates to estimates of prior period tax liabilities following closure of open issues with tax authorities in various jurisdictions. </div>  <div style="font-size: 50pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table>  <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Future tax charges, and therefore our effective tax rate, may be affected by factors such as acquisitions, disposals, restructurings, the location of research and development activity, tax regime reforms and resolution of open matters as we continue to bring our tax affairs up to date around the world. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK Government has confirmed that the Spring Finance Bill 2023 will include legislation introducing a 15% global minimum corporate income tax rate, to have effect from 2024 in line with the OECD&#8217;s Pillar Two model framework. The detail of the measures and how they are to be accounted for is still being finalised and so it is not possible to accurately quantify the impact for GSK at this stage. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Tax on items charged to equity and statement of comprehensive income</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(211</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(68</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(277</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total credit to equity and statement of comprehensive income</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(268</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All of the above items have been charged to the statement of comprehensive income except for tax on share-based payments. </div> <div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issues relating to taxation </div></div></div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The integrated nature of the Group&#8217;s worldwide operations involves significant investment in research and strategic manufacture at a limited number of locations, with consequential cross-border supply routes into numerous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-markets.</div> In line with current OECD guidelines, we base our transfer pricing policy on the arm&#8217;s length principle and support our transfer prices with economic analysis and reports. However, different tax authorities may seek to attribute further profit to activities being undertaken in their jurisdiction potentially resulting in double taxation. The Group also has open items in several jurisdictions concerning such matters as the deductibility of particular expenses and the tax treatment of certain business transactions. GSK applies a risk based approach to determine the transactions most likely to be subject to challenge and the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The calculation of the Group&#8217;s total tax charge therefore necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. At 31&#160;December 2022 the Group had recognised provisions of &#163;551&#160;million in respect of such uncertain tax positions (2021: &#163;858 million). The net decrease in recognised provisions during 2022 was driven by the reassessment of estimates, the agreement of a number of open issues with tax authorities in various jurisdictions and amounts related to discontinued operations. Whilst the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with the relevant tax authorities, or litigation where appropriate, the Group continues to consider that it has made appropriate provision for periods which are open and not yet agreed by the tax authorities. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A provision for deferred tax liabilities of &#163;157&#160;million as at 31&#160;December 2022 (2021: &#163;204 million) has been made in respect of taxation that would be payable on the remittance of profits by certain overseas subsidiaries. Whilst the aggregate amount of unremitted profits at the balance sheet date was approximately &#163;16&#160;billion (2021: &#163;15 billion), the majority of these unremitted profits would not be subject to tax (including withholding tax) on repatriation, as UK legislation relating to company distributions provides for exemption from tax for most overseas profits, subject to certain exceptions. Deferred tax is not provided on temporary differences of &#163;660&#160;million (2021: &#163;831 million) arising on unremitted profits as management has the ability to control any future reversal and does not consider such a reversal to be probable. </div> <div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Movement in deferred tax assets and liabilities </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Accelerated<br/> capital<br/> allowances<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/> assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Contingent</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">consideration<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Intra-Group</div><br/> profit</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Pensions&#160;&amp;<br/> other post<br/> employment<br/> benefits</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax<br/> losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> option<br/> and&#160;award<br/> schemes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">net<br/> temporary<br/> differences<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(223</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Acquisitions/Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(211</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,711</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(102</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Acquisitions/Disposals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(637</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(495</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer of assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(819</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">992</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,099</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;1,661</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,642</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;5,369</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax liabilities in relation to intangible assets predominately relate to temporary differences arising as a result of historic business combinations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group continues to recognise deferred tax assets on future obligations in respect of contingent consideration amounts payable to minority shareholders. These payments are tax deductible at the point in time at which payment is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A deferred tax asset is recognised on intra-Group profits arising on inter-company inventory which are eliminated within the consolidated accounts. As intra-Group profits are not eliminated from the individual entities&#8217; tax returns a temporary difference arises that will reverse at the point in time inventory is sold externally. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The deferred tax asset recognised on tax losses of &#163;1,661&#160;million (2021: &#163;1,450 million) relates to trading losses. Such deferred tax assets are recognised where it is probable that future taxable profit will be available to utilise losses, as supported by long-range product level forecasts. Current forecasts indicate the assets will be utilised by around 2030. Other net temporary differences included accrued expenses for which a tax deduction is only available on a paid basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are recognised on the balance sheet as follows:</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,658</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,369</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,662</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrecognised tax losses</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax&#160;losses<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Unrecognised<br/> deferred tax<br/> asset</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax&#160;losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Unrecognised<br/> deferred tax<br/> asset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trading losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Within 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">967</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">175</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">192</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,203</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,658</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capital losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,326</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">548</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,356</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">557</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,326</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">548</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,356</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">557</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets are only recognised where it is probable that future taxable profit will be available to utilise losses. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348380006496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">15. Earnings per share </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> pence</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22.0</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total basic earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">371.4</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">109.6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">144.4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109.2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">257.0</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total diluted earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;366.2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;108.2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;142.6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37).</div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Basic earnings per share has been calculated by dividing the profit attributable to shareholders by the weighted average number of shares in issue during the period after deducting shares held by the ESOP Trusts and Treasury shares. The trustees have waived their rights to cash dividends on the GSK shares held by the ESOP Trusts. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Diluted earnings per share has been calculated after adjusting the weighted average number of shares used in the basic calculation to assume the conversion of all potentially dilutive shares. A potentially dilutive share forms part of the employee share schemes where its exercise price is below the average market price of GSK shares during the period and any performance conditions attaching to the scheme have been met at the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted average number of shares in issue</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> millions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,026</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dilution for share options and awards</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,084</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,052</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Restated to reflect the impact share consolidation (see <div style="display:inline;"><div style="display:inline;">N</div>ote</div> 37). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367622288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDividendsExplanatory', window );">Dividends</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">16. Dividends </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:19%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paid/payable</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">First interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 July 2022</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">704</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 July 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">9 July 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Second interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6 October 2022</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">654</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">7 October 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 October 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12 January 2023</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">13 January 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">14 January 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fourth interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13 April 2023</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">7 April 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 April 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61.25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,468</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,011</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,989</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The estimate for the fourth interim dividend for 2021 disclosed in the 2021 annual report was &#163;1,152&#160;million, &#163;5&#160;million less than the dividend that was ultimately paid. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">&#160;Dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. See details in Note 37. </div></td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2022 financial statements recognise those dividends paid in 2022, namely the third and fourth interim dividends for 2021, and the first and second interim dividends for 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The demerger of the Consumer Healthcare business was effected by GSK declaring an interim dividend in specie of Haleon plc shares. The fair value of the distribution was &#163;15,526&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts recognised in each year were as follows:</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash dividends to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,467</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends in specie to shareholders in Haleon plc shares (Note 41)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,526</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,993</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,977</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDividendsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDividendsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367622288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">17. Property, plant and equipment </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Plant,<br/> equipment<br/> and&#160;vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Assets in<br/> construction<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;21,483</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(214</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(315</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(576</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,205</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(217</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,174</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(74</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(102</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,778</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,050</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,245</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(222</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,067</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,959</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,343</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,648</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,953</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,451</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,310</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,450</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(715</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(982</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,062</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,025</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(191</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(310</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(501</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(226</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(726</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(952</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#f4f1f0">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">376</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,130</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#f4f1f0">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,506</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,275</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,469</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,744</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(280</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(551</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(857</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(821</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">84</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(260</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(472</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(774</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,846</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,535</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,941</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(10,518</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,898</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,414</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,864</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,176</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,667</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,558</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,707</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,113</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,012</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,808</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,933</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><br/></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate for capitalised borrowing costs in the year was 4% (2021: 3%). Disposals and write-offs in the year included a number of assets with nil net book value that are no longer in use in the business. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The impairment losses principally arose from decisions to rationalise facilities and were calculated based on fair value less costs of disposal. The fair value less costs of disposal valuation methodology uses significant inputs which are not based on observable market data, and therefore this valuation technique is classified as level 3 of the fair value hierarchy. These calculations determine the net present value of the projected risk-adjusted, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows of the relevant asset or cash generating unit, applying a discount rate of the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> weighted average cost of capital (WACC) of 7%, adjusted where appropriate for specific segment, country and currency risk. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Assets that continue to be used by the Group are generally assessed as part of their associated cash generating unit on a value in use basis. For value in use calculations, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows do not include the impact of future uncommitted restructuring plans or improvements. Where an impairment is indicated and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> cash flow calculation is expected to give a materially different result, the test would be reperformed using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> cash flows and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate. The Group WACC is equivalent to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate of approximately 9%. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The net impairment losses have been charged to cost of sales: &#163;11&#160;million (2021: &#163;46 million), R&amp;D: &#163;7&#160;million (2021: &#163;3 million) and SG&amp;A: &#163;55&#160;million (2021: &#163;54 million), and included &#163;34&#160;million (2021: &#163;20 million) arising from the Major restructuring programmes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Reversals of impairment arose from subsequent reviews of the impaired assets where the conditions which gave rise to the original impairments were deemed no longer to apply. All of the reversals have been credited to cost of sales. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, &#163;39&#160;million (2021: &#163;74 million) of computer software was reclassified from assets in construction to intangible assets on becoming ready for use. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428867968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right of use assets</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">18. Right of use assets </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Plant and<br/> equipment<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;830</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">215</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(149</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(59</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(213</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">740</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">233</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(192</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">561</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">687</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table>  <div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has entered into some commitments for lease contracts that have not yet commenced. See Note 36. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An analysis of lease liabilities is set out in Note 30, &#8216;Net debt&#8217;. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348379902720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">19. Goodwill </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,552</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations (Note 41)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other movements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,552</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,597</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>   <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All Goodwill is allocated to the Group&#8217;s segments as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:89.5%;border:0">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,148</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total R&amp;D</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">898</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2021, prior to changes in the Group&#8217;s segment reporting (Note 6) Goodwill was allocated as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pharmaceuticals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,060</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill of &#163;5,183&#160;million allocated to Consumer Healthcare was transferred to &#8216;assets held for sale/distribution&#8217; prior to the Consumer Healthcare demerger (Note 41). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of disposal is calculated using a discounted cash flow approach, with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> discount rate applied to the projected risk-adjusted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> cash flows and terminal value. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount rate used is based on the Group WACC of 7% (2021: 6.5%), as most cash generating units have integrated operations across large parts of the Group. The discount rate is adjusted where appropriate for specific segment, country and currency risks. The valuation methodology uses significant inputs which are not based on observable market data, therefore this valuation technique is classified as level 3 in the fair value hierarchy.</div> <div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The R&amp;D segment is evaluated on an arms length pricing model, see assumptions below.</div></div><br/></div><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8.5pt;;display:inline;">Details relating to the discounted cash flow models used in the impairment tests are as follows:</div></div></div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>
<td style="vertical-align:bottom"/>
<td style="width:21%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Valuation basis</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Fair value less costs of disposal</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Key assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Sales growth rates</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Profit margins</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rate</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Determination of assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Growth rates are internal forecasts based on both internal and external market information.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Margins reflect past experience, adjusted for expected changes.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rates based on management&#8217;s estimate of future long-term average growth rates.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rates based on Group WACC, adjusted where appropriate.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rates based on appropriate rates for each jurisdiction.</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Period of specific projected cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Five years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate and discount rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Terminal growth rate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Discount&#160;rate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Commercial operations</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">R&amp;D</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Vaccines</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Consumer Healthcare</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2.5% p.a.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">6% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr></table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The terminal growth rate does not exceed the long-term projected growth rates for relevant markets, reflects the impact of future generic competition and take account of new product launches. Goodwill is monitored for impairment at the segmental level and the valuations indicated sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment of the related goodwill. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428979952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Other intangible assets</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">20. Other intangible assets </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer<br/> software</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Licences,<br/> patents,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;amortised<br/> brands etc.</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Indefinite&#160;life</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">brands</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(207</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(157</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">346</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,594</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(221</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,156</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">74</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42,489</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,109</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">317</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,964</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">775</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(236</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,772</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,781</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">39</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,959</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25,717</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,676</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,932</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,254</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(956</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,181</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">737</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,369</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,262</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(307</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(340</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(204</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(931</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,135</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">148</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">254</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">554</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,223</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,181</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,404</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,487</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(245</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,760</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(362</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(455</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">362</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">392</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,779</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(141</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(313</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">270</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(81</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,954</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,742</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,410</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,304</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(12,054</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13,358</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,053</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,403</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18,368</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,824</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,697</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18,418</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,079</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value at 31&#160;December 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,663</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,318</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The weighted average interest rate for capitalised borrowing costs in the year was 4% (2021: 3%). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The net book value of computer software included &#163;479&#160;million (2021: &#163;526 million) of internally generated costs. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The carrying value at 31&#160;December 2022 of intangible assets, for which impairments have been charged in the year following those impairments, was &#163;83&#160;million (2021: &#163;694 million). The carrying value at 31&#160;December 2022 of intangible assets, for which impairment reversals have been charged in the year following those impairment reversals, was &#163;776&#160;million (2021: &#163;104 million). No individual intangible asset accounted for a material impairment. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The patent expiry dates of the Group&#8217;s most significant assets, where relevant, are set out on pages 282 to 284. Please refer to Note 2 to the Group&#8217;s accounting policy and estimate of the useful life for intangible assets over the exclusivity and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity</div> periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortisation</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;impairment&#160;losses</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a) </div>&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">663</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">750</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">&#8211;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">65&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">307</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">299</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">373&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">1,088</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">367</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">438&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Licences, patents, amortised brands etc. includes a large number of acquired licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> agreements and marketing rights, which are either marketed or in use, or still in development. Note 41, &#8216;Acquisitions and disposals&#8217; gives details of additions through business combinations in the year. The book values of the largest individual items are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tesaro Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,858</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis portfolio</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,855</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Momelotinib</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,499</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,473</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">541</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Alector Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">509</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">iTeos Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">288</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Okairos</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">BMS Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Spero</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vir Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/FluLaval</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">147</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Stiefel trade name</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CureVac Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lamisil<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,797</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,663</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,697</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Disposed of as part of the Consumer Healthcare demerger (Note 41). </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;July 2022, GSK completed the acquisition of Sierra Oncology Inc, The main asset is momelotinib. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 15&#160;August 2022, GSK completed the acquisition of Affinivax, Inc. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Indefinite life brands related to healthcare brands used within the Consumer Healthcare business. Indefinite life brands were disposed of as part of the Consumer Healthcare demerger (Note 41). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group do not consider that any reasonably possible changes in the key assumptions would cause the recoverable amount of the Intangible assets disclosed above to fall below their carrying values. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128__IAS38_g118-128_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428953424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in associates and joint ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments in associates and joint ventures</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">21. Investments in associates and <div style="letter-spacing: 0px; top: 0px;;display:inline;">joint</div> ventures </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">76</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">88</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">349</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">364</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(278</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(278</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of interest in associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit/(loss) after tax recognised in the consolidated income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">64</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">76</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="margin-block: 0em;"/><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 20&#160;May 2021, the Group agreed with Innoviva Inc to sell all of its shares in Innoviva back to Innoviva for &#163;277&#160;million. Following settlement of the transaction, GSK no longer held any Innoviva stock. A loss of &#163;46&#160;million (including &#163;10&#160;million of recycling of exchange differences in Innoviva) is presented in Loss on disposal of interest in associates in the 2021 Consolidated income statement. The transaction did not include any changes in Innoviva&#8217;s commercial interest in royalties paid by GSK. Loss on disposal of interest in associates in 2021 also includes a &#163;10&#160;million gain from a disposal of another immaterial associate. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Please refer to the Income statement information on associates and joint ventures in Note 13. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428735648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current equity investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock', window );">Current equity investments</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">22. Current equity investments </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,087</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments represent Haleon <div style="letter-spacing: 0px; top: 0px;;display:inline;">plc</div> shares held after the demerger of Consumer Healthcare. Shares are held for trading and measured at fair value through profit or loss (FVTPL) based on the Haleon plc share price. Changes in fair value after the demerger are presented as Other operating income/expense in continuing operations. The Group&#8217;s investment in Haleon plc at the end of December 2022 is held by Glaxo Group Limited (5.4%), Scottish Limited Partnerships (SLPs) which were set up to collateralise agreed additional funding for GSK&#8217;s UK Defined Benefit pension schemes (7.5%) (Note 31) and the ESOP Trusts (0.6%). Net fair value movement through profit or loss of &#163;233&#160;million includes a fair value gain of &#163;229&#160;million and &#163;4&#160;million of other adjustments. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfCurrentEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of current equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfCurrentEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Other investments</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">23. Other investments </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(716</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(220</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(220</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,153</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,467</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,126</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Non-current other investments comprise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> equity investments which are recorded at fair value at each balance sheet date. For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price. For other investments, the fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments, recent financing rounds and discounted cash flows of the underlying net assets. Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net fair value movements include the impact of other exchange gains of &#163;134&#160;million through Other comprehensive income and &#163;nil through profit or loss (2021: gains of &#163;15&#160;million through Other comprehensive income and &#163;2&#160;million through profit or loss). Other investments include listed investments of &#163;823&#160;million (2021: &#163;1,736 million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has elected to designate the majority of its equity investments as measured at fair value through Other comprehensive income (FVTOCI). The most significant of these investments held at 31&#160;December 2022 were in Vir Biotechnology, Inc. which had a fair value at 31&#160;December 2022 of &#163;180&#160;million (2021: &#163;266 million) and Nimbus Therapeutics, LLC which had a fair value at 31&#160;December 2022 of &#163;139&#160;million (2021: &#163;32 million). The fair value of the investment in CureVac N.V., disclosed as a significant investment at 31&#160;December 2021, was &#163;75&#160;million at 31&#160;December 2022 (2021: &#163;380 million). The other investments include equity stakes in companies with which GSK has research collaborations and in companies which provide access to biotechnology developments of potential interest. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On disposal of equity investments measured at FVTOCI, the accumulated fair value movements are reclassified from the fair value reserve to retained earnings. Investments measured at FVTOCI with a fair value of &#163;220&#160;million (2021: &#163;240 million) were disposed of during the year. The cumulative gain on these investments after tax was &#163;14&#160;million (2021: &#163;132 million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain other investments, such as investments in funds with limited lives and investments acquired with an intention to sell, are measured at fair value through profit or loss (FVTPL). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428637696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Other non-current assets</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">24. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts receivable under insurance contracts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">857</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">849</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">108</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">1,676</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amounts receivable under insurance contracts are held at cash surrender value with movements through profit or loss. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the other receivables of &#163;108&#160;million (2021: &#163;86 million), &#163;34&#160;million (2021: &#163;44 million) is classified as financial assets of which &#163;13&#160;million (2021: &#163;23 million) is classified as fair value through profit or loss. On the remaining balance of &#163;21&#160;million (2021: &#163;21 million), the expected credit loss allowance was immaterial at 31&#160;December 2022 and 2021. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366539280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">25. Inventories </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Raw materials and consumables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,576</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,284</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,146</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">5,783</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428881312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradesAndOtherReceivableTextBlock', window );">Trade and other receivables</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">26. Trade and other receivables </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade receivables, net of loss allowance</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,452</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accrued income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prepayments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">343</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest receivable</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee loans and advances</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,226</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,053</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">7,860</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no trade or other receivable balances (2021: &#163;nil) due from associates and joint ventures. The most significant component of other receivables comprises receivables for taxes other than corporate income tax. Other significant balances within other receivables are royalties receivable and amounts receivable from collaboration partners. </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss allowance - trade receivables</div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Subsequent recoveries of amounts provided for</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">150</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the total trade receivables balance, &#163;58&#160;million (2021: &#163;86 million) is considered credit impaired, against which a &#163;26&#160;million (2021: &#163;4 million) expected credit loss allowance has been applied. No amount was purchased or originated credit impaired. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Within the other receivables of &#163;1,226&#160;million (2021: &#163;1,266 million), &#163;683&#160;million (2021: &#163;553 million) is classified as financial assets of which &#163;nil (2021: &#163;nil) is classified as held at fair value through profit or loss. At 31&#160;December 2022 an expected credit loss allowance of &#163;6&#160;million (2021: &#163;5 million) was recognised in respect of financial assets with no charge reported in profit or loss during the year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For more discussion on credit risk practices, please refer to Note 44. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTradesAndOtherReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTradesAndOtherReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428743936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">27. Cash and cash equivalents </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash at bank and in hand</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">879</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term deposits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,844</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">4,274</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>During 2022 &#163;1,421&#160;million was transferred to assets held for sale relating to the Consumer Healthcare business that was demerged during the year (see Note 41). Cash and cash equivalents included &#163;0.2&#160;billion (2021: &#163;0.2 billion) not available for general use due to restrictions applying in the subsidiaries where it is held. Restrictions include exchange controls and taxes on repatriation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428704960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">28. Assets held for sale </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">22</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets and disposal groups are transferred to assets held for sale when it is expected that their carrying amounts will be recovered principally through disposal and a sale is considered highly probable. They are held at the lower of carrying amount and fair value less costs to sell. </div>In Q2 2022, the Consumer Healthcare business was classified as held for sale. Following completion of the demerger of the Consumer Healthcare business in Q3 2022, a total of &#163;12.9&#160;billion of net assets and liabilities were distributed/derecognised as part of the gain on the demerger.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428881312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">29. Trade and other payables </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,866</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,488</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare put option</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,093</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">299</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Customer return and rebate accruals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,627</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other accruals</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,346</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,242</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,263</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17,554</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other payables included &#163;nil (2021: &#163;nil) due to associates and joint ventures. The Group provides limited supplier financing arrangements to certain customers. The amounts involved at 31&#160;December 2022 were not material. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Revenue recognised in the year that was included in deferred income at 1&#160;January 2022 was &#163;85&#160;million (2021: &#163;29 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Customer return and rebate accruals are provided for by the Group at the point of sale in respect of estimated rebates, discounts or allowances payable to customers as more fully described in the Group financial review on page 94. At 31&#160;December 2022, Customer return and rebate accruals included &#163;5,717&#160;million (2021: &#163;5,044 million) in respect of US Commercial Operations. Accruals are made at the time of sale but the actual amounts paid are based on claims made some time after the initial recognition of the sale. As the amounts are estimated, they may not fully reflect the final outcome and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The level of accrual is reviewed and adjusted quarterly in light of historical experience of actual amounts paid and any changes in arrangements. Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pfizer&#8217;s put option over its shareholding in ViiV Healthcare is currently exercisable. Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. The amount of the liability for this put option, which is held on the gross redemption basis, is derived from an internal valuation of the ViiV Healthcare business, utilising both discounted forecast future cash flow and multiples-based methodologies. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:top"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability and loss/(gain) in Income statement</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">149</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(99</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecast*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(149</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(48</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">* The sales forecast is for ViiV Healthcare sales only in respect of the ViiV Healthcare put option. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other accruals includes interest accrued on financial liabilities at amortised cost of &#163;207&#160;million (2021: &#163;244 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An explanation of the accounting for ViiV Healthcare is set out on page 71. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428819360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Net debt</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">30. Net debt </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:43%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:40%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Listing exchange</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,274</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,790</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,335</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,191</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank loans, overdrafts and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(448</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.850% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,483</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.875% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,113</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(665</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,038</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(167</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,952</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,601</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.800% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(926</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(629</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(925</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(204</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(420</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(926</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% US$ US Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(829</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(739</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(884</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(836</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(663</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(627</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.625% US$ US Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(827</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(620</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(587</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(885</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(838</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(442</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% &#163; Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(306</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(595</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.875% US$ US Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,450</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,294</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% &#163; Euro Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(744</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(743</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(822</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(733</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(441</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(418</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.750% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2030</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(663</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(628</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(616</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2033<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(640</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(984</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.375% US$ US Medium Term Note 2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(412</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(368</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.625% &#163; Euro Medium Term Note 2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(744</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(744</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% US$ US Medium Term Note 2038</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,264</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,022</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% &#163; Euro Medium Term Note 2039<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(695</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(695</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2042</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(472</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(987</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.200% US$ US Medium Term Note 2043</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(408</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(364</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.250% &#163; Euro Medium Term Note 2045</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(366</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(789</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other long-term borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(841</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(812</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Partially purchased and cancelled on 13&#160;February 2023. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current assets </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Liquid investments are classified as financial assets at amortised cost. At 31&#160;December 2022, they included US Treasury Notes and other government bonds. The effective interest rate on liquid investments at 31&#160;December 2022 was approximately 0.1% (2021: approximately 0.1%). Liquid investment balances at 31&#160;December 2022 earning interest at floating rates amount to &#163;67&#160;million (2021: &#163;2 million). Liquid investment balances at 31&#160;December 2022 earning interest at fixed rates amount to &#163;nil (2021: &#163;59 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Balances reported within cash and cash equivalents have an original maturity of three months or less. The effective interest rate on cash and cash equivalents at 31&#160;December 2022 was approximately 3.1% (2021: approximately 0.6%). Cash and cash equivalents at 31&#160;December 2022 earning interest at floating and fixed rates amounted to &#163;3,441&#160;million and &#163;10&#160;million respectively (2021: &#163;3,906&#160;million and &#163;39 million) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing holdings amounted to &#163;272&#160;million (2021: &#163;329 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s policy regarding the credit quality of cash and cash equivalents is set out in Note 44, &#8216;Financial instruments and related disclosures&#8217;. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Short-term borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">GSK has a $10&#160;billion (&#163;8.3 billion) US commercial paper programme, of which $900&#160;million (&#163;748 million) was in issue at 31&#160;December 2022 (2021: $nil). GSK has a &#163;5&#160;billion Euro commercial paper programme, of which <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>500&#160;million (&#163;443 million) was in issue at 31&#160;December 2022 (2021: <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>300&#160;million (&#163;252 million)). In February 2022 GSK cancelled the &#163;1.9&#160;billion three year and $2.5&#160;billion (&#163;2.1 billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities in September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#163;1.6&#160;billion and $2.2&#160;billion (&#163;1.8 billion) respectively. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate on commercial paper borrowings at 31&#160;December 2022 was 3.5% (2021: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-0.5%).</div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average interest rate on current bank loans and overdrafts at 31&#160;December 2022 was 7.8% (2021: 7.9%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-swap</div> interest rate of notes classified as short-term at 31&#160;December 2022 was 0.4% (2021: 3.0%). </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-term borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end,</div> GSK had long-term borrowings of &#163;17.0&#160;billion (2021: &#163;20.6 billion), of which &#163;11.1&#160;billion (2021: &#163;11.7 billion) fell due in more than five years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, three bonds were repaid earlier than original maturity, those being the 2.800% US$ US Medium Term Note 2023, the 3.375% US$ US Medium Term Note 2023 and the 0.000% US$ US Medium Term Note 2023. Also, during 2022 GSK undertook a tender on outstanding Sterling Notes, repaying face values of &#163;292&#160;million on the 3.375% &#163; Euro Medium Term Note 2027, &#163;350&#160;million on the 5.250% &#163; Euro Medium Term Note 2033, &#163;522&#160;million on the 5.250% &#163; Euro Medium Term Note 2042 and &#163;429&#160;million on the 4.250% &#163; Euro Medium Term Note 2045. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-swap</div> interest rate of all notes in issue at 31&#160;December 2022 was approximately 3.5% (2021: approximately 3.3%). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Long-term borrowings repayable after five years carry interest at effective rates between 1.4% and 6.4%, with repayment dates ranging from 2027&#160;to 2045. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Both effective rates exclude the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> premiums associated with the early repayment of the Sterling Notes. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pledged assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group held pledged investments in US Treasury Notes with a par value of $56&#160;million (&#163;47 million), (2021: $56&#160;million (&#163;42 million)) as security against irrevocable letters of credit issued on the Group&#8217;s behalf in respect of the Group&#8217;s self-insurance activity. Provisions in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 32, &#8216;Other provisions&#8217;. </div><div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease liabilities </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The maturity analysis of discounted lease liabilities recognised on the Group balance sheet is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due within one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">167</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">201</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">97</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due after five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">336</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">341</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total lease liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,008</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,015</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428649792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other post-employment benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Pensions and other post-employment benefits</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">31. Pensions and other post-employment benefits </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Pension and other post-employment costs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">114</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">185</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">58</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other overseas pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">170</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">415</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">466</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Analysed as:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Funded defined benefit/hybrid pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">231</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">318</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded defined benefit pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">23</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">291</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined contribution pension schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">133</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">415</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">466</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">104</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">128</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">136</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">167</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">52</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">291</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK entities operate pension arrangements which cover the Group&#8217;s material obligations to provide pensions to retired employees. These arrangements have been developed in accordance with local practices in the countries concerned. Pension benefits can be provided by state schemes; by defined contribution schemes, whereby retirement benefits are determined by the value of funds arising from contributions paid in respect of each employee; or by defined benefit schemes, whereby retirement benefits are based on employee pensionable remuneration and length of service. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension costs of defined benefit schemes for accounting purposes have been calculated using the projected unit credit method. In certain countries pension benefits are provided on an unfunded basis, some administered by trustee companies. Formal, independent, actuarial valuations of the Group&#8217;s main plans are undertaken regularly, normally at least every three years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Remeasurement movements in the year are recognised through the statement of comprehensive income. Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. Discount rates are selected to reflect the term of the expected benefit payments. Projected inflation rates and pension increases are long-term predictions based on the yield gap between long-term index-linked and fixed interest Gilts. In the UK, mortality rates are determined by adjusting the SAPS S3 standard mortality tables to reflect recent scheme experience. These rates are then projected to reflect improvements in life expectancy in line with the CMI 2021 projections with a long-term rate of improvement of 1.0% per year for both males and females. In the US, mortality rates are calculated using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRI-2012</div> white collar table adjusted to reflect recent experience. These rates are projected using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MP-2020</div> to allow for future improvements in life expectancy. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2042 for an individual then at the age of 60 is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Projected for 2042</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28.5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29.5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28.8</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">30.1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The assets of funded schemes are generally held in separately administered trusts, either as specific assets or as a proportion of a general fund, or are insurance contracts. Assets are invested in different classes in order to maintain a balance between risk and return. Investments are diversified to limit the financial effect of the failure of any individual investment. The physical asset allocation strategy for three of the four UK plans is 36% in return-seeking assets and 64% in liability-matching assets. During 2019, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-in</div> insurance contract was purchased to cover substantially all of the obligations of the other UK plan. At 31&#160;December 2022, the value of the insurance contract was &#163;402&#160;million (2021: &#163;570 million). The asset allocation of the US plans is currently set at 25% return-seeking assets and 75% liability-matching assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The pension plans are exposed to risk that arises because the estimated market value of the plans&#8217; assets might decline, the investment returns might reduce, or the estimated value of the plans&#8217; liabilities might increase. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In line with the agreed mix of return-seeking assets to generate future returns and liability-matching assets to better match future pension obligations, the Group has defined an overall long-term investment strategy for the plans, with investments across a broad range of assets. The main market risks within the asset and hedging portfolio are against credit risk, interest rates, long-term inflation, equities, property, currency and bank counterparty risk. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The plan liabilities are a series of future cash flows with relatively long duration. On an IAS 19 basis, these cash flows are sensitive to changes in the expected long-term inflation rate and the discount rate (AA corporate bond yield curve) where an increase in long-term inflation corresponds with an increase in the liabilities, and an increase in the discount rate corresponds with a decrease in the liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The interest rate risk and credit rate risk in the US are partially hedged. The targets are based on an accounting measure of the plan liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For the UK plans, there is an interest rate and inflation hedging strategy in place. The targets are based on an economic measure of the plan liabilities. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the UK, the defined benefit pension schemes operated for the benefit of former Glaxo Wellcome employees and former SmithKline Beecham employees remain separate. These schemes were closed to new entrants in 2001 and subsequent UK employees are entitled to join a defined contribution scheme. In addition, the Group operates a number of post-retirement healthcare schemes, the principal one of which is in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following a period of consultation with impacted employees, it was announced on 17&#160;December 2020 that the UK defined benefit plans would be closed to future accrual effective from 31&#160;March 2022. As a result, post closure the accrued benefits of active participants will be revalued in line with inflation (RPI for the legacy Glaxo Wellcome plans and CPI for the legacy SmithKline Beecham plans subject to the relevant caps for each arrangement) rather than capped pay increases. In addition, all defined benefit plan participants who were still active at 1&#160;April 2022 received a defined pension contribution of &#163;10,000 each. The effect of closure and the defined contribution enhancement together resulted in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-off</div> cost of &#163;74&#160;million in 2020. As announced, the plan was closed to new entrants at 31&#160;March 2022. From 1&#160;April 2022, former defined benefits plans employees were transferred to the defined contribution plans. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">It was announced on 9&#160;September 2020 that the US cash balance pension plans would be closed to future accrual from 1&#160;January 2021. This change resulted in a credit of &#163;56&#160;million. On 1&#160;June 2020 and 9&#160;September 2020, two amendments were made to the retiree healthcare plans in the US resulting in a credit of &#163;55&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has applied the following financial assumptions in assessing the defined benefit liabilities:</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Rest of World</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rate of increase of future earnings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected pension increases</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash balance credit/conversion rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.90</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inflation rate</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.10</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.20</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.50</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.25</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.30</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.30</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sensitivity analysis detailing the effect of changes in assumptions is provided on page 228. The analysis provided reflects the assumption changes which have the most material impact on the results of the Group. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31&#160;December 2022 in relation to the defined benefit pension and post-retirement healthcare schemes were as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">113</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">183</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,169</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">261</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(872</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">116</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">186</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">856</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">348</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement losses recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(96</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(90</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts included within past service costs in the UK included &#163;6&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;26&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;23 million) of augmentation costs which arose from Major restructuring programmes, together with a charge of &#163;<div style="display:inline;">nil</div> (2021: &#163;<div style="display:inline;">nil</div>; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div>: &#163;70 million) in relation to the impact of the closure of the defined benefit schemes to future accrual. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2020, the past service credit of &#163;49 million in the US reflected the closure of the cash balance pension plans from 1 January 2021. Amendments to the retiree healthcare plan in the US in 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(2)</div> resulted in a credit of &#163;53 million to past service costs in post-retirement benefits in 2020. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">These numbers do not include remeasurement gains/(losses) related to the demerged Consumer Healthcare business. </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the table below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Pensions and other post-employment benefits:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in deficit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,585</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,870</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(994</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,243</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,363</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,579</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,113</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,650</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">In the event of a plan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wind-up,</div> GSK believes the UK pension scheme rules provide the company with the right to a refund of surplus assets following the full settlement of plan liabilities. As a result, the net surplus in the UK defined benefit pension schemes is recognised in full. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other defined benefit pension schemes in the Group are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,159</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,101</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">605</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,595</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,329</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">691</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,694</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">(645</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(375</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,144</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,353</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,500</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(483</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(603</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,585</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(483</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,710</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(253</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,513</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The multi-asset funds comprise investments in pooled investment vehicles that are invested across a range of asset classes, increasing diversification within the growth portfolio. The value of funds in this asset class with a quoted market price is &#163;211&#160;million (2021: &#163;350 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The &#8216;Other (liabilities)/assets&#8217; category comprises cash and mark to market values of derivative positions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Index-linked gilts held as part of a UK repo programme are included in government bonds. The related loan of &#163;2,376&#160;million at 31&#160;December 2022 (2021: &#163;513&#160;million; 2020: &#163;650 million) is deducted within &#8216;Other assets&#8217;. </div> <div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;Rest&#160;of&#160;World<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(130</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asset&#160;ceiling&#160;restrictions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13,299</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,644</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,191</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">333</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,129</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(273</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,870</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">333</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">541</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">686</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2020&#160;&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,055</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13,858</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,445</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,007</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21,310</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,104</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(353</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,124</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,104</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,092</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">177</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,428</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in fair values of assets</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,432</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">372</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,056</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">313</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">105</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(641</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(999</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,206</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(184</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">262</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">424</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">312</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">105</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(982</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,062</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">370</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(578</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">919</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">117</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(624</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(649</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,080</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(135</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,014</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,870</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,144</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During March 2022, GSK transferred 7,004 GSK Consumer Healthcare Holdings Limited (GSKCHH) C Ordinary Shares (representing 11.03%. (in aggregate) of GSK&#8217;s interest in GSKCHH to three Scottish Limited Partnerships (&#8220;SLPs&#8221;), each providing a funding mechanism for a separate GSK UK defined benefit pension scheme. As part of the steps relating to the demerger and separation, the SLPs transferred their applicable portion of GSKCHH C Ordinary Shares to Haleon plc (&#8220;Haleon&#8221;) in consideration for shares in Haleon. The SLPs together hold shares representing 7.5% of the total issued share capital of Haleon. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on the Haleon shares until it has received an aggregate amount equal to an agreed threshold (&#8220;Proceeds Threshold&#8221;). The Proceeds Thresholds total &#163;1,080&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or &#8220;technical provisions&#8221; deficits in the three pension schemes shown by the 31&#160;December 2020 valuations. Once the applicable Proceeds Threshold has been reached the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-controlled</div> General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. If a pension scheme does not receive aggregate cash equal to the applicable Proceeds Threshold within 18 months after separation, then the trustee of that pension scheme will have the ability to require the SLP to instruct a broker to liquidate any remaining Haleon shares on behalf of the SLP in accordance with an agreed mandate. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, the Group made additional funding contributions to the UK pension schemes of &#163;691&#160;million (2021: &#163;44&#160;million; 2020: &#163;76 million) but no additional funding (2021: &#163;nil; 2020: &#163;nil) to the US schemes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As at 31&#160;December 2022, total cash contributions totalling &#163;735&#160;million were made towards the Proceeds Thresholds leaving a principal amount of &#163;345&#160;million outstanding to the UK pension schemes. The cash contributions of &#163;735&#160;million include voluntary cash contributions made by GSK in Q4 2022 to two of the UK defined benefit pension schemes totalling &#163;334&#160;million in response to the market volatility in the UK gilt markets. <br/></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The outstanding accelerated contributions were collateralised by the creation of three Scottish Limited Partnerships (SLPs), into which GSK inserted a total of 692,593,037 Haleon ordinary shares across the three SLPs. Each of the three principal UK defined benefit pension schemes (two benefiting current and former Glaxo Welcome employees, with the third benefiting current and former SmithKline Beecham employees) has an interest in one of the SLPs as shown below: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:33%"/> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">General Partner</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Limited Partners</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No. 1) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP1 Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Scheme</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK (No. 2) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK GP1 Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Fund</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK (No. 3) Scottish Limited Partnership</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK GP2 Ltd</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">GSK LP Ltd</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">SmithKline Beecham Pension Plan Trustee Ltd acting on behalf of the SmithKline Beecham Pension Plan</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under each of the SLP partnership agreements, the limited partners have no involvement in the management of the business and shall not take any part in the control of SLP. The general partner (in all cases, controlled by GSK plc) is responsible for the management and control of each SLP and, as such, each SLP is consolidated into the results of the Group. Each SLP therefore takes advantage of the exemption in Regulation 7 of The Partnership (Accounts) Regulations 2008 Act to not prepare and deliver audited accounts to the UK registrar. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the SLP partnership agreement, distributions will be made from partnership income to the defined benefit pension schemes if equivalent payments have not already been made to the three defined benefit pension schemes by another GSK entity. To date, &#163;735&#160;million has been paid to the defined benefit pension schemes by GSK under this structure and once contributions under this structure reach &#163;1,080&#160;million, the defined benefit pension schemes interests&#8217; in the SLPs ends. The remaining economic interest in the SLPs will be held by GSK LP Ltd, a 100% owned subsidiary of GSK plc. At 31&#160;December 2022, &#163;345&#160;million of these additional contributions remains to be paid. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Employer contributions for 2023, excluding special funding contributions stated above, are estimated to be approximately &#163;350&#160;million in respect of defined benefit pension schemes and &#163;100&#160;million in respect of post-retirement benefits. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in defined benefit obligations</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,506</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(43</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(259</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(168</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,161</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(82</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">641</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">999</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,858</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,310</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,363</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">218</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(216</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">439</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">982</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,248</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,191</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,243</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(371</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(495</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(125</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(388</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,011</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">621</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">649</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,080</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">135</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,117</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,031</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,352</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,500</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(994</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table>  <div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The defined benefit pension obligation is analysed as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Funded</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(13,887</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19,419</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20,504</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(613</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(772</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(806</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(14,500</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20,191</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21,310</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The liability for the US post-retirement healthcare scheme has been assessed using the same assumptions as for the US pension scheme, together with the assumption for future medical inflation of 7% (2021: 6.25%) in 2022, grading down to 5% in 2031 and thereafter. At 31&#160;December 2022, the US post-retirement healthcare scheme obligation was &#163;870&#160;million (2021: &#163;1,059&#160;million; 2020: &#163;1,124 million). Post-retirement benefits are unfunded. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The movement in the net defined benefit liability is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,129</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,104</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,921</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(87</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(216</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(291</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Return on plan assets, excluding amounts included in interest</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,883</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,056</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">92</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(62</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,868</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">716</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,340</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience (loss)/gain</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(949</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(215</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employer contributions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">919</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">312</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">313</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expenses</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,129</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,104</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The remeasurements included within post-retirement benefits are detailed below: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">219</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">35</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(93</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience gains</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">78</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(82</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The defined benefit pension obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,390</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,196</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,660</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,540</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,115</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,257</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,570</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,880</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,393</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,500</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20,191</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,310</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The post-retirement benefit obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">306</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">494</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">551</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">688</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">748</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">808</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">994</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,243</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,363</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average duration of the defined benefit obligation is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">years</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension benefits</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">16</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr> </table>  <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Membership numbers are not restated as the disclosure relates to the post-retirement benefit obligations. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sensitivity analysis </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The effect of changes in assumptions used on the benefit obligations and on the 2023 annual defined benefit pension and post-retirement costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of the plan memberships. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Discount rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,341</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(61</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Inflation rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">945</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(827</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">1 year<br/> increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Life expectancy</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">1%</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">increase<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Rate of future healthcare inflation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7__IAS19_g2-7_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428819360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Other provisions</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">32. Other provisions </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Legal<br/> and&#160;other<br/> disputes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/> &#160;restructuring<br/> programmes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Employee<br/> related<br/> provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Other<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,471</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversed unused</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(261</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(539</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(119</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications and other movements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to Pension obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,184</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled within one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">652</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled after one year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">234</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">532</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,184</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in a substantial number of legal and other disputes, including notification of possible claims, as set out in Note 47, &#8216;Legal proceedings&#8217;. Provisions for legal and other disputes include amounts relating to product liability, anti-trust, government investigations, contract terminations and self insurance. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in significant legal proceedings in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, the Group would provide appropriate disclosures about such cases, but no provision would be made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The net charge for the year of &#163;133&#160;million (including reversals and estimated insurance recoveries) primarily related to provisions for product liability cases, commercial disputes and various other government investigations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount on the provision is &#163;3&#160;million in 2022 (2021: &#163;nil). The discount was calculated using risk-adjusted projected cash flows and risk-free rates of return. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s position could change over time, and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial accounts. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">It is in the nature of the Group&#8217;s business that a number of these matters may be the subject of negotiation and litigation over many years. Litigation proceedings, including the various appeal procedures, often take many years to reach resolution, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-court</div></div> settlement discussions can also often be protracted. Indemnified disputes will result in a provision charge and a corresponding receivable. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is in potential settlement discussions in a number of the disputes for which amounts have been provided and, based on its current assessment of the progress of these disputes, estimates that &#163;190&#160;million of the amount provided at 31&#160;December 2022 will be settled within one year. At 31&#160;December 2022, it was expected that &#163;nil (2021: &#163;4 million) of the provision made for legal and other disputes will be reimbursed by third parties. For a discussion of legal issues, See Note 47, &#8216;Legal proceedings&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Major restructuring programmes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, the Group had two major restructuring programmes in progress: the Separation Preparation programme which focused on preparing for the separation of GSK into two new companies and the Significant Acquisitions programme which is focused on the integration of recent acquisitions. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Restructuring provisions primarily include severance costs when management has made a formal decision to eliminate certain positions and this has been communicated to the groups of employees affected and appropriate consultation procedures completed, where appropriate. No provision is made for staff severance payments that are paid immediately. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The discount on the provisions increased by &#163;1&#160;million in 2022 (2021: increased by &#163;2 million). </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension augmentation includes &#163;6&#160;million relating to the defined benefit plan arising from staff redundancies, as shown in Note 30, &#8216;Pensions and other post-employment benefits&#8217;. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee related provisions </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Employee related provisions include obligations for certain medical benefits to disabled employees and their spouses in the US. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the provision for these benefits amounted to &#163;66&#160;million (2021: &#163;69 million). Other employee benefits reflect a variety of provisions for severance costs, jubilee awards and other long-service benefits. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Given the nature of these provisions, the amounts are likely to be settled over many years. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other provisions </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Included in other provisions are provisions for onerous contracts, insurance provisions and a number of other provisions including vehicle insurance and regulatory matters. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92__IAS37_g84-92_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428743936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory', window );">Contingent consideration liabilities</a></td>
<td class="text"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">33. Contingent consideration liabilities </div></div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,479</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,275</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(765</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(107</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,869</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,063</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(742</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(114</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,076</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,645</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movement through reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Initial recognition from business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">482</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,058</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(69</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(79</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,890</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">501</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,068</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the contingent consideration payable at 31&#160;December 2022, &#163;1,289&#160;million (2021: &#163;958 million) is expected to be paid within one year. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture, Affinivax and the Novartis Vaccines business are expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, shown above. The Shionogi-ViiV Healthcare contingent consideration liability is discounted at 8% (2021: 8%), the Affinivax contingent consideration liability is discounted at 9.9% and the Novartis Vaccines contingent consideration liability is discounted at 7.5% (2021: 7.5%) for commercialised products and at 8.5% (2021: 8.5%) for pipeline assets. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Shionogi-ViiV Healthcare and Novartis Vaccines contingent consideration liabilities are calculated principally based on the forecast sales performance of specified products over the lives of those products. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Affinivax contingent consideration is based upon two potential milestone payments, each of $0.6&#160;billion (&#163;0.5 billion) which will be paid if certain pediatric clinical development milestones are achieved. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">and loss/(gain) in Income statement</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Shionogi-</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">ViiV</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;Healthcare</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Novartis</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">556</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">834</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(506</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(833</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(759</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(199</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(198</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(292</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">214</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">328</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(347</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(38</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(501</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(398</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">171</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(91</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(130</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in probability of milestone success</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in probability of milestone success</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(82</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The sales forecast is for ViiV Healthcare sales only in respect of the Shionogi-ViiV Healthcare contingent consideration. </div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">An explanation of the accounting for ViiV Healthcare is set out on page 71. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428881312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory', window );">Other non-current liabilities</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">34. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accruals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">85</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">805</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">823</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">899</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">921</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other payables includes a number of employee-related liabilities including employee savings plans.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current liabilities. [Refer: Other non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingent liabilities</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">35. Contingent liabilities </div></div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, contingent liabilities where GSK has a present obligation as a result of a past event, comprising guarantees and other items arising in the normal course of business, amounted to &#163;58&#160;million (2021: &#163;126 million). At 31&#160;December 2022, &#163;0.5&#160;million (2021: &#163;0.2 million) of financial assets were pledged as collateral for contingent liabilities. Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow. If it is not possible to meaningfully assess whether the outcomes will result in a probable outflow, or to quantify or reliably estimate the liability, if any, no provision is recorded. Descriptions of the significant legal and other disputes to which the Group is a party are set out in Note 47, &#8216;Legal proceedings&#8217;. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 86<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428649792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">36. Commitments </div></div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual obligations and commitments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contracted for but not provided in the financial statements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,659</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,082</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">743</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">616</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">138</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">146</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase commitments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">161</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">484</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and post-retirement benefits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">345</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">44</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest on loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,322</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,603</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Future finance charges on leases</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease contracts that have not yet commenced</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">395</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;18,909</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,188</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The commitments related to intangible assets include milestone payments, which are dependent on successful clinical development or on meeting specified sales targets, and which represent the maximum that would be paid if all milestones, however unlikely, are achieved. The amounts are not risk-adjusted or discounted. The net decrease in intangible asset commitments in 2022 is mainly attributable to the termination of certain agreements, offset by a number of new R&amp;D collaborations including collaborations with Spero Therapeutics, Inc., Wuxi Biologics Ireland Limited, SpringWorks Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2022, GSK reached an agreement with the trustees of the UK pension schemes to make additional contributions of &#163;1,080&#160;million, to eliminate the pension deficit identified at the 31&#160;December 2020 actuarial funding valuation. Prior to the Consumer Healthcare demerger, GSK agreed to collateralise this commitment and accelerate funding with additional contributions (see Note 31). At 31&#160;December 2022, &#163;345&#160;million of these additional contributions remained unpaid. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group also has other commitments which principally relate to revenue payments to be made under licences and other alliances. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Commitments in respect of future interest payable on loans are disclosed before taking into account the effect of interest rate swaps. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428649792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital and share premium account<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory', window );">Share capital and share premium account</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">37. Share capital and share premium account </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Following completion of the Consumer Healthcare business demerger on 18 July 2022, GSK plc Ordinary shares were consolidated to maintain share price comparability before and after demerger. The consolidation was approved by GSK shareholders at a General Meeting held on 6 July 2022. Shareholders received 4 new Ordinary shares with a nominal value of <span style="-sec-ix-hidden:hidden69050743">31</span><div style="vertical-align:top;display:inline;;font-size:7.8px">1</div>&#8260;<div style="vertical-align:bottom;display:inline;;font-size:7.8px">4</div> pence each for every 5 existing Ordinary share which had a nominal value of 25 pence each. Earnings per share, diluted earnings per share, adjusted earnings per share and dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary&#160;shares&#160;of&#160;25p&#160;each&#160;pre-share&#160;consolidation</div><br/> Ordinary&#160;shares&#160;of&#160;31<div style="vertical-align:top;display:inline;;font-size:6px">1</div>&#8260;<div style="vertical-align:bottom;display:inline;;font-size:6px">4</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">p&#160;each&#160;post-share&#160;consolidation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share capital issued and fully paid:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,383,102,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,087,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,385,189,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,825,442</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,387,015,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impact of share consolidation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,077,403,011</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,731,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,311,343,341</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,440</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, of the issued share capital, 59,878,735 shares were held in the ESOP Trusts, 217,124,760 shares were held as Treasury shares and 4,034,339,846 shares were in free issue. All issued shares are fully paid and there are no shares authorised but not in issue. The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 45, &#8216;Employee share schemes&#8217;. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364906608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMovementsInEquityExplanatory', window );">Movements in equity</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">38. Movements in equity </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Retained earnings and other reserves amounted to &#163;5,811&#160;million at 31&#160;December 2022 (2021: &#163;10,407&#160;million; 2020: &#163;9,960 million) of which &#163;463&#160;million (2021: &#163;476&#160;million; 2020: &#163;440 million) related to associates and joint ventures<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cumulative translation exchange in equity is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Net translation exchange included in:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Retained<br/> earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Fair&#160;value<br/> reserve</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-<br/> &#160;&#160;&#160;&#160;&#160;&#160;controlling<br/> interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;translation<br/> exchange</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(524</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(652</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(93</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(259</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(993</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(692</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(209</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(906</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to discontinued operations<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">263</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">375</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(429</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(531</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">(a) Includes &#163;(554)&#160;million reclassification to the Consolidated income statement of exchange movements related to the demerger of the Consumer Healthcare business. </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of other comprehensive income by equity category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">109</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">113</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(754</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(754</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(786</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(786</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">211</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">211</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(464</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(695</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,187</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">375</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">356</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(89</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(714</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(831</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(911</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(911</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">131</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">131</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement losses on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">941</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">941</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(223</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(223</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">454</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(771</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(337</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(51</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(59</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,348</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,348</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(220</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(220</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement gains on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(187</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(187</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(133</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,137</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">970</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Information on net investment hedges is provided in part (d) of Note 44 &#8216;Financial instruments and related disclosures&#8217;. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The analysis of other reserves is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ESOP&#160;Trust</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">shares</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Fair&#160;value</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(135</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">409</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(48</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,355</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(207</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,117</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(609</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(609</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">529</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">529</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(195</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,205</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Transferred to income and expenses in the year on impairments of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">168</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">168</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(139</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(139</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(780</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(770</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">383</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,463</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Balances derecognised on demerger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(169</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(169</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(698</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">141</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(557</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,200</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,200</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">911</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">911</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(353</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(308</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,448</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other reserves include various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-distributable</div> merger and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-merger</div> reserves amounting to &#163;1,849&#160;million at 31&#160;December 2022 (2021: &#163;1,849&#160;million; 2020: &#163;1,849 million). Other reserves also include the capital redemption reserve created as a result of the share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back</div> programme amounting to &#163;280&#160;million at 31&#160;December 2022 (2021: &#163;280&#160;million; 2020: &#163;280 million). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMovementsInEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Movements in Equity Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfMovementsInEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428706192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory', window );">Non-controlling interests</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">39. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests </div></div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests includes the following individually material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests are individually not material. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ViiV Healthcare </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK holds 78.3% of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group,</div> giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information available at the latest practicable date in respect of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> is as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,619</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,637</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,848</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,528</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,087</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">762</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">94</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(17</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,622</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,070</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">795</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,716</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,796</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,354</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,711</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,070</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,507</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,762</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,121</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,983</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8,472</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,745</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11,593</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,675</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6,086</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash inflow from operating activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,442</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,249</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from investing activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(174</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(287</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(294</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from financing activities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,718</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,608</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,483</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in cash and bank overdrafts in the year</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">233</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(528</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The above financial information relates to the ViiV Healthcare group on a stand-alone basis, before the impact of Group-related adjustments, primarily related to the recognition of preferential dividends. The profit after taxation of &#163;1,528&#160;million (2021: &#163;1,087&#160;million; 2020: &#163;762 million) is stated after charging preferential dividends payable to GSK and Pfizer and after a charge of &#163;1,483&#160;million (2021: &#163;1,218&#160;million; 2020: &#163;1,112 million) for remeasurement of contingent consideration payable. This consideration is expected to be paid over a number of years. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the ViiV Healthcare group are included in GSK&#8217;s financial statements: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of profit for the year attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">415</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">196</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;223</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">480</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">224</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">419</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(611</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(570</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(539</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21">&#160;</div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consumer Healthcare Joint Venture </div></div></div></div>  <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK held 68% of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> until the demerger on 18&#160;July 2022 (see details in Note 41), giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information in respect of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> at 31&#160;December 2021 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:91%;border:0">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:97%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29,200</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,251</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">34,451</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4,238</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,733</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,971</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26,480</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The above financial information relates to the former Consumer Healthcare Joint Venture on a stand-alone basis, before the impact of Group-related adjustments and the classification of cash pooling accounts with Group companies outside the Consumer Healthcare Joint Venture but after Major restructuring charges. </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the Consumer Healthcare Joint Venture were included in GSK&#8217;s financial statements in prior years: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,609</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,538</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364906608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party transactions</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">40. Related party transactions </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, there were no loans due to GSK from related parties (2021: &#163;4.6&#160;million was due from Medicxi Ventures I LP). Cash distributions were received from investment in Medicxi Ventures I LP of &#163;6.0&#160;million (2021: Medicxi Ventures I LP of &#163;5.5&#160;million, Longwood Founders Fund, LP of &#163;3.0&#160;million and Apollo Therapeutics LLP of &#163;0.1 million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">As part of the joint venture agreement with Qura Therapeutics LLC, the Group has an obligation to fund the joint venture up to April 2025, with both GSK and its joint venture partner committing financial support in the amount of &#163;21.6&#160;million. At December 2022, the outstanding liability due to Qura was &#163;8.3&#160;million (2021: &#163;10.7 million). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group had no other significant related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The aggregate compensation of the Directors and GLT is given in Note 9, &#8216;Employee costs&#8217;. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368227424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and disposals<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Acquisitions and disposals</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">41. Acquisitions and disposals </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Details of the acquisition and disposal of significant subsidiaries, associates, joint ventures and other businesses are given below: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;July 2022, GSK completed the acquisition of 100% of Sierra Oncology, Inc., a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $1.9&#160;billion (&#163;1.6 billion). The main asset is momelotinib which targets the medical needs of myelofibrosis patients with anaemia. Total transaction costs were &#163;52&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 15&#160;August 2022, GSK completed the acquisition of 100% of Affinivax, Inc. a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts focused on pneumococcal vaccine candidates. The consideration for the acquisition comprised an upfront payment of $2.2&#160;billion (&#163;1.8 billion) as adjusted for working capital acquired paid upon closing and two potential milestone payments each of $0.6&#160;billion (&#163;0.5 billion) to be paid upon the achievement of certain paediatric clinical development milestones. The estimated fair value of the contingent consideration payable was &#163;482&#160;million. The values are provisional and are subject to change. The total transaction costs were &#163;71&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Since acquisition, no sales arising from the Sierra Oncology or Affinivax businesses have been included in Group turnover and no revenue is expected until regulatory approval is received on the acquired assets. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK continues to support the ongoing development of the acquired assets and consequently these assets will be loss making until regulatory approval on these assets is received. The development of these assets has been integrated into the Group&#8217;s existing R&amp;D activities, so it is impracticable to quantify these development costs or the impact on Total profit after taxation for the period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill of &#163;1,127&#160;million (&#163;162&#160;million for Sierra Oncology and &#163;965&#160;million for Affinivax), which is not expected to be deductible for tax purposes, has been recognised. The goodwill represents workforce in place, and specific synergies available to GSK from the business combinations. The goodwill has been allocated to the Group&#8217;s Commercial Operations and R&amp;D segments, (refer to Note 19 &#8216;Goodwill&#8217; for allocation methodology). </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Sierra<br/> Oncology<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,497</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,467</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,964</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">52</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">53</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">175</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">109</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">284</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(55</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(77</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(117</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(259</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(236</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(495</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,435</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,307</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,742</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">162</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">965</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,127</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,272</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,869</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,790</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,387</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of contingent consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">482</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">482</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 24&#160;November 2022 GSK signed an agreement to buy out the 25% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in Glaxo Saudi Arabia Ltd for SAR94&#160;million (&#163;21&#160;million), to be paid in 2023. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"/> <div style="margin-top: 1em; margin-bottom: 1em"/></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demerger of Consumer Healthcare business </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 18&#160;July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. The separation was effected by way of a demerger of 80.1% of GSK&#8217;s 68% holding in the Consumer Healthcare business to GSK shareholders. Following the demerger, 54.5% of Haleon was held in aggregate by GSK shareholders, 6.0% remains held by GSK (including shares received by GSK&#8217;s consolidated ESOP trusts) and 7.5% remains held by certain Scottish Limited Partnerships (SLPs) set up to provide collateral for a funding mechanism pursuant to which GSK will provide additional funding for GSK&#8217;s UK defined benefit pension schemes (Note 31). The aggregate ownership by GSK (including ownership by the ESOP trusts and SLPs) after the demerger of 13.5% was measured at fair value with changes through profit or loss. Pfizer continued to hold 32% of Haleon after the demerger. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under IFRIC 17 &#8216;Distributions of Non-cash Assets to Owners&#8217; a liability and an equity distribution are measured at the fair value of the assets to be distributed when the dividend is appropriately authorised and it is no longer at the entity&#8217;s discretion. The liability and equity movement, and associated gain on distribution were recognised in Q3 2022 when the demerger distribution was authorised and occurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The asset distributed was the 54.5% ownership of the Consumer Healthcare business. The net carrying value of the Consumer Healthcare business in the consolidated financial statements, including the retained 13.5% and net of the amount attributable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, was approximately &#163;11.0&#160;billion at the end of June. GSK&#8217;s &#163;6.3&#160;billion share of the shareholder loans made in Q1 2022 in advance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-separation</div> dividends was eliminated in the consolidated financial statements. The assets distributed were reduced by Consumer Healthcare transactions up to 18&#160;July that principally included <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-separation</div> dividends declared and settled after the end of Q2 2022 and before 18&#160;July 2022. Those dividends included: &#163;10.4&#160;billion (&#163;7.1&#160;billion attributable to GSK) of dividends funded by Consumer Healthcare debt that was partially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-lent</div> during Q1 2022 and dividends of &#163;0.6&#160;billion (&#163;0.4&#160;billion attributable to GSK) from available cash balances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of the 54.5% ownership of the Consumer Healthcare business distributed was &#163;15.5&#160;billion. This was measured by reference to the quoted average Haleon share price over the first five days of trading, this being a fair value measured with observable inputs which was considered to be representative of the fair value at the distribution date. A gain on distribution of this fair value less book value of the attributable net assets of the Consumer Healthcare business of &#163;7.7&#160;billion was recorded in the Income Statement in 2022. There was an additional gain of &#163;2.4&#160;billion to remeasure the retained 13.5% from its book value to fair value of &#163;3.9&#160;billion using the same fair value methodology as used for the distributed shares. The gain on distribution and on remeasurement of the retained stake upon demerger was presented as part of discontinued operations. Any future gains or losses on the retained stake in Haleon will be recognised in continuing operations. In addition, there was a reclassification of the Group&#8217;s share of cumulative exchange differences arising on translation of the foreign currency net assets of the divested subsidiaries and offsetting net investment hedges from reserves into the Income Statement of &#163;0.6&#160;billion. The total gain on demerger of Consumer Healthcare was &#163;10.1&#160;billion. These transactions were presented in profit from discontinued operations in 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the Consumer Healthcare business distributed (54.5%)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the retained ownership in Haleon plc (13.5%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,853</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the net assets and liabilities distributed/de-recognised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,887</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest de-recognised</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,038</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on demerger before exchange movements and transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">554</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total gain on the demerger of Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,084</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right"/> <div style="margin-top: 1em; margin-bottom: 1em"/></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Consumer Healthcare was presented as a discontinued operation as at 30&#160;June 2022 and disclosed as such in the interim financial statements. The Consolidated Income Statement and Consolidated Cash Flow Statement distinguish discontinued operations from continuing operations. Comparative figures have been restated on a consistent basis. Financial information relating to the operations of Consumer Healthcare for the period is set out below and includes financial information until 18&#160;July 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This financial information differs both in purpose and basis of preparation from the Historical Financial Information and the Interim Financial Information included in the Haleon prospectus and from that which will be published by Haleon on 2&#160;March 2023. As a result, whilst the two sets of financial information are similar, they are not the same because of certain differences in accounting and disclosure under IFRS. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total results</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,581</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,418</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,745</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,730</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,575</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,947</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">851</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,843</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,798</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(235</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(263</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(513</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax rate %</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.6%</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.3%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28.5%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">616</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other gains/(losses) on demerger</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,433</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,651</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation on demerger of discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,700</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in discontinued operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">205</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">511</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">409</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,495</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,069</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">876</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6p</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26.7p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22.0p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other business disposals </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There were no other material business disposals in 2022. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;demerger</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">- other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,392</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">284</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(933</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,108</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(933</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(79</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(141</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,187</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,074</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;)</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash consideration for business acquisitions included &#163;5&#160;million related to other business acquisition activity. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021 </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK completed no material business acquisitions in 2021. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business disposals </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK made a number of business disposals for net cash consideration received in the year of &#163;10&#160;million. The profit on the disposal of the businesses in the year of &#163;24&#160;million was calculated as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration including currency forwards, purchase adjustments and deferred consideration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets sold:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deal costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals in 2021</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Associates and joint ventures </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 20&#160;May 2021 GSK agreed with Innoviva, Inc. (&#8220;Innoviva&#8221;) to sell all of its approximately 32&#160;million shares of common stock of Innoviva back to Innoviva at a price of $12.25 per share, raising gross proceeds of approximately $392&#160;million. Following settlement of the transaction, GSK will no longer hold any Innoviva stock. See details in Note 21 &#8216;Investment in associates and joint ventures&#8217;. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows </div></div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020 </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business acquisitions </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK completed one smaller business acquisition when it acquired 55% of Pfizer Biotech Corporation Taiwan, a part of Pfizer&#8217;s consumer healthcare business, which was not previously recognised as part of the Consumer Healthcare Joint Venture, on 28&#160;September 2020 for non cash consideration of &#163;129&#160;million. This represented goodwill of &#163;124&#160;million, cash of &#163;21&#160;million and other assets acquired of &#163;18&#160;million less <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#163;14&#160;million and net liabilities of &#163;20&#160;million. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> consideration (settlement of a promissory note)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business disposals </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed public company. GSK received a 5.7% equity stake in Hindustan Unilever and &#163;395&#160;million in cash. GSK disposed of its equity stake in Hindustan Unilever during May 2020. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The divestment in Bangladesh closed on 30&#160;June 2020. Total cash consideration received was &#163;177&#160;million. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cash divested as part of the disposal of the India and Bangladesh Consumer Healthcare entities was &#163;478&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></div><div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="LOGO" src="g382677dsp001b.jpg"/> </div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div/><div><div style="background-color:white;display: inline;"/></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The profit on the disposal of the businesses in the year of &#163;2,795&#160;million <div style="display:inline;">was </div>calculated as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Horlicks</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">divestment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration receivable including currency forwards and purchase adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">492</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">157</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">649</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equity investment in Hindustan Unilever Limited</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,616</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">157</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,773</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets disposed:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">142</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">143</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">103</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">118</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">68</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">478</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">481</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(155</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(154</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">536</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">126</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">662</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">240</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">240</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">288</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">316</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,792</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,795</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The exposure to share price movements embedded in the agreement to merge GSK&#8217;s Indian listed Consumer Healthcare entity with Hindustan Unilever Limited as part of the divestment of Horlicks and other nutrition products in India and a number of other countries was recognised as a derivative between signing of the agreement in 2018 and completion of the transaction in 2020. &#163;240&#160;million is recorded as a cost in the table above for the derecognition of the derivative asset. This largely reflects fair value gains recognised in the Income Statement in prior periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Associates and joint ventures </div></div></div></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During the year, GSK made investments into associates of &#163;4&#160;million and &#163;4&#160;million was paid in cash. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">investments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received/(paid)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">786</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents acquired/(divested)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(481</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">259</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Other includes Consumer Healthcare disposals where the income statement impact is not restated. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428824144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adjustments reconciling profit after tax to operating cash flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory', window );">Adjustments reconciling profit after tax to operating cash flows</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; margin-left:5%; text-indent:-5%; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">42. Adjustments reconciling Total profit after tax to operating cash&#160;flows </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit after tax from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on profits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates and joint ventures</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense net of finance income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">803</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,061</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment and assets written off</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">481</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of businesses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(185</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on sale of investments in associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in working capital:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase)in inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(269</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(158</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(780</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">494</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Increase) in other receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(349</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration paid (see Note 33)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,058</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(742</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(765</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> increase in contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,628</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">885</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension and other provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">346</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(283</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(170</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(122</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,944</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,994</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,422</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash generated from operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,876</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,243</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,096</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of adjustments reconciling profit after tax to operating cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364906608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of net cash flow to movement in net debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory', window );">Reconciliation of net cash flow to movement in net debt</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">43. Reconciliation of net cash flow to movement in net debt</div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt, at beginning of year, as adjusted</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25,215</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in cash and bank overdrafts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,597</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,579</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in liquid investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in long-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,025</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of short-term Notes</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,074</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of/(increase in) other short-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,021</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(301</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of medium term notes (MTNs)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,594</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of lease liabilities</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt of subsidiary undertakings acquired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,531</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> movements</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(134</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(102</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,536</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,177</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,027</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net debt at end of year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis&#160;of&#160;changes&#160;in&#160;net&#160;debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;fair&#160;value</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Demerger</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">At</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(450</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">137</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(298</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,597</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">407</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,496</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,818</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(545</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(909</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,191</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,426</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(173</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(186</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(167</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(150</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,073</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(220</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,612</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,654</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,559</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,466</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,145</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(223</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,615</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,559</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,789</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,654</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16,194</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(725</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(59</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">186</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(841</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,485</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(777</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,059</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,222</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,615</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,059</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,667</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,424</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(865</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">670</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,983</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,450</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(301</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(912</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">718</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,710</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,670</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,888</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis of changes in net debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;in&#160;fair&#160;value<br/> &#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;Cash&#160;flow<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;31&#160;December</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,274</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">574</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(456</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,262</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,414</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,818</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(252</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,350</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,596</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(230</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(203</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(94</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,695</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,694</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,210</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,145</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,760</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(887</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(132</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(812</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,425</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">313</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(132</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,694</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,572</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(128</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">778</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,838</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(753</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(244</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26,441</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(775</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,976</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(23,983</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of net cash flow to movement in net debt explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428706192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments and related disclosures</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44. Financial instruments and related disclosures</div></div></div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-top: 1em; margin-bottom: 1em"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The objective of GSK&#8217;s Treasury activities is to <div style="letter-spacing: 0px; top: 0px;;display:inline;">minimise </div>the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-tax</div> net cost of financial operations and reduce its volatility to benefit earnings and cash flows. GSK uses a variety of financial instruments to finance its operations and derivative financial instruments to manage market risks from these operations. Derivatives principally comprise foreign exchange forward contracts and swaps which are used to swap borrowings and liquid assets into currencies required for Group purposes as well as interest rate swaps which are used to manage exposure to financial risks from changes in interest rates. These financial instruments reduce the uncertainty of foreign currency transactions and interest payments. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives are used exclusively for hedging purposes in relation to underlying business activities and not as trading or speculative instruments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s financial strategy supports the Group&#8217;s strategic priorities and is regularly reviewed by the Board. GSK manages the capital structure of the Group through an appropriate mix of debt and equity. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The capital structure of the Group consists of net debt of &#163;17.2&#160;billion (see Note 30, &#8216;Net debt&#8217;) and total equity, including items related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests, of &#163;10.1&#160;billion (see &#8216;Consolidated statement of changes in equity&#8217; on page 184). Total capital, including that provided by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests, is &#163;27.3&#160;billion. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group continues to manage its financial policies to a credit profile that particularly targets short-term credit ratings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-1</div> while maintaining single A long-term ratings consistent with those targets. The Group&#8217;s long-term credit rating with Standard&#160;&amp; Poor&#8217;s is A (stable outlook) and with Moody&#8217;s Investor Services (&#8216;Moody&#8217;s&#8217;) it is A2 (stable outlook). The Group&#8217;s short-term credit ratings are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-1</div> with Standard &amp; Poor&#8217;s and Moody&#8217;s respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s policy is to borrow centrally in order to meet anticipated funding requirements. The strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. Each day, we sweep cash to or from a number of global subsidiaries and central Treasury accounts for liquidity management purposes. GSK utilises both physical and notional cash pool arrangements as appropriate by location and currency. For notional cash pools, liquidity is drawn against foreign currency balances to provide both local funding and central liquidity as required and with balances actively managed and maintained to appropriate levels. As balances in notional pooling arrangements are not settled across currencies, gross cash and overdraft balances are reported. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, GSK had &#163;4&#160;billion of borrowings repayable within one year and held &#163;3.8&#160;billion of cash and cash equivalents and liquid investments of which &#163;3.1&#160;billion was held centrally. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has access to short-term finance under a $10&#160;billion (&#163;8.3 billion) US commercial paper programme; $900&#160;million (&#163;748 million) was in issue at 31&#160;December 2022 (2021: $nil). GSK has access to short-term finance under a &#163;5&#160;billion Euro commercial paper programme; <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>500&#160;million (&#163;443 million) was in issue at 31&#160;December 2022 (2021: <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>300&#160;million (&#163;252 million)). In February 2022 GSK cancelled the &#163;1.9&#160;billion three year and $2.5&#160;billion (&#163;2.1 billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities of September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#163;1.6&#160;billion and $2.2&#160;billion (&#163;1.8 billion) respectively. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These committed facilities were undrawn at 31&#160;December 2022. GSK considers this level of committed facilities to be adequate, given current liquidity requirements. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK has a &#163;20.0 billion Euro Medium Term Note programme and at 31 December 2022, &#163;10.3 billion of notes were in issue under this programme. The Group also had $9.7 billion (&#163;8.1 billion) of notes in issue at 31 December 2022 under a US shelf registration. GSK is currently in the process of renewing its US shelf registration statement in order to maintain access to the US debt markets. GSK&#8217;s borrowings mature at dates between 2023 and 2045. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The put option owned by Pfizer in ViiV Healthcare is exercisable. In reviewing liquidity requirements GSK considers that sufficient financing options are available should the put option be exercised. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating rates over time. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s main interest rate risk arises from borrowings and investments with floating rates and refinancing of maturing fixed rate debt where any changes in interest rates will affect future cash flows or the fair values of financial instruments. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the Board. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#8217;s net interest charge. Short-term borrowings including bank facilities are exposed to the risk of future changes in market interest rates as are the majority of cash and liquid investments. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s objective is to minimise the exposure of overseas operating subsidiaries to transaction risk by matching local currency income with local currency costs where possible. Foreign currency transaction exposures arising on external and internal trade flows are selectively hedged. GSK&#8217;s internal trading transactions are matched centrally and inter-company payment terms are managed to reduce foreign currency risk. Where possible, GSK manages the cash surpluses or borrowing requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating currency. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In order to reduce foreign currency translation exposure, the Group seeks to denominate borrowings in the currencies of our principal assets and cash flows. These are primarily denominated in US Dollars, Euros and Sterling. Borrowings can be swapped into other currencies as required. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated as a hedge against the relevant assets. Forward contracts in major currencies are also used to reduce exposure to the Group&#8217;s investment in overseas assets (see &#8216;Net investment hedges&#8217; section of this note for further details). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Credit risk is the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group and arises on cash and cash equivalents and favourable derivative financial instruments held with banks and financial institutions as well as credit exposures to wholesale and retail customers, including outstanding receivables. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group considers its maximum credit risk at 31&#160;December 2022 to be &#163;10,180&#160;million (31&#160;December 2021: &#163;11,417 million) which is the total of the Group&#8217;s financial assets with the exception of &#8217;Other investments&#8217; (comprising equity investments) which bear equity risk rather than credit risk. See page 249 for details on the Group&#8217;s total financial assets. At 31&#160;December 2022, GSK&#8217;s greatest concentration of credit risk was &#163;1.1&#160;billion with a wholesaler in the US (2021: &#163;0.9&#160;billion with a wholesaler in the US). See page 247 for further information on the Group&#8217;s credit risk exposure in respect of the three largest US wholesaler customers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There has been no change in the estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for financial assets at amortised cost or at FVTOCI since the adoption of IFRS 9 at the start of the 2018 reporting period. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury-related credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK sets global counterparty limits for each of GSK&#8217;s banking and investment counterparties based on long-term credit ratings from Moody&#8217;s and Standard&#160;&amp; Poor&#8217;s. Usage of these limits is actively monitored. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK actively manages its exposure to credit risk, reducing surplus cash balances wherever possible. This is part of GSK&#8217;s strategy to regionalise cash management and to concentrate cash centrally as much as possible. The table below sets out the credit exposure to counterparties by rating for liquid investments, cash and cash equivalents and derivatives. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The gross asset position on each derivative contract is considered for the purpose of this table, although, under ISDA agreements, the amount at risk is the net position with each counterparty. Table (e)&#160;on page 257 sets out the Group&#8217;s financial assets and liabilities on an offset basis. </div>  <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, &#163;60&#160;million (2021: &#163;54 million) of cash is categorised as held with unrated or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-investment</div> grade rated counterparties (lower than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BBB-/Baa3)</div> of which &#163;nil (2021: &#163;7 million) is cash in transit. The remaining exposure is concentrated in overseas banks used for local cash management or investment purposes, including: &#163;23&#160;million in Nigeria held with United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank; &#163;14&#160;million with Halk Bank in the UK; &#163;6&#160;million with Produbanco in Ecuador; &#163;2&#160;million with J Trust Royal Bank in Cambodia; &#163;2&#160;million with Banco Do Brasil in Brazil; &#163;1&#160;million with Banco de Honduras in Honduras; and &#163;1&#160;million with BAC San Jos&#233; in Costa Rica. Of the &#163;49&#160;million of bank balances and deposits held with BBB/Baa rated counterparties, &#163;1.4&#160;million was held with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BBB-/Baa3</div> rated counterparties, including balances or deposits of &#163;1&#160;million with State Bank of India in India. These banks are used for local investment purposes. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK measures expected credit losses over cash and cash equivalents as a function of individual counterparty credit ratings and associated 12&#160;month default rates. Expected credit losses over cash and cash equivalents and third-party financial derivatives are deemed to be immaterial and no such loss has been experienced during 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Credit ratings are assigned by Standard&#160;&amp; Poor&#8217;s and Moody&#8217;s respectively. Where the opinions of the two rating agencies differ, GSK assigns the lower rating of the two to the counterparty. Where local rating agency or Fitch data is the only source available, the ratings are converted to global ratings equivalent to those of Standard&#160;&amp; Poor&#8217;s or Moody&#8217;s using published conversion tables. These credit ratings form the basis of the assessment of the expected credit loss on Treasury-related balances held at amortised cost being bank balances and deposits and Government securities. </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,215</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">146</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,253</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">188</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">188</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,399</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,403</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,978</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,687</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">77</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,825</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">61</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">200</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">200</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,449</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,887</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">78</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,535</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK&#8217;s centrally managed cash reserves amounted to &#163;3.1&#160;billion at 31&#160;December 2022, all available within three months. This includes &#163;2.2&#160;billion of cash managed by the Group for ViiV Healthcare, a 78.3% owned subsidiary. The Group has invested centrally managed liquid assets in bank deposits, Aaa/AAA rated US Treasury and Treasury repo only money market funds and Aaa/AAA rated liquidity funds. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Wholesale and retail credit risk </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Outside the US, no customer accounts for more than 5% of the Group&#8217;s trade receivables balance. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the US, in line with other pharmaceutical companies, the Group sells its products through a small number of wholesalers in addition to hospitals, pharmacies, physicians and other groups. Sales to the three largest wholesalers amounted to approximately 79% (2021: 75%) of the sales of the US Commercial Operations business in 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group had trade receivables due from these three wholesalers totalling &#163;3,001&#160;million or 55% of total trade receivables (2021: &#163;2,430&#160;million or 39%). The Group is exposed to a concentration of credit risk in respect of these wholesalers such that, if one or more of them encounters financial difficulty, it could materially and adversely affect the Group&#8217;s financial results. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This concentration of trade receivables is reflective of standard market practice in the US pharmaceuticals sector where a significant portion of sales are made to these three wholesalers, as disclosed in Note 6. GSK&#8217;s assessment is that there is limited credit risk associated with these customers. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s credit risk monitoring activities relating to these wholesalers include a review of their quarterly financial information and Standard&#160;&amp; Poor&#8217;s credit ratings, development of GSK internal risk ratings, and establishment and periodic review of credit limits. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All new customers are subject to a credit vetting process and existing customers will be subject to a review at least annually. The vetting process and subsequent reviews involve obtaining information including the customer&#8217;s status as a government or private sector entity, audited financial statements, credit bureau reports, debt rating agency (eg Moody&#8217;s, Standard&#160;&amp; Poor&#8217;s) reports, payment performance history (from trade references, industry credit groups) and bank references. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables consist of amounts due from a large number of customers, spread across diverse industries and geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable and, where appropriate, credit insurance is purchased or factoring arrangements put in place. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amount of information obtained is proportional to the level of exposure being considered. The information is evaluated quantitatively (i.e. credit score) and qualitatively (i.e. judgement) in conjunction with the customer&#8217;s credit requirements to determine a credit limit. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables are grouped into customer segments that have similar loss patterns to assess credit risk while other receivables and other financial assets are assessed individually. Historical and forward-looking information is considered to determine the appropriate expected credit loss allowance. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group believes there is no further credit risk provision required in excess of the allowance for expected credit losses (see Note 26, &#8216;Trade and other receivables&#8217;). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit enhancements </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group uses credit enhancements including factoring and credit insurance to minimise the credit risk of the trade receivables in the Group. At 31&#160;December 2022, &#163;332&#160;million (2021: &#163;315 million) of trade receivables were insured in order to protect the receivables from loss due to credit risks such as default, insolvency and bankruptcy. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Each Group entity assesses the credit risk of its private customers to determine if credit insurance is required. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Factoring arrangements are managed locally by entities and are used to mitigate risk arising from large credit risk concentrations. All factoring arrangements are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recourse.</div> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value of financial assets and liabilities excluding lease liabilities </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table on page 249 presents the carrying amounts and the fair values of the Group&#8217;s financial assets and liabilities excluding lease liabilities at 31&#160;December 2022 and 31&#160;December 2021. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair values of the financial assets and liabilities are included at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following methods and assumptions are used to measure the fair values of significant financial instruments carried at fair value on the balance sheet: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Other investments &#8211; equity investments traded in an active market determined by reference to the relevant stock exchange quoted bid price; other equity investments determined by reference to the current market value of similar instruments, recent financing rounds or the discounted cash flows of the underlying net assets </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Trade receivables carried at fair value &#8211; based on invoiced amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Interest rate swaps, foreign exchange forward contracts, swaps and options &#8211; based on the present value of contractual cash flows or option valuation models using market sourced data (exchange rates or interest rates) at the balance sheet date </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Cash and cash equivalents carried at fair value &#8211; based on net asset value of the funds </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Contingent consideration for business acquisitions and divestments &#8211; based on present values of expected future cash flows. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following methods and assumptions are used to estimate the fair values of significant financial instruments which are not measured at fair value on the balance sheet: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Receivables and payables, including put options, carried at amortised cost &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Liquid investments &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Cash and cash equivalents carried at amortised cost &#8211; approximates to the carrying amount </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Long-term loans &#8211; based on quoted market prices (a level 1 fair value measurement) in the case of European and US Medium Term Notes; approximates to the carrying amount in the case of other fixed rate borrowings and floating rate bank loans </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Short-term loans, overdrafts and commercial paper &#8211; approximates to the carrying amount because of the short maturity of these instruments. </div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Notes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Fair <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;<br/> &#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,789</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,789</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,734</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,734</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings excluding obligations under lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bonds in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,322</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,311</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,017</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11,930</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,373</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bank loans and overdrafts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(447</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(447</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; commercial paper in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other borrowings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total borrowings excluding lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">f&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,605</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26,860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(41,442</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(41,068</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45,058</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(48,760</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net financial assets and financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,708</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,334</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31,515</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(35,217</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The valuation methodology used to measure fair value in the above table is described and categorised on page 248. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other receivables, Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets, Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities are reconciled to the relevant Notes on pages 251 to 252. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value of investments in GSK shares </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Employee Share Ownership Plan (ESOP) Trusts held GSK shares with a carrying value of &#163;354&#160;million (2021: &#163;28 million) and a market value of &#163;861&#160;million (2021: &#163;373 million) based on quoted market price. The shares are held by the ESOP Trusts to satisfy future exercises of options and awards under employee incentive schemes. In 2022, the carrying value, which is the lower of cost or expected proceeds, of these shares has been recognised as a deduction from other reserves. At 31&#160;December 2022, GSK held Treasury shares at a cost of &#163;3,797&#160;million (2021: &#163;4,969 million) which has been deducted from retained earnings. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(a) Financial instruments held at fair value </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables categorise the Group&#8217;s financial assets and liabilities held at fair value by the valuation methodology applied in determining their fair value. Where possible, quoted prices in active markets are used (Level 1). Where such prices are not available, the asset or liability is classified as Level&#160;2, provided all significant inputs to the valuation model used are based on observable market data. If one or more of the significant inputs to the valuation model is not based on observable market data, the instrument is classified as Level&#160;3. Other investments classified as Level&#160;3 in the tables below comprise equity investments in unlisted entities with which the Group has entered into research collaborations and investments which provide access to biotechnology developments of potential interest. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,309</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,567</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,533</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(77</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(106</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,251</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,927</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,943</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">199</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">59</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,449</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,202</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">419</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,806</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,076</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(171</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(57</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,304</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Movements in the year for financial instruments measured using Level&#160;3 valuation methods are presented below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,657</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5,064</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses recognised in the income statement</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,627</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,024</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains recognised in other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">185</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration related to business acquisitions in the period</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(482</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlement of contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,137</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">856</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">97</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">99</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and settlements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfers from Level&#160;3</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(694</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,411</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5,657</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Of the total net losses of &#163;1,627&#160;million (2021: &#163;1,024 million) attributable to Level&#160;3 financial instruments which were recognised in the income statement, &#163;1,623&#160;million (2021: &#163;1,024 million) were in respect of financial instruments which were held at the end of the year and were reported in Other operating income/expense. Charges of &#163;1,431&#160;million (2021: &#163;1,026 million) arose from remeasurement of the contingent consideration payable for the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#163;231&#160;million (2021: &#163;32 million) arose from remeasurement of the contingent consideration payable for the acquisition of the Novartis Vaccines business. The acquisition of Affinivax in 2022 resulted in the addition of &#163;482&#160;million of contingent consideration to Level&#160;3 financial liabilities, with a further &#163;17&#160;million remeasurement charge arising for the period between acquisition and 31&#160;December 2022. There were no transfers into or out of Level&#160;3 financial instruments in the year (2021 &#8211; transfers related to equity instruments which transferred to a Level&#160;1 valuation methodology as a result of listing on a recognised stock exchange during the year). Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net gains and losses include the impact of other exchange movements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial liabilities measured using Level&#160;3 valuation methods at 31&#160;December included &#163;5,890&#160;million (2021: &#163;5,559 million) in respect of contingent consideration payable for the acquisition in 2012 of the former Shionogi-ViiV Healthcare joint venture. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products and movements in certain foreign currencies. A further &#163;673&#160;million (2021: &#163;479 million) is in respect of contingent consideration for the acquisition in 2015 of the Novartis Vaccines business. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products, the achievement of certain milestone targets and movements in certain foreign currencies. As a result of the Group&#8217;s acquisition of Affinivax in 2022, contingent consideration payable of &#163;501&#160;million is recognised at 31&#160;December 2022. This consideration is expected to be paid over a number of years and will vary in line with the achievement of certain development milestones and movements in the USD/GBP exchange rate. Sensitivity analysis on these balances is provided in Note 33, &#8216;Contingent consideration liabilities&#8217;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(b) Trade and other receivables and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets in scope of IFRS 9 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table reconciles financial instruments within Trade and other receivables and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial assets are predominantly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> earning. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> instruments include tax receivables, pension surplus balances and prepayments, which are outside the scope of IFRS 9. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables (Note&#160;26)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,166</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">887</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,053</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-current assets (Note&#160;24)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,160</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,632</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,676</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,200</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,047</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,247</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,851</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,876</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,660</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,536</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade and other receivables include trade receivables of &#163;5,452&#160;million (2021: &#163;6,246 million). The Group has portfolios in each of the three business models under IFRS 9: &#163;50&#160;million (2021: &#163;59 million), measured at FVTPL, is held to sell the contractual cash flows as the receivables will be sold under a factoring arrangement, &#163;2,327&#160;million (2021: &#163;1,943 million), measured at FVTOCI, is held to either collect or sell the contractual cash flows as the receivables may be sold under a factoring agreement, and &#163;3,075&#160;million (2021: &#163;4,244 million), measured at amortised cost, is held to collect the contractual cash flows and there is no factoring agreement in place. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(c) Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities in scope of IFRS 9 </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table reconciles financial instruments within Trade and other payables, Other provisions, Contingent consideration liabilities and Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial liabilities are predominantly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> instruments include payments on account, tax and social security payables and provisions which do not arise from contractual obligations to deliver cash or another financial asset, which are outside the scope of IFRS 9. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At&#160;FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-<br/> financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;At&#160;FVTPL</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial<br/> &#160;&#160;instruments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables (Note&#160;29)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,198</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16,263</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions (Note&#160;32)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,121</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,184</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,358</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities (Note&#160;33)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities (Note&#160;34)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(815</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(899</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(869</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(921</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(14,212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,280</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,134</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,414</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15,596</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21,672</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,350</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26,022</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(d) Derivative financial instruments and hedging programmes </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives are only used for economic hedging purposes and not as speculative investments and are classified as &#8216;held for trading&#8217;, other than designated and effective hedging instruments, and are presented as current assets or liabilities if they are expected to be settled within 12 months after the end of the reporting period, otherwise they are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> The Group has the following derivative financial instruments: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Fair&#160;value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Interest rate swap contracts<br/> (principal amount &#8211; &#163;nil (2021: &#163;1,996 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;167&#160;million (2021: &#163;160 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;7,197&#160;million (2021: &#163;5,469 million))</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">111</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts<br/> (principal amount &#8211; &#163;5,908&#160;million (2021: &#163;9,728 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(76</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives classified as held for trading</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total derivative instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">206</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022 and 31&#160;December 2021, the Group had no designated fair value hedges. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net investment hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, certain foreign exchange contracts were designated as net investment hedges in respect of the foreign currency translation risk arising on consolidation of the Group&#8217;s net investment in its European (Euro), Singaporean (SGD), Canadian (CAD) and Japanese (JPY) foreign operations as shown in the table above. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying value of bonds on page 249 included &#163;6,322&#160;million (2021: &#163;4,982 million) that were designated as hedging instruments in net investment hedges. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flow hedges </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2021 and 2022, the Group entered into forward foreign exchange contracts which have been designated as cash flow hedges. These were entered into to hedge the foreign exchange exposure arising on cash flows from Euro denominated coupon payments relating to notes issued under the Group&#8217;s European Medium Term Note programme, and to hedge foreign currency payments due on collaboration or licensing arrangements. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group manages its cash flow interest rate risk by using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">floating-to-fixed</div></div> interest rate swaps. In addition, the Group carries a balance in reserves that arose from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-hedging</div> fluctuations in long-term interest rates when pricing bonds issued in prior years and in the current year. The balance is reclassified to finance costs over the life of these bonds. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In the current year, the Group has designated certain foreign exchange forward contracts and swaps as cash flow and net investment hedges. Foreign exchange derivative financial assets and liabilities are presented in the line &#8216;Derivative financial instruments&#8217; (either as assets or liabilities) on the Consolidated balance sheet. The following tables detail the foreign exchange forward contracts and swaps outstanding at the end of the reporting period, as well as information on the related hedged items. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments to ensure that an economic relationship exists between the hedged item and hedging instrument. The Group enters into hedge relationships where the critical terms of the hedging instrument match exactly with the terms of the hedged item, and so a qualitative assessment of effectiveness is performed. If changes in circumstances affect the terms of the hedged item such that the critical terms no longer match exactly with the critical terms of the hedging instrument, the Group uses the hypothetical derivative method to assess effectiveness. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The main source of hedge ineffectiveness in these hedging relationships is the effect of the counterparty and the Group&#8217;s own credit risk on the fair value of the foreign exchange forward contracts and swaps, which is not reflected in the fair value of the hedged item attributable to changes in foreign exchange rates and ineffectiveness on rolling the cash flow hedges of the divestments mentioned above. No other sources of ineffectiveness emerged from these hedging relationships. No ineffectiveness was recorded from cash flow hedges in 2022 (2021: &#163;nil). No ineffectiveness was recorded from net investment hedges (2021: &#163;nil). </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:89%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> currency</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.23</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">USD</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.16</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.14</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">167</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic<br/> change in<br/> value for<br/> calculating<br/> hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">JPY</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">CAD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SGD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,341</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,322</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(300</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,981</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,851</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(617</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for calculating hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow hedge reserve/foreign<br/> currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Balance&#160;in&#160;cash&#160;flow&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve&#160;arising&#160;from&#160;hedging&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">relationships&#160;for&#160;which&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">accounting is no longer&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">applied&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from a highly probable forecast transaction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">617</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,120</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for<br/> calculating</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">USD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">578&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SGD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">JPY</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,998</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,982</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">459&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,719</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,176</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,118&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for&#160;calculating&#160;hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow&#160;hedge&#160;reserve/foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on<br/> Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#163;3&#160;million (2021: &#163;19 million) of balances in the ca<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>h flow hedge reserve arise from hedging relationships for which hedge accounting is no longer applied. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line&#160;item&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">Finance income or expense</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><span style="-sec-ix-hidden:hidden69050893">Intangible</span></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets&#160;</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">4</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(2</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(617</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">194</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="-sec-ix-hidden:hidden69049975">Discontinued</span></div><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;">operations<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit&#160;or&#160;loss<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Line item in&#160;<br/> profit or loss&#160;<br/> in&#160;which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049915">Other </span>operating income/ (expense)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">Other operating income/ (expense)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(1</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">1,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassified to the Consolidated income statement on demerger of the Consumer Healthcare business </div></div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group manages its cash flow interest rate risk by using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">floating-to-fixed</div></div> interest rate swaps, where at quarterly intervals the difference between fixed contract rates and floating rate interest amounts calculated by reference to the agreed notional principal amounts are exchanged. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are none of these swaps outstanding a<div style="display:inline;">t</div> 31&#160;December 2022. At 31&#160;December 2021, the interest rate risk on an element of future debt issuance had been managed by entering into forward starting interest rate swaps, effectively to lock in the interest rates on the debt in advance. These were closed out at the time of issuing the debt, and the resulting gain or loss held in the Cash flow hedge reserve and reclassified to income statement as the interest payments on the debt impacted the income statement until the debt was derecognised on demerger of the Consumer Healthcare business in July 2022. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Forward starting interest rate swaps </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The forward starting interest rate contracts, exchanging floating interest for fixed interest, <div style="display:inline;">were</div> designated as cash flow hedges to hedge the interest variability of the interest cash flows associated with the future fixed rate debt. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate swaps </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables provide information regarding interest rate swap and forward starting interest rate swap contracts outstanding and the related hedged items at 31&#160;December 2021. There were no such swaps at 31&#160;December 2022. Interest rate swap contract assets and liabilities are presented in the line &#8216;Derivative financial instruments&#8217; (either as assets or liabilities) on the Consolidated balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">&#163;24&#160;million (2021: &#163;11 million) of balances in the cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fair value for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Average</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">recognising</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Fair value&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">contracted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">principal</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">assets/&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fixed rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(liabilities)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.1038</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">668</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.3385</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">935</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 30 years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.4515</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">393</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;in</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">cash flow</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value used for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge&#160;reserve</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">calculating</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">for continuing</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedges</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">after tax</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rate</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future<br/> cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer<br/> expected to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item<br/> affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049944">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049945">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)<br/> recognised&#160;in<br/> reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness<br/> is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expected to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049946">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049947">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income&#160;or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049948">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049949">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">4</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">3</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&gt;30 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(e) Offsetting of financial assets and liabilities </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial assets and liabilities are offset and the net amount reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. There are also arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be offset in certain circumstances, such as bankruptcy or the termination of a contract. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables set out the financial assets and liabilities that are offset, or subject to enforceable master netting arrangements and other similar agreements but not offset, as at 31&#160;December 2022 and 31&#160;December 2021. The column &#8216;Net amount&#8217; shows the impact on the Group&#8217;s balance sheet if all offset rights were exercised. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross<br/> financial<br/> assets/<br/> (liabilities)<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross<br/> financial<br/> (liabilities)/<br/> assets&#160;set&#160;off</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Net&#160;financial<br/> assets/<br/> (liabilities)&#160;per</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">balance&#160;sheet</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related<br/> amounts&#160;not<br/> set off in the<br/> balance&#160;sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,166</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net&#160;financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">amounts&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">balance</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,832</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">206</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">206</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(192</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,450</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,431</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(228</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">192</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amounts which do not meet the criteria for offsetting on the balance sheet but could be settled net in certain circumstances principally relate to derivative transactions under ISDA (International Swaps and Derivatives Association) agreements where each party has the option to settle amounts on a net basis in the event of default of the other party. As there is presently not a legally enforceable right of offset, these amounts have not been offset in the balance sheet, but have been presented separately in the table above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(f) Debt interest rate repricing table </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as all classes of borrowings other than lease liabilities. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating and fixed rate debt less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,785</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,398</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,714</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,490</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,576</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,505</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,425</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,411</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,001</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,953</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Original issuance profile:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fixed rate interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,355</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating rate interest</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,624</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(803</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(g) Sensitivity analysis </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tables below illustrate the estimated impact on the income statement and equity as a result of hypothetical market movements in foreign exchange and interest rates in relation to the Group&#8217;s financial instruments. The range of variables chosen for the sensitivity analysis reflects management&#8217;s view of changes which are reasonably possible over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange sensitivity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group operates internationally and is primarily exposed to foreign exchange risk in relation to Sterling against movements in US&#160;Dollar, Euro and Japanese Yen. Foreign exchange risk arises from the translation of financial assets and liabilities which are not in the functional currency of the entity that holds them. Based on the Group&#8217;s net financial assets and liabilities as at 31&#160;December, a weakening and strengthening of Sterling against these currencies, with all other variables held constant, is illustrated in the tables below. The tables exclude financial instruments that expose the Group to foreign exchange risk where this risk is fully hedged with another financial instrument. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">99</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">155</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(121</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The equity impact, shown below, for foreign exchange sensitivity relates to derivative and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial instruments hedging the Group&#8217;s net investments in its European (Euro) foreign operations and cash flow hedges of its foreign exchange exposure arising on Euro denominated coupon payments relating to notes issued under the Group&#8217;s European Medium Term Note programme. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,290</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(964</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation in Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,034</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,515</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,080</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">814&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,557</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,176&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tables below present the Group&#8217;s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the composition of net debt as shown in Note 30 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect future foreign currency cash flows. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(999</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(767</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,570</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,199</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">444</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">698</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">846</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">661</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,222</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">959</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(375</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(542</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate sensitivity </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is exposed to interest rate risk on its outstanding borrowings and investments where any changes in interest rates will affect future cash flows or the fair values of financial instruments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#8217;s net interest charge, although the majority of cash and liquid investments earn floating rates of interest. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below hypothetically shows the Group&#8217;s sensitivity to changes in interest rates in relation to Sterling, US Dollar and Euro floating rate financial assets and liabilities. A 1% (100 basis points) movement in USD interest rates would cause an increase of &#163;nil to equity (2021: &#163;197 million). A 1.5% (150 basis points) movement in USD interest rates would cause an increase of &#163;nil to equity (2021: &#163;297 million). A 1% (100 basis points) or 1.5% (150 basis points) movement in EUR or Sterling interest rates is not deemed to have a material effect on equity. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of interest rate movements</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(34</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(51</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Euro interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Euro interest rates</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(h) Contractual cash flows for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial liabilities and derivative instruments </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following tables provide an analysis of the anticipated contractual cash flows including interest payable for the Group&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivative</div> financial liabilities on an undiscounted basis. For the purpose of this table, debt is defined as all classes of borrowings except for lease liabilities. Interest is calculated based on debt held at 31&#160;December without taking account of future issuance. Floating rate interest is estimated using the prevailing interest rate at the balance sheet date. Cash flows in foreign currencies are translated using spot rates at 31 December. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in net debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,786</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(594</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,362</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(19,934</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(570</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,097</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,607</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(531</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,034</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,207</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(489</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,386</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(472</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(2,324</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,765</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,810</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,641</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(9,458</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,063</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,134</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(9,199</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,086</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,322</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,008</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(146</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,553</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(51,115</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and&#160;other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities not<br/> in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,399</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,432</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,745</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,042</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(620</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,804</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(120</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,188</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,938</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(924</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,939</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,440</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,046</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,703</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,438</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,033</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,639</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,571</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11,392</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,296</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,603</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,015</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(153</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(24,377</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56,444</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below provides an analysis of the anticipated contractual cash flows for the Group&#8217;s derivative instruments excluding equity options which do not give rise to cash flows, and other embedded derivatives, which are not material, using undiscounted cash flows. Cash flows in foreign currencies are translated using spot rates at 31 December. The gross cash flows of foreign exchange contracts are presented for the purpose of this table although, in practice, the Group uses standard settlement arrangements to reduce its liquidity requirements on these instruments. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:38%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash inflows</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash outflows&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash inflows</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash outflows&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> &#160;&#160;&#160;&#160;exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&#160;<br/> &#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign<br/> exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward&#160;<br/> starting&#160;<br/> &#160;&#160;&#160;&#160;interest&#160;rate&#160;<br/> swaps&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign&#160;<br/> &#160;&#160;&#160;&#160;exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> and&#160;swaps&#160;<br/> &#163;m&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,418</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24,410)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(13)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(41,290)</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">259</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(220)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,418</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24,410)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">351</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41,252</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(337)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(41,290)</td></tr></table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee share schemes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Employee share schemes</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45. Employee share schemes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK operates several employee share schemes, including the Share Value Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost after a three-year vesting period and the Performance Share Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost, subject to the achievement by the Group of specified performance targets. The granting of these restricted share awards has replaced the granting of options to employees as the cost of the schemes more readily equates to the potential gain to be made by the employee. The Group also operates savings related share option schemes, whereby options are granted to employees to acquire shares in GSK plc at a discounted price. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Grants of restricted share awards are normally exercisable at the end of the three-year vesting or performance period. Awards are normally granted to employees to acquire shares or ADS in GSK plc but in some circumstances may be settled in cash. Grants under savings-related share option schemes are normally exercisable after three years&#8217; saving. In accordance with UK practice, the majority of options under the savings-related share option schemes are granted at a price 20% below the market price ruling at the date of grant. Options under historical share option schemes were granted at the market price ruling at the date of grant. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The value of the plans for participating employees has been maintained after the demerger of the Consumer Healthcare business through the effect of the share consolidation (see Note 37). The total charge for share-based incentive plans in 2022 was &#163;314&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;345&#160;million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;330 million). Of this amount, &#163;243&#160;million (2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;258million; 2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px">(1)</div>: &#163;266 million) arose from the Share Value Plan. See Note 9, &#8216;Employee Costs&#8217; for further details. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated to reflect on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business. See Note&#160;41. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK share award schemes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share Value Plan </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the Share Value Plan, share awards are granted to certain employees at no cost. The awards vest after two and a half to three years and there are no performance criteria attached. The fair value of these awards is determined based on the closing share price on the day of grant, after deducting the expected future dividend yield of 3.2% (2021: 3.8%; 2020: 5.0%) over the duration of the award. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares and ADS issuable</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shares<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ADS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$34.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,284</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,353</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,416</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,014</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$36.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,074</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,776</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,705</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$30.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,718</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,314</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27,975</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15,429</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated to reflect the demerger of the Consumer Healthcare business and aid year on year volume comparability of awards granted to GSK employees. </div></td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance Share Plan </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Under the Performance Share Plan, share awards are granted to Directors and senior executives at no cost. The percentage of each award that vests is based upon the performance of the Group over a defined measurement period with dividends reinvested during the same period. For awards granted from 2016 to 2019, the performance conditions are based on three equally weighted measures over a three-year performance period. These were adjusted free cash flow, TSR and R&amp;D new product performance. For awards granted from 2020, the performance conditions are based on four measures over a three-year performance period. These are adjusted free cash flow (30%), TSR (30%), R&amp;D new product performance (20%) and pipeline progress (20%). For awards granted from 2022, the performance conditions are based on five measures over a three-year performance period. These are TSR (<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div>%), pipeline progress (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%), profit measure (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%), sale measure (<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>%) and ESG environment (<div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>%). </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of the awards is determined based on the closing share price on the day of grant. For TSR performance elements, this is adjusted by the likelihood of that condition being met, as assessed at the time of grant. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">During 2022, awards for the continuing business were made of 4.0&#160;million shares at a weighted fair value of &#163;13.36 and 1.0&#160;million ADS at a weighted fair value of $35.88. At 31&#160;December 2022, there were outstanding awards over 12.6&#160;million shares and 2.8&#160;million ADS. <br/></div> <div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/> <div style="position:relative;float:left; margin-left:3%;width: 6%;padding-right:0%;padding-bottom: 8pt;overflow:visible;padding-top: 14pt;"><div style="margin-top:0pt;margin-bottom:0pt;text-align:right">
<img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/><br/></div></div><div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div/><div style="clear:both;max-height:0pt;"/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0">
<tr style="font-size: 0px;">
<td style="width:100%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Annual Report 2022</div></div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45. Employee share schemes </div></div>continued<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share options and savings-related options </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For the purposes of valuing savings-related options to arrive at the share-based payment charge, a Black-Scholes option pricing model has been used. The assumptions used in the model are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;Grant</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.37%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.74%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.07)%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.3%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.8%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.2%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected life</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Savings-related options grant price (including 20% discount)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;11.39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;12.07</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;10.34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom: 0.375pt; vertical-align: bottom;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding for the Share Save Plan</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Savings-related</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">share option schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/> 000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Weighted<br/> exercise<br/> price</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,803&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;11.38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Range of exercise prices on options outstanding at year end</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;10.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;&#160;&#160;&#160;&#163;14.15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average market price on exercise during year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;16.15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average remaining contractual life</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.0&#160;years</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Options over 1.2&#160;million shares were granted during the year under the savings-related share option scheme at a weighted average fair value of &#163;4.34. At 31&#160;December 2022, 5.3&#160;million of the savings-related share options were not exercisable. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There has been no change in the effective exercise price of any outstanding options during the year. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Share Ownership Plan Trusts </div></div></div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group sponsors Employee Share Ownership Plan (ESOP) Trusts to acquire and hold shares in GSK plc to satisfy awards made under employee incentive plans and options granted under employee share option schemes. The trustees of the ESOP Trusts purchase shares with finance provided by the Group by way of loans or contributions. The costs of running the ESOP Trusts are charged to the income statement. Shares held by the ESOP Trusts are deducted from other reserves and amortised down to the value of proceeds, if any, receivable from employees on exercise by a transfer to retained earnings. The trustees have waived their rights to dividends on the shares held by the ESOP Trusts. </div><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share award schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">59,814</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23,065</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">860</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">371</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share option schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428679328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory', window );">Principal Group companies</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color:#f36f21;display:inline;"><div style="font-weight:bold;display:inline;">46. Principal Group companies </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following represent the principal subsidiaries and their countries of incorporation of the Group at 31&#160;December 2022. The equity share capital of these entities is shown in the percentage columns. All companies are incorporated in their principal country of operation except where stated. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">England</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Group Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Operations UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Wellcome UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Capital plc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Export Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Finance plc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Holdings Limited<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline IHC Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.2) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.3) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.4) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property Development Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Research &amp; Development Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Services Unlimited<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline US Trading Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Setfirst Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">SmithKline Beecham Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare Finance Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare UK (No.3) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Viiv Healthcare UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scotland</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.1) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.2) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.3) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(d) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corixa Corporation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Capital Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Holdings (Americas) Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Equity Investments, Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Human Genome Sciences, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Stiefel Laboratories, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tesaro, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"/><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline AG (Switzerland)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline B.V. (Netherlands)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Biologicals SA (Belgium)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline GmbH &amp; Co. KG (Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Pharma GmbH (Austria)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Pharmaceuticals SA (Belgium)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline S.A. (Spain)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline S.p.A. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Single Member A.E.B.E. (Greece)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Trading Services Limited (Republic of Ireland)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Capital B.V. (Netherlands)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Services Sp z o.o. (Poland)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Vaccines GmbH (Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Vaccines S.r.l. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">JSC GlaxoSmithKline Trading (Russia)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">Laboratoire GlaxoSmithKline (France)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">Laboratorios ViiV Healthcare, S.L. (Spain)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="display:inline;">ViiV Healthcare GmbH </div>(Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">ViiV Healthcare S.r.l. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">ViiV Healthcare SAS (France)</div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78.3 <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Others</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Saudi Arabia Limited (Saudi Arabia)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Wellcome Manufacturing Pte Ltd (Singapore)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline (Thailand) Limited (Thailand)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Australia Pty Ltd (Australia)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Brasil Limitada (Brazil)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Far East B.V. (Taiwan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. (Turkey)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Inc. (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline K.K. (Japan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Korea Limited (Republic of Korea)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Limited (Hong Kong)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Mexico S.A. de C.V. (Mexico)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Pakistan Limited (Pakistan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Pharmaceuticals Limited (India)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Enterprise Management Co, Ltd (China)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Pharma Vietnam Company Limited (Vietnam)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ID Biomedical Corporation of Quebec (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare K.K (Japan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare ULC (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"/><div style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Directly held wholly-owned subsidiary of GSK plc. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Tax resident in UK. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP <div style="display:inline;">1</div> Limited&#8217;s share capital is <div style="display:inline;">99</div>% indirectly owned by GSK plc and <div style="display:inline;">1</div>% owned by Berkeley Square Pension Trustee Company Limited. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#8217;s share capital is <div style="display:inline;">100</div>% indirectly owned by GSK plc. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The subsidiaries and associates listed above principally affect the figures in the Group&#8217;s financial statements. Each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Captial BV and GlaxoSmithKline LLC, is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Capital BV and GlaxoSmithKline LLC. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">See pages 307 to 314 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfPrincipalGroupCompaniesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Principal Group Companies Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfPrincipalGroupCompaniesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428824960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfLegalProceedingsExplanatory', window );">Legal proceedings</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47. Legal proceedings </div></div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in significant legal and administrative proceedings, principally product liability, intellectual property, tax, anti-trust, consumer fraud and governmental investigations. The most significant of these matters, other than tax matters, are described below. The Group makes provision for these proceedings on a regular basis as summarised in Note 2, &#8216;Accounting principles and policies&#8217; and Note 32, &#8216;Other provisions&#8217;. Note 2 also describes when disclosure is made of proceedings for which there is no provision. Legal expenses incurred and provisions related to legal claims are charged to selling, general and administration costs. The Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">At 31&#160;December 2022, the Group&#8217;s aggregate provision for legal and other disputes (not including tax matters described in Note 14, &#8216;Taxation&#8217;) was &#163;218&#160;million. There can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#8217;s financial statements. If this were to happen, it could have a material adverse impact on the results of operations of the Group in the reporting period in which the judgements are incurred or the settlements entered into. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intellectual property </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Intellectual property claims include challenges to the validity and enforceability of the Group&#8217;s patents on various products or processes as well as assertions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement</div> of those patents. A loss in any of these cases could result in loss of patent protection for the product at issue. The consequences of any such loss could be a significant decrease in sales of that product and could materially affect future results of operations for the Group. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coreg </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2014, GSK initiated suit against Teva for inducing infringement of its patent relating to the use of carvedilol (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coreg</div></div>) in decreasing mortality caused by congestive heart failure. In June 2017, the case proceeded to a jury trial in the US District Court for the District of Delaware. The jury returned a verdict in GSK&#8217;s favour, awarding GSK lost profits and reasonable royalties for a total award of $235.51&#160;million. On 29&#160;March 2018, the trial judge ruled on post-trial motions filed by Teva and found that substantial evidence at trial did not support the jury&#8217;s finding of induced infringement, overturning the jury award. GSK appealed, and on 2&#160;October 2020, a divided panel of the Court of Appeals for the Federal Circuit reversed the district court&#8217;s ruling and reinstated the jury award in GSK&#8217;s favour. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 2&#160;December 2020, Teva filed a petition for rehearing en banc. The court granted Teva&#8217;s petition, but only for a rehearing by the three-member panel that issued the original decision. On 5&#160;August 2021, the original panel issued its rehearing opinion where the majority again reinstated the jury&#8217;s damages award of $235.51&#160;million in GSK&#8217;s favour. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Teva again filed a petition for rehearing en banc which was rejected by the Court of Appeals for the Federal Circuit on 11&#160;February 2022. On 11&#160;July 2022, Teva filed a petition for writ of certiorari with the Supreme Court of the United States seeking to overturn the Federal Court decision. On 3&#160;October 2022, the Supreme Court invited the United States Solicitor General to file briefs expressing the views of the United States. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dolutegravir Proceedings </div></div></div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Tivicay/Triumeq </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In September 2021, ViiV Healthcare received a paragraph IV letter from Lupin relating to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tivicay</div></div> 5mg dosage for oral suspension, challenging only the crystal form patent. On 2&#160;November 2021, ViiV Healthcare filed suit against Lupin in the US District Court for the District of Delaware. No trial date has yet been set. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Dovato </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In September 2019, ViiV Healthcare received a paragraph IV letter from Cipla relating to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dovato</div></div> and challenging only the crystal form patent. On 4&#160;November 2019, ViiV Healthcare filed suit against Cipla in the US District Court for the District of Delaware. A settlement has been reached in the case. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8211; Juluca </div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In January 2020, ViiV Healthcare received a paragraph IV letter from Lupin relating to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div> and challenging the crystal form patent as well as a patent relating to the combination of dolutegravir and rilpivirine that expires on 24&#160;January 2031. On 28&#160;February 2020, ViiV Healthcare filed suit against Lupin on both patents. A settlement has been reached with Lupin. Additionally, on 12&#160;June 2020, Cipla sent ViiV Healthcare a paragraph IV letter related to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Juluca</div></div>, and on 22&#160;July 2020, ViiV Healthcare filed suit against Cipla in federal court in Delaware. The court has not set a trial date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product liability </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is currently a defendant in a number of product liability lawsuits. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Avandia </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There are two pending US class actions brought by third-party payers which assert claims under the Racketeer Influenced and Corrupt Organizations Act (RICO) and state consumer protection laws. In December 2019, the Third Circuit Court of Appeals reversed the summary judgements granted in favour of the Group and remanded the third-party payer cases back to district court. Discovery is underway in the district court but no trial dates have yet been set. It is possible that a class certification hearing will be held in 2023. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2019, the Group was contacted by several regulatory authorities regarding the detection of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-Nitroso-dimethylamine</div> (NDMA) in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> (ranitidine) products. Based on information available at the time and correspondence with regulators, the Group made the decision to suspend the release, distribution and supply of all dose forms of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> to all markets pending the outcome of the ongoing tests and investigations. Also, as a precautionary action, the Group made the decision to initiate a voluntary pharmacy/retail level recall of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> products globally. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 30&#160;April 2020, the European Medicines Agency (EMA) recommended the suspension of ranitidine medicines. Following the publication of the EMA&#8217;s recommendation, the Company communicated a decision not to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-enter</div> the market. In the US, FDA requested that all manufacturers withdraw ranitidine products from the market. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has been named as a defendant in approximately 4,500 personal injury cases in US state courts and the federal Zantac Multidistrict Litigation (MDL)&#160;court proceeding in the Southern District of Florida. There are approximately 84,000 plaintiffs named in these cases. A significant majority of these plaintiffs were named in a series of multi-plaintiff complaints filed in Delaware state court and most of these plaintiffs were previously in the MDL Census Registry. They were removed because they allege a cancer other than the 5 cancers being pursued by the MDL plaintiffs. In the MDL, plaintiffs originally identified 10 different types of cancers they wished to pursue. Plaintiffs subsequently dropped 5 of the 10 cancers, and proceeded only as to bladder, esophageal, gastric, liver, and pancreatic cancers, although plaintiffs in state courts continue to pursue claims beyond the 5 designated cancers. There are 46,697 unfiled claims relating to the Group and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendants</div> (32,970 mapped to the Group) concerning the 5 designated cancers in the MDL Census Registry. There are also over 2,000 California state court cases subject to an agreement between the Group and the plaintiffs which suspends the statute of limitations to allow the plaintiffs to bring their claims at a later date. These filed and unfiled counts are subject to change. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 6&#160;December 2022, the court presiding over the federal MDL proceeding granted Defendants&#8217; Daubert motions, finding that Plaintiffs&#8217; experts&#8217; causation opinions regarding whether <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> can cause the five cancers at issue in the MDL (liver, bladder, pancreatic, esophageal, and stomach) are unreliable and thus inadmissible. Without expert causation opinions, the MDL Court granted summary judgment to GSK and the other brand defendants. The MDL Court found that &#8220;there is no scientist outside this litigation who concluded ranitidine causes cancer, and the plaintiffs&#8217; scientists within this litigation systemically utilized unreliable methodologies,&#8221; and failed to use &#8220;consistent, objective, science-based standards for the even-handed evaluation of data.&#8221; This ruling effectively dismissed approximately 2,200 filed cases in the MDL and is binding on all of the claims in the Census Registry. Plaintiffs have indicated they will appeal the MDL decision. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the California <div style="font-style:italic;display:inline;">Zantac</div> litigation Cases JCCP 5150 (JCCP), the Court held a Sargon hearing regarding the admissibility of expert witness testimony, including the testimony of general and specific causation expert witnesses, for the first bellwether trial. The hearing occurred over a four-day period in February and March 2023. The first bellwether trial, which is a bladder cancer case, was expected to start on 27 February 2023 in the California JCCP, however the Court has moved the trial date to 24 July 2023. Three other California bellwether trials have been scheduled for May, August and October 2023, although these dates are likely to be extended as well.</div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Illinois Supreme Court recently consolidated all Illinois ranitidine cases in Cook County for pretrial proceedings with trial dates to be set at a later date, including the previously scheduled Madison County trial. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Beyond the personal injury actions, class actions alleging economic injury and a third-party payer class action also have been filed in federal court. Plaintiffs have moved to stay the class actions pending appeal of the Daubert ruling. Defendants oppose the request for stay and are asking the Court to dismiss the class actions. Outside the US, there are seven class actions pending against the Group in Canada, along with a class action in Israel. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">Given the complex ownership and marketing of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> prescription and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (OTC) medicine over many years, numerous claims involve several defendants. As a result, some defendants have served one another, including the Group, with notice of potential indemnification claims about possible liabilities connected particularly with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div> OTC. Given the early stage of the proceedings, the Group cannot meaningfully assess what liability, if any, it may have, nor can it meaningfully assess the liability of other parties under relevant indemnification provisions. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">In addition, on 20&#160;March 2020, the Department of Justice (DOJ) sent the Group notice of a civil investigation it had opened into allegations of False Claims Act violations by the Group related to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zantac</div></div>. On 18&#160;June 2020, the DOJ served a Civil Investigative Demand on the Group, formalizing its request for documents. On the same day, the New Mexico Attorney General filed a lawsuit against multiple defendants, including the Group, alleging violations of state consumer protection and false advertising statutes, among other claims. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL;text-indent: 0px;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran </div></div></div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group was a defendant in over 400 product liability cases involving <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> pending in a Multidistrict Litigation (MDL)&#160;proceeding in the District of Massachusetts. The cases alleged that children suffered birth defects due to their mothers&#8217; ingestion of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> and/or generic ondansetron for pregnancy- related nausea and vomiting. Plaintiffs asserted that the Group sold <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> knowing it was unsafe for pregnant women, failed to warn of the risks and illegally marketed <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label&#8221;</div> for use by pregnant women. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;June 2021, the MDL Court granted the Group&#8217;s motion for summary judgment on federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-emption</div> grounds. The Court found that the FDA was fully informed of all relevant safety information regarding <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zofran</div></div> and had repeatedly rejected any attempt to add a birth defect warning to the label. At that time, the Court granted judgment for the Group in all cases pending in the MDL (approximately 431 cases) and closed the MDL proceeding. Plaintiffs appealed this decision and, on 9&#160;January 2023, the United States Court of Appeals for the First Circuit affirmed the district court&#8217;s decision in favour of the Group. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There remains one state court case and four proposed class actions in Canada. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales and marketing and regulation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s marketing and promotion of its Pharmaceutical and Vaccine products are the subject of certain governmental investigations and private lawsuits brought by litigants under various theories of law. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GSK Korea &#8211; Proceedings under Fair Trade Laws </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In August 2020, GSK Korea was indicted under Korea&#8217;s Monopoly Regulation and Fair Trade laws in relation to government tenders of HPV (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cervarix</div></div>) and PCV (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synflorix</div></div>) vaccines in 2018 and 2019. The prosecutor alleged that GSK Korea, through the actions of at least one of its employees, interfered with the tender process under the National Immunisation Programme by using &#8220;straw bidders.&#8221; </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A former GSK Korea employee was also charged in his individual capacity by the prosecutor in relation to the same matter. Further, a number of wholesalers are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendants</div> in the proceedings. On 1&#160;February 2023, the court rendered a guilty verdict in respect of all defendants. GSK Korea was fined KRW 70&#160;million which is approximately &#163;45,000. Appeal proceedings are ongoing. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Korea Fair Trade Commission also has commenced proceedings regarding the same matter. GSK Korea is cooperating with the authorities on these matters. </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-trust/competition </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Certain governmental actions and private lawsuits have been brought against the Group alleging violation of competition or anti-trust laws. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal </div></div></div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Purported classes of direct purchasers filed suit in the US District Court for the District of New Jersey alleging that the Group and Teva Pharmaceuticals unlawfully conspired to delay generic competition for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lamictal</div></div>, resulting in overcharges to the purchasers, by entering into an allegedly anti-competitive reverse payment settlement to resolve patent infringement litigation. A separate count accuses the Group of monopolising the market. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 13&#160;December 2018, the trial judge granted plaintiffs&#8217; class certification motion, certifying a class of direct purchasers. The Group filed a Rule 23(f) motion in the Court of Appeals for the Third Circuit, challenging the class certification decision. On 22&#160;April 2020, the Court of Appeals vacated the lower court&#8217;s grant of class certification and remanded the issue back to the lower court for further analysis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 9&#160;October 2020, the district court heard argument on plaintiffs&#8217; renewed motion for class certification after remand. On 9&#160;April 2021, the district court denied Plaintiffs&#8217; motion for class certification of the putative direct purchaser class, leaving a potential class of brand-only purchasers. Plaintiffs moved to supplement their expert report and seek additional discovery to support the addition of certain generic purchasers. On 21&#160;January 2022, the district court denied Plaintiffs&#8217; motion to supplement their expert report and seek additional discovery and held that the issue of generic purchasers had already been decided and denied in the court&#8217;s ruling on decertification. The parties have conducted briefing on class certification as to the remaining brand-only purchasers, with plaintiffs also seeking to add a smaller category of purchasers. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On 1&#160;February 2023, the district court denied Plaintiffs&#8217; renewed class certification motion. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> complaint was filed in the US District Court for the Eastern District of Pennsylvania on 2&#160;February 2023 by a group of alleged purchasers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial and corporate </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group is involved in certain contractual and/or commercial disputes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Royalty Dispute </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In October 2012, Tesaro, Inc. (now a wholly owned subsidiary of GSK) entered into two worldwide patent license agreements with AstraZeneca UK Limited related to niraparib (later approved as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zejula</div></div>). In May 2021, AstraZeneca filed a lawsuit against Tesaro in the High Court, England and Wales alleging that Tesaro failed to pay some of the royalties due under the license agreements. Tesaro has counterclaimed based on a calculated overpayment. A trial is scheduled for March 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfLegalProceedingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfLegalProceedingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428824144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post balance sheet events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Post balance sheet events</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48. Post balance sheet events </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">There is no material post balance sheet event that requires an adjustment or a disclosure within the financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366342272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles and policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingStandardsApplied', window );">Parent company financial statements</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent company financial statements </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of the parent company, GSK plc, have been prepared in accordance with UK&#160;GAAP and with UK accounting presentation. The company balance sheet is presented on page 268 and the accounting policies are given on pages 269 to 272. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consolidated financial statements include: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the assets and liabilities, and the results and cash flows, of the company and its subsidiaries, including ESOP Trusts </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of the results and net assets of associates and joint ventures </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">&#8211;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;">the Group&#8217;s share of assets, liabilities, revenue and expenses of joint operations. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The financial statements of entities consolidated are made up to 31&#160;December each year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Entities over which the Group has the power to direct the relevant activities so as to affect the returns to the Group, generally through control over the financial and operating policies, are accounted for as subsidiaries. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the Group has the ability to exercise joint control over, and rights to, the net assets of entities, the entities are accounted for as joint ventures. Where the Group has the ability to exercise joint control over an arrangement, but has rights to specified assets and obligations for specified liabilities of the arrangement, the arrangement is accounted for as a joint operation. Where the Group has the ability to exercise significant influence over entities, they are accounted for as associates. The results and assets and liabilities of associates and joint ventures are incorporated into the consolidated financial statements using the equity method of accounting. The assets, liabilities, revenue and expenses of joint operations are included in the consolidated financial statements in accordance with the Group&#8217;s rights and obligations. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Interests acquired in entities are consolidated from the date the Group acquires control and interests sold are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date control ceases. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Transactions and balances between subsidiaries are eliminated and no profit before tax is taken on sales between subsidiaries until the products are sold to customers outside the Group. The relevant proportion of profits on transactions with joint ventures, joint operations and associates is also deferred until the products are sold to third parties. Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests are recorded directly in equity. Deferred tax relief on unrealised intra-Group profit is accounted for only to the extent that it is considered recoverable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Business combinations</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business combinations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognised in the income statement. Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition date is reported within operating cash flows. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the consideration transferred, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in the period in which they are incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is capitalised as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and associates. Goodwill is denominated in the currency of the operation acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognised directly in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where not all of the equity of a subsidiary is acquired the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest is recognised either at fair value or at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of the net assets of the subsidiary, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis. Changes in the Group&#8217;s ownership percentage of subsidiaries are accounted for within equity. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign currency translation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Foreign currency transactions are booked in the functional currency of the Group company at the exchange rate ruling on the date of transaction. Foreign currency monetary assets and liabilities are retranslated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On consolidation, assets and liabilities, including related goodwill, of overseas subsidiaries, associates and joint ventures, are translated into Sterling at rates of exchange ruling at the balance sheet date. The results and cash flows of overseas subsidiaries, associates and joint ventures are translated into Sterling using average rates of exchange. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Exchange adjustments arising when the opening net assets and the profits for the year retained by overseas subsidiaries, associates and joint ventures are translated into Sterling, less exchange differences arising on related foreign currency borrowings which hedge the Group&#8217;s net investment in these operations, are taken to a separate component of equity within Retained Earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When translating into Sterling the assets, liabilities, results and cash flows of overseas subsidiaries, associates and joint ventures which are reported in currencies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hyper-inflationary</div> economies, adjustments are made where material to reflect current price levels. Any loss on net monetary assets is charged to the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Turnover </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that GSK enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, vaccine and (prior to the demerger of the Consumer Healthcare business) consumer healthcare products. The average duration of a sales order is less than 12 months. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue is recognised when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Estimates associated with returns and rebates are revisited at each reporting date or when they are resolved and revenue is adjusted accordingly. Please refer to Note 3 for the details on rebates, discounts and allowances. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has entered into collaborative agreements, typically with other pharmaceutical or biotechnology companies to develop, produce and market drug candidates and vaccines that do not qualify as joint arrangements. When GSK has control over the commercialisation activities, the Group recognises turnover and cost of sales on a gross basis. Profit sharing amounts and royalties due to the counterparty are recorded within cost of sales. Cost of sales includes profit sharing costs and royalties due to the counterparty of &#163;1,635&#160;million (2021: &#163;640&#160;million; 2020: &#163;4 million). When the counterparty controls the commercialisation activities and records the sale, the Group is not deemed principal in the customer contract and instead records its share of gross profit as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> income, on a net basis, within turnover. The nature of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> activities is such that the Group records no costs of sales. Commercial Operations turnover includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> revenue of &#163;3 million (2021: &#163;7 million; 2020: &#163;12 million). Reimbursements to and from the counterparty under collaboration agreements for &#8216;selling, general and administration&#8217; and &#8216;research and development&#8217; costs are recorded net in the respective lines in the Consolidated income statement. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other operating income and royalty income </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK enters into development and marketing collaborations and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licences</div> of the Group&#8217;s compounds or products to other parties. These contracts give rise to fixed and variable consideration from upfront payments, development milestones, sales-based milestones and royalties. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Income dependent on the achievement of a development milestone is recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, which is usually when the related event occurs. Sales-based milestone income is recognised when it is highly probable that the sales threshold will be reached. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occurs. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For all revenue, if the time between the recognition of revenue and payment from the customer is expected to be more than one year and the impact is material, the amount of consideration is discounted using appropriate discount rates. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Value added tax and other sales taxes are excluded from revenue. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory', window );">Expenditure</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. Manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs between validation and the achievement of normal production are expensed as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Advertising and promotion expenditure is charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shipment costs on inter-company transfers are charged to cost of sales; distribution costs on sales to customers are included in selling, general and administration expenditure. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Restructuring costs are recognised and provided for, where appropriate, in respect of the direct expenditure of a business reorganisation where the plans are sufficiently detailed and well advanced, and where appropriate communication to those affected has been undertaken. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Software as a service (SaaS) configuration costs are expensed as they are incurred where the software being configured is controlled by the SaaS provider. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and development </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group&#8217;s policy. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory', window );">Environmental expenditure</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental expenditure </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Environmental expenditure related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible is charged to the income statement. The Group recognises its liability on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">site-by-site</div></div> basis when it can be reliably estimated. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This liability includes the Group&#8217;s portion of the total costs and also a portion of other potentially responsible parties&#8217; costs when it is probable that they will not be able to satisfy their respective shares of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> obligation. Recoveries of reimbursements are recorded as assets when virtually certain. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory', window );">Legal and other disputes</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and other disputes </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Provision is made for the anticipated settlement costs of legal or other disputes against the Group where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome. In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover asserted and unasserted claims. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In certain cases, an incurred but not reported (IBNR) actuarial technique is used to determine this estimate. In addition, provision is made for legal or other expenses arising from claims received or other disputes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases is included but no provision is made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Costs associated with claims made by the Group against third parties are charged to the income statement as they are incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Pensions and other post-employment benefits</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pensions and other post-employment benefits </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of providing pensions under defined benefit schemes are calculated using the projected unit credit method and spread over the period during which benefit is expected to be derived from the employees&#8217; services, consistent with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Pension obligations are measured as the present value of estimated future cash flows discounted at rates reflecting the yields of high-quality corporate bonds. Pension scheme assets are measured at fair value at the balance sheet date. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of other post-employment liabilities are calculated in<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>a similar way to defined benefit pension schemes and spread over the period during which benefit is expected to be derived from the employees&#8217; services, in accordance with the advice of qualified actuaries. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The service cost of providing retirement benefits to employees during the year, together with the cost of any curtailment, is charged to operating profit in the year. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Actuarial gains and losses and the effect of changes in actuarial assumptions are recognised in the statement of comprehensive income in the year in which they arise. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s contributions to defined contribution plans are charged to the income statement as incurred. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Employee share plans</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee share plans </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Incentives in the form of shares are provided to employees under share option and share award schemes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The fair values of these options and awards are calculated at their grant dates using a Black-Scholes option pricing model and charged to the income statement over the relevant vesting periods. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group provides finance to ESOP Trusts to purchase company shares to meet the obligation to provide shares when employees exercise their options or awards. Costs of running the ESOP Trusts are charged to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Shares held by the ESOP Trusts are deducted from other reserves. A transfer is made between other reserves and retained earnings over the vesting periods of the related share options or awards to reflect the ultimate proceeds receivable from employees on exercise. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property, plant and equipment </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Property, plant and equipment (PP&amp;E) is stated at the cost of purchase or construction, less provisions for depreciation and impairment. Financing costs are capitalised within the cost of qualifying assets in construction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Depreciation is calculated to write off the cost less residual value of PP&amp;E, excluding freehold land, using the straight-line basis over the expected useful life. Residual values and lives are reviewed, and where appropriate adjusted annually. The normal expected useful lives of the major categories of PP&amp;E are: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:45%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Freehold buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Leasehold land and buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Lease term or 20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Plant and machinery</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">10 to 20 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equipment and vehicles</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">3 to 10 years</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">On disposal of PP&amp;E, the cost and related accumulated depreciation and impairments are removed from the financial statements and the net amount, less any proceeds, is taken to the income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group recognises right of use assets under lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. Rights to use assets owned by third parties under lease agreements are capitalised at the inception of the lease and recognised on the consolidated balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The corresponding liability to the lessor is recognised as a lease obligation within short and long-term borrowings. The carrying amount is subsequently increased to reflect interest on the lease liability and reduced by lease payments made. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">For calculating the discounted lease liability on leases with annual payments of &#163;2 million or more, the implicit rate in the lease is used. If this is not available, the incremental borrowing rate with a lease specific adjustment is used. If neither of these is available, and for leases with annual payments of less than &#163;2 million, the incremental borrowing rate is used. The incremental borrowing rate is calculated at the rate of interest at which GSK would have been able to borrow for a similar term and with a similar security the funds necessary to obtain a similar asset in a similar market. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Finance costs are charged to the income statement so as to produce a constant periodic rate of charge on the remaining balance of the obligations for each accounting period. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Variable rents are not part of the lease liability and the right of use asset. These payments are charged to the income statement as incurred. Lease rental costs for short-term and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> leases which are not capitalised are also charged to the income statement as incurred. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-lease</div> components are accounted for separately from the lease components in plant and equipment leases but are not separately accounted for in land and buildings or vehicle leases. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If modifications or reassessments of lease obligations occur, the lease liability and right of use asset are remeasured. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Right of use assets where title is expected to pass to GSK at a point in the future are depreciated on a basis consistent with similar owned assets. In other cases, right of use assets are depreciated over the shorter of the useful life of the asset or the lease term. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Goodwill is stated at cost less impairments. Goodwill is deemed to have an indefinite useful life and is tested for impairment at least annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the fair value of the interest acquired in an entity&#8217;s assets, liabilities and contingent liabilities exceeds the consideration paid, this excess is recognised immediately as a gain in the income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Other intangible assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other intangible assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Intangible assets are stated at cost less provisions for amortisation and impairments. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and marketing rights separately acquired or acquired as part of a business combination are amortised over their estimated useful lives, generally not exceeding 30 years, using the straight-line basis, from the time they are available for use. The estimated useful lives for determining the amortisation charge take into account patent lives (exclusivity period), where applicable, as well as the value obtained from periods of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity.</div> For Pharmaceutical intangible assets, depending on the characteristics, competitive environment and estimated long-term profits of the asset, between 80% to 90% of the book value is amortised over the exclusivity period on a straight-line basis and the remaining book value is amortised over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusivity</div> period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-15</div> years on a straight-line basis. For Vaccines intangible assets, cost is usually amortised over the exclusivity period plus 10 years, or 30 years if no exclusivity period is granted, on a straight-line basis. Asset lives are reviewed, and where appropriate adjusted, annually. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Contingent milestone payments are recognised at the point that the contingent event becomes probable. Any development costs incurred by the Group and associated with acquired licences, patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> or marketing rights are written off to the income statement when incurred, unless the criteria for recognition of an internally generated intangible asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Acquired in process R&amp;D and marketed products are valued independently as part of the fair value of businesses acquired from third parties where they have a value which is substantial and long term and where the brands either are contractual or legal in nature or can be sold separately from the rest of the businesses acquired. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of acquiring and developing computer software for internal use and internet sites for external use are capitalised as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset controlled by the Group. ERP systems software is amortised over <span style="-sec-ix-hidden:hidden69044974">seven</span> to ten years and other computer software over <span style="-sec-ix-hidden:hidden69044975">three</span> to five years using the straight-line basis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of non-current assets</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The carrying values of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available for use are tested for impairment annually. Any provision for impairment is charged to the income statement in the year concerned. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Impairments of goodwill are not reversed. Impairment losses on other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investments in associates, joint ventures and joint operations</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investments in associates, joint ventures and joint operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in associates and joint ventures are carried in the consolidated balance sheet at the Group&#8217;s share of their net assets at date of acquisition and of their post-acquisition retained profits or losses and other comprehensive income together with any goodwill arising on the acquisition. The Group recognises the assets, liabilities, revenue and expenses of joint operations in accordance with its rights and obligations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventories </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realisable value. Cost is generally determined on a first in, first out basis. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-launch</div> inventory is held as an asset when there is a high probability of regulatory approval for the product. Before that point a provision is made against the carrying value to reduce it to its recoverable amount; the provision is then reversed at the point when a high probability of regulatory approval is determined. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Financial assets are measured at amortised cost, fair value through other comprehensive income (FVTOCI) or fair value through profit or loss (FVTPL). The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. For financial assets other than trade receivables a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> expected credit loss (ECL) allowance is recorded on initial recognition. If there is subsequent evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are recognised in the income statement on financial assets measured at amortised cost and at fair value through other comprehensive income apart from equity investments. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock', window );">Current equity investments</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current equity investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. Dividend income is recognised in the income statement when the Group&#8217;s right to receive payment is established. Purchases and sales of Current equity investments are accounted for on the trade date. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory', window );">Other investments</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other investments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Other investments comprise equity investments and investments in limited life funds. The Group has elected to designate the majority of its equity investments as measured at FVTOCI. They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Investments in limited life funds are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Dividends on equity investments and distributions from funds are recognised in the income statement when the Group&#8217;s right to receive payment is established. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Purchases and sales of Other investments are accounted for on the trade date. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade receivables</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Trade receivables </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Trade receivables are measured in accordance with the business model under which each portfolio of trade receivables is held. The Group has portfolios in each of the three business models under IFRS 9: to collect the contractual cash flows where there is no factoring agreement in place (measured at amortised cost), to sell the contractual cash flows where the trade receivables will be sold under a factoring agreement (measured at FVTPL), and both to collect and to sell the contractual cash flows where the trade receivables may be sold under a factoring arrangement (measured at FVTOCI). Trade receivables measured at amortised cost are carried at the original invoice amount less allowances for expected credit losses. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether, and the extent to which, settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Subsequent recoveries of amounts previously provided for or written off are credited to the income statement. Long-term receivables are discounted where the effect is material. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Cash held in deposit accounts is measured at amortised cost. Investments in money market funds are held at fair value through profit or loss because the funds fail the solely payments of principal and interest (SPPI) test. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Borrowings </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative financial instruments </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by GSK are foreign currency swaps, interest rate swaps, foreign exchange forward contracts and options. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivative financial assets and liabilities, including derivatives embedded in host contracts which have been separated from the host contract, are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading</div></div> and are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory', window );">Hedge accounting</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedge accounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Derivatives designated as hedging instruments are classified at inception of hedge relationship as cash flow hedges, net investment hedges or fair value hedges. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective and accumulated in the cash flow hedge reserve. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in the cash flow hedge reserve are reclassified to the income statement when the hedged item affects profit or loss, or if the hedged forecast transaction is to purchase a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset, the amount deferred in the cash flow hedge reserve is transferred directly from equity and included in the carrying value of the recognised <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> asset. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Net investment hedges are accounted for in a similar way to cash flow hedges which are reclassified to the income statement when the hedged item affects profit or loss. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Taxation </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Current tax is provided at the amounts expected to be paid, applying tax rates that have been enacted or substantively enacted by the balance sheet date. The tax charge for the period is recognised in the income statement, the statement of comprehensive income or directly in equity, according to the accounting treatment of the related transaction. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company and its subsidiaries intend to settle their current tax assets and liabilities on a net basis. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are not recognised if the temporary differences arise from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction (other than a business combination) that affects neither the accounting nor the taxable profit or loss. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where an uncertain tax position is identified, management will make a judgement as to what the probable outcome will be, assuming the relevant tax authority has full knowledge of the situation. Where it is assessed that an economic outflow is probable to arise, a provision is made for the best estimate of the liability. In estimating any such liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory', window );">Discounting</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discounting </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Where the time value of money is material, balances are discounted to current values using appropriate discount rates. The unwinding of the discounts is recorded in finance income and finance expense. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets and liabilities held for sale or distribution and discontinued operations</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets and liabilities held for sale or distribution and discontinued operations </div></div></div></div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Disposal groups are classified as held for sale or distribution if their carrying amount will be recovered principally through sale or a distribution to shareholders rather than through continuing use, they are available for sale or distribution in their present condition and the sale or distribution is considered highly probable. Assets held in Assets held for sale or distribution are measured at the lower of their carrying amount and fair value less costs to sell or distribute. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets included in Assets held for sale or distribution are not depreciated or amortised. Assets and liabilities classified as held for sale or distribution are presented in current assets and current liabilities separately from the other assets and liabilities in the balance sheet. </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A discontinued operation is a component of the Group that has been disposed of, distributed or is classified as held for sale or distribution and that represents a separate major line of business. The results of discontinued operations are presented separately in the Consolidated income statement, the Consolidated statement of other comprehensive income and the Consolidated statement of cash flows and comparatives are restated on a consistent basis. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Current Equity Investments Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for discounting .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for legal and other disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Other Investment [Text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfAccountingStandardsApplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for accounting standards applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfAccountingStandardsApplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for borrowings. [Refer: Borrowings]
Effective 2023-01-01: The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.
Effective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for environment related expense.
Effective 2023-01-01: The description of the entity's material accounting policy information for environment related expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for expenses.
Effective 2023-01-01: The description of the entity's material accounting policy information for expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for hedging.
Effective 2023-01-01: The description of the entity's material accounting policy information for hedging.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of assets.
Effective 2023-01-01: The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.
Effective 2023-01-01: The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]
Effective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]
Effective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428741504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting principles and policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory', window );">Summary of Expected Useful Lives of Property Plant and Equipment</a></td>
<td class="text">The normal expected useful lives of the major categories of PP&amp;E are:<div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:45%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Freehold buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Leasehold land and buildings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Lease term or 20 to 50 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Plant and machinery</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">10 to 20 years</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equipment and vehicles</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">3 to 10 years</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428764352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exchange rates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SignificantCurrenciesAndTheRelevantExchangeRates', window );">Summary of Currencies Translations and Relevant Exchange Rates</a></td>
<td class="text">The currencies which most influence these translations and the relevant exchange rates were:
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Average rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">161</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">137</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Period end rates:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US$/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Euro/&#163;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Yen/&#163;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">155</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SignificantCurrenciesAndTheRelevantExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about significant currencies and the relevant exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SignificantCurrenciesAndTheRelevantExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377421872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTurnoverBySegmentExplanatory', window );">Turnover by Segment</a></td>
<td class="text"><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by segment</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,232</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segment Profit and Operating Profit</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Segment profit<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"> </div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,590</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,060</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,567</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,397</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#8211;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">55</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,530</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(379</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(407</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment profit and operating profit</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,718</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(2,136</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(677</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Operating profit</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,433</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(879</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(769</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on disposal of interest in associates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits/(losses) of associates and joint ventures</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">33</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">33</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before taxation from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,628</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(707</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(83</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">(67</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation for the year from continuing operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">3,516</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">5,103</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td colspan="4" style="height:3pt"/>
<td colspan="4" style="height:3pt"/>
<td colspan="4" style="height:3pt"/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Depreciation and amortisation by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160; <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">829</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">467</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">378</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">355</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,296</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated depreciation and amortisation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">112</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">739</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">761</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">724</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and amortisation</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,147</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">2,122</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;">2,050</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E, intangible asset and goodwill impairment by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">55</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">85</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">124</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">63</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment and total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">420</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">392</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">583</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">501</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">540</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">712</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">PP&amp;E and intangible asset impairment reversals by segment</div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated impairment reversals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other reconciling items between segment impairment reversals and total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(35</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total impairment reversals</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(26</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(12</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(54</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 7.5pt; width: 742.547px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility: hidden; line-height: 0pt; color: white;">
<td style="width: 542.188px;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.875px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.3125px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td>
<td style="vertical-align: bottom; width: 6.32812px;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td><div style="display:inline;"/></td> </tr>
<tr style="break-inside: avoid; font-size: 6.5pt;">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating assets by segment</div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><br/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(revised)<div style="font-size: 6.5px; vertical-align: top;;display:inline;">(2)</div></div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="display:inline;"/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial Operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,288</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,440</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,299</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,461</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Segment net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,587</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,901</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate and other unallocated net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">264</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,504</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued operations</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25,208</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net operating assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,851</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">39,613</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="1" style="height:9.75pt">&#160;</td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:9.75pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19,838</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments in associates and joint ventures</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current Equity Investment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,087</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(22</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current and deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,176</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,479</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Assets held for sale (excluding cash and cash equivalents)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="1" style="height:3pt">&#160;</td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="height:3pt"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,096</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,342</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Geographical Information</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Geographical information </div></div></div></div> <div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The UK is regarded as being the Group&#8217;s country of domicile. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Turnover by location of customer</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">695</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">656</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">659</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,542</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,914</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,148</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,087</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,126</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,547</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">External turnover</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,354</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location of subsidiary</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,134</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,618</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,024</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17,852</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Belgium</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,415</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,065</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Switzerland</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,552</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,559</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15,390</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,166</div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">51,477</div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables. There are no other countries with individually material external revenue or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the new segments. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesExplanatory', window );">Turnover by Product &amp; Service</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercial Operations:</div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(revised)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">HIV</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,749</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,777</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,876</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Oncology</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">602</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">489</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">372</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immuno-inflammation,</div> respiratory and other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,609</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,027</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,960</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,293</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,309</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">958</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Specialty Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,269</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,251</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,969</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,116</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">961</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,029</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Influenza</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">714</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">679</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">733</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Shingles</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,958</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,721</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,989</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Established Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,085</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,970</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,231</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,873</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,331</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pandemic Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">64</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">447</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,937</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,778</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,982</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Respiratory</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,548</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,048</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,006</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,570</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,619</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,275</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">General Medicines</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,118</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,667</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10,281</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Commercial Operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,324</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,696</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24,232</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been revised to reflect the Commercial Operations segment.</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTurnoverBySegmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of turnover by segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTurnoverBySegmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProductsAndServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's products and services. [Refer: Products and services [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProductsAndServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428864272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income/(expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory', window );">Summary Information about Other Operating Expense</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Upfront settlement income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">922</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">256</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposal of businesses and assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">215</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value remeasurements on contingent consideration recognised in business combinations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,607</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of ViiV Healthcare put option liabilities and preferential dividends</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments on derivative financial instruments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(235</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(504</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,463</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:14.25pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy concerning ViiV Healthcare&#8217;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#163;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other operating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367387664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating profit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OperatingProfitLineItems', window );"><strong>Operating Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory', window );">Summary of Information About Profit Loss</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">The following items have been included in operating profit:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee costs (Note 9)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,693</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,680</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8,555</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Advertising</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">735</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">433</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">361</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distribution costs</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">192</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">169</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">885</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">855</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">822</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of property, plant and equipment, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">176</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">179</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">182</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of right of use assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,088</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,046</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">435</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">230</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of intangible assets held for sale, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of goodwill allocated to a disposal group, net of reversals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net foreign exchange (gains)/losses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">99</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventories:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of inventories included in cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,137</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,885</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,934</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">687</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">800</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">607</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of prior year write-down of inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(483</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(325</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(250</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-value</div> lease charge</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variable lease payments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fees payable to the company&#8217;s auditor and its associates in relation to the Group (see below)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.9</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">31.7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Summary of Auditors Remuneration</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Fees payable to the company&#8217;s auditor and its associates:</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit of the company&#8217;s subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.7</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">27.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28.3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.3</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4.0</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.6</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total audit services, audit-related and other assurance services</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.9</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">31.7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OperatingProfitLineItems', window );"><strong>Operating Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Summary of Auditors Remuneration</a></td>
<td class="text"> In addition to the above, fees paid to the auditor in respect of the GSK pension schemes were: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Audit</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.2</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OperatingProfitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OperatingProfitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367466864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory', window );">Summary of Employee Costs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,110</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">763</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">775</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs, including augmentations (Note 31)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">314</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Severance and other costs from integration and restructuring activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">137</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,693</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">7,680</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">8,555</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory', window );">Summary of Cost of Share-based Incentive Plans</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cost of share-based incentive plans is analysed as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share Value Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">243</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Performance Share Plan</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share option plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash settled and other plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">314</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">345</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">330</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNumberOfEmployeesExplanatory', window );">Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors)</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average number of persons employed by the Group (including Directors) during the year: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> Number</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> Number</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Manufacturing</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,946</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,642</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,542</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,874</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,744</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total Continuing Operations</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,130</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">71,345</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">73,257</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discontinued Operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,292</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">20,616</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22,628</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90,422</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">91,961</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">95,885</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Note: Consumer Healthcare divested on 18 July 2022 is shown as Discontinued Operations in the above table. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory', window );">Summary of Compensation of the Directors and Senior Management</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The compensation of the Directors and senior management (members of the GLT) in aggregate, was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension and other post-employment costs</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of share-based incentive plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">60</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">51</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of compensation of directors and senior management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfNumberOfEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfNumberOfEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428844800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major restructuring costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory', window );">Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations</a></td>
<td class="text">The analysis of the costs charged to operating profit from continuing operations under these programmes was as follows:<div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in provision for Major restructuring programmes (see Note <div style="display:inline;">32</div>)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">138</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">321</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">606</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amount of provision reversed unused (see Note 32)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(111</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(140</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(71</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses recognised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges/(credit)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">62</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other cash costs</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">179</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">204</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">234</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock', window );">Summary of Major Restructuring Charges from Continuing Operations by Income Statement</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of Major restructuring charges from continuing operations by income statement line was as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">102</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">102</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">585</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">180</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">277</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">45</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">198</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsExplanatory', window );">Summary of Major Restructuring Charges From Continuing Operations</a></td>
<td class="text">The analysis of Major restructuring charges from continuing operations by programme was as follows:<div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:84%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">177</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">287</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Significant acquisitions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">206</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">321</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td style="font-size:9pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Separation Preparation programme</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">353</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">412</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Legacy programmes</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">385</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">39</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of analysis of Major restructuring charges from continuing operations by income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Analysis of the costs charged to operating profit from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfRestructuringCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Major Restructuring Charges from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfRestructuringCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428914688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestIncomeExplanatory', window );">Summary of Finance Income</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:74%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance income arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains arising from the forward element of forward contracts in net investment hedge relationships</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">76</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest income. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428935536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Summary of Finance Cost</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities at amortised cost</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(789</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(735</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(811</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses arising from:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial instruments mandatorily measured at fair value through profit or loss</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">743</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(565</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">382</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retranslation of loans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(761</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">565</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(384</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of hedges from other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discounts on provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense arising on lease liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other finance expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(33</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(23</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(879</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(769</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(874</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367290944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and joint ventures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory', window );">Summary of After Tax Profits and Losses of Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group&#8217;s share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits and losses of associates and joint ventures is set out below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses of joint ventures</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">2021 and 2020 comparatives have not been restated, as the demerged Consumer Healthcare business contained no associates or joint ventures. </div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory', window );">Summary of Group Held for Significant Associate</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The results of Innoviva included in the summarised income statement information below represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information at the balance sheet date. Figures for 2021 include share of Innoviva&#8217;s turnover, profit and total comprehensive income until the date of the disposal. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td>
<td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="border-bottom: 0.75pt solid black; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">108</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">253</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory', window );">Summary of Aggregated Financial Information</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Aggregated financial information in respect of GSK&#8217;s share of other associated undertakings and joint ventures is set out below: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/> &#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">53</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of total comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">45</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of aggregated financial information of associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfGroupHeldSignificantAssociateExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of group held significant associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share of after tax profits and losses of associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366581376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory', window );">Summary of Taxation Charge Based on Profits</a></td>
<td class="text"> <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;">The Group&#8217;s tax charge is the sum of the total current and deferred tax expense. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Taxation charge based on profits for the year</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">200</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(45</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rest of World current year charge</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,351</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">593</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">745</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge/(credit) in respect of prior periods</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,491</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">931</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">711</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(784</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(848</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(644</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory', window );">Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for the year. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 59%;"><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td>
<td style="width: 2%; vertical-align: bottom;"><div style="display:inline;"/></td>
<td><div style="display:inline;"/></td>
<td style="white-space: nowrap;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td><div style="display:inline;"/></td> </tr>
<tr style="font-size: 6.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 7.5pt;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of taxation on Group profits</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>&#163;m</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/>%</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)<br/></div>&#163;m</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"><div style="display:inline;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/>%</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td>
<td colspan="4" style="height: 3pt;"><div style="display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,628</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,599</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,170</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK statutory rate of taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,069</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.0</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">685</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">984</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Differences in overseas taxation rates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">318</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">302</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">8.4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">363</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Benefit of intellectual property incentives</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(600</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10.7</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(382</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(10.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(516</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9.9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(119</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(103</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Permanent differences on disposals, acquisitions and transfers</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">275</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(316</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.5</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">90</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year current tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-assessments</div> of prior year deferred tax estimates</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(233</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4.1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(281</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(283</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in Tax Rates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.4</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(353</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9.8</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(163</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3.1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax charge/tax rate</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.6</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2.3</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12.9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"/>  <div style="font-size: 50pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory', window );">Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Tax on items charged to equity and statement of comprehensive income</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> &#163;m</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">&#160;</div><br/> &#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred taxation</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based payments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit plans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(211</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(68</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(277</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total credit to equity and statement of comprehensive income</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(268</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory', window );">Summary of Movement in Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">Movement in deferred tax assets and liabilities </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Accelerated<br/> capital<br/> allowances<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Intangible<br/> assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Contingent</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">consideration<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Intra-Group</div><br/> profit</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Pensions&#160;&amp;<br/> other post<br/> employment<br/> benefits</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax<br/> losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> option<br/> and&#160;award<br/> schemes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">net<br/> temporary<br/> differences<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(223</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Acquisitions/Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(211</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,711</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(102</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Credit/(charge) to income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Credit/(charge) to statement of comprehensive income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Acquisitions/Disposals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(637</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(495</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">R&amp;D credits utilisation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer of assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(819</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">992</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,099</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;1,661</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,642</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;5,369</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Summary of Deferred Tax Assets and Liabilities Recognised on the Balance Sheet</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Deferred tax assets and liabilities are recognised on the balance sheet as follows:</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,658</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,369</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,662</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrecognised tax losses</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax&#160;losses<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Unrecognised<br/> deferred tax<br/> asset</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Tax&#160;losses<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Unrecognised<br/> deferred tax<br/> asset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trading losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Within 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">967</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">175</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 10 years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">192</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,203</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,658</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capital losses expiring:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Available indefinitely</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,326</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">548</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,356</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">557</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,326</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">548</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,356</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">557</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of current and deferred tax relating to items charged or credited directly to equity and comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of income tax expense benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of movement in deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reconciliation of actual tax charge and profit charged at UK tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376671152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Basic and Diluted Earnings Per Share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> pence</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div><br/> pence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">110.8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22.0</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total basic earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">371.4</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">109.6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">144.4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109.2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">257.0</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26.4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total diluted earnings per share</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;366.2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;108.2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;142.6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37).</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory', window );">Schedule of Numbers of Shares Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted average number of shares in issue</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> millions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(2)</div><br/> millions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,026</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dilution for share options and awards</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Diluted</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,084</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,052</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Restated to reflect the impact share consolidation (see <div style="display:inline;"><div style="display:inline;">N</div>ote</div> 37). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of weighted average numbers of shares earnings per share explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377655168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInterimDividendExplanatory', window );">Summary of Interim Financial Reporting</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:19%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Paid/payable</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Paid</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Dividend<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share<br/> (pence)<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(3)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">First interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 July 2022</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">704</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 July 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">9 July 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Second interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6 October 2022</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.25</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">654</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">7 October 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 October 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12 January 2023</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">13 January 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">14 January 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fourth interim</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13 April 2023</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.75</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">7 April 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">8 April 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61.25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,468</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,011</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,989</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The estimate for the fourth interim dividend for 2021 disclosed in the 2021 annual report was &#163;1,152&#160;million, &#163;5&#160;million less than the dividend that was ultimately paid. </div></td></tr></table><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">&#160;Dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. See details in Note 37. </div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsPaidExplanatory', window );">Summary of Dividends to Shareholders</a></td>
<td class="text">The amounts recognised in each year were as follows:<div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash dividends to shareholders</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,467</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends in specie to shareholders in Haleon plc shares (Note 41)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,526</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,993</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,977</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDividendsPaidExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of dividends paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDividendsPaidExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfInterimDividendExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of interim dividend explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfInterimDividendExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428908448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Property, Plant and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Plant,<br/> equipment<br/> and&#160;vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">Assets in<br/> construction<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;21,483</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(214</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(315</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(576</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,205</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(217</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,174</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(74</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(102</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,778</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,050</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,245</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised borrowing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(222</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,067</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,959</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,343</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,648</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,953</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,451</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,310</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,450</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(715</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(982</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,062</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">54</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,025</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(191</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(310</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(501</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(226</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(726</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(952</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#f4f1f0">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">376</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,130</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#f4f1f0">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,506</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,275</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,469</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,744</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(280</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(551</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(857</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(821</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and write-offs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">84</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(260</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(472</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(774</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,846</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total depreciation and impairment at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,535</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,941</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(42</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(10,518</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,898</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,414</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,864</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,176</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,667</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,558</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,707</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,113</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,012</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,808</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,933</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367210544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets', window );">Summary of Disclosure of Detailed Information About Right Of Use Assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Land&#160;and<br/> buildings<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Plant and<br/> equipment<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">Vehicles<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;830</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">215</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(149</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(59</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(213</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">740</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">233</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(192</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">561</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">687</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377354752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory', window );">Summary of Changes in Goodwill</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,552</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations (Note 41)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other movements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,552</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,597</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory', window );">Summary of Goodwill Allocated to Segments</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">All Goodwill is allocated to the Group&#8217;s segments as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:89.5%;border:0">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,148</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total R&amp;D</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">898</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,046</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">In 2021, prior to changes in the Group&#8217;s segment reporting (Note 6) Goodwill was allocated as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pharmaceuticals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vaccines</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,060</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,552</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory', window );">Schedule of Discounted Cash Flow Models Used in Impairment Tests</a></td>
<td class="text"><div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8.5pt;;display:inline;">Details relating to the discounted cash flow models used in the impairment tests are as follows:</div></div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:26%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>
<td style="vertical-align:bottom"/>
<td style="width:21%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Valuation basis</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Fair value less costs of disposal</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Key assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Sales growth rates</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Profit margins</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rate</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rate</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Determination of assumptions</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Growth rates are internal forecasts based on both internal and external market information.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Margins reflect past experience, adjusted for expected changes.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rates based on management&#8217;s estimate of future long-term average growth rates.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Discount rates based on Group WACC, adjusted where appropriate.</div> <div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;">Taxation rates based on appropriate rates for each jurisdiction.</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Period of specific projected cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Five years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;">Terminal growth rate and discount rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Terminal growth rate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Discount&#160;rate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Commercial operations</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">R&amp;D</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Vaccines</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0% p.a.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Consumer Healthcare</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2.5% p.a.</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">6% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of allocation of goodwill to segments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information for cash-generating units. [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367261856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of Other Intangible Assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer<br/> software</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Licences,<br/> patents,</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;amortised<br/> brands etc.</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Indefinite&#160;life</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">brands</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(207</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(157</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">346</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,594</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(221</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,156</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">74</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42,489</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,109</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Capitalised development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">317</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,964</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">775</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(236</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,772</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,781</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">39</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,959</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25,717</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,676</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,932</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,254</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(956</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,181</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">737</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,369</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,262</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(307</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(340</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(204</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(931</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,135</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">148</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">254</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">554</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,223</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,181</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,404</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 1&#160;January 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,487</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(245</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,760</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(362</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(455</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">362</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">392</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,779</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(141</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(313</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">270</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversal of impairments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and asset write-offs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(81</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,954</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,742</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,410</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total amortisation and impairment at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,304</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(12,054</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13,358</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 1&#160;January 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,053</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,403</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18,368</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,824</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net book value at 31&#160;December 2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">964</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,697</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">18,418</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,079</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net book value at 31&#160;December 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,663</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,318</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory', window );">Schedule of Amortisation and Impairment Losses, Net of Reversals</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortisation</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;impairment&#160;losses</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div><br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a) </div>&#160;&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">663</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">750</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">&#8211;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">65&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">307</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">299</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">373&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">1,088</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">367</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">438&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory', window );">Summary of Book Values of Largest Individual Items</a></td>
<td class="text">The book values of the largest individual items are as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tesaro Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,858</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Meningitis portfolio</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,855</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Momelotinib</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,499</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,473</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dolutegravir</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benlysta</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">541</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Alector Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">509</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">iTeos Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shingrix</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">288</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Okairos</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">BMS Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Spero</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Vir Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluarix/FluLaval</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">147</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Stiefel trade name</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">CureVac Assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lamisil<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Others</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,797</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,663</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,697</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Disposed of as part of the Consumer Healthcare demerger (Note 41). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of licences included in intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of impairment loss and the reversal of impairment loss. [Refer: Impairment loss; Reversal of impairment loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348378535424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in associates and joint ventures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory', window );">Schedule of Investments in Associates and Joint Ventures</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"><br/></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Joint<br/> ventures<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Associates<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">76</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">88</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">349</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">364</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(278</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(278</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Distributions received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment of interest in associates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit/(loss) after tax recognised in the consolidated income statement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">64</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">74</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">76</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of investments in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367573424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current equity investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock', window );">Summary of Current Equity Investments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,087</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about&#160;current equity investments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428884016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory', window );">Schedule of Other Investments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments<br/> designated&#160;as<br/> measured at<br/> FVTOCI</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Investments</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">measured&#160;at</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">FVTPL</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(716</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movements through profit or loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(220</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(220</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,153</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,467</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,126</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of schedule of other investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428882448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory', window );">Summary of Other Non-Current Assets</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amounts receivable under insurance contracts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">857</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">849</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">108</div></div></td>
<td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">1,676</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of receivables in other non current assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348378466832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory', window );">Summary of Inventories</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Raw materials and consumables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,576</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,284</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,146</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">5,783</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366962240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Summary of Trade and Other Receivables</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade receivables, net of loss allowance</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,452</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accrued income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Prepayments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">343</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest receivable</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employee loans and advances</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other receivables</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,226</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,053</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">7,860</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory', window );">Summary of Loss Allowance</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss allowance - trade receivables</div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(60</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Subsequent recoveries of amounts provided for</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">150</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the allowance relating to impairments of financial assets due to credit losses. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428920944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash at bank and in hand</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">879</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Short-term deposits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,844</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">4,274</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure for detailed information about cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428986048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAssetsHeldForSaleExplanatory', window );">Summary of Assets Held for Sale</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">98</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;">22</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAssetsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of assets held for sale explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAssetsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376686672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SummaryOfTradePayablesExplanatoryTextBlock', window );">Summary of Trade and Other Payables</a></td>
<td class="text">&#160;
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,866</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Wages and salaries</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,488</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Social security</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare put option</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,093</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">299</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Customer return and rebate accruals</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,627</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other accruals</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,346</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,242</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,263</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">17,554</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory', window );">Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:top"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability and loss/(gain) in Income statement</div></div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">149</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(99</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecast*</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(149</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) increase in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(48</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.50% (150 basis points) decrease in discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(32</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:4pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">* The sales forecast is for ViiV Healthcare sales only in respect of the ViiV Healthcare put option. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income statement and balance sheet sensitivity of put option to reasonably possible changes in key assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SummaryOfTradePayablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of trade payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SummaryOfTradePayablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376677520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of Current Assets, Short and Long Term Borrowings</a></td>
<td class="text"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:43%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:40%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Listing exchange</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,274</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,790</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,335</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,191</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank loans, overdrafts and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(448</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.850% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,483</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.875% US$ US Medium Term Note 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,113</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(665</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> European Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,038</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(167</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,952</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,601</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term borrowings:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">2.800% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(926</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(629</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(925</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(204</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(420</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">0.534% US$ US Medium Term Note 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(926</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% US$ US Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(829</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(739</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(884</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(836</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(663</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(627</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.625% US$ US Medium Term Note 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(827</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(620</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(587</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(885</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(838</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.000% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(442</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% &#163; Euro Medium Term Note 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(306</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(595</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.875% US$ US Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,450</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,294</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.250% &#163; Euro Medium Term Note 2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(744</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(743</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.375% US$ US Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(822</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(733</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.375% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(441</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(418</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.750% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2030</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(663</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(628</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3.125% <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div> Euro Medium Term Note 2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(616</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2033<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(640</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(984</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.375% US$ US Medium Term Note 2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(412</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(368</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.625% &#163; Euro Medium Term Note 2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(744</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(744</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% US$ US Medium Term Note 2038</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,264</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,022</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">6.375% &#163; Euro Medium Term Note 2039<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(1) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(695</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(695</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">5.250% &#163; Euro Medium Term Note 2042</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(472</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(987</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.200% US$ US Medium Term Note 2043</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">New York Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(408</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(364</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">4.250% &#163; Euro Medium Term Note 2045</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom">London Stock Exchange</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(366</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(789</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other long-term borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(841</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(812</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Partially purchased and cancelled on 13&#160;February 2023. </div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock', window );">Schedule of Lease Obligations</a></td>
<td class="text"><div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The maturity analysis of discounted lease liabilities recognised on the Group balance sheet is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due within one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">167</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">201</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">97</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rental payments due after five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">336</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">341</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total lease liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,008</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,015</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of lease obligations explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368687568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other post-employment benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory', window );">Summary of Average Life Expectancy Assumed</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2042 for an individual then at the age of 60 is as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size:1pt">
<td style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/>
<td colspan="4" style="height:0.75pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Male<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female<br/> Years</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Projected for 2042</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28.5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29.5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28.8</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">30.1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory', window );">Summary of Financial Assumptions in Assessing Defined Benefit Liabilities</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The Group has applied the following financial assumptions in assessing the defined benefit liabilities:</div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">UK</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">US</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Rest of World</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">%&#160;pa</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">%&#160;pa</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Rate of increase of future earnings</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.30</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected pension increases</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.40</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash balance credit/conversion rate</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.90</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inflation rate</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.10</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3.20</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.50</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.25</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.30</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.30</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory', window );">Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31&#160;December 2022 in relation to the defined benefit pension and post-retirement healthcare schemes were as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">113</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">183</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px">(1)</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,169</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">261</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(872</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">116</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement gains/(losses) recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">186</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">856</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Post-retirement</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(2) </div></div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Amounts charged to operating profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Current service cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost/(credit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Net interest (income)/cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Gains from settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">348</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement losses recorded in the statement of comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(96</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(90</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory', window );">Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the table below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in surplus</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Recognised in Pensions and other post-employment benefits:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension schemes in deficit</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,585</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,870</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(994</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,243</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,363</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,579</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,113</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,650</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory', window );">Summary of Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other defined benefit pension schemes in the Group are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,159</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,101</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">605</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,595</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,329</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">691</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,694</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">(645</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(375</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,144</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,353</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,500</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(483</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">229</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(603</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,585</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(770</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(483</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,710</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(253</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,513</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table> <div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;Rest&#160;of&#160;World<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(130</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">91</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Asset&#160;ceiling&#160;restrictions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13,299</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,644</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,191</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">333</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,129</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(273</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,870</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">333</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(724</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(738</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">541</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">686</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:85%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At&#160;31&#160;December&#160;2020&#160;&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Multi-asset funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corporate bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;unlisted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government bonds:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#8211;&#160;listed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,055</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Insurance contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Present value of scheme obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13,858</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,445</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,007</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21,310</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net surplus/(obligation)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,104</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Included in Pensions and other post-employment benefits</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(353</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,124</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,104</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Actual return on plan assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,092</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">177</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,428</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory', window );">Summary of Movements in Fair Values of Assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in fair values of assets</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,432</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">372</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,056</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">313</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">105</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(641</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(999</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,206</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(184</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">262</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">424</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">312</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">105</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(982</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,906</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,062</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">370</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(578</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,883</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Employer contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">919</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">117</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(624</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(649</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,080</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(135</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Assets at 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,014</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,870</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,144</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory', window );">Summary of Movements in Defined Benefit Obligations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Post-retirement</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">benefits</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Movements in defined benefit obligations</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Rest&#160;of&#160;World</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Group</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,506</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(291</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(43</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(259</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(408</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(39</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(168</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,161</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(82</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">641</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">248</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">999</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,858</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,310</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,363</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">218</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(216</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(289</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">439</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">982</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,248</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,191</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,243</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(371</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(495</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(125</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(388</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(32</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Remeasurement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,011</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Scheme participants&#8217; contributions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">621</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Benefits paid</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">649</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,080</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">135</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;">Obligations at 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,117</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,031</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,352</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,500</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(994</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Summary of Net Defined Benefit Liability</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The movement in the net defined benefit liability is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,129</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,104</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,921</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(87</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(216</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(291</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Past service cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest cost</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlements and curtailments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Return on plan assets, excluding amounts included in interest</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,883</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">424</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,056</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">92</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(62</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,868</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">716</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,340</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience (loss)/gain</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(949</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(215</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Employer contributions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">919</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">312</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">313</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expenses</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,356</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,129</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,104</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory', window );">Summary of Defined Benefit Pension Obligation Analysed by Membership Category</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The defined benefit pension obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,390</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,196</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,660</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,540</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,115</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">11,257</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,570</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,880</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,393</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,500</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20,191</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,310</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory', window );">Summary of Post-Retirement Benefit Obligation Analysed By Membership Category</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The post-retirement benefit obligation analysed by membership category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Active</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">306</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">494</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">551</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Retired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">688</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">748</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">808</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">994</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,243</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,363</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory', window );">Summary of Weighted Average Duration of Defined Benefit Obligation</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The weighted average duration of the defined benefit obligation is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">years</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">years</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pension benefits</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">16</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Post-retirement benefits</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Summary of Changes In Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs</a></td>
<td class="text"><div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The effect of changes in assumptions used on the benefit obligations and on the 2023 annual defined benefit pension and post-retirement costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of the plan memberships. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Discount rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,341</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Decrease)/increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(61</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.25%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Inflation rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">0.75%<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">945</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(827</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">1 year<br/> increase<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Life expectancy</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual pension cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in pension obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">1%</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">increase<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Rate of future healthcare inflation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in annual post-retirement benefits cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in post-retirement benefits obligation</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember', window );">Defined benefit pension and post-retirement healthcare scheme. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Summary of Analysis of Defined Benefit Pension Plans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:93%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Pension and other post-employment costs</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">UK pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">114</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">185</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">58</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other overseas pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">170</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">415</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">466</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Analysed as:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Funded defined benefit/hybrid pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">152</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">231</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">318</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded defined benefit pension schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">23</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unfunded post-retirement healthcare schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined benefit schemes</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">291</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Defined contribution pension schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">133</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">119</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">415</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">466</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Summary of Analysis of Defined Benefit Pension Plans</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(a)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cost of sales</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">104</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">128</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Selling, general and administration</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">90</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">136</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">167</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Research and development</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">52</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">291</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">347</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Summary of Net Defined Benefit Liability</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The remeasurements included within post-retirement benefits are detailed below: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain from change in demographic assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain/(loss) from change in financial assumptions</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">219</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">35</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(93</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Experience gains</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">78</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(82</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of average life expectancy assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of balance sheet presentation of defined benefit Pension and post retirement explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of defined benefit pension and post retirement charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit pension obligation analysed by membership category explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit plan actuarial assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movement in defined benefit liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfMovementsInFairValuesOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in fair values of assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of post retirement benefit obligation analysed by membership category explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 138<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_138&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about the maturity profile of a defined benefit obligation. This will include the weighted average duration of the defined benefit obligation and may include other information about the distribution of the timing of benefit payments, such as a maturity analysis of the benefit payments. [Refer: Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 147<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428827952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Summary of Other Provisions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Legal<br/> and&#160;other<br/> disputes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Major<br/> &#160;restructuring<br/> programmes<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Employee<br/> related<br/> provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Other<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;provisions<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,471</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Charge for the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reversed unused</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(261</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Unwinding of discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Utilised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(539</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to assets held for sale/distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(119</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions through business combinations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassifications and other movements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(29</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfer to Pension obligations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,184</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled within one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">652</div></div></td>
<td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">To be settled after one year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">234</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">532</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">218</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,184</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376691648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory', window );">Summary of Fair Value of Contingent Consideration Liabilities</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,479</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,275</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(765</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(107</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(120</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,869</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,063</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(742</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(114</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,076</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement through income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,645</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movement through reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Initial recognition from business combinations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">482</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: operating cash flows</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,058</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash payments: investing activities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(69</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(79</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,890</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">501</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,068</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory', window );">Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.</div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Increase/(decrease) in financial liability</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">and loss/(gain) in Income statement</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Shionogi-</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">ViiV</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;Healthcare</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Novartis</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shionogi-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ViiV</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Healthcare</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Vaccines</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">556</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% increase in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">834</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">154</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(555</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(103</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(506</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15% decrease in sales forecasts*</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(833</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(759</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(199</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(55</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(198</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% increase in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(292</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(80</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">214</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% decrease in discount rate</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">328</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(347</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(38</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of US&#160;Dollar</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(501</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(398</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">171</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(91</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of Euro</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(130</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% increase in probability of milestone success</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">82</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10% decrease in probability of milestone success</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n/a</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(82</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">n/a</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The sales forecast is for ViiV Healthcare sales only in respect of the Shionogi-ViiV Healthcare contingent consideration. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of fair value of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428931520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory', window );">Summary of Other Noncurrent Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Accruals</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deferred income</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">85</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other payables</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">805</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">823</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">899</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">921</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non current liabilities details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366199696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory', window );">Schedule of Contractual Obligations and Commitments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual obligations and commitments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contracted for but not provided in the financial statements:</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,659</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12,082</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">743</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">616</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">138</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">146</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Purchase commitments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">161</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">484</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Pensions and post-retirement benefits</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">345</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">44</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest on loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,322</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7,603</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Future finance charges on leases</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease contracts that have not yet commenced</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">395</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;18,909</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21,188</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Contractual Obligations And Commitments Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428832880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital and share premium account (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory', window );">Summary of Share Capital and Share Premium</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:93%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary&#160;shares&#160;of&#160;25p&#160;each&#160;pre-share&#160;consolidation</div><br/> Ordinary&#160;shares&#160;of&#160;31<div style="vertical-align:top;display:inline;;font-size:6px">1</div>&#8260;<div style="vertical-align:bottom;display:inline;;font-size:6px">4</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">p&#160;each&#160;post-share&#160;consolidation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Share<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share capital issued and fully paid:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,383,102,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,087,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,385,189,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,825,442</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,387,015,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impact of share consolidation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,077,403,011</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Issued under employee share schemes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,731,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,311,343,341</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,440</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of classes of share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365731184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock', window );">Summary of Cumulative Translation Exchange in Equity</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The cumulative translation exchange in equity is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Net translation exchange included in:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Retained<br/> earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Fair&#160;value<br/> reserve</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-<br/> &#160;&#160;&#160;&#160;&#160;&#160;controlling<br/> interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total<br/> &#160;&#160;&#160;&#160;&#160;&#160;translation<br/> exchange</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(524</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(652</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(93</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(239</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(259</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(993</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(692</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(209</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(906</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Movement attributable to discontinued operations<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">263</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">375</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(429</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(531</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL">(a) Includes &#163;(554)&#160;million reclassification to the Consolidated income statement of exchange movements related to the demerger of the Consumer Healthcare business. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory', window );">Summary of Other Comprehensive Income by Equity Category</a></td>
<td class="text">  <div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The analysis of other comprehensive income by equity category is as follows: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">109</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">113</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(28</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(754</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(754</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(786</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(786</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">211</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">211</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(464</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(695</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,187</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">375</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">356</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(89</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(714</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(831</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(239</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(25</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(911</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(911</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">131</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">131</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement losses on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">941</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">941</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(223</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(223</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">454</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(771</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(337</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Retained</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">earnings</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">controlling</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">interests</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that may be subsequently reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets and net investment hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(51</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(59</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on cash flow hedges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(18</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of cash flow hedges to income statement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Items that will not be reclassified to income statement:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange movements on overseas net assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,348</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,348</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on fair value movements on equity investments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(220</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(220</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement gains on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(187</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(187</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on remeasurement defined benefit plans</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">69</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive (expense)/income for the year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(133</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,137</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">970</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Information on net investment hedges is provided in part (d) of Note 44 &#8216;Financial instruments and related disclosures&#8217;. </div>  <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory', window );">Summary of Analysis of Other Reserves</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The analysis of other reserves is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:86%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ESOP&#160;Trust</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">shares</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Fair&#160;value</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;reserve</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(135</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">409</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(48</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,355</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(207</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,117</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(609</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(609</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">529</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">529</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(195</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,205</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Transferred to income and expenses in the year on impairments of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">168</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">168</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(139</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(139</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(780</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(770</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">383</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,463</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(36</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transferred to retained earnings in the year on disposal of equity investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(21</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Balances derecognised on demerger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(169</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(169</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net fair value movement in the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(698</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">141</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(557</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Ordinary shares acquired by ESOP Trusts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,200</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,200</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Write-down of shares held by ESOP Trusts</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">911</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">911</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(353</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(308</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(20</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,129</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,448</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of cumulative translation exchange in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the analysis of other comprehensive income by item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reserves within equity. [Refer: Other reserves [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366426656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory', window );">Summarised Financial Information of Joint Venture</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ViiV Healthcare </div></div></div></div> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK holds 78.3% of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group,</div> giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information available at the latest practicable date in respect of the ViiV Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> is as follows: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,619</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,637</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,848</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,528</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,087</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">762</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other comprehensive income/(expense)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">94</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(17</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">33</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,622</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,070</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">795</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,716</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,796</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,354</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,711</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,070</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,507</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,762</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,121</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8,983</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8,472</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,745</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11,593</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net liabilities</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,675</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6,086</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash inflow from operating activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,442</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,249</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from investing activities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(174</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(287</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(294</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net cash outflow from financing activities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,718</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,608</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(2,483</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in cash and bank overdrafts in the year</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">233</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(528</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember', window );">ViiV healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory', window );">Schedule of Amount Attributable to Joint Venture Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the ViiV Healthcare group are included in GSK&#8217;s financial statements: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of profit for the year attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">415</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">196</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;223</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividends paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">480</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">224</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">419</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(611</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(570</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(539</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember', window );">Consumer health care joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory', window );">Summarised Financial Information of Joint Venture</a></td>
<td class="text"> <div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">GSK held 68% of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> until the demerger on 18&#160;July 2022 (see details in Note 41), giving rise to a material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. Summarised financial information in respect of the Consumer Healthcare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> at 31&#160;December 2021 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:91%;border:0">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:97%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">29,200</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5,251</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">34,451</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4,238</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,733</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,971</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26,480</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory', window );">Schedule of Amount Attributable to Joint Venture Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following amounts attributable to the Consumer Healthcare Joint Venture were included in GSK&#8217;s financial statements in prior years: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:96%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:7pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2020</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the Consolidated balance sheet</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6,609</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,538</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Information About The Amounts Attributable To Non Controlling Interests Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of information about the amounts attributable to non controlling interests explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366059456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and disposals (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations', window );">Summary of Profit After Taxation on Demerger of Discontinued Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the Consumer Healthcare business distributed (54.5%)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of the retained ownership in Haleon plc (13.5%)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,853</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the net assets and liabilities distributed/de-recognised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,887</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest de-recognised</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,038</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on demerger before exchange movements and transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">554</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total gain on the demerger of Consumer Healthcare</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,084</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinancialInformationRelatingToDiscontinuedOperations', window );">Summary of Financial Information Relating to Discontinued Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total results</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Turnover</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,581</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,418</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">9,745</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expense</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,730</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,575</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7,947</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit before tax</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">851</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,843</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,798</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(235</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(263</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(513</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax rate %</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.6%</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">14.3%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28.5%</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">616</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other gains/(losses) on demerger</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,433</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Remeasurement of discontinued operations distributed to shareholders on demerger</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,651</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit after taxation on demerger of discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,700</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,580</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,285</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in discontinued operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">205</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">511</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">409</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings attributable to shareholders from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,495</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,069</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">876</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Earnings per share from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">260.6p</div></div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">26.7p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">22.0p</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory', window );">Summary of Cash Flows from Business Combinations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">investments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received/(paid)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">786</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(27</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents acquired/(divested)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">21</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(481</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">259</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyAcquisitionMember', window );">2020 Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill</a></td>
<td class="text">his represented goodwill of &#163;124&#160;million, cash of &#163;21&#160;million and other assets acquired of &#163;18&#160;million less <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of &#163;14&#160;million and net liabilities of &#163;20&#160;million. <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">124</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> consideration (settlement of a promissory note)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory', window );">Summary of Cash Flows from Business Combinations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:8pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">acquisitions</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;demerger</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disposals</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">- other</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,392</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(34</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">284</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(933</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(9</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,108</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(933</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs paid</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(79</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(141</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(3,187</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,074</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;)</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory', window );">Summary of Profit on Disposal of Businesses</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The profit on the disposal of the businesses in the year of &#163;2,795&#160;million <div style="display:inline;">was </div>calculated as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Horlicks</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">divestment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Other<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration receivable including currency forwards and purchase adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">492</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">157</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">649</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Equity investment in Hindustan Unilever Limited</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,124</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,616</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">157</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,773</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets disposed:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">142</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">143</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">103</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">118</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">68</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">478</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">481</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net (liabilities)/assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(155</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(154</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">536</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">126</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">662</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">240</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">240</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">36</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">288</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">28</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">316</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,792</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,795</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwothousandtwentyoneacquisitionMember', window );">2021 Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory', window );">Summary of Cash Flows from Business Combinations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Business</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Associates</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">and joint</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ventures</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">disposals</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net deferred consideration paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents (divested)/acquired</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash (outflow)/inflow</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory', window );">Summary of Profit on Disposal of Businesses</a></td>
<td class="text">The profit on the disposal of the businesses in the year of &#163;24&#160;million was calculated as follows: <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:97%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Consideration:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash consideration including currency forwards, purchase adjustments and deferred consideration</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets sold:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other net assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Costs:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Deal costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Reclassification of exchange from other comprehensive income</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gain on disposals in 2021</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember', window );">2022 Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:91%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:10pt;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Sierra<br/> Oncology<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Affinivax</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,497</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,467</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,964</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Property, plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">52</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">53</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">175</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">109</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">284</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(55</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(56</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(40</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(77</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(117</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Taxation</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(259</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(236</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(495</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,435</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,307</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,742</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Goodwill</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">162</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">965</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,127</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,272</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,869</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,790</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3,387</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value of contingent consideration</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">482</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">482</div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure Of Cash Flows From Business Combinations Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of&#160;profit after taxation on demerger of discontinued operations .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of profit on disposal of businesses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinancialInformationRelatingToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of&#160;financial information relating to discontinued operations .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67__IFRS03_gB64-B67_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwothousandtwentyoneacquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwothousandtwentyoneacquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428835248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adjustments reconciling profit after tax to operating cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory', window );">Summary of Cash Generated from Operations</a></td>
<td class="text"><div style="margin-top:10pt; margin-bottom:0pt; margin-left:5%; text-indent:-5%; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">42. Adjustments reconciling Total profit after tax to operating cash&#160;flows </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total profit after tax from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,921</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tax on profits</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">707</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits of associates and joint ventures</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Finance expense net of finance income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">803</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,061</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Amortisation of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,086</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Impairment and assets written off</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">481</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of businesses</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(36</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of intangible assets</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(185</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Loss on sale of investments in associates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Profit on sale of equity investments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Changes in working capital:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase)in inventories</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(269</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(158</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(780</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in trade payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">494</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">(Increase) in other receivables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(349</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration paid (see Note 33)</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,058</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(742</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(765</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> increase in contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,628</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in other payables</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">885</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in pension and other provisions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(962</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Share-based incentive plans</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">346</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fair value adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(283</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(170</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(122</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from continuing operations</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,944</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Operating cash flow from discontinued operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">932</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,994</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,422</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total cash generated from operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,876</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,243</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,096</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of adjustments reconciling profit after tax to operating cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366400384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of net cash flow to movement in net debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory', window );">Summary of Net Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:91%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt, at beginning of year, as adjusted</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,838</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25,215</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in cash and bank overdrafts</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,597</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,579</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase/(decrease) in liquid investments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Increase in long-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,025</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of short-term Notes</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,074</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of/(increase in) other short-term loans</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,021</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(301</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of medium term notes (MTNs)</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,594</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Repayment of lease liabilities</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt of subsidiary undertakings acquired</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,531</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> movements</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(134</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(102</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from continuing operations</div> </td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,536</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Decrease/(increase) in net debt from discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,177</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,100</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,027</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total net debt at end of year</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory', window );">Summary of Analysis of Changes in Net Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis&#160;of&#160;changes&#160;in&#160;net&#160;debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2022</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;fair&#160;value</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Demerger</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cash&#160;flow</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">At</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">31&#160;December</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,723</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(450</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">137</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(298</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,597</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">407</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,496</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,818</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(545</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,425</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(909</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,191</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,426</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,146</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(173</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(186</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(167</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(150</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,073</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(220</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,612</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,654</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,559</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,466</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,145</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(223</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,615</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,559</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,789</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,654</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16,194</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(725</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(59</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">186</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(841</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,485</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year attributed to discontinued operations</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(777</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,059</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9,236</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,572</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,222</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,615</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,059</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(8,667</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,035</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(19,838</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,287</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,618</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,424</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17,197</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(865</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(207</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">670</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,983</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,450</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(301</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(912</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">718</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">11,710</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,670</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,888</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div/>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"><div style="font-weight:bold;display:inline;"/></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160; </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Analysis of changes in net debt</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At&#160;1&#160;January</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Exchange</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Other</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Interest</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;expense</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Change</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;in&#160;fair&#160;value<br/> &#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Reclass-</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;ifications</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;Cash&#160;flow<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">At</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;31&#160;December</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">61</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,274</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Overdrafts</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,030</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">574</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(456</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,262</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,414</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,818</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due within one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Commercial paper</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(243</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(252</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,350</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,596</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(230</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(203</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(94</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,695</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,694</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,210</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,145</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Debt due after one year:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">European/US MTN&#160;&amp; Bank facilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,760</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Lease liabilities</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(887</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(132</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(812</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,425</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">313</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(132</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,694</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,572</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net debt</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,780</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(128</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">778</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,838</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Interest payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(753</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(244</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(22</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total liabilities from financing activities*</div> </td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26,441</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(775</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,976</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(23,983</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7.5pt;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Excluding cash and cash equivalents, overdrafts and liquid investments. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of analysis of changes in net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of net cash flow to movement in net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365090576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory', window );">Summary of External Credit Exposure</a></td>
<td class="text"><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> &#163;m</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,215</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">146</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">146</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,253</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">188</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">188</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,399</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,403</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">49</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,978</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AAA/Aaa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">AA/Aa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">A/A<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BBB/Baa<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">BB+/Ba1<br/> and&#160;below<br/> /unrated<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Bank balances and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,687</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">77</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,825</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">US Treasury and Treasury repo only money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquidity funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,395</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">61</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Third party financial derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">200</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">200</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1,449</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">67</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2,887</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">78</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">54</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4,535</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Summary of Financial Assets and Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Notes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;</div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div><br/> &#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div></div></td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/> &#160;<br/> &#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Fair <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value<br/> &#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;<br/> &#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,789</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,789</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Liquid investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,324</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial assets</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,734</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,734</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities measured at amortised cost:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings excluding obligations under lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bonds in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,322</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,311</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12,017</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11,930</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,373</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; bank loans and overdrafts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(447</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(447</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; commercial paper in a designated hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(443</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#8211; other borrowings</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total borrowings excluding lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">f&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,605</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26,860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(41,442</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(41,068</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(45,058</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(48,760</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net financial assets and financial liabilities excluding lease liabilities</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,708</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,334</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(31,515</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(35,217</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Summary of Fair Value of Financial Instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,153</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,327</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Current equity investments and Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,401</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">50</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,399</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">7,309</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,567</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,533</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(77</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(106</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,251</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets measured at fair value through other comprehensive income (FVTOCI):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments designated at FVTOCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,927</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,943</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial assets mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">199</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">59</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,449</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,202</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">419</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,806</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities at fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Contingent consideration liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,076</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(171</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments (fair value movements through OCI)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(57</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,304</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory', window );">Reconciliation of financial instruments with Trade and other receivables and Other non-current assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">financial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At<br/> FVTOCI<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;Total<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables (Note&#160;26)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,166</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">887</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,053</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other non-current assets (Note&#160;24)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,160</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,194</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,632</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,676</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,327</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">3,810</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,200</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,047</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,247</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,851</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,876</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2,660</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">9,536</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory', window );">Reconciliation of Financial Instruments Within Trade and Other Payables, Other Provisions, Other Non-current Liabilities and Contingent Consideration Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">At&#160;FVTPL<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Non-<br/> financial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;instruments</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;At&#160;FVTPL</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;Amortised<br/> cost</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial<br/> &#160;&#160;instruments</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Non-</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;instruments<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables (Note&#160;29)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,198</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16,263</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,554</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other provisions (Note&#160;32)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,121</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,184</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,358</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration liabilities (Note&#160;33)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,068</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities (Note&#160;34)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(815</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(899</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(869</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(921</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,068</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(14,212</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,280</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,134</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(25,414</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,076</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(15,596</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21,672</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,350</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(26,022</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory', window );">Summary of Fair Values of Derivatives Held</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">2022</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">2021</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Fair&#160;value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Interest rate swap contracts<br/> (principal amount &#8211; &#163;nil (2021: &#163;1,996 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Cash flow hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;167&#160;million (2021: &#163;160 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment hedges &#8211; Foreign exchange contracts<br/> (principal amount &#8211; &#163;7,197&#160;million (2021: &#163;5,469 million))</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">111</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives designated and effective as hedging instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(106</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Current</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts<br/> (principal amount &#8211; &#163;5,908&#160;million (2021: &#163;9,728 million))</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">163</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(76</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Embedded and other derivatives</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivatives classified as held for trading</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">165</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(77</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(171</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total derivative instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">206</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory', window );">Summary of Debt Interest Rate Repricing</a></td>
<td class="text"><div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as all classes of borrowings other than lease liabilities. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating and fixed rate debt less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,785</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,398</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,714</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,490</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,576</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,505</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(748</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,425</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,411</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,001</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,953</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Total</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Original issuance profile:</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Fixed rate interest</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,355</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Floating rate interest</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,624</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(803</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19,979</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,158</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock', window );">Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line&#160;item&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">Finance income or expense</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><span style="-sec-ix-hidden:hidden69050893">Intangible</span></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets&#160;</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">4</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(2</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(617</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">194</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="-sec-ix-hidden:hidden69049975">Discontinued</span></div><div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;">operations<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px">(1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="14" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount reclassified to profit or loss&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount<br/> of&#160;hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedged<br/> future&#160;cash<br/> flows<br/> no&#160;longer<br/> expected&#160;to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Due to<br/> hedged&#160;item<br/> affecting<br/> profit&#160;or&#160;loss<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Line item in&#160;<br/> profit or loss&#160;<br/> in&#160;which&#160;<br/> reclassification&#160;<br/> adjustment&#160;<br/> is&#160;included&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to hedged<br/> item affecting<br/> balance sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in balance&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">sheet in which&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is&#160;included&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">Variability in cash flows from a highly probable forecast transaction</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049915">Other </span>operating income/ (expense)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">Other operating income/ (expense)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(1</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Net investment in foreign operations</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">1,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">(7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">Finance income or expense</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;">&#8211;&#160;</td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9.75pt; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassified to the Consolidated income statement on demerger of the Consumer Healthcare business </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Summary of Offsetting of Financial Assets and Liabilities</a></td>
<td class="text"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross<br/> financial<br/> assets/<br/> (liabilities)<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross<br/> financial<br/> (liabilities)/<br/> assets&#160;set&#160;off</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;Net&#160;financial<br/> assets/<br/> (liabilities)&#160;per</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">balance&#160;sheet</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related<br/> amounts&#160;not<br/> set off in the<br/> balance&#160;sheet</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,166</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14,065</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(183</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Gross</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net&#160;financial</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">assets/</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">(liabilities)</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Related</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">amounts&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">offset</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Net</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">balance</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,832</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">206</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">206</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(192</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,450</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15,431</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Derivative financial instruments</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(228</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(228</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">192</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ForeignExchangeSensitivityEquityImpactTextBlock', window );">Foreign exchange sensitivity impact on equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,290</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(964</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation in Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,034</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,515</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">equity&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">equity&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,080</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">814&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,557</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,176&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Summary of Anticipated Contractual Cash Flows Including Interest Payable for the Non-Derivative Financial Liabilities on Undiscounted Basis</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2022</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities&#160;not</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in net debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,786</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(594</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,362</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(19,934</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(570</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,097</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,607</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(531</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,034</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,207</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(489</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(3,386</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(472</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(2,324</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,765</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,810</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,641</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(9,458</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,063</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,856</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,134</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(9,199</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(20,086</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,322</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,008</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(146</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,553</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;">(51,115</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8">)&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At 31&#160;December 2021</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest<br/> on&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Lease<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Finance</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">charge<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease<br/> liabilities</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables<br/> and&#160;other</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">liabilities not<br/> in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Due in less than one year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,399</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(203</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,432</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(20,745</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,042</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(620</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,804</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(120</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,188</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,938</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(924</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,939</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between five and ten years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,440</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,046</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,703</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9,438</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than ten years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,033</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(2,639</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,571</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11,392</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(23,296</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,603</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,015</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(153</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(24,377</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(56,444</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities', window );">Summary of Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:38%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="9" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="6" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash inflows</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross cash outflows&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash inflows</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Gross cash outflows&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> &#160;&#160;&#160;&#160;exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&#160;<br/> &#163;m&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward<br/> starting<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest&#160;rate<br/> swaps</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign<br/> exchange<br/> forward<br/> contracts<br/> &#160;&#160;&#160;&#160;and&#160;swaps<br/> &#163;m</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Forward&#160;<br/> starting&#160;<br/> &#160;&#160;&#160;&#160;interest&#160;rate&#160;<br/> swaps&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Foreign&#160;<br/> &#160;&#160;&#160;&#160;exchange&#160;<br/> forward&#160;<br/> contracts&#160;<br/> and&#160;swaps&#160;<br/> &#163;m&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than one year</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,418</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24,410)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(13)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(41,290)</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between one and two years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between two and three years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between three and four years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Between four and five years</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Greater than five years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">259</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(220)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8211;&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Gross contractual cash flows</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24,418</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(24,410)</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">351</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">41,252</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(337)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;">(41,290)</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock', window );">Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">recognised</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future<br/> cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer<br/> expected to<br/> occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due&#160;to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item<br/> affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049944">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049945">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:bottom">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="12" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Amount reclassified to profit or loss</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Hedging<br/> gains/(losses)<br/> recognised&#160;in<br/> reserves</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Amount</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">of hedge<br/> ineffectiveness<br/> recognised in<br/> profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in profit or</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">loss in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">which hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness<br/> is included</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;future</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">cash flows</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">no longer</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expected to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">occur</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Due to</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedged&#160;item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">affecting</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">profit or loss</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Line item</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;profit&#160;or&#160;loss</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in which</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reclassification</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">adjustment</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">is included</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049946">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><span style="-sec-ix-hidden:hidden69049947">Finance</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">income&#160;or</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">expense</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rates:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Matured in the past</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049948">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td rowspan="3" style="vertical-align:bottom">&#160;&#160;</td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"><span style="-sec-ix-hidden:hidden69049949">Finance</span> <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income&#160;or</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">expense</div> </td>
<td rowspan="3" style="white-space:nowrap;vertical-align:top">&#160; <div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">4</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">3</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:top"><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;</div><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top;text-align:right;">&#8211; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:top">&#160; <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&gt;30 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:1pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Sensitivity Analysis for Each Type of Market Risk</a></td>
<td class="text"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of interest rate movements</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Sterling interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">55</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(34</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in US&#160;Dollar interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(51</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1% (100 basis points) increase in Euro interest rates</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">1.5% (150 basis points) increase in Euro interest rates</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(19</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency', window );">Foreign exchange sensitivity impact on income statement</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">99</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">155</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income statement impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-functional</div> currency foreign exchange exposures</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">income</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">income</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(84</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(121</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Sensitivity Analysis for Each Type of Market Risk</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The tables below present the Group&#8217;s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the composition of net debt as shown in Note 30 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect future foreign currency cash flows. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(999</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(767</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,570</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,199</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">444</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent appreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">698</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen appreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen appreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impact of foreign exchange movements on net debt</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">in&#160;net&#160;debt</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">in&#160;net&#160;debt</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">846</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">661</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the US&#160;Dollar</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,222</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">959</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(375</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 cent depreciation of the Euro</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(13</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(542</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">10 yen depreciation of the Yen</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(12</div></div></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">15 yen depreciation of the Yen</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17</div></div></td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Summary of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Movements in the year for financial instruments measured using Level&#160;3 valuation methods are presented below: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">&#163;m</div></div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div> </td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;">&#160;</div> </td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,657</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5,064</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Exchange adjustments</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net losses recognised in the income statement</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,627</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(1,024</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net gains recognised in other comprehensive income</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">185</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Contingent consideration related to business acquisitions in the period</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(482</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Settlement of contingent consideration liabilities</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,137</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">856</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Additions</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">97</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">99</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Disposals and settlements</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(16</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(19</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Transfers from Level&#160;3</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(694</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,411</div></div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(5,657</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">Interest rate swap contract [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory', window );">Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items</a></td>
<td class="text">The following tables provide information regarding interest rate swap and forward starting interest rate swap contracts outstanding and the related hedged items at 31&#160;December 2021. There were no such swaps at 31&#160;December 2022. Interest rate swap contract assets and liabilities are presented in the line &#8216;Derivative financial instruments&#8217; (either as assets or liabilities) on the Consolidated balance sheet. <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:92%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fair value for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Average</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">recognising</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Fair value&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">contracted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">principal</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">assets/&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">fixed rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(liabilities)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-10</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.1038</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">668</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-30</div> years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.3385</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">935</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">3&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">More than 30 years</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.4515</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">393</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:94%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;in</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Change in</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">cash flow</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">value used for</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge&#160;reserve</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">calculating</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">for continuing</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedge</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">hedges</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">ineffectiveness</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">after tax</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-hedging</div> of long-term interest rate</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeForwardContractsAndSwapsMember', window );">Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statement [LineItems]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory', window );">Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items</a></td>
<td class="text"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:89%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="font-size:6pt;white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2022&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> currency</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Notional<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/> value<br/> &#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.23</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">USD</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">100</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.16</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">50</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">1.14</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">(7</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#8211;&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">167</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">5&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic<br/> change in<br/> value for<br/> calculating<br/> hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(103</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">JPY</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">CAD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SGD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">6,341</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,322</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(300</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">13,981</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,851</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(617</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:92%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2022&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for calculating hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow hedge reserve/foreign<br/> currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Balance&#160;in&#160;cash&#160;flow&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">reserve&#160;arising&#160;from&#160;hedging&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">relationships&#160;for&#160;which&#160;hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">accounting is no longer&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">applied&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from a highly probable forecast transaction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">&#160;&#160;Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">617</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,120</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for<br/> calculating</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Buy foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">USD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">3 to 6 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedging instruments</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Average<br/> exchange&#160;rate</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Foreign<br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;currency</div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notional<br/> value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">change&#160;in&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">value&#160;for&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">calculating&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">hedge&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ineffectiveness&#160;</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Foreign exchange contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Sell foreign currency:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">578&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SGD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">JPY</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Borrowings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Less than 3 months</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Over 6 months</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">EUR</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">4,998</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(4,982</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">459&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">10,719</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(5,176</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">1,118&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:94%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedged items</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Periodic&#160;change&#160;in&#160;value<br/> for&#160;calculating&#160;hedge<br/> ineffectiveness</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Cumulative&#160;balance&#160;in&#160;cash<br/> flow&#160;hedge&#160;reserve/foreign</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">currency&#160;translation&#160;reserve<br/> for continuing hedges</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#163;m</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flow hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Variability in cash flows from foreign exchange exposure arising on<br/> Euro denominated coupon payments relating to debt issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="font-weight:bold;display:inline;">Net investment hedges</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Net investment in foreign operations</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,117</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(873</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Detailed Information about Effectiveness of Hedging Relationships and Amounts reclassified from hedging reserve to profit or loss [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Assets And Non Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial liabilities and non financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ForeignExchangeSensitivityEquityImpactTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange sensitivity equity impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ForeignExchangeSensitivityEquityImpactTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange sensitivity impact of non-functional currency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDebtSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about hedged items. [Refer: Hedged items [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about hedging instruments. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExternalCreditExposuresExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of external credit grades. [Refer: External credit grades [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG24<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_IG24&amp;doctype=Implementation%20Guidance&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExternalCreditExposuresExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Offsetting financial assets and financial liabilities<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F__IFRS07_g13A-13F_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeForwardContractsAndSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeForwardContractsAndSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428816080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee share schemes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareValuePlanExplanatory', window );">Schedule of Number of Shares and ADS Issuable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares and ADS issuable</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">Shares<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">ADS<div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px">(1)</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;Number&#160;(000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">fair value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 1&#160;January 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$34.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,284</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,353</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,416</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,014</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$36.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,074</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,776</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,705</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;13.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$30.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,538</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Awards cancelled</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,718</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">(1,314</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">27,975</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">15,429</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12pt;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">The 2021 and 2020 comparatives have been restated to reflect the demerger of the Consumer Healthcare business and aid year on year volume comparability of awards granted to GSK employees. </div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory', window );">Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge</a></td>
<td class="text">The assumptions used in the model are as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022&#160;Grant</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2021&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">2020&#160;Grant</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.37%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.74%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.07)%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.3%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.8%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.2%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36%</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Expected life</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Savings-related options grant price (including 20% discount)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;11.39</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;12.07</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;10.34</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory', window );">Summary of Option Outstanding</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom: 0.375pt; vertical-align: bottom;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding for the Share Save Plan</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Savings-related</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;">share option schemes</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/> 000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">Weighted<br/> exercise<br/> price</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">At 31&#160;December 2022</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">5,803&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;11.38</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Range of exercise prices on options outstanding at year end</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;10.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;&#160;&#160;&#160;&#160;&#163;14.15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average market price on exercise during year</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;16.15</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Weighted average remaining contractual life</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2.0&#160;years</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory', window );">Summary of Shares Held for Share Award Schemes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share award schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">59,814</div></div></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">23,065</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">353</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">860</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">371</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares held for share option schemes</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Number of shares (000)</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">65</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#163;m</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">&#163;m</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Nominal value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8211;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Carrying value</div></td>
<td style="vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt;background-color:#e7e7e8">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Market value</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfEmployeeShareValuePlanExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee share value plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfEmployeeShareValuePlanExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share options and savings related options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share options outstanding savings related schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of shares held for share award schemes and shares option schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428955568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Schedule of Principal Subsidiaries and Their Countries of Incorporation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">The following represent the principal subsidiaries and their countries of incorporation of the Group at 31&#160;December 2022. The equity share capital of these entities is shown in the percentage columns. All companies are incorporated in their principal country of operation except where stated. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">England</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Group Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Operations UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Wellcome UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Capital plc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Export Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Finance plc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Holdings Limited<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline IHC Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.2) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.3) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property (No.4) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property Development Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Intellectual Property Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Research &amp; Development Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Services Unlimited<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(a) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline US Trading Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Setfirst Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">SmithKline Beecham Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare Finance Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare UK (No.3) Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Viiv Healthcare UK Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Scotland</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.1) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.2) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(c) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK (No.3) Scottish Limited Partnership<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(d) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Affinivax, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Corixa Corporation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Capital Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Holdings (Americas) Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Equity Investments, Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Human Genome Sciences, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Stiefel Laboratories, Inc</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Tesaro, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"/><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline AG (Switzerland)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline B.V. (Netherlands)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Biologicals SA (Belgium)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline GmbH &amp; Co. KG (Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Pharma GmbH (Austria)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Pharmaceuticals SA (Belgium)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline S.A. (Spain)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline S.p.A. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Single Member A.E.B.E. (Greece)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GlaxoSmithKline Trading Services Limited (Republic of Ireland)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Capital B.V. (Netherlands)</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px">(b) </div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Services Sp z o.o. (Poland)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Vaccines GmbH (Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">GSK Vaccines S.r.l. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">JSC GlaxoSmithKline Trading (Russia)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">Laboratoire GlaxoSmithKline (France)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">Laboratorios ViiV Healthcare, S.L. (Spain)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;"><div style="display:inline;">ViiV Healthcare GmbH </div>(Germany)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">ViiV Healthcare S.r.l. (Italy)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"><div style="display:inline;">ViiV Healthcare SAS (France)</div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;">78.3 <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;">&#160;</div> </td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160; <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">&#160;</div> </td></tr></table></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:98%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Others</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;">%</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Saudi Arabia Limited (Saudi Arabia)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">Glaxo Wellcome Manufacturing Pte Ltd (Singapore)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline (Thailand) Limited (Thailand)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Australia Pty Ltd (Australia)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Brasil Limitada (Brazil)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Far East B.V. (Taiwan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. (Turkey)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Inc. (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline K.K. (Japan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Korea Limited (Republic of Korea)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Limited (Hong Kong)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Mexico S.A. de C.V. (Mexico)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Pakistan Limited (Pakistan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GlaxoSmithKline Pharmaceuticals Limited (India)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Enterprise Management Co, Ltd (China)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">GSK Pharma Vietnam Company Limited (Vietnam)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ID Biomedical Corporation of Quebec (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare K.K (Japan)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;">ViiV Healthcare ULC (Canada)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td></tr>
<tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr></table></div><div style="clear: both; font-size: 0pt; max-height: 0px;"/><div style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Directly held wholly-owned subsidiary of GSK plc. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">Tax resident in UK. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP <div style="display:inline;">1</div> Limited&#8217;s share capital is <div style="display:inline;">99</div>% indirectly owned by GSK plc and <div style="display:inline;">1</div>% owned by Berkeley Square Pension Trustee Company Limited. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:12.75pt;vertical-align:top;text-align:left;">(d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;">GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#8217;s share capital is <div style="display:inline;">100</div>% indirectly owned by GSK plc. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428637696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Presentation of the Financial Statements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems', window );"><strong>Disclosure of adjustment for each financial statement line item affected by application IFRS 16 line items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PeriodCoveredByFinancialStatements', window );">Period covered by financial statements</a></td>
<td class="text">These financial statements cover the financial year from 1 January to 31 December 2022, with comparative figures for the financial years from 1 January to 31 December 2021 and, where appropriate, from 1 January to 31 December 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DateOfEndOfReportingPeriod2022', window );">Date of end of reporting period</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DateOfEndOfReportingPeriod2022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of end of reporting period 2022.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DateOfEndOfReportingPeriod2022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of adjustment for each financial statement line item affected by application IFRS 16 [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PeriodCoveredByFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the period covered by the set of financial statements or notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PeriodCoveredByFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365237296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Principles and Policies - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales', window );">Profit sharing costs and royalties due to the counterparty included in cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,635<span></span>
</td>
<td class="nump">&#163; 640<span></span>
</td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CostOfSalesOnCoPromotionalActivities', window );">Cost of sales on co promotional activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RevenueFromCoPromotionalActivities', window );">Revenue from co-promotional activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 3<span></span>
</td>
<td class="nump">&#163; 7<span></span>
</td>
<td class="nump">&#163; 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_VaccinesMember', window );">Vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years, or 30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments', window );">Lease liability on leases with annual payments</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Pharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisableProportionOverExclusivityPeriod', window );">Amortisation rate, Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Pharmaceuticals [member] | Remaining Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments', window );">Lease liability on leases with annual payments</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Pharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisableProportionOverExclusivityPeriod', window );">Amortisation rate, Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Pharmaceuticals [member] | Remaining Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences and franchises [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ERPSoftwareSystemsMember', window );">ERP software systems [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ERPSoftwareSystemsMember', window );">ERP software systems [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 Years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_OtherComputerSoftwareMember', window );">Other computer software [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_OtherComputerSoftwareMember', window );">Other computer software [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems', window );"><strong>Disclosure of accounting principles and policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 Years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AmortisableProportionOverExclusivityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortisable proportion over exclusivity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AmortisableProportionOverExclusivityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CostOfSalesOnCoPromotionalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of sales on co promotional activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CostOfSalesOnCoPromotionalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfAccountingPrinciplesAndPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting principles and policies [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit sharing costs and royalties due to the counterparty included in cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RevenueFromCoPromotionalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from co-promotional activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RevenueFromCoPromotionalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold for applying implicit rate of interest to annual lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_PharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_PharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=gsk_RemainingBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=gsk_RemainingBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ERPSoftwareSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ERPSoftwareSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_OtherComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_OtherComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368128272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_FreeholdBuildingsMember', window );">Freehold buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Useful lives of property plant and equipment</a></td>
<td class="text">20 to 50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_LeaseholdLandAndBuildingsMember', window );">Leasehold land and buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Useful lives of property plant and equipment</a></td>
<td class="text">Lease term or 20 to 50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndMachineryMember', window );">Plant and machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Useful lives of property plant and equipment</a></td>
<td class="text">10 to 20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_EquipmentAndVehiclesMember', window );">Equipment and vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Useful lives of property plant and equipment</a></td>
<td class="text">3 to 10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_FreeholdBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_FreeholdBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_LeaseholdLandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_LeaseholdLandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_EquipmentAndVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_EquipmentAndVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363308768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax charge for the year</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Tax payable, current</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssets', window );">Tax recoverable, current</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Tax payable, non-current</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UncertainTaxPositionsRecognised', window );">Uncertain tax position charge</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LegalCosts', window );">Legal costs</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvision', window );">Provision for legal and other disputes</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities', window );">Contingent consideration and put option liabilities</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">7,068<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
<td class="nump">&#163; 5,869<span></span>
</td>
<td class="nump">&#163; 5,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DefinedBenefitPlanSurplusNet', window );">Surplus on UK defined benefit schemes</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PensionSurplus', window );">Pension surplus</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ActuarialAssumptionPercentageRateAxis=gsk_ActuarialAssumptionPercentageRateChangeMember', window );">Actuarial assumption percentage rate change [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax charge for the year</a></td>
<td class="nump">&#163; 707<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_SensitivityAnalysisForActuarialAssumptionsMember', window );">Sensitivity analysis for actuarial assumptions [member] | Actuarial assumption percentage rate change [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfDecreaseInDiscountRate', window );">Percentage of decrease in discount rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInPlanDeficit', window );">Net pension deficit</a></td>
<td class="nump">&#163; 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfIncreaseInDiscountRate', window );">Percentage of increase in discount rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInPlanDeficit', window );">Net pension deficit</a></td>
<td class="nump">&#163; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">Increased annual pension cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInAnnualPensionCost', window );">Decrease in annnual pension cost</a></td>
<td class="nump">&#163; 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_SensitivityAnalysisForActuarialAssumptionsMember', window );">Sensitivity analysis for actuarial assumptions [member] | Discount Rate at 0.75% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfDecreaseInDiscountRate', window );">Percentage of decrease in discount rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInPlanDeficit', window );">Net pension deficit</a></td>
<td class="nump">&#163; 1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfIncreaseInDiscountRate', window );">Percentage of increase in discount rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInPlanDeficit', window );">Net pension deficit</a></td>
<td class="nump">&#163; 1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">Increased annual pension cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInAnnualPensionCost', window );">Decrease in annnual pension cost</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember', window );">Estimated Rebates Discounts or Allowance Payable To Customer [member] | US Pharmaceuticals and vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">14,542<span></span>
</td>
<td class="nump">11,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CustomerReturnsDiscountsAndRebates', window );">Incidental deductions to turnover</a></td>
<td class="nump">15,272<span></span>
</td>
<td class="nump">12,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment', window );">Customer return and rebate accruals</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember', window );">Shionogi ViiV healthcare joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">5,890<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">&#163; 7,068<span></span>
</td>
<td class="nump">&#163; 6,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer return and rebate accruals, includes (only in Dec 31, 2022) Cash discount and Channel Management Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CustomerReturnsDiscountsAndRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer returns discounts and rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CustomerReturnsDiscountsAndRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseInAnnualPensionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in annual pension cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseInAnnualPensionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseInPlanDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in plan deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseInPlanDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DefinedBenefitPlanSurplusNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan surplus net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DefinedBenefitPlanSurplusNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on contingent consideration and put option liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInAnnualPensionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in annual pension cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInAnnualPensionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInPlanDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in plan deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInPlanDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LegalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LegalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PensionSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PensionSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfDecreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of decrease in discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfDecreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfIncreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfIncreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UncertainTaxPositionsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions recognised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UncertainTaxPositionsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for legal proceedings. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 10 A court case<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ActuarialAssumptionPercentageRateAxis=gsk_ActuarialAssumptionPercentageRateChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ActuarialAssumptionPercentageRateAxis=gsk_ActuarialAssumptionPercentageRateChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_SensitivityAnalysisForActuarialAssumptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_SensitivityAnalysisForActuarialAssumptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ActuarialAssumptionPercentageRateAxis=gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ActuarialAssumptionPercentageRateAxis=gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SegmentConsolidationItemAxis=gsk_USPharmaceuticalsAndVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SegmentConsolidationItemAxis=gsk_USPharmaceuticalsAndVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366177440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfForeignExchangeRatesLineItems', window );"><strong>Disclosure of foreign exchange rates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rates</a></td>
<td class="nump">1.24<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="nump">1.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Period end rates</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="nump">1.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfForeignExchangeRatesLineItems', window );"><strong>Disclosure of foreign exchange rates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rates</a></td>
<td class="nump">1.17<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Period end rates</a></td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">1.19<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Yen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfForeignExchangeRatesLineItems', window );"><strong>Disclosure of foreign exchange rates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rates</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Period end rates</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfForeignExchangeRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfForeignExchangeRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364834064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and Segment Information - Additional Information (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;) </div>
<div>Segments </div>
<div>wholesalers</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfReportableOperatingSegments', window );">Number of reportable operating segments | Segments</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments', window );">Description of factors used to identify entity's reportable segments</a></td>
<td class="text">GSK has revised its operating segments from Q1 2022 and from Q2 2022. Previously GSK reported results under four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. For the first quarter 2022, GSK reported results under three segments: Commercial Operations, Total R&D and Consumer Healthcare. From Q2 2022, GSK reports under two segments from continuing operations as the demerger of the Consumer Healthcare segment was completed on 18&#160;July 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods', window );">Revenue recognised in year from performance obligations satisfied in previous periods</a></td>
<td class="nump">&#163; 1,601<span></span>
</td>
<td class="nump">&#163; 1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RevenueFromChangesToEstimatesOfRARAccruals', window );">Turnover from changes to estimates of RAR accruals</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods', window );">Milestone income</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods', window );">Royalty income</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">29,324<span></span>
</td>
<td class="nump">24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liability</a></td>
<td class="nump">&#163; 7,068<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">&#163; 5,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOperatingSegments', window );">Number of Operating Segments | Segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=gsk_PfizerMember', window );">Pfizer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PutOption', window );">Pfizer put option</a></td>
<td class="nump">&#163; 1,093<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi-ViiV Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liability</a></td>
<td class="nump">&#163; 5,890<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfWholesalers', window );">Number of wholesalers | wholesalers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gsk_Wholesalers1Member', window );">Wholesalers 1 [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 4,045<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gsk_Wholesalers2Member', window );">Wholesalers 2 [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gsk_Wholesalers3Member', window );">Wholesalers 3 [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 3,227<span></span>
</td>
<td class="nump">&#163; 2,670<span></span>
</td>
<td class="nump">&#163; 2,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone income recognised from performance obligations satisfied in previous periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfReportableOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfReportableOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholesalers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PutOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Put option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PutOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RevenueFromChangesToEstimatesOfRARAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from changes to estimates of RAR accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RevenueFromChangesToEstimatesOfRARAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty income recognised from performance obligations satisfied in previous periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the factors used to identify the entity's reportable segments, including the basis of organisation (for example, whether management has chosen to organise the entity around differences in products and services, geographical areas, regulatory environments or a combination of factors and whether operating segments have been aggregated). [Refer: Geographical areas [member]; Operating segments [member]; Products and services [member]; Reportable segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ShionogiViivHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ShionogiViivHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gsk_Wholesalers1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gsk_Wholesalers1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gsk_Wholesalers2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gsk_Wholesalers2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gsk_Wholesalers3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gsk_Wholesalers3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376544128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and Segment Information - Turnover by Segment (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365299952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and Segment Information - Turnover by Product &amp; Service (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_SubTotalMember', window );">Sub Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">8,960<span></span>
</td>
<td class="nump">7,293<span></span>
</td>
<td class="nump">6,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">29,324<span></span>
</td>
<td class="nump">24,696<span></span>
</td>
<td class="nump">24,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | HIV [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">5,749<span></span>
</td>
<td class="nump">4,777<span></span>
</td>
<td class="nump">4,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Immuno-inflammation, respiratory and other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Pandemic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Specialty Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">11,269<span></span>
</td>
<td class="nump">8,251<span></span>
</td>
<td class="nump">6,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Meningitis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Influenza [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Shingles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Established vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">3,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Pandemic Vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">6,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Sub Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">7,873<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
<td class="nump">6,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">6,548<span></span>
</td>
<td class="nump">6,048<span></span>
</td>
<td class="nump">6,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Other General Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | General Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">10,118<span></span>
</td>
<td class="nump">9,667<span></span>
</td>
<td class="nump">10,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProductsAndServicesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProductsAndServicesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_SubTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_SubTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_HIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_HIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_ImmunoInflammationRespiratoryAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_ImmunoInflammationRespiratoryAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_PandemicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_PandemicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_SpecialtyMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_SpecialtyMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_MeningitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_MeningitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_InfluenzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_InfluenzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_ShinglesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_ShinglesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_EstablishedVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_EstablishedVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_PandemicVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_PandemicVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_RespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_RespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_OtherGeneralMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_OtherGeneralMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_GeneralMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_GeneralMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363700288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and Segment Information - Segment Profit and Operating Profit (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">&#163; 6,433<span></span>
</td>
<td class="nump">&#163; 4,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 5,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">(879)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalOfInterestInAssociate', window );">Loss on disposal of interest in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after-tax profits/(losses) of associates and joint ventures</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before taxation</a></td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">3,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxation</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Profit after taxation for the year from continuing operations</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">17,851<span></span>
</td>
<td class="nump">39,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(17,197)<span></span>
</td>
<td class="num">(19,838)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentsInJointVenturesAndAssociates', window );">Investments in associates and joint ventures</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">Current equity investments</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial instruments</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentAndDeferredTaxation', window );">Current and deferred taxation</a></td>
<td class="nump">5,176<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale (excluding cash and cash equivalents)</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">21,342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before taxation</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxation</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SegmentConsolidationItemAxis=ifrs-full_OperatingSegmentsMember', window );">Operating Segments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">8,530<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">17,587<span></span>
</td>
<td class="nump">12,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SegmentConsolidationItemAxis=ifrs-full_UnallocatedAmountsMember', window );">Corporate and Other Unallocated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="num">(379)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SegmentConsolidationItemAxis=ifrs-full_MaterialReconcilingItemsMember', window );">Other Reconciling Items between Segment Profit and Operating Profit [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="num">(1,718)<span></span>
</td>
<td class="num">(2,136)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member] | Operating Segments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member] | Operating Segments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">13,590<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">10,288<span></span>
</td>
<td class="nump">9,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember', window );">Research and Development [Member] | Operating Segments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Segment profit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="num">(5,060)<span></span>
</td>
<td class="num">(4,567)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract', window );"><strong>Depreciation and amortisation by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Total depreciation and amortisation</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>PP&amp;E, intangible asset and goodwill impairment by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentReversalsBySegmentAbstract', window );"><strong>PP&amp;E and intangible asset impairment reversals by segment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total impairment reversals</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#163; (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">&#163; 7,299<span></span>
</td>
<td class="nump">&#163; 3,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentAndDeferredTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current and deferred taxation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentAndDeferredTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalOfInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on disposal of Interest in associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalOfInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpairmentReversalsBySegmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment reversals by segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpairmentReversalsBySegmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentsInJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in joint ventures and associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentsInJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at fair value through profit or loss classified as held for trading. [Refer: Financial assets at fair value through profit or loss, classified as held for trading]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 129<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_129_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SegmentConsolidationItemAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SegmentConsolidationItemAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SegmentConsolidationItemAxis=ifrs-full_UnallocatedAmountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SegmentConsolidationItemAxis=ifrs-full_UnallocatedAmountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SegmentConsolidationItemAxis=ifrs-full_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SegmentConsolidationItemAxis=ifrs-full_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366642784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Turnover and Segment Information - Summary of Geographical Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">31,166<span></span>
</td>
<td class="nump">51,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">5,134<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">14,024<span></span>
</td>
<td class="nump">17,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">6,559<span></span>
</td>
<td class="nump">15,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BE', window );">Belgium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">5,415<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Switzerland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember', window );">Customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">29,324<span></span>
</td>
<td class="nump">24,696<span></span>
</td>
<td class="nump">24,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember', window );">Customer [member] | UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember', window );">Customer [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">14,542<span></span>
</td>
<td class="nump">11,914<span></span>
</td>
<td class="nump">11,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember', window );">Customer [member] | Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 14,087<span></span>
</td>
<td class="nump">&#163; 12,126<span></span>
</td>
<td class="nump">&#163; 12,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets; Types of insurance contracts [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365295808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income/(expense) - Additional Information (Detail)<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfBusinessesAndAssets', window );">Disposal of businesses and assets</a></td>
<td class="nump">&#163; 215<span></span>
</td>
<td colspan="2" class="nump">&#163; 552<span></span>
</td>
<td class="nump">&#163; 2,621<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value remeasurements on contingent consideration</a></td>
<td class="num">(1,607)<span></span>
</td>
<td colspan="2" class="num">&#163; (1,058)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentAxis=gsk_HaleonPlcMember', window );">Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss', window );">Gain or loss on remeasurement of investments measured at fair value through profit or loss</a></td>
<td class="nump">229<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=gsk_HindustanUnileverLimitedMember', window );">Hindustan Unilever Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Gains on embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LossOnSaleOfBusiness', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member] | Horlicks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfBusinessesAndAssets', window );">Disposal of businesses and assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_VaccinesBusinessAcquisitionMember', window );">Vaccines business acquisition [member] | Novartis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value remeasurements on contingent consideration</a></td>
<td class="nump">193<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember', window );">Shionogi ViiV healthcare joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value remeasurements on contingent consideration</a></td>
<td class="nump">&#163; 1,431<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GileadSciencesIncMember', window );">Gilead Sciences, Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems', window );"><strong>Disclosure of other operating income expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 922<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfRoyaltyPayableOnFutureSales', window );">Percentage of royalty payable on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income expense line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalOfBusinessesAndAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of businesses and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalOfBusinessesAndAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain or loss on remeasurement of investments measured at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on sale of business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfRoyaltyPayableOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable on future sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfRoyaltyPayableOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination; Business combinations [member]; Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentAxis=gsk_HaleonPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentAxis=gsk_HaleonPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_HindustanUnileverLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_HindustanUnileverLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_HorlicksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_HorlicksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_VaccinesBusinessAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_VaccinesBusinessAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377145568">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other operating income/(expense) - Information about Other Operating Income Expense (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[2]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract', window );"><strong>Disclosure of other operating income expense [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UpfrontSettlementIncome', window );">Upfront settlement income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#163; 922<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments', window );">Fair value remeasurements of equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">256<span></span>
</td>
<td colspan="2" class="nump">&#163; 37<span></span>
</td>
<td colspan="2" class="num">&#163; (6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfBusinessesAndAssets', window );">Disposal of businesses and assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">215<span></span>
</td>
<td colspan="2" class="nump">552<span></span>
</td>
<td colspan="2" class="nump">2,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value remeasurements on contingent consideration recognised in business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,607)<span></span>
</td>
<td colspan="2" class="num">(1,058)<span></span>
</td>
<td colspan="2" class="num">(1,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends', window );">Remeasurement of ViiV Healthcare put option liabilities and preferential dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(85)<span></span>
</td>
<td colspan="2" class="num">(48)<span></span>
</td>
<td colspan="2" class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Fair value adjustments on derivative financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td colspan="2" class="num">(4)<span></span>
</td>
<td colspan="2" class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td colspan="2" class="nump">17<span></span>
</td>
<td colspan="2" class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#163; (235)<span></span>
</td>
<td colspan="2" class="num">&#163; (504)<span></span>
</td>
<td colspan="2" class="nump">&#163; 1,463<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#8217;s Biktarvy concerning ViiV Healthcare&#8217;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#163;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#8217;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalOfBusinessesAndAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of businesses and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalOfBusinessesAndAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of put option liabilities and preferential dividends</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UpfrontSettlementIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront settlement income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UpfrontSettlementIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination; Business combinations [member]; Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366599696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Profit - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOperatingProfitLineItems', window );"><strong>Disclosure of Operating Profit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Net foreign exchange gains (losses)</a></td>
<td class="num">&#163; (11.0)<span></span>
</td>
<td class="nump">&#163; 4.0<span></span>
</td>
<td class="num">&#163; (99.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Major restructuring costs</a></td>
<td class="nump">321.0<span></span>
</td>
<td class="nump">424.0<span></span>
</td>
<td class="nump">1,178.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PurposeAxis=gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember', window );">Reporting Accountant Work Performed In Connection With Consumer Healthcare Demerger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOperatingProfitLineItems', window );"><strong>Disclosure of Operating Profit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">All other services</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_LiquidationOrDisposalOfInterestInAssociatesMember', window );">Liquidation Or Disposal Of Interest In Associates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOperatingProfitLineItems', window );"><strong>Disclosure of Operating Profit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalOfInterestInAssociates', window );">Gain loss on disposal of interest in associates</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember', window );">Liquidation Or Disposal Of Overseas Subsidiary [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOperatingProfitLineItems', window );"><strong>Disclosure of Operating Profit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Net foreign exchange gains (losses)</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OtherAuditorsMember', window );">Other Auditors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOperatingProfitLineItems', window );"><strong>Disclosure of Operating Profit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Another audit fee of the company's subsidiaries</a></td>
<td class="nump">&#163; 0.1<span></span>
</td>
<td class="nump">&#163; 0.0<span></span>
</td>
<td class="nump">&#163; 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOperatingProfitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Operating Profit [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOperatingProfitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalOfInterestInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on disposal of interest in associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalOfInterestInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PurposeAxis=gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PurposeAxis=gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_LiquidationOrDisposalOfInterestInAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_LiquidationOrDisposalOfInterestInAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OtherAuditorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OtherAuditorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365712512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Profit - Summary of Information About Profit Loss (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee costs (Note 0)</a></td>
<td class="nump">&#163; 7,693.0<span></span>
</td>
<td class="nump">&#163; 7,680.0<span></span>
</td>
<td class="nump">&#163; 8,555.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdvertisingExpense', window );">Advertising</a></td>
<td class="nump">735.0<span></span>
</td>
<td class="nump">433.0<span></span>
</td>
<td class="nump">361.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DistributionCosts', window );">Distribution costs</a></td>
<td class="nump">192.0<span></span>
</td>
<td class="nump">169.0<span></span>
</td>
<td class="nump">176.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">885.0<span></span>
</td>
<td class="nump">855.0<span></span>
</td>
<td class="nump">822.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment, net of reversals</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="nump">424.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets</a></td>
<td class="nump">176.0<span></span>
</td>
<td class="nump">179.0<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentOfRightOfUseAssets', window );">Impairment of right of use assets</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation of intangible assets</a></td>
<td class="nump">1,086.0<span></span>
</td>
<td class="nump">1,088.0<span></span>
</td>
<td class="nump">1,046.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentOfIntangibleAssetsNetOfReversal', window );">Impairment of intangible assets, net of reversals</a></td>
<td class="nump">365.0<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale', window );">Impairment of property, plant and equipment held for sale, net of reversals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment of goodwill allocated to a disposal group, net of reversals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Net foreign exchange (gains)/losses</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Cost of inventories included in cost of sales</a></td>
<td class="nump">6,137.0<span></span>
</td>
<td class="nump">5,885.0<span></span>
</td>
<td class="nump">5,934.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Write-down of inventories</a></td>
<td class="nump">687.0<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="nump">607.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfInventoryWritedown', window );">Reversal of prior year write-down of inventories</a></td>
<td class="num">(483.0)<span></span>
</td>
<td class="num">(325.0)<span></span>
</td>
<td class="num">(250.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short-term lease charge</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Low value lease charge</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities', window );">Variable lease payments</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract', window );"><strong>Operating lease rentals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Fees payable to the company's auditor and its associates in relation to the Group</a></td>
<td class="nump">&#163; 26.9<span></span>
</td>
<td class="nump">&#163; 31.7<span></span>
</td>
<td class="nump">&#163; 29.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment loss recognised in profit or loss property plant and equipment held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpairmentOfIntangibleAssetsNetOfReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of intangible assets net of reversal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpairmentOfIntangibleAssetsNetOfReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpairmentOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Right Of Use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpairmentOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease and sublease payments recognized as expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to the distribution of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366125248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Profit - Summary of Auditors Remuneration (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit</a></td>
<td class="nump">&#163; 20.6<span></span>
</td>
<td class="nump">&#163; 27.7<span></span>
</td>
<td class="nump">&#163; 28.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AuditorsRemunerationForOtherAssuranceServices', window );">Audit-related and other assurance services</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices', window );">Total audit services, audit-related and other assurance services</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">29.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">GSK PLC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit</a></td>
<td class="nump">&#163; 9.7<span></span>
</td>
<td class="nump">&#163; 14.5<span></span>
</td>
<td class="nump">&#163; 14.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditors remuneration for audit related and other assurance services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AuditorsRemunerationForOtherAssuranceServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor's remuneration for other assurance services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AuditorsRemunerationForOtherAssuranceServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376707888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs - Summary of Employee Costs (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Short-term employee benefits expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">&#163; 6,110<span></span>
</td>
<td class="nump">&#163; 5,858<span></span>
</td>
<td class="nump">&#163; 6,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostEmploymentBenefitExpense', window );">Pension and other post-employment costs, including augmentations (Note 31)</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TerminationBenefitsExpense', window );">Severance and other costs from integration and restructuring activities</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee benefits expense</a></td>
<td class="nump">&#163; 7,693<span></span>
</td>
<td class="nump">&#163; 7,680<span></span>
</td>
<td class="nump">&#163; 8,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PostEmploymentBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PostEmploymentBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TerminationBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 171<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_171&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TerminationBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366742496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems', window );"><strong>Expense from share based payment transactions with employees [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">&#163; 314<span></span>
</td>
<td class="nump">&#163; 345<span></span>
</td>
<td class="nump">&#163; 330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember', window );">Share Value Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems', window );"><strong>Expense from share based payment transactions with employees [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember', window );">Performance Share Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems', window );"><strong>Expense from share based payment transactions with employees [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionPlanMember', window );">Share option plans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems', window );"><strong>Expense from share based payment transactions with employees [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_CashSettledAndOtherPlansMember', window );">Cash settled and other plans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems', window );"><strong>Expense from share based payment transactions with employees [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans</a></td>
<td class="nump">&#163; 12<span></span>
</td>
<td class="nump">&#163; 31<span></span>
</td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense From Share Based Payment Transactions With Employees [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_CashSettledAndOtherPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_CashSettledAndOtherPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366094176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail) - Employee<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems', window );"><strong>Disclosure of employee costs and numbers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageNumberOfEmployeesFromContinuingOperations', window );">Continuing Operations</a></td>
<td class="nump">69,130<span></span>
</td>
<td class="nump">71,345<span></span>
</td>
<td class="nump">73,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations', window );">Discontinued Operations</a></td>
<td class="nump">21,292<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
<td class="nump">22,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of employees</a></td>
<td class="nump">90,422<span></span>
</td>
<td class="nump">91,961<span></span>
</td>
<td class="nump">95,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ManufacturingMember', window );">Manufacturing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems', window );"><strong>Disclosure of employee costs and numbers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageNumberOfEmployeesFromContinuingOperations', window );">Continuing Operations</a></td>
<td class="nump">22,946<span></span>
</td>
<td class="nump">23,562<span></span>
</td>
<td class="nump">24,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_SellingGeneralAndAdministrationMember', window );">Selling, general and administration [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems', window );"><strong>Disclosure of employee costs and numbers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageNumberOfEmployeesFromContinuingOperations', window );">Continuing Operations</a></td>
<td class="nump">34,642<span></span>
</td>
<td class="nump">36,909<span></span>
</td>
<td class="nump">37,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems', window );"><strong>Disclosure of employee costs and numbers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageNumberOfEmployeesFromContinuingOperations', window );">Continuing Operations</a></td>
<td class="nump">11,542<span></span>
</td>
<td class="nump">10,874<span></span>
</td>
<td class="nump">10,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AverageNumberOfEmployeesFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average number of employees from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AverageNumberOfEmployeesFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AverageNumberOfEmployeesFromDiscontinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average number of employees from discontinuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AverageNumberOfEmployeesFromDiscontinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfEmployeeCostsAndNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee costs and numbers line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfEmployeeCostsAndNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_SellingGeneralAndAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_SellingGeneralAndAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367633616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EmployeesBenefitAbstract', window );"><strong>Employees Benefit [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Wages and salaries</a></td>
<td class="nump">&#163; 31<span></span>
</td>
<td class="nump">&#163; 27<span></span>
</td>
<td class="nump">&#163; 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts', window );">Social security costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension and other post-employment costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based incentive plans</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">&#163; 66<span></span>
</td>
<td class="nump">&#163; 60<span></span>
</td>
<td class="nump">&#163; 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EmployeesBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employees Benefit [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EmployeesBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_KeyManagementPersonnelCompensationSocialSecurityCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation, social security costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_KeyManagementPersonnelCompensationSocialSecurityCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376378048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Restructuring Costs - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TotalRestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">&#163; 321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AssetImpairments', window );">Asset impairments</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherNonCashCredit', window );">Other&#160;non-cash&#160;credit</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember', window );">Separation Preparation programme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseProvisionReversalRestructuring', window );">Increase decrease provision reversal restructuring</a></td>
<td class="nump">&#163; 111<span></span>
</td>
<td class="nump">&#163; 140<span></span>
</td>
<td class="nump">&#163; 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AssetImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset impairments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AssetImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfRestructuringCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of restructuring costs line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfRestructuringCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseProvisionReversalRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease provision reversal restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseProvisionReversalRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherNonCashCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other&#160;non cash&#160;credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherNonCashCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Major restructuring costs considered to be significant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TotalRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TotalRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377651968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MajorRestructuringCostsAbstract', window );"><strong>Major Restructuring Costs [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes', window );">Increase in provision for Major restructuring programmes</a></td>
<td class="nump">&#163; 138<span></span>
</td>
<td class="nump">&#163; 321<span></span>
</td>
<td class="nump">&#163; 606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfProvisionsForCostOfRestructuring', window );">Amount of provision reversed unused</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment losses recognised</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherMaterialNoncashItems', window );">Other non-cash charges/(credit)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherCostsCashSettlement', window );">Other cash costs</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CostChargedToOperatingProfit', window );">Cost charged to operating profit</a></td>
<td class="nump">&#163; 321<span></span>
</td>
<td class="nump">&#163; 424<span></span>
</td>
<td class="nump">&#163; 1,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CostChargedToOperatingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost charged to operating profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CostChargedToOperatingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in provision for major restructuring programmes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MajorRestructuringCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Major Restructuring Costs [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MajorRestructuringCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherCostsCashSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other costs cash settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherCostsCashSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherMaterialNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of material non-cash items other than depreciation and amortisation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherMaterialNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfProvisionsForCostOfRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversals of provisions for the cost of restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfProvisionsForCostOfRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364810656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashRestructuringCharges', window );">Cash restructuring charges</a></td>
<td class="nump">&#163; 206<span></span>
</td>
<td class="nump">&#163; 385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonCashRestructuringCharges', window );">Non cash restructuring Charges</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCosts1', window );">Restructuring costs</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember', window );">Separation Preparation programme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashRestructuringCharges', window );">Cash restructuring charges</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonCashRestructuringCharges', window );">Non cash restructuring Charges</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCosts1', window );">Restructuring costs</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ArrangementTypeAxis=gsk_LegacyProgrammesMember', window );">Legacy Programmes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashRestructuringCharges', window );">Cash restructuring charges</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonCashRestructuringCharges', window );">Non cash restructuring Charges</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCosts1', window );">Restructuring costs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">&#163; 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ArrangementTypeAxis=gsk_SignificantAcquisitionsMember', window );">Significant Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashRestructuringCharges', window );">Cash restructuring charges</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonCashRestructuringCharges', window );">Non cash restructuring Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCosts1', window );">Restructuring costs</a></td>
<td class="nump">&#163; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfRestructuringCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of restructuring costs line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfRestructuringCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NonCashRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash restructuring charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NonCashRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RestructuringCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring costs1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RestructuringCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ArrangementTypeAxis=gsk_SeparationPreparationProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ArrangementTypeAxis=gsk_LegacyProgrammesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ArrangementTypeAxis=gsk_LegacyProgrammesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ArrangementTypeAxis=gsk_SignificantAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ArrangementTypeAxis=gsk_SignificantAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365961552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">&#163; 9,554<span></span>
</td>
<td class="nump">&#163; 8,163<span></span>
</td>
<td class="nump">&#163; 7,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="nump">8,372<span></span>
</td>
<td class="nump">7,070<span></span>
</td>
<td class="nump">7,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CostChargedToOperatingProfit', window );">Cost charged to operating profit</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RestructuringCostsAxis=gsk_CostOfMajorRestructuringMember', window );">Cost of major restructuring [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfRestructuringCostsLineItems', window );"><strong>Disclosure of restructuring costs [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CostChargedToOperatingProfit', window );">Cost charged to operating profit</a></td>
<td class="nump">&#163; 321<span></span>
</td>
<td class="nump">&#163; 424<span></span>
</td>
<td class="nump">&#163; 1,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CostChargedToOperatingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost charged to operating profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CostChargedToOperatingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfRestructuringCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of restructuring costs line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfRestructuringCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RestructuringCostsAxis=gsk_CostOfMajorRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RestructuringCostsAxis=gsk_CostOfMajorRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376618400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income - Summary of Finance Income (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems', window );"><strong>Disclosure Of Financial Income and Expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost', window );">Financial assets measured at amortised cost</a></td>
<td class="nump">&#163; 31<span></span>
</td>
<td class="nump">&#163; 11<span></span>
</td>
<td class="nump">&#163; 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss', window );">Financial assets measured at fair value through profit or loss</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations', window );">Net gains arising from the forward element of forward contracts in net investment hedge relationships</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other finance income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">&#163; 76<span></span>
</td>
<td class="nump">&#163; 14<span></span>
</td>
<td class="nump">&#163; 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialIncomeAndExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Income and Expense [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialIncomeAndExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on the ineffective portion of hedges of net investments in foreign operations recognised in profit or loss. [Refer: Hedges of net investment in foreign operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_24_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on financial assets designated at fair value through profit or loss. [Refer: Interest income; Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367091536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expense - Summary of Finance Cost (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsAbstract', window );"><strong>Finance expense arising on:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss', window );">Financial liabilities at amortised cost</a></td>
<td class="num">&#163; (789)<span></span>
</td>
<td colspan="2" class="num">&#163; (735)<span></span>
</td>
<td class="num">&#163; (811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue', window );">Net losses arising from: Financial instruments mandatorily measured at fair value through profit or loss</a></td>
<td class="nump">743<span></span>
</td>
<td colspan="2" class="num">(565)<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReTranslationOfLoan', window );">Retranslation of loans</a></td>
<td class="num">(761)<span></span>
</td>
<td colspan="2" class="nump">565<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax', window );">Reclassification of hedges from other comprehensive income</a></td>
<td class="num">(2)<span></span>
</td>
<td colspan="2" class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Unwinding of discounts on provisions</a></td>
<td class="num">(7)<span></span>
</td>
<td colspan="2" class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Finance expense arising on lease liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td colspan="2" class="num">(27)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other finance expense</a></td>
<td class="num">(33)<span></span>
</td>
<td colspan="2" class="num">(3)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance Costs</a></td>
<td class="num">&#163; (879)<span></span>
</td>
<td colspan="2" class="num">&#163; (769)<span></span>
</td>
<td class="num">&#163; (874)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReTranslationOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re translation of loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReTranslationOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets mandatorily measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Financial assets at fair value through profit or loss, mandatorily measured at fair value; Gains (losses) on financial assets at fair value through profit or loss; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense for financial liabilities that are not at fair value through profit or loss. [Refer: At fair value [member]; Interest expense; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24E<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24E_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366846080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after-tax profit / losses of associates and joint ventures</a></td>
<td class="num">&#163; (2)<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember', window );">Joint ventures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after-tax profit / losses of associates and joint ventures</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember', window );">Associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after-tax profit / losses of associates and joint ventures</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 36<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial information of associates and joint ventures [line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366095168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and joint ventures - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfJointVenturesAndAssociatesLineItems', window );"><strong>Disclosure of joint ventures and associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">&#163; (831)<span></span>
</td>
<td class="num">&#163; (337)<span></span>
</td>
<td class="nump">&#163; 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SalesToAssociatesAndJointVentures', window );">Sales to associates and joint ventures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after tax profits and losses of associates and joint ventures</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember', window );">Innoviva Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfJointVenturesAndAssociatesLineItems', window );"><strong>Disclosure of joint ventures and associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of after tax profits and losses of associates and joint ventures</a></td>
<td class="nump">&#163; 33<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfJointVenturesAndAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Joint Ventures And Associates [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfJointVenturesAndAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SalesToAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales to associates and joint ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SalesToAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365063536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324<span></span>
</td>
<td class="nump">&#163; 24,696<span></span>
</td>
<td class="nump">&#163; 24,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit after taxation</a></td>
<td class="nump">15,621<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">6,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">&#163; 14,790<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">7,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_InnovivaIncMember', window );">Innoviva Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit after taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 106<span></span>
</td>
<td class="nump">&#163; 174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial information of associates and joint ventures [line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_InnovivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_InnovivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366160128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Share of after-tax losses</a></td>
<td class="nump">&#163; 15,621<span></span>
</td>
<td class="nump">&#163; 5,096<span></span>
</td>
<td class="nump">&#163; 6,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Share of other comprehensive income/(expense)</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Share of total comprehensive income/(expense)</a></td>
<td class="nump">14,790<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">7,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_OtherAssociatesMember', window );">Other associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of financial information of associates and joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Share of after-tax losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Share of other comprehensive income/(expense)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Share of total comprehensive income/(expense)</a></td>
<td class="num">&#163; (11)<span></span>
</td>
<td class="nump">&#163; 28<span></span>
</td>
<td class="nump">&#163; 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial information of associates and joint ventures [line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_OtherAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=gsk_OtherAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365295344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Summary of Taxation Charge Based on Profits (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxExpensesincomeAbstract', window );"><strong>Current tax expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Charge/(credit) in respect of prior periods</a></td>
<td class="num">&#163; (60)<span></span>
</td>
<td class="nump">&#163; 219<span></span>
</td>
<td class="nump">&#163; 11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Current taxation</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxation</a></td>
<td class="num">(784)<span></span>
</td>
<td class="num">(848)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total tax</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxExpensesincomeAbstract', window );"><strong>Current tax expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxExpensesincomeAbstract', window );"><strong>Current tax expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="nump">&#163; 1,351<span></span>
</td>
<td class="nump">&#163; 593<span></span>
</td>
<td class="nump">&#163; 745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxExpensesincomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax expenses (income).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxExpensesincomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363244096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProvisionsForUncertainTaxPosition', window );">Provisions For Uncertain Tax Position</a></td>
<td class="nump">&#163; 551<span></span>
</td>
<td class="nump">&#163; 858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Provision for deferred tax liabilities</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnremittedEarnings', window );">Unremitted profits</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided', window );">Unremitted profits for which deferred tax not provided</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxAssetsRecognizedOnTradingLosses', window );">Deferred tax assets recognized on trading losses</a></td>
<td class="nump">&#163; 1,661<span></span>
</td>
<td class="nump">&#163; 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid, classified as operating activities</a></td>
<td class="nump">&#163; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OverseasMember', window );">Overseas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Provision for deferred tax liabilities</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">&#163; 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Payments of corporation tax</a></td>
<td class="nump">&#163; 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Reduced Tax Rate Cancelled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_GbMember', window );">Uk [Member] | Increase In The Headline Rate Of Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncomeTaxExpenseBenefitsLineItems', window );"><strong>Income tax expense benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HeadlineUkTaxRateEffective2023', window );">Headline UK tax rate effective 2023.</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxAssetsRecognizedOnTradingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets recognized on trading losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxAssetsRecognizedOnTradingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HeadlineUkTaxRateEffective2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Headline UK tax rate effective 2023.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HeadlineUkTaxRateEffective2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncomeTaxExpenseBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense Benefits [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncomeTaxExpenseBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProvisionsForUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions for uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProvisionsForUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UnremittedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unremitted earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UnremittedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UnremittedProfitsForWhichDeferredTaxNotProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unremitted profits for which deferred tax not provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UnremittedProfitsForWhichDeferredTaxNotProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OverseasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_OverseasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EventAxis=gsk_ReducedTaxRateCancelledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EventAxis=gsk_ReducedTaxRateCancelledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_GbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_GbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EventAxis=gsk_IncreaseInTheHeadlineRateOfTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EventAxis=gsk_IncreaseInTheHeadlineRateOfTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365967376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract', window );"><strong>Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="nump">&#163; 5,628<span></span>
</td>
<td class="nump">&#163; 3,599<span></span>
</td>
<td class="nump">&#163; 5,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">UK statutory rate of taxation</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Differences in overseas taxation rates</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives', window );">Benefit of intellectual property incentives</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxEffectOfResearchAndDevelopmentCredits', window );">R&amp;D credits</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers', window );">Permanent differences on disposals, acquisitions and transfers</a></td>
<td class="nump">275<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other permanent differences</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates', window );">Re-assessments of prior year current tax estimates</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates', window );">Re-assessments of prior year deferred tax estimates</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxEffectOfChangeInTaxRate', window );">Changes in Tax Rates</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax charge/tax rate</a></td>
<td class="nump">&#163; 707<span></span>
</td>
<td class="nump">&#163; 83<span></span>
</td>
<td class="nump">&#163; 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">UK statutory rate of taxation</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Differences in overseas taxation rates</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives', window );">Benefit of intellectual property incentives</a></td>
<td class="num">(10.70%)<span></span>
</td>
<td class="num">(10.60%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfResearchAndDevelopmentCredits', window );">R&amp;D credits</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers', window );">Permanent differences on disposals, acquisitions and transfers</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other permanent differences</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates', window );">Re-assessments of prior year current tax estimates</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates', window );">Re-assessments of prior year deferred tax estimates</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
<td class="num">(5.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxRateEffectOfChangeInTaxRate', window );">Changes in Tax Rates</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(9.80%)<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Tax charge/tax rate</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of benefit of intellectual property incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxEffectOfChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of change in tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxEffectOfChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxEffectOfReassessmentsOfPriorYearEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of reassessments of prior year estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxEffectOfReassessmentsOfPriorYearEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of reassessments&#160;of prior year deferred tax estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxEffectOfResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effect of research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxEffectOfResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of benefit of intellectual property incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of change in tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Permanent Differences On Disposals Acquisitions and Transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Permanent Differences Percentage On Disposals Acquisitions and Transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of reassessments of prior year estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of reassessments&#160;of prior year deferred tax estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxRateEffectOfResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxRateEffectOfResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366626704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxationAbstract', window );"><strong>Current taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Share-based payments</a></td>
<td class="num">&#163; (3)<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="num">&#163; (14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome', window );">Current Tax On Fair Value Movements On Cash Flow Hedges Charged Or Credited Directly To Comprehensive Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome', window );">Current Tax On Fair Value Movements On Equity Investments Charged Or Credited Directly To Comprehensive Income</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Total equity and comprehensive income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract', window );"><strong>Deferred taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Share-based payments</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome', window );">Defined benefit plans</a></td>
<td class="num">(211)<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome', window );">Fair value movements on equity investments</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Total equity and comprehensive income</a></td>
<td class="num">(277)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Total credit to equity and statement of comprehensive income</a></td>
<td class="num">&#163; (268)<span></span>
</td>
<td class="nump">&#163; 89<span></span>
</td>
<td class="nump">&#163; 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax on defined benefit plans charged or credited directly to equity and comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax on fair value movements on cash flow hedges charged or credited directly to comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax on fair value movements on equity investments charged or credited directly to comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax on share based payments charged or credited directly to equity and comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CurrentTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CurrentTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax on share based payments charged or credited directly to equity and comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax relating to defined benefit plans charged or credited directly to comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax relating to fair value movements on cash flow hedges charged or credited directly to comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax relating to fair value movements on equity investments charged or credited directly to comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax relating to items charged or credited directly to equity and comprehensive income [abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate current and deferred tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Deferred tax relating to items credited (charged) directly to equity; Retained earnings; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Retained earnings; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362474800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">&#163; 1,662<span></span>
</td>
<td class="nump">&#163; 687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">201<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="num">(495)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">5,369<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionAndAwardSchemesMember', window );">Share option and award schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent Consideration [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="num">(3,711)<span></span>
</td>
<td class="num">(3,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="num">(637)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="num">(819)<span></span>
</td>
<td class="num">(3,711)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=gsk_AcceleratedCapitalAllowancesMember', window );">Accelerated capital allowances [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax losses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Share option and award schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Contingent Consideration [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Intangible assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Accelerated capital allowances [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Tax losses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember', window );">Origination and reversal of temporary differences [member] | Other temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember', window );">Pensions and other post-employment benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">64<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember', window );">Pensions and other post-employment benefits [member] | Origination and reversal of temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=gsk_IntraGroupProfitMember', window );">Intra group profit [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 1 January 2021</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome', window );">Credit/(charge) to statement of comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisitions/Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation', window );">R&amp;D credits utilisation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset', window );">Transfer of assets held for sale/ distribution</a></td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">At 31 December 2022</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=gsk_IntraGroupProfitMember', window );">Intra group profit [member] | Origination and reversal of temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Changes in deferred tax liability (asset) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credit/(charge) to income statement</a></td>
<td class="nump">&#163; 258<span></span>
</td>
<td class="num">&#163; (31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax relating to items charged or credited directly to equity and comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through research and development credits utilisation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through transfer of assets held for sale or distribution deferred tax liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionAndAwardSchemesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionAndAwardSchemesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=gsk_AcceleratedCapitalAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=gsk_AcceleratedCapitalAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxReformsPeriodOfApplicationAxis=gsk_OriginationAndReversalOfTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=gsk_IntraGroupProfitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=gsk_IntraGroupProfitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367596192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxation - Summary of Net Deferred Tax Asset (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">&#163; 5,658<span></span>
</td>
<td class="nump">&#163; 5,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Total</a></td>
<td class="nump">&#163; 5,369<span></span>
</td>
<td class="nump">&#163; 1,662<span></span>
</td>
<td class="nump">&#163; 687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376281776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxLosses', window );">Tax losses</a></td>
<td class="nump">&#163; 1,203<span></span>
</td>
<td class="nump">&#163; 1,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses', window );">Unrecognised deferred tax asset</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalLosses', window );">Tax losses</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses', window );">Capital losses</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_LaterThanOneYearAndNotLaterThanTenYearMember', window );">Within 10 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxLosses', window );">Tax losses</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses', window );">Unrecognised deferred tax asset</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember', window );">Greater Than Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxLosses', window );">Tax losses</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses', window );">Unrecognised deferred tax asset</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_AvailableIndefinitelyMember', window );">Available indefinitely [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxLosses', window );">Tax losses</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses', window );">Unrecognised deferred tax asset</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalLosses', window );">Tax losses</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses', window );">Capital losses</a></td>
<td class="nump">&#163; 548<span></span>
</td>
<td class="nump">&#163; 557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CapitalLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CapitalLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognised deferred tax asset on capital losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UnrecognisedDeferredTaxAssetOnTradingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognised deferred tax asset on trading losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UnrecognisedDeferredTaxAssetOnTradingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_LaterThanOneYearAndNotLaterThanTenYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_LaterThanOneYearAndNotLaterThanTenYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_AvailableIndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_AvailableIndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366193792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail) - &#163; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share from continuing operations</a></td>
<td class="nump">&#163; 1.108<span></span>
</td>
<td class="nump">&#163; 0.829<span></span>
</td>
<td class="nump">&#163; 1.224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share from discontinued operations</a></td>
<td class="nump">2.606<span></span>
</td>
<td class="nump">0.267<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total basic earnings per share</a></td>
<td class="nump">3.714<span></span>
</td>
<td class="nump">1.096<span></span>
</td>
<td class="nump">1.444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share from continuing operations</a></td>
<td class="nump">1.092<span></span>
</td>
<td class="nump">0.818<span></span>
</td>
<td class="nump">1.209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share from discontinued operations</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">0.264<span></span>
</td>
<td class="nump">0.217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted earnings per share</a></td>
<td class="nump">&#163; 3.662<span></span>
</td>
<td class="nump">&#163; 1.082<span></span>
</td>
<td class="nump">&#163; 1.426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428707648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average number of shares in issue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic</a></td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,003<span></span>
</td>
<td class="nump">3,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Dilution for share options and awards</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted</a></td>
<td class="nump">4,084<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376446480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends - Summary of Interim Financial Reporting (Detail) - GBP (&#163;)<br> &#163; / shares in Units, &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend per share (pence)</a></td>
<td class="nump">&#163; 0.6125<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Total dividend</a></td>
<td class="nump">&#163; 2,468<span></span>
</td>
<td class="nump">&#163; 4,011<span></span>
</td>
<td class="nump">&#163; 3,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_FirstInterimMember', window );">First interim [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsPaidDate', window );">Paid/payable</a></td>
<td class="text">Jul.  01,  2022<span></span>
</td>
<td class="text">Jul.  08,  2021<span></span>
</td>
<td class="text">Jul.  09,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend per share (pence)</a></td>
<td class="nump">&#163; 0.175<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Total dividend</a></td>
<td class="nump">&#163; 704<span></span>
</td>
<td class="nump">&#163; 951<span></span>
</td>
<td class="nump">&#163; 946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_SecondInterimMember', window );">Second interim [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsPaidDate', window );">Paid/payable</a></td>
<td class="text">Oct.  06,  2022<span></span>
</td>
<td class="text">Oct.  07,  2021<span></span>
</td>
<td class="text">Oct.  08,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend per share (pence)</a></td>
<td class="nump">&#163; 0.1625<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Total dividend</a></td>
<td class="nump">&#163; 654<span></span>
</td>
<td class="nump">&#163; 951<span></span>
</td>
<td class="nump">&#163; 946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_ThirdInterimMember', window );">Third interim [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsPaidDate', window );">Paid/payable</a></td>
<td class="text">Jan. 12,  2023<span></span>
</td>
<td class="text">Jan. 13,  2022<span></span>
</td>
<td class="text">Jan. 14,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend per share (pence)</a></td>
<td class="nump">&#163; 0.1375<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
<td class="nump">&#163; 0.2375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Total dividend</a></td>
<td class="nump">&#163; 555<span></span>
</td>
<td class="nump">&#163; 952<span></span>
</td>
<td class="nump">&#163; 946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_FourthInterimMember', window );">Fourth interim [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsPaidDate', window );">Paid/payable</a></td>
<td class="text">Apr. 13,  2023<span></span>
</td>
<td class="text">Apr.  07,  2022<span></span>
</td>
<td class="text">Apr.  08,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend per share (pence)</a></td>
<td class="nump">&#163; 0.1375<span></span>
</td>
<td class="nump">&#163; 0.2875<span></span>
</td>
<td class="nump">&#163; 0.2875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Total dividend</a></td>
<td class="nump">&#163; 555<span></span>
</td>
<td class="nump">&#163; 1,157<span></span>
</td>
<td class="nump">&#163; 1,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDividendsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDividendsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendsPaidDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendsPaidDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid by the entity on ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2022-03-24<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2022-03-24<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_FirstInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_FirstInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_SecondInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_SecondInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_ThirdInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_ThirdInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_FourthInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_FourthInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical) - Fourth Interim [member]<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of Dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDividendPayables', window );">Provision for dividend payable</a></td>
<td class="nump">&#163; 1,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalProvisionForDividendPayable', window );">Additional provision for dividend payable</a></td>
<td class="nump">&#163; 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalProvisionForDividendPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional provision for dividend payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalProvisionForDividendPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDividendsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDividendsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDividendPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current dividend payables. [Refer: Dividend payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDividendPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_FourthInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_FourthInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366788048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends - Additional Information (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of Dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfInterimDividendRecognitonAndPayment', window );">Description of compliance with IFRSs applied For interim financial report</a></td>
<td class="text">Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2022 financial statements recognise those dividends paid in 2022, namely the third and fourth interim dividends for 2021, and the first and second interim dividends for 2022.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_DemergerOfConsumerHealthcareBusinessMember', window );">Demerger of Consumer Healthcare Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsLineItems', window );"><strong>Disclosure of Dividends [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfAssetdistributedAsDividendInSpecie', window );">Fair Value of Asset Distributed as Dividend in Specie</a></td>
<td class="nump">&#163; 15,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfInterimDividendRecognitonAndPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of interim dividend recogniton and payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfInterimDividendRecognitonAndPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDividendsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDividendsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfAssetdistributedAsDividendInSpecie">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair&#8203; value&#8203; of asset &#8203;distributed as dividend in specie.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfAssetdistributedAsDividendInSpecie</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_DemergerOfConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_DemergerOfConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367140656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dividends - Summary of Dividends to Shareholders (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDividendsAbstract', window );"><strong>Disclosure of Dividends [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashDividendsPaidToShareholdersRecognizedInYear', window );">Cash dividends to shareholders</a></td>
<td class="nump">&#163; 3,467<span></span>
</td>
<td class="nump">&#163; 3,999<span></span>
</td>
<td class="nump">&#163; 3,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear', window );">Dividends in specie to shareholders in Haleon plc shares</a></td>
<td class="nump">15,526<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsRecognisedInYear', window );">Dividends to shareholders</a></td>
<td class="nump">&#163; 18,993<span></span>
</td>
<td class="nump">&#163; 3,999<span></span>
</td>
<td class="nump">&#163; 3,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashDividendsPaidToShareholdersRecognizedInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash dividends paid to shareholders recognized in year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashDividendsPaidToShareholdersRecognizedInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDividendsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDividendsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend paid to shareholders on demergerd entity recognized in year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendsRecognisedInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends recognised in year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendsRecognisedInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366801456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation', window );">Weighted average interest rate for capitalised borrowing costs</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage', window );">Weighted average cost of capital post tax discount rate percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage', window );">Weighted average cost of capital pre-tax discount rate percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="nump">&#163; 70<span></span>
</td>
<td class="nump">&#163; 87<span></span>
</td>
<td class="nump">&#163; 424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Assets in construction reclassified to intangible assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_CostOfSalesMember', window );">Cost of sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=gsk_ResearchAndDevelopmentMember', window );">Research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=gsk_SellingGeneralAndAdministrativeExpensesMember', window );">Selling general and administrative expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=gsk_MajorRestructuringProgrammesMember', window );">Major restructuring programmes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="nump">&#163; 34<span></span>
</td>
<td class="nump">&#163; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average cost of capital after tax discount rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average cost of capital pre- tax discount rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2022-03-24<br> -Paragraph 26<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_26_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=gsk_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=gsk_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=gsk_MajorRestructuringProgrammesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=gsk_MajorRestructuringProgrammesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348361926896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">&#163; 9,932<span></span>
</td>
<td class="nump">&#163; 10,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Charge for the year</a></td>
<td class="num">(885)<span></span>
</td>
<td class="num">(855)<span></span>
</td>
<td class="num">&#163; (822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment losses</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">8,933<span></span>
</td>
<td class="nump">9,932<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">20,778<span></span>
</td>
<td class="nump">21,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="num">(576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions through business combinations</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Other additions</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment', window );">Capitalised borrowing costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(3,343)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">19,451<span></span>
</td>
<td class="nump">20,778<span></span>
</td>
<td class="nump">21,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(10,025)<span></span>
</td>
<td class="num">(10,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(501)<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Charge for the year</a></td>
<td class="num">(952)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(9,744)<span></span>
</td>
<td class="num">(10,025)<span></span>
</td>
<td class="num">(10,450)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(821)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment losses</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairments</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(774)<span></span>
</td>
<td class="num">(821)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(10,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(10,518)<span></span>
</td>
<td class="num">(10,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,113<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">7,212<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="nump">403<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions through business combinations</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Other additions</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment', window );">Capitalised borrowing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">6,648<span></span>
</td>
<td class="nump">7,212<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member] | Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(3,281)<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(191)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Charge for the year</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(3,275)<span></span>
</td>
<td class="num">(3,281)<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member] | Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member] | Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(3,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(3,535)<span></span>
</td>
<td class="num">(3,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember', window );">Plant, equipment and vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">4,558<span></span>
</td>
<td class="nump">4,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">4,012<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
<td class="nump">4,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember', window );">Plant, equipment and vehicles [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">11,816<span></span>
</td>
<td class="nump">12,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="nump">542<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions through business combinations</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Other additions</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment', window );">Capitalised borrowing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(1,959)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">10,953<span></span>
</td>
<td class="nump">11,816<span></span>
</td>
<td class="nump">12,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember', window );">Plant, equipment and vehicles [member] | Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(6,744)<span></span>
</td>
<td class="num">(7,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(310)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Charge for the year</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(6,469)<span></span>
</td>
<td class="num">(6,744)<span></span>
</td>
<td class="num">(7,140)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember', window );">Plant, equipment and vehicles [member] | Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(514)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment losses</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairments</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(514)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember', window );">Plant, equipment and vehicles [member] | Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(7,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(6,941)<span></span>
</td>
<td class="num">(7,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets in construction [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets in construction [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="nump">105<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions through business combinations</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Other additions</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment', window );">Capitalised borrowing costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(874)<span></span>
</td>
<td class="num">(1,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets in construction [member] | Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and write-offs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Transfer to assets held for sale/distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">&#163; (26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets in construction [member] | Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">&#163; (42)<span></span>
</td>
<td class="num">&#163; (43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_ix&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PropertyPlantAndEquipmentAndVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348361842096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, beginning of the year</a></td>
<td class="nump">&#163; 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">&#163; (179)<span></span>
</td>
<td class="num">&#163; (182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, end of the year</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, beginning of the year</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetsExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations', window );">Additions through business combinations</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdditionsToRightOfUseAssets', window );">Other additions</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetDisposal', window );">Disposals</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetImpairments', window );">Impairments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, end of the year</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings [member] | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, beginning of the year</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetsExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations', window );">Additions through business combinations</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdditionsToRightOfUseAssets', window );">Other additions</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetDisposal', window );">Disposals</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetImpairments', window );">Impairments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, end of the year</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndEquipmentMember', window );">Plant and equipment [member] | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, beginning of the year</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetsExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdditionsToRightOfUseAssets', window );">Other additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetDisposal', window );">Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetImpairments', window );">Impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, end of the year</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember', window );">Vehicles [member] | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, beginning of the year</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetsExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdditionsToRightOfUseAssets', window );">Other additions</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetDisposal', window );">Disposals</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RightOfUseAssetImpairments', window );">Impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Net book value, end of the year</a></td>
<td class="nump">&#163; 120<span></span>
</td>
<td class="nump">&#163; 98<span></span>
</td>
<td class="nump">&#163; 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to right of use assets through business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherAdditionsToRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other additions to right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherAdditionsToRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RightOfUseAssetDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RightOfUseAssetDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RightOfUseAssetImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RightOfUseAssetImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset transfer to assets held for sale or distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RightOfUseAssetsExchangeAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets exchange adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RightOfUseAssetsExchangeAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gsk_PlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366312800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined', window );">Description of basis on which unit's recoverable amount has been determined</a></td>
<td class="text">The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of disposal is calculated using a discounted cash flow approach, with a post-tax discount rate applied to the projected risk-adjusted post-tax cash flows and terminal value.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill', window );">Goodwiil&#160;Transfer to assets held for sale/distribution</a></td>
<td class="nump">&#163; 5,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in goodwill due to classification as held for sale. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the basis on which the cash-generating unit's (group of units') recoverable amount has been determined (ie value in use or fair value less costs of disposal). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366094752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in Goodwill (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill Beginning balance</a></td>
<td class="nump">&#163; 10,552<span></span>
</td>
<td class="nump">&#163; 10,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additions through business combinations (Note &#8226;)</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill Ending Balance</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill Beginning balance</a></td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">10,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill', window );">Exchange adjustments</a></td>
<td class="nump">550<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additions through business combinations (Note &#8226;)</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(5,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill Ending Balance</a></td>
<td class="nump">&#163; 7,046<span></span>
</td>
<td class="nump">&#163; 10,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase &#8203;in goodwill&#8203; due &#8203;to pension &#8203;liabilities &#8203;payment to &#8203;non&#8203; controlling &#8203;interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in goodwill due to classification as held for sale. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365852928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Summary of Goodwill Allocated to Segments (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#163; 7,046<span></span>
</td>
<td class="nump">&#163; 10,552<span></span>
</td>
<td class="nump">&#163; 10,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_PharmaceuticalsMember', window );">Pharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_VaccinesMember', window );">Vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#163; 6,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_PharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_PharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348365706544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal', window );">Valuation basis</a></td>
<td class="text">Fair value less costs of disposal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections', window );">Key assumptions</a></td>
<td class="text">Sales growth rates &#160; Profit margins &#160; Terminal growth rate &#160; Discount rate &#160; Taxation rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal', window );">Determination of assumptions</a></td>
<td class="text">Growth rates are internal forecasts based on both internal and external market information. &#160; Margins reflect past experience, adjusted for expected changes. &#160; Terminal growth rates based on management&#8217;s estimate of future long-term average growth rates. &#160; Discount rates based on Group WACC, adjusted where appropriate. &#160; Taxation rates based on appropriate rates for each jurisdiction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows', window );">Period of specific projected cash flows</a></td>
<td class="text">Five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_PharmaceuticalsMember', window );">Pharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_VaccinesMember', window );">Vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_CommercialOperationsMember', window );">Commercial Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal growth rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=gsk_ResearchAndDevelopmentMember', window );">Research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal growth rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of key assumptions on which management has based its cash flow projections for the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). Key assumptions are those to which the unit's (group of units') recoverable amount is most sensitive. [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of key assumptions on which management has based its determination of fair value less costs of disposal for a cash-generating unit (group of units). Key assumptions are those to which the unit's (group of units') recoverable amount is most sensitive. [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph f<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_f_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the valuation techniques used to measure fair value less costs of disposal for a cash generating unit (group of units). [Refer: Valuation techniques [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_f_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the period over which management has projected cash flows based on financial budgets/forecasts approved by management including, when a period greater than five years is used for a cash-generating unit (group of units), an explanation of why that longer period is justified. [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_PharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_PharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_CommercialOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_CommercialOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363100160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets - Additional information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation', window );">Weighted average interest rate for capitalised borrowing costs</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged', window );">Intangible assets, for which impairments have been charged</a></td>
<td class="nump">&#163; 83<span></span>
</td>
<td class="nump">&#163; 694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed', window );">Intangible assets, for which impairments have been charged or reversed</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MethodsOfGenerationAxis=ifrs-full_InternallyGeneratedMember', window );">Internally generated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComputerSoftware', window );">Net book value of computer software</a></td>
<td class="nump">&#163; 479<span></span>
</td>
<td class="nump">&#163; 526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets, for which impairments have been charged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets, for which impairments have been charged or reversed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2022-03-24<br> -Paragraph 26<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_26_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComputerSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 119<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_119_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComputerSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MethodsOfGenerationAxis=ifrs-full_InternallyGeneratedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MethodsOfGenerationAxis=ifrs-full_InternallyGeneratedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364338064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets - Summary of Other Intangible Assets (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">&#163; 30,079<span></span>
</td>
<td class="nump">&#163; 29,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Charge for the year</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment losses</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">14,318<span></span>
</td>
<td class="nump">30,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=gsk_BrandsWithIndefiniteUsefulLifeMember', window );">Brands with indefinite useful life [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">18,418<span></span>
</td>
<td class="nump">18,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">42,489<span></span>
</td>
<td class="nump">41,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalisedDevelopmentCosts', window );">Capitalised development costs</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions through business combinations</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Other additions</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(1,156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(20,781)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">27,676<span></span>
</td>
<td class="nump">42,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member] | Brands with indefinite useful life [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">18,626<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalisedDevelopmentCosts', window );">Capitalised development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Other additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(19,772)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(9,631)<span></span>
</td>
<td class="num">(9,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(340)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Charge for the year</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(10,404)<span></span>
</td>
<td class="num">(9,631)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(2,779)<span></span>
</td>
<td class="num">(2,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(141)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment losses</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Reversal of impairments</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(2,954)<span></span>
</td>
<td class="num">(2,779)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Impairment [member] | Brands with indefinite useful life [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Reversal of impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(12,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(13,358)<span></span>
</td>
<td class="num">(12,410)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Depreciation, amortisation, and impairment [member] | Brands with indefinite useful life [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalisedDevelopmentCosts', window );">Capitalised development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Other additions</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(513)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">2,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(1,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Charge for the year</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(1,223)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment losses</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Reversal of impairments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [member] | Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(1,460)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember', window );">Licences And Franchises Amortised Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">10,697<span></span>
</td>
<td class="nump">10,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">13,663<span></span>
</td>
<td class="nump">10,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember', window );">Licences And Franchises Amortised Brands [Member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">21,439<span></span>
</td>
<td class="nump">20,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="nump">934<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CapitalisedDevelopmentCosts', window );">Capitalised development costs</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions through business combinations</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Other additions</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(496)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">25,717<span></span>
</td>
<td class="nump">21,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember', window );">Licences And Franchises Amortised Brands [Member] | Depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="num">(7,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(307)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Charge for the year</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(9,181)<span></span>
</td>
<td class="num">(8,262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember', window );">Licences And Franchises Amortised Brands [Member] | Impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(2,480)<span></span>
</td>
<td class="num">(2,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange adjustments</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment losses</a></td>
<td class="num">(313)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Reversal of impairments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals and asset write-offs</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">(2,873)<span></span>
</td>
<td class="num">(2,480)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember', window );">Licences And Franchises Amortised Brands [Member] | Depreciation, amortisation, and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="num">(10,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="num">&#163; (12,054)<span></span>
</td>
<td class="num">&#163; (10,742)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AmortisationOtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortisation other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AmortisationOtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CapitalisedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalised development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CapitalisedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease through classified as held for sale or distribution intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetImpairmentLossesOtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net impairment losses other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetImpairmentLossesOtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=gsk_BrandsWithIndefiniteUsefulLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=gsk_BrandsWithIndefiniteUsefulLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_LicencesAndFranchisesAmortisedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348361819952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Amortisation of intangible assets</a></td>
<td class="nump">&#163; 1,086<span></span>
</td>
<td class="nump">&#163; 1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment of intangible assets, net of reversals</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember', window );">Cost of sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Amortisation of intangible assets</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment of intangible assets, net of reversals</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_SellingGeneralAndAdministrativeExpensesMember', window );">Selling general and administrative expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Amortisation of intangible assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment of intangible assets, net of reversals</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmortisationOtherIntangibleAssets', window );">Amortisation of intangible assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetImpairmentLossesOtherIntangibleAssets', window );">Impairment of intangible assets, net of reversals</a></td>
<td class="nump">&#163; 299<span></span>
</td>
<td class="nump">&#163; 373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AmortisationOtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortisation other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AmortisationOtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetImpairmentLossesOtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net impairment losses other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetImpairmentLossesOtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=gsk_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363212608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#163; 14,318<span></span>
</td>
<td class="nump">&#163; 30,079<span></span>
</td>
<td class="nump">&#163; 29,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">13,663<span></span>
</td>
<td class="nump">10,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | iTeos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Alector [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Tesaro assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">2,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Meningitis Portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Dolutegravir [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Benlysta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Lamisil [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | BMS Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Fluarix FluLaval [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Okairos [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Others products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Stiefel trade name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Vir Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Curevac Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Affinivax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Momelotinib [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Spero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember', window );">Licences, patents, amortised brands etc [member] | Shingrix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#163; 288<span></span>
</td>
<td class="nump">&#163; 268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesAndFranchisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BenlystaAxis=gsk_IteosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BenlystaAxis=gsk_IteosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BenlystaAxis=gsk_AlectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BenlystaAxis=gsk_AlectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_TesaroAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_TesaroAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_MeningitisPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_MeningitisPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_DolutegravirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_DolutegravirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_BenlystaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_BenlystaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_LamisilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_LamisilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_BMSAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_BMSAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_FluarixFlulavalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_FluarixFlulavalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_OkairosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_OkairosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_OthersProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_OthersProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_StiefelTradeNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_StiefelTradeNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_VirAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_VirAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_CurevacAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_CurevacAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_AffinivaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_AffinivaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_MomelotinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_MomelotinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_SperoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_SperoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_ShingrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntityAxis=gsk_ShingrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376624768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates and Joint Ventures - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Aggregated individually immaterial associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of Investments in Associates and Joint Ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates', window );">Gain on disposal of interest in associates</a></td>
<td class="nump">&#163; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember', window );">Innoviva Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of Investments in Associates and Joint Ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates', window );">Number of shares owned</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfInterestInAssociate', window );">Disposal of interest in associate</a></td>
<td class="nump">&#163; 277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates', window );">Gain on disposal of interest in associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RecyclingOfExchangeDifferencesInAssociate', window );">Recycling of exchange differences in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of investments in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalOfInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of interest in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalOfInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RecyclingOfExchangeDifferencesInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recycling of exchange differences in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RecyclingOfExchangeDifferencesInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense from subsidiaries, jointly controlled entities and associates that the entity does not separately disclose in the same statement or note. [Refer: Associates [member]; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Associates [member]; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348361815824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of Investments in Associates and Joint Ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Beginning of investments</a></td>
<td class="nump">&#163; 88<span></span>
</td>
<td class="nump">&#163; 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Exchange adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures', window );">Additions</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInAssociatesAndJointVentures', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures', window );">Distributions received</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures', window );">Net fair value movements through Other comprehensive income</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries', window );">Impairment of interest in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Profit/(loss) after tax recognised in the consolidated income statement</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Ending of investments</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember', window );">Joint ventures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of Investments in Associates and Joint Ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Beginning of investments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Exchange adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInAssociatesAndJointVentures', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures', window );">Distributions received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures', window );">Net fair value movements through Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries', window );">Impairment of interest in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Profit/(loss) after tax recognised in the consolidated income statement</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Ending of investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_AssociatesMember', window );">Associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems', window );"><strong>Disclosure of Investments in Associates and Joint Ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Beginning of investments</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Exchange adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures', window );">Additions</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInAssociatesAndJointVentures', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures', window );">Distributions received</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures', window );">Net fair value movements through Other comprehensive income</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries', window );">Impairment of interest in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Profit/(loss) after tax recognised in the consolidated income statement</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Ending of investments</a></td>
<td class="nump">&#163; 64<span></span>
</td>
<td class="nump">&#163; 76<span></span>
</td>
<td class="nump">&#163; 349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionsInInvestmentsInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions in investments in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionsInInvestmentsInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of investments in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributions received in investments in associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value Adjustment investments in associates and joint ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of investments in associates joint ventures and subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376394688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Equity Investments - Summary of Current Equity Investments (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">At 1 January</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Exchange adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">&#163; (15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">At 31 December</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMember', window );">Current [Member] | Investments measured at FVTPL 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">At 1 January</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Exchange adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesFairValueMeasurementAssets', window );">Additions</a></td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments', window );">Net fair value movements through profit or loss</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading', window );">At 31 December</a></td>
<td class="nump">&#163; 4,087<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about current equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value movements through profit or loss current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at fair value through profit or loss classified as held for trading. [Refer: Financial assets at fair value through profit or loss, classified as held for trading]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the fair value measurement of assets resulting from purchases of those assets. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376329360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Equity Investments - Additional Information (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentAxis=gsk_InvestmentInHaleonPlcMember', window );">Investment in Haleon plc [member] | Glaxo Group Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnership', window );">Percentage of ownership</a></td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentAxis=gsk_InvestmentInHaleonPlcMember', window );">Investment in Haleon plc [member] | Scottish Limited Partnerships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnership', window );">Percentage of ownership</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentAxis=gsk_InvestmentInHaleonPlcMember', window );">Investment in Haleon plc [member] | ESOP Trusts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnership', window );">Percentage of ownership</a></td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember', window );">Current Equity Investments Measured As FVTPL [Member] | Current Equity Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments', window );">Net fair value movements through profit or loss</a></td>
<td class="nump">&#163; 233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember', window );">Current Equity Investments Measured As FVTPL [Member] | Current Equity Investments [Member] | Investment in Haleon plc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems', window );"><strong>Disclosure Of Detailed Information About Current Equity Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueGainThroughProfitOrLoss', window );">Fair value gain through profit or loss</a></td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdjustmentsOfFairValueMeasurementAssets', window );">Other Adjustments of Fair Value Measurement Assets</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments', window );">Net fair value movements through profit or loss</a></td>
<td class="nump">&#163; 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about current equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueGainThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value gain through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueGainThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value movements through profit or loss current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherAdjustmentsOfFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other adjustments of fair value measurement assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherAdjustmentsOfFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentAxis=gsk_InvestmentInHaleonPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentAxis=gsk_InvestmentInHaleonPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_ScottishLimitedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_ScottishLimitedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_EsopTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_EsopTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363213744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ListedInvestments', window );">Listed investments</a></td>
<td class="nump">&#163; 823<span></span>
</td>
<td class="nump">&#163; 1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember', window );">Equity investments measured at fair value through other comprehensive income (FVTOCI) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition', window );">Fair value of investment disposed during the year</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Cumulative gain loss on disposal of investments</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForForeignExchangeOtherInvestments', window );">Exchange adjustments</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember', window );">Equity investments measured at fair value through profit or loss (FVTPL) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForForeignExchangeOtherInvestments', window );">Exchange adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_VirBiotechnologyIncMember', window );">Vir Biotechnology, Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentFairValue', window );">Investment fair value</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CureVacNVMember', window );">CureVac N.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentFairValue', window );">Investment fair value</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NimbusTherapeuticsLLCMember', window );">Nimbus Therapeutics, LLC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentFairValue', window );">Investment fair value</a></td>
<td class="nump">&#163; 139<span></span>
</td>
<td class="nump">&#163; 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForForeignExchangeOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for foreign exchange other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForForeignExchangeOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ListedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Listed investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ListedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative gain (loss) on disposal of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value at the date of the derecognition of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CureVacNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_CureVacNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NimbusTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NimbusTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>253
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376120880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments - Schedule of Other Investments (Detail) - Non-current [member] - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Beginning of other investments</a></td>
<td class="nump">&#163; 2,126<span></span>
</td>
<td class="nump">&#163; 3,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments', window );">Exchange adjustments</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToOtherInvestments', window );">Additions</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome', window );">Net fair value movements through Other comprehensive income</a></td>
<td class="num">(716)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments', window );">Net fair value movements through profit or loss</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsAndSettlementsOtherInvestments', window );">Disposals and settlements</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Ending of other investments</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember', window );">Investments designated as measured at FVTOCI [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Beginning of other investments</a></td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments', window );">Exchange adjustments</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToOtherInvestments', window );">Additions</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome', window );">Net fair value movements through Other comprehensive income</a></td>
<td class="num">(716)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsAndSettlementsOtherInvestments', window );">Disposals and settlements</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Ending of other investments</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember', window );">Investments measured at FVTPL [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherInvestmentsLineItems', window );"><strong>Other investments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Beginning of other investments</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments', window );">Exchange adjustments</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsToOtherInvestments', window );">Additions</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments', window );">Net fair value movements through profit or loss</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsAndSettlementsOtherInvestments', window );">Disposals and settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Ending of other investments</a></td>
<td class="nump">&#163; 314<span></span>
</td>
<td class="nump">&#163; 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionsToOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionsToOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsAndSettlementsOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals and settlements other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsAndSettlementsOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through exchange adjustments of other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value movements investments through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value movements through profit or loss other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gsk_OtherInvestmentsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gsk_OtherInvestmentsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>254
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364967872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Current Assets - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other receivables</a></td>
<td class="nump">&#163; 108<span></span>
</td>
<td class="nump">&#163; 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">15,734<span></span>
</td>
<td class="nump">13,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherNonCurrentReceivablesMember', window );">Other Non Current Receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherNonCurrentReceivablesMember', window );">Other Non Current Receivables [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherNonCurrentReceivablesMember', window );">Other Non Current Receivables [member] | Remaining Balance [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#163; 21<span></span>
</td>
<td class="nump">&#163; 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherNonCurrentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherNonCurrentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_RemainingBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_RemainingBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>255
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428728688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Current Assets - Summary of Other Non-Current Assets (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousNoncurrentAssetsAbstract', window );"><strong>Miscellaneous non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesRelatedToInsuranceContracts', window );">Amounts receivable under insurance contracts</a></td>
<td class="nump">&#163; 857<span></span>
</td>
<td class="nump">&#163; 849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan', window );">Pension schemes in surplus</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other receivables</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total</a></td>
<td class="nump">&#163; 1,194<span></span>
</td>
<td class="nump">&#163; 1,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReceivablesRelatedToInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables related to insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReceivablesRelatedToInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit asset. [Refer: Net defined benefit asset]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>256
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348379905488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Raw materials and consumables</a></td>
<td class="nump">&#163; 1,576<span></span>
</td>
<td class="nump">&#163; 1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in progress</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">&#163; 5,146<span></span>
</td>
<td class="nump">&#163; 5,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>257
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366002208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#163; 5,452<span></span>
</td>
<td class="nump">&#163; 6,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,053<span></span>
</td>
<td class="nump">7,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">15,734<span></span>
</td>
<td class="nump">13,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade and other receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired', window );">Expected credit loss allowance on trade receivables credit impaired</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount', window );">Expected credit loss allowance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade and other receivables [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherReceivableMember', window );">Other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis=ifrs-full_FinancialInstrumentsCreditimpairedMember', window );">Financial instruments credit-impaired [member] | Trade and other receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">&#163; 58<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember', window );">Associates and joint ventures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other receivables [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTradeAndOtherReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit loss allowance on trade receivables credit impaired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross carrying amount of financial assets that have been modified since initial recognition at a time when the loss allowance was measured at an amount equal to lifetime expected credit losses and for which the loss allowance has changed during the reporting period to an amount equal to 12-month expected credit losses. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35J<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35J_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_OtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis=ifrs-full_FinancialInstrumentsCreditimpairedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis=ifrs-full_FinancialInstrumentsCreditimpairedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>258
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348368629056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables - Summary of Trade and Other Receivables (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables, net of loss allowance</a></td>
<td class="nump">&#163; 5,452<span></span>
</td>
<td class="nump">&#163; 6,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccruedIncomeOtherThanContractAssets', window );">Accrued income</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EmployeeLoansAndAdvances', window );">Employee loans and advances</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Total trade and other receivables</a></td>
<td class="nump">&#163; 7,053<span></span>
</td>
<td class="nump">&#163; 7,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EmployeeLoansAndAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee loans and advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EmployeeLoansAndAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccruedIncomeOtherThanContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing income that has been earned but is not yet a receivable, other than contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccruedIncomeOtherThanContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>259
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367252448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables - Summary of Loss Allowance (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems', window );"><strong>Disclosure of trade and other receivables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowance', window );">Beginning balance</a></td>
<td class="nump">&#163; 150<span></span>
</td>
<td class="nump">&#163; 151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowanceExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance', window );">Charge for the year</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale', window );">Transfer to assets held for sale</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance', window );">Subsequent recoveries of amounts provided for</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowanceUtilised', window );">Utilised</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedCreditLossAllowance', window );">Ending balance</a></td>
<td class="nump">&#163; 91<span></span>
</td>
<td class="nump">&#163; 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTradeAndOtherReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other receivables [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTradeAndOtherReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedCreditLossAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit loss allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedCreditLossAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedCreditLossAllowanceExchangeAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit loss allowance exchange adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedCreditLossAllowanceExchangeAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit loss allowance transfer to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedCreditLossAllowanceUtilised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit loss allowance utilised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedCreditLossAllowanceUtilised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInExpectedCreditLossesAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in expected credit losses allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInExpectedCreditLossesAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsequent recoveries of amounts provided for expected credit loss allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>260
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428716288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup', window );">Cash and cash equivalents not available for general use</a></td>
<td class="nump">&#163; 200<span></span>
</td>
<td class="nump">&#163; 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember', window );">Consumer Healthcare Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer', window );">Transferred to assets held for sale</a></td>
<td class="nump">&#163; 1,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at the time of transfer, of all assets transferred to structured entities. [Refer: Unconsolidated structured entities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 27<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_27_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of significant cash and cash equivalent balances held by the entity that are not available for use by the group. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>261
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428903616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at bank and in hand</a></td>
<td class="nump">&#163; 879<span></span>
</td>
<td class="nump">&#163; 1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">&#163; 3,723<span></span>
</td>
<td class="nump">&#163; 4,274<span></span>
</td>
<td class="nump">&#163; 6,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>262
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377640752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held for Sale - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts', window );">Gain on demerger before exchange movements and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 9,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember', window );">Consumer Healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts', window );">Gain on demerger before exchange movements and transaction costs</a></td>
<td class="nump">&#163; 12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net assets and liabilities distributed / derecognised as part of gain on the demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>263
<FILENAME>R165.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363260384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets Held for Sale - Summary of Assets Held for Sale (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AssetsHeldForSaleLineItems', window );"><strong>Assets Held For Sale [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">&#163; 8,933<span></span>
</td>
<td class="nump">&#163; 9,932<span></span>
</td>
<td class="nump">&#163; 10,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Total assets held for sale</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember', window );">Assets held for sale [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AssetsHeldForSaleLineItems', window );"><strong>Assets Held For Sale [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAssetsNet', window );">Other</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Total assets held for sale</a></td>
<td class="nump">&#163; 98<span></span>
</td>
<td class="nump">&#163; 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Assets Held For Sale [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>264
<FILENAME>R166.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366059408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure of trade and other payables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other current payables</a></td>
<td class="nump">&#163; 16,263<span></span>
</td>
<td class="nump">&#163; 17,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Revenue recognized in deferred income</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CustomerReturnAndRebateAccruals', window );">Customer return and rebate accruals</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost', window );">Interest accrued on financial liabilities at amortized cost</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember', window );">Estimated rebates, discounts or allowances payable to customers [member] | US Pharmaceuticals and vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure of trade and other payables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CustomerReturnAndRebateAccruals', window );">Customer return and rebate accruals</a></td>
<td class="nump">5,717<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember', window );">Associates and joint ventures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure of trade and other payables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other current payables</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CustomerReturnAndRebateAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer return and rebate accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CustomerReturnAndRebateAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with disclosure of trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTradeAndOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InterestAccruedOnFinancialLiabilitiesAtAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest accrued on financial liabilities at amortized cost .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SegmentConsolidationItemAxis=gsk_USPharmaceuticalsAndVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SegmentConsolidationItemAxis=gsk_USPharmaceuticalsAndVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>265
<FILENAME>R167.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366952816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables - Summary of Trade and Other Payables (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems', window );"><strong>Disclosure of trade and other payables [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">&#163; 3,866<span></span>
</td>
<td class="nump">&#163; 4,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WagesAndSalariesPayable', window );">Wages and salaries</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Social security</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PutOptionPayable', window );">ViiV Healthcare put option</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Deferred income</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CustomerReturnAndRebateAccruals', window );">Customer return and rebate accruals</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">&#163; 16,263<span></span>
</td>
<td class="nump">&#163; 17,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CustomerReturnAndRebateAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer return and rebate accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CustomerReturnAndRebateAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfTradeAndOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with disclosure of trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfTradeAndOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PutOptionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Put option payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PutOptionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WagesAndSalariesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Wages and salaries payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WagesAndSalariesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>266
<FILENAME>R168.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364866688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember', window );">10% increase in sales forecasts or sales multiple applied [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">&#163; 100<span></span>
</td>
<td class="nump">&#163; 89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember', window );">15% increase in sales forecasts or sales multiple applied [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember', window );">10% decrease in sales forecasts or sales multiple applied [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember', window );">15% decrease in sales forecasts or sales multiple applied [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_DiscountRateMeasurementInputMember', window );">Discount rate, measurement input [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember', window );">1.50% (150 basis points) increase in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember', window );">1.50% (150 basis points) decrease in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember', window );">10 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember', window );">15 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember', window );">10 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember', window );">15 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember', window );">10 cent appreciation of the Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember', window );">15 cent appreciation of the Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember', window );">10 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember', window );">15 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems', window );"><strong>Disclosure of information about activities subject to rate regulation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInFinancialLiability', window );">Increase/(decrease) in financial liability</a></td>
<td class="num">&#163; (35)<span></span>
</td>
<td class="num">&#163; (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInFinancialLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in financial liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInFinancialLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>267
<FILENAME>R169.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348360216208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Debt - Additional Information (Detail)<br> &#8364; in Millions, &#163; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments', window );">Effective Interest rate on liquid investment</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EffectiveInterestRateOnCashAndCashEquivalents', window );">Effective Interest rate on cash and cash equivalents</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper issued</a></td>
<td class="nump">&#163; 1,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts', window );">Weighted average interest rate on current bank loans and overdrafts</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">&#163; 17,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageEffectivePreSwapInterestRateNotesIssued', window );">Average effective pre-swap interest rate notes</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#163; 3,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 4,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 6,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_UsCommercialPaperProgramMember', window );">US commercial paper program [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CommercialPaperAuthorized', window );">Commercial paper authorized</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper issued</a></td>
<td class="nump">748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_EuroCommercialPaperProgramMember', window );">EURO Commercial Paper Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CommercialPaperAuthorized', window );">Commercial paper authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper issued</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember', window );">Floating interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidInvestments', window );">Liquid investment</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Fixed interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidInvestments', window );">Liquid investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#163; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member', window );">Commercial paper [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageInterestRateOnBorrowings', window );">Weighted average interest rate of borrowings</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_LetterOfCredit1Member', window );">Letter of credit 1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PledgedInvestments', window );">Pledged investments value</a></td>
<td class="nump">&#163; 47<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="nump">&#163; 42<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_NonInterestBearingMember', window );">Non interest bearing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#163; 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember', window );">Two Point Eight Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember', window );">Three Point Three Seven Five Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember', window );">Zero Point Zero Percent European Medium Term Note Two Thousand Twenty Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember', window );">Three Point Three Seven Five Percent Euro Medium Term Note Two Thousand Twenty Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Drawn amount</a></td>
<td class="nump">&#163; 292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember', window );">Five Point Two Five Percent Euro Medium Term Note Two Thousand Thirty Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Drawn amount</a></td>
<td class="nump">&#163; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember', window );">Five Point Two Five Percent Euro Term Note Two Thousand Forty Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Drawn amount</a></td>
<td class="nump">&#163; 522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember', window );">Four Point Two Five Percent Euro Medium Term Note Two Thousand Forty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Drawn amount</a></td>
<td class="nump">&#163; 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">&#163; 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than 5 years [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryInterestAtEffectiveRates', window );">Interest at effective rates</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RepaymentYear', window );">Repayment dates</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than 5 years [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryInterestAtEffectiveRates', window );">Interest at effective rates</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RepaymentYear', window );">Repayment dates</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities', window );">Cancelled committed facilities and replaced with revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,100<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member] | Post Separation of the Consumer Healthcare Business [Member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Revolving credit facilities</a></td>
<td class="nump">&#163; 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=gsk_ShortTermNotesMember', window );">Short-term notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageEffectivePreSwapInterestRateShortTerm', window );">Average effective pre-swap interest rate on short term notes</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Later than one year and not later than three years [member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities', window );">Cancelled committed facilities and replaced with revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Later than one year and not later than three years [member] | Post Separation of the Consumer Healthcare Business [Member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Revolving credit facilities</a></td>
<td class="nump">&#163; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AverageEffectivePreSwapInterestRateNotesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average effective pre swap interest rate issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AverageEffectivePreSwapInterestRateNotesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AverageEffectivePreSwapInterestRateShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average effective pre swap interest rate short term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AverageEffectivePreSwapInterestRateShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancelled committed facilities replaced with revolving credit facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryInterestAtEffectiveRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carry interest at effective rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryInterestAtEffectiveRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CommercialPaperAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial paper authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CommercialPaperAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate on available for sale financial investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EffectiveInterestRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate on cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EffectiveInterestRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiquidInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquid investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiquidInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PledgedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pledged Investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PledgedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RepaymentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RepaymentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageInterestRateOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageInterestRateOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on current bank loans and overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_UsCommercialPaperProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_UsCommercialPaperProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_EuroCommercialPaperProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_EuroCommercialPaperProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_LetterOfCredit1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_LetterOfCredit1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_NonInterestBearingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_NonInterestBearingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PurposeAxis=gsk_PostSeparationOfTheConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PurposeAxis=gsk_PostSeparationOfTheConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_ShortTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_ShortTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>268
<FILENAME>R170.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364541904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#163; 3,723<span></span>
</td>
<td class="nump">&#163; 4,274<span></span>
</td>
<td class="nump">&#163; 6,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">20,769<span></span>
</td>
<td class="nump">18,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankLoansoverdraftsAndOther', window );">Bank loans, overdrafts and other</a></td>
<td class="num">(448)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="num">(3,952)<span></span>
</td>
<td class="num">(3,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(17,035)<span></span>
</td>
<td class="num">(20,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Net debt</a></td>
<td class="num">(17,197)<span></span>
</td>
<td class="num">(19,838)<span></span>
</td>
<td class="num">&#163; (20,780)<span></span>
</td>
<td class="num">&#163; (25,215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherLongtermBorrowingsMember', window );">Other LongTerm Borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 2.850% US$ US Medium Term Note 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 2.875% US$ US Medium Term Note 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 2.800% US$ US Medium Term Note 2023 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 3.375% US$ US Medium Term Note 2023 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 3.000% US$ US Medium Term Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(829)<span></span>
</td>
<td class="num">(739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 3.625% US$ US Medium Term Note 2025 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(827)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 0.534% US$ US Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 3.875% US$ US Medium Term Note 2028 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 3.375% US$ US Medium Term Note 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(822)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 6.375% US Medium Term Note 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(2,264)<span></span>
</td>
<td class="num">(2,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 4.200% US$ US Medium Term Note 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 0.000% US$ US Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember', window );">New York Stock Exchange [member] | 0.534% US$ Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 0.125% &#8364; Euro Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 0.000% &#8364; Euro Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.375% &#8364; Euro Medium Term Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(884)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 4.000% &#8364; Euro Medium Term Note 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.000% &#8364; Euro Medium Term Note 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(620)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.250% Euro Medium Term Note 2026 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(885)<span></span>
</td>
<td class="num">(838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 3.375% Euro Medium Term Note 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.25% Euro Medium Term Note 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.375% &#8364; Euro Medium Term Note 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.750% Euro Medium Term Note 2030 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 5.250% Euro Medium Term Note 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(640)<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 5.375% US Medium Term Note 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 1.625% Euro Medium Term Note 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 6.375% Euro Medium Term Note 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 5.250% Euro Medium Term Note 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 4.250% Euro Medium Term Note 2045 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 3.125% &#8364; Euro Medium Term Note 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(616)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 3.000% &#8364; Euro Medium Term Note 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LongtermBorrowingsAbstract', window );"><strong>Long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term borrowings</a></td>
<td class="num">(442)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 0.000% &#8364; European Medium Term Note 20230.000% &#8364; European Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="num">(443)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember', window );">London Stock Exchange [member] | 0.125% &#8364; European Medium Term Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Short-term borrowings</a></td>
<td class="num">(665)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_Debt1Member', window );">Net debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidInvestmentsCurrent', window );">Liquid investments</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">&#163; 3,790<span></span>
</td>
<td class="nump">&#163; 4,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BankLoansoverdraftsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank loans and overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BankLoansoverdraftsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiquidInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquid investments current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiquidInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LongtermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LongtermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherLongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OtherLongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=gsk_NewYorkStockExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=gsk_LondonStockExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_Debt1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=gsk_Debt1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>269
<FILENAME>R171.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367130736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Debt - Schedule of Finance Lease Obligations (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">&#163; 1,008<span></span>
</td>
<td class="nump">&#163; 1,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Between 1 and 2 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Between 2 and 3 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Between 3 and 4 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Between 4 and 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseObligationsGross', window );">Total future rental payments</a></td>
<td class="nump">&#163; 336<span></span>
</td>
<td class="nump">&#163; 341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinanceLeaseObligationsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Obligations, Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FinanceLeaseObligationsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>270
<FILENAME>R172.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362445264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">&#163; 9,554<span></span>
</td>
<td class="nump">&#163; 8,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 7,929<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="nump">8,372<span></span>
</td>
<td class="nump">7,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,488<span></span>
</td>
<td class="nump">5,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpensePlans', window );">Pension and other post-employment cost</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">466<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitAndDefinedContributionPlansMember', window );">UK Defined Benefit and Defined Contribution Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit pension and post retirement cost</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UsDefinedBenefitAndDefinedContributionPlansMember', window );">US Defined Benefit and Defined Contribution Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit pension and post retirement cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_OtherOverseasPensionPlansMember', window );">Other overseas pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpensePlans', window );">Pension and other post-employment cost</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedPostRetirementPensionPlansMember', window );">Unfunded post retirement healthcare schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit pension and post retirement cost</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed', window );">Pension and other post-employment cost Analysed</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_FundedDefinedBenefitPensionPlansMember', window );">Funded defined benefit pension plans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed', window );">Pension and other post-employment cost Analysed</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedDefinedBenefitPensionPlanMember', window );">Unfunded defined benefit pension plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed', window );">Pension and other post-employment cost Analysed</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember', window );">Defined benefit pension and post-retirement healthcare scheme. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Defined benefit pension and post retirement cost</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitSchemesMember', window );">Defined benefit schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed', window );">Pension and other post-employment cost Analysed</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedContributionPensionSchemeMember', window );">Defined contribution pension scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems', window );"><strong>Disclosure of pension and other post employment plan [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedContributionPlans', window );">Pension and other post-employment cost Analysed</a></td>
<td class="nump">&#163; 133<span></span>
</td>
<td class="nump">&#163; 124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#163; 119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of pensions and other post employment plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-employment benefit expense, defined benefit plans analysed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PostemploymentBenefitExpensePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Postemployment benefit expense plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PostemploymentBenefitExpensePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitAndDefinedContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitAndDefinedContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UsDefinedBenefitAndDefinedContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UsDefinedBenefitAndDefinedContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_OtherOverseasPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_OtherOverseasPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedPostRetirementPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedPostRetirementPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_FundedDefinedBenefitPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_FundedDefinedBenefitPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedDefinedBenefitPensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UnfundedDefinedBenefitPensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitSchemesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedBenefitSchemesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedContributionPensionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_DefinedContributionPensionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>271
<FILENAME>R173.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362574800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Additional Information (Detail) - GBP (&#163;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Sep. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage', window );">Long term rate of improvement per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AugmentationCostsIncludedInPastServiceCosts', window );">Augmentation costs included in past service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 6,000,000<span></span>
</td>
<td class="nump">&#163; 26,000,000<span></span>
</td>
<td class="nump">&#163; 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AugmentationCostsFromRestructuringProgrammes', window );">Augmentation costs arising from major restructuring programmes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TotalValueOfTheInsuranceContract', window );">Total value of the insurance contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 402,000,000<span></span>
</td>
<td class="nump">402,000,000<span></span>
</td>
<td class="nump">570,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(43,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Additional contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">919,000,000<span></span>
</td>
<td class="nump">312,000,000<span></span>
</td>
<td class="nump">313,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished', window );">Fair value of investments in fund assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000,000<span></span>
</td>
<td class="nump">&#163; 211,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships', window );">Subsidiary shares transferred into Limited Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,593,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalContributionDueToBePaid', window );">Additional contributions due to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 345,000,000<span></span>
</td>
<td class="nump">&#163; 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GSKLPLtdMember', window );">GSK LP Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_HaleonMember', window );">Haleon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SubsidiariesSharesTransferredToFundPensionSchemes', window );">Subsidiary shares transferred to fund pension schemes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipInterestRepresentedByTransfer', window );">Percentage of ownership interest represented by transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwneshipInterestHeldByTheTransferee', window );">Percentage of ownership interest held by the transferee company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AgreementTypeAxis=gsk_SlpPartnershipAgreementMember', window );">SLP Partnership Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 735,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset', window );">Maximum contributions to plan in net defined benefit liability asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Employer contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Employer contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember', window );">UK defined benefit plans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset', window );">Contributions to plan, net defined benefit liability (asset)</a></td>
<td class="nump">&#163; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DefinedBenefitObligationAtPastServiceCost', window );">Defined benefit obligation, at past service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_VoluntaryCashContributionsMadeToThePlan', window );">Voluntary Cash Contributions Made To The Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember', window );">UK defined benefit plans [member] | SLP Partneships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets', window );">Cash And cash equivalents contributed to fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 735,000,000<span></span>
</td>
<td class="nump">735,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember', window );">UK defined benefit plans [member] | SLP Partneships [Member] | Glaxo Smith Kline Consumer Healthcare Holdings Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MaximumProceedsThresholdAmount', window );">Proceeds threshold to be received by partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember', window );">UK defined benefit plans [member] | SLP Partnership Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemainingAmountDueToBeContributed', window );">Remaining amount due to be contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000,000<span></span>
</td>
<td class="nump">&#163; 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UsCashBalancePensionPlanMember', window );">US cash balance pension plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Accrual of Future pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AllocationToReturnSeekingAssets', window );">Percentage allocated to return seeking assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AllocationToLiabilityMatchingAssets', window );">Percentage allocated to liability matching assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Additional contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 691,000,000<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Accrual of Future pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103,000,000)<span></span>
</td>
<td class="num">(103,000,000)<span></span>
</td>
<td class="nump">333,000,000<span></span>
</td>
<td class="num">(276,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets', window );">Loans on structured debt amount contributed to fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,376,000,000<span></span>
</td>
<td class="nump">&#163; 2,376,000,000<span></span>
</td>
<td class="nump">513,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AllocationToReturnSeekingAssets', window );">Percentage allocated to return seeking assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AllocationToLiabilityMatchingAssets', window );">Percentage allocated to liability matching assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Additional contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation', window );">Assumption for future medical inflation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Accrual of Future pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (770,000,000)<span></span>
</td>
<td class="num">&#163; (770,000,000)<span></span>
</td>
<td class="num">&#163; (724,000,000)<span></span>
</td>
<td class="num">(810,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | 2031 and thereafter [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation', window );">Assumption for future medical inflation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Unfunded [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">US post retirement healthcare scheme obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 870,000,000<span></span>
</td>
<td class="nump">&#163; 1,059,000,000<span></span>
</td>
<td class="nump">1,124,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Retiree healthcare plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems', window );"><strong>Disclosure of Pensions and Other Post-employment Benefits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Accrual of Future pension plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 55,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ActuarialAssumptionOfExpectedRatesOfMedicalInflation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of medical inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalContributionDueToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional contribution due to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalContributionDueToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AllocationToLiabilityMatchingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation to liability matching assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AllocationToLiabilityMatchingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AllocationToReturnSeekingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation to return seeking assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AllocationToReturnSeekingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AugmentationCostsFromRestructuringProgrammes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Augmentation costs from restructuring programmes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AugmentationCostsFromRestructuringProgrammes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AugmentationCostsIncludedInPastServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Augmentation costs included in past service costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AugmentationCostsIncludedInPastServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DefinedBenefitObligationAtPastServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit obligation at past service cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DefinedBenefitObligationAtPastServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent pensions and other post-employment benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in Fund Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans on structured debt amount contributed to fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contributions to plan in net defined benefit liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MaximumProceedsThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum proceeds threshold amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MaximumProceedsThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortality projections model, long-term improvement parameter, per year, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfOwnershipInterestRepresentedByTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of owneship interest represented by transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfOwnershipInterestRepresentedByTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfOwneshipInterestHeldByTheTransferee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of owneship interest held by the transferee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfOwneshipInterestHeldByTheTransferee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemainingAmountDueToBeContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amount due to be contributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemainingAmountDueToBeContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SubsidiariesSharesTransferredToFundPensionSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiaries shares transferred to fund pension schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SubsidiariesSharesTransferredToFundPensionSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SubsidiarySharesTransferredIntoLimitedPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary shares transferred into limited partnerships.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SubsidiarySharesTransferredIntoLimitedPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TotalValueOfTheInsuranceContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total value of the insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TotalValueOfTheInsuranceContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_VoluntaryCashContributionsMadeToThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary cash contributions made to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_VoluntaryCashContributionsMadeToThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 142<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_142_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 147<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_147_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 148<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_148_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GSKLPLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GSKLPLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_HaleonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_HaleonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AgreementTypeAxis=gsk_SlpPartnershipAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AgreementTypeAxis=gsk_SlpPartnershipAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UkDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransfereeAxis=gsk_SLPPartneshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransfereeAxis=gsk_SLPPartneshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_UsCashBalancePensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_UsCashBalancePensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=gsk_TwoThousandThirtyOneAndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=gsk_TwoThousandThirtyOneAndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_RetireeHealthcarePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_RetireeHealthcarePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>272
<FILENAME>R174.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366519904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Current. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MalePensionersAverageLifeExpectancyAtSixty', window );">Male Years</a></td>
<td class="text">27 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FemalePensionersAverageLifeExpectancyAtSixty', window );">Female Years</a></td>
<td class="text">28 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Projected at 2042 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MalePensionersAverageLifeExpectancyAtSixty', window );">Male Years</a></td>
<td class="text">28 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FemalePensionersAverageLifeExpectancyAtSixty', window );">Female Years</a></td>
<td class="text">29 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Current. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MalePensionersAverageLifeExpectancyAtSixty', window );">Male Years</a></td>
<td class="text">27 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FemalePensionersAverageLifeExpectancyAtSixty', window );">Female Years</a></td>
<td class="text">28 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Projected at 2042 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MalePensionersAverageLifeExpectancyAtSixty', window );">Male Years</a></td>
<td class="text">28 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FemalePensionersAverageLifeExpectancyAtSixty', window );">Female Years</a></td>
<td class="text">30 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FemalePensionersAverageLifeExpectancyAtSixty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Female pensioners average life expectancy at sixty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FemalePensionersAverageLifeExpectancyAtSixty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MalePensionersAverageLifeExpectancyAtSixty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Male pensioners average life expectancy at sixty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MalePensionersAverageLifeExpectancyAtSixty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_CurrentPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_CurrentPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_ProjectedPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_ProjectedPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>273
<FILENAME>R175.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366107168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems', window );"><strong>Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Rate of increase of future earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Expected pension increases</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">Inflation rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems', window );"><strong>Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ActuarialAssumptionOfCashBalanceCreditRate', window );">Cash balance credit/conversion rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">Inflation rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems', window );"><strong>Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Rate of increase of future earnings</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Expected pension increases</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ActuarialAssumptionOfCashBalanceCreditRate', window );">Cash balance credit/conversion rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">Inflation rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ActuarialAssumptionOfCashBalanceCreditRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial assumption of cash balance credit rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ActuarialAssumptionOfCashBalanceCreditRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>274
<FILENAME>R176.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364315760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">&#163; 146<span></span>
</td>
<td class="nump">&#163; 216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#163; 291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="num">(786)<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(187)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member] | Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">255<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits', window );">Net operating cost</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="num">(872)<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(90)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member] | Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(53)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits', window );">Net operating cost</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">93<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits', window );">Net operating cost</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="num">(1,169)<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits', window );">Net operating cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(96)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member] | Continuing operations defined benefit pension and post-retirement healthcare scheme [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost/(credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest (income)/cost</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Gains from settlements</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits', window );">Net operating cost</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gains/(losses) recorded in the statement of comprehensive income</a></td>
<td class="nump">&#163; 261<span></span>
</td>
<td class="nump">&#163; 186<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#163; (45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit pension and post retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses net defined benefit liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpensesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating charge for pensions and other post retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from settlements. Settlements are transactions that eliminate all further legal or constructive obligations for part or all of the benefits provided under a defined benefit plan, other than a payment of benefits to, or on behalf of, employees that is set out in the terms of the plan and included in the actuarial assumptions. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>275
<FILENAME>R177.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363218032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan', window );">Post-retirement benefits/Pension schemes in deficit and surplus</a></td>
<td class="nump">&#163; 229<span></span>
</td>
<td class="nump">&#163; 741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Benefit plans</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="num">(3,113)<span></span>
</td>
<td class="num">&#163; (3,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [member] | Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan', window );">Post-retirement benefits/Pension schemes in deficit and surplus</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember', window );">Pensions and other post-employment benefits [member] | Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Post-retirement benefits/Pension schemes in deficit and surplus</a></td>
<td class="num">(1,585)<span></span>
</td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(2,287)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember', window );">Pensions and other post-employment benefits [member] | Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Post-retirement benefits/Pension schemes in deficit and surplus</a></td>
<td class="num">&#163; (994)<span></span>
</td>
<td class="num">&#163; (1,243)<span></span>
</td>
<td class="num">&#163; (1,363)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit pension and post retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit asset. [Refer: Net defined benefit asset]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>276
<FILENAME>R178.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363405824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Present value of scheme obligations</a></td>
<td class="num">&#163; (14,500)<span></span>
</td>
<td class="num">&#163; (20,191)<span></span>
</td>
<td class="num">&#163; (21,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actual return on plan assets</a></td>
<td class="num">(5,883)<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GroupMember', window );">Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed', window );">Equities, listed</a></td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">5,207<span></span>
</td>
<td class="nump">3,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Equity, unlisted</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MultiAssetFunds', window );">Multi-asset funds</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="nump">2,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed', window );">Property, listed</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Property, unlisted</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed', window );">Corporate bonds, listed</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted', window );">Corporate bonds, unlisted</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed', window );">Government bonds, listed</a></td>
<td class="nump">5,329<span></span>
</td>
<td class="nump">6,762<span></span>
</td>
<td class="nump">7,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets', window );">Insurance contracts</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets', window );">Other (liabilities)/assets</a></td>
<td class="num">(375)<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">19,088<span></span>
</td>
<td class="nump">19,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DefinedBenefitPensionAssetCeilingRestrictions', window );">Asset Ceiling Restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Present value of scheme obligations</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(1,356)<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="num">(2,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actual return on plan assets</a></td>
<td class="num">(5,513)<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GroupMember', window );">Group [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GroupMember', window );">Group [member] | Pensions and other post-employment benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(1,585)<span></span>
</td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(2,287)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed', window );">Equities, listed</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MultiAssetFunds', window );">Multi-asset funds</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="nump">2,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Property, unlisted</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed', window );">Corporate bonds, listed</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed', window );">Government bonds, listed</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">6,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets', window );">Insurance contracts</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets', window );">Other (liabilities)/assets</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of assets</a></td>
<td class="nump">9,014<span></span>
</td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Present value of scheme obligations</a></td>
<td class="num">(9,117)<span></span>
</td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(13,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actual return on plan assets</a></td>
<td class="num">(4,710)<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Pensions and other post-employment benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed', window );">Equities, listed</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Property, unlisted</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed', window );">Corporate bonds, listed</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed', window );">Government bonds, listed</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets', window );">Other (liabilities)/assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of assets</a></td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Present value of scheme obligations</a></td>
<td class="num">(3,030)<span></span>
</td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(770)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actual return on plan assets</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Pensions and other post-employment benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(770)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed', window );">Equities, listed</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Equity, unlisted</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed', window );">Property, listed</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted', window );">Property, unlisted</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed', window );">Corporate bonds, listed</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted', window );">Corporate bonds, unlisted</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed', window );">Government bonds, listed</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets', window );">Insurance contracts</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets', window );">Other (liabilities)/assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of assets</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DefinedBenefitPensionAssetCeilingRestrictions', window );">Asset Ceiling Restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Present value of scheme obligations</a></td>
<td class="num">(2,353)<span></span>
</td>
<td class="num">(3,644)<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">(483)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actual return on plan assets</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member] | Pensions and other post-employment benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Net surplus/(obligation)</a></td>
<td class="num">&#163; (603)<span></span>
</td>
<td class="num">&#163; (873)<span></span>
</td>
<td class="num">&#163; (1,124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate bonds contributed to fair value of plan assets listed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate bonds contributed to fair value of plan assets unlisted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DefinedBenefitPensionAssetCeilingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit pension asset ceiling restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DefinedBenefitPensionAssetCeilingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit pension and post retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity instruments amount contributed to fair value of plan assets listed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity instruments amount contributed to fair value of plan assets unlisted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government bonds contributed to fair value of plan assets listed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance contracts amount contributed to fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MultiAssetFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multi asset funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MultiAssetFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities assets amount contributed to fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property amount contributed to fair value of plan assets listed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property amount contributed to fair value of plan assets unlisted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_GroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=gsk_PensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>277
<FILENAME>R179.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348358705984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">&#163; (20,191)<span></span>
</td>
<td class="num">&#163; (21,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">87<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">&#163; 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="num">(919)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(13,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="num">(691)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">9,014<span></span>
</td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(9,117)<span></span>
</td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(13,858)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
<td class="nump">12,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="num">(4,981)<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(649)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">9,014<span></span>
</td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK [member] | Present value of defined benefit obligation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(13,858)<span></span>
</td>
<td class="num">(13,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(9,117)<span></span>
</td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(13,858)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(3,030)<span></span>
</td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="num">(324)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(326)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member] | Present value of defined benefit obligation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
<td class="num">(3,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(371)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(3,031)<span></span>
</td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(3,644)<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(2,353)<span></span>
</td>
<td class="num">(3,644)<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member] | Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">122<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="num">(578)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember', window );">Rest of World [member] | Present value of defined benefit obligation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(3,644)<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
<td class="num">(3,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(124)<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="num">(3,644)<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member] | Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, beginning balance</a></td>
<td class="nump">19,062<span></span>
</td>
<td class="nump">19,206<span></span>
</td>
<td class="nump">18,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">408<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="num">(5,883)<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">19,062<span></span>
</td>
<td class="nump">19,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member] | Present value of defined benefit obligation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
<td class="num">(20,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(495)<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(388)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="num">(20,191)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">(994)<span></span>
</td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member] | Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Assets, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member] | Present value of defined benefit obligation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems', window );"><strong>Disclosure Of Defined Benefit Pension And Post Retirement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations beginning balance</a></td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Scheme participants' contributions</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Obligations ending balance</a></td>
<td class="num">&#163; (994)<span></span>
</td>
<td class="num">&#163; (1,243)<span></span>
</td>
<td class="num">&#163; (1,363)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of defined benefit pension and post retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpensesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses net defined benefit liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpensesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer to assets held for sale/distribution net defined benefit liability (asset).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from settlements. Settlements are transactions that eliminate all further legal or constructive obligations for part or all of the benefits provided under a defined benefit plan, other than a payment of benefits to, or on behalf of, employees that is set out in the terms of the plan and included in the actuarial assumptions. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in reimbursement rights related to defined benefit obligation, resulting from the effects of business combinations and disposals. [Refer: Business combinations [member]; Reimbursement rights related to defined benefit obligation, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>278
<FILENAME>R180.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376114336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation</a></td>
<td class="num">&#163; (14,500)<span></span>
</td>
<td class="num">&#163; (20,191)<span></span>
</td>
<td class="num">&#163; (21,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember', window );">Funded [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation</a></td>
<td class="num">(13,887)<span></span>
</td>
<td class="num">(19,419)<span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember', window );">Unfunded [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation</a></td>
<td class="num">&#163; (613)<span></span>
</td>
<td class="num">&#163; (772)<span></span>
</td>
<td class="num">&#163; (806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>279
<FILENAME>R181.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376453104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of net defined benefit liability</a></td>
<td class="num">&#163; (1,129)<span></span>
</td>
<td class="num">&#163; (2,104)<span></span>
</td>
<td class="num">&#163; (1,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Exchange adjustments</a></td>
<td class="num">(87)<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset', window );">Past service cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Settlements and curtailments</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Remeasurements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets, excluding amounts included in interest</a></td>
<td class="num">(5,883)<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gain from change in demographic assumptions</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="num">(1,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">(Loss)/gain from change in financial assumptions</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience gains/(losses)</a></td>
<td class="num">(949)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer contributions</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset', window );">Expenses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Ending of net defined benefit liability</a></td>
<td class="num">&#163; (1,356)<span></span>
</td>
<td class="num">&#163; (1,129)<span></span>
</td>
<td class="num">&#163; (2,104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments in expenses net defined benefit liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from settlements. Settlements are transactions that eliminate all further legal or constructive obligations for part or all of the benefits provided under a defined benefit plan, other than a payment of benefits to, or on behalf of, employees that is set out in the terms of the plan and included in the actuarial assumptions. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from business combinations and disposals. [Refer: Business combinations [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>280
<FILENAME>R182.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376319680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gain from change in demographic assumptions</a></td>
<td class="num">&#163; (5,868)<span></span>
</td>
<td class="num">&#163; (716)<span></span>
</td>
<td class="nump">&#163; 1,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gain/(loss) from change in financial assumptions</a></td>
<td class="num">(92)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience gains</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gain from change in demographic assumptions</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gain/(loss) from change in financial assumptions</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience gains</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Total</a></td>
<td class="nump">&#163; 228<span></span>
</td>
<td class="nump">&#163; 78<span></span>
</td>
<td class="num">&#163; (82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>281
<FILENAME>R183.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376363328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit pension obligation analysed by membership category</a></td>
<td class="nump">&#163; 14,500<span></span>
</td>
<td class="nump">&#163; 20,191<span></span>
</td>
<td class="nump">&#163; 21,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit pension obligation analysed by membership category</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">20,191<span></span>
</td>
<td class="nump">21,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember', window );">Active [member] | Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit pension obligation analysed by membership category</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">4,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember', window );">Retired [member] | Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit pension obligation analysed by membership category</a></td>
<td class="nump">8,540<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember', window );">Deferred [member] | Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit pension obligation analysed by membership category</a></td>
<td class="nump">&#163; 4,570<span></span>
</td>
<td class="nump">&#163; 4,880<span></span>
</td>
<td class="nump">&#163; 5,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>282
<FILENAME>R184.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366159968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Post-retirement benefit obligation analysed by membership category</a></td>
<td class="nump">&#163; 14,500<span></span>
</td>
<td class="nump">&#163; 20,191<span></span>
</td>
<td class="nump">&#163; 21,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember', window );">Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Post-retirement benefit obligation analysed by membership category</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember', window );">Active [member] | Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Post-retirement benefit obligation analysed by membership category</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember', window );">Retired [member] | Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Post-retirement benefit obligation analysed by membership category</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember', window );">Deferred [member] | Post-retirement benefits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Post-retirement benefit obligation analysed by membership category</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostretirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationActiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationRetiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_DefinedBenefitObligationDeferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>283
<FILENAME>R185.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366654832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail) - yr<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember', window );">Pension schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems', window );"><strong>Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageDurationOfDefinedBenefitObligations', window );">Weighted average duration of the defined benefit obligation</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostRetirementBenefitMember', window );">Post retirement benefit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems', window );"><strong>Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageDurationOfDefinedBenefitObligations', window );">Weighted average duration of the defined benefit obligation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageDurationOfDefinedBenefitObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average duration of defined benefit obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageDurationOfDefinedBenefitObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_PensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=gsk_PostRetirementBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=gsk_PostRetirementBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>284
<FILENAME>R186.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430458720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember', window );">Actuarial assumptions of 0.25% increase in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">(Decrease)/Increase in annual pension cost</a></td>
<td class="num">&#163; (19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember', window );">Actuarial assumptions of 0.25% decrease in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">(Decrease)/Increase in annual pension cost</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember', window );">Actuarial assumptions of 0.75% increase in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">(Decrease)/Increase in annual pension cost</a></td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember', window );">Actuarial assumptions of 0.75% decrease in discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">(Decrease)/Increase in annual pension cost</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember', window );">Actuarial assumptions of 0.25% increase in inflation rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember', window );">Actuarial assumptions of 0.25% decrease in inflation rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfLifeExpectancyRatesMember', window );">Actuarial assumptions of 1 year increase in life expectancy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInAnnualPensionCost', window );">(Decrease)/Increase in annual pension cost</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionForFutureHealthcareInflationMember', window );">Actuarial assumptions of 1% increase of rate of future healthcare inflation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation', window );">(Decrease)/Increase in post-retirement benefits obligation</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember', window );">Actuarial assumptions of 0.75% increase in inflation rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember', window );">Actuarial assumptions of 0.75% decrease in inflation rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost', window );">Increase/(decrease) in annual post-retirement benefits cost</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreasePensionObligations', window );">(Decrease)/Increase in pension obligation</a></td>
<td class="num">&#163; (827)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in annual post-retirement benefits cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInPostretirementBenefitsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in post-retirement benefits obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInPostretirementBenefitsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreasePensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Pension Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreasePensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInAnnualPensionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in annual pension cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInAnnualPensionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfLifeExpectancyRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfLifeExpectancyRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionForFutureHealthcareInflationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionForFutureHealthcareInflationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>285
<FILENAME>R187.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366709840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other provisions - Additional Information (Detail) - GBP (&#163;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions', window );">Discount on the provisions</a></td>
<td class="nump">&#163; 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermLegalProceedingsProvision', window );">Short term legal proceedings</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated', window );">Legal proceedings and other disputes provision estimated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PensionObligationProvisions', window );">Pension augmentations arising from staff redundancies</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TitleOfIndividual1Axis=gsk_DisabledEmployeesMember', window );">Disabled employees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsForEmployeeBenefits', window );">Provision for employee benefits</a></td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">69,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember', window );">Legal and other disputes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions', window );">Charges on other provisions</a></td>
<td class="nump">133,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=gsk_MajorRestructuringProvisionsMember', window );">Major Restructuring Provisions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions', window );">Discount on the provisions</a></td>
<td class="nump">&#163; 1,000,000<span></span>
</td>
<td class="nump">&#163; 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional provisions net of reversals and recoveries other provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LegalProceedingsAndOtherDisputesProvisionEstimated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal proceedings and other disputes provision estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LegalProceedingsAndOtherDisputesProvisionEstimated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PensionObligationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension obligation provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PensionObligationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from a change in discount rate. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermLegalProceedingsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for legal proceedings. [Refer: Legal proceedings provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 10 A court case<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermLegalProceedingsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TitleOfIndividual1Axis=gsk_DisabledEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TitleOfIndividual1Axis=gsk_DisabledEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=gsk_MajorRestructuringProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=gsk_MajorRestructuringProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>286
<FILENAME>R188.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364668400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Provisions - Summary of Other Provisions (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, beginning balance</a></td>
<td class="nump">&#163; 1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Exchange adjustments</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Charge for the year</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed unused</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Unwinding of discount</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilised</a></td>
<td class="num">(539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Additions through business combinations</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Reclassifications and other movements</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToPensionObligations', window );">Transfer to Pension obligations</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, ending balance</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">To be settled within one year</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">&#163; 841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">To be settled after one year</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember', window );">Legal and other disputes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, beginning balance</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Exchange adjustments</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Charge for the year</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed unused</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Unwinding of discount</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilised</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Reclassifications and other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToPensionObligations', window );">Transfer to Pension obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, ending balance</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">To be settled within one year</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">To be settled after one year</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Major Restructuring Programmes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, beginning balance</a></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Exchange adjustments</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Charge for the year</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed unused</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Unwinding of discount</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilised</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Additions through business combinations</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Reclassifications and other movements</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToPensionObligations', window );">Transfer to Pension obligations</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, ending balance</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">To be settled within one year</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">To be settled after one year</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=gsk_EmployeeRelatedProvisionsMember', window );">Employee Related Provisions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, beginning balance</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Exchange adjustments</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Charge for the year</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed unused</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Unwinding of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilised</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Additions through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Reclassifications and other movements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToPensionObligations', window );">Transfer to Pension obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, ending balance</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">To be settled within one year</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">To be settled after one year</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=gsk_OtherProvisionMember', window );">Other Provision [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, beginning balance</a></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Exchange adjustments</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Charge for the year</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversed unused</a></td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Unwinding of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilised</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToAssetsHeldForSaleDistribution', window );">Transfer to assets held for sale/distribution</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Additions through business combinations</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Reclassifications and other movements</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferToPensionObligations', window );">Transfer to Pension obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions, ending balance</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">To be settled within one year</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">To be settled after one year</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">&#163; 306<span></span>
</td>
<td class="nump">&#163; 301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransferToAssetsHeldForSaleDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer to assets held for sale/distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransferToAssetsHeldForSaleDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransferToPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer to pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransferToPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in other provisions through adjustments arising from the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=gsk_LegalAndOtherDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=gsk_EmployeeRelatedProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=gsk_EmployeeRelatedProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=gsk_OtherProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=gsk_OtherProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>287
<FILENAME>R189.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364847920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems', window );"><strong>Disclosure of contingent liabilities in business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">&#163; 6,076<span></span>
</td>
<td class="nump">&#163; 5,869<span></span>
</td>
<td class="nump">&#163; 5,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Initial recognition from business combinations</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Remeasurement through income statement</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination', window );">Exchange movement through reserves</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Cash payments: operating cash flows</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(742)<span></span>
</td>
<td class="num">(765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPaid', window );">Cash payments: investing activities</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">7,068<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember', window );">Shionogi ViiV healthcare joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems', window );"><strong>Disclosure of contingent liabilities in business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">5,559<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">5,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Remeasurement through income statement</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Cash payments: operating cash flows</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPaid', window );">Cash payments: investing activities</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">5,890<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems', window );"><strong>Disclosure of contingent liabilities in business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Initial recognition from business combinations</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Remeasurement through income statement</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination', window );">Exchange movement through reserves</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Cash payments: operating cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPaid', window );">Cash payments: investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisMember', window );">Novartis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems', window );"><strong>Disclosure of contingent liabilities in business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Remeasurement through income statement</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Cash payments: operating cash flows</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPaid', window );">Cash payments: investing activities</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_OtherBusinessMember', window );">Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems', window );"><strong>Disclosure of contingent liabilities in business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Initial recognition from business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination', window );">Remeasurement through income statement</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Cash payments: operating cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPaid', window );">Cash payments: investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">&#163; 4<span></span>
</td>
<td class="nump">&#163; 38<span></span>
</td>
<td class="nump">&#163; 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in contingent consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContingentConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContingentConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange movement through reserves contingent liabilities recognised in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement through income statement Increase (decrease) in contingent liabilities recognised in business combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_OtherBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_OtherBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>288
<FILENAME>R190.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348359709936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInProbabilityOfMilestoneSuccess', window );">10% increase in probability of milestone success</a></td>
<td class="nump">&#163; 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInProbabilityOfMilestoneSuccess', window );">10% decrease in probability of milestone success</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 1% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 1.5% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 1% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 1.5% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 10 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 15 cent appreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 10 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member] | 15 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInProbabilityOfMilestoneSuccess', window );">10% increase in probability of milestone success</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">&#163; 17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInProbabilityOfMilestoneSuccess', window );">10% decrease in probability of milestone success</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10% increase in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInSalesForecastAmount', window );">Increase in sales forecasts</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15% increase in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInSalesForecastAmount', window );">Increase in sales forecasts</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10% decrease in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInSalesForecastAmount', window );">Decrease in sales forecasts</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15% decrease in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInSalesForecastAmount', window );">Decrease in sales forecasts</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 1% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 1.5% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 1% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 1.5% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15 cent appreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10 cent appreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfEuro', window );">Appreciation of Euro</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15 cent appreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfEuro', window );">Appreciation of Euro</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 10 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfEuro', window );">Depreciation of Euro</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis vaccines [member] | 15 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfEuro', window );">Depreciation of Euro</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10% increase in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInSalesForecastAmount', window );">Increase in sales forecasts</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15% increase in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInSalesForecastAmount', window );">Increase in sales forecasts</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10% decrease in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInSalesForecastAmount', window );">Decrease in sales forecasts</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15% decrease in sales forecasts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInSalesForecastAmount', window );">Decrease in sales forecasts</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 1% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 1.5% increase in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseInDiscountRateAmount', window );">Increase in discount rate</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 1% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 1.5% decrease in discount rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseInDiscountRateAmount', window );">Decrease in discount rate</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15 cent appreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfUSDollar', window );">Appreciation of US Dollar</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(347)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfUSDollar', window );">Depreciation of US Dollar</a></td>
<td class="num">(501)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10 cent appreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfEuro', window );">Appreciation of Euro</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15 cent appreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AppreciationOfEuro', window );">Appreciation of Euro</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 10 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfEuro', window );">Depreciation of Euro</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember', window );">Shionogi ViiV healthcare [member] | 15 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems', window );"><strong>Disclosure of sensitivity of key model input to measure contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DepreciationOfEuro', window );">Depreciation of Euro</a></td>
<td class="num">&#163; (130)<span></span>
</td>
<td class="num">&#163; (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AppreciationOfEuro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Appreciation of euro.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AppreciationOfEuro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AppreciationOfUSDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Appreciation of US dollar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AppreciationOfUSDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseInDiscountRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in discount rate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseInDiscountRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseInProbabilityOfMilestoneSuccess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>decrease in probability of milestone success.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseInProbabilityOfMilestoneSuccess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseInSalesForecastAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in sales forecast amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseInSalesForecastAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DepreciationOfEuro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of euro.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DepreciationOfEuro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DepreciationOfUSDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of US dollar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DepreciationOfUSDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through change in probability of milestones success contingent liabilities recognised in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInDiscountRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in discount rate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInDiscountRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInProbabilityOfMilestoneSuccess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in probability of milestone success.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInProbabilityOfMilestoneSuccess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseInSalesForecastAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in sales forecast amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseInSalesForecastAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=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">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=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">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViivHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>289
<FILENAME>R191.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430257600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Consideration Liabilities - Additional Information (Detail)<br> &#163; in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems', window );"><strong>Disclosure of fair value of contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationLiabilitiesCurrent', window );">Contingent consideration payable</a></td>
<td class="nump">&#163; 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalOfInterestInAssociate', window );">Milestone Payment</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (36)<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis Vaccines [member] | Commercialised Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems', window );"><strong>Disclosure of fair value of contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPayableDiscountedPercentage', window );">Contingent consideration liability discount percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember', window );">Novartis Vaccines [member] | Pipeline Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems', window );"><strong>Disclosure of fair value of contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPayableDiscountedPercentage', window );">Contingent consideration liability discount percentage</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember', window );">Shionogi-ViiV Healthcare JV [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems', window );"><strong>Disclosure of fair value of contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPayableDiscountedPercentage', window );">Contingent consideration liability discount percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember', window );">Affinivax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems', window );"><strong>Disclosure of fair value of contingent consideration [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContingentConsiderationPayableDiscountedPercentage', window );">Contingent consideration liability discount percentage</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalOfInterestInAssociate', window );">Milestone Payment</a></td>
<td class="nump">&#163; 500<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContingentConsiderationLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContingentConsiderationLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContingentConsiderationPayableDiscountedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration payable discounted percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContingentConsiderationPayableDiscountedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFairValueOfContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFairValueOfContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalOfInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on disposal of Interest in associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalOfInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_NovartisVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_CommercialisedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_CommercialisedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_PipelineAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_PipelineAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ShionogiViiVHealthcareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>290
<FILENAME>R192.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376733344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherNoncurrentLiabilitiesAbstract', window );"><strong>Other non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accruals</a></td>
<td class="nump">&#163; 11<span></span>
</td>
<td class="nump">&#163; 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets', window );">Deferred income</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentPayables', window );">Other payables</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="nump">&#163; 899<span></span>
</td>
<td class="nump">&#163; 921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-current liabilities [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current accrued income other than non-current contract assets. [Refer: Accrued income other than contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>291
<FILENAME>R193.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348379946736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingent Liabilities - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract', window );"><strong>Disclosure of contingent liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Contingent liabilities, comprising guarantees, discounted bills and other items</a></td>
<td class="nump">&#163; 58.0<span></span>
</td>
<td class="nump">&#163; 126.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Financial assets were pledged as collateral for contingent liabilities</a></td>
<td class="nump">&#163; 0.5<span></span>
</td>
<td class="nump">&#163; 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 86<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>292
<FILENAME>R194.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348383554496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Additional Information (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit', window );">Additional contribution towards pension scheme to eliminate the pension deficit identified at the 31 December 2020</a></td>
<td class="nump">&#163; 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalContributionUnpaid', window );">Additional contribution unpaid</a></td>
<td class="nump">&#163; 345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalContributionUnpaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional contribution unpaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalContributionUnpaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional contribution were to be made towards 2020 pension deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>293
<FILENAME>R195.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366917040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Schedule of Contractual Obligations and Commitments (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract', window );"><strong>Disclosure Of Contractual Obligations And Commitments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">&#163; 10,659<span></span>
</td>
<td class="nump">&#163; 12,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitmentsOfInvestments', window );">Investments</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments', window );">Purchase commitments</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitmentsOfPensions', window );">Pensions and post-retirement benefits</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans', window );">Interest on loans</a></td>
<td class="nump">6,322<span></span>
</td>
<td class="nump">7,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges', window );">Future finance charges on leases</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced', window );">Lease contracts that have not yet commenced</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContractualObligationsAndCommitments', window );">Total contractual obligations and commitments</a></td>
<td class="nump">&#163; 18,909<span></span>
</td>
<td class="nump">&#163; 21,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments of future finance charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments of interest on loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitmentsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments of investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitmentsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitmentsOfPensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments of pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitmentsOfPensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations and commitments of purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations lease contracts that have not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Contractual Obligations And Commitments [abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 122<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_122_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 74<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_74_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>294
<FILENAME>R196.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364320496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Share capital issued and fully paid beginning balance</a></td>
<td class="nump">5,387,015,059<span></span>
</td>
<td class="nump">5,385,189,617<span></span>
</td>
<td class="nump">5,383,102,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ImpactOfShareConsolidationShares', window );">Impact of share consolidation (Shares)</a></td>
<td class="num">(1,077,403,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes', window );">Issued under employee share schemes</a></td>
<td class="nump">1,731,293<span></span>
</td>
<td class="nump">1,825,442<span></span>
</td>
<td class="nump">2,087,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Share capital issued and fully paid ending balance</a></td>
<td class="nump">4,311,343,341<span></span>
</td>
<td class="nump">5,387,015,059<span></span>
</td>
<td class="nump">5,385,189,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">&#163; 21,342<span></span>
</td>
<td class="nump">&#163; 20,808<span></span>
</td>
<td class="nump">&#163; 18,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued under employee share schemes</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">21,342<span></span>
</td>
<td class="nump">20,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued under employee share schemes</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">3,440<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued under employee share schemes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital [member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued under employee share schemes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">&#163; 1,347<span></span>
</td>
<td class="nump">&#163; 1,347<span></span>
</td>
<td class="nump">&#163; 1,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Classes Of Share Capital And Share Premium [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ImpactOfShareConsolidationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of share consolidation shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ImpactOfShareConsolidationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued and fully paid under employee share schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares transferred to employee share trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>295
<FILENAME>R197.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430587408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital and Share Premium Account - Additional Information (Detail) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Jul. 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_EmployeeShareOwnershipPlanMember', window );">Employee share ownership plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,878,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number Of Shares Authorised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,124,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_FreeIssueMember', window );">Free issue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,034,339,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember', window );">Share consolidation as a result of Consumer Healthcare business demerger [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DateOfShareConsolidationApproval', window );">Date of share consolidation approval</a></td>
<td class="text">Jul.  06,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ConsumerHealthcareBusinessDemerger', window );">Consumer Healthcare business demerger</a></td>
<td class="text">Jul. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember', window );">Share consolidation as a result of Consumer Healthcare business demerger [member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems', window );"><strong>Disclosure Of Classes Of Share Capital And Share Premium [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value of newly issues shares</a></td>
<td class="nump">&#163; 0.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares', window );">Par value of shares surrendered in lieu of new shares</a></td>
<td class="nump">&#163; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SurrenderedSharesForEveryFourNewSharesReceived', window );">Surrendered shares for every four new shares received</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SharesReceivedForEveryFiveExistingShares', window );">Share received for every five existing shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ConsumerHealthcareBusinessDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consumer Healthcare business demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ConsumerHealthcareBusinessDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DateOfShareConsolidationApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of share consolidation approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DateOfShareConsolidationApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Classes Of Share Capital And Share Premium [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ParValueOfSharesSurrenderedInLieuOfNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Par value of shares surrendered in lieu of new shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ParValueOfSharesSurrenderedInLieuOfNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SharesReceivedForEveryFiveExistingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares received for every five existing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SharesReceivedForEveryFiveExistingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SurrenderedSharesForEveryFourNewSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrendered shares for every four new shares received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SurrenderedSharesForEveryFourNewSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_EmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_EmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_FreeIssueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_FreeIssueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>296
<FILENAME>R198.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377421744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Movements in Equity - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RetainedEarningsAndOtherReserves', window );">Retained earnings and other reserves</a></td>
<td class="nump">&#163; 5,811<span></span>
</td>
<td class="nump">&#163; 10,407<span></span>
</td>
<td class="nump">&#163; 9,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserve</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">&#163; 2,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_AssociatesAndJointVenturesMember', window );">Associates and joint ventures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RetainedEarningsAndOtherReserves', window );">Retained earnings and other reserves</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MiscellaneousComponentsOfEquityAxis=gsk_NonDistributableMergerAndPreMergerReservesMember', window );">Non-distributable merger and pre-merger reserves [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserve</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MiscellaneousComponentsOfEquityAxis=ifrs-full_CapitalRedemptionReserveMember', window );">Capital redemption reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserve</a></td>
<td class="nump">&#163; 280<span></span>
</td>
<td class="nump">&#163; 280<span></span>
</td>
<td class="nump">&#163; 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RetainedEarningsAndOtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retained earnings and other reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RetainedEarningsAndOtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MiscellaneousComponentsOfEquityAxis=gsk_NonDistributableMergerAndPreMergerReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MiscellaneousComponentsOfEquityAxis=gsk_NonDistributableMergerAndPreMergerReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MiscellaneousComponentsOfEquityAxis=ifrs-full_CapitalRedemptionReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MiscellaneousComponentsOfEquityAxis=ifrs-full_CapitalRedemptionReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>297
<FILENAME>R199.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363248240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Beginning balance</a></td>
<td class="num">&#163; (993)<span></span>
</td>
<td class="num">&#163; (709)<span></span>
</td>
<td class="num">&#163; (652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">85<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Ending balance</a></td>
<td class="num">(531)<span></span>
</td>
<td class="num">(993)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToContinuingOperations', window );">Movement attributable to continuing operations</a></td>
<td class="num">(906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations', window );">Movement attributable to discontinued operations(a)</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember', window );">Retained earnings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Beginning balance</a></td>
<td class="num">(803)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">109<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Ending balance</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToContinuingOperations', window );">Movement attributable to continuing operations</a></td>
<td class="num">(692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations', window );">Movement attributable to discontinued operations(a)</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember', window );">Fair value reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Beginning balance</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Ending balance</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToContinuingOperations', window );">Movement attributable to continuing operations</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non- controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Beginning balance</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Ending balance</a></td>
<td class="nump">97<span></span>
</td>
<td class="num">&#163; (181)<span></span>
</td>
<td class="num">&#163; (161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToContinuingOperations', window );">Movement attributable to continuing operations</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations', window );">Movement attributable to discontinued operations(a)</a></td>
<td class="nump">&#163; 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MovementInTranslationExchangeAttributableToContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Movement in translation exchange attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MovementInTranslationExchangeAttributableToContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Movement in translation exchange attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>298
<FILENAME>R200.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367382016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification adjustments on exchange differences on translation, net of tax</a></td>
<td class="num">&#163; (2)<span></span>
</td>
<td class="nump">&#163; 25<span></span>
</td>
<td class="num">&#163; (36)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member] | Demerger [Member] | Consumer Healthcare Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification adjustments on exchange differences on translation, net of tax</a></td>
<td class="nump">&#163; 554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EventAxis=gsk_DemergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EventAxis=gsk_DemergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>299
<FILENAME>R201.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364228560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be subsequently reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">&#163; 113<span></span>
</td>
<td class="num">&#163; (239)<span></span>
</td>
<td class="num">&#163; (59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax', window );">Reclassification of cash flow hedges to income statement</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax on fair value movements on cash flow hedges</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests', window );">Exchange movements on overseas net assets of non-controlling interests</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value movements on equity investments</a></td>
<td class="num">(754)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments', window );">Tax on fair value movements on equity investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement losses\gains on defined benefit plans</a></td>
<td class="num">(786)<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax on remeasurement losses/(gains) on defined benefit plans</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperations', window );">Other comprehensive (expense)/income for the year from continuing operations</a></td>
<td class="num">(1,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive (expense)/income for the year from discontinued operations</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive (expense)/income for the year</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember', window );">Retained earnings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be subsequently reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">109<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax', window );">Reclassification of cash flow hedges to income statement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax on fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests', window );">Exchange movements on overseas net assets of non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value movements on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments', window );">Tax on fair value movements on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement losses\gains on defined benefit plans</a></td>
<td class="num">(786)<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax on remeasurement losses/(gains) on defined benefit plans</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges', window );">Fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperations', window );">Other comprehensive (expense)/income for the year from continuing operations</a></td>
<td class="num">(464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive (expense)/income for the year from discontinued operations</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive (expense)/income for the year</a></td>
<td class="num">(89)<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember', window );">Other reserves [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be subsequently reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax', window );">Reclassification of cash flow hedges to income statement</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax on fair value movements on cash flow hedges</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests', window );">Exchange movements on overseas net assets of non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value movements on equity investments</a></td>
<td class="num">(754)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments', window );">Tax on fair value movements on equity investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement losses\gains on defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax on remeasurement losses/(gains) on defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges', window );">Fair value movements on cash flow hedges</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperations', window );">Other comprehensive (expense)/income for the year from continuing operations</a></td>
<td class="num">(695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive (expense)/income for the year from discontinued operations</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive (expense)/income for the year</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non- controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be subsequently reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges', window );">Exchange movements on overseas net assets and net investment hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax', window );">Reclassification of cash flow hedges to income statement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax on fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests', window );">Exchange movements on overseas net assets of non-controlling interests</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value movements on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments', window );">Tax on fair value movements on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement losses\gains on defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax on remeasurement losses/(gains) on defined benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges', window );">Fair value movements on cash flow hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperations', window );">Other comprehensive (expense)/income for the year from continuing operations</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive (expense)/income for the year from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive (expense)/income for the year</a></td>
<td class="num">&#163; (28)<span></span>
</td>
<td class="num">&#163; (20)<span></span>
</td>
<td class="num">&#163; (34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange movements on overseas net assets and net investment hedges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange movements on overseas net assets of non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income Before Tax Gains Losses On Cash Flow Hedges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income deferred tax on fair value movements on equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from continuing operations. [Refer: Continuing operations [member]; Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from discontinued operations. [Refer: Discontinued operations [member]; Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to cash flow hedges, before tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>300
<FILENAME>R202.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348361779456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Movements in Equity - Analysis of Other Reserves (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, beginning balance</a></td>
<td class="nump">&#163; 2,463<span></span>
</td>
<td class="nump">&#163; 3,205<span></span>
</td>
<td class="nump">&#163; 2,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments', window );">Transferred to retained earnings in the year on disposal of equity investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovements', window );">Net fair value movement in the year</a></td>
<td class="num">(557)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEsopTrusts', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BalanceAmountDerecognisedOnDemerger', window );">Balances derecognised on demerger</a></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments', window );">Transferred to income and expenses in the year on impairments of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, ending balance</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_EsopTrustMember', window );">ESOP trust shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, beginning balance</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments', window );">Transferred to retained earnings in the year on disposal of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovements', window );">Net fair value movement in the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEsopTrusts', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BalanceAmountDerecognisedOnDemerger', window );">Balances derecognised on demerger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments', window );">Transferred to income and expenses in the year on impairments of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, ending balance</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember', window );">Fair value reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, beginning balance</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments', window );">Transferred to retained earnings in the year on disposal of equity investments</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovements', window );">Net fair value movement in the year</a></td>
<td class="num">(698)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEsopTrusts', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BalanceAmountDerecognisedOnDemerger', window );">Balances derecognised on demerger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments', window );">Transferred to income and expenses in the year on impairments of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, ending balance</a></td>
<td class="num">(308)<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfCashFlowHedgesMember', window );">Cash Flow Hedges Reserve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, beginning balance</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments', window );">Transferred to retained earnings in the year on disposal of equity investments</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovements', window );">Net fair value movement in the year</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEsopTrusts', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BalanceAmountDerecognisedOnDemerger', window );">Balances derecognised on demerger</a></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments', window );">Transferred to income and expenses in the year on impairments of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, ending balance</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember', window );">Other reserves [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, beginning balance</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeAdjustments', window );">Exchange adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments', window );">Transferred to retained earnings in the year on disposal of equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFairValueMovements', window );">Net fair value movement in the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves', window );">Ordinary shares acquired by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WritedownOfSharesHeldByEsopTrusts', window );">Write-down of shares held by ESOP Trusts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BalanceAmountDerecognisedOnDemerger', window );">Balances derecognised on demerger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments', window );">Transferred to income and expenses in the year on impairments of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves, ending balance</a></td>
<td class="nump">&#163; 2,129<span></span>
</td>
<td class="nump">&#163; 2,129<span></span>
</td>
<td class="nump">&#163; 2,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BalanceAmountDerecognisedOnDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance amount derecognised on demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BalanceAmountDerecognisedOnDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFairValueMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFairValueMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares acquired by Esop trusts included in other reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transferred to income expenses impairments of equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transferred to retained earnings on disposal of equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WritedownOfSharesHeldByEsopTrusts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Writedown of shares held by Esop trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WritedownOfSharesHeldByEsopTrusts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_EsopTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_EsopTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=gsk_FairValueReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_OtherReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>301
<FILENAME>R203.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367211872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests - Additional Information (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit after taxation</a></td>
<td class="nump">&#163; 665<span></span>
</td>
<td class="nump">&#163; 711<span></span>
</td>
<td class="nump">&#163; 639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition', window );">Remeasurements Of Contingent Consideration Payable For Acquisition</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember', window );">ViiV healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit after taxation</a></td>
<td class="nump">&#163; 1,528<span></span>
</td>
<td class="nump">&#163; 1,087<span></span>
</td>
<td class="nump">&#163; 762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Percentage of common stock held</a></td>
<td class="nump">78.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember', window );">Consumer health care joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Percentage of common stock held</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfNoncontrollingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non-controlling interests Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfNoncontrollingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurements of contingent consideration payable for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>302
<FILENAME>R204.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363431104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests', window );">Share of profit for the year attributable to non-controlling interest</a></td>
<td class="nump">&#163; 460<span></span>
</td>
<td class="nump">&#163; 200<span></span>
</td>
<td class="nump">&#163; 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest in the Consolidated balance sheet</a></td>
<td class="num">(502)<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">29,324<span></span>
</td>
<td class="nump">24,696<span></span>
</td>
<td class="nump">24,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit after taxation</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(expense)</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Total comprehensive income income/(expense)</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">39,377<span></span>
</td>
<td class="nump">60,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">20,769<span></span>
</td>
<td class="nump">18,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">60,146<span></span>
</td>
<td class="nump">79,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(22,810)<span></span>
</td>
<td class="num">(23,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="num">(27,240)<span></span>
</td>
<td class="num">(34,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(50,050)<span></span>
</td>
<td class="num">(57,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">21,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash inflow from operating activities</a></td>
<td class="nump">7,403<span></span>
</td>
<td class="nump">7,952<span></span>
</td>
<td class="nump">8,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash outflow from financing activities</a></td>
<td class="num">(8,772)<span></span>
</td>
<td class="num">(1,777)<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash outflow from financing activities</a></td>
<td class="nump">823<span></span>
</td>
<td class="num">(7,589)<span></span>
</td>
<td class="num">(10,132)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember', window );">ViiV healthcare [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests', window );">Share of profit for the year attributable to non-controlling interest</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterests', window );">Dividends paid to non-controlling interests</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest in the Consolidated balance sheet</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">5,619<span></span>
</td>
<td class="nump">4,637<span></span>
</td>
<td class="nump">4,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit after taxation</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(expense)</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Total comprehensive income income/(expense)</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">2,716<span></span>
</td>
<td class="nump">2,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">3,354<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">6,070<span></span>
</td>
<td class="nump">5,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(3,762)<span></span>
</td>
<td class="num">(3,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="num">(8,983)<span></span>
</td>
<td class="num">(8,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(12,745)<span></span>
</td>
<td class="num">(11,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(6,675)<span></span>
</td>
<td class="num">(6,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash inflow from operating activities</a></td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">2,128<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash outflow from financing activities</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash outflow from financing activities</a></td>
<td class="num">(2,718)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
<td class="num">(2,483)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInCashAndBankOverdrafts', window );">(Decrease)/increase in cash and bank overdrafts in the year</a></td>
<td class="nump">&#163; 550<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember', window );">Consumer health care joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfNoncontrollingInterestsLineItems', window );"><strong>Disclosure of noncontrolling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest in the Consolidated balance sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,609<span></span>
</td>
<td class="nump">&#163; 6,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 26,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfNoncontrollingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non-controlling interests Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfNoncontrollingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInCashAndBankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash and bank overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInCashAndBankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Example 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Implementation%20Guidance&amp;dita_xref=IFRS05_ex11__IFRS05_ex11_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ViiVHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_ConsumerHealthCareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>303
<FILENAME>R205.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430229792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail)<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_MedicxiVenturesILimitedPartnerMember', window );">Medicxi Ventures I Limited Partner [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions', window );">Loans outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.0<span></span>
</td>
<td class="nump">&#163; 4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Income from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ApolloTherapeuticsLLPMember', window );">Apollo Therapeutics LLP [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Income from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_LongwoodFoundersFundLPMember', window );">Longwood Founders Fund LP [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Income from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_QuraTherapeuticsLLCMember', window );">Qura Therapeutics LLC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions', window );">Loans outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 8.3<span></span>
</td>
<td class="nump">&#163; 10.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AgreementExtensionPeriod', window );">Agreement extension</a></td>
<td class="text">April 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentObligation', window );">Investment obligation | $</a></td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LoansReceivableMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans receivable made by entity related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LoansReceivableMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_MedicxiVenturesILimitedPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_MedicxiVenturesILimitedPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ApolloTherapeuticsLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_ApolloTherapeuticsLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_LongwoodFoundersFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_LongwoodFoundersFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_QuraTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_QuraTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>304
<FILENAME>R206.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348423323488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)<br> $ / shares in Units, &#1585;.&#1587; in Millions, &#163; in Millions, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jul. 18, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Nov. 24, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Nov. 24, 2022 </div>
<div>SAR (&#1585;.&#1587;)</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 7,046.0<span></span>
</td>
<td class="nump">&#163; 10,552.0<span></span>
</td>
<td class="nump">&#163; 10,597.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted', window );">Total profit on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,795.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096.0<span></span>
</td>
<td class="nump">21,342.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additions through business combinations (Note &#8226;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDemergerOfDiscontinuedOperation', window );">Total gain on the demerger of Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,084.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves', window );">Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ArrangementTypeAxis=gsk_ConsumerHealthCareBangladeshMember', window );">Consumer Health Care Bangladesh [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashTransferredOnDisposal', window );">Cash transferred on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_GskShareholdersMember', window );">GSK Shareholders [Member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_GskAndGsksConsolidatedEsotTrustsMember', window );">GSK and GSKs Consolidated ESOT Trusts [Member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_ScottishLimitedPartnershipsMember', window );">Scottish Limited Partnerships [Member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_GskAggregateHoldingMember', window );">GSK Aggregate Holding [Member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDivested', window );">Percentage Of Ownership Divested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfHolding', window );">Fair value of holding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 3,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilityEliminatedOnDemerger', window );">Liability Eliminated On Demerger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionalGainOnRemeasurementOfRetainedStake', window );">Additional gain amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest', window );">Carrying Value Of Investment Net Of Non Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gsk_GskHoldingMember', window );">GSK Holding [Member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount', window );">Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 7,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=gsk_PfizerMember', window );">Pfizer [member] | Haleon plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember', window );">2021 disposals [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total consideration value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember', window );">Consumer Healthcare Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageofGSKHolding', window );">Percentage of GSK holding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendFundedByDebtFinancing', window );">Dividend funded by debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 10,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsDistributedFromCashBalance', window );">Dividends distributed from cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfTheAssetsDistributed', window );">Fair value of the assets distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendFundedByDebtFinancingAttributableToGsk', window );">Dividend funded by debt financing attributable to GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendsDistributedFromCashBalanceAttributableToGsk', window );">Dividends&#8203; distributed from&#8203; cash balance attributable to GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember', window );">Consumer Healthcare Business [Member] | GSK Holding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember', window );">Associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashInvestmentsInJointVenturesAndAssociates', window );">Cash investment in associates and joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration paid (received)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember', window );">GSK Consumer Healthcare Limited With Hindustan Unilever Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfOwnershipDistributed', window );">Percentage Of Ownership Distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration paid (received)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (395.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember', window );">GSK Consumer Healthcare Limited With Hindustan Unilever Limited [member] | Disposal groups classified as held for sale [member] | 2020 disposals [Member] | Bangladesh Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total consideration value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember', window );">Pfizer Biotech Corporation Taiwan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration', window );">Non-cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 129.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate', window );">Non controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_HorlicksMember', window );">Horlicks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnEmbeddedDerivativeTransaction', window );">Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total consideration value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | 2021 disposals [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted', window );">Total profit on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member] | Innoviva Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InvestmentOwnedNumberOfSharesDisposedOff', window );">Investment owned number of shares disposed off | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare', window );">Disposal of interest in associates consideration receivable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GrossProceedsFromDisposalOfInterestInAssociates', window );">Gross proceeds from disposal of interest in associates | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_SierraOncologyIncMember', window );">Sierra Oncology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PaymentsMadeForTransactionCostsAndOther', window );">Payments Made For Transaction Costs And Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additions through business combinations (Note &#8226;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxIncMember', window );">Affinivax, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="nump">&#163; 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PaymentsMadeForTransactionCostsAndOther', window );">Payments Made For Transaction Costs And Other</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche', window );">Business combination potential milestone payment per tranche</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additions through business combinations (Note &#8226;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="nump">&#163; 482.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember', window );">2022 Business acquisitions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration paid (received)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_GlaxoSaudiArabiaLimitedMember', window );">Glaxo Saudi Arabia Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BusinessCombinationConsiderationPayableForStepAcquisition', window );">Business Combination Consideration Payable For Step Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21.0<span></span>
</td>
<td class="nump">&#1585;.&#1587; 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired', window );">Business combination step acquisition remaining equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionalGainOnRemeasurementOfRetainedStake">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional gain on remeasurement of retained stake.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionalGainOnRemeasurementOfRetainedStake</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BusinessCombinationConsiderationPayableForStepAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination consideration payable for step acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BusinessCombinationConsiderationPayableForStepAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BusinessCombinationPotentialMilestonePaymentPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination potential milestone payment per tranche.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BusinessCombinationPotentialMilestonePaymentPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination step acquisition remaining equity interest acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingValueOfInvestmentNetOfNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of investment net of non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashInvestmentsInJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash investments in joint ventures and associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashInvestmentsInJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashTransferredOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash transferred on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashTransferredOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of interest in associates consideration receivable per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendFundedByDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend funded by debt financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendFundedByDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendFundedByDebtFinancingAttributableToGsk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend funded by debt financing attributable to GSK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendFundedByDebtFinancingAttributableToGsk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendsDistributedFromCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends distributed from cash balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendsDistributedFromCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendsDistributedFromCashBalanceAttributableToGsk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends&#8203; distributed from&#8203; cash balance attributable to GSK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfHolding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of holding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfHolding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfTheAssetsDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets distributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfTheAssetsDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on disposals of business including signed but not completed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnEmbeddedDerivativeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on embedded derivative transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnEmbeddedDerivativeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOnDemergerOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on demerger of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOnDemergerOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GrossProceedsFromDisposalOfInterestInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from disposal of interest in associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GrossProceedsFromDisposalOfInterestInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentOwnedNumberOfSharesDisposedOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment owned number of shares disposed off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentOwnedNumberOfSharesDisposedOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilityEliminatedOnDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability eliminated on demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilityEliminatedOnDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PaymentsMadeForTransactionCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PaymentsMadeForTransactionCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfOwnershipDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership of the Consumer Healthcare business distributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfOwnershipDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfOwnershipDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership of the Consumer Healthcare business divested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfOwnershipDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageofGSKHolding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of GSK holding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageofGSKHolding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of consideration paid received consisting non cash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph o<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_o_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ArrangementTypeAxis=gsk_ConsumerHealthCareBangladeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ArrangementTypeAxis=gsk_ConsumerHealthCareBangladeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_GskShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_GskShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InvestmentAxis=gsk_HaleonPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InvestmentAxis=gsk_HaleonPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_GskAndGsksConsolidatedEsotTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_GskAndGsksConsolidatedEsotTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_ScottishLimitedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_ScottishLimitedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_GskAggregateHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_GskAggregateHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gsk_GskHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gsk_GskHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_ConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandTwentyBusinessDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandTwentyBusinessDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_BangladeshConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_BangladeshConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_HorlicksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_HorlicksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_InnovivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_SierraOncologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_SierraOncologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_GlaxoSaudiArabiaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_GlaxoSaudiArabiaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>305
<FILENAME>R207.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362513056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsAcquiredAbstract', window );"><strong>Net assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">&#163; 687<span></span>
</td>
<td class="nump">&#163; 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="nump">&#163; 10,552<span></span>
</td>
<td class="nump">&#163; 10,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember', window );">Pfizer Biotech Corporation Taiwan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsAcquiredAbstract', window );"><strong>Net assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate', window );">Net Assets Liabilities Excluding Goodwill As Of Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">&#163; 124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NoncashConsiderationForSettlementOfAPromissoryNote', window );">Non-cash consideration (settlement of a promissory note)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember', window );">2022 Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsAcquiredAbstract', window );"><strong>Net assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventory</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate', window );">Trade and other receivables</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Trade and other payables</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxationRecognizedAsOfAcquisitionDate', window );">Taxation</a></td>
<td class="num">(495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate', window );">Net Assets Liabilities Excluding Goodwill As Of Acquisition Date</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate', window );">Total</a></td>
<td class="nump">3,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total cash consideration</a></td>
<td class="nump">3,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Fair value of contingent consideration</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember', window );">2022 Acquisition [Member] | Sierra Oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsAcquiredAbstract', window );"><strong>Net assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventory</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate', window );">Trade and other receivables</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Trade and other payables</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxationRecognizedAsOfAcquisitionDate', window );">Taxation</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate', window );">Net Assets Liabilities Excluding Goodwill As Of Acquisition Date</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate', window );">Total</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total cash consideration</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember', window );">2022 Acquisition [Member] | Affinivax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsAcquiredAbstract', window );"><strong>Net assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate', window );">Trade and other receivables</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Trade and other payables</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TaxationRecognizedAsOfAcquisitionDate', window );">Taxation</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate', window );">Net Assets Liabilities Excluding Goodwill As Of Acquisition Date</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate', window );">Total</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total cash consideration</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Fair value of contingent consideration</a></td>
<td class="nump">&#163; 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities Recognized As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetAssetsAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetAssetsAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net assets liabilities including goodwill as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NonControllingInterestRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-controlling interest recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NonControllingInterestRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NoncashConsiderationForSettlementOfAPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash consideration for settlement of a promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NoncashConsiderationForSettlementOfAPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TaxationRecognizedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxation Recognized As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TaxationRecognizedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other receivables recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for customer-related intangible assets acquired in a business combination. [Refer: Customer-related intangible assets [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_PfizerBiotechCorporationTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyTwoAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_SierraOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_SierraOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gsk_AffinivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>306
<FILENAME>R208.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348428890560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed', window );">Fair value of the Consumer Healthcare business distributed</a></td>
<td class="nump">&#163; 15,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc', window );">Fair value of the retained ownership in Haleon plc</a></td>
<td class="nump">3,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TotalfairValueOfDistributedandRetainBusiness', window );">Total fair value</a></td>
<td class="nump">19,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed', window );">Carrying amount of the net assets and liabilities distributed/de-recognised</a></td>
<td class="num">(12,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingAmountOfTheNciDerecognized', window );">Carrying amount of the non-controlling interest de-recognised</a></td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts', window );">Gain on demerger before exchange movements and transaction costs</a></td>
<td class="nump">9,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries', window );">Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</a></td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainOnDemergerOfDiscontinuedOperation', window );">Total gain on the demerger of Consumer Healthcare</a></td>
<td class="nump">&#163; 10,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingAmountOfTheNciDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the NCI derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingAmountOfTheNciDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the net assets and liabilities distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfTheConsumerHealthcareBusinessDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the Consumer Healthcare business distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfTheConsumerHealthcareBusinessDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfTheRetainedOwnershipInHaleonPlc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the retained ownership in Haleon plc</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfTheRetainedOwnershipInHaleonPlc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net assets and liabilities distributed / derecognised as part of gain on the demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainOnDemergerOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on demerger of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainOnDemergerOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TotalfairValueOfDistributedandRetainBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total&#8203; fair&#8203; value of&#8203; distributed&#8203; and&#8203; retain&#8203; business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TotalfairValueOfDistributedandRetainBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>307
<FILENAME>R209.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364870016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail) - GBP (&#163;)<br> &#163; / shares in Units, &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems', window );"><strong>Disclosure of Financial Information Relating To Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 29,324.0<span></span>
</td>
<td class="nump">&#163; 24,696.0<span></span>
</td>
<td class="nump">&#163; 24,354.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="nump">5,628.0<span></span>
</td>
<td class="nump">3,599.0<span></span>
</td>
<td class="nump">5,170.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxation</a></td>
<td class="nump">707.0<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">67.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Tax rate %</a></td>
<td class="nump">1,069.0<span></span>
</td>
<td class="nump">685.0<span></span>
</td>
<td class="nump">984.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare until 18 July 2022</a></td>
<td class="nump">10,700.0<span></span>
</td>
<td class="nump">1,580.0<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger', window );">Remeasurement of discontinued operations distributed to shareholders on demerger</a></td>
<td class="num">(7,651.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests', window );">Non-controlling&#160;interest in discontinued operations</a></td>
<td class="nump">205.0<span></span>
</td>
<td class="nump">511.0<span></span>
</td>
<td class="nump">409.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent', window );">Earnings attributable to shareholders from discontinued operations</a></td>
<td class="nump">&#163; 10,495.0<span></span>
</td>
<td class="nump">&#163; 1,069.0<span></span>
</td>
<td class="nump">&#163; 876.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Earnings per share from discontinued operations</a></td>
<td class="nump">&#163; 2.606<span></span>
</td>
<td class="nump">&#163; 0.267<span></span>
</td>
<td class="nump">&#163; 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems', window );"><strong>Disclosure of Financial Information Relating To Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Turnover</a></td>
<td class="nump">&#163; 5,581.0<span></span>
</td>
<td class="nump">&#163; 9,418.0<span></span>
</td>
<td class="nump">&#163; 9,745.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Expense</a></td>
<td class="num">(4,730.0)<span></span>
</td>
<td class="num">(7,575.0)<span></span>
</td>
<td class="num">(7,947.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="nump">851.0<span></span>
</td>
<td class="nump">1,843.0<span></span>
</td>
<td class="nump">1,798.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxation</a></td>
<td class="num">(235.0)<span></span>
</td>
<td class="num">(263.0)<span></span>
</td>
<td class="num">(513.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Tax rate %</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">(Loss)/profit after taxation from discontinued operations: Consumer Healthcare until 18 July 2022</a></td>
<td class="nump">616.0<span></span>
</td>
<td class="nump">1,580.0<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherGainsLossesOnDemerger', window );">Other gains/(losses) on demerger</a></td>
<td class="nump">2,433.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger', window );">Remeasurement of discontinued operations distributed to shareholders on demerger</a></td>
<td class="nump">7,651.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations', window );">Profit after taxation on demerger of discontinued operations</a></td>
<td class="nump">10,700.0<span></span>
</td>
<td class="nump">1,580.0<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests', window );">Non-controlling&#160;interest in discontinued operations</a></td>
<td class="nump">205.0<span></span>
</td>
<td class="nump">511.0<span></span>
</td>
<td class="nump">409.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent', window );">Earnings attributable to shareholders from discontinued operations</a></td>
<td class="nump">&#163; 10,495.0<span></span>
</td>
<td class="nump">&#163; 1,069.0<span></span>
</td>
<td class="nump">&#163; 876.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Earnings per share from discontinued operations</a></td>
<td class="nump">&#163; 260.6<span></span>
</td>
<td class="nump">&#163; 26.7<span></span>
</td>
<td class="nump">&#163; 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial information relating to discontinued operations [Line Item].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherGainsLossesOnDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other gains/(losses) on demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherGainsLossesOnDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit after taxation on demerger of discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-measurement of discontinued operations distributed to shareholders on demerger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from discontinued operations attributable to owners of the parent. [Refer: Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations attributable to non-controlling interests. [Refer: Profit (loss) from discontinued operations; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Example 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Implementation%20Guidance&amp;dita_xref=IFRS05_ex11__IFRS05_ex11_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>308
<FILENAME>R210.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430340640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Net assets sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange from other comprehensive income</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="num">&#163; (25)<span></span>
</td>
<td class="nump">&#163; 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember', window );">2021 disposals [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments', window );">Cash consideration including currency forwards, purchase adjustments and deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Net assets sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsOtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DealCostsPayable', window );">Deal costs payable.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusiness', window );">Gain on disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyBusinessDisposalMember', window );">2020 Business disposals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments', window );">Cash consideration including currency forwards, purchase adjustments and deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfEquity', window );">Equity investment in Hindustan Unilever Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Net assets sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsGoodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsOtherNetLiabilitiesOrAssets', window );">Other net (liabilities)/assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Deal and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnEmbeddedDerivativeTransaction', window );">Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupLiabilityNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusiness', window );">Gain on disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyBusinessDisposalMember', window );">2020 Business disposals [member] | Horlicks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments', window );">Cash consideration including currency forwards, purchase adjustments and deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfEquity', window );">Equity investment in Hindustan Unilever Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Net assets sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsGoodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsOtherNetLiabilitiesOrAssets', window );">Other net (liabilities)/assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Deal and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnEmbeddedDerivativeTransaction', window );">Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupLiabilityNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusiness', window );">Gain on disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyBusinessDisposalMember', window );">2020 Business disposals [member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments', window );">Cash consideration including currency forwards, purchase adjustments and deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalOfEquity', window );">Equity investment in Hindustan Unilever Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Net assets sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsGoodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsOtherNetLiabilitiesOrAssets', window );">Other net (liabilities)/assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Deal and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnEmbeddedDerivativeTransaction', window );">Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Reclassification of exchange from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalGroupLiabilityNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainLossOnDisposalsOfBusiness', window );">Gain on disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash consideration including currency forwards and purchase adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DealCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deal Costs Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DealCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalGroupAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group assets, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalGroupAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalGroupLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalGroupLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>disposal of equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsOtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals other net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsOtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsOtherNetLiabilitiesOrAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals other net liabilities or assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsOtherNetLiabilitiesOrAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnDisposalsOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on disposals of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnDisposalsOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainLossOnEmbeddedDerivativeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on embedded derivative transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainLossOnEmbeddedDerivativeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransactionCostsOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransactionCostsOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyBusinessDisposalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandTwentyBusinessDisposalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_HorlicksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_HorlicksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>309
<FILENAME>R211.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362365344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="num">&#163; (8,772)<span></span>
</td>
<td class="num">&#163; (1,777)<span></span>
</td>
<td class="nump">&#163; 2,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | 2022 Acquisitions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | Associates and joint ventures 2022 disposals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | 2022 disposals demerger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredConsiderationReceived', window );">Net deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashOutflowInflowExcludingTransactionCosts', window );">Cash outflow/inflow excluding transaction costs</a></td>
<td class="num">(933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="num">(933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="num">(1,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | Cash flows in 2022 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="num">(3,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredConsiderationReceived', window );">Net deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashOutflowInflowExcludingTransactionCosts', window );">Cash outflow/inflow excluding transaction costs</a></td>
<td class="num">(3,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="num">(3,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember', window );">Business combinations [member] | 2022 disposals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredConsiderationReceived', window );">Net deferred consideration</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashOutflowInflowExcludingTransactionCosts', window );">Cash outflow/inflow excluding transaction costs</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="num">&#163; (43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember', window );">2021 disposals [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredConsiderationReceived', window );">Net deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember', window );">Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received/(paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DeferredConsiderationReceived', window );">Net deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents acquired/(divested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransactionCostsOnDisposal', window );">Transaction costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash (outflow)/inflow from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashOutflowInflowExcludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow inflow excluding transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashOutflowInflowExcludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DeferredConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DeferredConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransactionCostsOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransactionCostsOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_BusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AcquisitionsTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AcquisitionsTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_CashFlowsInTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_CashFlowsInTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandTwentyTwoBusinessDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ContinuingAndDiscontinuedOperationAxis=gsk_TwoThousandTwentyTwoBusinessDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_TwoThousandAndTwentyOneBusinessDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>310
<FILENAME>R212.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430148000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile profit (loss) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Total profit after tax from continuing operations</a></td>
<td class="nump">&#163; 4,921<span></span>
</td>
<td class="nump">&#163; 3,516<span></span>
</td>
<td class="nump">&#163; 5,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Tax on profits</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures', window );">Share of after-tax profits of associates and joint ventures</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance expense net of finance income</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortisation of intangible assets</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff', window );">Impairment and assets written off</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForProfitOnSaleOfBusinesses', window );">Profit on sale of businesses</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(2,815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets', window );">Profit on sale of intangible assets</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Loss on sale of investments in associates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments', window );">Profit on sale of equity investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease/(increase)in inventories</a></td>
<td class="num">(269)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Increase in trade receivables</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase in trade payables</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">(Increase) in other receivables</a></td>
<td class="num">(458)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid', window );">Contingent consideration paid (see Note 0)</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(742)<span></span>
</td>
<td class="num">(765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities', window );">Other non-cash increase in contingent consideration liabilities</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Increase in other payables</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Increase/(decrease) in pension and other provisions</a></td>
<td class="num">(962)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based incentive plans</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Fair value adjustments</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations', window );">Operating cash flow from continuing operations</a></td>
<td class="nump">7,944<span></span>
</td>
<td class="nump">7,249<span></span>
</td>
<td class="nump">7,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations', window );">Operating cash flow from discontinued operations</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Total cash generated from operations</a></td>
<td class="nump">&#163; 8,876<span></span>
</td>
<td class="nump">&#163; 9,243<span></span>
</td>
<td class="nump">&#163; 10,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in contingent consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in other non cash increase in contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForImpairmentAndAssetsWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment and assets written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForImpairmentAndAssetsWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForProfitOnSaleOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for profit on sale of businesses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForProfitOnSaleOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForProfitOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for profit on sale of equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForProfitOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for profit on sale of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share of after tax profits of associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Working Capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals investments in subsidiaries, joint ventures and associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>311
<FILENAME>R213.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430056432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_StatementsLineItems', window );"><strong>Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Net debt, at beginning of year, as adjusted</a></td>
<td class="num">&#163; (19,838)<span></span>
</td>
<td class="num">&#163; (20,780)<span></span>
</td>
<td class="num">&#163; (25,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations', window );">Increase in cash and bank overdrafts</a></td>
<td class="num">(7,597)<span></span>
</td>
<td class="num">(2,504)<span></span>
</td>
<td class="num">(1,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseIncreaseInLiquidInvestment', window );">Increase/(decrease) in liquid investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in long-term loans</a></td>
<td class="num">(1,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Repayment of short-term Notes</a></td>
<td class="nump">5,074<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings', window );">Repayment of/(increase in) other short-term loans</a></td>
<td class="num">(1,021)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="nump">3,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Repayment of medium term notes (MTNs)</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PaymentsOfFinanceLeaseLiabilities', window );">Repayment of lease liabilities</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DebtOfSubsidiaryUndertakingsAcquired', window );">Debt of subsidiary undertakings acquired</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExchangeOnNetDebt', window );">Exchange adjustments</a></td>
<td class="num">(1,531)<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_OtherAdjustmentsForNoncashItemsToNetDebt', window );">Other non-cash movements</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations', window );">Decrease/(increase) in net debt from continuing operations</a></td>
<td class="num">(4,536)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="nump">2,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations', window );">Decrease/(increase) in net debt from discontinued operations</a></td>
<td class="nump">7,177<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Net debt at end of year</a></td>
<td class="num">&#163; (17,197)<span></span>
</td>
<td class="num">&#163; (19,838)<span></span>
</td>
<td class="num">&#163; (20,780)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DebtOfSubsidiaryUndertakingsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt of subsidiary undertakings acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DebtOfSubsidiaryUndertakingsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseIncreaseInLiquidInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease increase in liquid investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseIncreaseInLiquidInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseIncreaseInNetDebtFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Increase In Net Debt From Continuing Operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseIncreaseInNetDebtFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Increase In Net Debt From Discontinued Operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExchangeOnNetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange on net debt to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExchangeOnNetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and cash equivalents before effect of exchange rate changes for continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_OtherAdjustmentsForNoncashItemsToNetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other adjustments for non-cash items to net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_OtherAdjustmentsForNoncashItemsToNetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PaymentsOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PaymentsOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (repayments of) other current borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_StatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_StatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>312
<FILENAME>R214.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348358490304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">&#163; (23,983)<span></span>
</td>
<td class="num">&#163; (26,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(2,450)<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(912)<span></span>
</td>
<td class="num">(775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangeInFairValueOfNetDebt', window );">Change in fair value</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">11,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(5,670)<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(20,888)<span></span>
</td>
<td class="num">(23,983)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember', window );">Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(3,145)<span></span>
</td>
<td class="num">(2,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(223)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="num">(4,615)<span></span>
</td>
<td class="num">(2,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(3,654)<span></span>
</td>
<td class="num">(3,145)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Long Term Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(20,572)<span></span>
</td>
<td class="num">(23,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(2,222)<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangeInFairValueOfNetDebt', window );">Change in fair value</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">4,615<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">10,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(8,667)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(17,035)<span></span>
</td>
<td class="num">(20,572)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_NetDebtMember', window );">Net Debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(19,838)<span></span>
</td>
<td class="num">(20,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(2,287)<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangeInFairValueOfNetDebt', window );">Change in fair value</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">11,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(6,424)<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(17,197)<span></span>
</td>
<td class="num">(19,838)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_AccruedInterestMember', window );">Accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(865)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member', window );">Commercial paper [member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(909)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember', window );">European/US Medium Term Notes &amp; Bank Facilities [member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(2,596)<span></span>
</td>
<td class="num">(2,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(174)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="num">(4,426)<span></span>
</td>
<td class="num">(2,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(2,146)<span></span>
</td>
<td class="num">(2,596)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember', window );">European/US Medium Term Notes &amp; Bank Facilities [member] | Long Term Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(19,760)<span></span>
</td>
<td class="num">(22,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(1,386)<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(16,194)<span></span>
</td>
<td class="num">(19,760)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [Member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations', window );">Beginning balance adjusted for discontinued operations</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [Member] | Long Term Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations', window );">Beginning balance adjusted for discontinued operations</a></td>
<td class="num">(725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(812)<span></span>
</td>
<td class="num">(887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherCurrentDebtMember', window );">Other [member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations', window );">Beginning balance adjusted for discontinued operations</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsContinuingOperationsMember', window );">Long term borrowings continuing operations [Member] | Long Term Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations', window );">Beginning balance</a></td>
<td class="num">(20,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(1,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">4,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(17,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsDiscontinuedOperationsMember', window );">Long term borrowings discontinued operations [Member] | Long Term Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations', window );">Beginning balance</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangeInFairValueOfNetDebt', window );">Change in fair value</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">10,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(9,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember', window );">Short Term Borrowings Attributed to Continuing Operations [Member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations', window );">Beginning balance</a></td>
<td class="num">(3,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="num">(4,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">4,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(3,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember', window );">Short Term Borrowings Attributed to Discontinued Operations [Member] | Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations', window );">Beginning balance</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReclassificationOfNetDebt', window );">Reclassifications</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(1,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember', window );">Liquid Investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalentMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations', window );">Beginning balance adjusted for discontinued operations</a></td>
<td class="nump">3,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">4,274<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">99<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">7,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(7,734)<span></span>
</td>
<td class="num">(1,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_BankOverdrafts1Member', window );">Overdrafts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations', window );">Beginning balance adjusted for discontinued operations</a></td>
<td class="num">(450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(456)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndBankOverdraftsMember', window );">Cash and cash equivalents and overdrafts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashAndCashEquivalentsAndNetOfOverdrafts', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativeFinancialInstrumentsMember', window );">Derivative financial instruments [member] | Assets held to hedge liabilities arising from financing activities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ChangeInFairValueOfNetDebt', window );">Change in fair value</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(640)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">&#163; (22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsCashAndCashEquivalentsMember', window );">Liquid investments, cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidInvestmentsCashAndCashEquivalents', window );">Beginning balance</a></td>
<td class="nump">3,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToContinuingOperationsMember', window );">Liquid Investments Attributed to Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations', window );">Beginning balance</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="nump">7,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="num">(7,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember', window );">Liquid Investments Attributed to Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations', window );">Beginning balance</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities', window );">Demerger</a></td>
<td class="num">(7,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flow</a></td>
<td class="nump">&#163; 7,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashAndCashEquivalentsAndNetOfOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and net of overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashAndCashEquivalentsAndNetOfOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ChangeInFairValueOfNetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ChangeInFairValueOfNetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through Demerger dividend, liabilities arising from financing activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities, opening balance as on 01.01.22 adjusted for amounts attributed to discontinued operations". [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributed to discontinued operations; Liabilities].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to discontinued operations; Liabilities].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiquidInvestmentsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquid investments cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiquidInvestmentsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReclassificationOfNetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReclassificationOfNetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_NetDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_NetDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_AccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=gsk_AccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaper1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherCurrentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OtherCurrentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_LongTermBorrowingsDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_BankOverdrafts1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_BankOverdrafts1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndBankOverdraftsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndBankOverdraftsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>313
<FILENAME>R215.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348419689520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Additional Information (Detail)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">&#163; 17,197.0<span></span>
</td>
<td class="nump">&#163; 19,838.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20,780.0<span></span>
</td>
<td class="nump">&#163; 25,215.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity including non-controlling interests</a></td>
<td class="nump">10,096.0<span></span>
</td>
<td class="nump">21,342.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,808.0<span></span>
</td>
<td class="nump">18,357.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquityAndDebtNet', window );">Total capital including that provided by non-controlling interests</a></td>
<td class="nump">27,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Short-term finance access</a></td>
<td class="nump">1,191.0<span></span>
</td>
<td class="nump">252.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan', window );">Carrying value of shares held by trust under employee share ownership plan</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan', window );">Market value of shares held by trust under employee share ownership plan</a></td>
<td class="nump">861.0<span></span>
</td>
<td class="nump">373.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares at cost</a></td>
<td class="nump">3,797.0<span></span>
</td>
<td class="nump">4,969.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">7,068.0<span></span>
</td>
<td class="nump">6,076.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5,869.0<span></span>
</td>
<td class="nump">&#163; 5,479.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">5,452.0<span></span>
</td>
<td class="nump">6,246.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,053.0<span></span>
</td>
<td class="nump">7,860.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New liabilities contingent liabilities recognized in business combination</a></td>
<td class="nump">482.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=gsk_FinancialLiabilitesOneMember', window );">Financial Liabilites One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Liabilities transferred out of level three</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">Interest rate swap contract [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied', window );">Cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied</a></td>
<td class="nump">24.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied', window );">Cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember', window );">Bonds In A Designated Hedging Relationship [member] | Net Investment Hedged [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments', window );">Carrying value of bonds</a></td>
<td class="nump">6,322.0<span></span>
</td>
<td class="nump">4,982.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member', window );">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">5,452.0<span></span>
</td>
<td class="nump">6,246.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,053.0<span></span>
</td>
<td class="nump">7,860.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member', window );">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member] | Amortized Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">3,075.0<span></span>
</td>
<td class="nump">4,244.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member', window );">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member] | Financial assets at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member', window );">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member] | Financial assets at fair value through other comprehensive income, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">2,327.0<span></span>
</td>
<td class="nump">1,943.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember', window );">Shionogi ViiV healthcare joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">5,890.0<span></span>
</td>
<td class="nump">5,559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense', window );">Total net losses on financial instruments held</a></td>
<td class="nump">1,623.0<span></span>
</td>
<td class="nump">1,024.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement', window );">Total net losses on financial instruments held</a></td>
<td class="nump">1,627.0<span></span>
</td>
<td class="nump">1,024.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Affinivax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">501.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Affinivax, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New liabilities contingent liabilities recognized in business combination</a></td>
<td class="nump">482.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Gain loss measured in profit or loss fair value measurement liabilities</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Shionogi ViiV healthcare joint venture [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfTheContingentConsiderationPayable', window );">Remeasurement of the contingent consideration payable</a></td>
<td class="nump">1,431.0<span></span>
</td>
<td class="nump">1,026.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">5,890.0<span></span>
</td>
<td class="nump">5,559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member] | Novartis Vaccines Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_RemeasurementOfTheContingentConsiderationPayable', window );">Remeasurement of the contingent consideration payable</a></td>
<td class="nump">231.0<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration liabilities</a></td>
<td class="nump">673.0<span></span>
</td>
<td class="nump">479.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NG', window );">Nigeria [member] | United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=gsk_GbMember', window );">Uk [Member] | Halk Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_EC', window );">Ecuador [Member] | Produbanco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_HN', window );">Honduras [Member] | Banco De Honduras [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_KH', window );">Cambodia [Member] | J Trust Royal Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CR', window );">Costa Rica | BAC San Jose [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BR', window );">Brazil | Banco Do Brasil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashAndCashEquivalentsAndLiquidInvestments', window );">Cash and cash equivalents and liquid investments</a></td>
<td class="nump">3,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld', window );">Cash and cash equivalents and liquid investments held centrally</a></td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme', window );">Amount held at European medium term note programme</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme', window );">Notes issued at European medium term note programme</a></td>
<td class="nump">10,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NotesIssuedUnderUsShelfRegistration', window );">Notes issued under us shelf registration</a></td>
<td class="nump">8,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member] | Not later than 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities', window );">Cancelled committed facilities and replaced with revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,100.0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member] | Not later than 1 year [member] | Post separation of the consumer healthcare business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Revolving credit facilities</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member] | Later than one year and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities', window );">Cancelled committed facilities and replaced with revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [member] | Later than one year and not later than three years [member] | Post separation of the consumer healthcare business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Revolving credit facilities</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">10,180.0<span></span>
</td>
<td class="nump">11,417.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits held with counter parties</a></td>
<td class="nump">1,324.0<span></span>
</td>
<td class="nump">2,825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [member] | Not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashReserves', window );">Cash reserves</a></td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_WholesaleAndRetailCreditRiskMember', window );">Wholesale and retail credit risk [Member] | Due From Three Wholesalers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#163; 3,001.0<span></span>
</td>
<td class="nump">&#163; 2,430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_WholesaleAndRetailCreditRiskMember', window );">Wholesale and retail credit risk [Member] | US [member] | Due From Three Wholesalers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfAccountsReceivableByMajorCustomer', window );">Maximum percentage of trade receivables balance</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_ForeignExchangeRiskMember', window );">Foreign exchange risk [Member] | Cash flow hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectiveness', window );">Ineffectiveness of hedges</a></td>
<td class="nump">&#163; 0.0<span></span>
</td>
<td class="nump">&#163; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_ForeignExchangeRiskMember', window );">Foreign exchange risk [Member] | Hedges of net investment in foreign operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectiveness', window );">Ineffectiveness of hedges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=ifrs-full_ExternalCreditGradesMember', window );">External credit grades [member] | Credit risk [member] | Wholesaler In The US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditExposure', window );">Concentration of credit risk</a></td>
<td class="nump">1,100.0<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember', window );">BBB/Baa [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits held with counter parties</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_BBB-OrBaaThreeRatedMember', window );">BBB -/ Baa3 Rated [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits held with counter parties</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_LowerThanBBBBaa3Member', window );">Lower than BBB-/Baa3 [Member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashHeldAtUnratedCounterparties', window );">Amount of cash held at unrated counter parties</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement', window );">Cash in transit</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember', window );">Interest rate sensitivity [member] | 1% (100 basis points) movement in USD interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements.', window );">Impact on equity through interest rate movements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember', window );">Interest rate sensitivity [member] | 1.5% (150 basis points) movement in USD interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Impact on equity through interest rate movements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">297.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember', window );">Interest rate sensitivity [member] | 1% (100 basis points) movement in EUR or Sterling interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements.', window );">Impact on equity through interest rate movements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember', window );">Interest rate sensitivity [member] | 1.5% (150 basis points) movement in EUR or Sterling interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements.', window );">Impact on equity through interest rate movements</a></td>
<td class="nump">&#163; 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Wholesale and retail credit risk [Member] | Non USA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfAccountsReceivableByMajorCustomer', window );">Maximum percentage of trade receivables balance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=gsk_StateBankOfIndiaMember', window );">State Bank of India [member] | BBB -/ Baa3 Rated [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Balances or deposits with banks</a></td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInsuranceContractsAxis=gsk_GroupCreditEnhancementsAndCreditInsuranceMember', window );">Group credit enhancements and credit insurance [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">332.0<span></span>
</td>
<td class="nump">315.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gsk_UsCommercialPaperProgramMember', window );">US commercial paper program [member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Issue amount</a></td>
<td class="nump">748.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Short-term finance access</a></td>
<td class="nump">8,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gsk_EuroCommercialPaperProgrammeMember', window );">Euro Commercial Paper Program [Member] | Liquidity risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Issue amount</a></td>
<td class="nump">443.0<span></span>
</td>
<td class="nump">&#163; 252.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Short-term finance access</a></td>
<td class="nump">&#163; 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=gsk_InLineWithOtherPharmaceuticalCompaniesMember', window );">In Line with Other Pharmaceutical Companies [member] | Wholesale and retail credit risk [Member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ConcentrationsOfRiskRevenuePercentage', window );">Percentage of sales of US Commercial Operation business to three largest wholesalers</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareMember', window );">ViiV healthcare [member] | Credit risk [member] | Not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CashManagedForSubsidiaryCompany', window );">Cash managed by group for subsidiary</a></td>
<td class="nump">&#163; 2,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AmountHeldAtEuropeanMediumTermNoteProgramme">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount held at European medium term note programme.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AmountHeldAtEuropeanMediumTermNoteProgramme</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BankBalancesAndDepositHeldWithCounterparties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank balances and deposit held with counter parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BankBalancesAndDepositHeldWithCounterparties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancelled committed facilities replaced with revolving credit facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>carrying value of bonds that were designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of shares held by trust under employee share ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashAndCashEquivalentsAndLiquidInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and liquid investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashAndCashEquivalentsAndLiquidInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and liquid investments held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashHeldAtUnratedCounterparties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash held at unrated counterparties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashHeldAtUnratedCounterparties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash held at unrated counterparties cash in transit element.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashManagedForSubsidiaryCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash managed for subsidiary company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashManagedForSubsidiaryCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CashReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CashReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ConcentrationsOfRiskRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentrations of risk revenue percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ConcentrationsOfRiskRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EquityAndDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of total capital consisting of equity and net debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EquityAndDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares held by trust under employee share ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains losses attributable to level 3 of fair value hierarchy recognised in income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInEquityThroughInterestRateMovements.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in equity through interest rate movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in income through interest rate movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses attributable to level 3 financial instruments reported in other operating income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes issued at European medium term note programme.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NotesIssuedUnderUsShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes issued under US shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NotesIssuedUnderUsShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfAccountsReceivableByMajorCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of accounts receivable by major customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfAccountsReceivableByMajorCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_RemeasurementOfTheContingentConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of the contingent consideration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_RemeasurementOfTheContingentConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreditExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exposure to loss resulting from credit risk. [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_IG24_a&amp;doctype=Implementation%20Guidance&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG25<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_IG25_b&amp;doctype=Implementation%20Guidance&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreditExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the reserve of cash flow hedges in relation to hedging relationships for which hedge accounting is no longer applied. [Refer: Reserve of cash flow hedges]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=gsk_FinancialLiabilitesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=gsk_FinancialLiabilitesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_ShionogiViiVHealthcareJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=gsk_AffinivaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_NovartisVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_NovartisVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_GbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_GbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_HalkBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_HalkBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_EC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_EC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_ProdubancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_ProdubancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_HN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_HN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_BancoDeHondurasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_BancoDeHondurasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_JTrustRoyalBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_JTrustRoyalBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_BacSanJoseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_BacSanJoseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_BancoDoBrasilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_BancoDoBrasilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PurposeAxis=gsk_PostSeparationOfTheConsumerHealthcareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PurposeAxis=gsk_PostSeparationOfTheConsumerHealthcareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_WholesaleAndRetailCreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_WholesaleAndRetailCreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_DueFromThreeWholesalersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_DueFromThreeWholesalersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_ForeignExchangeRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_ForeignExchangeRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=ifrs-full_ExternalCreditGradesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=ifrs-full_ExternalCreditGradesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=gsk_WholesalerInTheUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=gsk_WholesalerInTheUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_BBB-OrBaaThreeRatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_BBB-OrBaaThreeRatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_LowerThanBBBBaa3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_LowerThanBBBBaa3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=gsk_InterestRateSensitivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_NonUsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_NonUsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=gsk_StateBankOfIndiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=gsk_StateBankOfIndiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInsuranceContractsAxis=gsk_GroupCreditEnhancementsAndCreditInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInsuranceContractsAxis=gsk_GroupCreditEnhancementsAndCreditInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gsk_UsCommercialPaperProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gsk_UsCommercialPaperProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gsk_EuroCommercialPaperProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gsk_EuroCommercialPaperProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=gsk_InLineWithOtherPharmaceuticalCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=gsk_InLineWithOtherPharmaceuticalCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>314
<FILENAME>R216.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430503680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail) - Credit risk [member] - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits</a></td>
<td class="nump">&#163; 1,324<span></span>
</td>
<td class="nump">&#163; 2,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds', window );">US Treasury and Treasury repo only money market funds</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidityFunds', window );">Liquidity funds</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentSecurities', window );">Government securities</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Third party financial derivatives</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">4,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_AAAOrAaaMember', window );">AAA/Aaa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds', window );">US Treasury and Treasury repo only money market funds</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LiquidityFunds', window );">Liquidity funds</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_AaOrAaMember', window );">AA/Aa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentSecurities', window );">Government securities</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_AorAMember', window );">A/A [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Third party financial derivatives</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember', window );">BBB/Baa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GovernmentSecurities', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExternalCreditGradesAxis=gsk_BBPlusOrBaOneMember', window );">BB+/Ba1 and Below/Unrated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems', window );"><strong>Disclosure of external credit grades [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BankBalancesAndDepositHeldWithCounterparties', window );">Bank balances and deposits</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RatedCreditExposures', window );">Total</a></td>
<td class="nump">&#163; 60<span></span>
</td>
<td class="nump">&#163; 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BankBalancesAndDepositHeldWithCounterparties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank balances and deposit held with counter parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BankBalancesAndDepositHeldWithCounterparties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GovernmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GovernmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LiquidityFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LiquidityFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Us treasury and treasury repo only money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExternalCreditExposuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExternalCreditExposuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RatedCreditExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of credit exposure that has been rated by external rating agencies. [Refer: Credit exposure]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG24<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_IG24_c&amp;doctype=Implementation%20Guidance&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RatedCreditExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_AAAOrAaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_AAAOrAaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_AaOrAaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_AaOrAaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_AorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_AorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_BbbOrBaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gsk_BBPlusOrBaOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gsk_BBPlusOrBaOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>315
<FILENAME>R217.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364584640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#163; 15,734<span></span>
</td>
<td class="nump">&#163; 13,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(41,442)<span></span>
</td>
<td class="num">(45,058)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFinancialAssetsLiabilities', window );">Net financial assets and financial liabilities excluding lease liabilities</a></td>
<td class="num">(25,708)<span></span>
</td>
<td class="num">(31,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">15,734<span></span>
</td>
<td class="nump">13,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(41,068)<span></span>
</td>
<td class="num">(48,760)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue', window );">Net financial assets and financial liabilities fair value excluding lease liabilities</a></td>
<td class="num">(25,334)<span></span>
</td>
<td class="num">(35,217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityAndOtherInvestmentsMember', window );">Current equity investments and Other investments [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherInvestmentsMember', window );">Other investments [member] | Financial assets at fair value through other comprehensive income, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember', window );">Trade and other receivable [member] | Financial assets at fair value through other comprehensive income, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember', window );">Trade and other receivable [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember', window );">Trade and other receivable [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember', window );">Liquid Investments [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member', window );">Cash and cash equivalents [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member', window );">Cash and cash equivalents [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember', window );">Derivatives designated and effective as hedging instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember', window );">Held for trading derivatives that are not in a designated and effective hedging relationship [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember', window );">Held for trading derivatives that are not in a designated and effective hedging relationship [member] | Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities [member] | Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(19,605)<span></span>
</td>
<td class="num">(26,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(19,979)<span></span>
</td>
<td class="num">(23,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial Liabilities at Amortised Cost, Category [member] | Trade and other payable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,431)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial Liabilities at Amortised Cost, Category [member] | Other provisions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial Liabilities at Amortised Cost, Category [member] | Other non current liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities fair value</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember', window );">Bonds In A Designated Hedging Relationship [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(6,035)<span></span>
</td>
<td class="num">(5,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(6,322)<span></span>
</td>
<td class="num">(4,982)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherBondsMember', window );">Other Bonds [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(11,930)<span></span>
</td>
<td class="num">(20,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(12,017)<span></span>
</td>
<td class="num">(17,373)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_BankLoansAndOverdraftsMember', window );">Bank Loans and Overdrafts [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaperInADesignatedHedgingRelationshipMember', window );">Commercial paper in a designated hedging relationship [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(443)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(443)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherCommercialPaperMember', window );">Other commercial paper [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(748)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">(748)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherBorrowingMember', window );">Other Borrowing [member] | Financial Liabilities at Amortised Cost, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue', window );">Borrowings excluding obligations under finance leases fair value</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease', window );">Borrowings excluding obligations under finance leases:</a></td>
<td class="num">&#163; (2)<span></span>
</td>
<td class="num">&#163; (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BorrowingsExcludingObligationsUnderFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings excluding obligations under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BorrowingsExcludingObligationsUnderFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings excluding obligations under finance lease at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net financial assets and financial liabilities at fair values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NetFinancialAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net financial assets liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NetFinancialAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_LiquidInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_TradeAndOtherPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_TradeAndOtherPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_OtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_OtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_OtherNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_OtherNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_BondsInDesignatedHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OtherBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_BankLoansAndOverdraftsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_BankLoansAndOverdraftsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaperInADesignatedHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_CommercialPaperInADesignatedHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OtherCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=gsk_OtherBorrowingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=gsk_OtherBorrowingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>316
<FILENAME>R218.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348360034416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">&#163; 15,734<span></span>
</td>
<td class="nump">&#163; 13,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(41,068)<span></span>
</td>
<td class="num">(48,760)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember', window );">Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Current equity investments and Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">10,533<span></span>
</td>
<td class="nump">5,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(7,251)<span></span>
</td>
<td class="num">(6,304)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial assets at fair value through other comprehensive income, category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial assets at fair value through other comprehensive income, category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial assets at fair value through other comprehensive income, category [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Current equity investments and Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Contingent Consideration Liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Financial Liabilities at Fair Value Through Other Comprehensive Income [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">7,309<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Current equity investments and Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Contingent Consideration Liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 1 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Other Comprehensive Income [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,567<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial assets at fair value through other comprehensive income, category [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Current equity investments and Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Contingent Consideration Liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 2 of fair value hierarchy [member] | Financial Liabilities at Fair Value Through Other Comprehensive Income [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial assets at fair value through other comprehensive income, category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial assets at fair value through other comprehensive income, category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial assets at fair value through other comprehensive income, category [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Current equity investments and Other investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Other Noncurrent Assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Contingent Consideration Liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Held for trading derivatives that are not in a designated and effective hedging relationship [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At Fair Value [Member] | Level 3 [member] | Financial Liabilities at Fair Value Through Other Comprehensive Income [member] | Derivatives designated and effective as hedging instruments (fair value movements through OCI") [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities at fair value</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities line Items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CurrentEquityAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>317
<FILENAME>R219.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348378211616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail) - Level 3 [member] - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurements of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinancialAssetsAndLiabilities', window );">Beginning balance</a></td>
<td class="num">&#163; (5,657)<span></span>
</td>
<td class="num">&#163; (5,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities', window );">Exchange adjustments</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities', window );">Net losses recognised in the income statement</a></td>
<td class="num">(1,627)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities', window );">Net gains recognised in other comprehensive income</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Contingent consideration related to business acquisitions in the period</a></td>
<td class="num">(482)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PaymentOfContingentConsiderationLiabilities', window );">Settlement of contingent consideration liabilities</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities', window );">Additions</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities', window );">Disposals and settlements</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities', window );">Transfers from Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinancialAssetsAndLiabilities', window );">Ending balance</a></td>
<td class="num">&#163; (6,411)<span></span>
</td>
<td class="num">&#163; (5,657)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AdditionsFairValueMeasurementAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions fair value measurement assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AdditionsFairValueMeasurementAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value measurements of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals and Settlements Fair Value Measurement Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinancialAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FinancialAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains losses recognized in other comprehensive income fair value measurement assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (losses) recognised in profit or loss, fair value measurement, assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exchange adjustments of fair value measurement assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PaymentOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PaymentOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfers out of level three of fair value hierarchy assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>318
<FILENAME>R220.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364723632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">&#163; 7,053<span></span>
</td>
<td class="nump">&#163; 7,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">15,734<span></span>
</td>
<td class="nump">13,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member', window );">Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,053<span></span>
</td>
<td class="nump">7,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,247<span></span>
</td>
<td class="nump">9,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Category [member] | Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category [member] | Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Amortised cost [member] | Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">4,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_FinancialInstrumentsMember', window );">Financial Instruments [member] | Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">6,166<span></span>
</td>
<td class="nump">6,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">6,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_NonFinancialInstrumentsMember', window );">Non Financial Instruments [member] | Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets and non financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#163; 2,047<span></span>
</td>
<td class="nump">&#163; 2,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_FinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_FinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_NonFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=gsk_NonFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>319
<FILENAME>R221.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348429830256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="num">&#163; (1,184)<span></span>
</td>
<td class="num">&#163; (1,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(899)<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">(41,442)<span></span>
</td>
<td class="num">(45,058)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member', window );">Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(16,263)<span></span>
</td>
<td class="num">(17,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="num">(1,184)<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liabilities</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(899)<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">(25,414)<span></span>
</td>
<td class="num">(26,022)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss, Category [member] | Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liabilities</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Amortised cost [member] | Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">(14,212)<span></span>
</td>
<td class="num">(15,596)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_FinancialInstrumentsMember', window );">Financial Instruments [member] | Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liabilities</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(6,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">(21,280)<span></span>
</td>
<td class="num">(21,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_NonFinancialInstrumentsMember', window );">Non Financial Instruments [member] | Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(2,198)<span></span>
</td>
<td class="num">(2,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="num">(1,121)<span></span>
</td>
<td class="num">(1,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(815)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="num">&#163; (4,134)<span></span>
</td>
<td class="num">&#163; (4,350)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_FinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_FinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_NonFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=gsk_NonFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>320
<FILENAME>R222.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362339904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentAssets', window );">Financial assets, current and Non current</a></td>
<td class="nump">&#163; 190<span></span>
</td>
<td class="nump">&#163; 206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentAssets', window );">Financial assets, current and Non current</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash Flow Hedges [member] | Interest rate swap contract [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsNoncurrent', window );">Financial assets, Non current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Cash Flow Hedges [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsCurrent', window );">Financial assets, current</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Net Investment Hedges [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsCurrent', window );">Financial assets, current</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentAssets', window );">Financial assets, current and Non current</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsCurrent', window );">Financial assets, current</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] | Embedded and Other Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsNoncurrent', window );">Financial assets, Non current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentAssetsCurrent', window );">Financial assets, current</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentsLiabilities', window );">Financial liabilities, current and Non current</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] | Cash Flow Hedges [member] | Interest rate swap contract [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesNoncurrent', window );">Financial liabilities non current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] | Cash Flow Hedges [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesCurrent', window );">Financial Liabilities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] | Net Investment Hedges [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesCurrent', window );">Financial Liabilities, current</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesCurrent', window );">Financial Liabilities, current</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentLiabilities', window );">Total derivative instruments</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesCurrent', window );">Financial Liabilities, current</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember', window );">Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member] | Embedded and Other Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesNoncurrent', window );">Financial liabilities non current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_HedgingInstrumentLiabilitiesCurrent', window );">Financial Liabilities, current</a></td>
<td class="num">&#163; (1)<span></span>
</td>
<td class="num">&#163; (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingInstrumentAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging Instrument Assets Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingInstrumentAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingInstrumentAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging Instrument Assets Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingInstrumentAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingInstrumentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging instrument, liabilities current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingInstrumentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingInstrumentLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging instrument, liabilities noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingInstrumentLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_HedgingInstrumentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedging instruments liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_HedgingInstrumentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a hedging instrument, recognised as an asset. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a hedging instrument, recognised as a liability. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_EmbeddedAndOtherDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_EmbeddedAndOtherDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>321
<FILENAME>R223.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362964528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">167,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">13,981,000,000<span></span>
</td>
<td class="nump">10,719,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Interest rate swap contract [member] | Cash Flow Hedges [member] | Non Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Foreign Exchange Contracts [member] | Cash Flow Hedges [member] | Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] | Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">7,197<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember', window );">Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] | Foreign Exchange Contracts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems', window );"><strong>Disclosure of detailed information about hedging instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Principal amount</a></td>
<td class="nump">5,908<span></span>
</td>
<td class="nump">9,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NominalAmountOfHedgingInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal amount of a hedging instrument. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NominalAmountOfHedgingInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>322
<FILENAME>R224.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348363628800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember', window );">Cash Flow Hedges [member] | Variability in cash flows from a highly probable forecast transaction [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (2)<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges', window );">Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1', window );">Balance in cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember', window );">Cash Flow Hedges [member] | Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges', window );">Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1', window );">Balance in cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember', window );">Net Investment Hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">617<span></span>
</td>
<td class="num">(1,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges', window );">Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges</a></td>
<td class="num">(1,120)<span></span>
</td>
<td class="num">&#163; (873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1', window );">Balance in cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">167,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 5<span></span>
</td>
<td class="num">&#163; (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 5<span></span>
</td>
<td class="num">&#163; (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member] | Buy Foreign Currency Less than 3 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">USD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">89,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="num">&#163; (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member] | Buy Foreign Currency 3 to 6 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="nump">1.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">EUR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="num">&#163; (1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="num">&#163; (1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member] | Buy Foreign Currency over 6 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.15<span></span>
</td>
<td class="nump">1.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">EUR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Cash Flow Hedges [member] | Sell Foreign Currency Less than 3 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="num">(7,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">13,981,000,000<span></span>
</td>
<td class="nump">10,719,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (6,851)<span></span>
</td>
<td class="num">&#163; (5,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (617)<span></span>
</td>
<td class="nump">&#163; 1,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Sell Foreign Currency Less than 3 months [member] | EURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">EUR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">6,559,000,000<span></span>
</td>
<td class="nump">5,348,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (103)<span></span>
</td>
<td class="nump">&#163; 58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (317)<span></span>
</td>
<td class="nump">&#163; 578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Sell Foreign Currency Less than 3 months [member] | SGD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SGD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Sell Foreign Currency Less than 3 months [member] | Japanese Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">155.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">JPY<span></span>
</td>
<td class="text">JPY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">194,000,000<span></span>
</td>
<td class="nump">121,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (9)<span></span>
</td>
<td class="nump">&#163; 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Sell Foreign Currency over 6 months [member] | SGD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">SGD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">174,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Sell Foreign Currency over 6 months [member] | CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">CAD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="nump">&#163; 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="nump">&#163; 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Borrowings Less than 3 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">EUR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Borrowings Less than 3 months [member] | EURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Borrowing 3 to 6 months [Member] | EURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Borrowings Over 6 months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">EUR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (4,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember', window );">Foreign Exchange Contracts [member] | Net Investment Hedges [member] | Borrowings Over 6 months [member] | EURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DescriptionOfForeignCurrency', window );">Foreign currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional value</a></td>
<td class="nump">6,341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Carrying value</a></td>
<td class="num">&#163; (6,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Periodic change&#160;in&#160;value for&#160;calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DescriptionOfForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DescriptionOfForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve of cash flow hedges, hedging relationships for which hedge accounting is no longer applied 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the reserve of cash flow hedges or the reserve of exchange differences on translation in relation to continuing hedges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial instruments designated as hedging instruments. Hedging instruments are designated derivatives or (for a hedge of the risk of changes in foreign currency exchange rates only) designated non-derivative financial assets or non-derivative financial liabilities whose fair value or cash flows are expected to offset changes in the fair value or cash flows of a designated hedged item. [Refer: At fair value [member]; Derivatives [member]; Derivative financial assets; Derivative financial liabilities; Financial instruments, class [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_22_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on the change in fair value of the hedged item used as a basis for recognising hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NominalAmountOfHedgingInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal amount of a hedging instrument. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NominalAmountOfHedgingInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=gsk_NetInvestmentHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_ForeignExchangeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyLessThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyLessThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyThreeToSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyThreeToSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyOverSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BuyForeignCurrencyOverSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_SellForeignCurrencyLessThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_SellForeignCurrencyLessThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=gsk_EuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=gsk_EuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=gsk_SgdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=gsk_SgdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=gsk_JapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=gsk_JapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_SellForeignCurrencyOverSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_SellForeignCurrencyOverSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=gsk_CADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=gsk_CADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BorrowingsLessThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BorrowingsLessThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BorrowingThreeToSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BorrowingThreeToSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_BorrowingsOverSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_BorrowingsOverSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>323
<FILENAME>R225.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364545760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember', window );">Pre-hedging of long-term interest rates [member] | More than Five Years Not Later Than Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember', window );">Pre-hedging of long-term interest rates [member] | More than Ten Years Not Later Than Thirty Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember', window );">Pre-hedging of long-term interest rates [member] | More Than Thirty Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember', window );">Pre-hedging of long-term interest rates [member] | Matured in the past period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="num">&#163; (23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness', window );">Line item in profit or loss in which hedge ineffectiveness is included</a></td>
<td class="text">Finance income or expense<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="nump">&#163; 3<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments', window );">Line item in profit or loss in which reclassification adjustment is included</a></td>
<td class="text">Finance income or expense<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember', window );">Cash Flow Hedges [member] | Variability in cash flows from a highly probable forecast transaction [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="num">&#163; (5)<span></span>
</td>
<td class="nump">&#163; 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness', window );">Line item in profit or loss in which hedge ineffectiveness is included</a></td>
<td class="text">Finance income or expense<span></span>
</td>
<td class="text">Other operating income/ (expense)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">&#163; (7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments', window );">Line item in profit or loss in which reclassification adjustment is included</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other operating income/ (expense)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets', window );">Due to hedged item affecting balance sheet</a></td>
<td class="nump">&#163; 8<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem', window );">Line item in balance sheet in which reclassification adjustment is included</a></td>
<td class="text">Intangible assets <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember', window );">Cash Flow Hedges [member] | Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="nump">&#163; 4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness', window );">Line item in profit or loss in which hedge ineffectiveness is included</a></td>
<td class="text">Finance income or expense<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="num">&#163; (2)<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments', window );">Line item in profit or loss in which reclassification adjustment is included</a></td>
<td class="text">Financeincome&#160;or&#160;expense&#160;<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets', window );">Due to hedged item affecting balance sheet</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember', window );">Cash Flow Hedges [member] | Variability in cash flows [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments', window );">Line item in profit or loss in which reclassification adjustment is included</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember', window );">Hedges of net investment in foreign operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments', window );">Hedging gains/(losses) recognised in reserves</a></td>
<td class="num">(617)<span></span>
</td>
<td class="nump">&#163; 1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss', window );">Amount of hedge ineffectiveness recognised in profit or loss</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness', window );">Line item in profit or loss in which hedge ineffectiveness is included</a></td>
<td class="text">Finance income or expense<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax', window );">Hedged future cash flows no longer expected to occur</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax', window );">Due to hedged item affecting profit or loss</a></td>
<td class="nump">&#163; 194<span></span>
</td>
<td class="num">&#163; (7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments', window );">Line item in profit or loss in which reclassification adjustment is included</a></td>
<td class="text">Discontinued operations<span></span>
</td>
<td class="text">Finance income or expense<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets', window );">Due to hedged item affecting balance sheet</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated amount of fair value hedge adjustment on a hedged item that is included in the carrying amount of the hedged item, recognised in the statement of financial position as an asset. [Refer: Hedged items [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the line item in the statement of comprehensive income that includes the reclassification adjustments. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the line item in the statement of comprehensive income that includes the recognised hedge ineffectiveness. [Refer: Gain (loss) on hedge ineffectiveness]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the line item in the statement of financial position that includes the hedged item. [Refer: Hedged items [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognised in profit or loss on hedge ineffectiveness. [Refer: Gain (loss) on hedge ineffectiveness]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments on cash flow hedges for which the hedged future cash flows are no longer expected to occur, net of tax. [Refer: Reclassification adjustments on cash flow hedges, net of tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24E<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24E_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments on cash flow hedges for which the hedged item affected profit or loss, net of tax. [Refer: Reclassification adjustments on cash flow hedges, net of tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24E<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24E_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the accumulated gains and losses on hedging instruments that hedge investments in equity instruments that the entity has designated at fair value through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=gsk_MoreThanFiveYearsNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=gsk_MoreThanFiveYearsNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=gsk_MoreThanThirtyYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=gsk_MoreThanThirtyYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=gsk_MaturedInThePastPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=gsk_MaturedInThePastPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_VariabilityInCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>324
<FILENAME>R226.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348430613152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail) - Interest rate swap contract [member]<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">Pre-hedging of long-term interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Change in value used for calculating hedge ineffectiveness</a></td>
<td class="num">&#163; (11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges', window );">Balance in cash flow hedge reserve for continuing hedges</a></td>
<td class="num">&#163; (8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">More than Five Years Not Later Than Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageFixedInterestRateOfHedgingInstrument', window );">Average contracted fixed rate %</a></td>
<td class="nump">1.1038%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional principal value &#163;m</a></td>
<td class="nump">668,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Change in fair value for recognising hedge ineffectiveness &#163;m</a></td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DerivativeFinancialAssetsLiabilities', window );">Fair value assets/ (liabilities) &#163;m</a></td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">More than Ten Years Not Later Than Thirty Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageFixedInterestRateOfHedgingInstrument', window );">Average contracted fixed rate %</a></td>
<td class="nump">1.3385%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional principal value &#163;m</a></td>
<td class="nump">935,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Change in fair value for recognising hedge ineffectiveness &#163;m</a></td>
<td class="nump">&#163; 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DerivativeFinancialAssetsLiabilities', window );">Fair value assets/ (liabilities) &#163;m</a></td>
<td class="nump">&#163; 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember', window );">More Than Thirty Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems', window );"><strong>Disclosure of detailed information about hedged items [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AverageFixedInterestRateOfHedgingInstrument', window );">Average contracted fixed rate %</a></td>
<td class="nump">1.4515%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalAmountOfHedgingInstrument', window );">Notional principal value &#163;m</a></td>
<td class="nump">393,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness', window );">Change in fair value for recognising hedge ineffectiveness &#163;m</a></td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DerivativeFinancialAssetsLiabilities', window );">Fair value assets/ (liabilities) &#163;m</a></td>
<td class="nump">&#163; 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AverageFixedInterestRateOfHedgingInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average Fixed Interest Rate Of Hedging Instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AverageFixedInterestRateOfHedgingInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DerivativeFinancialAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial assets liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DerivativeFinancialAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on the change in fair value of the hedged item used as a basis for recognising hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on the change in fair value of the hedging instrument used as a basis for recognising hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NominalAmountOfHedgingInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal amount of a hedging instrument. [Refer: Hedging instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 23B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24A<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24A_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NominalAmountOfHedgingInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfCashFlowHedgesContinuingHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the reserve of cash flow hedges in relation to continuing hedges. [Refer: Reserve of cash flow hedges]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfCashFlowHedgesContinuingHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=gsk_PrehedgingOfLongtermInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_MoreThanFiveYearsNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_MoreThanFiveYearsNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=gsk_MoreThanThirtyYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=gsk_MoreThanThirtyYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>325
<FILENAME>R227.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376135488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember', window );">Trade and other receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure of offsetting of financial assets and financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial assets/(liabilities)</a></td>
<td class="nump">&#163; 6,166<span></span>
</td>
<td class="nump">&#163; 6,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial (Liabilities)/assets set off</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition', window );">Net financial assets/(liabilities)per balance sheet</a></td>
<td class="nump">6,166<span></span>
</td>
<td class="nump">6,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets', window );">Related amounts not set off in the balance sheet</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Net</a></td>
<td class="nump">6,166<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=gsk_DerivativeFinancialAssetsMember', window );">Derivative financial assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure of offsetting of financial assets and financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial assets/(liabilities)</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial (Liabilities)/assets set off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition', window );">Net financial assets/(liabilities)per balance sheet</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets', window );">Related amounts not set off in the balance sheet</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Net</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_TradesAndOtherPayablesMember', window );">Trades and other payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure of offsetting of financial assets and financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial assets/(liabilities)</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial (Liabilities)/assets set off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition', window );">Net financial assets/(liabilities)per balance sheet</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities', window );">Related amounts not set off in the balance sheet</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Net</a></td>
<td class="num">(14,065)<span></span>
</td>
<td class="num">(15,428)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_DerivativeFinancialLiabilitiesMember', window );">Derivative financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure of offsetting of financial assets and financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial assets/(liabilities)</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Gross financial (Liabilities)/assets set off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition', window );">Net financial assets/(liabilities)per balance sheet</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities', window );">Related amounts not set off in the balance sheet</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements', window );">Net</a></td>
<td class="num">&#163; (20)<span></span>
</td>
<td class="num">&#163; (36)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of offsetting of financial assets and financial liabilities line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial instruments subject to an enforceable master netting arrangement or similar agreement that are not set off against financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG40D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG40D&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial instruments subject to an enforceable master netting arrangement or similar agreement that are not set off against financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG40D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG40D&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets set off against financial liabilities when an entity: (a) currently has a legally enforceable right to set off the recognised amounts; and (b) intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of recognised financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities set off against financial assets when an entity: (a) currently has a legally enforceable right to set off the recognised amounts; and (b) intends either to settle on a net basis or to realise the asset and settle the liability simultaneously. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of recognised financial liabilities that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount remaining after deducting the amounts subject to an enforceable master netting arrangement or similar agreement that were not set off against financial assets, from the net amount of financial assets subject to offsetting or subject to an enforceable master netting arrangement or similar agreement presented in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement, presented in the statement of financial position. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount remaining after deducting the amounts subject to an enforceable master netting arrangement or similar agreement that were not set off against financial liabilities, from the net amount of financial liabilities subject to offsetting or subject to an enforceable master netting arrangement or similar agreement presented in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of financial liabilities that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement, presented in the statement of financial position. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 13C<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13C_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=gsk_TradeAndOtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=gsk_DerivativeFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=gsk_DerivativeFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_TradesAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_TradesAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_DerivativeFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=gsk_DerivativeFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>326
<FILENAME>R228.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366008624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">&#163; (19,979)<span></span>
</td>
<td class="num">&#163; (23,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InterestBearingDebt', window );">Total interest bearing</a></td>
<td class="num">(19,979)<span></span>
</td>
<td class="num">(23,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Later Than One Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(3,785)<span></span>
</td>
<td class="num">(3,398)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Between 1 and 2 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(1,714)<span></span>
</td>
<td class="num">(4,030)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Between 2 and 3 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(1,490)<span></span>
</td>
<td class="num">(1,576)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Between 3 and 4 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(1,365)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Between 4 and 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(748)<span></span>
</td>
<td class="num">(1,425)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Between Five and Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(4,736)<span></span>
</td>
<td class="num">(4,411)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember', window );">Floating and Fixed Rate Debt [member] | Greater Than Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_Debt', window );">Total debt</a></td>
<td class="num">(6,001)<span></span>
</td>
<td class="num">(6,953)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Fixed interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InterestBearingDebt', window );">Total interest bearing</a></td>
<td class="num">(18,355)<span></span>
</td>
<td class="num">(22,355)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember', window );">Floating interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems', window );"><strong>Disclosure of debt interest rate repricing [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_InterestBearingDebt', window );">Total interest bearing</a></td>
<td class="num">&#163; (1,624)<span></span>
</td>
<td class="num">&#163; (803)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_Debt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_Debt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfDebtInterestRateRepricingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt interest rate repricing [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfDebtInterestRateRepricingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_InterestBearingDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest bearing debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_InterestBearingDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=gsk_FloatingAndFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>327
<FILENAME>R229.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362494848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember', window );">10 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">&#163; 99<span></span>
</td>
<td class="nump">&#163; 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(767)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember', window );">15 cent appreciation of the US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">(1,570)<span></span>
</td>
<td class="num">(1,199)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember', window );">10 cent appreciation of the Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in Equity</a></td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember', window );">15 cent appreciation of the Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in Equity</a></td>
<td class="num">(2,034)<span></span>
</td>
<td class="num">(1,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenAppreciationOfYenMember', window );">10 Yen appreciation of the Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenAppreciationOfYenMember', window );">15 Yen appreciation of the Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember', window );">10 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember', window );">15 cent depreciation of US Dollar [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember', window );">10 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in Equity</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember', window );">15 cent depreciation of Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in Equity</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenDepreciationOfYenMember', window );">10 Yen depreciation of Yen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenDepreciationOfYenMember', window );">15 Yen depreciation of Yen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures', window );">Increase/(decrease) in income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures', window );">(Increase)/decrease in net debt</a></td>
<td class="num">&#163; (17)<span></span>
</td>
<td class="num">&#163; (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in Equity through foreign currency exchange exposures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in income through foreign currency exchange exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in net debt through foreign currency exchange exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenAppreciationOfYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenAppreciationOfYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenAppreciationOfYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenAppreciationOfYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenDepreciationOfYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskTenYenDepreciationOfYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenDepreciationOfYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_CurrencyRiskFifteenYenDepreciationOfYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>328
<FILENAME>R230.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348362256320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember', window );">1% (100 basis points) increase in sterling interest rates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="nump">&#163; 36<span></span>
</td>
<td class="num">&#163; (25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember', window );">1.5% (150 basis points) increase in Sterling interest rates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember', window );">1% (100 Basis Points) Increase in US Dollar Interest Rates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember', window );">1.5% (150 basis points) increase in US Dollar interest rates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="num">(51)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember', window );">1% (100 Basis Points) Increase in Euro Interest Rates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember', window );">1.5% (150 basis points) increase in Euro interest rates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements', window );">Increase/(decrease) in income</a></td>
<td class="num">&#163; (19)<span></span>
</td>
<td class="nump">&#163; 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_IncreaseDecreaseInIncomeThroughInterestRateMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in income through interest rate movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">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</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>329
<FILENAME>R231.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366035856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail) - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">&#163; (1,008)<span></span>
</td>
<td class="num">&#163; (1,015)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(20,086)<span></span>
</td>
<td class="num">(23,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(6,322)<span></span>
</td>
<td class="num">(7,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(23,553)<span></span>
</td>
<td class="num">(24,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(51,115)<span></span>
</td>
<td class="num">(56,444)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Not later than 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(3,786)<span></span>
</td>
<td class="num">(3,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(594)<span></span>
</td>
<td class="num">(686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(15,362)<span></span>
</td>
<td class="num">(16,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(19,934)<span></span>
</td>
<td class="num">(20,745)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Between 1 and 2 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(1,717)<span></span>
</td>
<td class="num">(4,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(570)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(3,607)<span></span>
</td>
<td class="num">(5,804)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Between 2 and 3 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(531)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(3,207)<span></span>
</td>
<td class="num">(3,188)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Between 3 and 4 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(3,386)<span></span>
</td>
<td class="num">(2,938)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Between 4 and 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(751)<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(2,324)<span></span>
</td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Between Five and Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(4,765)<span></span>
</td>
<td class="num">(4,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(1,810)<span></span>
</td>
<td class="num">(2,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(2,641)<span></span>
</td>
<td class="num">(2,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">(9,458)<span></span>
</td>
<td class="num">(9,438)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember', window );">Non Derivatives Financial Liabilities [member] | Greater Than Ten Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Debt</a></td>
<td class="num">(6,063)<span></span>
</td>
<td class="num">(7,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt</a></td>
<td class="num">(1,856)<span></span>
</td>
<td class="num">(2,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinanceLeaseLiability', window );">Obligations under finance leases</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FutureFinanceChargeOnFinanceLeases', window );">Finance charge on obligations under finance leases</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables and other liabilities not in net debt</a></td>
<td class="num">(1,134)<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="num">&#163; (9,199)<span></span>
</td>
<td class="num">&#163; (11,392)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FutureFinanceChargeOnFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Finance Charge On Finance Leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FutureFinanceChargeOnFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankBorrowingsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankBorrowingsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=gsk_NonDerivativesFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>330
<FILENAME>R232.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348429943456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail) - Derivative Instruments [Member] - GBP (&#163;)<br> &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">24,418<span></span>
</td>
<td class="nump">41,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="num">(24,410)<span></span>
</td>
<td class="num">(41,290)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Not later than 1 year [member] | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Not later than 1 year [member] | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">24,418<span></span>
</td>
<td class="nump">41,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="num">(24,410)<span></span>
</td>
<td class="num">(41,290)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 1 and 2 years [member] | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 1 and 2 years [member] | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 2 and 3 years [member] | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 2 and 3 years [member] | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 3 and 4 Years [Member] | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 3 and 4 Years [Member] | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 4 and 5 years [member] | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Between 4 and 5 years [member] | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Greater than five years | Forward starting interest rate swaps [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">&#163; (220)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember', window );">Greater than five years | Foreign Exchange Forward Contracts and Swaps [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows', window );">Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables on derivative financial instruments undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables on derivative financial instruments undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DebtInstrument1Axis=ifrs-full_InterestRateSwapContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DebtInstrument1Axis=ifrs-full_InterestRateSwapContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DebtInstrument1Axis=gsk_ForeignExchangeForwardContractsAndSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DebtInstrument1Axis=gsk_ForeignExchangeForwardContractsAndSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>331
<FILENAME>R233.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348364650896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Share Schemes - Additional Information (Detail)<br> &#163; / shares in Units, shares in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;) </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>&#163; / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;) </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;) </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans | &#163;</a></td>
<td class="nump">&#163; 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember', window );">Savings-Related Share Option Schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AtPercentageBelowMarketPrice', window );">Share options granted at percentage below market price</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement', window );">Weighted average fair value of options granted | &#163; / shares</a></td>
<td class="nump">&#163; 4.34<span></span>
</td>
<td class="nump">&#163; 4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement', window );">Number share options were not exercisable</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember', window );">Share Value Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans | &#163;</a></td>
<td class="nump">&#163; 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedFutureDividendYieldPercentageShareGranted', window );">Expected future dividend yield percentage share granted</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of awards granted</a></td>
<td class="nump">10,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare', window );">Weighted average fair value of awards | &#163; / shares</a></td>
<td class="nump">&#163; 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember', window );">Share Value Plan [member] | American Depositary Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of awards granted</a></td>
<td class="nump">6,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare', window );">Weighted average fair value of awards | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 30.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember', window );">Performance Share Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Cost of share-based incentive plans | &#163;</a></td>
<td class="nump">&#163; 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of awards granted</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingAwards', window );">Number of outstanding awards</a></td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement', window );">Weighted average fair value of options granted | &#163; / shares</a></td>
<td class="nump">&#163; 13.36<span></span>
</td>
<td class="nump">&#163; 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember', window );">Performance Share Plan [member] | American Depositary Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of awards granted</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare', window );">Weighted average fair value of awards | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 35.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingAwards', window );">Number of outstanding awards</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_FreeCashFlowMember', window );">Free Cash Flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfPerformanceSharePlan', window );">Percentage of performance share plan</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_TsrMember', window );">TSR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfPerformanceSharePlan', window );">Percentage of performance share plan</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_RAndDNewProductPerformanceMember', window );">R&amp;D New Product Performance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfPerformanceSharePlan', window );">Percentage of performance share plan</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PipelineProgressMember', window );">Pipeline Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_PercentageOfPerformanceSharePlan', window );">Percentage of performance share plan</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember', window );">Adjusted Free Cash Flow TSR and RD New Product Performance [Member] | 2016 to 2019 Performance conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfEmployeeShareSchemesLineItems', window );"><strong>Disclosure of employee share schemes [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_EquallyWeightedMeasuresOverPerformancePeriod', window );">Equally weighted measures over performance period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AtPercentageBelowMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>At percentage below market price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AtPercentageBelowMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfEmployeeShareSchemesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee share schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfEmployeeShareSchemesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_EquallyWeightedMeasuresOverPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equally weighted measures over performance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_EquallyWeightedMeasuresOverPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedFutureDividendYieldPercentageShareGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected future dividend yield percentage share granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedFutureDividendYieldPercentageShareGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of awards outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share awards granted in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options not exercisable in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_PercentageOfPerformanceSharePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of performance share plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_PercentageOfPerformanceSharePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value at measurement date share awards granted per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value of share option granted in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AwardType1Axis=gsk_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AwardType1Axis=gsk_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PerformanceSharePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_FreeCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_FreeCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_TsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_TsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_RAndDNewProductPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_RAndDNewProductPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PipelineProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_PipelineProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AwardType1Axis=gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AwardType1Axis=gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>332
<FILENAME>R234.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348366008288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail) - Share Value Plan [member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingShareAwards', window );">Number of shares, Beginning balance</a></td>
<td class="nump">28,244<span></span>
</td>
<td class="nump">28,244<span></span>
</td>
<td class="nump">28,874<span></span>
</td>
<td class="nump">28,874<span></span>
</td>
<td class="nump">29,459<span></span>
</td>
<td class="nump">29,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of shares, Awards granted</a></td>
<td class="nump">10,987<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
<td class="nump">11,220<span></span>
</td>
<td class="nump">11,220<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
<td class="nump">11,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement', window );">Number of shares, Awards exercised</a></td>
<td class="num">(9,538)<span></span>
</td>
<td class="num">(9,538)<span></span>
</td>
<td class="num">(10,074)<span></span>
</td>
<td class="num">(10,074)<span></span>
</td>
<td class="num">(10,284)<span></span>
</td>
<td class="num">(10,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement', window );">Number of shares, Awards cancelled</a></td>
<td class="num">(1,718)<span></span>
</td>
<td class="num">(1,718)<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingShareAwards', window );">Number of shares, Ending balance</a></td>
<td class="nump">27,975<span></span>
</td>
<td class="nump">27,975<span></span>
</td>
<td class="nump">28,244<span></span>
</td>
<td class="nump">28,244<span></span>
</td>
<td class="nump">28,874<span></span>
</td>
<td class="nump">28,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare', window );">Weighted fair value, Awards granted | &#163; / shares</a></td>
<td class="nump">&#163; 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_AwardType1Axis=gsk_AmericanDepositarySharesMember', window );">American Depositary Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingShareAwards', window );">Number of shares, Beginning balance</a></td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">16,116<span></span>
</td>
<td class="nump">16,116<span></span>
</td>
<td class="nump">15,850<span></span>
</td>
<td class="nump">15,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement', window );">Number of shares, Awards granted</a></td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement', window );">Number of shares, Awards exercised</a></td>
<td class="num">(4,919)<span></span>
</td>
<td class="num">(4,919)<span></span>
</td>
<td class="num">(5,240)<span></span>
</td>
<td class="num">(5,240)<span></span>
</td>
<td class="num">(5,353)<span></span>
</td>
<td class="num">(5,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement', window );">Number of shares, Awards cancelled</a></td>
<td class="num">(1,314)<span></span>
</td>
<td class="num">(1,314)<span></span>
</td>
<td class="num">(1,705)<span></span>
</td>
<td class="num">(1,705)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfOutstandingShareAwards', window );">Number of shares, Ending balance</a></td>
<td class="nump">15,429<span></span>
</td>
<td class="nump">15,429<span></span>
</td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">16,116<span></span>
</td>
<td class="nump">16,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare', window );">Weighted fair value, Awards granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfOutstandingShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Outstanding Share Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfOutstandingShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share awards exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share awards forfeited in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share awards granted in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value at measurement date share awards granted per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareValuePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_AwardType1Axis=gsk_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_AwardType1Axis=gsk_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>333
<FILENAME>R235.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348377051648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail) - Share Options and Savings-Related Options [member] - &#163; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems', window );"><strong>Disclosure of share options and savings related options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.37%<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="num">(0.07%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DividendYieldShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_ExpectedLifeOfShareOptionsGranted', window );">Expected life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SavingsRelatedOptionsGrantPrice', window );">Savings-related options grant price (including 20% discount)</a></td>
<td class="nump">&#163; 11.39<span></span>
</td>
<td class="nump">&#163; 12.07<span></span>
</td>
<td class="nump">&#163; 10.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share options and savings related options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DividendYieldShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend yield share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DividendYieldShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_ExpectedLifeOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_ExpectedLifeOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SavingsRelatedOptionsGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings related options grant price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SavingsRelatedOptionsGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionsAndSavingsRelatedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionsAndSavingsRelatedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>334
<FILENAME>R236.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348376714336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionsAndSavingsRelatedOptionsMember', window );">Share Options and Savings-Related Options [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems', window );"><strong>Disclosure of share options and savings related options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_SavingsRelatedOptionsGrantPriceDiscount', window );">Savings-related options grant price discount</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share options and savings related options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_SavingsRelatedOptionsGrantPriceDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings related options grant price discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_SavingsRelatedOptionsGrantPriceDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionsAndSavingsRelatedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionsAndSavingsRelatedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>335
<FILENAME>R237.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367272096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Share Schemes - Summary of Option Outstanding (Detail)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>yr </div>
<div>shares </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionSchemesMember', window );">Share Option Schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Shares | shares</a></td>
<td class="nump">5,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember', window );">Savings-Related Share Option Schemes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement', window );">Share option schemes - shares Weighted exercise price</a></td>
<td class="nump">&#163; 11.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement', window );">Weighted average market price on exercise during year</a></td>
<td class="nump">&#163; 16.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption', window );">Weighted average remaining contractual life | yr</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember', window );">Savings-Related Share Option Schemes [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement', window );">Range of exercise prices on options outstanding at year end</a></td>
<td class="nump">&#163; 14.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember', window );">Savings-Related Share Option Schemes [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement', window );">Range of exercise prices on options outstanding at year end</a></td>
<td class="nump">&#163; 10.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share option exercisable in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share option exercised in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share option outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life of outstanding share option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionSchemesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_ShareOptionSchemesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_SavingsRelatedShareOptionSchemesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>336
<FILENAME>R238.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367603440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail) - Employee share ownership plan [member]<br> Unit_pure in Thousands, &#163; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfSharesHeldForShareAwardSchemes', window );">Shares held for share award schemes, Number of shares</a></td>
<td class="nump">59,814<span></span>
</td>
<td class="nump">23,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NominalValueOfSharesHeldForShareAwardSchemes', window );">Shares held for share award schemes, Nominal value</a></td>
<td class="nump">&#163; 19<span></span>
</td>
<td class="nump">&#163; 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingValueOfSharesHeldForShareAwardSchemes', window );">Shares held for share award schemes, Carrying value</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MarketValueOfSharesHeldForShareAwardSchemes', window );">Shares held for share award schemes, Market value</a></td>
<td class="nump">&#163; 860<span></span>
</td>
<td class="nump">&#163; 371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NumberOfSharesHeldForShareOptionSchemes', window );">Shares held for share option schemes, Number of shares | shares</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_NominalValueOfSharesHeldForShareOptionSchemes', window );">Shares held for share option schemes, Nominal value</a></td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_CarryingValueOfSharesHeldForShareOptionSchemes', window );">Shares held for share option schemes, Carrying value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_MarketValueOfSharesHeldForShareOptionSchemes', window );">Shares held for share option schemes, Market value</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingValueOfSharesHeldForShareAwardSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of shares held for share award schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingValueOfSharesHeldForShareAwardSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_CarryingValueOfSharesHeldForShareOptionSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of shares held for share option schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_CarryingValueOfSharesHeldForShareOptionSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MarketValueOfSharesHeldForShareAwardSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market value of shares held for share award schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MarketValueOfSharesHeldForShareAwardSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_MarketValueOfSharesHeldForShareOptionSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market value of shares held for share option schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_MarketValueOfSharesHeldForShareOptionSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NominalValueOfSharesHeldForShareAwardSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Of Shares Held For Share Award Schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NominalValueOfSharesHeldForShareAwardSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NominalValueOfSharesHeldForShareOptionSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value of shares held for share option schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NominalValueOfSharesHeldForShareOptionSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfSharesHeldForShareAwardSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held for share award schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfSharesHeldForShareAwardSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_NumberOfSharesHeldForShareOptionSchemes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held for share option schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_NumberOfSharesHeldForShareOptionSchemes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_EmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gsk_EmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>337
<FILENAME>R239.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348358860032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoGroupLimitedMember', window );">Glaxo Group Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Glaxo Group Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoOperationsUkLimitedMember', window );">Glaxo Operations UK Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Glaxo Operations UK Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeUkLimitedMember', window );">Glaxo Wellcome UK Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Glaxo Wellcome UK Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalPLCMember', window );">GlaxoSmithKline Capital PLC [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Capital plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineExportLimitedMember', window );">GlaxoSmithKline Export Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Export Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineFinancePLCMember', window );">GlaxoSmithKline Finance PLC [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Finance plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsLimitedMember', window );">GlaxoSmithKline Holdings Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Holdings Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIhcLimitedMember', window );">GlaxoSmithKline IHC Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline IHC Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember', window );">GlaxoSmithKline Intellectual Property (No.2) Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Intellectual Property (No.2) Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember', window );">GlaxoSmithKline Intellectual Property (No.3) Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Intellectual Property (No.3) Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember', window );">GlaxoSmithKline Intellectual Property (No.4) Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Intellectual Property (No.4) Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember', window );">GlaxoSmithKline Intellectual Property Development Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Intellectual Property Development Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GlaxoSmithKline Intellectual Property Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Intellectual Property Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember', window );">GlaxoSmithKline Research &amp; Development Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Research & Development Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineServicesUnlimitedMember', window );">GlaxoSmithKline Services Unlimited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Services Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineUnitedKingdomLimitedMember', window );">GlaxoSmithKline UK Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline UK Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineUsTradingLimitedMember', window );">GlaxoSmithKline US Trading Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline US Trading Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SetFirstLimitedMember', window );">Setfirst Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Setfirst Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SmithKlineBeechamLimitedMember', window );">SmithKline Beecham Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">SmithKline Beecham Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareFinanceLimitedMember', window );">ViiV Healthcare Finance Limited [Member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare Finance Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember', window );">ViiV Healthcare UK No.3 Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare UK (No.3) Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareUnitedKingdomLimitedMember', window );">ViiV Healthcare UK Limited [member] | England [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Viiv Healthcare UK Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">England<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.1ScottishLimitedPartnershipMember', window );">GSK (No.1) Scottish Limited Partnership [Member] | Scotland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK (No.1) Scottish Limited Partnership<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Scotland<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.2ScottishLimitedPartnershipMember', window );">GSK (No.2) Scottish Limited Partnership [Member] | Scotland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK (No.2) Scottish Limited Partnership<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Scotland<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_AffinivaxIncMember', window );">Affinivax, Inc [Member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Affinivax, Inc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_CorixaCorporationMember', window );">Corixa Corporation [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Corixa Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalIncMember', window );">GlaxoSmithKline Capital Inc. [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Capital Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsIncMember', window );">GlaxoSmithKline Holdings (Americas) Inc. [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Holdings (Americas) Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLLCMember', window );">GlaxoSmithKline LLC [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline LLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEquityInvestmentsLimitedMember', window );">GSK Equity Investments, Limited [Member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Equity Investments, Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_HumanGenomeSciencesIncMember', window );">Human Genome Sciences, Inc. [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Human Genome Sciences, Inc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_StiefelLaboratoriesIncMember', window );">Stiefel Laboratories, Inc. [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Stiefel Laboratories, Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_TesaroMember', window );">Tesaro, Inc. [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Tesaro, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareCompanyMember', window );">ViiV Healthcare Company [member] | US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineAgMember', window );">GlaxoSmithKline AG [Member] | Switzerland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline AG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Switzerland<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineB.v.Member', window );">GlaxoSmithKline B.V. [Member] | Netherlands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline B.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Netherlands<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBiologicalsSAMember', window );">GlaxoSmithKline Biologicals SA [member] | Belgium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Biologicals SA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Belgium<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineGmbHAndCoKGMember', window );">GlaxoSmithKline GmbH and Co. KG [member] | Germany [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline GmbH & Co. KG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaGmbhMember', window );">GlaxoSmithKline Pharma GmbH [Member] | Austria [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Pharma GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Austria<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePharmaceuticalsSAMember', window );">GlaxoSmithKline Pharmaceuticals SA [member] | Belgium [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Pharmaceuticals SA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Belgium<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSAMember', window );">GlaxoSmithKline S.A. [member] | Spain [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline S.A.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Spain<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSPAMember', window );">GlaxoSmithKline S.p.A. [member] | Italy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline S.p.A.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Italy<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineSingleMemberA.e.b.e.Member', window );">GlaxoSmithKline Single Member A.E.B.E. [Member] | Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Single Member A.E.B.E.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Greece<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineTradingServicesLimitedMember', window );">GlaxoSmithKline Trading Services Limited [member] | Ireland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Trading Services Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Republic of Ireland<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskCapitalB.v.Member', window );">GSK Capital B.V. [Member] | Netherlands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Capital B.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Netherlands<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKServicesSPZOOMember', window );">GSK Services Sp z o.o. [member] | Poland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Services Sp z o.o.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Poland<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesGmbHMember', window );">GSK Vaccines GmbH [member] | Germany [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Vaccines GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesSRLMember', window );">GSK Vaccines S.r.l. [member] | Italy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Vaccines S.r.l.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Italy<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_JscGlaxosmithklineTradingMember', window );">JSC GlaxoSmithKline Trading [Member] | Russia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">JSC GlaxoSmithKline Trading<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Russia<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoireGlaxoSmithKlineMember', window );">Laboratoire GlaxoSmithKline [member] | France [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Laboratoire GlaxoSmithKline<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">France<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoriosViiVHealthCareSLMember', window );">Laboratorios ViiV Healthcare, S.L. [member] | Spain [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Laboratorios ViiV Healthcare, S.L.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Spain<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareGmbhMember', window );">ViiV Healthcare GmbH [Member] | Germany [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare GmbH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareSRLItalyMember', window );">ViiV Healthcare S.r.l. [Member] | Italy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare S.r.l.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Italy<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareSASMember', window );">ViiV Healthcare SAS [member] | France [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare SAS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">France<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSaudiArabiaLimitedMember', window );">Glaxo Saudi Arabia Limited [Member] | Saudi Arabia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Glaxo Saudi Arabia Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Saudi Arabia<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeManufacturingPteLtdMember', window );">Glaxo Wellcome Manufacturing Pte Ltd. [member] | Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Glaxo Wellcome Manufacturing Pte Ltd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineThailandLimitedMember', window );">GlaxoSmithKline (Thailand) Limited [Member] | Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline (Thailand) Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Thailand<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineAustraliaPtyLtdMember', window );">GlaxoSmithKline Australia Pty Ltd [Member] | Australia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Australia Pty Ltd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Australia<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBrasilLimitadaMember', window );">GlaxoSmithKline Brasil Limitada [Member] | Brazil [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Brasil Limitada<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Brazil<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineFarEastB.v.Member', window );">GlaxoSmithKline Far East B.V. [Member] | Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Far East B.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Taiwan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKKMember', window );">GlaxoSmithKline K.K. [member] | Japan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline K.K.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Japan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member', window );">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. [Member] | Turkey [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Turkey<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineIncMember', window );">GlaxoSmithKline Inc. [Member] | Canada [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKoreaLimitedMember', window );">GlaxoSmithKline Korea Limited [member] | Republic of Korea [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Korea Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Republic of Korea<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLimitedMember', window );">GlaxoSmithKline Limited [Member] | Hong Kong[member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineMexicoS.a.DeC.v.Member', window );">GlaxoSmithKline Mexico S.A. de C.V. [Member] | Mexico [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Mexico S.A. de C.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Mexico<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePakistanLimitedMember', window );">GlaxoSmithKline Pakistan Limited [member] | Pakistan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Pakistan Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">82.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Pakistan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember', window );">GlaxoSmithKline Pharmaceuticals Limited [Member] | India [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GlaxoSmithKline Pharmaceuticals Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">India<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEnterpriseManagementCoLtdMember', window );">GSK Enterprise Management Co, Ltd [Member] | China [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Enterprise Management Co, Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">China<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskPharmaVietnamCompanyLimitedMember', window );">GSK Pharma Vietnam Company Limited [Member] | Vietnam [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK Pharma Vietnam Company Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Vietnam<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_IDBiomedicalCorporationOfQuebecMember', window );">ID Biomedical Corporation of Quebec [Member] | Canada [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ID Biomedical Corporation of Quebec<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareK.kMember', window );">ViiV Healthcare K.K [Member] | Japan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare K.K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Japan<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUlcMember', window );">ViiV Healthcare ULC [Member] | Canada [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">ViiV Healthcare ULC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.3ScottishLimitedPartnershipMember', window );">GSK (No.3) Scottish Limited Partnership [Member] | Scotland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">GSK (No.3) Scottish Limited Partnership<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Scotland<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of a subsidiary. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoOperationsUkLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoOperationsUkLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeUkLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeUkLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineExportLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineExportLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineFinancePLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineFinancePLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIhcLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIhcLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineServicesUnlimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineServicesUnlimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineUnitedKingdomLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineUnitedKingdomLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineUsTradingLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineUsTradingLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SetFirstLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SetFirstLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SmithKlineBeechamLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_SmithKlineBeechamLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareFinanceLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareFinanceLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareUnitedKingdomLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthCareUnitedKingdomLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.1ScottishLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.1ScottishLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=exch_BOFS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=exch_BOFS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.2ScottishLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.2ScottishLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_AffinivaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_AffinivaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_CorixaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_CorixaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineCapitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEquityInvestmentsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEquityInvestmentsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_HumanGenomeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_HumanGenomeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_StiefelLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_StiefelLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_TesaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_TesaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBiologicalsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBiologicalsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineGmbHAndCoKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineGmbHAndCoKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_AustriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_AustriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePharmaceuticalsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePharmaceuticalsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineSPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineSingleMemberA.e.b.e.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineSingleMemberA.e.b.e.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_GreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_GreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineTradingServicesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineTradingServicesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskCapitalB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskCapitalB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKServicesSPZOOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKServicesSPZOOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesSRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GSKVaccinesSRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_JscGlaxosmithklineTradingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_JscGlaxosmithklineTradingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoireGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoireGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoriosViiVHealthCareSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_LaboratoriosViiVHealthCareSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareSRLItalyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareSRLItalyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViiVHealthcareSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSaudiArabiaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSaudiArabiaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_SaudiArabiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_SaudiArabiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeManufacturingPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoWellcomeManufacturingPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineThailandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineThailandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_ThailandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_ThailandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBrasilLimitadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineBrasilLimitadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineFarEastB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineFarEastB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKoreaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineKoreaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlineLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineMexicoS.a.DeC.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklineMexicoS.a.DeC.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePakistanLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxoSmithKlinePakistanLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_PK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_PK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEnterpriseManagementCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskEnterpriseManagementCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskPharmaVietnamCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskPharmaVietnamCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=gsk_VietnamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=gsk_VietnamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_IDBiomedicalCorporationOfQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_IDBiomedicalCorporationOfQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareK.kMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareK.kMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_ViivHealthcareUlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.3ScottishLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskNo.3ScottishLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>338
<FILENAME>R240.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367097472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp1LimitedsShareCapitalMember', window );">GSK GP 1 Limiteds Share Capital [Member] | Berkeley Square Pension Trustee Company Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp1LimitedsShareCapitalMember', window );">GSK GP 1 Limiteds Share Capital [Member] | GSK plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp2LimitedsShareCapital.Member', window );">GSK GP 2 Limiteds Share Capital. [Member] | GSK plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp1LimitedsShareCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp1LimitedsShareCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gsk_GskPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gsk_GskPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp2LimitedsShareCapital.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=gsk_GskGp2LimitedsShareCapital.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>339
<FILENAME>R241.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140348367267040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings - Additional Information (Detail)<br> $ in Thousands, &#8361; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;) </div>
<div>Plaintiffs</div>
</th>
<th class="th">
<div>Feb. 01, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 01, 2023 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfLegalProceedingsLineItems', window );"><strong>Disclosure of Legal Proceedings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvision', window );">Provisions for legal and other disputes | &#163;</a></td>
<td class="nump">&#163; 218,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DamagesAwardedToGSK', window );">Damages&#8203; Awarded to GSK | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | Plaintiffs</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=gsk_GSKKoreaMember', window );">GSK Korea [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_DisclosureOfLegalProceedingsLineItems', window );"><strong>Disclosure of Legal Proceedings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gsk_FinePayable', window );">Fine Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 45,000<span></span>
</td>
<td class="nump">&#8361; 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DamagesAwardedToGSK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Damages&#8203; Awarded to GSK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DamagesAwardedToGSK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_DisclosureOfLegalProceedingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal proceedings line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_DisclosureOfLegalProceedingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_FinePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fine payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_FinePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gsk_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency, number of plaintiffs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gsk_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gsk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for legal proceedings. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 10 A court case<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=gsk_GSKKoreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=gsk_GSKKoreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>340
<FILENAME>d382677d20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:gsk="http://www.gsk.com/20221231"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gsk-20221231.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn08_05_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_HorlicksMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:HorlicksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis">gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:OtherAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostRetirementBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BangladeshConsumerHealthcareMemberifrsfullJointVenturesAxis_DisposalGroupsClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandTwentyBusinessDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:BangladeshConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandTwentyTwoBusinessDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ManufacturingMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FirstInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:SecondInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ThirdInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FourthInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:AcquisitionsTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UsCashBalancePensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:RetireeHealthcarePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:HIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SpecialtyMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:MeningitisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:InfluenzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ShinglesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:EstablishedVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:GeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_ReducedTaxRateCancelledMemberGSKEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:EventAxis">gsk:ReducedTaxRateCancelledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:OtherAuditorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:HindustanUnileverLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:HorlicksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:FreeCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:TsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PipelineProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HorlicksMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:HorlicksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis">gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:LaterThanOneYearAndNotLaterThanTenYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:AvailableIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:MajorRestructuringProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis">gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:OtherAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostRetirementBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ManufacturingMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:MajorRestructuringProgrammesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FirstInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:SecondInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ThirdInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FourthInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenYenAppreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenYenAppreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenYenDepreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenYenDepreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:MedicxiVenturesILimitedPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:JapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:SgdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:HIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SpecialtyMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:MeningitisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:InfluenzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ShinglesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:EstablishedVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:GeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LetterOfCredit1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:InLineWithOtherPharmaceuticalCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:LegacyProgrammesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:OtherAuditorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:ForeignExchangeRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:ForeignExchangeRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:FreeCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:TsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PipelineProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:LiquidationOrDisposalOfInterestInAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:PurposeAxis">gsk:ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:NetDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCurrentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:EventAxis">gsk:IncreaseInTheHeadlineRateOfTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:GbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:BankOverdrafts1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:FreeholdBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseholdLandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:LeaseholdLandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PlantAndMachineryMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:EquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:RestructuringCostsAxis">gsk:CostOfMajorRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:LaterThanOneYearAndNotLaterThanTenYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:AvailableIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfIncreaseInDiscountRatesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfDecreaseInDiscountRatesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfLifeExpectancyRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:MajorRestructuringProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:ActuarialAssumptionForFutureHealthcareInflationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisMemberdeiLegalEntityAxis_VaccinesBusinessAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:VaccinesBusinessAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">gsk:RemainingBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_VaccinesMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:ERPSoftwareSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:OtherComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:ERPSoftwareSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:OtherComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis">gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionsAndSavingsRelatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:OtherAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:CurrentPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:CurrentPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ProjectedPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ProjectedPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:OtherProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostRetirementBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:CashFlowsInTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandAndTwentyTwoDisposalsDemergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandTwentyTwoBusinessDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ManufacturingMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:SellingGeneralAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:CashSettledAndOtherPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">gsk:MajorRestructuringProgrammesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FirstInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:SecondInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ThirdInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FourthInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TaxReformsPeriodOfApplicationAxis">gsk:OriginationAndReversalOfTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageIncreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gsk:Wholesalers3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenYenAppreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenYenAppreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenYenDepreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenYenDepreciationOfYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskTenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskFifteenPercentageDecreaseInSalesForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:MedicxiVenturesILimitedPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedContributionPensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndTwentyTwoBusinessAcquisitionsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandAndTwentyTwoBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:JapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:CADMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:SgdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UsDefinedBenefitAndDefinedContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedPostRetirementPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis">gsk:ActuarialAssumptionPercentageRateChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:SensitivityAnalysisForActuarialAssumptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ActuarialAssumptionPercentageRateAxis">gsk:ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">gsk:SensitivityAnalysisForActuarialAssumptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:OtherOverseasPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentAppreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:FundedDefinedBenefitPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UnfundedDefinedBenefitPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:DefinedBenefitSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:HIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ImmunoInflammationRespiratoryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SpecialtyMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:MeningitisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:InfluenzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ShinglesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:EstablishedVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:SubTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PandemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:OtherGeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:GeneralMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskTenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskFifteenCentDepreciationOfEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LetterOfCredit1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoOperationsUkLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoWellcomeUkLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineCapitalPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineExportLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineFinancePLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIhcLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIntellectualPropertyNo.2LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIntellectualPropertyNo.3LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIntellectualPropertyNo.4LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineResearchAndDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineServicesUnlimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineUnitedKingdomLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineUsTradingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:SetFirstLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:SmithKlineBeechamLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareFinanceLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareUnitedKingdomNo.3LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViiVHealthCareUnitedKingdomLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">exch:BOFS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskNo.1ScottishLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">exch:BOFS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskNo.2ScottishLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">exch:BOFS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskNo.3ScottishLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:AffinivaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:CorixaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskEquityInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:HumanGenomeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:StiefelLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:TesaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineGmbHAndCoKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:AustriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklinePharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlinePharmaceuticalsSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:ES</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineSPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:GreeceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineSingleMemberA.e.b.e.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineTradingServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskCapitalB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:PL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GSKServicesSPZOOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GSKVaccinesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GSKVaccinesSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:RU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:JscGlaxosmithklineTradingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:LaboratoireGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:ES</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:LaboratoriosViiVHealthCareSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareSRLItalyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViiVHealthcareSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:SaudiArabiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSaudiArabiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoWellcomeManufacturingPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:ThailandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineThailandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineAustraliaPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineBrasilLimitadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineFarEastB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineKoreaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:MX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklineMexicoS.a.DeC.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:PK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlinePakistanLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxosmithklinePharmaceuticalsLimitedIndiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskEnterpriseManagementCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:VietnamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskPharmaVietnamCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:IDBiomedicalCorporationOfQuebecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareK.kMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViivHealthcareUlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonUsaMemberifrsfullGeographicalAreasAxis_TopOfRangeMemberifrsfullRangeAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:NonUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:InLineWithOtherPharmaceuticalCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:SignificantAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:SeparationPreparationProgrammeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:LegacyProgrammesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwothousandtwentyoneacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:ZeroPointFiveThreeFourNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:ThreePointZeroNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:ThreePointSixTwoFiveNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:ThreePointEightSevenFiveNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:ThreePointThreeSevenFiveNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:SixPointThreeSevenFiveNotesDue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:FourPointTwoZeroZeroNotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfEachClassAxis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:OtherAuditorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LongwoodFoundersFundLPMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:LongwoodFoundersFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ApolloTherapeuticsLLPMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ApolloTherapeuticsLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:ForeignExchangeRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:ForeignExchangeRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:FreeCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:TsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:RAndDNewProductPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PipelineProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMemberGSKAwardType1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">gsk:LiquidationOrDisposalOfInterestInAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:PurposeAxis">gsk:ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:NetDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LongTermBorrowingsDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ShortTermBorrowingsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCurrentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:BankOverdrafts1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:EventAxis">gsk:IncreaseInTheHeadlineRateOfTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:GbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DemergerOfConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:DemergerOfConsumerHealthcareBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:SierraOncologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AffinivaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentMovementInUSDInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:InterestRateSensitivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignExchangeForwardContractsAndSwapsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AgreementTypeAxis">gsk:SlpPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GSKLPLtdMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GSKLPLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AffinivaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FinancialLiabilitesOneMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">gsk:FinancialLiabilitesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:GskPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskGp1LimitedsShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:BerkeleySquarePensionTrusteeCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskGp1LimitedsShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GskGp2LimitedsShareCapital.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:GskPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GskGp2LimitedsShareCapital.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InvestmentInHaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:ScottishLimitedPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EsopTrustsMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:EsopTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:InvestmentInHaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_DemergerMemberGSKEventAxis_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:EventAxis">gsk:DemergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">ifrs-full:InternallyGeneratedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:RemainingBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CureVacNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreditImpairmentOfFinancialInstrumentsAxis">ifrs-full:FinancialInstrumentsCreditimpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:CommercialisedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:PipelineAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VaccinesMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:OverseasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">gsk:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BEifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CHifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:EuroCommercialPaperProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DisabledEmployeesMemberGSKTitleOfIndividual1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfIndividual1Axis">gsk:DisabledEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:EuroCommercialPaperProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AaOrAaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BbbOrBaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BBPlusOrBaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanFiveYearsNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MoreThanTenYearsNotLaterThanThirtyYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AAAOrAaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShionogiViivHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:TesaroAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:MeningitisPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:DolutegravirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:BenlystaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:BenlystaAxis">gsk:AlectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:BenlystaAxis">gsk:IteosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:ShingrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:OkairosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:BMSAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:VirAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:FluarixFlulavalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:StiefelTradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:CurevacAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:LamisilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:OthersProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PfizerMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">gsk:TradesAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">gsk:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:JapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermNotesMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ShortTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">ifrs-full:ExternalCreditGradesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:WholesalerInTheUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:LowerThanBBBBaa3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BankLoansAndOverdraftsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaperInADesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherBorrowingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePercentEuroMediumTermNotesTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherLongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:OtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonInterestBearingMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:TwoThousandAndTwentyOneBusinessDisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInsuranceContractsAxis">gsk:GroupCreditEnhancementsAndCreditInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FourthInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FreeIssueMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FreeIssueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">ifrs-full:InternallyGeneratedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:RemainingBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherNonCurrentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:DebtInstrument1Axis">gsk:ForeignExchangeForwardContractsAndSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:NonDerivativesFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:CureVacNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreditImpairmentOfFinancialInstrumentsAxis">ifrs-full:FinancialInstrumentsCreditimpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:CommercialisedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:PipelineAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">gsk:USPharmaceuticalsAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:OverseasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:OtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">gsk:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:EuroCommercialPaperProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BEifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CHifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:PerformanceSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DisabledEmployeesMemberGSKTitleOfIndividual1Axis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TitleOfIndividual1Axis">gsk:DisabledEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:UsCommercialPaperProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:EuroCommercialPaperProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BbbOrBaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BBPlusOrBaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:SavingsRelatedShareOptionSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:NonFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:PrehedgingOfLongtermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">gsk:MaturedInThePastPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AAAOrAaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShionogiViivHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ShionogiViivHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:TesaroAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:MeningitisPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MomelotinibMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:MomelotinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AffinivaxAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:AffinivaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:DolutegravirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:BenlystaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:BenlystaAxis">gsk:AlectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:BenlystaAxis">gsk:IteosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:ShingrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:OkairosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:BMSAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_SperoMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:SperoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:VirAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:FluarixFlulavalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:StiefelTradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:CurevacAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:LamisilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">gsk:OthersProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesAndFranchisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:PurposeAxis">gsk:PostSeparationOfTheConsumerHealthcareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:PurposeAxis">gsk:PostSeparationOfTheConsumerHealthcareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PfizerMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">gsk:TradesAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">gsk:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:AaOrAaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">gsk:FloatingAndFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:EmbeddedAndOtherDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BuyForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingThreeToSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:BorrowingsLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:EuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:JapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyLessThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:CADMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">gsk:SgdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">gsk:SellForeignCurrencyOverSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:CommercialOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:SegmentConsolidationItemAxis">ifrs-full:UnallocatedAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermNotesMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:ShortTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">ifrs-full:ExternalCreditGradesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:WholesalerInTheUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NGifrsfullGeographicalAreasAxis_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GbMemberifrsfullGeographicalAreasAxis_HalkBankMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:GbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:HalkBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ECifrsfullGeographicalAreasAxis_ProdubancoMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:EC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ProdubancoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_JTrustRoyalBankMemberifrsfullJointVenturesAxis_KHifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:JTrustRoyalBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BancoDoBrasilMemberifrsfullJointVenturesAxis_BRifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:BancoDoBrasilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BancoDeHondurasMemberifrsfullJointVenturesAxis_HNifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:HN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:BancoDeHondurasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BacSanJoseMemberifrsfullJointVenturesAxis_CRifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:BacSanJoseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:LowerThanBBBBaa3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BBB-OrBaaThreeRatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis_StateBankOfIndiaMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">gsk:StateBankOfIndiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gsk:BBB-OrBaaThreeRatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">gsk:Debt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:NovartisVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AffinivaxMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BankLoansAndOverdraftsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaperInADesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherBorrowingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:BondsInDesignatedHedgingRelationshipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">gsk:NetInvestmentHedgedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePercentEuroMediumTermNotesTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:NewYorkStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">gsk:LondonStockExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherLongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:TradeAndOtherPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:OtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">gsk:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:OtherProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:SierraOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:AffinivaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyTwoAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonInterestBearingMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandThirtyOneAndThereafterMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">gsk:TwoThousandThirtyOneAndThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInsuranceContractsAxis">gsk:GroupCreditEnhancementsAndCreditInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:DueFromThreeWholesalersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">gsk:WholesaleAndRetailCreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">gsk:ForeignExchangeContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaleonMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:HaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TransfereeAxis">gsk:SLPPartneshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AgreementTypeAxis">gsk:SlpPartnershipAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P12_31_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">gsk:RemainingBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationRetiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">gsk:DefinedBenefitObligationDeferredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_JPYsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ViiVHealthCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:ConsumerHealthCareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">gsk:ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">gsk:NonDistributableMergerAndPreMergerReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:MiscellaneousComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:HorlicksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">gsk:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:TwoThousandTwentyBusinessDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConsumerHealthCareBangladeshMemberGSKArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ArrangementTypeAxis">gsk:ConsumerHealthCareBangladeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P05_20_2021To05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-20</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-20</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-20</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">gsk:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_09_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:RetireeHealthcarePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="P12_17_2020To12_17_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2021_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UsCashBalancePensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:HaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2022To12_31_2022_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:TransfereeAxis">gsk:SLPPartneshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:UkDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">gsk:GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_GskShareholdersMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_GskAndGsksConsolidatedEsotTrustsMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskAndGsksConsolidatedEsotTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:ScottishLimitedPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskAggregateHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_PfizerMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gsk:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_GskHoldingMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="PAsOn07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:ConsumerHealthcareBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gsk:GskAggregateHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gsk:InvestmentAxis">gsk:HaleonPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="P06_26_2019To06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="PAsOn06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:QuraTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-26</instant>
        </period>
    </context>
    <context id="P07_01_2022To07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:SierraOncologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:SierraOncologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="P08_15_2022To08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AffinivaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:AffinivaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:GlaxoSaudiArabiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-24</instant>
        </period>
    </context>
    <context id="PAsOn05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-20</instant>
        </period>
    </context>
    <context id="PAsOn05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:ContinuingAndDiscontinuedOperationAxis">gsk:AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:BusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:InnovivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-20</instant>
        </period>
    </context>
    <context id="P09_28_2020To09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-28</startDate>
            <endDate>2020-09-28</endDate>
        </period>
    </context>
    <context id="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:PfizerBiotechCorporationTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">gsk:FourthInterimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">gsk:GSKKoreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:ShionogiViiVHealthcareJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IntraGroupProfitMemberifrsfullJointOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCurrentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:NetDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:BankOverdrafts1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndBankOverdraftsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:BankOverdrafts1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:NetDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCurrentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:LegalAndOtherDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:EmployeeRelatedProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">gsk:OtherProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gsk:AwardType1Axis">gsk:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareValuePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LongTermBorrowingsDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PropertyPlantAndEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ShortTermBorrowingsAttributedToDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">gsk:AcceleratedCapitalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">gsk:IntraGroupProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gsk:ShareOptionAndAwardSchemesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">gsk:LicencesAndFranchisesAmortisedBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">gsk:BrandsWithIndefiniteUsefulLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">gsk:NetDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:LongTermBorrowingsContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:LiquidInvestmentsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:CommercialPaper1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:BankOverdrafts1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:OtherCurrentDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">gsk:ShortTermBorrowingsAttributedToContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gsk:OtherInvestmentsNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gsk:OtherBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gsk:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMeasuredAsFVTPLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gsk:CurrentEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">gsk:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:PensionDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">gsk:PostretirementBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">gsk:EsopTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131399</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="Unit_SAR">
        <measure>iso4217:SAR</measure>
    </unit>
    <unit id="Unit_Segments">
        <measure>gsk:Segments</measure>
    </unit>
    <unit id="Unit_GBP_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Employee">
        <measure>gsk:Employee</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_wholesalers">
        <measure>gsk:wholesalers</measure>
    </unit>
    <unit id="Unit_Plaintiffs">
        <measure>gsk:Plaintiffs</measure>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To12_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001131399</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P01_01_2022To12_31_2022">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P01_01_2022To12_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2022To12_31_2022">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2022To12_31_2022">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To12_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P01_01_2022To12_31_2022">1-15170</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">GSK plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">980 Great West Road, Brentford</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">Middlesex</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">TW8 9GS</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P01_01_2022To12_31_2022">GB</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Victoria Whyte</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">980 Great West Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Brentford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">TW8 9GS</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">44 20</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">8047 5000</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">company.secretary@gsk.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">GSK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">0.534% Notes due 2023</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">GSK/23C</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_ZeroPointFiveThreeFourNotesDue2023MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">3.000% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">GSK/24</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_ThreePointZeroNotesDue2024MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">3.625% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">GSK/25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_ThreePointSixTwoFiveNotesDue2025MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">3.875% Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">GSK/28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_ThreePointEightSevenFiveNotesDue2028MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">3.375% Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">GSK/29</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_ThreePointThreeSevenFiveNotesDue2029MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">6.375% Notes due 2038</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">GSK/38</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_SixPointThreeSevenFiveNotesDue2038MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">4.200% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">GSK/43</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022_FourPointTwoZeroZeroNotesDue2043MemberGSKTitleOfEachClassAxis">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">4311343341</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2022To12_31_2022">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2022To12_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2022To12_31_2022">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="P01_01_2022To12_31_2022">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityShellCompany>
    <dei:AuditorName contextRef="P01_01_2022To12_31_2022">Deloitte LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P01_01_2022To12_31_2022">London, United Kingdom</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="P01_01_2022To12_31_2022">1147</dei:AuditorFirmId>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      id="hidden69044974">7 Years</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      id="hidden69044975">3 Years</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      id="hidden69049915">Other operating income/ (expense)</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      id="hidden69049944">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      id="hidden69049946">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments
      contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      id="hidden69049945">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis"
      id="hidden69049947">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      id="hidden69049948">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      id="hidden69049949">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments
      contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      id="hidden69049975">Discontinued operations</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis"
      decimals="4"
      id="hidden69050743"
      unitRef="Unit_GBP_per_Share">0.3125</ifrs-full:ParValuePerShare>
    <ifrs-full:DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      id="hidden69050893">Intangible assets </ifrs-full:DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">24354000000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9554000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">8163000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7929000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">19770000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">16533000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">16425000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8372000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7070000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7437000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5488000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5019000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4793000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:RevenueFromRoyalties
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">758000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">417000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">321000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-235000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-504000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1463000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6433000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4357000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5979000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">879000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">769000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">874000000</ifrs-full:FinanceCosts>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnDisposalOfInterestInAssociate>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5628000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3599000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5170000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4921000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3516000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5103000000</ifrs-full:ProfitLossFromContinuingOperations>
    <gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3049000000</gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger>
    <gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1580000000</gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger>
    <gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1285000000</gsk:ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-7651000000</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10700000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1580000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1285000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15621000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5096000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6388000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">460000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">200000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">230000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4461000000</ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3316000000</ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4873000000</ifrs-full:IncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">205000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">511000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">409000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10495000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1069000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">876000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15621000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5096000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6388000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">665000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">711000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">639000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14956000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4385000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5749000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15621000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5096000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6388000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.108</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.829</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.224</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">2.606</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.267</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.22</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">3.714</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.096</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.444</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.092</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.818</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.209</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">2.57</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.264</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.217</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">3.662</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.082</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.426</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15621000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5096000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6388000000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-339000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-416000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-54000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">120000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-355000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-363000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-10000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-754000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-911000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1346000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-56000000</ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-131000000</ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">220000000</ifrs-full:IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-786000000</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">940000000</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-164000000</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated>
    <gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-211000000</gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated>
    <gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">223000000</gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated>
    <gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-55000000</gsk:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated>
    <gsk:FairValueMovementsOnCashFlowHedgesNotReclassified
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:FairValueMovementsOnCashFlowHedgesNotReclassified>
    <gsk:FairValueMovementsOnCashFlowHedgesNotReclassified
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:FairValueMovementsOnCashFlowHedgesNotReclassified>
    <gsk:FairValueMovementsOnCashFlowHedgesNotReclassified
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:FairValueMovementsOnCashFlowHedgesNotReclassified>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1307000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-83000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1007000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1187000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-438000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">644000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">356000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">101000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations>
    <gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">326000000</gsk:OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14790000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4759000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7358000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14153000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4068000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6753000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">637000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">691000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">605000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14790000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4759000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7358000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8933000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">9932000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">687000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">740000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7046000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14318000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">30079000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">88000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1467000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2126000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5658000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5218000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1194000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1676000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">39377000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">60429000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5146000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5783000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTaxAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">405000000</ifrs-full:CurrentTaxAssets>
    <ifrs-full:CurrentTaxAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">486000000</ifrs-full:CurrentTaxAssets>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7053000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7860000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">188000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4087000000</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3723000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4274000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">20769000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">18674000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">60146000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">79103000000</ifrs-full:Assets>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3952000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3601000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1289000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">958000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">16263000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">17554000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">227000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">471000000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">489000000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">652000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">841000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">22810000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">23670000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17035000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">20572000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">127000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">180000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">289000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3556000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2579000000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3113000000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">532000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">630000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5779000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5118000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">899000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">921000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">27240000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">34091000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">50050000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">57761000000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10096000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21342000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3440000000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3301000000</ifrs-full:SharePremium>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4363000000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7944000000</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1448000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2463000000</ifrs-full:OtherReserves>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10598000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">15055000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-502000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">6287000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10096000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21342000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1346000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3174000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4530000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2355000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">11405000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6952000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">18357000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">5749000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">5749000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">639000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6388000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-133000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1137000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1004000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">970000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">5616000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1137000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6753000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">605000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7358000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1208000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1208000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-131000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-131000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</ifrs-full:DividendsPaid>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">163000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-163000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-44000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IssueOfEquity>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-78000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-531000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">609000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-529000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">529000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">381000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">381000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">381000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1346000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3281000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6755000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3205000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14587000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6221000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">20808000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4385000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4385000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">711000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5096000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">454000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-771000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-317000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-337000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4839000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-771000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4068000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">691000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4759000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">642000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">642000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</ifrs-full:DividendsPaid>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:IssueOfEquity>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-132000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-168000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">168000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">367000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">367000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">367000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:TransactionsWithNoncontoliingInterests>
    <gsk:TransactionsWithNoncontoliingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:TransactionsWithNoncontoliingInterests>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3301000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">7944000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2463000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">15055000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6287000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21342000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14956000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14956000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">665000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15621000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-89000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-714000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-803000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-831000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14867000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-714000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14153000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">637000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14790000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1409000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1409000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2960000000</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:NoncashDistributionsToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2960000000</gsk:NoncashDistributionsToNoncontrollingInterests>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3045000000</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-3045000000</ifrs-full:IncreaseDecreaseThroughDisposalOfSubsidiary>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3467000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3467000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3467000000</ifrs-full:DividendsPaid>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15526000000</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15526000000</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NonCashDividendToShareholders>
    <gsk:NonCashDividendToShareholders
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-15526000000</gsk:NonCashDividendToShareholders>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:IssueOfEquity>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-911000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">911000000</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-114000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1086000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1200000000</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <gsk:SharesAcquiredByEsopTrusts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:SharesAcquiredByEsopTrusts>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">357000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">357000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">357000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <gsk:HedgingGainLossTransferredToNonFinancialAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:HedgingGainLossTransferredToNonFinancialAssets>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3440000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4363000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1448000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_EquityAttributableToOwnersOfParentMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">10598000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-502000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10096000000</ifrs-full:Equity>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4921000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3516000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5103000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3023000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3733000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2571000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7944000000</gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations>
    <gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7249000000</gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations>
    <gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7674000000</gsk:CashFromUsedInOperationsBeforeTaxesContinuingOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1310000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">972000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1086000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations>
    <gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6634000000</gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax>
    <gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">6277000000</gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax>
    <gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6588000000</gsk:CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax>
    <gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">932000000</gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations>
    <gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1994000000</gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations>
    <gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2422000000</gsk:CashFromUsedInOperationsBeforeTaxDiscontinuedOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">163000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">319000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations>
    <gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">569000000</gsk:IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations>
    <gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">769000000</gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax>
    <gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1675000000</gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax>
    <gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1853000000</gsk:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7403000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7952000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">8441000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1143000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">950000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">989000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">146000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">49000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1115000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1704000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">956000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">196000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">641000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">343000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">143000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">162000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">411000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3108000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">238000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">202000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3269000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-79000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-114000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-120000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">117000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <gsk:PurchaseOfInvestmentInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:PurchaseOfInvestmentInAssociatesAndJointVentures>
    <gsk:PurchaseOfInvestmentInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:PurchaseOfInvestmentInAssociatesAndJointVentures>
    <gsk:PurchaseOfInvestmentInAssociatesAndJointVentures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:PurchaseOfInvestmentInAssociatesAndJointVentures>
    <gsk:ProceedsFromDisposalOfAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ProceedsFromDisposalOfAssociatesAndJointVentures>
    <gsk:ProceedsFromDisposalOfAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">277000000</gsk:ProceedsFromDisposalOfAssociatesAndJointVentures>
    <gsk:ProceedsFromDisposalOfAssociatesAndJointVentures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ProceedsFromDisposalOfAssociatesAndJointVentures>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">64000000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <gsk:IncreaseDecreaseInLiquidInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:IncreaseDecreaseInLiquidInvestments>
    <gsk:IncreaseDecreaseInLiquidInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</gsk:IncreaseDecreaseInLiquidInvestments>
    <gsk:IncreaseDecreaseInLiquidInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:IncreaseDecreaseInLiquidInvestments>
    <ifrs-full:DividendsReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:DividendsReceivedClassifiedAsInvestingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:DividendsReceivedClassifiedAsInvestingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:DividendsReceivedClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-4981000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1655000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1355000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-3791000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-122000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">806000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-8772000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1777000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2161000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1594000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1025000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3298000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5074000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2304000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3738000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1021000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">301000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-3594000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">202000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">181000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">182000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">848000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">772000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">851000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3467000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">521000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">239000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">442000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">376000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">40000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-89000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-9251000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-7126000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-9543000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10074000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-463000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-589000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">823000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-7589000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-10132000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-546000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1414000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">470000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3819000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5262000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">4831000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">152000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-39000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-546000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1414000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">470000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3425000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3819000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5262000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3723000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4274000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6292000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">298000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">455000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1030000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3425000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3819000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5262000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Presentation of the financial statements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK is a global biopharma group which makes innovative vaccines and specialty medicines to prevent and treat disease. GSK&#x2019;s R&amp;amp;D focuses on the science of the immune system, human genetics and advanced technologies primarily in the following four therapeutic areas: infectious diseases, HIV, oncology and immunology/respiratory. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Compliance with applicable law and IFRS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and the International Financial Reporting Standards as issued by the IASB. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Composition of financial statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consolidated financial statements are drawn up in Sterling, the functional currency of GSK plc, and in accordance with IFRS accounting presentation. The financial statements comprise: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Consolidated income statement &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Consolidated statement of comprehensive income &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Consolidated balance sheet &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Consolidated statement of changes in equity &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Consolidated cash flow statement &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Notes to the financial statements. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Composition of the Group &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A list of the subsidiaries and associates which, in the opinion of the Directors, principally affected the amount of profit or net assets of the Group is given in Note 46, &#x2018;Principal Group companies&#x2019;. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial period &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;These financial statements cover the financial year from 1 January to 31 December 2022, with comparative figures for the financial years from 1 January to 31 December 2021 and, where appropriate, from 1 January to 31 December 2020. Income statement and cash flow comparatives have been restated on a consistent basis from those previously published to reflect the classification of the Consumer Healthcare business as a discontinued operation (see Note&#160;41). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounting principles and policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements have been prepared using the historical cost convention modified by the revaluation of certain items, as stated in the accounting policies, and on a going concern basis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements have been prepared in accordance with the Group&#x2019;s accounting policies approved by the Board and described in Note 2, &#x2018;Accounting principles and policies&#x2019;. Information on the application of these accounting policies, including areas of estimation and judgement is given in Note 3, &#x2018;Critical accounting judgements and key sources of estimation uncertainty&#x2019;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Parent company financial statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements of the parent company, GSK plc, have been prepared in accordance with UK&#160;GAAP and with UK accounting presentation. The company balance sheet is presented on page 268 and the accounting policies are given on pages 269 to 272. &lt;/div&gt; </ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:PeriodCoveredByFinancialStatements contextRef="P01_01_2022To12_31_2022">These financial statements cover the financial year from 1 January to 31 December 2022, with comparative figures for the financial years from 1 January to 31 December 2021 and, where appropriate, from 1 January to 31 December 2020.</ifrs-full:PeriodCoveredByFinancialStatements>
    <gsk:DateOfEndOfReportingPeriod2022 contextRef="P01_01_2022To12_31_2022">2022-12-31</gsk:DateOfEndOfReportingPeriod2022>
    <gsk:DescriptionOfAccountingStandardsApplied contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Parent company financial statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements of the parent company, GSK plc, have been prepared in accordance with UK&#160;GAAP and with UK accounting presentation. The company balance sheet is presented on page 268 and the accounting policies are given on pages 269 to 272. &lt;/div&gt;</gsk:DescriptionOfAccountingStandardsApplied>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Accounting principles and policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consolidated financial statements include: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the assets and liabilities, and the results and cash flows, of the company and its subsidiaries, including ESOP Trusts &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the Group&#x2019;s share of the results and net assets of associates and joint ventures &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the Group&#x2019;s share of assets, liabilities, revenue and expenses of joint operations. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements of entities consolidated are made up to 31&#160;December each year. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Entities over which the Group has the power to direct the relevant activities so as to affect the returns to the Group, generally through control over the financial and operating policies, are accounted for as subsidiaries. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the Group has the ability to exercise joint control over, and rights to, the net assets of entities, the entities are accounted for as joint ventures. Where the Group has the ability to exercise joint control over an arrangement, but has rights to specified assets and obligations for specified liabilities of the arrangement, the arrangement is accounted for as a joint operation. Where the Group has the ability to exercise significant influence over entities, they are accounted for as associates. The results and assets and liabilities of associates and joint ventures are incorporated into the consolidated financial statements using the equity method of accounting. The assets, liabilities, revenue and expenses of joint operations are included in the consolidated financial statements in accordance with the Group&#x2019;s rights and obligations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Interests acquired in entities are consolidated from the date the Group acquires control and interests sold are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;de-consolidated&lt;/div&gt; from the date control ceases. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Transactions and balances between subsidiaries are eliminated and no profit before tax is taken on sales between subsidiaries until the products are sold to customers outside the Group. The relevant proportion of profits on transactions with joint ventures, joint operations and associates is also deferred until the products are sold to third parties. Transactions with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests are recorded directly in equity. Deferred tax relief on unrealised intra-Group profit is accounted for only to the extent that it is considered recoverable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business combinations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognised in the income statement. Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition date is reported within operating cash flows. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the consideration transferred, together with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in the period in which they are incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill is capitalised as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and associates. Goodwill is denominated in the currency of the operation acquired. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the cost of acquisition is below the Group&#x2019;s interest in the net assets acquired, the difference is recognised directly in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where not all of the equity of a subsidiary is acquired the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest is recognised either at fair value or at the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&#x2019;s share of the net assets of the subsidiary, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;case-by-case&lt;/div&gt;&lt;/div&gt; basis. Changes in the Group&#x2019;s ownership percentage of subsidiaries are accounted for within equity. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Foreign currency transactions are booked in the functional currency of the Group company at the exchange rate ruling on the date of transaction. Foreign currency monetary assets and liabilities are retranslated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On consolidation, assets and liabilities, including related goodwill, of overseas subsidiaries, associates and joint ventures, are translated into Sterling at rates of exchange ruling at the balance sheet date. The results and cash flows of overseas subsidiaries, associates and joint ventures are translated into Sterling using average rates of exchange. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Exchange adjustments arising when the opening net assets and the profits for the year retained by overseas subsidiaries, associates and joint ventures are translated into Sterling, less exchange differences arising on related foreign currency borrowings which hedge the Group&#x2019;s net investment in these operations, are taken to a separate component of equity within Retained Earnings. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;When translating into Sterling the assets, liabilities, results and cash flows of overseas subsidiaries, associates and joint ventures which are reported in currencies of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hyper-inflationary&lt;/div&gt; economies, adjustments are made where material to reflect current price levels. Any loss on net monetary assets is charged to the consolidated income statement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that GSK enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, vaccine and (prior to the demerger of the Consumer Healthcare business) consumer healthcare products. The average duration of a sales order is less than 12 months. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Product revenue is recognised when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Estimates associated with returns and rebates are revisited at each reporting date or when they are resolved and revenue is adjusted accordingly. Please refer to Note 3 for the details on rebates, discounts and allowances. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has entered into collaborative agreements, typically with other pharmaceutical or biotechnology companies to develop, produce and market drug candidates and vaccines that do not qualify as joint arrangements. When GSK has control over the commercialisation activities, the Group recognises turnover and cost of sales on a gross basis. Profit sharing amounts and royalties due to the counterparty are recorded within cost of sales. Cost of sales includes profit sharing costs and royalties due to the counterparty of &#xa3;1,635&#160;million (2021: &#xa3;640&#160;million; 2020: &#xa3;4 million). When the counterparty controls the commercialisation activities and records the sale, the Group is not deemed principal in the customer contract and instead records its share of gross profit as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; income, on a net basis, within turnover. The nature of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; activities is such that the Group records no costs of sales. Commercial Operations turnover includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; revenue of &#xa3;3 million (2021: &#xa3;7 million; 2020: &#xa3;12 million). Reimbursements to and from the counterparty under collaboration agreements for &#x2018;selling, general and administration&#x2019; and &#x2018;research and development&#x2019; costs are recorded net in the respective lines in the Consolidated income statement. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other operating income and royalty income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK enters into development and marketing collaborations and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licences&lt;/div&gt; of the Group&#x2019;s compounds or products to other parties. These contracts give rise to fixed and variable consideration from upfront payments, development milestones, sales-based milestones and royalties. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Income dependent on the achievement of a development milestone is recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, which is usually when the related event occurs. Sales-based milestone income is recognised when it is highly probable that the sales threshold will be reached. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occurs. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For all revenue, if the time between the recognition of revenue and payment from the customer is expected to be more than one year and the impact is material, the amount of consideration is discounted using appropriate discount rates. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Value added tax and other sales taxes are excluded from revenue. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expenditure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. Manufacturing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;start-up&lt;/div&gt; costs between validation and the achievement of normal production are expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Advertising and promotion expenditure is charged to the income statement as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Shipment costs on inter-company transfers are charged to cost of sales; distribution costs on sales to customers are included in selling, general and administration expenditure. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Restructuring costs are recognised and provided for, where appropriate, in respect of the direct expenditure of a business reorganisation where the plans are sufficiently detailed and well advanced, and where appropriate communication to those affected has been undertaken. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Software as a service (SaaS) configuration costs are expensed as they are incurred where the software being configured is controlled by the SaaS provider. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group&#x2019;s policy. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Environmental expenditure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Environmental expenditure related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible is charged to the income statement. The Group recognises its liability on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;site-by-site&lt;/div&gt;&lt;/div&gt; basis when it can be reliably estimated. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;This liability includes the Group&#x2019;s portion of the total costs and also a portion of other potentially responsible parties&#x2019; costs when it is probable that they will not be able to satisfy their respective shares of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; obligation. Recoveries of reimbursements are recorded as assets when virtually certain. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and other disputes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Provision is made for the anticipated settlement costs of legal or other disputes against the Group where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome. In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover asserted and unasserted claims. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In certain cases, an incurred but not reported (IBNR) actuarial technique is used to determine this estimate. In addition, provision is made for legal or other expenses arising from claims received or other disputes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases is included but no provision is made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Costs associated with claims made by the Group against third parties are charged to the income statement as they are incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pensions and other post-employment benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of providing pensions under defined benefit schemes are calculated using the projected unit credit method and spread over the period during which benefit is expected to be derived from the employees&#x2019; services, consistent with the advice of qualified actuaries. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Pension obligations are measured as the present value of estimated future cash flows discounted at rates reflecting the yields of high-quality corporate bonds. Pension scheme assets are measured at fair value at the balance sheet date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of other post-employment liabilities are calculated in&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;a similar way to defined benefit pension schemes and spread over the period during which benefit is expected to be derived from the employees&#x2019; services, in accordance with the advice of qualified actuaries. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The service cost of providing retirement benefits to employees during the year, together with the cost of any curtailment, is charged to operating profit in the year. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Actuarial gains and losses and the effect of changes in actuarial assumptions are recognised in the statement of comprehensive income in the year in which they arise. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s contributions to defined contribution plans are charged to the income statement as incurred. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee share plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Incentives in the form of shares are provided to employees under share option and share award schemes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair values of these options and awards are calculated at their grant dates using a Black-Scholes option pricing model and charged to the income statement over the relevant vesting periods. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group provides finance to ESOP Trusts to purchase company shares to meet the obligation to provide shares when employees exercise their options or awards. Costs of running the ESOP Trusts are charged to the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Shares held by the ESOP Trusts are deducted from other reserves. A transfer is made between other reserves and retained earnings over the vesting periods of the related share options or awards to reflect the ultimate proceeds receivable from employees on exercise. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Property, plant and equipment (PP&amp;amp;E) is stated at the cost of purchase or construction, less provisions for depreciation and impairment. Financing costs are capitalised within the cost of qualifying assets in construction. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Depreciation is calculated to write off the cost less residual value of PP&amp;amp;E, excluding freehold land, using the straight-line basis over the expected useful life. Residual values and lives are reviewed, and where appropriate adjusted annually. The normal expected useful lives of the major categories of PP&amp;amp;E are: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:45%"/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Freehold buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Leasehold land and buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Lease term or 20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Plant and machinery&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;10 to 20 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equipment and vehicles&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;3 to 10 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On disposal of PP&amp;amp;E, the cost and related accumulated depreciation and impairments are removed from the financial statements and the net amount, less any proceeds, is taken to the income statement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group recognises right of use assets under lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. Rights to use assets owned by third parties under lease agreements are capitalised at the inception of the lease and recognised on the consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The corresponding liability to the lessor is recognised as a lease obligation within short and long-term borrowings. The carrying amount is subsequently increased to reflect interest on the lease liability and reduced by lease payments made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For calculating the discounted lease liability on leases with annual payments of &#xa3;2 million or more, the implicit rate in the lease is used. If this is not available, the incremental borrowing rate with a lease specific adjustment is used. If neither of these is available, and for leases with annual payments of less than &#xa3;2 million, the incremental borrowing rate is used. The incremental borrowing rate is calculated at the rate of interest at which GSK would have been able to borrow for a similar term and with a similar security the funds necessary to obtain a similar asset in a similar market. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Finance costs are charged to the income statement so as to produce a constant periodic rate of charge on the remaining balance of the obligations for each accounting period. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Variable rents are not part of the lease liability and the right of use asset. These payments are charged to the income statement as incurred. Lease rental costs for short-term and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; leases which are not capitalised are also charged to the income statement as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-lease&lt;/div&gt; components are accounted for separately from the lease components in plant and equipment leases but are not separately accounted for in land and buildings or vehicle leases. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;If modifications or reassessments of lease obligations occur, the lease liability and right of use asset are remeasured. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Right of use assets where title is expected to pass to GSK at a point in the future are depreciated on a basis consistent with similar owned assets. In other cases, right of use assets are depreciated over the shorter of the useful life of the asset or the lease term. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill is stated at cost less impairments. Goodwill is deemed to have an indefinite useful life and is tested for impairment at least annually. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the fair value of the interest acquired in an entity&#x2019;s assets, liabilities and contingent liabilities exceeds the consideration paid, this excess is recognised immediately as a gain in the income statement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Intangible assets are stated at cost less provisions for amortisation and impairments. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Licences, patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and marketing rights separately acquired or acquired as part of a business combination are amortised over their estimated useful lives, generally not exceeding 30 years, using the straight-line basis, from the time they are available for use. The estimated useful lives for determining the amortisation charge take into account patent lives (exclusivity period), where applicable, as well as the value obtained from periods of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusivity.&lt;/div&gt; For Pharmaceutical intangible assets, depending on the characteristics, competitive environment and estimated long-term profits of the asset, between 80% to 90% of the book value is amortised over the exclusivity period on a straight-line basis and the remaining book value is amortised over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusivity&lt;/div&gt; period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-15&lt;/div&gt; years on a straight-line basis. For Vaccines intangible assets, cost is usually amortised over the exclusivity period plus 10 years, or 30 years if no exclusivity period is granted, on a straight-line basis. Asset lives are reviewed, and where appropriate adjusted, annually. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Contingent milestone payments are recognised at the point that the contingent event becomes probable. Any development costs incurred by the Group and associated with acquired licences, patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; or marketing rights are written off to the income statement when incurred, unless the criteria for recognition of an internally generated intangible asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Acquired in process R&amp;amp;D and marketed products are valued independently as part of the fair value of businesses acquired from third parties where they have a value which is substantial and long term and where the brands either are contractual or legal in nature or can be sold separately from the rest of the businesses acquired. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of acquiring and developing computer software for internal use and internet sites for external use are capitalised as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset controlled by the Group. ERP systems software is amortised over &lt;span style="-sec-ix-hidden:hidden69044974"&gt;seven&lt;/span&gt; to ten years and other computer software over &lt;span style="-sec-ix-hidden:hidden69044975"&gt;three&lt;/span&gt; to five years using the straight-line basis. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The carrying values of all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available for use are tested for impairment annually. Any provision for impairment is charged to the income statement in the year concerned. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Impairments of goodwill are not reversed. Impairment losses on other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investments in associates, joint ventures and joint operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Investments in associates and joint ventures are carried in the consolidated balance sheet at the Group&#x2019;s share of their net assets at date of acquisition and of their post-acquisition retained profits or losses and other comprehensive income together with any goodwill arising on the acquisition. The Group recognises the assets, liabilities, revenue and expenses of joint operations in accordance with its rights and obligations. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realisable value. Cost is generally determined on a first in, first out basis. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-launch&lt;/div&gt; inventory is held as an asset when there is a high probability of regulatory approval for the product. Before that point a provision is made against the carrying value to reduce it to its recoverable amount; the provision is then reversed at the point when a high probability of regulatory approval is determined. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Financial assets are measured at amortised cost, fair value through other comprehensive income (FVTOCI) or fair value through profit or loss (FVTPL). The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. For financial assets other than trade receivables a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; expected credit loss (ECL) allowance is recorded on initial recognition. If there is subsequent evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expected credit losses are recognised in the income statement on financial assets measured at amortised cost and at fair value through other comprehensive income apart from equity investments. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current equity investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. Dividend income is recognised in the income statement when the Group&#x2019;s right to receive payment is established. Purchases and sales of Current equity investments are accounted for on the trade date. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other investments comprise equity investments and investments in limited life funds. The Group has elected to designate the majority of its equity investments as measured at FVTOCI. They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Investments in limited life funds are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Dividends on equity investments and distributions from funds are recognised in the income statement when the Group&#x2019;s right to receive payment is established. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Purchases and sales of Other investments are accounted for on the trade date. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade receivables are measured in accordance with the business model under which each portfolio of trade receivables is held. The Group has portfolios in each of the three business models under IFRS 9: to collect the contractual cash flows where there is no factoring agreement in place (measured at amortised cost), to sell the contractual cash flows where the trade receivables will be sold under a factoring agreement (measured at FVTPL), and both to collect and to sell the contractual cash flows where the trade receivables may be sold under a factoring arrangement (measured at FVTOCI). Trade receivables measured at amortised cost are carried at the original invoice amount less allowances for expected credit losses. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether, and the extent to which, settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Subsequent recoveries of amounts previously provided for or written off are credited to the income statement. Long-term receivables are discounted where the effect is material. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Cash held in deposit accounts is measured at amortised cost. Investments in money market funds are held at fair value through profit or loss because the funds fail the solely payments of principal and interest (SPPI) test. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Borrowings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by GSK are foreign currency swaps, interest rate swaps, foreign exchange forward contracts and options. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivative financial assets and liabilities, including derivatives embedded in host contracts which have been separated from the host contract, are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-for-trading&lt;/div&gt;&lt;/div&gt; and are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedge accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivatives designated as hedging instruments are classified at inception of hedge relationship as cash flow hedges, net investment hedges or fair value hedges. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective and accumulated in the cash flow hedge reserve. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in the cash flow hedge reserve are reclassified to the income statement when the hedged item affects profit or loss, or if the hedged forecast transaction is to purchase a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; asset, the amount deferred in the cash flow hedge reserve is transferred directly from equity and included in the carrying value of the recognised &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; asset. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Net investment hedges are accounted for in a similar way to cash flow hedges which are reclassified to the income statement when the hedged item affects profit or loss. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Taxation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Current tax is provided at the amounts expected to be paid, applying tax rates that have been enacted or substantively enacted by the balance sheet date. The tax charge for the period is recognised in the income statement, the statement of comprehensive income or directly in equity, according to the accounting treatment of the related transaction. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company and its subsidiaries intend to settle their current tax assets and liabilities on a net basis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax assets and liabilities are not recognised if the temporary differences arise from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction (other than a business combination) that affects neither the accounting nor the taxable profit or loss. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where an uncertain tax position is identified, management will make a judgement as to what the probable outcome will be, assuming the relevant tax authority has full knowledge of the situation. Where it is assessed that an economic outflow is probable to arise, a provision is made for the best estimate of the liability. In estimating any such liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Discounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the time value of money is material, balances are discounted to current values using appropriate discount rates. The unwinding of the discounts is recorded in finance income and finance expense. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets and liabilities held for sale or distribution and discontinued operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Disposal groups are classified as held for sale or distribution if their carrying amount will be recovered principally through sale or a distribution to shareholders rather than through continuing use, they are available for sale or distribution in their present condition and the sale or distribution is considered highly probable. Assets held in Assets held for sale or distribution are measured at the lower of their carrying amount and fair value less costs to sell or distribute. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets included in Assets held for sale or distribution are not depreciated or amortised. Assets and liabilities classified as held for sale or distribution are presented in current assets and current liabilities separately from the other assets and liabilities in the balance sheet. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A discontinued operation is a component of the Group that has been disposed of, distributed or is classified as held for sale or distribution and that represents a separate major line of business. The results of discontinued operations are presented separately in the Consolidated income statement, the Consolidated statement of other comprehensive income and the Consolidated statement of cash flows and comparatives are restated on a consistent basis. &lt;/div&gt; </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <gsk:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consolidated financial statements include: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the assets and liabilities, and the results and cash flows, of the company and its subsidiaries, including ESOP Trusts &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the Group&#x2019;s share of the results and net assets of associates and joint ventures &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;the Group&#x2019;s share of assets, liabilities, revenue and expenses of joint operations. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The financial statements of entities consolidated are made up to 31&#160;December each year. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Entities over which the Group has the power to direct the relevant activities so as to affect the returns to the Group, generally through control over the financial and operating policies, are accounted for as subsidiaries. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the Group has the ability to exercise joint control over, and rights to, the net assets of entities, the entities are accounted for as joint ventures. Where the Group has the ability to exercise joint control over an arrangement, but has rights to specified assets and obligations for specified liabilities of the arrangement, the arrangement is accounted for as a joint operation. Where the Group has the ability to exercise significant influence over entities, they are accounted for as associates. The results and assets and liabilities of associates and joint ventures are incorporated into the consolidated financial statements using the equity method of accounting. The assets, liabilities, revenue and expenses of joint operations are included in the consolidated financial statements in accordance with the Group&#x2019;s rights and obligations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Interests acquired in entities are consolidated from the date the Group acquires control and interests sold are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;de-consolidated&lt;/div&gt; from the date control ceases. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Transactions and balances between subsidiaries are eliminated and no profit before tax is taken on sales between subsidiaries until the products are sold to customers outside the Group. The relevant proportion of profits on transactions with joint ventures, joint operations and associates is also deferred until the products are sold to third parties. Transactions with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests are recorded directly in equity. Deferred tax relief on unrealised intra-Group profit is accounted for only to the extent that it is considered recoverable. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business combinations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognised in the income statement. Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition date is reported within operating cash flows. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the consideration transferred, together with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in the period in which they are incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill is capitalised as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and associates. Goodwill is denominated in the currency of the operation acquired. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the cost of acquisition is below the Group&#x2019;s interest in the net assets acquired, the difference is recognised directly in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where not all of the equity of a subsidiary is acquired the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest is recognised either at fair value or at the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&#x2019;s share of the net assets of the subsidiary, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;case-by-case&lt;/div&gt;&lt;/div&gt; basis. Changes in the Group&#x2019;s ownership percentage of subsidiaries are accounted for within equity. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Foreign currency transactions are booked in the functional currency of the Group company at the exchange rate ruling on the date of transaction. Foreign currency monetary assets and liabilities are retranslated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On consolidation, assets and liabilities, including related goodwill, of overseas subsidiaries, associates and joint ventures, are translated into Sterling at rates of exchange ruling at the balance sheet date. The results and cash flows of overseas subsidiaries, associates and joint ventures are translated into Sterling using average rates of exchange. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Exchange adjustments arising when the opening net assets and the profits for the year retained by overseas subsidiaries, associates and joint ventures are translated into Sterling, less exchange differences arising on related foreign currency borrowings which hedge the Group&#x2019;s net investment in these operations, are taken to a separate component of equity within Retained Earnings. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;When translating into Sterling the assets, liabilities, results and cash flows of overseas subsidiaries, associates and joint ventures which are reported in currencies of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hyper-inflationary&lt;/div&gt; economies, adjustments are made where material to reflect current price levels. Any loss on net monetary assets is charged to the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that GSK enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, vaccine and (prior to the demerger of the Consumer Healthcare business) consumer healthcare products. The average duration of a sales order is less than 12 months. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Product revenue is recognised when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Estimates associated with returns and rebates are revisited at each reporting date or when they are resolved and revenue is adjusted accordingly. Please refer to Note 3 for the details on rebates, discounts and allowances. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has entered into collaborative agreements, typically with other pharmaceutical or biotechnology companies to develop, produce and market drug candidates and vaccines that do not qualify as joint arrangements. When GSK has control over the commercialisation activities, the Group recognises turnover and cost of sales on a gross basis. Profit sharing amounts and royalties due to the counterparty are recorded within cost of sales. Cost of sales includes profit sharing costs and royalties due to the counterparty of &#xa3;1,635&#160;million (2021: &#xa3;640&#160;million; 2020: &#xa3;4 million). When the counterparty controls the commercialisation activities and records the sale, the Group is not deemed principal in the customer contract and instead records its share of gross profit as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; income, on a net basis, within turnover. The nature of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; activities is such that the Group records no costs of sales. Commercial Operations turnover includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promotion&lt;/div&gt; revenue of &#xa3;3 million (2021: &#xa3;7 million; 2020: &#xa3;12 million). Reimbursements to and from the counterparty under collaboration agreements for &#x2018;selling, general and administration&#x2019; and &#x2018;research and development&#x2019; costs are recorded net in the respective lines in the Consolidated income statement. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other operating income and royalty income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK enters into development and marketing collaborations and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licences&lt;/div&gt; of the Group&#x2019;s compounds or products to other parties. These contracts give rise to fixed and variable consideration from upfront payments, development milestones, sales-based milestones and royalties. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Income dependent on the achievement of a development milestone is recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, which is usually when the related event occurs. Sales-based milestone income is recognised when it is highly probable that the sales threshold will be reached. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occurs. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For all revenue, if the time between the recognition of revenue and payment from the customer is expected to be more than one year and the impact is material, the amount of consideration is discounted using appropriate discount rates. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Value added tax and other sales taxes are excluded from revenue. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1635000000</gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales>
    <gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">640000000</gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales>
    <gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales>
    <gsk:CostOfSalesOnCoPromotionalActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CostOfSalesOnCoPromotionalActivities>
    <gsk:RevenueFromCoPromotionalActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:RevenueFromCoPromotionalActivities>
    <gsk:RevenueFromCoPromotionalActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:RevenueFromCoPromotionalActivities>
    <gsk:RevenueFromCoPromotionalActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:RevenueFromCoPromotionalActivities>
    <ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expenditure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms. Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation can be reliably estimated. Manufacturing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;start-up&lt;/div&gt; costs between validation and the achievement of normal production are expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Advertising and promotion expenditure is charged to the income statement as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Shipment costs on inter-company transfers are charged to cost of sales; distribution costs on sales to customers are included in selling, general and administration expenditure. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Restructuring costs are recognised and provided for, where appropriate, in respect of the direct expenditure of a business reorganisation where the plans are sufficiently detailed and well advanced, and where appropriate communication to those affected has been undertaken. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Software as a service (SaaS) configuration costs are expensed as they are incurred where the software being configured is controlled by the SaaS provider. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group&#x2019;s policy. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Environmental expenditure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Environmental expenditure related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible is charged to the income statement. The Group recognises its liability on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;site-by-site&lt;/div&gt;&lt;/div&gt; basis when it can be reliably estimated. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;This liability includes the Group&#x2019;s portion of the total costs and also a portion of other potentially responsible parties&#x2019; costs when it is probable that they will not be able to satisfy their respective shares of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; obligation. Recoveries of reimbursements are recorded as assets when virtually certain. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory>
    <gsk:DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and other disputes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Provision is made for the anticipated settlement costs of legal or other disputes against the Group where an outflow of resources is considered probable and a reliable estimate can be made of the likely outcome. In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover asserted and unasserted claims. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In certain cases, an incurred but not reported (IBNR) actuarial technique is used to determine this estimate. In addition, provision is made for legal or other expenses arising from claims received or other disputes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases is included but no provision is made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Costs associated with claims made by the Group against third parties are charged to the income statement as they are incurred. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pensions and other post-employment benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of providing pensions under defined benefit schemes are calculated using the projected unit credit method and spread over the period during which benefit is expected to be derived from the employees&#x2019; services, consistent with the advice of qualified actuaries. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Pension obligations are measured as the present value of estimated future cash flows discounted at rates reflecting the yields of high-quality corporate bonds. Pension scheme assets are measured at fair value at the balance sheet date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of other post-employment liabilities are calculated in&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;a similar way to defined benefit pension schemes and spread over the period during which benefit is expected to be derived from the employees&#x2019; services, in accordance with the advice of qualified actuaries. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The service cost of providing retirement benefits to employees during the year, together with the cost of any curtailment, is charged to operating profit in the year. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Actuarial gains and losses and the effect of changes in actuarial assumptions are recognised in the statement of comprehensive income in the year in which they arise. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s contributions to defined contribution plans are charged to the income statement as incurred. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee share plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Incentives in the form of shares are provided to employees under share option and share award schemes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair values of these options and awards are calculated at their grant dates using a Black-Scholes option pricing model and charged to the income statement over the relevant vesting periods. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group provides finance to ESOP Trusts to purchase company shares to meet the obligation to provide shares when employees exercise their options or awards. Costs of running the ESOP Trusts are charged to the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Shares held by the ESOP Trusts are deducted from other reserves. A transfer is made between other reserves and retained earnings over the vesting periods of the related share options or awards to reflect the ultimate proceeds receivable from employees on exercise. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Property, plant and equipment (PP&amp;amp;E) is stated at the cost of purchase or construction, less provisions for depreciation and impairment. Financing costs are capitalised within the cost of qualifying assets in construction. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Depreciation is calculated to write off the cost less residual value of PP&amp;amp;E, excluding freehold land, using the straight-line basis over the expected useful life. Residual values and lives are reviewed, and where appropriate adjusted annually. The normal expected useful lives of the major categories of PP&amp;amp;E are: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:45%"/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Freehold buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Leasehold land and buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Lease term or 20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Plant and machinery&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;10 to 20 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equipment and vehicles&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;3 to 10 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On disposal of PP&amp;amp;E, the cost and related accumulated depreciation and impairments are removed from the financial statements and the net amount, less any proceeds, is taken to the income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">The normal expected useful lives of the major categories of PP&amp;amp;E are:&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:45%"/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Freehold buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Leasehold land and buildings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Lease term or 20 to 50 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Plant and machinery&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;10 to 20 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equipment and vehicles&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;3 to 10 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">20 to 50 years</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_LeaseholdLandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">Lease term or 20 to 50 years</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_PlantAndMachineryMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">10 to 20 years</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment contextRef="P01_01_2022To12_31_2022_EquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">3 to 10 years</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group recognises right of use assets under lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. Rights to use assets owned by third parties under lease agreements are capitalised at the inception of the lease and recognised on the consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The corresponding liability to the lessor is recognised as a lease obligation within short and long-term borrowings. The carrying amount is subsequently increased to reflect interest on the lease liability and reduced by lease payments made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For calculating the discounted lease liability on leases with annual payments of &#xa3;2 million or more, the implicit rate in the lease is used. If this is not available, the incremental borrowing rate with a lease specific adjustment is used. If neither of these is available, and for leases with annual payments of less than &#xa3;2 million, the incremental borrowing rate is used. The incremental borrowing rate is calculated at the rate of interest at which GSK would have been able to borrow for a similar term and with a similar security the funds necessary to obtain a similar asset in a similar market. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Finance costs are charged to the income statement so as to produce a constant periodic rate of charge on the remaining balance of the obligations for each accounting period. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Variable rents are not part of the lease liability and the right of use asset. These payments are charged to the income statement as incurred. Lease rental costs for short-term and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; leases which are not capitalised are also charged to the income statement as incurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-lease&lt;/div&gt; components are accounted for separately from the lease components in plant and equipment leases but are not separately accounted for in land and buildings or vehicle leases. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;If modifications or reassessments of lease obligations occur, the lease liability and right of use asset are remeasured. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Right of use assets where title is expected to pass to GSK at a point in the future are depreciated on a basis consistent with similar owned assets. In other cases, right of use assets are depreciated over the shorter of the useful life of the asset or the lease term. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments
      contextRef="PAsOn12_31_2022_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments>
    <gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments
      contextRef="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments>
    <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill is stated at cost less impairments. Goodwill is deemed to have an indefinite useful life and is tested for impairment at least annually. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the fair value of the interest acquired in an entity&#x2019;s assets, liabilities and contingent liabilities exceeds the consideration paid, this excess is recognised immediately as a gain in the income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Intangible assets are stated at cost less provisions for amortisation and impairments. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Licences, patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and marketing rights separately acquired or acquired as part of a business combination are amortised over their estimated useful lives, generally not exceeding 30 years, using the straight-line basis, from the time they are available for use. The estimated useful lives for determining the amortisation charge take into account patent lives (exclusivity period), where applicable, as well as the value obtained from periods of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusivity.&lt;/div&gt; For Pharmaceutical intangible assets, depending on the characteristics, competitive environment and estimated long-term profits of the asset, between 80% to 90% of the book value is amortised over the exclusivity period on a straight-line basis and the remaining book value is amortised over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusivity&lt;/div&gt; period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-15&lt;/div&gt; years on a straight-line basis. For Vaccines intangible assets, cost is usually amortised over the exclusivity period plus 10 years, or 30 years if no exclusivity period is granted, on a straight-line basis. Asset lives are reviewed, and where appropriate adjusted, annually. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Contingent milestone payments are recognised at the point that the contingent event becomes probable. Any development costs incurred by the Group and associated with acquired licences, patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; or marketing rights are written off to the income statement when incurred, unless the criteria for recognition of an internally generated intangible asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Acquired in process R&amp;amp;D and marketed products are valued independently as part of the fair value of businesses acquired from third parties where they have a value which is substantial and long term and where the brands either are contractual or legal in nature or can be sold separately from the rest of the businesses acquired. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of acquiring and developing computer software for internal use and internet sites for external use are capitalised as intangible fixed assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset controlled by the Group. ERP systems software is amortised over &lt;span style="-sec-ix-hidden:hidden69044974"&gt;seven&lt;/span&gt; to ten years and other computer software over &lt;span style="-sec-ix-hidden:hidden69044975"&gt;three&lt;/span&gt; to five years using the straight-line basis. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">30</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <gsk:AmortisableProportionOverExclusivityPeriod
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</gsk:AmortisableProportionOverExclusivityPeriod>
    <gsk:AmortisableProportionOverExclusivityPeriod
      contextRef="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</gsk:AmortisableProportionOverExclusivityPeriod>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P12_31_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">5</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_PharmaceuticalsMemberifrsfullSegmentsAxis_RemainingBookValueMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_TopOfRangeMemberifrsfullRangeAxis">15</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_VaccinesMemberifrsfullSegmentsAxis">10 years, or 30 years</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_ERPSoftwareSystemsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">ten years</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill contextRef="P01_01_2022To12_31_2022_OtherComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">five years</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The carrying values of all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available for use are tested for impairment annually. Any provision for impairment is charged to the income statement in the year concerned. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Impairments of goodwill are not reversed. Impairment losses on other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investments in associates, joint ventures and joint operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Investments in associates and joint ventures are carried in the consolidated balance sheet at the Group&#x2019;s share of their net assets at date of acquisition and of their post-acquisition retained profits or losses and other comprehensive income together with any goodwill arising on the acquisition. The Group recognises the assets, liabilities, revenue and expenses of joint operations in accordance with its rights and obligations. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realisable value. Cost is generally determined on a first in, first out basis. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-launch&lt;/div&gt; inventory is held as an asset when there is a high probability of regulatory approval for the product. Before that point a provision is made against the carrying value to reduce it to its recoverable amount; the provision is then reversed at the point when a high probability of regulatory approval is determined. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Financial assets are measured at amortised cost, fair value through other comprehensive income (FVTOCI) or fair value through profit or loss (FVTPL). The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. For financial assets other than trade receivables a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; expected credit loss (ECL) allowance is recorded on initial recognition. If there is subsequent evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expected credit losses are recognised in the income statement on financial assets measured at amortised cost and at fair value through other comprehensive income apart from equity investments. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <gsk:DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current equity investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Current equity investments comprise equity investments which the Group holds with the intention to sell and which it may sell in the short term. Where acquired with this intention, they are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. Dividend income is recognised in the income statement when the Group&#x2019;s right to receive payment is established. Purchases and sales of Current equity investments are accounted for on the trade date. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock>
    <gsk:DescriptionOfAccountingPolicyForOtherInvestmentExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other investments comprise equity investments and investments in limited life funds. The Group has elected to designate the majority of its equity investments as measured at FVTOCI. They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Investments in limited life funds are measured at FVTPL. They are initially recorded at fair value and then remeasured at subsequent reporting dates to fair value. Unrealised gains and losses are recognised in the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Dividends on equity investments and distributions from funds are recognised in the income statement when the Group&#x2019;s right to receive payment is established. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Purchases and sales of Other investments are accounted for on the trade date. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForOtherInvestmentExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade receivables are measured in accordance with the business model under which each portfolio of trade receivables is held. The Group has portfolios in each of the three business models under IFRS 9: to collect the contractual cash flows where there is no factoring agreement in place (measured at amortised cost), to sell the contractual cash flows where the trade receivables will be sold under a factoring agreement (measured at FVTPL), and both to collect and to sell the contractual cash flows where the trade receivables may be sold under a factoring arrangement (measured at FVTOCI). Trade receivables measured at amortised cost are carried at the original invoice amount less allowances for expected credit losses. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether, and the extent to which, settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Subsequent recoveries of amounts previously provided for or written off are credited to the income statement. Long-term receivables are discounted where the effect is material. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <gsk:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Cash held in deposit accounts is measured at amortised cost. Investments in money market funds are held at fair value through profit or loss because the funds fail the solely payments of principal and interest (SPPI) test. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Borrowings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by GSK are foreign currency swaps, interest rate swaps, foreign exchange forward contracts and options. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivative financial assets and liabilities, including derivatives embedded in host contracts which have been separated from the host contract, are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-for-trading&lt;/div&gt;&lt;/div&gt; and are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedge accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivatives designated as hedging instruments are classified at inception of hedge relationship as cash flow hedges, net investment hedges or fair value hedges. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective and accumulated in the cash flow hedge reserve. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in the cash flow hedge reserve are reclassified to the income statement when the hedged item affects profit or loss, or if the hedged forecast transaction is to purchase a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; asset, the amount deferred in the cash flow hedge reserve is transferred directly from equity and included in the carrying value of the recognised &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; asset. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Net investment hedges are accounted for in a similar way to cash flow hedges which are reclassified to the income statement when the hedged item affects profit or loss. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Taxation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Current tax is provided at the amounts expected to be paid, applying tax rates that have been enacted or substantively enacted by the balance sheet date. The tax charge for the period is recognised in the income statement, the statement of comprehensive income or directly in equity, according to the accounting treatment of the related transaction. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company and its subsidiaries intend to settle their current tax assets and liabilities on a net basis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax assets and liabilities are not recognised if the temporary differences arise from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction (other than a business combination) that affects neither the accounting nor the taxable profit or loss. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where an uncertain tax position is identified, management will make a judgement as to what the probable outcome will be, assuming the relevant tax authority has full knowledge of the situation. Where it is assessed that an economic outflow is probable to arise, a provision is made for the best estimate of the liability. In estimating any such liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <gsk:DescriptionOfAccountingPolicyForDiscountingExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Discounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where the time value of money is material, balances are discounted to current values using appropriate discount rates. The unwinding of the discounts is recorded in finance income and finance expense. &lt;/div&gt;</gsk:DescriptionOfAccountingPolicyForDiscountingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets and liabilities held for sale or distribution and discontinued operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Disposal groups are classified as held for sale or distribution if their carrying amount will be recovered principally through sale or a distribution to shareholders rather than through continuing use, they are available for sale or distribution in their present condition and the sale or distribution is considered highly probable. Assets held in Assets held for sale or distribution are measured at the lower of their carrying amount and fair value less costs to sell or distribute. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets included in Assets held for sale or distribution are not depreciated or amortised. Assets and liabilities classified as held for sale or distribution are presented in current assets and current liabilities separately from the other assets and liabilities in the balance sheet. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A discontinued operation is a component of the Group that has been disposed of, distributed or is classified as held for sale or distribution and that represents a separate major line of business. The results of discontinued operations are presented separately in the Consolidated income statement, the Consolidated statement of other comprehensive income and the Consolidated statement of cash flows and comparatives are restated on a consistent basis. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Critical accounting judgements and key sources of&lt;br/&gt; estimation uncertainty &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In preparing the financial statements, management is required to make judgements about when or how items should be recognised in the financial statements and estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. The following are considered to be the critical accounting judgements and key sources of estimation uncertainty. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Reported Group turnover for 2022 was &#xa3;29,324&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;24,696 million). &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Gross turnover is reduced by rebates, discounts, allowances and product returns given or expected to be given, which vary by product arrangements and buying groups. These arrangements with purchasing organisations are dependent upon the submission of claims some time after the initial recognition of the sale. Accruals are made at the time of sale for the estimated rebates, discounts or allowances payable or returns to be made, based on available market information and historical experience. &lt;/div&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10.5pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Sales of pharmaceutical and vaccine products in the US have complex arrangements for rebates, discounts and allowances. Turnover of Commercial Operations products in the US for 2022 of &#xa3;14,542&#160;million (2021: &#xa3;11,914 million) was after recording deductions of &#xa3;15,272&#160;million (2021: &#xa3;12,518 million) for rebates, allowances, returns and other discounts. At 31&#160;December 2022, the total accrual amounted to &#xa3;5,855&#160;million (2021: &#xa3;5,044 million). Due to the nature of these accruals it is not practicable to give meaningful sensitivity estimates due to the large volume of variables that contribute to the overall rebates, chargebacks, returns and other revenue accruals. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;As there can be significant variability in final outcomes, the Group applies a constraint when measuring the variable element within revenue, so that revenue is recognised at a suitably cautious amount. The objective of the constraint is to ensure that it is highly probable that a significant reversal of revenue will not occur when the uncertainties are resolved. The constraint is applied by making suitably cautious estimates of the inputs and assumptions used in estimating the variable consideration. Because the amounts are estimated they may not fully reflect the final outcome, and the amounts are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The constraints applied in recognising revenue mean that the risk of a material downward adjustment to revenue in the next financial year is low. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The level of accrual for rebates and returns is reviewed and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Market conditions are evaluated using wholesaler and other third-party analyses, market research data and internally generated information. It is reasonably possible that there could be a significant adjustment within the next 12 months to recognise additional revenue, if actual outcomes are better than the cautious constrained estimates. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The amount of turnover recognised in the year from performance obligations satisfied in previous periods is set out in Note&#160;6, &#x2018;Turnover and segment information&#x2019;, and is an indication of the level of sensitivity in the estimate. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Future events could cause the assumptions on which the accruals are based to change, which could materially affect the future results of the Group. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Taxation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The tax charge for the year was &#xa3;707&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;83 million). At December 2022, current tax payable was &#xa3;471&#160;million (2021: &#xa3;489 million), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; corporation tax payable was &#xa3;127&#160;million (2021: &#xa3;180 million) and current tax recoverable was &#xa3;405&#160;million (2021: &#xa3;486&#160;million). &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has open tax issues with a number of revenue authorities. Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the outcome of the dispute. If insufficient information is available, no provision is made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;If sufficient information is available, in estimating a potential tax liability GSK applies a risk-based approach which takes into account, as appropriate, the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. These estimates take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the Group had recognised provisions of &#xa3;551&#160;million in respect of uncertain tax positions (2021: &#xa3;858 million). Due to the number of uncertain tax positions held and the number of jurisdictions to which these relate, it is not practicable to give meaningful sensitivity estimates. No uncertain tax position is individually significant to the Group. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Factors affecting the tax charge in future years are set out in Note 14, &#x2018;Taxation&#x2019;. GSK continues to believe that it has made adequate provision for the liabilities likely to arise from open assessments. Where open issues exist, the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of negotiations with the relevant tax authorities or, if necessary, litigation proceedings. &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10.5pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 comparative results have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see page 238). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and other disputes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Legal costs for the year were &#xa3;144&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;50 million). At 31&#160;December 2022 provisions for legal and other disputes amounted to &#xa3;218&#160;million (2021: &#xa3;196 million). &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Management makes a judgement of whether there is sufficient information to be able to make a reliable estimate of the likely outcome of the dispute and the legal and other expenses arising from claims against the Group. If insufficient information is available, no provision is made and disclosure of the claim is given. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The estimated provisions take into account the specific circumstances of each dispute and relevant external advice, are inherently judgemental and could change substantially over time as each dispute progresses and new facts emerge. Details of the status and various uncertainties involved in the significant unresolved disputes are set out in Note 47, &#x2018;Legal proceedings&#x2019;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The company&#x2019;s Directors, having taken legal advice, have established provisions after taking into account the relevant facts and circumstances of each matter and in accordance with accounting requirements. In respect of product liability claims related to certain products, there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group may become involved in legal proceedings, in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability. In these cases, appropriate disclosure about such cases would be provided, but no provision would be made and no contingent liability can be quantified. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. The position could change over time and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions reported in the Group&#x2019;s financial statements by a material amount. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The 2022 income statement charge for contingent consideration was &#xa3;1,645&#160;million (2021: &#xa3;1,063 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the liability for contingent consideration amounted to &#xa3;7,068&#160;million (2021: &#xa3;6,076 million). Of this amount, &#xa3;5,890&#160;million (2021: &#xa3;5,559 million) related to the acquisition of the former Shionogi-ViiV Healthcare joint venture in 2012. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Any contingent consideration included in the consideration payable for a business combination is recorded at fair value at the date of acquisition. These fair values are generally based on risk-adjusted future cash flows discounted using appropriate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; discount rates. The fair values are reviewed on a regular basis, at least annually, and any changes are reflected in the income statement. See Note 33, &#x2018;Contingent consideration liabilities&#x2019;. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pensions and other post-employment benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Judgement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Where a surplus on a defined benefit scheme arises, or there is potential for a surplus to arise from committed future contributions, the rights of the Trustees to prevent the Group obtaining a refund of that surplus in the future are considered in determining whether it is necessary to restrict the amount of the surplus that is recognised. Two UK schemes are in surplus (2021: three UK schemes), with a combined surplus of &#xa3;109&#160;million at 31&#160;December 2022 (2021: &#xa3;606 million). There are further recognised pension surpluses totalling &#xa3;120&#160;million spread across five countries (2021: &#xa3;135&#160;million across six countries). GSK has made the judgement that these amounts meet the requirements of recoverability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of providing pensions and other post-employment benefits are assessed on the basis of assumptions selected by management. These assumptions include future earnings and pension increases, discount rates, expected long-term rates of return on assets and mortality rates, and are disclosed in Note 31, &#x2018;Pensions and other post-employment benefits&#x2019;. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. A sensitivity analysis is provided in Note 31, &#x2018;Pensions and other post-employment benefits&#x2019;, a 0.25% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#xa3;424&#160;million and an increase in the annual pension cost of approximately &#xa3;19&#160;million. Similarly, a 0.25% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#xa3;400&#160;million and a decrease in the annual pension cost of approximately &#xa3;19&#160;million. A 0.75% reduction in the discount rate would lead to an increase in the net pension deficit of approximately &#xa3;1,341&#160;million and an increase in the annual pension cost of approximately &#xa3;52&#160;million. Similarly, a 0.75% increase in the discount rate would lead to a decrease in the net pension deficit of approximately &#xa3;1,147&#160;million and a decrease in the annual pension cost of approximately &#xa3;60&#160;million. The selection of different assumptions could affect the future results of the Group. &lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">14542000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">11914000000</ifrs-full:Revenue>
    <gsk:CustomerReturnsDiscountsAndRebates
      contextRef="P01_01_2022To12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">15272000000</gsk:CustomerReturnsDiscountsAndRebates>
    <gsk:CustomerReturnsDiscountsAndRebates
      contextRef="P01_01_2021To12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">12518000000</gsk:CustomerReturnsDiscountsAndRebates>
    <gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment
      contextRef="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">5855000000</gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment>
    <gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment
      contextRef="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">5044000000</gsk:CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">471000000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">489000000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">127000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">180000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">405000000</ifrs-full:CurrentTaxAssets>
    <ifrs-full:CurrentTaxAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">486000000</ifrs-full:CurrentTaxAssets>
    <gsk:UncertainTaxPositionsRecognised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">551000000</gsk:UncertainTaxPositionsRecognised>
    <gsk:UncertainTaxPositionsRecognised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">858000000</gsk:UncertainTaxPositionsRecognised>
    <gsk:LegalCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">144000000</gsk:LegalCosts>
    <gsk:LegalCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">50000000</gsk:LegalCosts>
    <ifrs-full:LegalProceedingsProvision
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:LegalProceedingsProvision>
    <ifrs-full:LegalProceedingsProvision
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">196000000</ifrs-full:LegalProceedingsProvision>
    <gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1645000000</gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities>
    <gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1063000000</gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5890000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5559000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:DefinedBenefitPlanSurplusNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">109000000</gsk:DefinedBenefitPlanSurplusNet>
    <gsk:DefinedBenefitPlanSurplusNet
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">606000000</gsk:DefinedBenefitPlanSurplusNet>
    <gsk:PensionSurplus
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">120000000</gsk:PensionSurplus>
    <gsk:PensionSurplus
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">135000000</gsk:PensionSurplus>
    <gsk:PercentageOfDecreaseInDiscountRate
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</gsk:PercentageOfDecreaseInDiscountRate>
    <gsk:IncreaseInPlanDeficit
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">424000000</gsk:IncreaseInPlanDeficit>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:PercentageOfIncreaseInDiscountRate
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</gsk:PercentageOfIncreaseInDiscountRate>
    <gsk:DecreaseInPlanDeficit
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">400000000</gsk:DecreaseInPlanDeficit>
    <gsk:DecreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionPercentageRateChangeMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:DecreaseInAnnualPensionCost>
    <gsk:PercentageOfDecreaseInDiscountRate
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0075</gsk:PercentageOfDecreaseInDiscountRate>
    <gsk:IncreaseInPlanDeficit
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1341000000</gsk:IncreaseInPlanDeficit>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:PercentageOfIncreaseInDiscountRate
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0075</gsk:PercentageOfIncreaseInDiscountRate>
    <gsk:DecreaseInPlanDeficit
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1147000000</gsk:DecreaseInPlanDeficit>
    <gsk:DecreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMemberGSKActuarialAssumptionPercentageRateAxis_SensitivityAnalysisForActuarialAssumptionsMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</gsk:DecreaseInAnnualPensionCost>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. New accounting requirements&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Amendments to accounting standards issued by the IASB and adopted in the year ended 31&#160;December 2022 did not have a material impact on the results or financial position of the Group.&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 31&#160;December 2022 reporting periods and have not been adopted early by the Group. These standards, amendments and interpretations are not expected to have a material impact on the results or financial position of the Group in future reporting periods.&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Exchange rates &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group uses the average of exchange rates prevailing during the period to translate the results and cash flows of overseas subsidiaries, joint ventures and associates into Sterling and period end rates to translate the net assets of those entities. The currencies which most influence these translations and the relevant exchange rates were: &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Average rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US$/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Euro/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Yen/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Period end rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US$/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Euro/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Yen/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <gsk:SignificantCurrenciesAndTheRelevantExchangeRates contextRef="P01_01_2022To12_31_2022">The currencies which most influence these translations and the relevant exchange rates were:
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Average rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US$/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Euro/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Yen/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Period end rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US$/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Euro/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Yen/&#xa3;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:SignificantCurrenciesAndTheRelevantExchangeRates>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.24</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.38</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2020To12_31_2020_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.29</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.17</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.16</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2020To12_31_2020_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.13</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">161</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">151</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2020To12_31_2020_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">137</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.2</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.35</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2020_USDsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.36</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.13</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.19</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2020_EURsrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.11</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2022_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">159</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2021_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">155</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn12_31_2020_JPYsrtCurrencyAxis"
      decimals="0"
      unitRef="Unit_pure">141</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Turnover and segment information &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the GSK Leadership Team (GLT). GSK has revised its operating segments from Q1 2022 and from Q2 2022. Previously GSK reported results under four segments: Pharmaceuticals, Pharmaceuticals R&amp;amp;D, Vaccines and Consumer Healthcare. For the first quarter 2022, GSK reported results under three segments: Commercial Operations, Total R&amp;amp;D and Consumer Healthcare. From Q2 2022, GSK reports under two segments from continuing operations as the demerger of the Consumer Healthcare segment was completed on 18&#160;July 2022. Members of the GLT are responsible for each segment. Comparative information has been retrospectively revised on a consistent basis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;R&amp;amp;D investment is essential for the sustainability of the business. However for segment reporting the Commercial Operating profits exclude allocations of globally funded R&amp;amp;D. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Total R&amp;amp;D segment is the responsibility of the Chief Scientific Officer and is reported as a separate segment. The operating costs of this segment includes R&amp;amp;D activities across Specialty Medicines, including HIV and Vaccines. It includes R&amp;amp;D and some SG&amp;amp;A costs relating to regulatory and other functions. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s management reporting process allocates intra-Group profit on a product sale to the segment in which that sale is recorded, and the profit analyses below have been presented on that basis. &lt;/div&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover by segment&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,232&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;122&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#x2019;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;This business was excluded from the Consumer Healthcare Joint Venture but was included in the Consumer Healthcare segment performance in 2020. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For 2022, product sales are reported within three product groups: Specialty Medicines, Vaccines and General Medicines. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial Operations:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;HIV&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,749&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,777&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,876&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Oncology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;602&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;489&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;372&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immuno-inflammation,&lt;/div&gt; respiratory and other&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,609&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,027&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,721&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,960&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,293&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pandemic&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,309&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;958&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Specialty Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,269&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Meningitis&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,116&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;961&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,029&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Influenza&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;714&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;679&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;733&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Shingles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,958&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,721&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,989&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Established Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,085&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,970&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,231&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,873&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,331&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pandemic Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;447&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,937&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Respiratory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,548&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,048&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,006&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other General Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,570&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,619&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,275&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;General Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,118&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,667&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,281&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Commercial Operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,232&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;122&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been revised to reflect the Commercial Operations segment.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;During 2022, sales were made to three US wholesalers of &#xa3;4,045&#160;million (2021: &#xa3;3,159&#160;million; 2020: &#xa3;2,928 million), &#xa3;4,161&#160;million (2021: &#xa3;3,081&#160;million; 2020: &#xa3;3,085 million) and &#xa3;3,227&#160;million (2021: &#xa3;2,670&#160;million; 2020: &#xa3;2,795 million) respectively, after allocating &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;final-customer&lt;/div&gt; discounts to the wholesalers. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;Revenue recognised in the year from performance obligations satisfied in previous periods totalled &#xa3;1,601&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px"&gt;(1)&lt;/div&gt;: &#xa3;1,438 million) including &#xa3;898&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px"&gt;(1)&lt;/div&gt;: &#xa3;949 million) impacting turnover arising from changes to prior year estimates of RAR (returns and rebates) accruals, &#xa3;115&#160;million (2021: &#xa3;61 million) of milestone income and &#xa3;588&#160;million (2021: &#xa3;428 million) of royalty income recognised in the current year. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment profit&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,590&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,297&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,060&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,955&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(379&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment profit and operating profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(2,136&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(677&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Operating profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,433&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(879&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Loss on disposal of interest in associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits/(losses) of associates and joint ventures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before taxation from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,599&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(67&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation for the year from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;3,516&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#x2019;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed company. GSK completed the divestment of Bangladesh on 30&#160;June 2020. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other reconciling items between segment profit and operating profit comprise items not specifically allocated to segment profit. These include impairment and amortisation of intangible assets; major restructuring costs, which include impairments of tangible assets and computer software; transaction-related adjustments related to significant acquisitions; proceeds and costs of disposals of products and businesses, significant legal charges and expenses on the settlement of litigation and government investigations, other operating income other than royalty income and other items. Please refer to the detail of Other reconciling items between segment profit and operating profit in the analysis of adjusting items (Group financial review). &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation and amortisation by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;378&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;739&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;761&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,147&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;2,050&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PP&amp;amp;E, intangible asset and goodwill impairment by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;87&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;124&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment impairment and total impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;420&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;583&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;501&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;540&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;712&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PP&amp;amp;E and intangible asset impairment reversals by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment impairment reversals and total impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(35&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(26&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 7.5pt; width: 742.547px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility: hidden; line-height: 0pt; color: white;"&gt;
&lt;td style="width: 542.188px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.875px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.3125px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.32812px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 6.5pt;"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating assets by segment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(revised)&lt;div style="font-size: 6.5px; vertical-align: top;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,288&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,440&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,299&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,461&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,587&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;264&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,504&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,208&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,851&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,613&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Investments in associates and joint ventures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current Equity Investment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,087&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current and deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,176&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,479&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Assets held for sale (excluding cash and cash equivalents)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;22&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,096&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,342&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Commercial Operations segment includes the Shionogi-ViiV Healthcare contingent consideration liability of &#xa3;5,890&#160;million (2021: &#xa3;5,559 million) and the Pfizer put option of &#xa3;1,093&#160;million (2021: &#xa3;1,008 million). &lt;/div&gt;  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Geographical information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The UK is regarded as being the Group&#x2019;s country of domicile. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover by location of customer&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;695&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;656&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;659&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,542&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,914&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,148&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,087&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,547&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;External turnover&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets by location of subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,134&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,618&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,852&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Belgium&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,415&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,552&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,559&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,390&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,166&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;51,477&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; receivables. There are no other countries with individually material external revenue or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been revised to reflect the new segments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments contextRef="P01_01_2022To12_31_2022">GSK has revised its operating segments from Q1 2022 and from Q2 2022. Previously GSK reported results under four segments: Pharmaceuticals, Pharmaceuticals R&amp;D, Vaccines and Consumer Healthcare. For the first quarter 2022, GSK reported results under three segments: Commercial Operations, Total R&amp;D and Consumer Healthcare. From Q2 2022, GSK reports under two segments from continuing operations as the demerger of the Consumer Healthcare segment was completed on 18&#160;July 2022.</ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments>
    <gsk:NumberOfReportableOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Segments">4</gsk:NumberOfReportableOperatingSegments>
    <gsk:NumberOfOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Segments">2</gsk:NumberOfOperatingSegments>
    <gsk:DisclosureOfTurnoverBySegmentExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover by segment&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,232&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;122&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfTurnoverBySegmentExplanatory>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24232000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">122000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">24354000000</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfProductsAndServicesExplanatory contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial Operations:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;HIV&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,749&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,777&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,876&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Oncology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;602&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;489&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;372&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immuno-inflammation,&lt;/div&gt; respiratory and other&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,609&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,027&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,721&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,960&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,293&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pandemic&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,309&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;958&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Specialty Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,269&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,969&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Meningitis&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,116&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;961&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,029&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Influenza&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;714&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;679&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;733&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Shingles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,958&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,721&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,989&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Established Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,085&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,970&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,231&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,873&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,331&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pandemic Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;447&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,937&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Respiratory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,548&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,048&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,006&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other General Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,570&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,619&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,275&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;General Medicines&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,118&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,667&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,281&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Commercial Operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,232&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;122&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been revised to reflect the Commercial Operations segment.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfProductsAndServicesExplanatory>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5749000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4777000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_HIVMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4876000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">602000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">489000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">372000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2609000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2027000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ImmunoInflammationRespiratoryAndOtherMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1721000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">8960000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7293000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6969000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2309000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">958000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">11269000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">8251000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SpecialtyMedicineMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6969000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1116000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">961000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_MeningitisMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1029000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">714000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">679000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_InfluenzaMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">733000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2958000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1721000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_ShinglesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1989000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3085000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2970000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_EstablishedVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3231000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7873000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6331000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_SubTotalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">64000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">447000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_PandemicVaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7937000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6778000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_VaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6548000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6048000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6006000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3570000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3619000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OtherGeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4275000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10118000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9667000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_GeneralMedicinesMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10281000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24232000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">122000000</ifrs-full:Revenue>
    <gsk:NumberOfWholesalers
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="INF"
      unitRef="Unit_wholesalers">3</gsk:NumberOfWholesalers>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">4045000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">3159000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">2928000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">4161000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">3081000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">3085000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">3227000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">2670000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_Wholesalers3MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_GBP">2795000000</ifrs-full:Revenue>
    <ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1601000000</ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods>
    <ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1438000000</ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods>
    <gsk:RevenueFromChangesToEstimatesOfRARAccruals
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">898000000</gsk:RevenueFromChangesToEstimatesOfRARAccruals>
    <gsk:RevenueFromChangesToEstimatesOfRARAccruals
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">949000000</gsk:RevenueFromChangesToEstimatesOfRARAccruals>
    <gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">115000000</gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods>
    <gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">61000000</gsk:MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods>
    <gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">588000000</gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods>
    <gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">428000000</gsk:RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment profit&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,590&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,297&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,060&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,955&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(379&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment profit and operating profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(2,136&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(677&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total Operating profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,433&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(879&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Loss on disposal of interest in associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits/(losses) of associates and joint ventures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before taxation from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,599&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;(67&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation for the year from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;3,516&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt;
&lt;td colspan="4" style="height:3pt"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation and amortisation by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;378&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;739&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;761&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and amortisation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,147&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;2,050&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PP&amp;amp;E, intangible asset and goodwill impairment by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;87&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;124&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment impairment and total impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;420&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;583&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total impairment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;501&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;540&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;712&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PP&amp;amp;E and intangible asset impairment reversals by segment&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other reconciling items between segment impairment reversals and total impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(35&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total impairment reversals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(26&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 7.5pt; width: 742.547px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility: hidden; line-height: 0pt; color: white;"&gt;
&lt;td style="width: 542.188px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.875px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.3125px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6.32812px;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 6.5pt;"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating assets by segment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(revised)&lt;div style="font-size: 6.5px; vertical-align: top;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,288&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,440&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,299&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,461&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Segment net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,587&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate and other unallocated net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;264&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,504&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,208&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="font-family: ARIAL; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,851&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,613&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:9.75pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Investments in associates and joint ventures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current Equity Investment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,087&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current and deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,176&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,479&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Assets held for sale (excluding cash and cash equivalents)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;22&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="1" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="height:3pt"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,096&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,342&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">13590000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">11467000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">11297000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5060000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4567000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4397000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">8530000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">6900000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">6955000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-379000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-407000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-299000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1718000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2136000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">-677000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6433000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4357000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5979000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">879000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">769000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">874000000</ifrs-full:FinanceCosts>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnDisposalOfInterestInAssociate>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5628000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3599000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5170000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4921000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3516000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5103000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">829000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">915000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">904000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">467000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">378000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">355000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1296000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1293000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1259000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">112000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">68000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">739000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">761000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">724000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2147000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2122000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2050000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">87000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">85000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">124000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">420000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">392000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">583000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">501000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">540000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">712000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_MaterialReconcilingItemsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">35000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">26000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">54000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">10288000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021_CommercialOperationsMemberifrsfullSegmentsAxis_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">9440000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7299000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3461000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">17587000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021_OperatingSegmentsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">12901000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">264000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021_UnallocatedAmountsMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">1504000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25208000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17851000000</gsk:NetOperatingAssets>
    <gsk:NetOperatingAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">39613000000</gsk:NetOperatingAssets>
    <ifrs-full:NetDebt
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17197000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:NetDebt>
    <gsk:InvestmentsInJointVenturesAndAssociates
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">74000000</gsk:InvestmentsInJointVenturesAndAssociates>
    <gsk:InvestmentsInJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">88000000</gsk:InvestmentsInJointVenturesAndAssociates>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4087000000</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:DerivativeFinancialLiabilities>
    <gsk:CurrentAndDeferredTaxation
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5176000000</gsk:CurrentAndDeferredTaxation>
    <gsk:CurrentAndDeferredTaxation
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1479000000</gsk:CurrentAndDeferredTaxation>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10096000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21342000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_ShionogiViivHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5890000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_ShionogiViivHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5559000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:PutOption
      contextRef="PAsOn12_31_2022_PfizerMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1093000000</gsk:PutOption>
    <gsk:PutOption
      contextRef="PAsOn12_31_2021_PfizerMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1008000000</gsk:PutOption>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Geographical information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The UK is regarded as being the Group&#x2019;s country of domicile. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Turnover by location of customer&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(revised)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;695&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;656&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;659&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,542&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,914&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,148&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,087&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,547&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;External turnover&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,696&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 7.5pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets by location of subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0px; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,134&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,618&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,852&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Belgium&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,415&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,552&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,559&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,390&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align: top; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,166&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(231, 231, 232); border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;51,477&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; receivables. There are no other countries with individually material external revenue or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: ARIAL; font-size: 6.5pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been revised to reflect the new segments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">695000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">656000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">659000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">14542000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">11914000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">11148000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">14087000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">12126000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">12547000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">29324000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">24696000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_CustomerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">24354000000</ifrs-full:Revenue>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">5134000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">6618000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">14024000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">17852000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022_BEifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">5415000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021_BEifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">5065000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022_CHifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021_CHifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">6552000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">6559000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">15390000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">31166000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">51477000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Other operating income/(expense) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Upfront settlement income&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;922&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value remeasurements of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;256&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposal of businesses and assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;552&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value remeasurements on contingent consideration recognised in business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement of ViiV Healthcare put option liabilities and preferential dividends&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value adjustments on derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(235&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(504&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,463&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:14.25pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:14.25pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#x2019;s Biktarvy concerning ViiV Healthcare&#x2019;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#xa3;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#x2019;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Fair value remeasurement on equity investments in 2022 included a gain/loss of &#xa3;229&#160;million from the remeasurement of the Group&#x2019;s retained investment in Haleon plc to fair value at 31&#160;December 2022 from the initial recognition fair value &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(five-day&lt;/div&gt; average share price after the demerger). See details in Note 22. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Disposal of businesses and assets in 2022 includes milestone income and the reversal of provisions no longer required. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Disposal of businesses and assets in 2021 included a net gain on disposal of the rights to the royalty stream for cabozantinib and a net gain on disposal of the cephalosporin antibiotic brands to Sandoz. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Disposal of businesses and assets in 2020 included a net profit on disposal of the Horlicks and other Consumer Healthcare nutritional brands and two subsidiaries in India and Bangladesh of &#xa3;2,815&#160;million, which reflected reversal of &#xa3;240&#160;million of embedded derivative gains on the value of the shares taken in prior years. This was partly offset by the related &#xa3;476&#160;million loss on the shares in Hindustan Unilever Limited, including fair value remeasurement losses between their acquisition as consideration for the divestment of GSK Consumer Healthcare Limited in India and their subsequent disposal. Other operating income also included an increase in profit and milestone income from a number of asset disposals. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Fair value remeasurements on contingent consideration recognised as business combinations included &#xa3;1,431&#160;million related to the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#xa3;193&#160;million payable to Novartis related to the Vaccines acquisition, together with fair value movements on related hedging contracts. &lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Upfront settlement income&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;922&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value remeasurements of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;256&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposal of businesses and assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;552&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value remeasurements on contingent consideration recognised in business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement of ViiV Healthcare put option liabilities and preferential dividends&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value adjustments on derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(235&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(504&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,463&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:14.25pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:14.25pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#x2019;s Biktarvy concerning ViiV Healthcare&#x2019;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#xa3;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#x2019;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory>
    <gsk:UpfrontSettlementIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      id="Fact_69050196"
      unitRef="Unit_GBP">922000000</gsk:UpfrontSettlementIncome>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">256000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045263"
      unitRef="Unit_GBP">37000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045264"
      unitRef="Unit_GBP">-6000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments>
    <gsk:DisposalOfBusinessesAndAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">215000000</gsk:DisposalOfBusinessesAndAssets>
    <gsk:DisposalOfBusinessesAndAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045266"
      unitRef="Unit_GBP">552000000</gsk:DisposalOfBusinessesAndAssets>
    <gsk:DisposalOfBusinessesAndAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045267"
      unitRef="Unit_GBP">2621000000</gsk:DisposalOfBusinessesAndAssets>
    <ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1607000000</ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045269"
      unitRef="Unit_GBP">-1058000000</ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045270"
      unitRef="Unit_GBP">-1286000000</ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-85000000</gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends>
    <gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045272"
      unitRef="Unit_GBP">-48000000</gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends>
    <gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045273"
      unitRef="Unit_GBP">52000000</gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045275"
      unitRef="Unit_GBP">-4000000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045276"
      unitRef="Unit_GBP">20000000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045278"
      unitRef="Unit_GBP">17000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045279"
      unitRef="Unit_GBP">62000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-235000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045281"
      unitRef="Unit_GBP">-504000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69045282"
      unitRef="Unit_GBP">1463000000</ifrs-full:OtherOperatingIncomeExpense>
    <gsk:UpfrontPayment
      contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-7"
      unitRef="Unit_USD">1250000000</gsk:UpfrontPayment>
    <gsk:UpfrontPayment
      contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">922000000</gsk:UpfrontPayment>
    <gsk:PercentageOfRoyaltyPayableOnFutureSales
      contextRef="PAsOn02_15_2022_GileadSciencesIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</gsk:PercentageOfRoyaltyPayableOnFutureSales>
    <gsk:GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">229000000</gsk:GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss>
    <gsk:DisposalOfBusinessesAndAssets
      contextRef="P01_01_2020To12_31_2020_ConsumerHealthcareMemberifrsfullSegmentsAxis_HorlicksMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2815000000</gsk:DisposalOfBusinessesAndAssets>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives
      contextRef="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <gsk:LossOnSaleOfBusiness
      contextRef="P01_01_2020To12_31_2020_HindustanUnileverLimitedMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">476000000</gsk:LossOnSaleOfBusiness>
    <ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1431000000</ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_NovartisMemberdeiLegalEntityAxis_VaccinesBusinessAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">193000000</ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Operating profit &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The following items have been included in operating profit:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employee costs (Note 9)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,693&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,680&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,555&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Advertising&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;735&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;433&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;361&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Distribution costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;192&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;176&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation of property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;885&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;855&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;822&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of property, plant and equipment, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;87&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation of right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;176&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;182&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;40&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,088&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,046&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of intangible assets, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;435&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;230&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of intangible assets held for sale, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of goodwill allocated to a disposal group, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net foreign exchange (gains)/losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventories:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of inventories included in cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,137&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,885&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,934&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;687&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;800&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;607&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of prior year write-down of inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(483&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(325&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(250&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Short-term lease charge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-value&lt;/div&gt; lease charge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variable lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fees payable to the company&#x2019;s auditor and its associates in relation to the Group (see below)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The reversals of prior year write-downs of inventories principally arise from the reassessment of usage or demand expectations prior to inventory expiration. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Net foreign exchange (gains)/losses include a net loss of &#xa3;2&#160;million (2021: &#xa3;35&#160;million gain; 2020: &#xa3;36&#160;million loss) arising from the recycling of exchange on liquidation or disposal of overseas subsidiaries. The recycling of exchange on disposal of overseas associates of a loss of &#xa3;nil (2021: &#xa3;10 million) is reported through loss on disposal of interest in associates. The recycling of exchange on disposal of overseas subsidiaries does not include recycling of exchange on disposal of Consumer Healthcare subsidiaries as this is reported as Profit after taxation on demerger of discontinued operations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Included within operating profit are Major restructuring charges of &#xa3;321&#160;million (2021: &#xa3;424&#160;million; 2020: &#xa3;1,178 million), see Note 10, &#x2018;Major restructuring costs&#x2019;. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fees payable to the company&#x2019;s auditor and its associates:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit of the company&#x2019;s subsidiaries&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total audit services&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit-related and other assurance services&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total audit services, audit-related and other assurance services&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The other assurance services provided by the auditor related to agreed upon procedures and other assurance services outside of statutory audit requirements. In addition to the above, fees paid to the auditor in respect of the GSK pension schemes were: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There were immaterial fees of &#xa3;0.1&#160;million paid in 2022 (versus 2021: &#xa3;nil; 2020 &#xa3;0.2 million) to other auditors in respect of audits of certain of the company&#x2019;s subsidiaries. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Audit related and other assurance services include &#xa3;4.4&#160;million (2021: &#xa3;2.4 million) due to reporting accountant work performed in preparation for the Consumer Healthcare demerger. &lt;/div&gt;&lt;div style="font-size:36pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:14.25pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory>
    <gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The following items have been included in operating profit:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employee costs (Note 9)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,693&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,680&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,555&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Advertising&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;735&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;433&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;361&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Distribution costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;192&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;176&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation of property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;885&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;855&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;822&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of property, plant and equipment, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;87&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation of right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;176&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;182&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;40&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,088&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,046&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of intangible assets, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;435&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;230&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of intangible assets held for sale, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of goodwill allocated to a disposal group, net of reversals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net foreign exchange (gains)/losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventories:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of inventories included in cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,137&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,885&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,934&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;687&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;800&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;607&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of prior year write-down of inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(483&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(325&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(250&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Short-term lease charge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-value&lt;/div&gt; lease charge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variable lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fees payable to the company&#x2019;s auditor and its associates in relation to the Group (see below)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7693000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7680000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">8555000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AdvertisingExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">735000000</ifrs-full:AdvertisingExpense>
    <ifrs-full:AdvertisingExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">433000000</ifrs-full:AdvertisingExpense>
    <ifrs-full:AdvertisingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">361000000</ifrs-full:AdvertisingExpense>
    <ifrs-full:DistributionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">192000000</ifrs-full:DistributionCosts>
    <ifrs-full:DistributionCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">169000000</ifrs-full:DistributionCosts>
    <ifrs-full:DistributionCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">176000000</ifrs-full:DistributionCosts>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">885000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">855000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">822000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">70000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">87000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">424000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">176000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">179000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">182000000</ifrs-full:DepreciationRightofuseAssets>
    <gsk:ImpairmentOfRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">40000000</gsk:ImpairmentOfRightOfUseAssets>
    <gsk:ImpairmentOfRightOfUseAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:ImpairmentOfRightOfUseAssets>
    <gsk:ImpairmentOfRightOfUseAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ImpairmentOfRightOfUseAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1086000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1088000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1046000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <gsk:ImpairmentOfIntangibleAssetsNetOfReversal
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">365000000</gsk:ImpairmentOfIntangibleAssetsNetOfReversal>
    <gsk:ImpairmentOfIntangibleAssetsNetOfReversal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">435000000</gsk:ImpairmentOfIntangibleAssetsNetOfReversal>
    <gsk:ImpairmentOfIntangibleAssetsNetOfReversal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">230000000</gsk:ImpairmentOfIntangibleAssetsNetOfReversal>
    <gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale
      contextRef="P01_01_2022To12_31_2022"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale
      contextRef="P01_01_2021To12_31_2021"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale
      contextRef="P01_01_2020To12_31_2020"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-99000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6137000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5885000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5934000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:InventoryWritedown2011
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">687000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">800000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">607000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:ReversalOfInventoryWritedown
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">483000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">325000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">250000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:AuditorsRemuneration
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_GBP">26900000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_GBP">31700000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_GBP">29900000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">35000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="P01_01_2020To12_31_2020_LiquidationOrDisposalOfOverseasSubsidiaryMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <gsk:GainLossOnDisposalOfInterestInAssociates
      contextRef="P01_01_2022To12_31_2022_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnDisposalOfInterestInAssociates>
    <gsk:GainLossOnDisposalOfInterestInAssociates
      contextRef="P01_01_2021To12_31_2021_LiquidationOrDisposalOfInterestInAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:GainLossOnDisposalOfInterestInAssociates>
    <ifrs-full:ExpenseOfRestructuringActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">321000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">424000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1178000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fees payable to the company&#x2019;s auditor and its associates:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit of parent company and consolidated financial statements including attestation under s.404 of Sarbanes-Oxley Act 2002&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit of the company&#x2019;s subsidiaries&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total audit services&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit-related and other assurance services&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total audit services, audit-related and other assurance services&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2022To12_31_2022_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">10900000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2021To12_31_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">13200000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2020To12_31_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">13800000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2022To12_31_2022_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">9700000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2021To12_31_2021_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">14500000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2020To12_31_2020_SubsidiariesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">14500000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_GBP">20600000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_GBP">27700000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_GBP">28300000</ifrs-full:AuditorsRemunerationForAuditServices>
    <gsk:AuditorsRemunerationForOtherAssuranceServices
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_GBP">6300000</gsk:AuditorsRemunerationForOtherAssuranceServices>
    <gsk:AuditorsRemunerationForOtherAssuranceServices
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_GBP">4000000</gsk:AuditorsRemunerationForOtherAssuranceServices>
    <gsk:AuditorsRemunerationForOtherAssuranceServices
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_GBP">1600000</gsk:AuditorsRemunerationForOtherAssuranceServices>
    <gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_GBP">26900000</gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices>
    <gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_GBP">31700000</gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices>
    <gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_GBP">29900000</gsk:AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"> In addition to the above, fees paid to the auditor in respect of the GSK pension schemes were: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Audit&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-5"
      unitRef="Unit_GBP">200000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-5"
      unitRef="Unit_GBP">200000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-5"
      unitRef="Unit_GBP">200000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="P01_01_2022To12_31_2022_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-5"
      unitRef="Unit_GBP">100000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="P01_01_2021To12_31_2021_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="P01_01_2020To12_31_2020_OtherAuditorsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-5"
      unitRef="Unit_GBP">200000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:AuditorsRemunerationForOtherServices
      contextRef="P01_01_2022To12_31_2022_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis"
      decimals="-5"
      unitRef="Unit_GBP">4400000</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices
      contextRef="P01_01_2021To12_31_2021_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMemberGSKPurposeAxis"
      decimals="-5"
      unitRef="Unit_GBP">2400000</ifrs-full:AuditorsRemunerationForOtherServices>
    <gsk:DisclosureOfEmployeeCostsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Employee costs &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,110&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension and other post-employment costs, including augmentations (Note 31)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of share-based incentive plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;314&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Severance and other costs from integration and restructuring activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;137&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,693&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7,680&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8,555&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group provides benefits to employees, commensurate with local practice in individual countries, including in some markets, healthcare insurance, subsidised car schemes and personal life assurance. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The cost of share-based incentive plans is analysed as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share Value Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;243&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Performance Share Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share option plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash settled and other plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;314&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average number of persons employed by the Group (including Directors) during the year: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; Number&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; Number&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Manufacturing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,946&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,642&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,909&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,542&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,874&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,744&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total Continuing Operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,130&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,345&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73,257&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discontinued Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21,292&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,616&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,628&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91,961&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,885&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Note: Consumer Healthcare divested on 18 July 2022 is shown as Discontinued Operations in the above table. &lt;/div&gt;  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average monthly number of Group employees excludes temporary and contract staff. The numbers of Group employees at the end of each financial year are given in the financial record on page 277. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The compensation of the Directors and senior management (members of the GLT) in aggregate, was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension and other post-employment costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of share-based incentive plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Further information on the remuneration of the Directors is given in the sections of the Annual Report on remuneration labelled as audited within pages 133 to 164. &lt;/div&gt; &lt;div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; </gsk:DisclosureOfEmployeeCostsExplanatory>
    <gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,110&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension and other post-employment costs, including augmentations (Note 31)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of share-based incentive plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;314&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Severance and other costs from integration and restructuring activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;137&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,693&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7,680&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8,555&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6110000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5858000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6464000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">763000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">793000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">775000000</ifrs-full:SocialSecurityContributions>
    <gsk:PostEmploymentBenefitExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">369000000</gsk:PostEmploymentBenefitExpense>
    <gsk:PostEmploymentBenefitExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">415000000</gsk:PostEmploymentBenefitExpense>
    <gsk:PostEmploymentBenefitExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">466000000</gsk:PostEmploymentBenefitExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">314000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">345000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">330000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">137000000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">269000000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">520000000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7693000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7680000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">8555000000</ifrs-full:EmployeeBenefitsExpense>
    <gsk:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The cost of share-based incentive plans is analysed as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share Value Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;243&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Performance Share Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share option plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash settled and other plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;314&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">243000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">258000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">266000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">51000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_CashSettledAndOtherPlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">314000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">345000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">330000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <gsk:DisclosureOfNumberOfEmployeesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average number of persons employed by the Group (including Directors) during the year: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; Number&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; Number&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Manufacturing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,946&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,642&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,909&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,542&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,874&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,744&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total Continuing Operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,130&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,345&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73,257&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discontinued Operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21,292&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,616&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,628&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91,961&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,885&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Note: Consumer Healthcare divested on 18 July 2022 is shown as Discontinued Operations in the above table. &lt;/div&gt; </gsk:DisclosureOfNumberOfEmployeesExplanatory>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_ManufacturingMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">22946</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021_ManufacturingMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">23562</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_ManufacturingMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">24536</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">34642</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">36909</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_SellingGeneralAndAdministrationMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">37977</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">11542</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">10874</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="0"
      unitRef="Unit_Employee">10744</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Employee">69130</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_Employee">71345</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_Employee">73257</gsk:AverageNumberOfEmployeesFromContinuingOperations>
    <gsk:AverageNumberOfEmployeesFromDiscontinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Employee">21292</gsk:AverageNumberOfEmployeesFromDiscontinuingOperations>
    <gsk:AverageNumberOfEmployeesFromDiscontinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_Employee">20616</gsk:AverageNumberOfEmployeesFromDiscontinuingOperations>
    <gsk:AverageNumberOfEmployeesFromDiscontinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_Employee">22628</gsk:AverageNumberOfEmployeesFromDiscontinuingOperations>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Employee">90422</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_Employee">91961</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_Employee">95885</ifrs-full:AverageNumberOfEmployees>
    <gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The compensation of the Directors and senior management (members of the GLT) in aggregate, was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension and other post-employment costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of share-based incentive plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <gsk:KeyManagementPersonnelCompensationSocialSecurityCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:KeyManagementPersonnelCompensationSocialSecurityCosts>
    <gsk:KeyManagementPersonnelCompensationSocialSecurityCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:KeyManagementPersonnelCompensationSocialSecurityCosts>
    <gsk:KeyManagementPersonnelCompensationSocialSecurityCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:KeyManagementPersonnelCompensationSocialSecurityCosts>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">28000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">66000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">60000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">51000000</ifrs-full:KeyManagementPersonnelCompensation>
    <gsk:DisclosureOfMajorRestructuringCostsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Major restructuring costs &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&amp;amp;D sites, are likely to take several years to complete. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Major restructuring costs are those related to specific Board-approved Major restructuring programmes, including integration costs following material acquisitions, which are structural and are of a significant scale where the costs of individual or related projects exceed &#xa3;25&#160;million. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In January 2020, the Board approved a Separation Preparation programme to prepare for the separation of GSK into two companies. Materially all of the Separation Preparation restructuring programme has been included as part of continuing operations. The legacy Consumer Healthcare Joint Venture integration programme is now included as part of discontinued operations. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;After the acquisition of Sierra Oncology (July 2022) and Affinivax (August 2022), the Board approved a Major restructuring programme for the Integration of significant acquisitions designed to integrate and achieve synergies. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The total restructuring costs of &#xa3;321&#160;million in 2022 were incurred in the following areas: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:8.25pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Restructuring costs to prepare for separation of GSK into two companies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:8.25pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Continued transformation of central functions, including GSK technology platforms and interfaces, to deliver greater digital synergies, simplification of applications and staff reductions &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:8.25pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The integration of acquisitions. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of the costs charged to operating profit from continuing operations under these programmes was as follows:&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in provision for Major restructuring programmes (see Note &lt;div style="display:inline;"&gt;32&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;606&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amount of provision reversed unused (see Note 32)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(111&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(140&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(71&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses recognised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;122&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charges/(credit)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;62&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other cash costs&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;179&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;204&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;234&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Provision reversals of &#xa3;111&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;140&#160;million; 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;71 million) reflected provision releases mainly related to the Separation Preparation programme. Asset impairments of &#xa3;122&#160;million and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; credit of &#xa3;7&#160;million principally comprised fixed asset write-downs of manufacturing facilities and accelerated depreciation where asset lives have been shortened in the supply chain manufacturing network as a result of the Major restructuring programmes, offset by profit on disposals. All other charges have been or will be settled in cash and include site closure costs, consultancy and project management costs. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of Major restructuring charges from continuing operations by programme was as follows:&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:84%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Separation Preparation programme&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;177&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;110&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;287&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Significant acquisitions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Legacy programmes&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;206&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:80%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Separation Preparation programme&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;353&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;59&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;412&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Legacy programmes&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;385&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of Major restructuring charges from continuing operations by income statement line was as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:74%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;102&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;102&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;585&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;180&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;277&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;198&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfMajorRestructuringCostsExplanatory>
    <gsk:RestructuringCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">25000000</gsk:RestructuringCosts>
    <gsk:TotalRestructuringCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">321000000</gsk:TotalRestructuringCosts>
    <gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory contextRef="P01_01_2022To12_31_2022">The analysis of the costs charged to operating profit from continuing operations under these programmes was as follows:&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in provision for Major restructuring programmes (see Note &lt;div style="display:inline;"&gt;32&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;606&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amount of provision reversed unused (see Note 32)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(111&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(140&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(71&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses recognised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;122&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charges/(credit)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;62&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other cash costs&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;179&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;204&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;234&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory>
    <gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">138000000</gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes>
    <gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">321000000</gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes>
    <gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">606000000</gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes>
    <ifrs-full:ReversalOfProvisionsForCostOfRestructuring
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">111000000</ifrs-full:ReversalOfProvisionsForCostOfRestructuring>
    <ifrs-full:ReversalOfProvisionsForCostOfRestructuring
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">140000000</ifrs-full:ReversalOfProvisionsForCostOfRestructuring>
    <ifrs-full:ReversalOfProvisionsForCostOfRestructuring
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">71000000</ifrs-full:ReversalOfProvisionsForCostOfRestructuring>
    <ifrs-full:ImpairmentLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">122000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">347000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:OtherMaterialNoncashItems
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:OtherMaterialNoncashItems>
    <ifrs-full:OtherMaterialNoncashItems
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:OtherMaterialNoncashItems>
    <ifrs-full:OtherMaterialNoncashItems
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">62000000</ifrs-full:OtherMaterialNoncashItems>
    <gsk:OtherCostsCashSettlement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">179000000</gsk:OtherCostsCashSettlement>
    <gsk:OtherCostsCashSettlement
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">204000000</gsk:OtherCostsCashSettlement>
    <gsk:OtherCostsCashSettlement
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">234000000</gsk:OtherCostsCashSettlement>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">321000000</gsk:CostChargedToOperatingProfit>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">424000000</gsk:CostChargedToOperatingProfit>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1178000000</gsk:CostChargedToOperatingProfit>
    <gsk:IncreaseDecreaseProvisionReversalRestructuring
      contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">111000000</gsk:IncreaseDecreaseProvisionReversalRestructuring>
    <gsk:IncreaseDecreaseProvisionReversalRestructuring
      contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">140000000</gsk:IncreaseDecreaseProvisionReversalRestructuring>
    <gsk:IncreaseDecreaseProvisionReversalRestructuring
      contextRef="P01_01_2020To12_31_2020_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">71000000</gsk:IncreaseDecreaseProvisionReversalRestructuring>
    <gsk:AssetImpairments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">122000000</gsk:AssetImpairments>
    <gsk:OtherNonCashCredit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:OtherNonCashCredit>
    <gsk:DisclosureOfRestructuringCostsExplanatory contextRef="P01_01_2022To12_31_2022">The analysis of Major restructuring charges from continuing operations by programme was as follows:&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:84%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Separation Preparation programme&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;177&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;110&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;287&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Significant acquisitions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Legacy programmes&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;206&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:80%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:9pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Separation Preparation programme&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;353&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;59&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;412&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Legacy programmes&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;385&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:48pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; </gsk:DisclosureOfRestructuringCostsExplanatory>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">177000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">110000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2022To12_31_2022_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">287000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2022To12_31_2022_SignificantAcquisitionsMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2022To12_31_2022_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">206000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">115000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">321000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">353000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2021To12_31_2021_SeparationPreparationProgrammeMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">412000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2021To12_31_2021_LegacyProgrammesMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:RestructuringCosts1>
    <gsk:CashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">385000000</gsk:CashRestructuringCharges>
    <gsk:NonCashRestructuringCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">39000000</gsk:NonCashRestructuringCharges>
    <gsk:RestructuringCosts1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">424000000</gsk:RestructuringCosts1>
    <gsk:DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of Major restructuring charges from continuing operations by income statement line was as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:74%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;102&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;102&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;585&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;180&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;277&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;198&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">102000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">102000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">585000000</ifrs-full:CostOfSales>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">180000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">277000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">395000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <gsk:ResearchAndDevelopmentExpenses
      contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</gsk:ResearchAndDevelopmentExpenses>
    <gsk:ResearchAndDevelopmentExpenses
      contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">45000000</gsk:ResearchAndDevelopmentExpenses>
    <gsk:ResearchAndDevelopmentExpenses
      contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">198000000</gsk:ResearchAndDevelopmentExpenses>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">321000000</gsk:CostChargedToOperatingProfit>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2021To12_31_2021_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">424000000</gsk:CostChargedToOperatingProfit>
    <gsk:CostChargedToOperatingProfit
      contextRef="P01_01_2020To12_31_2020_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1178000000</gsk:CostChargedToOperatingProfit>
    <ifrs-full:DisclosureOfFinanceIncomeExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. Finance income &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:74%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance income arising from:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at amortised cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net gains arising from the forward element of forward contracts in net investment hedge relationships&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other finance income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfFinanceIncomeExplanatory>
    <ifrs-full:DisclosureOfInterestIncomeExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:74%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance income arising from:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at amortised cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net gains arising from the forward element of forward contracts in net investment hedge relationships&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other finance income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfInterestIncomeExplanatory>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:FinanceIncome>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Finance expense &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense arising on:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities at amortised cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(789&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(735&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net losses arising from:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial instruments mandatorily measured at fair value through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;743&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(565&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;382&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retranslation of loans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(761&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;565&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(384&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of hedges from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unwinding of discounts on provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense arising on lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(30&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other finance expense&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(33&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(879&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(769&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(874&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense arising on:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities at amortised cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(789&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(735&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net losses arising from:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial instruments mandatorily measured at fair value through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;743&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(565&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;382&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retranslation of loans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(761&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;565&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(384&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of hedges from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unwinding of discounts on provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense arising on lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(30&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other finance expense&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(33&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(879&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(769&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(874&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="font-size:40pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfFinanceCostExplanatory>
    <ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">789000000</ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045438"
      unitRef="Unit_GBP">735000000</ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">811000000</ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">743000000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045441"
      unitRef="Unit_GBP">-565000000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">382000000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue>
    <gsk:ReTranslationOfLoan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">761000000</gsk:ReTranslationOfLoan>
    <gsk:ReTranslationOfLoan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69048662"
      unitRef="Unit_GBP">-565000000</gsk:ReTranslationOfLoan>
    <gsk:ReTranslationOfLoan
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">384000000</gsk:ReTranslationOfLoan>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045444"
      unitRef="Unit_GBP">2000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045447"
      unitRef="Unit_GBP">2000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69048665"
      unitRef="Unit_GBP">27000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045450"
      unitRef="Unit_GBP">-3000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-23000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">879000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69045453"
      unitRef="Unit_GBP">769000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">874000000</ifrs-full:FinanceCosts>
    <gsk:DisclosureOfAssociatesAndJointVenturesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. Associates and joint ventures &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits and losses of associates and joint ventures is set out below: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:86%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits of associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; losses of joint ventures&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;2021 and 2020 comparatives have not been restated, as the demerged Consumer Healthcare business contained no associates or joint ventures. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Following the disposal of Innoviva, Inc in May 2021 (see details in Note 41), at 31&#160;December 2022 and 31&#160;December 2021 the Group held no significant individual associates. At 31&#160;December 2020, the Group held one significant associate, Innoviva, Inc. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Summarised income statement information in respect of Innoviva until May 2021 is set out below. The Group&#x2019;s 2021 share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits of associates and other comprehensive income included a profit of &#xa3;33&#160;million and other comprehensive income of &#xa3;nil in respect of Innoviva. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The results of Innoviva included in the summarised income statement information below represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information at the balance sheet date. Figures for 2021 include share of Innoviva&#x2019;s turnover, profit and total comprehensive income until the date of the disposal. &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;108&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Aggregated financial information in respect of GSK&#x2019;s share of other associated undertakings and joint ventures is set out below: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of other comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;53&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of total comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s sales to associates and joint ventures were &#xa3;nil in 2022 (2021: &#xa3;nil; 2020: &#xa3;nil). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Please refer to the Balance sheet information on associates and joint ventures in Note 21. &lt;/div&gt;</gsk:DisclosureOfAssociatesAndJointVenturesExplanatory>
    <gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits and losses of associates and joint ventures is set out below: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:86%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits of associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; losses of joint ventures&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;2021 and 2020 comparatives have not been restated, as the demerged Consumer Healthcare business contained no associates or joint ventures. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:DisclosureOfGroupHeldSignificantAssociateExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The results of Innoviva included in the summarised income statement information below represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information at the balance sheet date. Figures for 2021 include share of Innoviva&#x2019;s turnover, profit and total comprehensive income until the date of the disposal. &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 0.75pt solid black; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="border-bottom: 0.75pt solid black; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;108&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfGroupHeldSignificantAssociateExplanatory>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">108000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">253000000</ifrs-full:Revenue>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">174000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">174000000</ifrs-full:ComprehensiveIncome>
    <gsk:DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Aggregated financial information in respect of GSK&#x2019;s share of other associated undertakings and joint ventures is set out below: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of other comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;53&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of total comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">45000000</ifrs-full:ComprehensiveIncome>
    <gsk:SalesToAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:SalesToAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:SalesToAssociatesAndJointVentures
      contextRef="P01_01_2020To12_31_2020"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL;text-indent: 0px;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;14. Taxation &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Group&#x2019;s tax charge is the sum of the total current and deferred tax expense. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Taxation charge based on profits for the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK current year charge&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;200&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;119&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(45&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World current year charge&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,351&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;593&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;745&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge/(credit) in respect of prior periods&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,491&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;931&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;711&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(784&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(848&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(644&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;In 2022, GSK made corporate income tax payments globally of &#xa3;1.5&#160;billion for continuing and discontinued operations, of which &#xa3;48&#160;million was UK corporation tax paid to HMRC. These amounts are for corporate income tax only, and do not include the various other business taxes borne by GSK each year. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The deferred tax credits in each period reflect current year losses where offset against taxable profits in future periods is probable and the release of deferred tax liabilities. The latter relates primarily to the unwind of deferred tax liabilities on intangible assets. The deferred tax credit in 2021 also reflected the impact of the remeasurement of deferred tax assets and liabilities following enactment of the increase in the headline rate of UK corporation tax from 19% to 25%. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for the year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 59%;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 6.5pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 7.5pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of taxation on Group profits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;br/&gt;&lt;/div&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;br/&gt;&lt;/div&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before tax&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,628&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,599&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,170&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK statutory rate of taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,069&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.0&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;685&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;984&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Differences in overseas taxation rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;318&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;302&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;363&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Benefit of intellectual property incentives&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(600&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10.7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(382&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(516&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(119&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(103&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Permanent differences on disposals, acquisitions and transfers&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;275&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(316&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other permanent differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;90&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-assessments&lt;/div&gt; of prior year current tax estimates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-assessments&lt;/div&gt; of prior year deferred tax estimates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(233&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(281&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(283&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Changes in Tax Rates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(353&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(163&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax charge/tax rate&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;As a global biopharmaceutical company, we have a substantial business and employment presence in many countries around the world. The impact of differences in overseas taxation rates arose from profits being earned in countries with tax rates higher than the UK statutory rate, the most significant of which in 2022 were the US, Belgium, Germany and Japan. This adverse impact was offset by the benefit of intellectual property incentives such as the UK Patent Box and Belgian Innovation Income Deduction regimes, which provide a reduced rate of corporation tax on profits earned from qualifying patents. We claim these incentives in the manner intended by the relevant statutory or regulatory framework. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;In 2021, &#x2018;Changes in tax rates&#x2019; included credits in relation to the enactment of the increase in the headline rate of UK corporate income tax from 19% to 25% (effective 2023). In 2020, &#x2018;Changes in tax rates&#x2019; included credits in relation to the UK, where a reduction in the corporate income tax rate from 19% to 17% was cancelled, and India, where the tax treatment of dividends changed with effect from 1&#160;April 2020. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;Permanent differences on disposals, acquisitions and transfers in 2022 includes tax on internal restructuring to simplify the group structure. The tax credit in 2020 reflected the tax impact of the disposal of Horlicks and other Consumer Healthcare brands to, and subsequent disposal of shares received in, Hindustan Unilever. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Group&#x2019;s 2022 tax rate has also been influenced by updates to estimates of prior period tax liabilities following closure of open issues with tax authorities in various jurisdictions. &lt;/div&gt;  &lt;div style="font-size: 50pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Future tax charges, and therefore our effective tax rate, may be affected by factors such as acquisitions, disposals, restructurings, the location of research and development activity, tax regime reforms and resolution of open matters as we continue to bring our tax affairs up to date around the world. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The UK Government has confirmed that the Spring Finance Bill 2023 will include legislation introducing a 15% global minimum corporate income tax rate, to have effect from 2024 in line with the OECD&#x2019;s Pillar Two model framework. The detail of the measures and how they are to be accounted for is still being finalised and so it is not possible to accurately quantify the impact for GSK at this stage. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax on items charged to equity and statement of comprehensive income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(211&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(277&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total credit to equity and statement of comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(268&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All of the above items have been charged to the statement of comprehensive income except for tax on share-based payments. &lt;/div&gt; &lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issues relating to taxation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The integrated nature of the Group&#x2019;s worldwide operations involves significant investment in research and strategic manufacture at a limited number of locations, with consequential cross-border supply routes into numerous &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-markets.&lt;/div&gt; In line with current OECD guidelines, we base our transfer pricing policy on the arm&#x2019;s length principle and support our transfer prices with economic analysis and reports. However, different tax authorities may seek to attribute further profit to activities being undertaken in their jurisdiction potentially resulting in double taxation. The Group also has open items in several jurisdictions concerning such matters as the deductibility of particular expenses and the tax treatment of certain business transactions. GSK applies a risk based approach to determine the transactions most likely to be subject to challenge and the probability that the Group would be able to obtain compensatory adjustments under international tax treaties. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The calculation of the Group&#x2019;s total tax charge therefore necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. At 31&#160;December 2022 the Group had recognised provisions of &#xa3;551&#160;million in respect of such uncertain tax positions (2021: &#xa3;858 million). The net decrease in recognised provisions during 2022 was driven by the reassessment of estimates, the agreement of a number of open issues with tax authorities in various jurisdictions and amounts related to discontinued operations. Whilst the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with the relevant tax authorities, or litigation where appropriate, the Group continues to consider that it has made appropriate provision for periods which are open and not yet agreed by the tax authorities. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A provision for deferred tax liabilities of &#xa3;157&#160;million as at 31&#160;December 2022 (2021: &#xa3;204 million) has been made in respect of taxation that would be payable on the remittance of profits by certain overseas subsidiaries. Whilst the aggregate amount of unremitted profits at the balance sheet date was approximately &#xa3;16&#160;billion (2021: &#xa3;15 billion), the majority of these unremitted profits would not be subject to tax (including withholding tax) on repatriation, as UK legislation relating to company distributions provides for exemption from tax for most overseas profits, subject to certain exceptions. Deferred tax is not provided on temporary differences of &#xa3;660&#160;million (2021: &#xa3;831 million) arising on unremitted profits as management has the ability to control any future reversal and does not consider such a reversal to be probable. &lt;/div&gt; &lt;div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movement in deferred tax assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:34%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Accelerated&lt;br/&gt; capital&lt;br/&gt; allowances&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Intangible&lt;br/&gt; assets&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Contingent&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;consideration&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intra-Group&lt;/div&gt;&lt;br/&gt; profit&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Pensions&#160;&amp;amp;&lt;br/&gt; other post&lt;br/&gt; employment&lt;br/&gt; benefits&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Tax&lt;br/&gt; losses&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Share&lt;br/&gt; option&lt;br/&gt; and&#160;award&lt;br/&gt; schemes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;net&lt;br/&gt; temporary&lt;br/&gt; differences&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Credit/(charge) to income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;312&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Credit/(charge) to statement of comprehensive income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Acquisitions/Disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits utilisation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Credit/(charge) to income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Credit/(charge) to statement of comprehensive income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Acquisitions/Disposals&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(637&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits utilisation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer of assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(819&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;992&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,099&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;1,661&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,642&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;5,369&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax liabilities in relation to intangible assets predominately relate to temporary differences arising as a result of historic business combinations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group continues to recognise deferred tax assets on future obligations in respect of contingent consideration amounts payable to minority shareholders. These payments are tax deductible at the point in time at which payment is made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A deferred tax asset is recognised on intra-Group profits arising on inter-company inventory which are eliminated within the consolidated accounts. As intra-Group profits are not eliminated from the individual entities&#x2019; tax returns a temporary difference arises that will reverse at the point in time inventory is sold externally. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The deferred tax asset recognised on tax losses of &#xa3;1,661&#160;million (2021: &#xa3;1,450 million) relates to trading losses. Such deferred tax assets are recognised where it is probable that future taxable profit will be available to utilise losses, as supported by long-range product level forecasts. Current forecasts indicate the assets will be utilised by around 2030. Other net temporary differences included accrued expenses for which a tax deduction is only available on a paid basis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax assets and liabilities are recognised on the balance sheet as follows:&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,658&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(289&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,556&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,369&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,662&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrecognised tax losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax&#160;losses&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrecognised&lt;br/&gt; deferred tax&lt;br/&gt; asset&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Tax&#160;losses&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Unrecognised&lt;br/&gt; deferred tax&lt;br/&gt; asset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trading losses expiring:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Within 10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;967&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;More than 10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Available indefinitely&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;192&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,658&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capital losses expiring:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Available indefinitely&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;548&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,356&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;548&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,356&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax assets are only recognised where it is probable that future taxable profit will be available to utilise losses. &lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Group&#x2019;s tax charge is the sum of the total current and deferred tax expense. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Taxation charge based on profits for the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK current year charge&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;200&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;119&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(45&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rest of World current year charge&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,351&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;593&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;745&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge/(credit) in respect of prior periods&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,491&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;931&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;711&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(784&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(848&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(644&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">200000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">119000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-45000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1351000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">593000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">745000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">219000000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1491000000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">931000000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">711000000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-784000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-848000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-644000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">1500000000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:IncomeTaxesPaidRefund>
    <gsk:HeadlineUkTaxRateEffective2023
      contextRef="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.19</gsk:HeadlineUkTaxRateEffective2023>
    <gsk:HeadlineUkTaxRateEffective2023
      contextRef="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</gsk:HeadlineUkTaxRateEffective2023>
    <gsk:DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for the year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 59%;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 6.5pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 7.5pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of taxation on Group profits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;br/&gt;&lt;/div&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;br/&gt;&lt;/div&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 1pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt; background-color: rgb(231, 231, 232);"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before tax&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,628&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,599&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,170&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK statutory rate of taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,069&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.0&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;685&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;984&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Differences in overseas taxation rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;318&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;302&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;363&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Benefit of intellectual property incentives&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(600&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10.7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(382&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(516&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(119&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(103&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Permanent differences on disposals, acquisitions and transfers&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;275&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(316&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other permanent differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;90&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-assessments&lt;/div&gt; of prior year current tax estimates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-assessments&lt;/div&gt; of prior year deferred tax estimates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(233&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4.1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(281&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(283&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Changes in Tax Rates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(353&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(163&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax charge/tax rate&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt;  &lt;div style="font-size: 50pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5628000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3599000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5170000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1069000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">685000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">984000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">318000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.056</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">302000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.084</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">363000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.07</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-600000000</gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.107</gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-382000000</gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.106</gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-516000000</gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.099</gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives>
    <gsk:TaxEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-119000000</gsk:TaxEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxRateEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.021</gsk:TaxRateEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-100000000</gsk:TaxEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxRateEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.028</gsk:TaxRateEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</gsk:TaxEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxRateEffectOfResearchAndDevelopmentCredits
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.02</gsk:TaxRateEffectOfResearchAndDevelopmentCredits>
    <gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">275000000</gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers>
    <gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.049</gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers>
    <gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers>
    <gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers>
    <gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-316000000</gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers>
    <gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.061</gsk:TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">82000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.015</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">90000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.017</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <gsk:TaxEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</gsk:TaxEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.011</gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">219000000</gsk:TaxEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.061</gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:TaxEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.002</gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates>
    <gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-233000000</gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.041</gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-281000000</gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.078</gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-283000000</gsk:TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.055</gsk:TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates>
    <gsk:TaxEffectOfChangeInTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-25000000</gsk:TaxEffectOfChangeInTaxRate>
    <gsk:TaxRateEffectOfChangeInTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.004</gsk:TaxRateEffectOfChangeInTaxRate>
    <gsk:TaxEffectOfChangeInTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-353000000</gsk:TaxEffectOfChangeInTaxRate>
    <gsk:TaxRateEffectOfChangeInTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.098</gsk:TaxRateEffectOfChangeInTaxRate>
    <gsk:TaxEffectOfChangeInTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-163000000</gsk:TaxEffectOfChangeInTaxRate>
    <gsk:TaxRateEffectOfChangeInTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.031</gsk:TaxRateEffectOfChangeInTaxRate>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.126</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.023</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.129</ifrs-full:AverageEffectiveTaxRate>
    <gsk:HeadlineUkTaxRateEffective2023
      contextRef="P01_01_2021To12_31_2021_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.19</gsk:HeadlineUkTaxRateEffective2023>
    <gsk:HeadlineUkTaxRateEffective2023
      contextRef="P01_01_2022To12_31_2022_GbMemberifrsfullGeographicalAreasAxis_IncreaseInTheHeadlineRateOfTaxMemberGSKEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</gsk:HeadlineUkTaxRateEffective2023>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_ReducedTaxRateCancelledMemberGSKEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_GBifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</ifrs-full:ApplicableTaxRate>
    <gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax on items charged to equity and statement of comprehensive income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;&#160;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred taxation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(211&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(277&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total credit to equity and statement of comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(268&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory>
    <gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">89000000</gsk:CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">41000000</ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">18000000</gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-211000000</gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">223000000</gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-51000000</gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-68000000</gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-167000000</gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">131000000</gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-277000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">104000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-268000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">89000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">187000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <gsk:ProvisionsForUncertainTaxPosition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">551000000</gsk:ProvisionsForUncertainTaxPosition>
    <gsk:ProvisionsForUncertainTaxPosition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">858000000</gsk:ProvisionsForUncertainTaxPosition>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">157000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021_OverseasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-6"
      unitRef="Unit_GBP">204000000</ifrs-full:DeferredTaxLiabilities>
    <gsk:UnremittedEarnings
      contextRef="PAsOn12_31_2022"
      decimals="-9"
      unitRef="Unit_GBP">16000000000</gsk:UnremittedEarnings>
    <gsk:UnremittedEarnings
      contextRef="PAsOn12_31_2021"
      decimals="-9"
      unitRef="Unit_GBP">15000000000</gsk:UnremittedEarnings>
    <gsk:UnremittedProfitsForWhichDeferredTaxNotProvided
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">660000000</gsk:UnremittedProfitsForWhichDeferredTaxNotProvided>
    <gsk:UnremittedProfitsForWhichDeferredTaxNotProvided
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">831000000</gsk:UnremittedProfitsForWhichDeferredTaxNotProvided>
    <gsk:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 10pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movement in deferred tax assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:34%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Accelerated&lt;br/&gt; capital&lt;br/&gt; allowances&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Intangible&lt;br/&gt; assets&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Contingent&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;consideration&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intra-Group&lt;/div&gt;&lt;br/&gt; profit&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Pensions&#160;&amp;amp;&lt;br/&gt; other post&lt;br/&gt; employment&lt;br/&gt; benefits&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Tax&lt;br/&gt; losses&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Share&lt;br/&gt; option&lt;br/&gt; and&#160;award&lt;br/&gt; schemes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;net&lt;br/&gt; temporary&lt;br/&gt; differences&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Credit/(charge) to income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;312&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Credit/(charge) to statement of comprehensive income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Acquisitions/Disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits utilisation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Credit/(charge) to income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Credit/(charge) to statement of comprehensive income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Acquisitions/Disposals&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(637&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;R&amp;amp;D credits utilisation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer of assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(819&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;992&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,099&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;1,661&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,642&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;5,369&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-296000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3982000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">843000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1024000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">874000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1060000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1104000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">687000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-41000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">65000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">312000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-31000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">391000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">232000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">1002000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-223000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">164000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-48000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">58000000</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">58000000</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-211000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3711000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">850000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">999000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">640000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1450000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1554000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1662000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-264000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-40000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">64000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">160000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-102000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">122000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">142000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">258000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-32000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">104000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-22000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_OriginationAndReversalOfTemporaryDifferencesMemberGSKTaxReformsPeriodOfApplicationAxis"
      decimals="-6"
      unitRef="Unit_GBP">888000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">182000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">42000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">201000000</gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-637000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-495000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-76000000</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-76000000</gsk:IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">62000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3667000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-118000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-250000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3291000000</gsk:IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_AcceleratedCapitalAllowancesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-57000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_IntangibleAssetsOtherThanGoodwillMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-819000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_ContingentConsiderationMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">992000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_IntraGroupProfitMemberifrsfullJointOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1099000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">794000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_UnusedTaxLossesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1661000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_ShareOptionAndAwardSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1642000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5369000000</ifrs-full:DeferredTaxLiabilityAsset>
    <gsk:DeferredTaxAssetsRecognizedOnTradingLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1661000000</gsk:DeferredTaxAssetsRecognizedOnTradingLosses>
    <gsk:DeferredTaxAssetsRecognizedOnTradingLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1450000000</gsk:DeferredTaxAssetsRecognizedOnTradingLosses>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Deferred tax assets and liabilities are recognised on the balance sheet as follows:&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,658&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(289&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,556&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,369&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,662&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5658000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5218000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">289000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3556000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5369000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1662000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrecognised tax losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax&#160;losses&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrecognised&lt;br/&gt; deferred tax&lt;br/&gt; asset&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Tax&#160;losses&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Unrecognised&lt;br/&gt; deferred tax&lt;br/&gt; asset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trading losses expiring:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Within 10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;967&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;More than 10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Available indefinitely&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;192&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,658&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capital losses expiring:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Available indefinitely&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;548&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,356&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;548&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,356&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;557&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <gsk:TaxLosses
      contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">967000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">175000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1068000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTenYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">198000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">390000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">62000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">192000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">41000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">200000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">43000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1203000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">229000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:TaxLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1658000000</gsk:TaxLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnTradingLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">303000000</gsk:UnrecognisedDeferredTaxAssetOnTradingLosses>
    <gsk:CapitalLosses
      contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2326000000</gsk:CapitalLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses
      contextRef="P01_01_2022To12_31_2022_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">548000000</gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses>
    <gsk:CapitalLosses
      contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2356000000</gsk:CapitalLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses
      contextRef="P01_01_2021To12_31_2021_AvailableIndefinitelyMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">557000000</gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses>
    <gsk:CapitalLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2326000000</gsk:CapitalLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">548000000</gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses>
    <gsk:CapitalLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2356000000</gsk:CapitalLosses>
    <gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">557000000</gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; pence&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; pence&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; pence&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic earnings per share from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;110.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;260.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.0&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total basic earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;371.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109.6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144.4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted earnings per share from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;257.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total diluted earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;366.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;108.2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;142.6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Basic earnings per share has been calculated by dividing the profit attributable to shareholders by the weighted average number of shares in issue during the period after deducting shares held by the ESOP Trusts and Treasury shares. The trustees have waived their rights to cash dividends on the GSK shares held by the ESOP Trusts. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Diluted earnings per share has been calculated after adjusting the weighted average number of shares used in the basic calculation to assume the conversion of all potentially dilutive shares. A potentially dilutive share forms part of the employee share schemes where its exercise price is below the average market price of GSK shares during the period and any performance conditions attaching to the scheme have been met at the balance sheet date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average number of shares in issue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; millions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;br/&gt; millions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;br/&gt; millions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dilution for share options and awards&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,084&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,052&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Restated to reflect the impact share consolidation (see &lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;N&lt;/div&gt;ote&lt;/div&gt; 37). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; pence&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; pence&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;br/&gt; pence&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic earnings per share from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;110.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;260.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.0&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total basic earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;371.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109.6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144.4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted earnings per share from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;257.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total diluted earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;366.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;108.2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;142.6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41) and/or the impact of Share Consolidation (see Note 37).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.108</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.829</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.224</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">2.606</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.267</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.22</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">3.714</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.096</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.444</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.092</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.818</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.209</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">2.57</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.264</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">0.217</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_GBP_per_Share">3.662</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.082</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_GBP_per_Share">1.426</ifrs-full:DilutedEarningsLossPerShare>
    <gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average number of shares in issue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; millions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;br/&gt; millions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(2)&lt;/div&gt;&lt;br/&gt; millions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dilution for share options and awards&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,084&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,052&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Restated to reflect the impact share consolidation (see &lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;N&lt;/div&gt;ote&lt;/div&gt; 37). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_shares">4026000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_shares">4003000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">3981000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_shares">58000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_shares">49000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">49000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_shares">4084000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_shares">4052000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">4030000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfDividendsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;16. Dividends &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:19%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paid/payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Paid&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Paid&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;First interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1 July 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;704&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 July 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;9 July 2020&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Second interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6 October 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7 October 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 October 2020&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12 January 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;13 January 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;14 January 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fourth interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13 April 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7 April 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;*&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 April 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,468&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,011&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,989&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The estimate for the fourth interim dividend for 2021 disclosed in the 2021 annual report was &#xa3;1,152&#160;million, &#xa3;5&#160;million less than the dividend that was ultimately paid. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;&#160;Dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. See details in Note 37. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2022 financial statements recognise those dividends paid in 2022, namely the third and fourth interim dividends for 2021, and the first and second interim dividends for 2022. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The demerger of the Consumer Healthcare business was effected by GSK declaring an interim dividend in specie of Haleon plc shares. The fair value of the distribution was &#xa3;15,526&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The amounts recognised in each year were as follows:&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash dividends to shareholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividends in specie to shareholders in Haleon plc shares (Note 41)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,977&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDividendsExplanatory>
    <gsk:DisclosureOfInterimDividendExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:19%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:16%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2020&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Paid/payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Paid&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Paid&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Dividend&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per&#160;share&lt;br/&gt; (pence)&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividend&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;First interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1 July 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;704&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 July 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;9 July 2020&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Second interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6 October 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7 October 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 October 2020&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12 January 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;13 January 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;14 January 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fourth interim&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13 April 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;7 April 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;*&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;8 April 2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,468&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,011&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,989&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The estimate for the fourth interim dividend for 2021 disclosed in the 2021 annual report was &#xa3;1,152&#160;million, &#xa3;5&#160;million less than the dividend that was ultimately paid. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;&#160;Dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. See details in Note 37. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfInterimDividendExplanatory>
    <gsk:DividendsPaidDate contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis">2022-07-01</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.175</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2022To12_31_2022_FirstInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">704000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis">2021-07-08</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2021To12_31_2021_FirstInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">951000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis">2020-07-09</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2020To12_31_2020_FirstInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">946000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis">2022-10-06</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.1625</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2022To12_31_2022_SecondInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">654000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis">2021-10-07</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2021To12_31_2021_SecondInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">951000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis">2020-10-08</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2020To12_31_2020_SecondInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">946000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis">2023-01-12</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.1375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2022To12_31_2022_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">555000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis">2022-01-13</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2021To12_31_2021_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">952000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis">2021-01-14</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2020To12_31_2020_ThirdInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">946000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis">2023-04-13</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.1375</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2022To12_31_2022_FourthInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">555000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis">2022-04-07</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2875</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1157000000</ifrs-full:DividendsPaidOrdinaryShares>
    <gsk:DividendsPaidDate contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis">2021-04-08</gsk:DividendsPaidDate>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.2875</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2020To12_31_2020_FourthInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1151000000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_GBP_per_Share">0.6125</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2468000000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_GBP_per_Share">1</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4011000000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_GBP_per_Share">1</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsPaidOrdinaryShares
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3989000000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:CurrentDividendPayables
      contextRef="PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1152000000</ifrs-full:CurrentDividendPayables>
    <gsk:AdditionalProvisionForDividendPayable
      contextRef="P10_01_2021To12_31_2021_FourthInterimMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:AdditionalProvisionForDividendPayable>
    <gsk:DescriptionOfInterimDividendRecognitonAndPayment contextRef="P01_01_2022To12_31_2022">Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2022 financial statements recognise those dividends paid in 2022, namely the third and fourth interim dividends for 2021, and the first and second interim dividends for 2022.</gsk:DescriptionOfInterimDividendRecognitonAndPayment>
    <gsk:FairValueOfAssetdistributedAsDividendInSpecie
      contextRef="P01_01_2022To12_31_2022_DemergerOfConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">15526000000</gsk:FairValueOfAssetdistributedAsDividendInSpecie>
    <gsk:DisclosureOfDividendsPaidExplanatory contextRef="P01_01_2022To12_31_2022">The amounts recognised in each year were as follows:&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash dividends to shareholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividends in specie to shareholders in Haleon plc shares (Note 41)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,977&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDividendsPaidExplanatory>
    <gsk:CashDividendsPaidToShareholdersRecognizedInYear
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3467000000</gsk:CashDividendsPaidToShareholdersRecognizedInYear>
    <gsk:CashDividendsPaidToShareholdersRecognizedInYear
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</gsk:CashDividendsPaidToShareholdersRecognizedInYear>
    <gsk:CashDividendsPaidToShareholdersRecognizedInYear
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</gsk:CashDividendsPaidToShareholdersRecognizedInYear>
    <gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15526000000</gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear>
    <gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear>
    <gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear>
    <gsk:DividendsRecognisedInYear
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">18993000000</gsk:DividendsRecognisedInYear>
    <gsk:DividendsRecognisedInYear
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3999000000</gsk:DividendsRecognisedInYear>
    <gsk:DividendsRecognisedInYear
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3977000000</gsk:DividendsRecognisedInYear>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;17. Property, plant and equipment &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Land&#160;and&lt;br/&gt; buildings&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Plant,&lt;br/&gt; equipment&lt;br/&gt; and&#160;vehicles&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Assets in&lt;br/&gt; construction&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;21,483&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,091&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised borrowing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,174&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,212&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,778&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,153&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised borrowing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;146&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,067&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,959&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,648&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,953&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,451&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,450&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,062&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(501&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(726&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(952&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#f4f1f0"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;376&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,130&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#f4f1f0"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,506&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,275&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,469&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(857&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(821&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(472&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(774&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and impairment at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,846&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and impairment at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,535&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,941&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(10,518&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,898&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,414&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,864&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,176&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,667&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,558&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,707&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,012&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,808&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,933&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The weighted average interest rate for capitalised borrowing costs in the year was 4% (2021: 3%). Disposals and write-offs in the year included a number of assets with nil net book value that are no longer in use in the business. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The impairment losses principally arose from decisions to rationalise facilities and were calculated based on fair value less costs of disposal. The fair value less costs of disposal valuation methodology uses significant inputs which are not based on observable market data, and therefore this valuation technique is classified as level 3 of the fair value hierarchy. These calculations determine the net present value of the projected risk-adjusted, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; cash flows of the relevant asset or cash generating unit, applying a discount rate of the Group &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; weighted average cost of capital (WACC) of 7%, adjusted where appropriate for specific segment, country and currency risk. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Assets that continue to be used by the Group are generally assessed as part of their associated cash generating unit on a value in use basis. For value in use calculations, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; cash flows do not include the impact of future uncommitted restructuring plans or improvements. Where an impairment is indicated and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; cash flow calculation is expected to give a materially different result, the test would be reperformed using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; cash flows and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate. The Group WACC is equivalent to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate of approximately 9%. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The net impairment losses have been charged to cost of sales: &#xa3;11&#160;million (2021: &#xa3;46 million), R&amp;amp;D: &#xa3;7&#160;million (2021: &#xa3;3 million) and SG&amp;amp;A: &#xa3;55&#160;million (2021: &#xa3;54 million), and included &#xa3;34&#160;million (2021: &#xa3;20 million) arising from the Major restructuring programmes. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Reversals of impairment arose from subsequent reviews of the impaired assets where the conditions which gave rise to the original impairments were deemed no longer to apply. All of the reversals have been credited to cost of sales. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2022, &#xa3;39&#160;million (2021: &#xa3;74 million) of computer software was reclassified from assets in construction to intangible assets on becoming ready for use. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. &lt;/div&gt; </ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Land&#160;and&lt;br/&gt; buildings&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Plant,&lt;br/&gt; equipment&lt;br/&gt; and&#160;vehicles&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;Assets in&lt;br/&gt; construction&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;21,483&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,091&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,205&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised borrowing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,174&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,212&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,778&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,153&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,245&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised borrowing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;146&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,067&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,959&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,648&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,953&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,451&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,450&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,062&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(501&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(726&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(952&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#f4f1f0"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;376&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,130&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#f4f1f0"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,506&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#f4f1f0"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,275&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,469&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(857&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(821&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and write-offs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(472&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(774&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and impairment at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,846&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total depreciation and impairment at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,535&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,941&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(10,518&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,898&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,414&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,864&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,176&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,667&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,558&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,707&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,012&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,808&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,933&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">7488000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">12105000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1890000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">21483000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-214000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-315000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-47000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-576000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1091000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1205000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">217000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">940000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1174000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">202000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">906000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1182000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-74000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">38000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">102000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">7212000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">11816000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1750000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">20778000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">403000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">542000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">105000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1050000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">79000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1153000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1245000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">64000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">222000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">291000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">689000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-874000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-39000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">1067000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">1959000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">317000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">3343000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">6648000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">10953000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1850000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">19451000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3310000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7140000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10450000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">100000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">191000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">291000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">267000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">715000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">982000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-169000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-893000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1062000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-54000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3281000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10025000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-191000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-310000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-501000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">226000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">726000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">952000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-47000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-181000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-228000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-376000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1130000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1506000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3275000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6469000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-280000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-551000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-26000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-857000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-30000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-76000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-13000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-119000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-54000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-37000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-112000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-264000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-514000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-821000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-24000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-47000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-61000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-45000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-83000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-37000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-45000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-84000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-260000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-472000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-42000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-774000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7258000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10846000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3535000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6941000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-42000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10518000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">3898000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">4414000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">1864000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">10176000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">3667000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">4558000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">1707000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">9932000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">3113000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_PropertyPlantAndEquipmentAndVehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">4012000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">1808000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8933000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.04</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.03</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <gsk:WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.07</gsk:WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage>
    <gsk:WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.09</gsk:WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">46000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_MajorRestructuringProgrammesMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;18. Right of use assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Land&#160;and&lt;br/&gt; buildings&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Plant and&lt;br/&gt; equipment&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Vehicles&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;830&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;233&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(192&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;561&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;687&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has entered into some commitments for lease contracts that have not yet commenced. See Note 36. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;An analysis of lease liabilities is set out in Note 30, &#x2018;Net debt&#x2019;. &lt;/div&gt; </ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Land&#160;and&lt;br/&gt; buildings&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Plant and&lt;br/&gt; equipment&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Vehicles&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;830&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;233&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(192&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;561&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;687&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2020_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">699000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2020_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2020_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">830000000</ifrs-full:RightofuseAssets>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">152000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">62000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">215000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">149000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">213000000</ifrs-full:DepreciationRightofuseAssets>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-53000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2021To12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-13000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-70000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2021To12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:RightOfUseAssetImpairments>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2021To12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:RightOfUseAssetImpairments>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">633000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2021_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">740000000</ifrs-full:RightofuseAssets>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">47000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:RightOfUseAssetsExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</gsk:RightOfUseAssetsExchangeAdjustments>
    <gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations>
    <gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations>
    <gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations>
    <gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</gsk:AdditionsToRightOfUseAssetsThroughBusinessCombinations>
    <gsk:OtherAdditionsToRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">140000000</gsk:OtherAdditionsToRightOfUseAssets>
    <gsk:OtherAdditionsToRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:OtherAdditionsToRightOfUseAssets>
    <gsk:OtherAdditionsToRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</gsk:OtherAdditionsToRightOfUseAssets>
    <gsk:OtherAdditionsToRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">233000000</gsk:OtherAdditionsToRightOfUseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">131000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">58000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">192000000</ifrs-full:DepreciationRightofuseAssets>
    <gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-115000000</gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution>
    <gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution>
    <gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution>
    <gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-127000000</gsk:RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetDisposal
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</gsk:RightOfUseAssetDisposal>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2022To12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-39000000</gsk:RightOfUseAssetImpairments>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2022To12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RightOfUseAssetImpairments>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RightOfUseAssetImpairments>
    <gsk:RightOfUseAssetImpairments
      contextRef="P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-39000000</gsk:RightOfUseAssetImpairments>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_LandAndBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">120000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">687000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;19. Goodwill &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;550&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations (Note 41)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other movements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,597&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All Goodwill is allocated to the Group&#x2019;s segments as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:89.5%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,148&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2021, prior to changes in the Group&#x2019;s segment reporting (Note 6) Goodwill was allocated as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pharmaceuticals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,060&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill of &#xa3;5,183&#160;million allocated to Consumer Healthcare was transferred to &#x2018;assets held for sale/distribution&#x2019; prior to the Consumer Healthcare demerger (Note 41). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of disposal is calculated using a discounted cash flow approach, with a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; discount rate applied to the projected risk-adjusted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; cash flows and terminal value. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The discount rate used is based on the Group WACC of 7% (2021: 6.5%), as most cash generating units have integrated operations across large parts of the Group. The discount rate is adjusted where appropriate for specific segment, country and currency risks. The valuation methodology uses significant inputs which are not based on observable market data, therefore this valuation technique is classified as level 3 in the fair value hierarchy.&lt;/div&gt; &lt;div style="width: 91%; overflow: visible; padding-top: 3pt; padding-right: 0%; padding-bottom: 8pt; float: left; position: relative;"&gt;&lt;div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The R&amp;amp;D segment is evaluated on an arms length pricing model, see assumptions below.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8.5pt;;display:inline;"&gt;Details relating to the discounted cash flow models used in the impairment tests are as follows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:26%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:26%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:24%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="width:21%"/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Valuation basis&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Fair value less costs of disposal&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Key assumptions&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Sales growth rates&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Profit margins&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rate&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Discount rate&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Taxation rate&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Determination of assumptions&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Growth rates are internal forecasts based on both internal and external market information.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Margins reflect past experience, adjusted for expected changes.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rates based on management&#x2019;s estimate of future long-term average growth rates.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Discount rates based on Group WACC, adjusted where appropriate.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Taxation rates based on appropriate rates for each jurisdiction.&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Period of specific projected cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Five years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rate and discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;Terminal growth rate&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;Discount&#160;rate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Commercial operations&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;R&amp;amp;D&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Pharmaceuticals&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Vaccines&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Consumer Healthcare&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2.5% p.a.&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;6% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The terminal growth rate does not exceed the long-term projected growth rates for relevant markets, reflects the impact of future generic competition and take account of new product launches. Goodwill is monitored for impairment at the segmental level and the valuations indicated sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment of the related goodwill. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. &lt;/div&gt; </ifrs-full:DisclosureOfGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;550&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations (Note 41)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other movements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,552&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,597&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">10597000000</ifrs-full:Goodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">550000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-55000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1127000000</ifrs-full:AdditionalRecognitionGoodwill>
    <gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest>
    <gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5183000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">7046000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">10597000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7046000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <gsk:DisclosureOfAllocationOfGoodwillToSegmentsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All Goodwill is allocated to the Group&#x2019;s segments as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:89.5%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,148&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,046&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2021, prior to changes in the Group&#x2019;s segment reporting (Note 6) Goodwill was allocated as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pharmaceuticals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vaccines&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,060&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,552&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfAllocationOfGoodwillToSegmentsExplanatory>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6148000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">898000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7046000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4228000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1264000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5060000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10552000000</ifrs-full:Goodwill>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5183000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill>
    <ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined contextRef="P01_01_2022To12_31_2022">The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of disposal is calculated using a discounted cash flow approach, with a post-tax discount rate applied to the projected risk-adjusted post-tax cash flows and terminal value.</ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.07</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.065</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: ARIAL; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8.5pt;;display:inline;"&gt;Details relating to the discounted cash flow models used in the impairment tests are as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:26%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:26%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:24%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="width:21%"/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Valuation basis&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Fair value less costs of disposal&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Key assumptions&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Sales growth rates&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Profit margins&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rate&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Discount rate&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Taxation rate&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Determination of assumptions&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Growth rates are internal forecasts based on both internal and external market information.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Margins reflect past experience, adjusted for expected changes.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rates based on management&#x2019;s estimate of future long-term average growth rates.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Discount rates based on Group WACC, adjusted where appropriate.&lt;/div&gt; &lt;div style="font-size: 1pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Taxation rates based on appropriate rates for each jurisdiction.&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Period of specific projected cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Five years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: ARIAL; line-height: normal;"&gt;Terminal growth rate and discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;Terminal growth rate&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;Discount&#160;rate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Commercial operations&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;R&amp;amp;D&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Pharmaceuticals&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;Vaccines&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0% p.a.&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Consumer Healthcare&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2.5% p.a.&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;6% p.a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory>
    <ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal contextRef="P01_01_2022To12_31_2022">Fair value less costs of disposal</ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal>
    <ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections contextRef="P01_01_2022To12_31_2022">Sales growth rates &#160; Profit margins &#160; Terminal growth rate &#160; Discount rate &#160; Taxation rate</ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections>
    <ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal contextRef="P01_01_2022To12_31_2022">Growth rates are internal forecasts based on both internal and external market information. &#160; Margins reflect past experience, adjusted for expected changes. &#160; Terminal growth rates based on management&#x2019;s estimate of future long-term average growth rates. &#160; Discount rates based on Group WACC, adjusted where appropriate. &#160; Taxation rates based on appropriate rates for each jurisdiction.</ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal>
    <ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows contextRef="P01_01_2022To12_31_2022">Five years</ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2022_CommercialOperationsMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2022_ResearchAndDevelopmentMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2021_PharmaceuticalsMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2021_VaccinesMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis"
      decimals="3"
      unitRef="Unit_pure">0.025</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn12_31_2021_ConsumerHealthcareMemberifrsfullProductsAndServicesAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;20. Other intangible assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer&lt;br/&gt; software&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Licences,&lt;br/&gt; patents,&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;amortised&lt;br/&gt; brands etc.&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Indefinite&#160;life&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;brands&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,410&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,594&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(935&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,439&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42,489&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,109&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;317&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,964&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;775&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(236&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,959&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,717&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,676&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,254&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(956&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,181&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;737&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,369&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(307&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(340&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;148&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;254&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,223&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,181&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,760&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(455&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;362&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,779&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(141&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(313&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;270&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total amortisation and impairment at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,410&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total amortisation and impairment at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,304&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,054&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13,358&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,053&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,368&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,697&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,418&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,079&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,663&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,318&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The weighted average interest rate for capitalised borrowing costs in the year was 4% (2021: 3%). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The net book value of computer software included &#xa3;479&#160;million (2021: &#xa3;526 million) of internally generated costs. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The carrying value at 31&#160;December 2022 of intangible assets, for which impairments have been charged in the year following those impairments, was &#xa3;83&#160;million (2021: &#xa3;694 million). The carrying value at 31&#160;December 2022 of intangible assets, for which impairment reversals have been charged in the year following those impairment reversals, was &#xa3;776&#160;million (2021: &#xa3;104 million). No individual intangible asset accounted for a material impairment. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The patent expiry dates of the Group&#x2019;s most significant assets, where relevant, are set out on pages 282 to 284. Please refer to Note 2 to the Group&#x2019;s accounting policy and estimate of the useful life for intangible assets over the exclusivity and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusivity&lt;/div&gt; periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortisation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;impairment&#160;losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a) &lt;/div&gt;&#160;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&#x2013;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;116&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;65&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;307&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;373&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;1,088&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;367&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;438&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Licences, patents, amortised brands etc. includes a large number of acquired licences, patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; agreements and marketing rights, which are either marketed or in use, or still in development. Note 41, &#x2018;Acquisitions and disposals&#x2019; gives details of additions through business combinations in the year. The book values of the largest individual items are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tesaro Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,858&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,677&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Meningitis portfolio&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,855&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,889&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Momelotinib&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,499&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Affinivax Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,473&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dolutegravir&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benlysta&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;541&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Alector Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;509&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;iTeos Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;444&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shingrix&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;288&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;268&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Okairos&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;BMS Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;196&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Spero&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vir Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fluarix/FluLaval&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;147&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Stiefel trade name&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;CureVac Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lamisil&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Others&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,797&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,697&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Disposed of as part of the Consumer Healthcare demerger (Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;July 2022, GSK completed the acquisition of Sierra Oncology Inc, The main asset is momelotinib. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 15&#160;August 2022, GSK completed the acquisition of Affinivax, Inc. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Indefinite life brands related to healthcare brands used within the Consumer Healthcare business. Indefinite life brands were disposed of as part of the Consumer Healthcare demerger (Note 41). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group do not consider that any reasonably possible changes in the key assumptions would cause the recoverable amount of the Intangible assets disclosed above to fall below their carrying values. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;GSK has assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that there are no material impairments. &lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer&lt;br/&gt; software&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Licences,&lt;br/&gt; patents,&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;amortised&lt;br/&gt; brands etc.&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Indefinite&#160;life&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;brands&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,410&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,594&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(935&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,439&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42,489&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,109&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Capitalised development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;317&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,964&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;775&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(236&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,959&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,717&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,676&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,254&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(956&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,181&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;737&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,369&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(307&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(340&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;148&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;254&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;554&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,223&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,181&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,760&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(455&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;362&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,779&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(141&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(313&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;270&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversal of impairments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and asset write-offs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total amortisation and impairment at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,410&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total amortisation and impairment at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,304&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,054&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13,358&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 1&#160;January 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,053&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,368&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net book value at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,697&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,418&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,079&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net book value at 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,663&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,318&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">2403000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">20822000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">18613000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">41838000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-207000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">65000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-157000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">346000000</gsk:CapitalisedDevelopmentCosts>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">346000000</gsk:CapitalisedDevelopmentCosts>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">184000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1410000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1594000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">221000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">935000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1156000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-50000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">2424000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">21439000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">18626000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">42489000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">934000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1112000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">2109000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CapitalisedDevelopmentCosts>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">317000000</gsk:CapitalisedDevelopmentCosts>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CapitalisedDevelopmentCosts>
    <gsk:CapitalisedDevelopmentCosts
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">317000000</gsk:CapitalisedDevelopmentCosts>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">2964000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">2964000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">149000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">626000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">775000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">203000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">236000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-513000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-496000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19772000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20781000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1959000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">25717000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">27676000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1322000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7932000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9254000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">65000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">225000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">956000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1181000000</gsk:AmortisationOtherIntangibleAssets>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-165000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-572000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-737000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1369000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8262000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9631000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-307000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-340000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">204000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">931000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">1135000000</gsk:AmortisationOtherIntangibleAssets>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-129000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-148000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">254000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">300000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">554000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1223000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9181000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10404000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2487000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">-245000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2760000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">93000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">362000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">455000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-30000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-362000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2021To12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-392000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-91000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2480000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">-208000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2779000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-138000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-141000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">72000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">313000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">402000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">226000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">270000000</gsk:DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-73000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P01_01_2022To12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-80000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-81000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2873000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2954000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1460000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10742000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">-208000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12410000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1304000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12054000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_GBP">-13358000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1053000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">10403000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">18368000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">29824000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">964000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">10697000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">18418000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">30079000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_ComputerSoftwareMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">655000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesAmortisedBrandsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">13663000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14318000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.04</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.03</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:ComputerSoftware
      contextRef="PAsOn12_31_2022_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis"
      decimals="-6"
      unitRef="Unit_GBP">479000000</ifrs-full:ComputerSoftware>
    <ifrs-full:ComputerSoftware
      contextRef="PAsOn12_31_2021_InternallyGeneratedMemberifrsfullMethodsOfGenerationAxis"
      decimals="-6"
      unitRef="Unit_GBP">526000000</ifrs-full:ComputerSoftware>
    <gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">83000000</gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged>
    <gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">694000000</gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged>
    <gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">776000000</gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed>
    <gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">104000000</gsk:IntangibleAssetsForWhichImpairmentsHaveBeenReversed>
    <ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortisation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;impairment&#160;losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a) &lt;/div&gt;&#160;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&#x2013;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;116&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;65&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;307&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;373&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;1,088&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;367&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;438&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">663000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">750000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">116000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">126000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">66000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">65000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">307000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">212000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">299000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">373000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1086000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:AmortisationOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1088000000</gsk:AmortisationOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">367000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:NetImpairmentLossesOtherIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">438000000</gsk:NetImpairmentLossesOtherIntangibleAssets>
    <gsk:DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory contextRef="P01_01_2022To12_31_2022">The book values of the largest individual items are as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tesaro Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,858&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,677&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Meningitis portfolio&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,855&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,889&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Momelotinib&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,499&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Affinivax Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,473&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dolutegravir&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benlysta&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;541&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Alector Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;509&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;iTeos Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;444&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shingrix&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;288&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;268&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Okairos&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;BMS Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;196&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Spero&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Vir Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fluarix/FluLaval&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;147&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Stiefel trade name&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;CureVac Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lamisil&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Others&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,797&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,697&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Disposed of as part of the Consumer Healthcare demerger (Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2858000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TesaroAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2677000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1855000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MeningitisPortfolioMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1889000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_MomelotinibMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1499000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AffinivaxAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1473000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1150000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_DolutegravirMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">1093000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">541000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_BenlystaMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">644000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">509000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_AlectorMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">509000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_IteosMemberGSKBenlystaAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">444000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">288000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ShingrixMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">268000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">202000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OkairosMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">191000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">196000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_BMSAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">219000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_SperoMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">163000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">159000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_VirAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">212000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">147000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_FluarixFlulavalMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">180000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">142000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_StiefelTradeNameMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">151000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_CurevacAssetsMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">164000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LamisilMemberifrsfullIntangibleAssetsMaterialToEntityAxis_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">259000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1932000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OthersProductsMemberifrsfullIntangibleAssetsMaterialToEntityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1797000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">13663000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn12_31_2021_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_GBP">10697000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;21. Investments in associates and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;joint&lt;/div&gt; ventures &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:66%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint&lt;br/&gt; ventures&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Associates&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint&lt;br/&gt; ventures&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Associates&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;76&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;88&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;349&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;364&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(278&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(278&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Distributions received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through Other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of interest in associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit/(loss) after tax recognised in the consolidated income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;76&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-block: 0em;"/&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 20&#160;May 2021, the Group agreed with Innoviva Inc to sell all of its shares in Innoviva back to Innoviva for &#xa3;277&#160;million. Following settlement of the transaction, GSK no longer held any Innoviva stock. A loss of &#xa3;46&#160;million (including &#xa3;10&#160;million of recycling of exchange differences in Innoviva) is presented in Loss on disposal of interest in associates in the 2021 Consolidated income statement. The transaction did not include any changes in Innoviva&#x2019;s commercial interest in royalties paid by GSK. Loss on disposal of interest in associates in 2021 also includes a &#xa3;10&#160;million gain from a disposal of another immaterial associate. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Please refer to the Income statement information on associates and joint ventures in Note 13. &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:66%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint&lt;br/&gt; ventures&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Associates&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint&lt;br/&gt; ventures&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Associates&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;76&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;88&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;349&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;364&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(278&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(278&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Distributions received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through Other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment of interest in associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit/(loss) after tax recognised in the consolidated income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;76&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">88000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2020_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2020_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">349000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">364000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <gsk:AdditionsInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AdditionsInInvestmentsInAssociatesAndJointVentures>
    <gsk:AdditionsInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:AdditionsInInvestmentsInAssociatesAndJointVentures>
    <gsk:AdditionsInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:AdditionsInInvestmentsInAssociatesAndJointVentures>
    <gsk:AdditionsInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:AdditionsInInvestmentsInAssociatesAndJointVentures>
    <gsk:AdditionsInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:AdditionsInInvestmentsInAssociatesAndJointVentures>
    <gsk:DisposalsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DisposalsInAssociatesAndJointVentures>
    <gsk:DisposalsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DisposalsInAssociatesAndJointVentures>
    <gsk:DisposalsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DisposalsInAssociatesAndJointVentures>
    <gsk:DisposalsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">278000000</gsk:DisposalsInAssociatesAndJointVentures>
    <gsk:DisposalsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">278000000</gsk:DisposalsInAssociatesAndJointVentures>
    <gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures>
    <gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures>
    <gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures>
    <gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures>
    <gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures>
    <gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures>
    <gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures>
    <gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures>
    <gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures>
    <gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:FairValueAdjustmentInvestmentsInAssociatesAndJointVentures>
    <gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries>
    <gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries>
    <gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries>
    <gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries>
    <gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</gsk:ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2022_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2022_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">64000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021_JointVenturesMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021_AssociatesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">88000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <gsk:DisposalOfInterestInAssociate
      contextRef="P05_20_2021To05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">277000000</gsk:DisposalOfInterestInAssociate>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates
      contextRef="PAsOn05_20_2021_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates
      contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">46000000</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <gsk:RecyclingOfExchangeDifferencesInAssociate
      contextRef="P01_01_2022To12_31_2022_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:RecyclingOfExchangeDifferencesInAssociate>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates
      contextRef="P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <gsk:DisclosureOfCurrentEquityInvestmentsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;22. Current equity investments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,852&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,087&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Current equity investments represent Haleon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;plc&lt;/div&gt; shares held after the demerger of Consumer Healthcare. Shares are held for trading and measured at fair value through profit or loss (FVTPL) based on the Haleon plc share price. Changes in fair value after the demerger are presented as Other operating income/expense in continuing operations. The Group&#x2019;s investment in Haleon plc at the end of December 2022 is held by Glaxo Group Limited (5.4%), Scottish Limited Partnerships (SLPs) which were set up to collateralise agreed additional funding for GSK&#x2019;s UK Defined Benefit pension schemes (7.5%) (Note 31) and the ESOP Trusts (0.6%). Net fair value movement through profit or loss of &#xa3;233&#160;million includes a fair value gain of &#xa3;229&#160;million and &#xa3;4&#160;million of other adjustments. &lt;/div&gt;</gsk:DisclosureOfCurrentEquityInvestmentsTextBlock>
    <gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,852&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through profit or loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,087&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2021_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:PurchasesFairValueMeasurementAssets
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3852000000</ifrs-full:PurchasesFairValueMeasurementAssets>
    <gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">233000000</gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments>
    <ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading
      contextRef="PAsOn12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4087000000</ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading>
    <gsk:PercentageOfOwnership
      contextRef="P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.054</gsk:PercentageOfOwnership>
    <gsk:PercentageOfOwnership
      contextRef="P01_01_2022To12_31_2022_InvestmentInHaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</gsk:PercentageOfOwnership>
    <gsk:PercentageOfOwnership
      contextRef="P01_01_2022To12_31_2022_EsopTrustsMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.006</gsk:PercentageOfOwnership>
    <gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">233000000</gsk:NetFairValueMovementsThroughProfitOrLossCurrentInvestments>
    <gsk:FairValueGainThroughProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">229000000</gsk:FairValueGainThroughProfitOrLoss>
    <gsk:OtherAdjustmentsOfFairValueMeasurementAssets
      contextRef="P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:OtherAdjustmentsOfFairValueMeasurementAssets>
    <ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;23. Other investments &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:54%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;br/&gt; designated&#160;as&lt;br/&gt; measured at&lt;br/&gt; FVTOCI&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;br/&gt; designated&#160;as&lt;br/&gt; measured at&lt;br/&gt; FVTOCI&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through Other comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(716&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(902&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(902&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through profit or loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(220&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,153&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,126&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Non-current other investments comprise &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; equity investments which are recorded at fair value at each balance sheet date. For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price. For other investments, the fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments, recent financing rounds and discounted cash flows of the underlying net assets. Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net fair value movements include the impact of other exchange gains of &#xa3;134&#160;million through Other comprehensive income and &#xa3;nil through profit or loss (2021: gains of &#xa3;15&#160;million through Other comprehensive income and &#xa3;2&#160;million through profit or loss). Other investments include listed investments of &#xa3;823&#160;million (2021: &#xa3;1,736 million). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK has elected to designate the majority of its equity investments as measured at fair value through Other comprehensive income (FVTOCI). The most significant of these investments held at 31&#160;December 2022 were in Vir Biotechnology, Inc. which had a fair value at 31&#160;December 2022 of &#xa3;180&#160;million (2021: &#xa3;266 million) and Nimbus Therapeutics, LLC which had a fair value at 31&#160;December 2022 of &#xa3;139&#160;million (2021: &#xa3;32 million). The fair value of the investment in CureVac N.V., disclosed as a significant investment at 31&#160;December 2021, was &#xa3;75&#160;million at 31&#160;December 2022 (2021: &#xa3;380 million). The other investments include equity stakes in companies with which GSK has research collaborations and in companies which provide access to biotechnology developments of potential interest. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On disposal of equity investments measured at FVTOCI, the accumulated fair value movements are reclassified from the fair value reserve to retained earnings. Investments measured at FVTOCI with a fair value of &#xa3;220&#160;million (2021: &#xa3;240 million) were disposed of during the year. The cumulative gain on these investments after tax was &#xa3;14&#160;million (2021: &#xa3;132 million). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Certain other investments, such as investments in funds with limited lives and investments acquired with an intention to sell, are measured at fair value through profit or loss (FVTPL). &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
    <gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:54%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;br/&gt; designated&#160;as&lt;br/&gt; measured at&lt;br/&gt; FVTOCI&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;br/&gt; designated&#160;as&lt;br/&gt; measured at&lt;br/&gt; FVTOCI&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;measured&#160;at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;FVTPL&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through Other comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(716&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(902&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(902&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movements through profit or loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(220&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,153&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,126&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1927000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2126000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2020_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2939000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2020_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">121000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2020_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3060000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">75000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments
      contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">100000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments
      contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">87000000</gsk:AdditionsToOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</gsk:AdditionsToOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">150000000</gsk:AdditionsToOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">125000000</gsk:AdditionsToOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</gsk:AdditionsToOtherInvestments>
    <gsk:AdditionsToOtherInvestments
      contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">177000000</gsk:AdditionsToOtherInvestments>
    <gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-716000000</gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome>
    <gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-716000000</gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome>
    <gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-902000000</gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome>
    <gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-902000000</gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome>
    <gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments>
    <gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments
      contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments>
    <gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments>
    <gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments
      contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments>
    <gsk:DisposalsAndSettlementsOtherInvestments
      contextRef="P01_01_2022To12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">220000000</gsk:DisposalsAndSettlementsOtherInvestments>
    <gsk:DisposalsAndSettlementsOtherInvestments
      contextRef="P01_01_2022To12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">220000000</gsk:DisposalsAndSettlementsOtherInvestments>
    <gsk:DisposalsAndSettlementsOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</gsk:DisposalsAndSettlementsOtherInvestments>
    <gsk:DisposalsAndSettlementsOtherInvestments
      contextRef="P01_01_2021To12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:DisposalsAndSettlementsOtherInvestments>
    <gsk:DisposalsAndSettlementsOtherInvestments
      contextRef="P01_01_2021To12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">251000000</gsk:DisposalsAndSettlementsOtherInvestments>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2022_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1153000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2022_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">314000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2022_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1467000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1927000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_InvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2126000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <gsk:AdjustmentsForForeignExchangeOtherInvestments
      contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">134000000</gsk:AdjustmentsForForeignExchangeOtherInvestments>
    <gsk:AdjustmentsForForeignExchangeOtherInvestments
      contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:AdjustmentsForForeignExchangeOtherInvestments
      contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:AdjustmentsForForeignExchangeOtherInvestments>
    <gsk:AdjustmentsForForeignExchangeOtherInvestments
      contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:AdjustmentsForForeignExchangeOtherInvestments>
    <gsk:ListedInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">823000000</gsk:ListedInvestments>
    <gsk:ListedInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1736000000</gsk:ListedInvestments>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2022_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">180000000</gsk:InvestmentFairValue>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2021_VirBiotechnologyIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">266000000</gsk:InvestmentFairValue>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2022_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">139000000</gsk:InvestmentFairValue>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2021_NimbusTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</gsk:InvestmentFairValue>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2022_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">75000000</gsk:InvestmentFairValue>
    <gsk:InvestmentFairValue
      contextRef="PAsOn12_31_2021_CureVacNVMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">380000000</gsk:InvestmentFairValue>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition
      contextRef="PAsOn12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">220000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition
      contextRef="PAsOn12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition>
    <ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;24. Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amounts receivable under insurance contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;857&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in surplus&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;108&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Amounts receivable under insurance contracts are held at cash surrender value with movements through profit or loss. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Within the other receivables of &#xa3;108&#160;million (2021: &#xa3;86 million), &#xa3;34&#160;million (2021: &#xa3;44 million) is classified as financial assets of which &#xa3;13&#160;million (2021: &#xa3;23 million) is classified as fair value through profit or loss. On the remaining balance of &#xa3;21&#160;million (2021: &#xa3;21 million), the expected credit loss allowance was immaterial at 31&#160;December 2022 and 2021. &lt;/div&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amounts receivable under insurance contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;857&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in surplus&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;108&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory>
    <gsk:ReceivablesRelatedToInsuranceContracts
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">857000000</gsk:ReceivablesRelatedToInsuranceContracts>
    <gsk:ReceivablesRelatedToInsuranceContracts
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">849000000</gsk:ReceivablesRelatedToInsuranceContracts>
    <ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">229000000</ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">741000000</ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">108000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">86000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1194000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1676000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">108000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">86000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis_RemainingBalanceMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssets>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;25. Inventories &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Raw materials and consumables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,889&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,284&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;5,783&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Raw materials and consumables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,889&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,284&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;5,783&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1576000000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1772000000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2286000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1889000000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1284000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2122000000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5146000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5783000000</ifrs-full:Inventories>
    <gsk:DisclosureOfTradesAndOtherReceivableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;26. Trade and other receivables &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade receivables, net of loss allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,452&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Accrued income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Prepayments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest receivable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employee loans and advances&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,226&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,053&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;7,860&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There were no trade or other receivable balances (2021: &#xa3;nil) due from associates and joint ventures. The most significant component of other receivables comprises receivables for taxes other than corporate income tax. Other significant balances within other receivables are royalties receivable and amounts receivable from collaboration partners. &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss allowance - trade receivables&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Subsequent recoveries of amounts provided for&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Utilised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Of the total trade receivables balance, &#xa3;58&#160;million (2021: &#xa3;86 million) is considered credit impaired, against which a &#xa3;26&#160;million (2021: &#xa3;4 million) expected credit loss allowance has been applied. No amount was purchased or originated credit impaired. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Within the other receivables of &#xa3;1,226&#160;million (2021: &#xa3;1,266 million), &#xa3;683&#160;million (2021: &#xa3;553 million) is classified as financial assets of which &#xa3;nil (2021: &#xa3;nil) is classified as held at fair value through profit or loss. At 31&#160;December 2022 an expected credit loss allowance of &#xa3;6&#160;million (2021: &#xa3;5 million) was recognised in respect of financial assets with no charge reported in profit or loss during the year. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For more discussion on credit risk practices, please refer to Note 44. &lt;/div&gt;</gsk:DisclosureOfTradesAndOtherReceivableTextBlock>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade receivables, net of loss allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,452&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Accrued income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Prepayments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest receivable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employee loans and advances&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other receivables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,226&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,053&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;7,860&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5452000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">6246000000</ifrs-full:TradeReceivables>
    <ifrs-full:AccruedIncomeOtherThanContractAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:AccruedIncomeOtherThanContractAssets>
    <ifrs-full:AccruedIncomeOtherThanContractAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:AccruedIncomeOtherThanContractAssets>
    <ifrs-full:Prepayments
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">343000000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">315000000</ifrs-full:Prepayments>
    <ifrs-full:InterestReceivable
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:InterestReceivable>
    <ifrs-full:InterestReceivable
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:InterestReceivable>
    <gsk:EmployeeLoansAndAdvances
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:EmployeeLoansAndAdvances>
    <gsk:EmployeeLoansAndAdvances
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">18000000</gsk:EmployeeLoansAndAdvances>
    <ifrs-full:OtherReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1226000000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1266000000</ifrs-full:OtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7053000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7860000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TradeReceivables>
    <ifrs-full:OtherReceivables
      contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherReceivables>
    <ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss allowance - trade receivables&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Subsequent recoveries of amounts provided for&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Utilised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory>
    <gsk:ExpectedCreditLossAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">150000000</gsk:ExpectedCreditLossAllowance>
    <gsk:ExpectedCreditLossAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">151000000</gsk:ExpectedCreditLossAllowance>
    <gsk:ExpectedCreditLossAllowanceExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:ExpectedCreditLossAllowanceExchangeAdjustments>
    <gsk:ExpectedCreditLossAllowanceExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</gsk:ExpectedCreditLossAllowanceExchangeAdjustments>
    <gsk:IncreaseDecreaseInExpectedCreditLossesAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-35000000</gsk:IncreaseDecreaseInExpectedCreditLossesAllowance>
    <gsk:IncreaseDecreaseInExpectedCreditLossesAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-52000000</gsk:IncreaseDecreaseInExpectedCreditLossesAllowance>
    <gsk:ExpectedCreditLossAllowanceTransferToAssetsHeldForSale
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</gsk:ExpectedCreditLossAllowanceTransferToAssetsHeldForSale>
    <gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance>
    <gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-39000000</gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance>
    <gsk:ExpectedCreditLossAllowanceUtilised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-24000000</gsk:ExpectedCreditLossAllowanceUtilised>
    <gsk:ExpectedCreditLossAllowanceUtilised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</gsk:ExpectedCreditLossAllowanceUtilised>
    <gsk:ExpectedCreditLossAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">91000000</gsk:ExpectedCreditLossAllowance>
    <gsk:ExpectedCreditLossAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">150000000</gsk:ExpectedCreditLossAllowance>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">58000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialInstrumentsCreditimpairedMemberifrsfullCreditImpairmentOfFinancialInstrumentsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">86000000</ifrs-full:TradeAndOtherReceivables>
    <gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired
      contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired>
    <gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired
      contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired>
    <ifrs-full:OtherReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1226000000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1266000000</ifrs-full:OtherReceivables>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">683000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_OtherReceivableMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">553000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount
      contextRef="PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount>
    <ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount
      contextRef="PAsOn12_31_2021_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;27. Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash at bank and in hand&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;879&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Short-term deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,844&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;During 2022 &#xa3;1,421&#160;million was transferred to assets held for sale relating to the Consumer Healthcare business that was demerged during the year (see Note 41). Cash and cash equivalents included &#xa3;0.2&#160;billion (2021: &#xa3;0.2 billion) not available for general use due to restrictions applying in the subsidiaries where it is held. Restrictions include exchange controls and taxes on repatriation.</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash at bank and in hand&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;879&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Short-term deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,844&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory>
    <ifrs-full:Cash
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">879000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1427000000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2844000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2847000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3723000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4274000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:AssetsTransferredToStructuredEntitiesAtTimeOfTransfer
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">1421000000</ifrs-full:AssetsTransferredToStructuredEntitiesAtTimeOfTransfer>
    <ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">200000000</ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup>
    <ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup
      contextRef="PAsOn12_31_2021"
      decimals="-8"
      unitRef="Unit_GBP">200000000</ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;28. Assets held for sale &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets and disposal groups are transferred to assets held for sale when it is expected that their carrying amounts will be recovered principally through disposal and a sale is considered highly probable. They are held at the lower of carrying amount and fair value less costs to sell. &lt;/div&gt;In Q2 2022, the Consumer Healthcare business was classified as held for sale. Following completion of the demerger of the Consumer Healthcare business in Q3 2022, a total of &#xa3;12.9&#160;billion of net assets and liabilities were distributed/derecognised as part of the gain on the demerger.</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <gsk:DisclosureOfAssetsHeldForSaleExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:8pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</gsk:DisclosureOfAssetsHeldForSaleExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:PropertyPlantAndEquipment>
    <gsk:OtherAssetsNet
      contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:OtherAssetsNet>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
      contextRef="PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
      contextRef="PAsOn12_31_2021_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts
      contextRef="P01_01_2022To09_30_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis"
      decimals="-8"
      unitRef="Unit_GBP">12900000000</gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;29. Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,866&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,488&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare put option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;307&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Customer return and rebate accruals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,627&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other accruals&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,242&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,554&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade and other payables included &#xa3;nil (2021: &#xa3;nil) due to associates and joint ventures. The Group provides limited supplier financing arrangements to certain customers. The amounts involved at 31&#160;December 2022 were not material. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Revenue recognised in the year that was included in deferred income at 1&#160;January 2022 was &#xa3;85&#160;million (2021: &#xa3;29 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Customer return and rebate accruals are provided for by the Group at the point of sale in respect of estimated rebates, discounts or allowances payable to customers as more fully described in the Group financial review on page 94. At 31&#160;December 2022, Customer return and rebate accruals included &#xa3;5,717&#160;million (2021: &#xa3;5,044 million) in respect of US Commercial Operations. Accruals are made at the time of sale but the actual amounts paid are based on claims made some time after the initial recognition of the sale. As the amounts are estimated, they may not fully reflect the final outcome and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The level of accrual is reviewed and adjusted quarterly in light of historical experience of actual amounts paid and any changes in arrangements. Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the Group. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Pfizer&#x2019;s put option over its shareholding in ViiV Healthcare is currently exercisable. Pfizer may request an IPO of ViiV Healthcare at any time and if either GSK does not consent to such IPO or an offering is not completed within nine months, Pfizer could require GSK to acquire its shareholding. The amount of the liability for this put option, which is held on the gross redemption basis, is derived from an internal valuation of the ViiV Healthcare business, utilising both discounted forecast future cash flow and multiples-based methodologies. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below shows on an indicative basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Increase/(decrease) in financial liability and loss/(gain) in Income statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% increase in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;149&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(99&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% decrease in sales forecast*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(149&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.50% (150 basis points) increase in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) decrease in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.50% (150 basis points) decrease in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL"&gt;* The sales forecast is for ViiV Healthcare sales only in respect of the ViiV Healthcare put option. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other accruals includes interest accrued on financial liabilities at amortised cost of &#xa3;207&#160;million (2021: &#xa3;244 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;An explanation of the accounting for ViiV Healthcare is set out on page 71. &lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <gsk:SummaryOfTradePayablesExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">&#160;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,866&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Wages and salaries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,488&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Social security&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare put option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;307&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Customer return and rebate accruals&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,627&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other accruals&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,242&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,554&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:SummaryOfTradePayablesExplanatoryTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3866000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4535000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <gsk:WagesAndSalariesPayable
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1488000000</gsk:WagesAndSalariesPayable>
    <gsk:WagesAndSalariesPayable
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1470000000</gsk:WagesAndSalariesPayable>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">152000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <gsk:PutOptionPayable
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1093000000</gsk:PutOptionPayable>
    <gsk:PutOptionPayable
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1008000000</gsk:PutOptionPayable>
    <ifrs-full:OtherCurrentPayables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">418000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">518000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">299000000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">307000000</ifrs-full:ContractLiabilities>
    <gsk:CustomerReturnAndRebateAccruals
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6627000000</gsk:CustomerReturnAndRebateAccruals>
    <gsk:CustomerReturnAndRebateAccruals
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">6322000000</gsk:CustomerReturnAndRebateAccruals>
    <gsk:OtherAccruals
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2346000000</gsk:OtherAccruals>
    <gsk:OtherAccruals
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3242000000</gsk:OtherAccruals>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">16263000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">17554000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">85000000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:RevenueAndOperatingIncome>
    <gsk:CustomerReturnAndRebateAccruals
      contextRef="PAsOn12_31_2022_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">5717000000</gsk:CustomerReturnAndRebateAccruals>
    <gsk:CustomerReturnAndRebateAccruals
      contextRef="PAsOn12_31_2021_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMemberifrsfullAssetsAndLiabilitiesAxis_USPharmaceuticalsAndVaccinesMemberGSKSegmentConsolidationItemAxis"
      decimals="-6"
      unitRef="Unit_GBP">5044000000</gsk:CustomerReturnAndRebateAccruals>
    <gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below shows on an indicative basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Increase/(decrease) in financial liability and loss/(gain) in Income statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% increase in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;149&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in sales forecasts*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(99&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% decrease in sales forecast*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(149&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.50% (150 basis points) increase in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) decrease in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.50% (150 basis points) decrease in discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(32&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL"&gt;* The sales forecast is for ViiV Healthcare sales only in respect of the ViiV Healthcare put option. &lt;/div&gt;</gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">100000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">89000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">149000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">133000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-99000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-89000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-149000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-134000000</gsk:IncreaseDecreaseInFinancialLiability>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-32000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-30000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-48000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-45000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="P01_01_2022To12_31_2022_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">35000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="P01_01_2021To12_31_2021_DiscountRateMeasurementInputMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">66000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">103000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">81000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-56000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-47000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-80000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-64000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">46000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">41000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-24000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-22000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-35000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:IncreaseDecreaseInFinancialLiability
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-32000000</gsk:IncreaseDecreaseInFinancialLiability>
    <gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">207000000</gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost>
    <gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">244000000</gsk:InterestAccruedOnFinancialLiabilitiesAtAmortizedCost>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;30. Net debt &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:43%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:40%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Listing exchange&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,790&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,335&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term borrowings:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank loans, overdrafts and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(448&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.850% US$ US Medium Term Note 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,483&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.875% US$ US Medium Term Note 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,113&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; European Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; European Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.534% US$ Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,038&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,952&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,601&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term borrowings:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.800% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(629&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(925&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(420&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.534% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.000% US$ US Medium Term Note 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(739&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.375% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(884&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(836&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(627&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.625% US$ US Medium Term Note 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(827&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(620&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(587&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.250% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(885&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% &#xa3; Euro Medium Term Note 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(595&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.875% US$ US Medium Term Note 2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,450&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,294&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.250% &#xa3; Euro Medium Term Note 2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(743&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% US$ US Medium Term Note 2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(822&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(733&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.375% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(441&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(418&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.750% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2030&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(628&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2032&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(616&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.250% &#xa3; Euro Medium Term Note 2033&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(1) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(640&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(984&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.375% US$ US Medium Term Note 2034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(368&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.625% &#xa3; Euro Medium Term Note 2035&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(744&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;6.375% US$ US Medium Term Note 2038&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,022&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;6.375% &#xa3; Euro Medium Term Note 2039&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(1) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(695&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(695&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.250% &#xa3; Euro Medium Term Note 2042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(472&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(987&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.200% US$ US Medium Term Note 2043&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(364&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.250% &#xa3; Euro Medium Term Note 2045&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(789&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other long-term borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(812&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,572&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Partially purchased and cancelled on 13&#160;February 2023. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Liquid investments are classified as financial assets at amortised cost. At 31&#160;December 2022, they included US Treasury Notes and other government bonds. The effective interest rate on liquid investments at 31&#160;December 2022 was approximately 0.1% (2021: approximately 0.1%). Liquid investment balances at 31&#160;December 2022 earning interest at floating rates amount to &#xa3;67&#160;million (2021: &#xa3;2 million). Liquid investment balances at 31&#160;December 2022 earning interest at fixed rates amount to &#xa3;nil (2021: &#xa3;59 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Balances reported within cash and cash equivalents have an original maturity of three months or less. The effective interest rate on cash and cash equivalents at 31&#160;December 2022 was approximately 3.1% (2021: approximately 0.6%). Cash and cash equivalents at 31&#160;December 2022 earning interest at floating and fixed rates amounted to &#xa3;3,441&#160;million and &#xa3;10&#160;million respectively (2021: &#xa3;3,906&#160;million and &#xa3;39 million) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing holdings amounted to &#xa3;272&#160;million (2021: &#xa3;329 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK&#x2019;s policy regarding the credit quality of cash and cash equivalents is set out in Note 44, &#x2018;Financial instruments and related disclosures&#x2019;. &lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term borrowings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;GSK has a $10&#160;billion (&#xa3;8.3 billion) US commercial paper programme, of which $900&#160;million (&#xa3;748 million) was in issue at 31&#160;December 2022 (2021: $nil). GSK has a &#xa3;5&#160;billion Euro commercial paper programme, of which &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;500&#160;million (&#xa3;443 million) was in issue at 31&#160;December 2022 (2021: &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;300&#160;million (&#xa3;252 million)). In February 2022 GSK cancelled the &#xa3;1.9&#160;billion three year and $2.5&#160;billion (&#xa3;2.1 billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities in September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#xa3;1.6&#160;billion and $2.2&#160;billion (&#xa3;1.8 billion) respectively. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The weighted average interest rate on commercial paper borrowings at 31&#160;December 2022 was 3.5% (2021: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-0.5%).&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The weighted average interest rate on current bank loans and overdrafts at 31&#160;December 2022 was 7.8% (2021: 7.9%). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average effective &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-swap&lt;/div&gt; interest rate of notes classified as short-term at 31&#160;December 2022 was 0.4% (2021: 3.0%). &lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term borrowings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end,&lt;/div&gt; GSK had long-term borrowings of &#xa3;17.0&#160;billion (2021: &#xa3;20.6 billion), of which &#xa3;11.1&#160;billion (2021: &#xa3;11.7 billion) fell due in more than five years. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2022, three bonds were repaid earlier than original maturity, those being the 2.800% US$ US Medium Term Note 2023, the 3.375% US$ US Medium Term Note 2023 and the 0.000% US$ US Medium Term Note 2023. Also, during 2022 GSK undertook a tender on outstanding Sterling Notes, repaying face values of &#xa3;292&#160;million on the 3.375% &#xa3; Euro Medium Term Note 2027, &#xa3;350&#160;million on the 5.250% &#xa3; Euro Medium Term Note 2033, &#xa3;522&#160;million on the 5.250% &#xa3; Euro Medium Term Note 2042 and &#xa3;429&#160;million on the 4.250% &#xa3; Euro Medium Term Note 2045. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average effective &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-swap&lt;/div&gt; interest rate of all notes in issue at 31&#160;December 2022 was approximately 3.5% (2021: approximately 3.3%). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Long-term borrowings repayable after five years carry interest at effective rates between 1.4% and 6.4%, with repayment dates ranging from 2027&#160;to 2045. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Both effective rates exclude the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-off&lt;/div&gt; premiums associated with the early repayment of the Sterling Notes. &lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pledged assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group held pledged investments in US Treasury Notes with a par value of $56&#160;million (&#xa3;47 million), (2021: $56&#160;million (&#xa3;42 million)) as security against irrevocable letters of credit issued on the Group&#x2019;s behalf in respect of the Group&#x2019;s self-insurance activity. Provisions in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 32, &#x2018;Other provisions&#x2019;. &lt;/div&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The maturity analysis of discounted lease liabilities recognised on the Group balance sheet is as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due within one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;201&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due after five years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;336&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,008&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:43%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:40%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Listing exchange&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,790&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,335&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term borrowings:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank loans, overdrafts and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(448&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.850% US$ US Medium Term Note 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,483&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.875% US$ US Medium Term Note 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,113&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; European Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; European Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.534% US$ Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,038&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,952&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,601&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term borrowings:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;2.800% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(629&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(925&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(420&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;0.534% US$ US Medium Term Note 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.000% US$ US Medium Term Note 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(739&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.375% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(884&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(836&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(627&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.625% US$ US Medium Term Note 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(827&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(620&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(587&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.250% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(885&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.000% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% &#xa3; Euro Medium Term Note 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(595&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.875% US$ US Medium Term Note 2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,450&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,294&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.250% &#xa3; Euro Medium Term Note 2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(743&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.375% US$ US Medium Term Note 2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(822&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(733&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.375% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(441&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(418&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.750% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2030&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(663&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(628&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3.125% &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt; Euro Medium Term Note 2032&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(616&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.250% &#xa3; Euro Medium Term Note 2033&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(1) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(640&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(984&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.375% US$ US Medium Term Note 2034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(368&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.625% &#xa3; Euro Medium Term Note 2035&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(744&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;6.375% US$ US Medium Term Note 2038&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,022&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;6.375% &#xa3; Euro Medium Term Note 2039&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(1) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(695&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(695&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;5.250% &#xa3; Euro Medium Term Note 2042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(472&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(987&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.200% US$ US Medium Term Note 2043&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;New York Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(364&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;4.250% &#xa3; Euro Medium Term Note 2045&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom"&gt;London Stock Exchange&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(789&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other long-term borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(812&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,572&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Partially purchased and cancelled on 13&#160;February 2023. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <gsk:LiquidInvestmentsCurrent
      contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</gsk:LiquidInvestmentsCurrent>
    <gsk:LiquidInvestmentsCurrent
      contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</gsk:LiquidInvestmentsCurrent>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3723000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4274000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2022_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3790000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2021_Debt1MemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4335000000</ifrs-full:CurrentAssets>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1191000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">252000000</ifrs-full:CommercialPapersIssued>
    <gsk:BankLoansoverdraftsAndOther
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">448000000</gsk:BankLoansoverdraftsAndOther>
    <gsk:BankLoansoverdraftsAndOther
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">550000000</gsk:BankLoansoverdraftsAndOther>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1483000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1113000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">665000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1038000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">167000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">203000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3952000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3601000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">926000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">629000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">925000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">204000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">420000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">926000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">829000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">739000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">884000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">836000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">663000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">627000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">827000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">738000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">620000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePercentEuroMediumTermNotesTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">587000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">885000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">838000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">442000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">306000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">595000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1450000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1294000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">744000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">743000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">822000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">733000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">441000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">418000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">663000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">628000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">616000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">640000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">984000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">412000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">368000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">744000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">744000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">2264000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">2022000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">695000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LondonStockExchangeMemberdeiEntityListingsExchangeAxis_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">695000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">472000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">987000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">408000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMemberifrsfullBorrowingsByNameAxis_NewYorkStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">364000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">366000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis_LondonStockExchangeMemberdeiEntityListingsExchangeAxis"
      decimals="-6"
      unitRef="Unit_GBP">789000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_OtherLongtermBorrowingsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">841000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">812000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17035000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">20572000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17197000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:Borrowings>
    <gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.001</gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments>
    <gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.001</gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments>
    <gsk:LiquidInvestments
      contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</gsk:LiquidInvestments>
    <gsk:LiquidInvestments
      contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:LiquidInvestments>
    <gsk:LiquidInvestments
      contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      unitRef="Unit_GBP"
      xsi:nil="true"/>
    <gsk:LiquidInvestments
      contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</gsk:LiquidInvestments>
    <gsk:EffectiveInterestRateOnCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.031</gsk:EffectiveInterestRateOnCashAndCashEquivalents>
    <gsk:EffectiveInterestRateOnCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.006</gsk:EffectiveInterestRateOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3441000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3906000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2022_NonInterestBearingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">272000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn12_31_2021_NonInterestBearingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">329000000</ifrs-full:CashAndCashEquivalents>
    <gsk:CommercialPaperAuthorized
      contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="INF"
      unitRef="Unit_USD">10000000000</gsk:CommercialPaperAuthorized>
    <gsk:CommercialPaperAuthorized
      contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-8"
      unitRef="Unit_GBP">8300000000</gsk:CommercialPaperAuthorized>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_USD">900000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2021_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <gsk:CommercialPaperAuthorized
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-9"
      unitRef="Unit_GBP">5000000000</gsk:CommercialPaperAuthorized>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_EUR">500000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_EUR">300000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2021_EuroCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</ifrs-full:CommercialPapersIssued>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">1900000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_USD">2500000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_GBP">2100000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_GBP">1600000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_USD">2200000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_GBP">1800000000</ifrs-full:UndrawnBorrowingFacilities>
    <gsk:WeightedAverageInterestRateOnBorrowings
      contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.035</gsk:WeightedAverageInterestRateOnBorrowings>
    <gsk:WeightedAverageInterestRateOnBorrowings
      contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.035</gsk:WeightedAverageInterestRateOnBorrowings>
    <gsk:WeightedAverageInterestRateOnBorrowings
      contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis"
      decimals="3"
      unitRef="Unit_pure">-0.005</gsk:WeightedAverageInterestRateOnBorrowings>
    <gsk:WeightedAverageInterestRateOnBorrowings
      contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis"
      decimals="3"
      unitRef="Unit_pure">-0.005</gsk:WeightedAverageInterestRateOnBorrowings>
    <gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.078</gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts>
    <gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.078</gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts>
    <gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.079</gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts>
    <gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.079</gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts>
    <gsk:AverageEffectivePreSwapInterestRateShortTerm
      contextRef="PAsOn12_31_2022_ShortTermNotesMemberifrsfullMaturityAxis"
      decimals="3"
      unitRef="Unit_pure">0.004</gsk:AverageEffectivePreSwapInterestRateShortTerm>
    <gsk:AverageEffectivePreSwapInterestRateShortTerm
      contextRef="PAsOn12_31_2021_ShortTermNotesMemberifrsfullMaturityAxis"
      decimals="3"
      unitRef="Unit_pure">0.03</gsk:AverageEffectivePreSwapInterestRateShortTerm>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">17000000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021"
      decimals="-8"
      unitRef="Unit_GBP">20600000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_GBP">11100000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_GBP">11700000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.028</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.03375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">292000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.03375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">350000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.0525</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">522000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.0525</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">429000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn12_31_2022_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMemberifrsfullBorrowingsByNameAxis"
      decimals="5"
      unitRef="Unit_pure">0.0425</ifrs-full:BorrowingsInterestRate>
    <gsk:AverageEffectivePreSwapInterestRateNotesIssued
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.035</gsk:AverageEffectivePreSwapInterestRateNotesIssued>
    <gsk:AverageEffectivePreSwapInterestRateNotesIssued
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.033</gsk:AverageEffectivePreSwapInterestRateNotesIssued>
    <gsk:CarryInterestAtEffectiveRates
      contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="3"
      unitRef="Unit_pure">0.014</gsk:CarryInterestAtEffectiveRates>
    <gsk:CarryInterestAtEffectiveRates
      contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.064</gsk:CarryInterestAtEffectiveRates>
    <gsk:RepaymentYear contextRef="P01_01_2022To12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_LaterThanFiveYearsMemberifrsfullMaturityAxis">2027</gsk:RepaymentYear>
    <gsk:RepaymentYear contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis_TopOfRangeMemberifrsfullRangeAxis">2045</gsk:RepaymentYear>
    <gsk:PledgedInvestments
      contextRef="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</gsk:PledgedInvestments>
    <gsk:PledgedInvestments
      contextRef="P01_01_2022To12_31_2022_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">47000000</gsk:PledgedInvestments>
    <gsk:PledgedInvestments
      contextRef="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</gsk:PledgedInvestments>
    <gsk:PledgedInvestments
      contextRef="P01_01_2021To12_31_2021_LetterOfCredit1MemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">42000000</gsk:PledgedInvestments>
    <gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The maturity analysis of discounted lease liabilities recognised on the Group balance sheet is as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due within one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;201&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rental payments due after five years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;336&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,008&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">167000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">203000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">201000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">185000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">127000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">120000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">97000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">93000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">80000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">73000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">336000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseObligationsGross
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">341000000</gsk:FinanceLeaseObligationsGross>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1008000000</gsk:FinanceLeaseLiability>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1015000000</gsk:FinanceLeaseLiability>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;31. Pensions and other post-employment benefits &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pension and other post-employment costs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;114&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;185&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;48&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other overseas pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;170&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded post-retirement healthcare schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;415&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;466&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Analysed as:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Funded defined benefit/hybrid pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;152&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;231&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;318&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded defined benefit pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded post-retirement healthcare schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;236&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined contribution pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;133&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;119&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;415&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;466&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;104&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;128&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;136&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;167&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;52&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;236&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK entities operate pension arrangements which cover the Group&#x2019;s material obligations to provide pensions to retired employees. These arrangements have been developed in accordance with local practices in the countries concerned. Pension benefits can be provided by state schemes; by defined contribution schemes, whereby retirement benefits are determined by the value of funds arising from contributions paid in respect of each employee; or by defined benefit schemes, whereby retirement benefits are based on employee pensionable remuneration and length of service. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Pension costs of defined benefit schemes for accounting purposes have been calculated using the projected unit credit method. In certain countries pension benefits are provided on an unfunded basis, some administered by trustee companies. Formal, independent, actuarial valuations of the Group&#x2019;s main plans are undertaken regularly, normally at least every three years. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Remeasurement movements in the year are recognised through the statement of comprehensive income. Discount rates are derived from AA rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used. Discount rates are selected to reflect the term of the expected benefit payments. Projected inflation rates and pension increases are long-term predictions based on the yield gap between long-term index-linked and fixed interest Gilts. In the UK, mortality rates are determined by adjusting the SAPS S3 standard mortality tables to reflect recent scheme experience. These rates are then projected to reflect improvements in life expectancy in line with the CMI 2021 projections with a long-term rate of improvement of 1.0% per year for both males and females. In the US, mortality rates are calculated using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PRI-2012&lt;/div&gt; white collar table adjusted to reflect recent experience. These rates are projected using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MP-2020&lt;/div&gt; to allow for future improvements in life expectancy. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2042 for an individual then at the age of 60 is as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;UK&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;US&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Male&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Male&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Projected for 2042&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29.5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.8&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The assets of funded schemes are generally held in separately administered trusts, either as specific assets or as a proportion of a general fund, or are insurance contracts. Assets are invested in different classes in order to maintain a balance between risk and return. Investments are diversified to limit the financial effect of the failure of any individual investment. The physical asset allocation strategy for three of the four UK plans is 36% in return-seeking assets and 64% in liability-matching assets. During 2019, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;buy-in&lt;/div&gt; insurance contract was purchased to cover substantially all of the obligations of the other UK plan. At 31&#160;December 2022, the value of the insurance contract was &#xa3;402&#160;million (2021: &#xa3;570 million). The asset allocation of the US plans is currently set at 25% return-seeking assets and 75% liability-matching assets. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The pension plans are exposed to risk that arises because the estimated market value of the plans&#x2019; assets might decline, the investment returns might reduce, or the estimated value of the plans&#x2019; liabilities might increase. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In line with the agreed mix of return-seeking assets to generate future returns and liability-matching assets to better match future pension obligations, the Group has defined an overall long-term investment strategy for the plans, with investments across a broad range of assets. The main market risks within the asset and hedging portfolio are against credit risk, interest rates, long-term inflation, equities, property, currency and bank counterparty risk. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The plan liabilities are a series of future cash flows with relatively long duration. On an IAS 19 basis, these cash flows are sensitive to changes in the expected long-term inflation rate and the discount rate (AA corporate bond yield curve) where an increase in long-term inflation corresponds with an increase in the liabilities, and an increase in the discount rate corresponds with a decrease in the liabilities. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The interest rate risk and credit rate risk in the US are partially hedged. The targets are based on an accounting measure of the plan liabilities. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For the UK plans, there is an interest rate and inflation hedging strategy in place. The targets are based on an economic measure of the plan liabilities. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In the UK, the defined benefit pension schemes operated for the benefit of former Glaxo Wellcome employees and former SmithKline Beecham employees remain separate. These schemes were closed to new entrants in 2001 and subsequent UK employees are entitled to join a defined contribution scheme. In addition, the Group operates a number of post-retirement healthcare schemes, the principal one of which is in the US. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Following a period of consultation with impacted employees, it was announced on 17&#160;December 2020 that the UK defined benefit plans would be closed to future accrual effective from 31&#160;March 2022. As a result, post closure the accrued benefits of active participants will be revalued in line with inflation (RPI for the legacy Glaxo Wellcome plans and CPI for the legacy SmithKline Beecham plans subject to the relevant caps for each arrangement) rather than capped pay increases. In addition, all defined benefit plan participants who were still active at 1&#160;April 2022 received a defined pension contribution of &#xa3;10,000 each. The effect of closure and the defined contribution enhancement together resulted in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-off&lt;/div&gt; cost of &#xa3;74&#160;million in 2020. As announced, the plan was closed to new entrants at 31&#160;March 2022. From 1&#160;April 2022, former defined benefits plans employees were transferred to the defined contribution plans. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;It was announced on 9&#160;September 2020 that the US cash balance pension plans would be closed to future accrual from 1&#160;January 2021. This change resulted in a credit of &#xa3;56&#160;million. On 1&#160;June 2020 and 9&#160;September 2020, two amendments were made to the retiree healthcare plans in the US resulting in a credit of &#xa3;55&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has applied the following financial assumptions in assessing the defined benefit liabilities:&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;UK&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;US&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Rest of World&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rate of increase of future earnings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expected pension increases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash balance credit/conversion rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inflation rate&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.30&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;Sensitivity analysis detailing the effect of changes in assumptions is provided on page 228. The analysis provided reflects the assumption changes which have the most material impact on the results of the Group. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31&#160;December 2022 in relation to the defined benefit pension and post-retirement healthcare schemes were as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains/(losses) recorded in the statement of comprehensive income&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,169&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;261&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(872&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost/(credit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest (income)/cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains/(losses) recorded in the statement of comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;856&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost/(credit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest (income)/cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement losses recorded in the statement of comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(96&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(90&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The amounts included within past service costs in the UK included &#xa3;6&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(2)&lt;/div&gt;: &#xa3;26&#160;million; 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(2)&lt;/div&gt;: &#xa3;23 million) of augmentation costs which arose from Major restructuring programmes, together with a charge of &#xa3;&lt;div style="display:inline;"&gt;nil&lt;/div&gt; (2021: &#xa3;&lt;div style="display:inline;"&gt;nil&lt;/div&gt;; 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(2)&lt;/div&gt;: &#xa3;70 million) in relation to the impact of the closure of the defined benefit schemes to future accrual. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2020, the past service credit of &#xa3;49 million in the US reflected the closure of the cash balance pension plans from 1 January 2021. Amendments to the retiree healthcare plan in the US in 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(2)&lt;/div&gt; resulted in a credit of &#xa3;53 million to past service costs in post-retirement benefits in 2020. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;These numbers do not include remeasurement gains/(losses) related to the demerged Consumer Healthcare business. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the table below: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Recognised in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in surplus&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Recognised in Pensions and other post-employment benefits:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in deficit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Post-retirement benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,363&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,579&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,650&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;In the event of a plan &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;wind-up,&lt;/div&gt; GSK believes the UK pension scheme rules provide the company with the right to a refund of surplus assets following the full settlement of plan liabilities. As a result, the net surplus in the UK defined benefit pension schemes is recognised in full. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other defined benefit pension schemes in the Group are as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;605&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,692&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,595&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;558&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,329&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,694&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(645&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(375&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,014&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,353&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,500&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(483&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(603&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(483&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,710&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(253&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,513&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The multi-asset funds comprise investments in pooled investment vehicles that are invested across a range of asset classes, increasing diversification within the growth portfolio. The value of funds in this asset class with a quoted market price is &#xa3;211&#160;million (2021: &#xa3;350 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The &#x2018;Other (liabilities)/assets&#x2019; category comprises cash and mark to market values of derivative positions. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Index-linked gilts held as part of a UK repo programme are included in government bonds. The related loan of &#xa3;2,376&#160;million at 31&#160;December 2022 (2021: &#xa3;513&#160;million; 2020: &#xa3;650 million) is deducted within &#x2018;Other assets&#x2019;. &lt;/div&gt; &lt;div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;522&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;731&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;502&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,503&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,334&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Asset&#160;ceiling&#160;restrictions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,299&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,644&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,191&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;333&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(273&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,870&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;333&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;541&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2020&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,911&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;585&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,066&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,333&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,055&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;758&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,989&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,206&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,858&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,445&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,007&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,310&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(353&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,124&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,092&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,428&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movements in fair values of assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,432&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;372&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;836&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;313&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;105&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,989&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,206&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;424&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;312&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;105&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,062&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;370&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;919&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(649&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(326&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,014&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,870&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In connection with the demerger of Consumer Healthcare, the 31&#160;December 2020 pension scheme valuations identified cash funding or technical provisions deficits in three GSK UK Pension Schemes. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During March 2022, GSK transferred 7,004 GSK Consumer Healthcare Holdings Limited (GSKCHH) C Ordinary Shares (representing 11.03%. (in aggregate) of GSK&#x2019;s interest in GSKCHH to three Scottish Limited Partnerships (&#x201c;SLPs&#x201d;), each providing a funding mechanism for a separate GSK UK defined benefit pension scheme. As part of the steps relating to the demerger and separation, the SLPs transferred their applicable portion of GSKCHH C Ordinary Shares to Haleon plc (&#x201c;Haleon&#x201d;) in consideration for shares in Haleon. The SLPs together hold shares representing 7.5% of the total issued share capital of Haleon. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Each pension scheme, through its SLP interest, is entitled to receive a distribution from that SLP in an amount equal to the net proceeds of sales of Haleon shares, and to receive dividend income on the Haleon shares until it has received an aggregate amount equal to an agreed threshold (&#x201c;Proceeds Threshold&#x201d;). The Proceeds Thresholds total &#xa3;1,080&#160;million (as increased by notional interest on the remaining balance from time to time), and payment of this amount would fully fund the cash funding or &#x201c;technical provisions&#x201d; deficits in the three pension schemes shown by the 31&#160;December 2020 valuations. Once the applicable Proceeds Threshold has been reached the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GSK-controlled&lt;/div&gt; General Partner of each SLP is entitled to sell the remaining Haleon shares held by the SLP and distribute the proceeds to GSK. If a pension scheme does not receive aggregate cash equal to the applicable Proceeds Threshold within 18 months after separation, then the trustee of that pension scheme will have the ability to require the SLP to instruct a broker to liquidate any remaining Haleon shares on behalf of the SLP in accordance with an agreed mandate. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2022, the Group made additional funding contributions to the UK pension schemes of &#xa3;691&#160;million (2021: &#xa3;44&#160;million; 2020: &#xa3;76 million) but no additional funding (2021: &#xa3;nil; 2020: &#xa3;nil) to the US schemes. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;As at 31&#160;December 2022, total cash contributions totalling &#xa3;735&#160;million were made towards the Proceeds Thresholds leaving a principal amount of &#xa3;345&#160;million outstanding to the UK pension schemes. The cash contributions of &#xa3;735&#160;million include voluntary cash contributions made by GSK in Q4 2022 to two of the UK defined benefit pension schemes totalling &#xa3;334&#160;million in response to the market volatility in the UK gilt markets. &lt;br/&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The outstanding accelerated contributions were collateralised by the creation of three Scottish Limited Partnerships (SLPs), into which GSK inserted a total of 692,593,037 Haleon ordinary shares across the three SLPs. Each of the three principal UK defined benefit pension schemes (two benefiting current and former Glaxo Welcome employees, with the third benefiting current and former SmithKline Beecham employees) has an interest in one of the SLPs as shown below: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:34%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:15%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:15%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:33%"/&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Scottish Limited Partnership&lt;/td&gt;
&lt;td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;General Partner&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;Limited Partners&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK (No. 1) Scottish Limited Partnership&lt;/td&gt;
&lt;td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK GP1 Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK LP Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Scheme&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK (No. 2) Scottish Limited Partnership&lt;/td&gt;
&lt;td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK GP1 Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;GSK LP Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Berkeley Square Pension Trustee Company Ltd acting on behalf of the GSK Pension Fund&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;GSK (No. 3) Scottish Limited Partnership&lt;/td&gt;
&lt;td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;GSK GP2 Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;GSK LP Ltd&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;SmithKline Beecham Pension Plan Trustee Ltd acting on behalf of the SmithKline Beecham Pension Plan&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under each of the SLP partnership agreements, the limited partners have no involvement in the management of the business and shall not take any part in the control of SLP. The general partner (in all cases, controlled by GSK plc) is responsible for the management and control of each SLP and, as such, each SLP is consolidated into the results of the Group. Each SLP therefore takes advantage of the exemption in Regulation 7 of The Partnership (Accounts) Regulations 2008 Act to not prepare and deliver audited accounts to the UK registrar. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under the SLP partnership agreement, distributions will be made from partnership income to the defined benefit pension schemes if equivalent payments have not already been made to the three defined benefit pension schemes by another GSK entity. To date, &#xa3;735&#160;million has been paid to the defined benefit pension schemes by GSK under this structure and once contributions under this structure reach &#xa3;1,080&#160;million, the defined benefit pension schemes interests&#x2019; in the SLPs ends. The remaining economic interest in the SLPs will be held by GSK LP Ltd, a 100% owned subsidiary of GSK plc. At 31&#160;December 2022, &#xa3;345&#160;million of these additional contributions remains to be paid. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;Employer contributions for 2023, excluding special funding contributions stated above, are estimated to be approximately &#xa3;350&#160;million in respect of defined benefit pension schemes and &#xa3;100&#160;million in respect of post-retirement benefits. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movements in defined benefit obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(43&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;641&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21,310&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,363&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(216&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(289&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;439&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,243&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(495&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(125&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(388&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,011&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;621&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;649&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,031&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,352&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,500&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The defined benefit pension obligation is analysed as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Funded&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(13,887&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19,419&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20,504&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(613&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(772&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(806&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14,500&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20,191&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21,310&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The liability for the US post-retirement healthcare scheme has been assessed using the same assumptions as for the US pension scheme, together with the assumption for future medical inflation of 7% (2021: 6.25%) in 2022, grading down to 5% in 2031 and thereafter. At 31&#160;December 2022, the US post-retirement healthcare scheme obligation was &#xa3;870&#160;million (2021: &#xa3;1,059&#160;million; 2020: &#xa3;1,124 million). Post-retirement benefits are unfunded. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The movement in the net defined benefit liability is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,129&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,921&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(87&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;65&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(216&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(291&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurements:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Return on plan assets, excluding amounts included in interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,883&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,056&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Loss)/gain from change in demographic assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;92&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain/(loss) from change in financial assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,868&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;716&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,340&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Experience (loss)/gain&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(949&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(215&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;110&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;919&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;312&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;313&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The remeasurements included within post-retirement benefits are detailed below: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain from change in demographic assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain/(loss) from change in financial assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;219&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;35&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(93&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Experience gains&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(82&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The defined benefit pension obligation analysed by membership category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Active&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,196&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,660&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,540&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,115&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,257&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,570&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,880&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,393&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,500&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,191&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,310&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The post-retirement benefit obligation analysed by membership category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Active&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;306&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;494&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;551&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;688&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;748&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;808&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;994&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,243&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,363&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The weighted average duration of the defined benefit obligation is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;years&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;years&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Post-retirement benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Membership numbers are not restated as the disclosure relates to the post-retirement benefit obligations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sensitivity analysis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The effect of changes in assumptions used on the benefit obligations and on the 2023 annual defined benefit pension and post-retirement costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of the plan memberships. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,341&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inflation rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(827&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;1 year&lt;br/&gt; increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Life expectancy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;1%&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;increase&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate of future healthcare inflation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:93%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pension and other post-employment costs&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;UK pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;114&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;185&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;48&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other overseas pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;170&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded post-retirement healthcare schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;415&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;466&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Analysed as:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Funded defined benefit/hybrid pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;152&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;231&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;318&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded defined benefit pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unfunded post-retirement healthcare schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined benefit schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;236&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Defined contribution pension schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;133&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;119&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;369&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;415&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;466&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">114000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046392"
      unitRef="Unit_GBP">185000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_UkDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046393"
      unitRef="Unit_GBP">239000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046395"
      unitRef="Unit_GBP">40000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_UsDefinedBenefitAndDefinedContributionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046396"
      unitRef="Unit_GBP">58000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2022To12_31_2022_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">154000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2021To12_31_2021_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046404"
      unitRef="Unit_GBP">153000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2020To12_31_2020_OtherOverseasPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046405"
      unitRef="Unit_GBP">170000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046413"
      unitRef="Unit_GBP">37000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046414"
      unitRef="Unit_GBP">-1000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">369000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69046407"
      unitRef="Unit_GBP">415000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69046408"
      unitRef="Unit_GBP">466000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2022To12_31_2022_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">152000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2021To12_31_2021_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046416"
      unitRef="Unit_GBP">231000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2020To12_31_2020_FundedDefinedBenefitPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046417"
      unitRef="Unit_GBP">318000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2022To12_31_2022_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">31000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2021To12_31_2021_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046419"
      unitRef="Unit_GBP">23000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2020To12_31_2020_UnfundedDefinedBenefitPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046420"
      unitRef="Unit_GBP">30000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046398"
      unitRef="Unit_GBP">37000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_UnfundedPostRetirementPensionPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046399"
      unitRef="Unit_GBP">-1000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2022To12_31_2022_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">236000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2021To12_31_2021_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046422"
      unitRef="Unit_GBP">291000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed
      contextRef="P01_01_2020To12_31_2020_DefinedBenefitSchemesMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046423"
      unitRef="Unit_GBP">347000000</gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed>
    <gsk:DisclosureOfDefinedContributionPlans
      contextRef="P01_01_2022To12_31_2022_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">133000000</gsk:DisclosureOfDefinedContributionPlans>
    <gsk:DisclosureOfDefinedContributionPlans
      contextRef="P01_01_2021To12_31_2021_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046380"
      unitRef="Unit_GBP">124000000</gsk:DisclosureOfDefinedContributionPlans>
    <gsk:DisclosureOfDefinedContributionPlans
      contextRef="P01_01_2020To12_31_2020_DefinedContributionPensionSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046381"
      unitRef="Unit_GBP">119000000</gsk:DisclosureOfDefinedContributionPlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">369000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      id="Fact_69046410"
      unitRef="Unit_GBP">415000000</gsk:PostemploymentBenefitExpensePlans>
    <gsk:PostemploymentBenefitExpensePlans
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_69046411"
      unitRef="Unit_GBP">466000000</gsk:PostemploymentBenefitExpensePlans>
    <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cost of sales&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;104&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;128&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Selling, general and administration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;90&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;136&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;167&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;52&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;236&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;291&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;347&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">104000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046383"
      unitRef="Unit_GBP">106000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046384"
      unitRef="Unit_GBP">128000000</ifrs-full:CostOfSales>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">90000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046386"
      unitRef="Unit_GBP">136000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046387"
      unitRef="Unit_GBP">167000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">42000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046389"
      unitRef="Unit_GBP">49000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046390"
      unitRef="Unit_GBP">52000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">236000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046401"
      unitRef="Unit_GBP">291000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_DefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046402"
      unitRef="Unit_GBP">347000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.01</gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage>
    <gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2042 for an individual then at the age of 60 is as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;
&lt;td colspan="4" style="height:0.75pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;UK&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;US&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Male&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Male&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female&lt;br/&gt; Years&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Projected for 2042&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29.5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.8&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory>
    <gsk:MalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis">P27Y3M18D</gsk:MalePensionersAverageLifeExpectancyAtSixty>
    <gsk:FemalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis">P28Y2M12D</gsk:FemalePensionersAverageLifeExpectancyAtSixty>
    <gsk:MalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">P27Y3M18D</gsk:MalePensionersAverageLifeExpectancyAtSixty>
    <gsk:FemalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">P28Y7M6D</gsk:FemalePensionersAverageLifeExpectancyAtSixty>
    <gsk:MalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis">P28Y6M</gsk:MalePensionersAverageLifeExpectancyAtSixty>
    <gsk:FemalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_ProjectedPeriodMemberifrsfullMaturityAxis">P29Y6M</gsk:FemalePensionersAverageLifeExpectancyAtSixty>
    <gsk:MalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">P28Y9M18D</gsk:MalePensionersAverageLifeExpectancyAtSixty>
    <gsk:FemalePensionersAverageLifeExpectancyAtSixty contextRef="P01_01_2022To12_31_2022_ProjectedPeriodMemberifrsfullMaturityAxis_USifrsfullGeographicalAreasAxis">P30Y1M6D</gsk:FemalePensionersAverageLifeExpectancyAtSixty>
    <gsk:AllocationToReturnSeekingAssets
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.36</gsk:AllocationToReturnSeekingAssets>
    <gsk:AllocationToLiabilityMatchingAssets
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.64</gsk:AllocationToLiabilityMatchingAssets>
    <gsk:TotalValueOfTheInsuranceContract
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">402000000</gsk:TotalValueOfTheInsuranceContract>
    <gsk:TotalValueOfTheInsuranceContract
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">570000000</gsk:TotalValueOfTheInsuranceContract>
    <gsk:AllocationToReturnSeekingAssets
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</gsk:AllocationToReturnSeekingAssets>
    <gsk:AllocationToLiabilityMatchingAssets
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</gsk:AllocationToLiabilityMatchingAssets>
    <ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset
      contextRef="P12_17_2020To12_17_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_GBP">10000</ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset>
    <gsk:DefinedBenefitObligationAtPastServiceCost
      contextRef="PAsOn12_31_2020_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">74000000</gsk:DefinedBenefitObligationAtPastServiceCost>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn01_01_2021_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn09_09_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:SurplusDeficitInPlan>
    <gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has applied the following financial assumptions in assessing the defined benefit liabilities:&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;UK&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;US&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Rest of World&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;pa&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;%&#160;pa&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Rate of increase of future earnings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expected pension increases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash balance credit/conversion rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inflation rate&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.30&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.02</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.02</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.034</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.029</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.026</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.048</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.02</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.014</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.053</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.027</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.023</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.034</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.011</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.006</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.031</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.032</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.024</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.023</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.021</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.039</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.02</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.019</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.008</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.002</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <gsk:ActuarialAssumptionOfCashBalanceCreditRate
      contextRef="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.001</gsk:ActuarialAssumptionOfCashBalanceCreditRate>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.031</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.032</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.025</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.02</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.023</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.019</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.013</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31&#160;December 2022 in relation to the defined benefit pension and post-retirement healthcare schemes were as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains/(losses) recorded in the statement of comprehensive income&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.8px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,169&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;261&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(872&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost/(credit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest (income)/cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains/(losses) recorded in the statement of comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;856&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Amounts charged to operating profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Current service cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost/(credit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Net interest (income)/cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Gains from settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement losses recorded in the statement of comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(96&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(90&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">35000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1169000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">261000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-872000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046500"
      unitRef="Unit_GBP">53000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046501"
      unitRef="Unit_GBP">9000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046502"
      unitRef="Unit_GBP">119000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046503"
      unitRef="Unit_GBP">181000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046504"
      unitRef="Unit_GBP">17000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046515"
      unitRef="Unit_GBP">27000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046516"
      unitRef="Unit_GBP">2000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046517"
      unitRef="Unit_GBP">-10000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046518"
      unitRef="Unit_GBP">19000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046519"
      unitRef="Unit_GBP">-3000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046530"
      unitRef="Unit_GBP">3000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046531"
      unitRef="Unit_GBP">18000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046532"
      unitRef="Unit_GBP">7000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046533"
      unitRef="Unit_GBP">28000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046534"
      unitRef="Unit_GBP">22000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046545"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046546"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046547"
      unitRef="Unit_GBP">2000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046548"
      unitRef="Unit_GBP">2000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046549"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046560"
      unitRef="Unit_GBP">15000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046561"
      unitRef="Unit_GBP">12000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046562"
      unitRef="Unit_GBP">2000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046563"
      unitRef="Unit_GBP">29000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046564"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046575"
      unitRef="Unit_GBP">98000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046576"
      unitRef="Unit_GBP">41000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046577"
      unitRef="Unit_GBP">116000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046578"
      unitRef="Unit_GBP">255000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046579"
      unitRef="Unit_GBP">36000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046590"
      unitRef="Unit_GBP">572000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046591"
      unitRef="Unit_GBP">98000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046592"
      unitRef="Unit_GBP">186000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046593"
      unitRef="Unit_GBP">856000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046594"
      unitRef="Unit_GBP">68000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046505"
      unitRef="Unit_GBP">58000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046506"
      unitRef="Unit_GBP">72000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046507"
      unitRef="Unit_GBP">125000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046508"
      unitRef="Unit_GBP">255000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046509"
      unitRef="Unit_GBP">22000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046520"
      unitRef="Unit_GBP">93000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046521"
      unitRef="Unit_GBP">-49000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046522"
      unitRef="Unit_GBP">1000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046523"
      unitRef="Unit_GBP">45000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046524"
      unitRef="Unit_GBP">-53000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046535"
      unitRef="Unit_GBP">3000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046536"
      unitRef="Unit_GBP">23000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046537"
      unitRef="Unit_GBP">8000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046538"
      unitRef="Unit_GBP">34000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046539"
      unitRef="Unit_GBP">36000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046550"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046551"
      unitRef="Unit_GBP">-12000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046552"
      unitRef="Unit_GBP">7000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046553"
      unitRef="Unit_GBP">-5000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046554"
      unitRef="Unit_GBP">6000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046565"
      unitRef="Unit_GBP">9000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046566"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046567"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046568"
      unitRef="Unit_GBP">9000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046569"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046580"
      unitRef="Unit_GBP">163000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046581"
      unitRef="Unit_GBP">58000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046582"
      unitRef="Unit_GBP">127000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046583"
      unitRef="Unit_GBP">348000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046584"
      unitRef="Unit_GBP">-1000000</gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046595"
      unitRef="Unit_GBP">51000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046596"
      unitRef="Unit_GBP">-96000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_69046597"
      unitRef="Unit_GBP">-45000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046598"
      unitRef="Unit_GBP">-90000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      id="Fact_69046599"
      unitRef="Unit_GBP">-73000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <gsk:AugmentationCostsIncludedInPastServiceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:AugmentationCostsIncludedInPastServiceCosts>
    <gsk:AugmentationCostsIncludedInPastServiceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:AugmentationCostsIncludedInPastServiceCosts>
    <gsk:AugmentationCostsIncludedInPastServiceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">23000000</gsk:AugmentationCostsIncludedInPastServiceCosts>
    <gsk:AugmentationCostsFromRestructuringProgrammes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AugmentationCostsFromRestructuringProgrammes>
    <gsk:AugmentationCostsFromRestructuringProgrammes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AugmentationCostsFromRestructuringProgrammes>
    <gsk:AugmentationCostsFromRestructuringProgrammes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">70000000</gsk:AugmentationCostsFromRestructuringProgrammes>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_UsCashBalancePensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-49000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_RetireeHealthcarePlansMemberifrsfullDefinedBenefitPlansAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <gsk:DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the table below: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Recognised in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in surplus&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Recognised in Pensions and other post-employment benefits:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension schemes in deficit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.7em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Post-retirement benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,363&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,579&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,113&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,650&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory>
    <ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan
      contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">229000000</ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan
      contextRef="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">741000000</ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan
      contextRef="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1585000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1870000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2287000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">994000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1243000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1363000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2579000000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3113000000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3650000000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other defined benefit pension schemes in the Group are as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;605&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,692&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,595&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;558&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,329&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,694&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #716258;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(645&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #716258;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(375&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #716258;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,014&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,353&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,500&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(483&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;229&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(603&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(770&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(483&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,710&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(253&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,513&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;522&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;731&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;502&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,503&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;975&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,334&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Asset&#160;ceiling&#160;restrictions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,299&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,644&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,191&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;333&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(273&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,870&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;333&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(724&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(738&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;541&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&#160;31&#160;December&#160;2020&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Group&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,911&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Multi-asset funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;585&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corporate bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,066&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,333&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;unlisted&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government bonds:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&#x2013;&#160;listed&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,055&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;758&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Insurance contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,989&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,206&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Present value of scheme obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,858&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,445&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,007&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,310&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net surplus/(obligation)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Included in Pensions and other post-employment benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(353&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,124&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,104&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="3" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Actual return on plan assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,092&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,428&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1351000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">437000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">371000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2159000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1101000000</gsk:MultiAssetFunds>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1101000000</gsk:MultiAssetFunds>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">464000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">140000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">605000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1692000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">779000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">124000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2595000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">4048000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">723000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">558000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5329000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1003000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">691000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1694000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-645000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">181000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">89000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-375000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">9014000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2260000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1870000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">13144000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">9117000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3030000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2353000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14500000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-770000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-483000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1356000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">109000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">120000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">229000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-212000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-770000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-603000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1585000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-770000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-483000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1356000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4710000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-253000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-550000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5513000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">211000000</gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished>
    <gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">350000000</gsk:FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished>
    <gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2376000000</gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets>
    <gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">513000000</gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets>
    <gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">650000000</gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3954000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">522000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">731000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5207000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1415000000</gsk:MultiAssetFunds>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1415000000</gsk:MultiAssetFunds>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">68000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">68000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">502000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">154000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">657000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1503000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">975000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">140000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2618000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">5054000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">724000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">984000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6762000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1334000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">917000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2251000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-130000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">149000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">72000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">13632000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2524000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2932000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19088000000</ifrs-full:PlanAssetsAtFairValue>
    <gsk:DefinedBenefitPensionAssetCeilingRestrictions
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-26000000</gsk:DefinedBenefitPensionAssetCeilingRestrictions>
    <gsk:DefinedBenefitPensionAssetCeilingRestrictions
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-26000000</gsk:DefinedBenefitPensionAssetCeilingRestrictions>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">13299000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3248000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3644000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20191000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">333000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-724000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-738000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1129000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">606000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">135000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">741000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-273000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-724000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-873000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1870000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">333000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-724000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-738000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1129000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">541000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">97000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">686000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2686000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">539000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">686000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3911000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2075000000</gsk:MultiAssetFunds>
    <gsk:MultiAssetFunds
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2075000000</gsk:MultiAssetFunds>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">447000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">136000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">585000000</gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1113000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1066000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">154000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2333000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">6055000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">758000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">999000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7812000000</gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1409000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">988000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2397000000</gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-203000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">136000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">13582000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2635000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2989000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19206000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">13858000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3445000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">4007000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">21310000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-276000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-810000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1018000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2104000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherNoncurrentAssetsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-353000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-810000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1124000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis_PensionsAndOtherPostemploymentBenefitsMemberifrsfullAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2287000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-276000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-810000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1018000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2104000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1092000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">159000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">177000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1428000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <gsk:DisclosureOfMovementsInFairValuesOfAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movements in fair values of assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,432&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;372&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;836&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;313&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;105&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,989&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,206&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;424&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;312&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;105&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,906&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,062&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;370&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,883&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;919&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(649&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(326&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Assets at 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,014&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,870&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfMovementsInFairValuesOfAssetsExplanatory>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">12981000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2789000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2019_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2662000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">18432000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-86000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">138000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-256000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-87000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-372000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">836000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">72000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">148000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">1056000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-156000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-124000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-313000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-105000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-641000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-248000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-110000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-999000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-123000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13582000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2635000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2989000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">19206000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">31000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-184000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-153000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-187000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-57000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-262000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">354000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">40000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">424000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-139000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-40000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-133000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-312000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-105000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-618000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-267000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-97000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-982000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-120000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13632000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2524000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2906000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">19062000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">286000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">122000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">408000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-271000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-71000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-370000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-35000000</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:ExpensesNetDefinedBenefitLiabilityAsset
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExpensesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4981000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-324000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-578000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5883000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-755000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-50000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-114000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-919000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-117000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-624000000</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-624000000</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-649000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-326000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-105000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1080000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-135000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">9014000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2260000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1870000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13144000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn12_31_2022_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PlanAssetsAtFairValue>
    <gsk:SubsidiariesSharesTransferredToFundPensionSchemes
      contextRef="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis"
      decimals="0"
      unitRef="Unit_shares">7004</gsk:SubsidiariesSharesTransferredToFundPensionSchemes>
    <gsk:PercentageOfOwnershipInterestRepresentedByTransfer
      contextRef="P03_01_2022To03_31_2022_HaleonMembersrtOwnershipAxis"
      decimals="4"
      unitRef="Unit_pure">0.1103</gsk:PercentageOfOwnershipInterestRepresentedByTransfer>
    <gsk:PercentageOfOwneshipInterestHeldByTheTransferee
      contextRef="PAsOn12_31_2022_HaleonMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</gsk:PercentageOfOwneshipInterestHeldByTheTransferee>
    <gsk:MaximumProceedsThresholdAmount
      contextRef="P03_01_2022To12_31_2022_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1080000000</gsk:MaximumProceedsThresholdAmount>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">691000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">735000000</ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets>
    <gsk:RemainingAmountDueToBeContributed
      contextRef="PAsOn12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">345000000</gsk:RemainingAmountDueToBeContributed>
    <ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets
      contextRef="PAsOn12_31_2022_SLPPartneshipsMemberGSKTransfereeAxis_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">735000000</ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets>
    <gsk:VoluntaryCashContributionsMadeToThePlan
      contextRef="P01_01_2022To12_31_2022_UkDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">334000000</gsk:VoluntaryCashContributionsMadeToThePlan>
    <gsk:SubsidiarySharesTransferredIntoLimitedPartnerships
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">692593037</gsk:SubsidiarySharesTransferredIntoLimitedPartnerships>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">735000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <gsk:MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_SlpPartnershipAgreementMemberGSKAgreementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">1080000000</gsk:MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GSKLPLtdMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <gsk:AdditionalContributionDueToBePaid
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">345000000</gsk:AdditionalContributionDueToBePaid>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">350000000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">100000000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <gsk:DisclosureOfMovementInDefinedBenefitLiabilityExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pensions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;Post-retirement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Movements in defined benefit obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UK&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Rest&#160;of&#160;World&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Group&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(291&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(43&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(408&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;641&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;248&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21,310&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,363&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(216&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(289&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;439&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,243&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(495&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(125&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(388&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(32&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,011&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Scheme participants&#x2019; contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;621&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Benefits paid&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;649&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;135&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7pt; font-family: ARIAL; line-height: normal;"&gt;Obligations at 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,031&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,352&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,500&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfMovementInDefinedBenefitLiabilityExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13293000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3506000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2019_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3554000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2019_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">20353000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2019_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">1418000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">118000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-188000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-70000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">147000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">291000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-98000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">259000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">110000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">408000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">39000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-38000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-38000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-785000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-168000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-208000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1161000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-82000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">641000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">248000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">110000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">999000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13858000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3445000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">4007000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">21310000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">1363000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-40000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">258000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">151000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">216000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">289000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">164000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">439000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-24000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">618000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">267000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">97000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">982000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">120000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13299000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3248000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3644000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">20191000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">1243000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-371000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-124000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-495000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-125000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">260000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">388000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">3812000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">360000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">839000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">5011000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">621000000</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">621000000</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</gsk:TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">649000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">326000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">105000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">1080000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">135000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_GBifrsfullGeographicalAreasAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">9117000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">3031000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_RestOfWorldMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2352000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">14500000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis_PresentValueOfDefinedBenefitObligationMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_GBP">994000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">13887000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">19419000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">20504000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">613000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">772000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">806000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">14500000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">20191000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">21310000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation
      contextRef="PAsOn12_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation>
    <gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation
      contextRef="PAsOn12_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation>
    <gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation
      contextRef="PAsOn12_31_2022_TwoThousandThirtyOneAndThereafterMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">870000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1059000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_USifrsfullGeographicalAreasAxis_WhollyUnfundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1124000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The movement in the net defined benefit liability is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,129&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,921&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(87&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;65&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(216&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(291&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Past service cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Settlements and curtailments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurements:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Return on plan assets, excluding amounts included in interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,883&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;424&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,056&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Loss)/gain from change in demographic assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;92&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain/(loss) from change in financial assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,868&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;716&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,340&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Experience (loss)/gain&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(949&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(215&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;110&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Employer contributions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;919&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;312&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;313&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(35&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,356&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,104&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1129000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-2104000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">-1921000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">87000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-65000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">146000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">216000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">291000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-5883000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">424000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1056000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-92000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">62000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-69000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-5868000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-716000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1340000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">949000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">215000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-110000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">919000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">312000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">313000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">35000000</gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset>
    <gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">21000000</gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1356000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-1129000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-2104000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The remeasurements included within post-retirement benefits are detailed below: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain from change in demographic assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain/(loss) from change in financial assumptions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;219&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;35&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(93&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Experience gains&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;228&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(82&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">219000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">35000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-93000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2021To12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="P01_01_2020To12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">-82000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <gsk:DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The defined benefit pension obligation analysed by membership category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Active&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,196&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,660&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,540&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,115&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,257&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,570&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,880&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,393&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,500&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,191&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,310&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1390000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4196000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4660000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">8540000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">11115000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">11257000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4570000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4880000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">5393000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">14500000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">20191000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">21310000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <gsk:DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The post-retirement benefit obligation analysed by membership category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Active&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;306&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;494&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;551&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Retired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;688&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;748&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;808&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;994&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,243&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,363&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">306000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">494000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">551000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">688000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationRetiredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">808000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_DefinedBenefitObligationDeferredMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">994000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2021_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1243000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn12_31_2020_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_GBP">1363000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The weighted average duration of the defined benefit obligation is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;years&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;years&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pension benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Post-retirement benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">12</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2021To12_31_2021_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">15</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2020To12_31_2020_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">16</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2022To12_31_2022_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">10</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2021To12_31_2021_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">12</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <gsk:WeightedAverageDurationOfDefinedBenefitObligations
      contextRef="P01_01_2020To12_31_2020_PostRetirementBenefitMemberifrsfullDefinedBenefitPlansAxis"
      decimals="0"
      unitRef="Unit_Y">12</gsk:WeightedAverageDurationOfDefinedBenefitObligations>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The effect of changes in assumptions used on the benefit obligations and on the 2023 annual defined benefit pension and post-retirement costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of the plan memberships. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,341&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Decrease)/increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.25%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inflation rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;0.75%&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decrease&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(827&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;1 year&lt;br/&gt; increase&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Life expectancy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual pension cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in pension obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:14pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:87%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;1%&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;increase&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate of future healthcare inflation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in annual post-retirement benefits cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in post-retirement benefits obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-400000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">424000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1147000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1341000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-61000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">70000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">301000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-290000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">945000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-827000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseInAnnualPensionCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:IncreaseInAnnualPensionCost>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreasePensionObligations
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">432000000</gsk:IncreaseDecreasePensionObligations>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionOfLifeExpectancyRatesMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost>
    <gsk:IncreaseDecreaseInPostretirementBenefitsObligation
      contextRef="P01_01_2022To12_31_2022_ActuarialAssumptionForFutureHealthcareInflationMemberifrsfullActuarialAssumptionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</gsk:IncreaseDecreaseInPostretirementBenefitsObligation>
    <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;32. Other provisions &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Legal&lt;br/&gt; and&#160;other&lt;br/&gt; disputes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Major&lt;br/&gt; &#160;restructuring&lt;br/&gt; programmes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Employee&lt;br/&gt; related&lt;br/&gt; provisions&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Other&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;provisions&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,471&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversed unused&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unwinding of discount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Utilised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(539&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications and other movements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to Pension obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;To be settled within one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;To be settled after one year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;532&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and other disputes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is involved in a substantial number of legal and other disputes, including notification of possible claims, as set out in Note 47, &#x2018;Legal proceedings&#x2019;. Provisions for legal and other disputes include amounts relating to product liability, anti-trust, government investigations, contract terminations and self insurance. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group may become involved in significant legal proceedings in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, the Group would provide appropriate disclosures about such cases, but no provision would be made. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The net charge for the year of &#xa3;133&#160;million (including reversals and estimated insurance recoveries) primarily related to provisions for product liability cases, commercial disputes and various other government investigations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The discount on the provision is &#xa3;3&#160;million in 2022 (2021: &#xa3;nil). The discount was calculated using risk-adjusted projected cash flows and risk-free rates of return. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In respect of product liability claims related to certain products, provision is made when there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s position could change over time, and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#x2019;s financial accounts. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;It is in the nature of the Group&#x2019;s business that a number of these matters may be the subject of negotiation and litigation over many years. Litigation proceedings, including the various appeal procedures, often take many years to reach resolution, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-of-court&lt;/div&gt;&lt;/div&gt; settlement discussions can also often be protracted. Indemnified disputes will result in a provision charge and a corresponding receivable. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is in potential settlement discussions in a number of the disputes for which amounts have been provided and, based on its current assessment of the progress of these disputes, estimates that &#xa3;190&#160;million of the amount provided at 31&#160;December 2022 will be settled within one year. At 31&#160;December 2022, it was expected that &#xa3;nil (2021: &#xa3;4 million) of the provision made for legal and other disputes will be reimbursed by third parties. For a discussion of legal issues, See Note 47, &#x2018;Legal proceedings&#x2019;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Major restructuring programmes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2022, the Group had two major restructuring programmes in progress: the Separation Preparation programme which focused on preparing for the separation of GSK into two new companies and the Significant Acquisitions programme which is focused on the integration of recent acquisitions. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Restructuring provisions primarily include severance costs when management has made a formal decision to eliminate certain positions and this has been communicated to the groups of employees affected and appropriate consultation procedures completed, where appropriate. No provision is made for staff severance payments that are paid immediately. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The discount on the provisions increased by &#xa3;1&#160;million in 2022 (2021: increased by &#xa3;2 million). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Pension augmentation includes &#xa3;6&#160;million relating to the defined benefit plan arising from staff redundancies, as shown in Note 30, &#x2018;Pensions and other post-employment benefits&#x2019;. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee related provisions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Employee related provisions include obligations for certain medical benefits to disabled employees and their spouses in the US. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the provision for these benefits amounted to &#xa3;66&#160;million (2021: &#xa3;69 million). Other employee benefits reflect a variety of provisions for severance costs, jubilee awards and other long-service benefits. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Given the nature of these provisions, the amounts are likely to be settled over many years. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other provisions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Included in other provisions are provisions for onerous contracts, insurance provisions and a number of other provisions including vehicle insurance and regulatory matters. &lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Legal&lt;br/&gt; and&#160;other&lt;br/&gt; disputes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Major&lt;br/&gt; &#160;restructuring&lt;br/&gt; programmes&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Employee&lt;br/&gt; related&lt;br/&gt; provisions&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Other&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;provisions&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;322&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,471&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Charge for the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reversed unused&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Unwinding of discount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Utilised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(539&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to assets held for sale/distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions through business combinations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassifications and other movements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfer to Pension obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;To be settled within one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;To be settled after one year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;532&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;218&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">196000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">652000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">322000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">301000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1471000000</ifrs-full:OtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">85000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">145000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">144000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">125000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">141000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">555000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">131000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">40000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">261000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">277000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">45000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">539000000</ifrs-full:ProvisionUsedOtherProvisions>
    <gsk:TransferToAssetsHeldForSaleDistribution
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-16000000</gsk:TransferToAssetsHeldForSaleDistribution>
    <gsk:TransferToAssetsHeldForSaleDistribution
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-60000000</gsk:TransferToAssetsHeldForSaleDistribution>
    <gsk:TransferToAssetsHeldForSaleDistribution
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-22000000</gsk:TransferToAssetsHeldForSaleDistribution>
    <gsk:TransferToAssetsHeldForSaleDistribution
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:TransferToAssetsHeldForSaleDistribution>
    <gsk:TransferToAssetsHeldForSaleDistribution
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-119000000</gsk:TransferToAssetsHeldForSaleDistribution>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <gsk:TransferToPensionObligations
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToPensionObligations>
    <gsk:TransferToPensionObligations
      contextRef="P01_01_2022To12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:TransferToPensionObligations>
    <gsk:TransferToPensionObligations
      contextRef="P01_01_2022To12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToPensionObligations>
    <gsk:TransferToPensionObligations
      contextRef="P01_01_2022To12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferToPensionObligations>
    <gsk:TransferToPensionObligations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:TransferToPensionObligations>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">351000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">309000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">306000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1184000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">259000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">75000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">128000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">652000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">92000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">234000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">178000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">532000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_RestructuringProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">351000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_EmployeeRelatedProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">309000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_OtherProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">306000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1184000000</ifrs-full:OtherProvisions>
    <gsk:AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions
      contextRef="P01_01_2022To12_31_2022_LegalAndOtherDisputesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">133000000</gsk:AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions>
    <ifrs-full:ShorttermLegalProceedingsProvision
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:ShorttermLegalProceedingsProvision>
    <gsk:LegalProceedingsAndOtherDisputesProvisionEstimated
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_GBP">4000000</gsk:LegalProceedingsAndOtherDisputesProvisionEstimated>
    <ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions
      contextRef="P01_01_2022To12_31_2022_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions
      contextRef="P01_01_2021To12_31_2021_MajorRestructuringProvisionsMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions>
    <gsk:PensionObligationProvisions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:PensionObligationProvisions>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2022_DisabledEmployeesMemberGSKTitleOfIndividual1Axis"
      decimals="-6"
      unitRef="Unit_GBP">66000000</ifrs-full:ProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="PAsOn12_31_2021_DisabledEmployeesMemberGSKTitleOfIndividual1Axis"
      decimals="-6"
      unitRef="Unit_GBP">69000000</ifrs-full:ProvisionsForEmployeeBenefits>
    <gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;33. Contingent consideration liabilities &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shionogi-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ViiV&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Healthcare&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Novartis&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,479&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,275&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(765&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,359&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(742&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,076&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,645&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movement through reserves&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Initial recognition from business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(79&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,890&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Of the contingent consideration payable at 31&#160;December 2022, &#xa3;1,289&#160;million (2021: &#xa3;958 million) is expected to be paid within one year. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture, Affinivax and the Novartis Vaccines business are expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, shown above. The Shionogi-ViiV Healthcare contingent consideration liability is discounted at 8% (2021: 8%), the Affinivax contingent consideration liability is discounted at 9.9% and the Novartis Vaccines contingent consideration liability is discounted at 7.5% (2021: 7.5%) for commercialised products and at 8.5% (2021: 8.5%) for pipeline assets. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Shionogi-ViiV Healthcare and Novartis Vaccines contingent consideration liabilities are calculated principally based on the forecast sales performance of specified products over the lives of those products. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Affinivax contingent consideration is based upon two potential milestone payments, each of $0.6&#160;billion (&#xa3;0.5 billion) which will be paid if certain pediatric clinical development milestones are achieved. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Increase/(decrease) in financial liability&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and loss/(gain) in Income statement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shionogi-&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ViiV&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Healthcare&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Novartis&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shionogi-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ViiV&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Healthcare&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Vaccines&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;556&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% increase in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% decrease in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(833&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% increase in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% increase in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(292&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% decrease in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;214&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% decrease in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;328&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;411&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;645&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(347&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(501&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(130&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in probability of milestone success&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in probability of milestone success&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The sales forecast is for ViiV Healthcare sales only in respect of the Shionogi-ViiV Healthcare contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;An explanation of the accounting for ViiV Healthcare is set out on page 71. &lt;/div&gt; </gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory>
    <gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shionogi-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ViiV&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Healthcare&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Novartis&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,479&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,275&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(765&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,359&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,869&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(742&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,076&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement through income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,645&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movement through reserves&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Initial recognition from business combinations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: operating cash flows&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash payments: investing activities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(79&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,890&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2019_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5103000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2019_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">339000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2019_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">37000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">5479000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1114000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">161000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1275000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-751000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-765000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">107000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">120000000</gsk:ContingentConsiderationPaid>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2020_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5359000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2020_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">477000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2020_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5869000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1026000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1063000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-721000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-742000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">105000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">114000000</gsk:ContingentConsiderationPaid>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5559000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">479000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">38000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1431000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">231000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1645000000</gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1031000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-27000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1058000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">69000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ContingentConsiderationPaid>
    <gsk:ContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">79000000</gsk:ContingentConsiderationPaid>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5890000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">501000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_NovartisMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">673000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_OtherBusinessMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:ContingentConsiderationLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1289000000</gsk:ContingentConsiderationLiabilitiesCurrent>
    <gsk:ContingentConsiderationLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">958000000</gsk:ContingentConsiderationLiabilitiesCurrent>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2022_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2021_ShionogiViiVHealthcareJointVentureMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="3"
      unitRef="Unit_pure">0.099</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2022_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2021_CommercialisedProductsMemberifrsfullBusinessCombinationsAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis"
      decimals="3"
      unitRef="Unit_pure">0.085</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:ContingentConsiderationPayableDiscountedPercentage
      contextRef="PAsOn12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_PipelineAssetsMemberifrsfullBusinessCombinationsAxis"
      decimals="3"
      unitRef="Unit_pure">0.085</gsk:ContingentConsiderationPayableDiscountedPercentage>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-8"
      unitRef="Unit_USD">600000000</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:GainLossOnDisposalOfInterestInAssociate
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-8"
      unitRef="Unit_GBP">500000000</gsk:GainLossOnDisposalOfInterestInAssociate>
    <gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Increase/(decrease) in financial liability&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and loss/(gain) in Income statement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shionogi-&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ViiV&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Healthcare&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Novartis&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vaccines&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shionogi-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ViiV&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Healthcare&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Vaccines&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;556&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% increase in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;154&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(506&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15% decrease in sales forecasts*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(833&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% increase in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% increase in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(292&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% decrease in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;214&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% decrease in discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;328&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;411&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;645&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(347&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of US&#160;Dollar&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(501&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(91&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of Euro&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(130&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% increase in probability of milestone success&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10% decrease in probability of milestone success&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n/a&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;n/a&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The sales forecast is for ViiV Healthcare sales only in respect of the Shionogi-ViiV Healthcare contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">556000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">103000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">506000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">834000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">154000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">759000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:IncreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageIncreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">92000000</gsk:IncreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-555000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-506000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskTenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-57000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-833000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-153000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-759000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:DecreaseInSalesForecastAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskFifteenPercentageDecreaseInSalesForecastsMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-79000000</gsk:DecreaseInSalesForecastAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-199000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-55000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-198000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-38000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-292000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-80000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-286000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:IncreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-55000000</gsk:IncreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">214000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">65000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">213000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">45000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">328000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">101000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">319000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:DecreaseInDiscountRateAmount
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">70000000</gsk:DecreaseInDiscountRateAmount>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">411000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">45000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">343000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">645000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">71000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">495000000</gsk:AppreciationOfUSDollar>
    <gsk:AppreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:AppreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">347000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">38000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">299000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">501000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">398000000</gsk:DepreciationOfUSDollar>
    <gsk:DepreciationOfUSDollar
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:DepreciationOfUSDollar>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">109000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">102000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">160000000</gsk:AppreciationOfEuro>
    <gsk:AppreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</gsk:AppreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">85000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">130000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_ShionogiViivHealthcareMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">124000000</gsk:DepreciationOfEuro>
    <gsk:DepreciationOfEuro
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</gsk:DepreciationOfEuro>
    <gsk:IncreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">82000000</gsk:IncreaseInProbabilityOfMilestoneSuccess>
    <gsk:IncreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:IncreaseInProbabilityOfMilestoneSuccess>
    <gsk:IncreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:IncreaseInProbabilityOfMilestoneSuccess>
    <gsk:DecreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-82000000</gsk:DecreaseInProbabilityOfMilestoneSuccess>
    <gsk:DecreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2022To12_31_2022_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10000000</gsk:DecreaseInProbabilityOfMilestoneSuccess>
    <gsk:DecreaseInProbabilityOfMilestoneSuccess
      contextRef="P01_01_2021To12_31_2021_NovartisVaccinesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</gsk:DecreaseInProbabilityOfMilestoneSuccess>
    <ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;34. Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Accruals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;805&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;823&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;899&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;921&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other payables includes a number of employee-related liabilities including employee savings plans.&lt;/div&gt; </ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory>
    <gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Accruals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;805&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;823&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;899&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;921&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory>
    <ifrs-full:Accruals
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:Accruals>
    <ifrs-full:Accruals
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:Accruals>
    <ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-83000000</ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets>
    <ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-85000000</ifrs-full:NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets>
    <ifrs-full:OtherNoncurrentPayables
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">805000000</ifrs-full:OtherNoncurrentPayables>
    <ifrs-full:OtherNoncurrentPayables
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">823000000</ifrs-full:OtherNoncurrentPayables>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">899000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">921000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;35. Contingent liabilities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, contingent liabilities where GSK has a present obligation as a result of a past event, comprising guarantees and other items arising in the normal course of business, amounted to &#xa3;58&#160;million (2021: &#xa3;126 million). At 31&#160;December 2022, &#xa3;0.5&#160;million (2021: &#xa3;0.2 million) of financial assets were pledged as collateral for contingent liabilities. Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow. If it is not possible to meaningfully assess whether the outcomes will result in a probable outflow, or to quantify or reliably estimate the liability, if any, no provision is recorded. Descriptions of the significant legal and other disputes to which the Group is a party are set out in Note 47, &#x2018;Legal proceedings&#x2019;. &lt;/div&gt; </ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">58000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">126000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_GBP">500000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_GBP">200000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;36. Commitments &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual obligations and commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contracted for but not provided in the financial statements:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,659&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,082&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;743&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;616&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;146&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Purchase commitments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;161&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;484&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pensions and post-retirement benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;345&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;44&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest on loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,322&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,603&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Future finance charges on leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease contracts that have not yet commenced&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;395&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;18,909&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,188&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The commitments related to intangible assets include milestone payments, which are dependent on successful clinical development or on meeting specified sales targets, and which represent the maximum that would be paid if all milestones, however unlikely, are achieved. The amounts are not risk-adjusted or discounted. The net decrease in intangible asset commitments in 2022 is mainly attributable to the termination of certain agreements, offset by a number of new R&amp;amp;D collaborations including collaborations with Spero Therapeutics, Inc., Wuxi Biologics Ireland Limited, SpringWorks Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2022, GSK reached an agreement with the trustees of the UK pension schemes to make additional contributions of &#xa3;1,080&#160;million, to eliminate the pension deficit identified at the 31&#160;December 2020 actuarial funding valuation. Prior to the Consumer Healthcare demerger, GSK agreed to collateralise this commitment and accelerate funding with additional contributions (see Note 31). At 31&#160;December 2022, &#xa3;345&#160;million of these additional contributions remained unpaid. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group also has other commitments which principally relate to revenue payments to be made under licences and other alliances. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Commitments in respect of future interest payable on loans are disclosed before taking into account the effect of interest rate swaps. &lt;/div&gt; </ifrs-full:DisclosureOfCommitmentsExplanatory>
    <gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual obligations and commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contracted for but not provided in the financial statements:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,659&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,082&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;743&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;616&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;146&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Purchase commitments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;161&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;484&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Pensions and post-retirement benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;345&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;44&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest on loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,322&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,603&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Future finance charges on leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease contracts that have not yet commenced&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;395&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;18,909&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,188&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10659000000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">12082000000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">743000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">616000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <gsk:ContractualObligationsAndCommitmentsOfInvestments
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">138000000</gsk:ContractualObligationsAndCommitmentsOfInvestments>
    <gsk:ContractualObligationsAndCommitmentsOfInvestments
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">146000000</gsk:ContractualObligationsAndCommitmentsOfInvestments>
    <gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">161000000</gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments>
    <gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">484000000</gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments>
    <gsk:ContractualObligationsAndCommitmentsOfPensions
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">345000000</gsk:ContractualObligationsAndCommitmentsOfPensions>
    <gsk:ContractualObligationsAndCommitmentsOfPensions
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">44000000</gsk:ContractualObligationsAndCommitmentsOfPensions>
    <gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">6322000000</gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans>
    <gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7603000000</gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans>
    <gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">146000000</gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges>
    <gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">153000000</gsk:ContractualObligationsAndCommitmentsOfFutureFinanceCharges>
    <gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">395000000</gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced>
    <gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">60000000</gsk:ContractualObligationsLeaseContractsThatHaveNotYetCommenced>
    <gsk:ContractualObligationsAndCommitments
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">18909000000</gsk:ContractualObligationsAndCommitments>
    <gsk:ContractualObligationsAndCommitments
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">21188000000</gsk:ContractualObligationsAndCommitments>
    <gsk:AdditionalContributionWereToBeMadeTowards2020PensionDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1080000000</gsk:AdditionalContributionWereToBeMadeTowards2020PensionDeficit>
    <gsk:AdditionalContributionUnpaid
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">345000000</gsk:AdditionalContributionUnpaid>
    <gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;37. Share capital and share premium account &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Following completion of the Consumer Healthcare business demerger on 18 July 2022, GSK plc Ordinary shares were consolidated to maintain share price comparability before and after demerger. The consolidation was approved by GSK shareholders at a General Meeting held on 6 July 2022. Shareholders received 4 new Ordinary shares with a nominal value of &lt;span style="-sec-ix-hidden:hidden69050743"&gt;31&lt;/span&gt;&lt;div style="vertical-align:top;display:inline;;font-size:7.8px"&gt;1&lt;/div&gt;&#x2044;&lt;div style="vertical-align:bottom;display:inline;;font-size:7.8px"&gt;4&lt;/div&gt; pence each for every 5 existing Ordinary share which had a nominal value of 25 pence each. Earnings per share, diluted earnings per share, adjusted earnings per share and dividends per share were retrospectively adjusted to reflect the Share Consolidation in all the periods presented. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary&#160;shares&#160;of&#160;25p&#160;each&#160;pre-share&#160;consolidation&lt;/div&gt;&lt;br/&gt; Ordinary&#160;shares&#160;of&#160;31&lt;div style="vertical-align:top;display:inline;;font-size:6px"&gt;1&lt;/div&gt;&#x2044;&lt;div style="vertical-align:bottom;display:inline;;font-size:6px"&gt;4&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;p&#160;each&#160;post-share&#160;consolidation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Share&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Number&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share capital issued and fully paid:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,383,102,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,087,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,385,189,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,825,442&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,387,015,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impact of share consolidation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,077,403,011&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,731,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,311,343,341&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,440&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, of the issued share capital, 59,878,735 shares were held in the ESOP Trusts, 217,124,760 shares were held as Treasury shares and 4,034,339,846 shares were in free issue. All issued shares are fully paid and there are no shares authorised but not in issue. The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 45, &#x2018;Employee share schemes&#x2019;. &lt;/div&gt; </gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory>
    <gsk:ConsumerHealthcareBusinessDemerger contextRef="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis">2022-07-18</gsk:ConsumerHealthcareBusinessDemerger>
    <gsk:DateOfShareConsolidationApproval contextRef="P07_18_2022To07_18_2022_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis">2022-07-06</gsk:DateOfShareConsolidationApproval>
    <gsk:SharesReceivedForEveryFiveExistingShares
      contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">4</gsk:SharesReceivedForEveryFiveExistingShares>
    <gsk:SurrenderedSharesForEveryFourNewSharesReceived
      contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">5</gsk:SurrenderedSharesForEveryFourNewSharesReceived>
    <gsk:ParValueOfSharesSurrenderedInLieuOfNewShares
      contextRef="PAsOn07_18_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_GBP_per_Share">25</gsk:ParValueOfSharesSurrenderedInLieuOfNewShares>
    <gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:93%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary&#160;shares&#160;of&#160;25p&#160;each&#160;pre-share&#160;consolidation&lt;/div&gt;&lt;br/&gt; Ordinary&#160;shares&#160;of&#160;31&lt;div style="vertical-align:top;display:inline;;font-size:6px"&gt;1&lt;/div&gt;&#x2044;&lt;div style="vertical-align:bottom;display:inline;;font-size:6px"&gt;4&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;p&#160;each&#160;post-share&#160;consolidation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Share&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;premium&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Number&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share capital issued and fully paid:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,383,102,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,087,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,385,189,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,825,442&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,387,015,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impact of share consolidation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,077,403,011&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Issued under employee share schemes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,731,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,311,343,341&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,440&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_shares">5383102231</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">1346000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3174000000</ifrs-full:Equity>
    <gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">2087386</gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P01_01_2020To12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">5385189617</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">1346000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3281000000</ifrs-full:Equity>
    <gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">1825442</gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:IssueOfEquity>
    <gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P01_01_2021To12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P01_01_2021To12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">5387015059</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3301000000</ifrs-full:Equity>
    <gsk:ImpactOfShareConsolidationShares
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">-1077403011</gsk:ImpactOfShareConsolidationShares>
    <gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">1731293</gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:IssueOfEquity>
    <gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P01_01_2022To12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P01_01_2022To12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">114000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">4311343341</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-6"
      unitRef="Unit_GBP">1347000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3440000000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">59878735</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn12_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">217124760</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn12_31_2022_FreeIssueMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">4034339846</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">0</ifrs-full:NumberOfSharesAuthorised>
    <gsk:DisclosureOfMovementsInEquityExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;38. Movements in equity &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Retained earnings and other reserves amounted to &#xa3;5,811&#160;million at 31&#160;December 2022 (2021: &#xa3;10,407&#160;million; 2020: &#xa3;9,960 million) of which &#xa3;463&#160;million (2021: &#xa3;476&#160;million; 2020: &#xa3;440 million) related to associates and joint ventures&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The cumulative translation exchange in equity is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Net translation exchange included in:&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Retained&lt;br/&gt; earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Fair&#160;value&lt;br/&gt; reserve&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;controlling&lt;br/&gt; interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;translation&lt;br/&gt; exchange&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(93&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(803&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Movement attributable to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(692&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(209&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(906&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Movement attributable to discontinued operations&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;263&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;375&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(429&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(531&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL"&gt;(a) Includes &#xa3;(554)&#160;million reclassification to the Consolidated income statement of exchange movements related to the demerger of the Consumer Healthcare business. &lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of other comprehensive income by equity category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(754&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(754&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(786&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;211&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;211&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(464&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(695&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,187&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year from discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;375&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;356&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(89&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(714&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(831&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(911&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(911&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;131&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;131&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement losses on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;941&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;941&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(223&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(223&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;454&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(771&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(337&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(51&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(59&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,348&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,348&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(220&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(220&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(187&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(187&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(133&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,137&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;970&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Information on net investment hedges is provided in part (d) of Note 44 &#x2018;Financial instruments and related disclosures&#x2019;. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;The analysis of other reserves is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:86%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ESOP&#160;Trust&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;shares&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Fair&#160;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserve&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cash&#160;flow&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;reserve&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(135&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;409&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(48&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,355&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(207&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(609&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(609&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of shares held by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;529&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;529&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(195&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,205&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transferred to income and expenses in the year on impairments of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;168&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(139&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(139&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(780&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(770&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;383&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,463&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Balances derecognised on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(169&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(169&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(698&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;141&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(557&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,200&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of shares held by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;911&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;911&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(353&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(308&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,448&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Other reserves include various &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-distributable&lt;/div&gt; merger and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-merger&lt;/div&gt; reserves amounting to &#xa3;1,849&#160;million at 31&#160;December 2022 (2021: &#xa3;1,849&#160;million; 2020: &#xa3;1,849 million). Other reserves also include the capital redemption reserve created as a result of the share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;buy-back&lt;/div&gt; programme amounting to &#xa3;280&#160;million at 31&#160;December 2022 (2021: &#xa3;280&#160;million; 2020: &#xa3;280 million). &lt;/div&gt;</gsk:DisclosureOfMovementsInEquityExplanatory>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5811000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">10407000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">9960000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2022_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">463000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2021_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">476000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:RetainedEarningsAndOtherReserves
      contextRef="PAsOn12_31_2020_AssociatesAndJointVenturesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">440000000</gsk:RetainedEarningsAndOtherReserves>
    <gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The cumulative translation exchange in equity is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Net translation exchange included in:&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Retained&lt;br/&gt; earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Fair&#160;value&lt;br/&gt; reserve&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;controlling&lt;br/&gt; interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;translation&lt;br/&gt; exchange&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(93&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(803&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Movement attributable to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(692&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(209&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(906&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Movement attributable to discontinued operations&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;263&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;375&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(429&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(531&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:6.5pt; font-family:ARIAL"&gt;(a) Includes &#xa3;(554)&#160;million reclassification to the Consolidated income statement of exchange movements related to the demerger of the Consumer Healthcare business. &lt;/div&gt; </gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-524000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-127000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">-652000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-51000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-93000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-539000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-161000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-709000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-239000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-259000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-803000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-181000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-993000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">109000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">85000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <gsk:MovementInTranslationExchangeAttributableToContinuingOperations
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-692000000</gsk:MovementInTranslationExchangeAttributableToContinuingOperations>
    <gsk:MovementInTranslationExchangeAttributableToContinuingOperations
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</gsk:MovementInTranslationExchangeAttributableToContinuingOperations>
    <gsk:MovementInTranslationExchangeAttributableToContinuingOperations
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-209000000</gsk:MovementInTranslationExchangeAttributableToContinuingOperations>
    <gsk:MovementInTranslationExchangeAttributableToContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-906000000</gsk:MovementInTranslationExchangeAttributableToContinuingOperations>
    <gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">263000000</gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations>
    <gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">112000000</gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations>
    <gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">375000000</gsk:MovementInTranslationExchangeAttributableToDiscontinuedOperations>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-429000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">97000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-531000000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_DemergerMemberGSKEventAxis_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">554000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory contextRef="P01_01_2022To12_31_2022">  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The analysis of other comprehensive income by equity category is as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(754&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(754&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(786&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;211&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;211&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(464&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(695&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,187&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year from discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;375&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;356&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(89&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(714&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(831&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(239&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(911&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(911&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;131&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;131&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement losses on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;941&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;941&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(223&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(223&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;454&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(771&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(337&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Retained&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;earnings&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;controlling&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;interests&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that may be subsequently reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets and net investment hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(51&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(59&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements on liquidation or disposal of subsidiaries and associates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on cash flow hedges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(18&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of cash flow hedges to income statement&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Items that will not be reclassified to income statement:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange movements on overseas net assets of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,348&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,348&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on fair value movements on equity investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(220&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(220&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement gains on defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(187&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(187&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on remeasurement defined benefit plans&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive (expense)/income for the year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(133&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,137&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;970&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Information on net investment hedges is provided in part (d) of Note 44 &#x2018;Financial instruments and related disclosures&#x2019;. &lt;/div&gt;  </ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">109000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">113000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-754000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-754000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">56000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-786000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-786000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-211000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-211000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges>
    <gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-464000000</ifrs-full:ComprehensiveIncomeFromContinuingOperations>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-695000000</ifrs-full:ComprehensiveIncomeFromContinuingOperations>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:ComprehensiveIncomeFromContinuingOperations>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1187000000</ifrs-full:ComprehensiveIncomeFromContinuingOperations>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">375000000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">356000000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-89000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-714000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-831000000</ifrs-full:OtherComprehensiveIncome>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-239000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-239000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-911000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-911000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">131000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">131000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">941000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">941000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">223000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">223000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">454000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-771000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-337000000</ifrs-full:OtherComprehensiveIncome>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-51000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-59000000</gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-54000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-54000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1348000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1348000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-220000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-220000000</gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-187000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-187000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-69000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-69000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-133000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1137000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">970000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;The analysis of other reserves is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:86%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ESOP&#160;Trust&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;shares&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Fair&#160;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserve&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cash&#160;flow&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;reserve&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(135&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;409&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(48&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,355&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(207&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(609&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(609&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of shares held by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;529&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;529&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(195&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,205&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transferred to income and expenses in the year on impairments of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;168&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(139&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(139&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(780&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(770&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;383&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,463&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transferred to retained earnings in the year on disposal of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Balances derecognised on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(169&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(169&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net fair value movement in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(698&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;141&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(557&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Ordinary shares acquired by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,200&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Write-down of shares held by ESOP Trusts&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;911&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;911&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(353&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(308&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(20&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,129&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,448&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2019_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-135000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">409000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-48000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2129000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">2355000000</ifrs-full:OtherReserves>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</gsk:ExchangeAdjustments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-207000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-207000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2020To12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1100000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2020To12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-1117000000</gsk:NetFairValueMovements>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">609000000</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">609000000</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2020To12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">529000000</gsk:WritedownOfSharesHeldByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">529000000</gsk:WritedownOfSharesHeldByEsopTrusts>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-195000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1302000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-31000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2129000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3205000000</ifrs-full:OtherReserves>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:ExchangeAdjustments>
    <gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">168000000</gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments>
    <gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments>
    <gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments>
    <gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments>
    <gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">168000000</gsk:TransferredToIncomeExpensesImpairmentsOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-139000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-139000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2021To12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">780000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2021To12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-10000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">770000000</gsk:NetFairValueMovements>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">383000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2129000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2463000000</ifrs-full:OtherReserves>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-28000000</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ExchangeAdjustments>
    <gsk:ExchangeAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</gsk:ExchangeAdjustments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments>
    <gsk:BalanceAmountDerecognisedOnDemerger
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:BalanceAmountDerecognisedOnDemerger>
    <gsk:BalanceAmountDerecognisedOnDemerger
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:BalanceAmountDerecognisedOnDemerger>
    <gsk:BalanceAmountDerecognisedOnDemerger
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">169000000</gsk:BalanceAmountDerecognisedOnDemerger>
    <gsk:BalanceAmountDerecognisedOnDemerger
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:BalanceAmountDerecognisedOnDemerger>
    <gsk:BalanceAmountDerecognisedOnDemerger
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">169000000</gsk:BalanceAmountDerecognisedOnDemerger>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">698000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-141000000</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NetFairValueMovements>
    <gsk:NetFairValueMovements
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">557000000</gsk:NetFairValueMovements>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1200000000</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1200000000</gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">911000000</gsk:WritedownOfSharesHeldByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2022To12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:WritedownOfSharesHeldByEsopTrusts>
    <gsk:WritedownOfSharesHeldByEsopTrusts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">911000000</gsk:WritedownOfSharesHeldByEsopTrusts>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_EsopTrustMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-353000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-308000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">-20000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">2129000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1448000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1849000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1849000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_NonDistributableMergerAndPreMergerReservesMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1849000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2022_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">280000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2021_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">280000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn12_31_2020_CapitalRedemptionReserveMemberGSKMiscellaneousComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_GBP">280000000</ifrs-full:OtherReserves>
    <ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;39. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interests &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests includes the following individually material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests are individually not material. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ViiV Healthcare &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK holds 78.3% of the ViiV Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group,&lt;/div&gt; giving rise to a material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. Summarised financial information available at the latest practicable date in respect of the ViiV Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; is as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,619&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,637&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,848&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,528&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,087&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;762&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;94&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,622&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,070&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;795&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,716&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,796&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,354&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,711&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,070&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,762&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,121&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8,983&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,472&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,745&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,593&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,675&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,086&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash inflow from operating activities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,442&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,128&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,249&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash outflow from investing activities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(174&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(287&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(294&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash outflow from financing activities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,718&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,608&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in cash and bank overdrafts in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;550&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;233&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(528&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The above financial information relates to the ViiV Healthcare group on a stand-alone basis, before the impact of Group-related adjustments, primarily related to the recognition of preferential dividends. The profit after taxation of &#xa3;1,528&#160;million (2021: &#xa3;1,087&#160;million; 2020: &#xa3;762 million) is stated after charging preferential dividends payable to GSK and Pfizer and after a charge of &#xa3;1,483&#160;million (2021: &#xa3;1,218&#160;million; 2020: &#xa3;1,112 million) for remeasurement of contingent consideration payable. This consideration is expected to be paid over a number of years. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following amounts attributable to the ViiV Healthcare group are included in GSK&#x2019;s financial statements: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of profit for the year attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;415&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;196&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;223&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividends paid to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;480&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;224&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;419&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the Consolidated balance sheet&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(611&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(570&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(539&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #f36f21"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consumer Healthcare Joint Venture &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK held 68% of the Consumer Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; until the demerger on 18&#160;July 2022 (see details in Note 41), giving rise to a material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. Summarised financial information in respect of the Consumer Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; at 31&#160;December 2021 is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:91%;border:0"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:97%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,238&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,733&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,971&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,480&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The above financial information relates to the former Consumer Healthcare Joint Venture on a stand-alone basis, before the impact of Group-related adjustments and the classification of cash pooling accounts with Group companies outside the Consumer Healthcare Joint Venture but after Major restructuring charges. &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following amounts attributable to the Consumer Healthcare Joint Venture were included in GSK&#x2019;s financial statements in prior years: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the Consolidated balance sheet&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,609&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,538&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory>
    <gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ViiV Healthcare &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK holds 78.3% of the ViiV Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group,&lt;/div&gt; giving rise to a material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. Summarised financial information available at the latest practicable date in respect of the ViiV Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; is as follows: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,619&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,637&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,848&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,528&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,087&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;762&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other comprehensive income/(expense)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;94&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,622&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,070&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;795&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 0.375pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,716&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,796&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,354&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,711&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,070&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,762&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,121&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8,983&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,472&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,745&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,593&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,675&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,086&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash inflow from operating activities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,442&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,128&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,249&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash outflow from investing activities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(174&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(287&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(294&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net cash outflow from financing activities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,718&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,608&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in cash and bank overdrafts in the year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;550&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;233&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(528&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5619000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4637000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4848000000</ifrs-full:Revenue>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1528000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1087000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">762000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">94000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1622000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1070000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">795000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2716000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2796000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3354000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2711000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6070000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5507000000</ifrs-full:Assets>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3762000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3121000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8983000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8472000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12745000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11593000000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6675000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6086000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3442000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2128000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2249000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-174000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-287000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-294000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2718000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1608000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2483000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <gsk:IncreaseDecreaseInCashAndBankOverdrafts
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">550000000</gsk:IncreaseDecreaseInCashAndBankOverdrafts>
    <gsk:IncreaseDecreaseInCashAndBankOverdrafts
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">233000000</gsk:IncreaseDecreaseInCashAndBankOverdrafts>
    <gsk:IncreaseDecreaseInCashAndBankOverdrafts
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-528000000</gsk:IncreaseDecreaseInCashAndBankOverdrafts>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1528000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1087000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">762000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1483000000</gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition>
    <gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1218000000</gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition>
    <gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1112000000</gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition>
    <gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following amounts attributable to the ViiV Healthcare group are included in GSK&#x2019;s financial statements: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of profit for the year attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;415&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;196&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;223&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividends paid to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;480&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;224&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;419&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the Consolidated balance sheet&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(611&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(570&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(539&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; </gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">415000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">196000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">223000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:DividendsPaidToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">480000000</ifrs-full:DividendsPaidToNoncontrollingInterests>
    <ifrs-full:DividendsPaidToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">224000000</ifrs-full:DividendsPaidToNoncontrollingInterests>
    <ifrs-full:DividendsPaidToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">419000000</ifrs-full:DividendsPaidToNoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-611000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2021_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-570000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2020_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-539000000</ifrs-full:NoncontrollingInterests>
    <gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"> &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK held 68% of the Consumer Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; until the demerger on 18&#160;July 2022 (see details in Note 41), giving rise to a material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. Summarised financial information in respect of the Consumer Healthcare &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-group&lt;/div&gt; at 31&#160;December 2021 is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:91%;border:0"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:97%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,238&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,733&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,971&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,480&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">29200000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5251000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">34451000000</ifrs-full:Assets>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4238000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3733000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7971000000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">26480000000</ifrs-full:NetAssetsLiabilities>
    <gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory contextRef="P01_01_2022To12_31_2022_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following amounts attributable to the Consumer Healthcare Joint Venture were included in GSK&#x2019;s financial statements in prior years: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:96%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:7pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2020&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the Consolidated balance sheet&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,609&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,538&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2021_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6609000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="PAsOn12_31_2020_ConsumerHealthCareJointVentureMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6538000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;40. Related party transactions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, there were no loans due to GSK from related parties (2021: &#xa3;4.6&#160;million was due from Medicxi Ventures I LP). Cash distributions were received from investment in Medicxi Ventures I LP of &#xa3;6.0&#160;million (2021: Medicxi Ventures I LP of &#xa3;5.5&#160;million, Longwood Founders Fund, LP of &#xa3;3.0&#160;million and Apollo Therapeutics LLP of &#xa3;0.1 million). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;As part of the joint venture agreement with Qura Therapeutics LLC, the Group has an obligation to fund the joint venture up to April 2025, with both GSK and its joint venture partner committing financial support in the amount of &#xa3;21.6&#160;million. At December 2022, the outstanding liability due to Qura was &#xa3;8.3&#160;million (2021: &#xa3;10.7 million). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group had no other significant related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The aggregate compensation of the Directors and GLT is given in Note 9, &#x2018;Employee costs&#x2019;. &lt;/div&gt; </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <gsk:LoansReceivableMadeByEntityRelatedPartyTransactions
      contextRef="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:LoansReceivableMadeByEntityRelatedPartyTransactions>
    <gsk:LoansReceivableMadeByEntityRelatedPartyTransactions
      contextRef="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">4600000</gsk:LoansReceivableMadeByEntityRelatedPartyTransactions>
    <ifrs-full:InvestmentIncome
      contextRef="P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">6000000</ifrs-full:InvestmentIncome>
    <ifrs-full:InvestmentIncome
      contextRef="P01_01_2021To12_31_2021_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">5500000</ifrs-full:InvestmentIncome>
    <ifrs-full:InvestmentIncome
      contextRef="P01_01_2022To12_31_2022_LongwoodFoundersFundLPMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">3000000</ifrs-full:InvestmentIncome>
    <ifrs-full:InvestmentIncome
      contextRef="P01_01_2022To12_31_2022_ApolloTherapeuticsLLPMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">100000</ifrs-full:InvestmentIncome>
    <gsk:AgreementExtensionPeriod contextRef="P06_26_2019To06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis">April 2025</gsk:AgreementExtensionPeriod>
    <gsk:InvestmentObligation
      contextRef="PAsOn06_26_2019_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_USD">21600000</gsk:InvestmentObligation>
    <gsk:LoansReceivableMadeByEntityRelatedPartyTransactions
      contextRef="P01_01_2022To12_31_2022_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">8300000</gsk:LoansReceivableMadeByEntityRelatedPartyTransactions>
    <gsk:LoansReceivableMadeByEntityRelatedPartyTransactions
      contextRef="P01_01_2021To12_31_2021_QuraTherapeuticsLLCMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-5"
      unitRef="Unit_GBP">10700000</gsk:LoansReceivableMadeByEntityRelatedPartyTransactions>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;41. Acquisitions and disposals &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Details of the acquisition and disposal of significant subsidiaries, associates, joint ventures and other businesses are given below: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;July 2022, GSK completed the acquisition of 100% of Sierra Oncology, Inc., a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $1.9&#160;billion (&#xa3;1.6 billion). The main asset is momelotinib which targets the medical needs of myelofibrosis patients with anaemia. Total transaction costs were &#xa3;52&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 15&#160;August 2022, GSK completed the acquisition of 100% of Affinivax, Inc. a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts focused on pneumococcal vaccine candidates. The consideration for the acquisition comprised an upfront payment of $2.2&#160;billion (&#xa3;1.8 billion) as adjusted for working capital acquired paid upon closing and two potential milestone payments each of $0.6&#160;billion (&#xa3;0.5 billion) to be paid upon the achievement of certain paediatric clinical development milestones. The estimated fair value of the contingent consideration payable was &#xa3;482&#160;million. The values are provisional and are subject to change. The total transaction costs were &#xa3;71&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Since acquisition, no sales arising from the Sierra Oncology or Affinivax businesses have been included in Group turnover and no revenue is expected until regulatory approval is received on the acquired assets. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK continues to support the ongoing development of the acquired assets and consequently these assets will be loss making until regulatory approval on these assets is received. The development of these assets has been integrated into the Group&#x2019;s existing R&amp;amp;D activities, so it is impracticable to quantify these development costs or the impact on Total profit after taxation for the period. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Goodwill of &#xa3;1,127&#160;million (&#xa3;162&#160;million for Sierra Oncology and &#xa3;965&#160;million for Affinivax), which is not expected to be deductible for tax purposes, has been recognised. The goodwill represents workforce in place, and specific synergies available to GSK from the business combinations. The goodwill has been allocated to the Group&#x2019;s Commercial Operations and R&amp;amp;D segments, (refer to Note 19 &#x2018;Goodwill&#x2019; for allocation methodology). &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sierra&lt;br/&gt; Oncology&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,497&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,467&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,964&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;52&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;53&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;175&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;284&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(55&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(77&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(117&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(259&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(236&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(495&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,435&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,307&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,742&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;162&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;965&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,127&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,272&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,869&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total cash&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,790&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,387&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of contingent consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 24&#160;November 2022 GSK signed an agreement to buy out the 25% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in Glaxo Saudi Arabia Ltd for SAR94&#160;million (&#xa3;21&#160;million), to be paid in 2023. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt;text-align:right"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt;&lt;/div&gt;&lt;div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Demerger of Consumer Healthcare business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 18&#160;July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. The separation was effected by way of a demerger of 80.1% of GSK&#x2019;s 68% holding in the Consumer Healthcare business to GSK shareholders. Following the demerger, 54.5% of Haleon was held in aggregate by GSK shareholders, 6.0% remains held by GSK (including shares received by GSK&#x2019;s consolidated ESOP trusts) and 7.5% remains held by certain Scottish Limited Partnerships (SLPs) set up to provide collateral for a funding mechanism pursuant to which GSK will provide additional funding for GSK&#x2019;s UK defined benefit pension schemes (Note 31). The aggregate ownership by GSK (including ownership by the ESOP trusts and SLPs) after the demerger of 13.5% was measured at fair value with changes through profit or loss. Pfizer continued to hold 32% of Haleon after the demerger. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under IFRIC 17 &#x2018;Distributions of Non-cash Assets to Owners&#x2019; a liability and an equity distribution are measured at the fair value of the assets to be distributed when the dividend is appropriately authorised and it is no longer at the entity&#x2019;s discretion. The liability and equity movement, and associated gain on distribution were recognised in Q3 2022 when the demerger distribution was authorised and occurred. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The asset distributed was the 54.5% ownership of the Consumer Healthcare business. The net carrying value of the Consumer Healthcare business in the consolidated financial statements, including the retained 13.5% and net of the amount attributable to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest, was approximately &#xa3;11.0&#160;billion at the end of June. GSK&#x2019;s &#xa3;6.3&#160;billion share of the shareholder loans made in Q1 2022 in advance of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-separation&lt;/div&gt; dividends was eliminated in the consolidated financial statements. The assets distributed were reduced by Consumer Healthcare transactions up to 18&#160;July that principally included &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-separation&lt;/div&gt; dividends declared and settled after the end of Q2 2022 and before 18&#160;July 2022. Those dividends included: &#xa3;10.4&#160;billion (&#xa3;7.1&#160;billion attributable to GSK) of dividends funded by Consumer Healthcare debt that was partially &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-lent&lt;/div&gt; during Q1 2022 and dividends of &#xa3;0.6&#160;billion (&#xa3;0.4&#160;billion attributable to GSK) from available cash balances. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair value of the 54.5% ownership of the Consumer Healthcare business distributed was &#xa3;15.5&#160;billion. This was measured by reference to the quoted average Haleon share price over the first five days of trading, this being a fair value measured with observable inputs which was considered to be representative of the fair value at the distribution date. A gain on distribution of this fair value less book value of the attributable net assets of the Consumer Healthcare business of &#xa3;7.7&#160;billion was recorded in the Income Statement in 2022. There was an additional gain of &#xa3;2.4&#160;billion to remeasure the retained 13.5% from its book value to fair value of &#xa3;3.9&#160;billion using the same fair value methodology as used for the distributed shares. The gain on distribution and on remeasurement of the retained stake upon demerger was presented as part of discontinued operations. Any future gains or losses on the retained stake in Haleon will be recognised in continuing operations. In addition, there was a reclassification of the Group&#x2019;s share of cumulative exchange differences arising on translation of the foreign currency net assets of the divested subsidiaries and offsetting net investment hedges from reserves into the Income Statement of &#xa3;0.6&#160;billion. The total gain on demerger of Consumer Healthcare was &#xa3;10.1&#160;billion. These transactions were presented in profit from discontinued operations in 2022. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of the Consumer Healthcare business distributed (54.5%)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of the retained ownership in Haleon plc (13.5%)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,853&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,379&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying amount of the net assets and liabilities distributed/de-recognised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying amount of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest de-recognised&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,038&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on demerger before exchange movements and transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total gain on the demerger of Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,084&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt;text-align:right"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt;&lt;/div&gt;&lt;div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Consumer Healthcare was presented as a discontinued operation as at 30&#160;June 2022 and disclosed as such in the interim financial statements. The Consolidated Income Statement and Consolidated Cash Flow Statement distinguish discontinued operations from continuing operations. Comparative figures have been restated on a consistent basis. Financial information relating to the operations of Consumer Healthcare for the period is set out below and includes financial information until 18&#160;July 2022. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;This financial information differs both in purpose and basis of preparation from the Historical Financial Information and the Interim Financial Information included in the Haleon prospectus and from that which will be published by Haleon on 2&#160;March 2023. As a result, whilst the two sets of financial information are similar, they are not the same because of certain differences in accounting and disclosure under IFRS. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total results&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,581&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,418&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,745&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expense&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,730&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,575&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,947&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;851&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,843&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,798&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(235&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(263&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(513&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax rate %&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27.6%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.3%&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28.5%&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Loss)/profit after taxation from discontinued operations: Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;616&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,580&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,285&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other gains/(losses) on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,433&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement of discontinued operations distributed to shareholders on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,651&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation on demerger of discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,700&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,580&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,285&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;205&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;511&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;409&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Earnings attributable to shareholders from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,495&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,069&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;876&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;260.6p&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26.7p&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;22.0p&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other business disposals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There were no other material business disposals in 2022. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;acquisitions&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;demerger&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;- other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents (divested)/acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;284&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(933&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,108&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(933&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(79&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(141&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,187&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,074&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Cash consideration for business acquisitions included &#xa3;5&#160;million related to other business acquisition activity. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK completed no material business acquisitions in 2021. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business disposals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK made a number of business disposals for net cash consideration received in the year of &#xa3;10&#160;million. The profit on the disposal of the businesses in the year of &#xa3;24&#160;million was calculated as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consideration:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration including currency forwards, purchase adjustments and deferred consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets sold:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other net assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Costs:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deal costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on disposals in 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; width:91%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Associates and joint ventures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 20&#160;May 2021 GSK agreed with Innoviva, Inc. (&#x201c;Innoviva&#x201d;) to sell all of its approximately 32&#160;million shares of common stock of Innoviva back to Innoviva at a price of $12.25 per share, raising gross proceeds of approximately $392&#160;million. Following settlement of the transaction, GSK will no longer hold any Innoviva stock. See details in Note 21 &#x2018;Investment in associates and joint ventures&#x2019;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Associates&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;and joint&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ventures&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents (divested)/acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK completed one smaller business acquisition when it acquired 55% of Pfizer Biotech Corporation Taiwan, a part of Pfizer&#x2019;s consumer healthcare business, which was not previously recognised as part of the Consumer Healthcare Joint Venture, on 28&#160;September 2020 for non cash consideration of &#xa3;129&#160;million. This represented goodwill of &#xa3;124&#160;million, cash of &#xa3;21&#160;million and other assets acquired of &#xa3;18&#160;million less &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest of &#xa3;14&#160;million and net liabilities of &#xa3;20&#160;million. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets acquired:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt; consideration (settlement of a promissory note)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business disposals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;April 2020, GSK completed its divestment of Horlicks and other Consumer Healthcare nutrition products in India and a number of other countries (excluding Bangladesh) to Unilever and the merger of GSK&#x2019;s Indian listed Consumer Healthcare entity with Hindustan Unilever, an Indian listed public company. GSK received a 5.7% equity stake in Hindustan Unilever and &#xa3;395&#160;million in cash. GSK disposed of its equity stake in Hindustan Unilever during May 2020. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The divestment in Bangladesh closed on 30&#160;June 2020. Total cash consideration received was &#xa3;177&#160;million. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The cash divested as part of the disposal of the India and Bangladesh Consumer Healthcare entities was &#xa3;478&#160;million. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:6%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;
&lt;img alt="LOGO" src="g382677dsp001b.jpg"/&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div/&gt;&lt;div&gt;&lt;div style="background-color:white;display: inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The profit on the disposal of the businesses in the year of &#xa3;2,795&#160;million &lt;div style="display:inline;"&gt;was &lt;/div&gt;calculated as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Horlicks&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;divestment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consideration:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration receivable including currency forwards and purchase adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;492&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;649&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equity investment in Hindustan Unilever Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,616&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,773&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets disposed:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;142&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;143&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;68&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;478&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other net (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(155&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(154&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;536&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;126&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;662&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Costs:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;240&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;240&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;288&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;316&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,792&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,795&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The exposure to share price movements embedded in the agreement to merge GSK&#x2019;s Indian listed Consumer Healthcare entity with Hindustan Unilever Limited as part of the divestment of Horlicks and other nutrition products in India and a number of other countries was recognised as a derivative between signing of the agreement in 2018 and completion of the transaction in 2020. &#xa3;240&#160;million is recorded as a cost in the table above for the derecognition of the derivative asset. This largely reflects fair value gains recognised in the Income Statement in prior periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Associates and joint ventures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During the year, GSK made investments into associates of &#xa3;4&#160;million and &#xa3;4&#160;million was paid in cash. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;acquisitions&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Associates&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;and joint&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ventures&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;investments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration received/(paid)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents acquired/(divested)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(481&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;259&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Other includes Consumer Healthcare disposals where the income statement impact is not restated. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:CashTransferred
      contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_USD">1900000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="PAsOn07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_GBP">1600000000</ifrs-full:CashTransferred>
    <gsk:PaymentsMadeForTransactionCostsAndOther
      contextRef="P07_01_2022To07_01_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</gsk:PaymentsMadeForTransactionCostsAndOther>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:CashTransferred
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_USD">2200000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_GBP">1800000000</ifrs-full:CashTransferred>
    <gsk:BusinessCombinationPotentialMilestonePaymentPerTranche
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_USD">600000000</gsk:BusinessCombinationPotentialMilestonePaymentPerTranche>
    <gsk:BusinessCombinationPotentialMilestonePaymentPerTranche
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-8"
      unitRef="Unit_GBP">500000000</gsk:BusinessCombinationPotentialMilestonePaymentPerTranche>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <gsk:PaymentsMadeForTransactionCostsAndOther
      contextRef="P08_15_2022To08_15_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">71000000</gsk:PaymentsMadeForTransactionCostsAndOther>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1127000000</ifrs-full:AdditionalRecognitionGoodwill>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P01_01_2022To12_31_2022_SierraOncologyIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">162000000</ifrs-full:AdditionalRecognitionGoodwill>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">965000000</ifrs-full:AdditionalRecognitionGoodwill>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:10pt;white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sierra&lt;br/&gt; Oncology&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Affinivax&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,497&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,467&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,964&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Right of use assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;52&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;53&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;175&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;284&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(55&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(77&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(117&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(259&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(236&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(495&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,435&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,307&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,742&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;162&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;965&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,127&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,272&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,869&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total cash&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,790&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,387&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of contingent consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1497000000</ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1467000000</ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2964000000</ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</ifrs-full:RightofuseAssets>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate>
    <gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate>
    <gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">175000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">109000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">284000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate>
    <gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-55000000</gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate>
    <gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-56000000</gsk:LeaseLiabilitiesRecognizedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">40000000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">117000000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <gsk:TaxationRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-259000000</gsk:TaxationRecognizedAsOfAcquisitionDate>
    <gsk:TaxationRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-236000000</gsk:TaxationRecognizedAsOfAcquisitionDate>
    <gsk:TaxationRecognizedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-495000000</gsk:TaxationRecognizedAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1435000000</gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1307000000</gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2742000000</gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">162000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">965000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1127000000</ifrs-full:Goodwill>
    <gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1597000000</gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2272000000</gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3869000000</gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1597000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1790000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3387000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_SierraOncologyMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoAcquisitionMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <gsk:BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired
      contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</gsk:BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired>
    <gsk:BusinessCombinationConsiderationPayableForStepAcquisition
      contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_SAR">94000000</gsk:BusinessCombinationConsiderationPayableForStepAcquisition>
    <gsk:BusinessCombinationConsiderationPayableForStepAcquisition
      contextRef="PAsOn11_24_2022_GlaxoSaudiArabiaLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</gsk:BusinessCombinationConsiderationPayableForStepAcquisition>
    <gsk:PercentageOfOwnershipDivested
      contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.801</gsk:PercentageOfOwnershipDivested>
    <gsk:PercentageofGSKHolding
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</gsk:PercentageofGSKHolding>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskShareholdersMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.545</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskAndGsksConsolidatedEsotTrustsMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.06</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_ScottishLimitedPartnershipsMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.135</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_HaleonPlcMemberGSKInvestmentAxis_PfizerMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.32</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_GskHoldingMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.545</gsk:PercentageOfOwnershipDistributed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.135</gsk:PercentageOfOwnershipDistributed>
    <gsk:CarryingValueOfInvestmentNetOfNonControllingInterest
      contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-5"
      unitRef="Unit_GBP">11000000</gsk:CarryingValueOfInvestmentNetOfNonControllingInterest>
    <gsk:LiabilityEliminatedOnDemerger
      contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-8"
      unitRef="Unit_GBP">6300000000</gsk:LiabilityEliminatedOnDemerger>
    <gsk:DividendFundedByDebtFinancing
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-8"
      unitRef="Unit_GBP">10400000000</gsk:DividendFundedByDebtFinancing>
    <gsk:DividendFundedByDebtFinancingAttributableToGsk
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-8"
      unitRef="Unit_GBP">7100000000</gsk:DividendFundedByDebtFinancingAttributableToGsk>
    <gsk:DividendsDistributedFromCashBalance
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-8"
      unitRef="Unit_GBP">600000000</gsk:DividendsDistributedFromCashBalance>
    <gsk:DividendsDistributedFromCashBalanceAttributableToGsk
      contextRef="P07_18_2022To07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-8"
      unitRef="Unit_GBP">400000000</gsk:DividendsDistributedFromCashBalanceAttributableToGsk>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.545</gsk:PercentageOfOwnershipDistributed>
    <gsk:FairValueOfTheAssetsDistributed
      contextRef="PAsOn07_18_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-8"
      unitRef="Unit_GBP">15500000000</gsk:FairValueOfTheAssetsDistributed>
    <gsk:GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount
      contextRef="P07_18_2022To07_18_2022_GskHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-8"
      unitRef="Unit_GBP">7700000000</gsk:GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount>
    <gsk:AdditionalGainOnRemeasurementOfRetainedStake
      contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-8"
      unitRef="Unit_GBP">2400000000</gsk:AdditionalGainOnRemeasurementOfRetainedStake>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P07_18_2022To07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.135</gsk:PercentageOfOwnershipDistributed>
    <gsk:FairValueOfHolding
      contextRef="PAsOn07_18_2022_GskAggregateHoldingMembersrtOwnershipAxis_HaleonPlcMemberGSKInvestmentAxis"
      decimals="-8"
      unitRef="Unit_GBP">3900000000</gsk:FairValueOfHolding>
    <gsk:ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves
      contextRef="P07_18_2022To07_18_2022"
      decimals="-8"
      unitRef="Unit_GBP">600000000</gsk:ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves>
    <gsk:GainOnDemergerOfDiscontinuedOperation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">10100000000</gsk:GainOnDemergerOfDiscontinuedOperation>
    <gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of the Consumer Healthcare business distributed (54.5%)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value of the retained ownership in Haleon plc (13.5%)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,853&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,379&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying amount of the net assets and liabilities distributed/de-recognised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying amount of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest de-recognised&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,038&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on demerger before exchange movements and transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total gain on the demerger of Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,084&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations>
    <gsk:FairValueOfTheConsumerHealthcareBusinessDistributed
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15526000000</gsk:FairValueOfTheConsumerHealthcareBusinessDistributed>
    <gsk:FairValueOfTheRetainedOwnershipInHaleonPlc
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3853000000</gsk:FairValueOfTheRetainedOwnershipInHaleonPlc>
    <gsk:TotalfairValueOfDistributedandRetainBusiness
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">19379000000</gsk:TotalfairValueOfDistributedandRetainBusiness>
    <gsk:CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-12887000000</gsk:CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed>
    <gsk:CarryingAmountOfTheNciDerecognized
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3038000000</gsk:CarryingAmountOfTheNciDerecognized>
    <gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">9530000000</gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts>
    <gsk:ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">554000000</gsk:ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries>
    <gsk:GainOnDemergerOfDiscontinuedOperation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">10084000000</gsk:GainOnDemergerOfDiscontinuedOperation>
    <gsk:FinancialInformationRelatingToDiscontinuedOperations contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total results&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Turnover&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,581&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,418&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,745&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expense&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,730&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,575&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,947&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;851&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,843&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,798&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Taxation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(235&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(263&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(513&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax rate %&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27.6%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.3%&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28.5%&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Loss)/profit after taxation from discontinued operations: Consumer Healthcare&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;616&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,580&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,285&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other gains/(losses) on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,433&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Remeasurement of discontinued operations distributed to shareholders on demerger&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,651&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit after taxation on demerger of discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,700&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,580&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,285&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;205&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;511&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;409&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Earnings attributable to shareholders from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,495&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,069&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;876&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Earnings per share from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;260.6p&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26.7p&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;22.0p&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:FinancialInformationRelatingToDiscontinuedOperations>
    <ifrs-full:Revenue
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5581000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9418000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9745000000</ifrs-full:Revenue>
    <ifrs-full:OperatingExpense
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4730000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7575000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7947000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">851000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1843000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1798000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-235000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-263000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-513000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_GBP">27600000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_GBP">14300000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_GBP">28500000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">616000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1580000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1285000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <gsk:OtherGainsLossesOnDemerger
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2433000000</gsk:OtherGainsLossesOnDemerger>
    <gsk:OtherGainsLossesOnDemerger
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherGainsLossesOnDemerger>
    <gsk:OtherGainsLossesOnDemerger
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:OtherGainsLossesOnDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7651000000</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger>
    <gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">10700000000</gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations>
    <gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1580000000</gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations>
    <gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1285000000</gsk:ProfitAfterTaxationOnDemergerOfDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">205000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">511000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">409000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">10495000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1069000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">876000000</ifrs-full:IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="1"
      unitRef="Unit_GBP_per_Share">260.6</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="1"
      unitRef="Unit_GBP_per_Share">26.7</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis"
      decimals="1"
      unitRef="Unit_GBP_per_Share">22</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:8pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;acquisitions&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;demerger&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;- other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents (divested)/acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;284&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(933&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,108&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(933&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(79&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(141&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,187&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,074&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">3392000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredConsiderationReceived>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredConsiderationReceived>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</gsk:DeferredConsiderationReceived>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">284000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-933000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <gsk:CashOutflowInflowExcludingTransactionCosts
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3108000000</gsk:CashOutflowInflowExcludingTransactionCosts>
    <gsk:CashOutflowInflowExcludingTransactionCosts
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-933000000</gsk:CashOutflowInflowExcludingTransactionCosts>
    <gsk:CashOutflowInflowExcludingTransactionCosts
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</gsk:CashOutflowInflowExcludingTransactionCosts>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">79000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">141000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionCostsOnDisposal>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_CashFlowsInTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3187000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyTwoDisposalsDemergerMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1074000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndTwentyTwoBusinessAcquisitionsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory contextRef="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis">The profit on the disposal of the businesses in the year of &#xa3;24&#160;million was calculated as follows: &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consideration:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration including currency forwards, purchase adjustments and deferred consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets sold:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other net assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Costs:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Deal costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on disposals in 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory>
    <gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted
      contextRef="P01_01_2021To12_31_2021_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted>
    <gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">10000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:CashTransferred
      contextRef="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:CashTransferred>
    <gsk:DisposalsOtherNetAssets
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:DisposalsOtherNetAssets>
    <gsk:DisposalGroupAssetsNet
      contextRef="PAsOn12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</gsk:DisposalGroupAssetsNet>
    <gsk:DealCostsPayable
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-16000000</gsk:DealCostsPayable>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-35000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <gsk:GainLossOnDisposalsOfBusiness
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</gsk:GainLossOnDisposalsOfBusiness>
    <gsk:InvestmentOwnedNumberOfSharesDisposedOff
      contextRef="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_shares">32000000</gsk:InvestmentOwnedNumberOfSharesDisposedOff>
    <gsk:DisposalOfInterestInAssociatesConsiderationReceivablePerShare
      contextRef="PAsOn05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.25</gsk:DisposalOfInterestInAssociatesConsiderationReceivablePerShare>
    <gsk:GrossProceedsFromDisposalOfInterestInAssociates
      contextRef="P05_20_2021To05_20_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_InnovivaIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_USD">392000000</gsk:GrossProceedsFromDisposalOfInterestInAssociates>
    <gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022_TwothousandtwentyoneacquisitionMemberifrsfullBusinessCombinationsAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Associates&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;and joint&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ventures&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents (divested)/acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-43000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-277000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-51000000</gsk:DeferredConsiderationReceived>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DeferredConsiderationReceived>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransactionCostsOnDisposal>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">277000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">0.55</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <gsk:PortionOfConsiderationPaidReceivedConsistingNonCashConsideration
      contextRef="P09_28_2020To09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">129000000</gsk:PortionOfConsiderationPaidReceivedConsistingNonCashConsideration>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis">his represented goodwill of &#xa3;124&#160;million, cash of &#xa3;21&#160;million and other assets acquired of &#xa3;18&#160;million less &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest of &#xa3;14&#160;million and net liabilities of &#xa3;20&#160;million. &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:97%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets acquired:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-cash&lt;/div&gt; consideration (settlement of a promissory note)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:Goodwill
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">124000000</ifrs-full:Goodwill>
    <ifrs-full:CashTransferred
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:CashTransferred>
    <ifrs-full:OtherAssets
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:OtherAssets>
    <ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn09_28_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate>
    <gsk:NonControllingInterestRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-14000000</gsk:NonControllingInterestRecognisedAsOfAcquisitionDate>
    <ifrs-full:Goodwill
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">124000000</ifrs-full:Goodwill>
    <gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">129000000</gsk:NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate>
    <gsk:NoncashConsiderationForSettlementOfAPromissoryNote
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">129000000</gsk:NoncashConsiderationForSettlementOfAPromissoryNote>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">129000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <gsk:PercentageOfOwnershipDistributed
      contextRef="P01_01_2020To12_31_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="3"
      unitRef="Unit_pure">0.057</gsk:PercentageOfOwnershipDistributed>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P04_01_2020To04_01_2020_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-395000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_BangladeshConsumerHealthcareMemberifrsfullJointVenturesAxis_DisposalGroupsClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">177000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <gsk:CashTransferredOnDisposal
      contextRef="PAsOn12_31_2020_ConsumerHealthCareBangladeshMemberGSKArrangementTypeAxis"
      decimals="-6"
      unitRef="Unit_GBP">478000000</gsk:CashTransferredOnDisposal>
    <gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyAcquisitionMemberifrsfullBusinessCombinationsAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The profit on the disposal of the businesses in the year of &#xa3;2,795&#160;million &lt;div style="display:inline;"&gt;was &lt;/div&gt;calculated as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Horlicks&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;divestment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Other&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Consideration:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration receivable including currency forwards and purchase adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;492&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;649&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Equity investment in Hindustan Unilever Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,616&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,773&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net assets disposed:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;142&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;143&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;68&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;478&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other net (liabilities)/assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(155&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(154&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;536&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;126&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;662&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Costs:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;240&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;240&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Reclassification of exchange from other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;288&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;316&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gain on disposals&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,792&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,795&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory>
    <gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2795000000</gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted>
    <gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">492000000</gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments>
    <gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">157000000</gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments>
    <gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">649000000</gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments>
    <gsk:DisposalOfEquity
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3124000000</gsk:DisposalOfEquity>
    <gsk:DisposalOfEquity
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DisposalOfEquity>
    <gsk:DisposalOfEquity
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3124000000</gsk:DisposalOfEquity>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3616000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">157000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3773000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <gsk:DisposalsGoodwill
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-142000000</gsk:DisposalsGoodwill>
    <gsk:DisposalsGoodwill
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:DisposalsGoodwill>
    <gsk:DisposalsGoodwill
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-143000000</gsk:DisposalsGoodwill>
    <gsk:DisposalsIntangibleAssets
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</gsk:DisposalsIntangibleAssets>
    <gsk:DisposalsIntangibleAssets
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</gsk:DisposalsIntangibleAssets>
    <gsk:DisposalsIntangibleAssets
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-118000000</gsk:DisposalsIntangibleAssets>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">56000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">68000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <gsk:DisposalsInventory
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:DisposalsInventory>
    <gsk:DisposalsInventory
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:DisposalsInventory>
    <gsk:DisposalsInventory
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:DisposalsInventory>
    <ifrs-full:CashTransferred
      contextRef="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">478000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">481000000</ifrs-full:CashTransferred>
    <gsk:DisposalsOtherNetLiabilitiesOrAssets
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-155000000</gsk:DisposalsOtherNetLiabilitiesOrAssets>
    <gsk:DisposalsOtherNetLiabilitiesOrAssets
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:DisposalsOtherNetLiabilitiesOrAssets>
    <gsk:DisposalsOtherNetLiabilitiesOrAssets
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-154000000</gsk:DisposalsOtherNetLiabilitiesOrAssets>
    <gsk:DisposalGroupAssetsNet
      contextRef="PAsOn12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-536000000</gsk:DisposalGroupAssetsNet>
    <gsk:DisposalGroupAssetsNet
      contextRef="PAsOn12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-126000000</gsk:DisposalGroupAssetsNet>
    <gsk:DisposalGroupAssetsNet
      contextRef="PAsOn12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-662000000</gsk:DisposalGroupAssetsNet>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">40000000</gsk:TransactionCostsOnDisposal>
    <gsk:GainLossOnEmbeddedDerivativeTransaction
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</gsk:GainLossOnEmbeddedDerivativeTransaction>
    <gsk:GainLossOnEmbeddedDerivativeTransaction
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:GainLossOnEmbeddedDerivativeTransaction>
    <gsk:GainLossOnEmbeddedDerivativeTransaction
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</gsk:GainLossOnEmbeddedDerivativeTransaction>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <gsk:DisposalGroupLiabilityNet
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">288000000</gsk:DisposalGroupLiabilityNet>
    <gsk:DisposalGroupLiabilityNet
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:DisposalGroupLiabilityNet>
    <gsk:DisposalGroupLiabilityNet
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">316000000</gsk:DisposalGroupLiabilityNet>
    <gsk:GainLossOnDisposalsOfBusiness
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2792000000</gsk:GainLossOnDisposalsOfBusiness>
    <gsk:GainLossOnDisposalsOfBusiness
      contextRef="P01_01_2020To12_31_2020_OtherMemberifrsfullJointVenturesAxis_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:GainLossOnDisposalsOfBusiness>
    <gsk:GainLossOnDisposalsOfBusiness
      contextRef="P01_01_2020To12_31_2020_TwoThousandTwentyBusinessDisposalMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2795000000</gsk:GainLossOnDisposalsOfBusiness>
    <gsk:GainLossOnEmbeddedDerivativeTransaction
      contextRef="P01_01_2020To12_31_2020_HorlicksMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">240000000</gsk:GainLossOnEmbeddedDerivativeTransaction>
    <gsk:CashInvestmentsInJointVenturesAndAssociates
      contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:CashInvestmentsInJointVenturesAndAssociates>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:91%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;acquisitions&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Business&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;disposals&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Associates&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;and joint&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ventures&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;investments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash consideration received/(paid)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net deferred consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents acquired/(divested)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(481&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash (outflow)/inflow&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;259&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-786000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <gsk:DeferredConsiderationReceived
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</gsk:DeferredConsiderationReceived>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:TransactionCostsOnDisposal>
    <gsk:TransactionCostsOnDisposal
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:TransactionCostsOnDisposal>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">-481000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis_TwoThousandTwentyTwoBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis"
      decimals="-6"
      unitRef="Unit_GBP">259000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:5%; text-indent:-5%; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;42. Adjustments reconciling Total profit after tax to operating cash&#160;flows &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total profit after tax from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on profits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits of associates and joint ventures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense net of finance income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;803&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,061&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,034&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment and assets written off&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;481&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;529&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of businesses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(185&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Loss on sale of investments in associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Changes in working capital:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase)in inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(269&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in trade receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(158&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in trade payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;229&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Increase) in other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration paid (see Note 33)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(765&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; increase in contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,063&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;885&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension and other provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based incentive plans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(122&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Operating cash flow from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,944&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,674&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Operating cash flow from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,994&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total cash generated from operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,876&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,096&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory>
    <gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:5%; text-indent:-5%; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;42. Adjustments reconciling Total profit after tax to operating cash&#160;flows &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total profit after tax from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tax on profits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;707&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profits of associates and joint ventures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Finance expense net of finance income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;803&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,061&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,034&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Amortisation of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Impairment and assets written off&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;481&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;529&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of businesses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(185&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Loss on sale of investments in associates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Profit on sale of equity investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Changes in working capital:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase)in inventories&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(269&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in trade receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(158&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in trade payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;229&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;(Increase) in other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration paid (see Note 33)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(765&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; increase in contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,063&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;885&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in pension and other provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Share-based incentive plans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fair value adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(122&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Operating cash flow from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,944&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,674&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Operating cash flow from discontinued operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;932&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,994&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total cash generated from operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,876&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,096&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">4921000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">3516000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">5103000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">707000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures>
    <gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures>
    <gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-33000000</gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-803000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-755000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-842000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1061000000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1034000000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1004000000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1086000000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1088000000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1046000000</ifrs-full:AdjustmentsForAmortisationExpense>
    <gsk:AdjustmentsForImpairmentAndAssetsWrittenOff
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">481000000</gsk:AdjustmentsForImpairmentAndAssetsWrittenOff>
    <gsk:AdjustmentsForImpairmentAndAssetsWrittenOff
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">529000000</gsk:AdjustmentsForImpairmentAndAssetsWrittenOff>
    <gsk:AdjustmentsForImpairmentAndAssetsWrittenOff
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">684000000</gsk:AdjustmentsForImpairmentAndAssetsWrittenOff>
    <gsk:AdjustmentsForProfitOnSaleOfBusinesses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:AdjustmentsForProfitOnSaleOfBusinesses>
    <gsk:AdjustmentsForProfitOnSaleOfBusinesses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">47000000</gsk:AdjustmentsForProfitOnSaleOfBusinesses>
    <gsk:AdjustmentsForProfitOnSaleOfBusinesses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2815000000</gsk:AdjustmentsForProfitOnSaleOfBusinesses>
    <gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-185000000</gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets>
    <gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-539000000</gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets>
    <gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-279000000</gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets>
    <ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-36000000</ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates>
    <gsk:AdjustmentsForProfitOnSaleOfEquityInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:AdjustmentsForProfitOnSaleOfEquityInvestments>
    <gsk:AdjustmentsForProfitOnSaleOfEquityInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:AdjustmentsForProfitOnSaleOfEquityInvestments>
    <gsk:AdjustmentsForProfitOnSaleOfEquityInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">69000000</gsk:AdjustmentsForProfitOnSaleOfEquityInvestments>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-269000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">51000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">100000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-158000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-780000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-279000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">494000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">229000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-458000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-382000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-349000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1058000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-742000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-765000000</gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid>
    <gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1628000000</gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities>
    <gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1063000000</gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities>
    <gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1275000000</gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1505000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">885000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-962000000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-299000000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">428000000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">346000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">343000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">337000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-283000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-31000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">373000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-170000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-122000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-13000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7944000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">7249000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">7674000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">932000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1994000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2422000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">8876000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">9243000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">10096000000</ifrs-full:CashFlowsFromUsedInOperations>
    <gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;43. Reconciliation of net cash flow to movement in net debt&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt, at beginning of year, as adjusted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25,215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in cash and bank overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,597&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in long-term loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of short-term Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,074&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of/(increase in) other short-term loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of medium term notes (MTNs)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,594&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt of subsidiary undertakings acquired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,531&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; movements&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(102&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase) in net debt from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,536&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase) in net debt from discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,177&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,027&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total net debt at end of year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Analysis&#160;of&#160;changes&#160;in&#160;net&#160;debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&#160;1&#160;January&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Exchange&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Interest&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Change&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;fair&#160;value&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Reclass-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ifications&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Demerger&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cash&#160;flow&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&#160;December&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(450&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(298&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,411&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,425&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;407&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,496&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,818&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(545&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,425&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(909&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,559&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,466&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,145&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,615&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,559&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,789&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(725&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(777&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,059&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,236&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,572&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,222&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(249&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,615&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,059&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,667&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,424&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities from financing activities*&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,983&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,450&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(301&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(912&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;718&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,710&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,670&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,888&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Excluding cash and cash equivalents, overdrafts and liquid investments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Analysis of changes in net debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&#160;1&#160;January&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Exchange&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Interest&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;expense&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Change&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;in&#160;fair&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Reclass-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;ifications&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;Cash&#160;flow&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;31&#160;December&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,274&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;574&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,262&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,414&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,818&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,596&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,695&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,694&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,210&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,145&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,760&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(887&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(812&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,425&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;313&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,694&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,572&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(128&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;778&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(753&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(244&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities from financing activities*&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,441&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(775&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,976&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(23,983&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Excluding cash and cash equivalents, overdrafts and liquid investments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory>
    <gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:91%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2020&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt, at beginning of year, as adjusted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25,215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in cash and bank overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,597&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase/(decrease) in liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Increase in long-term loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of short-term Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,074&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of/(increase in) other short-term loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of medium term notes (MTNs)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,594&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Repayment of lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt of subsidiary undertakings acquired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,531&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; movements&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(102&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase) in net debt from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,536&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Decrease/(increase) in net debt from discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,177&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,100&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,027&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total net debt at end of year&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">20780000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_GBP">25215000000</ifrs-full:Borrowings>
    <gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-7597000000</gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations>
    <gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-2504000000</gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations>
    <gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-1579000000</gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations>
    <gsk:DecreaseIncreaseInLiquidInvestment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:DecreaseIncreaseInLiquidInvestment>
    <gsk:DecreaseIncreaseInLiquidInvestment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-18000000</gsk:DecreaseIncreaseInLiquidInvestment>
    <gsk:DecreaseIncreaseInLiquidInvestment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:DecreaseIncreaseInLiquidInvestment>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1025000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3298000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5074000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">2304000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">3738000000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1021000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">301000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-3594000000</gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">1594000000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <gsk:PaymentsOfFinanceLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-202000000</gsk:PaymentsOfFinanceLeaseLiabilities>
    <gsk:PaymentsOfFinanceLeaseLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-181000000</gsk:PaymentsOfFinanceLeaseLiabilities>
    <gsk:PaymentsOfFinanceLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-182000000</gsk:PaymentsOfFinanceLeaseLiabilities>
    <gsk:DebtOfSubsidiaryUndertakingsAcquired
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">24000000</gsk:DebtOfSubsidiaryUndertakingsAcquired>
    <gsk:ExchangeOnNetDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-1531000000</gsk:ExchangeOnNetDebt>
    <gsk:ExchangeOnNetDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">314000000</gsk:ExchangeOnNetDebt>
    <gsk:ExchangeOnNetDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-128000000</gsk:ExchangeOnNetDebt>
    <gsk:OtherAdjustmentsForNoncashItemsToNetDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-207000000</gsk:OtherAdjustmentsForNoncashItemsToNetDebt>
    <gsk:OtherAdjustmentsForNoncashItemsToNetDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-134000000</gsk:OtherAdjustmentsForNoncashItemsToNetDebt>
    <gsk:OtherAdjustmentsForNoncashItemsToNetDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">-102000000</gsk:OtherAdjustmentsForNoncashItemsToNetDebt>
    <gsk:DecreaseIncreaseInNetDebtFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-4536000000</gsk:DecreaseIncreaseInNetDebtFromContinuingOperations>
    <gsk:DecreaseIncreaseInNetDebtFromContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-158000000</gsk:DecreaseIncreaseInNetDebtFromContinuingOperations>
    <gsk:DecreaseIncreaseInNetDebtFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2408000000</gsk:DecreaseIncreaseInNetDebtFromContinuingOperations>
    <gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">7177000000</gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations>
    <gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">1100000000</gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations>
    <gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">2027000000</gsk:DecreaseIncreaseInNetDebtFromDiscontinuedOperations>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">17197000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">20780000000</ifrs-full:Borrowings>
    <gsk:DisclosureOfAnalysisOfChangesInNetDebtExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Analysis&#160;of&#160;changes&#160;in&#160;net&#160;debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&#160;1&#160;January&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2022&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Exchange&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Interest&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Change&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;fair&#160;value&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Reclass-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ifications&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Demerger&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cash&#160;flow&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31&#160;December&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,723&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(450&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(298&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,411&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,425&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;407&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,496&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,818&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(545&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,425&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(909&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,146&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(167&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(150&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,559&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,466&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,145&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,615&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,559&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,789&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(725&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(841&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year attributed to continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year attributed to discontinued operations&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(777&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,059&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,236&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,572&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,222&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(249&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,615&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,059&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,667&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,838&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,287&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,618&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,424&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17,197&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities from financing activities*&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,983&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,450&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(301&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(912&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;718&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,710&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,670&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,888&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Excluding cash and cash equivalents, overdrafts and liquid investments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div/&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 30pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: ARIAL;"&gt;&lt;div style="font-weight:bold;display:inline;"/&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Analysis of changes in net debt&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&#160;1&#160;January&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Exchange&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Interest&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;expense&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Change&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;in&#160;fair&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Reclass-&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;ifications&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;Cash&#160;flow&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;At&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;31&#160;December&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,274&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Overdrafts&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,030&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;574&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(456&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,262&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,414&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,818&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due within one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,596&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,695&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,694&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,210&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,145&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Debt due after one year:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;European/US MTN&#160;&amp;amp; Bank facilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,760&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(887&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(812&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,425&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;313&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,694&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,572&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net debt&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,780&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(128&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;778&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,838&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Interest payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(753&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(244&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(22&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total liabilities from financing activities*&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,441&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(775&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,976&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(23,983&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Excluding cash and cash equivalents, overdrafts and liquid investments. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </gsk:DisclosureOfAnalysisOfChangesInNetDebtExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-61000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-67000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3861000000</gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-99000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7496000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7734000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3723000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations
      contextRef="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">450000000</gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-137000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">298000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations
      contextRef="PAsOn12_31_2021_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3411000000</gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-114000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7496000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7597000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LiquidInvestmentsAttributedToContinuingOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3425000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations
      contextRef="PAsOn12_31_2021_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-407000000</gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-37000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7496000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsAttributedToDiscontinuedOperationsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7052000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <gsk:LiquidInvestmentsCashAndCashEquivalents
      contextRef="PAsOn12_31_2021_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3818000000</gsk:LiquidInvestmentsCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-151000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">545000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LiquidInvestmentsCashAndCashEquivalentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3425000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">909000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1191000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2596000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">174000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4426000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5050000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2146000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">173000000</gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">186000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-201000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">167000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations
      contextRef="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">87000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">150000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations
      contextRef="PAsOn12_31_2021_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3073000000</gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">220000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4612000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4255000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_ShortTermBorrowingsAttributedToContinuingOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3654000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations
      contextRef="PAsOn12_31_2021_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">72000000</gsk:LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:ReclassificationOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1559000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShortTermBorrowingsAttributedToDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1466000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3145000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">223000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4615000000</gsk:ReclassificationOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1559000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2789000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3654000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19760000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1386000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">43000000</ifrs-full:InterestExpense>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4426000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-569000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">16194000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">725000000</gsk:LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">243000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-186000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">841000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations
      contextRef="PAsOn12_31_2021_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20485000000</gsk:LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1445000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">243000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">43000000</ifrs-full:InterestExpense>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4612000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-569000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LongTermBorrowingsContinuingOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17035000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations
      contextRef="PAsOn12_31_2021_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">87000000</gsk:LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">777000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:InterestExpense>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</gsk:ChangeInFairValueOfNetDebt>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</gsk:ReclassificationOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10059000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongTermBorrowingsDiscontinuedOperationsMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9236000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20572000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2222000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">249000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">47000000</ifrs-full:InterestExpense>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</gsk:ChangeInFairValueOfNetDebt>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4615000000</gsk:ReclassificationOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">10059000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">8667000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17035000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2287000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">267000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">47000000</ifrs-full:InterestExpense>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</gsk:ChangeInFairValueOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">11618000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6424000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17197000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">244000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">33000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">865000000</ifrs-full:InterestExpense>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">92000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-848000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">207000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">670000000</gsk:ChangeInFairValueOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">640000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">23983000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">2450000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">301000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">912000000</ifrs-full:InterestExpense>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">718000000</gsk:ChangeInFairValueOfNetDebt>
    <gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">11710000000</gsk:IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">5670000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">20888000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-78000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-61000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6292000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1988000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4274000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1030000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-574000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_BankOverdrafts1MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">456000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5262000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">29000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1414000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <gsk:CashAndCashEquivalentsAndNetOfOverdrafts
      contextRef="PAsOn12_31_2021_CashAndBankOverdraftsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3818000000</gsk:CashAndCashEquivalentsAndNetOfOverdrafts>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">243000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_CommercialPaper1MemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2350000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:InterestExpense>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2494000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2247000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2596000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">230000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">200000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-215000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">203000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">98000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_OtherCurrentDebtMemberifrsfullBorrowingsByNameAxis_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">94000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2695000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-29000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2694000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2210000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3145000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22538000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-306000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:InterestExpense>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2494000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_EuropeanUsMediumTermNotesAndBankFacilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19760000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">887000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-200000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LeaseLiabilitiesMemberifrsfullBorrowingsByNameAxis_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">812000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">23425000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-313000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">132000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:InterestExpense>
    <gsk:ReclassificationOfNetDebt
      contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2694000000</gsk:ReclassificationOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20572000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20780000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-314000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">128000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:InterestExpense>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-778000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_NetDebtMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19838000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">247000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">30000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">753000000</ifrs-full:InterestExpense>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-786000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_AccruedInterestMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">244000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">74000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">72000000</gsk:ChangeInFairValueOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_DerivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">26441000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-342000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">157000000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">775000000</ifrs-full:InterestExpense>
    <gsk:ChangeInFairValueOfNetDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">72000000</gsk:ChangeInFairValueOfNetDebt>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-2976000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">23983000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44. Financial instruments and related disclosures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The objective of GSK&#x2019;s Treasury activities is to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;minimise &lt;/div&gt;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-tax&lt;/div&gt; net cost of financial operations and reduce its volatility to benefit earnings and cash flows. GSK uses a variety of financial instruments to finance its operations and derivative financial instruments to manage market risks from these operations. Derivatives principally comprise foreign exchange forward contracts and swaps which are used to swap borrowings and liquid assets into currencies required for Group purposes as well as interest rate swaps which are used to manage exposure to financial risks from changes in interest rates. These financial instruments reduce the uncertainty of foreign currency transactions and interest payments. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivatives are used exclusively for hedging purposes in relation to underlying business activities and not as trading or speculative instruments. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Capital management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK&#x2019;s financial strategy supports the Group&#x2019;s strategic priorities and is regularly reviewed by the Board. GSK manages the capital structure of the Group through an appropriate mix of debt and equity. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The capital structure of the Group consists of net debt of &#xa3;17.2&#160;billion (see Note 30, &#x2018;Net debt&#x2019;) and total equity, including items related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests, of &#xa3;10.1&#160;billion (see &#x2018;Consolidated statement of changes in equity&#x2019; on page 184). Total capital, including that provided by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests, is &#xa3;27.3&#160;billion. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group continues to manage its financial policies to a credit profile that particularly targets short-term credit ratings of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;P-1&lt;/div&gt; while maintaining single A long-term ratings consistent with those targets. The Group&#x2019;s long-term credit rating with Standard&#160;&amp;amp; Poor&#x2019;s is A (stable outlook) and with Moody&#x2019;s Investor Services (&#x2018;Moody&#x2019;s&#x2019;) it is A2 (stable outlook). The Group&#x2019;s short-term credit ratings are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;P-1&lt;/div&gt; with Standard &amp;amp; Poor&#x2019;s and Moody&#x2019;s respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity risk management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK&#x2019;s policy is to borrow centrally in order to meet anticipated funding requirements. The strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. Each day, we sweep cash to or from a number of global subsidiaries and central Treasury accounts for liquidity management purposes. GSK utilises both physical and notional cash pool arrangements as appropriate by location and currency. For notional cash pools, liquidity is drawn against foreign currency balances to provide both local funding and central liquidity as required and with balances actively managed and maintained to appropriate levels. As balances in notional pooling arrangements are not settled across currencies, gross cash and overdraft balances are reported. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, GSK had &#xa3;4&#160;billion of borrowings repayable within one year and held &#xa3;3.8&#160;billion of cash and cash equivalents and liquid investments of which &#xa3;3.1&#160;billion was held centrally. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK has access to short-term finance under a $10&#160;billion (&#xa3;8.3 billion) US commercial paper programme; $900&#160;million (&#xa3;748 million) was in issue at 31&#160;December 2022 (2021: $nil). GSK has access to short-term finance under a &#xa3;5&#160;billion Euro commercial paper programme; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;500&#160;million (&#xa3;443 million) was in issue at 31&#160;December 2022 (2021: &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;300&#160;million (&#xa3;252 million)). In February 2022 GSK cancelled the &#xa3;1.9&#160;billion three year and $2.5&#160;billion (&#xa3;2.1 billion) 364 day committed facilities and replaced them with new revolving credit facilities of equivalent size with maturities of September 2025 and September 2023 respectively. Post separation of the Consumer Healthcare business these facilities were reduced to &#xa3;1.6&#160;billion and $2.2&#160;billion (&#xa3;1.8 billion) respectively. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;These committed facilities were undrawn at 31&#160;December 2022. GSK considers this level of committed facilities to be adequate, given current liquidity requirements. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK has a &#xa3;20.0 billion Euro Medium Term Note programme and at 31 December 2022, &#xa3;10.3 billion of notes were in issue under this programme. The Group also had $9.7 billion (&#xa3;8.1 billion) of notes in issue at 31 December 2022 under a US shelf registration. GSK is currently in the process of renewing its US shelf registration statement in order to maintain access to the US debt markets. GSK&#x2019;s borrowings mature at dates between 2023 and 2045. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The put option owned by Pfizer in ViiV Healthcare is exercisable. In reviewing liquidity requirements GSK considers that sufficient financing options are available should the put option be exercised. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Market risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest rate risk management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK&#x2019;s objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating rates over time. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s main interest rate risk arises from borrowings and investments with floating rates and refinancing of maturing fixed rate debt where any changes in interest rates will affect future cash flows or the fair values of financial instruments. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the Board. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#x2019;s net interest charge. Short-term borrowings including bank facilities are exposed to the risk of future changes in market interest rates as are the majority of cash and liquid investments. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign exchange risk management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s objective is to minimise the exposure of overseas operating subsidiaries to transaction risk by matching local currency income with local currency costs where possible. Foreign currency transaction exposures arising on external and internal trade flows are selectively hedged. GSK&#x2019;s internal trading transactions are matched centrally and inter-company payment terms are managed to reduce foreign currency risk. Where possible, GSK manages the cash surpluses or borrowing requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating currency. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In order to reduce foreign currency translation exposure, the Group seeks to denominate borrowings in the currencies of our principal assets and cash flows. These are primarily denominated in US Dollars, Euros and Sterling. Borrowings can be swapped into other currencies as required. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated as a hedge against the relevant assets. Forward contracts in major currencies are also used to reduce exposure to the Group&#x2019;s investment in overseas assets (see &#x2018;Net investment hedges&#x2019; section of this note for further details). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Credit risk is the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group and arises on cash and cash equivalents and favourable derivative financial instruments held with banks and financial institutions as well as credit exposures to wholesale and retail customers, including outstanding receivables. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group considers its maximum credit risk at 31&#160;December 2022 to be &#xa3;10,180&#160;million (31&#160;December 2021: &#xa3;11,417 million) which is the total of the Group&#x2019;s financial assets with the exception of &#x2019;Other investments&#x2019; (comprising equity investments) which bear equity risk rather than credit risk. See page 249 for details on the Group&#x2019;s total financial assets. At 31&#160;December 2022, GSK&#x2019;s greatest concentration of credit risk was &#xa3;1.1&#160;billion with a wholesaler in the US (2021: &#xa3;0.9&#160;billion with a wholesaler in the US). See page 247 for further information on the Group&#x2019;s credit risk exposure in respect of the three largest US wholesaler customers. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There has been no change in the estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for financial assets at amortised cost or at FVTOCI since the adoption of IFRS 9 at the start of the 2018 reporting period. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Treasury-related credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK sets global counterparty limits for each of GSK&#x2019;s banking and investment counterparties based on long-term credit ratings from Moody&#x2019;s and Standard&#160;&amp;amp; Poor&#x2019;s. Usage of these limits is actively monitored. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK actively manages its exposure to credit risk, reducing surplus cash balances wherever possible. This is part of GSK&#x2019;s strategy to regionalise cash management and to concentrate cash centrally as much as possible. The table below sets out the credit exposure to counterparties by rating for liquid investments, cash and cash equivalents and derivatives. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The gross asset position on each derivative contract is considered for the purpose of this table, although, under ISDA agreements, the amount at risk is the net position with each counterparty. Table (e)&#160;on page 257 sets out the Group&#x2019;s financial assets and liabilities on an offset basis. &lt;/div&gt;  &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, &#xa3;60&#160;million (2021: &#xa3;54 million) of cash is categorised as held with unrated or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-investment&lt;/div&gt; grade rated counterparties (lower than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB-/Baa3)&lt;/div&gt; of which &#xa3;nil (2021: &#xa3;7 million) is cash in transit. The remaining exposure is concentrated in overseas banks used for local cash management or investment purposes, including: &#xa3;23&#160;million in Nigeria held with United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank; &#xa3;14&#160;million with Halk Bank in the UK; &#xa3;6&#160;million with Produbanco in Ecuador; &#xa3;2&#160;million with J Trust Royal Bank in Cambodia; &#xa3;2&#160;million with Banco Do Brasil in Brazil; &#xa3;1&#160;million with Banco de Honduras in Honduras; and &#xa3;1&#160;million with BAC San Jos&#xe9; in Costa Rica. Of the &#xa3;49&#160;million of bank balances and deposits held with BBB/Baa rated counterparties, &#xa3;1.4&#160;million was held with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB-/Baa3&lt;/div&gt; rated counterparties, including balances or deposits of &#xa3;1&#160;million with State Bank of India in India. These banks are used for local investment purposes. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK measures expected credit losses over cash and cash equivalents as a function of individual counterparty credit ratings and associated 12&#160;month default rates. Expected credit losses over cash and cash equivalents and third-party financial derivatives are deemed to be immaterial and no such loss has been experienced during 2022. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Credit ratings are assigned by Standard&#160;&amp;amp; Poor&#x2019;s and Moody&#x2019;s respectively. Where the opinions of the two rating agencies differ, GSK assigns the lower rating of the two to the counterparty. Where local rating agency or Fitch data is the only source available, the ratings are converted to global ratings equivalent to those of Standard&#160;&amp;amp; Poor&#x2019;s or Moody&#x2019;s using published conversion tables. These credit ratings form the basis of the assessment of the expected credit loss on Treasury-related balances held at amortised cost being bank balances and deposits and Government securities. &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AAA/Aaa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AA/Aa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A/A&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB/Baa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB+/Ba1&lt;br/&gt; and&#160;below&lt;br/&gt; /unrated&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank balances and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,215&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US Treasury and Treasury repo only money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;146&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquidity funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,253&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third party financial derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;188&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;188&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,399&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,403&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,978&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AAA/Aaa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AA/Aa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A/A&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB/Baa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB+/Ba1&lt;br/&gt; and&#160;below&lt;br/&gt; /unrated&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank balances and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,687&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;77&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,825&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US Treasury and Treasury repo only money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquidity funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third party financial derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;200&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;200&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,449&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,887&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,535&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK&#x2019;s centrally managed cash reserves amounted to &#xa3;3.1&#160;billion at 31&#160;December 2022, all available within three months. This includes &#xa3;2.2&#160;billion of cash managed by the Group for ViiV Healthcare, a 78.3% owned subsidiary. The Group has invested centrally managed liquid assets in bank deposits, Aaa/AAA rated US Treasury and Treasury repo only money market funds and Aaa/AAA rated liquidity funds. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Wholesale and retail credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Outside the US, no customer accounts for more than 5% of the Group&#x2019;s trade receivables balance. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In the US, in line with other pharmaceutical companies, the Group sells its products through a small number of wholesalers in addition to hospitals, pharmacies, physicians and other groups. Sales to the three largest wholesalers amounted to approximately 79% (2021: 75%) of the sales of the US Commercial Operations business in 2022. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the Group had trade receivables due from these three wholesalers totalling &#xa3;3,001&#160;million or 55% of total trade receivables (2021: &#xa3;2,430&#160;million or 39%). The Group is exposed to a concentration of credit risk in respect of these wholesalers such that, if one or more of them encounters financial difficulty, it could materially and adversely affect the Group&#x2019;s financial results. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;This concentration of trade receivables is reflective of standard market practice in the US pharmaceuticals sector where a significant portion of sales are made to these three wholesalers, as disclosed in Note 6. GSK&#x2019;s assessment is that there is limited credit risk associated with these customers. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s credit risk monitoring activities relating to these wholesalers include a review of their quarterly financial information and Standard&#160;&amp;amp; Poor&#x2019;s credit ratings, development of GSK internal risk ratings, and establishment and periodic review of credit limits. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;All new customers are subject to a credit vetting process and existing customers will be subject to a review at least annually. The vetting process and subsequent reviews involve obtaining information including the customer&#x2019;s status as a government or private sector entity, audited financial statements, credit bureau reports, debt rating agency (eg Moody&#x2019;s, Standard&#160;&amp;amp; Poor&#x2019;s) reports, payment performance history (from trade references, industry credit groups) and bank references. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade receivables consist of amounts due from a large number of customers, spread across diverse industries and geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable and, where appropriate, credit insurance is purchased or factoring arrangements put in place. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The amount of information obtained is proportional to the level of exposure being considered. The information is evaluated quantitatively (i.e. credit score) and qualitatively (i.e. judgement) in conjunction with the customer&#x2019;s credit requirements to determine a credit limit. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade receivables are grouped into customer segments that have similar loss patterns to assess credit risk while other receivables and other financial assets are assessed individually. Historical and forward-looking information is considered to determine the appropriate expected credit loss allowance. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group believes there is no further credit risk provision required in excess of the allowance for expected credit losses (see Note 26, &#x2018;Trade and other receivables&#x2019;). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Credit enhancements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group uses credit enhancements including factoring and credit insurance to minimise the credit risk of the trade receivables in the Group. At 31&#160;December 2022, &#xa3;332&#160;million (2021: &#xa3;315 million) of trade receivables were insured in order to protect the receivables from loss due to credit risks such as default, insolvency and bankruptcy. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Each Group entity assesses the credit risk of its private customers to determine if credit insurance is required. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Factoring arrangements are managed locally by entities and are used to mitigate risk arising from large credit risk concentrations. All factoring arrangements are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recourse.&lt;/div&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value of financial assets and liabilities excluding lease liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table on page 249 presents the carrying amounts and the fair values of the Group&#x2019;s financial assets and liabilities excluding lease liabilities at 31&#160;December 2022 and 31&#160;December 2021. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair values of the financial assets and liabilities are included at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following methods and assumptions are used to measure the fair values of significant financial instruments carried at fair value on the balance sheet: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Other investments &#x2013; equity investments traded in an active market determined by reference to the relevant stock exchange quoted bid price; other equity investments determined by reference to the current market value of similar instruments, recent financing rounds or the discounted cash flows of the underlying net assets &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Trade receivables carried at fair value &#x2013; based on invoiced amount &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Interest rate swaps, foreign exchange forward contracts, swaps and options &#x2013; based on the present value of contractual cash flows or option valuation models using market sourced data (exchange rates or interest rates) at the balance sheet date &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Cash and cash equivalents carried at fair value &#x2013; based on net asset value of the funds &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Contingent consideration for business acquisitions and divestments &#x2013; based on present values of expected future cash flows. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following methods and assumptions are used to estimate the fair values of significant financial instruments which are not measured at fair value on the balance sheet: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Receivables and payables, including put options, carried at amortised cost &#x2013; approximates to the carrying amount &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Liquid investments &#x2013; approximates to the carrying amount &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Cash and cash equivalents carried at amortised cost &#x2013; approximates to the carrying amount &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Long-term loans &#x2013; based on quoted market prices (a level 1 fair value measurement) in the case of European and US Medium Term Notes; approximates to the carrying amount in the case of other fixed rate borrowings and floating rate bank loans &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7.5pt;vertical-align:top;text-align:left;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Short-term loans, overdrafts and commercial paper &#x2013; approximates to the carrying amount because of the short maturity of these instruments. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Notes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Fair &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at amortised cost:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,789&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,789&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,825&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,825&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current equity investments and Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,734&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,734&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,543&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,543&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities measured at amortised cost:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings excluding obligations under lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; bonds in a designated hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,322&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,311&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(11,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; bank loans and overdrafts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; commercial paper in a designated hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total borrowings excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;f&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,605&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total financial liabilities excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(41,442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(41,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45,058&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48,760&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net financial assets and financial liabilities excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,708&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,334&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31,515&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35,217&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The valuation methodology used to measure fair value in the above table is described and categorised on page 248. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade and other receivables, Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets, Trade and other payables, Other provisions, Contingent consideration liabilities and Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities are reconciled to the relevant Notes on pages 251 to 252. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value of investments in GSK shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the Employee Share Ownership Plan (ESOP) Trusts held GSK shares with a carrying value of &#xa3;354&#160;million (2021: &#xa3;28 million) and a market value of &#xa3;861&#160;million (2021: &#xa3;373 million) based on quoted market price. The shares are held by the ESOP Trusts to satisfy future exercises of options and awards under employee incentive schemes. In 2022, the carrying value, which is the lower of cost or expected proceeds, of these shares has been recognised as a deduction from other reserves. At 31&#160;December 2022, GSK held Treasury shares at a cost of &#xa3;3,797&#160;million (2021: &#xa3;4,969 million) which has been deducted from retained earnings. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(a) Financial instruments held at fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following tables categorise the Group&#x2019;s financial assets and liabilities held at fair value by the valuation methodology applied in determining their fair value. Where possible, quoted prices in active markets are used (Level 1). Where such prices are not available, the asset or liability is classified as Level&#160;2, provided all significant inputs to the valuation model used are based on observable market data. If one or more of the significant inputs to the valuation model is not based on observable market data, the instrument is classified as Level&#160;3. Other investments classified as Level&#160;3 in the tables below comprise equity investments in unlisted entities with which the Group has entered into research collaborations and investments which provide access to biotechnology developments of potential interest. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Current equity investments and Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,087&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,309&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,567&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,533&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(106&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,251&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,927&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,943&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;59&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,449&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,185&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,202&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;419&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,806&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,076&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,304&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Movements in the year for financial instruments measured using Level&#160;3 valuation methods are presented below: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,657&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,064&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net losses recognised in the income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,627&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,024&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net gains recognised in other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;185&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration related to business acquisitions in the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(482&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Settlement of contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,137&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;856&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;97&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfers from Level&#160;3&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(694&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,411&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,657&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Of the total net losses of &#xa3;1,627&#160;million (2021: &#xa3;1,024 million) attributable to Level&#160;3 financial instruments which were recognised in the income statement, &#xa3;1,623&#160;million (2021: &#xa3;1,024 million) were in respect of financial instruments which were held at the end of the year and were reported in Other operating income/expense. Charges of &#xa3;1,431&#160;million (2021: &#xa3;1,026 million) arose from remeasurement of the contingent consideration payable for the acquisition of the former Shionogi-ViiV Healthcare joint venture and &#xa3;231&#160;million (2021: &#xa3;32 million) arose from remeasurement of the contingent consideration payable for the acquisition of the Novartis Vaccines business. The acquisition of Affinivax in 2022 resulted in the addition of &#xa3;482&#160;million of contingent consideration to Level&#160;3 financial liabilities, with a further &#xa3;17&#160;million remeasurement charge arising for the period between acquisition and 31&#160;December 2022. There were no transfers into or out of Level&#160;3 financial instruments in the year (2021 &#x2013; transfers related to equity instruments which transferred to a Level&#160;1 valuation methodology as a result of listing on a recognised stock exchange during the year). Movements arising on the translation of overseas net assets for consolidation into the Group accounts are recorded as Exchange adjustments. Net gains and losses include the impact of other exchange movements. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Financial liabilities measured using Level&#160;3 valuation methods at 31&#160;December included &#xa3;5,890&#160;million (2021: &#xa3;5,559 million) in respect of contingent consideration payable for the acquisition in 2012 of the former Shionogi-ViiV Healthcare joint venture. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products and movements in certain foreign currencies. A further &#xa3;673&#160;million (2021: &#xa3;479 million) is in respect of contingent consideration for the acquisition in 2015 of the Novartis Vaccines business. This consideration is expected to be paid over a number of years and will vary in line with the future performance of specified products, the achievement of certain milestone targets and movements in certain foreign currencies. As a result of the Group&#x2019;s acquisition of Affinivax in 2022, contingent consideration payable of &#xa3;501&#160;million is recognised at 31&#160;December 2022. This consideration is expected to be paid over a number of years and will vary in line with the achievement of certain development milestones and movements in the USD/GBP exchange rate. Sensitivity analysis on these balances is provided in Note 33, &#x2018;Contingent consideration liabilities&#x2019;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(b) Trade and other receivables and Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets in scope of IFRS 9 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table reconciles financial instruments within Trade and other receivables and Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial assets are predominantly &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; earning. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-financial&lt;/div&gt; instruments include tax receivables, pension surplus balances and prepayments, which are outside the scope of IFRS 9. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTOCI&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTOCI&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables (Note&#160;26)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,166&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;887&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,053&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,832&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other non-current assets (Note&#160;24)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,632&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,200&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,047&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,247&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,851&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,876&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,660&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,536&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Trade and other receivables include trade receivables of &#xa3;5,452&#160;million (2021: &#xa3;6,246 million). The Group has portfolios in each of the three business models under IFRS 9: &#xa3;50&#160;million (2021: &#xa3;59 million), measured at FVTPL, is held to sell the contractual cash flows as the receivables will be sold under a factoring arrangement, &#xa3;2,327&#160;million (2021: &#xa3;1,943 million), measured at FVTOCI, is held to either collect or sell the contractual cash flows as the receivables may be sold under a factoring agreement, and &#xa3;3,075&#160;million (2021: &#xa3;4,244 million), measured at amortised cost, is held to collect the contractual cash flows and there is no factoring agreement in place. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(c) Trade and other payables, Other provisions, Contingent consideration liabilities and Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities in scope of IFRS 9 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table reconciles financial instruments within Trade and other payables, Other provisions, Contingent consideration liabilities and Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities which fall within the scope of IFRS 9 to the relevant balance sheet amounts. The financial liabilities are predominantly &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-financial&lt;/div&gt; instruments include payments on account, tax and social security payables and provisions which do not arise from contractual obligations to deliver cash or another financial asset, which are outside the scope of IFRS 9. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&#160;FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;br/&gt; financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;At&#160;FVTPL&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;br/&gt; &#160;&#160;instruments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables (Note&#160;29)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,198&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other provisions (Note&#160;32)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,121&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration liabilities (Note&#160;33)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities (Note&#160;34)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(815&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(899&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(869&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(921&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21,280&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,414&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,596&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,672&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,350&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,022&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(d) Derivative financial instruments and hedging programmes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Derivatives are only used for economic hedging purposes and not as speculative investments and are classified as &#x2018;held for trading&#x2019;, other than designated and effective hedging instruments, and are presented as current assets or liabilities if they are expected to be settled within 12 months after the end of the reporting period, otherwise they are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; The Group has the following derivative financial instruments: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Fair&#160;value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash flow hedges &#x2013; Interest rate swap contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;nil (2021: &#xa3;1,996 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash flow hedges &#x2013; Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;167&#160;million (2021: &#xa3;160 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment hedges &#x2013; Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;7,197&#160;million (2021: &#xa3;5,469 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Embedded and other derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;5,908&#160;million (2021: &#xa3;9,728 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Embedded and other derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives classified as held for trading&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total derivative instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value hedges &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022 and 31&#160;December 2021, the Group had no designated fair value hedges. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, certain foreign exchange contracts were designated as net investment hedges in respect of the foreign currency translation risk arising on consolidation of the Group&#x2019;s net investment in its European (Euro), Singaporean (SGD), Canadian (CAD) and Japanese (JPY) foreign operations as shown in the table above. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The carrying value of bonds on page 249 included &#xa3;6,322&#160;million (2021: &#xa3;4,982 million) that were designated as hedging instruments in net investment hedges. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2021 and 2022, the Group entered into forward foreign exchange contracts which have been designated as cash flow hedges. These were entered into to hedge the foreign exchange exposure arising on cash flows from Euro denominated coupon payments relating to notes issued under the Group&#x2019;s European Medium Term Note programme, and to hedge foreign currency payments due on collaboration or licensing arrangements. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group manages its cash flow interest rate risk by using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;floating-to-fixed&lt;/div&gt;&lt;/div&gt; interest rate swaps. In addition, the Group carries a balance in reserves that arose from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-hedging&lt;/div&gt; fluctuations in long-term interest rates when pricing bonds issued in prior years and in the current year. The balance is reclassified to finance costs over the life of these bonds. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign exchange risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In the current year, the Group has designated certain foreign exchange forward contracts and swaps as cash flow and net investment hedges. Foreign exchange derivative financial assets and liabilities are presented in the line &#x2018;Derivative financial instruments&#x2019; (either as assets or liabilities) on the Consolidated balance sheet. The following tables detail the foreign exchange forward contracts and swaps outstanding at the end of the reporting period, as well as information on the related hedged items. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments to ensure that an economic relationship exists between the hedged item and hedging instrument. The Group enters into hedge relationships where the critical terms of the hedging instrument match exactly with the terms of the hedged item, and so a qualitative assessment of effectiveness is performed. If changes in circumstances affect the terms of the hedged item such that the critical terms no longer match exactly with the critical terms of the hedging instrument, the Group uses the hypothetical derivative method to assess effectiveness. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The main source of hedge ineffectiveness in these hedging relationships is the effect of the counterparty and the Group&#x2019;s own credit risk on the fair value of the foreign exchange forward contracts and swaps, which is not reflected in the fair value of the hedged item attributable to changes in foreign exchange rates and ineffectiveness on rolling the cash flow hedges of the divestments mentioned above. No other sources of ineffectiveness emerged from these hedging relationships. No ineffectiveness was recorded from cash flow hedges in 2022 (2021: &#xa3;nil). No ineffectiveness was recorded from net investment hedges (2021: &#xa3;nil). &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:89%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; currency&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notional&lt;br/&gt; value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt; value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;calculating&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Buy foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.16&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.14&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;167&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&lt;br/&gt; change in&lt;br/&gt; value for&lt;br/&gt; calculating&lt;br/&gt; hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;JPY&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;CAD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;SGD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,341&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,322&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(300&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,981&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,851&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;change&#160;in&#160;value&lt;br/&gt; for calculating hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cumulative&#160;balance&#160;in&#160;cash&lt;br/&gt; flow hedge reserve/foreign&lt;br/&gt; currency&#160;translation&#160;reserve&lt;br/&gt; for continuing hedges&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Balance&#160;in&#160;cash&#160;flow&#160;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserve&#160;arising&#160;from&#160;hedging&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;relationships&#160;for&#160;which&#160;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;accounting is no longer&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;applied&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from foreign exchange exposure arising on&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Euro denominated coupon payments relating to debt issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment in foreign operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,120&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&lt;br/&gt; calculating&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Buy foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;USD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;calculating&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;578&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;SGD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;JPY&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,998&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,982&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;459&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,719&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,176&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,118&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;change&#160;in&#160;value&lt;br/&gt; for&#160;calculating&#160;hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cumulative&#160;balance&#160;in&#160;cash&lt;br/&gt; flow&#160;hedge&#160;reserve/foreign&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;currency&#160;translation&#160;reserve&lt;br/&gt; for continuing hedges&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from foreign exchange exposure arising on&lt;br/&gt; Euro denominated coupon payments relating to debt issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment in foreign operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&#xa3;3&#160;million (2021: &#xa3;19 million) of balances in the ca&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;h flow hedge reserve arise from hedging relationships for which hedge accounting is no longer applied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount reclassified to profit or loss&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;br/&gt; of&#160;hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedged&lt;br/&gt; future&#160;cash&lt;br/&gt; flows&lt;br/&gt; no&#160;longer&lt;br/&gt; expected&#160;to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;br/&gt; hedged&#160;item&lt;br/&gt; affecting&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line&#160;item&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;which&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to hedged&lt;br/&gt; item affecting&lt;br/&gt; balance sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in balance&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;sheet in which&#160;&lt;br/&gt; reclassification&#160;&lt;br/&gt; adjustment&#160;&lt;br/&gt; is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden69050893"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets&#160;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Net investment in foreign operations&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="-sec-ix-hidden:hidden69049975"&gt;Discontinued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;"&gt;operations&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount reclassified to profit or loss&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;br/&gt; of&#160;hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedged&lt;br/&gt; future&#160;cash&lt;br/&gt; flows&lt;br/&gt; no&#160;longer&lt;br/&gt; expected&#160;to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Due to&lt;br/&gt; hedged&#160;item&lt;br/&gt; affecting&lt;br/&gt; profit&#160;or&#160;loss&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Line item in&#160;&lt;br/&gt; profit or loss&#160;&lt;br/&gt; in&#160;which&#160;&lt;br/&gt; reclassification&#160;&lt;br/&gt; adjustment&#160;&lt;br/&gt; is&#160;included&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to hedged&lt;br/&gt; item affecting&lt;br/&gt; balance sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in balance&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;sheet in which&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049915"&gt;Other &lt;/span&gt;operating income/ (expense)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;Other operating income/ (expense)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Net investment in foreign operations&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;1,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9.75pt; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassified to the Consolidated income statement on demerger of the Consumer Healthcare business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest rate risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group manages its cash flow interest rate risk by using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;floating-to-fixed&lt;/div&gt;&lt;/div&gt; interest rate swaps, where at quarterly intervals the difference between fixed contract rates and floating rate interest amounts calculated by reference to the agreed notional principal amounts are exchanged. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There are none of these swaps outstanding a&lt;div style="display:inline;"&gt;t&lt;/div&gt; 31&#160;December 2022. At 31&#160;December 2021, the interest rate risk on an element of future debt issuance had been managed by entering into forward starting interest rate swaps, effectively to lock in the interest rates on the debt in advance. These were closed out at the time of issuing the debt, and the resulting gain or loss held in the Cash flow hedge reserve and reclassified to income statement as the interest payments on the debt impacted the income statement until the debt was derecognised on demerger of the Consumer Healthcare business in July 2022. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward starting interest rate swaps &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The forward starting interest rate contracts, exchanging floating interest for fixed interest, &lt;div style="display:inline;"&gt;were&lt;/div&gt; designated as cash flow hedges to hedge the interest variability of the interest cash flows associated with the future fixed rate debt. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest rate swaps &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following tables provide information regarding interest rate swap and forward starting interest rate swap contracts outstanding and the related hedged items at 31&#160;December 2021. There were no such swaps at 31&#160;December 2022. Interest rate swap contract assets and liabilities are presented in the line &#x2018;Derivative financial instruments&#x2019; (either as assets or liabilities) on the Consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&#xa3;24&#160;million (2021: &#xa3;11 million) of balances in the cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value for&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notional&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognising&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contracted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;principal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets/&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ineffectiveness&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(liabilities)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-10&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.1038&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;668&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-30&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.3385&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;935&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;More than 30 years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.4515&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;393&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash flow&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value used for&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&#160;reserve&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;calculating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for continuing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ineffectiveness&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount reclassified to profit or loss&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;br/&gt; gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;of hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;profit&#160;or&#160;loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due&#160;to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;future&lt;br/&gt; cash flows&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;no longer&lt;br/&gt; expected to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due&#160;to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;item&lt;br/&gt; affecting&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in which&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049944"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049945"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Matured in the past&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:1pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount reclassified to profit or loss&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;br/&gt; gains/(losses)&lt;br/&gt; recognised&#160;in&lt;br/&gt; reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;of hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;br/&gt; is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;future&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;cash flows&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;no longer&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expected to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;affecting&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;profit&#160;or&#160;loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in which&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049946"&gt;Finance&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049947"&gt;Finance&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;income or&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;income&#160;or&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;expense&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;expense&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Matured in the past&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049948"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049949"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-10&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-30&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&amp;gt;30 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:1pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(e) Offsetting of financial assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Financial assets and liabilities are offset and the net amount reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. There are also arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be offset in certain circumstances, such as bankruptcy or the termination of a contract. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following tables set out the financial assets and liabilities that are offset, or subject to enforceable master netting arrangements and other similar agreements but not offset, as at 31&#160;December 2022 and 31&#160;December 2021. The column &#x2018;Net amount&#x2019; shows the impact on the Group&#x2019;s balance sheet if all offset rights were exercised. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross&lt;br/&gt; financial&lt;br/&gt; assets/&lt;br/&gt; (liabilities)&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Gross&lt;br/&gt; financial&lt;br/&gt; (liabilities)/&lt;br/&gt; assets&#160;set&#160;off&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Net&#160;financial&lt;br/&gt; assets/&lt;br/&gt; (liabilities)&#160;per&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;balance&#160;sheet&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Related&lt;br/&gt; amounts&#160;not&lt;br/&gt; set off in the&lt;br/&gt; balance&#160;sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,166&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Gross&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;offset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&#160;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Related&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;amounts&#160;not&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;offset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;balance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,832&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,829&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;206&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Amounts which do not meet the criteria for offsetting on the balance sheet but could be settled net in certain circumstances principally relate to derivative transactions under ISDA (International Swaps and Derivatives Association) agreements where each party has the option to settle amounts on a net basis in the event of default of the other party. As there is presently not a legally enforceable right of offset, these amounts have not been offset in the balance sheet, but have been presented separately in the table above. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(f) Debt interest rate repricing table &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as all classes of borrowings other than lease liabilities. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Floating and fixed rate debt less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,785&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,714&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,490&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,576&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,505&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,736&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,411&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,001&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,953&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Original issuance profile:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fixed rate interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18,355&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Floating rate interest&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(803&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(g) Sensitivity analysis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The tables below illustrate the estimated impact on the income statement and equity as a result of hypothetical market movements in foreign exchange and interest rates in relation to the Group&#x2019;s financial instruments. The range of variables chosen for the sensitivity analysis reflects management&#x2019;s view of changes which are reasonably possible over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign exchange sensitivity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group operates internationally and is primarily exposed to foreign exchange risk in relation to Sterling against movements in US&#160;Dollar, Euro and Japanese Yen. Foreign exchange risk arises from the translation of financial assets and liabilities which are not in the functional currency of the entity that holds them. Based on the Group&#x2019;s net financial assets and liabilities as at 31&#160;December, a weakening and strengthening of Sterling against these currencies, with all other variables held constant, is illustrated in the tables below. The tables exclude financial instruments that expose the Group to foreign exchange risk where this risk is fully hedged with another financial instrument. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;99&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;155&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(121&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The equity impact, shown below, for foreign exchange sensitivity relates to derivative and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivative&lt;/div&gt; financial instruments hedging the Group&#x2019;s net investments in its European (Euro) foreign operations and cash flow hedges of its foreign exchange exposure arising on Euro denominated coupon payments relating to notes issued under the Group&#x2019;s European Medium Term Note programme. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;equity&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(964&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation in Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,515&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;equity&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,557&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,176&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The tables below present the Group&#x2019;s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the composition of net debt as shown in Note 30 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect future foreign currency cash flows. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impact of foreign exchange movements on net debt&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(767&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,199&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;444&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;698&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impact of foreign exchange movements on net debt&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;846&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;661&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,222&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(375&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(542&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest rate sensitivity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is exposed to interest rate risk on its outstanding borrowings and investments where any changes in interest rates will affect future cash flows or the fair values of financial instruments. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group&#x2019;s net interest charge, although the majority of cash and liquid investments earn floating rates of interest. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below hypothetically shows the Group&#x2019;s sensitivity to changes in interest rates in relation to Sterling, US Dollar and Euro floating rate financial assets and liabilities. A 1% (100 basis points) movement in USD interest rates would cause an increase of &#xa3;nil to equity (2021: &#xa3;197 million). A 1.5% (150 basis points) movement in USD interest rates would cause an increase of &#xa3;nil to equity (2021: &#xa3;297 million). A 1% (100 basis points) or 1.5% (150 basis points) movement in EUR or Sterling interest rates is not deemed to have a material effect on equity. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of interest rate movements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in Sterling interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in Sterling interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in US&#160;Dollar interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(34&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in US&#160;Dollar interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in Euro interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in Euro interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(h) Contractual cash flows for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivative&lt;/div&gt; financial liabilities and derivative instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following tables provide an analysis of the anticipated contractual cash flows including interest payable for the Group&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivative&lt;/div&gt; financial liabilities on an undiscounted basis. For the purpose of this table, debt is defined as all classes of borrowings except for lease liabilities. Interest is calculated based on debt held at 31&#160;December without taking account of future issuance. Floating rate interest is estimated using the prevailing interest rate at the balance sheet date. Cash flows in foreign currencies are translated using spot rates at 31 December. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest&lt;br/&gt; on debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Lease&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;charge&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables&lt;br/&gt; and other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;liabilities&#160;not&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in net debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Due in less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(19,934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,607&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,034&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,508&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(2,324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,765&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(9,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,063&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,856&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,134&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(9,199&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,086&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,322&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,008&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(146&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,553&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(51,115&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest&lt;br/&gt; on&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Lease&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;charge&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables&lt;br/&gt; and&#160;other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;liabilities not&lt;br/&gt; in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Due in less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,745&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(620&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(935&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,804&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,188&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,938&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,703&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,438&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,033&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,639&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,571&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(11,392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,296&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,603&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,015&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(153&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,377&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56,444&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The table below provides an analysis of the anticipated contractual cash flows for the Group&#x2019;s derivative instruments excluding equity options which do not give rise to cash flows, and other embedded derivatives, which are not material, using undiscounted cash flows. Cash flows in foreign currencies are translated using spot rates at 31 December. The gross cash flows of foreign exchange contracts are presented for the purpose of this table although, in practice, the Group uses standard settlement arrangements to reduce its liquidity requirements on these instruments. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:38%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:6%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:5%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="9" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross cash inflows&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross cash outflows&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross cash inflows&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross cash outflows&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;exchange&lt;br/&gt; forward&lt;br/&gt; contracts&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; exchange&#160;&lt;br/&gt; forward&#160;&lt;br/&gt; contracts&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&#160;&lt;br/&gt; &#xa3;m&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Foreign&lt;br/&gt; exchange&lt;br/&gt; forward&lt;br/&gt; contracts&lt;br/&gt; &#160;&#160;&#160;&#160;and&#160;swaps&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Forward&#160;&lt;br/&gt; starting&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&#160;&lt;br/&gt; swaps&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Foreign&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;exchange&#160;&lt;br/&gt; forward&#160;&lt;br/&gt; contracts&#160;&lt;br/&gt; and&#160;swaps&#160;&lt;br/&gt; &#xa3;m&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24,410)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(13)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(41,290)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than five years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(220)&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24,410)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,252&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(337)&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(41,290)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; </ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">17200000000</ifrs-full:Borrowings>
    <ifrs-full:Equity
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">10100000000</ifrs-full:Equity>
    <gsk:EquityAndDebtNet
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_GBP">27300000000</gsk:EquityAndDebtNet>
    <ifrs-full:Borrowings
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-9"
      unitRef="Unit_GBP">4000000000</ifrs-full:Borrowings>
    <gsk:CashAndCashEquivalentsAndLiquidInvestments
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">3800000000</gsk:CashAndCashEquivalentsAndLiquidInvestments>
    <gsk:CashAndCashEquivalentsAndLiquidInvestmentsHeld
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">3100000000</gsk:CashAndCashEquivalentsAndLiquidInvestmentsHeld>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis"
      decimals="-9"
      unitRef="Unit_USD">10000000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis"
      decimals="-8"
      unitRef="Unit_GBP">8300000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_USD">900000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2021_LiquidityRiskMemberifrsfullTypesOfRisksAxis_UsCommercialPaperProgramMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:NotionalAmount>
    <ifrs-full:CommercialPapersIssued
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-9"
      unitRef="Unit_GBP">5000000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">500000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2022_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_EUR">300000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn12_31_2021_EuroCommercialPaperProgrammeMemberifrsfullClassesOfAssetsAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</ifrs-full:NotionalAmount>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">1900000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_USD">2500000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities
      contextRef="PAsOn02_28_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_GBP">2100000000</gsk:CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_LiquidityRiskMemberifrsfullTypesOfRisksAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_GBP">1600000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_USD">2200000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis_PostSeparationOfTheConsumerHealthcareBusinessMemberGSKPurposeAxis"
      decimals="-8"
      unitRef="Unit_GBP">1800000000</ifrs-full:UndrawnBorrowingFacilities>
    <gsk:AmountHeldAtEuropeanMediumTermNoteProgramme
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">20000000000</gsk:AmountHeldAtEuropeanMediumTermNoteProgramme>
    <gsk:NotesIssuedAtEuropeanMediumTermNoteProgramme
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">10300000000</gsk:NotesIssuedAtEuropeanMediumTermNoteProgramme>
    <gsk:NotesIssuedUnderUsShelfRegistration
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_USD">9700000000</gsk:NotesIssuedUnderUsShelfRegistration>
    <gsk:NotesIssuedUnderUsShelfRegistration
      contextRef="PAsOn12_31_2022_LiquidityRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-8"
      unitRef="Unit_GBP">8100000000</gsk:NotesIssuedUnderUsShelfRegistration>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">10180000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">11417000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis"
      decimals="-8"
      unitRef="Unit_GBP">1100000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_ExternalCreditGradesMemberifrsfullExternalCreditGradesAxis_WholesalerInTheUsMemberifrsfullJointVenturesAxis"
      decimals="-8"
      unitRef="Unit_GBP">900000000</ifrs-full:CreditExposure>
    <gsk:CashHeldAtUnratedCounterparties
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</gsk:CashHeldAtUnratedCounterparties>
    <gsk:CashHeldAtUnratedCounterparties
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</gsk:CashHeldAtUnratedCounterparties>
    <gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement>
    <gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_LowerThanBBBBaa3MemberifrsfullExternalCreditGradesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_NGifrsfullGeographicalAreasAxis_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_GbMemberifrsfullGeographicalAreasAxis_HalkBankMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_ECifrsfullGeographicalAreasAxis_ProdubancoMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_JTrustRoyalBankMemberifrsfullJointVenturesAxis_KHifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_BancoDoBrasilMemberifrsfullJointVenturesAxis_BRifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_BancoDeHondurasMemberifrsfullJointVenturesAxis_HNifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:CreditExposure>
    <ifrs-full:CreditExposure
      contextRef="PAsOn12_31_2022_BacSanJoseMemberifrsfullJointVenturesAxis_CRifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:CreditExposure>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">49000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-5"
      unitRef="Unit_GBP">1400000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <ifrs-full:BalancesWithBanks
      contextRef="PAsOn12_31_2022_BBB-OrBaaThreeRatedMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis_StateBankOfIndiaMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:BalancesWithBanks>
    <ifrs-full:DisclosureOfExternalCreditExposuresExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AAA/Aaa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AA/Aa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A/A&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB/Baa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB+/Ba1&lt;br/&gt; and&#160;below&lt;br/&gt; /unrated&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank balances and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,215&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US Treasury and Treasury repo only money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;146&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;146&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquidity funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,253&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third party financial derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;188&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;188&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,399&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,403&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,978&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AAA/Aaa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AA/Aa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A/A&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBB/Baa&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB+/Ba1&lt;br/&gt; and&#160;below&lt;br/&gt; /unrated&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Bank balances and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,687&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;77&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,825&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;US Treasury and Treasury repo only money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquidity funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Third party financial derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;200&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;200&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,449&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,887&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,535&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfExternalCreditExposuresExplanatory>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1215000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">49000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1324000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds
      contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds>
    <gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds>
    <gsk:LiquidityFunds
      contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2253000000</gsk:LiquidityFunds>
    <gsk:LiquidityFunds
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2253000000</gsk:LiquidityFunds>
    <gsk:GovernmentSecurities
      contextRef="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</gsk:GovernmentSecurities>
    <gsk:GovernmentSecurities
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</gsk:GovernmentSecurities>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">188000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">188000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2399000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1403000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">49000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">3978000000</ifrs-full:RatedCreditExposures>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2687000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:BankBalancesAndDepositHeldWithCounterparties
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2825000000</gsk:BankBalancesAndDepositHeldWithCounterparties>
    <gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds
      contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds>
    <gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds>
    <gsk:LiquidityFunds
      contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1395000000</gsk:LiquidityFunds>
    <gsk:LiquidityFunds
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1395000000</gsk:LiquidityFunds>
    <gsk:GovernmentSecurities
      contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">60000000</gsk:GovernmentSecurities>
    <gsk:GovernmentSecurities
      contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:GovernmentSecurities>
    <gsk:GovernmentSecurities
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</gsk:GovernmentSecurities>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">200000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">200000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_AAAOrAaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1449000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_AaOrAaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_AorAMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2887000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_BbbOrBaaMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">78000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_BBPlusOrBaOneMemberifrsfullExternalCreditGradesAxis_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">54000000</ifrs-full:RatedCreditExposures>
    <ifrs-full:RatedCreditExposures
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">4535000000</ifrs-full:RatedCreditExposures>
    <gsk:CashReserves
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis"
      decimals="-8"
      unitRef="Unit_GBP">3100000000</gsk:CashReserves>
    <gsk:CashManagedForSubsidiaryCompany
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="-8"
      unitRef="Unit_GBP">2200000000</gsk:CashManagedForSubsidiaryCompany>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_NotLaterThanThreeMonthsMemberifrsfullMaturityAxis_ViiVHealthCareMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <gsk:PercentageOfAccountsReceivableByMajorCustomer
      contextRef="P01_01_2022To12_31_2022_NonUsaMemberifrsfullGeographicalAreasAxis_TopOfRangeMemberifrsfullRangeAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</gsk:PercentageOfAccountsReceivableByMajorCustomer>
    <gsk:ConcentrationsOfRiskRevenuePercentage
      contextRef="P01_01_2022To12_31_2022_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="2"
      unitRef="Unit_pure">0.79</gsk:ConcentrationsOfRiskRevenuePercentage>
    <gsk:ConcentrationsOfRiskRevenuePercentage
      contextRef="P01_01_2021To12_31_2021_InLineWithOtherPharmaceuticalCompaniesMemberifrsfullSegmentsAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</gsk:ConcentrationsOfRiskRevenuePercentage>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">3001000000</ifrs-full:TradeReceivables>
    <gsk:PercentageOfAccountsReceivableByMajorCustomer
      contextRef="P01_01_2022To12_31_2022_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="2"
      unitRef="Unit_pure">0.55</gsk:PercentageOfAccountsReceivableByMajorCustomer>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">2430000000</ifrs-full:TradeReceivables>
    <gsk:PercentageOfAccountsReceivableByMajorCustomer
      contextRef="P01_01_2021To12_31_2021_DueFromThreeWholesalersMemberifrsfullBorrowingsByNameAxis_USifrsfullGeographicalAreasAxis_WholesaleAndRetailCreditRiskMemberifrsfullTypesOfRisksAxis"
      decimals="2"
      unitRef="Unit_pure">0.39</gsk:PercentageOfAccountsReceivableByMajorCustomer>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis"
      decimals="-6"
      unitRef="Unit_GBP">332000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021_CreditRiskMemberifrsfullTypesOfRisksAxis_GroupCreditEnhancementsAndCreditInsuranceMemberifrsfullTypesOfInsuranceContractsAxis"
      decimals="-6"
      unitRef="Unit_GBP">315000000</ifrs-full:TradeReceivables>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Notes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Fair &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;value&lt;br/&gt; &#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;br/&gt; &#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at amortised cost:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,789&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,789&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Liquid investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,825&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,825&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Current equity investments and Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,b&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,734&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,734&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,543&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,543&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities measured at amortised cost:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings excluding obligations under lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; bonds in a designated hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,322&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,311&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(11,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; bank loans and overdrafts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; commercial paper in a designated hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#x2013; other borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total borrowings excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;f&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,605&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;d&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,c&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through Other comprehensive income)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;a,d,e&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total financial liabilities excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(41,442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(41,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45,058&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(48,760&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net financial assets and financial liabilities excluding lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,708&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,334&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31,515&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35,217&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3789000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3789000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4830000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4830000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">67000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_LiquidInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">61000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1324000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1324000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2825000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtAmortisedCostCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2825000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1153000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1153000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1927000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1927000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4401000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4401000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">165000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">165000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2399000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2399000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1449000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1449000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15734000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">15734000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">13543000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">13543000000</ifrs-full:FinancialAssetsAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6322000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6035000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4982000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5311000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">12017000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">11930000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">17373000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBondsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">20746000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">447000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">447000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">550000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_BankLoansAndOverdraftsMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">550000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">443000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_CommercialPaperInADesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">252000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherCommercialPaperMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherBorrowingMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19979000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19605000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLease
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">23158000000</gsk:BorrowingsExcludingObligationsUnderFinanceLease>
    <gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">26860000000</gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15431000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_TradeAndOtherPayableMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15431000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherProvisionsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">84000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">84000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostCategoryMemberifrsfullClassesOfFinancialLiabilitiesAxis_OtherNonCurrentLiabilitiesMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">41442000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">41068000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">45058000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">48760000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <gsk:NetFinancialAssetsLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-25708000000</gsk:NetFinancialAssetsLiabilities>
    <gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">-25334000000</gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue>
    <gsk:NetFinancialAssetsLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-31515000000</gsk:NetFinancialAssetsLiabilities>
    <gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">-35217000000</gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue>
    <gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">354000000</gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan>
    <gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan>
    <gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">861000000</gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan>
    <gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">373000000</gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">3797000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">4969000000</ifrs-full:TreasuryShares>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,327&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Current equity investments and Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,087&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,399&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,309&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,567&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,533&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(106&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,251&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets measured at fair value through other comprehensive income (FVTOCI):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments designated at FVTOCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,927&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,943&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial assets mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;199&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;59&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,449&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,185&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,202&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;419&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,806&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Financial liabilities mandatorily measured at fair value through profit or loss (FVTPL):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,076&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Held for trading derivatives that are not in a designated and effective hedging relationship&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments (fair value movements through OCI)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,304&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">823000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">330000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1153000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">4087000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">314000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CurrentEquityAndOtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4401000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">165000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">165000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">2399000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2399000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">7309000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">2567000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">657000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">10533000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">7251000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1736000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">191000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1927000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">199000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_OtherNoncurrentAssetsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivableMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1449000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_CashAndCashEquivalents1MemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1449000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialAssetsAxis_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">3185000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">2202000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">419000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">5806000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_ContingentConsiderationLiabilitiesMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMemberifrsfullClassesOfFinancialLiabilitiesAxis_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">57000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="PAsOn12_31_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_GBP">6304000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Movements in the year for financial instruments measured using Level&#160;3 valuation methods are presented below: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 6.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,657&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,064&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Exchange adjustments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net losses recognised in the income statement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,627&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,024&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net gains recognised in other comprehensive income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;185&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration related to business acquisitions in the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(482&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Settlement of contingent consideration liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,137&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;856&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Additions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;97&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Disposals and settlements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(19&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Transfers from Level&#160;3&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(694&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,411&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,657&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <gsk:FinancialAssetsAndLiabilities
      contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5657000000</gsk:FinancialAssetsAndLiabilities>
    <gsk:FinancialAssetsAndLiabilities
      contextRef="PAsOn12_31_2020_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5064000000</gsk:FinancialAssetsAndLiabilities>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">46000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities>
    <gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities>
    <gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1627000000</gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities>
    <gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1024000000</gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities>
    <gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">91000000</gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities>
    <gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">185000000</gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-482000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <gsk:PaymentOfContingentConsiderationLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1137000000</gsk:PaymentOfContingentConsiderationLiabilities>
    <gsk:PaymentOfContingentConsiderationLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">856000000</gsk:PaymentOfContingentConsiderationLiabilities>
    <gsk:AdditionsFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-97000000</gsk:AdditionsFairValueMeasurementAssetsAndLiabilities>
    <gsk:AdditionsFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-99000000</gsk:AdditionsFairValueMeasurementAssetsAndLiabilities>
    <gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities>
    <gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities>
    <gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities>
    <gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">694000000</gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities>
    <gsk:FinancialAssetsAndLiabilities
      contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6411000000</gsk:FinancialAssetsAndLiabilities>
    <gsk:FinancialAssetsAndLiabilities
      contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5657000000</gsk:FinancialAssetsAndLiabilities>
    <gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1627000000</gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement>
    <gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1024000000</gsk:GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement>
    <gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1623000000</gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense>
    <gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1024000000</gsk:LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense>
    <gsk:RemeasurementOfTheContingentConsiderationPayable
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1431000000</gsk:RemeasurementOfTheContingentConsiderationPayable>
    <gsk:RemeasurementOfTheContingentConsiderationPayable
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1026000000</gsk:RemeasurementOfTheContingentConsiderationPayable>
    <gsk:RemeasurementOfTheContingentConsiderationPayable
      contextRef="P01_01_2022To12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">231000000</gsk:RemeasurementOfTheContingentConsiderationPayable>
    <gsk:RemeasurementOfTheContingentConsiderationPayable
      contextRef="P01_01_2021To12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</gsk:RemeasurementOfTheContingentConsiderationPayable>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">482000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
      contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities
      contextRef="P01_01_2022To12_31_2022_FinancialLiabilitesOneMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5890000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_ShionogiViiVHealthcareJointVentureMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">5559000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">673000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_NovartisVaccinesBusinessMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_GBP">479000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn12_31_2022_AffinivaxMemberifrsfullBusinessCombinationsAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-6"
      unitRef="Unit_GBP">501000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTOCI&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&lt;br/&gt; FVTOCI&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables (Note&#160;26)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,166&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;887&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,053&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,830&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,832&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other non-current assets (Note&#160;24)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,632&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,327&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,200&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,047&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,247&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,851&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,876&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,660&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,536&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3789000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6166000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">887000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7053000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4830000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6832000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1028000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7860000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">34000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1160000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1194000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">21000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1632000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1676000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3810000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6200000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2047000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8247000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">82000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4851000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6876000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2660000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9536000000</ifrs-full:FinancialAssets>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5452000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6246000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">50000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">59000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2327000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1943000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2022_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3075000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn12_31_2021_AmortizedCostMemberifrsfullCategoriesOfFinancialAssetsAxis_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4244000000</ifrs-full:TradeAndOtherReceivables>
    <gsk:DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;At&#160;FVTPL&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;br/&gt; financial&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;At&#160;FVTPL&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;Amortised&lt;br/&gt; cost&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;br/&gt; &#160;&#160;instruments&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Non-&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;instruments&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables (Note&#160;29)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,198&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other provisions (Note&#160;32)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,121&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Contingent consideration liabilities (Note&#160;33)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7,068&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities (Note&#160;34)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(815&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(899&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(869&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(921&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,068&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,212&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(21,280&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(25,414&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,076&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,596&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,672&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,350&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26,022&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2198000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">16263000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15431000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15431000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2123000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">17554000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">63000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1121000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1184000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">113000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1358000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1471000000</ifrs-full:OtherProvisions>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">84000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">84000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">815000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">899000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">52000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">869000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">921000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">7068000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14212000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">21280000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4134000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">25414000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6076000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtAmortisedCostMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15596000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_FinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">21672000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_NonFinancialInstrumentsMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4350000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn12_31_2021_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">26022000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;2021&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Fair&#160;value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash flow hedges &#x2013; Interest rate swap contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;nil (2021: &#xa3;1,996 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Cash flow hedges &#x2013; Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;167&#160;million (2021: &#xa3;160 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment hedges &#x2013; Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;7,197&#160;million (2021: &#xa3;5,469 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives designated and effective as hedging instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Embedded and other derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;br/&gt; (principal amount &#x2013; &#xa3;5,908&#160;million (2021: &#xa3;9,728 million))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Embedded and other derivatives&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivatives classified as held for trading&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(77&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(171&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total derivative instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="INF"
      unitRef="Unit_pure">0</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="INF"
      unitRef="Unit_pure">1996</ifrs-full:NominalAmountOfHedgingInstrument>
    <gsk:HedgingInstrumentAssetsNoncurrent
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentAssetsNoncurrent>
    <gsk:HedgingInstrumentLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentLiabilitiesNoncurrent>
    <gsk:HedgingInstrumentAssetsNoncurrent
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:HedgingInstrumentAssetsNoncurrent>
    <gsk:HedgingInstrumentLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:HedgingInstrumentLiabilitiesNoncurrent>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="INF"
      unitRef="Unit_pure">167</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="INF"
      unitRef="Unit_pure">160</ifrs-full:NominalAmountOfHedgingInstrument>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentLiabilitiesCurrent>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="INF"
      unitRef="Unit_pure">7197</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_LaterThanOneYearMemberifrsfullMaturityAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="INF"
      unitRef="Unit_pure">5469</ifrs-full:NominalAmountOfHedgingInstrument>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">106000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">111000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">53000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</ifrs-full:HedgingInstrumentAssets>
    <gsk:HedgingInstrumentsLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-106000000</gsk:HedgingInstrumentsLiabilities>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">123000000</ifrs-full:HedgingInstrumentAssets>
    <gsk:HedgingInstrumentsLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-57000000</gsk:HedgingInstrumentsLiabilities>
    <gsk:HedgingInstrumentAssetsNoncurrent
      contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentAssetsNoncurrent>
    <gsk:HedgingInstrumentLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentLiabilitiesNoncurrent>
    <gsk:HedgingInstrumentAssetsNoncurrent
      contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:HedgingInstrumentAssetsNoncurrent>
    <gsk:HedgingInstrumentLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentLiabilitiesNoncurrent>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="INF"
      unitRef="Unit_pure">5908</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="INF"
      unitRef="Unit_pure">9728</ifrs-full:NominalAmountOfHedgingInstrument>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">163000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">76000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">169000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <gsk:HedgingInstrumentAssetsCurrent
      contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:HedgingInstrumentAssetsCurrent>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_EmbeddedAndOtherDerivativesMemberifrsfullHedgingInstrumentsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2022_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">165000000</ifrs-full:HedgingInstrumentAssets>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">77000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2021_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">83000000</ifrs-full:HedgingInstrumentAssets>
    <gsk:HedgingInstrumentLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">171000000</gsk:HedgingInstrumentLiabilitiesCurrent>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:HedgingInstrumentAssets>
    <ifrs-full:HedgingInstrumentLiabilities
      contextRef="PAsOn12_31_2022_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:HedgingInstrumentLiabilities>
    <ifrs-full:HedgingInstrumentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">206000000</ifrs-full:HedgingInstrumentAssets>
    <ifrs-full:HedgingInstrumentLiabilities
      contextRef="PAsOn12_31_2021_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:HedgingInstrumentLiabilities>
    <gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments
      contextRef="PAsOn12_31_2022_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">6322000000</gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments>
    <gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments
      contextRef="PAsOn12_31_2021_BondsInDesignatedHedgingRelationshipMemberifrsfullBorrowingsByNameAxis_NetInvestmentHedgedMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">4982000000</gsk:CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_ForeignExchangeRiskMemberifrsfullTypesOfRisksAxis_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory contextRef="P01_01_2022To12_31_2022_ForeignExchangeForwardContractsAndSwapsMemberifrsfullHedgingInstrumentsAxis">&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:89%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="font-size:6pt;white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; currency&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notional&lt;br/&gt; value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt; value&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;calculating&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Buy foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.16&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.14&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;167&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&lt;br/&gt; change in&lt;br/&gt; value for&lt;br/&gt; calculating&lt;br/&gt; hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;JPY&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;CAD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;SGD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,341&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,322&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(300&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,981&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,851&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:92%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;change&#160;in&#160;value&lt;br/&gt; for calculating hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cumulative&#160;balance&#160;in&#160;cash&lt;br/&gt; flow hedge reserve/foreign&lt;br/&gt; currency&#160;translation&#160;reserve&lt;br/&gt; for continuing hedges&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Balance&#160;in&#160;cash&#160;flow&#160;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserve&#160;arising&#160;from&#160;hedging&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;relationships&#160;for&#160;which&#160;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;accounting is no longer&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;applied&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from foreign exchange exposure arising on&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&#160;Euro denominated coupon payments relating to debt issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment in foreign operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,120&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&lt;br/&gt; calculating&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Buy foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;USD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;3 to 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Average&lt;br/&gt; exchange&#160;rate&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;currency&lt;/div&gt;&lt;div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notional&lt;br/&gt; value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carrying&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;change&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;value&#160;for&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;calculating&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedge&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Foreign exchange contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Sell foreign currency:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;578&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;SGD&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;JPY&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Borrowings&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than 3 months&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Over 6 months&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;EUR&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,998&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,982&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;459&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,719&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,176&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,118&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Periodic&#160;change&#160;in&#160;value&lt;br/&gt; for&#160;calculating&#160;hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Cumulative&#160;balance&#160;in&#160;cash&lt;br/&gt; flow&#160;hedge&#160;reserve/foreign&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;currency&#160;translation&#160;reserve&lt;br/&gt; for continuing hedges&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5em; text-indent: -0.5em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows from foreign exchange exposure arising on&lt;br/&gt; Euro denominated coupon payments relating to debt issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Net investment in foreign operations&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.23</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">USD</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">100000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.16</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">50000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.15</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">24000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">1.14</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">-7000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">167000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">1.14</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">6559000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-103000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-317000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">160.9</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">JPY</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">194000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">1.57</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis">CAD</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">270000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">18000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_CADMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis"
      decimals="2"
      unitRef="Unit_pure">1.59</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">SGD</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis"
      decimals="-6"
      unitRef="Unit_pure">174000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">293000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-293000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">150000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-150000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BorrowingThreeToSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">6341000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6322000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-300000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">13981000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6851000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-617000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges>
    <gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges>
    <gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">617000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges
      contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1120000000</gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges>
    <gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1
      contextRef="P01_01_2022To12_31_2022_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.32</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">USD</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">89000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_BuyForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.17</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">48000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyThreeToSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="2"
      unitRef="Unit_pure">1.17</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_BuyForeignCurrencyOverSixMonthsMemberifrsfullHedgedItemsAxis_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">23000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_pure">160000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-3000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">1.18</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">5348000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">58000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_EuroMembersrtCurrencyAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">578000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis">SGD</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_SgdMembersrtCurrencyAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="2"
      unitRef="Unit_pure">155.19</ifrs-full:AverageForeignExchangeRate>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis">JPY</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_pure">121000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_JapaneseYenMembersrtCurrencyAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis_SellForeignCurrencyLessThanThreeMonthsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">252000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-252000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_BorrowingsLessThanThreeMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DescriptionOfForeignCurrency contextRef="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis">EUR</gsk:DescriptionOfForeignCurrency>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">4998000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4982000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_BorrowingsOverSixMonthsMemberifrsfullHedgedItemsAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">459000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_pure">10719000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue
      contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5176000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1118000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1117000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges
      contextRef="P01_01_2021To12_31_2021_NetInvestmentHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-873000000</gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges>
    <ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied
      contextRef="PAsOn12_31_2022_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied>
    <ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied
      contextRef="PAsOn12_31_2021_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied>
    <gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount reclassified to profit or loss&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;br/&gt; of&#160;hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedged&lt;br/&gt; future&#160;cash&lt;br/&gt; flows&lt;br/&gt; no&#160;longer&lt;br/&gt; expected&#160;to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;br/&gt; hedged&#160;item&lt;br/&gt; affecting&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line&#160;item&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;which&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to hedged&lt;br/&gt; item affecting&lt;br/&gt; balance sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in balance&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;sheet in which&#160;&lt;br/&gt; reclassification&#160;&lt;br/&gt; adjustment&#160;&lt;br/&gt; is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden69050893"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets&#160;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Net investment in foreign operations&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(617&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="-sec-ix-hidden:hidden69049975"&gt;Discontinued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: ARIAL; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt;"&gt;operations&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount reclassified to profit or loss&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount&#160;reclassified&#160;to&#160;balance&#160;sheet&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;br/&gt; of&#160;hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedged&lt;br/&gt; future&#160;cash&lt;br/&gt; flows&lt;br/&gt; no&#160;longer&lt;br/&gt; expected&#160;to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Due to&lt;br/&gt; hedged&#160;item&lt;br/&gt; affecting&lt;br/&gt; profit&#160;or&#160;loss&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Line item in&#160;&lt;br/&gt; profit or loss&#160;&lt;br/&gt; in&#160;which&#160;&lt;br/&gt; reclassification&#160;&lt;br/&gt; adjustment&#160;&lt;br/&gt; is&#160;included&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to hedged&lt;br/&gt; item affecting&lt;br/&gt; balance sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in balance&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;sheet in which&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is&#160;included&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;Variability in cash flows from a highly probable forecast transaction&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049915"&gt;Other &lt;/span&gt;operating income/ (expense)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;Other operating income/ (expense)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net investment hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;Net investment in foreign operations&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;1,117&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;Finance income or expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: ARIAL; font-size: 6.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9.75pt; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: ARIAL; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: ARIAL; font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassified to the Consolidated income statement on demerger of the Consumer Healthcare business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-5000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments contextRef="P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Financeincome&#160;or&#160;expense&#160;</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-617000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">194000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2022_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis">Other operating income/ (expense)</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1117000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments contextRef="P01_01_2021To12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis">Finance income or expense</ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments>
    <ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets
      contextRef="PAsOn12_31_2021_HedgesOfNetInvestmentInForeignOperationsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets>
    <ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory contextRef="P01_01_2022To12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis">The following tables provide information regarding interest rate swap and forward starting interest rate swap contracts outstanding and the related hedged items at 31&#160;December 2021. There were no such swaps at 31&#160;December 2022. Interest rate swap contract assets and liabilities are presented in the line &#x2018;Derivative financial instruments&#x2019; (either as assets or liabilities) on the Consolidated balance sheet. &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:92%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value for&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notional&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognising&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contracted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;principal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets/&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ineffectiveness&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(liabilities)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedging instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-10&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.1038&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;668&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-30&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.3385&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;935&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;More than 30 years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.4515&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;393&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:94%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash flow&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value used for&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&#160;reserve&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;calculating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for continuing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedge&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hedges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ineffectiveness&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hedged items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory>
    <ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied
      contextRef="PAsOn12_31_2022_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied>
    <ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</ifrs-full:ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied>
    <gsk:AverageFixedInterestRateOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="6"
      unitRef="Unit_pure">0.011038</gsk:AverageFixedInterestRateOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_pure">668000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DerivativeFinancialAssetsLiabilities
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:DerivativeFinancialAssetsLiabilities>
    <gsk:AverageFixedInterestRateOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="6"
      unitRef="Unit_pure">0.013385</gsk:AverageFixedInterestRateOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_pure">935000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DerivativeFinancialAssetsLiabilities
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:DerivativeFinancialAssetsLiabilities>
    <gsk:AverageFixedInterestRateOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="6"
      unitRef="Unit_pure">0.014515</gsk:AverageFixedInterestRateOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_pure">393000000</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness>
    <gsk:DerivativeFinancialAssetsLiabilities
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_MoreThanThirtyYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</gsk:DerivativeFinancialAssetsLiabilities>
    <ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
      contextRef="P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness>
    <ifrs-full:ReserveOfCashFlowHedgesContinuingHedges
      contextRef="PAsOn12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-8000000</ifrs-full:ReserveOfCashFlowHedgesContinuingHedges>
    <gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock contextRef="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2022&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount reclassified to profit or loss&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;br/&gt; gains/(losses)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;of hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;recognised&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;profit&#160;or&#160;loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;br/&gt; ineffectiveness&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due&#160;to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;future&lt;br/&gt; cash flows&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;no longer&lt;br/&gt; expected to&lt;br/&gt; occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due&#160;to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;item&lt;br/&gt; affecting&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in which&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049944"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049945"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Matured in the past&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:1pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Amount reclassified to profit or loss&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Hedging&lt;br/&gt; gains/(losses)&lt;br/&gt; recognised&#160;in&lt;br/&gt; reserves&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Amount&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;of hedge&lt;br/&gt; ineffectiveness&lt;br/&gt; recognised in&lt;br/&gt; profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in profit or&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;loss in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;which hedge&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ineffectiveness&lt;br/&gt; is included&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;future&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;cash flows&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;no longer&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expected to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;occur&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Due to&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;hedged&#160;item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;affecting&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;profit or loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Line item&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;profit&#160;or&#160;loss&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in which&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;reclassification&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;adjustment&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;is included&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flow hedges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Variability in cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049946"&gt;Finance&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049947"&gt;Finance&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;income or&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;income&#160;or&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;expense&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;expense&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-hedging&lt;/div&gt; of long-term interest rates:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Matured in the past&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049948"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden69049949"&gt;Finance&lt;/span&gt; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&#160;or&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;expense&lt;/div&gt; &lt;/td&gt;
&lt;td rowspan="3" style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-10&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-30&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top;text-align:right;"&gt;&#x2013; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160; &lt;div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&amp;gt;30 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:1pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-23000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">-11000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_MaturedInThePastPeriodMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanTenYearsNotLaterThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments
      contextRef="PAsOn12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4000000</ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments>
    <ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
      contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_MoreThanThirtyYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross&lt;br/&gt; financial&lt;br/&gt; assets/&lt;br/&gt; (liabilities)&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Gross&lt;br/&gt; financial&lt;br/&gt; (liabilities)/&lt;br/&gt; assets&#160;set&#160;off&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;Net&#160;financial&lt;br/&gt; assets/&lt;br/&gt; (liabilities)&#160;per&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;balance&#160;sheet&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Related&lt;br/&gt; amounts&#160;not&lt;br/&gt; set off in the&lt;br/&gt; balance&#160;sheet&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,166&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(14,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Gross&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;offset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&#160;financial&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;assets/&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;(liabilities)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Related&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;amounts&#160;not&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;offset&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Net&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;balance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,832&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,829&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;206&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15,431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6166000000</ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6166000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6166000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">190000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets
      contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">163000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities
      contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">14065000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">183000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities
      contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">163000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2022_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6851000000</ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6832000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6829000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">206000000</ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">206000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets
      contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">192000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets>
    <ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialAssetsMemberifrsfullTypesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15450000000</ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15431000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities
      contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_TradesAndOtherPayablesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">15428000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition
      contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">228000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition>
    <ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities
      contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">192000000</ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities>
    <ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
      contextRef="PAsOn12_31_2021_DerivativeFinancialLiabilitiesMemberifrsfullTypesOfFinancialLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements>
    <ifrs-full:DisclosureOfDebtSecuritiesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as all classes of borrowings other than lease liabilities. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Floating and fixed rate debt less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,785&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,714&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,490&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,576&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,505&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(748&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,736&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,411&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(6,001&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,953&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Original issuance profile:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Fixed rate interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18,355&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Floating rate interest&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(803&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19,979&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,158&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfDebtSecuritiesExplanatory>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3785000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3398000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1714000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4030000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1490000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1576000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1505000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1365000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">748000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">1425000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4736000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">4411000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6001000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021_FloatingAndFixedRateDebtMemberifrsfullTypesOfInterestRatesAxis_LaterThanTenYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">6953000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">19979000000</gsk:Debt>
    <gsk:Debt
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">23158000000</gsk:Debt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2022_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">18355000000</gsk:InterestBearingDebt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2021_FixedInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">22355000000</gsk:InterestBearingDebt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">1624000000</gsk:InterestBearingDebt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">803000000</gsk:InterestBearingDebt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">19979000000</gsk:InterestBearingDebt>
    <gsk:InterestBearingDebt
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">23158000000</gsk:InterestBearingDebt>
    <gsk:ForeignExchangeSensitivityImpactOfNonFunctionalCurrency contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;99&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;155&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(84&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(121&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:ForeignExchangeSensitivityImpactOfNonFunctionalCurrency>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">99000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">155000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-7000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-26000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-41000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-84000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-4000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-121000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-6000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">32000000</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures>
    <gsk:ForeignExchangeSensitivityEquityImpactTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;equity&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(964&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation in Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,515&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-functional&lt;/div&gt; currency foreign exchange exposures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&#160;in&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;equity&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,080&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,557&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,176&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:ForeignExchangeSensitivityEquityImpactTextBlock>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1290000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-964000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-2034000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1515000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1080000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">814000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1557000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1176000000</gsk:IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures>
    <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk contextRef="P01_01_2022To12_31_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The tables below present the Group&#x2019;s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the composition of net debt as shown in Note 30 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect future foreign currency cash flows. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impact of foreign exchange movements on net debt&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(767&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,570&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,199&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;444&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent appreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;698&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen appreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impact of foreign exchange movements on net debt&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Increase)/decrease&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;846&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;661&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the US&#160;Dollar&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,222&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(375&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 cent depreciation of the Euro&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(542&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;10 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;15 yen depreciation of the Yen&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-999000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-767000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1570000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-1199000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">444000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentAppreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">698000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">20000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenAppreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">846000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfUSDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">661000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">1222000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfUsDollarMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">959000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-9000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-375000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-13000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenCentDepreciationOfEuroMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-542000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-12000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskTenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-15000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2022To12_31_2022_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-17000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures
      contextRef="P01_01_2021To12_31_2021_CurrencyRiskFifteenYenDepreciationOfYenMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-21000000</gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">197000000</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">297000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMemberifrsfullTypesOfRisksAxis_InterestRateSensitivityMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:IncreaseDecreaseInEquityThroughInterestRateMovements.>
    <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk contextRef="P01_01_2022To12_31_2022_InterestRateRiskMemberifrsfullTypesOfRisksAxis">&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:94%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income statement impact of interest rate movements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in income&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Increase/(decrease)&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in income&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in Sterling interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in Sterling interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;55&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in US&#160;Dollar interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(34&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in US&#160;Dollar interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1% (100 basis points) increase in Euro interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;1.5% (150 basis points) increase in Euro interest rates&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;</ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">36000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-25000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">55000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-38000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-34000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-51000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">17000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-13000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">3000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2022To12_31_2022_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">-19000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements
      contextRef="P01_01_2021To12_31_2021_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMemberifrsfullTypesOfRisksAxis"
      decimals="-6"
      unitRef="Unit_GBP">5000000</gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest&lt;br/&gt; on debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Lease&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;charge&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables&lt;br/&gt; and other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;liabilities&#160;not&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;in net debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Due in less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(19,934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,607&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,034&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,508&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(3,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(2,324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,765&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(9,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,063&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,856&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,134&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(9,199&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,086&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,322&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,008&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(146&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,553&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;(51,115&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest&lt;br/&gt; on&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Lease&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liabilities&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;charge&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on&#160;lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade&#160;payables&lt;br/&gt; and&#160;other&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;liabilities not&lt;br/&gt; in&#160;net&#160;debt&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Due in less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(20,745&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(620&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(935&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(5,804&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(3,188&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,938&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between five and ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,703&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(9,438&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than ten years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,033&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,639&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,571&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(11,392&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,296&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,603&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,015&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(153&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,377&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(56,444&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3786000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">594000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">167000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">15362000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">19934000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1717000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">570000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">201000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1097000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3607000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1496000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">531000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">127000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1034000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3207000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1508000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">489000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">97000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">15000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1277000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3386000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">751000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">472000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">80000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1008000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2324000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4765000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1810000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">201000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">41000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2641000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9458000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6063000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1856000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">135000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1134000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9199000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">20086000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2022To12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6322000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1008000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">146000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23553000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">51115000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">3399000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">686000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">203000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">25000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">16432000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">20745000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4042000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">620000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">185000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">22000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">935000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">5804000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1582000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">574000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">120000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">893000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">3188000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1372000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">538000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">93000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">16000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">919000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2938000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1428000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">500000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">73000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">14000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">924000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2939000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">4440000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2046000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">205000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">44000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2703000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanFiveYearsAndNotLaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">9438000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7033000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2639000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">136000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1571000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_LaterThanTenYearsMemberifrsfullMaturityAxis_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">11392000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">23296000000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="P01_01_2021To12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">7603000000</ifrs-full:InterestExpenseOnBorrowings>
    <gsk:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1015000000</gsk:FinanceLeaseLiability>
    <gsk:FutureFinanceChargeOnFinanceLeases
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">153000000</gsk:FutureFinanceChargeOnFinanceLeases>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">24377000000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_GBP">56444000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:38%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:6%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:5%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="9" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross cash inflows&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross cash outflows&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="4" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross cash inflows&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Gross cash outflows&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; &#160;&#160;&#160;&#160;exchange&lt;br/&gt; forward&lt;br/&gt; contracts&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&lt;br/&gt; &#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; exchange&#160;&lt;br/&gt; forward&#160;&lt;br/&gt; contracts&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;swaps&#160;&lt;br/&gt; &#xa3;m&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Forward&lt;br/&gt; starting&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest&#160;rate&lt;br/&gt; swaps&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Foreign&lt;br/&gt; exchange&lt;br/&gt; forward&lt;br/&gt; contracts&lt;br/&gt; &#160;&#160;&#160;&#160;and&#160;swaps&lt;br/&gt; &#xa3;m&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Forward&#160;&lt;br/&gt; starting&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;interest&#160;rate&#160;&lt;br/&gt; swaps&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#xa3;m&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Foreign&#160;&lt;br/&gt; &#160;&#160;&#160;&#160;exchange&#160;&lt;br/&gt; forward&#160;&lt;br/&gt; contracts&#160;&lt;br/&gt; and&#160;swaps&#160;&lt;br/&gt; &#xa3;m&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Less than one year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24,410)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(13)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(41,290)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between one and two years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between two and three years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between three and four years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Between four and five years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(26)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Greater than five years&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(220)&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2013;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Gross contractual cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(24,410)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,252&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(337)&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;(41,290)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">24418000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">24410000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">41252000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">13000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">41290000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">12000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">24000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">28000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">26000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">259000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_GBP">220000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">24418000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">24410000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">351000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">41252000000</gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">337000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows
      contextRef="PAsOn12_31_2021_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_ForeignExchangeForwardContractsAndSwapsMemberGSKDebtInstrument1Axis"
      decimals="-6"
      unitRef="Unit_GBP">41290000000</gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45. Employee share schemes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;GSK operates several employee share schemes, including the Share Value Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost after a three-year vesting period and the Performance Share Plan, whereby awards are granted to employees to acquire shares or ADS in GSK plc at no cost, subject to the achievement by the Group of specified performance targets. The granting of these restricted share awards has replaced the granting of options to employees as the cost of the schemes more readily equates to the potential gain to be made by the employee. The Group also operates savings related share option schemes, whereby options are granted to employees to acquire shares in GSK plc at a discounted price. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Grants of restricted share awards are normally exercisable at the end of the three-year vesting or performance period. Awards are normally granted to employees to acquire shares or ADS in GSK plc but in some circumstances may be settled in cash. Grants under savings-related share option schemes are normally exercisable after three years&#x2019; saving. In accordance with UK practice, the majority of options under the savings-related share option schemes are granted at a price 20% below the market price ruling at the date of grant. Options under historical share option schemes were granted at the market price ruling at the date of grant. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The value of the plans for participating employees has been maintained after the demerger of the Consumer Healthcare business through the effect of the share consolidation (see Note 37). The total charge for share-based incentive plans in 2022 was &#xa3;314&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;345&#160;million; 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;330 million). Of this amount, &#xa3;243&#160;million (2021&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;258million; 2020&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.1px"&gt;(1)&lt;/div&gt;: &#xa3;266 million) arose from the Share Value Plan. See Note 9, &#x2018;Employee Costs&#x2019; for further details. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated to reflect on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business. See Note&#160;41. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;GSK share award schemes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share Value Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under the Share Value Plan, share awards are granted to certain employees at no cost. The awards vest after two and a half to three years and there are no performance criteria attached. The fair value of these awards is determined based on the closing share price on the day of grant, after deducting the expected future dividend yield of 3.2% (2021: 3.8%; 2020: 5.0%) over the duration of the award. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares and ADS issuable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shares&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Number&#160;(000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ADS&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Number&#160;(000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$34.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,353&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,416&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,014&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$36.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,074&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,776&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,705&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,529&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$30.64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,718&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,975&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,429&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated to reflect the demerger of the Consumer Healthcare business and aid year on year volume comparability of awards granted to GSK employees. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Performance Share Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Under the Performance Share Plan, share awards are granted to Directors and senior executives at no cost. The percentage of each award that vests is based upon the performance of the Group over a defined measurement period with dividends reinvested during the same period. For awards granted from 2016 to 2019, the performance conditions are based on three equally weighted measures over a three-year performance period. These were adjusted free cash flow, TSR and R&amp;amp;D new product performance. For awards granted from 2020, the performance conditions are based on four measures over a three-year performance period. These are adjusted free cash flow (30%), TSR (30%), R&amp;amp;D new product performance (20%) and pipeline progress (20%). For awards granted from 2022, the performance conditions are based on five measures over a three-year performance period. These are TSR (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;%), pipeline progress (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;%), profit measure (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;%), sale measure (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;%) and ESG environment (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;%). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The fair value of the awards is determined based on the closing share price on the day of grant. For TSR performance elements, this is adjusted by the likelihood of that condition being met, as assessed at the time of grant. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;During 2022, awards for the continuing business were made of 4.0&#160;million shares at a weighted fair value of &#xa3;13.36 and 1.0&#160;million ADS at a weighted fair value of $35.88. At 31&#160;December 2022, there were outstanding awards over 12.6&#160;million shares and 2.8&#160;million ADS. &lt;br/&gt;&lt;/div&gt; &lt;div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/&gt; &lt;div style="position:relative;float:left; margin-left:3%;width: 6%;padding-right:0%;padding-bottom: 8pt;overflow:visible;padding-top: 14pt;"&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;
&lt;img alt="" src="g382677dsp001b.jpg" style="width: 35px; height: 880px;"/&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; height: 0pt; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div/&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:91%;border:0"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:100%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;GSK Annual Report 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45. Employee share schemes &lt;/div&gt;&lt;/div&gt;continued&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share options and savings-related options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;For the purposes of valuing savings-related options to arrive at the share-based payment charge, a Black-Scholes option pricing model has been used. The assumptions used in the model are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;Grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;Grant&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2020&#160;Grant&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.37%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.74%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.07)%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.3%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.8%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.2%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Savings-related options grant price (including 20% discount)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;11.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;12.07&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;10.34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom: 0.375pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options outstanding for the Share Save Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Savings-related&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;share option schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;br/&gt; 000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Weighted&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,803&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;11.38&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Range of exercise prices on options outstanding at year end&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;10.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&#160;&#160;&#160;&#xa3;14.15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Weighted average market price on exercise during year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;16.15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Weighted average remaining contractual life&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.0&#160;years&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Options over 1.2&#160;million shares were granted during the year under the savings-related share option scheme at a weighted average fair value of &#xa3;4.34. At 31&#160;December 2022, 5.3&#160;million of the savings-related share options were not exercisable. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There has been no change in the effective exercise price of any outstanding options during the year. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Share Ownership Plan Trusts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group sponsors Employee Share Ownership Plan (ESOP) Trusts to acquire and hold shares in GSK plc to satisfy awards made under employee incentive plans and options granted under employee share option schemes. The trustees of the ESOP Trusts purchase shares with finance provided by the Group by way of loans or contributions. The costs of running the ESOP Trusts are charged to the income statement. Shares held by the ESOP Trusts are deducted from other reserves and amortised down to the value of proceeds, if any, receivable from employees on exercise by a transfer to retained earnings. The trustees have waived their rights to dividends on the shares held by the ESOP Trusts. &lt;/div&gt;&lt;div style="font-size:24pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares held for share award schemes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Number of shares (000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;59,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,065&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Nominal value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Market value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares held for share option schemes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Number of shares (000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Nominal value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Market value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <gsk:AtPercentageBelowMarketPrice
      contextRef="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:AtPercentageBelowMarketPrice>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">314000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_GBP">345000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_GBP">330000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">243000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">258000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">266000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <gsk:ExpectedFutureDividendYieldPercentageShareGranted
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.032</gsk:ExpectedFutureDividendYieldPercentageShareGranted>
    <gsk:ExpectedFutureDividendYieldPercentageShareGranted
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.038</gsk:ExpectedFutureDividendYieldPercentageShareGranted>
    <gsk:ExpectedFutureDividendYieldPercentageShareGranted
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.05</gsk:ExpectedFutureDividendYieldPercentageShareGranted>
    <gsk:DisclosureOfEmployeeShareValuePlanExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares and ADS issuable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;Shares&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Number&#160;(000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;ADS&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:5.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;Number&#160;(000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 1&#160;January 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$34.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,353&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,416&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,014&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$36.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,074&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,776&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,705&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,529&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;13.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$30.64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Awards cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,718&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,314&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,975&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,429&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12pt;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;The 2021 and 2020 comparatives have been restated to reflect the demerger of the Consumer Healthcare business and aid year on year volume comparability of awards granted to GSK employees. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </gsk:DisclosureOfEmployeeShareValuePlanExplanatory>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2019_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">29459000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2019_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">15850000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">11115000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">13.58</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">6633000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">34.43</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">10284000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">5353000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1416000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1014000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2020_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">28874000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2020_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">16116000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">11220000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">13.28</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">6358000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">36.68</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">10074000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">5240000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1776000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2021To12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1705000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">28244000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2021_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">15529000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">10987000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">13</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">6133000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.64</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">9538000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">4919000</gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1718000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">1314000</gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2022_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">27975000</gsk:NumberOfOutstandingShareAwards>
    <gsk:NumberOfOutstandingShareAwards
      contextRef="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">15429000</gsk:NumberOfOutstandingShareAwards>
    <gsk:EquallyWeightedMeasuresOverPerformancePeriod contextRef="P01_01_2022To12_31_2022_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMemberGSKAwardType1Axis">P3Y</gsk:EquallyWeightedMeasuresOverPerformancePeriod>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2022To12_31_2022_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2021To12_31_2021_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2020To12_31_2020_FreeCashFlowMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2022To12_31_2022_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2021To12_31_2021_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2020To12_31_2020_TsrMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2022To12_31_2022_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2021To12_31_2021_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2020To12_31_2020_RAndDNewProductPerformanceMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2020To12_31_2020_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2021To12_31_2021_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:PercentageOfPerformanceSharePlan
      contextRef="P01_01_2022To12_31_2022_PipelineProgressMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:PercentageOfPerformanceSharePlan>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">4000000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">13.36</gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement>
    <gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">1000000</gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare
      contextRef="P01_01_2022To12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">35.88</gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare>
    <gsk:NumberOfOutstandingAwards
      contextRef="PAsOn12_31_2022_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">12600000</gsk:NumberOfOutstandingAwards>
    <gsk:NumberOfOutstandingAwards
      contextRef="PAsOn12_31_2022_AmericanDepositarySharesMemberGSKAwardType1Axis_PerformanceSharePlansMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">2800000</gsk:NumberOfOutstandingAwards>
    <gsk:DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory contextRef="P01_01_2022To12_31_2022">The assumptions used in the model are as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&#160;Grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2021&#160;Grant&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;2020&#160;Grant&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.37%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.74%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.07)%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.3%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.8%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.2%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Savings-related options grant price (including 20% discount)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;11.39&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;12.07&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;10.34&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0337</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0074</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">-0.0007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <gsk:DividendYieldShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.033</gsk:DividendYieldShareOptionsGranted>
    <gsk:DividendYieldShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.038</gsk:DividendYieldShareOptionsGranted>
    <gsk:DividendYieldShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_pure">0.062</gsk:DividendYieldShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.36</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.27</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.27</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <gsk:ExpectedLifeOfShareOptionsGranted contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P3Y</gsk:ExpectedLifeOfShareOptionsGranted>
    <gsk:ExpectedLifeOfShareOptionsGranted contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P3Y</gsk:ExpectedLifeOfShareOptionsGranted>
    <gsk:ExpectedLifeOfShareOptionsGranted contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">P3Y</gsk:ExpectedLifeOfShareOptionsGranted>
    <gsk:SavingsRelatedOptionsGrantPriceDiscount
      contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:SavingsRelatedOptionsGrantPriceDiscount>
    <gsk:SavingsRelatedOptionsGrantPriceDiscount
      contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:SavingsRelatedOptionsGrantPriceDiscount>
    <gsk:SavingsRelatedOptionsGrantPriceDiscount
      contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</gsk:SavingsRelatedOptionsGrantPriceDiscount>
    <gsk:SavingsRelatedOptionsGrantPrice
      contextRef="P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">11.39</gsk:SavingsRelatedOptionsGrantPrice>
    <gsk:SavingsRelatedOptionsGrantPrice
      contextRef="P01_01_2021To12_31_2021_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">12.07</gsk:SavingsRelatedOptionsGrantPrice>
    <gsk:SavingsRelatedOptionsGrantPrice
      contextRef="P01_01_2020To12_31_2020_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">10.34</gsk:SavingsRelatedOptionsGrantPrice>
    <gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:95%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom: 0.375pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options outstanding for the Share Save Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Savings-related&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 6.5pt; font-family: ARIAL; text-align: right; line-height: normal;"&gt;share option schemes&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;br/&gt; 000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;Weighted&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;At 31&#160;December 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,803&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;11.38&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Range of exercise prices on options outstanding at year end&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;10.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&#160;&#160;&#160;&#160;&#xa3;14.15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Weighted average market price on exercise during year&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;16.15&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Weighted average remaining contractual life&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.0&#160;years&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_shares">5803000</ifrs-full:NumberOfOutstandingShareOptions>
    <gsk:WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">11.38</gsk:WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement>
    <gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_BottomOfRangeMemberifrsfullRangeAxis_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">10.34</gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement>
    <gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">14.15</gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement>
    <gsk:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">16.15</gsk:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement>
    <gsk:WeightedAverageRemainingContractualLifeOfOutstandingShareOption
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="1"
      unitRef="Unit_Y">2</gsk:WeightedAverageRemainingContractualLifeOfOutstandingShareOption>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">1200000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_GBP_per_Share">4.34</gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement>
    <gsk:NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement
      contextRef="PAsOn12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">5300000</gsk:NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement>
    <gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares held for share award schemes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Number of shares (000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;59,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,065&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Nominal value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;353&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Market value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:96%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares held for share option schemes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Number of shares (000)&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xa3;m&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa3;m&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Nominal value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2013;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Carrying value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt;background-color:#e7e7e8"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Market value&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#e7e7e8"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;background-color:#e7e7e8"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory>
    <gsk:NumberOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_pure">59814000</gsk:NumberOfSharesHeldForShareAwardSchemes>
    <gsk:NumberOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      unitRef="Unit_pure">23065000</gsk:NumberOfSharesHeldForShareAwardSchemes>
    <gsk:NominalValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">19000000</gsk:NominalValueOfSharesHeldForShareAwardSchemes>
    <gsk:NominalValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">6000000</gsk:NominalValueOfSharesHeldForShareAwardSchemes>
    <gsk:CarryingValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">353000000</gsk:CarryingValueOfSharesHeldForShareAwardSchemes>
    <gsk:CarryingValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">27000000</gsk:CarryingValueOfSharesHeldForShareAwardSchemes>
    <gsk:MarketValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">860000000</gsk:MarketValueOfSharesHeldForShareAwardSchemes>
    <gsk:MarketValueOfSharesHeldForShareAwardSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">371000000</gsk:MarketValueOfSharesHeldForShareAwardSchemes>
    <gsk:NumberOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">65</gsk:NumberOfSharesHeldForShareOptionSchemes>
    <gsk:NumberOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">139</gsk:NumberOfSharesHeldForShareOptionSchemes>
    <gsk:NominalValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NominalValueOfSharesHeldForShareOptionSchemes>
    <gsk:NominalValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">0</gsk:NominalValueOfSharesHeldForShareOptionSchemes>
    <gsk:CarryingValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:CarryingValueOfSharesHeldForShareOptionSchemes>
    <gsk:CarryingValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:CarryingValueOfSharesHeldForShareOptionSchemes>
    <gsk:MarketValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">1000000</gsk:MarketValueOfSharesHeldForShareOptionSchemes>
    <gsk:MarketValueOfSharesHeldForShareOptionSchemes
      contextRef="PAsOn12_31_2021_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_GBP">2000000</gsk:MarketValueOfSharesHeldForShareOptionSchemes>
    <gsk:DisclosureOfPrincipalGroupCompaniesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color:#f36f21;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46. Principal Group companies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following represent the principal subsidiaries and their countries of incorporation of the Group at 31&#160;December 2022. The equity share capital of these entities is shown in the percentage columns. All companies are incorporated in their principal country of operation except where stated. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;England&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Group Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Operations UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Wellcome UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Capital plc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Export Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Finance plc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Holdings Limited&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline IHC Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.2) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.3) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.4) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property Development Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Research &amp;amp; Development Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Services Unlimited&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline US Trading Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Setfirst Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;SmithKline Beecham Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare Finance Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare UK (No.3) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Viiv Healthcare UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Scotland&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.1) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(c) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.2) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(c) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.3) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(d) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Affinivax, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corixa Corporation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Capital Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Holdings (Americas) Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Equity Investments, Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Human Genome Sciences, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Stiefel Laboratories, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tesaro, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare Company&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="clear: both; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline AG (Switzerland)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline B.V. (Netherlands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Biologicals SA (Belgium)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline GmbH &amp;amp; Co. KG (Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Pharma GmbH (Austria)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Pharmaceuticals SA (Belgium)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline S.A. (Spain)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline S.p.A. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Single Member A.E.B.E. (Greece)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Trading Services Limited (Republic of Ireland)&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(b) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Capital B.V. (Netherlands)&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(b) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Services Sp z o.o. (Poland)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Vaccines GmbH (Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Vaccines S.r.l. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;JSC GlaxoSmithKline Trading (Russia)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Laboratoire GlaxoSmithKline (France)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Laboratorios ViiV Healthcare, S.L. (Spain)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare GmbH &lt;/div&gt;(Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare S.r.l. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare SAS (France)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3 &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Saudi Arabia Limited (Saudi Arabia)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Wellcome Manufacturing Pte Ltd (Singapore)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline (Thailand) Limited (Thailand)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Australia Pty Ltd (Australia)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Brasil Limitada (Brazil)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Far East B.V. (Taiwan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. (Turkey)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Inc. (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline K.K. (Japan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Korea Limited (Republic of Korea)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Limited (Hong Kong)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Mexico S.A. de C.V. (Mexico)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Pakistan Limited (Pakistan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Pharmaceuticals Limited (India)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Enterprise Management Co, Ltd (China)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Pharma Vietnam Company Limited (Vietnam)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ID Biomedical Corporation of Quebec (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare K.K (Japan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare ULC (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="clear: both; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="font-size:0pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Directly held wholly-owned subsidiary of GSK plc. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Tax resident in UK. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP &lt;div style="display:inline;"&gt;1&lt;/div&gt; Limited&#x2019;s share capital is &lt;div style="display:inline;"&gt;99&lt;/div&gt;% indirectly owned by GSK plc and &lt;div style="display:inline;"&gt;1&lt;/div&gt;% owned by Berkeley Square Pension Trustee Company Limited. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(d)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#x2019;s share capital is &lt;div style="display:inline;"&gt;100&lt;/div&gt;% indirectly owned by GSK plc. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"&gt;The subsidiaries and associates listed above principally affect the figures in the Group&#x2019;s financial statements. Each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Captial BV and GlaxoSmithKline LLC, is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc, GlaxoSmithKline Finance plc, GSK Capital BV and GlaxoSmithKline LLC. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;See pages 307 to 314 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;</gsk:DisclosureOfPrincipalGroupCompaniesExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The following represent the principal subsidiaries and their countries of incorporation of the Group at 31&#160;December 2022. The equity share capital of these entities is shown in the percentage columns. All companies are incorporated in their principal country of operation except where stated. &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;England&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Group Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Operations UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Wellcome UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Capital plc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Export Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Finance plc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Holdings Limited&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline IHC Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.2) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.3) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property (No.4) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property Development Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Intellectual Property Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Research &amp;amp; Development Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Services Unlimited&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(a) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline US Trading Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Setfirst Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;SmithKline Beecham Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare Finance Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare UK (No.3) Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Viiv Healthcare UK Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Scotland&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.1) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(c) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.2) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(c) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK (No.3) Scottish Limited Partnership&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(d) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Affinivax, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Corixa Corporation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Capital Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Holdings (Americas) Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Equity Investments, Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Human Genome Sciences, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Stiefel Laboratories, Inc&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Tesaro, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare Company&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="clear: both; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline AG (Switzerland)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline B.V. (Netherlands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Biologicals SA (Belgium)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline GmbH &amp;amp; Co. KG (Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Pharma GmbH (Austria)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Pharmaceuticals SA (Belgium)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline S.A. (Spain)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline S.p.A. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Single Member A.E.B.E. (Greece)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GlaxoSmithKline Trading Services Limited (Republic of Ireland)&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(b) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Capital B.V. (Netherlands)&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.2px"&gt;(b) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Services Sp z o.o. (Poland)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Vaccines GmbH (Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;GSK Vaccines S.r.l. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;JSC GlaxoSmithKline Trading (Russia)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Laboratoire GlaxoSmithKline (France)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Laboratorios ViiV Healthcare, S.L. (Spain)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare GmbH &lt;/div&gt;(Germany)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare S.r.l. (Italy)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;ViiV Healthcare SAS (France)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3 &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; text-align: left; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"&gt;&#160; &lt;div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt"&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:98%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt"&gt;
&lt;td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-size: 11pt; color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;%&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Saudi Arabia Limited (Saudi Arabia)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;Glaxo Wellcome Manufacturing Pte Ltd (Singapore)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline (Thailand) Limited (Thailand)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Australia Pty Ltd (Australia)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Brasil Limitada (Brazil)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Far East B.V. (Taiwan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. (Turkey)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Inc. (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline K.K. (Japan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Korea Limited (Republic of Korea)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Limited (Hong Kong)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Mexico S.A. de C.V. (Mexico)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Pakistan Limited (Pakistan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GlaxoSmithKline Pharmaceuticals Limited (India)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Enterprise Management Co, Ltd (China)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;GSK Pharma Vietnam Company Limited (Vietnam)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ID Biomedical Corporation of Quebec (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare K.K (Japan)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 7.5pt; font-family: ARIAL; line-height: normal;"&gt;ViiV Healthcare ULC (Canada)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px; font-family:ARIAL; font-size:7.5pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="clear: both; font-size: 0pt; max-height: 0px;"/&gt;&lt;div style="font-size:0pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Directly held wholly-owned subsidiary of GSK plc. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;Tax resident in UK. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;GSK GP 1 Limited is a subsidiary undertaking of GSK plc and Berkeley Square Pension Trustee Company Limited and is the general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK GP &lt;div style="display:inline;"&gt;1&lt;/div&gt; Limited&#x2019;s share capital is &lt;div style="display:inline;"&gt;99&lt;/div&gt;% indirectly owned by GSK plc and &lt;div style="display:inline;"&gt;1&lt;/div&gt;% owned by Berkeley Square Pension Trustee Company Limited. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:12.75pt;vertical-align:top;text-align:left;"&gt;(d)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6.5pt; font-family: ARIAL; text-align: left; line-height: normal;"&gt;GSK GP 2 Limited is a subsidiary undertaking of GSK plc and is the general partner of GSK (No.3) Scottish Limited Partnership. GSK GP 2 Limited&#x2019;s share capital is &lt;div style="display:inline;"&gt;100&lt;/div&gt;% indirectly owned by GSK plc. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">England</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Group Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Operations UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoOperationsUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Glaxo Wellcome UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoWellcomeUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Capital plc</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineCapitalPLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Export Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineExportLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Finance plc</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineFinancePLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Holdings Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline IHC Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIhcLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.2) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.2LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.3) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property (No.4) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyNo.4LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property Development Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Intellectual Property Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineIntellectualPropertyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Research &amp; Development Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineResearchAndDevelopmentLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Services Unlimited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineServicesUnlimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoSmithKlineUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline US Trading Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxosmithklineUsTradingLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Setfirst Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SetFirstLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">SmithKline Beecham Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_SmithKlineBeechamLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare Finance Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareFinanceLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare UK (No.3) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViivHealthcareUnitedKingdomNo.3LimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Viiv Healthcare UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_ViiVHealthCareUnitedKingdomLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Scotland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Scotland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Scotland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.1ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.1) Scottish Limited Partnership</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.2ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.2) Scottish Limited Partnership</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BOFSifrsfullGeographicalAreasAxis_GskNo.3ScottishLimitedPartnershipMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK (No.3) Scottish Limited Partnership</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">US</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Affinivax, Inc</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_AffinivaxIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Corixa Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CorixaCorporationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline Capital Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineCapitalIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline Holdings (Americas) Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineHoldingsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GlaxoSmithKline LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">GSK Equity Investments, Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GskEquityInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Human Genome Sciences, Inc</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_HumanGenomeSciencesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Stiefel Laboratories, Inc</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_StiefelLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis">Tesaro, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_TesaroMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_USifrsfullGeographicalAreasAxis_ViiVHealthcareCompanyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CHifrsfullGeographicalAreasAxis_GlaxosmithklineAgMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">GlaxoSmithKline B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Biologicals SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlineBiologicalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline GmbH &amp; Co. KG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GlaxoSmithKlineGmbHAndCoKGMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_AustriaMemberifrsfullGeographicalAreasAxis_GlaxosmithklinePharmaGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Pharmaceuticals SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_BEifrsfullGeographicalAreasAxis_GlaxoSmithKlinePharmaceuticalsSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_GlaxoSmithKlineSAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">GlaxoSmithKline S.p.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineSPAMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis">GlaxoSmithKline Single Member A.E.B.E.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis">Greece</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineSingleMemberA.e.b.e.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GreeceMemberifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis">GlaxoSmithKline Trading Services Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis">Republic of Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineTradingServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_IEifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">GSK Capital B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GskCapitalB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NLifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis">GSK Services Sp z o.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GSKServicesSPZOOMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PLifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK Vaccines GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_GSKVaccinesGmbHMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">GSK Vaccines S.r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GSKVaccinesSRLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ITifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis">JSC GlaxoSmithKline Trading</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis">Russia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_JscGlaxosmithklineTradingMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_RUifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Laboratoire GlaxoSmithKline</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_LaboratoireGlaxoSmithKlineMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Laboratorios ViiV Healthcare, S.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_ESifrsfullGeographicalAreasAxis_LaboratoriosViiVHealthCareSLMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_DEifrsfullGeographicalAreasAxis_ViivHealthcareGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare S.r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_ITifrsfullGeographicalAreasAxis_ViivHealthcareSRLItalyMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare SAS</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_FRifrsfullGeographicalAreasAxis_ViiVHealthcareSASMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis">Glaxo Saudi Arabia Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis">Saudi Arabia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSaudiArabiaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SaudiArabiaMemberifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis">Glaxo Wellcome Manufacturing Pte Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoWellcomeManufacturingPteLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_SGifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis">GlaxoSmithKline (Thailand) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineThailandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_ThailandMemberifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_AUifrsfullGeographicalAreasAxis_GlaxoSmithKlineAustraliaPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Brasil Limitada</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_BRifrsfullGeographicalAreasAxis_GlaxoSmithKlineBrasilLimitadaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis">GlaxoSmithKline Far East B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineFarEastB.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TWifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis">GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineIlaclariSanayiVeTicaretA.s.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_TRifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GlaxoSmithKline Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_GlaxoSmithKlineIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis">GlaxoSmithKline K.K.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKKMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_JPifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis">GlaxoSmithKline Korea Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis">Republic of Korea</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineKoreaLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_KRifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis">GlaxoSmithKline Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis">Hong Kong</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlineLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_HKifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis">GlaxoSmithKline Mexico S.A. de C.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklineMexicoS.a.DeC.v.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_MXifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis">GlaxoSmithKline Pakistan Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis">Pakistan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxoSmithKlinePakistanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_PKifrsfullGeographicalAreasAxis"
      decimals="3"
      unitRef="Unit_pure">0.826</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis">GlaxoSmithKline Pharmaceuticals Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GlaxosmithklinePharmaceuticalsLimitedIndiaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_INifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">GSK Enterprise Management Co, Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CNifrsfullGeographicalAreasAxis_GskEnterpriseManagementCoLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis">GSK Pharma Vietnam Company Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis">Vietnam</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GskPharmaVietnamCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_VietnamMemberifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ID Biomedical Corporation of Quebec</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_IDBiomedicalCorporationOfQuebecMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare K.K</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_JPifrsfullGeographicalAreasAxis_ViivHealthcareK.kMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">ViiV Healthcare ULC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P01_01_2022To12_31_2022_CAifrsfullGeographicalAreasAxis_ViivHealthcareUlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="3"
      unitRef="Unit_pure">0.783</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.99</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="P01_01_2022To12_31_2022_GskGp2LimitedsShareCapital.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis_GskPlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <gsk:DisclosureOfLegalProceedingsExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;47. Legal proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is involved in significant legal and administrative proceedings, principally product liability, intellectual property, tax, anti-trust, consumer fraud and governmental investigations. The most significant of these matters, other than tax matters, are described below. The Group makes provision for these proceedings on a regular basis as summarised in Note 2, &#x2018;Accounting principles and policies&#x2019; and Note 32, &#x2018;Other provisions&#x2019;. Note 2 also describes when disclosure is made of proceedings for which there is no provision. Legal expenses incurred and provisions related to legal claims are charged to selling, general and administration costs. The Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;At 31&#160;December 2022, the Group&#x2019;s aggregate provision for legal and other disputes (not including tax matters described in Note 14, &#x2018;Taxation&#x2019;) was &#xa3;218&#160;million. There can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group&#x2019;s financial statements. If this were to happen, it could have a material adverse impact on the results of operations of the Group in the reporting period in which the judgements are incurred or the settlements entered into. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intellectual property &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Intellectual property claims include challenges to the validity and enforceability of the Group&#x2019;s patents on various products or processes as well as assertions of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-infringement&lt;/div&gt; of those patents. A loss in any of these cases could result in loss of patent protection for the product at issue. The consequences of any such loss could be a significant decrease in sales of that product and could materially affect future results of operations for the Group. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Coreg &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2014, GSK initiated suit against Teva for inducing infringement of its patent relating to the use of carvedilol (&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Coreg&lt;/div&gt;&lt;/div&gt;) in decreasing mortality caused by congestive heart failure. In June 2017, the case proceeded to a jury trial in the US District Court for the District of Delaware. The jury returned a verdict in GSK&#x2019;s favour, awarding GSK lost profits and reasonable royalties for a total award of $235.51&#160;million. On 29&#160;March 2018, the trial judge ruled on post-trial motions filed by Teva and found that substantial evidence at trial did not support the jury&#x2019;s finding of induced infringement, overturning the jury award. GSK appealed, and on 2&#160;October 2020, a divided panel of the Court of Appeals for the Federal Circuit reversed the district court&#x2019;s ruling and reinstated the jury award in GSK&#x2019;s favour. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 2&#160;December 2020, Teva filed a petition for rehearing en banc. The court granted Teva&#x2019;s petition, but only for a rehearing by the three-member panel that issued the original decision. On 5&#160;August 2021, the original panel issued its rehearing opinion where the majority again reinstated the jury&#x2019;s damages award of $235.51&#160;million in GSK&#x2019;s favour. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Teva again filed a petition for rehearing en banc which was rejected by the Court of Appeals for the Federal Circuit on 11&#160;February 2022. On 11&#160;July 2022, Teva filed a petition for writ of certiorari with the Supreme Court of the United States seeking to overturn the Federal Court decision. On 3&#160;October 2022, the Supreme Court invited the United States Solicitor General to file briefs expressing the views of the United States. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dolutegravir Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2013; Tivicay/Triumeq &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In September 2021, ViiV Healthcare received a paragraph IV letter from Lupin relating to the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tivicay&lt;/div&gt;&lt;/div&gt; 5mg dosage for oral suspension, challenging only the crystal form patent. On 2&#160;November 2021, ViiV Healthcare filed suit against Lupin in the US District Court for the District of Delaware. No trial date has yet been set. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2013; Dovato &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In September 2019, ViiV Healthcare received a paragraph IV letter from Cipla relating to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dovato&lt;/div&gt;&lt;/div&gt; and challenging only the crystal form patent. On 4&#160;November 2019, ViiV Healthcare filed suit against Cipla in the US District Court for the District of Delaware. A settlement has been reached in the case. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2013; Juluca &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In January 2020, ViiV Healthcare received a paragraph IV letter from Lupin relating to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Juluca&lt;/div&gt;&lt;/div&gt; and challenging the crystal form patent as well as a patent relating to the combination of dolutegravir and rilpivirine that expires on 24&#160;January 2031. On 28&#160;February 2020, ViiV Healthcare filed suit against Lupin on both patents. A settlement has been reached with Lupin. Additionally, on 12&#160;June 2020, Cipla sent ViiV Healthcare a paragraph IV letter related to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Juluca&lt;/div&gt;&lt;/div&gt;, and on 22&#160;July 2020, ViiV Healthcare filed suit against Cipla in federal court in Delaware. The court has not set a trial date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Product liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is currently a defendant in a number of product liability lawsuits. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Avandia &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There are two pending US class actions brought by third-party payers which assert claims under the Racketeer Influenced and Corrupt Organizations Act (RICO) and state consumer protection laws. In December 2019, the Third Circuit Court of Appeals reversed the summary judgements granted in favour of the Group and remanded the third-party payer cases back to district court. Discovery is underway in the district court but no trial dates have yet been set. It is possible that a class certification hearing will be held in 2023. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In 2019, the Group was contacted by several regulatory authorities regarding the detection of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;N-Nitroso-dimethylamine&lt;/div&gt; (NDMA) in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; (ranitidine) products. Based on information available at the time and correspondence with regulators, the Group made the decision to suspend the release, distribution and supply of all dose forms of &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; to all markets pending the outcome of the ongoing tests and investigations. Also, as a precautionary action, the Group made the decision to initiate a voluntary pharmacy/retail level recall of &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; products globally. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 30&#160;April 2020, the European Medicines Agency (EMA) recommended the suspension of ranitidine medicines. Following the publication of the EMA&#x2019;s recommendation, the Company communicated a decision not to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-enter&lt;/div&gt; the market. In the US, FDA requested that all manufacturers withdraw ranitidine products from the market. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group has been named as a defendant in approximately 4,500 personal injury cases in US state courts and the federal Zantac Multidistrict Litigation (MDL)&#160;court proceeding in the Southern District of Florida. There are approximately 84,000 plaintiffs named in these cases. A significant majority of these plaintiffs were named in a series of multi-plaintiff complaints filed in Delaware state court and most of these plaintiffs were previously in the MDL Census Registry. They were removed because they allege a cancer other than the 5 cancers being pursued by the MDL plaintiffs. In the MDL, plaintiffs originally identified 10 different types of cancers they wished to pursue. Plaintiffs subsequently dropped 5 of the 10 cancers, and proceeded only as to bladder, esophageal, gastric, liver, and pancreatic cancers, although plaintiffs in state courts continue to pursue claims beyond the 5 designated cancers. There are 46,697 unfiled claims relating to the Group and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-defendants&lt;/div&gt; (32,970 mapped to the Group) concerning the 5 designated cancers in the MDL Census Registry. There are also over 2,000 California state court cases subject to an agreement between the Group and the plaintiffs which suspends the statute of limitations to allow the plaintiffs to bring their claims at a later date. These filed and unfiled counts are subject to change. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 6&#160;December 2022, the court presiding over the federal MDL proceeding granted Defendants&#x2019; Daubert motions, finding that Plaintiffs&#x2019; experts&#x2019; causation opinions regarding whether &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; can cause the five cancers at issue in the MDL (liver, bladder, pancreatic, esophageal, and stomach) are unreliable and thus inadmissible. Without expert causation opinions, the MDL Court granted summary judgment to GSK and the other brand defendants. The MDL Court found that &#x201c;there is no scientist outside this litigation who concluded ranitidine causes cancer, and the plaintiffs&#x2019; scientists within this litigation systemically utilized unreliable methodologies,&#x201d; and failed to use &#x201c;consistent, objective, science-based standards for the even-handed evaluation of data.&#x201d; This ruling effectively dismissed approximately 2,200 filed cases in the MDL and is binding on all of the claims in the Census Registry. Plaintiffs have indicated they will appeal the MDL decision. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the California &lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt; litigation Cases JCCP 5150 (JCCP), the Court held a Sargon hearing regarding the admissibility of expert witness testimony, including the testimony of general and specific causation expert witnesses, for the first bellwether trial. The hearing occurred over a four-day period in February and March 2023. The first bellwether trial, which is a bladder cancer case, was expected to start on 27 February 2023 in the California JCCP, however the Court has moved the trial date to 24 July 2023. Three other California bellwether trials have been scheduled for May, August and October 2023, although these dates are likely to be extended as well.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Illinois Supreme Court recently consolidated all Illinois ranitidine cases in Cook County for pretrial proceedings with trial dates to be set at a later date, including the previously scheduled Madison County trial. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;Beyond the personal injury actions, class actions alleging economic injury and a third-party payer class action also have been filed in federal court. Plaintiffs have moved to stay the class actions pending appeal of the Daubert ruling. Defendants oppose the request for stay and are asking the Court to dismiss the class actions. Outside the US, there are seven class actions pending against the Group in Canada, along with a class action in Israel. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;Given the complex ownership and marketing of &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; prescription and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt; (OTC) medicine over many years, numerous claims involve several defendants. As a result, some defendants have served one another, including the Group, with notice of potential indemnification claims about possible liabilities connected particularly with &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt; OTC. Given the early stage of the proceedings, the Group cannot meaningfully assess what liability, if any, it may have, nor can it meaningfully assess the liability of other parties under relevant indemnification provisions. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;In addition, on 20&#160;March 2020, the Department of Justice (DOJ) sent the Group notice of a civil investigation it had opened into allegations of False Claims Act violations by the Group related to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zantac&lt;/div&gt;&lt;/div&gt;. On 18&#160;June 2020, the DOJ served a Civil Investigative Demand on the Group, formalizing its request for documents. On the same day, the New Mexico Attorney General filed a lawsuit against multiple defendants, including the Group, alleging violations of state consumer protection and false advertising statutes, among other claims. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL;text-indent: 0px;"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-indent: 0px;"&gt;The Group was a defendant in over 400 product liability cases involving &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran&lt;/div&gt;&lt;/div&gt; pending in a Multidistrict Litigation (MDL)&#160;proceeding in the District of Massachusetts. The cases alleged that children suffered birth defects due to their mothers&#x2019; ingestion of &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran&lt;/div&gt;&lt;/div&gt; and/or generic ondansetron for pregnancy- related nausea and vomiting. Plaintiffs asserted that the Group sold &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran&lt;/div&gt;&lt;/div&gt; knowing it was unsafe for pregnant women, failed to warn of the risks and illegally marketed &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;off-label&#x201d;&lt;/div&gt; for use by pregnant women. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;June 2021, the MDL Court granted the Group&#x2019;s motion for summary judgment on federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-emption&lt;/div&gt; grounds. The Court found that the FDA was fully informed of all relevant safety information regarding &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zofran&lt;/div&gt;&lt;/div&gt; and had repeatedly rejected any attempt to add a birth defect warning to the label. At that time, the Court granted judgment for the Group in all cases pending in the MDL (approximately 431 cases) and closed the MDL proceeding. Plaintiffs appealed this decision and, on 9&#160;January 2023, the United States Court of Appeals for the First Circuit affirmed the district court&#x2019;s decision in favour of the Group. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There remains one state court case and four proposed class actions in Canada. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales and marketing and regulation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group&#x2019;s marketing and promotion of its Pharmaceutical and Vaccine products are the subject of certain governmental investigations and private lawsuits brought by litigants under various theories of law. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;GSK Korea &#x2013; Proceedings under Fair Trade Laws &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In August 2020, GSK Korea was indicted under Korea&#x2019;s Monopoly Regulation and Fair Trade laws in relation to government tenders of HPV (&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cervarix&lt;/div&gt;&lt;/div&gt;) and PCV (&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Synflorix&lt;/div&gt;&lt;/div&gt;) vaccines in 2018 and 2019. The prosecutor alleged that GSK Korea, through the actions of at least one of its employees, interfered with the tender process under the National Immunisation Programme by using &#x201c;straw bidders.&#x201d; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;A former GSK Korea employee was also charged in his individual capacity by the prosecutor in relation to the same matter. Further, a number of wholesalers are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-defendants&lt;/div&gt; in the proceedings. On 1&#160;February 2023, the court rendered a guilty verdict in respect of all defendants. GSK Korea was fined KRW 70&#160;million which is approximately &#xa3;45,000. Appeal proceedings are ongoing. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Korea Fair Trade Commission also has commenced proceedings regarding the same matter. GSK Korea is cooperating with the authorities on these matters. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Anti-trust/competition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Certain governmental actions and private lawsuits have been brought against the Group alleging violation of competition or anti-trust laws. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lamictal &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;Purported classes of direct purchasers filed suit in the US District Court for the District of New Jersey alleging that the Group and Teva Pharmaceuticals unlawfully conspired to delay generic competition for &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lamictal&lt;/div&gt;&lt;/div&gt;, resulting in overcharges to the purchasers, by entering into an allegedly anti-competitive reverse payment settlement to resolve patent infringement litigation. A separate count accuses the Group of monopolising the market. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 13&#160;December 2018, the trial judge granted plaintiffs&#x2019; class certification motion, certifying a class of direct purchasers. The Group filed a Rule 23(f) motion in the Court of Appeals for the Third Circuit, challenging the class certification decision. On 22&#160;April 2020, the Court of Appeals vacated the lower court&#x2019;s grant of class certification and remanded the issue back to the lower court for further analysis. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 9&#160;October 2020, the district court heard argument on plaintiffs&#x2019; renewed motion for class certification after remand. On 9&#160;April 2021, the district court denied Plaintiffs&#x2019; motion for class certification of the putative direct purchaser class, leaving a potential class of brand-only purchasers. Plaintiffs moved to supplement their expert report and seek additional discovery to support the addition of certain generic purchasers. On 21&#160;January 2022, the district court denied Plaintiffs&#x2019; motion to supplement their expert report and seek additional discovery and held that the issue of generic purchasers had already been decided and denied in the court&#x2019;s ruling on decertification. The parties have conducted briefing on class certification as to the remaining brand-only purchasers, with plaintiffs also seeking to add a smaller category of purchasers. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;On 1&#160;February 2023, the district court denied Plaintiffs&#x2019; renewed class certification motion. A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follow-on&lt;/div&gt; complaint was filed in the US District Court for the Eastern District of Pennsylvania on 2&#160;February 2023 by a group of alleged purchasers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial and corporate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;The Group is involved in certain contractual and/or commercial disputes. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zejula&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; Royalty Dispute &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;In October 2012, Tesaro, Inc. (now a wholly owned subsidiary of GSK) entered into two worldwide patent license agreements with AstraZeneca UK Limited related to niraparib (later approved as &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Zejula&lt;/div&gt;&lt;/div&gt;). In May 2021, AstraZeneca filed a lawsuit against Tesaro in the High Court, England and Wales alleging that Tesaro failed to pay some of the royalties due under the license agreements. Tesaro has counterclaimed based on a calculated overpayment. A trial is scheduled for March 2023. &lt;/div&gt;</gsk:DisclosureOfLegalProceedingsExplanatory>
    <ifrs-full:LegalProceedingsProvision
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_GBP">218000000</ifrs-full:LegalProceedingsProvision>
    <gsk:DamagesAwardedToGSK
      contextRef="PAsOn08_05_2021"
      decimals="-4"
      unitRef="Unit_USD">235510000</gsk:DamagesAwardedToGSK>
    <gsk:LossContingencyNumberOfPlaintiffs
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_Plaintiffs">84000</gsk:LossContingencyNumberOfPlaintiffs>
    <gsk:FinePayable
      contextRef="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis"
      decimals="-6"
      unitRef="Unit_KRW">70000000</gsk:FinePayable>
    <gsk:FinePayable
      contextRef="PAsOn02_01_2023_GSKKoreaMemberifrsfullConsolidatedStructuredEntitiesAxis"
      decimals="0"
      unitRef="Unit_GBP">45000</gsk:FinePayable>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL"&gt;&lt;div style="color: rgb(243, 111, 33); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;48. Post balance sheet events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"&gt;There is no material post balance sheet event that requires an adjustment or a disclosure within the financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_69045263"
          xlink:label="Fact_69045263"
          xlink:type="locator"/>
        <link:footnote id="FN_241566" xlink:label="FN_241566" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 2021 and 2020 comparatives have been restated on a consistent basis from those previously published to reflect the demerger of the Consumer Healthcare business (see Note 41).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045263"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045264"
          xlink:label="Fact_69045264"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045264"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045266"
          xlink:label="Fact_69045266"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045266"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045267"
          xlink:label="Fact_69045267"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045267"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045269"
          xlink:label="Fact_69045269"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045269"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045270"
          xlink:label="Fact_69045270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045270"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045272"
          xlink:label="Fact_69045272"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045272"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045273"
          xlink:label="Fact_69045273"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045273"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045275"
          xlink:label="Fact_69045275"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045275"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045276"
          xlink:label="Fact_69045276"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045276"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045278"
          xlink:label="Fact_69045278"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045278"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045279"
          xlink:label="Fact_69045279"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045279"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045281"
          xlink:label="Fact_69045281"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045281"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045282"
          xlink:label="Fact_69045282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045282"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045438"
          xlink:label="Fact_69045438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045438"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045441"
          xlink:label="Fact_69045441"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045441"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045444"
          xlink:label="Fact_69045444"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045444"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045447"
          xlink:label="Fact_69045447"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045447"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045450"
          xlink:label="Fact_69045450"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045450"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69045453"
          xlink:label="Fact_69045453"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69045453"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046380"
          xlink:label="Fact_69046380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046380"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046381"
          xlink:label="Fact_69046381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046381"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046383"
          xlink:label="Fact_69046383"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046383"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046384"
          xlink:label="Fact_69046384"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046384"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046386"
          xlink:label="Fact_69046386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046386"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046387"
          xlink:label="Fact_69046387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046387"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046389"
          xlink:label="Fact_69046389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046389"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046390"
          xlink:label="Fact_69046390"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046390"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046392"
          xlink:label="Fact_69046392"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046392"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046393"
          xlink:label="Fact_69046393"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046393"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046395"
          xlink:label="Fact_69046395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046395"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046396"
          xlink:label="Fact_69046396"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046396"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046398"
          xlink:label="Fact_69046398"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046398"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046399"
          xlink:label="Fact_69046399"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046399"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046401"
          xlink:label="Fact_69046401"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046401"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046402"
          xlink:label="Fact_69046402"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046402"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046404"
          xlink:label="Fact_69046404"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046404"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046405"
          xlink:label="Fact_69046405"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046405"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046407"
          xlink:label="Fact_69046407"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046407"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046408"
          xlink:label="Fact_69046408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046408"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046410"
          xlink:label="Fact_69046410"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046410"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046411"
          xlink:label="Fact_69046411"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046411"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046413"
          xlink:label="Fact_69046413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046413"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046414"
          xlink:label="Fact_69046414"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046414"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046416"
          xlink:label="Fact_69046416"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046416"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046417"
          xlink:label="Fact_69046417"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046417"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046419"
          xlink:label="Fact_69046419"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046419"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046420"
          xlink:label="Fact_69046420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046420"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046422"
          xlink:label="Fact_69046422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046422"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046423"
          xlink:label="Fact_69046423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046423"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046500"
          xlink:label="Fact_69046500"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046500"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046501"
          xlink:label="Fact_69046501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046501"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046502"
          xlink:label="Fact_69046502"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046502"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046503"
          xlink:label="Fact_69046503"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046503"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046504"
          xlink:label="Fact_69046504"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046504"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046505"
          xlink:label="Fact_69046505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046505"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046506"
          xlink:label="Fact_69046506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046506"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046507"
          xlink:label="Fact_69046507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046507"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046508"
          xlink:label="Fact_69046508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046508"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046509"
          xlink:label="Fact_69046509"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046509"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046515"
          xlink:label="Fact_69046515"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046515"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046516"
          xlink:label="Fact_69046516"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046516"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046517"
          xlink:label="Fact_69046517"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046517"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046518"
          xlink:label="Fact_69046518"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046518"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046519"
          xlink:label="Fact_69046519"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046519"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046520"
          xlink:label="Fact_69046520"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046520"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046521"
          xlink:label="Fact_69046521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046521"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046522"
          xlink:label="Fact_69046522"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046522"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046523"
          xlink:label="Fact_69046523"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046523"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046524"
          xlink:label="Fact_69046524"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046524"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046530"
          xlink:label="Fact_69046530"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046530"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046531"
          xlink:label="Fact_69046531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046531"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046532"
          xlink:label="Fact_69046532"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046532"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046533"
          xlink:label="Fact_69046533"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046533"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046534"
          xlink:label="Fact_69046534"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046534"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046535"
          xlink:label="Fact_69046535"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046535"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046536"
          xlink:label="Fact_69046536"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046536"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046537"
          xlink:label="Fact_69046537"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046537"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046538"
          xlink:label="Fact_69046538"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046538"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046539"
          xlink:label="Fact_69046539"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046539"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046545"
          xlink:label="Fact_69046545"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046545"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046546"
          xlink:label="Fact_69046546"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046546"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046547"
          xlink:label="Fact_69046547"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046547"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046548"
          xlink:label="Fact_69046548"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046548"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046549"
          xlink:label="Fact_69046549"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046549"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046550"
          xlink:label="Fact_69046550"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046550"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046551"
          xlink:label="Fact_69046551"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046551"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046552"
          xlink:label="Fact_69046552"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046552"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046553"
          xlink:label="Fact_69046553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046553"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046554"
          xlink:label="Fact_69046554"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046554"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046560"
          xlink:label="Fact_69046560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046560"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046561"
          xlink:label="Fact_69046561"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046561"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046562"
          xlink:label="Fact_69046562"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046562"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046563"
          xlink:label="Fact_69046563"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046563"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046564"
          xlink:label="Fact_69046564"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046564"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046565"
          xlink:label="Fact_69046565"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046565"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046566"
          xlink:label="Fact_69046566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046566"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046567"
          xlink:label="Fact_69046567"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046567"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046568"
          xlink:label="Fact_69046568"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046568"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046569"
          xlink:label="Fact_69046569"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046569"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046575"
          xlink:label="Fact_69046575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046575"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046576"
          xlink:label="Fact_69046576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046576"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046577"
          xlink:label="Fact_69046577"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046577"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046578"
          xlink:label="Fact_69046578"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046578"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046579"
          xlink:label="Fact_69046579"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046579"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046580"
          xlink:label="Fact_69046580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046580"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046581"
          xlink:label="Fact_69046581"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046581"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046582"
          xlink:label="Fact_69046582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046582"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046583"
          xlink:label="Fact_69046583"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046583"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046584"
          xlink:label="Fact_69046584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046584"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046590"
          xlink:label="Fact_69046590"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046590"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046591"
          xlink:label="Fact_69046591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046591"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046592"
          xlink:label="Fact_69046592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046592"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046593"
          xlink:label="Fact_69046593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046593"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046594"
          xlink:label="Fact_69046594"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046594"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046595"
          xlink:label="Fact_69046595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046595"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046596"
          xlink:label="Fact_69046596"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046596"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046597"
          xlink:label="Fact_69046597"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046597"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046598"
          xlink:label="Fact_69046598"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046598"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69046599"
          xlink:label="Fact_69046599"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69046599"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69048662"
          xlink:label="Fact_69048662"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69048662"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69048665"
          xlink:label="Fact_69048665"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69048665"
          xlink:to="FN_241566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_69050196"
          xlink:label="Fact_69050196"
          xlink:type="locator"/>
        <link:footnote id="FN_241567" xlink:label="FN_241567" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On 1&#160;February 2022, ViiV Healthcare reached agreement with Gilead Sciences, Inc (Gilead) to settle the global patent infringement litigation relating to the commercialisation of Gilead&#x2019;s Biktarvy concerning ViiV Healthcare&#x2019;s patents relating to dolutegravir, an anti-retroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV). Under the terms of the global settlement and licensing agreement, Gilead made an upfront payment of $1.25&#160;billion (&#xa3;922 million) to ViiV Healthcare on 15&#160;February 2022. In addition, Gilead will also pay a 3% royalty on all future US sales of Biktarvy and in respect of the bictegravir component of any other future bictegravir-containing products sold in the US. These royalties will be payable by Gilead to ViiV Healthcare from 1&#160;February 2022 until the expiry of ViiV Healthcare&#x2019;s US Patent No.&#160;8,129,385 on 5&#160;October 2027 and will be recorded as Royalty income in the Income Statement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_69050196"
          xlink:to="FN_241567"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>341
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MW,KU2&TEHVEIE&<C$@3)**>\&,PNRV>W<G8I=CKC!;N52.WRG,K':Y:)P]4
M#YX>W/'U1IL'H]GEEJ[9/=-_;6\EW(T:+RG/6:&X*)!DJZO!.WPQ)XDQ*!%_
M<W901]?(4%D(\=7<?$JO!H$9$<O84AL7%+[V[(9EF?$$X_A6.QTT_VD,CZ^?
MO'\HR0.9!57L1F3_\%1OK@:3 4K9BNXR?2<.O[.:4&S\+46FRD]TJ+'! "UW
M2HN\-H81Y+RHONE#'8@C YQT&)#:@-@&48=!6!N$SS6(:H.HC$Q%I8S#G&HZ
MNY3B@*1!@S=S40:SM ;ZO#!YO]<2?N5@IV<WHE BXRG5+$5*PQ<D52.Q0DN1
M0R5M3(KW#/$"[AD:HH_7M^C5K[_@)'S[&E7?\"/ZS+,,\J@N1QI&97R/EO4(
MKJL1D(X18((^BT)O%'I?I"P]=3 ".@TG\L3IFO1ZG+/E&Q3BWQ )"/$,Z.;Y
MYMAC/G^^>=##)FPR%);^P@Y_]]]-RK]TH;2$&?2?+_J5]\COW;25"[6E2W8U
M ,>*R3T;S$Q:@[>^R)W3V?Q,SDZB&C51C?J\S[X(33.TE6+%-8+VB?2&H4=&
MI2^$E:ND=&4:Z7Z&X\34QOXX-BXJ#J;)*6CN@I)P,FE )USBADO<6R&?H#X4
M$* :.L,C6C#HX@O%ONV@:+)'Z,[+C"K%5QRFN!900X7FQ8X7:P3+AZ2F_ZJG
M6FI:P(4O$/$Y:^F<SN9G<G82_Z2)?]);2^\?EAM:K!G*Q;Z,G4*PHL&U5(PJ
M5,#J#?%G\)@6:7G+BSU3NIS4&Y:NF;=M5G\:'U<=#JV:<S'#,)Q:-><!13CQ
MU]RXX3SNY7S7%-6R+"#3G)@W#AG_MC/K2PF2*.5J*Q3,/3!H0F3JE:><2LZJ
M((%KL>10BM[(C!U"Q(J+BQB2V J+BPD[@C)I@C+I#<H'RB7:TVQGA6!)U0:M
M0&+U9'OBCAA/+%8NQN;D\S+UDYHVI*8OSK1-R+05NX'X2$[=DHXLCAZ(E=RY
M"XDC/T<<M#(HZ&4Y9RLFI6F0],&D;/4#J:S_ZGB UI2\\4"&5K;G/@SN6"KP
MD=[#O41_RF+AC0+V9#*PX^""AF%L5[47E80=H2!M*,ASU\T#R%=4"&WB<<;U
MLA[ F1;,LWJ;G\O;:?!;58M[Y=T+%DWH-X4HAB8-4L N _+ "\U@4-H__4)/
M\[=;J1<4V'7G >&@H^Q:Y8G[I6?7*@%SD.O'(VW@9Q>Y8QK'=A?UH:88V_Q<
M% ZCCD40MW(4]ZJMV9?^%OI,GK';Y1.;I8O!H4/2!0T)Z<IBJ_EPO^B[ T)4
M[62U-7N5"2A6]7JTIKPH6:9L!18I-)2"F3W&-J,=NV.//!M/'*HN:AHY]>IQ
MA9.NM;&5>KA?Z]7YE">,*\*C5R7AUR]C[-%O=FW>>$"0MM!F[**.5H]3OJV*
MPS]/QF&/ G-RZ6*<3/9!3FFU.@[W"[FS+G=>[JXP&^(P&-OT/;")DUB/#@R.
M7)V^&&IE'NF7>7_"-E]:;U'8PQ:NV,E; +22(O>'PL><^*0:GMC,?; HM'6?
M!Y5$'9.8M+J/].L^'_,ZJ2YQV*35W*$FOD/=U6:ATZ@](!S8C=KGB70L1J05
M>:17Q]0O>K[+VTN->+8KXZFM83VP:!S;FW /:AS&'7*>M#**]+\=?"8]1+66
M?+'3=)$QF.5>M4K.^JKPK-[FY_)V&N96LY%^S7:_H1!?D:4@3[VA\RBI",?V
MZQH/+ H2IP&XJ&0<=VQW2"O+2+\L^^,E(IJXJBD)G7[F 4V=:>T!!1UK-&GE
M%^F77S\RK1/W=:YO6KLPW[1V49YI/3HZH,F97)<'70J&ORMT=:[1/&T.T]Z5
M1TC6\VM\,:^.Q%HWU0G=9RK71GIF; 4N@S=C"+BL#KVJ&RVVY3'00F@M\O)R
MPR@4M ' [RLA]-.-^8/FZ''V/U!+ P04    " ":66I6R3Z[SF8'  "0)0
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M_ &G].4O:/<?E37Z4%:5[8+F9F2L@[:>T71_M]>[NY' W=[(Z7-$\3-$$D*
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MFT/5J N?NL05N9I%;TZ3.#5Y/ONUO%0&HNW\'.S,?*SF2QQ9X4@,(,HY&LT
M0%.+2O'<A!/1&^+*)!-G0YQ\HE(V:YIJG2N7W'A9N?'^5ZFAPWM2"C^J\4.9
MMG-['8[3:Z.91K<+P=L%158X$@,(YV:SV,S4A%(\+^%$]%;IG2-Q6\=CJS1>
MWC2/<@,J2:U,Z<*4TF8L*?$P,1XFP9%T1$["&497LG>#Q&T'?ZWS5DXWU?-Q
M^&A.NNYDL?'NOWCQQU_NO$_UX\#UD: ^;(DC*QR) 60:F/(D &5!*9Z;<"*Z
MS+TM)&Y?>.ZPV5J- [4<)2[JWY8XL@*0:&ZJ:S.!.<U) &@:^I:Z:(F$$]'5
M[5T@<=O H[K3;B%[T]D_-;QV1O!09 ,+D[9'8G-S7@= EKBX^1N358+'2<?$
M$<XXNK2]]2-N[_=)S3S4M:QYH<* 2>*FP+CEPY%X1$X)'B8=$48XP^CR]K:/
MN'U?OP:J)M&#JY_4!T6VC9+RH9:S!C!@_1.@&#5[6 Q0860N;B9@+'-Q,X7*
MQ8.Y.;F&LJ1TP+:0WA(2MR?\MF508GNHP%^$IN*X)\21&$ XFUM:X\YP5" !
M4!$9DKFWA\3M#_^0]5 "V3!S=6P)4);JN',$$!Y8 PI0H"@BINY0L8G5OP&*
M#HPKM/>/U.T?7[$P2FT7Q:/ G#P#E*DVCL107G-F3NP "I ;BN6'QF@H "I<
M#'1SVKM$ZG:)KULAI8#3"CDU%<>='X[$.)+@2(HC JN4KO35GJ';^;UVH93:
M'LK:+\1](8[$.)+@2(HCPEDC7>7>%5*W*WS1LAX%W!E;+*P1 [>".!*/RRS!
M(Z7C(@EG)%W>W@U2MQO\OJM[%'>..++"D1A "*-F2X"[C-1L#-PX.A&](7KC
M2$<8QS]K=8^B-F^)(RL<B0'$7/H&D*FYW8CG))R(WB:]XZ1NQXFN[5';AU'3
MO0,,,84$PEA*XEN*.)*.*+!PAM&5[,TE=9O+UZSM472?;HDC*QR) 61*S&E;
M E 6E.*Y"2>BR]Q;2>JVDB]<?:*VT6*A-0?!+22.Q&.R2O XZ9@XPAE'E[:W
MC]1M'S_52L1L?9KL/>?M[H63/=M;$:L7X[811V(<27 DQ1'AKI)^(JQWBPQQ
MB]^TR,> S3US' 88ZTP8;A-'Y)3@8=(1880SC"YO[PZ9VQV.7.0CH,BVC:*$
M6>80P!05F5+;%&.^N<@'4-'"VAZ$"L:M75NH7(%OKA@*  OI?,#&L-XL,K=9
M_,:SCK:A(D%H33$ S.K:N$V$,N.+P#P?AD=*QT42 !:& P?$V-6A4K=A_$/6
M^1C@R.;6@1N LG0?<<X4RLLZ9PI $3'WP,%0OGDN#Z+HP*DQUCM)YG:2KUCG
M8X![X]'"O#X"F"4W;A7!S.;67 3 (,&A8,0Z"0E@(1L:4WK+R-R6\75+?0SP
M782;^ZA+ +-$QWT@CB0XDN*(0&NE:]U;0>:V@MU]".NLV75F^R+ZRS4']O;H
M(K0Z.KX?B2,QCB0XDN*(0&NE:]Z;1O9]3Z(RVV%9]PG@QA%'8AQ)<"3%$>&L
MD:YR[QG9]SF2RH!#G.:JQ1* +'UQ\X@C"8ZD."*0.ND*]]:1(2=3Y?IR@]MY
M^;2[WU-V=V_>-_DFS^I<PAI#^W8^#TR5<>.((S&.)#B2XHA :Z7?[])[1^[V
MCB_:*N# 3A[CUNH'@)G2XD@\+K,$CY2.BR2<D71Y>^_(W=[Q^VX5</S *8ZL
M<"0&$'-:EP#,U)K[X7D))Z(W0^\DN=M)7LU$3MU]5&^WK=:4! $USXL G"4Q
M[B1'YI;@H=*1H80SE*YT[R2YVTG^J5LR'#_!BB,K'(D!Q!J'(+-I-@Q^>M6)
MZ&UR=5/CJ-.KPULRW+9:U+Q> HPE)!XFQL,D.)*.R$DXP^A*]NZ1N]WC:[9D
M.&K$ECBR<A>P>V#&V^:0K>6[R>%\)_KDMKO?W_\)NCD>R'"ZL-9F <J"4KSL
MPHGH+=)[3#YJN_$%)[,Y:LZ6.+("$&)>[6((\N?6B [?DFCU>=Q4.A%=X-Y0
M<K>A?.'V& <.CUJW] .0I2_N(,=DE>!QTC%QA#..+FWO(KG;17[;O@T'_)9I
MT0'&$ABWD"-R2O PZ8@PPAE&E[>WD-QM(87</'2._"'+2W,3H>UV)K>R[H:,
MLXG?YF56JAE+T4U=Y,#88;LP<^T/0"SI<5^)(PE>EA1'A#,C_:;^WE,&;D\Y
M<L.,@O?UGT)KC];P[3/:$&9OF $4X]S4&J XLVYSA'+DW#S# !8_6)C='<"F
M@6^>KIQ=/1VH>Q[5SUFM.G3C%7*KDOEO(M5J]>D13Z<W;74X/C#HOFK;:G_\
M=R<SY6\Z0'V_K:KVZYON&427!VW=_A]02P,$%     @ FEEJ5E/G;M&Z"0
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M0(:)4=& 9"0B-EL*HH@;HIX[=))3\>RF&GB\]4JQX=5Y5@%2\HV]3D!%?&,
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M%;A1J^_?=I0T>Y=O++=-  &$6^8#I@!O8?V.G0"J$,>V?%'(%;B1ZU?G32<
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MREA_Y)OAJEEMK<V&LDN4K4*7H1\1>=BO98G.EG-N6$KE*BM.(TO4SLXUGIP
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M 3?U^%B0S,CQ!GR?6S1U^\(&NA];3O\%4$L#!!0    ( )I9:E9KN0F;K2(
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MS8U"3E*U6*T!&V3SXVV(*<VSM5'G4KJ1 9:999ITSW;<<0VY@FSU@A(C]78
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M7D[95GAVPK.;JZD?BB6T!JOB3T."!ZMH13]GO 4RZ(DD\M=Y,69Q.O=GLO:
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MEB;41>CBRCU=,2(K)@MH*5>M"4^N)D')5493.5FAA):+(:A^/;O60FK-$:8
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M!11LOW/JQ[]'Q8683N89T5FZE4<=,@Q[-DF--0$?-IK-DF]+S[-C$?@.2>'
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MSX/&!?#Z0FO:.DZ@^Y?-_@)02P,$%     @ FEEJ5IGZS(5'#0  (B8  !D
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M0H42&,0$#<RT6_O0;8"6M2PIFQX3GX_-D&<Y0=(-G2G.NR%8WXV[H1.KI^7
MU_;0LF-GFI;VIXZ64E(WX")2)LDAE&#M/:Q%R8@<@:4.,"+Q+@BF=T@,6J,^
MJ'RD.WB,?$!^KEJN*O>RT@V*3G]W/*UU&ATG.X'H6'8&P7^Y*/22C6E0:'8A
M<@ W<IN2=[(YR 4[JM)9QSF9775958.%[Y"YICW(0<PD-N40G^(!J22)*/H@
M*9 ,V2&'.DJQ4=P<!Y:-9 7ROA5@OKKP$EQ\$T0(@EVY8BM _4+,V^H7$RY$
MC;) J'2H_FW5(;/<@,!C#XF+=K<5$VZ".Y,6R&SH:DNR;-'P-0&L9DNA)>_O
MK>CO('7HSHJ0'HBFY7@A7801R:=#?A?9@VG?\Q@!G0AU(8F2V4^JJZ8:F!%Z
MC4*&/(N<T3TW L1:@"A4_^+(QQYO"3S#%?("X%X2+EL0$D4@2P4O4RD%#$@
MM5/IL>*Q+P\K4CM6*1]_U*2WD /C8!%)_E*S?,WANL@*Z:UNK0XTA8$5(L3)
M11)<.Y$]^]BM.HZTZF-/ZPCL&_HZO@;RIL,:@F=Z+Q_IQ*&]4*ZPE^W]'SC^
M-X'C]P@>VKM&UC%+*P&X1X!E04<KZ'*'*&[$#D'5JTG>(4Y60*2B5A.42=;4
MJDGM43HJ((LZ0T!0\$:>H=3]+D@ V=0PJ:Z'*M8LTY8])*V;V_N$U'8D2$M>
M+,6BV<(H9PS]8"53U5@^4BTH=='Y[ZW6KFE+C60%R@;)3,QG?[2%5-X&'E6C
MR?-N$]->=^&N;GJ7I"D=D"?,.Z9:\B6R0X9H7QH0S&\WO*)NTISM092FY)WA
MZ61.ER@U>4E=9&6:5G*0KGY9QM\'RYHLIA^C&05 $7<*@)J1(=24T>?LLN2I
MI.JYH!7"G"HU::'2V?=P,U.-=0-=**UI2PSDCG7K/IQP4CGDVY/Y[ 5'6:8D
MVBGCGFL=[JS3_25W:FA/R8U=8'HG8(GM[Z^T5(T]P&%O5#/S@ZQ3Z0[5KT>_
M0?+54OH5>H[+0B#NZ)OKZF%Z*BVJ(GIX7N2A)0&$C%S?%-W#\U&GT5/@%^9"
M7Q78?Q=O([TV^PX0NZ992-[#.22R3=MU1#LP_5N.3_ON_%@"D_\J8!_?@6=>
M7JISKI?6@^QF@E;D6V#%<6H\[*[W8."Q>Q ECH;WN"V\%A4C/H ./1<(#U[;
M.^R(4Q@4 -^!3;_FE:-%X#+T6/#-#KA3-+2WC1[Z(.@EX#+VC&N-!@-@\<!'
M)^ZXO2GTN>FN-4:+:BK)*G4/IMBCOV,%)A6T= CL[0?9CH*$KL*W[&1*F\.V
MQVZ@*"I03L#U[^AW(+.+U(^=OX&G)RE.&F#$M]/+Z 4]O-XCHM*<HR8'I)%?
M882A*IBZ_8V'HE]W='4H0"<$OF_OMQ(=V" BT#8YO86J*;Z<R IBM%9HEVWG
MJ]:9).&&/E)Z@'KQHI &/?-\#)X[N[F!Y=KQM(+ 2!P 82=6Z'AJ2LZOR=TB
MRTD4EG<2*_;(A][T;TOD3M]!7/^NS@IO]%FA9&A=XGAVT=8UZ> E\ [0P4 !
MP-Z.AT.?%^B%;_3[G?'[1T)M>K\()G+)CPU!K7B B9K2;==54#="U<Y'Q_5,
MR[?B9:[?S]#1^PBH9ZG4]E,7' S>8 ;V.F%)S%Q7Z:)3DFW9=,[C6)[OJBIR
M\.1E>&U!V?YJA3&Q+!Y]+HK/XY2O;;:D!:K"Y(8.@-GHC9-VR\"*$WOZQ".P
M@N$PYJ1O-"X7Q9]P(R!6&+U#R-T1@PTX,$D,0_9P?(/F@8MEG6Y6A-7OO7HC
M)7SZ1;_+6*;T+H.IEW'=BZ_[+UATJZ3DR<6Z0.+@]]]<="_ :$9_YO(=JQ=8
M#9. A4&(OV3VZ0K]MQ7 F(YC)<B\^.?X,06V@L:_H6?,:8JM@]1!ML&_P(]F
M+V_1 B V6=.Q/_5^8_8K.H+,..M#.49LP6<]GX4(O]BP98.8"DMW]IR7RZ)=
M8Y(/;$CG+ !^Z %AV9(,K58&@;O#>*A<P@DL+['O<>)!S!"=-(5(Q,8CU?3U
M_RIL(MO_IZ>K%=_V+\GG;.J3D-/1=SN*5_HZR7B[_H2G?]I_ /5,?_<S3-=?
M3[U#UX:$AR9N@:7V/ J.6*V_2-(WC=BHKX"N18/H4)<K]2$%3<#X0D!X<T,;
M])^%G?\%4$L#!!0    ( )I9:E8?$(-RE <  /P1   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;)U886_;1A+][E\QT%T+&5 DD;)D)[$-U,FE-JY-
M@KCV?3C<AR6Y$K<FN>SN4HKZZ_MFEV081W:# PR+I';?S+R9>;/4^4Z;!YM+
MZ>AS653V8I0[5[^:S6R:RU+8J:YEA6_6VI3"X=9L9K8V4F1^4UG,XOE\-2N%
MJD:7Y_[91W-YKAM7J$I^-&2;LA1F?R4+O;L81:/NP2>UR1T_F%V>UV(C;Z6[
MJS\:W,UZE$R5LK)*5V3D^F+T4_3JZH37^P7W2N[LX)HXDD3K![ZYR2Y&<W9(
M%C)UC"#PL95O9%$P$-SXH\4<]29YX_"Z0W_G8T<LB;#RC2[^HS*77XS.1I3)
MM6@*]TGOKF4;SY+Q4EU8_Y]V8>UB,:*TL4Z7[69X4*HJ?(K/+0^##6?S)S;$
M[8;8^QT,>2_?"B<NSXW>D>'50.,+'ZK?#>=4Q4FY=0;?*NQSEQ]<+@TAQT8X
M56U(5:DNY6PL/R/M5AZ?SQRL\-I9VB)>!<3X"<0HIE]UY7)+_ZHRF7T-,(-[
MO8]QY^-5_"SB6YE.:1%-*)['\3-XBS[FA<=;/('WF_SL*"ET^D#_%8EU!J7Q
MOT.!!IB3PS#<+J]L+5)Y,4(_6&FV<G3YXS^BU?SU,TZ>]$Z>/(?^?R7F6<3#
M_IY.Z>\L'3'MQ($M7I><@XC&T?'PP7SXX.BN7AL4 %GI7"'1P*Z%I'%\3"\]
MUED<1:^[SZ-W0AG:BJ*1Z/-2"ML8O\^27I/\HU%N#XBMM"X\C9<K6IS2>$7'
M1V^5K;45!2]-&HN8K9661)61P!6OCI:T7,843U9Q])RMBE+X#0K895Q:E7E.
MO/RD>E,I*S,XTMO!HC)1E5]BP<%D-3^E8[Z8+\_"17S&3GX:6F)/[Y6ZIVLI
M"I>GPDBJ&SRNO:E"B405RJDV"N1J+0WV*029J2V<JC)8.UNRA1.VLXR'88GL
M]Z9C"GB(06T%:Q^MX6N5,HZJ4/9-6+, "D#B^5&HA#99JXBB4UK%1^-XX4TM
MY[PLFIRL%D><[]]R&:J!O?15@'VU,-Z6I5S 8B(EDV>=<*".53@0:QT3 3E5
MEE M);E<6\FQ;I5N;+$'(TFAH&L9.<WJSS*.51+QE-)LN&+7_OX-\!")&=+9
M)VALI:3WVDDZB8ZG1UR 'RJ*Z)U,3(,AY"5E\DTZ,-Y2-BTV1H:<[93+Z6=5
M8.[1;:IDE4H[H9LJI7%X>LQ^AI+W;FT*G8#H6KC0 &O#A>6Q.+F;KJZ*T'38
MS+O ($+A%"D;5B#*8, WR^EK2U?JP0FSW3.3J305;W\40+\VF+=?V<ETT3BY
M,6*KS 3)PY]3+XQT1N,)?"YEIM)@O4'%3[!I(WUI>!:TO_2+F.2)]QV,.<J;
M$G"J+)M*8S(JS].>@-H@%=<W]\=3NL-0,#Y6)TUINRRV= TT@ZNJ4"G/?_C=
M9V+29:$4F63OFU9N:K'ONNN?T31>$KJHX!C&09A8>,KPR.?J<<ZQ$D+Q56%,
MD6"T4Z:8B][P#B D"JO9) IZ\0,9O0?.WA<XOEPW#KU.=[<$89(^QCYI');R
M/5%S1;?A)RKM4N*[2%=M**+:MX2WH(.5+UBN<.YB?FJCLR9%IJTNO %&O;N=
M<I>BL8*#+"G>^T2R[R)!K2;[+JX#G/C6?-0MU*!<"H^/":'P]%L]Z^L/%'P,
M'?!>3^EL$L4O)PLH%XA:TH?4Z021 ?74\]+YQFIK,NX_2Y]::EM5:B.["7>W
MK"N<]2D]I>MLZL ( 8X/!K!%XTW1!E3."FU]OD+-Q/'+KF8ZF?H&/B3P9Z.;
MN@\;S00P/RPZDVSQ&M4 I+I(F>SU0+(=SC>$<XXL6T+B+_:08*_][0SR?3G8
M.UY#;E]D*,6_'X6/HK8<'/Q#M77\\N(0Y%::%JMF8;!^QE6:"EVQ^AHFU<AL
M^MUFHR'9%=XWF' _H08 WC:?I&TGB5UO6=:8DO >0JE(])^L6I5*@IUG\5)9
MYP*)K34TV*M=HK13*25&\"B%H5M<Z#^_/Y;YXUC T5JY0]:OM8&,/020T,J'
M1E;5..-SBYVM7SX7.TR5)L%11 G#_0O[-Q5N_+=7HMH4T$&;#VIV<@8=:ZMV
M0KM<I7DW0.'N,+'MAI-Y7^1\WD()9AS8X.# S/K#! <4RJZ-SN9P'A2*!PQZ
M^%8;A03MI3"6M0?C?2=X#!E7L%"LP2%+3BBQPI\*@A<GIZO>B]"$U=  =X^J
M,AQL(/EW%<H68= OJE2.)U3(!@OA^BD=8%  )=+M^% ";"P4*:K8AIX2]M&A
MCTO-GSA4W\0\C6__?3"!K2]?)RA8X02B71B@JXZGCMUAL'PI+B8U1>%;&=CU
M5<;(WW2NUPL48^,EA$<'%VQOT#XMD=]]] 5#AX^^O;\AES@C0LZZ;'9Y;OMY
M2'E;1/S; GR^S?%,;]2+QV/H=ZW@UA:^\03DZ%L[+Q>]E6Z>P<I[O46]*?O8
M\KU(_8EEZ,+CP\V@?$J]_4)/!X53X8:SQ73Q>R-H/?2R-QN\D?OC*O_NP*1A
M>(:7\_YI_]/&3^&-_LOR\+O(K\)LN/L*N<;6^?1T.0H*V=TX7?OW^T0[ITM_
MF6.>2\,+\/U:X_S;WK"!_@>?R[\ 4$L#!!0    ( )I9:E8V0R545 <  #@2
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*58VV[CMA9]]U=LN$ 1
M XZLBRW;N0&9F5X&/=,.)G/:AX,^T!)MLR.)*DG%\=]W;4IV'(^3ICT/EB6*
M7/N^N*FKC39?[%I*1P]E4=GK_MJY^F(TLME:EL(&NI85WBRU*87#HUF-;&VD
MR/VBLAC%89B.2J&J_LV5'_MH;JYTXPI5R8^&;%.6PFS?R$)OKOM1?S?P2:W6
MC@=&-U>U6,D[Z?Y;?S1X&NU1<E7*RBI=D9'+Z_YM=/%FS//]A%^5W-B#>V)+
M%EI_X8?W^74_9(5D(3/'" )_]_*M+ H&@AI_=IC]O4A>>'B_0__>VPY;%L+*
MM[KX3>5N?=V?]2F72]$4[I/>_"@[>R:,E^G"^BMMVKEQW*>LL4Z7W6)H4*JJ
M_1</G1\.%LS"9Q;$W8+8Z]T*\EJ^$T[<7!F](<.S@<8WWE2_&LJIBH-RYPS>
M*JQS-[_4T@BGJA751B^5NQHYH/*[4=8AO&D1XF<0HI@^Z,JM+7U7Y3)_"C""
M.GN=XIU.;^(7$=_)+* D&E(<QO$+>,G>QL3C)<_@?98/CA:%SK[0_\3".H-4
M^/V4H2W,^#0,E\>%K44FK_O(?RO-O>S??/M-E(:7+R@YWBLY?@G]58%X$>&T
M?K. CI%[G]>2EKI /?*@<K*TM!;WDA925J2JK&@02-R0/EIZX4-";'1R6?)#
M1&?1X' @/!SH?5?6A=Y*29FVSM+9S]I)F@]H.DSG"5]G(<V&D\FD=YO?2^.4
M96'39$+C)*$DC7KO% *F%HVOX18EFL<4I7.*IFGOG82MF1+^M5ZRGM#9;8=4
M%Z)R)*J<Y)^-JD$DCF:S"<TF^,5Q[WU9"V7\\-^M&U(E_2PCH:05A:4I])[2
M.!Y_I8%A'N";QDH2UDK6>)KB!XUGQW)/S1Z'-*&X=UMJ=L@>6%5.5"NU*!YA
MA^$L]=<97\?I$?A7*TX8DJ3L:\A+PK];36M9Y,@<<+HHY FL;[^9Q5%T2='N
M[@AQI76^445! LF7"8<D<YH$Y<K6&@BT,KJI7P#>_<>]GS$%FH!T*Y(/V1J:
M2CI;81>R@U&AH2_<@^0<TX#F\][[ZAXZ:*.DO>B]11:U!NX'GV1]UKUG*RVE
MPRB9TF3(N3,9SI-Q[S>#FCG/]:8Z1DF1$[,PI#2<]CYUVK?9I>"UK12&-L\N
M/AO/$FA[EL03_HLG(0UZ=VLDP;F3IJ1"8O<AF&I@:DI3V-?[C]Z<WXNBD113
M0I/>K\(HP1%K)]=BR[ZWA-0+>?[W$H(PZN? ]V[-I8D@55OOV^FE)='D"BKY
M$E!8B^!KSF_O)02E:#.R6_T#AXS.K&3Z *4,*$Z#.>@[F%(\QQVSS6,DGW.&
M/?8&9E69JI$I6X)1,&9I=.E%HOG@^-I=6C46[0,!,T?#PG7[4&//]UK:3AJ4
MW8%O^;TR_G5 K\FC+C>0J)R8/,A26XJ+L2D7!?OCC-GPHAM&0>W&&>O2,^/^
M9;I_R6 #;Q_SWH&%V38K> B"]FKQ? 5.RCM*,(^%@VF:70S/H+]:6)4KP6X,
M.O<_ W=R_4&\,2R.#*Y4\=14)%9GS8"4A:P:&<N5O49FK-;=\J>R0"T26Y3C
MA'H4]V^4/326<HU+I=T^8J_">HLT:4IIZ$<I"K?.A)%/82'&K6':H748^^BW
M1!)+V$)./'11J3@-)6K4,#@$9>B.5-5@4;>=0EY [W>$LU$ _WJK)5;C@_@#
M469/F29SC>'7+0$<1"3!)GPR";$[[5X\3<!H&$UG^Z@-B8O7[\Q1.&PY-KT\
M*9JWWXXG@O^32TZU$D_:B%T+<<L0GC?@$11\)\)#PK56%UP0<.1250*4@:!:
M%+]LB:_-!%9>.$AM68$:=*K8Q8)Q.&;D.V$6HI+V_)>'0F[I-G-0(423$8*_
MHB2(^3)[U.24I4\R9@[RB\;!Q%]ZG[6#4MX5Q&V9RC E#H.4XBFSY"Q(6NQS
M3ZZ<7;!-0XIAAS4&9LG'E6F0T#@ G0?I2>AA^_PZL!-D_>Q<).:]XI1=;+T+
M=L'=">*]?&4D[IH:3L;T3.:-X0IZ204<%>$YZ7=<Q*?Q'-V:9+@%,VTHN61(
MY!@^V'W$ DPPI&6;BBK?CW>J^0W+\G:PB]L/=S]1W1TJ_1$7*S<@HXO>/\K'
M$$FQ^\%IJ%4&(86C+>B D]#KM"_2,'@L4J\H-/,"SYC)&DN'A0N.O3P4RD+V
M' L+.U>V-MHC(_VPEYRAH16J>DW&!G3;.?P5.;-CUXYE@O%I^HD?7PPH;SQ'
MM/SIRS'+=,,=IO/G=L3$\">&M@-#1XUJ;VN5^TU6_Q1-[Y@VZ/&A@Y/7QXVU
M]^[S)C/.O3P\XAA/!$S(R"A/(CAD,+?@? ^2[[9AS0T4.A>E&XLFI&X6A<)!
M.V_M6/)W!:_8(=T_I^BBP0:/EJ5ME#S7CJ-!0*<.CJ.#T[Q'YF\6EKR[VH/]
M?G3_6>2V_1KP.+W]IO(!6P4Z&72#2RP-@^FDWYXX=@].U_[;P$([ITM_NY8"
MY,@3\'ZIH6KWP +V'XMN_@)02P,$%     @ FEEJ5HE:J9/@!0  P P  !D
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M*1P]2:D[)-AE%\C(^C(T0*7;;VO@E+["3"47(EO3'0;:6EKZ68K*EQE'\<G
M6_I5:L_,W,5U:U8YTF@D^XSFRG5V,;YK]J9 O"'&'1JPQ*.2U@KZ16/[,(LU
M'7UJJX!)>ASH<%,42JNE>*&CFW:!72C.O0'80<KV$-WOA 47=HFV2U)LJ3P5
MBV23"AE)FI4*]4=NK:5=!$0YL=YX$'%?X<%,).$D338LA,X0#*UDR'766@MC
M7<_;5A!P$>[]X-T/\S1)/M"7/>I?\?![.-CKN^L!PRZD73Q==:(9B,"%6;0Z
MZPIW6_6LU\NLU!&Y!K7'PK&M<KXL6AHW"IC.984CCZ4%8F$FY&JA.%=] D\
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M<M43D+ 6\,F9W::K9=^911A62TZ<^_^IQOXP4-G[P\")"BM8+!W4@I+=(;(
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M34D/X/[6N:HYH07:#^A?_ ]02P,$%     @ FEEJ5G%'F7ZY!   = L  !D
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MOYV&/'L Q0,Z XRD]+R?1T66_0&,.,D? ^,9(>'3=0_!/":NG$8EF7M4_.6
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M9WD$IGM_NHG3NW#G%]K1"Q+$FIYL--Z UC>:&/03'V#X$[#^#E!+ P04
M" ":66I6@$D&_" '   2$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6R-6%UOV[@2??>O&'C1H@&\MJ783IHO($UWNQ_8O4&;VWU8[ ,MT18;2E1)
M*D[^_9XA95G)=9(+!)%$S@S/S)P9DC[;&'OK"BD]W9>Z<N?#POOZ9#)Q62%+
MX<:FEA5F5L:6PN/3KB>NME+D0:G4DW0Z74Q*H:KAQ5D8N[879Z;Q6E7RVI)K
MRE+8AP]2F\WY,!EN!SZK=>%Y8')Q5HNU_"+]?^MKBZ])9R57I:R<,A59N3H?
M7B8G'V8L'P2^*KEQO7=B3Y;&W/+'K_GY<,J I):99PL"CSMY);5F0X#QO;4Y
M[)9DQ?[[UOK/P7?XLA1.7AG]E\I]<3X\'E(N5Z+1_K/9_");?^9L+S/:A?^T
MB;)I.J2L<=Z4K3(0E*J*3W'?QJ&G<#Q]1B%M%=* .RX44'X47ER<6;,AR]*P
MQB_!U: -<*KBI'SQ%K,*>O[BDS'Y1FE]-O&PQF.3K-7\$#739S23E/XPE2\<
M_53E,G]L8 (8'99TB^5#^J+%CS(;TV$RHG2:IB_8.^Q\.PSV#I^Q=R/O/2VU
MR6[I;[%TWH("_^QS-)J9[3?#97'B:I')\R%X[Z2]D\.+MS\DB^GI"R!G'<C9
M2]9?3,"+FOMQ4?)^3%N; PXD1S,97!GG27A*Z#=1-2@_2J:C^3P-C_='@Y_N
MLT)4:TDB_P;6H>R\H_E\2N_F<SH87.:YXBIRY MKFG5!R\8!CW.4F7*I*A%G
MW_UIO*19<D#)*$F/Z.T/QVF2G [^XPMIJ31W,EINQ['ZX,:*RJTPZPT)YR1F
M"ZES0L,A)[2<Y JI4\LF5/&[^2@Y/J2#SO+6L<.$P!]9+F'I:#2=+5H'!W^B
MLW%7H#NA&_E2#/Y7\CFC=*EU%V52CH0&S827.7L!7^D3HE0'C$>GCIQ<1[^%
M@U^0W;B3D!S +TMI,R4TH=':-HR+43(['MP8C^'/;T59GWZDX_?'_Q?"7ZN0
M\1'55ID0U9A91ZIZ'AH:;&VL5]6ZS>'B8.?@1O0]?.)#,K@N!/IC)I&A3&A'
MLU&:'@^^BBQCAH )Z6(&1RLT?J#\10KMBTQ82?/1=#%]Q:DVX!T6LR*NO</3
M2(028Z&[]Q.P;RWVP;=4LU$LQ&!Q^BKIVECM LI1W+=&#G;;-<:Z,AC3#62M
MS,!\*Y8:[I6F82; #S:3"5?06E8A]0A^4RFF"8PQ+/SEQ(6V)D$KH6P;(QT+
MST4[P%H;H$9]Y5*/Z>=7!<%89"IK=(C8=@%,9PP.0P'6"CDF4=?6B*P886/R
M!:1@P?_HQ?WNA5W<ZA+\D+ (&UB$]\N<3(]W]-?EU15C.7I#[Y@])[08S]\<
MC)A6)=?R_H@4XDZ"P%ZN;<#<*Q:160,OM4#HJ19V%]RPXG@//J[8T.=@:8/.
M)*.;2##/!A+4,E,KE6WK8T1!'3U#5 A/ PY5V0-9Y6Y=7($#'A!1*7UA<J/-
M^H$C@1I3ZXJ-":ROJKH!PDVALB+DN3)^%R>SY#X>B((STBTJ(\>N/F)O<%HQ
M$/<%P._6\C(K*O6]"3YE&J3!0K%(M;R3F@ZW9=^C3Z$0/)L5#Q'YML-L6P$L
MR;A"!"7P9TLV6*U! 40IX\0$MHV@%;C:E'5,QY(/>F,4L!<*S<!*'?/8ULU>
MD@53KJ5-A*O*&H #'B]=5Q.[UO.UBP&B!\BOLG[PNWQXA/0+"MW1&ALVO&)>
M.+JV9J4\QWZM('$C+<Y<*)B>$'U\1*4;<1]1\-< 7D>5,(3%^^M]ZJ_$[C"?
M+9OGS"(:OE<Q2P/13H!)A]-,_&B9H:IX)H?M,?W1(@9+^,"+.D IR7M4B0)1
MY6C'=V8W3V0A!7%K&._UM(>F%!6.Z)R-;N- 4E3)$8"7J\8W\$>;:OTC!X $
MMSN48]_:^''D>M9WG6'T0EV.'\>ZI]\OWC@5G$37HF\-2C17X0HP'EPC'"9G
MQ%U]0_-;&XLM'<$EW!3H00KK!GLIP.EXW%%>9\I+^_WT#=5C,>:FB.=@6Y!/
MAO=NMD]DNEWWR?B^[2I%XXU"B_ ,S<#O<R0WL,B-2MYGDC?/HI_L70@?D8=S
M@.I'*ZE\RUDWVA+4=44.LNX8%/H^LH)#92V]BA<W!-N+6T0]B]&$>(7K'I;-
M&VAKT52XJ[KQHQ-9:;!O&-L2OM=-<+[@I=MF!T=CGPRK]-LXGY= G- $7;,"
M5Q2K%[CY6F-*C(%>OH Y :>$,Q7:]@/OBDYQ_V[/TVA[MT_Z#M U.,W?2HAC
M&F=W7"&Y[Z'1]H"VFUAHH!S;UCFX^>5W[(=N=T)@L>^-T,H+ON,&7_!=^>W
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MG5-? C-K2EK<QQ7D!M>AI%Z$+###!KX-=PKIIN>F@PO"A'C=?+_II:Y[HI#
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M!?TU0.,/T/Y4$^,;P1M8_]D8_PM02P,$%     @ FEEJ5J@H]58J P  80<
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULE55-;]LP#+WG5Q >,&Q
M%\>.FZ1M$J ?&[9#T:+=UL.P@V+3L5!9\B0YR?[]*-EQ,S0)T(NM#_+Q/4JD
MIFNEGTV!:&%3"FEF06%M=1Z&)BVP9*:O*I2TDRM=,DM3O0Q-I9%EWJD483P8
MC,*2<1G,IW[M7L^GJK:"2[S78.JR9/KO%0JUG@51L%UXX,O"NH5P/JW8$A_1
M_JCN-<W"#B7C)4K#E02-^2RXC,ZO$F?O#7YR7)N=,3@E"Z6>W>1;-@L&CA *
M3*U#8/1;X34*X8"(QI\6,^A".L?=\1;]B]=.6A;,X+423SRSQ2R8!)!ASFIA
M']3Z*[9Z3AU>JH3Q7U@WMO%I &EMK"I;9V)0<MG\V:;-PX[#9'# (6X=8L^[
M">19WC#+YE.MUJ"=-:&Y@9?JO8D<E^Y0'JVF74Y^=GYG"]0@E?R4UEJCM,",
M06NFH25T9Q.F+=)5@Q0?0(IBN%72%@8^RPRS_P%"HM5QB[?<KN*CB#>8]F$8
MG4 \B.,C>,-.Z]#C#0_@?<>-A850Z3/\8@MC-5V)W_N$-C#)?AA7)N>F8BG.
M JH#@WJ%P?S]NV@TN#A",NE()L?0WW0@1Y'V\XR3/KP*T7,)!B=A>%&Z;$?;
M2>^R5+6TANHO1;YB"X%0T_%JX-+4FLD4(:53=ZDT,#D=PR0YZ]VW1>M;"!JR
MI:+7E:@-Q/$9C).HUW!X0340#28P&?6BD^@L@>AD-![!FX(SC5"@R(!92)DI
M7$@2Y\Q73-1(A64+*-6**#E06VA5+PNHM,JY!:5!*&/Z\$1F1)CX@7I%4N5M
M9AS;D@OA9'YP&3MO-R:C[?K'DW9IF.PW3;KUC\ -I().FN<<28*!G$L2R)EH
MS]^%7A<\+;8$AOM!X^$Q4,:WV3@D_ZZ1KM%U="Z7U/.$SW0GG6['_LC1CG*'
M@9N*>B]%3C5F%,,% ";H'?" :R+$Z2FPJ+U,2[4.5/-8+BCK_DHRF?GKV(=]
ME17NM+T2]=(W=Y+L+DW3 ;O5[OVX;-KFBWGS^-PRO:1+!0)S<AWTQ]2N==/0
MFXE5E6^B"V6I)?MA06\@:F= ^[E2=CMQ ;I7=?X/4$L#!!0    ( )I9:E:2
M%V 360(  "<%   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(5436_;
M, R]YU<0'K!3$-O*E]<F!IIVQ7HH4+3;>AAV4&S&%B)+GJ34W;\?92=>!B39
M11(IOJ='B=2BT69K2T0'[Y54=AF4SM5786BS$BMN1[I&13L;;2KNR#1%:&N#
M/&]!E0Q9%,W"B@L5I(O6]V32A=XY*10^&;"[JN+F]PJE;I9!'!P<SZ(HG7>$
MZ:+F!;Z@^U8_&;+"GB47%2HKM *#FV5P$U^M)CZ^#?@NL+%':_"9K+7>>N,A
M7P:1%X02,^<9.$UO>(M2>B*2\6O/&?1'>N#Q^L!^W^9.N:RYQ5LM7T7NRF60
M!)#CAN^D>];-%]SG,_5\F9:V':'I8AD+(-M9IZL]F!140G4S?]_?PQ$@B<X
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M_>)J"0POD^C-AU5$Z8T7Z@@OW4T-.CJF<Y1\I0*]#X)P/MNMGY(,(8,WLD!
M%Y3C(SW)JA82PP&)-1YF1."VE'E)HE.0SHXKGMSKY=L:#^>]RA_2NQ1 RXQG
MM:Z5Y&)([TW'%&VQ5S<6=Q9(";EEY5IJX1\#'-+7-B8#*X_C$NRWP-ID/HHY
M9O@>]XZZV3P[+CZ=9@_)4X@-9 JP ?8*,#4R6NTB!@A:ZO;I?Z0>/%(3XTQX
M6L%)V@B%>N%+:YIU&:)H!0+ 2F!T2#_$2<P,Y/9_T+\GY@E2IO<^AML( 8UZ
MX&(-QLP%Y4')(W]#B0AU,6_3"C7:6-\>>X@<1=!*O=XGW9#0):':H9(4TJ%S
MB6T;_CH'4--NH")T87EX-6K%"(_0U[49^MZ@CDTF0SKV@(X.&IR* 2RT<2'P
M$6YMK[-?W7>*EVV#="_>MIGOX!<R@A2O<'0\?#'M UMLW=J)-W5LEY;&H_F*
MPQ+=+ML@@/V5 =)N$@SL^^?%OU!+ P04    " ":66I6F,R!74H"   R!0
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M>H4%".&)G(R7/6?4'^F!Q_:!_7/(W>6R9!866OS@-3:S:!R1&E9L*_!)[[[
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MYPQ,UW2=0;H)%WVAR;5-&);NG4+C ]S\4FO:&7Z!_N7+_@!02P,$%     @
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M3/B\$6Z<;OTG!71Z[*S^LA)8\@P)X/U::S?<T '[;TS7?P%02P,$%     @
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M \,)VNT[S*RJ 3"HY<TV<H'-984 0(55KL;D^Y(1-I\S,S$"$U O0"22@GE
MLF('\&T(9 7P:5U+\<1A>F2@+>AAWJ*>?>]BQYNS\;9*8.(L4*F[=V!45MC?
M]PAAT1PZ9M/T(UJ%NFJ C1:MTT$75_*BP(&X!6*?^]WC_Q,*_@1:WPVAXL7+
MO:/IQN:WW5:2U6!FX++B>LDK.V_L'#R6%*Q$*R(D7X"[%# ?ZT9R_4S$'/Q
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M&(,N;!R^-4+$<.&86FH9F[J>F[42FDMC0BE*.V9"Z;"X;Z%%VN+-GDQ7953
MRYIF&BTN*G8NYG-R!_W?PC1OIE]#R7^3HJG)DA4YJ=NWF\T3Y+_M_LP@I9!K
MI/4JW.)-%+].IF'?SYPY?:[<L6S=WYQA6ZE89CL$NJ!8-PB'?/,H,J/N@FE0
MK''CMDZ9])QW9C?B]/5MQI:TF*,0;1&U7<?K98H5<RB0("&V-_8T @",R9T4
MCQS/.-0K'J\I)%OWLVU/A-O4:_JYZ6\6V"SWW2U4O[I!A6(9;)0RNK>N&?A]
M%;6SQ)I57RBWYP<T:-]@4<AOSXH;7>$&;>M1;%%)EHE%99KV32UVG26Q)U#
M"'M^411BA9\/]WZN_@:.8RK1LW6A'!RDU0GXH8D2@E\L(0WL7-N%!RXV>7,E
MVM#R78]X:720"E?;;(MEP-)Y$#:>[QZF,^M-PR8:V1+"?#4]#-(LMFU>GP%2
MER2[J;:211#$) B]D^\"UVZ;QG-<F%'AOQ>170<:DXW3)6@!%N8,#7(0VMH>
M-/5/^V.Z=_9T:KW<GO%]H1(RC0(0<R!UQTDT(M*>F]D;+6IS5C436HO27"X9
MA3J$"^#]7(#CMC>X07]X>?,_4$L#!!0    ( )I9:E;#@VB_H2   !9I   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;-5=6W/;1I9^YZ_H\I2GJ"I:
MPH6XQ4FJ%"=QO$DF7LO9>=C:!XB$2,0@P % R?KW^YUSNAL "9*2,[L[6Y70
MO#2Z3Y_KUZ=/M[Y^J.I/S3K+6O5Y4Y3--R_6;;O]ZNJJ6:RS3=I<5MNLQ"]W
M5;U)6WRL5U?-ML[2)3^T*:X\QPFO-FE>OOCV:_[N??WMU]6N+?(R>U^K9K?9
MI/7C=UE1/7SSPGUAOOB0K]8M?7'U[=?;=)7=9.WOV_<U/EW97I;Y)BN;O"I5
MG=U]\^+:_>J[.;7G!O^19P]-[[VBF=Q6U2?Z\&[YS0N'",J*;-%2#RG^N<_>
M9$5!'8&,?^@^7]@AZ<'^>]/[CSQWS.4V;;(W5?'W?-FNOWD1OU#+["[=%>V'
MZN&G3,\GH/X65='PJWJ0MO/Y"[78-6VUT0^#@DU>RK_I9\V'W@.Q<^0!3S_@
M,=TR$%/Y?=JFWWY=5P^JIM;HC=[P5/EI$)>7))2;ML:O.9YKOWTO_&U46BY5
MU:ZS6FVKIGV5;;9%]0CNM^HV*[.[O&V^OFHQ(#UVM="=?R>=>T<Z=SWU:U6V
MZT;]4"ZSY;"#*U!JR?4,N=]Y)WO\/EM<*M^=*<_QO!/]^7;Z/O?G'^GO8_89
M$RRJQ2?UG^EMT];0DO\:FZAT,Q_OABSGJV:;+K)O7L TFJR^SUY\^]>_N*'S
M^@21<TOD_%3O?U9&)SL?)]UW+]4S1IWHMB>:+O"Y8:DIXHO_>D,?7#5-+_I?
M./TO)K__K+:Z9_9&6:-<=Z[<.%">GTQ^OSGX>1ZKN:.">/(;4U'=9W63I<UA
M-P&Z"7SE1L[D]_)N1^HI--=9F]<9T[S.TJ)=+](ZL\_A$3]24U==3/PP47,W
M4/,PG%R7:?'8H(NT^6KRH_0&UP!6+PV3KM:/MW6^'*'$PV1<*'7<4;+W[,%#
M:.^!DB^F_?N]_DT3SP^5EX"8>63;+&#!=7Z[8R=Z0+T/'GK@I9OT&:(^KC,M
M\NI.011'9T0:\P3:Z?UBG=8K=)&7W&->+JH-6K1I*X]!S'=5@2@#&3Q3T=Z
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M0">T#!%8QA%Y^ P-W6/;3!;7AVV&Y!WV2F9\K%.1T$ '.B]L],1^F9LH+PL
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MP/Q0[0KZKL=S[>!@ O7.0A3R2KSL\UW 2,J*45J.0!5HAWZ#X!DSASO:R;)
M^NC&9/\I>S=BC\0ASBWEB$>W% 4Y"B^'*X/.8*8?WK^SREEDJQ0.?4\C-=Z
MBKPY;#NBF=(>ZO0'+Q$K;@YG#DH($J9;25UPWJ67G[H@>UYS*BREU,66TE-8
M/W9KPCV]HH@[)H(]1JPK,0' $CR@>04ANNH:*E5(UIW69KP0[Q1[:_,P/04'
MMR4KZCHSQW%X$N):.MQIQ&7#QYBE9.6:H"]K?%O!*=',1>HZ*T=J_JJZNU/O
M1O0R43?9MAW5RQL)@@9;#U'C>>5DE735OZ7E+JT?>>U($X292?S<(U+'",N7
M( 10*PH3IM'1KLR$1.+'/MTP[0> $[!AJ7.B)*I-NLPZQ2'/D/7=@H;;-A@)
M163TXR0%'4D?!Q".%H6\E& L;SQ'MY;@1>=6ULS4-:UE[/)U7_5Z84*O%-6'
M3!+G?Z_J8BE9=ZRG4UF0FW>.??>EOTX^F.6[008=J,+"O03%C2JO\,0E5)9?
MZ)/YW[^<T[<)O83.9)#Z4?/+6#_B4K/@TJ>/$;W@'3_J7KJ.<NC1'PRD.DSG
M^-3(O_3HP7@XOB?C<\>N,WG3UUZ1Y15,AQ=^!ID-R4\LA0D1$M.+1R_H[=T0
MTNV1X5T&].(%AC6^[L6E=S<:/5(N(^4]K)Q@/Q:OA5&"GM5WZ'*@-LT@44I;
M^<K#@E^6^J93VT3G>1J#YW4_MG>)>9SAI18;"@]VHT""FLF,B54,TZ9ZV W)
MM^%,9KT\M6=$L.!<7M-&A%XV566<N4!DZT=/3];&6A[:OO_DUA?[BWZ.QF[,
MOM][V&[',B4P4+/?!4,U;P<&:[\5AS'Z:7*M>6FVWS K03F\_*HKC&@30SK%
MSYE]Y?HJ4JX7*G<>0B,F[RDM/6@1*EXNNZ_MO_:;R=\XNZMQ,+>>NJZZ )?A
M8MU8^=[D+2WVQ)UC60CT)@YVO\\IF'&A7TWO9,<E6:T[5_ VIJD?R/XHVLYC
MY6(&;NRKP)\,4^>\RKR:(L"@BXL#+3NO4%,7!+DS-TQ $VT(AJZ:QA%1"--Y
MFH3QA'?Q?R_EP"=YN"03%V#R4,I74W%QF%JD/$S;P2S1?NJ#T0,I3X4[%U?<
M,?$>"N3%I#M/%C5+>E30 701XWN)_2V)U1PTN^ _(J@?_K.E'$"@&,.-0Q4#
M-81/%*SS+R)8<-\#SP+FSIC]=I)-?#6=DRZ[:@X3"LZ*UO,53'A.3#\C6@AM
M&J%G=!NB5RO/Y$#XG6 Q<R+?A<+YL&,VZ:%L1:A?(E.871*2EF&B>$U(FZ<1
M)CP(/&A=[*ACG;S:[O.N0W<_=XU%9A9?0@^,F=/_): \_4_OWY4&7-*Z<=#Y
M'C:$6$QW?3QY9[:ZUIF%\SJ.G@#7H]#YNL.VIQ%MCX"\5$;3)^0,94$O2V8@
M$"SBJ];PA9;_I\Q2=EULL.6ZAN7)@H;+"?'P_V'EQ;4NGN2]62,B*=[DXJU2
M9P#ZB.AL!F>O:&MLWQ^SI,1KM6N-#'GS#PT 2<:J;0:5-L85?>CVE=&+5&B5
M5?E*\JRMK2(SA%'*9U=OBUT#]Y.HB)QU[.]U\XPRM:_&1B#N+')"%[,@9I-V
M9W'$5NW-O!BN9W+,6</ZD[D\X<U]>>.'Y/OP:!"1/YSZ,T(1_"8,J%>=7LON
MM9=)Q32P+EN^VFUGK)5W:5[+WH(%M[T=EGZB6?\*)T*_P+#."'O6+<4E=;I:
MU=F*E7N9MBDC76'B.:W1>B JENY!U.OV$!E_<4";_*!S\U]95U_DO!,'=L,?
MSWVX^<A5WLP-DHEILBMUH_TP 0@P^956TZ]D-T$J:@#&'/>@+7]+6YN\(W P
M_D%SH* 1"N;A'#@32RX5.L'DS;!>86128>*I".I#A750I"0X/RE"-\'D[;#H
MX;#O^<R94UA'>$1\#&:^EV#]>+#O"1H<Q^] >>(R57-=53GM:>#%E=;,:<@!
MD5!@3. NPJ?)CU:1NVT>E<P<0MTS+P1+V-9<6,E\#CZS"^L>T(4$_?*P:0*#
MBL2@'%^;J1^(]<UG =:X CVTY[B:=D]3$X=;1F+@\]A8;4#8XIV)PV/>2;E.
MT@,E#KFDP1//<$2@V?5Z=(2.IH,]T.0TE==4.53HS3^E0[/A[70^BUSABO D
M8*<S#6:!:S#*YD#Y&>GD37\'E U\6U4%3\YN]=UG6)YSU8=LQ/:VQ>WFWG!;
MS^R0STRJA'"GW>5>=!EK[5!6=?4 QV3W]61!OU?_QFVY=,&.8+:"_K&K>MO
MF-:"=U7$ET!X0W#UE?[!!YOT#Q<R(HLZ?'U<X\U.[X*V82J@(</%1A 4J0%1
M(14!W::TKGBK\_M4DMI5P^E>3O[VRGE65+LC11!4P)S6.ES C];9EJLD5W6Z
MH1HT%D.GB7NU3WH+S "EHDI[65X83]0!SG3$;P_X1%JD&[_FX&Y^"'L,5)Q$
M6NX88&K1#M@Y8.#E2+1PGQ0M.$H<CP[^+ GF*L 4(G0?S#PG.N](YVH^&AVH
ML/DP.N#;IT>',*8EX $%@>-).;H*@^@)T2& <TC@72FB>+/0'>GR"Z-#,'-
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M&(Z$-Q0#SE5-''-B6S0*C"5PB,#?R25DXQ ,F'9D/PRMN?:G9GF*B%A_.&X
M))#%$T8/6<0RM0LAYV:U%XR."JDR0G-L"F MMPKA4=5>*0SYG)H3 6HLRFIK
M24UHEZRQ2_7*4A+:L'?335/<,4.Q16"$:Z@SRHC@Z?0?F=$8B<]/AB-Q9+ ;
MT@1 M*L>-H%6>W: H?<I>]J8]?HI&3''O3@^-?99I<M%S8<0% MLM* ":3TZ
MVTC\#@FREZMN.-0H7 K9'2C^YV>[</Q"^#&(92@40B(G1*().O$QW FAZ":$
MM40@=L3%+^X.'8*3^X9WWRDX$JK@UG;7[98(K*7)Z@B=#2\CN<VXX+I]\/W3
MW=^A!F5 YE1J1]U[@^DL]FQ6VIOZWF5H"2X>AP[5:M?73%LA6:TZ91@Q&,(]
M(2/QY=#[AK>Z(:09C!T-,<RMF7'>A1;9ZVYKV?1"P2^Z,("H+,"'NF&A>?Y5
M7?LUC2O!5^U8!)<B33%U1<>!T #)G14EC^M,Q?,V=BZ7 =@DHC_K8>XFJN]Q
M%C,1![A0V#$D^^W>@#@"\HZ, MQ,/33U(K"1C['/,_5:NJ/!\4A'3J**Q_\S
M2/%Y ^07ZR12PW,SU9&U:5NMH_9,*NL5616<CFEKYK5Y*[M_L&%N5.A")%I5
MN (-%6BG2#W/9]PJ@_>81>HJIW:EXG%L;795>QB;G+4%&^WI'[61;'\:\L9@
MB<JZ4F[?H32#6B]4+SUKT-D_CU/&&I110C!UM@K):V2%AJ^\#Z10;AJIWJ"'
MJ;8!?[M[AEKW"3+6MU.=HL#J ;\Q!UT2]IAW?ME+9GB'U%C6B</(0Z]A45W4
M9Y5_C.-N_U1P4*)#\;W&1 @I<B=MWL]'8:K5*;W?TEFG8R0^Z:TZ,GBX/G*'
M>_,C8;_0]T \^=EK4$^&B,-7:)C<.74\&IG#AUQ3^]ZAUUF:+YHS-0\@S;S7
MWTI<T!L GLCNQI:M G<6JB>'3QMJ18<4&O/C##42QUY/CGOOC''H6O&;<;(/
MD0FOC]N[[<OW=^&=<[<\O+G_C$,EC$ W7&+KV>A\-L"AA]^&AQ_>;/@-],)X
M;TJ^7"O0DZ4%>+XT*,+X@Q2T_Y*X^1]02P,$%     @ FEEJ5FH\LC>L!P
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M=.4+.%]IM.[=@AGTGT*O_PM02P,$%     @ FEEJ5EIN$5UT @  B@4  !D
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M2]V2?RVI/47M#&A]I4A//W !AH9W\2]02P,$%     @ FEEJ5J&MQVL@"
M_Q\  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULY5G;CMLX$GWW5Q!>
M8.$&.FU15ZMO0#J38+) +DAZ=QX6^T!+M*V))'I(JB]_OX?4Q7);]J2=GL$
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M&I$KGN^("]S=Z.BHS8V'+RJI/7. (QP7@4 [HWFGKK/':!-Z2&F;Q&P;KHE
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MU<3M]QN^<&S-WC<X3Q*E7MW@<[8(ADX0"DRM8V#T>L-K%,(1D8RO/6>P,^F
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M%ZC=!EK/%;G1#YR!W?_*\A]02P,$%     @ FEEJ5N7(XUEY%   4CH  !D
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M42A\_Q&;E-M*X3RA^R0U8UTIT!_61>& CFFV.WJ1IK^VR:/Q2*O/<]G)D,Q
M$!\7C^31'5N<S6PV^W6R!D),9@QPT#%7RF*9-E[H@8(&.A2)QO^YQ5 MP-_F
M-2&)RLCG,!E]M5^" /2>>SE][RT6$PQ@"0^][/^AK .E6T0\;EM8TB<\KA/2
M2 P,Y13U<%:2KW5.1-"!%317L"'*Z1EB:"SD[HL#1!<ED@+RM4CDHQF# :A
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MP#2.X618@P^JDUV)@'?4'BU"1_V3Q%?CL>I*W2(480QYFD*1B. ]4M1*Y;E
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M_(_/!'1(?I'%YA6Y-8UD)9<=VYG^D3AJ$",4MM/.$40T6 !N!U@@3GEDJG_
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MTW)+Y-ZDZ[RPC$D8S,L6_@>KNDHS$*4U2A3\8/$)%OR#PMG?I.M=D*5 R3L
MXTXIH$;:[/!J$+)-7>UAKO*X7\&:8+)M4:V0WXZK!L!*:SVK8,#5'>OJB"H(
M%8!=A8-4K0U83HXM+ )UPZIJ=\%A=]_D:QA/9!\X%#X08(<*C&Q:T_)%R36>
MO( ,@CE@Y4*@'>M:E6N0&/ #!@9K0@<^P']6IW=PYS9%K8+@@V=0FE' AR@
MA\R),.G'/%,,,TY:&!J[2+'#IXTF?D97W.5PHQF179Q"8XDOT<1DF7(76BBX
M&-!WT]@A@.AFA;@X L5#%N@(5*:-:ML"IUC7%3"'+ _(&09;_@;Q@P!4P(N
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M_Y."^LVQ)@ID"AR^HH'(XY6D6%!'N>_SQJIJ0FP:4') U9BTN6?C+*EXLJD
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M?R0EALT90L]&KYQ3E=2L8&@!D(KE15BU-V'7@A.&6G/9EDI#N+P$)XA0BO-
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M1$U7SK4?%:SAQDDXGM&-SKMI.$DB]YTH$Y.#:X@="%7\&D7VSX#F@8D6$[R
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M&'K;1YNBZC?+-S;'K*&=7MATVA$6)]T6WW>(1Q%.8RG0&(51UVOZ@HZSPOI
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MLQ.SM?PJA1AJO*4I1%%@^6RL_H#B.DL)^<=>Q2H,##?@;J+@FD:$3+%Q ]\
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M-D9)R0=P?^Y 6ND'#^@^_'S]/U!+ P04    " ":66I6)OE!2$8"  !$!0
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MJ\(6_0$> JP!X+4"_&J]..(;FY]GCR]6V?K1>KTPWN. @,<TWN.9\3ZVIK5
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M+ ])O!DTM]H]L +T2J-SN/&\JTR7Y+ A@U/&P[=@ MQNI& P.0#/% TCG\C
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M36=*IC U9X"!=L@=@FN7G*1VPZKOA[AW:E=%VV[;@;K(7@A'_L.]V^T!DT!
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M$V4Z5DN.BVPCOTOZ%!AI57 *WJ6OK.=&?<@6/B@',<4,X*0*2\</>3],JSH
M#I!4*$R!V;B&ZGGOH&_&:IJ+Y7(:SO\$3("NYV+U^B1EW&DD; <QN$)Y.!/4
M,; Y07?!?*I)_1X8F6238CY\RSG=GRM@6WO  %:.DK'G,1\7J&!P(7MR=O$$
MRUET_V)*9H^SIBH9BTKF)2$/,R$!SB[CT)5/DBU>5J=>\@3SW!BTZT5GTFIA
ME:%*F^7"@E\F!$PF"V#S QE2;Y+<7(['QO8.=!@*.FF2B<N$E\JF_JG13*NT
M;8%85ZFZ';*33G*<9820-8O**$I?;>*#FFRB.X0SNP$3!(Z2*%?2.23D"X8
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M0VD"\2CW?_TR21AC=TLOO_;:D'-MM.-IJ^<_=^UWILH1???;3<XXMB8+9Y<
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MD\93OW7%+G;L0?^TIJXGS8QBNZ.-77'7#LT\"LZ#_M' ]9-<PYSSDK1BX84
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M<^VHV\.RI/&*Q@/H?*FUVQH^0#^PL[]02P,$%     @ FEEJ5LY 0)&L @
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M\2$)'#]*)E3/3AI3<B#L>XZ_H%B=V(LII-B?]]87KA-B&A:>LX@]6. 8G$=
MP^F<'.,3!A/^B3-ABI2(FV'7:(/6,4)O#K^WR!.;1^PA7<AM30WT&HRRMMEG
M:XFM9^@"/AMC<3*P.'G[<*GP%:>["N">W T4L$E?\;J4"K#(R"A*_3&BCOH;
M'38_<Z\[]]7@'DXJ3JS6>_F/?SR=4J98GBN>,\,=V&)._S>7Z"8.WE=ON^-P
M>/@XXKU7KC8<*#A<WGBI 9(:@C?=5?[<N@TF<0RQ2Q/P6+EG!Z\ZI%MNWZX:
MG;6UZ1YXP]?A>7S5O0I_B'=OZWNF\A(="[Y!5?<LP6M#=>_5;F-D8]^(:VGP
MQ6F7!3[QN2(!/-](I'Z_(0?#'PW+?P%02P,$%     @ FEEJ5K\]^3Z$!
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M<VJ,T? !>K[21+5=\ 5=J[WX"U!+ P04    " ":66I6J"M@V[<"  #O!0
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M'/L,^N LSKVK3K39FL8G8<99%G"6X/7UGA^Z=$K2$-O':9C23QQBYB5^PM*
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MB@H?-)AM67+]=H-2[>8!"PZ"1[$IK!.$BUG--[A$^VO]H.DK;%%R46)EA*I
MXWH>7+/+F]3M]QM^$[@SG36X2%9*/;N/S_D\B!PAE)A9A\#I]8*W**4#(AI_
M[S&#UJ4S[*X/Z/<^=HIEQ0W>*OF[R&TQ#R8!Y+CF6VD?U>X3[N/Q!#,EC7_"
MKMF;3 /(ML:J<F],#$I1-6_^NL]#QV 2O6,0[PUBS[MQY%G><<L7,ZUVH-UN
M0G,+'ZJW)G*B<D596DU:079V<2=>1(Y5;N##$U])-!>ST!*NTX;9'N.FP8C?
MP6 Q?%65+0S\5.68?PL0$J&657Q@=1.?1;S#;  )ZT,<Q?$9O*2-,O%XR3MX
M3_AJ8255]@Q_\)6QFIKASU.!-C##TS#N@%R:FF<X#^@$&-0O&"Q^_(&-HJLS
M)(<MR>$Y],6R.1>@UO"YLJA%"?>BXE4FN(1'K)6VHMJ<8GT6]S1KEUB77>8>
M4>^!BSRL^9MK 3CT!'Q(+N!)67+O]/]#WKL7VE@0^S 8?-G*-U],8.-!&L$X
M&L*DE1*)9#!.89HRF+;2Z" =CGI+S!0Y. ".X)?,JA7J/>9H$*<P2H<P[BJZ
ML).NHHO\5 A]!*96_L*KK2L#[4N ^7UIFM*JJXE;:/(^[&I8!_M>;;4MCN )
M7-=:R.^AQT<QX4Z<F/59.H:/1+M5L8Z*]9KTCY@+/.X/1Q-@403#?L287R7]
MZ63:^PA/!0(:*VA^(= ,!UNX]S>\\D/]G-Y[RH7)I#+H$N,MO)17%*6D4>Q:
M$7;<@.O]Y,HQBFDX24ESMK\7I@<!T% Q!,(;I-8921H0FI^>'E6]IG8:]%P;
M'>=2334S!=<(.Z2'1JN5J=%/<S+A^5\T)8FI5>Z2<-/>^UEZDUM5&25%SOT5
M0,%P*;V:4(5RZ.Y$4![R 2R1V*'E0AJW\V=%&4O& SASM-/V:*?_]6@? R/"
MGF2A9([:G#K89U%/'VQ7<%ZJ;64-Y2-3FTKLZX@\*^ -N6X229E?*TF7LKGL
M?3<-;KDIVD)YHJ9#E'IK.!J[#IM.W7,\[AV#(C^N. +_946:3UPBE:&66:.B
M2\=G><@N@*7]-!Y1\TQBQJX.[QZ;D)NDZ^QD/<+.#5BBWOA[WD#F\M!<AJVT
M_96X;F[0X_;F/^0KUQM1&6K;-9E&=.0"T,W=WGQ85?O[=*4LW<Y^6=#O$&JW
M@?1K13'M/YR#]@=K\0]02P,$%     @ FEEJ5K=&.9M,!0  [ T  !D   !X
M;"]W;W)K<VAE971S+W-H965T-CDN>&ULG5?;;ALW$'W75PQ4H+"!;<3K7A);
M@.VD:(JF-1*W?2CZ0$F4Q69WJ2PIR_[[#DEI9<>24A>PE\L5Y\S,F0O)L[7M
M/KN%UA[NF[IUY\.%]\O7HY&;+G2CW"N[U"W^,K==HSQ.N]N16W9:S:)04X\8
M(?FH4:8=CL_BM^MN?&97OC:MON[ K9I&=0^7NK;K\R$=;C]\-+<+'SZ,QF=+
M=:L_:?_[\KK#V:A'F9E&M\[8%CH]/Q]>T->7(JR/"_XP>NT>O4/P9&+MYS!Y
M/SL?DF"0KO74!P2%PYV^TG4=@-",+QO,8:\R"#Y^WZ+_&'U'7R;*Z2M;_VEF
M?G$^+(<PTW.UJOU'N_Y);_R1 6]J:Q>?L$YK!6J<KIRWS488YXUITZCN-SP\
M$BC) 0&V$6#1[J0H6OE6>34^Z^P:NK :T<)+=#5*HW&F#4'YY#O\U:"<'U]W
M&-_./V2PK%7K0;4ST%]69HG$>SBY49-:N].SD4==06(TW>!>)EQV )<R^&!;
MOW#PKIWIV5. $1K96\JVEEZRHXAO]?05<)H!(XP=P>.]YSSB\0-X-_K>PZ2V
MT\_PEYHXWV&"_+W/T00C]L.$HGGMEFJJSX=8%4YW=WHX_OX[FI,W1XP4O9'B
M&/KX4ZH5L'/81>JZC]2[;:3VV7T4>;_=OP30\!]59'#AG/8.3 LWUJL:@E_\
M33.XL@X-\$#A9]6N@H$8% I%)LH2*,LHD4"SLB+ *'[C@W?WTX5J;S6HV3^8
MU,%D!R>,"CB%$TYE&$01GK+(X73PFU_H#A?/3*A=!S2'"I$S4E%\,B('5VII
MT"3C] PFMD->37L+4S3,H9DEH_1-/Z(TS0=OC5M:IVH7/5QWQNL?['P>[8BJ
M*T'"D"8THP5:-_BHI[5RSLS-5"5;T%6H2!Z7E"RLC0MO.M6Z.5KM+:C$VT+7
M,\#&":A5CV8&D\Q,5K$;G>0\NEY&7?&!L*<]LYP")KQN)@BXX99A35%D-7B3
M%1*Y)5E1E/NY%82#%"@0(T$D&5ST9/I%9U>W"YBL'":%<\A:,S'MQCT)2'0!
MG#P/ H>B0C0J>0B">%D0T =&CP0AC[G 6&0T)@3#8.\+ !4YY&4%)V61\J=Z
M.?W(2;Z)<R6KE(5QSC,N^.% ,,BS7"!#!.4"#24&@E:9D.B;QDJ:&I6VFV?5
M$:!IS+ BHS'5MM1@[!$ O^R/)25!!=TQ6='!U4)UN"QXAU&"!ZTZ)"RY5,1Z
MZL&KD*2'B:=Y!67%=\6"S+ 7TLF*\+=%D.(9%<_2&<E@9<S[/"N$^(H,PN0A
M,DX"$S%<3QB4).3*?E98'EF)PXX5>905;$:T?$0Y*U]("2]"F5).'A$K2?XM
M9EADII")&9%73VQ.5 W>-TMENKA#[TDS5L8DDS+RE)PO97&(4'24 $?9PV2@
M$\$;3'=:/59>6Z0A]L^H,!5CJBK*8NG>Z0X!P_9E>K%=:Y @H/K*F^>9PE)G
MD&FS$+%OED'E@02)U9P6)P;$L4!7(=02<KK/,1Z5"=FWI)+_![>JW=N+DP90
M&8-2'&>%!59(VC1COQ1I'TH;4=RJ9T_R#'TVWZ"99S(YBCN-+'=48SF6(O^?
MN#&=)=^D<R7HSEC$E13U#'[%JT<XML.=JE=Z3T9S/$F4(#*!0<6&B^F LK3(
M]T@^<XMG.39%D4D9C@\%*:#**LZ^+<I0E&+*BXR$?3<K20DEBG+8=ZP;/3J!
M-QI[4+AGA(UUU?IT&.^_]E>9BW2"WRU/]Z /V,(,[G*UGJ,H>57((73I;I$F
MWB[C>7YB/=X.XNL"KV.Z"POP][FU?CL)"OH+WOA?4$L#!!0    ( )I9:E;R
M:D9X9@,  'H'   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;(55;6_;
M-A#^[E]Q4($B 89(I"R_)+:!I.FP#.L:-&GW8=@'2CI;7"C1(ZDX^_<[4K+J
M!H[W011?[IZ[YXYW7.RT>;(5HH.76C5V&57.;2_CV!85UL)>Z"TV=++6IA:.
MEF83VZU!40:E6L4\229Q+603K19A[]ZL%KIU2C9X;\"V=2W,OS>H]&X9L6B_
M\45N*N<WXM5B*S;X@.[K]M[0*AY02EEC8Z5NP.!Z&5VSRYNQEP\"WR3N[,$<
M/)-<ZR>_N"N74>(=0H6%\PB"?L_X 97R0.3&/SUF-)CTBH?S/?K/@3MQR87%
M#UK](4M7+:-9!"6N1:O<%[W[!7L^F<<KM+)AA%TG.^41%*UUNNZ5R8-:-MU?
MO/1Q.%"8)6\H\%Z!![\[0\'+6^'$:F'T#HR7)C0_"52#-CDG&Y^4!V?H5)*>
M6X4L@%Y#:Q&$M>@LG#V*7*$]7\2.+'BYN.C1;CHT_@8:X_!)-ZZR\+$IL?P1
M(";7!O_XWK\;?A+Q%HL+2-E/P!/.3^"E ]\TX*5OX#WBBX-<Z>()_A2Y=8:N
MQ5_'B'8PX^,POE0N[584N(RH%BR:9XQ6[]^Q27)UPLGQX.3X%/KJH:L0GY9;
M:0NE;6LPK- )J;"$NZ:K1W^QKW,J-N@2^7D-7RF1UR&1QVB=-'R<UF^B*<%_
M]THT+LR^824+NB+PJ)U0X(FG5_7H=VHBO@#A6:B6KI,#!K^*IO5<*'\,)O,Y
ML!DPEL(L348?7XI*-!N2+/^FJTZU[F_?',[AC/DA"S,:1]=E*3U9"RSCA#KA
MP%DVND5RLY!=',[8>#YH96'*R=#YB&*XU58HPLY2OST.N&$Z34C@KMX*:7KS
M4]I^_V[&&;L:_G[S"+N4448*K',T/;\TA3G,9S =O\%N/!U 9Y!E!\1<972[
MJ2!O+67%6BATG<M&=*?D^&NGLG3TV55D6GP/SC@!#G,&/$U?!R<-(0VDLUD(
MP)P3JT<C&KLF%*?W]5^A*H'N%U#,,"XE58G,VQZ&94-Z6#?RZ8\Q]NM>(MA)
M)Z]#G,Z/Q=CO_G^0.603"C0PGL!D-H5CY18?],,:S29T?1_0MG%=:QQVAX?E
MNNNGW\6[5^F3,!M)D56X)M7D8II%8+I.WRV<WH;NFFM'O3I,*WH<T7@!.E]K
M[?8+;V!X;E?_ 5!+ P04    " ":66I6(82,(!\%  "D#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970W,2YX;6R-5TU3XS@0O?M7=&5J*:C*)K:)0X:/5$$8
M&'9K9BG(,(>M/2AV)Q;(EE>2"?S[;<F.,:P)<\&1U'IZW7K=:H[74CWH%-'
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MPRUX^XV3^PYO_QV\.3X96 @9/\#?;*&-(BW\T^5H!3/JAK'Y<:@+%N-)CQ)
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M:A=@OQ=*T7;B"O2W;?(/4$L#!!0    ( )I9:E9J_]J:# ,  -@&   9
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M%LJZR0IB[;XRU-[ W2^5LGO%!^@_Q^(?4$L#!!0    ( )I9:E:AJYC/30(
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MH/'9Y3D#TTY>:Y!N0K<O-;G9"<O2/59H?(#;7VE-.\,?T#]_V5]02P,$%
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MJQ/E=L7)_HKIVW;5)T PA[WN+CMJE[VJEVV4ZQ2:*GP8Z$4'(>5U>1S)GNV
MK)__M3.99V.:D[@@DJ&&L)^N [/L<R;F7(96W6275HT.S3I<MO5AEY3QCYJG
MR"73%=SYG-O\J*U^2A4%>+CRZ6C^H^:(6GHH<#T7<2'R+N;9TKK)\FVF\[7[
M##/W+,H+!?,!*RX03,YE*$\OBJ(1:?V2(9%,#79[QW;GMDMN&.X,_DS.'1$B
MB83Q,?EHEI9YM"R)&[;MM$%TR#55KF40,>MHX.6BTLR9IQT816T!!6,^[JQW
MC2*3C*N6X=RF*'DN/+!$VR .Z^&Z5N64V@Y&UUAVG\2/D:E4S$(8&M\8&MNI
MS)<CC55RYQ*)K@D5*HNZF+6]J8FM6_K&\+E!;<TDQ0)(0)/=:L!J,VZ'G2#"
M)E.]U^-9!5?!18<.SZ[HT);9&J?R>EE2%0UV>I?# Z9L"_=8\W;FSGUNN&)X
M(K4QGLFY)//< TP^"9@:D,- =.:A=)D$RGT,+^?"]D_KK,O<7B"Z4.9C(.+I
M="!Z 47'1Q1(&P$H" 40I3\!B!)R"*'(!%XQ]WC/D&<"4<YMT.$#X&'@,F_N
M>V( B ZBVB8BA>8#-Y*/ I%K6'#$SY0O\'X0 G*>(\B\:",3XIH#F$%@:=_*
ME@KC(J*G:#N/EP9\Q^F1CESI<QIX,:L(JWA!P!*9>,'5P86PYSSD8^AU'*0%
MQ#,=(0<&%!P1TRGH>G9;&>#(R1%A?0-T?0-.0T?@.YU8RAHA<12W$C%?Z%.1
MP N\'I3:_Q?N$RJ-5%(Z(4U*&.;\M()+)GM0*^:V?XQ:_70Z:J6/?SWNT_4A
M-235R,&FN$]=9IG;GJ>Q#N_@.!.B B#</HU;#[B%_L!YAM!C?Q[P(=RZ'7<1
M!@'1$?JCN!7:ZM-*?:H5#>)6!H1;#WH,W 84<L#>>I,!&,@*=Z[).!$3V-JA
M"A@;/NX^A:\!'Q@7 R;SP'A@;KLG4>C[+0@!2$IQS@9AY?$;0KB!7)W)G")T
M%(MH'9*? &=!,B0I@K%L)FRRF7!J-O,!:F:J$EAW;VK3ETR,#M^?3)RN#^V1
M<I!W5/SX;I6C*H5!*,7^.TIWQ QMVCCI,<7O/K09FNV!^\'<=42GZK9<1^DC
MDHS5/W=%N5_1F06>Q@T"VK;'^[I25-59!&(GJ 8LL>-WQZVJ/S/ME'BGTD=X
MZ-3][CJE)%)0*'49Q<E0V="$8'9G@/UZ44 HQS*I*@R3TI:I?];:#MW7MB2^
MWQG@<C2!:R$U=\B\(8\P^2?;1GF)Q'X;@1 ]B/_30=\VD <(!-46K+I<@][Q
MBD)WKNDU'ID;T(1AQ1,=-S:R.W),@Q9IFO0PWHP'IKR@03TD01Z0>]!K\/HD
MR&6/"/VS1:A-HC\H0 >N!5$A0BU7N">E!Q=+^1\DZ(# ,Z5'@9I/T>6A]"K;
MYFF20_,9",,->TQX_"@,)+N,,-";"#T!Z'%ZN6$'P\A#:D[9>0#DV7UR,Y:;
M=^7FR+/EIGD1#,H-[HYL#3E XS*D'Y@$*0BZVC<@21_>'QD5!]$A9?O<GR[)
MWE2!T/@)T4/Q@+EH\X21U5HE9O]"$25JL8J+9ISC%7MF(>9/3?\1PDW4;0)V
M*&#E%@/C'XG?PVHB!E/VAH@1_\CM=L>2?9:'/*S _;6-:'IW+(W.\ET<Y6%Q
MK!MC?2]WV5EEC\\TJ515<96V5UW(.I6J2R+(FP/]FF,$Q9S3.XU XT"7'!R/
M-DH@^HJ28[4]>DT"@'9>\\ <:016%1D3688&<3I//'IK"V-%[V,\_5X% *6>
M4K9VQ#02,NPX)T??D-FI;IYG)1 KX)]_:!O\JC#N&8-JU_E;M21!TTQ%^ZQC
M38B[C9'3UP?X) <L]!MB6R<6<+J'\C_RNY-B^;94/QY"N=162(H/ N8>2%1J
M[3+LER92X";Q#_L%*H+ZM:F@MW>U7SX4*:]>=IFQM,*((&PJ"L^2*/?I7[_-
MIS51Y.#!94-7_.!<*59)AF\X<2Q%'9OXE,B3_X7S/2%$/JTBTKQX.2%$*H)K
M5NO>;E@Q7FI>=N5CWM28950>P35"$/T"]3I<:/U.7[!6*8!G0D@#>U.N-?;%
M$<^5+)2L\X[]( JC!!SFRD9 '5)1C7.]X>%LGUQ'D;(!ZK<Y9P\RIO_(=0\1
MCTR$]K+ %1L_#"=\0EW$0?7;0!&FWL1Z5?6[?ELWYI([FXCY5)=,58&A/8Q/
MO7YX=.A^/\SH]=>F<K7U.Z84,P]M2'PZW#@Z\1WM==>CUC6ZID! 3T*RUOV(
MFU&1@7FR4I$#<%50JDTD'X:4,8T:V8>F,6@MC7/2&%(@;U,DN8<.,.-C7X%C
MSM0?5':A\FZ]L2WN%&+:319U4$PICDY3K=FO65%<+F@KB]EB47%'QT2;[#&/
MMNMXN;>W-!04FQ*_0KTWP^R N3SLWK\Q%13 &?O<TXZ,O)3.'/)84;W-C&2H
MF84FQ!4:NW"D0R$\Q>V4A2&/?B:X]YS!<2*CDY9*9EIW#LJX]1N<'G4;PZIH
ML2JF8G7HG75K7]AU&B5/>GO%$_N@"2S6\9;=1*5ZS/)^0(_./_PZ>^A5<ALU
M0Z5;:C8M-<N*FM,@IQUP>T#O/*!R'VVY ?\1<;APJAX^/<\F?"#07[%@+BD_
MI]JQI#]"^A9XJ/)<OS25/G4+8*0EAG"LRM16_KF*M<9DV!Y6X*/'#+HRU)G(
MQZ,M-KTR?#-=AF<<<R 9#FR9^7^7H8-4QX5_DY(WTO,06OB(G0([:*76!(8(
M9\DAFA#*1,-CHFJ/;/#)9S9^TT>$,&E]>./M+F\V* UGK[WR.?,PQ]>:A/I4
MQZI#0M^NX8[@^@1C-B5KL327MKEL=A<UY7BJ:0$WWO .(G)/%!&/LKX]=\$G
M'[RXT0ZD8._3O9,7GTD/06)/R6!^<ELYZZ#N!O?]588S#VBHAP>U-/L!*]+-
MX8N&]%U%.@FMK[Z@7X^8KR$3!_<IO<MXSJYPBC$*O6EGI2B*T-T@_"N$7S$1
M9 X%4G<Z27*O%+EW1 4;,\43*Z/?*7Q J #'N31'*K26'6A==Z\244+/Z!U;
ME"1FLVBBZJ8Z0FGM1G%EV5="_L#TY_[!#6L&IZK/7EPNFF,AQ$;#BGKI=99)
M\8#>JZ$;+F:KNG.WSY#FFJWG9L_GP+0]_@P)M6T"I\%.0Q-V1]$% \'!"5]S
M I_/6KM.PZ3XIK4+L[/Z&6N'&]5U'XK8^#>M7Q=>?'M/$_8/O9Q:6I<=R)Q,
MVC[0IV<MCDW;XJE.L2>#9TPJ[2;"GSII2'N> PHD+6-]K5_WC^@U8PU-*D1O
MDW$Y[W7I(<MU#II,D*#C6OR'YJ14<Y:K.K_5.9T2UU)]/N'\V50).>J'VO-/
M?/P U-MGV-RCDSA7[._&VO6>1AV?^<SCJ+S=-\[][W-JEI^QN_LTG>T.83YY
MB[ )AN-B+/^YA8_I]^9G[-3MA@W]^Q6,G^T)=*/#0+=]0*<K#_?:TNLF'D@F
MG-#Z?'?T-4)?.KT85+M+R+\6@,/Q,+3U32((AD7]G-+&'37IQ!BZ.+[Q@(X7
M,MJ?YWJ>U60?$8+&=V:T@RADL7ZZS^-5#R4"B^%(CX.6DE,[CM$>X8YS-NV'
M:*V;"-I;A#S.<?VF3;=D<$Q]]2:>(ZKH,&34IK2[1/CX-I'!$'K46IRQ-^0D
M"D7[XD[8W\=:B#->S9VFLZUFBLG5S&^R%N/3#,?^QAX,)&3//,9)U_49K,'3
MJ./I]I@5HKQ';R*+$M)XVS5[MJBVKA+:&3IGCR \IWH="(Y62 VH5E9%,+;>
MQ\8]>L4&6Y0OU[K92GU!GK'5Q+D"B3P%IUW\$0F?3&;#=0]-&)V<BFCH+Z!E
MC0S7I"14I-1'%XAK!-F"-ND19B*2K"XPENL,<0'$\"7.=D7RQ+8[Q '%VIQ<
MR]4#_8I()8^- C?S6CXW&&^'1]V3Q?>[ C(K"C8KE&)_R>@,.;^\&D.^:.MW
M8G+][MFU]O&AAS4RWRL8MV5@.APR%DP=YXZ3*^^_/*-V3(7MD/G/KQL+*O(B
MB@Z=_8JQ/H-9[1(2M %=B("V6^J7N[UB7'1^@D4K"/W0#$6>2$;-K[$T3YL?
ML[DV/^'2-C>_A/,!:*7I$_6 KI1)7+#<_+B,N2FSK?Y!E_NL++.-O@3R5RJG
M!OC^(8/&53<T0?,3/Z__%U!+ P04    " ":66I6$Z #!XP#  "/!P  &0
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MFU8N;T?M2N^R0,,P=RN9Z$6AZMJO= [3I:&$I^+*IZH0=?6W)L0OF>':?K'
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MRAK0_YV4YK2P 88G>_4O4$L#!!0    ( )I9:E:M:(.%\@<  $P@   9
M>&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;.5:68_;-A!^]Z\@7*#0 MM8U&GM
M!62W";H%<F"S;1Z*/M 2;;.11(>D]OCW'5(R+:\E)7:V18"\R"1%S@SG^#A#
M^>R>BT]R2:E"#T5>RO/Q4JG5R60BTR4MB'S!5[2$-W,N"J*@*Q83N1*49&91
MD4\\UXTF!6'E^.+,C+T7%V>\4CDKZ7N!9%441#Q>TIS?GX_Q>#UPPQ9+I0<F
M%V<KLJ ?J/IC]5Y ;V*I9*R@I62\1(+.S\<O\<EEI.>;"7\R>B];;:1W,N/\
MD^Y<9^=C5PM$<YHJ38' SQV]HGFN"8$8GQN:8\M2+VRWU]1?F[W#7F9$TBN>
M?V296IZ/IV.4T3FI<G7#[W^CS7Y"32_EN31/=%_/#>,Q2BNI>-$L!@D*5M:_
MY*'10VO!U.U9X#4+/"-WS<A(^2M1Y.),\'LD]&R@IAMFJV8U",=*;90/2L!;
M!NO4Q1M^1T''2B)6(OJY8NH1.;=DEE-Y=#91P$'/FZ0-M<N:FM=##7OH#2_5
M4J)794:S;0(3$,W*YZWEN_0&*?Y*TQ?(Q\?(<SUO@)YO]^L;>GX/O5OZH- L
MY^DG]!>9227 +?[NVFA-)N@FHT/E1*Y(2L_'$ N2BCLZOOCY)QRYIP-"!E;(
M8(CZQ8<Z0A"?HZNJJ'*B/1?="E)*W09G?O60+DFYH-IJKXS5NO8PR*5[#^AV
M2<'O+%/58DI;3!M781(1B>8\A^"6)Z.W@"(]*]*\ H^ QLGHABI "^AHA?FG
M!7I-F$!W)*^H'7K+RU]LYY8KDJ][HY<*8?0[*2NM(G +%SFA%Z CY&#S\&+]
M$X4>.AI9/176ST$L: M)0? 2Y"524A@F96:ZK+RC4NFI:$FS!95 W="=ZH=O
M^"0^D+ZA:0YKV9RE]6;!6K237<Y 65DS2:",R167L"%88"61U4RRC!'!:"T+
MD.8I(PJZ?@1[GWH8G]I?/])J\#&"^*#%C(JU(OS$"&@4$1FY8S=Y+D5XAOI:
M!@<8 GTO3/Y7;0##EA ;86"T0R<8#.?Z&YU,C4X28\'GT D&[0; 77O'-/P?
MU>#MJ, ;K<$<$:4$FU5*XSA2'*4 RJRL6+E <)P+PQ4T&26>UD9HS.C6GN-&
MH)E>0B!F0PO"MTV*'"$O\JTL&$X"/PX[#.(A)_"2-=LDUCYK; (4KFN4D$VH
M.V$8',&AE^=U!O!$M2". K"Z OX\UZHT\)+R@B*IH&<VT*U_07,SO2&1P;!8
M@'PP>TVR@B'T&R6Y6J9$4#2K)&"6E"_0 ,"'%N##KP7X=\!0 ,<",'BIDQT
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M3D0FQ/-&=UQA>/L4$#5$HQ$[LDF4!,=]&)EJJH70F>5:D1/J9Q*.KMMO5$K
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M%SP?Q)HFZVE?G1FC $0J46/DWTJ"N5V"S8'IF0%<=BMFEBML+H!BLZT  JF
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M'E"X-5,[:J##=VW6#W1]-X[](6S6&XJPV6-0 #+ KS^"I)!\4 ^*&IH\!*G
MCY$H&2!K*UDTB:)!G!"?0"+45"98%3N#2A^\JA;%H2%64A1OT"-K54,?&0.+
MB,%Q@0\=C;@52,82R/EG+X4&QMB0)"SP.@GA?KIPM_!80PXD&6"P6VR07MI#
M5X4@($1W#E$C&4L2Y.K3J.\M= "&=LI []I>I_R5]?[*'DKLZ*,3NVE:3\Q_
M:-\&I+^R#TA_1B.0]IU ^NA6X-,C[!.:?D^NJN[,GZJI" 08%L</AE$GI-/U
M4_*HRFDLNCJ/"(P4HR+(.>E;?9>+/KK-]:18^)1VUH_'PF 8"&%K\W2?<XP<
M,%I#/@IF>33[WH@W$>;<\1AG/V^,6PKU&OYP,PA21N40H*8#CC]A-,-8T@:R
M-EZT4>*EL#FV-44(E@<_& #"$9"'L05E-MEJI7U7ATZW=6Q/\]$(_X0&SL,@
MV'<9:/PK$?YG-"9HWYF@D^V!_W,!/RW,N+*?);@;)V?KM2S!+:[O27!'ZNFQ
M)- -EC'^1C$D+,LH>, UNU3((_A%!#_0XM[L34^1A Q2MT&R&/796.1-EN20
MK((PRRGWCS%K76(5-GLG$(Z&7XYL]'!L+NF$45V&W5/$!W7[ORZP,*(,^_JA
MK=*8;_N V 6&>M\-?.P&^QYN5!RP09(=,;*,\"5E<0MZ;KC$B2QF^'TLZBI_
MVPBP+_%K NRBZR?Q-U_?ZG;R!O=[O($9),S^'[/XQ>#+M:VV\?L\NN"^K.J/
MV-W3[F\ SNHOW_WT^@\(WG.]D5#3YV(-2[W#&&*=KK_)UX-*[>QW\)6J*E78
MVZV '=<X =ZOE:K: 3+H_C+B]']02P,$%     @ FEEJ5J6,0 <'!0  _0H
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M$[F)T2D=P=]*@Q[-B_6WBB>'ON@Q.O5O;HR,T^G["#$Z'-K2'!FWE>Q J$L
M7RJ%QX'?5"BK:=Z+@JGFPM7A2]_WA@)C-+ K6CUU F70 ]<G*AC6C,<[D33;
MI8 (F'EE'(XR;WIPM^7A]E8"_:5!K>Q[1G'_QHBKU8GO1118B>*X8VA,U ^^
M"E38,D9<6 TD0!C!*3#*;1$Y%&/F%+$10 ;N=:P34,:/ ]T^""FJ!)AS=/S3
M4?'J$;T0&[T0/SRN4^)EVVBC[S DH*-]CPAHDPJD!4DK-:@SEVT5TK]EM;0-
M^9?+-<P;_8>6+_0BJR2,6S%@*,G*NV2+' ;NSWS(Z184JGXRU>OSO)#@P6!@
M;I4 W[;Z[*>E9ZZ.^#7^_@/Z$TZ]ZN.< X>Y?]*7$K[I#Z2='*0V)I_!$G&Q
MT+V1WAG+>IN5ED':R%Q K8%DXMBP+@"M!&(R-1Y1I,&EV)O^? U6.EVFV %.
M>,^_Q3 -K==A::P]45*RS2 =]/#8J=?1 K"D7<81(>-.4T?E'"MF3^5-U;#F
M6V3-MW);I'. >;!R:K3G82%[OY* BO5:95M8A9:#*1G*=Q7XSA((1.5 "!!>
M_PSN])95.>"C)3/0/@-DW50VKLAU&'H_3W3!<+1-4F%Y!99_).O[,BW)#?X$
MM%'2A[TPN%M6BEUO[@UK[*"CUM,+]> Z3RJUR##/WMQW8</2$D(:6R"H%RA(
M:B[;70&3TU.#(=7T;0/!0H+])99)UFMB(M)XK?P4,2.LBK)^V/W":IR,FI]N
MJD/!DGHF%.'OX@/L>4F#Y)ED]S(I0&& !TO1>]M%"VY=R^I.2FJ"G51WN6J*
M^4<[)+L!9A^SCZ8MME%M5X6436LOIA2E[2NC9UJK5@K ?%<TS7U*O('%1I_"
M-%>-:#H?3><Z5PACB$Y;I8T0$KC033T5I%%0>RJW^G,A 24:W:V&8.8<3F8Q
M5KJ/4-O*#M8Y0>MUD8*V0X^J+'=8O$2KZ;5\!.MR@W3#0"#E8$S)41)TUE!J
MOZD="#+^#L(P,/JHBFB56O*CB_=J19XA@\"-7[0R?]M:<Y-K#4[G#G47^/>-
M-EP6^:;UC%(**-QO3(3A95X.>MSC,!ZO;!:R2M)U2;IF?S9X<RB*4&J>E5@0
MH&95]&;5?=;,K!L[>:0DU"+<=#OIM64'6NDB.*:*9ZT:F;<)&(S+&3XHRW-\
M*+_-E,^?9C4\97M%L,L:S8"%HRRMY 8;[T$!=^Y6Z7Q%W@%<=K&6EEH#PT@(
M2VN1\72G,/"@09K)SLG73A;_L]/N27LHW?>J.V)GB Z>S @]]\GZ+2FT"D5%
M3K% _+XDNB9LE=ZNUO<(\HUB(3#E$EI5:,^S,J$R[9G?<@AH>66BQ3!+,&LR
M VU]J"HP0L,+CDF* ] 2?PJPY;Y+8TPG/%>JPI2,/=L5.?!\EF]2<L?F8$[A
M/JS:R+4@-D?QR&M#5.Z@G?> R:B:BJ/G/.QU[M]-,S/!?*L77JAY>?@@/&,,
MY&E:SM52#N?5[HSWBT=H@?[_23P[G9\L5L<*[I<2OR:92POF9LD-[$*W-.75
MR@/9Y9+--+?TV>";BEYG;7&\*ODJ LAMSL.'J(;P0:H!1?+MGD"A8<7@7+Y.
M%PJ/NIO2;'Q0:P%P_6^1RDOS "R>"F#Z9%VMYIA!N-D!:5 HQKPBT7A%XEBO
MZ/5R"0I;D?+$6N?QL8ZO08'5$LR/CB:RURGKZ8IOW>:MWC33?N905G4T\DT!
M;K,.[U^UULD'PHVXV&W4-RY\51RO4SK26O2,!"1-T+$?D.S=F89++\#W\MHJ
M>B"< _ELHL1^415HGM8$S@>BLIWO+^N8?Z[X[ !AQ[NN"5S[KYA-&^BNYHX3
M:8]) EB& %HHDX%!)CP5\31Z,;#1[% (L!]T*[CW<++[MJ?BD0!)$TEVZ1PC
M)T?0FB(L>SDZA&BF5HAC&J39N,5'MUP][L6D2BPR *B4U=F O"O51D5-@UKC
MA"U=383@F2Z6T@,M59!YN<N4057)ESENEI&7LX6DLW,T"KK&JN::HUI9W&%S
ME;S: B3S)M6#JEK925C,"HH!Q $&^;D_\$"JC>I,V X%J'5%H?5M9[60!V;%
M;2=R6 0\7,]GI*F/54\V#T>S:KS9<<>/WG)W!<[O/-TJ!?"D%=Q2OMASY=:\
M,%$T$P#4F36*7 *8&(]M"4XCE>V(.,SJ0X9;+U'-P'#729D.6[P3]O8-6;RG
M[0B7@;VI%\(06>U_@)B!C]#$PY0&,7JCG=71Q0:9K,9":.@MI]G!8!G5[\;$
MJ$%("16=0W$#H8O(8^3DJ5B:+@*F) N%GFA? '!8'%)0+G#"8P)M!)5.LPFJ
M?8YU5[I.UQ;=K@Y&X73],"66J"L=F!.AALJ-@LD(G:^ \2B91"FH.B7GZ")B
MM:EI,GJG<XTJF]U@RM.)Q(!.8K .T7APKTX<1C[EO&CK!:^SB(2FV,9R*.P'
M;7P[:-Q:+N!>"R>JZSH,S1R=>PMTM,[WU8@^NM?^ 5_BRW'Z"=SMJD3C+*"I
M"<=M<7< %I<RBKC/Q!_G;G"_J#0]$$3XR&^X.R;$8ZF3-\W;OMX8$Y+$Z?YB
MRHNZQ(ZX676:LUUB1=^-" J:ECJG_@2(;33%UYR\#>C'4:#0YAN*B\<4N<5^
MXDF^]CQB9T"51C=M!=)=A(1]X&MWC*]#D&]72X)+$N\&;5GS]18(W*$JIAD;
MU 0IDQ!43RVN6OZ)G84'F"35!3SA310U\69?*3]Z8^D1I@WM5\MNM6I*;/;,
M[&$P&;]V'@\IH1V*U]N*BDH^J/5]Q\@U@PU:NO')-*Z+QC=VEF:$Y=:M?%?U
M[HTTPXSG75*T2CZTM_F9[ELO^WK!N.^8/XE:WC->.XT[[8%]\#&'ZBKMC)[?
MF(Z8W%$M6D,%9IA1=3'5I_ F^AS2').=1N.=#FF14_OL:(&']->JQP4M[+1[
M'%$'4Z1WP<;79'?=L*'[F$)HM@#Q\3U W7J*(BU_9__>*-,Y^":,\=Y.?!4&
M;XHR>?AYWMC!3RBCG(:S*<SCXY5Y?XV\WSB,_]DI/I,>."X? . /1_F[C^]E
M"$[)(AS,M"UWU4X58\-SV:T*M'>R";J9&N;/P'%R.N%-(;^O:70X[GSP&^L5
M%GP0'E7)!B8:9J(=^*L_W0<DBPRA#U'T,Z1Z!@G54M$-S7"N\XK@S.?SW2@5
M$QH$8/\F]#R<B:'UV'XJPC@%87W+:HALSJR:$6JRM]AFD 4>GFP1(TSF?P\+
MU(/OF+&X\[WKL(-O^[&^NZU^@ 9DT ]V,V8#FB),/E&%V0I)7M4%5.A1/TN
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ML)DO>G18O1E[3P&!:<3-#L3-GB6.D53>5L^2-QL2XP0]\@PV\_[]9?5H+'E
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MOT!H.K]*IV!K57V:W^<(]0RU7SB(UZ%5Z,P& >L-BN)@'O;*HMADY<^4E4Z
MJONQO?"_J]DNKX4^+]#G?\F)$O%[AE:D$)\X:J:73C#@&X)ET2=@:!0Z@^L'
M*O<[GEY#/&"E'K!=/MQV4V%5RZN1N6'!CUVGSYS!R OZS 'I@HZYUU 96,D,
M;-<9URFO$T;EB%%5];;-:SO"4G%S)D*-B1N3=%,)Z.N6;%>$&6<+[*<9.UT
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M6/NFA_8++W?-JPQ6)1<5</-1E&NBIZ2!^/V^+/G3%WF"P_LVKOX$4$L#!!0
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MW3?);Y.JW-FSNW<G-$&NUZW1Z) (T8N/2 M-S!9ZOP]=BKTOV6,^S8,<O#A
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M<,Z+.D!\?YOGU>.;>H#M(UEF_P%02P,$%     @ FEEJ5K"P'6(%#   *5P
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MH7H)WCZ ?8ZV/D?.6_VKK&M/]JC3K%Z4=9I[Y;TLN4;(FMVH'C*MZW*2I8T
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MM?4%]L,&,A+%W&H# +>-0F*AA3-3QQ:A)D'B1D'E]%3<P37?9K8S$I&1]7R
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M2ZT;:DW9H9NR]VAFJ"R-JI9@J76#M_.ROYNE]VIFP,0QXR.KJ4'SRT%HKC6
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MIT[O*;A/G?Y3Z #J[ $*74"=?<"@#YBS#QCT 7/V 8,^8,X^8- 'S-D'#/J
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M*_BJ%%.$9C&A\&3WIG?LC>/7O#GF\?U:ADPM>GI8"FT.]2N'^O\W6!F)8%=
MC<$- 8^*QZ;HF-$H$HN,*Q9CD]D! 4QIR#/#8@6B?^3 %>1<+6IC&U?'']3
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MM8CSQQ!8 -((X/NE$'HS,!^H;H=G_P-02P,$%     @ FEEJ5L"T+K+.!0
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M%@?WQ8T667Z4/1=:BR2_7#,:,6D \/M2"/UZ8UY0_7TR^P]02P,$%     @
MFEEJ5FLJ&/C. P  9A(  !H   !X;"]W;W)K<VAE971S+W-H965T,3$Q+GAM
M;+5878^C-A3]*Q:5VEUIE^^09#9!F@SMMMJ.&DWZ\;#J@P,WB;6 L[:9;/_]
MVH8AD! F,Z)Y"!CN.=QSS+6-9P?*OO =@$#?LC3G<V,GQ/[&LGB\@PQSD^XA
MEW<VE&58R";;6GS/ "<:E*66:]N!E6&2&^%,7UNR<$8+D9(<E@SQ(LLP^V\!
M*3W,#<=XNO! MCNA+ECA;(^WL +QUW[)9,NJ61*20<X)S1&#S=RX=6XB9Z0
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M.$58R:LEO"O;KY8;G.?I!N;T1&]'E.><]687U[3!U1(]KD6/>T4OJUE4S^G
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MU9PBJ9MAI5E8M:O;][VR- S4KR7-=Z@=@+[G2MG3PAW038S)-U!+ P04
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M&@6<SP1N:3LP"W2-\OQ_4$L#!!0    ( )I9:E8VA]TR10,  )4.   :
M>&PO=V]R:W-H965T<R]S:&5E=#$R,BYX;6S%5UMOFS 4_BL6DZ966LLMH;<$
M*0F[5:L4M5OW,.W!)8?$J[$SVTFZ?S_;$!I2RCH)J2_@R_D^^WS'QW &&R[N
MY0) H8><,CET%DHMSUU7I@O(L3SF2V!Z)N,BQTIWQ=R52P%X9D$Y=0//B]P<
M$^;$ SLV%?& KQ0E#*8"R56>8_%G#)1OAH[O; >NR7RAS( ;#Y9X#C>@OBVG
M0O?<BF5&<F"2<(8$9$-GY)\GOF< UN*6P$;NM)%QY8[S>]/Y/!LZGMD14$B5
MH<#ZM88)4&J8]#Y^EZ1.M:8![K:W[!^L\]J9.RQAPNEW,E.+H7/JH!ED>$75
M-=]\@M*AON%+.97VB3:EK>>@="45STNPWD%.6/'&#Z40.P _>@80E(!@']![
M!A"6@/"E@%X)Z%EE"E>L#@E6.!X(OD'"6&LVT[!B6K1VGS 3]QLE]"S1.!6/
MI.0IP0HDPFR&+CEA"MT"4RNAAX[037$>$,_0*%,@T%?\@*:"9T05B"]<2FUI
MYENI#A)0F-!#S?EQ/$4';]_X47AQB(HW(@Q=$4KU49 #5VG'S/;<M'1B7#@1
M/..$'Z KSM1"HO=L!K,Z@:L5J60)MK*,@U;&!-)C%/KO4. %0<.&)B^'^PWP
MY.5PK\6;L IR:/G"Y_B(3"F7.@XF3AEAF.E 42UZ<7&8!-03N![ 7S: ZVT
M?QA61!3D\F=3B(HM])JW8*ZO<[G$*0P=?3])$&MP8A-[[Z))WB[)DH[(:M+W
M*NE[;>SQS0(7JF.3/4=*9\_29@]R$:U2IU7Y)K&+12.[J+G:U_&1/J;K70F?
MFH1AW21I-:FYVZ_<[;>Z>[EW9G+([T TGI=6HO\]+UV2)1V1U02,*@&CUT_5
MJ$OINR1+.B*K27]227_R&JE:+-K?3=6]/)S\VR1Y:N(U9^IIY>UIJ[<[7^NV
M+&TE^=^CTB59TA%93;RS2KRSU\_2LRZE[Y(LZ8BL)KWO/?ZQ>J^1I^6JNU]#
M?R]/&TS":"]1FVSV/ZKNSO]Z#F)NZQZ)4KYBJOA'K4:KVFID*XJ]\;&IN6P=
M\$A3%&Q76,P)DXA"IBF]XQ-]=8BB!BHZBB]M57#'E:XQ;'.AZT80QD#/9YRK
M;<<L4%6B\5]02P,$%     @ FEEJ5EL$&=98 P  !0X  !H   !X;"]W;W)K
M<VAE971S+W-H965T,3(S+GAM;,5776_3,!3]*U:0T)#8\M6UW=9&6A<^]C Q
M,0$/B <ON6T,CEULMQW_GNLDRYHNC3:(X*6-G7N.?<Z]N;(G&ZE^Z S D+N<
M"SUU,F.6IZZKDPQRJH_D$@2^F4N54X-#M7#U4@%-"U#.W<#SAFY.F7"B23%W
MK:*)7!G.!%PKHE=Y3M6O&7"YF3J^<S_QD2TR8R?<:+*D"[@!\VEYK7#DUBPI
MRT%H)@51,)\ZY_YI['L64$1\9K#16\_$2KF5\H<=7*93Q[,[ @Z)L104_]9P
M 9Q;)MS'SXK4J=>TP.WG>_:WA7@4<TLU7$C^A:4FFSICAZ0PIRMN/LK->Z@$
M'5N^1')=_))-%>LY)%EI(_,*C#O(F2C_Z5UEQ!; '^X!!!4@V 4,]@#""A ^
M%3"H (/"F5)*X4-,#8TF2FZ(LM'(9A\*,PLTRF?"YOW&*'S+$&>B<ZUEPJ@!
M3:A(R7?)A"%K$&:E<.J0G*<ILPFBG%R*LLQLN@YB,)3Q5QCQ;G9-#EZ^\(?A
MV2M2_A,FR!7C'"/UQ#6X3;N8FU1;FI5;"O9LR0_(E10FT^2-2"%M$KBHKQ89
MW(N<!9V,,21')/1?D\ +@I8-73P=[K? XZ?#O0XU89VRL. +]_$QG7"I,4%$
MSG<S9I-('W+ZU8(),Y#K;VV9*%<:M*]D>\ZI7M($I@XV%0UJ#4YD4^R=M;G8
M)UG<$UG#X4'M\*"+/?I@,E DD3ER9[;'K=%#@6-H\[#D&A9<MLVNH\-QB'6R
MWO:F)2@,1\V@^''0R<BK8QI2CFLIQYU2;BC',C!RNR@>?^AMLCIYVQ- VJJB
M)Y[X[WD:!@YK X?=!F:T_-#HW&!1&'I'EDK.F2E]Q ]1HZ7V_7,-+M<]WBZ)
M8*=J'H>$X4[-#!_5S%9(0_&H5CSJ5'PIA%RS-<6&GY"O.>2WH%J;1R?-<YM'
MGV1Q3V0-^\:U?>-_UI['?3K<)UG<$UG#X9/:X9,>VW,GUS/ZV!_P[+>O)[*&
M?;[W<.;S_E-/JQ;>TXY*(Y\0$W<+>*Y![M;Y. >U*.X9&BMH)4QYBJQGZ[O,
M>7&"WYF?V3M.<>Y^H"DO2%=4+9C0A,,<*;VC$39M5=XYRH&1R^(4?BL-GNF+
MQPSO::!L +Z?2VGN!W:!^N87_0902P,$%     @ FEEJ5OQ@=ER1 P  #0X
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M7)W/@&N >KY@3.X&^@^:$U_\$U!+ P04    " ":66I6112PBJ #  "H#P
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ME:&Z-#K"U#7LH[SPD9*C'#82TKF/Y)9G=5E8-P2M=*'T0H4LN_3K5I;2P%2
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MD,DRLH(<L[-L""S[6P!1\BA7^0?)2?&I4DNH*)C J7BGU-??!RJHKD !<)X
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MJSOG^D+0K>XEGZF0G:D>9D!28 H@[Z\I%6\7Z@'M_R\6_P%02P,$%     @
MFEEJ5EG7GI)Y"P  MEP  !H   !X;"]W;W)K<VAE971S+W-H965T,3,P+GAM
M;+V<;X_;N!&'OPKA H<$J&.1DB@IV5T@NWMM4S2X(+FV+PY]H;6Y:_5DRR=I
M=Q.@'[Z4_&=$D1I)-NTW6=L9C7X:BO.,2(I7KUG^>[$4HB3?5^FZN)XLRW+S
M?C8KYDNQBHMWV4:LY?\\9ODJ+N77_&E6;'(1+^J#5NF,.0Z?K>)D/;FYJG_[
MDM]<9<]EFJS%EYP4SZM5G/^X%6GV>CVAD_T/7Y.G95G],+NYVL1/XILH_[GY
MDLMOLX.71;(2ZR+)UB07C]>3C_3]'76BZHC:Y%^)>"T:GTEU+0]9]GOUY=/B
M>N)4DD0JYF7E(Y9_7L2=2-/*E13RQ\[KY'#2ZL#FY[WWO]17+Z_F(2[$79;^
M.UF4R^M)."$+\1@_I^77[/5O8G=%?N5OGJ5%_2]YW=DZ$S)_+LILM3M8*E@E
MZ^W?^/LN$HT#*.\X@.T.8.T#O(X#W-T!;GVA6V7U9=W'97QSE6>O)*^LI;?J
M0QV;^FAY-<FZ:L=O92[_-Y''E3>_QM_C.IY3\FW;E"1[))^S%R$;JR3)FMR+
M1Y'G8D&D*?E8%*(L2+Q>D'\D\4.2)F4B"O+F7I1QDKZ57OYZ^X6\^>E/E+L?
MWI+MW\K+YR1-Y6F*JUDI55?GGLUW"F^W"EF'0LJDG'6Y+,C/ZX58J YF\G(/
MU\SVUWS+4(_W8OZ.N/3/A#F,&03=#3^<(G+<0Q.XM3^WP]_=,EX_R2#**"WV
ML2YEK--=@'^0-W$5]K?DM_BA*'-YY__'%,;M63SS6:I\\+[8Q'-Q/9$=OA#Y
MBYC<5.WC?#"%P)(S)2#>(2 >YOWF8TDH^7N\?J[N1CW(VZO=NN"UBRI9O=Q0
MSF5KOC2O0C?B87"P4<3Y!W$^*N[G[_.ZO4B\^*_LGE4O,=[46R]^X]13ZK3U
M&8Q<;M;'#_HXJN].WCY).7LC5>9/XBTI,U*4<;GMSK)KS[.5;+)EE8E?A+SG
MY'=ATL\U:<RA+?FZS=0+S?*#@_P ;_OY'\])D50IJ9C=)\4F*^+4&.# </+(
M;RDT&%&SP/ @,$0%?OTI7FT^W)-Y'>>"/)>RCQ9U#C6I#'4! 6^)U&W\CBA&
M!Y$1*O+7/%X7,I54#1YO4_92I LBN4]D/,6,+!*929*'YR[=D:;)95&[_5$1
M1R8)Z@"YG+XTX5*)I[E8/<A+[4CFMSLO2GA='K4NQ6"EY!-58X.N%-7X3?9"
M0;+-MF21U(Q?XWQ!ZG),IOS?5K5V8SK'/8_-Y[:\J7%@$ =V$<;M3F,K*):\
MJ4$![E.4HL,XM_/1O#&U?FBPX4['K0L0ICB%AX)NYT;I.6U]NDF7/, PQ3EL
MBW/4!&KM G0CVL$1"J"F.*F'HX[JH'7:"C$352"@F.(L'HDZJL-64XF9J"J!
MQQ0'\NFLHP9(MRLU7,2QJ0)X3G&@#V6=CFT_:%^);A-UW,L,6,QP%M_))[1$
M)@O9]^3'(EF(?/M8B1$.]SDVF=ORID8 2,_H10C'K&+?EC<U*(!]AA)T&.%V
M/IHW9.BW,X?)R',[;EL@,,,)/)1Q3 >L)A S4>4!@AF.8%N,8QA_=_('(YH!
MHAF.Z.& 8SI?-8&8B2H0",QP H\$'.O',&JBJ@0,,QS#IP..]9,9UW!LH@"(
M,QSB _G&=%)'41O5!J-F/E$5 H$93N!/ZU)FBN0A%?M&0-%FZ=%X=T7G>-!V
M >ZN<YD!2JN\M^5-#0KPWL6?[ >A;>=#'> +M,<+HUD4=HP^N(!?%\?O4+RY
M.ERGC'MME08KKZ-R=!N#WSB";3'.[4<T:J+*!T2[/6/5@QGGZH2=<K==G1NL
MNC0"AUV<PR,QY_;#&#5150*,71S&IV/.U>'K<JY%&)5Q;-X FKL] ]S#2.<:
M1JY#VAZU-%DI^445"3AV>W \GXNT>H23F7X>;Y(R3DF<IMEKO)[W#%OBGD<G
M^7,\=KL ?3>Z#/FLE@.VO*F3<U .>+WC[@.FY_3Q]"G3P&>TBCIFP#Q@LX>S
M>2CW/ -W6;N/&8QHQQRB!V3V<#+;HIZG,[F=JU$353Y V^L9N1Y,/4]G[E2[
M"W2;CB=[KS&%C'-Y)/.\_B=DU$15"63V<#*?SCQ/)[$^"XZ*.#9? -B]GG'N
M8<3S#+/)VN"ER8AU\<X#*'L]C]A53L]D ^!LP[V,3>.VO*G7#(SWPHNPS;,*
M?%O>U*  \+W><?8!;--'T*FGC5B:K)RN:3D?Z.OC]!V\_D1':WO=@<&D:W6$
M#^SU<?;:(INO8]?3EL_H-EWQ!3+[/4/6@]'FZV#5'C8,-ET* ;X^#M^1://[
M'XQ1$U4E -C' 7PZVGS# W/85HZ*.#)=^(VU8#TCW,/0YANFCSEOET$F*Z]K
MX-('_/HX?G\IEU*:[(";+*^RVB)YE,TB>A_D<+=C\[HM;VH0 /!^<!'8^58K
M %O>U*! !>#W#KKWP\[71].I[[?'!DU6U/$Z[EW L8_C>##L#*SE6I;3C3HZ
M%P<:\YYY;UNK+4TH;N/.8$1Y1XPY )OW#&0/!A[7<:NM93383+LD I,YSN21
MQ..&@6I=J&[4M>J2 YHYCN;3H<<-S\M,JRUQ&4<F#@YLY[T+M(=@CQM6AG&M
MB#-9-1.,JA'0S'$T_Y(G3\DZ/BR\S,6+R&4;5$TS'H;XR<;F?5O>U- T5HCS
MB\"06ZT0;'E3@P(5 L>'  R9?)NN(:$;8Z"/P(=ANTHU&%''Z9C>X\!OCO/[
M^%N<_(^<L#(9ES6ZW<_QQ,^AQ."7&>+G5H?X;7E3W\& LB887=8,Z0R!:3B_
MG>\-1JRC#@N@B GP(N:DKG#4XD5<T-CVMN5-#1\46,%EEN<'5I?GV_*F!@6*
MN6#TRH1!G4"OX*A6]!B,.N:4 JC* KPJ.ZD/C%O>A"L9W<[G&,0)H%(,_,O<
M_%9K1%O>U*! C1B,?HUPT,VOS\]0UG[T,ABYM*,:"AHO#N(%W$FW_PD+'G!9
MHYO]'$-" 924P64FA0*K):(M;VI0H$0,\%&H8_N"85!*KX9T(^Z;NT((Y5N(
MEV\G=86!<Z&XA+$M;,N;&C H'\/+O+P16BT*;7E3@P)%83AZC<J0VS[4!]::
M(\&[2].-W*ZWD$*HV$*\8COIOC]VG@37-+K-SS&R%T(-&7J7Z0A6"T1;WM2@
M0($8CG[5=%!',,SG1>V17(,1<SMJH1"JMQ"OWKYL-]K9;M22U3?V)BO*J;RY
MT^Q'/3GQ(-;B,>FI\_'3C&[&<XSPA5 @AI>9 PRM%GRVO*E!:>QF86$.,-1G
M][BGW<F&UVZ"CF'\$&JOT,X,8&BHHS3HZ#;3KJ6<$11;T66F "/#[%[8+A<-
M1E/&.E9+1E#_1+;F "-LR<U.X^!5.1'4(I'5&<"H?UDL:J*JA/HC.O?T7V28
M_M,FLG$51Z:,"&J$R,KL7Z3/ZP51NTL:C)J9154(P(YP8!^#OZH"M#IEB&L<
MBPE;WM2(0D$176;*,+):4-CRI@8%"HKH+%.&D>FE'2W1ZT8=KT5$P/H(9_VG
MM6P8\I1GSQNRR3-Y^^,WL-4Q'%O>U&MO;(AUF6F^R.HTGRUOK1VTFEMH67B7
M9^]$?>U:WT'+4, XK*,"I$YC#RW'SNL\>S_JXB-M#QJ#54?7DO(;(B_S1L_^
M/.@V.JA-ZQ(:VU$YMM[JV7O"10Y>54R=QJY4CM47>_;N<*6#7^VA3F.#*N?<
M+_?LSZ ^L=#V\I(>(4>GD<9.5HZ55WSV;M048<@DNEDSW[1D-O:S<G!@(P"T
M7O[U:!F]59TM=ZW@-;;9<BXS-;0_C[7 G&5G+J>Q-9=SENFAO=OF[K3,U_NV
M;C5UVR/EL\8&T"LA553[8A>2.<_K<KLO\N'7P^;;'^L=IUN_WU:;<M<;2X.;
M[8[>G^7%)?*1*A6/TJ7SKIJ?SK=[9&^_E-FFWF;Z(2O+;%5_7(IX(?+*0/[_
M8Y:5^R_5"0Y;E=_\'U!+ P04    " ":66I6X.9O5IX"  #G!P  &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q,S$N>&ULK55;3]LP&/TK5B9-( UR:T(':20@
MVN6!J0*V/4Q[<-,OK8<39[9[V;_?9R>-2ANJ"O'2^'+.\7>.73M9"?FDY@":
MK$M>J9$SU[J^=%V5SZ&DZES44.%,(61)-7;ES%6U!#JUI)*[@>?%;DE9Y:2)
M'1O+-!$+S5D%8TG4HBRI_'<#7*Q&CN]L!N[9;*[-@)LF-9W! ^CO]5ABS^U4
MIJR$2C%1$0G%R+GV+[/(X"W@!X.5VFH3XV0BQ)/I?)V.',\4!!QR;10H?I9P
M"YP;(2SC;ZOI=$L:XG9[H_[)>D<O$ZK@5O"?;*KG(V?HD"D4=,'UO5A]@=:/
M+3 77-E?LFJP%PC.%TJ+LB5C!26KFB]=MSEL$?S!"X2@)03'$L*6$!Y+&+2$
M@4VFL6)SR*BF:2+%BDB#1C73L&%:-MIGE=GV!RUQEB%/IX]T3>T&G)&'9N>)
M*,@W/&\9%" E3 E"R+52.'22@::,GR+X\\V8G+Q_Y\?AU2EIOH15Y(YQCFHJ
M<3469Y9P\[:0FZ:0X(5",LC/2>A_(($7!#WTV^/I?@\].Y[N/:>[F&@7:]#%
M&EB]\ 6]._I'2)*+LA855%J94#7F"&O\ORH@)ZS"23@EO^A$:8FG_W=?9,TB
M@_Y%S(UPJ6J:P\C!O[P"N00G-7OA7?4%^)9BV1N)/0LW[,(-#ZFGW<DTB5)S
M,GO/6R,26Q%S^RW3*(Z&B;O<#J4'%/@[H.Q@.:\T.^C,#HXWRQF=,,XT@U['
MC5*T9>8L&'[<<=P#"J,HWK%\L*A76HXZR]%!RX]"4][G+]K?K##>];</\N,X
MV+&W#XJ'%QVFJ=K=NE7-$WA'Y8Q5BG HD.6=7Z"(;)Z5IJ-%;2_:B=!X;=OF
M'%]BD : \X40>M,Q=W?WMJ?_ 5!+ P04    " ":66I6@@U8*BT$  "@$P
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M%F@$TAJ8]VLA]/.#_4!Q*+?\%U!+ P04    " ":66I6'9J);SP#  !%"P
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M66S\K<,? CMY,$8FDA7G#V;RLY@YGA$$%')E&+#^;.$&*#5$6L;?CM/IMS3
MP_&>_;N-7<>RPA)N.+TGA2IGSM1!!:QQ0]4=W_V +IZ)X<LYE?87[3I?ST%Y
M(Q6O.K!64!'6?O%CEX<#@!^?  0=(!@"HA. L .$KP5$'2"RF6E#L7G(L,)I
M(O@.">.MV<S )M.B=?B$F6-?*J%7B<:I]!L6C+"-1#7HRU!B >@S6NK+5304
M$%^C7TVU B'-<&F6)>HA"PVQ-O0A X4)_:BQLG7J/H2A6T*I/F&9N$KK-;NZ
M>:=MWFH+3FCS W3+F2KUEJR XIC U8'VT0;[:.?!6<8,\@L4^I]0X 7!B*";
MU\/]$7CV>KAW)IJP/[O0\H4G^.[MI88"X2T(_481LV=ECNHY_43*!L9RWW)'
MX]RFVES)&N<P<W0YD2"VX*3OW_FQ]W4L;V])EKT1V5%.HSZGT3GV=(XER<?2
MU<(F%F9JZ3:-O"!.W.UA&L:<O/#8*7OI%%Y._=[I2/:DESTY*SLCM+%U5#>"
M[AGSVA@DPDQ?D!T6Q>@+G+P0,YD.@GKI$ET.0CKK<A10W <4_S^@X9MO)<<C
M29Y& ]%C3I-@('O,*?0&PMV#XEJ!V-@F)5'.&Z;:RM-;^SYX;<O_P#[7_;%M
M9\\T;7.]Q6)#]%%16&M*[^*+EB3:AM5.%*]M"5]QI1N"'9:ZQX,P#GI]S;G:
M3\P&_;^&]!]02P,$%     @ FEEJ5C)URV;)!   IQP  !H   !X;"]W;W)K
M<VAE971S+W-H965T,3,U+GAM;+5976^C.!3]*Q8KK5II-F 32-))(K5ENSLC
M55NU,[L/HWUPP4FL 9RUG63FWZ^!! (XA"KN2\/'N2?W'L/)43W=,?Y=K B1
MX$<2IV)FK:1<W]BV"%<DP6+ UB15=Q:,)UBJ4[ZTQ9H3'.5%26PCQ_'M!-/4
MFD_S:T]\/F4;&=.4/'$@-DF"^<\[$K/=S(+6X<(S7:YD=L&>3]=X25Z(_+I^
MXNK,+EDBFI!44)8"3A8SZQ;>!,C+"G+$WY3LQ-$QR$9Y9>Q[=O(IFEE.UA&)
M22@S"JP^MN2>Q''&I/KX;T]JE=^9%1X?']@?\N'5,*]8D'L6_T,CN9I98PM$
M9($WL7QFNS_)?J"\P9#%(O\+=GNL8X%P(R1+]L6J@X2FQ2?^L1?BJ #Z)PK0
MO@#U+7#W!6[?@N&^8)@K4XR2ZQ!@B>=3SG: 9VC%EAWD8N;5:GR:9NO^(KFZ
M2U6=G =T2R.21@+\!EZ*M0=L 3ZEDG":@ >:XC2D. ;/9,VXI.D27 5$8AI?
MJXH_[I[ U:^_0-_]> V*3V #L<*<"$!3\#6E4GPXW%$7'FD<J^464UNJYK,6
M['#?Z%W1*#K1*$3@D:5R)<#O:42B.H&MIBY'1X?1[U G8T#" 7#A!X <A#0-
MW?<OAYKRH'^YTS&-6RZDF_.Y)Q=2A#$3&TZR]8O*9?V6 0&5)!'_ZE0O6(=Z
MULQU;L0:AV1F*5L1A&^)-<^6T_FH4\PD66"(K*;FL%1SV,5>OA9@37CQ/(,K
M9;4AN=9I6' I;\G(,J?=SIV!#Y$WM;?'\A0X_P@&ZXB@"U$;Q"L'\3H'^<*D
M>GD/CX.N>:_UE6CHCQN=MT%#!S:;;X/<R7BB[]\O^_<[^W^@7$CE'(4=?4M(
M\DJX]D'NY'GK@VR2+#!$5M-O5.HW>A=;&)E4TR198(BLIN:X5'/<^30^81K9
M:_P3O\9$IUIW]>=-/ # 49Y_\B>G%\&X(-#^Z/0BF!0$73\[DU*1B4&C++A&
M-9^$HZ9-3G1VBMPF+CB/JXT$G2H3.1>:YI[@V.M&SK QAP8T\9JFJ0,-_1,3
M'*4ZV#G!"PF96I0^OMG-]-97W2A;8(JMKB*J5$3O8IY[6E.2FF0+3+'5):U2
M*NR,;6<=]$SY7Z',#,SOL-!^#*,.#^W',#YOHK"*F]!DWH3:P G]5N#4 S56
MV@-8GZS*G_#2  K;N='W6E[:!FF\5 ,ZZ:55 H7=$?3+BO*>5FHT@QIE"TRQ
MU46L8BA\GQP*C091HVR!*;:ZI%46A9>%T3/EGW$Z ! 5+N9JU>I#X)ZVXJ 7
MP5#KQ'5-JC0*3<91J$V0L&6/]WJ@SD??F$E1E4G1I9D4M9.DYS4GT8 F'FI,
MH0.=\E%495+4G4D?V(;+52\C[69ZZUMOE"TPQ597L<JDZ'TR*3*:28VR!:;8
MZI)6F11=EDG/E-^N>>6#6B/M0U!&4JV3]F/0_V.@KDH529')2(KTD;1MI7H@
M&K>LM >P/ED52=&ED12U@Z3&2ML@"+U1<PPMJOE?7?MH!R<A?)GOA D0LDTJ
MBQV-\FJYVW:;[S$UKM_!FZ#8,ZMHBBV\1\R7-!4@)@M%Z0Q&JC%>[(H5)Y*M
M\WVB5R8E2_+#%<$1X1E W5\P)@\GV1>4>Y/S_P%02P,$%     @ FEEJ5IG7
M78%Y @  E@4  !H   !X;"]W;W)K<VAE971S+W-H965T,3,V+GAM;)64;4_;
M,!#'O\HIDR8F#?)0RB9((U$Z-EX@5:!M+Q OW.3:6/@ALR\M?/O93AJZK53:
MF\9GW_W]NW/O\HTV3[9&)'B60ME)5!,UYW%LRQHELR>Z0>5.EMI(1LXTJ]@V
M!ED5@J2(LR0YBR7C*BKRL#<W1:Y;$ESAW(!MI63F98I";R91&FTW[OBJ)K\1
M%WG#5GB/]+V9&V?%@TK%)2K+M0*#RTETF9Y/Q]X_./S@N+$[:_"9++1^\L9-
M-8D2#X0"2_(*S'W6>(5">"&'\:O7C(8K?>#N>JM^'7)WN2R8Q2LM?O**ZDGT
M.8(*EZP5=*<WW[#/)P"66MCP"YO>-XF@;"UIV0<[ LE5]V7/?1UV K+LC8"L
M#\@"=W=1H)PQ8D5N] :,]W9J?A%2#=$.CBO_*/=DW"EW<53,^)I7J"H+QW#?
M/0SH)=PH0L,E7'/%5,F9@#MLM"&N5G T0V)<?("C.3.HJ$;B)7/V,5SKUE ]
M1#](E LTC_#^77HVN@"NX)8+X5[#YC$Y>L\0ESWIM"/-WB =P:UVEUGXHBJL
M_HR/7=9#ZMDV]6EV4'"&Y0F,TH^0)5D*7Z=S..HX/QP0'PUU'07QT9MUM:70
MMC7HR_E:Y0?O")Q0VL=]->A43_>K^@X]MPTK<1*Y%K1HUA@5'CJY.,!\.C"?
M'E(OYD:O>>@VU^Q0]<S0L!>V$+B/MM,["WJ^_==%FHZS/%[OH1@/%..#%)=5
MQ7W#NO]<\]] XW^ QG_1Q#N](M&LPD2P4.I64=<VP^XP="Z[7GMU[R;6+3,K
MKBP(7+K0Y.23N]UT4Z S2#>A\Q::7!^'9>T&)QKOX,Z76M/6\!<,H[CX#5!+
M P04    " ":66I6FTRHNVX#  "Q"   &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q,S<N>&ULM59M;],P$/XKIR AD$;3IFN+1EMIW1A,:-*T\O(!\<&-+XV%
M8P?[TK)_S]GILB*Z(B'QI8GMN^=Y[L6]3+?6??<E(L'/2AL_2TJB^BQ-?5YB
M)7S/UFCXI+"N$L1+MTY][5#(Z%3I-.OWQVDEE$GFT[AWZ^93VY!6!F\=^*:J
MA+M?H+;;63)('C;NU+JDL)'.I[58XQ+I4WWK>)5V*%)5:+RR!AP6L^1\<+:8
M!/MH\%GAUN^]0XAD9>WWL+B6LZ0?!*'&G *"X,<&+U#K ,0R?NPPDXXR..Z_
M/Z!?Q=@YEI7P>&'U%R6IG"6O$Y!8B$;3G=V^QUT\HX"76^WC+VQ;V\EI GGC
MR58[9U90*=,^Q<]='O8<7O>?<,AV#EG4W1)%E9>"Q'SJ[!9<L&:T\!)#C=XL
M3IE0E"4Y/E7L1_-+M5$2C?3P"LZE5"%50L.U:>L=$O?B$DDH_1*>/QN,AV]
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MN56QY75GJQ>25:;6SYE4G<-,<_4S %P;J/,%8W*[T!>TOQ?Q?U!+ P04
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M#K+U%=GZ--GV_58MDG=V'+"Z8U(@7T-;--+C0!%N0!/N$(0+(-YZYC*.R(C
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MFJS3HA&H__T^SZO3#\T-GO/BUX/9M_\'4$L#!!0    ( )I9:E;P/:18W@<
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MP^+CEKD>2_( _OLZCK/GC7P'U2NYB_\!4$L#!!0    ( )I9:E;?FLH"S0,
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M>Y6\[9+CA<".Q#EOQ3GO0R>Q+3>BVFM!MU%8H/=M(7@!M1+N)QLTVZ!A2XG
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MPH)EPES+]4<H"9U8O$ *G?\GZW*L-R!!IHV,2V/T(.9)\<GNRT#L8D!+ _K
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MC5]!$B5)3T+7O^X>GTDG[=1./5YZ"H^;0BBSU@AJ2=7FE,3R0%^VH%ZCG>Y
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M2(T>LC+%SK$]<7 /(NEP#P*P,=V#2#BX)T/O023ZN@1*0RTXX+9$8+JEGG#
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MMD&"M@]!'VAI;!%+D2Y)V^G?EZ1DV9)EM2E4("^62,T<G3F<D8><[+GX)C,
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MDV#]5.3?B&HC]5%-Q;6K>CTD(M7;>/^(NL[8FI?(;UZZ7-1O[IX*9KQ:!]T
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MT8!TQ**UZUUFB[K*MNNZX60"<_(ICP;$9>6QO2SGB0D']L(<7%-;S8:!"<S
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M5Q+>P2P,F=&.QKJC=(!1\LTE*LKBM_#C#Z3?>0\LA06+8]TEQZ[2H$QJ-Z@
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M%>$QT4+^A2LD-A_BJN,13(C&A35H*HS&()Z;""V!5?0^*?4^>8W".&E3CY;
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M2X-]T@T+_).!L@'X?BFE>9[89MG]&[._4$L#!!0    ( )I9:E:5)H1OS@(
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MNU[!KF=D]_%P8)K8[2#\RH.QZP8'[)J"@A/L_(*=?X9VC0W4Q-,_HM!W?.^
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M7VG =]NQNPO)5MF.YHQ)R9+L= EJ@+@.4/_/&9/["[U)6FR*C_\#4$L#!!0
M   ( )I9:E90##1<[@(   L)   :    >&PO=V]R:W-H965T<R]S:&5E=#$V
M,"YX;6RMEEMOFS 4Q[^*Q:2IE;9R"R1I$Z0VW:4/5:-VEX=I#PZ<!%2#F>TD
M[;??,5!$B</ZL!? </['OW.QS6S/Q:-, 11YREDAYU:J5'ENVS).(:?RC)=0
MX)<U%SE5.!0;6Y8":%*)<F9[CA/:.<T**YI5[Y8BFO&M8ED!2T'D-L^I>+X"
MQO=SR[5>7MQGFU3I%W8T*^D&'D!]+Y<"1W;K)<ER*&3&"R)@/;<NW?/%5-M7
M!C\RV,O.,]&1K#A_U(.;9&XY&@@8Q$I[H'C;P0(8TXX0XT_CTVJGU,+N\XOW
MSU7L&,N*2EAP]C-+5#JW)A9)8$VW3-WS_5=HX@FTOY@S65W)OK%U+!)OI>)Y
M(T:"/"OJ.WUJ\M 1N*,C J\1>&\5^(W KP*MR:JPKJFBT4SP/1':&KWIARHW
ME1JCR0I=Q0<E\&N&.A5]$S0!0HN$W*D4!+F'&+(=73&0Y"-YJ&M+^)H,&9Y<
M@Z(9.T7%EZLE.7G_S@W]BU-2WTE6D-N,,:R:G-D*H?74=MP 7M6 WA' :XC/
MB.]^()[C>0;YXNUR][7<QE2U^?+:?'F5/_^?^>)5&D0G#;_H2BJ!C?G;%&;M
M=V3VJQ?KN2QI#',+5Z,$L0,KTOES+DQ!_R=GKU+@MRGPA[PW*>@$_H$4N-U@
MCS N):$,=P9:Q&!*0NTYK#SK#687!:, R[KK!G=H%'JCL#5Z!3UJH4>#T)=Q
M++:08"_&/#>BU?J@,ZL[[8$93#PS5M!B!8-82P$E?<9=41F71G PH3_R>U &
M&S<P4X4M53A(=5,HP+Y1G2*;Z,*#F?N5/+3PS63CEFP\2/8I+QE_!L!6HX6L
MUB%-=KK;C/D;'Q;,[2$:3"9FQDG+.!EDO.MO#":RB:&5O+#'9C(*CRR$:4LW
M'5Z]7%%&U/%MS$0[/5B18R?H-Z+!:!(Z/5J[<U3IWX1;*C895I+!&F7.V1BC
M%?716P\4+ZO3:\45GH758XI_*R"T 7Y?<ZY>!OI ;/]_HK]02P,$%     @
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M[>*II0\\]!.S,EE&Q;GY="=Z2LX!/,N'+W4^?6E0BX?/F8C"1-_'0K^X\SJ
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MDBC[N"/^AJ0B@'^_33A+Q8%HH'P?:_8O4$L#!!0    ( )I9:E;PLFBQ(!
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MB$]%U1:0[\_*LOG^HFW@J:R^=)M]\S]02P,$%     @ FEEJ5HE0>]YD P
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M*J1>*W2)F[N,VZO C4U6P<16<PWV>L,D-6NF.!-U#DM3^>+K1\L&[PWF^L'
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M,AWC\[<.QN>#6XZNHM -A@?='&YK#K=6#F^?<[5UJR+)*Q-PG,O.F;OM'$.
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M2<G2XG(') :N ]3O&\;D\4:_H#ZXGO\'4$L#!!0    ( )I9:E;]#=!H]0D
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M+"\#Q-^7F6"I_E*>8/\RFZM_ 5!+ P04    " ":66I6NK<9$\8#  !*$P
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M8%"F)#A#A'$])@B&]+XUA6 8A=02D=(8V*TQQLYOL:D1SAA#^@07@/%8KZP
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M "#;')8I0<G<@G*<@<( 21GK[BD$HOJD' )9:]G!.02WICS6/6'0XB\WF@N
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MBKH#R+_?5U7[\J6[P/X=I+/_ 5!+ P04    " ":66I6RD;B:C83  #0IP
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M?$D;VTSPIL(<JK-&G@IP1(N%9,X!JB!K"A*E"X\7@H44TUB(W4TH*&T ?@]
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MXEGQ4\]XIDR8%_3S&>=J?6$4U.?F)O\!4$L#!!0    ( )I9:E9RZ3M\U0,
M  41   :    >&PO=V]R:W-H965T<R]S:&5E=#$X-RYX;6RU6-MNXS80_15"
M!8I=H(U$R7;BK&T@=GI9H$&-!&T?%GV@I9'%KB2J)&7O_GV'E"+?%'83V'ZP
M18ISR'-FAAQZLA7RL\H -/E2Y*6:>IG6U:WOJSB#@JDK44&);U(A"Z:Q*=>^
MJB2PQ!H5N1\&P<@O&"^]V<3V+>5L(FJ=\Q*6DJBZ*)C\.H=<;*<>]9X['ODZ
MTZ;#GTTJMH8GT']42XDMOT-)> &EXJ(D$M*I=T=O%W1D#.R(/SELU=XS,516
M0GPVC8_)U O,BB"'6!L(AC\;6$">&R1<Q[\MJ-?-:0SWGY_1?[;DD<R**5B(
M_"^>Z&SJW7@D@935N7X4VU^A)30T>+'(E?TFVV;L"&>,:Z5%T1ICN^!E\\N^
MM$+L&2#1?H.P-0B/#08O&$2M062)-BNSM.Z99K.)%%LBS6A$,P]6&VN-;'AI
MW/BD);[E:*=GO^L,)*FDV'#C&45^)'=)PHW$+"<?RR90C.#O[D$SGK_'$;_,
ME^3=]]_14?3A_<37N P#YL?ME/-FRO"%*6E('D2I,T5^*A-(#@%\7']'(GPF
M,0^=B/<07Y&(_D#"( Q[%K3X=G/J6$[4:1I9O.@E/*[B7*A: A$I$<<*?S+C
M"==0J+_[U&O !_W@)JUO5<5BF'J8MPKD!KR9\47PH8_YF< .=!AT.@Q<Z%8'
M49>:8/2@"'L:]-%NL$86RVP^FUD4V,_$W^PS<L[Y1D;#CM'0R>@I$U(3#;(@
M.:PQ09!2#)#P<MW+J4$;[G&BXZ"7E7/>-[(:=:Q&3E:_'5,AK$S:N$VXJFH-
M:N<\ DISW!..,[=A[)SIM<$[.@F)P9%X!WRO.[[73K[+]A1B]1H/)&VW-^0L
MD5ZY)JD4!5&:I2D>4TE=)JR,.?2Z]_K$O:->YSJ7\T;GWG1D;_XO"=DJAX1
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M=8#Z?I/G\LN;*L'IP2RW_P-02P,$%     @ FEEJ5I-!3YC!!@  ="P  !H
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M J_>N&/'F!B,@3;CB<6=8U+\I+(F>P_P,\9G+4UET8TJ7T1N>WY554H[6L0
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M0ELL4J")+HXO26T#<:1N6VP61H-F'XH^T-+8)DJ)7I*V$V _OJ2DR*:CJ%9
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MJ[F.7K1WHG:@>&VO%5NN]"7%OI;Z'@G"&.C_]YRKAX&YJ?0WT_Q_4$L#!!0
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M N9X2R6. $Y"D-]9<!+370QN5BNV2R3X ![RF0'8&IP*N@B(Q#2Z5%&_W2[
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M8+524H#Z?<V8?+E('U >G,_^!U!+ P04    " ":66I6/F_D)FD$  !I%P
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q.3<N>&ULQ9A=CZ,V%(;_BD6E52MM
M X9\S6P2:3;3U6ZE=J.=;7NQZH4#)XFU!E/;)#-2?WQM8"!,B#6I/)J;!+#/
MBY_#,;SV[,#%=[D#4.@^99F<>SNE\FO?E_$.4B('/(=,MVRX2(G2IV+KRUP
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M1>I7NJG2<>,#F&YGKRL/8+S]!5J;P1O]Z93^=&K]^<;H242$Y&2ZDG@: TJ
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MM0AH-35OG( 5QK3E"Y1 \_7 +9+_37%#!))#ISKG]MJ7FGOU%OKRUD144_.
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MOUR+:"&*RD#]_S+/Y>N;:H+#TR'O_@]02P,$%     @ FEEJ5@=HUC)1!P
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M0A7C9+PP]]%ZN#OR)F:4 R;T0IA0!4,E3<; UFERY$U,$T=6Z(U9X7'0:NZ
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MK@**:>7TBEW3*];1:R"OTQHK!6&F&B,!841-G%ZQF5XG4;D"GQ+6[ N=+]G
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M:P/V_2+/J^</=8#MHY+C_P%02P,$%     @ FEEJ5OB]=0B[ P  (!   !H
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M ?'V(\MVM!QHL2L:M+70V.X5KU@_\)YF#/![(H1^')@%ZC\%@I]02P,$%
M  @ FEEJ5I"4/[=O"   'S,  !H   !X;"]W;W)K<VAE971S+W-H965T,C T
M+GAM;+V;6W/CMA7'OPI&G>GLSM0KXL+;QM9,+#:;M+.I)VZW#YD^4!)DL4L1
M*@C9FV]?D)0%"3B$+J'S8HO2P<'Y'X#@#X?D[8N07^L5YPI]6Y=5?3=:*;7Y
M.![7\Q5?Y_4'L>&5_F4IY#I7^E ^C>N-Y/FB;;0NQR0(HO$Z+ZK1Y+;][D%.
M;L56E47%'R2JM^MU+G^[YZ5XN1OAT>L7OQ1/*]5\,9[<;O(G_LC5OS8/4A^-
M]UX6Q9I7=2$J)/GR;O0]_IBQM&G06GPI^$M]\!DU4F9"?&T.?EK<C8(F(E[R
MN6I<Y/K?,Y_RLFP\Z3C^MW,ZVO?9-#S\_.K]AU:\%C/+:SX5Y;^+A5K=C9(1
M6O!EOBW5+^+E1[X3%#;^YJ*LV[_H96<;C-!\6RNQWC76$:R+JON??]LEXJ !
MCGH:D%T#8C=@/0WHK@$]MP';-6!M9CHI;1ZR7.636RE>D&RLM;?F0YO,MK66
M7U3-N#\JJ7\M=#LU^5E4-W-1*2E*_=,3*BK%):]5C6[08SL7BIHOT ]%E5?S
M(B_13U4WV9I!$TOTI2B^H!]Y7JK5/)<<?9)BNT%YM4"?'O^.IJ+2$XK+0XN_
M"=T'^L(KM=5'[S*N\J)\K[O[=/^ WOWY3SBBW[U'W7\=#OI<Z,BTG]NQTGJ;
MJ,?SG;;[3AOIT88)^JREK6KTUVK!%\<.QCI1^VR1UVS=$Z_'C,\_((K_@DA
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M )L@A)7AP!!)<'H5V4JI"0'E=<T5?.D/G+YI2F-;!6 6!8RDEA!_2%<N$?@
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M7/)<@]]8DV#[J=EEM;*;!W%F>?45-5N3A=1X7[_NP)H=-BBZZRTZOL;:D@'
MHLXZ!52W#K<*Q\]5&&YB)[CI]:&BKKZ%V@+7?]NGBIYW3Q7YREU^[Y<68P;U
ME@WE[3BS!M+8'U+N8H.6NP;UE@WE[3C#A@V9GPV'+8OX.[LXT<!=URBP2]8[
MJ\/E(0IIWTEM )*=#Y#]<.%W<K%@H#R6 @]*O<EC9 ?/D?D1\_0VT>_@XJRX
M%!J2T-YO#-7G<5(,@[)S;K)Z4C(0-^Y2XL*J)CDW)V\!J\S *O/#ZIG[3K^7
MBU/C@ND-(]1FGZ$Z/4Z-X5QV@G//WY[Z/5V<'@!K:>R0TE"='J?'4#([I[9X
M*C%>'Q<G!H#A.(V=4VJ@3H\38]":G;Y3[%ED!JH?[C+B<C>)G'LZV5"==AD9
M'[PYH)'ZJ7T#HT9SL:U4]UC\_MO]6Q[?M^\V6-_?XX]9]ZZ&<=.].O(YET]%
M5:.2+[7+X$.LQUQV;V-T!TILVO<39D(IL6X_:K)?<-D8Z-^70JC7@Z:#_3LQ
MD_\#4$L#!!0    ( )I9:E9LL)EK200   87   :    >&PO=V]R:W-H965T
M<R]S:&5E=#(P-2YX;6R]F&UOVS80Q[_*00N&%&@M47Z(D]H&$FO9,B2 E[3=
MBV(O:.EL$Y5$E:3M%-B'+RDYLN0J2@P0\0M+E'@_\OX4'^Y&6RZ^R16B@L<D
M3N7862F57;BN#%>84-GA&:;ZS8*+A"I=%$M79@)IE!LEL>M[WL!-*$N=R2A_
M-A.3$5^KF*4X$R#724+%CRN,^7;L$.?IP3U;KI1YX$Y&&5WB ZK/V4SHDEM2
M(I9@*AE/0>!B[%R2BX"<&8.\QA>&6UFY!^/*G/-OIG 3C1W/] AC#)5!4'W9
MX!3CV)!T/[[OH$[9IC&LWC_1KW/GM3-S*G'*XW]9I%9C9^A A NZCM4]W_Z%
M.X?ZAA?R6.;_L-W5]1P(UU+Q9&>L>Y"PM+C2QYT0%0/??\; WQGXKS7H[@RZ
MKS7H[0QZN3*%*[D. 55T,A)\"\+4UC1SDXN96VOW66K&_4$)_99I.S6YQY@J
MC&!&A?H!GP1-)<U'1,('N(PB9NYI##=I\8V9L3H-4%$6OX/??R.#[D=@*=RQ
M.#9&[^&D6ARY2O?1M.2&N_Y,B_[XS_2'^'#'4[62\$<:850'N-JYTD/_R<,K
MOY7X]SKM@#]X#[Y'SN'S0P"G)^^:.M:."3#L0)<8C._#GU<S."W<;V(%KV>1
M%E;-WVXYHMT<WGL&?H<1"Q\9?,%4K05*N(%;EK"G04Y1P-<$DSF*_QIZ?M4*
M-ZO0A<QHB&-'+S,2Q0:=B>F[][%)4INPP!*L)FJO%+67T[O/C1B38<REUA/X
M E1UFLQ1;1'-(EC,I$R+S+3L7PT#M.Z);!2Z9U-HF[# $JPF=+\4NM_Z]=YR
M+2WH#4HJFD8L739)UXHX5KH"-LAA9I?<3+R1NZGJ4=0@O4J57F=05JKY.2C]
M'+3Z>9.&/$%8")[H!7.#4NG-5#4YV\HYUMD"UJ]X,CAPMJA!_$J5?J??[.Q9
MZ>Q9J[.7&8]C#I]6*&B&:\5"";>WL]9UJ)5XK-LV88$E6$W)8:GD\*W7H:%-
MH6W" DNPFM#GI=#GEN9G*^=8_<Y_G7U>AQQ,44LMUG0AWO[ Z+VP0J?++><1
M7/.U/J()"=?Z"B],YW;HL3)9I06V:'5!*R=P\M9S>M>B+;5MT@);M+K:_EYM
MW]+$;@<=+:+_R];;/9C7MAJL*[./&TA[X/#/6M##/7K:/JFM!@M6:8$M6EW,
M?;Q WCQ@(%8C!JNTP!:MKO8^:" 6HH9VQM'Z-40%PT[7J_X.-^XF&^)USII/
MUV0?2Y#V8.)R*1#-,@;XJ(J<7*, +U RP6*3DN@W^FLS#@ELT>J"[>,1TAZ0
MW)0+/_!YS)9%7NM_.&F4K6"18674?-(Y")RF[4T>+9#5*,.M) @3%,L\T2HA
MU"<X5632RJ=E,O<R3V$>/)^:)&^>>-QCB@SQ'15+IB=AC N-U!^U_M9%D70M
M"HIG>1IRSI7B27Z[0JH/D*:"?K_@7#T53 -EZGOR$U!+ P04    " ":66I6
M!Z?>)[X;  !MRP$ &@   'AL+W=O<FMS:&5E=',O<VAE970R,#8N>&ULQ=UM
M<YM6PL;QK\*DG4YV9AM+Z+E-/9.8YX>33)/NOMBY7V )6]Q%X 7D-#O[X6^0
ML-&1R+&5^S_C-XTMB1^69:YRX.+P]DM>_%FNX[C2_MJD6?G;JW55W?UR<5$N
MU_$F*M_D=W%6/W.3%YNHJK\M;B_*NR*.5KN%-NF%/AA,+S91DKVZ?+M[[&-Q
M^3;?5FF2Q1\+K=QN-E'Q]7V<YE]^>S5\]?# [\GMNFH>N+A\>Q?=QI_BZH^[
MCT7]W<6CLDHV<58F>:85\<UOK]X-?Q'#P;198O>2?R3QE_+@:ZUY+]=Y_F?S
MC;OZ[=6@^9'B-%Y6C1'5_]S'5W&:-E3]@_R[55\]KK19\/#K!]W:O?OZW5Q'
M97R5I_],5M7ZMU?S5]HJOHFV:?5[_L6)VW<T:;QEGI:[_VI?VM<.7FG+;5GE
MFW;A^B?8)-G^W^BO]C=QL("N?V,!O5U ?^X"HW:!T7,7&+<+C(\6&"V^L<"D
M76#RW#5,VP6FSUU@UBXP>^X"\W:!^7,76+0++)Z[P'#P\,D-GKW(XX=]\FF/
MO[7(P\<]?/;G/7SXP(?/_L2'#Q_Y</>97^S_?'=_^T9419=OB_R+5C2OK[WF
MB]T&M%N^_I-/LF9C_U05];-)O5QU^6[Y[VU2)LUV5VI1MM*,I+S+RR@MM9\U
M?:#K?V_^.]P]57\QT*0%?M;>K5:[KZ-4<[-]]C2;\&LCKJ(D_9OVHW:AE>NH
MB$LMR;0_LJ0J_Z[]],-P,I_\^F;W[^S7YIDP2=.&W#TY'1T]U@G=8S\>?OOV
MHJI_&<U;NEBV;]S9OW']&V]\J&MAGE7K4C.S5;R2@8OZM_CXJ]0??I7O=:7X
M;GO[1AM.=K\P7;/??]1>[]_+WWI^NBNUY6W3VIH_SS*>80V&S[-,M15&7VNF
M_9OXXY.AO?Y1^HSW__2XEMK]%-^]T?3]^QT\]3/:3WP.=\7C^WW2<M26$2_?
M:*-G_N[<YUO#IRSO^=:3[]%76R*_KW_WX^>]Q^ <Z].[WW?6X<;>AX;G;%CM
M7UT/(\[9#GH9:;L?/4;H:.>.OO59).4RS<MM$6OY3;V?T01?O*K3J8O#Z+K>
MS]*NMV6]:%EJRWQSG63[I_[5<%I2Q9OR?WK>T_O]NL?]ZVYV!7\I[Z)E_-NK
M>E^OC(O[^-5E\^D-?NT+'1(S2,PD,8O$;!)S2,PE,8_$?!(+2"PD,0%A4NJ,
M'U-GK-(O[3Q??:GW?OHR0[GDN9E!8@:)F21FD9A-8LX>F^ZP9NQ^?SD;C*=O
M+^X/L^#T1</!9*++K_)Z7[68R:_RR9\^(+&0Q 2$25OOY''KG2BWWL]Y58^8
M[HK\)JFT>B]@U8ZZ^K9FI73NUDQB!HF9)&:1F$UB#HFY).;ML<E!..BSQ>0H
M&\@U!B06DIB ,"D;IH_9,%5FP[NRC*M2>YTFT762)E42EWVCG?=*Y=Q<(#&#
MQ$P2LTC,)C%G>K+U#0>#Q?'_YD]?I0]'X^/_S9,_F$]B 8F%)"8@3-KB9X];
M_$R]Q;<'44NM6A?Y]G;=>ZB@C@215['VTP]S79_V'DAYKUS/N9E 8@:)F21F
MD9A-8L[L-!.&^M'>NDNNT2,QG\0"$@M)3$"8E!SSQ^28/V,<<1LE63.*J-:Q
MMHHW<7$;%\VQR*LZ-+;UMYH31VFU7D9%W!<:RE6<&QHD9I"826(6B=DDYLS[
M=B3FXZ/4(%?ID9A/8@&)A20F($Q*C<5C:BR4J?%[O$RCLDQNDN7^)$2=%<OM
M9IM&3?%"B_]:KJ/LMLZ2Y.8F+N)L&9=:5"3U+LGM+F:**"O3QR5O\B).;K-:
M*)K7?M6RN-*B_2"F.2%2DV45K[1R>UTFJZ2&XOVIYOSFIGY1U:C-(DG6O' 3
M9Y6VCE>W]8O:=]YW/O&]\AV>&UJ+D^-BT\% WF(,<H4FB5DD9I.80V(NB7DD
MYI-80&(AB0D(DR)K..B**@-E:!WMS&A7]=Z,]K[.J31:Q>5:^U<8;Z[CHO<D
MJIH^-RU0S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4$I<D1<]"%&[Y@DZ-=.15"
MI&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ@M+D$-*[$-+5^SE1O3.S&V+58Z^B
MCI\G3@^KN;-CA=0,5#-1S4(U&]4<5'-1S6NUPP-,X]G\Z#0QNLH U4)4$Y0F
MIT77/1TJ2V:7]B=?^]24KM=YNHJ+\G$8I/U7<Z(TKL/C+EVJ!T=HQ135#%0S
M4<U"-1O5'%1S4<U#-1_5 E0+44U0FIPT7=]T.'[)P1%9[;M"-0/53%2S4,U&
M-0?57%3S4,U'M0#50E03E":'4%>;':I[LQ_C8AEG570;:Q]NM ]?LGJ79YW<
M-5<M5D5RO:V.K^1KTP7MT+;:<'BP"SQX,QD?=24-=*TFJEFH9J.:@VHNJGFH
MYJ-:@&HAJ@E*DW.CJ]0.U9W:9IC4G'*N_RUWM9@\3591<U;:_/3AL_:YV);5
M=XV=T!(NJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J*:H#0Y?KI^[W#VDF,GM/6+
M:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@F*$T.H:XJ/%1WA;]W[(36@UNM.=%_
M,'8:3(^'3FCS%]4L5+-1S4$U%]4\5/-1+4"U$-4$I<FQT76%A^JR\*=E7E5)
MN=:"9),T(Z:/45&UV?%=0R:TN8MJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J"8H
M39Y+K:O[ZH,7'#+I:"$8U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U%-4)H<0ETA
M6%=V_;YWR*16STZ78=_IIL'L^'03NE83U2Q4LU'-0347U3Q4\U$M0+40U02E
MR;FA=[FA[O VIYO>W=X6\6U4Q9J3IZOF(L?SQTKJU9P=)&BW%]5,5+-0S48U
M!]5<5/-0S4>U -5"5!.4)L=-5P+67W(&6AWM!Z.:@6HFJEFH9J.:@VHNJGFH
MYJ-:@&HAJ@E*DT.HZP?KRNK?=X^5R'KB5:L=C96&HY.Q$KE6$]4L5+-1S4$U
M%]4\5/-1+4"U$-4$I<FYT55Z]>^M].[GC>D-#;3/J_?V>>>#X7%HH'U>5+-0
MS48U!]5<5/-0S4>U -5"5!.4)H=&U^?5U7U>*TH*[3Y*M[L1SWI_@*4W*=""
M;JL=3A0U6IS,%(6NTT0U"]5L5'-0S44U#]5\5 M0+40U06ER3G3%6UT]LV[0
MSJ']53/39-,<\8A7VH=,,]I9,GLC ZW3ZJ>3N$Y'IY&!UF11S4(U&]4<5'-1
MS4,U']4"5 M135":'!E=3597UV0/[FBXFU<WVN3;K.H-"K09JY].W*J/3X,"
M+<:BFH5J-JHYJ.:BFH=J/JH%J!:BFJ T.2BZ8JRN+L9>147QM3FO^X_=..3#
MC>9V,]B*N&H>$7G67&Y8%7F:-B]ULRJN?Y;^.$&+L?KIG+;#DP,::-T5U2Q4
MLU'-0347U3Q4\U$M0+40U02ER;<0[>JN(_7LMDUCY/M[(FK\W.A -0/53%2S
M4,U&-0?57%3S4,U'M0#50E03E":'3%=G';WD_+8CM/6*:@:JF:AFH9J-:@ZJ
MN:CFH9J/:@&JA:@F*$T.(;T+(74W]CM[(FKU['31^T[YGD[AA*[51#4+U6Q4
M<U#-134/U7Q4"U M1#5!:7)N="77T1,SW;8W.5L]Y,3#[8>Z4\%IL\MRG>=_
M=J>&FUNB1=5^@>@ZC4]N3E0N\ZQ*LFV]'_2XU_/M0[[JG_'L%!J='*.9S4X.
M^:+K-%'-0C4;U1Q4<U'-0S4?U0)4"U%-4)J<05W'=:3LPEU^O$G^$Q?:OS9G
M'Z A&WM7J&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ@M+D?.FZL*/)2QZ@05NS
MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ@M+D$.JZM2-UM_9[#]"@3=M6.YHG
M;J0?CXW0JBVJ6:AFHYJ#:BZJ>:CFHUJ :B&J"4J38Z.KVH[455M]H \?;U3V
M.#&<UK\G@E9L4<U -1/5+%2S4<U!-1?5/%3S42U M1#5!*7)D=)5<4?SEQP.
MH?5=5#-0S40U"]5L5'-0S44U#]5\5 M0+40U06ER"'4UWY&ZYOLYKZ*T#I:L
M3%9QL8^6W>FEWDQ!.[RH9J":B6H6JMFHYJ":VVJ'EWD,C\[X>>@:?50+4"U$
M-4%I4E*,NP[O6-WAW=VY60J*OHA0(^=&!*H9J&:BFH5J-JHYJ.:VFA011PF!
MKM!'M0#50E03E"8G1%? ':OGDVWN/+;=Q(7FQ%%:K9=1/;)Y_S!V49T_5KMG
MAP;:K44U$]4L5+-1S4$U%]4\5/-1+4"U$-4$I<GYHG?YHK_@ 9,Q6L%%-0/5
M3%2S4,U&-0?57%3S4,U'M0#50E03E":'4%?4':N+N@?GC^L0:BYL5,S/I+;.
MSI11WUGCZ?SHK#&Z4A/5+%2S4<U!-1?5/%3S42U M1#5!*7)8=$U:L?*1EV]
MQW*?K.)LI=ULLU73P?]:[[9<5]I-O5.2+;\5&F3G[ZK5I)D2!J<SKZ K-5'-
M0C4;U1Q4<U'-0S4?U0)4"U%-4)H<&EU-=JR>,O8A-,KN8J Z.FZ*?*,MFV.P
MUU%:AT?O"1JU?'9T3$Z.U$U/@P.MMJ*:A6HVJCFHYJ*:AVH^J@6H%J*:H#0Y
M.+IJZ_B<:6-WUP;N+P5<J;NM:O;LU)B>'M^?3$YS ^VVHIJ%:C:J.:CFHIJ'
M:CZJ!:@6HIJ@-#DWNF[K6-UM?7*4(E]C7.7-88_>($&+K^/3N65GP],<00NM
MJ&:AFHUJ#JJYJ.:AFH]J :J%J"8H3<Z1KM Z5L\M^SAP^>F'N3X8_7HR?GEX
M_' 8\^QL0?NLK79X5*3GF A:4T4U"]5L5'-0S44U#]5\5 M0+40U06ERM'0U
MU?$3L]$^IUJB_5?KFVBR-TW0)BNJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HIJ@
M-"EV)EWG=3)XP<;)!.W*HIJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J"4J30ZBK
MU4[4M=KOG+% K9Z=+GOMR2DET;6:J&:AFHUJ#JJYJ.:AFH]J :J%J"8H3<X-
MO<L-]52T[\HR7R91%9>/4[KUY@3:>T4U ]5,5+-0S48U!]5<5/-0S4>U -5"
M5!.4)J=)UWN=C%YR*(0695'-0#43U2Q4LU'-0347U3Q4\U$M0+40U02ER2'4
M]6DGRNK=_AKDI+L/67,#PVXO)\I6VO_F2?WX??UDG51E;]207<$K5#-0S40U
M"]5L5'-0S44UK]4.:PQC>=#LHRL,4"U$-4%I<GYTU=J)NEI[.H>!=A<E*^UU
M$2_CY#Y>_:TW,=!6+:H9J&:BFH5J-JHYJ.:BFM=J4U5BH)U:5 M135":G!A=
MIW:B[M0V)Y3[3CX'R29I:BW_3*JUYB39:EM64:;]D=6CHOOZI0_/*X^\H+U;
M5#-0S40U"]5L5'-0S44U#]5\5 M0+40U06ER!'7UW,GL)8^\H)U=5#-0S40U
M"]5L5'-0S44U#]5\5 M0+40U06ER"'7=WHFZV_N])Z'1UBZJ&:AFHIJ%:C:J
M.:CFHIK7:D<UA<%D=CQ^0HN[J!:BFJ T.3>ZXN[DB>+N]QUQ0>NYJ&:@FHEJ
M%JK9K79X'.+GT>*H\>.@ZW11S4,U']4"5 M135":%!K3KG8[54\U2QUTT?[;
M[)_L;MFAW1;Y]JX>&J51628W2?VJJ-36<;K2ZF&45K\B/EQ,'^B#T]M]-,^\
MC[+;-%K%=:SU_8BJBP[4[_K<5$,U ]5,5+-0S48U!]5<5/-0S4>U -5"5!.4
M)J=?U_>=#E_P>,\4K06CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:H)2I-#2.]"
M2%T>/NN^(&KK[$Q!*\2H9J*:A6HVJCFHYJ*:UVK2G(:SXT,\Z"H#5 M135":
M'!5=,WCZQ(RX^]O&OT_R*EXVHZ+B+F\3XW.4?*D':*J3X&K\[.Q F[^H9J*:
MA6HVJCFHYJ*:AVH^J@6H%J*:H#0Y9+KF[W3\DH,BLN1XA6H&JIFH9J&:C6H.
MJKFHYJ&:CVH!JH6H)BA-#J&N/CQ5UX=%GOV\?-9MT-30V8&"5H91S40U:WI:
M?1WJ"WG/WD97Z:":BVH>JOFH%J!:B&J"TN2<Z$K#TR=*PWF^^I*D:6\RH*5?
M5#-0S40U:]HSK; ^/DX&M,N+:BZJ><_Y=?CH*@-4"U%-4)J\P7<5W:EZ!MUZ
MQZ#9)ZB*/$V;J>>2K(KK]52] 8 6;E'-0#43U:Q6DW8-3K9_M$:+:BZJ>:CF
MHUJ :B&J"4J3@Z*KT4Z?7:.-EO_>)D5_;5:MG)T1:&T6U4Q4LUKMZ YID\EQ
M3*!]6%1S4<U#-1_5 E0+44U0FAP376MV>FYKMC<ET)8LJAFH9J*:-3WMM>K#
MXXA IZ9%-1?5/%3S42U M1#5!*5)$3'K.K(S=4?V0[6.B_8&/WWAH%[\W'!
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MHYS6-D>,8FEC?CS^SI/.UJ2U9:O"-O&C*)C,W>T(8C0@1O\14=FD$IAI<B=
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MA:!Y>;DC6(X3!9"_;R@53S>J@>:X;?$74$L#!!0    ( )I9:E8T?[:ZF@D
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M%O(!J';=2S)<YTU$:!#Q6(-B-3@F0NOR !;FL9 >=%4U<EG>)O?),A>OK+2
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MR0/$_GF>EX\_9(#-_TF8_0]02P,$%     @ FEEJ5@P<U&2_!@  G!P  !H
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M^ )<>J\2&.ZJ.0IK;K3<U(=##U)KN:XO5QR$:&4 \/M"@K9I;\P+#@>2T_\
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M^WRS:7M_FZZ:<<BHWKZZ"+<NVAGO^?*-\)+8NSA_5OM!F86^#P>S3H3!(<*
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M+%UF96O0_/M=4=3[7]H&7HKR\S;LR_\#4$L#!!0    ( )I9:E9S5B<=HR(
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ME8_J3[;12P=Q:**/:CZJ!:@F4$VBFD(UC6J&TIK-6B7ZWED3?0]-]%'-1[4
MU02J2513J*91S5!:LYNJ1-][2:+_\D%<-[5W/;?]T.F>K<;+2?NYZ?8C&US-
M:+:/:A+5%*II5#.4UGS!6Y7M3^S9_H=U\>,_N8N=W^+X-V<=A9M\O2K?!O!?
M25P,VQZ*,T!YWK"-INQ[&/KS']5\5 M03:":1#6%:AK5#*4U.Z::/S 9GW,T
M-4%G!Z":CVH!J@E4DZBF4$VCFJ&T9C=5LP,F]J?-?^U+#R8]#Z!?+-MWQ_JV
MFG;NC]D/<7!9HS$]JDE44ZBF4<U06K.LJYA^8H_I?SP\_M&SCYO05TBCFH]J
M :H)5).HIE!-HYJAM&9+U-XE/3GKN D-YE'-1[4 U02J2513J*91S5!:LYNJ
M8'[RDI=F[Z+\,'DERIRB??H;IWSS7V_#]+Q >>:VI^GW;35J/_?.MQ_LX )'
MLW)4DZBF4$VCFJ&T9H%76?GD)6_B_I<*O!N-%P7>OO/:MU5/@:,1.JH)5).H
MIE!-HYJAM&:!5Q'ZY,0#Y%N7".4BDMNBPN.'\$_K^A&[.WBD@Z;7J!:@FD U
MB6H*U32J&4IK]DF57D_.FEY/T/0:U7Q4"U!-H)I$-85J&M4,I36[J4JO)_;T
M^JOOM_8L41^UW_UMW_?@ZD?3;E03J"913:&:1C5#:8WJGU9I]]2>=MO&7-\X
M>K>R#KSL^-!3!:KYJ!:@FD UB6H*U32J&4IK-DL5=$_/&G1/T: ;U7Q4"U!-
MH)I$-85J&M4,I36[J0JZI_:@^R]]B>^TFW-W7^)K/\#!+8*&YJ@F4$VBFD(U
MC6J&TIHM4H7F4WMH+L.BY,N[O<XV"LOSSJ$'FLMTZ^M!CEMM6SW4VR ]#X1O
MWPFV']W@_D 3=%03J"913:&:1C5#:<W^J!+TJ353[+MZ :;OVG<Z>!R&!N>H
M%J":0#6):@K5-*H92FLV416<3\^ZHGV*KFA'-1_5 E03J"913:&:1C5#:<UN
MJE+ZJ3VE?Q_5!V%%0^7KJ'YIT[S'?!]^+M=)]?9-3PP_\=HWF/NV&KGM1Z#:
MCWEPG:-A/:I)5%.HIE'-4%JSSJNP?FH/Z[\V-IEVW_/>,TV];ZON-'7[(0XN
M:S1;1S6):@K5-*H92FN6=96M3^VO<.^YHO@Y>0C3/,Z<W\+5JKSYY%P^W82R
M9B-HC(YJ/JH%J"903:*:0C6-:H;2FHU3Q>C3L[[4?8J^U!W5?%0+4$V@FD0U
MA6H:U0RE-;II5L7R,WLLCUU%S'K>T=ZYB.C9R&N_K<I^P$.+'-4$JDE44ZBF
M4<U06K/(JSA]9G_N_-=>0AS9QFL_YNUE&CT;3>;M"PC[ 0XN:C351C6):@K5
M-*H92FL6=95JSTZDVO%=E,9A_0+BXRXNWWI[&>Y^/[SM^>UM&J_";YS_%Q5_
ML#Y\_1OG[6I57E$<-BH?I?,A#W?7\<K1E[]>/7[5=K%A/ZBAPR-4\U$M0#6!
M:A+5%*II5#.4UFRR*A>?>>>\V)BAZ]!1S4>U -4$JDE44ZBF4<U06K.;JA1]
M9D_1BW'8JNB+X^"K:*A5&MW$N9/&V>^][3'IN:9H#[_0U!O5 E03J"913:&:
M1C5#:<VBKU+OF7VY^,??Z\_95>'F]Q>,LM H&]5\5 M03:":1#6%:AK5#*4U
M6Z2*LF>SLXZRR#CT"M5\5 M03:":1#6%:AK5#*4UNZD*S&<G _-AHZQN!#Z>
MM$=9Z%)U5 M03:":1#6%:AK5#*4UB[Z*TV?V.#U8[<.;)*T/M=ZER<W^NCA?
M)/:Q%AJ?HYJ/:@&J"523J*903:.:H;1FHU3Q^>RL\?D,C<]1S4>U -4$JDE4
M4ZBF4<U06J.;YE5\/K?'YT/'6O-N -Z:0GMEW^/0FD>U -4$JDE44ZBF4<U0
M6K/FJS1];D_35;*[V:=A5A]K71Z&67[D=/ZPMPO0]>>HYJ-:@&H"U22J*533
MJ&8HK=DP55(_/^MKV.=H)(]J/JH%J"903:*:0C6-:H;2FMU41?)S^U+UP4.N
MGO7G[2$7&IRC6H!J M4DJBE4TZAF**U9\U5P/C\1G(?;Z^2FG.Q5#;F,\VNZ
MSW+G??*Y.&&<C!3M>QA\ED!3=U0+4$V@FD0UA6H:U0RE-3NF2MWG9UUK/D<#
M>E3S42U -8%J$M44JFE4,Y36[*8JH)_;UYH/'G-U%XNW'XEEW^/@FD=C=%03
MJ"913:&:1C5#:<V:KV+T^:D8/<M#YWV\"LO[6V^OG _ASC%)%MF'6>@3XE'-
M1[4 U02J2513J*91S5!:LTFJV'U^UB?$S]%L'M5\5 M03:":1#6%:AK5#*4U
MNZG*YN<GGQ _;)C5\^KR]C +3=!1+4 U@6H2U12J:50SE-:H^465H"_L"?IE
M&OXSWE018N(47\F*K]A&679SZ'D!U7Q4"U!-H)I$-85J&M4,I35[I$K<%V=]
M'/P"C>-1S4>U -4$JDE44ZBF4<U06K.;JCA^<?*]YX-&68ON$][;-[/L>QQ<
M\VAHCFH"U22J*533J&8HK5GS56B^./%2]/B/?5P4^>=#E5L?2FV7!I\-T&@=
MU0)4$Z@F44VAFD8U0VG-SJBB]<7DK&,K-'9'-1_5 E03J"913:&:1C5#:<UN
MJF+WA7VQ^U68K0]/%5J5OXB*D\Y#N#DT2OG%S>$L5/3/0Y3EA_[I;9GN>\^]
MQ:C]X%[[@0QN!30S1S6!:A+5%*II5#.4UFR%*C-?G,C,![;"X67JSN.5R6;S
MN;<SNK&Z-^YV!IJLHUJ :@+5)*HI5-.H9BBMV1E5LKZP)^MOM\E^ES_6>Y@[
MP3Y-[J-PYVR+R_#]ULFC=.OLDCPJWS]UEX;;;>\#1Q?=9>ON:-3M!C1"1[4
MU02J2513J*91S5!:LQNJ"'UA7[G^<U'IF1-GV3[ZE]IAT<T"1UZW'= ,'-4"
M5!.H)E%-H9I&-4-IS7:H,O"%/0-OM,-^=Q.ESCYSLN)D<>NDT5V<'6_<]O9
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MJLU%F-C?!< ,WQ[W87T"\W$;^_"-G1J <H+E),LIEM,L9S"N5>>UJ0$3^]2
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M1[URKI,\3[:'7Q;76C=16FY0_/EMDN1/OREW\"E)?S]\FV_^!U!+ P04
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MN#90]Y>,R><3_=6G^LHW^Q]02P,$%     @ FEEJ5N+M;4*_"P  [V@  !H
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MI(X:P"G0@Y.!&LYXAWU6[U+D5AYMLE%5S90W<;\6X+1P4E4M-*JJF?(FY@I
M,!RFJAW;HT:6S5Z&T@XUB)'GX)41 G2%P\2UT^LYE-4S)&C$2!DTT$^HIY_K
M/%N6Y'U&WI!;F"=_U\Z,?SHZ,V[B)EP?XN#^.H9D%@*>A9-*9J%1R<R4-S%7
MP(.AG@?'N D/4<&,]AD7,_.HK4#<$%@MU.MJYF[!0TQ HTY_5SK,S(U"U<
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M<=<&_/^K/*^>W]1?>7/XCJ.K_P%02P,$%     @ FEEJ5IX&.S*I$   _=<
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M3L%331'V4F'W9-H<O)#*_6EB\S_EJY34JEX[):7]5-G$VG#:GU+KM=.A%'N
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M1-)JS/$JJ)\-(RH2X G*(KL:<UKW3;)TO?H 2H^;6&H!=J@Q]UDPN"X:(>/
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MP.?+.);W)^H5H.R5K]F_4$L#!!0    ( )I9:E8ESWCN-P0  .D6   :
M>&PO=V]R:W-H965T<R]S:&5E=#(R,RYX;6S-6&UOVS80_BN$!@PMD$6B'+\H
MLPVTSH(&: :C[;H/P3[0TMDB*I$>2=DIL!^_HZS(EBT+=B/ S8=8E.X>W3UW
MCWC@<"W5-QT#&/*<)D*/G-B8Y:WKZC"&E.EKN02!3^92I<S@4BU<O53 HMPI
M35S?\WINRKAPQL/\WE2-AS(S"1<P541G:<K4]_>0R/7(H<[+C4]\$1M[PQT/
MEVP!G\'\M9PJ7+DE2L13$)I+013,1\X[>CNA@77(+;YR6.N=:V)3F4GYS2X>
MHI'CV8@@@=!8"(8_*YA DE@DC./? M0IWVD==Z]?T._SY#&9&=,PD<G?/#+Q
MR!DX)((YRQ+S2:X_0)%0U^*%,M'Y?[(N;#V'A)DV,BV<,8*4B\TO>RZ(V'&@
M-T<<_,+!/]6A4SAT\D0WD>5IW3'#QD,EUT19:T2S%SDWN3=FPX4MXV>C\"E'
M/S.^YX*)D+.$<*&-RK!"1A,F(JQ1P@Q$).(Z3*3.%&CR&[EG7)&O+,EP)>?D
M#A1?,5L)33Y $I$W4Z80(@;#0Y:\)6_NP#">O!VZ!J.U[W3#(K+WF\C\(Y'=
M07A-.O2*^)[OU[A/3G>G57<7.2J)\DNB_!SOYAA14F%+"/+'<Q@SL0 RD<(H
M[$)-GE)(9Z#^(?^1"=,QN4=M(!O1 K;/ZO)O?*'5[ZU>LA!&#@I4@UJ!,_[U
M%]KS?J]CHR6P"C>=DIM.CMXYQG79(K8GHKSBV#E<;#XSN5QG^ TA,9+"Q:+2
M:T\6C7 #J:YEJ=,F2RV!55BZ*5FZ:>R@J>*HM"5*C:4R$Z8NV0U"-T>P7^#5
MF/;Z7OXW=%>[F=19>GN6E3"[99C=%AK]3]QA'@3*WM@JGM+MC6\]MXXM@54(
MZI4$]2[7[;TV66H)K,)2OV2I_^IN[Q_V<"<8T-I^K['U^C1HZOA!&>J@N>/+
M/?"=UF"W/[.SSY$OL9+9(B93)>?<$*G(1ZGU%7G$79(9J;Z31V"V':*JXQ7N
M!@86UF!'. _" +)MB,*'1*_9DH2%P$[:2*SVL,,FF;+[+'EZ/*ZXQJS/[:66
MP"H%"LH"!9=37- F2RV!55BBWG:6\UZMN0)B5TC[4JLQH4'0JQ<9W9DTZ<\C
MLU>.:_;9"0IKSOC<YFD+K5J?[8!+_<NIC+8Z[+:%5F5J.^[2QCGQ-)UUZD:Y
M?:75&1W9S>AVSJ3-@^9/*+3F<?%4M36F?78/M816+=)VRJ;="ZJMU6&[+;0J
M4]MQFS;.J:>IK7<@)!P.#^1V:-6]Z05']+:==&GSJ/N#>ILD3&L^YU9GQ>D)
MUIY\42S">O^PVFKI:4S@['YH":U*]W9:IX,+*J?5H;DMM"I3V[&9-LZ;IRDG
M.-1$X WVE7-H%?3]P9YRW)US2'L(_,@4%D"3!.;HYEWWT5]MSE4W"R.7^='D
M3!HCT_PR!A:!L@;X?"ZE>5G8T\[R='O\/U!+ P04    " ":66I666W*X(0,
M   6<0  &@   'AL+W=O<FMS:&5E=',O<VAE970R,C0N>&ULU9UM;^,V$H#_
M"N$"AQ9H8E'OVB8!-LENN\6E&VRP/12+?F!L.A8J2SY)3C; _?BC7FR*$C62
M;&K5]D,W=JCAS$B<>3*B1A<O4?Q7LJ8T15\W09A<SM9INGTSGR>+-=V0Y#S:
MTI#]9A7%&Y*RC_'3/-G&E"SS@S;!7-<T>[XA?CB[NLB_NX^O+J)=&O@AO8]1
MLMML2/QZ38/HY7*&9_LO/OE/ZS3[8GYUL25/](&FG[?W,?LT/TA9^AL:)GX4
MHIBN+F=O\9L;C*WLB'S([SY]22H_H\R6QRCZ*_OP87DYTS*5:$ 7:2:#L'^>
MZ0T-@DP44^2_I=398=+LP.K/>^GO<^N9-8\DH3=1\!]_F:XO9^X,+>F*[(+T
M4_3R"RTMRA5<1$&2_Q^]E&.U&5KLDC3:E <S#39^6/Q+OI:>J!R@ZRT'Z.4!
M>M\#C/( (S>TT"PWZY:DY.HBCEY0G(UFTK(?<M_D1S-K_# [CP]IS'[KL^/2
MJ_=^2,*%3P+T(4S2>,=.49H@$B[1)QJ0E"[1K9\L@BC9Q31!9^BA.-\H6J%;
MFA(_8",^A,7UE)T6]CUS+W->B-Y]7:Q)^$2S+UY(O$0W49C&[+PE/Z*'%[)-
MT,==FJ1L+C]\$J;\A2Z?,KDIW23H^V*>']"_OL.V\1/R0W3G!P&;++F8I\P%
MF2'S16GN=6&NWF(NUM$=TV*=H'?ADBY% 7/FNX,#];T#KW50XBU=G",#_XAT
M3=?1S]?WZ/M"T1\DVMWTEX4!68*BQN%,&[EPLT7X#4G6Z#U;MX5[$_1E0S>/
M-/X3_0_]3F*?//J!G[YF_EUD0U=L:()6<;1!!*W9:@A>T3:.'LEC0!$[X92-
M2A$[H6%"BB6Y%R@[+:!N6;!ZDVS)@E[.6#1*:/Q,9U>9Z=I/,B\J$B:XT3RX
MT<RE&VWGZ+ <LFM]N5\#?F4-D$<6,-&ZN(C]_"+^DHDI?I:ZQU3I'D7"!/=8
M!_=8X%5V3V,_6OH+5*S]0JX?%O\^DV"77SO%QP4)%CNVXK/EGWN+>9&N5C2/
M["%-I.N[F-[.I\^2U//5F7XQ?Z[:WQR"#R,$H^R#439HU#4)6)"DPM(H-2X]
M.%^506^QBV,:+EZ+A1$4%T0Y*+,<+5CX\</=P6:ID84Z5L6"NHW-$6<M1CH'
M(YT3C40L2B29XGE0R'Z5?8AI866R]EE(STQ\6?N+=7DH62RB79B?8C]!882"
MB%T6,2+;;>#7 W!AO-,P3:L9#QIRY 7N'MSDCA5&]]<(W2=&^G5;1)*]8]FU
M\FX71RRLA!%+]GDR9/[;LN^WY+7(S86_V> T&_>8,K\F.S8.BKZ@24/#BR)A
M@O>]@_>]":*OI](]BH0)[L$:QSEMVOA;SB]$'J.V/F$=C_5!!6GQWRM<E_I
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M9KDU.#$;/"DQ)UTEJS+2W&5BH8BP43@<DYH-HE3H(W[7V;Z1[VMN$O!>'^I
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MBNW+"MLO+%_7S_L_YHSE:7VXHD%$B\J _W^1YVSWI?J!]I61^?]02P,$%
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MH&M2%%>:Q8OBZ_Q6\)DKQ9-\N (2@S &^OL%Y^KMQ2Q072R/_P-02P,$%
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M]@EP@,^$DN%N"Q1+J0.!W(*<!^X2N$?-&Y-%33 ^Z2__O;?QFW%P4]K_T2K
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M_OOL@"?K]!;VQX3S)$J?KHBW(%0&B/>72<)W!_*N^.*_(,S^ U!+ P04
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MF4N$+W[M^()'D22)>OQ=04<'35FP^?J)3HN#%P=SYV=\D41_AD&^NAB=CDC
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M,.4@^!*0 F9TP<VC7'V')A[G8"ZY=D^R:FRC@.0+;:1HP.B!8)5_T[=&ARU
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MC").4\?$HJ<.64AB1D.R7YV/C_UJW(#1T;TENPAE73F4T?X2[^01RABKB>6
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MH 6$B[7;/6K7D <$'#T@K\ND2K/UW\-DFN"9:V[ZJ[F)'#@1%0@@%0C(J4!
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MED@H\T&J[<?%SF?0$!/I93Y U?VYYMG9A'"Q+OMQI;_XZ5A#3"29.;NHTE<
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MNUKO#E#OKM:[ ]2[K_7N ?7N:[U[0+W[6N\>4.^^UKL'U+N/#[L!]>YKO7M
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M/==ZSX!ZS[7>,Z#><ZWW#*CW' ][ ^H]UWK/@'HOM=X+H-Y+K?<"J/=2Z[T
MZKW4>B^ >B^UW@N@WDNM]P*H]U+KO0#JO=1Z+X!Z+[7>"Z#>2V =0+W5DNL
M^JT68*<!"JX69*<!&JX6:*<!*JX6;*<!.JX6<*<!2JX6=*<!6JX6>*<!:JX6
M?*<!>JX6@*<1BIX DR$PDV 2BIX($Z$PDV$B'&9"3(3$3(J)L)B),1$:,SDF
MPF,FR$2(S"29!).I0)DBJ$P%RQ3!9<K)Z@E%#YHI@LU4X$P1=*:"9XK@,Q5
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M']?3VT2_KF. WUGO\\O/KF^___7RUXOY-KSF>OM^C-.G?P!02P,$%     @
MFEEJ5KYZQ(L+!   Q80  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=O+3MM
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M;W!S+V%P<"YX;6Q02P$"% ,4    " ":66I6VK.3;.T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ":66I6
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( )I9:E8/M!2UBP@  !0V   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ":66I6
M_\6C4@X(  !T)   &               @('-$   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ FEEJ5IVL'Z<6!@  AAP  !@
M     ("!$1D  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M )I9:E;)/KO.9@<  ) E   8              " @5T?  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " ":66I6R![FIRX+  !T2P  &
M            @('Y)@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ FEEJ5E/G;M&Z"0  K3,  !@              ("!73(  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )I9:E;/%K 7NP8  '@1
M   8              " @4T\  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " ":66I6:[D)FZTB  !O=   &               @($^0P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ FEEJ5NH*LT/?
M#P  I"\  !@              ("!(68  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( )I9:E;_XUPIVP(  /(&   9              "
M@39V  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ FEEJ
M5@&H5TP& P  UP8  !D              ("!2'D  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " ":66I6F?K,A4<-   B)@  &0
M        @(&%?   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( )I9:E8?$(-RE <  /P1   9              " @0.*  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ FEEJ5C9#)514!P  .!(
M !D              ("!SI$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " ":66I6B5JID^ %  # #   &0              @(%9F0
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )I9:E;M@3<L
MK@8  #,0   9              " @7"?  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ FEEJ5D"3>*^I @  [@4  !D
M ("!5:8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " ":
M66I6#'!Q"'0#  !L!P  &0              @($UJ0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )I9:E:0JF(2D 0  #(+   9
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M970R,RYX;6Q02P$"% ,4    " ":66I6N]-GN*L#   0"   &0
M    @($.U@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M )I9:E: 20;\( <  !(1   9              " @?#9  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ FEEJ5HQ=;SGA"0  A1D  !D
M             ("!1^$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " ":66I6)#@E(5H$   M"@  &0              @(%?ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )I9:E94/95QBP(
M )X%   9              " @?#O  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ FEEJ5IS\<-$%!0  > P  !D              ("!
MLO(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " ":66I6
MJ"CU5BH#  !A!P  &0              @('N]P  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( )I9:E:2%V 360(  "<%   9
M      " @4_[  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ FEEJ5F-C?0[J!   2PL  !D              ("!W_T  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ":66I6F,R!74H"   R!0
M&0              @($  P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( )I9:E:K&X %1 (   4%   9              " @8$% 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ FEEJ5D9U$06R
M!P  ;Q(  !D              ("!_ <! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " ":66I6"FQZ@#8)  #('   &0
M@('E#P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )I9
M:E;#@VB_H2   !9I   9              " @5(9 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ FEEJ5F& !B#:"0  GA@  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( )I9:E:?QPU2@ 0  /P*   9
M  " @7I8 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MFEEJ5J&MQVL@"   _Q\  !D              ("!,5T! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " ":66I6&>;C,,4%  "[#@  &0
M            @(&(90$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( )I9:E9(.-MMY0,  +L(   9              " @81K 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ FEEJ5N7(XUEY%
M4CH  !D              ("!H&\! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " ":66I6<K"<R?$$   +"P  &0              @(%0
MA $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )I9:E9Z
MY9X=RP<  *<7   9              " @7B) 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ FEEJ5B9'%4_3)P   XL  !D
M     ("!>I$! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )I9:E8V8PX&*24  )"&   9              "
M@2G@ 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ FEEJ
M5GGJR6VG @  O 4  !D              ("!B04" 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " ":66I6SD! D:P"   "!@  &0
M        @(%G" ( >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( )I9:E9^=]0MV0@   L:   9              " @4H+ @!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ FEEJ5KHOV1AA!0  > L
M !D              ("!6A0" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " ":66I6I+8.F&(%  !&#@  &0              @('R&0(
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( )I9:E9EQWLK
M\@0  $ ,   9              " @8L? @!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ FEEJ5K\]^3Z$!   =@L  !D
M ("!M"0" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " ":
M66I6J"M@V[<"  #O!0  &0              @(%O*0( >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( )I9:E:<MXOG@ ,  &D'   9
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M970V."YX;6Q02P$"% ,4    " ":66I6MT8YFTP%  #L#0  &0
M    @($11@( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M )I9:E;R:D9X9@,  'H'   9              " @91+ @!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ FEEJ5B&$C" ?!0  I P  !D
M             ("!,4\" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " ":66I6L&7L_LP'   _%   &0              @(&'5 ( >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( )I9:E:@K)E@- ,
M "0'   9              " @8I< @!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ FEEJ5KWND#N- @  >04  !D              ("!
M]5\" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " ":66I6
M:O_:F@P#  #8!@  &0              @(&Y8@( >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( )I9:E9= D0X=P(  %0%   9
M      " @?QE @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ FEEJ5F=$A/MD @  *P4  !D              ("!JF@" 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " ":66I6Z*F&64T#  !>!P
M&0              @(%%:P( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( )I9:E:Q06(960(  "@%   9              " @<EN @!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ FEEJ5J&KF,]-
M @  "@4  !D              ("!67$" 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " ":66I6TK!QS5\$  #P"@  &0
M@('=<P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( )I9
M:E;PVHY2M 4  -<1   9              " @7-X @!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ FEEJ5A-=BNT4$P  [D<  !D
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M=#@W+GAM;%!+ 0(4 Q0    ( )I9:E:%"-V"/@,  +X'   9
M  " @;:A @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @
MFEEJ5JUH@X7R!P  3"   !D              ("!*Z4" 'AL+W=O<FMS:&5E
M=',O<VAE970X.2YX;6Q02P$"% ,4    " ":66I6\#OGD&$%  #@$   &0
M            @(%4K0( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4
M Q0    ( )I9:E88R.B-FPD  "4A   9              " @>RR @!X;"]W
M;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ FEEJ5J6,0 <'!0
M_0H  !D              ("!OKP" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX
M;6Q02P$"% ,4    " ":66I6Q!OSF.X'   #&   &0              @('\
MP0( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( )I9:E9*
M4EE-6AD   QQ   9              " @2'* @!X;"]W;W)K<VAE971S+W-H
M965T.30N>&UL4$L! A0#%     @ FEEJ5A_*R">=!0  $ X  !D
M     ("!LN," 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )I9:E92)6+@X@@  'M#   :              "
M@9G^ @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( )I9
M:E9.;7HZ@@,  .40   :              " @;,' P!X;"]W;W)K<VAE971S
M+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( )I9:E:*)[RN20<  'DO   :
M          " @6T+ P!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+ 0(4
M Q0    ( )I9:E;R$:HC+ ,  &D-   :              " @>X2 P!X;"]W
M;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( )I9:E;.E5YV\ <
M )Y%   :              " @5(6 P!X;"]W;W)K<VAE971S+W-H965T,3 T
M+GAM;%!+ 0(4 Q0    ( )I9:E:PL!UB!0P  "E<   :              "
M@7H> P!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    ( )I9
M:E:NYH\Q304   8G   :              " @;<J P!X;"]W;W)K<VAE971S
M+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( )I9:E;STY<3DP<  "XU   :
M          " @3PP P!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;%!+ 0(4
M Q0    ( )I9:E9O* 9?[P8  ) 5   :              " @0<X P!X;"]W
M;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( )I9:E:X +!7B 0
M "D6   :              " @2X_ P!X;"]W;W)K<VAE971S+W-H965T,3 Y
M+GAM;%!+ 0(4 Q0    ( )I9:E; M"ZRS@4  $H9   :              "
M@>Y# P!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0    ( )I9
M:E9K*ACXS@,  &82   :              " @?1) P!X;"]W;W)K<VAE971S
M+W-H965T,3$Q+GAM;%!+ 0(4 Q0    ( )I9:E8V2!=)C0,   0+   :
M          " @?I- P!X;"]W;W)K<VAE971S+W-H965T,3$R+GAM;%!+ 0(4
M Q0    ( )I9:E:(R%V#XP,  #P5   :              " @;]1 P!X;"]W
M;W)K<VAE971S+W-H965T,3$S+GAM;%!+ 0(4 Q0    ( )I9:E;O['W="P0
M  (3   :              " @=I5 P!X;"]W;W)K<VAE971S+W-H965T,3$T
M+GAM;%!+ 0(4 Q0    ( )I9:E;/'IY?.@,  .X)   :              "
M@1U: P!X;"]W;W)K<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0    ( )I9
M:E:*JN[A8@,  .4-   :              " @8]= P!X;"]W;W)K<VAE971S
M+W-H965T,3$V+GAM;%!+ 0(4 Q0    ( )I9:E:^ZA1VAP,   D+   :
M          " @2EA P!X;"]W;W)K<VAE971S+W-H965T,3$W+GAM;%!+ 0(4
M Q0    ( )I9:E;><P#U! 0  -T3   :              " @>AD P!X;"]W
M;W)K<VAE971S+W-H965T,3$X+GAM;%!+ 0(4 Q0    ( )I9:E:'SR)GNP,
M ',.   :              " @21I P!X;"]W;W)K<VAE971S+W-H965T,3$Y
M+GAM;%!+ 0(4 Q0    ( )I9:E:]P!$.4P,  #T*   :              "
M@1=M P!X;"]W;W)K<VAE971S+W-H965T,3(P+GAM;%!+ 0(4 Q0    ( )I9
M:E;6!\<CG@0  #0/   :              " @:)P P!X;"]W;W)K<VAE971S
M+W-H965T,3(Q+GAM;%!+ 0(4 Q0    ( )I9:E8VA]TR10,  )4.   :
M          " @7AU P!X;"]W;W)K<VAE971S+W-H965T,3(R+GAM;%!+ 0(4
M Q0    ( )I9:E9;!!G66 ,   4.   :              " @?5X P!X;"]W
M;W)K<VAE971S+W-H965T,3(S+GAM;%!+ 0(4 Q0    ( )I9:E;\8'9<D0,
M  T.   :              " @85\ P!X;"]W;W)K<VAE971S+W-H965T,3(T
M+GAM;%!+ 0(4 Q0    ( )I9:E8\X)85C0,  /T-   :              "
M@4Z  P!X;"]W;W)K<VAE971S+W-H965T,3(U+GAM;%!+ 0(4 Q0    ( )I9
M:E9%%+"*H ,  *@/   :              " @1.$ P!X;"]W;W)K<VAE971S
M+W-H965T,3(V+GAM;%!+ 0(4 Q0    ( )I9:E:0B^3;>P4  ( @   :
M          " @>N' P!X;"]W;W)K<VAE971S+W-H965T,3(W+GAM;%!+ 0(4
M Q0    ( )I9:E8V<U/QCP4  .D9   :              " @9Z- P!X;"]W
M;W)K<VAE971S+W-H965T,3(X+GAM;%!+ 0(4 Q0    ( )I9:E9+L/M(-@0
M ,L0   :              " @663 P!X;"]W;W)K<VAE971S+W-H965T,3(Y
M+GAM;%!+ 0(4 Q0    ( )I9:E99UYZ2>0L  +9<   :              "
M@=.7 P!X;"]W;W)K<VAE971S+W-H965T,3,P+GAM;%!+ 0(4 Q0    ( )I9
M:E;@YF]6G@(  .<'   :              " @82C P!X;"]W;W)K<VAE971S
M+W-H965T,3,Q+GAM;%!+ 0(4 Q0    ( )I9:E:"#5@J+00  * 3   :
M          " @5JF P!X;"]W;W)K<VAE971S+W-H965T,3,R+GAM;%!+ 0(4
M Q0    ( )I9:E8=FHEO/ ,  $4+   :              " @;^J P!X;"]W
M;W)K<VAE971S+W-H965T,3,S+GAM;%!+ 0(4 Q0    ( )I9:E9WD"PPR@(
M $$(   :              " @3.N P!X;"]W;W)K<VAE971S+W-H965T,3,T
M+GAM;%!+ 0(4 Q0    ( )I9:E8R=<MFR00  *<<   :              "
M@36Q P!X;"]W;W)K<VAE971S+W-H965T,3,U+GAM;%!+ 0(4 Q0    ( )I9
M:E:9UUV!>0(  )8%   :              " @3:V P!X;"]W;W)K<VAE971S
M+W-H965T,3,V+GAM;%!+ 0(4 Q0    ( )I9:E:;3*B[;@,  +$(   :
M          " @>>X P!X;"]W;W)K<VAE971S+W-H965T,3,W+GAM;%!+ 0(4
M Q0    ( )I9:E97!)%]R@(  &H(   :              " @8V\ P!X;"]W
M;W)K<VAE971S+W-H965T,3,X+GAM;%!+ 0(4 Q0    ( )I9:E8_R XB'04
M (L>   :              " @8^_ P!X;"]W;W)K<VAE971S+W-H965T,3,Y
M+GAM;%!+ 0(4 Q0    ( )I9:E84S +N7Q   /2>   :              "
M@>3$ P!X;"]W;W)K<VAE971S+W-H965T,30P+GAM;%!+ 0(4 Q0    ( )I9
M:E;P/:18W@<  )X[   :              " @7O5 P!X;"]W;W)K<VAE971S
M+W-H965T,30Q+GAM;%!+ 0(4 Q0    ( )I9:E;?FLH"S0,  !T,   :
M          " @9'= P!X;"]W;W)K<VAE971S+W-H965T,30R+GAM;%!+ 0(4
M Q0    ( )I9:E9:41$?K0,  .H-   :              " @9;A P!X;"]W
M;W)K<VAE971S+W-H965T,30S+GAM;%!+ 0(4 Q0    ( )I9:E9T)0@&Q@,
M .T7   :              " @7OE P!X;"]W;W)K<VAE971S+W-H965T,30T
M+GAM;%!+ 0(4 Q0    ( )I9:E8R6HNBD 4  !L>   :              "
M@7GI P!X;"]W;W)K<VAE971S+W-H965T,30U+GAM;%!+ 0(4 Q0    ( )I9
M:E8-Z*.B5P,  '\*   :              " @4'O P!X;"]W;W)K<VAE971S
M+W-H965T,30V+GAM;%!+ 0(4 Q0    ( )I9:E;.<%!J^PT  %MT   :
M          " @=#R P!X;"]W;W)K<VAE971S+W-H965T,30W+GAM;%!+ 0(4
M Q0    ( )I9:E9.X#@<]0,  .(1   :              " @0,!! !X;"]W
M;W)K<VAE971S+W-H965T,30X+GAM;%!+ 0(4 Q0    ( )I9:E;(R5TE]P<
M '11   :              " @3 %! !X;"]W;W)K<VAE971S+W-H965T,30Y
M+GAM;%!+ 0(4 Q0    ( )I9:E;:K0I<7@,  +<,   :              "
M@5\-! !X;"]W;W)K<VAE971S+W-H965T,34P+GAM;%!+ 0(4 Q0    ( )I9
M:E8%<[3>[P4   4F   :              " @?40! !X;"]W;W)K<VAE971S
M+W-H965T,34Q+GAM;%!+ 0(4 Q0    ( )I9:E9*;&!$@P,  '4-   :
M          " @1P7! !X;"]W;W)K<VAE971S+W-H965T,34R+GAM;%!+ 0(4
M Q0    ( )I9:E:Q+CO4S@,  &00   :              " @=<:! !X;"]W
M;W)K<VAE971S+W-H965T,34S+GAM;%!+ 0(4 Q0    ( )I9:E:0/J'L700
M -\4   :              " @=T>! !X;"]W;W)K<VAE971S+W-H965T,34T
M+GAM;%!+ 0(4 Q0    ( )I9:E97.D/CKP0  %<6   :              "
M@7(C! !X;"]W;W)K<VAE971S+W-H965T,34U+GAM;%!+ 0(4 Q0    ( )I9
M:E:@,8!N5@,  '(.   :              " @5DH! !X;"]W;W)K<VAE971S
M+W-H965T,34V+GAM;%!+ 0(4 Q0    ( )I9:E;"6T;,J (  "<'   :
M          " @><K! !X;"]W;W)K<VAE971S+W-H965T,34W+GAM;%!+ 0(4
M Q0    ( )I9:E:5)H1OS@(  )L'   :              " @<<N! !X;"]W
M;W)K<VAE971S+W-H965T,34X+GAM;%!+ 0(4 Q0    ( )I9:E8;Y&X^8 0
M " 7   :              " @<TQ! !X;"]W;W)K<VAE971S+W-H965T,34Y
M+GAM;%!+ 0(4 Q0    ( )I9:E90##1<[@(   L)   :              "
M@64V! !X;"]W;W)K<VAE971S+W-H965T,38P+GAM;%!+ 0(4 Q0    ( )I9
M:E:&6,JU5 ,  -<)   :              " @8LY! !X;"]W;W)K<VAE971S
M+W-H965T,38Q+GAM;%!+ 0(4 Q0    ( )I9:E;[BZ6DTP(  +D(   :
M          " @1<]! !X;"]W;W)K<VAE971S+W-H965T,38R+GAM;%!+ 0(4
M Q0    ( )I9:E;/_:BKE0(   4(   :              " @2) ! !X;"]W
M;W)K<VAE971S+W-H965T,38S+GAM;%!+ 0(4 Q0    ( )I9:E:IDVT4[ (
M 'X)   :              " @>]"! !X;"]W;W)K<VAE971S+W-H965T,38T
M+GAM;%!+ 0(4 Q0    ( )I9:E:?.^>X\P(  (,,   :              "
M@1-&! !X;"]W;W)K<VAE971S+W-H965T,38U+GAM;%!+ 0(4 Q0    ( )I9
M:E8"8E9OUP,  .P-   :              " @3Y)! !X;"]W;W)K<VAE971S
M+W-H965T,38V+GAM;%!+ 0(4 Q0    ( )I9:E;,!&X$.0,  %4*   :
M          " @4U-! !X;"]W;W)K<VAE971S+W-H965T,38W+GAM;%!+ 0(4
M Q0    ( )I9:E8!7,V-H@8  ",S   :              " @;Y0! !X;"]W
M;W)K<VAE971S+W-H965T,38X+GAM;%!+ 0(4 Q0    ( )I9:E;?V>@(N1,
M )DV 0 :              " @9A7! !X;"]W;W)K<VAE971S+W-H965T,38Y
M+GAM;%!+ 0(4 Q0    ( )I9:E;L$??0%@\  !RX   :              "
M@8EK! !X;"]W;W)K<VAE971S+W-H965T,3<P+GAM;%!+ 0(4 Q0    ( )I9
M:E9ZB'>I^ ,  ( 6   :              " @==Z! !X;"]W;W)K<VAE971S
M+W-H965T,3<Q+GAM;%!+ 0(4 Q0    ( )I9:E9.+-RZF0<  )LU   :
M          " @0=_! !X;"]W;W)K<VAE971S+W-H965T,3<R+GAM;%!+ 0(4
M Q0    ( )I9:E;PLFBQ(!   "'-   :              " @=B&! !X;"]W
M;W)K<VAE971S+W-H965T,3<S+GAM;%!+ 0(4 Q0    ( )I9:E:)4'O>9 ,
M *X.   :              " @3"7! !X;"]W;W)K<VAE971S+W-H965T,3<T
M+GAM;%!+ 0(4 Q0    ( )I9:E85S::@< 0  ,06   :              "
M@<R:! !X;"]W;W)K<VAE971S+W-H965T,3<U+GAM;%!+ 0(4 Q0    ( )I9
M:E;]#=!H]0D  -A&   :              " @72?! !X;"]W;W)K<VAE971S
M+W-H965T,3<V+GAM;%!+ 0(4 Q0    ( )I9:E:ZMQD3Q@,  $H3   :
M          " @:&I! !X;"]W;W)K<VAE971S+W-H965T,3<W+GAM;%!+ 0(4
M Q0    ( )I9:E:VQ<?\;PL  (]4   :              " @9^M! !X;"]W
M;W)K<VAE971S+W-H965T,3<X+GAM;%!+ 0(4 Q0    ( )I9:E;*1N)J-A,
M -"G   :              " @4:Y! !X;"]W;W)K<VAE971S+W-H965T,3<Y
M+GAM;%!+ 0(4 Q0    ( )I9:E9<CON!$ ,  "$-   :              "
M@;3,! !X;"]W;W)K<VAE971S+W-H965T,3@P+GAM;%!+ 0(4 Q0    ( )I9
M:E8NB]2S[00  -$2   :              " @?S/! !X;"]W;W)K<VAE971S
M+W-H965T,3@Q+GAM;%!+ 0(4 Q0    ( )I9:E8)([)LQ@,  *(.   :
M          " @2'5! !X;"]W;W)K<VAE971S+W-H965T,3@R+GAM;%!+ 0(4
M Q0    ( )I9:E8KG9)TQ ,  #$5   :              " @1_9! !X;"]W
M;W)K<VAE971S+W-H965T,3@S+GAM;%!+ 0(4 Q0    ( )I9:E8J>/EXPP,
M $ 5   :              " @1O=! !X;"]W;W)K<VAE971S+W-H965T,3@T
M+GAM;%!+ 0(4 Q0    ( )I9:E8]JUZ+) ,  "$,   :              "
M@1;A! !X;"]W;W)K<VAE971S+W-H965T,3@U+GAM;%!+ 0(4 Q0    ( )I9
M:E:*$;UZV04  $,G   :              " @7+D! !X;"]W;W)K<VAE971S
M+W-H965T,3@V+GAM;%!+ 0(4 Q0    ( )I9:E9RZ3M\U0,   41   :
M          " @8/J! !X;"]W;W)K<VAE971S+W-H965T,3@W+GAM;%!+ 0(4
M Q0    ( )I9:E;@W NZ$ D  *1%   :              " @9#N! !X;"]W
M;W)K<VAE971S+W-H965T,3@X+GAM;%!+ 0(4 Q0    ( )I9:E:304^8P08
M '0L   :              " @=CW! !X;"]W;W)K<VAE971S+W-H965T,3@Y
M+GAM;%!+ 0(4 Q0    ( )I9:E8)Z?T,6@P  +B'   :              "
M@='^! !X;"]W;W)K<VAE971S+W-H965T,3DP+GAM;%!+ 0(4 Q0    ( )I9
M:E:LW!6JJ 0  .8=   :              " @6,+!0!X;"]W;W)K<VAE971S
M+W-H965T,3DQ+GAM;%!+ 0(4 Q0    ( )I9:E;%D3!$A@(   T'   :
M          " @4,0!0!X;"]W;W)K<VAE971S+W-H965T,3DR+GAM;%!+ 0(4
M Q0    ( )I9:E:]-S9QCP(  #\&   :              " @0$3!0!X;"]W
M;W)K<VAE971S+W-H965T,3DS+GAM;%!+ 0(4 Q0    ( )I9:E9G K8#40(
M ! %   :              " @<@5!0!X;"]W;W)K<VAE971S+W-H965T,3DT
M+GAM;%!+ 0(4 Q0    ( )I9:E;B%^U\;@,  *4*   :              "
M@5$8!0!X;"]W;W)K<VAE971S+W-H965T,3DU+GAM;%!+ 0(4 Q0    ( )I9
M:E8KJ6!I@04  $0?   :              " @?<;!0!X;"]W;W)K<VAE971S
M+W-H965T,3DV+GAM;%!+ 0(4 Q0    ( )I9:E8^;^0F:00  &D7   :
M          " @; A!0!X;"]W;W)K<VAE971S+W-H965T,3DW+GAM;%!+ 0(4
M Q0    ( )I9:E:J/.=N5P,  (@.   :              " @5$F!0!X;"]W
M;W)K<VAE971S+W-H965T,3DX+GAM;%!+ 0(4 Q0    ( )I9:E:?BDB+@@4
M  ,@   :              " @> I!0!X;"]W;W)K<VAE971S+W-H965T,3DY
M+GAM;%!+ 0(4 Q0    ( )I9:E;RD8YG\P(  )D(   :              "
M@9HO!0!X;"]W;W)K<VAE971S+W-H965T,C P+GAM;%!+ 0(4 Q0    ( )I9
M:E:OZM-*R0D  "E2   :              " @<4R!0!X;"]W;W)K<VAE971S
M+W-H965T,C Q+GAM;%!+ 0(4 Q0    ( )I9:E8':-8R40<  #8Y   :
M          " @<8\!0!X;"]W;W)K<VAE971S+W-H965T,C R+GAM;%!+ 0(4
M Q0    ( )I9:E;XO74(NP,  " 0   :              " @4]$!0!X;"]W
M;W)K<VAE971S+W-H965T,C S+GAM;%!+ 0(4 Q0    ( )I9:E:0E#^W;P@
M !\S   :              " @4)(!0!X;"]W;W)K<VAE971S+W-H965T,C T
M+GAM;%!+ 0(4 Q0    ( )I9:E9LL)EK200   87   :              "
M@>E0!0!X;"]W;W)K<VAE971S+W-H965T,C U+GAM;%!+ 0(4 Q0    ( )I9
M:E8'I]XGOAL  &W+ 0 :              " @6I5!0!X;"]W;W)K<VAE971S
M+W-H965T,C V+GAM;%!+ 0(4 Q0    ( )I9:E8C.&^)\PD  )IA   :
M          " @6!Q!0!X;"]W;W)K<VAE971S+W-H965T,C W+GAM;%!+ 0(4
M Q0    ( )I9:E:",]><KP,  *H)   :              " @8M[!0!X;"]W
M;W)K<VAE971S+W-H965T,C X+GAM;%!+ 0(4 Q0    ( )I9:E;0RVMDXP4
M 'H;   :              " @7)_!0!X;"]W;W)K<VAE971S+W-H965T,C Y
M+GAM;%!+ 0(4 Q0    ( )I9:E8T?[:ZF@D  -=3   :              "
M@8V%!0!X;"]W;W)K<VAE971S+W-H965T,C$P+GAM;%!+ 0(4 Q0    ( )I9
M:E:M/Q-EL <  #-!   :              " @5^/!0!X;"]W;W)K<VAE971S
M+W-H965T,C$Q+GAM;%!+ 0(4 Q0    ( )I9:E8,'-1DOP8  )P<   :
M          " @4>7!0!X;"]W;W)K<VAE971S+W-H965T,C$R+GAM;%!+ 0(4
M Q0    ( )I9:E;(7ABPY 0  +82   :              " @3Z>!0!X;"]W
M;W)K<VAE971S+W-H965T,C$S+GAM;%!+ 0(4 Q0    ( )I9:E:NG(N1^!$
M &:=   :              " @5JC!0!X;"]W;W)K<VAE971S+W-H965T,C$T
M+GAM;%!+ 0(4 Q0    ( )I9:E9S5B<=HR(   07 @ :              "
M@8JU!0!X;"]W;W)K<VAE971S+W-H965T,C$U+GAM;%!+ 0(4 Q0    ( )I9
M:E9>YNM]^@0  /$;   :              " @678!0!X;"]W;W)K<VAE971S
M+W-H965T,C$V+GAM;%!+ 0(4 Q0    ( )I9:E;B[6U"OPL  .]H   :
M          " @9?=!0!X;"]W;W)K<VAE971S+W-H965T,C$W+GAM;%!+ 0(4
M Q0    ( )I9:E:>!CLRJ1   /W7   :              " @8[I!0!X;"]W
M;W)K<VAE971S+W-H965T,C$X+GAM;%!+ 0(4 Q0    ( )I9:E;$YYL\% 0
M (0,   :              " @6_Z!0!X;"]W;W)K<VAE971S+W-H965T,C$Y
M+GAM;%!+ 0(4 Q0    ( )I9:E9X/Y:"2 4  *$A   :              "
M@;O^!0!X;"]W;W)K<VAE971S+W-H965T,C(P+GAM;%!+ 0(4 Q0    ( )I9
M:E9H?BI9Z@4  "LD   :              " @3L$!@!X;"]W;W)K<VAE971S
M+W-H965T,C(Q+GAM;%!+ 0(4 Q0    ( )I9:E:I=@=JK@8  /XU   :
M          " @5T*!@!X;"]W;W)K<VAE971S+W-H965T,C(R+GAM;%!+ 0(4
M Q0    ( )I9:E8ESWCN-P0  .D6   :              " @4,1!@!X;"]W
M;W)K<VAE971S+W-H965T,C(S+GAM;%!+ 0(4 Q0    ( )I9:E99;<K@A P
M !9Q   :              " @;(5!@!X;"]W;W)K<VAE971S+W-H965T,C(T
M+GAM;%!+ 0(4 Q0    ( )I9:E82 "[%A @  .<_   :              "
M@6XB!@!X;"]W;W)K<VAE971S+W-H965T,C(U+GAM;%!+ 0(4 Q0    ( )I9
M:E8T@!7-@P0  ,<2   :              " @2HK!@!X;"]W;W)K<VAE971S
M+W-H965T,C(V+GAM;%!+ 0(4 Q0    ( )I9:E:&=FO1R 0  )4:   :
M          " @>4O!@!X;"]W;W)K<VAE971S+W-H965T,C(W+GAM;%!+ 0(4
M Q0    ( )I9:E;ZO<WZX 0  'H?   :              " @>4T!@!X;"]W
M;W)K<VAE971S+W-H965T,C(X+GAM;%!+ 0(4 Q0    ( )I9:E:XN;2WR 8
M #XR   :              " @?TY!@!X;"]W;W)K<VAE971S+W-H965T,C(Y
M+GAM;%!+ 0(4 Q0    ( )I9:E99"3Z>+00  &06   :              "
M@?U !@!X;"]W;W)K<VAE971S+W-H965T,C,P+GAM;%!+ 0(4 Q0    ( )I9
M:E9K(3-??@@  .\Y   :              " @6)%!@!X;"]W;W)K<VAE971S
M+W-H965T,C,Q+GAM;%!+ 0(4 Q0    ( )I9:E97IYIPXP8  !%!   :
M          " @1A.!@!X;"]W;W)K<VAE971S+W-H965T,C,R+GAM;%!+ 0(4
M Q0    ( )I9:E8*0VICGPD  $EB   :              " @3-5!@!X;"]W
M;W)K<VAE971S+W-H965T,C,S+GAM;%!+ 0(4 Q0    ( )I9:E:[NNMT5@4
M #@>   :              " @0I?!@!X;"]W;W)K<VAE971S+W-H965T,C,T
M+GAM;%!+ 0(4 Q0    ( )I9:E:1_C@SA0,  -X*   :              "
M@9AD!@!X;"]W;W)K<VAE971S+W-H965T,C,U+GAM;%!+ 0(4 Q0    ( )I9
M:E97TWDXW (  (H(   :              " @55H!@!X;"]W;W)K<VAE971S
M+W-H965T,C,V+GAM;%!+ 0(4 Q0    ( )I9:E8<C#@U>0,  'H-   :
M          " @6EK!@!X;"]W;W)K<VAE971S+W-H965T,C,W+GAM;%!+ 0(4
M Q0    ( )I9:E:DWD5!2P,  !L+   :              " @1IO!@!X;"]W
M;W)K<VAE971S+W-H965T,C,X+GAM;%!+ 0(4 Q0    ( )I9:E9RRU9<\18
M ,3]   :              " @9UR!@!X;"]W;W)K<VAE971S+W-H965T,C,Y
M+GAM;%!+ 0(4 Q0    ( )I9:E;X)L51+@,  ( *   :              "
M@<:)!@!X;"]W;W)K<VAE971S+W-H965T,C0P+GAM;%!+ 0(4 Q0    ( )I9
M:E9PT@[;Y0,  #42   :              " @2R-!@!X;"]W;W)K<VAE971S
M+W-H965T,C0Q+GAM;%!+ 0(4 Q0    ( )I9:E8C^A;GQ@,  'D=   -
M          "  4F1!@!X;"]S='EL97,N>&UL4$L! A0#%     @ FEEJ5I>*
MNQS     $P(   L              ( !.I4& %]R96QS+RYR96QS4$L! A0#
M%     @ FEEJ5E<4H'=C#@  H)T   \              ( !(Y8& 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( )I9:E8F$__S#@8  -B,   :
M      "  ;.D!@!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( )I9:E:^>L2+"P0  ,6$   3              "  ?FJ!@!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    #Y /D 5$4  #6O!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>342
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>343
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>344
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1935</ContextCount>
  <ElementCount>1116</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>647</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated income statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated income statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated statement of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome</Role>
      <ShortName>Consolidated statement of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated balance sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated balance sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated statement of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity</Role>
      <ShortName>Consolidated statement of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated cash flow statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ConsolidatedCashFlowStatement</Role>
      <ShortName>Consolidated cash flow statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Presentation of the financial statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PresentationOfTheFinancialStatements</Role>
      <ShortName>Presentation of the financial statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Accounting principles and policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AccountingPrinciplesAndPolicies</Role>
      <ShortName>Accounting principles and policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty</Role>
      <ShortName>Critical accounting judgements and key sources of estimation uncertainty</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - New accounting requirements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NewAccountingRequirements</Role>
      <ShortName>New accounting requirements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Exchange rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ExchangeRates</Role>
      <ShortName>Exchange rates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Turnover and segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformation</Role>
      <ShortName>Turnover and segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Other operating income/(expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherOperatingIncomeExpense</Role>
      <ShortName>Other operating income/(expense)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Operating profit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OperatingProfit</Role>
      <ShortName>Operating profit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Employee costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCosts</Role>
      <ShortName>Employee costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Major restructuring costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCosts</Role>
      <ShortName>Major restructuring costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Finance income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceIncome</Role>
      <ShortName>Finance income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Finance expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceExpense</Role>
      <ShortName>Finance expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Associates and joint ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVentures</Role>
      <ShortName>Associates and joint ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/Taxation</Role>
      <ShortName>Taxation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Dividends</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/Dividends</Role>
      <ShortName>Dividends</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Right of use assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/RightOfUseAssets</Role>
      <ShortName>Right of use assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Other intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssets</Role>
      <ShortName>Other intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Investments in associates and joint ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures</Role>
      <ShortName>Investments in associates and joint ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Current equity investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CurrentEquityInvestments</Role>
      <ShortName>Current equity investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Other investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherInvestments</Role>
      <ShortName>Other investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Other non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentAssets</Role>
      <ShortName>Other non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherReceivables</Role>
      <ShortName>Trade and other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssetsHeldForSale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Net debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NetDebt</Role>
      <ShortName>Net debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Pensions and other post-employment benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits</Role>
      <ShortName>Pensions and other post-employment benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Other provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherProvisions</Role>
      <ShortName>Other provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Contingent consideration liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentConsiderationLiabilities</Role>
      <ShortName>Contingent consideration liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Other non-current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentLiabilities</Role>
      <ShortName>Other non-current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Contingent liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentLiabilities</Role>
      <ShortName>Contingent liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Share capital and share premium account</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount</Role>
      <ShortName>Share capital and share premium account</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Movements in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquity</Role>
      <ShortName>Movements in equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NonControllingInterests</Role>
      <ShortName>Non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Acquisitions and disposals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposals</Role>
      <ShortName>Acquisitions and disposals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Adjustments reconciling profit after tax to operating cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows</Role>
      <ShortName>Adjustments reconciling profit after tax to operating cash flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Reconciliation of net cash flow to movement in net debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt</Role>
      <ShortName>Reconciliation of net cash flow to movement in net debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Financial instruments and related disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures</Role>
      <ShortName>Financial instruments and related disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Employee share schemes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemes</Role>
      <ShortName>Employee share schemes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Principal Group companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PrincipalGroupCompanies</Role>
      <ShortName>Principal Group companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Legal proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/LegalProceedings</Role>
      <ShortName>Legal proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Post balance sheet events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PostBalanceSheetEvents</Role>
      <ShortName>Post balance sheet events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Accounting principles and policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies</Role>
      <ShortName>Accounting principles and policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AccountingPrinciplesAndPolicies</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Accounting principles and policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables</Role>
      <ShortName>Accounting principles and policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AccountingPrinciplesAndPolicies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Exchange rates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ExchangeRatesTables</Role>
      <ShortName>Exchange rates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/ExchangeRates</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Turnover and segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationTables</Role>
      <ShortName>Turnover and segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/TurnoverAndSegmentInformation</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Other operating income/(expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherOperatingIncomeExpenseTables</Role>
      <ShortName>Other operating income/(expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherOperatingIncomeExpense</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Operating profit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OperatingProfitTables</Role>
      <ShortName>Operating profit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OperatingProfit</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Employee costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCostsTables</Role>
      <ShortName>Employee costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/EmployeeCosts</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Major restructuring costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCostsTables</Role>
      <ShortName>Major restructuring costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/MajorRestructuringCosts</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Finance income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceIncomeTables</Role>
      <ShortName>Finance income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/FinanceIncome</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Finance expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceExpenseTables</Role>
      <ShortName>Finance expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/FinanceExpense</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Associates and joint ventures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVenturesTables</Role>
      <ShortName>Associates and joint ventures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AssociatesAndJointVentures</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Taxation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationTables</Role>
      <ShortName>Taxation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/Taxation</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/EarningsPerShare</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Dividends (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/DividendsTables</Role>
      <ShortName>Dividends (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/Dividends</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Right of use assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/RightOfUseAssetsTables</Role>
      <ShortName>Right of use assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/RightOfUseAssets</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/Goodwill</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Other intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssetsTables</Role>
      <ShortName>Other intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherIntangibleAssets</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Investments in associates and joint ventures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables</Role>
      <ShortName>Investments in associates and joint ventures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Current equity investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CurrentEquityInvestmentsTables</Role>
      <ShortName>Current equity investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/CurrentEquityInvestments</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Other investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherInvestmentsTables</Role>
      <ShortName>Other investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherInvestments</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Other non-current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentAssetsTables</Role>
      <ShortName>Other non-current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherNonCurrentAssets</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/Inventories</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherReceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/TradeAndOtherReceivables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/CashAndCashEquivalents</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Assets held for sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssetsHeldForSaleTables</Role>
      <ShortName>Assets held for sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AssetsHeldForSale</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/TradeAndOtherPayables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Net debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NetDebtTables</Role>
      <ShortName>Net debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/NetDebt</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Pensions and other post-employment benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables</Role>
      <ShortName>Pensions and other post-employment benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Other provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherProvisionsTables</Role>
      <ShortName>Other provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherProvisions</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Contingent consideration liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables</Role>
      <ShortName>Contingent consideration liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/ContingentConsiderationLiabilities</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Other non-current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables</Role>
      <ShortName>Other non-current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/OtherNonCurrentLiabilities</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/Commitments</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Share capital and share premium account (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables</Role>
      <ShortName>Share capital and share premium account (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Movements in equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquityTables</Role>
      <ShortName>Movements in equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/MovementsInEquity</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Non-controlling interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NonControllingInterestsTables</Role>
      <ShortName>Non-controlling interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/NonControllingInterests</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Acquisitions and disposals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsTables</Role>
      <ShortName>Acquisitions and disposals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AcquisitionsAndDisposals</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Adjustments reconciling profit after tax to operating cash flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables</Role>
      <ShortName>Adjustments reconciling profit after tax to operating cash flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Reconciliation of net cash flow to movement in net debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables</Role>
      <ShortName>Reconciliation of net cash flow to movement in net debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Financial instruments and related disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables</Role>
      <ShortName>Financial instruments and related disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Employee share schemes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesTables</Role>
      <ShortName>Employee share schemes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/EmployeeShareSchemes</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Principal Group companies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PrincipalGroupCompaniesTables</Role>
      <ShortName>Principal Group companies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gsk.com/role/PrincipalGroupCompanies</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Presentation of the Financial Statements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail</Role>
      <ShortName>Presentation of the Financial Statements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Accounting Principles and Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail</Role>
      <ShortName>Accounting Principles and Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail</Role>
      <ShortName>Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail</Role>
      <ShortName>Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Turnover and Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Turnover and Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Turnover and Segment Information - Turnover by Segment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail</Role>
      <ShortName>Turnover and Segment Information - Turnover by Segment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Turnover and Segment Information - Turnover by Product &amp; Service (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail</Role>
      <ShortName>Turnover and Segment Information - Turnover by Product &amp; Service (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Turnover and Segment Information - Segment Profit and Operating Profit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail</Role>
      <ShortName>Turnover and Segment Information - Segment Profit and Operating Profit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Turnover and Segment Information - Summary of Geographical Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail</Role>
      <ShortName>Turnover and Segment Information - Summary of Geographical Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Other operating income/(expense) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail</Role>
      <ShortName>Other operating income/(expense) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>1108 - Disclosure - Other operating income/(expense) - Information about Other Operating Income Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail</Role>
      <ShortName>Other operating income/(expense) - Information about Other Operating Income Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>1109 - Disclosure - Operating Profit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail</Role>
      <ShortName>Operating Profit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>1110 - Disclosure - Operating Profit - Summary of Information About Profit Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail</Role>
      <ShortName>Operating Profit - Summary of Information About Profit Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>1111 - Disclosure - Operating Profit - Summary of Auditors Remuneration (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail</Role>
      <ShortName>Operating Profit - Summary of Auditors Remuneration (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>1112 - Disclosure - Employee Costs - Summary of Employee Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail</Role>
      <ShortName>Employee Costs - Summary of Employee Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>1113 - Disclosure - Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail</Role>
      <ShortName>Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>1114 - Disclosure - Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail</Role>
      <ShortName>Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>1115 - Disclosure - Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail</Role>
      <ShortName>Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>1116 - Disclosure - Major Restructuring Costs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail</Role>
      <ShortName>Major Restructuring Costs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>1117 - Disclosure - Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail</Role>
      <ShortName>Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>1118 - Disclosure - Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail</Role>
      <ShortName>Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>1119 - Disclosure - Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail</Role>
      <ShortName>Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>1120 - Disclosure - Finance Income - Summary of Finance Income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail</Role>
      <ShortName>Finance Income - Summary of Finance Income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>1121 - Disclosure - Finance Expense - Summary of Finance Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail</Role>
      <ShortName>Finance Expense - Summary of Finance Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>1122 - Disclosure - Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail</Role>
      <ShortName>Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>1123 - Disclosure - Associates and joint ventures - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail</Role>
      <ShortName>Associates and joint ventures - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>1124 - Disclosure - Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail</Role>
      <ShortName>Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>1125 - Disclosure - Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail</Role>
      <ShortName>Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>1126 - Disclosure - Taxation - Summary of Taxation Charge Based on Profits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail</Role>
      <ShortName>Taxation - Summary of Taxation Charge Based on Profits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>1127 - Disclosure - Taxation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationAdditionalInformationDetail</Role>
      <ShortName>Taxation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>1128 - Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail</Role>
      <ShortName>Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>1129 - Disclosure - Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail</Role>
      <ShortName>Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>1130 - Disclosure - Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>1131 - Disclosure - Taxation - Summary of Net Deferred Tax Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail</Role>
      <ShortName>Taxation - Summary of Net Deferred Tax Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>1132 - Disclosure - Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail</Role>
      <ShortName>Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>1133 - Disclosure - Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail</Role>
      <ShortName>Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>1134 - Disclosure - Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail</Role>
      <ShortName>Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>1135 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail</Role>
      <ShortName>Dividends - Summary of Interim Financial Reporting (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>1136 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical</Role>
      <ShortName>Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>1137 - Disclosure - Dividends - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/DividendsAdditionalInformationDetail</Role>
      <ShortName>Dividends - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>1138 - Disclosure - Dividends - Summary of Dividends to Shareholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail</Role>
      <ShortName>Dividends - Summary of Dividends to Shareholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>1139 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>1140 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>1141 - Disclosure - Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail</Role>
      <ShortName>Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>1142 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/GoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>1143 - Disclosure - Goodwill - Summary of Changes in Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail</Role>
      <ShortName>Goodwill - Summary of Changes in Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>1144 - Disclosure - Goodwill - Summary of Goodwill Allocated to Segments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail</Role>
      <ShortName>Goodwill - Summary of Goodwill Allocated to Segments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>1145 - Disclosure - Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail</Role>
      <ShortName>Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>1146 - Disclosure - Other Intangible Assets - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Other Intangible Assets - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>1147 - Disclosure - Other Intangible Assets - Summary of Other Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail</Role>
      <ShortName>Other Intangible Assets - Summary of Other Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>1148 - Disclosure - Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail</Role>
      <ShortName>Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>148</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>1149 - Disclosure - Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail</Role>
      <ShortName>Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>1150 - Disclosure - Investments in Associates and Joint Ventures - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail</Role>
      <ShortName>Investments in Associates and Joint Ventures - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>1151 - Disclosure - Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail</Role>
      <ShortName>Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>151</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>1152 - Disclosure - Current Equity Investments - Summary of Current Equity Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail</Role>
      <ShortName>Current Equity Investments - Summary of Current Equity Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>152</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>1153 - Disclosure - Current Equity Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Current Equity Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>153</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>1154 - Disclosure - Other Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Other Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>154</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>1155 - Disclosure - Other Investments - Schedule of Other Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail</Role>
      <ShortName>Other Investments - Schedule of Other Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>155</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>1156 - Disclosure - Other Non-Current Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail</Role>
      <ShortName>Other Non-Current Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>156</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>1157 - Disclosure - Other Non-Current Assets - Summary of Other Non-Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail</Role>
      <ShortName>Other Non-Current Assets - Summary of Other Non-Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>157</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>1158 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>1159 - Disclosure - Trade and Other Receivables - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail</Role>
      <ShortName>Trade and Other Receivables - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>159</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>1160 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail</Role>
      <ShortName>Trade and Other Receivables - Summary of Trade and Other Receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>160</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>1161 - Disclosure - Trade and Other Receivables - Summary of Loss Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail</Role>
      <ShortName>Trade and Other Receivables - Summary of Loss Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>161</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>1162 - Disclosure - Cash and cash equivalents - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail</Role>
      <ShortName>Cash and cash equivalents - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>162</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>1163 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>163</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>1164 - Disclosure - Assets Held for Sale - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail</Role>
      <ShortName>Assets Held for Sale - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>164</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R165.htm</HtmlFileName>
      <LongName>1165 - Disclosure - Assets Held for Sale - Summary of Assets Held for Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail</Role>
      <ShortName>Assets Held for Sale - Summary of Assets Held for Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>165</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R166.htm</HtmlFileName>
      <LongName>1166 - Disclosure - Trade and Other Payables - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail</Role>
      <ShortName>Trade and Other Payables - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>166</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R167.htm</HtmlFileName>
      <LongName>1167 - Disclosure - Trade and Other Payables - Summary of Trade and Other Payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and Other Payables - Summary of Trade and Other Payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>167</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R168.htm</HtmlFileName>
      <LongName>1168 - Disclosure - Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail</Role>
      <ShortName>Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>168</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R169.htm</HtmlFileName>
      <LongName>1169 - Disclosure - Net Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NetDebtAdditionalInformationDetail</Role>
      <ShortName>Net Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>169</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R170.htm</HtmlFileName>
      <LongName>1170 - Disclosure - Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail</Role>
      <ShortName>Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>170</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R171.htm</HtmlFileName>
      <LongName>1171 - Disclosure - Net Debt - Schedule of Finance Lease Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail</Role>
      <ShortName>Net Debt - Schedule of Finance Lease Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>171</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R172.htm</HtmlFileName>
      <LongName>1172 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>172</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R173.htm</HtmlFileName>
      <LongName>1173 - Disclosure - Pensions and Other Post-employment Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>173</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R174.htm</HtmlFileName>
      <LongName>1174 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>174</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R175.htm</HtmlFileName>
      <LongName>1175 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>175</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R176.htm</HtmlFileName>
      <LongName>1176 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>176</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R177.htm</HtmlFileName>
      <LongName>1177 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>177</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R178.htm</HtmlFileName>
      <LongName>1178 - Disclosure - Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>178</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R179.htm</HtmlFileName>
      <LongName>1179 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>179</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R180.htm</HtmlFileName>
      <LongName>1180 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>180</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R181.htm</HtmlFileName>
      <LongName>1181 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail</Role>
      <ShortName>Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>181</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R182.htm</HtmlFileName>
      <LongName>1182 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail</Role>
      <ShortName>Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>182</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R183.htm</HtmlFileName>
      <LongName>1183 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail</Role>
      <ShortName>Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>183</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R184.htm</HtmlFileName>
      <LongName>1184 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail</Role>
      <ShortName>Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>184</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R185.htm</HtmlFileName>
      <LongName>1185 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail</Role>
      <ShortName>Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>185</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R186.htm</HtmlFileName>
      <LongName>1186 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail</Role>
      <ShortName>Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>186</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R187.htm</HtmlFileName>
      <LongName>1187 - Disclosure - Other provisions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail</Role>
      <ShortName>Other provisions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>187</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R188.htm</HtmlFileName>
      <LongName>1188 - Disclosure - Other Provisions - Summary of Other Provisions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail</Role>
      <ShortName>Other Provisions - Summary of Other Provisions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>188</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R189.htm</HtmlFileName>
      <LongName>1189 - Disclosure - Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail</Role>
      <ShortName>Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>189</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R190.htm</HtmlFileName>
      <LongName>1190 - Disclosure - Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail</Role>
      <ShortName>Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>190</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R191.htm</HtmlFileName>
      <LongName>1191 - Disclosure - Contingent Consideration Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Contingent Consideration Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>191</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R192.htm</HtmlFileName>
      <LongName>1192 - Disclosure - Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail</Role>
      <ShortName>Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>192</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R193.htm</HtmlFileName>
      <LongName>1193 - Disclosure - Contingent Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Contingent Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>193</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R194.htm</HtmlFileName>
      <LongName>1194 - Disclosure - Commitments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CommitmentsAdditionalInformationDetail</Role>
      <ShortName>Commitments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>194</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R195.htm</HtmlFileName>
      <LongName>1195 - Disclosure - Commitments - Schedule of Contractual Obligations and Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail</Role>
      <ShortName>Commitments - Schedule of Contractual Obligations and Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>195</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R196.htm</HtmlFileName>
      <LongName>1196 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail</Role>
      <ShortName>Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>196</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R197.htm</HtmlFileName>
      <LongName>1197 - Disclosure - Share Capital and Share Premium Account - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail</Role>
      <ShortName>Share Capital and Share Premium Account - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>197</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R198.htm</HtmlFileName>
      <LongName>1198 - Disclosure - Movements in Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail</Role>
      <ShortName>Movements in Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>198</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R199.htm</HtmlFileName>
      <LongName>1199 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail</Role>
      <ShortName>Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>199</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R200.htm</HtmlFileName>
      <LongName>1200 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail</Role>
      <ShortName>Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>200</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R201.htm</HtmlFileName>
      <LongName>1201 - Disclosure - Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail</Role>
      <ShortName>Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>201</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R202.htm</HtmlFileName>
      <LongName>1202 - Disclosure - Movements in Equity - Analysis of Other Reserves (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail</Role>
      <ShortName>Movements in Equity - Analysis of Other Reserves (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>202</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R203.htm</HtmlFileName>
      <LongName>1203 - Disclosure - Non-controlling interests - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail</Role>
      <ShortName>Non-controlling interests - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>203</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R204.htm</HtmlFileName>
      <LongName>1204 - Disclosure - Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail</Role>
      <ShortName>Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>204</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R205.htm</HtmlFileName>
      <LongName>1205 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>205</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R206.htm</HtmlFileName>
      <LongName>1206 - Disclosure - Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail</Role>
      <ShortName>Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>206</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R207.htm</HtmlFileName>
      <LongName>1207 - Disclosure - Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail</Role>
      <ShortName>Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>207</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R208.htm</HtmlFileName>
      <LongName>1208 - Disclosure - Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail</Role>
      <ShortName>Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>208</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R209.htm</HtmlFileName>
      <LongName>1209 - Disclosure - Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail</Role>
      <ShortName>Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>209</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R210.htm</HtmlFileName>
      <LongName>1210 - Disclosure - Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail</Role>
      <ShortName>Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>210</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R211.htm</HtmlFileName>
      <LongName>1211 - Disclosure - Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail</Role>
      <ShortName>Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>211</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R212.htm</HtmlFileName>
      <LongName>1212 - Disclosure - Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail</Role>
      <ShortName>Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>212</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R213.htm</HtmlFileName>
      <LongName>1213 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail</Role>
      <ShortName>Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>213</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R214.htm</HtmlFileName>
      <LongName>1214 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail</Role>
      <ShortName>Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>214</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R215.htm</HtmlFileName>
      <LongName>1215 - Disclosure - Financial instruments and related disclosures - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail</Role>
      <ShortName>Financial instruments and related disclosures - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>215</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R216.htm</HtmlFileName>
      <LongName>1216 - Disclosure - Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>216</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R217.htm</HtmlFileName>
      <LongName>1217 - Disclosure - Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>217</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R218.htm</HtmlFileName>
      <LongName>1218 - Disclosure - Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>218</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R219.htm</HtmlFileName>
      <LongName>1219 - Disclosure - Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>219</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R220.htm</HtmlFileName>
      <LongName>1220 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail</Role>
      <ShortName>Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>220</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R221.htm</HtmlFileName>
      <LongName>1221 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail</Role>
      <ShortName>Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>221</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R222.htm</HtmlFileName>
      <LongName>1222 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail</Role>
      <ShortName>Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>222</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R223.htm</HtmlFileName>
      <LongName>1223 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail</Role>
      <ShortName>Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>223</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R224.htm</HtmlFileName>
      <LongName>1224 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>224</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R225.htm</HtmlFileName>
      <LongName>1225 - Disclosure - Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>225</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R226.htm</HtmlFileName>
      <LongName>1226 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail</Role>
      <ShortName>Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>226</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R227.htm</HtmlFileName>
      <LongName>1227 - Disclosure - Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>227</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R228.htm</HtmlFileName>
      <LongName>1228 - Disclosure - Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail</Role>
      <ShortName>Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>228</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R229.htm</HtmlFileName>
      <LongName>1229 - Disclosure - Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail</Role>
      <ShortName>Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>229</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R230.htm</HtmlFileName>
      <LongName>1230 - Disclosure - Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail</Role>
      <ShortName>Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>230</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R231.htm</HtmlFileName>
      <LongName>1231 - Disclosure - Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail</Role>
      <ShortName>Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>231</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R232.htm</HtmlFileName>
      <LongName>1232 - Disclosure - Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail</Role>
      <ShortName>Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>232</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R233.htm</HtmlFileName>
      <LongName>1233 - Disclosure - Employee Share Schemes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail</Role>
      <ShortName>Employee Share Schemes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>233</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R234.htm</HtmlFileName>
      <LongName>1234 - Disclosure - Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail</Role>
      <ShortName>Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>234</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R235.htm</HtmlFileName>
      <LongName>1235 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail</Role>
      <ShortName>Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>235</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R236.htm</HtmlFileName>
      <LongName>1236 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail</Role>
      <ShortName>Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>236</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R237.htm</HtmlFileName>
      <LongName>1237 - Disclosure - Employee Share Schemes - Summary of Option Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail</Role>
      <ShortName>Employee Share Schemes - Summary of Option Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>237</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R238.htm</HtmlFileName>
      <LongName>1238 - Disclosure - Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail</Role>
      <ShortName>Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>238</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R239.htm</HtmlFileName>
      <LongName>1239 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail</Role>
      <ShortName>Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>239</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R240.htm</HtmlFileName>
      <LongName>1240 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail</Role>
      <ShortName>Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>240</Position>
    </Report>
    <Report instance="d382677d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R241.htm</HtmlFileName>
      <LongName>1241 - Disclosure - Legal Proceedings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail</Role>
      <ShortName>Legal Proceedings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>241</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 12 fact(s) appearing in ix:hidden were eligible for transformation: ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments, ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness, ifrs-full:DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem, ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill, ifrs-full:ParValuePerShare -  d382677dex152.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="d382677d20f.htm">d382677d20f.htm</File>
    <File doctype="20-F" original="d382677dex152.htm">d382677dex152.htm</File>
    <File>d382677dex11.htm</File>
    <File>d382677dex121.htm</File>
    <File>d382677dex122.htm</File>
    <File>d382677dex131.htm</File>
    <File>d382677dex151.htm</File>
    <File>d382677dex23.htm</File>
    <File>d382677dex48.htm</File>
    <File>gsk-20221231.xsd</File>
    <File>gsk-20221231_cal.xml</File>
    <File>gsk-20221231_def.xml</File>
    <File>gsk-20221231_lab.xml</File>
    <File>gsk-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g382677dsp001b.jpg</File>
    <File>g382677f_01a.jpg</File>
    <File>g382677f_01b.jpg</File>
    <File>g382677f_02a.jpg</File>
    <File>g382677f_03a.jpg</File>
    <File>g382677f_03b.jpg</File>
    <File>g382677f_03c.jpg</File>
    <File>g382677f_04.jpg</File>
    <File>g382677f_05.jpg</File>
    <File>g382677f_06.jpg</File>
    <File>g382677f_07.jpg</File>
    <File>g382677f_08a.jpg</File>
    <File>g382677f_08b.jpg</File>
    <File>g382677f_08c.jpg</File>
    <File>g382677f_100a.jpg</File>
    <File>g382677f_100b.jpg</File>
    <File>g382677f_103b.jpg</File>
    <File>g382677f_105.jpg</File>
    <File>g382677f_107.jpg</File>
    <File>g382677f_108.jpg</File>
    <File>g382677f_122a.jpg</File>
    <File>g382677f_122b.jpg</File>
    <File>g382677f_129.jpg</File>
    <File>g382677f_12a.jpg</File>
    <File>g382677f_12b.jpg</File>
    <File>g382677f_132.jpg</File>
    <File>g382677f_134.jpg</File>
    <File>g382677f_135.jpg</File>
    <File>g382677f_136.jpg</File>
    <File>g382677f_139.jpg</File>
    <File>g382677f_13a.jpg</File>
    <File>g382677f_13b.jpg</File>
    <File>g382677f_14.jpg</File>
    <File>g382677f_142.jpg</File>
    <File>g382677f_144.jpg</File>
    <File>g382677f_146a.jpg</File>
    <File>g382677f_146b.jpg</File>
    <File>g382677f_15.jpg</File>
    <File>g382677f_165.jpg</File>
    <File>g382677f_167.jpg</File>
    <File>g382677f_273.jpg</File>
    <File>g382677f_275.jpg</File>
    <File>g382677f_29.jpg</File>
    <File>g382677f_297.jpg</File>
    <File>g382677f_30.jpg</File>
    <File>g382677f_317.jpg</File>
    <File>g382677f_318a.jpg</File>
    <File>g382677f_318b.jpg</File>
    <File>g382677f_318c.jpg</File>
    <File>g382677f_33.jpg</File>
    <File>g382677f_34.jpg</File>
    <File>g382677f_38.jpg</File>
    <File>g382677f_39.jpg</File>
    <File>g382677f_41.jpg</File>
    <File>g382677f_53a.jpg</File>
    <File>g382677f_53b.jpg</File>
    <File>g382677f_65.jpg</File>
    <File>g382677f_73a.jpg</File>
    <File>g382677f_73b.jpg</File>
    <File>g382677f_73c.jpg</File>
    <File>g382677f_73d.jpg</File>
    <File>g382677f_74a.jpg</File>
    <File>g382677f_74b.jpg</File>
    <File>g382677f_75.jpg</File>
    <File>g382677f_89.jpg</File>
    <File>g382677f_96.jpg</File>
    <File>g382677f_97a.jpg</File>
    <File>g382677f_97b.jpg</File>
    <File>g382677f_97c.jpg</File>
    <File>g382677f_97d.jpg</File>
    <File>g382677f_97e.jpg</File>
    <File>g382677f_97f.jpg</File>
    <File>g382677f_97g.jpg</File>
    <File>g382677f_97h.jpg</File>
    <File>g382677f_98a.jpg</File>
    <File>g382677f_98b.jpg</File>
    <File>g382677f_98c.jpg</File>
    <File>g382677f_99a.jpg</File>
    <File>g382677f_99b.jpg</File>
    <File>g382677f_99c.jpg</File>
    <File>g382677f_cov.jpg</File>
    <File>g382677f_toc.jpg</File>
    <File>g382677g0309011809629.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="63">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="4093">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>347
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d382677d20f.htm d382677dex152.htm": {
   "axisCustom": 17,
   "axisStandard": 59,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 63,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 4093
   },
   "contextCount": 1935,
   "dts": {
    "calculationLink": {
     "local": [
      "gsk-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gsk-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d382677d20f.htm",
      "d382677dex152.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gsk-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gsk-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gsk-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 2153,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 12,
    "total": 15
   },
   "keyCustom": 545,
   "keyStandard": 571,
   "memberCustom": 478,
   "memberStandard": 129,
   "nsprefix": "gsk",
   "nsuri": "http://www.gsk.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gsk.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677d20f.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - New accounting requirements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.gsk.com/role/NewAccountingRequirements",
     "shortName": "New accounting requirements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
     "shortName": "Critical accounting judgements and key sources of estimation uncertainty - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:UncertainTaxPositionsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_USDsrtCurrencyAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AverageForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail",
     "shortName": "Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_USDsrtCurrencyAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AverageForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:NumberOfReportableOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Turnover and Segment Information - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
     "shortName": "Turnover and Segment Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:NumberOfReportableOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Turnover and Segment Information - Turnover by Segment (Detail)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail",
     "shortName": "Turnover and Segment Information - Turnover by Segment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1104 - Disclosure - Turnover and Segment Information - Turnover by Product & Service (Detail)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
     "shortName": "Turnover and Segment Information - Turnover by Product & Service (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfProductsAndServicesExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_SubTotalMemberifrsfullProductsAndServicesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromOperatingActivities",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1105 - Disclosure - Turnover and Segment Information - Segment Profit and Operating Profit (Detail)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
     "shortName": "Turnover and Segment Information - Segment Profit and Operating Profit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1106 - Disclosure - Turnover and Segment Information - Summary of Geographical Information (Detail)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail",
     "shortName": "Turnover and Segment Information - Summary of Geographical Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:DisposalOfBusinessesAndAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1107 - Disclosure - Other operating income/(expense) - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
     "shortName": "Other operating income/(expense) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_HaleonPlcMemberGSKInvestmentAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:UpfrontSettlementIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1108 - Disclosure - Other operating income/(expense) - Information about Other Operating Income Expense (Detail)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail",
     "shortName": "Other operating income/(expense) - Information about Other Operating Income Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:UpfrontSettlementIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1109 - Disclosure - Operating Profit - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail",
     "shortName": "Operating Profit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ExpenseOfRestructuringActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Exchange rates",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.gsk.com/role/ExchangeRates",
     "shortName": "Exchange rates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1110 - Disclosure - Operating Profit - Summary of Information About Profit Loss (Detail)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail",
     "shortName": "Operating Profit - Summary of Information About Profit Loss (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1111 - Disclosure - Operating Profit - Summary of Auditors Remuneration (Detail)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
     "shortName": "Operating Profit - Summary of Auditors Remuneration (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1112 - Disclosure - Employee Costs - Summary of Employee Costs (Detail)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail",
     "shortName": "Employee Costs - Summary of Employee Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1113 - Disclosure - Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
     "shortName": "Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShareOptionPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfNumberOfEmployeesExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:AverageNumberOfEmployeesFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1114 - Disclosure - Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail",
     "shortName": "Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfNumberOfEmployeesExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:AverageNumberOfEmployeesFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Employee",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1115 - Disclosure - Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail",
     "shortName": "Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:TotalRestructuringCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1116 - Disclosure - Major Restructuring Costs - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
     "shortName": "Major Restructuring Costs - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:TotalRestructuringCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1117 - Disclosure - Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail",
     "shortName": "Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CashRestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1118 - Disclosure - Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail",
     "shortName": "Major Restructuring Costs - Summary of Major restructuring charges from continuing operations by programme (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CashRestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1119 - Disclosure - Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail",
     "shortName": "Major Restructuring Costs - Summary of Major Restructuring Charges from Continuing Operations by Income Statement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CostOfMajorRestructuringMemberGSKRestructuringCostsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Turnover and segment information",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformation",
     "shortName": "Turnover and segment information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1120 - Disclosure - Finance Income - Summary of Finance Income (Detail)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail",
     "shortName": "Finance Income - Summary of Finance Income (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1121 - Disclosure - Finance Expense - Summary of Finance Cost (Detail)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail",
     "shortName": "Finance Expense - Summary of Finance Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1122 - Disclosure - Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
     "shortName": "Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory",
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_AssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherComprehensiveIncome",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1123 - Disclosure - Associates and joint ventures - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
     "shortName": "Associates and joint ventures - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "lang": null,
      "name": "gsk:SalesToAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "true"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1124 - Disclosure - Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
     "shortName": "Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfGroupHeldSignificantAssociateExplanatory",
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2021To12_31_2021_InnovivaIncMemberifrsfullSignificantInvestmentsInAssociatesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1125 - Disclosure - Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
     "shortName": "Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory",
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_OtherAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1126 - Disclosure - Taxation - Summary of Taxation Charge Based on Profits (Detail)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail",
     "shortName": "Taxation - Summary of Taxation Charge Based on Profits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ProvisionsForUncertainTaxPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1127 - Disclosure - Taxation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
     "shortName": "Taxation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ProvisionsForUncertainTaxPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1128 - Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail",
     "shortName": "Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:TaxEffectOfForeignTaxRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1129 - Disclosure - Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail",
     "shortName": "Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Other operating income/(expense)",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.gsk.com/role/OtherOperatingIncomeExpense",
     "shortName": "Other operating income/(expense)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1130 - Disclosure - Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "130",
     "role": "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1131 - Disclosure - Taxation - Summary of Net Deferred Tax Asset (Detail)",
     "menuCat": "Details",
     "order": "131",
     "role": "http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail",
     "shortName": "Taxation - Summary of Net Deferred Tax Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:TaxLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1132 - Disclosure - Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail)",
     "menuCat": "Details",
     "order": "132",
     "role": "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail",
     "shortName": "Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:TaxLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BasicEarningsLossPerShareFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_GBP_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1133 - Disclosure - Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail)",
     "menuCat": "Details",
     "order": "133",
     "role": "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail",
     "shortName": "Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1134 - Disclosure - Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail)",
     "menuCat": "Details",
     "order": "134",
     "role": "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail",
     "shortName": "Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfInterimDividendExplanatory",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1135 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail)",
     "menuCat": "Details",
     "order": "135",
     "role": "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
     "shortName": "Dividends - Summary of Interim Financial Reporting (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfInterimDividendExplanatory",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP_per_Share",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfInterimDividendExplanatory",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentDividendPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1136 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical)",
     "menuCat": "Details",
     "order": "136",
     "role": "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical",
     "shortName": "Dividends - Summary of Interim Financial Reporting (Detail) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfInterimDividendExplanatory",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_FourthInterimMemberifrsfullMaturityAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentDividendPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DescriptionOfInterimDividendRecognitonAndPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1137 - Disclosure - Dividends - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "137",
     "role": "http://www.gsk.com/role/DividendsAdditionalInformationDetail",
     "shortName": "Dividends - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DescriptionOfInterimDividendRecognitonAndPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R138": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CashDividendsPaidToShareholdersRecognizedInYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1138 - Disclosure - Dividends - Summary of Dividends to Shareholders (Detail)",
     "menuCat": "Details",
     "order": "138",
     "role": "http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail",
     "shortName": "Dividends - Summary of Dividends to Shareholders (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:CashDividendsPaidToShareholdersRecognizedInYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R139": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1139 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "139",
     "role": "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
     "shortName": "Property, Plant and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "2",
      "lang": null,
      "name": "gsk:WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Operating profit",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.gsk.com/role/OperatingProfit",
     "shortName": "Operating profit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R140": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1140 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)",
     "menuCat": "Details",
     "order": "140",
     "role": "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
     "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R141": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1141 - Disclosure - Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail)",
     "menuCat": "Details",
     "order": "141",
     "role": "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail",
     "shortName": "Right of use assets - Summary of Disclosure of Detailed Information About Right of Use Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_RightofuseAssetsMemberifrsfullClassesOfAssetsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:RightOfUseAssetsExchangeAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R142": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1142 - Disclosure - Goodwill - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "142",
     "role": "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
     "shortName": "Goodwill - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R143": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1143 - Disclosure - Goodwill - Summary of Changes in Goodwill (Detail)",
     "menuCat": "Details",
     "order": "143",
     "role": "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
     "shortName": "Goodwill - Summary of Changes in Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R144": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1144 - Disclosure - Goodwill - Summary of Goodwill Allocated to Segments (Detail)",
     "menuCat": "Details",
     "order": "144",
     "role": "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
     "shortName": "Goodwill - Summary of Goodwill Allocated to Segments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAllocationOfGoodwillToSegmentsExplanatory",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_PharmaceuticalsMemberifrsfullSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R145": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1145 - Disclosure - Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)",
     "menuCat": "Details",
     "order": "145",
     "role": "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
     "shortName": "Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R146": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1146 - Disclosure - Other Intangible Assets - Additional information (Detail)",
     "menuCat": "Details",
     "order": "146",
     "role": "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Other Intangible Assets - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:IntangibleAssetsForWhichImpairmentsHaveBeenCharged",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R147": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1147 - Disclosure - Other Intangible Assets - Summary of Other Intangible Assets (Detail)",
     "menuCat": "Details",
     "order": "147",
     "role": "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
     "shortName": "Other Intangible Assets - Summary of Other Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020_BrandsWithIndefiniteUsefulLifeMemberifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R148": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:AmortisationOtherIntangibleAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1148 - Disclosure - Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail)",
     "menuCat": "Details",
     "order": "148",
     "role": "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
     "shortName": "Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CostOfSalesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:AmortisationOtherIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R149": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1149 - Disclosure - Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail)",
     "menuCat": "Details",
     "order": "149",
     "role": "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
     "shortName": "Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_LicencesAndFranchisesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEmployeeCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Employee costs",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.gsk.com/role/EmployeeCosts",
     "shortName": "Employee costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEmployeeCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R150": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1150 - Disclosure - Investments in Associates and Joint Ventures - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "150",
     "role": "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
     "shortName": "Investments in Associates and Joint Ventures - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P05_20_2021To05_20_2021_AggregatedIndividuallyImmaterialAssociatesMemberifrsfullSignificantInvestmentsInAssociatesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R151": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1151 - Disclosure - Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail)",
     "menuCat": "Details",
     "order": "151",
     "role": "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail",
     "shortName": "Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:AdditionsInInvestmentsInAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R152": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1152 - Disclosure - Current Equity Investments - Summary of Current Equity Investments (Detail)",
     "menuCat": "Details",
     "order": "152",
     "role": "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
     "shortName": "Current Equity Investments - Summary of Current Equity Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock",
       "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrentEquityInvestmentsMeasuredAsFVTPLMemberifrsfullCategoriesOfFinancialAssetsAxis_CurrentEquityInvestmentsMemberifrsfullClassesOfFinancialAssetsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R153": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "gsk:PercentageOfOwnership",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1153 - Disclosure - Current Equity Investments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "153",
     "role": "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
     "shortName": "Current Equity Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_GlaxoGroupLimitedMembersrtOwnershipAxis_InvestmentInHaleonPlcMemberGSKInvestmentAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "gsk:PercentageOfOwnership",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R154": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ListedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1154 - Disclosure - Other Investments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "154",
     "role": "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
     "shortName": "Other Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ListedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R155": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory",
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1155 - Disclosure - Other Investments - Schedule of Other Investments (Detail)",
     "menuCat": "Details",
     "order": "155",
     "role": "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail",
     "shortName": "Other Investments - Schedule of Other Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory",
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020_OtherInvestmentsNoncurrentMemberifrsfullClassesOfAssetsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R156": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherNoncurrentReceivables",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1156 - Disclosure - Other Non-Current Assets - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "156",
     "role": "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
     "shortName": "Other Non-Current Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_OtherNonCurrentReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R157": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ReceivablesRelatedToInsuranceContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1157 - Disclosure - Other Non-Current Assets - Summary of Other Non-Current Assets (Detail)",
     "menuCat": "Details",
     "order": "157",
     "role": "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail",
     "shortName": "Other Non-Current Assets - Summary of Other Non-Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ReceivablesRelatedToInsuranceContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R158": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1158 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "menuCat": "Details",
     "order": "158",
     "role": "http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R159": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeReceivables",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1159 - Disclosure - Trade and Other Receivables - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "159",
     "role": "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
     "shortName": "Trade and Other Receivables - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_TradeReceivablesMemberifrsfullClassesOfFinancialInstrumentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Major restructuring costs",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.gsk.com/role/MajorRestructuringCosts",
     "shortName": "Major restructuring costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R160": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeReceivables",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1160 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Detail)",
     "menuCat": "Details",
     "order": "160",
     "role": "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail",
     "shortName": "Trade and Other Receivables - Summary of Trade and Other Receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AccruedIncomeOtherThanContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R161": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ExpectedCreditLossAllowance",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1161 - Disclosure - Trade and Other Receivables - Summary of Loss Allowance (Detail)",
     "menuCat": "Details",
     "order": "161",
     "role": "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail",
     "shortName": "Trade and Other Receivables - Summary of Loss Allowance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:ExpectedCreditLossAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R162": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1162 - Disclosure - Cash and cash equivalents - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "162",
     "role": "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail",
     "shortName": "Cash and cash equivalents - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R163": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1163 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail)",
     "menuCat": "Details",
     "order": "163",
     "role": "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
     "shortName": "Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R164": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1164 - Disclosure - Assets Held for Sale - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "164",
     "role": "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
     "shortName": "Assets Held for Sale - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To09_30_2022_ConsumerHealthcareMemberifrsfullSegmentsAxis",
      "decimals": "-8",
      "lang": null,
      "name": "gsk:GainOnDemergerBeforeExchangeMovementsAndTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R165": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1165 - Disclosure - Assets Held for Sale - Summary of Assets Held for Sale (Detail)",
     "menuCat": "Details",
     "order": "165",
     "role": "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail",
     "shortName": "Assets Held for Sale - Summary of Assets Held for Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAssetsHeldForSaleExplanatory",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R166": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayables",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1166 - Disclosure - Trade and Other Payables - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "166",
     "role": "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
     "shortName": "Trade and Other Payables - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RevenueAndOperatingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R167": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1167 - Disclosure - Trade and Other Payables - Summary of Trade and Other Payables (Detail)",
     "menuCat": "Details",
     "order": "167",
     "role": "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
     "shortName": "Trade and Other Payables - Summary of Trade and Other Payables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R168": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInFinancialLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1168 - Disclosure - Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail)",
     "menuCat": "Details",
     "order": "168",
     "role": "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail",
     "shortName": "Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInFinancialLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R169": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1169 - Disclosure - Net Debt - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "169",
     "role": "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
     "shortName": "Net Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_UsCommercialPaperProgramMemberifrsfullClassesOfFinancialInstrumentsAxis",
      "decimals": "-8",
      "lang": null,
      "name": "gsk:CommercialPaperAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Finance income",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.gsk.com/role/FinanceIncome",
     "shortName": "Finance income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R170": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1170 - Disclosure - Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail)",
     "menuCat": "Details",
     "order": "170",
     "role": "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
     "shortName": "Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:BankLoansoverdraftsAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R171": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1171 - Disclosure - Net Debt - Schedule of Finance Lease Obligations (Detail)",
     "menuCat": "Details",
     "order": "171",
     "role": "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail",
     "shortName": "Net Debt - Schedule of Finance Lease Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:FinanceLeaseObligationsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R172": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1172 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail)",
     "menuCat": "Details",
     "order": "172",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:PostemploymentBenefitExpensePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R173": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1173 - Disclosure - Pensions and Other Post-employment Benefits - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "173",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R174": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:MalePensionersAverageLifeExpectancyAtSixty",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1174 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)",
     "menuCat": "Details",
     "order": "174",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrentPeriodMemberifrsfullMaturityAxis_GBifrsfullGeographicalAreasAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:MalePensionersAverageLifeExpectancyAtSixty",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R175": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1175 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)",
     "menuCat": "Details",
     "order": "175",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_GBifrsfullGeographicalAreasAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R176": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1176 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail)",
     "menuCat": "Details",
     "order": "176",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R177": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1177 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail)",
     "menuCat": "Details",
     "order": "177",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:NoncurrentProvisionsForEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R178": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1178 - Disclosure - Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail)",
     "menuCat": "Details",
     "order": "178",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_GroupMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R179": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1179 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail)",
     "menuCat": "Details",
     "order": "179",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfMovementsInFairValuesOfAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019_GBifrsfullGeographicalAreasAxis_PlanAssetsMemberifrsfullNetDefinedBenefitLiabilityAssetAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:PlanAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Finance expense",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.gsk.com/role/FinanceExpense",
     "shortName": "Finance expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R180": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1180 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail)",
     "menuCat": "Details",
     "order": "180",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_WhollyOrPartlyFundedDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R181": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1181 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail)",
     "menuCat": "Details",
     "order": "181",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
     "shortName": "Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R182": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1182 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail)",
     "menuCat": "Details",
     "order": "182",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail",
     "shortName": "Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R183": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1183 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail)",
     "menuCat": "Details",
     "order": "183",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
     "shortName": "Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R184": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1184 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail)",
     "menuCat": "Details",
     "order": "184",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail",
     "shortName": "Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_DefinedBenefitObligationActiveMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_PostretirementBenefitsMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R185": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:WeightedAverageDurationOfDefinedBenefitObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Y",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1185 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail)",
     "menuCat": "Details",
     "order": "185",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail",
     "shortName": "Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_PensionDefinedBenefitPlansMemberifrsfullDefinedBenefitPlansAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gsk:WeightedAverageDurationOfDefinedBenefitObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Y",
      "xsiNil": "false"
     }
    },
    "R186": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseInAnnualPensionCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1186 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)",
     "menuCat": "Details",
     "order": "186",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail",
     "shortName": "Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ActuarialAssumptionOfIncreaseInDiscountRatesOneMemberifrsfullActuarialAssumptionsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseInAnnualPensionCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R187": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1187 - Disclosure - Other provisions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "187",
     "role": "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
     "shortName": "Other provisions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R188": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1188 - Disclosure - Other Provisions - Summary of Other Provisions (Detail)",
     "menuCat": "Details",
     "order": "188",
     "role": "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail",
     "shortName": "Other Provisions - Summary of Other Provisions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R189": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1189 - Disclosure - Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail)",
     "menuCat": "Details",
     "order": "189",
     "role": "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
     "shortName": "Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Associates and joint ventures",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.gsk.com/role/AssociatesAndJointVentures",
     "shortName": "Associates and joint ventures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R190": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseInProbabilityOfMilestoneSuccess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1190 - Disclosure - Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail)",
     "menuCat": "Details",
     "order": "190",
     "role": "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
     "shortName": "Contingent consideration liabilities - Disclosure of sensitivity of key model input to measure contingent consideration (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_AffinivaxMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseInProbabilityOfMilestoneSuccess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R191": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ContingentConsiderationLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1191 - Disclosure - Contingent Consideration Liabilities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "191",
     "role": "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
     "shortName": "Contingent Consideration Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ContingentConsiderationLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R192": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Accruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1192 - Disclosure - Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail)",
     "menuCat": "Details",
     "order": "192",
     "role": "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail",
     "shortName": "Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory",
       "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Accruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R193": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1193 - Disclosure - Contingent Liabilities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "193",
     "role": "http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail",
     "shortName": "Contingent Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R194": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:AdditionalContributionWereToBeMadeTowards2020PensionDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1194 - Disclosure - Commitments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "194",
     "role": "http://www.gsk.com/role/CommitmentsAdditionalInformationDetail",
     "shortName": "Commitments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:AdditionalContributionWereToBeMadeTowards2020PensionDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R195": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1195 - Disclosure - Commitments - Schedule of Contractual Obligations and Commitments (Detail)",
     "menuCat": "Details",
     "order": "195",
     "role": "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail",
     "shortName": "Commitments - Schedule of Contractual Obligations and Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R196": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory",
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1196 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail)",
     "menuCat": "Details",
     "order": "196",
     "role": "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail",
     "shortName": "Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory",
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R197": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1197 - Disclosure - Share Capital and Share Premium Account - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "197",
     "role": "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
     "shortName": "Share Capital and Share Premium Account - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullComponentsOfEquityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R198": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:RetainedEarningsAndOtherReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1198 - Disclosure - Movements in Equity - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "198",
     "role": "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
     "shortName": "Movements in Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:RetainedEarningsAndOtherReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R199": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1199 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail)",
     "menuCat": "Details",
     "order": "199",
     "role": "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
     "shortName": "Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated income statement",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.gsk.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated income statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Taxation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.gsk.com/role/Taxation",
     "shortName": "Taxation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R200": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1200 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "200",
     "role": "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
     "shortName": "Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ConsumerHealthcareBusinessMemberGSKContinuingAndDiscontinuedOperationAxis_DemergerMemberGSKEventAxis_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R201": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1201 - Disclosure - Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail)",
     "menuCat": "Details",
     "order": "201",
     "role": "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
     "shortName": "Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R202": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherReserves",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1202 - Disclosure - Movements in Equity - Analysis of Other Reserves (Detail)",
     "menuCat": "Details",
     "order": "202",
     "role": "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
     "shortName": "Movements in Equity - Analysis of Other Reserves (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:ExchangeAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R203": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1203 - Disclosure - Non-controlling interests - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "203",
     "role": "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
     "shortName": "Non-controlling interests - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R204": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1204 - Disclosure - Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail)",
     "menuCat": "Details",
     "order": "204",
     "role": "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
     "shortName": "Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ViiVHealthCareMemberifrsfullBusinessCombinationsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R205": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:LoansReceivableMadeByEntityRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1205 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "205",
     "role": "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_MedicxiVenturesILimitedPartnerMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:LoansReceivableMadeByEntityRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R206": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1206 - Disclosure - Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "206",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
     "shortName": "Acquisitions and Disposals - 2022, 2021 and 2020 Acquisitions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R207": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1207 - Disclosure - Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail)",
     "menuCat": "Details",
     "order": "207",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
     "shortName": "Acquisitions and Disposals - Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020_PfizerBiotechCorporationTaiwanMemberifrsfullBusinessCombinationsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R208": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:FairValueOfTheConsumerHealthcareBusinessDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1208 - Disclosure - Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)",
     "menuCat": "Details",
     "order": "208",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail",
     "shortName": "Acquisitions and disposals - Summary of Profit After Taxation on Demerger of Discontinued Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:FairValueOfTheConsumerHealthcareBusinessDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R209": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1209 - Disclosure - Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail)",
     "menuCat": "Details",
     "order": "209",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
     "shortName": "Acquisitions and disposals - Summary of Financial Information Relating to Discontinued Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:FinancialInformationRelatingToDiscontinuedOperations",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_DiscontinuedOperationsMemberifrsfullContinuingAndDiscontinuedOperationsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.gsk.com/role/EarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R210": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1210 - Disclosure - Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail)",
     "menuCat": "Details",
     "order": "210",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
     "shortName": "Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (2022, 2021 and 2020 Acquisition) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2021To12_31_2021_TwoThousandAndTwentyOneBusinessDisposalsMemberGSKContinuingAndDiscontinuedOperationAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R211": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1211 - Disclosure - Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail)",
     "menuCat": "Details",
     "order": "211",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
     "shortName": "Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2020To12_31_2020_AcquisitionsTwoThousandAndTwentyTwoMemberGSKContinuingAndDiscontinuedOperationAxis_BusinessCombinationsMemberifrsfullBusinessCombinationsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R212": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1212 - Disclosure - Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail)",
     "menuCat": "Details",
     "order": "212",
     "role": "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail",
     "shortName": "Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
       "gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForIncomeTaxExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R213": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1213 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail)",
     "menuCat": "Details",
     "order": "213",
     "role": "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail",
     "shortName": "Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
       "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R214": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfAnalysisOfChangesInNetDebtExplanatory",
       "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1214 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail)",
     "menuCat": "Details",
     "order": "214",
     "role": "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail",
     "shortName": "Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R215": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1215 - Disclosure - Financial instruments and related disclosures - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "215",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
     "shortName": "Financial instruments and related disclosures - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-8",
      "lang": null,
      "name": "gsk:EquityAndDebtNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R216": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExternalCreditExposuresExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:BankBalancesAndDepositHeldWithCounterparties",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1216 - Disclosure - Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail)",
     "menuCat": "Details",
     "order": "216",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExternalCreditExposuresExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_CreditRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R217": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1217 - Disclosure - Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "217",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:NetFinancialAssetsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R218": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1218 - Disclosure - Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail)",
     "menuCat": "Details",
     "order": "218",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_AtFairValueMemberifrsfullMeasurementAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R219": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:FinancialAssetsAndLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1219 - Disclosure - Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail)",
     "menuCat": "Details",
     "order": "219",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2020_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis",
      "decimals": "-6",
      "lang": null,
      "name": "gsk:FinancialAssetsAndLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDividendsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Dividends",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.gsk.com/role/Dividends",
     "shortName": "Dividends",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDividendsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R220": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherReceivables",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1220 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail)",
     "menuCat": "Details",
     "order": "220",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
     "shortName": "Financial instruments and related disclosures - Reconciliation of financial instruments and other receivables and other non-current assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9MemberifrsfullClassesOfFinancialAssetsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:OtherNoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R221": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1221 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail)",
     "menuCat": "Details",
     "order": "221",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
     "shortName": "Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9MemberifrsfullClassesOfFinancialLiabilitiesAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R222": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:HedgingInstrumentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1222 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail)",
     "menuCat": "Details",
     "order": "222",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
     "shortName": "Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:HedgingInstrumentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R223": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_ForeignExchangeContractsMemberifrsfullHedgingInstrumentsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NominalAmountOfHedgingInstrument",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1223 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "223",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
     "shortName": "Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:NominalAmountOfHedgingInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R224": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1224 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)",
     "menuCat": "Details",
     "order": "224",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R225": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1225 - Disclosure - Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail)",
     "menuCat": "Details",
     "order": "225",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_MoreThanFiveYearsNotLaterThanTenYearsMemberifrsfullPastDueStatusAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R226": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1226 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail)",
     "menuCat": "Details",
     "order": "226",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
     "shortName": "Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2021To12_31_2021_InterestRateSwapContractMemberifrsfullHedgingInstrumentsAxis_PrehedgingOfLongtermInterestRatesMemberifrsfullHedgedItemsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R227": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1227 - Disclosure - Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "227",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail",
     "shortName": "Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_TradeAndOtherReceivableMemberifrsfullTypesOfFinancialAssetsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R228": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:Debt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1228 - Disclosure - Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail)",
     "menuCat": "Details",
     "order": "228",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
     "shortName": "Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:Debt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R229": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:ForeignExchangeSensitivityImpactOfNonFunctionalCurrency",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1229 - Disclosure - Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail)",
     "menuCat": "Details",
     "order": "229",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
     "shortName": "Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:ForeignExchangeSensitivityImpactOfNonFunctionalCurrency",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CurrencyRiskTenCentAppreciationOfUSDollarMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.gsk.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R230": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1230 - Disclosure - Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail)",
     "menuCat": "Details",
     "order": "230",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail",
     "shortName": "Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMemberifrsfullTypesOfRisksAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R231": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfLeaseObligationsExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1231 - Disclosure - Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail)",
     "menuCat": "Details",
     "order": "231",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
     "shortName": "Financial instruments and related disclosures - Summary of Anticipated contractual cash flows including interest payable for the Non-Derivative Financial liabilities on undiscounted basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_NonDerivativesFinancialLiabilitiesMemberifrsfullHedgingInstrumentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R232": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1232 - Disclosure - Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail)",
     "menuCat": "Details",
     "order": "232",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
     "shortName": "Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_DerivativesMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateSwapContractMemberGSKDebtInstrument1Axis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R233": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1233 - Disclosure - Employee Share Schemes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "233",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
     "shortName": "Employee Share Schemes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_SavingsRelatedShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "2",
      "lang": null,
      "name": "gsk:AtPercentageBelowMarketPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R234": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfEmployeeShareValuePlanExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2021_ShareValuePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gsk:NumberOfOutstandingShareAwards",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1234 - Disclosure - Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail)",
     "menuCat": "Details",
     "order": "234",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail",
     "shortName": "Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R235": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1235 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail)",
     "menuCat": "Details",
     "order": "235",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
     "shortName": "Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R236": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "gsk:SavingsRelatedOptionsGrantPriceDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1236 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "236",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail",
     "shortName": "Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShareOptionsAndSavingsRelatedOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "gsk:SavingsRelatedOptionsGrantPriceDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R237": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1237 - Disclosure - Employee Share Schemes - Summary of Option Outstanding (Detail)",
     "menuCat": "Details",
     "order": "237",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
     "shortName": "Employee Share Schemes - Summary of Option Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_ShareOptionSchemesMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R238": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gsk:NumberOfSharesHeldForShareAwardSchemes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1238 - Disclosure - Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail)",
     "menuCat": "Details",
     "order": "238",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail",
     "shortName": "Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022_EmployeeShareOwnershipPlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gsk:NumberOfSharesHeldForShareAwardSchemes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R239": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NameOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1239 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)",
     "menuCat": "Details",
     "order": "239",
     "role": "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
     "shortName": "Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis_GlaxoGroupLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NameOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Right of use assets",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.gsk.com/role/RightOfUseAssets",
     "shortName": "Right of use assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R240": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfVotingPowerHeldInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1240 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "240",
     "role": "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
     "shortName": "Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_BerkeleySquarePensionTrusteeCompanyLimitedMemberdeiLegalEntityAxis_GskGp1LimitedsShareCapitalMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfVotingPowerHeldInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R241": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LegalProceedingsProvision",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1241 - Disclosure - Legal Proceedings - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "241",
     "role": "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail",
     "shortName": "Legal Proceedings - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn08_05_2021",
      "decimals": "-4",
      "lang": null,
      "name": "gsk:DamagesAwardedToGSK",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.gsk.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Other intangible assets",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.gsk.com/role/OtherIntangibleAssets",
     "shortName": "Other intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Investments in associates and joint ventures",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures",
     "shortName": "Investments in associates and joint ventures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Current equity investments",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.gsk.com/role/CurrentEquityInvestments",
     "shortName": "Current equity investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Other investments",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.gsk.com/role/OtherInvestments",
     "shortName": "Other investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated statement of comprehensive income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
     "shortName": "Consolidated statement of comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Other non-current assets",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.gsk.com/role/OtherNonCurrentAssets",
     "shortName": "Other non-current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.gsk.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Trade and other receivables",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://www.gsk.com/role/TradeAndOtherReceivables",
     "shortName": "Trade and other receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Cash and cash equivalents",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://www.gsk.com/role/CashAndCashEquivalents",
     "shortName": "Cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Assets held for sale",
     "menuCat": "Notes",
     "order": "34",
     "role": "http://www.gsk.com/role/AssetsHeldForSale",
     "shortName": "Assets held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Trade and other payables",
     "menuCat": "Notes",
     "order": "35",
     "role": "http://www.gsk.com/role/TradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Net debt",
     "menuCat": "Notes",
     "order": "36",
     "role": "http://www.gsk.com/role/NetDebt",
     "shortName": "Net debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Pensions and other post-employment benefits",
     "menuCat": "Notes",
     "order": "37",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits",
     "shortName": "Pensions and other post-employment benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Other provisions",
     "menuCat": "Notes",
     "order": "38",
     "role": "http://www.gsk.com/role/OtherProvisions",
     "shortName": "Other provisions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Contingent consideration liabilities",
     "menuCat": "Notes",
     "order": "39",
     "role": "http://www.gsk.com/role/ContingentConsiderationLiabilities",
     "shortName": "Contingent consideration liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated balance sheet",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.gsk.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated balance sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Other non-current liabilities",
     "menuCat": "Notes",
     "order": "40",
     "role": "http://www.gsk.com/role/OtherNonCurrentLiabilities",
     "shortName": "Other non-current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Contingent liabilities",
     "menuCat": "Notes",
     "order": "41",
     "role": "http://www.gsk.com/role/ContingentLiabilities",
     "shortName": "Contingent liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Commitments",
     "menuCat": "Notes",
     "order": "42",
     "role": "http://www.gsk.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Share capital and share premium account",
     "menuCat": "Notes",
     "order": "43",
     "role": "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount",
     "shortName": "Share capital and share premium account",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMovementsInEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Movements in equity",
     "menuCat": "Notes",
     "order": "44",
     "role": "http://www.gsk.com/role/MovementsInEquity",
     "shortName": "Movements in equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMovementsInEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Non-controlling interests",
     "menuCat": "Notes",
     "order": "45",
     "role": "http://www.gsk.com/role/NonControllingInterests",
     "shortName": "Non-controlling interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Related party transactions",
     "menuCat": "Notes",
     "order": "46",
     "role": "http://www.gsk.com/role/RelatedPartyTransactions",
     "shortName": "Related party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Acquisitions and disposals",
     "menuCat": "Notes",
     "order": "47",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposals",
     "shortName": "Acquisitions and disposals",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Adjustments reconciling profit after tax to operating cash flows",
     "menuCat": "Notes",
     "order": "48",
     "role": "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows",
     "shortName": "Adjustments reconciling profit after tax to operating cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Reconciliation of net cash flow to movement in net debt",
     "menuCat": "Notes",
     "order": "49",
     "role": "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt",
     "shortName": "Reconciliation of net cash flow to movement in net debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated statement of changes in equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
     "shortName": "Consolidated statement of changes in equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "PAsOn12_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Financial instruments and related disclosures",
     "menuCat": "Notes",
     "order": "50",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures",
     "shortName": "Financial instruments and related disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Employee share schemes",
     "menuCat": "Notes",
     "order": "51",
     "role": "http://www.gsk.com/role/EmployeeShareSchemes",
     "shortName": "Employee share schemes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Principal Group companies",
     "menuCat": "Notes",
     "order": "52",
     "role": "http://www.gsk.com/role/PrincipalGroupCompanies",
     "shortName": "Principal Group companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfLegalProceedingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Legal proceedings",
     "menuCat": "Notes",
     "order": "53",
     "role": "http://www.gsk.com/role/LegalProceedings",
     "shortName": "Legal proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfLegalProceedingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Post balance sheet events",
     "menuCat": "Notes",
     "order": "54",
     "role": "http://www.gsk.com/role/PostBalanceSheetEvents",
     "shortName": "Post balance sheet events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DescriptionOfAccountingStandardsApplied",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Accounting principles and policies (Policies)",
     "menuCat": "Policies",
     "order": "55",
     "role": "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies",
     "shortName": "Accounting principles and policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DescriptionOfAccountingStandardsApplied",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Accounting principles and policies (Tables)",
     "menuCat": "Tables",
     "order": "56",
     "role": "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables",
     "shortName": "Accounting principles and policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SignificantCurrenciesAndTheRelevantExchangeRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Exchange rates (Tables)",
     "menuCat": "Tables",
     "order": "57",
     "role": "http://www.gsk.com/role/ExchangeRatesTables",
     "shortName": "Exchange rates (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SignificantCurrenciesAndTheRelevantExchangeRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfTurnoverBySegmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Turnover and segment information (Tables)",
     "menuCat": "Tables",
     "order": "58",
     "role": "http://www.gsk.com/role/TurnoverAndSegmentInformationTables",
     "shortName": "Turnover and segment information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfTurnoverBySegmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Other operating income/(expense) (Tables)",
     "menuCat": "Tables",
     "order": "59",
     "role": "http://www.gsk.com/role/OtherOperatingIncomeExpenseTables",
     "shortName": "Other operating income/(expense) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated cash flow statement",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
     "shortName": "Consolidated cash flow statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForReconcileProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Operating profit (Tables)",
     "menuCat": "Tables",
     "order": "60",
     "role": "http://www.gsk.com/role/OperatingProfitTables",
     "shortName": "Operating profit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Employee costs (Tables)",
     "menuCat": "Tables",
     "order": "61",
     "role": "http://www.gsk.com/role/EmployeeCostsTables",
     "shortName": "Employee costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfEmployeeCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Major restructuring costs (Tables)",
     "menuCat": "Tables",
     "order": "62",
     "role": "http://www.gsk.com/role/MajorRestructuringCostsTables",
     "shortName": "Major restructuring costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "gsk:DisclosureOfMajorRestructuringCostsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Finance income (Tables)",
     "menuCat": "Tables",
     "order": "63",
     "role": "http://www.gsk.com/role/FinanceIncomeTables",
     "shortName": "Finance income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Finance expense (Tables)",
     "menuCat": "Tables",
     "order": "64",
     "role": "http://www.gsk.com/role/FinanceExpenseTables",
     "shortName": "Finance expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Associates and joint ventures (Tables)",
     "menuCat": "Tables",
     "order": "65",
     "role": "http://www.gsk.com/role/AssociatesAndJointVenturesTables",
     "shortName": "Associates and joint ventures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfAssociatesAndJointVenturesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Taxation (Tables)",
     "menuCat": "Tables",
     "order": "66",
     "role": "http://www.gsk.com/role/TaxationTables",
     "shortName": "Taxation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "67",
     "role": "http://www.gsk.com/role/EarningsPerShareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfInterimDividendExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Dividends (Tables)",
     "menuCat": "Tables",
     "order": "68",
     "role": "http://www.gsk.com/role/DividendsTables",
     "shortName": "Dividends (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDividendsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfInterimDividendExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "69",
     "role": "http://www.gsk.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Presentation of the financial statements",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.gsk.com/role/PresentationOfTheFinancialStatements",
     "shortName": "Presentation of the financial statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Right of use assets (Tables)",
     "menuCat": "Tables",
     "order": "70",
     "role": "http://www.gsk.com/role/RightOfUseAssetsTables",
     "shortName": "Right of use assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "71",
     "role": "http://www.gsk.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Other intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "72",
     "role": "http://www.gsk.com/role/OtherIntangibleAssetsTables",
     "shortName": "Other intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Investments in associates and joint ventures (Tables)",
     "menuCat": "Tables",
     "order": "73",
     "role": "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables",
     "shortName": "Investments in associates and joint ventures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Current equity investments (Tables)",
     "menuCat": "Tables",
     "order": "74",
     "role": "http://www.gsk.com/role/CurrentEquityInvestmentsTables",
     "shortName": "Current equity investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfCurrentEquityInvestmentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Other investments (Tables)",
     "menuCat": "Tables",
     "order": "75",
     "role": "http://www.gsk.com/role/OtherInvestmentsTables",
     "shortName": "Other investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Other non-current assets (Tables)",
     "menuCat": "Tables",
     "order": "76",
     "role": "http://www.gsk.com/role/OtherNonCurrentAssetsTables",
     "shortName": "Other non-current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "77",
     "role": "http://www.gsk.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Trade and other receivables (Tables)",
     "menuCat": "Tables",
     "order": "78",
     "role": "http://www.gsk.com/role/TradeAndOtherReceivablesTables",
     "shortName": "Trade and other receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfTradesAndOtherReceivableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Cash and cash equivalents (Tables)",
     "menuCat": "Tables",
     "order": "79",
     "role": "http://www.gsk.com/role/CashAndCashEquivalentsTables",
     "shortName": "Cash and cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Accounting principles and policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.gsk.com/role/AccountingPrinciplesAndPolicies",
     "shortName": "Accounting principles and policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAssetsHeldForSaleExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Assets held for sale (Tables)",
     "menuCat": "Tables",
     "order": "80",
     "role": "http://www.gsk.com/role/AssetsHeldForSaleTables",
     "shortName": "Assets held for sale (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAssetsHeldForSaleExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SummaryOfTradePayablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Trade and other payables (Tables)",
     "menuCat": "Tables",
     "order": "81",
     "role": "http://www.gsk.com/role/TradeAndOtherPayablesTables",
     "shortName": "Trade and other payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:SummaryOfTradePayablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Net debt (Tables)",
     "menuCat": "Tables",
     "order": "82",
     "role": "http://www.gsk.com/role/NetDebtTables",
     "shortName": "Net debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Pensions and other post-employment benefits (Tables)",
     "menuCat": "Tables",
     "order": "83",
     "role": "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables",
     "shortName": "Pensions and other post-employment benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Other provisions (Tables)",
     "menuCat": "Tables",
     "order": "84",
     "role": "http://www.gsk.com/role/OtherProvisionsTables",
     "shortName": "Other provisions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Contingent consideration liabilities (Tables)",
     "menuCat": "Tables",
     "order": "85",
     "role": "http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables",
     "shortName": "Contingent consideration liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Other non-current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "86",
     "role": "http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables",
     "shortName": "Other non-current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Commitments (Tables)",
     "menuCat": "Tables",
     "order": "87",
     "role": "http://www.gsk.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Share capital and share premium account (Tables)",
     "menuCat": "Tables",
     "order": "88",
     "role": "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables",
     "shortName": "Share capital and share premium account (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Movements in equity (Tables)",
     "menuCat": "Tables",
     "order": "89",
     "role": "http://www.gsk.com/role/MovementsInEquityTables",
     "shortName": "Movements in equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfMovementsInEquityExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Critical accounting judgements and key sources of estimation uncertainty",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty",
     "shortName": "Critical accounting judgements and key sources of estimation uncertainty",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Non-controlling interests (Tables)",
     "menuCat": "Tables",
     "order": "90",
     "role": "http://www.gsk.com/role/NonControllingInterestsTables",
     "shortName": "Non-controlling interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Acquisitions and disposals (Tables)",
     "menuCat": "Tables",
     "order": "91",
     "role": "http://www.gsk.com/role/AcquisitionsAndDisposalsTables",
     "shortName": "Acquisitions and disposals (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Adjustments reconciling profit after tax to operating cash flows (Tables)",
     "menuCat": "Tables",
     "order": "92",
     "role": "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables",
     "shortName": "Adjustments reconciling profit after tax to operating cash flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Reconciliation of net cash flow to movement in net debt (Tables)",
     "menuCat": "Tables",
     "order": "93",
     "role": "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables",
     "shortName": "Reconciliation of net cash flow to movement in net debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExternalCreditExposuresExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Financial instruments and related disclosures (Tables)",
     "menuCat": "Tables",
     "order": "94",
     "role": "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables",
     "shortName": "Financial instruments and related disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExternalCreditExposuresExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEmployeeShareValuePlanExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Employee share schemes (Tables)",
     "menuCat": "Tables",
     "order": "95",
     "role": "http://www.gsk.com/role/EmployeeShareSchemesTables",
     "shortName": "Employee share schemes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gsk:DisclosureOfEmployeeShareValuePlanExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Principal Group companies (Tables)",
     "menuCat": "Tables",
     "order": "96",
     "role": "http://www.gsk.com/role/PrincipalGroupCompaniesTables",
     "shortName": "Principal Group companies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gsk:DisclosureOfPrincipalGroupCompaniesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PeriodCoveredByFinancialStatements",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Presentation of the Financial Statements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail",
     "shortName": "Presentation of the Financial Statements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PeriodCoveredByFinancialStatements",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Accounting Principles and Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
     "shortName": "Accounting Principles and Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gsk:ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_GBP",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail",
     "shortName": "Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382677dex152.htm",
      "contextRef": "P01_01_2022To12_31_2022_FreeholdBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 647,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia [member]"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BELGIUM",
        "terseLabel": "Belgium [member]"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil [member]",
        "verboseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada [member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland [member]"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COSTA RICA",
        "verboseLabel": "Costa Rica"
       }
      }
     },
     "localname": "CR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany [member]"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_EC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ECUADOR",
        "terseLabel": "Ecuador [Member]"
       }
      }
     },
     "localname": "EC",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain [member]"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France [member]"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "UK [member]"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG",
        "terseLabel": "Hong Kong[member]"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONDURAS",
        "terseLabel": "Honduras [Member]"
       }
      }
     },
     "localname": "HN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland [member]"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIANA",
        "terseLabel": "India [member]"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy [member]"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAMBODIA",
        "terseLabel": "Cambodia [Member]"
       }
      }
     },
     "localname": "KH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "Republic of Korea [member]"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico [member]"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NIGERIA",
        "terseLabel": "Nigeria [member]"
       }
      }
     },
     "localname": "NG",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Netherlands [member]"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PAKISTAN",
        "terseLabel": "Pakistan [member]"
       }
      }
     },
     "localname": "PK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland [member]"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia [member]"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE",
        "terseLabel": "Singapore [member]"
       }
      }
     },
     "localname": "SG",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "Turkey [member]"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TW": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAIWAN, PROVINCE OF CHINA",
        "terseLabel": "Taiwan [Member]"
       }
      }
     },
     "localname": "TW",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro [member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Yen [member]"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD [member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_BOFS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BANK OF SCOTLAND PLC - SYSTEMATIC INTERNALISER [Member]",
        "terseLabel": "Scotland [member]"
       }
      }
     },
     "localname": "BOFS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AAAOrAaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AAA/Aaa.",
        "label": "AAA Or Aaa [member]",
        "terseLabel": "AAA/Aaa [member]"
       }
      }
     },
     "localname": "AAAOrAaaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AaOrAaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AA /Aa.",
        "label": "AA Or Aa [member]",
        "terseLabel": "AA/Aa [member]"
       }
      }
     },
     "localname": "AaOrAaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AcceleratedCapitalAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated capital allowances.",
        "label": "Accelerated Capital Allowances [member]",
        "terseLabel": "Accelerated capital allowances [member]"
       }
      }
     },
     "localname": "AcceleratedCapitalAllowancesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AccruedFixedAssetRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Fixed Asset Related Costs [abstract]",
        "label": "Accrued Fixed Asset Related Costs [abstract]"
       }
      }
     },
     "localname": "AccruedFixedAssetRelatedCostsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_AccruedInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest [member]",
        "label": "Accrued interest [member]",
        "terseLabel": "Accrued interest [member]"
       }
      }
     },
     "localname": "AccruedInterestMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AcquirerAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquirer [Axis]"
       }
      }
     },
     "localname": "AcquirerAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_AcquirerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquirer [Domain]"
       }
      }
     },
     "localname": "AcquirerDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AcquisitionsTwoThousandAndTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Acquisitions.",
        "label": "Acquisitions Two Thousand and Twenty Two [Member]",
        "verboseLabel": "2022 Acquisitions [member]"
       }
      }
     },
     "localname": "AcquisitionsTwoThousandAndTwentyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionForFutureHealthcareInflationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial assumption for future healthcare inflation.",
        "label": "Actuarial assumption for future healthcare inflation [member]",
        "verboseLabel": "Actuarial assumptions of 1% increase of rate of future healthcare inflation [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionForFutureHealthcareInflationMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfCashBalanceCreditRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial assumption of cash balance credit rate.",
        "label": "Actuarial Assumption Of Cash Balance Credit Rate",
        "terseLabel": "Cash balance credit/conversion rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfCashBalanceCreditRate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_ActuarialAssumptionOfDecreaseInDiscountRatesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of decrease in discount rates one [Member]",
        "terseLabel": "Actuarial assumptions of 0.25% decrease in discount rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDecreaseInDiscountRatesOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of decrease in discount rates Two [Member]",
        "terseLabel": "Actuarial assumptions of 0.75% decrease in discount rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDecreaseInDiscountRatesTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Decrease In Expected Rates Of Inflation One [Member]",
        "terseLabel": "Actuarial assumptions of 0.25% decrease in inflation rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Decrease In Expected Rates Of Inflation Two [Member]",
        "terseLabel": "Actuarial assumptions of 0.75% increase in inflation rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDecreaseInExpectedRatesOfInflationTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Discount Rates at Zero Point Seven Five Percent [Member]",
        "terseLabel": "Discount Rate at 0.75% [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesAtZeroPointSevenFivePercentMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected rate of medical inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation.",
        "label": "Actuarial assumption of expected rates of medical inflation",
        "terseLabel": "Assumption for future medical inflation"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfMedicalInflation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_ActuarialAssumptionOfIncreaseInDiscountRatesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Increase In Discount Rates One [Member]",
        "terseLabel": "Actuarial assumptions of 0.25% increase in discount rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfIncreaseInDiscountRatesOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of increase in discount rates Two [Member]",
        "terseLabel": "Actuarial assumptions of 0.75% increase in discount rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfIncreaseInDiscountRatesTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Increase In Expected Rates Of Inflation One [Member]",
        "terseLabel": "Actuarial assumptions of 0.25% increase in inflation rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Of Increase In Expected Rates Of Inflation Two [Member]",
        "terseLabel": "Actuarial assumptions of 0.75% decrease in inflation rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfIncreaseInExpectedRatesOfInflationTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionOfLifeExpectancyRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial assumption of life expectancy rates.",
        "label": "Actuarial Assumption Of Life Expectancy Rates [member]",
        "verboseLabel": "Actuarial assumptions of 1 year increase in life expectancy [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionOfLifeExpectancyRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionPercentageRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Percentage Rate [Axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionPercentageRateAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ActuarialAssumptionPercentageRateChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial assumption percentage rate change.",
        "label": "Actuarial Assumption Percentage Rate Change [Member]",
        "verboseLabel": "Actuarial assumption percentage rate change [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionPercentageRateChangeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ActuarialAssumptionPercentageRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial Assumption Percentage Rate [Member]"
       }
      }
     },
     "localname": "ActuarialAssumptionPercentageRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AdditionalContributionDueToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contribution due to be paid.",
        "label": "Additional Contribution Due To Be Paid",
        "terseLabel": "Additional contributions due to be paid"
       }
      }
     },
     "localname": "AdditionalContributionDueToBePaid",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionalContributionUnpaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contribution unpaid.",
        "label": "Additional Contribution Unpaid",
        "terseLabel": "Additional contribution unpaid"
       }
      }
     },
     "localname": "AdditionalContributionUnpaid",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionalContributionWereToBeMadeTowards2020PensionDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contribution were to be made towards 2020 pension deficit.",
        "label": "Additional Contribution Were To Be Made Towards 2020 Pension Deficit",
        "verboseLabel": "Additional contribution towards pension scheme to eliminate the pension deficit identified at the 31 December 2020"
       }
      }
     },
     "localname": "AdditionalContributionWereToBeMadeTowards2020PensionDeficit",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionalGainOnRemeasurementOfRetainedStake": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional gain on remeasurement of retained stake.",
        "label": "Additional Gain On Remeasurement Of Retained Stake",
        "terseLabel": "Additional gain amount"
       }
      }
     },
     "localname": "AdditionalGainOnRemeasurementOfRetainedStake",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionalProvisionForDividendPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional provision for dividend payable.",
        "label": "Additional Provision For Dividend Payable",
        "terseLabel": "Additional provision for dividend payable"
       }
      }
     },
     "localname": "AdditionalProvisionForDividendPayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional provisions net of reversals and recoveries other provisions.",
        "label": "Additional provisions net of reversals and recoveries other provisions",
        "terseLabel": "Charges on other provisions"
       }
      }
     },
     "localname": "AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionsFairValueMeasurementAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions fair value measurement assets and liabilities.",
        "label": "Additions Fair Value Measurement Assets And Liabilities",
        "negatedLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsFairValueMeasurementAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionsInInvestmentsInAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions in investments in associates and joint ventures.",
        "label": "Additions in Investments in associates and joint ventures",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsInInvestmentsInAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionsToOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions to other investments.",
        "label": "Additions To Other Investments",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToOtherInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdditionsToRightOfUseAssetsThroughBusinessCombinations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions to right of use assets through business combinations.",
        "label": "Additions To Right of use Assets Through Business Combinations",
        "terseLabel": "Additions through business combinations"
       }
      }
     },
     "localname": "AdditionsToRightOfUseAssetsThroughBusinessCombinations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Free Cash Flow TSR and RD New Product Performance [Member]"
       }
      }
     },
     "localname": "AdjustedFreeCashFlowTsrAndRdNewProductPerformanceMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease increase in contingent consideration paid.",
        "label": "Adjustments For Decrease Increase In Contingent Consideration Paid",
        "terseLabel": "Cash payments: operating cash flows",
        "verboseLabel": "Contingent consideration paid (see Note 0)"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease increase in other non cash increase in contingent consideration liabilities.",
        "label": "Adjustments For Decrease Increase In Other Non Cash Contingent Consideration Liabilities",
        "terseLabel": "Other non-cash increase in contingent consideration liabilities"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForForeignExchangeOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for foreign exchange other investments.",
        "label": "Adjustments For Foreign Exchange Other Investments",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "AdjustmentsForForeignExchangeOtherInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForImpairmentAndAssetsWrittenOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for impairment and assets written off.",
        "label": "Adjustments For Impairment And Assets Written Off",
        "terseLabel": "Impairment and assets written off"
       }
      }
     },
     "localname": "AdjustmentsForImpairmentAndAssetsWrittenOff",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForProfitOnSaleOfBusinesses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for profit on sale of businesses.",
        "label": "Adjustments For Profit On Sale Of Businesses",
        "negatedLabel": "Profit on sale of businesses"
       }
      }
     },
     "localname": "AdjustmentsForProfitOnSaleOfBusinesses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForProfitOnSaleOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for profit on sale of equity investments.",
        "label": "Adjustments For Profit On Sale Of Equity Investments",
        "negatedLabel": "Profit on sale of equity investments"
       }
      }
     },
     "localname": "AdjustmentsForProfitOnSaleOfEquityInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForProfitOnSaleOfIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for profit on sale of intangible assets.",
        "label": "Adjustments For Profit On Sale Of Intangible Assets",
        "terseLabel": "Profit on sale of intangible assets"
       }
      }
     },
     "localname": "AdjustmentsForProfitOnSaleOfIntangibleAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for share of after tax profits of associates and joint ventures.",
        "label": "Adjustments For Share Of After Tax Profits Of Associates And Joint Ventures",
        "terseLabel": "Share of after-tax profits of associates and joint ventures"
       }
      }
     },
     "localname": "AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments in expenses net defined benefit liability asset.",
        "label": "Adjustments In Expenses Net Defined Benefit Liability Asset",
        "negatedLabel": "Expenses"
       }
      }
     },
     "localname": "AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AffinivaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinivax assets.",
        "label": "Affinivax Assets [Member]"
       }
      }
     },
     "localname": "AffinivaxAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AffinivaxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinivax, Inc.",
        "label": "Affinivax, Inc [Member]",
        "terseLabel": "Affinivax, Inc [Member]"
       }
      }
     },
     "localname": "AffinivaxIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AffinivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinivax [Member]",
        "label": "Affinivax [Member]",
        "terseLabel": "Affinivax [Member]"
       }
      }
     },
     "localname": "AffinivaxMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AgreementExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement extension.",
        "label": "Agreement extension period",
        "terseLabel": "Agreement extension"
       }
      }
     },
     "localname": "AgreementExtensionPeriod",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_AgreementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement type.",
        "label": "Agreement Type [Axis]",
        "terseLabel": "Agreement Type [axis]"
       }
      }
     },
     "localname": "AgreementTypeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_AgreementTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement type.",
        "label": "Agreement Type [Member]",
        "terseLabel": "Agreement Type [member]"
       }
      }
     },
     "localname": "AgreementTypeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AlectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alector [Member].",
        "label": "Alector [Member]"
       }
      }
     },
     "localname": "AlectorMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AllocationToLiabilityMatchingAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation to liability matching assets.",
        "label": "Allocation To Liability Matching Assets",
        "terseLabel": "Percentage allocated to liability matching assets"
       }
      }
     },
     "localname": "AllocationToLiabilityMatchingAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AllocationToReturnSeekingAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation to return seeking assets.",
        "label": "Allocation To Return Seeking Assets",
        "terseLabel": "Percentage allocated to return seeking assets"
       }
      }
     },
     "localname": "AllocationToReturnSeekingAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Shares [Member]",
        "terseLabel": "American Depositary Shares [member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AmortisableProportionOverExclusivityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortisable proportion over exclusivity period.",
        "label": "Amortisable Proportion Over Exclusivity Period",
        "terseLabel": "Amortisation rate, Intangible assets other than goodwill"
       }
      }
     },
     "localname": "AmortisableProportionOverExclusivityPeriod",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AmortisationOtherIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortisation other intangible assets.",
        "label": "Amortisation Other Intangible Assets",
        "negatedLabel": "Charge for the year",
        "terseLabel": "Amortisation of intangible assets"
       }
      }
     },
     "localname": "AmortisationOtherIntangibleAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AmortizedCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost [Member]"
       }
      }
     },
     "localname": "AmortizedCostMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AmountHeldAtEuropeanMediumTermNoteProgramme": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount held at European medium term note programme.",
        "label": "Amount Held At European Medium Term Note Programme",
        "terseLabel": "Amount held at European medium term note programme"
       }
      }
     },
     "localname": "AmountHeldAtEuropeanMediumTermNoteProgramme",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A/A.",
        "label": "A or A [member]",
        "terseLabel": "A/A [member]"
       }
      }
     },
     "localname": "AorAMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ApolloTherapeuticsLLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo Therapeutics LLP.",
        "label": "Apollo Therapeutics LLP [member]",
        "terseLabel": "Apollo Therapeutics LLP [member]"
       }
      }
     },
     "localname": "ApolloTherapeuticsLLPMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AppreciationOfEuro": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Appreciation of euro.",
        "label": "Appreciation Of Euro",
        "terseLabel": "Appreciation of Euro"
       }
      }
     },
     "localname": "AppreciationOfEuro",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AppreciationOfUSDollar": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Appreciation of US dollar.",
        "label": "Appreciation Of US Dollar",
        "terseLabel": "Appreciation of US Dollar"
       }
      }
     },
     "localname": "AppreciationOfUSDollar",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Type [Axis]",
        "terseLabel": "Arrangement Type [axis]"
       }
      }
     },
     "localname": "ArrangementTypeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Type [Domain]",
        "terseLabel": "Arrangement Type [domain]"
       }
      }
     },
     "localname": "ArrangementTypeDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AssetImpairments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset impairments.",
        "label": "Asset Impairments",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "AssetImpairments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AssetsHeldForSaleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Assets Held For Sale [line items]",
        "label": "Assets Held For Sale [line items]",
        "terseLabel": "Assets Held For Sale [line items]"
       }
      }
     },
     "localname": "AssetsHeldForSaleLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_AssetsHeldForSaleTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held For Sale [table]",
        "label": "Assets Held For Sale [table]",
        "terseLabel": "Assets Held For Sale [table]"
       }
      }
     },
     "localname": "AssetsHeldForSaleTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_AssociatesAndJointVentureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associates And Joint Venture [abstract]",
        "label": "Associates And Joint Venture [abstract]"
       }
      }
     },
     "localname": "AssociatesAndJointVentureAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_AssociatesAndJointVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associates and joint ventures.",
        "label": "Associates and joint ventures [member]",
        "terseLabel": "Associates and joint ventures [member]"
       }
      }
     },
     "localname": "AssociatesAndJointVenturesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associates And Joint Ventures Two Thousand And Twenty One Disposals",
        "label": "Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member]",
        "terseLabel": "Associates And Joint Ventures Two Thousand And Twenty One Disposals [Member]"
       }
      }
     },
     "localname": "AssociatesAndJointVenturesTwoThousandAndTwentyOneDisposalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associates And Joint Ventures Two Thousand Twenty Two Disposals",
        "label": "Associates And Joint Ventures Two Thousand Twenty Two Disposals [Member]",
        "verboseLabel": "Associates and joint ventures 2022 disposals [member]"
       }
      }
     },
     "localname": "AssociatesAndJointVenturesTwoThousandTwentyTwoDisposalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AtPercentageBelowMarketPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At percentage below market price.",
        "label": "At Percentage Below Market Price",
        "terseLabel": "Share options granted at percentage below market price"
       }
      }
     },
     "localname": "AtPercentageBelowMarketPrice",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditors remuneration for audit related and other assurance services.",
        "label": "Auditors Remuneration For Audit Related And Other Assurance Services",
        "totalLabel": "Total audit services, audit-related and other assurance services"
       }
      }
     },
     "localname": "AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AuditorsRemunerationForOtherAssuranceServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail": {
       "order": 1.0,
       "parentTag": "gsk_AuditorsRemunerationForAuditRelatedAndOtherAssuranceServices",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor's remuneration for other assurance services.",
        "label": "Auditors Remuneration For Other Assurance Services",
        "terseLabel": "Audit-related and other assurance services"
       }
      }
     },
     "localname": "AuditorsRemunerationForOtherAssuranceServices",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AugmentationCostsFromRestructuringProgrammes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Augmentation costs from restructuring programmes.",
        "label": "Augmentation Costs From Restructuring Programmes",
        "terseLabel": "Augmentation costs arising from major restructuring programmes"
       }
      }
     },
     "localname": "AugmentationCostsFromRestructuringProgrammes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AugmentationCostsIncludedInPastServiceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Augmentation costs included in past service costs.",
        "label": "Augmentation Costs Included In Past Service Costs",
        "terseLabel": "Augmentation costs included in past service costs"
       }
      }
     },
     "localname": "AugmentationCostsIncludedInPastServiceCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_AustriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austria",
        "label": "Austria [Member]",
        "terseLabel": "Austria [Member]"
       }
      }
     },
     "localname": "AustriaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AvailableIndefinitelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available indefinitely.",
        "label": "Available Indefinitely [member]",
        "terseLabel": "Available indefinitely [member]"
       }
      }
     },
     "localname": "AvailableIndefinitelyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_AverageEffectivePreSwapInterestRateNotesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average effective pre swap interest rate issued.",
        "label": "Average Effective Pre Swap Interest Rate Notes Issued",
        "terseLabel": "Average effective pre-swap interest rate notes"
       }
      }
     },
     "localname": "AverageEffectivePreSwapInterestRateNotesIssued",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AverageEffectivePreSwapInterestRateShortTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average effective pre swap interest rate short term.",
        "label": "Average effective pre swap interest rate short term",
        "terseLabel": "Average effective pre-swap interest rate on short term notes"
       }
      }
     },
     "localname": "AverageEffectivePreSwapInterestRateShortTerm",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AverageFixedInterestRateOfHedgingInstrument": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average Fixed Interest Rate Of Hedging Instrument",
        "label": "Average Fixed Interest Rate Of Hedging Instrument",
        "terseLabel": "Average contracted fixed rate %"
       }
      }
     },
     "localname": "AverageFixedInterestRateOfHedgingInstrument",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_AverageNumberOfEmployeesFromContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_AverageNumberOfEmployees",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of employees from continuing operations.",
        "label": "Average Number Of Employees From Continuing Operations",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "AverageNumberOfEmployeesFromContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_AverageNumberOfEmployeesFromDiscontinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_AverageNumberOfEmployees",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of employees from discontinuing operations.",
        "label": "Average Number Of Employees From Discontinuing operations",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "AverageNumberOfEmployeesFromDiscontinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_AwardType1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type 1 [axis]",
        "terseLabel": "Award type."
       }
      }
     },
     "localname": "AwardType1Axis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_BBB-OrBaaThreeRatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BBB -/ Baa3 rated.",
        "label": "BBB -Or Baa Three Rated [member]",
        "terseLabel": "BBB -/ Baa3 Rated [member]"
       }
      }
     },
     "localname": "BBB-OrBaaThreeRatedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BBPlusOrBaOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BB+/Ba1 and Below/Unrated.",
        "label": "BB Plus Or Ba One [member]",
        "terseLabel": "BB+/Ba1 and Below/Unrated [member]"
       }
      }
     },
     "localname": "BBPlusOrBaOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BMSAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS Assets [Member]",
        "label": "B M S Assets [Member]",
        "terseLabel": "BMS Assets [member]"
       }
      }
     },
     "localname": "BMSAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BacSanJoseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BAC san jose.",
        "label": "BAC San Jose [Member]"
       }
      }
     },
     "localname": "BacSanJoseMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BalanceAmountDerecognisedOnDemerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance amount derecognised on demerger.",
        "label": "Balance amount derecognised on demerger",
        "negatedLabel": "Balances derecognised on demerger"
       }
      }
     },
     "localname": "BalanceAmountDerecognisedOnDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BancoDeHondurasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Banco de honduras.",
        "label": "Banco De Honduras [Member]"
       }
      }
     },
     "localname": "BancoDeHondurasMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BancoDoBrasilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Banco do brasil.",
        "label": "Banco Do Brasil [Member]"
       }
      }
     },
     "localname": "BancoDoBrasilMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BangladeshConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bangladesh Consumer Healthcare.",
        "label": "Bangladesh Consumer Healthcare [Member]",
        "terseLabel": "Bangladesh Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "BangladeshConsumerHealthcareMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BankBalancesAndDepositHeldWithCounterparties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank balances and deposit held with counter parties.",
        "label": "Bank Balances And Deposit Held With Counterparties",
        "terseLabel": "Bank balances and deposits",
        "verboseLabel": "Bank balances and deposits held with counter parties"
       }
      }
     },
     "localname": "BankBalancesAndDepositHeldWithCounterparties",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BankLoansAndOverdraftsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank loans and overdrafts.",
        "label": "Bank loans and overdrafts [member]",
        "terseLabel": "Bank Loans and Overdrafts [member]"
       }
      }
     },
     "localname": "BankLoansAndOverdraftsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BankLoansoverdraftsAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank loans and overdrafts.",
        "label": "Bank LoansOverdrafts And Other",
        "negatedLabel": "Bank loans, overdrafts and other"
       }
      }
     },
     "localname": "BankLoansoverdraftsAndOther",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BankOverdrafts1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank overdrafts.",
        "label": "Bank Overdrafts 1 [member]",
        "terseLabel": "Overdrafts [member]"
       }
      }
     },
     "localname": "BankOverdrafts1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BbbOrBaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BBB/Baa.",
        "label": "BBB Or Baa [member]",
        "terseLabel": "BBB/Baa [member]"
       }
      }
     },
     "localname": "BbbOrBaaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BenlystaAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benlysta [Axis]"
       }
      }
     },
     "localname": "BenlystaAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_BenlystaDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benlysta [Domain]"
       }
      }
     },
     "localname": "BenlystaDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BenlystaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benlysta [member]",
        "label": "Benlysta [member]",
        "terseLabel": "Benlysta [member]"
       }
      }
     },
     "localname": "BenlystaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BerkeleySquarePensionTrusteeCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Berkeley square pension trustee company limited.",
        "label": "Berkeley Square Pension Trustee Company Limited [Member]",
        "terseLabel": "Berkeley Square Pension Trustee Company Limited [Member]"
       }
      }
     },
     "localname": "BerkeleySquarePensionTrusteeCompanyLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BondsInDesignatedHedgingRelationshipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds in a designated hedging relationship.",
        "label": "Bonds In A Designated Hedging Relationship [member]",
        "terseLabel": "Bonds In A Designated Hedging Relationship [member]"
       }
      }
     },
     "localname": "BondsInDesignatedHedgingRelationshipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BorrowingThreeToSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing three to six months.",
        "label": "Borrowing Three to Six Months [Member]",
        "terseLabel": "Borrowing 3 to 6 months [Member]"
       }
      }
     },
     "localname": "BorrowingThreeToSixMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BorrowingsExcludingObligationsUnderFinanceLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings excluding obligations under finance lease.",
        "label": "Borrowings Excluding Obligations Under Finance Lease",
        "negatedLabel": "Borrowings excluding obligations under finance leases:"
       }
      }
     },
     "localname": "BorrowingsExcludingObligationsUnderFinanceLease",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings excluding obligations under finance lease at fair value.",
        "label": "Borrowings Excluding Obligations Under Finance Lease At Fair Value",
        "negatedLabel": "Borrowings excluding obligations under finance leases fair value"
       }
      }
     },
     "localname": "BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BorrowingsLessThanThreeMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings less than three months.",
        "label": "Borrowings Less Than Three Months [Member]",
        "terseLabel": "Borrowings Less than 3 months [member]"
       }
      }
     },
     "localname": "BorrowingsLessThanThreeMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BorrowingsOverSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings over six months.",
        "label": "Borrowings Over Six Months [Member]",
        "terseLabel": "Borrowings Over 6 months [member]"
       }
      }
     },
     "localname": "BorrowingsOverSixMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BrandsWithIndefiniteUsefulLifeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brands with Indefinite Useful Life.",
        "label": "Brands with Indefinite Useful Life [member]",
        "terseLabel": "Brands with indefinite useful life [member]"
       }
      }
     },
     "localname": "BrandsWithIndefiniteUsefulLifeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BusinessCombinationConsiderationPayableForStepAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination consideration payable for step acquisition.",
        "label": "Business Combination Consideration Payable For Step Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationPayableForStepAcquisition",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BusinessCombinationPotentialMilestonePaymentPerTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination potential milestone payment per tranche.",
        "label": "Business Combination Potential Milestone Payment Per Tranche",
        "terseLabel": "Business combination potential milestone payment per tranche"
       }
      }
     },
     "localname": "BusinessCombinationPotentialMilestonePaymentPerTranche",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination step acquisition remaining equity interest acquired.",
        "label": "Business Combination Step Acquisition Remaining Equity Interest Acquired",
        "terseLabel": "Business combination step acquisition remaining equity interest acquired"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionRemainingEquityInterestAcquired",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_BuyForeignCurrencyLessThanThreeMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy Foreign Currency Less than three months [member]",
        "label": "Buy Foreign Currency Less than three months [member]",
        "terseLabel": "Buy Foreign Currency Less than 3 months [member]"
       }
      }
     },
     "localname": "BuyForeignCurrencyLessThanThreeMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BuyForeignCurrencyOverSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy Foreign Currency over six months [member]",
        "label": "Buy Foreign Currency over six months [member]",
        "terseLabel": "Buy Foreign Currency over 6 months [member]"
       }
      }
     },
     "localname": "BuyForeignCurrencyOverSixMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_BuyForeignCurrencyThreeToSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy Foreign Currency three to six months [member]",
        "label": "Buy Foreign Currency three to six months [member]",
        "terseLabel": "Buy Foreign Currency 3 to 6 months [member]"
       }
      }
     },
     "localname": "BuyForeignCurrencyThreeToSixMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CADMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAD.",
        "label": "CAD [Member]"
       }
      }
     },
     "localname": "CADMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancelled committed facilities replaced with revolving credit facilities.",
        "label": "Cancelled committed facilities replaced with revolving credit facilities",
        "terseLabel": "Cancelled committed facilities and replaced with revolving credit facilities"
       }
      }
     },
     "localname": "CancelledCommittedFacilitiesReplacedWithRevolvingCreditFacilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CapitalLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Losses",
        "label": "Capital Losses",
        "terseLabel": "Tax losses"
       }
      }
     },
     "localname": "CapitalLosses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CapitalisedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalised development costs.",
        "label": "Capitalised development costs",
        "terseLabel": "Capitalised development costs"
       }
      }
     },
     "localname": "CapitalisedDevelopmentCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryInterestAtEffectiveRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carry interest at effective rates.",
        "label": "Carry Interest At Effective Rates",
        "terseLabel": "Interest at effective rates"
       }
      }
     },
     "localname": "CarryInterestAtEffectiveRates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_CarryingAmountOfTheNciDerecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the NCI derecognized",
        "label": "Carrying amount of the NCI derecognized",
        "terseLabel": "Carrying amount of the non-controlling interest de-recognised"
       }
      }
     },
     "localname": "CarryingAmountOfTheNciDerecognized",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the net assets and liabilities distributed",
        "label": "Carrying amount of the net assets and liabilities distributed",
        "terseLabel": "Carrying amount of the net assets and liabilities distributed/de-recognised"
       }
      }
     },
     "localname": "CarryingAmountOfTheNetAssetsAndLiabilitiesDistributed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "carrying value of bonds that were designated as hedging instruments.",
        "label": "Carrying Value Of Bonds That Were Designated As Hedging Instruments",
        "terseLabel": "Carrying value of bonds"
       }
      }
     },
     "localname": "CarryingValueOfBondsThatWereDesignatedAsHedgingInstruments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of investment net of non controlling interest.",
        "label": "Carrying Value Of Investment Net Of Non Controlling Interest",
        "terseLabel": "Carrying Value Of Investment Net Of Non Controlling Interest"
       }
      }
     },
     "localname": "CarryingValueOfInvestmentNetOfNonControllingInterest",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of shares held by trust under employee share ownership plan.",
        "label": "Carrying Value Of Shares Held By Trust Under Employee Share Ownership Plan",
        "terseLabel": "Carrying value of shares held by trust under employee share ownership plan"
       }
      }
     },
     "localname": "CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryingValueOfSharesHeldForShareAwardSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of shares held for share award schemes.",
        "label": "Carrying Value Of Shares Held For Share Award Schemes",
        "terseLabel": "Shares held for share award schemes, Carrying value"
       }
      }
     },
     "localname": "CarryingValueOfSharesHeldForShareAwardSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CarryingValueOfSharesHeldForShareOptionSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of shares held for share option schemes.",
        "label": "Carrying Value Of Shares Held For Share Option Schemes",
        "terseLabel": "Shares held for share option schemes, Carrying value"
       }
      }
     },
     "localname": "CarryingValueOfSharesHeldForShareOptionSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashAndBankOverdraftsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and bank overdrafts.",
        "label": "Cash and Bank Overdrafts [member]",
        "terseLabel": "Cash and cash equivalents and overdrafts [member]"
       }
      }
     },
     "localname": "CashAndBankOverdraftsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CashAndCashEquivalentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent.",
        "label": "Cash and Cash Equivalent [member]",
        "terseLabel": "Cash and cash equivalents [member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CashAndCashEquivalents1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents.",
        "label": "Cash and cash equivalents [member]",
        "terseLabel": "Cash and cash equivalents [member]"
       }
      }
     },
     "localname": "CashAndCashEquivalents1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CashAndCashEquivalentsAndLiquidInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and liquid investments.",
        "label": "Cash and cash equivalents and liquid investments",
        "terseLabel": "Cash and cash equivalents and liquid investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndLiquidInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashAndCashEquivalentsAndLiquidInvestmentsHeld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and liquid investments held.",
        "label": "Cash and cash equivalents and liquid investments held",
        "terseLabel": "Cash and cash equivalents and liquid investments held centrally"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndLiquidInvestmentsHeld",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashAndCashEquivalentsAndNetOfOverdrafts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and net of overdrafts.",
        "label": "Cash And Cash Equivalents And Net Of Overdrafts",
        "negatedPeriodEndLabel": "Ending balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndNetOfOverdrafts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents.",
        "label": "Cash And Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_CashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents.",
        "label": "Cash And Cash Equivalents [Table]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash consideration including currency forwards and purchase adjustments",
        "label": "Cash consideration including currency forwards and purchase adjustments",
        "terseLabel": "Cash consideration including currency forwards, purchase adjustments and deferred consideration"
       }
      }
     },
     "localname": "CashConsiderationIncludingCurrencyForwardsAndPurchaseAdjustments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashDividendsPaidToShareholdersRecognizedInYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash dividends paid to shareholders recognized in year.",
        "label": "Cash Dividends Paid to Shareholders Recognized in Year",
        "terseLabel": "Cash dividends to shareholders"
       }
      }
     },
     "localname": "CashDividendsPaidToShareholdersRecognizedInYear",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows from used in operating activities continuing operations net of tax.",
        "label": "Cash Flows From Used In Operating Activities Continuing Operations Net Of Tax",
        "totalLabel": "Net cash inflow from continuing operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows from used in operating activities discontinued operations net of tax.",
        "label": "Cash Flows From Used In Operating Activities Discontinued Operations Net Of Tax",
        "totalLabel": "Net operating cash flows attributable to discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperationsNetOfTax",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashFlowsInTwoThousandAndTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows In Two Thousand And Twenty Two [Member]",
        "terseLabel": "Cash flows in 2022 [member]"
       }
      }
     },
     "localname": "CashFlowsInTwoThousandAndTwentyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CashFromUsedInOperationsBeforeTaxDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash from used in operations before tax discontinued operations.",
        "label": "Cash From Used In Operations Before Tax Discontinued Operations",
        "terseLabel": "Cash generated from operations attributable to discontinued operations"
       }
      }
     },
     "localname": "CashFromUsedInOperationsBeforeTaxDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 3.0,
       "parentTag": "gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash from used in operations before taxes continuing operations.",
        "label": "Cash From Used In Operations Before Taxes Continuing Operations",
        "totalLabel": "Cash generated from operations attributable to continuing operations"
       }
      }
     },
     "localname": "CashFromUsedInOperationsBeforeTaxesContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashHeldAtUnratedCounterparties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held at unrated counterparties.",
        "label": "Cash Held At Unrated Counterparties",
        "terseLabel": "Amount of cash held at unrated counter parties"
       }
      }
     },
     "localname": "CashHeldAtUnratedCounterparties",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashHeldAtUnratedCounterpartiesCashInTransitElement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held at unrated counterparties cash in transit element.",
        "label": "Cash Held At Unrated Counterparties Cash In Transit Element",
        "terseLabel": "Cash in transit"
       }
      }
     },
     "localname": "CashHeldAtUnratedCounterpartiesCashInTransitElement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashInvestmentsInJointVenturesAndAssociates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash investments in joint ventures and associates.",
        "label": "Cash investments in joint ventures and associates",
        "terseLabel": "Cash investment in associates and joint ventures"
       }
      }
     },
     "localname": "CashInvestmentsInJointVenturesAndAssociates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashManagedForSubsidiaryCompany": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash managed for subsidiary company.",
        "label": "Cash Managed For Subsidiary Company",
        "terseLabel": "Cash managed by group for subsidiary"
       }
      }
     },
     "localname": "CashManagedForSubsidiaryCompany",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashOutflowInflowExcludingTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow inflow excluding transaction costs.",
        "label": "Cash Outflow Inflow Excluding Transaction Costs",
        "terseLabel": "Cash outflow/inflow excluding transaction costs"
       }
      }
     },
     "localname": "CashOutflowInflowExcludingTransactionCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashReserves": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash reserves.",
        "label": "Cash Reserves",
        "terseLabel": "Cash reserves"
       }
      }
     },
     "localname": "CashReserves",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashRestructuringCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash restructuring charges.",
        "label": "Cash Restructuring Charges",
        "verboseLabel": "Cash restructuring charges"
       }
      }
     },
     "localname": "CashRestructuringCharges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CashSettledAndOtherPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash settled and other plans.",
        "label": "Cash settled and other plans [member]",
        "terseLabel": "Cash settled and other plans [member]"
       }
      }
     },
     "localname": "CashSettledAndOtherPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CashTransferredOnDisposal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash transferred on disposal.",
        "label": "Cash Transferred On Disposal",
        "terseLabel": "Cash transferred on disposal"
       }
      }
     },
     "localname": "CashTransferredOnDisposal",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ChangeInFairValueOfNetDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of net debt.",
        "label": "Change In Fair Value Of Net Debt",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "ChangeInFairValueOfNetDebt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Working Capital.",
        "label": "Changes In Working Capital [Abstract]",
        "terseLabel": "Changes in working capital:"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ClassOfCommonStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of common stock.",
        "label": "Class Of Common Stock [Axis]"
       }
      }
     },
     "localname": "ClassOfCommonStockAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ClassOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of common stock.",
        "label": "Class Of Common Stock [Member]"
       }
      }
     },
     "localname": "ClassOfCommonStockMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CommercialOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial operations.",
        "label": "Commercial Operations [Member]",
        "terseLabel": "Commercial Operations [Member]",
        "verboseLabel": "Commercial Operations [member]"
       }
      }
     },
     "localname": "CommercialOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CommercialPaper1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial paper.",
        "label": "Commercial Paper 1 [member]",
        "terseLabel": "Commercial paper [member]"
       }
      }
     },
     "localname": "CommercialPaper1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CommercialPaperAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial paper authorized.",
        "label": "Commercial paper authorized",
        "terseLabel": "Commercial paper authorized"
       }
      }
     },
     "localname": "CommercialPaperAuthorized",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CommercialPaperInADesignatedHedgingRelationshipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial paper in a designated hedging relationship.",
        "label": "Commercial paper in a designated hedging relationship [Member]",
        "verboseLabel": "Commercial paper in a designated hedging relationship [member]"
       }
      }
     },
     "localname": "CommercialPaperInADesignatedHedgingRelationshipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CommercialisedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialised Products [Member]"
       }
      }
     },
     "localname": "CommercialisedProductsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ConcentrationsOfRiskRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentrations of risk revenue percentage.",
        "label": "Concentrations of risk revenue percentage",
        "terseLabel": "Percentage of sales of US Commercial Operation business to three largest wholesalers"
       }
      }
     },
     "localname": "ConcentrationsOfRiskRevenuePercentage",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_ConsumerHealthCareBangladeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Health Care Bangladesh [Member]",
        "label": "Consumer Health Care Bangladesh [Member]"
       }
      }
     },
     "localname": "ConsumerHealthCareBangladeshMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ConsumerHealthCareJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer health care joint venture.",
        "label": "Consumer Health Care Joint Venture [member]",
        "terseLabel": "Consumer health care joint venture [member]"
       }
      }
     },
     "localname": "ConsumerHealthCareJointVentureMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/NonControllingInterestsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ConsumerHealthcareBusinessDemerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare business demerger.",
        "label": "Consumer Healthcare business demerger",
        "terseLabel": "Consumer Healthcare business demerger"
       }
      }
     },
     "localname": "ConsumerHealthcareBusinessDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "gsk_ConsumerHealthcareBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer healthcare business.",
        "label": "Consumer Healthcare Business [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareBusinessMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer healthcare.",
        "label": "Consumer Healthcare [member]",
        "terseLabel": "Consumer Healthcare [member]"
       }
      }
     },
     "localname": "ConsumerHealthcareMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ContingentConsiderationLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liabilities current.",
        "label": "Contingent consideration liabilities current",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilitiesCurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContingentConsiderationLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liabilities.",
        "label": "Contingent Consideration Liabilities [member]",
        "terseLabel": "Contingent Consideration Liabilities [member]"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilitiesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ContingentConsiderationPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration paid.",
        "label": "Contingent consideration paid",
        "negatedLabel": "Cash payments: investing activities"
       }
      }
     },
     "localname": "ContingentConsiderationPaid",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContingentConsiderationPayableDiscountedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration payable discounted percentage.",
        "label": "Contingent Consideration Payable Discounted Percentage",
        "terseLabel": "Contingent consideration liability discount percentage"
       }
      }
     },
     "localname": "ContingentConsiderationPayableDiscountedPercentage",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_ContinuingAndDiscontinuedOperationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing and discontinued operation.",
        "label": "Continuing And Discontinued Operation [Axis]",
        "terseLabel": "Continuing and discontinued operations [axis]",
        "verboseLabel": "Continuing And Discontinued Operation [Axis]"
       }
      }
     },
     "localname": "ContinuingAndDiscontinuedOperationAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ContinuingAndDiscontinuedOperationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing and discontinued operation.",
        "label": "Continuing And Discontinued Operation [Member]",
        "terseLabel": "Continuing operations [member]"
       }
      }
     },
     "localname": "ContinuingAndDiscontinuedOperationMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing operations defined benefit pension and post-retirement healthcare scheme. [member]",
        "label": "Continuing Operations Defined Benefit Pension And Postretirement Healthcare Scheme [Member]",
        "terseLabel": "Continuing operations defined benefit pension and post-retirement healthcare scheme [member]"
       }
      }
     },
     "localname": "ContinuingOperationsDefinedBenefitPensionAndPostretirementHealthcareSchemeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ContractualObligationsAndCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments.",
        "label": "Contractual Obligations And Commitments",
        "totalLabel": "Total contractual obligations and commitments"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsAndCommitmentsOfFutureFinanceCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 7.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments of future finance charges",
        "label": "Contractual Obligations And Commitments of Future Finance Charges",
        "terseLabel": "Future finance charges on leases"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitmentsOfFutureFinanceCharges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsAndCommitmentsOfInterestOnLoans": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 6.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments of interest on loans.",
        "label": "Contractual Obligations And Commitments Of Interest On Loans",
        "terseLabel": "Interest on loans"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitmentsOfInterestOnLoans",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsAndCommitmentsOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 3.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments of investments.",
        "label": "Contractual Obligations And Commitments Of Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitmentsOfInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsAndCommitmentsOfPensions": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 5.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments of pensions.",
        "label": "Contractual Obligations And Commitments Of Pensions",
        "terseLabel": "Pensions and post-retirement benefits"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitmentsOfPensions",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsAndCommitmentsOfPurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 4.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations and commitments of purchase commitments.",
        "label": "Contractual Obligations And Commitments Of Purchase Commitments",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "ContractualObligationsAndCommitmentsOfPurchaseCommitments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ContractualObligationsLeaseContractsThatHaveNotYetCommenced": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 8.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations lease contracts that have not yet commenced.",
        "label": "Contractual Obligations Lease Contracts That Have Not Yet Commenced",
        "terseLabel": "Lease contracts that have not yet commenced"
       }
      }
     },
     "localname": "ContractualObligationsLeaseContractsThatHaveNotYetCommenced",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CorixaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corixa Corporation.",
        "label": "Corixa Corporation [member]",
        "terseLabel": "Corixa Corporation [member]"
       }
      }
     },
     "localname": "CorixaCorporationMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CorporateBondsContributedToFairValueOfPlanAssetsListed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds contributed to fair value of plan assets listed.",
        "label": "Corporate Bonds Contributed To Fair Value Of Plan Assets Listed",
        "terseLabel": "Corporate bonds, listed"
       }
      }
     },
     "localname": "CorporateBondsContributedToFairValueOfPlanAssetsListed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CorporateBondsContributedToFairValueOfPlanAssetsUnlisted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds contributed to fair value of plan assets unlisted.",
        "label": "Corporate Bonds Contributed To Fair Value Of Plan Assets Unlisted",
        "terseLabel": "Corporate bonds, unlisted"
       }
      }
     },
     "localname": "CorporateBondsContributedToFairValueOfPlanAssetsUnlisted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CostChargedToOperatingProfit": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost charged to operating profit.",
        "label": "Cost Charged to Operating Profit",
        "totalLabel": "Cost charged to operating profit"
       }
      }
     },
     "localname": "CostChargedToOperatingProfit",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CostOfMajorRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of major restructuring [member]",
        "label": "Cost Of Major Restructuring [Member]",
        "terseLabel": "Cost of major restructuring [member]"
       }
      }
     },
     "localname": "CostOfMajorRestructuringMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CostOfSalesOnCoPromotionalActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales on co promotional activities",
        "label": "Cost of sales on co promotional activities",
        "terseLabel": "Cost of sales on co promotional activities"
       }
      }
     },
     "localname": "CostOfSalesOnCoPromotionalActivities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CureVacNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CureVac N.V",
        "label": "Cure Vac N V [Member]",
        "terseLabel": "CureVac N.V. [Member]"
       }
      }
     },
     "localname": "CureVacNVMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurevacAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Curevac Assets [Member]"
       }
      }
     },
     "localname": "CurevacAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenCentAppreciationOfEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Cent Appreciation Of Euro",
        "label": "Currency Risk Fifteen Cent Appreciation Of Euro [Member]",
        "terseLabel": "15 cent appreciation of the Euro [member]",
        "verboseLabel": "15 cent appreciation of Euro [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenCentAppreciationOfEuroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenCentAppreciationOfUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Cent Appreciation Of US Dollar",
        "label": "Currency Risk Fifteen Cent Appreciation Of US Dollar [Member]",
        "terseLabel": "15 cent appreciation of the US Dollar [member]",
        "verboseLabel": "15 cent appreciation of US Dollar [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenCentAppreciationOfUsDollarMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenCentDepreciationOfEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Cent Depreciation Of Euro",
        "label": "Currency Risk Fifteen Cent Depreciation Of Euro [Member]",
        "terseLabel": "15 cent depreciation of Euro [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenCentDepreciationOfEuroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenCentDepreciationOfUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Cent Depreciation Of US Dollar",
        "label": "Currency Risk Fifteen Cent Depreciation Of US Dollar [Member]",
        "terseLabel": "15 cent depreciation of US Dollar [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenCentDepreciationOfUsDollarMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Percentage Decrease In Sales Forecasts Or Sales Multiple Applied",
        "label": "Currency Risk Fifteen Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [Member]",
        "terseLabel": "15% decrease in sales forecasts or sales multiple applied [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Fifteen Percentage Increase In Sales Forecasts Or Sales Multiple Applied",
        "label": "Currency Risk Fifteen Percentage Increase In Sales Forecasts Or Sales Multiple Applied [Member]",
        "terseLabel": "15% increase in sales forecasts or sales multiple applied [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenYenAppreciationOfYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Risk Fifteen Yen Appreciation Of Yen [Member]",
        "terseLabel": "15 Yen appreciation of the Yen [Member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenYenAppreciationOfYenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskFifteenYenDepreciationOfYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Risk Fifteen Yen depreciation Of Yen [Member]",
        "terseLabel": "15 Yen depreciation of Yen [member]"
       }
      }
     },
     "localname": "CurrencyRiskFifteenYenDepreciationOfYenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk One Fifty Basis Points Decrease In Discount Rate",
        "label": "Currency Risk One Fifty Basis Points Decrease In Discount Rate [Member]",
        "terseLabel": "1.50% (150 basis points) decrease in discount rate [Member]"
       }
      }
     },
     "localname": "CurrencyRiskOneFiftyBasisPointsDecreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk One Fifty Basis Points increase in discount rate",
        "label": "Currency Risk One Fifty Basis Points increase in discount rate [Member]",
        "terseLabel": "1.50% (150 basis points) increase in discount rate [Member]"
       }
      }
     },
     "localname": "CurrencyRiskOneFiftyBasisPointsIncreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenCentAppreciationOfEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency risk 10 cent appreciation of Euro.",
        "label": "Currency Risk Ten Cent Appreciation Of Euro [member]",
        "terseLabel": "10 cent appreciation of the Euro [member]",
        "verboseLabel": "10 cent appreciation of Euro [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenCentAppreciationOfEuroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenCentAppreciationOfUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency risk 10 cent appreciation of US dollar.",
        "label": "Currency Risk Ten Cent Appreciation Of US Dollar [member]",
        "terseLabel": "10 cent appreciation of the US Dollar [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenCentAppreciationOfUSDollarMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenCentDepreciationOfEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro exchange rates.",
        "label": "Currency risk ten cent depreciation of Euro [member]",
        "terseLabel": "10 cent depreciation of Euro [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenCentDepreciationOfEuroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenCentDepreciationOfUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Dollar exchange rates.",
        "label": "Currency risk ten cent depreciation of US Dollar [member]",
        "terseLabel": "10 cent depreciation of US Dollar [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenCentDepreciationOfUSDollarMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Ten Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [member]",
        "label": "Currency Risk Ten Percentage Decrease In Sales Forecasts Or Sales Multiple Applied [member]",
        "terseLabel": "10% decrease in sales forecasts or sales multiple applied [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency Risk Ten Percentage Increase In Sales Forecasts Or Sales Multiple Applied [member]",
        "label": "Currency Risk Ten Percentage Increase In Sales Forecasts Or Sales Multiple Applied [member]",
        "terseLabel": "10% increase in sales forecasts or sales multiple applied [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenYenAppreciationOfYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "10 Yen appreciation of the Yen.",
        "label": "Currency Risk Ten Yen Appreciation Of Yen [member]",
        "terseLabel": "10 Yen appreciation of the Yen [Member]"
       }
      }
     },
     "localname": "CurrencyRiskTenYenAppreciationOfYenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrencyRiskTenYenDepreciationOfYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency risk ten yen depreciation of yen.",
        "label": "Currency Risk Ten Yen depreciation Of Yen [member]",
        "terseLabel": "10 Yen depreciation of Yen [member]"
       }
      }
     },
     "localname": "CurrencyRiskTenYenDepreciationOfYenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrentAndDeferredTaxation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current and deferred taxation",
        "label": "Current and deferred taxation",
        "terseLabel": "Current and deferred taxation"
       }
      }
     },
     "localname": "CurrentAndDeferredTaxation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CurrentEquityAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current equity and other investments.",
        "label": "Current Equity And Other Investments [Member]",
        "verboseLabel": "Current equity investments and Other investments [member]"
       }
      }
     },
     "localname": "CurrentEquityAndOtherInvestmentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrentEquityInvestmentsMeasuredAsFVTPLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current equity investments measured as FVTPL.",
        "label": "Current Equity Investments Measured As FVTPL [Member]",
        "verboseLabel": "Investments measured at FVTPL 2022 [Member]"
       }
      }
     },
     "localname": "CurrentEquityInvestmentsMeasuredAsFVTPLMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrentEquityInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current equity investments.",
        "label": "Current Equity Investments [Member]",
        "terseLabel": "Current [Member]"
       }
      }
     },
     "localname": "CurrentEquityInvestmentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrentPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current period.",
        "label": "Current Period [member]",
        "terseLabel": "Current. [member]"
       }
      }
     },
     "localname": "CurrentPeriodMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CurrentTaxExpensesincomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current tax expenses (income).",
        "label": "Current tax expenses income [Abstract]",
        "verboseLabel": "Current tax expense (income)"
       }
      }
     },
     "localname": "CurrentTaxExpensesincomeAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current tax on defined benefit plans charged or credited directly to equity and comprehensive income.",
        "label": "Current Tax On Defined Benefit Plans Charged Or Credited Directly To Equity And Comprehensive Income",
        "terseLabel": "Defined benefit plans"
       }
      }
     },
     "localname": "CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current tax on fair value movements on cash flow hedges charged or credited directly to comprehensive income.",
        "label": "Current Tax On Fair Value Movements On Cash Flow Hedges Charged Or Credited Directly To Comprehensive Income"
       }
      }
     },
     "localname": "CurrentTaxOnFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current tax on fair value movements on equity investments charged or credited directly to comprehensive income.",
        "label": "Current Tax On Fair Value Movements On Equity Investments Charged Or Credited Directly To Comprehensive Income"
       }
      }
     },
     "localname": "CurrentTaxOnFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current tax on share based payments charged or credited directly to equity and comprehensive income.",
        "label": "Current Tax On Share Based Payments Charged Or Credited Directly To Equity And Comprehensive Income",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CurrentTaxationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Taxation [Abstract]",
        "terseLabel": "Current taxation"
       }
      }
     },
     "localname": "CurrentTaxationAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_CustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer.",
        "label": "Customer [Member]",
        "terseLabel": "Customer [member]"
       }
      }
     },
     "localname": "CustomerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_CustomerReturnAndRebateAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer return and rebate accruals.",
        "label": "Customer Return And Rebate Accruals",
        "terseLabel": "Customer return and rebate accruals"
       }
      }
     },
     "localname": "CustomerReturnAndRebateAccruals",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer return and rebate accruals, includes (only in Dec 31, 2022) Cash discount and Channel Management Payment.",
        "label": "Customer Return And Rebate Accruals Inclusive Of Cash Discount And Channel Management Payment",
        "terseLabel": "Customer return and rebate accruals"
       }
      }
     },
     "localname": "CustomerReturnAndRebateAccrualsInclusiveOfCashDiscountAndChannelManagementPayment",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_CustomerReturnsDiscountsAndRebates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer returns discounts and rebates.",
        "label": "Customer Returns Discounts And Rebates",
        "terseLabel": "Incidental deductions to turnover"
       }
      }
     },
     "localname": "CustomerReturnsDiscountsAndRebates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DamagesAwardedToGSK": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Damages\u200b Awarded to GSK.",
        "label": "Damages Awarded To G S K",
        "terseLabel": "Damages\u200b Awarded to GSK"
       }
      }
     },
     "localname": "DamagesAwardedToGSK",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DateOfEndOfReportingPeriod2022": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of end of reporting period 2022.",
        "label": "Date Of End Of Reporting Period 2022",
        "verboseLabel": "Date of end of reporting period"
       }
      }
     },
     "localname": "DateOfEndOfReportingPeriod2022",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "gsk_DateOfShareConsolidationApproval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of share consolidation approval.",
        "label": "Date of share consolidation approval",
        "terseLabel": "Date of share consolidation approval"
       }
      }
     },
     "localname": "DateOfShareConsolidationApproval",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "gsk_DealCostsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deal Costs Payable",
        "label": "Deal Costs Payable",
        "terseLabel": "Deal costs payable."
       }
      }
     },
     "localname": "DealCostsPayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_Debt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt.",
        "label": "Debt",
        "negatedLabel": "Total debt"
       }
      }
     },
     "localname": "Debt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_Debt1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt.",
        "label": "Debt 1 [member]",
        "terseLabel": "Net debt [member]"
       }
      }
     },
     "localname": "Debt1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DebtInstrument1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument 1.",
        "label": "Debt Instrument 1 [axis]",
        "terseLabel": "Debt Instrument 1 [axis]"
       }
      }
     },
     "localname": "DebtInstrument1Axis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DebtInstrumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument [domain]",
        "label": "Debt Instrument [domain]",
        "terseLabel": "Debt Instrument [domain]"
       }
      }
     },
     "localname": "DebtInstrumentDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DebtOfSubsidiaryUndertakingsAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt of subsidiary undertakings acquired.",
        "label": "Debt of subsidiary undertakings acquired",
        "negatedLabel": "Debt of subsidiary undertakings acquired"
       }
      }
     },
     "localname": "DebtOfSubsidiaryUndertakingsAcquired",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseInAnnualPensionCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in annual pension cost.",
        "label": "Decrease In Annual Pension Cost",
        "terseLabel": "Decrease in annnual pension cost"
       }
      }
     },
     "localname": "DecreaseInAnnualPensionCost",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseInDiscountRateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in discount rate amount.",
        "label": "Decrease In Discount Rate Amount",
        "terseLabel": "Decrease in discount rate"
       }
      }
     },
     "localname": "DecreaseInDiscountRateAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseInPlanDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in plan deficit.",
        "label": "Decrease In Plan Deficit",
        "terseLabel": "Net pension deficit"
       }
      }
     },
     "localname": "DecreaseInPlanDeficit",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseInProbabilityOfMilestoneSuccess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "decrease in probability of milestone success.",
        "label": "Decrease In Probability Of Milestone Success",
        "terseLabel": "10% decrease in probability of milestone success"
       }
      }
     },
     "localname": "DecreaseInProbabilityOfMilestoneSuccess",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseInSalesForecastAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in sales forecast amount.",
        "label": "Decrease In Sales Forecast Amount",
        "terseLabel": "Decrease in sales forecasts"
       }
      }
     },
     "localname": "DecreaseInSalesForecastAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseIncreaseInLiquidInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease increase in liquid investment.",
        "label": "Decrease Increase In Liquid Investment",
        "terseLabel": "Increase/(decrease) in liquid investments"
       }
      }
     },
     "localname": "DecreaseIncreaseInLiquidInvestment",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseIncreaseInNetDebtFromContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease Increase In Net Debt From Continuing Operations.",
        "label": "Decrease Increase In Net Debt From Continuing Operations",
        "terseLabel": "Decrease/(increase) in net debt from continuing operations"
       }
      }
     },
     "localname": "DecreaseIncreaseInNetDebtFromContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseIncreaseInNetDebtFromDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease Increase In Net Debt From Discontinued Operations.",
        "label": "Decrease Increase In Net Debt From Discontinued Operations",
        "terseLabel": "Decrease/(increase) in net debt from discontinued operations"
       }
      }
     },
     "localname": "DecreaseIncreaseInNetDebtFromDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease through classified as held for sale or distribution intangible assets and goodwill.",
        "label": "Decrease Through Classified As Held For Sale or Distribution Intangible Assets And Goodwill",
        "terseLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "DecreaseThroughClassifiedAsHeldForSaleOrDistributionIntangibleAssetsAndGoodwill",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredConsiderationReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred consideration received.",
        "label": "Deferred consideration received",
        "terseLabel": "Net deferred consideration"
       }
      }
     },
     "localname": "DeferredConsiderationReceived",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxAssetsRecognizedOnTradingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets recognized on trading losses.",
        "label": "Deferred Tax Assets Recognized On Trading Losses",
        "terseLabel": "Deferred tax assets recognized on trading losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsRecognizedOnTradingLosses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax on share based payments charged or credited directly to equity and comprehensive income.",
        "label": "Deferred Tax On Share Based Payments Charged Or Credited Directly To Equity And Comprehensive Income",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 8.0,
       "parentTag": "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax relating to defined benefit plans charged or credited directly to comprehensive income.",
        "label": "Deferred Tax Relating To Defined Benefit Plans Charged Or Credited Directly To Comprehensive Income",
        "terseLabel": "Defined benefit plans"
       }
      }
     },
     "localname": "DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 9.0,
       "parentTag": "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax relating to fair value movements on cash flow hedges charged or credited directly to comprehensive income.",
        "label": "Deferred Tax Relating to Fair Value Movements on Cash Flow Hedges Charged or Credited Directly to Comprehensive Income",
        "terseLabel": "Fair value movements on cash flow hedges"
       }
      }
     },
     "localname": "DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 10.0,
       "parentTag": "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax relating to fair value movements on equity investments charged or credited directly to comprehensive income.",
        "label": "Deferred Tax Relating to Fair Value Movements on Equity Investments Charged or Credited Directly to Comprehensive Income",
        "terseLabel": "Fair value movements on equity investments"
       }
      }
     },
     "localname": "DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax relating to items charged or credited directly to equity and comprehensive income.",
        "label": "Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income",
        "terseLabel": "Credit/(charge) to statement of comprehensive income"
       }
      }
     },
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax relating to items charged or credited directly to equity and comprehensive income [abstract].",
        "label": "Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income [abstract]",
        "terseLabel": "Deferred taxation"
       }
      }
     },
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DefinedBenefitObligationActiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit obligation active.",
        "label": "Defined Benefit Obligation Active [member]",
        "terseLabel": "Active [member]"
       }
      }
     },
     "localname": "DefinedBenefitObligationActiveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DefinedBenefitObligationAtPastServiceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit obligation at past service cost.",
        "label": "Defined benefit obligation at past service cost",
        "verboseLabel": "Defined benefit obligation, at past service cost"
       }
      }
     },
     "localname": "DefinedBenefitObligationAtPastServiceCost",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DefinedBenefitObligationDeferredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit obligation deferred.",
        "label": "Defined Benefit Obligation Deferred [member]",
        "terseLabel": "Deferred [member]"
       }
      }
     },
     "localname": "DefinedBenefitObligationDeferredMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DefinedBenefitObligationRetiredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit obligation retired.",
        "label": "Defined Benefit Obligation Retired [member]",
        "terseLabel": "Retired [member]"
       }
      }
     },
     "localname": "DefinedBenefitObligationRetiredMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DefinedBenefitPensionAndPostretirementHealthcareSchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit pension and post-retirement healthcare scheme.",
        "label": "Defined Benefit Pension and Post-retirement Healthcare Scheme [member]",
        "terseLabel": "Defined benefit pension and post-retirement healthcare scheme. [member]"
       }
      }
     },
     "localname": "DefinedBenefitPensionAndPostretirementHealthcareSchemeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DefinedBenefitPensionAssetCeilingRestrictions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit pension asset ceiling restrictions.",
        "label": "Defined Benefit Pension Asset Ceiling Restrictions",
        "terseLabel": "Asset Ceiling Restrictions"
       }
      }
     },
     "localname": "DefinedBenefitPensionAssetCeilingRestrictions",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DefinedBenefitPlanSurplusNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan surplus net.",
        "label": "Defined benefit plan surplus net",
        "terseLabel": "Surplus on UK defined benefit schemes"
       }
      }
     },
     "localname": "DefinedBenefitPlanSurplusNet",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DefinedBenefitSchemesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit schemes.",
        "label": "Defined Benefit Schemes [member]",
        "terseLabel": "Defined benefit schemes [member]"
       }
      }
     },
     "localname": "DefinedBenefitSchemesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DefinedContributionPensionSchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution pension scheme.",
        "label": "Defined contribution pension scheme [member]",
        "terseLabel": "Defined contribution pension scheme [member]"
       }
      }
     },
     "localname": "DefinedContributionPensionSchemeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DemergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demerger [Member]"
       }
      }
     },
     "localname": "DemergerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DemergerOfConsumerHealthcareBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demerger of consumer healthcare business.",
        "label": "Demerger of Consumer Healthcare Business [Member]"
       }
      }
     },
     "localname": "DemergerOfConsumerHealthcareBusinessMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DepreciationOfEuro": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation of euro.",
        "label": "Depreciation Of Euro",
        "negatedLabel": "Depreciation of Euro"
       }
      }
     },
     "localname": "DepreciationOfEuro",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DepreciationOfUSDollar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation of US dollar.",
        "label": "Depreciation Of US Dollar",
        "negatedLabel": "Depreciation of US Dollar"
       }
      }
     },
     "localname": "DepreciationOfUSDollar",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DerivativeFinancialAssetsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial assets liabilities.",
        "label": "Derivative financial assets (liabilities)",
        "terseLabel": "Fair value assets/ (liabilities) \u00a3m"
       }
      }
     },
     "localname": "DerivativeFinancialAssetsLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DerivativeFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial assets.",
        "label": "Derivative Financial Assets [member]",
        "terseLabel": "Derivative financial assets [member]"
       }
      }
     },
     "localname": "DerivativeFinancialAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial instruments [member]",
        "label": "Derivative financial instruments [member]",
        "terseLabel": "Derivative financial instruments [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DerivativeFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial liabilities [member]",
        "label": "Derivative financial liabilities [member]",
        "terseLabel": "Derivative financial liabilities [member]"
       }
      }
     },
     "localname": "DerivativeFinancialLiabilitiesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives designated and effective as hedging instruments.",
        "label": "Derivatives designated and effective as hedging instruments [member]",
        "terseLabel": "Derivatives designated and effective as hedging instruments [member]",
        "verboseLabel": "Derivatives designated and effective as hedging instruments (fair value movements through OCI\") [member]"
       }
      }
     },
     "localname": "DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for basis of consolidation.",
        "label": "Description of accounting policy for basis of consolidation [text block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for cash and cash equivalents.",
        "label": "Description of accounting policy for cash and cash equivalents explanatory [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Current Equity Investments Explanatory.",
        "label": "Description Of Accounting Policy For Current Equity Investments Explanatory [Policy Text Block]",
        "terseLabel": "Current equity investments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCurrentEquityInvestmentsExplanatoryPolicyTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForDiscountingExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for discounting .",
        "label": "Description of accounting policy for discounting [text block]",
        "terseLabel": "Discounting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDiscountingExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for legal and other disputes.",
        "label": "Description of Accounting Policy for Legal and other Disputes [text block]",
        "terseLabel": "Legal and other disputes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingPolicyForOtherInvestmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Other Investment [Text block]",
        "label": "Description Of Accounting Policy For Other Investment [Text block]",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForOtherInvestmentExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfAccountingStandardsApplied": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for accounting standards applied.",
        "label": "Description Of Accounting Standards Applied",
        "terseLabel": "Parent company financial statements"
       }
      }
     },
     "localname": "DescriptionOfAccountingStandardsApplied",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DescriptionOfForeignCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of foreign currency.",
        "label": "Description of foreign currency",
        "terseLabel": "Foreign currency"
       }
      }
     },
     "localname": "DescriptionOfForeignCurrency",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DescriptionOfInterimDividendRecognitonAndPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of interim dividend recogniton and payment.",
        "label": "Description Of Interim Dividend Recogniton And Payment",
        "terseLabel": "Description of compliance with IFRSs applied For interim financial report"
       }
      }
     },
     "localname": "DescriptionOfInterimDividendRecognitonAndPayment",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DetailsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Axis]"
       }
      }
     },
     "localname": "DetailsAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DetailsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Member]"
       }
      }
     },
     "localname": "DetailsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DisabledEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disabled employees.",
        "label": "Disabled Employees [member]",
        "terseLabel": "Disabled employees [member]"
       }
      }
     },
     "localname": "DisabledEmployeesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting principles and policies [line items]",
        "label": "Disclosure of accounting principles and policies [line items]",
        "terseLabel": "Disclosure of accounting principles and policies [line items]"
       }
      }
     },
     "localname": "DisclosureOfAccountingPrinciplesAndPoliciesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAccountingPrinciplesAndPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting principles and policies [table]",
        "label": "Disclosure of accounting principles and policies [table]",
        "terseLabel": "Disclosure of accounting principles and policies [table]"
       }
      }
     },
     "localname": "DisclosureOfAccountingPrinciplesAndPoliciesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of adjustment for each financial statement line item affected by application IFRS 16 [line items]",
        "label": "Disclosure of adjustment for each financial statement line item affected by application IFRS 16 line items [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16lineItemsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of adjustment for each financial statement line item affected by application IFRS 16 [table]",
        "label": "Disclosure of adjustment for each financial statement line item affected by application IFRS16table [Table]"
       }
      }
     },
     "localname": "DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIfrs16tableTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of adjustments reconciling profit after tax to operating cash flows.",
        "label": "Disclosure of adjustments reconciling profit after tax to operating cash flows explanatory",
        "terseLabel": "Adjustments reconciling profit after tax to operating cash flows"
       }
      }
     },
     "localname": "DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of aggregated financial information of associates and joint ventures.",
        "label": "Disclosure of Aggregated Financial Information of associates and joint ventures [text block]",
        "terseLabel": "Summary of Aggregated Financial Information"
       }
      }
     },
     "localname": "DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAllocationOfGoodwillToSegmentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of allocation of goodwill to segments explanatory.",
        "label": "Disclosure Of Allocation Of Goodwill To Segments Explanatory [text block]",
        "terseLabel": "Summary of Goodwill Allocated to Segments"
       }
      }
     },
     "localname": "DisclosureOfAllocationOfGoodwillToSegmentsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAnalysisOfChangesInNetDebtExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of analysis of changes in net debt.",
        "label": "Disclosure Of Analysis Of Changes In Net Debt Explanatory",
        "terseLabel": "Summary of Analysis of Changes in Net Debt"
       }
      }
     },
     "localname": "DisclosureOfAnalysisOfChangesInNetDebtExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAssetsHeldForSaleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of assets held for sale.",
        "label": "Disclosure Of Assets Held For Sale [abstract]"
       }
      }
     },
     "localname": "DisclosureOfAssetsHeldForSaleAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAssetsHeldForSaleExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of assets held for sale explanatory.",
        "label": "Disclosure of Assets Held for Sale Explanatory",
        "terseLabel": "Summary of Assets Held for Sale"
       }
      }
     },
     "localname": "DisclosureOfAssetsHeldForSaleExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAssociatesAndJointVenturesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Associates and Joint Ventures Explanatory",
        "label": "Disclosure of Associates and Joint Ventures Explanatory",
        "terseLabel": "Associates and joint ventures"
       }
      }
     },
     "localname": "DisclosureOfAssociatesAndJointVenturesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVentures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfAuditorsRemunerationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of auditors remuneration..",
        "label": "Disclosure Of Auditors Remuneration [line items]",
        "terseLabel": "Disclosure Of Auditors Remuneration [line items]"
       }
      }
     },
     "localname": "DisclosureOfAuditorsRemunerationLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAuditorsRemunerationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Auditors Remuneration [table]",
        "label": "Disclosure Of Auditors Remuneration [table]",
        "terseLabel": "Disclosure Of Auditors Remuneration [table]"
       }
      }
     },
     "localname": "DisclosureOfAuditorsRemunerationTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfAverageLifeExpectancyAssumptionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of average life expectancy assumptions.",
        "label": "Disclosure of average life expectancy assumptions [text block]",
        "terseLabel": "Summary of Average Life Expectancy Assumed"
       }
      }
     },
     "localname": "DisclosureOfAverageLifeExpectancyAssumptionsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of balance sheet presentation of defined benefit Pension and post retirement explanatory.",
        "label": "Disclosure Of Balance Sheet Presentation Of Defined Benefit Pension And Post Retirement Explanatory [text block]",
        "terseLabel": "Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits"
       }
      }
     },
     "localname": "DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfCashFlowsFromBusinessCombinationsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure Of Cash Flows From Business Combinations Explanatory.",
        "label": "Disclosure Of Cash Flows From Business Combinations [text block]",
        "terseLabel": "Summary of Cash Flows from Business Combinations"
       }
      }
     },
     "localname": "DisclosureOfCashFlowsFromBusinessCombinationsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Classes Of Share Capital And Share Premium [abstract]",
        "label": "Disclosure Of Classes Of Share Capital And Share Premium [abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of classes of share capital and share premium.",
        "label": "Disclosure of classes of share capital and share premium explanatory[text block]",
        "terseLabel": "Summary of Share Capital and Share Premium"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Classes Of Share Capital And Share Premium [line items]",
        "label": "Disclosure Of Classes Of Share Capital And Share Premium [line items]",
        "terseLabel": "Disclosure Of Classes Of Share Capital And Share Premium [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfClassesShareCapitalAndSharePremiumTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of classes share capital and share premium.",
        "label": "Disclosure Of Classes Share Capital And Share Premium [table]",
        "terseLabel": "Disclosure Of Classes Share Capital And Share Premium [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesShareCapitalAndSharePremiumTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of commitments.",
        "label": "Disclosure of Commitments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of compensation of directors and senior management.",
        "label": "Disclosure of Compensation of Directors and Senior Management Explanatory",
        "terseLabel": "Summary of Compensation of the Directors and Senior Management"
       }
      }
     },
     "localname": "DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfContingentConsiderationLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of contingent consideration liabilities.",
        "label": "Disclosure Of Contingent Consideration Liabilities [text block]",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "DisclosureOfContingentConsiderationLiabilitiesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfContractualObligationsAndCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Contractual Obligations And Commitments [abstract].",
        "label": "Disclosure Of Contractual Obligations And Commitments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsAndCommitmentsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfContractualObligationsAndCommitmentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Contractual Obligations And Commitments Explanatory.",
        "label": "Disclosure Of Contractual Obligations And Commitments Explanatory",
        "terseLabel": "Schedule of Contractual Obligations and Commitments"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationsAndCommitmentsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfCumulativeTranslationExchangeInEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of cumulative translation exchange in equity.",
        "label": "Disclosure Of Cumulative Translation Exchange In Equity [Text Block]",
        "terseLabel": "Summary of Cumulative Translation Exchange in Equity"
       }
      }
     },
     "localname": "DisclosureOfCumulativeTranslationExchangeInEquityTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of current and deferred tax relating to items charged or credited directly to equity and comprehensive income.",
        "label": "Disclosure Of Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income Explanatory",
        "terseLabel": "Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income"
       }
      }
     },
     "localname": "DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfCurrentEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of current equity investments.",
        "label": "Disclosure Of Current Equity Investments [Text Block]",
        "terseLabel": "Current equity investments"
       }
      }
     },
     "localname": "DisclosureOfCurrentEquityInvestmentsTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDebtInterestRateRepricingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of debt interest rate repricing [abstract]",
        "label": "Disclosure of debt interest rate repricing [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDebtInterestRateRepricingAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDebtInterestRateRepricingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of debt interest rate repricing [line items]",
        "label": "Disclosure of debt interest rate repricing [line items]",
        "terseLabel": "Disclosure of debt interest rate repricing [line items]"
       }
      }
     },
     "localname": "DisclosureOfDebtInterestRateRepricingLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDebtInterestRateRepricingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of debt interest rate repricing [table]",
        "label": "Disclosure of debt interest rate repricing [table]",
        "terseLabel": "Disclosure of debt interest rate repricing [table]"
       }
      }
     },
     "localname": "DisclosureOfDebtInterestRateRepricingTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of debt.",
        "label": "Disclosure of debt [line items]",
        "terseLabel": "Disclosure of debt [line items]"
       }
      }
     },
     "localname": "DisclosureOfDebtLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDebtTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of debt.",
        "label": "Disclosure Of Debt [table]",
        "terseLabel": "Disclosure of debt [Table]"
       }
      }
     },
     "localname": "DisclosureOfDebtTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of defined benefit pension and post retirement charges.",
        "label": "Disclosure of defined benefit pension and post retirement charges explanatory",
        "terseLabel": "Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined benefit pension and post retirement.",
        "label": "Disclosure Of Defined Benefit Pension And Post Retirement [line items]",
        "terseLabel": "Disclosure Of Defined Benefit Pension And Post Retirement [line items]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPensionAndPostRetirementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined benefit pension and post retirement.",
        "label": "Disclosure Of Defined Benefit Pension And Post Retirement [table]",
        "terseLabel": "Disclosure Of Defined Benefit Pension And Post Retirement [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPensionAndPostRetirementTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined benefit pension obligation analysed by membership category explanatory.",
        "label": "Disclosure Of Defined Benefit Pension Obligation Analysed By Membership Category Explanatory [text block]",
        "terseLabel": "Summary of Defined Benefit Pension Obligation Analysed by Membership Category"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined benefit plan actuarial assumptions.",
        "label": "Disclosure of Defined Benefit Plan Actuarial Assumptions [text block]",
        "terseLabel": "Summary of Financial Assumptions in Assessing Defined Benefit Liabilities"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items].",
        "label": "Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]",
        "terseLabel": "Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined benefit plan actuarial assumptions.",
        "label": "Disclosure of defined benefit plan actuarial assumptions [table]",
        "terseLabel": "Disclosure of defined benefit plan actuarial assumptions [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDefinedContributionPlans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of defined contribution plans.",
        "label": "Disclosure Of Defined Contribution Plans",
        "terseLabel": "Pension and other post-employment cost Analysed"
       }
      }
     },
     "localname": "DisclosureOfDefinedContributionPlans",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure for detailed information about cash and cash equivalent.",
        "label": "Disclosure of detailed information about cash and cash equivalents [text block]",
        "terseLabel": "Summary of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about current equity investments.",
        "label": "Disclosure Of Detailed Information About Current Equity Investments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about\u00a0current equity investments explanatory.",
        "label": "Disclosure Of Detailed Information About Current Equity Investments Explanatory [Text Block]",
        "terseLabel": "Summary of Current Equity Investments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsExplanatoryTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about current equity investments.",
        "label": "Disclosure Of Detailed Information About Current Equity Investments [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about current equity investments.",
        "label": "Disclosure Of Detailed Information About Current Equity Investments [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCurrentEquityInvestmentsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Detailed Information about Effectiveness of Hedging Relationships and Amounts reclassified from hedging reserve to profit or loss [text block]",
        "label": "Disclosure of Detailed Information about Effectiveness of Hedging Relationships and Amounts reclassified from hedging reserve to profit or loss text block",
        "terseLabel": "Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLosstextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about employee costs.",
        "label": "Disclosure of detailed information about employee costs explanatory",
        "terseLabel": "Summary of Employee Costs"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of analysis of Major restructuring charges from continuing operations by income statement.",
        "label": "Disclosure Of Detailed Information About Major Restructuring Charges Explanatory TextBlock",
        "terseLabel": "Summary of Major Restructuring Charges from Continuing Operations by Income Statement"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutMajorRestructuringChargesExplanatoryTextblock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other operating income (expense).",
        "label": "Disclosure Of Detailed Information About Other Operating Income Expense Explanatory",
        "terseLabel": "Summary Information about Other Operating Expense"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutProfitLossExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about profit (loss).",
        "label": "Disclosure Of Detailed Information About Profit Loss Explanatory",
        "terseLabel": "Summary of Information About Profit Loss"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutProfitLossExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Right Of Use Assets",
        "label": "Disclosure Of Detailed Information About Right Of Use Assets",
        "terseLabel": "Summary of Disclosure of Detailed Information About Right Of Use Assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutRightOfUseAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangements.",
        "label": "Disclosure of Detailed Information about Share Based Payment Arrangements Explanatory",
        "terseLabel": "Summary of Cost of Share-based Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationOfInventoriesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information of inventories.",
        "label": "Disclosure Of Detailed Information Of Inventories [Text block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationOfInventoriesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of investments in associates and joint ventures.",
        "label": "Disclosure of detailed information of investments in associates and joint ventures [text block]",
        "terseLabel": "Schedule of Investments in Associates and Joint Ventures"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDividendsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of dividends.",
        "label": "Disclosure of Dividends [abstract]",
        "terseLabel": "Disclosure of Dividends [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDividendsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDividendsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of dividends.",
        "label": "Disclosure of Dividends [line items]",
        "terseLabel": "Disclosure of dividends [line items]"
       }
      }
     },
     "localname": "DisclosureOfDividendsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfDividendsPaidExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of dividends paid.",
        "label": "Disclosure of dividends paid [text block]",
        "terseLabel": "Summary of Dividends to Shareholders"
       }
      }
     },
     "localname": "DisclosureOfDividendsPaidExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfDividendsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Dividends [table]",
        "label": "Disclosure of Dividends [table]",
        "terseLabel": "Disclosure of Dividends [table]"
       }
      }
     },
     "localname": "DisclosureOfDividendsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfEmployeeCostsAndNumbersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee costs and numbers line items.",
        "label": "Disclosure of Employee Costs and Numbers [line items]",
        "terseLabel": "Disclosure of employee costs and numbers [line items]"
       }
      }
     },
     "localname": "DisclosureOfEmployeeCostsAndNumbersLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfEmployeeCostsAndNumbersTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee costs and numbers.",
        "label": "Disclosure of Employee Costs and Numbers [table]",
        "terseLabel": "Disclosure of Employee Costs and Numbers [table]"
       }
      }
     },
     "localname": "DisclosureOfEmployeeCostsAndNumbersTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfEmployeeCostsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of employee costs.",
        "label": "Disclosure of employee costs [text block]",
        "terseLabel": "Employee costs"
       }
      }
     },
     "localname": "DisclosureOfEmployeeCostsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfEmployeeShareSchemesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee share schemes.",
        "label": "Disclosure of employee share schemes [line items]",
        "terseLabel": "Disclosure of employee share schemes [line items]"
       }
      }
     },
     "localname": "DisclosureOfEmployeeShareSchemesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfEmployeeShareSchemesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Employee Share Schemes [table].",
        "label": "Disclosure Of Employee Share Schemes [table]",
        "terseLabel": "Disclosure Of Employee Share Schemes [table]"
       }
      }
     },
     "localname": "DisclosureOfEmployeeShareSchemesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfEmployeeShareValuePlanExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee share value plan.",
        "label": "Disclosure of Employee Share Value Plan [text block]",
        "terseLabel": "Schedule of Number of Shares and ADS Issuable"
       }
      }
     },
     "localname": "DisclosureOfEmployeeShareValuePlanExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of estimated useful lives of property plant and equipment.",
        "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [text block]",
        "terseLabel": "Summary of Expected Useful Lives of Property Plant and Equipment"
       }
      }
     },
     "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value measurement of assets and liabilities [abstract]",
        "label": "Disclosure of fair value measurement of assets and liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value measurements of assets and liabilities.",
        "label": "Disclosure of fair value measurements of assets and liabilities [line items]",
        "terseLabel": "Disclosure of fair value measurements of assets and liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value measurements of assets and liabilities",
        "label": "Disclosure Of Fair Value Measurements Of Assets And Liabilities [table]",
        "terseLabel": "Disclosure Of Fair Value Measurements Of Assets And Liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFairValueOfContingentConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value of contingent consideration.",
        "label": "Disclosure Of Fair Value Of Contingent Consideration [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfContingentConsiderationAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of fair value of contingent consideration liabilities.",
        "label": "Disclosure of fair value of contingent consideration liabilities [text block]",
        "terseLabel": "Summary of Fair Value of Contingent Consideration Liabilities"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfFairValueOfContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value of contingent consideration.",
        "label": "Disclosure of fair value of contingent consideration [line items]",
        "terseLabel": "Disclosure of fair value of contingent consideration [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfContingentConsiderationLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFairValueOfContingentConsiderationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of fair value of contingent consideration.",
        "label": "Disclosure Of Fair Value Of Contingent Consideration [table]",
        "terseLabel": "Disclosure Of Fair Value Of Contingent Consideration [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfContingentConsiderationTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinanceExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of finance expense.",
        "label": "Disclosure of finance expense [abstract]",
        "terseLabel": "Disclosure of finance expense [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinanceExpenseAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialAssetsAndLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial assets and liabilities line Items.",
        "label": "Disclosure Of Financial Assets And Liabilities [line items]",
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Assets And Non Financial Assets [abstract]",
        "label": "Disclosure Of Financial Assets And Non Financial Assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndNonFinancialAssetsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Assets And Non Financial Assets",
        "label": "Disclosure Of Financial Assets And Non Financial Assets Explanatory",
        "terseLabel": "Reconciliation of financial instruments with Trade and other receivables and Other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial assets and non-financial assets.",
        "label": "Disclosure of financial assets and non financial assets [line items]",
        "terseLabel": "Disclosure of financial assets and non financial assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialAssetsAndNonFinancialAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial assets and non financial assets.",
        "label": "Disclosure of financial assets and non financial assets [table]",
        "terseLabel": "Disclosure of financial assets and non financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndNonFinancialAssetsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialIncomeAndExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Income and Expense [line items]",
        "label": "Disclosure Of Financial Income and Expense [line items]",
        "terseLabel": "Disclosure Of Financial Income and Expense [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialIncomeAndExpenseLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialIncomeAndExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Income and Expense [table]",
        "label": "Disclosure Of Financial Income and Expense [table]",
        "terseLabel": "Disclosure Of Financial Income and Expense [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialIncomeAndExpenseTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Information About The Amounts Attributable To Non Controlling Interests Explanatory.",
        "label": "Disclosure Of Financial Information About The Amounts Attributable To Non Controlling Interests Explanatory",
        "terseLabel": "Summarised Financial Information of Joint Venture"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial information of associates and joint ventures.",
        "label": "Disclosure of Financial Information of Associates and Joint Ventures [abstract]",
        "terseLabel": "Disclosure of Financial Information of Associates and Joint Ventures [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationOfAssociatesAndJointVenturesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial information of associates and joint ventures [line items].",
        "label": "Disclosure of Financial Information of Associates and Joint Ventures [line items]",
        "terseLabel": "Disclosure of financial information of associates and joint ventures [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial information of associates and joint ventures table.",
        "label": "Disclosure Of Financial Information Of Associates And Joint Ventures [table]",
        "terseLabel": "Disclosure Of Financial Information Of Associates And Joint Ventures [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial information relating to discontinued operations [Line Item].",
        "label": "Disclosure of Financial Information Relating To Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial information relating to discontinued operations [Table].",
        "label": "Disclosure of Financial Information Relating To Discontinued Operations [Table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInformationRelatingToDiscontinuedOperationsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of financial liabilities and non financial liabilities.",
        "label": "Disclosure Of Financial Liabilities And Non Financial Liabilities Explanatory",
        "terseLabel": "Reconciliation of Financial Instruments Within Trade and Other Payables, Other Provisions, Other Non-current Liabilities and Contingent Consideration Liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesAndNonFinancialLiabilitiesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfForeignExchangeRatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of foreign exchange rates.",
        "label": "Disclosure of foreign exchange rates [line items]",
        "terseLabel": "Disclosure of foreign exchange rates [line items]"
       }
      }
     },
     "localname": "DisclosureOfForeignExchangeRatesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfForeignExchangeRatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Foreign Exchange Rates [table]",
        "label": "Disclosure Of Foreign Exchange Rates [table]",
        "terseLabel": "Disclosure Of Foreign Exchange Rates [table]"
       }
      }
     },
     "localname": "DisclosureOfForeignExchangeRatesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of group held significant associate.",
        "label": "Disclosure of Group Held Significant Associate Explanatory",
        "terseLabel": "Summary of Group Held for Significant Associate"
       }
      }
     },
     "localname": "DisclosureOfGroupHeldSignificantAssociateExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of income statement and balance sheet sensitivity of put option to reasonably possible changes in key assumption.",
        "label": "Disclosure Of Income Statement And Balance Sheet Sensitivity Of Put Option To Reasonably Possible Changes In Key Assumption [text block]",
        "terseLabel": "Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement"
       }
      }
     },
     "localname": "DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfIncomeTaxExpenseBenefitsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of income tax expense benefits.",
        "label": "Disclosure Of Income Tax Expense Benefits [text block]",
        "terseLabel": "Summary of Taxation Charge Based on Profits"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExpenseBenefitsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of indicative basis in income statement and balance sheet put option to reasonably changes in key assumption.",
        "label": "Disclosure Of Indicative Basis In Income Statement and Balance sheet Put Option To Reasonably Changes In Key Assumption [abstract]"
       }
      }
     },
     "localname": "DisclosureOfIndicativeBasisInIncomeStatementAndBalanceSheetPutOptionToReasonablyChangesInKeyAssumptionAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about maturity profile of defined benefit obligation.",
        "label": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [abstract]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]",
        "label": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]",
        "terseLabel": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about maturity profile of defined benefit obligation",
        "label": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [table]",
        "terseLabel": "Disclosure of Information About Maturity Profile of Defined Benefit Obligation [table]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfInterimDividendExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of interim dividend explanatory.",
        "label": "Disclosure Of Interim Dividend Explanatory",
        "terseLabel": "Summary of Interim Financial Reporting"
       }
      }
     },
     "localname": "DisclosureOfInterimDividendExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of investments in associates and joint ventures.",
        "label": "Disclosure of Investments in Associates and Joint Ventures [line items]",
        "terseLabel": "Disclosure of Investments in Associates and Joint Ventures [line items]"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfInvestmentsInAssociatesAndJointVenturesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Investments in Associates and Joint Ventures [table]",
        "label": "Disclosure of Investments in Associates and Joint Ventures [table]",
        "terseLabel": "Disclosure of Investments in Associates and Joint Ventures [table]"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfJointVenturesAndAssociatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Joint Ventures And Associates [line items]",
        "label": "Disclosure Of Joint Ventures And Associates [line items]",
        "terseLabel": "Disclosure of joint ventures and associates [line items]"
       }
      }
     },
     "localname": "DisclosureOfJointVenturesAndAssociatesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfJointVenturesAndAssociatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of joint ventures and associates.",
        "label": "Disclosure Of Joint Ventures And Associates [table]",
        "terseLabel": "Disclosure Of Joint Ventures And Associates [table]"
       }
      }
     },
     "localname": "DisclosureOfJointVenturesAndAssociatesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfLeaseObligationsExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of lease obligations explanatory.",
        "label": "Disclosure Of Lease Obligations Explanatory [Text Block]",
        "terseLabel": "Schedule of Lease Obligations"
       }
      }
     },
     "localname": "DisclosureOfLeaseObligationsExplanatoryTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfLegalProceedingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of legal proceedings.",
        "label": "Disclosure Of Legal Proceedings [abstract]"
       }
      }
     },
     "localname": "DisclosureOfLegalProceedingsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfLegalProceedingsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of legal proceedings.",
        "label": "Disclosure of Legal Proceedings Explanatory",
        "terseLabel": "Legal proceedings"
       }
      }
     },
     "localname": "DisclosureOfLegalProceedingsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfLegalProceedingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of legal proceedings line items.",
        "label": "Disclosure of Legal Proceedings [line items]",
        "terseLabel": "Disclosure of Legal Proceedings [line items]"
       }
      }
     },
     "localname": "DisclosureOfLegalProceedingsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfLegalProceedingsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of legal proceedings",
        "label": "Disclosure Of Legal Proceedings [table]",
        "terseLabel": "Disclosure Of Legal Proceedings [table]"
       }
      }
     },
     "localname": "DisclosureOfLegalProceedingsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of licences included in intangible assets.",
        "label": "Disclosure Of Licences Included In Intangible Assets [text block]",
        "terseLabel": "Summary of Book Values of Largest Individual Items"
       }
      }
     },
     "localname": "DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Analysis of the costs charged to operating profit from continuing operations.",
        "label": "Disclosure Of Major Restructuring Costs Charged To Operating Profit Explanatory",
        "terseLabel": "Summary of Analysis of Costs Charged to Operating Profit From Continuing Operations"
       }
      }
     },
     "localname": "DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfMajorRestructuringCostsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of major restructuring costs.",
        "label": "Disclosure of major restructuring costs [text block]",
        "terseLabel": "Major restructuring costs"
       }
      }
     },
     "localname": "DisclosureOfMajorRestructuringCostsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of movement in deferred tax assets and liabilities.",
        "label": "Disclosure of movement in deferred tax assets and liabilities explanatory",
        "terseLabel": "Summary of Movement in Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfMovementInDefinedBenefitLiabilityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of movement in defined benefit liability.",
        "label": "Disclosure Of Movement In Defined Benefit Liability [text block]",
        "terseLabel": "Summary of Movements in Defined Benefit Obligations"
       }
      }
     },
     "localname": "DisclosureOfMovementInDefinedBenefitLiabilityExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfMovementsInEquityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Movements in Equity Explanatory",
        "label": "Disclosure of Movements in Equity Explanatory",
        "terseLabel": "Movements in equity"
       }
      }
     },
     "localname": "DisclosureOfMovementsInEquityExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of movements in fair values of assets explanatory.",
        "label": "Disclosure Of Movements In Fair Values Of Assets Explanatory",
        "terseLabel": "Summary of Movements in Fair Values of Assets"
       }
      }
     },
     "localname": "DisclosureOfMovementsInFairValuesOfAssetsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfNetDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of net debt abstract.",
        "label": "Disclosure of net debt [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNetDebtAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfNonControllingInterestsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of non controlling interests.",
        "label": "Disclosure Of Non Controlling Interests [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonControllingInterestsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfNoncontrollingInterestsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of non-controlling interests Line Items",
        "label": "Disclosure of noncontrolling interests [line items]",
        "terseLabel": "Disclosure of noncontrolling interests [line items]"
       }
      }
     },
     "localname": "DisclosureOfNoncontrollingInterestsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfNoncontrollingInterestsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of non-controlling interests.",
        "label": "Disclosure of Non-controlling Interests [table]",
        "terseLabel": "Disclosure of Non-controlling Interests [table]"
       }
      }
     },
     "localname": "DisclosureOfNoncontrollingInterestsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfNumberOfEmployeesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of number of employees.",
        "label": "Disclosure Of Number Of Employees [text block]",
        "terseLabel": "Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors)"
       }
      }
     },
     "localname": "DisclosureOfNumberOfEmployeesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of offsetting of financial assets and financial liabilities.",
        "label": "Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of offsetting of financial assets and financial liabilities line items.",
        "label": "Disclosure of offsetting of financial assets and financial liabilities [line items]",
        "terseLabel": "Disclosure of offsetting of financial assets and financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]",
        "label": "Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]",
        "terseLabel": "Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOperatingProfitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Operating Profit [line items]",
        "label": "Disclosure of Operating Profit [line items]",
        "terseLabel": "Disclosure of Operating Profit [line items]"
       }
      }
     },
     "localname": "DisclosureOfOperatingProfitLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOperatingProfitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of operating profit [table]",
        "label": "Disclosure of operating profit [table]",
        "terseLabel": "Disclosure of operating profit [table]"
       }
      }
     },
     "localname": "DisclosureOfOperatingProfitTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOtherNonCurrentAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other non-current assets.",
        "label": "Disclosure Of Other Non Current Assets [line items]",
        "terseLabel": "Disclosure Of Other Non Current Assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherNonCurrentAssetsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of other non current liabilities details.",
        "label": "Disclosure Of Other Non current Liabilities Details Explanatory",
        "terseLabel": "Summary of Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfOtherNoncurrentAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other non-current assets.",
        "label": "Disclosure Of Other Non-current Assets [table]",
        "terseLabel": "Disclosure Of Other Non-current Assets [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOtherOperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other operating income expense.",
        "label": "Disclosure of other operating income expense [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpenseAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOtherOperatingIncomeExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other operating income expense line items.",
        "label": "Disclosure Of Other Operating Income Expense [line items]",
        "terseLabel": "Disclosure of other operating income expense [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpenseLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfOtherOperatingIncomeExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other operating income expense table.",
        "label": "Disclosure Of Other Operating Income Expense [table]",
        "terseLabel": "Disclosure Of Other Operating Income Expense [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpenseTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfPensionAndOtherPostEmploymentPlanLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of pensions and other post employment plan.",
        "label": "Disclosure of pension and other post employment plan [line items]",
        "terseLabel": "Disclosure of pension and other post employment plan [line items]"
       }
      }
     },
     "localname": "DisclosureOfPensionAndOtherPostEmploymentPlanLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfPensionAndOtherPostEmploymentPlanTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of pension and other post employment plan.",
        "label": "Disclosure of pension and other post employment plan [table]",
        "terseLabel": "Disclosure of pension and other post employment plan [table]"
       }
      }
     },
     "localname": "DisclosureOfPensionAndOtherPostEmploymentPlanTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent pensions and other post-employment benefits.",
        "label": "Disclosure of Pensions and Other Post-employment Benefits [line items]",
        "terseLabel": "Disclosure of Pensions and Other Post-employment Benefits [line items]"
       }
      }
     },
     "localname": "DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfPensionsAndOtherPostemploymentBenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Pensions and Other Post-employment Benefits [table]",
        "label": "Disclosure of Pensions and Other Post-employment Benefits [table]",
        "terseLabel": "Disclosure of Pensions and Other Post-employment Benefits [table]"
       }
      }
     },
     "localname": "DisclosureOfPensionsAndOtherPostemploymentBenefitsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of post retirement benefit obligation analysed by membership category explanatory.",
        "label": "Disclosure Of Post Retirement Benefit Obligation Analysed By Membership Category Explanatory",
        "terseLabel": "Summary of Post-Retirement Benefit Obligation Analysed By Membership Category"
       }
      }
     },
     "localname": "DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfPrincipalGroupCompaniesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Principal Group Companies Explanatory",
        "label": "Disclosure of Principal Group Companies [text block]",
        "terseLabel": "Principal Group companies"
       }
      }
     },
     "localname": "DisclosureOfPrincipalGroupCompaniesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of\u00a0profit after taxation on demerger of discontinued operations .",
        "label": "Disclosure Of Profit After Taxation On Demerger Of Discontinued Operations",
        "terseLabel": "Summary of Profit After Taxation on Demerger of Discontinued Operations"
       }
      }
     },
     "localname": "DisclosureOfProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfProfitOnDisposalOfBusinessesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of profit on disposal of businesses.",
        "label": "Disclosure of profit on disposal of businesses [text block]",
        "terseLabel": "Summary of Profit on Disposal of Businesses"
       }
      }
     },
     "localname": "DisclosureOfProfitOnDisposalOfBusinessesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of reconciliation of actual tax charge and profit charged at UK tax rate.",
        "label": "Disclosure of reconciliation of actual tax charge and profit charged at uk tax rate explanatory",
        "terseLabel": "Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reconciliation of net cash flow to movement in net debt.",
        "label": "Disclosure of Reconciliation of Net Cash Flow to Movement in Net Debt Explanatory",
        "terseLabel": "Summary of Net Debt"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfRestructuringCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of restructuring costs abstract.",
        "label": "Disclosure of restructuring costs [abstract]"
       }
      }
     },
     "localname": "DisclosureOfRestructuringCostsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfRestructuringCostsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Major Restructuring Charges from continuing operations.",
        "label": "Disclosure Of Restructuring Costs Explanatory",
        "terseLabel": "Summary of Major Restructuring Charges From Continuing Operations"
       }
      }
     },
     "localname": "DisclosureOfRestructuringCostsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfRestructuringCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of restructuring costs line items.",
        "label": "Disclosure of restructuring costs [line items]",
        "terseLabel": "Disclosure of restructuring costs [line items]"
       }
      }
     },
     "localname": "DisclosureOfRestructuringCostsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfRestructuringCostsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of restructuring costs table.",
        "label": "Disclosure of restructuring costs [table]",
        "terseLabel": "Disclosure of restructuring costs [table]"
       }
      }
     },
     "localname": "DisclosureOfRestructuringCostsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfScheduleOfOtherInvestmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of schedule of other investment.",
        "label": "Disclosure of Schedule of Other Investment [text block]",
        "terseLabel": "Schedule of Other Investments"
       }
      }
     },
     "localname": "DisclosureOfScheduleOfOtherInvestmentExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfShareCapitalAndSharePremiumExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of share capital and share premium.",
        "label": "Disclosure of Share Capital And Share Premium [text block]",
        "terseLabel": "Share capital and share premium account"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalAndSharePremiumExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccount"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share of after tax profits and losses of associates and joint ventures.",
        "label": "Disclosure of Share of After Tax Profits and Losses of Associates and Joint Ventures Explanatory",
        "terseLabel": "Summary of After Tax Profits and Losses of Associates and Joint Ventures"
       }
      }
     },
     "localname": "DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share options and savings related options.",
        "label": "Disclosure of share options and savings related options [line items]",
        "terseLabel": "Disclosure of share options and savings related options [line items]"
       }
      }
     },
     "localname": "DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of share options and savings related options outstanding.",
        "label": "Disclosure Of Share Options And Savings Related Options Outstanding Explanatory",
        "terseLabel": "Summary of Option Outstanding"
       }
      }
     },
     "localname": "DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfShareOptionsAndSavingsRelatedOptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Share Options And Savings Related Options [table].",
        "label": "Disclosure Of Share Options And Savings Related Options [table]",
        "terseLabel": "Disclosure Of Share Options And Savings Related Options [table]"
       }
      }
     },
     "localname": "DisclosureOfShareOptionsAndSavingsRelatedOptionsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share options outstanding savings related schemes.",
        "label": "Disclosure Of Share Options Assumptions Related To Savings Related Schemes [text block]",
        "terseLabel": "Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge"
       }
      }
     },
     "localname": "DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of shares held for share award schemes and shares option schemes.",
        "label": "Disclosure Of Shares Held For Share Award Schemes And Shares Option Schemes Explanatory",
        "terseLabel": "Summary of Shares Held for Share Award Schemes"
       }
      }
     },
     "localname": "DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfTradeAndOtherPayablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with disclosure of trade and other payables.",
        "label": "Disclosure of trade and other payables [line items]",
        "terseLabel": "Disclosure of trade and other payables [line items]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfTradeAndOtherPayablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to disclosure of trade and other payables.",
        "label": "Disclosure of trade and other payables [table]",
        "terseLabel": "Disclosure of trade and other payables [table]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfTradeAndOtherReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of trade and other receivables [line items]",
        "label": "Disclosure of trade and other receivables [line items]",
        "terseLabel": "Disclosure of trade and other receivables [line items]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfTradeAndOtherReceivablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of trade and other receivables.",
        "label": "Disclosure of Trade and Other Receivables [table]",
        "terseLabel": "Disclosure of Trade and Other Receivables [table]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfTradesAndOtherReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of trade and other receivables.",
        "label": "Disclosure Of Trades And Other Receivable [Text Block]",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "DisclosureOfTradesAndOtherReceivableTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfTurnoverBySegmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of turnover by segment.",
        "label": "Disclosure Of Turnover By Segment Explanatory",
        "terseLabel": "Turnover by Segment"
       }
      }
     },
     "localname": "DisclosureOfTurnoverBySegmentExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [abstract].",
        "label": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [abstract]"
       }
      }
     },
     "localname": "DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration Explanatory.",
        "label": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration Explanatory",
        "terseLabel": "Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities"
       }
      }
     },
     "localname": "DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table].",
        "label": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table]",
        "terseLabel": "Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table]"
       }
      }
     },
     "localname": "DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of weighted average numbers of shares earnings per share explanatory.",
        "label": "Disclosure of Weighted Average Numbers of Shares Earnings Per Share [text block]",
        "terseLabel": "Schedule of Numbers of Shares Earnings Per Share"
       }
      }
     },
     "localname": "DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]",
        "label": "Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]",
        "terseLabel": "Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract]"
       }
      }
     },
     "localname": "DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_DisposalGroupAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group assets, net.",
        "label": "Disposal Group Assets, Net",
        "negatedTerseLabel": "Total"
       }
      }
     },
     "localname": "DisposalGroupAssetsNet",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalGroupLiabilityNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group liability net.",
        "label": "Disposal Group Liability Net",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DisposalGroupLiabilityNet",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalOfBusinessesAndAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal of businesses and assets.",
        "label": "Disposal of businesses and assets",
        "terseLabel": "Disposal of businesses and assets"
       }
      }
     },
     "localname": "DisposalOfBusinessesAndAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalOfEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "disposal of equity",
        "label": "Disposal of equity",
        "terseLabel": "Equity investment in Hindustan Unilever Limited"
       }
      }
     },
     "localname": "DisposalOfEquity",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalOfInterestInAssociate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal of interest in associate.",
        "label": "Disposal Of Interest In Associate",
        "terseLabel": "Disposal of interest in associate"
       }
      }
     },
     "localname": "DisposalOfInterestInAssociate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalOfInterestInAssociatesConsiderationReceivablePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal of interest in associates consideration receivable per share.",
        "label": "Disposal Of Interest In Associates Consideration Receivable Per Share",
        "terseLabel": "Disposal of interest in associates consideration receivable per share"
       }
      }
     },
     "localname": "DisposalOfInterestInAssociatesConsiderationReceivablePerShare",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals and Settlements Fair Value Measurement Assets And Liabilities",
        "label": "Disposals and Settlements Fair Value Measurement Assets And Liabilities",
        "negatedLabel": "Disposals and settlements"
       }
      }
     },
     "localname": "DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsAndSettlementsOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals and settlements other investments.",
        "label": "Disposals and Settlements Other Investments",
        "negatedLabel": "Disposals and settlements"
       }
      }
     },
     "localname": "DisposalsAndSettlementsOtherInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals goodwill.",
        "label": "Disposals Goodwill",
        "negatedLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalsGoodwill",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsInAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals in associates and joint ventures.",
        "label": "Disposals in Associates and Joint Ventures",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsInAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals intangible assets.",
        "label": "Disposals Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisposalsIntangibleAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals inventory.",
        "label": "Disposals Inventory",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalsInventory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsOtherNetAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals other net assets.",
        "label": "Disposals Other Net Assets",
        "negatedTerseLabel": "Other net assets"
       }
      }
     },
     "localname": "DisposalsOtherNetAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DisposalsOtherNetLiabilitiesOrAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals other net liabilities or assets.",
        "label": "Disposals Other Net Liabilities Or Assets",
        "terseLabel": "Other net (liabilities)/assets"
       }
      }
     },
     "localname": "DisposalsOtherNetLiabilitiesOrAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DistributionsReceivedInInvestmentsInAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions received in investments in associates and joint ventures.",
        "label": "Distributions Received in Investments in Associates and Joint Ventures",
        "negatedLabel": "Distributions received"
       }
      }
     },
     "localname": "DistributionsReceivedInInvestmentsInAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DividendFundedByDebtFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend funded by debt financing.",
        "label": "Dividend Funded By Debt Financing",
        "terseLabel": "Dividend funded by debt financing"
       }
      }
     },
     "localname": "DividendFundedByDebtFinancing",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DividendFundedByDebtFinancingAttributableToGsk": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend funded by debt financing attributable to GSK.",
        "label": "Dividend Funded By Debt Financing Attributable To GSK",
        "terseLabel": "Dividend funded by debt financing attributable to GSK"
       }
      }
     },
     "localname": "DividendFundedByDebtFinancingAttributableToGsk",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend paid to shareholders on demergerd entity recognized in year.",
        "label": "Dividend Paid To Shareholders On Demergerd Entity Recognized In Year",
        "terseLabel": "Dividends in specie to shareholders in Haleon plc shares"
       }
      }
     },
     "localname": "DividendPaidToShareholdersOnDemergerdEntityRecognizedInYear",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DividendYieldShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend yield share options granted.",
        "label": "Dividend Yield Share Options Granted",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "DividendYieldShareOptionsGranted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_DividendsDistributedFromCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends distributed from cash balance.",
        "label": "Dividends Distributed From Cash Balance",
        "terseLabel": "Dividends distributed from cash balance"
       }
      }
     },
     "localname": "DividendsDistributedFromCashBalance",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends\u200b distributed from\u200b cash balance attributable to GSK.",
        "label": "Dividends Distributed From Cash Balance Attributable To GSK",
        "terseLabel": "Dividends\u200b distributed from\u200b cash balance attributable to GSK"
       }
      }
     },
     "localname": "DividendsDistributedFromCashBalanceAttributableToGsk",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DividendsPaidDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid date.",
        "label": "Dividends Paid Date",
        "terseLabel": "Paid/payable"
       }
      }
     },
     "localname": "DividendsPaidDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "gsk_DividendsRecognisedInYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends recognised in year",
        "label": "Dividends recognised in year",
        "terseLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "DividendsRecognisedInYear",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfDividendsToShareholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_DolutegravirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dolutegravir [member]",
        "label": "Dolutegravir [member]",
        "terseLabel": "Dolutegravir [member]"
       }
      }
     },
     "localname": "DolutegravirMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_DueFromThreeWholesalersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from three wholesalers.",
        "label": "Due From Three Wholesalers [Member]"
       }
      }
     },
     "localname": "DueFromThreeWholesalersMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ERPSoftwareSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERP software systems.",
        "label": "ERP Software Systems [member]",
        "terseLabel": "ERP software systems [member]"
       }
      }
     },
     "localname": "ERPSoftwareSystemsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EffectiveInterestRateOnAvailableForSaleFinancialInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate on available for sale financial investments.",
        "label": "Effective Interest Rate On Available For Sale Financial Investments",
        "terseLabel": "Effective Interest rate on liquid investment"
       }
      }
     },
     "localname": "EffectiveInterestRateOnAvailableForSaleFinancialInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_EffectiveInterestRateOnCashAndCashEquivalents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate on cash and cash equivalents.",
        "label": "Effective Interest Rate On Cash And Cash Equivalents",
        "terseLabel": "Effective Interest rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectiveInterestRateOnCashAndCashEquivalents",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_EmbeddedAndOtherDerivativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded and other derivatives.",
        "label": "Embedded And Other Derivatives [member]",
        "terseLabel": "Embedded and Other Derivatives [member]"
       }
      }
     },
     "localname": "EmbeddedAndOtherDerivativesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EmployeeLoansAndAdvances": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee loans and advances.",
        "label": "Employee Loans And Advances",
        "terseLabel": "Employee loans and advances"
       }
      }
     },
     "localname": "EmployeeLoansAndAdvances",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_EmployeeRelatedProvisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related provisions.",
        "label": "Employee Related Provisions [member]",
        "terseLabel": "Employee Related Provisions [Member]"
       }
      }
     },
     "localname": "EmployeeRelatedProvisionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EmployeeShareOwnershipPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee share ownership plan.",
        "label": "Employee Share Ownership Plan [member]",
        "terseLabel": "Employee share ownership plan [member]"
       }
      }
     },
     "localname": "EmployeeShareOwnershipPlanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EmployeesBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees Benefit [abstract]",
        "label": "Employees Benefit [abstract]"
       }
      }
     },
     "localname": "EmployeesBenefitAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_Entity1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity 1",
        "label": "Entity 1 [Member]",
        "verboseLabel": "Entity [Member]"
       }
      }
     },
     "localname": "Entity1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EquallyWeightedMeasuresOverPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equally weighted measures over performance period.",
        "label": "Equally Weighted Measures Over Performance Period",
        "terseLabel": "Equally weighted measures over performance period"
       }
      }
     },
     "localname": "EquallyWeightedMeasuresOverPerformancePeriod",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "gsk_EquipmentAndVehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment and vehicles.",
        "label": "Equipment And Vehicles [member]",
        "terseLabel": "Equipment and vehicles [member]"
       }
      }
     },
     "localname": "EquipmentAndVehiclesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EquityAndDebtNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of total capital consisting of equity and net debt",
        "label": "Equity And Debt Net",
        "terseLabel": "Total capital including that provided by non-controlling interests"
       }
      }
     },
     "localname": "EquityAndDebtNet",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_EquityAwardDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [domain]",
        "terseLabel": "Equity Award [domain]"
       }
      }
     },
     "localname": "EquityAwardDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity instruments amount contributed to fair value of plan assets listed.",
        "label": "Equity Instruments Amount contributed To Fair Value Of Plan Assets Listed",
        "terseLabel": "Equities, listed"
       }
      }
     },
     "localname": "EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity instruments amount contributed to fair value of plan assets unlisted.",
        "label": "Equity Instruments Amount Contributed To Fair Value Of Plan Assets Unlisted",
        "terseLabel": "Equity, unlisted"
       }
      }
     },
     "localname": "EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investments measured at fair value through other comprehensive income.",
        "label": "Equity investments measured at fair value through other comprehensive income [member]",
        "terseLabel": "Equity investments measured at fair value through other comprehensive income (FVTOCI) [member]"
       }
      }
     },
     "localname": "EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investments measured at fair value through profit or loss.",
        "label": "Equity investments measured at fair value through profit or loss [member]",
        "terseLabel": "Equity investments measured at fair value through profit or loss (FVTPL) [member]"
       }
      }
     },
     "localname": "EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EsopTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESOP Trust.",
        "label": "ESOP Trust [member]",
        "terseLabel": "ESOP trust shares [member]"
       }
      }
     },
     "localname": "EsopTrustMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EsopTrustsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESOP trusts.",
        "label": "ESOP Trusts [Member]"
       }
      }
     },
     "localname": "EsopTrustsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EstablishedVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Established vaccines.",
        "label": "Established Vaccines [member]",
        "terseLabel": "Established vaccines [member]"
       }
      }
     },
     "localname": "EstablishedVaccinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated rebates discounts or allowance payable to customer.",
        "label": "Estimated Rebates Discounts or Allowance Payable To Customer [member]",
        "terseLabel": "Estimated rebates, discounts or allowances payable to customers [member]"
       }
      }
     },
     "localname": "EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EuroCommercialPaperProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro commercial paper program.",
        "label": "EURO Commercial Paper Program [Member]"
       }
      }
     },
     "localname": "EuroCommercialPaperProgramMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EuroCommercialPaperProgrammeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro Commercial Paper Programme.",
        "label": "Euro Commercial Paper Programme [Member]",
        "terseLabel": "Euro Commercial Paper Program [Member]"
       }
      }
     },
     "localname": "EuroCommercialPaperProgrammeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EURO [Member].",
        "label": "EURO [Member]"
       }
      }
     },
     "localname": "EuroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EuropeanUsMediumTermNotesAndBankFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European US Medium Term Notes and Bank Facilities [member]",
        "label": "European/US Medium Term Notes and Bank Facilities [member]",
        "terseLabel": "European/US Medium Term Notes &amp; Bank Facilities [member]"
       }
      }
     },
     "localname": "EuropeanUsMediumTermNotesAndBankFacilitiesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_EventBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event basis.",
        "label": "Event Basis [Axis]"
       }
      }
     },
     "localname": "EventBasisAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_EventBasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event basis.",
        "label": "Event Basis [Domain]"
       }
      }
     },
     "localname": "EventBasisDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ExchangeAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange adjustments.",
        "label": "Exchange Adjustments",
        "negatedLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "ExchangeAdjustments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange movement through reserves contingent liabilities recognised in business combination.",
        "label": "Exchange Movement Through Reserves Contingent Liabilities Recognised In Business Combination",
        "terseLabel": "Exchange movement through reserves"
       }
      }
     },
     "localname": "ExchangeMovementThroughReservesContingentLiabilitiesRecognisedInBusinessCombination",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 9.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange movements on overseas net assets and net investment hedges.",
        "label": "Exchange movements on overseas net assets and net investment hedges",
        "terseLabel": "Exchange movements on overseas net assets and net investment hedges"
       }
      }
     },
     "localname": "ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange movements on overseas net assets of non-controlling interests.",
        "label": "Exchange movements on overseas net assets of non controlling interests",
        "terseLabel": "Exchange movements on overseas net assets of non-controlling interests"
       }
      }
     },
     "localname": "ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange movements on overseas net assets of non controlling interests restated.",
        "label": "Exchange Movements On Overseas Net Assets Of Non Controlling Interests Restated",
        "terseLabel": "Exchange movements on overseas net assets of non-controlling interests"
       }
      }
     },
     "localname": "ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterestsRestated",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExchangeOnNetDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange on net debt to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Exchange On Net Debt",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "ExchangeOnNetDebt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedCreditLossAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected credit loss allowance.",
        "label": "Expected credit loss allowance",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ExpectedCreditLossAllowance",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedCreditLossAllowanceExchangeAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected credit loss allowance exchange adjustments.",
        "label": "Expected credit loss allowance exchange adjustments",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "ExpectedCreditLossAllowanceExchangeAdjustments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected credit loss allowance on trade receivables credit impaired.",
        "label": "Expected credit loss allowance on trade receivables credit impaired",
        "terseLabel": "Expected credit loss allowance on trade receivables credit impaired"
       }
      }
     },
     "localname": "ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedCreditLossAllowanceTransferToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected credit loss allowance transfer to assets held for sale.",
        "label": "Expected Credit Loss Allowance Transfer To Assets Held For Sale",
        "terseLabel": "Transfer to assets held for sale"
       }
      }
     },
     "localname": "ExpectedCreditLossAllowanceTransferToAssetsHeldForSale",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedCreditLossAllowanceUtilised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected credit loss allowance utilised.",
        "label": "Expected credit loss allowance utilised",
        "terseLabel": "Utilised"
       }
      }
     },
     "localname": "ExpectedCreditLossAllowanceUtilised",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ExpectedFutureDividendYieldPercentageShareGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected future dividend yield percentage share granted.",
        "label": "Expected Future Dividend Yield Percentage Share Granted",
        "terseLabel": "Expected future dividend yield percentage share granted"
       }
      }
     },
     "localname": "ExpectedFutureDividendYieldPercentageShareGranted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_ExpectedLifeOfShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected life of share options granted.",
        "label": "Expected Life of Share Options Granted",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "ExpectedLifeOfShareOptionsGranted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "gsk_ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense From Share Based Payment Transactions With Employees [line items]",
        "label": "Expense From Share Based Payment Transactions With Employees [line items]",
        "terseLabel": "Expense from share based payment transactions with employees [line items]"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense From Sharebased Payment Transactions With Employees [table]",
        "label": "Expense From Sharebased Payment Transactions With Employees [table]",
        "terseLabel": "Expense From Sharebased Payment Transactions With Employees [table]"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_ExpensesNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses net defined benefit liability asset.",
        "label": "Expenses Net Defined Benefit Liability Asset",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "ExpensesNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueAdjustmentInvestmentsInAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value Adjustment investments in associates and joint ventures",
        "label": "Fair Value Adjustment Investments In Associates And Joint Ventures",
        "terseLabel": "Net fair value movements through Other comprehensive income"
       }
      }
     },
     "localname": "FairValueAdjustmentInvestmentsInAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueGainThroughProfitOrLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value gain through profit or loss.",
        "label": "Fair Value Gain Through Profit Or Loss",
        "terseLabel": "Fair value gain through profit or loss"
       }
      }
     },
     "localname": "FairValueGainThroughProfitOrLoss",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueMovementsOnCashFlowHedgesNotReclassified": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 16.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value movements on cash flow hedges not reclassified.",
        "label": "Fair value movements on cash flow hedges not reclassified",
        "verboseLabel": "Fair value movements on cash flow hedges"
       }
      }
     },
     "localname": "FairValueMovementsOnCashFlowHedgesNotReclassified",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfAssetdistributedAsDividendInSpecie": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair\u200b value\u200b of asset \u200bdistributed as dividend in specie.",
        "label": "Fair Value Of Asset Distributed As Dividend In Specie",
        "terseLabel": "Fair Value of Asset Distributed as Dividend in Specie"
       }
      }
     },
     "localname": "FairValueOfAssetdistributedAsDividendInSpecie",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfHolding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of holding.",
        "label": "Fair Value of Holding",
        "terseLabel": "Fair value of holding"
       }
      }
     },
     "localname": "FairValueOfHolding",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investments in Fund Assets.",
        "label": "Fair Value Of Investments In Assets Where Price Quotations Published",
        "terseLabel": "Fair value of investments in fund assets"
       }
      }
     },
     "localname": "FairValueOfInvestmentsInAssetsWherePriceQuotationsPublished",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of shares held by trust under employee share ownership plan.",
        "label": "Fair Value Of Shares Held By Trust Under Employee Share Ownership Plan",
        "terseLabel": "Market value of shares held by trust under employee share ownership plan"
       }
      }
     },
     "localname": "FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfTheAssetsDistributed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets distributed.",
        "label": "Fair Value of the Assets Distributed",
        "terseLabel": "Fair value of the assets distributed"
       }
      }
     },
     "localname": "FairValueOfTheAssetsDistributed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfTheConsumerHealthcareBusinessDistributed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the Consumer Healthcare business distributed",
        "label": "Fair value of the Consumer Healthcare business distributed",
        "terseLabel": "Fair value of the Consumer Healthcare business distributed"
       }
      }
     },
     "localname": "FairValueOfTheConsumerHealthcareBusinessDistributed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueOfTheRetainedOwnershipInHaleonPlc": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the retained ownership in Haleon plc",
        "label": "Fair value of the retained ownership in Haleon plc",
        "terseLabel": "Fair value of the retained ownership in Haleon plc"
       }
      }
     },
     "localname": "FairValueOfTheRetainedOwnershipInHaleonPlc",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FairValueReserveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value reserve.",
        "label": "Fair Value Reserve [member]",
        "terseLabel": "Fair value reserve [member]"
       }
      }
     },
     "localname": "FairValueReserveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FemalePensionersAverageLifeExpectancyAtSixty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Female pensioners average life expectancy at sixty.",
        "label": "Female Pensioners Average Life Expectancy At Sixty",
        "terseLabel": "Female Years"
       }
      }
     },
     "localname": "FemalePensionersAverageLifeExpectancyAtSixty",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "gsk_FinanceLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Liability.",
        "label": "Finance Lease Liability",
        "negatedLabel": "Obligations under finance leases",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FinanceLeaseObligationsGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Obligations, Gross.",
        "label": "Finance Lease Obligations Gross",
        "totalLabel": "Total future rental payments"
       }
      }
     },
     "localname": "FinanceLeaseObligationsGross",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FinancialAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Assets And Liabilities",
        "label": "Financial Assets And Liabilities",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FinancialAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of\u00a0financial information relating to discontinued operations .",
        "label": "Financial Information Relating To Discontinued Operations",
        "terseLabel": "Summary of Financial Information Relating to Discontinued Operations"
       }
      }
     },
     "localname": "FinancialInformationRelatingToDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_FinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [member]",
        "label": "Financial Instruments [member]",
        "terseLabel": "Financial Instruments [member]"
       }
      }
     },
     "localname": "FinancialInstrumentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FinancialLiabilitesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial liabilites one.",
        "label": "Financial Liabilites One [Member]"
       }
      }
     },
     "localname": "FinancialLiabilitesOneMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial liabilities at fair value through other comprehensive income.",
        "label": "Financial liabilities at fair value through other comprehensive income [Member]",
        "terseLabel": "Financial Liabilities at Fair Value Through Other Comprehensive Income [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category.",
        "label": "Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]",
        "terseLabel": "Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FinePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fine payable.",
        "label": "Fine Payable"
       }
      }
     },
     "localname": "FinePayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_FirstInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First interim.",
        "label": "First Interim [member]",
        "terseLabel": "First interim [member]"
       }
      }
     },
     "localname": "FirstInterimMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point three seven five percent US medium term note two thousand thirty four.",
        "label": "Five Point Three Seven Five Percent US Medium Term Note Two Thousand Thirty Four [member]",
        "terseLabel": "5.375% US Medium Term Note 2034 [Member]"
       }
      }
     },
     "localname": "FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point two five percent European medium term note two thousand thirty three.",
        "label": "Five Point Two Five Percent Euro Medium Term Note Two Thousand Thirty Three [Member]",
        "terseLabel": "5.250% Euro Medium Term Note 2033 [Member]"
       }
      }
     },
     "localname": "FivePointTwoFivePercentEuroMediumTermNoteTwoThousandThirtyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point two five percent European term note two thousand forty two.",
        "label": "Five Point Two Five Percent Euro Term Note Two Thousand Forty Two [Member]",
        "terseLabel": "5.250% Euro Medium Term Note 2042 [Member]"
       }
      }
     },
     "localname": "FivePointTwoFivePercentEuroTermNoteTwoThousandFortyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FloatingAndFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating and fixed rate debt.",
        "label": "Floating and fixed rate debt [member]",
        "terseLabel": "Floating and Fixed Rate Debt [member]"
       }
      }
     },
     "localname": "FloatingAndFixedRateDebtMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FluarixFlulavalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fluarix FluLaval [Member]",
        "label": "Fluarix FluLaval [member]",
        "terseLabel": "Fluarix FluLaval [member]"
       }
      }
     },
     "localname": "FluarixFlulavalMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ForeignExchangeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange contracts.",
        "label": "Foreign Exchange Contracts [member]",
        "terseLabel": "Foreign Exchange Contracts [member]"
       }
      }
     },
     "localname": "ForeignExchangeContractsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ForeignExchangeForwardContractsAndSwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Forward Contracts and Swaps [member]",
        "label": "Foreign Exchange Forward Contracts and Swaps [member]",
        "terseLabel": "Foreign Exchange Forward Contracts and Swaps [member]"
       }
      }
     },
     "localname": "ForeignExchangeForwardContractsAndSwapsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ForeignExchangeRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange risk.",
        "label": "Foreign exchange risk [Member]",
        "terseLabel": "Foreign exchange risk [Member]"
       }
      }
     },
     "localname": "ForeignExchangeRiskMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ForeignExchangeSensitivityEquityImpactTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange sensitivity equity impact.",
        "label": "Foreign Exchange Sensitivity Equity Impact [Text Block]",
        "verboseLabel": "Foreign exchange sensitivity impact on equity"
       }
      }
     },
     "localname": "ForeignExchangeSensitivityEquityImpactTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_ForeignExchangeSensitivityImpactOfNonFunctionalCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange sensitivity impact of non-functional currency",
        "label": "Foreign Exchange Sensitivity Impact Of Non Functional Currency",
        "verboseLabel": "Foreign exchange sensitivity impact on income statement"
       }
      }
     },
     "localname": "ForeignExchangeSensitivityImpactOfNonFunctionalCurrency",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four point two five percent European medium term note two thousand forty five.",
        "label": "Four Point Two Five Percent Euro Medium Term Note Two Thousand Forty Five [Member]",
        "terseLabel": "4.250% Euro Medium Term Note 2045 [Member]"
       }
      }
     },
     "localname": "FourPointTwoFivePercentEuroMediumTermNoteTwoThousandFortyFiveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four point two percent US medium term note forty three.",
        "label": "Four Point Two Percent US Medium Term Note Two Thousand Forty Three [member]",
        "terseLabel": "4.200% US$ US Medium Term Note 2043 [Member]"
       }
      }
     },
     "localname": "FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FourPointTwoZeroZeroNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.200% Notes due 2043.",
        "label": "Four Point Two Zero Zero Notes due 2043 [Member]",
        "terseLabel": "4.200% Notes due 2043 [Member]"
       }
      }
     },
     "localname": "FourPointTwoZeroZeroNotesDue2043Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four point zero zero percent European medium term note two thousand twenty five.",
        "label": "Four Point Zero Zero Percent Euro Medium Term Note Two Thousand Twenty Five [Member]",
        "terseLabel": "4.000% \u20ac Euro Medium Term Note 2025 [Member]"
       }
      }
     },
     "localname": "FourPointZeroZeroPercentEuroMediumTermNoteTwoThousandTwentyFiveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FourthInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth interim.",
        "label": "Fourth Interim [member]",
        "terseLabel": "Fourth interim [member]"
       }
      }
     },
     "localname": "FourthInterimMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FreeCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free cash flow Member.",
        "label": "Free Cash Flow [Member]",
        "terseLabel": "Free Cash Flow [Member]"
       }
      }
     },
     "localname": "FreeCashFlowMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FreeIssueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free issue.",
        "label": "Free Issue [member]",
        "terseLabel": "Free issue [member]"
       }
      }
     },
     "localname": "FreeIssueMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FreeholdBuildingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Freehold buildings.",
        "label": "Freehold buildings [member]",
        "terseLabel": "Freehold buildings [member]"
       }
      }
     },
     "localname": "FreeholdBuildingsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FundedDefinedBenefitPensionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded defined benefit pension plans.",
        "label": "Funded defined benefit pension plans [member]",
        "terseLabel": "Funded defined benefit pension plans [member]"
       }
      }
     },
     "localname": "FundedDefinedBenefitPensionPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_FutureFinanceChargeOnFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Finance Charge On Finance Leases.",
        "label": "Future Finance Charge On Finance Leases",
        "negatedLabel": "Finance charge on obligations under finance leases"
       }
      }
     },
     "localname": "FutureFinanceChargeOnFinanceLeases",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GSKKoreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Korea.",
        "label": "GSK Korea [Member]",
        "terseLabel": "GSK Korea [member]"
       }
      }
     },
     "localname": "GSKKoreaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GSKLPLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK LP Ltd.",
        "label": "G S K L P Ltd [Member]",
        "terseLabel": "GSK LP Ltd [member]"
       }
      }
     },
     "localname": "GSKLPLtdMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GSKServicesSPZOOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Services Sp z o.o.",
        "label": "G S K Services S P Z O O [member]",
        "terseLabel": "GSK Services Sp z o.o. [member]"
       }
      }
     },
     "localname": "GSKServicesSPZOOMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GSKVaccinesGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Vaccines GmbH.",
        "label": "G S K Vaccines Gmb H [member]",
        "terseLabel": "GSK Vaccines GmbH [member]"
       }
      }
     },
     "localname": "GSKVaccinesGmbHMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GSKVaccinesSRLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Vaccines S.r.l.",
        "label": "G S K Vaccines S R L [member]",
        "terseLabel": "GSK Vaccines S.r.l. [member]"
       }
      }
     },
     "localname": "GSKVaccinesSRLMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GainLossOnContingentConsiderationAndPutOptionLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on contingent consideration and put option liabilities.",
        "label": "Gain (loss) on contingent consideration and put option liabilities",
        "terseLabel": "Contingent consideration and put option liabilities"
       }
      }
     },
     "localname": "GainLossOnContingentConsiderationAndPutOptionLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainLossOnDisposalOfInterestInAssociate": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 13.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on disposal of Interest in associates.",
        "label": "Gain (Loss) On Disposal Of Interest In Associate",
        "terseLabel": "Loss on disposal of interest in associates",
        "verboseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "GainLossOnDisposalOfInterestInAssociate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainLossOnDisposalOfInterestInAssociates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on disposal of interest in associates.",
        "label": "Gain Loss On Disposal Of Interest In Associates",
        "terseLabel": "Gain loss on disposal of interest in associates"
       }
      }
     },
     "localname": "GainLossOnDisposalOfInterestInAssociates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainLossOnDisposalsOfBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on disposals of business.",
        "label": "Gain Loss on Disposals of Business",
        "terseLabel": "Gain on disposals"
       }
      }
     },
     "localname": "GainLossOnDisposalsOfBusiness",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on disposals of business including signed but not completed.",
        "label": "Gain Loss On Disposals Of Business Including Signed But Not Completed",
        "verboseLabel": "Total profit on disposal"
       }
      }
     },
     "localname": "GainLossOnDisposalsOfBusinessIncludingSignedButNotCompleted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainLossOnEmbeddedDerivativeTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on embedded derivative transaction.",
        "label": "Gain Loss on Embedded Derivative Transaction",
        "verboseLabel": "Derivative"
       }
      }
     },
     "localname": "GainLossOnEmbeddedDerivativeTransaction",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainOnDemergerBeforeExchangeMovementsAndTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net assets and liabilities distributed / derecognised as part of gain on the demerger.",
        "label": "Gain On Demerger Before Exchange Movements And Transaction Costs",
        "terseLabel": "Gain on demerger before exchange movements and transaction costs"
       }
      }
     },
     "localname": "GainOnDemergerBeforeExchangeMovementsAndTransactionCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainOnDemergerOfDiscontinuedOperation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on demerger of discontinued operation.",
        "label": "Gain On Demerger Of Discontinued Operation",
        "terseLabel": "Total gain on the demerger of Consumer Healthcare"
       }
      }
     },
     "localname": "GainOnDemergerOfDiscontinuedOperation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount.",
        "label": "Gain On Distribution Of Fair Value Less Book Value Of The Attributable Net Assets Of Discontinued Business Amount",
        "terseLabel": "Gain on distribution of fair value less book value of the attributable net assets of discontinued business amount"
       }
      }
     },
     "localname": "GainOnDistributionOfFairValueLessBookValueOfTheAttributableNetAssetsOfDiscontinuedBusinessAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain or loss on remeasurement of investments measured at fair value through profit or loss.",
        "label": "Gain or Loss on Remeasurement of Investments Measured at Fair Value through Profit or Loss",
        "terseLabel": "Gain or loss on remeasurement of investments measured at fair value through profit or loss"
       }
      }
     },
     "localname": "GainOrLossOnRemeasurementOfInvestmentsMeasuredAtFairValueThroughProfitOrLoss",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains losses attributable to level 3 of fair value hierarchy recognised in income statement.",
        "label": "Gains Losses Attributable To Level 3 Of Fair Value Hierarchy Recognised In Income statement",
        "terseLabel": "Total net losses on financial instruments held"
       }
      }
     },
     "localname": "GainsLossesAttributableToLevel3OfFairValueHierarchyRecognisedInIncomeStatement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains losses recognized in other comprehensive income fair value measurement assets and liabilities.",
        "label": "Gains Losses Recognised In Other Comprehensive Income Fair Value Measuremen tAssets And Liabilities",
        "verboseLabel": "Net gains recognised in other comprehensive income"
       }
      }
     },
     "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (losses) recognised in profit or loss, fair value measurement, assets and liabilities.",
        "label": "Gains (losses) recognised in profit or loss, fair value measurement, assets and liabilities",
        "negatedLabel": "Net losses recognised in the income statement"
       }
      }
     },
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GB.",
        "label": "GB [Member]",
        "terseLabel": "Uk [Member]"
       }
      }
     },
     "localname": "GbMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GeneralMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General Medicines Member",
        "label": "General Medicines [Member]",
        "terseLabel": "General Medicines [member]"
       }
      }
     },
     "localname": "GeneralMedicinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GileadSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead sciences Inc.",
        "label": "Gilead Sciences Inc [Member]",
        "terseLabel": "Gilead Sciences, Inc [member]"
       }
      }
     },
     "localname": "GileadSciencesIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Group Limited.",
        "label": "Glaxo Group Limited [member]",
        "terseLabel": "Glaxo Group Limited [member]"
       }
      }
     },
     "localname": "GlaxoGroupLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoOperationsUkLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Operations UK Limited.",
        "label": "Glaxo Operations UK Limited [member]",
        "terseLabel": "Glaxo Operations UK Limited [member]"
       }
      }
     },
     "localname": "GlaxoOperationsUkLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSaudiArabiaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo saudi arabia limited.",
        "label": "Glaxo Saudi Arabia Limited [Member]",
        "terseLabel": "Glaxo Saudi Arabia Limited [Member]"
       }
      }
     },
     "localname": "GlaxoSaudiArabiaLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineAustraliaPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Australia Pty Ltd.",
        "label": "Glaxo Smith Kline Australia Pty Ltd [member]",
        "terseLabel": "GlaxoSmithKline Australia Pty Ltd [Member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineAustraliaPtyLtdMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineBiologicalsSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Biologicals SA.",
        "label": "Glaxo Smith Kline Biologicals S A [member]",
        "terseLabel": "GlaxoSmithKline Biologicals SA [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineBiologicalsSAMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineBrasilLimitadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Brasil Limitada.",
        "label": "Glaxo Smith Kline Brasil Limitada [member]",
        "terseLabel": "GlaxoSmithKline Brasil Limitada [Member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineBrasilLimitadaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineCapitalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Capital Inc.",
        "label": "Glaxo Smith Kline Capital Inc [member]",
        "terseLabel": "GlaxoSmithKline Capital Inc. [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineCapitalIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineCapitalPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Capital PLC.",
        "label": "Glaxo Smith Kline Capital PLC [member]",
        "terseLabel": "GlaxoSmithKline Capital PLC [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineCapitalPLCMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Consumer Healthcare Holdings Limited.",
        "label": "Glaxo Smith Kline Consumer Healthcare Holdings Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineExportLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Export Limited.",
        "label": "Glaxo Smith Kline Export Limited [member]",
        "terseLabel": "GlaxoSmithKline Export Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineExportLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineFinancePLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Finance PLC.",
        "label": "Glaxo Smith Kline Finance PLC [member]",
        "terseLabel": "GlaxoSmithKline Finance PLC [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineFinancePLCMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineGmbHAndCoKGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline GmbH and Co. KG.",
        "label": "Glaxo Smith Kline Gmb H And Co K G [member]",
        "terseLabel": "GlaxoSmithKline GmbH and Co. KG [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineGmbHAndCoKGMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Holdings (Americas) Inc.",
        "label": "Glaxo Smith Kline Holdings Inc [member]",
        "terseLabel": "GlaxoSmithKline Holdings (Americas) Inc. [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineHoldingsIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Finance PLC.",
        "label": "Glaxo Smith Kline Holdings Limited [member]",
        "terseLabel": "GlaxoSmithKline Holdings Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineHoldingsLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Inc.",
        "label": "Glaxo Smith Kline Inc [member]",
        "terseLabel": "GlaxoSmithKline Inc. [Member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineKKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline K.K.",
        "label": "Glaxo Smith Kline K K [member]",
        "terseLabel": "GlaxoSmithKline K.K. [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineKKMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineKoreaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Korea Limited.",
        "label": "Glaxo Smith Kline Korea Limited [member]",
        "terseLabel": "GlaxoSmithKline Korea Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineKoreaLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline LLC.",
        "label": "Glaxo Smith Kline L L C [member]",
        "terseLabel": "GlaxoSmithKline LLC [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineLLCMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Limited.",
        "label": "Glaxo Smith Kline Limited [member]",
        "terseLabel": "GlaxoSmithKline Limited [Member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlinePakistanLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Pakistan Limited.",
        "label": "Glaxo Smith Kline Pakistan Limited [member]",
        "terseLabel": "GlaxoSmithKline Pakistan Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlinePakistanLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlinePharmaceuticalsSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Pharmaceuticals S.A.",
        "label": "Glaxo Smith Kline Pharmaceuticals S A [member]",
        "terseLabel": "GlaxoSmithKline Pharmaceuticals SA [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlinePharmaceuticalsSAMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineResearchAndDevelopmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Research and Development Limited.",
        "label": "Glaxo Smith Kline Research And Development Limited [member]",
        "verboseLabel": "GlaxoSmithKline Research &amp; Development Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineResearchAndDevelopmentLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline S.A.",
        "label": "Glaxo Smith Kline S A [member]",
        "terseLabel": "GlaxoSmithKline S.A. [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineSAMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineSPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline S.p.A.",
        "label": "Glaxo Smith Kline S P A [member]",
        "terseLabel": "GlaxoSmithKline S.p.A. [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineSPAMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineServicesUnlimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Services Unlimited.",
        "label": "Glaxo Smith Kline Services Unlimited [member]",
        "terseLabel": "GlaxoSmithKline Services Unlimited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineServicesUnlimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineTradingServicesLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Trading Services Limited.",
        "label": "Glaxo Smith Kline Trading Services Limited [member]",
        "verboseLabel": "GlaxoSmithKline Trading Services Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineTradingServicesLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoSmithKlineUnitedKingdomLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline UK Limited.",
        "label": "Glaxo Smith Kline United Kingdom Limited [member]",
        "terseLabel": "GlaxoSmithKline UK Limited [member]"
       }
      }
     },
     "localname": "GlaxoSmithKlineUnitedKingdomLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoWellcomeManufacturingPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Wellcome Manufacturing Pte Ltd.",
        "label": "Glaxo Wellcome Manufacturing Pte Ltd [member]",
        "terseLabel": "Glaxo Wellcome Manufacturing Pte Ltd. [member]"
       }
      }
     },
     "localname": "GlaxoWellcomeManufacturingPteLtdMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxoWellcomeUkLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Wellcome UK Limited.",
        "label": "Glaxo Wellcome UK Limited [Member]"
       }
      }
     },
     "localname": "GlaxoWellcomeUkLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline AG.",
        "label": "GlaxoSmithKline AG [Member]",
        "terseLabel": "GlaxoSmithKline AG [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineAgMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineB.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline B.V.",
        "label": "GlaxoSmithKline B.V. [Member]",
        "terseLabel": "GlaxoSmithKline B.V. [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineB.v.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineFarEastB.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Far East B.V.",
        "label": "GlaxoSmithKline Far East B.V. [Member]",
        "terseLabel": "GlaxoSmithKline Far East B.V. [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineFarEastB.v.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIhcLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline IHC Limited",
        "label": "GlaxoSmithKline IHC Limited [Member]",
        "terseLabel": "GlaxoSmithKline IHC Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIhcLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S.",
        "label": "GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. [Member]",
        "terseLabel": "GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIlaclariSanayiVeTicaretA.s.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Development Limited",
        "label": "GlaxoSmithKline Intellectual Property Development Limited [Member]",
        "terseLabel": "GlaxoSmithKline Intellectual Property Development Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyDevelopmentLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Limited",
        "label": "GlaxoSmithKline Intellectual Property Limited [Member]",
        "terseLabel": "GlaxoSmithKline Intellectual Property Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIntellectualPropertyNo.2LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property (No.2) Limited",
        "label": "GlaxoSmithKline Intellectual Property (No.2) Limited [Member]",
        "terseLabel": "GlaxoSmithKline Intellectual Property (No.2) Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyNo.2LimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIntellectualPropertyNo.3LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property (No.3) Limited",
        "label": "GlaxoSmithKline Intellectual Property (No.3) Limited [Member]",
        "terseLabel": "GlaxoSmithKline Intellectual Property (No.3) Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyNo.3LimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineIntellectualPropertyNo.4LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property (No.4) Limited",
        "label": "GlaxoSmithKline Intellectual Property (No.4) Limited [Member]",
        "terseLabel": "GlaxoSmithKline Intellectual Property (No.4) Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyNo.4LimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineMexicoS.a.DeC.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Mexico S.A. de C.V.",
        "label": "GlaxoSmithKline Mexico S.A. de C.V. [Member]",
        "terseLabel": "GlaxoSmithKline Mexico S.A. de C.V. [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineMexicoS.a.DeC.v.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklinePharmaGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Pharma GmbH.",
        "label": "GlaxoSmithKline Pharma GmbH [Member]",
        "terseLabel": "GlaxoSmithKline Pharma GmbH [Member]"
       }
      }
     },
     "localname": "GlaxosmithklinePharmaGmbhMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklinePharmaceuticalsLimitedIndiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GlaxoSmithKline Pharmaceuticals Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklinePharmaceuticalsLimitedIndiaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineSingleMemberA.e.b.e.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Single Member A.E.B.E.",
        "label": "GlaxoSmithKline Single Member A.E.B.E. [Member]",
        "terseLabel": "GlaxoSmithKline Single Member A.E.B.E. [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineSingleMemberA.e.b.e.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineThailandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline (Thailand) Limited.",
        "label": "GlaxoSmithKline (Thailand) Limited [Member]",
        "terseLabel": "GlaxoSmithKline (Thailand) Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineThailandLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GlaxosmithklineUsTradingLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline US Trading Limited.",
        "label": "GlaxoSmithKline US Trading Limited [Member]"
       }
      }
     },
     "localname": "GlaxosmithklineUsTradingLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GovernmentBondsContributedToFairValueOfPlanAssetsListed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government bonds contributed to fair value of plan assets listed.",
        "label": "Government Bonds Contributed To Fair Value Of Plan Assets Listed",
        "terseLabel": "Government bonds, listed"
       }
      }
     },
     "localname": "GovernmentBondsContributedToFairValueOfPlanAssetsListed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GovernmentGrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government grants domain.",
        "label": "Government Grants [domain]",
        "terseLabel": "Government Grants [domain]"
       }
      }
     },
     "localname": "GovernmentGrantsDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GovernmentSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities.",
        "label": "Government Securities",
        "terseLabel": "Government securities"
       }
      }
     },
     "localname": "GovernmentSecurities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GreeceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Greece",
        "label": "Greece [Member]",
        "terseLabel": "Greece [Member]"
       }
      }
     },
     "localname": "GreeceMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GrossProceedsFromDisposalOfInterestInAssociates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from disposal of interest in associates.",
        "label": "Gross Proceeds From Disposal Of Interest In Associates",
        "terseLabel": "Gross proceeds from disposal of interest in associates"
       }
      }
     },
     "localname": "GrossProceedsFromDisposalOfInterestInAssociates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_GroupCreditEnhancementsAndCreditInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group credit enhancements and credit insurance.",
        "label": "Group Credit Enhancements And Credit Insurance [Member]",
        "terseLabel": "Group credit enhancements and credit insurance [member]"
       }
      }
     },
     "localname": "GroupCreditEnhancementsAndCreditInsuranceMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group.",
        "label": "Group [member]",
        "terseLabel": "Group [member]"
       }
      }
     },
     "localname": "GroupMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskAggregateHoldingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK aggregate holding.",
        "label": "GSK Aggregate Holding [Member]"
       }
      }
     },
     "localname": "GskAggregateHoldingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskAndGsksConsolidatedEsotTrustsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK and GSK's consolidated ESOT trusts.",
        "label": "GSK and GSKs Consolidated ESOT Trusts [Member]"
       }
      }
     },
     "localname": "GskAndGsksConsolidatedEsotTrustsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskCapitalB.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Capital B.V.",
        "label": "GSK Capital B.V. [Member]",
        "terseLabel": "GSK Capital B.V. [Member]"
       }
      }
     },
     "localname": "GskCapitalB.v.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Consumer HealthcareLimitedWithHindustanUnileverLimited.",
        "label": "GSK Consumer HealthcareLimitedWithHindustanUnileverLimited[member]",
        "terseLabel": "GSK Consumer Healthcare Limited With Hindustan Unilever Limited [member]"
       }
      }
     },
     "localname": "GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskEnterpriseManagementCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Enterprise Management Co, Ltd.",
        "label": "GSK Enterprise Management Co, Ltd [Member]",
        "terseLabel": "GSK Enterprise Management Co, Ltd [Member]"
       }
      }
     },
     "localname": "GskEnterpriseManagementCoLtdMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskEquityInvestmentsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Equity Investments, Limited.",
        "label": "GSK Equity Investments Limited [Member]",
        "terseLabel": "GSK Equity Investments, Limited [Member]"
       }
      }
     },
     "localname": "GskEquityInvestmentsLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskGp1LimitedsShareCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK gp 1 limiteds share capital.",
        "label": "GSK GP 1 Limiteds Share Capital [Member]",
        "terseLabel": "GSK GP 1 Limiteds Share Capital [Member]"
       }
      }
     },
     "localname": "GskGp1LimitedsShareCapitalMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskGp2LimitedsShareCapital.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK GP 2 limited's share capital.",
        "label": "GSK GP 2 Limiteds Share Capital. [Member]",
        "terseLabel": "GSK GP 2 Limiteds Share Capital. [Member]"
       }
      }
     },
     "localname": "GskGp2LimitedsShareCapital.Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskHoldingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK holding.",
        "label": "GSK Holding [Member]"
       }
      }
     },
     "localname": "GskHoldingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskNo.1ScottishLimitedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK (no.1) scottish limited partnership.",
        "label": "GSK (No.1) Scottish Limited Partnership [Member]",
        "terseLabel": "GSK (No.1) Scottish Limited Partnership [Member]"
       }
      }
     },
     "localname": "GskNo.1ScottishLimitedPartnershipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskNo.2ScottishLimitedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK (no.2) scottish limited partnership.",
        "label": "GSK (No.2) Scottish Limited Partnership [Member]",
        "terseLabel": "GSK (No.2) Scottish Limited Partnership [Member]"
       }
      }
     },
     "localname": "GskNo.2ScottishLimitedPartnershipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskNo.3ScottishLimitedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK (no.3) scottish limited partnership.",
        "label": "GSK (No.3) Scottish Limited Partnership [Member]",
        "terseLabel": "GSK (No.3) Scottish Limited Partnership [Member]"
       }
      }
     },
     "localname": "GskNo.3ScottishLimitedPartnershipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskPharmaVietnamCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Pharma Vietnam Company Limited.",
        "label": "GSK Pharma Vietnam Company Limited [Member]",
        "terseLabel": "GSK Pharma Vietnam Company Limited [Member]"
       }
      }
     },
     "localname": "GskPharmaVietnamCompanyLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK plc Member",
        "label": "GSK Plc [Member]",
        "verboseLabel": "GSK plc [Member]"
       }
      }
     },
     "localname": "GskPlcMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_GskShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK shareholders.",
        "label": "GSK Shareholders [Member]"
       }
      }
     },
     "localname": "GskShareholdersMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV.",
        "label": "HIV [member]",
        "terseLabel": "HIV [member]"
       }
      }
     },
     "localname": "HIVMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HaleonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Haleon.",
        "label": "Haleon [Member]"
       }
      }
     },
     "localname": "HaleonMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HaleonPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Haleon plc.",
        "label": "Haleon plc [Member]"
       }
      }
     },
     "localname": "HaleonPlcMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HalkBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Halk bank.",
        "label": "Halk Bank [Member]"
       }
      }
     },
     "localname": "HalkBankMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HeadlineUkTaxRateEffective2023": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headline UK tax rate effective 2023.",
        "label": "Headline UK Tax Rate Effective 2023",
        "terseLabel": "Headline UK tax rate effective 2023."
       }
      }
     },
     "localname": "HeadlineUkTaxRateEffective2023",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_HedgingGainLossTransferredToNonFinancialAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging gain loss transferred to non financial assets.",
        "label": "Hedging Gain Loss Transferred To Non Financial Assets",
        "terseLabel": "Hedging gain after taxation transferred to non-financial assets"
       }
      }
     },
     "localname": "HedgingGainLossTransferredToNonFinancialAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HedgingInstrumentAssetsCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging Instrument Assets Current",
        "label": "Hedging Instrument Assets Current",
        "terseLabel": "Financial assets, current"
       }
      }
     },
     "localname": "HedgingInstrumentAssetsCurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HedgingInstrumentAssetsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging Instrument Assets Noncurrent",
        "label": "Hedging Instrument Assets Noncurrent",
        "terseLabel": "Financial assets, Non current"
       }
      }
     },
     "localname": "HedgingInstrumentAssetsNoncurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HedgingInstrumentLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging instrument, liabilities current",
        "label": "Hedging instrument, liabilities current",
        "negatedLabel": "Financial Liabilities, current"
       }
      }
     },
     "localname": "HedgingInstrumentLiabilitiesCurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HedgingInstrumentLiabilitiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging instrument, liabilities noncurrent",
        "label": "Hedging instrument, liabilities noncurrent",
        "negatedLabel": "Financial liabilities non current"
       }
      }
     },
     "localname": "HedgingInstrumentLiabilitiesNoncurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HedgingInstrumentsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedging instruments liabilities.",
        "label": "Hedging Instruments Liabilities",
        "verboseLabel": "Financial liabilities, current and Non current"
       }
      }
     },
     "localname": "HedgingInstrumentsLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held for trading derivatives that are not in a designated and effective hedging relationship.",
        "label": "Held for trading derivatives that are not in a designated and effective hedging relationship [member]",
        "terseLabel": "Held for trading derivatives that are not in a designated and effective hedging relationship [member]"
       }
      }
     },
     "localname": "HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HindustanUnileverLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hindustan unilever limited",
        "label": "Hindustan Unilever Limited [Member]",
        "terseLabel": "Hindustan Unilever Limited [member]"
       }
      }
     },
     "localname": "HindustanUnileverLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HorlicksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horlicks",
        "label": "Horlicks [Member]",
        "terseLabel": "Horlicks [Member]"
       }
      }
     },
     "localname": "HorlicksMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_HumanGenomeSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human Genome Sciences, Inc.",
        "label": "Human Genome Sciences Inc [member]",
        "terseLabel": "Human Genome Sciences, Inc. [member]"
       }
      }
     },
     "localname": "HumanGenomeSciencesIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_IDBiomedicalCorporationOfQuebecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ID Biomedical Corporation of Quebec.",
        "label": "I D Biomedical Corporation Of Quebec [member]",
        "terseLabel": "ID Biomedical Corporation of Quebec [Member]"
       }
      }
     },
     "localname": "IDBiomedicalCorporationOfQuebecMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ImmunoInflammationRespiratoryAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immuno inflammation respiratory and other [member]",
        "label": "Immuno inflammation respiratory and other [Member]",
        "terseLabel": "Immuno-inflammation, respiratory and other [member]"
       }
      }
     },
     "localname": "ImmunoInflammationRespiratoryAndOtherMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ImpactOfShareConsolidationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of share consolidation shares.",
        "label": "Impact Of Share Consolidation Shares",
        "terseLabel": "Impact of share consolidation (Shares)"
       }
      }
     },
     "localname": "ImpactOfShareConsolidationShares",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment loss recognised in profit or loss property plant and equipment held for sale.",
        "label": "Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment Held For Sale",
        "terseLabel": "Impairment of property, plant and equipment held for sale, net of reversals"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentHeldForSale",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ImpairmentOfIntangibleAssetsNetOfReversal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of intangible assets net of reversal.",
        "label": "Impairment Of Intangible Assets Net Of Reversal",
        "terseLabel": "Impairment of intangible assets, net of reversals"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsNetOfReversal",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of investments in associates joint ventures and subsidiaries.",
        "label": "Impairment Of Investments In Associates Joint Ventures And Subsidiaries",
        "terseLabel": "Impairment of interest in associates"
       }
      }
     },
     "localname": "ImpairmentOfInvestmentsInAssociatesJointVenturesAndSubsidiaries",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ImpairmentOfRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Right Of Use Assets.",
        "label": "Impairment Of Right Of Use Assets",
        "verboseLabel": "Impairment of right of use assets"
       }
      }
     },
     "localname": "ImpairmentOfRightOfUseAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ImpairmentReversalsBySegmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment reversals by segment.",
        "label": "Impairment Reversals by Segment [abstract]",
        "terseLabel": "PP&amp;E and intangible asset impairment reversals by segment"
       }
      }
     },
     "localname": "ImpairmentReversalsBySegmentAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_InLineWithOtherPharmaceuticalCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In line with other pharmaceutical companies.",
        "label": "In Line With Other Pharmaceutical Companies [Member]",
        "terseLabel": "In Line with Other Pharmaceutical Companies [member]"
       }
      }
     },
     "localname": "InLineWithOtherPharmaceuticalCompaniesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_IncomeTaxExpenseBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense Benefits [line items]",
        "label": "Income Tax Expense Benefits [line items]",
        "terseLabel": "Income tax expense benefits [line items]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_IncomeTaxExpenseBenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense Benefits [table]",
        "label": "Income Tax Expense Benefits [table]",
        "terseLabel": "Income Tax Expense Benefits [table]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 14.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax relating to remeasurements of defined benefit plans of other comprehensive income restated.",
        "label": "Income Tax Relating To Remeasurements Of Defined Benefit Plans Of Other Comprehensive Income Restated",
        "negatedLabel": "Tax on remeasurement losses/(gains) on defined benefit plans"
       }
      }
     },
     "localname": "IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncomeRestated",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 2.0,
       "parentTag": "gsk_CashFlowsFromUsedInOperatingActivitiesContinuingOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes paid refund classified as operating activities continuing operations.",
        "label": "Income Taxes Paid Refund Classified As Operating Activities Continuing Operations",
        "negatedLabel": "Taxation paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes paid refund classified as operating activities discontinued operations.",
        "label": "Income Taxes Paid Refund Classified As Operating Activities Discontinued Operations",
        "negatedLabel": "Taxation paid from discontinued operations"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInAnnualPostretirementBenefitsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in annual post-retirement benefits cost",
        "label": "Increase Decrease in annual post-retirement benefits cost",
        "terseLabel": "Increase/(decrease) in annual post-retirement benefits cost"
       }
      }
     },
     "localname": "IncreaseDecreaseInAnnualPostretirementBenefitsCost",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInCashAndBankOverdrafts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash and bank overdrafts.",
        "label": "Increase Decrease In Cash And Bank Overdrafts",
        "totalLabel": "(Decrease)/increase in cash and bank overdrafts in the year"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndBankOverdrafts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and cash equivalents before effect of exchange rate changes for continuing operations.",
        "label": "Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes For Continuing Operations",
        "verboseLabel": "Increase in cash and bank overdrafts"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChangesForContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in Equity through foreign currency exchange exposures",
        "label": "Increase decrease in Equity through foreign currency exchange exposures",
        "terseLabel": "(Increase)/decrease in Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquityThroughForeignCurrencyExchangeExposures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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.": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in equity through interest rate movements.",
        "label": "Increase (decrease) in equity through interest rate movements.",
        "terseLabel": "Impact on equity through interest rate movements"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquityThroughInterestRateMovements.",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInExpectedCreditLossesAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in expected credit losses allowance.",
        "label": "Increase decrease in expected credit losses allowance",
        "negatedLabel": "Charge for the year"
       }
      }
     },
     "localname": "IncreaseDecreaseInExpectedCreditLossesAllowance",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInFinancialLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in financial liability.",
        "label": "Increase decrease in financial liability.",
        "terseLabel": "Increase/(decrease) in financial liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancialLiability",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in income through foreign currency exchange exposures.",
        "label": "Increase decrease in income through foreign currency exchange exposures",
        "terseLabel": "Increase/(decrease) in income"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in income through interest rate movements.",
        "label": "Increase decrease in income through interest rate movements",
        "terseLabel": "Impact on equity through interest rate movements",
        "verboseLabel": "Increase/(decrease) in income"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeThroughInterestRateMovements",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInLiquidInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 29.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in liquid investments.",
        "label": "Increase decrease in liquid investments",
        "negatedLabel": "Decrease/(increase) in liquid investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiquidInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in net debt through foreign currency exchange exposures.",
        "label": "Increase decrease in net debt through foreign currency exchange exposures",
        "terseLabel": "(Increase)/decrease in net debt"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInPostretirementBenefitsObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in post-retirement benefits obligation",
        "label": "Increase Decrease in post-retirement benefits obligation",
        "terseLabel": "(Decrease)/Increase in post-retirement benefits obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInPostretirementBenefitsObligation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseInProvisionForMajorRestructuringProgrammes": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": 1.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in provision for major restructuring programmes.",
        "label": "Increase decrease in provision for major restructuring programmes",
        "terseLabel": "Increase in provision for Major restructuring programmes"
       }
      }
     },
     "localname": "IncreaseDecreaseInProvisionForMajorRestructuringProgrammes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreasePensionObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease Pension Obligations",
        "label": "Increase Decrease Pension Obligations",
        "terseLabel": "(Decrease)/Increase in pension obligation"
       }
      }
     },
     "localname": "IncreaseDecreasePensionObligations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseProvisionReversalRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease provision reversal restructuring.",
        "label": "Increase Decrease Provision Reversal Restructuring",
        "terseLabel": "Increase decrease provision reversal restructuring"
       }
      }
     },
     "localname": "IncreaseDecreaseProvisionReversalRestructuring",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through change in probability of milestones success contingent liabilities recognised in business combination.",
        "label": "Increase Decrease Through Change In Probability Of Milestones Success Contingent Liabilities Recognised In Business Combination [Line Items]",
        "verboseLabel": "Disclosure of sensitivity of key model input to measure contingent consideration [line items]"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangeInProbabilityOfMilestonesSuccessContingentLiabilitiesRecognisedInBusinessCombinationLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through Demerger dividend, liabilities arising from financing activities",
        "label": "Increase (decrease) through Demerger dividend, liabilities arising from financing activities",
        "terseLabel": "Demerger"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughDemergerDividendLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through exchange adjustments of fair value measurement assets and liabilities.",
        "label": "Increase Decrease Through Exchange Adjustments Of Fair Value Measurement Assets And Liabilities",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExchangeAdjustmentsOfFairValueMeasurementAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through exchange adjustments of other investments.",
        "label": "Increase Decrease Through Exchange Adjustments Of Other Investments",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExchangeAdjustmentsOfOtherInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through research and development credits utilisation.",
        "label": "Increase Decrease Through Research And Development Credits Utilisation",
        "verboseLabel": "R&amp;D credits utilisation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughResearchAndDevelopmentCreditsUtilisation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through transfer of assets held for sale or distribution deferred tax liability asset.",
        "label": "Increase Decrease Through Transfer Of Assets Held For Sale Or Distribution Deferred Tax Liability Asset",
        "terseLabel": "Transfer of assets held for sale/ distribution"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransferOfAssetsHeldForSaleOrDistributionDeferredTaxLiabilityAsset",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInAnnualPensionCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in annual pension cost.",
        "label": "Increase in annual pension cost",
        "terseLabel": "(Decrease)/Increase in annual pension cost",
        "verboseLabel": "Increased annual pension cost"
       }
      }
     },
     "localname": "IncreaseInAnnualPensionCost",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInDiscountRateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in discount rate amount.",
        "label": "Increase In Discount Rate Amount",
        "terseLabel": "Increase in discount rate"
       }
      }
     },
     "localname": "IncreaseInDiscountRateAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInPlanDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in plan deficit.",
        "label": "Increase In Plan Deficit",
        "terseLabel": "Net pension deficit"
       }
      }
     },
     "localname": "IncreaseInPlanDeficit",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInProbabilityOfMilestoneSuccess": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in probability of milestone success.",
        "label": "Increase In Probability Of Milestone Success",
        "terseLabel": "10% increase in probability of milestone success"
       }
      }
     },
     "localname": "IncreaseInProbabilityOfMilestoneSuccess",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInSalesForecastAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in sales forecast amount.",
        "label": "Increase In Sales Forecast Amount",
        "terseLabel": "Increase in sales forecasts"
       }
      }
     },
     "localname": "IncreaseInSalesForecastAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseInTheHeadlineRateOfTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in the headline rate of tax.",
        "label": "Increase In The Headline Rate Of Tax [Member]"
       }
      }
     },
     "localname": "IncreaseInTheHeadlineRateOfTaxMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in equity through other contributions by non-controlling interests.",
        "label": "Increase through other contributions by noncontrolling interests, equity",
        "verboseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase \u200bin goodwill\u200b due \u200bto pension \u200bliabilities \u200bpayment to \u200bnon\u200b controlling \u200binterest.",
        "label": "Increase In Goodwill Due To Pension Liabilities Payment To Non Controlling Interest",
        "verboseLabel": "Other movements"
       }
      }
     },
     "localname": "IncreaseinGoodwillDuetoPensionliabilitiespaymentTononControllinginterest",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InfluenzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza.",
        "label": "Influenza [member]",
        "terseLabel": "Influenza [member]"
       }
      }
     },
     "localname": "InfluenzaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InnovivaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva Inc.",
        "label": "Innoviva Inc [member]",
        "terseLabel": "Innoviva Inc [member]"
       }
      }
     },
     "localname": "InnovivaIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InsuranceContractsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance contracts amount contributed to fair value of plan assets.",
        "label": "Insurance contracts amount contributed to fair value of plan assets",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "InsuranceContractsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IntangibleAssetsForWhichImpairmentsHaveBeenCharged": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets, for which impairments have been charged.",
        "label": "Intangible Assets, For Which Impairments Have Been Charged",
        "terseLabel": "Intangible assets, for which impairments have been charged"
       }
      }
     },
     "localname": "IntangibleAssetsForWhichImpairmentsHaveBeenCharged",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_IntangibleAssetsForWhichImpairmentsHaveBeenReversed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets, for which impairments have been charged or reversed",
        "label": "Intangible Assets For Which Impairments Have Been Reversed",
        "terseLabel": "Intangible assets, for which impairments have been charged or reversed"
       }
      }
     },
     "localname": "IntangibleAssetsForWhichImpairmentsHaveBeenReversed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "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": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest accrued on financial liabilities at amortized cost .",
        "label": "Interest Accrued On Financial Liabilities At Amortized Cost",
        "terseLabel": "Interest accrued on financial liabilities at amortized cost"
       }
      }
     },
     "localname": "InterestAccruedOnFinancialLiabilitiesAtAmortizedCost",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InterestBearingDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest bearing debt.",
        "label": "Interest bearing debt",
        "negatedLabel": "Total interest bearing"
       }
      }
     },
     "localname": "InterestBearingDebt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1% (100 basis points) increase in Euro interest rates.",
        "label": "Interest rate risk one percent increase in Euro interest rates[member]",
        "terseLabel": "1% (100 Basis Points) Increase in Euro Interest Rates [Member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1% (100 basis points) increase in sterling interest rates.",
        "label": "Interest rate risk one percent increase in sterling interest rates [member]",
        "terseLabel": "1% (100 basis points) increase in sterling interest rates [member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1% (100 basis points) increase in US Dollar interest rates.",
        "label": "Interest rate risk one percent increase in US dollar interest rates[member]",
        "terseLabel": "1% (100 Basis Points) Increase in US Dollar Interest Rates [Member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1% (100 basis points) movement in EUR or Sterling interest rates.",
        "label": "Interest Rate Risk One Percent Movement In EUR Or Sterling Interest Rates [Member]",
        "terseLabel": "1% (100 basis points) movement in EUR or Sterling interest rates [member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePercentMovementInEUROrSterlingInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePercentMovementInUSDInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1% (100 basis points) movement in USD interest rates.",
        "label": "Interest Rate Risk One Percent Movement In USD Interest Rates [Member]",
        "terseLabel": "1% (100 basis points) movement in USD interest rates [member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePercentMovementInUSDInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate risk one point five percent increase in euro interest rates.",
        "label": "Interest Rate Risk One Point Five Percent Increase In Euro Interest Rates [Member]",
        "terseLabel": "1.5% (150 basis points) increase in Euro interest rates [Member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePointFivePercentIncreaseInEuroInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate risk one point five percent increase in sterling interest rates.",
        "label": "Interest Rate Risk One Point Five Percent Increase In Sterling Interest Rates [Member]",
        "terseLabel": "1.5% (150 basis points) increase in Sterling interest rates [Member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePointFivePercentIncreaseInSterlingInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate risk one point five percent increase in us dollar interest rates.",
        "label": "Interest Rate Risk One Point Five Percent Increase In Us Dollar Interest Rates [Member]",
        "terseLabel": "1.5% (150 basis points) increase in US Dollar interest rates [Member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePointFivePercentIncreaseInUsDollarInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.5% (150 basis points) movement in EUR or Sterling interest rates.",
        "label": "Interest Rate Risk One Point Five Percent Movement In EUR Or Sterling Interest Rates [Member]",
        "terseLabel": "1.5% (150 basis points) movement in EUR or Sterling interest rates [member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePointFivePercentMovementInEUROrSterlingInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.5% (150 basis points) movement in USD interest rates.",
        "label": "Interest Rate Risk One Point Five Percent Movement In USD Interest Rates [Member]",
        "terseLabel": "1.5% (150 basis points) movement in USD interest rates [member]"
       }
      }
     },
     "localname": "InterestRateRiskOnePointFivePercentMovementInUSDInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InterestRateSensitivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate sensitivity.",
        "label": "Interest Rate Sensitivity [Member]",
        "terseLabel": "Interest rate sensitivity [member]"
       }
      }
     },
     "localname": "InterestRateSensitivityMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_IntraGroupProfitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intra group profit.",
        "label": "Intra Group Profit [member]",
        "terseLabel": "Intra group profit [member]"
       }
      }
     },
     "localname": "IntraGroupProfitMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment.",
        "label": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_InvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment.",
        "label": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InvestmentFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment fair value.",
        "label": "Investment fair value",
        "terseLabel": "Investment fair value"
       }
      }
     },
     "localname": "InvestmentFairValue",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InvestmentInHaleonPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in haleon plc.",
        "label": "Investment In Haleon Plc [Member]",
        "terseLabel": "Investment in Haleon plc [member]"
       }
      }
     },
     "localname": "InvestmentInHaleonPlcMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_InvestmentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment obligation.",
        "label": "Investment Obligation",
        "terseLabel": "Investment obligation"
       }
      }
     },
     "localname": "InvestmentObligation",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InvestmentOwnedNumberOfSharesDisposedOff": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment owned number of shares disposed off.",
        "label": "Investment Owned Number Of Shares Disposed Off",
        "terseLabel": "Investment owned number of shares disposed off"
       }
      }
     },
     "localname": "InvestmentOwnedNumberOfSharesDisposedOff",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_InvestmentsInAssociatesAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in associates and joint ventures.",
        "label": "Investments In Associates And Joint Ventures [abstract]"
       }
      }
     },
     "localname": "InvestmentsInAssociatesAndJointVenturesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_InvestmentsInJointVenturesAndAssociates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in joint ventures and associates.",
        "label": "Investments In Joint Ventures And Associates",
        "terseLabel": "Investments in associates and joint ventures"
       }
      }
     },
     "localname": "InvestmentsInJointVenturesAndAssociates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_InvestmentsMeasuredAtFairValueThroughProfitOrLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments measured at fair value through profit or loss.",
        "label": "Investments measured at fair value through profit or loss [member]",
        "terseLabel": "Investments measured at FVTPL [member]"
       }
      }
     },
     "localname": "InvestmentsMeasuredAtFairValueThroughProfitOrLossMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_IteosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "iTeos [Member].",
        "label": "iTeos [Member]"
       }
      }
     },
     "localname": "IteosMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_JTrustRoyalBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "J trust royal bank.",
        "label": "J Trust Royal Bank [Member]"
       }
      }
     },
     "localname": "JTrustRoyalBankMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_JapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japanese Yen [Member]"
       }
      }
     },
     "localname": "JapaneseYenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_JscGlaxosmithklineTradingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JSC GlaxoSmithKline Trading.",
        "label": "JSC GlaxoSmithKline Trading [Member]"
       }
      }
     },
     "localname": "JscGlaxosmithklineTradingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_KeyManagementPersonnelCompensationSocialSecurityCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Key management personnel compensation, social security costs.",
        "label": "Key management personnel compensation, social security costs",
        "terseLabel": "Social security costs"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSocialSecurityCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LaboratoireGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratoire GlaxoSmithKline.",
        "label": "Laboratoire Glaxo Smith Kline [member]",
        "terseLabel": "Laboratoire GlaxoSmithKline [member]"
       }
      }
     },
     "localname": "LaboratoireGlaxoSmithKlineMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LaboratoriosViiVHealthCareSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratorios ViiV Healthcare, S.L.",
        "label": "Laboratorios Vii V Health Care S L [member]",
        "terseLabel": "Laboratorios ViiV Healthcare, S.L. [member]"
       }
      }
     },
     "localname": "LaboratoriosViiVHealthCareSLMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LamisilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lamisil [member]",
        "label": "Lamisil [member]",
        "terseLabel": "Lamisil [member]"
       }
      }
     },
     "localname": "LamisilMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LaterThanOneYearAndNotLaterThanTenYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Later than one year and not later than ten year.",
        "label": "Later Than One Year And Not Later Than Ten Year [member]",
        "terseLabel": "Within 10 years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTenYearMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease and sublease payments recognized as expenses.",
        "label": "Lease and Sublease Payments Recognized as Expenses [Abstract]",
        "terseLabel": "Operating lease rentals:"
       }
      }
     },
     "localname": "LeaseAndSubleasePaymentsRecognizedAsExpensesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_LeaseLiabilitiesRecognizedAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities Recognized As Of Acquisition Date",
        "label": "Lease liabilities Recognized As Of Acquisition Date",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesRecognizedAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LeaseholdLandAndBuildingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold land and buildings.",
        "label": "Leasehold land and buildings [member]",
        "terseLabel": "Leasehold land and buildings [member]"
       }
      }
     },
     "localname": "LeaseholdLandAndBuildingsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LegacyProgrammesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy programmes [Member]",
        "terseLabel": "Legacy Programmes [Member]"
       }
      }
     },
     "localname": "LegacyProgrammesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LegalAndOtherDisputesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal and other disputes.",
        "label": "Legal And Other Disputes [member]",
        "terseLabel": "Legal and other disputes [member]"
       }
      }
     },
     "localname": "LegalAndOtherDisputesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LegalCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal costs.",
        "label": "Legal costs",
        "terseLabel": "Legal costs"
       }
      }
     },
     "localname": "LegalCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LegalEntity1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "legal Entity 1",
        "label": "legal Entity 1 [Axis]",
        "verboseLabel": "legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntity1Axis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_LegalProceedingsAndOtherDisputesProvisionEstimated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal proceedings and other disputes provision estimated.",
        "label": "Legal Proceedings And Other Disputes Provision Estimated",
        "terseLabel": "Legal proceedings and other disputes provision estimated"
       }
      }
     },
     "localname": "LegalProceedingsAndOtherDisputesProvisionEstimated",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LetterOfCredit1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit.",
        "label": "Letter Of Credit 1 [member]",
        "terseLabel": "Letter of credit 1 [member]"
       }
      }
     },
     "localname": "LetterOfCredit1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities, opening balance as on 01.01.22 adjusted for amounts attributed to discontinued operations\". [Refer: Cash flows from (used in) financing activities; Liabilities]",
        "label": "Liabilities Arising From Financing Activities Adjusted For Discontinued Operations",
        "negatedPeriodStartLabel": "Beginning balance adjusted for discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAdjustedForDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].",
        "label": "Liabilities Arising From Financing Activities Attributable To Continuing Operations",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAttributableToContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributed to discontinued operations; Liabilities].",
        "label": "Liabilities Arising From Financing Activities Attributable To Discontinued Operations",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAttributableToDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to continuing operations; Liabilities].",
        "label": "Liabilities Arising From Financing Activities Attributed To Continuing Operations",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAttributedToContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities attributable to discontinued operations; Liabilities].",
        "label": "Liabilities Arising From Financing Activities Attributed To Discontinued Operations",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilitiesArisingfromfinancingactivitiesAttributedToDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiabilityEliminatedOnDemerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability eliminated on demerger.",
        "label": "Liability Eliminated On Demerger",
        "terseLabel": "Liability Eliminated On Demerger"
       }
      }
     },
     "localname": "LiabilityEliminatedOnDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LicencesAndFranchisesAmortisedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licences And Franchises Amortised Brands [Member]",
        "terseLabel": "Licences And Franchises Amortised Brands [Member]"
       }
      }
     },
     "localname": "LicencesAndFranchisesAmortisedBrandsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments.",
        "label": "Liquid Investments",
        "terseLabel": "Liquid investment"
       }
      }
     },
     "localname": "LiquidInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiquidInvestmentsAttributedToContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquid Investments Attributed to Continuing Operations [Member]"
       }
      }
     },
     "localname": "LiquidInvestmentsAttributedToContinuingOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidInvestmentsAttributedToDiscontinuedOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquid Investments Attributed to Discontinued Operations [Member]"
       }
      }
     },
     "localname": "LiquidInvestmentsAttributedToDiscontinuedOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidInvestmentsCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments cash and cash equivalents.",
        "label": "Liquid Investments Cash And Cash Equivalents",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiquidInvestmentsCashAndCashEquivalents",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiquidInvestmentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments, cash and cash equivalents.",
        "label": "Liquid Investments, Cash And Cash Equivalents [Member]",
        "terseLabel": "Liquid investments, cash and cash equivalents [Member]"
       }
      }
     },
     "localname": "LiquidInvestmentsCashAndCashEquivalentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidInvestmentsCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments current.",
        "label": "Liquid Investments Current",
        "terseLabel": "Liquid investments"
       }
      }
     },
     "localname": "LiquidInvestmentsCurrent",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LiquidInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments.",
        "label": "Liquid Investments [member]",
        "terseLabel": "Liquid Investments [member]"
       }
      }
     },
     "localname": "LiquidInvestmentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidationOrDisposalOfInterestInAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidation Or Disposal Of Interest In Associates [Member]",
        "terseLabel": "Liquidation Or Disposal Of Interest In Associates [Member]"
       }
      }
     },
     "localname": "LiquidationOrDisposalOfInterestInAssociatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidationOrDisposalOfOverseasSubsidiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidation or disposal of overseas subsidiary.",
        "label": "Liquidation Or Disposal Of Overseas Subsidiary [member]",
        "terseLabel": "Liquidation Or Disposal Of Overseas Subsidiary [member]"
       }
      }
     },
     "localname": "LiquidationOrDisposalOfOverseasSubsidiaryMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LiquidityFunds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity funds.",
        "label": "Liquidity Funds",
        "terseLabel": "Liquidity funds"
       }
      }
     },
     "localname": "LiquidityFunds",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ListedInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listed investments.",
        "label": "Listed investments",
        "terseLabel": "Listed investments"
       }
      }
     },
     "localname": "ListedInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans on structured debt amount contributed to fair value of plan assets.",
        "label": "Loans on structured debt amount contributed to fair value of plan assets",
        "terseLabel": "Loans on structured debt amount contributed to fair value of plan assets"
       }
      }
     },
     "localname": "LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LoansReceivableMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans receivable made by entity related party transactions.",
        "label": "Loans Receivable Made By Entity Related Party Transactions",
        "terseLabel": "Loans outstanding"
       }
      }
     },
     "localname": "LoansReceivableMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LondonStockExchangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London Stock Exchange [member]",
        "label": "London Stock Exchange [member]",
        "terseLabel": "London Stock Exchange [member]"
       }
      }
     },
     "localname": "LondonStockExchangeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LongTermBorrowingsContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term borrowings continuing operations",
        "label": "Long term borrowings continuing operations [Member]"
       }
      }
     },
     "localname": "LongTermBorrowingsContinuingOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LongTermBorrowingsDiscontinuedOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term borrowings discontinued operations",
        "label": "Long term borrowings discontinued operations [Member]"
       }
      }
     },
     "localname": "LongTermBorrowingsDiscontinuedOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LongtermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Longterm borrowings [Abstract]",
        "terseLabel": "Long-term borrowings"
       }
      }
     },
     "localname": "LongtermBorrowingsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_LongwoodFoundersFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Longwood Founders Fund LP.",
        "label": "Longwood Founders Fund LP [member]",
        "terseLabel": "Longwood Founders Fund LP [member]"
       }
      }
     },
     "localname": "LongwoodFoundersFundLPMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency, number of plaintiffs.",
        "label": "Loss Contingency Number Of Plaintiffs",
        "verboseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "gsk_LossOnSaleOfBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on sale of business",
        "label": "Loss on sale of business"
       }
      }
     },
     "localname": "LossOnSaleOfBusiness",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Losses attributable to level 3 financial instruments reported in other operating income expense.",
        "label": "Losses attributable to level 3 financial instruments reported in other operating income expense",
        "terseLabel": "Total net losses on financial instruments held"
       }
      }
     },
     "localname": "LossesAttributableToLevel3FinancialInstrumentsReportedInOtherOperatingIncomeExpense",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_LowerThanBBBBaa3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower than BBB-/Baa3.",
        "label": "Lower Than BBB Baa3 [Member]",
        "terseLabel": "Lower than BBB-/Baa3 [Member]"
       }
      }
     },
     "localname": "LowerThanBBBBaa3Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MajorRestructuringCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Restructuring Costs [abstract]",
        "label": "Major Restructuring Costs [abstract]",
        "terseLabel": "Major Restructuring Costs [abstract]"
       }
      }
     },
     "localname": "MajorRestructuringCostsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_MajorRestructuringProgrammesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major restructuring programmes.",
        "label": "Major Restructuring Programmes [member]",
        "terseLabel": "Major restructuring programmes [member]"
       }
      }
     },
     "localname": "MajorRestructuringProgrammesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MajorRestructuringProvisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Restructuring Provisions",
        "label": "Major Restructuring Provisions [Member]"
       }
      }
     },
     "localname": "MajorRestructuringProvisionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MalePensionersAverageLifeExpectancyAtSixty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Male pensioners average life expectancy at sixty.",
        "label": "Male Pensioners Average Life Expectancy At Sixty",
        "terseLabel": "Male Years"
       }
      }
     },
     "localname": "MalePensionersAverageLifeExpectancyAtSixty",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "gsk_ManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing.",
        "label": "Manufacturing [member]",
        "terseLabel": "Manufacturing [member]"
       }
      }
     },
     "localname": "ManufacturingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MarketValueOfSharesHeldForShareAwardSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market value of shares held for share award schemes.",
        "label": "Market Value Of Shares Held For Share Award Schemes",
        "terseLabel": "Shares held for share award schemes, Market value"
       }
      }
     },
     "localname": "MarketValueOfSharesHeldForShareAwardSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MarketValueOfSharesHeldForShareOptionSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market value of shares held for share option schemes.",
        "label": "Market Value Of Shares Held For Share Option Schemes",
        "terseLabel": "Shares held for share option schemes, Market value"
       }
      }
     },
     "localname": "MarketValueOfSharesHeldForShareOptionSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MaturedInThePastPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Matured in the past.",
        "label": "Matured in the past period [Member]"
       }
      }
     },
     "localname": "MaturedInThePastPeriodMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum contributions to plan in net defined benefit liability asset.",
        "label": "Maximum Contributions To Plan In Net Defined Benefit Liability Asset",
        "terseLabel": "Maximum contributions to plan in net defined benefit liability asset"
       }
      }
     },
     "localname": "MaximumContributionsToPlanInNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MaximumProceedsThresholdAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum proceeds threshold amount.",
        "label": "Maximum Proceeds Threshold Amount",
        "terseLabel": "Proceeds threshold to be received by partnerships"
       }
      }
     },
     "localname": "MaximumProceedsThresholdAmount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MedicxiVenturesILimitedPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicxi Ventures I Limited Partner.",
        "label": "Medicxi VenturesI Limited Partner [member]",
        "terseLabel": "Medicxi Ventures I Limited Partner [member]"
       }
      }
     },
     "localname": "MedicxiVenturesILimitedPartnerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MeningitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meningitis.",
        "label": "Meningitis [member]",
        "terseLabel": "Meningitis [member]"
       }
      }
     },
     "localname": "MeningitisMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MeningitisPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meningitis portfolio.",
        "label": "Meningitis Portfolio [member]",
        "terseLabel": "Meningitis Portfolio [member]"
       }
      }
     },
     "localname": "MeningitisPortfolioMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone income recognised from performance obligations satisfied in previous periods.",
        "label": "Milestone Income Recognised From Performance Obligations Satisfied In Previous Periods",
        "terseLabel": "Milestone income"
       }
      }
     },
     "localname": "MilestoneIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MiscellaneousComponentsOfEquityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous Components Of Equity.",
        "label": "Miscellaneous Components Of Equity [axis]",
        "terseLabel": "Miscellaneous Components Of Equity [axis]"
       }
      }
     },
     "localname": "MiscellaneousComponentsOfEquityAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_MiscellaneousComponentsOfEquityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous Components Of Equity [domain]",
        "label": "Miscellaneous Components Of Equity [domain]",
        "terseLabel": "Miscellaneous Components Of Equity [domain]"
       }
      }
     },
     "localname": "MiscellaneousComponentsOfEquityDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MomelotinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Momelotinib.",
        "label": "Momelotinib [Member]"
       }
      }
     },
     "localname": "MomelotinibMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MoreThanFiveYearsNotLaterThanTenYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "More than five years not later than ten years Member.",
        "label": "More than Five Years Not Later Than Ten Years [Member]"
       }
      }
     },
     "localname": "MoreThanFiveYearsNotLaterThanTenYearsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MoreThanTenYearsNotLaterThanThirtyYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "More than ten years not later than thirty years member.",
        "label": "More than Ten Years Not Later Than Thirty Years [Member]"
       }
      }
     },
     "localname": "MoreThanTenYearsNotLaterThanThirtyYearsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MoreThanThirtyYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "More than thirty years member.",
        "label": "More Than Thirty Years [Member]"
       }
      }
     },
     "localname": "MoreThanThirtyYearsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortality projections model, long-term improvement parameter, per year, percentage.",
        "label": "Mortality Projections Model, Long-Term Improvement Parameter, Per Year, Percentage",
        "terseLabel": "Long term rate of improvement per year"
       }
      }
     },
     "localname": "MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_MovementInDeferredTaxAssetsAndLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in deferred tax assets and liabilities line items",
        "label": "Movement In Deferred Tax Assets And Liabilities [line items]",
        "terseLabel": "Movement In Deferred Tax Assets And Liabilities [line items]"
       }
      }
     },
     "localname": "MovementInDeferredTaxAssetsAndLiabilitiesLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_MovementInDeferredTaxAssetsAndLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in deferred tax assets and liabilities table.",
        "label": "Movement In Deferred Tax Assets And Liabilities [table]",
        "terseLabel": "Movement In Deferred Tax Assets And Liabilities [table]"
       }
      }
     },
     "localname": "MovementInDeferredTaxAssetsAndLiabilitiesTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_MovementInTranslationExchangeAttributableToContinuingOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in translation exchange attributable to continuing operations.",
        "label": "Movement In Translation Exchange Attributable To Continuing Operations",
        "terseLabel": "Movement attributable to continuing operations"
       }
      }
     },
     "localname": "MovementInTranslationExchangeAttributableToContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MovementInTranslationExchangeAttributableToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in translation exchange attributable to discontinued operations.",
        "label": "Movement In Translation Exchange Attributable To Discontinued Operations",
        "terseLabel": "Movement attributable to discontinued operations(a)"
       }
      }
     },
     "localname": "MovementInTranslationExchangeAttributableToDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_MultiAssetFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multi asset funds",
        "label": "Multi asset funds",
        "terseLabel": "Multi-asset funds"
       }
      }
     },
     "localname": "MultiAssetFunds",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetAssetsAcquiredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Assets Acquired [Abstract]",
        "verboseLabel": "Net assets acquired"
       }
      }
     },
     "localname": "NetAssetsAcquiredAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate",
        "label": "Net Assets Liabilities Excluding Goodwill As Of Acquisition Date"
       }
      }
     },
     "localname": "NetAssetsLiabilitiesExcludingGoodwillAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net assets liabilities including goodwill as of acquisition date.",
        "label": "Net Assets Liabilities Including Goodwill As Of Acquisition Date",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "NetAssetsLiabilitiesIncludingGoodwillAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net debt.",
        "label": "Net Debt [Member]",
        "terseLabel": "Net Debt [member]"
       }
      }
     },
     "localname": "NetDebtMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NetFairValueMovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net fair value movements.",
        "label": "Net Fair Value Movements",
        "negatedLabel": "Net fair value movement in the year"
       }
      }
     },
     "localname": "NetFairValueMovements",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net fair value movements investments through other comprehensive income.",
        "label": "Net Fair Value Movements Investments Through Other Comprehensive Income",
        "terseLabel": "Net fair value movements through Other comprehensive income"
       }
      }
     },
     "localname": "NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetFairValueMovementsThroughProfitOrLossCurrentInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net fair value movements through profit or loss current investments.",
        "label": "Net Fair Value Movements Through Profit Or Loss Current Investments",
        "terseLabel": "Net fair value movements through profit or loss"
       }
      }
     },
     "localname": "NetFairValueMovementsThroughProfitOrLossCurrentInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetFairValueMovementsThroughProfitOrLossOtherInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net fair value movements through profit or loss other investments.",
        "label": "Net fair value movements through profit or loss other investments",
        "terseLabel": "Net fair value movements through profit or loss"
       }
      }
     },
     "localname": "NetFairValueMovementsThroughProfitOrLossOtherInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net financial assets and financial liabilities at fair values.",
        "label": "Net financial assets financial liabilities at fair value",
        "totalLabel": "Net financial assets and financial liabilities fair value excluding lease liabilities"
       }
      }
     },
     "localname": "NetFinancialAssetsFinancialLiabilitiesAtFairValue",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetFinancialAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net financial assets liabilities.",
        "label": "Net Financial Assets Liabilities",
        "totalLabel": "Net financial assets and financial liabilities excluding lease liabilities"
       }
      }
     },
     "localname": "NetFinancialAssetsLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetImpairmentLossesOtherIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net impairment losses other intangible assets.",
        "label": "Net Impairment Losses Other Intangible Assets",
        "negatedLabel": "Impairment losses",
        "terseLabel": "Impairment of intangible assets, net of reversals"
       }
      }
     },
     "localname": "NetImpairmentLossesOtherIntangibleAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetInvestmentHedgedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net investment hedged.",
        "label": "Net Investment Hedged [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NetInvestmentHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net investment hedges.",
        "label": "Net Investment Hedges [member]",
        "terseLabel": "Net Investment Hedges [member]"
       }
      }
     },
     "localname": "NetInvestmentHedgesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NetOperatingAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating assets.",
        "label": "Net operating assets",
        "terseLabel": "Net operating assets"
       }
      }
     },
     "localname": "NetOperatingAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NetOperatingChargeForPensionsAndOtherPostRetirementBenefits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating charge for pensions and other post retirement benefits.",
        "label": "Net Operating Charge for Pensions and Other Post Retirement Benefits",
        "terseLabel": "Net operating cost"
       }
      }
     },
     "localname": "NetOperatingChargeForPensionsAndOtherPostRetirementBenefits",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NewYorkStockExchangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Stock Exchange.",
        "label": "New York Stock Exchange [member]",
        "terseLabel": "New York Stock Exchange [member]"
       }
      }
     },
     "localname": "NewYorkStockExchangeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NimbusTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nimbus therapeutics LLC.",
        "label": "Nimbus Therapeutics LLC [Member]",
        "terseLabel": "Nimbus Therapeutics, LLC [member]"
       }
      }
     },
     "localname": "NimbusTherapeuticsLLCMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NominalValueOfSharesHeldForShareAwardSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal Value Of Shares Held For Share Award Schemes.",
        "label": "Nominal Value Of Shares Held For Share Award Schemes",
        "terseLabel": "Shares held for share award schemes, Nominal value"
       }
      }
     },
     "localname": "NominalValueOfSharesHeldForShareAwardSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NominalValueOfSharesHeldForShareOptionSchemes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal value of shares held for share option schemes.",
        "label": "Nominal Value Of Shares Held For Share Option Schemes",
        "terseLabel": "Shares held for share option schemes, Nominal value"
       }
      }
     },
     "localname": "NominalValueOfSharesHeldForShareOptionSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NonCashDividendToShareholders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash dividend to shareholders.",
        "label": "Non Cash Dividend To Shareholders",
        "terseLabel": "Non-cash dividend to shareholders"
       }
      }
     },
     "localname": "NonCashDividendToShareholders",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NonCashRestructuringCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash restructuring charges",
        "label": "Non cash restructuring Charges"
       }
      }
     },
     "localname": "NonCashRestructuringCharges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NonControllingInterestRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-controlling interest recognised as of acquisition date.",
        "label": "Non Controlling Interest Recognised As Of Acquisition Date",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "NonControllingInterestRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NonDerivativesFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non derivatives financial liabilities.",
        "label": "Non Derivatives Financial Liabilities [member]",
        "terseLabel": "Non Derivatives Financial Liabilities [member]"
       }
      }
     },
     "localname": "NonDerivativesFinancialLiabilitiesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NonDistributableMergerAndPreMergerReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-distributable merger and pre-merger reserves.",
        "label": "Non distributable merger and pre merger reserves [Member]",
        "verboseLabel": "Non-distributable merger and pre-merger reserves [Member]"
       }
      }
     },
     "localname": "NonDistributableMergerAndPreMergerReservesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NonFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non financial instruments.",
        "label": "Non Financial Instruments [member]",
        "terseLabel": "Non Financial Instruments [member]"
       }
      }
     },
     "localname": "NonFinancialInstrumentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NonInterestBearingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Interest Bearing",
        "label": "Non Interest Bearing [Member]",
        "terseLabel": "Non interest bearing [member]"
       }
      }
     },
     "localname": "NonInterestBearingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NonUsaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non USA .[member]",
        "label": "Non USA .[member]",
        "terseLabel": "Non USA [member]"
       }
      }
     },
     "localname": "NonUsaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NoncashConsiderationForSettlementOfAPromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash consideration for settlement of a promissory note.",
        "label": "NonCash consideration for Settlement of a Promissory Note",
        "terseLabel": "Non-cash consideration (settlement of a promissory note)"
       }
      }
     },
     "localname": "NoncashConsiderationForSettlementOfAPromissoryNote",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NoncashDistributionsToNoncontrollingInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash distributions to noncontrolling interests.",
        "label": "Noncash Distributions To Noncontrolling Interests",
        "terseLabel": "Non-cash distribution to non-controlling interests"
       }
      }
     },
     "localname": "NoncashDistributionsToNoncontrollingInterests",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NotesIssuedAtEuropeanMediumTermNoteProgramme": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes issued at European medium term note programme.",
        "label": "Notes Issued At European Medium Term Note Programme",
        "terseLabel": "Notes issued at European medium term note programme"
       }
      }
     },
     "localname": "NotesIssuedAtEuropeanMediumTermNoteProgramme",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NotesIssuedUnderUsShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes issued under US shelf registration.",
        "label": "Notes Issued Under US Shelf Registration",
        "terseLabel": "Notes issued under us shelf registration"
       }
      }
     },
     "localname": "NotesIssuedUnderUsShelfRegistration",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [member]",
        "terseLabel": "Novartis [member]"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NovartisVaccinesBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis vaccines business.",
        "label": "Novartis Vaccines Business [Member]"
       }
      }
     },
     "localname": "NovartisVaccinesBusinessMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NovartisVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis vaccines.",
        "label": "Novartis Vaccines [member]",
        "terseLabel": "Novartis vaccines [member]"
       }
      }
     },
     "localname": "NovartisVaccinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments.",
        "label": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "gsk_NumberOfOutstandingAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of awards outstanding in a share-based payment arrangement.",
        "label": "Number of awards outstanding in share-based payment arrangement",
        "terseLabel": "Number of outstanding awards"
       }
      }
     },
     "localname": "NumberOfOutstandingAwards",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfOutstandingShareAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Outstanding Share Awards",
        "label": "Number Of Outstanding Share Awards",
        "periodEndLabel": "Number of shares, Ending balance",
        "periodStartLabel": "Number of shares, Beginning balance"
       }
      }
     },
     "localname": "NumberOfOutstandingShareAwards",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfReportableOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reportable operating segments.",
        "label": "Number of reportable operating segments",
        "terseLabel": "Number of reportable operating segments"
       }
      }
     },
     "localname": "NumberOfReportableOperatingSegments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "gsk_NumberOfShareAwardsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share awards exercised in a share-based payment arrangement.",
        "label": "Number of share awards exercised in share-based payment arrangement",
        "negatedLabel": "Number of shares, Awards exercised"
       }
      }
     },
     "localname": "NumberOfShareAwardsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share awards forfeited in sharebased payment arrangement.",
        "label": "Number Of Share Awards Forfeited In Sharebased Payment Arrangement",
        "negatedLabel": "Number of shares, Awards cancelled"
       }
      }
     },
     "localname": "NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfShareAwardsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share awards granted in sharebased payment arrangement.",
        "label": "Number Of Share Awards Granted In Sharebased Payment Arrangement",
        "terseLabel": "Number of awards granted",
        "verboseLabel": "Number of shares, Awards granted"
       }
      }
     },
     "localname": "NumberOfShareAwardsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options not exercisable in share based payment arrangement.",
        "label": "Number Of Share Options Not Exercisable In Share Based Payment Arrangement",
        "terseLabel": "Number share options were not exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfSharesHeldForShareAwardSchemes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares held for share award schemes.",
        "label": "Number Of Shares Held For Share Award Schemes",
        "terseLabel": "Shares held for share award schemes, Number of shares"
       }
      }
     },
     "localname": "NumberOfSharesHeldForShareAwardSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfSharesHeldForShareOptionSchemes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares held for share option schemes.",
        "label": "Number Of Shares Held For Share Option Schemes",
        "terseLabel": "Shares held for share option schemes, Number of shares"
       }
      }
     },
     "localname": "NumberOfSharesHeldForShareOptionSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued and fully paid under employee share schemes.",
        "label": "Number of shares issued and fully paid under employee share schemes",
        "terseLabel": "Issued under employee share schemes"
       }
      }
     },
     "localname": "NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_NumberOfTreasurySharesTransferredToEmployeeShareTrusts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares transferred to employee share trusts.",
        "label": "Number Of Treasury Shares transferred to employee share trusts",
        "terseLabel": "Ordinary shares acquired by ESOP Trusts"
       }
      }
     },
     "localname": "NumberOfTreasurySharesTransferredToEmployeeShareTrusts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholesalers.",
        "label": "Number of wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "gsk_OkairosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Okairos.",
        "label": "Okairos [Member]",
        "terseLabel": "Okairos [member]"
       }
      }
     },
     "localname": "OkairosMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oncology [Member]",
        "verboseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePercentEuroMediumTermNotesTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One percent European medium term note two thousand twenty six.",
        "label": "One Percent Euro Medium Term Notes Two Thousand twenty six [Member]",
        "terseLabel": "1.000% \u20ac Euro Medium Term Note 2026 [Member]"
       }
      }
     },
     "localname": "OnePercentEuroMediumTermNotesTwoThousandTwentySixMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One point seven five zero percentage European medium term note two thousand thirty.",
        "label": "One Point Seven Five Zero Percentage Euro Medium Term Note Two Thousand Thirty [Member]",
        "terseLabel": "1.750% Euro Medium Term Note 2030 [member]"
       }
      }
     },
     "localname": "OnePointSevenFiveZeroPercentageEuroMediumTermNoteTwoThousandThirtyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Six Two Five European Medium Term Note Two Thousand Twenty Five.",
        "label": "One Point Six Two Five Euro Medium Term Note Two Thousand Twenty Five [Member]",
        "terseLabel": "1.625% Euro Medium Term Note 2035 [Member]"
       }
      }
     },
     "localname": "OnePointSixTwoFiveEuroMediumTermNoteTwoThousandTwentyFiveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One point three seven five percent European medium term notes thousand twenty four.",
        "label": "One Point Three Seven Five Percent Euro Medium Term Notes Two Thousand Twenty Four [Member]",
        "terseLabel": "1.375% \u20ac Euro Medium Term Note 2024 [Member]"
       }
      }
     },
     "localname": "OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyFourMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% European Medium Term Note 2029",
        "label": "One point three seven five Percent Euro Medium Term Notes Two Thousand twenty nine [Member]",
        "terseLabel": "1.375% \u20ac Euro Medium Term Note 2029 [Member]"
       }
      }
     },
     "localname": "OnePointThreeSevenFivePercentEuroMediumTermNotesTwoThousandTwentyNineMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five European Medium Term Note Two Thousand Twenty Eight.",
        "label": "One Point Two Five Euro Medium Term Note Two Thousand Twenty Eight [Member]",
        "terseLabel": "1.25% Euro Medium Term Note 2028 [Member]"
       }
      }
     },
     "localname": "OnePointTwoFiveEuroMediumTermNoteTwoThousandTwentyEightMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One point two five percentage European medium term note two thousand twenty six.",
        "label": "One Point Two Five Percentage Euro Medium Term Note Two Thousand Twenty Six [Member]",
        "terseLabel": "1.250% Euro Medium Term Note 2026 [member]"
       }
      }
     },
     "localname": "OnePointTwoFivePercentageEuroMediumTermNoteTwoThousandTwentySixMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OperatingProfitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating profit.",
        "label": "Operating Profit [Line Items]"
       }
      }
     },
     "localname": "OperatingProfitLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitTables"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares acquired by Esop trusts included in other reserves.",
        "label": "Ordinary Shares Acquired By Esop Trusts Included In Other Reserves",
        "negatedLabel": "Ordinary shares acquired by ESOP Trusts"
       }
      }
     },
     "localname": "OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OriginationAndReversalOfTemporaryDifferencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Origination and reversal of temporary differences.",
        "label": "Origination and reversal of temporary differences [member]",
        "terseLabel": "Origination and reversal of temporary differences [member]"
       }
      }
     },
     "localname": "OriginationAndReversalOfTemporaryDifferencesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 8.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accruals.",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherAdditionsToRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other additions to right of use assets.",
        "label": "Other Additions To Right Of Use Assets",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "OtherAdditionsToRightOfUseAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherAdjustmentsForNoncashItemsToNetDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other adjustments for non-cash items to net debt.",
        "label": "Other adjustments for non-cash items to net debt",
        "terseLabel": "Other non-cash movements"
       }
      }
     },
     "localname": "OtherAdjustmentsForNoncashItemsToNetDebt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherAdjustmentsOfFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other adjustments of fair value measurement assets.",
        "label": "Other Adjustments of Fair Value Measurement Assets",
        "terseLabel": "Other Adjustments of Fair Value Measurement Assets"
       }
      }
     },
     "localname": "OtherAdjustmentsOfFairValueMeasurementAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets net.",
        "label": "Other Assets Net",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsNet",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Associates.",
        "label": "Other Associates [member]",
        "terseLabel": "Other associates [member]"
       }
      }
     },
     "localname": "OtherAssociatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherAuditorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other auditors.",
        "label": "Other Auditors [Member]",
        "terseLabel": "Other Auditors [member]"
       }
      }
     },
     "localname": "OtherAuditorsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other bonds.",
        "label": "Other Bonds [member]",
        "terseLabel": "Other Bonds [member]"
       }
      }
     },
     "localname": "OtherBondsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherBorrowingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Borrowing [member]",
        "label": "Other Borrowing [member]",
        "terseLabel": "Other Borrowing [member]"
       }
      }
     },
     "localname": "OtherBorrowingMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other business.",
        "label": "Other business [member]",
        "terseLabel": "Other [member]"
       }
      }
     },
     "localname": "OtherBusinessMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other commercial paper.",
        "label": "Other Commercial Paper [Member]",
        "terseLabel": "Other commercial paper [member]"
       }
      }
     },
     "localname": "OtherCommercialPaperMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive expense income for the year from continuing operations.",
        "label": "Other Comprehensive Expense Income For The Year From Continuing Operations",
        "terseLabel": "Other comprehensive expense for the year from continuing operations"
       }
      }
     },
     "localname": "OtherComprehensiveExpenseIncomeForTheYearFromContinuingOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1": {
       "order": 4.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive expense income for the year from discontinued operations.",
        "label": "Other Comprehensive Expense Income For The Year From Discontinued Operations",
        "terseLabel": "Other comprehensive income for the year from discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveExpenseIncomeForTheYearFromDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income Before Tax Gains Losses On Cash Flow Hedges.",
        "label": "Other Comprehensive Income Before Tax Gains Losses On Cash Flow Hedges",
        "terseLabel": "Fair value movements on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnCashFlowHedges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 13.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income before tax gains losses on remeasurements of defined benefit plans restated.",
        "label": "Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans Restated",
        "verboseLabel": "Remeasurement (losses)/gains on defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRestated",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income deferred tax on fair value movements on equity investments.",
        "label": "Other comprehensive income deferred tax on fair value movements on equity investments",
        "terseLabel": "Tax on fair value movements on equity investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other computer software.",
        "label": "Other computer software [member]",
        "terseLabel": "Other computer software [member]"
       }
      }
     },
     "localname": "OtherComputerSoftwareMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherCostsCashSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": 5.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other costs cash settlement.",
        "label": "Other Costs Cash Settlement",
        "terseLabel": "Other cash costs"
       }
      }
     },
     "localname": "OtherCostsCashSettlement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherCurrentDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current debt.",
        "label": "Other Current Debt [member]",
        "terseLabel": "Other [member]"
       }
      }
     },
     "localname": "OtherCurrentDebtMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherGainsLossesOnDemerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other gains/(losses) on demerger.",
        "label": "Other Gains(Losses) On Demerger",
        "terseLabel": "Other gains/(losses) on demerger"
       }
      }
     },
     "localname": "OtherGainsLossesOnDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherGeneralMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other General Medicines [Member]",
        "label": "Other General Medicines [Member]",
        "terseLabel": "Other General Medicines [member]"
       }
      }
     },
     "localname": "OtherGeneralMedicinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherInvestments1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments.",
        "label": "Other investments 1 [abstract]"
       }
      }
     },
     "localname": "OtherInvestments1Abstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_OtherInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments.",
        "label": "Other investments [line items]",
        "terseLabel": "Other investments [line items]"
       }
      }
     },
     "localname": "OtherInvestmentsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments [member]",
        "label": "Other investments [member]",
        "terseLabel": "Other investments [member]"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherInvestmentsNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments non-current.",
        "label": "Other Investments Noncurrent [Member]",
        "terseLabel": "Non-current [member]"
       }
      }
     },
     "localname": "OtherInvestmentsNoncurrentMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments [table]",
        "label": "Other investments [table]",
        "terseLabel": "Other investments [table]"
       }
      }
     },
     "localname": "OtherInvestmentsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities assets amount contributed to fair value of plan assets.",
        "label": "Other Liabilities Assets Amount Contributed To Fair Value Of Plan Assets",
        "verboseLabel": "Other (liabilities)/assets"
       }
      }
     },
     "localname": "OtherLiabilitiesAssetsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherLongtermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long term borrowings.",
        "label": "Other LongTerm Borrowings [member]",
        "terseLabel": "Other LongTerm Borrowings [member]"
       }
      }
     },
     "localname": "OtherLongtermBorrowingsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Member.",
        "label": "Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherNonCashCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other\u00a0non cash\u00a0credit.",
        "label": "Other Non Cash Credit",
        "terseLabel": "Other\u00a0non-cash\u00a0credit"
       }
      }
     },
     "localname": "OtherNonCashCredit",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_OtherNonCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non current liabilities .",
        "label": "Other non current liabilities [member]",
        "terseLabel": "Other non current liabilities [member]"
       }
      }
     },
     "localname": "OtherNonCurrentLiabilitiesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherNonCurrentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non current receivables.",
        "label": "Other Non Current Receivables [member]",
        "terseLabel": "Other Non Current Receivables [member]"
       }
      }
     },
     "localname": "OtherNonCurrentReceivablesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Noncurrent Assets [member]",
        "label": "Other Noncurrent Assets [member]",
        "terseLabel": "Other Noncurrent Assets [member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherNoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-current liabilities [abstract]",
        "label": "Other non-current liabilities [abstract]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_OtherOverseasPensionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other overseas pension plans.",
        "label": "Other Overseas Pension Plans [member]",
        "terseLabel": "Other overseas pension schemes [member]"
       }
      }
     },
     "localname": "OtherOverseasPensionPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other provision.",
        "label": "Other Provision [member]",
        "terseLabel": "Other Provision [Member]"
       }
      }
     },
     "localname": "OtherProvisionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivable.",
        "label": "Other Receivable [Member]",
        "terseLabel": "Other receivable [member]"
       }
      }
     },
     "localname": "OtherReceivableMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskFifteenPercentageDecreaseInSalesForecastsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk fifteen percentage decrease in sales forecasts.",
        "label": "Other Risk Fifteen Percentage Decrease In Sales Forecasts [Member]",
        "terseLabel": "15% decrease in sales forecasts [member]"
       }
      }
     },
     "localname": "OtherRiskFifteenPercentageDecreaseInSalesForecastsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskFifteenPercentageIncreaseInSalesForecastsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk fifteen percentage increase in sales forecasts.",
        "label": "Other Risk Fifteen Percentage Increase In Sales Forecasts [Member]",
        "terseLabel": "15% increase in sales forecasts [member]"
       }
      }
     },
     "localname": "OtherRiskFifteenPercentageIncreaseInSalesForecastsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskOnePercentageDecreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk one percentage decrease in discount rate.",
        "label": "Other Risk One Percentage Decrease In Discount Rate [Member]",
        "terseLabel": "1% decrease in discount rate [member]"
       }
      }
     },
     "localname": "OtherRiskOnePercentageDecreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskOnePercentageIncreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk one percentage increase in discount rate.",
        "label": "Other Risk One Percentage Increase In Discount Rate [Member]",
        "terseLabel": "1% increase in discount rate [member]"
       }
      }
     },
     "localname": "OtherRiskOnePercentageIncreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk one point five percentage decrease in discount rate.",
        "label": "Other Risk One Point Five Percentage Decrease In Discount Rate [Member]",
        "terseLabel": "1.5% decrease in discount rate [member]"
       }
      }
     },
     "localname": "OtherRiskOnePointFivePercentageDecreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk one point two five percentage increase in discount rate.",
        "label": "Other Risk One Point Five Percentage Increase In Discount Rate [Member]",
        "terseLabel": "1.5% increase in discount rate [member]"
       }
      }
     },
     "localname": "OtherRiskOnePointFivePercentageIncreaseInDiscountRateMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk ten percentage decrease in sales forecasts.",
        "label": "Other Risk Ten Percentage Decrease In Sales Forecasts [Member]",
        "terseLabel": "10% decrease in sales forecasts [member]"
       }
      }
     },
     "localname": "OtherRiskTenPercentageDecreaseInSalesForecastsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "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": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risk ten percentage increase in sales forecasts.",
        "label": "Other Risk Ten Percentage Increase In Sales Forecasts [Member]",
        "terseLabel": "10% increase in sales forecasts [member]"
       }
      }
     },
     "localname": "OtherRiskTenPercentageIncreaseInSalesForecastsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OthersProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Others products.",
        "label": "Others Products [member]",
        "terseLabel": "Others products [member]"
       }
      }
     },
     "localname": "OthersProductsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_OverseasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overseas.",
        "label": "Overseas [member]",
        "terseLabel": "Overseas [Member]"
       }
      }
     },
     "localname": "OverseasMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PandemicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pandemic [Member].",
        "label": "Pandemic [Member]",
        "terseLabel": "Pandemic [Member]"
       }
      }
     },
     "localname": "PandemicMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PandemicVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pandemic vaccines member.",
        "label": "Pandemic Vaccines [Member]",
        "terseLabel": "Pandemic Vaccines [member]"
       }
      }
     },
     "localname": "PandemicVaccinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ParValueOfSharesSurrenderedInLieuOfNewShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Par value of shares surrendered in lieu of new shares.",
        "label": "Par Value Of Shares Surrendered In Lieu Of New Shares",
        "terseLabel": "Par value of shares surrendered in lieu of new shares"
       }
      }
     },
     "localname": "ParValueOfSharesSurrenderedInLieuOfNewShares",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables on derivative financial instruments undiscounted cash flows.",
        "label": "Payables On Derivative Financial Instruments Undiscounted Cash Flows",
        "negatedLabel": "Gross cash ouflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps,"
       }
      }
     },
     "localname": "PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PaymentOfContingentConsiderationLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration liabilities.",
        "label": "Payment of Contingent Consideration Liabilities",
        "terseLabel": "Settlement of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentOfContingentConsiderationLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PaymentsMadeForTransactionCostsAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs and other.",
        "label": "Payments Made For Transaction Costs And Other",
        "verboseLabel": "Payments Made For Transaction Costs And Other"
       }
      }
     },
     "localname": "PaymentsMadeForTransactionCostsAndOther",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PaymentsOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of finance lease liabilities.",
        "label": "Payments of finance lease liabilities",
        "negatedLabel": "Repayment of lease liabilities"
       }
      }
     },
     "localname": "PaymentsOfFinanceLeaseLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PensionObligationProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension obligation provisions.",
        "label": "Pension Obligation Provisions",
        "terseLabel": "Pension augmentations arising from staff redundancies"
       }
      }
     },
     "localname": "PensionObligationProvisions",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PensionSurplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension surplus.",
        "label": "Pension surplus",
        "terseLabel": "Pension surplus"
       }
      }
     },
     "localname": "PensionSurplus",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PensionsAndOtherPostemploymentBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pensions and other post-employment benefits.",
        "label": "Pensions and other post-employment benefits [member]",
        "terseLabel": "Pensions and other post-employment benefits [member]"
       }
      }
     },
     "localname": "PensionsAndOtherPostemploymentBenefitsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PercentageOfAccountsReceivableByMajorCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of accounts receivable by major customer.",
        "label": "Percentage of accounts receivable by major customer",
        "terseLabel": "Maximum percentage of trade receivables balance"
       }
      }
     },
     "localname": "PercentageOfAccountsReceivableByMajorCustomer",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfDecreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of decrease in discount rate.",
        "label": "Percentage of decrease in discount rate",
        "terseLabel": "Percentage of decrease in discount rate"
       }
      }
     },
     "localname": "PercentageOfDecreaseInDiscountRate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfIncreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in discount rate.",
        "label": "Percentage Of Increase In Discount Rate",
        "terseLabel": "Percentage of increase in discount rate"
       }
      }
     },
     "localname": "PercentageOfIncreaseInDiscountRate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership.",
        "label": "Percentage of ownership",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "PercentageOfOwnership",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfOwnershipDistributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership of the Consumer Healthcare business distributed.",
        "label": "Percentage Of Ownership Distributed",
        "terseLabel": "Percentage Of Ownership Distributed"
       }
      }
     },
     "localname": "PercentageOfOwnershipDistributed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfOwnershipDivested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership of the Consumer Healthcare business divested.",
        "label": "Percentage Of Ownership divested",
        "terseLabel": "Percentage Of Ownership Divested"
       }
      }
     },
     "localname": "PercentageOfOwnershipDivested",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfOwnershipInterestRepresentedByTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of owneship interest represented by transfer.",
        "label": "Percentage Of Ownership Interest Represented By Transfer",
        "terseLabel": "Percentage of ownership interest represented by transfer"
       }
      }
     },
     "localname": "PercentageOfOwnershipInterestRepresentedByTransfer",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfOwneshipInterestHeldByTheTransferee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of owneship interest held by the transferee.",
        "label": "Percentage Of Owneship Interest Held By The Transferee",
        "terseLabel": "Percentage of ownership interest held by the transferee company"
       }
      }
     },
     "localname": "PercentageOfOwneshipInterestHeldByTheTransferee",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfPerformanceSharePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of performance share plan.",
        "label": "Percentage Of Performance Share Plan",
        "terseLabel": "Percentage of performance share plan"
       }
      }
     },
     "localname": "PercentageOfPerformanceSharePlan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageOfRoyaltyPayableOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payable on future sales",
        "label": "Percentage of royalty payable on future sales",
        "terseLabel": "Percentage of royalty payable on future sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPayableOnFutureSales",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PercentageofGSKHolding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of GSK holding.",
        "label": "Percentage of GSK Holding",
        "terseLabel": "Percentage of GSK holding"
       }
      }
     },
     "localname": "PercentageofGSKHolding",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_PerformanceSharePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance share plans.",
        "label": "Performance Share Plans [member]",
        "terseLabel": "Performance Share Plan [member]"
       }
      }
     },
     "localname": "PerformanceSharePlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PfizerBiotechCorporationTaiwanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Biotech Corporation Taiwan",
        "label": "Pfizer Biotech Corporation Taiwan [Member]",
        "terseLabel": "Pfizer Biotech Corporation Taiwan [member]"
       }
      }
     },
     "localname": "PfizerBiotechCorporationTaiwanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [member]",
        "terseLabel": "Pfizer [member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceuticals.",
        "label": "Pharmaceuticals [member]",
        "terseLabel": "Pharmaceuticals [member]"
       }
      }
     },
     "localname": "PharmaceuticalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PipelineAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipeline Assets [Member]"
       }
      }
     },
     "localname": "PipelineAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PipelineProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pipeline progress Member.",
        "label": "Pipeline Progress [Member]",
        "terseLabel": "Pipeline Progress [Member]"
       }
      }
     },
     "localname": "PipelineProgressMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant And Equipment [Member]",
        "terseLabel": "Plant and equipment [member]"
       }
      }
     },
     "localname": "PlantAndEquipmentMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PlantAndMachineryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plant and machinery.",
        "label": "Plant and machinery [member]",
        "terseLabel": "Plant and machinery [member]"
       }
      }
     },
     "localname": "PlantAndMachineryMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PledgedInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledged Investments.",
        "label": "Pledged Investments",
        "terseLabel": "Pledged investments value"
       }
      }
     },
     "localname": "PledgedInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PortionOfConsiderationPaidReceivedConsistingNonCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of consideration paid received consisting non cash consideration.",
        "label": "Portion of Consideration Paid Received Consisting Non Cash Consideration",
        "terseLabel": "Non-cash consideration"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingNonCashConsideration",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PostEmploymentBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of post-employment benefit expense.",
        "label": "Post Employment Benefit Expense",
        "verboseLabel": "Pension and other post-employment costs, including augmentations (Note 31)"
       }
      }
     },
     "localname": "PostEmploymentBenefitExpense",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PostRetirementBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post retirement benefit.",
        "label": "Post Retirement Benefit [member]",
        "terseLabel": "Post retirement benefit [Member]"
       }
      }
     },
     "localname": "PostRetirementBenefitMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PostSeparationOfTheConsumerHealthcareBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post separation of the consumer healthcare business member.",
        "label": "Post Separation of the Consumer Healthcare Business [Member]",
        "verboseLabel": "Post separation of the consumer healthcare business [Member]"
       }
      }
     },
     "localname": "PostSeparationOfTheConsumerHealthcareBusinessMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-employment benefit expense, defined benefit plans analysed.",
        "label": "Post-employment benefit expense, defined benefit plans analysed",
        "terseLabel": "Pension and other post-employment cost Analysed"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PostemploymentBenefitExpensePlans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Postemployment benefit expense plans.",
        "label": "Postemployment Benefit Expense Plans",
        "terseLabel": "Pension and other post-employment cost"
       }
      }
     },
     "localname": "PostemploymentBenefitExpensePlans",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PostretirementBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-retirement benefits.",
        "label": "Post-retirement benefits [member]",
        "terseLabel": "Post-retirement benefits [member]"
       }
      }
     },
     "localname": "PostretirementBenefitsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PrehedgingOfLongtermInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-hedging of long-term interest rates.",
        "label": "Pre-hedging of long-term interest rates [member]",
        "terseLabel": "Pre-hedging of long-term interest rates [member]"
       }
      }
     },
     "localname": "PrehedgingOfLongtermInterestRatesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PresentationOfTheFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presentation Of The Financial Statements [abstract]",
        "label": "Presentation Of The Financial Statements [abstract]"
       }
      }
     },
     "localname": "PresentationOfTheFinancialStatementsAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_ProceedsFromDisposalOfAssociatesAndJointVentures": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 33.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from disposal of associates and joint ventures.",
        "label": "Proceeds From Disposal Of Associates And Joint Ventures",
        "terseLabel": "Proceeds from disposal of associates and joint ventures"
       }
      }
     },
     "localname": "ProceedsFromDisposalOfAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ProceedsFromRepaymentsOfOtherCurrentBorrowings": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (repayments of) other current borrowings.",
        "label": "Proceeds from (Repayments of) Other Current Borrowings",
        "negatedLabel": "Repayment of/(increase in) other short-term loans",
        "terseLabel": "Increase in/(repayment of) other short-term loans"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfOtherCurrentBorrowings",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ProdubancoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Produbanco.",
        "label": "Produbanco [Member]"
       }
      }
     },
     "localname": "ProdubancoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ProfitAfterTaxationOnDemergerOfDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit after taxation on demerger of discontinued operations",
        "label": "Profit after taxation on demerger of discontinued operations",
        "terseLabel": "Profit after taxation on demerger of discontinued operations"
       }
      }
     },
     "localname": "ProfitAfterTaxationOnDemergerOfDiscontinuedOperations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 15.0,
       "parentTag": "ifrs-full_ProfitLossFromDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss from discontinued operations and other gains losses from demerger.",
        "label": "Profit Loss From Discontinued Operations And Other Gains Losses From Demerger",
        "terseLabel": "Profit after taxation from discontinued operations and other gains/(losses) from the demerger"
       }
      }
     },
     "localname": "ProfitLossFromDiscontinuedOperationsAndOtherGainsLossesFromDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit sharing costs and royalties due to the counterparty included in cost of sales.",
        "label": "Profit Sharing Costs And Royalties Due To The Counterparty Included In Cost Of Sales",
        "terseLabel": "Profit sharing costs and royalties due to the counterparty included in cost of sales"
       }
      }
     },
     "localname": "ProfitSharingCostsAndRoyaltiesDueToTheCounterpartyIncludedInCostOfSales",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ProjectedPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Projected period.",
        "label": "Projected Period [member]",
        "terseLabel": "Projected at 2042 [member]"
       }
      }
     },
     "localname": "ProjectedPeriodMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PropertyAmountContributedToFairValueOfPlanAssetsListed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property amount contributed to fair value of plan assets listed.",
        "label": "Property Amount Contributed To Fair Value Of Plan Assets Listed",
        "terseLabel": "Property, listed"
       }
      }
     },
     "localname": "PropertyAmountContributedToFairValueOfPlanAssetsListed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PropertyAmountContributedToFairValueOfPlanAssetsUnlisted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property amount contributed to fair value of plan assets unlisted.",
        "label": "Property Amount Contributed To Fair Value Of Plan Assets Unlisted",
        "terseLabel": "Property, unlisted"
       }
      }
     },
     "localname": "PropertyAmountContributedToFairValueOfPlanAssetsUnlisted",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PropertyPlantAndEquipmentAndVehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment and vehicles.",
        "label": "Property Plant and Equipment and Vehicles [member]",
        "terseLabel": "Plant, equipment and vehicles [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndVehiclesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ProvisionsForUncertainTaxPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisions for uncertain tax position.",
        "label": "Provisions for Uncertain Tax Position",
        "terseLabel": "Provisions For Uncertain Tax Position"
       }
      }
     },
     "localname": "ProvisionsForUncertainTaxPosition",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PurchaseOfInvestmentInAssociatesAndJointVentures": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 28.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of investment in associates and joint ventures.",
        "label": "Purchase Of Investment In Associates And Joint Ventures",
        "negatedLabel": "Investments in associates and joint ventures"
       }
      }
     },
     "localname": "PurchaseOfInvestmentInAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PurposeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose [Axis]"
       }
      }
     },
     "localname": "PurposeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_PurposeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose [Domain]"
       }
      }
     },
     "localname": "PurposeDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_PutOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option.",
        "label": "Put Option",
        "terseLabel": "Pfizer put option"
       }
      }
     },
     "localname": "PutOption",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_PutOptionPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option payable.",
        "label": "Put Option payable",
        "terseLabel": "ViiV Healthcare put option"
       }
      }
     },
     "localname": "PutOptionPayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_QuraTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qura Therapeutics LLC.",
        "label": "Qura Therapeutics LLC [member]",
        "terseLabel": "Qura Therapeutics LLC [member]"
       }
      }
     },
     "localname": "QuraTherapeuticsLLCMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RAndDNewProductPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D new product performance Member.",
        "label": "R And D New Product Performance [Member]",
        "terseLabel": "R&amp;D New Product Performance [Member]"
       }
      }
     },
     "localname": "RAndDNewProductPerformanceMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ReTranslationOfLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re translation of loan",
        "label": "Retranslation of loan",
        "negatedLabel": "Retranslation of loans"
       }
      }
     },
     "localname": "ReTranslationOfLoan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables on derivative financial instruments undiscounted cash flows.",
        "label": "Receivables On Derivative Financial Instruments Undiscounted Cash Flows",
        "terseLabel": "Gross cash inflows,Forward starting interest rate swaps, Foreign exchange forward contracts and swaps"
       }
      }
     },
     "localname": "ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReceivablesRelatedToInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables related to insurance contracts.",
        "label": "Receivables Related To Insurance Contracts",
        "terseLabel": "Amounts receivable under insurance contracts"
       }
      }
     },
     "localname": "ReceivablesRelatedToInsuranceContracts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves.",
        "label": "Reclassification Of Cumulative Exchange Differences Arising On Translation Of Foreign Currency Net Assets Of Divested Subsidiaries And Offsetting Net Investment Hedges Reserves",
        "terseLabel": "Reclassification of cumulative exchange differences arising on translation of foreign currency net assets of divested subsidiaries and offsetting net investment hedges reserves"
       }
      }
     },
     "localname": "ReclassificationOfCumulativeExchangeDifferencesArisingOnTranslationOfForeignCurrencyNetAssetsOfDivestedSubsidiariesAndOffsettingNetInvestmentHedgesReserves",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries",
        "label": "Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries",
        "terseLabel": "Reclassification of exchange movements and net investment hedge movements on disposal of overseas subsidiaries"
       }
      }
     },
     "localname": "ReclassificationOfExchangeMovementsAndNetInvestmentHedgeMovementsOnDisposalOfOverseasSubsidiaries",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReclassificationOfNetDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of net debt.",
        "label": "Reclassification of net debt",
        "negatedLabel": "Reclassifications"
       }
      }
     },
     "localname": "ReclassificationOfNetDebt",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of net cash flow to movement in net debt explanatory.",
        "label": "Reconciliation Of Net Cash Flow To Movement In Net Debt Explanatory",
        "terseLabel": "Reconciliation of net cash flow to movement in net debt"
       }
      }
     },
     "localname": "ReconciliationOfNetCashFlowToMovementInNetDebtExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_RecyclingOfExchangeDifferencesInAssociate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recycling of exchange differences in associate.",
        "label": "Recycling Of Exchange Differences In Associate",
        "terseLabel": "Recycling of exchange differences in associate"
       }
      }
     },
     "localname": "RecyclingOfExchangeDifferencesInAssociate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReducedTaxRateCancelledMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced tax rate cancelled.",
        "label": "Reduced Tax Rate Cancelled [Member]"
       }
      }
     },
     "localname": "ReducedTaxRateCancelledMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RemainingAmountDueToBeContributed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount due to be contributed.",
        "label": "Remaining Amount Due To Be Contributed",
        "terseLabel": "Remaining amount due to be contributed"
       }
      }
     },
     "localname": "RemainingAmountDueToBeContributed",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RemainingBalanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining balance.",
        "label": "Remaining Balance [member]",
        "terseLabel": "Remaining Balance [member]"
       }
      }
     },
     "localname": "RemainingBalanceMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RemainingBookValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining book value [Member].",
        "label": "Remaining Book Value [Member]"
       }
      }
     },
     "localname": "RemainingBookValueMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 16.0,
       "parentTag": "ifrs-full_ProfitLossFromDiscontinuedOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re-measurement of discontinued operations distributed to shareholders on demerger.",
        "label": "Remeasurement Of Discontinued Operations Distributed To Shareholders On Demerger",
        "negatedLabel": "Re-measurement\u00a0of discontinued operations distributed to shareholders on demerger",
        "verboseLabel": "Remeasurement of discontinued operations distributed to shareholders on demerger"
       }
      }
     },
     "localname": "RemeasurementOfDiscontinuedOperationsDistributedToShareholdersOnDemerger",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of put option liabilities and preferential dividends",
        "label": "Remeasurement of put option liabilities and preferential dividends",
        "terseLabel": "Remeasurement of ViiV Healthcare put option liabilities and preferential dividends"
       }
      }
     },
     "localname": "RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RemeasurementOfTheContingentConsiderationPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of the contingent consideration payable.",
        "label": "Remeasurement of the Contingent Consideration Payable",
        "terseLabel": "Remeasurement of the contingent consideration payable"
       }
      }
     },
     "localname": "RemeasurementOfTheContingentConsiderationPayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement through income statement Increase (decrease) in contingent liabilities recognised in business combination",
        "label": "Remeasurement through income statement increase (decrease) in contingent liabilities recognised in business combination",
        "terseLabel": "Remeasurement through income statement"
       }
      }
     },
     "localname": "RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RemeasurementsOfContingentConsiderationPayableForAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurements of contingent consideration payable for acquisition.",
        "label": "Remeasurements Of Contingent Consideration Payable For Acquisition"
       }
      }
     },
     "localname": "RemeasurementsOfContingentConsiderationPayableForAcquisition",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RepaymentYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment year.",
        "label": "Repayment Year",
        "terseLabel": "Repayment dates"
       }
      }
     },
     "localname": "RepaymentYear",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "gsk_ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Accountant Work Performed In Connection With Consumer Healthcare Demerger [Member]"
       }
      }
     },
     "localname": "ReportingAccountantWorkPerformedInConnectionWithConsumerHealthcareDemergerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail": {
       "order": 3.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses",
        "label": "Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development.",
        "label": "Research and development [member]",
        "terseLabel": "Research and Development [Member]",
        "verboseLabel": "Research and development [member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve of cash flow hedges, hedging relationships for which hedge accounting is no longer applied 1.",
        "label": "Reserve Of Cash Flow Hedges, Hedging Relationships For Which Hedge Accounting Is No Longer Applied 1",
        "terseLabel": "Balance in cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied"
       }
      }
     },
     "localname": "ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied1",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A component of equity representing the reserve of cash flow hedges or the reserve of exchange differences on translation in relation to continuing hedges.",
        "label": "Reserve of cash flow hedges or exchange differences on translation continuing hedges",
        "terseLabel": "Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges"
       }
      }
     },
     "localname": "ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RespiratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Respiratory.",
        "label": "Respiratory [member]",
        "terseLabel": "Respiratory [member]"
       }
      }
     },
     "localname": "RespiratoryMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of world.",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest of World [member]"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RestructuringChargesByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges By Type [Axis]"
       }
      }
     },
     "localname": "RestructuringChargesByTypeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_RestructuringChargesByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges By Type [Domain]"
       }
      }
     },
     "localname": "RestructuringChargesByTypeDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RestructuringCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major restructuring costs considered to be significant.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RestructuringCosts1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring costs1.",
        "label": "Restructuring Costs1",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCosts1",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RestructuringCostsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring costs.",
        "label": "Restructuring Costs [Axis]",
        "terseLabel": "Restructuring Costs [axis]"
       }
      }
     },
     "localname": "RestructuringCostsAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_RestructuringCostsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Costs [domain]",
        "label": "Restructuring Costs [Domain]",
        "terseLabel": "Restructuring Costs [domain]"
       }
      }
     },
     "localname": "RestructuringCostsDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RetainedEarningsAndOtherReserves": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained earnings and other reserves.",
        "label": "Retained Earnings And Other Reserves",
        "terseLabel": "Retained earnings and other reserves"
       }
      }
     },
     "localname": "RetainedEarningsAndOtherReserves",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RetireeHealthcarePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retiree healthcare plans [Member]",
        "terseLabel": "Retiree healthcare plans [Member]"
       }
      }
     },
     "localname": "RetireeHealthcarePlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_RevenueFromChangesToEstimatesOfRARAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from changes to estimates of RAR accruals.",
        "label": "Revenue from changes to estimates of RAR accruals",
        "terseLabel": "Turnover from changes to estimates of RAR accruals"
       }
      }
     },
     "localname": "RevenueFromChangesToEstimatesOfRARAccruals",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RevenueFromCoPromotionalActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from co-promotional activities.",
        "label": "Revenue From Co Promotional Activities",
        "terseLabel": "Revenue from co-promotional activities"
       }
      }
     },
     "localname": "RevenueFromCoPromotionalActivities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RightOfUseAssetDisposal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset disposal.",
        "label": "Disposals"
       }
      }
     },
     "localname": "RightOfUseAssetDisposal",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RightOfUseAssetImpairments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset disposal.",
        "label": "Right Of Use Asset Impairments",
        "terseLabel": "Impairments"
       }
      }
     },
     "localname": "RightOfUseAssetImpairments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset transfer to assets held for sale or distribution.",
        "label": "Right Of Use Asset Transfer to Assets Held for Sale or Distribution",
        "terseLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "RightOfUseAssetTransferToAssetsHeldForSaleOrDistribution",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RightOfUseAssetsExchangeAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets exchange adjustments.",
        "label": "Right of Use Assets Exchange Adjustments",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "RightOfUseAssetsExchangeAdjustments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty income recognised from performance obligations satisfied in previous periods.",
        "label": "Royalty Income Recognised From Performance Obligations Satisfied In Previous Periods",
        "terseLabel": "Royalty income"
       }
      }
     },
     "localname": "RoyaltyIncomeRecognisedFromPerformanceObligationsSatisfiedInPreviousPeriods",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_SLPPartneshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SLP partneships.",
        "label": "SLP Partneships [Member]"
       }
      }
     },
     "localname": "SLPPartneshipsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SalesToAssociatesAndJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales to associates and joint ventures",
        "label": "Sales to associates and joint ventures",
        "terseLabel": "Sales to associates and joint ventures"
       }
      }
     },
     "localname": "SalesToAssociatesAndJointVentures",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_SaudiArabiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Saudi Arabia",
        "label": "Saudi Arabia [Member]",
        "terseLabel": "Saudi Arabia [Member]"
       }
      }
     },
     "localname": "SaudiArabiaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SavingsRelatedOptionsGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings related options grant price.",
        "label": "Savings Related Options Grant Price",
        "terseLabel": "Savings-related options grant price (including 20% discount)"
       }
      }
     },
     "localname": "SavingsRelatedOptionsGrantPrice",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_SavingsRelatedOptionsGrantPriceDiscount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings related options grant price discount.",
        "label": "Savings Related Options Grant Price Discount",
        "terseLabel": "Savings-related options grant price discount"
       }
      }
     },
     "localname": "SavingsRelatedOptionsGrantPriceDiscount",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_SavingsRelatedShareOptionSchemesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings related share option schemes.",
        "label": "Savings Related Share Option Schemes [member]",
        "terseLabel": "Savings-Related Share Option Schemes [member]"
       }
      }
     },
     "localname": "SavingsRelatedShareOptionSchemesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of adjustments reconciling profit after tax to operating cash flows.",
        "label": "Schedule of Adjustments Reconciling Profit After Tax to Operating Cash Flows Explanatory [text block]",
        "terseLabel": "Summary of Cash Generated from Operations"
       }
      }
     },
     "localname": "ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about the amounts attributable to non controlling interests explanatory.",
        "label": "Schedule of Information about the Amounts Attributable to Non Controlling Interests Explanatory",
        "terseLabel": "Schedule of Amount Attributable to Joint Venture Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_SchemeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scheme.",
        "label": "Scheme [Axis]"
       }
      }
     },
     "localname": "SchemeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_SchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scheme.",
        "label": "Scheme [Member]"
       }
      }
     },
     "localname": "SchemeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ScottishLimitedPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scottish limited partnerships.",
        "label": "Scottish Limited Partnerships [Member]"
       }
      }
     },
     "localname": "ScottishLimitedPartnershipsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SecondInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second interim.",
        "label": "Second Interim [member]",
        "terseLabel": "Second interim [member]"
       }
      }
     },
     "localname": "SecondInterimMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SegmentConsolidationItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment consolidation item.",
        "label": "Segment Consolidation Item [Axis]",
        "terseLabel": "Segment consolidation items [axis]"
       }
      }
     },
     "localname": "SegmentConsolidationItemAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_SegmentConsolidationItemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment consolidation item.",
        "label": "Segment Consolidation Item [Member]",
        "terseLabel": "Entity's total for segment consolidation items [member]"
       }
      }
     },
     "localname": "SegmentConsolidationItemMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SellForeignCurrencyLessThanThreeMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Foreign Currency Less than three months [member]",
        "label": "Sell Foreign Currency Less than three months [member]",
        "terseLabel": "Sell Foreign Currency Less than 3 months [member]"
       }
      }
     },
     "localname": "SellForeignCurrencyLessThanThreeMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SellForeignCurrencyOverSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Foreign Currency over six months [member]",
        "label": "Sell Foreign Currency over six months [member]",
        "terseLabel": "Sell Foreign Currency over 6 months [member]"
       }
      }
     },
     "localname": "SellForeignCurrencyOverSixMonthsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SellingGeneralAndAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, General and Administration.",
        "label": "Selling, General and Administration [member]",
        "terseLabel": "Selling, general and administration [member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrationMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expenses.",
        "label": "Selling general and administrative expenses [member]",
        "terseLabel": "Selling general and administrative expenses [member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SensitivityAnalysisForActuarialAssumptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity analysis for actuarial assumptions.",
        "label": "Sensitivity Analysis For Actuarial Assumptions [Member]",
        "verboseLabel": "Sensitivity analysis for actuarial assumptions [member]"
       }
      }
     },
     "localname": "SensitivityAnalysisForActuarialAssumptionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SeparationPreparationProgrammeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation preparation programme.",
        "label": "Separation Preparation Programme [Member]",
        "terseLabel": "Separation Preparation programme [member]"
       }
      }
     },
     "localname": "SeparationPreparationProgrammeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SetFirstLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Setfirst Limited.",
        "label": "Set First Limited [member]",
        "terseLabel": "Setfirst Limited [member]"
       }
      }
     },
     "localname": "SetFirstLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SgdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SGD.",
        "label": "SGD [Member]"
       }
      }
     },
     "localname": "SgdMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share consolidation as a result of Consumer Healthcare business demerger.",
        "label": "Share consolidation as a result of Consumer Healthcare business demerger [Member]",
        "terseLabel": "Share consolidation as a result of Consumer Healthcare business demerger [member]"
       }
      }
     },
     "localname": "ShareConsolidationAsAResultOfConsumerHealthcareBusinessDemergerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of associates and joint ventures realised profits on disposal of equity investments.",
        "label": "Share of associates and joint ventures realised profits on disposal of equity investments",
        "terseLabel": "Share of associates and joint ventures realised profits on disposal of equity investments"
       }
      }
     },
     "localname": "ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ShareOptionAndAwardSchemesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share option and award schemes.",
        "label": "Share Option and Award Schemes [member]",
        "terseLabel": "Share option and award schemes [member]"
       }
      }
     },
     "localname": "ShareOptionAndAwardSchemesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share option plans.",
        "label": "Share Option Plan [member]",
        "terseLabel": "Share option plans [member]"
       }
      }
     },
     "localname": "ShareOptionPlanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareOptionSchemesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share option schemes.",
        "label": "Share Option Schemes [member]",
        "terseLabel": "Share Option Schemes [member]"
       }
      }
     },
     "localname": "ShareOptionSchemesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareOptionsAndSavingsRelatedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share options and savings related options.",
        "label": "Share Options And Savings Related Options [member]",
        "terseLabel": "Share Options and Savings-Related Options [member]"
       }
      }
     },
     "localname": "ShareOptionsAndSavingsRelatedOptionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShareValuePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share value plan.",
        "label": "Share Value Plan [member]",
        "terseLabel": "Share Value Plan [member]"
       }
      }
     },
     "localname": "ShareValuePlanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SharesAcquiredByEsopTrusts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares acquired by ESOP trusts.",
        "label": "Shares Acquired By ESOP Trusts",
        "negatedLabel": "Shares acquired by ESOP Trusts"
       }
      }
     },
     "localname": "SharesAcquiredByEsopTrusts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_SharesReceivedForEveryFiveExistingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares received for every five existing shares.",
        "label": "Shares Received For Every Five Existing Shares",
        "terseLabel": "Share received for every five existing shares"
       }
      }
     },
     "localname": "SharesReceivedForEveryFiveExistingShares",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_ShinglesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shingles.",
        "label": "Shingles [member]",
        "terseLabel": "Shingles [member]"
       }
      }
     },
     "localname": "ShinglesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShingrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shingrix.",
        "label": "Shingrix [Member]"
       }
      }
     },
     "localname": "ShingrixMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShionogiViiVHealthcareJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shionogi-ViiV healthcare joint venture.",
        "label": "Shionogi-ViiV Healthcare Joint Venture [member]",
        "terseLabel": "Shionogi ViiV healthcare joint venture [member]",
        "verboseLabel": "Shionogi-ViiV Healthcare JV [member]"
       }
      }
     },
     "localname": "ShionogiViiVHealthcareJointVentureMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShionogiViivHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shionogi ViiV healthcare.",
        "label": "Shionogi ViiV Healthcare [member]",
        "terseLabel": "Shionogi-ViiV Healthcare [member]",
        "verboseLabel": "Shionogi ViiV healthcare [member]"
       }
      }
     },
     "localname": "ShionogiViivHealthcareMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShortTermBorrowingsAttributedToContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Borrowings Attributed to Continuing Operations [Member]"
       }
      }
     },
     "localname": "ShortTermBorrowingsAttributedToContinuingOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShortTermBorrowingsAttributedToDiscontinuedOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Borrowings Attributed to Discontinued Operations [Member]"
       }
      }
     },
     "localname": "ShortTermBorrowingsAttributedToDiscontinuedOperationsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ShortTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term notes.",
        "label": "Short Term Notes [Member]",
        "terseLabel": "Short-term notes [Member]"
       }
      }
     },
     "localname": "ShortTermNotesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SierraOncologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sierra oncology inc.",
        "label": "Sierra Oncology Inc [Member]"
       }
      }
     },
     "localname": "SierraOncologyIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SierraOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sierra Oncology [member]",
        "label": "Sierra Oncology [Member]"
       }
      }
     },
     "localname": "SierraOncologyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SignificantAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant acquisitions.",
        "label": "Significant Acquisitions [Member]"
       }
      }
     },
     "localname": "SignificantAcquisitionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByProgrammeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SignificantCurrenciesAndTheRelevantExchangeRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about significant currencies and the relevant exchange rates.",
        "label": "Significant Currencies And The Relevant Exchange Rates",
        "terseLabel": "Summary of Currencies Translations and Relevant Exchange Rates"
       }
      }
     },
     "localname": "SignificantCurrenciesAndTheRelevantExchangeRates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_SixPointThreeSevenFiveNotesDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.375% Notes due 2038.",
        "label": "Six Point Three Seven Five Notes due 2038 [Member]",
        "terseLabel": "6.375% Notes due 2038 [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFiveNotesDue2038Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point three seven five percent European medium term note two thousand thirty nine.",
        "label": "Six Point Three Seven Five Percent Euro Medium Term Note Two Thousand Thirty Nine [Member]",
        "terseLabel": "6.375% Euro Medium Term Note 2039 [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentEuroMediumTermNoteTwoThousandThirtyNineMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point three seven five percent US medium term note two thousand thirty eight.",
        "label": "Six Point Three Seven Five Percent US Medium Term Note Two Thousand Thirty Eight [member]",
        "terseLabel": "6.375% US Medium Term Note 2038 [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SlpPartnershipAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SLP partnership agreement.",
        "label": "SLP Partnership Agreement [Member]",
        "terseLabel": "SLP Partnership Agreement [member]"
       }
      }
     },
     "localname": "SlpPartnershipAgreementMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SmithKlineBeechamLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SmithKline Beecham Limited.",
        "label": "Smith Kline Beecham Limited [member]",
        "terseLabel": "SmithKline Beecham Limited [member]"
       }
      }
     },
     "localname": "SmithKlineBeechamLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SpecialtyMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Medicines.",
        "label": "Specialty Medicine [Member]",
        "terseLabel": "Specialty Medicines [member]"
       }
      }
     },
     "localname": "SpecialtyMedicineMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SperoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spero.",
        "label": "Spero [Member]"
       }
      }
     },
     "localname": "SperoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_StateBankOfIndiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Bank of India.",
        "label": "State Bank Of India [member]",
        "terseLabel": "State Bank of India [member]"
       }
      }
     },
     "localname": "StateBankOfIndiaMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_StatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements [Line Items]",
        "terseLabel": "Statement [LineItems]"
       }
      }
     },
     "localname": "StatementsLineItems",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies",
      "http://www.gsk.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables",
      "http://www.gsk.com/role/NonControllingInterestsTables",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_StatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements [Table]",
        "terseLabel": "Statement [table]"
       }
      }
     },
     "localname": "StatementsTable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies",
      "http://www.gsk.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables",
      "http://www.gsk.com/role/NonControllingInterestsTables",
      "http://www.gsk.com/role/OperatingProfitTables",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_StiefelLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stiefel Laboratories, Inc.",
        "label": "Stiefel Laboratories Inc [member]",
        "terseLabel": "Stiefel Laboratories, Inc. [member]"
       }
      }
     },
     "localname": "StiefelLaboratoriesIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_StiefelTradeNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stiefel Trade Name [member]",
        "terseLabel": "Stiefel trade name [member]"
       }
      }
     },
     "localname": "StiefelTradeNameMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SubTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sub Total [Member]",
        "terseLabel": "Sub Total [Member]"
       }
      }
     },
     "localname": "SubTotalMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent recoveries of amounts provided for expected credit loss allowance.",
        "label": "Subsequent recoveries of amounts provided for expected credit loss allowance",
        "terseLabel": "Subsequent recoveries of amounts provided for"
       }
      }
     },
     "localname": "SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_SubsidiariesSharesTransferredToFundPensionSchemes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiaries shares transferred to fund pension schemes.",
        "label": "Subsidiaries Shares Transferred To Fund Pension Schemes",
        "verboseLabel": "Subsidiary shares transferred to fund pension schemes"
       }
      }
     },
     "localname": "SubsidiariesSharesTransferredToFundPensionSchemes",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_SubsidiarySharesTransferredIntoLimitedPartnerships": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary shares transferred into limited partnerships.",
        "label": "Subsidiary Shares Transferred Into Limited Partnerships",
        "terseLabel": "Subsidiary shares transferred into Limited Partnerships"
       }
      }
     },
     "localname": "SubsidiarySharesTransferredIntoLimitedPartnerships",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of receivables in other non current assets explanatory.",
        "label": "Summary Of Receivables In Other Non Current Assets Explanatory",
        "terseLabel": "Summary of Other Non-Current Assets"
       }
      }
     },
     "localname": "SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_SummaryOfTradePayablesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of trade payables explanatory.",
        "label": "Summary Of Trade Payables Explanatory [Text Block]",
        "terseLabel": "Summary of Trade and Other Payables"
       }
      }
     },
     "localname": "SummaryOfTradePayablesExplanatoryTextBlock",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gsk_SurrenderedSharesForEveryFourNewSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surrendered shares for every four new shares received.",
        "label": "Surrendered Shares For Every Four New Shares Received",
        "terseLabel": "Surrendered shares for every four new shares received"
       }
      }
     },
     "localname": "SurrenderedSharesForEveryFourNewSharesReceived",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "gsk_TaxEffectOfBenefitOfIntellectualPropertyIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of benefit of intellectual property incentives.",
        "label": "Tax Effect Of Benefit Of Intellectual Property Incentives",
        "terseLabel": "Benefit of intellectual property incentives"
       }
      }
     },
     "localname": "TaxEffectOfBenefitOfIntellectualPropertyIncentives",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxEffectOfChangeInTaxRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of change in tax rate.",
        "label": "Tax Effect Of Change In Tax Rate",
        "terseLabel": "Changes in Tax Rates"
       }
      }
     },
     "localname": "TaxEffectOfChangeInTaxRate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxEffectOfReassessmentsOfPriorYearEstimates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of reassessments of prior year estimates.",
        "label": "Tax Effect Of Reassessments Of Prior Year Estimates",
        "terseLabel": "Re-assessments of prior year current tax estimates"
       }
      }
     },
     "localname": "TaxEffectOfReassessmentsOfPriorYearEstimates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of reassessments\u00a0of prior year deferred tax estimates.",
        "label": "Tax Effect Of ReassessmentsOf Prior Year Deferred Tax Estimates",
        "terseLabel": "Re-assessments of prior year deferred tax estimates"
       }
      }
     },
     "localname": "TaxEffectOfReassessmentsofPriorYearDeferredTaxEstimates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxEffectOfResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of research and development credits.",
        "label": "Tax Effect of Research and Development Credits",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "TaxEffectOfResearchAndDevelopmentCredits",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax losses.",
        "label": "Tax losses",
        "terseLabel": "Tax losses"
       }
      }
     },
     "localname": "TaxLosses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax On Items Charged To Equity And Statement Of Comprehensive Income [Abstract]",
        "terseLabel": "Tax On Items Charged To Equity And Statement Of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "TaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_TaxRateEffectOfBenefitOfIntellectualPropertyIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate effect of benefit of intellectual property incentives.",
        "label": "Tax Rate Effect of Benefit of Intellectual Property Incentives",
        "terseLabel": "Benefit of intellectual property incentives"
       }
      }
     },
     "localname": "TaxRateEffectOfBenefitOfIntellectualPropertyIncentives",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxRateEffectOfChangeInTaxRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 8.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate effect of change in tax rate.",
        "label": "Tax Rate Effect Of Change In Tax Rate",
        "verboseLabel": "Changes in Tax Rates"
       }
      }
     },
     "localname": "TaxRateEffectOfChangeInTaxRate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rate Effect Of Permanent Differences On Disposals Acquisitions and Transfers.",
        "label": "Tax Rate Effect Of Permanent Differences On Disposals Acquisitions and Transfers",
        "terseLabel": "Permanent differences on disposals, acquisitions and transfers"
       }
      }
     },
     "localname": "TaxRateEffectOfPermanentDifferencesOnDisposalsAcquisitionsAndTransfers",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rate Effect Of Permanent Differences Percentage On Disposals Acquisitions and Transfers.",
        "label": "Tax Rate Effect Of Permanent Differences Percentage On Disposals Acquisitions and Transfers",
        "terseLabel": "Permanent differences on disposals, acquisitions and transfers"
       }
      }
     },
     "localname": "TaxRateEffectOfPermanentDifferencesPercentageOnDisposalsAcquisitionsAndTransfers",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxRateEffectOfReassessmentsOfPriorYearEstimates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate effect of reassessments of prior year estimates.",
        "label": "Tax Rate Effect of Reassessments of Prior Year Estimates",
        "terseLabel": "Re-assessments of prior year current tax estimates"
       }
      }
     },
     "localname": "TaxRateEffectOfReassessmentsOfPriorYearEstimates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 9.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate effect of reassessments\u00a0of prior year deferred tax estimates.",
        "label": "Tax Rate Effect Of ReassessmentsOf Prior Year Deferred Tax Estimates",
        "terseLabel": "Re-assessments of prior year deferred tax estimates"
       }
      }
     },
     "localname": "TaxRateEffectOfReassessmentsofPriorYearDeferredTaxEstimates",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxRateEffectOfResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate effect of research and development credits.",
        "label": "Tax Rate Effect of Research and Development Credits",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "TaxRateEffectOfResearchAndDevelopmentCredits",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_TaxReformsPeriodOfApplicationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Axis that defines period of applications for tax reforms.",
        "label": "Tax reforms period of application [axis]",
        "terseLabel": "Tax reforms period of application [axis]"
       }
      }
     },
     "localname": "TaxReformsPeriodOfApplicationAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_TaxReformsPeriodOfApplicationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domain member that defines period of applications for tax reforms.",
        "label": "Tax reforms period of application [domain]",
        "terseLabel": "Tax reforms period of application [domain]"
       }
      }
     },
     "localname": "TaxReformsPeriodOfApplicationDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TaxationRecognizedAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxation Recognized As Of Acquisition Date",
        "label": "Taxation Recognized As Of Acquisition Date",
        "terseLabel": "Taxation"
       }
      }
     },
     "localname": "TaxationRecognizedAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TesaroAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tesaro assets.",
        "label": "Tesaro Assets [Member]",
        "terseLabel": "Tesaro assets [member]"
       }
      }
     },
     "localname": "TesaroAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TesaroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tesaro.",
        "label": "Tesaro [member]",
        "verboseLabel": "Tesaro, Inc. [member]"
       }
      }
     },
     "localname": "TesaroMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Text block [abstract]",
        "label": "Text block [abstract]",
        "terseLabel": "Text block [abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://www.gsk.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gsk_ThailandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thailand",
        "label": "Thailand [Member]",
        "terseLabel": "Thailand [Member]"
       }
      }
     },
     "localname": "ThailandMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThirdInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third interim.",
        "label": "Third Interim [member]",
        "terseLabel": "Third interim [member]"
       }
      }
     },
     "localname": "ThirdInterimMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointEightSevenFiveNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Notes due 2028.",
        "label": "Three Point Eight Seven Five Notes due 2028 [Member]",
        "terseLabel": "3.875% Notes due 2028 [Member]"
       }
      }
     },
     "localname": "ThreePointEightSevenFiveNotesDue2028Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point eight seven five percentage US medium term note two thousand twenty eight.",
        "label": "Three Point Eight Seven Five Percentage U- S- Medium Term Note Two Thousand Twenty Eight [member]",
        "terseLabel": "3.875% US$ US Medium Term Note 2028 [member]"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point one two five percent euro medium term note two thousand thirty two.",
        "label": "Three Point One Two Five Percent Euro Medium Term Note Two Thousand Thirty Two [Member]",
        "terseLabel": "3.125% \u20ac Euro Medium Term Note 2032 [Member]"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentEuroMediumTermNoteTwoThousandThirtyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointSixTwoFiveNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2025.",
        "label": "Three Point Six Two Five Notes due 2025 [Member]",
        "terseLabel": "3.625% Notes due 2025 [Member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFiveNotesDue2025Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point six two five percent US medium term note two thousand twenty five.",
        "label": "Three point six two five percent US medium term note two thousand twenty five [member]",
        "terseLabel": "3.625% US$ US Medium Term Note 2025 [member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointThreeSevenFiveNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2029.",
        "label": "Three Point Three Seven Five Notes due 2029 [Member]",
        "terseLabel": "3.375% Notes due 2029 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFiveNotesDue2029Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point three seven five percent European medium term note two thousand twenty seven.",
        "label": "Three Point Three Seven Five Percent Euro Medium Term Note Two Thousand Twenty Seven [Member]",
        "terseLabel": "3.375% Euro Medium Term Note 2027 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentEuroMediumTermNoteTwoThousandTwentySevenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Seven Five Percent US Medium Term Note Two Thousand Twenty Nine.",
        "label": "Three Point Three Seven Five Percent US Medium Term Note Two Thousand Twenty Nine [Member]",
        "verboseLabel": "3.375% US$ US Medium Term Note 2029 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentUsMediumTermNoteTwoThousandTwentyNineMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point three seven five percentage US medium term note two thousand twenty three.",
        "label": "Three Point Three Seven Five Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]",
        "terseLabel": "3.375% US$ US Medium Term Note 2023 [member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointZeroNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Zero Notes Due 2023.",
        "label": "Three Point Zero Notes due 2024 [Member]",
        "terseLabel": "3.000% Notes due 2024 [Member]"
       }
      }
     },
     "localname": "ThreePointZeroNotesDue2024Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three point zero percent euro medium term note two thousand twenty seven.",
        "label": "Three Point Zero Percent Euro Medium Term Note Two Thousand Twenty Seven [Member]",
        "terseLabel": "3.000% \u20ac Euro Medium Term Note 2027 [Member]"
       }
      }
     },
     "localname": "ThreePointZeroPercentEuroMediumTermNoteTwoThousandTwentySevenMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Zero Percent US Medium Term Note Two Thousand Twenty Four.",
        "label": "Three Point Zero Percent US Medium Term Note Two Thousand Twenty Four [Member]",
        "verboseLabel": "3.000% US$ US Medium Term Note 2024 [Member]"
       }
      }
     },
     "localname": "ThreePointZeroPercentUsMediumTermNoteTwoThousandTwentyFourMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold for applying implicit rate of interest to annual lease payments.",
        "label": "Threshold For Applying Implicit Rate Of Interest To Annual Lease Payments",
        "terseLabel": "Lease liability on leases with annual payments"
       }
      }
     },
     "localname": "ThresholdForApplyingImplicitRateOfInterestToAnnualLeasePayments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TitleOfEachClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of Each Class.",
        "label": "Title Of Each Class [Axis]"
       }
      }
     },
     "localname": "TitleOfEachClassAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_TitleOfEachClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of Each Class.",
        "label": "Title Of Each Class [Domain]"
       }
      }
     },
     "localname": "TitleOfEachClassDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TitleOfIndividual1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual 1.",
        "label": "Title of individual 1 [axis]",
        "terseLabel": "Title of individual 1 [axis]"
       }
      }
     },
     "localname": "TitleOfIndividual1Axis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_TotalRestructuringCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total restructuring costs.",
        "label": "Total Restructuring Costs",
        "terseLabel": "Total restructuring costs"
       }
      }
     },
     "localname": "TotalRestructuringCosts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TotalValueOfTheInsuranceContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of the insurance contract.",
        "label": "Total Value of the Insurance Contract",
        "terseLabel": "Total value of the insurance contract"
       }
      }
     },
     "localname": "TotalValueOfTheInsuranceContract",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TotalfairValueOfDistributedandRetainBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total\u200b fair\u200b value of\u200b distributed\u200b and\u200b retain\u200b business.",
        "label": "Total Fair Value Of Distributed And Retain Business",
        "terseLabel": "Total fair value"
       }
      }
     },
     "localname": "TotalfairValueOfDistributedandRetainBusiness",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitAfterTaxationOnDemergerOfDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TradeAndOtherPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payable.",
        "label": "Trade and Other Payable [member]",
        "terseLabel": "Trade and other payable [member]"
       }
      }
     },
     "localname": "TradeAndOtherPayableMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payables, other provisions and other non-current liabilities in scope of IFRS 9.",
        "label": "Trade And Other Payables Other Provisions And Other Noncurrent Liabilities In Scope Of IFRS 9 [Member]",
        "terseLabel": "Trade and Other Payables, Other Provisions and Other Non-Current Liabilities in Scope of IFRS 9 [member]"
       }
      }
     },
     "localname": "TradeAndOtherPayablesOtherProvisionsAndOtherNoncurrentLiabilitiesInScopeOfIfrs9Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TradeAndOtherReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other receivable.",
        "label": "Trade And Other Receivable [member]",
        "terseLabel": "Trade and other receivable [member]"
       }
      }
     },
     "localname": "TradeAndOtherReceivableMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other receivables and other noncurrent assets in scope of IFRS 9.",
        "label": "Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]",
        "verboseLabel": "Trade And Other Receivables And Other Noncurrent Assets In Scope Of IFRS 9 [Member]"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesAndOtherNoncurrentAssetsInScopeOfIfrs9Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other receivables recognised as of acquisition date.",
        "label": "Trade And Other Receivables Recognised As Of Acquisition Date",
        "verboseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TradesAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trades and other payables.",
        "label": "Trades and other payables [member]",
        "terseLabel": "Trades and other payables [member]"
       }
      }
     },
     "localname": "TradesAndOtherPayablesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TransactionCostsOnDisposal": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs on disposal.",
        "label": "Transaction Costs On Disposal",
        "negatedLabel": "Transaction costs paid",
        "verboseLabel": "Deal and transaction costs"
       }
      }
     },
     "localname": "TransactionCostsOnDisposal",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransactionsWithNoncontoliingInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transactions with non-contoliing interests.",
        "label": "Transactions with noncontoliing interests",
        "terseLabel": "Transactions with non-controlling interests"
       }
      }
     },
     "localname": "TransactionsWithNoncontoliingInterests",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransferToAssetsHeldForSaleDistribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer to assets held for sale/distribution.",
        "label": "Transfer to Assets Held for Sale Distribution",
        "terseLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "TransferToAssetsHeldForSaleDistribution",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer to assets held for sale/distribution net defined benefit liability (asset).",
        "label": "Transfer To Assets Held For Sale Distribution Net Defined Benefit Liability Asset",
        "terseLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "TransferToAssetsHeldForSaleDistributionNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransferToPensionObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer to pension obligations.",
        "label": "Transfer To Pension Obligations",
        "negatedLabel": "Transfer to Pension obligations"
       }
      }
     },
     "localname": "TransferToPensionObligations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransfereeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transferee.",
        "label": "Transferee [Axis]"
       }
      }
     },
     "localname": "TransfereeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_TransfereeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transferee.",
        "label": "Transferee [Member]"
       }
      }
     },
     "localname": "TransfereeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TransferredToIncomeExpensesImpairmentsOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transferred to income expenses impairments of equity investments.",
        "label": "Transferred To Income Expenses Impairments Of Equity Investments",
        "terseLabel": "Transferred to income and expenses in the year on impairments of equity investments"
       }
      }
     },
     "localname": "TransferredToIncomeExpensesImpairmentsOfEquityInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransferredToRetainedEarningsOnDisposalOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transferred to retained earnings on disposal of equity investments.",
        "label": "Transferred to Retained earnings on disposal of equity investments",
        "terseLabel": "Transferred to retained earnings in the year on disposal of equity investments"
       }
      }
     },
     "localname": "TransferredToRetainedEarningsOnDisposalOfEquityInvestments",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfers out of level three of fair value hierarchy assets and liabilities.",
        "label": "Transfers Out Of Level Three Of Fair Value Hierarchy Assets And Liabilities",
        "negatedLabel": "Transfers from Level 3"
       }
      }
     },
     "localname": "TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_TsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR",
        "label": "TSR [Member]"
       }
      }
     },
     "localname": "TsrMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Eight Five Percent US Medium Term Note Two Thousand Twenty Two [member]",
        "label": "Two Point Eight Five Percent US Medium Term Note Two Thousand Twenty Two [member]",
        "terseLabel": "2.850% US$ US Medium Term Note 2022 [Member]"
       }
      }
     },
     "localname": "TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point eight percentage US medium term note two thousand twenty three.",
        "label": "Two Point Eight Percentage U- S- Medium Term Note Two Thousand Twenty Three [member]",
        "terseLabel": "2.800% US$ US Medium Term Note 2023 [member]"
       }
      }
     },
     "localname": "TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Eight Seven Five Percent US Medium Term Note Two Thousand Twenty Two.",
        "label": "Two Point Eight Seven Five Percent US Medium Term Note Two Thousand Twenty Two [Member]",
        "verboseLabel": "2.875% US$ US Medium Term Note 2022 [Member]"
       }
      }
     },
     "localname": "TwoPointEightSevenFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandAndTwentyOneBusinessDisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty One Business Disposals",
        "label": "Two Thousand And Twenty One Business Disposals [Member]",
        "terseLabel": "2021 disposals [Member ]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneBusinessDisposalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandAndTwentyTwoBusinessAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty two business acquisitions.",
        "label": "Two Thousand and Twenty Two Business Acquisitions [Member]",
        "terseLabel": "2022 Business acquisitions [member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyTwoBusinessAcquisitionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandAndTwentyTwoDisposalsDemergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty two disposals demerger.",
        "label": "Two Thousand And Twenty Two Disposals Demerger [Member]",
        "terseLabel": "2022 disposals demerger [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyTwoDisposalsDemergerMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Sixteen To Two Thousand Nineteen Performance Conditions [Member]",
        "terseLabel": "2016 to 2019 Performance conditions [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenToTwoThousandNineteenPerformanceConditionsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandThirtyOneAndThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand thirty one and thereafter.",
        "label": "Two Thousand Thirty One And Thereafter [Member]",
        "terseLabel": "2031 and thereafter [member]"
       }
      }
     },
     "localname": "TwoThousandThirtyOneAndThereafterMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandTwentyAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Acquisition",
        "label": "Two Thousand Twenty Acquisition [Member]",
        "terseLabel": "2020 Acquisition [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyAcquisitionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandTwentyBusinessDisposalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty business disposal.",
        "label": "Two Thousand Twenty Business Disposal [Member]",
        "terseLabel": "2020 Business disposals [member]"
       }
      }
     },
     "localname": "TwoThousandTwentyBusinessDisposalMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandTwentyBusinessDisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TwoThousandTwentyBusinessDisposalsMember",
        "label": "Two Thousand Twenty Business Disposals [Member]",
        "terseLabel": "2020 disposals [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyBusinessDisposalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandTwentyTwoAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twothous and twenty two acquisition .",
        "label": "Two Thousand Twenty Two Acquisition [Member]",
        "terseLabel": "2022 Acquisition [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoAcquisitionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwoThousandTwentyTwoBusinessDisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Business Disposals [Member]",
        "terseLabel": "2022 disposals [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoBusinessDisposalsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TwothousandtwentyoneacquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one acquisition .",
        "label": "TwoThousandTwentyOneAcquisition [Member]",
        "terseLabel": "2021 Acquisition [Member]"
       }
      }
     },
     "localname": "TwothousandtwentyoneacquisitionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_TypeOfIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type Of Income.",
        "label": "Type Of Income [Axis]"
       }
      }
     },
     "localname": "TypeOfIncomeAxis",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "gsk_TypeOfIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type Of Income.",
        "label": "Type Of Income [Domain]"
       }
      }
     },
     "localname": "TypeOfIncomeDomain",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_USPharmaceuticalsAndVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Pharmaceuticals and vaccines.",
        "label": "U S Pharmaceuticals And Vaccines [Member]",
        "terseLabel": "US Pharmaceuticals and vaccines [member]"
       }
      }
     },
     "localname": "USPharmaceuticalsAndVaccinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UkDefinedBenefitAndDefinedContributionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UK defined benefit and defined contribution plans.",
        "label": "UK Defined Benefit and Defined Contribution Plans [Member]"
       }
      }
     },
     "localname": "UkDefinedBenefitAndDefinedContributionPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UkDefinedBenefitPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UK defined benefit plans.",
        "label": "UK defined benefit plans [member]"
       }
      }
     },
     "localname": "UkDefinedBenefitPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UncertainTaxPositionsRecognised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions recognised.",
        "label": "Uncertain tax positions recognised",
        "terseLabel": "Uncertain tax position charge"
       }
      }
     },
     "localname": "UncertainTaxPositionsRecognised",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UnfundedDefinedBenefitPensionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded defined benefit pension plan.",
        "label": "Unfunded defined benefit pension plan [member]",
        "terseLabel": "Unfunded defined benefit pension plan [member]"
       }
      }
     },
     "localname": "UnfundedDefinedBenefitPensionPlanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UnfundedPostRetirementPensionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded post retirement pension plans.",
        "label": "Unfunded post retirement pension plans [member]",
        "terseLabel": "Unfunded post retirement healthcare schemes [member]"
       }
      }
     },
     "localname": "UnfundedPostRetirementPensionPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank.",
        "label": "United Bank for Africa, Zenith Bank, Access Bank and Stanbic IBTC Bank [Member]"
       }
      }
     },
     "localname": "UnitedBankForAfricaZenithBankAccessBankAndStanbicIbtcBankMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UnrecognisedDeferredTaxAssetOnCapitalLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognised deferred tax asset on capital losses",
        "label": "Unrecognised deferred tax asset on capital losses",
        "terseLabel": "Capital losses"
       }
      }
     },
     "localname": "UnrecognisedDeferredTaxAssetOnCapitalLosses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UnrecognisedDeferredTaxAssetOnTradingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognised deferred tax asset on trading losses",
        "label": "Unrecognised deferred tax asset on trading losses",
        "terseLabel": "Unrecognised deferred tax asset"
       }
      }
     },
     "localname": "UnrecognisedDeferredTaxAssetOnTradingLosses",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UnremittedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unremitted earnings.",
        "label": "Unremitted Earnings",
        "terseLabel": "Unremitted profits"
       }
      }
     },
     "localname": "UnremittedEarnings",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UnremittedProfitsForWhichDeferredTaxNotProvided": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unremitted profits for which deferred tax not provided.",
        "label": "Unremitted profits for which deferred tax not provided",
        "terseLabel": "Unremitted profits for which deferred tax not provided"
       }
      }
     },
     "localname": "UnremittedProfitsForWhichDeferredTaxNotProvided",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "upfront payment",
        "label": "upfront payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UpfrontSettlementIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront settlement income.",
        "label": "Upfront Settlement Income",
        "terseLabel": "Upfront settlement income"
       }
      }
     },
     "localname": "UpfrontSettlementIncome",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_UsCashBalancePensionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US cash balance pension plan [Member]",
        "terseLabel": "US cash balance pension plan [Member]"
       }
      }
     },
     "localname": "UsCashBalancePensionPlanMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UsCommercialPaperProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US commercial paper programme.",
        "label": "US Commercial Paper Program [member]",
        "terseLabel": "US commercial paper program [member]"
       }
      }
     },
     "localname": "UsCommercialPaperProgramMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UsDefinedBenefitAndDefinedContributionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US defined benefit and defined contribution plans.",
        "label": "US Defined Benefit and Defined Contribution Plans [Member]"
       }
      }
     },
     "localname": "UsDefinedBenefitAndDefinedContributionPlansMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Us treasury and treasury repo only money market funds.",
        "label": "US Treasury And Treasury Repo Only Money Market Funds",
        "terseLabel": "US Treasury and Treasury repo only money market funds"
       }
      }
     },
     "localname": "UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_VaccinesBusinessAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccines business acquisition.",
        "label": "Vaccines Business Acquisition [member]",
        "terseLabel": "Vaccines business acquisition [member]"
       }
      }
     },
     "localname": "VaccinesBusinessAcquisitionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccines.",
        "label": "Vaccines [member]",
        "terseLabel": "Vaccines [member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]",
        "label": "Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]",
        "terseLabel": "Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member]"
       }
      }
     },
     "localname": "VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variability in cash flows from a highly probable forecast transaction [member]",
        "label": "Variability in cash flows from a highly probable forecast transaction [member]",
        "terseLabel": "Variability in cash flows from a highly probable forecast transaction [member]"
       }
      }
     },
     "localname": "VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VariabilityInCashFlowsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variability in cash flows.",
        "label": "Variability in cash flows [member]",
        "terseLabel": "Variability in cash flows [member]"
       }
      }
     },
     "localname": "VariabilityInCashFlowsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VietnamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vietnam.",
        "label": "Vietnam [Member]",
        "terseLabel": "Vietnam [Member]"
       }
      }
     },
     "localname": "VietnamMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViiVHealthCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vii V health care.",
        "label": "Vii V Health Care [member]",
        "terseLabel": "ViiV healthcare [member]"
       }
      }
     },
     "localname": "ViiVHealthCareMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/NonControllingInterestsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViiVHealthCareUnitedKingdomLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare UK Limited.",
        "label": "Vii V Health Care United Kingdom Limited [member]",
        "terseLabel": "ViiV Healthcare UK Limited [member]"
       }
      }
     },
     "localname": "ViiVHealthCareUnitedKingdomLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company.",
        "label": "Vii V Healthcare Company [Member]",
        "verboseLabel": "ViiV Healthcare Company [member]"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViiVHealthcareSASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare SAS.",
        "label": "Vii V Healthcare SAS [member]",
        "terseLabel": "ViiV Healthcare SAS [member]"
       }
      }
     },
     "localname": "ViiVHealthcareSASMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareFinanceLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Finance Limited.",
        "label": "ViiV Healthcare Finance Limited [Member]"
       }
      }
     },
     "localname": "ViivHealthcareFinanceLimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare GmbH.",
        "label": "ViiV Healthcare GmbH [Member]",
        "terseLabel": "ViiV Healthcare GmbH [Member]"
       }
      }
     },
     "localname": "ViivHealthcareGmbhMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareK.kMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare K.K.",
        "label": "ViiV Healthcare K.K [Member]",
        "terseLabel": "ViiV Healthcare K.K [Member]"
       }
      }
     },
     "localname": "ViivHealthcareK.kMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareSRLItalyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare S.r.l. (Italy).",
        "label": "ViiV Healthcare S R L Italy [Member]",
        "terseLabel": "ViiV Healthcare S.r.l. [Member]"
       }
      }
     },
     "localname": "ViivHealthcareSRLItalyMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareUlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare ULC.",
        "label": "ViiV Healthcare ULC [Member]",
        "terseLabel": "ViiV Healthcare ULC [Member]"
       }
      }
     },
     "localname": "ViivHealthcareUlcMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ViivHealthcareUnitedKingdomNo.3LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV healthcare united kingdom no.3 limited.",
        "label": "ViiV Healthcare United Kingdom No.3 Limited [Member]",
        "terseLabel": "ViiV Healthcare UK No.3 Limited [member]"
       }
      }
     },
     "localname": "ViivHealthcareUnitedKingdomNo.3LimitedMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VirAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vir Assets [Member]"
       }
      }
     },
     "localname": "VirAssetsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VirBiotechnologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vir biotechnology inc.",
        "label": "Vir Biotechnology Inc [Member]",
        "verboseLabel": "Vir Biotechnology, Inc [member]"
       }
      }
     },
     "localname": "VirBiotechnologyIncMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_VoluntaryCashContributionsMadeToThePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voluntary cash contributions made to the plan.",
        "label": "Voluntary Cash Contributions Made To The Plan",
        "terseLabel": "Voluntary Cash Contributions Made To The Plan"
       }
      }
     },
     "localname": "VoluntaryCashContributionsMadeToThePlan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_WagesAndSalariesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wages and salaries payable.",
        "label": "Wages And Salaries Payable",
        "terseLabel": "Wages and salaries"
       }
      }
     },
     "localname": "WagesAndSalariesPayable",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average cost of capital after tax discount rate percentage.",
        "label": "Weighted average cost of capital after tax discount rate percentage",
        "terseLabel": "Weighted average cost of capital post tax discount rate percentage"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average cost of capital pre- tax discount rate percentage.",
        "label": "Weighted Average Cost Of Capital Pre Tax Discount Rate Percentage",
        "terseLabel": "Weighted average cost of capital pre-tax discount rate percentage"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_WeightedAverageDurationOfDefinedBenefitObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average duration of defined benefit obligations.",
        "label": "Weighted average duration of defined benefit obligations",
        "terseLabel": "Weighted average duration of the defined benefit obligation"
       }
      }
     },
     "localname": "WeightedAverageDurationOfDefinedBenefitObligations",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of share option exercisable in share based payment arrangement.",
        "label": "Weighted average exercise price of share option exercisable in share based payment arrangement",
        "terseLabel": "Range of exercise prices on options outstanding at year end"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of share option exercised in share based payment arrangement.",
        "label": "Weighted average exercise price of share option exercised in share based payment arrangement",
        "terseLabel": "Weighted average market price on exercise during year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of share option outstanding in share based payment arrangement.",
        "label": "Weighted average exercise price of share option outstanding in share based payment arrangement",
        "terseLabel": "Share option schemes - shares Weighted exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value at measurement date share awards granted per share.",
        "label": "Weighted Average Fair Value at Measurement Date Share Awards Granted Per share",
        "terseLabel": "Weighted average fair value of awards",
        "verboseLabel": "Weighted fair value, Awards granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value of share option granted in share based payment arrangement.",
        "label": "Weighted average fair value of share option granted in share based payment arrangement",
        "terseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "gsk_WeightedAverageInterestRateOnBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on borrowings.",
        "label": "Weighted Average Interest Rate On Borrowings",
        "terseLabel": "Weighted average interest rate of borrowings"
       }
      }
     },
     "localname": "WeightedAverageInterestRateOnBorrowings",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on current bank loans and overdrafts.",
        "label": "Weighted average interest rate on current bank loans and overdrafts",
        "terseLabel": "Weighted average interest rate on current bank loans and overdrafts"
       }
      }
     },
     "localname": "WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "gsk_WeightedAverageRemainingContractualLifeOfOutstandingShareOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual life of outstanding share option.",
        "label": "Weighted average remaining contractual life of outstanding share option",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOption",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "gsk_WholesaleAndRetailCreditRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wholesale and retail credit risk [Member]"
       }
      }
     },
     "localname": "WholesaleAndRetailCreditRiskMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_WholesalerInTheUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler in the US.",
        "label": "Wholesaler In The US [Member]"
       }
      }
     },
     "localname": "WholesalerInTheUsMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_Wholesalers1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesalers 1.",
        "label": "Wholesalers 1 [member]",
        "terseLabel": "Wholesalers 1 [member]"
       }
      }
     },
     "localname": "Wholesalers1Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_Wholesalers2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesalers 2.",
        "label": "Wholesalers 2 [member]",
        "terseLabel": "Wholesalers 2 [member]"
       }
      }
     },
     "localname": "Wholesalers2Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_Wholesalers3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesalers 3.",
        "label": "Wholesalers 3 [member]",
        "terseLabel": "Wholesalers 3 [member]"
       }
      }
     },
     "localname": "Wholesalers3Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_WritedownOfSharesHeldByEmployeeStockOwnershipPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-down of shares held by ESOP trusts.",
        "label": "Write-down of shares held by ESOP Trusts",
        "terseLabel": "Write-down of shares held by ESOP Trusts"
       }
      }
     },
     "localname": "WritedownOfSharesHeldByEmployeeStockOwnershipPlan",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_WritedownOfSharesHeldByEsopTrusts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Writedown of shares held by Esop trusts.",
        "label": "Writedown Of Shares Held By Esop Trusts",
        "terseLabel": "Write-down of shares held by ESOP Trusts"
       }
      }
     },
     "localname": "WritedownOfSharesHeldByEsopTrusts",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gsk_ZeroPointFiveThreeFourNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.534% Notes due 2023.",
        "label": "Zero Point Five Three Four Notes Due 2023 [Member]",
        "terseLabel": "0.534% Notes due 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointFiveThreeFourNotesDue2023Member",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point five three four percent us medium term note two thousand twenty three .",
        "label": "Zero Point Five Three Four Percent Us Medium Term Note Two Thousand Twenty Three [Member]",
        "terseLabel": "0.534% US$ Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointFiveThreeFourPercentUsMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Five Three Four US Medium Term Note Two Thousand Twenty Three.",
        "label": "Zero Point Five Three Four US Medium Term Note Two Thousand Twenty Three [Member]",
        "terseLabel": "0.534% US$ US Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointFiveThreeFourUsMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point One Two Five Percent European Medium Term Note Two Thousands And Twenty Three.",
        "label": "Zero Point One Two Five Percent Euro Medium Term Note Two Thousands And Twenty Three [Member]",
        "terseLabel": "0.125% \u20ac Euro Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointOneTwoFivePercentEuroMediumTermNoteTwoThousandsAndTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point one two five percent european medium term note two thousand twenty three.",
        "label": "Zero Point One Two Five Percent European Medium Term Note Two Thousand Twenty Three [Member]",
        "terseLabel": "0.125% \u20ac European Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointOneTwoFivePercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point zero percent european medium term note two thousand twenty three.",
        "label": "Zero Point Zero Percent European Medium Term Note Two Thousand Twenty Three [Member]",
        "terseLabel": "0.000% \u20ac European Medium Term Note 20230.000% \u20ac European Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointZeroPercentEuropeanMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point zero percent us medium term note two thousand twenty three.",
        "label": "Zero Point Zero Percent Us Medium Term Note Two Thousand Twenty Three [Member]",
        "terseLabel": "0.000% US$ US Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointZeroPercentUsMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "gsk_ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Zero Percentage European Medium Term Note Two Thousand Twenty Three.",
        "label": "Zero Point Zero Percentage Euro Medium Term Note Two Thousand Twenty Three [Member]",
        "verboseLabel": "0.000% \u20ac Euro Medium Term Note 2023 [Member]"
       }
      }
     },
     "localname": "ZeroPointZeroPercentageEuroMediumTermNoteTwoThousandTwentyThreeMember",
     "nsuri": "http://www.gsk.com/20221231",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Accruals": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals",
        "terseLabel": "Accruals"
       }
      }
     },
     "localname": "Accruals",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccruedIncomeOtherThanContractAssets": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing income that has been earned but is not yet a receivable, other than contract assets. [Refer: Contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accrued income other than contract assets",
        "terseLabel": "Accrued income"
       }
      }
     },
     "localname": "AccruedIncomeOtherThanContractAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "auth_ref": [
      "r77",
      "r90",
      "r186",
      "r203",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Depreciation, amortisation, and impairment [member]"
       }
      }
     },
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r90",
      "r551",
      "r564",
      "r568",
      "r569"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Depreciation and amortisation [member]"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The accumulated amount of fair value hedge adjustment on a hedged item that is included in the carrying amount of the hedged item, recognised in the statement of financial position as an asset. [Refer: Hedged items [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated fair value hedge adjustment on hedged item included in carrying amount, assets",
        "terseLabel": "Due to hedged item affecting balance sheet"
       }
      }
     },
     "localname": "AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "auth_ref": [
      "r313",
      "r362",
      "r494",
      "r517",
      "r525",
      "r551",
      "r564",
      "r568",
      "r569"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated impairment [member]",
        "terseLabel": "Impairment [member]"
       }
      }
     },
     "localname": "AccumulatedImpairmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value",
        "verboseLabel": "Total cash consideration"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, intangible assets other than goodwill",
        "verboseLabel": "Additions through business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, other provisions",
        "terseLabel": "Additions through business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, property, plant and equipment",
        "terseLabel": "Additions through business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates",
        "verboseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of inflation",
        "verboseLabel": "Inflation rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of pension increases",
        "terseLabel": "Expected pension increases"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases",
        "terseLabel": "Rate of increase of future earnings"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [axis]",
        "terseLabel": "Actuarial assumptions [axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [member]",
        "terseLabel": "Actuarial assumptions [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)",
        "negatedLabel": "Gain from change in demographic assumptions",
        "terseLabel": "Gain from change in demographic assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)",
        "negatedLabel": "(Loss)/gain from change in financial assumptions",
        "verboseLabel": "Gain/(loss) from change in financial assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from experience adjustments, net defined benefit liability (asset)",
        "negatedTerseLabel": "Experience gains/(losses)",
        "terseLabel": "Experience gains"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "terseLabel": "Charge for the year"
       }
      }
     },
     "localname": "AdditionalProvisionsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalRecognitionGoodwill": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional recognition, goodwill",
        "verboseLabel": "Additions through business combinations (Note \u2022)"
       }
      }
     },
     "localname": "AdditionalRecognitionGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "totalLabel": "Diluted"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for amortisation expense",
        "terseLabel": "Amortisation of intangible assets"
       }
      }
     },
     "localname": "AdjustmentsForAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for current tax of prior periods",
        "verboseLabel": "Charge/(credit) in respect of prior periods"
       }
      }
     },
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease/(increase)in inventories"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "terseLabel": "(Increase) in other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for fair value losses (gains)",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "AdjustmentsForFairValueGainsLosses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income (cost)",
        "negatedLabel": "Finance expense net of finance income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals investments in subsidiaries, joint ventures and associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates",
        "negatedLabel": "Loss on sale of investments in associates"
       }
      }
     },
     "localname": "AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Tax on profits"
       }
      }
     },
     "localname": "AdjustmentsForIncomeTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in employee benefit liabilities",
        "terseLabel": "Increase/(decrease) in pension and other provisions"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other operating payables",
        "terseLabel": "Increase in other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "terseLabel": "Increase in trade payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 4.0,
       "parentTag": "gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss)",
        "terseLabel": "Adjustments reconciling profit after tax to operating cash flows"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based incentive plans"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdvertisingExpense": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from advertising."
       }
      },
      "en-us": {
       "role": {
        "label": "Advertising expense",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember": {
     "auth_ref": [
      "r242",
      "r426",
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the aggregation of associates that are individually immaterial. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated individually immaterial associates [member]"
       }
      }
     },
     "localname": "AggregatedIndividuallyImmaterialAssociatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r201",
      "r205",
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]",
        "terseLabel": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r32",
      "r281",
      "r292",
      "r293",
      "r337",
      "r412",
      "r413",
      "r415",
      "r421",
      "r457",
      "r496",
      "r501"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r107",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortisation of intangible assets"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "UK statutory rate of taxation",
        "verboseLabel": "Tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r28",
      "r266",
      "r267",
      "r272",
      "r396",
      "r400"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "verboseLabel": "Net assets sold:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [axis]",
        "terseLabel": "Assets and liabilities [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [axis]",
        "terseLabel": "Assets and liabilities classified as held for sale [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are classified as held for sale. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [member]",
        "terseLabel": "Assets held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [member]",
        "terseLabel": "Assets and liabilities [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are not classified as held for sale. It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities not classified as held for sale [member]",
        "terseLabel": "Assets and liabilities not classified as held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets held to hedge liabilities arising from financing activities. [Refer: Assets; Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets held to hedge liabilities arising from financing activities [member]",
        "terseLabel": "Assets held to hedge liabilities arising from financing activities [member]"
       }
      }
     },
     "localname": "AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsTransferredToStructuredEntitiesAtTimeOfTransfer": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at the time of transfer, of all assets transferred to structured entities. [Refer: Unconsolidated structured entities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets transferred to structured entities, at time of transfer",
        "terseLabel": "Transferred to assets held for sale"
       }
      }
     },
     "localname": "AssetsTransferredToStructuredEntitiesAtTimeOfTransfer",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssociatesMember": {
     "auth_ref": [
      "r130",
      "r140",
      "r144",
      "r264",
      "r425",
      "r430"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entities over which the investor has significant influence."
       }
      },
      "en-us": {
       "role": {
        "label": "Associates [member]",
        "terseLabel": "Associates [member]"
       }
      }
     },
     "localname": "AssociatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AtFairValueMember": {
     "auth_ref": [
      "r201",
      "r205",
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "At fair value [member]",
        "terseLabel": "At Fair Value [Member]"
       }
      }
     },
     "localname": "AtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AuditorsRemuneration": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor's remuneration",
        "terseLabel": "Fees payable to the company's auditor and its associates in relation to the Group"
       }
      }
     },
     "localname": "AuditorsRemuneration",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AuditorsRemunerationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration [abstract]",
        "terseLabel": "Auditor's remuneration [abstract]"
       }
      }
     },
     "localname": "AuditorsRemunerationAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for audit services",
        "terseLabel": "Audit"
       }
      }
     },
     "localname": "AuditorsRemunerationForAuditServices",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for other services",
        "verboseLabel": "All other services"
       }
      }
     },
     "localname": "AuditorsRemunerationForOtherServices",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Average effective tax rate",
        "totalLabel": "Tax charge/tax rate"
       }
      }
     },
     "localname": "AverageEffectiveTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      },
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average exchange rate",
        "verboseLabel": "Average rates"
       }
      }
     },
     "localname": "AverageForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Average number of employees",
        "totalLabel": "Average number of employees"
       }
      }
     },
     "localname": "AverageNumberOfEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_BalancesWithBanks": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      },
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Balances or deposits with banks"
       }
      }
     },
     "localname": "BalancesWithBanks",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "auth_ref": [
      "r497",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Bank borrowings, undiscounted cash flows",
        "negatedLabel": "Debt"
       }
      }
     },
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Bank overdrafts",
        "negatedPeriodEndLabel": "Overdrafts"
       }
      }
     },
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "totalLabel": "Total basic earnings per share",
        "verboseLabel": "Total Basic earnings per share (pence)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from continuing operations",
        "terseLabel": "Basic earnings per share (pence) from continuing operations",
        "verboseLabel": "Basic earnings per share from continuing operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Basic earnings per share from discontinued operations",
        "label": "Basic earnings (loss) per share from discontinued operations",
        "terseLabel": "Basic earnings per share (pence) from discontinued operations",
        "verboseLabel": "Earnings per share from discontinued operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings",
        "negatedLabel": "Net debt",
        "negatedPeriodEndLabel": "Net debt at end of year",
        "negatedPeriodStartLabel": "Net debt, at beginning of year, as adjusted",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings [abstract]",
        "terseLabel": "Short-term borrowings:"
       }
      }
     },
     "localname": "BorrowingsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]",
        "terseLabel": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]",
        "terseLabel": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Borrowings, interest rate"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r275",
      "r298",
      "r415",
      "r480",
      "r482",
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]",
        "verboseLabel": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]",
        "terseLabel": "Business combinations [axis]",
        "verboseLabel": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/NonControllingInterestsTables",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BusinessCombinationsMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for transactions or other events in which an acquirer obtains control of one or more businesses. Transactions sometimes referred to as 'true mergers' or 'mergers of equals' are also business combinations as that term is used in IFRS 3."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [member]",
        "terseLabel": "Business combinations [member]"
       }
      }
     },
     "localname": "BusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CapitalRedemptionReserveMember": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the reserve for the redemption of the entity's own shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital redemption reserve [member]",
        "terseLabel": "Capital redemption reserve [member]"
       }
      }
     },
     "localname": "CapitalRedemptionReserveMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Capitalisation rate of borrowing costs eligible for capitalisation",
        "terseLabel": "Weighted average interest rate for capitalised borrowing costs"
       }
      }
     },
     "localname": "CapitalisationRateOfBorrowingCostsEligibleForCapitalisation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r77",
      "r86",
      "r186",
      "r192",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r313",
      "r362",
      "r363",
      "r588",
      "r590"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r86",
      "r192",
      "r202",
      "r204",
      "r205",
      "r313",
      "r362",
      "r363",
      "r517",
      "r524"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash at bank and in hand"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r20",
      "r221",
      "r254"
     ],
     "calculation": {
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 14.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, amount contributed to fair value of plan assets",
        "terseLabel": "Cash And cash equivalents contributed to fair value of plan assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of significant cash and cash equivalent balances held by the entity that are not available for use by the group. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents held by entity unavailable for use by group",
        "terseLabel": "Cash and cash equivalents not available for general use"
       }
      }
     },
     "localname": "CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents if different from statement of financial position",
        "periodEndLabel": "Cash and bank overdrafts at the end of year",
        "periodStartLabel": "Cash and bank overdrafts at the beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents if different from statement of financial position [abstract]",
        "terseLabel": "Cash and bank overdrafts at end of year comprise:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents in subsidiary or businesses acquired or disposed",
        "verboseLabel": "Cash and cash equivalents acquired/(divested)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowHedgesMember": {
     "auth_ref": [
      "r199",
      "r341",
      "r348",
      "r355"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flow hedges [member]",
        "terseLabel": "Cash Flow Hedges [member]",
        "verboseLabel": "Cash flow hedges [member]"
       }
      }
     },
     "localname": "CashFlowHedgesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 27.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities",
        "terseLabel": "Disposal of businesses"
       }
      }
     },
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r207",
      "r223"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "terseLabel": "Net cash outflow from financing activities",
        "totalLabel": "Total net cash inflow/(outflow) from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flow from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, continuing operations",
        "totalLabel": "Net cash outflow from continuing financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, discontinued operations",
        "terseLabel": "Net financing cash flows attributable to discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r207",
      "r223"
     ],
     "calculation": {
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "terseLabel": "Net cash outflow from financing activities",
        "totalLabel": "Total net cash (outflow)/inflow from investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flow from investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 19.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, continuing operations",
        "totalLabel": "Net cash outflow from continuing investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 34.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, discontinued operations",
        "terseLabel": "Net cash investing cash flows attributable to discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r207",
      "r223"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "terseLabel": "Net cash inflow from operating activities",
        "totalLabel": "Total net cash inflows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flow from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, continuing operations",
        "terseLabel": "Operating cash flow from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, discontinued operations",
        "terseLabel": "Operating cash flow from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "auth_ref": [
      "r471",
      "r475"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "verboseLabel": "Total cash generated from operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 26.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities",
        "negatedLabel": "Purchase of businesses, net of cash acquired"
       }
      }
     },
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashTransferred": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Cash and cash equivalents",
        "label": "Cash transferred",
        "verboseLabel": "Cash consideration"
       }
      }
     },
     "localname": "CashTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]",
        "terseLabel": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]",
        "terseLabel": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]",
        "terseLabel": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in deferred tax liability (asset) [abstract]",
        "terseLabel": "Changes in deferred tax liability (asset) [abstract]"
       }
      }
     },
     "localname": "ChangesInDeferredTaxLiabilityAssetAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInIntangibleAssetsAndGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in intangible assets and goodwill [abstract]",
        "terseLabel": "PP&amp;E, intangible asset and goodwill impairment by segment"
       }
      }
     },
     "localname": "ChangesInIntangibleAssetsAndGoodwillAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r154",
      "r158",
      "r274",
      "r291"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]",
        "terseLabel": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r154",
      "r274",
      "r291"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]",
        "terseLabel": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "auth_ref": [
      "r182",
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of contingent liabilities [axis]",
        "terseLabel": "Classes of contingent liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r374",
      "r375",
      "r411",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r362",
      "r366",
      "r368",
      "r369"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r362",
      "r366",
      "r368",
      "r369"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial Instruments, Class [Member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r374",
      "r375",
      "r411",
      "r423"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]",
        "terseLabel": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]",
        "terseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of current inventories [abstract]",
        "terseLabel": "Inventories:"
       }
      }
     },
     "localname": "ClassesOfInventoriesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]",
        "terseLabel": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      },
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Period end rates"
       }
      }
     },
     "localname": "ClosingForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_CommercialPapersIssued": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Commercial papers issued",
        "negatedLabel": "Commercial paper",
        "terseLabel": "Commercial paper issued",
        "verboseLabel": "Short-term finance access"
       }
      }
     },
     "localname": "CommercialPapersIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that may be subsequently reclassified to income statement:",
        "verboseLabel": "Items that may be subsequently reclassified to continuing operations income statement:"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that will not be reclassified to income statement:",
        "verboseLabel": "Items that will not be reclassified to continuing operations income statement:"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r2",
      "r47",
      "r230",
      "r232",
      "r249",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "positiveLabel": "Total comprehensive income for the year",
        "terseLabel": "Share of total comprehensive income/(expense)",
        "totalLabel": "Total comprehensive income for the year",
        "verboseLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "terseLabel": "Total comprehensive income for the year attributable to:"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r2",
      "r50"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "terseLabel": "Non-controlling interests",
        "totalLabel": "Total comprehensive income income/(expense)"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r2",
      "r51"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "terseLabel": "Shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeFromContinuingOperations": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The comprehensive income from continuing operations. [Refer: Continuing operations [member]; Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income from continuing operations",
        "terseLabel": "Other comprehensive (expense)/income for the year from continuing operations"
       }
      }
     },
     "localname": "ComprehensiveIncomeFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The comprehensive income from discontinued operations. [Refer: Discontinued operations [member]; Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income from discontinued operations",
        "terseLabel": "Other comprehensive (expense)/income for the year from discontinued operations"
       }
      }
     },
     "localname": "ComprehensiveIncomeFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerSoftware": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software",
        "terseLabel": "Net book value of computer software"
       }
      }
     },
     "localname": "ComputerSoftware",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerSoftwareMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software [member]",
        "terseLabel": "Computer software [member]"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ConsolidatedStructuredEntitiesAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Consolidated structured entities [axis]"
       }
      }
     },
     "localname": "ConsolidatedStructuredEntitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Construction in progress [member]",
        "terseLabel": "Assets in construction [member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an obligation of the acquirer to transfer additional assets or equity interests to the former owners of an acquiree as part of the exchange for control of the acquiree if specified future events occur or conditions are met."
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration [member]",
        "terseLabel": "Contingent Consideration [member]"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "auth_ref": [
      "r183",
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities [member]",
        "terseLabel": "Contingent liabilities [member]"
       }
      }
     },
     "localname": "ContingentLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities recognised as of acquisition date",
        "negatedLabel": "Contingent consideration liabilities",
        "terseLabel": "Contingent liabilities recognised as of acquisition date"
       }
      }
     },
     "localname": "ContingentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities recognised in business combination",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contingent consideration liabilities",
        "verboseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing and discontinued operations [axis]"
       }
      }
     },
     "localname": "ContinuingAndDiscontinuedOperationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]",
        "terseLabel": "Continuing involvement in derecognised financial assets by type of instrument [axis]"
       }
      }
     },
     "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ContinuingOperationsMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing operations [member]"
       }
      }
     },
     "localname": "ContinuingOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r277",
      "r279"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "terseLabel": "Deferred income"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 1.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Contractual commitments for acquisition of intangible assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "ContractualCommitmentsForAcquisitionOfIntangibleAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail": {
       "order": 2.0,
       "parentTag": "gsk_ContractualObligationsAndCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contractual commitments for acquisition of property, plant and equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CommitmentsScheduleOfContractualObligationsAndCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by employer, net defined benefit liability (asset)",
        "negatedLabel": "Employer contributions",
        "terseLabel": "Employer contributions",
        "verboseLabel": "Additional contributions"
       }
      }
     },
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by plan participants, net defined benefit liability (asset)",
        "terseLabel": "Scheme participants' contributions"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan, net defined benefit liability (asset)",
        "terseLabel": "Contributions to plan, net defined benefit liability (asset)"
       }
      }
     },
     "localname": "ContributionsToPlanNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of inventories recognised as expense during period",
        "terseLabel": "Cost of inventories included in cost of sales"
       }
      }
     },
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r0",
      "r64"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 10.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0
      },
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail": {
       "order": 1.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSalesMember": {
     "auth_ref": [
      "r537",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales [member]",
        "terseLabel": "Cost of sales [member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]",
        "terseLabel": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [member]",
        "terseLabel": "Counterparties [member]"
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfDomicileMember": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office."
       }
      },
      "en-us": {
       "role": {
        "label": "Country of domicile [member]",
        "verboseLabel": "England [member]"
       }
      }
     },
     "localname": "CountryOfDomicileMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "auth_ref": [
      "r138",
      "r142",
      "r235",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary",
        "terseLabel": "Country of incorporation"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CreditExposure": {
     "auth_ref": [
      "r515",
      "r518",
      "r521"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exposure to loss resulting from credit risk. [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit exposure",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "CreditExposure",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CreditImpairmentOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r362",
      "r368"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Credit impairment of financial instruments [axis]",
        "terseLabel": "Credit impairment of financial instruments [axis]"
       }
      }
     },
     "localname": "CreditImpairmentOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CreditImpairmentOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r362",
      "r368"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all statuses of credit impairment of financial instruments. A financial instrument is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial instrument have occurred. This member also represents the standard value for the 'Credit impairment of financial instruments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Credit impairment of financial instruments [member]",
        "terseLabel": "Credit impairment of financial instruments [member]"
       }
      }
     },
     "localname": "CreditImpairmentOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r491"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit Risk [member]",
        "terseLabel": "Credit risk [member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cumulative gain (loss) on disposal of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cumulative gain (loss) on disposal of investments in equity instruments designated at fair value through other comprehensive income",
        "terseLabel": "Cumulative gain loss on disposal of investments"
       }
      }
     },
     "localname": "CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r386",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk [member]"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate current and deferred tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Deferred tax relating to items credited (charged) directly to equity; Retained earnings; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current and deferred tax relating to items credited (charged) directly to equity",
        "totalLabel": "Total credit to equity and statement of comprehensive income"
       }
      }
     },
     "localname": "CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r33",
      "r245",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentDerivativeFinancialAssets": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 12.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current derivative financial assets",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "CurrentDerivativeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 32.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "negatedLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "CurrentDerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDividendPayables": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current dividend payables. [Refer: Dividend payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current dividend payables",
        "terseLabel": "Provision for dividend payable"
       }
      }
     },
     "localname": "CurrentDividendPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading": {
     "auth_ref": [
      "r439",
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 16.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets measured at fair value through profit or loss classified as held for trading. [Refer: Financial assets at fair value through profit or loss, classified as held for trading]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current financial assets at fair value through profit or loss, classified as held for trading",
        "periodEndLabel": "At 31 December",
        "periodStartLabel": "At 1 January",
        "terseLabel": "Current equity investments"
       }
      }
     },
     "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "negatedTerseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r34",
      "r247",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 28.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "negatedLabel": "Current liabilities",
        "negatedTotalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current payables on social security and taxes other than income tax",
        "terseLabel": "Social security"
       }
      }
     },
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current service cost, net defined benefit liability (asset)",
        "negatedLabel": "Service cost",
        "terseLabel": "Current service cost"
       }
      }
     },
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxAssets": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 10.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax assets",
        "terseLabel": "Current tax recoverable",
        "verboseLabel": "Tax recoverable, current"
       }
      }
     },
     "localname": "CurrentTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax expense (income)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "totalLabel": "Current taxation"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 33.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "negatedTerseLabel": "Current tax payable",
        "terseLabel": "Tax payable, current"
       }
      }
     },
     "localname": "CurrentTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 37.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, non-current",
        "negatedLabel": "Corporation tax payable",
        "terseLabel": "Tax payable, non-current"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Retained earnings; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax relating to items credited (charged) directly to equity",
        "totalLabel": "Total equity and comprehensive income"
       }
      }
     },
     "localname": "CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for customer-related intangible assets acquired in a business combination. [Refer: Customer-related intangible assets [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Customer-related intangible assets recognised as of acquisition date",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) through tax on share-based payment transactions, equity",
        "negatedLabel": "Tax on share-based incentive plans"
       }
      }
     },
     "localname": "DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughClassifiedAsHeldForSaleGoodwill": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in goodwill due to classification as held for sale. [Refer: Goodwill; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through classified as held for sale, goodwill",
        "terseLabel": "Transfer to assets held for sale/distribution",
        "verboseLabel": "Goodwiil\u00a0Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "DecreaseThroughClassifiedAsHeldForSaleGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through classified as held for sale, property, plant and equipment",
        "negatedLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssets": {
     "auth_ref": [
      "r25",
      "r29",
      "r72"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 23.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "terseLabel": "Deferred taxation"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "terseLabel": "Credit/(charge) to income statement"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r25",
      "r29",
      "r72"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 38.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liabilities",
        "terseLabel": "Provision for deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "periodEndLabel": "At 31 December 2022",
        "periodStartLabel": "At 1 January 2021",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/TaxationSummaryOfNetDeferredTaxAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax relating to items credited (charged) directly to equity",
        "totalLabel": "Total equity and comprehensive income"
       }
      }
     },
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, at present value",
        "negatedLabel": "Defined benefit obligation",
        "negatedPeriodEndLabel": "Obligations ending balance",
        "negatedPeriodStartLabel": "Obligations beginning balance",
        "negatedTerseLabel": "Present value of scheme obligations",
        "terseLabel": "Defined benefit pension obligation analysed by membership category",
        "verboseLabel": "Post-retirement benefit obligation analysed by membership category"
       }
      }
     },
     "localname": "DefinedBenefitObligationAtPresentValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]",
        "terseLabel": "Defined benefit plans [axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
      "http://www.gsk.com/role/OperatingProfitTables",
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [member]",
        "terseLabel": "Defined benefit plans [member]"
       }
      }
     },
     "localname": "DefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
      "http://www.gsk.com/role/OperatingProfitTables",
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r64",
      "r257",
      "r392",
      "r402",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "terseLabel": "Total depreciation and amortisation"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense [abstract]",
        "terseLabel": "Depreciation and amortisation by segment"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r84",
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedLabel": "Charge for the year",
        "terseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation of right of use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial assets",
        "terseLabel": "Third party financial derivatives"
       }
      }
     },
     "localname": "DerivativeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial liabilities",
        "negatedLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativesMember": {
     "auth_ref": [
      "r479",
      "r481",
      "r495",
      "r505"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivatives [member]",
        "terseLabel": "Derivative Instruments [Member]"
       }
      }
     },
     "localname": "DerivativesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for borrowings. [Refer: Borrowings]\nEffective 2023-01-01: The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for borrowings [text block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for business combinations [text block]",
        "terseLabel": "Business combinations"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for derivative financial instruments [text block]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Pensions and other post-employment benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for environment related expense.\nEffective 2023-01-01: The description of the entity's material accounting policy information for environment related expense."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for environment related expense [text block]",
        "terseLabel": "Environmental expenditure"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for expenses.\nEffective 2023-01-01: The description of the entity's material accounting policy information for expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for expenses [text block]",
        "terseLabel": "Expenditure"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for goodwill [text block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for hedging.\nEffective 2023-01-01: The description of the entity's material accounting policy information for hedging."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for hedging [text block]",
        "terseLabel": "Hedge accounting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForHedgingExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of assets.\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of assets [text block]",
        "terseLabel": "Impairment of non-current assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Taxation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]",
        "terseLabel": "Investments in associates, joint ventures and joint operations"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]\nEffective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block]",
        "terseLabel": "Assets and liabilities held for sale or distribution and discontinued operations"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Employee share plans"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other receivables [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the basis on which the cash-generating unit's (group of units') recoverable amount has been determined (ie value in use or fair value less costs of disposal). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of basis on which unit's recoverable amount has been determined",
        "terseLabel": "Description of basis on which unit's recoverable amount has been determined"
       }
      }
     },
     "localname": "DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": {
     "auth_ref": [
      "r166",
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Discount rate applied to cash flow projections",
        "terseLabel": "Discount rate",
        "verboseLabel": "Discount rate applied to cash flow projections"
       }
      }
     },
     "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "New accounting requirements"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NewAccountingRequirements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "auth_ref": [
      "r165",
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Growth rate used to extrapolate cash flow projections",
        "terseLabel": "Terminal growth rate"
       }
      }
     },
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections": {
     "auth_ref": [
      "r163",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of key assumptions on which management has based its cash flow projections for the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). Key assumptions are those to which the unit's (group of units') recoverable amount is most sensitive. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of key assumptions on which management has based cash flow projections",
        "terseLabel": "Key assumptions"
       }
      }
     },
     "localname": "DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal": {
     "auth_ref": [
      "r160",
      "r167"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of key assumptions on which management has based its determination of fair value less costs of disposal for a cash-generating unit (group of units). Key assumptions are those to which the unit's (group of units') recoverable amount is most sensitive. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of key assumptions on which management has based determination of fair value less costs of disposal",
        "terseLabel": "Determination of assumptions"
       }
      }
     },
     "localname": "DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the line item in the statement of comprehensive income that includes the reclassification adjustments. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of line item in statement of comprehensive income that includes reclassification adjustments",
        "terseLabel": "Line item in profit or loss in which reclassification adjustment is included"
       }
      }
     },
     "localname": "DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the line item in the statement of comprehensive income that includes the recognised hedge ineffectiveness. [Refer: Gain (loss) on hedge ineffectiveness]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of line item in statement of comprehensive income that includes recognised hedge ineffectiveness",
        "terseLabel": "Line item in profit or loss in which hedge ineffectiveness is included"
       }
      }
     },
     "localname": "DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the line item in the statement of financial position that includes the hedged item. [Refer: Hedged items [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of line item in statement of financial position that includes hedged item",
        "terseLabel": "Line item in balance sheet in which reclassification adjustment is included"
       }
      }
     },
     "localname": "DescriptionOfLineItemInStatementOfFinancialPositionThatIncludesHedgedItem",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of useful life, intangible assets other than goodwill",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of useful life, property, plant and equipment",
        "terseLabel": "Useful lives of property plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the valuation techniques used to measure fair value less costs of disposal for a cash generating unit (group of units). [Refer: Valuation techniques [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of valuation techniques used to measure fair value less costs of disposal",
        "terseLabel": "Valuation basis"
       }
      }
     },
     "localname": "DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "totalLabel": "Total diluted earnings per share",
        "verboseLabel": "Total diluted earnings per share (pence)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from continuing operations",
        "terseLabel": "Diluted earnings per share (pence) from continued operations",
        "verboseLabel": "Diluted earnings per share from continuing operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from discontinued operations",
        "terseLabel": "Diluted earnings per share (pence) from discontinued operations",
        "verboseLabel": "Diluted earnings per share from discontinued operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Dilutive effect of share options on number of ordinary shares",
        "terseLabel": "Dilution for share options and awards"
       }
      }
     },
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Critical accounting judgements and key sources of estimation uncertainty"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the allowance relating to impairments of financial assets due to credit losses. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of allowance for credit losses [text block]",
        "terseLabel": "Summary of Loss Allowance"
       }
      }
     },
     "localname": "DisclosureOfAllowanceForCreditLossesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure of the analysis of other comprehensive income by item."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of analysis of other comprehensive income by item [text block]",
        "terseLabel": "Summary of Other Comprehensive Income by Equity Category"
       }
      }
     },
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of analysis of single amount of discontinued operations [line items]"
       }
      }
     },
     "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of the single amount of discontinued operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of analysis of single amount of discontinued operations [table]"
       }
      }
     },
     "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of auditors' remuneration [text block]",
        "terseLabel": "Summary of Auditors Remuneration"
       }
      }
     },
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Presentation of the financial statements"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PresentationOfTheFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of borrowings [text block]",
        "terseLabel": "Net debt"
       }
      }
     },
     "localname": "DisclosureOfBorrowingsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of business combinations [text block]",
        "terseLabel": "Acquisitions and disposals"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [line items]",
        "terseLabel": "Disclosure of detailed information about business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]",
        "terseLabel": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [abstract]"
       }
      }
     },
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]",
        "terseLabel": "Disclosure of changes in accounting estimates [line items]"
       }
      }
     },
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the changes in accounting estimates."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [table]",
        "terseLabel": "Disclosure of changes in accounting estimates [table]"
       }
      }
     },
     "localname": "DisclosureOfChangesInAccountingEstimatesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities in business combination [line items]",
        "terseLabel": "Disclosure of contingent liabilities in business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable": {
     "auth_ref": [
      "r305",
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities in business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities in business combination [table]",
        "terseLabel": "Disclosure of contingent liabilities in business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of debt instruments [text block]",
        "verboseLabel": "Summary of Debt Interest Rate Repricing"
       }
      }
     },
     "localname": "DisclosureOfDebtSecuritiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities Recognised on the Balance Sheet"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [abstract]",
        "terseLabel": "Disclosure of defined benefit plans [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [text block]",
        "terseLabel": "Summary of Analysis of Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [line items]",
        "terseLabel": "Disclosure of defined benefit plans [line items]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]",
        "terseLabel": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Schedule of Current Assets, Short and Long Term Borrowings"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [text block]",
        "verboseLabel": "Summary of Fair Values of the Assets Acquired in Business Combinations, Including Goodwill"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r358",
      "r366",
      "r376"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Summary of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedged items [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgedItemsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsExplanatory": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about hedged items. [Refer: Hedged items [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedged items [text block]",
        "terseLabel": "Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgedItemsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedged items [line items]",
        "terseLabel": "Disclosure of detailed information about hedged items [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgedItemsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgedItemsTable": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of hedged items."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedged items [table]",
        "terseLabel": "Disclosure of detailed information about hedged items [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgedItemsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedging instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about hedging instruments. [Refer: Hedging instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedging instruments [text block]",
        "terseLabel": "Summary of Fair Values of Derivatives Held"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedging instruments [line items]",
        "terseLabel": "Disclosure of detailed information about hedging instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutHedgingInstrumentsTable": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of hedging instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about hedging instruments [table]",
        "terseLabel": "Disclosure of detailed information about hedging instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutHedgingInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Summary of Other Intangible Assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Summary of Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDividendsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of dividends [text block]",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "DisclosureOfDividendsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/Dividends"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for the effect of changes in foreign exchange rates."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]",
        "terseLabel": "Exchange rates"
       }
      }
     },
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of employee benefits [text block]",
        "terseLabel": "Pensions and other post-employment benefits"
       }
      }
     },
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Turnover and segment information"
       }
      }
     },
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Post balance sheet events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PostBalanceSheetEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExternalCreditExposuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of external credit grades [abstract]"
       }
      }
     },
     "localname": "DisclosureOfExternalCreditExposuresAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfExternalCreditExposuresExplanatory": {
     "auth_ref": [
      "r515",
      "r520"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of external credit grades. [Refer: External credit grades [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of external credit grades [text block]",
        "terseLabel": "Summary of External Credit Exposure"
       }
      }
     },
     "localname": "DisclosureOfExternalCreditExposuresExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExternalCreditExposuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of external credit grades [line items]",
        "terseLabel": "Disclosure of external credit grades [line items]"
       }
      }
     },
     "localname": "DisclosureOfExternalCreditExposuresLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfExternalCreditExposuresTable": {
     "auth_ref": [
      "r515",
      "r520"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to external credit grades."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of external credit grades [table]",
        "terseLabel": "Disclosure of external credit grades [table]"
       }
      }
     },
     "localname": "DisclosureOfExternalCreditExposuresTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of financial instruments [text block]",
        "terseLabel": "Summary of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of plan assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfPlanAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of plan assets [text block]",
        "terseLabel": "Summary of Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfPlanAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance cost [text block]",
        "terseLabel": "Summary of Finance Cost"
       }
      }
     },
     "localname": "DisclosureOfFinanceCostExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income [text block]",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]",
        "terseLabel": "Disclosure of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial instruments and related disclosures"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r358",
      "r366",
      "r376"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]",
        "terseLabel": "Disclosure of financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]",
        "terseLabel": "Disclosure of financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [abstract]"
       }
      }
     },
     "localname": "DisclosureOfGeographicalAreasAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [text block]",
        "terseLabel": "Summary of Geographical Information"
       }
      }
     },
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [line items]",
        "terseLabel": "Disclosure of geographical areas [line items]"
       }
      }
     },
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [table]",
        "terseLabel": "Disclosure of geographical areas [table]"
       }
      }
     },
     "localname": "DisclosureOfGeographicalAreasTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGoodwillExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of goodwill [text block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisclosureOfGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of impairment loss and the reversal of impairment loss. [Refer: Impairment loss; Reversal of impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of impairment loss and reversal of impairment loss [text block]",
        "terseLabel": "Schedule of Amortisation and Impairment Losses, Net of Reversals"
       }
      }
     },
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Taxation"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/Taxation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about activities subject to rate regulation [line items]",
        "terseLabel": "Disclosure of information about activities subject to rate regulation [line items]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to activities subject to rate regulation."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about activities subject to rate regulation [table]",
        "terseLabel": "Disclosure of information about activities subject to rate regulation [table]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about the maturity profile of a defined benefit obligation. This will include the weighted average duration of the defined benefit obligation and may include other information about the distribution of the timing of benefit payments, such as a maturity analysis of the benefit payments. [Refer: Defined benefit obligation, at present value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about maturity profile of defined benefit obligation [text block]",
        "terseLabel": "Summary of Weighted Average Duration of Defined Benefit Obligation"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information for cash-generating units. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information for cash-generating units [text block]",
        "terseLabel": "Schedule of Discounted Cash Flow Models Used in Impairment Tests"
       }
      }
     },
     "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]",
        "terseLabel": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInterestIncomeExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interest income. [Refer: Interest income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interest income [text block]",
        "terseLabel": "Summary of Finance Income"
       }
      }
     },
     "localname": "DisclosureOfInterestIncomeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of investments accounted for using equity method [text block]",
        "terseLabel": "Investments in associates and joint ventures"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVentures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of investments other than investments accounted for using equity method [text block]",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]",
        "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]",
        "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [text block]",
        "terseLabel": "Summary of Net Defined Benefit Liability"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [line items]",
        "terseLabel": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table]",
        "terseLabel": "Disclosure of net defined benefit liability (asset) [table]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of non-controlling interests. [Refer: Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-controlling interests [text block]",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "DisclosureOfNoncontrollingInterestsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]",
        "terseLabel": "Summary of Offsetting of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Segment Profit and Operating Profit"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [line items]",
        "terseLabel": "Disclosure of operating segments [line items]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [table]",
        "terseLabel": "Disclosure of operating segments [table]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [text block]",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current liabilities. [Refer: Other non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current liabilities [text block]",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income (expense) [text block]",
        "terseLabel": "Other operating income/(expense)"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]",
        "terseLabel": "Other provisions"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [text block]",
        "terseLabel": "Summary of Other Provisions"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Disclosure of other provisions [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]",
        "terseLabel": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesExplanatory": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [text block]",
        "terseLabel": "Turnover by Product &amp; Service"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [line items]",
        "terseLabel": "Disclosure of products and services [line items]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesTable": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the entity's products and services."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [table]",
        "terseLabel": "Disclosure of products and services [table]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of profit (loss) from operating activities [text block]",
        "terseLabel": "Operating profit"
       }
      }
     },
     "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in goodwill [abstract]",
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [abstract]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in goodwill [text block]",
        "terseLabel": "Summary of Changes in Goodwill"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in goodwill [line items]",
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "verboseLabel": "Disclosure of Goodwill"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in goodwill [table]",
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]",
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]",
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]",
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]",
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block]",
        "terseLabel": "Summary of Analysis of Other Reserves"
       }
      }
     },
     "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]",
        "terseLabel": "Summary of Changes In Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]",
        "terseLabel": "Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]",
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [table]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Employee share schemes"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r140",
      "r144",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [text block]",
        "terseLabel": "Schedule of Principal Subsidiaries and Their Countries of Incorporation"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r140",
      "r144",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]",
        "terseLabel": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Accounting principles and policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block]",
        "terseLabel": "Summary of Trade and Other Receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]",
        "terseLabel": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of voluntary change in accounting policy [abstract]"
       }
      }
     },
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DiscontinuedOperationsMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Discontinued operations [member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      },
      "en-us": {
       "role": {
        "label": "Discount rate, measurement input [member]"
       }
      }
     },
     "localname": "DiscountRateMeasurementInputMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r323",
      "r582"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for groups of assets, which are to be disposed of together as a group in a single transaction, and the liabilities directly associated with those assets that will be transferred in the transaction."
       }
      },
      "en-us": {
       "role": {
        "label": "Disposal groups classified as held for sale [member]",
        "terseLabel": "Disposal groups classified as held for sale [member]"
       }
      }
     },
     "localname": "DisposalGroupsClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, intangible assets and goodwill",
        "negatedLabel": "Disposals and asset write-offs"
       }
      }
     },
     "localname": "DisposalsAndRetirementsIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, property, plant and equipment",
        "negatedLabel": "Disposals and write-offs"
       }
      }
     },
     "localname": "DisposalsAndRetirementsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedLabel": "Disposals and asset write-offs"
       }
      }
     },
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DistributionCosts": {
     "auth_ref": [
      "r64",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs relating to the distribution of goods and services."
       }
      },
      "en-us": {
       "role": {
        "label": "Distribution costs",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "DistributionCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaid": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised as distributions to owners",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "DividendsPaid",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidOrdinaryShares": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends paid by the entity on ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid, ordinary shares",
        "terseLabel": "Total dividend"
       }
      }
     },
     "localname": "DividendsPaidOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid, ordinary shares per share",
        "terseLabel": "Dividend per share (pence)"
       }
      }
     },
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid to equity holders of parent, classified as financing activities",
        "negatedLabel": "Dividends paid to shareholders"
       }
      }
     },
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterests": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends paid to non-controlling interests. [Refer: Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid to non-controlling interests",
        "verboseLabel": "Dividends paid to non-controlling interests"
       }
      }
     },
     "localname": "DividendsPaidToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid to non-controlling interests, classified as financing activities",
        "negatedLabel": "Distributions to non-controlling interests"
       }
      }
     },
     "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsReceivedClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 31.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from dividends received, classified as investing activities. [Refer: Dividends received]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends received, classified as investing activities",
        "terseLabel": "Dividends from associates and joint ventures"
       }
      }
     },
     "localname": "DividendsReceivedClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised as distributions to non-controlling interests",
        "negatedLabel": "Distributions to non-controlling interests"
       }
      }
     },
     "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Summary of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareSummaryOfBasicAndDilutedEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r64",
      "r441"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Employee costs (Note 0)",
        "totalLabel": "Employee benefits expense"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail",
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "auth_ref": [
      "r140",
      "r144",
      "r264",
      "r427",
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for associates [member]",
        "terseLabel": "Entity's total for associates [member]"
       }
      }
     },
     "localname": "EntitysTotalForAssociatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r307",
      "r314"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]",
        "terseLabel": "Entity's total for business combinations [member]",
        "verboseLabel": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsTables",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/MajorRestructuringCostsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/NonControllingInterestsTables",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Consolidated structured entities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for consolidated structured entities [member]"
       }
      }
     },
     "localname": "EntitysTotalForConsolidatedStructuredEntitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForExternalCreditGradesMember": {
     "auth_ref": [
      "r429",
      "r493",
      "r503",
      "r515",
      "r518"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for external credit grades [member]",
        "terseLabel": "Entity's total for external credit grades [member]"
       }
      }
     },
     "localname": "EntitysTotalForExternalCreditGradesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForJointOperationsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint operations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for joint operations [member]",
        "terseLabel": "Entity's total for joint operations [member]"
       }
      }
     },
     "localname": "EntitysTotalForJointOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForJointVenturesMember": {
     "auth_ref": [
      "r140",
      "r144",
      "r262",
      "r427",
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for joint ventures [member]",
        "terseLabel": "Entity's total for joint ventures [member]"
       }
      }
     },
     "localname": "EntitysTotalForJointVenturesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]",
        "terseLabel": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r140",
      "r144",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]",
        "terseLabel": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r28",
      "r38",
      "r229",
      "r231",
      "r266",
      "r267",
      "r272"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity at end of period",
        "periodStartLabel": "Equity at beginning of period",
        "totalLabel": "Total equity",
        "verboseLabel": "Total equity including non-controlling interests"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]",
        "terseLabel": "Total [member]"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimate of contributions expected to be paid to plan for next annual reporting period",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "EstimateOfContributionsExpectedToBePaidToPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities",
        "terseLabel": "Contingent liabilities, comprising guarantees, discounted bills and other items"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense due to unwinding of discount on provisions",
        "negatedLabel": "Unwinding of discounts on provisions"
       }
      }
     },
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Cost of share-based incentive plans"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseOfRestructuringActivities": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense of restructuring activities",
        "terseLabel": "Major restructuring costs"
       }
      }
     },
     "localname": "ExpenseOfRestructuringActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "verboseLabel": "Low value lease charge"
       }
      }
     },
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "verboseLabel": "Short-term lease charge"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities",
        "verboseLabel": "Variable lease payments"
       }
      }
     },
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows": {
     "auth_ref": [
      "r164",
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the period over which management has projected cash flows based on financial budgets/forecasts approved by management including, when a period greater than five years is used for a cash-generating unit (group of units), an explanation of why that longer period is justified. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of period over which management has projected cash flows",
        "terseLabel": "Period of specific projected cash flows"
       }
      }
     },
     "localname": "ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExternalCreditGradesAxis": {
     "auth_ref": [
      "r429",
      "r493",
      "r503",
      "r515",
      "r518"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "External credit grades [axis]",
        "terseLabel": "External credit grades [axis]"
       }
      }
     },
     "localname": "ExternalCreditGradesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExternalCreditGradesMember": {
     "auth_ref": [
      "r429",
      "r493",
      "r503",
      "r515",
      "r518"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for credit grades that have been provided by external rating agencies."
       }
      },
      "en-us": {
       "role": {
        "label": "External credit grades [member]",
        "terseLabel": "External credit grades [member]"
       }
      }
     },
     "localname": "ExternalCreditGradesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FactorsUsedToIdentifyEntitysReportableSegments": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the factors used to identify the entity's reportable segments, including the basis of organisation (for example, whether management has chosen to organise the entity around differences in products and services, geographical areas, regulatory environments or a combination of factors and whether operating segments have been aggregated). [Refer: Geographical areas [member]; Operating segments [member]; Products and services [member]; Reportable segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of factors used to identify entity's reportable segments",
        "terseLabel": "Description of factors used to identify entity's reportable segments"
       }
      }
     },
     "localname": "FactorsUsedToIdentifyEntitysReportableSegments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value at the date of the derecognition of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition",
        "terseLabel": "Fair value of investment disposed during the year"
       }
      }
     },
     "localname": "FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 12.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      },
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance costs",
        "negatedTerseLabel": "Finance expense",
        "negatedTotalLabel": "Finance Costs"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 11.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      },
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income",
        "totalLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r357",
      "r362",
      "r363",
      "r368",
      "r494"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "gsk_NetFinancialAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Financial assets",
        "totalLabel": "Financial assets",
        "verboseLabel": "Total financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]",
        "terseLabel": "Financial assets at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value",
        "positiveTerseLabel": "Total financial assets fair value",
        "verboseLabel": "Financial assets at fair value"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through other comprehensive income, category [member]",
        "terseLabel": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]",
        "terseLabel": "Financial Assets at Fair Value Through Profit or Loss, Category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss classified as held for trading category. [Refer: Financial assets at fair value through profit or loss, classified as held for trading]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, classified as held for trading, category [member]",
        "terseLabel": "Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets mandatorily measured at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss, mandatorily measured at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, mandatorily measured at fair value, category [member]",
        "terseLabel": "Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]",
        "terseLabel": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r374",
      "r375",
      "r411",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]",
        "terseLabel": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets pledged as collateral for liabilities or contingent liabilities",
        "terseLabel": "Financial assets were pledged as collateral for contingent liabilities"
       }
      }
     },
     "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsTypeMember": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated types of financial assets. It also represents the standard value for the 'Types of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, type [member]",
        "terseLabel": "Financial assets, type [member]"
       }
      }
     },
     "localname": "FinancialAssetsTypeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gross carrying amount of financial assets that have been modified since initial recognition at a time when the loss allowance was measured at an amount equal to lifetime expected credit losses and for which the loss allowance has changed during the reporting period to an amount equal to 12-month expected credit losses. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets with modified contractual cash flows while loss allowance measured at lifetime expected credit losses for which loss allowance changed during reporting period to 12-month expected credit losses, gross carrying amount",
        "verboseLabel": "Expected credit loss allowance"
       }
      }
     },
     "localname": "FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialInstrumentsCreditimpairedMember": {
     "auth_ref": [
      "r362",
      "r368"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments that are credit-impaired. [Refer: Credit impairment of financial instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments credit-impaired [member]",
        "terseLabel": "Financial instruments credit-impaired [member]"
       }
      }
     },
     "localname": "FinancialInstrumentsCreditimpairedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial instruments designated as hedging instruments. Hedging instruments are designated derivatives or (for a hedge of the risk of changes in foreign currency exchange rates only) designated non-derivative financial assets or non-derivative financial liabilities whose fair value or cash flows are expected to offset changes in the fair value or cash flows of a designated hedged item. [Refer: At fair value [member]; Derivatives [member]; Derivative financial assets; Derivative financial liabilities; Financial instruments, class [member]; Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments designated as hedging instruments, at fair value",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets": {
     "auth_ref": [
      "r490",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial instruments subject to an enforceable master netting arrangement or similar agreement that are not set off against financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial assets",
        "negatedLabel": "Related amounts not set off in the balance sheet"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities": {
     "auth_ref": [
      "r490",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial instruments subject to an enforceable master netting arrangement or similar agreement that are not set off against financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities",
        "terseLabel": "Related amounts not set off in the balance sheet"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "gsk_NetFinancialAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "negatedLabel": "Total financial liabilities",
        "negatedTotalLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r380",
      "r440"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]",
        "terseLabel": "Financial Liabilities at Amortised Cost, Category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, class [member]",
        "terseLabel": "Amortised cost [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "gsk_NetFinancialAssetsFinancialLiabilitiesAtFairValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value",
        "negatedLabel": "Financial liabilities at fair value",
        "negatedTerseLabel": "Total financial liabilities fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial Liabilities at Fair Value Through Profit or Loss, Category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss designated as such upon initial recognition or subsequently category. [Refer: Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently, category [member]",
        "terseLabel": "Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss that meet the definition of held for trading category. [Refer: Financial liabilities at fair value through profit or loss that meet definition of held for trading]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss that meet definition of held for trading, category [member]",
        "terseLabel": "Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]",
        "terseLabel": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r374",
      "r375",
      "r411",
      "r423"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]",
        "terseLabel": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesTypeMember": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated types of financial liabilities. It also represents the standard value for the 'Types of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, type [member]",
        "terseLabel": "Financial liabilities, type [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesTypeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinishedGoods": {
     "auth_ref": [
      "r446",
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "FinishedGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FixedInterestRateMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fixed interest rate [member]",
        "terseLabel": "Fixed interest rate [member]"
       }
      }
     },
     "localname": "FixedInterestRateMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FloatingInterestRateMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Floating interest rate [member]",
        "terseLabel": "Floating interest rate [member]"
       }
      }
     },
     "localname": "FloatingInterestRateMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ForeignCountriesMember": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign countries [member]",
        "terseLabel": "Rest of World [member]"
       }
      }
     },
     "localname": "ForeignCountriesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ForeignExchangeRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange rates [abstract]"
       }
      }
     },
     "localname": "ForeignExchangeRatesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) on the change in fair value of the hedged item used as a basis for recognising hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item."
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on change in fair value of hedged item used as basis for recognising hedge ineffectiveness",
        "positiveLabel": "Periodic change\u00a0in\u00a0value for\u00a0calculating hedge ineffectiveness",
        "verboseLabel": "Change in value used for calculating hedge ineffectiveness"
       }
      }
     },
     "localname": "GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) on the change in fair value of the hedging instrument used as a basis for recognising hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item."
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on change in fair value of hedging instrument used as basis for recognising hedge ineffectiveness",
        "terseLabel": "Change in fair value for recognising hedge ineffectiveness \u00a3m"
       }
      }
     },
     "localname": "GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnHedgeIneffectiveness": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item."
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on hedge ineffectiveness",
        "terseLabel": "Ineffectiveness of hedges"
       }
      }
     },
     "localname": "GainLossOnHedgeIneffectiveness",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r349",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) recognised in profit or loss on hedge ineffectiveness. [Refer: Gain (loss) on hedge ineffectiveness]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on hedge ineffectiveness recognised in profit or loss",
        "terseLabel": "Amount of hedge ineffectiveness recognised in profit or loss"
       }
      }
     },
     "localname": "GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on remeasurement, net defined benefit liability (asset)",
        "terseLabel": "Remeasurement",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on remeasurement, net defined benefit liability (asset) [abstract]",
        "terseLabel": "Remeasurements:"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from settlements. Settlements are transactions that eliminate all further legal or constructive obligations for part or all of the benefits provided under a defined benefit plan, other than a payment of benefits to, or on behalf of, employees that is set out in the terms of the plan and included in the actuarial assumptions. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) arising from settlements, net defined benefit liability (asset)",
        "negatedLabel": "Gains from settlements",
        "negatedTerseLabel": "Settlements and curtailments",
        "terseLabel": "Settlements and curtailments"
       }
      }
     },
     "localname": "GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": {
     "auth_ref": [
      "r59",
      "r435"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      },
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on cash flow hedges, before tax",
        "terseLabel": "Fair value movements on cash flow hedges"
       }
      }
     },
     "localname": "GainsLossesOnCashFlowHedgesBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "terseLabel": "Fair value adjustments on derivative financial instruments"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on exchange differences on translation, before tax",
        "terseLabel": "Exchange movements on overseas net assets and net investment hedges"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r12",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "negatedLabel": "Net foreign exchange (gains)/losses",
        "terseLabel": "Net foreign exchange gains (losses)"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets mandatorily measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Financial assets at fair value through profit or loss, mandatorily measured at fair value; Gains (losses) on financial assets at fair value through profit or loss; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on financial assets at fair value through profit or loss, mandatorily measured at fair value",
        "verboseLabel": "Net losses arising from: Financial instruments mandatorily measured at fair value through profit or loss"
       }
      }
     },
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on the ineffective portion of hedges of net investments in foreign operations recognised in profit or loss. [Refer: Hedges of net investment in foreign operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on ineffectiveness of hedges of net investments in foreign operations recognised in profit or loss",
        "terseLabel": "Net gains arising from the forward element of forward contracts in net investment hedge relationships"
       }
      }
     },
     "localname": "GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) recognised in profit or loss, fair value measurement, entity's own equity instruments",
        "terseLabel": "Fair value remeasurements of equity investments"
       }
      }
     },
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities",
        "terseLabel": "Gain loss measured in profit or loss fair value measurement liabilities"
       }
      }
     },
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains on change in fair value of derivatives",
        "terseLabel": "Gains on embedded derivative"
       }
      }
     },
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r407",
      "r453",
      "r484",
      "r512"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r407",
      "r453",
      "r484",
      "r512"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilitiesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Goodwill": {
     "auth_ref": [
      "r15",
      "r161",
      "r173",
      "r313"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 19.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill",
        "periodEndLabel": "Goodwill Ending Balance",
        "periodStartLabel": "Goodwill Beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r77",
      "r186",
      "r203",
      "r206",
      "r313",
      "r363",
      "r368",
      "r494",
      "r588",
      "r590"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost [member]"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets set off against financial liabilities when an entity: (a) currently has a legally enforceable right to set off the recognised amounts; and (b) intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross financial assets set off against financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements",
        "terseLabel": "Gross financial (Liabilities)/assets set off"
       }
      }
     },
     "localname": "GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gross amount of recognised financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross financial assets subject to offsetting, enforceable master netting arrangements or similar agreements",
        "terseLabel": "Gross financial assets/(liabilities)"
       }
      }
     },
     "localname": "GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities set off against financial assets when an entity: (a) currently has a legally enforceable right to set off the recognised amounts; and (b) intends either to settle on a net basis or to realise the asset and settle the liability simultaneously. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross financial liabilities set off against financial assets subject to offsetting, enforceable master netting arrangements or similar agreements",
        "negatedLabel": "Gross financial (Liabilities)/assets set off"
       }
      }
     },
     "localname": "GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gross amount of recognised financial liabilities that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements",
        "negatedLabel": "Gross financial assets/(liabilities)"
       }
      }
     },
     "localname": "GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossProfit": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 8.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_HedgedItemsAxis": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedged items [axis]",
        "terseLabel": "Hedged items [axis]"
       }
      }
     },
     "localname": "HedgedItemsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_HedgedItemsMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedged items [member]",
        "terseLabel": "Hedged items [member]"
       }
      }
     },
     "localname": "HedgedItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_HedgesOfNetInvestmentInForeignOperationsMember": {
     "auth_ref": [
      "r200",
      "r341",
      "r348",
      "r355"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the entity's monetary items that are receivable from or payable to a foreign operation, for which settlement is neither planned nor likely to occur in the foreseeable future. A foreign operation is an entity that is a subsidiary, associate, joint venture or branch of a reporting entity, the activities of which are based or conducted in a country or currency other than those of the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedges of net investment in foreign operations [member]",
        "terseLabel": "Hedges of net investment in foreign operations [member]",
        "verboseLabel": "Hedges of net investment in foreign operations [member]"
       }
      }
     },
     "localname": "HedgesOfNetInvestmentInForeignOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_HedgingInstrumentAssets": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a hedging instrument, recognised as an asset. [Refer: Hedging instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Hedging instrument, assets",
        "totalLabel": "Financial assets, current and Non current"
       }
      }
     },
     "localname": "HedgingInstrumentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_HedgingInstrumentLiabilities": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a hedging instrument, recognised as a liability. [Refer: Hedging instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Hedging instrument, liabilities",
        "negatedLabel": "Total derivative instruments"
       }
      }
     },
     "localname": "HedgingInstrumentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "auth_ref": [
      "r336",
      "r341"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedging instruments [axis]",
        "terseLabel": "Hedging instruments [axis]"
       }
      }
     },
     "localname": "HedgingInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_HedgingInstrumentsMember": {
     "auth_ref": [
      "r336",
      "r341"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedging instruments [member]",
        "terseLabel": "Hedging instruments [member]"
       }
      }
     },
     "localname": "HedgingInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired (liabilities assumed)",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLoss": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": 3.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss",
        "terseLabel": "Impairment losses recognised"
       }
      }
     },
     "localname": "ImpairmentLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r152",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss",
        "terseLabel": "Total impairment"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "terseLabel": "Impairment of goodwill allocated to a disposal group, net of reversals"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61",
      "r82"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Impairment losses",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "verboseLabel": "Impairment of property, plant and equipment, net of reversals"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income from continuing operations attributable to owners of the parent. [Refer: Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from continuing operations attributable to owners of parent",
        "terseLabel": "Profit attributable to shareholders from continuing operations"
       }
      }
     },
     "localname": "IncomeFromContinuingOperationsAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income from discontinued operations attributable to owners of the parent. [Refer: Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from discontinued operations attributable to owners of parent",
        "terseLabel": "Profit attributable to shareholders from discontinued operations",
        "verboseLabel": "Earnings attributable to shareholders from discontinued operations"
       }
      }
     },
     "localname": "IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r55",
      "r67",
      "r70",
      "r71",
      "r135",
      "r259",
      "r394"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": -1.0
      },
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Taxation",
        "label": "Tax expense (income)",
        "negatedLabel": "Taxation",
        "terseLabel": "Tax charge for the year",
        "totalLabel": "Total tax",
        "verboseLabel": "Tax charge/tax rate"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTaxationChargeBasedOnProfitsDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r57",
      "r69"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 9.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      },
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 13.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to cash flow hedges included in other comprehensive income",
        "negatedLabel": "Tax on fair value movements on cash flow hedges",
        "negatedTerseLabel": "Deferred tax on fair value movements on cash flow hedges"
       }
      }
     },
     "localname": "IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r57",
      "r69"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 15.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income; Reserve of gains and losses from investments in equity instruments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to investments in equity instruments included in other comprehensive income",
        "negatedLabel": "Tax on fair value movements on equity investments"
       }
      }
     },
     "localname": "IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r57",
      "r69"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to remeasurements of defined benefit plans included in other comprehensive income",
        "negatedLabel": "Tax on remeasurement losses/(gains) on defined benefit plans"
       }
      }
     },
     "localname": "IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "terseLabel": "Income taxes paid, classified as operating activities"
       }
      }
     },
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "terseLabel": "Payments of corporation tax"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "terseLabel": "Increase/(Decrease) in cash and bank overdrafts in the year",
        "totalLabel": "(Increase)/decrease in cash and bank overdrafts"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in contingent consideration asset (liability)",
        "verboseLabel": "Contingent consideration related to business acquisitions in the period"
       }
      }
     },
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination; Business combinations [member]; Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in contingent liabilities recognised in business combination",
        "terseLabel": "Fair value remeasurements on contingent consideration",
        "verboseLabel": "Fair value remeasurements on contingent consideration recognised in business combinations"
       }
      }
     },
     "localname": "IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities",
        "terseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from business combinations and disposals. [Refer: Business combinations [member]; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations and disposals, net defined benefit liability (asset)",
        "terseLabel": "Transfer to assets held for sale/distribution"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in reimbursement rights related to defined benefit obligation, resulting from the effects of business combinations and disposals. [Refer: Business combinations [member]; Reimbursement rights related to defined benefit obligation, at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations and disposals, reimbursement rights",
        "terseLabel": "Disposals"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughBusinessCombinationsAndDisposalsReimbursementRights",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations, deferred tax liability (asset)",
        "verboseLabel": "Acquisitions/Disposals"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from a change in discount rate. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through change in discount rate, other provisions",
        "terseLabel": "Discount on the provisions"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)",
        "negatedLabel": "Exchange adjustments",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughDisposalOfSubsidiary": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the disposal of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through disposal of subsidiary, equity",
        "terseLabel": "Deconsolidation of former subsidiaries"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughDisposalOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities",
        "negatedLabel": "Exchange"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities",
        "negatedLabel": "Cash flow"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": {
     "auth_ref": [
      "r492",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through foreign exchange, financial assets",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, deferred tax liability (asset)",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, goodwill",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillSummaryOfChangesInGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, other provisions",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Exchange adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, liabilities arising from financing activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, property, plant and equipment",
        "terseLabel": "Capitalised borrowing costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based incentive plans"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in other provisions through adjustments arising from the passage of time. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through adjustments arising from passage of time, other provisions",
        "terseLabel": "Unwinding of discount"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, equity",
        "terseLabel": "Changes to non-controlling interests"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers and other changes, other provisions",
        "terseLabel": "Reclassifications and other movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "terseLabel": "Assets in construction reclassified to intangible assets",
        "verboseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets and goodwill",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Ordinary shares acquired by ESOP Trusts"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InsuranceContractsMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for contracts under which one party (the insurer) accepts significant insurance risk from another party (the policyholder) by agreeing to compensate the policyholder if a specified uncertain future event (the insured event) adversely affects the policyholder. It also represents the standard value for the 'Types of insurance contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of insurance contracts [member]",
        "terseLabel": "Types of insurance contracts [member]"
       }
      }
     },
     "localname": "InsuranceContractsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsMaterialToEntityAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets material to entity [axis]",
        "terseLabel": "Intangible assets material to entity [axis]"
       }
      }
     },
     "localname": "IntangibleAssetsMaterialToEntityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IntangibleAssetsMaterialToEntityMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets material to the entity. It also represents the standard value for the 'Intangible assets material to entity' axis if no other member is used. [Refer: Intangible assets material to entity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets material to entity [member]",
        "terseLabel": "Intangible assets material to entity [member]"
       }
      }
     },
     "localname": "IntangibleAssetsMaterialToEntityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r15",
      "r192"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 20.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r193",
      "r459",
      "r485"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible assets [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversalsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets with indefinite useful life [axis]",
        "terseLabel": "Intangible assets with indefinite useful life [axis]"
       }
      }
     },
     "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets with an indefinite useful life. It also represents the standard value for the 'Intangible assets with indefinite useful life' axis if no other member is used. [Refer: Intangible assets with indefinite useful life]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets with indefinite useful life [member]",
        "terseLabel": "Intangible Assets with Indefinite Useful Life [Member]"
       }
      }
     },
     "localname": "IntangibleAssetsWithIndefiniteUsefulLifeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest costs [abstract]",
        "terseLabel": "Finance expense arising on:"
       }
      }
     },
     "localname": "InterestCostsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r258",
      "r391",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense for financial liabilities that are not at fair value through profit or loss. [Refer: At fair value [member]; Interest expense; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense for financial liabilities not at fair value through profit or loss",
        "negatedLabel": "Financial liabilities at amortised cost"
       }
      }
     },
     "localname": "InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense (income), net defined benefit liability (asset)",
        "negatedLabel": "Interest cost",
        "verboseLabel": "Net interest (income)/cost"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on borrowings",
        "negatedLabel": "Interest on debt"
       }
      }
     },
     "localname": "InterestExpenseOnBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedLabel": "Finance expense arising on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest revenue for financial assets measured at amortised cost",
        "terseLabel": "Financial assets measured at amortised cost"
       }
      }
     },
     "localname": "InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on financial assets designated at fair value through profit or loss. [Refer: Interest income; Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on financial assets designated at fair value through profit or loss",
        "terseLabel": "Financial assets measured at fair value through profit or loss"
       }
      }
     },
     "localname": "InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as financing activities",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestRateRiskMember": {
     "auth_ref": [
      "r386",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate risk [member]",
        "terseLabel": "Interest rate risk [member]"
       }
      }
     },
     "localname": "InterestRateRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRateSwapContractMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate swap contract. [Refer: Swap contract [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate swap contract [member]",
        "terseLabel": "Interest rate swap contract [member]",
        "verboseLabel": "Forward starting interest rate swaps [Member]"
       }
      }
     },
     "localname": "InterestRateSwapContractMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRateTypesMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate types [member]",
        "terseLabel": "Interest rate types [member]"
       }
      }
     },
     "localname": "InterestRateTypesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestReceivable": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a receivable."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 30.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as investing activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InternallyGeneratedMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for items that have been internally generated by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Internally generated [member]",
        "terseLabel": "Internally generated [member]"
       }
      }
     },
     "localname": "InternallyGeneratedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r18",
      "r114",
      "r444"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 9.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory recognised as of acquisition date",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r61",
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Write-down of inventories"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r17",
      "r260",
      "r397"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 21.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "terseLabel": "Investments in associates and joint ventures"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentIncome": {
     "auth_ref": [
      "r133",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investment income, such as interest and dividends."
       }
      },
      "en-us": {
       "role": {
        "label": "Investment income",
        "terseLabel": "Income from investment"
       }
      }
     },
     "localname": "InvestmentIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r324",
      "r381"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments that the entity has designated at fair value through other comprehensive income. It also represents the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [member]",
        "terseLabel": "Investments designated as measured at FVTOCI [member]"
       }
      }
     },
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in subsidiaries, joint ventures and associates",
        "periodEndLabel": "Ending of investments",
        "periodStartLabel": "Beginning of investments"
       }
      }
     },
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments other than investments accounted for using equity method",
        "periodEndLabel": "Ending of other investments",
        "periodStartLabel": "Beginning of other investments"
       }
      }
     },
     "localname": "InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issued under employee share schemes",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_JointOperationsAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Joint operations [axis]",
        "terseLabel": "Joint operations [axis]"
       }
      }
     },
     "localname": "JointOperationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_JointVenturesAxis": {
     "auth_ref": [
      "r140",
      "r144",
      "r262",
      "r427",
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Joint ventures [axis]",
        "terseLabel": "Joint ventures [axis]"
       }
      }
     },
     "localname": "JointVenturesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_JointVenturesMember": {
     "auth_ref": [
      "r140",
      "r144",
      "r262",
      "r425",
      "r430"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Joint ventures [member]",
        "terseLabel": "Joint ventures [member]"
       }
      }
     },
     "localname": "JointVenturesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Key management personnel compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Pension and other post-employment costs"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Cost of share-based incentive plans"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Wages and salaries"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LandAndBuildingsMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Land and buildings [member]",
        "terseLabel": "Land and buildings [member]"
       }
      }
     },
     "localname": "LandAndBuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": {
     "auth_ref": [
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years and not later than ten years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years and not later than ten years [member]",
        "terseLabel": "Between Five and Ten Years [Member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r421",
      "r496",
      "r500",
      "r504"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "Later than 5 years [member]",
        "verboseLabel": "Greater than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r421",
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than four years and not later than five years [member]",
        "terseLabel": "Between 4 and 5 years [member]"
       }
      }
     },
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r496",
      "r499",
      "r504"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than three years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r421",
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]",
        "terseLabel": "Between 1 and 2 years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r31",
      "r516",
      "r523"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]",
        "terseLabel": "Later Than One Year [Member]",
        "verboseLabel": "Current [Member]"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTenYearsMember": {
     "auth_ref": [
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than ten years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than ten years [member]",
        "terseLabel": "Greater Than Ten Years [Member]"
       }
      }
     },
     "localname": "LaterThanTenYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r421",
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than four years [member]",
        "terseLabel": "Between 3 and 4 Years [Member]"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r421",
      "r496",
      "r504",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than three years [member]",
        "terseLabel": "Between 2 and 3 years [member]"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]",
        "terseLabel": "Lease liabilities [Member]"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LegalProceedingsProvision": {
     "auth_ref": [
      "r461",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provision for legal proceedings. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Legal proceedings provision",
        "terseLabel": "Provision for legal and other disputes",
        "verboseLabel": "Provisions for legal and other disputes"
       }
      }
     },
     "localname": "LegalProceedingsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r107",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]",
        "terseLabel": "Level 1 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]",
        "terseLabel": "Level 3 [member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r107",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethodDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r28",
      "r266",
      "r267",
      "r272",
      "r396",
      "r401"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 27.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "negatedLabel": "Total liabilities",
        "negatedTotalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]",
        "terseLabel": "Liabilities arising from financing activities [axis]"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [member]",
        "terseLabel": "Liabilities arising from financing activities [member]"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "periodEndLabel": "Ending of net defined benefit liability",
        "periodStartLabel": "Beginning of net defined benefit liability"
       }
      }
     },
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LicencesAndFranchisesMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity and the right to operate a business using the name, merchandise, services, methodologies, promotional support, marketing and supplies granted by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Licences, patents, amortised brands etc [member]",
        "label": "Licences and franchises [member]",
        "terseLabel": "Licences and franchises [member]"
       }
      }
     },
     "localname": "LicencesAndFranchisesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItemsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiquidityRiskMember": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r491"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liquidity risk [member]",
        "terseLabel": "Liquidity risk [member]"
       }
      }
     },
     "localname": "LiquidityRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LongtermBorrowings": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 36.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current portion of non-current borrowings",
        "negatedLabel": "Long-term borrowings",
        "terseLabel": "Long-term borrowings"
       }
      }
     },
     "localname": "LongtermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Long-term borrowings [member]",
        "terseLabel": "Long Term Borrowings [Member]"
       }
      }
     },
     "localname": "LongtermBorrowingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]",
        "terseLabel": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]",
        "terseLabel": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other Reconciling Items between Segment Profit and Operating Profit [member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [text block]",
        "terseLabel": "Summary of Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows"
       }
      }
     },
     "localname": "MaturityAnalysisForDerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Summary of Anticipated Contractual Cash Flows Including Interest Payable for the Non-Derivative Financial Liabilities on Undiscounted Basis"
       }
      }
     },
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r32",
      "r281",
      "r292",
      "r293",
      "r337",
      "r373",
      "r412",
      "r413",
      "r415",
      "r421",
      "r457",
      "r496"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetail",
      "http://www.gsk.com/role/DividendsSummaryOfInterimFinancialReportingDetailParenthetical",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAverageLifeExpectancyAssumedDetail",
      "http://www.gsk.com/role/TaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "auth_ref": [
      "r365",
      "r438"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk",
        "terseLabel": "Maximum exposure to credit risk"
       }
      }
     },
     "localname": "MaximumExposureToCreditRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r201",
      "r205",
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]",
        "terseLabel": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstrumentsDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MethodsOfGenerationAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Methods of generation [axis]",
        "terseLabel": "Methods of generation [axis]"
       }
      }
     },
     "localname": "MethodsOfGenerationAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MethodsOfGenerationMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all methods of generation. It also represents the standard value for the 'Methods of generation' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Methods of generation [member]",
        "terseLabel": "Methods of generation [member]"
       }
      }
     },
     "localname": "MethodsOfGenerationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous non-current assets [abstract]"
       }
      }
     },
     "localname": "MiscellaneousNoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NameOfSubsidiary": {
     "auth_ref": [
      "r137",
      "r141",
      "r234",
      "r238"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Name of subsidiary",
        "terseLabel": "Name of subsidiary"
       }
      }
     },
     "localname": "NameOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r477",
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets (liabilities)",
        "terseLabel": "Net assets",
        "totalLabel": "Net assets"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDebt": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Net debt",
        "negatedLabel": "Net debt"
       }
      }
     },
     "localname": "NetDebt",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset) [axis]",
        "terseLabel": "Net defined benefit liability (asset) [axis]"
       }
      }
     },
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset) [member]",
        "terseLabel": "Net defined benefit liability (asset) [member]"
       }
      }
     },
     "localname": "NetDefinedBenefitLiabilityAssetMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount remaining after deducting the amounts subject to an enforceable master netting arrangement or similar agreement that were not set off against financial assets, from the net amount of financial assets subject to offsetting or subject to an enforceable master netting arrangement or similar agreement presented in the statement of financial position."
       }
      },
      "en-us": {
       "role": {
        "label": "Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements",
        "terseLabel": "Net"
       }
      }
     },
     "localname": "NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net amount of financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement, presented in the statement of financial position. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position",
        "terseLabel": "Net financial assets/(liabilities)per balance sheet"
       }
      }
     },
     "localname": "NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount remaining after deducting the amounts subject to an enforceable master netting arrangement or similar agreement that were not set off against financial liabilities, from the net amount of financial liabilities subject to offsetting or subject to an enforceable master netting arrangement or similar agreement presented in the statement of financial position."
       }
      },
      "en-us": {
       "role": {
        "label": "Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements",
        "negatedLabel": "Net"
       }
      }
     },
     "localname": "NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net amount of financial liabilities that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement, presented in the statement of financial position. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position",
        "negatedLabel": "Net financial assets/(liabilities)per balance sheet"
       }
      }
     },
     "localname": "NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination]"
       }
      },
      "en-us": {
       "role": {
        "label": "New liabilities, contingent liabilities recognised in business combination",
        "terseLabel": "Initial recognition from business combinations",
        "verboseLabel": "New liabilities contingent liabilities recognized in business combination"
       }
      }
     },
     "localname": "NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NominalAmountOfHedgingInstrument": {
     "auth_ref": [
      "r337",
      "r340"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal amount of a hedging instrument. [Refer: Hedging instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Nominal amount of hedging instrument",
        "positiveLabel": "Principal amount",
        "terseLabel": "Notional principal value \u00a3m",
        "verboseLabel": "Notional value"
       }
      }
     },
     "localname": "NominalAmountOfHedgingInstrument",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interest in acquiree recognised at acquisition date",
        "terseLabel": "Non controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterests": {
     "auth_ref": [
      "r26",
      "r233",
      "r237"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests",
        "terseLabel": "Non-controlling interests",
        "verboseLabel": "Non-controlling interest in the Consolidated balance sheet"
       }
      }
     },
     "localname": "NoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]",
        "terseLabel": "Non- controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current accrued income other than non-current contract assets. [Refer: Accrued income other than contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current accrued income other than non-current contract assets",
        "negatedLabel": "Deferred income"
       }
      }
     },
     "localname": "NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r33",
      "r246",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 17.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "terseLabel": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale",
        "terseLabel": "Assets held for sale (excluding cash and cash equivalents)",
        "totalLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 15.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets; Types of insurance contracts [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentDerivativeFinancialAssets": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 24.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current derivative financial assets",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "NoncurrentDerivativeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 41.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current derivative financial liabilities",
        "negatedLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 22.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current investments other than investments accounted for using equity method",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "negatedLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r34",
      "r248",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 35.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "negatedLabel": "Non-current liabilities",
        "negatedTotalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 39.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions for employee benefits",
        "negatedLabel": "Benefit plans",
        "negatedTerseLabel": "Pensions and other post-employment benefits"
       }
      }
     },
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentRecognisedAssetsDefinedBenefitPlan": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit asset. [Refer: Net defined benefit asset]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current net defined benefit asset",
        "terseLabel": "Pension schemes in surplus",
        "verboseLabel": "Post-retirement benefits/Pension schemes in deficit and surplus"
       }
      }
     },
     "localname": "NoncurrentRecognisedAssetsDefinedBenefitPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current net defined benefit liability",
        "negatedLabel": "Post-retirement benefits/Pension schemes in deficit and surplus"
       }
      }
     },
     "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-derivative financial liabilities, undiscounted cash flows",
        "negatedLabel": "Total"
       }
      }
     },
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r30",
      "r292",
      "r293",
      "r421",
      "r496",
      "r504"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Not later than 1 year [member]",
        "verboseLabel": "Non Current [Member]"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlowsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtScheduleOfFinanceLeaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r516",
      "r522",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than three months [member]",
        "terseLabel": "Not later than three months [member]"
       }
      }
     },
     "localname": "NotLaterThanThreeMonthsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotionalAmount": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      },
      "en-us": {
       "role": {
        "label": "Notional amount",
        "terseLabel": "Issue amount",
        "verboseLabel": "Drawn amount"
       }
      }
     },
     "localname": "NotionalAmount",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r295",
      "r297",
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of options granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number Of Shares Authorised"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Share capital issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued and fully paid",
        "periodEndLabel": "Share capital issued and fully paid ending balance",
        "periodStartLabel": "Share capital issued and fully paid beginning balance"
       }
      }
     },
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "terseLabel": "Expense"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OperatingSegmentsMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Operating segments [member]",
        "terseLabel": "Operating Segments [member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r146",
      "r545"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments to reconcile profit (loss)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAssets": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAssetsMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets [member]",
        "terseLabel": "Other assets [member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 24.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities",
        "negatedLabel": "Purchase of equity investments"
       }
      }
     },
     "localname": "OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 25.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities",
        "terseLabel": "Proceeds from sale of equity investments"
       }
      }
     },
     "localname": "OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r5",
      "r46",
      "r58",
      "r253"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "positiveLabel": "Other comprehensive (expense)/income for the year",
        "positiveTerseLabel": "Share of other comprehensive income/(expense)",
        "terseLabel": "Other comprehensive income/(expense)",
        "totalLabel": "Total other comprehensive (expense)/income for the year",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income/(expense) for the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments": {
     "auth_ref": [
      "r35",
      "r59",
      "r333"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 12.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income, before tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before tax, gains (losses) from investments in equity instruments",
        "terseLabel": "Fair value movements on equity investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r35",
      "r59",
      "r553"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans",
        "positiveLabel": "Remeasurement gains/(losses) recorded in the statement of comprehensive income",
        "terseLabel": "Remeasurement losses\\gains on defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r35",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Exchange movements on overseas net assets and net investment hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": {
     "auth_ref": [
      "r35",
      "r58"
     ],
     "calculation": {
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments",
        "terseLabel": "Fair value movements on equity investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Items that may be subsequently reclassified to continuing operations income statement"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "totalLabel": "Items that will not be reclassified to continuing operations income statement"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 13.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Liquid investments"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r23",
      "r255"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 30.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "negatedLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncome": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income",
        "terseLabel": "Other finance income"
       }
      }
     },
     "localname": "OtherFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income (cost)",
        "verboseLabel": "Other finance expense"
       }
      }
     },
     "localname": "OtherFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or expense from subsidiaries, jointly controlled entities and associates that the entity does not separately disclose in the same statement or note. [Refer: Associates [member]; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other income (expense) from subsidiaries, jointly controlled entities and associates",
        "verboseLabel": "Gain on disposal of interest in associates"
       }
      }
     },
     "localname": "OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as financing activities",
        "terseLabel": "Other financing items"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 32.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as investing activities",
        "terseLabel": "Contingent consideration paid"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherLongtermProvisions": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 40.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current provisions",
        "negatedLabel": "Other provisions",
        "terseLabel": "To be settled after one year"
       }
      }
     },
     "localname": "OtherLongtermProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherMaterialNoncashItems": {
     "auth_ref": [
      "r395",
      "r402"
     ],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": 4.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of material non-cash items other than depreciation and amortisation."
       }
      },
      "en-us": {
       "role": {
        "label": "Other material non-cash items",
        "terseLabel": "Other non-cash charges/(credit)"
       }
      }
     },
     "localname": "OtherMaterialNoncashItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 25.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "positiveLabel": "Other non-current assets",
        "totalLabel": "Total",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r23",
      "r256"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 42.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current financial liabilities",
        "negatedLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 43.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "negatedLabel": "Other non-current liabilities",
        "negatedTerseLabel": "Other non-current liabilities",
        "totalLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentPayables": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current payables",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherNoncurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherNoncurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherNonCurrentAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      },
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other operating income (expense)",
        "totalLabel": "Other operating income expense",
        "verboseLabel": "Other operating (expense)/income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisions": {
     "auth_ref": [
      "r37",
      "r175"
     ],
     "calculation": {
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions",
        "negatedLabel": "Other provisions",
        "periodEndLabel": "Other provisions, ending balance",
        "periodStartLabel": "Other provisions, beginning balance",
        "totalLabel": "Other provisions"
       }
      }
     },
     "localname": "OtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]",
        "terseLabel": "Other provisions [member]"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "periodEndLabel": "Other reserves, ending balance",
        "periodStartLabel": "Other reserves, beginning balance",
        "positiveLabel": "Other reserves",
        "verboseLabel": "Other reserve"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r8",
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Other reserves [member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherShorttermProvisions": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 34.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current provisions",
        "negatedTerseLabel": "Short-term provisions",
        "terseLabel": "To be settled within one year"
       }
      }
     },
     "localname": "OtherShorttermProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 6.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_OtherTemporaryDifferencesMember": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other temporary differences [member]",
        "terseLabel": "Other temporary differences [member]"
       }
      }
     },
     "localname": "OtherTemporaryDifferencesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "presentationGuidance": "Par value of newly issues shares"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ParentMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      },
      "en-us": {
       "role": {
        "label": "Parent [member]",
        "terseLabel": "GSK PLC [member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PastDueStatusAxis": {
     "auth_ref": [
      "r494",
      "r589"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [axis]"
       }
      }
     },
     "localname": "PastDueStatusAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PastDueStatusMember": {
     "auth_ref": [
      "r494",
      "r589"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [member]"
       }
      }
     },
     "localname": "PastDueStatusMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Past service cost, net defined benefit liability (asset)",
        "terseLabel": "Past service cost",
        "verboseLabel": "Past service cost/(credit)"
       }
      }
     },
     "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments from plan, net defined benefit liability (asset)",
        "terseLabel": "Benefits paid"
       }
      }
     },
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Repayment of lease liabilities"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PensionDefinedBenefitPlansMember": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for pension defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Pension defined benefit plans [member]",
        "terseLabel": "Pension schemes [member]"
       }
      }
     },
     "localname": "PensionDefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail",
      "http://www.gsk.com/role/OperatingProfitTables",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostRetirementHealthcareSchemesDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostRetirementBenefitsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired",
        "verboseLabel": "Percentage acquired"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PeriodCoveredByFinancialStatements": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the period covered by the set of financial statements or notes."
       }
      },
      "en-us": {
       "role": {
        "label": "Period covered by financial statements",
        "terseLabel": "Period covered by financial statements"
       }
      }
     },
     "localname": "PeriodCoveredByFinancialStatements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets, at fair value",
        "periodEndLabel": "Assets, ending balance",
        "periodStartLabel": "Assets, beginning balance",
        "totalLabel": "Fair value of assets"
       }
      }
     },
     "localname": "PlanAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PlanAssetsMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets [member]",
        "terseLabel": "Plan Assets [Member]"
       }
      }
     },
     "localname": "PlanAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents",
        "negatedLabel": "Cash consideration received/(paid)",
        "verboseLabel": "Cash consideration paid (received)"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVenturesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "auth_ref": [
      "r553",
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined benefit plans",
        "terseLabel": "Defined benefit pension and post retirement cost",
        "verboseLabel": "US post retirement healthcare scheme obligation"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Prepayments": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      },
      "en-us": {
       "role": {
        "label": "Prepayments",
        "verboseLabel": "Prepayments"
       }
      }
     },
     "localname": "Prepayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentValueOfDefinedBenefitObligationMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Present value of defined benefit obligation [member]",
        "terseLabel": "Present value of defined benefit obligation [member]"
       }
      }
     },
     "localname": "PresentValueOfDefinedBenefitObligationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementsInFairValuesOfAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from contributions of non-controlling interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations",
        "totalLabel": "Total",
        "verboseLabel": "Total consideration value"
       }
      }
     },
     "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Issue of share capital"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from non-current borrowings",
        "negatedLabel": "Increase in long-term loans",
        "terseLabel": "Issue of long-term notes"
       }
      }
     },
     "localname": "ProceedsFromNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 23.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of intangible assets, classified as investing activities",
        "terseLabel": "Proceeds from sale of intangible assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 21.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities",
        "terseLabel": "Proceeds from sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r404",
      "r483"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]",
        "terseLabel": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r404",
      "r483"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]",
        "terseLabel": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/GoodwillAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTestsDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "terseLabel": "Another audit fee of the company's subsidiaries"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r45",
      "r208",
      "r230",
      "r232",
      "r396",
      "r399",
      "r478",
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncomeAlternate1": {
       "order": 5.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "disclosureGuidance": "Total profit after taxation for the year",
        "label": "Profit (loss)",
        "positiveLabel": "Profit after taxation for the year",
        "positiveTerseLabel": "Share of after-tax losses",
        "presentationGuidance": "Total profit for the year",
        "totalLabel": "Total profit after taxation for the year",
        "verboseLabel": "Profit after taxation"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) [abstract]",
        "terseLabel": "Segment profit"
       }
      }
     },
     "localname": "ProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r48",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "positiveLabel": "Profit after taxation",
        "terseLabel": "Profit after taxation",
        "verboseLabel": "Total profit attributable to\u00a0non-controlling\u00a0interests"
       }
      }
     },
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Total profit attributable to shareholders"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r318",
      "r441",
      "r442",
      "r507",
      "r508"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Profit before tax",
        "totalLabel": "Profit before taxation",
        "verboseLabel": "Profit before taxation"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "auth_ref": [
      "r45",
      "r251",
      "r396",
      "r399"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 5.0,
       "parentTag": "gsk_CashFromUsedInOperationsBeforeTaxesContinuingOperations",
       "weight": -1.0
      },
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations",
        "positiveVerboseLabel": "Profit after taxation for the year from continuing operations",
        "terseLabel": "Profit after taxation from continuing operations",
        "totalLabel": "Profit after taxation from continuing operations",
        "verboseLabel": "Total profit after tax from continuing operations"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations attributable to non-controlling interests",
        "positiveTerseLabel": "Share of profit for the year attributable to non-controlling interest",
        "terseLabel": "Profit attributable to non-controlling interests from continuing operations"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "auth_ref": [
      "r56",
      "r63",
      "r252",
      "r317"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from discontinued operations",
        "terseLabel": "(Loss)/profit after taxation from discontinued operations: Consumer Healthcare until 18 July 2022",
        "totalLabel": "Profit after taxation from discontinued operations"
       }
      }
     },
     "localname": "ProfitLossFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations attributable to non-controlling interests. [Refer: Profit (loss) from discontinued operations; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from discontinued operations attributable to non-controlling interests",
        "terseLabel": "Profit attributable to\u00a0non-controlling\u00a0interests from discontinued operations",
        "verboseLabel": "Non-controlling\u00a0interest in discontinued operations"
       }
      }
     },
     "localname": "ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r458",
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "terseLabel": "Operating profit",
        "totalLabel": "Operating profit"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) on disposal of investments and changes in value of investments",
        "verboseLabel": "Realised after tax losses on disposal or liquidation of equity investments"
       }
      }
     },
     "localname": "ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r86"
     ],
     "calculation": {
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      },
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 18.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetail",
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r87",
      "r459",
      "r485"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment recognised as of acquisition date",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r139",
      "r143",
      "r241"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Percentage of common stock held",
        "label": "Proportion of ownership interest in associate"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/NonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r139",
      "r143",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Proportion of ownership interest in subsidiary"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": {
     "auth_ref": [
      "r139",
      "r143",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in subsidiary",
        "terseLabel": "Proportion of voting rights held in subsidiary"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "Utilised"
       }
      }
     },
     "localname": "ProvisionUsedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provisions for employee benefits",
        "terseLabel": "Provision for employee benefits"
       }
      }
     },
     "localname": "ProvisionsForEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 22.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchasesFairValueMeasurementAssets": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in the fair value measurement of assets resulting from purchases of those assets. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchases, fair value measurement, assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "PurchasesFairValueMeasurementAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CurrentEquityInvestmentsSummaryOfCurrentEquityInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r275",
      "r298",
      "r415",
      "r480",
      "r482",
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r275",
      "r298",
      "r415",
      "r480",
      "r482",
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "verboseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesAdditionalInformationDetail",
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/LegalProceedingsAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/OtherIntangibleAssetsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RatedCreditExposures": {
     "auth_ref": [
      "r515",
      "r519"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of credit exposure that has been rated by external rating agencies. [Refer: Credit exposure]"
       }
      },
      "en-us": {
       "role": {
        "label": "Rated credit exposures",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "RatedCreditExposures",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "auth_ref": [
      "r64",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      },
      "en-us": {
       "role": {
        "label": "Raw materials and consumables used",
        "terseLabel": "Raw materials and consumables"
       }
      }
     },
     "localname": "RawMaterialsAndConsumablesUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax": {
     "auth_ref": [
      "r60",
      "r436"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      },
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 12.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to cash flow hedges, before tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges, before tax",
        "negatedTerseLabel": "Reclassification of cash flow hedges to income statement"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments on cash flow hedges for which the hedged future cash flows are no longer expected to occur, net of tax. [Refer: Reclassification adjustments on cash flow hedges, net of tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges for which hedged future cash flows are no longer expected to occur, net of tax",
        "terseLabel": "Hedged future cash flows no longer expected to occur"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments on cash flow hedges for which the hedged item affected profit or loss, net of tax. [Refer: Reclassification adjustments on cash flow hedges, net of tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges for which hedged item affected profit or loss, net of tax",
        "terseLabel": "Due to hedged item affecting profit or loss"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax": {
     "auth_ref": [
      "r60",
      "r353",
      "r356",
      "r436"
     ],
     "calculation": {
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges, net of tax",
        "negatedLabel": "Reclassification of hedges from other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinanceExpenseSummaryOfFinanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax": {
     "auth_ref": [
      "r60",
      "r119"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      },
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on exchange differences on translation, net of tax",
        "negatedLabel": "Reclassification of exchange from other comprehensive income",
        "negatedTerseLabel": "Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries and associates"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses20222021And2020AcquisitionDetail",
      "http://www.gsk.com/role/ConsolidatedStatementOfComprehensiveIncome",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "verboseLabel": "Repayment of medium term notes (MTNs)"
       }
      }
     },
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfCurrentBorrowings": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of current borrowings",
        "negatedLabel": "Repayment of short-term loans",
        "terseLabel": "Repayment of short-term Notes"
       }
      }
     },
     "localname": "RepaymentsOfCurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of non-current borrowings",
        "negatedLabel": "Repayment of long-term loans"
       }
      }
     },
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedCashFlowStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfCashFlowHedgesContinuingHedges": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the reserve of cash flow hedges in relation to continuing hedges. [Refer: Reserve of cash flow hedges]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of cash flow hedges, continuing hedges",
        "terseLabel": "Balance in cash flow hedge reserve for continuing hedges"
       }
      }
     },
     "localname": "ReserveOfCashFlowHedgesContinuingHedges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the reserve of cash flow hedges in relation to hedging relationships for which hedge accounting is no longer applied. [Refer: Reserve of cash flow hedges]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of cash flow hedges, hedging relationships for which hedge accounting is no longer applied",
        "terseLabel": "Cash flow hedge reserve arise from hedge relationships for which hedge accounting is no longer applied"
       }
      }
     },
     "localname": "ReserveOfCashFlowHedgesHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfCashFlowHedgesMember": {
     "auth_ref": [
      "r410",
      "r443"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the accumulated portion of gain (loss) on a hedging instrument that is determined to be an effective hedge for cash flow hedges. [Refer: Cash flow hedges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of cash flow hedges [member]",
        "terseLabel": "Cash Flow Hedges Reserve [Member]"
       }
      }
     },
     "localname": "ReserveOfCashFlowHedgesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the accumulated gains and losses on hedging instruments that hedge investments in equity instruments that the entity has designated at fair value through other comprehensive income."
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of gains and losses on hedging instruments that hedge investments in equity instruments",
        "terseLabel": "Hedging gains/(losses) recognised in reserves"
       }
      }
     },
     "localname": "ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r3",
      "r224",
      "r225",
      "r228",
      "r414",
      "r541"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]",
        "terseLabel": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail",
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestructuringProvisionMember": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Restructuring provision [member]",
        "terseLabel": "Major Restructuring Programmes [Member]"
       }
      }
     },
     "localname": "RestructuringProvisionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r447",
      "r449"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r8",
      "r443"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Retained earnings [member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r3",
      "r224",
      "r225",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]",
        "terseLabel": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesPolicies",
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/FinanceIncomeSummaryOfFinanceIncomeDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail",
      "http://www.gsk.com/role/PresentationOfTheFinancialStatementsAdditionalInformationDetail",
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail",
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebtDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfLossAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Return on plan assets excluding interest income or expense, net defined benefit liability (asset)",
        "terseLabel": "Actual return on plan assets",
        "verboseLabel": "Return on plan assets, excluding amounts included in interest"
       }
      }
     },
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r52",
      "r250",
      "r318",
      "r390",
      "r398",
      "r404",
      "r405",
      "r408",
      "r441",
      "r442",
      "r478"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 9.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Turnover"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail",
      "http://www.gsk.com/role/NonControllingInterestsSummarisedFinancialInformationOfViivHealthcareGroupAndGskConsumerHealthcareJointVentureDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSummaryOfGeographicalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue and other operating income",
        "terseLabel": "Revenue recognized in deferred income"
       }
      }
     },
     "localname": "RevenueAndOperatingIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from performance obligations satisfied or partially satisfied in previous periods",
        "terseLabel": "Revenue recognised in year from performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromRoyalties": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      },
      "en-us": {
       "role": {
        "label": "Royalty income",
        "terseLabel": "Royalty income"
       }
      }
     },
     "localname": "RevenueFromRoyalties",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r153",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss",
        "negatedLabel": "Total impairment reversals"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets held for sale, net of reversals",
        "terseLabel": "Reversal of impairments"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61",
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Reversal of impairments"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfInventoryWritedown": {
     "auth_ref": [
      "r61",
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of inventory write-down",
        "negatedLabel": "Reversal of prior year write-down of inventories"
       }
      }
     },
     "localname": "ReversalOfInventoryWritedown",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfInformationAboutProfitLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfProvisionsForCostOfRestructuring": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail": {
       "order": 2.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversals of provisions for the cost of restructuring. [Refer: Restructuring provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of provisions for cost of restructuring",
        "negatedLabel": "Amount of provision reversed unused"
       }
      }
     },
     "localname": "ReversalOfProvisionsForCostOfRestructuring",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfitFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 26.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Net book value, end of the year",
        "periodStartLabel": "Net book value, beginning of the year",
        "verboseLabel": "Right of use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail",
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssetsMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets [member]",
        "terseLabel": "Right-of-use assets [member]"
       }
      }
     },
     "localname": "RightofuseAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r158",
      "r278",
      "r396",
      "r454",
      "r513"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [axis]",
        "terseLabel": "Segments [axis]"
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r158",
      "r278",
      "r403",
      "r454",
      "r513"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [member]",
        "terseLabel": "Segments [member]"
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssetsHeldForSaleAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectorsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/GoodwillSummaryOfGoodwillAllocatedToSegmentsDetail",
      "http://www.gsk.com/role/OtherOperatingIncomeExpenseAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTables",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverByProductServiceDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationTurnoverBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      },
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail": {
       "order": 2.0,
       "parentTag": "gsk_CostChargedToOperatingProfit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedLabel": "Selling, general and administration",
        "terseLabel": "Selling, general and administration",
        "verboseLabel": "Selling, general and administration"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/MajorRestructuringCostsSummaryOfMajorRestructuringChargesFromContinuingOperationsByIncomeStatementDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfPensionAndOtherPostEmploymentCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sensitivity analysis for types of market risk [text block]",
        "terseLabel": "Sensitivity Analysis for Each Type of Market Risk"
       }
      }
     },
     "localname": "SensitivityAnalysisForEachTypeOfMarketRisk",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r54",
      "r393",
      "r402",
      "r426"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedIncomeStatement": {
       "order": 14.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "definitionGuidance": "Share of after tax profits and losses of associates and joint ventures",
        "disclosureGuidance": "Share of after-tax profits/(losses) of associates and joint ventures",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method",
        "positiveLabel": "Share of after-tax profit / losses of associates and joint ventures",
        "positiveTerseLabel": "Share of after tax (loss)/profits of associates and joint ventures",
        "verboseLabel": "Profit/(loss) after tax recognised in the consolidated income statement"
       }
      }
     },
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/ConsolidatedIncomeStatement",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium account"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Share premium [member]"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Associates [member]; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates",
        "terseLabel": "Number of shares owned"
       }
      }
     },
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_ShorttermBorrowings": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 29.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current borrowings",
        "negatedLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShorttermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/NetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowingsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermBorrowingsMember": {
     "auth_ref": [
      "r472",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term borrowings [member]",
        "terseLabel": "Short-term borrowings [member]"
       }
      }
     },
     "localname": "ShorttermBorrowingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, classified as cash equivalents",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense [abstract]"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ShorttermLegalProceedingsProvision": {
     "auth_ref": [
      "r461",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provision for legal proceedings. [Refer: Legal proceedings provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current legal proceedings provision",
        "terseLabel": "Short term legal proceedings"
       }
      }
     },
     "localname": "ShorttermLegalProceedingsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "auth_ref": [
      "r140",
      "r144",
      "r264",
      "r427",
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Associates [axis]",
        "terseLabel": "Associates [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfAggregatedFinancialInformationDetail",
      "http://www.gsk.com/role/AssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociateDetail",
      "http://www.gsk.com/role/InvestmentsInAssociatesAndJointVenturesAdditionalInformationDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r140",
      "r144",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]",
        "terseLabel": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail",
      "http://www.gsk.com/role/OperatingProfitAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupDetail",
      "http://www.gsk.com/role/PrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParentheticalDetail",
      "http://www.gsk.com/role/TaxationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SocialSecurityContributions": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Social security contributions",
        "terseLabel": "Social security costs"
       }
      }
     },
     "localname": "SocialSecurityContributions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedStatementOfChangesInEquity",
      "http://www.gsk.com/role/MovementsInEquityAdditionalInformationDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategoryDetail",
      "http://www.gsk.com/role/MovementsInEquityAnalysisOfOtherReservesDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityDetail",
      "http://www.gsk.com/role/MovementsInEquitySummaryOfCumulativeTranslationExchangeInEquityParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubsidiariesMember": {
     "auth_ref": [
      "r129",
      "r140",
      "r144",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [member]",
        "terseLabel": "Subsidiaries [member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OperatingProfitSummaryOfAuditorsRemunerationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SurplusDeficitInPlan": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Surplus (deficit) in plan",
        "terseLabel": "Net surplus/(obligation)",
        "verboseLabel": "Accrual of Future pension plan"
       }
      }
     },
     "localname": "SurplusDeficitInPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUkAndUsDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroupDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "terseLabel": "Differences in overseas taxation rates"
       }
      }
     },
     "localname": "TaxEffectOfForeignTaxRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "UK statutory rate of taxation",
        "verboseLabel": "Tax rate %"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFinancialInformationRelatingToDiscontinuedOperationsDetail",
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect of foreign tax rates",
        "terseLabel": "Differences in overseas taxation rates"
       }
      }
     },
     "localname": "TaxRateEffectOfForeignTaxRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUkStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TerminationBenefitsExpense": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Termination benefits expense",
        "terseLabel": "Severance and other costs from integration and restructuring activities"
       }
      }
     },
     "localname": "TerminationBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r275",
      "r298",
      "r415",
      "r480",
      "r482",
      "r584"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AccountingPrinciplesAndPoliciesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 31.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "negatedLabel": "Trade and other payables",
        "terseLabel": "Trade and other current payables",
        "totalLabel": "Total trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet",
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r19",
      "r36"
     ],
     "calculation": {
      "http://www.gsk.com/role/ConsolidatedBalanceSheet": {
       "order": 11.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayables": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "negatedLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNonCurrentLiabilitiesAndContingentConsiderationLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherPayablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables recognised as of acquisition date",
        "negatedLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposalsSummaryOfFairValuesOfTheAssetsAcquiredInBusinessCombinationsIncludingGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows": {
     "auth_ref": [
      "r497",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables, undiscounted cash flows",
        "negatedLabel": "Trade payables and other liabilities not in net debt"
       }
      }
     },
     "localname": "TradeAndOtherPayablesUndiscountedCashFlows",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfAnticipatedContractualCashFlowsIncludingInterestPayableForTheNonDerivativeFinancialLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "auth_ref": [
      "r19",
      "r36"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other receivables",
        "terseLabel": "Trade and other receivables",
        "totalLabel": "Total trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsAndOtherReceivablesAndOtherNonCurrentAssetsDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeReceivables": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "positiveLabel": "Trade receivables, net of loss allowance",
        "verboseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r361",
      "r367",
      "r494",
      "r540"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]",
        "terseLabel": "Trade and other receivables [member]"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Liabilities transferred out of level three"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r145",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "terseLabel": "Treasury shares at cost"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury shares [member]"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ShareCapitalAndSharePremiumAccountAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of financial assets [axis]",
        "terseLabel": "Types of financial assets [axis]"
       }
      }
     },
     "localname": "TypesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of financial liabilities [axis]",
        "terseLabel": "Types of financial liabilities [axis]"
       }
      }
     },
     "localname": "TypesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfHedgesAxis": {
     "auth_ref": [
      "r341",
      "r348",
      "r355",
      "r434"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of hedges [axis]",
        "terseLabel": "Types of hedges [axis]"
       }
      }
     },
     "localname": "TypesOfHedgesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfHedgesMember": {
     "auth_ref": [
      "r341",
      "r348",
      "r355",
      "r434"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Hedges [member]",
        "terseLabel": "Hedges [member]"
       }
      }
     },
     "localname": "TypesOfHedgesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParentheticalDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfInstrumentMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of instrument [member]",
        "terseLabel": "Types of instrument [member]"
       }
      }
     },
     "localname": "TypesOfInstrumentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfInsuranceContractsAxis": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of insurance contracts [axis]",
        "terseLabel": "Types of insurance contracts [axis]"
       }
      }
     },
     "localname": "TypesOfInsuranceContractsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]",
        "terseLabel": "Types of interest rates [axis]"
       }
      }
     },
     "localname": "TypesOfInterestRatesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricingDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r335",
      "r359",
      "r360",
      "r416",
      "r417",
      "r418",
      "r420"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r335",
      "r359",
      "r360",
      "r416",
      "r417",
      "r418",
      "r420"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/ContingentConsiderationLiabilitiesDisclosureOfSensitivityOfKeyModelInputToMeasureContingentConsiderationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovementsDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresImpactOfNonFunctionalCurrencyForeignExchangeExposuresDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposureDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresTables",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail",
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfCostOfShareBasedIncentivePlansDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesAdditionalInformationDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesScheduleOfNumberOfSharesAndAdsIssuableDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfOptionOutstandingDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemesDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeDetail",
      "http://www.gsk.com/role/EmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParentheticalDetail",
      "http://www.gsk.com/role/OtherInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnallocatedAmountsMember": {
     "auth_ref": [
      "r509",
      "r510"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for items that have not been allocated to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Unallocated amounts [member]",
        "terseLabel": "Corporate and Other Unallocated [member]"
       }
      }
     },
     "localname": "UnallocatedAmountsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationSegmentProfitAndOperatingProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UndrawnBorrowingFacilities": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Undrawn borrowing facilities",
        "terseLabel": "Revolving credit facilities",
        "verboseLabel": "Revolving credit facilities"
       }
      }
     },
     "localname": "UndrawnBorrowingFacilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresAdditionalInformationDetail",
      "http://www.gsk.com/role/NetDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused provision reversed, other provisions",
        "negatedLabel": "Reversed unused"
       }
      }
     },
     "localname": "UnusedProvisionReversedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/OtherProvisionsSummaryOfOtherProvisionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Tax losses [member]"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ValuationTechniquesMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Valuation techniques [member]",
        "terseLabel": "Valuation techniques [member]"
       }
      }
     },
     "localname": "ValuationTechniquesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Valuation techniques used in fair value measurement [axis]",
        "terseLabel": "Valuation techniques used in fair value measurement [axis]"
       }
      }
     },
     "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/RightOfUseAssetsSummaryOfDisclosureOfDetailedInformationAboutRightOfUseAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "terseLabel": "Wages and salaries"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EmployeeCostsSummaryOfEmployeeCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]",
        "terseLabel": "Weighted average number of shares in issue"
       }
      }
     },
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/EarningsPerShareScheduleOfNumbersOfSharesEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for wholly funded or partly funded defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wholly or partly funded defined benefit plans [member]",
        "terseLabel": "Funded [member]"
       }
      }
     },
     "localname": "WhollyOrPartlyFundedDefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WhollyUnfundedDefinedBenefitPlansMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for wholly unfunded defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wholly unfunded defined benefit plans [member]",
        "terseLabel": "Unfunded [member]"
       }
      }
     },
     "localname": "WhollyUnfundedDefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WorkInProgress": {
     "auth_ref": [
      "r446",
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current work in progress",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "WorkInProgress",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.gsk.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/ExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRatesDetail",
      "http://www.gsk.com/role/FinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/TurnoverAndSegmentInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/AcquisitionsAndDisposals20222021And2020AcquisitionsAdditionalInformationDetail",
      "http://www.gsk.com/role/CurrentEquityInvestmentsAdditionalInformationDetail",
      "http://www.gsk.com/role/PensionsAndOtherPostEmploymentBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gsk.com/role/TradeAndOtherPayablesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "148",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_148_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "48",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_48&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS21_g51-57__IAS21_g51-57_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "23",
   "Paragraph": "26",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2022-en-r&anchor=para_26_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_ix&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "34",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2022-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "129",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_f_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_f_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "135",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS37_g84-92__IAS37_g84-92_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "122",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2022-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "86",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2022-en-r&anchor=para_86_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "48",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_48&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "10",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "27",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_27_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Section": "Nature of the risks associated with an entity's interests in consolidated structured entities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS12_g14-17__IFRS12_g14-17_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r270": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Section": "Explanation of activities subject to rate regulation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS14_g30-31__IFRS14_g30-31_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r280": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r290": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r300": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_o_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r310": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_vi&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67__IFRS03_gB64-B67_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r320": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r330": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r340": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24A_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r350": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_b_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24E",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24E_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r360": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35J",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35J_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r370": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r380": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B51&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F__IFRS07_g13A-13F_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "22",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_22_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r390": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r400": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r410": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "6.5.11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.11&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r420": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39G",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39G_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r430": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "22",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_22_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_22&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_c&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_d&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "24",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_24_c&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r440": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r450": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r460": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Example 10 A court case",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r470": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r480": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Example 11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Implementation%20Guidance&dita_xref=IFRS05_ex11__IFRS05_ex11_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r490": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B33&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r500": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG40D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40D&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r510": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "IG4",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_IG4&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG24",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_c&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r520": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG24",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG25",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG25_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r529": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r530": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r531": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r532": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r533": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r534": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r540": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r550": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "171",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_171&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r560": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r570": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r580": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&doctype=Standard&book=b&dita_xref=IFRS04_g36-39M__IFRS04_g36-39M_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r590": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "92",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_92&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ix&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "74",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_74_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>348
<FILENAME>0001193125-23-067105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-067105-xbrl.zip
M4$L#!!0    ( )M9:E:ORT.QZ-P" -3S+  /    9#,X,C8W-V0R,&8N:'1M
M[+U;E^*XEN_[?L8XWZ%&G8?]5)65F=VG>^59:^U!$)>D,C*@ R*J:[_$4-@"
MM-)(E&0307_Z(\D&;.,K&+"LN<?>>U4&QEC_^9O3NDQ-_?U_OR^\GU:8"\+H
M/W[^^.MO/_^$J<-<0F?_^#GPI[_\Y\\__>]__M__U]_GOKQ07DS%EYGX\8^?
MY[Z__/+AP]O;VZ_RW[\Z;/'ATV^?/GW\]/GCS]%U'J')"]]?N?<KXS-YY6^?
M/ZB/7Y' F\O5IR[9?B%^\?_[(?QP>^G>K=\^ZVL__NUO?_N@/]U>*DC6A?*F
M'S_\]_?[L3/'"_0+H<)'U$D\"REX]O3U+DX]N,#.KS.V^B _T+IL+B2"_=NG
MC_]1=.OPBMV=EQP[R,=N[G?^]@%QAS,/?]A=O/FZPP+J\W7VPT4?)A[0"3B7
M!.1](_HT\17\[LRS+U>?)"ZEB#@B^UK]4>)B09SL2^4'R0O])<^Y4GZ2N/3=
M*Y#^O^]CX 0^+U!<?KHUZ92+7Z:!%]U9;)Y!_5U_P4?OC+)%*-HOOWW^Y=._
M?=A^:=L&[F]_;HK$J_ZF_&.2GO>\1_JHF)3<X_^^>KS?7>YG7[^[](//$153
MQA?(ER% _=IOO_SVZ9>/G^*N4"1:VHWEC_XBY4]\8V..HM_]^.^__/:?OVRC
M1[YWJTCTLPY)&+GJ?WWB>_B?\KEO__XA_&_YQP7VT4\.HSZF4@0?O_L?U!?_
MOY^<.>("^_]XFMRJX*9^Y1?\5T!6__BY'U[^RV2]Q#]_4'?YL/F-5^:N?Q+^
MVL/_^'F!WG]Y(ZX___(3"GP6/LN___/OZ*<YQ]-__/S_^,SY^9\3].KAG]CT
MI^BNXN\?T#_E#?]=7>Z2572W_^42L?30^LM/E%'\O_[Y=_+^1?THYN%_$M?%
M5/^G_/PA6&!.G)\H6LCGD+'E2V^!J2O_GW_KH=G/88/?_4?U&*/?/K[(_ZOX
MF;"/GUX^A__]\S^GR!/X[Q\2M\S_A6OF!/H'B'"0-Y*?,O=6_DU4_+7;/RO_
MU V5YEOWY8]QY VHB]^_X77%G_E-!O2/GS]^_MO?]G[N0U)':2.L@A@6__R[
M@O>+T.\ >?N?])OCBR_-_X^?!5DL/46U_EMH6?FF^V7SEOOU7<@H^R&ZQ\8+
MZM[E10;L7R7PFRM4&"]P-AWEY5>$U$@[SOWN=S>WB%X&Q:]'>1.VQ-PG6.R_
MB*N_72N_XH_6R<73NCK)KQ!*K%+)0Z]U59)?P9XU LD05E<@^14G\$SSM@^I
M2*?_*5C ];]T__9+%%A_(FY^8/WIGS]%5V,=G;?_)*[ZPY1@_I,.H#CSC=\?
M?$O&YO27Y?T^9-Y_J=\TVW_*_C;WKV77]I]A+^JC_+^;;^X^VSVKN[OVXR?9
MK=C]BAM=^2'U.Q\2HA1K]#&FT<=V:O2QAD8?3Z'1;S&-?FNG1K_5T.BW!C7J
MB2%MH8^%HUH_PVLVGQS?VO9X2ZRU'T_5VO9P'VOM;PVW]K?_?/GMWUML6SFL
M_.W?&VGM;__Q\O$_HW?D[K];T^KT._(_?OGXGQ7?D8EK&XMM'__6&FUV1'S\
M6X/\9[_M7N287ZCAYU>,/'_N((Z_X\6KO.^4"S7K,\8S-:86O7<B7KXR>5OG
MATA>,N+,#1QY"77'F*^([+>IJ\\A:$1,^(S1OUWY>^]+^9S$#Y_S)Y?(C\-Y
MX^ULUI=XP^2CRK[WESPM_OXA\[[U?B]?)?73267S?_!#NL7F="5R +PG?P7$
MU8.6(;\F8LD$\H;3H9KJQTB,@U=!7(+X.L4EF5%)@2/]84!76/C:F .ZO9Z8
M06'U9BA,:HIE$T=])OSA]#OZ%^./4D<N?2W@A,[")M^-OR7^JJYN+Q_*U+F/
M&T:JHL;:9/:15()CGW"L6G2%*9X2/_6"NE;3:]B-/AQYB+;7]+O0D/_4BH"B
M=MMD_V="GL/W=7^O[W(5"*F@$'VV>"541TT3#%_PV,KR62VVR>(#2MF*K-"
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M5!!R5Y.W45."&YS'#>Q]:8(;@!MLW0#Z&^ @X" %#A+=.6-#2+?WN>RN*5,
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M%??RACK'9X+IGQCQ% 2)*74K"$I-B>\^R%&JD7EXP/90;&^E)MH:\L7PP'S
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ML-M'2[*W'B5'/4M&U5!(&N>O0)5'TE,2W"44\?5X+J- &EX/":$4UQ]&=S6
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MK^M!>[=X_=JC;I]]NP-D]Y#=4^<LP%Y;!6PO$#XGJ,JF@=3+;S1'?(&DC>:
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MX*G.7?P3$]RFN/F)[EN9HHT0GJ6?WDE=T0Z >&W$']A*MH.(35G'JT"H_Q$
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M7V3FN"2G#UAI30W%B/$>0!2':"L((%1Q\N[U=<BO$,2B.$9)40"EBBA=C;Q
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M+MJM6^6GCCKG;Z0J#NI/AM-[1F?R5HOX#<7^7;"KSO\R@8(3GL-7\RF2FNF
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M3Z<3OJ [O5MA(^@M6>FY+!%?F9M@"BB6H5A!.8#SR*@8J9E0&")EM4A913L
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MZ@JW=WWM0M-Z9GF.MN>$5>S;@-MT$-@31(MLJKKB,S4& ^ PX#!5'*8S P(
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M"3V"6!K4G3X0/@5?CL!]#Q/FVF!H'E[A^AR^D#[_- .EY>E2 KW LL_I/%L
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M0=F"6T9AS>&MI\46.X:++ADS7JEI>IDVQ-8X2VHO%G_^&X:;8'7^P,X%)23
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MG4B^'3U,L/R)[4X)7YX4.W%M:A%[F8!RY_(9LV7HN9-Y?C&!4"7S0**$"1H
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M?&?J"[%:8JRQLN$MWF/#7"KBQ6Q*@"U-U2=2M6Y8?7C7_YA7YX?OK0E6 \N
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M>MK_Z)_26WY6Y3]W4OXS=G)O[].[_7S[:;%[JS@(K)#0F$*P$=Z6D_9#/_"
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M.:P(7KQ=8W\(OM\?QG(M(8$/O^T?[KWO[YV]ZX-P1"&6S>@V VUWF]1X[@N
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M6EO%<'?49"6CR:TP>XUNMC#T1_W#-5MX7FD#7T4F@G2R(.$[%5<B2E:HL=5
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M2EON8#&]"^'8HF$/_/:IRUNVY32<O>/LG<9):L<5W,F[DW<G[[BH/?9.[4-
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M2>>5"6?SMT/:#7>: V=D1? ;>&5_+(37;7<[WB19K@)TK5\)+Q79.LHS;Q'
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M-\04S4E=(7'5'7,J4N0R/&Y#<DT:55&,3_, 4Y=D/Z&LRE$$B&\\&<BC5Y[
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MS$&_0HOE889<%O(+LOO%%+=.ECU[6#*)YP[)CI^5#]>"V\".% ERF>CLO;S
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M:N?"DU<GHF=K6=*FIW1 0)OC4Z*:D@[=&7GI:WG)Y.5\9E@;'Y(D7B>XJ/'
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M!P[]N60]K5%F/3/R"V-IGLE:7IJ=C#6LW]W4RE0?0'*$D_F/-& B;N#PN^R
MW1EO/_\3O$[4"[ [?ZYA.YA)/Z)6"%-\T!%W%!P.B'<=!]V%!_!Y:2EW(+Q
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M-@8([-T*9?]+X4$OCE,&,A^'*Y9X*_C8W"$&X>^N1?)J;,"!Q%B%<S -L.-
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MMJ:X0KMGP#GI=G^6W0ED_< 7*NM;#O#"%6J!PR0@VPN'%+GVF1-[\>[PDY3
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M,L@*)P!\_Q'>YLUX@AS-6U\VZ<NF#MW&Z,LF?=ET'[?T"S7+R/2A@^VX8/"
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M?P]Y+DK%]^"=B/D.[CM"C_HA*'66#2GT:I9'!R2 1R7NCAM&H('H71!=</M
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MB@NN%\5.KJ7->H=:>/$]$7%4T](EX7I"[F2CVNV(&ZM7+>3M5?OH:)6B?JB
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MF@2=IFW")#\8B!X31$TZ2=4?,[P]G:1KTDE./)VDM9=\DH?=)[G=UU+$Z <
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M(,N'G.KW8QX*AS/KU)!7$7KC/-&V,H\=%YL+;Q( Z4A 3"T,!4L\^S+S]Z(
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M3DD*Y/!4X$^!2U?C0@3FSA5@:]R$EU9  3(:H+!8$(7C9-HQO!_+;]G)0[\
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MD;RT0G&#W]FPJY$?+:D1M?Q^Q:W38:<J&X":''OC.;QCG"7,H\G8)T+69_G
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M C/#:!.QMQ W4?Q-2J2G2OIZE^>,)[:5@/3WIZ!KL$FDF&&+4-7F$GF1_&H
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M]\\?_I%&8Z!_TA5 7)C QEU(/=@Y/*AV#8=0+ZHYMOZU= ^T>GY8E7RO],L
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M4P> %JCZ!%ZY&"%0N166PB[M#"[X4;Q@O:)[_5/2(/I"3^.7S\^DM=XZI,A
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MQ(LHI^&AH/5S<;JQA]VBZ9*YI"VA&H;SQOJ!O>+NVK*T'Y</8],53%O(KN*
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M>QS8H>QPC,P&XCM0""7U%!UG8C%"0K)YF'#N-/'0!X%N,ADM*IP2H]@74XI
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M2EWNL:#@EEQ5R(-05-9E13[DZ9 L*%"M&T%A!,7C.JG9POU=3.#E/M'5+/;
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MEP'K$'AN)UKW*MG+F_P-:\.3F!P-Q@179FO=6*05KZE)0]V&NN]_%<:V+)0
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MH'/%L0"E%7+#PIL(A?3 _X;\"JN#S9%_*I%,"P45 J"AT#3U,O9IL#V)R7$
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MDT<P/(8ONPD0&;_ 8<IAP?7DO!]>N^T7OZB@X''BHT3$;J%T"3W,FO /-!/
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M6^,XV%'*R3 <HM383J9NME123+#B;9+0CE7J$N7WJ,QJK%.A# \,JUU[ ?\
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MV&:#^1*>X9C$8?21LVO:=LNOP0#TJ'B**S4QN*X'5*P@3X$>C4YF\C8^,:O
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M/#.*IV/R%K#ITZ I6N_[J(Q#N'_2Q28ZDKP#21KWJ"E^[+/*A4[4OV&Y_JK
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MN$&%S+1*()O$;I1A:+A:D.NIW_8*) 9-&_WL<U)]> >FN'B@LAFL1;8T*>H
M$N:7][L@DFK$2>D5F1P-AZR"IK(O7CU=S#CA3<.XTHK)FN["."9)!Z,2YQVI
M8+.(+?N15Q 90Y EN C>C*"$:AU:XS5JQLLZ+)(!5@M019*/@ [Q$O]9 :70
MJFO+.-D&_C_8CZC2W)@;5-77]T!"(0OY+))-:6;52I*>(@/;/T15%C,=J&,6
M\D*DL8QTHJ(R0MV.B((9WEAI#/+0X[G]D*\+?>AX@KOK.#,P(8&00,$YKX:7
M_CNFE292AZ^! D ]T*#VPHR('97Q=(9*4V%F"W_LP5^.>X B=YV9RXQH3#V6
M"J=")VX:0%@#1?+PJYJ"<CXN\BF_(AI5Y7R?X<OY:.*K>(;DRWS"G-A^ \JE
MNL(T$>YAXVWGGN:Q-"Z5]T91SA-H-'&=$>+F@!4#K!TXS-R0/JX(E^9Q15F/
M.9"<]-5I_$4%'S\4H@ZI;\K5=4+"2\I4R7DDR(H",JL3Y  'B3-MJM6:'9V#
MY)CV> -AQ\X^OSV_>&"LH-ED)[B1W8ZPBL>(J^=.C6HN%[#*RB0-#D,IJY"C
MA,0!R#I7+5+RHD$5(!A3D+O\,GZ,;EOIL1[\NZ:D\ U,6-2-JQ2("@7>0VV?
ML8G,'8R#^:Z@!USV '=E7&DV!N@.)L401'&))H$FE$]>E>;+VHA:@?F6E"@7
MR-IAO>8:(\]-#=,CV[RN#I%:8WL0ALH</ WB=]KV_MIA)/3PP)$$GCTH9TJ-
MT!"K'NR^MMJ58,$Q>S(&&!M864#$N'Q'1M'2\Q-E8=2AK>0%)ZM1+L_60KFT
M&UY[R?Z6>JS8P="N20 ;K5#0MTGWVPIWOF7MDIU8 'JFAD-1&JTMLUB(+Y3@
M\FJKV=MUK2G:NVJ;CW=;MOJZ&$(".35V LGI$NC3(7MJ#'M8$5]&$3_-R0\!
MFCO*$__YCM(>D=*VFM06<^;0LY%GY$ 'QIC&VA7;U!VV]7&IZVJ;B4O,(9&3
M=151#)--^*T.'S,HGK J0*9*G(9&FKM1QKM!KF]19!R'MIZP:[#DX2V7#H34
M?D'9?\$^BK5-QD"3;[' 8^-:EAJZT='A\3/>?O@BPH#R(>IE)&AD?NJKI'DW
MCG?,2I,,>3,/9?.(P7P;XR+0'UFQ6^2F#LG %5E>YKI)D];?R%JDL6+:I[G$
M ]F#7UA?M\]5AW%1D'8+=NNL*G059V9#XF)JG02IRB:P$*"G!\N,_.0":V(=
MN[ G1H$R@7^@!VR5]6YC#R51^V5<ND )XL"!<6KZ"H^K,Q$[$U%9EM/"F8 <
M:_2&U[O3:3OK::GU1-S9.*&7^YO9S1QZF3O-MK.;VHD,]8PF#,4ZD$#?JE)2
M/O3-]-+-AB:'^Y$ML$>D'.1_(]EKC3F[\$>:@-8S<BW^'L8)#5LX3LHZ<,D+
M3<97H.O1!4$<1C!]7,\,T0BEP#O2^%IT-ON<A Y='-*\@6(+B#01EN  ->PO
M+),I!Z[P?U&1)JQ&-;.1&A@(%/)1O- !Z>: +[J.YYQ_SZ?1JYG6!#H88J5N
MCOV;A#B)@WL #&]ES6&C& R'B0\S:> 0'JAN[5@4R 18\"S)D@5(M[&M\SO+
M-:':HS_ 2$+OKQ;3(9Y3<>!>TYU*Z(!Q3+Y6VD +3 ;=&>P=OH (YLBOX?<P
M$JO_R=1N&)&^MC4^<!3GW"!),,4SX<L3'IDQ;.!XM'A[T8N<9%]@56 CO?V*
M(!QJ&IN;65I7,78F*>/A)6$D\EXD(#P$U]"[.>TD'_=H2NR.=IYP,4EZA%-Q
M2_& 6DBNB)Z88?HE;(+< XK9P*^C(BYC!\,SNKI9+#U6S4SL1_9G5!4,44'\
M5^'3O1!IN#_NSEGJ3+0$'T]U<!D1BM-T+M5(M^=%5]WY--$DO ?8%:LTH!4'
M##,8!5T5L[32'O^+X:<9;L8!+!P!5D5N5FGCUQ9@@6"Y702_GW3@]TV WV]T
M4K<2W*/]Z+_CPN&Z#=- 0*[4(470CI<-\@!%T)WKI@G"I4M5QB6*NST'-B4\
M4,$Q=$\GLH$]] >Q#"Y#ICV-1TH\+DFYWR*3,?*1%T/E.W>&/NC:<=U$<E:<
M4\(P'A]('CAP+)R\U^39S%1"41$ %JYB<N]8;-!U@2H*N:&T\>&%K*P$<E<'
M?U; J/ 3"L9/$T1C7\5I9?UL)!5&GKPBKPK/8H] GG;36Y^Y5.F(Q!#&(2N#
MS-7[>!QVMAH$LH-K(#M/8A]P#-=>(QP#1H6O%:*%X>P,@+&YMK:9@ 0H#3@8
MN7A]F-X"F+?U1A785$@D5P/%S,H2^:EZ!*^8E0S@4$.E-0J+/ZN\J*8>8+8$
MXHMU2;Y7=E;J0(0PL!INGW51% Y<3'NN!5ULAUK9IP>$W0'H"\7(-NM9_]@]
M4V,#Q[^'21#6STF_P/]'E6KT1UX5J#[8 \Y\G_[2.2T'>;O-E^/8?T#E-%/7
M9NX4Z8<=*1EO()O-VDL1@S:GX%XBX(5NB ,X6J>W%O4$?QR:,;.J &ZM&8X.
M"IE24]944<-#M>,ZL[_VV SU[PD&=]Y7PD--N"T['"4+ YIX/"CR":W"=SL;
MA3)PT\N@ZBN>$#9ZU_'<J9</AYQ5^]'O("KB!%%T3H]]N#0*SPPH?)BW07@S
MR39-M78HK8  *[LDD0=)=J5T68>SL(1C[)G@3YQU8[)R!L#;P)JHV\<,+I37
M+,#4,Y+>O9!-":N+WVW!;HT<D8F-#8 \(?D:S56,JR@$%H<]7Q!VEUG;A%B!
M&B(.<E2Q<2^6GE7AX;.Q2HP)7Z"X*&L"/$Q#PNW60"887R-.:!<+0OO/BJ_A
M=5S K2XUI['HDNZMFL[2?.X#?*QCT,QJY9X04",0)"3OAR TKY0U8QE0SY1"
M5W48ZTNYP 5^43*[1=4GA1_*5B5C8KQF,I<$BV\9@W)>6H8P.5]FJX9QAMP$
MR!*./=' UX@EQJ,1<@1+?L+H^8RG\1?V30B&"8TLC)0EB "XS*_Q@,BO 8>&
M6XC RE[H=,'X)[R@FBI[1FU'L^:)^*H&;2"R7!8TONQNBSL/!#@[!7:/.DU!
MDRC%0L<9SDC7P;P6!)!FDX?CBF/DBMC+V<A\OX#.P[CE@ANE4)E"FED6[4L"
M_XY03*7K!#/&BGQ:@')#%1S@F*YB_0#K)X7>DK83E80EUH!05&)(7D[?1+_Q
M(@B%PYM2O*=?,A3"]M,Z23'IU>>T("U1 L=\S^L:*[DA8R(EN5X8\I<X?]*.
MCB!>,5"*Z)!=0OA3QV3@&^:TY-ME_PRI;\*-W9/T-B?N9&0X+N7S_A+3F4C-
MQ>]9WT##17@]O)MQEPFSE)YG9.&I&^%#\,IKF]T6IHDB!Q@JX$LCIJI\.JTR
MI"KG>UT)&UEZV:=UF@$!.<N-WV?($?5P9B)R:#L28)L#+WD.XXPPDY43$D?8
M.A/B4\S$W\8*IGE=IDK3H8/-)YBLT>CP9%CT6]EX&*$VFZ/!@'!L/"C+O8&X
M%.\ZG:+==M$VS.*-7\\3X2B]VD1X[J?YA6A9S%H& 0968OT%/6\R[;)=/DUS
MYXJT OZAN.YD/_J03),RMK!WIXVO-.6R/#N +<#+51IK+J<<*)5,LD?BXA@]
M*? 61ZFWL&0*6H\C I=BG]5,D(TNVEKAC +A7(@L]UFF)5N79 4,O6 ^E R5
M<]5;YT)5:H/]^3TC:OH'4/(HGUI]1SZF'H.LH<%+4>W#@IW"]$V"OO\H+J0V
MI+U'SE!>H8L.+W/$%R'+,VOID8PB1EH1C@:?=<(J%E]U!3IR+;^3]JPDG3+A
MM!,L8^!<&LA1,*MNAEY#&FRD8)$DG%+L^V,=<#D_/2L0/3_D @+ _Z>X$R2"
M7;W<-+[6-@H! A14(?CUPUW*R_WHE[IWQ^_Q_K!:D>]]FIL+TY) Z_FM\ R0
MN;H,PI@K(\(J:GZKD'Z2,.]UP9O@E'$;2)9PP<UZ0C'5E$=6?KAZ)\5<Q2FR
M=\%15\- Q0MFX(SR U@V:,VP,Q0E)6DS*TTN'RQ%XGN<CN&]%^U70W"MF+^%
MBZM-8&"O4NY98L=]$(NP 2#!YNAX;(S".AYAYI>\*MB;/*-;+58W_*K_U'N)
M1#?-9"R_:/6FP@%70TF5MK]@00RG&XSKL2#K@B7_X!24,[SUF)6%^RYNP-:%
M()]H?$B>05#622,GUU_;;]LQIE(00'[8&-JZ^8SW$7C<Y5P3X_'FA-&,?#K
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MP UMTQP>S:8]YT5+U]6CXQ\]:FGAMO6I/Y E7#L+:L"2X(Z.JB%I(MXA6ZD
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M;/D]J(ZHIQ>D/1[[PFJ4SX@11E0:,B5@: D2#KFX@?5(WI*9\Y(U'X9N#1M
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M0MU3%(WC8 OP^#<Y- :.<XGT1(V:D)1AD9"V6\_I6("K-PE[8<I'Y+W*Y>R
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M)I6?:Z2"<?U%87V&V-%!X+V1REEK><9ABXV(;/:S"(E+'+HHZJ[407 >!-
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MLG8#G'>AOD=>-QC3,XF]@TUO4KA76^TONUC'ZR4^T5(J"1.EL9O05^:Y;D2
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MG_TET<__>ME+!W.,*J;C^+?_#U!+ P04    " ";66I6[#.8OCG.  "\=0<
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M4Z>D7O3:P1GS2Z"E_6]T#Y(;'QQ7O<S'R3?MDPG&].+#(F\4Y^W_*%.9)R=
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M<BAV9^J&.EM+@!GB?P$1KB_74_^P@=6$"\*G9\K<N?5LTG-S%"G0I?K^8K%
M!7J>;X>P=&85],@6AL#-G\)T0NL'2IV_D!QEQZ14+U?98I5DRE?8<-F/CU6R
M*G.4+'.1%J6CS%RHCQJZUKL0A:WNO1#_0\>"?@.I%E0]ZJI]5. AI46ZT?=M
MWV0E: J9H32X7$D\SU+T DG0[<_3B1YJ9Y)\/FI/2PM+GND5TQ("HW-+>)G5
M7VQ.,_C@*+MH#U/ &:W/D0R@6'@BU^(][W&\(\Z[^]X?#T&WH270I!GYY?W[
MV'ZA9Z]V5F\&KPW_)(A\\V]HB&-O,:,E*>"CZ41_;SV$30GC_444[V&\+[2F
M  TTA_%7"'+>L2SXC9P5.GPS64-$&O1Z46M#"TP_[>K!5__0,ZY!/MYH'VFA
MM;KEU34KV'Z\7D6MPPH&JJ*<@V#KO;31JBV;9WF&509D @*W>G)_U[U.]":[
M]]-/CP8C<7,B]=NUKD0^O&1=L:?@X:_N"C@YP) 6^A]];V2:GT[X*O<U4;-B
M%,F_L:D>[&B^EB43@BV;'<&6SG(E_OH\:IG#!X[9W#/CC5&O0PBN=JOT'[,%
MZG %/%2]$BSHL\2>#T6I1;"83IJB>P>T=2JYE,#61C5#+<-)R[NYXUR"HEG)
MG+2#?S,P&?<R?O[#FU]/26@;0$M1QYK6RY#;5B=X2LLJ(S"H@#6$M)_1$7K7
M\J<28@*H@'%?:U/A$E*#\ M?DX$/7EW(5.]^_6C*@>M'Z'6BOQM[$Z\&FYW?
M7 V7GF<7^G:$=O+_#F,4[V4BETNM289RACTS#O]T DSNO?(I(?=OX@7:GBG,
M I(:U:>)/J0K><YT@NI&H8BL/N[1U1GV0%](+SB1N-B$_E25R5* C02K"U&*
MC"3?T_"#$%\8#UB%LKI:?#$BPTQU]EC;$*3H<@6%5(58HVBB_I.I,9HJ1M*9
M( T]C&TEN([N.A1Y*Z'<<;>!9&8#46W\YK7G^"#>\D9D:=)L>J?%G\&F6.AY
M9:!\A?WS0(9O^^S /LM%)W1A#BK\#-T=DE7$NL&;L6>7EEDT4S%G(8KDM?Z#
MJ,N*%6@-D#A]>%7X!>.ZHL;6VT%>"&V J:T6@4%8^;P!I8?IJP-,7^\B!=N6
MK\40K3N9IQ.RUI7\=V-:)N*!(H4VV_5JS;5!7C6;F@A9P1XU 2/XU?J(6C7K
M^YY34*B".)A^!EC]_C!AV"6^!HZ$Y^(2W>VYU">5/O2ZVF088IF+?E4QZVC/
MY)SH+HS=3IYTT>B_M#Z9D6:%6]/*;E9;I6TB_U)T,Q,OC*:_7I/!!$FX9<:B
M8#V/CC+W+VX/31L/,[ Y*FE%?N9;=,:8<4/<>W(FQ&AB07,X>OFEUY<8"EEK
MLYR"%?@ -8@W[8O>M6<#3&;-(/,!G@5*BKQ?,= [69=D'<+Q!OE<^#X9J+YW
MRG2U3IMJJ5B)"V,U!:8;]N!Y#"[<?UI?PK"47%08N=CY(NTW9A1RQ'<(GHW^
M/\5^S#?TY(Z]\ ]>W?G&S#KI9O$H&F*"[1 [5EIR!"7)4KEIZJT;!'X;KF*U
M+:@A<WN+Z_777T EX,4%TP9#*OR;O><@!!%&U/8@Y:*I* I4-;OB\+@657F1
MF<1I5]A8VX$/55JK$Y3K="*1A6B!:FII[0-\T^;LAP_Z7%ME7X7G*\QHI,ZG
M$)6^S3F5K/J.!!R:V^0BJ^I&VH"LG<<@WDC?I*^,"*#V)YO+!8]KUH9L+5$"
M).FQX69V^:<3>WF%I6:$&FG[#V&XH#5:%OV/#3[TW6T$X8<_"S38_T>/*"W7
MO2_KUTH;;<DO>E^)C+CT7Y45B&J1G,(^*=*QA07OQ[#@YY:IT+ZS/@+M$2MP
M'$;V1$Q0LLM^0VAC -,'_G=N8""R3^J'NGL,X)8VN<A$\FD6,=HWU@)O:1'0
M3VZ"<P5_==.;N>71US3D4H%UX>:O;V>_(__68^S+[VKY&T1JMR4)TXG)Y;,P
ML!6IQ57:A$="_K/[2-2-.SJLU1_>&MQ NJ7\H,]]4&-T4JY@P?0=Z3>T/^GP
M='[EFLKJT55I9><$&K%- 8J<>YEZ<@$R,:.SUQL-' ?^B*83T>A[:M>83@-]
M]G3DJ&7>#N)MT0NX-*U;KUQ^M.(-.\%T4DG>=!;+H6V3M$%#Z1+X9#!YC9;/
M/*<H_Y.7KU^]L]ILI0^B.VJC?;:?B_*R$IMOGA:E7@ PJB!1JG<$?/\I':TF
M>:X8&J8:C)&F/:_+FE:(H\$'VVEJ99.8>0[TM*;%TW-PV _E(E+&,&IR4:'R
M0R_91.E[1<T%GTUB(("E4(H>[LJVL9):G,W'F*$QH%W(7(![4R#=+"P;F%KZ
MA5@0@FKFH*_T.M0UV;",;#JFCR'F:T?=-Q;*;,!@CC@ C/N4W,=C?0/M,EKG
M$I8JP,7TXDE89?JAA'F9@N]:;4I(6I/&_0^][O9!2A/AH\5N29H"K#O$',5[
MB0 BPHCA,0A1$+TN!7J6?!A3A-*<C1G%V3C'R_ RU-,+R,U!,D@K0&54EKM/
M!P_YA5;F-WW 07-TE$%^>V#FYY2CTH*E13[#:".\/[=$ C-21L[N=MYLQ'/N
MP'-^/T \Y^_9&CV6WS.!B(_ML%"=[[0:RNW0=D;R0$7G/!,.,0ALZS3C?3G3
MU@NF4-B-Y0""L54,I@R<3U+RZRC7>\OU@P'*];,51'V0<@$.Q<$)M1^X7=!8
MP=S%K*V6P,I5[;"DHY_4%<J#U;9@'S3#IVS7+\+VK]\./PQP.[R%VBMMK]:U
M6*Q(29Z1"AS4SCAC^Y;]H8I&+;Q1RP_:)@:3C#3XS"$A3 XD4ZHQP-VRHBR(
M?X>L9G^3;X[!!6!17A :12C*YP6I%02N9 7$_[VMF6H?5)N\B$D%L]TXLO8+
M-FMJ2N\J#XE"X51WLU(2E&L-L!_V;Q<N)#TSUU#$!(9%S[^;G%TU'[\RA\]&
MESKG.+I***LRG: +<0GI%:^N*/0C8@'/OIK@QR%J @D(->"RN/4:P-8RE!30
M(V@>5<8I-"L)C.)]R.F2Z:3<^(=O"P1,H*F[R;O6;JPA_5I(_ [\K+!:+N5R
M*=B9:U$4E-&")Z[M0W"N[LW0=+2JH*GP#L=;XFV\N]YD>R>[=[>+2=P=6?;A
M^]N??;C52O+A )7D7Z+*+!*&;:>AJDFJ-V(C0?4GX&=0W]2J4>I1K?"I5:]M
M[!ZHN ZZ<CHY,J%C?7>P7EI>.644+K4O#O#%8]"U%P##2!.9X65>@55!@;0B
MX8BY&2FI6QP+/(&K.@5HKDK*.\NRJ>H5.O-%J?6O=E<N1-Y8! @?!SP-_*/6
M\C2](P?O]B"UX7<P*@"VEY9UU51;;23AUXYARBXT*PI+^2[(?-,#J3KL"YA#
M4W(CL)ZGDXGKS-A'Y=Y-3O*\_X7[<5Z!1U[KUIV0"1X<,YH _%Y@P1I8N.LR
MI<0[W']FSQ9]1,!E<!+M&O\LF3= T^!BR.ZN'!FU:0$ F%$$5#G$I![W15E3
MQ-%4QW'VPV9#YH@W^;!M"<.UZ8^RD'?J509U093YV%=@V!_X:('A;QW/DB-_
M>> ?0!^E?VL!+O0#K1 4%I?=NS VY%R84#3EXVA5](;4;^:"45^F<MAN8S_&
M=>S>AJE..D:K9CJ!D^^\A-&T1<V5QO;9'A>^YL1]879"5]VH$N#9$' VW[6K
MB> W7$PR7J2^*#FO2@!&+X-5-R]&BRQ&^J$N#A;>H$9@RSEYY7M2/496M48W
MG:!M1"8AJ:GH[.Q[CC\:X#G^1K_#Y(U^Y4UR"IMZ8*?XJ3[0Y*4UT[7H+5AR
MT47QO)@*"B[EOQOHT.=4-H.ZVPX17!SJ^DU3+59"40Z0_ QE;($,Y+Z\+.SE
MGG' .ZSU!#T ERW3:D(@0$QO5 IDXNC%O"K/!8$(+ T#.3 [;LKY6"AK%5N7
M88X;<-\-^-, -^# 0PS7FU*%-8R[IAS# 7P8,6Q-<*NU*/^MK82%W!W( /:)
MUL8-HWLE'&AHN9?U3!]^"$AF%L?R@JL[+! C!5R."7JFF0)"$.^L;&6Z:HY5
ML@$V V,$_P!&/4U[B3 0_2<$(J2F'D2@(:]_4%Y(8E=@,J;0]F7#^FZ F_>-
MV)J^@\@F0-5!@]K+[51:#ZF!M>B-76FLQXK]MIR::"R$6J$&"*UV0,-5"X0Z
MZ4-O ^WJ4%%LQ-908)F505*'JGROM\HY^K-<N 8 2;_,K>N?W\6^=[S;[/W
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MLMSNGJX63WPE3JVKF="J3Z//+))5?Y*EC5$51UY1*(S^/=]WB6;6O%;^6 #
M@$="][Q0-!(()VW\L I$&&CJ;D5A)/@M6Y2!:(@VUX%M++/$0 HFE0*]U9=1
M=TKU&.,;<'CQL[W3!EJJMB+"ID"J=G .3PJ^8'CCF7XMRG.%8Z3C!GKRW@#U
M)+W006G#LY"9-(S<MHE(R7E"*LF2_HM,GPN<EMWMW'6@!V7+E/%-@9N1OIY5
MV!8-Z4!-&*,L;+.KTAAPU#?(!'/#QD&5UZ=.:Z1UUJR/4;>0U4J*">,:R&JY
MS#Z0;MEM:;77 6XF!=CF?F[^J,7K:F-!T \'N7Y,--5V2#)V\W0"AC,%7BS[
M- 6\X4J$<L%#";!@C@D+^H&&>L?PY_:CA>IH3[Z[%PN'%R;="[!A[Q/\Q)C!
MV+3/K!X7M(H<@_;MKU;RHGQ/4(J-/C?UM!'149B6A]8-URNIJ!]9VZV!6[)>
MQF5#.*"@IV2*!D.K3BR-!LMM8&=H^A/X*]]ZAGVS6$BE2I)'WWZU\[9A-I)C
M?))[<WKUX&9ZZN1JT$WG"A+M ,GJ,^7;LN_Y6SB?2T&/B6;OWNK\_@#5^;ML
MS8R- U3LO$&M 9I*N283!V/4Z)ZCJ/MVCD60>OFNTF]Y:AQ=LQ.L.&^$4C*-
MI%#[2_00&>M_MZZ&?NO_C>BBWQA=-"CA!A\N!#^5RU;68K[K:.!S XI;D'#;
MZ/T=#6SNCHQ][]YWMS_K<+L5PQ#+3$Y-X[SG#5K2UX(F7Y7%G3=DM1JLY* T
M"**5%\Z<M%X)!8,XBL,=!E(&L=@(BA=$0)\(C55&%8??96T$JL8V'RR9VX6M
M<7ZPS4RE8KOC7L9)XY"$6-2-R%WPNZ;T 9958F89<+#26JV_B *Q<2^*\QSN
M.H= +WX9B&ELY<42\JYZ<J!0M$@GR'JCCJ]*1Z0)Y8D9"XN1=V=E6"PL^2,4
M?N<FR]0 V%+37"M6A18K4W]CY K ,&YD+N(&*7?MJU'<#'&V@EHF(Q0',4.8
M8VX%_MQKJMR4.OG$:.GLK]"&6%QQUFC_GI79B6&)2=XYQHLAFO2%!5^01TGJ
M:5<//N%"TY8'AZN77;NPFP9$IA..B)A83==LNB)6TQNJ28A?C;-D%&'@$B\!
M:=$>%V8NC?;&JHYLR0K39"EG7-G63?/OI(&&@#F/5 ^)"*]\Y8]%!B84<I%5
M=2/=(*,CO[<R&"*&_DUY*;&MZO-L"=G3HD9BJD%M_A!452+ZA0SRL*"$ U!I
M,).YK"\EN_:H"VI)<5/C/E%)E0^77;);1+N-3"/8!<8 P?W$1V<4_[W%?XAH
M]C?. 'IF7.&3] (/@.'N :/V 8[R7NDSK)[9<FS+E^45]&94,<),HX+G1]'Y
M;M-;3&28= 7'RU'^V5K' +%'!V2JXGQ.+C",Z? U=P]OK.PP:%,?Z8V7X;&E
MC\BRR?4Q!K:M26CR=V?F8.KD7H]#-^,S^@/Z\&L[!+:+JI]]0!-"/T!4 62>
MSEF?'AEP+#M=BHXZ.5B&]:5E%+2%',[FB\;]/@IMB(CR5PSW(GT&F^_4698
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MBO%$4?R$B/80>63_E\[ W<'K^&9O3^SZ5>F\4D=M&X#G^F@R3*\&8S!E+@:
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M:UJQ<B+-%7!3"&GN'R<FE+1',7%9=0+<?3UE^Z[MZ)1]).WF;B.8L%K<T]"
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MO6-?AM*542&=F+>@T\G.%>TL7N8#-@/\IX6?PN(0\\5RR;/>_=*85J+U(4_
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M!,F492' YC:@Q:@79!KT:7'GS!7Z,?K-MS_JZ]/X!"ZH<4S;F63,(I38(M0
MY78X-"Z[T')\IA/OB^B >GR-:%BUC2GG;AG/.-AJK6[..S<<G>0>%0 >ZFW?
M$\"5W=O-S$[9=KY@\7"4'^(U"CQ^_'PZ0=@3=<28M?WTW3/OVI_@^K/R %YO
MA'IB06F^]8SC'GR4LXY5\O !//;A(S22V>+R/-<@3Z:D71T_ZM"90FF_>#<F
M:#_!"AHB']D;CB^15\HR-ERW=,>1;*-GW!C &/V*-R )-B>6]MV009U[X-Y-
M)W DBY3(<E*Z\&9[$SW#(&2H%?66]INH U_2Z6PS+U6&WC)T/3E?\4[M*I9+
MJ$.^-GP5+*HQ(/QQ7$(O2,//8(H<2=ERM+ZOR1SCD,@9LS8/O9DM!283Q!AM
MJHQ;W'-?.BJ:; 4@\5A E*:%#X\HH_<@9O3&K<*'R'UW"GU@]2]@#(7[>'_U
M_14?VK?#5WW9 YHP@4:RDLO HK9YU4#M]Q*OJ)!!P3O1II.']_"HX*#L/E'6
M-@L0]0TRH6#75<+V!UV)"VK1)(M6C+@[?C[AE5N'V4YGQNN :F%DW>T#ZP:N
M@3YRW=I1RQQINU^ABMP9I45"4DNM!V8),=0?B2#6_!9CO<D[_<5.]+KKZ_?-
MR"R_;2D9]_VM=_6YYQ4+SW.0JTQ9YD]&_J&1V>2B,MMB%V([BL9M@FSW!U7V
M5+"V1YYI@&=@>;L3_!C E +3-N)<0($6^UOH:NS0CLI4:WH*$,'@,5#Y%6#!
M%RM H*)4ZE.TRBP&K2,G2^)N"^3$XDJU#U)65FH=QV8,6'T%^$7N@@;O'A+F
MYT6F3*\?-F"I8KL5V.RD]>;;$$QD8AT=JW ZT>*E&D'-C3K@A%F0]&G%L5'Q
M^F2-UQB/O78NQ^@Q$\6W\=LO[3 0C]&:1:P%9L.IVL$\>"]3G>S>]G L^Z(]
M/F*6Z2#;[OF0MMU)7Z,%5_Z_8B%=8LM"6TXM& ?(E>%N'YCO=\@^?6*_Z<1G
M]O/Q+W"GC@A3RUO+!Z@_HXZ3LU:^%/D./FFP ?O@WJ/[#Q:+M^-#<6?N$?X;
M(GM["S=]L[C?%T03BG"<PG+K,BN(USY/:7/. <;X0BI/(G\"&Q5ZT#*A1UL5
M<HM,+\QQXBZ#;JC3B38:-V7%VY^>RGT%@<GT@UPTV.@.\898E2"!9KKR!@-L
MU=AR#^ADW!.3,.?D1@75$?IB?3>MAY9(/DVN$XU,4?M:[KTL>3U,$,>FK-86
M&DGZ%7PQ@PJ_1%[B<RII]#_@!=!:!K)572W%C/6%H7VV)!>&J;NKV;4QP0UW
M#9P;.SV&+*]\!]2O!6$2\=9F;&9&UFZG1ELXZP(6P3!"\SR"3)>YJ"^/K\T4
M\=X2RY)'J2=N>@ZU)A.A>WNKO"&2X+^%,M[-GNHN,FK?HC3'%0<)0.1B7/-K
MB&MV.Z,']4C@M6=@HE=0@;RA(V=&1&M,V\\11VZ@>Q1V%*#F1_R0/PM =DPG
M_Z-/C;1<$TV ]TER5E,=DVU^ATWSEED7\.[:*5GMU=]N0#]@]+7+/T2DPY"5
MP?WO>I7!U1N[M0]OOM&O7 *]I.&6/::>'53HKS?Y@T=<_6'WJ]*6=FT:J@F?
M#R"H<#PVS:6QX ^_^XG-P3TL%J0V3/ N1'!SKUME8QEU>4Z!!$2&'6D_A<%1
M(;G2,48+7),4<DELY:2!GF%J#Q>KW59EEF@7I28=I)=05)GIK- #4,.88WG)
MV-D3X]:<+.KDWD\/[_%5JER;SE:F5#3DA9I.<.R/8]SO*TC:['$ SX-^ED@J
MUGL$BS2M8(=?=VJ"+W?-L=GSR-%ID!!EVM8@1"7K-(.?A>#&G@B7+-J(R0$J
M#%KF&9KM&+/Q="%E&?@++:&A&;+4$._NC4RYQ%AR'V>QX<TM']5G/Z)HYE]*
MPCI'5%3?AU+?(]+?J<SU9JMLS+,/:G8D*>?::OQD8IA>M8JVB79"XI,??X)\
MZ3$Q0YFG,M;=!X73/O9YLO6#M5-*[T/O S@@$S'7PT2F;^_:&>#S99$R'[;)
MY;1W@E&2@>,(R2=WHH!-NFN#Q ##I^Z0BR%O$+;?L96S"]I;;:^:N8+J<>P$
MQ>*+$,\]&.[A@&/CYH)QK7 0*)&EK</E_H,#62_X9_'>ZZQ&9T'$8!U*VD<C
M[""!7U#@V?X*>W(:@0R:NQ,/.YN#W-?SFEUPB'X9GT+;V3IVO?.3?7UT7V9L
M4'= \X$%3XSW&UR^2NKOF(O]3J7"F.*JQ):+:RA$3_T,+";C[B8(*JXO2^RD
M"V^?DG3S1AL'&7?4[3AA]O"O9/#45C=JK*FE5GA!GU33?<))#O#ISQCG)-V:
M8-=6^X"C2I[K5XU:$J:MQT*":!MH&+E$<DK(QXJZJ;1.M-/VH+"5!$O#M-NH
MY$7YWAC=Z% H^A(\D=MFX$P>V[X:#O/5%%ATC>5LAN^%Y@!B'$QBYJ<^U[T#
MHQ>PJZD@U=U=E6"?3F G;_03F2.6,[W4%1ESJ&;6%]2[SG5%[S13P3>#73PD
M;&QZNGX8D&HAD$[T(8-<,Q@G:H+ZW$!]XN[=T#-K2[8 :?H"S="6H99 L:*M
MW^S0&LY0F.=R(1JC]6JY6.FK]8CU9?K5K2'8MM ;AD:LWT7J"JH7V29#.K21
M%2#^&,/R0S8J;DU9RKO@#-8[%A5SIA:51/BMSX$E</_JC0<E*A9$J)5/5FHM
M"]I 7V$V,6!YV'DL2HQ--45M=-S<F"W,7@B%+[2Y4['E)U%,4"27986Z77\2
MP:J?@ \98BON/\2';-VLD[_@C.$^\X14'A0J[E5Y+2B.T5%8^W#OOC;&BGK%
M<%69BPV@S/ (;QDZ-F*I"-@JZDZWD K".!F81+5@[H*LGEUQ#+?&Y!EO<$VW
M<9N!8N'81> 2]'U? D*_-5&,"V?(/. ]%:VQ*CM'J&X Z(I1F'UV[! ;*;\$
MDVV8NW1/["J<-\15B.8G9T%<*H*-TI9WRDF1?0SX@#V?*K(]_\_BY6DDVI4J
M4G<CKP/@IH%TT<QT:Z'!67I%)LH5R%^FCV#MWB\@DT/6W2QP!)9EF)6F(AN>
M(@W=\0Y?/\-]-933BL!LDN=4Y IS)IUB;NX/52BK.6RA0I>,.*)"]]8A0^R3
M]@Q2#'EN^S*C+C%-AD[L3AF4<CFA74M;!](MCOF;?<TVU+W5SQ!WD0=M;Q_3
MVMB%I(O>0H7-'^H;7&1EHZ!Q*)GA=LU:0:6EGT6DP(#=IOK.V2* [9N 2W#3
M2Z%<M*:57]TC=XL11$KVPGX7UR,%KL77'5,PA(.&IEX.(S)AX/$J6PB!]W[?
M9A?P L;>BLNL.[92H)5Z(YPH"UU[YF"%0,^@B)L45X?@-.K"/73A$)LIG$GM
M^X(_\)'<M5_0ML(@G<(NKMU&/WX-72N@:!H*(W':C#O%:C50Z*VH%#*\E*E6
M% NB9C15>,JL#-]N.K&>":DOCTG2-0,0S'6@[1*]._4^=XT648-  *,L"F[Q
M;'$R%P"E,5V?Q;PJSP--R]7)HJ[%8N713MK'.BK+N\G+5FG[K"?&:C5*47I4
MCX+C[5Z%L"BF$],_@C_51M^, Z59%39@L54]3,)I?#M^ ;E"@U2_T[H!CZ^S
MQLGN)29GSA^(^H*ZSZN=FR5O]1@K:2GWWLIU>0$E8,ODN2T4C8IQ?\7X:(AM
M&#R^Q\Y+'81*_).L*Z=?;*@4#1Z[5SR7+NS$UJYM/DHS12DKU!"YOEL!>]-^
MPTN%&< !P- $I0 +DP,T& 2M(H@")KI+>^^$(?+?6_EGSOLSTV(=Q.1_&VVX
MFK-S6!OD%?<<,T/]=S!4,+6=[%O!-N#2T27L'L:$W;BW_B!)GP&^#<?&,W:=
MM>')IM!0C\6PU]J53D-(OX,8[_YS$R$#/JL'DV1"G;GA[:!'0K/2Z<3HE9DA
M#M"?+*$F76A#?R&*!3'D*TIPI)E' D^-R9!FC5'M30W%[99YLMV'K*W#,&E)
M@\4@!;<PHQE2MHLO7F8?C*FP [[OK57,F^R_DX?(_6MW\B^84KB%^SC(E3#)
M^WX;-MF]7Z>3N&%O_X8=)%M/44".T(LU#-<5/:DA*X_$PCCH3K1)BWGH:_+>
M\*' G":@P)G)0.RX(>V<"M<&<0W3"><&3-?2$M"G")-4$OM]@[W_Y.7K5^^L
MJ;G*:GE';<1"_ER4EY70+[>2=[Q _I-OX?M/0\::F/S;?U\-D1+F)1\!?Z%>
M'QP!UHV.O5UI(G>B\1Y1@:6K)Z[].X6G69^Y"U25N%.FD[WVBMDG_A;GIM]D
M.7LUGE+[=!G@G0V1NXDC8Q8O[JV]]]80X736R#0A<:TYSR +BP>9E:]!;;C3
MT*)#F]%,H^)I!&T-0,K)'0;E<;*H^_U(Q?/V]A7>CH@?[3;QJWGEATU6^7F?
MK&)T*_S>.N".U*ZFXL>[W-@=S8_VLXU[=VHT+_?9JD/$T;WACA0OC#[6SLU
MK<M7I9%4/R_9.N+X_/./0QO3=46,-[,!96I.-B^F8WRUMDE*8)>?XP'VZ04*
M@RJ!KTW/1V ,7P-:LL5,\1BE*A9['T(0!B4)89&U0AQZF/1\<!^J1)1?19V*
M;4\1M:UP[6+C$-M'KN9TPBDK0GQXA*56ZQQ1T9E7"Z/(CIE+P]F1'CO:=8(/
M&O2(A"(;;-=*'GB&3<S9$.*K$[_S.0)H?:#;1[O4(<,5V%>9:;@.3!#>8OC/
MMU81VRJ(1&9#Y:-U_%TSIEC;\]$6SA!1OF^ @H1MZ;?&1!BHB7/BK!FPQHW3
MSB4S_3$P@F$M?;L=P/!9T4BVX:F _N,VPRDW&(:3[Z-,)GNU5YS,X^.J879H
MZE4%34G+ALBO1Y9V?W3[T^XW6L+/L!G0&2;9@=/M1M(W"\3/AHF%$[=&BR!%
MHQ&@V*&A +9%*:H\DQ6T0<&F:9X/#;!*H9BTW3C4$-^"PGSC(D\G%I/>O8.-
MKGU\; VQG?]_>U_:V\:5;?M=@/X#@0=<6 #C[G3F 0&<..EGO-M);F)W\#X6
MR4/IQ,4J=@V2^>_?67LX0PT495MY9:D^-#H6R1KWV6</:Z_E:X2^_.?N)R_K
M9BZBG;QO31&1C<*T[EN_L,VZ,&BB&]<?%I+21!CQ9[LA=]XK7&]]&9J"1FP"
MF2V&R1:B*0\>QU:3CZ95UCSDM?UZ+D$]R&3;^4J(87"D7_H5T$^5B-&C(?*9
M$<)N+=>,LH="[2,="HIU<9'PMX4B!H=H0_$CE 0J/G76!;#?5B&8O?0#*A#<
MEY'V!M<B&R4#?A]&NN202?KFI:Y"59EA= V%,==, YJMB=B1!_'PJ]G,[\_,
M9SM_KW9N*['O3(-ZX+Y-W0B7:9[[D2.J4D7 %?"Q'?FX,ATR1I?>&A-F(>9J
M\?VMDDF1)?H<MJQ"_;5NE12/R%@0#[-VV/[J4!.E&%"'5R;+:49QV/4*L# $
M1[;6J/@;#.O-/O@^K&N:QI6MR._>2!HF/8"=K>MHWHL-2"Q.1F*3CYXHV;$S
M'H*C%@/C7UZSPOMK)02L+\ACU_8-37="( ^, \)!]#9F/$<2]V7%DPHDR(Q7
MAHECLN)UU>X;)BC=[<O6&98'-F/0V&WKEC99J83GAWDSO4=#F9ZEP.'MJ_+*
MKJPXH3R[8;_&+=!0+YHMXSXM8WJFL38@I>YAUIR)7-NJ:3W(/ 7N+;B6SK@\
MV2%E,XH54SJ#%>CTW+(U_578Q>UXP33LI@OEO7)F48NDM?9&TN<F7+]"BHF$
M"\3/)K34CP*"ZW;UD?^-]BWB.&-N3)S:F/AJBHP(SWQ(>-=FQ"-^SP]#3?5'
MZ#-[US(R8\=>A(.UD#XH7ME'^Q&YKP=$#Z0;Q#T?< D"2!CZHC+UYF#>/B3C
M?$U*)>@IR938+#^,J4VQ>V3^5)>S@U*\<-]N]R771"/T-6A4.?Y@$6HZG"AP
MI6"I*C#%C-RS=+G.S_BD?%D#Q;81W7.ZLOLKQ+W'GHBJ%01J298<H'?>?R%X
MG,<>V(>O@_K5PP>2?,BN?$3%Y;A?[KC1N_OIVW108X%[6>SJ+>!C\GRDX,.B
M%SY8ZWX:*8?8*G(O-E!\$4WK(2;V6@%1$RY'&,!$*,(P/5@'1']^1MVC09K#
M\%4^O4!<=^KN>=,A^4'AN>3:O'2D(O96\\94:Q DX7/L/E?N:1L_E+IM"R)C
MJY<\^./^7^G6\/VVL?[Y) ^C<T/%INLM_5/M*%[@^@*9W&U3?C%Y'<YI!9AW
M0UH8_@)F:OJ'KY7P(\U8J]C*6@F+CX42*K\7J='P=%N$7DM^SW(V;H<W/(EV
M07S2&NU@PR9$':FLU*=,J2;,C&D?C2]QTU:R#FR*+E]19,@QBQ?ID<CD>#R0
MY4#C$9M3[0*VVHK SD!H@W.N=:V;;=;F_ _GFF(9FD"HS2'NPID>C^27E5_W
M8RYK[&)%570/02OS9F\*^(SP8#H.E=C#-V97#$9JBNG/B$&B(7=XQ%D<>7I,
M>MLYN6XN7D/ ,_/B41HSP@<Y>):5-"KT$$+J[:ZU+J,^;#H3D<2YSE-G_I8'
MSA!+>I"+IRVN2@P[)LXCQ#3/8/ISS [U7ASJ#U-RJ!'L/F&Y%Q=+:>NZ&;=D
M6A@:?80Q(#B?L-1BKPV-TU/<-N6=. R%3O O)LG F5&?EV*X1CT:L;-V:&K0
M9KLI^'@VPO93Z);U%J>O#Y)JCCLX9;^XHJ$@1YDG<6?:2LP6_VG+JMT1,;\\
MHZ>+WU56321C!YZ 5!]CS'6/.=Q'L5E<I8P_ZRL%A+BXO]6(_E<=-@E6%2 1
M 7?WG(W# 8)7/+Z'3E1X2G%X=AMW=QO/)^4VCJS<I* ^]+VOY[;4/0D#3\E$
M;#]?),NH.\V8?LM* G:68G*'D7'S,.01D4?HG!B<MDN+[T3:$@VW]U4UEZR3
M$GE(TKQ6V$?:'(N4UH)NI:5I450M=RYPAKYV?HCF8FTR$J!S.CO,Z?A?DD ,
M1L-X0[K*6.>8?T<8D=G9WI<*_9364LFZ&U?.')D83"($#&!KQ6@DT5G<D/P&
MBW>2Z6*.FMJB*?8(@L$1=& VK/LRK$E9EEK-R1,G:0UA+$6<M_)36MQ3I#K_
M\8V"%R<Z;_<R27X2D$8D_11WSBB+Y;(-V$5AP:1=),4_TI,6#HM0G6M8%83=
M[&Z?EP=I89Z?&?^(9*%X#9.XLD8U>.&N0D6+^J:19A/RQ3I5N;O3#9'$6T<H
M=FTWH=U,DMR&>Y&L,65Z,8W+?!'6<*L6/UA["9:^VI5O1D<1R\IXY&TR $GW
MD6=V1\]BD^W<F@F(U[0 2*E^=NDBGSHMBTF>'=.*];Z;% 3P+2Q,FL>19XDT
MEN6P:U-=DU\SS0V@Z(S?%6RNGB2H^A%SP <UBO_)WQ]^!_6O'\6WQ37PVCJL
M.[Y,W"J*L1L1(8M&]UQ!)B>0%&(]^MRM\ANB;G6Y2$[5%W(&A&5?4D'7KNU>
M66)0M-E:!O'Y6NY%UZ>X97NR4V$7LJ15(430G4(:8Q9R:]I01TKN)6D*]O!N
MIVP2=S=\D)H:#$__%EW)\OSLQ[BE\*O[3VK0S,)$=XA1IJC)T)5CP;N?<7B/
M X?W,B'1!H^OA#V2(V<[U.N7"/&4$81A5:1IF1V41YP:8L(2AN[C8#,Q<!Y*
MU<JW+OS?E[Z9QRSW=%PZ(J*@,"9YZX&H49VW&RUQ\8W(L5J R>+VC+:;^]WF
MBXA47XCTJ79@+VF\:3M77Q]#]?6_:'KHFT_X9G8@R,+>O#B8K/J&5L5L!8^@
M< B/(2N?_8D&AR=(_K!?/:7"<]?,WSW@MTW]:X$RP/$#E>,BO9K (% 5S>JK
M'J866O+SU,5#PX&]Z&ZJ$@2X/9=-@F$Y?G,DF[&%EXM-C>3\=H; HBP^@GUI
MQPAFQ>#ZZRP/PU7A^&Q]X$EK-,X@) &!B6X(AD9]H]S%*0TQ&(;1 3ZDBN=0
MS>K*@Y%VQH]D$1)T:ZL:T/^\I%$G0I7[\(# H=%G4KWUZ=GYV<LK&I/""?U%
M9*\-TDMF."&O,8""QS_YXB4OQM9"E6(/8(VO^*Y7BBT*(8R\)U8@IU,0GYQB
MFI9CCYR0'>NF97@L8BC4H4SN$O"*W@&#G4*B2@\"6KR7[H5?$=H4L%?BN+6C
M4=/L5!Y0T!0;!*>6]<"J$[M3\!/7="CU(,M;PM2CV9AU67#UI-;>L 4LAVN?
MS$^Z;7-H;>FP"-LZUOTWL]4]@B#M)%]&6XB:#?WGD%/K@'!3:Y)Z>D3D3X-+
M4-&YK 0?*CQ MDI!KQ0R(KS"9VZWD"3ZR):'U#918Z[,UEUDX?D1XWV.*J*W
MF_V<G#RLYG.<B( @B(9:8-4:;E3.0*\S;C8-&EDG1 K-( HUF%>#?;7\-X"8
M4<2Q3"#>"*F6VA'R]NE\>0U(=M&X2&)]E167*BTX.^:'#(T6=?D1A;# @EQG
M!X+D: -F&0#W&E%O++"U&]]Y9#6P*JH/QI5&B:?1"-*&Z<%GX\I*OLW X5SZ
MCDWOG+1D-G#8% )+?3.J6T8PNQ13IVKA 1B4I6U60D+'TP72YEZ7O _)N6@H
M0G#3R5P<HOY%E349C9A4AG_(LR*0.L"1^9#S.GN'ULT417B?22N1Y-"BKN'D
M("9ICR%#QHZIHBKSG8-DS4"S8&,P6U![W3.:_XQU<E=M;4FP(YWDHCS85"@I
MU'14 2JXS:H_#$H2 K *%A=\0R.F'QA,X>,9IO#^80HK<R@%R^+WJS"Z&[?D
M?PQF#-M&N8?]M3/ 8>A!"+Q6IC *.9 :+$5LMH@E+MW3EX**U=+<9L%<"8DM
MSQ)ZIWOS*2HT>WS%N/N>=^J'TWOO<^#H\E<<$ 8Z,AHUKK)K0ZH\2Q=/-B:G
MM,H6< 7$^.JG?>&<B"A!V_65:=JJ4(983Q/0YV\8)6^HNDI!0SMN1+LB@R6B
M')R$NWY*<(38P:,@Z3%0/$_'7)>UC%3[&X6<F*E0Y::;E$<%(.>ZC915=Q+_
M@^ZYV+3KIG/M6I@,P80*DT;,#AZ:)3M !Y3ULM,!I!'(;8M[ZA5 .>;?11S/
MOC2*.W/A'.8 >S.1Q,':H-W!V(6F3SVG0-4-Q5+-%</+0>E!)A2]A?XU=%\H
MW@K6GCQ-8@A"42F^QJS6*4>/Y4NO:,XV'G[G\'AL+T/UW=#>ZXS+;'X/U+,,
M ;Q&_QK$$P+SLN3J%2JUSO!759D%4L(N6<HMLQ6S-9X0+7TVP6C) U#A^/[I
M$M_6DG.&'3RL88O -R0,0TPK-."TQ2'[O&*IL&,YIB#VSL_<3R_#(Z.,69XF
MDYPZ<VFKK&!NMP%6-3^57UMWPUGEFWDN7[PL1?FL*)NE7Y9'=Q]?G\Z$.(D:
M,=AK,H#VRNU2LGJ2F'8[><%<=DVYO.W@R[!+H1P&,I*0=BF;#6UN;D/3($Q_
ML>6G$>Y>8($7^DWW$ 6$( ]*F&PZW*D#]XP2AU;IB<J?QV+H_=/=7AF:EUGT
MYF-*44PG""9!UCDH6 [%9*MR<T#LXWQBA9$5F6ZL$Q4!/ K4Y>W&(L^EH[D\
M5EXC.54741GG?FN^RR.E%ZJXX''BS(OHQ!&C/#/R>=["H8)PUWG_7!Y]FD&:
MFR$6'#4+*J$S ,-\8V%P6JPAO/71:62=;J$^WK[1J1B^73E*@(NZ^)'E=@\Q
MJ67$+JU]E)1I>G#?NJNS>BO0?Q<(_@*?&$3>,\;_#IOEYQ/<+'\HBVUNB:%Z
M2[+,>*_2FR9")-IL=!.Z2Q'Y$=O!PRA#O(QCC66,M8$7$LX=85V$J0B@ 7&$
MVS6,\X*M@-:"IUR&>(;))I#C5XK8P0B]"T&TP[>0D;"$-8C&#@.-FTN\#^.I
MKT]7UX-F_@3^[(MOW#+X]I5?"=_^[=5WL'!\]N4W%W-Z\/"3U7B>T!@*;U*/
MUXW?U%:46-"L<P$/A0 =_R7L35R?:@*:!\*]W@H118<C@O:IY/D^ @GY^M4>
M\[5VC0"&*TN=&$=#_' %-"]-,<@&PL2YC\H\WD.67R9R8A3((=[2,I/<B;:_
M%U?E#:TI87/F%2<7WI27'/F'TV:A"VD+1&;T-,_/0D"=B*'Y,XZNN0^G]_:/
MA]][>ZRN:U+HF6=QDOO$%CK:EBQS_0)GIRB0E\12XZMMG>]1OA3J#N3]. .7
MJMWYF7@.0B9*8)!XQJ>+WXF8@<Z5<5N"QNWXL&[3OK2 ?"<UC<!&JIST4C\F
MQB@/U(EK#G05(3O'C7'OH/ *8,()D9PI1 S'&9&S:WY.7\\\/8\$F-Y?#&JZ
MJ0(G;W.9KW/Y[3SD^3S3$<90?-!<N)\3/R9MABD%I5L6OJOB%\NQ4<+9 A\:
M2/V=39#R-1OKQFII*V4N];!&HM[FN6A5I^(:(65_H6^;FS3F<Q$J>U(%2PE!
MQVRI#YV9](\K4\6YQB5WW/SNWHT9O,U0"?N&?AU&!YT)-RV7^)U)UNO*KGCS
M=WGY,]Z,S\^^^H*RQE??B41![Q0A#HKS^M]T-?VNY^AD^//,V2/9VD/CS!,!
M=2-@G=^)AQ$N^ $\R2ZTQ'4L=+:U=Z3G9Y[$/FH,1)GP4GIO';HAX$M:!@0Z
MQ_\W[4Y(WV5+3ILCUO@^QO57&D]91.LE3#!Y/^Z^U5\F''0\6<G]VQUE#11+
M#]]Z8%T[/V/:M8%YUHW)<MI-E,SM^$50':01TB29<YK']1YO)*1C%^4JMY=L
MR8K? JBK-B3YC)+:>EU6&^I4<YB$1C@9)1MRIYUN720>[R:G+(_9"A_)\%S8
M.$*1E22D- ;JVVFY:D">N'@2NAFDV-!<54HT;:N%,T3;9W-S;C+I3U_$>P:?
MVA+884LH3Z"@*/YIKJR[3&PGAV4ZIT>K1L16HI6#C2;WI:#D) G]K$YA@]NX
MK"3\PN?Q3SKAV "4,MMN,PL0ESRX$I!$EX0P=3(3I[@;QZT$=DFZ-+W7]>S[
M[VO574]MT;&SEF F)!:^1NA,VSGX5+[GB9*$#7P_*&MHT,1(I(4_V?D9NB D
M#<2'OICK+O=G<9,SN.#E Z7O-;IA:2U.=1(H56![LW7PL!EKN'JD]88$P@[)
M-A%1 ^PKR[Y5V$H]Y^E ").LBO2BYI++.^!ROI@@+N<7&6\8@BW,^)M'@;]Y
MD2!%;:UP6_3!^,_Y@<&E_E]J(KPK9J$CYOFY>QSJ)4M;\<<(.YU[\_A/Z@C3
MP<"+<DAC0IK9V;FK#?B'<<@#Q9=BOQW^E,%T[0Y3(Q\.*."3&13P4#W'I/!,
MOP9@NQ$N?UFB.D*8@(\Z2^_;5]\%?C9RB:^^6\:NR(5(<S_\,13-5UR</M X
M15Q)3C>:92H!,;3%)'R%,1>1FA6-;^E.Y@\_9_N/H=+K!6"X5ST^S=*SK"<Q
MN0[P1^W&$LX)-+5E\:<(KOL?!M$EE-@2LIUQ'1E*N:!TZFG#:^9LBS004C&(
M(/$P&_"C*!+#[<E8N70@J/'%I=X,-&D[MD'O!$43MZ[+M<WB>'UK:F9-"_K6
MVD5+AZD$*.__.NAB!1D7N>MN01H^6%;-;*R/H;:Z,H&GKS.*&/O?2H<KH_'#
M- 98F6Z^B3U=2,V"K9Z?11.$_L]'>"+N9M!SB?:1E&A'[79[JNULP Z &BVK
MFQ4A"X()\??76>&^@5ZP'[R@7L-E1KT&YRT%H$DC3-2K6OLV<52CBRDS!X7
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MDSHL<@D-:"1#QE^58]%S8^Q<CM4AFQ3&P#Y9KO2RR25(56RDT[(]PNU8SXW
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M(+=JKLA9VSJ3FH37E/&_44BU43T-5F>6SWE-,5-7O7"/Y8JI6GP CLE:/<!
M><\#(XX&73B*Q\,JJTVGFA-3"X.6G!@'4,+95RY9SLTEL\%LL-"=P7$Y?RVL
M'#+D&Z[4_2&X"Q+!*_USE+N=E^H])<!O)KM0!\K5[V[<7/(+,1>R!#X\3=GH
M(A;%JIZE!C2X7R%LUCW-NFA5+-Y^40A'H'\F?C4<F6SX<'KLG\T]]@?K6*;O
M5_9MM;[*F+=LER'@+%B];AM)V667X&IC6A_ M'GCWD(C;K"CMN1M,!Z="OLS
M_V+TEZI5!YDW'BGM"77/&^!#9DY^YO<S#W7;&+/CW0%#3H4)J55V:V(%M 8I
M))>+O.3A9&)!(_2"_^S\3#Z\"$4(WHQLM7A=E#>YV;C-ZHFH0@YG8Q<=_&VI
MLQ=K+OVFTX"XCSUR2.=,G\;P"5JG>19$ H%59Z8V]X5UMK<-*P *]9^DH.LL
M7[=,7TL$NS4K'R[D258:+^ W='3!'8;I$A9.=)LNJB)MI3^[B"9:%#YO+Z^@
MG'R=N4!!IC82"O5P84_=F^C I]W^X!Y$@1)D$)N,43;=@3 /L5D9NKB&T2S]
MGPP<V>LG[BOS9[L!;E U.OR/0]P]\'O8E4^;9P=T+P[HQRDY(,8Z#]1Q3G$V
M=6>5!^ZH#N4H]4+5JMU>R2XN_;%R>]+O9].[%]/[:4JF]X+=->&5 @PP8SE
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MNP(JA62EX88*/_D^_+2PT8"+'=FOV^):Z,]FVT:.0580<,.D-Z$N-,HVNTQ
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MV9/;)6***)IL<BD !D4C_]FCKL.*RS/*(?06A\>A/.O3M?M/:+[5G5(T]7!
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M4%3,77 =S><L;D@7#?['G3,WERYKH:P(F^/:_<,=8N4R&!];OK; :W "Y[D
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MOQ:BL\YYTV[LA52R&:"F\WRTWD<:V=H.&"BV16>%"/U@^W4@*0M]8+0/7(!
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M%!X;W0DGH2,:=I'6"]6 4,1N^CD<?T)[]MEC&BKVZ1-)--HO*_\&4$L#!!0
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MF<G@1M@XJ?%DPI/]6>')WJ$;G3PZVIT?G?P!MVV35[Q_7G%K,XB[G95F"QL
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MMI&-OQ9E4Y"%0&N#L0@IM3/K+A0"U6R<(9>#"(XW]JFJD"R,"NS2%&<X*"G
M@N8'P]GP1 QS;E6GQHD_+G!V+\.\5-Z+L_,_7YKU1.K"( S0?Z-B\2A _S
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MR 24_]OT&F_!M$,VI9G+(LP9/ !?_B1 &*7W,0IC?X0AB%/O*BU!_J/P0O(
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M"NP[@[TLX7L#] (0%OS"_^/;J7K)@85KI-+7S%=,@G43D<M-A#NW.!#OI%1
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M%:A9,-^^@WD&A;H5PW9*GYL?)XN I@/EI-=1MO0>BC4EB(FD8&WOB#L3C;T
M*;ZR3";8P)$(=S1CEQ/?F0R/UDR46M]&#%#.3Q!MD;NVJ0#.RL,WG=W;QV^.
M-QIC68 8OVW,Y8-EKOP64B1P4ZEU),:Y@(7BF#PKP5Q7,%KL!#6_@K.KV^/=
M]$[Z5:^+6P58&AA[T^RB ;)/U5.M&;9>;]5Y,VS=[HD9'SA/O5.7AP8'OQ$<
M?".'CZ6@9-.]+AYU\4 8_/Q,7G?V_^H6UWQ&_G7\;,[];_:H]F9G MXLD,S5
MY09L-UGT)FXY95O^2CJ"1H[C+=ZHNW?7?,VL5SIG<'850>* $D7=$TH%\&'B
M(240N*!EAI0),;+'9$@'0[A#S)O?<Q66&+(A^Y@3D,0_F]@",=MJ[*C468]+
MZ02Q[H]_7&+@_S][W\+41I)E_5<J>F(VX%N)EL2[O3L1 MQMIHU- &W/SA=?
M;)2DE%3M>FCJ =;\^N^>>S.SLO2PL2V!@-J=<-L@U2/S9N9]G'O.V$\%13:V
MH'B#S^!@W>0'!#:'_=H;T:#G')W3WY"W><B!YJJQX0IVC".O9H*,>#(P2*@)
MZ#3GE[$3>S]6M?N6H,&\SE?KQOL+0X:Z)['N2:Q[$C>])_'K&U]GKB%QK2"&
MBJ-RGR/>>=*]E<%(.@\'(ZE0Q2S)Q\\OR[7.P<.%(V_H=Z'TP2PX/)YD#IH;
M>-?"S;J_)E;5U5RNO?)X>O?@F]-:JUL#!\?WQ$U6J>^^EZ9S/8NW<D#^Q[^*
M)'_%67[O'<4!5PF%(_+#5]X*-1%'N5YPG=83'<+.S[OI(/LB"9:SWN>,U#JC
M>66Y6-:KD@KQ!SZYLE76GG^!53,T+N4T^*)RTFR$^IT\3#_P')I*T41F#VK-
MZQYC9 (8 G7KAX\PM%F *+[3:A\^JU&E\,^-Y3W!0(%*^#&L=[8]2A;4F_,/
M#XI,_Y'&C^IX?6XZ?I4;#=,_S>C9*$G[7>*0PS7_BSJD_S\R3CLXQ8N,(0/>
M7&W)?-8-HS *,Z'7KMDZG[)?N=BK^UX_<.]XM9<[6.GEON"DWN-$UP6>>YW4
M#_'9=?H \TD&;P$*YMZ\]%^CL;_O[;YY,Z\DS>[!D/NMNRQGQ]LS%(R7EJ)E
MY6B:E5^PIS(,1[,?^EGF!M[>U?4'3XC5_4$1YHST'P0#X/8,B&?("I1!S/S^
MK_]H>'_WR6R_= 8\""GG[D99P_Q X._V6S\>X<GU@IS627]!K]N8KIH&GRMS
MRT0$0;1Z^VRWFNC%-1W/@$=#65&$%_S<.S_S/D(*=R/8<#?+3DYM>8WE8C4S
M@YL#A:8:&I:UI!QY<B7\/7NEF[^@0S$&;/C\7,8_B;UW!V^OO5Z:^(-PVHQ5
MD:>&+\.G>_:2P;0Z2[CR;[0AC)*[>I*J6WMPF^3"W<%#?$XS$$ T&_73D9HD
M.>V0?6:LHH$-$C"5X%?%'S?G&;U>,D'/AV)M%,8B#Z$_VI]NY# O(#)^L!-T
MQI1[8LL8LIZ:!$!#IQE@U(BW-'QZ9(A5RIX0?+X_3I.8,=.H;^=!YIT(:IL1
MV%AN=BZSO!BP9HU,T Q7\H_'I\_+S7G]>>*+9 Y:;]1$1<FG(/)[SH!:X6O!
MN3MKQ=W(5GX*G;]M[MN3;DSK,.=& R8/42".,G)2BNPL3B;C(&RRQ&YL8^5Z
M05;F^@0-5$RBY)Q'5@S^%\_O_ZL(=.\Q64.7MK4XN/4_>R-1]BHISHSH"BWN
M"XI[9_NQ[-D%]>TF@!Q".%3ZG "JT!D6)?VDK\6V,6.O9I_A.E!IZGOOX[Z^
M.J\]U@$,:5^.@YXT_4_IG\. 3D?0K]CV&K97/_95%/C>EM,&F!6]*&":$/9X
M_[C>EB8]%GQBJ5URPQBDPI>XGD".YV9,KS%AIJ=L?DARU0N $XJ\-R<@<?/0
MS4EN'=->5<^1/LZ1[]J3OG\W<KZ_",:[CJ31?8KC>T>/7AR?7UK/I##[WFF!
MM)Q9]RG1.L.W8 .[9Z.9N3-8:10DE$/N%45FM4@GX,A91GR3)_3C,9HT3UBT
MJQ<8@;<O0L<:"Q!CC04@+L-TDQ0YK4[A>2-OT&A#FRY@%[RP#&]GFDU]$5T:
M8O?5AY+(#C$1"3?+6]X!9MU96WN?Q?R9X6?Q<#HJT? &[DDLUMU7^XV]HR-9
MMY%H434 ;SS^*P*'[NNKAK?'?SW%7UE%CZ[:YK<WO 0E](W98IV$.9\ M.(Q
M'%[?G_@6*&G:I(4T=T3;86_!D:0[?R,%L4=SNTZG.@E[A\X\S(186YFFAO$Z
M1]L[W@40F\*E4*'>%4VLS<_N#,E++M,[.Y4<P)K,"%N'<W[9703G"9O]$#.>
MEP<B^L+][)>GR1EU/'E$QBCMJ3U"W^%2T;W[]ATNJ$XUO'+MM;Z1/6FWMH_G
M91]OSC^X]K!;V\/+M@=VUSB.^QEDS$'*P9AK(GNUB;QL$TETH.\:Q?YRHUA)
M:_?>\:/'H%_RPU*#ILZ5'[%H>59A069BF"%([N^J_36@'QDP7];4H3N%'RYY
M/%&A!^<4<\/W#)&Z4"V;O :T7R7EX[+[+(F(&F4Z:>:6B+;0U2,T9.P^LLNX
MX^$=,R'VRO+,RM5GM@.(-1GTFX 7*:>15+EFQ &U"/T'"NVYE]\%Z.=R^7?X
M3:2^B1?ND]D%?::6G@JQBW._!63$YEY"X(%HLQDE T.[5JJ&RT"FS$+2G_;1
M1>*^_E?BO7O@QY]MEN+2C#^S3WU6_:*DA2JSB@^6MF "1OU((@Q2!S4OZ@0:
MAOY=B+VOM$6-"'0"XDJN SG@T&2X]6>3=.3'>NNB*:"#:%!^J?9Q7K2%#1+P
M/]%N-X Z QC *_VEFI;+&Q8I$BPNTZ4FLJOMYT7;SS"0I#7@WW=:@F"LPDE9
M]S)YUM(;<8RHMIX7;3WBT4),9E$U&.2$13:N2"&8BHA#=7"/2&R3.*9J"K"-
MGIZ:>FA#*< .OH$";$ED^\)8(N;^]"P)VH\SH=4<8!NT$%\6!]AN:XG?\9!D
M'3_6[O>M3[J4Q>+KXMO?AC^:XT%9:V;O1;*EU%"TQTWR_CJ?5%N6.9O+DCU,
MRE??M6$4"OQ0]P=D#59B.SAVD$/+BA],&LY*,H>MOVJ0&JC$N6!0"C]4^,YP
MA<K7N#@S+B+ZIRZ @+ >/5O,9NZPNEGP>_O 0&Y+L#8_#M*.,3<QF[8O@*40
MY!F$KHNA'[I@??=2:X.K&79]OS\.U*TC0=I$V8F1O@'939[,U)8PCJ;SG5\A
M](N8MFJ-"V3$U%R;3978'I_[]:Q;2I*FZC:@:%=?0GWNJXG&\LTTT5D4<]E+
M)T!CQT(V'U6VO&>0AA4]@:7V0=E6Q.D ELM %YAM O.RL>AQ<D%L$WOE('#$
M]/L#IUS8;FG-2>C.6^T8*_6>X4*AP MA$HP*W6]E1E81^@.Y!C\NA,['_N=U
MKAPN/$90K85J"%21?%'YMGUGI>3 )P6%*A^R1.9U6:?WEBR?)SI5]&^\#+TD
M]CY)&^;,---#%\U?!0?*!6;L%T;V9) 6(T<ZAR[\I^H[.4A X[&>8L;XFFUJ
M"SCX3JM]W&1@J16]IT_33P_HI^VC[88!G)*-:Q'1<I\CGW>8A$$B-F=DD0P]
MY]-9AU5T9\5H[895EX^7>A9GJRJFK-W-H$76HZ=1&H<LP';K^F1+R&CII075
M@14,X&T1#WR$(5Q:M+!S/BIA+M)+(XNQX6P !M&1EAIC8Y]EQFGKQAH3M5K&
M;HLX$]3P9..+DBRO".V5(LA&H^EN/'4?>\+2R+[5:4X3KD'8S8GQ(4Y[@DDW
M+\'90U(:3P5H!MYZ+-+RPL*+D^H<41F4L^IB_8LJ9K O4MH=RT*1&XAJ6.85
M7!FC]4)VD1N73]?(1/B5G>Q>H+_;'R?)#.1'"W():HB;4M'[R >FG$<E3 K?
M:G@I;H^GRC1"*?Z4F;X7_+@Y3/I%I@:.AA34O2JX*<9\]273X'Q(G,P;%4WH
MQ<H6A_;Q-A!/K,E&_R6OCNPUR,8 '&@AJG$PJ>H%RJ4ZN_2*%XIUL;T_?O=.
M@J1'S]NP[O%;N7<B$E&_24^-9_,B%D7V1RRJ=8(=.Z5YHWO%:+DKG_)HNRX\
MONRU:EN"W/4*HV3W$"WTO##UDIM-NFEO<_$!L6A!^L*5X-%"9,=S[NY!-:2D
MG:"(4XC1AZR]&.BP+HC+FP)6Z$57[[H-:7L5EO _BULXWOH$E^53'GU5:33R
M6$=)7)!O#9(!-;N0GSW0]=GZH;^N!I3Q$%YHF"2?1)N0;Z_,DR6%J-4Z&%9)
MR2WQRB@L5)\G-%65]]8K.N+ CWW*4I'@M1P_5L6V]M9>U E@,W8ZH?+'-5O+
M(^>+3LCKRV?R17(PN3*2WJ!@.Z<P9 2U/0[&3*1T1YXCQU)]7N'T>K0<R$+(
MN?1[7X3-U*[/2S!\Y)FM\;-P-0Q$UPOZ"7D(,?L^.M%:J8<\\NJX2B@>FDFF
M6OG'<@6,(-J:,"B!V7GZ/D<Y=$2D=(';("WJ1?#"%T%E 3RR54O3R<R6[[@Z
MM@: G'G(M;0BFH@#E!8]LB>_,7.*]<=!.$@A!(1\8[M#BSO.Q[75UU8O5D_;
MN;_Z<D1^ES0'2:9YS3UR3@(*-3=AB9VJ]';VY) U)FFWB3\)PC")].'@,D.-
M@C2DM3:B ^08ATQ[CQ?;*<7B?KV>ZO5D8@@QB VP]1,5A],L]RM>DHU_-?.N
M8 183MX+"R1Q8S49B[NT]?;=-A\N<Y[B)KZ9R RJ0>!3W-2?I5N3-WS[KEZI
M+WNENCJ)AD>+XQYX1DD_9&B-H:YMN-R3#2G:5/*_'(^3C8WI+I[/\(I<R 9=
MF$]63"9<7Y3X:9V<E,,B[M^[GZHNUHO;73"F9FEWT?WXP1XT67J7I)]D8^LG
M4:32/E ETMTKB:%,(QG]@4)U#%%#D!?R&]3K@UA@4VD%3FSQ,A6:@(:I7^ +
MU7(Z%R\R#\G5I,3X(/Z8J9)4=4@9V1/YX#(>!:'N5XYZ ;,<-#@5C G!ZJKR
M-0BYPF# M^%%5\21RBW((%9JD#E *+F]4]+7<SA=)P+*9+)1:ZF"1XTE.;@L
M5Q%76"AT%GK@,)UJ?E':IVAZ0H\Q.5)[JA*95LA+Y_" FB]"I_<7D*0Z#'4M
M#7.Z)],I9KRD1J8GBVA$+?.I<]W][?6C-ND%"R979.0HC':VK*UI4LG9*2MS
MZG,_R$W-P-06&K/PS$J93JJ!=$+$ID)>EO7Y)T.&L3@)*;X&NU\:K,)K05?$
MZ8EY2=.'^P$?%N;F@D2+I[K.WI#/&58:KZ?$.@1@"@(3W)IK^@*7' P$Q+;0
M&/&^;DU>+GY!__+)CZW0RW*2D,XPAJ"R5/.JC[(^!8ZR<^@#3:]EO<>!#X5L
M+4A7?^=_7-PT.ZW] T/NS*Q0V31F&67C$#095T@^Q)_%"#4JU$XM-Q"/V\?B
M'T%E,UP]1#:@SY*%#(.^T\RUTEO<-.&LZJNK>.2/@I+0/]"2WM;\& Z)=__G
M6$5RD):O7V(C;]Y>'=%^G] 1)8Z3PYKN2;B]]>;DP[:8K%W$_JR!ZG%&7?UM
M,%2>%DP7!FAP6CCGV()Z_4RMVZ6+K%;>'8;QV9!G,S&;?DA#W6PW,4]Y.IV0
MCU()D 9*T S]J4&&RW&R\@>Y>M=MJ@'OIA8SVA_#-XDXX<0>JH71SFS:M+_,
M\UW[9$QRF"]CON93Z'YDU^Q$1/Y4[\3,>[WS)%J27U+'^/!_ZW[QNDUU/1WD
MA]4HK>X@_VH'N?,4:^_W_I'\T.&\H/EW-MHN[F5>64-PW;I<MRX_X=9E-[G:
MWG%>8_%;=6RVVOP$NJFBH/J7X>[!L-.^EW3-?=*4#SO[#TBN,*<CH9&^BZ0D
M[I.,K!C94U=4^:'JP;=.Q<UBC1#N?BXRY>;8\B0)M23'YR!"_@))&$1#?>EY
M-"U0E<YS+0KABZB(C6=W3+M#V2P\29$C$D&SY$ZEW.=Y_O/%6^:@Q7U&3CL5
MYWWQ-9X#)[EEDGCR\Q(;>X\][/LS=MVE*BCD0(7-NR0-![JQE]ZE!Z0C@QU-
M98][QCG9O#3@IQB>1Q>J:P'$6] :)B"9(HU-*QK=%0-DDN$J9452EK(<\6SP
M0_#M!C8WYR-'O>/]2B-G5; 9BM_'2X%LTXM5D?)K(1]+IYR(@R%_9Y174N5*
MS.F)$IOA:\WWVN/+?@I7;78GD&EW>XKI[<AQ\1GDGV%F,Q/\?H*A>CW>L-!Z
MS%U&W$2'!)?;;,2MM3K?A)1V,9%6W7(2='L3:(U9Y XXZ[5E><]$]S.1ON B
MTWWWF5EIILFJ!G&_J+)N1OMF/]<)K3DJ;I>R6Z\DSC31"R8"=RVIN7NJGT2&
MQT$-9@H MNF@AA&\:'M;W((I_2M<OG/;.C/I579M+%;#(!?N B[*6&J VMQJ
M<YLWMU3UTR+(]4EGS4K( AI?\AW9VYRQTAH;<F]/_]Q2%<PPBM@V8^MU5WRQ
M2D'UP9 A-\G GRXF?"HI4%"SK CCT8>!4$J8;:DWG6%Y4O DN8,TB('VD,]P
M1QZ.6?LYVUYN-[4D'B72?N16WYT&;:>Y6W=]"]J0PB>*<ZJD4C3((%H9@IQ2
M:"6BGDJM@ 8J.1I>!>*L7PN6%GQ#840^;K PB8&7X+9J.$1"SP],N=*LKV(B
MZ!A0V(@"H19*Q(_[_H2OZB.FI5")0BM>8@9\@F<WHR%CI<FQ/CK>/E>[ -_!
MG7DH$-=G.G$$D(I^:K[<F9%]I*&Y3@KZ:7>8TLV$<T/(0Q2TDN&G@_ "N""6
MC(TS>=0!-\'+P*9)KZ!SR#QCJF8[>TH&C35Y[^=B>PL8!(1\A)XZ4JF5S-2Q
MH$X;&A"$L14CPLBN&@77M/71\;K?,F#//\GZ\@5,0)H^3$#="SU#[4!6+9"V
M:A4/-+-2]0VD>6H8#.E%P-U4$;F1<UPN[0I$6YHBXZX6]/G0^WNAY<$UC0E?
MSY1)<T"+Z(89F$O<.!?*531Z@1;+82RLKKOK]5]]XK*VC4$/LESC53CJK4J>
M&^R#?DY\\/3L^ "T#J:"+&")9HD(&)6"F4'VY8LR3Q+%VT4*&9_0H%D4#5G!
MD\%M+!)2^T!5LF!/PJ:/'/T\'=%SZ4I?MHBN%;-AS>ZKM!4:]"?]LCR-4J7S
M 0RILXQ#G ]@0Y44")NU3+$GT93>NQRPH5]N>A5$H<EW,;& [$1P39J1')W#
M0(4#K=AZ>G5^?7E%IT\2*^19U@$B8B:P9C$QJJ18QM(3U9"'L[Q< ]ZZ865V
MO,KM!OK K!U9H&8AL,9NF =TAISKMV<$T#6=/;E&,>(S)\SP4'X$N.!0]*D$
M6G5^PY]]XZ,79> 2E=#53A(0"_+ NUAE[5#(%;H 0%*X (S#"6/UQR",01JM
M4<)QWD]4[-W(YH)/TL&'Q4XG7U!$WMT8)ZJ;B)H[7==V#-RP&ZLSUYF+U=2>
MBF"'W(>3=!M25:P09F:+%@#G-?'@HJ<%^C9Y_UE3T]]=R@N#J:2MZE>R\3[.
M"];C<NEFL!/-\<T$&1/!R<MHX)!E@:,;M _,>30C1Z\9?JQCQL+2J(!&LI+*
MY#YON?PRTJKDZ)+QVN0=D9PR_J]N=]# 7S>ER;1#XD[@[/E$CQVJ ; Q/9 L
M&'$QB]7)RG9SC7"K0+Y,<G.Z(Q L>2#..K,WIJ&4E=PN[_;,,.IL!I;:9\K?
M-@<GCT%Y7-(I'V*M\H8C9UJF9JZN@<TZK<G; ">,X0C(VS#0_YX$=M]OW]KR
M6,^;MUO)36(]IT$/>X))7".;:?R8>5HH_F?((\&MRYGCI.UX[_5.;CU-<@N*
M% M*=FEA1@RRK)"]J1<F"<6\FNP"3"#"-*7H[@'LBK]@LLN.N8H:'MGI) T4
M#>K4IIH=%6VF%4D<94"8'#+H*7F9N>R[MTE(_AV_!&?U8>%P:S@?3:,3RZF3
M&<(WKFPP9)TE[7 'ZU;II+/)5*=J-LFB-?9VO"[].N/0!-2S%O>:5 AV 2$R
MA1.Z^:*3M+(=TX&#XY#\,!<T& @X-A+=N&K<K3F$JI17=*R,R;(%08Q]A)=O
M3TV"VR2EB8YKDL6EL?E)$80\ZBMW(&@LQQ0JFOY5,0L(78IE2L1E,-\S;MB#
M!?OR5"KF4I"FE=.] $I@Z6E9]BF#\KNX=''L*IQ_#UGS?+P$L6R^RI28:!N@
M)Z9'$8PYMB5RL.X2T<[$YW6[Q2_FS$7Y;>I$88+)-/OU%X,PG=W*':%,6DOV
M K3ST8M4F_T6%#C7V'6@?13:67IDD#F-A3(Q%V=(LGSM!FIV*]>AI;'AV;(X
MV]*--\FI4DB5GO7.G^IL"I10X;%K&RBMW^&SM1FF]D$+ZT&E-/@]'^P:-%5@
M!45L9KMNZ)4KX.JW23Q *;/B;S6\&XHEN[?!;<.[' <AN3#A9!R(A1JW^)0)
M2LW:XZ<JYUR9 U"O4N1U,YL&M:]MB1AA\B@;\>M@,33$(,F<:#HDIG+S6X:=
ME=_\#D=6$<+= - /]VQX!<4'DHAHE+>A]T[9M6+GK4)Y&IA",O-;-6V]ODHB
MYYX\.MWCOE#9M2$E<\RI2O7J'I$O+6&W3J#@L#8AC>9M=+)),WU3?(#'O#+-
MWB(E^1HP_<#8E?8RP&"EB+ (3+M>#&&M#U;CO3=+'^RH1G?7^F#U0MS QHM:
M'ZP&V=<@^^>F#_8E!:LHH2!.TG,,K!/R (F6]%\,")@#&,7I 3I4TMG:^:W.
M*]N68(JS1E*^3T(-!-6A*I*%=P)LT #11*=)YPI<DFFTZ*N%Q!Y5"@ID0RJR
M$R7;Q&>;0T<BI+'ZL#].8MJ[^\DX"6WS-P6D?IZ4O=1;[[K7;];'LM -LZ11
M$EG,-V;_3F^BIRPC7X.&::1LO.]6=/34%%'BV(DM\ Z"$=B?$(J/RYI#]]SE
M[:'X/D.*-D#:8;8&;>DH)/&?Z:*I])Q(/;F2D@B+>-30C*&(>E$2UZ".NX2N
M8]])?W>=Q;'56\[[SS0(@R8=P+8D:LJ3Y!)>)+0<BM!/^75/R9B+W%3J+PP'
MQ=;YQ>G%MA&S "#"$76 BLJL)<@]9\J;9ZHOR!TH+#6TW@S*!R[H2&<S%I:S
MZ0&QQA/)/2+S6$'95Z'XW;?7#:\;_IO\[TBE=@IQD4L?&!RR'_/3M4WH^_DD
M,0W$C$C(;.)%?=:@C$J11>-AG"R7@9L:L%69Y3M5J>JE?B9*&KH*BCLS;PZM
M':X;H;N>5E6?YQQ%,Q8 U%G7=Q_.S\Z[J!V/PJ1'HZLS2W01^LX8Q6L!40_S
M.]KR%LL (C$L53!^Y>I(U##]%X5CO:3=O'N^T*!6ON5USYN,S50#O>79HZ0!
MY)]DJDNM3UH[)EWML+K(,J 3U?%$H$,GVY9D8<L.+/:YH:?#/"2Q(--\Z8V9
MP:$)$Q##<7FURLC8'4J?A\"*H\I%!^,(>I#C2-="W4*^*?)4'[%L7C*T4DS]
M:&#J7$RE_5,_O=[5G3H*7:+''41^'ZN8BZLU"OU%KU[+/L6V8BJ/)866,#.%
M 9TZ(LZT\C4]4$T-  C<92T2/5R5D&?4R\" DFGQ^7>Z"!H8U(QP:&$1[0E*
M6J]YAK&4+-J\26@TC4'Z:FB8):<JF/9QG&03^*Q2L^$55-ZHK+08O-T2=$ V
M46ALF]#XDE<3&=8PBWMP(:.:<XKQE0$',-8ILAM8#?:_=^[D<EX+R@@O+Q&;
M>;!BORW& R245;!D)>W5S D#9(VMV%8Q"U9WRO4N&>\VBZFB.#>YT^@"EJ[2
MZHL6""ID<!)D#05VO[B'B8(K]E![:IIP>58[N'34^=J]99\]BZ#T&DE((C1[
MEG?,E;8JCS&M7:TQT()M*N_:*_*R$3;4XZ+Q\7>6B!).<2A>N$(@?<N(.L$B
MZZJO35GTDWC(ZY'5;!VX6@5=5F(NO@(R_YH'['TU&[..HN<& Z _6NS[(A0@
MC7BFPELKJ"V9"J#W4<B>@[G\+K!#?QX?Z%KO AAC!3K+_E\X-3AW@8+5>E(O
MT4MB5M6M"$@01OC1[D ;@%'1@6E(C V&5=T_P;*?L@&5DH-SEC=UY )A@#9M
MB:]I9TRVZ%1T9WUH?QIZ6' +T"UX'].]%W;#W!$JV+$/I6HZ#K'QT2,/@E2Q
M\^_GAL&4X;0NRZS->.(5T!*"W17"Z]QCPH07R)@*92\?/P:UR@E8.EC,%3@\
MHZ>M9.7H1TSY"8H"(&"MD]5D#MV44T]# QNMXY,7O?)$ U/G)_W,.6MMQR+%
MS6.#SEMY='+Z_L/Y6;-]K ,3ZS-R5T*GI<,%0,;<I=M3%EZIG4W:%@K.D59:
M\MPN0E>Q>@';-LMCTV"X>\?:,(@-PYC+*6#414(=6Y'K<TI>U@>_7SUUJ^]2
M=G[IGB]IHL@4"%,\A]V:WP@0A%X"Q+;-0^N7-R4D?<N&5&I,%YP$64/EYZ*8
M1UXG!Y%RU05<V66WV[KMA/'F8;'CG3!^,HE-%XR&D=/6&Z)3U>>TD1].P:EM
M.R# N<)LU,[H9?Y0Y=,&:'3Z.?94.E*T+H&42<R/&J9.1O>@R=.U,@V3Q]6=
M >$$DL.H6L:OVN.I=]\7O?O2.@H$3#ZK)FR/\U_6D.6]>M]\<WUF-B&[X,]G
MZ)N1PUU#119Q$SB*,YN.XJBOFZ;)';.#R=[/E:Z9/EOL.PRO':J428ZW,(+;
M-O*U:F_^%P/(5]+;HR8!FCPI](FEWYV.EV:&!YMCO)9,DT#$R<%+1C&\M#<G
M'[PSG)_8Q_48GCN[[$,-W3D(PDTCGW"!SQ!$+VH?GZ<#-X_."0S3'Z'!!KK/
M7PG9&8V!V<J<[G I3^.Z-BE_>75^?6&'DP40:#BM4^Z4X[+U.!AVR ++K,T"
M;@_&XSU'GF[4I$+4>$7XIHA'UJ<O!3>?%7UZ?=*]Z)-N7BD*2:&MJ-O+MFUK
MQ;PMX.\/)I'V#W5;#*85 UZ+BH'Q9<T!O/(;E(H@]IS@'?]#D((^IHQP&ACU
M.UH@^*]D&6RCF[.OUVOW1:]=)'@!V5_0;6T:\AD2./;I"[J$)N1.RU/XDOQ*
M[L@+RX12 V[=+7U%UQ&#M,QR"2&ITLUUIY!,@>=QHF_.#)N<22O#6HM=P]82
MJ7R<#"I)LCY=)-$(*5U^E8@P[B=@17!^I,E5!:XP3/T1(^0:!K^%_RXAY]%M
M>MYI&O0_E? Q4S32S(MNEIQK,]Q/UP='A6[;G&O)GR?H$9ZJ>J&^[(6*3(VX
MY(,"]D C&("04V@-9+UF$["85"E:9NRW!**Q*2-&N$"JIZ(>$UC<&L<,H^!6
M6JI+; -@ ];39WHEAPY!@=B D8KIM&F>TRS(&?NNS?I%F_7*_:-Y.; 9G:ZR
M$E7D25/7RBU,UG+DEE0SIF1:"8S'_.G:>%^T\3(H7RN,LIZ@<)V WP%.-F>-
MR%DRV72W*B&,+KR52P7 I4"\#@!\UBSF>0+(\EUB"AG<TVYS, ",!IQAD/Z
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M07$Y>YFB0?- ;-XVOIE[M=W[!%LS2LB@I.F)^0ZY!^8)6(P83.7%G//'F$[
ME0YSD%@@GIPG@HF\99QZDD\GAE]4>B[YM#'^)7M(?Q:Z7\P>;'&2 SF]EL[Y
M1QJQA=W96K=4E(!=2'3*6DN]J=Y2Q7AFM]0[?RJSP)I\<G"O:;>T&V&E2]?5
MB'%S!%IT2W=,3OPXY@Z6@+&&VB>1J=]M'.RWM&L>3%C.=3V-!.U6L[.OZ3P
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MP%BX<DQ2J8L3EVJ39E[R]>(B<G%N4/2-:Y@J.P6-\DVS(AWZ?67I!S -:)L
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M0!K(N+J(:4IB%5O4+LI%H<J:41%-LF9:]'#%9GGMN7Q2O4TLV2;>J!2]55D
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M8U\&A7/AXX.YBZ^7/X/T1F9)7T)AMAY)EJF8_JTW7=I.R_= M90!1/@QGQR
M(R0#]@JP<P*%DRW[L@G=Y2N V(K360K2.:T3=C_W^RE[D2RNJH3>V UV/X[I
MI:IW&08 U^0HFZ4,=9<;97S&3YW[S1T4? :8DT$S'0E&+HB4^'CB0LXQ,&T^
M?G'@3\F8FH.99H4P&'ZA5/U$NXQ6M!PF"5FIMD31\4E"F_JA0"'3>01.^$C^
MJS0NE.QR[C< \"?HTYD#\)308M#, 0ND,?!T ;*N+&+!4@2DH5*3M1XOFV^N
M7X#;+G)P']EI>5?T_7 FN(C4) F#?YOP8EW.-QM3J(I/-%9&!'SE-]DZ?]O<
MWRY=3*<7-R[82ZKN]7,<"AQ955PN(UE*]JXY8B2_&5LB!K/W,W5#)<5J5FV%
M<'UY*G;K^G67IL"D3%):E?A4D7$"1VCP_ R]NDDXG63>UNG5]=V[R^UJ$M@;
MT>E40!TR9^)ZO46$4SJS DD%O?[MLBL(KS&=DFGEV]DT'J3@,MIZ\_IZ>]U"
M&QNX( #)LB&U0Q14^M4E5Y#O[;6BT7IZSLD]"-7 Q*E38"WG26LV<U,\:+;;
MW.+1)"^TNBE*ONAU5WJ5'F[@-$O7N.32HAD>"A$& BZ&&:,? 8$W"^"5,.S-
MLU&+4D=[?I 463AME(UK@H#GK4R'SU(^,QAWJ)@GV03WXQ>?C*<9_<:/K9N8
MP!/ OK4.7?)E<Y0)N20_=[4%C@/AC+;E>)2/UZX-;" 4;GU.U)06G.C@/)BH
M*/D4T/G9D,Q1):?(]3PZ4!FBZ;.NJ59K<L&K#BW+;!9R)6..<]'D*(I8:^R<
M:A&>==[--AJ)ZXH>R('N%N#S$OU%;(3R,VE-Y!_N>&?ER"*_,%!@;Y7,;4\Y
M"]1>$?1ZTGU@NHB%1RL09CTL@HKL5T\Y39HVG\K3CA:9=$'[0U7(:"8-CFW-
MS<OU%.*T.2DY%I,L7PT7DI.\X>%D9N.@P[>A$T0";J:3V_+1Z>O0TJ!;&L[5
M.NVQG/0@)]<&0_U@"0V6[A..E;$H@%YU15*4O+,H0K>3K]59$_-P7U312\>J
M@$<7#&@=Y;JFI_'?]/4 P6!%[F] GXR3G'<6(.[ YQ$(3+>G8C4,\I^9G@;'
M8!#24=+-6)00]#!LO /5#\!2@HN(X+T4C=C4Z:24M/E4] 1YY_I:E]++-D%
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M=P-U>D5&6&@6XW&0509FAD0'R-/U9[S1XT1W-/DMBY=)0 ;,3*M2&Q;F'!D
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MA_7V=IW'WCMZR&7%)^3X.?^#=V/-]@V<=EL'HYU7-F4'M\4*M^I?A1)G1!\
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MU2[<\;>#1ATP3.>[P# [^]CXOAT/L_ $:\^<8,OP$$OZ/9[\KF12%#]?J5'
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M26FT]X\,XX<;2#9$,1*=@U<"-"K<_@W1/J*_G^#?3=7_+G([8PPP8#N!7E*
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M#5Q#) +9,P<J6\4#^&O,+:,ES!I6,KT4D<KE-@#F<)SIS!(!^(80]H;@.K&
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M+@G@#\S+#Q>_4,@*G2.Y&J#EYINLV4+.W 5"LHN/<*)T2D UO9 ?H\)1)L"
M[A8Z[(D\+:SEAP%N]80CY":W-@>+>+Y#)#RD[)7)$C#E 41;-S$ ;/3\R#O\
MT4L=(@8V)5+ <"-!%-&?!]L-/QZJ]'93>/?PR4IOV-'>57MCMS43PM9@HP0;
M4W\*5Q3B\94AZIH(2ZDT\)QOXH5LY54FX]]+4[:?-FAVKZO=&^7N2RXK\)[X
MB9**ZDXM7J1DG(F!J>\Y]R:S(0J:FKC&//:_#!$'=;N(%?/Y@H2LB)3A#O$?
M79<CRH'/B4<+UW0O:911LE!VJ?@H1<B(>XMQ+)F[#+SKX=@B*!5U5:]G^LG[
MR(D@04'\G\Q$AC*,>Y(R]QWH^$%J^0&R%YE0V7SD0V0;"@)5Z54<,\#WRTL+
M2QHFSD.T(_N!9(0YE1RG\!YC2P80C,$D/%JMNE[C[?4:]0W) 4=X) 8AGY2)
MA^ RB<.QV\6$A7!4I",L:Z#[*-LDHBRO,28^E8)/9%&2?CI %-6"\Q+GNJ\I
MJCT]/?H**(D4C^LU_@,.0910;ARL-HJ.$31WJ&W);)UEQ$QGABK5V)LAM%1Y
M(5.5EW*!BU25G_<.F60.GODH<_(,\*8)4=8,V0I97HJY+8^*V?@1H2N#W]TA
MITD5E'*)OO,P5/% S1O>+.K0,P@S':TSR&0,I2<-Q3 DFSI2]PW-'%-M%A1'
MKB!)-5 7<>.4@^C4,O%]R81IL^B5%#5_S510($NA%I"7+2 ?XBN=)C&YMVI1
M>-&B<$II1: 3&D+]75@Z$*4391Z#M1:/ERD>'P">8]*=)01FM4"\;($X-]F7
M W38Q)4&4@L&#1]78=Z%CI#,6^@>U_3 ;!5.TO$,."^9R%E^2(\TUA^F;%QA
M I QY4QJQMBD+V-6BBF^!Q9F$3)7&3](YA@GKCI3DQ0G-B3(Z'4@,?V^3B,B
MMDHF&U9-4S,(&\-Q)NHU&XUA*&@SX $NJ6F&$<QDY)037%4#68IH5)ODR^YM
M#BXJB00+@RN64S\44/]IN5J>AP8>HCS$4$GM#DSN0XXL847CN<;D7Y]G+'MR
ME#?,,)@@3IMH"D.:1R3>[E**'>PHLDS1*5YYI74QF(J$N"2>%^OVV-(S:KEW
M+]?,=^W<PAWVBAN++RR3]_1O/8I5;_RG[#WB.+5M<N'<6<X79 34M&A+F%:<
MF(GX#M<(CG"1TFUGBE_HOL9_$E6?G6!Q3AH7$RLHOW3V8AA%Q0N#Q8QBQX<.
MDA2&C@'JW\]-*CB_%S-(,"N1/&.&%4TESE2>4L4(HX#P**+&M1%Y4$,5%>2Z
MF7":)6>B]T2[8Y_D:/D!=S1!OZ#O=BX9V9G)_,<: MBYB5>8$S1P_;^[3/';
M6N#8?: KH0=Z/01];.X#_YK3\:@PQ=1P:8L8G9>YJ3-GEL^[]^R54[GO6%#,
MG??7C$*^I(R=IS:9?RJ-EB=-7;F,J<J5M.5:B)(P=5.DZDJ#C.?>[&4V[<.U
MR:F5AYI[9)6Y-8;H@<.;/?N&*<#+*>B41^ F@@M7.V=?%%@^MEBNI_HZ]@Z2
M<OI=BC+72O5*>%N;62]:<DYDC#5@"I0)BAUG.=?)@>O1%(;A@DNUG+QH.4$-
M(Z,N0I_"U/@*AAKL6MRR6C9>M&P8'>)5\I 9WCV]6C!>MF <4YM,B84/,,L5
M#0*?]W!?A]Y+YM[\RFG![/JK6+5/QK[YY>-7(M '5,V1CAWNJ->M<LK*K]A7
M5(5O4(0RI8;::(!59R*1$\9F)W[Q?0)@U7%33IQWP7$0N7#XB;$>E7A]\N7D
MS8[X0%Y;L$JO-!57YP'0T&GU$/UF0FDDS[U%.DR>RN!2O#:?B[!25FKJ5ZL>
M2(7[" V-*CJC=S 1KR75HX6)FA:=YA%8X+*K5&SN2'X(UAOH3[Y+TW"Z8Z]&
M?+OYZLW*;,NS&)E,IB$R5>_L,2<)]$A0A-;H3*CD?#C7^*SL6EETR&XU+O4
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M7/R<098+-O"BX?OQ&PU'>&@!;-A*?_]RW M*+ED8K7'G37_[/#^8-ZAP(Z&
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MU) ;]0OAYJX7U?%7"U@.:$@36ZND&1!FR5UC=Q$R>49C5'>V!)@$0O$!\Y@
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M. J= \D>%ZJ#:LO_X$J>P);*%5+<QK/!(=# B*VBHX]_OGNUM?M<XIJF\%U
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M^]^]D>_ZG+TLXG)P<].%](L\TM:?5PL:C_ZH&<HZ+HMF-"X:"=RQ#I&-8,^
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MQ4&)I8 [I2";J?'"PL=PHZMK(07F9;ML2-.09X^J.U V6M);H-)Y*5%_K6)
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M3'C\"UULJW$H?,;45GM+3VRX=B!C+3*UG6&SI;"%^)^.T**S C9JIV)['L*
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M+2I@AW'GJ%TO!*@[WAYM=\E$2(+XT/(NV9"5@,XM0J/Z):PG>)AIBB6/]B/
M\RO2D3KQ<L'^UNZ.?L,CXG[E\A6F.G+?KK.F@"M#:*8DPHY)0)6!K7_C^C];
M"218>S./MN<#OU5CX/$MJS#W:=6N84)%E?YSD Z'O,1<6-4W]:E1'+Z7?$_
M1?>G-Y# BOOELA#QFF90ZH_42CYC +[P0CE -?9=2Y<&$N/"%UE)OB,HF%BB
M;ICH2OB@4MQK:<E!KUUMT^)Z8H?7+RY\=%U:M)K(I+QJCMS?TT"'.VE )Q4.
M-$=/A>/,%9;88IRB75GB'W)3M0L!Q"C(,5XPY?CC\&PWB@;^8>G.W1^0Z%S=
MNNK"J<YWKP\CFSL*/"D?Z&LAPP&Q9QO7X!:GM$DO;S6/ZWI:_?+SSZ>GI]NI
MB;>+<O1SR=CCZF<);VV)^[:E@MLO?_[O&#!_/=OXN/N9++(MN'%;;M!;_=D6
MU/26'?Q6_A\XNE7-%!<5]-SN4]D3OY/8N@+L^Y+N_\$[8._N[H"_4'\I]!:S
MZ&-39T7Q58L5C\;QE,.CO6CZ_'$O&A2G.2E+ /(8+\\QA[-DFFL[K4@7<N\M
MW/MGJ$YDD7N=D-Z8D.[?72$]=-'.3^)B_U#E#(T<*.BV<G:!V2V-!GB='$^K
M<\1=_CI;YN][BN'291:WJ0QSDZIDNR[&76W>NJIFGUZB:G:Y?'1%KEW/X:Y>
MLZO7W(!ZS1LZUYZY4PV:S_LQ,D^_[ 05\)<[Y)[:,^ZL,TE3X_J3I;^0[_8/
MKO5VN\N_O/CM;M-8YJV+-=UNK;;*W!;9Q[Y4B7[Y\<N7CQ]^V=E^2C^+JB*C
M)_QMA_]OWD667Z_-N5WNRGX*D>4_7U[Q[UYU )).X)J,P+1J36_T_7-IM>'\
M+7_PBK4MF!VQMJXTC; \;.G@G9W'8PU+W,C0KWK'5?>]];-\L_K%)EDY+N7:
M9<F;2B[O1V@=EVZ^LWOE@X [[N#(E5WS>H_E_8N1;%W,LE@]$]U-[_I-KTWB
MGGF)*XM3\FGR?_RT_].9SU\>E@EQ@&<KXN6Z;)7'=UG=ON *GZU"[SJ*\XM"
MNB1G>'YU>P >O&A5NR?SO/;44%"SK,#KL&1^^R)0U&#IG_P@$9P_QR\I@A;L
MF'*M]V(1-Q/"HFB\&LNZQ$+P.P'YJ92^M=:LS=HBU."R?B=QPG\PU;?>2P!G
M0OD"K*;EA %\"O5\N!-7X](C<\N\S0P=OM_<J:WE<2)E!ML+-LGY^F6E.KS#
MJFG!2=J?<Y(N*2U_*30M@+E)U;6L9Q^[GX%__/>6;'LL)E,9T^>'V0@8M%[T
M+A^DPGG_*?Z:@CI(P8B>Y-P*$C0&;TGM+V0OB].) A7EZ;EIZC+.MF_E-EW+
M<AS6TF:@-57T+]E0--V_Q]4X_6IGVTYMOTFSFD'@VH&@I,TL<SB.2^T1<#NG
M<7<=T_AE"1&V1X>.XS:L,\H;QK"0UEMDFM:/N/1&X)VMG1&P:?0-4+*M\U'@
MYWL[CW>46%M6"V#;F-O?<N]<^D6"(LI*&CLP7-^2WP7$7A9N;<]B3^O@VBKJ
MPQ<0PD$;A6RVJ$K/#"@NL-C^S3RE__?L,F;F&3>YC4KV^P5/ZQ;9K_>UBS<^
MC%4IE6X@5Q_(%<VS<P:R#A?O@M=NY'Z_XFI^X%H3WNZ^T&>RQ1^X,IY'DY_Y
M@_=%/I)QHJQ"?Z3U/COT0_FOE*-TYNX5-_PQ']M\//.AZ\@>[/ELN*G..)W>
M7K/H"@80=XU2&T;?N1.I*XK4H=;:@PQ2AK @2^3DVMWL6GC)!V)&:BOC^RAR
MGZ4M&& 0<9:%\],PQ>MB5WF+HGT@_] V\_-8LNL(2SXY+Q#^_<?JLI-\XV._
MG8%Q73I'B KDX<60;0;'6,!_>=:".VQ3=P/I!G+__*[.XUK#.KXO3M5SRNI@
M(<7Q>B2.5O9]CM;B21A@8I%ZNF2R_?)H@#/=]5L!]^E&V(VP&^'WC+!#]70W
MO?N>G0O\'&Q0X.>NHWK>+6L6L+I# -H"X-K+-@;8$(#-Z^6SQH@I)IG+&4 S
M+4V23FU?\8?(R _C+'O4BX9940SD^M9%O:A.!VA<C^][?G72? #NS&PP3$$5
M93\?T_-!'&;_)LD<<$?ZTE1-5B/DQE190N*T ,]J8PQBZ5Q?E*O6=#'TNU(#
MG!\UOGO*XT80"KZW 2UYFFA/[[BV9&N@ LP]$^#4E&E6M>3)2AD$J])V'X:I
MY4Q5TU"^FBP=XVJZ(RA%DZ8V+='8CMX6IV <['F\ 5W+CQ#]$3Z%6Y=;1E.A
MJ%ZA4^8:NM,E@)O1<V9@T;N=T)2U JX\1=D"6@, GD44$%.3\90&071\J @@
MY?S26E# A1 H#,@-!8$2EZW.("C+S6:R)"B4"9MGT:.K,XX)S[X8#XHI,] &
M.),(E. C47X\D-NYQFN!'T&3 F0$@!:H-RN4?:;5V R$77/*3>EY:KBA) 3
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MCAN<+LL1;\JY?,4%_)C_7 SI\"E)8*-X%),K0]K39"E#$TG5?C4SM.&E\[D
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MZD1SIMHA&I&EE (%KL/Q()KK.X@IT1H6G+%FE4%?PGQFGJ :O0Z]&AA>@2=
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M'KD(1L+)!,'U@, UT!V-#06^#F@<?#;Q H#::"O@0V\"+!:F<,"G'!<-7,3
MX'0#XI*%1NP1'!?^.^;^5,8V8-,2940!BB8AO%K<05:$U@FF0N,1U+-A2H\
M_QN3?P9#E;]?>Y\ROOCE@^.G,*&Q Z8$WX/3BT$R:0A *9X0Q(GX(,5P8<QC
MM+4< P@1J:"\ ?^2,>,/H?^ ]XU2;T FB$SG/4P6__B)D,E7^4PTN$)&V?7]
M3U__@F#K-_UA.#9!9IH*#$&-'0;93SV? L!0V#^Y6")B!SEK%X(=$/UG-0 @
M$W(5[*^;1A'<[<\8N(XP4<XC0DL,CQW0 =3T;/SX*\1? M_! .8T[9?L/3_G
M[V'77__ZY><;YHRY,U!/\9TT .>AG@D72&@9TV!]()\SX8]AA+'>5(1?B-O
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M]@'=)/WVC@9, _D,5@Q8=(/F0J:V9C1#8E.?<Y@>@G=@7)^$4[>5(J ?P2S
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MRV1: %R98)4B/36AU14+?%^B5H. 5^E .HPIJ KGD7JMK)<(5J]&9V6/(&9
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M!B0*)W2],!)9%/+I7[_]_-KNL<\P%C[Q7"OO8,K@B4$(GQ%<\L0R'\P8^[:
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M@U"B00!=!AO2[@^B,)R<"]]@[JFO%NV\6,^=4"0EUGXP/) \U,(*M=0'NE#
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M.AQ!9C:2,!N(IP/A8D)'@@;24W ^:G@+>40%6:XK%[?>R!DB(7.US@GN4T@
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M*^V<SKK,D!MWO\RH%-OM'-(\Y&_V GKW6L4Y6B,6I?BH#V)WFFX!:._\ 2T
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M>R_"J4ZQ^/6!4\XVF>6WT BN1>=(B_T6N#7UUPV(9.WV%<U ]5F6GM:93.\
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MI#MP>';T76$F:8\221NA%34TD?18W8FR1Q51P:XE>Q2N\<%Q!3^-Y!#*'KU
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M]OPZ>VG"[R:@W?:9X,QZ#[/_G@W2;5WPI1@%3EMK8-Z9#J^"0U\)Z/JI67H
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MO+86:;IU@0NFVQ A,E&UB_ORS*='JV0V;?(Q\JEXZ^N#SFB_LM#5^^-Q@;I
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M=<>MX2:;(>]U$S[3@6>TSI!3]=T/7T  ]!,*<V,=*8Z_),P0LTI+^RR8&C
MNB;\N(C.8<0N* N!OES.?ETS5.]! _X%4#U%TSS#'#]]^I/3ZD]SRO^D@S+O
ML+G%+8*5]11U.7SD;\>6K"XHS";?K> S_/NCATXP9"$]81_WF;\S.@Z<':)U
M)'8M5VR*]864KP&ZI<7;"H?.=,EW<N0&M;4=)O>''Z[7\$[@;LN).S_./2X
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M7;@8P6&/B7-V=@C$^\,:QNBBUNPIZ'^)DG*P>I)>8A7'F<8'T*/<*^G'A.7
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M> -9'0'VXH?K-3P]7<)E)SZQ77C*MN:@MSQ/A2<#ETTNHA4S$0@SV, ,W+2
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MTG0V)(P4#["( ,]#%@P!3)*Q1K+8A5Q7K[W1$:Z.7'H\<.G)!Z8/OGPBU0#
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M-UJ&<I\]Y5[.JS8T^RQIMFWH=9WIM5WE6#+$^O2)M8QTT AVB!T:L:>E'_+
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M[KUDLM+(8DCY.9+R!0IA"'J]";J]LO:LH>6G3\N_H$7ES8#JA7@!EN7"[!]
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M9&)+"S)\U:0#/X/U+OJMGBF)[GR=FI_))"\_)WFY8[+ZZG<J=L.<2OU.9:6
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M W6983H8VQMY8F@QV N>]4#XGKB3:X3GXG0T0F8>)/ PT$R/5#A$9H+I+(V
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MXQ1Q?@!K!79#7 KQ[9YF'(C,%4>@Q=%+IBG)MX)0(RGYBXCX.R0G4FI3:*T
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M2:S5E3$N2EG-)GG>=-RI +JI0G'@CCM.33KN/%2L]*&T4JP^4ZNV+Q7IK'J
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MK)Y16$N/&7NB'G[4+Q\U#9HN53J,HS3H!&C]3#&&,F-<<7GP%(]TS2-_QH.
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M4KY&!'[_571&B-$%FWF6P&"[SZF+?3GKP\.9*S,7"531_=?)B>=@*EQQ_#*
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M)%=!_Z*LSO1$.HI@D])@(OX4:.@>J-NA:A40JQ+#B)D?HZX(6]OE[08*^33
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M^=<?GRYVVB=Z:FD<4J@K?=F"I\#:ZZN$34 967N(,T.J/WA[T&;J[P1AB+^
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M%>-;8U?R0(+1"_]G%R]JZ+KBB$)@,5R](AAJ+80+:2KQ><MS12/D0^,8)@L
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MB+=:IIA,\5H<=)@GH,Z"P*PXA+7T;)D<=XVGI@;#OL1B\K'8JT%XHSN%4JI
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MI8MU^'!Y4R1E:B>!9BU5(2A%M>^E;"+4.1+8&!4AB&/+?2*1'6@@=QI(PV7
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MI,1V494C ^/E%C+(:O UQM7'#6HXU%]RV2R.KQ$X$,,+,$5"5=,M.8KHL9<
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M%DJ[6RBVETPPIX"M]H9F/FM1CU41W$-&_02#R71SM"JT]![\=54WYPP[*7W
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MO'QD4LI&+%]%09R(3U;;-1-E6.ZJ9U$'%[YJW5/3YDY%;D[9_<_)@$498G;
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MM-5%O:]4%,#^V2XJLZD;).N>F:)R+Q;TFI_:$VGGV)V>+$S*C*46]X6HRBI
M^E)D29ZB?*(>D /E!V@8D4RCG,/I\K&>X2;7LC(G9[RU!->)4#B7 ;58^ALE
MKIK25$W]Y.8%<#8Q9NG":;)/@#N)/C)Y[AD>EDZZU>G/B4KS,$N;][](-*<:
M'GU2Q1G;-6QN=RMU4-RY$_',QMIVFC:PNA]'<0QV2XYJ1PYD0%)$L/5NQ^_C
M\&"P^.P3!+9"&XY4C8%]^ KMHAW!;PDK_!^)G)#J,\DB0M^&($US5?@;/; 6
MZ:(,Y+]K@\&WP93I]4N/#]V2(+I1*=G*.$0G"527?ME-X@%?(<X9$%?*P_Y-
M"?N2/^G'P)#5/8#74V-U"01K8ALUZ/+- GC-4PONA8@M::A]@"1D4>?>\$&L
MOZ> XCM>(!3?P4*Q\]JO%CK<\=YZ0?'1*2P9C.\)H/%F-78?Q]#G$]#-L*>3
M_EQ3M(YE%QR83$%<32'ZU]A^K]/%,_.Z_ A0=@92_.R/LLF)6FN4<_=T&<B%
M(ELQ8:0.B-9ZLCC;O)YE8C?C++?NO&A+0Q8@91]K]XDN(\?>G)&K])Y8Z6W5
M;J.J.Y"^W0P(:)4WV^3,X_Z: O"N3/NNY/M^4F4G*NP:F!3 M<J2;$HHPQ]Y
M?V%.N?>P1?L,M].+P5(((FR896H1R%=M '3DK4S8#4<]7TWA>Z6+EG%IWY^D
MZK9<_T4NGXQ<<.3P1[=14RNPLO@]%=SIC+8=VY397E.WO36_G'\3&"]SF30"
M_)?WN.CP1A@/Z!3UD5.W].8WM(<88&:5(^,QSL$JP7@UXD60>F%,+?H*!<)M
M7G7S&">* *6(+'>*?HB59GVZF1^!9>@^A74=K:G+7Y4]&V81^^MY#(]RYR[,
M<I /N^R1>: 5,05W6 ,GY?[,/LKF@0YG=W8V#W0TUS@//?E @YJQ\>YO4V.3
M(38]9*?AT:*ZUC3TDJDTV#-46W<,Z6OS<+>]^79K1<[JU[:SNETZJQ_3*6:O
M< $OS(O[^A%>W&6WM#L>\_A46<$$8K?(H:%'W806==RAKJ%!'?O0_G9"_WFK
M21$;U%EG,;$?W>[Q ;RNG) HVLY5)E5^;&]+<S.Z^[K-V;-8>K<X=V^FOS=/
MVQRRN:/> Y=K#H^^:['G6NS-J<%,K;LLM\7>W4[).2IL$;N55ICB7L&94C!?
M?-#O[\3?U&OX[['^Q4XB_2!/23,48PU S7?M":%26UO$@6$VJ^:\KQ<87G\]
M;V^Z13V\A"'=?-Q\W'PF_7-"8VZ6:*4>!2P1V%CTCU_V#PLFIC7O-NM;U@3+
M+\_PW5?;-.YRE-ERGN7+:]*HC7+\(2MQ3-W:Q*P$:D'=%*_@ F0+=^KQ20I+
MR<QYU-!C#S70[$J7XE:^G2N?4AYL#ZMVXV[FN$OU%VG[[.SK]^]?O[S9VWT-
M7Q%L1OYMC_[3*&1G"J<(K;&)F@@7>[L'^+ZW4U]C%*J/&4;,OLS9.523@O+8
M][Z]1>\-:13J313?)O*)_7@V5-<$!6/N37:$] P(:=;,<4Z$U+D.C@ = <Y=
M6F_<Y7_O)+_]\]( I@=AD(T<?3GZFI>^KK"Q5]TD=Z3D2.DQ(+0#S!3&A%2]
M(W(P?$M\J\K%2H0K1W:.[.8EN]/<#S*+X/B?ET%Z[:C+4=>\U'6I!GFD6Z2L
M@IX>Y><[F-JK,_&;8SX=-^9S'W.IGKS%,(W5E*$NN>[Z>YS)4$0YUOAAMF(2
M(SJZ*D!;9@J4K4[FK$+:S$<L#;)DPNM7[5"Z_TB7O-RG%:A'3[KV=3MJ=WNW
M[DC=[7TV1^UN[]8=Z5;?WE?N]KK;N\U'NM6W]\#=7G=[M_E(M_KV'KK;ZV[O
M-A_I5M]>9_>ZV[O51^IN[S8?M8LJNS'79$P755X1FG>>)(CUIK%CG4#??B[_
M? 2Z?=*G5%>L'BCW>6:G_QPN].+S-S=AQ.=PLL_LLFXUJW;L^9FRYV=VI%M]
MB9V^Y2[T<SO2K;[0[A*[2_P<CM1=XN=VXNX2;]V1NDO\#$[<A2C=F&LRI@M1
M/C9$>14DXO<XDEE?1N)J-(@C?]K61TY0/X9M/]&+FT3FT1HMW]&6HRU'6X^G
MK4T(A+K0JCM9=[)KP!"?0!X<KM'RGP-M;<(==US#G>P](SK_DAMS3<9T_J7'
M^I?>#092_)3A( W5R#F6GH>RYXQ_IQ(X9<^=K#M9=[+N9-?Q'-S)NI-U)[M9
MY^"<*F[,;1K3.54>ZU3Y)(-(?)'>M70N%>=2<2X5IQ X5<^=K#O9#3@'=[+N
M9-W);M8YN)-U)^M<*F[,]1_3N50>G:<2!O^5'97UQ1?O#Z7$*8R<I&4'T>?(
MP9^3?Z4M7NR_7*,M> [TM:;RW.E^[F3=R6[P.;B3=2?K3G8-E!BGQSGZ<O2U
MZ"UP_B8WYIJ,Z?Q-C_4W723BHPS%F4P2YV1Z+L+#)?$XD\:9-.YDW<DZ>8#;
MNO_TQL2SHZ]-N.>.<[B3=2>[6>?@4HG<F-LTIG/M/-:U<]Z72:A2<28C+XF[
MF?/N/ ]MWGEW'&TMB[8<?*;3.)TMX4[6G:R3!TX>.-IR>JRCK4VDK0/QXL"E
M3[DQW9C.QS9G^M1I%"EQIF3H_&O/0W8XO<31UM+2NGDN3ZZ<."+;8B)[M4;+
M?PZTM0F..>?J<US#)0DZ^GI"5[)X<>CHR]&7<_EMNCO)C;G^8SJ7WUP5DTDR
M$N?B(E#9?YW;[WG(#^?V<U:SLYK=R;J3=?* [(DU6OYSH*U-N...:[B3=2>[
M6>?@"B;=F-LTIO/LS.'9^5VEJ1(?XM@?2 >']4PT>>?9<;3E"F0<;6T:;;D\
M+D=;SKNU';2UIG:M\X&XDW4GN\'GX+Q;;LQM&M-YMQ[KW?HK2<5EW(]4XOQ:
MST.'=WXM1UN.MK:#MM94,W16A#M9=[).'K@XAZ.M;:[<<O2UQ?3UQ+JL\ZZY
M,==D3.==FR-W[$>0]F4HKH+K:^E<;,]#=#C5Q!G,SF!VG.-1<#J.<SC.X3B'
M.UEWLNYDW<FNY3FX]"DWYC:-Z1P\CW7PV#.BIV[Y&YTX]-_Z03H,Y>A-$.'#
M\.U+E06)\L5 #3HJ28T[Z/DZA=:4-3LQ[D[6G>P&GX,[67>R[F0WZQS<R;J3
M=2>[6>?@'"%NS&T:TSE"'NL(^0%#!>),1CV7Y?),8M4NR\71UU*!;%SK%Z=T
M.G/"G:P[62<3G,[AZ,O1EZ,O1U^NL,R-N25C.G?;HPO+Y$")'\%-H*)(B?/X
MSCG=G !Q"HHSG9WI[#A',^=HBQ=MQSD<YW"<PYVL.UEWLL_O9)^3M%\#.\$Y
MFMR8:S*F<S0]UM'T>11%XEV8JJ@OH]1YF9ST<+:BHZ]YZ<O!W#CZ<KZN[:*O
M3;!RG=WL.(?3?!Q].?IZ3O2U"7+$55*Z,;=I3.=QFP,S_+/,DT")#V$P\/JN
M,]]ST0T.7<&;TPV<U>I.UIVLDPFEIWS?R03'.1SG<)S#:9/K3E^;<,^=I\F-
MN4UC.D_3:L#+_\P1M%S$78%[D@5Q)$,Q4"J#_7%0YLN7J_9IA2K+5$*/P3N1
M7N[>"DU-=V_'SVZVDS9+O.](GT"A6=T&'#[IVM?MJ-WMW;HCW>K;^[_^=KS?
M;C_M#JS;@;L[O'5'NM5WN.UNK[N]VWRD6WU[#]SM=;=WFX]TJV^OD[WN]F[U
MD6[U[7WE;J^[O=M\I%M]>Y^]YKRP:-ZKL5A>8U#NH7L^8U;#8P9=Z-"+_)9;
MNUN[6[M;NUO[YJ]]87+UV,Z2*?-SRE2>A>2^S)/6\KVO1$3)*JD((M%)I'>M
MLE3X*HHS);+BUYC+8A)8!.A(7A]_F2J!O>QN C^7(7RN$B44+"7HA/!P+"1H
M19&_*ZZ4$F>Q3'PA(]R)P2" WRCA]6744_"Z/(&!Q?[>_KZ((X';S130WC_8
M%1<JDP$,#U,H'QTHFC4%,%^_%>EU$,)7<'AU-U1)H")/"9G@!+TP]Y6/ZX,I
M!XGH!'$/]+I^ &_.(Q\61Z,<O<7=H&F:4?5<4G'R&I?3WMO;U?I777_C_3^R
MSFCBH;7QL^;CJ"IZ4Q'L7)E2>V.94GOS)DI5EK"<7:JKP/"'!(+[YWTO;>_#
M>-8[]\H?]1OW\*I.FOU WNW<!G[6?P,T\.M;>Q/A1S-WLH'P@TZ< %F]8<NB
M/;P3?U.OX;_'^A<[B?2#/'U#&]&!*]=+8B#$'6 1<?+&?-<8,#A=G'W-H.&L
M/FN.PSBE5+,WB0IE%MRHM]TPEMD;G.5;P;-_=?QK,4XQV]K Q_"N&&@-GKY]
M<Q.D>)DKDQE[L[6O1^-'.49VAU6NU6[7*8P(K/H*WAJ1]#HO]E\=M$2[W6Z)
M@X.70"-SF%[+-=O>7YZ+O_X0YW$RC!,)[/0#;FLDD3.=Q[X258O.^K-Y;P]F
MW]N3;=W: +<QD*'-[9>_G<?CW%!OZ*=(2,^#VTVG>QMD)!\%D("6)2D=>8L^
M95'8ERAG89,&L"8??B$S<=Z720CRY@R&2>)N1E]*E >\F60;7&UU(^&';L,&
M[(I/_ #(8I"]O4298>&=^#F^6PZ'23Q, J3'_X#4#KH@4I!ML/ LN1$*O Y\
M'Q:6^T%FB=[:NV%FN) NK:(SHK=<R:0C(Y7N?+T+U4B<>AE*[_V]O?T6O:9I
M[?!8@%J(KX:*I!%M(TMM$/<R0A4!1J'QE0<J0X82_-T=:Q'F)>V3@U<MG)(<
MX#"@?=Q+!8]@6-MZJ<[CP3 ,Y%-?I4(+0W(8ADJFBH@Q4<!&,Z85H I2%H$N
M;R6IKMT\#)%&S0J**PCDCD(,"5P3S_BE++ZL[CPUQ-N WR4>73PN#HZ;2*E<
M45VM:=!JQG6,L?'NE^+VAA[\6DCUDZ>5ZOS.5],>\#=K2^%4_Y,'B4*F!4KM
M *\];#UP /H"BLT4QDC@9.#*XWX('[[N93%8+/K88C!#Y V8"%*;'7B280R:
MLKB-DVMX&GGC58!DT>;=_UU&N4Q&2$1P.8&7)/CB=\4[+LP[C"50G5!?PG<Z
M2D4\:Z9/?"N<!Y@3Q5OU+/B7@UWQO1\@.P<:]6@<?$1O *T<%VK>)),$V1I^
MSCL@HY&(U&W3+)&KQT&4\40^7/TQ'].;\3Q1]NDRAU;EOI2'2Y<VCL(1"!@X
MK52&N/MI/\Y#'Z6,7C0>X*[XZVKR)BBXX/%($;T )>-P@6?&(P$61WFJ95=E
MU/<Q/H RY"(1'^%4SF#P."HX009OXJM'EJNPM\X."@@=%9B9D?\91SO%V?'Q
M%"?(I*RZ7?A)=)-X8 CU-._E:4;,#G4'(!_4*HDSV8132'TBRH'*5DH %8Y-
MTYC$MGFF'C#C(,U@XD 00+IA0#H ,ENXI,$0-:")O!J>3Q404YYIBUZ;Z/1
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M:%/1-(_DIS&[KBK8>GU90 -."FP3/A)(&C(:R)^0(KAO9"/2%,,8V.PIU9H
M-7GD]8?R6YJX. N=W#H^,K#/L07)/VY@WF&CT)ZG;3RHK,8-PLAVU: )MJ//
M98K-7X3/;CT:#F7P]?F-3R^89+ 0*]H-[.SFUI?5UQB3@XI=RT8=G\-Z0_&+
M[6'!BBG-CXOL^)N=RHO(,71R4#5*4UI-1016R#&F'GL/(C&W 5C&^;0EL]2(
MD#KQ5E==)Y&4DM4U>5PWI56P+(QRJ,ZF_"&=?^2+5['8>SPM?C[E$62I3@N<
M[U!L]/PA;:1:K4!6_CG9B'1JKW,>O_(!/YEB,(<F*4V-DV02T[S1_Z$+2S."
M%5+ZQ((JAGRP;/BL2+V=@PFHAJG5_J*Q%U2/"#M,<S*#ZZH7&9Q2,(*J9DC2
MF+(X8PY)5A.R2&>L++T>V(Z@V+S-7VS\M,;>X#0)]C).T/C4GJ!%3G81C:B9
M8OA#G D9II1/#IYYYZS1*45O3Y,P]?KLS+5?&J&/6FN_'F_ZV9J=Z16IA__S
M__AG.AG1V5K__.##IW>?'D15F?S\8/3XQ=ZSY\^'_WWY,MG^:SIZ\.._HC6:
MF]>V%LA<L4F=F"S3J?GYP<X#_EDEDW_6IRDTZ^#3AP_[GP_?O++_N @1P4^R
M<"]W7>9EY\$JQ@U]W59BS6=V-L&3L)C&^\X8]IV7RZ%E<WFU.:%;\D'PV(6L
M%BLJ]_!HZ5@#B6/"ACF1,PQ&=>O0-W3RT3ID)_&L<@(\+MLAV'^\Y/_\Y+@P
M3G\*EOO'53G*[1>/Z7%^0-&K:'?[V7/_F0S*?QS.<\0334,B>[LTPY\?_*,N
M$CJ1Q,5$8#''Z5+]\\=XV>2* O[G]<UK(%[())BR_6N9#SI)TSR41-:1K71Q
MW-3%3ZT0 7^T+LS"907YW>%OT7Z>PPC\(D$'CA%?P)%>'JIM)2E?;#3H'Z)@
MPC\O^C*7/3@OF4:&IKW&,S(=_/S G.X^_>]>?2K'W7^?/7_P3>NTM[?YY,R2
MX>\]>_#-RIM79']LXD'TM1@9-B"U3E^M3TQKA6F_B#CL/;FB$2W/A!\UIIO
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M1XVZ7=#M@O>Y(IW0R$" ;A?TOX-6<4N#1RZVQ.RM,%FLSX72-_;@&32BB.B
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M0>=Z;]XYMS0?_?+:TR'BM=[P;,C+J^9" @0KGZ2>,L33LG"$&JZW<$Q CQ9
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MH>(ST 'B5H:9+:9=HSUL%S9S%@F9[R<(XXA_G7.PG2&P&N(%2S$RT'"BH$%
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M@J<97$"2,A/*FK,],#:^S'T4BA*Y+>1E5S12B?5Z&T;2EK3@XX8L:;OC@E2
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M=6VQ1 G.$PGZ"7E% LY$ZRXI>85<SW)I,5<!2W@]/XV.FJV9#C2B<,W4:W<
M57?[ UF6LLN1,::GOGDZBSWC3K$%G19%J%ZIJ%9PZ2/X,6SR0:RRJ(BCU[_O
MB^,L/;:L++IG N!",IL%J&1M5;4G?]>%_/UT!SX[VDT)!:RV+&$0K$.H+;:(
MZ <7*V86PVI1^?3".%T]+E..-%M +%/J#1I8]]SF2=1\L/$0" 08S**]79\5
M/Y?\JAPOD2A)G,_OW*2@5Q,T8LQI#X!D4QIX08_F-(*.?!D<CPP48:.R'P$T
M)P,_D;;V0K^)*0XZ<<0C4A95W8[2+ G/T(WPZ_E#&Q1A<BA.&Q*H)$B!]&<<
M0[^YY]QU50&H/F?;)2"S.@>1'68L@C0%%J9:GJ6P['VH0]83Z!2'7<[-V$BT
M?F6&*LLN11()NTB['P@L'UMPC @; \*,.=+M$% C"9'6X=<W'R-(O!S%OI,/
MB]BP*?D=;)0O#B1R ,DBT:L%H#@MBDP;UX._L#)*U#0G1L.(#L.&SB252IS0
M<G;BK$_SQ2/5]K<_,7*VW@6\][7Y;4^^H]=V VYZ,\;[SX[\Z9+D3UT;^8["
M9FUD4(\[,JBNC?PM:B/?,25U3$D=4Y)5,3>1*>DZR8BN2HQTS;>[ UGN:S-O
M.H*B:\QE&RG[*,VT$:#9YEML=?B"2S<\NQ,9] UGQ<]MCK>)55VPWC<?A%V6
M]/"/N:T41]U;W;ZWVEW76]TS] L.</1/+HT .M(<&6=.(?ESG7.'8[I+%""8
MAS[1G@@(_2Y#7SC7/VCJF86TN/(GEQ0*D3%+J_&YZ9-256A&*6#0<408':!D
M69K[7,8/P"A2- R9(R&2)!CW#FQW#0S3VUG8<5%+NBPC2H(^7/T8C$N(!.*Q
M%KSBP)NV2Q=O!]NPA*M'7'9=VJZWFCVU>J,I-LDU2^=T'B,^#,(B8Q0P2ER$
M65Z.;4%C*&J=W"RVTQL7A>M3"?X.NE8XV&CN@KZ5MJ K#OJ06 Z."BWJ,X8;
MC1P]E< @K)BPBE2V#]K,O+5;'#/ZNVK,C6YLD8^J"G[ M#03M*C"@]#=+S,C
M[>N7N&:>(X1C<NEU8U6QT/ZT$ C:2:F83.B1'@^%^)J6/3&:HM*,\HT4F^];
MH>CABGX9@JYGC8D&*1WP(+*;BUO*W"-=7YI1D\4H:>TY+%90,KRD_::FP4F
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M3*+(Y.L]<J('(R,;'JXQYS[)!K)=B3S1D[#PN!M8RRIFY]+5P,R7M4Z++$T
MTB@<K&#6VF.]^<E M^@\(7&FC>W[12\*I ,Z]!;!G<N)88)I3$MN9I=X'"&[
M]TMV%L<"9DN&)7K*J@A5*;EH258[*9+=V+R"UPL2IN@?!)*1<X2]!=6[9^BP
M3QXO<>TPL-4JXD\CD"]4>V^YCF"*J*H VAR%1\[$ ,&<5I/*@SQHLLE>&#7&
M\1!!=,[$8[ Z+(&Z)EU1(+[DHQO]61AG^CHNC7 0! Q6&$-NLDJH,;0C4 )S
MBK/U(?*$PUAI;GL<N3MWP9-[YSE8XUL4ES6IV6B"Q!R0_SJ,/HO<?!J2I@]
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MF0Y<^A=<ZO1+N$6">(!]MLK.Z_%.$/%E'8>:_*HN9U&_&-C.#CA"2=X')#4
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M3/L2,*9G<^V/,5S/"O)V6^0'9M6!5",U9?2U;*K: H9GKD35T;/&TD].5R5
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M[OE2;CUU*NX1$.0O730;M] XL1P8J3(-V[=M$/!E5F['3*M<MG:),/P>2<[
M<%D]/B(G'I%U/]>_FJ#:5Z3E;'-0M*W/],LY[U+\"S7Z7:IU99V4KVPM&%-H
MYE*8MN)VV'!>[Y)JX[KH^6_CW'Z,<[+7)D'Q-S=RLGG3FY'%7@GR6N)LML@Y
M;(4^E[3+*;U T2$L]4&I];L/7V7;!JJ<;USI3>EZO0.385H%PO:SO>%:'-/@
MT SHKS;F_]+WBB.K[]C_!XY\$!B:@0G>&4"KM!D=D=_'Q/D3&51.A[[]U(O>
M@V+@8YP<Q>A5.#A.JY:OH2PRW!30]<:LZ?@>H/'$''^)TBYHHQ77/FZ.M,"E
MI(%XFIL&R!*RQ*Y&07/:"NR3H@2RA-SQ+Y[#W%U DF-];Z9J"- B\8A>&($-
M,5;(_QBFWAV57G:X'3[ R<(6AX43P_>_1VVMVG:EU, @)V^1. X;#.J106^9
M'OY8160%I71M"8&9U\2!]*G=N"W7]\ 46PH<4M+VGZ:V?0@>#P*9G.,VFL=G
M>[,I27F3<R:58M,L4<X@N-"\FJ!PFI9I)NX;;C37'84'U(9)L6%KJBE0C]Q7
M)05T\Q '$O,1D5A!]\U?XNQ@C;+ET1)HB->9B& ('\VG9D&@K9><SON_H$&2
ML T).HG'.KE95K')^+CPG+'L%OA$-I$0U.#5T#/.HE:8WCEQ*"\/25EL2!EB
M1<D.IR=4;!8 4<,]Q)@(BKEL'.6/@_Y;Z*7E/7KSR9H..F!$N;4:D?FAPUB&
M-,2-XDD_U<9F[VMY+01 /#YU@53) 63]K##Q\@@F!-"Q0J*LZ,&DR1PB33MD
M<\0<O35',S51' LV^7B#RISG,ERIR3<-O9!>0VV,D83IT!20<3FJ4VMV9M!S
M;F 5*Y2Y@_!@5K7L;B7BQVEBJ&=U;8'C$9[I.5Q\0!+&/R[!]_"DO8_0;HZG
M6K21:K!28DH-Z9)T@FYQEB.,EPW"U3<^J6%X(T.BG5P$CN%:P?3*#U8QW0]T
M8,#X<V*RI.".Y_)N$H83#<71ZP6".6Q!]>Y7!_]\!%K;]7#@NY(4R':T)&C,
MCU\5*ZX7HK_,,1Z<%C&GA"X>^H7RW'NR/-'B Y3K"/7>59N47)[O0;CX'J2%
M@U:P#,K0^E!LILZS(*KF=3W)V>UW24O7U+V2,*./%MG7T^?@C>F?8Y--)9/D
MD)E5BO:60\NBSZH7V N7S=1OBZ!6VK*HJW6]=[6*'QJR_SZF!DEL.8 .?%)1
M#R$DK%$9(M$_-,,C+59KESY6AK[A6Y"2I#-TT)"3/=<KS_:=H;MF13[".K"1
MJA9S^_:VD;Q_P+*[DA0?TN% #]5&&>^XG7<FR237M$U5LAN?!,@MW:@-QN$$
MI;V8%FRBQN61J;L>.=U.^=<7$K\J.DPGG%Y ?W<V^Z)W8EH>DNW%WAX96'[#
M+-DK7$OV1]A,T$MI)3?II.W>2]MK@XXNZ.1"M@#WUK3ZV?OAUD?X(TW_"(KV
MO/0A[!(OU]C0="JY\LU.Z#JA^U(@?WM0D)M2ABH.D)I08;4$I\>WM-U4'6.K
M<!Q8HJQQ()U@O<6A[UVTC5+,+./WJ@3^QUT3$<VHX\RV @[C6-I?L5KHO8W
MKQ@JH'::^'24I%34^$A+[W%?G;+[KKIQF\T&?>=\85L</1.^R&+EX]0NAA"6
M>K)\<KF=1/00T.V;-LX!=UA$!MDP5:O3'>ED1O*)"WDF+HLQK#Z(7AESQ'O(
M?ME3M>-3;*GY L$YXA,D9BS#/5V]&+%LSY0%;]F 4MA++6['</]35M&78IS#
MC\&MOYA)DQOMEC:'E1("=<2IA9=?F.Z7$-WO[>P]66>T>H$86\@$0A>_F4H
MLK NO.@:3@$)E.PVU)[=I]+ K@];5^"TME+!W:Y4L.O#UO5AZ^KHNCJZFU)'
M=[D%N;O U[;#(MV9+N1D727<=!EA.M]PV]W;B^<LMZ7C?'*E<=[ZPLNOBQYA
M/\YBVP=KWG<54;"(K)@#36V2.=?7B,[TTE3LSDZD> $P>+B%@-CG..9#AW2^
MIQI7)K6* 9![@M"#B86\*E\>&31<XK0L/Y:^:6NQM+#.-B7CV^?FQ,,!F!L/
M,*CEA#I27)<7)]&@C"T*44L&+.C?FQR5U"^20)ACA>C$]P?"-T>$ZC"9 K3
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ML5Z>I@4=/K/HX6?^^U$XL[(Y)-W)6\9_;3O:Q^Z;I'DZ:28]--"U>H2/9U9
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M9KB;E2L0==U95*?!UTFEL: "']*\EB84.F-HCG;X[A4/6XI1?5]/,9+[1=Z
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M:COO,L2Y!T.$DKQ^PNO,$,DS%=]D:"W?HO$$?L73-48^SI@PI*/RJK:%"I^
MJP0$&_GQA)>IJ,XP]\)U04I0V=6=GXYYB3Q<PD#\ VG=3 V-F(*4<6<@1Q(S
M3\./:7X)V/H)*DX6EGC\YJ >.)5@)\Q)Z/S(6VI>210&LR*-[L81T2D!VU"D
M4>Q+,Y/AWU&0A2DBBKV-/&WA(I __C4G^34_[@,]#J<%E(>W('<4;P7-KAE*
M1X8W8/A[AT0Q%#E +6(/X809!IMPO[*>Q13V?(OH"*QS"]<-K@#(<#4.!:]@
M%J3 <TAXN#!N3F#%>C@'(LK2@&#8AA(UY])Y) >)7,\T-G#UMO^]BM==Z[X/
M[+V4PVKJ(S0?MB:677%[\$EPS;LK1>AJOKV)]5[#@,I\=ZP7.6QPU0?<?HWB
MT/D@XQB^"K=,QBP*XXPG?[2J3)H+9I)GF@%;P'H@KD@MF.$96T= _?GK*0E(
MZ2G?U_#_/$QS96=R=,4Z]+F!Q>92//M+\?X&=,[_DV-4.J\J-Z!ELS_RNF%\
M6Q@G4^E2LB%A\!OSE(95&U;='JO^+'TO]MUO=GG5=1IG-S>!3*J\NP-YN8)5
M54T3[\C2PKETY#W0E+H(0Z<^*#1T>L!H&H'EG9(32(X&FH]X??^;>3?:F$6M
M!0:;9"O?>$2)&,F;C*81:E<DR8":YJ'S1T/9D>K>'/JLLM&/X%%%WW K=QAI
M0YAQ"K&AW!EE,:E;,T$+3,@0&(A&"-J#QF@NW^(U;C*^[=AC!-?@B?T")C:P
M0NA<SR;@FB3K!@HVH=\Z<"^EIH/%I[K)HJZ<3R0YL'%R+I<?SB1"6TQVVYUE
M>K%GM)/^29ZP_L>H/QCUNBO%WN;%AYY!9&U)>:^2.^O>HV<MB,K ]OL40KNA
MW3(F66%3F\S>_.B(23YF%\,J-'(3]+VO%2/&6WR0<_"#"<950+>CHZO$JYJG
MN6P;)T7(^QU.$_T8XC+5W0I$PLJ^Y7P$SR/Z!N;+,,I2_(@?^F@$M=0,9S"K
MLQB-N);C8^PV2:B;5.UO*J,I_@HCEAAZ!;<^F26IG/!(3#<+4IRM"982IE#)
M9*) ZU1-VP2K"+\WR@*<82QNS*!<#+*&KD_1!66V@!^%U&R!99OZ-\+,",80
M5N"3DHN!NF!;E4]/[9I>C^O0249RO.3]V!_Z8-H!P6,,0EO/T^M7H3B*92<I
M,0(.NZ:9IA0_I&73N%B:#QQ-^65Q%F)X.8ZRFS&2%W\9Q3<B]!-:?\N,":[9
MK]H<CBX-$GBXF$B,#,(')FA2.G$TS)1)ZH'V"2.,Y_^=^4CO$$X.""UP71@!
M5&,JO2S6$7X\_66VW7+[\\DJJ5_ES,%(\2WPVIKS/=?2\JO)U=WOU9.N3S?[
M5:%4Y$WB9$F&T@!NB!D;+AS@/!XX;L9E&R'6=GZ/5)1?Y\[4#:#L20R.42"4
M[R$F$PKJYY1NP:-33+;@]T#@P%40.(M0+P]/(LFF/!;8&MMMYTYNE)0BSPU>
M^0WV!XY9%*LWT",F<"RS)LAM/'@NEGGZ 1"3MV/5D,]])__]%H2E5FV!"#$;
MDLBIB,VL;1P _1;S*1/PGW^6(DC'+N:NX$)@"3[Q)_:EJ)2,G;;+KXAA5@&^
MN:2OT41ABD;H]].,,.$:-<=SY<U7HZD"$2.5(3QZ>ZY/[-UPPM)/X"*C4H.?
M3+-AX+N.%[D9YX)9DZ4QJG^@BDB2R/5I,G<@;^#+E,#CCZY2;-O<H2=]A^2]
MC%V:KQY1@A5^:_1 E0WP[^;+&ZE\ZWD^F#6^6_WX_P-M(=R"#IORZ'?8BU"-
M:Y8!.9PI,_YCGCK5*DK7I!7$!'S'A,V:J_#LKX++Y0B8<-<&N1+CRB5J ?O<
M2 JWFGJ/MQ\^MRCG(P/IL@6O:D3P*1(XVF6/0B?ILSC&?X)'X[$3Y(!.2D,9
M<]*?7*K*[=M* G7DW\I3-/3492J\'7:<\C6*LP M*_JW1.\0;#H<]<::E+2-
M4:'D0Q>J:=O.!Q61]F0J_(#+9A*98DT"W3C@/+X8W=[E2M>N<6,X,(2^K,PI
M+X'"8+E@\^(>79F/SAC6&. ZI4?V=VTH0A^^-H"D.P[Q_I,?H7^:QTZPKHAL
M>[.EFSS<C5\!?UZ*2=OY QG.#]T@\[3*RBO=Y&T49)I =5[X1. !(7-K?!#C
MDVMCJVI.Y?8377I/!EB*I-]I%HP/P-(V^@66[\439>>I5=/.\YIH_#SFHD#Z
MCGS*0;%CQ1&$.$$?+1CA3LA;5>)#2994:;HB%>^0C*ACX,,N<XM4CIHMQJ0V
M497U7#$R\=\86WGKQRYJSY;:B/,ECC"WG6;\A ^XQZV+J5[G](.64%QOHNE?
MM''58194>MNY9A-?!K-6B3K%!*$A!8:-$A0Z?C*N91H[".;)6QE$4QW9,GJ"
MDHJJ/@OYB0F,3&:%PO*P#QI81=Z@"X!%<U@W('1Q 7JY>&D,D^57@8-2^+T\
M[A;,-'?"+B>PDG'"SK*FD7D.^B';/[FM/U![8J<B.:781<$8!(?,7Y!]/:0^
MMR/N.:RTG2UK0O22::?3'39MB$^S#7&_38=G:S0=SC$9GUF/H+6*G7?T-??F
M6-IWZ[L>EURN#=SQI@VR:8,\WC;(QVQ?7(<5GFJHXV.([K-5%C##MIE$NEF,
M,=\]ACLXWH"-2%*GC,"C A=QBCXBEBCDI2,JU@Q>V/PD$78S4=\:!1#8LR]X
MJ132$'?<G2=QS3>4Y3$I5N7AH81.5(8G=+*I1Q[R6R+4)Y$RH;X$\+N3MY^^
MO%1E#U8CD9AR"%UU:&DIA7^_D>!_CC% 23ZN-PN!)BY&*"3XG#*\]>,H1)<6
MO==*?UB01$5?>RA#=PST_Z;V@D1,X3C@+7RP$[U>76 +J_9##QSK>$:M7J>F
MU<OXT"WG&WB5(4:.\!V_Z_S91_B^GV8I'==U"MS#I;O 17]@$ INP\U,T>E:
M,]0'XYF?_/[Q^H_3M]<?7NJ($/8S@J<2PN(3V."MY+PY\( NS?3X&.@</WTI
MTX2:TVSJ3D$>8.!$IR;RC@(*EZGSG14:'^D@,:JD8JLT6L#EOL;"2:K "&]+
MT;IT>PP)R\4UJ@BZAFWSU!#5^O@4U!5Y$8%>%H8FPAOLP:3GP>>HKL $R_-6
M1UC:!)8BJ<>5-:<>"XSH1+"DFTRVG!):(H?(A0>B5";EBZ-61H8NW-&$2XC:
M^@'$FX['$;H,?D8]J+&$9:L")N2/G.^0DE@Q+[D2[/UG7#,*IF26.+_Y\%85
MQ%.YIO)Z^"1,\(=H<"N"C.QE-"^!G$E3M;.PDH4B:#BKW,5>TK7KL3<1_!\B
MO#*WU!2'3)Q@$*NE:@9,4=DH"SFKC]QE]WK2RD$^88"RQ EPC548485AN: M
MJO+SMQH2G/SZ]6/R$B/ (!$L7@_PD1PP=>,H26BE*'0E<MF;A$K>8DGI'I.Y
M,7FM.VF)-@RZW6@1H_K+0Y;:N02E:*A(!?Q%!#.0S4E%I4@@4P2?=";X8OSP
MJ1>#; LYV(P-SEC05XJ2JN5SA1X6#($^Q<#^+2Z*/@RRT$O@9=*6B+GH89F7
MGU$NO*PRQAU69[X'$\"G=)F2?^5 M+R'SX><9C1E(G6612RQUY>JIT(*#^.>
M*%F@#HYY;02:-G:0+UI."$_COR71A&/>*-L].:):4"!I2PDMKJ%*A)U0(CB
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M%+"8*8DQG2+T"6Z\+NZVP_N!IU9!'WUC @8G;^@G;U[FYVD$GQ]Z<HH(:7@
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MH,*M@GCAR7(Z[;!,>NU8BJA4\ZTORL= :MCN5JSP>FW^R;[*"^W-JIVLJYS
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M*CV3CT+=Y*:90E^91IA 1K)8L+[42("5&7F]KRYZIG\P/Z-\3F1@L3.R[D'
M[A:R4P78W0+VHW#"C!0SS>E0=%+0M$BGE:ZG4\=:;;M_$#1<X(=*OY-"3-0,
M&!822I7'W/A"E+1@@"TGW=*=H>XNHR>90Q0>M5D6,)IUH1@90NCV<]$=%VEQ
M]9C/HT<1PF0F*?K '6$$7,L*72)FN+ 635_0"VHAD E"ZK!U 3;%'/.GI:T*
M]92*>+1LJDZ[5["IP*\'SOX=>RO[O47)A9:V)C[369NW&0N"&@AIB@'/-6[L
MA[W:#\>H0$HJW=2P.ZFXS\-U3U.96")(Q_UPUTBC+-62Q=1\&F%D3^5>U4W1
M7DHN)O%-'!R[D2&Z ::0>)&4$7PN8L8-GC8DFQ8N@Y)PR?78=*6S;I&H,JA]
MIDFLJ!T44)^3C*5,&SG3R)EEJ)23J<"(LQH?!C:'"&]\#>M8G[LY?@FS*.*C
M0Q $ZT"?T[%_G0>XB2*/@&;SSMX*W>CKN6SR#9DKF1'7E=.T?BG5:$KU/90H
M,+T.=QC/0(..AMNIT(\U",@L Q,E\8W,!=191UD_$Q518J3E7MNYUE90K[.&
M%519:6,,'820:H(I2R3BOPVXJ(*+)DL@+>8/FR#)%BA=JMWZM^__V_E9BB =
MXV3%IQPN69P)SZU3#1)?<'YIU$/HH@',J#^YN4ES(V9SN5:-+O*Q_""A^7$T
M00WX7$^ E?<J@4[@)@B],=%Y_AP:2+^<(O")P$FRQ?PV+BH+06]Z.JZ/ 0;E
MJ8]P2!I\%A$R9L;P"+DJ@G51M]TM9C=4SQ8W;<]+=;1R<]@HFX(YG"?VQ7P2
MU=CNE63+8L:U-&:_OY+&?+ML,58VHE&?C8V_KD8K\J<#7K0JWWF:TM58]Q0H
M8!0AE=C4.3Y=+O-E!/P36Q1Y: #AUK8:*.:8/]((DHI<FR?*FDO=7.JE<W%"
M4,[ +];%]@C<7L9/_%HO<=K5[ J\YG5$TH.\\PHX,^[!&"])-DQP4D^8&II:
MTH-=>,19U[???"B_ZIVJ#:.K"JT^#!0;== 6X*7S[ZB6@3U]CX;_#3,].9RQ
MML;^%.V1G\$,([RLE"!1V!;"^D[UY9V4FX91>*HQ[^$+JNJ4DG@RV<%X-HL"
M__+D:1X+56_6Q^=FDXQ[N,@P!7I;AJUT9VZ T5QCI9UUM2'VQOT[\^U2V'>P
MA A,7&-^+0-DF&.:+6ER;'K\&W#\IE/Y<<#Q+YJ>_P8<OP'';QKBFX;X0P''
M/Q)0^R<+OO>^@,69#VF>U<QEUI[7'H'WBFZAGYA+3\U,!KB>@N<H9PV",:@X
MV/6I&25MC^\J[8M&JEJ3!M_)(,)7U$[W5,!D(,'A;*<Q8E+37#B"'Q=4LS$!
M%\%3 :*02M? +IA.(W"6*(Q$F,08 <\CV7,J]BM J?BPNEFCY G%/HT!TYUM
MJ8Z'E0);&@M^B//H0]7A@/MA7]=4*YKGT0QG='@P$J:+,2M+TU2C@0)E/#AR
MQDWW(%#E)OG6!DII:&?\?6$F/3-< <L^GTYJCKUTR 4(<WQ RSIS-7Z;G&CJ
M[B.7F_VX4"X;R[P]C&UXFT^#TO.IV6K0A*&:C1V>@R66\8WSOA5='V50SUNE
MRED<7$VS\J2;Q7E?YWOM*-,S$RQ+:COO2LA[93CCXN#WK]S)>?+F?[^^=%(I
M)CD#5ZX1GVDM["VR7[VCC9/2!0_>]0V&-FR/YQ^H\<4, .C'DZ1<<F&*E?-!
MRS)'X=0H[/D #=@';T-=(C6.$BMD(\*]A*\A60EI,)$&W5#QJZX@\PG6'=8@
M/7M>.JTBC/"GB83#PANB#P\K34R5[]ZX,4%([=3(4LF2U-SENR@+L- [P%GF
MB!DYB<#G1ID5,1BWDJO81(-#IT_E/; 81:T4**,*<J.(I5FR*4M*EHIX'#5]
ML2I?^JJ&"!;DR]JS=/:*PV/ =VR?>Q5/N]9E9V=DL4--%A/NF(9?+H7KJ?_V
MCLI'K!<Y;-G5ESE07SU=C,"V0_(;M@JB6,,C3YY'<DWORH+QT?#'L^>/NS'W
MX1B>D/=C?^AS*J6 (&TZ2,$,"@*)EA 9FEBE"1HMF:"ICIJJ,+E]Q3C_)CJZ
M8CH%-(V$1*$,44WKGAK&VZ;V(96TPKZ;4!DG6M,6K@OED]14"!J]?H-6//H+
M44B#C=%_P?GOI*.C@--HRI"G2M'N9=OY.;I#"Z:LO3T_GW#AC*.[PLQD> 4V
M&E.I4?WSEV&)C,"?P5"C=A,HD%;T-O)!(0AQ'=_*&8<VC?U-J?<Z-';+12(3
M4*36R&D>_:/FPF5@PC/W\(+5>UQ476P0-K;+LY,[%8_86"T6W'@N:1I-]>PY
M!K/G-[&R<1L3IF$,8^+&(H23B$$/SW3D(Y\71_'&RAB\7,,U#/3L&<@-1%SV
MG6TM!+P"-HPK\NH73%;CQ_4DS8:)GCT3T4?L 7D4I>4X3"U< 8,:Z!S']2Q)
MY21I.6]R6#OFM2]QA-/X$N?D^LV7EPVK-:Q6&^M#)\SR@&D.N,[>-#SS['DF
M^>8':A2YO)_*V-?!P"('[3-N4PQ>O!T+&M5-HW2#&<TG+LQ9UO.B\P7K)&5M
M'(2_7_P&U4#[MR+%^(I*[$KNQ:)1BO@=93.J<5QF)CC-RBH,]_I9W#+*HI4F
M$\,(2VM5W*5E9;!$:$V!LY-<C#)JAIWG..+6H:C$4+\</\*X5@*J(J&<F]YK
M731E2T>FKD UGVV3N'[.F:F'L 72-BIUMS>/MQ%C!R_&RK:Y':MM<1)LI*VG
M5C%P2V(/[HI4V6V-3?QH$@_C[E3]:EJQHKPB1N$3V)4P=MBC,!1;23)X5#J&
MKZ-4>O/3)\HB3^P$LEUL4R=*1K"*/+GOAZ,@TUH"Q5<Z]N%E*'27U7\\Y_FL
MY9&)Q3/<>C'8U1,EX_MR4=0JE#L"&];N3-CNW*'S[MISA\X6S!TZ.Y_?]K"H
MVU*)["ZW."SNI*SY[#Z'''6/9>I,Y3)8(N61FAFW^-SCY*^Z'I[M3#6B#L_?
M< Q%BI9-?'1CF6@#G\3,T>Z"U<+='31G/K>K%Q,9C)N.Q:3'>>YPQ!?-$<^C
MS@<_AGN=C$6L2I8YIG K@L(L&A;SQ\D >/&QZJ5A@L5,0(<,7E^QV6TG[>B]
MSNF'QX8[V(1@_Q=+ZR4C,M? @C2\-I]TO\L[R@:H(%S>1J&CI\?)$1@-;0Y]
M_J'?IR9^C"9DCH,YG*D8NX))/M+#'S@G& (3WW1O%<>MX#>7+_<5RL/"4OPC
MI*++-%9H_N">)3Y\%$16- P,:#T"?\2^F^IVH1)V_3CR.=)6[@9K0FV+0VU:
MCCEQE'(;X9HQMDT#NI7V/3]'QJ:0+JY+6BF=J@RF! \V9&*1,'9-W7([6;+#
MSJ;/65RT-\UB8/U>1B'F))531LS546$_-KC;CB# PGQ?P+RP!\/2<Y%@J QY
M+!*>H8208@3_L\.],K2B@*,89DFJ!RKJA%1Y;F]Y.@4'PVE(DUW?\?;#YQ81
M208H?Y@XL006=>ESY0@[&_HZ45B,ZS,FD1':-1S"/8^6J"M68U/SH2I&IR;5
MT%%VTB\"S,N8VF?[>VN4\^V\9+%)SAP\5>4Q@K1#,=!@!K\,/<S3Z?Q&",<T
MER1V&QX-S\ ^YD2*24"S*7-G&FWJB<#ZT5"H? 9VPEK8]OR.VO9GS' V,GB)
M#%96QIXE;[4-4J%^YVWG/6[VCB93S&#A?P,[58Y,Z D0VK-BDEK/4J"?V<@9
M.!@F\14.JC6>0,L$>(%,<Z[[).)O6(;P)L,>4/S.-<C"C%[(E+N6\2T.JG$^
MXQ5 9^9LEX(PR2^BAO](N$068<E5 \_B!IBZN7GX]4HI0JG]OD4:SHLD]^+0
M=20%J9BG6C* ,P*58>4P3I!=L9%:TV^-OL7*EHA^W>VP"K6[DKD\0P%9V@R3
MCD%X^(F&TQTB2)M&:Z/#M2(VE7(3^-X$2#;*@GPX+4K;LG@F9'R<G"-(KH'^
M,'H_9S;;(M!'I<?OT@/&,I@ZHRPF_33A\4),%QSSD>AD+4I1/GR?BUN',KU#
ML6O?!WV495/SH"'$GA.^FY=,.YWNL$%X>YH(;_O%<[ML\-S6Q'.S5K%S]+7F
MWAP+,F(]0MV2R[5!V5P#6== UC60=0UDW<.DU=:3B;]'X2DY# KB--$>[!Z!
M[NRAKCP0W0P"0Y!S-9N%W3&>0Z;P'@3VB!+V%7M3Y,)[<C<(X+54 H<7%(@%
M"<&37^N\7Q-*K6_>F&#VPV=_D\ HDLQG$R+)L(F,4==WOS-X&2I!7>R39 A!
MQZ%>^MPIW7R"IU>#MW%\8SXBSI!&/P'V-!'HL1*87FN^5V[YLE3MC"ODV(,=
MB-[?V4ZCP'=GY< O!RE5I$$'-JR0"I&B&',!ADC$2-YDH 9UTLX>N+?U+<&M
M.>4 =0Y7OY E\\G!&!W!(]=4X/"(#C$P273DS6K(L5'R>IWN%8'C(4#<^W2,
MUAY&RD*/RMM5E.):Q$,1RN3T\WT@9\X;GKG<ZW00, W^/L05$)VQ%CX /8'D
M<C%LI%8QDB*EHX!E4T#9X#.6XT[(O'OCFR4-.TY-Q*]B>E7JP#> 7][_A2&L
M0'4XK^::0\^ZO+O76;N\N[X@G'_7O]K1XW8RFT<58<R?SG.V[G2>ZA./I;CC
MV W2+YQB>;6763QUO-+_;@>G\@:,R?W)3<J1JAE\G1:LR='CR]*(="TEH6ZE
MSJV0UF5KRTK+&RG,1C!:9KYM1%7+5# ]!C*:T[!\CBTG"SGABM!>B[J,*TIV
MN0'[D'%?RVN\S@ZJQNLIWO%K;;RN=LVW?(5K[Z<G_\XP4V;L:H*"=L"5 ([S
MDS&B#$=Y F^A?6ZC,FLP8RH$P^\"H\"M0W!NJLB :S)!NW:'D^L:[?AT;LX'
MK&80TR>F'=$C3*,49/]((KC\C*3\7ITL)QD3/#=>4GGO8K_U>>>%P2[@>+["
MX<8:,/S,E*!Y$#P=]:7KQVXV23"&A(ZL#MO$&OA[B)E]2L4ZPD,0>K@@.G:A
M59Z-ZDT_!Q)CJ H>CUA2C9!HA,1J)C2!]&+IT1.3%';@3D5MU'Q(K.Y3TPA)
M4(#2UF,N\1:#M:E&G>Q/I%2L93-^PJJQ;SMOPIG^#HD?BDS[B8,[P.JAJ3K.
MAQD)1V3O.IUV_X)B^J6C1^J_/OY[N77.^V+"LB*HO>C'?MWWZS:K,L%=AL]%
MH%Z*T$P2[GJ6:AN 7=NA#*([JW;9+,[4AZ,K0?6)"=:C/$(^0T?+$2X+I6I"
MR=9"@-_/)POK](8(K)#""/^%*U=[3]QH2GY3'G0P\GK'"0TS!+=<YT\O-O6H
ML53CD7$(,HCQ&Y$/S-'%NSLQ6&W>:9?K1];5 OV5^]H>\LF=ZHJB! $5U5E)
M@LSK-W/6?]Y<&;BRW%MYU9M4V<R?M3D'-&L])?9O'/6UK8J@M=?ZB:N\15@(
M;R[*!1728XL75O_*>34S.]_KCZHDFW?:.^= ;N@]PE(.GMC=37?X)P7";5*O
M:#TUDN, S%_L4U^QKF@WE"@#E:+M\/;#YX.\*QMOE@/;'TRF"$NCXR@(S"G4
M[[?0!W=4&WXG$[A@F!ZP0_N/(*46T'S5FN+>,RYVY)ZZFM(R*D>*_00L^A/6
M 9.7:T(*]M>N.5FGE'=9)]#H/]W>5:D/Z*%UE8.Y=96_1W %+G7W;6T'MTH6
M)Z8'C4?@4CW>2*)CIZ+[ZB&J$*PXUW11K]GC8@ _N(!X<:NJHHSO+2$+YQII
MDFL2N3X5ME(UH HEX 8"*49MYT.)_/@I-9LL=):?8TO'4C]3_2SF(^!D1WX>
M4@VIK<?I7EWML"&U-#^WQ82JEH[F5QKGH<74QIU70XR473=H]_G^P2L"]-Y5
MZ-A3OS]KGQ5_KQ]O#D6W%] ,.Q6[H.9-<QZJN;4R="Z?.&-*C5,>V :/ 1\?
MQ0_\$K>6TN#HB8QON$27HQ(ASGF+G9\E2("Q2S.>U00UK&W5 XI-AHJBS]B0
M+-U\3/#UK\Y4AE26F;AC>(5%G$Z[5]C\PVB=ATGZW?:@/G^F8]V8ZSO!,1B@
M&,_;O1<OVSA$V9JT;(A Y%;CU..4H  42 /^YF$KY:3<6-S*?-'P'>"!N5F_
M?>$CY$PC./G'N= (1!?.648@!)Z*;.,]Z]2A:O:=SVYYX-'<X>YY&9V#II,4
MNICV!@YA32C$G9BYDOO,VU#CN#=G7K9B/0MONQ9OW":SZCRX]:,L89KSF* *
M#H:=#,[%C1H"8$]DIQ(J&;M4$VU7HZB!C?AB'A;=8%/,JZ4 1ZWE#$4@:$(G
MDI0N44*5Y4.:I8F#/W>#S+WX.H18@$ 2+<S9COHHF!=&2]?N8QF[<5B^25UD
M3U)093IRT!U1L3CJK(*V\T=QMKDM,HH]CSQ?@_*8ULM:SIUDF2O@;T%P:M=7
M<;S=S=2<"YU N$&C)M0ZP8VB&!2$,!@:^6TDI^ST#OMU"!?"'V:,K:74]S0;
MZM%)*D<19R'I2;CD.$DRR#.U^N7<*)!/W:C";Q6%5RQ=Z5.6Q@%]/4%D'5A9
M/F$N-^@P;H%#1;CAQQ:\O1(I\V00=K[(5 EXZP35(=L]$V\C3ZI=RA 9HH3*
MD0-U4#-EBRM#0^Q]JAYMS:)PW(ES-U8:93D[XH^,;\#8/4A@)) ?$@8(G2CR
MH@VF@<OB6UAK%N=@4Z%7!!,QXV4G0(B 1Q&GV EVTTPGF"\2D6M4LSL.%5,7
M3)L2^*&]]O']981%F!&8)\[4*XL-2D=B[]")GYO!#*%2W,U+#92"QK.X!;>(
M>_M#YR;YU@;6*B-[6:YKE,5\/0@M!MN/IE)\<_Z<*J(@WUHV%U6$XOPVPO>#
MGV1A(.X0 L;EM2SCP<L-J';T3 CW/P":_@@W&7S.M77O)LXX18A4\[68@%'Y
MU4^^5<90[>SU5P@)!1Q*^$#' .?RG-!V1O^YNG(;K)T&,V07Z#M7#?K.FN@[
ME3\I0O _WY=)A*/V;L U"+U3WA\%#\P9.+5'MG,\G]WDK[:#5;,UP)='@*;Q
MO1^^D_?=\__TTGL6V_^YR"7<6FJZU]N_@56S_-[5=P\60D27=^ GNN"K)CIV
MKR()#4;.UC%RSLX>/='T9'W3"AM/HSN,$.S1'T50['G+0*<2'$8L6PTY7O3G
MKT#-&S\)\F 5NI%OT/0(./7R1J6-*-_"SBF&KA!I-<[P,V*(@=PR)+1RRS64
M-(6B];(H(C4SR#6,KJQ_J8%3U,-XG0RP[(<8B\&YET&F2UL) I?&:"38KHB?
MK?F$"B"I-W(@N^7XH^);[% 3_%4O"9Z7^E0?G.8PUTHE_21#&<-_/ZFYNSEJ
M!Z-I6R39,1*Z.3.:'5R@+58RY_1%+K#1W1,IOVT_<Q'+4T(5AT/0Y>1$L7QL
M\1P* E]A/BCV* I<"[;"@<.=4?--?O*$L.1*D4@5U!;Y[X![L,L6@X&U XN/
M .NCF>-;K6I:=8[O$(?1PG4;BO!;G$US6Z494?]L>8(D15(5%:!;;OTXS61>
M*X%) HP($P84%U08"=YPTK/GI"0;C="D0<.!)_),Q[.$4,480AU+;(KY,39[
M;C5,F]%-F*R:K\4:7GOVO(;S3+!%#LS!BN<P8:LLS\!3O0>5B)@Y!8E_[TS@
M%V/&QD-O0#?=*9^BX=&&1S?CT4*/.8\/&DI.H]I:-A!W#;<TW!)3,T320ND2
ML2+%,6;TTY)  E]33E,EC^BS#0,U#%0>@,><8X>(5N*2IF2G/BR*92J![W)9
MF,9#WF>4]$TA(J8*>+PLG7%-6(V/UNMT!E3I1?E< 49/FG'0U ]56#3%H"8^
MJ\7 :;IXNX7/II?AS_U0_5T3H4"#B*83,EJ!^8 )@AFDZ$+ 3\?ZA'.C8FD4
M[S6%^LRON':& 4@DPQV;4]AQW;2V_+ (,J'13ECY-(U25:>$EB4/'M4KTH%F
MNH88"\SCLV\5*O.U=&.9BAB(40QM(A("E9-+3[<__)U%<38Q]-!D$%:$V =%
M<1<Z^0#4?'D6F7 WOT<35=N9V$4X;Z-X&F'QGO,3%8-2]-(NNN3=X_N_8L0]
MY5*QM_E-"*U"VJ%(_"1G*T7")!LF()5@71A%Y:[2G0[8#'.3'VTM6E4Q-J[#
MR6JJG&H#X'))70];.3(]X8NXD 8D+B([JV;,"@CB70Z],FP9E<GA6+RQ"&^X
MH:2(<99_EP=/(HD+QZ]+WH&BU'O4=MYC!]+=6(9YNH N8.%[K4(DF/$WQ)!\
M&V6>8EDK_(YZ^,S$/!(Q*87G)Y$:>@94H#K>"AK\B%9;O!E, ZHJ!4567%'.
M*+AA=QQ%[$Q)ZEB1Q9P&K9%*@:>F^<9@/]GEKE2V*E#6^%,C\+CU92A2EG5)
MEDRE,JN*;[!2*E'<XI+<0- $TR2*X:)K0)O"5XW*W7*/W?FCISX72\I-9(NJ
MGHXMX5*]3$4F3IR3N?+H)1ZS-7FU5RTCQPQ]WGFFM(SN$,FO[UAX/"Z5)-8T
MQA8TE%]:&6EX?/7%O*P]+EW50K.)&IJ13SD-9N45IGB'47_@3%DO'UM+.#6:
MY^N%<6%/2A>EM?+7HXXPQ%D$WO9DXL;^D#4/=3">=59J8?RJVL'PHLUX\*MP
M%1^0R=32$T&1*DPH:XAD:4QC&.57"?[O"_@_0+ZW <@#6/B;O \0CP;%)UQU
M&>/7C1V"63@:-ZJ&5U*8YR;T1V"YF[R<4/BQ1F3M)\&I P&V""9A<QM1!C'B
MM5M98)S0K!HT++%<F&#,I@'FQNGWG"0W%D+]MYHJ_;DF_T>[$<RC7LH]MR?I
M\1T8W40]>A-+W;'C8:,*C2<U5@Q>4L+RMM:-"%K4EO&OR 8=5]LQ<J[8[H&@
MX2'H70.N"DI?R@F*#]-.TO#-0KZ9L)C1=R\_I#URT/_B(.W1C$U8/]:2V>?E
M%2<GGY#D'U%-C;*-JK[C2[)5?6H?<J7Q18;@L8W\8GD,Z4,TP*3-H7?C""?G
MHLP?(?_9$Z*IF6FJ-8U1<=111*@@R/!*5ZS3,?N<.?$MN11(-5*"$9,3)VL;
MDXI4X[Z[C;R(G V*6>1K0$W/;>1QC.OFICMEN82P$-]3Q3<H^K+0$RJSJ'E&
M#0173&):T^996K]+GU[G%YK>M/T2%:T*DKV\(C+SN*^=Y"T_M$4)GP!M#W(4
MC/J5P-81>:&5T\@KK00]B@9*#'VPQTI$LM[.5@LL+?<T\O7H, H-GPB3O-D/
M["9NL.*+!S^1DVD0S28\MSO) B[]0A,D7XO!WZ975 >MEQ4'M10ZP(,AE\"Y
M(D-G=\J&.HW7OB/,_QLX8#3>.%)%/C1_"\A^2S&DT%K&+I$O\MXS;3MID\G:
MKI*([^^EF]% CTHT4(,MY-Q<0 (A S<+ D3<3:R:OC(!21)^E9,LE+%:!:.
MFEA274.=?L-'ZH5#09MPU=H2PCU:(](^?-C-&Y&:L=]/NA5IKXU'_4Y1MS:-
M1\W8[R.]-\W8[R<^]GM>(U,S]GN'+4U/8>SWT4_WO+A<>QQG;\$XSM[V1?2E
M+:)KAD+,'1HTZ@]&O>Y2+&.+2F?6#7Y,&-FY<FT%M.2C#-JP*:1=Q#G2>#W4
M5*?;6>4TNRN>YEY9>MOPVPM*J^:@ :LXYS2+09Y*$RSX\]>:&&EKT:$I^#]G
M&K@F>DK9+L[M];M,Y7?2I6Y #@?0]$),F+]:?,(KP3X__@GOZ%2?FY38CEA8
M"1M]'9YYT$#112RQBTE<E=DJ.YG$-5@^B:O[L)E-FI#[X[9KNPMVWG%O<][5
M3NCU!0XR.6*.6F&VVP,I1'<M+]&YR4MTM%@YFL.FK5Q1G6NWWVU.>QZ)WE/^
M1V(-SHU"S3RV4^YVSYOSG4><:HHJGQX 9J@I=\6<J:_$XC&=_6! "<7NX*+A
M@7E$T@E!NQCVV ZZ=]%'6=[OGJUSSC5^I$YWT(OW'9>9-XY;@>7ZKO80$\1S
M9C :+'V&,TNQ]<ONY!E*!PPT%TLA3;'./(<S1V*U\=[I&5@.:=[N3_#CJ/%?
M;7"=>JO?IMZ.SZ!Q,[=C^)?XL_$O#T9W-/[EH>BIQK]<29,3QG..T6_&:4@N
M#=, XT=T\+2M<Q6U32/^[T!--\(1HL/X7__3NSQ'C=N[:IR5N33\S?^&;1VC
MC*I\/9Q%$TT+0Q=4I=RQ,4<7C[XY^05"02:2L-AI+$E^\-@TB)-VCE @=/F^
M7S:'/H]"/^K2;"Y+ ,]D[$^/[IS/KHAISSO-0<\/0E'!<WIT<ONLB2K-I<T7
M71C/J ]YFS7U3'@4:<B"5+7G4K^"5,'FH[OCW0[ZZ;2MAB7FD^FMB(?  %(!
MIAW=,9^=\Q$/FB.>1R+EHO-A="]Z>3[AV Z[V^U1=K![1OZ9]M/RB8[TSRYU
MO0_Z<VOU-P5R./AAR:8YS9;QO@+G]D-7IXLQ"*U:\.:$H8\46GIWA::#SMJ%
MIF<+"DW[@ZT7FM9%%S>]U?/N]L;B8MZ#CR'T^5OD&DB:0F-#?4]#HY;**4Z%
M]N&*J9_"+Q+I[9'#MKB3#W7@*J2*$(4E<;H79*/T&G=SOF>2CYY%WR0+:7PL
MHED9VNXV$[X'-F&XFGQ#C)S$C$(CKP=-M'%^/")O]\86^B!".TK&V$&-C878
MVIVX8[A[N_!@]L <A=9QJW2O888:8OTE,#J%O" G49!QNH&&[V@S]CB9X'?$
M\9M.41*"C=R<__+S5WFGA@V>(QO\#J)RZZ.CIC@[:C)%C:)&1_E)DG'O$)9R
MI3-J ')%,FZXJ^&NW7$73YY#3.@ ,2(15_6_A'8Z!!+Y"(Q)&#RI^ 9O;ECQ
M*;/B%Q%C8MW&N2H X@K$8'())!FUG^*7G%,:[GC2W&%G]12<E;*#%%Q9@*Q!
M$%_C* "9T?##4^:'Z_R@G3MC*1,*GPR](_6/E\;8N*GDK FAK,D7NG+O>;#'
M6JTHSXL]WI20*N?HCB-ED'G*X_O%2%.72U.Q5T\4@?:/!;U)Z_62] \U2]S,
MJ*HV0ZTSMI'F*GBQN L1_YDZ 6*)",7<W58>I(T?P+GM,O#IAP2N^SZ\ 7=E
M;'P;G*&G9Z3!YW23:P53AX:M1&'(M2UZ2)%(-;8<CW0<XH 3:E;04,.!/_%U
M@1M/B4_2V.=I!_G(E:$:#P.K:3<3V1INOT,8?S5RHSB(K0"=#HQXY7RBHOA>
MI]<W$.CP)734,3HM@2]'\(A7ZXYPZYT]6U5T[<?.+U$HX'Z'SO5L$H&9NB[N
M^28U56_'PH^7 S(_]/$%ECD&K.+ME-$-C@)*>O2?JRNW 9)N '%W 2W=70-:
MVK!)S0^LUPZ%^^TFCK+0.V513VD+\W*G=JW/&*NZ\J?S_?;HNG/TZX>*/KV:
M9;*OV^^59%_MJ9U>]CMKF[WS3#KUL&56W<5<JVZ?^,[+]7[-.I>996<MIW?6
MQ3\Z!VV7S2/<\?Y9CU&^V-;TO1^^D_?=\__TTGN^-__IY^K5XI6KY<PRJ&"6
M[Y97YM&A4(VV/,)S^;#;OR];Y<I8*I=7E58 %K$/[ ;HKP\[W5W4#;#5IYU?
MS#>K5HAW]U>.=C_DDUNS]*Z6Q<3[:#%O!4VHH)/)4"*5ZM/ /E!<]".+;2K^
M^,,0A\[/X7JK/PY:'WQ$1"O?S#":*S77@P-:$13(]'_L_NG-=7K.U\GX%B6E
M?]']KOBZO]!#0'!6/1*8XDAF8I@:MFXU8Y:=DJTP\@K'IS6*5>"FZMN6^,=;
M)&NWW]^;=&CN;W-_:^YOK_[^*G] SP' !%9N'#_W2SMH+FUS:1_STO;K+^W<
M<9Q)-IE01>RSOK?GE_N]M]_/!6"PF?;L_# "?X_U9[??6R'80N-B'AYJM>IR
MRABO]?&IVMQ?,^ZR&7?99/<.:=QE[Q#&72Z/</=Z>RU2J6FKKNZC)H)O.?.'
MO+VY"8A\^6L_DNBR:M"BF<&YM1F<.Z@L>H<3ZJRR_];B(J;!!J_Z'.K:-E6I
M6;AYAIU:SD='3)QI($7"\PQ4R:@39;%3=UNQ'1(E9]OY V/+?N@&F2<39S*K
M,&/+D?? S'Z()>NX!O-:P[]W4?R-@]0XO:]%;Q6+''SS_I8CM/. 6ZPL5_D7
M/+:A7"]HU\\[(J7%D8ORYJ=/+06@:_ MQM&=<R>Q&!6'%B*-HJFDZ4[XM2_\
M'K.']N(S[2[GG^IDA"=2-P@JV!Q\W5DMS^U6Z=G?X(Z\2=0Q U,$(DD5#\)9
M^]AJX64N_$(XH;RK7:X?\HII" C2#7WP;\#STLT( *7 M_ I3P;8Y:/X-04F
M(@2=T)5+F&8308!] [@#$<<BO-$-)9+ P54M+"PMEG=8/8L,;:\2_XUG24^P
MU@LR8^ASC78B4YJR(EADF$$Y?TX]O"),I*ZCRHTM,CB)"$!NW,3173K&ETW
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MWWJJ+6+*OO$UM0=3SY^[I)V$$EU5")^J:;2Y-HIPH!<6R8SUGC2L$;:1[&O
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MV!QJ,$U_85B<..+A&0^L#<E#/86T-?Q3K]XH-14>8G30[O3>^8>\@/^]5+\
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M3@[UCFY6-='OK%I1T_#W$^3O0>])\W>O-;BX6NC\/-""/5MIW.9N\HX\R?,
M'KK51V_S4\>V]X<_^G X[$ >O8O+?OAU7,^R/?.+F-%0]:F,$0,7I\HVC9J[
M**AH&C4/\UQ6-(*>8O73L1"\B;8?;#3[T-?WC,R7>6/,%L;0U<BJ811FR;;
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M*)XY[^1(QK'T'-7 ^2,V<#I? A$Z)^_>_/CE);=T.AY]3@0)E5KT.KV> \_
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MTK#4FW?7_%7\P#_[Y^V+W@7;:,D833C\G/D,/_ZL^OA.BQXV$< )8$/2PVY
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MC)D5,U1< =!PZY4BS42Y9J*<]>G>^9*2I.=X[,U$N06&0.]LU[-6#['PM)'
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M;=28FNR1C6ICENY9Y^.(@ZBHJBQ15:(.,!%]>TBR6GF593;%/Y\BQGKKHOQ
MI&)76<V+EV[SZN)85WSGB.]!<Z#P72*^_U=O=B[4%JVVZ*-LT6'35Q+UC2.R
MQXC:L)5">V'J8+O95SM(F0CO*H27O64/MF[9!4;&/$R9B_?\Z"EWR1,+PEG&
MCF4Y3ZB^#4?L;4',  9<V-1:N)[X@MDNQL#@BY:%_YHVX,G&>!I_A"-B; .#
M5T1H03A+%'C G@W&,#P!8PTLQYY<PMNSX(1'[5&X=X0ONAY&I&!P@N-S\ME^
M9"Z&5OQK/H+/$;:K"_&:UKH@G+ES9F DAK604+QW9C,3Z,@P,@)FY P $;$4
M\*^\-_>FU",.L!,)G!TB"$5&#0&:.)O#L/"1*T"?RVZ?\;M^G D>F0*=!20S
MV=0N$0ZPAFR84[L@0P88%R_A*H8 1?!DL'6FK,B+'8CQ1;IQ]PWGQ*<<>6'@
M1N%,<Y_/'9=%X5&)2! 0*\.W)/4QV&E(79S )N\_?A?# 28PQB2,2YDQ+@(@
MALQF./.8.[/\0VW>?_OK\X=++2BE@NK 1PC=M/B4F(W;KFI(A6@E5$A0!8Z6
MMPG;W6$PYVW;QM89#S#:;NMFJ!.XA_FLK=2]Z991]^8;(.;19$\HF'$-0B<4
MR.7M"#?*OI<LUU59 9$[6"05<=[.PM&IHB%/-^O,%[<&\*@41BMJNV]*T]_>
M^YP68[24K3NM0)68:0/KB;W6I;"Y !!L?FE,J3UAN(W&]#63@8N.?4,8Y7C-
MZI*);P:!A["U^V*7'9&1SW%C076_@"=QUY\YN$_"-C?A["D(9\171APV*QMC
M:UV/P_:>\-W"%LL=UR7WL*D! -Z"?&4C$]@EV,S^HH;XHQ&8"3AI!!!N7<M]
M;VV[4TQ_]DS_@5G ?!P8=NQ;UJ5@5;#?P-*#CS[!MC4/& ATJTQ): ^:NB3R
MT+0LM'=>_Z\VN""W'[\WR/]J^@6:/&]D$.Z2:0-FAE'T7O!L>R >E4^.'!\8
MY7)D3B(G2,CY%&SFY4!HD=+Y HTLFI2 V!Q:.(<&%J,8GV(8.'"(%$:4BW4F
MQ]\CU!P40QL;SP3;TS36'[^?PJC<?(YO/])<#0Q/H1HB4]5S$A;D<<Q&I3"4
MPHA<EU(YK.TID9[H-[2K((I_%BB*^'&M$=OVIC '"W<JUY\'Z@>^F7/3X:9G
MNN(\BP=9<=04!ZKQ6![S8'N6YVS8/*WL(G3T0YB2)B5-D31]O+L7&Y<^:/;F
ML*.V>]&.>A7NJ,C,4T9'^&!DXDF61@&L*N/NGZ"1\"G&\*8U6[O&:D>L&'ZB
MS9^3Y^A,I]M4*$F"[=>@7AMO'@1C7G.&KJ%'=C.V'.I)WDO<,ND7-T1R?O?B
M)LP3$"[6Z];R@P 2F/D&O6\PV-/UH^F:@/OH&01>%[>+>RQLS;$KA-*<3<#X
M\GYY]>7;IV^@);CQRZN)WF]W>[WQ?P8#H_GW?/+J[:]DT_(-"VPMD?XPO2$A
MZZ\*42!HSY?+!]!%DS=QRLKYB3FH!MK2/U41CU3:I>IV-7F$>Q5]O?)S4LML
M8+=X@AU>T*YP"!,9.!':AL*M?4VM)[IP(WZ;1A@.?'4#\=]-P)PZK"]&G;>;
MW&_-O@[3+0$BUT1K=GO+SR10RX_C:"$"+P 2)5/.QK^\^LES# S3%TF&8_(>
MGD7G^L]O:5J2W#(1]=>?5U&TYHL4^T1$ Y)*LA@W& PO+I)?2WS 7FC::_MK
MXB(=/;/A)U*U!<[:0_;@S5?O^_+=I_L_0I?^=W$ EI<O&;@M$Z!:/R<XXZ'R
M\9]9('W)KI9Y/UMJO4(WL&S8UG+"=L 1TB5"1#9Y+#<8#QVF[8/]E@'Y^B$7
MD'7/^[VC"^%UB7O@7U,P7,'X?9/ 7H33\H#+E'$<WUY26/"<\K==#_,!)J81
M=RN+.]XHASM.YSVQJQ]V3Q^[P%Y6?K!'T0V]* 21N"9R7>:ZPJ\0B#DR*J/&
M-*76!7&G\L(?70BPVRTOOLWD;7AX^83/F3:LU!SY\@;*%9C*@$,ZX4RZ0;S$
MLH(+Z1EZ- )OB7AB)'VY"P0(;_Z74QCBW9FXD@\N)L*2"O&!J>4Z@ .\2X-Y
M/W#R.]YOBRH:40V%..9,F_S3MQ9!H0\9)X" P/8 :Q#&RFK)AI(+9,BB%T&=
MB *KC=RZRZH3R^M&0(/$>4K$0&.%J'BZ=X$%W+$I(CVHI*D+EKE 9$K9E6"I
M<;;#B W N'!RXX@B$"41A6%3#YBK23YCM0JT_'V+\D80N9$826SR&#TAHQ_,
M.4.4-U)OPP03 [<P^'4$[P,E^/8@@^J6;2@LQJ"=;RV#=JZC]=JEG#;+"N$M
M+P;A?J<BWUW#)%N\AI8Q7J.<,A+Z 64DJD[336>LN[C9$.3Y'8.Z&3,4(EI=
M52B6/P6H%!?47FVX\O#8[V:;.IKKJ8W#,]KAF0*\]L].3%@](X:AK*8=-WG>
M?_Q&A.L8+,LH]!5,WAGS"%X3QJQI9_BWO -T]Q>.%(&H38&6N#Q%_? Z>2KD
M8MD2]DQF3X#8=F17BMUSZ)O6Z.<A?XO>N.C( :<RWUL68_MLV\ZC^'.O8AX'
ME&%:'0D5U,9AT@OU9[NC+ O&HGRN&V2^TR-S!X_*>&:PV1.(<CR$#0Z/CS*&
MAQCPMXD!=**VW@CV5\N9RQI_XGRE]?&@B-_-IWC"U-]R,+W$01?XH9G_\?+A
MR;F$(Q4?!1I&Q)B&+(N@C!W##T*]35M$)#APXH1Q\ 3L'MLL*.Z>:,_:.!NN
ME;(*QOZSE<SB]S"M.080; \C829@]KO"/[-!T]'1H[ B?["%<$#!>?NU+$.)
MSIGO]W^1;[>A5#3(D,U-[CR:W&5V@TP82),YPLD:9$1ANI&/.1]BX!&;LYGS
MPYS1X1LRDQX9BADI8\RAD+NMU*4C9IBNN,_'C!7/M/ =,09./Z,R145Q\)EP
M\/OH+B/BWZ0*1M4GLH^H(0*^?O_\%P'NIH%?<<F]%O5M0\1A'CG&\G;.F>>/
M$I5K&L*&0-CART?<DP+OE;S<>@2;E'I4/(0[U9 [= 2&J,U\V&0L$!A8( BY
M.71&"_)G]\O]"0E()=*+]Y6SJ@!=]H;C&P;(Z-C')$(7;2DW(:RQNX&QCR[?
M**H:>%T8+2C>4>PT?IJ68K"4ZMOQV+3-1_K<(/<F5@,GWVP\$D\6X<O<P?L$
M,+- 5DQCN^W3.9)+Y.1.?4=UPQ7<UOP#6#*VO,5:7K7G%9!1,.QIMR1'<[KL
M!SHZ72R+@7FJ#MCU.&#?[\Y7:Z3DV;PDS^R$S!UU'MC&4UJ+B).E ;8].CJ6
MZ84ROT-+)H%A"P9YO2VXJA&S'(Y\"GC <(3)(GD(.#),?_I 6EHID-XQ&PM6
MT$2X#DK^D>'Z@,Y>)RV(Z!1T4%5.+^K(E667%=G941IWA;)($^+Q6N[K_]MM
M7> Q4*IKG02:^DV#<#:VF'3BS#%W#@X2(S8S#?ABB%>N#>'ZF#!G H>Y*7PN
M/3J!)1":AUZJG:%.?66<^MHG?.I[[\SF(#98]&=.@T!KX+N:')Y\VW*,'VQ$
M'JGEJP-430Y00>BB&SG5K$48QRBN]ES0?B/?8C)%&%-%L$=97RXUBH%MDB\8
M@PH:-8R!1+/XH\^=.0O*>8G0S%,Z1%7%%E &S&XN_\HH5JQ!GW'\CD=H*E$?
M8V*;LC<>IMVC[6#.P' 1-S\ RP_F$; #8!74M+U%K/K=D:V@_Z.V1XV$#63!
M0B94&23*(,G7#2TK--7$!_W1?C0!7#RN4*M![AUAJM?'EOJ$28*VS!7[>/_I
M#3$X&\DP(E=$B44Q8\3CV"<4E%EPV17FPB@#K!X&V#U&L(@X4(M1X34$@L>3
MC4+_=9CC%.97?;*<(3#U[XQ:WK1!8BPO#JN?T0OIAG?\'_!=UX2]*Y81I8PQ
M98P=PQA#(TJRO"ORN2Y#SN?4_B$*"X(ZP_@PE 0,>H:C29-\AR_A%=N?#>%X
MH>$SM^+0@N;:\LKFLSUBSV&F(.F#Y(A"Q$$*F6?.9!A:VQ9U@N__06?SFSOR
MWN%S1^QS@3S2H6FAN-PN<R2C<KA3"BLQQ%T_""  "*]$"E>96^K6/S=SBQB^
MA;MZ3<P6%"R49=AJIN9<62#UL$ ^<"Q.Q^D<),=YLB7Q\.2+OO"  6_"V$8D
M,8?C+U::"Y^)BKJC>^B],P*3Y8$*/_E7:H/P1S9)/(M,&#7OIPXH=WDFI[.9
MNF0_FTOVC[.YY2P8(\R>A"SBSW$K[VL7Y#5:J[Y+>OT+W*7;K;;VYH18HRJ&
MG[)6]XD.CP>9HC8+?.;";6A1&QV,PD9<[H#$8W06G-\>''M!_NTX(T+G<P=5
MYHB\O_\F1D(E^GYJLC'Y+2JA\&T\!M7(R0?FPL+1)(C>JZ2EJ5)N5SCM[%)N
M/\.Q"79\XP>M3<+M;]^2-U\BT]9T5:9MQH*)9;)7_'2TK#3SPN.&LL82HB)+
M6B^Q&K8#"K/0KQ.MA/8HAX^_M2Y$K5XBJNJ"!DOI0B370]J]9O\B]8%$DT#R
MO^UN-$\GFJ<7G^?8UN(YZ(,7FF^YMT545G'I"B-1OCNJW1U6[*ZD@7HJPG<6
MKM#W&)T)GQKF/,H<-Z@[)5@YM2;>T%GD_%*>T'IX0N\V-]TP5AARV:PC\-0'
MI@GVGERU6O!]T)/-8]LDRKE9$A\]<&J[PM,=!)4%[NWP$G^92]1J#I(V=)1*
M]"@N0H<+PO"VLM5N-S#R$LN)_D O:3!2>DK2\BW]A'BN*J:6L@\S>$UQKYXP
M42\<6ZQA\'!4(3(\0?;6F1\?96RYU2^[*NDKITUE8ZKH1I5NH=(MZF5AJG0+
MM?N?_NZOTBV4QUD9)"K^3]DD+[1)9!B(='L^,&,:BY+"-A3V&*1(I 8$_"$>
M-&7$_R.&+;,PO,KU^2-;@%WAB,8J%L8K&]A!&BU'&62%T549=,ISC3?MZE\Z
M)8;[>5-OT9B\]]?%_9PZ,7V\_W1-1F%62X.P__K(]S$YP OI#Q\_OSE61Z9O
M/B=CDX.1'N]^(W(:@OX88 J9-H!FH&3&.B@%78P >$)G0V$IN0V";7+ ,!)Q
MM[9HZ$@ZO:9XRL3Z%&A#.6 RP0!1743X2/A<'H/:N^[<C)ITA'?\AN-;(S)D
M8G0PQ9XHYS@(*J?@4<[@PU&3/&!97[I8.B+#E @@R16YC8_^$(R.3T1DPI6Y
MS#8307*K_8""YD\BJ-B<-4*/:"KLRU)+$YD--6$V#(N%TT'=8?9?5.7T7_?R
MGS\(0"[1P;RI;1H(5_)YT1W*95M <,D3XVQ7GRHLZ-\$ZB\#I"?+O#X,#<1D
M+#"!16G5&<.\%M&XZ+M MP#Q"YO@Q+)=7-!L*]'":]EL:PEP E"$)>P )K&Q
M"N[*<E.6&33\"$)QVY*7/-EL"1W-3XQ,Z8ATVA=;"*!K3?T"R;!$.WZL=<3'
M?\0^QCL4X/^_[N1$HG=ZM*'-G;EOR5&?IB9&I".$XAE8:=Q%/F/,2^-.M\!V
M6)_M2&X:9";OC&33*E':7?09"^@771U9BS@9342>.X\ZO-L>-X=!^VE8%"(F
ML93?G2>@#6^ S>:)_3TY84@Z.3)[QH'9:'U<Q-,.$0N,DAW84_VCM_:/'KGS
M5DL;J@[2I]E!NDP[2.NTUHY82<MQMX%S;OVB8U 4WMU9R4UVN3ENY_7T#M@[
MA.L /Y+>VN"%R:M=6W[-NRO83GIW#^+UEN.%'GW/O3'Y;H*H]M[U:._=WBU:
M:PKA1 CY%W-%S![8#7?W=^3+PV="\1CNEMW%>WG;)9HCH;]'5)U(Z< 9.1K0
MCT#M1=0X#E<0N<)&HGPI\>?87DSXCF)#"5^3YWK8?@P;O(@EBR;)(LPQZNT<
M>0NB.0+GQYS#).9<5+X.6EVG.2A$5_'0[X6ML>'8+J^_H[;;LCL4QI7+OCIX
ML)]1S":G+B8_<@?F@B4T\+S*;#%2E,KU&)+/]P 9+*STZJ)#PL>5^.B7L!;X
M3.0>2P *LT]AHB%C=AA=)UT>2T3@X3ON<<>#.KI6T,A;#AH$D;(B_0S? #HX
M[#?(5?LB;+(--DM+4EZXCQ C#)UVP4%>N'+0QQ>2)&K+%=W1OFZW+MY@ ?.P
MSV"0\!-\'N7EK,1HO=;AZP A<A<B#_??Y<=-\L%T@\Q54_@Z %0NNWXGS.T\
M>M;9IG49,(+$O*1Z JR8QR2X8TMC5P>AQ'1 ;AJN !:X5-RYC"0K(.]&3"=G
M$8(8(25H@2X[+&&_<;KZ_#K^I<@FD5\@$WWP120JPIT[*9 9+T,;&E%L.B/
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M DA^\SU<ZW=&1PLRY\Z$T]F,B05PWX#O\%D!Q9PN9KC7QR,</&I:.&;T'C"
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M*NZ!33NZ]R4C><^,0\4C&>!WTQDU"8" UZB<+>^>X[>F\GH4H J,L$ZSUX]
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MKU6\,]L6V"O?_&X+[)V6ZBQYAMJBYFER48?$&L)^56--IW>4MCA#;5&'Q"W
MTNF)6]4[T6^!O=U5JN+\5$4M6E9O,^6OZBMQG1IK"[V=VO+Z5'HFGVSTS/>
M#-B5UN&>B+UPQL3%RVO90'E1=OB,O",-NL&*V_ PKBQ*A,+;^4_<\>?1W;F(
M00&8,8;-%/UZW2GE; J+9KPF+6%+O,D=M ]L];KSU\H/6;&+IF.5>DLQGUZ\
M,0AK1'XB]'2YX1U3C!G]><C?_GI1\-W#B=$ED^V9[;8R-A.14^5R@;G6$V,/
MZ+6C0R\CM&:**4^.*37%E!F8\D4.!'W3,;^S>LS?Z\D]2R1LF4QY%+(7,(@;
M\%7T+Z1DW^VI:W.<)$TSMIKM(RVLD@6L,J,R6PYE\<TZEG%ZZ<Q?QIJ/:Y[W
M&MV!?GPD5(WP2NMMT7K ,_U6>4M3=LJ!=DJ-"RU]2/H/39G;%H^4K5*N<]Z2
M>] D:9+[6M.;^ILCK:V291].;N<J8\W'-5GB-,_R4\?*2,='6M4812G*+8IR
M?QX;# ;EH>+G$@I9C,V)SYD;[KGR8HT.G4<6IMAR-K:8X:'W !.079AMQ,C(
MYY@3RR@\@1MU=#-HSF"1(I]Y!H/(-TR11BNN"# !E 7U)Z@K2E XOB<O.R<,
MTW!E\GJ[U6N2WYTG!FAJ$(.ZT]@MXX@9%@P@+ 4 ?L[DA"*%]PF3HJ5_K0TJ
MH4]@Q19FZ[Y&E^%UE+';TK3PJS>$+M/:81P=4';1)'>6S'-GC/SI>(QH7;S9
M] 32@I0>( @L1RYR[' R]KF'B?LCYE'32KWYS(MVZW>SIKLL%M =-#2]%:\)
M@G!30":F6-O^; A0PE+GS)D#P8/G1B%9!28#A/6TAMZY>K..CT&5T"%RX07M
M[>#V&3AC[G/@.I<%/#M<Q.NN)-8J6:ZM-<DFI[(!J^?7! ";WI#0@EWU@P?F
M\O/E\@&\ ]ZZ[-0;;Y)8]EH%E%PB.[HE!':D7.6#ZC1G$T(M[Y=77[Y]^@:'
M)V[\\FJB]]O=7F_\G\' :/X]G[QZ^VLM:'&$:(2!M@Q&>$'X 08SE'$\30DQ
M/:I%J74V9'FM!$RM,%W*![%IU^Q L=-'DY-46&,<)\[.*RR''\7H,&2@2X$.
MUA-=N!$#3R.2!?;G0/QW$[D@GF.Q*R!,Z=$WI-G78;HE0 1.^,UN;_F9!&KY
M<1S/1" :0*)D"F;"+Z]^\AP#E+&0!]A=WL.SN!G\_):FR%V,&;#V!^-))$GH
M0>6;=IQOA$9+>"0P"B?\1"JR(##GD!O-S3Z,?=GNT_T?Y-:V?=@>OS,,\Y([
MSDLO+U<!U=<JAKP0SDU&;VZ0KH?QO1#2 )M<8M.QDP5;#'C?M'TP9C( GB'X
ML%]J\.$A5'B))9'9AEAN/4>.!MUL!-8]'#0JSQ<$5DJKWH;3"2"?8:4KST.+
M-<X*$;>7!^:^(:E$*U4[?'R&M6/5*40-[!L;)>>0&%15@[ Z8O,>SW.@_.'
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M_56V7Q]O[K@F2MXU9Q;%9=^,+8=ZDA$2/B,=CLN2 [L7-X'(7 JKZ+JU_""
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M2.(\].W* 9:*+%;6Z%:RRN(3_\?SL:H@<GCH^3/&IS@*CCL;U%IL4'[Y9,G
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MI=S:KN7YH CPXUL+)(\93*W<9&)B!X$MI^3&2R>;KC&+^P,Y]7,$JD "B2]
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M&*(*II@D@O8IMG7I/N'/J>%1=_DSP?V8A3"5(\X>L/TX^3OID"G3";):ZIF
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MC^C3/4B05A524G&:#CHJNV;,Q8)5_NW1W>0MR9$M98LKV?1Z<9%/;=8[&B&
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M[NRLNCO[4=V;'@L5B'+]V(F-3WCR$ROR?7".I3 E1WB&CGUQA&,Y#A)K3UC
MX=, /D]^2_^4V^L6ITK6 V@N"JY_$VB7,^Y8'"?.?NO97W5=EN#28MG]P[4B
M-_M9D5N.I# 92ED4GQ7@+3EKC;J)=R#7J^]SMEUI=:IR\T(?*&F_95III</?
MJ#'\OU6^OKKH>\;=?XZ,1B^EX^*.I!][ J!/&_J\"1@/F6DHE+T5EI@D]Q9/
MYVZ=D+RD?"NIC,YMOSJN1#2HN@%LD@',/?VG>R\"C#/(F V#/[KS" >9P,+C
MT88<OP?ELO4[JPFD'FC81(&<5LA?"U>,;,OFSE8277(ZG1S(\H!'TK2&--U&
M@W^$%<*"NTM3^8]Q)W7G.N3-Y>^GO) [;+CR<DYOAXZ.--O( )UH\D\3LU>8
MV4GAYY_^[(4*68%R2M0_0D_]=RK\$2;MNY8@8:B>,)#FSS]=&G8_E==_"F[5
M$"2-!8AE2S=97+MY^E%U"1+C\JY/W+?&ZM=FHVFN2!@KZB6&8"U!E.DFUJZW
MXG$-1<F#&C&55L"4B<-/R\R+-_TI$S>)B<GW(L':BY58Y^>M3!'_^>;M[0$$
MKTF"1X)'@G=\P3-KW>J(WG&!(0;?$X-_F6*=WHH!<CMQ=ZM*W$V&A>2N/(:E
M70K!6Q'7BRM%I4CDX$W+A3,]>;+59$5LNM0D/_GV4L,-55MJ&C46_VA>:?2.
MYJIW[ :A]N\N$>2'#E-OHF=7EJ5NV0WDB.E"4B_NI+[6D;I]I+!O]*(#P4]H
MV6U9O;+Z3@XDH:%DX%6-2MOZA&9JEU?;VTTLO;FA_U:>MR[[1 ?!767AJ_Q^
M-_9CNP?P8_&@>]B#Z%+WP(+Q87OI[5<PKJRX4>SAF_J]FTPX^YL[D\ 1,^V"
M SNZJ)J%HPIS4];=HEZ35RJ TA.WC*VU&V:MA>-!*XYGW5B7U-@I>:'"FRM2
M*$;--%LUH_W\!)DR[GC;G-7-+[Q6?6,EPM9- RU/TFT9V*:D\EW$&*V^66OT
MC)+MA"22)+*J$MEI=T B6R7;B<8,75),E@SL0K>PUZKU^\^/-]9K)V1<R+A4
M5B)K[7:CUFM5P+SL(XEJ/]<,FR<]E>F]3Z<2[74GE8;Q3'9-EVB5O43[P&V7
M?0)MP^D*3>-@I5[W$!5 Z6FOT%I=<-KZ[<IC63?&)25V^AN72FZN2)TT,5+2
MZ59ROSK6G&WL(E/HY-Q#)[))IE&VG9#PD?"5#.S"N&6["_:Q;.DE6E8V5P:'
M6H-=R,3-;JW1:)9L)V1!R(*4#.PBX>OVS%J_VRO93O;>-J!,-T]TXU5N&,]D
MU]3^8"\3-M_>4N\#ZGU O0^.#R2AH63@58U*U/N >A_H#5_E]UO^M*WD;$A9
M6WG'^JW/_L,=]IK[ON<>-^7A>9*4*.-AC<U4)_FE_!@];=)6N]VLM?K]JB-9
M-[8E!78Z3JCNWHI42;O5K9G=4Y71G(B4ZU_3[>V^3ZOKOG5<S/(*>CE%N$@X
MS4:GUFB43#A)[$CLR@-U81)SRP";>*IR[Z.)W>'9N"H8U!EJ_5)\R6Z0W3A+
ML3-;O5JKW2_71I8OL. ''S@B%]:P',']5[#H^'K"'Y/P;T-*6QS$*,[7Z*P;
M:5Z9\='9)EB\'&1!@N"VF"4<)R;(+Q>-"_GO>%WY[Q@"A4>Y/K,BWQ=N*&D!
M6(SQW6B\6#?4'A,%%G#X-(#/D]_2/^5V=I&_P5CW;B(!K+GJ3B++M!C1QUS>
MJ^?UUXJO+EU"Q(_+/^_S#N+Y&X?#1NR^>R%WV-#VA15Z?B"M:_>:V2Z\4P1A
M;M8)?&HYT5 $;"!<,;(M&[Z:/LFX.V21>P^_"T W3DIA\"XW\X3KA2R(!O_
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M6#G6_#9J;@#&FPH7O_KG'^F; #GP*O6:6-NML(8QKI1V!_P"/+;GPB-9@CP
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M86B $ 7$QE.D%%/YBJGD<3%SGK-@>=O%4_=N^-G2C<J8E68++8IAU)@)5N5
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MB.ED5M@T/K0<\4'DX[:8)1PG/N;]<M&XD/^.UY7_CB%0>)3K,ROR?>&&DAB
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MGWN#U##V!&F,35]AT\/XUR1RA:^BVQ9\WW8C<.W6 +P [@6PC=XBU!+H8O<
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M<I)])V)J9!&VBIV6I?+GN1BD%E"=T3Z.%U.M5B76.\?^/SX0X9A]LOX0@MW
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M7N+,Q8.ON-3B6D,8*0.T1)DI7X4OBXJP\XZTN^RKP]T*IYL9M7[7K+5-X\@
ME@,[[6:MU2L8.GT4U.Q_.UNAO!R4,HUNK=$L:,I.7/RKV:SUF@5M"\\MP?O
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M38O2Z2"N<>D%!9$Z"Q[OS/ U;TDWBHMTF#]8+._@H4 _B.=PHAGS._E35&+
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M8G2@DNX8%A*CU\<QEP'Q\'MG/C=AIT0LUQZ;T18,4HJ8BJ,?*)IJ.SG$]-[
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MFVHT2(@F5LF%(1ID:PA=-16D^?.W52Z<?_T.GNJ#L)<BWAG^?NG!IG@R3O4
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MU4_>B)A_U/VC!D-J-X2OPD%M.N3>HJ&'TW_+-RG\X(F,=T!S$ - 3H[:&'O
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M:WO196VU>_OA7"+9GP9(@<P1U['M"7$VU5111D.E:A6KJZ?I9V?H=^N#7JP
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MJ>D7FE[=T20?X>N<%N2T8"W2@J2#WT@%*X:(^D5G-.IR:I!3@RU*M>10IY)
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MBIT,_:S3U[,;=MG+J*=9*E6\"G0_^MU.=Y3&J\#N![L?![D?7^P'X?F8V//
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ML,O U,)6HS@M."MW[@1R<K'W*-V#:4PL",L( D-5+ >;K[MT?,&DIP8) R?
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MM0/7,TJU#'GLX,D%8I@?=.5=_1?A2%D/=AF8LC+757>):Y'I,H'3@K-RYTX
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M#W<P%IF_,MS#8K&R6# RQ%+1-!Y2YX0E8VF&2EVB42W"5-#K+E= =AE;J%]
M.!N.9:5I70<;*R ,66T]9-407:I8'W8&SV(XJ]'7-Q3.:AZQ"@_N@)BY<1QV
M?3<1L>,&GO-7Z >)\R*?,I9[J1-I'&Y$9B@+O^7C;3O-G,)YN^U=F5F3MO=?
M,&=_J"G3R*6RV[;%)N^#H3>6C=)D@_$W%HU&@G#EI@KMA'2\$9S>@'@T 8CC
M?+*&VQ &XUA@&)%C1(X1N0TI%,-R#,OMP/4,RRT#R\6.CY#/#D-I5M4_>%5M
M'AD0XQ6N%=::[4A2;I537N &@%.LQ9M99,XFW/45;EJ1*K;>M2P[HSR,\NPF
MRK..6E1LQABK8:R&L9H&837_B4#IO/ '9A[&A-STQ<!SGB;.UX?;.^<Q&L<[
MSXC":8!9N.T1>O5/.06?)U^'HT$X$>(A";O?R2?L^Z.[@1LPR+/2^F_SY8TE
M7E0DO TIHG39Z3##8O.FK#X<I'()8 %810"81L-"P2 *@RA[ J)4IS1,AV&(
M90>N9XAE.3J,VY5;7R3V#%BAE[]2[RYM9QR.Z,490>&%KHLM4["D"A?=J7/%
M&X(O=5KMBW+K].[$NB]*]%ICX3<()75:1^TVPXDU:CG#1ON\^HP/,3ZTN_C0
MFMK!0! #03MP/0-!RP!!!T\NE"+R@ZZ\J_\B'"GKP2ZC0!8;,>C*U8[%M:!_
M'_M2:)[[."TX*W?N!+)*'R,Y(W0/1HE8$)81!"XEQ'*P^;I!QZ=<.:A!PL I
M7"P(3<"BV$XT6SP8K&*P:C?!JAJTIVJKR&@6HUF,9C4(S7IT7Z&0=KSGH)8V
MI-JP*H,J9^<V8&1KWYS3BJ6!X:TF"</"?F052\-F0:X+IM$TS3PPT-4H:=BT
M?6@:W,46HW$6@R$OAKRV'?+:L)FMUC[N#.SU@7&O1E_? -SK\^W]]=?[@\^W
MCX^WOWUL'Y[+2YPX',B[_:V-_YN6[X9"8_\4GGS L_,LCV>.VY-:Y23NJXO&
M*0'[TA,19 (FH6,/WM9G1RFTLZQ62O-QT/,#-^CZ[H#T#-KCB?F9AL[R\[YH
MJRUPQ_7W\Q(?LAPI7BWOKW)UH:/I8[JBCZ%TJ'[1LW^%T[X;.%\M*\J2V !)
M;#C&R(*X+X*X!>7561CW11@W6?Z,!9$%L;&@+DLG2^<VXLG-ELD58.DRY:@)
M@&$1Y+J.=VXBG[,B]:UV5]CT0C9 >%<"NSL$E2X!Y_(WEOP&@]_E@=_+*<I5
MXAQW:(ZO11?=! =,T=OFHNF^WL8-3:T>9F.2&W+[W%S%M\%&@/:<XE/')\NF
M-NRP6+(2LQ*OJ,2;:ZUZW#HYR2L@QSK,.LPZO(P.;Y:]?M(Z/CMF/68]9CU>
M4X\W6LWUY&19TN0.BR4K,2OQBDK<M*ABI]TZO6359M7>;]5>F-I01+?KBLD6
M*[=_VC[:#[6>E_#  >(MM03;%"!>RD*4NFVW+_.::6QZC1H@EQ@]E/\!YVKV
MCAAL.QLEGZP@7CO]587PVG9P$^X,$PDW=+IB,!BYGB??YQ_OVN_P=_5^^'MV
MKK_<?OMV=??P]:/^84' \HR"I&'DB>BC7 [?2_H?.^WVW]\5BH=.A3KIZ_"R
MLQ%-6YD@1BGG\_]9F,J9_[VE0Z-6U/-L?M33>I"#3YH3!W4#QPW<P23V8VBM
MCL=D)U+G9$=^.()?I%)ZCBM_<:,$+OL]3(1S?-%RD,ET]NFW\$5 6J+\1N (
MU&7\R_FG0Z>(<"T2)\=^[8MI\5+_M>XW"F,?=/IC) 8NE/KYU!N$;D)SG@DN
M'__]DZ-6^N^?E&@>H'W\V$X_4".13_XDWS22-_OQ\<6/??D>YAH8/&:T+?-B
M,U89A= ?/CON0)JO;[>_WDJMB+K_>/=\?'%T=G[NQ:-VN_-T^-?H^=U//SOS
M)J [$&[TT9$/ZG]R]*)/BX\2L=>#]()7D,B9NZVW/#5I/U$ :"TO.W\W=F!*
M^3/O#Z^;H_1D,S9?0JO:':!S<;+ _&?^JH4BYP/KL3-;&VZ*YN%.[E@M^4)B
MQY2 P4?6K#\)N;O+61_\<">Q$=>^62"UI5[B_SZ9W-%7>T/X:<[>YAQ>',O'
MI0-R/CJ=P[/S]#,:5/JQ/<\.3K0<DNOT(W!4_I:$7:A!!M(OS>87\&X"R'%T
M\R:7TB#_=^J_2\]LYEN6?8&J9R*:^CO-R<7AJ1_,;$X9$HX[3D+]"=E'_$C>
M;N/Z[;RMX,[;&NZ@S#LEZKBSA!=0ORO^Z\/_.5=!,'8'SKT8A7)#SV4RJ6G1
MML!9QT\Y;L]Q4U9S6F?_Z\QHT)RM:]JT9 =Z-#-.'&9VE*1\3O3\]/[HY+CE
M=#J=EG-\_&'Y)&AI#O  X8)WU77CO@..A7R._ "\J9+>JG,RYZVD&76DO^=,
MI*_@B,"3H\AEN3F+1["D2^ 4=]92A2_'.]N$N0)KDYY+:*X^MFW[N9SU.D^-
M5X':,?2=X^Q7BOR\[[<M;V,XR]L8LHA"Y[#=7@XLMQ"T[(V=\N]LF,E'TWJQ
M]$/R=C\X3\95O,E.S,Y:>V]!C(">50I9>MXFO>Q_I]V2I::ATXAI./XTS+[!
MEHCX/@EWB>+:R3]4GI_^_9.3<PR8$IE/Z3=.#T]&K^]^?M_YT"@%R(@T"_-N
M"W.;A;D4P<OQ(J?2Z;*/G9LC-BW"!=+*BGVE6)2VLL<OG*YJT9A5M+9AZ6E?
M#';0B\*A$XY$) _2P;,#D<T7>;@6\2(W9+63QK*V?"/7+Q3ODF^WO3?BZZN\
M?L6-8+I*YD*CNLH72MH"UA\KFW\P_W=1V/.3Z:*<:-R!(>,'8[#NRLZ'0>S8
M4"X;^:6,_"ZP=DI^HV9SQ4@YH)K(+U(AOAA]N#7J4',9D9/6I3SZ+Z23[;K8
M+:O'*Q4N6G$25^AIL+J8=2PQZY29U'O:R6,M5C&QO)9J+=O66K;+6\O35J>=
ME]A9TL2RJ[EY5W/%4CD-]$:OO+_&<4+\SDA(/>GZD*/AC*:\5*@4GV(/AM 0
M%X;8ED\8FFM-JBJ<5]E3\LS:R='&WJRZE(]:)G-KG"9._;"LRR]A=*_LBTBW
M[+H;.[?:1P5J+K#LEI3NN8-VNS*1K^ID<7Y<R!EM^-;#8K6B6%5TR#EJG9[G
MX2+UK0['7CGVNO1Q!Z.ISR* @XSP,B%5@-I=J_P$G'AR 7G&X!F#WSVG'0IZ
M@W8 B/;O6'@W00J@?<:LK$?W5<0-@.3/6Y<G)PS)[P2,6X'45>1'G[>.3N9T
M&F&$OJ:EK<B7/6^=G><9% ;L&;!OG ?[J!DC(]?W&HJ^5W"V;L M&39GV+S2
MHFJP8]X$W7!(.^.=5'"YO<FQ?QFX<>SW?.%=Q;<Z"'=E^+\-\,D[K>-.@:+D
MNRW=\^JM,01:R(W<H%94=&:X/,^K-%CMZGTH?_]BP:M,\"HZT71:[8M"=++J
M1(_A^2;!\[MS_EEN2_Y=)$16\H,TAVH6U5\JG8J/5GRT:I[SR4>K(L$-H"S.
M )*+-F]I1&Y[T@>H^4QUUCH[7CK.L9=BS9[M:LA\)=I0T5GJK'5TGM>ZD(E,
M+'(5G:+.6J<7>1U &L]QNL01+'<F6?T[)9VCRAHT$YU6(#K)?5>=BN3%3'5B
MJM/>4YVN+8W86%CE\KA JYI=E\']8<,L)W,5.=J=UN5EA6P87MH"2UL9:?_D
MJ%!$BHE.3'3:M >;(3J1 [NTE\I0/4/U6^KU[#Y47W+8O1$.>Z=(2_?=EFYF
M036)C-*((\5QIU#F!/.@]ECTJBK&=+9AT6,>%/.@JC@> ;,IKR#3^M ^'YKX
MT-0\MY(/3:7PF_(WY0TQG,YS-^>-KW#CQ)H]UHK()JMI0V6!E[/S4V8XL=#5
MFRER<;K9^F!\0.(#TN8311[#Q!TX039=)%Z]YPX?HO@0M:7>YKX>HM)BB\7V
M\=K+7IWDEI7?^%HV3H#9<UVQR.AZ<E]9X:W+T_K3Z/E8U"SAJNCX<]$Z.=G*
M,K:<XK'W*1YK]1'U@Q<1<Q_1]8\(J]UN>V_$UU=Y/5.H-T^AWA+S?S>.NGTW
M%D[8@VY-TI5*)BU'&OT@<=S <\1_Q_X(&@:P0><DOFU&:^;0TJP.@$H3;GMW
M2@_N0 NN N^KU@&;JG:C79^-03F=5N=D:2AGJ^2R& EXR]*_-BB(514H/,TK
MVKG&O,]GW?):%UWKBJ".RXN2R]>707-EQW4/'=<H[ KAJ>!J+(6775AV87?:
MA2W0PQI5 J#Q!ZD0\?:XLB=Y=69WQY'=13^V =)8%84RMUY*%?//2]X0M[;*
MIDSLU+)3NP(:ZP>)&SS[D'\E-44D7$:-W=>M=E^7 $-NC.Q?H>@WS%MM=3IY
M*1:[XZ_N._!:DOQ5EN)SWBZYMMH^(JXE+7)50.MIH=8K#+2R3[H)H)6]4_9.
M=\H[70';:+B7>LF8ZK9Y+YL3PJKZ;13CQ3.46M]*5^2O'N=RD1A"97=U<Q J
M1/Z3B<I2@* #>ZGLI6ZUE[H0WKA-^B*"+)T[=X(2_QA>=:4:1.(K*L-M="V>
MDIL@3J(Q_OVVAU_Y&B34.*E9/BP37+?/M6FJC%:%QIZ5S!;8'RQV0X)0%8>@
M4_)9AQ%;=H'7=8&?QK&\1IX7XQ;6)9(?86DBE_3,*]LAWK#) ;BA-G2!_>K]
M\:M-W0E5<^(I<?U #@0:C4;AX+;W,'Z2UL5W([GQW$:X37TVNM<LK_JXU6GG
M=21EO[K1[E0C1;0<I[KGOPKOX/\340AS=W'4Z7QBV'AK9* <?[I6&6!OFKWI
MM?@/#"VS"[Q;+G!AL.9>=(4_2NS0Y#9BRT?'N^T#[Z,+O#$9K0A;EG=C/WBK
M!*$J=D7KJ%@+,G:'V1VNU!W^@DTGGN7=0 /@G:.TP3+[P.P#;[,/7"QB>4-M
M'6['"?W;@XVF=N<VEE,D/UM4]WKIWEA;)90["?36+X6KNZ_%I+#3X7RUIJSU
MZAYJP;4^JK(:''NJ[*D6]%2OY681QNX@2X-@P@-[NNSI+D%X .3D6Q@WE^M0
M;%MB)O$..D=U"VGE?O(YN\GKMP6J01"JZJ-:M@"PZ\RN\PJN\TU*:W#\ "H\
MA%W?342,!77_"OT@<5[D7\<1.]3L4+-#/=]7@8;>=LDAK5<WP951JJO ^Q>H
MU!]*H^I.LF/'>-O<H1J$K:IL.79P-[6B5:6],=K++NOF7=8L3=>SL-]:O5=F
M+#1GZ]\'M_.-;<.J(*1#(;>]37F=Q;([=L?MW$6OLWI9JXI&>UXAK,8K6KW3
MR;EA['0VT>F\D2(OA3]Q(J"9OY1?3H'=R2W;TG?2G4SC;%K@[Y6\-RNEZRP/
MBV"?<OL\D-(%KBHTLV3P:[?]RM)7M2)$\XB#\.Q<;MZYO!9=^;ZQ^.F]']!/
M'R 8/_#_.Y8OSI4'V.G<::<34(@;)?A:%6Z";RC]%C]E4WS2W8Z:[X^KN::8
M5<X(S2M2P1[F6_'R-5:S*EHGA\AWVJ'\?'M__?7^X//MX^/M;Q_;A^?R&B<.
M!_)V?VOC_Z:7LK$^ISQQR7OI,/J*H7-G^0DIZ)JN>^.MO>7*4[JZGUS@B;OG
MT]3QTDWTME-LQIB AF*\R_K=>RG&:UO@:B>RGJ>L@DR6)?T5 <Z%:D#5LU L
M8AL6L:I*C14ZK52V4GR>V?QY9DL.*[^+A)I9A%07A<XL72Q0-I8JI#!R^,DU
MVL1@.8/EV^R^+Y<33V7@<S:5+T9+;D>J@M_F2C.T+B]V&T[?IR2T*B6Q<K2]
M=79ZRAEJZY=@*&6UJT+C6\=E+S([L,UR8'<'D#<^;NK+XJ]8!]!QDR3RG\:)
M^S00<K>"M#?E_@K/"8V",5+/2/TVN4N,U)?IZE];1F'SSOYQZ_QR:6=_UP2\
MV'F $=9J3Q[+*4;E9X^C0KT^2EW ^8<3EKU*CT'+B5Y%!Z&+=EXPM?%0?X<\
M_F7.'ZM^I:3S4CDCYC-3P3/3<GOQ8YBX ^R-C0>K]RJ8\.$G/TB#"O,C"7RV
MXK/5-KF>?+8J\VRUJ5/41>O\/,]=W/BJ\BEJ:SS9BE6@^EC->;&R+GQBVH43
M4]TYP*W.V582H2YQ!,L=-E;_3DD'I+(&S;RHY<\_7W0XB4XZ/3]P@^YR)QUF
M3I5VN^V]$5]?Y?7,*M@\JV!+S/]-'(\%%+Z-^VXDG*X[\A-WL&-M&H[/JQD3
MTV=WFSZ[Z#!BU[T$19)#>  UJCO-[2B/H;8[A-A=Y,.6+EI55<,MN1S!OA!<
MEUZ_JJ")0DF 3%YE-[-2-_->C-P)5%,!5W,0!L\'<K\8RI_<MPBG#!7LQ=:]
MY5[BPM"($?[XMO=[&'3'421_^1Q&4?A#CJ?V%EZMT\O=KGV[DQE454E9.8YC
MK47W>1FY=P+[C_OD/QJ8,O4=@S#A!'WV';?;=UP&1FB$Z]AFK''#5F)CMJCA
MCM.JJE)59:36T66%Y7C9=V+?:17L+>Z'4<+@&SM0.^) +06^?=FP^W3::I\S
M\K9UGD<U,E95P+9UW*ZRRSHO9&T.Y/EQR0XD]P)@#W*USJ74',/Q@Y_>1Y8[
M^<$)D[Z(V*MDKW*GO,IBK:[MW>(6]&#3_B7 <[M=&W,7W<NJA:TB1_.XS=3
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M^1/.EAQ??A>)TX7VUB$I%B'WH#9^ .W;WFAVS4 [ ^W;Z><OW'%@;_D%MAG
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M67%&[;.D>&2Y1(?.7%TQ6< Y,K:.#U03SG0Q']4N!FKGP$UT=BX$2^,^V*$
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MS?F.(LO+L;PY$3HNFS<<9#V,U0#$J_1U@=7@C2-M2R(3M"77[A#BO4".U#D
M<OH&,'9(G[$W.C--1ASF>B@IL>2VEZJ."1)?@3X(;Q7F%^]PLU??N9#FI YM
MDT:$D'/'H$1ZE!EN*XT+%S/S__X_\GI^O;JZ0R%7G[X=.M:3DX7T_5A?2IX>
M %3.T=F%T;#<'42J,QE>]8U8?N42K,G1^5'FI)RAYA4X.J^?:#&'7GJT*_32
MA_%0/FPB?_"? W2H@R0U,'=JB:IGEUYN$;OT""S\DC[P'O-*+XOS2B\1/%IR
M%T0AG?P21HHJG08)Y(552^YIF^&N7-C86H/FT:WH5, ,IS0Z=+E$TNY6AX?0
M"<D]+;2L8P Y[AE@2_Y=^5O:]4':G;S,CDC8)\ZO#[=WSF,TCBUWD0.3^RUZ
M63PE[KN1.9G:4I>-.5D1+D0L0E^Z^X!7(2S,HL6B]89HD1BULI9.@1I93$->
M3*)E@/'E8^65P)4 ITDW#"&=S.8.KSAT/0&L:8Q=D-R: (9PNWT,DE0(N'W5
M(\-(%.77I$'BOAO3&3W\ 7&JT/$P"JT4?B!>7$"OI$/Y0C>)0X"4Y749D$PJ
M>F X#7CCEH74)7WYR7,??=4H'#@Y(3$$H&E5L\!T9([DX"N%$0+:UGZVS/%[
M_E'96>@5YQ:1VMH@.)QCECCT'!4_3L%YH^"=Y:5KQ>+GB_Q_,) X*^1D8#",
M*%Y%U/5CH2R*+9KD9^&"@$Q3BD-VP]/:WE)MEY6&Y4IK=C<\=-8;G!R;?$P$
MW$.P/2WG:9S@+<QX*3T.(T26'QD^22---A,'EEYDX]%JI\\\8.H#S-Z;?D=W
MVC O]YIQBNU -MQ@3)EX\+J9F9[DSW#J?A#T9SLJ<X#WA4X+/ A(XM$HC%3X
M3)FWQ:>W-(RGF*%#D?1#;&.7PHLTU+4V/SU(."J:^%Z1PV6!2)H2IRG1J7";
MPI0S 4<1MXN1&WRCC&IE7XWB%"IXDLJ9^G9LM(:2C_3-Y0UH6\X4OK"J:SFJ
MO-;2X(4G#NP!JNH=V6'J,74QR_,MDE7=V/&:I25*V0]+*Z)4:0TE+QZUVYVG
M;!6E9B_/QBLHO5U Z>WZ2>C5EU@]:6$?O3I+)9W-E$K*'F)R(<F<#ZS'KE09
MJ(2R2TM776I&T:5:ZR.Q(A97Q,U6,<NO(;5 6]? 6([;<R"6.HM*%2M_-1,3
M6G&DB^LHI53(@A6Q&A6&W:_R7B4SM[<\OKA\"-[(>GV#+!3WW-7H_RS&M00@
M=KSL$ZK#NAXC-XBIMC1)ER(\Q<Z32'X MRJ;D"2/OF+@#Z6Y18 :8CFA3B8B
MO\Y)W%= >1+W.U&>8G<P[W8@X ,"D*/0&W=5J1 \94O+WAW'\F5$%#OA. $'
M(3VH:ZA&0<S ^0>6(C%":3Q4F\E^/P0KLDA-*P<6R29= 6 UB$/'$ST1(<WZ
M[4$G?3_R@+26(+[\.#. TJ&#( P.%#0 1544=)""%C"Z2 !D(SP%T%.!*<*7
M#IUK_6JP=').?=%SD-@K?;.!'Q-\%;D'!)&HU9X!\L)@,-'[L11D9,P"'Y:N
MQ90(#U)E<"Q2!<'I>0/#6$#R6D2647D17\+ADT^EB-:E>3&5=/9J/<U &C#S
M7"<A)G\ LSAO"JHBPJ=2/BVZ)H&LA\X-M"/U>SZ>LW+P56)-I-3LS)\T](B!
M.^$"!]$#EG;/]2,'\BP$_&:/ ' ]S3@E!:'M .V6TDJI/?-NAN D(K@$CUM_
M [@XF-A#S3RAZKR,S$#F#2(S>SZP[F'&XYA>%,.;60(NPJ"40:8**( Q>0Z4
MD:+:>U,)7(?.G3LQD=:Y0Y&S.^[2#I-]IA[C1.T,CJM"!+C,09BDQG7N"*K-
MAY![#8:58+Y&]*X.^4D@\V210^D1^5!B2]/R3<9 9J54#"!_BE!C4MG%!5,9
M!; FD#84O,#](1\E#?KJT$).00--22KT"G):04"$OF&Z,%*YU=)-ZU;>(--(
M<<I^JG")TE#67!5OR5=\%E#<,0VHU.PFM.2>W17"R[,CV0CFTN90A3GE[6.E
MY4I=I"X]AZ'WPQ\,M V,5804Z0$H1UF9PT!.7RZ$\"RQR"9L*O%0F<CR-\-:
MF.B8%Y29\RI<\U_5:Z'GXX[\1/E1:#UB2E\2F&1G:0?.=4[^O]&.1$T1_$R:
M9K^OOL-T*#+CSAXZ]M#D7A=J7U[?Q:K 1U4&M+SJY:Q)5>@UI^S-DP#[,1MO
MU%*LW\**MV>ET%-=?KI"2Z+:/&R_N&8;3F\-&XDKET7-NXK]PA2D,C$AKUMY
M&1NP$E.3)GRT65FG)(QT8EK-@\OG'<[6MTBGLT5IJZ6/L_0;@FX?/$T.X%_;
MH]8YME_2<E*SRA'^".09NN^/P"1"9 *REF9,S8S+K'9+?4B<1Y1:[YPF_R_/
M%\$7977PM#RH*;7AA(]T>:4\:$72C2!)UZ3.DUW^. Q4!;4/PO![NG'-J2*;
M4CL,KSW1_@@JC8-;<30&@Z(3L$U&;?K(0V=F0,-0VA8PRO/2<Q%WT=-GDX#R
MQBJ'%2'@!.Z/&1L-2PUY]BQTZ'S5EZ8[6SZSI\8-[3:PR#;R-5MS4Q+2; )T
M]N5HM4.(Z0@ $T%)\ZD<A#>Y5\3ZG)YU77%XU6F>)H:E)X=5Q_GV, FO< $F
M4R*:&?'ZO-7.7O)6CY>!Z4^6X:W.WTS6@>>-=KO>7V-R]T%P?)2.'WVA*X&)
M #ZPO5Y]L%90N"ZN@\6#I%%RI;''FA:EBZX\'L(Y3^3;)1HYPBWTW=ZT57T*
MHP@['JAZ9TY?>,\BQZV!MYTY!<76B46; @Q$ .<\/7G!7B"M-]5"4ZZV\G?N
M]>1\=2.8U8JA@2#=7^7$9(U FLPU0_$LU1+1/--VI: 2WZR(XKN6[M+V)W*=
M#H"O2XT"HHER:>7Q DZE..R,U*MD"*KS!!!6! %_JW02C1BB0;XTWP/Q(@9R
M]:[DGC\(8PP'@<Q,;]MP1,\B"AFFZ-Q]L^R0Q3V=J^CO]T3BK<CS/6//-\?S
M57.^K).[V !<[NB$/8ZC &GV-6= DS\?B:[ *FR:\(Z)">/1:("./SB2,>4)
M8#>2@15.=I^EB0> "8AML;Z31V[>T/TKC!3V@F"#"R%>#&4"K0N9?3%9:MK$
M,&L"@]SJ?O M^0 PX;#=#1"+Q"I/F)@PE4N!!PXQD .(\)G4T*B+37Y<Z0>K
MYD5HN-]+TQ9&VDXMTR7W UHU_&L__:N.8*MT N5N>N.TNI)KOQK82MS=Y6P$
M3N?(P0J 5>Z0=S1 L\99_ D]()/?0I- ZPZ56EP,)&F;KA:?WG2$&Z!<4=KZ
M]"WP*S$AHW*5A]I)PK"$OL-L DV:JQ9VY1Z$.XU9T9GGUS97<C.G8C7&5PIA
M7R24+CUY]?Q71>5XD=X"\4NSD<(_<C]';\[J@.421Y;FWPZ3R0^Q,.%8UZ)R
MH:<5L4RH, Y^V.U&8W= .J&#5-(_'(./8I($,;=*/!&4?9\*A0[#I:% V',5
M5X,8"'UIR:#H8A0^X<M0L:Y,]A#,7"1?Q%2[,_5RN^/A>*![7^OI3>40\'08
M JZ_,B,84$X;<-EUPL9*,$TL3KV2>CWUJN#EA-(A"".U/N0.(8/B68XF2M'J
M 5AIVV"-55;D0#S+GRR3T[*+ R;27?*@8+ KC2'D"D74Q0QI9E'X%U4.EN+X
M76 LT/-5'L_7M 2:]BQ58:6<A5*>)1SC$BNRFQ86([@E,@>:B?J&=,)>U*M;
M^F]F@=*0P,!.#IV[ 88&(Z"RP-12A3O+P$J+/(CIY(&C:LT5RHK#M6E"&VXE
M^OPD'8"!^Q2JHJCN<R2(QMIRDLD(5FN@:MB%B+EG=PF8O2<_-+WD)FE)9LS*
M!5<X'+64O:<%5LOJ16,(A,JU]8P(FGYYJ"->B++]7RE3?F^2)B5:=I 2$P/<
M(.'-9G)UY7"&D*X'<3 =3M(!XI8%TAFEDL_6W@6%&"D>I#8C+#89@5.O / [
M(B4!\H_ R3!=V"B<R/W.QZIV(G7Q >B.(+(VR1*DU#$P\\!#N;7:SS><BU'V
ML12_+/90>3/ 5HX_J6/#+Q$!C59%('JI![HYC""^"KQ[?>?KL7@,I4!]L>YZ
MHT"_FP NO^T]P' +'B+&TM3@%?^6/_SYZ^>[=U)NNE+-!_$_WAV<O7/D(0-4
MX2Q;#3@8#P^\,#E0U[[[N=,Z.S[5P)1^*X4C25T88$5:*-O[<=,3T+$FH%/>
M!)R=M-]^_4]8>GCCK]^V7K]=WNN?S+R\H][[@[(2,[J@S$6\T%2HO0!4-39>
MAVT_E"O@@?'TTD+X:71;^7!ZGU04*KF?N.F-L>J-CB&2F5&*+DU;^;&]\$#>
M?1C"JYJ()F .*CH)OAM:N9:V3=HRDJ,1N(FJ&%K'T&Q>#Z!,2*Q0P'EJPF$6
MY\NU)9NW4E#O]"/<P96Y>Z5&ZR 671#<'S!0*%L>A+-":\@H9@O0<NG<IFQA
MLTN9/:&.5=#N4(%-1#G)O\@[;&*J9^W#L3,SUTMN"ZN_4D46_WSN*Q4U]:N_
M4D56O'/TEAF_%_[P29YT5:85@.N!E52?,>[CP$.#:]Q;L&K&O44/796ACL6
M(@CJ0*T./?(8+H\L]$V%_N-?U+?@C.M& &!C46[T=.'6^E+EE-D^'AV'=5FJ
M$8"C+P)K#QD*Q9N](AM4M94S[XMFWO?^[)R=<]X]I_M6D8E_OD0F_IS(RYXE
MSL_\US&U"-8O2%!Y*OXZ*=#G<POBE9-F7EJN-F>5<U8Y9Y7O3+BV4%9YQB(O
MEO5]R>\^688X=KH,<6P^%V.QK.XJL> 60QQIGI8Z?Z7 ^F2Z!7L-S(/IX+]U
MU+3B*10&L,ZZI%ZE@T+A.#F0&HN\.J6M-MO9L.20Z2:=)XC@IPGK<O@JC&3R
MU)$[E_(=GC'4">45Y;6+0L1T\A^/Y#] OU+IEJW,%,FI%'$2!A#O043MX,F%
M,&CZ>39P4FFQ0)0=3X#:(@E0-S?K^W+$ND>WFS_^/ Y"S1'FEN(M^!!*'E-H
M4 /KFE@)]U"7R[E\R)MQK43+O9"&W0& CT3<A[H'.+PG>+B<PTI3Q.P728-L
M")0K=:#LN$2>D07%P:$XA-!QOBFB0%K,P:XE@30*(C2H^:OL?7Z!=*G!0*]Y
MR_%)BQ-_*$S1#!J?H0=:?;MH[U8)LRG^IL,<?HQA?6H ',(*#;%$!]!W0 "0
M#JRYPOYP!!$12#=7Y,K6M(QFE!YH,BJ$;KH/6NTWS1^)OE[A'/Y!R?">ITI8
M8-E1-&]*3MU77;OD525%X%2I.:R,T?E555_EPA.E>P@XM9Z/D:\:?0#[L?YT
M\0$%)5LD*"F'L8A>_*Y(289D7Y&GZ.=W++,Y/,!"(WH#.+.D=)H%#;PIB]HC
MA=N/%:#N:MY4FB.?':"K.#\OVGOY85)O4W7'W(+T_G(#(QL/-Y7;@B%I'3J_
MN<&X!T-&&D3ISHX\?D?)P7ADCB7PGMHXOKBF$T_:ABVSD5,? 6W8=1JYJHV,
M&=8UI(1?>8A:DI4D?A4%>6@@J5 M2F^O9[@/?9_\'A4&#2C-]D!GT>GJ!?%T
M2GZ&./,)-H$D\I_&)$'Z7LHNVR6>IG/6"@2#[)FK<"KNI:!'8RW<V7"2TGZU
MH"^^1RDMN=VHLQI(V>C8+<$6 -1-T]4Y$F'T[ ::")$J*6PHJN[4N->#DWL
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M!)/V,2=\@4)6D F,@RGKY+0!R XP-X/9J?%];%L0XE((WFE' WAO 6[T^FH
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M-(RN#MA)T0Z'<EOK0K,X EWM(K"(4:I>#NDEQ)%!ON0XDCN^H%R1M#CO]#1
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M->+SA9L43:1H8$Y!DDR)5SC=+KB6SHUSAN<K2H4Y_[RWJK;D]P/_0&*N/=E
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M \R,P*Z-L::*;ZIP!0IJO*6\RP@(!WR'V^Q49NG _ J_J,945\?<GIUAT@2
MC\X? \F4_)0LT.Y5J@;Q&(/IF-LD,J4-XR([$GO2G!G[33/&F'7$6-T>,RZL
MW02[1#5>SM?Z1R2&"?6/WV),PM!NRA[^?6EPT<&YIJS0[%6F%)&"QLUVXB9E
MBDM:\[NI0=/_@O8O+4RU(M/7N.DZQCALV]+=++@ES-8881::).\I4XWM^**8
M$TFF(@HFU5C+W(5#*YJ.B9"\ZY#5+NR+Z/PEH61,G[G!+=3AWM^C7BAPL#QU
M.HL4^>1N70NZ,L9WW'K41CQU)KG4<0_A'!Z4>R,^XC:C_ M%2Z'R,CU$B2_J
M<^KS8^MSRFZ2ZUGTR)2'%Y3@A-(FT$'+"HX;)3@A2Z4$)S5V\<&NH9/T=7'P
M(L%)) _J=]]<LHCJ&&NWN/2_T3WO+)Y/WI\J9TG-F4[HUVUZ*,_*DSZ9$J<<
M.!#(W>^9.(7</;G[REMYE=P]1:\>:4*6WZ[_HO0K%8K-HRC6JJ1?^0&F$?YK
MQ"YUMJ<CNHU^9TAI6BA-R[%EL-@G34L)=MII]/O].F:Z(&.H@3'LD\ZE%&,8
M]&N9VV@WS2/4:SKU(;Z2D?+9]?&D?Z+USXV!@S%](1%4(9I&(J@R(LBSCX(G
ME5XS_IPXZ2#200=*_?;20269:F<0OV11%PB1/533'O:20B790[M/23!I!RCA
MOF<]1%*P14'(,A>SJ=%W/9\O#1-:.-'5N2SHWG"W([$JN&:M%<2FE)N'QT$I
MI4N==*"TV.N P7[W#17FTALTTX)GVE:CU]QMNXRLF'+)4"*,"FC6:KJ59BOY
M[EZ-<4JV>^RVNY>^KJ+M*HT^EK,]2-LEA5[('F6ZG &T$T@[@355@'?+AWO3
M4?6"7?2@,>PU:7./-O>.;3,C+)1*LKY^HS5LUW%_@B!> XB']41)$._!!%/+
M+6DB^+0%%[<%=ZO"K>;:B';"#H^PT4Y8G7;"/$LL?%6Z39M=M-E5!9YRQ OF
M>VUVE>0YAMW!@:Z(DW&2<6:UFU6,<1Y/\4D2LR1FX\1L1'$"TK6'1Y=)U]9)
MUZZ,TK/)HD,WE$;KE77;LH%69UB1PB4278C"+=N'#!JM[J&&?Y&=DIUF)7;+
MMM-T6[3UPB0)WR--)?.5&X 8S=%BQ2R%D%((:=D=5Z;$]"VD\&,!BA*?HXQB
M3BGF]$ #\O92<Z69Z["77,15%41D$=6TB+UT4XD36+-%,:VDANJCAO!<Z)(;
M_U-)#%6(IY$8JHP86AE(T2> E XI(5)"Q\;[]DM34I*M]OJU)'UD$#4PB/UR
M?Y0U>;5K>7B55-"1JJ"[&0!&CP]O)!%$(JCLCBLUZ-"UC\(/T[UV*(94$*F@
M R5]^T7WE6.LZ7*Z515$9!'5M(C]XNC*LHAA/8MND ZB0V%Q4NF3[:@/NF;/
M^)C]I8[H5-B!4D,Z%58G@1:P2L\HBZZGTV@.NG0LC(Z%E4]?COBXR5["L7PG
MTFH,^_%)9P\(E62IQVZI>PG:\BVUW6BU#_4()\E?RN!_;-21M%QEM%QI*<<'
M_?BH#=ILH\VV ]U:V&^SK:SDZ>T4]*NJ("*+J*9%[+?95EHY@0%5]":U<5";
M;5ZV4]II.V!>2#MM=5)GGDF6M.[6V^U4&%DK[;'1RGT%]&+)[J/3H9+99*1'
M8*29%!DHQDBIV !)79*ZI' /ES.3PJV3PBV)FO8;PW8\.2T;7G4&$XE;XLV%
MB-NRUL0:_3[5SB/S/ +SW$O6EF:>:79FZP7%G12MJ^-22$NIIC)1M3L^O!HA
MH]63K=^YO=# ]$SKA9+'5(C)DIZLC)X,F$CA,T^W0_EC**3UZ +X]E)Q9=IK
M\Q5[K0N.R"BJ:11[::=2C:(97Q2GPCBBW3[:[8N333?.C%OL,S? ]'0J+W[(
M')$V_^HDUH1ANG:Y,LO"SY9W7\D"43;6ZHPLV@FDK89"-&0UW$A/.=3JQ62K
M9*M92=LJV&JGT>K'9X^K-RY)!Y,.CM/!I("/@$N3 JZ3 BYY)E2:#479;=.2
M+);4+S'J"JC?DEW(L-'KT3%/,M,C,-.]A&_Y,WUK0#E4*3#V6,6O2!/&?*-E
MOM62##X\4DTRN$8R.,.<_L-&NT59BTC05H"5'#%3WD?09N@,.HW>,'DT8XW1
M119W[!:WCS;-U.):;3I^25NKQZHN#7L)AL=^XZKNS$:JQ4E;'AZ_)6U9LK:4
M5N8;60Y36YH\>65CI<[((%5)''=755DQ-W! N");.W9;6]>3!=C:YIYEZZ"E
M)/RC/NA\\VE"@_1 @ 2T3=/_U54VS:!@PSMC?^ -V8CK^D(=CZ%M/Y\T3\3O
M;EO%[^$N^W#SY<O5[=VG"^^'L.YQ7SG0,+D+:EIC;EU KVIC9W:A-)MO3A+)
MQ34%Z'Z])08L0NP%307E&_3FJ7*V]1Q\]#=3Z\: ).S%2\+ @YAX4IQ(G'&&
M4Q=3C3'^T 3;FR]47)]YY#:;J8^</7!N,(L_:C8? Z3@QXG.1PYSX+N1FY?,
MEK9W'@LOUX2^H0%KH[A.B 08"W;!8!UP&W>6GP;NOS!M#5MY87%=O.7E1#=5
M1XY'2)6WWUPRB87>FTL7O&^%;[QH^A^X+8.67)HPXG"SIPOH*@W><W4-OHQ8
MS$CSHAL>6<!4FT\9.+R?3[[<?+X!N[%&/Y],VX-6K]^?_%!Z_?._%].3=^]9
MB+@&GCK2N6I=,'C,[))Y<%@'E@N^Y[?^!<^(U8V[[3=8!7D'N7(B1W*HO%GY
MB9.XE3/W=:.<@O I>RU&13=O:^ZO;?-SOI)(&78WE-":14?#+0 0L:"UAA#\
M*-!M#QPF7^@V_4E]L5=XFZUZV)680_'?Y6J5\#GH\=_%3%[L?-"&Q_D-8A=,
M.>_U_<]DH_R/@]W"1+] DU0VLY!'_.28(W"? K[F!)?9'&0;_WZG1FIP_)?]
M>^U?KY$;(EK0@M4HL-4PA+X5 ,0('LVMM;_+/AF<=S5C8]X)+3ZJ2\?T/I'N
M37RT=KNTDU/\>F5:\'V^^X-=&<82YICO?&%:#DY4K8V>W;6A[69&[0S*C."_
M++.F*DI&3?UF.C"[PUR.<_A$,U1#3.&VHSI<L&9!P34@X^,DC8]H^UK3E<%Z
MRT7#P^V6X&?6].&TU6DWX'65!FNWSW9EM[L/Q7/$4#R'A@+?)SR;L>0LPY^+
MLJ$5NX_+8--*<QV8XJ:LWCF[7UH&=IX@MRXG!6<J!1X*T" :?, 7UD06/U,
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MMWW8:^F'N)1>Z97T#-,G-(;-*'!2O$91]+$""$A/"G./OR":5WN:]\&T%B9
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MZ*^FI_WI4P6)1\5Q_)E(TZ\(9H^6(!/_8PC8([?93'WD[ &W-#!)O8B3016
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MI9MX<Z&^>#'?_V=KDL1;>7%$O>YFZX?2%7KKAWR0-]HPUE_Y_(%;2#N0=7R
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M=[II"QQM<U,8/"-31]T8:S'/U_YCW&Q2XRMG%5=S/[/,Y7063#Z5:$WMQV\
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M=S(MC=L7Q8B5W>Y6T_O0Y7E<3MZJ#M[JO)^#O\+2O3*F=.6WX.>1OASS,?P
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MBJ0%[7M4C8-E8U*YB8<ZT"R2#G6%;5Z5OSI1%3-J@%M2!\>N#FY$1NA0EL(
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MXJ0D<[O\#'S"!"M8R-*(*S^AX_O;X'&@7U^"%2%?*<"W2@EXSJYLFSM,6P6
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M$MYDW_C"=CS<7-LA4)XPSDXKHV'&I42QK$:J:1F-%/=_%]4(5!>FAJ5;8W2
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M/.?./7?PJ!/^?0//6\)'[#>NF]YLK#OPVJ4+0W9=]LKEG/UI>YQUM==-%L\
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M <"BL9]5U4-5L4*05U'>A\-M:LK[*F3"[\I[TJ;//B/I>S@<&)6:]/85?UK
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M1='#.YAH>DA/R;?76[O5V>GP]G.XO<CFVP#3O=N&8>B].UWQQ*:_?CN+'&P
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M\)$+KD(J>CK>"Y\.*8SW-&UOU8F*X(( 7LIQQ'0(#Q^XR!+AR8X;[C]5H0I
M=@\3DG5R]M;)-^Z*SCG_MAUS0H9*!50N,E2*,U0^V@Z\V[H!(GJ.L7UX+V\%
MJM&YB#_'3N8+F2]J:G>YFB^E<N3%<&^MH(I@A4"O/NC#%DVIH.]7P[HAXZ9
MX^;( ED*VC\WPLAY^VKL\(GAO=[J)[IP#-MA"^ U>^+FD+YXO+649:#[S)7
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M=Y%'45DG@5<O'H$[QT7%\]C.(2I!E'9':S#_1_MU3=Y*STOCWS[CBK=?MY/
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MK#2#G)KQMO>4):P.# C/1>,YDYTDK\:\%4D[)5 K!NJ3 9V3\U\C."LTD<K
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M?W8W,)NMZ>GGL S%OZMU0O93<.M\&Q[!SG825@BT9J^_.[#5QU=!PC!!F:L
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M&9LE>>1B'I?Y5OR1HZ+G6ZYG(LZD3/M3^#-&SMMWPEG=N9J72]020+2>_$%
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MQQ#3Y_;20KKIS[B\^#:@'DS>>V8N;O SVX2+8=(P-AC 0F[U2#HN!C'ADR4
M4BR!QT!>LP7:]_A^SYB+#P%TX]GJ3F:X0)T)SY&*UQ%DPM>NR3A!FAGHI'@C
MJ;T0;HH-'N37W'F#+6QUZQG^>H"QVP ?.1F</3<-";0)>S2\&4X89H_D1983
MG^OCL2!ODUV[,2_DS+*]X+.FCCT73S(L((TQ6>HF@W<+_(L\Z/Z5F);#8<TM
M!&X4ML54$#TS7 ##-.%ZX'0W9I4V\P,ZP?@G#*0:=RS=-)]SQGO$6H472L@
ML8LCDE$N=6)$]E8C%NGG])N(_Y=/;JT[1Y_ ^DJ=H."TB6C#2HI9H(F)TW@%
MK]0N"YBC%IBCEN4<NQ%)0<R?WFM?'@N9YLEA^BO;9-^7P%91X@U9) "(1] (
M :^"H8&+1E)J(<I](0BWBL\DBTGLCP#V#[IAKD2<+*C&_9<W4/Z[RP4P$3+@
MZ!D^M^[?"&,&'X,"CIEX)A9GS\>ZBQQ]LX21 @NM/Q(,.Q;[S6R]'ZU>[[]1
M/%T'$6!-6+O5:3694'&9!:B/WJ(,:VPN)U*6.$N.C+G@%C(#GM+SI5%0$J/L
MPDT!MK_-G%'2@P0&30 ,-F.SA<F5^G,YY[C=[2@^ACL&$@%5;Z<!S''WP]/"
MU$%<@<!(R$4<$+2 AWLPA]CD@,Q4AA5T@,I![6$+2K:4V"/=Q/ R;'<<5D%'
MPF+(V;W<%7N!7*0VC",P]-;FS\W(-UH4/@AU-;$88VZ:"WV"\/_E1>N%^!M5
MLM7?877NYO;+E^NOWS]<KGY)DL-Q]6A,O-FEUFJ]O!K9#NS@ERU_?)<MIB\]
M^T5<EA5K+9ZNMG) Y-,&%R]?)#T Z@^@$[KCX*_9/C*SM)A>)FDQR<)*V<>K
MUGE&[6UHI7Y'I.D?X ^3>Z@U^6"64&)^VL_3U=7$<$%N/%\:%F;H;-TKR/TH
MDW9&H('L7AUGOZ7]*9)^1L[;=_Y&.U]E .64!Y3O(W->W@R)KFT1/1^J'%7,
M09,<GJ*<@+CC:J2/_[D7VSF8"J;M7/[$^_!_@_2/HMH$X6R]B/T\506"@TMS
M<O)W_ N*%HG[Y=?)$RI7ZJ?PSDECJ#"O7.\BZM!6KDNA&K9J<#3C2"1E:#5?
M--H9'U$^=3L\HK9.-ELA%>G9OQ$&K%G:#<]Q-SPFC]G8\0/FM2>V!U%QJMKL
MB*]KMR7F *<,-\9.X^)"E:I_Y1WU.G%GK=&9LLS=*4=OBUEF*J@@V9((MB+F
M7!E34ZE$D+)7336D4OY3<4EZF4:/>XEJ2A:7Y[2)C<:% 0>IPX I8JY'Y36>
M&INM?)BRWTH=INQF'Z:LVR-S#:9N#9'Y8V0^_#8>EV8'F?TJQ\A:GO&UW&._
ME8XT%J=#!*L^5"?F2\@L"YDB=JU2N%KUVOJEN?FSS=2)UOE6+OQ39%2^\NTO
M*Y#EMDF?#8N\HHK>U&;7 !5;3LZG)F40I5^A1"&U *OUXJ-E@3<Q^:J8 -KQ
MO".7.)B4+#\1Z2BA)4\Q1:WT*586LT4C=S_'5X%BY\/E:?FV9([=XD&%=,OR
M4R'SRJJD/,SC>D0%SNG@Z1/#0>6JF/23XYY&SZGE<XX"RY'O.+?+*Y<FF$^^
M(>4GIMX@_BW//FLM]LQUA](2SS(M,?ZL\CI4F:P/PA?=D_53;RW^?P%/U];D
M3]M;?WK'+?PT7/[E#]U;8L&"C&M81O:HJTTNX]&IC$?LYK4C3&VY-6A%;Q^'
M.*9\@D+\K/4OB)^/T*I5/+.3:&,)U;A0"8B-5B^WXS[5347/52@IBX4A'?PB
MBTXQB^X/VQ$E=<BH(S4Q6Z/.EZQN$:*U&U5XF]0],M]JS)?YF6]%<J[6(<XE
M0ZU0R'6&V?8R)8OL2(NLR$5/=-B(;*^:V%[UZ6.YKNJ)SYP:P 3<?,X\DXC.
M1M/9Z#R,P35\/P?06XRO+4K>E[VJJB$Y/WE!]#UW29&Y>5J:+.E&M<@J>]E5
M@SJUWBS"7BZ-!]JM)#8S-3Q2$6.9&_#E2>(H9V%1BTEV/MGY^=GY'NMHDFKO
M^5BP$AGYI+I7P<C/,EFJW4H;#CI';)+93KQ?%;,]0Q.D3>40R0Y7P@[/M QB
M9&,)LJRK@)JL+>L,<QPB%2FE3>5>2D.SEY6%F^6#3KJ>TI'?W>@+P]--JD!
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M'U:!KU)L6K7SE!0QY\HZ^%)YZ//0;GM:^BHJYXABDA(D)=0. V1G"+4;W=Z
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ME+$F<M&X:.^>JPWMQLW\@+,G:5)HA4L'%B)D5'UX6IBZI7NV\YPP' $R3U_
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M/Q)X\Y4-A("'/5[BR0F8Z?H:'+Q0+M-,; =I0H$TYO=,-V&=O]Q^NH7U=\:
MM,Z@W>OWIS^T7K_Y]^+^Q=MU7N[.],<FH.^2P6MF5VSE-]U.GO>=M$]O-A=@
M5MW>E,TC%J>$G,*AMDDI/"*)4!Z;*"//H5RML-WJ[^@:6SP=#;?@\0-TZF\A
M!#\*D&W$08H!V<Q'_=E=XVVVIK"O;@W%OTTYM*?@H9:W,2FOK#GHP.LV V*7
M3&OV^IO/Y* V'P?)P@1=8$@ZFSDHD'_R[/&+=W<"OO84,],]3-K_^:V^I8EN
M?K*?MWZN!KFC4 H9NUX%MEZ&T%T!0(SQX(BS];VDR:!Y85@[9VM" 1A,J%U]
M(L6;GV/+4@=V$L5LTH(/$_FOY=F];_+LGC@SL4/:8T?::64TT+A,L^R&JFD9
M#17#7"(S*?;(S#JI/='H#Q\MT@9Q^?K!W4G GSGWHU?M;J<!\]4:K--Y?<72
MRK>3UN*(O8PEUS$V.U$V2D7HU<%XJ-8,3"1Z7NWUT<#5)]KB::7Q33N]*5@T
M6_.,.EX1/*V^.63QU;$7L)$]?S5UR[NV)A_^LS06B*Z\#UP,>ZU872O!*;B"
MH:KUFVQ%J@9#RLC36'Q%KGC,!L;<3GVD(\U2OA?'$=%ZD78&'AH:V4LOKR5^
MQU0[<,+V*XLL0EOLKY5%MD^["YWF:(=O2?+[N3]6**(L"U7</]?"TMK$\8[Z
M@ W,<G.HL.RS[Y/U)_@"8DJ. WZ1N?2CI6$BJ[J[J?49$R#O9Q9/3B%$&Y)P
M:^$O_UP3^H'/#+#AB;SIR2L.WV+>EZ0=;$HN[#5";2!JIJ;F279,PNH,\ETQ
M.7[I#)Y0^>_4=IA6^O@C3N:Q_$ 5L:5N!?K#KXT)H&^#\V#$78T;DF4?9*AW
M]*/TCBBE(CW3Y7_8R<;B$1[3)&G"?>_C8)I2LSDE/?RX1QQ3J"W6%MI7*:KU
MXY-CN^Z-[CC/6*%!5 @(ETL*?W<]'B_G2ZPR,GG/%PX?&](:F]LP#5?^;DT^
MSQ>ZX>#+X8^(-V#%AQ^HOL'7OZY4MJW7FCILF.X>,S[;LA']1G<059HY#QCD
M!1M"7C+DQ4/*FOROK^&6BT:MW=!:,;VQ"(ZYP/$FH)!_MN A]\ZZC$TZ&)2'
M["SK^0V&,:5;B\%?0BVH=B<_,YZ1FB5"ZK:C9-@A0@,])$%Z80V!3U8?67T)
MK;X/3^.9;MUSO^KE7.8^U,K<>W5(1GZVQK#F+G_/Y7_O9@">^]F?W%M1Y[TQ
MG7*'6V/N)A6H,0V5S\A(=&$1X+.#8KJ;K7+TNB[:.>%6'1,S&98[6L:&)F$Y
M#RR?G7V:#+W=F,3R@L!+9FH-S%2E^+Q.S'G13U"?H<+,\9IL6;)E3[1E;[T9
M5NCW6Y_4S8P])%E7+5]<088[D*6^;%W5D;^QYR/#$G*LLI)5L5"G%B64*;!$
M6%7'<MV+WR'%Z97'[]E9JP>BJ:UA3"]8BJ:2F9IPCBKQ=RV8LAV98E,?\Y2L
M4[).3VXFL# \&"(VBQK9CF,_8CNSL>W6+N"Z+F]'FB31(H56'>,;%GOPC? -
MDRY='^\%*=)GH$CGS])UY4/2G4EW)MUYW0;"7=@N\)6HI_'H(/KMZ;1NBO/!
MZ/F:#M?8D]LS'%GCIZHB5+%H3ELK-P-&7<W][(!9@=!--^-#1016LBTSU&DI
MF9",R[R3"6NVZV09D-'Z4<<JZF-44KX@696G6I7?^!CW8V,*8SW'C,$8Y]R=
MHUONE#ON1\>>1VLU596PJAF<K3;E7Q%RZV*1MB@;-M/#;_G#^>QLUF2';4!]
M'F0LF<E^)?M5';ZO$[.2H4N&;EF&[I$EQ16TA5<R!UN)Z+*^\HR;$V0]Y@)#
M O! #!FCI:BRG%_9VMC=+:^.9KF]Y;C01'@GN/']$WQR[?X&R_'1=K[#8E15
M^BMF?O>BJH/E"[QX-3"/RN3$,S7@&?4-_TZB4X3$1\1'9^AQV.]HJ /C'..K
M.),VWL5/6G&/1[WWZ@P%0V1DJ'1TD>.C]!O4<'Q4Q*NQZFG2\9N:@/@1@H"Z
MFB2L!$[.@DU7D[9&T?KS0)[Z)K>F-094?*I0.)+E&@Z1]R^HJTGI)F7%[<6Z
M[1Q9I@8V^OTHOVI](MMDWY%]1]U+<DJ%S:B@=CO@6&N3+;BJE-]*%#DFU?L\
MP:J^^7C1)5>&\@ F@S,<$2FUB2N9FV=@;I[%]I1I+>9('Q"9J&2BDHGJFZCK
M4M+,D]*$C?P:TD#D31'I,[-:K\<@+5U)F"Q+:RLB8Q6S5TO5G*JK[-<=I.K;
MJ=2>1&'@DGV:9\$K,D_)/#VO_2C# REDE9)52E8IM<HLI;V3(N)4,1M4HY I
M8;7"IFA_2/A5';]DD6Y5L;HH5>B247H.1NDY[$^9MLKL4JM,LD[).J56F27U
M3U-$II9KGTZ-)SYY\U_NV($>G:3?$T*5MDH)M95!+=FBX=9J9(B2(5JY5K.*
M;$0Y\R'9GF1[DNU)K69#XC2KWFJ*B%#%HJ&]J*+U)V"$FG=6%9?*V9B[.D.[
MW%XH!%8R+8L[W$"->L[/M#RW32?#O6%8;X.2BM"214EM9G/QM>?1Y4P1^:J8
ML:EUJ5(H(;<NYFAO0)FXRK>9/7.#-5GGRD%DZTJR7<EVK6B3644VL1Q8M1.U
MYY"92V9N 68N-9G=(@@UF3TQ*I%/$RY%I+]JQG>CU4M4&D3U-G_4'[/>;*.^
MY:\UAA>);']B)6*E,_0Z[+=@DA6H4IUUJ-DL-9LMN=FL(AMVAJ*AT>E&%0HH
M'5_D BG]!G*!%->1MDTN#Y5:/I(/8QUR;?2ZB4KQ%@,FLKO.A0TJX)-H-8;)
MJBP1;]21-\C)$/;0#9)U!5:<&<C+0%Z&/%L4U\)MH T;W8O4Z?_GPB9'N@V&
M@B#IS'3U[U'#BU 1%T&0P=%5X'L*_J5;2]UY1D>!5K,3! <]N4<)V=:/.*D)
MMG5 <-;5I$^8V=;H:(E4-CK?6T]<*F%C)\-JOZ%U":O16%V7@Z.J6I0^GF$0
MM08B+@=)I+7 ]JEWER$*B"H<$*V(*;-JF\WTR=]+UQ-%$VIFNY3;4UP+Y*)H
M2@E=Q4*86BMCQ;$N>B/A5V6[Z( #MM2JNNIBFFPALH6*JS!<>U%(Y:)*"@:I
M:0&1R91K@N@,WL#%D5AOQMDSUYV:64P)\O8WXJI&8E0QBZB=[%CJ&;K2SQ:@
MZIL\?:W<<J_J@I9L'K)Y\CE$5TM9EYU(&@ZBRJ/7QZ:A.! 9-=14)1-?>E9E
MQ-45JZIFN6D]*AI*D%78ZDE8,728Z*C9^<&8K!^R?G*(^-1?^N6QUS9:O7J;
M1&01J6L1U:=4"%5+S?HM1RG ^1214G='4-6$:Q=?OXZJ+! WG9%U21Q6 0Z+
MMW057QBJJ4$U-9*:W>>V2^0@S"^B>@N5CCL5F(VL]/*M](J8X-NE.**J=E(Q
MCB0G@M62MZK:N)U&>Y#QF9[:)+B=!2XK9"WV&OUNN?T+U<4JA2,I'*E,,0ZU
M1%P^Q3A:[:B\\/I$'"D)DXP9*L9QNHZ8[Q'><&<8E:2NJ@9/YB4,:J-"$I1K
M8"-1:4VRD,A"4J#;?>VE8AX1I%:]BW60344V%57K*+<8@KH"5;5J'>T>:9($
M4.7LH/W5.@BT9/Z0^5.5:AWJRKH,JW5<U/MH&ADU9-10M0ZE2A^H*U95C0IU
M,ZY,6!>MD1"KAM&3,+:9=2IG76!,Q@\9/PH7ZU!7^N5QYK,]J+4]1.900G-H
MVIUJTQ:5ZJ!2'<H>?2[IV*BZ^X&J]ENGG\COK_B!];I7$B!VJK)QV= ZB7(+
MB<FH7$=&Y3JB5,0"*PBL7E^^\5#XI!4WO,]MH\A%GE^THI2FTJ&G K^1L5Y^
M[+(^QGJ2HAYM,M*5*M.@EOQ7UNYNM/N)^F-EBK3XI#RR"LZ922ID3?<:W60-
M0HAQR)RFZI?5-:=5B&.?@_#/048/8^I-E8ZF*J?W#@5%TIFDZM^CAL5<$7-X
MP\YH#/NV\+]T:ZD[SU3?,JGX;07%[X:DYVV/M@=4_N)\0%@A>^_B@LH.G0\P
M;VS+]9REF,]G/!9W[W!7%2B6?$26,J-KD!E=0Z;-HWGJ1=2QHOJD.M/13X7#
MIQ4Q!L^@1FBY%<1B>]#4WV;<7RJ$CLH16!6W+0\4(2<$$X*5,T+WYXN4"5FR
M/&M@>1)W9UWG+VH;J8^-2B8JF:C_C[UO;6X3Z=;]?JK.?^CR5'8E58HB)%N2
M[9E4.7:2R3N>."?V._,QA5!+8H)  \B7_>O/ZFX0($ ""42#UNQW.Q86T)=G
M77M=L#J13+5>I.&ALAYB9DNS0\6^^0"5P@C-!MIL"=@(VN:#5NK#3P4M4+1
MZU$52AJ*+H,,E:3D![0ZT>I$JS,>)6M83%@VS-S<WEAIM0"W,/_O5+.FINX
M^V,ZQ41W[VQVO;YL55;SLXN1BHC8VMNC9]@I'E%<0P.U5W!<"D;G'I^%>O0D
M7HK%BFU<T&3%4DA[6K7?*0S440UB38B^HN0-MBT6/VIF>8JFUPW9)H)]0KB;
M-%T8RV$U;C86L:XM$E1]"$K&R-Y,[A;)20A+)F')I(R'O,?#;0KLA'KLM930
MQ);7Q*Z)_1RMG9142!BK)V4I-8 GOXF50?#0['A *(59GO$P5T%@'@\PI3Z?
M/2TX@!C/9_%\M@%$6T;UI,1 -#QQ17,0S<$CJIZT/9BEU(S_U)Y@:#2F>_50
M,T?<UM'.1#,3P5QCV[3:Q TT38_!-#T20B_#NYZ[ETRMJ /-631GL=*25#5!
MI.&F1V*[-D7;/SY\ULA&/<7"U0A:^6W13"'U6&<)3='*ZRQ)0]!EM)EN]A$J
MFIQH<F*9)2G+?4C#566U/7O5!I+)J\@C8NMDC1:LYR.*&X/B8S)/\:CT^.S3
MHZ?P,F)^DY2BYMBK>$:*!NO!*RC5TFRM//]>&BY;;=O4B?Y,QV__E]I6J-84
M'C\A8&4W7_'<'S%</^-58M:+-FL#;%:D< G*&C6"*M!BK=YB;4Y9X =;-9T)
MM0&WA E5UR$S:HP9X1%@1Q2 !^)8'RT9?6&QX+)"Y*(Y'5R_T2<Z'5\YO\-N
M?++L>]B+^I:RD_8H.%-(I^3%,X^]_FSCB4<*L[[(4VDD*"2H(_0Q9,Q6;  %
M83UGK.><-9B\X<RFC+/ZW/G,QT);Z!M!W\@A2SYWT2,B5?G4(XL7R%I<NG-P
ME3(]+!.MLB.BB#IY+@:'-[R02I!*9'='G#:"+.1U2%3Z^B.AL!+(8C X=-^U
M#1AZL\6\RV(#GPI;+H_)*?<M<EC#-3%U'RQ7-8 D C+CA<#TK18P-CW*W2$@
M$S,[;I.UUSK#_%9$:,U,R$&K>S9$U")J93?IL)-2]2>_-3_6/2YZ+J-D?*<U
M/.TW.H(=DZ[QF%9FVQ5/;^72YKJ2<G^)K>3>X>-M\= *R:4Q)GN_=7Z:J7D/
MDA"2$/H/\$@8CX0;3WSE&/MG2B;7<'T.C/MY35\Y;T!KO%AK_"MUR<BR?I)'
MU5A29GI[EO=_5'.IVB];#HW1\-XK=6\G1MRIMM)9@ET[/#\TL\0\4FG *(7Y
MN%D!;IUF:UB, &TB0"4H41;7,%O#?A,@*:M9)-WY,68.[T:]!9)<IZ4,<I_@
M'@M8T:I$J[),JS)G,#+:E8?7E!3I[,I^'PM^'2T8ZV!7GF4+($: -A&@<MJ5
M@TX3>";:E6A7EFE7*@66M6Z=]Y).V"O?-AFPBF8EFI6'-BLQ3E@J1:DKG5FI
M*)DRJB17D5!KWPF,=3 K.TH3JLHB0'<"J)QFY;#3!$\'FI5H5I9I5G:+([DA
MF)6YF_P>"U:%Q00_U9%!V2]BF;XNY\ CM??KG]-,&6:U1 T9N$+"-LHP;/5Y
M5H7X)_3$A>7H;'<N;&JHKOY(+R>&I;H7S!"*6D6]5Y?D21^[LXO^J\N%.F;J
M\%N._8M.<,$;"[S[TH*]@8<]73SJC@YS77V'#9]GL^::6XSD3MX#?O3YE*@&
M /'V[O,= -36?CN9]H;=_F P=A:=CC)J_[.8GKP+)A]? U";5/L"K#-W=DE\
MPZVS,N^$P>=9B<]O@R\\,TS$'[?G)C&B8- @&C4,;\E^.^F<\,\>5OGG*-U<
MW]W>7GV[_WCA_Y+%W+X4&WJNO+H<6?:8VA>=DU27AS?CM2QQ_@"ETWEUDNXV
M*;O*U>&(NLM4B:T4'0%: )#W"9<BR(FQ+<[P5J,@JV&DX8U[*=8 QRZ%-F!$
M@77#!AA/ZHL3X'>VVBR/89[S_RY7N>3/EZ&M?A<=00@C[6$/7A@,B5P0I=T?
M!-?$L(++X34G?-%A4"J9V4P._>):VLG[!TX.UH1<,^'%^V"K28078A :?(W:
M:PLE)C!LG^EFF)EP5A?Q_ZA+U_*O" ['+YT@<>8FSFH5I<_W?Y KTURJ!OE.
M%Y;MAGQLFR@XK_<PM ^]3HI?<#?](?Z3A(>_UU 5I:"A?K5<ZK"V?NZ,DHEN
MJJ:FPY([KNI2WKB>JYVZN:3C+(-/&/O:T)7A^LCYP*/C%HR,V-/1Z^YIKP73
M55JDUWMS2?*";J^MV$E1RZRA!3RB?)5L\YX,XQ[Q4C?E<%Q$&;2);U*UR((9
M5;SL!_7-J@@. J@?;( DRM'"F 1CPAN0*%>BCW\[>0"6?$\-RLVR'_WSSNGY
M>;^S0:OH[K/Y(_O=%@K9Z_D/P'+$XM Q40'?(,Y 48+5IHY+;.! O,&HIBYT
M%\20 ]\":6I;3[ /P)8<8$ZZR1G7"U@!Y$EUR#;S^MI_%E_2[_"*N\D'_YG7
M[)$?0=XQ^OIDV=$O9VJ9O&Z(+Y8V#5OBW94A_K:[S1\;L\)?D=?L#/FBBEE&
M.B45.,NXK^'5FS:Y 3*Q''@6)]8GF_D.K,DDNM^ZJ1G+,8,.@<>R4SC0,[WN
MM$^Z.R.F;A S>G;GSE1@ #8EID4,RYQ2]ABR=*C_Y-'2 <)TG':2M1D"?G]/
MW(?J#AD6<ZJ2A0T3TA>J8;S ""T8TL0&;9NME /KPH6TS?>(TP*9 #\R0+Q0
M;Y& :H!4#$UD-Y.1RN@%P#&!]WBS-V!B'N' 4HV]16X3-J"M7^-_%)QH3MV9
M-09Q,'UA:^?P_&9] NHC3$<W%TNV S-=FWE+[0:CL48.M1^Y'@ZK]Q-V9ZRZ
M:HM/ =;?YB8._*8[H?>Y5)N9^K\P-+BLK7I_P6;#6!^I07ILH&YT%C,=&(JM
MS5[X_)Q@<?ABCBFPF3EL-;^-H60!7(=MA[C;>]["MOX!9@OOLG7GYUMU_,_2
M@4^MJ'$2\FT1S[F56R;"&KMO7?79@YVF.C/"Y+WC#P5T"/K(Y1>#..&,$;XS
MI29EL "6R(@25G*Q,%BJ.I %O$1C^>J"EWK/^0Q6ZJ+T\<?X.L,3&X+'S<GK
MOZ^NK]^P*\G<;.K\O/C;>\B5> ;C7'<3CU]=36!X#^KSC3='QN6^49M9C_#5
M7-[2/=A7/.CM%>R AQ*@ 4:4L"&@@=BZ+\^<!=P-Q$(<.F4,H$7X!.P73@3:
MTK:IJ;UPP)7)A:X$I^0<T5=\&(\944;3P$!>0G!A="R0QMD38UB.(,"%:KL>
MM(#TX"\6JZD ?TM")^, JD=A'M\%SJ #MP5!%+T>IM86'\D!26YL<:[E21C^
M=L:P-3[3R=(%P,!\-&L^UUW.'*@X.UO:;*9,S708@<(]-NCMW(YJD[\%&LPP
M[]>92!L#X^2D8C)95OPT;9HTR_ *LW'0YX7@=("!*=@J,!3 /07<LBT?ZY,)
M#)_Q$NHL#5=LB<L4M2=K:8P9;&P*>C8C%W@($Z/3@\W%.<S:1?BI$)N"/!@O
MXVL(9@6@F"T3K.)AQ\.U'\9JGG6V;[!GNS'6;S:MG*V>Q]EJV0H94P'B2MD,
MQ!= FYI$F\&S!77XH@R4(NI<$&;^]RZWZ>1!39E;>/1WJEF@,@$/Y6?M$]V]
ML]GUW!U,(];'#[&1K!7JVLG]GU1U8#M*.**/UT43[A!87X.M@V>R5+I(T3:O
MAU^DA J^Q%N?-RWR_7_4^>+R1BH@?0==F"G/<.<-T["M1;RR4FG+%5>J9(=4
MI<L5-Z%7X.)B\?XS!]B55 "[IS!"<_I9Z)1P_]48K#$=U"CN*/T(RHCI'(Q
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ME]##3#6S-*#K_/!MGGO/VHE&LO .:=2)N^)B;V$!+C\^LP8TUZIMO^CF5'3
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M;QJAFTL)830V<\"ZVXDG@R*N980U&JH;\N6*9<YHI!Z7D8IBK'3E*4G*-,;
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M)J\4VY\/,8DV8AW9(QJ(#340ZRU)RF;T:.6AE7?45MZJ #=QA;^(C+S*V[#
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M-AAF*"5*9^)5PTX"4D-[#L^Q<I5A2"KHB(48LF9^RL5=I3^^:O7Z66HP'EN
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MY2QM>C<)+,=;RV$']M\]HWO]3Q^?X>6FZEKV2T8'-P73<<&$BKWT/'U\?:Y
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MX>B:120<WJ21RRO;K4.@(-+#L=##L0,;';+HD)7"(?MEO@!*9T1-K D!,J9
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MH>@%I=W9]BSVLA&(,M =O2O*XMG74B>]_@24Y^B[(I.(JD4:2+4E"Q"[7MK
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MPB/EPB82P4R1KHU!+ZXO$V\6L'/^:7+Q6NOG^S_(# 0]*$(:@P"H!6/*RG2
M_L3%^%S]!VQB4"<!$#K@(D&YA-OG'K6L:949Z/WUI[\>[JZ_P"0?V-LLQ^55
M0O0):/BFZRE%#HV\<$8-_J;U0W?"\$6>0+]CRNE?,(P/.FB1VLRT#&OZTB+
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ME >0,5_?5296F1HV;#.96S8E8]W1EL"Q ''P/X^_V+KS$P;')JY1IT46!LO
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M\N[2(+-J:$B_37L0")<5A,M4N0>A5*NGA2%!6CTE'%@<#CQP:>C6W%'#O;E
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M[=2#[R-_WD-O_/:R.3:8S66+9_P,C0=XS=%TF\R$#/AJKYVOCK,HA]@D.0=
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MRI3OUG,B#B*)/41BE9#$YKD)726&8\)VA.WRQ'8%[D(D9LB:FJ'3=9RK4*]
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ME]A\8L #'?'PX#G+I\.HC:9LJCUQ<<7,<ESH&P H$"NFSV T77P-_LWFSL*
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M/D*'X'\=X7_YTM@WECVW;-!2]F"98]HCF!MX60[\!QSWRFT-[%T46-9)<UY
M<-*/9.VEX"3'N2XL-&D5F(N@X*3VP4DFOK#(_7_="PI.*#BI6'!":Q,U*=Z@
MT3@-R%CR?':4"R3,2)BQ&,Q8^H1VI+X09"3(6&+(6+Y\]A<+VFG*LY@IH9TG
M>@E&OHH9[<Z9TAD4G]^D2<\UI=V*<S(7Q2=93G91X4FW6Z"Z4WQ2^_@D&W=8
M7'C2/6NWJ.">(A2*4(Z,4+Z:SL+6S!$7FHZ*1)PD:2&4Y=C>^$,;M]ZQ)&&(
M>J8H)<"DY9QW6D$H2OZ+ NF]"ZJ*)Y">'4C/S%\42?#2NXBJUB*<OHIAVQ7
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MBYT;EGH4\(O/U4_3\ 3K)IYM&CLO&<V8! LCTFUX(Z6[M5JA[75,-,E*,TY
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M<I""X;\P+ZXG@ >/("C<D6LVE%CG5&7IR.$9[**<P2Z>3S=T9M0B[W7O1"/
M_X>/B<Y^Q'-N@[8MXIQ;9MRXI+^OY>P:+O&\O'@GWS:EW$^7QY.7TUUMLP2D
M8.4ON4PDGCLO$ "+\ON[N1](CU:Q-* L, Z)U0LXJYE%PEF86*94A#-3,?+,
M=(R8TP-'TB/C?-1IMVO3=>6L+)HHE++2:/>PQ#6_F<W-:V\V.HH 22TUF-+"
MLG ;_1YN!^5HE MT+?N-II19$1]RW,AQG]R7D=HL[W;E2=KC&9W#3R,8M<K
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M(5P;!XXVN-'LL6[:2XL.IS\ S]RZW!JK#K,0RKE!XY=7QJ6KCFF]106(S4"
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MFRM=#8CDG=>#(6Q%_-/,;4NE M5F6%%793S[#QBHUM<08*"*@2H&JJD%J@\
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MV<]*D1WQ..=.K);:J:(ALL;]9# CC-.#<;E2:9J=.'T8$,8(8S$(LWBH[E<
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M;-CWV:RMC)<KAY5)@NO!>"[([10LW);_/3'A8H"8M0U<V14^L1N&;K]D670
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M]D_)WOX=V>LH _N02#S?[IKQ#$1)GR^N_<OZ\9*./83Y]4T92WM:V<%]]N_
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MV)H9BJ7W'!>K8M^-/H2[KJ=FCW73!@LXG![H)0D3 4^K.J;U%LM&G!$*C[R
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MYLD?A(+O!B 1BB)#44(H8@\DL3=]2Y(X?35VM&>*Y;""[37A#G"BO9M-#C!
M_CEW%K5!5?ZCZDNZ]UB67Y'7X!JR2?]Z!*)&[>%T53_D<\WP+N."?WE49 A5
MG'=?E(;2E[!0%@ME2U;BE[W6RQ76^E9#[D<?"E4>1*)JE5*UI$JK5J<3O: *
MC4B,^.H>\=WSU(8)AGR"N9 8\@D3\GDJ4N8EJM=HMS#F.VUW&"._ZKJGT9%?
M!91?EANR7*+^2:A<U5*NZ-BO&LK5;)>H42[&@-A1Z8@P$9Z;6GOC1.RD)*CW
M*DS?&HQ(TXI(?6TL\\+9:K2[1X:DJ/=95;%B>Y9JM6?),C*NAA'J]1)LW90
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MUAA0K?2:G6YW8B\D21Y=_+UX.H/P)DH 8YVJ%J\FG%T2WS9M1WV>(7P]7W^
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MLX-W9E^%*].G]<W8ZL5L>N B&2YC]]MB]3WB-9'ATZ0V(T*XUSXV;<=VH[I
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M^Y_O'R..7G_%^3=[&+_5W&X!)3S82>#![O-=Y2/'IM^;A1S;>H!, K_W>68
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MZT*)#1&@U8P><SW4 .(_R,WUX6:)-S4YW)XV5MU'/SYE#9>J66KM*P2"JL9
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ME^BR-.&4?BON=!Z&4\IC!$S40C:0+C2B]#%1Z_3^1OV=B3Q$IPAEB&?6T1]
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M:GHS377HAZ4+1'/][>*W[_]>1\-'EAZ+E;"=X\='"H]YI,[JOD]/,&#QIUB
M97,_VO<6-]\-ZOIZ^\"WSR>P?B9;%V?SP)9G$V]&"2,:$P;5HSHQ^*%,X!KX
MC4<8XT]U.=3DE_N/T'UJL:N#1[)U(.N%(!-_)9JKT*$8[E=VH:%M_PZ_^F03
MPS7T7RX>@ .^4Y/R"?[HWK2N;KJM+O/,WV]<_BL)7."0%"QLUV!_'/#Q&T]T
M.#5MU1LP_SSJK'?>#,FSH7NS0??-<*'J.BSE)=?3@];Z"U]\^B M["0;/.QY
M\&2X!HC?ZAHF<API29)')GS;XKBY/5S\"CK-F#\2(.@O%\ 7CO;+Q6.GW^[V
M>M,?2K?7_&OQ>/'^UY\GSOMU6':+ II)56= X$6S(0G0A WQ#Z"+E\OU!2],
M2VT_+G13/Z16=H(B476W7Q>&'I]5K\8I2CX'MC_PF+E&3=-?J5\N6A?\=__Q
M_'=_(!/;T:G#7T.TI0.*RN/J/V 2<J.\B8=MML$=\2RV?9CJPH7O@T^K/T7F
M=Y$(%H;_O$Z7$>-16L"F%WL@Q[U#W<;<" ?=MMZZL5FR-1GNLW!VKGRQ.VB[
MT]EFBKU[J) =+CHAX?!9>ELVPK+ <;Y-66#?A2@\H:#A&87-9_75#3TS^L_,
MB5OJE2QW&*&$:4*<Q\E;Y;K3(,&/=T/0$$D"K'2:[3Z[.S+P9K<7,W;_ZV&8
MU(33&H:MDIG#MK2?/%M;29 %N^(P GX*[GW@8@C[!MLRV=[R\WLUJL1"HPUQ
ME$:9)[BA505%^LUKPPIS'U?O$2A677IV\(W0ZORKB^R:P3<N;\=?OHSNOW\:
M!!_2P-)#,5ZF.WP%TSI(VAD'[)#UHD]RE">W8(>1D04[O$F^T87M>"&L.[LA
MG S;AZC>:24 \H=YGML_-S*ICABJHN0TU*^V!^:];]M-#4NU- -(OC(*7;).
M,DLS^IC!;XQ=Z2<X'!']N]9J[2NFT!2E03J@U ZT"PY?BY>8M7B)K$5_X6W8
M'QD,T;5:*-[RW+TN_41/L)B%*4^5=/I-\L?*GS$L0CEL&.& %9>7-RP29Y<(
M]HFX1UM>-G,R3=M=.G0\'5FJ^>H:[GB:5'7GP^L=B/*G%WBYI7JV\YHR/X""
M.[I@&[&SI!=B3&E\M)M>_V*M,T;>QD6CQ8):^NK2'THRRRK'\.P#J#/5IPVO
M/L*H ^,*D2=P@">O 4. LTP?@4($[E%=>*P)LN8.XIRKD/QWM[VA>*6QH22*
M,3\^TFGS<N0P)?['0Y(9PNW(P [QC:-!*VP7K2P*KFD,$\@SF!DZF'/1\#1?
M$*$4.+ 6;[7T^V\RG['W1QIW8_*C0L 6F^P6U)>\'\CV,]5TD7)(.:2<!#^3
MIGNPBY:HQKMQKMJ&J0C. 1D>GE"]M<_M!8_DM?VVG<:$R%$!AUA6V7'MBR(6
M*@YT.\JIC(D%!4L>>A41[THL%2=RG7+P<?,8#O53K@X8CE+ <!B/=(;S H]2
M%?W,<^1I[EE)PM"."-8C0R-#'[YJ7VWK4A)^#N5[23(B(T@[0Q%#$3MXU;)9
MJ0^VIYH'!P>*X+KL 8\5CQ;.J7BLILAC-;L!Q(J6>V,0N$N\F>K!NU[)A/(J
MU/2?)3S?? WE2XE$I\W4J$'>!>"*+E>+U]?@^D.2N.OU(-3T]=;TS6OLH)8-
M>STN+3+7*H!Y#S7Y2'RPHJL@_M@:^\OYE7HCOI@C2X?/=ZN5_)TO9!4*Y,3W
M=CMRP4KGI.)*6*)(G$ D..;IGPPJ61[BVMFA-* TG% :Y.UY40O!D*"";2[\
M65I4.TKDG7'MPD^O5HMR)],A>=9"V]=%O2A6J/+"[Q89!!H0:#A-6T0INR&B
MD2G#$7=)ZD8E]Y*J#H>A/U9O42D/KC@CMPSEHS;R@0 & AC5\<80P,"VI0AL
M(+"!P,9I@ U6&I8\L=JP41A#4]T98?4',$U"7JOR-Q48]HOMNDRWW\**?88%
M$T#U!UYV2![\X4RM1?2KCAOJWC*4^8E L;A".J-(Z5=!$-ZA)-1Y+T   0&$
MZG@]"" <40\\-Z51[EZ("$&F(N(($2!$< 1$ #J (0)31 JJ:QV*^H"PDM]X
M94KK\<&.JOODHH((("" @()QL&#( "O@H2.))H+2@5@#8@V2^D^(-125K%"T
M*BEUVT0  E,4$'\XX=F+3=!A7<D'X0<)[<B=F6J8N""AY8B>554E0@; 0<'"
M#A)-!.4"H0:$&JKE*2'44-"Y"-FR'))W2@092@49NED]>CEOJ#_(4&S-X&?#
M-.$/'BL<C+6"\7KYKJ]LB=_<'H0P<KTU_(EK!=O3:/OQD*E%?%LKLW$$!M[E
M=@.4K08DB%J?'(M(6R!N//UJ6[<QB ("UPC0H5 <)!18VP<E0CJ)2#A%4Y)(
ME 5;IZS:4=\#J@A@(X!]VG-YY6B4<K4"@MAX5 \QCE-7\Z'<)@@U/T+ 01[?
M:AVX3$J #FJUA8YK?W;L^;HXO7MG";/OSG(]9\F_0A@"G:[JBLK>T@4GD!49
M,NMZUY5(K<,20;B]8-(=)MW)YG0A9E%8+:'RM4O)VRM"&0AE()0A2=4A1#0D
M-CD9D)VT'0"[4L>A.JSOV&)XU9]L<4-P=[ 7K!86@0P$,E!"CI>0$_9YONZB
M>,@S$10/A"H0JI#=J4*H(O_&SR7KE%(V4(0EL!81HA*EU2*:4]5=.EPO,!Q"
MIU/F=9()M>"31X #+80B*A4Q7IT!CU3#CZPT6'L?Q4)_$.M\SY99$F B);+=
MKX0/AH%C:9RPDTL.G@9!P )E!=$+":0&T0M$+V1/M"A6PY1LDB*J@<D6"&N4
MG&SA1- -A#:J8G/&U-9/H?:E;_F4\O"AHM35ZD1?K8YR@[ &B@J*"J(:IQ<:
M1#40U9"D9O-)]$O)UBAB&IBI475(X\/XV\=/WRX_C!\>QG\,6LT>7$-<VX3'
M_M3B_VVRK;RH1U*UC/0=K4EV<J3$15(\6%I;(\>QRYF"'(^T1SL+2(*AY&;9
M5IDACQ;3FM&C8@*ZHUQ:\1(J0]&/#)E;4K/EON0NE--*R^DIQ;1R2%&5^?)@
M.3T$<,I3",[/=RZ=E/6"K4YI>I1J2)R<;ZK,)9B24QG\JB(-R;AR ;J&M MY
M2U\6\)&^>^_W(0-1)W =>:6J0Z:./>=:Q;"6P.+$7E"'=S_$E!V)?-9UP"-F
MYV!EL6Y7*SA>+: D4%*Z+>:JBP4J42AD$0HIT)N;:Y0(E A)) +[R6 _&3F]
M*$RN*>S(4-Y:I(A&Z VEW\/4&<0>ZHL]G"AW1AYX IC71RBHG@J@P/R:VH8%
M]VY.'T/,(AT6LG,KZ_0R.'Q59D2,UU=:, \U&X^13!D &>6F)N*)^32UEL\3
MB">FT51A^\0T&DRCJ11QR]=D.5KSA];>18G#0U]U!*Z4YG6KJL#5@^W!E.VL
M\%5JA"H-;0Y"J&(?+*UED^/8I7"$:U$HIW^PVRL9\V5T>[/+9-4(@M(H3?F=
ME)4/E0Q)<E*S'LHBRJ+\]7WR3T:2F@<+$\KC@:?C./[\W.#225DOX*E8_56$
MD=XYL'X0BED.>5+P4YV8-(I<A/ &I1U"*59#VX8R7C;DFB\5>S+1J&DN5%V'
M&?YRT;K@O_LSYK]'5_-V_.7+Z/[[IT'P(0N*,WPV=&\V4%JM-\.)[>C4&;2&
M8JB#%E&7GGVQ@1T]&:XQ,4S880<S0]>I%851.$0C&(*STB9,)-[7[[_9L1O$
M,YP_TK@;DQ^UGFZ737:+N:,(B\P_4TT7*8>40\I)\#-INOF#\=TX,-[?/8+=
M1H%M?GAXGL>^#7T;;)=WBP>33$EE*Q605KJ*YK0OBEBH.*L\>W@EM)C=Y,A)
MZ%5$O"NQ&:+ M8/HR(F'0WUX_8#A* 4,A_%(9S@O,+FYZ&>>(T]S?U 2AG9\
MD!H9&AGZX%7[:EN7DO!S".J59$1&@#BCB*&(';QJV:Q4GH(2-E!/SG79\>H5
MCQ;.J>>=!H8EDI)3N>X\.G>)-U,]>-<KF5#B+B<N_6<)SS=?B4,U4W5=8VI0
M'5Q,XF=UN9[J\4K?@[S+(F55NW@]7B_9]:AL:Z%L"VF6\.E%FZG6XT:K!/CL
MN%1UB44] NJ6PM>JI?-?#0M\5X^WDMS71P$+T9VB>'JPI'\$*SJVQOYZ?J7>
MB*_FR-+A\]UJ*7?7+U5"T7%%EKS7=B=#XJN\23M8?ZL Z5B=-Y2.'9 ;D!N0
M&\YSY\1-$ \"ULPI:0FGY!@/Y-L*T='X06!B3PF-]4I, ^Q)W;_(866G%K;+
MSOU-.49DZ(;J&%1X*O!$6S-4#]T3F93L.D%W<]5'^E]+H5!!Z09Z^*,QG5*'
M6AIKM?#@J)9K\HM! 8^G#^J+)/[*;@V-58)12- NE7,BR W(#7)R@T0;*.Z%
MZ*S4PEF1M=TT^B&XJ>*F*D'EQ1VM_5;M_]+YG,56H]BYR59BCT7N1UV(W' 6
MNO#L-1LZ#^@\)!8N5%^8KS!%'T)>38G[YJDG(A,W[ 7F1*$9$.QOE(%MUN.#
M'=T^Q].LU6FD\2WJV]8/Q0*5)')#;90DJCST.M#KR))RM>EJQ!VN0_<#=U;<
M6:6&[7:F!4@<TDC9XJU=A=T8Y0*U)'+#66I)U'G'.B#=K-9^%6ZHL -2;(F/
M9\,TX0\>J_.!I3WP>KP^V_6(\M1"R9ZXM(<]C4P@;$40WXS(;!" O7*Y71EP
MJS(?0DGH)*&3A-R W"!GR"YM683Q]*MMW=K;3;_2@8N2=0QK5<'EQCR'<Q,3
M9'6,;Z/G<_B1/,HWC5 %0W1#T/!$PU/*'75_+\?@$'OHI,IGQYZO2W.Y=Y8P
M$^\LUW.6_*OJQ+IOE.26D1)Q&EJAJ$%1@Z(&+=Q3J:X^1%<%794##P"BQR*%
MAL7]]M03D8D;DB' I(T6E!=U'*J#M(\MAD[\R40]!!0&N^Q*S&7P4W:GI>WH
M:%\=MD+Y0&V)W' >VA)U'WHBZ(GL.!0XIZJ[=+B0$9.C <P%T>F45<\F$VK!
M)X\ CUGHA<BC2??#/*LC#)&:3I'U!B/QHUCG#V*9[]DJ5Z&^^LU5174Q6AYH
MAR(W(#<@-^!>FK^+4MEM$5V4TEV4["W=Y?5B_'B*$W%F,KHP1_>X3U3-*1XL
MDRP6-78I@N(Q):A2J/%CB_>=N!E5NY-^5Y":6?>E'1TMPU4C2+VD=Y^Q7N6E
M0-9$UI1T*9 U*\V:<MH\:+Y@EF 5'%]P2%NE.+X%N+U<0('"(0DE;^G+ C[2
M=^_]2CH@6P2N(Z]4=5)[OVFH<I#W&_O@BNP$1XU=9GBS"D[LU?75H;M M7CN
M:$FL&3TJ)H,''\N0(?<SW9F,7B]#E$%JULN()Z$LHBS6HGR)U#R(0HE"60[L
MD$ZP.IU>?25+^-SP4YV8-.KCACQ3I1WR9U<OV'9Z7S:XE=.&/9EHU#07JJ[#
M.'^Y:%WPW_UQ\]^CY+L=?_DRNO_^:1!\R.+O#Y\-W9L-E%;KS7!B.SIU!JVA
M&.J@1=2E9U]LH Q/AFM,#!-T\V!FZ."=1QUN[LQKMFD[ [YVFX"">%^__R9K
M5<]@I'$W)C]J/=TNF^P6-T4]<IE_IIHN4@XIAY23X&?2=/.';;MQL*V_>P2[
MC0+[ZO#PP-6^K74;ELT,QH7><,R]?"3/8B>:V*:^?378/:U@3P__+"/%:07O
MMR^*6*@X@S0[$!]:S&XRQAYZ%1'O2CPS(X#0 $T_\7"HC\<>,!RE@.$P'ND,
MYP4FVA7]S'/D:>YT2<+0C@]O(D,C0Q^\:E]MZU(2?MXNB'_J$6T5Y$<10Q'+
MO&H/MJ>:9\9!F*]3I.-7D_Y6<_65M;9REQ.7_K.$YYNOV.<*K\?K,UZ/RK86
MRO;$?:Y42^>_KLLI^LW.L9R)/.'?M*TT1I8.G]=%H$2[UJ30<"L4&FX5G\"8
M+IY\78DSVECA^[R$0X;$PCX*!@H&EG&1<B(R<</IU&01YL!-1;4>>F=U\,Y:
MPCL[KH9D &UI*A='>TIHK'MF&F ^Z/Y%#F%<9KLP=;B!@66&;JB.087+!D^T
M-4/UT$^3\BS9YJ*/]+^6?EW>L15HX8_&=$H=:FFL7-:#HUJNR2\.6I!4RF_K
M=*N@J-$>0>L4N0&Y ;E!#FZ09Q_%+1%=EUJY+N6V$=94=T:FIOV,T2/<6W%O
ME8$;]AXEC91KO@4!_@SR*^"^54GGZH1'E*HBA2@)J!>1&^JH%U'+H5.!3L71
M#7_1MY! :^(>>NJ)R,0-AU35C>ZDV0OHENER[-Z#,1,+Y0*UI)P3D8D;3JXE
M4>>AWX%^1Z;4K$UG(^XT(CH@N+7BUEK=Q('*QSJR5'N7EIU0+E!+(C?44TNB
MSCO6 >EFM?:K<$.%'9!B:Z(\&Z8)?_!8812LA8+7X_79KD>4IQ9*]L2U4.QI
M9 )A*X+X9D1F@P#LE<OM$H=;)0812D(G"9TDY ;D!CEC=FFK)XRG7VWKUM[N
M>Y4.7)2K:5:G$BXW)CJ<FY@@JV-\&SV?PP_K4;YIA$H^HAN"AB<:GG+':I(2
MP8)3[J%3*Y\=>[XNX.7>6<)*O+-<SUGRKV0(=>_.-VMTKBJ1<H:B@HH3N0$5
M9T%IM]55@^B8H&-RX($_]$^D4*RXS9YZ(C)QPP[$+VF'!>U%'8?J(.YCBX$1
M?S)9#^&"P?:ZDG,9_))T@&&;=965?U]&<!P5)RI.5)Q%Q4VJJP;1/T'_)/E@
MX)RJ[M+AXD8>&4# _!*=3EFE;3*A%GSR"/"8A:Z)1#IU/^BS.L80*?(466^P
M'#^*A?X@UOF>+7.EBK$K_5Y%M3*:(VB<(C<@-R WX+9::!W%RNZ0Z+>4[K=\
M&'_[^.G;Y8?QP\/XCT&KV8-KB&N;\-B?6OR_37Z0U[7Q0R].Q,/)Z-B0[ 1)
MZ?RD>+"TBCS'L<L0-H^I395"GQ];UD\2!ZJ;H<QNE7GV:$FN&3TJ)L/[K/<J
M+P6R)K*FI$N!K%EIUI32\D$C!I,+*^0$@W/:*L4)+L %YG(*% X)*GE+7Q;P
MD;Y[[Y?; <DB<!UYI:J3VA-.0Y6#/.'8!\LDD$6-76K4LU(NK=+I'+H=2,9]
M^\*&1PMEU0A2+W$L5AI/>J9-Z62(.E29Y5 $*RV"!>^(U:UR(C4/XKY8:Z$L
M5";SV^5N>ADR@BO&/L+5AI_JQ*2)KNW5MF?;6GFHW&?M;[NL?(P7O]Y9@KB\
M&X7%BQ.NC\$%+2D,ERP<^PG\>AW^2A:JXY&W^CM6O_"K[5%R=44X_-H=?C8L
MU=*8AV^LS[ 2U=*)P[ MN!]FK9DV@[9<?D]OV"0K?Q>6D?&.82WYB/RO8&6_
MPI,<0]OEW;_$>/<O$<>]O_ VJ+QZ<^BI"]LUV,L'?,3 U<.I::O>@.$#4;"@
M\V9(G@W=FPVZ;X8+5==AE2^Y- Y:ZR_\T;"7LQJ0K-7'X,EP#5C1U35L"AQG
M29H?6\_M%=Y4 A>_ K,;\T>BFB M7\:_C4&*'.V7B\=.O]WM]71WT6HID^9?
MB\>+]^O);]- ,ZGJ# B\:C8D 9ZQP5,!>/)RN;[@A:F-[<?EL%!,BID0$(V:
MID^V7RY C;#??0GCOT<%_7;\Y<OH_ONG0? A1@BVD*BA6-0;Y<UP8CLZ=0:M
MBT3PSY_U1@(/?X#2:KVY2 80TX%F\4-,D^D>7H',NG]3M3V+-9[8IKY]=9N9
M-$)K)>NN-5O\NLUX47Z9J-K?CXZ]M/1+S39M9\!U\NJ]9/7B)"[CD-V&O+"O
M0B2?\ RR@6H^JZ_NFFMGJ^41;_[IAO\W7(&A+\/0XKZ/CB#$%<U^!UZX'A)A
M^37=WOH[,:SUUV$J$TYF&)1*9@[;(G_R;(VETC ! *7+"IF)4\KJ)BUC_^$T
M/X2^X9M"RD:CS(2._EE0!38:PPKK):XU(PBKNO3LX!NA+/E7%Q+(^&X1WRWA
MG-USE.\]XKW/ "Q6X'_[_F\RLF"7-LDWNK#!' ";KKVE SA-]EDOR<!\: 4Z
MK03(/>O(PRAX^"<)#_ZHH2I*3D-EIA5O!\;" M.58;6JR^\2WU:B>IK!QXQ]
M8^A*/\%(C)@&7&$0YW'RMGW5:<!TE0;I=-X=:NX>N!2Q!A&)V+SAN%5&*V^M
M'/(QZPY>DF3#O9@U*4^%=/I-LCI@RKP*OPA'>/'7_%W:L$A4B85^1AR1+6?X
MX\JM&4\#M'=DZ=Q'#@[/"MCITPO+=E4]VWE-\I3;(4^Y?4$H>,(+M@,[2]^Y
MYD09@8W_ #=_IR;E;N^/[DWKZJ;;ZE]L.TX_;[A6Q- W[AXM%M32Q3-N>OT?
MRD6*FT*O3#+%VGN9_":!Q1] [P&ES%?7X+7R;1Y'=7SJ,J]4=>$^$T3/'<2Y
M,2'5UE[KBT3U48K+L3L('C(N5W:)/]!!R[>3(D8&5SF&"?PUF!FZ3JUH$)I3
M.F3CQ5HQ_>Z;".*V_]Q+,,R8^Q(?M(VK)&\!Y?Q,,6B</<X>9W\6LS_4@4M4
MZ-T81R['@RR%G9#92 AK7ZSI$3%]%69P'_K>??YK5J^KFYR4%7H3$:]*:MSS
M?7POZ/#@+%V_Z_*I!^7.5+!XLH]%*6 LC#B=X3SDX1>0IES8(\^0H\.RS<KZ
MB$^\ J(<W.T;\\C>R-X'+!CK&"OHP. 7.3B:ATS%H)"YD;D/7S .'<G!TP'D
M@IR,UO7!RY9/G";IYX/MJ68$KSTQEV:?;HBGB^3L;3]WXR13FH-,60\-5?#Z
MX5:4_"?:@__K[Z%F/F>A,F5WR'',:>0115#F7ZJU5)U7%A1N)3'S03"'1+EY
M%:^I%,2H-D)0(W=L!:$GY>;')]=><"SD9&>(KG?E=DK"&]MYT!DKATDRC^KP
M>(XLOJIV[%]>[A&=J];.,].58 SD;ZEUN'_5>,K0DL^F_?P[3^H^D4;?W5U(
M$D9!A5YAA7[" Y?MAM*NJ3[?ZPT=R_T[7I [LY66318E]"[?_F@RE2*EI1$N
M/WV0IW1WKI/=D4(7M\I+N5,&$(Q",*H0,.K3BS93K4=*5/VO9:2I'T)1)[;J
M6".B8'E&Z]5)=Y3_U(C4[O9#E> 0=%]**#Y9"1(B)R G("<@)Z#WC]Z_3(3+
MWVXLUQ)$+ "Q ,0"I,$"'AS5<D6#6W:<WO'KHQ+J%TAEIX^#TKN\[2:PK>T"
M >QI<"IY71,)400TI-"DEBHLS@R#D(RSZOG1"LACZZ,OT@$ZE+63=?%I(FF-
MCIT%727A*(R?HXY$'8F<@+"#=$X6P@[)A#N=>5&RI8#X1 ('O$.  @&*\@&*
MK]0C4W P"#^93^9^6;0P+H&H ]I1:%%+EL4"<KO"!5:U#"N%)R@-I849+9),
MH_9,+]=1%*4*4!HR/N[[B)\@?E(%PA6Q9Q1C\^Q0_8B-8.X&0B/20"-C1S<L
M5DM$U,$DJ@8F(4ODF+P25J^3\,, F)0A42@^6++O?,5&_H)]>%T=W7#O+,U<
MZE2_LW:=XRO]!,CNYO:5J-2 D7?T%]!S1$Y 3D!.0 Q!4F<),82#<C"*M2O+
ML1017<#,B_. %[+7JI44@?BOP\12MY\M=A[$AR%FU$P+0>1?/#H]A66U-'(<
M^FF#H9PY&&^,IV);^AT8([PE28UI7&>H5E9A;BN@(GR%J5$QV=OC2U5X(9 M
MD2TE7 AD2V1+"1?B8+8\&,#*<^GKZ+*GQ[C*H&2]8+"B/8YR?(A3\T25.0#Q
ML'KA8=4 NT8>Z?A-?#Y2C8,1!+OXR)-?D[T"M@0U4Y4;[.*#/%Y<D?<RCE/M
MR2CNM-H58''D\ IK<;D.3W64"O [JO0*JW3LXX/I7)5PQC&=J_@^/GDB5IU&
MNX5]?!"00D"J H 4]O&1P*K;D92;H2"[$@I **=*>4*W!1F\W@<VD!.0$Y 3
MD!/0ZT>O7[Y#7(?:BV58@.CZX^$L]/WS8L^-KCN&I=ES<.,MG="7!;5<NM5W
MQY@O5,/A.@%;[TAA Z4LB'['U_:3OZQWZV7,4 ]=#G2@VZ\ /H"NP+F(0:EI
M+5/CA>J7_TL=.^3\H##(, T4!A"&LA)@4"8J,0V4"9")\I)DSD82$"M#K.SD
M&3+%JXYRG":$U#";!A$U:;)IL!-VI<W,.H4DT>&H3"?LDC&IE(<*.U7(T,=4
M+M21J".1$Q"4D,[)0E!"DD[8A\,2QUL*B$]@RL]Y !2UJ<=\1+-L+,5<Z- E
M,.HJO!!8=[/";+G#8,K4^_*$Z3];=E.OG[XSN-2<M@>$0<&KL. 5(G=RE=I1
M:B*&*(6UE4*TRK#LM'R@'I:=SA'W.WP[S=$B[25OA:=FA"HO.X)]-0/[JH'D
M)12;5C"O2 [TXH R;46>W$OG+;6K<((/TT+DP D.XO#3HG*=?J<"#([\76$5
M+A?\U<:2;<CPA2ITK#2-*6NRN.*8LG;J2M,YXE7MQE4WV5K#W#,\&X=HE#1H
M%%::EL"JRZ=R8#L4?FB?JI94IUL!NP[]%CG\EJ,87)(3>95 7I'?J\_O<N%3
M"G;^DV0:-6=[K/6$&)7\_CEB5(?4>CI4*12PGUTA8(6 %0)6\@-66,RIIA9B
M_D?L3P&(G8T1B8Y292I9R8F;88(+"H9,^\,I"JUOPVJ]"D@%"L79" 6B;XB^
MR0\V(/HF25$S1.FD6W\\Y8@PW0E@N@^JJ5H:=4'@':K9CY;A4IWC<71.G4>:
M6*T,D;?2C4A_K49S8&_O8VB]8 _P5PLA-G2:D-]+A]*0[2LQ#9G8?H>]GQO?
MRP&5=:MPA P1Y!KJ?43%$!63PKE'5"Q_5"PO+5'.3H>X%^)>B'O)@WL=4:<?
MD2^YJR4CUH5.OZ0<GE<%TQ/"6UM63_>F"B<KT;^OA3:7['#E5162(Y'SZ\#Y
MB&4AEB6%PXY8UHG+UQ>$7EU?)^<T(WJ%Z!6B5_*@5V-'-RS5>27N3'6H2U0-
MMGUVTG+R2CY]']\3CGC@J4F)_/M@R;[S%1OY"_;A=85/N7>69BYUJM]9NZI!
MRE5&3&FT6^D;@*'[?SZB<#))P&0O1 10&$Z8 88R(>TT4"8024,D31;P )&T
M_)&T8G5'68X3XFV(MYT'WI:]@;&DD-Q_'2:6NOULL0IF/BXWHV9:3.[H#N-)
M6VR%VUM7K,]X\J[$F8/QQG@J-J;?@3'"FY+4(-^-DC[-H<+<=K0$UHH:*'L5
MA14KS',H@2B!]<$R*\QZ*(@HB%4'4"O,< >+W\$X;)XL7D?<*3U46P8EZX7F
M%JVORG&$3\T35>8 !'7K#.HJS>M614'=D4<ZBJ#>1ZIQ2X<PE9)RXTXS\T-
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MZ-=V-FZ=H(E.\.H4!,L*@@DL@64P,4."%2Z)?7Z++2J]\J(&@9+NZ>HTTZ1
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MW-;R;/LQ0L614R9U!3'3"5=R3C,[9]$Y*4/J-ODTV\IA/SMW$'L2DX_*('&
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M'*<BD8- ZE1#=<J(BRFE3X<!_2Z0'3[;%/;JU4"K5F->!/^+:;.M\40KD90
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MD?TP!U'PZ__P>UZL&5Y\L],^9<C][N5!FTH.4\LKQ1[DT!3TD(1W)@'9<5I
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MB[#!E:D7(\C;(6\'G9S7]L+#GL(W[PP+_TM>36/M5QY $PX@^!,0RE=+3F=
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M24F::5K V+-B\-9N_Z+MWA6HE3$";GM:Q ;&51:\IRF1>\_YVTE4M?0-<X
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M1<<BJN6F]-/\E*KXK8(L[QB^[6\;9Z0+JKF@\BYU)6.S'[.F@F2':'>#S05
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MV>$[Q=JOQF-GP2<!-94PVYU>KL$D1SC8M48Q;@4$:\<B'*4'=A[&V%0?5%9
M?%+&N9-9JC"<JZ((#,YR]0\=H0S0S'%U**(>+50-&![(QN0,' [K?WR(8N$\
MBM59AY?^#<Y?6AD*30.OP7B,H[R RF]SGX;L&(\Z& W.IM*(Z"8#^GC.X@$>
M0</!E0\5NB[WW-^Y.;FS?^>3>Y[[OGML++\BL?D<2,W72&B2=_Z(C9'<O9F&
M7Y5K+M@'K+Y.DDI[J':$&$.,(<8<(V.R9P'(V/M7Z[-N./_2S07?<A@ ;>G^
MEEY]M2[5A)*5:A1C=DTBEA_C)2,G(VO4QJADX1[5H982VR:MSVY$HOI7BKC7
M]H)*(^[:Z5F[KA'W.]O3S?CYFVP*IBN(OEOW3 ^-UW_ECK[G(<A._DCJC0N'
MO7L]Y8#1]P(WA'ZKU].VAX)[\B<W%-Q>P)HJ6O6I]BUC'$5OAYA,68PF$:U-
MY7"!W6-G.YR/2E9201'<OOBXP-#R8(<S-DB*U-AK"\BQ'#9)H>R&V&QIRIND
M4)8]366,HCF*4N:HGP]RE8^31*H?[R]>#YH6[R_T7+3S85J75U7\4BAH#O]B
M;WTRN!F%)/MS[S(6ZFQ'O_J!SG8\=BL"C$@TO"4;<].<ZY,)O-0_3MHGXG?_
M)<7O2;I^O/GV[>K'[?5%\,.&R&Y?Q$I'MC/AS@60WIAXLPNMW7YUDB]RO!P4
MEC>0$=C5Z&]<PS"<"X3]K\U=-ND7;A]'CH6(^]DAXMB3F'A41M#X^GEL+I K
M; Q['=.MB?R!_WMA/(("69[;8C:\RL31IYXKOF :\,<),ZQ'<+-$INN4)0+*
MR]*$RH7*;%@+W=>NY4^RZ*!U5NFP1(;A,@T$"4[>?[8=-ETX&'J M4HC@!8)
M_A_NJ>)$%<MC,DKFPE>8Y8^,9B[G[+OM<=9MMYA =_W+8)ZT^'5P&;UR^L)3
MM8,MK7M)6U+N.+== U=]X7!3)!HOIZ:M>U)\$CF%[JM+)N6V_^K25[6W8@.X
M:$<?^&M!FB%7X69/%X]@AH%1X7=P^2(-L]6[K>P[)^]!'8R'>Z:;8'R_W7RY
M 35WQN!F=8>=_F P<>?MMC8Z_6M^?_(N>OE5&HQ-KCL7#!XU2XB_KR+/H52C
MB3QY7SQ?*K)BTMY('IYKKT)[MFS$$B3 -TXS7M+Z59)"2\N/5;>GB0ZR3?M9
MIFS%30TFX)9$ S^*D6K$P8P J<PG_<6-)&T6DG5LF[9S\=NY^-]EF-)\CF])
M[[+V5W8Z[,(#HR6Q"Z:=]@?19W)9T<=QZC!!'EB4SF8. J/?/'M\\OY."*X]
M91\138G&&_W]$CU6J)-@P4@?_WT/?I$U>2M?3R";D!$LE6\Q8S#F&)%+_EF2
M8WAZ9E@KFV(B4:HO/#OX1!HS\9&P+8?5R?4JN5XCA7@6J(];X([J78(OM_]D
M5Q9L]";[R>>VXS% \)T5G14T"31V'U34;6> HMT\M]5_66+M>ZQ4TPI:*6(5
M%SC& .S$VNU<3_>X &C,!UM\DF?Q*6M?6KJ6!;H2^[:P%LRY'[WN]+HM>%VM
MQ;K=-X!%MQ2X?3BQPX:?'X!%AJ$8Q)70RAA@UT[;FYRO3N@!!9]H\^? )YUV
M^U/PFI?@IO1YOR\>N&.,5SSU3X8[-FUWX?!8S5JLO.WZ&9ADZ9[MO&1%O3JQ
MJ%?GA''PR>>X.3@+/R\C1/(*X.$=7'S+32Z\[U_]\W;O?- Y/\EBJJ:<B%9G
M3WN]4_8YK:56.&="3$'-)R'WW*2IC?[=R\W?-PB6Z?BFP##\["1<>D)JM_&6
MI++VAH4IZY(3RXQ)IB"OD?:K^9Q;D_"KO[3UCM<&9W@U)."+_1UL#?;H+WSF
MHP"$L"_[OJS+[C#\O7!>8C5BS! [RCYR_6!8QH/A<M],X^:4 (&Q"!GS0V1;
MZQVPW'OKZ<^^5*$+/X:/\ 6CC="><T>P*-"1R6+,F0$J\VBCH)B&]X(O.^(6
MGQH> W_3PG/LHG@(2H)[BC1C"Q>(H[-'W3$X7)9X4%P;X7[R#_))2VN8;.B/
MQ\L?P+S><V3XW_!:CN'^[=?T 26!JM$=3UE4B>RRN6/ [>:Z:;X +1[@5_CR
M5%8%,>Z7!>$'3[HS$8*)44^Y+/=)G[L,.#.>,=WA^+(37 I^#AY&<,!?/ ZD
MBS)F6#M\;;QP' X/AU4X&$("2N.#V!?P'^9LOG" 74@]> 3 =/RO$0SVA%?A
MF8_W*<&?Y\*D1;1%JL4($POF)&X,%+H3-$NGM2\0** +X)?CZ7"U9*U/-O_%
M0$H<W7)ED%A2P8A-)ET*AJ4K<7\/)8ZS.:0/QQB>"Y\!OY'8,SZYQXA>2&Z@
MAC2(8*. <N#)<<=\P:^,X#J+NVY<[_&E+-M#YL#+BM@@W-2=\_%"&M4XZ3:]
M;([XW2H*;LA&_5&?&UB2*X47R<5R;<4Q\N6(?F;*2MR^QWT"U(?[%^8NYNB,
MN4+JA7Z&W_:_ Y@0;(?M1&)AH*K<@QB ^,!/CP9_ OD;O8A[?+#!G$@3*=]8
MWGKL4P%%9NRA\H):A<^$GT3*%6[/]/G<L>&): @>C&?\GHC&XI/1F'@O9:K6
MW>:U@JET#1=M^32*%<//B&ZZEYLR7]'QJ.M26YU-J:UAF-HZWU31-CA=K2&1
M2&QDF":N\76.2/<;P0!/5)=+-K3  @1I ]C"']P0=2X!AD)V>%C]6[%)V;!F
MZ]Z7@,#L8GHB+P>NQ>JKHG[[=+7L.H7Z/M$_@FRAKR;(&#KN^&ZQ/4V2W^<+
M)C(P;,2T8>\-[&^"0;X$QSGDS738G!S[T9A(9:V>0V WUG$(ZZXD;ZZL"99:
M@016Q*7.X'0U^9O@4MDV)S0MPCV(XSY$C9'AGH-T"& %7]#9&""+(=@Z-4SN
M\UC'P)]OG3U8$<(R=P9&_BT>SQQ<@Y@1(1R(5N&2</56\ZF%-J/PV_\(;P^W
M,Q$9@Y#!_T<QQU("^.B*F38Z:?C"P9OZ=AOUZ<GP9D M@$4!A00R7-H HULD
M:":OOO7@W6"K\P-1^@.\R _;=L*K0=JO0+=E>-I>>*9M_RV-J+C^#]N>O(1?
M_BJRJ "P;KGS:(R!OZ]]BY#X7FB+83%X_\[* ]+>(YOY"!YKS/TX'U@*"_#Y
M23J#)9I+W]?<""..&;1^$TX=^L/H5JF 787A>_'#$=(%99A3<H2#"[NB"'H*
MN\DYHD4P@N#]XCXZ!5<']=;W17V/!?4DA,'RMO &W'&-Z8OOU.+[N_;"07U$
M%^D>3*XCW&;T"8'P9@2*A<&6=HB-'%L'CW@\1I\JX:1*)QZ>?JV#;SO1 40]
MH;_+^5Q&&.#;6+" 7JS.8)\:P3O!P^Y->X2(=#%R85D8<_"C$I("\<C-V%Z@
M,XLN8/06,08&_J ?QL"P!WJ'F%=G\]F+BTFCP/N#C4^@"5C8W+;A8T>\OA]G
M=!-8'2"%:8^E>RF6YOO*IPQ+,%9O!H @6A_0?^+H3W#EO8Y^Y:K'#:^/011!
M3Q_&R#7C0\V0QW&B1+?78X&(T *'=]1]@^!327XE8*:$L_$7-3E\&<AWY4:W
MP+*1X WQY<12$L0"2XONM MJ:^(CQHX-PA%%2EKL7GX2%."$Y3:QA<)-')$\
MXY,R <F5Q[J:W-@^\;'H7Q?9NI80F1G(=J&^SJ_0VOP$8Y/LE[][F6.W//Y!
M-MN#F_(-N.#< 1Z^L?C_QW4G><4?.KAL"")S=-2?YT:(J^/_DB >=#06%P,F
MR0-JA*2A<;(X>X&E"L[.N+F>@J(# >0 <##^YSJJPH)/)+&^1F57A=&V.#S=
M/5T]@&N%7IFE9AGE97B-C D61SL<%:$D_38YC4]@TH0<A7M@K/INM="ND(JR
MWGEU.9/5=,@6N9-..;D3:?S<V,8>0]9!D%^$56'O_C^;C.-'^^&!.X@*?NAS
M@!U?71?>K3A#^:>[](0?CGWOZ \9\TBRQY#\>?MI1Z.IK0X?6@I]Y-M':D.J
MW35^F!* 8#Z9WK _;S&%XZ\0/'Q8(H(@7.,#O]PL:]]];'+U@.!00<(MRUC^
MROWS=I:0/6PG9,K3:)_AQ:O;,7L(A.M)EYDR5"JF9T _]AH;+BZ*%#5-;3*^
M=?D82?D$CJ7+K9/WEF&N4/'-*=MJ5RC/WETO'#N=0@]\(XV*1#GYMX?5'NGD
M[H"OM-;NK<0T@OJY__OOA>U=WAD/X#1]YT_LIPVNG?QPE[*S8;??"\I6"K0B
M!V/9]9\_=[0D9X>PMLJ(=GXZ]7HIV_EN%K?60J[54<B[U0OY >FT1]/DV6IB
M.11RV!F_6NPS'SD+W7F1$HU;Y1CW0Q-#8)A1W^S)^]]&TA@@TI//8=CU)P<1
M'O/)_QK>["=_M,U'[-46"8[H2RE$;W=^=88^CEN*)%U9DWA\Z6[F</&YFQUB
M.DR 0#L]W[!Y>KCV*.:4@=NJH'%5P;UE'V*+]._I)BBR5N&;1,0]<N@I,:O(
M@X7-!=,= LX)\BSG3QR?2&@6'F2 WH)-S0GH%:0N8Y?9TUC4D&'P1E[W(-_/
M_\HMGWOAKGHFGI7XJ+N4%/R!=:,NG^N.WR@J:W^P,@.+C=GO7#>]V1AC\6'=
MG*S$C"WMB8M0/=83BOQ!OOWB3TLD0<*P^5KIB+NCU9JQ7TBBVY!"-].[&0_(
M$U'G@T\<>2\P_3]DXJEH0[@Z[R*INFNL7P&4+TLOBZ?Q/N9Q8P%9R?)='RKO
M(\DI09K0?FY3N+!G+1)8LE0K+6S:PO+SM!E>BXR'B%*;"7?0,AJNS)B*E$_:
M?47%/=,G8,N!<2UV#R\9)'Z]6!(WF;XOCP1A0&<C.I6X'G-(5Q[B]SG7K3]@
MEUH\W''G 0LJ0PBO8)*ITSY=]7-8(O@B7X;AV\CZT##X(LRJ$ *VE"+>1#31
MI2@C6G6DFM9>$ZD7)<&B"U,H2^CCR_"?T(60@K%*+0:+L$5>?0U,C]'M3[S=
MG^[MC)O3G_S>$&4L\.W2R+7[WG%^NCI/D^5&U8=\YWUR.>N0<"@BR0A04HW"
M@/&?M\S%5\:*^_"=I9$U@O(13Q9 (4H%Z1)1:!LO /PL:[/=]-O$"HP3]5-!
M&5,4T<9;PRU$I7M8PA2OSHK5/@CT+5X*JYCA3]Q[XF#0!=1&J]%I]\[*+J>=
M+SQFSR5^?[)DP?./*5R'0V#8OPSC7W$<#Y3DSQAX<;%F0P0N9%L#DB]] UK9
MYN!]W<5TBL6Y0,]HW+I<A:S=T1]UPQ1E(>[,7I@R!!);ZH@'Z]A<WW/,U8E_
M1*UP6]<C;I:L\X92[6NBQTZ5NLZH&5768(;=HJ@;7$PUQS]BHTW88R=:._VB
M2[\X3GP]T2Z$2OCL%_.)VA91 BI,$A:H,,_ /;B"JO[P5=&P+G4Z"B[HCJC
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M\N(V7V-YD"PJ"G[Y<[0".6G%Y@.YG/\MV\FY93_@ZGDRN"*I',U(0V58.-'
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MEDU"X@?B!^*',CRC$G*(1I8]JFS&EM+J*.M'VY-\D'R4)A]US&HD 2$!*4]
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M9(:1A0L^YQ0"3L[\<$->/F?<G,BC9IUHH;P^A4!]:;C/<)\+0U@:&D,_#G.
M#1G+JMHCW(2>G3J=X@#6W>SP@3!(>%HD<%W#6!/LXLM(:S3_M_LJ0%XO#X>\
M]K=!7B^*05X%Z+?&,NLJ$:ZR^52,[5$P@^/"HJJVYD,1"\&=$\YT/VQ9"5$<
M[)+I CL]@0?(,0 )\1WFP57BP<)14N&2.0Y"1A!)7D:+J>"*Z,[$$,P/[_UJ
MN9SUSU@43D;DQ7%$ET[=$:R-SX.GPU^&/M<%;!.1$+C> A;$CT6T)5_NQ^$Y
M0"DOK<6J0$0'-K= DU@V.E5(Z4?1D(9)5H?/ CK%XSB!Y@*Q;?ZH\R=/BG6;
M_;-4;1!/(]KN0C>E)A)(,DCLG;?$WGZC.E\,V3?+LM>&)T8 ZZ%!=&!8"T%L
M>!,L SQ3[BO+.017XN,A% 3>TIV9N!X_ 3]8MS1]$AFM]PJQ4H42?X3!,+PS
M6&G!@LYR_%^AJX1FE6-YY*Z@. 2K$W35Q5Q Z8L/P]N?P!ZR\<HCO(D!$QI@
M97#6H"U 0TJ%GO1D1!WY/TLDD;Q9P(V6@5(X!IMDX@W1E9-K+EAB%C)NL&9
M='>)8@&C>0@[V()<+D11$_?%%#[549^K\#"4AI!/\!%<Q&8MGR9C,'#J4L"4
MMBLX8>SS!0-C;TZ>V6O^P+Y8EO;L#Z6UD<%.PP<NU&<Q3F 1,5506 Q4%PP4
MGBQC$4]G34&X\8QT1$TTF#U<X U20A.G@JP"A@TOWL[03&#Q["L&+#8;,K\.
M9(73_**3GV_""WXB/ODB!R?N/[(8!Z_N1[)?Q_;;2H]/PJ9[&NI^;G9ZBYFM
M91&(VB5]#DQM@,$&+\Z>@&/;'73Z%Q?3'TK_XNR_BX>@K$J.G'4O$;/VR7RI
M])#0;]^)=8LAR[DN87XKB"D 8MMPP@W#H^=O)^T3\;<'S(N_XUD"U[>?/X^^
MW7V\\G])T+MKQ6%#2;-+Y=5P;-D:MZ_:LE[,7FEG)BY3VNU7)VD%@=EJU9*'
ML7M#\LW.6$)AF1S$VG;%.O=U>A?KJQO/9F O#T:)<S5*V:;4B80]D.0/(F,:
MJY._4=^:VANY+R3R0H(-&):X7Q,9N:C&6R$C?A19U#$'2P"+:CRIST[ ]3,[
MOA_URZ7X-PQ*''\.([SS-H60[&S0A=>% V)73#GK7X2?R4&%'T<7CXG5@R&I
M#)Q6" )_<:T)^'="B,"IN<:P%LSGKV_5!&&-K YZY1 'Q[Z6HP='1C=7%W(8
M59U@N%W+_T2J3/'1#J63F:HBM]UZ0^]P)-P?]EU8>0$^LC2%N.U N^V<QAG-
MMHO^S&VDBI+32#'\";9<DMRU,-S,,OC-FDP9E+HMO,]*[&#VMDWB0IM5N(NR
M:WA3]XWZ7N^,?8I$JN#7+R5/RXU[0T3L'AJ B98QI@CXOKP!IV8.Y):'6*,<
MPXMMD*Y!04C7&J8%0W(@A$2+++>A(SM;JMRMCNR/!Y%]BSD+<$ TIDYLRT$(
M2@";?KB)J SRY$,$4T8L084@\]9\L 1*( -2_J@:/@D=/[0%-K;,%14.(_5V
MXW&L?BI(.!=\8<L'UG 7'6)Y$(@@/ =Y6=HB9L;W+.W)3$7(#*+\J3KQ027;
MQNP,*52+)=[$@*6+S7% U$/2'F<6A3$DN(&XGLA>\ !"W*Z1]LU K EOXEYJ
M-1MS05I+^/HP;XFIQ* 1QR<Y//>?I8H(AQ 7XYF]UL]@IAZ]G EXEA(H@,N,
MU:O^N]0DH4Z12/#&_RY-N=/A0X;KN(N/E?%_EKKM41FFHG'007/,[5!C6%>A
M1%^3!(2Z!#HB<%0WDG?D>+OP$CF=J8^<.3 ^$ YF(/,O5%2BIIB+A%ICH"5X
M_>CRBLR0V N#?)&0R;T<.1R+?)(8#$Q?USR,[ \!^$B!@@? PCZIMO;&L*R_
MUU P)\()<4+C\D2$!!D(%%$( XMYP0NMIZ(S?,)-G#$W=([9S0$V;5ILNK0%
MB:($A6&C7K9,GY,$\,U_"KS0RRX(QBZ2Q9*FAWN<#N<2,._T6TRP:7\H.2-<
MG,B2>8Q\2KF$:1;_VE/JY@QI+Z6FS/3!D)N6N,"3A.&$V'!$[YO:NID @0%9
M 4%WI+Q$6=#CLH0](C/<TSMCZ>DE1>2$9,Y1%J/SBG(BI!F97J7.C4^#Q.<$
MWV((CR//.SFDFY8O[F^O%YB;T!0:*NOI'LPCWVGR[N:34+HX+JE/!?*(0@#J
MUO7WJJ,W"!]1& KT&-%@A@+B[:+CYB2?JDL#]])-!W=L<!O$WWRPEPMW\ERD
M=?FHPBBD0I![.;Y9=9)$6F:)RAV@<!,K9CCU::(_Z1NB(N?R*=E-E;O$7J:]
M-1&Y!N-G.5W?#\=KEEYV!#A6^@/.4&[UPD^A"\5B"G<_2I38KC@X[[A#F.(N
MXSMB&%VD"(YY57!;6R[@WS? <]82@HNSV%Y*ZBY5G;,A!MO$B)?[Q(CK@%M#
M/)!/JFXS#' $RKSN69M8&:*.=4-*!WB-GC> F]$\]EW9CHO<8 (^08"?=7J7
MH(RXXT4>()<@;L]"[+Q '><B8N1@RDYRZOY>5$BKIQ,/2?I&*3I<2)COQAFJ
MPKB)3!"-R?P75/43+H.Z)Y&M-?8-G-246#H #Y*/%-D!JBZ^ 'UH.E.L2 G>
M\2SJ!3RK"1I87.)Y)&/N/G%N!EE"*FZDZ0M5K*$<RES4. E-RC10SH63T,+X
M"!=\SMV9Y150P427\X7,PHZ9##FZ)&:+)C!-$[%)9%M=$GT:D4WI)WLE),R9
M<>Y>)4UZ'WB0E;1K*VGM[]5&]]8R[<:>)&WKRDVF]4W7M?VN2!_I#2>F)=^]
MS[9- I/YE>N1%S%I;I,[AHIB"*]Z4#*,-QV&+I60J_ KX;5JGJBI,@_/DZK
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M^!++(^4TB?>)]]_=S4!W1IB_Q3 %0+/5J;??. G;&2W4!7#:-NIUS"?JT@E
M @=?ANTC1)_(L%%%)+YY*7A+:,=;Z?+*YM;'?K[]_39>(ZLYBW9;&8LJV;?O
M4@MWJK0\U:A^32A1E-.M<%5LL<DNG=X@GI[R8MEJ,CL<6Y5I<CI/3M6[A=>M
MDB1FE\1-YQ\4*YO)M;T;Q'4/#X>*?:G8EXI]&Y/'VJ!BWZW3H"^W28-6V@DC
ME=+:V3H._S5VKLGZH?<!N6^G'T0W1*[=A!5WH[&U=(-%NPG7[.-/H)6I8J>F
M3,U(3QAW)A!"@D-A+_E!K#Z:[1 HD&2[:D>\D*V<@$'?]P%>LMG>L47> &)W
M;/R5'IG+(W-ST?J;733FC9&MV S6/NOBJ4J1\XR*/SD,; 0(DBF/RHA)4>ZG
MDQ4X^$[U!U_L(Q,HL<)="KI!N[[QL"%%8@!1\]4A/BV+3[$TIZA)%6HV*KB2
M:0_.<PW3AU\TIXBX.BWX3/N9VS"SGYY8\^4MSW D;+6(AJD^G+ >?ONNF!()
MP4. )^+R]],WUI*WT8+RW;*YNFQR9_]Y[>T%RD41N^.;ZDWS6)_HQJ<D4MJ2
M;3W[[G >GT'YRJ%TZ8I(5!FKE]=2K8ZV#$^JF7JTR2H-R^JC<]W_IU1SP2-7
M-,:Q*8P4Y5%#:5R?T)'X%WD)1H(W<' /(":AA[#FA^:JE6[^-97*(Y%$T0.F
M"B)3I)T\G!0>1/+6#"1+ 9XB^W]K2)+W\$M!A9=0N=Y)7K<,U_*(?N$7\+_!
M@9^U[RU5.6LB/>,DEE ELMR$[.JFQDWXY(WX*,*9Z6W]4SCSTVK3H6B)8;S2
MXBK-G=L)AMK2DAS@\HV<FN_3Z#F-? Y=7L3E.YG,[I868X?K\[%N>3YHK^MK
M9B#[!1A(V=NKD*:@7K<MSQ64]C=7&[O_+E36)R1%,./]=]_VGT"^ECTS.=)?
M<%"@-_\)'1;1W=0W._!N1T*X7FX]OG+QR!WY[N\U>+_7JLL?+/LYW@K;^U3'
M?MBK]V.';:$]OEJF)^KRFY5'&**=<^+].9[XO7Y4?<&<4356S\O+:QQACDL'
MC%Q$UOY"0(K4 :F#O!VA8ERI'.V<<H2,79);V1#NR:@AB9%V7%?"+@B[* >[
M>.$8,,(9"&>@&*,Q.(.0])&I"?,9=H$\A.'LMBX&EQ1=$-A BN"P8 /IA&JQ
M?I-CQO(#Q0IQ=Z\UZ+8)=J@S[' LW$38 V$/Y6 /Z^W *7V0@O\C\/G+=_2E
MJ-V$DG8(L]6_(/^>8GZ2_\/&_*0**L'Q38[3R@_.JL'4E%A0ZPB_X4Q$@3T%
M]N4$]JEG-%%\3_']$?CW+SOU*!TC4\/_? Q%0\EN;(HP?OD9,*75[?3(NZ=
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MTFZ_.GEWB$Y=APU_.KW+-<]YQ1(ELUN$000@N\(A^%&$;&,.UA?(9CRIST[
M;[. PE[T<"G^#8/LO9_#R.J\79^:7-2S01=>%PZ(73'EK'\1?B8'%7X<)0L3
M=($AJ6QFHT?QBVM-P*0(]K6F0D-C3NJO;]4$*D36;@)7<3M.?SEZ,%RZ&5UF
MH9%B,+>Z="W_$ZF(Q$<[H.>9@/%MN>3WNW^SD0FJUV#?^<*R7881;:HJVG:@
MW79.XTPK]<QMI(J2TTBE[?0L:KCOX+C@/,E:8<_:@=W-,/B$L:\,71FD.$\Q
M&R+$D-D/X]>=7K<%TU5:K-L]W=ZQV&<E=O$/,OL!H;4HW/#OZLX6LR+EV91>
M[XR%9UQ%J^+1DQ6K EP-MTT,"P,,)\84 =^7-^ X4T9_KGB=3-=^.[D'17X'
M/K"($$>+!3>U'_W+=N_RHG/Y0VF?A)([<C==K:0RD-+9+-)KRJ@A#/0I##C!
M NOF(W=<R4 0?Z(M<F;J*MMDT"O=/61RY+*N(C7.!X@NL3Y%V,"64. ?YPO#
M>N:<W>' V.V3R6ULVL*^&:K)7G^\N_UV"G'ATG&Q6X2A12?QI+LSID+4;-O/
MN,D<S!O?UAVF8RK7WAT"+[F=BE<[V'3F_;-XU9\F.,/^R,2WP;AP6"7E[77/
MUP%J24<@KX$S>HV0SM4AIYMC\DUG?=N.>1,]%>I/10[\F[O9USG Q"J[QH/^
M>I^@G=:XH*GFN+[=B^X+"SQ6/=#KGZ6%-LY;ZH6M3_@90\3-$WK4$D(1C)^E
M @$-X2L(< H=L#;.])E-ERX"</PGMR>Z@V#+E%D+T1)*,M.3:FL.3 Y(P[BO
MA'038Q'L*>-,9N!-.F?LQHQHJ[BJ:;&GF3Z9(8Z'7X*S \^"]TPL1QPQR7\N
MP'C!9!:V->%<<UKX+5SJ!+.9J0X;<VX*L.C!%,@??(0MG+6E7..I#0&8C\XY
MW'[$4:4K5=2/@C[WM@ AGP/"N:@KQ=!>EIPP*\]_A.2HLM1>Z^)R'4[>6BAV
MF46>J82MR_[E"_PN.2=8?KG<L/ABM6WNJF#/-<95VP1V<S; @L?L\;Q63U-<
M9B$%\6-@2W1[4&5-+0.4 NH+@0@Y$8!?:(S?;6NY^#^_##K*Q=!)3JR+@LH)
M$_*48/)NA+I8&#IPD8[\!4LPUTTQEAF'^\.'G+'_@'+A#*(_$:FU?!TLE*_P
M'%79L4LJ9:F#Q5;'Z\_\D1M,.?6?X2PG,_\^OR6]^JCJABH>+'9 <'+B!%YO
M:L^H0"=8JJQ/=:G_Q&.ER(-*$["_AM\8AMB4@NLF"*/KYF+I!EA A B6!J,2
M(\1!!+;%&J/^%/B49U\TU55!QX-M,#F.:6[9W%/26[P)QH\3W? >.?V00U^<
M=O?,V[B(^O#I5_O;2QZ?C3GPG>R2AKS&_UD*,L?#@26(D(/KC"9/,)APJ*5F
M"MA3Z"@!T E. @J@%5)MN ;4!:RK)?==)+M&7R$?Y"T>L!#PA*#@6 ?NFLQ,
MR:0:SL):R%N \@L+04,IR_A2QTU2?A'%U@DQCU0(9 7RB.T0KMF+#T%X?3N-
MN%6!DHF4VW_\"<K(Q/:7SRMVI:W\:$O+>&]%K20'^[% ^-->\I-#H/T(" =P
MOT>IJ[:'F6X-_@\N?>P_0P]R;P"Q.S;^>HR/S&T?I9^PC[*"U2D($.Z>E9&R
ML> !Z-5U&](<Z"0/H?@<]:!4H7-2Q#)MVBC;%LOOI]<-1-[$Y*M22@FV[3F9
MY6?$(BK;[U@H!<VR.YR7F%Q'S%E]YNP0<^[_2&++O-FR2VQ);+G#@N63:9#7
M3]&#:=>LA2+X>7OR1+B_2!FH:NNT:K1F*SF9K8KEOEON/:_AEU&H<H\S@]+4
M=AZ',I9S>06'= 27[U"IV*#GD'8G[?ZB=E_3UU[5RNH>DW_TBI5Z] I[_>FO
M^]OKF],KTN]5&=(17%Y/O4SZG?1[*?H]JIK6]Y*CQW*Y3.KO!AT%G[GAF-<1
M/>O!&Y$+X[W6O<,/D;CB#,/T%WB'*(HEN8Y:TQMA3'<[,E' >$IDP_H/G=NX
M2[_R''&=DW2=>(P8U$W()H?H)S_HK"<*%L%>Q-7UX.I.';EZJO_DVIO_<=M"
M3AAT%&5X>*8F=JX .W?KR,[K6;K=+'TR"^+G'1SM6C7F\2?Q$F):\^91QR;Z
M59!9I:6<)[E6A;)9!>2&(F6*E#-'RB]TQ*'PN+;J-Z?P6##'R-3$X+X'G'&L
M\03Q=F5X>_\@^7"\O5X*W.IVLG24HW"Y^8R]?[A,2IN"9@J:ZZ@ :F"2*':F
MV/FH8^?U+"*(G;$B%F[=E%&TL*VI+FO!+<<1643?/E,2476&= 27US/YAY*(
M2+V7#HU>RW;72>TDPD;;D4\)+\W/\_9H_U&0WG>)=]I/VNS$?Q-F^=;^#$;Y
M2VC-O2%ID1L."<;FV:NI/:@ W$2<?QR<OS=4VPP\BE#68V'XO2'<'-.6E*1#
MOPB!)02V)@AL@Y1#G@Y<K[W>1Y? 68K>*7I?*0$J[30O"OY+W':K1\0NDV"_
M6J;'+_(%Q[8/3[Q> U[/J>:(>)VXO,)<GE,IT@&X?+VVX8 UHQ374UQ?>X50
M;4FF2)XB>8KDJ43IJ%0R%2U1W'UDW-ZH,J;S [9(H,B[TGQ.54T4>U/L3;%W
MY>J<$FT61=\4?5/T[44.>+ RRA!S06KQ/$T-9/11Q0,R\1Q@/&;7._@2#\Z,
M]=F$B)U/IUP>ICGCV@/>;G-#'J XTQ<4OC=(JR.C?++L>\DF'T(NN0<F&=G\
MJ^7>F!\"]@#]_]%GCC\D;WR/L,86B5T'SJ^OE'](0D)"4L54_/5MC_[YX:6$
MY(/DHQJ9^Y4R(@0R$,A FF1'35*TB21P@L ) B?\$GW5F0F<88*_8*'^(X@6
MU>+G6X,%M 7UB/_Y&%)8J5'IU:$A@J3V6I>7AX]_B.$;S?!4>4_1_C'P.87M
M%+93V$XJ(?\>J(E.&D7@%($7%(&_O_W^X>/W-^]O[^]OOURUSR[@$N98!CSM
ME[;XM\I.%0W2(WA;>DJ Z@19 4 XUU[*YGJO(ZU3Y]8CEY_Z353QW.4TZ6/;
MTR];0)3AN?L;]1Q?4DEW,\(3R;CKR/&0UYN0&_*T/%4\8Z5DU[,41B8Q)#&L
MV7$P.7J-6?(:ZB&&)( D@ V%8*HM@#L@.7D*385CT]+G?.1X4+-T5<%6_M"\
M6@'Y).RH(MB1<G;>SH0=931>69ZW2Q"7^-R\?<B]7E))'[)J"0T7K6X[2T)#
M*8M/K%MYUJU2P-XZ[V<Y#J,>K$M,6QS35JBQ?_^\_BR[=Y2['YM5V(LN?<['
M'>7FF++?;IUWMVWH=R1,3:$A)?:_F#.P'9>%![$:NCK6#=W5N1,_>/5EL=LI
M JC^ 9_-F4$=+Z_GL:AY/8=4/*GXC*=G1Y4V':%-.KY&E]=3-Y..)QU??GTN
MW 41)IZB#8$ZSMX6)?51]7^,I;J?P^D74,,1$/TZ2O/(.S=MT$>'%]NE3QYW
M0F''%MOSJR^K95XM%>H2N^_![E2I6^E*W=?$Z7EQ>H7VT"Y:[?X@5V8_I7K=
MXZK7)<60@V(H7J(;4[%[FB)3%)134$X=O9L8W93JH97;,Y$"_[J*1D7<GF.3
MC0HES5YD23\L*G"J*DQ 4G$(J:A;Z2EU_R(TH=)HPO$HD(+M(<$.!#N44^U)
MG<*H4]@!JJT*-4.%M![8#>=.:T)P+-D-U>Z6<@PB61'7L,$R62%P16GWRQ;*
M5 "&FHB1B3R$.-8-U:FVB:2&8M10K$H04R,55]$.P*$YEQ G0IRV1YPHW*NM
M>TE8!3%O?;&*RD7U@Z3&,!35$^=6O=E8UD*)BO,N!<$4!%<H",Y3/COG"@6,
MZ0$C_%#'!E]_I(P;.Q!?13;#V^&?WE9X.QJPX:.1E/A$-N&&L5 US%WY[:1]
M(O[V9BC^CE/[^O;SY]&WNX]7_B]9PK#ADZZYLRNEW7XU'%NVQNVKMC>^JS93
MEZYUDA81"\JNA''R:8/+5R=9T_3] <3NV/CK,3XRM_B[GQ!_>VSF\Z0"\CK<
MW8U+%@4_?6,?62U6SD<NZRI2%#_PB="O#-2N$A?\LI(^ LRF<U+$,FTRDYDR
M>"*KVT]/SHF\B<E79:@DRNNG<&3EK_Y";C%+I:!9=H?SPCB)F+..S-DAYMS_
MD<26>;-EE]B2V+(B;!G]>6^YJG%$O'FLFY-4;)]/(VM5M+>G'M8-F@%=GN?E
MI&!)P1I)*G-#UV@+<[R Q)$D+Z:++"_101H+A:B%=&6&1)>3BB456Z&&42)%
M%A3F(W=<66(9+=1TF52AQ]CZ::L#J90=2O!+/,)][T2_'V)0-R&;9#\'.L<L
MJ]9%-TOUU%'V;3I*OMX[!? 0?%VIUC*U[[?4)';>.R^P&FKZ,BEAJ4;\7*V<
MO;VDJ.;G?%977BLA:*W+3E&]B2H@!12N4KBZ&JYB+S$N&@A)W,_F$ZX_8KKF
M49XUU!!EFE.,*IAC9&IB<-\#SCA6EYYXNS*\O7^<>CC>3G([>EG*W2KLX1-C
M5R9B):5-<2O%K:5);0WL"(6OU0U'*7S-(:&%CD2G?!:ZG/)92,.6D,]"L&")
MOFKTX(@OH9GSGJ-%;CBV9)9*!IO$YA5F<\IMJ0*F0@Q>&(,W)=OELMX<?G"@
MA%##&DIP=46/X,/J!JL4W.80W$;'&&5HYG'TUAV>0'[>3):V#2.6#.@AE10Z
M-TAAYQDZ?[5,CU_D"XXUL"!>KS"OYQ0_$Z\3EU>8RW,*H@_ Y6ON?*?F264'
M#QDHD*ZA%%=;_"B8KFYP3,$TE9*0FT3%)13Z$K<WN-SDO.;[:\3G%0Y^2:M3
M^$OA[P'EN.J&A@+@Z@:T% #O%0#_P0T-)8*Y((/ BB UP<G=S)VI+E-M#K>Z
M3#>9&NL+"$$S]X_S9C-YFC<$T(:*4N/,] 5%T W2T<@HGRS[7K))Y'SW>V"2
MD<V_6NZ-F7S6NW?2^_<(:V17[?4\I)@";Q*2TH6D0F<A7R2UI*I1'$/BT3SQ
MJ-"!RQ5H8%OK2(:B?)+^ X # ]H=KU>P3^# 7N# M>K,1)P_P5_X/TN06(/J
MJ?/5RTADT'7XGX\AA94MO)N#:_8#A^@)385ZO0IL&!+#-YKA#Q=N5Q*3(CYO
M*)\?+FYN')\?W,NGP/D8Y;AXSXJ"X.H&M94*@K<_A[NB<7($OTK?%5>=8&,<
M".?:2WFZWNM(E\>Y]<CEIWZ_1SRMM+!SS--L6(;G[F]7<WQ))3V^"$\DXY@C
MQT,R;T)NR-..5/%$AI*]OU(8F<20Q+!FAT?DZ -FJM&MAQR2!)($-A0&(0&L
M0D19JM@?#R;3+ 53M&TNB2<K(&X$X%04P*%(JHY^7-4V]KLM97#>&-^'6+=H
MUJU0U-QIP?@;P[K$M,4Q;87RU'M*EC0J8MDJN+X4:18ADCE6EK<&[:2Z#PK.
M*#@[KA3S[9@I/#K1T-6Q;NBNSIWX48DO"]%./OBAC[4[IAG0Y7E>3EJ6M*R1
MJC?IW%E2LW0YJ5E2LT742\)=$$[!DS'VQ-G;HEXYJH&/L73R<SC] M+S Z)?
M1VD>>>>F?=_H\&*;O\GC3LC9WV+7=_5EM4RRI,))8O<]V)TJ)RM=.?F:.#TO
M3J_07DZ_U;[(M^_0*=5/UF 'A:0Y!VDN7@SK5D%YFB(A%!=37$Q-AFL<8)3J
M))7;$XYB[[J*1D6<F&.3C0KE3RH72LV#%S(931&+NI4"5AB_HHB^MA']\4A]
MT5:,8O\*Q_*5BOVI?1*U3SIX]4NA5J60RN[=H..T&N]CV>6O1UU/DT6R(IY>
M@V6R0@C'>98SDW+EZE0,I.K%=F0AFRF-=0-6ZF$AFUY7V,S*5[+]Q6F;@HUV
M TMZ"?*I&>1#\59M'3P""XAYZPL65"VL[G0&%%<3Y]:P^U+6C'WB70I#&QZ&
MYBE4W7:/8C;\H8X-_LXGQ5>(W&U](O^>B&*-I2IID[QYC/O$\:UC^(1%HYE!
M-$R*C"'RO(7EZ/B2*YG2_<B'4\-2W2O<>([O0G=?#=F3KKFSJ_ZKX4+5, WD
MC1"'JW;X@3<2>//0 OK#PYZN'G5'AYD&U^#@102WS<36A%!$:?K\@:D&L-KG
MV]]O@07MR6\G#]U!IW]QH3F+=EL9G_UW\7#R]AU+(\#$X*I]Q>!%LR'S=\G;
MP5ZZW%WWMN1_O@DO^(G<L/:T_98'>1YY@DVX87C4^NVD?2+^]GA4_!T7B^O;
MSY]'W^X^7OF_9 ERAW(M+Y57P[%E:]R^:I^DX0C>=.-I,>)VI=U^=9(&1)18
M<E&L''?.VYMD./JMSQ0)'T1>.U8G?S_8UM+4WDPLP[*OA 8+7LX2QQKA+Y$!
MLL)@^%&$ZF,.FABH;CRIST[ KK-@@>1[?[D4_X8!MO)S&%G<M^NTDCQQ-NC"
MZ\(!L2NFG/4OPL_DH,*/HW1F@M P))7-;#0JO[C6Y.3=O>!^:\JP6$V><ZTF
M$5?\9+_F1]>(<IG >[D=_UK28W!VKIM1/2249"Q31UVZEO^)U(WBHQ,2[2U$
M^[#^UN]W_V8C$VROP;[SA66[#!RES@;YWS:]*[( W79*XM9N7O'ZSU33M^U(
M%26GD7ZU7*P[LY@[XVP:M,ER7-7U<LD\_X=K60:?,/:5H2N#U9&+@<?'+;4%
MLQ_&KSN];@NFJ[18MWLZ9-LRW#XKL8M7E]F?"Q5#X0[<RPLR6$]7+'1%RE,?
MO=X9"SN_1;,F,;52K IP-=PV,2P,L)P84P1\7]Z 69I]_346EZR%G1^"*42
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M+X(H_:6HVLL:\080NV/CK_1(>F3S'YD;QM7?C'$Q;XQL);YB[;,NIB,-R\R
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M .:/+X'IV4Q_IG&VT>7\Y#T^429X7@NW%ZKM/GO"L>J^(E R 0=;=Z5M\=1
M!"A<086RZ*26Y_'KN)SP8#Y%S#E4O.M/C\F0Z]KZ>"EQ&UB1"*^M#4(Z,])'
MB=,+L2I0L4+!"FQF)9SR7JSIOJ%Q&/X$@J+2D6C15\MKSBH71]RT^A[PQ6T<
MNO#P7E@AX*$->6&_ QM@SM:M*;3B3?Q%*WA#6_G1EHC.O15!=S!J_ 2SE(#
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MO>";-^M\5^B9S;OW1368>:([8% 1@T\^4<7L7Y(PO2NYPE20FW8[_T1=53=
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MK1C+">4J!Y2M.8F>MRF9FN3#%J5SNR^ Y*!'-P43"6-,_&[9XK_"+$.IA.;
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M(R#1GYE1NMFA\$A*P6BGO-M;O#V:X[O23MA'*PWQ";2O]U8<%MI;\925.,8
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MIJC(#-HQ:,=4W8[9ZI;*8=#TDN0Y&C1HT)01J2G7LDFJ18.6#5HVV<=G>'D
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MW8F84E/9Y#BH\FG%SZ* CF>=OE43'&Q*7JEJ;\/]82&\A'VVX_*L<RBZ&&[
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M<< B=YGSS 3=Z,0&C<M%&6R_6,&[0K$)B]09&[H-8O!#W8"G=68\\[)O/F9
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M&X<4EJ+WDO_G.C1;7F,U'L#[.54%S8L.O"Z:$ %[H-D[CSX3DXH^CI.%<+K
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M;VO=H N"N?PFM_RCN-_TS6WY;R"2\&+2-[3I+B[^!R[^\UA_F^N&UYBHG/L
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MA]5!LJM LDX@N25C*)!4('D8(%E<*X_5L#+V/@68=0',PIA$X:;"S</ S5+
M4@%D30!2H:)"Q;>!BCON!Y?&Q> EY+_H9'JMM,=J@N-NF4+!HX+'^L%C83TB
MTY 8#$S"D54NY)O UJ(X2N&IPM/ZX6F1#0G3D*K:/503\0K<<P5Z"O3J GK%
M]YF> [P^D0,KX*L.\!6^[PKT%.C5 /0*:B\/PXQP& 5IE8"T8G9509B"L#I
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M*\Y]. ZNMH2;2/E-G-'UH]&5I$<K*229=Y!J;;X=&<P<1U9^H>O1K\?T9*F
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M6?^4W=H3L*5G$<,3>T1T8 +D>,,B3!B%A7""UEUS:6==6%H;?VRPLGC#'<+
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M$I:5QG[@K-EI=%K* Z=8LX*LN;#.N<;;H%BS]JQY2+<U*3?'_LW..I^%$BO
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MG[MUN8]8Y]"3#'6$"U6!O>5,,G4,4&VGII0=@:0IFT?F/?PIM@&8 6Y .](
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M+A7CBUC$!B5CZV+$VWI!^Q4?O<[YCM=7M0VKH0N-;U)-_&<*OTO![]^ _^$
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M]X@(@C6"->%@O=>%EK *$:L[T0<@"=$'H!-@3N%XJ%RZ-0V;BF)E5N/A+MI
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MR=R70V/:$3IM$?W]6R]'"UNV&_.G6+2K_\7H>?#R@VTS9XBTL]).>P*O?K(
MHF6;X"K7SQ2OS8_UDM\^_U-[%P1S;ZI]8FD_[RS$%D+1L0.UC9K&6=1OMK:1
MOFS9?>)(T^BY[K*^NHSQQIMZP3B-H(R'YV726?OW/Q="_/;NW9_T!#E?=&U/
MJ<6OGSYKIF&N",$G-IF/.5?X><$:YIP4_!IY#^QK&/UW20LNEHWH4^93WOU[
M<'3S[^+W:'LO>DD_B]_T.M'8A*/&F45'V\O_\X*C4.+Q?TPTSGD"_A'QUOT
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M[.:36*I8"F+?]OW"K87B5FS4U.7(%/4AUEM_B\*OR3U('' ,.%;GO 6" <&
M8$ P>><M$ P(!@0#@E&>M\"Q[N!8HSDLLD[2NEVSLNH,9=AE$'Z-/,$WN>_7
MR=I7#VKBE  KOG8<P;YZ(X=NI='J3[]\:D>E('FR3TQQ\"H]U)*S)4 6( N0
M)>A" %GUX0 @"Y %R )D9019HA8%U#:AU28AM?F2U:L7W1F^86,V81,2U8\0
M  (T6Q9[RO7F!_6?V.F_D;4PR;###R8LX#_Y+OO182UYMGL :$':;'5Z=(S]
M_<-?)URF^8II7]\]R8'.8S^@;?[QNGHJ"R268O5UUQDU+"$UDYVT[7>H%J@)
M>[#U!-<JU",%->T?28)E%5,.)S-+RF%DU7ZU#,Q:)E$/@DLHPB5LW>T/P"4
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MC8+P@? A\K:KG)0UKKL"3,$H$A@%L0.Q0USLZ L+'4A=29<E0?R@813L&D(
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M-1O"XSOI\69WEU(@EB"6*N '36)IZ?:PO>O4I3$\PFPGPZR-JT/@\=WR^/;
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MR%N6S \*P5-TTA(YRTYER" (-4&0LQ2=L_P4)C@;?E#&DM+)3Z(!E<3I1^@
MZPYQ]1(5:+7J20E42J1*L  0708(TT+:LCAGU_F<!(6L#+!!U(9GE>//'5EB
MD"A'%KSO6=. D+6$(! $64L)LY:?GX-;;F_D+0\@%0:AE 3-@%KCZ05Y6041
M)6#Q(0@GUK?14L$*:A.DLH*@!R0JU, *FU#7&6K3X[S:N0U%R$25+#?(A/0
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MTU))=C<#CZ :EB3G$9;>-VM*^$EC,FQMD -Z"9>+(!.2^9B$^QH%RD>Q$P2
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MUE=W]R(\B2>I=A:2=JEB*8A]:0:R]5#<BHV::OY)41]BO?6W*/R:W(/$ <>
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M7S[^?]GC?/*\"VKYD*SJ&1EJ;;^S&BA:JI#C!$<GKRB@?LB@DT;!(<N\=R"
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M$<(@M+=!;6:8 P)30_!Z@P(^ AU$H4.%C%PWZ,.Y62E\JK&O<6Y62LS4I03
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MOKQA*_\'6Q_[(H9FP+'^<"UWK%L>EVWY[KD<RQC9V@XW[#:,N!VF7[WG>.W
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MJ7J<@0S5S_"%=FKA#4N&\[;@>AWA>A^"V^F<!?_K@>H1BL6@>CM/N^9!%\G
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MO]^%]^52$C7_A)+!V*+8+:0UC=YPAJ)_W(Q.O>1[:/5&LZH#)57Z#V^H< #
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M1^&4_^1N62SN!_PE+*;4Z03[^2@[$5AV<M!%)_!1U)Q@;__LQX%N%3,JB<T
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M!.S:.<"O@'X"^-;)#/NU)&B75O'TE+-XC-(TM[J4LX:5ZT>/]8:LYD36QT!
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M5>+%//2R%I'D6K((*[+@;S?C*&8^V;WJ7M^\(K#QN \:0IWW=ETJ)PL#EOC
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MVYHUK%Y[?,CP>[*1=ZL/M@?ZRO33[9/FU/3Y\@TM_34EBHH/"J_M4><GBI/
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M@S\$6ADQM^9@WKQYSWK8:+364'85E)W:<F/D%Y+?\1ZM]42R2X]1C_0XV';
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MRS&)?G*5N^)R6^F^(5K &OH+UD;"+;_T,!XRB0\@Q;S@?3H"+X7 !I&@34<
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MG%%<+'91E%$,PN3=X0K!BEX:@,&_Z.*)*)V/F@9K&N7,1&0865V$D@Q"FB(
M# ,#@^&1,'S Y'?FH1>5(VPB%J7IHACHGHX^*9\^@F<JBE3\990&JP<ZWIKS
MNH9IO&W"V]E7X>FBVJ3O5_ZZ"WV_/5,CI4<CY'].AR/L7KS_\LJH&:;%.>)B
M]CKOO^3I^%E=25(43%G01JB",.X;?[VZERICDRGN4:PN,SV3]LE-00;]E;B#
M-+8TB30UY5KZ&@]3!7%*A&<)NP55!&5-H44.-:U\"Y&I@-VJ3NTF]CCAO\]K
M9Y1EKN)%2MBH(K)"-F^: C6>W:)1[R<R7>U-L0C-9CP42W)<%F5=?-+TU9P[
MZFC\K*M1#B<5,H*SA"V5LVY*Z*I6,.HU_*0:#J]XN([>:['>$&N6TKA+8!0(
M%-Y5L.88EM.SW36U%-4(T\9)_R$[W%+[3:V/]MEM(;BC S'X"CT)2^?A&'2:
MMLSF]'4/X<3/_QPQ):TS2//%[H'2%P'R)*4%9_4$WMC<W('2\I)HLGPD>X>Z
MBK-P-A%PS.M($*:*,TB+[DP!@>853*?37Y7!OD@!V'W_]>KBE0G_F01]5?XG
M:9;6;P9B%]70\NU,Y3]-JPI+O=6*#. U2>/%:J>EME@Z2=TME[/F'<BU0DE#
M5?P _,/WS?R&M'XE;VN9HLEH'QG=I;<Y'_)=H5J_N!28^Z_UVYS +M*2I4:!
M"(UQK";4-%+>6))P_TW@0C)]F_-H-M6N9[T07H>L8 &7&S,JS<2> +]3&-B#
M(J@LW;63H0K0M'S"1&?QSFJ3BZO1VR5/0I9\DJ6CE,:(9-/ M<!.*WBB6#@_
MLP W[@K+3](L#D1@%D(O7#&]ABZE+=0X9C2JF(#'09:!1C-N:$L<=2H=="Z&
MO!M9E%VG"3NEM S=:;3R <_,[]&N:M5Q+E5?E,F.]R;7Z4*9N";_3-?V 5(I
MF MNFLVH)*EI+Y<5]&2UHZ8(%/@C2EU%+"L41Q?%E "5_)GH>?*%'!)=VXTY
M?[X*RA>4N8R>56X/AG--;B5)!Y$I9UK9[:-?E\F=*^Z"T6S4M;3./R,%(Q72
MOI&%.4M3V0SEHU#N&S>=TJ15X,)\'S72P!$R%%*K+7DAFM8;&P6Y4!)(JA+'
M@ ?:KQFJH@]9.4P*E4>%1PWY&%NTK[P56)NDFNZV#XX0T^V#D^($(.5YT4GO
M^@J9<72FYMLKI#(6AI*H^E^5]3K==D$S^U6FPA0U/4!@FB(<:&'%5</!W$T1
M5?O7,B^HQH8A@8)?P64]Y?W2SAASQL9YACI *:^DH8N636H8X+]4A5VLCNHG
MRN=:S#[6'CN=5314=S\=;:2(BVM:1%:.7@&F5!R=C:L:8Z:%>J&D ^2/SC0^
M,F."!V$2Z[:+V9ZP>!79-N.:RM(QI.I&:*+(2L[@X%UF"L^R\4[*L1BEPT2T
M>:4&<!:*#;6?#6 #W>56E0*ZY"_1T[-+=,YM7EN63B/)\G]*!:[:@S3M=T)E
M2IUROT^Y3'4(S4&1]Z;*>8]&7)FW5 _",/[-B8XA7LY]C(:6SJ7[1N\::C"7
M:D&BI%0Q$3 WW()53#19^H(N'>,<'?A/*82OL&22M_3^8=\:88IU<W1GCG6Y
MIAHXEE9>@OZFFW1D-9Q9W\^4&+3?,F4BYJB+5?]9/7?NS\BM3U0T'#8E%+DT
M3@30R-!/G?J@0<K\?_;>O;MM(TD?_BHXWLWO2/O2#"^ZQILYQ[&=Q),X]EK.
MYLQ?<R"R*6$, AQ<)',__5NWO@ $)5(B*9+J/;..38) H[NZJKKJJ:?&42$A
M9MA["3<RS'2LP29ST#\U%HA*>+&%4J6'7Z,JJ?*6UD50ZH5:W!N153U% 2G0
MAA!<IEVVJM-EL-7U!6QKI(4PZ0#G1*QQ>F&6H5;AJ_0<QBGZI>!RZ:"J=# @
M2SJ37Y%@)0<=)**.L/9"FT275Z5E>4)&91S7,*OHP9BR :S_E_50ZJL +BF\
MB.IQ&,&I*"-&=RX>J:0ZM(ZT!5#-ZR '?[&I!%%,$I51"@S9B2>:=(<;D$E.
MAH[QSGATL+U>%NX4,;1IC@A"RJ[MT,9U33!L7EBVU5B*H0GP<SF,$8N#<W1*
M=>NFJH-B@[T6:VE^U0(-&Y$[$9M(ESEGXN-^1\==L .8?G0*MUL!,1#Q'G3@
MXB[)LCFM.7P&V*$:3_.TC6A>6O-(2ZP;P0)_"[N%I2H'JZ#8OQ##;,*$Z*J8
MXXY'9FX;,M/3 >\U-G.S2,PSC\3T=,![L6\\'; 'FWJPZ:Z!33T9S,:1%*]A
MDX 6CBY5INO)LJRD@UMP\/JGUV\.JW4&G@YFOY$U6T4'LW!;R3ED#'$3,,Y&
MVBOH&PWU6*)!)76Q;MXZ46+#DIX-9GO98!Q"#\GP**Y5)D&<H4\1!FI-;#Q1
M62Y%_#:/07!'ISK;"*"E6)$L#D@%DQ\:"*.!_+:#]P4%RU"RLY1Z0KM)98T,
MEH _9FL+PQ&=<S+$8#J='(NF",UK,'6G_2768>.E6K*IOM\(MM,%4PA<*,DR
MTZWRCLZ/Q%:-"45Y!XRJ,1)*.J?SRU-.3\$;*9E/&D@R0B 11Z-1-]C]V)KE
M5\3D+V=_'-"6T_DRM*TMZ2T28K)D;E?"XR:2'ZIP([[7U N47=< =^)M'FOS
M12_E@"<L?L64KINYJ/[*:0WN0)E<G*K7(=O#^?&%,@/ZJ*&+(Q"CEJ6(/7(X
M2<&DJ"(JN&.BQB3H3=; Q@.;.4<Z2[9;;-K<^@.+Y><6AL3,B?4?)8B7)@]W
MB#HHB2%9AJGDP96+]+22>0W/1Q!0>DN6C* !244+A 9G-0)K'! #OR/O:\Q%
MOXUR/0I4NYPI<_LRVHU5:1&M<L:_4]M<"LY+P1%5FY1YR5P?&A9"X%M\P3CZ
M*N2YIEQ XSTH=3+? ;"0>A++=2;H#67(%6:.5,80ETG(>!<>6BR=&4D-CV>D
MTZ9U6CH5QLERW9-R:N95X/W2R32,IR"2/%FVDNJ2=CJB8PO4G,R#BWFM,>40
MJR@T1"B!\-J</?,2>U6WU0!X-J$)IUDGR.KQDHK<\-3H9-)<$+!XUS-LC%67
M?88U#6YV#=X"O>Z<_69J93 [RH4@[$=<EE$\)#WI)E*#*NLC:-1"W!_"483L
M=ZEKZ8+"^IA([\.X0O#NO H=6P16;ZKF3/N":NF?'D>[XBC1S/UB3QB,PC(M
M0!R2Z-R98.=(PDETO1PS#A%#=@U^!/P+(FW6G741/T5@6Z'[QE=%C;=>9%&E
M $::V'(/9 --E2HP. 6^%% ; 06D6T<5-DC6+:2:2*I3XHZS!#:TBT'S5"MY
M6.<[4F-EBT$0L5\YL@26\Z4$:AA_F!<O730DR1>2E0[!\T8N05OB4#%N@W 2
M:DB'!CBZ6&2W,"]-+E%**7<LKX=U(-4L<C6'7L.IWU<@'=P;F5E'^G>KD<FU
M;2-E+1P#-S XW$2P#K =XI ^UL)N,:&T-OK<B[@00]3&Z(:UDFN]P:,=I]70
M=VUI+6PPCM("'=_P_^ @"/^-E50)I+>DN^<9@\R4T5!XZ#J])?#)S F?3L$Q
MG32E"LBI,J9PCT(M.P&]2;T#A@@X'1D'L"6]E>D8'$]U_1[5=AM8*I[IJM4X
MZ#AA5"!B_RN08AQ$M_$'KDV@S'VURPM3< J=GIIP4O!2@3V.X#Z";#& 30%8
MTX26B3FDDP;"TI!8-R=:KPI$.\P5KC7_P"":MA^YAV7:+^'U!S'LN$I<W"DN
M1GE3\03+6@3R2WO.=&O"K#2=K+0[+2GI<E)KP5ZXT")KM3E6(FW5G%U"#S#P
M<JD"U-TCI+]%W6>OX)T(&2H^Q/@2L>$D'7.:6@@ZJL!:=VYP!%.IJW<-<JBQ
MVP6ATBKZ2Z/]B.D50U?1F Z=QL)7YF+-E5PU^8PDG#:)DL1B^.7@R=<RK-="
M96\SQ*@E=2>S5CGEE-$WQ(K9F[DB<#7Z<AA9:-9V-@%J2MZK1K[6!$U@H]:'
M:K#)%5B;IDQ.N"15G#3GA2@23@*@.0M)NS35C+,"Y.HB\]9N7[@J':*M^ALJ
MDCX\1R DUB!/8^6T()$!&^5I>C39Z*.I^^27I 6D.Z+ZE8'S*E+15Z5/7,4'
M<I@0J""");::+7#<H"J_Z6M$H+I P->F DZJ*TSS'3-+SLUPP+G8*IXU]U7,
MZQ->VCDUX("Y#PP_:[T:'\,$TF"(*R-DV6<:.LJ+JV\8K-$Q@5I$S*T@I4,)
MK3IU!QP1:X2C?20T/-:-_MC#)9H+'2S32&!'SVC#O@DU\Y<M(N!M1:UC:/T,
M0K- ]9T74BDF]5%C@JJ:KCJ"]:TFR#2VE]L8U;#79#RHJ(IAX[84W**X6W77
M1U>0KG%&?EZ^%117;=V$4<R6R+2#<%I.@8RLF0VW+1X 4=0HS*[$,[++"HM+
M TD:J7567N^=M1G>7AG U96BXFN71[C:\,J#?;<-[.MI6#UD<6W@WW,/_O4T
MK)Z&U2-C/3+6(V,],O9O;UST />[7BS#ZK&P>R(!NX6%E>)I;G:H);<>3VP"
MS#:@9 W]P" =ZGB @<W6V,#<L);':VPMO-6*1UTFF)'2M%BS/(8,X2&6C$E$
ME*>F,Y\C(G5X]6S[J4KXV>V3E(>QA36,4PV!;&8P?F6P(@:9/1MROJ9>T@/!
M(EEZB>#@US>?\L-6)80KCQ:J"[D_%KT+#R]'2C20JC M"*6=5URJ5TRTP%3&
M0AL@_"R(]:,B"F)DA']D,%V'%5A+=:L:(^.VF6+Z#XEXU?.()C)<*$GO:G[J
M1=H;.A#BH8J1JE9:HA.'$?_04AG ZQF>X=<&HHHLMU%1X^.-$M/UVI28NUG3
M[R_AHQ$3,(RBV&!B#'I9L MHIZ:(,DXGN"!QE1:APE!"-%DPD;"(2P&Q':Y,
MMV7B)?$0%*9UHN6]NIQ6'\"R&]V@N,".1P=[--(9GGJS1R<?XI 35 #@(3=R
M;( +P[0CK8WQ1,S6Y=@Z T_'(-DQHZT,/R@)JN'0M5ED!\-LAVBAVO#LZS ;
M"\M>7$H/<Q+C"K>RM#H5XU!EB/'V8'N@RG]I4D0V @1_C8WZ%GY29#8$11U/
MK0Y#-J,HG: PA$;KMQA"FF,K-E2(R,Z#M$;5+FV\H1T>?@E_N\PR##35#@98
MH=&4=*ERM:BK<ZRL(<4),8B278VDR9^E [+T^I(\%\#256IY(8UF6GGP_<W'
M_WW_]F57PFHZ83Q!:/4X&K0(NP&C)-X.F^0BY!M,<3HFBJ@Q9A\-E9/!)R-G
MWW":P/H.1(-H\Z.!SCIM:; =7S#-?DV\UHZ:AYNFQ F'3)S,T(+[VTW.2W+6
M,54@'3<1Q<6PB7%%;6M+XE0QE+ETB338(O,+UF%.'MQP4&GMWK*JO16@"1>3
M/27U8K#K:(?<L7PO6 56=&&66;HHU&A./$2^8$@-K8!4C.0EK4\[^"12[":I
MB8F&2=Z1^;ZXGK:J<1;=ZB_+#&MXQ';$(29#12\.&LY#0OQ:5ZH=O$.X?3@J
MJ/D##6-4QF8[.0.A%8-MH%P2?NQ,R( GQ'UA PN-!M,["C:-3J:9M4A-9^7
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MJ# ;7+]D=CH+@-<( /*1$-XR1EY:Q$YBMJZ"5:QW6&_20-K-V3O@W9VY.<:
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M(U,MK?OC2)Y@=YBES.6"7P&H49$$\C.'DVC(33V2*PWA *?MEHKW$IC5-%G
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MA\_MAP:YL*-?GJ!^0V<#GE9](G!/9 OY]HV'!#YOW.W"DSF0$OCN*W*>ES@
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M\0?X%7C3/5O[7^6<!#,W(P(P>[@ N."8$2YB#8>AHW0 8T,$UQ"6C'J$#]4
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MI  50S^L:M%RJL-+</((\7DYGJKH*04H3K- -H"6VY6QS[O*E#PM36;F@-_
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M=)W-[!''5D%LY_UZVW:_I2.*I\M%%.N*L=^D&%'8UJN]9W9[E" BXX?@);'
M+/;."^G "J"&;O[H_?]  I*?XG#P]7,Z^-H*WB>#G3>IC9*S@7$&33B@^2>:
MK1YVDWO0ZW=;YZ?'K:-.9X4&XJ3=(P/1.YPG<EL]43M]8MV1F=SJ83?ME./V
MR?EW._8>7I#W47?ZM5OE;O9'%7]4\4>5ISRJO$V'5TKT2SB&&7Z3?O,'%N^&
M-1O=XW[KZ.2HU>V<K<'H]OV!Q>^4'1QVLXO3.?('EN<JR-ND._W:K7(WS^WL
MSDQEETA4YO"22=7*7E:_\,0^MM;E=!6U+HN>,_3 >O/.%^[B4QTN)=KNWU1S
M?CLOT\DEOBL\3SS5Z<&F?*F@##.]LVPSQ'6+/9B(5--6I]6J".O$@&O9;?U'
M[[:^WVWKW&T]O]OF-_B&C8+-?*ACK2W=U>6:U*FV=][J]H]:)V?]1L:B4!?Z
MXF;LM<Z..JW3[FGP/R7,%;<9M-2B[Y.\R$JF;SB@UHSA0%KROHU&(X6EN^K0
M;UN_;=G_]-OVP=OV_+S5/SUMG9T>->[:[O%1JW-VTNKUCY :;,U;;F=KX,&Y
ML/Q6R'D(/TBQAQSH.KRF4M>.[.M($":T,T-NU4:$S-1X4AA"N/'DDY$6;TTK
MFI4K/FIDLPF]MU A/*GA#64[FO3B9EN"G:Q4?\RC3#K9,L:D!JSI\COK,4NC
M@Q=JN/R.=!L(5IL'#O-)I].]I/:!M17H'^-=M;HY.R/Y_][T(%NW2IMSYPI7
MT6PGN&!.*[B >\'9V]MF<!5?RN8XX=V=>%'W&$F.Y(_#5_.[PW7[[=X9_K@R
M4&X$-P,SYH\?VR!NCI2NM1N<U^AKU>A/V_:QN07>$[F-_<XCO)A5]1+D0:RJ
M0&B19H++<+8]P83P(%;574_:)8.S_;B9>:##NSHRN\56?,N]]09[L>6-(Q_<
MC&$7:0P7Z_AAMM3F!K8XB^)6]]39C?XC#[4"NROQ*^=XO2RG+[$9M9QH)EEZ
ME87CL=I#-E ,=OV4(N<_AKHNE4K0D<>>7SD3<EKN]3".TV(FD,CQ+*&S#<[G
MT3#/X;MEYO9)>@OWJ-])-[,(30^R495,%X<W#K]B.[%L ,/GN]<B<"@@>7GY
M+XR-PO5.)P%SXTAIZF&Z&/GKJ?,A,J2RLWL9YA$E'9%77AS@7Z3;Q0?N=A$<
MO/[EPV$;OC6=V/2P9KJ<"</Q -DSXU@-6]+Y+[>-=G+3M*'$&^";YS!C.6=3
MF TSG0@C.4P4"*AM?; 8^?Z^<)9B%QV[10>HF?.J2,ADXB3*G O9<B84RW.F
MO]5$=%H523BOJEM>X4J3"TE0@TP$U!Y/]VVEABVN+-QBHXO*CM-##T*,@43C
MDAKW_*O$/GWP;L%Q1[H^PCS&D6E-T Z<5D]U"6PM(FS4=JF\S-6_2R:!UQTL
M,/!-+-SF%[B36!R)(GBXG.31/ALR@Z_RO:(6DO+WV.<'&^Y&"6D ;( QBG3#
MW$P9J8G5C8KSV0:Q$<DE=PB&*]*);@<YRA1.9WZ-?LBMF[*8PFF=>LG4)86Z
M9I"QL#HNCW"+]#K=H\U,^9?J^XTB[$5<7,/&BXI@F"I.W-B.!IBF8?)TLAFL
MAZEKI=45F.KN]/ILE<P.A6TF"1M.Y*089T/A1(4R*@LDH<[7ZXEHIGD8('[#
MF@@M79F7M G() VF:#EE&VN+ERD88,+->D/NRS0 U:6R*/2\\'>[E]+55%1-
ME#<T8=\;)W#<]*XM]'R8+;W>C4=]&\0E03YFC";H% P4SFT4B"8//^^_.CYK
M2U?I2[9EX#\5O(D1VM6B^^#EN.^ZJRS)DP[.Q;5LK!AF'K/F>M-?3IMG1-.4
M__SEXATFW=6W76JYO"U4Y)N+UY_WGC45^<;YQ1?B3=ILS=U\R_/HL/6F(QV3
M+!JH+><$W">ZTO6NZ;R<P+)_HE&=]QVQ1;&QG7O)MDK25@UFU\5Z5<+V .'L
M.D*X56NZ58/Q O9@ >L\2OMMD0QL'WL%!A^N,FSI[KXQTJ0$\D?O</5/?;K[
M/3U*\[E01,!!7Z(#?P^3,LRF#_1#%A'0A_8D:8SA+?C$3?N1#YN^A[_AT_K.
MW9-V[WBU'NW>+_8J=\'R+M2B5='=?OMHB698*QG<CLS,:?OT_/%^S+V#]@Z(
M=T">AP-2ST]X%\2[((N[($?M_IEW0?;1!3EI=TZ]"S+/.?,NB'=!O NR"A?D
M?3) \(3Z_F"H^&^'W@7Q+LC"[WS0[1U^YUV0/71!>IT&GD?O@/SMH'?4/KE+
MYKT+XET0[X(LKG=_A2?6,=_>!_$^R.)AD+.V#J-Y'V2O;&WWI-T]]UY(T\R<
MM8].O _B?9!5^R";0T4_%__F]]F2MJT#O*[7==HTU?E>6>HMG;TG=OEZ[?,[
MS-_^3+,7TIW1.EN%Z5[<D>RVS[O;.^2MFE0OB6N51-#I*\CL/NED;X9W<,N(
M(;!XFXMZP\OT1@6Y0@*<L@C&T7 8V\+N."6N<"HAS"L,!X:K([=%AH%.2!*U
M2;?WG7 C]/"74<X_Q8)P8B(@ G*^OE(@W>UTN$@::\*[W\UR2U#E>>,XW;&D
M2= //H39X)KH&9P"\NY1^ZCW8+Z)!C*#?>?*X@DM,J3"D)4JKI$ !-<C#^!C
M6/'FLOTE2=RVI@/1/)+@765F'OVS=W[:R,O<Z[K$S+V3D\T2,^^0'"RM&/97
M+_P1$H$-\K9E(1%ZB";>3YZ341K'Z2U9(3*:VERV#+L<-VK(J:7&("R0,0L_
MOL9$&;+H($G27;:U3E-GS&N=.B]E_?L[&$J\K_[9Z[<7^JL__G'Q[A[KMG6,
MF9YCI/;U]I*![-9MUTU=,N](4R^Z[K3[=%;9JG/>_57D)SM11;XYNZ>U,<\8
MJ^2MC;YMU6#FRYAE*MBFX3W]D+9J,(LLGU<15"'V]F*[-<)#\0%=MHP+Y='/
M9O+HR_QZ-@N_QE][#^$9> A__L:A/SRG<91PJZ9WJP;C+?7>+]]6;]6+_]SF
M7;H)Z[E1^_<<;>_S5%.[KAGF)9K7_2=6.VS50F[58+Q4/>S/W]/;K5K'K1J,
M%RJOJKQ4;8M4;:6JVJHR%W^_;2J(>9Y%*Q;K]E_[7%]XY)D>Y\Y,S\],T\ST
MC]HG)WYFFF>FM\J9\49Y)^[GC?*FC/+/ZC)#GG*RR_MLEH_;G;Y7L7/,<L?/
M3)/Q.6D?>9F99Y97R27JS?).W,^;Y4V99>D>LO=6^:A]O$2E\#/2L-U^^\RS
M-3?:GN/VB9>9.5;YZ,Q;Y>=V/V^5-V65*Z7#^VV6SWVD=IY97J6*W9^9Z9]Z
MF9EKED^]67YV]_-F>5-F^8_TYKF8Y97Z]WLT,_UV[\C/3+/Q.?9TQXTSTVT?
M>[/\[.[GS?*FS/+'09$^#ZO<\QIVCE7V5/O-MJ?O96;.S'3:G55&][U5WHG[
M>:N\*:M\H2;%\S@M]U<;=MNCF4&F>S\S3=:GUS[R6??&UHUG[9.M07P]3=,>
M_]1=>^I3>!4/Z<'Q7'R/_RG##'YP%R'WGG5IW-RSUI3'7]>+^A6;F\AX)!C?
MK]A&5VP%N >_8IM=L4Z[L_D]YAU>_U3O\#YOA[?#^F %(3BOV^?X3V?MWB-+
M]KPUWNR*/3X8Z5=LHRMV=-0^]GMLEU9L!<%;[_'ZIV[C4[W'NPL>[]_+1'EG
M=PW.;O^16!EOB#>[8B?M4Q\LW*45.SIMG_J _$ZM6+=]_DC<CW=V_5.W\:G>
MV=UJ9U?P#(;GUGN[*_6=3A_-.>8M\697[/C16'Z_8IOV=A]+1.Q7;+,KUFEW
M?6CWV7B S^FIWMO=!6_71>]VO<.[VF#A8\MGO3'>-'KWS <+=VG%CH[:1X\D
MCO$KMEGT[EF[NWGTB7=X_5.]P_N\'=XF]*[W>%<<,'QLMR=OC3?N\7HLZ"ZM
MV%&OW?<KMDLK!AYOY]A[O,_%"WQ.3_4>[RYXO!J]ZYW=%9,S]+VSNU,KUGLT
MHYA?L4UGQSV>8:=6K'_</ML\0MX[N_ZIWME]WLYN';WKO=T5>[M=GVC=J17K
MML\]>G>75JQ__N@N.'[%-KMB_4?WLMVTM[MJ+\O?;YO\Q>?I"?Y#A:N'M>X&
MK_<*0*9[RGB^ C#GGL[,"D"3>SHS*P G>DN]>_?SEGI++'5GGRWU4?O$][.9
M1R'I6X_/B0@\MCIT7V>FWSY:I<QX2[T3]_.6>CLL-9XY]]=2G_DS]5P?YK&8
MISV=F:/3=M_[,',:K#RVQ,!;ZMV[W].@)=)L"$:.9<E-IW1: ?[OL'[);30L
MKF'<[5-Z>/5+>M(/09[&]'CO!<QX 6</Q%BL<YD>IA/7.*05Z=M-CW!.MJ&W
MA)5[UI/J)7&MDMAK'RWA53SK2?62N$Y)1+[B);)ISWI2O22N4Q+[Q^VC)>(6
M3SJI=#R /\++6%7\V$$,+N</<-/K5^/PF_9Y.W2N$S]S::_7=;K[<YSN37C3
M_P5?!OW 0)3[0<5_KC^?GW6VZ+&AX0V<.RP[5KU6KG]?'Z4(Q,EWKX(4I&P4
MI[<_!#=1'L&BXDEN.(1'.=.N/\GX'-/YSGZD7^1LYOS3AZO@SB'\%3^ GZ1Y
M5$0I2'*FXK"(;E33X4R$G??& ^9OV?FJR+#L)35<?MYAZT;CJR",BQ]?P!D\
M&_SXXJI_UCLY/1W]LW=ZW/[7Y.I%;?[[)WA/?3H\[^ _7WPOZQ7<O83Z5S0I
MO/<"VGS58SW-F-F-YIR_"V*+NA"U3#!0<2SB]N.+S@OZM]R7_BTC8+5&]P\&
M99;!$9_6$Y0:3_=Y][M%3_NB(N'W<3C)X7/]-_-5Y<5>S(UKV6^'M<7O=F ;
M/6',I<D0K6H?T4AO6>8NTW@X>W7O_'0F!/$8TS)GE[AR3/&8NASC9\XL7JI1
MFN$LQK?A-+>WO\Z:5B^P(3:8&\<0=X_[K4#_<4A[NGFK8-OQ,_QQ9:#MD].&
ML<K'K]S)#6AV89AA<)VIT8\O_J-(!V9')&4<OZI$O%@<O]"V2D?!&[@5?)[_
M]_>AT3IS]/$ KE-9;9UE,L[:QU$"PN%<SAI?WD#,1E@6:<U&T$</L> /5%!W
MRN3Z_8A?+GX+7B=)&<;!9S5)LX*Z%=RCZ>\92K^S!?/!@WB8SI_]\W$3TNUN
MP83P():=D(OK,%/7\&R5!5$RPG Q.DR@6I(B2DHU?.3,/-"VN^4-1ZC4NMU6
MT ?%MJ85WW+'I$$#DFNQ4E=Z.<^YDF;H+3)1O=F3X/QE;CQ.=G'B%DZ\K';:
MEQ;T;F_#DOXZ">-I'N5H9G.]K>&7>1 6C1#*WB)[H+O0VMZY"?@6FW?/>8SL
MGK,G<*_#SD[6UGCLYSWCL#<Z]##6N0E_^ZM[__K<;[OT8>CD<8>AYQD^G3LD
M@R3HF:U;-U#DVSS!F)N.K'^4J$#Y+=+1?U]FW\]U,I;],QP,TI).1UNT7ELU
MF%T7GN^TW/!_B[0(8R]"7H26$*%52<I<423GT0N0%Z![_FPPA-LJ.AX)NA/W
M\S4;<]":3QQ%_I4C"2:RD#<$!=<-15]6*G?Y=GZ._!SY.7K\[;S9WXG[>;._
MJ2*-/R>(*^NV.IU]YD\X.FL=G?EB^*:I.3WVQ8?-,]-I]SW347,E;^OH]*S5
M[7H2A6=W/V^9-V69T29WT3@?[[EQ[G9;YSW/F3"'3>)XE?7O^S,SG?:Q)\1J
MFIC><:M[=M0Z[:_2W?7&>2?NYXWSIHSSL3;.W4YGS\USKW7N&5^;HPKM8Q]3
M:'1;'MV+8$\GYKC?.CKOM$Y/O7%^=O?SQGEC)V>RR5T3V-YS WWRV*9Y>ZIL
MN^V.YQMLM$+M8R\QC:YN_[1U=MYO=8]6&5OP]GDG[O<4]GF]<,?G:/L_PC0_
MTNH_"6+XZ8:T3R1&?4_KYN7PZ>6PLY2#]:SGU OB.@7QO+<4N.=93ZJ7Q+6:
MYM;Y6:?5.S]I'9\L$?Q\>IY!?W#;]OOMW\%MBS:XUXKKU(HG1ZW^Z?'VCGFK
M9M6+XCI%L=OIM#M+]+Q]UK/J1=&+XI;,JA?%=8HBV.=NM]4_ZL/_=[=WZ/[8
MLGOW\WB0.3FAIZ8V4/$PN)QZ0H.UWL[/D9\C/T>>T."9W,\;^TT!0-XG>1$5
M)5)5AW$0)L/@39I-TBPL5,"TYOD>8T%[K?Y*&^;NS\STVZ=+A!2>T<2<=-NG
M2QQMG]',]%HG)YW6:?^H=7ZZRGH6;[-WXG[>9F_.9L,CHF$9QCE9[+2X5AFL
MI+;;E^DPJE,,[I6F.>FVSL^]>6J$,)VT^WYF&M,D_?:1+W!I+' YZ[2.CDY;
MI]U52HXWVSMQ/V^V-V6V?RG#+$R*:?!'.H9/5![\'HUA$PV#@]=O/P>?LO0J
M"\=C=;C'EMN?G)H!\,OD[Y_1Q'3/VZ>>ZJII9LZ.^ZU._[AU=NZY$9[=_?8/
MPOL<_0'*G(=Y\ 46)"^SJ;0&""ZGP2\7O_E:S&>%G-H5M-13C]!+X7HK,3V0
MU OB%@CB<;NS1 KI6<^I%\1U"F*O>]KJ]HY:IR>[HACI< !_8*?G:J?L6(79
M#W#3ZU?C\)OV>*7S]++]NL]F7>Z3.2[W4K[TV<-\Z;]_"CZDV568!&^NPUP%
M/X7)U^"/UT&4!\6U"MXJZL<>@I,]2C/Z:)".X3 V_7__<09+_"H/7H]5!FN9
MZ&M3N/:S&JAH4E!\[C"8Z !=._C2=(.W%P'X[W"<R#&FER;TF#_^<?&N'7S,
MAE&"3[]@%S]3$_@/''"P*5CC:-Y^ML]KX:(/KO%EQF$"9S@$W-;>JT7/SM05
M/CV#*R)^?A*.%;8=FQM\; >OBZ ?? @S>$*OT^NWYE\;7..1Y>RXUSHY.VUU
MCKIWOUBOTS[K?8=/QY%$>5["+>B0$PS""0P[#@[4MT%<4F^TVC'HL'UW=_6=
M$<V9Z:5EH=:/.#4"LL*_UB=3EO#/B^ 6CHDP[<%M5%P'IBT]_.2T>](ZZQS5
M?]JBO'#U08YL.,]$J<6[PWU.CT]G'W#4.Z%ZCN->!Z]M!V] YX4P,EY5V&KU
M4>.3Z:[P*!88$-;++/U*3\PD6YV(:('XP4]@<'D9%W?,3:8&H!3Q]PWO82<*
MMDB2%E8,PR*Z45H"[8TO5:)&T2 ""33/R/1E\,MHJ)*!:K[R'KF46-G1H@&)
M!A%T;[&LM&E#T#S"2JBCM\@0>[/VR+%G/9",H-OMMH)^?YY1Z^*(%P[^K.A]
MH^&/+]2W[O$_>\6W_EGOY/3TGT>G+Q;<Z-VS^LQT>PNMWOR96?:UYKW$V?&+
MA\X4S\Y;1(ZH9)@O(L4GCQ;BD]7+L(C5T=EWKX(4/+!1G-[^$-Q$>00.#\8X
MN7$PW;_/44_^)&.Q[WQG/]+O0 L.-PKA>XP,PA5H5Z,4G+I,Q:1%'F0L'CAY
M*S="CL,"+S_-@Z&1@W^#M8=[Q5/2W(,4;7<)>KQ(X=6+,DO 6.?7^$\RS%I?
M%M=96EZ!4U+8F\&LQ=%@V@ZLE&5JC-8"_"J5DU\ BA0'DB;P#]*XV#;;O;5^
M*H[FEXO?2/-?)5&NV)6+X+=@@40]V]>HC6\SWL/').CU65S_7B8*#3SL^+!@
M<Z-NZ07>)S<J!W\R^',R# OPYO##7,';EW@A7#W*TC'^M@>6D+P^F"NT6[5Y
M!>L<QV"1< YB-88)!!MX5<(E9&/#X*B#TW#2X1%-5#; 2:YLGH;3P]+"! +T
M$L;.4QMDL#M2(PZT1/3".+Y@,(53!_O+M9=A6\^KK[Y-U !?AB0-GE=DT25A
MTJTC W."%U6F91-OEM.)@0611+E,!M=A<H6>\^XISXH#T-UC!V!!2S\S!?VG
M,/0/M>A+E8):G0R*08YA356;C]>7B\WA^@P=A3Y 3X)C@'HV%T7KJB S Z'\
M"T\L.C00ASGH9-0T4Q6B*?E2_RU>C:$%.";GX!W0<1LT+QQ AFD<PV_0!H23
M"2@Z&@N<<DEGH$I1BYT@MD9]8,2+7F*@XE@<IQ]?=%[0O^6^]&\9 0^1[A^$
M99'JO<^?#,HL \- &^A5H#5$!YVRQ;*LHD@&.,^3'#[7?S-?5=[UQ5PX@_UV
M6',M3V$T3>6'\G4?QCH7.V)_U?S7NA>[V+U6\JLS\U9+XP=.EL,/U-UKTK)/
M$AK_!VS@K8C;SHW2&U1([\6V35]3/'R"@9&MFM&M&LR\(6WSDKHC?\R??U[\
MYQQ+='K<H+ 05%2W/Z_LCX[;1Y-O+_YVT#VLSJS!P^P'5JVWBUBPYXG7P@/Z
M'D.S3[KMWA+<BLV#6Z$".&GW2 'T! __A##>9JUYUNMV7ZWAA?N'@5=S7LT]
MH9KK[K&:.]OE2HM&A$J[>^(UA=<43Z(I]KE1X#YJBI[7%%Y3/(6FZ)Y[3;%+
MFJ+3]9K"%]SMG18Z\V5USPJ^OXQF?M8SNBMB.,=:G:V\]&''L_"KR;F?K"+G
MOJ@1U ,[:O>.F])C%#YUEI^ FI0ANE]<Y_QVQ@K*Y8P!76QR%C*"CS9Y)P\L
M/D <95*&<3!2!)C\STZ[TS<8EH,THT\ZI\?F,_RO8$(/#>)P< TO-5-WDF93
M!L>$X[1,BCS(K]/;A"I17+A-#GY09($SEVJ4RA7.V*)</Z0&CUG/QEX(_'[G
MQN[YC;WFC=WS&WO^QA[^JZ0Z,PU:H^J;X$V:D/%$Y&H2'!"F.$WB*1Q%L@BN
M)$!;<!W>**J3N50*MJO<ZM#%;0_5( ZQQH8 <KA]HT1C<%&/T)VIQ*=[-''P
M=#B<_^G2UZV@>X(K7O^V)U!GN'&WCVY _8(^7= .7EO0'3QQYMKK,.<7,&.E
M7Q_)K[T2\4J$LJE>B=P%EI7]$J2ZC,_LN0RK7V\82SLERZUK/XQ7$,:#DO&O
MEV%NBUXK<%?\L"M%$J]!"\54!BDUM.6XY.J:11[+NJ6%&@25A^@)*E_\SVZ[
M<[SB/3^W\NA\U95'E1 )PDN?KA0)"QU0L4XR=1.E91Y/X2FTPE2I$A6V6*-(
MM>8-PJ!WZJIFLYC:.HVB+"_@QO%(&X\6_JAWYX]R-4CAG^ZO:.'#X.AX[@]1
MN((#Q\=L,(R'P:4NO>$:U@(=3WRG80-(_C8M8S1_ RQ0QNH6F!$UX5+9>987
MY@:+1:A2EEX%R[##JZM,7>&6V%0%"U9>7<*P2GCF)W#1A[P-+[#>BTK/53;&
M$MS!@+;_53QM!65NB]+=5Z)J&"I>,E7J1A1FUSLM,Y@>.4>8U8,[HNZE:BW'
MGF.E5+6,&*N#HES*@JG %RO(K.1AU=!"\H+_Q7#AG.>P&FI^#Y(D*BB^#8Y/
MYM^CA</#Z;<BD<*.CQ)3V<03*"]_C\^& I[A4L%UY61NC='.E+^_5; )XEP7
M5P]G/$PN!-,G2%WN!7),!618,9?3B?(*%%^"4_U'"M+</4$98M62A D5:).B
MPE_EK8!D].25<6A%9A]<%CA;*?0T-<%RU_66"I'DZZE#*P__";/%JX5V/':V
M^Q4LY[WFT=Q1'=*=7U.RZ)V>Y#(__ T/__D4#RU_ +M/VW6?\K3W/^R,[4X&
M=,=*HU;NR[_[]E*[2^+/HS>T56NV58/9=0'ZS!Q'?I'W>9$_.0>;K9K8/<)[
M;=W]/-)T4Q@O"6?O,=A4$P[]K"XS\.BF_"\\LN\P"'6-TW7DIVNI+FE.IF8M
M<^5-C#<QNVUB"-[0WV,3TSWC.W\(IX'7E'-[4_E)6MB<_+V,5SY+WI!X0[+;
MAJ2W]X;D5+S)\JK,"Z\F[S.X?I[NF:<>W_GCH$@O5>;/)[MS/V]6-F96^GMO
M5D[XSG^D-VJ\+CVP1]-UZJ=KF>GJRIDE3#!@B)MIB5YDWKX\'_OB2_37D[YY
MF.WRY=%;5E.^>(ZF5\W1+*ERG_4D>\E<JV3VO61ZR7SJ$=[EI9J2NET1RY66
MY&D7A=P8OD% =ZAZB>3CF%L:M_&.XH69%G!+%R^<K:9X86X9XLF652&Z%;(L
MI ^8O\?4M6@Y5L/EYQVV332^"L*X^/$%G$2RP8\OKKCEWC"?=#K=R_:_)E<O
M:BO0/\:[:J$Z.R.Q^EY6K*E:YED)[LIKTL^[VU1B0Q4_6Q/;7',]V/DL;]KC
MU?B,%%>JZ_ 46I=:_,R9,R[RA3F+;\-I;F]_G36M56 #"S WCM'K'F-9GOQQ
M2#NX>6-T^^W>&?ZX,M#VR6G#6.7C5^[D!C2[,,PPN,[4Z,<7_U&D@Q=_^T*[
M)!UA(6B!U8O__7W8,#NN?L6^?BJKK:-N\],^CA)8_!G" AFAF $N;*OH?/KH
MA=^XZ]VX]Y6.K'<K8WW_:V9=^JRPDV8S7/8QNWOQ(%&_\PAC=>=K+CV(A]F[
MV3_O,?M+5QD_P83P():=D NG@VN4C#!DJ*O>J:'L\)$S\T"_9G7EUXNM^)8[
M90WV@K3S$S92?C8M29MZDI\]HB?YIC? W)[D)X_L2?ZS87 P5 /$0+!+' -;
MTJ%\6=]M#Z@.;%O+)0OK[V_6^=P*WM_=P&IO11AQ7ZH]W_HJS]U.\3_3-+SP
M=G7AD,@,7&&2I&4R('JE/4:6]4[J1(4>^>.WW::VG01F?E&)RN"_'Y2"H_/5
M'F^W_MI*J/Q>\WMM(1/7>ZXFSI?D^5WW9+NN_]QV77<#$'R_^_SNNW/W?<I4
M'(V)NOA[O1./GMM.[/OR#K\)G_Z0)]GW27D9P[Q@('^/]YR&3W__(<P&U\;X
M^7WGRY;V<$_#UT46798/WM0>E;^KJ'S2;\\%C;_XMFKH27$V9U=OHB?%>P>?
M%%ZFU L&VYV,0:=/L9W'("Z'N@L*-X'!OA34'3&+!MCQ ]SEFS"*&;J9!&F9
M!;?J,H?9#L(BN,J_MN%V[<!]TC@<JNJO\/;Z5\-4Y=23#;NN%%&!+5LFX*)S
MXPQX7D7'U%L=S8,@[%BKHH?BWW:QR4;3L2M?O,?&4INM_X2;K?D]<4]%>5YR
M'RG<"+]?O./N3EEMET1P>:)N\R!7V0WL/NK9,^7KXCR%CY-"W^3/B^!"#<H,
MI%!Q,YEWNA?9FW0\AB=27\2+=V\.3:N9/_YQ\:Y5&\Q8#:.0KIC=M<Y>7V4[
MF?V5=(OORDAYK4O*%VO(LQXI_V(-")_I\FL2P!K8&NPQ^ >@S>\4JV"4I6-N
MET0-]$;N,;$=.%!;O-$T4#%VY031Y=YYU-LS&LGUV$5/C>%!N@63<R_\J#+
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M6O(<TFPV2=.MD[J[U2)OL!TH:$'EOKY=_<U=IP[.G$.V4.3GBY/[/[C]*\8
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MU+G\*"@F<IHXFO>/4.3OR(F/A+ISLZ[<$HS,Z%GW542E\"\L'?1 ;G0R#,4
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M'BG-N') %(JI*J8)-#23.-B"]$3W>%'*46L<$69_ ?-%I-(O^)LN[E0.5HF
MJ12CTW'#.48:G5^C8XRU65\1"A]/<&_!CGG_C[=M6ZVZC0G.KK.#[[BMIF7;
M]ENESI0T9)4%=^Q*V526)02G:H5"LA\-5=0=8Z=%GL5$8B<@U<QO!)8C]O)
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M!7H\]6TD,2);H#3V*5(<8?6A=K8!ZF(*ZH#L<8QN^XE%=AG_IG2)DCN#]>?
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MUYF+I5[/"V?WY.BHT^OO[^2__$#;-5#;M?5:MIS?VP,0229W[(V[-H3L<>>
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MR  E#8MX#<>K@XO+I(BH10X3&AK>B36#4@K?1'=?!1J7'D#:<C>WMO*C8;"
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M"9$)G4'^>I'/0SZ9P*\Q.8S\*HNG,1Z6,4+7DP$Z"AA'0QJS]S"GV"J^BZX
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M@LCAX(V[Y6%<!"PUSWO[^)CG4];@9^RY!UMR,Y6P<M/M_@5I*@VUOA59H^+
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M\I[)#:H*7 T^#3X-/I\3G]B[)?5%*I/*)^X9-!H3]Y5@LD\YW$(5\_+( -,
MTP#SV8$IN8C)'D(R4>GN/K[$J*NTD'^<!(QT:U\J70'^E*2)[=OGW5G6!,$
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M#M:N#HZ2@%;:U3%*8%EF04^*<Q;'0I*_!14 SDL:CI1QT*<A&UNPR=<<N]'
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M:\U?YN>O6%DS$2*$7UU2/_U@3F"?';J]6<U\E>7,H'49(W1(#]0RPY0(YH,
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M2;%Q01:(C(I,^?!T1DG \.*8R0!;M@%6F+0*]VD9=)Y"_)&KU2>3R-]F;)G
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M=JOZ/H#6S;"&A]/"<I/=1@,,ZUF4X%ZMMKW1TL9?:^1#GS1<I]>S?+Q)/O[
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M&O(;M6>;L#316P0!V"<SG2D=*M&NZWE-Z$REJ: NHS=U@F>LRJ!4EY<^7+=
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M(F?5=)B:J07!BN5ZK=0U P,/&,A,BA_G>^=J"I;(JX@LF6(),^F[4&LZ_C*
M1\!&("H;41VC!2MAPE++X]^(OBJU:2;]EXX= <'7U;NSI%^Y=I;HOQK1W[(
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M%="[RS/B-,%3)5@'FP\Y+%.I=1N-2A5*2#(#<3W&Y(V9'R' U29>K[>++Z8
MO4#.T"I)MU0J5P0CT%%]R6)*3H[/2*M!3KZ"!22 [1 ]4R$"4/Z,86EQD5<'
M!:ZKP=VOYZ0N5MNG\Z#V&/E560VMQFZ^QBJ-$LS7G[^<CWSEMV,CP_]Z3N=6
M9&3+D?)8_?VXR-DK$+[@A@?D_-7KY.!^'Y2X3[ N[B;6Y5^_=5W'.23].,;-
M&UT:3YG9SWN^K]'PK[PYM]O8?[W%:/EA*[A8O9/+-Z34)6X%;.[&FE?O6WQ'
M]&9YQC?[I0!+.?X&OQ;SGP?-\@",.HU/G'H#MS9^8PW\?_ZW?3#3>); ZW!E
M[L0/BYO+D35<Z5O1N#O!MM*,?VB^#PD7>LZ&PX4/W%]LW4);>PW6'BN<CVF&
M2T!E:9,14U2H#%1-3R&G\.-^),05_KYH.;0VF%B:VPJVN3.S6Q.[,Z\\-(K9
M]BK0H+BF<U@X&0G8$&A)*-L#/(=A)F.>A-J;4#;P);ED?J8;M"I;9.Y\JW)4
M"7;O)'N7)\<O:AAPBC(U<>7'!,+/<+*UW*"<Y>['5&(5JWCIJ!!@B%'P8FHX
M"B&7VC,I\Z=6C"@/7>4V^C##CM)HI^-S,1FPD$;#(B:DIER#YV?Z1#N/OT&2
M.@KB=>0:H1N4WEE%6!F)),?^]KYN-)6H=11@I(&QF^!(\C'J1F3@A^',KQF8
MVI+X&.?!" \?SO(H6.FC@YF>(_71,Z3X#YO!LH(01)3AT4NX77(_!:<%E@<6
M'5Z*O@".H1@;/@Z?_83/8EG)*0B7!/P=/\00FII*^Y#"$+#_3<KRN=6*O\!
MU5G/.]?5E&]?12LX#FY?G?(HNGT-',Z_5[P &ZW<OC9@$8?5NWTY!3Y@Q0M*
M">1Z@KINGAPK$B0<N(%*,F;@#&OO&P 1ZUI:&OV(3^!O\(&2O+-'3C?TBZDJ
MT8N$G9]<FBQT3IV\BU4LDOL9?*664U*SPQ)%M:A$!A'%Z_.F #7TP.<.=Y'?
M@I_,?\;8@137-();\T=+0\ ;P6'/(@VY@O::\0K2!J6\F81&P-!L.$0I4%,
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MTP3^H""$\G3 E+2.]1QPM O6+ MJ@E()[QZS-$\=TU)9!\5\K=J!:5#: O%
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M(]\"^?.!_W'<E-.P:?;)I"K/:"EBV3KU>6S0[#.:FC4:O,F5]9#?YF5\DR^
M*4G&2,%\,WIW">I\?9XO-WTOT?J _RM*D#]N7L0PPS,)$A<QB_JRZ#)&BN<D
M*9LIL:19R>"H$52<>0<Z\ (,?J^"^F1L4"[J,&^&$X]400<=!^_RU%U*^LW'
MO^-_7WV$2P?:<$5*257..9&7/?2:88%RWPE2C S@:^!_=V$N< U;T+.!N<"
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M%@I@J.!QU<(QK-#1(X=C; J!R9 =J-W;6%L*JDZ7[027^6\NM/U9ZR1#T[B
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M";?NU'QQ+F\[/LW[D7#=@]F6QW38#_UV<(,"FYF#*UWSU;'I.L<Y3BX-9E,
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M>O/K*@IVT(1)S,)+5(S#!\SMV*4A3%)!@HD#3<:!.!)-#_8Q<Z$VS9_"3)>
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M>$1/Q.PY412'=3\/G]Y5_SC)!;T-JHKV%4S5Z'P>$98?B_\H<5I=YZ#[^MN
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M3"NPQ?(:@3UDQB=H:$'X=GNK*[XXHT2]#)]Z(YA8=?>0"L1QF]O308YZK7Z
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MI/RJ.)N3L$7<^Q8(IT(L2R)K=@T(_DER&=MDUA(!#;-IRWX;=5Q,!-TTW9#
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M'&=J=]1$MZ.6!SQ[1YMWM F3=H%4GU0RN0K49-+Z1WMC4V@Y6^3MPO<6+DV
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ME6#M\Z2Q^.WTI=LQMXN.=+L[YU?_55ORNU/D>Y0SEB+CP4!##U<GJ(1-&!(
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MWFL,)\K,J3R_QDER-^UB12T*R1D-<9,3?E^QSL^]9<3ON[#VVC%3H)5)%9S
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MZBSH34$\/H 4,2T<_3MTYC$JO^8_:=VZF@"]VV>^]EW\M:AW"(R(ODMPH0U
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MY)]%OUTC)HNLAKL7<\_ZD#(/ 2Y3N;U$:U>AOZQO? S!B(C&@<\ ?Z-$4Q<
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MHT3 :]N6-&;I",6H:"Y@C19:8?ZQJ\2C8-5^AD\M^2,D4.?2U[);AU%S-0F
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M)^Q%#1*P$JRKLIA;LA(^]Q#AZ230;@H&."DD/"*+B<:KB(DS O9D;,[VX/"
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M@4^"52/:A5>4X"JVTB#0&CXX%I9%N%K(6>8<N<F9>WNJ];9SFLH8S?\L31;
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MOAF+=\*O4K0T6+)BH;]D,&WXM5Q<LZ>TYN$W]VQE#:TM*A6$F8$NJIM\Y13
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MA:JF;.O%W./"<<7$3169XF-#UBC>^\3;6#&^LZ(/>TR2*%%B.1T0>9O,23F
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M1^"E<F6'I+$S B"16RFWX,B*@&9,P\R32%N1'M!1J-DBB4T)G??PR.WRXZ]
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M [<ZL<!*]4<(X6 67CZC9 6Z+"__\!M\@+@%;(1A)#Q1TU&8CD)P%*A[ (X
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MZ$I&CA+;7>W5E17=1X5[$V3?DQ5/6F09 \,W+5>F!2\W+0]X2L7@2!W7+$/
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M)T ]XS[C)(K;%L@MO .;N **%?=OI[,*'/DLZ(NR1>"QT.RB26G2$9S/WD"
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M*3J[H[D%)6JD636Z)!&AF!HH)P?\](IP.DYUNU^@[<F!>N/9#O5,($5JD-R
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M3XK%,["36>%V+G C*9SPE;0PJW=,D,<*X@.TK3[LZC:PD,.'<@*NS>JQ!B!
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M; H=2G8_6GD$(M&4YC_KLEDIR&#;=8CZ$CX47M.]7C$J*W?>G?^[!#'%5@J
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MO]F$Q @>!>CIX)).H/5]!Q[H5]X#?6><3_<H C=W/E8>HB,R%BJ$![@%D N
M P0>7N.%> N+Q,0NL'E7PI@)!!,^G XR3V"DAUV62!%W:A(!+N$/HUA[6OSJ
MGB4R];(QR_>&"_'+^@:OXU^9>V@*ZYY.HG[Z<G$U8+A@ZH@AQ07R6]R#RO7R
M]X]=T/T$"S'*W7$Q_K0L"T^O;T&$S)#.*3A_DONA[T8(*P,@FY6P"3@7@\?
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M?-A3 IG]5D%#;8544I^&)O*P!C7X(T_^<('5/<J&QTSZ?6%J-58.T']N>R;
M /\L<5G.I"?>+2T'7//4<CQP\YKP)?JL_(A0J@3_0*F9:ZW6TSJE/4+@$QZT
MI;R60K! &V1;@T$CF.5U$<DJ7N2Z#?!G"= 5\^_.G81T(1]^Y+P[FS8V"V26
MV4\*H1LK^Q$L7<S;#\!TF<^$ X643A-)^U7Q=@=\0T\V\NQA#"I W.KN]WV?
M6EB@]3< 7X?45?S2 U%'*Y_VHX*OC#@"6CM#[ 'WQQLG".VA%\P>-'2(M*L(
M((RB*R,#@ZG!3KY?;JO#EODI>%H?<6#0KTK %J*=;&1I\QDV/OL'8&A% DE
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M! YPF_]GUQZ:U:O?$=T2<H\!!H5A",2V6*Y[<C;D\GQCULG6+H9@)-I()U"
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MP!)(M45K(-/$I,?'*3*/W.H$[DIU42,FW$XX,8UW#F^MA@'+HD^YX+;W#J3
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M0)@BQM??,#87\L)B=TY:XH(I#%5QK$$&.&)(0D]:&[ /=*&X*KQ5?2?=!*9
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M#7H5B[J&FU_F3*X3%FGWY7+38,@UQ-&S-/<!_5S!(.C,CT;/N0XJUOO;UN-
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MGTTZ\<60%T-F6J,L1=()FGU;$SN.%)\X>S0'NXJYV\IF\%/+W;F^+[O<F4K
MP)DL<3?DH<,H%YO02\&]:/%_HN@/70B32)U^,*=4_Z ,1IDDJ3NUAMT>[>%S
M;A 5!,MD_6%/4^'>R-,L#Q6ZL:.[6]K-RU:<V8IL2.+MM0@MA:#[K!."OZ+
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M 3DRL9:99] 6V1Z//1_E0/@0T#SA0:.SJ_2*49@.[1BT(CPS>,$$9&19&'
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M%V28AG-K*,<I<R7+XI>:54Y>![@*$J.^D*&(6)RQ:,-43H]D(CO,8^I\YRK
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MT!K.3>Y].0G)%1BI:&L2"NLU#%M(?+%!N)PAL,RQIS#&?):9CTI(M++=5!$
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M'8:&,] !$D((T,ZH[[T])"=VFG9*_U2?YNF]]UW[?=_[WED^6CY.?I0:$S,
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MA]UPV!>!&"H:#D'K-6&^:K"PL)]EPF$F$O'X.5: &D)1#Q-D0AXV[,M$>#8
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M.GSDZ+%W/OSHXT].?/K9UV>^.?OM=]\[D<GHA<=FM5KM=EL>FNRTSIYNH^W
MW=)U79V/:5WOB&]JW]J6WL%>XJ]_<LZ>?0GYY(SCFP-SMPW.Y)*G=CXU+WCI
M4"C%SV]0;KJS6T7V+A-*R\-;;L8&G[YRUEV[=J.GGKNUMYX%/2LR$?.YI_+:
MU+MR>.RV>Q]]_HVC)[Z-]JT2-]Q^WV,OO'GLT^^NBEV[>NW&.^Y__,6WWOGL
M^_&/0N]]\-Z+9W]^]HN7CKST]R=*7][PMW>OAX@UY;<G(^R;C+!_,L*!R0@'
M)R,<FHQP>#+"D9H?-3]J?M3\J/E1\Z/F1\V/FA__!WX<^R=02P,$%     @
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M OP\TD 9[N?Q?VP5H(Y.)E SB__8@O_;EO=_M162=K P<;)ST+2SL_W/ BI
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MZDWPKI\W#;2$(YFZEULW],::B]U^6G]SX?G!J4R>0@]-(!N)_LB5L7I:,@(
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M"4?E$E,/QN[Y;X$T,[YK602X^2:/<VW*#W[-[8A$+:@M=:K-GU2OCF>C#V8
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MKU5RP;A.2P)J6;2MXCJ[V[F9F[II?GE>#Z'SP P(=SC&JLKV4CHO8+>:@91
MX@Z\YG51-.RG\;YP-%D]E1GQ(";BU*#Z?5$6=9+4*@=@-5D02K&[?N'+'B9E
MM1)6XG$7FCXYB](KS_QZT<BC[?OV:6]O"U9?DXOXQ%0%^9%*D177.L?[%%\"
MRY6'S _7.W%8#'N+:#N5W!^'S14PO.L5G/%-J0NV- L(WTY*;BDTYW]>8O_8
MA+RB8H<K6XEH,LM 'U+.YCFIHSV:Z,8K16"=M.S%38\4+7]Z2QX^V/RPVM_4
MX%O;7 4)CN42F>.Z9&!6C/EM:_3WZX\A_\_\@Y]^SZN7: QI#,57UD7R6R?
MWA;>OK-@F\[OT;4>Q1 $B[3LSUMC+A]-Y/5]+-EH&]AX(X^FSC:J'X>5$3I
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MZ%15OA#19!S.;5D_OO7M-E)W3^8<EJ!D =1(WC*\MK^>S/D3VG6?_<]C<)\
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M(V_+Y_6C]6ZQ<72RN>ZA+K@>5.N;DF-$ML9#8 '3+[BC7I-CEYEW(Q:Z"7.
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M6-34P/N-B/<FUN77%+G\R(JFVKI:I;2H-\L<EU/,W%O-J>)?B.. $MN K8>
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M ,JD9:OS.=2KQ[TB06VV2^PZYR!((6#384\:5J1Y:A+E.%6V6^"$XU/;T_\
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M2R1%@<CGE' <?;F@]@7(&NJ=,6,<<P>BM:WPKP]F6/OJ$7:?!,B[QQIU\O\
M,<:Q:%(5'AJ:*0;S<$I3\R([S036'"20E3@J7543P"CKEEX[0=+/B[:ZU8M:
M0"\+3P.>FK @E33EJ9>0M#J5I7_FRAT'J(Y:$\CA))2"!7A36/$URW'7C69$
M43A\ TTS>7>CK![E*:5'MD6-1+:''V64\_2:7S-I=2ZI8==:K\#A^(:L#<;Q
MO%6]M1NV^T?XM*.^VBQZ5^V<-E32K*EXJ1TU?,#FZAYP0ODH"2DB@WXZC=>7
M;CFA[JD9:6\?Y5%(2Z>D+MJ^F1TL>C,K63S.-%:G$U)45(ZBU%"O\$@:!=WV
M>JIC#9/S8!46^XGH>LL9GEL;+K#*UJ<,9J5/C..**J**'F9 Z:U-GE"A0I'#
MSU?BOIQ_,JA-86KU\L84U]CMO<OL&PA-FE7RXXN&E"Z8AE<MW-L3GQ$H4A G
MV+(&)UO;/Q%OKMI;<2A0JL[#60CNA(>W*L;+9B-2I2IK=F?5=VTRNS_NU(QW
M_9_)C0C%<M]M4AJ'!N!;<Y';;8R7)=IBR6G*H=B+=BJ!*5QEMI5RW8V2,/F1
MG,5AK@-70_%P]_[:B-DF*W.Q^JNR7!M;5RM>9PI>-VVZLQI*"F.94*^/P;G(
M<?*83R&XRG$MDML=.H;24*2$3WFF[M""/'I+?:<*Q<37VET'#X"5]@QKTC^F
M2VQ+?VYDPVG6F(,.;CKMK6I82U+?GV13LIOJ*%2MTM( 6K;FVVH",YT?#'82
MS:_""^'2>!<6N4'L.2\"E:MU/))N+&!OB(;(7#B&AP ([LTXA:D \C\56Q%=
MQS?>(-*%8%*+&X5[0==IMY"^$.''ZNP]HX]M<5O(C#.YI''Z'V\**Y!_)MN*
M_P M*ZM@#.JA)KY0^^GZ>6^GTF%$.4K7S_D\=%+D,:+!K_<WT8TC7 T2[3@?
M>!YGS\J#;0/KJ0<ZT'E"AIX ^6YIQ]NHW%74\94I.;W_ %_S:9C4JT^N2C_K
M)?CL?^EYU?.GS"]O'6NR?&>^NF0_R6?NBN,D&FWA])WKJ-3[:E6C![/'C7CM
M_=TB4AS[Z-2#7Q\Z\OU;:4"BLTBG#]-AY^W2TF=&IK7;:N]?'P-:[G@-%)PH
MT;D;_2>/ZN.BDHY*?+]/U[Z%YTE&@$[&F^^P'\FDI[1@M&I \JTV_3C_ #Z2
MG4P/JXRS]P?2?ZH,V+[<;]U?3QWGO3;[G3Y&GH?;G(U12>J"V29)0 % A1(%
M-]0W! @>?\I^O"KVUQ^=N=O%^J=@_P"D*\$WHO[+OW_#L9LCQ=B/1K3:VWY%
M79"0R\T'KV\EM""&75RIBP0H\H422HF@3YDZ^WX6UY)<9@N*98)@U>808)^T
M_03H39M=K%'+@ !Q50<7)VDGV5:O<[/:<;1 LEL$6 PRAN REU<:*DN+#$9K
MF7S-,H;?D*2$ 445K"14FFN)1"YW2=KPV261[BJ N)7'( G*NQS30[;9/?.Y
MD4+6@C40T #CC4 .XG8GO!ZFLAG7[#NYV/VGM=:.I L L5R:N\:[JCN/L7&Z
M2WHTE+3+JI3:VTDA:T],('+4U[OTW\ETY9"&:QD_J1*R%XT:>0Q"D(AX#C7
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MW'92]'C5 JEL!_JA % 4)KO7;B_6;B=S<Q25</J&5=EZ*8#MFM$0'ZS]]/\
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M?N1CLYB#W#[/]R3'*VA(EV+'K.^PB,M7+SKCQ\FF+/W@H\I)\@3MI6]([*'
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M[@Y;#RW,ID>&N19+0S"AV['E-LN'Y%R9%=DQ79',Y^.MOF'.FC8Y=SY]ZO\
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MKL>!!S_96:E$OD@2M<WP\01_C5U+%M#6/%M@*4VF(IM*7$\JT%(4BBFUT6"
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M)M,S&KU(;9D*0VR]?)"($22$J64@RX4-]Q;8K7X5D"B3I2]L8U.( [2E-0G
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M'%0$7$' @>(X!P"XYURS<NC.EKC>'[S?68&Y/CT.FB_AREJ@XD>%YP&+VDH
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MZPVW\*^/"E!K(VAS[ZHSC%P&>FGSCT*=O(>'UZOBL>*V-+2UIR7N2B179)X
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M87<]TDB+FZB1]E(O+<N:F15/7+Y<!@=-<GD2HK;25)H2:C:A \=ZZVG;MO\
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MX^4W%NT"X1W)$*3,4J/$EK:>#2X<61R*2_/0/C+*?C#9"N!U9W'=K?;"T7.
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MN#8@=-\&47)*FT/MJ+G311.M4MV.L+N.SF+Y9VO&DHX!R\<SDN.* BLK=/\
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M8NEKCA0#CZ;6TJY366@=W'#;(3Y"1Q533A@<:1>-5?\ \16T1,K](_;:[XU
M=BVA-AE=P;;%Y?BAVF1>*6IMQ( Y5_E5Y)]R2=<U]4+;YGI]T:*X/:[_ $@_
MC7O3^P'=V[7ZR133E+=UK- ?_;OA('OCKSA6W+%LO=%U9V41N34 'E\>.O*,
ML+FG# _;7WINMD9/")HT((6K8?X5N;-V_P!6.$QE/I0UDEHRK&U<RZ!3LRQ2
MY<5!\RJ5!0![3KIOI1=.@ZD9"\_S&/;[VG[Q7@[^^SII]WZ ;K,&J^SFMK@=
M@9.QKC_H>:M3S%IQ&79:XG8_O-?:;>=TE;\1KT3*=#BX<S7PB:Q0">5-3?\
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MM(CL2%NO)#*GT1PADT6D !024A- #KD?J#-N?5.ZWG5%Q'&9[N=TDN@(&/<
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M5TRZW&]OK9MI,[^$U.Q4Y\ZR>V]%[#M=])N%M&?/D7,J N:<EYUP6NYTB"[
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MLEYU)!U1(PB_MX2P @:2Y?"\C%71C4&G_-CBT)EXNH]UBV>;887)8S/#CFH
M"%HY-?@7#LPS-2%Q?M6Q<&8[RK0_:+#(43);D=5Q<Z0VT'D)<"G@M[XF0>0+
M 52AH!\6Y33^4W0U2XC.L1!;%WB?DN53?P#M1:9<=MN?#A-1%V>+*6DJ7'9A
M0)"'WH<J"MM*V24-K2CII4Z$D%)^+<T6N>H)*N/'G60T 8(@6G]P+&+=#EW>
M\"T1X4" VBTV&/'5\:HBED.2W"YTU.*N!;0%J)-4BIV*=33/<!Y:G5@343&
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M3MIA#B5/.G3BR61!0]%6^AJ0A/RR2EY3:VVJK4VCF6ZGJ*;<%4T4VA0V/@E
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MU@ZBWC>.HXH8M[D%V;<DL0Z0"Y 7NTD:G)F<?8M0]'^DW0G0!N[GI+;H "!
MW[\MI+UP\XM<]RL:26L:)'N#&-)*,C1J\*[3'=BZEQ=VZMX9EI83;H*)DGYJ
M(MUUTAU+_226X$L(:'-(6A#K@'+2F^M'N-B!882YB8N.D(Y#B2"4)Q.33GB3
M6W16T#2UH#3&2ONR Y]V('+A3T>G3U?9IV%S:[7R'%CW6'D]MCV*\0PB*](0
MVF8767X+CZ^1YQD.J0$*4@.\P)Y>4#6_>F'4#?3;<)KRQ@-Q!=1-9(TG2\AI
MU,+26D @ERM(0KFH6N1^OWH]:^L73-KMDM[\AN-A</E@D+"^+QLTR,E8'!Q!
M :0]I5I;D0XU:9Z0IG=/U =Q[YZI[MVY5?F\-BVNS6>Q0$,QY4N5:I<N3BD)
M+JD1K;-FVQ<E<N0!S&$TIF@(4*^F^@'[SU9OD_7-Q:,9&QC(XV (XMC<71JX
MH'O!<Y[U0,&D- 6O"OK!9[%Z3="6OI/L^Y27=[/,^>>0H&@S,:R<LC!<8H7!
MK(XPI+W"0N<2#5Z#MH&6XBW:LRMB67+S:HPO=LBSW0J!,=0V^XS#NL)4=],B
MWR0.20RI"@XCF01MKT.8O/MO*N@"7-&H ^W CB#D1Q"UXY7RWZHCD<"GVCMY
M4RL+LGV][4WQ/=)W(\]E1\7MCK;%OR'*)%\MD27."+8]>G')3:)SLIV*^ACE
M<>^5;2 YR<PKK%-VRQVV3^HO?,YL;<&N=J0GPZE.))" J=(&*5;^8ENA\NUD
M8<XY@)VI7>EXUA7=C*['D\;(K[#O&#R[7-?BXOE"6[9?+<B1+E6VWY'$BAUN
M5;EW!I;@2"TXX&RDJ4V2G3A%9[K<,NB7B> @HU^#@J@. S"X\#@BI1JDM8G1
M(TMD!&(Q!1"1R*45W#[-X+DF61,YR?(LLMK2A;XURQVWY JW8OD;EM^*!^;0
MFV/F%J90@!0:>;2M"-QQ)7<-MLIIQ>W3Y1D"UKD:XC$:@BGV$ TV*YF;'Y,8
M;@J$A2%S0T]L.2Q+;1(C.MR(LE/7COLJ2MEQM=35"T$H4FM?=K--<'M#VE0<
M0:IE04.%"7;;=/7&<GVZ!.<@OIDPG)L*-+<A24$%,B&N0TXN+(20*+;*5"G'
M32UKDU $@J%"H>8Y&G!SFJ&D@'D<ZW":;G8>).ESIN5<BY7)F'#F2W.<,08T
MF9(4A"UK#$1EQ]XH0D%2STVS1(!*M*XZ&%YQ0$^[&C$E!QIO<![DXEW&;EOX
MI<HUU9B,Q7Y$J%)9F,-_-*>0EAUUE2NA)2IE7P*HHI',-M4=OW*'< XQ?"T#
M$%1CVCCAB*FN+:2V3S CCSPI<NM-N)<9=0AYIQ"FW&W$)<;=:<24K;<;6"E:
M'$*(4D@@@T.L@0"$*$5!F%QI*X[BF+8+#G1L<M;5JC39*YLM")$I]2W2"&T)
M7-D2%LQ([?P,L-E++*-D)2-06]I;VH+;9@8'%2B_1!P&0X"G2ROD(=(2YP"#
MZ??4?>ZB[CF;5[^48<D6^P07(L)@*"$7+);X\U:;/#0I54U3)EA2S0\B-]6A
MV57)-.5VSLXL>'6Z+\HF"9<BXW14=*4(HJY377^LI*-DKF((>(XCJ4.XU5D(
M+RE3)@!Q Q^G=2Z4?#R^O4=.'.L]AQ)_7I:;G39W*7=69<Q06@-B2^$44*\G
M45R CP^&FH\"4J\T(T% B5S4SKJ\ZE2)10!Q^Z012E#5*MZ>6E0#*G9Y5TDN
MS75AM4A*5D4!*E>T;T'CIN"4J&F3]14.\_[-KTW$6N2ZJ%+Y6FDK6XH!DA02
MD E1(/ :;X5'):@N@X6SS'B_2>%0Z]+[$N(U&;?BR6*%2?Q6'6J;D?TTITZ0
MI*K<:Q^W%+32_ FIZY'<+BW9R(C#KJ@B@0A"U$FFVP' Z?-(0WPU?B:#C3 X
M[,S&=<I+<^S3D,(=/0*HZR%HYMO"I\=,M9GH0[*JMW&J:&G$TX>3VNZO8Y,_
MZ'FEY;*T<J8RBI1+9Y>7;CJEU$0[:9 W%Y:<..5;)Z?#R>IH))59'J&)P QX
MU$;"O2;W![AW)<[(6UX+B?66MZZ71@*NT]KF)+=FLZEI<<4H;!Y\ML@\.>E-
M<2VKHW<]U>);H&VLUQ<X>(C_ "-S]I0=]>VNI_6_I?I2T%KM)&Y[V&H&1E(F
M'G++EA^A@<_GISJ?>#]M,$[/VG\BPVUI@?.H0;K=Y2Q)OU\>;3\#MUN)"5%
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M\33VZ2ERK(>W??Q_GTM-[J9NZW4(N,U"E"B)DA.^]*.K ]GAHT$_#5OS&M:
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M8\=;2E,F6M^0U'MUN0EJ-ORMMK;2/N!(W(4+5#6L"CFI^^HW/U %,,Z]67I
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M;4ZVU4JA2.K'50HU<:=0U#E6$DC,,FAV?VU93@TE\6&V?B]=E41DMN'XB4%
M4GXMZBFDH!YTOT+Z@)!IP_2GAI*?2#[C3<WMEECW+!K(YD\Z'-2;CC<25"@W
M2Z0'6RV/RR9<I$2 AR)((<<;<<076ZA*@H451W 71A#K0:G@XM! +AV$D )G
MCG5BV,7F'S2@3 G)>U%]E=? '<FNN(1'L[LRK7=ISLB1(QZXKMTY=NC%83#C
MRTPW9L$R.FGG4D..E'-RE500"T$[K0"\"/<2K20Y.PYC[:'EC)M<!0CB%![4
MR(%* L8]B\2==&;?:;+'::+\Y^WVV'!6XA!JD+$-AE<AQ3BJ(3N5+4 -SJ33
M;VK'2AK(V@8D #[!3I9[FZ(%Q))*0<-;G/3NU$I0L>16W(F7WK<XZ3&=2U(8
MD-]"2RI:>=M3C)4HA#J0>4\#0^1TL%Q'<L+XR<"A7.HW,+"CN-<#N6]FD?![
M^]V\A)N.7M,1W+5#,N+!=>2B;&7/3$D36GH?S_Y<EWH)="4+=Y4\R20H1WGS
M/RK_ )-/F4\*E.]%"*F2X+3X?*\UOG%(UQX^],47-.%0B[?YOWAQ7NU9;;F^
M$Y67<@MKSN.V.+B-U4X]"NMXZ,BY9%E,*XW#'($FU1E+=?9D-Q7&U!%0*BNJ
MV+]TM;]@GC=J>"C=)5'.Q<YX):" ,04(K)2PV\UN7QO: TH3J&8X!N!0\\:Q
MS["\=C^H.9C]G[G6G%LIO\]$N%9K3B:[WE9;S%E*I<E\NWME,=B*M"WF),6,
MVTAOF^:ZJ0K1=V43=W=!'+IFD<J-8KAK&..KAF"!A^9:6&5_R8E?$7L 12Y
MK3D,.(0$''E4_H[L*P0K5:)UW<E2(\!B*W+N+K*KE=/D&&([]PD!AMEMR0\J
MCCJD(2CG6: "@UMIDBMVMCD?BB!<24P7+WFL2CGDO:,%7L"\/IC1=WL&+YA!
MALW^R63)[:Q,C7: Q>;;#NT)J?&#B8MP8CSF7V42F$NK"5A/,D*(\3I7PP7+
M )6LDC74% (7@<>-#7R1DEA+7$(4*8<L*9[N'EF:2;C9&>WDJP2[-\I/CW-,
MZ4F+(MK\>CS=P9BOE+4ZVMQ&5I4RD)=24\R4K&PQ5W<W<\\<6V/"@.!4HA"(
M0N8 4$9\@:M1QPLB<ZY52B)BO9V'MKM9OW:Q["[9.E7"8U(EV0VP7R.T"?RI
MBX-LN_.2FZAY#"VGT\A 552P#P52>_W6&Q!;\4C47D%Q4\<N5106LDZ$9.!T
M]J?56N9\_O)VI%UPV]S,-N%T?7)Q>^2K9-"6S;YBF6I<NSSA$=N%KGL)< !
M0XA27$$@))/XF[[9JC/E2.*M*'@<"04)!"X'L-*1\I.CQJ08A>8Y\"*,P'MQ
M^Z\",YF-RA9_F+-PDW1.5W&QPVY5N?E1V8JHUB+_ ,W)M41+31/*TX@<SBJ
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MMMGN):TDN="PDG#B2M?G]]4.N_4*VZ_WW;!N5PV.VWB\A:&O< UL=Q(P 8C
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M](=26?5>W.W:T$D;=>DL*G2X(K1BA:<' X'L0)4%W%)970C<TDDG$H>T( "
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M ]VZQ#QL"% ,2I72$PQ)0@A%PJ:/;FQ?NK/NLFY_FMU[A.@6>]Y#>28DV.7
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M>ZE-129 'A38'("X\<J>%F_?((8B@\WP6F6^GS0FV1F4 ^0*U5^C5JYR;'V
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MVP\\/?\ M2O18:@TX$&GZ>&O+F=;2:Q!W&XXBH]_D171C0E,_)_XS(_]D/\
M_"KTPYU5HH*IMX5T4A%')Y2*U^K?R]_GI%/"F5E0 [;GP!X: 3GPI:R"MN/#
MCMP]VK#9L/%G3P[G1J3S GRI]NIP\$@"GARU]T^G4-%%&M.<E0:<IW-17ZJ>
MS24A"TR'<CM%(O=Q=SOMS<&\;S_E0JX1W'W8EDS-,9L(::O"F*KMM\;92$,7
M-M*E!("'TN-@%N6.73@[%M4I[1KPK,'_ %5M]K.^5S2J9CF=09T:ZV1Q$>[,
MS8X:O=E6JH:-VB-<Z)=O> JS.C\\=]'Q)41OJ; XMRK&*YITOS&=28:EVF]Q
MFYD"2DI>2%)DPW4*0M)&U>3F0H"O Z0 C*E)!%-IEF#0;U E6B[P(M_QF:\W
M)G6*1U4Q%2F5*<9N5OZ+C<FSW:.M14E^,XT2HUJ%;ZCGMX+F,Q7# Z,G(\^8
MY$<#2QR21/#XB6N^F'<:4%F@1[;A2\2[?IMU@1 MDB%9&E/S'#;9;A<=2[-<
M?>DW&2X]*6I3SJW%O+*BHJ)U$;9L5J;>T2,!I#3R)X\^_C3VR%THEE5V*GNK
M6[4.=S2SD#O<&R1L>6+JEFPPF,@B9"_)ALH6'KL])@H#4)$Q90&V2XMSX2I7
M+4#5/;([^-K_ )T *X:1JU=Y49+AA4TY@)!@*X8E$[O=3O@N*"W7U$ 54IQQ
M1(  W45J)UE:KI[J(#R7 OH.-/\ (KE7TEI<*%<M:*"5%2%>\#30*$'#&FRS
MO(;(]:+ICU]Q]F_VB[0Y%NNT"X3(4*V2XDE!;>B279,A"EA])H$MI4NM*;Z2
M2*.:-T4H#HG!"#D0>!H9*^)XD82) 5!'"FLBWR5A6)-6;$\-CX'C+*G'?G47
M+Y]++;M.=]R5/*'^HI" GJ.%PI2E(&P #(+:&UC$-LT-C' ?1??39)7R'5(5
M<:4N&R\;OL'YEJ_6F5%6>:>Y"NC<VX7)T&JT7&Y]0O(CDCXFVZ5&U:;&P5I@
M3C7<R+O'VZQ1L-3\DM$,MCIAGYR.DCD!"6VVPOG<4 -DH2I7D-(!3M0R&%1R
MR#U$9IGTJ1CG8_"KC?7MVGLDFQS&ML0$?$^I,Q<6.PD5^$S'8X4?NH<X:4Z6
M?&:&-?(? TFC^W?8.XR)'[V=R;SD<C*I"GB_$%R98AQ'0I*4+;5!D2E70%I2
MPTI9BL,B@3%.RA"^8#%M7HH'N!8_PM'OJ3EDL%FQV*U"L=MBVUAL;",T$O.*
M4:K<D25<TF4\ZOXEK<6I:U;DG5=SW..:U>#6M: @P[*AOZE.^;MMEGM]C$LB
M:ZCGO$ME=5LLFJ>F"#4*<WIY)W\13GO5G41@<-KLBDSOB(.0KU_Z&>E#'VG_
M #?OT:M*>4UPX^T<./;APJM3N)?YZ8BV6EKW"^9534J())XU))XZY;?3.#'-
M!->U>E-KMG3"1X'[*@#G*;E)D/./=17,24DU.U2?;].M3N'/)(%>HNFC9P0M
M:Q!3*R+=++JCTUG>OM^K?QUCBUYYI71(KJ#2BBM%R-);!YFE[>/*?(GCPU&8
MW(I&%6&S0NR<*XLE\)YN<%!2"?([;ZI3ZV,)&2&LK:1_Q6$(1J'VTG7/1QW!
MR'.9N1+[DV['E7:1^\EIMEWES+>N9%F+1-APXCCD[HN\Z%@)H@(IQIKZH=)=
M:;/%TIM4DD@=Y>WVK7$'4YNF!@(3L3):_)[ZO=,[E)ZL=601#1JZBW5S0< 5
MO9R..17-*G'F."_[5^S4+M7D<^?;YC+K5NE3+<T)/0>C])0=>/(\E+2^6M3M
MOK8[O=[8W7]1MG@P2-U-U%%'MXUSNTVZY^2%E.T^<QVEP9B ?92N].GI?[?>
MFUJ^W2W9[=[Q<LPM'Y/<X:%,1Q&:4E8%.BR"YNZ:K(3R^6VN=]1]3RWQ#;AK
M&Q1.*$*2?MK==EV..Q!= ]YED8A!(P^RMSM3Z%NQF*]Q+!W"AW*]3[M8LB_>
M40)5S5.B2GD2%S&V9M6&&PU\V4E2!S<X%"::HOZTO=VM7V#"TL+$*-((&6?-
M*EM^F;:QN6W3E)#EQ*J>ZK.'\J$U]$1#OX95S/+KY_>3QXD5UA([0@*1C6=E
MN@,%5U:F19OT6TVZ)(+82V&^9"MQ7[W \3]FI660)U."FH'W:8,&/.E*C+(S
M.-MI*DA,>("$5&ZN0GG3_P!M622?'?4)L7&7/,U(+J/0I74F5-S>LH?@Q;1(
MD/ IDMIYUI51(4ZCJA.YKLDT/M&K3+4*0F(JNZZ<$TTE[EF"51"I+H/,M7+1
M6U!M7<5I34C+9'9&HY+E[F@$H.RMM[* [BC" _1?.21S;T))!IXZ!;(\N(PI
MAE<8P%Q!KM8W>4W&Q.%2^=<100XFH)4VJI3MQJDCSTSR=+TYTOF%S<<Q2PQF
M762$*-%)4*&O%-/AIY5!TR:+#GA3V.QJ1MC<4XRW4U^%.^QKP.^WEJD(5*D)
M5P/<B+3C69*6W6SX*()I3:OOXG5EL*C*HO,.K#.G;2PV]$"A0U3[:E-.'&NV
MHO+TNP%/U$N4UN6QM#T5V*JA'+L..XKR\=^.VDDB+2'$84 DG"NI:F5AJ0@)
M"EQ^1NCE:4)4L $\-DZJSQ D%N52,?@AK:?M-BR5B7:+[:XMRB7"'-A2[?+2
M2Q*9FQ7(LN,JA!4U*864*!J.;E53F2DBM&K7%O,4LK00">%48=Z>WTKL7G\W
M#@W)GV*$M5[QBX2CU77L:N_.8C)4^VLNR8CL;Y26HJ4GJM*505%7OB\QJ\:2
M*3RSI.*4;G;\3/.S#-^1!1(E6)<#YNU/.-/JCQ%K;++Q'(ZPT[&K4T2A(2NG
M )I1= CDXU?$RLJ.O?NTM9EZ4\_Q(.-/REXU<+I$>+@?/S-M8>EJ=:<6Q#<=
M<Z <:HE( 33B03JH]A#\>=2R!LMJZ-<2VF9_A6X39[IZHHF0(M_<+YK&_3#!
M[BF^W-EESMA>I/=V_L8JY!Q*2P06,GQ=&)/,7)MX*==0ZA8Y4(3S:'LU[?7O
M4&X03,M1:VTIA:6D_, M#' R@_\ =R!Y=&A0(1F<.6^F_IWMO3^VV75$-W=2
M;C<17/F0N ^7873.C_A$%1)'Y.F34-1U-X-KTXX[%+CC<)YSD0M)#:ET4E*@
M/@.YKR$\36OLUNC=32 <JZPJ!13TPV)K%H>@S $NPU-W2W2&5E33C;1##X;6
M$@U#;@*DFBARU(UD;<D1EAX8C[ZQUSI,HD'' BN.TRT[+8O4%L)#4EI4^,CC
M&>ZB0I]">(C.*X@?<4?(BEIA.L$<Q4$BEA!R2HR]R+2NR9?=X*P4MKDN2XYI
MLJ/*<4ZBFV_+6A]VB=NF7338"'1(,ZZ$^0F/,D!TTY[;;JUX);9M\5*-_"BP
M5?3I\Y'G$'-!]@J.$D189*?>M1"]<><8/C$'M.,RN;$!;ULOHAA^2A@NI:39
M%/)3S;N<BGDUIPKJ+<0[3&!FA^P59VV:*-TGFD@FJWD^I'L39+C#EFXQYGR<
MIMY2$.OO\W36"0$MIHHTUBRR0CDHK(F]MFE0N!J48_B9>G*UVIIE#%SDOL,$
M%N-CSZTU2G9(6M"4G57Y)QQ("UD!OUN $$G=PI5__E*.S'_O'?O_ (C;_P O
M4OR7=4?];9^A_P!7XU=%?0?SN[;&@N,O?_T]?ZJZFD_F'OJ>#^2S]T?97+":
M@TK44X?:=)4M'!) ]NWD!N -J:%IAHYOX5!2#0@U!IX@U! X$Z,001PH*$(<
MJ\MG\2[ ,,P_OCG&.6/'[5=;#<H<*_3K9<X*I;MNNEV@1;G??D+A"?A3$1F7
M+B%-H6M3J OE"BE(&N$3[?MFS]5W-MM4TUKY4C'#3(K0^5OF&/2X.PU%0,@,
M#PKZ?>D>[[OU;Z2[;N/438YKM[9H0XL35#;R&)DA1/'I: XA-2:@%)JG!WMQ
MV0O3LMF3B\F+&*PE]=EOS\F+'>ZB!\<"\LW!]O85Y4.5X#FIOK?K7?.K+-S"
MRX:]R8>9& 2$_4PM!Y*6^RH]RV/IV=L@\DAHST/) *_I<'$<\'=BTLK)Z3\0
MQI]G-NVV=]S\<?7TU-2L=6UDL,+82MQ3-TM+#*'X[9;:)//1H)4!\7 [AL_6
MVX[B/D=XM[61"?B!8>]KCG[,2ARKEN_]+[?8/-SMTMRS4!D0\=Q"8#ZJ=G,Y
MV-Y#AMV[8YG>Q->OEGE6Y5\DVA-C@W1V7"?B)1<8JB+9#E/L,E%6%)0M7]!!
M)UTWIZ*1LC;V!NE@=\*ZDQ7 YD=X/MKCG4CHRQ]M.=6II"HBJ.(R!X8)50WI
MWRVX]M\ZO';.]%$2]8K=)^,7-B45(DK<L[JHT9=5.5*+A!2P^E5.127*BNVN
MV3,$]NR^AQ#FC#AWG+\>>5<&MI#;S.L?AFC>0<R<, 1WM0X89U/:3FC+WSI6
ML)0!\*4/12Y$6&V4!J6E+(4Y#6XSSGF;*"":*T6JJ(VX!<<U/=VKG^%,O$D&
M)*@X=_/]E<=G*(ZDD//%*U%X!UM4Q1;0ZXXM"W'&$-E<4/R2E*_Q6PF@)&LS
M$Y7:>/V=]:[=-4E/B6E1:;N5LNK1*"XR0Y*=C) >=8<"UJ=,8R)2TCF<H0E*
MTN)4K@-]9 (<@<.?TQK$.5<<*=^!W)??9:9E2>=!B_*H=<BQ9)$=;05$?>2E
MI4AMP%205\JB/-7BAC#G$ %1[JB\Q"BX+2<OW<):[D5?EZ$EAEMMJ0$,.(>5
M5#<:565":62AMVM14A/W2=2Q1*NK  #/B>&1Y4PN!*'!#6[90Y?41UWDM28Z
MD-2&XA<8*@VM:!)6VIY"FPZV72X$)"![174I!:08VJWW\\47ZJCU-<H)*+],
M<DKH9-^Z<3-^USMN:A!V; R2V2%(<Y%R'6[1%FL.OQ2RZRJ0I5F"$N %"SLH
M#2 OT.#@= RQ4'L'+M![@:C>5<&-32Y>'#N3L^NN[D;%IE6N1&2^IYAR2W\Q
M!<"(@1\R TOEZ$9R(RX\F4[RJYB%)"J5X!(_!('D!K^?%.>>.'#//G39&AP:
M7# 9\"E1K>Q]IR F&(C-M5&7S1U+$EM"Y2%*<>;:D/RW&4N/1G%D ?'5/,%<
M*9+6 ",W!5'V8</?BO#A2T-D#I, P NP*G2%P.'L)'L6NG:%/0O[,5*1R*+D
M=X+FAQY"4-E:S(;8C6YQ2.L>:J0JGQ#91)8]H(>7%':B$1,3GF2G#@F6=2L&
MLAWA3#+$#),#FB\SQIP;9?5I;4W\PH 2$]1*76&GPI@LI<4M,M8<>>00 'PK
MF4H %5#M6ECC,FIH*!O:<\@F2]G+'$U8CF<]@,AQR 7$\SAP'/A@,*4J+G&'
M5=25E1<:)?CNP%.\J.BH&2MEE);04 %+D<K1SIY5 *(.HW*07D(%'WA.WZ\J
ME)0X_$AKC76[K3%EE+ZQ+3.9Z?3ESE1G2XAOF*GOE$24'K=-0*D(6HJ4 :TJ
MQ J@!%'T7MIP!TJ5Q'L]WWTS<B^X;<[Y!M6;R;K^[<N1.CWE%L<D)DR@0RE4
M=J2MWJ-1'BA2"M 4ZI)%"D_$.5^K?65WTOT^R+; T[M=.+6D_P#=M&+W@!%<
M%:&+@"5*HAZ'Z<]*VG4N\.;N#G"PMV!ST!\;B@:Q> *$N(Q0$!,ZD!?,MR3N
MW%A]O>QEK1A&"0T-V^\Y_.B._DELBM-!M-ML-M08SM\N:64TZ3"TMM$?C/-[
M$^*#JFD=+=J5))'YG$\S]]>KVQQ[="'0Z73!H#4"-8!@.]. ILYMCP'TY746
M;L;9,F[M]_>X7);[G.E0K5>\SS%YE:GH\!@K;C6W',5MKRNH(S7R\)JO5DN.
M.?BZ7S)[^5EL'-CM(^&3&\R?U.[<^ PJ:Q9'M\<V[WK727,K2AQ\QP&.AB)I
M:,](0<7*<:V.SEH[EQ^XM\S+N%!O.;=X('/;9.+0YL>W=N>TJ9/3=E6:^9I=
M7$VR\YC)C$,K;MD>2Q"2I3;163UC[(]+N@=DV/:XNH#*RZO+F(Z96%6AIP(C
M**3^LE,1I0(5\K^H_7&\[]N#MIFBDM+&"11 <#J;D9."I\("YJI-3FBISV[1
MFYCEN[<6%<Q++8MCDK+;XJ,S)DLFBIZEV/\ %"@@UZ'3H*$_$".LN<UK=*N0
M>S\?9C7+=)+M9'&G7[29CD&*91:+@Y"L@59[U NGSEJD79IT2H3C<]"T1YCT
MA*D]6'3[XV-0*TTRYMXKNWDMG_!(US"/WFD'AVT-<YK@>6/UUZU;9<X]ZMEK
MO4585%O-M@7:*M)^$Q[G$9G,$;< U(&O&,\#K69]M)\<3W,/>TEI^RMR:_6T
M.&1"UM@_%L#0T^C4=.[Z:&009$C_ -D/?\*O49S-5:)TE%9)40>.WB.(^K12
M$+6R#4@T'L-16GNXZ0BFU]'CM3^7244!L?*OV^SV:GB>F/OY]E.:4HT&OO\
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M+:2(<U:Z,]SFDH>S[*D(U<D2P)=PN<,M,IZC<&&2W$;5L4+=+BE2IKR:@(J
MD*^ZCFU;3C6JZN9K1N%N=OZ>=<1J#&(%),V.%SWD$?"68B2VM@$<"\M)%=VS
MH^VD(4J,JX[6$6"WJ$J'9HTJY()4W<KDRW-?972G.R'@&HU#O^&E!IXZ6FZ3
M2:NF!6*XL2I'<!4'*F7%AXQ\C;1(L4-#95T6H=BYD6M*4<WWW0ZZX>*O#2TA
M 3'*H^S>T7;?*[M+8PS$L0M,!I13<;OC..6N#SR*D*C?.1XB++%4G?G2EN;)
M' MH^]I'2:!B34D=N^;X1X>?T^ZECCOIR[7V/E=>L3-TD\W.M4D*0THJ YD+
M*%_-/-*/%"W.D?\ 5@;:@=.XY8"K\=E&U"_Q'ZJ>Z!"A6J&S;[9#B6Z!' 2Q
M"@QF(D1D 4'3CQVVV4&G$@5/CJ$E<3G5P -"-P%=!+M./#?8>&XX?1I$7.E6
MDWFV1-8SB-^OSBN1-OM[SB5$T(<4.F@U\""JH]VJE]/\K:OGY#[:VCHO97=0
M]4V6T@*V28%PYAOB3VD 'L-4>XI?Y.?95E>33'%/NS+I)Z9*BKE:0XI#3:?$
M(2E( UP"*X=N.Z37$AU*\CV5]6-YVN'I?8['9X&AK&0M)[R%)^NNMD^)&:ER
MJ"JM3PW%:^&YV.B\M'.RR3.J>S;Z+=P(.-,%>NV(D.J28_,%'^K7Q]HU@);!
MRIPKI^W]8F)@(<A%<5KLFP_12XB!4;_#Q^BA.D9MCR/$,*R#_426/!KS[ZU+
MEV*@EAP?*@'E_HBA]GA]NB3:_"N9J>S]2KD2#Q\:BIW([12[4B0N*TL@)<H.
M4UIRF@J* @:UO<K-\;7)R-=OZ-Z[@O98VS$*7-^VI28;F-LMS]C^<3&DR;7:
M;5#*Y,:+(=83'@QVE-MN/-J6@)4@[ [:]\=,VR=,[> T &Q@) R)\IF)%?G$
M]5KCS?57J65NDG_F'<4*8I\Y,B&DQ+REFRY'?[D;B7XN1W826&&&D,NVX);Y
M2'FTO%2FU>%$@^S6UW\OGP0QAJ&)I'?VUSFQ@,$\TA<$D<N65<J;W!B*4^I*
MRM2%*H>9/Q;[^)4/+?6J7EN9VEB9U>MYO+D+G.R.'XTZ';O/.A:9$[J\J94A
MP-!2DFJ64I;)YJT)4M)]U-/VVPCMXB2NISOLIUU=EY &24Y,/N$CE4ZI[XEJ
MY04FI^'B?;].LNV$CX<JIB0KB,:YJ\Y$J8MTN[!9%:@UH:5(J::?Y)3MIGF.
MS%*.X9^ANV(2ESF*D[BHI]T[DUTUL3U0X 4XRE *XM\S=%QM$)I3I^(H2L [
MLA/!2-]C7AI6PG4O"F/D4 #"D2K*W.@8;K]7&EFJN>A4A0^$CQWV.I_("ZD\
M-1EX."Y4I(N4E=E0SU!S(/+Q-#0D5'GMXZB,*O[*>'DL &5+OMMDW,_<H"U4
M#T1:TBNWP$$T]HK]NF20:4=P6I(GXEIIX;!<J2HZDJH0OD(KL:< :;\!J-S
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M&<N5"F_%A./[?<TOD^$ED2N\UG(RB6N]M*_=0U-.NJ?./]&C.$>K[=RTQY#
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M,P4>8;GO[12+Y%3EZ?U>2 [SGA@D.A_5"71$-9@^_3G?T2AC@_O)JDV'_B&
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M2B)<&B,'5CEZLJX^?![BH.NSVPJ?*WM(2 @NMSV6S:\UU3$;:SU@OVX\$46
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MI8)3UQ#YP2K32LI,8O9XK!R0 ?P*Z.UZ5X,TJ<UFO:<6,C3""E,*9L4T0O3
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MN%BG:(IZC1H?#E67)2'K]WV.I:A?-\XZ#8[&ZWJE[-:<CIP4Y^&P3:HUD8P
M%Z!@#=3^1:DO2W'+%N0"-U&.%2TAP?JG3USA98I'W3ATL:/?(D]^DS+NV]-M
M-N:4ZB_-QR^QE:$JQU7A_(0;T -NB@'(LF[]K#.Q7MPARBO]Q(/Z0IVU*VR
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M?W&#6_7K_+W_[EQO9 __"U!+ P04    " ";66I64A_I100J  !+,   $
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MW3#&]BL3DS388Z!^*N0XWA+)\E(U3/!EN0QFPG'I!NWR,L18$^+EI4%R]!/
M@^SY&G\F"=QB@7(Z5LVZ#Y/&O[CB N&G#$Z63J K9ZCM35SE5W3D5Y7ROKBT
M/(#]<TTS?BTXPG4R8)A' RT906!K;T%ZF49G<J93P<23\2PX?PSR#<Q&/@0E
MDB"'M5[K65>+>PM_@D;$[O9)\7ZQ=+[\DOI.S4;7*L?J<7QE,F13N".:E4O5
MD,?6TB<UDXERZE%  ?4WS9><8RDG3'AEB(D^@V9%O.,7KX&0/)N9 HZV%=>O
MX$*73!A5?F&DJ_UB*)-Q)@IQO,ENG=KH5#%658S/A6YP'.&9U*O?[]_;S..+
M;NOHH=6I?BRM2L4W6+8D_1#X<"DHIT(,15;T!"BTYM_%Z644Y/_(AT]+E!OT
M3EX_>DS"H6Q5>57Y%*1@3,S/3GF6:3MF*:_$%$=$].YX=[\JC8ZFVGF4]P,S
M&BR9G_]')8^VI6(WE45X./)"V/(E6BRZ;U6($0(MT(1 =K\DWB:9S_]8)',W
M$+9U2\ZW<>ER.1U=8LY&/K,B'^.@7^O4739)(D(OOP-4TL,F+<'KDSOL]YB*
MIO) PU5%"&]_F@V/.4I)RX0-"^.8XB@-)LVMP$U.S1(7FBR3D.8S,4VZ8XCF
M(VW,T5 VA8T=9]4B?0<8%;*L;")\ +9J+K_B:N_CYD+F-Z,)27+)Y/@4-M]H
MVR'UR&QQ7.$U]QNH>Z3XL6%HSMF".CO::=.[24\IW=TFD^LX"C2VZ!6<\Q8X
M/(KJ<&,#/YQAV_0AF0 ?C'>;&W0Q=R[&ORW N@^O>CLZ!%2=@AIL<&WF)!J4
M=S)E0UP1BEF:A8BFBING,Y9])E:@PG+61(0B*3H:>5C&:VSZYO5@-M08G^[J
M?8$MB HF;Q&NRYFR5J\*27LG=?./5XC@BB6]1/B-;/;GEK%%[D/G$\^0]23?
MUYWZK\MI]>W+!"5'^L"RDFWZ"$X#W[8$[L%Y<+V.K;'8156C1")!MVR0=+;(
M;C]"6,G$4@?I4=L5'J$ 8M2!?=CD -&&YA^B2 X0O17H>E.&J&ZC=)K(@)22
MZ%&V,$%\6X@QES*Z)XQ)^P=C.TOQD!A-<5#&L>D?C-+H-J/W\B(X$P_*%:?,
MN&3V'W'8OG^<%O^VO"< ?X:@:X:;>*=3J35@4J.A.SN$77DK]M.L@8%&9:/1
M3)ENNUFUX/N% KU*TB'56=^?@#"0!=*+<DJ3SKP-V:$X&CI@%QD>J:X K>UJ
MNSW8F9=)G/HO5T>1OJV(2M#S>!R+_?F[I9U S[FS.'V#"NO3GE-P1QT+B-EV
M(&2UTJ0F2XK"%_#/]S$?PVF/G"?@VUIG P0=+G(XW@#-51?]!&PDYN:'Y;NS
MY^8BD[B1;WR@1[';X&G#X8II]Z)MX 9XDU,-Y?,C"ZP[TA01D7HM.N8JOSTD
MZJ]Q<HZ7:5,PE;]_T[Q[D,;__^V-<<>*,@OP'/_.<2^O &F3QC)N8R[. NK[
MCC!#MOFR]E9;Z>H*V"WGF/K'R;N'K:%.*)+A8 ,#:.JVQ/BAO\?2SL(I5(GD
M0_C8 >^WQ)+PF\THGTX.[K!V,C*R8O5.(4U-".G^M[CHK/1IBKX.2L6I#@U9
M''Y%GWYG#WL%->V 2DV#U1);(R0R)#?79=>&:AO?_W%S49K$7/M)\F'&\K>^
M>;-Y_L@_^R-.>"KF4W%<1"8]^K*F@R[EZ#H<-F&-8=LB:S*S_2<TAVPG&4V#
MG?O)%Y.[YI=JYX,> K[!+WO\'84#]P5C"XKU;>)FJ#]N#!;3,4"1B;[W;7W&
M@X90N$M(.8ZYXS%P5:H#ZFFSB/L)'JM(VS)<!PU3$\L)$JF77T@9L"E.']&^
M6GXVFQQ,AM-JOONMR-#8BS%-;R9_WP0J1@(Y=QTMOL3!_ GHB/T)."%PN8KW
MTYB:T3AJ\%C)N&D]N3F9,RU8_@D0>GJ.4^KX] JN\1/P?.)I-^S$?>2:A^;<
MVK_4[_^U""Z?-',Z[T^ =\.!=L<]QUO04=QM.XM^V7K]8^^_1E86%7@/NS7N
M^JR/5Q:G[OI<4XY7'NUZ8LF6=%'[>_I9&"B<1+ERU.FB]11S#0O&G>GQI\?G
M I/-">77S$-FPO/$Y2X<?+0@1;[B<Q7<2,-2F5>J&J&L?4_G2@!+:1\90U,7
MBLV""=L?:?K)10"S=KK%N.JNF)_-NS[\OJ.F45G4B$7XC*!.3#'+T%%FSK![
M?#3<UAQ%(K3GN+ZR6%,0NPDI9EXZJ&F-]E*_@Z"*C*HYKTO'Z]:RR#K;#7H2
M:(."LJCL/GJRL*8,@MTC80NG^#CX(T4ND?!#^<JV2(3VZ[]M66D8>D#P?)%;
M);!T @%=U\>U6-(BBQ WBZZ]8U_5IHD?J$01($<1ANBQK.S,F'@VC)05;(H]
M0IFC:%N#O97BXJHP>T0NC<ZA>-ME0\;FP_5<;2HIB;A"5A4A=2L.,>R0':DE
MFUW*KXIW-HL9>64(9F:>+%*+W0S=1S 8_P1@-_8X\]X/W6<^#[X<6Z"N3L+^
M(!!2RZ9\_QQ<.$3:W0$K?.8$9:\-B29GK-PF0NOL+=OGQ%?5]3/M?**-MD6X
MOV'08*#\K!T:WW@?ETM527A"%@V.9F9E:RS-+9=U@1&3WDL<[=$K*& 8\"R
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M>.#%9N9[SR N0QOY>&8XIXJEFL=Y4119PHFIJA @KA'.Y3X/@A)BSM9IY!(
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MQF[F 7@B]D9@ $!"XAG@+N!7NMD"8 K;@(P= '  1%A>#U8TCXA@:&UMP<W
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M'Z\]N$(YNU@GKGXV^RKYVC1 M^1Q7B</_?H),3S;9KSU]0W@%>]H[<&I%KI
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M3COQD'RU/YW3J]L&33K.+M\%MU7_T..#"ZKT\F:U2[/[G);+8/ELD>6O+0J
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M8<;D+3/*D/>3WZPE N,IJ9@^$A7U<X?%,[5GOPE03GIS^P\MY7]L[UG/8*Z
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M-1"!1[@[]]V'(L0/3D@XF .6PW/NQ:6E*7=MHKTRAJ>/>CZB_?3R_=R'ZFK
MB#M;,JHA@MJ_14@'-;.=5440@8$QR,-\"2\@I*=<A<QX.Z'1R^]T+;WC%:&E
MZ<9:22 "781%FF%\R4"O;E%F)&X9D^C<KJ),4:NG[8\)X\, -&T=H#[^GL-7
MI,P=[X4$F+PP+IC%U>KYY9 .:N*(CY#>%",X'SBF^[5#IZ>X[.S0-*>;H^TL
MEO\KF1E8IG!Y>HL+!%64D1_MW#AF(QUX@->5SB14%-"%^PRTIW\EY-.Z!8T-
M3>*SSKE;F=F F ]'IU/$Z82PF*83QKS3_J:@2,'1\2)]UB>$[XO*9SFO]L5W
M_NK<D$4S3:\NC11+J(K3XF[<>P!]0B7>%](X MS]E5<1?I#-Q8^S$8_UXUDE
MM4HU<BX$ C,O9J21Y!5)'9R])FVN'E[S+-4W4[(D6A_FZ@\/]05MX2IG+F:1
M?)T2KV9+F.^7V[H!H.J&\8':1-)N (K[JG'&UV4JR-))L?7=M&;]G\E#916R
MPM667-<#R@&TV>U!T.A<'KHEN"IM)!PL;]%H\#U/-L+55Q9BWOI1WF#UU*7.
ME[;BZ>/ :#T_S3#J_Q"YEK2.,O"L+^@EAU,=;HA+#RZ:%3K!LK9^D&K4H6?%
M=D@@_]/@5LP[#+S7Y(,6P/Q+168+E-Y^[F"2ZT+5Z$L6MV9MH>SFOCY0*YRM
M!/<VTU/ATN>JI$"]1UTS54)+D6%TB<D3@H50C[#,'FDNXC,'V@X[W(B>H+TJ
M2M7 !Y_,(G96J=K:NYBH!Z9,NJ #JB-?KZAZ37)<J'K-/VEBQT**^("MC9^:
M_+ $ CMZJCO70L $Y5.RV2"<5CWYE7K>4%!#0-?Z)JX O<8C]0%C8C]'0FI"
M8O&3B>9@TRGCAQFLSK8L#!)0WL<:T>E ?;9P6:RABB[KX\Y5RD642)^./1;]
MOO;4;G^?2S:'6!X)^YPTVDZF5:$:LG<EN[P7"..[#BMBIF_%%G)VBFJ0.]Z\
M).3R@2)-A0:#DR5%NL:6<M6%X<A)GG*;KF@I6=88[]:&QCI6H:"FWV/!).5Y
M:-G*."*$=-0:0XHP&P&2#C99HEN997@X6:$W=I12++ZD?&!0-/:>JIBL(R&B
M-+JMTNMQ.0//,PWN&C-)]42[3RAE',%+%"/'^^[)DS7LR1 /Z8[[EN,)9H6J
M%P_J M((Q,IE[% C@>-.P8CC"FEO*,W]WPXN9X*+QHV&@(()Q?=7]VO>0[8R
MB+O$]-Q[V,"R+W2WDHVD@CBH^,VEJ1M;@<M"44 &4IPP1N2VK@YYN>/E66??
M:)U,K:2>%!EZZ0[U99'/W^*1;@!]@8'!815+&#QW"AE3$=M/#9B#-/K8K#B_
M]BPJLP3^OR-3ZQDP.$<.#--[4Z+9_30FJ*W^GY*0M:/NU%'Z8(UJOO\[B:_W
MR(FI;2'L:'E@,UHL7Y.XRMKQ[Y"7&D851BFHAAYJI",^;/\L(8-*_#6^[6$I
MT:?B\0&DTN=Y&,;"C_\A\?;L7HZ>0XMV.,L>VH<I?W,2:Q^<1U,13FE6GQ+Q
M2I[C3#YD6AJ;MU5;VY=;X61-,XIN  (*N*@?=V^+ SHYNMK8_3J =W2+/[.!
M!BV;2UZ(546EDY.D'V#2J<@(=S,7#<YUY3LJ]$XSR>[8OJ:+,@DK8.XK>&+M
MS=3^<::=DC[VW=G)+.BU4,_D$P8!S%$;% ?<$&$?OL&]UUG4[B#UVG)\W%C1
M+XZ=[;(R()*U8C6Z4?A$))$,BM2N%YUB\?$1@487::!OU4+ X$</F)_> %29
MT51)AWL\0:J1@:Z>TB6&Z;M+>E,=V\6.46HHJQY/D3O"<!A/, 0EX52>>I!/
MO6'QLC?,HL=B#%;I_2(OC$S^2/U#"<&3O='%%FUBGCZ!$"(BLLU2(<W4+\B*
MV2TXK338E$X@82R3!'=L5"?;LSGO5O&N,5FO(-<9MJ*4%@K)#:Q,D1G6.HD
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MX;O^I)SYJ4ON[VD-[4FN._L%,JV'L'0-Q4"IL[IOZ,>7Z]1O !HLF95?I(3
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MW[<M42#XH7]BEDX:VHY?/U9SW3395&[FZNT:GCOEK$SV0VD3W82/8?(YS0]
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M17&(D6< HO*L^LW(V6DM$>(B8MIK_&SFZ^(Z \F9F.?>&CR+>9=3-4#>0\3
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M]1[0TOWZI-%![O_\I[#Z[S9<*6)X)">]Q(CFWC/,A4Z5D6"T[;R_VD__3[Z
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M%ZRG>Z@;'.% )9BEV.7(*Z(7';:.^-:53&CU7HW"&7(5QPJW6J3L[TR.%W>
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MZ'-HB6(\;PJ@DF!MK 1B7F@ >0$T?WL!H,8.\;KSQ0EE$(TL9(V+A4&H%AM
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M#+YTT<>P[H1H4=ZY$+]\8ISGP32#@%08<JD13OE?;6//"X"9_H:P_6:=#W;
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MX9!:=8 1G._32_O7B.P :X837 9^N?B89UW4K.VLY 0&1*C8=/H6:9R#42^
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M86K__6"[72":(E>VDE5D)Q>7QD9QN\2XD;7=WD[3UY-JGF>^\HU.[V>=I!>
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M"C4Y/!C*34,_'6Y3>36RHV>YP'O8P80QJLY(?/F*+K1W-0;84?0,+[A"^T8
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M,:4XO.'TA%O$(,ZBBX6;OSG],5/BY[C&4H<LQ?((B[%SP#E JTJ]3KCI]_"
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M::<4"W6Z3%3\2E#/K:I*O[68>]T)K9MQ!SLRT-<<U]&'@KM)(A9\L2]*T2G
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MF?Y(:A)2%S=]Q*>>OSJ@AW#K7"]*5=61HD7-2"D$/>FGIT3D?:&.0TC&/>>
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M7=PSGF9SZTD,OX0@T&9W(GLZU48<$;M>&3$:_2%%J*^H*8^0/HC9^@I=;OY
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MAGG3.+/Z<&>YG,.;$V9[';</'9Z(+9'U*^#JI0K<VTNF[N?:CW&+":F7PL#
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M50"-S!@R<@>W3G@Y8PUQ!Z3-#:;5CTLJW>XN\C><F]@/3(!Q%ERV6+DM_J;
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MJ@V-&OV/?7BZ<5;^UKS7/&V7]H,DYPH5QS;KE[L QV,/CVWR:K(*"T8 \1,
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M*67Y-:.:]_.&3OCXJ-$R]*B="[N"98JHXP^[]I9ETT5F0;MP/EVA.ZO1(=M
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M:]=X]Q'#*+:25Q0I 59[C?[[HQ]ET@NWZ!-P^M3WKBLBO7$#/(&[*'9GQYE
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M=J)Z$D0Q6=K5YXF(971L(=-VS-@M%I7_;5]T_YGA\G<2!\D]L4]G(*X">/8
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M<QW:E_JKS1:5L9UK((^CDR$^49*'#E630I"C+;(ZD.5PI*\\0PI6$U.QHB-
MT()Y\G7G +S*A&24EO,C7,8]0R9!<[J2'%Z_4-\DC+XG:_?<#KRNUY+=S+2'
M?_=L]AO)CYV.K\Y]!<#PKHMP)O:X3/B<$%?.>XBK$1SB39_3?C_/SDT/,W&1
M+:?VVGRJRT]&NJKQ=]G5E2PCOE/+V@2PKL.S"G3$UHW'8NC]I7?[?[<!15[]
M\$[GQJUM9^PM;N/M<!%4RT/$"(G]X?6#K\J3JY^3V.W_=1O_2PUP;X*T&!^*
MT5R_G.(EDS)L?[,R1[L'N^[&UZ]]%)5A&#9\,\1+*=LX@W9Y$V.6?T\;.PY
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MJ!B3IXQS7?@K(!E<*LQRI3=JY,!<)4N0-_;\&^U*7@]/54;><#I?;&:X/%Z
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MVV>"BR$EMY$O"K1R5K1RUI]BDK['),7$/+T6K#)H9!"+65)90^:C<.'IYZH
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M3[[ GXY%MYP^"$B8ENH1:O#+FM%O\VT(7^LV_1VPD]*0$G(OX"=*K/WCFP%
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MIT(3QVB18*0Z2D0DX&T^1T Q_,SZ$B99W IW"E!3G=+TR&$(1[2$UV55Z1Y
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MC,/=PXKTXI@>T3ZK_G>#3Y4^"\,CF<__<?87:CE1.$:H&U!V5I*E[NFXQOW
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M@&@3E&\"7]>\*-:=$R9AU[C:V6D:W.R/G"D@8*@/:%$<NB%!^1$8H[JPOH5
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MLR[@'BQZ[<+WBI<P:-'=TZ]_QH7.171^@N/Z[9J<=G@ C)!=&C\^^X=*,@.
MP3C%J."X6$3 (7^-%'/#VV,5&?U:(<[*CXK9.&I]]SEUKW< ?AO@:Y3+ Q:@
MZ8GMXK9_&VAK+8TQ:QF,[U'<(RI/%%;P6Y9^& H&XB%KB-./'RI$JJTXQ3A*
M5Z#<8WP%R[0^P[^OQ^*?WI00%-A@;-ZEB.4Q[[^)"0PWV<,OOKU" .E,ROH1
M3@<I;BXG5VPCWTM$*% JEFY;/.!L-V?0>A=&FFR P\Q(9W/LL,E)3'<5+HRS
M(P6)")B/@\NZ:06"HE_[#8)XC$I\Q<J1FT#7OGAY9S$%5[%&JCLO.1O(*U7*
MDG89V;=..JL=?$8)8J.4QCWWX%^TI#?ELX[1GM/!3A\%KL-0&6XDECJ("?T&
M6IZ!" 3"M=G-EU+:ZJX0D '5-D,T/1_A#6[!R5H?'*>Q)OIQVR%O $M/1-^U
M= 27*AXT!WS<75#Y%)A+>Z<O3BW/SA:ODIZ432_)MN=4#&@LOZC7Q35;$8!&
M%YM^%\4<23Z+AKS1,7X V&)[P&^UL< BWR6S$WJXA  A@>&1#.7@DFI,D5H]
M ]01,)U9E7X$Q=@-R7)9UZ&8Q0@P;Y<)<J:EQ:Z"Y(+[>>1C&\<* 7M9IZ4"
MOQ/\MED8C<<=98Z02[,0@AFS%#2HS$II'2'2I^8'$ P@/CH#JK*T-45.[CO.
M'KVQX>4OIQ1=ZNK"V%)@(&@O;'MKO4]U#%MP.?3..%P!2I3,D7"J<6#=/Z8\
MO9N=724#C<,!E*$) F(S*ST5/Y&E#(VP]]%1$1&.<5(<9X[RZ9E,<FBNM<"5
MI3/Z"CS8#6 +9<,X\W>??,DH ?.H-NG!_#BB*O6!V9J#SY]#66X@K'&=1R#G
M9/NND5U11Y(+-G_L?QB*4*E?"ANN9=N1#4BDCIVX(.01120'8Z3*P0-7N5\1
M63<T!WFR\X>&3T'X&!:4AT.H6(]G=T07Z"U'ET"%,TVAKVT>L.HD3DLQY.VV
M5&/:OH$R,B\I"<\&/B9LZ[Y] ^I.C4U_7F1"^')/.*Z/A'X=> ,OX9M7MQ8_
MP*),TB  SNNHK]AV+]/31W%PW<2&:?O%8SHP++67M&,)$];.>-(C!%'10)EF
MQG9/SXXUI Y._3'!&^,V._\D_)TT%#:1'E;(\!^K3JXUDDFB]S\@%?I 464U
MFZ*C&F8\,LL72WZ"9$2P(S5493>D3& &;Q1 OT7[,W?NP Z"%:+PUXM*HZ;&
M*^]WNB^FD]E@,NF(-7Q 38.)+I$YB:RD&H9AI3<)AR13FVZ6U*#>=IT-$QV'
M1_YX$T;"W7D_"?W37!:ND[+X%LO(=>58"TJW87Z+P9Y9#&[W#9A7 YTG38+
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M# 73?:5E'M$F1QP85]6T<)"E/APQ3 M ;@LRYO;@>@M6TJ1<CQ>\*\1;EPB
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MB.V*B/) !?2X:6L9S@%06#5].E7[!)=0^UKFZYN-A (O]I F2B1]VG_6(F!
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MBTQLJWN+BEB2\U^@PAO!"4W3%76)1"$L@]<6Z]+$9,L,Z\)P3GKWD)&!W'C
M@:2)?@_A^@;XV@%N/^J- L:5L;L R)KWJSTR1,%9(K-C \MX'^N1"O0CNH,T
M69I#FTOY"E?[<U5E]PTH<T'^7549GTO:@;:1>Z\K\;J8DTSJ-H>^6T8201I!
M?7-2(?C5"0"BKKD,FV/^7^9_=[R%X_,X!@C$@V+9AP"@@ZBEU:IA11_7W0QT
M1B(F25*Y06 W0@JV7+B)6?;YN1?1/7Q:D#;=[F^ BOJ5#V+UA&:6.1KB+7FL
MYUM]4=700D3L,";,SZ28F-E\=9YBMXA\R=H7=WH>&K0*KWWZ;*<V% \K;(J1
M;\!#9 D0*F1V^%Q>W[_:%_P3@ATR0%_)"':RBQ+ YMO8/TS_#5^2>&1$&!I*
MW;9KU_99:E,4L#!.D%%MK4R8'%3LJ-.]DB-$^@;;_G+CGTN<'93HL3#CJ_A+
MGT:\N%:1AJ<Q5_YU^-%-HK5W$QZ"G_\)TDQCLC:@#4K6'_@#F7S7<OM+!/0R
M-Q#0[;^'KK\9#%W.6L7-Z&\$*Q9G7401P;SJ(/C4.#2&Y\ZRMY]V;4Z/\T*5
M\9_:G7](]YDA0@QK,J)ECGDJJ7&E"X-/M]"B90U+&@BUG_.M!E'71 U/C)BC
M.S(;2*5L +DW,I>$^=^$F+TH1Y+2;TA8B-KP#:*=_!QFTUGL/]>;_A7@&#5!
M'#%.3(BAIGK#W0>6K$DRQOT;UT#F)IA8*ZNHU?(VQ [*:5=88#2B+S[BJ?B<
MR.(!:R^%1,I!:F#C"1NM?%+ P;2*&FQH*":>$$.7_X,6V#F"]%D-X,O18P8G
MC?#<( 'C.N@FL!? AX*$ ,QQ]*@6Q2V_<ZATQ60(DK:YJ"SQ9161J$EZ"D01
M*1 .4<+ O5N*=%TP" MO*E!$H7]61%B7PFE  "+AT^2UY34K$\EL79=!#.XC
M>(Q&Z3S!JQ;B 76!S*AW4LB:ST6!F'IL1C5] 8)N6?:B\$;M0T8_^_&A&5@Z
M4 U/X#'/ ]A[2 ,A"?]E(9+](TP1N(JT)FG:#6;7.^$"SL/W$ZEC?B+P4W^;
M'B3ED/#&&C #?J):ZC6S1C,-%_='V5[9/(AK*M*-_U7N9)=JZ_TW3YYWF=--
M\K7/GYS9'N7VYXE_K^1";P>WY/"[>;U@N(E.O2>)F_. DQQ3&,<\B;7+#S21
MZ%88],QRU;Y0DI(R=0?'P$$!O?,3,JC280#EU)!?L*AP83?XW]W6OU?J;U4]
ME=KGLD3+D(*\SG[Q6(O"K!&CE^NU"PPL4M.M,GTWS_!IFNI9/];_><_0ZI&V
MR3MYE6OZ-,O\'Q7Z#.#[$!INQP@A3% N3_Z3;OI/PHG^S\-GLX^M71W9>JH$
M'%'H>/2CH[?Z"%LO"Z!FU =WNV4."[0^^)/1W'_S,\E@/G$]F.H<D'0/6-&8
MA2NW-,]>>AC&5G$X,,<36EDT1[+X]0EHB&=6#L [8W*".3N+?2Y432)GRLD"
MLI1L]#9:#SGDU _P__ MII!>888^0 >]C204+T=2Y:7"*1#+5]$^Y+_Q\I;!
M=2U+FN@6;S$S,Y/%S,RRF,EB)HN9+69F9K286;*D+69FM)AES;D#$=/=Y[[W
MYMWICLB(+S._JJSZL=:*REJ510&+7E!"7'E'N.\($$UF_]7S7<.XL1M7&9$R
M\PGPW!QULS8/'6PI=Z[^#C;8JM$_<,]I/"9G1EB>(,1+85:1+\JA67=/LT9&
M7,_;&]Z%>;3'*I8Q@E\3$\1:VO@U:S9!7!34?&.0I#GGANY>\ D )Z.Z/$-7
MIM>_@LHN\EY)1A)SH7;QRGGK->G# V"Z*I0(6AD2+9AZHG*J-NV/X!B'_4?!
M P;$H*EP2SGQ<[XSZ5)";8NE:BS]F2" :%AUKWR)W&]-G%>T+L/O_P/XN]Y_
MR2P'32R0)$;9[1HY"$RPT40N3Q\1H-+Z"8BP"6HO7GH%3W'"I$\6D:DLQD+&
M!N6=$@7Q%Y%,8!QY?SMUH&ELD+HNIB-&<93"HH0?21P7[D$4;!K9$X-.<NQ0
MC[AE^ VC0/0])IBNX>5(:F55U)ZQ!KU%(J1OR>SWC/YC2/."%'D<V.CE$UA0
M4H4T-;1H2GHB[>ZB-XA)]-<<LB3CE$VM0+_4:#D*!B++5Q;M8%!WTO9/JT&"
M2/Q)[2!I+LYCN9Q!G;%=IX/\,E3A"#2>/O0(T$UJ<+"\\# _K<N=!*][A%H)
MB;:YRD=V>:G$I/@6H43$EW"NGK*6.B?(EH%4J^(STE * A?UV.G*7)*:9O9H
M]F\YZ9UB<H'%^8Z=@1Z-K%G*['S#?^*.6"/A$W6Z@&VGO_"BWE2=-F GD-%1
M?,AP#UB@XNTW+9]Y>]Q!>G"OR@Y$.C\HN1A7[T,RNNPVS.Q[:.28I:A6FUY,
M:P,<L".50^&,4;[@F=QXD: [SY$H1\O+*4AEG4UKC9P-(,R+P@?6B+8?="*Q
MRZ)*6\N<X+?'IKZ&TAB55Q?(1V%0YB6E\N./Z&."Y\-(C*8 +@ZO$\@[I.ZN
MF,JP/@%E+T7QQO",;! 0"SS:MN-7QD^4V20& ,L"__.!_ @GELV:Y !3^<Q1
MX)HDV=2UC-PX$5U_/[Q:A8Y$3+$2#Z/.BO5I-K<H^PBECKQ1^I?F?$W,^#UP
M"9)&<C062\&DLWQT3SVU B23-LW;-XUYJRZ;Q-#[5AAK<=1 ^9>7Y!,=N.RA
M^2)/ULO1:Q.G0E[AMFF63#BX(+4")50Q<OPPD:($?JV*L%]+B%I%1BIR^:5=
MV2WBVNFSHXS;5.F^!=*>E 29CL!3\,/'8#(6\4JJA=4^OOYVA!)&ALVE\LJ6
MK!C7U*TM>^APRPXE?#;T$PN4WGN'BUC&V[326CW>W66D-K?!6D+'\_#_G\;D
M;X;F@]C1.#R?H4>,>_H*YW\]Y#^,W)+[XTX,B60(33-7ESPX;3F&<UCME5X8
M!8PZ&+^.WZ^HWJFBZ,U;TPCR[6":N(7183OO)+%#LIGV(]2_Y$N2&Z>;NBY?
M,:"T\#4#KOZL!:I!I(!\_47R,W8JA<]J@]$M$74@4_38SP.$=E"Q4Q84J <!
M#0GQP#R:LLW^X CB&8Y;;^BMBD+)+D6<E45IJ>U<:%:O#K7!FH:;OG"T?I2#
MC9]^,/H#+)X<W-H:B<5CXP2_L"+Z$=24:]0A).'-LMTCVH#&68038:6]I/4J
M<UK@T&VE68P2]"-O(Q':UHJ$(@G>JY-W5GU+F;AB>G)JBA70,LN)B3WU A3]
M<T7RQ'(/='"Z=KO4C.R4%+:A]%K0"U&Z/H*7]N))["UGG:J-I?UZ,#EU<8R\
M:K#V=) 5_!ZX'&RK*L!->W9PYC8=;D9XJU;H8&-6HP.2>*.Q ?IHH;;Q='"6
MC(E=IB], %="=NA<^V0X".?DQI!FG#O?@":F;$42%J00;M3+$IH3(4CM,2G(
MM@@,7I9?B/F\T7PH9DMBFBNZ3'7E20H,JNJHQ:Q6M.IE?-C?!OSC575(9J@E
M]T\(ZQ^C!QL,8[:*#CN%236TSL$3 2O*]IN[O]0L:4S3%P CT%J08B<V_3&,
M''DVIE):6L:F$F&2I*B%G*U!\R,<0'KA -WA,N[ =(V:&H+GVTRP4?&UZ4)=
M&U,L#[5PD_1N72Z.XM7@FDA"I_&5(9^B5-AD:WT2NVH: 8I235ZLOET_;.G#
MJJS;=3$2:4>'^4HMYO@TM9A@TV5I4Y43"5-R2LV)"ND2\S@RY-!>)=R9+A5"
M"T*O0O4(?#JYLS'<#?@ )$GXX&RR$];2(-<#@OMF[E][/$6'*&.)IVU'RC@,
M1<%W]@&MYZ27&P-BM-/@59QH;MD 7*UT&D7>KV0ER^J^0"R4?3"C)!$T+Y37
M] 3:87S &H$!30.(W$ICC$2.;F\]+2(>$2"K@B#03,OGXJ8OP!#Z2O#^VQ?_
MS$34G;L\SOU#GIB%C/PG4)-A+RB1V(43O-P58:5KA-XMWQTZEK:/M-4.D_-L
M<Z^?6]P"4H1]E2,4V_ T+!V&A1LL).J'". ]V(<@G/^\IHMPBC16\ATP% <D
M*4&P)#VN'G\R52V/GA+;E C:4S8I8DZ-D#Q1)D0.\K3:FH0%N;NV%?J\02L7
MP.9C!X/+$-!:74$18W!:LLY UN.+N^+, WZP<>!)N 3+*7* G_1$T#B0YS!U
M4=B<,>'B-V;4TTC0*X4S<4.<E/)DJ2UCZ/PH.P$\H-"'//L 9I>(*[;AK21\
M809 '@9KO_.[@_N-+O2$ <*D$#NJJ=P=0H5)\&&_R3'5(Y 9V?HSN[7$A%'=
ME5OXJ+3%S9MP.]Q[JGW/N(:U"KA/Y6UEM(TXY7F#Q!"<<HU0P,7Q20=XET[O
MH-"BC.0(=MW<?HE.%O?!/J^>YX-2QC3_]"EU?I6D4J\[^1;-:^VJE,Q(Y+0P
MGYE:;+90!TVB9T&Q"@Z?[+[OW]-> #\()8SI5/@D@19HR?7SA;52_$(JD2,&
MSP3V.KZ*Y&:@.M_#0?TC&86;Y&??>E3PF2>*Y#C<A4N4M<5TI#WN9+Y+BN3E
MY$_Z9;*XG8ZR9&2O(Z;!.EQL**RM1#(H/49AI5*GNE"3[F_T)[R%#Z\C[&4P
M?$;BQ";+2)$Y+YP+NK)XX-\$F#\!7ODVP56BDMX-,V4Z@\AX= Z.6&($W.-
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M+/C:GS5*GW>5E(2)B3Z/[KQRZ@Q.%<E??)A8\F#)4ZY#H"OH)"X6Q!%3JAK
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M^&F2$F7.(NNB5I8+9X=>[P+0B9?\WX_Q*$E!\_F;JTH29G7[PB<(6B]VL&/
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M,PND]L:$4X28FO=U*;$$O\D;E[-@NC%*I_2?I.JU2KK(15G?WHLXZAGQ$![
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M\S8+^1FXM7IK3]@A'190KFKMA+_[M0-+('>:=%J,>Y"'2L8\+LB(QH8)IU.
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M*$S)QG%X4>>?:D1:WEJN+D]L#!UJ".L'FA22+AGE)A4"N7%D"Y3'PAR%XE%
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M!35:W'5Q ]!"S"-^P@MJO>^Y4&1],Q*FU!B"[.9G@#J@!+.!?*B<K-1-IJ.
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MDE>';]#2-:M,6H9ZL$QS^X8"M6VI8/8-K3=ZO6?! %:B\++)C)OBER_N%L]
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ME_YO!^-7>-&=)\!+:2]#XFGJ-I#EY1K,M5!\_MFUG293T-?5%A'.&$;_5\*
M/O>,BJBH*[+>,&EC==MN=(Q0YUVYW@&W"*<K:+1_P3S^U*@1KXDQ;Y)%)(3/
M?"_G&6A_N_VK52W_Z7PS*@-I&<E7E!2#WSXVF';-FZQ6,7?O<WY,W_9$'6 "
M+LL;7DG 6G94;JFN9WRWMX[+&ED2UD=/K[H1X%M$Y:P6/Q]V0<<@G2'F'$W$
M2Z$K"9OE'#[4QCI)H3P2 QU;R_!;@WUMU7U!C2790OI[KM?:+SA&IM$P0VF3
M!Z^H2R\=AN3OW 6Q+Y#D'&;9U0=+[L)2^4IP%/!("-5V@>8HN^2X]))] 85
M'A9@M^3V4@_YE2"XP:O)S1J:3A:^/T07T-CV)GP^NW\\O4AD[;M0@'[SV0[A
MY(4WZF'9Y8G3*^*I P\!\F< _^>,V W(9_.-:=^-)A9)(NMI4/76T /?,Y 1
M)44?]=N=7?GMZPYO_[/*?57_S?%_Q?!O%:S97*X'&*&V1L\;JS2')SA5?J-G
M('^548RPA[?J"?F?I-;Y#5!BJ&,RQ<"1;?6< ([7EU)/4!ODGZ;B^8SJPNDN
M[??]KJ#Q!RG]_NWV4\/LY UVP&?"5,Z[V'N3F0"82WN<[*[IK+(G'LE"DX;7
M8E?B'%N9YV3"?DT-/@%S3O.L+85LLO)>@/1QH8M*+G&F\+Y;ZO"-J],-^G^(
M[I'^]9C<]8!DMI?2 D,7EW>1]N&RQW?_2DC[]TCYA1LW=I\!X#_DH&%M;G1I
M#7[K>;?1_Y3P=)[9)KP=_@SX_A'H@PX' \#BP.$  +;KHLV/11OS/\L_]LJ7
M?X,#AW]'++X%V@&"/1W@'QL\.=K$ZYQP.NE_0\"J+3]0RB#].P=0ZDN.V_WU
MMV+_ X/\^T!  ?[CAB3RNV #_ML;TE6-)"^VSG_% I4FC&%[>5@/O!"'_QL&
M)BLZ#0"P://_WI5B((H4ABT,P1[]Q]\Q0C*.\B< Y0N4OX]GS: R1Q0 L]Y@
M3\K]#;-.#N"E0F 4FVG^=BZ?-+210T2<XXP,KOX;AFL.@&FHA'FEJO7AC2Q#
MUM^02C#_H6?8OP=+- 7<#@^\F9/Y,?87?0__H[>A_\7@8 O_*".R4&)"W2E^
MBP,0C8^?@?_U=ZKPYZ G_BA1#?%"P$'2?W0:]HO;?^9\"/Y3Z"[D=P''B]Q
M^,^:Q?N# ]8?/D' #!Z6-B<)P [[AY*Y_CF'Q">_"_@OP$O:@7:CER(2@)[H
M?V[M&;AZ^H,5SO@/5J7_(![F?V=]!N[^I*BO 0"!.;QTJ@75Y-]X5?Y=O5];
M_$;@_]8&XWK8US#823 4?XBO%_EWR53"OPN4KS$//W[?H.R_3SE"C,"_J?JB
M36/D'ZC_A[;W (MBR<*&>P+#D'-.PY"C9$GJD'/.47(2)(B(BCCD*!E%DF3)
M.8/D#"(Y2T9)$A0)$OSUWKUWW=V[^^WW/?O7S-.GZJU3=<ZI.E75W4]W5PAS
MG $*H'7N\!Q@!,?\51. $OM^&$J E_$._CQ8#@!A(>!0 &*9@0)$B!S_TH-9
M!YSA[,YYAE#F&%F^F;]LUY\.2OCO&OUG(/IE[/_\LQ/\55/]^GOPIVG.ZK\=
M,?ZPM.EO5GM8Z]S*GOH4_*(IT.@W(>"U+6X/K1IOG :+WZ7">/L,P\4SZ4^W
MNW;0OQG/6GT=9Z;VP/\I^A?E @$(&OR'@T,   T( 2C$?S+G'T.S>QN(^]<*
M,6680G)^Y;""GF(U,[8I F"HP.^,($F++XE^M0#X&BSC9UH,8BS'RH):!J B
M6JC?&#+D 9@A[,=@Y!'XK2.QL=M'] B%(G]$4;_7N@8'P-B<*VB E ;^6Y$1
M5#E,A=8% #C2?W-+4$L!G90AWX_6T&*#_O?V_)\"\?S?W>XWY:%_)FM_LXY&
M[Z]Z])3U1Q8[^E\S<LM_%H)(_=U!$G].(##%/]_T5,[X[S0C]/O;J%(F:?L-
M %5._%$I0N@G@ 6__8_"&?Y65.E?//+RYF_& -)_:-7VAY0_]8S]F00#X+\[
M-HL9XN=0^,75$9P 2)#]%R4M+'Y,NY!? )CDCP/\ER*X/P6#?UTN.5#_70/\
M8P!)/1]UX$L"L<:JYHUC5/\5B[\V(@90C/,'P-(.X*3_IE),I7\<RRJ ]C\A
MNFUM?[.4X&\1/+3HCR,N"/L/Q5 JFO%A<;L"%5]3?T>,)J]B3H-71VK^$"._
MKB[,]FXN<8[[T>\ 8W$VK@)L"_+HO[>?-$M9O@K]"X!C9+;&:_@+  J?;NMZ
M\4-+\!P'XC<$&;J+$G7_$8%V_-YIW9LHW-B?OF,K\/N\J\GP$763X$<$[O#[
M(FJ5P<['R_@C$H.%^@W@!1K[\&-^MN;?A!.^XX%ZG_V(R/$$_@; +S +M,TS
M?J@X1O8["W@Y\*=C %#_W],$B99EA@4_ZX/^W0+0K\;\%FC_Z\;X&7BJ<_[L
MI@0T]8])1:G@CUX+_.ULA,2_]5\'Z&6_[T\-E_X9+_K;2<7S7R:$A)\ RY_)
MWX8VJ/K:K\4^O_^;&1RO_KG&)N_?^-TH_H$_^&_JOS3Y9_Y8Y=]SZ'Z7UCK?
M]C=6\!\:_5#Z=VG07USTMXX$$?^"Q+<!BN _VXG,$_'C2([=]B<"W/GA=QCH
M/PV=IOMI* 1Z_'?3O8K_K_KBSV#$#J!!I',V<8!28#S[7[+PFW!TM>$$&\,]
MC87TT?]%G:!_0>[]TPJ,_#?K]37=/Z,D? >QS?=G)Z]F^ZW$@]U=%4'OQY:"
MN?7^K@'W4\;RI>X/+IX13,%$.5IR;L +N:;GH"6-MC\KB;%/#H7])U5Q#ECZ
M.7K_&Z/^?0 CGSX3:OL587 6)4W]I5*0AA6*_USEE],7&.MGN!8U*/]/X 3-
METNH(?E+)6@,E$[]=O.?:6F$I3)AQJ^J]L]860,]V'^FJ2?B'F!E2/V= 9/N
M/(;_[I? _Z0]J W\G[+_7P*84N?O0[+Z^@\D2_N705H[?P=PK/I[NH8*#0 J
M<K]RS*J@_\]BL'[Q,[*?9]WDTFV_9/^8'I'9(G]6>>3SLPB\Y!<U:'X( ?V2
MMOBM'-XOB/-/X)=//B2,_=1+_!=?#FL#8-N(7VRW1/]8<2-_T0/W1[4X'+]X
MO\8/H%+^ESI>_CC/^NVK$2 (Z!8A:84T^WOD)N  66;[=:_=[P#/[.NLR*QZ
MIL6[+-LK1&&'.G^Y)>\HMU*H4NP,W)&D2S@)I>!;;ISF2^@PFBW_C%KH3](L
M)I)E1A(BKW:!^J><G^1ZW^+.27P(94\^'_FAI@#9AWO7,RA+,K.@&B-K]V)F
M%H3C J:_ZFYTE._JN>2MWB9J:H[G%@U3<PE(M'3>,^Y JBCCW7(H:N\ 9;6*
MH!0^)Q.;-KNVD"*$:&)#89I:Y18^+LY:'_G8-;65$19%F-HM1PX(['&)#1"F
M9 ;$(76U9BRZ0^FF7]\=,JYV^2R)46'M.]X\?>@^2H%C6.J.\IUA_HSN#!I5
MI2[BZWK).8[L'6#5)I1_83]>7DKJUQM&2%PF2*I:QQC?H;8,96K2ZHDIGUUL
M.68>"\]T] >?KI8N$H,<8J#)$_3:AP+&066]XV\#S4Q[6^-GHU4XHVK.NG8D
M@\R4OT.]CV7X'!=;O>>0$2\,&\^UA3ZHGB5AQ.2A.5J [V4O(1<_^VS%LN<7
M7Y_02G]/A(]8# /=0]7L_/%UNYXW,B#ND?9$A0V=)45/)FIE3/8GI!#96+3B
MT8A ADL@#LE[U?J[J2HO*8UJ*3,?2>AVX4&"CH3(], L8RUWS"NF!*,ZJJ^-
M?-$+%GQWJ_Y+O5@SO_0>!/D,I?7BJ,*Q:Q4QYYO"1A_?54A"YTP$&RKO+L!3
M-Z$.<!!@LZ0TFMF/9O4+6K5W84*;"S 0??HZHQ^]EI&%,J8Q+Y-1CL =:SO%
MI^*RGLFC<!:7US%C_>)MXDFR"LG.$*@X@_ .M?"?8>2 6P_/C(3<Q6HJFE65
M"A)+21*?4.I8*Q><(])>L(9-?J!\PZ;DU3ND.*$4/NF0]HV<TH&8?WQ,=.92
MG)AB.+_@ZYWRZBQNX>.;RS?,VKHI8(SJB]LBU1I,C"4$2M(",C*BXI24/-:&
MFVO/98?[FOP'57=8;RI]!Z+;6V)AK &[G:\EW]U1E;R1/U%L%P.+/;R7R?)>
M-T?".5?VJ6G3SBA$(=#%[Y"X%0-K2,M$%@G(2&6(XHXW1'21. ,_]WPUT\67
M!? )5K0\O+CF\SM>F&2.6&CS>LCM;)T_&<&G>M0D_NHRDWC]H>OJ$'Z?2!(L
MX-NA@(>Q4_$<:?:@5YQG,"0+SW0S?U37"D>=2RLO3LY"-?!M8(?;=<:B'!<_
M[AO>ZI+""_I,+U6Z9E(_WX)03ST)E7)H#!L#!YB)Q>(WTJSHF+YF_Z;V64(2
M9R#46OHT"$0HYJ)2-G-$KGYY7U"=>*H/FSP-:5."/M @PK:HY*>[1?.()4N-
M@N&TLEI]Q9;.6,(GN;X^&%KF+L=5#4'WJE'4A'&B9:W]R]FX9&^.'+-*B:NV
MW.-2#<7T*Z;M:U S.F?UY/??A27SPZ>9>'4G9HEE!N4!$*ZMIS"Z\C !J:H'
M+A2OSG^R#&KF/]OUTEKMY%YWP]LZ/MA,?V.:9#'(P\1 A,Y>UL9D[G[P3H2O
MT68N&!F"T :_)T/((ZVO^'*N^S;$DG=B5"VJOX!%:1'QYSE1J862[EAM^@8A
M'.*S)&)7^(.>K=\LLWCD3;_$1%,CU+&P]O2.OM> %B.YN&D1_$KEB)[P$Y@[
M@E$[^YMP-U6X/;FAUJM 9Q8_]6 ":9F@7DGK2RWCMQT2#0H,]=.F$A+1IO(V
MN9U"-G!95>7H[X#AO.*/.366)X\S/)0X8$2B/>XK!9V*T^AR[P?& 1TK:<R=
ME[DI:/8C"%UY=7F$?NAN)@?X?>GR^RG<HT GKPMT!.G\FC(VTJR$\%E_EZ 7
MFY*-75+7\E+EXFM4%VAH$^M4+Z]A(_=&/M5>M>I%(_("OULVX?Q)"7E_@# M
M" Q$A3%1)MO!E3MH:0A,.G"IOK7X?%69\;&!EC/NO!F;L^BY:PFX/^\>>\<S
MR'G\RN\5:)P^-/P;?I($!PRJEQR\C6:V[<;LF;_!$NO2+@QQJ;6THGY=ZIQ?
M8KK=;$IN'YJWRHIFL2R(*>+2DFOV:[R#>6TK\1BJFO0E]6VZ$('9$'N7.ZR^
MB&>B/0,2]&!DD"R,I*CJ=&J+&@\BRPTL0P]=B[$^5V7J,V-((]@$\'G%R1?1
M:-&/8Q;M\BV"LN5]6</U(SO,K^_Z[U*Q5AMWE9&I1T* 7=VWE.4 B,#_8]]\
M"6S&Z1"'GT<7JJ4)Y>$@X""(QLHK8=,C>^@#9#Q /5D (T()]>0 CZ/NC,QQ
M;%SF%#95J.8*<!&7CEDB&BX@SI,5EE#>&2EFM[V=33W+<1M[DW%&U#>0B% V
M=%<A5CR*P'X?<W% U4*]-'GI:9^DTN?RQU<>4H 6@_L;@C#<6V3.6-([\BNT
M^+C@H=V;!7!2V,PU;;/4&9#+!N=#T]R:7G=+_)/ 5^ ,37 6@*'G"0KNYLJ&
M15F_IJ/V!N04D$SD^1PNN'3=I3EE!2F ZYS'4%UE7PWI7<@)<E9^EA& T)\)
MBAIG$<I:1TT=CI>53TXE29GBR!5%I]ADZDM FX,C&XQKZS.XV@S6;98CJ1:(
M*'0JO0W#Y2%6ETC08'J5%_K2P\KJ3D!5Z(=,F0EO>:GVW.AU6GV/0P>^4(Q5
M'>4G\=2SRP32,=]:^/+VN,^&TQK<V4K2S[/2X@E1_O+,>\I#@U0-J6^G'TRE
MUGCRE;@RX7*]AC1 4O1L:E1PF;]9"-4,D4\!B3YX6@7@;#6681X4K'_>&6/S
ML=-0=BC7/1VTT9BW3G'),IYTE Y^>WD4+A&Q5+_1 ZDY2QTWNB@ X9GDB[?L
M@TNG>U<2<Z7T1>J"U(:%H.BB2EX"*K5!,LH]AQ=WCQ<S\(D'S*0[&"_.2F/2
M:A'G(#20;2N0[7!!?8 47H:G>6MN2+OYIL'KQV=UFF!X,+D+\8B8YU1P>%#8
MXU24NATX;S,+N;085OV1&,"$EN?1[!5'83!IV[ ^RXEB\+?-&VF*B.%\C<=$
MARXE-=G>E? ^#;]?E76HH<,P/!"RD+#-W0$Z>XRG1<X9#G*+TN-9D@1PG3#D
M,<86A&:SXV$!W3"?(?>D5CYI['4:%6I@X$!EQ!*=/=S,"$O='L[HCUY]\Z2]
M6>@%:"W\<X4<?;&,P&R[PGOXT\FFBKG9?+:.K<_U5#R?\X"8N[I^9OAJVA6\
M'UQ&*:_6SNURI!U(HH#Z6UDJ3%?S0W+1X#T'P950TJ!Z:0 *UH1+1@W)OH^/
M- 7\^7B=B2+%^QV2:+UKWNN:D'MVB#F(ENH=^5[ST=$VJGPJA)$%-I=M21TB
M^"HR.R+"U9!E)C(IHIRR>PF.FN@%3=G3&R</01@ ?^\#%:DB0C39@!^$WD"
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M>KYOQM*)90]F,3%BCU1N[_,3F2KB029>ADK0[:J+[32;9BJ)=?)73K$X6Z(
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MC*NE*P8-!HK'N0BM>G'<"T$-$-DL]VKAP_TH^C.]T(:=C,(/'5X?#Q,'":&
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MPXMI'\ZZ%UUC?Q<41LY-O96V9^WT^@XT7HM94 /"[WT8XQP<<G?_.U!*5Q!
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M_+;IY*DAD,,Z88I_2)[OC5>]5:?'3^G?K<U>/+X5;7^X>_5_!PT6;+T=/6:
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M]K_(DR.Q>(YY'$'Q'EX*T8C')Q.\VB5,;[5DD<P,W*2RL['4P>DQ.HL2<L0
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MKD+%TEELUQM]H29/?'P"LTZ19F. >[G'BB&:N:MT&C*2C#MH$X3JEBO@Y(-
M?/3=)(I2$Q&BNW2.4AM<@7I-3L#-QUR7S-0*%,GV_#,Y!W)ZFD#C&W^(BRJ6
MITWZXJ2>>'?1B3@!(K#QZ0L-,%3O""AS,3L:L"U%4II!QGFYZ*6?"!Q\]=/G
MJ??EX[5KSC5+@;I/L3]Y./WB\W &*3]UYXS\&G.T=JR+7'?ORZRP&HG/W*_A
M,\X>Y66*Y+"RJ1#%,=;TO9GOX#WMU +S/9HU%7T\!5T_U]^-6-!\&6@POSDW
MOQIV=\P)7]]D\7.5U';RZ F^TQ= R[/H7"NG:*#I;W+N??X)+$WL-5 HBL\?
MC*7S=2Y:^[[MU#,@4+<\^-OBO8Y/N_AZU]G)G.$8Q.43X_S7DZNOU(.)JH%7
MW[DR);-=N7Z"?H1WS3^EB'$<(V@%&-:<IA-#N0=^>AB@%"90 _J&VF:KLW@C
M?K9#N-V0RH<,LH[UL&$$@D.VO*W_V@IT-"))OC(&Q+:VW$1SJ(0"7OT<F#GQ
M?8DR"4;Q,/%KTC^$Q,);;*=X1<3**5QF"0 ,H-,3GRNI4.*\*_LC;GG*<08$
MHNBHFT6WW* 8KY.RM= 7%(  C[@!) #$9BLXA<_)O BBD19?#GD)N(M>-V%;
MTQ&&*T"X808G-=SY_@I,A^34+&SG@@FY7FLOK*Z&@_CMJR>5]3OZ9FGC;.Z<
M9/W:R"<KCU!5IJ50W.!+,BLS[$8W*C]/V])NP#ODT!PYJ(38"MW<Q.4_C6+[
M+K(AQM2&?[.->'5%B!EF)<Z<#^:LO #R 0% M!VH?P(TTUOT&?H.J&MJB6M^
MV;RC)=[P^I!I!V(2B5N\5!42]#*W;@ ,%QV652?8S='5I>'?GEV^K0[BU=J+
M8^U5?;?<.U=:&"'W1Z[<B!H'=D:(Z]BDHW7)+9"L((X&$SLQ)J2D>#C_WBH_
MT8#J4W]DU.P3SZ?Y/W]3Y:I"GKH]>S-FWTQ'><W)^NKKHU2_N,N;GE$Q"7&R
M:O[EL95@ %3BR@!9A23"G-A-82*Q?$BPV$3G2'W8 1(L]!B!&?6]:>66F=58
M4/B<]+P6()/6R%#JCC6\3$Y2G&#K.)ZVANWS43=97P #XQI:F)]!\C7XFC^2
MI$C1-^L<KA0/$4DHEIX8.7;J!!V^S'&O?R)?7EV.#TL<N*JSN%DN:*SKFEIM
M*98SX2U7:/P/Y&KS504?NHT+("/1;! W;LA0Q5K+,BAK\E"E.E^3=K-TQ^_$
M@CE[X.T=X4]XW;A."O!]Y8<UE3XD<&$=FAFT6:?Q"/+L7$1#(/_1<1'WVFES
M6.3&A_T$EI>]9'5/&5;5AJ^N&BEA(@_>7[H?[0+Q;P'JF_%*S>2Z#T! O$LK
MNT!L0\>D C%>\#EX)*AV[1*>*8]6,DOI4*+!*Y:]_(K3$(5+66W7,RKV?XV_
M?C7 VU>N19YX#+T"$2$LG/?Y[J=O,OCX*[!5JHD9F&# 7X*=;QQKQ]#M9[>J
M2TNRI$$0=:\<_6@4I7H-I,+)N6(RW6Q.E.#X(3RDO>('2[R /]_Q87UJB*JJ
M]=A6X1);J2B'G?CC<^GNG1N;9K2\3\S,M_I5[ER['BG&[;IY-?<_Q9U;F5LC
M'$H[NR'$BI^B-<8 WUC"3LU>RF.)$BU4\XUEKC$OV8-K.Q__=7O@V <S%:BA
M,93SP'] =*D,ZD>W(N9T#J2'%L=TK%8#.L/5[T]'GX8^,WM7+FJG[5?[,5XI
M Q:XGU[?O2$QE_D-*:/Q-=/[^<=2J&6PP]?)RJX?O5B>:UH??S<KN?N>J[YG
M?MZZ_U%3XY&QVLI@6/=SA[<_LM=?81D>2K(!=DWD/N;/-YT@:;P/;CF40O@F
M\*4-*X?^K7EY%%Z%82OTJE<-^M/1\RUW=ZF<9[8>I=T_C[-C%R6,<DC*H,X_
M_-O1W T$<EI:!'9BFLXK>.D"H$%F-#NBP-H$.'F#7J[L(R&?GGIAG6M "-[-
M_^Y,FHQ2]C>U2/KE'W-OTP\3#]4_*]];55RFVM,>Z:I*FQD:LV$M+/$P+6&&
M1SCRI$]*!6Z>B9OOXX[%AK=4=R(P$(@)#,RPPZ,R%WL#4Q<M>][K87! I+=5
M".F_ -;$JLP;)0.\+X A>$AL6+]:W,[>GL?:5=7W7_GNX1("A9GG)!ADP[,*
M.J5+S4KA2B>QE-<W4)9NR JTL!V&/-MNI%E%F7E)2.H63>NAH)=Y&K6H,]J;
MC<R%L]<G$8O47+<,2]<7@?5$MJA1S"-H!&5-GC7?.7"] &1Q"=P/AQ7]YQML
MFAPZ_PUL?UC_1>UB%0;>1GM;;[;<!;FUV ?PO!EV_H];+S<^O)G_+[K?%]IL
M\>BYVS_9+_X%C:9IU\H0C]"KI*'14QWURMD%,]>-_S9B!R\Z.\:NYHMXLGFY
M^PY=MK!QH9S7B_\."KNTY:4 IS6PFI#VV$P]_^U!0-K6:1_6;D25GO$>/<0L
M_L7_:Y9 4KW!,RA_*57I7H-TKXV$\-W6A('K>5K#@4;+(.C[Z_UE?,(F[; 1
MWVFVGML:9?464DDMN5 (*]WC>G!6652[%Y^Q<S7A<Z7@)H--TR!!'3P'M>1V
M*)*=EL52PXDUI?B92>VHO"\>OJH\MV@*(H-A7JZZ\SV?6M)T>IC4RC1#!63\
MC] N@R1;.^73-5E6)I+10+V]Y*LG!_A:$R6&"D)%C;61B(4G!"'=^N./6)$H
MYLK/H8(&Y25J:BRSU;UPN8 :8]%&&7XSG4B<&!]LNBP6UDC?KV*_T4[[E3A7
M)'JY6F28*WXZMA3GUBD;GMF:--U)RY7)X$BN1IWZ(M,^7M-B*-^@C#03VGPO
M5>J7869'44;O6R\,EE&7[[(TS\>@R/T!A1Q1CIJ3_:S*695@S  S8'QECQ\&
M'FA&J0@<\=[3 A2U5H#:4\!V5BE^E]H-\,TJKYM0C_Z=>%24R4E<P\1#YN@#
M"7Q'@)7<(FEWSS=N0>SSBV+>O"D%Q2I23GBX^][+[G(>JUQ'*"/DD/PCLB40
MLXZ60)%W23!SX%!66",W9(\2?"\ $U=QN='D1AR:E))M>(M"FFZ(NXS)^MH^
M/(U^&I&L5#^LT.(>8(HV=L0BRP=)^TEE9>8 NK5 7>4@X.7+*IVLGQS\'2!+
M)D,N>"PK1OM%/T:)8J#2NEW"R)@]9ZAOJ-B0DSZUW,,/*  ?$C&%BNY#QBC3
MVO)&<FC'YKHV7#B983\/BGN0?;G5:\:J>,&(@8=;NSHM-!4E(WTW=O_E5:)H
M+L<T9F"%9GG:-4XB] )8NJF-H.WF]OYD,"Q"CS^5H[ES8RFSBAPD6KI7+'?+
M2 <*R9)W%Y82/^0_,Z]ECXPLEZONC"US(QKE*42B-XH#^'L%I(Q2[6?Q<.:-
M$$T!?6M) $'NKD6=IJR](LXMU*=H><(%]3!R4ZHTTSACXRBBKY>6I,.\O!Y(
M+>K-5;)XS6ZCB_]>_3<SLU5"5MZ"N#C#LAG3>%SCEEA/)552 E4'3 >:0OBV
M/? #N<0=; F-D*SEU[&$T70!5"T?2H@6@!O YA_WMA+QS@N<,\MO\3V0R5@.
M[>PU:J7.=P5B?F5BUS"8/#ZKS<!P9:_,W+Z<EZUR4MUY5&V/%QVU^SQ(KYCF
M-D]=\5W6+$;]8/Z?2G::2!PU30?C/04L XX9'Z[3P4>(Q#;AERK/E#-Y41FU
MST"@IX1: A\2<01SO@"8SMAP2I1 GJ-2'D,91[L0% ;@1:?3[%@4JM>6SHKW
MC+?\<?:>03<L&#$ZE:DTUGE1;K%<TY*03:XLK1TGJA F9G85&C-MST>UH2;;
M73<^=*)MCEDL5W),R@7Y)Y%5 2T^0MM7P@MTTX13CB*3_%:;^!-%ZQB2UX2>
M4Y^5&0W%PQ$-P14,METB)KU"A'EP>7%F#IYVOR-QSX-NELEOS^"V>+'[M9SP
MG%GE3GIJ6%0LA'. W=$[T\2!)6NM/Q)FR^!U##<_I60B&%]G=[KJ@>E$&1>P
MPXA/I6+C>&C,%%0P,A+O"M_%!D4'<DV0Z])&1UZR7DB 4,S5#'X \ I0'TGP
M8WPP;Y51BXT@%J>+,/&#C%$RH6MS.H4KLT^GGD3[#.6 2LEP%8SNK4MOYOJ3
MZZ"&S*'F>J'R&7-7Z:7K2\4/NLY"3A-*:4"6>2#G ;68I)L7P,HS0\VW[)IZ
MK%;L>H=BS0,/[' *J"^7 RY7HN'[(Y5J#3BQ+##3[8FE1;$&@N\'1+VRJLA^
MD&O1<Z4G.@N;H!+15Y W0L$Z>. J]2C2*@46C@TKX87A_?'P/6#Z%TL%#QED
MEA(<6\ !>!0^R0Z4FF)0;3,I':42DK"6S"#_NTT'R&FU;[[&G] HX+8;!G9I
M:5'&^_M"@U]-J5OQ AX G@<A;0"G7(@\HO:XE\-L?-\B"1M/@-)&W&H!H-O]
M:Z7C*?!^=V83O#55J4''79A0^!B2M^ " -W:''.M\I0I?=<UD*C]:+[J^_F7
M!?SF"ZZSM*PU.5C+8VY2[R=<P7L[?ZV?8K763?U1[+ @?"A1JA2JHRK$=PPB
M<?EUD#=^B7O_IY#S!V1,S^D@8= S$J,;I_->/$9GKV]H/TTTKQIZE+.,#8OI
MNT&RR2_Y_<64:,52!LD)1&T'(,D?T,R=4I2ZSP'_YT%1E1C9[EN)H+A.+;<'
M2(S7)N0I@55R^_L]46\[YCPQ+,@"SWIUX@2>"4_0\=KQ3C1"!)M>(U#$,59B
M!MS X+AN\HH( G0/B&[=ICX!6?M#'6>Y"++[HP\Z;Y'11\*0.#RX'A_X4BW[
MG7#VF5F.?'SF2UIMNX\B4=3#MXFC]YC,AM!Y/C!F\B=ZB>5:5UH>% /#M;%Z
M Y9^VK\,45+A"*D9YC+]3%W[9"P?F3].J<#I*4 A*Q#7*3F_?-_FG3G=NI(:
M,*+-%H,7:5Y3(C7C%R!/7\3*Y<W-(ZEA6YY;XU&#ESLHAG-#>3 ::1OT_JT#
MJ%0*EWI_I63QIVS1%\ L^=+^I5@/MP$!J$+L+*23U]AYC<4 7%]J99-W8);[
MM882<PEMI(W-#:\UXI##PLAX?B!A3#>+6GS[?Q&E'[*Y.#V(6AMNQ;R2W1LL
MK>@-N2O![?20@RL4I-YB<\C%C&'E(T%O4\L9K.Z4:FOS#65#C$ ?%3WZV<E8
M>4*H?2L=\,]TQ2U-XT;WO /A':'O&/"Q+YS'R9Z4%PMS5:G9L/I6X0=15Y34
M]UC.S#\2O*D%^2:P8(CA@X>2_#E[IP?;'$-K+XOIU"(UK;!75XS,L,7:(33A
M T83!_=1UO8OJ^N?,04PZ #P^CVRJZ0A;\DHI$_]1]^/6XV_6C.TN81,>J;3
M(\O%W_*JRI -_DK)%Z*?5]ZW)3<5+;F5\MTW@FQ1M.<F0J* C34J?<B]!]G%
M2]X+!ET^7\-$$11[KD)MVR:(=QPHG\?59SZASHI/OS&XY]-T$HO)>XU^1]4S
MG(?,%5@'__89*XY'Y!R?MZ1[C.XE6E)Y&^]*/KGYU.Y2$PT-@N$>11!;"1FX
M#S O]8MRUQCD=UGYWM"K9D;V(F?2<F]>3(WQ&;O(:_-\#R7IG,I5N$],C_-#
M-_5(;O<M!)JS0=JE=:J.YERRDC6)H@ZG5LL9[&Y-NTUG6!.Q>JGL1.-A]V@@
MS6RR)VXN3[3\O%<3KY7]=ZLT!@Q<N>W3BY@RQ=@"L'A(SY\/][B6$P"<U<'7
MFA YN^ZRPGJ?FXY18/:*1-%"&I=M_>;:3QU>VPS)"(!-U#%]A8*ZPL:^!<'#
M?^[BH&<(%^'?=CS(,( W+&V(W642OFO[-)6R7<J7B[QLL68Z+%M*QPNE&\>$
MD><'@Q7%]<:YGJAM6CI9?U="$D\*(I'XMS:@@]ZA]C6X*D8F1$MJQVG[SPF!
M +7C095K,<\M:*S&RYT!EJ1D W2XYO&V780I]0U54#K-1A(K^;B[FV4.G?:G
M=3K<"Y8\M1?G0RI]6RBE?4:G%L4D^&.]Q_2E^!@8E#,>#%;B7U;<QRM[H#V9
M9LHFP(7V>G\NIWST$"Z]SW,;#)6A_'K;^?I#D>;386L%RGJQ<5_X7<K=LHF$
MN8/73@]Z.-;;^.G@^R3-:,['1$1+%^='G[ +8/=E1J+,QMM/.M^&5:*IO?Y#
M_"64V;[\G%#]5Q%J^MU8^^H%8/\OHGSDKW?5:&7)?Y?L?Y-?:DX%OE.N-"^W
MKYC]#A'8[ 2DH.CCL$\7P+\6MC8G+?;L1VY.\;VXF=%0C61Y*R+6 ]RYT_/Z
MD8%+AF'7J>*SS?]0%".4H;@93A2A>PZ;Y6N$V>26)^(N!>!RGL"M\A0Z)-K'
MXO7B!2#O.C!"KG:]S+@&$YJ,TEV37]3M&T#FO!FT0AM4UX(4@"_'%\".(OO>
M)O\KB-?,FJE1B0KN?GJ*R,ZOA0O@R]>!H&R)\CW4H'7Q,Y[_T=#F[Y<[/X?"
MAUL/!&>UO__,V54IGO[]BO,CI588)4=P^YT!X7^>%-5[94IAJT3_#D6>J."K
M2$Q^#K+=FN;U!8#Z?@'\8)@_^O@^G-'PRB/V6S&_'EU[D_OAY^<GSV)LNS].
M?/W]W>7-,XG5;V__OT]EIWZ0]'>>VA][E,$5TJ'8I=-VN>ZVW/^?=_2/*<^4
MO_[$5$.(;-]#Y\TD4PVQ&^=R!+AMQG0('Y9-@G8I,(\SQ!#)I" ]Y6871#7P
M"PF/OP 4?I=X2[\1V<-)E$[="/EI! =B$H\J 7!]'[#21^V,AG9;WH_,;@:@
M2&(2UH0_P$1DF#IU9<Q-\[QZ<(4@4,DNYU[Z?*# 5D+6+X?)4%016V=39V0U
M .^PVL_M$A/R%1(76V3DS[QB>NVZY  YY7MXE(1;)LJTZNXNY94/OUZ4CRNZ
M/<ME8INX)Z93F#^N]K$R2<Q\&8JP3^YT)POA&#2R93(A5X %(? O1JSGLRO
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M9#?](GB:Z(=4!28>=#**>E"76E3NYK?73$Q$#W%)BX9ZI6]02F/WQB,\0 $
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M,7O9YR0^3<6,QAMSZL ]):^8&2#<5\9*(,</\GZ>)JGS%[ADV1Q%Q[G:]_/
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MW@JPQ?5;55+>FHFE\Q5/RP&[('=79&VM[!:!IZ-=?9RL/0'C(E@1@?')=OZ
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M;_6C93F-8)7-X^H__(UHYV=E:\;5O\]RX9'P<9Z?D/'.Z )\[1OIZGOHVL-
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MN0&=(T+ZT>A$SU)=6@8*H*@<36Z="F[(ZKM Q7KS8_8'[)&5)8+WZ@@S9&5
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M_E)0"TJ1\=6[LL^6'OC>#$-0%H/!J2L R66,S+"-7^?95*4Y[;VKS<\EI$\
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M;^@?8/Z.5M(9#^;%8]J_D?G*&-O(7:>6)2[8NX,\A-]LV&W^!T50QB;7Y*E
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MEA"5EM-"IZ\Y4Q>=ON_ZKG.=WS_O<R^_YW??]W._R@?*(<"8$<$- @!75RM
M$_@;RN< S"F<'1H)0(!Y*INC<@U!L2%2J<@&@Q%(T$R.D 6BV4(^)H(IPN#0
M6 Q@:Q\A8K)#02F<!09S!73$RX8F!)S+H2.VD#RP'B)',(3K$B4&O:,V^K"C
M0MDT#L+>#FX;81/!%_%!*1,>P0\32&PBZ(BOE]NHSE_<& 3\:XHTE(Y8]R4
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M J,J!_,_3SWG4NW/E^.WW549W[8?%*A67JS:;>44H/NU88!S1?4/091]0"P
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MO.D"Z:/NL]?-CHBSS2FUVN57BASV%-_OV)9A*%<$QO*3 0N7:WNUL'EWZ4H
M;]A3U#'4?K."U7/\**TG72>M-%'LYTY63,5^,ME9P#O JK18(DUM5ILGMY6H
M[WY5ZEU_/;1PJS0!QGVA[;Q4?WUG78*>Y&RY-'GS+X.E[)\[4PW\.;[5(@]F
M0L/)N+SZ"XP7%YK/B@H.<OO+D&?3"A<45=S8'AK$4!=:OZ_5<'QDFIVUS/\8
M<+ZV&.YV.$\7RRJB^"SQ+W5*OLB\>=C8\E[+ZG'<6^<C3H<LO,5YB>J\OIU=
MQ<,(/#0^TSW!N]8Y9]CT4TX1F5COO%*DU[T]SL0W)<FD_IW3,=X1:,C(+\\\
MJLZ44T,>!D#T YXJ_J35>C60'NKLS]RP_5AJ$7I7;9G#79XO(J!=6,1QM73;
MH<UPF(P(:3,\VOEI<#/)V#L]^)!Y9>71:WV"\HJZE8+>4)WCHU:EWI'5!HW]
M-,T_YHWVH=X<WT=V2> !F:$#%YUI?=).V7@W>JS TRRLLBJV"#NY*&\M&7]^
MNN80/S<L_IFV89_^S>B!ESTWFVJN#0TXNRQ-[/:XJK^8N&)<SSWULB.^P$P[
M\W1L4L;QV^4A>^?_A+QETGU,$@./VZ8SN@IQ2BZZ4?W&L*<_NL;7KJ@JN)#!
MFO?$^< VY"X.TI=;W=A7$C-=P]I$C!_Q.YA48K7#VCR)\O/]ARF3/I<G-FTM
M0>1O\MW9TNGW.VZ#\XX-1RK'G5=NMP![_!3G'^V:;_@JL][ 5>_%J$Y-&'L!
MX6WCHKZ@P13_.^A)EZB]1[R(&86Z/O(S3V-6]'G[EFV?BKNL=5OC8GK90';6
MUE.OKT>SUFBV.(0!Q2V']RU*O;_UBN$])9!B&3=N)KMJ$M*_!F94AI(G]\ZL
M:[^/=FCR.+A97((/,JVRZL*,'$TT;Q5O?.9>/5QNV^?(.R.]\+G<5)A[:+PQ
M>^8R>;?G&9L+]Z?8>'LCBXF.6U7.ZE-+_QB*O.1N'_KS[8[>]5G)"^PG3H15
M#(U,FE;7]O9;G\S(J+Q.>LX*:% HLIOR7VQ'V6]\%Z#+QXD_"I)D.M:M'9'U
M#7O$N4$&;8KV'"O=GK?E?HB9Y.)+-]:&WJ8[AF>[2/Q?+Z5N"_Q8PVYH"SZI
MD72]9:3B</-%Y]+AL;VXK!O:=+97FZ(QUW@90PF\:H^4G:UMVIB,?V:7F)7Q
M+F@+>@R=4#0FZ ]<>N,.4PE4KAX;J+D[$)8>X!,0V'9?\:;I](<FX?O/9N>V
M?>ZX/O4Y<&'7=+C&T0]=B@]-E.3)3U'Y?@W46Z[W<OP^G) T;;(QZIH*SCK7
M/'%2K@1&9(+FKL>KQW91;67/&U^X3SE)=0)'6CK?7&3\.2IPWCIM]^EDV^/+
MLA<3:0J3I3-1R8Q7VF9"VCGF4%+6?Q;,V#U_>:>_(?KY),C'1CTXF-/^SBXU
M97QOY/C%EJL=%'&.59<2>&*Z6&8H.:T$".:98WLBR)3JJ:B)2WOX6U:\1Y=&
M>U9,[[BY4PGLR'A]9W3MXVLMTU'0!HP2Z,AI&PR9&<-61?\&UBZ]+!_9%WSB
MU>WQO=G'ZP*- I4/_P)02P,$%     @ FUEJ5AQCD@$#!P  A @  !    !G
M,S@R-C<W9E\P,V(N:G!GC51Y5%-W%G[9(&4@)6P*Y4A(M Z6['L@4@B(D:(T
MQBFE6AOR'A)"7D(62: #C$A1D64<4$1:6Q48H)&Q5H6B!426@DO%I100AY&E
MV(+B&MPR#PXHIZ?'T_O7W;[[W7M_]SU[KWT(6!QA5B4 @%2Z L #K\3^&T ,
M-RG5%@ %8!$;1%Q#&$:BT:@3T>FP@:8 M?$03:G5T,T*'9U)8]"!X!"S3J%4
M0T92/+1%!8O)=QJ;R"05*"9_P(UF1.LD4*)J=9H>6I^V5JY,4RN%(#ED)2G8
M+#)K=!K(J""9-<FP0606DV>+BQ!]QDTGDV93C&HQ.70F0(J-CB%)M'J(Q*>Q
MJ$H&@T'B"VD@!+$5?#Z#'4AB,5@L.D- 9PJH3)Z(RQ"Q&:0Y(2.$>C!!) M?
M-4>'6&+RW%RIJ:FT5#9-J]]"9PJ%0CJ#16>QJ$@&U6"!C0HS%390YBN$0P:E
M7J4SJK0P:<96Q&M-1C&9/#^%1A<=_;+P'RY,HZ'/9QN,,BCA]=D&N44'T660
M06O2*R$DG;* ZO70F42D&U&X5FG20+!1&BXF(QX:J )%H0Q)J) 3Q@GC"\*8
MS(AP 9L9)F0SF5P^D\\5\ACS6"EL,"I@)32/5;W"LE^+%4GTD,*HU<NUVN3Y
M!Y3"R/946V 24T!CDO[Z@0H&M:F&@)G5SG4*Z55;(7"57JLAS>Y&I%K ;S(A
MY#R^4,EC<OA4-A_D4SD*)8,J2&!SJ2#$88-<D"^ XH7D.3"X8/!9,!_B*@4<
M'I_*50JY5(Z0S:8*.5R(R@"Y; Z7P>:!+ 69CK1#_]U3S[N0^YE17]XN8KR\
M?@A&3EZ/W+9]$B#,#@R S<@WA++W ]L!U)\7]"O!O)3YV&P8M3#R)\7>#!#Q
M@#O@CD$1 301A2&B[.> W0" U%KP!P!P#@#&$>^$ M 8U$(_U@&%<<2Y(@H6
MA\;B<'-N#!;G@';W7(0B>G@Y F[^E&7XN^2E&Q:_S?ML[W(B@$+CT#@,!CM'
M@4&AB6[N6$\/!\ ?Y^7(HBQEDCEWV?+MQ=P2>Q_@C%"BB1@B$ ),A)/>N)^R
MB#)M^R]/LFU/VZ; OJ2JV@-AD<:O> Z<#=JBS5T[#Q?+Y*M7FH+/2:N/9Z_+
M$2QV+G5NSFY]X]/]V82GIQH&@K8-W>HER[X$S@HD@JRC*GARL$W=R6\HC-D&
M.N&L 3Z11-=T2F?FDH$XC?54\EG+XLY%2X9NJ?)@]79U#I3 XK9ZQW8<(U@V
MFH+*_07ON56'?R/H[S_^@S@TM7];7Y3+N7V5V8:4]W<E'ME=ZHBI+A65A3TB
M-UR^*LE%+:UQ]V"'*KQ(.['F3P)1#ZC';L$GX"@[X%TN#JEVDM=],NYY5+Z_
M9.(Z1C!8/B(8V)Z\H2#B:=&-UL;@BA_AB"NG:^&,BIX+K/$G>4F4OFM%9>G%
M.S5=;2/BAKBA[_"K&FHI%4,CSSG?2;R:WC\>E/%1]OJ,%7W6[I7&VFA-YOK5
M755'[B6<G[H=="5-MK=P7:>\_?(_*KOE9:>5SAEY8]*G#U[\,#IV[A&MO9:;
M49%?46QU[<ZMHN+#A-3,YH-3M]/W2+OSZB][#%V""9-X.G'CYF=IYTTI;GL4
M_TP)&-RZE.OF_+ EQ<V[B!(<<[XX!K@$,Y3XJ=;RYIS/WN*=V9E_ZYT;6<*@
MO,K> >/C_.[ 3=+?3J[H*",,K_4NLX41]&FEPVL>:VRH$;4?I<2O7RQ[<;-Z
M=[[TRZ[6O_\H\RT^6:D*FVKS],S?'-5;LR6KOF6D;?2+MQN(QM9OQZ]Z!7AT
M_*_FT'L.J"2>3)Z"*[)X+_-WH8J\9%UE.XK^C?6-#<C*($;L(DH*G E3H]=^
M38\Y53&PCW Z:&+"I_L;UY0HG<O=$[IVIDM9?/!%"=>KT:D@[7#?\+O!^QJ?
M$.ZZ9&T]T9AL[3"8[WVX&_R;]4++AV^=],AA^M6Z-E_[2PGGCM.Q'5\;-M87
M_')2?>#)(8G44E="OU 3FVZQ7=OZH*?QT0GU=:Y?POU[$U/C08VBCYOJDP@%
MVH#EHE+KDD7^@2'Q=9T';8-C5W(S+MZV3?8=66/SC5@KO^\S,,E+?!%!SUM^
M[TQ]1^Y1L&<0"W?EI,>WOGO<,WVZ>@!]:2"N\'YZU#L!00?&5QC Z?T/;PY^
MVWB>=;53V5/ JXQ+ZO:Y;(NUI9F^OV$9?GKX[&BKM;>C;"]_V1TH0%%QJ.BK
M-S_?4U@7.JD:/CB1B__T\$?]D8\GQGH2=14W@](5-?\*O;*IKKTIKN_Y]+JO
MTU9:UDT;QC--OTZ!D[XC/AF#ZR-W57OL\\]YG!CY4[7MYIKR>O#GWF?_:52C
MXJH:=EP?#6A):!\[8PT7^VPN>5AUT1=>_B"SUP[XM3SI"VE^]N9/#\UGFWZQ
M \>>9VH+[3__'U!+ P04    " ";66I6$KQ':MH%  !M!P  $    &<S.#(V
M-S=F7S S8RYJ<&>-4WLT5'D<OV,(6RM#+RF-JTVLF7OG>6>&R<&0QXXBD])S
MW'LQF$?S,LI66VTO6\E*20];K4>44"(])%;T<E"4W>UP=-HD.GILJ7;V<HRT
M9T^GSU^_[^/S_7R_W_N]QG9C)S#-WR"+ 8"@('? "O@(8R] $>G0A&2 !)@3
M-D:X.LEPG%:K$D"00D.78LIHG(XJY9!!JH(8=!@"O+P-*BF:@&NIT7BL3"$$
M^ZNN@%09)@0C.6)8K/+#XV2!:]7XHK6A$>C:!)2/@=[SJ%X&@4&NDN-:*=4@
M3U1H! 8A.%Q<0+R'W!!('4[1)@A!GZ$ =8EX(=5/J<:I")U)0V$8IB)\.H;C
M+"F"P"P/*A-F,B&8!S%X- 97P($%+)@Z I 05&,Q@G!1P(@<80G!D;F2DI+H
M22RZ4AT+,?A\/@0S(2:31F30-,D*K=1 4VA<3!5$N 95RU1:F5)!';*ET4J=
M5@B"IBGD*K%XM/#_+DPNATS9&FTX'O/Y;$U$L@J'PG&-4J=&<2+=98S4YZE#
MB40W I$2U<EQA39() 0)#QV380(_WP ?/C< \45XO@R&OXC']F7RV4R12,05
M,?S8L(D;I-!HI0H4-W%E'[G<SW(%?FI<JE6J(Y3*1-,'#%(0VY/%*J@,'IU!
MG1LI4V#*)(W;T&I'.L75,CV.!:B5<NKP;@2R,?HZ'2'.1?@HE\%&:"P$0VAL
M*0K3>#$L#@W#V2R,@R$\/)H/CI"Q,8,/DQ&<@_+87(3&0?D<&IO/8M'X; Y.
M@S$.B\V!65R,*04AHAWH/Y_:Y"+N9^@Y>KN$,7K]N((X>35QV\8^P&9X8 "K
M)OXADK$#V *0OAQF'T$>A2DV'":-C7PAC-4 Q0J@ !0RB0*844AD"LE8"WQ/
M- 9\ FM+$D#^U#?.RMK2%B"9$^(6UJ-.,[*Y!<G*$K"?I%ML75K6DM&ZC\MS
M(&H3[9F3+2U&\LS()'.+<98 Q<Z^)-VJ4S,I@HM,<P:;M1+C V "H61&(5,
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MO$36)X.;W\M1:8#XL^R_C)LLA7]KEMOFJD)_&C"H<FTERF""[DMC>Y2R8T0
M2-*5/RJ0H^TT62P8 7/>P(Z]TR$)_*@])OV?<%?J:1A86S- +QT6@Q)"S@/E
MK;L0 :V#;R79GSB/_)-3L9+[:H9RGZ08(1P F=E]2 FAV&B*!"\S)')"WEY^
M_:KUUFS?&Y$)_JY:ROOI@@6N]&GXOBP4]EG6U<ZVQPY7+2H59J&B5%V/N$PF
M"%[%,_&V"6_N@^7> CYC).6W%UW=ZQ(8B?4W@&<WCV6U$ NL950ON16T '4#
M! [>ZA2F9#$?N4SIMU4B%>BYP-%:YREOI^1;3/LDS- AG%F(2W%ZM/6!8<\F
M$G?FW,@<^WJO:(SAF+LK40ZU%)<UO0']1>[;:ZJ6MV4GBKJ!0@88[YWM7H5T
M\*'$XPN$TK4AHSB!V$>2 0$M5?\X;+J!'0[!7(V6D!J84%&ISN.*7;<'[O-,
MHVJ2B' ]^U&$: #Z4H-T;)G3>[& +P!&&"&R&_)1+Z2Y#Y.)HF)64]X\*D(Y
M$:+Y'/7R2JS[0$TP36=\IMGV;5MJ:7+K>7'XOE[I#;!B]OR#[0CU?_SNE>&Z
M^M0RVR:X=#@68WY[5N9M33.]L@Q3#XJJO\W='S@+NOB^\JF%'W;0DD$EEUMG
ML#:N-8)*)=6)1I#V_12C$KOC'[]+7#%9RO1QZMJY)$$1DZ/"F)_F<'K24BJA
M/W"8G<=9TRN;Y H.3:CM5?_8^MR? 6"K4/UFD#?>YZ1^K%'.\V;EM AT(_![
M[2SENFK%=@(@R1/#NTV:*TJ\ ?!1\$CQ$GJ)T,MCJ<\5BB5QVB7S_4^2T4*,
MOR#A=^T#+JTR"H=LD\]@J2/7 %-@901$%(JJ[TKX<%Y8S)@Y[H9QVS5QK9UF
M$%Q,ESBDKQ7$[3:$)TEI$R.JZOA?3]>$D^NI[>1D PG3RD':>T_<+QV*>3AM
M?2>\.X_5,FBZ*;QK<&3;E?1'4SB)=M]$?Y*7AS&]IJ43H$5(HHIC0G1I]E>G
MBYQ7"T_$3.% EY<_   3'OP=;43$=@W$C]2)M;!K55%,W( JI2BN!QX7-A%\
M [I2EG8N@I.';1+-DA!"_/)RV9#FI\NQIM_*MQRV[78X4I_);97D9'-(&;L;
MA@F87BW1OXC("8RT=2X9OZQKZ!^]8GB)R"C1?C9+CD;"]]PZ[\-HU16FB7<[
MU)MYBM#P <8BE>?8RC:%&1*3!R!645(S;<11HWL!+XT^2[#;P49'5*W&FF:
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MWM>82M**T!!A_6[.NR9Y.8#UQ&W=YH?GH:9T>P,HOP(UW6)1;U%0 8?O3YF
M/&[Z;%"[Y@,ZTGREK0\V<%(,LBH#5@9B[F+/JJ]RD3OT79.I4![R<?!1:.]D
M5!Z$.K?9F12ICF]ZS6]V2VVS:;\65T)F0(SE#7"UQI/R!A"HV7D%;\R36*K]
MSS?#7+07\9P4%?X&>#T=GA9OL)^;?(_N=(EH@'"(-+%QWUJ'RE4"Z]&E"]N$
M?0U34Z?IXEWU54F:'CW+5M1G;II/&AAX(J/;"8Q@:4FEI,CQ]]ERNC"#H8O(
MQ]&@!QI"K&\R#0<]0O/)_;"4N^I9:AE#U-PQW[;A>Q 0-WU'-91'Z!&(&(L
MOA80ALZ@#/GZ><3$F4U7F[##*S)9WZ/S!5+_^B$-87HN\X^B#.DE.-5Q;49T
MLKB:EBF,.K^B[7A87]!Y14MHFG:1$&3 K#=C>-AV1MS!+#)]U4SHT<&>,##4
MR0%V> *H$%O%W+PK#?=2#OD,!3KB7Z,292+23A.\\.$B_3OR;X!?NJDDM*Q0
M\M_IIVS9+GK\:-E$2>AVJJW-JB'U E:$!_=O@ \5Z*RL'XDK,1.^N"/K;0&Q
MV<ICYQ^5.G]0Y*8I6V(XOX(#?9\7S_:6L^E./D)[?]/;?@'VUQD9*OYNQQJ2
MZMLVO]2N4P;O(KJHVC>NI(R I!O*5BGVV,Z>D(FKDXULY85?11A4&) @R>'H
M<IBHOJWF6 M+9)H+K9?M7L"^R49=5+R(]8BI8W"Y;/+:3*_N)9F]_7R##H:$
M&/F]B$S(,)*;CM#-;D@SG,%W7%PH#W('_"ZM:XJ,JT_6?4YGWED'FQ0!U%A8
M0L+,+BO#HE#!TM\=C@$CQ0ERW8 SA)X%P _M4S8M0G6 I*$*KB1HKM&=+H9C
MJMY1TX>;#&\B4D4\5LQCDJV.E=O%?NVXB\LW=BXJ:E\]$ZH=VPJQKR+@*Q!R
M=?1TXQ&U)7;S[C&9POHE\\':Y:Y>[U.E:,A[1I5FVNE$RC?  +(/)5_8(YY'
MER1+>6$()^WY=]:C>B&E/Q7"1ROB1#_E*.K!2,Q\ITGNJQ93RC_@AS$=I1SU
M;W9HG['GN%P#=W/0_'8O>7YX_'09&H8DOYO/=28?_,.O.R2!5]$RUZQ"SX%1
M (Y,\4%#D.N3(_6#X:#K^-!6F/ %0,'+?V"QNV-B7;7I_V@27/IZYYT;,,$Q
M>.O,.!WZ1<GT0$G_N-/6+GQD[)CN_LN8&MO:YWL(WC1>4JM\+]W5*^NO=A0E
MQ+NQI85UE26/Y>LG!(RKFA<54,O<O(+NNHZ>\A^E%=9\,>>C,HB%D],Q"\<"
M]D$+WWYIK!8/]RR\_SR=ER;]8"7/-_T5[K2D/,)RE@_X4]=2E1Y:*MY$'ESC
M[N+?9F<&CQZ&&"!8%M<:Z@<]I&3A]+&&TVL,!.BNM"_;CY65- AJB%LIC*M5
M:)S)S0@VE]ML%VHMY@_[W<7N @09:3XI^(OHZN%(9[?-YSX[!)I)$ -=TT<"
M/P1UPR/@ 0Q:24-MY.]E^0A<Z0:3=FJ_@3(?U';!^7UBG"L:M9[E%W=OLGQ^
M[0#5F9=O-6*ZIWA[C5_$NT3ZQG0'51=)C=>^G:;_]O$]3M1R4;#6N7QEXWP=
M]:I#N]+#S$E?/F_A-S*C&$VX=&E(D@3ON5>EU&27\!*]\Y$]:-IT"HZJC8FK
M)B>4&.'/E>O/LD8=N.-:J6!%(S(8,4<:]2_HH1K[0117@Y,1M<AVZD3M)X(+
M EX$9J(,!Y0O*\9&[E19.H^M0N@DL&\1:X#Q,>.H?MIAXTW3Z%CPTK1FN0A[
M.'5%V-(\R2B77I8V5&,18X_FAY_C<9QC$=4_.S:YF&+;G7\YCN8,)D<FBI+G
M*U'S0<XJW"[\BL]NG*='Z.K;;)8> <' G%)JQYWSLY::]W ](17B8[@.\XYM
MV_ENP)5Q?$_'RB]S!A]R]P80%&@K[0\A=,V@5Y%&^G#8>;7UN<#B%HG@V$JU
M2 HM=1<.%2B)*]&D7L@BE\.M[L@U[?4L58BV6D)0,6L9A1LB]56EH.@-( EW
MZV,$W9-M;@F*>DU_[IV(=^34'@#013WB,DMC!KI(NK"5?\T@29L.6Q4D22O3
MI+$R$@[F5'^EVRKH#ETL\ZZQ,. LO>?+F&#J<BF0VOK!8;@;Y8T@@.YU&_G:
M-'8J+.<EJ?HE7*];+&3E#;"Y03QQ;=K[S!8.L0\5^1]NZ('I*\3W^<1#8F\
M>KS'IK$T/!HC(JKD,\[P%L@9J\IP]4"T 7I.PG0;'8067LK#ZB@EAV&:NNID
M_+/NQ9T,>K/=1;UK NR> 9Q>M! VH_R>UH"N_%PFUP%0"KQVIO%HRH1X%K1Z
M3Z<CBP_(Y\D1'GED.& 1 ^AJ(#E!*;0JENZ&P&*NYM6BU5/6B=H9,(8R-XXL
M+L),J!E-7T>TVFJ4");)D3+)O]%W\N5T69_HE"HLP>Z/!C T*!9Y&='^EN@1
M\DR/DA4?WM94JU10)UXI,#"GB%;Z-'*JYKM6WCH]O)#@CSM3Y?CYDDDGT;D(
MGBVY3,:!/CK(>8=_%AYY\^8;&A3V9CA<OH++J$;<#1N(VLR6FY\< 8\TOJ;J
M$(-\E-XOX93DWEH25I:AP&95ZX7)2?8&(-#E/>3F5;<;]H(GK>1=,KB@6*+:
MJQ F*K$"*;48% '44N7G^._WHB(5K$ LVJO+@Q$;/$\J_;6\@W[?G0WH D4B
MR HU@AFI.[[\XAD(=!/PR6(E#:_1?]GC054+8'!Q(<%''P'.2'4KP^$9R$H+
M\"O@MSE33FT+1A4,W!UJLJ\: #.V\"U9Z[%2>7^9EHY_SJW.MD86CB B4<;"
M-AQ 1F?)+@+,ZD8<:U;BC@K,ZB@65G%>76 .7+H4J$RPUK"Z%.".#;@E)71F
M@EA+]IM:[E9\RAQ&'8C.<BMT%ZUM5>@SG=^[SL8CIHV_ N>X+&+:(D@;\V@E
MZ2_@4J$+XB^/YU1S0K.3#._$+:-6.^W[PRS*[R#GN)(M"JHRKJ;,+#7,1V<!
M)#\"@N?TOI&)\@LCYA[BQ!%&AG%8/!.P+\6G=T)I]9@ QO)>\0.0/"U[7"G"
M[0WM+H>D=^7E5[/B"@(:/T^4EBT8U+0OR6TJE-9J'X58NI!K@,C+FQ)2<0>)
M))HP2;6KGW&"^S HW@ )EMU\4/E9H(B6(Y1C%)Q57Q7.O,W?I02]BV.(215;
M8V @$%!0M\++Q)4.E\>G6=P2^S!6H01F3@I,"WH#4(T07GXV$VF-@CZ+WA[/
MF_T(#S0Y3#[>.$2$(S/Q/WT#<(7^07.[C%[C$+^9_E!$@*$3MX!KW.4X&K?^
MB=**+$&%(',-VKGB_KR:PL=P;&SCWG!D8B!CL[N FB;IHF9T_O?"FGMRK.+D
M-IO5JN&31T*W_@O-C=$]6;=J9P#3<(L5;ENIMW/).5MHA3,@I)<8W<>IME?W
MY U 4NLC#S([\<"5=[\?0Y.OL[NYG? L6X#I_14B\X4G7PZB:V7+2+.YR-4B
M^$>-SL/PE0??WRPKQ(7$=X='?\)MNROWTW3W @L'?JL&6%/*WZ=@?M(CL[7N
M89/+(0L;Y$7$$R8%SO#1L*/<Z*<F78$GSTXI6=!QK<[>PSNN.<UQML*_+Q;G
M3%)Q]7'(+L@^H;"M?K_+65.1GX7ZL \6@GSID-^IT!?V%[2]-!#"J.[N6-DI
M#$Y^E],!W(B?&[%OT07E?JHF$[^^_"DU86)DI$WWD>?6MK5[].O,G)&\ 2/A
MRH]B,7\/!![#K%XTW$<QPKT!U  Z*6QK]A4LL-O6GYJ*O2PJB A!8\)G8+(?
MGTV'F?WF:G;,Z<=8G4DM/;-A2*W.T!O 91&H9OZ%>< >"J5BD^+1IW/AV/:>
MF#E=[C%;38$9+JG__3)J[&[@(#J6XQ;$T 0V/9^J \V+):YRS&C9Y?;N[7#>
M.#.4U+K*O'//PT.+!.UZ#'PJ'UHN>-U-.;$ERQ+((7\#%+O?M^;_;+EG'-#P
MJJC,C:JNLV4[9#7>SPW.P >I+CI2\U80!I?R'#C1>2&A1F&Y?.]TV0//X _O
MYALOSHJ$2!P*J'=Y6QVBLQ(<_@A^J+RV?Q_=$F56ZOB1EL5I82DG\ILJW&RT
M"C9&')W^_K;>(WX_7-S8 YUB"=,*/LPHJMJVO!7>76-J9%^R>T")AU($UBG\
MRO#&*<;1Q\G5?%&XB(AIB2-V9?GYPS> \1K_\T,%/:/@&V""Q<*0/AGM#PVR
M!,KS1SIA@W:FU8!&#2M,C]K.LW'?NZU$DNJ></T[.E7$=L_OO!AWK_&#;2MX
MKY/;A,Z2K+0NA"V<TM1,OR4GV]$GQ]:+.FL*.3:V,\XF4=?<);:XQ5-B/%(H
M$Z=*/+[?!Q4O7].@E'F.J11J%F; 3$QSOC\"1U>D!74X[-Q376S+HG[%K_*=
MW2LPW?H8E*Z[?V7CV53T&NY 1DR]QDY,GW"D$O]C,9P):,BCED4)S>LG>E4X
M@8H>Q)KU!V*-Z.JS5*<8D:P4'F%W!&YA]%7R$V?4B_547[P!.@D6&M>24M\
MN(MO@&USQ,VQHYK__H/0&&'[<[9U@=M*=H\-J=YY?Y*!@REG!FW[.T:->N2J
MOK(&.\J()Y^!J9:,>&.!FVF!22?J73X:??*ID\^:-/G*%]G(JFTS2F)C9<G
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M>O8AV29SWU<3R D\5X )NP25OQT:^7R(ERF6N[,BXB3I4_1XZ0NX/#>@#U6
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M/2N1VYG0"[,5CV1H7B3A]DO6XRL+09[_AEE 1>.VQ-)YLDY-BJ-@#N2E\$M
M;VSP3S+[E, *R#2AKN)J_I'V"#>RZ<S%EHB?>U;OI6_Z,'8;S5W%GX? 1=X<
M(NI7E>"3[X')I^ 5L>2E, ZO:KL4=R%?R?PCUR<?$_K)(!^*P,V\BHE@^]@6
MB5WB5\4$D00!\(]+FXOC)Q/]45PDX6R)G0?>SX7.YSL:>$B(F9;;5/OU"BLH
MI^X)K7G'6T$[A@NMLW=F$QP_/WR6K&%!&Z#77XW:^RG\ I\Y[FH+WI/Q^:H
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MKJF/2CE>:&K-_B-<"@[VCQU^^'GGX%^HT"Q*\\E-BBK20BW<N2&?HW)'[]2
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M\4%54ZJB*7$*O37'1\S(F,BR2C4(_(]7+GX?9ARV]408A\$JQU/ZEK5S]_\
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MA2$*$*F6>F$Y2>A%/;W+,D)6S@3F#B_:GRX)QIM.*8; "0U2&E5R)=TR;^7
MHP:3A@,EI6Z#G[%2=M-J$4$9(0(T=0OY/B/O.+L>%2B' <EF.MY+R ,LT)("
M)EF#EB*=ZD!6GVLN (C74KD?83Y51$Q8=M%-'R=(==94)<&(2S/4+UR)3H<3
MC2JH1]00%=;"Y[$:PL\^0<'$*AS;EH<$C*6>*&0!08)T^RW&YH;DZ5X(61NB
MC<&@!41<RX8+ 2-#F:#%7LQ!G046PRP0MB,+2 &MC1A5 K6@#WG+&J!IC1-X
MRJB_$*ZK'+E6.7+X2!J0/?CER\F1C55S5&H4+^)QRAPL>6M@BCDE>[R1Q/E?
MD2=C&N<Y!H3M:<L2U6S72+!\ER9S7:/F'<GNCW!O%+/4<DYUW$Y#R"[4L,\5
M5/0VP72Y/LMD?<PV1OR]NMK/5DC@'F+AN'E""W,1*Z9'$&@Y"@^"3V@D;0)+
M."3VFOXLF)[\UIDM'(+G<*FFKS&^"A93T-4YK8)I)A44]O-3 7P-I(XZ.&(-
M8YQ(+MQ3-R5QP[^5EZ;IH##3CS3&?2[;)::^B[7"W%E?<'2U3ZES9V&4S."S
M0T[FL$5+'Z88V5^XN8 A\?G'W3<U>$>5U]O^P[0MDS/F+O\ );7K#7P.?$Z)
MX=(UCG!"2)'-/F+"_P I) (RS(!Q\_N7-)TQQ7VBP"8ZKGDDC>*Z5,1IX)H@
MP.#GE\4 C<&M+AL>[)DS23D0@0=5P$SE@10\$]"U9<F$CV$_$#)./Q?D1B?Z
MM5"YT47JPD-<&/<LTA+_ % J21EXV^4GS$#,8V^G;B;/.K?&O'DLKJO3Q<CI
MM%G8XT%!EP-7RP1%7\@C,D DF].)GK1/8"]C3&X.EC+MI:$8UPT"^4(<U.I>
MW-1'"-0>\4^:Q]OT^402 \J$'@: MVM4<RO-+?15,=MC#6S@3/;&[TXZG<T(
MZ4N+2Y@(4O(4$;MR$C (;@7'&G&K#/M1+VP]$@DOI&D$XQ[/DPH5;O%T=3-=
M*QSXG-<T#<0YVU[3*6N)>&R>D2<P?,,QX"NXE. >. 5^G[>-XM)B^=1A\N';
M1!DG))?6C;''MCF<&/\ 45T9:&O8Y5F8U5C0!4USR3&;.X=0)#O[EL_LH^F2
M2=0JX-4VMUN#:::)T3S+(V4_-RAC8Q)Y0X$M!>U6D(I0E.JXSYEB[OS6M&P9
MQ<  $4#IHN0\C?)Z\2L=$]\K9=[BV1\S=I4-(5[!GJ0,P0N>%]56R*B>WC"I
M\P"9NHJ*>:$.AWLC;,D;1N4.W$EY<XG>W<OBOLSP[:EX6 P61OHSU$.#11'[
MR7.2:H- ^66>EJI*5TT,/G;*[U94]:, MD;''N0$'S$>S'JNC'3)Q@0R^6_<
M<@9:<A^14N_IQABXK8KE<7N9\JVQOHI8V@D7)M->V5E"Z2GWF<5M!0R>F&EI
MC02-:4(&/INRCHA&8R'Y'\U\1ZR\YZ3B9+$[WVYESH(+E;[D^U&DNC9N.<CM
M\$-QDX]>JHLKJ"J? #LN]GN#XI8ZF,/:V>)SVCSO8"[*X+L7&6/+GVKR\X:2
M8G$@,_R]OP4<ZVL_^*G%[WPKDC*+C7(XX*2ALEYK'RR2\,Y*#)\M15MT:]M+
M=.WUV,KHJ2X5#'RT--6-IYD8R&>)0W3#PFL3E[ZC\>%>*6G 1E$\WY]A]JK;
M=]-MZJ[KV2X"+C&^GNUGMO\ =V\4\C7,DI+M8Y#15])(QS6^>CJ&&)VH5N1(
M0X?V)U;6(.(H>X_DO*=3 COI-]3GWU^:D[2U9%&UYVA A_2T3,9M1?RX9Q]Z
MSG(I7@@/DE<UTCGEY5[7( 04\S<O% !B9C4%1GBR;OYK]>"IS((]N6:'VG 7
M"&0PI@C"U59,C I^$KF.HS]R8%)UP#GN2W+4YC)<BF:]/PS.*J65H50WC-#]
MF&K&"(SCFBZUU2CXN@R7/&C:/C09"B,[;4DE%Z.Z_P M<,3-573X6YK)FG^+
M,Y*?RY=>F%YHVEH,AFZS?V:3,Z>S-4Z8!<5;(\2!JB0BF>0<]KNOO]^!'$E+
M .0Z ZBH0G,E"OX=,3#S(X+%)#I_-KU*YZ >.F'+>9S4Q?4$J15*P@K[%7/!
MK>+9LB3XY)%NM2?3D&@3(K["<&!8I:0>2C7SF8I*05"'K[\$=*7,*X)KJ*4F
MHCST+>NH5?PPGN,"@0-:J1&X>/\ W1KK^&N,BOQ6HY_Z2Z%N_/=^Q]A^TG-N
MZ=^:V>GXO:)JBWVWU!'+>[[4EM)8K) 2=WJ72ZS11%P!,<9<\A&G%-[NK>RV
MT]S<\L1[R: =Y7T2[<%JV9G(+B$[Q]PN9]P>?<I[@<SNL]UY3S"\U=[O-8\G
M8:NJ<-E-2QDI36Z@IVLIZ:%OEAIXF,&3<?/AO9;B9NRD]PR+_P .7!>9NSG*
M1]4@@UPX_EDHU<DY-<88IF^J\-:'J=0B'VYIC7V_C 40,(5C27'^"(NP?(ZR
MNY_Q%DDCMLE[I 2XG0R:.Z9^W'H-I8!E$EW!0^H78BR<@&KWAUVE_3I0P5'&
M;._8TK14Y/\ 1W>F$T0IN_)C4 TALG7HMBQL!L&'R"F+#1!],]&DL:-I3H2$
MSZG3%F3!/O4=^_5ACK>*U.YJED<@)VA"'-S(+>AVX'=CJCI&*Z8,H4Q7,)]3
M="ZS<GD,;=G^<V#>6[20]X7W9#I@VSL'2Q'%?/\ K0(DX+.:K9_]#=3)+Q^V
M;BI2!2=$<A0!=<"W%L1NQDWL%N= D)V /J&?O_);JK!*#1TH852-C"NA0!OY
M\6BO3'!CBB.;.-Q 4($]F:'\,6*H,4&<DI3443FL!<YNUX "DD$J ,URQ7.N
M")B%&3EG'G3&20-)9)N.XL),9+LVN .69R.,H2U2T7,7]_-!($@QQ4:.0<2:
M;@TLB=JX@AI3XBH(Z Y)A5R"132E3%I$1=N2-./6$0&$>GL*-!(:2&],BF2X
MB(,C3!&B&[4[E-2D1AH:%#1F/TBW0G[!AMJ,*?%%%(L5[^3>'>5I7(HBJ">F
M:#[,)5CY@0HTEZ+)CH7D@%I!**4.6F>>9*XFI#QK\_<JF!>N"]5%K#AM?&I+
M2W0*$_\ -).)$;A(8%BI$3DAZHLX+G-=&,W*Q1D$Z.VY$C#@C;C%OJ"'.)%4
M9<+:Z@K &,#22H(:0/(-[<\M2$P2W(0EJ.'L%>U1Y#!2BM-U8Z*-P<T'(%/Z
M: D!3J"?9C0[4=P6(Q1=%=HG-\V1R3:GNSZ=,<I=L54EX@:,B-<R2/PS..HN
M=)LW):6/6>)J=-S5Z(#G[<03&-26"X:CDDBIYA1,)6I3=D0T?GR\,4]6WD0I
M0C<NX='2KYV$ YDN4Y=?+E^*XJ;\!@Z'*>@.:A-+W'[V-LW ><7.V/CDN-!Q
M+D-90C(AM9!:ZGY9=Q0D5!9KD4..%\:AVY^V:5N[B,[4HP/C,3SQHN8<<NMH
M;1<=@HJVMKJZ,VZ6*"*)\]=<*R&*HN3O7I'!K7ESRV1^XAOH [=KMKQ79>.J
M<VT#"'=\$U'.7W+D?(Z'BXA:RP<?K9YKO-3T[*>C?<0((YXO7<9'5M;%&_Y0
MN(!DJ)7(U6. 4W!_3,1R7ING_3P9.3VZAI+;7,@>KZJNC<ZJJHVM$4+81&(:
M0>F9C#$(G$0L<YGE&8<_<['R_P"Y)ZKVB1\IPY%?=_LZ(MV(SB*$5[5,SC-6
M&1THC#:)\2RB8#?)*P!S(S4>0[8IXVA6@]<]<>&G,>JV$GIW+ZWMX"5@2EXH
MF.&#=GMDCZ.GEE >^OB>0Z5TS9)0HB9$9(0T.#0U3\.N8Z'$&,Y2QIG\4[:O
M0MAO3.JC%NXU1;:*ZCI80?FWS21%OJ$12S" AY +4<QX,P*$%H(.CAA_:2C:
M@[G4_<.!"'N(7[\VT 0(PH'XORSX+Q4U+XV,=%+&(P4 GE>T@;G-<C96L.X[
M/*/T$0$G4LYF,7B13BKQM1F2)@ZN0':,"<\>:OMNLGI-A@6$Q,:)"V3<UFX2
M 9-+G;0_)R9-!]B8K#<&?@%.Q!N;< ZYUB3[=Z6)9:FLMI\L3WPL=*YKB'M$
M9=M<'.V 3!Z^52'*@.N'HZYV2 SBN+]O=P6=",+5^K@2I0-^)KQH@:O?41,>
M]\<D@W21/8W>QCU#FG87C8PAL@W*'-'CJ#FWS.,3JP'NJMZP+4CIB0":\TV5
MXJ]KJB>.!&2S+Z)].>';LVS.#2](X=L;B@Z9IF<)4<RP^2T0(FWZ1-0.P\DU
M-]C>8Z1X(>U7N<]I:UT@D4PC:04+(7%"THA54Q6C>$NA76J2$UEQG?'3$.;*
MZ-\[XP(G[6Q&1IVG9Y0J-+ETS7+#%EP=.2Q=_&&G6!XJ_)1'Y3<)XN4,N#7.
M]*FD;Z37NVB(.E1DDFYP]5T*'RD>8%",\>OZ;*-HQ)7Q_KD3>E<D: *2O;*^
M5-B9=;'!/Z<-1!+=++*[U/289:<.C8RI>0V6.HK:Z"4*-VP.#@[:3CZ7M9G0
M ]#5^Y?$^IO*3CS D$>W8CREN$M//'9;Q3T59Q/DH IV/DBA9;;C7U#YFL89
MJF*"E/[WA@]&,EK*:I;&QPV.\I2;D#K&!/B7G;\K9#5$LB?A^*C/W7LW-N!W
M2R7IU-%?K19KS46BMKV4<(J:VT2&L?'8;]ZACGAG$-3-"L@_:-C>8S\S,9 S
MTAXQP!?WY!+B,)$&;U&'XK:O].-79Y^V]OKN.5KJZS7>0WJG>9?6%-/5_P!G
MJZ*0@(RLBJ*)PJ&H#Z^]Y"OPUTN6JS,FD=5.2\EUQ[>]B"VH0]_/O4CHJUX@
M,?G0@A0FT9Z=>F-&I*S(B)+OX4$\@JBK@25VY$H-5Z =,2[T5)-@31 [*G^T
M- T!&7NZ_?@!Q?)"-1WHUM50DS#_ %7$X')='%DMS52DY^T )EE[\55V6.RH
M!>U3UPS9^"(&9&-JJ$/7X<\:-HC6A2%,4<6R?J!T=_/X^S!Y^;N52/ QXK-E
MG7=GU*CW'\N 3-65SY>Y#US<?EI,^@^[ ;JK982034D_+2 G(JGV_P"# LT$
M"HXIOZH@%Z^/X:)]QQ,/,K/XDC.D\X'^-[/?ARTU5:))D"E*&8"%J ]?#!;9
M\3\D2X2:9I$NDQ,<ITR7\$_/@S%P@2'B)Y*-W-Y' 3%<E.7VC^?!!BD;H#)L
M:-[O68>OE'XCW83OEP1S2]JI4B=SO'_N?7&6M/\ ^%2X_B\=VYIZW@/92VU3
MA24%)+S[E$,3R6RW"L-5:.,4M0P)YJ2EBK9]I_Z^-VH&/!_>>_GZMKI]LT U
MR[32([@Y[PO=;ZX*6WHSG\%ST<DM5153/>8W(KG$HFY,DSUS/V8\OM3+4 L3
M<7($ 1+R"C!W#M=53,F9&R17;FC:#UR \,@<>RZ?+5X4K;FYU81;#@048?3O
MQ>M;S[ATU3ZD;&7FCD;Z@(W#?NR49ICW?3[#Z2D.H;L>C* P)!]Q7;)]-L/I
M\6M+ 00*&#/0*&L1? 8Z[$1F0[EU[/IDM6T@3_5#^Y3)MZNI:@!%,8U) T?U
M"E,L5R3^?)-#W4I!5<<JV'^@=0H#=A!7Q"C$%5/E7-[]87!*>:_B<OD0U\;G
M-8#YBU[B-1E[1C3V C,-74OGGW'*5NL0*'Y_T*;7T6VIEKXY0HV3R,A*NU/F
M ]X/EPMOHQC?:."V/MJ1EM@3Q_C^*W%<4!=0TY=HX+X)F4!]H3"HHO6G!&SX
MW #>US55%!"@]0HTQ9\D-CBD*KAW@C_&1V?4(OB=<5(1(EBFNY+9V!SML0]&
M1OF#0?(Y0-R#0N)]RXSMS#QZH^91.+U&*9"Y<6<ZK41.D "M+%]I)49KEEC.
MF2;C'$E (+\$IT'&9 (W>EZ>F;T!&8S( #B<,Q.D9F05@ ,*HKALD+#^L+G
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MZ;D5=;Z2QS5%#ZE7:VU<#IZ.@NS1'+6&WQS!]!4>9QI'3,>T.W-. W!'TS+
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MJOQ7J9[ 2N&Y,DDG!>H>ST,DFYU.Q"C4$8*9$)N#6Z8'Z0X =ZK_ )9;U:I
ML<GHK51V)MTZ^I0QNW%"3&%*=%(&+@2!<,Z)#IMJ)<1;@_X)./8BCBN-LEBI
M&-$-3$6[&AOIM:[H0-?QSP_8W,XS !+9YNE;W2;9)F*2H5L,[:V*:TVV !A8
M#&QC&DHC&,VL(;X.U\=,;$:A_;W+?V\/3L1@ !+\U);C8E]*?U AW0I[T>#X
M)IBR,U623<8!^N;^T!<_, C<'.TVNS 4YXA6PQ38W7BD5?.Q\<;6@RJX;04!
M(5PZ@J<AB%$[<9C3)%EIL=+:X@QC!O S) 4J54]%&):KE=0!HX(B$XC4@[0
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MYO\ 2E<UKGR')Q/5Q74#[,( $XXYJLHP%#@PHDFP<XO3:>(-J'@DM"AS]",
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M"8FGM[47J?N[;V]M8LW[<&G"Y$$\I?Q2%:>:4M5NGDJQZP=ZJR-:Q(6RRAA
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MX*%?+R!-* 4/K@9^&:@^XG\<,V8@3((H13AV+RTB=7-(]YI5M+7;%#2PD($
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M1GDB(#[5."!B&(1IP.(4?.[W9/M_WGL9X]SRS.K(J266>T7BWU#[9R*P54@
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M8NU$367=9-)4;GM0Z$=<LL_SX/: =U83<IR+)*I8%33VX;MEBNEBG#H'9%?
MC7V 8-,8*!AWKS4/1?Y_L_$X#(JTJ!#%S=^J<G1J^_,#\^%[BB%$*5#A\J\9
M#,E?L4XH!FA'%D!SD@N*^W7WA,7B7*J^2\Q.\P4KF.N&;>*M U2\UY%./NS]
MO\V#@Y)A@AZZN @<%3+IURZG%QB$(C%1@Y],@ESZCKKGA@56?=S3+4U0M2P
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M_3R<K[4]TK%'%Z\USX#RF*FA:07/J(;545E*P D#=\S3M3P(P'<VQ.Q.$<3
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M6%I)\R*2,P#C%O,:C!(;Z $Q*&+GW,BFT6*-M-3@,&Q6A$52F1:I7-,"M.9
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M7NQ^!*^I?Z9=0'3_ +ML1G_*OQE:/:0\?^(!<V?<'MTY];='Q1L>V>GE^8@
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M1-@&'-EBVSC[:=Q'IH&C,Y@G3((,A[,.;?=:ZGS+R_4K9 8)SK#2!KVAP'E
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M[8*6MCBKME:9I'N&T2/I9)HS' UVV-&.#2J$DG3&:=YH#,=8?X+T,M@\=0K
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M0M6Q5PMLG;\F.FH7#38Q-N6FWQ]OCCQ>\(UD)J0 #"K!2,CE=\I,A&<3M?\
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MN)">8C:4(=EYB<CIHN.C$Y%@NQ*]U+I'/@I(U]6H=M:_S.?% P /F:&K\+/
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MCXC/3 6\=4YZ [EBCCK'(H#ES7[04 *## CE%W59;>,C0)?M]BCC=Z;8U)1
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M/Y3Q./<QT4*#:[<U#H<]P'3+!H:@.:6G9C,-*HYH!FXZ8Y&#TB"T!"6HJC4
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M7*X!7$D*$;HF>H0 8-!I17EMW<C&3C#!7./WUM0&H]" '#,[2>N8_I#),1(
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M?,(@#^\:_ -WK1Z79C>WUN,ZQ@#/OBP'N)?M 7'#>'O]63/<IW%=0&[BIZY
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M6.&2"N05DMVK8>(VI\L8D:*B^UL# V>UVX.VOB9-(/U%?<9 Z*'])GGDT:W
M;DY&/HP?437D/:@5XQ'F/E&7$\$86^A@H*>""EAB@IHHV4T-+ @BABB:UK(V
MARHQ@&J#-3J3@P].%L 8!5)<N<TJL5N0 VQ (YH#G,<XAV9Z* F9Z'7':=0?
M!1B&7V60M9&)'@N0(B%@VJ%R!W[E"[AE[\=-@QS5G8,5C2S.+ "T@@@!7M:
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MK <5AUMWA:=C9(6*7-)+PUA .1.1!+AX'+$$G/RJ)'@@ZX\@A&7K1EH&9;.
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M53R%T3'":FL?&:>M=43U!1IE;'$U7ORV.F;.=^[^ZF-.UM$$G^M(5$1Q)Q/
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M(00@W.8 \;0%5',U7!+;(-S(KH;_ (#W<-_$?JEGX\^0-H^X7;[EU@E8Z1S
MZLM-+2\JMQV@@2N6QRM:#IO.,OJPTW=M?P NF'=.$O\ FC%.[(ZHW[.9MB??
M"<?^6176U=N2-;'*CP=PZ',+U]H&*&@52R;.OY+YG 2 HHUUS]^*:G5"K_[^
M?_3_ /NMZNN)UKG"U"S<)IZ6_7IXC&=ZNCR=B?%7U!* 9==<(D!Z_%>"N6@9
MEW-3\TMTUE@ADW(%5H"A$'4G-.N(G$8+HV@"P#%%U#0!V32"2@0#7V>Y,"('
ME [T86"2V?O1C;K,UCV2MW;V'<TC)",M4P2)$0P1)[234Q3[<1Y7^[XV032.
M:UJ-4E -JC:0B[3J/;AD2C+#%1;M3MS#"KYIXJ;GU,R#_+&!6K^T 1,DZ$Y^
M..;D5H:R'<%-QR?G+YY'?+2DH4W->H(S4@ J<^N!3(>I0+EN5X-*@Q[U@V/G
MM13S-,TSM@U=OR!!&HR"G$?IZ6''F%2U9E:=C5\,BGOM7=FEIX6;JD&0 :[C
MJ.I 37%S*)SHFXW--:@\ED3]VX)=S75+6@^+RB'KGKEIB0&K&@7>IVNA:N[F
M0$D"JW@9MVNZ^TY:XB8>-%4R)%!3FA.K[@-G:6LD(3^L,S[U498%*,:DUD>"
M&Q)Q +Y(*N/)Y)U_6!0JH<RN@)<I7W8APS1&:K*S"0S)*''7=TD@+W*F7G)7
M[.B>.(<O2BJ-K '-7Q<HW.:7.R4 DO!R7,C,'+'.2I_; %P*!<&_\7#E7=#F
M/UI][J;N%7W&"JXORNIX_P 8ME9+,:.V<+HFQNXI#:H7GTH[?66B6.J#V!)7
MSEY)))QZS;W/5VUJ-K^3&# #C]1[27=:G2-I:V]F4XC]>Y,F9S+%@.R,: <.
MU:A;H^Y4Q>9&RECG;P]@W %A T+E(P4B4?%$,%JB,9>9)!N,KP&.+AM;H251
M1H"XA' G7$>K)P<UPA6N"\-J7O+TT:A)RW %$4GSY:88LW#+PG%!OVV&L+(:
MX%NYQ(1#N7(@D$DYIF!^7#"!J>+%)-??+9;FN%55PL>'9-;F\#4AVN9T ZG'
M>K"$29&A4QM7)%P$W-]NEKN\<WHWQ\3@Q[F1/B<(R U0%V JXY%=,)7+MN;@
M2H66A9 $1$@.5*7C=4:BV4DIV;YJ.C?NS<3O@:7/0IFJE!]^N*@^+2< AD!Z
MKU7ESWAQ)VM82A)4N:N1\&.7W_=AF  %,%2<3*GTI/4.5J;BU@4N4A#O: A:
M=$4D9JF+,<U24@(Z0,%8<""<T1 &%0@( <-REKE T5/MP720*)<DJ]M^% ""
M@<C7N$8(1<LU1-<L_ 97KFHI3BD>JVLEF.P[2YDC3FP-W-=&YNUR;G.<,_!%
MP"_%X@\$:U)BRLP2/<I(0A5!3<WR!20<_)[-,*D/1,=N"(K#+Z=<GE/F:&@G
M<%S*H20H Z(!U]K&V!\Q/A_)"N,".+K<!_ ^YA_=7Z]N5T3G$?WL^FGO;;(0
M4].>HM]FHK]#"1T<_P#=))]N#69 =2M0R(/R_@M?8C59(S$@?<?XJ>_&+O4U
M%DHWUDES@%SMM#7U%?4W?B_'J*K!C95UCXVTT=1<JN&>WSF:-Y;Z\L=)#)Z=
M06QU$/RCJ$YSWEZY,D"5VYKE$4J=)G7*,#;N_P#]/$TQ7[LZ%9C8Z+LK&UA
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MB4,>=Q0![T<UVW:QH:"$4EVT$DD%/8<.1.K##/W+S\O@LV-Q+W%H?$YD8V
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M]/KOK</_ ,P&'^_$Q^9![EVB<@Y;Z8E9ZS26O(+@]5 )!TZ983)&EX^4J['
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M@454OP%[T3+9F0';7-S;M! 4$+X>&F.+9K@BVU3&*1I4(TZ9AJ@9-7(A$TP
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MFI/$YKKAU%QY<@E6MK(XT56[0\$J U5Z-!:YG3H%ZX,)-%GJAE!M?<W!H)<
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M$H3,2NV#Z%*"*^?15].U<@F<>".I9'+O(DH[[>*5["1IL]%$Z )C(V!!M7
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M_,[>XE( &42\0<"1+7$/BU)0K33&8S(7[G^QIV=]]N;*5^+B=@6[I$97):9
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M*]#_ )-+^L/Y+?W_ ,D1?57_ +*J_P#V0_Y5%_MB_P!"_ __ $+_ /\ 0?\
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MS)A.7]U5EA^2QC_^1#]G\M<+RQ_PUWO4A>+_ .067_<I_P DH??_ ).SX?\
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M^Z;T_P CT^$__)_-BUKOP0KGER6_C^#W\??/_8G_ *-X)_J7^P_R[DG^D/\
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M(5N(>/JY>&%\15P\S_Y&0.$]L1Y$-R^BJPODYQQCY^KMI0"%_MZ%LYNN[M_
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M50O*RIFYYK]E9_T6)O?H^@LN[LJWEN.]?C]B-YF7+@I4S-W/C?2(C6BK5MR
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MEP-)MB%W2'NT=6_$N#..J0JB'F2FWV;:^\'Q0QD,9Y?L-!)0C@LY0T]UAM:
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MT!!SDJZ3FG EU&OAF<FR%.&(EXO\@D="DR18LOX&)--,-,6Q+SUSA6 \]Y0
MW!W,B-YV1)(J-5>-K\:-:>1(Z[&]QVBQ9PB)@4N]/)DPDOL$M;GK]T3SPE 8
MO"3RIFY_Q(M=>6E\8X_.*[U59=&H*;P@RC75*:_.0;MW Z&^E'$8'@B_H7]
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M)VB$QN/5G)-3@_Z)A597W5&KQ\:+_D=___X#8&5.8&9C)T#:^H-$KCH>0^\
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MT3J<,ZZ2>S1M(:@WR9-EFG$FC'*"0W,>4S]9H\LWBE2SI+[5/(41+\OLIKZ
MP'YLEQ:TSDL3]L)3*#&A<4G@14-^C6)1U>8<N*^G5FC^$1OC829V2[%PN?A
MTSW.\[@WPGS4^"OB7!A#+5G"]7M:Q:0K>36?Z3(FN1J9JLY$K6WF$B)M6(BL
M&!S(DRKPE0\N6K,#''I(*>9US?@M.F./C;?"+ZN.I5 05C%*;G(YR2D0BO=:
M?A32+'<V"*77-4G%WDW47!)VY7GEJH_ 18PY18<X-?[O6W,O-)34T#*V7+!E
MR9CH?(1R%]2FF'G:D,\=1'O&5S0_5##>%V=CX]^PX'R:25V3MGH5*"7GT^U:
MZ> S3ORP<AKA9QBH3]>'\@2J?:6^F"#DT3-<.O/(9L%V]R[S_/3P %A.O[]:
MF<TK@U]< 53A$&3)+(>\-(>I!ONJP&_9(%Z/ A(:3#VH8-&O>[L&)&3F*DUF
M @C,T98T\[(2#E+)F-);X8HYX#@_)+F9,VT7.6RUX5(UZ>>0X-CLYW+0<]QU
M:2@;.(6@/2T!H. R6,I^AB81L]8['$-*-A&X&DIH3<[3Z)]RK*%LS62<UP42
M:,&I=LED&0JHR*$:\AB>8V-\[/,8-%*ADMHUZN&-6L6N<BW$?Y ON:V^S%CB
MN;R5OW\VOE[W^VW,L9CS2__3IR46?,V&G8.+ZU7D-JR55R/-%NE+7AC8*,$X
MF0Y?7*/,J7FJ+BR;'&C\UE;^T,4OYK%]?^N[26I#T/@4=+*EN!S %A)6(6LM
M F'!0[RWE8>D9:(9^7:/[0J+E^Z1')B+) .YU7=P8V+*B+H:RE2T)[2)*R?!
M'03_ 9CRVL.A<D9O=@G/HB$>=AIX )X^"R.#O/Q&$28??44IV27^Q!1^8?1S
MFU 0K%"]0A/NACF2^6SU7\Z:_T2Y*2*Y_,@F=!03EM)1:9/5JL,*P\HJLD=?
M)M8O)_L [(;K"=6!Y&)=$F8UZBMS]AR0U3A.5H .Q/L#@;J/I-V]\%WD0Z.@
M^J7 -*[C+:?-M]XLF&?"46I94GA\E5U)&%=B2X;ZKS;E9FE%PS]:#^.ZHJ_1
MA);UA_:T%!P'C&>%<'2S::\U:D3/A\6L-,:H8S?U4:Q%?Y%0AM4U4I>::S\3
M4%%&\E)7H5C6>W1",!(.UDN7:M)&A"6));'@@W\?,5^1&[)%T=N5)2?/P'1^
M^JTJ@UP;JZG7S"Y#/$=T]_3]7@YC (.C1(5? [W(-Q_-U>"))(TM/&4V7>+Q
MK5UGM'(-PP9<3,EXUN\#@ 7[%LOOU:4ZE;WX&++R'7V.)CB?<I4O34KP<3?E
MR[>_.6:GESM0(VV97^X";J%[QOL23?@M\OKQ7UIS+D;]AG X.=DI5&VXX?<4
M3T5 T=J>K0/[U02="2^&[SN-_MLO 41;#@'.1QT]<[8C"E<8)8FY.J]_UB"J
M#$41#*:4V#WHA_.FS8%3>C"Y\<#L4OTDW>-.I#2G0NGU8'W"S3LIAJ/ 8D+*
M[W,$Z!NQA/9(:ELD:0:BA0<$$]SLJ3E*@\&W" $% 3;=F]U.VU&Q!_X_NV-N
MH8:'?3SS;,!VL6#=)P*\\.6J,F"<Q*2\XQB7XF"A3B>^U_S8\)<!0?NTFP80
MH"OVO&G]51Z\-&XZ?)T^FW[7U<O$1WR\8+_82U5'R3SFQRFSD[\DY<L^[A W
M*)"U?HZ-^!85*TN=VMQZ6_DG8+M$N1/*BBW58.",?JY''_]GH6('RR96CM5;
M4==:US0CR?@367,B;G[_[E=19]Z(WJ(\KE.);C'X0-F@W@K56ZG/AB5I$<UW
MP'=4-6O)2;/]RU:S?Q%&YQ9W0C^.$7-.D$/7Q;4R=_K*1"48XU+34*]?*:(6
M"Z=\KBNGQ\_/O2A).VY5G60[M^8#[U^@JG:674'47DB@_QLC^AY^^0OL64!"
M1>+">/DZ+V>SRMH'P/.J84=P*(T\&IIMNW]_7P9$F J=;)J[<W3%^*KH<KL1
MTYI70=^+"-NBVGMWZ(L5Y+7&[&D;R9W>%1Z5S #S6C)(Y AS6!$7('DL8" )
M(22Y_ !\Z&NZ7.'CZE%8EF0_:E[E!L$D[G3B[".C;+5G87O+1[#2@V+*W1>=
M,,QY'PB*BA_I3%KFZ^]BR#;C+7)B_ _9%^:A"#22[QO.J.-<5^1-K (\FJ]>
M[.L=]WXX(7E-KV>BK>&)>!4=\N^AL9K9K1]GSK<N^]5UCRZ@+4$9YVM:7*ZY
M627(Q*CSP$JT_Z:ND*6//,]?QZ'(/=WP_ .(U[U%K):FG$2">>SC2$G>R)/%
M4VGF38)3'1 PF*\6XDDYU4RH5&0-I6W;>9;&[0Z<ZM89\(/8-FEM9[A]K+M=
MZR'CFIH+&XURB5=]S&(P[RT";B-](^A#04<R]3G.3W*W19 F"M]SP#]*O+)E
M:GVNITQ<5F;R\X(JN+-,!A?76TG0;A7M0V#6INYO[I?G*HD^S@\?;&<5?1::
M:;U+*+3C+7!BW#!+5>Q\W!9DQ8\^BW>+RH%-?C)"7T+2A/M2IJ9!_5PA];.E
M(D"BU]^,?&%,7''#KG/MRM&^@<R-JBUY^+@C' X#26)LB]4%5TIT6![X)?WW
M(L<Q*\RWD!L,^%2$.7YU^+,Q]N5&3IB+4Q46627PAQ-Y#?5G]UZ1=(1)?N$L
M S1!RAM1(Z:*:LZ)C;#?$D\/]#HK@GBS/4?@+0K)*4\L *# _"B%^[?]Q79B
M7U2C-NA8)R6<8C;]CGI>R&(U.ICIJBXX7'>*-H9D,\N3#*9E9'$)29'U:CA?
MX[$1A!2&A%9_Z]V#K\&<M 48#WWNG? 8E89PU] AB(KL#=;]![3\V"('*^<2
M]@41VRHVGL7R&>\8$*?S+=;T.U$[T1+P'F4%K2/3I)>*D.,TX:$QN:"]O^;)
M8T^ WMW?Q_LC]TYXAE+)\\7>T64A<+*V+T@0?>9?TP%1T6A\ <W]!#)3?7KR
MP:6D(L7HD=[NU?6H")E+&5?S "0 F@CMA21\^"1Z*HLWV9,.C@%2QJ(,)*)H
MM<*9ZP"MH>UUI!H*U##*+X::ZMFP52C46B5(#!?&(?@V:40^&=L(4AF\?$!]
M;LI5OP7)3(JRM8!:6]_[_,SF#O.#JW] SJO@LY<I=QSQ!>V.I\#(:MWL?H$[
MY?_T6(+(.[KS(7#R<*8Q<B0AQ#ZF3$03O/ 9: 8N$=I@PHM4GTLKS<5)J^!C
M)FRCEA,[[?4W#0$CX5%5CL2BH=L$4$E,-?#FDG-2"#=910I+U')"E"*D,-@4
M$>;<[Y&(CU?6@_(@7.3VH^M#&\57%[(KO6FIZ[['%S%@4PL/AR,_?0!Z12'Q
M1]K":HH[A.5M]T4@,9"M?J$]HK[3[34M(,MG:NBWW8@AXZD:] 5HVMRVH99'
MO9;OEAD40Z%A=(2 +;MJ10S5K:P/4U-YT/63P$Y$PT!?2S(2:V<]@/W:*EB$
M5$..Y29/.D[@I(']$[IAL"U1-"$T./PH^_,'M1"HP_/DWA0(VE'3TW'_ /A8
MSKMAFIO K92^W @]@61W?S3+8H. #+(/=7LW4&V/F,D?@%J,\V(.\0R7=!);
M>CMSF=8P(E@=<@A5840_=6B458PW,26?VDD.2!E-"O<O@X][WE),K,8Y*3-I
MW[[(VJW+S8U'A_#'9O27T$PP+%#I&"?4!3.!& /" P6$PRC5W,A\X5CMK>10
MKZH,?K>+SF!<,HQ"CHHHR<AY4CN?5V(3I'FP$-+DP.\HC"F?&*#.5$BA4A0J
M17>+/$#;W5?%&+KZ'3>>N'BG[B0Z4$D-7\QXW.8_99]DV'O.%A$TN'+&0Q3&
MZ;<;22VG'&^W.+1MX&64RESV",H;,1YJ;R1,'TUT6+Q8]&Q1YGGL@&0MDF&+
M&.P=>G;:8.V0UBQP$!P+Z"+\D)B\O'.7W)B4=\_T8 ;'JR(0.M'U1P/D\/-3
M8(Q3Y7F(=-LDI2>$&F>/-S;XU7% C8I*;F&']CY06>#L7GG9^0_L \&GVLOZ
M]O'ZM+[IY \+9U<)?QW,NK8-MZ3'O.!IB^P8*W[6%UF%.=N;*<W83GA5OG31
MPZ147#1%U%'>\G!CW+;7:.F9Z[X!7 ;8FA_Q+5N-YW</?OKZ2'A$G>NM.RUF
M+6HO:ETN\!_N^\O>R6PPUMJUNS%+")F%.5IUA<SU6Z0D.9#:Z<S6V6W.Z:QD
MI91AQ;C-W##6SQR-$U%U2)X1&4G?URCW"]+$XC XM3U3=G7;*U+YF*>^W\PX
MWQ&!%&[W.3OKP? V@X=-CU_/>-KIRU8O.'[WW0?K4[PXO*+;N2>8:UG<-F/'
M&.$P6N4/A\[B'+]2@J.#]B':H.)H0X=.:IG"L5-]W2@G\$)F/ L8JL'JK)F1
M4,.-R]011ES,RG>+7A*K.V,(%I)<D0B[-J[R+?\Z)"4[9"'\W/"2]Q0BHP[9
M=A<=RD7XD3J>IE8!PU/DT#X>8;U41H9?L5-"]L>J>;..TBX C&>2O0G%]\EO
M>;8GLZ>B[KWT:6D']=B^I?'!*![2<\-1'\&_<"@%5Z&598*],O5QKO589DZC
M99T AK0KSJ$_\<96'WX5.>HV^/=#/>8Q,MVFC]:U1KG'!2>L3:"HL)8TUY\^
M_LTBDT3H"X/2^=,7RZ.6LO-GQK+7G$?=+PL8KH[<C"Z1)Z;M"(B=V B,,6/D
MU2N"*6?C=63TO<G>1((!!K JUF+LONC!Z;+#U)_];=K"H <1G8*O[A^B6P==
MIYX>?<4%^TQ^Q&4_K5;L5;E[CY:AAS2#-RUN/5'[@<EXV]IR:-UYAZ[S"?4.
M9P-PD8D4\I3CIJ[$(27HP39RB9!T@_:4 YQ"EY'9R@\ Y@.Y[0YC3O-50F,A
M?JO4\3@H4\^@8UK&(E+D6:#J#Q'L@:^MJ!B\RX\R+[B2./25,$^&%CGT4L/O
M]]RLJTG,CW%OB<<[0:N5RPLDP;+X+8:_D?S6,#<EUYG)_.U$RZN9XT/EX>\2
M 0.A(A3@;DEB:A?\L^WHVWWHAH2#N2!ZF2]UR[9;PV.'+'9>,9H0P5@=1#0?
M@"&BY#RT.78&]_Q^TI--TYT47?@\+<Z76K),/_K(-GDO>N]UBLQM:0QBMM&E
M*0TF,78<S_6?>X*80IB&'1<W':6V*L/5(]]HFI_R5W@3(2O"6Z8X&!E+H"J+
MV[ ."+08(JDH3+'(YN$X78WZT<$HKW4.;=Q4!TMI*(H?M>O!691D>KPR60!8
MU2(ECZGAE1!F-4P683>2S$7R&]K@LL67A%%PI!0HZ?KZ"#^B2BA':U<QV:AW
MHD@!4DR%Y9P3&"4.30*=G$C)VNL=ZIP#I8S!ZA  F-Q+ /P25/(^W%,P3#&3
MS5K8)#<D7@MK^3@UD4Q=?^R2:$Z%Z!E K!T!0U6^(B6A(K/Z(4USYKLGF8ES
MXK?TZ'DTB'P<!NUEZRUJ,FQ2@R$ ?9&Z JRXD@69"MJ3X3R^2]MS$%'R; F2
M%<N\+ U&6B:,9=DDC'$F/WU(FXT*08(TGC8%X[EXQ *I7(L9@SZ%[^\B<ID$
MXFJL[EX2.)0VAE,#/MV\W (>VYA$,*P=ATX]3LZQXO8GZ4'K"$W105,8NM8Z
MEBM JJM#KGP?6,E@F3PG4(-&"(/"(I2V748"14SZBYAI^T)QM?+8@HJDQB&-
MF$DHFC<&X90?.1NI"VE?O*4K%E84@$ UWGKJ=]A&M(?=<%Z@6IJ#F(=9=!\%
MB/YM]4<_[X5)-#BY&857-@A:!06J&-$VXY% &AT37E8FGU*),;*PQ:B5F_F!
M' 1_5U3D&%1[-?".**Q'Q/H!Z#($-RUPU_P?[^V8!["_/(<EZI-=358ME'?H
M'P!Q-,:>E>^5=J^$):PZWU6-B"(2)0#O'H+=@L_&#S93%/MA/ N(<GIQ 6HY
M]<)J*KK@B[0BV)V_/ E#H!B'Q'!+_X0SN ;156(9XHY 2+I="Z!+3+3(X,CV
M?RDR#=P4H.#+H@H:CI3F/@.&!$-Z']^HT93Z&9*_ITQ:7 QVAW\ XML=51^_
M"D[V_"%SO2X5M'"#?Q"OF#-"(9AE_$)<G1HN=8)YPX.BB7R$U-[4(_PM9K]B
MU2M\A$5P%/E:EO*7]DL"2B+K3_#J7_CXY6U,(<Y^_KEGU'=OXT*/>)>CTM19
M'5Z"]\RF$]TSBS5?DAB/M!4AFI/N7=!B46$)6;E>=D^'3$]Y-QUEGW2"O']U
M.([$K46>+SN EZ33P *@3E+)S%@?8M?6B:^_ X/EM-;GRW/OX6<KH73-RU'V
M[NCN['>7@'L:X&7"5@;$[B E";)TRIPQ*'?S(A2ER]KS_CV<&%LXWL1"F(#O
MTK8B-$'0FCS>6$JJ@B>XC>R(+_P?@#S$4".,]ZPA\)]F[C3CZ1<4EMVK[AA3
MHEM+\]%4_EHJ$V[\:Y@_$?P;1T'D.,/-'=-NB2(([%J^Y+7!4^QR^15<B1:V
M94LS6DP!E@\1&P[AW]Y/G3LLOB\=1^KW6>,%>CY:%3#D^B4QRXK(*Z0,LP7R
MOCWN.C$=DE^+9#2WEL#["5I,Z7['O9E ]C7K,*I&<W6X<PMS*H17(AY:HV!'
M(5IK8YSGS8Y]0&U=[\?Z4TPE+<"4#,,K_V<&K00E",9W::NBN@PF-^QA7B@"
MMMOYH<KM>V@@:3^A$S'G]K<MXZF^6[L?^WZ:LVX573G3?N[1)'XG';Y/^1ST
MA7NQHK1*)?E%\HT+&_KCB,Q?UX@H;?+2G.;_5DT_!BGPT#?4MS,C;2)F?  H
M4^+YD]AVJC*Y70GO7#I]G"/Y7X:Q^F#LHD,2RLQNU[5UGEPXZ5[].]P9(Q?L
MV,N47'GN@)NM2[]WH-8?!3.7<4BLNR)A5D_UAMOA *JWD/X1O;4)VDTX+V=W
MM>398?49;1OJ%4A7PU!T\GK/6OLTQ$#X6<YU?'QQO7GD[/EQWJ_HE!<70PJ;
M#_351-04S=_]':AX>J'U#8CP#E83$$NHAQ93%"1KMH 5"A&LU'*6.M*>(UQ:
MU8R40Q,J^V V8B4E]WR:+)OD-5O\U)6KQF,MQ^_YJU>>V%S'A$AV1D>CL7N$
M*!JAX2]L?3B+:-ZI8W]\OR.CHX@>NZH@9UW7NYQJTV_PCD!U=ZQV"!/_C/T
MF&\Y(*>#%.$GXR.EAJ>88RX!O*FV=FM[SJ0N?JW;BVWIMOU&=2'./H%$%=#N
M&XQM^+(;AE+L;=FF2-)M++Y:VSV%@@$'06H$PNH'30<]90XIC1M%U\]DK%PS
M7MU>R9>B+6)$=]P8ARO%R?MJZV?B&"6$M81XZ]V(VR'Y>IP]S3Y$9L4W M@%
MH*G8NPGN=?GI<?,G]7U38+9\<+X;<3H8.43-09#@,*]B%G'&)3;6=&?S7M8*
M6[-T^\UQ=.));YM7"DZ7XP)#(K__ L5L_U/+>[VV:;N4)X@LC5-%0?0$-5])
MH/%<MMYZ:UUN[Y<Z"T(PSK#B5BUPLLW;9=!2(^+[#K<C\*?N!&5Y7A;4SH-/
M:U.JTR/_2)/F*XL$&41T1AM8N, $<&>/2#_X9\1;0&LY1$A&_$3RZD"(DQW#
M<V-)^VSR(NTERX 6GB44R?T-Q)VCK8VOQ_06!D-+X:/@0>(T(00;_WW3NC0#
MHU<*O:&N0'0^0@JFG\[QZ/PQ6IXM-BLK!':(+EZSK>A88D[\,[&8D0&TB^$X
M_>JEQ*N7^Z(^?VSGM"Z 35>1[#1S^RC*P$F(49&NPH6+DV.RZ,&*$EJ4=?1,
MGL8BE%L:NQ"Q<%?7S<8EC;3=,PU]/WD1UD ZBJI;2G*5-ZUF!SR_HEA:&F/
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MQ;HZ.N%,! L,VY@1+ ^[IWZ1K:;>-S;X2T6*R^/A()>2 NA)+U\%\5+FAZY
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MMW.C*DAR/;(0#4+U.)6WW#]T_%^!5VYV\9T]0'#K4=KG5%(Z-X(?&\ARK5'
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MV"CU1&([F)30;_+&;EY#A0$^%P0M4HM%7$/4PT\S[U72D92+LDFVU\Z6, N
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M;^\4N8R6U+%@KI1A^H[UIF]/ME?Q[C%PP<OW:W)==MTO/']OE5GSND@M.XW
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M^/#  #)FYQI$H))U3JVGM*UP]2^(NH/%%USD[W8=1\>Q$=T0(Y%!)"GXB*$
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M@Q)G%J '%,49DW&KBF]WK:_/A>UK0YQ!+6M3)5<0TJ#J;[\5=6B2X"TMK=#
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M -<K0<QWUS[*8LEG@1"32#K#(UA&I%('49GW(F 7/4BE.)^$,4&,:A W,UZ
M@9K5,/4HABX0CWE:;+Q D&H7+,%0H[CA_H.(2M$!F Z&,MUC\;41$-:D>T]@
MPJ <Z>"/3 8@!UA,14A%JB =*C[\"0:2!+Y(JO!(S)6E2!7L 2F:)B+($$NH
MP(RXHJ,LIUJ2XAQ !4$-\-!W$C! AT1!XHCNO,=YAKX22JEK:$$J**@-$P>2
M 1(Z5S5U$K4 I05()HN>"8I89*;:M[$2,>]&NT@..32WK0T)0#M4X!$N"/4
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M*4<PZB2I<BD7N5FZ-DCS&FDK5JT_-(':4P; 9IJ0,2D'<@L#FJ21X=0 0U4
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M[@Z!X%C:7>VW#KNYLHHI&:)RR( .DUH!1JUQA*GG/<;NYI4XTZ8C&O$@!\W
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M:7@=I *=?MZKB<2\#U*!$8@](2/0_,2D4+G(0M$Z=03BFE\9/25<4 Y#)OX
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M!<G%:&XM*9I,1AU(^W?C[ "Z&! 2'%]N"QA<T*#Y8)C<XHI*$DA37$ZC=U2
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MV'.344[OP!?OQ  XK6KP8DQ^%('Q*L^[^7;A2(XJN[ 0')5EA,OA*/+!6/\
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M $\L#/-[?N=[9Q%.,A*U$@?#F!.F?Z)R?BQ!Z5UJXL+:ZI2\:/Q!M0PD.J7
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M,8_HC\:*+G3$0 "I[233J.TE>G9BY#9*A9%LTBE *CV'25J @3"@W- \T-L
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M^,]9]JG7):J3^:%,WZ7 /[ZW0'^QM&?0.([._$JKD"GMK.J^<9:"MBQS]P_
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M43 $;,=*"@!-0I[\1R7DZ7 &. R":]S?_%5V0<FL4]H#3EWD8@6K>+(=*FW
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M\O?PFF.4I*6D():I2B T[OOQ ]JMY$CJ0M@Z]_6JI5*],&F>"$![B3DJ>X
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M=HKJTM[.<,;-9M$08I'F%[6M1" J$]<QC.W5M*G5-2.1+]2UEC=1K4A3E]H
MS)8VG!Q="YDAE;&9GM=&'-+F:B&2OU/:LC8VN<6FE>E,+H79B0#D$NXM8 N.
M*-['A&]MF'DVHNX7$,>VV?#*&$>!H#7.BE(>T'26C,C%@+@51W27]"A>!&G)
MR,.:5!]-!<"V==[+,-4BMCGA,#@QE5\0 F4JC@2J8,&X([P[I1QN:-$GPI@5
M!R./1TXI7;/Z5[&)V-&WRL:Y&MCU,8W4YS=7Z1K&R.:#GXA@4YC6U6(;FE?O
M[=:$7HU2X4KO3SA/&MHA88]KB?*C2\W DG9#,QP(<ULSY(P7 ]*+BRMJ5J):
MHP#GBLMO?F/>[P&%:XEX8X!AZP ?6L?J/N<EO#+;[792WNZ7+7066WP:8VO>
M*"2[F*LMK5KG5>ZK@48"Y!B#NET81,88EBP36Q68K3%2M+12&,I<74;=WFA]
M-K>>QM8F<A]2N4/^:N?*$HM;&.Y;H:ZX*>=:6\;'AL;%$GDCHJCGTHRJ5)3G
MACCT<^MUTJ@?O6FE2#6-,-$?E'I3T?3WZ';KR/?7[[OKY-RW.Y='<;INEQ&6
MVL4,;08+&Q:&GY3:[8!(XF(">A)<3;^6=BN/,>Y"WMA_AXD:R[:0#Q/,K+>>
MO.MCY/V6I<W4P"7$(@/*4B&$8C!V]&"V(7]]R#;]L9L?$^#[G:7D8CM;:]WK
M<MAM]GLG.;^GW&2\V^_NKJ_\EWC8QELQ\KB 6LJW'H.A4W:QLX[/LFU5X7$(
MZ15JRI"V#X&H9QG*<VS $(R)P7C'<H;'O.YS\Q;_ +W1J6U0ZC1I4ZXNF&(H
MB,J<:<-61)J2BV(='VS[>-EVVUVTR"5]M"(Y)0W0'S+^D>UA^"/42& DD,12
M2N-9M5B=ML*=F9^)*(>4LM4CC(MP#Y#DL+N^X?O7<:E^(F$9EHQ)<Q@,(Q)&
M!(&:,O,:&D&NKV'V+B>QS"K4$F<QH>*- S*"I(&'(DD@#-$2!UI/W#VEY3PH
MW(G,GL)IB9"#8NH\N\1+@@!)(5Q![,NQ?MP\R!.."#.D".3J"#4%Q^RF Z"*
M)YW$!3X5]I!SJ4+B@P:'2BXS%K@F:.%1F#D47IA8"(.O&W3OB)H@ 1M2F:(
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M5H@ [: X2>:4 BR20:BN2DUR!(HN70=N'(A&BNY 4(?$T(J=3T->F%X]B;D
M<LT7D-IFJZ@>]$ 4H!7[L!F38?-7LD+#W'(]O<,Z8)*!8X(07G_)@,G KF.4
MCM!"5KW81($]24 CJV(\.HDD*>TN6E,T';B+5R3[,R4-N\Z1I4(''2,@21D*
M)EB'VH^#H<^9Y:T#-/$.I*$_BP3@9E$!Z$=^9_1;^YBY=/S<*U'UJ3X?3_JU
M-&[8?F+D@?Z:5,_SW)W8L(X,5.K4A,2$6$DE]SC\,BC)IHF:C,=<.Q)S556I
MXZ>(2+EA/DS%% C=0=[3GV4PIN*B' LM=7.@G,-Y:I_M)%2:@M!I["<&[A^E
M"B= E^F4S,Z?WHN45'1L1>T!$'M.(-M]M*)S<JQN_M"?S0I?_2X?_'SUJ/D0
MT 9KYK<^P#$BMEAS0VIS?0/#25LH+:FG0D#,T3LQ !6QZ\U:&DKW=N X07A"
M=$7I6GVYX6")#NYA)9CBO,BN%0R**6:])4J<\-/P2U8XD D$@TR]HP7UD"6"
MPN"BM5S[\*')%(!@>*"$>$]R853S*2B^=5=["GVG#_!&427* %<@%ZU089F<
M4D.#J7(__'O)'J9Z4E#6TWO4%*Z?+@TDH'$HY?YL+V8?]1K#B*<?:53;H&W.
MF?\ <GVKEL]8%\MQ:'ZG6TZ-TY>%Y+B0 6M>'5 1#7KBYN_M8J=MP/A5#P_$
MFH_A>.DC^N3A+P"'MOMTH*A3;7/AJ*J!A=$M< ?GQ]J@[YC:VI^K]XI^U=M_
MTN6C+[UA]3A-XBS]G2'HA-DUJ-135PQ;UB8F3+%WM04]UK#@=7J*WT>CUF(>
M)V<;6G2T=4H F78,9"\D]P0<EI]GEKL8GI/K3Q1VS7)6G5*G\&$Q9N[DK1FQ
MXH>RW8 $&5,@OVYX6 7P39EZ5D\IJJ@7++ TD8H:U1C4Y+WY8+!*0&=YC<%<
M30D!  A0%>_$>42$H,R+I',4DJ:EU$09YUQ%J  X(,X8Y(*QOF2 !@)<Y&BM
M7$^$>\X2')XDE(,80[V3+15]>7U'MYGZF,]--EO/,XGQ.3?-CLF02/\ )W7D
M]A8NEY7R"0M/E3P[<]HL+8$E&MD<T#S2GD_S7YXJ^:_F:-DV^7_0-GC5B2#A
M5N2#&<RV!T%Z<.6F1^LO:7R[^7P\K_+*?F7<(?\ 6MT%&6(8TK<D2IT\<=4P
M\ZG-XC**UH;C<0SL>7%[BQKXPYR!S2I(.8<*M -4 *8MHCO89*; Z0 D4;21
MR:X?+8[2Z$M0>- =#07N(#W$'N)3#I8I4IOD<$NFPO?MEJV:*KGMUJTN4B-0
MYQ8K6-&D+AJ8?K3T)N<,ED.T3!@+0V2*-H#@0CFZG*ZI*.\" ]H.(]0#2R>I
MST3?BCG8MAM;ZY?8748N X,;"YYD%S''(K!##/&6/::#XE:T9#%17N:]  T"
MQZG"T5I,5/CQ2N9Q^ZVZY='%:E[+=WE-?++($4^ .<V.-SLA5:XC_>IU 95<
M)GE^!3Q)BX&">;CV\\KVJ**.VD@VFU>R-LTUO;A]U,Y @;>W,D\L+"UH/@#2
M<0A*5Q4,9EH@Y!/5KF9HOR]'7_I3N^FNPGD7.MEN=ZFFW+R;MD[_ )N5]R7-
MB/F ,,KGAH<$H$ 3 C0A4KPHQ $3,/U!S[56U;VM1M*U4$ZHP88LQDV('#!V
M92#9#^V>2LDEUN<_>-0UFJ22@/87+6,M* 5.+2VI"I6$CGJ].*KJMQ]UL-%/
M#]6Q' 8+;MZ [>S;K62Z4,U>5$&N;IU1>2=43AH(<TAP!Z(*XZ9&^-M4HT*<
MF#:Y8\/A'_:]2X'OE+QXSE4Q!+#M+D^Y.MRCT\V7?V33;.^+9]V<7%HAC(VR
MZ>0'#SH&-U0EZD^9$$'5IQL+#S,:4P*H,X/EQ'4N4[GY6H70-2E^KK\"/A[1
MS]2BQR"SW3C^X3[7N]M)97<2%'A62Q_DW%M*W]'<02+1[21TH00.@VE6WO*0
MK6\M4#Z1T%<ROJ%SMMP;>\!A4 !RP(/$'(@^KBDXZ[+J$]<A_P O8,6'AC@H
M)K@YA!Y+B//56N?>.[/"P$H58<T737;6E5 7(=M$ /9^/"\D9DPQR1<^^ HB
M)U7  <X).J+.,D&DN,GZTK7H[K4D?R3!\61"I')UB;<@@G6,@<C4H F>6 R*
MI4D/@5&Z:\(7CPA%()RR:IHF QRXIL3K% GW+24:%!744(-*(>Q,\*C'G@4M
MYMWB@;RH5>G:514(*94PO'CDE Q&6:II:$J?"I[0N=*JIZX)L<$H2<8YK/#(
MTDA0H"]_3,]XZ8*0*#ODLTDL<;020 0AHI4]GXL(TDHSFW%%UU<,I5J(@7J"
M 0B%,^N#$71N(C%%/S+2\ G/(9C+,5[?OPZ(%G";E-\!D@UQ(P,1I_*)-*E1
M0'^?"XP)..2046F956E.M"@_'APPCR1APKFR]* FM/\ ESI7#9IE\$, KS*H
M'32%-#4'MSZX&B6>01ZN'%"K><:B 1J(0TI5-5.J)3#4G8D9)R$])Z4=6;QK
M8ND5H31$=]P3$2KDI(EKSS2A8]NO,(3D2,Z=YSQ#.2,%BA379D$-.0_E[,1Y
MYX8IZF(2+3."4F@_ZF7]QO.^!_ZK_79?!WX1X\/RX_%I_I?D]:F_=9_DS^R?
MC\'^TZNC-3;N2TSSC_KI>O\ UCO?B[![H4B7Q'K2<W/00Y3^3F@44/7N&##9
M=*@W4/\ 6))O:QT4XJ/T<E:Z2H/X<+BV/-02!(8K6OZ@^#FF] ]+L$>\=:Y'
M"H%X=JC4AJ,OTY)EI23RFX 328V*"Y"!4Z11:D8@4/VB1Z2K*[^/^@/8I=_2
MZX_\0=/Y)V]Q([4D;D.N>)E4=T=?X4G:OVZ/+25LQ<$!(-0,P>I0>\+BL]BV
M;88JQ@5Q7,&J9$UP)9(,^2M?1P7)33N7_)AR *02K5"T'NPZS1PS1.%13IAC
M(.EJQU1@=*,-Q6$D'+!A)D0< @\B(0![4';EA42Q2467%"H(%13KA_@C1+=5
MU#II/=VKAB>:! 9<D7\?)6^I'I,6M5;;>&*C15S(2&J:(4JJT[,.;-WMQKE\
MZ<?:53;GC?PCQ%%_3)ERU>KCPYCF>-1#-J,9<15CHQJ8$*( O=BVNAIJP!S4
M[;\:4V^F":'^&,TM^N;@[%<G[4W)K@W/^RW7B=50V,A2>S#E$_X@'\X>U5^^
M86=L_"XIGT+N/^D?;W7/K'ZJ&*H:_;6$TJEC&XA250EV+NX>0D?IQ6"W6+[U
M5@#D9^T+?-Z3V$D/&[>-RJT JX HIRH2<92YTRJRP6LV>)C91/YQ]2=V.$A
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M5FXCHI6BX&GBR2\"7) 05^XQDTD90$(,E SH[J<+%.7)$:M,\0L3MT8?R@"
MTD!PJG8*!,'ID[,DRK4X\SU+$-RC)4OS4HJ>S,UP6F>3(A7IG-U[^THD%1VU
M=G7[\#27R2_$AS"]^?::J2I_/'53]B8)L61N.!"]%^T$^/2I1=2D'+!Z2>"
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ME2!EA$J);BGH74I=V*O'+6N+7&1N;:ES?""H"D!21A!B4HF3K+'RUCU#9R\
M=J--?#6G:F$$)R,ZO')&MMRDT<V0.-2T U([7*$!IEDF&*D0SA.1G)^92RV_
ME+Y'Z2 KM&AS20UH&I4 !%,5-Q,1+\%-HR/U@Q4K/0K@T?/I;G==X,K=BVNX
M\GR(?,U;E=>6)76[I20(88&N!?I\3BC:5QS;SCYHJ;3&-G9"/WVI$DD_4B[
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M'"A>WL(/BR*X>%, @$)0&.+HM=<O)U.>7EZ"I1$'Y/><L*E$# ($-@%B#PT
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M+;[0G[O2R)SD3B92_.D<<,,@D]RBWDW"\;MNW0MN;YWZ2=[CHM]OA+@?.NI
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M%EUJ9>@^(&RTCV*6OTN'3ZB@4_L+JH1^6W\>)5;X E[2WWZ'+1);/&O.K31
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MYH+!A;,B58+#-!4<C@<$8S6-FK5[L ]"+O<<E<_2:(A!K^/[\$$>E\\D#?\
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MS)W8:W?S1L.WRJ0N;FF:OY,3K(Z].$>TAN*KH^6]XOM[JUK>A,4CJ )!#Y'
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M;;EX??W"W5]<'5^ENY4=*55#&P.#&(NEHIB],A2CIBL;=UCN-X:\@U(8 9X
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M,>*R#6W?.,[UMT;79,GN+&86KFDU)9<B-P]E,=%\H;P=MW:UW*)84:\)]D9
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MYB\<GA4>)#DE>SJ3B<" %6)(7 #;AX4JJ&B)V9=QQ45C^L*NK9O# XLD9/\
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ML]N/L[L5Q&O90EP,1[%\MO,=K]UW*4.+GVH1N-DQTA>& CW$?@Q=Z-899[6
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M(DEU9PB(X1P*,[-K6D5) )55+P '(_Q(0@(IT!SJF $50AL>(2LM8VN:QP<
MT#4TN:@:XJ"0  7!P3+/"HB38$MV*HN)]YN(3H<&LV7>ZVD#M#1)-&R0T00T
MUR-<=+ V.-I(32:>XZ+R_;_>;VG0_*D,>+/CZNG#IR66\P5S1LJE4/JC$D#I
M ?UY=932;7N+N0<YWS?T;HW/>;Z\MXY%I9B=S+*%KC73'91QM"_FXA7EQ&\W
MB=S!],ZA(Z(@M$=@6^O+0;3Y5MML;&E;P$OTB-4SVR)+]/0E5]0NX_LOT_W*
M[A0S/VR>VMFU#7WEY'\M:L:&M&O^LRMID5[\6-[1C7W"SH3/ZJ50$]41J)]
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MM43)&/D+04#E"ZLPXU**O=BJK7M,#3',*XM=NJ5(O/"+I 7^^S2/D&IQ#00
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M"ZF&A 0!%%1\.HTIB91B^!3%:>.*-O);^;_Y(_/?\79G_/B^:/\ R"HM4O\
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M2I<'_P!)Q%.B8]'>2X0!B)9Z?:7[,UQ7S)*;$1R=2+M+8"UB=\(=$TM#<B0
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M"K6D6@Q=T5S*69!:D%U"5"FCE14'9WX9F!)288' H&UK@"XIXB%5':2"URM
M4J6A/9UPFG#2[IV4G8#()2;0S1(S5^D<UKB&@:0I(1'&FL*%-$R]LJ@?UG%@
MJ^Y+0QP=2AX-*VW@?*/"(XH^H C#Y(X0KR"I>UIIW9X]&_(Z<:/GS;*A^*-8
M=G=(7$OF/3E<;)<T>=*4>L-EZ>*E'RW;V[OP-SM/F%EMYA R#2U' BH(/V8^
MLU6EXE@W(>Q?/B%:4+[',3/M4-_I?W)UC><TX9<.(FXERZX-LPGX=LWM\EQ
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MFID,RL9I'A%?#5' @EV90!2<O=BQH:8GI*J+FI)S'@E8L?YX_<C3\1_Z6?\
M/WXT+?\ H50?_=ITMP"WM\A1+RY[2?USZ%*]<?0"/PCJ7@V?QGK/M36<Q*0O
M /A <G\_>1A?%1*^1_13)MJ^0] YWLH4R#AB:,AU*N]J:_=E%[.A-7N%.X@Y
MX@SCJD3TJ\MAW!R9-YN+DY$TD4$# B(2JIU[<5=#[20_.*L+KXX\_#C[U)OZ
M;E_XG[2[H;>8>Q#$1B35^S)*CVQ/W^BWY9]A6UEP /VK]IQ51++:YX])]JMP
MHOP1*L".2"K Q?H07COA=VI3V], HQT+ 10'MP812 9^)7L;O$6]5 SIU0KW
MX!Z4F+.RTN?6;O;=S]?.2VS23%LVV;!L@6H:Z#:+>\F:H.D?UF]>O?V8^>/\
MQ.X_?OF3=4'<6]O0I=HIB9'89KV%\EK'[MY,HU@&E6K5:G]:9 ](CZ&4.K[:
MK:^@EC#0]FHAX+!I8Y[=)(=*"U!J]GV8\U[A<5;8&<2=+Y+T!MT8RJCFR:RP
MWG<N"[T_;;XODVF\D=Y4I+BUKE5J(7*S[L0+ZSMO,=C&YHL+V R]H6YL9SVR
MX\.;^#)O2GM=>V=Q:"9LK3JTO!+G-&DM+OB6M217'.1;U*-0QF""#DM]0E.0
M&3%1Z]7;JV?L6X/MWLDD@DM)HQ'(TD"&XC<YQ!4#P*M:8W'E2-0;E 2!$9:@
MY'.)]Z7=O]WF>0^GJ38\^>71N>"#K>TH:T>YKFM((((0T_#C4;,-,Y1Z%'HR
MU6H(4J?HHW5S(^8;:XN5TFVW@:SX&>8RYMY=!1U2V%>RB99U/FP"->A6XZ91
M]!!6/\S0$I4Y< /Q+8*W6Z61]%E/Q ,U2:F2>$M8$'B*@?;T&,N0(3)(:1X\
MUEC(2 B,=/O5M[* QKG$DE@C8A*.\2JB@Z6 T3L%%PBO,  R0HQ()TXI/WC0
M[5I+FE7AS@Q5"C0P')' T  H$'7%96 F7& 4^WEIS8A^T)+3M#'.< C@X%!I
M>WQ@JXE7*PFIZG*F(!' YJTC*68^%%TK!\+@UVHN >GA#9/%K)&;W-[R6K7#
M+8=*E@EP1DR!%I\;4:@1I<"C=);4Y%5_E2N$B3X<73NI\D>[.YWS#7-+' Z2
MA<:/\)"@ T<PT)%<2+?4):C@.2@W@TQ8_%FI#[3<FSV/=;IQ;IBV^UD8YVD-
M!??6S'!A[A("HJ5)ICO'RFKRM_.%E6P:,XD+D_FVB*]D;>.&K6#_ %25-GBP
M9O'$Q;.KYNW%H"$_%"51*%"?LQ]?=ND*VWQ.8,![']J^<&Z1-ON<XRP(JR;L
MD0H"\"B=QKZF.;;428F;]Q$;B&5&JZV?=;1KCWN$5V\ G%): T[^=+@0ZNKZ
M0K[5"M^3)O2MC^VDS6$,F?Z%E5 Z)5>M,:BGC3!6,K.:Y"UM_P 2&%AX3Z9W
M#@CX^:;S;M>$7^L; )BQ:^%XLQT-<<9^=D/^@V=0C*Z(],)?@]2]&_R[U#_\
MCW*D/K6,3Z*L1ZM7K6D_?7NCCD<_P2P.E<&EOA=$7M+@"X-)#4!]Q[<>?[(@
M27IJ_B!GTI-;)R4\7Y!L/)+64B?CN_[3OS(F%J.DV;<(K\,)*2QMN#&6@ (K
MCW8WNRW?W*ZHW8SI5(R]!=8;?+"&X[?<[?4PIUZ,X'^D"/>XZ5TP^E&XVN]/
MVS=-O?Y]EN8M-PLY&N#FRV5[%%=V\K7#,/AF:5QZGA(3TU(%Z<@"#S#8>I>&
MKNG.W,K2N"+F$M,AR,20?6EM]7NX-L?2BUM5\6Z;UM5HUN6H0LGO) Y"#ITV
M_3LQYZ_FFW0[;\E]T +3N#3I?UYQ?U!NU=V_EWV[[]\S;2H1A0MZD^H@,#ZU
MK4VN)K'-TDEH#0 [22T$ZVZ'A3XFN4?R&/CMI(F&&"^C\R=/>XI:!VJ E6N-
M5:X.#079@)X6E!1:C[<68/<;D%53#3?@BZ>4HFOQ:6M#B]'*#DY00:=0A3#4
MI2E!X-K2XQT@\D3R%^HJ4JYR$M"D5&JJ%VDU7VI6C+U-7>. *7&,SR6"1NMI
M0(I/ZNE0-18XOH"X-3!S!E!Y /P9.P#2P*"2.<&@_#77\/B.@T:'(@ 3L[L$
MY.:?C#$Z47SE7/TDD*\GX?$I1S6HJO"J,_OP@@LI-$ 2 EBA=HUQ<U7.:A\+
MD)4 >%JC3J8>T4!'V.407#9!-UAHU<TY=_ND.R<-BCF5ESO^Y#;V M +[*QC
M%Y>O<I)TND$+,O\ 2=F-'4K0MMF)&$ZU40_H :ID_P!D-S6?VVQJ[COSQQI6
ME$U.7?E+1#JPUGITIMKN>-]PQZ*?"62 E2:A'5U-<2B@4(IC.3D"08OASS[5
MM8TY0IZ#AS_$C:SE :PENE0I  +"\-8'5;4* "!WTPW4K/!I*FJTR92#XA0*
M^N#F<7#SQ^Y8]-TWGCMSLFV-IJDGN]X >YN;CY437/S_ "<=0^5VTSWBXKB?
M[/1K1J2Z!&!;TKHOD6 %M7!.52'L*&^E>W?W/X%LMI>-T[K?6T=_>QEI$D,D
MS6R1,F" ND$;E(S!)"+BB\T7 W7?:TZ!_P -3D81Z6XCH<*7N<O%NI-E$IS=
MGCW'>;D0V\9?XV_#2)I) 0N"A%-5R3%%5IQ@,,RJ&XG3MAJF1@I$<:X0W:HX
MKRX>R24MU.U!I;GJTL!):H<:$^[#8L)87%1L#@"L%N._RN:DJ$ 1#BW$IP67
MXB5D3FA-)TDB,M0Z4! : XA2I% <)-<Q&F# JC\$&3RRZ4HK2ZD_0O<_Q,=(
MQVI"XM<4:5".!$9JB#L[,2*=:;@DX@*%7IQQ '%.!L%[(9&G7K#0-4F;=*$D
M.*N?J(-.W[L:7:[DBJ""=&#\EG=QH TV&)Z,"G\XG? /B+'. ?H( <&J6D9%
MH!!;J7V^_':?+-]'5"IB ?<?<N8[[:B0Z0#FGUN'>:R&X4GSK>(.)0II.D'4
M"-12A/5,=UKF5:$*T<3. ](#.L'881E2_(F6]235TYH:X!WP@I0U0T';TSKB
MHKR9XR&2O:<22.;I'[@^C@'$ZJD-RUBB@Y^TG%/<2P*O+4<>*2%Y,[46AQ\*
M@ESG ZD"4: H:XE2%3%9*9!P5K"FXU'K23OIU*2 :FCQ$.)U%M 2F8=W+W'"
M8S(.*>E3@8Z1\7-)FZ>$>6G22A)<[Q$$ID6E&K7KEB2(ZDS-J< Q[P1(ZYTO
M>YSC\.D^(-T)X@40N#25IA^#A5\Y8+QER[/4#X5:?"$J4("BJ=,6%&1S&:K;
M@!W*4WSLGYCOW'7(?]++[L7[C_D%1,?^<3T7I'S]\JI\Y=GW^?)CZ$Q9AU!>
M"ZGQGK/M34\S<&P2=0B^\#\&%#-1*X[A/0F-$AUR)J74^E:57J<3N'8JY-WN
MA!NI5_UCJYKXN_$*18DJ]MOLQU)O-R3^\C!U-LPT"I4U 3)<5-$-5F/SBIMV
M'J0(S\./O4G/IO">IFT=IMY\G$5#8S7$JL'I)FV#WU C\N7L*VMO^(]AJ!V#
M%5%;0AB1TE68, \42K!H*L%BW2@K7_"1UP >!08G)8"J$+T3"D@ODL<+3)*Q
MBUD>QB_YS@T*309]<".,F/-$2P=: O7#>3R7U8]1]Y9)YC;SF>^NA<2C3!;[
ME-96P(-&AD-LW3TR[\< 'D#AO\J_F;NIW3SYNU\2\9W]5NJ,C ?V8A>__E]M
M\;#RG86H#2C;Q<=) D?223T9)D1?/M[O2YNIK]3"7 !A >@&EQ!)1RFA[L<[
MOZ$;NTE ?&V"Z#93-O<QDV"P\PX[;<@V:8EO]88POMW1NKYK5<T-'P*'C[S7
M'/MJW"KMM^QPI$M('K74Q;QO+,$9D!DV/"M^-P)N,;LXQWD#S$ XM:_0X"*,
MM:J#0>H).:XNM^L8PD-QML:,LVYYJTV.O,#[M6PJQEAU<DQGK;;[WPF/<723
MRS[7?->+60ZI =:.=&9 -+ T&BH5QK/*-6RW@TX0C&-U3/> ]1Z5?WA\6VDP
MQ8A#.22MO-JM9QH+)[.RF&D:@?/MHI6^6XD5:UV>!8P\.\J1.8E(>@JLM_V?
M#)U(/Z/+QMIR+=(347T3V!TCPTEED(O#H)#B5O313EBH\W0!IT:DBPC+'M'-
M9C?B:@T@90?UK9L_0Q[7*?U0.@D.>6@.".#D1P:[Q9'OR&,K4TPJ ]'T98J#
MSB3Q?T(#= 3('2.):W2T:'. #@@+2:,DU&IS!%.F(=<:V$OB&7XU,I2,)'!@
M43WCB"2'/:PM*M5U'H6R!C&KJ.NB_>4Q GFRGTQ$=[!)B5TBN<CB]O@#BT..
MJ,KK '5SLS[QGB+,L#(?%ET!6%,:@Q^%!GB@<2*ASM10$D %R-:X%I7PKTRP
MS*!$>^6)3^IRT0Z NS.E4<=6K4-+D* ![2*DYYH,L,RB3@,/>G(XXH?M;RZ:
M,*UI,PTN)!!0AH)"4:$%22>ZF'+0R,@'P?,IBY $3(YLGIWR\^0],>8WL97Y
M?:]ODU(''4W>MN8XJ$:QC&T!""N6.W_+F1CO=$Q/UACRQ^GN?%N;;O$5+VD)
M!P3/^Y)38]&-V;>[!M3O,U-ELK=RG,ZHP%<,@?P8^NOE2O\ >-DH5#F8#V!?
M.SSG;_=_,-S @.*DNS$J*'J?9_W6^K7T]O C(.16G)MC+RH:]]YM-S?6[5(
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MZ9TR_8ZT5\HB+7R2.?Y;'^9K+S293T:U[@X (J@4'OQYPL@[:<W7KR\A@DC
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M.R]I>8O,.P^7]OAN6]W5&WLYCNR)?Q'Q_5QB\IX,VD%3Y^GS^&/ND^]3[_\
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M(9\WLMU;-+9#+9R1J!)\(+:4(:/A"%"ZE5QWWY( 5//.V4B'!N"/[$_>N/\
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MPU3 ]0!'6OJ-\F-J&Q_+^RV\=VI"()'3,:Y'^VQZDI+0L#%)(+7>$@$!Q04
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MJJAIR<M3ECI'EJN8;A;QX"M$OVCUK*[I2,J$R,B"G4O)FDE2TD$U!- <Q0A
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MK7"C(8B:.QSCS+="YW"-E3+TJ!#_ *9Y\](QZ"5V7R-8BTVZINE4-4K=V/Z
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MWTN.G6"@ (JU6AH*N/Z34*A50IA(+8)Z="4R0 C<7Y>UJ2C2H726M!+%U@@
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M$)#DB.>2)WQ4;J4G5I)?D'#2!J(I[>S%C#+H0E#B3BB>X?X@]=7Y ! !#B7
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MU*%7MR0*I&99\\1^'FE'N5V7.>7. )HH+@7(W4&J=1KT*?S5)K1)(."F4*
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M?&YJ%KPV@;I:XEP\154!<P&B%>Q0,-RK&'PY'--"B9@DY.0E)97;W%H((0/
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M/,)JO]D?AS']X+1#ZI_OMS;_  N_>OD/]O\ [9_OF^_M/_6_G?TEQ\O?//\
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M&:H;PV P8Y2!%D(-A3+04%-':,+5#%1^8<U(_E0L"4?XA27^@]7\5RS2B$+
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M'8#2]H-%VM/RM?B=T?\ 4$L#!!0    ( )M9:E;BF;HA4I0  -R5   0
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MNK^;QMKR8ACUTG.=IB<3[B@MZ\K4350 BG5Y;N;#-'Y$CVC)1$NM-"[JHE>
MI@_T?!%T^PJHNVHW=^T*1OZ!#="./D-.A>U#&L 8EVN4_<CH 6%>YM)\!7#=
MOP*DSJZ_+F T$LO3ZD[(/(]"4G W[GD,&)WB3QD W^I4^'.W:'-),S'=61?%
M^\]+(NH._/--%W&;G*>07H34=->_$G_<%@O=Q??!$U%\U\,L@@2$U]F4-W%
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M;8!S.7;>[R@MG[NRG-'5@GJI/]$C,D='9Q467F7JZQM+%R 0P2+SP9/UP;O
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MXY_?YJW1PNG?^)6"H)B"WRK=I^>O@(!P1)HK",N,/V;>VP0>\1KP)T#4JZ9
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M_@G<C8N&%%%/FB\H92]^I2%DV!^O%Q[('MS0A3>I;VJH<=324FMKI,]2^U'
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M07*B.KM5E\^DE,O(2HU@L K!<1J7Y:2,<Q55G5%9F54H0QH6(=0:.M25.FK
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M$D9K1%E(+-(XH:%259@A 4AA"7&Q+?R!&BF$KELXQJUR:05"0 *X"G)GU::
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MCOPYZQ&#DUKJ-@1(X"K3)NH=TN9S:VS*^UU4:"E TL8\Q!%&"DDNJ,]2I'E
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MQQKJDY076A4YFA I6CZ34@L::<>U/AK#F<;H\;Q%3&3/@(U=9,\@@'<LI/\
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MY'ENI7+N[L6=W8DLS,22S,22S$DDFI-<+HJ(J;^]-*$TPCB,2"19,C_GN_\
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MW>W-S&LT;A&;+M(% 0U:9**@,U&TD@,!6N.P9WEY4*MH)%<M(! !U$5H0"
M3P7RL2./HE^7KQ%*P\VLPR>",_,)@2!IJV6](E)4L2^7:D\!5D$M93A=Z6\
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M(;!26'FFWNVV(JA@*BJ%MU5%73M;YZ?A/O'W$87M-QW$--),L1B$E(P)%%4
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M3U9#^120>)QW"BI?/26*@FOF[Q_P]M>N.;T*)]$'E9VT"1U#F),40VC,C(0
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MJ4]G14LAVT*$IZ2KDT9XPWM"NXGLT;1U?5;\AO9#X:_V"0?\=G1?/W-\-O-
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MJ)%6IEH+MSJ+7H]*2\80J254?9%90AM,GT[8YI9S!NPFWB^)!/=C<9?HNY3
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M>D[3>VES>UOC776@RV#QI2%P'BU:G(655-8&RFYNL^F87C5#=0U*W+8-[89
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M,L@#CG&=U*@B2=2XM);+B6;:^-VQK"%9EED-TJUK$3<>N^)!R;E_:9]I-R2
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M[Z'59! BVT"OL@WN-3)T9AQ,DQ>XR'8 :1KALL8#3.;OLJC>O4FW@NN[+'.
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M-@6'6Q(W#H;VK-8N1XZ>(\;*5A8AMLP712QOL;;=O;.H#@,R7 L5O:@G&/\
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M^OG7]K]K]R_RW]4/<OA;\N"_M?U^!D#])V" >???WQ#4^PK@*P#J_QZ@_S?
M_#?\A_8/&>I_4OXOX;T;@/X!, 08@H%"!T"C0\&@0[WW 0;_.@C_5_G_Z $P
ML'#P"%#0'Q"1H !0<%#_#QH4]%\B#,*'3X"_3L! P\) (R'"0"/\983^*P9
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MT*ZZ$^6';6T10Y-N+G9B')0J3YXZ>R9":L<U7D<:J1$LK9'VED3I (2:A6#
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MT2[A8T]+P6I*PRQ@1:3$C]:^&0XPLV)\W%HI;/HJ\H&4E-][Y]/ 6T+\BV@
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MS-C9ZX-%!P+ P2Y%:?T@X99>L'_7VK- \]+5VYR,KQE\FK1=\A-_U[F[TKI
ME\7W'S4?6"@9!7])DA-U_K)T?N2BA"=1@<]OZKT)%MYX@B,L+)HOG/7K\CB<
M<I8TT4]1;"+A?^TT.YMVR"M[V6?<SK2=$0SG@?1UA#D65ELX.:X)9']WCHL
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MMNA8 %72^H21"KJ/NW*ZE2:Y>YHXH,E).,9O_3^7&)L<$!2J$E6BD"@!I8)
MT3L;[RHD%@X%3O,W)UK2_13"O?1&%:1U,BI:F25:7U$1ZV*5NV@A<+\P+@@@
MC5_CA'8>IK'U/;0=;'Q U^RLOH?@*\>OYS^1\4]X\3!"+M::2C<3 Y.6T<I#
M5LV9J#SWZE*Y3Q^6R5@\-M/,+?TWT=95$925I/4CC]S]A8F;P4S&S ,N];;2
M0 U@2"5 ]46*WW-U!4#:3WBC5B5D7=&=#J1:_P -=?'3XUQ!P&SQWA/&\U%Q
M3D$O/IY#8B?%_N,PI@_IVEJ29.Q=N6;%VU/'6E*P&2 ."KCIK:<LF1FY2-F0
MC' M\V[ZKV.VP  UZV-NE:SB<#&E6R.VX#0+I^>YT'>K$I>YN5Y(N&Y!/FH,
M7B8;'K4\?BU^EHK-!&M5[,WT\X;Z^2]&39>2.1[!1V8!.W:I;C8\7?CK&7EM
M8DZG74#7M;I:P%Q;6K=$T,-AMM:[7.@)TT%[6U%=5<"_YV/C&3R4&<QTUEYT
MFJQQ1THU^0B*-]R\1KQ?JCN!*_+OTZ97DI-CVB4QR6MJ=;^8[WU^'6VM9CF$
MVR&%@%)'4=?+\WY*NVK^[K->&.I5M"I6C,+R_P#*$\\D9'[)(4DDED[(HU!*
ME&9?$#IO3F^.IVLN^]P-"!_TW\;V/GTQ&3C0PL=S R'H!V^/]OMJ <LR?[X?
M(4>'<7@S-^*K+3R61RUV7&\2HQ1"0S)EK*+8LYBZ$?KCZ*_*#^WEB.V_)>4Y
M@NN+PQC,I8;II%8Q1-I]*H5:5_+<!XN!I5UQ_$\7BH.0]SRR1XQ%TQX=IR9A
MV/S I!&?^)("3]R-JC'LYA.4?\SC,/*(.*QYC(M=L<<X9AN.XVAE6CF@C@(H
MW\-G+^3$.\RFI9MLGILNVWS+J-[J]G9N?$,[E^>Y>;(1?K5<6.)+@W B]!@%
M^G5F<DZ$GK6BPO>?"<?);C_;O%B#I>:7,EF/F9ER(K-YI&H'85W=Q^Y[X<&I
MK6P7MIQ3G>/5%2"M1QM+V7S*QLJ,LEBXD><XWER#N'9:^.^/8QUX;.GO+B\@
MIAR8G*X0-OX@.'./WXA-!(/_ )41\S6@W?TY]R 3<ID<APN:=3M8\ICGX)(T
M&3%Y RSCX4S'VNYC[E9D<T]Z_:_ 9#/T9!_!/&L'S&EA<#[=B.:*Q!G$Y?BX
MQS#EGN")H4<926"I6QP7TZ%6,F:Q8J<S@LSG)!E^X./Q\G*7_*3U_3CQ[V^=
M)$4S--< ^M9"EK1*FI;1X_O/AO:6$>#]@<QF8W&2_P#ZJ>3$,T^=H08GQI&&
M+!A6+#\*K2M-??DS261(YM7N?S#\.I76N4\+S3!1W(!3M?77.4>Y6 Q063ZJ
MW;K4\9PZA[B-78(8DB6MDRI8LMMQLU5?^J?!Q.8UQ,WBPXV[I),G.ACUW,OR
M8B9A73:CLDUKW:=OE,.6/^C_ +CR(Q&^5QO,&,[U$:8O&Y$NFU S29C\>&UW
M-:3&!L!^'4W%H\1FPW)L)3OT.21<IQ4!%58:</[MQ].S74+)1RF&+'(P9.JX
M_:ULBQEC?]:)3K6< ..Y/CXY<?+_ !F)%\FP*8EC9>J2P'^()%^\F02P.NP5
MA_<0Y3A>3DQLK"; SY/G+,?5>16Z213C^&T3#Z9,8!6'1V'6>!F  &P   "J
M%  Z #;H !K57TL*R7>_<T-R?$G27-%:_;HHK!8#Q.BCI6$E^=-A_;7J?O'E
MHII;PJJL-@L-Q][$N*H0P6K3L;N3=Y;>8ON6.[Y'-79+.5OGKT$LS!1T4 =-
M4^%@X/'%CB1A9'-V?5I'/B\C$R/^\QMT%A5UR?,<KRX5.2F9\>/1(P D,8\(
MX4"Q1C_ @OU-SK4B24DDAB3XG?\ /U\]6.AJKL/LI!FL+@N3TSCN2X;%YVD?
M"MF*%7(PHW@)(1;BE->5?)T[77R(U$SL'#Y* XW(PQ9&.?NR(KK^1@0#YC6I
MW&<IRG!Y/XSA<G(Q,K]>&1XF/D2A&X>(-P>XJ$#VYR>%!_@+W!Y1Q:%1M%@L
MX8_</BD0&W;'!C^3S'D6/@ &PCIY>M$H\$&L\/;4F$/_ +!GY>&G:)B,K''P
MCGW.@\HIHQX"M8?>N+R9_P#[9Q.!GRGK/$#@99\VEQ0()&_:FQ96/=NM:_N[
MWS=3!_&?M/64CM&3@]O>6SWEW_\ (,99]P5Q_J =0#,R[^((UVCQO=WT39O'
M[?UEQ)0WY&RF6_Y1Y4'._IH+2Q\;S;/_ ,-N0QMGP+K@![?  ^=+>/\ MI1H
MYB#E/+<[F?<7F-4L<?G.3"G%CN/%U[9!P_B>,@K<?XR7!V-B.*;(,ORO98;C
M4_$XI()1E94LF3G#H\EOE_\ #10$C^(&X]V-0.3]U396(W%<1C8_&<(WU0P;
MRTMNGXC(D9II_P#"S"('58A5H]V_S;DGQW\]_C\=]]6E96H3FY<QQ_.#DF(X
MYD.45LEC8L5GL9A;&)ARZS8Z:6?"96O%F;^*I7(XX[<]><>NLJHT94,%($&1
M)(,O\7"A=7C".!:_RDE&%R ;;F4ZWL1X5>XCXV=QG\JRYTQY(9C)"[AREG4+
M+&2BNRW*(ZG;MN&!L34)Y1RSW#GI)EJ7M>N,K4H[WU57EW(L7>LY+'M"C3P_
MP_Q!>06++5A']6L2619?Z8K$C.VVKWB6:=G@8&)W7Y&9@-L@/R[B";*URA;H
M+@FPUK@V%QT+!#F+*;_Z4;V\_FD$?EVMKU%>-_\ ,QF.3\PXG-+9R6)XEPG-
MW\M)Q+*4N+Q4LQDZS3Q3Y/D]+&Y3)-?_ (.@S)$%>Y);A$[RHJH&9V7Z)]F1
MIQ\ZKD_\QRZ(HE56;TU-K+'?7^(5U9=I(L2=+"N_X6/*W1X:E+* 7<AM?@ %
MOY?D-]:X]PO.(\I#R'A?!<6JTN-1U:.=SF#FR7'\;;RV0I0PR7[-+.6[&;Y+
ME;<E24O/8D:M K,(H54H[;3,PFB,6?R#G?,255MKL%4Z*"@"HHN-  3I<]0+
M_B-D:G&2Q:/6YTN2-3KYC35K>)ZU;'&+M^I&N-@J5LI'3PE/'^M:NP2W5%0S
MM_Q(XJYLBI!40I&\<WH/W*S*QW)HLQ4)]9FV7D)Z$#6PU)-KD]01?L+5.=AC
MLNX@ $WZGKYWL#?R[6KI3A7+*V,DFP$52Y5K6ZT=]VM-!<NY&Q%$K=T-281V
M*R^D=P1$(Y%8,.NQ&:S<-<BTS$%U:VEP +]"PN">UKDC4549$.-D;G927'>Y
ML-?/J?*]^UJZ+XUFKC8^S!?@=:Q=K KP1*AN_4;"-+=@/&\43U]F/8P+,I!Z
M;C68S<6&:50MM+W':W^_3I6<Y2&$.'Q+(ZGK8&WF.NO]O"DN0S9GIC'P"OBH
M;<2,8:U>5(F@C*_,T*QI"H[^HC4!#L-R0>EWQ<$2?Q2 1%HNHTOX'S[GJ*R<
MK%I-UV>4GYF)O<^-];_$G6J4I?\ TCW%H\AQV7I6LSCH'EAQEV_6[)*X0136
M[7'<?5R,B"@LGJ=\UJN(VZ[D^F#JY3ZW&MBS(XQW-BP4Z'L!(Q6]^FBF_3QI
M8R6<6;6W32O3CVXSON%8IU(T_;5I*RSR]]K%SBS$H4Q3U+%K(PQ4I;PV!#12
M+$O0;GJ/&N9QN'20LQ^<&V@86/>X"F^T^8O\-*L1<#SKH+%2Y]G:;+)C$KR*
MOT\-.W-;MQ@]>^S.*M.E+W+M_MJP&_1F\=9"<8=MN.9-P.I( 4_ 7+?E/V"G
MWM3_ -Z_'\^HE.N*AV:X7A,KDVY#4DO\<Y48EA/*>-SIC\M9AC'[*MF8I8;&
M*Y+2B_LPY*M:1!_M]AZZI<_@,'/R?Y@ADQN7"V&1 VR6PZ*^A29!^I,DB#L
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M2"I6AEL6IY3VQ05X$:6:>0^ 2*-2Q/P&N>1+#CP/DY#!,>-2S,38*J@LS$^
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M,W!Q'D0]'CBRLF&1D;7:X3:_521K5*^]'OCP3/\ MSR'"<"RN<Y+[DSKC;?
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M((N#0!P ^><F]Y>M^FHKN>4TY-O,/[3%)@"V&H "Q%40&" '@ZR"019; "$
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MXV) ]Q%*8LP=JTBNW^6>9^\=N=W\&3U6WRY!J>^CSV4E5]>U=!9R;M%!$DS
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M4'&J3(,Z&57(,TDSBQJ3:7'QW,P++;Q>HC3-RE%2K2=)W:'H?J/S4AS0X85
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M&MPFA&LT:%.JG"+S+4*&CK:$'%IJ3KG@[^[+J,(!BWV@<OSE8%'E"8>RK&7
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M%FT"[T\MNXA&R$9]Q& 5W_WP>Q/-41!W3AZ7"!IV[OL\8@JDPV/:XQGF?6/
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MJ:2=5\9I:\7WMM"=1-\X9;,L[EL?84+6:B+8J#RZ?,8]T3B$:3T>N:K%\)0
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MX4E)B%7]!,8@JG0CTR3Q-3%I]EGKI%?BY%>KM7> 8*/P,8$L?[[J-FHZ 7N
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M_/WIB>:9ZLW:3^V-_ZWC'9!"4I+SCY\H_S<1$9R6UUO)Y;>B<<3]Y&ZUQG=
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M9MP09Z0U/57Q-S!@%B>@/S.'^A4NO]KCL'+LT_SP\]";,['@.V#T'?!@^0Z
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MQ*<]AP0@<C#&:$'T70HFLNGO^F?QQNU%ZK9GBXRLA<%QX]K>[R=F#%DRAXU
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MDB,   4N   0    9S,X,C8W-V9?,3 U+FIP9^5X=524:[OW4-+=*0R-##'
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MNR?B$O@ Z& +,0!QQ*?!IWD2?S:/]N;T+6@@.#[#80?WSWIW5Q/G]D9&-@$
M0T]#EQ& 4N9(S(5VP9\AGP/,3HDJS!4/"_SD_VP2J\7FB[^ @%@/@"QO+AL.
M0'W)[OYG/12=ZI$,T)\YJ'T\88R,<0 4DTF3S%O)G3\-A*++G>?SYD_H;P
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M,#RL@_:^K;0\,N#SYLB2)(/0(4L)!_6QK"O"?A4HF >]-M9;D#;U^8/U&Y9
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MGI_7M"[EH]1)]/YU[V]K,'Q\()KN<;GJ8A;4W6K5G>[ZGI6_U*BFM5OJ,^;
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MIZ+^,/>VJ;A!FY;\!T/8$#%$?X!@1&SN%)B^UN=QU;<$2C[>I%$+LV'I,Z
M5S71"2O&C.234L*#4-2EUHD!/_O3KP$C9-< '9O/@0>W>^",_D]MA2N_U_N%
M?0[,\\YA2=[9.O B?=1!3<5@Q?U]DBTHPD@WY5M'^X'  PH?"V6-C9/#\M$
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MT"B&^&T53BN$B'AWURR,Y:@5O@&\4FZ+F';.IWM!E-N/W%;<2(!^%/FXW$-
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M_U2(2HE-T(F*BE8@JQ RC4KV;UQ2PQC(K2=FRL738I$,01%/*.=,\L'^(%Y
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MT7">]BQ*Q3:!_-1%#0/[UL-03,/ 6<]C[^=D*?(\7':M)LHCHBB1WI^X1 <
M@BD 0-H06J1N8F)&<R1@QKO/QQ8<D2D/I5/^0%FX30%3J]*U_M)6/$7;[:\
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M>F6]/Q:8,(PN1_T';754Q]$=EE"3-Q!Y+$A',=4U5F+\ O(J7Y\X&T;S!]>
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M\:CEH_?=!#^$H/Q$0\E(,5VPT+#M12!EYR5,Q,EQENU'*@UNGOY "MT4P_'
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MK1"W4XR-.]COLW>Y22;CP&OX^&+=:YH*7((M5]42"Y3LU" VY&1.=1@S=,.
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M&+)<,6B>OU%?@1W)WJ4[%LF?AH^NV/_]X+"-S(#YO?GX8!J&D*@4D[F4'[6
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MMCHR1 ;F\^U\!*-P5"3(;R,13WUC.+S+0G]N-VV.&?43. YY8Z[P%>/KOBR
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MY28$"V-JA(JT2%^783(VD[B+:48#92B>I*SPVR$5"MA76ZP!HR6 CPP;9;*
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MG9@TR7.Q/1R_NZF/=;:Y^[7"V?%C>JVN[7Q)UMJ<\N9V&16^._)DA)L \F
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M;Q4VN;H?)IM'_W_ROT>^ !:1LIU +#&W+36F)/#?<>5("'."',^)?RI4+CT
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M!D0VO^V=A,)=X^:, ;HII#"OP_UO,$^LA75S<(2Z@YZ] *P<5+>>;#GSS3]
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M13\6   7 /OHSS><!%H'A@P ,RW*@!-4[C].,Y1B00+-6/SD/0AKX=DS8P8
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M]VR+UB12CO$@FFSDS+'3O,L7(-^5#0,,G;"N/>#@JJO':OC->.*WSWI4<A,
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M+$!"ZB0/-8=B<5,@NV.PEN^>97?>F"-Q#TCX%32%W[_9U1:J3XX18B^/(;&
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MC.C-,!-5LL:Z3HZ=*#J<+"A]>D]!GG"AW<_\,7F>)Y&W;@?#<<H0F5!599Y
MJ;T_84D,$TK3QQ7WU+.YB>G83[_"F1W)>GV+<%D(31=.F;';R^CZ#F0:]F"5
M>'M-W!^?W_-V5>IX*/?-N3.N, IWDDM52*<Z\AV7YA0BD9UF25)3]< 4[VN%
M8>F&'@9&!6W6LSBM^1TDF+US1P*FY9+J I/G W\UI?5UQB!A 0<-?OB(XIN5
MX0F=.]+\(CMG3>9C2]]FIF[$3:@^E"-YR R45J1%I/1]X$L;DI)A08T.8XRT
M!$9@0-X3(9_G8Y7H]1LQX=_3X^.0(P\;^)#35T=$5=R,&LDOPEPB<7G8,*).
MTR$'!3D@CVH,0BJ+TOP6G![*0@@F%0E*=1OZ+Q^:OD,?5R@VE,=/K&_#,Y/
MVXJ_FYEZC>,]W5(<WO8YD<G1JI&T>2NV>)$F=T99(A-(+*SYF2&@$H- _R#3
MIRC;4.=ZV;;.B?/)?V@ BT^=ZQT-#4P\?X_!@,*(<&RBM[DC9UEJ/8*.@#Z7
M382+?VA>*BIMFV<</O)_>)\%2[[0\>/K#/G(Q02\!!G'9??4,"92GZC[@SM\
M;,D+J=>%VB^ D&TL6U!\O2H:+.ERBQ.WJB9>JFZQ<%8LGNZ,*;IO3++<M0\U
M6R.N9U=?/VYG;B!22(B4/X59,BORB:<GLKV428ZGI^D$-_6'K[ZU&3TE\<W>
MUXX;8#PQ_SQ*N',LNS  <AQX36J* ?<;@*@^3E'Z1X\'&3OR&H%>GH#1UWDI
M:U!MT4&-O*I"B3,,(-X5U_U\DS"NAU-/ML@8)U_!+@7C3(K#E]\L,USTU3Z^
MVFS_#]!DJGB1]5ZUE"9%JB00P&[D@K/?YIDM^20<>"UU2LY&17TWE-%%XHX$
M.#-OB8^?3L6>RM8%_4^;L':DLJD+>.TL?,L7\CJT$(H'3>CQZVU2G_H,09OS
M^>$6RNIB- 00U\*)"VCD[;)-  CQJAD*7.F&, 6G*ZRW$K9C"L^7\PD$ZEY^
MR=@5,ZRV\F&PFV6QAF^97M=+Z<-_;XZ5%OA.I5)+292Q!#.DC&8*FVI&\YQ'
MZ#4,6Y"_S-J\L:S?\:-4'<)<)FB2\6PTC+8V"EK/GV.<X76=5]W00(H,IW'@
M4LQQILM62AU1@_,U;B$^A2V_7,]39*;C_.'5;Y081+=:R,.GF9Q<&O:)]]3(
MQIE('*H?OBR-S8[SBMZR].>&B!JN!EIN864\K8?J?]''Y18M3]HL\^=EQ.9F
M$-95DXDTJI6#?8<_>K-\H-9,J1H3C()*C@[TSUAC,;Y*E9=%H24E\4\XT99#
M-_J2D+ZG@,P6F(?E,@W*J'>*LVYP^!2DA_!#US]'D0IJ"IJ6UQQ!9 RG0H39
M($/#=%K[#X>*,!C'QGOO#C%V/"P^4?[Y>\)V*-PFN;"/,*S<]"\ >ML]PR]
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MENO75M9)AQ%&['-Q&0X"<*W2!J%P/9\Y %LXN73>F.[G]<@"(5/GL>H3%UQ
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MF^=<#^T*:G$9P(4^V=X/,^PD2PMMJ:(@J24'\J'H7BP^O:GU'^@DPL*^>W?
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M^O N" YEZ.FX&51)$]VG"S)/TH07RFG+2^9]X#!7?X]I,W'+[P2IOA?<-I5
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M90FY"'T0]:;8FK#TP3DQW;E):<!7D$DL3$VE$X17EI5.+ 0VH>A,"#$+@1=
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MA4HG]5EFFPP3NH,\U0K<F>:H%T52<] P)@/Q-"YK+\@+8S-F].%F +<DU2%
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M-YZ%05.JA=&-O_HXW,,Q=%6(;<=()'/A43:_DZ+-"'W%-#I_Q&)WN96?P><
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MK?=N8Y(IU2]OX8!N]H>*#L),6GU[180Q5E0WZ@>GAC(MOFHLVE19:DPO(E0
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M'#TWNM_Q1FE=%^>WYOK;]@W;% V+))P"B>RLA52XTN3 S/'S2Z;,P-S]I$S
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M"[L9A2=4.!["-#; 4YMB. -=M,&*+,D(QO]%Z5NP#<8=:(ZK?YGZYKH_B6&
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MM"*T=L-JNYYG33*].SZ^[A!1QVBSA9NF H$GL0V+":4$'FHQA<R99J=-G<O
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MAO\9CDV_9!9FZZGP9R,9[4#*F,*AX@^ E;_T?X:'/(M?>?Z_"0!02P,$%
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M3(_Z6YI_8[LAOEKN'OXT^:K_<@I9ENKSC=S2&!Y:LU3Y@PAR$NPIP/]G^3,
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M9UN#W9;BXPY)\B"A 44B[+AP$P"I'H-'RV;FS0*XBS.&K,:<EZTMHK']UL%
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M!7"^=)O(?("N9UK@R@MEO\5O$V)E&\XDT;\?H,/JG2DVM-:VCY6%T;@R=9=
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M(\4W=1\=%L3MA1#2TZZ20E!JI3?(S)])?R?A<^N#^A;*-DZ\V^L3F*!O3KL
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M;@4= @ O([(4+60'VJI)SB.*6AY\KXR*DJEAC/*2.,C 5$ )HR+)GU\!  Y
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M M8! 72,HR42L(<G>G1!:56L1;D"(8'<:";]= -ZP6:Q"X:0,]4&R[<9%&@
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M$O$)<4(2RDUB1)%E_72EMDTO!INB]DUA4D*G3]E\[\B1N<;S7$-SMG+U-85
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M=B'BD2P=35DM+D3*04B(U /R$ICGD:FP_K&X(AX?GS-%*WPX$&3SVE)6TU,
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M2UTXZT\%-HVF<]N!WU?;9F*0=.6 LB)_,5V?I.66DI(4\&MCYN(+U3U&\7*
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M!77B:\T!$QFBN"4<NR8MV]5/A5$2CN4K:H]B\(T%9_TDQ>>4\S[ZEH#=+MX
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MO=^><^[MOZJZR[J?ZGI^78\KC]L ,EEO.VL 0%&1%8 .^'L\G@+P93PLH#X
M! #R+][RU]0V$K<M#.8BPL7EY,YI9NEL;L5IX>S(Y6WFPL7#R<T%>/;<V\7,
M FH%HS6WLK%S$@.>=_0 :>TLQ8!Z8%5N51=I*UL[!5\W*RU?-6T+7ZB%L"7P
MN3CM,V\1;T<71RN8&:VWHX.3NXBW&/!WXR*_Z-^FN8"TOXO H&) R=\6:/55
MU6FEG=VL: 4Y>3DLN+FY:06%.2VMK/C,! 6Y^=AI>;EY>;FXA;AXA#AX!$3
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MV7UG^5,N?8<2OE.\T@J=+-R0TTGP0"]CNS@9Y9/],&.+7N@Q!PS6$%:BY3-
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M&T!S<A1"XP[?2L;8V<^V:XY^D.9-SL72QKAYSPZ;/HJITIM9ZQ4*JV1[&F"
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MX"RP#!*T.1UM_\ P)1X7+9K%<51^U>2KN6]2?IJX?J+708V[8.10VQGN:'S
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M7@6$ N#^[PG^OPCA7_0W[Q]LN'_G_%_2<R\ !P7@"/B& (<#@,>!0\"!>QX
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MAW.*_UJ^Y=IZ1T0< XX^ VPI:2=SV!JI;#3WQ.QSV485TD=F ?^G)F8C),.
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MI-=@=M(4]X/43PVY9X#V27D1"0\WT2BZB<%*0=*$0T@0ZX-L4\&T;_VF(I;
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M#7E$365$;*7(_&#&)'QL::X@36E\349-:=HQ,C2-0/R"9;BJK"$N/CX&V.+
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M328&,F2)K1*CS.:1IX*DT]:H&&AZ?2OS(E&+PM+JX*4+SG)>T,>RU^9O)OU
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M#"VNY2!Q?K2=&*0F%Y8[2LS2EIPE\HF_X RI^-I9-#9D&UQ:BX,N#&J8LG#
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M3AXSD#$5VY_IL/VW1_TOU)_]\[?['WOWS^ _=K^Y_9\M[_QG;_\^ V#\8\$
MLV]_8@CN]PH@$ #W_P[P_PD(_P'_HOV##/?OE/]'^/T-@(4*B 1,(,!A >"Q
MX!"PX'[W OK^!/H?97\T_T<.0$9!0H5#>(4(C_87^U]I<"BH\$C("(BO, $
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MC4^+9 G) T,FE6-8-SWJ_T<38<$X+9U4+=VBT>TV0YG.:GP;EFAM+(-A_)+
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M9I.#M(UP%W*3O]81BC'@QBC\1/BVX#23+:LMVDGT$]?-;4T=PD/B:!0R^M_
MEHNF)4[5O*7*L%4CD!1<N+6+C]12.U V%I8FG.H];B=VF D;6=)\29^COG8S
MDO4/3BZAB_?(Q$72[%+,P@LV&J)_=!J_W=;[Q=5Q53Q2;+3:;1$6#Z;'[R?1
M-GRM' N7B24FVE.(?RXW7Q_I31KXDF9KK!J2$(_J>5<]&>LHK68RYY$[15-
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M-ZTU>(DBHP0&ECD)K($"JOTT]HJZT//,D6K?-27O\7:1*"VQ>FJN=NU:@X1
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MJT=V:I%Y<'IAOS.HXR"GV:P(ST\;A*AP>?VHQ/T8W4Y99%#'9[OD8S'9%-Z
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MF]$6=E&>DB X%,70OYN%Y&*A^R%92W28J@&E"7TN0K!B7+I8/;E3ER6UTGO
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M$:-I"\3@M!#&IG_KHKWIB/T]J=#04,50545"H)<25%-3\X\,%14%&H5"4'A
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MKY0C[FIL:; )C,\H_F9S/W_O\R!,^<,*:;-+N;2!T@$80+3)GJ2G9P"!& #
MOW2 Z&VY&#P8K[Q@BLG(+FD24T%D/C]EEV6HRL,[A1;G_MRS9A0<&,2\*\D7
MZRFAAOF] &"E39(.# (#] "'-4(O5TUO%!] P0;W,]5JXU4$7V^,2KE&V386
ML\L?5(>1'6!XEK.$VL1\:SV#PG;5E)^\!#Z9*='JE!&2G]. ."=;9YV\D&0=
M;)1#(6?_)&2-;4,3_&F[$>O :GR6@2SKZ1D6/2QN)@]",IW/;-%O\K3EZ=-H
M[^]@XR[HCEJ+,OJ^V&92Q/C60Y -8JG N35HL:&>PI^$4K6LA@&SH8_$.5.
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M-E=!KN 7&AB_V4P9+X!P#M@H?M/H&L:&QOM"6],T("@_>BC MPQ1EP"9LY&
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M<TE[^C$;+QCP$Y$OQT+)%VQ ]&H]X<I832$F6)KH$8EO2XS3+L;T@B&(8?>
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MT_[5M-'/N*IO7W%03KCO#T288/VQ*1P<N43IFZT%ETT'?+4K:;<I]H5\>QR
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MJV3K:1M\Y5#HI]7FT/K\R_#@E^O7(I]%1@Z&?Y1L+?S0OD"RO9TX?^]YU;L
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M:\N=3Z_@!47DXGH-9-$2K#30Y?XJ'5\AE@X^#Q:5C 8Y(60E$T ]_/%QK)R
MEZ(ZQKN,#DN*TZRW5S\8\[=>C1K)2?T0DQ'C]5V!)YTZU@!L^9#[WKIUO+,B
M#/]T1E-L"K" ,K;(<LKQ]ZU!E0I>N,U$&7>4O_0N_^9;=NNISGM1YA_9NW>6
MNO1>:(YM&RFIJ)"0A:T7T 9H8+>2=?_A9;?DC9=9?52;S0=5/<>+[Y_Q?7S
M\WWI2?N3 >KMJJ7?@.=OWIVJ"M63'_[2V3#1JSV7JK(IO#22K\P=%'$<\F5T
MYX-&W44EE5U_7H6SX];UKPS"B_AN!.7V+A*\^&*]IB_?F6U3;![9#'(I"E;U
MS <K/98AZVLHS13I#5_I((VLO)Y7>VFW^^S\X-ZUZ_OSK^H<K4M>7D[N_3>3
ML1N)I3_Y/(^!%;<9OQ3SL(@[/:@\O/K1UC_M_E$9E%?H& 8AR]5X"+!MSN,@
MI?-'IWDT;B7@'::]()KWN\0HU!CM1N&T%$8?V[P4'=[P[%P[HO"<(D:E$V3+
M"IANPN4X"1EK@GC8R.6_IEH3A(Y)'"KSY7@A^XX8UC['_BQ:ZL=7W&>4WAL[
M0PZC&\.)8L9K*\C1#"FP4;6DJ%M"@L0$,3D:\J:M\_X!WG4@I(DZ:;K+,T=Y
M[%T!WO$'PB 48#>@R7TI&RF!<"(!1R[XHZ'N;,$L4D-?<=TJ"7WS1.Y&\Q6P
MAZL<E:I6&[[M"ZKVKQP'W%!R1"QQ^79#[N-4S6_-X.:HW<]%X>[9GC4/T6/4
M +C%EB]#FMTE095[8]X^G+TM9'ME".AUFQ3_MHOIJ'T+Q K0 _?LX0/;B9%&
M8]"DC0I4H M=I2>O4W<C,'MA<E5(,C9AD3LSG8LI%B$U#*Z5L"+AS/5CN&;]
MS$_056? K)EGLV^AM$6YN(;6%I)/2,9*2,;1F\,9K=M*G0J'L!A.=XG9]X^G
MU'')85N>W9?+GO<')H%.%BHVW/)]%7XWRXVN0_S#Q0L?,E@+B+C=L3A0X!1*
M^,"BGD/DPX/MG>6ZZ4#-7_GCN T<9LL4?R+#@_'=5<4'2O(W$CO:A/VT/DI_
M*^(C?]8^J]G_Z!39<EZ=O^Q]Z-M+7XM4;V0$ZZZ],59%BV;UD_,MD*<W:4"K
M9Z7[(&"WX;*2RN=9_J[&7U''?K\!NP>+UD'W7L.V\E<[7[R_X1N:"/]89"1-
MWFA+K7\V-GK*>T)JRAN0ZT;ID+ZW=GA;)Q06<+=@Y_J)?5V6_+5#V-P&8N1,
M]=[73T7\_Q;B=AO4SQ>[Q=;?*%;/ZPO0,#F8P?P&R#8[*A, N^>C8B?F"S1X
M21H\S MM::;=RAX;O/[+0OHR_E/N"7NOL8F<(1#_'DVAFW6,E^.4>8#&!9(\
MW5X0)JE=W.?*5^DA<6$+5-STV"L('[U+%.EJF %%$!GS$-386^8:Q8ULKY?
MB7W-4GC"*,*OJZ>>0Y6K_,R#:L$[G+2*C:D?+Y5]@AM)]@1S"UZF8B4A[HP]
MF'G"J3"31_7^:W"NK"ONR(X!:,[9M=.>4UZAQ>.S1B8))_@R-493^+H^V.+@
M@>-EWJB.^#TUA"6"P/\JDA9/PT\AHW]DPQS-IRRD>GN:/+T*!(A*J!9XA."
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MZ>HR;5#"A>R@U4Q1RJBYM\4K#E6S2S)-G08/Q!OK'+]AGWG:JX,WJHPNI&^
M@,[ZOJJV6/^16OY1]E"]TI&Q[?M8_5567@9H:I.ESXWVB7E:.J[!8OH,FT:1
MUXB>!K7D0IPU2GW04+!C$V8$ >4TYZ>,%[BKD_C9+OL)J9"8T8"7SA!G_2;!
MI$:?^T'SZW.#(N?0#(_J(9O9WL63.'"7(.QK3C[CJ@T#69J6;E FQMK14"%>
M_TH\L.YZ+<VS>(TX:5%7CY>X<EIL+H2L5AN3%,V8@WHD61 ];3.O20T;9,AJ
M?.Z_(/8UY]6*[Y&O+\,[J2'_5@XT:=A_%DIYLT\C6O>G2QAH^L[*'!.S1 V
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M$'TWH&A//6SL!AK-BC%CX? ?(U9_NW.U=">J_^<&WK_I]SCY]^2G'+Z*;;>
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MD[BY@@),SB]994\,O%T\7U?/S",^Z3=[TE/0<J7YI_S9FY;S8/M=PSV29+'
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M@;3 %I;22];92/:,2:)6>J?)-'1FC3\MH@#UB(:#E\QR!Q1X?\&+'@&UPIP
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M5-8\I5-6)YZVV<1C0<"DL$#.FQFXF]YIS"EES*WT$D*M%2;*-9P\"+W)Z"P
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MTRZ4Q,JY/HP0DKZ>8Q[P;_R,FU^,V5+CY-;=T(:%.9RVXE& 6D8(WV+&HQT
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ML,2+<GZ3B/)+&#%SK;="'X->3_.^=+M&JW:262[OH>HFFU!VZ0>*.Z!AXR]
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MZFHXS<!U$673^>#C/AW(Z9;XZARP_+[-QOHCF#Y0D8>I:ZJJO>]-X$ :XT
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M;L#_:TRTIPH-X._O7P_"B)(0X8['#N7AW=.A7IR=P2E!(Z]#3(8#G19H.=$
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M#'WH^5T=H4;,88B*.[@$_.?E"C.TI2RF!#U1!%=P_+C?@L7@/WCOY(WL-4]
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M<C6NBJ..W,74#H "@."M@NNQ'$%>X >O)"*^_)1W,1/_'!-SKA2\O#12O?P
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MM8&O!KXA>DX\5$[LHPZ1/ KR_ZCL)1>);E"]R4-\<V:O_ J@A/KO457R]K6
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MX,]O8TB'W\'3;NLP]#8CLJ8GAFQIWJN]7-I'0"#5FTR:U0<S!O;)"'CE]*+
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M('3@WXY+!F8$[:+Q,W!)R4 IFP8I<D\$#@=?,#@$H[S%?,,I,C9;UIQ^C1A
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M*'PN'UM3]5[1RC1W84-,7XK2%R3"G#FPU?7+%^?C#O+_$'_+9UG8[*43V0.
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M@1S#_^0Y1$-$>70G*H%.? +JS5X$"+EV1H4R/?4/H]("[D T95&<S "&U9L
MA@QBNID QN0\E'_[Z7 4F.5:2=4UARYGOY>=D^,T$%._B0?%SL8'S_X8$1\,
M?%_7B_!&M&*76'+2&3=2C"..&BW@-7V""8"Q#!X[:U<VKY0=,G4"7CR82H);
MN71&7=ZDC^T\!#LFRZ@?+*N39';+16[UF:)Y3F54KT;,SOUXV-UOGNU<9]S?
M>>J74:$(*EKI6XDKG]>^R/37!]EZDG9F=:U.<2SH+@+=FJ*?"--_?VC-=LDX
M$%S\-'7Q..G!/^7B53^UTUIEZ@R:G)K,C"P6'!TYPU/>8#$N;KINNOYFF)5>
M9J?&\"61/EF.RL#>_L39PZZ[V]+OD-]N<^6*6BF 8*&T=*#T%VJ>"43?<B*1
M:^S8FS"RW J<(.$1J9!FFH@+7;-0MK7U7DAJ%1["&OS.198 Y_1(H.-M2.[;
M3%<0IUAH)> /4,4A<[*Q+D/S>&]IHWF91SVYF*RVBB-AH1C0L&R9[BA1-S)U
M@?35\%E%<B/$-.3C]!NBSF@8WI&ZAB/E8IDC$#X=<"R+V92.;"+A)Y^&2JO4
MOI/8WS.Q:JZ>NEX&LI-Q8;I+%IGQ,-X[W[YPH38#EMEXLZ?;SU59PB89S^N4
MS*= ]R&T8FPHY!$EMA@=JP>_Z3:/.U6P=OF-\"102XO&B9+:#57BSCPL&)WJ
MG?5V3OWN4Q)&BH1#VH>@,YE'H!0V\#-.#=Q(A#:&<VWSN%^\F.E7+T*4M(!V
M3*>!^1TOD;-U)%.2QHT=<+Z\UTL +#3)LYG$'T=L2"-_1]BT#7-8T'K57>N&
MIX*$Q^-5S>[D)F28(=>E4_4#/CZQ5D!9-5%#%N"G]9$G*[5NLZWG\AH>"S8A
MIL"&M/!J2\RL= @JY>,;<M4Z&V:%E7Y6)35IJ;C/F(_L?28CU/K\;LB46PM>
MGGV"7RC8AK6]Q*/=ZZ(S;<,2P3[L/'2!FF0V ]!IM3]EC;+X4V'4>JQ'%C#O
M3U^ESU%< D-)7\!,X;LGJV!-C4"HE3!O^D2FI4+'%-=AJPI**[!;JL2UC=JJ
M*STP'S(KN7\/9 $SFU9+Z"P7O<,'O:3#Z#22>M%Q <5-"9:?M#.]/ K<4>V)
M_W:W#;770J*H)S*"E#[XE'"8YTB7X:*&L9Q1U[CIA4[K% 29B*F"$9A?E!GF
M68C<H$N#ATX_ $[Q^6]&_?\[+B\?U!5%,ZF1>PANJ&F8!\SQ4"]G'5[E_$GR
MF6_(Q_UA0TWS*8G#2>D!C]10GEZ5L0 !;QI1U SD0B)8I0ST]S?GJ'/.LTQ+
M2Z,A%J?FYZ /Z$U.7&G:3OH6E1$*+E-_2-'W^=;>$7=!=R5PWQ*7(K(DHL2_
MD+JU[3WL9"Y+#",=YDR& 2DY=P"YL9[]=K\+NC+\F.7L[DZ<YY[M.E/N6-WN
M4M:\A"VG[#S=[*FB&QVV22..66P:%QH._:L9BI@FO%0X>3F\EN\2)B8G,NLY
M7>H9F'> .T"%<*^TA(0QES0VN4;_<#FMLD8Y3?-DA0T_1[C-\AJ\G9>U8\6K
M::*W7\F'T(NPP@JMJ]@G4>$54(=S8>A"@<*%%!HY?I:)\I[+5@U- .P="U1(
MD'"3>\#%#<A:*,3X"RC#]M.8#O'()?_2&A_ODY8:1]U:J=_+4TNSS#*RB75D
MC%]4((8UB)%_RFM3%Q:WGFL,,M7QO;JE3C%C5ARI%4"EXMK2X#75X?93CS=L
M0UH:$+J/C7SH.J] 8XA>9+53HV_^F<@"(N>I2TR#S)(N0W&=>'4K:2VU-*,I
MC>E'?@<^5W05N4L[*.[R1Y::IY[&?\?,J]SH&MT]RUZ%4H7[$L5774.4LNO<
MC#*_,H=)KGO\"M#K8(50"6Z>N(%.A7WB2S&D17"EMAVTF'+/V=B.E<P]FS^-
MI8[,K$W%G]^4O[LCHKR( V7+ 1+^>)_=7&]3_@50WBJ7*'NQ^1T#:Q<C1@I,
M?*!*"ZD-Y^GCMG8ZU73N]8'GK%%0;0G\Y(<P\$MH@)VH4Y6>8_' <AZ;KQ>P
MT$?7J]>\'WB'7-F).34<BO,N>+\\JIA9NKP;@7S"0FN]8?^\7RI3WNR+KQNU
M'22OL>6]N5JZVNC?&NGXT0E()70X!>TY*<P N;!MK%@_I%!,%@QML$/'T86P
MPH5<2$*[40UN0'LJ&*AU4+7*[H&["A8;[9^8HCI:/, D;PJT*+T4AK5T4E#D
MM@%W!9NZ6:TU-_RTUJE;O<">P'II'24J7+J<*$TZP(30-GB(EE6W_@,9.H'@
MBT(=M$)K&]1*LX+S6"XU<X.X7K\F'5 [:Q0!,=J1(7I:28!F>2M.<C'JY#E?
M*JBU;;(5.A4#2TA<R96<&TT&DMZQ^@6'59MD"HJ"6AS++",L'X\4W&:>$O;.
MO.$;WJ#"B'09  \@2HC'S,4842 K-(K@Q 1.Q)MA1DO\_R7*"$C7"<6/12Y
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MH@,"9 B%^SQ R'2ZY#0BIG*^C]KLX([B")ZCG5*N',X$JD'!E$),F/I1LJ3
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M -/[3K#I.6=\'QU2P!T39$/=FJ-DX< AL%5==(T/:,0OW7]^KH+Y.HTDALT
M%>51L"S%";/@C#3DG4( 2V?EHIVXX4 [YO:YK2AW9Y-?J8+YI@CE%X0;J;;X
MVS@;\2RE[PG8R^W!XV>*OW>H9D?]5T7BBL,]5"3'#J#!K@QH8])X"(/PJHB0
MC&']%8?2N<%U'X'PX7$J,/8<?IRPS4LX@+0&*^$(E6C/^[L,?VXVCVGM+-ZI
MK62YI^)YR,]52)J:^%FW]%JN!%UK!]+5"8-_7B[RV]^\L_&QTZ5*=,-2'-+
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MG!\XB"LXX+!2%O/$-VB;7#,S2#\,&[OCJ54E6IA[-A#,N3#EO@R]!C BDQU
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M"X.82:2U+=OU OSY9E(9#3!^XV\U8XR)\B9,8!/S>+2OF[G+UA)M#YAF\1/
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ME:G+<0W"9KU;V"I554&MMT+U/H[HAYG)U9?D!#:'5A)%9IMO?YVG*XM\[Y.
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MIG*\3Q)(O_L7X*;P:[:H\TK@:&U>V/EX9K9U_5(O]<H_V^$([2_#*</7]MR
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MTT/Y^O#_LS9JGO_)?T# 7^=*RJI0)3E%92D%99BRE*(K5%9*Q5T!( 6#*RK
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MO#\]8YE;T/F$MYI<9F,@>\Q9_3EE ":G8#B+*>\<B$=G2:P+D(/T?O4&U$J
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M]^42 =>Y5?>I-UO=X4H=;NUB"VG'L6W'',KYEIU"&U!'+I8F<-QXND3S C5
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MN+!S @_9Q4OO>-"ZV,HM4$&)1]Z:'>))?3ZY?K6NR)="_YY30]V@]<,3S=L
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MLP8W)B RL_V?*R+LR]YEO6OV[LP;ZK ;>3!/K*D:E;=-WRO1YZG3%R0RJHK
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M_"3)'"G.*JVJ6O:OA_*-QEQ+->6(N[BV.*PZI" %63K%"@P17.-*YR1H_1D
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MJSNPU]_16:'[65YUB!@1<MQ<DEJ*WJCV<8"M6#>D=-/Y#4 72H>P_6[E%DQ
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M-)@ L(+1.R'.5E+-:'VI6*CX]J]CI?G"/SM3OU,&A;\FSE$9,Z\I?)T0J4I
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M??=P@UH7<D8+VW*U))N>,WTY?/PH?.B9O$J#*V8UEU@1;4W\5[,43W#A*G>
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M>KI%[?$5VT/;^?7H3KF[<[#/IT4\3VZ9213M\V/-H&\MDQ2 -*CA4,ZCT1,
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M6",49TEQ*/7+4$-<G%I:#CUZC>Y53I?-ZX"VO+_5=:0.4/\+1/D?YQ"<_V7
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M>'B C27W75RYSG7P#6;MW<!+.Q,P:?3.Q.Q5CISV@HEV*9NPFK_;Z_:VYPU
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M)%=2-S("GEP)<Y2@V@&U=U@,E,NL;*E;] $+<3=;1,F4?Z%UCR;&6P9'IAF
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M?Q;09LXL>K>!4S=7/L85&+N#31-3V!Z<<%NV?\3;Y4'^0V60N[7:M(NU<J-
MF[PK,3Z!3J%[GE'=5SJD6:^5K6 S;;+GZ$-ALUQ"I+A=3G\U8\YSWE;^%%_/
MEB!*9A[)TT<SY;_ZRF<XE<BA2YFCE98LK1:NUDVW<S)[X+DB!"]265J/V05%
MY'WEODST/+(ZSN*"C'<C1"BW (!!DD&RA[GUR37SP=,X,@WA;LUL-QC]I!HY
MFTS21!64F-\-P&*G= ,H[AR^QQ 11$&XA*K*>)DKX/':QO:0Q.7PU/UEVMTX
M1I>#'*;*\E=$3J&L@VX))#+"K(GY90"> :G;L0 GUI*=O%O-/J?MJI1/WZF
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M=!O;B7=-N)SGQM(\N9$VF+$"046*N_B$2Y'9)4\2IIRTQQ;1A$A6E!P\'QY
M#[T7FY54ARU3,PC_^+D/?Z<<:4..U$N'.\3;?)@@Z3HTL?O1G1T.V5ZXYS+$
M6UDM(LMKR5A1\=)">N(&,!<D1*=38+OKN!3;2!C-$IW7Q6V!J"#"B9"/&%B0
M/;%@2 \BZN*,+' *'5 *^K!%)Q*GKBD-&-"F0;L0C  B/XQ$/2'Z.[*6QNQI
M D/H8Q5LFE#H[]<U3NE;7^+580YY/;]5"\AO ,'WM(!K&[U3?_M-?<K?4@KE
MB+]^YQKRR^ZA$^>MT'CJ3]2 .P-$O02' +)M^I/ZA8C4MN]5,6YWR[(@Y'Q>
M62"='78"8N7%@'O$ITT)I">\Z73"Z<,R3FKK,/7&+UL(7<OV:<M:'_8T;FO8
M)F6!HG<- [-0M<D"!L7P(4AYDK/11O I;U'8=T'3[V=W$L>F/M7W7,KP\M*_
MAF3^[\+ (N%,"7O2<ZO%8HIM4G="WCXEQ2\9PM7\=&+!0_>M8L-6IM5)89?.
MCG9-2'Z\< (9&37!G*?UG^AIJJ[5'.SY6[EX,Y;5ES8[RPPR#HZ@:75SG7WB
M[3DEXWEJ[$LZAC<E5B+Q;YS'$O;F\26_:!^5XXWG5U<DC0*X&MO/WR0:5<KF
M4[9\'J]_M%I?/A4$FES\ZM700,<DHARC;'7$#/B2+<.7&4ED,%[.2.TVHYV7
M$"]]FY2:9XMV!TR[0Y3U=ZR^NNICKNGISV?XH%<T2/;![[>>*!_*T9[<  CV
MQLU^)?YDBCA6&)9E9+U%R&V^XPR@L=,!J+<,\$_JE:YST.D,-4(S0Z;V]^2&
MET9EZ*0N3&0"-?F9]ZB_B*HCQY:$=Y6G \,%Z& M?>RSE>Q;/)N3?HGT&[MD
M N;<^?!IL81BU3*845%K1AYA>EW (,\7-EE2YS!4'\<<5O&;(BB;&=S(T9SF
MM1[+G,A$VK!>ENW1F,D=Q&N@J%-ER#\)W!8&D#J?6*/^5^ SJ9R=Y_^$^G*E
M7T$*Y13Z-)8V([KBK>#-$K4@&[05RK\4R5R\=8X!8V;ME'*R [!W-Q2U\_^8
M(I? O(CH\D;<3\(?<YU5^2H_YS>?1]@>[LN]*Y>'R.S";-<]$;EU$VN"/()
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M[Q \J(=:23SEV7"BYA3UG,))AZD-D.V\EBRO1E*Y5(7]V0ZN:VKROC32F.J
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M^T+< P!$@.M_VDY_NI:)Q9_Z^'@IB(G!O44=G#P=H:(03YB8OX.7F(2HN!A
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M0?3TIS1#/0/.+6<DD.RKBD+G-8LY[4<M<ZA-E/]2;TNIFUF*& ;$XQO'_&;
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M/S^3N^(E#*7%K.F?)B+'=S07X ;LL& A=@]L;5<XW&E7A,ZV)@S*[KR=#NX
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MO4;YJ8C51!HAY<&'!K-TV$2H\Z_AVP^L83:R*.4$)H+_K)S9PIRV\83CI.^
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MZGS]FC$<< [[_ Q6O)1?7^6F5GD^.GZ>0E+8[N:Y=_/WS#LQ5OL+2L_Y\"N
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MNPYK<OD_.3[F^QI_S0*?1?NWWO_\RTK![9($^I(X=LEH(F-L;K*^K]TFUDT
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MTX!7=C^QU'3D\",581;R'L-G**5]0&?\SB=R]4HBUT*C;@?#N?6?N<(@+8_
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M(A7E)7^I$&6D!0X7;G OGSBHT4B-U<H^][RI)1UBU77]*C @M%U*[Y&:&RV
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MOJ!,D/1HL$]//+306L1>JBDQ1)C9H5P\7U3ZK@I6L5)'28#)0X>RX@U:8N9
MMF)=?/>&'FL>ZF*<H8!:582L"W+SB#?V![R*7ZZJ]/6,7Z$387@!GE@JJ%)U
M75?L,3>$"@XZ^;/H^4'J1Y$(FM]"5K&/(_>?Y?GZW").YW5^* M+M$4"R-DI
M7A@,\.YK2&;2LAU]BSA0MJE+#$ KR<0;21M!B?RPQ^<IV2-J&I&_H-UT1&,Y
MG?7INVF=68,)2?U*^60TI.^K1I<482 QU_7UBG>4#KH2M_\$OA"G&:&K2/"]
M/,WV3#-1/'+:4FQXI\YB'OX3]7&>= *3:/SH[5,M5&S'+M]DRJ(5D;6=;Q!C
MPI.J:3Y?YR5(C[(BFG'/:N1[^,()B]T?K7Z^[PI/[#P!$-P:D=V;)?>9QS!I
M5L)'I]*++KWY(2LU]3IL>#&MX5JRBD-\C(P0%XDT@BMFK:]]<P7,L4.M=-[Q
MLB![V?'LNP$&$S!"-R]UA\5^F)@*!ARS\1U+!<*F^"-P^4$ /I<H1M*O+J;W
M?9P<.Z2BKE/ 8:EF4<5C8(_Y[((-:0T))(*GPK5H4>$(,LB>VCU\>%5Y,'JC
ML!!;9DO(I>9DOEQNZI48^9H0'1<AFVZ!8Z]5Z_5S9%O5H5!$N_XE)?(N>Z6J
MB>?MMF<;F:%I/V ]-?Z WLB=;,QU%U%(M;:U4%3IZY%?&P@*IQ#ZQEK[D7 T
M3:=$4HTR;)!*US:J6%S)W$O.W#XU<(0?_<F5</>^??J3&YIDJ=QF2P2[OMH1
M!89!;+V&Q916TR7KT7<#MK]V1D6*:45> C0Z-M+BMGV1(:8' (\'-Y<-':W3
M0_+:AR#)9WR<E6ISCDC@[@LU>&(_P0%?Z[!R#UG[8V1?-^,'I3^ 9!C)5=*N
M,>*-(%77G?',+M=BZ>L![]'XQ]25C\UC#M>6,*IW&"]ARWQAXGRI;XVO;1_&
M\0O3,JT_XQ_8\H^&<EA,?7/P*L6C2-QR^;IMU'>W>U_#L4.%4FO,+TLT'/;#
MG&A +>HSP+<PZP) 4"5'58),K2B*"F,"N%NY72N'F-ZWW>F6Y"\TX1G:[J^8
M> 6'K(B[@#(.Y8SQ6.P':II9T*.^+YK(VAB*3KX&(E%,;W4RF*[U-8;H_^4*
MX/;:STC::@-G3P8,AG!Q#N*:]K2;RPP"F/1,%Q9$9H&7I.S0?&\;@'=!\/63
M?7W[;57I>82%D2PA^F?%RAW],K0UNA//\D5+"RWJ+LX][O*A/4YF' OO A)S
MA@^M=#_N=I\\U.(#E,ZZVR+IH/)!#R\,QND-T5AJ%=S3;QXAI&3-QUA6)*PT
MNH=Y:"!A(\$AO O)^*<M_]UZ1<E2'8G.J H$V>MP/ZN"R70T(A?B<MPA@_12
M].-]D!AC^.=TE$C\H>$FT9T.^6*POEZWJ &X'[E+(BJA]5=-.<0@3Q>F"G/F
MXZW2*I=#IK=CUU9=$,CT&H$(! !&7>+$N"7YKMV:_PH\1Y^,OCWEH9$/!K=U
M'65:LQ2^Y720S$/6(I0'%E$&MC^H"]LA[^,U-AD!/-X/_@V'GCCT#%*)0*:_
M6G]A5,54;<\?%.'K2F4VP[U-//>J</S&#'-Z?X$.ER.6(XE-0,<??Q3-? #[
M#X#NOJBT'@S)D38:H(:HY7]XO5DMFT_P&IN1\(R/MYR%WH#21S^:0T$A#'5/
MV^T^ULIT:__TD]LIQP[JSX8P9J31\J6K&CVR\L =?;)"U2#?5+I3ZR(I=V74
MSE00^+K 6-DGNG4Z4;1_I[T-[:4^N+VNR%J<,^PSGJ$)B)H3F_BR;+O/%AKM
M&<%2K.96$G)VT22+-]O$YTYTUWZWDT%R%>^;EPX9A1LYG(1JUC_2Q&E\,6&"
MWN?S'TZ#]C@*B!#,T-KD9N&#BC8<2SM%I443T$DT;\TD-PH+!R0]QUE>_Z^8
MA9,.JZ-.N5N;H*L-<1YY>K/%J[KQ/N4:GSKQFDY\NY)B/]3V>0XGQ.?]@>L_
M>+$+GQ%!FA(*]L!F$[N]5RV9X&UQMJS@1>>W:K-.^E$>3Z]1>JR8BU]%E]8X
M;I?M?_E8LGAP_?CAAI7J7TI@X\3-"0RPG''QDML/:UO'%(ADXJJMZ@O- FUH
MQ_N\, /^YD9%I>?)XYG<1C,Q#6\SA<3B;_^:H&@0-OUV(CX7"'BO4;E28=A1
M NEWAMI"^\39_3Y.X6<,;N-&.)[Y$[>#!^F93N5G<9O1T GPR8:M4&"C6M(K
MI&DRKF-Y(YEIRMS18'WG!_Q_WNM1_@O\G\ %E@SU7-UJW5[9\<A,7E>TEG '
M(0D1<AT27G+8Z^V:#8VRVZ43^S)WCY 4\3M6.R#9-@WP1"<:=2BM]M7X^K$6
MAN^GOIWO?H/L XTP^LJ'+,*:%IQAM2A<A[E<4.A!+@W2/MABD]H7?99+%"-X
M17II]IP?4W#Z8@>O_+ML1HO]N^\HZB#C>%F3;F58MBE1E",N(Y1,*IB>F5TY
M-"2J!U7LI;+#;M(KIE/A>^6O?P W3!JB/#K2JT\S@:1C)-[[0<SJ0)9Q(JM9
MYJ/R()EM8R_6;(8P)6,09G3(YEW?U^!W6L.O?8,?2^2O'>+XP:Z4+\9_[N2V
ML,(FR\-#8<ZOV%G\B>"":?I5*HSPXFI"+]\2UE7>I]S[MI]B??93#:6O?>T_
M_9WX7T1X_[6=@TP)_1%$;I+"5HT2+>*@ @,=<0R!DWB/&3%Y3P3X>(>!![;T
M["7A7FX$45SHJZ>[=_6*UPI>>[,O)3%;?BK8H[+O44%4K0'DM&G6=<G93'T1
MU&ZD<;(6L6\SG\4:CLL7GI/[8U="%TH>-VJ.OHF-_PSODF)/^>P1=4,ZM3?J
MMO!RT*+]\UX47?1X2_#=L^_*QG/,7X_/MP>XX,UT>OTNBO2)[\(P![YFB#F&
MAJ"*T6]M=*_QYT:1M7]NC[6OGS\US>EYE3K_LS%'6O+>_]Q;DA(\C?2*".PU
MG2PQ$D6-.!OGZ 7D$D1?B&%#Q?BKF[U2HC:I7_COMS6&N&T$[_5^T7)DZ6PM
M)/TNS?CWLOF=>Y_]?_&1&N%GW#;V:1H=I756Y+%,%&X4=4*EB&&\:*L<[4OK
M3"O_"P(/M_8/H%O!?]WWW!^RO*EH%.,%_8U]W$QOMA(%#I<8.H5%L_,JR?7Y
MJ[8RH&9@%$,*7=!J T.3(@F3$M&%@.E^7V3[C[1R(U#XN&D+SO: \2?N _)$
M'BE<BT)Z"\G6112V.!S:_I:Y'<+I87[7MTK4; KOQ/Q4NM@7PDWE 3KWW$XQ
M+/;10 /R/?%(HNJ429;JFV0)&2X\<Q^[?@V-36'7=YR'V789Q?TJ-Q@"HH@&
M^E&T*'M._E)DAIBUM@8N-VQ!M"D93&YX:+!L75NG)SN^@F;J@O3H3"0M;2$T
MU[#XC:/B"V>%8%1V?O#W)&EV U3%.OJ!K7#D= BV!+&G0Z*$G?T=V-)X+#)F
M=#MFEC4S(H",Q$'BF_%2IJW>EV\6[LOSAR;Q4YAQVLX.ZTH1:_@+9DXZF=BD
M$WD+3-YNQK#!KD%.OPGR8FW=5G4H%SM&N7&2#@I_-(=^JI6221A!&#_V6MM7
ME_E8SO]M1@"=&5JM:EO@.&E\F4O(*O1R[S&=^Q6C?<=V/6Y2A2-U#&^T?:QR
M:]-H><Y=&S1&6E(%18M_^8Y_,:73']#W)4DO&FSA1EF*/T%#F6/L/28<X@L%
M2K<J;YFR>3FR8:P9SR/;)2'@5&)Z&>*=RM.T4:UIR$)$Z'==Q7A5#HGA=K3:
M-D -01U^<-:H-]K>',4U35(RI4""1(]@^:00YH5BTLYV2;X2>F;?&0&99PVO
ML:::RHC%Z'RQKMM\(27\V[4.Z^-CUQNJ+%1_'QPN_>7)97-"-C$HIW8<#\^-
MG(0)W"4[LTPXE\!D2/0XD]_]*_I=DTY^:"QP_YBD$K.Z3N?729?0"<^"*$<H
M<$/R0E&@@T,A"=8W!5I7:V=40O)H(!PM1?_<D=1VV1R1"!?08O".5:5F=GA#
M#I66SP,L\3K9I KW="M:X&*.F;DF]?691KNZHR#9]$'TD1/_6BQO[F 3G&+/
M!,;=ZF(P"E8 Q;N9OP8^5P?IQ0W&E?*M(K)ZF,.U:7GEA?KJM+^.9L2U]//\
MY@/=\E#.SWV/DGD)B+>K*)TH&*WPV7Z%9N4;(R'<(P9,$;0[S>2W?2=[#D*T
M=PJ)=4['&WI." ]2Y$'7:S$#\!I(#N1[U.'?;O8+4Q1AUS7--GW55T6'+57=
M$:5O/] FV%Q>1TO@XO[J%GRJ!HY.'S">DO<%8PN9="40$@R3PUYF7 \*! TM
M4EOKRCL2IJT[X'-J4'*D*NZBGSD\(J^@9]*'E<70",2)M=6';-Z2V*6>)2I*
M>'+)Z-$P,"04F@Y4G8P-+27-\6+HV<T. ,$1QEG*ZC;F+".;SXRRI3+'ZV3,
MLPO8)O=&5& K@Z1%CMG.4:>;Y7I]1E0?C2O6P^@[C4P>ALR-UBS4KV(@[96.
ML3GZ<-QIP,HXFZ;+MQILS.C%:=)T'MNU]#U-5G6FQ,6S9QW<.1'D@'0EG%P^
M&^.(.71.E9'PLP'W,C&8==0/3/1Z"@7M*Y08'(]M-=JRUTRV&V<-(X..GI/%
M,^@,'+=5><5I2BX<#<Z!7YS=1UL:C$4/: C_ /(4DYMXG=]02,HO%!4+%7%E
MU0U#F*Q2<QFGC(_".J%5JK#L'V*);1&"/CF1::(P!JH30>0IEXBR8Q)9_6\!
MPD,C!&Z='BXX2BKJ\.$Y*M!4IE*2P.!AW#F [.>J0'TJA\U5N1"1;+3!2/F1
M@N,?P(QL!O5X$L:38J1WOS26?!'=FY'1GM;QF2F*BQ=?)]7,Q\;$6YUXOZJD
M^%UB<5&9*9S8-W!HA?X!V&!%A5D1?;AQ>T>\/]]J)Q%432. &MD_NV*7C9+C
MT/XH4.]6Y>A%WP"343SPSZB-&W</Z<3R3,M;]4)'8^=E IFF)1*X(D49H>:R
M:$MUH$PHMI7:IRL_U9O@)6K1?!9-%>+,48*S)#GE4V6\&E_D$9_LC8PW!X0=
M8&.QQO\!$(#:+F67E,59#4:_?+*TF?!6P'+- 8*;F066TS%O8E>)4YF)?HST
MMA+MBZ&WZ#  DH79,G$R#1H$7/':YW7R[5MBR$B\*JQ=/R1\)7H?=.45K^?\
MK'4]7HTW0VEH[1S2TN%"4^#N#'I!RKQ0V$N]%>#6**<\O9QHOZ-@&ZI*,N4!
M+C1A7@Q51?&:2'-U&F9.@<OP2H6SDZ+I0+]O [KZ!.=I+"#:9<T3I#,OQA]6
MBU2;?=_ICYY9,NNLB#.B%LB] ,'F3,="AZ341TS:O*HG%/88705&N$P(ZL1-
M9-E7Z-E;4)VXJ7?WV^=+@62S0.\K)TJW3*_\75I*;55J*C?)!(O9,8ES:KSZ
M1V3\S>ORQ 99TH9\'2M"#-,G6:YY'=@NWTH!QHP X:$Q]V_1HZ0X"&LVWX2R
MJDVU3>)IBK^?HTC?+YV4>[.7?J 0E;% PTKZL$PK42J&KV& _:728Q-L(58&
M%7V['R9&U!6,+@ZUPUHZXHE$^NT?*[-A:=?IN+Z8+^N^54$SL^*W=_FM>(GN
M&UTV(Q*OCGQ.F7'QE+18$>S6'@WT3G:"1DR.R>%[ZP/F0YN;45<("G,:#6XQ
M A6VT*W-+5<JHJ0;(*9W@8 OE#Y.U,Z).A&Q M@QW3^UO_[AS<8ZE,K@)S"*
MPAB 0I-)SU,_*PBE,0'Q3BZ3V'_MM/+P<IK ?:.3O>N3#;,^E?_"/>OCBS7G
M?LD4KVJ[R"KJLVD?5Z+.F)SEY&5<CIM8[N+J!!&FW^86:[O#*993@IF\U?[G
M+E>0O2E\%ICX WC ?_/[*W EY9$/\I+I^(807Y672)@I4["I6[Q+K*E)I%'C
M'*'7TQ*&8E<LU!:W'%Y>!T8W$3-^>\_ME=D6Z1EE@^'7'>PI<:8/:[.^)W<1
M8^!4&\K1ZD(4@'SM==P5LS]1!OLK+,-WY.=U(7E+4RWAG$DJ)A&BDQC6Z/NT
M#1:E,.!/LD*AAG1;6]O$8Q4-/R#W<6HJGG6PK1'=6\MOQ1N33:YC IRZ98=*
M:7"XVA75,2Z"&1%PBCL?,<K9'0RMH4MZ:GY?YO"Z;>_]7<@OKS>WOT]8^C5^
M<':?L/_3:2"1DX7;BF^S<Q^F:KT.L9_^=F&$ </_N+T39YS\#T#>[*[XPU19
MW31<"S]DW*7Y#F>6 HZ8Y)+,U!YY)*?MZ&E@_[X@PILKO\ND2I-)E"&KZZW/
MUA6UA&Q<)P 0:_)PN:B#24@4O#_W 7DM4_EEHQ ( H&:E(A,L &KR-'J^\P;
M7AW=#\H_PP>_/42:7>S+LV?RLJ!<F79=7H*,1J:Q:M3IBZC*0)TUYH$W$AR5
M/7\ G';1B4LK:31R*2Q-0M<F_*=TC*YYMG5>D@YCU8[5JJ_8&IT,-?+AMPIV
M3#'#=F@\J!JWUIU*Q\0S #1=]?"'DZO5U$(Z8B'A*?HI#)K0PXF+J&DM.\U#
M#>9OTH'\4X9MW!DRTM*;,J%9QAPD:;(?\2+D37L )4!O"+?('\ ;/@3+#-U7
M<G'N;A:QT92F=>!GUT#V5@*RDD-^S+*5)W*E-@R,$#WVP/%GG9VB:R4?021!
M<38MA!IQ]I#<2$[>P'J1[JU#P-D? ''IX+H_5@+!#L]TO B=:0%]@T);$V_R
MG'IA@>R\+^)<GIXG&_\J=H.2DXQZ='&].=R*#$"&E'E^;JY/_[\MJW#?M$/8
M6KAA-8\H4M1J5Y-M_+MWJSM9QW4?2S]2C+8K5ABW(WDZV9EF4AVKC95-E9Z3
M9>IHG<J"'9DF*>1#=@]BEF'D,JB/2E%,9_8M$'/K#@JES E[*M;W*=7.T<QN
MGBFP<OAWJ1RE?(FQVS(\@<7.[T'U53%*)Z@FO91;(Y=XNN"]\0_+(W7R1>:%
M4-^3RO7MQU)<6SM^5TEL!T:9K>27QJS- _W3 J&[+N1S>.[(S398LCDD7FIF
MTP=A_JG9>M![5;MG[<%*YEQP[TPEU&E*_V.V ^5[2K;!!KL/TT>U.=>6FG'B
MM,F;E,UTK .>JOIP*D/D$?2+9+,[,JD].EV=M//YAWK*,3;A!8[B?+4,>\#"
MU?HT=^!9+)6 UK6&LTCK<BRVG;@0CE1CV$0#=V??ULNQ"3*)0.JZ8)(E"F]+
MT-B]0_2()%(]2PX)65TD;Y%@3%O-6E<6T$5#+YOQEX)PM^HZXU_+^XIWJ@3Q
M!P9II,DZRA"S[>LKH]3<LB5DO%1%BT+]F00I;@Y8IV![%YNX*0.QO;P6MGW;
M<+5"\RFZP^>#>*U<]@&W>J"GL2[_YG@R_7]C[ZVCZFJZ/L$+P=W=X>(0W-WU
MXBX!+N[N(;AS@8MK<'?WX [!@D.0BTN $"0DH9^GY^NUWOG6FO[F?6=-3W?/
M]]^I4V>O7^VJ7;OVJ=JU-V<2IC C=1P/.L+U$GOTYK%GY%!ZY-,BC94S,H7"
ML.<CO7.[ 463,K'!1-R'TJ725E<^_PD7M\7Q45;^5.*54C)=#A5H*X\\R0\.
MS,].Q=7DL;@V0$]S5?AA9TM:-*>W1EX-Y-&'FT#_M6:9K9WA?-PD#L5XK40T
M+&)'"Y=I,0I>#P&=5L:2^^>"F99A*<T@"R4"*T%S%$XQB8N$]N1?AX]1:V,#
ME9RRQ:0MI+;:J5)S@Z K87ESH^0LM&E-08-LB%BT340IUOSGIF/;-"55!Y%N
M?,\?V/4=:+J>(%R21,.4T5+<_=IZ]9AW?FPUI397+'=09'MM_V!A<X[DV4,F
MI03U[+I2<G0>E18/@)>,W !;3JIE-)0R)86A,A]5KF9$X'<KUJGCN^TCA7O+
MK!189?[JL7D>.2,HX!OY44O1+4E9!@9SA?TU?*'#G7Y8<.C]D)]7#IM=0=P^
M?GN>$KM=1ZF,IWOF._*BE6J0&*0$^_K/QY$<VJX_=WV:1T3 $;5E5'T5"<8?
MSCNDT+-IPH02V%BSUY<OJ/T4/$JEQ/"G*RQ<&1CVNSLH:#99FKBA%+43*Y_N
MOY7)<+&-HW@Y$M#VD<PH*_'=\K "R5L!%9[ZG:;^IU_9<&+9&[C68Y\.!Z<X
MWJ&5E9ICXLBW+5\+*;+^FC%GJWC:5K&&.*8!STGW'8'76(C-T^UO,LIQEA,]
M6"P9F8QP@M+8+0S#^#/-SR:YP@BD!@W#G$R;=E<R]D%(Y-:?_+8SI7YV?,#)
M&->>':E6J\^[G@^<\N:.MYY)*U)W)YCS/)-C]DVOR)!)[30<_S&6W@1AYUTT
M38'3A#!J+F556G'0/SJJ;,4GQN!8Q[8Q/AV\P<XX1'"M]SQ#]WYGB-.B)4_>
MRM5PR^#K;X8KB0>G9JJN0L2B:^*PRLRT#6AR46ULO(\C2_:;C1;TYA+S#<$7
M),S(NN_/FD[[;/GY+6D%EVO^SLW"-^RDOC(=VU8="?X#R^RPE654_K(3'^L=
MNI2<D4AU\\:<%9&@OA-,D@Q&H4C*2H,H;76FM J6Z;HL"*69\6%\+(_G02T0
M#%-7A%I]@:X%+$S0N!@SE/B0FUB%<: LWBA$#_#['%MC(2QCR8P\%Q_;."#P
M?Z(6E<%O5R(Q1*;S]9W465J_/<0+^-Z,YXFEGFRZ16[)Q*1K@C8 I$$+Q])/
MR4 9M@P7R*VL3H047F,D_DF@DMUF\,>MX8@I)E7 )LGA!\>T"U,S5>2C"?63
M;<_B;R\*=A>G=(T/DXXXH,TC]%SHL1RB*+C$HC?[$'W/3/>B3RS&TB*P4S3(
M;H2H<_]*H.@"Q\E6,*J39VU2X,ZAB!S*73%_1,GVQQ,A"B1:HB)U3>TYQS?J
M8TV/,N $2MQ>SV5V==O<5X ..5UX.BE^\$Q [9A,"W-^2K)]QDQVF0%_XXKD
MD=B;C9%;FEHM!HD:&7YIJW0%,9111:(CD*4V?;\># [12\FE9N3N9O>9=H-6
M:F8]T^^J>Z:P"'+:I&_ :Y'FCZ@%#TCJSH:+U0=QS:*RP=]VA6G%+5*D'4:W
MK*;8A_O7 A4_VVB%?4O::+<>J@DY^VHQ/^T5(*/0I4+!7>O5HA,ZGH'N2"^J
MOW(U[$+'HZ4V+&M!/,%)EB'N)$-)^AAB737,.("F'$.I>RCWE/&)LKE'@5HM
MZG.*Y794H0V[WTQ=V,!*P@X9K[)"Y"B\J8EN:BI]CI0F_#!TJ)JRY9V?5T2:
M@H^(:2=>;>IQ,'X6#4<LV;X*!_986GX]5_K,N#,N?0Q6]P#5]-YQF%8I6T*]
M1P"M:M(,B'=0F;:V/"#+/'"9XH5F:LL6EY_$5_O@$[+XGH.HA&^\Z SX"E.C
M9OB@PPT;M/T!C<F.4!+6SU^UAQJB5H"CT,ZQ:!*-*^+%'/W5=SC</2=[46V
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M- ET-=":K_ZB)-]]!1R:&OS&W(1]UG9J\(S_%R*KM=32_'=#-Q]GEOSH3;5
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MMPC95N;6"\T>@Z4+<V!:C,KHY-OO#==XA<J&1%*ZK\X3K0.3$@^<0\3Y^DO
MJ1P:3=+]G03HQ?TM#WIX4.XL@59[,*,?PA2VJ:UX7#LUI:H85[W@^=2\TC-I
MU(Q)1:J^+9Y61XM,D//NL?%2FLAD+H.*48*)%[E4_AZ";G49[%.9];'BS)]O
M?9WT]IG6"M5R.<\Y= H+K%J1_.Q)HB.B0>5?R4OO'L8GX8FZ5QRZ3V7T"YI/
M,TY1M"WFX&A)(W#R,<J!DZ<MJQ:+JS)#I(W(BM8M72:^+K(2UW$?F#BD!TK)
M'Y0UJZV;;X-$ZH+SL63\C;L."7!'"+3R:>I=%K[:L.J6%2@AW+[K75*,;XD6
M3_ S( J>]-@8\30:J4!?^;6Q'_=@%E\I])Z\"0*57>D6;AVWS,'=P$.R9.-H
M)M.K3,\N^P4< \$YUBM;L3#UZF'XW/'INIJ,PD"X?GH7$[$_C)U3X9^DOI"C
M46A;E-!X]V#E$CB%U[94VII&1B>P:5F',DX4#.R)3SC7O+\^,-TFREC,05NA
MM9(FPR&RI%1G%7JP7>]0BRI7:[:\X26J%^W.GV)6LXI()(MX\2X:42/M1 UK
MISILR[?YZ#>OH#517M^*V'!4%"- E]*YWZ^I:(,Q14.Y'DUO#ZL01+)/5=#E
MPTWYB-)\=9Y&%6@@ST#!B\HEO[(G5Y;@*%FWPS1FF%/*O59=JHKQOAF=E]?*
M%+V*C4EJ?3.[+1:*_RE1P68&E%\4O883R7:Y%;3[FTS7P<YCIE7M]P\-<?B3
M5X#>?=72!.<<[^,7L7OTC[\-EDI5*7KY/G_5_;[ ^>''.Y4D=L_+9<GW.I^E
MNE\!7]ZS\C7_)_'_F\2_.WKN%]]?0:N_CF']>-AS?@6X1M_(+FPE<G2\R+M&
M]? KEW_,_P<2[?+_@:RT$*?^&*L86[\+C(W3/8PQ0,M@9(H:,KJ!/NED9V5B
MX1QZQ*(SDP^?QAJTU[N-&"<<Q!Z<!I\05M6)#Q&_ @+>2=IB_]XX@F1^_3/6
M<%SFTZ;ZTW[[B#@FZ"CXWB933+ZBC.^O-YX)(_UW X$\,U1TR]IDP-]\@>^O
MK[Y<P\6UVX2*J0##\$X,4Y8WL,CG&C)W:-'7U;I+7"98P]4?\EPR*:\\O'U#
MT/;[ELNQ3#PRJ'\E*SW_X\+5\T/8^U_J@!&G#X-F4B&BE]_?Z3K8FJ;;8S.7
M)O1?&XV%+EW38,!W86!&HV\C(= C7I/_@3->ZSQLQTB7^"?"H?MNT/F/Q=]N
M/S)-^S]Z"1T0LQ0JO1AF)0O[QM.,]\A\V[S7YVH0ZFV_&G>7=T..Y+7PW7+=
MG%1IB#*(]:$GF^$A-K2*55 ;\\JLJN6[Y+JL&UR8/;]"#M&M[L>HC_-VE?]+
M*PL0'"<Z9!!IO]3*^,RT0%5082A#QI74,C/VD[>==3%"XTJC/4O.0501RC Q
M$1!J&T< QED8[CZ=F1<GH>)-BL^VD*#LX.;85Y?'JR:6X8JL[5(DB(2P_'9A
MM+"HKAQO>VIF9F4U0D(W;2]F(C:+X;I)?@$%"GFU%>,@2*O25+K_4= E:$'S
MX^Y#>V/05YOZQ?YO"W\+2=!N)#TT)]@1;S/GP/ N*:X9_,N</<=Q/Q:!DB9W
MBJP$5[\IEI;R:68EXXJ.QW=S:%\#Z\<E96>3=E_RAG6+(&*",N/22:0SMU($
M>EVARE.7%1JC+Y(<*T6!&6%L4[9-&IU,^@BB>Z1!E_3[S/Z?!)20IU85(<1L
MK5 NI/!Q(IKXM::9_H@@#,'.?:PAD])7  <<TM@SG6"6!TR4:52NMSMNAHP4
MG7)'VZQ_^.J:IFG9R(J6Q&:9N;^Q96^7:.:/"&&-"%GS'WD(K&/MQ/#+VJTA
M[#P@F2+("G*:=!U#,6.VKRU:R7G(&^-VM47[ /)I=*+0J^/(W&H9_(*ZNN7<
M_[!ETW$UL.7<<;V%[O(*0.PPWR'#B="X8_ C:^?MF^+LC1L -3^(RF_"^KPO
ME%JLY^)129N/#(>OM<D')M,\(@+%4(EQL]HO*=,13@+7VAN=-A^(?YM<=0QY
M"]Q+3A2[M"$Z$4[?*L>;IM3G=82_)9R%N0LKZ19U(^W\X5Q9O3E&:C)=]+@/
M5[C60+!IH,+QZ_(UL4%7@'RGGEN_,\7"32VE,_ _EHI5.+Z]7F?L88+CGLY)
ME6A'=11-' (:C)JB[ZON$B.);HNZM40Z0B)[77H$MUPR?PF^ C _QK@].1?1
M:T^EFZ/,!6#T7^&_838[3*3S,.>&$S('MB!5U;D (@$8TN*[,D^I+"8NK9%B
MHFX65_VAT*OVJ[_OWC>VVKP""!_^8&:] C)#73IV\EPZ7GQ-7#I^F6P.OP)*
M'D\7J-O^3CR0&*&9O<I;L"?BZ6-ZBI$!I<-3SO>'DA%2#>L$>RN@8'[&'NS$
M<_P I7?QU5U(G+F!H(*OHXD7%&S0%55^4JZRS&INSU"QJF->/3IA@OBE^<_%
MSN<-X]Y<QHN&P 6F_ZXR=Z>@F^[2UF$1@HUM%U/!=UG5<3E&57>L;G2\ J)?
M./Z2F@?S%XX_@AN..+_ZK_X2:I,;D]*0W+]KU/\:5,"6VU#'EJ_YBR2L8Z[S
M%9"[98\R"G4@C"D@U6 ,EIGVGE:#DA-SV(^C]TVM"7;WE-DJ]\!M7F"[V>K:
M.W,L7$,Y(3N97=IE):&-!3SIE% 9"//U#=CDI71CL8,/BT,#<R]5O"*R&R:O
M1.^T6D3;(L67BF3C".&FG<"37\Y6CD#=[_8E*JR4I 2M>T(D(ZR[^E?-^5.*
M%^-&/W2PN$9-M'FNRO$@%:[3X<SB\7>Z>7 >9WB@'4$>.[8NMV3X%66C'Z'T
MSJ3PR$D&.^]A.:0MSE<4!Z?77GX$H<34/-);B!T\JW(N]4!U*UGWA"BB'QV;
M^Z<)($*F7I>.U2V7SO9O3BZGNZL;3KNKOT0Y@K;^Y.*X=.YMN?3ZAE!/M+I^
M?G[PMD<!24YR_\H<'Y E.]QI=,V&,?/D"97U "G[QG4V.(723%M<>87DQ)?D
M"3>X5P=&)IO4VNO[_YI#F'$"2DFCY>NK!)? WSW3GSU)?NG$E_5$^GDDRE$S
M7H=YZ8#?6"-L0,4J(P@O.;[7X7AS<K1QB*L?7T90>4]J_[+.O:@'1LH5M2KV
MYD./!'S3Z$0T-@Z'%08.N_186[8=3VP0K[="453ZOX7@%P&%=/-V'S ;@W97
MV^N#=A\'9HQ73W<?^W\2M==+A2S\DQDKI'DRKBEL4B/)=]?:\-X%F:]M!)DO
M/J+_)?<] OV-_[9)F;<>S/_30DK4^'(RY5 ?:.NL</='Q_'DL9TENEA4E$YK
M?9F@3JC)>)4T'\V)A(O8RYD[4O"Z4[:NU%S1.8%LUM1D@5VNN.['//-F@<YX
MK[\APQXXR$=M>O57<=T,H(4L0XB#<<O5#P->'76$G6%W7$>;3#W+GGP+'-A9
M4KA90();KFF_N\#FQ8';@$HU0BT>&[YMLL#)O3MO0#B(A39&EM^<C[L-()HL
M/SOG*TP+:IGE&D^<&.!.!O?QVCY%<N29?.WXR^B\W&KI:GP%[/\YX6A0^T'U
MKQ[.)VC="&Y75^9_3Z0[D",54!PA54"FQ(>6X@HB/KQ##D[F0PT<CM5UE--W
M]W@;Q0<DH9O99$,PZ)B!52]6! 2D]G\U:BONKH2HFO.\R,2!V+,XS3)Y K0=
M8!_)1P^7%?QVV+J8IW&<4R%S88I,GE#&VR.5[%G0>3__0C^^ETZI3W$Y@Z^Z
M,?%,<RA7G4>" B\#1TXO/D0VK(513:&^P3E7#%.%S)K%.HR($R)'0?_T?NMM
MRT<R5\-A6>ZI+7\JE+ 2J9*E*$^UB/:7WI9641%!ONQ*%$$8<EU0KH6%OVM.
ME[CP 8-;3U.N'87O%ZJ"*=IR51ON5N[$UN[6;WV1,$$0GHQTU>PG1(4RC3N!
M*'Y4.KOT]N+,9LYX<%\,!7@X^ZD;CHC5K?P.]NV9U2"I0G&^6*<K"+S?PL+&
M*\-PS8&MKK( M@UBP[4PKY)#*4N(^ZH <25CLQB&W$R.JZ2,>_81\W<<7#:\
M HC21Z#13'D;//&7*C-TSF.X]KUOZ"8=^9OO!=3).-K;V,:S 7B S4=\@YYR
MK%? ]2M@:OEIY9%Z0,H#'3\22EXU[A#M_H[=(TWL'([3)%[=I-F:B4[&!8\]
M$L-_0.7GZ"DM1?&0*%I5B4PI+(K[H,6C7ME#-.L]^5]V8,=1%=^WZ-+:3)LY
M'NOLLLG$BO+^-9#0&MY,TV'99XT46_]M1#P[DGT;&6I"0>BN%YA\_2L2$]]8
M%>!ITM%,%9G!09!5U/XKZ.G]  M1%NR7!%*&?)%/)A<Z644&;:PR>-(4N!C7
M(98]T>+,C3>Q15), ^WL*=]!6VV7>PN2JI('5G^2H00N8"F;$9L^HHF@ SXO
M76Y5&Q%\9VI2 JH=#QR(-2QG9K2 ?V!=16$IZ>IM@L[(46.G<2 6*)CN<MR-
M],$W*Y_:L1#89.[6@F=S31_#W/_@C)3F6Z&R/,53IABHY7(V4EHFF8U0 +%P
M6TJTNC2S/HK,W-K8T("DH&]9>I,Y-MO@.:.^C'S$0T\4W]YXCX]FJY;O*%C)
MU[CYP75*@ZYP%!/BR$&!K^E_P@2CR'H+CK<D81@R+39U):I2PDS])"&R(3M]
M?(C-37-9M>!I'CFO4VR:N7N6N@%>'R& B9E?-M(JWG]#284%8'"GJ61E4X4]
M"VB&=G8H4$DM%9VQ?E'(UI$D\+=$-];>Q()#)X 3<GRW#9N\U\B^ON5WAPYQ
M0\JVCE1Y>!@%\B,D?"(R\#-5UFF2IGB?+9WB)9@TV#Y0V!]0R$4"^YO3I>$=
M--E8#<E1JX/1&LBOSU9,6(?CH9(,/O[RB=E;!]VXD ]X=CRLJ@J9FUQ/-U;#
M!A8GP457;WAIBK7=XU799&:;ZUW6<O,[K1K>C*WT8]P'+ADC9J<I=<51:-/;
MA]!,+FRX:B90U>MM4&NU'=3%3_YR&,1%PK)M7J-5AG+H(F-V>/;/":O/$H[B
M)IX??*T.;7X%^%:82?YMU@0Q"#+/FN3M*[(:<6=)K0[S"[-%V3%+&/&8"5FY
M+G\WS6G0?P50QM0[@:X8_:#UMB)*>RG$VKNT%!:K[>\NPNRL=^@=PYV(TZTZ
MF,<EDV5 F8Z^'\A3\=/-\K;1WVIV^0$5Z=?O<2NRL]$MWE*H,N7+C<6M)8DO
M,H"J22U)HF7<M563!WL"L/&&4AF$65%Q(A7*8WULHIB>=F568-WU\QR5I_/"
MPPMB>4C.!W'.JCPL/(:P?%8C9<R%7E0+ A;"%0QZ!CL#-(F8\A4>9D2XHT+9
MQ8=2VP!TII..R[;1*9&[KQ!/$-O8@07X'9D(L')$5".Y^+,P4%6JP@/*XQTP
MK,*44M0T[=JWZ$'3/-2<Q>>B#-10(=B< \*<C;!U.*?5UZ,M$RPY;TFM#XE@
M8ODH#4*YBJ6GK9MZQ!F?!B8(Y?&12+Y#20N7F7Q! AGG6LE1W:PH2OZ(*Q\1
M9Z,MZLD&CF994BIWQN52A ? :BUY*I55F>H964EVT>>?]39DR>9I&EL$,C?P
M=4AQIV:U9-ECXG':92T$T6C*9)J1WF10__XD<ZQ^_57AQ%?O.PH?XM'1N'"]
MK"?/R-?"Y.L&OTS/17P.<:6"*RO4-^?;GN/]2W/QZ4@G<A!]FO:;H#7*R"^O
M 'B4K:)Z%8Z" 14F:.H4$.*,W-]N$VF$1!:VT7=X@R86*,;Z@-C%_9FI;V2N
M,$Q])5VNF9YLM5R\"<]SQYDNFK/\;#)=XJ57ET_8RD!HE69D:?V/J,L2K$,U
MF0%]L@>UPG2\^JY/E6DF0?LO,7DO11J4J.VY6O+-,>'0[< &*#(B[9E6J)D[
M !RJ46<YKHO)G/UH19Q]AR17[Q&\69!QK/9S:LM%W^%\7OG&F%A[:Y%#(]A%
MPCG-B+WL:R*/<A)-DT[5OF(7+E0U^3Z^N%+JNRUIM$">DJ7A!%>7E.>X4&$5
M0?]"ANN%J3D7^RYFCFV=*DPKR].X,,VVNIBG;,K%T[FM8O@1DU9:.4*Z6OOC
M&L_CTD!*0=OQ29QN"\_8877L$L4'DA.Z4K?Y\L?W^8?(TNQ3'!XX2VX#S&XR
MNG'";C&&G'!J32U^<IHJ<%S0C!!;B?V/?EMG+23T5(YC0D.V6!%=1ZGT40.B
M3>K ;XQJ^R0/(CF/])_&:5(8*:KNO$8#+..H*'&,I0<CRT$JA$+7^7IL62 [
M*4H<1YQ)F'2A)?H$J0:0H%7Y+<L/3.89J/=W-:692,@(W&37N)C\04(A-7EA
MQM [2OQ\F7M[F,I'2.NB/F[0=+'/6Q!"B/SU[JQ"R3@J'FI!D/LM+%R4U]DJ
M7Q[<<*,V_3LEOXS)$4O\;:&E:<=!A5()32#2]7H;T2*M?>N; !00F18&ZHCQ
ML2GV3X2/^%3"(^2<$!E>OD;:"^;MB$QEZ*?.R?+U&;X^6V4LH>2IW?54Z&E3
M6J$Y&*F.@QF-(OBF1G<CB!GY^3XWJY$30>]"=J-'D[_6 A?#H?P8,5J<Z'-<
M<0#FU9(PA1\OZI%SR ]1CG-AHN1=L:LL8K7<C0+.T?0,!Z,M^ LO#!^2.'8S
MU;4XK+1347XE*AMHE2OEF*$(PO%MJ'[O60=FRF'R;(!X*6G3N7*F2M3WWF!!
MX*@Z6ER*C3XR#&4>4N?B(UP::<QP,6&#$%T^F4WS&#B]642JS!?.YRJ;^DF^
MB5>.EK6OD53S-X5SY-2N;<NE?]B!:K1B8K['"[AG5$G5QHP 6"@U'1K)I@+'
M,KD=H74N@9&L9N7O1:K @V9HA5H70DAM!Z6=L%=SB2CQ=G,#LIS1HV"R0YB7
M<L<,$4,1TS6=J>]FV/L7D+*#9_0C_V-C%Q%39-0(RPBH_TR]\F _[J*B+*?%
M]>0<I '!O:=7D4(5E]'S^D4MD(ZQAO_&2[UYGC&4GO!24Q5I<%UW3<Y\+%**
M'8 ;P2<%D*%7:V+G1<#97./R94?,LH0\;+U?B!1U6VBO7RC&]/XWQ/_+6)^7
M5GY/;7I3#'$[^U?54^U:%'36W.-3>,($UO</;T;@P(;UN)?8;'7DZ<9[L?K,
MI9$TIJUP3LG=#%_?-%1!GJUW&00RYB?5 U09S!*WFG.X:VDP%P3@^E6MW"7A
MM;;0R8I26MJR+'#'9$J3("_R5B.6*&E_OE35_*2<"5%/%.87:)W[[)FZP[]9
ML$-IS1%O[>=ARKN&^#L)CTVL(ZGOP"@)R M.FB4&%#EI=$D!_4ALL^:(:E?F
M/_B^G\+W=<3S'-?VD!B5RR]5:ZY(SU=F$*0I!37)@M78:]?IJ&;<S+=\35RG
M#S^] B)AG>>!"69>*?]2)M^R<.<M#K\$T4YI(,="MU6)$CI?\2;O3IJ7\J!^
M_O*<#MG5BE]'L3 )!NO@89DKR@RVRZ.?? KX8QJEU??&\<(9@1\G.G$U$T5W
MX#ISGZ?E#=O=OK-1?7'D?Z@'T36?BF5?$!>$\#T8=3:*>! F2\,F#/LN;BM;
MYOH#EF/K K$91<9.WB6)9[I<S/\UN1<"N%??BOQRN&QU,_<^8*.*F((T!ZP=
M:MCD!7ZOQ#6\IU+S29C_1!;$OK56(!3_OSKXZ%_@[S/K+^:K_\]@U:/M_].U
M]3_!_S<'EWU8GS'\2.Y:VUS_$&/AZ^"XND-TX];_X7?W.Y=.ER#GTQ"RLIK3
MD']H@X]0YO]@%E!L%<=[^MBH--2-:O+=RVG=NY6^,+&I#C&,+$?%O9]C0$87
MS,6+MN (,C1 J7?ZP[9:.H?;M9SZ/5]70]A=_A5P-<SRPO7AFH5)U>T/HX$G
M]-SG BOYY!5 []4M=G(RS'3*PE0WK6TF;_DGZ_LK(.5:0_CY)NXGFO(%3WJ6
MEN&'\E^O %C@^^OK,$>?('W#/B=M+@&N] N\EL&&Y3#.-6WNXL!N.F8;6Z)=
M^#$$NO:K(&S7G5X74\&+X;JCCL/QA/- ^7_HGK5W<5/_VJ!%\_T2> 7\:G4;
MZBQ]!7R2G' L:3ZU297F A+A)Z)61#8A+,M@H3"26FR.< &_84>@C'4\8/UX
M",'L+(;&_#.[,$HA->6>S(Q9/VB%8H6K;#)EW3DM,L9VM8G2C]1YF*_%4T5;
MNBN  :PXN<5OH#Q) !#[<"2-\0A*1,?:%'BL?'LH/-M'RI4ZL5\.<[79?E4]
M>^WH='O7KX(P-\I[HKH(6Y&H\DUO9[<DV!9V##+-2_91V*MOW_?D4R1(M,&0
M9E%:0_M)CJLV^%*0TR*7*U[(SYA%NE=F.,Y"(1W7O&(VH46*IT47V_+ID[5I
M'J8D?D^#T+CB22OX "PSOKFKD^\!<T+3Z<&#(K*<=N48ENH@YP^%:QZ0.$=(
M3G]G!': K4@;N"^-$?V'"A#PKEMCELO&.BL<@OS-4C95E&951$E]G!#P_7,]
M,86:6=9298H>DSA#DKE4#S;M)AMO.TDR\SY^Q418IA#H4Z3ZH?M40IU(%^'D
M%00J6#3Q7CK#DZP%ZD$%&0S&8\D&TRWUB35"F!2FZBZG7_(JS@R;O'NDPN&B
M(T-41Z=.2,YPW5G:R#FL8R^_3$'T859T=EC0V$,OCSIK!/O%:K5W+T9)E=_"
M]\L9Y([(?DTJUGFD@H6F6F8%7 6^S,O[9+\U(4^>LYI]TJ:-AC57*JDY.#E&
M/[-ZDGL"TJ/HNV(UFU46"/RG.)CKO#DA?4^D<+QKVOYOG NMKF*!UR1A8=_8
MP*O.93E_&(V6+BMC2$_0K!,1I9^./AJ!Y^\HW*\GP]:O^NASX'#CE&4<5!75
MSNX;\2N@3AMW)&&#W9""(UQA-$3#C2--JI-4ML'#IU[6-I@B2H/B1^M,JUTC
M"U3.DP2S'#V\/25MQ@ \*4PW?&W"(DQQ;-E45A9/O@0E4@6<9FZT.*ZT.&WE
M*&9F9"*>=";22&9F*<H&W% 9P-5B^S>GS7L>3_M_9V<B0S8F=$@_84S^N'ZZ
M$A8SS =.>63B^?2:P"&=O0)$FDX?R6!/,EX4"+OD(O*M[)GZ32SJ/CU%)1D,
M*I&")%0H#*GM!$L7KP">EP^KL_UP&#56ZZ0_-;"RK%$[<,.M?RQ7>9&#CPTF
M9G.(OE6(C4'(XM@0*)Y#N+SLU0X]0=J>T$O[1;P4&V8N=?& /!(WDSOD;<XY
MSAFAB38O&$FCDE>UCK>QTN[E,,RV%EB[C\&ZOE(%BH4Q=+([D<>G5R(,X4GO
M@XPJLPVC:4W]%ST/[VE4Q4_5IG";<YS1)<7WSVF^9<0EE/FY^J1\C-EB:'"'
M:>NGUV%^8]FNP)O"\%CA8'_#+SX'BJ77K:>M0:61+NU.WV#2P>*N/#9LX!O5
MKFL'ZB4BYI:I,_0U@[^7&FZKR(7U+8MV\O>-M2H^XA'@1)7L@7"22'_YJ+ 9
M%I+8<%9("KQ,&LXE,4UK/!D[40PIZPZ2V01(G1'H3:E9_F516XCY%98Z("*Y
MZ5K'[31E_H*D9CBVO0)(8DRBCZ">)KE%8?42&0<@;DZ_V9PW>@[%K8FNKX!8
MRYJVV5J&%GDSZYLXC[<S%"VJ^#I.TV.I'C6Z,ZQ6=B3+79W;ARF$/E$[(AEY
M2)922UHUAZ-1AU$!;BP6G/KQ/[!3#&$:31M]1P*LB703OF/NQS $)?8\HD8[
MKTBA:<*IXO%B-"8_G0*IDRU8/"<69Y85 !F1@X]M'?2IW&/6-WU"S$%T+KE9
MS81S>@/X []#+ ZUD#3.8Z#@2.?(^8RPV@4AXVJ0M#;&48&-B=LQ/1Y-"%9^
M0U_D<6 V%[@%%9/$3TP]V]75]_8Q7M^G'*^M;(*2K8(K8XN_,W3#'0?F_TAB
M+R]S4^%CW0(46-T5(AC)(]Q;]=R@5GZ"3T3NJS",^F/ EV;Q97&;G'S,&82.
M7Y?95#.MGA/P5>=94+5^$5%MCLC;PC1<-N6 .35,&4L0%)FFIL\+0GZV)-:H
MK$Y;-+,1^+3O8*YMEE!QU4(RH)!DQ;" %XJSZ93"E,S5]4=2_4V6"I[LQBX8
MSR\_?#W==3I!2M8S@8U#$QU/EL.#[[;XW<<&EF<=>?^4?@Z5]&,Y?&#*#VZ\
M.X@XIY =SDA20-$9F?!P6JR:]7M9MBKRY6V8PRKJ\D%N?OK+-#S9>Z?!ZK*?
MWR=Y=?TY3/&Q-6A=<[ <*NMBT..[I[@7KP/LD&U'2>'PM06/Y!L]'28@9P79
MRU7^"E81\PJ0HR3A<] ^--2,KQX4 EJSU75VUQU+OE7>F_&H)N*)FO<@&-<B
M5"4!^WU8T<>:T*CHA.F70>SZJ.FB;#-'-E8 *4":C#UQ8ZLOC,*8>UH:'^DF
M%.O7TEVZ$=37H790[!$TS[9*$38-FC!%>4B1%L505A&*"@1:+^L@C'MP9$4\
MU%G!S#Q>WEW%6*<I\P7())"FW$7YGA47I(WPTV>JD8OPV\8Y80+,P\]P%B*;
M?N)/*?9C(PA=0ERF9BEZU,OP6M!'=[YL#V.?(EN.*C\54RCY+\W-:+)W697'
M!Q;Z(ZM6$$6YBW L4X;;'8@Z8A)XG"6?I(J+)!5&[H92+WQZ38B:SJ#0CKLU
MRD*3-L/5]+>'Y>9_[&&)X3\I4C.TWJ';0BR0)MFAM#4I4Z[-1[+&K+0,R&+8
MTTV4[QVW3,8XY[1$,CY =42B^W:K:!&_UHY6\A6?%HT+F<BH?/<1K@@NM'^8
MQGR/Q)EF=X\RG&OWX=->?WU0B C.VG]#"SN2? *GO@)N*#[]WO6HI;Y[AR>A
M^+F#.JEI-D^W19ROE'*$9^PL(4 #O/P)#B'UU_%$]/ JHOSRK9[2\N9@^V37
M#)\!B7RG36TW$XBM>+!J_K9:#1&,SE!MK2U.Y?<A*$4^;XG>,BA3(6J3,&4-
MW?BVW/7"(/?7\1=:X;YV )_4?BC<-I!,M!!E^>A4"/=7)1)+Z/);*GNEG*3,
M-?[)Z^W.+DD$3V0;&1FG7+S,_+YHHGW#CC+62$,572L/2DNT:=6NU(R Z!Y/
MWK]^]]-^T_.\;T1_!;1^O8#\'9E/\/^!<ZFVUMNX";MF83DB\U59&,B!,BAN
MFE0/XV!93-':I<9H=W,%D[N,&0X+LQ:3V8_=@C)<]#I^;2-P$@:NXM.JU&S*
MH.#A%S(,8X,:Z+># D9$>I7 %W@=+#:O@)ZE-3%H@QZ!4G.UX7*MVF8[J\^8
MZX84YC;2Z6J%KT:/T+):6 _#2BEA.Q]]I+S.$/CWA)@*#>L0LII'C7*TF-#0
M5_IY//^,C&JA6X'NW&:<%1:Q16(O;"%93+5L]?N+J!9R#!Y^QK!.HX^4P"MG
MG-C-DVR9V#2N//P69@A7MXQIZ;S+HAV2M769_HK1JJMA=GB"6!K D!V7=1[#
M24T(CY),%3L1S/S"8(E&(;.>E(J2KR*5V@O7!PP9J=+)\!G>TQXT6R3PQ$%Z
MP&PP"[>)IDZ0UI>WR>58)CB0N6*''D2/084!!2.TODK/[+9ZM+*TWKTK4?'2
MOHH/>Q+R99Q^S0V8K,->5E<+D7<8*#+DZ-6E/6EGHAKX"(P=G\!(7HM4W_G?
MBZ6S?<WA#.Q+IN)D$5<*F'6=F\@?XDS&43% *D:[BI?*STL2'Y66 >3F%)\H
M&_NF3#-\)ZZS6-A[Y)8%RM,U7_-@+=6+V)%HH6=)I!*]&:2[2D/E4S::J_V(
M1T][I,V;R#PF Q?1/J(CRO*0PQ6MSJW<RFRX1M$C3A4K1+7!G#V.[1DGGY )
MG2/TEN"@M>&?YS,..!Q2P:&BQ^, !D15L^^Y1M)6EWR3B<(W9G"IK\87[!0$
M@J+@$>0(,L@8E%'AO:OQ&!EH@"+6HT0X1 #C(8"LD_%J>Y5LQK^?[UP]]M^+
M?\4QS)$9%G0?;/!>V^$=Y=222K)SW:<A"\P&D2OMQ>UK1\#/JS5GD<F1$V'V
M\T#-< 6*.4;"V0$]\62/7O*:42\[I8Q>@5_04#GYO?223NIY,CP]&:"[J[S6
M<;6BD<KA-I03'>9(=BSZFC8>^G'X(SK2Y\ H$G<5<;>)];>?4I=WB'N.N)J4
M*1? Y.GWX0(8 DI,RT#,<9ZV(WHJ[N].W18I9-OADCBS#&10]FA9J]1F"<##
M:LDR%3YT7?R76K?/4O1'<ZUA3;8)%%3U9/(UGC'VI>^,EN+L/HN+HEMEZHLF
MY%N>W7S<<SNT*KJM(IA@XXAIP"R(+5*P:<X(\TN00+K4!E;:>0":$U[Q1HAX
M;)T:Z8^O'^?3VCC?!X4B$O'UPSR[MK[S*1U!V*=5=%>*,J])E>F::7'D(8TR
M;7TC.]^P1S7'F+,&TP_BHA63B'$<DV@RYE1]IK)#$";'9Q?]VSS([T,K)S'>
M$):HU?=K2QG1V=9_B3(T>1E2-NCF6?Z%K] T862N/'0UI_YVMNN ;X/-W_Q,
M3/B.*7X'GU(L9IR0_W-6X2%F3)D"OH$@;YB(W-P8BB]#N PMTMX/S^#8:/:D
M4VSM-%2$%^+RQ%F&:?^^!YG9#.L_K-M]9[V!*_:>-8EJEQ7B%![NZ>4]D+?L
MZ-PQM4*,&.TE0G2$8>?)2.:I26)G]4[H.8LH:M+S@IS1LQZ'\>.*\J D-\VI
M(%,)>M[D*$\#/0:RI+E.TM82+<\),/J5A0PN()CQ)L..ZGU8VR*3'YK#"(8'
M>_48N_H06DO%6V[4:A8:4T=\,@](/[=2#A 3L>,-7?:L521RVKC4=VM'!'O=
MR&)XMX737+[D,D7#G\S;'TBD#13H,+YOFVWJ,_&?\-(Y0:<SIAE33F#JC8)*
M!YZHTZ7Y<;2#3%23-VS5RF.Z6R'#YZGVI8.&J8R\ 2/CHVC^$RUL]3Q2,RS^
M*;-$$FSF1>5VW7W*0-!GGABFDB^5#$O$%&U.^&32] R#*"77N*P7VN)OE@;>
MC+L)I(YXW-D^ W?6)@FF3*EM>(3ITR[*Y#$PAX[.I1F#_?W?>QM@.:EM\Z-C
MB6U5T#1]"Y;:'=*?IXA0VO1,;QFC_]S5G.&D1L:/%"L;"W\"LQO/YH9&J7+?
MZ=N<4J8)T>I@&[>-;'T)W6(#E>SS,:X/ J0QU;:04MKV2)8F"VZ]M!*O<4\,
M9T*3?: L@>91=Z9;$M[F/:#BTPV>;NWJ7AY!UYWL)@T:#Q654%;4J%!]3+7-
MH,7=/&L;?NAC0IY!6+UNCM(E>*6J63*#)X,U?WJSXACGIU8.DC!--J?XE([.
MU;8)R# @.C9I'_+XEX(6/;O '&C!I?2(I,=740Y^"(Y-=]5(<B0_#A#+"<.O
MIO=*,"D19#Q1O#N9?QG'\?"C48VF\^=&Z UEG?(5&6^JTR!AI(:WN:(G=<7Z
MC$SDE="ZE9>W_!(?XS>QMH$0%E07+O?K[KANY NG>;5*.Q+D@&O(/-*U[/@_
MVJ9'P@\::[U\4?TI.-O]F7@C^GLVJU+JI=FR ,7-U, /L80)HMMCV,46EC;5
MFFA!MQ,5YK*@_&)[A_F8W@(U?^+NLUO@2AP"Y;PDW$BR/8_,,[HI4%5?4-C?
M/&L4FKG/#')P:/&(X7Z4V+37JR5/T<I4$;T-0QO]D&.RB$<Y9/[X,<@!@J<0
MP;U+(G-%R$]F)S!AB.K"IM_@"1;17-\@HIUA!?8=?5GBRG=5UN'Q'3Q2X@!/
MH\S@(#!F_T T_?'MX#%I FE5Y] <W9G_7&*&Q1D(XO'=3Y^ *;/OC9YYJD[2
M\W-SSHW A\.[)' YS++/[8P :,UPD9>H>VIUGS4,>T#2.:V$)0\Y59->74,%
MD[PLEG97UCZ>NE=;580BHGDV8J1K^\@CSI2O ("+(51YD> ^ON6_7GS1]UYJ
M_XG+#79%!;L'QD\::P*6V95EC0\6FLDTL^WK@P@,DX4$NAH7,'OX#9 UGZG8
MVD\_Z+&?@50V,T5VC5MS":M;E'/IU,C&@0:F"V7(81S)# ]')=WE*,U(#]2*
MI0L-$T=A(R6*(8=EZI8]O>T2C03V:PJTV4X\X65US#,NFAX'NH%ML2EM%5+&
M1VAC(R0?$+T215:Y9+J&R3>>.>[(&-T)[$?TXS=0("R,?%ZL04QP#HAL#LT1
M++0Q%'$\&?MNZ- 5)9"FQ7**QSB>U(0'$<[74HT9U_9#K9+@Q*U% >3)+N%/
M]$R3S+FI>0SN256.K2;-G,5<%:.0T=KN88:6)_1(QZ%>IZO=K0\W#:*MB6>R
M[@G)O,(7L>O_BHN/*FO+?]<PII)QM$FC/9>EA_41?,2P?L(@ U)/QWFHY?>Y
M60SS7!>U<&+DR6K9.$0K.FF6LZN2#"V!OM"H&4[WEBZ?E6I7AJI$<;N^<4R(
M:W+N%>#J46VGIEJ\-M!^)ADTQ-=(J;-D3Q['#I9D:YGG08^ '<QY*+/=I37K
M,[AF9UI>7SWB==*IZ^I(*[I\)>D3-EB)%RD*Z<.G.#LE4=1N<,>HZSYA/&\5
M9A[,=,NQMJNLFZ++5;J%,B?H%$\W'P2'B01Y>VH'YN5F"F/K6=>/B'M><,B@
MY9_7G@8F0+?X<;J_],V*"@S?1G,)HF!5\YASYH,*=$4]TA (.:ZYG3]!4DM=
M6T1#!6E&*_.&C0_V_=PL$"QU5DKYJ2BBJ >2*R$>+)R:'F/="U-46DB$45UO
MM1$:>EP_NR-B7[J70XD-6L#C:K;,*-V"IEWW9:SMLZ0=@ F9&JW&BYS( !.*
M8\'93K*5^." JDM9HFQ'3+[88PJND>0CTFF!(>HEB-)8%*P[4LM8+(G(R6/*
MDZGBH1PU5.9HRIC,!*%..1UE"2^)L1I$\>G 1D(@$K2=><&I6<&2 A_!<9 O
MEXE622/8P:U^=(U)PC+,=ZWSHL*3PN20 7=O"?0PU:,%Z-H\\0R;SQC:M ^6
MT :JK8@P7R>6M087"&EQVR=;L0N*.XQA3-TL-&=BRR>^*_.JFKDH075N4/G9
M?\&H0,^<OXWJA8QL+7^+<#KJ&!&#7NTA(H?[VZ:"1<0O,C#U+LJ'Y:KR1[.#
MK B[+)6AOG%>-92T&JFH/R5UOVK]+!93B#/.%%V$PQO&C5#95-4_]O! ET,.
M<+1R@Q@MS26L1$Z&T>BEV\Y>;8CO-QAL/2%U-FT?2))'Y7_F2,[?O,L"C%&H
M6[DIE0L15-.48G"!!.%64,<D-<[(TY@+^RF !G+35[E638(&=?7.<I>#V]_I
MH>.,(.%=UV#A[^S%RCFWJ9S-5MRXBZ6:Q"SXRSAQ2@<R=X"NI:Y \?[$M:4#
MY_4ON5XOYG(:&66+LCNZ(BW6=;'EUWQ+8&B.=^;9WDV?8XT=5PR\R 0Y/W.J
MQ/C@4@[87R<=E@X*TPR(X$S?L\O B/^_Z9 HUO/X^15P5%W]H;7YY!6@7^13
M]2%%0O3&^Y&Z9*C!?^S!=H0@97Z[G9N<Q>G$&<TQ.4!F5,BA@NZ9V7!WM^_A
M=.9E6QBL'#]HM&U\B#./F+9NU:#0M1*9P>EJ':-^&RE7W<:JFGRS2A$=KO"0
MFB3ZS/E,3\TSHU<E'\& /3O:PSMMS:"L,X8O@:>%"(!&=O47R:7L?972"\R5
MQ)D$<09AI%<&Y\S8V-69FP3'@==-:<?'<^?5+N@@-4G<3*.?U=QZ+R?!#AJF
MTAS*TA;)[N$K'#3O'5Y"/]T].KP"3A@-7P'MF@84KX#)R@[^T/_C3%HRS<3K
M_,@%?D2'79)8RMC&,H2)\5"Y[-9XS(HOH8B_6,V '0PUT<%33VH>RU<I)J%%
MVB=A)U^7J0E,.\WA&;WM\&0"::T%!-@G8(3-,TX?4235>[2/#>?/C]^\ EB\
MG.78G'>8'PG![5?O*]ZY26F$T?W#%>I_^E#6='N]M=M_WUH/844>UY;0R_;$
MS[Z9:<,XJ+JWUPN_E*T%&AD]'DD$U!)L7@,T!D6O8=X1B@>0G&SN^#Z>E'U4
M"$A8G<,,$H6L7G1^$F?XR3MKWF$O7C#AY+/UM1#ZGO3XK0D?U?QA>\_5M\_*
M$HG?B>MSL>T\_I$8N;7KRK4WZ/N21JG8V(5MQ,:V;Z=9__,9TV*AU8]6Z<MK
M49.&W5_W::>?N0,WBA[\*.O7W$("E>_MLON=%_X7!>Y^^;M\5-:HD/-WN;/[
M^7^2AOTG\/_^P-TGR/UC6(TSCP&.[%[5H%PB!?8M^*MX_SYT5H%/I)VLTG5Y
M[1>4/+*U ?1H]3/)432^W?J$]4T&F%=5KX!4JL*3D4IDD5? LN6GG\TOO\V[
MNQ[^0HPH^'#6]/6WX>\_C2#QF-:NO9-W/YT%_]+WDA]JEY,M+Z_?IP=!<!TG
M=U#YL2F5VX[#A8_LF-89U"PV^#<NDHT6J<E)XS=:Z'G(*W ZW"U1!7!D7P&&
M!OWNGW_%='9?$O\#?_S0EW^.?:^'N9[++9=6#J#SKR#N"JOV5P#RP5:FV].I
M>/_G^=6+WD\<_U^-( ?#'W*75\!&A=4O\D#)EXU?HLSB_;,M;%'-\NZ/G"<W
M%OL-FG)X#:Y77:KIN+%@5#^JG2WSQ_[Z)[=_+KE@WK/[)?0CD37XYD!!_MDZ
M6RY_VS%>Q0YAL,'3A&=(?KF/U"LME!G+OYF6UW\XK/=#(A>R?3VTQB"9?BX;
MTG3'0&23Y+'9UEW++SQYE$;07=[**]NT2CTC1-D@'&]:R5'ZAD'WB4+&A3R-
M9+C?DUC?8A*'627*6/=BI89U"(._7&*LYT.? !]%\/>T!8<727$YR_4>R>P6
M[BMFCX#KKI_8/!9Z[%'Y#_.N(%IPZ<6*.G]!>D>[T9")J,,821_+N(5*/V,A
M7PW-6- 4="0Q2\!63>4;8>J6L.VE2_S&XCS7H27O:0AAH,I78$;V(_?T;.JJ
MGO-H;P=!H$T"'JMI]Z*P_3().C-7F/?]J;$+V>]0E2U#FQMGL^RCI_)KAUCN
MFL2VS2D\13+(YU;5/KA"D?%GJI#<5AB@'%(]Q5'TWK2@Z%Y]&L$JA& D7@B(
M6MX0//^(ZGC9UQ>.;%_!.XW_\&4V>[LN(3W[\*9J6P2?<U*S:F4#76?480W8
MF&D*2WW6"3R1:B7ZE9J=A0>P:HW$OU826KAFRAU,'@9J*U@_U;+-EJ0$)R=Y
M$'P'CN')J,?)W7'J^H4*<'&SR7P7L,T1*;.G![;5^KN[.>I'M64(-"62EE?!
M 4K?Q;UK"QJF<3+>**1LQG)**BE4%'T?#0];@]?MY&=!DHNV2AW?C\WE>1-7
M=_?&CA0S)7TOY2&#^S1?JF/"B%M%C8:O-0WPQ6L)_"/J[1QN7*9$PEX IX2K
M<V@?[]CV,>90R&B* ^GLY?1>HS91P'2.<XNJ5>X<</ %4R4/V!6'"X:SK,P0
M!RVZ=J"ZI/.""7\&SK-X>;U\R<UK1HF)2PHD#UPWG?8>>BMB_)&Y ((:W==Q
M^!@9[-5)S,U6\P:/0DF!SM7>X<<]V\FG0*K"]<)%Q4Q^==0 -Y54!0VP:8BX
M?=H!/QIC2Y]_?<X?YBMQ1=I<)9(CKABI>F4<#3H2W+(>J&N '; E=&F*7O\3
M*4/S(8SK2L)NPU]+#F;$,5:00\7)<D7%!.GMFT#_N$$_H.$$JNIVAG!>9X05
ME4;^/$<J1XXB0=F+MG>HY.FQ>8S.KK<>T.(/%SO$X!Q**[[2R@_OIK#5%]8E
M?%2,_:%YH#J"CR0GH$J2PF1'>D)4ACF=@$NGE(BJKFL55DFL\?F/S?!)_2@[
MZ^*X=<^'>8_+W(?GY,V#KO_2WEL&Q?5\_;Y#< LP#"[!W=V#R^"N(< P!(=A
M")X$M\%]L. .P1T2!AA@<'<2/ ($"Q+C_)XK5<]3]YX7SSWW2)WZO^Q:O3^K
MN_?>O5?WKOZNEI$&*\\R[>TL87$N5G:#H\W,U6$&!F+?2"'PF<FQ^B2=/H%Z
M20'043./J_AK]+/9'28R7?*BR?5FEZ <JEBVRV"I$B0MPT7S6]^\/4-X_/Y4
MB"IREE.J(F<\WG_,H.I<-',GL<\18 N1H2(,\IUS5BJH7O!,)BU0!%N"/K74
M*[HS@Y;<>.;+""E<F=T*1MBT<6S8,#Q7!?M)$PET>SL2%Y%')*KD[T+CEY4T
M5?YO24\R>3,/:F.2Z9Y;Z@8TDEM"MOF D.+N1C;)%G;)27'BDW*.E\5-F;(M
M-U5Y[J]+4\0[<U2\@U5<:C*$]*\\B\:UB;U>YO(]WM@7TV="*#A826F]BE-P
M><7WH0@>K#?7]V'="REF3ZUX)G4P_@#@X@H.K4'?TX^;RU8Z&:77+@<[;WTJ
M5MG38TMEYAI2.G=]V0RLG?]<15.02RT[%=T9)0K:\W#[Z>^[Y"=08T=]+X$B
M#>>.*9'AHMH\SY-VKI(Z_R"U*Q:SB(Z]<5X)BTGV!'T6(&;;?%*YI"+3"LEK
M&L-3(N;O9Y(XD+7A06UTVE3Y;MA8KKE717_GEJSRD=QE600V[5*\8"12#*'>
M1+>5NC$ZMN3])F:;.D9R826\N+LA0A?SI.\8Y0IU0E\<K4S*C$/U6CK-*61N
M&(/L;TI#ECXO<A.RL"SS/<:BH31\5TJ'HJ_VG5KO=$%TF%CA/4UTLM0P.$?^
MTO,:-&48;U8XS1$U._4HN_O5D, Z74Y"KF!Q(,.C[6<4H?.F8],75G;V\N8V
M I49R%A[1?+"@DNO_K&M#,K''>F  $^>LF7N$_@;-TEL+:=9RC>#+XG_VD/;
MU/S#8^%!=1',#3H , )(_QKGQ*8IB'B(?.%ZOMC\($M@3-=E[9[T@C[72IVA
MTZ6M?3)K,-A,B)5;5\!7O;W37V"&>)N:L,55/:^TNEN=4_Z<+4,Q='^M7/[W
M_#=&J/-:#XM?KXR]\1[Y/%K,\RV)^/03+IAVGZ]+8&Y'-Z]**G/T7.67CL:!
MS8XXNVR&,CU.MB]A SH66BO8"NS"=)'E>0C^0[U\#JBP^B0!#A:0,P&7]IF
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M>E8<7=@3]8+"'U:(J#4C@(H>SDFO[2EH5.5JLABT2KQ#&.8H=)&FYVAF[9L
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MRW1M.S8G3N!D-"()*:Z;*5X/K*<7.>?+Y#<H*0]4MXY@:@P9UV3C7CQ*20"
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M3 T$UB<_3T!=9067[T@KA??9ENI,BWB=27G!]<K#I3Y(AQL9%_3%XMUBMY2
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M2W_^?* )J6-W((YD>$KL@>/DY)O7I[@=_2W*U=M=),TWG#]VO]NG-47_"B_
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M<!D><^<R>)33>-$LOO.L;6"DH>-6M>$$56>%/=6B0_'YTM[0K[:A&+![KLB
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MV4!ORD[$OLZC'#*./=OBVWS2&-FAT*.6RSN<9N03T>X'/2;J>!/SHB?P'?N
M9L1HXD[=X7R\%LW WO:-=ZV)8*O^\<VSMO*%?J21I__5PK6M86:=[@+;D6JF
M=IUW?S]WZ*-C'T9WK;( -S>QT?I42B28FU>67[%VTRX&Q:6$:3,W1Z.MD@,I
M*@IQ#2;/9D>=W$>$[=,+[PQ1R84>D3<IU^CQ/C>/YY-%D^ER:83Z@X< X;%+
M:ID0:V-F9VV:\^-O\Z/3E<SM%ZS=RC^%#Q7JE7O>1@2K>QTD/5]D!%NZJ^HT
M_RG5PVOU!?C]G<>UKTO-,F.^Z5J([]@%#=NDJQ4'=/W[^]V=*Y_U,+LLB-<Z
M'_UM9!9KQ5X?."'"E<WE%1NJPJ9)7<=!Y4^]K0\5,1B[&&9<-@_SSC^1O%F^
M-K>+:O)M[+%EK.Y3M:!JKN_IU[9N9:W/J@M?++GGUOK?EJY*KVY:L-E==2CG
M_-&=)A7^"\!@\?E:X=3YQZZ%;F#!O#J.>ZG*]&O(JO9"9W37HDB&NUIR#8,,
MXPI7Q/S*8^3N5@!%T.*DJBC[9"8NF9!5&I/V@8!Y0A\->_H3?+4^1^BA-(Y@
M\B6PS/QT*:%9K3NT(/;3!=^V4Q[*+67=X!_7Y+WG.'^R(4_;E(TJ4W#>DOKI
M3A7"G&Q]+NJ0N=UJ6+KPVD>4/.O1K&M>P$U1T^37[)C]CIH\R,0]2_1"FR%'
M'7BCC>?Q""4N89^G@7 +7*?KOMR +##,Z5=YTKB+Q^7^0-)V^IQ*:AW&(TE>
MDTMHX;I"SQDZOD7K_"*.BH FB? MR(:0)L,"GA)!:#9B8:$G]HE4=<"[IVU4
M=]MJ-\N':%$VO LX_LA[5+G'Q&O3#6(5[&)4P/%H7O0S](\(NA%U[7WLX5N_
M#F#;VG?CI9M6ZS;(6G>_&%:MT[SP1&"X.&T7WMC,<KG7OJ?!<4-TF(/H>=CU
M$2%IY:R6,'\KM=0J4<ZV^1K6" 2/8Z"XI'O8,XD!C_K[DV2B 8OI&/ 6.#V!
M5RTW7TB/FO_\S+RMM26\_PMP7]BCK*I<T[O8J-&XZ6$%U]8>,^CAZ+^I92FU
M2Q8LO$0D>SU>A3OE4?6M-7D^QFUK@C9LXT0/]#3/)@QM,5JWU]HUZ,R%LD*S
M5'-6*M2H"^REB+GM]YH@1=#Z8UO-HXJE8FESEK-< R5<L)9*.3K8%U4]N#^"
M4??+FRUBDR5;2N&JV0.%</_X?2%]\?C9S_,54N71K;^U)*)W&7NP9MCRQNFK
M5O'F-]]@.SVZ@H=?YUX]1I.ROG6K''[^]<YQ7$C]?*MWSG9CI51CI&>KQD^[
M1DZ/S+451Z3S+*T1G*)!%]DAC-$&PJT19[3@2.[+4*+ M"VU%UM'?E08H&Q1
M6@I9("B3G J!#2<=%].2LI /:AQ380TLU7:*9H="[;?2:;NV?_W3C3FWW^;9
M3E)+!8G<J?,8+Z&WWE#SF=%0JP%?K:Q&#UJ^4YAOTN VL&XH'VWYY1&9$D<0
M%(V\H);Q5$S>/!XOV9F)2E2!U_0<+K*-+*=_?'?[U6VECKU'?4?XP3!0%3L&
M Z4JFCBHU35) V_@+48-8HV63VG1:*3?C\^0)D:XD+(/4)42YP")?^D.UK&=
MGN6U;)EEXQO\RG XO^]UJ37JX7:^N;41EG-E=Y[<TXU4T14;)U#C^?M,@H_A
MD8:(;F/KX7YS9KH' 94K95<8HN73S4(BL++W?EW+9C@M$7-\8.7/G&%UL=:H
MSN_9QGCF<O'J.[DH\KJ%5\$ 38F35&_K\A2J0Z-[I( 3=:J'%[<FHSAHRV],
M1:4R9LHDT3PK4"[@M,# UW8^B9OF:.$A:/3/ %8SY+0-Q\+*<$U,EVA[62M^
M+K_1($U49\6QK&Y9,R8!UIK6; <9O#?Z7YV?>7[(/:] OAU^2(0_L?Z(R+N9
MZH8;8;%^T]W .V;15X"\(/*>R#C'%&*4Z.C[]1S763"\U?SP:X4,"^IJ$5B$
M31ZVH&2,ZE"N"G9\JE9*EKO884OKP-Z=HE<9+4\?:T+Z!\:A0/!Y4KKMX%:Y
M&WMFSXC6WG>.FYXO(8?\G=R>'=M$J8>LZ=6U[A*OWDIQ414KOI5 (@TMP>LC
M(TAL;56WA?S#1@#MLU:JRS^E#&GBW/'XG]E28/"Z6=*!NZJZ\(-.S[ -R7VI
MP</6P,+#0F+Z@'[.T>S"6:4M3VA+@<#2A:;E#,&#N?;AFQZ'%F+6I6O-OKM<
M\4,U):'\,?5(?WBPNFM2+# ZD0Z<+8\'\1&FSFUX%#OV].>YJVKV[!!ZWG+?
M[\H3;QJ%S"0<T)5XDEV=V)[1(6U7A0]D5SIOAOZJ:C$=0GCRD/TY^R+;2[\S
MN]ORHI2QNVXH4#5\+IF\"]DN2OH0_=A>4%O1 _J<MKB[S.>Z>H#O]!I[ME_\
M$.M4)HG(G8;/$+:0_ES Z(01C]W4QS\X>*:4VBDJ["53O]*(1@,;1C_CHU@W
M/BSA]N23Z=6=D!&M'+9\]975&V.M,QME6JP4XNWSZ)_8T]=HBAYT)E#N*-D@
MD_U(FPM@?Q$=@6O;SWXSY)#.VA:P/)A?JAS9$FPY,,]ESYYLHE_>_7Z94?D7
MH-[9$>XI*_6_4_7PF1[$#I_B@-*R\<X00>BS@=.0^X=LBMJ^AZ 'BE?=:<Z<
M^G_GQIQ:J L#]52P'<LW0?(I TP^'*_')3/_ LYRGQ=$K[Q@1S0"FKR>=!V-
M<2T-@+HOB?_6SPF#.O+,[MF%X<MJ*R*NI_4%8?2)<*<=56N6$.\_L'YBO_I+
MS )W:&]2V^)$2^5U6CM_K&'L/^HS'XV_Y(8VY#R?\=FP'"OLQE4/IE,PB7C;
MC(/0KRSA!9>1(AZMLDGVGPA+,>3U;VE&;7E5/P<]E65P\5^T?/*-EOR'J>C
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M1BTNWUAI6YFGI5I2.6GD+(&AM5RBHFBS2RYR63?8<![L:L@")1<PGKZY#Z/
M!';[HUJ$_>L&L_E-G&X><V^L^'@%XNB%?WF/8+M'G"V&Q([E9\9T/E1</+E3
MD;=)[%P+\Z19&D*UGE#S<A4U>$O_GNXO-%%ZBS]Y17[\)H?45)(*3.A3T8M=
M_LILK;>&7ZK/*@!R4L]-5264PO335MARP=.LE4'T0/Q$S'"1?I]&"HBR3M>
MRU=&W%M!:IV;"B>VHITQLD4+!*&QO$K<>80-Z13P&9>X#_3<;:N=J!\6-+_V
M\S'&?)W23?NCR=2WS@E]"/U.]MB^+#8=H2=DU;:Y.EEF:>;86+I9>8.'[R.F
M4M2BSFWU]FYL%"J?9EMDM6S2>8?[>*W!ORZKS%OXPGH#*\ J(_E[\%%3[SH.
M C>20<B7Z*UMK*+.#XP;.%,*W,10M6:T6+3N\D2>&3E!#3HLEM0\H#UD)"V
M$+L0CZ :#&J;EE<_G5O/>?FZ\5\ C]G9'UON&1WGAJ%Q0]P+=N*L>CLBPA(V
M:=*"H ;%[V-3,EEY^V-8%Y)@6-M1W>-O8@(4LM@F9ECP'=^WDB0\[\3HGQ8L
M!MK[\KEY8/_<Q5>CEX$Z>>WZF8Q*4F47RV.Q\]1PG+*5UO4P.WD1=&$AN.DZ
M=&A^#E6S 1TOPA,D&8<'%?;:=C(#>VUDE(D"N?07#N3974O%R27L1 =)O"3I
MY\/J8DNJQZ>X8_R: AT=GH4>N=:"6HT2+#&*%&_KTT9JJTU%7WC=B&/$P])3
M]A2C9^OR4\8$Y8RR#]V.#8O1(XGB K]25ZBJ#F'\'F_NCU' ;DG,?S*OV< L
MH#V7;#"#9WUZ\&+*[+_*CF<LK(YIN]F) RTS+]L825M@F)'3J_%)PS'&$'$D
M4R,7MT=_>^V0 O."5LJMU^/X4T,V:).A6A;:"K0\M]*+;7GN='J^2!<PGO:P
MM:YBRAR?#,L"@[E8;1U]DK7LEK/MO-2H**=N&@0$Q'<07!WH[\"5KN++_,%\
M^?B8VZ'O?P&>P=):6D8\4PNT!JC5C/$"$]07-[\FIBP5-/@*- N)(5'V](<L
M_F\RL]@/:.[.?-(4[C)4&RMVE.NN<;-P]?61FRN:$T^[' -&R0\$?WAB D;,
MX#T5+D<&S<)_TIQR/4-P_P+BA]$O,[;2_:S$P>K]&>YI+*J?:G%^)L9QK4>:
M&Y0*NS9ZW&$3AF9 $ZG1818FXU?/X17<'Q.QZZW,;8-Y=\";??_M;$Q#G.L*
M2=9U$-W)4KO.=/(QY[[3X^SYCIH NDP%DY@S/^5(Z'T#1(14!\Y;E^8[>^1D
M?9Y">97O>MR,B+CCJ\N:[)/W4W?F+0-'H0Y<_$3=4B72O!^=?#R^;8IIS1/6
MQ^8N3/BNEMB,\^$KH#<?Y\@";Q7(#S^3R)Q)@\9@9R0)"57?NW=E\8S#0Q>[
MN(%O(S9\,/N.2V\DB2742N+2VLU85J3/%\KKZO.%4F\K8EFCR<Y3%0L*/H<G
MF%2*\H6*Z,,> UV+,?_T!.QJQ\;=:5PLA4V;34^?T[EU,??^!YJ$=J/D(P3B
M"NYTP=^.#.7+O+S</:RVVXFR8/Q+N87R+_4JV::BQI[)# E3E>D0DTU@[CE5
M?/5%IMOA-$@LMZ:1SOW/H[T&?964H@Z61?66,J.%*8/<,I5*#WN!D=<WWA )
M6X>"7T4_X7^<UG)I3^$6+\\TEZ09IP*MX=O(P,WS.!,M%L7(20S$0VO8"0[Q
MX#6)7]4<V'5-4J$]E9:@D<H<RX=AXU![,Z1+E?Q?/-^J(T/,TY5'.I!@%4;*
M_$4U+R)/O1<9IAZZ-$GP1&,FRS"?_8HW:$P3V2M+Y$7HJ<HHH5UOXSK+R$#-
MB91/;&5+V7G!06LM/PAZ&*QF=.W:/ :MHQB-)1D/VYXP8FQ3JR@E&B!5F0E!
MUIB)E!+U6T^OH3:!M@MHFB;#D18_,N+A_^/1\-_:$."N=5>#6:SU4)]JSB30
M9+7_F=,$^\ZLQ4]6'MW.?'K9N1(0J;GT2)DL-[0&4C^D#?DE'N!THQM#)?21
M$Z0N=2\/539,6.,?D'(Z^3N7E4ZP\E11E"XLLLKOIWZK>,7.KGB68@JQ"3-Y
M*7,VTZ75[#X8C%Y*-W&[+D$'#96<I$J6'+01YN;&$:WE4Q1*X[A1F(:BFLZ'
M'IZ,[JY0Z!0NV 5>W@]0*'S8'^L\+!J2I_LTK\%\'@I=4^D@CJ=?_QA7J%:.
M=?)G9K5-DXQVL:95'*,*E5+4MHS1#=*5A17#0 3 O"($/[VFO)Z%3J6E96I-
M%Z:88[16WH0!X3SHI=T&/KDUYFQNE !\67O]8_@I[)(D]$O !V!V+D8;X7W'
M? 8)BR$XF72G>!VCE/XD)XNA0V=C;18MCNNCE;5BC^'@@F@MNXLDZ_M7'B[D
M#N+Q *R%DUA>MQ*@2,YHQ6BC=D:UE781$)7'84Q7S-,/#2<[Z*Y\H#I<EN
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M)QR, E5I-LQ.]74_!,-/O>=*4+Y1OA(%[2DM)4G>OJO\/'0@Q'O0]<)X8'.
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MJ;3E34YX<;DI>H42J#IJ[&)\&T-K0BHQU^ R.?V5O8VK9#&Q%[^$ZWY!KYO
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MIZU^O:AX,4@X\Q77J,](XLW":G/:W-)*X64-I&<58'&Y')=?JI10N0FPM#C
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MG\:=4"]B"U+91/VE9H$+L&FE_HHO/&![^50<8UW-Q\T.^'V8DPDK>_4MBJ:
MZ>DT4P/YVSV9OM_6!Q3,9KJKN-]?MG<%8N!"TKX6DY; [2-#&5"!.4L@<\==
MZY>1$C>PHUPE=20/^Z#G1$ *)P76B:%S$)!@-,N3B?:ZMJ;A F97$K2"JW<_
M>2E]!<OX?4JP*T=<!W204O.]B"!%5LSR\HS!Q^C'+^^E9/<?,=#P2"<#MF;=
ML8I5^MP\<Q';#+&D6]7X&0-=?(.=EPB6 T8K[NN+?'V1CX.]T7PM>SZ@[I;H
M%[KQ+X*3E@AB^ YJE,536YQBU>5DLDI'^>C7F'[#]MOLCRO0B[M[H-O7?8)"
M#PL* 0'/_ 90U_^-J?<_Q27\ HU<%(#M=B_[ :6DDN'YQ0-N.6H)[N2,6\(P
M[.S3J<0=*-^2[]\GY54:(Q8$JAO/IEDMBTK^_?6VO9,>Q?$!M2QP71&X]0<I
ML>8#RNKZLF6KGVFR,[WV>;;<C@7C%MO<K7E] \/5/-E.E56^S":#0E]*@86+
MH64"$=^*2HCM-WR_C20Z#MFQ_E9;??Y_-'HZC@@$_=R-=TL]A,.K03&0LD54
M">-X13J"U^(SV2>B*>JV?*G9H:C8RY@P)O_*7&'@*@*H)/#C@[7$]:$Q4:^U
M6_H:MI"5?&@[UMYM+1S9:O9\S413LY[*.O^2F-),LP1'2L!'B$:;Y&69NP.H
ME:V9B=1F9Y ?RM'S).)3]%J(;RC@J55N1)2:<J:;XAP<S.M)0#DI<O0SOPI]
M;^IU8S%PW0LH"S7*MZG99)$O":M[YM$L*:ULM8R ]ZQQ$$@?-U)W3"?E.CG'
MJCVV+$]X$37'%(CJG:2?88.FSD>9<8EE\_EU-X8H<(0=3^.RRT-]_BA_.F7'
M'?T\PL23LXS:@6HE6]5DTNT2JG-[0@)9<N,]UV*"C+@[.<^+DB5GZJ_XW2QB
MB1U>R(4B$_?H''C2(@:YU6MJ,"NQD^BZ%E9$@#8WS/;A*)[V(X'M5!H\VE$O
M&(4ZOIUJ/ -)JC14"3=9?O=\L0I!2;8#58BJ-4JK2'[*MCLK12_&TOK=5D<\
MU!7+1:3V3G)J&=2>6(>LA/MOL7OK( T;N<H;^ $7*D__LL[V]E194W2<J^"A
M88>V.OG=28Z\5W$5A1Y44^B]<%==1Q'-F;H.Q?\;B*G_.80FXJ[AGQ+TR]O
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MOXQ--+HIT. D;S9)M-1._^KJA=7L>[.Z[L .U+280+?C4<RXQ1+(GNDCXJ/
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M(/V]M9OVX6^X_8ZI"$&L)5A""<O"=<YZ=EE>:N?"J=@,H;I$*W XDXFV>I]
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MRP_RT-U*ZY6X28$L^VXQJXI3I.,_A'^W9>HB.4R>OL9Z+\.2=(?R0?Y^$ZK
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M;$G]RN;0V[3(&LYMQH-#L;Z?5$Y6%FQ-R;R.&T/3H8#V+Z#>N_*AR?,'[69
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MC:)S+/X^*F#F*61F:N=1IQ&OT(*W&/5LL [34CG FPTCTY:TG&S2)OJF(6-
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M^$!WM77#V/SL9&IQ%3%<\ +83Q@/G,^>>^CX8P-O.@]$GQ\#7P 08<?:H,N
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M44W'I^QN?[3<FEFZC3+TC]:@UC6(P4S+:WA*ZJW!D>.R]9:5B;'O;P:&^G!
M^%^3>'9!_>&O/3\PZ0W3$;T/C%?**XIU<K/U^LB/'^@"E6W8Y3U EU:3B KN
MDV)DM>7>@8.C :5$-E#(M^JVU3N;+>-3_,WC6_H,)Z26.E;NT8Y41\W&]!^
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M]YN',O&IENT%+B08WWDD#)M?H)E= .4\B_;'O.GB^,*>5Z5P$^K4;OOP319
MALVH4^CSD>/ +O22.XE4F=WJ[[JI^@14]':9-#/#H"HR=_#*<.)7*@>EV67%
M\$NIE2(6?$D4\Z,E Y_COOCBA/\IL^J?[KNM.NS^!2"C8KP(*]7,4^!(%O:B
MNA^EO_G"_W >Z%/&0FO\Y.EIK=VEXTO_&HEX"6@DW8O[7[_ U1LV]=U7_@C<
MWY)^ :"<;JVL8_9\IGYES/4[Y\AD^\GWE^A?4(NJAEX *?X8OZGK FU<_BLR
MD=;[GBOG@L /-Y=G%\@F&PG1=<3/*M=<WP.ZGO+^ FRDM?L"@'6'/>,L]32U
MDP9Z2;!^,7D0G.[I>[R[?8? =3$RI!/S F!\)+Y_8_P\]1?PHW^.;BR]:N^K
M_1@OI-9YO#C0'1W2M01Z-S-7\P)X?#>S^ @4S?]_HI65XT;7D03N,J\51+?P
M4A+JK+34KH+SY-H/+:(MG$QEEC6.;M+#TO.L8\=;FOWA>!%ETYO()NL=WZ7^
M?BF_GKUCC7P-52J+0HM=@DJ);>P,&_[95;B.'[V0))"!A:YFD=T M1GOU.!H
M:[J71^A]=#7-= !_;M^6?$MMD@$XA^B1?V:NZP'CZ/(]?W[_FQY"ST#6;M-
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MVVB;Y+K>W!3R I4->C7DU)O4,0[/V3C<@\U <?N(=>K,17%(I%=\2+JNC?'
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ME9(8;2;\Z\*VA!-'XS??KZ"@]8:H9*3$(#GR4^W16-A,WZ3G!S,5BM4";M"
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M@'6;B;#Z @C_!8;[UR'_GS_DC>7SW>W0W5; 78^!49VO%V6;SB^?O+IYCQ?
MSR#CK>?X*]$S\>V3%\!OHX>M/*?3RPSH"^!\?L+G\$KC9>6_ %!+ P04
M" ";66I6\7\6YD1-  "'4P  $    &<S.#(V-S=F7S$S.2YJ<&?$NV587,VV
M+MI(T$ "P2VXNS>6X.ZN 9IN DT##31!$TAP=Y?@[M"X!'?WAA @:*-!DD#D
MYOOV6FOO<]=^]CT_[KEW_)C/K#'>(56S:LRJ6;-^K_[>!E I^SA!  !U=6X
M'N _Z?<)@$0) 8+Z C  V'_*#G]8VUB"+[V\W*4$!%P]^>T<W.S!_" WF("/
MG;N $+^@ $#FF8^['0@*]F*T!SLZN<HRGW?V,C,Z.<@RFXII"VJ[*X)?.JGY
M>8 -_72,0'Y0$-"!^9D<HXR/E _,'0;VLF/T@;FX>DKYR#+_;5SJS_U?; %F
MQK\A7E!99OF_!(QFVGJ,BFX>8$8)?F$^D*"@(*,$D-\!#!:QDY 0%.%E%!84
M%A80E!00DN03$I<2$Y02$63\!S'_<>CA )$R4%+YA[L_)5GF?]3KU:M7_*]$
M^-T\' 6$@$"@@*"P@+ PWQ\$GZ>OJY>=#Y^K)\L_+2B!/4$>3NY>3FZNC'^5
M[>S=$%ZRS,S_K 7,75O[7X;_VP:#P03^B?;T,@!#_F>TIY&O.UC  .SIAO
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MB+B#L!VSP)]P!/YOC_J?K#_]YZ_;?_7=/X5_]7ZPZY\N[_&G;_\^ Q#_76&
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M^B-_RQ14O>T$&M(E7S'+C:2MR;(Q#MD+$K,3GDJU])V!"-_:*5A8ZLX99FK
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M"^5QDMD]"<A)I$4'JL*?PV'IK?:*/:8+?9$VA[[PWN=2%NB6>M#48@L[=A7
M?5X5DXV+P'.*=B)N>YCX8Z)/Y-([],UI!DX[I 60V'2.(G28:8CS>E(&1<(2
M]-DF:MN2^J*P!ZF$#3=C!@\]$],\4V1W=H$SW(Z2UP;&K^..K]5V.6;%7<<+
M3O!,B"+\O$<J%)8*RZA!SA,UCSM-'/06:C87"X_GQPR5I\.IW*F@##KLD.:#
M'/6,=A%"7T<?-/8U5UGH_+8!';#AH3*Y:HTAUE,I+R!4;:QY<\ICBSS[H/C
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M.&*NK!3O?RG*5X6EH;M:JU#S0R.\88H(1Z6+WF<H6SS]?;;'$"D-1[/8*/Q
M)NP%O*NJ.^Q-"AJ>*S[^X%GY6XKHGI"G6I4N)&1\X:U1@,A&_,@:^]0&M+S8
M]#R;%&<UXQJMK9D2L>G.)#6W^W8;#PU-3LQ.EBEB#66^EXJ.A&T]O91J/E<C
MZPPL1'Z+#IW,?J5MKERWA :@)\?53Q/5F]:5&\C:-:E&KSZ-NY:PC265<3]1
M;&PN:W'9=BT](.>@&[D8T0\>(\9>\K<^B2;_-J:YZFM1B.T<HAEK;U/'\Y#M
M)QHH0G'9K+_[/)4+/ZP8:;T?*:D@D;EW(EE=D.]9<SU0CM'YU.8SG[D$Q=Q#
MV?;<QS3Q%OP45(5+//3+\9UGM[P6]AW'' KP52G4PYYXTA>A;,B+91FQFFFV
ME:>*=3<S<;W?3AUNN SD_2)(;CKE#2EY(-.5#T,CO=Y+7M[PG=/<KK!EIDT@
M7N-GZF2:/'W+ZY\TJ1D<_E3+BJU,*,QN_F<O>N5)H% X7=V[:IO;H6U4W!;-
M$*24X3UVC-19[2JI4^CD3"JH-;1Z$%LF>R[\><*/_8,L7W4+^X+74N:._5"=
M'BGUHL+TI2ERH8@T$HTU)'>W:ZYIK\TI%B96).&+I>K0TSZP6M-#H,,36_?N
MYRUTV2HX?='B7DJ#<"?88%&K2+--^ERJLXZT1TX=E8[GYD3$C+-[SD'3H [\
M&A[CV$JW0#1SZCDB]D*G]9Z_\2D#+"JX@O?!X8"('O+%KB:?=95Z"B9W^?I/
M[<TSHF?L/$ZCL]\_<*W.A#Z5XUZ8H=_BWW"8S"-R?),>;RGK<$/=$6\@];8@
MJMH0%YV$5&-EO%9<GM$^:[>/\&['Y+7Z*!6;]I/Q+25V2JB#0X"?^DD9<>O]
M@H"'Q$0\M<BSC+XW-US&/'PB\["CARK.!_R0^;+1I!P.TH,E)N7*'+OTIOM7
M++@B0K[0UM%0'<^FV^\'NB/WP)4)2BE<+*=N'B]O0I?K,7=Q3_--7I2AW\2Z
MG9]3!PXU+-%JI5CJ5:F$GP3W!*,T3QU3[@0D\5*.0L.Q(Y)DPU)V:9=['S9T
M374I?UCYM0'1@GE'"3KZABL^9>ADV>):(FW;^'QMY=#/P^[P:P8&8XM!JGF4
MAJCS1EE!H:_:R_R4;[P5NMO:I9_?B+M&NY%W0R5L6QN;3X/J<UGJ[N+$*N57
MJZ%K.Z(]0\YM!>G =V6+GY;3$@76"YB]V*. LJ565RF-;3_CP(DCF7-R^ZY7
M[3?U"!,^2FVNYA;V/%XR$OQC[S7/37'JU"A/<ERUAT$#LX\-2+LNC\9#PVA,
M*&-XJ$Q!(F\P$CL("QAG8#7.!EN-URIWBW6N3AT:=[3&&V>&>PI=W17BN4?!
MGCFIEF5:UV8KY=P&^ H)GZG1_0%+1T3;)X66I=E16X7TUA:]SC:E_,4MD+3U
MK[# IXKL6=*O3]:R\JWC(.?@EECD>"K$$>Q<\"LM$<^3X>7 YZ9T.E5$Z5).
M%9U'QP?&+6O:J/A.\<;C,+$MW3OQ2-.YX9E-;]GQ::@Q8;LK#1D6WQ)"N5[0
MLJ77R2@&A4L_%1#R\LJ@?L ZF5F%!CIH8"VK1"?QW%)HS=O,-#:W",&S=#IF
M/J>7WXN:N>/?\^\V?+_%25B25F$$$XQ>YF])@I<,<.Z#!EVE#[T5,E7\??WE
M"6/GPC:L5PS0\\*5MJ?^?N+77F8[#FH'Y.V!LD]7C;,O.J5GE;44#=,L+4B4
M!$2ND/D:F>-I6[[6PUZCD:>OLVKNW*R.:R)AC8O6PQLURZ<WQ^]+SY(>#M>@
MGMN//\Y&XGM]L_CTD51L>$XVZ !?G5)H<3@%Y;KMI& 5X[WW__#WWB=)FKMC
M5"G49HKV5;6SH[A/W27E81LMXKFW&&E1^7O-!PS-F.)]O7B2G'%3G/+&&+S#
M7@C@ZE@#H];+4(\PX;(F7K=X7F@ -9/]T4ZD;6P@=/X5"78M*H_X5Z@3#H3Q
M7IGR943U4B4FKVAF)24W&?L.5D7S1 /["!,I2(1=B.V12D(IW#QMD#%==7U\
MX*$.[ !)-+[PQ-/H:^9ID,\G+TM79*5[QLT'8_33 F@A3^)-__%%!M4GDG<C
M Y/B\,VSKC(;#SO_%X\X!-^HW56K-*U;M&E-9,Q)6T(T4 Z/E(!/*#I*QK+9
M7J_I>J>H7S[Z0,5BD5%)/,HI7#@52Q_1!KX>A;FRN=#7>B2U+W0KF&FZ>XS4
M[#-TGT[9==:PEVH3?% P/36(U3Q4=WK>)_A D<9>)8OB$F]R2('.\DO]L)EB
M;$$6I&[(L3NGZIDJ<-IS[:[]=#O][[^/*::83TD?F@QD>/8YY50]WJ^BGE"'
M:8QW;?XZ$RZV(YCVCSHYNW5LDLW-.)W*XV[*2WH(=<N&@W;8_4"^'U@+4MIE
M^<1[1323:'6C10:<-"X:UJNW@3.OCJXDR1#SB]ED:>:1H>]=9&JTOF6,F[+M
M[794$*H$E&L8WI.!Y&PF#X!WLAD;&8_SC"1)Z-\R![Y[X4)PD;;NT_(VW!.3
M*Y-8?/*5!DUU"A6PXI'T_0(O4-B M*7JEE/',^>[4/_4:J3)85J'H=Y\N3_D
M)_)TXD&!G;,\XDJ"X#N35(D)#954:9]WM!R1 >M56&XLQES"Q-,D;RU]#4N2
MY;"M5_Q: C!/H8ZS-7HYC-4T*%&MV-5+M(=$934W_Q34W.Q=2&2C,Q:%XYS"
M"4-FS6I).#LW7T2(VK""%.>"7JGD--M7@YE0 RNM9XFYXF@];XPT (R*Z%"[
MJD[\4*]H7^DE7G)6K[K8>V?&3_UF7QE<*XC?T7?Q"^<:3F3$ ,.3XC]^Z]]?
M"T<V+93@$1<TOU0?Y!/OU@</I01H;.84BW5J5ZX5 \6,CC/[F(-SXR@Z5!0;
ME4;3?LS/6AM(-Y&'F0\X3$T'F$UI'GD?>*,LV4_;M<XXJJ(JCFF(%&S&5SOF
MY_P:I4M;IR6"LF6$[GHZ"3)URZ9XL4&:KH:NYL2^DZUJE=*Q(V>38NOJ$:.T
MCEID58%AZPK630Z$I2?1@M%Y"XL8CR*BJY':Y2+R5/+0A^IB:\@/4[3VS< F
MO1!*6L .4]$3<__!-\-VTLPJ=\SSXIC+ ]B&KD;1^7IBTX71]7.KHV'15#@1
MWZ<HL*C)JI67Q!LI,*^BPT]-(%H20)] ? 27(B[TW@[8Y;6IUV/I>EM(X;\Z
MC#3TJ[A?,@,*PI9.*.CYX%CN*\LWH@H=2K.HQ^?1IP\3,Y(SPT7MOZ0752I0
M)Z"P]^QGL!0)K3I<4)]QU:J75]GT>2#.1F$Y3QFT^4N(,YB85I6\-R,FWMHQ
MZ6Z/,(QO31OEE%&?[90:VCS^Y%^DYL<:QJ9J8_E:I*9G_'+OK&V^OMFQZ6BW
ME<$J4,9=F+L;1@X"DZ2G",L/IV1BY8WX\H/P9F+3A*O!I%0&_IYK]RZ@V]5]
MWOZJG^%=B+0BAF]'2HP]MBX.(IAIN$*+\MP#^$9J<2KQ\1*$E ,&(A_]!S0L
MIX53JD9ST/'$5L@UON3C1;[I=8L;)PE7\6*'Q+&)-#0,;&[/8Z9A'HDC\0;X
M(EL^8IY&U2V=2]4UH'U&5EA=2-RC5:J(KJ#/G4<VM1&U\H*TL,6@V7K:A=;Y
M2,SOI^&L]E027 S*U]DM#DL8?;PS5 PVT:%/^1&"'&_,J;J5;?_<2LC^.E'_
MW?%ZHAP#\5I%)Z6580Y)TX%JV^:(*2C&!YD<IZ&R6LWK+LTU<*FQ./\PC,9W
M-?*MY=QY)>%Y$1'7VKK/X8IF\_)OP IFT[)W9<-  W ?UR[S(46W';DA'<C:
MIMK[\A8M>6QLCR<N-G6\*O>@.+=MD>0,GXLUH"UNRLEUF_=;'/*4\-N)1^2-
M+45WM .M=]UJ2J?L\WUDW>,Z"SRT7;U-=HMY\WCEC.M]]D+6,3E,_UC8X#L7
MF&7$U1X5'G==LEW=Z9LKTI*Q<JL;?1ZURB1-5O"<PJQR&8#P17.>L-)E9KI!
M';D(L?TOM#4IA<U:RB0SBM4FW_R$T/L"^YO\W0YS71VNE/@VC0V.-%O]G%L<
MHVE:F_>/]+%'DPM,E6S$]5;CR=EINDP6X/@ GX;G(*"4OL($/48IRE =/B8Y
M0)U;.$UQNI=.T+WTL;M5IQB_*DS4=FJPYCW++JH!RCF)P:/%CR<;8>F-_VJX
M\FLR22HH4B@"43',.D'5-0ZC5I%N]\Y[L V!K:5FCD \XS8<FX CKM+^(FO7
MEZ@8QR:9A4=_?4#N\N+?>:.#VF!CEKY"0S)>!L9AN^Q.NT_H<(V&;#,Y*[IJ
MT[52KH8Z4B'**/[8X)H6F@GW/6[<04[2'"BVF]A;?TI])-5*,@)I=(BRB.K+
MU!?\[/M(:IM5N"!IQVX)V<+35KQM/N(&">B!#D]$=]8&F*4O/C-<RH\&O[P[
M+'(DR(ZYF$?B41N$1M*S$$"@@J7>=D]&)T#<,&YHUX*ZC?''\UW\ YNG<0>M
M?!E[$_UBBO4WJT1I!(PB<8EO&S@>K*%+^SN)WAEW<KH]Q8J)UJ=B>]"!=M%\
M+3VI&<U-5]Y(#]Y/6[^*>]7$.P$9M;^V[5596J"XJ0^SXF8]"1DX*?AR[(+2
MO_Q LM84D00T^LJINTP@1"#L+C+;%DFM5R35;^F;TCX6CS@]$BQWMN8N$\V7
MSV\_B8)_\R8N"H9,Z+9&ICH@G6MFFHE0]$]<^%\2!6>*:,M?X1\G#>BK$^>'
M;J=GG4O&C(UH!YI<K4AF+'SD_6X--+ F4--Z(O&XL41Q7BNJGH"=#^?X\UU@
M9$36QSY\P[<SE$F)_M)7),*\;9XB.25:=BU@ZFY[[_:9E:\ 9^7A8^[S#KR1
MB_FSYF+H,6J-<3*4EG6\5*O+^B J)FP77T+XX?,"]QV]]:T($<FSDGQ".M"]
MP^E/O[MN?Y$RJ>&I;_<,V@M@PQ"8;6+PR2<RPQWLZ(Y6;!W !Q:@ [14 X]W
M53PSE&D[R?9.@<S;+#T\VXUJYS+]3,?$]V4JCXZQ"%W*&RGQ%+)-\NYS)O5,
MRI[H$@NPAOOHY.V'<9(7EM=M>;P!N_P5W*^H$+*?]WC?<*W_6E52NMXR(;(M
M((_T7-.L<T:9^X>UKSS*?UQ)KY78A[05L1N*6D)DXS]O8+2$L'H98)>\-S .
MV_'1!K4/B]WQ[65ZLCM;J6HOCFWF]*HEP=@WVF?K-)PJ$A.D%Z3V\UV*@Z$/
MN4D_7OM_.#-88NM]TK5[!%.W(/W3<%J?3^'AZ@+R*S(_KY;0QL>I,(^M^IHI
M2S3V\SN[^/&8@B>NB'1F,YYP]*!S<FG0VWNAO?[ PR1[T2M=ML$#(.++QFF
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MKSY^LTT[T(,.E^L,<P[KG6>D?95#LZ"POZ?<FC6POV8P;"]=[E<YN1UX^06
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MH0OW+''$4A-"1\ZYEX"7N)YY0)-FFSS]VB6'?-[8[:Q?1URX\C2KOTCN]Z9
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M=%+>>?9JX_S4J94O8P!94FA,$WQ]UGQ?L':7H_#[!=#7G#G,P(1&J ^Y(6(
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M$0L%*=K>D3:NL*6M\\6;,VH:=M(P+-:2LS8984R@-; <5(701SO-9N%B#S[
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M[YO=GD,$/;)7'_#PPU)<0' $ E1OJ^5FUKA'=%1L[;\V5G5I.$?7WP@,>[\
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M.?O<=5;5=E7M4[M.G;H?JQ\[ !QQ#TLS $!:F@8 "_AO^#@#H(JY&EM[ L
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MO/9U*PO5C</E2,:PF_B5U5,(TAWA^9!_<0>?UH!<WQVN]%,FP$M0F-[_8/
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M@<8&*XHG2,4&DCJLPWDTKQ5[T_=?<HZ<I[8]*A*^9.MTX+DQHS\UHXU72I6
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MWH_[Y@0/:\%VL+UG>&L>(-J7K.?5K=CUE1H66S.[F5(UQ6@X\,EN8\A;F5'
MKKAJ9888#]/?SXI5X1V!5E]%/'7WD*3'7[UGN?63[F6EVQC80WOVC2X>YUP3
MC&83^1(.) 3/C2?13RBOP *,RL].3T>_<_5A7"O$<_E'/;R.<?2"\NKW3,\Z
M5'3$UCP>5Z]F(ZD_ $W)&'/'$-=T(>7FXA+'DX1OO'*^T)J_GISX$Z$ &G\O
M?Y]%:B1SA@_1QV+$? L$]4NN7:0H,1,E[!)NZWZQ3]&#&]^ /G[SHEJ1FU)
M$LIV>1/X&5F[G1?-DB=!6J/D4Q>I3\+LKM+\N6QODEF_C2S*P]E+]%^ZR%";
M/'VBJ?^Z2)BJA)U<_U[0Y4J^R.]F!M&RZ65B1B@GUX85K4LAU8C L,4"EF+G
M"6?4)%V!7^SJ1_A#3<D8O#)5P(+:V=W^NY_TAMG&%0NS#_7H-?]RINF\,P64
MM")/19)B%4[L-V\47$*1KP-+T=$P9H^.NUOSB).<^(PSK\GX:U(&ML;P:-65
M0[>&!.3K*J0T[[N.>&(EI(S*]B>%!0@;=XI'S.@0UBAO/!$H^:1:S?$A/6(
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M9E"N<DPL?Z7J[KD3.]=> K(S,_J]/96[(M?H=_0'#W\&SEH.IN:"2(OJ,MD
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MSZE#S>:)N'Z#%U_NH/3!.WNG(5<*%FYT[(0/YU_$%F@'28LI,4(G3(RX'6@
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MGX^1W3PLK9IK#HFA3P!N0=WDZX<TTB/QT//.Z7U8P0R2[1, -I:SR' 7^ 2
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MPI6O7ECPQ%8+L^OY8A^*U59M:JEK<SN950C9GTQ/Q;N%I#4I!O*.0X<1D'1
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MZFP9+7DE\N*+7#[A2?$]RW]\IE5RB^/@*6824U-J/IM7F?[9M;&Z2NS56X7
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ME6UBJ[\0Z36G_7% 8F@R1;=JN%E<PA^E*[ K'6%#$8_M<?)ZN,A=2]H-XP"
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MMKWDYS7)=E;2':J)GO(2@3W0UHJR8&A^3Q^O-S<W=A)(7P.=RL PK<[(K($
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MPW6(C+4@RI^5YG/.*]5=CWSA_V$2+D+9RU[J)#J3W!D^JUT<(+Q76^'9J6&
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M*U:C@6HO3&2S57,S]\PF0PZ>F%UK^<,,=O?DU')M)X'*$,8,?H<;) I>:?Y
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MUIVR1G_]^NU*OG!4\;3T?P!02P,$%     @ FUEJ5B>#JS_M! $ :A0! !
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M$\)=TD>&Z0_BD@_??^GF9V+X \3#489)]B\##$9@+09Y9S<H@QB?$*^-@(
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M>;<'V_Y]"2#X0V  I._!AU!^KP-" 2C_>GGT]X+ZM_+GV!_#*/\X\B^6WWT
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MR>[9G7ANS70Q0UFW\)*CUE<U9"#QYFEIH,[4P3&;TE*W<K*V%&=,ZY"3Q9Q
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M,\?[N;*"R7;=W5X2E$-@]>4P>PUW0GY35(54=%CC"J3N#.I+L&ERY'J<A&U
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M*\F330[S^=%HJZC%9<> <ZV>?[]445&C!^=<_0)3FBG^)J$K*#\HEC:13GW
M1@W+G6O5:K)5:AJ%5)'B-LTNM^2K:B\6@O8$_-FNL5J=TX7UYAF2A$B(#XMN
MH5&N&S7H/\TOAG(#>3_&\/B;&9B'1*HV6P2'.T+52P2Y$O=8:JR;*/(.LD3
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MZV"A!*Q'V]JF6,B=J"W7!&(9-6+2PF7PQ!);L6@LR&:2TU&QZI$-L)@W0#'
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MH"BQ#(3?3<7O<P.D3V!RBXN@DN6@[3*>IP*$32/0[=4% /OH":# '++<8"$
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M^8)1-\^09P*9%&.,2O.,FBVKI4BU%$?S61IG-[W7B!K&&5E394<1C"H-*B>
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M-LL&+RG<>G[)X0,O.1.?CYA+TT:1^I 7DW <'WTF_U9;;PU0^'06L=7J'P@
M!ZQ1]#Z#31_^H7_QP_G' Y8*N.!9G@@BV#GPZ6"'*0@]9?KK -LE/'8%) %
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M\$>>J7RHZ>S,)4&@:I"CY?]$I( E4THF#Q28#W#_> *@K;X,   @\ % %9^
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MA2DD+Y&]7%&W0;EVS[_U*S3'6A 1&^M[Z30WK'@M9D*-S33$"N1"%_*#Z+2
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M>9B^(!PQS3^O0&LHQS4#L3.K 5:W;[\0/FA4>.F5_:")R'ATBF4N8,;+Y5?
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M:V_NW+-=".2_B^E2Z<O/&2>)+"1YC(N+Y_Y".@HZ>_IS ^RQ"6):^L<*/-^
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M"X^N=TE8P*R"Y$^M&9IKR-AOB\MOO]\5Y7@?];WN3L-Y?C3\?[=1E4@-'HK
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MRAR%UE$F\(?XQR\$4= Z%NLX)*VC9?-EH77%"YUE,RW]*FQ_/@9?C"^_@QV
M(/&$M7O.7FNGL;:H#B[?A;\K!+\!/"[X6QO>03!P.I55G<*^<)GVZR->S(\*
M4>L/"#^%]VV-6/YU\76JM&ZEUF6/;SN:_-R$(LLMC6"%/3Z!ZV]OPU+"GD+E
MM",QSHX#@2H*XZ]?/RDP>KC90H\B0!,-M&**;/F&IO8,-C\.?H:)?^B;X#RV
M_UB0II9(<J].;=SB^CD5,4"FJZ/I5SNB%?,(LG3)9Z)9WIPT +74Q(=UE:[_
MXF=+Y/^<41-/0Q"O[;O\MZ;(R]@MW@#O]'Z5+O75;_A/9<A;N894WKSKWT/D
M1NQ$[['E7_IWIC]FRQJRYE<US_Y'__]WQ(.^[Q*]^.?[Q D8QOJ6/V]1X0W@
M@R[8<)NR4VB>;=Q\;>8:=<[SO;KLI6IKBGY-)6O6MSSJ^W.2DD_/H7?"8F?Y
MM,\(3+[*DUY[AW69][OE=)"R:JN,;+D;SYX7_O2]!P2:@^5D_C\[[JOJ^>><
MX]K+]^WMS_R6S:;YZKRI2YR:^,$'#QRU^J<3^OU2!KW^*:4]#94<#BJ>JFV.
MCF\ E+_UYQO]J\7]P8V]X4PMEF!X<R!+6=KV+A&A G5IJL1^$EBA)+$O?7?T
M!U/Q"Y&HYE0I&16V:4X.M[A.XLQ)9H1[<UW_-Y%IY.79K[>J?5^?X<(;:CO^
MDC#,"]-<?=!AK(6PG.0+LMRKN[,BJS)1Q0[F2?TH(\LS^5249PI@_"Z<(%),
M.,PM(#Q!6!'<6FWF^86&*">*(&#0OW9YCK$_&HH'ZX?;#W$&<8NGOV7*_\OM
MI/_/!R>=H8$ZS7;7N&]:'$[6LR6<+OYPG&PKZ953JD*XAM;W01\FT3W_^S?K
M6-*$&ZG:;:A,V/B;:CK/<BJ)HBA19*JJJFPJD:494?R.( ( L,55.HY_!TM^
ML;*&BI,%?/I-D@7XT!=7'L4^?-N/+%UH#P!0O6>/ /OW\]\MYJKUS&;GOFNI
MTCES,Q<9;7); VN%QS@LLN[)^QPB+,%4!'($?BXI +9'WDQ[+IN-"=94W.^Q
MWJ;.S- Z\R912I/#5=\<0U$WE%J]Y:U/:9'(Y"OF@8O"A/FZ+$A]<UAJD?26
M@BQ;O7^JQASA@O[KIU'A?.*U*!FM8TO_AFO!<YCXD3\[2?_;Z$@*5+](58$.
MF\!P2B'B1[^FT,\UK+CJTE,$9UR-8QV5M2Q@EHC(QN.^RTD]_T:=J-3\P\6_
MNW/BC2WM;?"E1HR=ZLK-<%A;\L$)NJ'F@]HH'DPS#Z&M\\7<RZ ,E@!)CIN[
M;Z3\T%NDR595&P$_3U-<OE=IZLT?JIV IHO"-B>7L[$7;[$<\].DY0=5RU^X
M%:9.=8U+NUD;MWA*=@SSW:JI&M<YU#>^EE8T!O]?[S#]OSK08[Z<F5"?&I]R
M4[2")"0Q(^7V#(IGJ*K1U(M4UH_JHHBTF8VQ]#^7\+H.PX58?OB@.J?2HX_D
M)\ C>C1PN\R]5II6T?8<=^?)?5!Y<K(L!^>6&SO96&D:AW/,L>U,==<29R[E
M.71Z5^NRVGL C/Z^&D9H[ZD//=;?*S#:FN:V1)QQP%/,V%(CMKAAB 5 +>5F
MO4>_PGU4<R3?T/RM25E& Z_&=:0E)=AS!JL2RS.E<)9G,*,!1HNME^2![J[Y
M0B*JE7&0D.?,=IN_[.EI0SURHFX('*%YA.[(I_N)0-JS\I#'#L9D[1D2KEV_
M%$[98_FXIUZ*]_J$;*UYL"CV!J@-IO8&.[H]:8Y@8=EH$#'520***(EH:9C<
M1>M8JTA8&Q8J$=B-ABR$\;:JJVM5I9LUA_-'IB4^7[!3?LL%%H&B#U$..+'A
M,-TIN&GCG*&QKQ1DUI=*)EUUZKZO5L38OR !+134 M*>,\_2O\YBT!SZ4-.*
M#8J(KY"=WL1O6N:7R[%6&@ZH:'IZ%SU]Z6%=2K&XUO4DZ95$[/$"<XRMSN;4
M_2Y+A0TL./.Z5ZK',H<='*WKUIA-7M".X-C4KB__S%5M2)#;UJ9I&U-AL,(7
M&!@6.#2A9,PI55>57R!1!UO>4JM,AM1VM?)T>Z0B1MQ?KZ:5D;\ A\TYO))4
M3@IOG,=2VAYL_C.CO8\/2D=$B $.QZ-?E>_G*58[U2"BRF!M'!F2.W4>->B;
M\D^Q#Q;;:O)U>".T)N9HXUT1UE-3Y-73IJDS%0O0&KOVAQUR ;A&7FJ27<O(
M_"K%S"3+1:GCT!A2!?UWV6'JMLK,>8L%/&*%'](?#C/Q=CAERH>-+7NE/K.%
MU\M3?AT]M[5VC)[<2.PAV4E/J<()^T+E'Q8/JUB%?I9%!H'E)$[&J"WETA<J
M62-2JNR'#!&RK IC;EHZ9Z%Q@)FW!C6UYR_+Q6)K2T[<+EH'#5"%$951RFB+
M2>/8;;8N3'A D@HG==6;!3F,&4T_&Z2H,;9R5"^NF=!@$,AWMCL^.GV1JE]G
MU"+;'\1E&>[Z,H[]L5\6%E6AW380N]FU]@-==_^K#&:N75P#N-?PZ-MVXN<N
M(6.1E,9%^B\]N001*%"JKJ3"$F%Y>6$4"Q.)3)@]U#FI<DA5GOAN'*><T@ZH
MMVIPV&VTA]IXHXRV,&3JS$TM%KR'NY?-BE2R<]RE?F(1K<C<F[5&;6)4)15E
M%LU,?3VJ'='<VP-JB_L:-).S7,A!]A5 F:^@&1]W:3@RN=*$HX#AX:=8<_"P
M]HREDYG;[#<4NTW1VKM!H8RR@E0XJ=B+/1<,>4HC2S::P@75^*;9N,8*M>>X
MWPTUQ4+9MBH=:0W[<C]CSB-S-VEPSQ)Q;U0IERYB%DM0T&*H<MNZ>N##=QBM
MZ.0:)YA)*=%5*=M/BJ!E7/E-8L#7H;\UW=3FX!P2!Z(E\75K!KNYI5CUZ5'G
M&QSL)! M-E2&[=(F]:97#C86G[3AP(@+?((=0&4:EE06,H:FT9) LN\ISMK#
MR0G:##_KDQ,\"C-+!L*O0WW<]T^9B7]1C@KI4[$.KGUYA2H$ WN:,K.)%TOM
MH@H65<H9#=23%C@*B/ 7J&;NY&1(U;I50I-A'&!QF6))TCDIO^55)LLR?<Z.
ME7?_U&K!QN:N_CNKRA@6#K4HG#9.L7R&L3]IZ6=PT1S>+/$)TRP:ZVUT#Z/4
M4KDG$8=UIZLES@"Q40:.ORX*0"J":<TCY;0PM/+AZZ_K]Q&+[OS5%)70O)=I
MGH,^Y@T\<<#/_!;0[3*HE+W08>:VWN)3Z)>$OX&"RXM93,.3#E,&A?+CJAXQ
MQES^L%YFKP&O$M7AVDQJM*K2$L9Z.A8J:I9_$Y-'99%MC7*&,6LGDF[BVQ0P
MCH7*LI,4M87<'8D:DPJE5\_9N/#H\>C,)Z8Y$(4;I-0.!!-:*[C=>D>@_"R[
MZ= -UP2'Q'(/''2(C(6&LL/ 4(F3(5^6+_@\>QI;V]1-RWMRU:$63?70:XI(
M2(IKD!%HU]HS*I=&6,AMT[@,^)'X&QFLM":X;.\*-F,Z)<DRZ?/,R(6LL+#<
MN/+JGCH?\7ZO#65R(OV0(>N?:1PQB*"2-N 6/-'#N<*S#XJ/KQO7OC25"Q-C
M98V/(US\B".*@H@4YH;*)]SQ3(]<2ZGQG(]/B(_)RND:8A]^4I347\.:^@6-
M37,T:;(=>J 6%2HHB_>R++3L:S\7]>YZO0)7(66/5$KEPQSV)(T\U6RJ*Z(C
M+=;$VD>82(\\6PPC;IHQ-<)KCP,2I]6&\)A?3@VU@T2(-/&[.N>3C'*D*&4!
M5+@OMUM>CKKZ2ME9:4F-B[GE/QCACZJ&"!ZP<2P7TFY2OK1.V01YN!!QNL*[
MA2$^]@LJ?0)2214)99!J_SU],;O]LBFE09&*EK8Q^ORB1)5R6\C+Z)&=%C7*
MG.(!ZR:Q'[JSA2NB298#J15NE3F>04[\":7$'?FC$7CVM-+SS7!CYZM,V$M\
M7RZ\B1(SI@XP&Z.M5H^$,5 &J"C(T<G+I&GE!T^(4>X\3&Y1X!F4O,%*0&>@
M3TUA51<NI$Z^F\Z&'D5$2&J,70]_4I7TL]_5G U^S;K1L0#ZVL.;*[9O4LF=
MGI&M/3+N#<#WNF:=Y,[*2[<.T>%UJ?V+(JILCVS5Y\\=H=% X8<H2D")1"@
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M \,W]'@XHP'NO=0;O*_A-U=@H,O-^[77)0^(PG[64L8DCVVACW:'H-O\&V#
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M+__'2A^4\,47S_RE7)XN?/OMQ:#L.)LKS8M:L*V-<_U_$P!02P,$%     @
MFUEJ5ES#ME]P1P  @$\  !    !G,S@R-C<W9E\Q-#0N:G!GM+L%6%Q;LBC<
M!'=I-+B[NP=W"-:XNWMC01+<W2UXH&G<);A;<"?!@R80)/CCS,R9,T_N_>?>
M_[WU]??U7JN\5NU:57MW/R\_;P$(97SLK $ !04F !+@K_%\ L"6]K)P\ 7
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MB!#'.EVVS@3'!$I$,E*MLD.]+S1F:TH:BPD5L4)WZ\R@RZ'["+[]BE>Z9:Y
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MI5K=0<EY!2*2DQ(N6%6P]VS\@!X/5R0-#9#!HGSD]W&.>S8)._EP:Y.CV3.
M(-@QK+A#)/&&.GVP-Y[IE! __FL<];A(P7;<& ?8F][MI#.K5R!=*G>WC9VU
M*15AW)U^6 N%=R>GA4:[@B1YQ1?-:^FBV-9A:&.%T)*/SLR,$<U%]SY:$<I;
M/U-X'/*6 6\2QOHSGX;[R.;J;=EVD<:IA].1 EY.:S(K2&/>HH@=]]LY32_[
M%W$\CUG(_I2##;8X(UH@]U-'/"0R?[FS@3>$)$VQF?;U29_Z,>RR-T'29:),
MR"FKBB_X =AK;^UPSLBE!]IM$_;-9$R1@@&]&C)LTJ>JOP^7<T WRERE7*2B
M%V_UA*^])%WQRMWD>S3Q>Q]2W.A<VF84@'L;UBO,.ONJ@A%W@/5GL\Q.4,2B
M;?G)'H[[80Z!55(XWHQ"GRRVX.AEOO!40\OMZ29C08UQ*-4U6:XEOKX_QU(R
MQT/D@>N#X YGHJK\=E(9M//56V]WNML@VO,G6/*=,9'N^)6ZI-SL!J-$#$@O
MR %[)"B.!9U^OY>"Q(K$?9RXURYXBMK:#&=5^6[L]X49$"E3NH\.FR,J5)GJ
M/YJ\;66*0T=B'.+][D/+W**'"K?WGHY68M<K77:^LJQN1/QMN1XCGC5&871=
MK 5,S!WY* !P?G3^P,J4;JL-1=)L8YF=0A-+'C7;V&?D7?(8A9PM;72)9F7Y
M@V[QP5=C;:C@,N'&PG"F_=W[PO@.[C?8'79U13/-=F4)QV=G1X-&L^UE94]D
M&FW2P9')P;K5E/E-CJ8>9'6,,WZ_HUNTCDCV!.W>0JD!<@F/,VW(MPWC0S^-
M*2/JT#NMQ3KY()_K$A/6,1:*RR'"'9^[8W!=@X9>?2VZJL]]!F3M0]34F),:
M1 VHF]]2W:ODSV<8165E-3ZT618\25$]:N/]DK!S*N!8[*WEC1-:X9N!6TG6
M,,>#1%03EG@PI#I&?],@ ['2HEG@0:I7VJ2'L.@/,4E(0H;?$:=MH"50#VJT
MO8,/*TFF='=U <$&^5+;+"QCNO+57-^U+^_D*QX\2$;M"$P9/[+XIJ0,XY90
MT)T69_)#Y*B;8R_D&K_*SG<1:8Y[GA:5LZI[VSFI2/O;A2,%QV=H=/9 :*]\
MHFA-N#Z5)#N1,0*2D=.BTE6DN)DLX:2#-7X.>PQUOGHR9CF=$!.Y^ *^EO\9
M#EVQMO6RML;QR<HJ<K?Q6<D*<8XKTS=6OV 31N<G+\T>E8NHV_@*5/43]]W8
MG]E8#RMSI\\*#2MUIQ==_=QRR"I194U9?CSKF4E0NQACYI)2!;)])7<CO3[<
MI3C+!/,>_&M$.-JYR%F#R[[,4Y$6"VM:<@EMN\5V>6BUT/#0H.W6/2:A<,7\
ME=W5C9UN,:(%@;D-/AAL[*3J,?[)!)I2GMA >N>9GTLW>(1GJ&S\.7\0-3:<
MEH@[BE-86.BP\S! K8'FXSX?0E?EVAZSQ</8DQ]MPPW+[.F<)\N@=B2=%XFW
M?)(FGT&CLY4B(@YR,")CP;<'\=25&N^D'7NC%IUG /8X81:J_6"+SF//[H0J
M_"=!;N'XSY4/W@4>JK0:@V3<J1VR>=T/A6BAK]2*XT^)GN;,O/$3P3FHK76V
M=TS/@"WK#B#R4"'J!/_%*2<YZ")^@(KF3?HS8"](!0\'1L*$(U!Y^1E0X0;U
M#L1]_0R@OGT&M#P#6B?Z;\DOOD^LM;.ZW&<PS+D<Z,[]GMYY!G@_ Q2^>BP^
M V)TO%=KN[I+-BS *YS@BKM!?<7<.'_S9.O,"Y*C^]F;6E;/#NJ.41JD0TX[
MZI5%$HIN2M\EYGY$#F!N^5:#,?EVVZ8ZO@&U1DFK!-2C0[?8^\R@Q;QQT"%P
M?]7OC;D^7\FLL'U_6\'GWEM(AML3(Q\QL?.NWFR3S'8C5P/X<+;&'N;3M^W[
M$ . &>0[)E LWD#>'0+E_$1+U!'C57T8OZ-=-GQLHTX7FB!BQJC.CLZ)IW5C
MIG%%-Y.4L'XW[AF=)0.OK(T\1J&.T1>(VN_8HVTSI,$4(<W8Z8(%?@;@<_M2
MOP]1@1(2MX5P\\W>1\A9&QJ2/ -R%FKYCO=<X'M&2/>3RL0.]D;02=+)5+P[
MDV4G$%1_='KA+.2MG)].E^GC3G5"[?UBT8VS:K).VKW.EEY-P?-&6=AI%3C8
MN_8WPR?KUC?,8:,ENS]ZL-5EX6D-)W!*=RZZ#+[SNWD-Z?^Y<*2^\SX5ZCP@
M!116YMTGQGA]-+V>+K\-3,V-VC8G-S)0+8?=FU*22C78;^O@9[^P&%@M-S;/
M6OG&C)4&%N4!G_;CUJ>ZA@ :JQ$/BX^3#G@^ES<8;5U+/W55*FU^D\DJ@K(7
MO8:R+9]7DMHV*7\;> 9T0K':P]6S%F#SBL*!5#0<YU,YE+V_ W6$,>E'=NPF
M1YA/3Z?48T;8,'X0'Y>OGW=T#.U!AGY\$NBNW'-;O\DV]WEXT"1*[4 D:>AH
M,Z2EB\V6M4YJ/KYNK)J8K?T^RVWKJ/(]4<A$<^&L@?AU1XU]8DO6-]\?#CR>
MPJ#9^$F:2F=:O-,4"CSXO5PJ&3*&+/GB)A0$7553F"'QD)\/JF!GE;BAN1!Q
M"V]WUUA9R<V3"[&JS03J!I%0EFGJ!L$V(<NV'SP3;K\%JC49P<.DT)86PSVJ
M6'_'4V+;'T><#1W2-&<S#1VPJ$+UPH=+LMWIC5.="PL$7"])H-3F79496F,=
MN3Q/>M)ID%(2[)A"K82WM3R0NU2#,@T8)<5#=UX.4^>^*>FH0M7F&U7.']>4
M%#LDM71IPPTC2.+IBZ0W[=' +HG)Z(O3Q.3SG9O@0[KHX'&(_)WL-WA"N[L.
M.:),V8'=F2@@+*IP!7RYVM%]J_ZK#9EJW<_M7-7#JP@@47H+CM6/VPI[NB1$
MJG14"P<>&-K6E>^B6]0M",-A?3UFQUT_T^<]=.^[754]N4H";V!B6GE'QM!7
M[T5H*5,M5[$$A6,::K@QIWPCR!_$M[CX*I_@4O("5UJOHT>&^/@.S^9BU6.+
M[J(B&X#"3$R?X^>U2JFT*QQ6!WWE&9? D2$RPTDUGW1+F"IFR2<ID",!\I\K
MZ=! 6CY96CZ_7@[1_A"\'A]KI$(1,;Y2\QK3\H1F-&$ZH5.M/2?Q3DB+;<QZ
MQ%<=;Z^ZC MR@>G0K>PQPT8^!W1?__"]SX#:ZS[ZI?M7XS?2 :%=C=;61E<J
M[!7?FZ/&H<+&"\Q@"(4@<L5(9'A5@0CSDE7@0[!G)+Q];LP%7G]R$7+:V!X\
M'FPN8"4%^R4,85DMA$.'YB 931T=+&Z16<ZL^ZL- 576$];]Q40-V/;*4W76
M;3<\N[I^O]'.-$X[>56Z/EFE1B*:GB#.?#US172-&_<(%@YV(I@QWW"9O6XN
M-[!Q 3-=2<[5DY] XVI-G2 2);GSS*AQ^:K6@LGF>]Z2#7?'@F:V<CV 0GDS
MIH L]-'< H)S]M=]5E7N(FGZWH(T60;IV_4_&Q2P5O(5+-"-QC5#57:( I!S
M0.A%=VS=:;<QJ0>N5ZU3;!NKAL8B,DP>VG9Y.ZF5O20:Q+6UAR3#Q/+J?C&?
MX_VCFC055',:>=8#5)E,-&<M+;Y#<^LK^'Q15MPE.?R^&77$V5L$?_(99AMN
M%K:"^T[T%C9*,/H5V48WX>_K1WLOMJWO2@9D-+P#102VP05N@..C;S(W F(?
M]PKM(-PU* 5IG4D)3> ]DD5)9D$@L%Z*D7O,?$U6<FZF!/M>7\*:CU0F1@ZL
MDWXGI\E;,Z5-_,7ATQ)+%3.VQ\]=F][4*B\N)CZ,RIGM=P]:LBATI!#PUO E
M\$WA;8.?&'+_UM#R@%Q\E<"X>B])7>UC/;QM'].V2@U$AL0MV!/+^A$_]+/$
M?H/E\7[IJ#X+5,%1 :W:Y)V-O0)=K>2=G\CL.&6!!G_0@K;.Y5EUI2'=-;Q[
MC%%$VW+8[PG=E5H507HIII-DG"&F(CIF]8S ) (PPX? QCH4+]^)MUCC<5N&
M:MC9!4D[G%>%4WI?US,E,L=;E=W]G@$NKBO1*E4;?=;4"RMYYJ._JLVR>G5V
M! WC*G[R@L$?J;UA3F-" PLV5A%=$SPR'(T&^!HZ6%+R)'?G_J@7V1#5>7J*
MBD*5T=SIU 6CWW)%$Z)D6P&1W 0G1 #B#/'8'O]27WY&,T\MLD#"+87AC#4#
M,"K"#$A+OPL&$,K\E$J33-WE5)5*Q9!*?#,HJ R@Y51^16&>B1B)Y O'$9/^
M5XDJTQ--5\YO78@YXD$7*(6['@V\5<A)E4O=>_@F]K:/S4>ZCQ5\R 'H$CP*
M9H!YPQSQ#0  D$\EDR?"CB9NC@W>YSFJ*E;^L]:-9M1_2FP/@#Q-+-8;2:;M
M,OY5!TN#,%\Z]'CRZ2M96X%GP%4F6LOU,T!+XZ3R+X.*^+&V%S$37@H [8B7
M Z%IU KSZ<@HL?0O;1VSG\)?:@>P^#/ 2H>V:T83) [1_G%#HG8/^TZ\G7E?
M\E^8X0&^&?"OWLX\ [:IDY\!)X6IW92*9@391B)7O3,+F,HSC"VJY9=6^BOZ
M\;Z89M5JCNU5AA,T#8R^N/FRH\,BR3)S_%!M&*:HW(_FF0(82JB')R5Y+2S3
MO]"^JSUL7IX^GFJ*I0\M?8=4ONL7 CX#^+N$@_RUIDOKFN[H*OU!1\>EXYU^
MLXU/'R\?\SD[&NJ,'DB?6FAFZ"O*DL=XU<'U*'3:(\D#'*ERD3#!06*JLT$S
M<R 7;PV3R#CL'82V'Y[TS19FEY[KHGIB5#QRL:\/NK[DK\1%S,RY7EG^CIPA
MXW#(OY'TM^8CEU/I7TC9II;VZ:WVWT ^S5P.(.7'!*E_0G\&%*]];B9U:JD!
M4K]D.D>+U:T1[2]W72923?+*WV&D>STQ5$VW20:P=G9'7XADMX[&E,ZQBT1,
MET3/0J\G7F3-GY%5%6"_IAY"]]C\KN8XU/_]L-6O_IVT;0(A[[1_H6@#,69Q
MV=;1Z+]0.8K%YT1 Z =D(\]##&_:@6N<M7="SO\6FS&.ZJ>9'7?3GWR;7?@E
M5>-\0EL.$2?16WJZVIKR8WY+% Q%MKEO.GTB<>4B4EAKF^_%VU\8E[P4J/]D
M/7;RWQ?_W[,B=M7[.L%SE0)ZO=FE.[("B==B K=Z1&&Y,&UH+W!@?[DH2[8"
M$O;W &#'DWL"2*4ZO#1<_MIARQ=!Y?_>AJK]WXD+T*US(8_^C(8=?4O3S#Q(
M=-LNL7E9D_! V I%,O7CB?009T0PP%>.-OCJ^@\9FDOM'V;BOE%\,7$^;DR7
M)./$2]9809,JJW1,HHK*+0,C,(ZX1R)AIB)B(-8T_+&'Y_]S!/V;6OU?,D[G
MT4X4U3HR*Z]Z;'A*<L2 !84S+<8S9A%C3F7T[=O3#0J+HCKY=EF**.DW:.J8
MDQ^<R.5N9/4(F$HY8GZ]WGQ#/K0QO(OY&UH7Q/\,6%;>[_=GT&T)]@WY0BC]
MC<ST$@';G_JW+XR4LM[ &P"L^6AD9+"O>.9'#PI_%OK[C*)*3:B"6&R,?IU0
M;.HLU3YE]#D[MC==,-88$8B!*0K779).'>@.N(C8VTI?2//TTK@( \=37Y'/
M5<7AQ-C&AD974]( %6((7K68GL^&NXS$6 7H2<!&7OQ4[A]^+RT!H8N'_CC&
M)ZS#&>E5Y,(RQ0F_"F>F0Q[VZU.!/RJB^98,#VZWS53ID:\8DP(0ON&$"-D>
MC?:(]'Y'2T/^XZN/'O +\2-'U-^6J%PQ.?Q@D7)A)\B"_R- [+^#]#\!_LLB
M_@XH_B^(0*-Z.3-*'!Z)=3VC3-I.'+S<8]1C<AO*:6V:E3F"W\=S'^=<LSSZ
M@53 $_JP$<Y(63)2J7#[@(?;"O8?7OE\\P'X4Z)?7ZL*6>\9^#=?=3C@=T2*
M7)U]+IWJ^C$6RF7Z12NI=@ N>&205VUI[7ULO=4W&X;@6Y R>ISES)+-^;!J
M@ &QC^.1P&)?(P&L8E@RRUM:R]GB5PH>B23@7<?2X+)X!F3 ?B)C=C#*'FY/
MMM##VDW&@]-ZT.U+2)V'3CGRUU<.MDKWL5L_ S!D1I8T)X2T/A2I@',BF,K>
M,F1)KPWJX*MSP/ZDB!J1 .SL7MQZ4-S_$5J5_/3:AZGS<9)[.*>">6E.'63R
M&KE<ZF_32R$G.46G_&X*5=RV=-'5ALWR&))TRT&+N=N2L<V?[P*CJ\L<^>!5
MP!<(5]?8=>?L51,?7X_X_TQGNK*=3Y]?G9W7HB:N0*;D9IEIO1])#EFAJ_T0
M^LHCSS .]VCLR]":5NU"2FB+0KWMA<(WW2HF::HC]-:\N8/ 3@U4ABQNY94Y
M[79W17X!BM'CL%F*3VI:#!9R-@M=*2#PE?[-,X"= 8#TLEEOX-X@/B6-5Y;]
MY\_(_H.)/W*Y_:^6H/X8Z]FCF:',!H.KB+=I?KL*^/;+%RD-YS>$GR*W!?P:
MK.6)+D,:9V&KBNQP50;V&=](\](^GC537;M<J8\] ]1T#(QB3([&FZOJ>W2N
MP#M'-@[+-]0*8P/^J-*!2[4GPGPM3Z1CDLNDQD/?AYPW4&E^+&5R2XI>60I.
MM<)RZN",_;BKTB0O%BJ$0*RLB*K+=JF:WSUZV^JA-0ZZG>YS890[9:R<+]2?
MROR8( C?^)F!\*G+/,8G(JT</T:D>*Z:Y1FPT$!7U?FKY@F&P0NAU^GKN>Q1
MI;"J]3#X]8H7M>^'/K2K:/7O0^EOEW[OB"-TE;/;,]!.]R<P6(-2YE;4U^1F
MC)\!UW.%3ZX;SP!WE>XK=M+IL-?T3ZN>XE/$W6<*+4^E.VT_LUG'#K_^-'0I
MK$CV(H^,  7Y+&^HW?T^YCL73:BJ-1U?"-!EJ[F]%57**<@5^.6ZM;O-9]?H
MQ*-%L7"U8%.3KA1$9'A#2MYY*_H,2*B,7QI[5V_P>^R@]?OCP7#0SE%>3>JM
M9<MYVK3;S/UT_#-@>$'8A/%BU&6'.7^G^*: ] \B\&?M,OZ?ZRX4VW:8V_>A
M73.L9U.FI52!7V_KN>2:L8@I_3F?W';W'MEWW7;VO@$W?ZM^'>OX2\S(CX<
MS::+ I;T)ZZV,R%QW_.OO^_*'?;$]%@?K#S6/0-_[72?7ZG^]S33W$O^.J0C
M.BSW0TSX&4"N=?H.(O$,0%_<S7=!?C!V%ZO#NM9<%"NE'O@P>>*O.EQ_-]HC
M\29@<G)R=V^KQ^>6ONNP.FKM5B?H+S_]AXS+QVF[8ZO]XQ,VWWD_B56LWJK]
MD^CW?]?$-+O,!WZ#@9)!D^W[M$=W8R;VC",-QFLSFBNZ#[5(>I@3#->Y/2;T
M_!@D4O1=/_.ZT\!_^23I_ZD;_S=KM::#T/%/5CJ\'\S=@[3MMX;IYT.5II=I
MO'P%/S<09^1D1)#!]O]=R06BW_8M27'QB4\<;4I+RXV^*P$*TH\%4'X5-[6"
M8T;?GMP'@9\8(N)TPE^1UVZUO_[3;1?_#UW]O[N!&7SGNF0U?S>??9D\E,=J
M/VYCCS-LC;WO@U&:D72 ;^5Z@H7C=T"/\67=U^<ID"CRJYO#@J&![(Q-;F6]
M&7['9<X3*:_:2O_39>*(BY7YXU0S-:WV7RT-+C1(WDALX1E@[:#'5JAX@?M7
MIBQB#C*A_CPR&7C[?CS(Y4J&;:SHKU:+UO49L&<FMKC0_>[OC9+!_U>CY/4?
M-4J8NRN!2U//@-5_Z9/P"SQ'/S=-;H4)Q4DL&;P*42I8K#Q%IV9U5B29(>;7
M+&9&FAQL;@7SY9!^H*7),S1?]TN]P*Z7M6%9>"OM4RF-,C5]]G3LZEKY9T[7
M=X[0>^NRATZ.7-X"_QX5%E+E7)02825K5':0OJ2#K^6?(E2O9&SP&=(2G>9C
M8^EK+8N>$@FN-BG[U"*M3.L$X;.+2T!LA&CRV5:>7,EJ0Z>FM3NTJ_H)2R8#
MSU7\\*)^#ZM^+"V'U",7^30.$G#^(.$U@L7Z9BJ0&\;485N__T]KF^IM*BHG
MV!;YFMQ4.J$XLU<Z"YH&H@WVAY^^&*B>:L>U:]MA)H(&TB:]]BCHJ0>FUZ1K
M"#?F4[1P736SG'O*U61<Y^\/#)V[(EH^,K+2YXG.<F,W1CE8+-+:Z334",UM
M:J"H&X<LJ)E%A&5'N.&??O^8+':9X!Y-IQ5%)/&.NJ$% @WI"_WSF.OQ3PC@
MF:]W?8OF=7ICJ[?OX(TZMC#Y+D]GDU.+-+#4%S6@8KL%54:5MU>WHTFNQ;&W
M_EA^1- =7@(6-X:4*]U)FQ3VDY%4AXOFZD4.6^QEV,L)!;:(H#B/D?RT9C:8
MOJ4C4R69,-M M![@-*^<TL\RRA=%R3>05[&@KI5,G:!=1_CVS^W1G7-T_ U5
MTJ3-EJ5R'KF0[-<M7[1?J)?-]IMS:5>M@RZ:4N-F)X>'6A<?ZN'>Z[ ;\UK/
MM&GI6<EG6W/@-M@W)8\NL6*\QJZ<O1NW@YT'+F\U0JP48_6,U(@@56GM :<;
M[S4W<1*:\DKBQ@2M5>S/Z+XJ#+<BHB<+1-OE5>9!O%>;97*L3]: #<X+<#D4
M!9QQ(]'(:311$VZ<DV.2P6[8V.338=I?_UD9L*JV>6F%B5M-'\',$Y/UUB9[
MR:B9]$J,.+C1S9CYA*UJ]G+"T[+Z1\=7#2_J'D)@2@)K&7%K43TEVDB(9N$%
M5?.SJZ8__< SRI(,7]:ZKH^E8BU/2C(6<JNMSXW)<:(ZHAI$YQLAZ90I&2 Y
ML0A739&Q>LMT.KW"4"BH:A[A)(JO^.(UNQK5+O95S\;PS[*C]>;5:7'DI>N>
MCZ4[Q8SVBW2OCY=<OL<O)2[7C^L=9*\ZP]M *?62P.CF1.\-JFM;@.V[;ZK.
MII\@[K7_O$.,P:.7 >VZ<NRDU3<;H'P_:M&^"+4Y-E[#V,8KVOU?S:6\=ND=
M[:2AJV)[U*K50HFQ-43%NB61':G&W2J':]',>"W\1^/V[0&+[D+^6B"OB:Q*
M15;#FV1I-Y6$QMIX/[E9Y]V%U!30L6/'JC54$V.S\LQ8Y3(G@\M=J6I/TZ/2
MD<%[X4JO&.7/!!.C]$.42<VHF3==1B4]5:RBXR2[>J]QT=RAGH5/PP EJYKY
M;I&D231W:'$&9<,+I"W0!GLQP$H7LE\)QIBCVEK&:[J\U?F<TZ[\X;!HM-9D
MH>8>84:G&=2DK=H"ZM0U7AZ5#UU(3,%RFS#?)6-B8@I)K[=D )1)T4FCO*+'
MWN\3=#AK7D*I^#.?086[E39KTNVOONI^/6X4MO1"-3_*TCYMS,AHC=""9E]G
MT;/<\?&&->=V"#O"Y>%E3^!I]X<K8LLDNZY_<R>E2@\0721>(,6FK6A&?ZU!
MMJ+K);FXF 49M!QSV/VRX>[!O;IP5NMAT'[:6"6Y.BAIAG&)YSA1.YGK:D:X
M/(Z"/?JAE$V__FL5TY^Y&9]\8W7P:;Y\6+IWNK%*W_[&GF^H?%)!FMDTS,5V
MZ=KGF,?  8[83I[?O1:GJ&=BDR9DT5D"?L(3I**1V*,Q730+B7B#3URWK#3M
MV$Z25VT./K!OGARWE^,RDVU;A]8UFRWG\6$KW:DV\0U AWMKHZV8KNP65%,0
MIO!@!/%E1E5_/!&4M6K_52?;T\T=?EZR6Z]JV4"XAS7H!A5['0OE!E3G/\UH
MPFIMWX76Z +K&J.:M4L+FFI[708#=/7;;2&(=0H,%@(*VEA]Z4$JI-9QC%51
MY4UI#B;^YP[<GX+>=6?45@\RU.74Z;/@-'?P%&$SL!TRI*LY N.UG+_@&RR\
MY<0YQ=T]X"2]"@!IOB0U5OGYG .KDX7/=9TE]F.+=;+>IG+RRM 6FCRCXF);
MCVNAN2@;+WC>'8$!I&U9V$9!-18-J@7CN=P^@/KO _0+ H8]N8?<>4Y>GT_+
MS8C4N\I0@%:V+9ED]>4 4>36^LDU43C71MOES-/*9*?+P._8H$&IQ(FUO4']
MK%"5.)A/[H;AR$.<]4N*<F[(S0U--NZ)8"<G+Z<P3?/C73V19-"5JJ*04#>!
M8V*BQB2*+(O]7%YMWXJQ"/<7Y\57IL2,1S48YBVNR#D-@FUR$;.HR><]P:=D
MDBF@Z$8PVJ9/YBMDKU-5F0[;?KK9TY&S'C^QI0#2=P,"+73) UZPI#[0<7O%
M'G2X:AMS5N%:I)-U39E6_R1NP?#]=58(&P:?:H>=ANS3T;V2D[2K](+D45<9
M^NODP\JZG)(B/EYR?%(-IF]%6=(0),*M,3(3.I"J^E!A/R95!K6TSRVWL+[O
MMOW9U+W>JHW8VM%37*%?=WE[YN]RQAP^0WL2IU^[YF?3VI"):[V5%F$1--)%
M,+G.? #QTHHVY;MB(=MK">C4I[U0)]^F=ID+?(:PK-I*4>HKO95-096M) =C
M<*YF,=WE/K,5RHHZXP!0'*WN@@2N=M2:>7ZL4SN\-T6%.%*'CI]H)+.14*$X
M:4@'C&@JBGH:P*DP=(O+/:QO3R YT1Q="]O+C+U"@,"TS2:4NGTA.PCD'IDR
M^_387_TZXRA!E[?N]+4RR01M^ ](Q7D&0=//MIDM8)X=U:SZ7=5VJ0V+<A:_
M,7JJ&WZR]K=FYT'ZN/BBW,K@"*#W. F()=T 4=*6Y<"-Y\.HS"VON9WTD)1;
MO((UMDVD1+1[BJDTE[2T/C';14)$V[OE3G&*D5[S&K()X^1/*K^;]WSD43C,
MDP4^4M.EQ@W!Q/B.J2M2"8743S)L,*'R.W]/C_Y6=-3CE\R$[\XJ/=]<TCX)
M@M!4.L=F-^.2MJA3<S/$!*MS(]+CQ'M3YO:32#$;0&M/GH3%P?PVM5/;/[GK
M;']Q<L<,??47%K;[?AR< I,;KQ%:L7H&;UU_NI*4!Q'FY(VP(=5'Q,&Q,WD#
MI@O8K&K58=>*"<D*]V*. \V>M?_8N$9H6D.37LOD?]!BKU"F)#P=JXN_31(
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MU40R/0=6IS(M0P(&0%"&N?LEN<]"0K%P);QFI U90*>]VDB9U6V17B@?*#P
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MTC]9WFAS>WLQ'X8_FP..J,Z DD_*Q&/=A*:K)_M=9>3W:5 5&1T=V-<2_NP
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MFRFC!LQBC,:2)\Q0YTL8 LF=%^;I^4=7?.EGA43:ZE%QMA;B;"F:-' C!]D
MLV,E- D)G-XL62YFQT(R;M\5"@SVYIC+5ORS-7+H1OSJ)G%=;HG*'9\]=7S*
M:7^-0BDZ'C81[R47C]3E5-1P_$>2\]J^A<_DDQ3EC)MW_LZA9K:%C:!)ZCQO
MA^_$\6W9"^!=N=.O29E'?6'J\Q^69LTD_U8FI=4D:%SI?*?%.I<,V5V\^2XB
M0M9+*HT%#S5T8.7C=*DZ1T-2@L$OP_I9!XJJ=V'XPS568J8[B#,.KJVIY?L!
M1@=>*:3BL]?7O)!2%,IXNPQS6.80;5-S9;0M/"*%<T,G-KIJIU?-4A5:?B^
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MTX[BZVP8:9<+9NMLW_F&Y_KNDM-LRA/5R=:;'+ 'YO]!$#GQ<RR7/:0QIOL
M@!MKM%M_ <HG4O -*9SNER-1.-<J_3._&!O(HG8/V<JM%1E=C4G<TX$Q#!$,
M!I?\9GEX,&8(2%*-92^@J(;A"CD_(62!0M^-WBBT&#D&7MS47$3PC2]3?^N5
M&FDM\M^'\OG_X11Z=T28[+KX<B1F+)Z..=W,F$T>=FE=9R<6')TF5K5^E-:^
MO$YEO^/SLSC_$:K[;^1"R,"++<Y$@4%# 8JYJA$=NRJF=0+Z)R&NJ/B!MH(E
MY90MGR51K!9!K5T:Y0=;.W9OV)N;\SB1=7[=D<XN$7T< 29VW5ZRY"O&0O:W
M8JB$YI%2N,I!:<F5(0$=_+HJ:*[/_)"F,B)$^I?ANO-,MQUGWD-OB_]F@(#X
M=FU?]1!9V<=%].%5E#)GVUBBP^#4/:Q9<G@;/13V- \]S%PIUB.I=&UCAHXS
M':SKT4\.I&D2F8.DC(W*A X$,C)#A89B-PL5CB$1PV@A\!2DI#(99BJB@(4!
MG>QP4=BFCB.=>2:(%6-_XZ2&//_H#HZAM,PHU/')#PKO5Y?TX"'R*<SSG("\
M8IR2P9O!2.&U43HH[M47X/-WNO_:.N)0JI*%YSQ7+I!4BI9@G2R;A >)7J0@
M FTUF.T8"&^:(&.T$$P*? VICC.?--A6#^8/>2^ VI-L05-HPL8V<=U2#R.I
MFMI/MIEL(FO)O]HK66&!XK)E/S-3RL3L;PCA[,PXPU*-8.L5Y2%JQ_[^%@VB
MPH\TK[3 1UD-D90C>KY]?ZX#QL\_Q[Y0Q47'#OI8;LR#+:\Y2LPX&(5KQ$H@
M?FR+7#:)2IO$X4WI0?MV%9Z:X9*7-T9+:WQ2J_J4U/L<)# B8K)Z3X>9P87A
M6%&%,IJR\P0Y@<3Y-%?.P++49E8M,>IHU@_07'B^#4KZ<<A4"]703+Z"!T<N
MDJ;^Q]+Z"10<.;&F\'LU)\A;K3DWRA^1BNH2'[]6<3IU%DI^4(NG58M.7]RH
MC=DD25 T'LB:@T9$R5-I]L;;2!XJH4IG95:L1"3:,^_#7<'D8E:Y@0F/V5>#
M$1 R;(_!'8>[1] *")'EA-B-^]BG'?2..3\U5?=;8N[:(_;2MC"9HE#Z-TO^
M]< 'O;!MF;WO6AB$9]]\J\0O*7X>5" @W_[HG">]1_.\ L.\\3[_://Y,4+@
MEPUD4,<=,VC(3R+;ES- ].^*NK^>^2&>.!''4^?(&RJY=\'<M+P;2IPLJJ'Y
MWQ/@^70MR"8Q62U*KW5GG@'-LTK?_V3^!0#NZH4,PXM*Z)+Z?'U$8!!/(@N!
M4^HUI+=*AE$8II?'*MN/.O,=1>LU!88;@T$!8A5=?KN9.%Q56KTXC1^:S"/>
MX<G/S]KRV3@HO-7Y2,U+D_8U^AVYB)#^I3,8B95OG:E1T G(;$/Z<_FAYB)Y
M4+"#-D::KG4P*I;XSC-%@L 8?K-*_6A60=/F/=$L+Y<,7#)5#,Q!']Q\78E"
M,CI9LF0:6Z-5#[DW!_^[!#KA]NA?TAN!D[3%H;]PBP:-=>&S.6<QEVU;B4;U
MY3]S2A%_EL1+X&$E RKB+YEOZDQ2F_YJT5VTND%*03HF!?\<^)42?/!W[PSI
M_+\V7]Y/+;'.? I9W[\LKLWY7VTGII;ZFLQY&5BH_7SR+KKR2J6N^ND?E;?[
MRT&<Z5_*PD69[A?O7@!Q!/R*A'DS7#='/1^)?"(<?F)?PZ#12NRN.-EQA/<R
MB.&M??D&5M@5VXKBD4Q)F]V&YF-5Z)8*9JC5.9K"@WPJ7_5WHQ_H:32Z/#J]
M*[<IJ-359*JU;YUROFTLS7-744E&KT1?ZJ, &OL[OJ]4+O<BP^+.HZ3A'88T
M'%ZSUR\)O5#Q6[X*#K\D: Y*7<W4%L @(:Q^#&S81H.SHG-AQ&$E*=W<BE"'
M1P^?T ^NK,OX>N23V?8"(!ATOIHJG G6=$ 83TI;=88+[S89[@%\'GP;RSZ
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M/;VL+"4FEG)W5G4S(CG@=;[, 'K5^5IHU!PE2>T^:(NAAF74) '"O!= E4
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M76)+,%146HY<I57VSPU=#2E3,7\\Q"V"YGL!"/[ @+<@K'9'*T1=@SD(>Z;
M@-Y")79[GT1??J=KJ 3A(E5RQKO3<.M-;?EAG2918IE0S-)U^(CR\B>H3+6$
M3A%CO2&F:Q"=PT^U+P[;"Z8+7ZF"U;SLN<A*4EK$9%)<P260K1=?[TKB60SD
M%4PK15W,O9HMK [GJU8#S"@K2)5 2COW[+F2"XHE)FD7[C7(*JBL!?#3?Z3T
M9D@Z9<.%CEBU^?FS)5P5SDH73FWWAX5(4NY;VB$XB-HT1KAO9JVM@1.F?RSR
M)BKWF5*=L7P?J!/"K]BH!J22!88+%9&.WS):W1@BP(^N9F%0BGV&XNG^Q(]S
M/8'30.ATY@7F"PI%YP]>5"Y:3'9GCI[(8P;@QJA8!FW91H1T4^*0Q5Y+FR?3
M3663(0,^&8H)AD,A]S!:ZJS5RKK":GYB>4=I\H#N-G_P[: 0>2ECS,UE9A##
MJG%I]KT;NU[J_L^ 0[L= /]"+'OZ;]]0G0GR/\2NQUPR9-S8/7*MCF9]C_9F
MK-3;TV@S3-66C?^HNEK;:,_[$7MI:[WEI[[&R<UR4J=<G*0]AF*KW7X^WO 3
M@GG5;GUSHEH1=\]"$'I%MV.XJ8_R,!Y7*4@CBD.B4EQ",A-2R8+):$$"N4,+
MI;:(J*FNH48'N;X ^--/<_OA^]*CX@O@^^:( O;M\LUR4'Y!/LADG+DU1_U6
MDS8*-@<X\J#P6-OM$191T>OV$\^SO:5?89"HUKW1L:R"NMU4K,L*F/_ +[^S
M(D_["-^HA> 565U*50P=CT&OT?4>TS5IQIM*SS;07\ 3JVO%/75$8U\!N<R-
M\2R?/@E>]8U/#P(-<6]61$_S&X(?'NX,Q^!3O14VRO7$5#_[&P/]2=TOV#MW
MNT<ZTG(.E8P]].(5GO/Q]\*?ZQD-UIETFQHW>[?Z>P<#ZT/";&; 7 +",,VO
MC\LZ*\WSKL,3.I_G\;$I _3/Q_MLYI&I.$<]@BN/ZBB04,!?29.&%Q ]=*!W
MAM7%AEG%KOG%!K+ZO\%3%Z/:1 -1(*%<<X-\5NDZO A0OI\=UP[,8Z18$Y$9
MW+76@-N5KH_XH3;E\N85QE%%,5.;VPAB)AAH'8=,QF73)^QP,/!DEHDUTB![
M<[$P26%O::H5"H0^68!.[#Q%8Z+EM1>+IN9G5)HIB&+A=X*GPJ0;A0<-,B80
MBN8Y,K!BWG>@]F<KM4!KI^],<([P%!/O>@N.AR5L+H\LVRO?C)0I)SPV,4XP
M*LP-"1HYK>3S=,809$0X(\M\<V_S"8O<6>U=M5-WEXIE#V[(*J])<&BSMI%9
M:L$5LY&13+9D>[ (=H1!*JH3=SE?$[E2]>U3$=<_L8Z!O1VGY&R?69&:52"#
M0P2#EB0H3IP<WG@;B%P_/[M"KGF&A2X-[M0/KPN8$)*VT+1]>?#Q)6]>#JS2
M$-!\LBMYK)%INUE5FSA,&>SQ6<>.[[7;O'@!T ]K>.LF@)KL5:]3%IV 3>A4
MP.? JT[<QA3.H:Z=5 UA4J,4-LYADW>,"3@_E]CTM-<64XH=;9S%O@I<JN?J
M?>Y5+27I?@%\^L1XQ#]IM]+XM 4)/FA8!R4VK@=FM35N%]L[^%+B2H(HGDMS
M<F[EJYT6N1&7%2Z,;Y@.XAQ[3LIKDMM2]EZ7>7A*&M"5966C.^HAZLB<:A*'
M993?!4.-W6H%*%\24/:=9OZ!.>6J@]<BJ4\C:(1-1_6JFOZ*R$KB$]ETZQ&R
MYO91BKOG>371YJ#77JW<=F/15L2GPIG3K7B,N<(C @]WT]5"<KBB K=!E O)
M\@<&WKT$IYU:CY.F"ST'U?$5,Z)&MS$KCC-A&=/))JQQ&_X$JV]WTY&1F#(I
M3WVI:(VJ:B-#IL9:K8H.DPKBA$%@U%6;(H-QW;HJY4;K4SII_GS<;SB9FF<S
MA:*!Q.P&?L1;]-X:A_=AS",IU]N(\58[^I$Q%5I"C5R/OD919BY.ZAWNVOK-
M#^D&75R7H-4MJ^?A#9[X!1\[>VLYY-F5:K,)/H:84:I(3_=U=5R5_BQR\UDK
MS7YC*M]-4+8@E&&L".4*]CK&V.<'NE%M.G_[+(&&\;39O$@V#4>UXQ KR&\I
M#6'L67J3TV88A G0JT(-#"?V.0V'D WGB ^RJNTP"^S\4H*&\A7WF<DA$H)?
M?$#DY#J6#9(F"=B2^ZIDI@K:]LS(LCHS!V+?N9!LZSC0(NC%V;/,J$GLO-G^
M6)S @F>\FY_*>T;+K3Q-2_>333:L90-B<LW@\1)[3-@:'A4BQ^4@O>HWBSEX
M,9Y:K5(+H1(\T2-)Z'2\1 !?+U&X2F6[_)_@8D7[S=I? &\;*T8.1U,&M'ET
M<LMQ+_<_[))KM XQ9@!&$?9#=%CE0N:R@F91#\B3:4J3::>"EE1< P8K279,
MO5H=8+"E#\='#+O_>L4H?KLZA[RQFUO#!-^;(0MKR:'^+**BJ=D(1AK26]+1
M:&[L3P>WXJDX$U/()H20L8GGIEGM!I,"FO979:L^W<__R+\-W\J(/HI9"PM3
MS^1M'-D9FT3S2*K<TZ#3ZE<G,D:%<M>E ]HZ>#K40&LCPI'BBO!&25>S\+'\
MP!*R=-M,J"K@?LV+D,P,WG;9CD$FLLU].=QTM,.U9?T?8F)#PYI3:]["BM[Y
M&F-]C>C+,01_*CU2M.??W==5GKC:M=EOD&0^E+#"GRD2"Z!S>:_\644M? 9%
MQ;14%060(NLR/ P'3Q(HAQR(\D8'3KS21F=[+*CVK\U"I*8!IBR^46<XP4[P
M<O(27:=U8+-"M35%8%135#[K@9?+3KHJNU,0J(::TW ((1[@19TS'9=A>?!1
MQ 8]3@'G+NMI@(=]5F!?CAGY)@JF,]8=KX*2B]VGI=$(+:Z1%P0JS) A/8G4
M3J-0P/=A=:25.>(H22J@H")BC)9"5U4V_.EOC0S/T_1#@^P L=ZTX>@:*&!P
M+9 @L55.1;];PSOQF9.]D2RZ-3.+0?0I3V1I 5WO7C6?DZ\&*H_UO00I['#Q
M@VCM C.:0PL!-/HR4H)N;P1A Z:/"39JN([-&\>1VRDK!*KZ^0YZH\_YOJB/
M,649X%+27B.L")1@"&C>KX*(_N&62()S\H@W1RPU!3^PC:W3R)BFM=BA7/>G
M8RI*Q^"4V).[9$YMHF57TO#6QOCU,C..3FVVL_E[*&V@Z'?'MA?5M9;]&/QL
MQ\)> '4S_H&OST3Z1U58AHE.V4G\Q($>;8G."VLKK$($1/2A\ZNGVLYW+(ZJ
M+P#?W2Y"<!=E%-W.0TPAOCV(0QOJJ?.N-L/1?EVP=0,>"LXO!]+7N&UHEP$M
MI2D\+]57J.03#X6](ZO)QD QA)V)=,,W(&S :.6O9M&.%X PS^U![QC_[9?*
M2R;7 ,P:4WMZ=K:=XPQ>K-,%=\Q%HPF6YAW7AN0P8/V&VNMN._X);SNG=!W!
M\0QN=<M :,7\'IEKX?S<3JN_(\X)_,'ND74\N!@&GU9FE%3_7LA"1W7'/D?2
M'G%Q\RW"K%=-(N<@CD8SULS @E._H86A=#[2AV%B2P6GN3R%3!*&I&$9G#Y2
M0-VW6CC2]:OG\0R>&Z.X.+CE6KB2 599UFB5O-=#AA%--L(R;H?PX;8.J$A-
MY=02[Z2@DI215$C+-Z*26.YDU[ALUU1.[X0KV-_'(9M68^UN18QTP9F(7H!%
M8+Y1$LZVF-2MG8F$J IE0UX0_+Y\LYCD/7J<$H@M3.(DLG>,EJSF3/3RZM C
M(@]727UN.]*;*:@[;SI"/^]IR1M+=FHJGOUJ_%8"*PTT@^V+#3KE5Y#QF9%C
M&4]2Y-%E(%T8K*5;8-M+._:3&MG!_US++BQMH$HC<=I]N1 QG3R'UQ%EG<#+
MR41R19](N] T@V5E#'?O/EJY#<W IWS#3U^4I,:EDIY05/X%LR_;4@I'@M?.
MF27BUQ<S-G(Q<I0"OZ!VJ:0"\CE,[C)4HM+\]WA&+ATDC'X=HO-1'W67)4/W
MO+LUSU<6X7)@D9-OIE.^\:/SVWLY? @DI(J075Z?$/.BE5I1B6^(DGM?R1ZP
M+%.#PV*KFQ"9<.)B5:FLEJF3I$^1'3T3A^]#<D&3&NZ4ZO -(35>0U9JGCP8
M5?.]!KN$T7=-CFUL>B=.-(LD>8?Z5<+(F8TRBCHT/.5T%,G:X.ZC^\2]+@1/
ME<%$]3,L0POQ2-.1U6/+'ZM9;3@M*I&Q$BN80[U8JLV=TAR5R]:RL64R_NK"
MBD*N%T2*D<_$3*>Z/O=^%/;:(RD;YMA.3A<D*[6YN".SIV8#6#G]^$Y)IU+*
M^?I5#,N)N..9M.J8#'@=A91N>K%R5#$]V_L' XU[D'#IS!^T;Y#BS4:WD2M+
M=991(NCZK3,)U6-T$AM45*[88VAPGZ!>MQ[(R\W"&+T+#A5:]7ZKX0(1NO*/
MBTRH]]4*3I6C]2U.E1-;24MY]A&4CUN7W%PK][?,X]O\H9(/-TP?TP=BP%V)
MD<7,3;5P4BDG8G.="^5N6SA469BZ]DIFQ3F3Z;IQ8-^T/=MOQ_JU35*T+00*
M)-F-55L?0J)/<A568.?LT0;WPEQALT'#_2)75B(*[]%3"W[AW.=^BY@EA8-$
M">9[3;+0I,B@K\%\\U2!A#:).F!0M50=U,/??@]^K$!T8&,(?*/E.NNE4'N5
M%L^$' 6OE'6D'Z1*HXDLV'("&1Q[/)H_,)[-\466_7L)Q.OBOG=<'TH8F2$E
MM-'CCU05:0.2H_5 "5/C!G&(P)-^3GJ?IH.C)W+9,]VXK:NP=CS;<X?$0_JA
MN9""W&%M#@V%!B5ZP5VXU(A%3%"HH#PIVRD9<X7A&D&!4RQH/(8#QVHPFQ7/
M<2"-(@-EC..;K1C6;S]]W5E#U'!T%U3SL'MS;Y2SRD(WZ#PG'3KEGX+[]!VR
MXA\)0X<SS"%>4F2=WO:%Q?3AWO9=AP5H5\HI:H1,UQTI\2Q@-*WY9IKM;4I6
M"%;1GFTX "E09Z3L%T)=?*BKL2,-(_F/K1 <#MAVS4[SYH+-E%8"<YY*G/N-
M(]FBL!F-4:)OTR% *0JM2YHCY4!PTX0 _O9JGKY!7D6*=<ZR3DADQV%WZZ?R
M2#G;#=LM<VQZ5;2%*(2 3Y)IZL[R7+GRFII#  AGV27SGYF0A$Y(1ME9IYH'
M>:2&&SXDY]5Z+<+MW7?N19M,=4$WN=??0CNBN>D<4,)FCG,SLYJA*(DFG@4_
M:[+$^C4P6?#KK-&M*T_%>V>7"7 %/=9,GGY!U.#_6R,-TZ3E,+_74GCT[?-!
MP#\G>%PB7,9%UK;)4+!$7N1&1+3HEK?EW?W$,[7$GTK@1$@J$9C-9:@;H<%?
MN^W89=+3J!S9+E_&6,MR^>7[<1H?!+_6@J]4[)(NV\KH5SWM^S&W(!NGR^T9
MF2=T$[O%/9LP/YG!6(KZJV:*3_N"I?8JDN7[4B]CR@-D:Z B"I=8"$Y?8KQ.
MS8%4=Z;W7C39!$$+E]NZW:E/-@X/@5\I?_V(K(9>NI+FLYS;2=7-K&[(,(W\
M '&,T/5X#E;OBKVTS>8\^RV19+F&4?A29UY&QN#=Z6H;TU Q)>Y25%;SB']
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MCC3NX92PIHU P>0&74Z%P-0HE\)Z0?OLIFX9"5F@I8/V@O9POES@[JM'954
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MIX*$BH*!C8CZ#SHRRA, *AH>/L$S:L(6(CXO=$ZP9RNQ> .0QR-ML4V75*V
MBX8V52=]B80?@XQNP<Q%8E[+6P#OT3P"(C(*$B(*,M(_3>#A(U%S(C\15R-
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MOK;;V1OM#XX-GC<U:<HY4FGR-)0W(M&P4YUUO6Z=J.5]E]C45)XQTFEXM]-
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MK>WZNJRWEZJ!T7UGZ?N3)4GCW*42]A:;.:$[*1F0@^\T35E&"R,G;_.&NW)
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M];)"1QN=YY1L40+6']OSR<+2&+@/^7HS;XZX53B+L*!C _0",5S&(,^0GJO
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M:G!GC+EU5%Q1MB=<4#B$X"Z%!9<JW-W=K2#!G>#N%MP]N$NP ,&#NT,AP9U
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M[-Z;VUCU@6@M(=+K,Z9P.,'BRGC:;&<"V7KY^^#!L)&'4HN/>DO ;6"GQRL
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M&OXV'+*[($XSDD#&X1BDE_B$7UJ"T]/9H'SXKM-(FN6\I?Z[3'U;4(@XR.8
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M,M\73_3Y$%.Z=X+Z2Z90VD,QF^R:KUH;=ER*!J1GM$U-Y?M5H1%DJK_ K8A
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M(5HVCC8Z W9B<$9_AJ./0M P;8%A))89R0I/&:K<"QS41=*+$5+0K>]R?J^
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MT'W-_:K6'/HDDCK/RGFIQ(_BA6\EBIMJ)2M%M',%4(;?*W$?+'2(R<&WXIC
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M*8!:'AMQ?\H0EC53P'WXFD:GS+-NW97#7RK9L_X3]^(U20ES=\^C:_M-R<N
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MKJA_3ZD:>P?$FZ?] PIH@<2X#/R.%NF2!W-X?YE4!NW4?J47_6]<&TO'(VJ
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M,LA@,K@D&S1A9E&M".247&COFC/_ !?>N7GG@)+'N4R@=!.0*>NB'\MO@O\
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M(BY:+7 $X/%^WMX[CV^X5%1#NAIY&L"L*.4'=F,B2-<>6Z5[2V.QWAW48D3
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M(U9]*=.YV\N>5Z%JC=HN@\,\0+UPU91^UK28^"0W,?I_GXU2R5=*QSXX@72
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M-X:/B7+*J5E/)34M343T;GR!H@D:ZIC:8VRYC:YP<H](((QH;7W5/;3%GJ<
M(_S@_-B,!G6BQMY[2N3A*]TV?J1%=+5;M"MIGN]NNUA-;;ZN&JI*NF]VEJ87
M!\4T;FJV2-S2X.:\'[L>R%VU>V_K6B)6Y!P1@5XZY:N69FW<!$P6(.*W<"NU
MP9QF6W05&VEK9GBH9M:=S"[:XL<?5'[K  Y-6XOM;DQ;-N)\)D@Z(DB4O,$_
MO$)(([3,7.9&UE5,YY_"&@ *XKH-K5QL[9O2)H "L[<?U29XEE4MRON2+_\
M4CR^X,F6F_-_DJ$[_2*6A#*>%%*H6Q+X9X\1N92O;V6XRE</PP'T6YT[;^G<
M]*?G],D]]?MV)Z?]8[ -TP!RU/[,,^K$53!VIR)20YGRI]59)HXGB1Y+MK&.
MS)VI]Z9>&*7+T90,0:E%M6S9C(U=E$BS3/ECN4KR[<ZKDWAP((14'VX9  BP
MX*VU?02>*++?5@WF1KG9M!.6F:D'Y 8YJ<U0>:3)ZFR;N/7! I_*3@$99B,H
M@.'0?!3@E[(>IQ<IF^T02CNH4*+E*GQ) 4Y9:8/$@7%A;(/MB<_4*F#Q9Q;3
M1)D@;Y:$(5\TP:5:IL#PJ1W&I ZWQ9YEKLCFGK/VHN.A4%\'4VG!;DHP?4UR
M6\\6X]<+E:'D5%/3^ZQJIIN.U&]20,^F,[=V]<A EHOBBRAJLRN0<7!F%2=3
M_7%W7BNE51354<38*J:'.5Y.UDI:/X0$VC7"4MDP?7)&A8O%GNENP)T+?]5/
M+[\&"JKV(\ 3!DCSM) )S.2@9],+_MS&KNG(V9,^LGN"D=P#NLZO$7YBH+G/
M=ZG+ZE4!"- OWX)&.FK^)E0RF#I8LI]]O+DROAHY=REX!U'4A%ZIEBD;FH<U
MTXZH&614AZ4!L;<EZ+UUS/QQK6*1"SYTDMDT@ (S.67PSPP:GDH";'F+DVN.
MB/(S0=, GB1S5QBZ;>QUG_7)D0'H4^'GB+!!FP5HY]B2?>B3=QZYD%$IWZZ?
M@*:*N>'1XICM5+YT[29.&E<OG>"MN,7>"I]F5XV5,FYQ)&KG#RR <GGC])^P
MMI:N]/MZXO4K\4?W*ZA=VO4KQMS,2WXJ9_8^DN5?3TLCRZ0D-"(Y7-&7F0J:
M?NPU[QV\+5LZ0!%DC_;W=SW%PSNRU'%6<< X%R"HHXI8;/7R1HUQE%+/LT)/
MJV;2F/SIUN=N4R(%SRJOU?T"Y9]&)E..GM3E3\8JHFN#XG,<T %KV%K@1X@Y
M],>3) H077M8 2B# @@HN%FG!(+'*HT4IU\DQ37'(H@MSS6YMI<,B%)S.7W
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MXW@.9[*(B@@M?US&:8M Z)B0R3\_';F_'Z*N#MO00T_?&LA#6C^:,LU!$H)
M5.I^'SPW.9-D=J\\/^NF!P5UO"Z1C8;40@<&QY@$^!S_ +98Q[Q->"9_..*E
M+8Z)]:88(U.X $HI &9* ^&,T1E.6D8K1A=].W7L4C..T4-KHFA UK&A5R7(
MJOB5QO;*,;=O5*@"7)+DG$E4A?JWRLNG!JUK6;FQC>T-;N ,;PX.0?\ $W/
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M[,,SP2VZO0V\A9L#7>.(!J!Q)JPXG'(#-,KR'DEV[EVPV:[5G'9+#36]+I'
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M++BY[K70,?45KD<FP':V/-1NE=EXZX9V6UCO-R+#'3B>Q975-Y^WMZ(>>1^
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M:LSL2-,;?^7D>6(^#U"K)O7>[G]RN,U0Z[S0G\Q(]C&Q1$L:7JUFU['-!:
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MI(B7Q4B(RP*C/9KD#R.5@?EO(09H4R)/4!/+"VW!%WM1 /U9#)&/<F?=8JP
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MUC-Q<-KFMV@%Q.YJ)M'PPQ8NB::OVS:U T9,+PKN5_2'MI9YRP+Z2]P"M7:
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M:22GB/!"5(.GGBAP='/+!%#Q'NR .Y2FF6O[<#)#KJKQFS0*I\O@J=<L7 <
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M2<@GH^(\)H;[3SU,T)L\<['UMV,+XQ2P7:WV*1E'3MD]K;_3ZJXRTMII6/\
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MJH?8D>VGBE+=C=M+)*Y\CV;WRU\D@85:2;V[6B&DDF69Y_:G8J&[ZL]5!$4
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M,IF@0?#+%]15 2S%#HGDGJ?,(GSQ:)/-UR,H#X^.0RS'QZ8.)?%4)"/:4$H
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M_P!;62\+L<IH7PTRQTD]8P/<SC% QCHH&",!H$;!(61?S'F, 2296UUR OW
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M&J.N6@5<)SVI?DKB12:J[4NY6H<]/L&B:8!*V885"L)!)RJM3PN6Y2/#I]V
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M,0! JFY[AL#K74'5&*A\ ,T3K@E@^.O%5O1_2)S5-?>UDU->9]ON$/<_W"H
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M%U(QXJ\^@'FO8F+DA01^KV.'CERL=Q@]$QO<"!A:/Y;U:YJA,USQ;;_K%CB
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MADHT&8\#AFQ>(_3N&JI*/YXX)0\ZXE#<;=+*R,.:YCT(0H2,M- <-RM:JC%
MD W)0?OE)4V2OF@EW,V2D-*[06A"#FO7 @0:9A)F9$M.80VWW\.,;)7!RD /
M*;@>OC_=CA$Y(GJ1..*6L54V>,;2'9($(\_#X8XJ<<%K<" I.9( =X]-5Z8&
M0ISJ@4I+9&D'+(^0\0GF,!G1.6R\>*2',X3-:ZE$7V^H\B,M$/[<6LD:W3#/
M;(52'?NT2?U&<M( D,C7$IF3ZQHF2G'I+!#1D>"\]I>9B5#FVV^6'D-.4_\
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M\\/AAP("NJ_0Z^H&*JL57V>NE8^6CJVUDO'H)I&/FHS1ED]*YZ.#HVU,57)
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M#9B2K.O/Z>!T(\@1^[$^C#@H<K+^GM09#QUQ;TH%1J..2S;0MRR;\_['$^G
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M!H1U37'F[8<=Z]T1IPP9*D%'?!1AFX2(AD!_$Z\\^G3X=,$C(2BZK4%UE(A
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MVG%P-.*H=4NQ"XJ=2 F0US_OQS@E1.!B-1P1K#$%#0$T^WYKCD)_YD=T\0
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MVIU,PLW.D79$RMG5 \8$L1W4/>ODWN_I4HWX]4M1:S>Q'"0&![:_!3"O[/\
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M1D5SV-7JN$+0)![5HW?+$_Y0GC:!F#GUU0D_$X+(-B@NZS(/Q0IH?O\ ,G$
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M'J=-Z@8O^C*3Q_RG./9P7IKUN&\V>H!Y&#$_S"K%N*D%Q'W(.;RO>XN_.?\
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M",'15FS4^?[L2N6T^6.4'EBO-=<6$M)<*K:@Q7PW-S!Q?5$XA5,",*KW>_\
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M$5?-Z>TQU$U<13Q4PE#O=D]0BB+@UP]S8#(H!4%$Q>.TG*0$<2K7=U&,3*5
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MD&(/V^V:^P>X^OVMSMX[+9SU[<Q$YR'YLXQY?S$<6&2LE[?VV*S6BEW.#)G
M%[MSAN+@"\':X[G^(\%QVLZW"^)=4N?N+YE5DZL=3%([W6,W(3O)VMWE J@9
MKUTPR#P6+*!%.*,(H8Y"Y^TC>=R)DKLB0TA2@*9(AP35DEYE@CFD;! TEKHP
M@+4:#ZF)^$-5/Q.7RP.5O57- -TX$%%L,-HGOU.+OL_*R. C=+M*..K5=D%'
M7&)O]O$ F0?A1/6;]T0>R2) (LYWSRQ<:IY+9053)7PQ;9)GR1"1S 3D[VA&
MS<J HF,#]C/<3(MQ.AV=>JZ3J,/W>Z(!X/A\5SZ_7OW)DYIR[EETI7-%/8K'
M9.#4<K9"]DK6N%UO-0P @,89:_VO^+:O3'V;V;TX]/Z?;M2\\Y&X1VL #W!U
M\G]_[Z.ZW]Z=DO;MQC;!XYR;O+*D;O524]^HWRDMF>:EE$/8DV%TI:Q\439'
M,+HF>[3@CJHR.>7TK:S,?@OC^[&KQ*M]DK>)\'N%N1[KG?!R&.NFI&-=3FCL
MU)R5U#1;:R5TU1-^;:A<P N]L.0AS2-H$7;T3^5QCW+"D90ME_,QP^W)1_J;
MU)9>.TT=VI8*22I=#5-L\+YJ"JJV0%TEN=?&4DE.)(H'DS!DK#([>P$H$QHQ
MM&[=,;<B0!4X@<6?[8I4WX6K'JW8Z7KIJ">#@-]^2 6SF]7>)[I_TL4=3+Q'
MD='Z&N>ZN?36F6IBJIQN#G.IV40#(P2QCP'@*7[F?V8M@5)&H=U<$G<ZCZPE
MZ<&EI/>P<$]G#^*1E/4W.NM5WK6DSTDAI:RZ;]CS'<J6HBB95M4"03SP3%RY
M[ED)7;DR1;$XC.H'80:=B2M7)RMW)9%B>T$5^_XJ<O8GF')+]25-DDFJKFZ2
MII62LN3FRR5,=15M@IHVN>N\RFG8NY1O:1D2A\;U';PMW-5L !LL%[38W3=@
MQ'B_$JV?DG(;M:+KPRGO1-MN5WXG>*6.UOGIIZR"*R7>*ZNIY3%&70QBEIF[
MWJ'%\SB,@,>4].,A+37Q/\EZV]>G;E;C.DS ALZ%_N^:=;CE?4WF^T%VIJG\
MU-0ST=&]SY?ZA0P076VVZ\FW5+U=&6&":0M8=(P]BG),Z_;TQ,3F_+#-.V9F
M=Z-V-3$@<14 L4]_,N*05%NN='22MH[S81!R#BUTDD7^N6*X;'5]KF> 'QW6
MTB5KW>HN]MK)6A"#C'A.8E&1#QD\9#@1@>P_P6Q>M1,)0%+D&E$OYHG$=L?I
M56I?25W:N7)^ \=DO[/S];;_ '>.<J26G?+'7VUD3:*Z1M>\2NGKZ)T;RU@)
MD <$4#">ULQVN^E:B? ^J/8<OB"E^J&>[V@OS\YB8R[11^_%60V*H@?::MD+
M@Z-],]S2J@M>PH?LQ]<V5^-ZQ&0.2^+[NQ*Q?E"6+J-O /Y=SY6S^%EQF S.
MGJ(0=%!QKDNW8LR%-?:4L*F?925#@?PM.:#Q/748OFE]1$2.2E+P]Y?Q6QN.
MIIXS\?2$\NN,R;"1[2M";Z(L/RCZ!+^\S 6EB'^!A^;43X'/%P3I 1;D1H/8
MI+=D*K?0QA?X&$]3D#KY_P!V&ML7D0>"SP/$2I0U!W1Q^;5'V!O[\.%N]7G4
M 9:3]P1>2CF_!$Z8'B544HM-8?0#JA^&)&!XKI5D"HD?443_ *;N*(I@FS\/
M2B?//&+U&A^"/M\>]<__ #8?_P!T:%S0H%='D=/5$&H@(SVCY8K$M$#B@71J
MWUHC^8J0ULJ?Y3 IR:&_B7<F2'_"F"Q"TKP8E08^I7F8?<9J&&8"*"+VFLZ/
M>%,CW '-7(%ZIC8V-K47."S;LY6XRB6XA5(?4-?*I_$ZFUTKW?G>15M+9Z5K
M/QNEKZAD#0QJES@3)TR48W(@1#%>?ZA<)V\H#SR8#M*Z*_IUX=#VY[&=N.*Q
M1^U_1N*6L2Q[0US932,?+N &I>XGXXS-1U2EF25O" M0MV8X0A$=X%?F@O:H
MR7[O'7UCB7Q022,:X$G.)P*Z(H<?NQG=;GZ72SQ)'S3O2=O.YU,-@ 2_8E']
M5',YH[Q3<;IIG)3T],R0,S_ZB?U-8X#-4<%QG^V]L/0E?.?W+4ZW>_YJ-H^2
M,?F49_2+PF6_=^N$VY\9?%; ;K5^DN3\NUK(WO.@5\G@N6-3>'59%L5,Y ?>
M5YO>@RC&U_-<'P%?N72?>:QMLL,<:AK8J;4:(&CIETPQ.X+=H/@ J".J4I?E
MR7-%^J7WF5\?&*>I),\SY)6-?G[;'#TO /I#D(^&,SIX-[<RN'C]@$O?\5YQ
M^6+?%<Z%YNKZR_VZG#V_SKE#'H5>3-F<W$>HI\\>E #)2YY#(KJD_3!LABX[
M0U&T9[#H<@(US4!'$XSMV0=V()G91:))& 'SJN@3CS-M/$!IM!^&;DR\@,,;
M8/*J+N"\GY(^G"%?$#^R>>"S#2;) #:%H"=?+ Y/DJ%\EJ<,SY_-<+3!$JHU
MHTTYA%TT6UQ<-"I0#S_NQ /%$6K:'#5<]4^['.W8N(=:\U&:YC)<1*.8567I
M]1+40C/X^7WXHQ4+S9HI0G0?[5Q(B^*E>["-=.I^'SQ<,.U<Q6P  9E1EJ/]
M^(>M,59J50Z$ ,! UU^6GW8Y<A8R"?-<-0BP!2K5<(3 J'Y98-;\]%<CPN4/
M8/2/'/\ ;BEPD2JIA$$/FMP!55R33PPQ$O$*^:]74 YC[O#%EW+-;FE0OR/Q
MQR@!EECE)7B=<U^..=5TYU=?(<2H8J@7O!%LND3$(WQS*GI&1(^U1CR%EJKU
M>YE^GW*KGZEJ&G%IJ2]FU6A?2B.#@A)4-(*=<:=J9H"O)W0'JE-]-U'3"S48
M8,G1,+G9@$$ @N09G/1 @Q-V>+H&YB/2C2BM.[9TT7Y>% $;$T( $SZC+HN6
M/,[I]<EH]+ T!/1%#LJ1M'@0GI"(B>!7 K-+@6G<-*8.@EW:1(TIJ I^[[<:
M1YI:9JG#XJ"*0. Z(%.0*9$+AFR6"!*LJX)ON]DTC^(7.-C7.<ZEE8W:"3FP
MJ=,D7"VXD33F%:!(A(#)<@GU&4+[5W5Y 98_:=+5R3O4.:YX,A:NH_&"N/1[
M8O9 & "S;L=%TP&7X*6OT+5KI;\ZED<OM5S'L:XEHVO:S:0,@<S]N,SJ(TS$
MN(3>V(].8.;+IPX'M;:J$C_YWB77,[04^_"UG"B;O?U",F3C>2_?@[G4X""U
M%[HH^PZCXIH<6U54,O,2_%0V817=!_T[C\D4C/QQ6Z^A$L^;N3>VJE@=7/FD
M#7.#SM5%5KO X2A&.MRM"!,XD<DH;]?:.UTQ5S6N#2C?@.H!ZX9NWA#PQQ9#
M$69P64?>27F2YA\CB=GK(S1 Y.GD!EA,$DN:E&/D3(W!T@?(%\<D\>F: CP.
M&@:4P63<C5\TG6SO;* ]<CU)S7H5ZY8L#7DAL62IMLN]J$EHRR)4%WCEJ<2<
M$>'#-*^F;Z ?2"BG/,Y@+FFJX <46."!5P82T(- J@$Y$)X  8H0^/%-VRB^
M:H9"QH:6D9D@$*3UTR.1\L=$59'G(,P0.>KFFA(].TM*-3IX>&ASP>,0(N,4
MB[S8X*(_>NG9-!/D2]C20 3U\0G0*?AAVSY4G=/ZIX)A^U5N;47Z(0N:V6.J
MB*^/J"E?,8)+G@Q2]QZ$*Y?MK$8[13M<%)A8%4= T_[,9\?,>U:CCT(OBG3C
M=EKF,_EB_-#!HQ5.OU1]V.V_'>[/.>/7.^45BN]KKX/S-)7/;3^Y/6VZAN J
MJ=CO5)353*G)P53NQY'J6QN3WDYVH^ EZ<<U]O\ :'5[-KHUFSN+GZH!%<@]
M!\**%K^^' 9ZY]%2\CM52R1Y<(H:IC@7;B'.8%&]H=X!%TS&$_V=T5D""%[:
M'4]K(M&<3V%)'N954_+>.5--35LVRKC2"NH2))(GD.(5HRDC35KD^1Q-D&U,
M%A0X(F\'[JSH!(<8A5.<B^GN:W<N?R6\72FDIH*MMQDKF&J95,GW 05!@>\D
MS2%A:&L<?<+3F@)&W;W(N 1B""O,1Z+=C/7<D# 5H[J7=BO''>'\5AOLLSZF
M6KI(Y3)-*QE54MVD>R'O:_VX8VCU-8W:2H#7%7X]ML>G=-L]/_=W"#=G%W.7
M(<Q]N*Z_OQLA(@&4AA$4?OX<4D:OZ\N#<4LOY'AG';ARN^/NIM\4-'3$T\=4
MU[F.DB8X2U$_MH7&5P!V-)#AECSL^CVK^\-W4/3.>?\ !><ZE[ZO1V_[>U"1
MD,L(=N+R32]_>Y_->Z_$J62KKKE!15,0ECL,1GM]/65!?((*IT5,[WZC\H=B
MQ5(DC=[AS#@!AP[+;;6'Z0\;XFI^W8O+V>L=0ZKN(G<2(LMY1X8OV8GO=/-]
M*';*#B-KHYG4T(N=P:":C8_W-DH#Q[C')EO<0&HYP'4X\3UJ^;EPP!\ 7UWV
M_%K#R UG[!7B\!MKJ+C-GI;A4R30Q,CDBIMQ8T$QAI?(O\R5S 0UI>7;6Y-0
M8^?[JX97#II%ROIFU'IVXD>;2*\N')+1_'Z6KND%3-&S\A#%NE1K=DDC91L
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M;@X#?1U/#N31NKHN'2VRIC-RJ[ :F!L,\HA;<K!67""%K)VB62&J%%5.@9(
MYKHGQ-<US2X8\[M_#Z@F*"7R('W_ 'KT^]CZGI&V1ZA@#WQ<4/%BWP3A?1/S
MJ6LY+R>P4UU-!+7Q4,TGYC=3.I+W9*K\K6P3M.XQB:!S0V1@R14((&%>HP-N
MY;N1I5G[:BOQ5-D8W[%VV:L 6YX'[O@KYN"W9LG&_P#.WSP4;H*@!^_:_P!K
M)P>@:^.4G<UP 4'Y8]AT'<@V=!. 7SCW#LS;OZVQ9-;P4AETY.Q5<ZN<[,ZA
M",NF2X]D)$B/8%XS2QD /S%*"[2^U0UA5 &O/R"9I^W#.)29?#)2NX*LG#./
M.'2GCR4>KT@A?\00C&1>\Q[5J$-&#_RCZ)>WZ0"SN!R_D@CRS7PRR^>"/0!&
M-(A/QV#N#)((V!Q/H:-?\)!S!ZX:VWG)6<1I=\5,21^Z&)"IV(O34=</2/A^
MW!5D7+#$#ZET <XES#HJD@^9R&*!E!)H1]G6NL=Z!]_QRRQRXT->"B1]1#O_
M -'KBF2T\Q7RVG,'+&'U$O-N8^B9VPH3DN?_ +@3-INY%++(6LC95,?(]R$
M-A4#<>J8B <195,7W%J7^;[DLH^<44=)*R&9KG"%^PN(!5,RF10#/+#D(MBM
M&X(&KU59O>3EK;MR"XO$@="V1\<9S!=&PIZD!.94GXX]%L[1C;!S-5YO<W3.
MZ=7%0SH+2_NA]2'8_MY&U\\+N517^X,B)+6TEI(JOYK4(##)M )PW<(C;)/V
MR69*Q^ZWEFR['6_<*_<NG"]54/'^,U$@(CBM]L]M@)0 0P;&-4+DK1C,T_E"
M] 9:KAG+.OQ2/^EVVNK:^OODS2#+-),][B45S]^Y3D5&13H<8'N:XUF-@8FO
MP7I.@0$K]RYP 'Q3&]SKH_F/?-EMC=[D,O('R/*@AM-0$N<"A0^B$+T&[&OT
M^S^TZ3$G'1\RLK?3.YZJV1E\@K0_T[N(MNG<WF_+C&74]K9!9J21/2V0$2SA
MASSS"ZYC 'C.Y"#G5$:OC1([F&K>QD]+<2?C0?!E:%WFY)'9..7"8R;!'329
MJG\.9!3+3$;N>FV0AQB(Q>9HSE<57UU=TG<O[L<D?^;]V"WROI8P4(C<QSMS
MOX@K<E7+7#72K6C; D>(K,=[?J'SR)^5/H%7!Q^J-TY_8(&D.:*\.+2%R:6$
MC(Y%0<_B<:X#!^*6O2:!79W^FQ8_RO!;9,YCFNDC8?4"-&@#4G,?OQD[DOO
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MPA5A_4[;]UMJ6-8Y&@C:1_Q9_AZC0?'#UHU"\IN?#.3HP^G1@99Z6-"HA;\
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M ?Y!]$XE\>PV@(A_D9KU37YXF!<A6D?TA$\%EV4#:*\R58>6P3%LCET:6/\
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MR6DOE:I1=,VDZ)UQD7NJ2D=%HM]$[;VXK*;D!1GY!]>'!K4]XJ>0T46TE/\
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MWVQ-W>3@14VA+X.%79W8[>4=!P^HN\=,P54L7YIFV ,)9-1.FE1YW2&&&,O
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M_4K[14L-<XNVR-_, S.:)"'/W1,*Y >"YX]7M=D;4?4S:HX+&WV\AU'28Q,
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MQZNW8%B @/\ %>?V=L0MU;U#C_CR2,Y9S3V;?$#)MC#=JC( ;7;B0[;N!<U
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M'33UU11.3VJF"&=\;9*=Y<K) ='>DG1;=RY,68MJ!..!;[QQ2/7C9C&5W41
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M.8D'#CX,58M]55_DM_9+E;H9_P R^WT]?"6->R0RT+)9WTY+&E7QFED#7$9
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M@F1R!RP&=)5R3]FEGPYXJ!7*>"<EY!W\LES>VGDL=)71S4?L/;_*I;.Y7AS
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MN;2N>0CGDM]OMMQN+]\1LQ(NQA&=007H0W=4#-?.NJ'86;(A<D);><YP,@7
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M4^>X+]Y_LO7#)D'<*N"Q+@4.2?!?@?MQ&HY+EI<[+7('+]@^S$._:N1;5O\
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M@W*L;]1IKADR)N@9)BY:)VTA4R7Y]WUK6B[T/?ZXW:KB?$+HZL9M#"X1LBJ
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M\3W(OJ7IUG(/V?Q2^9RV[N3TVT]5]N33,D@[\2-[>?)5F)E@3GD$(/,+NT
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MC6P3< 7H+LPYD: D]SX*@SE=:^NK:B9[_P"=45$CR$S&Y^X[4" G<.F/16P
M$G,Z(B IDDE>HA0O9&Y%-(R9S=I)_F'( *-I&"PD)!\DO=&F6E6O?I9\3H;S
MW5J.47-@>RP6QL5*K0YL<]8Y9'DD;A_):0/CCS'N*YI$+/Y)FO<M/I4?US=+
M/&);M/\ !7.?47W+LU@X[7D5(:&12D )HR-P;F2$4C+XX\I*(O7&BS )NY.-
MF!$Y#602N5;O=]5_/3W<EL?;^IJIZF6I#06>X^$-?*YF>QI!)Z$+\,>CL;:Q
MZ0E<%=*\9O>LW)[CT]L?#' C-="'T16?E-]X+9KIRL3R5]=20F7\T#[CGR-8
MZ1Q71AS(\L86YCKO&,<'^55N>WH;Z5D[K>N=1SX/1@K Z/MK9IJXRSTD4DH&
MR(%C2&;D4*G4C%?VL'().E;.ZOB,0PJI&\([:V:WP,>RDB$C@"XF-F>:@
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MO%E\<]U?W+L&U=Z=T$:Y2!B;^ #N#Z8Q/*18<!FK!FM#&AK0 &A &@-: -
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M=5.7@H*8K]5)P0N-Y"9G('-<\_CYXXKD-843)>NJ_P"W+$@.J2"'0/!(^U/
M=<0H(2BB4@ ]&Y'7YIUQ0XJ$-B(0JF61.0_MGCL"I0D.S10/- /LUQ(H.:@D
MD-DLMVU7'7373S\QY8L:8<%0#%G06:=@:<P3U3/XH,\4<DUP5P&%%'_O_P!Y
M;'V6[9\JYWR"M92TEFM%;51;GM#YYXZ>1T,4;7$%SWO  3J1BD@9?IQ\Q5Q
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MEKNF2BEW0)--5_!W3R<0/-<8&Z/B3UJD0 H!"\BTW^OE4-?O]MN>2.<0[4Z
M#+$VXD@2"-;:,R3@R$6Z\U_.N2TE!2[GT5'-'[C@I:YX+5 VY* ,,S&B ,L4
M+<W92( K'AQ5MG9OCO\ 3[12-+ -L<8S!S+?(ZZX<V$,)#!G^*6O2!D?@I&
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M?6U?5'54D[*;D'&'3@>B6IM,X/J 0O\ R]0&Z)F _7'JK'7K@+7H? KS-SI
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MFJH[/Y8\[TS:"YN!*=1&O?DO0]1W9AM](H33NS4MZ"C_ #19NR8UNT99$ A
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M#!-775-DWN<-^[8YI&Q&@/</4P$%KPQ4+<CG]K(=+'7$U2,I:B2U7,5-OF?
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MUT. QJ>2)+@C.()ZB2!\%!ZY988@&0Y5*"UM06QDJC=253=\>FN*7)M04*F
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MHPW_ (EK,DS)& [@D6B1V(^TC&=Z(D,W^%4EOIDM/].[;V7<WU5$ GD.2K(
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MEJ!:*TK=Z%R(MRI=/!2/MM=<:V*%SWN<"T!!NZ#/!+(F:*X/V_!*B&@E?LW
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M\E,+AG!*>W0,:R!C2&MT: W+3I]V/1;>R"!+-UCSD+41B7Q*=,6ME)"'EJ$
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M2$9.)!!\CC-ZAUC;;&7IP8RX#[RM/IO0C* %F A#B0AEB^E^TP4X_-43G2R
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M[L%G[/I'4NISE'I^VOWY0#R%NW*;=ND%N3H\HKY:;BT&*XV^9[>D-;32[@4
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M:^(4\EV,,D8/N!Q <U7 9JFN1\NF(G>)%*(?[*$IJPWM?P^.V6FA=%'L6-I
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M3OG?FF3I'$CRQZ[I^Z&XV[_F%%YKJ=J-F^3$,"FU!PR"LE_BOOOQ*AUX2?\
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M%,EW'MD<DUJNK& OJJ*>U5#P,S+1._,4A=EM+C#,\!>C,*;@$-(YIFT7>W'
M'^!_%4B_5S5"/ZDN2T^T;F6'A4D@8" ]_P#I>UH\@$+Z44KG@8+S(^V 5K=
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MXI:Z!$T6MY,3D/1=?!<6P0V=:IJD;5.8 Z9Z!?#08L9,$:%N1DDO63KN)\P
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MNF6)39U8E0<>BI*:-IRDV>IV2+M0Y$#33+KCQ=^\9$DKVNWM",0,T'N=ND?
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M]$PG)\"G1($'2:I15%3>K8^GY%:6[J=Q]NMA#G%KXPXGU1AP&XGTDAHTR*'
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M^6]8C*/>0(R'=(+ZK+^Q?]I?<<2; %O>3P]#<ESSTZI _!6<=C.\]/W<X?\
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MK9/VNY)R=\CI)>==S>Y'+_>?M+YH[QRRXU%._<P[7-,&A&K4UQ%J0C>D(C
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M)6__ $D=T?\ 1';ODG)Y7!]+<*J>LCBF&4S+90NCA>!N!=%^8+@H50"F,?\
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MTL$-X!W5KN-WVEB%4ZEEI)6-D8XN]EX$A:&O:XG?&2@Z?'"%VV"YS6C:O$2
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M+5.I>9&V^V14C"/Y<+(1FBH-KCDNK\-W3IB+86="I,D@:MP:UC5'IC:,_O\
MVX7F7;@F[-9/FR*Z8))NT:2H\_'[=<"(^":P%4L*"1N^%$W%P!SR )'08M&A
MYH%U]))P6R;:)I TD.;(Y0A7\1((\DQ.?>J48-C1UC=1N-)/G_,B= [3\<9#
MF+XG:\XZ3,%>T6,H\U2O^J/PZ:FYCVA[E4;/3<N.WCB%PEV__-7';I'>+>I"
M^M])?I0/*/ 9Q)+C!E8 L1DZAI:^7VYG'MKYXQ/%&P/C<?6PA@)1I*GU81G
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M7B-[O[OJ&,27*->*_J*1V!K+34WTPS1C8&R3N"Y$@N<UP(#FCKU&+RVCS,I
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M>@[="4"GS7 C9F*@.$.5QRXH4_M!Q_CE?;W"FN$$D@W!C2YGX 3IM0(O5>F
M2MQ)8XJ8SED@E/(VTO=2/;%/"XEF1#GY@@([5PSP$Q:3(C$E+*QP1QS^Y3H-
MQ4^IH < TN#202'AI0A.N*E-P\J7<"33,:YI<X(&!2" %V[6H5(&14ZYXH2,
M5<#@G1H)HZ.@]IS=^]K1M#FAHU+M&KZ6A<4<%4D#@DS?:DQ1MFMCC)#&%JHM
M-VT*'-! R)^_RQ>+-10 YKB@ANE)<K>*9F4DOI1R.SS#F%0U6Y>(T3%W"@P,
M2FWBJY+%=BPR.IXIY?\ -1H&W\&W)P:U[NHR_=B)1$@B"9<54C.*\VJZ*&GI
MHYY'P.<PQE06YN4-4 N(CZ'(YY84,-!JC>H0&"LW^FCN;<;G4T=MK:MH]ES'
M1K(-Y+?PEH0*FI.H"G +T1$Z@G;%TD")70Y]-O=<72EIK+<9/^KHQ''3R^Z$
MFBVAX:"6@N+5R3#VUOG6)2Q(6%U/9QM1,K0_2.7!.-]8G%W<\[+&X0-?45O
M.5<:YS2MC#BM/05PM]V VM?O M5RDD* #^7TQH3FT2>1^:R]J&N:?Y@D!V\J
MIY;; *>5VYS&'4-0( GIS5W48R+D0 76I'PQ[%CRE[J>KO;9"3(32SD D N?
M2,!<%.15F?4ICK?E"X!P6P3H_1>MU[L5$I4ML_&[U7R>I4=4NIJ"(N1=35%%
MQH[2#[F/($K/ZC<;92B/S2 ^_P"Y6>5DFPDH5)37[SX 8U+A;M6/9!(?)84R
M."D9^(Z:=>N!!'(JV2/J=J9J26@>:KCN:EBMDSMVT=$.J'KY?''"H5CP3A<5
MA%):ZJN> '53S&Q2 ?:@5IUZ/D)/RPW:&FV9G$I"](SN"&02:GF]^L>\J6M<
M413GN37H$P$_-2].T_1 I?5,0-%T.OF?G@9(/P35H-!^;HRIX]H U(T.J$C3
M/SQ1%H(U^B%QOVDCH0%(&:>7A\.N.Y%1*-'"$U6;XGC+?"U5/@YP3Y!!BQ+,
M^!0(0U MC5;Z?^;%/$6C^9&]@'B=JM3K^(8(*4.859DD M0%,MW9XV>8=KNX
MO%0W=-=>)WC\HT@.2XVZG==;>=I0DBNH68#("42,F1XG28RD78U[%RM]\MHH
M:F8@@.B)<T(H49-&@S)^S'6I5B.:8W)TVU2KS^\R6WEE;(QHVE[SO)<@ <"\
M ;4(<IZ]$QJ$^*B\\30MBZF_]-MZ_.PPF(@-DA) !!*!"40JXJ3KUUSPM>#Q
M<9)[ILM43$\58%QWDU3Q:KH;@ _;'*R0.12 '-*Z[0@"8SY@5!3E^#CPY55B
M?!/J=X]5VN)EQJ&-FBA "2-:XD9;2UR .:<*CU .]&L]0\ A*V3(#X_51W[]
M]ZX^2"5M%,!2PL<U@!"9Y+GJYWW+ABQ"/]21<H!C<W$Q<N>&/#OHJM^3<PEF
MOSFPU,H/NE&L<FA7<Y.H.7PQHQT&/B )2-R<8W=(Q=.?9>57.*VQEM=(-S1F
M7E'#7/-05SPL8Q,F8.M& !MI&\BYI?X9"X53G@*03F2W-I&1Z[O'%HVX)2[X
M)>%:K'W=O%K*>EQ=D\A6N)!0+FG3--<1+:PD:*UK=SMAHED>7?ZBZ>"C>RLB
M+'H&[VR@M7PU<CD7 QL"<"&3$>I78EY$%0B[R?4-9ZV&:/WW$$%C@W80/%I\
M%!ZY ##=G91@,D/=]:N2CIB*JH?O;R"W<D,[A+ZMTDC24&9540(7$)UZX;C:
M%HZ1@LR,Y79>K)5F<PX\Z2]/JJ&:.,S/<B/<W:02"YK,^IR T.>&3&CLE+DP
M)G@G9X'QBL=3Q1U$SI0-[8P7ES!M5I>PJ=KG H<U).!$%TS:#VZIZ*>QW2G
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MDK5RUJ+?Q5A?$(FU%+$87-<XL#@8W@^>8!_;A*<0[Y*\X$TS2OFEN-.XC^:
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M8QSLFMW.)#040-PCO(2%N@R3>RD/7#X.HEU%33Q231O&W9(X$JF8R*J,D7&
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MCU48+KC*.0*6G9?$)=U-?VOY[:S3<CL\EHND@VBI9'-1RB4L=M<A#F@[O$?
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MEBT<*XJ8GQ,]"@E^8CH)T.US6AW\2$>C,ZYY8F67!4LDDF/ J@_ZI^+4]O\
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M4).JH@7Y8M&].)%70KAL3RTE,ER+Z=:2>&H>:-DCW=?:S*ZE0A*+AR._F,7
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MV"4UP[%\?()%%"",LF!6E,]IUT\<3&])4EH&(="[+P:EL3PR"/:T9IGF ?M
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MM7$>W=ZKJ[W)J:6*"%7JX-/N/:%$;6@D@D=4U(3%;VYMQ@T2Y*MM[%R5QR&
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MHI'4^7QP00;%#,G+H-44R* T = "$'AHN*D<%(*)JJ,BDJF.!):T2-.2#VW
MGPP)B'!1P1JC(8(MHG;FM=J@ /0_,AVF)B:EE:3N.U&5TA]^VO< 08$> NY&
MY!Q550)B3XAR"H)Z;I(Q)[%1_P#J 4DEK[QVJ[L>(!?.!V&61P5'2VNLNEK>
MYR *_P!NF8GP QF[EHW.3!-Q\H!Y_BH2BNNLT;'1U3GL(:K04#L\T711]YP
MRXE0+0QB'*PI(:Z>I9[ZOS&J-.TID=0?GG@<I@"BMH(J<5(+AG'J2K9$R>$+
MM"N#0' $(--<9M^[(8)S;P!+2J$_EJ[>4WMM="US@0"OXOD1IA+7(U.*>&C"
M(9D<5?&Q11"*)P:4&[)/2- <O'%7?%1J," <%MM5HG=)MD]N5CB @S.F9&61
M7[L=C08J1*,Z53JVWBFR)K]@WN&H&;0J'71Q&+^C,AU33")<.49?Z9;J]6IG
MGFGFJ:G%A9.:DD9,@5QX_3,I7JT/Z(0-N95!B\K8$>:M&>12 DMD0F:&QM 7
M(;<LCU'GA9T"1D#4HWKK5"+8S="PER:M"@%2.F1.),:.<TP+A%0:A-=/PJVW
M.J)EI8W$N((+<B%VY^/C\L6A(AA@J7+\KF)='DG9?CU11-::&%Q>S-(P"TIT
M500,.B-T@$2*I+T_+0247.Y_TFV#D+*AIME._P!UDC2XPC^+1"<B<],L/V[I
M@ "X(S2U[;VI5@ 2V"BU9OH4L-INKZIEIC9(9%+FTX38"H*] %S^.&)[NX:1
MD0L^STN%N>LPQ^"?VW_3C:[91/C-#3ANP[@^,$Y ?XNBCI\L#.XG+FM/TY"/
MF":OD'T[VBIGD(HX"20"#$UP13H0,&CN)"+N04#2328!/%#^*=E+=Q^:-T5&
MQK8WJC6)DH(('0XZ=^1QJ5T;8=X@!2.MT3;=3-B8=H#4":(C@GD$PO4U.*<B
M1"#%!:NX%VX-+B?P]4'E]OVXLP"!*1*+:=LD[_QHN69)\R 5R3'.J8U"75IM
M]."WW9FH"%(R4)DN*R*+$#N3IVI]LI6L_FM4 #) ,AX]5'VX%)RC1B1DE;%R
M*U4S6DSL4:@N  R'BF1QV% $0 @59"HN4T=20V.2,M=X(5R3Y'%)&8&%%4GB
MC9D3*INYJ%0/'-<O%,+7!JJ%QB)>(X+ V9KB26#5.N2+D/+"Y![U0Q Q062P
MM)T7P("H51%/]V(TG%5(EE@M7] _X?N;IX:_?B-*G3-.=1EONM!0@N"G7KYI
MJN/62(6#'$*1O#+G;8:..)\L4;VM*M<0"5S&NN*0\-PR.")<C*8+(XY!R.DI
MJ=SXRQQ *(5)(T\>N)NW(GP19BIM6I?F=,C6\YJ65@(E<@>"C79(N:]$ 7"$
MR/4\)S6M9MP]-B!J*?ZPU<%^L[8ZJ..I@JJ<1S0R-$D<D<C2',<UR@@@XU+0
MC=MF-P C @U!2<P;5WPEB% +ZDOI!?-27/E_:^E E DJKAQII'\TA7/DH%0,
M<F>W0^1QY;JG1/0D=SL 39%3#,<X\N5>2]/TWJXN1]"_2XU#QY*@;N[#6T%Q
MK*&LIYZ.KII)8:FDJ(W03P21DA[)8W@%CP0B:?+%-G(&*?W(!-,&5??<^-]5
MNC&YSG[AN'4A0A\SGF.J8]%M#X76!O1DH.<SX5=ZO?)2P/DU"-! )0E%(3:X
M',>/3&Q:N0 Q7G;MJ9DX3X?37;+O8;Q3MJH9!$&MW!VX[6^D_P 3$"'3+IA+
MJ,WAX4]TJ$X[@.&.:MQLW*88:"E:2'Q-8QSE4'-.A&3@.FAQY6<:KVL2 $O+
M5>:*M.Z(ACU5S2C2Y5S0'7X8"00K#BELVX/9"T-"'4*=4].A)U&%Y#BK8(C%
MR>:D1DY;D!4C8GJ :=-,9VZ81*-8&J06^Z5+C H)_!HN6?4#33,]1CR>\EXB
M0O7]/ML$V\L[_>=F6@.U&0 S3(A%\\9@G5:@#8)=< Y1+QODEMN)D(I_?C9.
M"2![3G@:+F<>G]I==N=!ZW9WL)-;U-+L*\[[LZ#:]Q] W'2[GGG Z3F)# JQ
MM\SN36ZDDMTNZEJ8HY7O80AWL:7#(KZO#'[:Z;U#;;W:PWMH@VIBG;_!?S_Z
MKTO>;#>W.G7HF-ZW(@]V?>M5/QEM&J, +1KD%.9">.6'Y[N)# I&&S,"\L5L
MEMX+'-R!:=4ZY*,BAP6S,DH=Z( 9F*#W+E$/#+)5U,SA[YBD]I?$M]/P.YP3
MSP?<%P)9)6T9&1@,3FHPV&IN/*+W7WFY.D>9IG&(/5PB;O!:QA.@35-3CSO5
M&TB(I+%>DZ7X9,?*$\MI@9&Z)?5\1F/B-<L9%F'C!.*V]W<,K+1P3>?4O7PV
MGM)R"J?M_P"[N#02F>QQ^?\ ?C9VY82.0@5@6@9[NV1@)/\ !4<\][?#F/#*
M>\6VE$]3"TRS"%H)<I)<XDIGF<L>9WL#/4/S"H7NNE[FW;OZ)EG"J<[_ %!;
M[1:KB\M_*54+9&>RY(W%X:]J("Q?<>NNBX\KN35I9+V^RK>Y:55'S.F=8X6W
MN5[355+R^EAR:C% 9[@ ]0]*IDH'QPK&.HMDMK4&-*(BI.X%+<Z2.BNM)'%*
MP@15<;07M<4#R2BH3T<'@#+SQ!L$>*%0JF>L,:$(MEM]+/70OA+9F-+)9)HT
MV-:'!"!DYR[5VH#GBQD8Q[5: ,BI$\<GGFH:>+VY!#[0<2&O8R1=NV/VI=PD
M!0 9*22F,R;F:T(P,6<5HKW?TZ/T@.\?U@5=OY9R6TUG;_M4Y\4C[Q5T#J6\
M<@C<62'^E0U+(_8IG1Y&H<QV[^$=< NSC;\)K=RC^)R^JU(1VNTAZ^^.D@L+
M8\Y//,#FRZW^UGZ5GT:_39P9])2<"L%ROT=$(:B\W*CIKI=ZBI<Q'225U:R6
M7>'9J-N$]Q=O2#3EI RC0#[<T$=9WE^X+6RA"WMWP &',XD]ZD/]*'T]=D>V
M[[M6V'@]FIJR[W":H;5&W4[YIGEY.Y\GM?PC\(S&7PPO9@-Q+U;[R@*-E\/O
M1>L;_>2D+5J9C !RQ:O<I&<FX7QODO-K;3P6:CV4!:%%/$&QIZI3M#0,@@P.
M]MK-V\(PB-+T HA;2_=L=.N3N2)G.@JCOC=BAM'<_P!JCC%-3^RGMQY,+FL&
M89D "#BUJT+>X BP *B4Q_LH&)$OO4SZ.VTM73MCGC:FT!=H709C+-5QOV;$
M+D2X7F97;EN;Q-7156< HWDOI#[,@5P,7\L;BOAZ25/7'3V$<8EC\TS#?W<)
M@$?$?-)"X6/DEI=[E-(Z>-NK51_VM!:[+R&$[EG<6C2HY_BF;=_;717PE9V[
MDU1"[VKC3O:[12U'9)EHAQUNY(TF&(5;NV$O%;D#]LTK(7V:Z@M=(ULCAEOV
MM=]X"_##$(PD:T*5D=Q:&#Q")+MQR:G8]T#63Q$$EK@'@@CJ/X3B+EK32A'R
M5[5Z%VAI+@FBO'#N/7CW(;K:Z<^X"W^;"US"N11Q&1SPC/:VR[T^B=M[B]9(
M-HFG/[E%KN!],MC(J)Z&STM?0S*Y]*^!DC UV9VMVD YY)C,W&PN0>5IV^V:
MV]KU/U6C*7IW/D5 _NQ]%''.46NJAI;+#!+*'(QU,7/@<\?A$A ("%$(082M
MB["3U [?BM*[N8S(]33IS^WV[%0I]4'T0<D[57P7>STTM#)OD*T['B&5KR7%
ML[-H:S=XHA\M<:MF_"0#N'X_=Q0S9]:V90.H#+M53G='@]QFND\5VIRRJ8?;
MD$[2Q\8<YVV1KQZ'1DZ$+UZX>MSB1Q"S[MJ<2Q#43"W?MI+8MKY::4T-:QW\
MSVR(VR*YR!P";4(3XX,.(2A!>N*K[[R\(H;9>ZF=D0C)+IO<C8K)%.KM PH?
MN^.-+;79:=(2UZW&?C.*:;C_ "FMX]<*=]),XQQ3QO<Q2TR,:X)N&;2-H1#I
MBU[;QNQ<XLNL[HVY>GB%9AVA[@35++9.][6LJ&QN>P$$>MC2X!'(-SG9+UTQ
MAW;(B6%5KSN  <%(;EEJ@N%*VX4>TF9G\Q<G KFV1P  (<.FN YJT3QP4<^6
MV..HHJFEDC]L.:DK4VC<YI!4[?\ UA"Y9E<7C0N@R;510)YC#5<3OC&6@2Q4
MQ>Z22(@O:'*!(&N (+7/!\TR.-6RUV!UXI+<#008J1':'N6/S4(IJO;*SVA4
M1//H:C4<YC2CMF\9Y(,L!NV0:2"O9N US"L:XOS"<QT-ZH)@VKI#'*US)  Y
MT:N 4.R0Z%"F,*]:8F& *V-O?PD,0K]OI2[_ -I[H]MGV^Y/+KW;*>&&=K'*
M9I*<M<R9S07.&\L^3@4.>$91-OPDN^"T)@7--V&:LVXIRNY7/C5#;N/1R5?Y
M^..,L8\* YJ.9(YR!C2N?EEBM2<V29:,O%^56Z6"HIN/\4XQQV-FQEEX[9;;
MF26@TENIHG(4"CW6DY=,>LC/3:C#(1'T7CKH-RY.8'FD3\T#?=)75&]I.TN1
M5(4*IT4JHQ64^"M&TT?%YDXW'>5-@V0U+B?PCW'$)GGZ@,P1IB871A+!5-LX
MC).K:WQWBH@B@</YSO4YNC(V@OD>O@U@)^.#Q!F0!@@S:$=1\R,^37:,I24W
MIAA:(F;3H&-#4R^&#SD"6& H$K"$I5Q.)22I(WS2-:027.&FJ'P/G@1!Q;)&
MD84BY#%.1:;?L8STJ1XH$77P\<6C$FD<$,^&B4 B8P>H-!!Z$GHOVYX*(Z1S
M0]3E>.F: 0NW3Y(F?SQ4R#U4@57F^.0$*W<FGP_O.)>)4L44UD:LJ&?PR0R#
M)%4MRU^& S#'DKQQ#\4B[?*UKG-<XY$MZZ@E"=,P,4";D"<,4L*,LF+HGE8Y
M(S$Y>NX9Y*AZ8L"\N2'=;2+@\S_%4T?J4<;GGY-VNJXFEKOZ+R>W2EJG>*.[
M4%1$UR*A KG$?'&7U B)B^+%,VFNPID5!;C7'IDCB>U2!GN&X,"DC+,ZGY>>
M,F]?C"/-.VK9D=(3@4W%7"<?RAZB,R 5 1WV9X3-\G%,?M7-4^7#;#[18K-$
MTUR(\<@#@$[CHHMBV=,5)BPVYK(F@M4;5\->F61..@[A5+B5$)NEEBJG.+6A
MC]NU ,BF0^!3KBTHN252535 ;99'03>IF34*$9%-"$\\=&V7JN8MX<4LX#)
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M$RTM(UTCXVNW")TCP0P:9!0<>@M;35 .  V)7CI;[=[B<O3U  L3DZA3R/\
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MJMW=BQUO ^3/@JGP1/@A94>K<)*8,:X+D=[57+,X#>!M2]6#NRZ7]+4SEZJ
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MR_@A\'<"GF"1>Y*1DD;'/&>7\*A5\\5EMO3#$H$O;LX^8Q':MLG.(V!KGPR
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M+R4K-LAR*ISKSW][N5%(;3+R.IFI9/Y?MN#W2@;=BCU/>U7)D3Y:X,+<2'9
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MNE;[E0VI:TC<I>PD!V9&:+ABWU+>P(\9(?@@SZ78E5R!PI_C\TO?_IH^1?\
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MY#X8."\4*7AN4P.*3%ZGEDBDB_X'M53T'5,*;B)E BN!6EL_!>A<_P P^JK
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M,0ZD.*I%5A]NN84)VR-)*#(;NJ8R[@\;YE:D"\8R3P6G^90A"OHUTS\CXXO
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M8TQU&<XJ#")Q ^"%5G++[20%M+=:V-!_ZNHE;J-"-Q0+XXM&,2:@.AFW!F
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MXAEXY8+&,Z U*B=Z,/#&@2XH. 2%/<1@ZJ$=\@F"B$D(SD*LG-LW'Z"TL#R
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MX#GCW)S:2AIJ2,,BC:QH:/P[0I&F@Z8<$1BDS<+^&B$G:T99?8G^_%G PP4
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M]D_YC\4(;W0JU04="-$_Z>--0?#0+CO]PO\ "/P4'81Q>7Q0F/NK<0Y!2T3
MI0B%OPU3+7%H;_< ZAI?L0KFRAI().'%&[.[EUC#0V.E:B@I"WI\2')\-,,?
M[ON\*?!9DNEV2<2MT?=^\%V3:;HO\H#[,ROVE<=_NV\-' [D,]+L\2R&-[PW
MP?A, UR$+0OQRQQZGN\S\EQZ=;CY2LF]W+Z]Q+S'M*>D1L&7FH\L5&_W)/F<
M]B%/91CFMS>ZMZ<2/=B8/$1,("_+08M^]W1_-\D+]M;'%EC/W5O#6E*AF8(
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MIJ:CD'YAP<T[0"6@@A$!"' KDB^D&B8L63(F7!06Y/#<N4U;A-+(]KW-0*2
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M%7_"%!^6+"%%0WFDPKDO)+4P EK&C:%R"($7P\/V8KI&"L9OVI-U?&X)#O\
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M$,D3E"@A)&-<"OV8-J!HIC=MG!>,N]LE.4\)5 1[C7%I34(53'..*XW 7'%
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M:D#,H?W_ "Q) R51J!J"OJ*HBHXYS-*QK&@N]3FHC0244C3RQ4#XKKT92.H
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MVE5T\">F+RE1HKK5JNJ02'N@>5(_$2HRS 3/7+ _RJ[?J%O,D[!,6R([7)-
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M?Y730<)X-';^3BL@AVA\H>[:TKJA71 <5O/<@47UX2(C5P589Q98J:%FYV3
M$)S &0'P"8KMXD N@[B0,Z)U[7(06JY5 \@I^>:8/FESBR6U/M<QOP"I_;PQ
M=D%B2AD;PTH#FJ#73]V. #55D>T<Q:FXY>"A ?'[,2#\5242>Q*RDJ@X(2J
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MCE8]Z%E1&6N:YC7$$!VY=%R=U^.&K@!\0P25DF,='"B8GNYR2"G[:UMK8_\
MGW:YV:W-CU]#:UMTG.:.],%M*E-2,([Z6G:&)S('W_<G=G#5N(G*+D_!E$=F
MYQ!* #Y^)T&,*/ +;>A0C,IFH\#]R9Y8A51_8RPSAKE")F1EF=/BN(+.JRDP
M3Z\?A8WVR@)49GHF>7AAF HDY$R*<I@ :$\!\3Y@_P!EP>)XI"8!-*K,DG7+
MJ0-1FGQSQVFC!#=:7C+P5<_+7/1,NOEBI![T6( %0B^4J<SI]W^W%2F(AHLZ
M+9B/454=0,T\<L\54\LE%?OI>64MHKAO +HG- !\ 2?BB],*SB3<I@$[,F-A
MQDN,_P#59YXR&S\EC]TG=%4Q- <"\O.]H+6(7'TCP0?;CZ!T*P)&$NPKQ'5Y
MB=UCB*?%<F]1)[\\C@2YTDKG%Q4EV]RDH@.NOW8],3JDJ1&D <ET)_I:]AWN
MHK9=ZJG<9[E/'5OWL(<!(X$-"YG:P*F,#J^XA&>@'RA4Z?9GNM_(B@ %>078
M'V,^EKM?=+/2"\\.M549XF.J"^DC>'R2 EQ1S"CBN/%;K>7A)HRQ7N[6UVUR
MWJN6H2AV!/??/T]_IDY"Q*OM[:(I'- <^*EB8?'\+6AITP(;W=C\Y2MWIW2[
MN-D1)_ED1\@E?VJ^BKL-VEIZZEL'#;6^&M<7O_-4L<QW/503)O4 >7PP.YN=
MU=(US+!6VFQV6QU?MH.9L^LZNX.E;>_I,[!\A!;<.WMBD+R2OY&G5<TS]M="
M=<#C=O1\LY(MVQLKW]:Q:/8X^A3-W_\ 35^F"_ESW\)HJ1[@@=2Q-A#=4 V!
MI&9R3+#5O?;N(83*2'2NDC_TIQ[)G[TR]^_1]^GZY^XZV.N-JE>59^7JYVB,
M]$!>6(#Y)AB/4][$CQ..;?@E#T785TW;X&3L63>V;]&GB%@Y;8^06[FEUDI;
M/=*2Y&BFEB?'**6?WV0N5F[87#/-4P:75MU*)@6J,A7[<TM<Z#&0,;=\Z3QB
M'5WO%;/%QZQVNS0D&.WTL-.PYH1$P-"@HNF,T<UN3/A S$0*<@R6$9_MIBP2
M4B1B$.A0Y*0<B4\/@1G@HHAU*9?NS9F5EJK&EH<K' !,BK?@BKY:83W$6&L'
M K6V\A.TTL%R6_JH=J8+SQGDD,E*V5E31UK9!L!):8)&J0JA[-Z@IH,>AZ3>
M!D#F*KRO7K G SC0CZBH7#C<Z*2V72OMDH=OH:ZIHWA?4#3SOB* %"7;,>ZB
M7 /)*1.J EF0NCS]$WF9I74UN=)M-%=Y(!Z@ &NE;("A5QW!^73&1UBV) C(
MQ=)]/_3ZQ,2\DF/Q#?4+LW_U(W_M/_U-W?+QTU\\>"]*7_UKW^L<?RLIHE2<
M@I/E\@,\L_VXV%B!:W*=-OAIGX_MP.40#S7#Y+.<^Y2E,SFNX?\ #T7/7"UP
M>!,V?#<8(KL)VUY;F07-S'BN$XEB>"UB/ PJ0EC<(OYD<H7\0'@A7Y],,0>I
M46L-*7?&HH;C<*:EG<_:]@*-(W= -<M<.;?>3VDQ=M@&0.?-*SVL-Q&4)N(D
M%23H."V=U-&[^>,E/J;FI4_PJ1CT0]R;\"@MMV'\5AGV]LIUD;CGG_!&D7!;
M2T>AM0<]?<'D,LLL2/<G4#60A\$"[[9Z;,:9Z_\ Q?P0UO";4F8F*)D9,_,_
MA0XO_P#(NH'^3X+.N^V.BQH1,GAJ_@CFVV:DM<3XZ9B,<\.<'E2H ;X#),9^
M\WM[?7!/<-J 8,&3FQV=CIUDV-D#&V9.7+E\,43\RI_=L%=&R-KG24U7$&)D
M\R4LK$S.:[DPA=#P(&)!^BV-C<GZT3,FDXGYKC_Y&)(;[>H@-GL7>YQ;5/I=
M%63M+?\ $ S;YH<>1VT#Z<7X!?I<WP;,"#^0?0)-NDD.37N"C//3X$(H"98<
MT#@E)7B^++Z.:4)ZW!"AW..1!.00Z)^W%)0B<%0723BE33RD1Q@YEJ>:>)3+
M7"DX53,;PTOFR.(Y7^R]Q/4$=$<XJ$:X)F#XG!;<0*)"_(U*&43P\L:[J41R
M:HJJ$S=^S#T(@1=9AN$RJEE11L85R+RU$ " J@&1_$!BX([U+IA>_P#53SV+
M^FP$Y_SY6]4#AF0JE %Q,"-;I+> >F3FJSN:V)_='CE]_J-4VFM]@>8XZ5LN
MT2^TX@!NW0R.8%7#;Z).,UA7"9_%#N7=X*'MKV"H**S5XBK7T#H!3Q/V[7AO
MM!FH5YU\,"M0$[TI<$&=TQAH%'H@'Z+_ -!_(/K(^IJI[]]Q[;+6]N> 7TU5
M.*N R4=]Y/%(V6!BR,VRTEK(WG^'W2T=,,CQ%O\ U9@@<AG+[AWG));S?#8[
M65Z0$KII$/C+CQ8#YK]!2RV6AXY:J.SVV".GI:*&."*.)C6M#8V!@  #0 @^
M[&G8M"S;$(X +P ,K]XW+A>1))YH\H;4ZHD]V0$M5<T^P>)RP4L3@H./A)=T
MK8Z>.G:&QM "=.OQQ8552!&@0>KE$<:*-Q5!UT_9BDRQ4@.BE@S+G:N]1\CK
MCHNRJ<76N5P<ISR!TS&81<L4E)Y,BVX,#,\&""0TTDK@T YG/+Q\<3B5#-'3
MF?M1+NV6LQQB1[20T @% O7-<2 ]13FJR &.*)^37B*@@D:9  P $D#MOVD%
MP<B>(^],1Y:F@4PAK+9.H?\ ->027>H?&UY]H$@-+E&I&X:YX7N3?!:-J&FA
M";^DMM.U^]X&XD.7JI*DZ>. AD6<Y.PHE= QC6A$R4')?@4.6"#!D$DH6V!%
M=HN@'W9=,7;X(!D">:&4\1>0$U*=-#_=CBJDYY)5TU,V%@=X?+KI\AB=+AS@
MJ@(#7MDKP:9C=S7$@@9_!,5YJ06DZ0,CZ_B=P$NYXIY"W<-  \Z],@#BF!88
MIZ M[FV1A<"=.UU,=RA;4F5IW!=NX$%-4T(3!82![4II()@<4'N-1 6%H1 B
M*57[LU.+2(PS4'@D)5S>WN"Y%0 ,L#D0%(!(?)-S?JMKV/:JJ'#4>>A(RP2
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M "#:FF;( HV@DH$5,D\%P[$%G"5-W3/24.X3+34M^;+<)S%%$2U@$;WKD4_
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M6N*Y>!!1/GAATJ _:@=:UPIS*=2"5^2_=B&JI,GH,$SEWKBZ61G0E,AH.O\
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M_FS3[\;[BU5514]#'[NX4PC]T)N:X@-&YH(:X(>J8*+LA0I.5B!GKS=(*ON
MNE?5UC9/=8Z<Q,D"I)'3 0M>T: /+2[YX0O2,KA)341HC18,! \SG]N*#Y+C
M6BVM)7_8?CF5S5,<R[ZA!IKBRBG#W$ @*T9+EGJ>@3%XQ)JEIEJ)2V?G4<4L
M8,Z$%N6\#)=5.+SE*V"[(]F,;C U*=NA[A4[F,!J(R4 )!"!0/-4PG^[8MFF
M9=/X):6[E,-8&D2->I'7)-!X##%N^)EGQ25W:2B*Q2H;4"9H+2<T^>2(OGA@
M%TJ8EV-1P0:4IE\_/+IB">=%VD#$52/Y-4>S12%2/04!S*@.^*X!>D!!$M1)
M+A4Q_6QR5U/8+NDA"1RZ'H&%3D<@-V>"]-G'6'K5DMO]M=E;U!Z1_BN%+ZVZ
M2Y<RY_7U+&OD;2S3JQK2\-:9'%Y: 4&9U3]N/J&P,#8J0_\ !>).JS=P)C7Z
MI)_1+VBGOG="EKJF!Q%+)&R(;?2W>]I+T(W=!U'7$;Z[Z5I@WB^Y#W-V4YPA
M#(NNYGZ)^W3;9:+2[V5+(J=?0 "-L8?EHB#'@>HWO$=2]WTS;"%B#5B(N>]7
M2\=I126^*(#/8T*F0R")U!RQBQJ'*T;P+@)0+J#J-<E7I\,L0Y!?)!6Q=<\R
M0<7#%=]5N8F7@3F I*)\NN)0R [E#6.ZC0??X?[<5&+*"Q',(5&I0:!5_MGK
M@HHJ-1#6$@!/'/\ MUQ)54/B**$*N3Y)XXL77 @%#6N(TT\!GFB#I\\6'-1,
MZ@Q0Z-ZHI&::G+P0>?EBXD4M*!%"B^^1>]12-3,Y'RU&FF0.(D=0<8)C;$VS
M*)\U%4K]8_ A?+%=(_;+BZ"8+M&Y?46D%OJ(3]F [/="U*0ED7"-N;1W#Q:D
MHZ?BN/SOI]-<CNZ%VK?RKEJ"7-(8X-#PXEOK.UH8 Y/5FN/76>L1A:$8F@6'
MMN@2C C2]PR)[T_7TA]D)^/]R;7</RCVM_DLW%FT.#)0X[F[CU'S PMN^LQG
M P)R1S[>N^K"ZS %=(_]$F\!_P#$7V^G]^F,/]Y:XYK7_P!ME]RM'U0JB!?
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M;:'  E0$"=%.N&(6A :KGP0;EXW"T4CN6\XH[93RM$[(VM!!)(:YV>0 4'/
M;UZFHT@CV=M(G"I40.:=Q9+E+-%'/MC4@,7\>:JYPRZ8S[FY<T-%KVMJ 0P3
M;Q7#\R_<XDDHJ'JN9.F66%];GDF90,0C^GF@C9N+FYY@'X%1I@\<*):0+KR:
MY0  !X73_;KICB0,:*#"1H$"=5^\TAA4#0Y9^(RQ(*XVV*$6ZE+Y-Q&I&?B#
M]ZXL%0A\<$XM&8Z>F5Q *',]2-,%.+)&;&=$E;S?8J1KY'/:T!3F<QU U7/$
M5DX&**+8B:U*@YWY[U5%)0U-NM\Y8=CP71O+3FH/J\4UQ;;VC*>HDF' HEPB
MT'PN'#DH"</O%7<^1RW">HEEEDF+G%SR6@DD A<D3YX8O 1AI H@7KLYP D:
MJ7=COM1::JCK(9GA@+'.:''/11D<R<9I!_XE%FZ8$ ^53IX?=?Z_;Z69B/)8
MQV7P&74 JNF&(2U1KBBWH")<8%*'D%<VCH9&RY(UWDA0Y=%5<L$ ?#%#@ 2H
MZU-T$]9(-VKL@$1%0'%9R>5$U&#!RB.Z(7M>OX7D-3+S4D?Q+B(AT.18\TK+
M/<&LI1&]P"-&6?\ AS'54_=BII3)5>KYIL^7U&Z9Y:?2\OT)Z'(ZZ*$P6 HB
M181)40.X,[A<H6[E4MW-T"%P3+IG]^&K7E2\0:D8%35^GJD+K7 [;EM!)*@E
MP: O3+"%RM[N1CX;5/YBGTY/4^U+'$#FN0'3(K]HP4,8N,70X@F-5'[D]P']
M28PDKN TS!W'J/$_9BK."4W"L0Z4=J>'M850$ D%$4!.GGTQ%NLFR47?*EG2
M/:TYYG0)_9,L,N'9*?5*:WR^IIZC,. .BC,]"<<K#YIPJ*0/B:NH R5?MQ0
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MGDN70 _;@0H2AW. 2Q;*6H&E2GX@>@^!ZG%G2R45OJNA*D!#X$'Q\R1@L"9
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M>:5KR&A2&MC:XC8T [3\1A:(8&<L2M$Q&F(B&"WVRF_*PM<U8W/+8HP,@"2
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MX;DE:^J# A.1&NN?QZXH0H$24(H9R)FG=DX@JJ#737QQ+LN(:0"-[[&70PS
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MNZ.D;2/3]O2Q9@(#L ;YXE?)/;-L=7ORW^Z+W;TC,]I+_(*^'L]8766T4S0
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M^>/C']V 8[W9O_\ 9G_YHK]&?V0D)=-Z@U?^9A_Y2L?J. D[.\PC !]R*W-
M(36Z4B?#)<?*+3^I'_5'_P P7W(>279]Z_*,^H$MF[]]XY8S*Y[NYW-(7E[M
MH]YM]J\@,\U\$!&/H\V]20'\Q^I7A;+BS'5P?YE-Q2.>UH+&.:UP4O:^0ASB
MXM>2!NR!)7SP:VX["JS$72BM]-+)41.;*2&S1/ <]H;O>\>K([\QDFN?3#!'
M@/!BE]0$@ !B!\U*:W0@4]." 2(6[]K&D$H'%2U =XZ(-<>'D^H]J]\?*_)'
M,UNFFM3Y&EQ89"Y'!QZC^%JD[1Y=/'&MTP@705YOJ?\ 3('\R)*6@_ITX<)
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MA#48,U4ID-$ZX-[W US;^9/>PY']G9_T#Z+H X$\BT0@ -_EM/S ^)ZC[L?
MM]_7/!U]GMGPOS3@0R;7@CQRSTS&$_HB52NIW[HP1ZE\0?!4ZZ8@,5QP=%M\
M874,Q&H:Y=5S ^T98- O+N0I!@R8F>GJ7S^@D>O4 D'QZ= ,6NBCH4 =5$?4
MU'<X6AX=)M(!R5"/\*:)^_&-=@"2ZVH/$(/5U]XI&N$4T@.:AP<=J%$"_MP
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M4G):.Z$,D<'!>I"N!4$-7737'1LR!=4EN!(-FG!XG;Z"JGC>R!3^+< I*E=
M"0H^P9X)*#!SBB[>?'%/1_2(O^P_^9%_RCI]FGWX!7YIW4>*Z,P50YA!H!XC
M(ZZKEX8W]2\2RRR *9J5\\OLZXEN*X8K)I*CH2BA>O7S\L\".)*L$U7,6N96
MR%I3UAPZYEH7/QUPG<\Y6CMSX$\G;^I=/;FP.<2#"W:"5_AR1J9:8)8\3Q*Z
M_$>&6:<^T6F45L;]J1O<%<A 4$'J@Z]<,P@8R=!NW7BV:07>R!L%HJC(W?M8
MYR@Y@Z>(\%Q]5]B3T2,PSB06=NO;_3_<6VN;#J /ISBSQ+2','ES4&)9#*YW
MM32;7?A;[K@",@C7@@!RC\.J_''W3:[G;W_ 1IN\#GV'[47YG]]_V@]P>VH3
MZATJ4MYT>(>1#^K; 'YX#$"OBC\ BB=TI):97*%/^8Y0NJM)5J@HB^.-2-J
MP ^"^)&=P4)+CM4FOIZ+G6?D>YQ<1=*;\2__ #HN1=FI7'P7^\< .H[)A_\
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M_,W%-Q)!>I"HC047%9?)+RF 0V"?/@;"UL3CFFW4G-0H.:KD>O7"K5*'>B[
M8I]VN>8&E=J9 $!R9*' (5.*9I4BJ^B9[X=%D 6([-%&A (09^6"Q\(1(1JD
MG;JB2P\B: =L4DZ*B!%&I\L_BF+S E%'Q[BI+N?'<J""7)SFAI7XIX=4PN"B
M@QF'S2GL\+61,:$:T]3F22BZ%1F,$#E3I P&(0;D#6QQN:TZ-)!\21UR R'^
M_!X#@HN']&N)31UM>VG%1(YR!K'$KH0T.*$E>ORQQJXS=)@.HQ<-J?\ 4W>.
MCHX2) :Y" K@#O)<$"A-OAI@4Y-$R'!-V@\ "K:N:U\5CX?24(>&'\LP;%0D
M; W\.>66 PD#IB.U0'D3<&2C0*X14DCO^T4GP1<R<.5;FNC<C&-'3*7NO/\
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M)I_]/W!R'*&0AP!.>PI\,?2O84M5V43Q!6KTJEU5@0\LJF$Q2%2'.W@Z92.
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MKF[8U=[DN6I^6!RD[-BI#@LR6]YOK+B&T5 W\I2M](VAH?(TC;O?D',8?#4
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M")FBX/"3XXJY%&."!]P*MDW&ZL$J&P2ZD _Y;U&>I./=^R[XCU>-O R#*-I
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M@$M*R%LL?_35MZ?_ #G;FO ;*ZG9M3(AKG+KC+WVYEM;&J(\4BPY)R%N4@#
MF-QZ'@ [GZ-Q76_QJV6SC]MI+3::>.CH*2%D44$3 UH#0  C0 '%,>3D92),
MJR*TX6XPB(QI'[?-+NFE!;& 5 'WDD%%T098N#3FASB7<9HQ:X#)?AF$R\/
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M 'U>??\ [)5__P"=*3'Z6_N?_P#X%M__ 'Q]"FNK_P!*[_\ R_O70?2_C?\
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M "I?^6?_ .5XDY*QQ2?[G_\ Q9['?^SY[_\ GFVX/=\D.S[T&/G*8ONE_P#
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MN>O;XZ\OB46*BHN4%BU64EJ\7$E):;GX1VGY?)$E_TX%HC9@R0*@&(B3DM
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M,?\@LXGZQWPV\<'N'C&).S1=HQ*!/UPV4<'J?R5W38A*G).[)$59N?X0*QQ
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MNH(8G:M;-L(;BREZ\?WI>J\?1>(6!*MGJOJ@V@E%!B]T5FZ)>US+V#L<_DM
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M\=W)F+W,\%^\5V[WG+HHL *)ZY?">[%IL8W>)6?69K#3:0V&O4]?/%LCK58
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M1CR80[CN^I3G-QTLH"-E\\#4@Z$6-FT>Y,-8U5W/"Q*0+G BKY."OB&GU+S
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MN]&=:K]]."DXQ@S;5O*;A.8A]B?KZ2V?]/]Z#^^_7R#JJ48*V_E'Q6QK,<M
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MX!$P3BLSM"G("> V?QO%[(C@KUAGSD;W#HPQJD51-"I?L8"]$$L+G196V1O
M()S5W-&&14F4DU4Q8BKG:]#OP&#O/^'PU?\W9W4XLON&0L$/%FRU])=AYG/\
MF3 :WP[\VVM#,>E95)4&U=L^@N"28K9ZZ&7%(ZAFJ(:]@L['3-KXV!8+ZQMY
MQ0K4. RAYQ6LOQXE(A^H4,,/@1U9U;4;2Y)JX(8$!:K8IW.2P- PJ6 K,;]?
M6Q:;"%&KWI$E<!LRK[LYJG@-I64K+0M0LTE**VGIFB54U?W+]]OCL31R/V+\
MXE>@2&Y];D2J:;!(9"[5Y(7N>54R<K'G7ZANXBB4R<<_'+R;Z, X?>'8D)XB
M&N]+'A4%=FF+3U[_+/])W))4K5+K3/TM!]Z=(63.GQ04!R:?XU_CU)M1DD!J
M_,F-<&/;KW;CJGY)J0K?>CSVB!U,!W6/6\ZL(-R8<8TT%J9\6MF<<O7NE=$%
M6V9=^=4G_7)$$+\GZAM]Q]OPKV%OSFA7SKQF\H+LXSN$F8>7;@V/$@;.LWOU
MI4%_-&[ ^[3*3>N^KJGNV?I9>U]V+1OI-&RA1$OZVB,D="J[QZ\>\?KO4@B\
MINJR+&/?BZA?)GJ4N+G/+J=G3<1&VF@*94:5^\DI3C#@P*K+9%TKR0G9L2TH
M[?Z-UA^B<_=^#9C*A'YKRKKVO\TD!]^5+/UO^<NQ>D+-B>2BB7)O].FS4&UW
M6]KIEI57B]#!) H9&P1%R5JB%;@:<*<=+[ ["P@[E,XMCO/.IEB8E\2;4(SX
MJ($^RTJ'9VX-0^:QPI0!1QC;90T=R J)I5F4=[77T(6"X'I@/Q;(L6_M5[Q.
M:.&/2$25>H<>$LNP$8%RP\BR;FWM4EZ _7<IKY&V^ <6W!^#QE(OT@/FPUYP
M!O(]'6C<$KB)>M=I5U@<5(8RBW1L_W$[I"=S2B$7ES\%O4)K,-;J+20^37J;
MZ[P"*U=A0[K4IMWHIKUS\C)*9.HPHI16;'==&S".#KL)JS+:W=6&I(BU:Q %
M*AW3NT5A+[,B?/V]L)F/9R1> ?^H61UPV6LX4);D8U&4OG[&V:P-.#]#+6,#
M_#*B\;CN=VL$O;C [&,A&A]VBS KMMWG;+3D+G(KI;S=3>I7ANJ<BR-$PF\>
MS'W7[H,+H^K-G] (KVX.2PT^%T=:-U3(J8HOSC[HYA"&. &4Z!=?Y)*08A>*
MB;7K_ @?PE##7B<?<J!95Z(?*U$.O[B?:0S ":>(ZC#N(58H_QA8C,+S;E$\
M\N*S5\LP3['4RI860;_XX/ :Q$"2W8C3Y%RI#UF5;Z7I$2)H*5AF<6\&\"&/
M/P2A*#)@;WEO]"L?X?X"(7(.7''F0W7#1G/!H3P9TQ-4G$:1\B;K/4JI.5\4
ML\V-89Q^=9=GUL?=#?T,OP=;%V'S@V'('".J*X85DI@O3\>2G92<?H&QMMG1
M\,XFJY@2$F0#B<2UL%&J7/B,@XKICLT(#VY35;U?"MY*%EM ((PH0*GDT=20
MR0P@%3*VI9&8-9&<D&$I)LQ)KH???9D45K+MIP,DD ]=<AIIQ+SJ6 7H)17+
M+,POD28[3B>I_"G!@=DXU<)LSQ]52=:)I/PS$](JYRNMOL8:(68-^E\Y?>96
MMH_EF4B*PETA]+W14$1]=&^(>18I%MEAJ<HDN4K$%!W\1[1WWV*5E!*U0XH:
MEA>Z=[E"'3 '_8[] PP=\1\QKV7H:"ZB7( C#N3O)[$HMFGT>C*'R0N3N?=S
M]?]8_D'N_;<5U"4#Y![")_WT=XQHJH@EB7N3:F*C,L;RE.Y71M,P="@P&;E,
M]!*"4IXR'G/RLLF-C1;AZ3Z0MAV\8V/F')+7B/8JZDMF+S)5(JG(,OHAL#GN
M/G$3JA\*'^O;Y%5@LUD1,2&.A?4>'!&*SA$*FU\I1M*>&&M(2U]M(#A&?O">
M\K4#%HKDMY:^Q.6#/]MR>ZVLBOU9U_=V+O"[O_10^W2L4]Q2<R?1\#%T9RQX
M6BCEZ*>T *D6?)),)5K\BO*P>!>P61 7!=PO$TB$WL.#$J0_$BHP<R756-A2
M.&EFZBH@O'_+GL@O!?L+YG]9D[9FUL)SD\X*?K0QQT%6UH0#8;#J3;S#A;I5
MP]R'Q7-F1UM?12Z=&#9O%G$^=(3X,[+Y74SH.H]#?I5KO";D+$RSB;P;W+?F
MU$S57LN^[M+#2VJC#[O$_LK\RJWV?!'1I;"WWW*EXTF!FV.(B^L"WRMY:7E7
M@AB,L9IM!];*4!EXQ'L7>X1A_<*%HV:(=I"^W.P/*/WMS]6V4FY9\ZS_/;KY
MOF06!D=L<JW9\MC>5&6>,@Q=\I?V5R GL3RVDOZ7(?OHS(+"VXE$WEF %DWH
M)NW;>+!YW;FM2CT['$YL@\O@TF;^AV>3_-VO'4-Q<CV+YY=F6[!IS$5LV#[Q
M7UB3R6PSZ@UB:Y29M3[KINYSUMWG;N(6F*3@K9D[K[; MXZ&PG@KNVS.]"*L
M.!\4#T!_$(U99/1*[SJZ^42%?DKSL?J44\( EP=.T/0D^B!NPB!N$C9R$F'C
M9".[_)F.6,PLWA;M_I)T^CZLSM&^>CATDVUG5O<<M>PR&7K!I9$@9N&D9&_%
M>]XMY/@B8CU93TF(S"H>R[QH]PX/B<JM[HW:(* (3NF_A>K>^H!@+5F!Y?FN
MW1@-47.='H:9\2;%T CM;<P&ZE5/1,00FQ3?!>18<^:*IVHZ%9S]I +ATE@:
M<B#.*<Q,@WN4'LS$D3)?DFCWINT(RL Q5X(3;<?-R>B>&L0)Q>41*;,&&#65
MA<U\Q-R1H?NM'!6VR)R!<7ESOP[BI.@'[$S):'CV0_VXRD*M?8LM*A6IJLXW
M@1272XQ;/C($)=K1^19Z7J9C3<3N\T?0Z&&+?"*B^O1AH&U1AHEYX2SFAXDJ
M5DZ"-CM0!SJ73Y5!,0\*E1G=(GK)-I8Q:'>>77CR[I%R3(-NQWIP6(E0NL]G
M0 V<-I;<O.MSF) [?/C!E8,XFQA R8G^;?P@;D_8-Y!;7J4(P5EAWZ%)S=,H
M#Z1<C;"H@\#YSN\Y%AL$ZLZ5\L_=A*[(6]B+T-\NES![9]S@3)#O6E6-N1TJ
MPGX<=1N\6G[N)->SJ$"$2F3WV)^B-BG<!G%8%&+W%&']!=]Q[Y"G!@U'#<PN
M6Y,5\.[.<C4P(>97FQC?-NN1?L7F?/ 1L9_;7XN<1]^\2>&TM)?<R&6!?PR,
M>V3+D5AZ>LT6X^8VQ8(5IC#SIS!U53.%.@:FT[7H/3%1\5]2-=]'@961JO\S
MNTEV%Z.AO,;3@,8QP<2OS'YNO<7'ND:L9,E12KJ9(&+DLF,6Y1-[A7*UM+E*
M3162=3Z^Q,\P4*O'-MM>6XAH5'=A_/;O6C/'R#7QT&WW2&CZ]T?2D:N4#NQK
MI_U.[ 1J-8A2]61F*A5,Y6#]1VU)4,//J_'<B'W8R'5WDU)1!$D7F580N?0%
M1](*QZYA=IX]RU+_F"94. Y#Y7L<A.5_]+KZB6:2\\*7&Q,AC@_*M8F]Y!Y/
M(T:4"Q7]T-,"N_3Z11 B=&XN$P@V;QLE"0]9SQYE9V57C'4SO!@^>AS)9Z=0
MAHJ4 T!;4O=40H:B>'8,68$NW49BK[&F\!5-6#+GUT7(IRR@/;B_5;1QE":K
M:H$Y+9W>2;$&-A?EG13]NF9Q$N%JF.O17<M/_IE5>+%PZQ7G+56/QFP]'C-J
M=C2B_/B\OKI9%[Q@X3@ONU1OSSU?HL9M?WCCY\\!K_%7"269Z*6^FG8T=VGB
MS;)M(899P".GCF1AAV4Y2H!Z%I/N&\-7'(]FQ'7^RNQ848T\?[-]H;%\.:\6
MA<_0)#QI]<W<,X5I>]M#9@9JHGTT,.!D>14A3"C_U!+";Q^>+I\2\WOT\^:X
M6;\]][;CJ7??LO]?+:H#@Q]*_K"#17SD6P^WF3UF[K("<.:PZ"=F&XR2$HP?
M_OHL,X3E5SJP*9;M]:5=5059Q6<+2TD;_2;9("A9;(IQUFD">J<E,N9XVL,<
M]-']D.W,PTD"[@R3P-N!?L\/XK^9PL"9]DZ?8@&YL$6M]+ +GKP0'_B3<051
M*L6L&X#H&U(')JM@0=SC-MAH49<SXY(6QFJ#:']:D2Q :2D:2.@TI0;DF(E0
MJI52Q1 \&X"NVU22/P/]'2"Z4'C+EFH^GPDLV#;%#(AH<!NZL[$&E< MQC8K
M61G.HGRXOZXC-205ZZ=$$1?<D<5>NP9V0K=$9?_'%J:POF#MRI:X[EMADP:@
M6W8KD%2EW6D+4QW0-F4XU_B8M:%K3! C1Y9[#Y?^PH%C+&+Y=2P%:XLU_S#.
M6_-I)Y+>/L@6DZ4H+,>H4_GDOYEO[Z#JOU;)7NP[AU<P(9],DZ 7OF0FGW/U
MF:S4GP[PRLU \94V>!MF0VST63H)9._9A"CUB) @?;3/PGS_V2_W3_$J0,G:
M-J#@V_KC S8#1&\6UKA5NG8IXG)K<^ W\/H6>H$MO+U;M!)%(A^BM\3<8685
M++4P#P 3X[2KSF:B2IR4N#-#GA0="?6_$G[6HG)T!V#+B8:T9Z3U0V7KKS:H
MOB1J3*AV)C2B?#+AS=@%7^3^*X60D<K_I-X3\M?1>+@H5/Y5U8D5MMTH(:L^
MA;/IAO[Z4/">6,%-TN::&>E_WK$33]R0523?O)YJ1<B-8<TAU:EA,^MN0C==
MW[%M4#4>UNPN."30,"[@R 3#:_LBS#H4.'"1,K%AU7UPA3C!&)[@^D\%!&L8
MNH]D?<?)+]O(SOX><?\ 95VA)P].'L+)>SF]+@ *:Z)P2[.[7.#W"$5US(&'
M@C*_*:"<_&X05^X)RZN^Y [B"LA]_D-CR50PZSHY?ZBPC@W$A HB3B"Y*S!7
M^C/<))3/1068H5=>"+>/;HUJ/KK:2HI"^>GG^O=)W#9LS- :$?@4)9L+O;#\
M;\^3,[V@=]TD\,+ZI$1L;, D$$]9).';1W8H2M'0EFC>RN+;45$"^1\)TT*H
M.57LSXB.!A6AV&0X-GIM/BZ(HE-%/"O%(K$&JO/=^\LAD.^!E>;?B'D?U)C3
M*8?H*<JQ^E@BL?:BZ(V@W/HG^/,FX ,=,:LI]2*0?G6+?DDMZ?!V9(:Z)1KS
ML1"CP0V_!;VGR"5(,"Q\%$6C"D\29\HQA%82#VG+,DP^9K%GQ20[?21"U%.2
MM+=KMYL8$E\[31QB^68RHM<H9:;=\HR($PLGI[1)^"! %74W!^K:%#\)S1GH
M1D*4W"0P(G:NW3NN4:T350F\5[G?)@J+#V3WUF)C5#$CWXYCWK9)?57L]U?3
M8^!>&]RFT3W;Y;@X2$"HV+<"]L#\W$P(N\<?TEP)99R^J/8"GBO$CVQ74XL4
M([\JQB(6&#BDZ-/<^2M6$UAFW++^@*(VV,<C/;']?'?QRY>3CC\93ON8U5Q9
M7_YIX;NU:\8F&J:IEX\A:3^L9UV3W2?<9 H'<6<'<0MK1R_\<W_I,8^XX[/^
MLJV;ANH=X A-=[7JS<35]/@5,6Y0,L' FO(^\ZRNYI/4V;;HL')ZD6/EWNV%
M.5DK/4Y->]G2ZT66&SM4D0>4S24ZNL.]NK$^6V=7'Q"&;7Q]@?+S).>[P0]5
MI_]7IK@'I24[<>?72]#XMM]LZ3#25H^>Z_Y:4"?SAH!J?.\4,H>Q0".]S?+2
M[HRJ(TJY:, 5E"=66-P/S1FQ-L:NH, P-!\SY.2^:IS,XG[A.$=/[DDMYWXF
M_2YK#QM&EA/;)*4]O5GEI3OFR>J2G;B]8@O!K?^)1K9LU@"T:"%%,U*=B0"W
MA>6-TBZ#YN5H^77M*AAH1!=FJ7N<6X:L(K@OJ=K&9$WS,2-:R5+->_VXNVQR
M^T[,^9E']<<3'DI@+F9"=E_:V*<-GXD^\!/B1KWN^O1>J-0D";B >=SI^V^9
M\,*[7D%'S?53*S$OZ+T9WC27:I)[QM0.CD0*QW>?US1TSJ.XW+5Y/(@[IN08
M.=%HX% 'S*1E#^(V8U8MTPB-<Y*SA+)[50)#!PCTML$]3=2?2<$%6Q[.);X#
M^ ,HAF%G;V@Z3_KV@;,'I .H*%!%]T2099<#@<X#KC#Y,<#7K71_P-QXF;3;
MMM-3[(V(V]15B@ 9;N$(L6HC1MX?;#S(/+C8:Q9T<ZPG)+VU>_V$2(-(K/RF
M6WI^=9,;5/-PQC&@D8;N5=#BAX)[H;X^X.]&&X,]*I+KT-">Z*D-/29R.^ZL
M*$ZFMA!-2]"+LE4N@S2OYX)N]DZLG%C2TE^9KW/,8Y* MCTH7#N?!H$)6B^<
MS7:3G=FRZ]IQ[X;'X(T203]!";)WXG!>9#T9@\2=*#7J6FFF8DZ4]]X4=6D$
MIZOJ<#23H*.9V23K'V#<^FD0!_)U2 /BJ>W)2_[1\)FTRS8=J"=WD>[+*Q@9
MR IXI3E> AD_-X2]*GDLQAR1ZD6H("C43#%;]MT0[7W'X8;\;3. $N]Q)% P
M[88P7%3Z)MQUG'!=UGO%&<QEB6GT*RZPKBYI^S>#57,3= J40,/4/50,K^7N
MW?_F,HM3\*AHJ1'3HB]NE4$!'\%K-DE<&MC3O)?[BV)[H@,'98GJ*D'(,%KG
MUNE*&!(3AN@IHRX\LQ%VPQ[G/8+A#4^G+7[B$WY,+<.AI'! 6&7O?-+]=L8[
M1KTOMBKTW9<< [%); _V2J'EC<C"#Y*7U4=H:)J>YJB2+G+V4*95P%#_C^_,
M\9[<35CF=;F#'C)C'?EWLK^]&<35(BNP5X]QWZ1: )/@T7XZ5="Z8NO+K0?%
M.C[0C^A:CU;=?N-+BIN+MX"<F)_L"&4*V_%"LT)H 1&V:6*@HJK3J4.#B4?K
MT/!X294346#77'M<(F"<NXM<-2N1%8!&]]8QL+5-/N.O?42NP/(Y:F(/.[AD
M-BHDIB. 2MS(JCC:D;K1_62$%U1[EO8-:UQ170.G.\N2Z3"Y46EF5= W-:P[
M+CN8'8[WM5J$FYW22'%.F-F:<<A//6]=>FTJ)7&A[M#(!_,+5SIZQ/#O^D[9
M1H^C:[K^?HM$_;QEZ[63=HH[&Y5[RYJW7QQSZDD^;TN9/O5+@BS@7>O#98<H
MRO-4WXT5VT9Y- +%['9C>5+GB[V]3SR:J]V?T(^(TD*VM/;]K5[I!HO"W[Y1
M58@4G&-Y%_-63EO[OC1G?\WM9_R>98?&;2]51>=<66FSGYE6:13W05]?,&;]
M]K>7W5W)_17>;_]G$516$NOBDG,6KT',R( E- [LC(C]3;[WJMP6+[&\%UH4
M50^'+9&^9L7)&KL3.'=KQ& 6J33T+[Q+R9EE(_)0O2\GTDQ9[ ?,K=7,BWEF
MB@DKF>ZGN)2XW[CSY "@)AJY^]K[M*]"VS@!;?8T?=D 6:ITYET:_X,'\P:6
MI$,W0G1]%1E?7S0NUVG(M^&TL-Q\Q(VQU%4*'[/LX2LF@:Z?CPAM81"$$XTY
MCZ&$%XMD3Z?887Y3A(\:U=WG55O472C1W? F7\&+G#09TJZ%%V#--TS"QXQ7
M/,I$>4*8#:*&*S 2$U5DDY6;;^" B#%>8I%4$9R+1G\5K:/E$Z7(3*5+@P2;
M1=166H&G%LK,'<<%BV?:%6PJL.$;5E@!/Z"5=#?^BSPUY-\=W*]>MVDI+-KC
M'8_<MX/+X(;,M0-0('P'YG: 'O\6GDIR_TP]Z8RLH LL0,+N/NV3_;EHZ+"S
M]$!GN-$&(_YA<7;2VN5"2X^1&RW&X0E".;T7)::ZD_1?&APK\MMDI33C92+G
M-E$! _M>9 NV#*MPW#UZS?E!G#J6IZ<?P"9%W6_B0P*'\L][5%5%1WV*.\ED
M&9O<:"GPC-B?167[;A8Z6U%F,[E#N5"6YUXQ%97MIPL$6\!?2S*_L2P**NCD
MD$Q6XP?LRS]6IQ*N%ZPD[3+C-;J2\I'[),7W;YLO+.)I)%9_5HYHL9M!0]HS
M["NZ-WLTNJPRQ6+<%(*QX0=!>,-Z@-\3[M[OJ_4B*'<+0F?[U!>_+"\3!W]
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M@]+;7I]E?UF!)ZE6GW)NJZ/[39^ UFF9YEX\$>3PRAO?)4#[9*_8(\2RXZB
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M4E1!G"IL:I3Z"#<=16-D&?J^ZP6*TV"33Q5(VB\ZO+TG-%,A"(+DZ3W,>JJ
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MN"U77=D@5HUV;DO_DOUB=0W5O3Q"*@>]#76O10(X ZQ-.E+/%T6)$NP=ATW
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MLCO:%TT!5KNM&P,R%"_4Y,GH/HH:#(A)694AT(?.7>$$5VYLD+./@B-:JQZ
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M60L(S-0]*(5O9]FW/!!ZQ(PKX+L7+UD4M&<#Z-LW*P<S!@<,V[U.+Y*YHC"
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M:Z+WANT--@]KNZS5SHB3T=?Z5+HL6FB#XC6HCD?_3ULX,_GLPC'JN%13O'N
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MK.>]]43AMJ1\0]SQJ@DRQW'-SNTCO:<;=G +*,^U1N(+ ]SO7OQ3/0[ON*8
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MB&7;RW\I-8%M]:EV/7\^_,<9--3N.D3XVG(U Y5&Y])>J,D?.[@M2O9_L^S
M9N\/G$N*99L4V:!3YI=Q/+Y=(?MZ'Z.^;CO]XV([1"R*QO^-)<<H'X"B??/_
M&?UPS@]]W"!Y-X;JFVM7$P7]#H':.U :4XT3 1J?:&FV&>]!(I#B^>?U&%=D
MC:C,D=+1>,KL['8<;7^Q*_-W1MJM+<]W0JTD9B3_*+Q8G9UDQB_SR#G !\!
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MFU4)?$WD_R3AP6LG4XR'H+ODY@-3#I5;N; ZQA,G?B1K@84V]HTS%W*O$=X
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M,2- 4F%F0:TK;)*!%,:5^>,-2Z;EGL;Q^6(UXZ^8=Q1MPA#A'FH7,BYX6%^
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M T\> M5^KH3B8D:J/I^E.NO:_V !8+3YPH9M@C5'7O$*NM(Q+QR!+V6\,*Q
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M36LK+=%2D+>$6>_+2?K><@=3<(WR_Z-?IP3P7#KMY#.>=N7JUX'%7$_2\4[
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MEN@BCUBM!>0G&H?[B?07:;\CF>#WMKOZ+-A+EDPB2?H4D/::SN9D]<$N=7[
M4?2FT":-HWH]:15_=CV#F*YT>,XK[$)=PXD*=?U+,IU K72UHHZ[;5R7)*Z/
MY2EIT!8DK_Q=&AD[:.53@E%^:L^2$#J $F2T0T_8G,KKG>*1*O%@-^7M@2[
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M$U"IJCP_R*M0?T^R(5G9AE:_T7"L441ST8)^4M%I.II@Y3#SIW]>QP>1;3G
M+?#3"<_K+RJ05V!JEG-C[?BQH7OH8C*P95MMR<A(9OZD2M]MB!Z5.V5A6<S\
MLY6*/EM-]JK@C*]4$<<%(BR95(9+;4+V@/G>2QXN"=DR9#!TO;+TV6+/X*LQ
MD1P/+_A!\5TH!4W7ZJM^-%W4WI-\D9\C0.!U9<O?1;6%IV&\'G\A#;6.'NT
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MIK>JU"<[%6%8_ZHEC*VMJ_\3+(OAR9C8H'1$:%!JA7:8&+K1(GR3%64N>MZ
MNZIJH3_]3T_U,+F*(CKKN66?-M7<DNH_D%.7MHU>!!9QM(N!V[K+)_G\$&RK
MZH.W3QXT#C#]5T;[7W#>=A6M4;P-^;EHF^(UP\765\G6CUW_11K!0%Y/YT4,
MZ!Z+W>P)>>>L(]<.\W[C9U/&9T5R<=5"-Z4F0#=*:&<X%'1)9N4:"ZF&,JUL
MLH\OTU;=@PD#$VB2>2*EYX9G.KROQ]$:F;P3L,)(8B5,A!^\N U=X,DK.V!3
M%79J'YU2AL\0H!Y9& 7 &Y/%/Y<9( XB/D$U8Z W(-7B?RRE"VJ;-W6ZOH1'
M5\+KU)Z\W!^*RH(X=.HY*+O9"NW'N3S)G519'V(6O&R-F9+1CK##1[0^(':1
M5>@S@7J)A7I-C YW<G/&=O:PMR((J\<UC*F^6\?/G11.FU88^!B5XBX^ [R"
M2OG:@-L'!1F-B:S?25$?F]XD\*-S\\;L0V9[$5WD+%/Z:\,=NW]AJ&,^>8:W
MY)-NHU)RZ<L%%!TY"\R9 '*Z2LKY^I,=Z .A\Z[UW@;U'4Y-P6T'W <"8#Y1
M8%UP\J'%----6!CTS6'&4N^(D4:TD1KWM*MPK#&1,S?4BX!'WRR+ZKH4O!_]
M.MAL)\\/%!F@K.1CI8^\OF[,*IH&Q"\[K7D+CZ@S:B7SD\G+GB2CJ))0\5KE
M([08+*TK#=RLL7-H;0B"02%7F(AZKXXS;5:EHB\ 'B0V,"+>:J8D7,(_8[.M
MB'DT/"#Q6$1F3U>ZQI.33=-7&[<+[[IZR;_T)JD)67)0(HT8/@)$XNGE8 .3
MO3;&9^3PI\>2O:;]\7QH\G(_@X?>JE&TLVU%3M!NKG<]^!2[$&9B+>L-6<IX
M(L)$CBDMP7$U 9I4)11M7&)C_2YX>#%L$/<(&&?HA^4KVIIR[^CH"Y().Y3U
M3ELT^_>:AP63?*'_4P>_DDPGI<RC_?B99.4- ?5>8775_3UKT;^U  QPF^#T
MR1Y\VHQ--STY4,YXQK13FQ:$%_PP3-E75@KM963J[Q]%21;/A:6+!Q55?<JU
MCSS5LG*\N^ +DN$<8(Z9B(GD;DJ:U)=SB@IW+C-_CN:GT;Y"E7-\LKEESB=G
MQ: /HHE# .=F:'Z.&#QQ#95K*&=_HEDUVL&G3D 9W!)Z:PYV35DUR]NQM7C
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M,?,4PXW;U[E$9TF%VF*:=R:443"O*F?,1*H!)I 07<U;.I^<@D61P<BE=38
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M*-,5D2?8#FKQRYTA_1F[X"I?K5=\JG]=P!9X;Y!:?]6;EX.F0N+<E.(]<.&
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M!F-&#H"R3T:5CM[9]!GQ"NX8PS*[A0?<N9DY\B:U'TDDX\I$0YV49D7=S],
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MN8!92\ZA5!1OUJPA]=7KVW>@.JI-8\0UN9^-K;-4:\J5__5T"?QPB!IE.![
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MI=2K[C/FEUYO@A_/::0Q^T,T&K#.-S%*Q]XJDV$E!ZQ!Y#'JS82TQF1'L@\
MPE^)\1+.9'K)(3=BT]":L<-EK]@J'))MH,:H7VAH70KJ*S\\QA"=!"Q([G8;
MKI<3C>5I(U65(YT4H9.RQ4GI& FF>@W?EVGG;>PT@KWU8P3\"@+OR-Z]T_?N
MG:3(DD-.2B86P])#3VR:&J'C9Z2R<65QZ3A$"ASZ#4Z*12P&BX@%/GDFP9;<
M$PZKPD*^5YWCI9CP'(+6SC-U@RDY-[%QTZW2F;B)3:;7;=$5-_L =W'":Q-6
M3PYDIN\;#RWNI*@6@STP@6< VZXU#4P4,B_>26&DL,F$TY=RX-/Y(+J+9'XK
M\/Q*BW+&-54VP(@M!HS& R40^T8LOL XGVE*X9))RL4<1+VKDN!45=ORF=A6
M?7A\4^!EPDEY#GS-B[P.%&X];YQZJW2ZUZY25QYV,6='.0M X"<)[^5U\BYO
M&%#NB&DK'WK-W LGX^<K&F)'1S+P)A5\KPE6I%[ =7PG9<F'8?RXT_J#I@<W
MLB2./!/\%NI\;OW[K"^P:[M\-28_FB6K\%@M1IROTKSKT!H>;UB2DP*KZQWP
M,P_RFLA/Y1T=.X_HBD?4"9"!$3ZKT(;_L@LQK119Z^NR50V\X;B]4>$IZ@TR
MV#V)YX.QV+?Q\-N^>%?F;+B_Q+38A&XRP>I"R)A?H"N[,4AH<Q@C!I R53HI
MU_N,XINEA=#>][TOO9MCG%JU"\@R"(@P/G+QFD^\%M TQR3]'4:_P@K$OH75
MN/-Z21W<7"\ATXBWZ#52=@Q3WVQDF N<%"-YHNQ@.FRC(_:S[9])!0BS7^ND
M5*JHZV)9_=Z-W<1H(;99=]XO0K\?C_B?66.4W1AGU8P.!X,>!U J#?L%O_'C
M'Q(V5EX"YH$,+7.?@N58H?:9/,+RKF.1R%$M3JBB4UB.4WL(J'>9M6I5([4_
MOI%,!@?+!EH^*P=(*NV=I!0;[J\O@C7&TD!1;]X])P4;9E5V84R4_C^/Q]?:
M%L-/MO>]6Z^KM?=)@DBXM"$@]>-QP$32#,7)H+-WC=!;6RS1M\-)B</'S<HP
M4AW);,@EW;S%^Q_MFV8*NL6V7HO45J,:D]QF:K:*S'QR$.!CI8+T^!<VH*^.
M6SJP>@E>;,F8,B,?EAE*&1#H%5))//<1X*K-X01>+$$C1$!2N4TF,(W?J]ZO
MU_5K;X2!W2J/W^[-+E%#^!%,0XXB\)]1A.,=/+#ZC!WDZBNVG-@VXR[5AL:3
M]5!/1X*9:! A A,81I813%\U?LO\JLFT=[ZK1]0VT,W2S)S<P:.NPDAU/-PQ
MN9L0V;?RE#7A\,LN)?ZF@WB%!N^:^(S63U7#4@ 45<S5OU&_T0,QG54!K/*L
MR$0 N[U)4EZJB<D&LJIBV=+)44C486 .C^/O1STA8.CD)K9WZ7SD==@N8.>%
M_7]XVZVU#>'CW6ROW_?K87J&;BL<9IJ*3V1A,?J0=5-%+%-FXVT_)V7?W4I@
MQ"Z)[;P;*N.\X5BO4MCM&OR2TM=[6/UA)C =L%&<MVS=U+,LF]U8+7%<ZS*!
M5PZ5E9?\D3=]UH<VJA+"SC@I)S_6O.N6E]WC%X+G#B;JXMV[P UA<W$-6&N,
M]Z/0(_?8T-O*780E%BQ ^@+BLS_+' *R"LG,7<"K6Z\V8A5RIB/-&ZCB(>3G
MZ^Z>>>V&70*?XKHD>VO<\&_8=H=O!U!EL7?WM#LIKPJ[$')!81\6U#35L3>Y
M3DJ2WU[XJ))HY!Z_O28^&<-*3=_ML*IN:IC=C>W8-J/U)%RU4TE[22ZI1+GW
M;?5R)Z5\-&++9V-;#%"WZQ7K6RVQHFPS9("1:%4T^]^GO*K+#W0Q*0PVK=18
M7];M/_B8D)AV-M-2\-).)\4#TBIMR'\NV_/Q?W4>%;252]!8LHF?6Z=>4F&:
MLCT4)^5^/'!]&V1R-;*K$7YI?;]*8FU_:/"OBYP4=2%BS"K(_^/Q*=B4H/$%
M5B2^WDD97LKXSV5HD:C]1.9UI*B XBU-S9X\:LRG7CN-!(/6KB)C-T1<WY'1
MJ?_(B6<[UH%_G?#^^T6YCVKF#[KYZ,Z4$N&WS3%Y+4V+ISUV4JZ,R[\?(C_4
M@6W_CBP;=N%QXXQ7\MVE)_;95R1,$,Q;_GD)MHHJBH@PG!_[*S_SS72OMDUE
ME_HS?KD5VADBB)Q^"24#H%@;I=X&+S)!89G%S=!/1DK2C%)-[F=YDC52K-"%
M;3:Q5CS%65H4>-JP&?=5+[=SJ[HN'-&>J/>W23]<3=2,&.'.*]@PJT=7AM'L
M8NE.KRKQK%"C@5:,L]]YN&:^OVW5ZB07D9:D#9*L.JQ=X, A=76Y!WW\-U\9
MSJ%8EL-+XG&]K!Y1VK+MC @:==6JCX),VWSL1*;!*RULC+_,6%&HI,5]N3"/
MC)A+'F:U=-V8M;5L9 E^U7UU -H6F.SBL%?SX_9N+I)B^?^!WA2>EC< ^1-B
MW2/$#^6])/BK!3 U*F!'EZ$I)P"%R>K:S=\LRBQ1?C09,:S!7FKK0UO==]B*
M"NNBJ^6JJE>1JR01K<I]0*_?'TXTJIL-_&W7VT</M)>Y:6YW&YJW_U\1XC\_
M'!\\\'F)0'!6*E/V=14$4[ZAQQ9%R3E%-R^W:>3O B,UN(F)475=FC>Z:U2[
MDN6L*WP;_I=F#FR[2U;S-8ED8S,K]N^_JE-?;$C=H\7+,*TQ(,M]/'-?DF7
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MQ9*>S--YER5IH?)]5+L&[VB,.O-;\+6A[C/O4SIZ@<-_#XN_;<YA<D7!%W]
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M&^"_*P\XY$P C"Q(6\6[<L+A ]GB#L*33):(F";VR/'1>33H*K(OC9/IS*B
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M9L9=$(Y5%)#72=L@S4:M&=?PS"%F!>.N7 OR<H\$3<!OV"W;5E#FG[\V8Y=
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M?LVT#\%=)D: Z?)D,^Y5OW65@Q()M&Z9QZ:X2/P'Z][8#D*S@3 ET.FDN'9
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M]0BHW*S\;5P57[BF?5E(Q$M68/\T+7P$5Q_ZMN%I,RK5'EOPO324@DSAA,6
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MH2=_UD?7)82 R=_XZU.@0@ZZ3%N)A=#C?DLA/CQ-<25FKJR)AH"BBXFV7T&
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MP69%TV</^K[QV5Z*$I\KTSUM6X>8WUF$\D)B<( *%L'_(().@ML@YK,>E43
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M]?KO9HP)@ZCR9;U$Y\J/ET\E"!RR2):BA)X]Y0P97;2#51)#$>%/<)CG)NZ
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M8>N,=!SSHRPU//6L N<9#&TF#02"WDW1#IS 93O*!4: H]$IT_B/&'B-"-)
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M3K<9H.<0ZW'56N"VNM I\<D.@T .;._GO'TR-<HC\Z' W #D R=A69J+#>9
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M+][QMX/>4^>YEGA*0:!.4GDC/XLN<5\GLLFK>44#Y%A0KW-Q#Z+X@*02*+3
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M7\?9)[%A9R+.XL;W !?[!BMJR6F0(M/6&$')0RKN!N7<M'7I-9Z_ZB>V]_*
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M/R:*Q=R[CQ1KC*^N[_DX0',M\L +@0Y*R$6A10Y1[M>B,3<,(:F*I:VC;.D
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MD2*9WF) 3CNU[,P<R;%[/H2&/6>F7WC?%W44Q#Q]L$Y_QV#S'VBW":FI_8"
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M/5?;YE8WC@94&OJ@Q?\NJ/UJW\K3T>)5]]<D:X[>I@Z^_7Q;1%VA!@LBVL:
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M*W@/9R[&P.MBM<A2B93&,#VVBKJ.XS0S^VM'\6(CS=")*4.CU>H+DR0I3))
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M5QA:W6U/=,G@JB^JK,VU&'_0!:=OA)M-S=Y NZ"/K.&Q+GBL54S\)$!I* K
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MU.BR(*R@ZCN 'H&5I5L^\9N=&]'+MR-R1KJV[=(1^Y83U.PKJ /097(\)%<
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M'?J3$X*K'_VDON$+J4;#LEDKV3[2\L%$%2S-EVAZ/C:GUH_$J1^,.))-4TH
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MCOOJ.F)9X]7C2\;K%6;;:D>*KMV+EIN7 *>[[BE209%7)AVX@J?>D+K(AZ9
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M'ZHPVKUPVZ8)0O@T:[@HG82P6C\C<HGE/)/=<^8*1]&YY0RM)ZWR-XI>SUI
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M"A+7NEA91C-S<V]#&6D33D@"G%B>9<;(4SUS*9)=^DC,W9_<2"84'M.8L,2
MD?0&_0"-D-9!$RWEIVH[>G9P9G*$%I3FGWV6O81U"<B?OL!;F R7Z'0->GC7
MP);?A=_R3N7F4?YJ9U*YEF,8.PDJQ9]>H?'#[IB>@[UN6$%YOY4S!C7EJY.(
MV#U4WN8U55?H<6#7R-G/[S<\X,:/\3I8',4741K#IPH@(@#  94AP%"D2]9L
M8[M2Y$=#H?&W<R7B1;HG61GSUXM@9+O;LMH/R][GZ936W Y_'34JJZ[]&:74
M_L+-ZXD&AC"I9MJ:;<^8C,LO;CM8$X+9GL?..*D%JQ&BA\CC4=. '.AH/CSV
M3[JF]ZXMJD2X4+%>LGK@:=?8#JP2L@-UOM%_49DSQN8BC*7?%9DPNK;+V""%
MZ!__J$HTJ"OP_(EY7JZ<L2";PSC9/?!PLIN9C< IYCU,3, _F,J+8!O_*@>_
MF@WT9[-!BM&R9,J_OK>9&-8N)'EO$YL8\ .I'1VT\]Y0UT"L-(;$:EL:\FI;
MC$":4W:WE%KNNU7*;GZCV#Q6VM:G5REE^FKBP7K4SFM>/,863>S'<\VM X8C
M5Q&VF%)YM] "G/0:@1,6 4+@G'9)>X5&;Q/VF8!_=ML\^"IF>1U\-*&A4^/'
MQ]C?2+IWL_,KP0NGZ\ZJ(_56NZ?DU:2/'V9K91G8=6?FX@YP?9O!/U(SI$R/
M$W*E7-J]@UU>])!HXX.B7RYW'HE58X#%6-;#<;@IJL3TH;-+TJ]N*_\?%_7^
MAWNK(MO+R-3I%;@N+R&_K(3'.AB'$'YA%V[&  Z1GB=^?L_+]S$X!8?9F6"4
M=ALO2R!DD^#P*?#O-;3PFKM?PHRMO!T"%Z^RB]]&X\BMG&8V/\_>-:[>NY [
MU0T2H=WQ R[>MA/L^*%+MZQ? I\"/\== O'[YYFKOU6$#TUH+Z?_#5!+ P04
M    " ";66I6./=UBZ_8 0!1\@$ $    &<S.#(V-S=F7S(W,RYJ<&><NP=8
M4\W6-AP@05J07BWT$D)+2"@BTA)Z"Z&$HK2$%D(1$+ !"M*B]"I*#:%)"1U%
MD-Z4+EU$0$1!!#N/^L7G/*?\W_6>]SOGWU<R>_;,6FMFS]RSYE[[VOO7_*^7
M@!)4A"\! # Q@0!8    $T"5@1%PBIZ#_?[3\R+TLS7][WL+"&"@G_T ?SOT
MO (]\&(F)$/\15]ODIBJAI*JF)R#+\DK\-)%>0!,!0975*'_5+&J*EHJ""T8
M0H&>PE7H+0!2CP& = LJ,)@*8]'?K++1BYG^RIL#_];"W\Z_W@&X#<,\_2/I
M=;\+O.A%+T%B/J&A05K*RJ2+2NZ_.Z+D&1B@'.$>I*RJI*(,T#X7$>3NZ8\/
M%?/ >_N2SDJ\[WPL(>;K=5;" 6&A8A%D@/?Q-8X*P=M&66(]H_P]-;TDSNF(
M:4=H100$!>!#W<4B HBDBUH19R7^-*Y%S_\N5I80^U,DU/^LQ-]NW]'"6LP@
M, 0OAE""*WJJJ*J*(9%*JFH()%(5*@93484IJ]!_2$55-2T$4@NF+O;7(4%O
M+<2+H(4Q1/_5%OWJK,1?-W7ITB6E2W"EP!!O955-3<W?-F P1;J$XL5(4JA[
MA"+IHN3?+="'WS/$-RC4-Y D]OO:W2,P+/2LA,3?;R$@Z!]F_\>Q^KN@E^<_
MY(+"0HA_-N[EJ8PGX@/PI-"+=%E5Y7\Q:F'QOYL-"/B'],505'CH_RY]$1L9
MA%?&X"\&AH5XXE'A]!8E_ZF.P1/^&W6Z^#^4@[S^C2J]@JX*_[.305H6@5Z^
MA$A#]U#\68E_B]R_B1J$X.EB_RH*4X1I8%5A6JJ:6BJ:3G\9I*/%RSW4_3\W
M&1B"#0PD_AU7_V9928AY>6H1 D,"W.D#ZAO@[HU7]@O">_]IQL)"RS#0,^SW
M;)D8GI6@ERAY^7IIJ1NH:>KKJ:+UU5%ZJJHH0PT$'(DR5$$@555@FG #]-]U
M34@70]U)GOB_Z_K^4Q?U[W7IPZAE'1+H%>:)#_E[WZWIF#;W]0AQ#XD44U57
M4OF-U+^U8>Q[D7Z?D7\AUQ8?_%>.Z"OV)TBTW#U_X_BLA&<@*1P?$HKWDOBK
M(L@]Q)V^ O$A%\]*$$(" \3<@X*(OI[NO\5_SZ58:.#_IRB<Y/779 ?Y!(8&
M7O0)#))0IK>F_,^&E?_O/OTUAO@0WW"\%_IW(W]"3\OW7T8F+(P^+'B"%Y+@
MH897A.'A"$4U57KBKNZIKNB.=,>K>'K D'@O58F_E+W^94K^5%;'(SPUU)#J
MB@A/3;JR)ARNJ*F&P"NJ>"'@:@@5.-(+YO[/KO[+ZOY[$=UE_-G[O_LJ^L4_
MO!V>1'=Q(71?]FL/P/GG; "\NND^D^'7$N F@.$_/QC_>3#]X_A[W9_5#/]:
M\Q\>O[H!W"Q <R8V)@9N ",W Q,WPZ\^P#< @)&) ?#;_%];"P#(P,@$8F9A
M/<;.]E<%TS\KZ75 $/,Q%E8VKM]Y$(@)=(S].,LQ$)"=@6Y5G$E5SP;([!X<
MPP/:3RMNZ)E\>>R#!(PW>XY%/WTZ<\9N5D &:8^1A-OR2:EA^:41J"PTP6/*
MT"L4'Q8>8N!Y\69<?&Q&V8!@R1-:4S^E\49I7[F0^JT<>H\9&(%,C&STAHZQ
M,#"!Z(US,XFK D%Z-CSNS,%IZ5,9T]C,F6,QQ9.\MFK\$C ,G*]!WTZ@IT32
MX*(A8O^E1TBI5&@9B^=-U(?81FG!7XL #J;?/6;B!IP#?,NPG%Q<?PPRD_P!
M,G0#9:BYC"]*$,37RX+M/#E:XPJ'C9\_(4U<OJV G"P+0?)FQ1GT=A/K76]
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MGUVZ/%J\^K&AW<]W^('WX>##D\O/WT6U^WY2"7YS)>]U\J;L( .=RNDR K@
MT4" V']S<7J\/-:S>73_[IWW4UCA@&*/<0U1Y"JK>*]J51#706_SCI1/%5%1
MI=%&@X1[V&GAT29">QF^6((3&17/OM!EIIX8W ^NCSR6%._/<87Y'>_+;1LH
M.:U- %S_'M>%;VAA :BP"_2?<.S5S3X3C$/ZWC8 !X)'+%3,FB89<60U]Y!^
MFF,I(=H<:'ER1!1AFO00G2L&O1D[8EDS':M4QBRB7E.@EN*?C/01H.+5NQ?(
M#_=QP_OR2I)@=F0 J+\ P!@_L%#MS.ZAS@^.13!N@G/2!^'A<06>IFT%#"QK
M-"+%;S)JR'A9G;\@1R*;F<RM@FO5]52D "5]%J0S,EZF;OLPQI1CA@7UU]!X
MF;X%*@&F#;7>'$)W7U@N;D"ZFDC?,">:4D,)M3Z"5&*SR%>PKO5"A)0+DA5K
M,9-Y$U<B+9LJ" 8,+N-&[+#"I4;\&5XM5G(]_&R-NO-9^N3L6+O35K!=XI:&
MA<R(C9*0BLV,3DY?[)CT^GUKFVQ_0$N$D_8;3; 2OEVO0ULBRV@J*=_-Q>AZ
M(4)<H_'A#;^KAA.=CLP?"XA-:2376_T61H8NMN0?G3/M$UCC916DGI%MQ-V+
M/RJQ+!:F\9@XHX-" ]7IMW!$9M4.HC+5Z3,/1XJA.Z,M&9M9\D9J_\H=9;OB
MYNJ6=Q>2LEH:*C\J;P]^''RK!3^;MOWCNJ;-@@VF$&EWU0 P'\W47A?W=O?I
MJRO#RV<>4>/(YDLTEY.NQX>O:Y[[X_K$^X[+!;=G Z[N0J8<[T==S3KRG\[_
M!:!L5FU>G(%@J0.G+]O<[&L2$M):=]CCW+[T"Q#XH@:M%'PTD,/[+>_%N9RC
MNG"$;6O4\@SOE3-6*TY;[<7C04'J-TY+'$G 4M;+!;'/'C@%AT9F8_]K*/]Y
M<:[ 5OM>V%=3HR^[VG(J2T;^V>:M:9U$$T%0''I!>,$[&G"I)B]H:$+?OE\F
M\-1T> )3#V'TYQ>?4<"7SK9Q;Q<S\^#:FPT*R%#(!R2^\9UDFUR.;YFO7E+
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M53F#DH7=>#(EH^<;,Q".2M-N2FQ -<;^ E0$>5%*NIEPJ%99)'"RD>[]U)E
M!7BHJGK C9OVQ.!7!D%BC8'W4$C2W((X?T:H@?$\"R@CS'/?*\#B5GXXN_<C
M;WFIFS 5G Y>"554UB'E,Y=._+BT7-Z 5 %*"01\X"X3*XK=Y3WYP.0A<_;)
M4H#^9@8AS2J1RH697ZKT,55W+$.3 :R)-9M*!FJ,/[?G:42+?.8!1OJ2 D_P
MU-V<K>F+Y-,,493Q V[ZY6>GHV-*&)%4(KZ[M[780C>7#PLA,P7>Y!24#^R#
MN#F")$T3Z@7>[9G4$]N(I!,\1)Y :')()75&,[L!DN^6'')7.RFJA$XNQ+UF
M/FE]YHTS ;@EFK3&ZP[?Y&N9YTGE'0DRLM$X)M\[E'2;JFGE(U.NIW6.]435
M#MYZ0]3&!A87^YPD^#T#XS:95\%QA?\3[WG#D)L[PZ0RKKP"E'NHNJRMC![Q
M1[]-6N8</^J-3OFQEEIUK4(TUU8[!7A)@50A_=:Z_1AIO4:D_]3;'R>O97;<
M6'AA.[P1%1_>;'G_F45T5VF"9V1TRA[#U5O+3W_NG5V:1<,+?MZK%ME\>0YY
M9?&;;,NE"J.+=B7-_)6EH<9'OP#OG)>V[G^^-=5XI^)>R?=9^<:1E*^60H:Y
M!DD_GBU?R.TX>6C!XI)_--#^P.C@R]:Q48OICL6%@?"-6LI7'6\:QV6(FD[!
MC?R77'HI>K?*KS:S#@1C;E1YSX2D%'W'YX5Y_#=HOZXN,Q;W%7'_Q;N)7E3G
M%$08K";$%%;8F1VP[G]B'#@#+Q'FJ&<8\=: ;@P4!-:3<A-Q(OUV$SX@CNVD
M[H4JX=(-=6/3,W/PB D#** &=T5.;8+4KH\8ME[-[?IZ7R)Q5"0(E-N+A?M(
M1GDHO7S-KNE%;">S0G4GR>362B+UM1ZEA=>QM7MBA9RRKQ/H]-0J>HHZJC],
MBUCS \48G"*NQ)I*C9A\)<]+<G<^I644F]@5U.L+L4(W1H>M%V+/MD)=A36\
M5";=W^,L7NF3<R6Y4XY%C5C&F*8T/RR-WL>I8\B,Z7.HZ*3LG@Z.)EV&Q=F,
M*R9JC&S.THV[W)CY]>J$7L,B^X!U7_Z^&34] T]BHV&!_NC0%P%,#D,.XT$C
M'=:(AC,S+1H/E"7#6YA2[ -FFAZBH]%Z9J%R,P"H]0H:)P85W3)IL&\3D1.^
MYH*A5KG(@_+<5C]6^11E1^8P0IR-*59R-G/]&&Q"9O0]VP9(!M81P<]V2VXQ
M"X6Q!D1+,P(Y $FBW7<%Q)):8N_J-@VV5FH,!_,.<BD^ 00G-7W+S>NXV\):
MA>FSXC#_Y@FH*MO2XTKWS5,S5+$L0YA'<.EV^0Y@X>D[CJ";7,9B?=P^B\A:
M#9N-D!$%OH.SB9\5=@]MCF [W_3'-KV]4/87ZV="F?0$>0%7!$<Z6U=KKU\*
MLVGW"SFZ^<%NM/OJF4/13<+T"S!X\$N0T[V[)X]_9/AXZ;MUZ,GK4P>A_J\K
MKVV':05<=+5YV#/ S26C>J'UFNN5Z:F].7%OF^ P1/_]T;K\Z[+J.N_\22ZM
M?A=""]8N=V:-6S^E1WK\HC9W?((4Q886O!Q>M"@OSC@[**JM/WLF2%QNT$E.
MK!2/:\C];U"+_!.TKX?<8WN27-C)OHNP)>UJI/\)<CZP)3>"ZJW_!&% Y,J:
MNI7TQ/&VT%>THVR*RKU^V!IY;<!)4IIC49,#T9"ZVAB8AR/7Z^*:/:%&_'J4
MXT)07-48OC;S5A:D/'= 2(QY_C3=;>*-F-QW,*34%17=>R\@ Y8USV.HW-80
MK$>NF*O?B!6OSUJ\;B*#UPLN=3<Q/6]96^/B^.0YXL++F.J@?>L>T28BK@7Q
M*44-6J D[]VW4-*31$?YJJ0B[W)#1DG1<[A=*MB6B[0O  O#B\0Q&=?G&5-4
MYIZ\^4 '+WQL'@E"H3!K:#8_OG52#V.)>=OZ!P0XZ6GYS 03^_&0_'0?$<81
MS ,F-; J;L;N 9H<$&/F:=KV0<A?=Y5&*J=^(,10G-$GZVTPX[JQT5*L3U@8
M=WT%OL@3Y6VM5](Q\X7<00M#D=@9U0@!)GZ$HD'>-4=J@)0]*+K?+$>L$J_X
M7$ L9N71;]9\2=H&VV@8"\B5 MT(-BVIU"X]#K$3$!]101GP3'1+%*.!)XZ'
MV.D^_RW/SZW=B$*YF%)@;J;ETJ;<2EZZSUI#'I29&"&'4H*QY4/9[?R*0!P^
MN\H\OBWOR;:)5FY'&GAX)KXR6X]#GTJ3QV-MQI!WM.V3S"19H7Z-YZP_^^]:
M65_6WOE&?&WUU!X/"7-\/7T\R!>0<(OE:YVW]VIS@1)%BPS-3XHH>Q9SZ5G;
MTH6HCW!:9:M@6(41:NCHT4?W[^=#'^'2AC_N5=[SA+LTO7F4!;GM$\W0],KC
M1_+!LZW91UAQRJS5J;GK<)W@*\ES[YP*\@NE6[_8!:@]WM/)^OBT-F-G(2KR
M;KD]UG/QA*8+N$3B"4GA$_.M"Q7/%QQJ3-1FK8:UQOE_\#_W^^YG4HA8#OF/
M8\&?I%K&=S*/F4^_6%YA%O8/ESI NMX0\] >1?KSNY +?+)>W=S%/23?XRY:
M\E2:PFF/Q!N8'\IE$S[L<\ F%S<+U'$<M%#+_KMQ=Q@&$N-N*'(TF7@7(&[;
M1:;8PID>MYM/1=[B3FU40]<&JL:E)\5O!_*[' ,E"]BJX5N,QL]@8>GK:G-#
MH@(6^=B56!F-J+F0"# 4[21@OL@RSP(=&5NHC4F*'WG2QJ%R@3\S#UN]SZ&F
M[Z\)NR<D&<X0\%9FAV6EA,F/OBH('Q=X6%^ ,LOU4FJ,\KR23>-KO B730SO
M,SI'BD?38SOBA#R/'6&,2&KL37IJWM06I,Y@H"SEHWT/*>>5GPC.CKE5[BU[
MFTF)64&F[X6D?=/NGO7\%$5FE\@\"\Z7MG/(HQ*#3UV=LEYA4VO0%6"41T+R
M0YZJ5U)M^US4^17)7>CB%GFB'R(B!^.;1K(K*%B#9&-6+G*+&7GD)S9V ZLL
M3'1Y@5C4C6!;&X<TTH5@2)PH*G_Z4D83#]$7]C)MOGPHU,5DX^2CF8Y;,=K%
M_-(S3+I[*#^A#"#;3:ZD.)&^!(FR9K)!EE;23;%\%<MB?1800N8AXZ[\:&N/
M/\:/L#6.B>"6>WX*&.*Y;+L#"]K WH9;P 6R-+E!KNBS,E8^@%390?X:O O'
M5H,VS=C?DE;:D7WAW/1%.VI^F,B!R!>6:+U&,:[.)J==](NK?FJ-;_*OP5^=
M?+FW^F(5?.+C(E7>3H=_[,CVH_UW+YL=[(&K:)VW@4+T2' U%K#-W+J38IQP
MH4K'\<IB<*9:Q_!D%03^;>FP;N/D"G@T_T?'2H#'OD[[FQ63Z68!4SJ=SZVP
MQKJ%BJR]+26__?1S^N$;=5?M0,?T@-+]U;=-.Y]K#6MV)&:%-_SGM8O^4]K<
M46^0](=HW\]?  =NBN5;Y54*NI(C\6D/ 8[#QS39@=_$<O2W0#?&I6\;6*1D
MFT^Q2PWDSEL)09]FY74&G'R &6\#8[BE/N=T-!1(!9>H.-)0J:-X<)4&MHD:
M[\B@RLC5ZO?4#O=PH,$3S(X<+VI+F?:]G]$1G#1B(0K59F)705*D"4/#WC*^
M? .&L<.9A\)NJ4L:7VO*/BC)K<3V+O87$$9!BWY\JGWXDJ>37^P#LGY0=D_A
M,_ H;YOXA%QWO^&&SP4-CWKPZBA+2<1->S$M -,ST(TPN7KCLK9\-<,AE!DS
M;%),&8>4U!4K7C<(0WI>?N0G-6JS1@3]CB"-9QS+$_-C]JT\3^L_Q:PQQ[1F
M)7L0%\CD^MA$%;,;ZO[N !IQ%D+PFUOB*NY""3(8"V[*".G/5$GJJEC/'XQ-
M(/V<CZ]V3[#*X]$:GGE!2]I5)]+WLV+<Q&@!#=AZ;I,.U@X!1GL+,Z\64Z Y
MJVDQUD>4O./,AJT/Z($<L@ER%"9%)979D&P69ZKX%3UT37598SQZ0__@^R3&
M:;#(4@7@4!]M.4K# @\"S*BL&USJ!25)<1 L+3#VJF$72M.TJL25&]152ZT$
MKSEDOMRPI!I"JOFY,0^4J+=N*(PF)G4DOLH&F=F:#UBO6\>9Y(Y(&[=56=ZF
MA-QAUG.[:'PG+M5)WF;F=7II]T[H^=:9T)]1MR^)GR\7:3K__+:1P'P EX1_
M2?]1Q^6D'XFAR^8'ZA85)AUO-BFS/:8\%A'/:EZ@ BF(*V27'-2,\""+ .9X
M-09P)PHJY22X79?] E&WK6Q@4EV +1G\>;A?\;0NU;I3M.#V JE:$/4+$/RY
M$^7_-*WZ>QC'G!G<M)C:_7)H*W<$=C?P0G/GXU57@4\4\FB(:X"2W,_+EVYU
M1NTFVREH)9A(K?H>:G^[DOMU0N8_>^ZQ$#MZ&?05GOCCI^,0*??DJK-VDI=?
MM0MX47IPK#&RD*O/(Q>F*B,S)AOR%.4^JT=A=P^ZNX?;5X_M"VC5'XK,)JXB
M*CN)UN-"NV*  ?BQYBE'B]F;ER\*N^TY#DUSQ#L!Q:^<J4N_ZV,O:4X$M+A!
M-SY Y.8=BPNYAX+O!>KWY <A!*B1G)HI,&M1>PS"Q0<VR:/RB+#"E>VI>(I=
M8/SE"8ONU-CQS'%'U9-E%/.RAYZ* OP9GN,3*R6?,@AY;N1YY>6&\725)6U[
MS%AQOCF7U)*0*XLNU%N)Q2_%#9ID6M.(\E(9Z&9B+1R5UVJTR%>V7E#<5_/W
MB) G16<(^40#PO.':5[UE50NZ_F"RFK4CU'-+A8P(&FX0:?7OHE*Y-E2F>LE
MVEO,S$K:)X_G!"9E?^7S!P%P)1<;69%"(C'1-M8](@RB-[$--JV&/LQLHEM^
MZ:ANW(A=A!?_!DXWF7D]RR0PS>NF(\N2AT52^0W/$#L.YQ]WR4S(\/7BH:L:
MZR[JIV'9(SU>Y_MNF@)264TZ.&\>W)5^*(V5^*.T^6BJFI$)<+9X X5V%:?/
M'(,:T_?NE0YY1A:T#[50(?%$Q7&N0AOE^DK6&4L-;N"PSU@]Q/P6YF']V7*I
MM]'W25Z:C0D.PLCM83FT@ND!KQU$WS=O1*Y"">E1U05G16V<J#>R5<F,S%)D
MGJW*D10\Y2E\XK,_9<MWJS'KI&FY[+%CB D9H&B-N"_K"(_MC;(Y\Y=S/N_\
MB2-/2^1[2K=_ 2:3WP3,?&RY*#O5,1=>/'IKJNPDIBQ23TPW]B6@:^_;Y4,X
MCK8C7C$S_M%AX)K.M^$#!;-.Q_8'2[MU#\N#+IA\N;10T6R9^"#*WAF>/3YY
M><?6_4N=;V*00&[6449'X<%D8(<C O'E3O/I\6M?+L&#][8:P^N<TV.OW(=_
M6M,#W. B7M"RK*J67%MP^X^>B)P>?YFM=XWCW 00G2O&TL=X"6V]9P,=MR>,
MLPD_%. 7H<SK(Q<;,N1-']S([(D1^U*SBMZWH[M6/^%)4.(C5=6NLZOK(RCM
MP7R9]OE70_A8W<^_GU<D#91B/SN=J9#F_9YG6:J84D+;%^0C]HRY!;4;%G(F
MK".7!)1A>=4!HG_LG$(-M(-5H@2@-5G,\C%AC7>2GJ)0=BE-GE'#A6R5V(6B
M"VZX^G*+P:3QS'B1L^?9D8/\9#1 QHR5#S:W0!NC959&C^=.K8LG]32E!A?-
M<W'1"74R5=&-[-N4-_(>DJ?#Z E >:VPDN*C7<KNR;SC6:6E555?C5\['P%=
MDJ?9.[=[*WFL^0'M+?5)\470>>F^E5CG+5I&WY1"'LV)8R1^%&$-BDZX#RPH
MHGX52<SB(,XCS9 #I7:8;CV)*>,)%F@YY"M#8S?*(%2Z0] X73?)CC=4Z1AI
M"M,?=\9"1'+I:7E#OPAS;U-FBSU.P)C5& Z=&[R49#'!'@)^U"8]T]UA &0!
M),;B&$@&M%9@1^HPM'=PV<A!138UP*R2OBV(I3+HWD/9BM$GC=T:9.8!$$3/
MFL2<-R-3^L*"UV3120+<.]A\0H2,=0M;1B5GE@(+3R"V?)V+FZM61ZJ)X$R0
M>!;L:IZ_93>NNI9/@-GAS<[P[;AM)PFL-F,>G# OY_GH-SLZ&T#L'-=*T>Z.
M->S/=JHUH=SG"UEM8)\XZJS4@*\>+\V9NE7KHU.>.?3Z,(O3'$MY?NQA=GPL
M=.O<L:&NF3WUL9.DWLJXSNGKEUQVKA&^M1Y<T%M5E!ZW3U\\VM%.^[(T_Z5E
M+ZXN"FU9#MV4[:I%7I]#BK4QO:?@^8_JVEU_TD'M,W#Q0L1S^+?D%X]S+M\)
M1]!2:H?U=(SJQR^?G]C2T"PSY/*4_GS%JZRC-.V3?W)RZ5AC\?^+KS#\L8H3
M4NZY]9TAWB"%RSL@6?[:!W^XS7+9V]L&V'XRN_!%EAJ_,^:ZN*BGZ/WOY$4)
M++SXHC!E/HTVTIA1Q-F$$PV,[<FN[,;'CM_+NL^S7M_G2Y;AY+GK36*3FD-!
M4IJ]QHM4S8W8 ]9H&4B7 ?TA_Z;5U$:#9P%O-1O7J?%.4-$K;V7'*I)%?&Z*
M-1 :<**M$S1"G20AF9--Z.TK(;<#:)DV3,AGOI$X+:T7SZCQQ*&F4">&@X&%
M<])1W<$F92K@]HN4RZTUA*\<J^PPJ@NCJ47F?"_P9I'IB'D&G2X04\;?M-C<
M_&&F"3<N#9(H;MQ'1Z/T9+H=D5"OB0,UG]T-7(M4U1&ST(28NXX"<C3I@VB3
MT,#+13/D.!C0)L>$CBUO(/@<"\D>C$4"@G"?P.BV?$ )AL(.>VO.'A,[WK$%
MR0;WTWD(3L*,0:W@V+S/) ^T]6EQ@PW->O[4_'<^)#;(M7R-1]B-E284]47:
M6DDXY6BF=8@5S.@6B:EF'&(T,/E4CHUN\WKMA5RDE,IFND+#RZUE!%VB98X!
M?S\EX><W ?=#XDPV%P:;$ZB%)ILG2[*,$D)2&"$R][EB62L \7U8N3R@K UB
MZ":/(:.;H0RXVV D:4U2Q\#KH?M>]8Y^\ ;!N<'.?-F4N].O;-M2;T3EO7V9
M65]LSZUB3%H!BMV;)=+6BHD5A1T>BY'E]YUY:L;!UN.4 Q=&-3*$J1^;EJ[S
M30B" [GL*W-=;A(Z"-6\BW?<3QN3'K][7XV7QSZU^S&T2.9TI^J"F7D2X[+K
M[E\RZ.K8>[]3BAO=\VN[;_C'LV\6+5]*#4)VJX./OFNG5WXYG#\W=;KX[5Y6
MIC^MB>P][28V<Z+[R;[IC\GEX[G?+=Y:L5\BW%UTL=I\/U:75? ;Z7Y+]M-7
M5,ZVE-MES2]FWCWU'*#GFW!OHNM-:XB@6\4Q1]H;UB?V&Z^TI<C\Z?^O&#.0
MW!%T:'*-(_+T-BM^7F4^AF6P_;<_5B=*OJ]?V<9U]4:IU9^@ %/4:US]#8R?
MOSGAELT-D<Y["%-WP]'PJ2NJWI%G['D]13T&4$$B1(T7'1#P&73E NMG:6]I
MLFEBF_7X.K);C*5Q/LC1I"/_.9M(G/B/TM"^,^2)1^ZRMJ;N-O$ \[U<W*A$
MNHC//0&HLWK2.A$T(C1'V.5B1WY0Y%!S;"12*YQ2ZG'$XOD]Q^%]@\@4@$6R
MIEJ]9]$X\O#4DH-V(== ='1L?T?#1".JW,#/4[1BG98AO;XO[//(ZS=3\4G$
MK'"MQXN(B362:N8@"8M<UB;5ANHUY9 -N/WM3QD>="I46]@24;,$48CI-#07
M",B7-G!38E?-\3%I\(ZA&87$#^P/3; K6L]+N^"H@:""='0N-+EF-8P[2*RX
M(W7%3'<M-3G^@VE)]9K?'"Y>FT^3+[W60A<@1QW6%>2HO[<M3V2/!B7Y6TNQ
ME(%N> 2M9>D^ENL=R7(<U1-W2P3+K&<9=+O 3TOD1X< [5+J6;%8P_AWMX!5
MG''M 0?E,\=S0]:3$EL.. W#&#E=;&:'+.LD(O6U;G IDJE6J51LDZQU/X-;
M[TA2H\_(@?ZTTL;W.'TQ4'V?T$HX2_4:,-M=^;265G1QF3CG6Z_+L_*O;! Q
MB65H&2&0'\&"3W&P8XAH=QX=R!$+J,(42PD\57FU%=NT#PL.E7,25ZF$RXH(
MM6<(C#NEW2TA./MT[5:CE"*%3:QK3AQ721#K$Q6[M-QD(33"9GJ'[]F+L[>/
MB#.GGGX?P'VDA<6[-HL*7.S,C#;$"S%Q?CI8W;U4[5SO5WKFXO60_%=IGY3'
ME+.7O*.:X+5M/PZM8KX\VW[[L7![\15E4XX ;_H%"!5 U'GN(,4GP/7I 1?:
M=%S^>#9-"A?WM$$X27Z[<>BP\?/ERCA^=*[V<4?UV<V1K6UON9:6\Z5^JMU<
MSAT*'\')GS\)S(Y:-GB_5I@C.;;M+F-]\$2O_P>Y^=!*.E3NN7O\(Z@;WY"M
M(.//D66Q%)!V&(![>/O6RZ)70'$=!4&R65*UJ)<QR(#PP8!CL %'<U]$Z@N$
M)SV)C'4DPU:2A47HL+XA=T&!.UVM.ZR$2P@J^AM98L:[(4]QH@,W K@8/ [E
M\U4,J1G%02Y&HFZ[4?U;SL(4*8XS*#QT)$G8I^5(P'PU$^EV_Y+H'Z-(1'0O
M>ABZ8+$&ZZ$]PDN:YTB&L[_J\?C@E1+#L$EW_9@!7\03@IAH0W<-8<Y%=QFZ
M8%,WX3-AT@C#K# /Z*X'JN"0EN@BM![*Q(06C@318^%3!F#!FB7Y+N9:QJ5P
MZ,:VI+7R(524^:MH ^6%2[A<AH'Q2DEW(W%6T@U@8Y.O9C573E\)5#91#O*-
MP-_O*?5-,,E#EW.FSIO&=9.39;YE8-8,HK*'B?7 ^2Q#']"(LRS<;5[/ "\]
M-L$R)"='TR.G<X-D]AE?%KE%2,T+Q+S'@'J-.ZY(-T.*^MI.?NVQ^LQ1[WNF
MP:0A@ITY_!T/U>.\T+CQ*,#4CBU[<[%\F!EZSSHCUR8;K"[_EI\])$O)H$HV
M4WJFI^,61"O.P328T_$H41Z1FOZAT;T=<J=,$\V@4Y&ZW9NETV)E-E3#B_&:
MO"D9HI5KD^JL.%SYZK:>)=[,M*M,UA)D+#%K4I$F)<82&\:+)GD1I"XY59K&
M8\[#>0;#;Y4[I<.#BP&BFP.\'[#E^BS0M)C;["A)F7HYG*A7-75\R\L97!!L
MGW>W%$LPXC?YH.H7CZ=,ICRXN=Z24F7@\FSN:MX1YFT^>S6>IFF^:6^+1QL>
M:Z^]:! C/J$"U+MRP^,],PW_^YVJ<YU6DF\??+\D2GJO$Q^^MY3<,;UVI_,<
M^DZYM\4L[L0] ^IK^5;XT)QF%@2UO/I1]U"H_]KD-]]#^[G&9;7%O%>&7:7?
M[A]>WGA \YQ9GGD30%\1$4K3V\\L=W#G*W(J\D9F M#:C&)Z;6X.;PI/M3QM
MF>K$4_+/R?M]S&G*<:T>KI0)%70?^5^?XCR&32IC_A"4_,&0TO)":[B@QZ$[
MT'(J//P NID6,A0<J]+&U4C8=YP)2$WE/=5\]W;"ZWF547>6=^_IKGU^5Y-#
MDM6M/G7]*UA%N-]3QB\](J41]D3"UZ1JFLP\R-B?WW]1J SH03J,I14\B?]@
MH,"E[K87^]1\#E)UPV/R(=21H\E%P**@)TA(5!G7> 3.14(W1@V@)]N@90-9
M]'U+2@ 3JK@%&W@7]Y952UQI,KXU-YDB8:\XR:<!! AT&[2[?4MI3)_H!4HJ
MG1W5Y!V@K.D1%A0+;+E5;62P&$]P8 >=5 &)H!PFC_AA!!.@(>,4>IQ[UV.X
M08GH7MONM5#B8M&KNT@CE><W6<5F]WT8FF&E$F&NE-I $#BSU&5<=P\WXJ*1
MD\W2QHU#FA&BW<KRLYG:98:)$^JMA08>^P4,'%=6X\ YJ.Z.M'PU;B'RB/,&
M*)WQ9=EB>8-#FMO*&Z0035?RQ1JE](&:DH@LO^+MNZ/Q!;'9O8P];64K(!>?
M9.88XHSFP4GV>&J(>ZSB2 75]P#*W%<%09KS4-^,B4672#,5F3 8_IXW9GI"
M34AG3  G\)K&N14:!XM%YQ.STQ5&^"L?)BH,-SN<%[?$L]CG*4J4R6)<3 52
MM),R""1(G'L#ACA<4J;(UP#/5($K)C6-.147Y')",O/NIB42!1+SVBC6Y&3C
MT;S,4O.(>U>+F]\[3A;:*MX=WJJ:YJM2.WJNP<+(<9)IWZ&NF?2]EO+],27#
M1/O.K2^E'9>O1WRTI5UC'7Z@IK-\5; K.^]\NP$]Y.T*KJUC"WTV,/,5/6H2
M(Z/P^?CHZ0+NMN**F6<T@3M;OP!/K=(ZR!V?Q@GQ2^&'/:<Q4<I.PV$/RZ%S
MF&H_9"E3"DLT^4FX\IQH^&;%,E%ASJOPLM6 <_P+ZM+[3O7U:==;^"C9_XWQ
MOW@S&A'[!S\=UC7,!6Z9XZGLLGD/X75,?NX#W>+KM"RPB,7DEO8H>3)V^"'X
M9>XT6E".L&_1D5(OU!>\WDA\..@HQLQ^#R6E-IL3/249VCTP_.0MUK3YG4A_
M"JB SF7BYX$M,1N.0TLQ]=8]2I+8OOCY^88,Y.@I27->\L1AC==7X$5AO^%"
MKJ&5-E"!B"=8 'P/7X#')XSJ9K^'#3?.V:VK])Q-_0C%YV+Q)3:.)K.?^><1
MQOJJC.^UGA %F->@HV:)X0FY\J0$H@][['"7EQ>1<;SA=U!JIJEM(9G8QK5.
M\R0NE#!&#./E/>-UB9.-((]YFI G<7"N,4/MMB28Z[X/= DZP5+I0:@]@46J
M[2/\+\_00X)M<C3.9%)D@PSX$]%Z)HHS]<PHF>$ 443KO><+S81YZ0NL5"XV
MT4J38*5)WO6,(4*]$(BI4IZES<].IKP;,S]%(=22M/F0]CYM0E+"@N!^@W2]
MY*$V 1!/CEB%@*,Z/Z>YPM!C2/[ME%QI:[,\.2$QMV@98+D-5M.2I8JM))+X
M 87"1!*T,52LICX$D@'(TJ^YC7MG65IY'E-H;0?P'3@E1ZT>TC2%\!N&5-BH
M<RGVL&8X;=EF5EB7B"7().+-4(T.PMJ)5T8.XL*\9E,=D14V6HWEM*:]FX]8
M*83GIZ3-&,LE-66L6T]?#)DU?F)#(+EW^,TD^'-.ZQ@O*>YT4/%0;1F7G)56
M_JOGX<CJF+S [,OV25?,Y<V/0Z8Z:)5O2,4&FNECL^4?[$3>1ZRSQ"34)\1M
M[Q[=+B5UU;TIL-"^<R?PQPMZM(KS_:22''"]Z$C\H_-WE\:VX=!KS86,-?+3
MOI76]WQ,)7.?3#UVN-+XK4%.P[?9MA>*^^/SM\D#F:A(E^<^BCKYK;'?K1Y$
M^6-#?QBEE>:/;,G/?!TA7GH4=(X%;9V2\^[L_:BIO<6(%9K4DLNS)T==X]6+
M83RT:XIJWTY9/BH=_/=OQ$:7PRY[/ 992?Y@A Z(1HT7"AR<H+"TG-" 2FET
MC'(:A))+FU>S.-[$4K0'G,,_;.)H)9I@6YVCU@J_ 1Q((?H05=J4?3S/'PB;
M%'8KC9>IG.2TY3E9AS/3NBTW_^>[ ,&Q "([*]P\"^PD$?X]4W4P]Q6P-*FG
M\8BY<O[,^<9L?&_NJ/:H3&B0ND^]^SF)\88R>EQ]"5IPVFV:F#2":LA66X!>
M269^D\P0X[,J<%R<7&]V/3<KY9ZT=/<$>R82T\-AZ\.H/CA&R^#W(RUIU"PH
MP\-A*AK?[4DHE.T3E<F7H S"':#?).\)%AM90Y-.P_5ZXFG)\!957*O>=&JO
MH3&[;%JC.B.3EQN-"/%AC)=.KJ2A"C*1B.3B^H"WLA!M,Q-EUB)!4$%8_PU"
MK"D+%&BY+36?5VWD5MP@;<7:1@]2;(H(.FQ1[1R3Q@*,GQ03NT#=288?BH/F
M>_O-\*A]0G%]@P$>F2W=&VQK@YU $#9DII[!NB,SD3IEL]Q%;!#$:6XY!3'=
M86/#&#ZLJ&QFP.^W$'EB]>MXNGFR#%=8-\]PTQ?$92 68B7W1=FT;"YF!%E2
MNN-.3XNMH[/[L+Q%(:9G'R;L<#Y@^%UFKT?DI=J);0KV\_/[&4EHQ7SF<HX-
MDW@X(F,' 358:'%M9'0/-88XR;],H/65S!@>C*A+N_B C"W+V@X@SIR#,U6P
MXLR2>[B2\JJ9ZL2;]=U#<25A?4^MUPCZ-.:TY#S2,_UF":F,9W -A<J".[SM
M$UH_KQ=Y4[<.PJILU780/S_M^0)%G4$+I;.KDRL.[SI,%4\AWS?YJKNJU?A)
MW,?X\[X5G+STQM]!UE9Z*FHUM/=31\#E'2$A@ XU53SJ!^+@V5;YBN*0[R?X
MDVKUGS?V[S^]GV;3]L"_Y<AEA4=GW&<E8.J3MU5Q_@A!_N$,95!76TN[6R@!
M;7NA&<GYP5>]4(WDE![B>_I9[2] Y^)*CH."5@("/?E:8:-B4._??-9PEU?B
M,7#H%T W;6P9YW[J:C4RM%=\8/&2V=-Z=] K48KTI1JJ-Y:G/((,XWUYG/\N
M><X1/)4(K\<MV\.+PCE5/-O=)5'=OJV5:O1P6/P1G<''"GDI [^U9&56=V\G
MK#GR$7O>[#8;YM7XF@:+WA004YMD95A4$/A6T&/SF8.=<7S+>>RWNQ:(S]4>
M%>;4;%&9=&OVE+&M%O;.\]2F(E)GD0/'!B[Q/Y/MEK_C-H2#32G-'0K1/3YE
M(%J%:1F'1/D0@98*2%,#1;]AFG&5QWATO=R5 =*DFSI45@G'U"/2W&+ G^%N
ME#OM3&0<[B*D(0-B"(?0V9)>$#@929RP?",?P+%2.]^P0\&796M; '#J#M;$
M"18Y8OR."\?E.LR"X@'2_TJ5\W%.0D\;YV;!;UJO]J%)M#40\R*!D 1H THM
M*,ZT 2N)Z.*2EPCP(>/+<C.\3!KUY(CHA\3&M7 %F2>-^&@V9T^3X+'F1/XT
MGQ,\$.IOOXWZACZ%K1JN5F2*M>.WT:[PH*>_/\B!)%.9@EBQ=HHCF"IZ">Y=
MQPS6[D/&: ,DJ?@X$&LGP]T.B3/(:2WG9\L8N>R8E$S5O!QI8TT-(>T968<=
M@T#X)3-+2JO$6L(CB18JYK?I)OE/V\HYFF3RAXG;?1BKD]^S+/$-5A@E,A\%
M6);XI^41U14L2R4$]2$SZ?J50/TWD%H3_S1'&1/,!!1; ,_T(Z"J[:1M!04>
M@C0![1=L8?Y,L*$!QTA^>>%AN*!MX5WO#2=Y836"\UOL;W9D,_GFJH/ZU$7L
MH:93'65+\\&7!V+]% FN^N'0-Y_40Y_S+UE4RJYIK_22IO>0TIXV?-/8H>_^
M'SV_V[_6$O"6GNH8"'O!<](R]_*.L..\4*[1R&.#*ZW?BJ^3'K$+;GWWHWFO
M_P+<?2%9\W;796Y;\>>*:,]ITM7[1Z@W(H,4>K1!'(?<KK0HT^O.$!AXY7NA
MK9.V6BOPI3SE%>)+IM%ASL,?,\_?B0PO/&(N*7LV+:4KX3;O,&:5@+\QEOD_
MAL5/P12#H*0_N)Y]9#TQ'I,@&GNC2IBS484[S5%[)*FD.RP6$&A]J"6>+N0F
M%(R#7V.:&4P][0"Z&:O10&&7O5[I*6G8<,+3T-TW-K'5G*T_I64V Q$[<$.M
M_\BP%4H)17'$I08+4Q;">_ R_J<\S;E5-.CL(S[+<0E56.=(*]&0#$^,*Y"_
M*.1S4[UF22%Z&I0L+) E 1O5^!;;']VKV_GX:7U&H.J&5@]SS.+L,^A  SK&
MI&3((Y=WX'Q89AZ"VDWWT@9(M\=<M QYR!ILHI%P)XV&VG 'W2T$$IE/V(,3
M9U-46TS]Y<]Q!POC6US]1M"4VC^A2R,T&[BGT0P% F;:*@J0#)XR!:)J/EV?
MP.D+01+EJ0O5SKQT?J,DTTT/)TR"";M<KT#@F9(UPW>8G@X!1E:D69@:N#X+
MG&%KO<S7.A967.J\7MSP"^!.99>5[3[/V%./V;29SL-+6Z<B^:HP9HE%/*OE
M]<0F%>/TGJYU.WX3#J0%)'%H.B<P-C]MQCBP(\MPP8>O"D*G1@=ZD*3R7J-:
MF>$0V<S/7WBH'8F;NXLS6%=4._*TJ1UGT48'*]95;[3^:X7UCFRJ^](CI>*P
M8TI]6 BH12@(931SHE.;V[KR1,MH#S]=^,7R?>LP_@W+<GK2ZC6](YJ&Z9N)
MT8G(2V,"V1V;M\W4-UBQL[:,,Y.6/ ?\?G/D"??":_LRB?*T!J=4;#%^L!5$
MIWQFP*LO3,ME\%*VF0IOKYB/#65Z/OE4$B9A)L*%DT</O=JVFTV\X<)Q8G[H
M\X"9X;8!FI/XDJG!)R^S1#/MZ5946+C#Z ST,@M,"BU@R-C<?"V<\, YP.+4
MM3H3;P??A<=\Z\^*?@'0[\N/8Z;:W_T.BB$G'B-D3D6E;@(.NM.)@"7^+Q6C
M+_*T"JO^4'0MV+:X>$[FRMHWA?*5=RZSOHIUCWR;#1MT7E]6_EP[^:G5;-2^
M.+_LRPRE5S;60Q<@VI/T8WKEU+?M+^/0Z[Y7-S4_GQXG?;LD&[2WUQ*^]\24
MM>MDQ2[@AHJ'XNTG7=T6"+NT3T<66MK#YO_C<KE_S)>I=^HQT S^@['/O3:1
M*1'7$EJWD+ $^G(?E#S(6)S--%9OU61/W+F3@(\V#6Y4D!?9?W?*#<#BSKGY
M3.RV)_'P4LW7_(%F48KX&8M[J,S-[FL,J0+$53F_#/P)TGI#P5I NI!/8NQX
M!QA<SW7L4NR ^?-;/N-G)%LG&E/7D:,14-STD_AWO+CAVYG";ODCYF55 _E0
MQ^', <<SG7KNLJA%%G>R$JSCY"BK%L'>,\9MQ(QGC<=0%;-@05;1%ZUH,1.&
MG4(7FRBH4I"B5]F%X5Z5B6W<#=XVHFJ.BK$#&'/PXOQ]2']#ORTWA?7V<VC9
M. ]Z#6V&'"'%UW)G]X/3:4A_=Q#X-J1FI>3GYLU[,C63I3,T+Z0+2Y84C=""
M!('3.RWR.6+C1\QX"0FLB?V$%Q)D0%+V-GBB33" ON',3*@W\;58$HK+]JSG
M_V N;@/00BCN+\<FU%O8-4V+DZ%%950G5NR#])>52/[B(N8U2DFEV_)OS1SP
M,D^E$NH&7DB^$J$\DF52*1Z_H"<K)2OE)[I'W])&0]Z9EGWB'<DRH#8QVLG4
MB-&7@1R@F5'FV%B6?C$C?1/1W=4%JK)0L>+KT2PNT2PGN+'\NKG< &O8P\XK
MO-3O"9OTO<3& =X94BZ1F:29]HE2QE^)&1IAZL&DJG<7>TD!@+V]CQ!*4ED;
M&E_B3+&,Y6EM@3D=3;;265 -H\@O=F$2HA^$-=.YXEJJ,5L&6#CTR=5:;#G9
M./"&PHBW@J)3I8P!FN05:%_($MSM.B8YYM6$@?F,-3L1,+'(48+"I@*RRW7S
MCCN0R[C!E_2N=MB2,]U(H-3*[X^3U2/UW@]/&]TOR[&?+#20SWKJ#?FYR5DV
MV/R)0X0IFM'K:/:+;%"7NU_+57-QS:[,9V/WD=>L?%IWI=Z_6>LZ(%?\ OB=
MOG0U[3)AN^-U.?[\V*;LS%6DV5W>L34=ON'F:WM[#M<^.J_FJV8^7[7-/Y=7
M>/3M>ML7?V>-I\N9O!O/W$2V'A6/BS7-ZQ]IP3"N-OVG'9K6MP^AU/_[8Q*&
M/UY61KM=Z9UXS/2;=TVZ6"SLM_'?;50/>W.2LM [VN.QI.::QZD&T&TG'&AY
MYHX"^U0/:\JS9>[\'ZZ^.YS-/OS7+B)J%T'-($+-F/7:,U:$)JB&D*)!JZ5T
MVB-$S5BEML2J&#&JK2V"E@JU5VE+JU7=[=N^)W[7.=>YSODGX\G\X_M9]WU_
MGZ<SCH8RU(I!AKK.-@9:>?^(&,3M^<_9)I+7C,8Q &/E?A5[G7J^]&VS)G59
M(;]Q27G!GQ'QGYN5]\-^2M/D1P!F/RC8;*4!ZX7>=7"A5,@7AK/$M&*CKHK
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M4G:U+RC>*7;SM=OCVHDRP!R=OIG.E'&^:-L7]IHKEWM/16PW^X=\>[7XSPM
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M96U.1K\6HH*R.IWH4/"T(KD?/$T-&BQ- .Z#]/!KU<]VRX):<9L6%M R"NZ
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MBCTU21W5EJ]J:$GC'?CPV3% *61'F_W#)S1+'@5$[W'?S["&BF1K5$1MAI#
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MGK,!4W']:OIK,RF+6G$F.ZHYHSIW+RV(!!*:9$+8N#-CRY3Q,W@T[:0PB3;
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M52Z4UU3Y2IGGQ[</*&=1)T_V^E<L>SW/ES4G$<[BT6&=L<Q'CQX[2TSG#]5
M3VU3\S>5&_5GV4S]VLK&4FHC9J-&VWUA>+XG&C#<WRH2;\QV>[YZD.ZL.D9"
MD]C/@P)6"W70._+EEZA=N)&]D;6DL?./%@SE%*7KH436[R3*8-)"H4%TDA+T
MU+=%:KY.OE1(_'H[/O^2<GODF&5,QD<T#5[RR#YQHD-=[[+"J+4N?K9:;[FA
M+75Z63XYJXP\:9M7R&#&%D_\F+;(,M+$2K\:2,4O##]KH4IWT4!_'%0Z,#-"
MU*D)6@B(F,$D3?L\EYMSZH?O*L5T#,D20/7@XVGV5?<U^ KELJ(8S?F:/I X
MZ-P(KOMI@Z397C[#B%&FJE)$)Q^K(K6J-TZQRZW;>&4^E);81<\"R)R"$'].
MU]HC]#_ QC#MG5,/#.OD!=V\#]K=7RHVRM2$33-OVT1M)@_5.8>OJ#5<$-HO
M<;7L[N9V\AL6Z7],3/'G:)'BLG*LU=]'IC=Z.;,(%[DO+D];%6J3SG7UBH;4
M1I6GD_<)]=H6#%*#!Y,2OOBS$'G;STFB8/^<A]6S042PNKCFD,-PAF/ACM[!
M:A;$O+K_T5QDQGE;9TP63PD2:L>R,T(6QW-5A5HL3^Y)-:]SRJ[B*/+AKT[I
M<$OQ8 G'Y4].-10K33D;AENZE;MCJX*_2IS=O &D.7%5.!5ODK%KY15MR93)
M;9_OE)50?H*1QAK,2N"6S![3-"$IGJ]L3<^]_RD7Y)H"4NK%?-;W:CUAE5,A
MK(BC0W'1T)(7M:I2-[ZU.A).2@/G2@"&J6K[+E_N&00KMGP#ONC WP;PE>?6
MG9"2G(P:0XMSI[_B\I,0N68W/-4Q>)6^+!6H/ZC3?G:!.XLH]-78\BK]">>U
M<6)F17@U"8DM.$A];N0W1[\R2M2&HIL&W2/*RVG-P24B4K5F3@QL-K8EE$2_
M8399X:9G69^I=':RX@):("P_ )B+<BD=A0"[NTL"&5BX!._YUZB)3]S^G)JB
MH%/ZY<Z;^-D;TSD;G#%\=&&YM4EC7>_8'?V9X+:4_. K4B&?$EF+75(".(C[
M+-QVBAOX665;>U:DUW?@A'JF(C5?K$+@2@)F*:MXF&N<\ P^%=#='#01/$!L
M B^=X8P17/<JPR&P0+FZ?)Q+*;NX9LX:L!1J17_&D@7ETR:=13-8< 3WJ@1%
M"KF6R#'Q %[XC7>IY6,1E] .GDO4+GR^"$BL AZI](&Z&FYH_X+?SWWD2TA=
MIC,0.Z& @I>9BO4)#8*KR->?Z&E*%FNYG^P BB#]W>'Q53MEU:D9PZ"\T,M3
MA"*@I'J-!+0MLHG9(#Q78O9(!#N0L_@>\19(VI6$+L<1FK/=LZR:C?&?G)+V
M-1AU]\C&UY7W1KD]N-M6!FU/(.0O.[,U*N@D8I"=(*[I[W&><'X)D^>J+>X$
MB;'+IG/PZ!# Y>]>:1[^"-@'.QFG1HB/4:/T'<7^QV\K?Q&BWINKSQ<R+5F^
M9NZUO;JM^WYZPO',A?/-.?(<!/7 X[PMP MYV];Y-A^SL4!ST*2@;HH2NIYM
MH$%N4!L>G_&P,Z^WC.![*?BBT>9DQ*Q3%4*@!1YMHWS$YEP;9"G9[(Y,5Z(P
MHS48C=2I:$&47Y:<V0E$6Z++55E'S:RM7<_XOA[QW25S]<;LNJ3@._.AVZJ*
M@]3D9M;25G8.^'0'M;+O$PT@_WCJ^A?PK?8>3-4J*R!YJQ^J4M)\X4!6VE-/
M.*4H@#OY6?(SHMJ6VG(OS@AGZH""-ZC[=.0/<U:9J:5)M^-H<[+5IJU;-X8N
M(N@1Y35W&QAM)+L<%#,F5]AH16YE093^4CJ[?3;J36X_*T.^DY(PA3M$I'\
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M2K-D-&=T0/1@MG*,YO::7..!PD9QG187;L^:Y,;N!0[:$L8]ATF_?:G7H@@
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MAA1=8N 94Y/'CRJ%%%Q[0';@B<F7MX#)CI%68.!@68G8A]!L,27+T1JJ.^F
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M(]7RZ'BV6FD*Q[PNYNTCI8*8(T&$6N@)?KM%H)%A=V_"F8(A7$DWS@8:;NH
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M][N1Z7] G?:P[C#+@$$@1$'9UTY>V^@ 62+/KLU-*V\^7Z5ZX[ D-(>OZ!1
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M=+'=5L*D$]R>+#=N?'M,5)9=Z*1N#,\?9*111#S:-9P(7<4PR2A;#9X;-]M
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M@2-E/IOP8+(DANV?_@BH)"'KU^B^LM*\Q5#S1U,X6JZ$I#TATKX?'5"%B:E
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ME5X?R!-].R635PH*E1R28G5@$V5@'V+42 -X$S+JN[&&?HU^ 8=**DFM39N
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M0VTR,8?4X(>R.7?8-\#,^YXL,G0$M!E?)FPB*PJ Y<@:R+T?D-)D+)/>MX%
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M%WIJB:[4) YJ5PQ&*5\\$R]F<M0)NZ@/9KGP=H1=NCV$IB^HK:;^0="7:<'
ME$CIQN*+;7"-N\R4["J]K#9FQX,83/G'>13=G#?5,MIJ5HB@_2T/^2[<-PYU
M*W78F$LX?@\P]FGG<2W1EQJFLNRG8CHZT^**Z5<BJLR*'2\U7J8YJ5[:R=R<
M:!FM!<J0:^?MP2D1N#)_!-"F07P\:K)3<;G16!#)/JE>I:KB\>SSA4J/8L_!
M%QX2?RC:6S6H]\GJBWF"6[46_J.@*%CF&052!,K!S4I])UKB-W/U$L6M'YC]
MO534J%3]<3S[V@+9;BCZWK_PCCOTVZ6B:Z4:<_U8^\;<NE'?B\&R2-R#RO&5
M:N!ZO8N3"T/!%RO1/CMZIY913DT\F#DMZ'++:)UGI+CG)\B99=0O@V*4C3Q@
M*BN5+VL?%H0<A'P7G6V$NY8>;Q]5>D88*(NV@'\'L_1,%.-=+(-K/(H97Y2X
M]%B/2/^]5-[&51;;G%M7K[XW%:=%78U[;NKV64]08!#/PR[>&KJP?-FR2^6!
M<L@)[C'>>[\1?@/+1 ?!+!4&=,PS/&C/(%[Y@UE_ (C+_4%?*MS5#E[I03+F
M&>YI(99[%;R=VBOTRW1,>6?J^]]F4W'?< _2N:GYZMO"^SV*F?VO9UN(TG!I
MY$79 ?ZFAZH]BN4_ 4]^J/ Z+VHFC0=3E7G)>:&W&2YF(<:C\#JSRUDO"OTR
MSV)!3>W%RF=[+6H@5];B!Q13=%87)0 N4MSJ:@_\SPBO/DZT'2":S7Z\A&(K
M[F+E0N<T:>6S[0/$'NZQ4N89.B"LXBF/MQ;"+UHU]/89FHM%L""C7BP(V'X9
M#P Q4E=/GZ5]3YJKC%"Y)ND82I9%H"OV3EQA(-0@ZA-CNUG,Q%B(0+J"1U2(
M*CXH+&_RNKDMC4]]NKVS.D$NZ'&=?4]<_&3/69&NJ&3.AEUR!7=]N@UP?6.A
MK1?ULJG5Y*$MLZ]/MN7/42;4>J.]O]2DQ$IL(\9*',.B/F"5<?*&732A);1L
M+&I2R>"$-807C_P6H:)&_BSL"2?(E1L_[-6AVA-SKQJ(L)@^*/-__Q4>[SZ[
M:9NCE3.AI"^U!,T'JC?\R#_>&T8PKVCP4)78M6^!'^#Y5-*+WO4] QP+RV93
MFGK[.5DW;-Z8B4G$2F\EX<^8M,)&;D:/E5J%98@-;+PY)G$(:U_ML/-D*WFX
MY 6[3Y@1L^R70[BF$\=V3[!9/<O!O,2+.PJ/?*S)T^S[NDKV4;Q3I;2D6I[6
MNLE;\-B!>)[.47TC&46LS:;L>,7*I=V=-B%_=H1YQP_STDBD43OWG,%7W4ST
MS9SR&<EXM].RB?7M7W!>+BZ3WZ&]'Y.1#HTY@1?/)H+;!4Y%^TP[5Q-13FA+
M*\&M4R@%NKCFN'-DUF)48ONBIN)T.7C%K %Y"OZ1-W%RAPD S @X8$&Q@XRE
MV\P6=W\8>)N*]/4YH(VM!?YX7?JC+:T]VN463M3!FT&%XNA"EWJH=$"1[W([
M_*VKL;H?$LP$?39-TLZXX,'(47/\^4_9D&/;6M=!83G,)AV5\[+?#QE4L#IQ
M0HNJ0VX$:PU=S+] @!W;5M@.\LKG$DQWO(?D5GU.8O.>37,@$W:?'?A )P\C
M8=O49LGG(^.G*D(K'UJ7.]SG1SPW4&3/O%$=D-X9+,ATD+YTF\*L_R"OPG<8
MA?\M<'Y;!0OZU'H<]-9\:N>P7\4![?' J7.XZ3,6Q-.6$6RY10+;#80WFEUT
M?EOP1K5OX:I$F&Z3F&+>';/]$%I X??N9E^M=]W!R2!CS ,22P]\/+EWN;*A
M-Y>!PN\Q7=G?OB-?4SMV68/<@A<V8%K>2PXY2L\SOT=J;1Y@059&_:_GY4H
MK\3FTSNG=3B=VW<]&LE<A/HLBKV/9(]H/8+^ :B ,'9M< S"2&@5Y#2CW'VE
M'QWB*7?J;WDH!=0 ]S/.G\B -_V[XJ8N@''47SHQV)("%1[6@ER==0^RM )<
MM,&7^;&@JE7RL:FV4<O4'&74E0CUX/D@7(U[ASL_?#L2<(%W2:PTB%[:;,C\
MR< 914TU(@&C7(#10(Z\X\^_FS<1#OWG/\8##U!P1R,(=+ZC9'?BA!+5@-S
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MM/M; L$9>\_NEVQ_NEL01T\U&W^>6S^=/.>K+TZQ=.+L.3?6$^9B>C3O\$?
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MJ5L:Q#4X)3#P)B[_5.5*6)(C74U_I"DU(OKZ\#=T!GW]80+L(; L>\G:9U$
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M5!3W4/)T85R[*F-<J\* *[W\N:E*RZU2JUIKO^W>5M.%W6]=<:0I(%$MAKH
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M+Q4IJGQ2$;:VL%E]U4S#SX3) 7@R769'.*&)0IUSUT9\Q[D3&0L?Z1"HB/1
M7E.CG6-59"HZ*OQI"% PK:3+E@54!W^@_%]C%E&_%%S_H$^+EHH\3G^C!9C2
M\98#;%OF3B&)#@"A >)=]W+TEM K;6=^A!#REMN&E_?$<5\9SH&5YN!6):Q,
M#%LHZ.O<>Z])2VG0/;_ZF%@W$%D;WGAGLINC$R"F1$<368?=AXRI!#58HGPQ
MHO;.XH4@';Q)3.Y'D*;-!$\R[Y[&'&14V:O@4)@K7>Q6!7WF!7%&%G%LQY$7
M0JN;Z!6&I^4$^4FPQKY$T.D/2Z^9*<(^-(?D2G7&2K4\8747"7K'9H4-LD:Z
ML1<'2Q?YPNU;%P=/Q*/DI]VG(8'IE:6BU<V@=2GL37)TGPL<$I:3Q:SS_]/
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M'@.,EDS1H5GJ#5YVS %#HG/O.STT3<VPIR1=2F /?[0(N&0AUCMI_\]G-66
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M0UIKT@11YR=T/,=W/N>V["/:M9VFY+JC5.&^:*3:5QB>]RKI"[-O'T_2HAM
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M.1<MW>+_;?2[_*SCA43W$_OJIP;\/QEN5H>L)18Q<O0\'69/N%8QM9+CQ;.
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MMXV$NF,P*Q*R+TM@AGLDK>Q%PWAX%(*R*07!TQ<-"&)03)\8Z/^>[^,"9.$
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MZ9)X;RZL"& ?]G)WX;I[?1-_&,,)^^5E8I>CP/;,V0_U$0)"(B((LN-V][L
MY.55EG4!"IJ,L9L!"0CUHP'=[BG;GJ9_EH)/::7SV4PC!?E/#IQ?;Q*6LYXQ
M+>75&RS /R^,V!Z]X[T4W!62MRAF[VI(U3#)WKBIN*'+M^?"\ZQ3?7*]YL.J
M_,ZS/J="W9FVPA)Z?5N#\\MZRDG%M5&QAJXVDF4R\YHBIT*U0PJ%?]=SJ]=Y
M(U9#ILI1E\8;'AD4R4%_KN] GI#,:V>"6'=EF"3?*%0]VHT@-JZX[3DVV^HX
M5%-[T?@+>D'8=W!HV#M]%D8!EVG&DJNXR:;=B128WC#<EN.=>45D31KNOJCT
M&7I!Y-1K+ARMDE$Y@($8I?>&NV\^5\*'%#S)+) ANU*G7UD#R@Z3CGI!CT;#
M>B679H9(#NZ]=;FD">EAIP=9RT4+G HXZNER2!0*^YI \2W=H>%;32'=J 6<
M"=+&?B^SDCE>R7,^ EHQ2NG>-L5(ZWJ]B [3009UXWD]*IPY3*9Y6'2I'!.<
M76#@"@K"49*8X;L6'[R9(!-SSD!@8+!8DR 8N!Q(DVXF_&^R/TP449"3Y=^E
MU#E8R.]6UJ($5;'(Q(:@R^?2@""F'A=% &FA2?P%_*]FL71CH92E= (,A#@F
M,+#G/X]$HM"37DIH(3 (2K4&DH#H.0%H<K1]\&BRWV$FR8[1/'-_ ?^2R$(_
MCI.%]O?250KEI_X+_',%L!*ULEU#*5%P&S9O!>^F0SO+17S:%MM]SM$W<L<V
M^<4YPNA2GG,9T8L.ZY>V,AT/WK8VN4\-36-_ 7A/-'NBY?,;_VX)W#*:]SEM
M^U.0[9=]U#50'TVM8#UM8:J<!0PDTSG+^>8TXR H8-V(I7UWI2GWR>Y"-&?)
M[M[O:Z7^AOOZ#X6!-& :T-5F&OY8C/R/Q^+!^)$<QEP!)Q1CX"%X8MQ#4C%?
M:OP' >OZX#PO8P3(,SQ11K<]%[J;C9)ZQD]MX+!MN^HBL!=XRU1%CF&@8MI\
M*83C8=&<5 C&"^WK%8BS\Q+GC?A*1 *."0Q/FZU,#V7ZS.\ DB H40,G\UO"
MH5$%PBDX'$(OZ7HV4L02D40M&JC6G5B12--<0DB)5Z6[I:YVK9A<2*'R].R<
M*?NF;!UJ1E+OXC1&&U'"TM&M.J*X*C E)3DHQ6I[2&.O^A@+>5S[BE)N+,9Y
MGZ8JY;9S:1>HGGUPJ+!#D\%><NPE/6G,IN,GL\,H\"2>24)%,9H+Z:-V#!DS
M98D)$<]%G*SA*;3)SS%T?HDS)0EN^8NU>[@V.7,Q6N5NG*F+MX(I@J;NP^!M
MA]5&M8+/;>/GEL]2AS,N"9<\F37G7%X:O>2C(JP#F+)HK/=*(!W6<0:/ZYYS
MU9/:<#9N!GLZQC7?)N2!/J]%V4]/7%OE[:)56A]7N?X4_P7XG3TD_AK\GW8V
MA*$F#IF2!5?\BG=! W6]]>ET9:.M3>W>FXUG.9@Y;$]ZK<4Y;]+>RW) PT(-
M)QWC]+\+MZ/_B'I.ZR1U4G!50+C\<_0C]:1YWW]S_@/5D^*@MDBM$T^Q!80&
MQ%'MH6UH('.,4:7[=4V)YU;X4AMQ@GHX$5WXP-LW NK_7<ZSPI."+Z.HWJ'[
MLM>[/<)D*LG&40?)Y70V@]+IVHB^%,^JK;0-0J.>7>1]#1.H>:N&KG?#QCLG
M=T7HQED;QRVJM7-*I>A#L1 YUX2W'P.6G.\44;31V)B;HI=AZ$X/+<9HN&(9
M;JW(.%U+%9O+<P\!?V6)BKD[-]S6!4E:%?BT;#>($ ECG$1*(EB]D?\WL'<M
MQ"8L^EF[9;B-@[FRJ'D]58D$18C+Z,-CF<[ Y6=B>ZGBUF)WZ;)<<S8"_ F&
M:,A"CVFAI.U(;(-G]%Z=*7]/HS5PT8G2AX2)-M%:;I\AL<%^M^QE2)W/H1/_
M2T1"#S>IGTROS;+9(GWP %X]GT/0>S@.[HL67T68-2J/I@7W&3=(B1/1C)<
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M"SBI^])'C9GVHW%6556R=TN6N6*)"?S)$$]HE(WA!/<8%TR55IFS[\-RB?2
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M,?6VP7;82(5%R.M/)G H=87GOC!3H:1M-R.0']# G&:6BRV= YX$ I49!O$
MS?, T'(Z,A.83A/Q"<A BG-JXDW0^?!YVIU!=L*#HBJ[2&:723#_3?F,N5S"
M;^W!2WL#S/]#VUM&Q=5&78*X!(?@D@0-4+AK".ZNA;N[:X!@A6NA17!W+RQ
M@.!6>&'!"X<@ 4+>R?O-3$]WK^[5T],]/_>ON]8]]^R[]WG.<\[!UU/+TKG!
M";5#,,Z0,\QN)-=9H$7_MDG/]8?9<$CX/?Q\NS%8\T3@!NHR$E)84*DW!"'K
M;5\;14$U-T1FLR-"[0OKN3#P]*%=@K%VU>9G9I\K786DW9D'BJT$^V??YHG"
MX?17*IB2*VNK8:@JK(0VG+&%2S]7&';9)$IO;SJD,:-^.++1)-08OCNT34I"
MNA^4"3$4W,)YMQYH+Q4,$QD=[("3N=8-%=!9NTP,-@N:8W_'HEXX(0G0PIN?
M0$:A,E&]?P8)CF@=[F](81#QD<3ZW0).F*]VA*=RT/ -<^0%9TB$E4AE173:
M/',=4"^M/+\ZD;C$LN0LB3>_11K?PY*AS*4O,!X8WT@.4<A-/Y3\1:Y,&''.
M^!N#MSL6L8_%\?D=]?EVLZA0;E3#/.15($F4;#W\1+=X3Z0\$.#DXW![)$P0
MY)^&-33BQ,)_>0\!FG(/-KNX=)#3H"U5E6*;-9"*WHKZIE;LTJ.53G+>F;+P
M-_3FKI;"3&V0DJG[E/=<.]-FQ19%%T4-T_83SR5/E@63'4^(Q:!NZ7NHXQPM
MJ)%+QB+VU<5;DS[2EI?6W68JX!J\@FP!_-BT_2=LQH]I75+28EFU 33^ A)=
M= ;I,(U/7*=^ R'$KMW!X(GY;_Z&I<,_9S)*O(TJF]M:+JM.&;\3O:%?)^OA
M%N^3WZ.H.&!,>R[,N*=<>?J&$"R4+P4>4_PV+K&F%LL.A:"?=LD#?HU^[7V2
MX/7-^]9V_RP52LP'S9"O\'Y_H\$J/L5,XLC+O@^4/#OAXM]ODNS?#+,T[LAK
M90R&%H<E2#!4Q'/5ISMRX+5'\F2UH#R33_G0+D;IV:34=4H^G[1S5(T7PARW
M;3;)RW0LW/0S BTYY1, 3UDWF\R3=NNZBK_<:OV6G(R],JZ_5.P_<2HP+\?[
M&%W*]IW<NSJ<#VK'YK-.&(Y#>"8&4)'(C;Q.M!+U451RR$E:??1(9>/BD0BY
M__/!;:B@%5%;SM*,6KES_$/'3D*\? /.FJ&OCB.'[I6]9QO:)K-Y'Q0_V"D\
M++LEFQ&X?^"GY&407G/ .:&[.5<347__#(/2[FAENLXH3+TH+;Q)F]9SM"3R
MCD"3)GG;6.W;00L5&'AA;SUE"%NT*60Y"NSM9  YJXL-?@^Z$B"4="R# ODB
MS++[&3U'A2]QAA;A4X]T>8=LE:+E/#@';K]E=WOQ9*E"8Z&5T$@3V8(9AS.&
M^.O+0>W$!Y\',SP*T2\9DTY7OH25X0]U,[4T4Z;J.@-OL/Y*2(:%6762P-PA
MXC7T$5_=R[9?X -"B3HSO0,0PB@[KM7-A"^%9*[C%S6_\;>1P)52T*:;KB['
M.(KP]^D1#U.E"C]XOLL<)RN;Y+<&KE>>G',?=YJSJ #SWM.:58<F\M2<)C#U
M<C[]'-6 .B/<5>M$94\^L%TB"=L5B$-WCET]"C#)V KHL130<P";:C%VS,6F
M%LJ#Y+]^1+\4_L7ZO=R /H"X3+:B%4F?02JD24?:05D: /_%.&X[E\O\><QR
M(T:&BP).N5,YH/;>E/[CWPA)O2UOH>9'N>-(7V/%ZG'=R6,V(J>7N/[X]M]Y
MR%L0E"AOBWC\J%DK;C*T(NRUW@>UMRA65HGA8#@7[:^R9ZD%;I+PFX#J<C.D
M,+%SE?6++_?^"WR4=8=>J5,"R:\1/U$>^NGN$AUR/=D/7I8N8@ZV7&U<'"W^
M''YMY\3V' [*?Y)H5+WKR<QT+8\*&+]2&/OD9+8D0-Z.7P_L]^MSHF7-HO&"
MTME+=>;<+#8PKHAW$#=QK6RN7!3"-UVIFLOCP>6-ZQ">,/QO)WC_(/4&U=_?
M,3[Q>[ZL<IV'?ET-L]9@MU^RYAP)@;3N(;Y>I, FTK#E?R';_=HJ;JZC$X%0
M&:G0H[K'YMJM*7]NNRD*WF%H5S,V!'W .N5-]HQ"8W+Y33SXKG_^T";O+79J
MD[2Q%=&2CA";*'XK '-QW=X'8Y)XM N[\PMR=Z!B! :%,A&=6)K\3WHU)C/4
MQ''BM[+)9,]I:CJ2S'Q=8!S.P9- P;4QCR3$'Q@WY!\DPF=>GBAC),8\!?Z&
M!A;E; UAU6V!DI2X(\B!NH)VBMHOWE4I<K]73^^;15BJKB'*$OQ2^!_?4[@W
MD;2QJ9!@F]8,G,XC*LP>P.)*<-*2CNWPHZPEG7J9\L_"WM1[[L7.U+HB1U4J
M WXM+^\N8GO?*F CX]JT:RKN0JOW_6\VR?3EK313'_2JNN<."TMJQ0GH)VYY
M53X9OS64N(P#UMHSWN'0:+",.WX73EF^RA3,K;=&C3RL9U(N=(2U10,;D#-Q
M0/1T]SP\F63S[5,_+]VPF4]25OBW6]1;EV@&%=[IQJ:A7MO]!ICJMV5SBDIS
M%&*TABT@=C<.:X+5BB43:,VKNY-4E[6+'#D2':6);AJ]E9J<W'MU5 9"2'PN
M#_.&G/"$?DALS+V1K8O1U/)S9J8YC*&@LO+*X2:2E+LYQ_0YSJQ(J7MP^P=I
MNW>]DT4&?LYZ)E3\5P,7IY>)2'7DQ&4-$>\:3/&';C?;<JT-_R+K[*6:UO'-
M*/U@CU@WJ+"AFE>/YIG\+-6DJ(RS3^;W[*%;HGC-:0;U7%8KE)W0K0I?YD;V
MP<#I$"RF28.P&>?LB'D"\>-J7OUG0T+^;X)#P4(C=!$LP]RG6VB+QF^%U?;L
MRHQ7R,0"E%#X4DBOSX\^4M_#E:Q24EWR$V\[8>H@OKVCCB_V2T$*FE/@>?K\
M@AL"5I05"FQIG.._'X5K5GY+S<"+VD;]BWGKZRV6JK7?^3E'F(+XE@S]ORWZ
M4:LZKC7X+LY)U\N9,A02[!RDNJ7_0:+D(M%R78@=]X$-]29+*'MX#BA,M@>(
MYH<0!&N(ML$(JU4_$_)<F='^\G!X<#$9JM*[W9-(2XSZL=5K*DO@K^:IQ( R
M*4]^WQ<@&D<WDKN"2B[H&:4H'IP-$8AA*;8SG(]BP&X4O.63H-;>06Z%XZ\T
M"A[2D2RT3.>AYV?CK:Z0],,;,,HK>,\]<*:A)!7$PZGP\QC:R9C=@-*.C25B
MV]CX(X=CU2XR:]+$C-'>^%T'#/8\Q3K'=2!A$Z=?KL"APX)[D_+T2O7>1_$8
M:LI?P9VU:N)COCN&'%A&8.GWK7[6_#=,V=(!Z29 ,>M#W1N2L6[G7/21>,:J
M<9MJPK?8>I&F)8P4K+X.5/P:0Q_M)O:$&8<GRY2*+@OFK@=B'."S7K*\X\1J
M8U7DKX13-1R+\#"(7BG^C1V./.$7O*,9"$65!H^>+!L]O5]EN!;)A':5'EDT
M2%>/Z1TQ,D_L:U%/E$#/MY[*O>&IEO;]8#(&\8'(FSF3!PQ^K'0$$GIKNB,G
M4H9; EG0T7DV_(O,_2<8.ZS<-*O[\_JA9K':P&*MSD[X'*X4>FC"1L,/-]JC
MQ>II80>2E^K0&#$PHGB5_Q^D1:=U<'7C6BS) 5W[,N23N6_\ID[=X8FN9:"(
M2R4?1(%SR)HY7:;&*B3AKF.\^?P9(UY4 NVU%9@SYROV;<=E[ZE_O<JBT_[3
MIQXZ(E-(7V7BP@3Q,:%<&G?:D,JB.^B0:>I8>R+FR^JN:JEE-/QU]T_^,U'=
M&PW?<$%I9M,&HR7\%-!\>2HJF*_%3+&JJJ9E.D5G OGMJ@?Y-92M6>\7!N)
MB=<Q)QHL@R6_B)A25[+[;I3.J'ZQ.DA!J;RO+Y/98G4X\#T0#A45M+BTCIBO
M3/.1BL+@O3%"-V4F[IE.@2&6"45*7%!,3_9(\LYOP;@(;<2AV54RB7[1C'%>
MS@N+?K9ZHL3QENRO]7HY3AC8H!R@WDZ73V*9E4ZB6\KL/;'O#-SU/?;I% :I
MFK[E ;(K6<T$FHW&G6DBU+D_LS , #N2VK\Q@ ^+/<6@88FF6!V_/N.M1)>D
M_'6XL3ICO)N$LM)?^I/)<)J!\O#  G\!HB/0/E1"_.'F3R>]5&L;67/G)%_\
M13TG2_;M"]N1U"N;40\\S,@U8-J@OS'I\ M74;#0B:D4S,V<2>O']ZTO">*X
M@YD&<GWB9?\@V0K.4NOU&+5]=7,,96E^XCJ&KXA^0X2XJ9=2'$O]-ML+H&@T
M4&MSXA)0['Z#N]%S5 IC+F5</Y>8OP^]E;669'J<JH^H\(E@'HLT974Q9Y][
MT/<J:V X==T^I#DP7 ?3)CZ(R;_0!KU1M"7V>FTU@&NJ5IDXD/<(3NC1=V4R
M?%%8 ?ZY.Q506U O)%GE3"GJ5E"QEN%=C'U/C$MXQ9/^R)'4L-0>J3#:Z,RU
M[5N0;Y^K-7[@=8Y7KA9.<".K*EX['U-(>%4P4V?1/:82;JP%B,GF+<MPLBYZ
M:Q'^WR"Z?X&YP$=H/%?%-2%0]IUKR[711F2!B9EJU?B0J4H$0J'SBUW;4XR&
M@'ZA"?D-=.I=*SW:! 7I76=@1[077CGH/MO;_]'1?<0 =3^L&Y85I!_68Z[8
MFG:!1H0U.(I!8S /KTC7=Q.M2UD.7=^TK&DF!:XPW(@?H$Y92!+QA<>-JNQ1
MQ3&<<3!-_!B^?EHL,@TD3NT$-0< \P.ZW] O;)0.'RY58HU-R0;QL \M&N^F
M^&M(XH%$(JDC,E&NN0;UVR3ZQ*],1DS50_>)=GK55/DD:LEY:KB]_=1?\E=2
M_%Z'QE:[F=&71S1%9_1TX$SW4!5&0\67;6)0A=,V\2"G_T[=@>3G$B-C> D%
M93.F.]R^_MI'8M$+;_(5_<&XI 9$-@M=G8?P9 /BO.7F$QDVCTQFH*TMQ"=R
MX5'+O"-4B_-%M,_--PV.(R\,[L/*1^FH'_&-S%%'56B":@;W31NB>K*80!BE
M4VWU2LJ)+<X\V4XN8!/5<J"5"C\*=J6)8D!ZM20*)T"'15]E*HO^;TBPB;LE
MFJ1R:VS(71&\1J4*CJSNN%BV ^?#:@!OIM:/4!I%)A1&8(8A*F>K+'$U\MOG
M*BO;"$PK71+9?W<SHD3PH1XVB_[$;>)'L9(\85,)2?!HF:YB;)$&S(.((5NR
M^2C#;8I2]Q?*21&&.<J& S(CHL@D8B$Z*&Q+I5D5)TN%%*.1*HEE+$@,8D04
M$WN(^.$N:0.F>70CNN)GSR<9&Y\&X%?EXW;JW!-?PQ.?:BU_?IS/L1+2C .K
MH <NJ%CTS:Q.[T;R5V_UK0C1^9W]@.?+@-O0[;;S]?+-"16F3(T\4^\Z7U>M
MQ=H[L]:\VKRIY6#(A!*@;(5X9\*%,4:@>?>KEH,/4*U3C98Y_A69557U]Z%0
MOOH5IP=:V7;1:A&3C"=R*^+R-"*:HG3;Z*:\X\S'@A/^T5BS9&EO%#0<&VLB
M&WWUD 1SK?G*=(>G5%5K,3_:"='\(^GK'[ESY5D8:G0RJ],LVL:'WRG3$Y'0
M<,Y(MNRY<_&=&254Z)GH@WL7VD4E,;2A8V%@V1PI"GS4"/48XB^"/H[[2&]3
M+7&B\Z]U2V8<MQ*-YDM3!=O#K8EH["G'S64"^,# /*MF49]N1^ZX@J98'/IZ
M.4:OF=_[)\GE=+F6!YE7X%4.8G=&;^4#'I=334345">U,)O^-7?6T[X?[PNO
ME)>J*3)32T<73<8BF]7,LGG9FT7C%MJ*=DW=XG$)Y9V_PHY\YWG\+/PF@2RM
M8VW<ZQ\DP4!FG:*^N6A>SE;:)F/Y91;2:645ODE>H.TLQT/L7PYKV;9:%LS]
MY@^$%@;.WS)["QX*QFA=,I-Q9_BAXAK( E;:"_5>)KCU,M,5+H$*JUSFIZ2L
M1&E5<P^"$S:I@-;,Z&-#>./F$,_ KX8?6_5TN:(S+0J=3ZC'23D-#DLSMB;(
M'(PB:3>K_0HE%].G]2(5H?X]O[\ELM6-<R%?S,0^<=VZ@2<XPY2BI_'RJ]LB
M6,]P#H%TI\!HFK2[BH-M4[,2C0KUQ'OWHF".XTVV?%2O3*,)-*2*:7!CEJ.?
MLV!ZF=8UGCRB9O'#>L8'^8G;Q&159/4DP33+ Z2'1K.M] UAAMG,<@!<]&U[
M"PJJ!4ZQ/,_XJ\1DZY0T+5W9_S[/_9^ X/62!'&VP9A^Q2&F</-&,RHJ.SFD
MRU&_!/;M=?(Y?@W0>4(E]Z83@7XV\NBT5G" VUMR(^6&-BSMWU@F-M\FK#3#
MCGK[R:-GW"Q?)^TGO.[VX<!9M^SP9FK@L1/]3KYF5K; Z$G'=9E]><]3DJ*0
M*:_$SH*>'BLV_LJ7##;XAA.V4:- W$Z/UZ'1,T[<2WTU^^]Z%3U&[QJ="-XT
MHF0T]%WSSCR)'I+2TEVV>S,+MQ1(0%Y"8.D:S 0Q/#A5(/LLQ87_^_VZ1+[.
M( 5X[/,>7L(,E/26+AJJ&0Z#6]U<?J?BFV]G4@;3_Q;S,',I59"!=0I)3T7O
M!"B/? \C-;3SA=N%JW)QGJEWJ;PBIV>/=X1H^F I"P$.9(IY@<UY'#9F1":P
M.-TV\<E7HAG: ^;^KL5,.=26>P@U?F8C[2F<=AVF;++_N!6LH[LCA4R]$\&G
M^-V/30D-Z^_[!: %!PVA;>))Q;NC"AX[H95HU,O8"(U]+::G]#QL$6)@5 &4
M"^6 =.FE5;'CU25Y-.E#L<IY+&5-L*I5"F5; JT_T5995;_K*BEQF:^_^(B7
MC4I'3:CD:'WTS0LIW.,F2'/.!@MEL(*O-5)/RNPMEC&V]*.+CH(FT:POH%%]
M\BM/;M6$[BI.WS7*(&D?1&)3;L1IP:L 0FR89]S)GH)+WQI"=-S8^:;LPW /
M3^7MDMWR#.&)1M4WJD"/'Y-31X(F/UM)G\B[W@#(S]SR-SP&J_Y!VO@'J>U7
M=D#/IK5;5,=+=;53(?$7+E0)DL;GGAJ[6GOO]II#;\K8[*5&HY%9;Q S4LY@
MR0^O%U0WLK;[I7PE>2)=I3<Z&U"OEW'3/A;V^J4.'I5*9!2E-I7$AW'\@'EL
MN?*(I<H,)"E!GGYR7.5$,UO[N#OQ7.X6VKD8:IVB@I+<A?)T7C3/WG(-2N+>
MFYT/*N]0+5IF=4F*$QL\71#:8Z)#[^B$ IC318X" 5LLTBD:*(,]))(_!)0\
M1"JKE"Q\$#8TEI?6.$@7S)-950SIAQ4:@)DLN@+5MYO#>-EQ9O4*:=/LC:#E
MXH4INTG7N)^TM7(8WLJW.@-G6@C#5A]!8QH D-U>8%IZM.[,]DG5@FHA1'"G
M0_.):$1"^0]B:_+6&@F5H<W"TFG>^#L#."AF&7!#TRCCB?>&G.(,M&E3TI[4
M8/^7F9X(6,81W2D<#QG1!<T@H?JEAF_QAXUM/]VR2IU7.%X?BUPPJJ2FV133
MDUVW@@ZW5D8 0,67%-5@FM-08+G@_)@NG@^!T$C7#U2KL];2'B'%X5\7/;U!
M:KQNW@KMZR3'Q8M/GZMTIVW-)P+M#H6-444L^EY8_-O)OYPSAV#Z/D9833C!
M%'I$28Y+85YJ)6>C:F5M_*G MRYQ(R&=,IN&-2*EIQPK7[L3EA(99UU\9IO#
M0 N& QM9&%X1;Y;77!C>8Z'?O#"/V$WHQDOBU&[[!E4\E1W/KO!2N5?: )=A
M18-(G&1)J9$/' ZN@S8I]/YN:LNJ%P*9U>$4RW'2@P2\9XGO2"/?T8^,(MAH
M7Z6K52?^E[6T_R9-(1OP"Q.ZO&/&W E;;I.@:X>U<KT&7CBY86Y%!L:E162N
M#/N_- C5"X+M)Y\[>V:5JN(;5'\=G/M+ZQ_WJ?"BTX]B+GJ'(E!@[]>PN6:?
M+^#LY#;5PR_^&PU7"GI6/!D[-4';^9/@C$NU,F%+5!SRP7;"TN'G; 6_:AV&
M6+-P(L*.%]B5&48%GKA&ZBKD_?QHS7@:]G63!\[(5_?<"T/H$MT\)N^<7:^:
M7+^XAM7(\!3-&(K:]>BIN$%T=4?M>K!H<,$-+V"-4AZ3NA[G>P^=0KV;GB'%
MS9"_&?F7(%*QNIEP63OA^XZ#_<TDRI-U\&O /+:41K-)BX)O=5T7./*GNPR-
MU@IY#'H4.<2+Q<0H0-J T_XN?V3)+QS5ZR\[MQG1JY#5Q!A9"L@K%44(0UHS
M77G;+4Z)LMNUB2S9]1*H_/)0\.)!ODSOR!VAE%;,"16UPY$["2AFQ)Z[RM)H
MR!8,07\Y"FD06S-F,@*M)A?0=>//^(QM6T)<RIS8Y#>6&#+>'B,"*ODQ],C*
M')W!2(B4&-[UBEW;&!!!3@AEECD'<.1)AT9#F^X8B'1R+3Q5P8;\)"+^/S8R
M+(R*I"V,6]$@3LA$E()BH9KI[Q$)2.*CNV(>\4[A'D$7Q8@75%8=OOQZM8)Z
M3O$+AZC20#,PO/W47TT:AGA[P/S+]A9<BC6X]94)ASWAVW#(W?W(^9[$RJE=
MD&#!E&2A<>[BZ9%AZ#&)<ZXTYK;H&ST+\\KGI)MME59X<J=7?&%SS?R5)/22
M)<0V4.*KHYL@&;[);\Q:CHD0ZVVMD;N:OI'+:LVNOAE!Z P/)V-CQXTI._K8
MTQWSMHZO.TFI"B,B>!75(^Y*^WCB)2MWL3PUD='&Y>TO^>&\*YQ+R<^5*I5K
M1)WN\>(8VCU3Q_-CBOBJ''1$ZCGW%!,W*FT(+<1*FO":" %3A"BS)?M,#JVR
MJ20Y/_6/-T:),,4#Z*>VOQYQY=M W!9CFU:IB&W@V(D6XM,^Y121WU))@CW_
M17FAO5FL,E*DL<^.$/894)YFQO&$'!=_&C_#TOD= 5&'?GTI =%W;]VNOQ+)
MN$PA$SPT-B3XP$':FAP$GOEC7-(%'LTO\:,X-Y:'[7B:+#+.,DXXKD@BZ?!L
M*$0G.*P+-S@M*^3ZG#/I%[N?NO.$(_'#.U#NNMMF</(6P5RH=QP?SK[6^I+K
MN)DSZ/XDDE209EH>75IR5V/]<^)R=9>_7#CL[/77$+8\L1Q_7Q&M18AV:/UH
M.&B/PK4Q0;,F/4/XJ:D]1)D21+E!GA8<89KIU1>5K?\@E0CJQPXO3A^()%(I
M C;I%4'_&D*M;N5=R=;-/Y:F71NNXW,/!(K/R,>A]!"^YY@$'!G7"@8*O*CH
MGWAO_%V YMTUH8$-EX*=!BS/ZHDOL^7'_5FPO"W5/FX@ ->ARQA)O'9?7_!4
M?_E5;(2_3M#/.KAX!=B<2TH:(BA(G&$0XC(DPO!**+=3<)S#ZXTZ;;F5I\0Q
M+>'_2"/]/X!H]H#UB/>.5=?!PQNKX,)PJYVZ8X.RO#9Y<7'^/QKGO/G60K:L
MLI#,4#<6*/Q2/^[V5U[J3Y13JK/3:'2+)6TI.5Y*\X(I/"6UG;8^&U38.VN'
M"O$2>"M&E1#TIY#>ZA^49^6GX+.<SERX>2P[EBHD$<SR\1<I,B0/6!^:4RX:
MGZA=*\SR/SAE48Y,:9&$%T[Q;/5RR KSK<$V'.]I:C*OVXC_ZAR.7W3G"04!
MK\! W !_+@(=MYS"T<(#U<(UN$LLZ8^M:,K3M7Q#"FBJ6)D!)(B=/TC_X-OG
M]T9(2#D1H,% @Y(@P0;+V_3EASBUP!7NJ<O/]93B/08<8TMZM%=Y#E5DHZL4
M>+5_O2,;Q"-+#6B+-?/KTH0DB4](M9FHMZZ0DJI2&G!Y?F DH.-RS>'#;3@A
M,,M#YM#_3 Z J3K,$QE:(-7)?D9;$OZLQT_4C[TCPX^BT*P32VQFNT1L@C//
M:H"/)JB<AH+4Q"V55VUQYBIG6* R?*X>-9=JP4"Y$X_S =G#EGVQCA*/S"54
MN5#7RH<?J6J2GEIN(.9BN4QE.!.KJ4^VIHK9!$6;J9L\G$3!4J !K8Q^L.SL
MHX#<9TOX<DX-D"$>C68FAYBVL?VUS$ G*V_2_'D[6S$5,9KU>]8B.NPZWQ7E
MA36JQ\09.PB?6E3Z43@:@XW!1'#/INNW3XNCRX4<QN[D&F<L.E4+Y_=FE4:,
M15WB;"'[]Y!SY[K3Q"67"ND^DTXE+@ G/J ZSW5'VK5\U^#D N'/XGYQ6,A5
MKF*@:LHK67*)&=1NW+N9S_%-MA#GR\OWO=N@3X.$+7P]W4L_8]:N?9G21=M$
M0W!'LI%]%[3'_8GMS6)D+'UW_T'BI57]<T>K+,$_]B6X"44M8S>>$X.D^]CG
M^/;*\C(P>4Y':>XHZR C  *4$!F6[4#11@FKJJD0+KCYJA>Q6 R;BGVWRT!;
MD^GDK?QSM.YD#N$/SKE(7S)VM?*:U2)=]W/P29 X$X*W?72F#O@!^NZMI\YB
M%:O$<F)EP4&'BM[K^J%H%UIM'\PQ7[#[=MQ*P>^J7;\'7VE[=PLSS5847>'F
M3R?E#XX$!^# +K1.:;D2O,_?K@!.24A*QXLE:L$)6#-JG8'6SY+<NL6>/539
MFRW/CR\&<J.\'D\,<=GIYEC-;(JOWC_Q-Q;4\6?,7@C&+.U/H0VN[4[SDZ\U
M_G1J]PW+I$]-$E;5>Z7Z*VQO6X(N5Q+$/'_!'/E$GTU%RI>KY9UH1#VXT:]5
M?-$^/K]A^,;8;9O'C*>5B^@B)N%)\-8L<UWND4K+@<27VY12G1LYY)O<9H+@
MPHE2ZVGH][ZG:1,((^*'1,)Q_\S3!V5K5-Y%(! )2<>%J2TNLE^C<MT5:,@8
M OSS52>T4T1<0V3R]G>%7OUK!$\389R+.,8(XIL&%D-2)V!T%^FS93?=[B8C
M&%F#Z-^EM[G_8R?V7P/4(0%P8>ER4*@=&>:'W6WD28I(9O*T;H?BZI:3YN*3
M\R $@JL"PJ"S?]1Y:3L[9N<M,O&:@%6 Q@*.9NH8/AB*N05)@^?G&;ZI[C?W
MKU:IF#H8NY6IMH%DUSUIN(AH  :3#^[4*V!1!<#=L"QXN]975W4NC!2Z>E44
M54;.U5X\M7ZC-_2MHOR>SO.?I]!DST:WZ:^YX*$LT,JN7P4/K=NR">B3PXOP
MZ\)ID%8NV3#%WA;YYZK.$;M@,I:1G+[P6=2#D4"=^'+*$^,L*CYZG9Y1G*D^
MC!3YC9JF]YA?_M),J8)._U1-]7 GH"ZQI&N_6>QLHA ENCFJ\E,1IUA3 RMM
M$]AF=J%W,JW4 6'(^\.[S9W,#(>203FMSP862#  _.476VZS3(&5)GF0HO;&
MTG?'B)L3H#T>F.T@9!KO%-6J*).XI$#,KGU^+<,$5DR5(@Y'.T:+$"D>@;6I
MSE,2*IZ?*('RD"/UBO'RD9NDQ?T9K_D^&97(HM$GAJ>AE0.QLS'8:/51BEGK
MHE3D$)IJ5P*9+/&RUMH;0P>ZS.'T=BXR1>*\ #00N32KKMPW[%XF3:896^9L
MX9@V,_\@(HH)MP0R_GP?HR])SW+WY0MM%<JMD!R+6I1EG@;TRY =JGDA42&N
MEF?(S3](IOU;2?#Y3)^EW2Z_0K/S?H<.8TY_QO*J"JS'G_4"7XQ7*%?T9G1K
M-1AFU&B* B-HYIU/L9Z/I-8LS&L$.2^.!3EX6\L3PZX!IA^:GMS]M^[R^XZ\
M?G_9N +MW@9Y,ON9$M'"#3JN)OE&O8UH@VB%=IXG 8S2?I2NVB=C_H&T01+"
MU F)@O@P.=QR_WS16U&7V+Z8,67MK9JDUJQME2%?A]L> E;N\(@H),$OHCX[
MWLJ_\WS'3C41GIFXN VH7NUD-R)'0;%6L<K9 U=1?P5(OSWCG9*E3J-"V??L
MK1\^F%;=[YQB::=E0F8.S<M(F%N$AN@$IYVI53 \9YYW _%UBOH.FAS)B=!;
MVF.P]J U\4-=A7II, *?#\8M?IQQ:V?"G*>.:4<0%AF[5J82L-XELU0,O%N>
M/<"H 5OWIITZ\6VM"&,OR_FZSJJ]Z<EL!65J'57@IY/S9$2C],QVV,^7G)T0
M8_.M>GPPATA- PP.P;Q5GCE4H\K=J,TC8"\RQ"NBQ.>+?V1.Z!%JF)]^8WKQ
M#Q(/QZ#P>KK&4'!Y<7\"A*6B(Z/6QA$ZP)^S@(IJ\\[!G'ON07^I6P00@KD<
M7!GVKP.R.7[6<.!_:$E.6C#2R&:7BRXR'!R@G3P NH*GZTI28D[\0\W*_RQ"
MQ%D01I*@M/&V5SY&[P@BT3 F+0>#R6[]SA<RJP^5O?/K\NTU,7C57-Z%XY3+
MLS-RIAZRQ2[$%Q7]OV.,__+,KM$A6$4MFCE#-Q#3\?1[^R:J3+W/V62^E'!?
MRE,:B^HH_1[I5>&U*]&B<89*Q,^&D\ML?F!.)9O6%]J^^F/ =ZF3P,_7G,YX
M"M *0J31L:$A@#GDK\L"!K=\ SVS0VGW8AJ&Z0^2R._I>NT<5>-4*8@"UGRC
M0ZA^<]MO (/C/34B)NKERF3&4^H#J!)\7.YO5[R$LW* QR"/UD_H>UN1Q1=&
M^8/7Y+X\$:!^T^6_(L6I$'6U53PW&^"_'=7<'I!M*3^KO[A$JFJR2LV=V&/8
M"Y^K$3M7JURU,_;HN&3-NVE4 "&,H/)05"GJ%8APY\!EPJY,;L NE&D<DIK'
MRBD!VQ,8#()K-)U'G?Y@Y,2N4X_[0%D4<0NPRY-?&N@>;["0'E5.=,BQ:$EW
MYKT"H'5,VVW1-TA$KP-R=A-7\P54IU(%HYA7PE47Y/C'QPC?2A'7O%4D4B\9
MZZ)Q5^I5<NERD\36C7DD=P[1G@)/2Z%B7\/#]G5CQHE9Q66O.5^GCTN!4-Y;
M3(:C@.'O.B9E<="(O\<U[QK*SDCT@LI89!TG\*YOZ,OTP"C8Q)LJ,1FMD7H[
MZ-^D!BZ5D^*KOO/D_EM_SC*AHL+.#<_.]7&\7?$5(JUEG=@+P6@>^4'Z/>(T
MI>T?)!<C=9!Z@PJ#SEYKHW.^<I80OH7JYP)9&0J\@U#$QB>P@0"^Z/FX]JL4
MDA\O.Y=N^:X=MT_RY:&-C2^8Y;36'Q;OF ,?+RI-[TXDAINCOL278,?A.DH^
MA):'@>8=VN"AT94+(_+8'KNA$K4; E3PF?L2=6WWD1UVF0I\HSAS>C%# W4N
M-"\H)(^69P&O$@=7$6VR7[&"E#=K/WF:+I<YG1FO*7$O&@0CP3[A+A%[+6KC
MXB*,ZX=V/.-HYD[F]]ZG1R0*.2JV&OC9Y1!<@B/HY_7"9IU5&L5 .^FP?NBY
ML=CY#*6M^ZK@&=L7,40D6=40MZY <]G/A?HUZYC+$S-UB'N-M@<\GX*:'A17
ME[O_*,'_0$2FX%%@S\GNL.[.Z&FRS/0==5K4+KE1;PIWLBL#AYJB@%S6A:60
M)?N31Z*W_9FH^^J#\5_*>+_O-#@L]=L(E)H]*,1Y*BH&^_LX@89+NA35_((E
M ^9@I>(_\7T&XB=<4[8FJ#L6A\+4R"U$S<%/DI=.7#K5?#O4G5/49,[4:GIT
M" >-DD]JX_%<4P=41UC$>#P>%#/T. ?K="?O_Y*+D5O?/TB+YC6=+'L230M_
M1KI9%&PE32!D9)_66D[+"40?_3(LFAW#3J[?H"^[/_7IC&K0P>[.8O(0N1AM
M.L6J7F/!HT\\9@?U>%V J@!8G]=>7;[+!2^$31K7PN%--;+OZ 9#O+R/[632
ML@<P %/=5E/S?X(P_BN =73C\S,W*+.&7UBDJ6<V<O2N:NMS5%?>&I1=1SM!
M@O#^\:P^]W>#4SL;4J_ ,.$\!3(A OV.(-B/KDM96?A+P -FGS;,+(H)P!92
ML/3DS3/?G10DX @M;J>A)4M%PRX8B<$YIIV5XY 8S?M@_>#OUUG?3 ;Q$$>I
M%Y8G7VNUC__57[*I46 (X1&AC'_[V:8YLSSL+1?Q2Z_1!:)!CZ'@,(W0 JEU
MN==4KI=7(H%W8*#%#L6^32P[NKI=E<!<0[)N*H&!Z!!RJ#(!I:HIS.K4MSKQ
M^"78)B_&E?Z32R87[A;R2B0&&<:,PDS.Q;GO68P %KZVB?[V_@=HD\SJ<. S
M%GS[)/( 2K7C"\^2)I]TS_D8F,V0"\.6Q.TB9-@T66A0T#6C !MU+19%3A?Q
M(YEX;K'T60KW,^F2X6G:I/ JXB%GY3#+ .JQZ*7?LU%AEQTW,6:R8:$X6H8G
M1&(ZE$3-M\P/K3)]U,%5B9MA76!L_?B#Z'7+NVR,-299)8_%&C455L94>DV\
MN29A5)S44I/Q2MXA1L.8=!).*JZ'U^G;#)IH[RRO%=Q1!:^K+=Y9&3;KSO'C
M55L]HP/)(S;B&0%&DR>F!NPPA^YZ^S:OM@QB)$(Z]O5U/S6[RT @;&2^]]@^
MZ XB\;7O*Q-%^9Z$ZGW&N5^[_S("@E\YJ@NJ^#T JE1^&XGLB#Q+U!R6?6$_
M">%<<Q.%N.CT*,\]=?9";@M.R^!7)K/&$/"4O;/NU&&-;F-.S>Y)EA.QR:[J
MKB7'Y'F7<5);,5HFF=(;X$8?>[H_Y_B$N^!,A7GYER <6YPBCE&M=E/R!6OV
MV[%SVR=-P@>P_&Z\A:78^;58;EBZ1P\!%HMR :R_J[4]&\$=OG_8@W5! I2'
MV_/?\8^=:R+0<FYD;)AV.Y-*P<"8+<#E01 U!(4UWX*Q,ZG;<G@/6JTBI!_(
MK*$NL4\G);>#[/9+EJ/4\4J!=MI61/,G)Z2<K6_Z]<W^Z+=)B@R<G<ZD^,/
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MX*KYU/0N,^=CU8/L>'U!N=-S)_0KA[V?UN(I6&0W)?(AMA_HVH^_!-(_LI8
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MEQ-$VTM=!^QE"Q:U!$I)TCWU$/.P=["'N)C3>=C;P9W%/"2 ?S87P_1_3X.
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MUGM^*=KZ<*<?P_0YWE=];%U<9G?4*[=BF(51>?"MCE-%>?"Z_I#.HT+TG@N
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M@P^**K9:&J<?ZB[N,W0?O)2>11]_R[MJ>?QSH17W.-X K_]H)V!7R6P;= /
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M ,(,KO:JL/](K7 WN#6+]#"BX3/>B%!V \VUQXLAWE*L?Q%L 3ZDL(N<O;7
MRV6J-M[^G!O ZH><6L=,<+)3&$."^8O71F>U?':6!I!;YIT"XSD#'8I= ;15
MH]F:#"SJ10DE2MIA>K79:5DJOU8/Y!;*RCI.(EO<;E?J%?3:%JP99 *[PN;)
MQ*YUF",Y2/.J>\_#EVD=I"CLPZF&>19J60]8/E']Z#0B#UL &R*9QRL6/_SH
M'U85Z!C@E \$7=LT?[X!Y%,C+NVO+8<(]H<WI<8O6$9;/-9N  #3E"O75A_2
M5;S+">^ &X"RR.+I[&5O=+?4QQN ]G:V\MGWTUM'W5O(B_5L'JG5DCG:<\VN
M&T#7XJJJK^B5PGFVY;G^\/TVB@(I$\2B[)G_#4#0]-L-8#1*^%KH!L '_I<P
M7T S[_F6[SG+P*/E+!:)J?_V^4I<4>3'@-J7#JXE!=GJ)DN+'B*>H@^/9/U+
M\0L#@[#/7>K5F/;X+2HN'0G0Z0HK'(97Z;Z<5O"'YOQ\R,G)EWT?#$:(?C8@
M;?<,1CZ5A^\]7:_H>G4MT<WNX'89L:(#+0CG?.=-GI\JFS2"]'/*SQ2PI9U7
MG$@/5()XF0'6+M$/VO/.=^8\)X*<46$KC;,L.FM>*!KRM)D/LFG5*5_-]TY_
M>$6S$=%G\[T^OW#-+%GQ3?=8"WLE*6]ZF-$8^&'PX0^[^KKL!UN%=35S5QQ#
M@K#0=VC!*!9MC^PB7[65]'<>I^DT"[,N!K&QOABSU5J]%I-LN="-JASL\])C
M@E1GL@0F&HMY[&J^X;E#]KR0IE:7$I8=ZKHE@*U&6+^CZR(3I8(;-'6>HV(O
MB,DX1GW!*)9GI^<+8@<>:RR5'$+'01^;7XBZ=(#<6-'0SE'QPSSM,N[M 3D_
M;E^ESKTHU'9JC;@+<,F$;SX[9",$66#U?8FE-<]Q&R:Q.+^Q1U&XR'/@ZF'Z
M?' E$,BY.2U<0CK"9'@^K.F@SS53RJ5.,-U@R>7%O4%5+?M!C<#,_/1K<B'U
MM'II-,[Y_3V<>F\X\^"R9]%,(^4!,FUU>[O7]%*S2_A>7U$9$S-')"DQ3=IL
M4<$65>_84*N[MZ-PQ-5AW\],>'>_JC*PLWNVYM2ZZS2*$/7-V#6E1G9:0@\J
M9F;GDJ<5KD]]-"R0E85QD+UBY.=&FQ*4M85L0WN-(GGIV_9"VV3VEA_E(>E4
M;'?0X_5\# \W\4;]..!%8I.SWS.BANKN-RXQ;]:T3(CJ=/:;[5&E5EA,E-T
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M[]B%)I1%>!]2J^SM"76;U(W8%"BYE6^3?WR<62&H;D[1N3.W^^AN7H(K'=/
M)&V=84%A4($2G*W=GR=;-S3W)1-Z8G-GPBJWV6EXMM8G@&B[^:0I<Y:6[P80
M_+D$WDJ2UUW9I+NK-?G#V&:Y57;6N%7'TE"HVOK*R;/VJWV)RU13M%#$"]HJ
M"FAO6]=IYI?!L<="DSW(@P7V%MZ*S?S*^#J4B:X/*/RE5N23)P^@UYX>QP:8
M+"$WRIQXTNOEF[?2/12TB%(:5G)I>:(&1_HA@ K6BQ3;B$!J>CBJH-]S);\@
M6&N\>4-LX3!IBKOJL>_GWGS6RLU#:U>5?+UD"(J*?!7VSB@-K$)90*8%-;(
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M#MF:'#"I_$7/;%,?D>[*O1>SD/8#B3W* DZ[2'U:DMXH]AK]_!T7AW#R=/;
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MAKE3]^(^XX=/5<='2)*K^49'^(OG^OIUU@])"7(^9.UNFP#YTFG[&J*UXJ'
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M&4W>O+'F5V<(/*>KGQ< &OLWO3**@E$"@ RWKX@S5TI*?@/8\,/K5TF+6K4
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M0@"M26KQXBWHSC);M;JLTS"A#,[YE7&KM*M#_/MT+QTO1#5CIFJOH$#<,83
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MSCVINRHPR"<'+Z):02!AO'NHAQY.RR;W/ACK>8C JD>G6]O&N[D6,:C2HD'
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M1-C>R=:KSZ@RNZB#@T5(T:=\#@])AI;)#_]F/F&97O\VQUB:9T<Y=ET;?R9
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MWWVV5CY,%X#^RR@(:B3V8[_6VV)JS ?5BNLL+V.59+[6BP(%1]?7NI]4[A1
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M04=N[0 -H:V+E+GO(KE70 V3X;?%JIW)Q!&."E\/1;ZQ]9'</O091T#2ZT$
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M3>7MPO*F0%M?7H?\'9/BO.9CD+9USN'VL;>>=MJ_K5U6=A:J%EY?@L$/HR%
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M2&M0/N[[?&]P^U'-4Y@T6MQN\UEXQ99G1/S:K;A=Q='D&]5*VGK(@7"9W0O
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M#<;1_^ ZV@VY?RJ_G;+".H+*I#R-5_IC00F.#31J3RD6'F":P]L)4H?K:6=
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M^]0PH29<&E,)LC_$1[='^;Y$A@<L4K<03'YB%5*PO*$\^EOL-5TP\_>SO#"
MV"Y"ZN57UM;]N.'Q)\%E.X+:L< LN$Y/;9&9OG/.A-@9;_FT491YBFUY=%E7
MI+\818Y7X,A.#X7AEJ"Q09_=ACNC\=J?)-G4$>R-T<%CH[%EHX,?X-5+HR<J
M6]D;GM@%P?@S^5W$\$;=46B!9.8E55SM:X<GIY_RP$1)1<\N "+>92X:U>,,
MBHD)5:)SBP^_9NH\]7Y 27,;16"XK65H<M_[T< -P2?3P_Y<NX-_D)'E[[S%
MCIPFIC$;C.[MXN6#SA\6[EB%D?GE65+PKM1\YO7XF4*99XP0J\^!IIMRUFTO
M>8[^4 =9,J+2% N83(TE_I;HGAQ"?R=.EE>^UM15#:8G^VCL?U9'.9Y5._H(
MTU\Q^P1>DA-1;2 V8E14CQV4RMUPR>M\;U_I>+N5:E%<)-OQMB/2:APC(V'A
M6.5"'AZ86]*JYG;'5HCI@2IC$2!ZHDIY-W@LO*%L>RQBK[OE@=@%P)7.2G"/
M<E[L3RZXO'(Y9"SE.4&Q<)+XNJO^I<^X&]\%]_:@3#F0K+OA+PW>35JQ\!;<
M]V^7^K5_<'N)_&<36R3RA8B_4*!1+A\_WXFFM#_>]X=<OH&)R<_PE6ZKL&.W
MES=H1/(:3SZ%#R\%1;@EJM]W(YD'Y7XR[2K)'>W[_8\YPUCD67!Q=?,9%2&%
MMP'3F\O-Q^X(*K3 A^DEW-'(EMNBJYBUJSU2BGCB]I(MTUQ;G]IF^AGN#_E@
M456%8.F28ONL:TT*EAC59>'P]'[A**?Z@+CPH'G%Y CEW-IRR0_7GN$T_0'*
M_8KN*F-;>MM6+9?%5@1RC\6R?;+OL[IC?4!/9K!,[#-)AAF?IM-/SEQYDUK#
MM)Y]3^UHOMJ+OFGNJ1_;BC3^*)NS=R3 TG5OYH4A4I4L#5Z>[94R=@%8<APS
M%O4D/Q?%VLL.VQE[_9&XR^DC$]X6;O=*]M'#1.X.VU$..%S&M?'/'.<Y]9'C
MLR/? ^9<,4_9XM\I83)=&M6;O(D?M!YT%]ZC!UMV^EFQ5\12@.D$!L+W!F7Z
MWHP7WQ\_\2SZMGJ/U5OU0WQ'\^AUQN NU:.O9L432AJU4V!@BE6HH&'/\](J
MUT_J$0NJCBE=BL_?@+M0N]K[5O=SY=7"BW@,0:0JA$"SR@K,C<T17HS2[[3[
MZAX6@0S-^& :<0OE!VGL>G.DI_QUY:=$ZR-T8US1PM%KSVY;G&+BK9%!MY$%
MCZ/?$=XIIO:VR-L_S@^=,,.NG]RWS%*%5+RCE;9W\K6/NQ.(D,V:;WH4WIZP
MQ-?[$T)._0CYWFE[NO=P$!4'^9_=T2),+P"_T5Q;QQX(T*"&7WEM'R:X/@>F
M._0Y(A.)-(K S$-U=NA.M,@]2-D>2SJ*[I37G7?IPRB73Z8MZ\Z+J:4?ZKP?
MPFJ9ES:LY4IPDA#KV*C2+!8W? N&L'F; L*%&\;LZ1 @);\8?ONMT<G,K#]L
MKV>'3,3IR066%5 "B1E+O7*G3_%3?KZ[YN.G<N>3D^?ZN[3+!O_=[I>PH/P_
MF4+D[D^?*K9_9PI]XJZ")#$@;#C'@VT?_BD<]!R!U^/)TIJ&R93#44*=DI!2
M6.UO=%J!MS,B2'5 !5L%TKG:-_#3,3<ZY/AJ/QRI/659D*;(3*0;(W<B>CS<
M_<UB2?B=6XYJFK[?#>/N>B(V=P?'/7;0R;DJ.\=_AGGRT;D:C7,WZN77H-3H
M/!]PW):/3]]+>(Z,/(WL%BF;GOS5D(:EO"6W/=L)V2G[C3:<=]%UFBE-QMKG
MT6G1#&J=+YYT6H!?T*=1+2G.*W_XSE*1'DM-)/RY\)!@SVU/\ AU$'9YKOK]
MP^R%]Z_&-L9NONQFL\$DD,=S=KRP^4@,HQ*1^'%=/*S=WZMQ3O[D>[]<=XGB
M08+R4Q>LMBK?/H8_]BY!-VOH0-?O'_:W6'L=R&]+IL'%W:T4WYAU+"_1.[HI
M]!SAS@Y3W,2J1'\'UXAN*KW\*?EJI%/FCZL.U58 8?T#B1+E(0A'X_!P=GHL
MV=O1A<.?,EM%DJ\.<XZ_X3TW,W$O*)6%MQYJ<)1E^S/MS?G&L63R<S1]$RG_
M!).P[PG^="*@,&%K\G0P_DO9KZWQ$ZOY#SJB)E""7_B*>F99RE4_ A?%^134
M,9G9"X'(_ZIAJ=+Q<9VHGK3IM2C[O\G7JUF4Z0Z3XAJSC3GTK/D\Q=A4(?C4
MY*SB^R>DS8=>(V9*K_"$#\E58Q\6BKX4V%36\AM)/=2U[4QBR#K ?L I*# J
MF(%]GASS3S^;/CYTK0[\Y)'Q>;,=360$=,HAMV<Q815_!5BHCSY(^2(FE?YA
M13.^K-+]5\0P+A2,#+'YCH@6[GRD'/*KC\!$>W"93F]V7%E'=?CC&RU*+4JO
M'F^[>H?'&MT!D545F[YV<'ECKTUZCE!'SI'S,^"OWP:M)$2W^2#$T=2YJS(Q
MN(+JMQ> / & 2]%9ZL@F,42-/FF;G6F[HH9F0[2E;FPK?NGCV"3L@=R16+"7
M/'B\7&RQ:C1E_7RBN<O*IFM<9Z]&Z9$=?>QGLL3XNRN2I]<9@OP8 $PT)3+[
M GWO!WM*K&I*YO CJJ^.YQ0P<>L$E4(JC&'],L@7_ =<#A-%(:(XOZ"-@!?0
M'1$L[HMX^B F[^<^?K2H!'*5W'+#.V"&>D.J/NU)!"@948VM0)3-9AH2;P\M
MJ+(P^;F1\<514(3EUHX.>Y=C!FUH":_;O@T:@>_F1^>MD(W(\$R$AZ[R.EC]
M*4ZL?^U!C@Q>,Q'/3BE<SIM''-./YC",?KP5)> YK?5UQ59D$*5+8'12/\5L
M<J6:"3-P$R _%[K+/UVW>@ZL?%5HM[;_^$Z>: 4S6GW]S<^"1T^KB"JMY;;L
M(>-A$5*%^,KC<'R:U!L1VQ@X9Z4]<=O-VS8O'&UBK&ZO%ZZ_U75TTWJX5L#*
M8O< NVC$_%VX$?.#L51(%W<R;"1#\DCED89H4+(5B55NLJ*156[*Y=_"XX!'
MML(! 3DL@%B_&W&_9J, MQ^Q_I*B95#E+&:OG%-M_7CY2.="_4?RJZ9)NXR=
M_&$6!]0C>+?*[NF,YD'01)UV+\V9^PIX+\3)-(?H5-SVO',,/S9R>,WV^1;E
M[P9X"K.T7J;]]GM3C;4&;>4AI@@7I@T.%U_U&)IK2?$+%5,L<@V\6@Z\PW5W
MQG.GO,U6:E2(7MAM$$[VO)MRJIN3=(O;&]U]?6Z8$=^*IWAM5W_J*H Y:]\,
M.IO8D9I:,O/8^#/&L-1]%"KXT*0&ER@=8T(E^/6!IP^#V**2;2LVX>&C"\"#
MH?>S7^Q5)6]T/]\_M"F?G(DP&5=SSXVMU>]Q2F88&?T(@XC'6->E[!$<H=;2
M]GXRMD]_<@O#,<5_M4GQ4L?$_8AXA='E?^5YX[;S8$)0K?]2^Z]]B3(S:,W:
M4<"&P2+.1F%R<GPR<1)#)9=$[VE;*FOL'N/&.>_*'OJ[=7XB=AYAY+9HP8=E
M=+%\F4U68,!#NBH#.R"PWL?EYJR:C)!U]W"IN^*C[[U.VF<7"6\4R22M5[[3
M?DM#E5R68J4DY\QHM?CXK6<VW^E85EA/TE(U2X#$EX>R?I5_4@F>])ON^8$(
M(X3&IE--VJI./F&^?U^V +NVL++,IK4\8V_OM$ K=O'<Q_;"NX6&OT0H$69H
MM%6"@F+Z#+5_U?4M+:N=NQS/.QVTV%>N+F&0^W-6X=DI[G9W'KZYVUV0[6G$
M_OT19[ ,%FK[H6-$B5?W( ]Q_M25/&/H<T\#\L4HHQ.5-'X"SH"MV[F^+-_Q
M+4*"OB"KC%^@WW@/MM\?1LE/D2A&_ .8=:/!("0+_8>;#H7.HAJF(-N6/N]B
MBUH;4%QJ'AW5XI?F3H2DB=V\!B,VFCA57A6!R 8:)/7O#F\?.J)S_H?-[LB.
MLYF;I=7^#@UW_YA;P5![@.;PI-^Y *B9^A:&?':G#_,^/QD YKX/_'.;X;10
MC\.<WSO/+(]4#WU==T9D-&%L$1Z;*3\\X;"[W&U&KULJA?!=WQY%=#<:I<&?
MOW,Q/62BZ3]9B6'Y9;B\)NU=+YJ/]1=(-%OJN0!\5YH 3%\ 8LY'I>TO +N;
MFR71<I(-_W\S('/,XL/^:P;D1L&Q:4.FR.DL4">R <[)X*0Y%ZK]4*GLD4Y<
M?JQ2K#H5.M:3.Y/I:K95;"Z'7"::;5CW:IM*[A)K@V.?9 Y%\>'\5G1HN",,
M9![Y?7^8I[N46>OS(YCXCL+0^HF[7K[XBTP]\0O G;K*D]-"JA4=,5EYLZX+
M0+8A2A,"N !83ZVM;(A 0 +/-8[2];3#UASS<%#. @2P>^7L2OZ*!AL=(6B[
M(O>DUQM<,;?[VMPR2G%P6?P$3H!*B+I>= AI-J^UOL3@QD7E.+.SX;\TDX!A
M?BOO0_4XJK+/I8)VA4=DUW=)K1]_'"J3\?2I1]">?867+O;N#57SVWMWG[8F
MIIH]]E-%%LH:"F#DN.I+G4>5ITV<B0U[_GB7.%:]J/A8.<B]&0;50KUF7OSF
M .:+BAH <\^)^-=? K,XWK.FJ8P,8TTGI\W3F*]2OJ7>_3\:F^>;'?_4%C_B
M EO-?%"/=:;FM+DKN!L6,_2"*%>-KU*KR7KV L#K::;YZT"FV[72Z_.2H6K!
M>.&RF"X1N1.UB#2$F&,_81FEU?16A"@;(=25X5EA)=Q6;9$V\[XQ31+95NPP
MUZ K<JAX&JU,^E]8D<_('^4@TS^Y;9?=.OFKUF<IZ.-+EAYLD<,W5[8V7D[]
M=?<<@N;:97-<4,MH3>NMYE&7%P9%#-(CCWE.0B4U9+KKI^PN %^<14??6-J)
MCF67^0K2K[";S/FA]CAL(?LO&W/)P[' ?/2'D9)?#ZB#)KS[6CE8\\,F$6ZW
M:*X-Y&)N\.5TZ#X_%EW(A\M>,RA6R[51&O.N'GMPHW%M3XKXQ3HR3;-YQKO<
M)$-OZ@*@BW/U7*:;(",@Z!,BC$ BQ^EFU]%C!R/%(E<2F 8*"-M/[]GW>S@C
MFF_\@K@]\Y=ZOH6)GGD,>@TL&3IEC,JV?\+$M4YX<1YR U$^/W\Z>X_.NO%@
M3VRK-V7/M*4H;&E&$2N./HS60U/(3(EB[1>)DA,K/Y&WQ2K2-ZQ!>9X>'[L#
MWYV(#X#*MQ>;3T\O+][]-U(:==7?=%#\E4]LO&Y,2%-R=D8_5-1=:HBS/F]Z
MHOZ!L5FU8X?D5[_G37[P[Z>[*DL;T8H4@8-U"ZY^=!2#WR1[GOR[J62 $@WQ
MHW]?,(C''TVG 87?9<UC37Q6V19\>T3Y>I=4-MP6SUF?(JOH2U.+=_?#LAQ.
M/,IUWM#'+3_N_8(19:,%EE/R\>"5 E#; D]=,_YL>:\TJ/\V>28[-]F^3]IO
M^.MG#[(@D"-VA?JX*5O ??^U(R,5QGXJ7]9_V;Y4M$(_#X7?:NPR$+J;'92!
M*#%QCA4=U\;Q9<4;*M*]#&I4L_DV>/E+61AAQ9#53949 /56I0.(K&EU/BR4
M7SS&B2M4)GO.8%GM=+6!7RZE[P>SBR=]U*^T\KC*"\#_P]=;!\7Y;-W"0R A
M"0&"!W<+%A)<0W!W'30XDQD8W$E(" &"N^O@;H,3W-T9?'#WP?GRN^\Y[WON
M_6[=OYZJKNZJKN[=O=?JO?9^V'W*.V' *BCXOL,_,J%K$^4*C6R!,YG;MKX7
M<V5BAARD2#%%<L19\+TVTM\A*4OW<8,OF\^5"@4OH3%-U("KAHK4V@YLO18V
MM83E7MGDYV>PG>.>JN_RY_F\P+Z<J5]^CU._5)85^CM.$)WRE7(.7L\[V]]]
M#)5R!SCLO.-/=;>611]$#[8VW=!G5;JVX#\_0"&+736U5@L"WFF?/CC!Q3;[
M9;ID?I$J_@J,#2=6JDZDQ@JR831SK2PY[9%SOL@K-&*T]IITU8'S\X]PA$9)
M313 YM&3Y":YU\;?[YODW"YK.%_ E1?M%S_2^(2&%AU:39(YRU)8:>!@*H;(
M_C!5EGY&ZR<AF@S?..!(KZY-D^3G<K+@:YE!W#KZ(M-'F0Y?S"HI*7T97"B?
M5;3U8V-ZGZXF5ZD81\%V#K)#(.?YBHQR201'YQ%=6(I!4(Z@4%.&*'D>B$7T
M8.S=N7URLEOS(<K3@AUNN;$P\>LO"_XQ+B1!+CMGZAJY4"DT8M#YUTE34?%(
M<\:>7^@;B?&)BAL5ORWAG"@,5!5[F51;G3_YXWQ7[E9N!PF6[KLIC&74?:I#
MH>L5\?$%//YMK,J+G#W0G2&X^\\)F:V#3:8<-9W(K]N2?V?._Y?=+JN07?UU
M?UIJL#S5=#$AD#0KU@E%<\KYEI3V$V>RTU:LO37L72TFN5$J3R]5,0K6^5_W
M"#U#T,C%!$^?;/X9<2MZ]PQ\IR K.%=B1U1F_@2.MT](NI+G_POSZ_UJYZUW
M6-++I-]7+*O29]1W<X^ 2RN$V\PC(/J_9)3+)C0/+G['2?^4M +^7\LS?FKE
MT/V?\HSYNO_DC O12TC]H0O2HK9\??J7IJB<VW8'OWO>C)_)89,QPP.Z&.-F
MN<W/35MW=[BY]E/&3QF#$6!L!Z[$SVEDDZV$V[8&3O5G*K,ER2S=R^(+[J'4
M94BATG_@Z7 3V'8>0XC_C6_9F%1AN$G0Z'+ $4HKOS!0G09K:4G$#_Q)IT K
MUV,SF*7#'Y.,3MQZ"D(A\._(9["\1D1. 09,GE9>C8$P,I\FS'04'UO&[CF&
MVGJ+(HJ@JHZZ/WV+ .Z7R%$3'AI\$ ZMT@^M:L[NM.%&M[%RR^'M&!%"*#&^
MZNJT-#D_':+YBK#OCOIF"D1'#M<BZ,Z!TSYEDP,ZUSZ8S2I[BKNF _J':/8)
M']LJ1.>MB/X(1H5Q8!VVA.X)+QOY<2'*<LBKPY)++P7H&\J=0BT:_:?:QBIS
M8>.=BSK#XA\2&3@'1<J*YQUI/^X21A'&/N$DC,6"R:M-XF4275+OS+80K89A
M1OZYC3R_L?TGY?=>Z]]BQI^0.%\@?0W_$R$-J$<,<H-#BL&7,NT+<GE7EYSG
M)J+"AZN[&A&#!H]+#O%UA[&+M[&,^PR/?UHZ^ "J;$90GBH_]Y*]SV'6R_-R
MP0'QT'7W_!J=WK#1R(H-D@G66];7_W1/2EGV>X^B6<E509/6T(46O^2H^/GJ
M6/W NWXY?>/+>-R,DN*JZV2&=Q1K]5&I(R#5<6*@_I[6_S)G=E6?=AU):PA+
M[R/ ]LIQG<>O<)^9/&$^.O,J*I=39(_X4IQO;!^I</M+O."+:V) R\:KP(TI
MR845 ]_86-H_9^"FY[2;"'>\?-I)QH'O@U2%_270S9I.6R&/M_YW:#4'EW8L
MP1\C<'X^$,.IO$5L@C]=3H9YAIE8XBGNG-?@&60P/G,%_TEF&0@>CX7UVA&X
M4AQ8"I25EI2[+WFD3Y;)[?:\69\X832R6ZL,_@_W_39(0>7G/)1_O"?Q&*#^
M:<RGNH?9V7[H>ND%C5#G%-72_J?2V)]\N8@X<<K>=XJFM6[/MDQS8O(#:M"J
MANO$XBK EZBZBYSV2J,Z(&)F=QX1-1]F_*4AS38!N_!<I:3)=:8<G(K](F\U
M"7+8ZKF[FE&1EQZ-9D/4-R[ <6*T=M8UW)KD?3ZH:UU5]T521F=EZ;2BD1_M
M*0XCCDJ?59YL6*>6OZP&HUCNK'$&1G-!S=Y6^N!%-])IQV*1I"+ZWJ\ <G#9
M*ZF,D[AAF_ (P(T9[Z%ZHB2'-7>/@3A@NL#'1CD+N1HED=KG>1!A?V&'8C:1
MU3<-O.NR7*S;+^TZV.P^Z!Y2F4=X>!C5!%"Z_[Z41 ])C@EIH- *2CR8".Y5
M#*6SXF)-'%IG[ <."@1RT7ZZ+#/?"8N;;U#-<SU,0B!_SQ_4CG60ATC;=8^-
M/(O%\:H1B>SJ<E@$3B.V="_X=B;AFB/D*/VE:_HOX:^X\3'4!#-^-D?*S")!
MAL^SGV%!=&7J"=6)RX_$H>+[1;7 ,F]^TL2J$[4Y<]QGG]K)$I/Z!LPI0RT]
M_:MIKZD*Q]FU$'8D%+))-QTS'1.XROP0N+FYST9J,XW%S]\^@Z5?U'@G.T/M
M<9QD&$OHLKF7/,W'TN]77)86Q\.]D-5U,8EI8QJ]=*"<V(Y(#LA7%14''D&N
MG\WM=WOVHN5GMZD^/2-(U"NB0H5T+Y93VLSNJ;V$X=68BF!CD0(^[@'C2/O5
MFJ*3B3P?J8M;U[UG+B#/:/=H%^>&X]3-)U@U'I]GJ3NN143*N&126%IU^' '
M\J1,P$BK>*MR8:SDG/L)E_&8:>:\Y$U-Z@_&)7I3/CW[NM >]UNN>=_]-_G?
M'P$V]ZT(\BYU/:QS?2?^D,_F60+Z;'AQN_W)]0Q\.7LF<%'N>J,C45[XX>T/
M</##YC IH[FO3N_ED^-YY,?=48J/67>)%^BY*]N'C4N>*M.:O*6(^@7@>TF%
MYDB%39Z&!+OQ9X5FA45@&".-OTP25MH+\5QX41@#JVU>ISM0$0UJ#S=@64GM
MP7:F *_Z34EEQ?X?.FHQ$HI6W50\$IJEF]OFM'ZZIZ4B8FE:TFIHXY@$N8&2
M?JT*=-XNZ('H!\C,&CPRDWPOGNG<.G5I[D)?\UTAWY!)5CD<$GXX+J6WG=8_
M8OYAOSO]_];E''JSK8L/YSW@_T_I"J[_K3;G]LQ&X;WCOVMSUF"=W'B!_I'A
MDMB))8VQ:&31=X02NN9)\S(S^&@I>>'?>&CEL][SYFLNQ.)1\&Z<WVZG?^+-
M^JT^<G#OK"EQ(//]<HP%#^KS'(675QMTSA*+E4YN<DEIDU6W$J_.X/!D/OV)
M++T/2\)FEKB7QO/Z"J8'\=Q?65K*34WBLBVP=R+C-RWIN4'&SU=O6!)^J,M2
MX$GS;(81JDGC=?0,_XH/:)EG[9B-K%\]OU1'PZ)8(NVY;)E8:(QB)XB-_-9F
M<89MWFS:EP =,XS*;092_7#FT\I"$V6E =EMW"S[-.] ?B\V)(-K[R"K\(,9
M$NZV(KG$X\X==*P .4P5AI?C&>;2S3L^63@9NXK8P;OV'< E8VDL&,SY!15I
M88JR''J 7"G6IL[AW9R;H[K@%R9%DD 944EZ$JPG&$[AO4R\:7?"]&\=HCF5
M](=R:K.GH]):<F:_RB*;M[:<9HSV"O919AX@\\H.YS[L6%@CAD:/>BEK3OQ0
MFDY]S9O>>8)\P,>\;:JV:]!Y__0B GS?W#75.<B=N!&[9&$Y]40.0?63>Y!!
MP%W95E)-X489T7SQ\]"U?>Z^$Q%@XF^OW/Q[0>!R41/D^<'C^0YT&U]K(*SF
M+*'/-\?:7^NC"PQKQZ0JF>G(>I)<M/06GC2[!.SA<1GDDPD$>$G;>$F8I/NH
M3LS<,TZZ+7(UA#\PPA<'[!G?<P9M-"0;4'(!1%L;5JK8"#K3H>.U(;+: 2@2
M^*U3@S S] OEU)O6'PL.VD07U7AG:HRT$ON^0"HX?DY-9)?R)VI+';@!.R0J
MP^.P:,<GO43(]0B&VNYLU%Z7#G^CG<<GU^[H#4';%WG>\S)@S#E>VYZ28#(N
M5;N\;^,PSC&PMF;\<OUJZ1FTMUWOI)."&Q!*-&NT6E_[^^S:[7!BY2@U&[W(
M'.)R08?IY$JHN6U>J=>3IJY9_T7QQ:O^,'F/\I"WNQ(:5R8J1_"PE(F='EV1
MOOJY'D7A[-.E^:IGG_VZ@S)X#QCJJM&#0$'GX9JUX/C\3+%"9V&>??[Q1T!J
M38?QLON=\0S:PZMAQI,FP'RT B9 J+ 9[)[U/\Z-C6HCZ&SV5;%O6,U=<GAU
M.LG:O"(#, &:J8>"!H'3.OJSFSZ+!<2;<?N?"CY#U\9U*A=_4CJ6CI\M$\6#
M;UY!MT15)>?P??-EX9705[=W%<:+N.SK<JBW4V^)OAU]=S:/-;<^3N23;_E1
MPXF%W']6$HEJ6VZ0[;+ ](MQ$I3#_1,0 5 %J)8;E[)__C@DT4,.NB\*K7D$
M-!I*FN\91$L#]5 K?PR]T,0_52LN>'D^\<S=*A^3O;]E?L'\L#7]5ES[!3IO
M\K.I!L-4OLL97-'(QDLV#?A#KRSEU(]'@,YGW4= _U,M.RP!YQYUZD? D[K+
MVG2%4[GEVV>*N%U.SFM:0:]$^GN G<X-\\DT^15C;<:\\AP.',Q/B*;/X1HR
M*X^ MB$UT(6[GX=ZVU%J1@H#X!+9_?ZS;.C39?V+6LE0=,J(K+6GTZ=D+^5(
M&,@GNW'CA#%'\^MVALY5CDZCM3M3 (+(/\5Q3)N(:%\6_7V>9$=[>I+"1\ V
MZV2=P)6V-I81WTP]@DS5_H,JB/+\F[2'[:7Q5'R27_HII63VK )A"4OY0D_5
M%H:;OU@L<.TJX.L)QFN75GK8=OZ0G(L3?.?^2;!V.GYIWIFQ/O&?RS?J\8^
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M&%G:42.HCK<T%]2\4+8\<<]!HJB?RN_U'0CU7(&R"R 05+09N'PR]Y_-\S.
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M^^,'C$'<M1SHH2Y0YA*?4,3!H=[?7+1U[SSJ&M<K'P$I?AI=8DD'0P^0]4?
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MKQJ0J4''(*(@[;TQ,,<--8Q4N>'YLJ-88Y,**JGLPX)0X*1QA9 ]LTO-MT<
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M>5K1539W14.8BV-__/<SJK-:2+*>\<+!C6\A7<@A'#N;3G&PPXQ5U+[?(_\
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MU4+^.HU^_4CW$<#?DN)I"^57_:)"_@@ ]JS>B3;^J0E6^&I>WT26T//-H(?
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MXBR)"EDW--5)! "B+9")E!HQD?H-+6YCS3UX:S!<N,AGHB,=._%498,:\U
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MIDP,?,BPIN%ITYM#?J$_S]WHJ[MO34YC1U%:7YGF<9._(M.^.79&F$BS.MD
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MVU-HMN8G9./CY*8R"VY- 2WCHRAH2M^Q]98-_A3U'QM5C;>BMXWIXO-[D?%
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M[ZLT@-9'C%C2&M(<3IW2"=!8!(  M:W2  D "W2 !H.0KKR:XE<2 !DG^O\
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MN/BE:%$?13PU7\/PGA^J.KW1D[5LV-P30N'#N[?H7?=)]#06--\ZA+7W3/$
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M(K5W72A9&W<-ED=;O<-7AKH->!;7#MH:=BT<'J5=V.X3=)>HEFV]\B0QN,@
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MFV9TSCYI<&RQA]*E[78.#0,-!)/V15?H3TM^<STCW'I:6UZGVNZVS=8(GO;
MP.N89Y*?)!.VCV%Y  \]C&L&;W47UNV!L7OGV+Q4?%-Y+;_=_:C'6[*AX> _
MM3/17W5+<F2\7@LC.R<5Q+Z_YBD,3BXM:C9A2C<^@^GWI-ZN^@3#MW1NZ1]3
M^G>LO_IUR/(N+8N)+S9R$O;I).HQ^8&EQ)$1<25\C=8=:^E/JY=NOMSM;GIS
MJAP ;/K%U;O  #6S/8R-^'RASHCI:/YK6B@Z+VIO7 [P8=5BWW6I\0^GD\+/
M:7#S&+?&BV9L&0EN0TI"A:Y2/8*^F>GNI]OZC@)MVRP7\>$MO,TLFB=Q#F',
M<G# ]F2\0Z@Z8W/IR9HN]$ME)C%/$X/AE;P+'BHRX5J.U9971KG*\E3D/L16
M'I4IUN/&C-./R'G%!*&66DE;CBR3HE"4DFBN112SRM@B!=,]P:T#,DX #O*T
M^[D7,U,5N&4TMID(7'P$)T$+BP5FZI;J#JF;D2E*UCBA 2C^$W-Q\2[A\,>U
MVPVF!P<^H=,\9.>/J@_8CR;S-7<13S*65**EG74J/]5/A]M5TJM-<3:10+6_
M<??^.V3@W\G*>0A:&U_),*4 5K2-7EC^J@VMXFPKI>F>G;KJ+<&VD0/D C6X
M<!R':>'+$KG]RW*UVJS?N-Z08V_*T_7=R_A'UO=Q7S_Q3&Z^]VXUN.N.1L*U
M(*^:&D-%947%#1()!X<![:^H(;?:^D=N;'$T><&T XU_3BOG+>=VW?K7='/E
M>[RJXG@&C  <  , !@%F'<KN9ANV6&7V[[?K:_%E,AO.9IHI*X@4FRT)6FX,
MI=]!?X!K4;+LUQO=R-YWBOD5^[C/'^SZ5H]ZW6WV:V.R;*0)Z?>RCZM> /%Y
M^&:X?R.>;1ZDF2\KTPLDJ4I3CTIU:B5:DE;BUJY\2:]4AMVQL\R2@;3] !^I
M>.W,US?78VO:F%\Y// <W.<?>2?I7578GLBYG##[A]QH:H^*C*1)VYMA]HJ+
MZQ93.0R,<CJ>>62/18Z3:X)%[5YYU5U0[4=MVXT=DYU<&CCCEWG@O4.ENE+;
M:HOQ$OWET_YI*8N/V&#,,[L79G#!;TWAO:?GI3&V]LLJ4MU089;;2H(93HCU
M'4  W _A(&HK'V/8[2PMSN^Z$>6!6IS/&@7"]9=6;EN^X#IC8&DW!=IPR;C0
MEU.7)7I'X'V:PAE22C)[SRB;I:)2M_UEBYU))0ELG4\ !6"1N/76X^3%6+9(
M>/U0/VGEF5??+L7I!LGXB>ESU5<Y-S>]_P"IK>)R 7-&\]PY*3#R6^=Q+5)C
MPYC&.=FK<0,?C)DYEY^+CXR%K#CLIUAE2B4)4;"YL"*]6V:RVK;9(MBMG,B>
MZ,R:3\[VL(#GN.0:": $CLK1?,_56X=9]41S]5MMIKYS)VP!S,8H9):EL432
M:N?3YW@&@IJ(! 6G]C=MMV_F%S*Y"G)&W>WD"04Y#-N(Z9&1"%@KC8]*[(4Z
M0+%6J6[ZW/PU/5'6]KL%L;';AJN'"@ S=VGB&]F97H'I7Z!Q_BV=4]<:;G=P
M0]L;O%#;G,8'"24<SX6G(5Q7;D');&[;XMKMUV]9C0)#<&2J"Q%8$J9F<JVE
M ;:>=#B%K?F+45./K4I02D]*5&R:\@?MNZWQ;O\ O37.M3(T.)-&QLXNIV84
M:!B3B0,5]%R=3[0;F;IC8YF?U=L#G1M%"9),FLKP!-:NX 4 )H%9L9M6%AHZ
M>XO=V:1)6>K%8.Q=D%W]YN+!AJ^-V2JVJK61S/ATT^\R[B?^&^B(_N*?>2Y"
MG%SW9!HY5QX+R6WZ6M^GW'KSU>G#MP:XB"W'B#3]5D,>;Y'<74PS) Q6I>XO
M=_(;C"H,ES\%VXUI%VUCW>D.MI_=<RK[?293I NI _E@^-=OTMT-;;8X7$8\
M_<S\T[QD>(C!^4=IQ/8O$_4WUFNMZ:;.[?\ A-A'R6<3J%P&1N'M^8\V-\ .
M!U+FC<O<UN,V8N,;2I9/I--MWZ.L_"A"0VE3CSA58!"02>5=N\;=M?BN'&6Z
M^R#EWG(!>?=.=(]=^I+A^ C&V]-?[:1I (Y1LP<\\LF]I5N1VPRT^"QO'O!N
M%>P-L22%8V!)8,G=^X.JQ1'V[M1*O72IZU@[(  O?IM7(7G5^Y;M<G:NG(S/
M./F$9TPQCG+-EAQ /M7TST_Z/^FWI;MPZCZNDC,PRN+L"2:1V8;;6^-"?JAK
M2[DMU;:[8;BR&!D.XC'QOR_=IUM@97=6XIB&^X.[8@%[Y/+.EF1"C2DZB'&]
M-!X657/27VS[9>-%VX[[U57P00BMM"[L J'N'%SJ]ZWNX7G6W6>WO-A3I#TZ
MI22\N7!E_<Q_N@EOX=CADT$//(9+?^P,OVVD;=R>S=A1V=R9;8VVLGGL3E-^
M>EB\+EC!?2N0C%XUXLSYF07\R?1+GHH<2=2 DFN(ZAL>H[/=X=ZWDNM;&^N&
MQO9;$N>P.%!J>*M#13$#41PQ*]!Z-WGH_=^FI^F.FGMO]PVJU<]C[QNEDA;]
M=K#I<2>#CI#LSA4GD7=_>3/YD/-;OW9(7";4?_(41;6"P$8)O9L8;&^@T\ -
M/YY=)YU[ELW1^U6 $VVVS?-(KYKJR2'M\Q]2/[ND+XQZO]4NI=WD?9;Y>O;$
M'%OX=A$40(/RB"*@=V:]9*Q6#E]PYG'_ (CMW;[J=OHZTC<&3=B;=VRGTK=:
M6\ME784)]:+CX65.*/A6?=WVS6$WX:YG\W</]E$#-+CE5K-6G^\0M=L_1W7'
M4-N+^VM/P6P#$W=ZX6EN!Q+?,#72=@C:[+->'=$N7AMI0-WYK=,!W#Y?*SL-
MBF=FF+-ESYF,;97/")V=5%<3%CJD(;,AK'R&"L]*5J.E8=A?7VY[O)LMA;BW
MNXHFR/,X<=#7DZ:M9X=1I4,+PZF) "ZC>NE>B^E.E8.K]]O+G>=OGN'01,LG
M1Q,EE8/O-+Y#YCHF'PF5H#:T J59ML[2[C=P4!_9?921F(+H^'<&]Y&:RT%(
M'[SP=R,O";:3XD-Q2D<*JW:38=K.CJ+?I!,,XH"R,]VB-KY/>Y5=*;GUGNX$
M_IMT%MUO:GY;JZ9)<$#[1GN'1Q5X^$%;.C=J>X^UFT?CW>CM%VTM\1QF$;VN
MU,BCFVE&'Q2I!6DC^NHWYUS8W#I*\/\ \.V7==P'VW^;I/:2]X'P"]#GF]8[
M5@_XDZPZ=V8_[*/R"YO8&L834=A/>K?DHTA?4R]^:G<F5Z004XG";QE-GC\*
M"TW AE)Y?$ 16RM8;1GBCZ8@B_\ *2P#WU+G? KE=SW7?YJQS>H=W..4%K='
MW%@C9_K"JN"<5VY7LV1$R'<;NIFMRNRTA&2C82/">:82%*4I"\IO1;9#G4$A
M"XYX=74/W:Q:]3C?FRVUAMD.T!E=!?J;7D=%O6O&H<.7:MB^YZ =T,ZUW'=]
M^N^J72:?. DCFI6NIK)+SR@S3X?%4X5I7!:[<V?LKB=R]XY7F_E-GPDJY_NI
M$Q2?K-=4VZWQ^4&U-[HYG?J:O+)(.CK<5DO>I']K[BV97W.>5[\?B=HP"/E\
MGW0;M_$-]8.,1_:Z8^#6./*DL&]7'\R+;C7G;O/TR!6HNH^C]O=_E[W?6D?9
MOHA\&P.69P]Q1\7TB)W)[IXHBQ27,Y@,ZW;P++YQ5T^^M1<]/33BLNW[9)W,
MDC/O'F?0NGVSU.L+=X;;;YO\)&6N2WF'N<(/IJL\B;^W0MIOY#O<I(T^'=&Q
MI3[9\G9.)_&F$@\S<:5S$_2]DQY\_9Z_^1N&@^P/\LKU.P]4;Z>%IM.H@UU/
M_P )LI"/:Z$SM^*O9G[BW"D)G0^Q'<SJT6AJ3 P^7<&EP&<JU!?#I]@-ZU;]
MKVRTR_K.W]['2,'M9K%%U=IUMU'> "-_3>['B(YVPRG^[+Y;J]BQW)[#V/U(
M.<[4[YV$^^M#:,CM60_D\0IUQ00CH$=4V&I*E'0:"JXI;]K2[;]SM+IK03ID
M\#P!G6M'+9/WNUF<V'?]BW"U,A#0Y@$\1)-  :.::GD5<4=BLA^&YG+;5WY"
M]/!9"-B\KB=ZPDX'+P)DMKU6([R.M,FZF]2KT>D @D@&]8;>N+BUNX;.ZA<]
MTS"]CX7>:QP!Q((_ZU>"V5QZ5=,;]MEQ?M_R[87Z)&R-=;R,)'UFNJ/:6T[5
MA\O ]QMKA3^1V_,EP$ZJR&$=1G,<I XN=492UMHL+_%TFNOL^LMENP(;H!LN
M6/@=[0ZE?82O!.IORR[LUS[_ *2O!I-3HD +#W21U:/:UO>LAVCW(E09(<Q6
M4?AR ?YD=#[D=TV-B%LN >J--4N)6FLN^VO9MZATGRY13 $#4/8:$=[2"O,K
M=GJEZ7W@ENH+N""M"^-Q?$X?QMU,-?LR CL"WJG>>#W3'#>Y<%#E/H3_ ,ZX
MH(Q.5;/'K6VD?)25"USHF]<:[8=RV:0G:KA[(B?Y<OWD9[,?$T+U"Q]1.G.K
M6-'45C$^^&4UO2WN >=!]V\]@HKUG,?N7%X+'8N'&CY[%2&59>+A]PPRSG)^
M-G-QW6S_ #EN-SXT=*;(^67U,J)ZDW-JY.TEVC<=VGN)7.MKECO+>^(ZH ]M
M1@0 6$G$ZQ1PR*^AKBZZIZ=Z7L;2!D>XVTC?-C9,#'>"-P:[2X$ELP:W#[HU
M:3BTK4,)&)B.9 ;65 VGFLBTN%.P^Z(#.9P\EI9"G(<*1D4N)Q$@/H2MMSTT
M/MJ%DK"20=M>V>ZPR1SRRS2VD;@YKX7EIPR+FM/C!&!%2TC,5Q65M&_=$=1[
M9-L^YV%BZZG86.9=1M+V$YADCAJ8015N3FG(T5+$[BRVV,FS S<>5AI84E3#
MRW%?*O\ @]$F()1TK.MPI2#XCA6\_$[;O$! TEQ%".'<0<NXCN7A.Z^EO5/1
M%W_4NG)9;BP:=0:"?-8/W2#XP.8QYA=,?+N[EVGC,_GX3"8&2R$K%8W.1ID)
M&1_$(*T)*9>.]9J2IMQ9NVX@*"@"2!:]>=W%U%LV[2[=M[W&5D8>^)S7%FAP
M^J^A&68-,P,5ZQLNTWW5_3MKO.^11L<^8LBN(Y&MF;+&<G,-"2",VU.!) 6O
M9F.W#M.1&?A+,A@J?<5D$.J=1D0\\IU*Y !4A#K23TZ<0-:WFWS[7N,#X9/"
MXTHP@#RZ"E&\2#GBM/U$SJ';;^WOH0TA@<#,PDB:KJASP:@$94']B]F0;Q&]
MF$+FL-XW.L _+9!"$D*7TE/2X;66A220;ZCD:Q'V]QMKJ,)DM#PKB.Y=9LG4
M$&XC3(&Q7I%"" 6OJ*$8BGZ<U.%O++NYJ:UW'RCIS@QD*!@I$6&A<')(QJVX
MD=J>XI;#<12X2E*]5D%/4E(4@$FL&VL!;P-@VF)OX(S.<^KJ.&O$E@QK0T&D
MXG&A65UKM-GNNOJ%\\PW*.U#0P1ZFCRZ 1O(IX7#46O;\N (*SZ#F7(*NMM7
MJ1EV]5F^A']9(ULH?;5F\LFS#Q"DHR*X?8MW?:NJTDQ.^9IY=G(KS9Z$WD&1
MDL=K<7<2G0IMQZDC@H58L;I\#_PMQD/TP6_W/:X;Z(;A98@XD?37M5NQ&3#!
M]!_U5]9:2TOYE3;4:SMW_4C>BM,SYAKX %*0&S\0N=*JO[1\KFRPD!H)U"E2
M[#"AKX:''(U61L.X0VD,MI>,<][P QU:!I!QPIC4=N"AE=O+AO+RF+0%QGOC
MFPT:BY-U2&$@_"?ZP]]+/<"1Y,Q\8R/ZBNFGL8-PB$,_S?4?Q'8>SZ%XV9%R
M@))LL"QX6_LGPM6=( ]M>*TC+::RF,,H[.\*]*CIR+1:N#,93U,K/%Y XI/B
M0*TSWFUDK_A$X]BW7X?\2P$'[YN1YCDK-Z!2M*BD=;:DW2M(6E121=*VSHM"
MAHI)^%:20=#2YB@O('6TX!B<".ZOZ>Q=7TMOU]L5\R\LWN9,TXT)%1Q!^*[$
MV/NR'N7$I*$,Q9D-MJ/D,>T$MMQP$]#3\5I( $)Q(^   (L4GAK\]]0;%<;%
M>F"2KK=U2Q_VAR/[PX\\^*^AMNW*#<[9M_:FK79C,M<<2#WY@\5DS[8_=-BD
MW -K@@\O8:Y\A=-9W-*<U9\9N;*[%E2$0$,2,7EWD-JC3'O1BXW*2%(98ROJ
M65Z49*E#YE(%E-B_[R1>RXN:#IH2>':NK?MK.IK/20[^I0,)8YHJ9&-%3$>9
MST'@[#(E=$X3#M86%\L'E2Y;[JYF4R+@ =R62?M\Q+7J>E!Z0AI%R&V4)0-!
M41QB-M,W$U)YGG^SD%YO/.ZX?K(HP"C6_9:,A^WF:E7>KBM)T16/<.Y<%M3&
MN9?<.1CXV"V0A*WE%3TEY9LW&AQF^J1,EO*T0VVE2U'0"L'<=RLMJMS<WSPR
M/(#-SCP:QHQ<X\  5L-LVK<-YNA9[=&9)J5.0:T<7/<:-:T<2X@+4.18[H=U
M6W(L-^?V>V'(24.9!Z.P_P!S=PQEVZA"QD@+@[-AOMDCU)@=F#_P8:*K@]RV
M[JWK9AM9IIMCZ9?@X1T_'SM.8+L6VK'#@-4O,#!=W8W?1W13Q<>7%OW4S,1J
M)&WP.'$TH^[>TX^'1%R><0M@; [:;([88Z1CMF8)G'*GK2]F<Q)<=R.Y-Q2D
MV_OFXMPS5.Y/+2+BZ0XOTFKV:0A.E=/TOTCTWT7MW]*Z9M(K6U)J\M%9)7<7
MS2&KY7GBY[CV4&"YCJCJ_J3K.^&X=273[B5@I&S!L,+?L00MI'$SL8T$YN+C
MBL^2XH7*24BQ!*"0;*T(N#P4#KXBNCR7-$ YI)5R-R;C6]_=>_"BE5.-N/T\
M:(CZC;[*(BB(U^GT\*(BB(HB*(BB(HBR_97_ #L[_P"(O?\ #1ZJ9\RM2_+[
M5M.KRQU\X/SK;"RN]]VXF6GMYVXS4?9':/>V]-I9???:/$]WU=P^XV'S&)=P
MO8J)C\M.B)PK6Y6PE\M14_BF54N\1YE,"4'2J:OH=B'ITG$XN1D\<G$9*1CH
M3V0Q*)34Y&+G.QFER\<B:PE#,Q,*0I30=0D)<">H  T5*N-$11%R[>L2JSJJ
M5ZFJJJ@7/$6_51$41.I1*B(HB=$2HB=$11$J(G1$41*B+5&\^]?;_8>5>P6X
M9V23EV8\>2N%!Q$R4?1EM>K'6F00S$6'$^#A ((-B#7SSZG_ )HO2'TBZ@?T
MKUA<WXZACACE,,%G++X)1JC(D.B(Z@#D\T((=0@A>H=(^CO7/6^UMWK8HK8[
M6^1[!)).QGB8:.!9XGBAYMQ%"*@KF#>7^99^4GMMW*V)VO[D[ZF; S'<)+ZL
M-F=T8]F)M?&=+[43'KW7F(\Z4G;$/-S5J9BRI2$Q?4:7ZKC2!UU1Z8?F;]/O
M5B:;_AZWW:WV^%X8;B[@CBA=(<= +)I'5 H7.+0UM1J(J%Z#<?E3]76=-W74
MNWV]K?6]G\\-O*Y\[A0N>8F.C8)3&*%S&.+R#X&N-0N\F7F9#+4B.\S(CR&F
MY$>3&>;D1I,=Y"769$>0RI;+[#S2@I"T**5I(()!KZ(!#@"T@M(P(Q'L7S>Y
MKV.+'@MD:2""""",""#B"#@0<0<U4J53BBWOHE%C.>VEB,\^QD'4O8_.0PD0
M=Q8I:8F9BA)^%I4D(4F;#\6)"76B"; $WK77NUV=](VXE;IO&?+*WPR-[ X9
MC]UU6]BVVW;W?[;&^VB<'[?)\\+_ !1.[=)^5W[[:.[>"HQLGEL1:/N=+4B.
M#TL[DQ[);B.(X)_%X/6X[BY!YK25QU'^))/2+T3KB(:+FCP,G@9_Q#@>T8*B
M:*SN3YMA5CSG$XUI_ [ZPY T<.W-8QNO(KSN11@(RKX2#Z,O-26U!3>1EA27
MHF)0XDE*H[%@Z^/XE]*3H#64,3^[]*Z/9[3^E6']6G!&X3AS8 <V,R=+3[3L
M6Q_NZG<0K3(=ZU@"P2G1 ' 6TX7X"U7%@RRZ&UXK&\_FH>$QTK(3' B-$;+C
MNH"G7 /Y;+=[=2W%6 'OX"L_;K"?<KMEE;"LKS3L XD]@X^[BM-<3L8'33&D
M314GD/V\E\V-W9_/]ZM\'%12LXQF2&U):*BR$MKT0G4I])H#_65<FOJKI[9K
M#I'9Q(1][2I)S).9/:?HP7SSU9OUWU)N?X&W-+9IH ,@/TQ[UGW<S>.+[%[(
M:VOMWTE;LS$52>M-BN$R$=+TQ[ILH!!59 _B7[Z;-M\W4^Y&^O*_@(W9?:/!
MH_7R"TF\7L?3VWBQLR/Q\@Q.>D<7']7,KYUY+<G4B1,E2'7>MQQV0^XHK>ER
M7#U+*EDE2UK4=3[J]?AMF1#4\!L;10 9 #( +Q^ZEN;R9NW;<"^ZE)QY?:>X
M_$E=1?EZ[&.YU<7N?W(CF+A8I3*VY@9*>A,CI^)G(3&G!JFP!;21K^\=+"N$
MZHZED>\[7MF,YP)'U1Q'?S*[_8.G+'8K1TTQ%*5DD.;S]D?N]G'BNDMV=P\A
M+R$'&;3DR(,AB2VC'.XQH.R4/"[:#&:ZTH4M*5GXB1;C<&Q&JLNF(FV$EQN0
M8X.;5P>2&TS.HY^SBN:OO4%SM\BM=L$IC!+6^4 Y^LX M!(!IQ.%,^"O[*<7
MVBP7XEDRC);YR[:EL1U%*UL.+!58Z72EN]UKX"K+&7G65ZVRM:Q[%!0%W @8
M5[2> 6!?W6T^F.W2[O>ALW5=ZY[F,J*@NJ0WL:P$:G9!<D[TW^M,B9E<G,,[
M)R>KK=ZKI;&MHL)!)#;21Q\;7->U[5LEIMMDUND16+,AQ<>;N;OH7QYOW4O4
M/6?4#[+:RZ[WZX-'R"NB)M?E9P8P>]Q%2L5[9]L9G>;(N[@W8VG'[$Q,TRW,
MBLNM2YJF&E-N8Z \IP1Q$6-7G2V5W'2A0%Q7(]6=1ML[@,L 3>O;I9&,0*G!
M[AG7D 0.)"^K?2KH<=,].&ROWL>0_P R:X( (-"3&PX"@J:D@D95X+H#,]RG
M\H["[7=G<2A$:.A$!O\ #VNEAAE!](NN+;^%IE(%RLZJ-:[:NE;7;XG=2]82
MT=\VEQQYT .9Y#@N>ZM]2]WZBOQT1Z9PNDE<=#I6_*T5H349-'%QSX+,X>W]
MK=C8;69W*XG=O<S+-*<A8\N)4(I ZE/+ZCU08#!(ZG#\2R+#72M9+?;MZA7#
MK#;1^#Z6A-'OIGR'[[SP:,!F<%F6^W=-^A]B-ZWIYW/U%NFGRV5%:\3C_*A;
M4:GG$Y $FBT#W)[G.;CAKSF7RL*5NYN:Y 4Q%<4AEK%EEI<<1H#ND81U=22Z
MA2O7&J^E8L>TZ8Z==TS>NL&PO;T\YGF![J5UU.;A\Q.'AIX3@*@U'F_J%UC;
M>J>PQ[IMUW [U#B>+<P1ZW$--"=+*'0P>(^97Q@ N(<-)T-MW;6[>Z>0DQMO
M(0G&Q"5YO=&2<,3;>%91J\Y,GK*4/NH3<^DV2HGB0*W?4'65OML(@B)8'8-8
MS&60\ T#(=JO^FOY>H&SC?.J=-YN#3K/F8014QU.K@2.16T-C8[ 0<^YMWL/
MA6>YV_(?4C.]W=VQPG8VS4)_XP_A8JNF,M;.O2JY)M<J(KB[VVN7V@W+K29U
MAM#_ .7:Q&MS.> <<Q7CP7LG_%T#[YW3GI=;1[GOL.$MY*--A9@9N)%&N+>#
M6FIXD#%9M)SFPNW^2D9MEX]Z.ZQ!&3[A[J=+^T\-+3HY&V]#19$E$57PI;BA
M#0MJ[Q%95KM>^;W;-L@W^C],'Y;:$4N)6\#,\XBN=75/)J\\W?JCI3I:_?O$
M\O\ Q/UZVM;VY-;.V=Q9:Q#PT;E2(#+Q2UJN9>Z'?1_+902]TYR;G)R22PT5
M#Y> BYNWB\8S:%C&D@Z%".NW[RS7H>U=,[5T[8T@9';QD=[W]KG'QO\ ::<@
M%XS==5]<>JG4)M;07.X2,=XG"C8( >644.&5!K(S<5<=M[6[M9K#8SN9BUP>
MU_;+-ISN,/<?>#<)W'/,0&OE\TK%0UR_GYLLH<<::Z63&>4EQ'J$CIKA=YZL
MV:\O']/>2;S<X7,>(6%VJI-65I1H;@":NU# T7U!T9Z-WG1]B.JKO<Q:,N(G
M-DTAF@-H=3C)("=="0"UM#CC6BM^'PF-R$K\+_+]VJRG=K.)=4<CW?[GQ%9'
M'(D?[I*Q& E?+[9Q45M1ZD*?:=<  )%;&62[\D7/7>YBQLJ>"SMWZ"1P:XMJ
M]QIP;[UR1?M-G=OLO1CIZ.^WA[B9=SN(O,HXYO#Y>-<:N>&C[)"K9SM?%D3!
M*[Y]]9.?S+" A>R^W#:=R2X'38)QYGAQC;.#0V/AZ 4! X)K9;?ODT4/D]&[
M0V"T/^/<_<M=^]2AFDKSXKANH.E;>\NC=^J/4DE[N3<[6S_S+V?N5JVU@IEB
M 1VK=7;3&=KX^S-^3MI[4Q."S_;S#Q<QMC(]QIHWUF<FW.R:(N09A0YCL?;N
M&D,EQ+X1'B/%2S92S?J3RG44_4L>]6$6XW,DUAN,QCF9:M_#L86MJTN< 9I!
M2HJYXP& X'N>B+'H2YZ7W6?9+&.#=MEM_-MI;]_XUY#R:AD;R+>$Z@#ICC.)
MQ<<QJ+/[XW?NI77N3=N>RR+61%,]V)C64<FV,; ,6 TR@:!(;L!7>6&S;5M@
MT[?:P1'[6D.>3S+W:G$GG5>+;UU-U#OQU;UN%Y<-X,,A9&!R$4>A@ R TT6N
M<CG,#@T]<M['P[FR2\MIM:SR ZU!2U'RO6\#)I!J>XZ>TX?L7+1,8^86]A"7
MW)P#8V%[C[&@E6-&[WL@E3F(Q&=RD=!(,C&8+)/Q18\/FTQDQ0?]>L.6^VFV
M=IGN(@_EJJ?<*KLK3T^]0MSC$MOMMS'">,VF$4[?,<UWP6Q<1O3)1>WVXH<C
MMLS(5-G1'(NXLKG=CXN3C'8P/6RM61SC69CLO>HD%"$I2HW!U)KCK^ZMYNI;
M:[M;RX;%&PZH613$/![ W0>\XA>T;!Z?WUIZ=WVT;W8[2;^=YTW3[J#[L_5J
MZAE;IP\+#0TX5*TV[N/<LA12RG:;/+^=O?;UQ[?EY,G7ZZ[,;Y"T5;;7A_\
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M"2G$;F9%OWW7(02I3R>8>94;US;+C;H)?*:ZZVVYX-E\<1/97A_"Y>J0;CU
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MF&RR41&GUR667_3*$(C,_)Q91+[E[ZI2A* ;J KFX8K;IFR;N>XQR33O=CI
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M7:*B<VBG*.7X)O @*3-BY,N1_=R^'!AK/+IXYY"_:=".>NF/!M)/"'<<I?4
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MZZA%Z3NW/3G9)Q%.[P]W_UA ^FN1*I$MU;VE&\=EA^>C; T6Z6UD,+'MZ3]
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M:Y:(:VWUH'AU3FP<''@W8]V$"&AO-%K8YF0RD5C056IA%I;2%>O?J\QYB);
M)%GXM=S2X)#GG6S+U-KRH.2XX6Y.^R0.9HP"6P^2GOJ"MI)??HYU-Y@.6]T&
M7'GLPC+YV*=FQ]4A/ QJ;YM4/NA/0#PT$:CXM"1+ET90, R2<91.=XOOLNHU
MD_?MBN;SC;&U%,'  G5/PEQOW,_1\T?-O+8FLW>OPP5&Q;C(UV9:N0W_ 2K3
MI1XQ]RJ_:W4OU:X6NNKDG:U>&DFH^DA0"M N7IO1MG1])K6%A*P84=+:7TX_
M80S7)8%912!(G.?-Q9-Q;C)XZ G40Y]W@^I#,_RO'  &-R@8GE@R0W#;CC(Z
MKV$0!L;.KE)+4BQJ;QX4Y]0O;YA[_,?[&V."LS=G3R_&W&'X'DIT0-8+;^F6
MXUDE85HEO$^"XV?Q@QY$V?K!.8F#<5/>:NJ)D7 "^]KJ0_7OI'_%>XW=GC!R
M1P6.KS:V[",%<%U6<K_GHRB];A-Z':?=^BGQZH./Q6+9GW"9B8-6QM>W,Y_F
MUGF=,#2AT)NW[/QBF:'/W3XWXK50FI,\IUJ4]I6/5E)IB[R?9#FD:4+5)?S/
M+-A,KFXS@RB)7AQ< 70&W8$G)_>*ZUZ7VPBK5Y%O:;A.[KIQ,-P/VEDOBY(O
M(Y^_M#8I!K-.[5:E)R&Y^3:BON[57Z_#?OT#J#4)5PXLFG'=<\7ZSX*5!?SP
MG1]XI'4$SNK_I$H6;O=]L>W6'W^5@\2/_;;E^B(9?0,CQ:[H:6D-TWFW0,_$
ME6U/7UM7I4P9W946Q!O >:^ZIO%(T_=QO\/\N>U/2E%QUX[X2M92_38Y>'W!
M#%BY["BS(SV2[GZ! RR$7)H7P6#=4ON7&@T_MYK)B&!=-++/0P.**%Q"S-D/
M0!=FM/%</7N"KY2GTL-<ODM=!S.W2'#5B#]#68#44N*Y&];1?WVQD!C1?I+P
M%=)\RE_YQ\%%B)95^3>CVY7TZP!V^#O8TR\W9Q.-R[LQ&T:D'EEJ% I9NZ-M
M*0]%?*1D1BD>-M9>#YJ"=7413@ZV:6YB6 5>6$7:X%4>$6Q%X(?]Y\13907U
MPE4@J6 1<5(%R,AF9:&AF/R[WCS2LBK)![^HA@(G@*Q(9>A79N<_@*YP&-H;
ML+=8*Q@4H=;\X@#[-5.2ZBE-)HGA729\1$1#BL?<[*@P96_=_,+ELG>3<C#%
M1$;(74D964$:5V-DXHI==_$'OP;,@O@'P/1$N3@,ETC=<4*V)I]0[V$DS*+V
MB5%S];N_%'^R[KE$7'<A'!/W5CS)A>C)O_)9.;%=[CM3>E2/9@A)U&-@YJ>E
MB6.#0C,O::]-Z2^GIT504OC]KLN[>THBLC'4C?.#M2VUK!@$"A3[UAD OW0M
MFG<*_@%\K\'?8X<H'E1V1R[_)$RC?,S>;7=8!S>NM9?"C5T*Y5]LK-4F7WB6
M!Q+^C+865\I3/TFG#Y_/=%^YB <(X=O^&?M;X@;, E_L9[I,^.(F!@I#>YH2
MW(F=P Q6:=<W+=9N4OL^(A?KY>HOJ&SLID%=44]&.,%>UKE+EZL?P$C(FD^4
M(=$_@%].!T7^>UOM)]9\:;_]U.6Y2XNE%2FMP8TDCD.(ES#SGMB^8DAUQP@%
MUX2#!V^K0=S WNNX;W##R/Z%2=/4M-:N.%![1M?(V:O.V)+$X2Z]QH65+WO0
M<2MMC[&3*:GB[>R7HI:">=>D&TU3)]"K&N:42";TL%>77T>+HP-$<[)G<I\>
M"U8[,,8AD@_99R"F;/DI3"!-%7'8"P:()#D/6[T 4J6F*Z\Z_':F0^W=?>Z;
MG#@&UGI[ :\H-HG@TED28,/IWLM_6YX*7[VU^;O5H_(<A^AB-$;,S"8[G\6K
M+\,76OVR,;F;?@]/+=VB;Z*S8A%)7IWQZ^/^+!KJ4T'7^@?E7[Y[4V,D.%=E
M/GUE\>XIFZ8BLE!6D7)VSG:[1-9J@HNTE-8OC5FWJ3G7YJ9H/'B/+@7-+_JZ
M$G*"69%W6_XUHIJ#5;HV';M<&HY8?2D89&\L>)@:)M2=-%?[MW\O;8"1I)D?
MPR*%FR?3F2X\F6\DN\E$,'^(].RF(D2O-MO": ;2]\<%H=1*Y%_]SX5/?MS>
MY.7U:&MN/#SR[8P-(OO )"T][9_T[,8*.E1^:Z%1L!";=VQ4 +DI[=GV)'ZW
MWB"4GB1CD^(ELK39;O>/R-V7JQHCXS>UU%<OP>?<A^"C4RK>G\:4Y/U0IGM-
M3PE-;?00.$?#]V/A7Y(AA7O@522^:_.Z375@.Z).)8I723+[+.#H=D%NJB]Z
M-I!#?8&UXZ!RX\P$UX2Q,T<L=EK,Q_4;F7B+2<+0.#TP/Q<8VB^(GJ:= ZG_
M!(+^ !3Y!^^>FT6'MBTI7]'5?@1UO;(XZQ'>7BQHYN]RA#T4Q$5/[#=.D_M-
M1R)2SW6'*V5_\W>ZZI((X\DN\<BO!B^=F7#J#JQT3VY</OT)SPJH2QL?DU@>
MV.L(K.QZ+8[&SO?*][]:(C_ L W?U.>EF;)C7$C^9LL=%1[_$8!B<_ZL]1/A
M7_W@1W WWYQSPE.U'&1HZO8-$UF&(04N%YN"8>L"C*JLO,GZQ,_?73ED;BM1
M3( I@>BQ;[4L9Y>3'S;L&$5>O[\Z:C9/G-RB6!7W3W':\<6ZR4M$O;+DE:VR
MV[%4R\N<V]=0 7,F_B+?4N=M7UG[T"3R^J%^D\>*C*!;E<J"@I@)([Y;$+BT
M*R\?6Z4.8#O3,>^JP<<6"=AIX;T<B(QCHY_.;VGZX;WF3ZR8.AEV(WND9I3F
MM)FY/#]436"(C-+::D->A'=>...B LQT?E<'6<X;0$0IZ1*9:V%W&X^^L!=M
MKP%?"CSTO4T,=VF*,>87#C8<F:1$$WN-\$^JX,&SLS.#E5V#\5I#LF3LS'4)
MT841VMC=<G$1K%4I@ >61?GS&$-8OP-RCBRI(!I!KMIPB7\3KL@EG98E1BL-
MV=^9=F99XW0:"3)+J&@KTASN/"-#&]1UY;*F/99HFO!V__%NPC>TF$QR&#J-
MXZ^;OE=,>EK!9X;OTST'\;'4 QV6CQ;@LRZ^Y6OT^16UTQ(U)F/5F&55<[2@
MGL =7E;#S%Y<$ZBHU :#3L!_C/E"L.EHU*?ZH9[Y('GYL40A$F)#AY1Z\AMC
M-U>JL9$1&[[&.X%;R!&U3Y#R._Y*6\WQ"CSXXEL<XYIF5.:JA3<R+&.9^A"5
M^LS#(PJ[7)6-&7+TV&1@*N9Q@1\.D#Y9Y=5!VZR!Q9KDU*CCL>UM !,N-O0]
M$94T%\556@ (2)I%7D3[OA>^93U<5;G?,!P"C%T;%BXZ<0MC$_"?MNL0C#T[
MPARB\U%+QL_1=2^=V/<) $-PS[+G?'D(?85YI63/AU+6!3;6WX0D.S(:ZJH'
MY<?'8;NL)%Y;LRBP#'_]BX'Y-#)-BO,%7*XG"E>RA-15SR<S93>0QSI\$ZUW
M7U"4:[QPQ?)E-0OT)>KH>@^^H-V:'1M'Y,D#XKG).]??6G7K)4SM,BK+\UV[
M[X]U_,X'+7LE$Q8F&Q@UE'NWO@5WZ2_,= H-W$IT9^H?K:;IWFH#G("%6 @Z
M9L7^[\KF42>*5^<O5+BP_*SW]O\QLJ+M22UE9R&X!P6.!JOP =LJHZO7+M-X
MYE(,7[[>P$B'(6%S:6&R*OKL#?>J)LCM*%&<#B>2;Q78'8M2_3W$O=)@?/FC
MYU=.P2\W7"AK/>V3R%LVGSZ^O\M;B%7'RVI@=X,1?^M-XM[Z%T)]A8[BV]SD
M;85QO%2L0,80V#] X@HL$'E,>^2*Q"UE9VWUW%@9]R:2+]2O *ZT2I T4@"\
MTD<&RZF5L$DW_8+N@QQATB"10L3F$PBRVY17055H:.MN7_C\G@B#B$2S5 +&
M-)K#Z2#_CN&[B7/E%EH&MQ@ E8L3$ZF5W=/5W!%IXOC9%,7X!U&,:)@*0"2&
MV5:-LCJCT#GA.I<@!GD]E+MF0CN-S$*'(O+HPOHU^MV<=2(_2D;I->!(V>]5
MFB>>GP?H>"8SCN>L,%'@UD3JHV#)R2I:;_S&^Z5>_[Q.(4&?V?3#I/M7;F,R
M1S6*KH3,49T%V) J*NR6%"[#3I/6U89EO]'ZT<='Z\?%Z$-HV_I,J<<M&),\
MBM)S:7(_WT>LH@6;,9/*^<@\C01;3XLT&5%241Y28N\30'O'>V4#87/,8L+%
MG&@8S7"6;*VNJ5#&Z:!9M"Z"0(4S,B?ZE\M=*H! NP!J )+;\]AN6,V 7Q;)
MC3\GD)?>7I&?O.@+Y_:&OAZ*4:%<69T%G 29_P.XL92\Q$[E3K5;\PT/:[']
M [!JSSRSC8QW@@/;.HSY(]F$^Z<N'JTE-3DL0 E+4A1O+9>*RUVX715=KL#F
M%L<;!61,22AK^NLS99>\IAK^;STQD#6. 4&7#!PS%R=J4U86#,/C+D?Z4D'Y
ML,5J]MT5GLM:/HC-)X1%N^+86P_)*:LS:9[! %_"?I<WTURTO*JC&A YW3\W
M+]6?7$E)R]DMG+S'F"K$.+(LP%S><5YU537TG']UWJM3E-/AHQ06G4^C#'6"
M99*\JMV=-N.<_(0A,K=^.QX^BFZ?:3\NXFI%WU*KU]^@ A?/ZSYK=J1^,MP8
M:$)OXF5TG5FX6NQJ\]").7?@]N,)T'PC+8O5H(3MY'EC;F9-0-NE9VU63Y"Y
MTU)?@[X[GO2EXA<U%S$=?^7V/EE2^HU$DI]9G'.1&SV\5? (Z.L3UN GBFVM
M:4NR4KG]08O?MF9,+AH./6O7S3>5D8I9JI'&7 *!IKFOIS30'1E%D3Y?VR5[
MN6#!NDW$8Z,#>>9^H>-_N42=I:.;LZ^<6<I3:$:"X?30Q+(]Z? B>]N)>[P[
MJN>6[$/$DV$OUO0/GG^ 68ARD>.Y(0=T.W%?UQ;E+OE/&"$$M6.UZSO-D:KF
ME-VUF$'ISAA(>M(GL*"VM!UWLUXS?#0M=$<"],<J@-0-C[AG<D6TSD[T?;,H
M:7JWN<\'TN<C*L]YBWZC_NJ&\A+01S495>8URO[ BYXOY5[?0.#U.Z+?JB2T
M-]$HM!3U;K^>.EN'?VY"(F3^7@#I?(DN=*=L_P&&'M.M,L]%WY<*L;(&DJ\R
MJXZ-9-!HDDYD_AY($<T:X/DL*2DIR\!)$MJ^/=,Q^A2%@>THUD0&H#8%Z<@.
ME.MVK'(ND;3F+O!T*]D6YV.IRJE[>Y(<%TB11ZA3_[&9@A"G+*U6,]L6,?\#
M<-A=8_S9<7K7G]LG$>1JU_[Z_841Q'9I(. -N@S[[I^_<9+6!^$U%2X;8VJA
M\,3BD%+-"9'CT=9FA95DDU!LM&8QTQQ,YEJB"])M7:5,UI55^?X3$VZ?RF43
M[I+2<88*-SY38S;U\IL[6M\V6\EMLZ$HH2*GOWA5:-#8*Q6;@T\G\5.7PH17
MMVNIYMPE"[ \U4 .&1U,SE><E-LU </PUB]5.K3S:HO4';X1K;EKPTJFEM]W
MM4AV @RN4UA2TT9721>&S=<,.U9$D-R.RCIR=12DVVHF>6_"[?AGVWDY^_Z4
M"L!3(X*M?UFT!=L[U'I!-X>?1/O2N%0D,\:?\!@@/NH_!K::'8-YX>:BK3O*
M9U?8T('<45LR?#8JP\H1B-JKO; ]63TU]&&>BBVV_MA;]6QF6,&U^O,HL/4^
M7DKTF[S3+2O_2C$U/I^'U++CQ*C\S2;89E=55TT[%-60@02[=@,2K]MV 0S[
M;S"#1 AOG[QL#SJ74Q%32@*R.EU)"FJJHY,&$SJGB:D;24*MVF(A+FU_3=KC
M-(<MY3A 7A*CMWC_  2]0WM5;&@M:O4-[5+279<UYG!?X:708-]W1,<*NKU9
M^^<KT7%)!+]C&7W_OT\6[Y+N*I(G+WM.VI]X0B<.UU+@ 2;=+>)Y9$R??*A@
M>69<+9:3^\*C:N_%Q^"!V9<O=[[0WNYO52<[!$D*;Z9^;R<CSF)6L2KO/LKQ
M04V_1 P-)LY;1_MU?S8T?O]CDM0TB2 SS^G@H,;#@Z65'M]BT/ W? FBJ59A
M\1\H7HW3F^/=/UPDKC^+#'O_ 5JT8;$<8<DB3]6ET9V,?W)9B >CKWOA=W^N
M)BN(L)CO=D'XW:#1Z,1ZK=P3T,G%Z1(68W9?,G64%..S8"E]7L OVA?:4T9>
MW$=$]/V\G)>"CIJ7@CZ[6@6!@E:L41Q#0FB&E=*$?))02'$KH[RU?478&VB4
MH(=X<5Q$<87\:(VGZ8TR0*Z!PSYB8Q<*>DQ:G=NH*PIW:*I!P<P6(%=Y@';%
M+>>&\$JA"US0#1L#++>_VMWN<%)NB1(I^B\J<CP= 2Y=B^_;F<Y+!^]]@@7O
M=Y_\-]DFNUAUV1Q,!6RU;(*VPMLP>?;ME .K3-(8M2L_6,H)RJJJG@KWT65:
M5/PNP:!<B J5&+/Y*8SMQ$@$:1;78X1$GX0225AID4<VEX=XTJ^B)<5OO[I?
MV<]AZ<?=2EXQ15V32NV75#&;5?[U2LW_RR(8Q,M%<23MA9)DC?I4:T"F,[[R
M@33U<C[:%-2#:.HFI7B("8Q@'C:4DUL/K/I072V]2:F&,%T(\I$YI0S33205
MVOQ%.L:R?<[K:(T3/=]&T;VC?6_VT9DZBVK)5PLA'$/])^:X5M&/OZ/C29/J
MG"O\Z=,09D;1);JO.001\X[]3Z;7)\WT/0I5X:[$#MT0X.;J?->7S37&C7KW
M7%_TQ('A)W2NHYT!GH.NC%F^0>PDYQWQV5<>EC=SXYL4\9D@UN/[^/ :"DR'
MHW$L%NOTFQ<SG)#PV\:&_[9I))>XP^@T8T(QOB,=)&CYV"P9WM=UFZ/G_?X?
M8 7ZU\07;>5C1D\87S9.EM>=SA\!_U^D?)IB 'ZH9G5)D@:[!:LLC5TB/8JE
M][)9WCWV?+M"T#D=V<D:V=<U<.-YGJ>UVQ11\$+RWO[55)/KI@__UCH\C<&J
MBY)K -=)S?#$8JG/)9_Y"<U <LIGJWT*0@BTW>P8Y][JNGSYG#T\9KWA5_1I
M+)C/+*/CM@FAA#68.\+0;E_"MNL1$,.2WK!!0-+5H1RC"18C'>Y,VG*@%<6E
M>I8(?/0U\.C]"J&'\\2N_=V4USM!=@27\M.4\VJ2KR.NI!,VLKTX5BM4U.QZ
M\ZJ;:#A?W2\I]K-]X*K=\F4U&;X?/U48N.*B*H8;Q(=VI?V/.;O(A$Z:WV=^
MB\[.,C883>O@_@WY"?3&'[U<8<S>B 8\,J4>_4WNTUZOC("4P;X]0971:W__
MS#DFWZU;HUEDSGZ))RB.$NK$%*&DOB16+FVS5I8(\%+_0(,L&-NL Y+BNR*Q
M$1G]Z9<7!P9$A);+:RF9855'7BE+A%-VWV84&6'W6O\ T;ZP-:R"YE6R13:"
MM,#._Q(TG*9A673;>H/BUSV0,5,<;W$^UQOJD;B?E;GI/VTXBE#7RXG_E49U
M1%I!@"<08ZG,PS_@$<ZW:A:K<R>TN;T]U'HQ6ZB!EP\X3$;9>;TG1E=^>-I;
M3)9%7_!U>2-?2SO(BF@LKF!]FU0G7P%\(>+JHV?[W"!B#WXSR\259U_>*' E
M?Q;@[H:#&%=YC KV$Z[8# ]YU19R)-QAT6RFO626XI57,%%KK.GU)1S*Y]Y
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M-+)+$ZPL9W5<DD'[9A'90H)O]T#[U"%TJOO)^H+H1S SGHE1N_>B.)N&VYM
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MW0[L;*X[3$")666P49Z(;#W*,U/]^Z\9P*[44F*040O8K.?W9E=\TJL&L>@
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M/STK3Z6D%Z]]X:4*YAL:5'<!OV.<4!O]^OJHT=[3P3;;K$%&QE,I3>V&/I=
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M&Q;+;LE#9'2J8L=$5"K<2T.IPWY@5L.C+*I=N4X\;R0.X9^_ +1==7=6-VR
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MS'<O$8W>/<O+8OMMM:9FLR,YANU^S)TP_,[?3&CHF# -2T8GY?(LL,N2C#$
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MK)7)>;01?BZ\I;BM2:HNKMFQV :S[R_E)IS>\YN/8/@  LR?7N=VZ:3PP-^
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MMPO)6M#N0EOE"W\; 5T_R8S92OI^)T]1Z$?E-Z\_FZZ^ZOW3^F^D5W=[/T=
MXM$\8$=W>.'^*YY!?!":_=PM+7D>*0ZCH;^A/IE^5K:]CV./<NM+6+<NI)\7
M1N!?;VPH"(V-P;+)]N5P(KX8QI&IUX_*O^;K/;L[TP>S.YL\]NJ)NK#9[(8"
M?.*)&7Q&3V[CUY=^.N8A"7I6*FXV.Z+/%19>2CI4 LBO7OR>>M'JCU+U!)T7
MZ@7<^ZV,UO)+!<3T=/#)$-18Z4 &2)[:BCZECP-)H2%S_P"8S\O73W37IP[U
M)Z?M&;==6=U!%/%'5L,T=P_RVN$9-&2L>6FK*!["[4*M!7U(K]$U\"HHB*(B
MB(HBS38G_/+O_B#_ /PT:JV9JU+\OM6WJNK'7S _/7N7&X;>45*)$O!3L-V*
MWYOK=>0E=]<OV,@;W[?;8S$!K(]OML.X?:^XQOK>;TC*+6F/,+4'')E,!Q+G
MSX4T5;?UKZ([$QV/QNUL2G%MY^/CYT9&7B8_<S\IS+8AC+)3/;PKL:6XZK$L
MXE#XCMP469A(;#+:4H0 "H6741%$7(H5KX>^L.BV=%('[JA0@&E2$J0G?S^R
MIJIJG[:E3WHN*)4)\>%$"*(BBE%$11$41%%"**441'Z:*$_.I2HR1=*;J6;(
M2"I:B;!*1JI1/@E(J%-''!OS'):&Q<A61<RV:4!?,963(:(!%XB%%N*-==&$
MI%5-RJO0=W8VT9!MS<K>!K3_ !4J[_6JEN;,L;<VWELW*5TLXZ#)F*\2(K)<
M"0-+EQSI3[ZS;*T??7<5G%_,ED:T?WC2OLS7(/#9)P'_ "#$_P (Q/P!7S&[
M<QW-Y]P9&<GGU6V),C+R5JU3UEU19!)OQ<455]13M9M>T-M(10:0QO<!3Z%Y
MIO$SKS<2YV6HN/OR_8L9[Y;G_'=X/H;<*X>"B_),V-T!Y7Q/$6N"0;"MELEO
M^&LA7YY'56H<PRRE_P!4"BP/L5C3DM_Y;<CZ;Q=I8=Y,=2A=*<ED@4)4DG0+
M:CI/G\596^3?<,M1F]PKW#%9(C_";6^3)\I)]@_M71^-ZLWN>#$)+B6#\PX0
M;CU'%'I*O,"M=,1;V;G\3@N0CB\ZX:.6*S'O+GVL?AL=M.&OI^92'YX2;6B1
MQU*2JQ&CJQ6%T];&6X??2<,&]Y_8J][DTP-M&9'%W</[5Q%E([NYLSC-OQ05
M2<S.:*T@$^G$0X CJ X ])5[$UVUU<"WMSCX6C'].]6ND]L#)9=WF'AC!#>U
M[AC3N&'M77>\51]H;0QFV,> ATQ66 VC0V" C@.:OTUQ^VAUW>NNI/E!6=NC
MBR#1_B/))5+*MG:W;W'81!#<W-7>G=.BU( #LB_ _O*2C7EI5^W=^-W5UR<8
MX\&_0/VK6W#/PNW-@&#GXGG1<J[DB/Y[)8S;;&DC-SV(( .C,;J2N6^JW[J&
M8Z3<^%ZZ.XNA;VQ=P:*_IWK+Z0VCSKX[C*/!$*COR'Z=BV;M*+ R6^9VX764
M*VUL#'B7&96D%IQ&(:1C]O0^D_"3*EH0LCG8UJIG26^ULLV&EW<NH3_%B\^Q
MN"RKUS;K=9+M^,,0PY>'+WNQ6DNZ67GRENW<7(R^;E*9!N5..RY[I6\4\RHN
M.=(\@*WL!CMK4,;A&T8=@ _8L/I_;7;EO/GS8QQG4>^M?I6<8C9D*3N#9_;B
M0I*=M=O,8K=._9"?]D]DEI1D,FVX1\*EJ5T1D Z\16C9=R16LVY-_P"]W#O+
MB'9D/^LNKWE[;BY;!_A,Q=W?I]*\6]-R.9[(Y;<,PIC,R%J<;;T0U Q41!;@
MQ&TZ!MJ-$0-. -ZVMA VT@9;MQ+1B>;CB3[2N.N&27EQ4"KG' =F0 7-#\_(
MY'J@L+D![=$V%EI\1"UD(@,H<:VIC2R"4^JB'*7,<TOZDQ"38MUGQ-C=,;R2
MFF,%K2?]=U>\:1W'FNPNHSMUC'L\)Q^:3^(C]/8 NB=XN-=K]@XOMMBR&\YG
M4-9?=LIL@.%;B IJ$I0U].,V>FQTO<UJ++5N>X.W.7^1'X8Q])]JUL[1%"(&
MYG-<WLH3F=P8/;+5_3F/_-9=Q)L(6V\:4RLY+6JXZ28:"TWJ+O.I UK?7<SH
M+1\C#28BC?XG8-^./L5_9=NCGN?Q5TVMC!1SOWCP9_>.?95;\[=Y[MEM_>>,
M[J]Q\9B)&!E9U_;FP=IJB1)V$P$7%!LNY/)XAQ+L=F#CX 6U"#S?I>JVMPW6
MELURVZP[C)8.V3;'O;.V,/EDJ0]Y=D [,DNQ=0UH0,B5N[.$WUV_=)P"2XZ1
MP%,SR &0'>OHK#S'<K),;J.'QVTLEL1T2'8N9EY9EM];"(;#S'X)A8*%J7C&
M6WE$G^2U<?#U'AYJ^+;8GQ"5TS;\9M#33/'4X_6-.TK>@LU E&YMR.M[7Q>,
MVW'9DIR,#'1HF7A(#GX\X[':;8E>LUU..I5J6VPHAH?" "*JM;4?B'37)(+7
M$EI^IS%.':>.:H%#CP4MD=UV8,^)L[,95H9C*;3Q,3"?,.(6U'EQX_\ ?&'&
MU$I1*<=(0;I!^"WC5&X;,]\?XZW9_EV3N=)08D$X'M S]JQW2#66GCDLGQVY
ML9$CST;IQT:3DUY'Y-M<9MJ+)881Z: 4):*&7G'9"P05A0N!;6K4UG<R2L=9
M/+;<,J:X@GZ0 .2M&0-%'9U5\E8S,[-;R+/XJW$AY!<:2G'NR5OY..AOI= '
MRP,=EY:?A(#A3QX<*M12VNYO9*&%SV5&H"C3[\2..2M2%T8(K2O!6%.4WW*R
M@R.,@9F5"!24O)9D"&MJP^$.J2&U)MX&LD66T,M_P\YC$ISQ&JOTK&=-<%^M
MM=/P6Y8&+CNL-9#(N1'LEDX1<& DNN(7&<6/Y3GS#:U-JD#][T[!.H!UO7/O
MOQ'(;:(/$,;Z&0"HPS%.7"JR/*+AK--1%:*HG)0X,1Z7,AF7/PS3<?'8QYCT
MX4=3BU!4M4==PZ^7#K<$<";U<DAFED;%;NTPS$ET@-7&E, > HK;7L#2Z05<
MS(<.])MC(3($O,[HDF=)4WU8K"![H;::<X27D)(Z&D)X)%BJWAQCS+:WN665
M@W34^.2E<1PKQ)^'>J"))(S-,:\F_K58X7'&/@(46!!2N<VY-R$Y8ZW4(]=2
M VE1/0A*4)OPO]=7!=3-DN)I7N\N,AK6\*TK[37!6RQA;&QH&IV)/Z9*TY5_
M&/9@QMKF2J3%D,M_)CK5U@$)/HV!!"SR.HOQJY:"XEM"[<VM$3FDZOV\J*B8
MLCF MR=0(P0F"F'^-RYF1>P:'_51*#;;<J9&6H);4AA)6EI*G5IU*B;"]6[B
M=L5M#$(_/<*:1D'4Q!/&@"JB8Z:9[@[RZY\PM<8UEMJ:U&_Q,[D8KLGYALNL
MJ;DMEE1)<0>M;;:^@Z@$WK;PRQW49N&VWDSM;I(PH:\.T<L%BW#);=PC?('Q
MDU!6UCM_#[?$O=L?()>G6*FCFF0$*D*;LTIE;2P0MM1ND*21?C6CGW.1[6[=
M,PMA.!\LU(%<<.T9K,AM*N_$1G4\?:R]ZQS'RMG8O%S\SN!;64G9)#S<DRD*
MD2E.*!*O22@E3:25_O: 5G78W"4LMMK!;&T MTX-IVD_0K,'D#5)>$:R2#JS
M6 [4QO;U2EY?+;=9R^47*Z(:I2UI;$=E:@Q9FZ>HMH'&]CX5M]PDW?RQ%;R^
M5%H\5!QICCWK&MQ:%Y+QK=JP[N"M*LQN*7NO?37;[%M9"8RTPSBTM"-"QV&>
MFQVD.*DO#TVTMQ A:@-"5*%688;9^SVW]9D,;"XZR:ESPUQ.''Q8>Q9$CI(;
MU_X5NLZ00!DTG#%8WMG8.Z-LR<EG^YTO"-,3G&&VYT,)W)!3/]((<D26H<IL
MPYCEO]U!:5:UR36=+N>W3QLL-E#R]H-&NK&[36M&ZAX@.S$*DLF\PW%T UI
MJ0-0KE4T.![UYMR;OSNVMTIP.VLQ$RC.2@0\LW(QF.:Q"Y41QU4=V\2,5A;T
M1:;*"200I)XWJJQMK7<+-\MW&YCXGEA#W:Z&E1XCP/[5<E=+;.86D.CD%00*
M=AP[%R7G=\;B[K]W,AM7!!N7E&FYF)F39!^31)QGR,F,M,B4M*4J^6E.703K
M86%=19[1:[+LYGN*BW<0\-SHZH. [0/?BKT]XR9\?X<??MJ''F.WN7A[I_\
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MD*02%))ZDUR=YN-TR\CW)CYKC9YVZPW4X#3W5P(Q!QP/L6VM[.X?)^#$9;>
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MVQG$H>F2HC[L3)J5_.9?;;6XP_$=/QI"BBVEB"+5C[E>#<[>*_VX_=L> YG
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M16Q$BA4%A<F!#>>GPD(BM!2>MH M_%>U:N7<]LA;'LQF:V]UM#@ZK:DXX$@
MXX8'/!6+UDTERZ0-)8 0"*''+V8XKF?>THN8.;'B/$SI0CQDMZI=4Y/DMLVZ
M" JZEO>R]=,#I87?4 /P5SIVU$F^6[9!0!^HUY-!<?H5Z@3GL=N3*LMR'E8+
MM;M8QH$7U%?)IW"Y :@R)B&>KTA,=EK4@K ZBE ' 5A0PM=:->0//NI,3QT
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M$%U#B:%M:@=ZSMW@Z6LMO@=L<AFWIMPT.:<(Z$'AQ(=2A*>\^T.P]\OY;_\
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M$%(%_96SEE\J!S^.DKJ>CK$2;B;EP\,,;G>VE!])7LV@DY3>)G+'4W\Y,DM
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M.QNV&NAEK%P0#\JX_(4')"I2FK+4$ =*2!<D51*Z]_%"&V@9''JTOE..MW$
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M!O:L#I^>_?L3[MCB;QDCAK=B13+V+(WF.VBWB.V(TVTC =+3IK7N6A>XD/\
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MY2Y"I+N:))LEO%1TC3B9A?6/K3>LH.!OV#@*_05Z-#:"WZ1)IC)J=\6M"VK
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M;?:.PMO]N<?@']P[WR.)9@[H8C%Q>Z?\2R(K2YKCOKJ6_&C-R7;-I;"4-H2
M #QUHVO=;S<)=RGD\NP9(3'6FCRP<,LS3.N)*Q)CIHW-Q5MVYVP[G,S,B]FL
M3(B=$2#*E8M"7GT^JFSL54R0L>E$DED>HXDGKZEFPUTSIMUVIT;1 \.!<0'8
M=QH.(K@."PI&OJ33%9YL2+N_"P2WN['9G*[<CN&5A\)#<?\ 5S\YTEAC'MNJ
M"4HQX)+CCEP  ;:FL'<?P<TFO;W1,O7"CGFG@:,2XCB[@!SSP"Q@YV4H)C'
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M!XUYA+K=87 2..F-[<AP/8.PK8F"WYW>VAM1C<6UMN/SML[M,K.1WI:'7LQ
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MR657_M:G4Z5@[/".L-FDFVZ$0GS'5<2 'O=74>\'-77[?+TWO%N[?9O\G)$
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MP#TB2I>(V%$GR83.+?;<ZVSN=N2TI\V 2SHWKU*526&SWG<';7:!D3;2A8\
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MG4<#<6.MBNK"\W1NU[\TFUN) &2@D.CD. :2,V.-*<CGFLS;;.Y9$V>S:':
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M]$^_0W%4')5EE8AWJW.7]0:?Q6N>=QXT!4-:T$%&.%H$I']3+3#[/44AT_\
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M([I_:K*V=>;66"Y?&1&TFGWA;X:8YUS'%6-SWT;M2.[B9'+J&MS6@>&N)-*
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M^W6SGMU;8W[O7>/;["R(ST/!9?*KG,[<C/\ I0HSN-5;ICL05J'4@%* %=0
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MZUL.I^G)NH)+:]V.8/NXZ :W>#2<W$\"N&Z8NMAM9;NTW(&TL22XG27.J,F
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MSB]P>[^XW-[]S)V2G[TRV!RKDC';CV\RPA2)F3ERFG)+#S.2>2VD)^!;"B+
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M]A67=I'&5;B5%?*?0R<)Q#J5_NJZ=2"#H3T*4*R[IU8JC@O->J;62&T\UO\
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M^5[5[5C;.3L+>$N(QB<GNN6/P;![BAPF^C'Y".STIC/2'&6QU+.BG--2K3-
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M(2;S>,N+FXT6VL%H91Q(:/JT\+109DY<."M>Z<3D=E#8V6@]T9'RF\D.9-S
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M;_=+=W;UC(8AV3DL9F$0S%;GOY%?X#C5R&@CYJ2I+SCTN3';7\##23U.6ZB
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M6.E"PI+O6I(ZPH%)ZK6M>J[A]1IX4_L6-<:GF2.2GDZ:=N(.HD^W"E,JKH*
M^M*ESYKRY#L9LRGWWE!3DB6\5!M2U6U6X^J]K  #06K6.H!08-^@!<G+"W0V
MTMFAK7'2 . X_!48JS,DWOU!)!)XW6;7*O.Y/N%&U:RI^8J[<,##Y8_EM  ]
MF:OBYNXXR\G%QB<?\@]!BK*ID1EZ2Q+:6\&G<=+<"E0GG?5*7"FRE(0+'G6)
M+X7-F<3I;7(D5[",B,J+2W-G97CHS+J\YKR!0D8&E:\QAAVE7#;OS1C16,@Z
M7LLTZAMU-TK#2)*$J;*G1JI[I4H'ETVUO5D22"'5( '.\1[R<N[)3=M:)B8Q
M2W:P4[2*C#V46T&DI<<!/^S2"KR]%A'@.'4E(^NK < *<?UE:24%K.W]97@:
M67G7GCJ7%J5[KWT]U6(1JE<_ADKK@(XFLX *Y1$=3_4;6927>/\ $-$Z?Z5J
MHF=PXK$</#3F5<%+])AUS@>@I3X]3ETCWV)-8,C@ 259=XB!P5H;;)-_>?KX
MUCPYEZJX*Y1FO4?;;XA1 -OO\.55O<K$KJ,+N*]&15\U*C14ZA3R;CA\(L![
M@D59<<AP"B(".,O/)2EO!;JB/W0KH3K_  I^$?8*H!!DIP"H8W2T<UX,3=_+
MY*;>[6+@)BLZ I^:FJ*G+*_K(99UMR6*L3NU/H,@/I56XGR[**#Z\LA<?X6"
M@]A<3[EY<BY\)%^)N;>).OOK"D/%9FT1:GA';"+\]OF=-*"IK#X=X(5;X42)
MSK49'^L60[;WU99BX#D*KM^K)/P/1+( :/O+MH[V1-+C_KZ5T?5]>-(HB*(B
MB(HB*(BB(HB*(BB(J BV#VV_Y]?_ .C7_P#E$6KD>:M2_+[5O&KJQUPS^=3=
MW=?:FUI4S;&RWMX]L<;L[<.Z>Y$=79;8_=V Q&VJXQG6WI,7=/YJ_P O<Y#D
M.+ 7);C18&6+RV00ZVM*6UE4T#V_IV+IWME@L=!Q>8W7#=QDR;W1S;7<3+Y?
M&8MW#IS#N0VYM_ X"1,AN9K/-*G0-E;=Q<!;S3R6WQ#2X$)4I5RI6R:(BB+A
MP&M95;L%2OY^[6IJ%-0I ^/V_?[Z@A00GJ?(T3Z%*H4(J:TR1,'SM]/VU)((
M1,$^( ]QUTY<:@'%04PNWGJ=;_HJ:<\D4P;VMK?W6_73#FE%!Y]F,TM^2\S'
M8:2%.OONH89:3<#K<=<4EMM-SQ) UJQ<7=M90/N[R2.&T8*N?(YK&-%:5<]Q
M#6BI J2!4JY#!/<RB"V8^2=QH&L:7.)SP:T$DTX *M8WM8^X\1QOY@C6LFCB
M: 8JR2,SDM![N[R/R-SCMCVHA1=W]PW6/F,B\M\IVQLG&%PL+SFZ<DREY+$5
MMT%+3* M^4\/390M744?/>Z^L=QU;U/+Z>^C8BW'>;=Q;>[B?%8;>*Z7#S!5
ML\X-0&,U-#QI\1#M/MG3OI?:[7T^.O\ U/?+8=*DTM[<"EW?R4U".%CJ4!%"
M][B&L8=3RT%H=GVSM@Q-N._C>8R$C=V^9311DMWY5L(D6=^)Z#@('6]&VYA4
M'1##!+BT@%YQU?Q5ZSTSTC9].L-S+))>]02C[Z\FQED)STYB*.ORQLH *5+C
MBN#ZHZQN^H -OM(H]OZ8B=]S90_RV 8!TKJ!T\Q&+I'\:Z&L;@L_ZN O>^GA
M:_ZJZOL7'F@4M?'W_HM4J,$[^ OX\J)WIT2I6H<ZR(6YYZ!=+<YJ/D$7X%;J
M/3>*2-2/69)]IJXP\%UT#C<[-%(?FC+HSW U'P(7KAJUM_6'[:R&KE[UE"5\
M^_S1[=&'[C-9UIOIC;HPT*:M2$=*1D<43B9MU#1;CD815&^M=]TQ<:[1T!S8
M[#N.(^-5]*>DFX?U3HG\ \UFL+E\>>/ER_>L]@=Y@"UYL"62G(0U$=)N0F^A
M"P=.7&]=+-B 5D]0VI;(R4#$%8)N*$ZAV8P+A2%N!!U&J%=32@#X6%4ZA3O7
M<[%*U[(9CV5^@J\367LC@,5)<9D,N!ALA,AEQE3K#R 6GFPZE)<8<18I6/A4
M-1I:KMO)0YU7+W\4-OO-U#$6N:'UP-:'B/I5QVD"R\IA1LEU)3;AXD>9-7Y'
M57.[Q$'Q>8T8M*-TX=IQ3O6D%$AO@1<%1!0J_P#K 'RJT'FE%G]/7):&GZS'
M#W5JO'AG?F,.+](=:*TD) 2 H$I5H.!*@2?.K49H=/ +=]16XCOW/;4L?1WO
MQ64;:G+N[&6"0JZ2#SO<?:#5]V78N'WBT&$[<PL$W-CWXF2+K=QU]3"N(_FM
M*,F&YIQ)*"G_ %JLR.% [DO1ND[F.ZL7VDN+2-0[B-#Q[B#[%?<%D I01<^G
M);0XV>0*A?I\!9RX-9 -6U"X[>MM=#*YI'WD;B#[/VC%6S=N(,R#,;""5= D
MM6O<J;^.P\;@$>^J-6'<MOTO>MM[V*1Y^[<=#JY4=A\#0K!-L*5B\I$DIN$+
M6$.^ U 4?  WN*RFR^;'VT6?U-M^ILL%,6FH[OTP6:;UVTD]$F*@(1(M-A+2
M!9M]M25NM)\/3<^(#^J:LA_ K4=+[LX'RY35[/"X'BTX?$8=X6FMT8Y/]SRK
M382U*NV\A(N&9:/AD,'PLY<C^R1XUD6DU'&-V:[M\'F0O8#5\8U#M8<C[L^T
M'DO1BW0^RE U6VGI4F]^MO\ 6D5EO7*RV_E2ZOJDX=Z\&X.U^>WCMG=.<Q$6
M(Y#V'C4YW*R)DZ-#+D"6\8BH&/:?*592:ZD*<+#?QAMI1&M@89<"W>QQ)#WN
MHT $DT%2<,@,,3Q-%F;=U9LUAO$'3VY:B-P^[J!5L3_\,R'@'&K:\ ZIP7SU
M[F;%D9J1A<8IR2YM_(Y1MO-8\:'+0F8\GHQ9=Z%+C3B^H--N@C522JZ017IO
M3FZPZ72N#?Q36> _9<2/%3B.)'?3%<=U_L]_LS9/(U"$.J: &K.5:9MS!KB,
M\%Y-XX#\NG83%QN^T7+Y+?G<+<7X2]MSMIMV;*A;7VIF\4(T%A[=F-?0GUYG
MJP$*=A+:Z%K=4/C20L[NRO.H>HKC_ASRV06D.KS+A[1K<UU74C=RH<' X #(
MX+R22Q?9V\^[7,DIVM]6LB:^HD-*$N'U&@_:%:Y<UV=VCV_F=A[DW_NB1 VO
MLSNAM*>SNZ/VV:RC+.V7-B]Q=BM8G)-P(8<08.0@36''%H;:2\W(=3UA042>
M%ZAN[.7;HH77!_#3-,0NW,JX312ZF!^6MI!H 74(KI((5@-NMTN8+>RMYG[0
M_2]UL'&E1A5M0:5I@Z@KD<UB_8;:N$[V9/NYO_N7@H^W7,D(&*[4Y:6]&BB;
M(Q$J6WN5O;4QD1T(GLJ5'0@+47;I=""2E5MON^X3=-[?9V1G;/%0FX(:= U@
M:/,:2ZC78]F5<US^^P6]_O0CV2TN+6ZB.DL>YNL.;3Q-I0U'OXU6/;VQ>_MI
MQY\',93<6Y,"V^Q$Q[^9EMC)0'7%*1$@L2IBT#(I>O8)ZBX.1Y5RVX]']+]1
MW$.X;.Z*TW6M7>4XZ)6"FJH83I(X. IP(RIVW3/6>][*7Q;_ &K[G;F4)D#0
MV5F.9- '@\:G5Q!6J=E,Y6=E9TO(;?VYD)"&GVV]H[P8?1*S4:&W\R]*P[['
MI.B5&#1N4.!1L04*%=C-:?TFQCLH;BXC;A29E'M83@!('5J#7C3L<"LS==ZV
MKJVX_%V<+': 6Z2YT4KA2IT$9T QSXBA767;+O'W#V"VYNK;?;Z%@-@[C@/0
M),3!QQ(V[%E^H4.Y)IA@+7%G!UH"0E:0KX ;<:Y+>>GK_<+"7;G;FV??8W!\
M3WM#7@ ?(X T<TXZ7#$5XT7-!G1DMU!YUK=0P%Y#W'QMJ3\Q<.1P<*9+3'<C
M?\G,YO#IG3T8\Y'(Q\C,S>)7ZTW&Q$3&C\Q ++@+<E#9*D!)!Z@*Y/HW=>I]
MSW)VV[I:O=:VT;V2L+"ULSZ$ .U@#3V# UJ5ZS>].[%MNRRW^WNM8+A\/W4C
MR"UI-*.%:CW!9_L")V7Q?Y@=O[NSFY\MNS8\-[Y_'92?"E+R&'R;!2Y&D;D@
MIB]3Z"ZC_:(OT*4%%-@2.GMMVW"QZ=N=KM=KEVV=@-8Z-T/:ZM1"X.(K^[6M
M,CD%P'4'3>^]2[3 ^6]MKJYB#6@-<P%YYG3@>RM.T+9W?/O=M"?W2V#.[?.X
MY. Q.^,=N'<F>2W';EY)MF6S=IPV,AN!%8*UJ2H6</L%:[I+J"2]_$[7N<%U
M#,;8LB:]CPTX8G*FJM  <:9+$/H]?Q; ^\<^,[K75HJ#@,F@Y8XDGN6??FR_
M,7M#&XR=M[M)D,=D)FY6GY&1W3CI$5:F&9S?PPL>M"B\"M*CZC@%@#;SKF-B
MWF\W'J2TVJ[AN6[=&ZCR8Y USVUH'$@ -J <:5P&2V/17IHZVL[C>MVT-O0Q
MWE,):7-P^>E<3GISQQ6C.\^Z'(W8O\N^V?5]!U[!IW!D&E!*W0J7)<4E+*O]
MH+MKZM3J#77;=NUG+ZC;E:2O%!&QK14:7&H!P.%0"!3O5/2O2UXSIR_NH&!E
MZQS]+G A[-()PH"=65%=>]&S=J=C<;VD[U[4P/X])7$$S-X+*S)66CS9"V&!
M>"P\XM4!Q"EK<0ILI*%ZVM6GO.J+;:CN>V0_AK6\P,18QD9>:D /H!J&50<Q
M6A!Q6=TI87O6=G)M?4<UQ+ S#Q$DBM*$89BF!6%;R[H][/S=R]M[6D06]K[#
ME!IMB%BG5!#T-:@C^]R$VZE]!LH))UTZN5:G;.C8+J =0]77(F;02-@C-(S]
M:KSF:\@?:NK@BZ?Z BELMAB?_4W--99!5PPR;P%,\/>L-S>T,WL+NE+[.;)D
M820E]M36*Q^8QT?(2XT@QTWDXR6]9<62WTD@?$DFWP&L-TNQ=;W#&7MZ;.2"
M,MD9&-(?$UY+0T5T4#32M*C/%;F&=UOTV.HI+:2YE'BQ<0"3]HUQ;7A197W'
M_+]N7M;VPG;Y>R;R)V#QAS#34YHI9=R;LA"I#3ALEQQ;CBKZJNI1U-=!OV^[
M!TUM,L>RPPQ7+VMA:YM"[30AKC4XZ:DU*YSHKJ/=NINH?P]ZYQ@>2=   KRP
M%:-&2Q/&=A^XG?/;.'[F9/<&'D8MO# 8]G'A4*+A'&/]NS)3*D/'YXJ2%%:U
M%!'!-KUQVR[3T9M,$U]OT[IK^05UDZ0T/:'![-.)=CF<CA0+N=SZL?MMZ.G[
M6$L >"10N+Z\,!4]GQ6N-F;F1LWO*U+WSO3'[@7MC'Q<?A,GA_1_"(LB*"J/
MBO2CH5';6A]5WEHNCU"23IIYW;[^=E-XS8ZO9<!S?->*/<*^'"M *=Z[VXV2
MYWK9HV-C\ECSXHR,0TD5=CC4\!W*UN;D[@]R^[6<W^EO\>S;4M^.SDF\Q^&8
MG&Q8;2A#;>RS3+RF8J6D:*Z/CN;&N=:YWE.GE?B:$E_S$G' 9^P=RV[[7:-E
MVJ':((RR$-P8UNHDG,D$XD\57Q7=29@M]YN;W)SD3,Q9>+3A%Y3#-29T;'N/
M-*>5@\4M'KO++JU+"R"IQW]Y1UL+4<E&ODB:2Y^-'>$GA[,,L.2R)MGCN-OA
M;;-;!)&_5I=08?:=E_9D%@>]-H[ASV)W/OEG&G![3@H;R4&+/CO#(3,:)+3"
M)#G61\J'/5Z^FQ(2G4^'07/3][:;(S>+K2P2/#0P8D5%:D\!R&?-7K#>K5E[
M!M4+A+*\EI>#0:J$X#CE2ISX*MVS[R[([,MMY7+QCD\@ZSZD2%B8KV0D%TA7
MHAYQKHC10I8&KCJ2!6C:7AI+*:^%<O:KN^;(=T(A<\L874-: TXTK]-%IG%;
M9W'W9R6XLOLC+KPFY'9$O*L8=UI*T3W9TE_(3#ZY39,@NO$-H  "4@:\:NPL
M9*\-<0VII7E7,K+W?='[%;Q1R-,M@& $\M( ;ARH,2LFV[B.ZTK#=W=A=X-P
MY$P8/;YW+8UJ>I47$-9-+3<[$RU2$H1U/)D,!*$_%TJ.@O5ZYM197#H'T+FX
M5&(-<?">T?L6E%]#>?@MQVMC&L?<AK]( =0'2X'L%:]R,Q\GG>R6&QNR=AN9
MF-C=Q.0,K+CXR9BWYF<F8&:W$S,)MPL278&+])TK+K:?F'5(T"1<[FQB>VWC
M,TWEL>\&,:O"/%1VK[-<,1P!JM<;BUM.H9WOD?K,)J:UH YI([>'<%F?91Q>
MZ-C;\[<N*<VTN+AG%2!D7&&WYB,(495R*^ZW':$2.X_$2%'J4KHX*U-=?M=K
M:=-=602[I6Y@D<X>%M8Q(X%H.DEPE K4 X$T-#2BP][D\TP75I%K<)&^*IU:
M2:'33+ G'&E<%M_L=VL:W)NG';ED3).;4PVR6'9#\A^+"?(^'%8WUE. PH+B
MEE2P2EQ:1QL2?3MOWJZEVAT<]K%9QA]-#6-:YY&4LFD"CRV@I0:278#(3N;_
M ,,YX%*EI8W^$TK[Z"I[_9]>=HXZ)AH"9;Z4_*XI"0VA6B94]0NTW;^)*5GK
M5Y6%<]-(Z5Y)S/T+S7=3+,X6=O7SYC3#@WB?U+SR)?XA,2DN^JZMU;CO$DO.
MD$J/(@7L/"D0P+^>7<KUS +2%MHP4BC;[R5LS;T4@H<((;9 5:W,#3[[_56/
M(\$KF[T$,TCYG?I^GM6P,M),.''@WL\XI,R8!Q"UI B,'S:;/41_656&0)'!
MG//N'[2M+8PZY7W?^&VK&=I^L5>MML$->HY<J6>?LUXCDD_;54IQ[%@WKADW
M)9FZJS;;?#K_ )Z_'I%TLI]XNKWUKIAYLK8AEF>X?M/T+5Q#%SSPP'?Q5PQ3
M24NN22 "VD6/-3[@Z J_$E#8)\JING@4'Z8+%N#4Z!^@"R@R/1Q[KE[+DD1F
MAI<-ILIPC[!6L?(0TGC^M8!9YDP:<FXG]2A&4$M<K@$Z\.&E_?5<;M$>.94R
MMU.[%ZL0IUQ#SCK3S'KK2 AZ0U(Z@WQ<:+3+0:;*R4A)ZC\.IO5B60/=A3 ?
MIQ*U[FR-<=9!IE1>Z>[9++ .JKNKY<BE M_HW/OK!G/ *@8NJJ+-[&_#2VG'
MCJ/953/"T*78!7+'7!D2+Z(2$H.O[ZM-+^ O5!*Q)/$X,"\T914_+EDZ-)++
M1T/QN*Z!;S"0:QR<W<E=D'A;'Q<:^Q>*3(#*7%DV2VA2B2? 7]UJIC-&%QS5
MS1KD:QN9-%[L(TJ-MV.\X.E_,OO95^_4%>F_TIB(4#:Q3$;;\*Q0:MU<\?T]
MBP=S>)MT=&W^7 T1CO;\Q]KRXJQ95ZR%K)L$)4>-K>WQK'D-33FNHV. N<*#
M%9QV6QSB,5F\VZDC\7R26(Q/\<;'(6E:TWUZ3*?6GVHJ(Q4EW!9GJ;=,9<6.
MR,(K:VVIXY/F(-#VZ6M/]Y;HJZO+T41%$11$41%$11$41%042N#]=O?0TR1+
MJO\ NB_CRM]=!R"+8/;8G\>D C_[6/F_C_>(O*JXS4^Q6I?E]JWG5Y8Z^3G^
M8;F]IP=Z[9&[]M[ >3MKL]OK?NT9^].PFZ._@W_N_ YS#)@]H7,=@HLB+M;#
M9DK;=?78Y'(J=28JVD0I(>*MN2^IV!F2,C@\-D)D%&,ESL5CIDK&M2$RVL?(
MDPV7GX+<I#3"9*(CJRV' A 6$WZ1>U%0KK1$41<-UJUND412'"_*JA15 @*0
M5J->/CI^NHP4844@=-?;[J40CDG4*$Z(BB(H$3/'V:?54FG!0%SO^:7/C#=H
M,I"2]T/[DR>+P3:$\78ZGSD)Z2>(1\M!(/\ I6YU\F_G5ZF_H7H7<[:U^FYW
MB_MK0 ?6C#S<3 _NZ(-+N>JG%?0'Y9]C.[>JEO>.;6#;K6:X)Y/T^5&>_5)4
M=U5\\\CWO[NXSMYE-HX7>C<*$U D(@2\XH^GCVPT4MQ9690DY-C"MG5384KI
M3H!T_#7YG[?ZX^J4O2</IE=;WN/_  2^1K'QQ4-T8#1KK=D]//,%/\ 2-:X>
M"H8=*^ZH?2'TUN^LH^K;S:62[L7@N;'@'OK7S!#_ "C,3_B%E:^(^+%?1[\L
M^S=@;4[0[5F]O\RUO")O+&P]U9KN(6U"=W S4Y@)EY^4MP!YN(EU*V8<71J%
M&0EI T45?LWZ1=*]&=)>GVV[?T'%Y?3\MLR5KS&8Y9B]H)DF:X!S9#EH</ !
MI&6/YU^M?4O6/4GJ+N+.MHOP>Y6%P^V99-=6*QBC<=-O'0EIH"'22?-,\F1Q
MJ:#?G"WGS_97I7>O*!@I=6O"]N'*B8\$PJW'F2?8/JI54T*D3QU\+?IHI 1?
M^USJ4IV+6N_F0U+PF3"="9./>6.5PF3'!^IRU5-.*ZCI]WFVES:',:9!_P U
MW_17@BK^)"KZ>P\+?IK(%%J+Z.A-0N?/S4[>.4V)B\XVB[NW<VV'3P(@YEOY
M)PW\IZ(Q]EZZ3IVX\J]\LY2-^(Q^BJ]*]$=R_#=1W6T//AO+4EH_?@.O_=F1
M<2;8DB'DXY)LB0V&E'Q4-+GSL:[\G5'VA>V;W:"2-^&(-5<]S,I^;4ZD?[1(
M/E=(*3]@%6:FBKZ?=6#RS]4JU1-Y9+)8)G:67ERI+6V'I(PBE+9<<;Q\A!,>
M"\Y(9=?^5B>ITH#:T62$C7I%501L9(Y[  7TKW\QVGBJ^H.G(K?<(]^M: 7#
M*2#'/ZV6!).()!(->:HXZ:MI]MP"Q20?MU%_*LTXA<]=6@<PM.2SO+L&=CO7
M3<E(#B3_ &5"ROJ58U8K0K3;:?P]SY;L <%@F&2J-,EQC;TG^F0V#PLYHL#E
M\+B3?VU;<ZDG>O0-PC%[M,<P_F1U:?9E\*++\6EMF05@B_4+D'GQMSMH:NEU
M5P]Y$9(2PYKU[M@)D--/-BP?3TA?'H>;Z5LN>U*@/JJV?$""J^E[Q]G<T=FP
MY<VG!P]WTK"<6R 5) "%(67T(UZFPM93):'/^1*0H>PCQI#(:%AS"ZSJ6W:7
M,NF8L>T-)YD"K3_>81[BMAN1D2\<9"4A3T=-W$@:J;_B-O!-[^PU63CV+@+=
MQMKSR'?([+O6F\ACODYZVVQ9IX>M&Y"XU](:\4"Z?8$^-3$_0\M.17I4LO\
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M_A/;>G]MAW;>HY;F_E(!:U^-:Z1BZIU#(XKF&%G-Z9C-PL$G;N25B-FR "]
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M?F<CZ DN)+2>ALZ*7I:NAV>78F[9<OGLY;F^<6L:&DN# ZI+VTR<2 &EU3F
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MN3LF)E>U/=+*X2/ADWW'M>45AW&N==WYN.6'$H>AN(U'PW0=#6;%91R,K(\
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M-4UJ-)63LEY)$X,!^\B-1VMY>S(]BP?%378<ES&/?O,*4N*H7 <9N%*;3?\
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MZ>N0)'VY.#@'#O&!^%#[%[?Z,S?AH;_I>ZE8;DTNHHP02-(#)\JT\)C=0X^
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MX=;[6.>$DG</J-//.F5%CHE2\H^N5(+BRXLN?&HK4I1_C=61\2K>Y/ "KT<
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M(4!U)4DE*AJ"15<0T,U5JYV*SXY8+B,30D.C.7Z<%D>':#RU2GQU,QK+4/\
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M\"($)L+9@)/B.MS^T*P1)=7)I;QDMKF[PM_:[W + .WSW9K?.K'_ +-E=/\
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M8-\?#LA=]ZR> 23M8/E\I[',9([A5[684.-*'[WVC\^%\-NE?U%T]'+U"(_
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M.8^"M&8VNE:"HMLR&)'PI<^(QI/3J$N $+9?0#=)N'$<4DCC >>XK:[=O'B
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MBN''DK-FERGISL62P88QSBHJ(%PI,<H.JNL72[ZO[WJ"X6""#8BL-C#<FO\
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M13UJ43N:444"D#^VH*@IU"A/Z_KY^-$4@3X#3R&OUU(JI"EKX@</+[JE2IW
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M-'']G,K:^,QL?$I/R?2_.4GI=R)3_+8!XM0@KD!H5VN>58QC=,?%A'RXGO\
MV+DKJ:2[(-QX8!DSB>UW[%=&L6D-&=/<7'A!1*GE7,B6L:EF(V3=Q2KZK_=3
M>_E5,D@C&EM-0]P6'+='5^'MP'3D8#@WM<?U*WOS"[E,;E&H$)UG%J<$;#S6
M52H#[#R%LO"2P76DO27&7%6<424K(4-0*P3&^Z!;J(CKGS/[%9FL==K)$'N$
M[\2\8&HQ XT%1D.&'->]QU$N0I]/SJF EIJ"UD7O7E1H;2$^A$<<_B$:Y2#J
M5 7)-[F_'%Y48C:*'LR5BRA?:6OER:1*22[3D>T=^?[%E&*@E)3,D"YT5'9(
MXGDZH'2P.J0>)\AK=9#7 _+Q6/<W&K[MGM/ZOVK,FFT0F!D):+J43\I&7J77
M./JN"]_30=?,U$KP!H;A^F2U#WNE>8(3A]8\NP=JL#BG'G%OOJ*W'%%:E'F3
MR]@\*P6L,KJ]JS0 QH8T8 (;:2/YBB.=KCV??6<V.F 5I[Z"B]DF(U\F):W7
M(TA84F,II72LMCJNIT&P6UJ0 >-ZGR1([2?E;B?[>:ULCO/?Y( <./9W<O8O
M% ZE 3Y NF.?1@A?%UY(L'2+:H9'Q$\+VJ_)X&>7'R^']JORT8!;,/B.+NP<
MO;DHS):6&U/+5_6-S8E2N)/M-68[<Y?6.:N0LUN  P6O-O[AB1<Y+WGG6'D8
M6(AW"[8FK21'DY9YU4?)R8ZE@,N+92DQT76#_M>D&M)NUTQKA;L^49_J'ZUM
M]QL9KFW9LM@YIO'4DE;Q#  6-/$9ZS_=JMBOY:/-;]>/(0\EP%=P3U#JU/4@
M_$DZ\^=:34#EBM5:[7<6\HCG86GMR/<<C[%YML88[IW)'B.#JQF.*,EE#_"M
MIIQ/R\4G367(2$D?U$K-67&IIP79W5XWIO89-P&%_,#%!V.</$__ ,VTD_Q%
MJZ@ZE<0;'C\.GU6L *E>*\*<%8<IMG;F<_YZV_A<J4GJ0N?C(<EU)/$AYQI3
MJ2?)58MS965XW3=11RC]YK3](JMA9;KNFVNU;?<SP._<D<WX @+",GV2[5Y9
M*A*V;!9*M.O&3LSAG +<E8G)0P#KX:URFZ>G70N\L+-QVRV>". <P^]CFE=;
MMWJCZA;40ZRW6Y%.#]$H]TC'K5&Z?RC;"S#2U[:W3W!V/D/26AA_'[D>SN.2
MZ0?2<DXO<:9SLA#:^*&Y+!4G3J!UKQ/JG\HWI'U+JFM&[GMFX:3IDMKR8@'@
M2R5SP:<@6U'$9KT[I_\ ,UU]M4C6[S;;3N]G4:FSVS8GEO$-EM_+H2.+F/H<
M:')?+?O_ +4[G_EZW)CXG<MF-GMK9Z2N+M/N5BF)1PF4?!*CA\FU+4^]MS<B
M6!UF(ZXMM] *F'70E71\#>LWY9>J_3:Z%Y-<2[EL+R1%=$O=C]B0/<XQ2?NZ
MBUV;7'&GZ ^B_7W0?K)M4@Z4K8=2VS-5QMLCF^8UO^U@<T-%Q!7 R!K7,-!(
MQE03K!CO'D<=NW8,O8;DEW?)W?MV)M6+C$ER?D<M/RD6&UBF6$$*E,Y-#RF7
MFC\"V5J"_AO7 >CNQ]5[3ZA[7N/3OF,WF.]B\O16I)>&N8>;'M):]IP+20<%
MWW4/1FS/Z1WB+K3RV]+';K@W!DH&M8V-S@\$Y/8X-=&X>(/#2W&B_2&O11T
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M."4I  "0- +5F KQJ_M2'$XU/Z8KP;UV?CNX>WE8>:M,7(Q5F7A,L4=3N-R
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MO=7N:"?>LA;P> QS?]^S,1:D\6,/%=GJOK\)E/&'"2?,%8K%==5-& D^_P"
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ML\42L?"B*H#J#XWOS)MPX"E450$'S^L?;1%(*-A]/+]%****7A5*I3HB*(I
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M:CQY"&VR4K6H)=M;]^UY:\LS^5;ZXO;.VLW7=R=-NRFL!I<14@ M:T%Q!)Q
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MJRD+3_$A0"T\Q5YKP[O63Y?FBC@6RC,']*'L(J#S51G(.!02H7;-K<QQT(/
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MQX #$E9+V[BP\3@GLN^^T_O+<+4>5G4DI^8PL<APP,*ANZELPX() 6/AD/\
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M^(NVXNCCI_Y1WZV*3.)Q2&)H><R#SZTQU0)+4/TTQ7&W09#;\7\1]"2U)8)
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M+8F^(X<SFLS0(& R$Y9G$E9&EB!ATAUTMS)PMTJT7'86> :01_.<!_C(Z;\
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MQT5BP6U6.S:9077!J/"?O148<2NEDZ)2@!*4(0A"$@!"&VVTA#;;:4@)0VA
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M*O/4<#;QXW]U2 H2ZO(?52B)=1O?W>ZE B52B*(BB(HB5_?[**:()\+&YM1
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MXV1\E'T;DQI;3.C>6(QS4I4I3I]27(=?7QN\XI9'D 39(]E76MY*\T",!D#
MT=@I_P JM#DXWZ64^0.NHJ\& !5!E360U"@A+[Q"ED]/GI].-58!4.+6Y9J\
M1(KKI+<9A;[@ ZN@:)M_$MP]+:$@GBH@5;<]K15QH%CR$#Q/-!^F7-79.,8;
MUGRNM5P?E(1"C_HN2E!2!_J)7[:Q7W36X-&/Z</VT4 2/_E"@^T[_J_MIW*]
M0X<]Y"F\3"1 CD$.OI'2HIYE^6XKK4/(JMY5AR3O<:NS[<?ADK<GX6$ZKE^N
M3@#^IH5LF0\1$)^;DKS$@7)9:66X*%#6SCY 2NUM0A)]M&022&KJ@=N?L"N-
MN9Y/Y31&WF<2?9^T^Q6%S)/R#Z$9+<>,A5TML(]-H$:72G4K(_K+*CX5G,BC
MA97C\56(:NU2DE_Z?I@K?D\_AMNQOF\K,:9ZB VAQ1+C[JB AIEL7=?=</[J
M4@DG0"L6>Z8P&I "R+>QGNWZ86U %3R XDG(#M."RS%[*S^Y&T3=UN/[4VZ>
MEQ.#C/)1N'*,D!24Y&6SUIPD=P:^DV7):D\2T=:T-SN3B-,67-:&^ZCL[$F#
M: +B\R\TC[MA_<:<9"/M.HRO!RV(F1!Q4%C#X&%'Q&)BH4AF+$;2R@!7[QLD
ME74XK5:U*4XXJY4HFM.]Y<:G$]JY4,N;Z=UU=O=)<..+G&I/_)P&0R  6![C
MQ<3-LH2I1C38X68>0; +D8K_ 'VW$FPDPW2/YC2M#Q%E $8SVB08KL]A=/M\
MNN,:H74U,.3OV$<",NT8+$-LYV9E1-Q3Z/3R&(GHQ61R,CUD8N$^X0EI,[)%
ME;+ 6DI6V5D+<96DV)O6,V?2"U^#FFE3E[UZ#N6S;=M<<.[2/:RPN8S(R,$&
M5U,PR.H<[&H-/"' @D8+K+:VW(NW,<EEIQ,J9*"7I^0 %Y;A'PI:()Z8;0-F
MTWX?$=2:JJ<UXUOV]3;U=ZRTQVD=6QQ_9'$NYO=]8^P8!7?)XZ#E\=-Q64CH
MEX[(1G8DR,Y?I=9>3TJ ((4AQ/[R%BRD+ 4"" :I?&R9ABE&ICA0CFM1!-+;
M3-N('%LS' @C@1^F7%:ZV9GYN+S<[MGN:2N3FL1!3E=LYE_1S=NT/4]%N8L\
M%9G!.D1IR0;J(0[:R[UJK*Z?%>.V>\-;IC-<;C_BQ5I7^.,T:\=SLBN@W:PB
MN=O9U)MK0+*23RYHQ_@7%*Z?_)RBKXCP\3,P%M D6&FA\1<<#RK;T7-(NK30
M>SP^VIP1(&Z@+\1;4V%R?$D #SJ0TG 9U4$@"IR"^!'YF>^.(W+^87?&7V1M
MO,;=PN,Q,;:V=S.:3-P.4W/O#&?.X^=FX6VW(T'+8R.K$+9B)4^M#TYIH.N)
M:0H=?Y0_FBW7ISJ/U0;N_2@O+'J6S:(;B4!UO)*Z.K!(/EDC!8?++G"LC *
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M&K"X!&MZPL;Z7:_ZELX']<L"9X1]O2/O(3^[*RK2/M:>*VGI_N>V6^]_T;J
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M;EY"T!M)M8*4+V%23088K7WCO)B\QD3Y75 TMI6A-*XT%&UJ>P*JA<L)"[J
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M/*E_0IY\/Z!'^ -^?^&)_P#/4G_YFGE3?H5(G@XU]R/\ ;\U_OB=?_AW)_\
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M]:[>^S@W:W\V#$.H>,$M/Y5RUI:]T#O$&N&9#@WU3^Z^#<S*]K;0CO[VW.@
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M(<0:APS';R/:G<FBB@0I(4D]24J2I)2M*@%)6E0Z5)4DCI*5)-B.!%#0C')
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MX<(L!0KXWJYG3"8'99J2 SP8-ZX;@7/ \EYR#HP9Y2A_$*;=B/WQ3+S7AZS
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M? >X5SSZ:VX\#)?(03#0]MZC\3IL9M$ _+[1DW\!!N.U-=7WR!9?A*8;.J[
M;E--$B^'H(,;=7@%6_F0RQ$.X<9&J%2VBY($?@2#G'=*PK\WJPG?26 IE8/U
MJ1%^ND 9:R)S#B&3>C'WX M@"L@%Y 9)KLO/*+6F:Y_:@)"8KK5(T73YB%BK
MU L(932(U!W1X\*[*M'1) E9=<H_:955_-/T'T7B"*=[YOSRM=_S9Z1/VN45
MI0>:Y17)8-NBD\]O7W?ENVYIJ"JJ$\DD#!O [M5(\T/ZRS&E;N97C_D$-5&!
MW:&(3QHH)C 0" \8^2G!?'3\>D\]TE2'O": 6,)#B66*@'@A+05.R(+]\1Y<
MP:ON BQ3CZ3] HO]V9>"Q^6-A>LT\_L;<CKY2:"EBM:<TN8\T^&6)M!9(])K
M]NS>6VM.RH.Y5O0%8"=BTK8C(N+N"?OB*#216[KWU=-QY<^XOS8&JZ_%LMNT
MD88",ER#OXIB[;/[V&-LYH-C;>;7S-:)YM!QE]T]8OPMJ");$>Q^]!=_NH%#
MDR,LIZD!C72XNM2<5(@O)I[O9RV "&9KWYE7>Q9KZBDW!VN7P#E:..?8A(Q3
MXA!0'DLI&7R.J)89JNW#3#PGE=*JYYR.%P2P\=I#/:M2EY>.KB?UH21IJ5*#
M@]-[P&IV:^22X-):5UV1\:<N#Z+%;CC6:.7A[N \!E/*>0=WTW3/7J*TK"(*
M:Z(;@\5RY9<F-C7$<J3QB8D+-UR"W*B@<3[9YB&/EW%W:.S,F'W:8+CMJJ82
MXNKG.6]@7KYXNQ(WX+L&U/41CW=?N:5\[W32*];D2(76\NW\[.+:) 6L1KZ0
MN#4FYNW,+RHZ)(P7;,$]H,M?3A5DWJ%Y\6,F="H^-6]*%^SV-Y6[Q54"60IZ
M8O]AY:O3"<J)N=)PC:-< PNH7'8B1>D;3.O.7_S/]^,1LP>HK0M,VO6S7KU^
M_Q^2"P_*'^<O /=J\RH!8H014XM)RZ2\_0FXK/?,%2Y,.0 +UT',AQP:<3V0
MZ>3=51R&V'S^<AK-"6H(&_C8\!ONB.K._(!!U &#ZC7#:G>IHRE/!ZOX]ZC3
MW%J3+0XSU+KDB=Q_-07_S_(<G9HPLRQAZ:ZW&\J5AM3>/ZG(0JQY@$VZ&,OQ
M(+L'^ _FK58?(&%FG8D^K3!7PU+B(O>/\XITY3*YJ?%M9\^0U:W]\>Y%W["C
M,/OVDLYJKTS "*4?3$<P4YT$;N,R# (+R#C@'DJHWARG-Z$]S"_JM1EP:;4>
MF7_V^FP-F+USIWZS4NRNDIPHJ1*IB(E)C$$-A4('[PT&.\-BRPG[.4EFH<@X
MZ)O!A?*A+;&H#ZQ$6OI,7>>,#G_E8,>,W%B>JB/+;]=2IW6F3?JW<QP_IA_6
MTA??)(:I!?EEWOV\X&UQI""I15!6.WQP3W*?1Q <D\Y(/;"E\9.%Y7Y)',R5
M/&:#/;T-FR@3$)N86>D/@SF!P;#WM&V.-&AG+9Z-)!*-@\@KNLO)HN,25*F#
MPAGOCHJ86]_A%KU-*Q@SQ3?G&%+7F@E>7RQ:UID">^Z8=SA</W0M4:<YM'U+
MDCE+^IE2<.355(W>P+!E$!JZ.N<OOM#"-13HP+N9T&UYUE*WM2A9RAT).<Z9
M"EH2"61J\U*5%8SI##7%=VV5-_^;.,M\Z%]VX#^?+Y]"WTCI0Z.D;$%-5C&"
M&NU_X0=ML[/)\U]C)'Z0;>!39L%Q-E?$GI4FW5/'9_WT\>\DLK:7VN7UQ9S!
M7+>:^^.K/=\V'WMN=.[B8VR.Z3>QYG9RB4C.C,E$]&@749UBCTL&4:UD!"TY
MG1/8H\&(36=@O>;9U-?!*\.X5I.\S*':5:4/3*ONIHJOAO=U*J<)51!WI8<G
M511L'G<A^[E5!\J#JXBLC_:\BN^<"5-W!G4'(8U)V_,MF@-*-5UBM)?F%==.
M*E['/PZ5>4W;3ZP\!\BK8V9?S=7UTD6K@:7]'N6CU*> /#5^UX?M.4W'1V]2
M-2'MD%>'WR)29T5#ZM[EX2TZC5@,1Z=M;F]*)2=W#3-@O6;64 H"37]Z(CDP
M;CV@; D#YR9VA]UCV:#03Y41"_5I2F=>-_6I5V%CJ;Q^E5_SXWYMQK'M$GJ,
MW5T-68(<MJ?_34!O$PAOJI[>7.B_J4UM"VI6=RZCU^C)"?,3SZMO*^Z/G1LW
MR0@<K<:ZH*BG<1B9F6F^>87+.JCF<)Q LKLV4+SP_JL0TB R3/.T?G$[.=D#
MD(%=OW?ZUJ]]+DX9TJUU_?JZLE4"MP7VESYX74#S9SFRMB8F1,Y4:?UTR%_3
MQ/)2;5YE;2JV-,VW_L<*@D3[.')WMEW:,I\1/42Z^$Q!LHH[9IKW4,LQ)ZN1
M_P7@=%VRMB0"Q'2!>=EOT9FY:&B:-0[%)LT^A@:)V328 %?]^RKC!(LI^5:/
MP!RPF2PQ2%_#("T406/OTNAL)V=QYA9C>./_%=^[AA<N7K!RWQS8 7>XU^0_
M\Q<I3MF+RG:U7A_$Y(X9^66GSZ-MJ&;/+TX0>!R[9WY:)=#9[/?9C[S+=*Y\
MIX1?G$T#Q7MW'M-EUXT;>E<L<*; 3E>VJ-]X38$[0_95>\UCH+C28/8AVF7H
MXQ!!(7]84(^S5>W\77'+L/Z*'OOX#AQ=^WB%K/D2&P'+F<ZR2%1$!:C;I>Q<
MQ4=;G(_F[:";O@,W1F;^>FX;&*2]GAGJFU">4KBE.WCZJ+IM-YK2<G&M\390
M=H)7)E^!S.=)$%Q6NASLG[;3%T-H%I4CV=V>5_\C9;Q4LD:8I1?U=ADLJ$4;
M\_0,92GDG% E[\K54J)WV@H4F5+RA=N+>FR5Y-XS]S!<WNM':DSH_\\.L8:6
M+!XA<]KA/1C.]J<)F'9P>F^C&==*/(5@^G\IPLX+8$X=_M3I-V$VT/YLTN3N
M\97=]7;KKG&-S, AP*W=)<_<QM&O6MFF!K*(O=$A(!=H[42YAJ ZX]!A28*-
MV>,,.NV_)\^[[7(GSKM;Z6WD(3.@W]/\@.[&*:?U*G+]SKIK2,/@?_)V[2T5
M[R>/ B*LGZSY=&D T:ZT\C&@))#R!>!/Q%P&S"&,5;(YO3@_O;X#.;"F(1G.
M:651"ON 9$! ;*[U"OH\K/-IJ/-6E3K(HR)'5HOV&\&KP5+:_,A0_<HQC42S
MR'S-,A!M,0&JR9](W $%-@,#M=*VR->]JL7 8A!F1;F6S8Y,KP*9R=+U>0$1
ML"0)? J_MQD:+*?-&2YB[\G*\YH;#"4,15J/^#:KQN'!U_O6CS._7*97. O'
ML,65N$27M@R#ORMM05E_3>^L7);U.W F0\*(D!%W)K<)$_._P(* %._XP3HR
M'R5!-# \O"$'3P1IXV3O1JN\PNMB/J>"H"*9"?A?-MTR+G<2T?0"$%(8&D\Z
M/[VIGHEK-  F?Z]UB]T\$_K+QE&NA,26O,LR:+!;:JSDX(%YVV +!ZOF/B*<
MP.Q_OR4X&1 EJY3W3)#C*9*Y];3^<I,7$,1A.R1Q[YS0"-#,7ZZBXVR#"B@Z
M_J 2V'@\R,_I>=,G.B^VG#XDPIBRE$;[ E ENLZ\$U(@*-@ZP]WO5/A(@ZV0
MKQL[YO60:X69BGEFD"> ^_,VR_( 8UA>Z=LL3D2FCW94:>D%>VFSA"A)DIS\
M6Y0FS =REL4VX^(HV97.84JLJ'?T-<CNUAYBO_@0>M^NE[5O.9PUH>FGG5+!
MWM][MFIH2C*-UZG>8L=TV%N75TR)'8XQ CWS'&B$%M*/<7S?D- U[DM7?8&"
M9T?^&%6K0VD:'_)S->;L%B;$FSWH.&ZJ<R[C'#T[+\H$B!79D 9%L+[:9<I_
M^V$7I6 CE+Z,I@/QE6PB8Q:(TZB1RVFVK$T:=2'":4MI,[/S:1'Z^RK#)Z9B
M]5K*/G5(V1H)N_2^*M^]0 )>A&0B%3]I/25W>KS> :P6[)C;$Y\9^ >[!/]N
MT;?+3CQR00T"8F&[HTE<2"2)8(#=SO55U\AQ1Z#SQ>L^^9$A3;"EP\=R(46R
M>DP27OQY5C(EZ7JC0TGE;9;7,I:_RA5)%\*>S4KVNY_AS5B43>V/]#J  +PQ
MM NRQ:[SM9$O!6XA65L#^3+&AKNAQX%IRN)->7-&;8>%52K+D^+-DOT\Q$LC
M-VX9N;:DTS,WWH)MZCWS+36QX/ +T]4GZ'/OP(X7>>K643-7#>+.V[%E;(?G
M5O;CK@1?NWK::&OTR(=B#G;YG;F*1"AA4]DS^$JM6KS4@P^RY.+1FDY1_\-X
M> LM6&^]P.'O-E5W_ %IR/XDGXTUAXM$::?(G?/ES^*-58Y?]N_N!#1$OA)H
M'$=BP.F;F^B![^0*]=%7+;"622?%]Z[#6[V/$=<O )3._ *\HG'SG8:6_LIR
M7?]>/&8GECC0,_6D]WTTP</9LE3KPL%0<5<!(K?L4B5/QZ'-@+YJRN4M'Y=A
M?;!U'"FZ]T^FW9B_HCK;X>5/2($'>?JK[CD';NNA]X@=NKOYB?(P5?W&6WIR
M>KLAAI3COP1D/^T<Q5JI\>>=L!*&C*B)(!=G:><U K.OKW23WS8>%":R^<\;
M"7R=%Z-K<R^^G;-I651S/#;_&S-F%^K==&^X.DDB-/VP_"0PVQ[P3X0>82+#
MQ8.--#6D4)O>O[,SBTJ;)J-.@=PMS%Q@G^[Z#YLNQ^5V2P]1M.?FYH7"]_-'
M*Y5IJ?=]@I<-[,I:)(9 _0,-2UEZ@;E3M1V4"PQ3TV;>J3QU#C(G'W.ZS=K6
M%*BY&TJ, P,X-E4HMB9^[^WTS X^EE[E$>Y?B4)P& +,649!A'+L^)HJ!A)3
M/-T"0.'8,)=T3[%*<!X,OO_&)HEV#VY@BAGZZN)#+J[-J_=&W(Z*B2(A<E\Y
M^O.0!1V':&K*P["!TY#W(IP/56??_RHF]="4'Q8P.-9L^'M_V[3 ;BNAN-KF
M[]O=I+A&SBA[SA-(S"#VC%/"Y+%G0[WN*BOYB)FSFQHREN&4QBKFX[%7TM=C
MRO$;-H_K<XOXK7<1JR6TIJ$85)&(I7W\4Q\T]P$I[:U)0R4*_EI_'!S0;2O<
MJZ1OIJNEZ\ @_V;(B;&,GB-PU6!D,_1N5U?:2*UZ 0?K!GUZO HJIK;/WE[%
MKE=BD%[.B[+L5YD^'K%U%P.(QY]X$. Z,U$,I!:K&/T"J39O][DQB3Y^B%WE
M=3!+_"YK.M84E]H,RDFC2(5^#G?U027L9X-?;D&*2U:;#H]-_E"5X%_N]KK
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M.EZ\Y;U5-6T?O#X9_?SAH!Y*2I'V>I_>/:3O9&0F>3)_A.:"+V)(G/#E].F
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MMY /CPC>4",DJQ"<T&!"8^SV,7DR3&?-]8E*B.-YD@$\=BQG>'HYWNT1.M_
M8BW8K3B.9KNO@U&;-R=GF-$3:6$M'[INN(APC_=$S[?JN*0SE(CXBV;9:6T=
M56\>)8<DLRDVXMI:!IU&?*AOI.9<BHJ;&%QJ&\H93 Z$-@GNB66P#O\P(7UT
M3?LQ;&U1)TESCV7"DV89=*A01J"!*QU2O!B6@=/452$@T3R2@1M&!"/B[/QF
M@ID/<HM*2]R%!44B2SO3*-J"VE3G2SSG'SCF#EM;&A=!91@3==I44:;:2$GO
M\+(\_Y^Q>F$LVEG+$!UQ#1+ZMK*OQ\;[>!(GMQERYWZ5QUCQ ,$L+M"#%\SA
MNT[E!A3QG\:!^UDBR]0>TO]%K"3/]0&7QC>;=N7;-KY8Y*P4KI6>24O[T[AX
M^VC)"]F4<NR!2;&3\P?2/]UZ4/ZFYKR%PX. -XG?O@VG_Y =EJP]X0/(6\T]
MK7N[,'O3<K''>M4J[ 2H[%<M<^IOX*'4+O!]BO:S!RL5X)^(FZ&.QX[=3CGP
MHA/U$*,-CTRX)JJL>N981,_^1P([R=$AVWL*5Q<G/ :^:2Q%VN^SLS%AX;"9
M8#D#MBL3BM**.$8,F9,:^[#*&27S7?PI!XX?"XGT#J< SR -9C0].,KLF0X?
MXYP5#?. J)@W@IKT'],%F=P?MOLHY[X<G6$YLN0HN)^Z?DL<1*(6 $>! 4N5
M1 H@THPW 5V)&2#"00 11L9-\W79T14WV@FT/U[^*BFLAV(YB6>"]#L[Q^]D
MZ3#KC$F6?^&.-D-5DQJ W;TF!D6V7);P*)X>E;TW94&.=;(92%><8?X%P>1!
M4&@8#=+9N"S_^39'O#:6M8+;/UB_L-D?*$S/3YO5:CBK&B5X%B%*8/"'"4&2
M?FT85<%8R3J_-<:*LH!6R=WR\I\#D'\6V&W]J4@@,4J%KQ\M?N7J,?^MK_%G
M8;Y<)D&'@::A^0KCB&AD=_T KD'RY:R"<W0UR\,:,A(C>&A*;F'/E@!U<?<P
M$:I=9Z@1XKNT40LY<#U=#NP;=KC/FP??(Q)3*N,K;>S,938=2Z7^FI&:YX&P
MOC_350!"\F%3HHL_SGXH(BS;U$;KSYD(U.)&M3N&:";<H";*C)TFH"_7&7?S
M1.%!OW) BF%L.NAR1JH8 ,>754]YYPP2'/6!F2GSR)FU6A9Y9NCY2WUQ!7H7
M#F 9FZP)HC H,UV9:['H.7,*]^3[7^FSYIT\U]11,NR8Z XJ3GIIL]#HHRJN
MTL# <T//5=7D)#8*DZ8H&I:1 -1'P7TYLVO<HK?IW2^E=\5H+CIE_DY2FF4V
M@Q=X(:[_,C,$& %#)#]P6_I_0OJ:\VB(E/; 7 V;+X!N2E6&-J]WN;1D;O)5
MZDV76TNST]?%#_<\OC7Z)7,5/1VV^<&ZZ2"OMS-?=^"AT^C;I=?>*I[OTDZK
M)H;K]-TO>]^8IJFH,P-"-%[,G!@O_7=;[(I2O"#ER^-JHYZVC*+TGZS^3?G;
M&U 0/,^PGPO'L :_Y6KFLSL,UN./UD$Z;$6#^OGW)3Y!=T=D_;E64WK(%&%9
M85RTJ&PNJ$?#\ZV?"TE YPP.?W$Z71")]Q_2)-@4:80'BF+Q)5/$AE*]-6Y4
M 9P_PXS97(".Q.].D..:4J-VM!)9[W(US5CN 43^HX@6&;B?;>.:BI<>#9C=
M.$LSG6S=S@ZF1Q.)YX296%^$_?A[\;(>'T8=FMETT29F5WVV@AX-+=03%/DV
MK*"-2MES@/J(,^$_.>R>30-[!Q;F#N-CI6K9MD6Q+$%1H=??C%XC\4.Z&_R(
M"X:@E#+%QP>Q1&6+8 Y<E8]9UK(2F!*4T<M1 [4-+=0A%YTPMB<:MC2RYKFF
MBM)B:=!**V>&&^F0?,29M+9.;;3J'R27'SC_+?X*04I.S\TPD--:+U3>\8>)
MCWTP.T)74T5B^CBVE$0%>:UB@;@HH>PN-%2G^Z7^-Q_>YC,W]+.V6]2QQ._$
M2SZ$#*<Z;P60'40N*NUQ=GY.4F3#V0,Y_MV+X39'"8]!_E99&1UY#UTA,L^.
MFW]?"@*Z>RC:C:FV,0I_$W6?[2_5N?K P9EM?ZX6P@K'.-D'<:XT23RA-64G
MY=:/8T/@B4?)D@VV'=D="Q_@5 /O>ON'.M=I,-+F9WD>0TP8_F16+H!E^M,/
MZ? ;;E$DG&"PR4K@F(L&&A@@_.L@Z AV]D[#9^N_=T8+V/:&A7M3B"9Q^VW0
ML/\NW!&A2$#F'@J%@X+.=4Y);URG; F<:=ZN?_/W@VT[5ONO'?]/L=QZ(9H=
M<=I /&VJ4.K*OC1K5I^$VI<)>3N6!1415U,Z2\UCXLP0[N0K\=,WM806_$>L
MYU# SB /GJJU*P"H1GK:*ABZAT DIZUE-W3;33%D2+09DR'D$,)">43MA[/N
MCKW=*/5U*):#FEAN'O59 J!VH"Y /K2$%]PE:#F)(8.1!,NE%=]95B36C$ED
M05C0R]OWAD)8EB],+.+P )>HC><YT07/N?4!RSF']#,U0D!1Q_^@<$?6#7EA
M/=34M\P]S*?^./GZ94X$D"]L4&VK;H]/K3-+VY4[^)DR&K?2O\SS9:TE(6!I
M$5+#N7*A.FVP=,1/SS#SQC[O0B[.PCE[<ME_NVL85#A/W::Y'!1M68?)-?OG
MH>9#W_J,A.?FBT0]CGJ?D4$#2D;<7=*?.\QTQ#[I?A^BZA@"47X_>UJNIE;[
MD"03.6Y/1>#X]R]!6K#=5F#@D4&DM8/#:EC//7R%G@==3(Z9Z'(]<Z&FNL*O
MIO1KSHT,17=U[^G2^*-G3"CY\,/W\S>-3I7:6$X3@+?+*9,TCV\4TSD>J4M@
MD$!.X#A8<45MW"*:;?VTC&Z-#"^U_<QLGF6#%X-79!Z>Q))O@9A6II^>*M#W
M D,^5)7)L2^_W6(@YEV+?BQ_'9A]4*8-R]U<@'+VL:*XM]CA 6L/P*H@9E?X
MZUZTF'":W<'@WA_#@W=P9CO:^CQXU5Y!_:G+L-O=L=U<>2D./C;'\^/F&C#<
M  ZG_U["QU+^:W<4E!F,6FVVK:OYI$N-WJ/!:U79C$G9$D!$7Y!B?UHZYL#>
M+BHXCOBFYO<?2UV]ZTU_5>)!)S[R;OI!?]5E*I=$E![[J88RQ= %13BPY)O>
MQ9C'[/@I>@05$7%W[#VIVLN Y?M7;I/@<9$1XKZ3K2@@Y=U[[#Q 0=#,7,@A
MJ<7TO:02_-$GJG2'#8- 5@8SS/!CCI*LGT$P\2K"WJV_0$",;0K(L+A!3$!0
MF*H2XF/ ,J4^G"?N,-AD?R=&H?,ZH]*I8N]_%Z# 4! DI65R0PL+1);+&]^.
MJ$$GC"!2691UEGF#3=!S9YE'^&C-L4((,W_@:\7,2Y;OT!/FW7!9OU/:$*J*
M=9(> W8C+5%S88Z)#/:K0:N0P@ZJ+<YW7PS"09&_!<;60H/\J:HX,#:.#$N[
M_^Q/TQ0#8&X3# CRK9SE8(LSF\(7ZO(B+SI&MP3L>I'X"E[TBA\$Z?QAACU)
M/:(QB(_CP! LN/EWXC_98?_I(L)_,Y):&A@8Q,9V.PN2V.T$)"INCA<$ '"E
M$*"ROYNMKN!YM$50L?-82F=\J7P8$6IF#OGS;LQ9/6S*!B4A0WO7(^FINTI:
M).K2[\1WD8RR+QZWUE'MO2B:^#K^+&M9E14F;U#[\:%9!*5)0=V8RNFP(&2(
M2P2+A?7LBQV*\_#<(>]<PEEFX%X5Z9*<K0 .+'1//H^KYDDJ%:8>TWG H:I[
M>ANWO^/DPQ]D&F8X+.' Q67+Y?*GYV>IRH,M:9V?8Q.@\$1Z]/\,!Q'E&LO0
M@I/I@O#_K)WD_H>)Z@6%W_E_;4OO_]C6?53$U_7@U;E"8>VC=!.CJ^#%\WP6
METI,-AD2%SB;I8U!B^DB4K?[G\RMP<E4+]&2S@GC=D(=U,9S+8#NEP#OM@G[
MX?XB)P&4\U-G9AB@B'".6+;O$;D[-<>$B!#J $P.\:T/JWR1 LS*;0G0_[ P
MZ%$#HHUW<30A2@4ES(^<>FZ+6=*LWN0\9A<ZM<&,<?6?-H&YD,BE$(-U=P"J
M6#"^ 0&24,?=0U*!&5MGF8)$EP*^&-;-MYR7TEOIKX^)-W?#.?H0*\1V;NY:
M(!Z@X,\NL\&#30ZS/ 88'9OYA[>ZQC6#%2!QD")+ 5E?3B9I-!>2C'F&J5YQ
M^,-$&7<OE%;_CFN7Y+$@JH[VN00D%ZP'@\<]\-](K8,4^X<XNOF9#WR,I8>+
M[<H^BI/P"O)9VQ*XAD&C=H:_CH<H#E".FZ0OA_4'XN])>G=]^8$>BLT7SORO
MTT<ND8QZ8+?E;R3*/ 1@6P+>\?!44Y4FKC$U71E,UU\K7.J4!V&URO=.-'%?
MCEFW&U%)Y2/3(X4K_-#1S"ND'1>.#UV8K4W+%WZPLG'K*TU"M-)Q=68SXY[I
MZ1D:6/K4,+U'QV-(<#Q*>7F>%]0.GM9"^JZQ<,82P:2PC_?,%_I$25D %N=E
M$# <?A(%'_S"78/'D8RRB @P"OX_8$B$DZ/__<-IP]ASDP7K(>4:KQ.:9;+7
M$U6<-ZO^:T)B6P(]59BRO8[_&5[MI8TNZO1%/4J$-&SYI\;2?'Z0("C';K_@
MPLZFF$Y[^C$0CBC4=&9PF@ZU,6QN-[O28_Z*)BG5C3= N.*(EA5K7/U7J$-%
MC^<'>>XY %2SL+HXO-TLAPD@<%B:A5C8+>HYLF7GDSFH0S!43(X"9 ;%!VQ0
M\W[ER+FS!MXG?=Q4X;)<62W53)+&YUPP2J2O'8K<+'Y5M(\H)(A01/RC/+!Q
MF[5:6)KOL/?U++U@#J/!0N'U^#+ "@$B>;[+P4 TMMG0G?;7&IY^AVP'Q<*_
M.3K.[.'-Z74I@;K.'6VP*G8 >\N0_5"*IH,X<BJ?!T8?(@6,+&C;W3ELZ_T=
MB?I;G=1_9P))W'G_F6&$ V'4AA'7-R_%SBY_1X/$I!DK]&+CQH<7<69:FQFP
M='9,YW<LLT[OWC]-84C5\>R+8$#(2L"@*6U7N"22(#VJ-CA)5?;T1A:)S"Z3
MU)#FG=\)B;LQT6!K#HPUC<3G2C+_GU@&0>[UKS'WN^LD7/M,$)WJ\1X'+F)[
M@@UUYFK+9SJG&#R<FE&K&L^5?";K;MI!S\;H_17SO,U>G&2Y/FG E7IOI^XX
M_= R@(,$D=3P-.G-K  J;#25K[#^<XW]# 82 ,;JP#@^9$-H_"_U8.:X+S^0
M.*6LPTYF0TV-FQ_Y]I)SNF^N1&'>X.G*ED!CKD,O[:K]/WN37EL"J?I; N[C
M]O\7U.P/-0>,/S*^/_8#LT P*:.IV'H;'P7VYYZSE7VZF2!?AX7GC* .A5W?
MY%($]78&P6T_]^VI'5! W*8R'MBOKY ,.7"6F[<QR6(2ZS&)+_U(RN P\ R
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M \MO"01BA,FP0!V"H#!#* -&!Q'!>#'A[?J'Y/]NCE%AZXQ8ZN$FV_!H,'K
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M*TT9\0);F>NQ%<,+\CW\R,RMFD4VR3MMRO-\4+";MI;EB?>C%G<=PQ%W;PE
M-_JT2DWK*U''ZZQE$T[75H>Z,A%F>:$ (M(\HV2$KE 0;7O+E152RN; 58D*
M9@S1C1)$LB3U7AV#N#-??.^#!_81\P0,FFJAM&%(.=^DO.?NSC#0Y7.S<S(=
M%!S.^B0>5,NFV[ZAH,"8+0%/,QA9LG)P89;FF@IBG.;(5 @#+OJ<8K0JAPR'
M*NLAVI$H,]6] _5-DTR HC_'!)@X"]L!P@)SZ3DZE6%SI*DEG:$H)Q$*Q12L
M/ AR%Z_MLOA%0\+]*T_79FGC0$?)#-%5L*<VCQ\:\3[XS*:]Y(RU)#V[#!@+
M"5 I7^*&W\I#4$HIG\:G1CWI9;'T+]F[)OF$V$!G,[L;29#O=9OD<2%'C@DE
MQI_5QGH0$=$BOMOPM>YZ5UO1G>+D-A#]I2P5ZX,9WSTQ-63^^C,+8.Z5O_&#
MWAF-5GP:8EZ52D#30SAP"^?L[CM9(T>>2>9@,Q%!U#W/L]GQ1">T)%49W05&
MMX/Q<9)+JSW/2U3_&J+\[<77[B;:$#A&V*B7%&Z*UQU-OYZ@N-$ET-9N#A%_
MU;/AR**B0H!4_R6?\M_,G_0H;>/;%$3Z;H]ZC((M"67N3J;7_Z 1\#Y8RN>2
MMR[[*U2** ?HWA!Q>J;^*R070HVE-'76-WU'XE0N"GUG+A%-_)O!_H-#@0K$
M:BX< G=<&2>9K 6P&'$#^4/+,Z,(50"]_'5)[NT&40O9>/_M;]+21JG0$Y1^
M[YFF/PRZ!&UW5ZT.0R4Y'BK2OM] =ZV"PP11@ +49G$5#?X\3$\LM):'(Z)D
M**IK82TAJ^-(--,@P>(Q1<:A%5'J[AEV>\0C9*4K.IFU5U9!H]RV+/;!CI"9
MFHVQ!6 #GC[F<=ZG%*1B2E8AP@S$%\BIQ*J(MHM(?R-I=CP.@]!QR2 .+OIM
MDJ^FRT%Q;W'XS)5$62>:6;HS95L0!\-8(HI[SV]4KW)VYC =,]USD3G-%K*)
MM;GX3#.[J-N#(X1WY#WNC',9LX/3:PS=KG.^@W6VE'.,9J)-I9A\H"71!\.;
MZ6S,-0O DF&/<.P!O @K:B?#V)O+Z@*9D7/0 418KB2[<_PCWY#UQ%^C*9 =
M!\VSN]9<4T6B CHS*^:I6%4R!?U(CVA*=$00N)UF83T@B)*2:(4OK$L)@3)D
ML8CTZ-HT(VT4E)ACX3M8G-B)SLX5J4,O@C(H6LD[Y+5U%%P85[.RC+@45;"G
M*/BXY^<^SZE!)/'._:AE(^=7-$A%.WB*3]3A<7T=9+BDY0@6 #?P"05DFW)K
M\)',!O&B%*R_,JN T;;S8US-%S*2UP:E;E<2303_6>XB%EEDVIC=*V6G)?YF
ML%305#ZI0L3)SC%8J873@V/U/T8(]V] ;#]D&?VI>O(K[KR8\\7UFD6=K)FX
M&9Y"M_NYRE]/<@;LR6V,)25=;))]M.Z0Y)!;+ @>]"O1.W&\X_D;;57G)!F%
M(OI]D GHM$$XE>P*J:O@(T=\:.UV79989BOD3F&XO.-&*C5:@JVA4$9'*P$V
M%A!D-1?W#QCS0X6S>/XS=WC<W6&@LIJB]2O3 1OEV4C7UF4L>HP04%HX)A'N
M'-OY@X BZC"ZT-MKF<I $LX)3J9#[%\$K1 IR?F4H((/>TGEI6#KQ.*F)1\:
M3GJ0)#*RG=^,,#NB1@HBHD&%EPAK7XVI6P)N+.(A4P.C+YU\XA=WBH5U@1<
M+,*>/D2N&=GM0BW]FZVZUN%D1)J,@[-DF!:$]1"HJF4]@Q#ZZ5BF-:!Z(!]>
M0"34QW-_ E#-GY@L*5X0X5BJ6!?N\ !MA51J24@OAF[KJ".Z(3?-*1"H79_G
MNP(Q5JXF/D\5=^X_E"A]>*&[Y2,9E%DY,S9,,M@H160P.W=;$TTM,+^<^B%\
MNCT^YF>R'-2UIW3R#-EE++:\%Z-SE8GI/\(;>,<J/I:J*BK 8%6<('"5[!=A
ML4ES7VD2VWOPAYM,KQ1G@H':^\U&+0?=<9J,C<?EW8VY?%2G2?)(!NY@@55Q
M$@1G03(@+?[3U(Y_0W&189=";!AD4SU12WDIH86@KO,^1,"'8+/P2^U=+AY@
M;9,O"37W_Y5J<>#"17E>QB 255J#P@DMDF(NAG)S=DQCTZH&;$'7(A ^5!T%
M[PJ"9D_ZX>B2[L8!*S?"$V;S25MGL2M<E@T893<[C(?G*>E*A@3[4IE[!MH_
M]6:V@J5?=-;7QR26I0)9KKL=3*>[/_GF%J',;JO$SAH$\3U]@:X,DI*+7YAA
M-H##-;RJ0W7]:&!$ZO]9F=CE3=<K0_D*HW!=8=H0O@(AHH^L&_50=.!9CC$(
MBC%::PV>3ALV<:=!H8VQ5)N*+J5.;44[I6+>1K\V!N%:ZFEOUXXDX@.D5>>Z
M_U!50S:Y,+OE76_]:Z-H$(8(DEOLI^(_U6FKH8<SLQ\?1OYDS2FM&^WL'F,.
MXKYE?D>\6^="CSSC$W(8"[)$S0@@%B_Z#)Y)1I0LPQ[IM9N" D'11\<]C0K=
M(0F+2K/EX^4_\%!SY7,% !&P%(JO"&'G,PW)O@3^K,BU0^J@EWE!81G'VPK<
MNMY;XP#-[<2-[56SS-J[:6)&W&@H48B"8*AV663^%M6G$(5K+'08Q4J;+(KN
M*&M7N (]VA1+6.-"5$'1A_00*:RH(^$F3*08[*M\N+-,*G%G;<R2&S#$U,;O
M6=3&@P+_R2V "N>)FH*2)6NK/-#*NO\L?FL-Q I\<W:NC65%.\=$L).HL.7!
M^L:XJ"OH_]\B]S]OZ#R9J[&\<!0"!Q7.!/.9H]RZ>1<1T1XN*@I_7J,LZ2'S
MB*GUD[(XLN0PU4$&MWSN<5@8+_QG%N7KO,O^NW7A&LNR0 *7:!#4?L^F"28-
MZ&"=UM8BF#P8GZ2FLHSNH1F,)544\0P19+1Y)^SY.1810 _<WAP9MB8(%K"B
M20H8"$K34\<A<V7 /N-2+B"E]\!YBM& CCOR,S*\O)[+Y(]T%3S%X&,^IF W
M-52M/GH\XXC(D3[OEHD17S,^K3]5^74L:9"&SR&SRO^_ #8'R?CV<+\:E4IT
MR4*:; @F_EX54<1@BJU0BDGC]E5\%!4ZA4)U"D9J8/U<Z!5E320;Z6X56,50
M<%(<?JTJ5 Y<%6\/IRJA$^-$3XZW%%&2D%6X_HJ*4R4$54@;_;<>VKC:D*#A
MFI:5*8)W%%((3HI112BB(]E%"J#2J<>"I*=5#)0G4HBI!4*0JI5#)2T\:A5*
M:=1X525%*E3M4*0*(HB=5#FB*E$5*)CV7J$4TG4?05!"@#%5* A2BI1%2B*(
MF+>%ZA0F.8HAYJ5_9]=4JE,6/$V'C:^OA3%$#CXT15 J^B=#[>'/PYT13UUO
M[OI:B)T1%K44(HI1;RJ0.:A%33@B*I4HHB*(BB(HB*(E1$Z(D>% @S4.H\+_
M '551543!)YU!4$*50H2(O[:D&BD&BIGB=-=+?T<ZJ^A0<TC>^O&I4*JD6'(
M505*13[?V5(*IQ"@1;SJ<TS2)YFI4HHBD$WJ"5%4RFPN*@%3BH54B5031$53
M6J(J%**(D3YT2BB3I[;5(4A1J54BHQHB7Z?#V5%,,4148*44K[T42!QMP^_V
M>)J@FI1%_(\+\/L]M$6K:MK(13L12!\M.%JD?%%*_"WGI?POQJ:(I$BU_JXU
M2,42N2?"X\2?>/"JLD4ZI1%5A%('4:7/ 7\>5"/<BJ!)4K4A)&G/S\*BH"BJ
MJ!%A8FY\=?UU"BM%/E14IU(S13"M>0]QL/U7H0,D4DDD'ER^P>?"A13Y^'Z*
MD*"I V\+&^OC:IS4'XJ=4J$Z*0>"DDVO]OVU4VJ@Z<BJ@/.J^"MY%54JY<OI
MI]54D*Y@<1DJE]?95.6*(HH11$P;:_0U-?>H(JF3?]6NO]%*DA **H. ]E5C
M)4'-.]%(*8HI!JG12BBE,?74*$PK7@/I]]$HI CA>_UU4J2I"B@%2N*G#VJJ
MH1>JN]*\E))M^D^X\JI(2JDG7Q\M=>)O;ARH<%(4^ UY:GW#C5/<B 0;CCQY
M5(J,44P>(OH>9'OX"E:HE52(J44^0/3PYD_HJ,,D4NI)-SH?>3]U*< BB%:D
M^VQOR\+<J!%5^_PJ41]/I]=$3J%"5%* :C X)13!/ARTI@J31.H4)\O*YM]E
M$4@H\./F==--/91%,*T' GGRMX^VB*1^NB)T1%55HH3O4*JJB>(\3]UC]=J<
M%':E?RM<<?*BG!'+Q^R_V\310@VTOYVX^&MJBJ(O?EH>!\2.5N/*B(\^5N/$
M_7SHBCU _P 5K7TL=?;1$B;>1O<C4WX&_@*FJ) DW\>9ORIC[$JEIH="?9X<
M-3QI534HOH/*H4*:2!XC34W/'GH/&B)$\Q8CGX7\QSHBCYDV\^)HB5$4@NPM
MQ]]2:(B_]G3F!Y\+D4')0D5$BWV\ZD]B*)%_ISJ%(P3&G#2I%#GFBD#YVMRU
M!(O4E0GU7&IMKYG3S\:I(HI25QX6L!]5S;ZZA%"]R;#]%O=4T4T1K[??P^RH
M48(HB+\^5$IP42;V^ZJ@JA@H_;12@T->")53WHBH)'L1%0*UP4H]MA[ZDYTH
MH4;W&FNMCR]]4E2EIXGC;B>-1BBU=5M9"*(I)\[6]U_UTQX9HD>5KWUO5P=J
M@UX*JCA]WT]M4'-2@6U]I_1>WE0H@]6MO*W#WT%.**52*HI)OU"W&^E3P4')
M>I73IU>'GQY\*I5)IP2%_P"+Q%N'CY>=$4A;6U2,D-4ZA0BJ\>"*2>(OPOI[
M>5ZI[\T586U_1X^=!5$QSO[JK[E3C7L50<!;A5*I11$]*A58*JC@/ISJY]56
MQ35BJJ;7U]WLJ#DJ_I_4JM4J$&]_KO13A1%!3BH11%(7Y>_A[N-2*\%!IQ51
M-^?T^JJQ7BJ32N&2/"]2H*8HI%>"E5(KQ52*E2BB)^%N.M1WY*._) MSO[K5
M*8\%4%K:5*H/;FI"]5#)2*^Q2-#7@JDO9Y?7K3OS5.'!33>P_P#<>'"_Q5!0
M9*J>!OPJD*M1TN+>'_N/]-2H4JC#VHG5:(J43^G+]'.B)4133:RO&Q^JHQKV
M(CXK#CRZ>'@?T4PKAFBJU*(HB*A$];#A]GZ:*.*.>OOH,DX8*=4JE,<[>_[*
M(F+:W\#;V\J(I)ORO;RMQ]].Y%4\/IRY^5$2TOSO?] ^RU2/@BE4(CZ>_6I-
M443;G3N4CL0;\O ^''E:H48)*_=/C9-_K_71%#6YOQMK?A]FMK?;1$STVYW^
MG'E4]]*IWH^&WG;7ZO/E0?!$OBZO[7N\/JX5"*)XF_&^M$1IKQ\OV^ZB)Z6Y
MWO\ JXT1,_V;VU]GZ_KHB0O8V\[\+V^^I*)5"(HB*(BB(JIJA%!6N*)U4B50
M:\$10HGR]_V>54G-$E=-O?\ T\=>-!6JJ%4OBOK^C[;<Z8)A3M0+6T^A]].]
M1QQ1X>.GU_TU"*"N)JH9*H9)<O.BE%2B*I.>")?J^GE5)KPR4H]M!6N-*41(
M7N;^[APUHW/L3#VI::^T7^OX:I/9DB@/WOB]WUZ<*<,$52J47__94$L#!!0
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MN4G/M_C3H=3:4NT9<!E?-HQ^#XH>$1J:2MN#1]VP)MS\\0,2I6TVR<8IYET
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MR ("&/Q;]67#WMS?+EK@H(OYR^YE$[5#?(F1/.>DH#C.IJ9&5:[AK:F.ICJ
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M%$/$C#CL*V,W]E]G[AP7QA/7(J]M+Y6%JOO7Y(V,3V>XF[]N-04!F(*"(CH
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M>FCQX5O]:X]KQF'TG23MTNAKW_[J3<E(%N@Y1E[S@#7K"F=\L9A4T=FG8#_
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M/&UG>3I1V6)TTLH^'T-)/_BA),S84V&V* " TWQN<[ICFC4,G0.&0 N MPO
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M^\J,DO/ONLI7SAO*_BJ@"-EC2E^46I;';\H)EDZ[KL1S< -W %QE( >4/C[
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MW3(.6M?T^8V!NO3+0*&OY(2.;C#](^J1(WOL(\.DU$"BZ[QQ$_WQGDR5&?I
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MY/9X?.,+]5<,<9=F-^3(B7MKC5=C[#J<5CP']N/O4KWT_0WCH2,9,0!*L]/
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MUSK3PXAS7EE'XE2U-UX*H'/XRD .(HK<@<$,18\>'?W#!N3;/*TG*?UK7C-
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M)L;T\-+C74&)3;VJ0FN XCM1=3/>-6<U8A*F7*N[1#*G\-FG4$:-1:S[KX!
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M)^/>-#;SVOQEE/6N-RFQ'L\9=[C:5S'EB^T#0]?K1K? =9C^/Z_\,?VY@9!
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M_YKZ'=9OZT_W#?58HG\W8?ZL_"]02P,$%     @ FUEJ5D@FX+_H$@  D10
M !    !G,S@R-C<W9E\S,3<N:G!GK51Y.-3MU_^.)50*V1(:@ZQC!F/&$%+V
M-8Q]BYDQ66:&,78J;9+($ME"]LAD7R.I[%N6D"V[+-GB22JONIYZGNN]WNMW
M_?YXSS_?^RR?\SGGW.?^[@_O3P&\FOZN+@"@JRL), /_R/X*P*[A@W4/ $
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MUTDI\88UA_L#R\T-R42MN>&73&TY6U)%M!>'.NVK)]6:8B7)CWQ:*TP_ /O
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M+F8 @0"B_SN(_PV2?^&?V%]AHO^,_!]Q\1Y 20K@!OB1$%$"B"F)2"B)+CH
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M^-Q2U1OK[8U5%RG)R<S)*?%H9N)C@EU'5O7SXVSGT[A9GJ9G-Z;=YFJ0(EB
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M5F3%!GV['0  '!\  !$   !G,S@R-C<W9E\S,3AB+FIP9XUW=524[=KO **
M2(,HTIU##3%(EY1T" +"S- S T,-(B$(TB,@(*ET2[> = @J#4-)2PPEG8?W
M/?O=>Z^SSOK6=_UU7_&[^GGN=5]/7B\ Z%71CG8 @(8&'X (\!^ZW@)0JGA"
MG'T >(!;-SST1K1 (.S@X>$*!@(1[D(V4*0M3 B"A /1-JY $2%A(."Q/-K5
M!N(,\V"QA=D[(F39=II:V5@<H;)LIB =81U799B#XY.7*)CARZ=&D)?.$&DH
MF[P<RV,T& UWA<,\;%C0<!>$.Q@MR_:W<_#-^2\QD(WE;Q,/9UDVQ;\4+&8Z
M>BS*2!2,15)(5! B+"S,(BDM!(7!Q&PD)87%!%A$A45%@<)20!$I01$),$@8
M+";,\B]BNPF(@MJ!#534_A7NAI-E^U==WM[>0MYB0DB4/5!$6EH:*"P*%!45
MO+$0=/=!>-B@!1'N[/]X4(&Y0U".KAZ.2 3+7[R-+=+30Y:-[9\JX*XZ.O]V
M_/]M&!P._,?:W<, 9O<_6[L;^;C"@ 8P=Z0G"@*[,6?_KU#_,_0OPYMLP"I(
MB"<<AO#04)%ENY$(01VA8)"XHK"(F(2JDJ2BA(B(JHJBFJ2$E*J4LJB$L*BD
MF++R/U@-A+N'#0("^P?K^!^LRO^(!2NC8#8>2)01$NGRSP U$#?=<[1'L(A(
M"8FP\)@Z(J!(;W?>OUK[KTQA*$<O&%0-A82S_-T;L.-_Q??TO DN(2D-D1 1
MEQ04DX1*"HK;0(0%I>S$0()0F+@8% 25E(+92K/]"PS]K\+_!DO"0! I<0E)
M01!$&B0H+BTF)B@M#H()"D-!8N(@83$)J*@-&_ F'>#_,^I_1#?[\]?QW[M[
MP_Q[^V&(FY5'W>SV]3: [.^" ="O-]\0WO4TX T [W]/^/\A@G_3/[J_U7C_
MK?E?TO57 "41@!:008!'"<"GQ".@Q+ON!.3=Y'?K+^?__@40$=Z^0PS ([B%
M3X('N(GSW[I;=VX3 ? (\0F(*0" VWBW\/[V3/B7"@^?X-8-DI**FH@&P$HK
MPD:GR$ZL+RJFQ,%I\UH9=/\FYHTU_BU"?/S;) 3_%T!YBY#J]AT -:N((IN^
M#0TMD2B[&^KU@I*M&"0VTZ"]HYK3^+XDEPG]-19 2G"3#"4!)4 ><.EU#6"E
MX^4GU*4[#"K9PN'\LOHHJKTCZ@ R85^0)+B<;>54JB1C:M5J6UX.FQ%EKJ+7
M9>5GGZUC??C38IAIN]#Y_(FS/E(X,\QHHG[E-Q]@=\1KHQ-TL?#)H8,\O9O)
MAX%Q^Z0_1 SWJBH,9@N0A'%GQ@XN62=4PW0VNS##W4UYC(Q*CBH_QV'&S'+_
M3&-#K%W!+=&SH'VS,XWIABA?"<NEWFQO$4V>",@V(([X_/SL1X] Z5@B.7?7
ME!<WJ$;4P)SDM#F[2L,1V*/%"K/>+KIX^:.?5#;]Z%?G_APEX.O.H^>FH1GZ
M<]W%M%M63'B)"B4=E_E(<K)0EWM8;=^)F>#9)^=&<JJU@UI'K9RZ<00/AE:!
M5+'&B4]Z*JUZP&:+L6F/>&055<*R0\)@3Y-/^E^POJ&=\>V?]HXY9CJI_:8<
M]Z4EU=NJGZVR-F[UR2^]"+LD'3J>&OQ/3?A=%D]8->ZU/%F8'>J;AF"VRT<6
M2RIV78J)M">.W<S5.;8M.RDVB[6$@DJ,:4)(&\,$/DV>DXW^"B>E8\1PGDG7
M<MZV=VU^O2@TW>"$XX8\*J$.LU$9SK3E^(#^VEOXP).68M*0IDMXRM???/(^
MP]UK !?I&ZVJ RJ[%VT)P0XB].LS.\Y'7D&)@CHL0<1%28]!O4=?(J\!$:D,
M_#N(7_HD"3 8?XEVY43=I,CY>6X0WX3^+0KV$M.Y-,X$Q.Z'0SH?;N:ITE)3
M'U5D0L7%(&7N81,TI#U;_UT<056\13>9$@<DI^C-5?L'OV9UKWQ9%_A$>C""
M#;HWI=4EZ 3$<=18E&?E3#>-67=TXAN57[)\),N5^;8W\LX+,5<_2Z41WK<H
MD,:Y!"FS_>(L <GQTU17BW(Z2L1+T-U@01_.\QV_)5DLWIQYX95\G]TJ\UDN
MJV.9+9BFZW),.FX]%FI2E0&$H)?2"?&>LH CWP?AV]Y>W-SQ<J_MP?H&Z109
M<L;_^/IZ[2VS,^>T!3\Z6%KSUBZ(+3>0I9R6]M3E1T_T->#+T8QOLS5MQ'02
M%4U=*J</;=RL% <E@J-80XEH3.%-L)JX.,IV;N'7JU;F>'L^B=SX4ENI2=[(
MW"Q_:321A'[5$'"5$I6:3*D1<'+ -L.Q!S+0,/E.):HF]&MD0MW)79UYA]\E
M]XH)%PHDIS%X_H.//LLH4?*=L'WF$=$LE- X=K20=C/I"YH_3@(TSLZ86FF8
M.#@H;E*[6Y]B'_> BBW7('L.JA:>D&Q)+R7^FV_+VJ\<8;S9XE(X0;_",Y[T
MW/E58.9\R>1PGW6/Y+,.Q59^J<;+&BR32(9&,CN!00/["[.%\COHUZJL?=;O
M9,B]W%J\J:,Q_(\D)YL*2A%KE2G\,LG:NKFL]38ZNLJ?I#0_DH\J +<%+ER6
M=9+[90) "?'D B<7-6D3B5['NSI^CN0^( U09;HY>\$V_4"*>OVY(LO^9N3M
MX4N+=DID!.Q!_XN!5VT+))DCX.B,H:S4>EYCE@25 6@"!0$@,/#\;6O^\8/I
M+M_.$P:-#9LD/(?H146^\8K@Q<?JK__\V:C;+QT8?]Q5CQ3LI>ZH+[/4P<.+
MVU:S)OCU2F%7[DY1*FY>!3P1^MRSM)DN5Z)/ #/92"95$[Q96JEM.;I&<L#Q
MH5:L#T88&5*OE;4.-TOQR[NG/J:T^A2PQ!@O-(G!LP<+Z:*PSYX[-=3[F>QO
MC!<7*7]*(1$=>INYL>$:L.PM@)RL@S;%',VI=\$MOFWZT24.K3>\58=/:T/,
M(U*RC74+?I?'R&M? S ,;T+,0PAB<_<1VF&1J&/&GT/UL*;X,"+0\BA$H%JT
MC)&3F"GE1]*0*HW*M]!&O'X=Q58GM.Y>!TB(&VFQG#<K_40_X_OH<ZB0MLC]
M$=:H*J+1^TY4_=8_A0U5:H;=)U;(2 2^+S=T*5:[4?<6^J'A;K59CBHV2U1O
M#/G?A>.,7V3D:J&3I*RKI((?F[A(.*F&V.7F"559S-RKE1U[^D,5%<0O9<SO
MPM%G41^N73K-X_J\W6Z5SQ[[*9R,T&TK0V]J^OR!^_NVF?=T B8;_&^$=9T4
M."+#EC.C],TV"Y5S"\9,LM0#W+A.EZ)J/G.[8HM3#^_9@ZI*!YL7*TCN55<X
M/2/+T_^DWP8K"ORF?TF^G%T:D]%D7 XC7+_WL3%<5RB>?DJ96O8]LC?%Q?QY
M3#@%08N7@B*AL0;7FM$*GA[)"\E<K+_.WONJIIYCDS:.J& 6@;RSV[$:>'2_
M OD&MPSZB\PPKH;%>="/X1<5]QHY>LB:0A:?D0DOLYS'J8UR8D>I'"(\&XO%
M0NY@G^0;E)2A=HWHR/+63I.G'#;LE!?58JERJ"?N^ZJD;#-**%$QY70R]GY)
MT%>SIV3U[^P'0-(^L<CEUKT:*W<[I_OV#HG@Q-R-8X5#1*J>_V"UTZ=QY<JS
MY]1-JB:G>W'O9>B4JR0[U(?L&A"U)?@I23ZRL.F==K$CDMX8(E 'S*43ID=_
MI'I%J\'(L92!L_D2Y_P%PG,1;]KXLP@EF?S<WJ?GCW%:)*=IE%-V[@H_*)_3
MV.*!T21Q+%<13WD!"O!.$A#FZYQV9++JO&G&WH>U%SE">AR9FL0IHG=9./I(
MN?*<AE_K)1::O]9[*>;I+X<<S!,Y]J9:1$I<:1X*LK=6-T<L=LN$T_/$+'I^
M"DHH=*01>M<IDOG;9?W8:Q[VN"RQX.A M+K=2WL(9A^N?4S7$AV:.32E3!H/
M7L'"TB J_'&_3XH",SD\F?"^*WV8]_$3J+=/0WA;X09^5?$GIB/$XCE#B]EB
ML=B2E^,,R;0TJBS#?I6)<3GX?AUY/\#^<M,NN*0W,U(2[5_'/Q Q<&:SQ&GY
M>.W_=L2Q.3[(#]NP?H5G^\GV3O7A+8^.!JGLLDDZ\R9D1)^7Y!:JUJ+\61KD
M[-9L.U\L,;M[P-[P?=[0$$T)&DR<HJKA$V.9&*I]DA>&%#KX"W).V$<W?814
M[D&W[3&" 0*KP\-:83B(;^CPL2@)ATUU%9X!5BWKDVA<S]KW.W-IJ7W",&%W
M6S@\IWW)ILYB>K(TIRE!T-#<O',LSN!-B-TP];-A^O(7@@]GL=H,&AWER7-V
MNX/:;H[(AZ5/GXH43_$R&#:@'@V5'YZH%3 97TS'<Z >%'"09$%_]!,'V5-A
M2WKX71XS#00'6,UG3ILZA<X./9OSBFMDCV"1B>;-)!0/"K&P>E>JZ1.\,*<R
MP["]%",@\EW2.%6J(4;MR?"L+7N#P' %98Z6GDI*1#ULJ-A@K#!4)C;,W;+K
M.SC*T3]SF6,Q6JX[/I%7M)J!=(LD8/5#66W\W)LFB5_@ F(^?HJ4#QKE><(H
M"5WQ+=Q>,KS!*9G4?Y'R@0GV:@IGE\BZQJ%Y2,7SAT7B$Q_6(TC=/L!5[F3I
M@@J1VM,-K6U+K3Q&;];OL(1"5F@&&1]*R"E4KG,%@I[<!C,OVW_.SWA:.]#P
M4%-'9CK*3TBD6OI^E+/8K=KJ[ H?NS@=)#X3&Z)_BZ%"7U7ZN5O:KP\4 #69
M:\"ZD*3S-:"VX_@!PN0"JY$UE?PBOJ6V=T2N5*1'8#!+]&D>R[EZ"(Q]S_I]
MTD-459J1R=N'=17>0$JK17:7"43B7NSG9[:O/?LS/7*-Z+@^W2,>0[7"?9.3
M]EMXO_'8HIEJ08[!!28K#GH-Q+R.4[>_9RR'L$X];8+3C2E)HP1'7W[DRT=
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MY678)G@XSK?!;Z=,4]69LO:RYU?_\9-0&T90/%OAPY1TB7GNZ,69:P!9]&$
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M.MS9, #_&*5^C#]VV[]?_C@?- I-.5W&JLPI4".K>BO[S2;W)]\[!J$'BDS
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M3$)4R:57WAND9TD^L6XU^>1W2.13D.Y_]"4G^2_:Z1F"/E%-L 4X6@0'GEK
MV=S+_2(*Z]C\(J7FZ'?3Y>P7L64O$4^QR(-[JEOO$X <([B*!!8=]F]WY],&
M,(,XP[#V_$-\@J%_CJ?I0,LMX19A-+O6Y%VQ]X$M(!EB[,N(5H @5/^;*V*!
MXYL,,<GMR;20K)C[-P'QI)Z+;^*!(MI-4CN2?T?L:]&)G]1G:8R[?L(NKGI
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MY!MG>8>E(H,_L$0R EJ&IME#L/:Z4.(2 WU5<$.%(X-';:Y'+PA=7Q,KMEX
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M'Q=P!Z92KBS@BJ0+N(_OGMK,7KR^@!O$LD-7V==VDO]I)ES M03W]N>K/UO
MS7'V324LX%Y9N66X+>"LD\[6+>!<GJ=,1*<,P0NX3\F17:73R+^/B/77<K 7
M:W3"U!1[VY RCWCXSR=9Z& #\_PVL'1L7!_^U[B:FJJN][Q-!9"XK9Y"TA&5
M!K]/;B1^LXVF]FM;L+E>5+$%4:A;AA)@#7FGOFHA8C&V)ZJ$>:!XCR*WZ <"
M:Q"C*>FMQ']V#8TCU#-/1?)9H(-%BN \@ 6$4MED?*?F)-6%.']//VKWQ,!
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MOB^-K#5DVC )#U5LW?TWBL9/F- ;NM[S]5+PJ/:C[%6/,^X&8)IEKPL(=/X
M05\71TMC,/QH$#D-\3J5<C93D",J#_%_NI>$DG)=CCZ23\T>"67]ZA!\].>X
M(CW^9]:)+^DKDCZAN52]J,'!]B<=+'S:KIR[9.M7S%+(+V+^O?],)H>S@ O/
MJ%_ %9K"1TY]Z5S 70USF_\E<@%G%]/\>):[@)/IOYTKP/R[M,[?1OKE9XGO
MMW46<'4?G&*W^TN]77UD-=*,UPP]$CL;7+DS7L]I8##1J.>%@,%&BZA-1-3$
MB_(YLSP8!;1O,P@ 3'!O(L!$R<FFKM*[/D=RFOXJ_@*/>^3S+HTS2!/@AFDI
M4KM;QHAQC+,5!B-N\IG#L))FN3-*55D!,04C=&CG),!/6RP+,>CO,4KO[Z^V
M>@*#7Y8>9G2&0!&"*;;UO/KZJQ6 T%-KU.W/GQ7,\U4E"D\805PEE>U&6>[C
M6J67;]7<W9]G1.0L<JHS(@\[,E_T;\&86O*[J'J,\6GV707(%-L7.CV*GXP>
MGPGM1*DYSLW72P=F&2RJ.?0#IO\*XII7E:>1[ 9O/5]GI/&$3\/\8VE?^RTN
MR7DJ(1H5@<-U< Y&*]:%7/(N>RFX*8D/GS&;JZ5<,IS<O"VNJ:DA/KI\)M?9
M8=[:$F ?VS[!:*<^\IN-DSP-8VD_.R,DA5* @R^XI3Z+>*H/DR+4) =?A9;7
M@"AJ+*0:^:'[\CP1>.L7MLA%T3]\A>&N'!Z,4WB& !0XD[H(1? R%8(7)J4G
M)\9'NZM+J-FZ26?G_</)"&_# FYYZ$8;S30?Y6N.6BJUH^/C8I8#=>61A*R6
M*2EI31!4L8TY=W9B(,8RS-+:""],N59_I41O\#Q=%#T":Z]>9\P(/E<O3P!W
M/<M7<^(?E2.P6L*;4P\>]F,),_IA9,I(-9;7/BT9JLJV,0_$7N5AGG4)2WB/
M?*MJ4R@VD_=_6< ='$WYL*KL[;QD4\^'G'\HPTQ(8_/9@8H/TZI&7QI#4[."
M;HYT#MI6*FF+?9]HWY=SHLN>"=D;W@XF4E:0K;C5=3,K;*-_"&#"+!@X(>*W
M0HL%(6Y&Y,!4!^F7NO'1,H: N.$SFQ?21W>LSS#*P"9H/1S E@Q@F4I\M)58
MLH_@]=6Z6' YG:96D)A57W[\B-0B&3/&53IOW4<]4>/1SK]+@,IME;H9<;K'
MGCZ)]%:0!C!?:CZ?'!MKG"A_&',['A&&#-*%1PBL[E,_,$N]4/Y782P8$D,9
M)"J*9,S^;!;6AI'57!NRN]YR>5]6VW$R:?/&G]T._#XE/RP5NC#A7>G-+V09
M%8GKWF=2CT./^?I>4Y@\\D\3%23RK*Z,#SYUQ?3*X?'%A9-"&AE??"M_R(._
M8:[.3AD*K&ZEGPDLDXV$UI);#_+]:7>:2[.>[C'$U$KRO1+!,L&>;#( 6EG;
MQ#&_6D?P29(VA-"/]T$;TZ#(R.CY>T9YCG_+2<OX*(F[?K!"H<*#QD3WN[YR
M;P7XM_/TB45F\10JB$GH-&(I?_W1GA%$_T%?6.9TPAL1&32H/U:7%M(00!YE
M35A]YGDGE')D-_R'Q9^R^!?T#[4/#'I^UPPDW25R9LWD\)J]B+5-UE./_$;,
M;^G?=HNK.0GV=;[DEIUO77U1<M5S?O 2QN[Z]H=C"+A"ZD])CL5 Z=;_F9,V
M?<M)Y3Y5!4.S]?Z5U&]8<VKD[-OK/9^(DHM7E0_K7)ZA\J)F0\M=U^B>3@@I
M:<9 GDDEHHOQP1,!+P28%N BNN_IH$&MSF%!L$C5/R,#AP-]J/(PN8=3#&-*
M/C5>'FUU#_KD4)P549>CF#FO":%U&/&F,4N"^9I'(,9^&-QC3H$Q*K1ZUIC.
M',QJN8+13/V?4I'".,#$6__/S8PIN BD_)Z1<&GU*A.<,-B3R%N]3L%2IN2M
M\-$KQT'5]R*GHC0NZ"BXSDCKI[)-)G>U90<$&3#FE"*4BL"L//W$C6&]?$.&
MQD!8YOSHM A!8I4:M+#99)D7 :8ZQYI_"Q\=,[D]99"ZL[9ZA#(-_P (?.0B
M 1.QJAKI9U'@+>]S4--'BSL/F=->V-\AP8I$(.LJGRB8^C#[8$7(62-2U6S(
MR8,F9J(RNTD/.USK+DE?+6QDHDAK: )X'E1^VK?Z8Z75M2&, _MG_L;PV2CB
MLQN%I,@IZ8T$0\A_(+(MGU1Q9*7+N^YC.6G&D2,HSV-)X9OS% &=7:K'H#/E
M4^\G$ -W2Q"@^!K+9U/RW7.**#_;E3L&--TSG:$N]4-_CQUI4N&L%&BP^"H9
MH8(A39  $B \Y5\MP3L<SWG'B*+S1L=*3HM:UUDD:[>5%"8:,-Z\'<V)?-^)
MN<?_))T4\]1+G3XI'^^G3"\7R+->[9[_8FPS//=PS@H=5Y1L\OS _S??!%6]
MTT\Q#35%JRO-*'.73, E_04Z298LH3TVN[[D;ZL5]&-CPI4J:]^W3<Y(KE2L
M@EH!%.%[UJV/?AHQ=.R!%21FOJG10F$2N+J^?H#-GWOO?DV/$>!<N8Q?4D!B
M[,_1I[_W6R3W"!RI":SM15S>U2CR(-C^[<5ISF?)@;S>FI(UY<ZMT40+:VL;
MM7M_;F1NC)U8_5B@2E][R2I5=C"(R=];H6J&5/\94.E-D0(U0L*B1L'P<@2M
MWI"&D_EI3QOY=?'^Z,[WL"(QTS.+:V3M&4%T$,XL_D,]LOGX=P1'?RWKH;MT
M_QN<Y1X;CNLQT_7LE+5"R9CJ$3+UZ2Q/S3N!-6OT&>RQ259F:P9[&.7D,@5T
M2#S.4(IQBYH=JIV]=R>P>)? '.!#@;D,>V!QFP]/(Q0]!C5*-+&@D7TI:*L@
M&$<F 8F'RSJT!-$5YH:^6\!2O]<9H+UMZU:F,+%;Q/?$?_U6!HDN[N;F$QRF
MLP>B0DZ+Z4FI<_4ODWI&REVT7J(\@V.3[ELJ%$U&)>VW3C9*_7@AD>]'L ?K
M <23HC/)#_?;]FH\050?'0D?J'KK/EG607)1"^9_6U5:K.^A1 '8."A[V@\'
MN?*>$;SR?K7/-=08FY5<*3;J,;E+7\ 9O_8>\ $XY[",8S,_6/*_,TY<<)*P
M=@'W=M&95AN-J-_)FOO;#^/T;[_BU0U@]O)_)9PSLHEZS?E4SX^'G@E@/@S8
M-R*%5'ZZ!L3D'A_ PH9>D'0M^?X\'%SIK-%_"Y4D0C!=ZJ7A_HQ_?-WC!LIY
M SH:L)7NKI#*+2F'%W?I&?ZC(^F38;)1I)8U,2&J&1W=S4.**)PL-1N\>]VN
M9PWW[C:G_Y$55:_Y5^[M\E!7O *=R'&9GZY5-G2'5JCOF^2?Z )4\ $]F@5K
MHR5I>[8BM>V-2T<;)[N\,:1C$#!J5EU!1-)6CR#QHN?RGHRQ6Q@A@(66Q+H)
M5O>KX+CZ!U5)[LSX22IQA\&/R^/Q>Q6ICR4Q7(R>DYE%53<U2FR4F=S%'5N%
M&/O%'(>J =NS1=4,(T8BI80V1F?E(:GIX0K08:JT-?#KO.A%A@-(VB?MF1FT
M(V@/)P?C,+/4(L,$>90PNA1691X]C.4L "2K?OG'0=R5&7L^TE%,#8\,U^M$
MX@5#5<\%\SMZODR(?8Y(D9]DD>D'LY( #65_^]C!E/#0E6K+$)>'S35"1<]J
MRK)!A[PT?$8 M\ROE8 !\E?/J%&JHU>UNS@>_%CV^X$8>'W5BO#VRQ/BTZ/0
MOKPT.,=B[EI*AF^7E4@OP\1ZZ+;"3U[2_>SB@13MH74WJ=>?SW4LX":U#D_.
M]\Y@J<8V OVB_A&3:;'RVOO3KR5S*O=F=O^]?@%WY%R!//GM?'7H=:6J^XSI
ME_\X9?.3NXT2];@4NUW5*:;*0G83@;R(&R3Z.[Z!2_#* ,0M;E[V%E*3GM82
M22*#EIFTF+PKAH$,DY&EEZ^-E6PH/%!M\$H S3P6VG/%OD92 EN(20+H [18
MJ  HGH//C1?WM^OE6YA(ZM/PA2J:_.(?Y3]>PWSX5A5]J.'>2/+J1J6_FUA&
M+XIL:,1"SF?70IVQJ'(Q(S-TO2OMT%W#/1VE]4D!SN@=9<@ #RRA8MZXN)U*
M#(FJ#=9AJ*GZA^3@Q\+O2QEMQ<+1"+?E<D[9#_DD5AG$'I:T\"1/^]GG!_*:
M@&*F7)2IHQ.FV7X3@A:7;Q?K7=Q3$^,(Z)CWS"Q)$%Q!<JWS8&Y()Q^[(637
MM:"4:AJ*L1+(;L NTZGA@W[>/ZGYF%;Q:)GO*ENY"%(NSQXK__C]INT^0B8"
M'[/B\NOH$)WUS;2"&8!H3WW^PN_%AT(A9Y6=D3PA?O&K7OLGJI[DME)<CG;V
M]TV,BPQ]2J'*JLOM_=Y[$9^"V_.Q&RZI0CH)G0U=!H7T2H[+-JTA_7$1:IA'
M^=J[T0^]B.=@Z?*DSV$]2"W8\-)1IUF6AL:UTT)VN8J:ZT=TGH0P@_+8XL.A
MUJ8E>B_88HVB,I\#8B$I).OF7OZZ[?>X_^4S?6O_\1FECZ7N([2J@Y^_(5/!
M*\=_D2E FK#4_^S]SZW?BE^$I&K/3^ILR<5?K;_F&J[U;12QD@@(MA<+X@)7
MV>HGK=C%S.RZ:=0GFX)UU^%/")\XIKRV?W3(2^@AXK<K IB#@1!*B0-)7Q<^
MY%,_3G4QB)5CKQFV(XL:OF9W!AGT5KK2;5H?GO8)M5RE'TT^,S#5>WG%<F)H
MMFYO_ZUY@^8+/Q3=-8(V#T-J74,)&Z]_7><"B4TP<)RAVJ(L0OQZQTNL2*H:
MPJEX)4],(*F=V['N""=V&#6: .WG?O>;*YF[9 Z;T-?*3QW9Y(Y'?![E,G9E
M,A%,SBR.<?78*B1!/\K:1D 60@Z_637WEN2*(2&\ NR;@DP4A0"2\.A5M2'T
M?>!B-<!N1PFF"..U9?<P"![!5)#A,][AOI8,3&&)G_$T#NUUW#<S!=[K5"&Z
M%FKW?9#ULYO<WK^L(&+Y;<L#6,-;!0^1'@3P]TW0OZVZITJ4'=6>&]3.D\,@
MYJOQL1'QT0?P6OG%Y*1>ULM5T.Z^]@'6\0YJ]F-92I*H"!/1N%-)S=I#R:W$
MSBOSSZ=)S$P06%2D\+<9L[BEY]+024(R[C;,E &=-X-LM]KI95I:S\RO$L9H
M026&&A'WCT0FIJ:34,^1*^E9&9*T(%LJXFG )*&020DU4^MS1M3?"$P]Q'@S
M.9JU@&OX4"^1/^E+F5:*\[Q3D.\V\Q65SGY#)>.OJ)3R=*9@NA4=)_XO3A-0
M]4XKQ505&L(P6C*!4',LYE>-E#&"!;,<*LZ#!WOJKYV8*%GSR<OS3>90 ZE2
MU8-R@4*-NOF?W0@B/A=Q&K-9#K+P/+V.0!6B"#UFKL68V?3$PKC?HT ?*%1M
M7*T792Z//^Y]FEJ]9C"'UY7O/&$E#<6Q3Q3/:5D]-^^FW2C;8[],1RNI"1N6
M-PLF59*8E,_D;\ )>^AE\3-@OL58I/I?")6:JE;ZS/'O\HN^TY1C>A.F*"X8
MW!H9_\N@'$_\IUB])[%L4E>4KRI.I<@;QD;&BMI-P'^(H:]&6RY3]Y)52U;&
M4)H]K\<'35O; 0B&1.JV?-:ZKDK#:%',S46=QUO<=#F!*MY10VDP8P]HO!\F
M&ESM7\#AVQI0Q8QV8F3R7^8S(N<[!RJ(8^O;\MMIB?H3\R:C[_+O:O3/SDF#
MU:SN$P6*B[+A:XUXKND:E2-US*H3IUGDL@Q&:899,7>4*Y.>#[&,Z&M]IN7L
MDB:JP$G+TJ+5^C. A)Y)33?1P1X2+SK5:=D!\)'%Y1/,W@+K3TYGGACO45/Q
MT5.[-+2S;GVU3\#I[K+?-#'6U!=!#C4$^0([C\)3"?/KC(7,[S*9^O+#(;*1
MQ/N5JB\%G]8W5^^<HD!F4CKT/1Y3C1\YDXX+N&=Q?;*9G\,E<PI7RUZY_54Z
M]S]\^-S_RCJJ_F?+/K?&_]34F3]R=6*]Z17Y[/7;2TW/]KX?!E=$GS-=WQ3/
MV:FZEA/QLAK]9?O?A]YN/?5+Z'<[:O\XG?/>UD?U[>'GM.91>4IFWZ8"6F-3
MZH.KN^.LW[RP>M2RUJAB+"KC]GME$];U>E:5_[,OGCI/(U-*1^OWI+[R<DL<
ML;OY:^V5C3]_O*MOXM"V1G-)O>)'UHV7/:RAI:[Q5;M-UU_;G;(WO^_+FZ+;
M=TJ DL%MT<+]I<+0]-/MKZ,NQYC]^ML:%>'O%EJ3K'7AP7J;\$XQFVG-T59_
M#L^>?-87H9"1G+^'X]O>L_NIGNN1R) BS?.3^'23O-JC@Y9E61\WB:_)-!M7
M_QB2_:<4<7K64Y-W?NKU?OV,EX7O.9JQC95*NX]9 0WZ3PAT_Y]I<TJ!DHLG
MXJ/E8RB/:%.3:TN*;'_F*.^&O$$ X!OZ4//*B&P1MSR46UBTN ZQZ""4TF>7
M##7")OF 8L94UA^+_Q@Y]&,<.2L .>;5%;UJ%..[ ]XG1<S!AOH5D>/U<3Z:
M/<)59NY-2NE:D6$)+(&M;>=/%F$:\O+T)UG[!MQ7+@K"?[00<FQ'X^" ]X'J
MH7.F6BO2UTZ,/\X==EMW3F='?9W$HMLKL-KI8J<N&I@)37XX-/&XT,I=2 HF
MD"TZ,"Q8O,6IR0ZJX'.]9JW'>>KLIG[F((-=)H42NKJ,2M$+U/=RC.\/LJJI
M:.DS@3VH)?@*)%C?F[??[OYI54@4HCL9)1\N32TRZN/2N)4,:O&H):-N>!Z:
M> !5O#3TD:.9<YPIG<N#[LWY$,J5SQO<$M^(]1*.)!;7+7[IC%F:2D'U(I;9
M*(V.(?JRX61MLFIEZ*MLR3[S4UTW#H.!%AW]A5-9AVO_/,#SGW];_[=XC[GX
M)0(EA(PW^>#L0-Q1F\T/N:(!WUP0A1E,!/AJ\E(^9B&K&WD4GN1@?;B"%B;'
MFFY8;Z@1DDF,=IU!KR]YP4OP06>9IN7O>RO Y.=#FNS\,F)H,9/_ L'R\NV@
M%RBT0?151IQZ,-:OLX"+[OFO0M;I!9SYP07< *UJ 6>Y6#!M] ])IJ>,Y7R<
M?_AL =>]R?.H8+$\ZO$E<<>?.T^U'_2Z$^?P_U'VGD%-QEWT8!0000'I2N\E
M"%CHO9<@2(  4J5)3>A=JB(0I4JHT@)(" *"]*I2!4%Z"[VWA":APZ*^[W_?
MW=DO^X&9S)!YTN[]W7ON.><^<JW?;'TOAL+N/93BYRP.+(/9>QB[C#+8Z^.;
M[;1LF ?7_02_O$^XN6+V:#1"$_0:<JQI$OP*KW. KQY[^*M!'/8YQ:WF.1E&
M^VRG^V@I9JQ?0^N9[5INX.*9XL%-8?([#0INQRVS@3=FS$TUH5\:/*:L,4(6
M"]B1!FCE3H5Q 6S6G9;I_-N7IXS<9P)!#Y299%]L"DJ5C[C\='FS$A/6BIM@
M''/P.B0A+CREEA9V>?QEJ:ERQX-7"S[U@5KO15$:?[>=75'GE/^878G=,F4?
M53;W\MC %*[D<V6C-_Y7C0)&ZYDYH)IGAE>V]P:;N7I HH;9PL(ZR:@C^M7X
MD=WK:HSRH< F#_9T9=WM%--EZ@9+%WKAS+ P\?:9X8E[&T-'5<F[:W>)M75$
M2C\U.%UAJ<CO+3G>9U->&AF^_6Q@WJ^&6EPH=#2:3DCU<2]H#J&$%*",:C<P
M0'*4&?R'2$7RT3)F@&VOJ\P@*Y%&=+Q7F _DI0CB#N[U+IXIE:6GBN;HF&2-
M>0&X=Y\L(/\:FS%9H&O1XLY@IL$][M:M(I.S407])7BDJ.I?^'@51^B_HU:;
M&*HF&G08I))E>B2>U*]4]JDKBSS%O)$P$=7.Z+#D(1)H&VW0;K#VER  4V*P
M(;[U47E!3R<,4^\7A1O)2 ,+J)IH07!O+<RT8K( P_ 0$E@02/71CP_>UE]\
MU;BC_A"V;!GZR!<YWN5Y.B(;%:2\Y@)2 Q#J(&&;SF.3\F>$%GAZ[%9+7 29
M/C<UK!6+UW7:*#%PQ>&WBZ=R9:.I=>?#VQF&J+,TX#^N>@\E=YP*F*H@$*)J
M#6(;!BN;9ASZ&1JT$B43/L_11 /N\9MP&Y#R&Q0S&""!UI2T_Z2!E(6.GT*O
M6L*-RC44,TJ3:[+<#4FI^D"VK.3YJM4;K>O)-;0.#_D/N:UZ)D*VM@HSC [U
M"CBND5;_Z=.:PB:*+(KA7SB:;W&9G0:BJ56=@OD-RBS^YH_T!@JAJNN@*RS>
MXF43HM,0J'P).+;\#[YFO_"Z!."R_F<>? G@N'K"(O?_F>E=<]Z;"*X5UCR_
M[A)SFNXJ6"]FL7IPC6 MH&P(^PG'F2=)QX']P/2A0UHXX1*0UF3:MC3L+MUB
M!QW=[8H1H$NJ/GO#:F)PJJEO%?+TPD*,1?'ECT-HXGY\^SH.[W87/_;F&V.^
M;=P9;)YQD[F]DCTL+CS&<WR5@//:<]\?5]>#*7=LL9+_:GFVFQ:DG8R?TZI_
M4+_PHNTH[8BLVOCJ_U!?2?]$Z7"S#MD8#O'XA5FI1^O>]UY^9W47EGO7#*9H
M?)-I1=&<MD>UWV6U9VE%7DL:SG3<3X9 B>YKSP6Z\KB\EE(40;#=(1EU<G"G
ME>A?>"115K3UEMF&((^H/)63C8J$0-F!Y"[5#=J[3!VDLZ9V=5=8H(PQ=O(B
MW,VRMS]7+;/%KNK4(14UNXN$ -&&==Q/DOF*9@<HC;-&_KDF_JB$A>>\\$U4
M<,+#P&VP+;%3#)TF%: .363 \_9=Z2'=(J85]ZGR0*_JJVV>YRXZS2]O5A=/
M]%*O2!_$3>1T]1/^&6!S_-4I-:><DM%(<@?QY8HRKT/ -/K<'<5^4QEX-UP+
M0Y?17(D;N(59^)B!*0G\":)S5?W^<?\)'$D*I"IO@\UGO2$(&M<2R!_22 7^
M@J^<DZ'@V7VP2=#+;P:0,J<_<W?5BVT"?9D )%E#H&B! YSKT'?R$M =R>V0
MP.4S6Q.AH/A#EXKG8NJEP_7</[LY#+D&W/=O[9Q2M)ATI]X/:Z6E<GT2SJ1/
M:#)Z-,I+#Z%Q%D+S_JDQY46EDD"X 0J.4'$$ _,"BAF0:(2N[KP!<# /8@NW
MI:0IY4-8@_\P/QQ12)AL4T,Q&PII1!QU-'5!"\G]H^3NC-@.J<\MH)$]YNU3
M')OS"X%JL[VC(U55V/G$,":R8,A39!EAJR!99&#9>M1_VPEAIA[]*8+.A@O-
M0 O6%_D[Q'@ YXTY+0GQJ2+IK--%EE#L;&\C<_V_G2*O<D :NGU>A9^]0H8:
MXI"7T?_(-\O_>] ='3+[/SE1?)43-64JLF1;A#ACTS@/SL(@ENDAL8M+P(0U
MS<SG5?%B]XKEJ(H*8:]]>^AY,8,AC]C\+XE[[OZ?AO3<!W1-'=TSE::63]3'
M+63$-6"^8M@&P24\)J8Z!?9H^L8/M;J5OLF[#&L8D4)-<7'!EP]C[GL])?>6
M,S]K\["I_.5<)>TUZP+%5?>4N&#8*X7@I<Y$V.$Q<I?2<,HBY.C P"_V87QW
MIVC50.]INK.[J_:O-!NGYV*//;\\IKT 3V*U[ E"W5-NV^<HP%S.\D.I]H'Z
MD;],:/:2=>^$)_%^JR/:%Q?$;1PD^^#)$GU#&KXR<;Q^E5\>]LO_)]7+-GHJ
M$P(-AQ/6F'%YY_'[6UQ-=5/F3&27 /]:P<=/;@ZS['6H3461[5UG8& RFS,+
M0+AM9ERE3.E?'J"R#*(42-FZ6)HE8KR H 2VK2 A5Z>?U-_U+RJZO)^IC__P
MAO',>EQ9HM(C.217H1+X*C#L^R4 8=&T269>)\0*@ D'LP8Y^1[HX**'GUUE
M!J4!J/SC/:0 +?A)P%\E^]3(VN<BM) # BA^O80J0LB5M!+$F:KWEOK-,^1O
M8VI(AVM04(3=7 4)P^LAHD1(V#_J0U$,>=M $R?O;7+5'&Y#[/[C?NG48QLL
M( ?1&'/D_H<BH>1F#'1'*>6Z3VTNZH5G;@(YHJ[0C2;H+4-2]#8ZK?0QK+N[
MJ5C$D">3%E3HP8$J,- I4>)XC81$ Y%12 <Z<MV5L>\52##3\-7?]P(J.-<,
MBMT.Q*V;CN0C114H<>2*_K,_J':&=!RD]T4=@>]<Y0/J*A>#AHT3$1O/D<01
MVP'MJ@^_^AQ= F!5AKPB9<YFLRV*6_QC=0!TW"+8[I#[K^5$ !,#*E8IE5[7
M*Z!Q$>XH+_HH( 27O;A@KD($ZA7KRSI[.<N.7H2M5H\./_\YG<I4*N /W7JN
MI]O8ULA@5_7X]O=DO;!'P<# ]5@:!?UU)9ADF07]\3O\J><AY^1F2;:-:U'S
MY"_F*<K1-_9*3*S4SF]JV@ZC-L/\G -&@@B.;0X%G/ -TPW:^_'R@XN'/GL3
M9II**O>SE=,>AQ8-,)5WV'[D>+3J92GB@>P.$S(@V;7]FDUT:-T7)B9=SO,]
MJ1O.$B/$]5KLS)'L_IU\07X]C6&CQ?R=7\[26%CJ42G2W7D<G]P4>R.BS#G4
MTXR<\,Y-RQJ?_6^^KLS3^>^2!PV)*]0D9..<(TQ69/.K>CGOS&EP<F\8Y>/B
MO[9B7^KLMWLS<B8X%R6*P6[Q-65N$#MZZ5AJ?3Z-I*]WEWTRY6\FIR7,RU\O
M;O$UB$PUAG*%D\=6<GE4J?\ <](PR<+H:E?9VC0)\^CN'1@=T#R"SLRZ>+_S
M?.2W_2)1O&N=M[92RL869D.8T%.$H"@.ECDL_& VZTJ]19]A )9W@ X/O"U)
M7O6&S=^G,NVQ(O3HI+:IJ6XB&M3DM&2'&WMI%@P,S)CV6J&^[-V9\.MRHE/R
M$IO553#M>LL_>F=O$!.;*R3UFN@.@N^Z%Y=3,#A+K-V=Z[[/QPIU$::'9.Z
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MKO;.?"H0^"0+Q,-QZYBD^*:U%,S[^,.S 3(Q:<,O.:?.?,B7>S?S: /A5 Q
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M(>V$N '[WRG)M@ 1M]@H]5#_99\8BJF<'H#KCGR.]"G@G0R^O!A]9%6[\H=
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MB5:)N!YH5]Z9Q:68/>NZ9S9E_;R3Z#?CND QUCL[IX'51S,IQ3,^I] %IUO
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M4;6(:=5I=V-7[$/9:S]LA_0"R,RAV?C-U&7/7\AK<#3D/0 '>+0[0W0?+CK
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M!<U1LOY8.-(^8"/'KO4PO&?Y60I^^Z;<\)M7^.8"R[I>2C)MQB5IK,V/>7)
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MSBB,$3(8/@'XBM8FBA^AG.\$S<6V31Q%.+CR5TG.)+=2,T9A_IU/ -7#'T\
ML^7->W9RA/G.BAWMJZ]=33S2X;XX>SE#^)#)TV-WXX&K]R_^U,"NPZD/WC#1
MWNH):[^G^5">$IJ<[L]_GE<5=6YG>P A!PIWYC^X>TD$GZD@A<<^+>HU%Y2-
MZ''R) :\M*&#&L.K2/ A]Y@NZZ^<Y&8T?XXI')LH;27=8[VB07XV4SNV:]:^
MRSMRV1WV%#H<SYQL<'@85I1,!5"]R'WU\VY*J"(3ZJTJGMKHGIG]92(%])HZ
M[D?%@CAS4C&[F-P];,@5D9D]M'WC3=^X)N9X%8^R(JG \W$]Z=R-SCD<,$*M
M*.VTVA&NI_YJ2U@$#;_V!Y?"NQ6.ZH5I'H?18Z,Q]<Z^3YH6<,_#CJAPF)LI
MA+.C_!Q^91>Z7$A,FGT N=;RN#@?,*3,X'#=W-25'M$FH&L)*S:6KYM_;MY<
MYMK4.1,_OIG6H#^B/GV)5S[\O=1$W"$\(#L^")'1J23^L$&:/7;'C_ERH?3%
M-I@"F#:7\^'M;O"[ZD='@MWYZV63H5M;HT%&94$V0:;;S#TU?SAX?G-803H(
MFP$=X5J<0],PQZ_++B J^6U8>>!/GRU/"VM:JHRP4$TQS[M[\!!F<@N0KY$S
M)).*^$5N##]L\:A-?UWL<LE_A AIU,YKJT!OMO,+-$WKP%AUQ#=P23*(.FCK
M6,2 HM:=0*Y.7J-N'8J(_J&QJJAFP&H*?1XF'78;Q:/Y4 M)?Z(L-2D]++:[
MB*<LC3&PV2CIS>56OFY_SG.Y>PSU9-G_Q;'*#UD=R-2RLNACRY>'T]=392OQ
MAZO72W]SJ<I*$N$8CWS='=;#)!29F7A.7JB98A*#LEB>IOQ=R52[UK7D/1%6
M]0ARIRNOB5^.96R_WN^%%4D-$E8H,ZL2D&@$V+=O_;>*V.L)\ C_GS+BB!NB
MLZ+8AKF<^]/EQV^;_@4W_Z!*A\KXG>2_QX:-9E@&F]T/+O_CHB%K[N#Y@,Z]
M=91+%Z8LN[3F.&FEJZMSK+5%?DTH05?E2_>39PX&"6D3O[!G-TN2H\CR%,F\
M#@2*K">$:U[1L9IGT!7]!]W^CY#\;F7SOG[$)'OV;0/V!&. !(U#OAX9V=]2
M!9V[(?TT3ZWKN4]1Q%6L>EHD(:#^LOR@RWPV.EVY#=@1;AL$IG"5,KM\G3SD
M[G"D^H6'* )-U^>MJE^8EF$G&TZM?C(N/R"[QPQVF.1%451X9W).5MMI#,IS
M-V&])-!(V!2X<W**^\0N[2-)SD%4^V $Q.)U2Q-#G?5U(6YVAM/#_@QHWJ;7
MP.-*').*;L)?O6\!EM94Z0'D9K398?ZHJ_*0.[TQH) YO<LJV9IE]'$;0:*#
M"Y-[.DW9_1@GXZWT!)QH 5H?%F J'"BQEOJU/NJ6L,?QJD&F^F;J#9SRD',W
MF-Q)38%KMM%GK$ A8U$EEIB%\">A4BLQ]T@R<_1YU:#GA^P_'-KAM&"9C*TX
MHZUXS:WXX.?DWT2XR9L7CCFI=VR=%NF5\)S*7M).?,.3)0@S<_=[ J!\LEH:
M+5Q9>6?9":+<=R"DC"[EP^XXK!N5BR>O]>QO7EFMB(04]P:Y>)!,W:C#FKX<
M2;KW>X?^7$#4917%/ Q2A&+\)CC=:W-%WVB# 98/;^2'UH;W/Z&W92^CHI&5
M/EVQ$5,N21=865 1,DV!8NFH_H7A']P2:</;X2+T1[[H8I^ RBHJH-X;8=*^
M2.XBKLM$\U2Q6)=-B<4S-SKW_,U,U8S<Q*+9FH>IP("*L4X=,-S@@)D&T?P3
MVH%H8GZA5N/BEA*:P&]LHC..]?B,*LK_A^9G(^C0^9\?W9Z=[.GA2;V_.:=G
M@+R\\A^U-Y3*1_G.F7C*18H^Y+%R<=<JZC@8KF7<W05]08D?XV-Z(J*LF[QY
MTEP.$>QY&[X+TL=],>, =YS3>D0'^Q T>MLY%,L&@N1T>7[IS<E QA^#45VR
M]]XZ>F#FNWYRE:'NT;'<8YX9?)HZX1&/K[IRJ85L:)K&P[GT>#&')Y#=1=FB
M8&- \0E@\*[M[V;GMB!+S49."KYO_K(7TG4IW]?=Z;O+ 2/?5Q>A9W_%?E\S
M?7;K#@D(5@+U=_*AAJ(G!(2NO.NG6Z(;N!HZPQMG)L-?@1ZM[:[R00X/*W4&
MY=5*B\@G0#N/*?#\)GI *7RNPJ+G0@;C1RH124K_V) T, PJW5\O/%#1=)SP
MS"Y(23<EX40)!Z1W0=.:/2^:C02:[8$][:X7!%G6/4=;IM\FL&8L;Y$.&))[
MD*NR:]&3WY(W5[^Y)$,M<='#O+EM'Y;:2%,I&&(2@2WNYNPR^2#O54HK?)!+
MF0@B7D/M**9 Y=EI3G'F[RJ)?]\=@-\=<V:D-S>Y6&@AX],\2J,N"36?E[*Y
MC(B'CZY3/6<EH^'O2\H2H_=I0/D7;L<?B_*W<5PAF\SYU+J%\]W.>!;W(NS'
M?*;R>D8F->JX!20(;D(OOZMUI'L-[Z#AY5[09J63VRZ^B[-V[R5O7'@P\*@N
M,38HRR1S=3TL8B3D>;MC_[6)]#L]C3 MDQ>OH7*X;)HV5V+@GEH2GV;UE O5
MT&6,:W^EK_S WB("9LJ\%[V.1>>S<XW4ST90OJ>MAE&;]WH'X QR75?=T/QN
MABL::1Q!6^KDO6H/"W[:TJYA#ZBDO.:CCTG1_$MUL1AFZD;.[G3S/,C%=6EU
MV37:2H\D7]Z0P3SG0'#U"&JE6>(PZ+GH.V:\:.ZZY-C;8E-422+,U<(LLMNR
M3=]F]I^#XH0O1OAMH6*U[)0NYE-7%:^VQL9XSZ,"Y.DGF'D;7\P4*KKL>(G$
M"M)7LH0TM=DW1+-'0*TI@E+MH4#@[_ 1H2U*%H<%O^\355Y#IC"G1LCFDNQ,
M>V.STZY&;B-*&VSTQ4WXNWIYP7EF,:$?"./>.GJ8'M1KL1DELM$M*\SSKCIE
M9.C4W+=4(\;8O9"6X&'2Q)MT_0P$K;Z5J<KQ=('1J(W;XSN)\/<24JG#\3$J
MQWVA$"'46VB?!57(</XSV[J/ETJT8_(_^4B?27JDZERGV&94A/5KO*F)G1EY
MVT.VO<#[Y>.'3MG4ZESGH8W.SR0CJ,@>&Z&EAD?)J3A9TTC95OS?Y47HNR74
MZ550B F\Z1)_SZ@?81LUK%$^-2?^$?5 7HIJ9]Z!56=7]5\PDUE<L*-E=UL8
M(C16(<3M]:-E'#$*\Z0Z6NE<):5SU'4)VIC<W!3D]_,K]ZFI;F8@UR'OP\NM
M(V%N<?'^Q>-_4#AEFU2E-*9+A)D*2/?#H<#-O,)L]XZ@1Y &R.A*VA@\'H!:
M/&"*XGOF\1/V$</^\L9$9)[D>,GUK) 3>POHH#RQYJS=P.+.Z$ ?H9L(6C4O
M#AYUEUF0M@!\$_D>)O&<>Q!&.&6TJO!-FDKZ#<%?(;8?K1XS^SW([J!S(YNA
MK]OM<WJ.&4E)NUC:P5N;+?,J"V;(B^^#K]PSQ+K(.9T^#[I812B'9=%+_V5X
MUKP^S%V0_8?IOH@VVQ23HFRK2=1S^"B7*R$#OA?0-_XEJVS9OM-:O_&<ACI/
MQ\1))F+K#$W,OYT]P+%UXDO!KV-V8 G1@W_V"O#*@*@M8<'P^#B@"'7-2.,+
MHG&6^;?L<BKU,)(!KGEJYX_PS33IS^*Y_L-%XQM9!^+4JZ>,E!O&QOLW;G?[
M'-A3,R3DID\ 9\WUH>RQ1\V V]5U3V]O2&UG"=<3P(//+<Q$I#UPM<4 4WKB
MA!I%,DPRL3_[_E94Z:3YX'Y'.3>9A_7'7A& [Q@2?L=:%LEA,)Y:\>N%L>]M
MR9 %1?\&@\JPRR]9#F==N;BUK;[ G?2H<ZF4\5_#T8&^@HIS][@!G^YJ75N.
MJ!]=[KP+F->Y7->M.:8\%6&\ O);V'JC;KT$6CD6O_<QZ\ Q\PV/YAR"DF8$
M#JXV[)L!Q5."C>/N\#-S]@RW/!@'#\Z."FF/SX&7*"4R+BI Y!4Q(X,A$Z5^
M 8"S*,A5^4&I*;QI;G))($B!XM,3@"2OLS1 &X$06=LR3IUI_43]!+@>XWIP
MW$F-Q7GT1T*3FS$;[?>P:UL$#D702B6#KF>KY92K'4W#9K*/F\%M[!PS?PP@
MK,SA$NN'[MUIYQHD(X6\._7AI+0@]4*G!1]4,0:?5=$?RX>SR='@CKHE8S<7
M7"@1>\9BBV)Z%I17VHV+<H"[6->MFK,7TS(<2WF8K<U1\WEDQ-[2]LLU1"*H
M#B78QN(B*-YJ.PQD#YXG@GOB,A#H[^5Q\%O0$F*A>5,E9I]F<]>:GQR)>C,6
M(UNZKET,A[3E%9%XE=)GI+-Y:S'V#,_8VEH9"*NY/G[]7>U$Y,%QE6<>7UO5
MN[+B^,7,@K-^=<37($&R=;QD^08X;>TL1IRPM3HF:-UCM1UW/EC*0RO_\77^
M=EJU4!#G/_@'+E_/&1EG\=IM!C["%R6B?>_5%FE:NU[:,S6_GCIX"9NI O8<
MTPP&0M12P,ONWO]R(K+R3R@*:IHY0-Q+!F W1XB7"SW" S*2=]NFY9])^/'J
MS&272/C%SOB68^XAAFTS\-9K8X5J*#DM3H95')0F2-@[H$MP,[XQ\9X57]O(
M\J8F;=:/"[N*AM(#8?>]'NZ(=OPSFB.<FR= B[?&-S6P.L(4B(MKM,V_/!ZG
M@UXE+>77&&T63&$"[C@:=C+[A>_XUT3_Y07]' L5T:[9"K)ZP*&B/CX;=KCU
M2]NEO>"@99B!Z0GPP6?K8[:!W1 FT->\/6"U[[ :HW5Y82MK37K'Z/W6?C@:
M+M\>'4D\<O2WWCZJ'VSC?@1I;C)QYH$Y6/V8=WG[\HV<D89S5:%5=5IV)/HM
M[JZ D_WY%<^LVAXS\]>+8BN*D('$F9I+>ONZW[^6W) VRO7NO*4)6]*G4H:\
MFM\?2&8DN0)0:CU"3I#1':'3RL/NM=7QVQXLKO 8\=_&A?R]9!,;4/HSBR.]
MV/?;6B \@:W @FN$[1P5\20C+,ED !ZPCT.!+N(0%G_!'EN!K[V=?VT+HO #
MOSH2--)78*9-*ED'#6(.61/E,PQK=OIIBCGE!=CYGR";52J%F)\W$WRYJV',
MU@_:-C;.".5O+'&N?ZU8,C.P5**CR1YW7PLF<CV2VT!$)G:;]Z]*_.+@Q\W0
MNFC>+!/J>^'A/OBB5?$3V92&EN"RWBU5DU]PYTFLY?:1TMNW:<1#'XW2X^#!
M*R@R;M8?F?6W"9H0<NRZF3\?!V[*X?Y)T*VVGQ!]P?9;:8&;=^Z93''S@VCT
M4U^# /SQ)E+DF44P0J73\4 !:K*^APF$ ![VH;%:B14#8#:J!?WFI-_Q:R7?
M<_W@VZ NSJ1J ^9ZQG7%4K/_B,G]M^2= 8]?BXYO_?@P/X^N:FRZ&T7CKRFA
M/"F_A>PXY"<188M\0,&U"Z_SU]@$R/<KGP!LN9K?]+16NQYUB^-C%)//(357
MND(K!,0TCG0_B?\%U28@9L@7 H.-TGWR)[D1&M8N6<>[*P4.J[_MBH!9A\&(
M&]4 7M%Z7GHL\A=V- +.]EH3&^%*WXZ4&EM3IHH8LVW@@_QG9%M+T:Y?4^&F
MHB3M$)W%(TW$P #<G#E_3HT"-<=')BH=7_0G-P[>FH3A;W'S8=,8D_0JT8"V
M)6(*Y[ *;%B8_"?^]BCA[1N8>"]_1J^+DTH8QJVQ43-WSOCIX^H38.%RY0FP
M3&WP!""N'LK9-:Y^W/5\ N2E_OOC!70&&BX^ :Z&)1_$S*]WG@#<1S0/L2[X
M#R>;@2?*@<K(P"N5ZH=7.=>E#U9V_X)P/ '.3P+7"^X[FP,OQ9LEKV#)3X ^
MU@?V?P&17)WGO(%KOR^B<YX 7^N? --]3X"8V/__$'Z?5\[_RR&M3X")P2=
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M>Z2-FR.<[V:+^<1%7YJLG :A30!>M,:ON\ 1[U\T\%EC(IH'?WM,2]@]:(!
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ME5TRUVMKPW402YSW?2QC!5SW&A- , "30"J['QCC&_<QW0;/QVW?<7^DN(&
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M=0X^"JXP;&PL1[:7OI4Q.(S*)$ZGMO\ EH+?"LJ#+%%$\:P)J:H$<:O2B(J
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MS7HU6Z<<UYA5@![:+JFXMRXO;6&RFX<Y,;@8C#0GI^0F.FS<>,RFZED7U))
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MF,<\]KRUH+CWN)7P]N&^;UN[(H]VO+NZC@;IC$TTDHC;E1@D<X,& P;17U*
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M0/B+6%>BP06X $='>"T'RW$N#<&]RV$Z3[YC[TV^X4O^=+Q+HBOJ/]:VB/\
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MU9*X-)Z@$@+E*N0%2C9(!)([ .-ZS>]L;#)(:,:*GP"PMF2W4[+> $S/<&M
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M9LI'3D&<:A25.MX^&\VN0_(%_P##!O\ *#JKC:PK@9>5;';<D@XG+<-_U#/
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MZF(L5LZ)%BHC4DFNPP7+9I VXQB'V^*ZE=3NEFU/KH"V=E;DBM1TLHBQ&D(
M!4EEKF-A_3?E-N\VM6NZZM3-Z43?Y(S/\1[N[[UI.D R;]RQ]N#?T>*A:GY
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M.D8>2^/\=_;3DLQ0M!L6?\%9L"*[3[9;B^_X?!9WL8ELF:XF^KD8A@(ZG$Z
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M(^V_&6.F:QD;4=2!W'NZY'Q7C'T_Z<]0L+NR$]!WIE4X^1*6IYO&RG9LJ67
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MQ[5_:.Z]>DC(S%=&=\-=:=@R))D,PIBA@M\X\<OS_5P9<DXW)$BX2J-)O_\
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ML ;IJ'"F)ZD 8@^.':M)C9'NUP5)KEG0=*]JL;V @*:;R2<HDP9 \QEU0(4
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ME2'9D4[CB<\%60Y<G+L2$;AQ^W<1EFVV&<$)4DI5+";MA*V9+Z5R%MI0+%)
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MQU0"!YBC?@*Z3O-]#&TV-HX//[[AE_A!Z]Y^"ZURO>;:%AVRR<'/RD<W(?W
M>I_BID,,SAZ#+=*SW<?OKK([UYC-*9'4Z(2DD]Y''LJG):1R5P;&B1>PL/AI
M6!\%/!7!E)X\1>W8-1;7[Z5Z*+@S.7B[?Q,W,3TNF)!0'7_);4ZXE!6E!7R(
M"E<B";J-M +UM[F=MK;ON'AQ:QI) %2:=@6^VO;Y=VW*';H7,9+,\-#GFC03
MVG]*Y#%/;^Y,)N*,W+Q4YB2AQ(*4H6DJU%] #\UJVFW;O8;FRMJ\>I3%IP</
MA^L8+E.1<3WSC,NC<X2(":-D;5T;O!W0_P!UU#W+M*!_97)KK/<N4"_XVJ+*
MF"YTBP'?0HT=5=<7B9N6>+,-I*^0 NN+6&V6@K4<Z]=2."0"3W5M;BZBM@/4
M/F.0&:U6L+\1DNY)P$# NPSEI4)V9(6XIA#LA;+#26T  H:Y0Z^X5+ N;)'=
M76]SW=SF%D9:V+K6OVT^Y;RV@+C4 EP[%T$](=FYO.2Y!S2XC_GJ+N/@NI2W
MYINI9*U(<=2D<V@)L+5U66."ZT3OE()RQ<-797M[L5S+;FY@;A'@.M%E?$8/
M#[0@)@8UD(:N72H*+S\IPZ*>6Z2I;A7:U^'=7*0PQVK>UQ6RDDN+V74^M?L"
MZON7<#<JV/9A(R2_/3#5CVVT3'_U%Q'F,H>:4/I(Z(38\YU;Q(38#EXFN\;3
ML+2&7NX"CJ:FM. ;WGM)Z 9+L&W;:(!ZTA(=G7(:?',UR %%C3*9M,>-N*4U
MD(H_34HPD#R$_JVX&G9BO.ERG9"@&F7YJVU#D;"-!K8 "NXQQ:G1M(/F.HU\
MK<.[L"YV.#4]C7 D.&IU,&X# ?#O5.ZM#>XMHL+QC\AF+#CJ+^[<D(:X*WT+
M?=6M*G/*<R;2U70B]@KE2$Z:48PR$.H23] K6GW!6G^ZR/JT$N_<%:]*#N/4
M]E2K=&SKFT\MD(F?Q8>QF6D$MX7&P8K\X/N+4F+/E27U<[@0E9*6RH!95?E
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MV>C!$8[W2/IZCO&1![\BNMN)S\K,ORQ C--,J3]%^EI/E/1@XJTE;JG7 _\
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M'SE0XXU;2\ X&'#<W4V +&^@TK0-DPRPW+))/3D>:#/RG'#O[.Y:,UX\ $A
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M:?')6Z%E6=H9;)Q-T,PL5LR7(<YVUX=4_+2)S 6U$DK<;"9!88+G,X .0 V
M))K-T1NHVNM]3KL#^*C0.H\3T6<[72QMF@=JN!0  T%#GW*4E"]D[I9S>+Q2
M=U/9.&EHN3ER<="_2\DV@E:+ *\Y,58M=(;;!-QW&EMW;F&9_IAIR !-1_;\
M2A!O+?2*1D.J34$C3_:KGO&!-V]-C[CV]G6,'@''6G$R=MSD2GIJ6PE;\3S&
M'%+F'B WHV.*@.-:=JX2@P3,UST_?&7?CEXYK2AEANX?3N-3I&_ND4QQH54[
MF8PF\\6SO_!8S-SUORG8RX.7BI;1%DPT)N7EM.NDQTJ*=&P.?O34@,MI*;.9
M[6MI6K3T/9W^*PM'3P_[G*(VRAN!KF"3T[5?L;.R._L"J#E9FT\7OJ*XM33#
M*68>3?Q+322W(;C.N.*C.)4%#F "N5-P #>M&1D=I-KA;(ZT[ZD5\>JVWEV^
M?TW.E=;$8D8@.)R/P76]G9K#8U<K8&><W#G6,[D&$MSHK[DG'8V67"TA"!)?
M0](;?=7=Q2!R@@6"N-;BYBEE:+R/0S0W+(D? +.YBD9(+JS8T"-IKJ'U#K\@
M.JK'%;BV)N!Z+M3$,M-./*CS7\U"3+.0@(6%<B0%-LP8WRA15S%6ER0!:M,&
M"ZBU73R7 8 =#^M9RP_U"!DKWL9$/-Y3D?'M[EV'>F"3EXW^8,/N3#Q]OJ<8
M5)7A<@W%98FH2"IN2]!<5*DR$/<P0DE1_P!$5H6\OI.])\9=)TJ*FGQPHMK9
MSVT[?1N_5,[:TJ":CM '<HLS=H]0\<(SKVY'\OMG%I0^].Q[BSDV(RD(7(@A
MR0L+6M2P+.<B^!-0_BK9VMNEK'GMRJD#I+29P]%OX623RUP+2<@32G1<FT,J
MQFGVMDR-D<F(9$E>/G"<5Y%MXH6\LS&3&^G;1(<0-$*_PR1QJ3L<P?B/5!D.
M?]BU+J/<+1\FY!S8V8 M_=I6@^.*K\4]O+&YS](>Q&$@[2$@"9CI$3_5,7"5
MRW<NZXTXE]"!?FL$6%N6M%YA<W7K<9/UJ7%OZC3N1N6F0,\I;F>P!H[^GVJK
MR$'?.,S(FX[,8_&;72LO>4PS _0)$(JOS3WW_,3)_P (ZK4Y=/\ =M4U0.;1
MP<9?M6FQNW7<(N;F=_K-&1^H'L'B?!3S<3/9:4C<&U=Y1(^W(Y\P.X2="CXM
MDMV#PR)3\KPN#S!\D6[+5&NC:-#VG7W]5H6HVR:)OXYTHN1F#C7'I_8C*)R6
M\"Q/V=ON*8N-:83DD[=G,06V9;2 7Y$U+?E+<:6NY2I=VK<*C71Q^5["2<EC
M;?TQ[2V_]1K@\Z:XU:<OC1<F0<S.ZHT*-LW?,%Z=C&6V\[_EZ1#9F/2TD\S\
ME;#8<>:L #R7:*@:K'PL),C#0Y8Y?.JPA&W2/D;=&1L6OR$XC33 =Q7+E']V
M2,7%B;9W!@G=R0TJ1N![%MXN1ED$J'E>>VD.I8*FP0X4I%SQMPJL-N'DR!PC
MZ(R*QN)9(7R/;;U&C5D13'[<JJ4YW>&+P$.=#Q&!=W9YKGULI<7S%,,?*&'U
MXMIY"6WG[GYB BXN$U1^'?(07.$73]:S,;;F9]BRY)@#12N /: >Y4*9"<3@
MV-W9/9'GY]$T-?3PWQ%@ON@%SZTK=9?>C-\X_H'.;]H%9D%[_29+_+[_ +EK
M2?CGD[;!*Q_\KQ-*TI7KA]BMF-;VE9SJ#D6LKMU^-/2Y,B-,/2Y2ICZU.\D!
M^*$&6TX+\0W8:*%:CWW/_L[2UXIW?:M.<W%O$+22!CIS'F,](H*D=OPQ5VQG
MZKNK+O;FPV[W)>"+Y5)QN7=\J) BJ7S&+.Q<Q:6H90B_*M('>E58.='$STWQ
MT>1@1V]H6V:+&WMPZ5LC+K13#J1U'7/-56=GY+)90X$[;Q>0V<9*%PI.)65R
MG5V\O]0:EEUR*^FQ(\NP%M.8'6L8PQC?4#R):8U^Y6SAET_CA,TRZ,0[[BVG
M<$MQ2\-BL?)Z?X#+9/%9IQ\%UYV,N/"<;=;(=QS4]2EH9<?#HN $H41:]ZVM
MQ%)=L)D <TC'K7YYK" /O+D75VPMM71FA:,B#@X@"F&/?W+APR'=BLXQC).?
M3QFX+RI3RTNK#2(8;\U:RE2G5V"B0$MK4L@V.ECY!?1R0WTM&%C&R$-PH" >
MG: %H[A;QRMI"=0&1KGV'XK(@DL[BD+8_4\1F-L2<*EG(8)6/\Y];\Y?FL2)
M,Q3J5);7$20J,ML+2;*-N%:&HW#M#RQUHYA#F%N-33&M<J="*]:C)==TF(9%
MLM<#7]/FK_D,IB-MX$N2&&48^(TTRAI:066&&6PEEL)5=(2A*0D"LIWQPL9$
M&!T9-*'(4RS6,3))9"6FC\UCW"];MI9+(M8N.\&4/%;:!;E;2L(44$< E-TV
M[K&MI>74 MS+"80Z+&C7 TZ8A;AEJ]S]-27'[?VJUYSJ[C\>^XVF4E82H_T&
MX%_CV6K6M);FX:'AP *S?:"/Z\"GL_JAC,]GXT%UV[<I#J7 LD)YFVU.M*58
MV%E)M?30UNIHM<1%TZMN?JH5HE@:*PFKPLS.Y#!*9*0S&*+E*DA*%)).O'B>
M;[:K#M<#?3CCBT'^Z*GQZU6B?Q#CJU.KXE67_*>+>>.0$9 2XGF$-;KC22-2
M% MGG0%@\#[ZAVJVG(E:3''_  C(]A[EJB\F8W16I[5S0ML[?><6#%*9+*O-
M$=]1=0E MRK1SW#[87WDV[0*SCVVWBEUESZ#(5P^ZJQ==3EM,*%<DV*[!+CC
M+G,RH$%#20VZTJ^CC0!Y"D'^I&@(X:UR3RTMP(6BPUS6%-VY9AR2TTZI'U"'
M VE0'+YC3IY;B^I'.;V["*U]GEECN]&)@?A\1^O]16K<1!T!=^\U==X:5VU<
M6L:=6<ZYMS8^7R;0/.D,LBQL;/.I21X#6M6%NN0-6ZV^W_$WC(3D2M&,3U7D
MORTMO _XB_+3RJO=1-M?=W\*Y)T  P7=)]BC$=6] MC\!,:E,-/RE!TE*24(
M4>47X7UNHW%;4NHZ@R74IV"*730Z05DJ%FX<='(AB.@$6T0FQ%AHJXUM^=;^
M"2$X/ 6_CN+,-^D _!5QS\50&C0MI\OR>'!)MVURC(;"<:9&M_7]B/=82 Z@
M#\ N9G(1Y'*E+B>=7 $C7C8#76N+W':OPS#/;NU0]1U'[0N,N+:)@]6!U6=1
MU"YSI[^%<-1:#'%4R[ZC[/=V4K4+5+C1=?GL<P4+74.WPT-9!2-U!10V_*7"
MF(^;ELM*@1I\R2#^-'"JLHU-[ULC&?3)CLR$?TNMH6/ E(N/&RJV[CV]%M .
MU<I[K\?#V[:Q'<J$B; FUC[?"IX_2B=[C3X?;XT'2N2+C!'9\MO^^O4Q%0BC
MJ!X'\J51%"B*'[4141%$2HB*4JB=$64ND7_$TG_LB3_O4*M:#Z_@M*;Z?BMD
M:W2VRTE]8?J7W-Z<X6WIFW\[Z>X<O<4#,,X3;W6C>^[MEY#<^YHBXC>,QN*R
M6W=K;EQ>$P<J5-9BRLME/IX$&1*8\UQ*5BBR:VO:MRL3(ES,7C9>0B?03Y6/
MAR)L#S69'T4M^.V[)B>?'=>8>^F>4I'.A:T*Y;A1!!HL5<*(BB+5TG7A8_;6
MA6N(6N!\DOS_ #J=ZJ5OYG[:M4*5^[NM_/6K2N:QJH WN.WVUX6HA[4B1QU[
MOY=E%1E1*][=HN#;A\+T* 42UX>/WU%>]+\J(BBJ*(BB+S#]7G[<<KU#]1G>
MLO33U ;SZ+=0I&'@8S*XE6*C;NZ<[A=Q+?D8_(S,"Y,Q>1Q625&Y6GWHTA27
M4(2?+YP2KQ7W%]B^&^XMX_==PB;'N\C0'R!H)?I;I;4U!!  %0<ADOH[VC_,
MGRGVLVIO'#;0W_'6R.<R-YT/CUNU/#7:7 @N)-'# DXT6A&2Z#_N<^G9X2F]
ME8#KQ@8:U%.>Z+[J+6?##1/*_)V;N7]$ROF%L7*(QE&^@)TKY3W[\I7*M@N?
MZIPB\FCN&&K702.:\$>!8^OA5?5VS_F4]C><P_@N6VYV^=XHX7$0=$:_WVA[
M*?XM*[+L3]T_=>R<FUM;JKC=R;.S;+OT\C;_ %3VWE-O9)#B%!#C33F5CQG'
M.4C^I"U)[;UP]I[G_F6]L7_A-T<-VL(S]-Y&Y[Z#,"7RRCQ)<M[NGY;_ &5]
MQ(#N7$;BWC<\5#[25H&.56-+H_\ D@KT5Z>?N ])]X,1SDTG'*=";2L;)9R$
M0E=CS<I6AQ*=>]1KUGC?YT^-2.%MSO:+[;+FH!?#2XB[R6G1(T=< ]?/G+/R
M:\WVG5-QRZAO8!6C9 8WTZ>9NIA/P:MJ(_4K:>[MO+R6T,U%R[,A:HJUQEGS
M(RPVE;B'VE +:<Y%BUQ8@Z5]6<.YOQ7G^TC>^(7L-[MNLL+F5!8\ $LD8X->
MQU"#1P&!J*A?,?(N%<GXAN@VGDMG+:W9&H!PJUS:D:F/;5KA4$8&HZ@%=*<=
M)O<\?'N-=U& HLF@1,#>Y4#B[:??X\?NK2<35<?<2G)<2;_'7V[:TSFN+<[5
MCT7*.VW;QI7HM/%5;2;J! TU[? _&H:YE#57%I-S[]!VUA1%<VT_TI[A^5%,
M:*K;3<\-!IV\>S[*HSJH<EB_J!T?P>_)"<LB=/P.YF(Z(\?-8]RX<;:OY34Z
M(I0;E-H)-C=*P#H:ZCR?A6S\J9KNP^*_:VC9HS1P&8#AD]H/1P7?N&>X^^\+
M_P!WMA'<;2Y^IT$@\M:4)8X>:-Q Q(J#U!6!Y<KJ_P!''O/S$)[.[>;4!_F#
M H>F1DM V"LC (,B,JW]1*2@?Z5>+7VS^X?MW(Z_VMSKS:6FI,0+A3_SEO7#
MO<PGQ"^@;#?O;#W4@;M^YM;;;PX4$<Y#'@_^9N!0.[FNTD_PE9HV1UZVMN5E
MI,Q]J,ZL@&0TH*8YM+AYN_.R1V]@-=LXQ[V\>W:EOO/^Z7.6O$Q$Y8X:HS7H
MX4'\2\]Y=[!\@V@NNN/.-Y;"I]-U&S =W[LGB"">Q;,8;])9Q$K=V4>C+P<)
MD/,EQ9+4SA\X2$D.MW("1P4;]PKTB^W5DH;%8O:YKV@ZFFH<"*C21A2F-:KQ
M3\%-!,Z"Z8YEPQQ!:X4+2#0AP.((/16E'4+I[S8C;N'>W+EOUB<6W8V#9>=;
MC>:Z)#:I#[3(1%84M1&JK\J=;<:ZE=O:)FQN=("[]T8@GQ:"&^+J57*QQ35,
MCO3P&9_3[EE"=/;@38KWZDB+$9;?;=QZF&75S4K0A,8KD.J+L812DD<M^>]C
M6Z]0, IA09#'X+:11.EJ VI/7L\%U_+[R89#"(J&I8D_5)6VEP-^4U'9,B1,
M?DE?(Q&CM)((Y2I:E)":Y[9-JEW6?UGC38QG&N;G5%&CQPKV!<]8;1J'J35
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MW=+2DSJ#JLCJSR0FZ5]Y]_#AKVUJQXG%<:RS)-"%2N;BM_>[K:CN'#7C7(1
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M/"2UCW&I<56+_P#!RE480VD!M3?*V ;ITLJW;6$\8$;+>(M$#<*,JT  4T@
M -%,*#)=3<Z22=UY,\ON9'%SG.-22<2XN.)).->U61V=ANF.'8P. Q[$&0M@
M*BM:.%:EHYD2I\A2R\\5#^\HJ43IH.&M8VA+1%"-,+,^WX5S/4DFJR;&^[EK
M(ZI/:L1PI^=R\]R7.S+CSLV2ZP_&>=:0_$=BLN/*^FA-.+=^A>81S-N$!)[;
M:UV2RL/Q<QM;>.A KJ(.FF ))IG4C#Y+L.VV)<14CTV_5A]).7CW*_MR79SN
M/;;8ASA#VEE\B)(F^3 Q[TU:DH==*R/U;)?3K\M24GRVTA1&@%_3+.RAVZT_
M#15#1(T'#S.ZD_W03CVY!<V=#2'-JQIDPZY8"@Z ]3X]JZ>O(R%;>V?G,6I>
M5G8C(RV#D]Y1_)PD-46>LR)D=I:[?IT5#W(R24!*6R;7%JY70W\3+#+Y6.:/
M+&<3A@#WX5/BM01X2,=1K3CA]9J.O>?[%49K)8K;>]V<MD<CELGC<]$?@P(6
MS'42\4MO*M&,QD'6DR6HKK <<)'S*<*_=6$,<L]F8XVL:]AJ2_!V!K2M*HUK
MIH1Z;:R-H?Y@H?+F/'[%62HNX.F>;0K$+QF"VU)E15[IG9S%,.QIN.*QYC[B
MWDJ,?Z5EQ9;#9YU*/;>U8M?#?Q'UM3[D Z TY'],ZK$Z+V(2&I<&^4-=B'=F
M&=<!16[=!P6VMR8;J3"EN[VAJ=<E8F%MB:6(LN"KS&E-*=(1%C16N;5)25*6
MFQ3Q-:EMZ\]N^P<!$^E"7"IK]Y)59JN8G6Q!CE.!+P?*1\SX#O5XW&QN''(P
M>\>FV)=VVK*8]C)B;F(D;(R([,QOG?@K0ZA4-IODNEQ9)NDZ$"]:,!@<7VU^
M_7I)% 2 :=>WP4B+;@.MKTL<QKB'!ITDD9'M';XI;WQ^ W_@XNZO\WX7*L8Y
MJ(WF(6WG>81,\VR/JFV\?# *Y3DA*@VI7RVX*":MH^:TE-N(G N)TEW\/2I/
M3M6E;2.MGF"5DP?0TU XM)PI7*HHKE!R&#ZC;7EY/';,SK.>VXW QCK.4?86
MS-;;84S'GO/Q2Z\0M$>ZT !7,;!5M:TY&36,X9)*WTI*G 9=HHH&W-G.+?7"
M8GU+3B*$FI;B!6E?!7;9N9W;G,5/VGO+/;7Q<]Q#;&T7)<3&XC(%MLJ2Y QX
M?6%O",R &W.4K2>!O6E=1VL<C9[9KWMS?B2/$T[>Q:5W;Q6<XN(Q-Z9'\S22
MZA/[QID">BZ1BY>V^DNX\MC=S.9W.JW#SP<M"P;KF3#!>4E9GY)QY]N,IQNV
MC:5*=()N!I?7E=+N$+70!K S$$X? =5N9(W7L+9+#T]<(J"^C:C^$"E23WK7
M3U'>M7TZ^DCJ_L_ISE]TX[ =0-YXC"[@VJQN=IA*)F+W!-?Q<%>+Q'U+$S*J
M?DLN,JY3="QRI2I=J\+]P/>=_!^16G'KK9MTW"REC9)<7%LT%D#'O+!G_F/;
MI+WM\M&TH230>K<$]JMR]R.+W&[,O;"R$<KXFPOD#997QM#W 5^@&H#30U-<
M@MW,LSN+?&TL5N+:\3$8V7.BK3E\AMTJER6WBHI2<>X^0]CDNMCF!Y?.%[ B
MU>NV\MK4.:\OA.+:Y$=X^]>01!\,[]MO;D@-(HUV1;V$]QJ"*JS;=FP9F(7T
MNW=U+<_S"^\ER! R.3D.3%L%'*K&3<DWS-H\QPW3'==YN\<*U96XFXBC_E5S
M H/@I<VUO;S_ (V* R663W,!#6N)PT]N1K2N=%U6'E-@=+LQ.P<C&9/<7ZK?
M&YE.WF$&'!0'0KG=>F*8;GR&G&Q\C7,D"_S7TH7OG;J#@W2/WCBMU/2]8)K&
MC'Q'566M74%-#6XYUQ)IT6@OK8Z<^M8==>C.Z?2)NW8F/Z+F+A)/4V#O-&?Q
M&[,,MK,&<_D]GQ\3&DX_<:LCA70TMF4Y&+$A%B5M*44^#^Y7MEO7+N26/*+'
M==QM7638VQPV\HCB:]LA>Z1S?WC("&OK4EK0VE"O9/;CW#X]LW&;W8]]V6SF
MFN'2:IGM<\N:8PQL8T@EA8X%S:T%75J"%Z69;+9!O;.)W5MS9C"=PS6S]6]D
ME%6-@38Y2E<EF PE)?4\Y=24*6E*.&MK5[>QTCP/4) .) S"\;C.XS.=M[WC
MT@T5P ET.'>?AV]JN,;,;PS6SW\_*V;@W=W1'T,?7-IE)QCK9;*CD'L:G53S
M2[ H#G(3J;<*M '::D,/3"JT6QWMG,W;HYRV)P):'$:J94!_=.=,%+:V5W]F
M\)F']T;<P><S./9+F'FIBNXT+5S'_9I<>+_AR$,-_,GDY%E(L=-:CPT'R5:.
MRM5C)!<;9(R*VG]&*4_2YP.-,ZT\H)ZTS*X=G97?V=?RD;>>W</FXT.-)?QG
MT,-6'?A+903'@A37FH=BNJ 2.8<XX@FH2,-%6^)K56:VN-K F@E,9D< [4X.
MU$GZLL.TE4VW<]NW<6=."W9L_#_H*5K;A)PZ'HT[$-H"UFSSZGA/#G+\_/R'
MFU!'"LL6@.:2#U)5DM[^P8^_8^LKA5^L@M=V4_4J!.Z_UC--[1RG3M<#;:99
M;B3HDSZK+LO.+\OZJ7'=:8C.M+L.9""%( T*JR&H#4'5?UJ,%CZ6Y,>Z_>/4
ME<WS-+1HTC$$&OQJN+,Y_ITV_)Z=+P^XV(;TY/U>XG(+7Z69D8K99#D-AQR:
MN&.=5W>4D&QY2-::GCSN+:]G[%M_4FN)&WD\3/1#:"-H(=0T.H&F)RIW*]-*
MVIL.#.V3B^HC.&W%G!'$2+#DS$,0RX4.A?UBFC"QDJ8T4I2HK0L@ZVIJ,AUN
M9Y1\2M"86M[*US()&6K"=;SB0:85'8#FNR[7PN]-LX?*2<Z6]THC1W7\&QGW
MBY.?GJ4%);CSPY]7+BJ22M2+KTU3:M-[VO/E-#W"BQN!;PN9;[?<^>0T(;Y6
M@=]<B30+K>$DN[XR$Q_J'MR/C'X<=Y\Y;$1W%P4P832U&/*ANEQYIQIE-D+0
M5<]@" =:NIS&T&7?1:OI7>TV]'Q,DC)PUT+M3CT[17%<<C)Q.HV3QD3I]NC<
M&-&W&&XD;"S''\<Z^&%**L@Q"<=6Q/86%!)20I:4BRDA)K2J*DN(#BN-ABM9
M"Z2^/I2DEP+0"*'+P(7>=Z9K);2P</"2-HX_+RLY ?B[AFPWEQ5,-N'RW$1H
MZ$J0W*=;/,I"E)3W  Z;:ZC=<Q/@:X@/:1J&8J*56EHN;^7U+=SI8(GB@-*D
M4S/=T5PQ;$0L09<'F$:5':=2RMM;3T>YY%,O-+ 4EQHI()U2;7!(UKR.^L;O
M;9A;7="^E00<"WM[1X%;&\:YLCFN!#@>JI<_B7NH6#E8[!Y_=6S)6.RKK"9[
M43Z)^0_$'(M:(SJBF;BWRJZ%\R>:UQ7'7EO-?VSH;.XFM9P:"1K6EPIG1LC7
M-<T]M,>A6RC>+:2LK6R,(RJ:?,8@JJV/BM_;+QQQ65SV.W-]8]+DR=RYF2["
M=AFS34>'%BJ^J6;M)Y^-N<GLM?';&;M:Q_A=QN&W-P:GU-#8A2N TM)Q \:F
MN0P64QLYAZD;7,I^Z/-7[E>=V=1,CLK;T+)9",,I& 1%D9."BT9R0%%OS24D
MI1YBAWVYC;PK-F\.LX'NW<LC9&:.>6G2:F@TD>(_6L#:12O)MZTZ-KBL5,]5
ML[N7*JCXC&2'HI=:2="4H4L(44DI!0DI*N_0U8]UVZ82,]?5I<6GL^'SIX]X
M6Y%B]M'EI&&96<<#A<RA,F2^_P"2I\<H;>)38H5>P3J; \";5L=H.X;@"^)H
MCC:2 7&E:'L%3\UA=NMHR&M\Q[L5C#J?FYF%BNXW-Q52,?E&W&&WVU<S)6!H
M4.?]4^TJRD_WM-*[%;QSMD#;AVEP/B#X%:+!&6&1AR^>*T]P^2>=S$=3Y6J+
M%E)>D.$D!:&%\P0%&P*E*2-.ZN%V;D%WNU^^U8#Z,9<'.Q#<"0*'K4Y+<36T
M<;!([,T6Q<B)NOJ%A'WH<(18J6ER(4V<LQT3'4<W*U$%E.NI<(*>>P;'?79P
MR.WC<(G!TY;AV5Z5*VVMM: D#KX+KW3C:ST'+)<W#Y8GAM]Z+CV70])B+93R
MNNOE-T%Q"";!!5;B:TF2WK["DPK-J\PSP(I0'+QIAV+(LC8[4W*F"R'N'"X?
M.X]^/DVFI;N+D?50) /EOB(\.=V,MQ!Y_++B5:<+FN1V[<G6DT>FOHO\KAV$
M?V46E+"7M-/J6&]]=--K[AV5NO$,XB(U(RVW,K%BS6V4+FQWWH+HCR([Z[K;
M>;<L000;UWJ.:5CP6N(Q[5L[.]GMKF.5KW ,>#2II2N*\#\+MDM3Y,6:'$R(
M<AR,M02.<*97R*46W 2H%7'@;US8(R.7:O8O6!:'#(XK;W8NYQB(;$3((6IM
MM"$ID,F]D@?+=*K=G<36RECU/JU<5?V1G.N.FKO6>]K3(F[)*(>+G)2^M:$$
MR$J92@K-M20=+]NM#$^-I<X8+@+MC]O9ZDS?+W8K83!=(8D5Q,C-S3-6DA7T
MT<%+)(U 4XKYBGP %;9]ZZFF/!<#<;W,]NB :6TSZK*B(S,5E+##:&66D\C;
M3:0E*$B]@ --*VM23J.9*X-Q+CJ<:E<9![ZI4!"I5=HTL!]W@>-!W+5"I'DW
M!T]VONO]M99CO5..2M+J>.GW6^/OK(+)IZ=%V?9\\PLFTVH_X<B["KFP'F'Y
M5=WRJK"0:FY)(*BHS69+D\1<^W8.^MMJ(% M'-=7W/O3:^SXJI>X\U!Q;24E
M26WGD&0YVV:CI)=63[K5U'EW.^'\#LOQ_+=PMK&"F >[^8_NCB;61Y_PM/BN
MS<9X;RCF-T+/C5E/=25H2UM&-_Q2.HQOQ->Y4&R.H>T>HL"7D-I99K*,8^2(
MDY"4E#T1]:/,;0^V22GS6]4G@=:VO!/</B7N3M+]YXA=?B;.*7TY 6.C?&^E
M0'L> 1J;YFG$$=<"!N^:<"Y3[?;C'M?*K;\/<RQ>I&0X.:]E:$M<,]+L' T(
M/<05W6N[98KIR*(E1$7[^Z_P''[*(C7NM5P1.HBC?6P.M*(G1% J%[7MI>_&
M]4)193Z0DG<\D'_S/*^(^J@V5X7[JU8?K^"TIOH'BME*W2VR\X_6ED,KNO>F
MW^BV!R>78D;IZ6;RS.YL7(WIT&Z:;6RNS7LKC-L9*,SO'JGT8ZO[S=W&^O*^
M7Y> 1CT0(R_/>D-OKB<\63>U>A&#BM0<+AX4=HL,0\7CXK+!GOY0LM1XC+3;
M1R<E2Y.1+:$ >>X2MZW.HW)JK%72B(HBU:)X>'\ZT .IS6M7%1TXU4ZJ).E^
M.NG9;^-%0,4B0;=NE$ *C\*BJ/NHB**HHB*(BB)>-,2$1<#7L]QJTZ(E?32Q
M/9V>_C[ZAPR1<9U)]N%9T!'<HEI[=G\:E:##)%3RY B19,A1L&67%\;7(2>7
MX\QH3TZJ@56OTM\.NK6?F*E*5<WOQK5;@%SEL/3B%<U;^;N%N_[_ .-0DE:%
MQ)T4DZU,L5LCB/%<Z$]OL*@J<UA3HK@R@6!\./OK$FGBHNK[\Z8]..K. .U.
MJ.P=G=1MM*E-S48'>VW,5N3%LSV4K;9GQHN6C26XD]I#B@A]KD=2%$!0O6WN
M;:WNXC!=,;)"<PX5!6\V_<MPVJY;>;9/+;W;<GQN+7#XC/P."T(ZB?M+^F'=
M#[N4Z<G=O1'/.%3B'ME99Z?@0Z=6PK;V:>?;:80JWR,/LCET KRKD7LOPO?V
M$"-UO(:_3YVX_P!Q]?L(7O\ Q'\T'N;QAS67<L6X6HIA*-#Z#_SD8%?]II6K
M>>]!GK/Z/N+F=-=[[<ZR86,5*9@IF.;8W/Y2+E 5!RKB(+SQ1V-2EGF[#7S5
MR[\I]ZQSKOCKXI7@DC0[TI/DXAI^#ROJ+BWYPN!;XUMIS*TFL92 "YS!+%7_
M !QU<!WN8%Z*>AV%ZAV=K[IE==MLY+9C3DK'1-L;?S<N+)RSJXJ9/ZGEO*C2
MI9@X]T*;::2X4K=*2L)"0"?7_P NO!O<#A%AN5MS&>1VV2R1?A89"'/86A_J
MR8$Z6O!8W2:$ENJF K\[_FAYA[6\LW+:Y/;UT<]_''*;J>-I#"UVCTHJEK=;
MVD/<2*AH<&UJ2!O:. [*^D5\K9^"Z9OCJ1M+IU$ARMT9)N$<BZ\UCXUT_422
MPE"GEH2I0"6F@M/,HZ7('&O-?<OW6XE[4[9#N7*))-=R\LABB;JDD+:%Y )
M#6 C4XD"I %2:+T#@7MMRCW(OI;+CT37,MVATLCB0Q@=4-!H"2YU#1HZ DT
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MP^Q6_?F(V#/$;JE$W WO6-*DJD8LXM+TW)/O,*2Z(+(>2E&+0Q<!7F>6EL<
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M9&='W2N3(CSF\\W!6HNG',I\G].D?2H0$E0<*B23K:M.Z8)K4;C+,6SM &D
M4TU[>W'P6G/HGLCN$EV1=L(;Z;VDC16@)<>HSPZ855)CI62V)GL[MCK'U@&
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MFW,OS4)5\UKD5M+R*""?TVDR0CKA\EI[CMFU[#R863)Y;W8FAKJ58),:U9K
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MQ*X.ZLH[<4?]1R"VOR;*,!E&Y^V([LES(Q6L4_CFE^:XZI!;\A]L:#G/)\_
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MD:]DTDQC#'-((<29*X4Q%#7*AJN-W?W<_+#:;;/'/>6=Y&Z-S3#%$9725%-
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M'+PK9P3;?+9NM9H_4NS6CLW:N@%,O"GS6PLCLTVT2V5[:>MO#P1'*P:G!^3
MP-.&-/+0U-<\EU#?NW.DO3G-XGU HW"WOQN9E53X:=G9"/N#);F4\EQ+[2I*
M'U-QXS;3A#JGE)2BP3:]A65O/?7<3MG+ T!M#J\ND=X[?@N9VB;D&[6SN%Q-
M8US6 .;<-,1B (-75&=:4H"YU?BN?=^_<4G;^VNJ?I]V29F;GNR71,WGC.5O
M KCK5'R$%W&09*CD)JB5-\WFH;"#>Q)%MO! 67#MOW.8LB:!@#@[LH3D%EMV
MUMCW:7C'++I]I:Q 5$4FIDA(!9H<\:6BE#D2,J#$CL.]H/6#K9TWVMGL''/3
MN7)YG<[&V<F;CI$O+P)2D#_RB7G,A&@E;8=0RA:-2.;F K2A?8[?>/;,WUXO
MW2:' ]HZGI5:6V2[)L._W%ON+&;IM[32)SM+O*1]3F8!SA736I (-!4X-W8^
M)ZT;9QNUM^]5L#G^H?3^"]'W#B,MN> _E\8TA3KK60G8]V0D_4B(4AU907$E
M-E6-;8WSK.Y=/9,TVSS@""!\#XK&RWN?BFZS;SL=O+:[3=OI'JA=Z9'5C)!E
MYJX G"G8NL].-[] ,R]_R4GP-V2I.W_KF<)NA&#:5@LXI!=DR8..*YC4UIM+
M@4EEQ;:$/=G$5I73+XUW)_DU$$T.708+D=]V3F6W6S^?W$44<-P]I?Z<NF9F
MJC6ES*' X5!J034TJ:<.PNM&Z\'U&_Y>Q^EFWSTOG34PXD/)_J"MSL27%^4<
MU(R3"_H$%_Y0J,EJR4#^LD$G1EA:ZV-RZ0/F/ACV!;G<^+V$_%'<J;NQEWP@
M.,?E<U__ )NKO,7#^(@"HH&@*.>@^H[&]7H>X<)G<KMK$PY*FX^W]O(1#VJS
MBE.A3S,_'O-O)R+DAI/^*](4M>EP4@ 5L?Q%L(_3(I*?O6G8R\ =P^:VW2T>
M[D#F&DI!U!]/*8W-HQK >E,?WJE77K!T"'4Z6.K.0WGA<W@&0)<G<4[,P)>'
MP<:,0IZ+'E(D*@8IN.I)!2@(5S=A-;%SG9$']/E1:7#.=3\7L9-BM[:*:ZF%
M*4+9'.=@-0+29,Z- Z845'@\EZ;NN6%RL*+O.>,]L+'IC91W(8+-0Y&=QN)2
MED9' ./12[EH3UK)Y0%$D:6(-8U<?I()ZCO6W]/FGMY-'>2P2V<-\XZ3Y'1E
MSS@US2ZC'@9 D&@Q!H:=<Z:=;.GV;W<>CD_I?FV=D?-'PFZESHB\]]:2?.E9
M+;990U!A3%:)2F4IYNPYKDD#0$C7NT8AW;T_X/%<OR3A&_;3LAYU=W=O+>%P
M>]C2=8K059*TT<X8>4-#: @%U*FV9GK#O?I]U!QNVNG'3?;\39#>0>9S,+=4
M69.SFZXA662I$J"_'B8!A*+J:2E,A878K4?Z1INE<Q_IZ=0.9_8M?:N*;/R'
MCLW(]UW9[-R#*@ M<&.I4-DU^9Y[0T, Z5.*[9UWW7U.P;D!SH_M^#T^AY-O
M'39N<CXU&X,Z_(4IJ0_":<GQTP($$.#D79E3S@%BM(N*TIY9!_[/B[OQI\%P
M?!+#BN[.E_UA,^-[0=# [TF.:!]6JI)/8UI:!A4%=DWGNOK%*Z68G<6!VYMK
M"]0),=YK-;NQ^#6_-0V$E#,_#XF4Z_C861DA))<4AU"57Y$ \-">1[(=4 K<
M4RZ5ZT&1[:+8[3;\9=RN2TW26=W&0^D<E6M<X84$D@;J#<P'#27=H5+T_P!S
M]8'^E&0F[KP.#WIO/"--M[;W)G\4ZS-<2E!YU9R)BEPHN6<A#E*2$LDW 636
MG#/.ZW+[EH_$]!6E>RH_X*K/D5MQ:#D\5OL<LO\ IUQ E<*2&/''TG.!.FE*
MUU!E:JP=%MY]4MT?YDB]9,)!W_ AF?E,;*:Q4?;.5QLQ-RWBV%PHSD1[%N*"
M4H0MHN-\0L\*V]E=75R7B[8&4RIA\,<_'HM[SK;>*;.+>3B4\DTK@/4:Y_J@
M-/\ SFINES3_ !-K1W0"BLNT>K6\=^;[G[)ZA=.MN1]CR'6H>&B[5:GM9O:J
M4%23(D2\B\Y'SR7PJ[_RQE$@%! '*=E:[K/=WCK&2 L8"<2:T_Q5I4'NI1;O
M>N+[1L?'X>2[9N1EOZ Z:-;JKTBTU<PCL=K!'U4.*>X.L'3:+NAWH\UTUW2Q
MLLN.QIV_7W8;DK]3;7Y464-LL(=D+PS2N8*6'UO65S!&G+6,^]V<-V=JE:ZI
MPK3R^%!C3^]V]H6WLN(;]N&U,YM;W,/X@?S&MUDRD4S+S1A-*_RZ =*@KM;[
MG1;H6\WM^9U3QV&WGON$<?AW,,K(@8Z#E4!;,K.92$RF/AH[J5)2V7U)(4NY
MY0#6X;/8[5)Z,LK(Y),@YPJ:X"G08Y5S/5<+?2\DYO$+]EO+=6UJ020S^6"V
MA<""2YY(P<&Y#H311Z4=&=^=*I>Z]S8DS)^&D0YV6E0<L_(S&!W%)$5QZ ^Z
ME]UQIZ0\]R\CK"TNN)-@H@UIV<-U;22NED,L5"0W'/,9Y?#-;CD7(K#>[6UM
MX8(;2[:YC72 -:0RH#@T#ZQ2I (HT]]53]/-T;]ZF[ICQ>L&VL?F-O,RBSC9
M.UL C RML-!?,IM$4O.-9;'%0YE!Q8>"OF"U?TUH[;=W]Z2R_@8R-IP-*4/@
M3C\$Y-9[!LT;9^-WMQ+>/8-;#(':P?[S&C13L(I3*ASOO4;>71SJ'D,KT#Z=
MR,OC\C% 7,<GP',5C]V2VRI#F,QT_P T-29,8"X:)!=N0F]K5O)KZUG=)M<<
MM+H#PIV@?K_6NN;;M^]6 M^57-LUVW%]1D[/ .=7$5_=)P\,*]VVAC=X=#.F
MTK(Y';,7=D?&(8A;2Q^XC)0[!D.%1$;ZYH^>[C&?ZBTJ_(39*D@VK.)Y@LR7
M$S/8,,P#W5Z^/1;;<K@;KO#?1++-LSO-2A(KF[3DTG*@(J<<,:VW9"-N]73/
MW?U(.)Z?9N !-S_U+C@P+C25)#<O"SEM^8@@!(+"AYB3_25 Z:EO<MNH?Q<K
M!&YN9=@!3K7##Y46QW&([/,=NMIY)X9,A&!5U<*.&.DDYY@YBF2SQ@''-QY>
M-N9K>^1W?L9UI&!V;!Q*Y.0QK(2UY4B?FTA* P\/IE K<)* 1?4UU+=-POSN
MT@?(7;<\,$3& %N572N('4B@-:-&!Q-%U:]C]"'T?2].X:ZK]50[N;B>F9PJ
M3CDNM[@W7A^F4S+8W=NWHB]CY.[\3&8?#0WY>6E/+2MV9D\B^P]):,60!RH1
M\Q-K%*=#YYR7<.+[#;S0\ECMXMHO'^4MC+WR2GS/<_ -:0ZFD"I=]51DM&)E
MQ=EDMJ2;F,8@F@#>P8]?@M>-_P#J>F;:\F;-&7PT7(-?78V%-87!D?IKKC@C
M.!EQ+2E-\B+<P%M*XAGNG"V.+79OM_49J:)V.8]S*D!X#@,#3"@IWK>C8I;C
M5H>TZ30Z:$ YTKVKL?0'U.(WGO&"^94R3C,8W-GY3S>9QE,2+$?4HJ5;ENMP
M)2D=I-<K9^X$.YR/LS'&*1/D<X?NMC&HN/8!1;*XV66VH7N-":?-;H__ &Q^
MW'TDMK6$*U"2A/ FW^GIPKNFT[M:7MHV:UN;9\3A4$.[5P\]GZ;R#JKX%7#%
M;[3U :RD;"9!$*9"CID1E26E+CNE:RCR7%MJ*VAS6(("M">ZM\Z.$O$WJ,+"
M:$-.%<^F16  8*$$_?\ :L&#9V<ZF3=T&9.CX7<.W4IQ7))94Y&R >^H<##D
MAM7,&D!',A8"QRN<*ZYO-M+N[9&[3)^%W&)CX27C4QX> X!U*$MZM(Z$X&JW
M<4C8=)F&J(D$4S%/UJU;8V'&Z<QG9T['(DS2DM/S'64/H41\JVD**>0,]P[1
MQO6TX+Q7:N)6 V^'S[DX 33/IK>>H'8RN31AU-2M]>SR79]75_*&( Z#P[>]
M=<D;IA8Z1+_1HL7%Q7GU2%1H;3<=D2';J>>\MI*$A3JC<]I-=M.Z;18'\-"(
MZ9G2 T5)Q-!3$G,KC:3OQ%:=^)7%A=ZR9F?Q+(EK+BLC%2@\Y6$E;Z$WY1J0
M >%<A9[O:W;S;QM;1S2/L6C)%,VCW$Z05N%&QV2QF9;DRLA#G8QZ-)CR&O+<
M:<2M8"HY"5E:5I#B1J2"*PBEB; 0WZ\#A]J..L8"A"LVZH\#+Q7,;-)4VZ%"
M%**K2(;Z05(1YO\ 4ME5K"^HX<.&YMKC'U6#%N8[0<*CO&:Q+,--<UT?'(4S
M C1UK"W(S:6'5#@7&KI5[@;7'A7>X7A\+7-Q! 7#O:6O(.:JE"X/N(^T5J+$
M_K5$>)[=3154JAQ%[^/OK#(H,E1K20>/:?<-?SJ@BM45(O2_MVUG7'!49JF7
MV?'\J-62HG1VWU'#QX5GT5/:K:Y:Q]Q^[6L@2J,"J0+Y%IU[>'VUDM2E0LI'
M?.V=O8;&.9S+,PW'P8[$=*7I,M]3!2E1:B1FWGRV@*3S*Y0D7&M;5S'.=1H6
M+(9920P5IGD!\S@KY#W=MR<VAQC*QP%BZ4O<S"^SBEU*2G0]M002DT#22M(B
MATG-=5ZG]5-M=,-E97>.4FPWT1$H8Q\(2V$N9+)R3R0X;0+@40I?S.6U2VE1
MH^&:,_S&.;X@C]2U[6W==3")IH,R>P=3^SM*T6VEO:"^]F<^ZJ.G,;KR"LUN
M'(!253,G/6E+39F2"?-<8Q\1M$>,U?RV&&TH0  ;\A8-;)EB0MW=0:CIC!#&
MB@\/[<R5W%?5"!%6I!E(;([%+"="+@\;6/Y5WS;-NN](? /*5QC["4BH!55B
MNL>WI#RT.Y>,A32N504\D *[C<W!%=O_ *?<^F/5B<"1F!5;4V]U":@$A:N>
MKKTTXWU88[ 2NEFY,;MOJQ'S&,BRI$>2RW&W=M5U]+66Q^2 4 WE<7'69$64
M05A"'&E!06@HTW[I=<<M'SN#C;#I0^4G(^!.!';0]M0<Y[]#FEH*])/3UT+V
MQZ>.EV Z<[:Y9!@,H>S66*.5_,YAQM(E37"27 R".5I*B2E U)))/C.[[M=[
MU?/OKMQ,CL@>@Z!;MK0T4"S=7&+)%$11%E?H[_Q1*_[&E?[U!K4B^KX+1G^C
MXK9FMRMHM#?6GTPZF=2X^#B=,MM]6<EN?'X+.O[.W1LO?G1?:VT-A]0%A+.U
MMU[DQW5#'Y[,OS,-+<\\2\1C9C[41+J$MN.+0VHLFD#.E%N]@V,E%PN(C9F2
MS-R\?%X]C*S(X<$>7DF8C3<Z2P'O\4,ORDJ4GF^;E(OK18JZ41%$6J=:"W**
M(BB*)-AXGA;QX5:(H D::&_?V7[#5SQ42O:_L!XBK@B1XFE?DB.S\?MK&J)4
M^Y$5#@JBB+E+[QXO._\ ZQ?\:NHY56.AG8/DHEUP\7%_%:OXU,2KI'0!0YB>
M)5\2:N*M %TCJ!(+6VY*+G_:GX\?7_1*^=8^(;H#C1:L7^8.Y8#6 5_9K]AK
M5&2US4%53*""#H0/CW]ONJ$J*XHTMVZ>_LK$*%5K8TOIQ_$V^/"JM-7-'"UK
M?</85B:5JL57LIUX"P%SH3W\*Q.=5.Y5R+7^'MK\:B454T+J]N-4*.56GC\*
MJP.2Y@*A6317P5OR^6AXJ!,ERB2Q$::+[:2.9P/N!OR]>"2@DJ/=I7%;E>NM
MP(HR ]S22X_N@#-;RWA$A+W_ $ TPZJV.]9MMR-NSL!';5!8EXV3CHS4&,E2
MVR^PII"8;3)L)-S="K?*H7->>7%Y R7SW,-1C0'S5Z4'4UZ+FFVXKJ =6O8M
M<=M[B7T[G0U;XRF=W1G<Y$G0L:]%<(@[;:2"[]1(QR4O/2'41UA(62E"UA24
M@$BN-M;>[V@0OWV\FN-PGKY&@>DP5#J:11Q(&'J'O "Y0,9>"5UJQD5M%IK5
MWF<3A2IP[]/08JESVX8VZD_H\K.P7]H[IP&[,'F$2&W&<IE]QPUM.0=HX4K_
M ,7ZQ<2/)7("; @<I/RFOH?B>U?@;-NY-:[\3)Z3VBE-#""=;J^(I6B[9L5E
M)MUN;MWJ"_!CD;1HTM94G4[.HJ6$' 8K$FXMQ1<#A.DW6KJ'M^=".WV9FTD=
M-MD3&W2V,DE_!H>G1WGA_BQ\,RS(<#X ORA U!KNT,3I)+C;+-]7.(?ZCQV>
M;##MJ,%V^UMG7ES=;)M\D,S92'^M**&D='&A%:5>2*CXJ[26-P0-W[PV;O\
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M,<5S+1&X@N 6*=]>IR5& 7]9R):#A+GG%OF24DW2DZVYDFU[5[]Q:]M8V#6
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M?Q%E(TDM< *$4P/:,:A:<FT[5L6X6DMR\7^V3,<7!K=)#FZ0 \-/F:2:CK4
M*DW/TZA]5=A8O<_6+J/C,IU)Z68UT[L;A92$K/XAZ#,=DQ'U8*&M#[&3R$(,
M'Y&TJ==4+G6M.&^=873H-NA(L[AWDJ#I-10C4<P#7P"W-ENLVS;E-!L$).U7
MLE(62-> X$:=+7N!#FAVK DT%2GE.K>S-Z;+'5+H-LB?-ZF;9S,>$]#WQAD,
MMX*:F/YCLZ3'BRU+RK<N(I?E)2X@74KF/RVK1;8SV=T-NW64-LI&$^1V#A7(
M$Y8Y_8MQ:[#<;3ND7&>27/X7:YXM8,4FICPUP\C"YM&.#Z$U&60Q5=NR#UXZ
MZ[#V/OW;3D_I7F81E/9#';(=FXA#V>@2W8JI,B6'5378GELA;3*U%M"5G0WO
M6VADVO;+V6VN&B>' -<X!V!%<NW'-;K;7\8XWO\ >[?NT$>Y[>"UL<KVM=1C
MF-<:M%*/!-"\=@I3%4V^MB]*NH.WW>L.X>I6#W)N79T+&(WI)PF89S>?B;@Q
M+30?QK$",\Y),UZ<PI+*$V;*CQ N:PM;V_LW?@8(CZ,I=H#@6X.RQIB*9G-8
M[!O7(MDD_P!/;9;N%M?/D,$<['1ZF2$T.LBCFAA%2<FC%<<_JWTWZB[!F]1N
MD6P,U*ZF[>GPV#A]W0&(L7!Y1UM<J+EY*X,E]>3B@L%2&D*;*ECE4I-C?;&R
MN[&9MC>S".VD:3@:@C(@5R*UV<6W;CF[VW%.278L=HO(B[U(I/4C<QI <QH<
M &O)(%#0 &M#DJR5N;K?Z@>CS@C8F#T]WECLK^G;FR^RX<S%Y#*-(CLR8[V.
ME//R).&;E*)#P84%$IL% $BMO-%M^W7P]0F:W+:CN-<C3/+!:\NU\7XAS1L.
MXD[MQQT#9&%P:2U[G$$2M;]8;2HZ8U(P5;"Z2[DZT;!PW3CJYU!;SF^=J.RI
MT'![FW+$=SKN'<L(65>Q<R2B3+#"0IM+ZT*4$ 'FUO6SNKR"*[-Q8L MC3"F
M1ZT[NY;=O*MNXIS"XY#PVW;%LTK&-T/C>UC7TK(UC])TU-"6_J76-@YOTQP\
ME_\ :W[FW1/F;DP4N6WCLM#P$N=M9R9*<4Z_MV'G6!Y"Y\=U)T2DM%9*0OF%
MJV,\\[I3<-\CS3!;G>&\\EFN/=*VLY+6RE:PO?"\5T,:&B1T9%7--*ZM(-,<
ML5;ME^HK%;3ZG*Z-M]#TS.ELK+I@8K.Y+*/PMS')2'@PK,.8UJ%*@1\6^^$I
M\DK+H; 457NFMA(2]VIY\_:,%O-TX)N^Z\6FY[/N<,^["#U3$6AU6,;72) 1
M1X;V"E<.]0&\_5-MGKO'D8 MX;IY*R+4!S8N-P./E;8_1C+LIV4J9&<G3,P6
MUE9E%Q)!%@D) %;5Q!<&C&/KU^U8VVV>V-WP2:[FN9&<N$#GM<Y[FN$H:2U@
MC!H65PIB3GJ4NK/IAZEYWJJSUGR6YYC:,<I&4:W/D,FYCX6W\/%5]0&\?+;>
MBP,1BHC=RH(Y$<M^:Y.NA+JUZJZ0#X?V+<<4Y]QVPX<_C=]M;)[R9A:YS0V0
MRO<*:G$^?57+"HP#55[DZ>^F[K+B\KUDQ/6':.4QF!<$K>,O&954V>U/B)2A
M34G'!'ZE+<DJ19A*4%+UQRDBME<B"ZK-J!:W,APH/%;+BW+N=\(MX>)1VL@E
MN!2&.:)S7G5_ < ['$DTIF2$=/>LGIHZYP\UM>;LGJ!'S.P,<^[A&\E@\6M>
MZL3B$):C.L>7DG/TW(.@)_P9&J0;]A%:$=[:7[G1,\TD;:T(S P\JTMXXQS_
M -N&1[O/*RV@W&?2]\,U&MDE<74E;I( S\S13I4KK'17U1[TS'527TNR?1K:
M3?35TKAX3$O'+IS^W'665F,]D,W_ .!Y5Z<X@&0A##*&U*^15AKQECO1O+_\
M&^%T<>(#L:BG;THN:YK[90;)P]_,&;J+K=SIDD80PLD+RT>2M7!PK@2?-3(8
M4M[^8]6\;U!X;(8J?.P>VXT@XYG:6'Q\1KI\K".25*=@2, ^W)7E)3S9YG9C
M[A>YTA04D6%<1<7W)V[TV*%H_INL=*M+3F2>VG6N!Z+<VUE[1NX')+(][N3>
MB3J+BV=LH& :!0!FJGE H1F2<5V;U']'^N74_>.V\_!S69_0(N08R6W<=M67
M*P>'PLQHI3];!AX)4=N7D_-2;ONEQP<+@"U:7)K/D-U>L.U3:+1I'E!TD=Y_
MB\5PWMQR3A&V;%)'R6R;+NKVD.D>WU0\']T$U#!E5M!CB25V;K/TVZB=?MAP
M=L1NHAWW*V6B+B-Y[9Q^X(\UK]::2VZB1N>#A7DNR\@VA02#)"@% @ *O6KR
M#;]SW';HH+&Y#+IK1ZE#0/=UJ1D>H!\5Q7!.1;%QCD-S>[K8%UA-(YUN7-+G
M11G(,#\"TUIJ94]":!/#;/WSC^D[OIXQO5MZ)O9C&G*)V+!W<RG=L/;7(67L
M2RPW*7GH&-=(*U1T*20C^Z$U8[3<&<?.V&Z__# %0XGS!O\ #7Z@._IEDL;W
M>MDN>>#E']-'^F"=+FZ#Z;Y:_P"813TR_P#N]:5(JN+T_P#3OJKT6VAG-O(S
MR<'_ )B^JB;.VWN5^+D65[D4VIPY';F.W 77#/0V@\_D)Y5JY>8$VK9<9L=\
MLK.XCW29KYB#Z0<=5'=M3T/\/=6F"U/<3?\ C.];I9W&R6KHX6O;^(<P&-SX
M_P"$@4H1T>:$5T@XKKW0K!]?L5U#W*]O;,;CWUM[)2'9FZ<7OV0_FL:^6/,#
M4S&!9;=P$MHD(08Y;;Y/D*"+6XGC+^9/WE\&]8[820=5/AZ=/A@,*9K?\XF]
MO&\;CN.,QMCWAK01HJ*]HFK75UQ/F!R.85OE=6>MV3ZO.;:W%M/:;W2]QUS#
M(Z=X[ *QRX4!R0$C(1=S+<DSW,VU8+*W4J:7JCD"3<<?)S#>SR4[!/8:MNDD
MT$4)-.CBXX'MIE3*BK.(\99Q)O)+?<)&[U'%Z@>7 -#J5+!&*%N(H"/-7$UQ
M!XMR]5NCTG,Y?HMC>G.[<%MR5D1#RG4*1+Q\MR%D(4H>5;;4)ER8K!F2V0Y(
M#JG4BRPT0"*V=YRGAT]S<<,#9(8W2:'2-:-.MCLZ5+BVHI4^-%K67'^:LMK7
MGTDL$]TR+U&1/>2_0]APU4#0[2ZNFF)PK5;"X786P.@,*#(VWU2V[&ZG[OQ3
M\39,*%N.$QE\X9,9;J/*BH=:<E)2E/,AM:;J<  '-7=-FVC;^,0NBLG WDL;
MM&MXJ\TJT-;7'&E,UYWR3DVY\TF:^^8\V$,K=>B,AL8U4=5Q!(PK7+M6#>BV
M'ZF1MV[B:ZE9+<747:F5R<G*YYK=4E^3,P[K:.=W)8*?(#AB\K3=EQ_]0X$C
M1*@%5UGC%YR?<-QFLN0Q:]MJ?-*,&',%M<P?X1\%V;ES>(V&UP7W&2(MT:T4
M;"2-8.!#Z&H(S#B:]#497J7U&Z<^H//*Z38O8^9V!"Q,Q8VKD=RNP7\?NZ4K
MF8>$E<5(;Q,PI;!C-O<R7$DCG"M#JG?>/<R#^.6DKXYF/JW  .T@@Z6@X=H&
M9"V;-HY%PO1R><02LD91X:36,.(/F<14XBCG 4!SPQ63]Q8/?G17IU(V1T@W
MY&QF=D34N9UK;DS%9B7M9I]M8"68UIJ<-*R;@-R$H4>2_&N<N8-QV+CXM-B!
M $% OK^2\9( 7&CG-:02:-QTU(&:ZU#>[7R/D9ON0D"Q?&?**M:YP(#:N\NJ
M@)J>N 3V[OC"=/-@Q=X=;-JYG<N\$O\ T<"3@&(;+^ZG6FRZ)N4C2"RS"E-V
M'GK;YD.J/,$I)(K?,WC^F[3%N7(&>G>N=IHQH+W','IIPS[\LUL9MK_JF\R;
M3QLZ['27@RN<&-%:$==6)%#3'KDJW9_33%]07G^L>$RC$/%3$RYCDJ>^U!FX
MUUY"UO8;(QWGDK;DLJ5Y?EW4E=@4$@@U?Z/9;J)-RMY91^)8?,T4(KT-30_P
MEORZ%;#<;^\LK(\<O&1-]$T(S)IB'"@ZYAU?V+(.Q-Y],$/8K;FXI.6.[=Q3
MEQ<2B*A/TD0,IYE.S>9)2EME"2MU2U(2A KI6R<OVZ0Q;3'./ZL_4!%I=J):
M3]6!TB@QJ13JNGWFV7$+3="/_=VG%QZ5RIBMBWNJO2O:S3N R$F%D7(W-'?G
M-.)6TZXD!+ACO!8!;2K@1>N>CW"Q-774\#9JG R8MH:4('4'.JXV2WG/FC#M
M)%<EBO,]5NG.S8TW=\Y@9#;W,$,E9*6VUO+"4><M%R;N?(D]JB!VUM>0<CV[
M8-G&\W\Q_IC9 USXP7@$UI6E*"N!)P!S6O;6TUW*+:+_ -H(P!P."H).;G[P
MV[%WUM#;&9CX":RY+:4F,ZZ8S"%%*UN (\YMM0',.9-PDUQL7*H+S;X]YV=D
MES92,):=)Q =2M 3AF0>HQ6Y= ^ &VF+6SZL<1]BPK/ZSC&.*:DY5QI:204J
M=(((X@C_ *-:5O[@VL@P8SY*':[EV()7!&ZW1\BZEA&6+JG"$A >))N;<+G6
MN6MN:02/:&L:"2.BV\FVW#6DN)6X$=K>V3P^-DPLO@UK=@Q%%AZ5(;?;!CH)
M\U9CK;\X'10%['MKGF26[7N<6'%Q/8,3\<%M7U:  /-056/LB=TMYG%8K=$:
M2WC<GE8L!4N&\V^PM+[Z&UEF0UY@96I*B4%:4F_9V5O67<>ES&1D!S2-0Z88
M>'=5:1$AZA;$P]F;$Q,9^+"Q#"_-0IMV7,6Y,FN)-P;R'B5(OW(Y16PAN/*-
M1=53SM=44 [EKEO7I?G7).53MBV0BL--Y%B,7@)WEDJ:?CLH4+2%-J((',%%
M)';6GN[+^]M&_@7 O$H-":$ -(('0UJ"*TZA:UN8HY"9!@1]JU:;SDQO,F,^
MR^DPEO.36%)6AYH1 5.-N(4D*0OY+6/:;5U;8M[?=;K*^</;' YQ>TBA:&="
M#U-,N]<K/9M;;@MI5U #T-?V+;3IKC9,#:\9^:GDEY5QS(N-$W+"7U$M,GQ0
M@ZCLKVW:(GQ6##**2O&LCL+L:?"JZI>.:ZX<&8L;@.^B[XK^D^XUR:VI5$H@
MGM^/Y>%$5.OB> X\/Q]]8FM4"HW-.TFZB;DWX5"JJ-?;[O[#[ZR!PZIU5*OL
M^-4+45&[?6PT\>(.GW5G]ZO3N5M>X'\^^LF]BR&/@K-+X&UNWC[^RM1M%KLK
M5=XZ?RN22I@&WFI4V+&VO]:;_%-OC6C..W-:4XH02LM\QOS</=IX5MZ+2PR6
M'O4#T9VWZA>BO4OHMNN+&E8GJ!M3)X5MR2VEP8W-%DR-NYM@J!+4O"9UF/);
M6FRDJ:T-/N0&A!7RA['1O#;FVLET[ZG-R9.Y^G>0R&T93&1D/"?&=P4MZ ME
MJ0H*>7'5Y!4PE7,D)_ITM63"ULFH$AW5<];7$K&"-X#F#*N?P/9W+5KJWO+I
MMA7'$YJ!N:4^XXH(93(BK9L2L60L<I4E&MP4BNT;=N]W%Y&D+=37,1;CJ;AT
M /ZPNS^F#:W1CJ7O"&[.@1=N0$R&W'G5&-DLYD$+4>=F/+D1T0,,3;_6>5(7
M;A8UW2V?<WT6HDN%,&UH*]_7X8+@)BU[L/M7UV>FK=NU,?M;!]/]OQX>-PV+
M@M1\'$C%/^$ D%27G/ZY+LI1*E.K)6IPZG6NC[_M=Q!(Z[>#0G'"@^ Z46Q#
MBUY:];75UE:J6OPHF->Y!J5HH14)?'LH2G7/HLL='?\ BB5_V-*_WJ#6<)\_
MP6E/] \5LU6[6T11$41%$11%J@5=VOOX6K1#5N$M.WM!]UNY-4]R*.O?H.%[
M_#P%*T1*^M^.M3+)$KTKBJBHB*(BB(HB*(O.W]R?=>0V[T6V]CX>&ZIRD9W>
M<9+FXNENU<IO*3MQ['PI,B.G/8;$X_)R#C,MYBFTK<;2TEU ^=*N4'Y\_,IL
MN\\DX%'L.S[;/N)FO8WR"-^D1MB#B"]M09 \F@&32-1Q 7U)^4BZXYMGN9+O
M'(K[;K2"#;Y&LCNW:&SNE<UI$<IPC?&!JKB7 Z:4)7A6KJ-N6,HA>[.O,=(X
M#(^G?>R%>Y1_2&^!%Z^ I?9CE+?JXS>@]Q/_ (R_3:/FOMA/]-_L!\+^+];5
MQ+ZT9.*KRW>I&^X[@L"G)=%-Z1% \02%14&]NRN/?[-\I(U-XUN6CM <</&A
M6^BWSV[G%676T$?W;Z$_J5_V_P!4=[;F?3%VUO?.9QXFWEL]+MY)M?\ I#BT
MH#31[^90M7!S^V^[6[RR;9;R-PZ&1H^PC!;TR\(]/U7R6>@C,7$;OE3->M7I
MLF[D'3?%PMR2@[F42Y*IR2RJ.^RN1)6XPF1"6\Z_%<\H@\JS>WA7Z4?EAL&;
M5[46NV5#;J.YN'/BUM>^$R2$M:_230EOF%:5!7YA?FDALY/<^XO;"-PVUUK$
M(WZ2&2!C*.+'$ / <:$BM#@MK&SPU^/#XZ5]$N'R7ROU5RCBR1?[N\?VU":K
M2ZJM1K:W#VTJ=.]0Y*N:XCCW_+QM:@6ET[U<V^S\^%8'QQ6*N+)X]PX?&]_L
MM40YJK1QM1*8U56U:]M;_</ U5B55(XZ7)L=/X=]7[UC7Y*S9^#M?-8Y[%;J
MB83*8E\I5(Q^;9B38;A;4%)4N+)#B%*0H7!Y;@BN*W&]V6*!T>[2VHMSF)7,
MH:=K7'&A[LUSFSV?(S=-GV*.\%XWZ7PMD#A7 T<VE*C/$8+6K?N'VH&L='VZ
M_@]O0<"L-0(,9YN+ ;@<R5&)'BQT*0VTA0*DIL +D=M>(>X._</O]OAM=JW"
MSAGMY&Z0VN@,!&IM&-I3"H _6O3]CX%[A;C<R7=Y97$D\]2]\KAK<[M)<XDG
MH25F38F Z@9F!+RKV4P&1P2@XWMR4<JY(A9,%"1#F,EF.]Y$=IP\IY[*2MLC
METKE[3<-QOBZ_P#]VDVDT= ^-V,K3D2 *-;\=6!P75;NR?M=U)M5VR:+<(ZM
ME8]OFC<,VYX_=0@JR]3-IMX_%*5NS()S,[*-/X=TNLMH_5\O/BOHQV,90A*$
MA4MY ;2JP)2"3;6O2^$/,N\Q-:T5B#GUH/*!F[NI5;S8X?6OVW4(<WTAJJT5
M(#?WO]DXK4N'-FY_,XB([-P*QU0V/D-F]:M[I>9@,[>W9MJ&K'X[:^)F/N,Q
M<9.8R4IYAQ ^4^8D(-Z]T<UL,+GZ9!^'E#X69ZF.-2X@9@BA'ABO3'B.WBD,
M;WUMKADMO&]M=<<CM3GNPJYNAK2'=.N"Z)CHVZ-X=/\ </2OHWC\WL7<70S*
MXG!0^H+4Y4?([AP;2L@XU*Q[S;3;N+9<EPU)>!4H.,A(O92A6O(^"WNV7VY.
M9-;W32XQD8-=A@>W X=ZY6EI:[I!O>]MCN+/<&/F=&T5#'G334*T=1KL",05
MSY7*[(#1Z^=)9V&ZK]7-NAG![EQTE.00R-P/X],#/.9L>5'?+$EEB1Y"VE%#
MI(4DV%:<;;FHV;< ZWL'C4TX5TUJW3TJ*BM<0I!'>M,?%MW=)9[/<%TK-8!=
MH:[4T-))#L7-J#B*8J_9;+=<MZ,]->M.Q9$GH]A$169&\=K0I*DXAQB/DC'W
M(K.R92.6?#9BQ75,*="2RT0H65<UM&MVRV-QMEV/Q$M2&/(QQ%6Z:9&IQ'4J
M06W'-L=N&R[G%^*GQ;!.UI!!+*QZ TU:_6X:AB''#)6#<^+Z%="MVPNO$K-2
M-^83?OZGC)+.Q9,3<<C)L9A2'YV9F."6AA3>.6T%$..<Y<(2D7J1S;KNMO\
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MD59N6UN#';?D.1_.3G<,PB'#<RRE:^0W)#26W4GF2H)%]JYU&%\=20<EHW/
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MS7AOK)?S.3FMMQY^0:FMHR"3Y;ODE(=4;?U$U-BL-TM=KN+/=;DB67",EU7
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M27E(2WEXT,J*Y$ <GEI<!)0KB$W%;J]CLN8P0V^S7+196LAU-&IF)I1P!H7
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M'B9X.)<AV>+@UCN =N5J26FN#W?O-;T=3NJ1TJ*K6;N7->-[_<>X-_8:-MO
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M2S*S<R Q%DPW$2I@DRF,));EW<BDE*W$D+*D@"MI)9[5M5^;:[?ZUL]@<VN
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M3S5+""7F0&KF "KJBN)H10YK5V_>?<;:6/X:RT;<7D$0 D%-(C((:ZI(;3#
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M$J(ZE33S2[+9>0I"P%)(KPX>YEQ#.8+F1\<C3I<UU06N&8(.1^]<._CD52'
M5[LB.T+K_3WK?OK=6XF,7^FRT)\](<6MHI"6RH!2@2.4V![[]U<I_P#4@@-;
M;SE\[R &@U))Z +C+G8X86ES@  MJNFOISQ(ZBQ=_9K<3LF#E<E*S"($EW&3
M84&7*D.29?T3[;9GPG5/*59IQPA!-P *YWC'M5!=;O'RM]TXB:4W+HHWA[)'
MDZJNH2,'_4.T$46QN=ZF-H;(1@-8T-U9&@& ^75>E4;!;$2&Q$=::6I*4I6E
M;:R%6T.MR03W]M>[2VTKJ.<Y]1F"%UD7,PJ*9K'.Y-])VIE7<8X4N)2A#T9U
M!'(]'7S!"P+FQ!24J'816]B9;!@,SVM<>W!8N+78X_)6)761DIMRVO<6YOYU
MN1%9?^6;\UHF@Z.^2Z1E'(N\5Y#*PI;./GQEQ79"'=&IL3YTRB@H%_K4)0GE
MOHH:&VE8WD+WLC?MTC=0<-9I6K12M>M0,CEA0X+*,L<2V0$!5V+WI'Q2$M1P
ME*$Z #0$=M^PWK=UMI\Y&_-9%S *4-/!7"?U&$UA<;2S@Y>/#70@CA8UKV\5
MI'('%X(^]:+GX>4'4L91][.-!]OS^534IYM5R";H7R'CJ"% \:V@WBU,CV2@
M:V.+>S(K,,F:T4Q!Q^:QSU2R<[+;9?R..;5(G19#$23,2=(&(FN7F27DI^9Q
MM"VD 6_I*[\+UH;S=13;2^>!M-+@QSQ^Y&[%[CVC #Q*W-@UWXL-F.!%0.UP
MR ^9^2Y-L91M6,P<[SRIG'.R(+!_]ZR5QV"I2E"Z;I2";=I/A6[V_<(C9PW>
M(8'F.,=U!B?@/B2M*YA/JR1_O$5/S*W BN^=!BO*U+L9E9MJ;J:23\:]#:?*
M#V@+KY;F.Q<:K7-KV\>-5.BX%\=./;[=]JQ=FC51.\;=MS[&H>BJI%]O'@>/
MMPJ#-9]%2KX>)X5F*JJA=UN2!I]_#AWUFK]ZMSAXV[KZ5D,ED,U;GP"FQ]^O
M'B:R;AX+5:237JJO!%"<C$)2D_[0R-0#<>8.-]"-:2?2D@.E;!+6M1LI2E!.
MB05$A(&@ !-@ !6TJ3FML&M;D %"HJE508*00LCY4J4.\ G[P*:7.^D%8ES6
M_40/$I**U)Y%DE(N"A5U)%_^BJXJ85KU2ASP4$!+5PRA+05<*+2$MW'<HH";
MCWU,\>Q9'$)\*QS52YAWCM]W;5HHHZZZ@_&]N/#NJX)51X$<.^_\:J9K)_22
M=%A[K*)+S;/UF.E18ZG%!"7)"GHKR6@I1 YUH95RCM(L-:U(J!^/8M&9M68=
M%M16Z6T11$41%$11%J81;[_NK0%>];E*A1%,T13JB5[T(HE$B;?SH#4TZJT4
M3K^%45&"N2.[V]C05J2@JEW^[V^-0@X>/3],DZK#7J#P/4_<_1?J%A.C&0Q&
M-ZHS,$L[,>S\N3C\-)RL9]B3^EY#)1&GY&-8RT=E<;ZA*%>2IT*(Y0:ZMSK8
M+_E/$;[CVV7<MC>W<.AL\9(>P:@74(Q&MH+"1B XKM_M_ONS<9YGM^_<@M!?
M;/;3ZY(33S#2X T.!+'$/ .!+:+P68Z)_O%91*?J^BO3'%NJ YU3.NVVWF@O
M4+*3%>D+4D_W3RZCC7PZ[\G^_22'U;^=[:G$S#'O^HE??C/S0^R<,8++&8.H
M,!"_#N^D9*\L^E']VW(6,G"] \0%<?JNK<N64'Q^BP<D$>XUJ-_)G>.H9KKY
MR_L!6+OS;>T4>$.VW3J=D/[7A7F/Z'_W19:>:?O/TW8AL)YG"=Z;QE\@U))+
M6T^2R>^];R/\EXIC=QU[Y'?J8ML_\XOMFP_R]EO'?_JXQ]\JU!Z^;<]:W0'.
MXS&;@SFTNIT=YMN1E)71^-F\_&Q24O(;>A9"3F&,*F/-4E7,CE#@L"3:MT[\
MDVN(EMS  X4#B^3#OIH!/=3-;FW_ #D<"<PRQ[)>!X.#2V+'X^H0*_&B]J,-
M@]Q;?Q>%9S3K<E]6%Q:G7F75.H*UPF5J^=:4**N8F]P-:^Z-@VIFS[3;;4QQ
M<+:WCBJ<SZ; RN/;2N*^*-_WZPY%N=SN5K&8VS7$DFD@ C6XNIAV5I@KWB\K
M(Q^1YVEH0EQ"T.^;_J^7BE2A>UTJX5SCHO590?4%UZ:"*6+S D ],U?7]RYJ
MW-'R6/01_HL D#P)3K>M@^VG&&L ^"PCBVMA_F6\SO\ :'ZE;(+W43<S\]G$
M9_',I@J90^I]<AI2//25-*2AEA?.E021QXBMI-9W0 K,:'LH%S;+SB=A&Q]U
M8R.>ZN&!&&&9(^Y5J>FO42>ZVJ?U#3$;YTJ7^GQY;KP2%746UONM("Q;0D$7
M[#7'R;3+)BZYF![C]H6\;SGC5JPMMMFB>:?\X6T/<0T5([<0>];&1T>6VTV5
M%PH;0A3BK<[A2D)+B^4 <RSJ?$URU:89KRUYU$N  !)-.@QR'<,@KDQQ5\/S
MHL3F%6H^^B8U52U_5[OYU0HY5:?=Q!M18]G8K/N*:N#BG%M!2G7G&8K:4_U%
M3RK<H\2!:M&X?HA)ZG#YK5B&J085"PIO;9#>5F85W.9IS - !^7/C<CP?0VT
M4N8M,=2D%Q]7RJ\PV0D]]>3<TV&/DVW_ (3\4^UTOJ9&EOTG#2 X@5.=3E3(
MY+LUA<&UDUE@<'-ICV]O]BY,5!V!%:G-R]T.QUAE#&%8$=M4V4XAE*6Y<T)^
M0-*>'*$IU(%^ZM;:Q:[3M5K:V\T;V10M9J<]H+@WRZCB,32N I58OB?=7#R0
M:$GH<*X]BPWO[;J<OA,CL'<CB-O87>,.0QFLAD&4PY<LGDDX]4:2M+*5/9"9
M'0UP*G^<(&MJ[][?[LZPWQMK%'J<]KG:NTLQJZ@Q)!..8H"NZ\*N[BPW/^HQ
M-+[B.A:VA+0&UU5 !(:!4U% TXG!:MY'?SF)B[;]4.Z]J1\QN*##E='\_P!+
M(;YC/,X1W,/LM[A?86F1)C(>AP!+!=1R.O*Y4JL-/>6VGJ%^PV\FF(GUFRGM
M ^GOQ.G#(+VJVVC\1-)PRTE:VV<\745P1FX1#R>736A=IU-->I"X,KM/:?3[
M<&XMO^I/=^11L7K-N&/E.ET4M3\IB<!D5KD<[<2*A3Z,%C'8V2C,!20EKG"0
MJVI&FVYN;V%D^R1#\5;1D2Y N&&9PU&H)[5O;"\O]SMK6_XA;Z=TV^V?^*(#
M0^1I#2"22/4-6/.!U4KGDHL[CZW[ZQV^?3YB-M1=EC 8]#W37J'M]J7#W4UM
MW;V0APV<1*E!UQMK(NQ2VKZIA25!"5HM8WK1?;[5:.BW>9YE$C_YD9Q;J<":
MCM%:X'N*?T_BNV,LN67DWXMEU<$W$! <WU)6NDU"GF+ X&K7 XT(( HK7ENC
MIWAMO#]1.M74F _U9Z)06,AO)^=F(SNZHN%P.2<R.)=?P[#WUS3N5QJ&DHY6
MD_5.+!LI2[G3&[-MIY;3;(/_ ,'W&#*#"KA0BIZ UZX!<C;<N9M5[?[1Q>QU
M<>W(F.$4-#)+$&N:'/!U!CR<-7D (P 5KW'Z@.CFV</ANO7IUZ=RNJN6R&3E
M;<WQA<U%E[:&WL>\U'GY2'D&VT.NKRTC_"5&"4J9Y?F*C;EK;?@-UG(VK=)!
M&P /:<#6E0"*'(=>JW>W\+YAO4\7".77GX6VB8R>,NT/UD!S&%A:X5:#JU5T
MN!H%497J=ZF9'4G875+HRAK:G1K>\#:WZGTZ8Q41\-P<HXTG-S\M(EP7'W-Q
M1/.<"74*0EL,I 3:]^._"6#8Y;>\?JO(]0J7=E:4[NX]JEGQOA$&U;KM7)+L
M'EUEZ[&R>JYH!B!,38P7&L;L#I-3YW9%6=[TR0NA'4?<757JKU'3@>D?4#]5
MQV\Y&]<NXK&9O*;H6%XN5,^H6[^HRVIJ0INR5*;0%6L@&N,GW*"XM!#%'2X;
M2F&0'3P6,_/;/?N)V>S\>VQS>66\L,D!9$#H:PCU*.%2&EA((KB2,S16?/[T
M](GHIW+&CS%97?\ MKK/ A9#*3NGC,+-[?P6%@NR!C,P_-D2F(4SSE37N6/%
M6X]Y:22!\H/%RNN+AH)&DCXU6X<WW']U'6[K:-EM=;2Z1H=J=$]TCPT.91S?
M*1I%=0H21V*EWEZP,QT!ZJX;"]+N@>%SWI_W9^@RCE9\:8]F,X<ZF,XYNB$O
M%O)A06VH+Z"U'6AQ3J4$K4#:VT>W4:2&KNU:NV>V]US7:9][W[='_P"H[=KX
MVQR!CA'Z1=_*?@#76#5S<J]1BH/J]<NW/5!_F+&;OSDOI-O#/1X>:V[@G4XW
M;.*V?()B);QN*+1;AR,;$=#R9+?^TN+02M9N:V$LTS9A&&DQ5 ^'WK9V\/M-
M<>WLDFN)G)8[=SVN<XMD,[1JTNH1J:XC1IQ%"*9*A9]$R?3OU<E>HW>74.'M
MGI>VYE7=WRMSS;1\U"W0S(A2F9<V0ZMW*R9LB6AQM #CSCJ;B]<<V-[;GUB\
M"(5KGE0UK7!;C<_<NSY-PEG%MLVR4;\61^AH8TADD;FO:YA!\H ::TIY255;
MR@>C+TNHQ7JKVSN./U*<S4R3CL#ANF\R/D4Y).3CJAYIJ6Z\XQCL*U%@RE*>
M$M2'.?E2E!5:MA*;+;O]_>7%N(&(=4D4(%,Z+;R[Q[E>X5B[@$T,43FB-TKW
MMDB<P1O#V$ZJ8N+: M!P).2H>I'J\Z9X_I)A>OOI'Z0?JVX\CG96-W%F]W8J
M*L[+>QZ([N5QLO&8.8X_E)DV.^E*5A]#'D+Y]39(X6[WJVM+07]E$USW.(RT
MT<<Z]Y!6I8\$Y-O.[R<.YGN,\=E!&R5L8E$GJMJ?3<RK0"UKFXZJFHI3,JQ[
M[]07J9]6?IEPF[^D>W6NE>XX.XY^-WMB-D-93!YK.3,1]))QK^/S,Q:<KCL9
M*;D)=\MAU/.Z"DK4D6K87FZ[I?;6VXVQKVO]0M?I\Q% #AG@:^/0K/;N'<)X
MKS63:>5313P&V;+;F4-8PAQ<UVL# O:6D#'2!B!4J[M^G[U2^KWTV;>VUUGW
M#N=7479F;R9QR<W-7D&9>((C#%97)164M,SID8>8SYSJ5N@)U7<DGCKS;MYW
MK96B=Y9.R4@AU&:Q04)IA48BOQ6,7)>#\&YQ,[98FS[9/:L=6,^H89-3@YC2
M2:-=1KJ-/7P5WV-Z7^D>S^GN/]+'J'ZQ[$Q6^W\A.W!MZ%E\Y"PV4C0,RIA"
M(#7G/ 8M<B0T7&4.*:+O-="3:MI_I^SDVENS;Q<M;=>J7Q .!<&D"K?-2HJ,
MA\%LMPY]NC^32\IXG8RG:S;-CG+HW:'2-+CJJRI!#30D_&A7 CJEZ+/2'G7/
M39N"-NC?N R$X2MUYS"1X63PVW,U*++#+!1E9L63FT^3_P"$&&E:&R+74H%-
M<6^\X;QEC^/WSG3^I*'OU-JUCJ:172<#3.E>]:,UK[B<VN(^86(CM3% 8X@U
MY8^1I=J)\P-03@W4!7,*T=<?6PQZ6.IF#VET7Z)[>'3^7':ES3NK%3WY&_$3
MD1W$OPF\$\VSA(L5E:?*44OO*-^9*1I7$;KSFVXS>NVG8[%AM0 ^1U2W745!
M;F:4R)SKE1:FT<$NN:6+=[Y#N,OX\:F1M\KQ%0^8/!%*EPQ#0*4S7%ZM=_\
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M4%*-N/=6ZLG63;$V7_-6[@ZN9JQWZ\OBM"1T[[CUW8N>".[$?J6QVT,<SC<
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MS52V;&_MV]O95"CE5I/ ^W"F2QI7!6/*9?'PI49F9R*+7^V(2NQ =^=MHD>
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MGUS[RZ[X'J]TGW/N*3&R4#&3L",9G,EM7&;5Q2VV)[&!1BL:\Q$4RYYZD/\
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M"A+IU%D%:2/?76]PY)M6S7/H[P_3,]H+& C4YN1<!_"#@3E6@S6_AMY+J"L
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MX"I150).GQTO^(JT4Z9HOVZ^UZO<G<D2.[L]C1*)&^GX=U%:H]K4199Z-?\
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MN$V#VW,,ZXKC8*@,DV.FNM=#E.FX?_B/WKK[7B*60]=1HNWPH[,5M+;" A(
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MY&,I+L26TE1%_F0H&RDD:5R.U[MN.RW8OMLE=#<@4J.H/0CJ%0XC)>.F2_\
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MOTHRM@]5-C;6@*C8/<D"3*;3D=RE4OSY<:;+P\H.1EI7>&XV0@VO?;.V_8;
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M:;%D^9RI2F3YX*?,')KP?X!K28[EY>PXCN_M7(V'M=MMMNQV7E=]+<VIA;)
M=1:&@DM<X:G.'J-.!IY:4PQHJ'<'3_U@=4.JO3GU+[5W/NG'0M_0MGO]2>GL
MJ7+PT/%;5>CLP]U[&8@0UHB(BQ8[DE+0Y.<N$.%?,>:M#_=HF&(@89?J.*QM
MI/;S9=GO.-;B;8;E;/D#'R:2YT@),<M>T^4T&'3)9!VU^W;MCH-U6R/7+/[W
MA;4Z2Y; YO;6X,-NO(PXVVW(6ZU,MPWGI<]U" J)-::=:%R0JY%<1/,'_P K
M"G7M7$[I[NP[MQZ';MLM9CO$4D<D9:W NC^JAS#2W4#AU'<KE-B?M^^A?//R
M<MO.-E(_75B(_E<;L1ES><1[%8I<A4#-OI@N+@QH+3LMQM)2LN+"U62JQMP\
MS8@PMD^GH'+B+WDON#S62%UC;B"YLW8/:7!V(HY@#P!7(G"F"ZCU"_<;Z&^F
M;?.&V[TLZ O[JZ5[HP^.SSF\)DQ.VXN;7DDM.LY#;N/CXZ6)(BQ'>59?+:UK
M!386O7'SW=O9,T- TX$Z?U5[D@X%S'FKC=[O=N=?PZF-8\5TXU(?H+:$NRQH
M.]8EZJ_N >LKIWUOC93;,# X7HONQ."G;?PNW]K1,GC9.T,@RR^SD5Y:8T_D
MO\PKQ\@O%25);"P!Y9&E=>W+?S;S".@,=*CJ2.U=EX[[2;3?[4^6663^H@N:
MYVH@ZVD@L(K@ X::9C.I6,]S=$/5A@/4NCJ0QN;>W4+;>\<[#RF;R<G+97R,
MUM3+.LB?C<A%:D,X\11A9*TLH2A*&^5) %M.*NKW=67H;I>82X8@&CFG^PKG
MMJL>"S\;<TNMH[V*-PH2T/CE8#2M<<'C'M\2LLS?03'Z);]9]3&$WOA,'T;V
MODV]Y2\I)FL2L4C$ID@Y'$LOQ7G&9CN2BN.16XZ0IUUYQ* DFN/OMHW*VO/Q
MKGL_ L<"7%PIIKY@?$&G>5Q=M[@[!N^Q.V 6\XWZ6(QB,1NJ):>5S3D '>:I
MP %22KMG$^B;:>U<MZT.D^]&=[S-I9:+D&-B;>;EP<YCMV+\UQB%N?&OQ?J-
MO8\#G7(?<0MM;((:"U* KK]QM>R6+QOUM=.EC9*"V,#S%W1N)P':3A1;.+?^
M8;G;GANZ6+())H'-?.7$L]/(O;04<X=&@U#LP**F@>L3IYZ@.@W4;JSZ6^B4
MS'^H39LJ#!S2):X6;;P*,@TZM&Y]J+3!8<S,IY+3B&$/M)3&=U<2Y9(.SO[G
M9VVSMUVRR]+=6R--7$D1EU?Y@ ./4## K86VV[^+R+8-\W0S\=DC<!2C72Z*
M5B<2*MS!-''4,!3%5_3[J!ZU/7!Z7-_],=Y;<:Z:=0XS\%K%[E&VFL#ENHN!
M:'FR(>?^B#3;?E2VT&1],TP'TVYP0"#HR[GR#D6WRV%J&ONPYI>YC=#I(\=3
M:]M:$TS%%L)-HXIP[>;?<IRX63P]K&/=Z@BD &EP%*D$:J:JZ36G2ERZ3>D3
M?FWO3YGNC'K:ZPXW!;4W1GF?\B9#/[I7A\1M;+I8<O Q4C-2T1FES$I*P$ )
M"D\!<UMXN.[G<V#['>97V=DU[7PF5U1K%=32"?I(/P/BM&^Y?M4&[Q;GQN!M
MW?ECFSB-A;6-U-+JAOU-([,:XY+L+6Q_1[^W#T_.'WQNR3U:VSU8?/ZMB\!D
ML5NIR="81<9E,M4MO"LM,'Y4-^;SO JY18$C93[5L6P,/^H)VWL-T &Q0M.&
MC%L@(.8K3'.JVKMXY+RZY8[9(/P3K,EQED=GJ%#&:MR.=*&E%;>HOK-Z2]&>
MAFWNK/H6Z6+RF D[E=PVY,IN':R7(F)6AH^9BI6V\3*698F+4!]2I\M)M\MU
M:C;7&^[%QZ.*YXI!_ODY<U\DY-  *^FYI.).?3N6$?'MZW^\?;<ON7"&!H>R
M.+3YB30/:0VE!D<#4Y@*U;CZO^KOUX>E^3)Z?;1Q?2O=^'W%&F.[<VQC\EM,
M[PP[(4&YSDJ7,F9".(LM(4&VW RO0D<!7$[GR7D?)-O_  VVQ%OH2@SMM0=1
M:1Y7"AK0' @8@XU6M;[)QKBF[MDW*02-FB<(G3T(:X$:@Z@I4C(GI@ %Q;9]
M-&_,UZ><GL;US]9E[,:SN6A.[+W1NW=TQR/M3,QD$IQ\*5FGWP@3FP2XA +8
MY0387KAX]EWS=+1T6_SR65FR0.MY+LNTEP!U,<":T(-0>GQ6=QOVTV&ZMFXQ
M;LN9W,(G9;MIY332X$#,$4[ZK(^P>F_0;T&](,]U)VENS$>H5:6"WDX>U-RP
M,XK+15!*9+$Z9C?U!&"B(:7S_,A2KVY4&]9V^T;=Q1CM]W6ZM-QCF_E^A#]#
MFNKF>G<3U7'[AN>[<MNX]GMX);$1G7ZCZZFEOP!->P=%TW9GJ.V9ZO-F]3NF
M/I-Z2Q.CW4_*8I$V7E591.4E9_'_ % 3E\/ F1<3AG<7.>:LKF_Q''6N<(4D
M@WX:ZN[*ZMWV/#=I-GR&7$D2>K*^$8O; 7&C79$@#46U#5OI+"ZVVZ@O>57W
MXS9HW4 H0ULI'D,C?WFY]HK2JX]A[ ZF>AWI[NOK9U^>F[DCY5N!MY/3'*3<
M@[B,^9#_ "--K<<$ER&N(4^<F4TTI: D@W"B*T+.+?-AL9+[F%I))L\I])MO
M<N)=.X^;"IJS335J%**7]QM/(]PBV[CKFQW\=9#/&W2(VMP.0&JM:4ZU[EWO
M9O6G9GK7V%NWI.QT^@>G?: $+)C>D;/O.;<RTF!*3+&,SF4RN/QS.*864AQ"
MRKRG%IY5*2>6^FZ7:N5;-)QOC]M:;-<%[97%SBYDFBO\N20XM&.H5P+F@%;*
M[MMPXMNT.^WTS]QH', -0YNH?6UM34BE#V!RM&Y>A^-]._1W+YST^[EQ?5#J
MY-RD#&+WATYW!CLW+V/ ?#K\R<).%DRTPIK\9CR6DDE:B[S=EZX6;9]PX!M@
MW47T4^ZSRZ&_AR7-@;0DN+AAJ=32W+J>BR&\LY9N[;#<(3;[5'&7ELF!E=4
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MH#A3%:XAB!T1:P73+J&U/W-UW3#R^X^@.]'$_K&%D.*4XO;N#W#.<?,EI@2
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M;*?D-C#(VYLHZNTT?I'7H3AXCY+=S>ZO']NNH-WV.VUN='IN QFFI%-#G.H
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MO]9\@93J31:1[T]!/66%FLKN?;\#&R]IK8E9>!M=S<B6MU8XH0X^G!%MZ(Y
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M>:0Y&>GR,FMQM4M]H!/^,ZE^P!M8W.BS9I9Y1-?WD-INQ&AT<V).>EP(R-*
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M!>-AR +EIY39/#122H5FQQK0YT6YMC22BP.E1''V%_#6M0?:N3>.HR5SC.:
M7'RV)UXW-0K:N%"KNRKNX]_VW^ZL<RM!V!5U:[?Q^RL3T4.2N#1L1VZ?;I4(
M!"T>JN2%=OW:V\.-89)THJYHW4G7A>P[]-=:S4PIFJT<1[Z(JA)%P>(XT15B
M%$ZVX=]C]U9$46"T4]2O1_+99F#C=FX]9QV6ER94E+4U$-6,R,V0Z\YD([KH
M4GRH[KA6ZV19;2["Q MYUS/99[BW:RQA]1DA(<VH;1SB3Z@K@-.)=VC#-=HV
M3<(H7E]TZCF@4-*U %-/QZ=AQ6'=R]+^E[N'PT/=#3C6R>G,F&=S+;E/1/\
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MA_85;*QXQQ82V$IABGD.H&:CBYM,JG##LP[>JR3N#]MM?J:VUT_V[ZB.N\+
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M:.]4W_\ >NUIB;#B;GZ,"W=7/6S_ '4-!--%3_[H?L7%3\/]EQ7TIH/A<?\
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M5*-^7DN]GA:Z"!K=+W59I;A7/#[O!<T.0\+L&.VW;HH_2GFUVX9'4>I4$AA
MP(-1@<&G%=;_ /M*O2CM-K&]*^JW6?;LO']6Y/\ FS82,IGDRFH;<IEN$\W
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MG[5.2S'6J3ZAX/J9Q+NP<?EW][Y%O]:A3<WC6V7E9.;#S#[4]]T):6E7FAQ
M=6JX-R==A/L^\-L7RLCMG-KJ,QE;J KF6UU ]*+3?R?:Q*+5S;D2T#!$(SI)
MRP=]);UJJC =4_VENJ_6]B9G-H;H_P"=Z)Z(<64G;P.V=V[@B+$>-(C2VLDN
M/$=GO-!85*8;+95\UB*VD5AM$EE_,FOHX7 U8T-])SNXDAP!/<1V56G/<<HB
M?_*9:/:*4<XGU&M_O 8$M']JZU#_ ')?69M/KY,Z,XOT\;=F[/Q^X7<1@\9G
M]BS9V2Q&#,Q;,5Z+NQI^,F7'CQK+25*6+6    K1BWFWM]N;,19/8PD-9)$Q
M\@Z4U'S5[ <%9^.074KB9+D2O +GLD+&$TSH, #UHKWUB_;=]6'7OKPYURV;
MUCAKV[NM4#*2Q^MSH&Y=MK\AI,K#IQ<%UN*AF 6RVVDA/*D6M8"MM'8[U=VK
MYH;-]PY[R62->T #L(J',([A3JM-N^;%M[6VDTHA]-M'-+":GM#J$.KG4FN*
M[9Z@=[>@[ICC,+T)]8N*WQU%W)MAE@IW)M.*SDYB"M#;;R,AD9.6QV0=E,/(
M4E92IT6 !-Q8;:&SM9YP^\?=Q[M&T NM]![SJ#R!7LQ6DZ?='@S;6+?^G/Q#
M9@X'N+=(.!71=Y]6.O.PXG3'_P"%C=-\WMST[;FPH>&XL# QN3RNX-QHG/1\
M@SO!F8F?'QDG&H;0&TCG4 X5E:N85QT>Z0[-<7'].NKJ NH=3QJDE([: M!:
M<- &':M9MBS<8VG?F02W3"1I!TLC:<1IQ!(=F79'X+(/59'0#>.!Z;1OW--X
MYW!]<FV)&4P$[;K#TK*3L#D7DJ5B\S"PC3#,)J$\V$(5Y;:'A8\02=**4;Q-
M+N6Z7=U#<.8&DB+U=31DXM+@6'LIX+;1-N=O)M]@A@FLM5:%^C2_KI=DX'KW
MA+JBQUA@;1Z7O_MB1<]&Z3*.7Q.[=S[:E/8'=4[+QY$;R(V9:=<:DQ\<TVM3
MB0>93A7S#05LY;IFSW+V;;<7X@<P%LS&N:Z1QS:[1733"C24C='>O/\ J!EM
M^*:<(W$:6-[6EWU$]2N_/;AZ?; VGM# _N,8-_JKU,R3K^X]K27)+.5W5@H#
MSB6WH&4GY):5KQ@D,\[%W%*!*DA)3:W#7.Z6$KC/R2+<YKTMP=#(ULVBM/YO
MJFFDFNG)V'8L&V=T^0GC$MO%9 ^;4VL>OM90$U SPIDMP-F])_2CZNMO[;P9
MP_5G8"(B)#O3\;&S^>V:K:+#*T<^X9[>& VWN)Y]+5^7((D,I85R)2E9*J[#
MQ3:^"\MCEVQL-[ZMP?2@86-E;%A5TLU6EI?6I<[4&AH &)JND\@W?D^P7S99
M987@ .>ZOUDX!K<:AH&0&-:DKT;Z6S^B.P-DM]+>FV8STW+[>,A,U6X'G,AD
M'2ET(DR),YQ#?(N2XGG*$ (YE$@:FO6?;V[X!QJV''.-78>YKGES'N>Z76W!
M^JHHQM14,%&-K@*DKS_?KG>=SF=N.X, +P*$ -:1TH!W=<3VJASF0+OF?XG(
M@ E;A-@E/:HF_ 5O>1[T'M>\NHP DE<3:08BN96MO5_H-Z=]U/,[FQF\-QCJ
MK&;#Z<5^NH3A\A-+2$E8P*75%+Z0E*4.#4V'->PMYAR?8.'Q[++R.PW)TFY!
MK7%N;)#4>73I&D@$Z3J.([UV2QW#<XY&VCXJ6M<Z8CX]G:M3]Z>BOU28_:V7
MF;3.U=\8F<IW)X_:$G<V0VKN;'+=!<=BXO/O8_)8![ZQP\Q:E);0A9-G==.+
MVWVWYU;EF[V\+&Q2@.,8>QS@#0AQ95OFI2H:X^%5RW^HMKIZ,H>", ZF!^\_
M8O/?)='/5YM+*P,3B.CFY,'O_.N\D&'O_>N#>PK; <+4M_'Y7:S^6QBWFP2$
M.OJNW=*BTHD"M?>-]OMMF&R;A&ZWO)00PB)VMW0EK7Z1XXX=HP64+[.X:;J)
MP?"WZO-AVT-*G[%WGKNSZU^@W3[84CJMB<D]TSBY?&S\ZK;6?3OQS&/8PAR*
MW+?QN/A26(T1:@]YCK02\6^4$*^4\+R/;=]M-KAL;R)T$,C@Z(N(#)"W&A\S
M@QW4 GOJ0M3;KK:[B\?+;T=* 0[#$5ZC 55%E^L&^MP0\4O8>5SFX%91#/T4
M'$8'<LW)*+R4A"%XV+B5RF%**A_6$V!XV%ZO$=[$W\BXA>)6X'*GP-:'YK>7
MEM'&-56AJ]6O1#T-ZK,VWGUH<E8MYZ./T/;\M]/UT<O(UR61CMN.(B* 59#*
MR'+WYTIT%>W\;XU<;O,+^^C=#M;!5K:D/D=FTX9-&9QJ[*E*KH^YW\ 'X:W(
M=(<R,@.P=I7IYC<G"QZ'L=-0T2RIQAT%(^<"Z>8&X^5Q.OQKUT1ZP/3(#@!@
M "Q T[^ZWK:!I=@589VY48J4MF*[_LROG8*U<QY#Q05'^I3:C;W5I7-[;VK@
MRZP<14'M4!D=7TZ$+H^Y=X,LM(G//(2GS PI1/+;S$J4D:JUU0:X;==^BM[=
MLL!\FK2?B,/N6I%;OGDTNSHL$[^.<R\!S=6SE#(9*$V&9&%0$>?DX[:@2Y 6
MI:4&9'2X?\,V\Q(T/, #T;<V'<G_ -2MG4FH YO:!D1WCL[,ERUHYD'^[7 \
MAQ![/'N6M^\'.I/5WHYOS:VTL*_(W%EYV+VPN%-F,8?Z)EO+L2\ZJ8],<;2C
MZ6-!+2VQS+4IRUN-:D++FVVR3!S[F<MC8T9TK5[NE  *>)HMW_N\5VQ[R!$T
M%Q/PP^=:_!7OH-Z?)FQ\)D<7U'P[RI>5CM,O.B>EV-R-.(<#,&9CW>5ORUH2
M=2"JVHM6K=6,;ML=8;A!)%;R.94UH7$'50%I. I4CKU"TY;_ %RB6T>"YM>F
M7P*QQUBPVZ>B[[.58>.4V;D<@B'CLJT5*EP93X*V<=EHZ1_AN+Y%!IY-VW;6
M^59Y:X6WV&2VE$;#KA)\KNO;0]X^W-<E!>Q7;:.&F4#$=/$?I@LDX+(9E'2:
M9N'(!\Y;,YK;,/%8]L%4A3$N>4M^8V!SE<Q0^5)UL+UW=NS%FSR6K<;V1\1I
MV-UX ^.=.X%<<Z5AOVC 1-:ZIZ5IT7J)TVP,O;>R<#C,CIDA#1*R"+W\J7*
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MVW(P6(@PL5BF(#C$/%XN)'QV-B-MMGRVHL"&VS$C-(";!*$  <!7>V-:P!C
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MWD=T?K]$1EI[J/Z^"TY7[NT 6WX4VIQ:V74'#_BUP\5P[JZN>M/8N\=J[?\
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M]T2,[C<ON.%@,$V-D8G)HEK>W-L[/B*)V,A8M+OF)92I2$, ^798"JX)M_\
M[L]L3J2Y-;IR/2F%?M6A>;%8R3-NGL#BP EY>?/3M&JA/8""J+97H-Z_]"=V
M;BZR=6>O&+R'I?D0,F[N_#IW!)>P^\<-DD+3#8;A,SW,?+SWU#S;D=:$./\
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M9D:-M'I_OJ:S&:3U"E[?BM0L+CLZY)7'DX;(YF1'#;#\A*PM*D>99Q7+6P=
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MJ'0+]NK<O0C-Y7JIE/5#TYW[M3#"1D!C>G^[8&:5F)9NY&C3H$#,3E22\\
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MY E( ' W>[3[O8W)B8(X8FM#&_PL<]H=XN=AJ/=04"P9&RWNXPYQ+G5U'M<
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MS*C9-B#J3VZZV\.RU,5*MIAT2)! 2._C_;13ICF%'AV_-K?2_NMII1/N02.
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M9R*$.+4\TE!("AS$*O;CC'=[I?TH()FXC0XBE<#B<<<,*=%/6].W+HJTR.L
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M8EQ&;@*T:.N).%#9=4I&ORV]14]3V =U<RL:;VZ!;F]/3^W7AG,EN[;&?O\
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M;FL)IY0'.I\*TJM6"6Q>X6MI(PEHR!Q[_P! MO-C^N#H5TWVU@\1'DP<<B1
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MD&^^A&;C9*)TIW!M21+=RDQ6>BP9;*,U*S+#[D::YD ^H3)CK;[*D W4D)2
MFPL*]-V3DW&=VDDM=HN877;'D/CKID#@2#5CJ..(P(!%,C1;3DW N<<:ACN^
M0V%S%8RQM='+IUQ%KFAS:2,JP8'$$@@YBJS<>)KL9S721DJ1Q=S8:Z\>W2^E
MJ=R*F4>SXUB5DWM5.XH?9?\ A^)HLN]4+RB!>]B3W7TMX\!5%*HK:XHFY[KV
M_C6?BBMS[G$7[-=.T<*R&>"S8%99+O9IX_=68[5KCL77I3H^;N%QQ/XBM1JW
M,;50QVE2)#;2 2IQ:4@ 7U4;=GOK(F@6LXAK2>Q;5[=@C&XB'&L$E+22KQ*@
M#<^-S7'O.HU7#N=YB3U*O%A?4\.'$?G46E05T]5$DDD#CIK;C[]*=R''$XA1
MLD&QOX]EB/MO45ZI:'B2#V^PHF621( ))X\?#^-Z9J?<@D:]WM[Z(EKV6]O@
M:*J/-8V^_NXZ6JT12OV=MKV_G411-AI:]S>US]MZR%<T1>_$6 /?VCW5*=B+
M,'17_BN5_P!B2O\ >X%:L/U_!:4OT?%;35NEMEYM^M7,0MN[M+V/R6WXF2W=
MT#ZA;+ZDA>P^M.^\OB^B\S*X]><W;GSTFR\)K9^UMOR9#R6<K(;,]E<F68?.
ME$DLEFW);[['B/P=L8N(J1MN3CX["6MNKVG'E1\&C:K:0G;+$4RLEE52E,84
M,I4^AT-/J'.A"$D)!8+MM$11%I_H03;^?&ML3C1;NJB#QMW?8.ZJ>]1(]G;I
M4 (^:B5ZB)4[D141%$11$41%$2O<7'>/RJJI%6MNWN[ZBH"B3K;P'P\*HKFJ
M!\TCQOP]M*5-$HHE6H U/=5H",<U5 JU!XC7^'=>I7#Q1:_=6\,6IC&4;3\D
MQ(2X0+#SFA8G3_238^-:C#3-<A8R9L*PJRX4*'9KP-O&M8+D'M5_B/W-K^)]
MKUB1\EM'BB['&<)M[Q;7[ZTUMWC#'-7AA8&IXW[^'9P[:BT%=FCPU]C_ !K
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MMZ +=5[$JARP413O1*E?@B*B(J(BB(HB7?551>UNZB442;W^R_A\:9X*T4?
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M .ZCQKK.Y[M(PFVVX:[C(NS:W]I^P+O7%/;N3<G-W#?M46W9B/)[QW]6M/\
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MRVA* E#=SRIM<DW)U+."UVG9VF/_ #9Y)'//:0=('P R^*X&[DEO+HEWTM
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MC=59VD_ID,G!,9^8_:HYY!H<EBWI^_OZ9EU8;]*G09$)_P O(HEMNQT8](6
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MJ!H%I5>]K: WKK6X;'N ),]:+?0[7(_"F*MKG4[%Y;S659>)#CLM<\F0^O\
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MB'NK=&U<S'D1,K,Q;CV,C2TN-.R,GB75.R<:VA1'^U.P7''$HMS$M<HN3:N
MBV2>%TL3,)G,%,\2TUI\J_);NX]*5C''Z <? KONS_5ABI'4+#X:<_Y"\A)>
MQJ XLIY9C\=Y$1K4$A;\D);3V<RP*XNWL;Z*_CFQU#5\RT@?:I+;Q.MW!N>'
MWKMN_P#U2;<98E052D><E+B%-N* 4"#RV4DG0I*=:X_<VW]V#%*TX+*TLXXR
M'56@LWU:JQN5R.VA->QF)W%-2YCLO!8D23C=Q.<K#9EPX;;DJ1B\@RVE+ZFT
M+6P4)<"2@+MQVQV\&V-ELMQ);92OUAU*^F^E"2!CI<  :9$ TS7+SP>KIEBH
M96BE.T?M'3Q6>/39L_J_ZC]XS,9-W9BX_3S N(5NW=>!RT/,.I;?/-&P.+;C
M.O)9SN492I0$A*?IV4EQ0ORI5ZCP_P!N6<TO_3MY6G:HZ&65A#J#/0W/SN&5
M<AB1D#Q&Z;K'M, <6_[T_!C3A_M'^Z.M,S@O<CISL7IYTFP#6!V1MO'X.(E*
M#(<9:2YD<D^.8JEYC)N!4W*37%*)+CRUJN=+#2OK/8^);/QVQ;MVS0,@MFYT
M U./\3W?4]QZEQ/=0+SZ\W"XNI/6N7ZGGM. [@.@[A17/.YQI32^8-I18Z )
M &E[]PK+<((HV^FT5>5QK[HO&EN(7F3ZPNM<;IQAF<VTM),24!+"%)#B8+MV
MY+J /F66D?-8<>7M-A7&10_@7,NWCR!PKX+E]O87PN:[.F"\-^N7JYR&=;<C
MX!;V2EJ0\[!:B++JUMMH+CJV@D\KB?)3?CJ!I7N.P\DL[.U$D>D5 Q[5QUWJ
M:=/5>3O5+K[U'R[CT1K,F.A\K\Y@!\N-DD!2;(*4J4GQL+Z5SUSSF66/TXC0
M=U N+<UQ/<LO>DS;6]I>73NB0QE),]4AE."=GB0AV;F)"U1XBVF$(<+49GS5
M% 4@I<<(*OE3<=>DY5(QK_YE'$'4:X4&=3]_<N9V2WB=N,3KD$V[7@NIB2 >
MPD5\*@TKDO5[K[O/K_MK:*NFRNFBLALJ4[B\U,S_ "L+DJ7!@QHZ)"Q*_P!J
M2\$,?(VFRDI*B;\W+7YV^[?,]LYISV7=C(_\+:Z8HWBFEP9J+G #$-<]SL<B
M*%>GV5L8X28VBKB3IJ?*"<!CV=^*URZ8]-<MUIWKM_9&+FHQ3N>4^[(RDELN
M-8_'-,AZ7(4QS(*W6VSR(1IS+(U UKI=_N'X: /AH\N(#?CU\*+-K:$E_0$K
M=O<?IWR7HOQ^9ZA['W)G]\NR\.B)E(;V*QBWHX:?3)^LQD6"Q'6I;;G,%-J>
M/.D\>8"NO37=RZZ8+UK7VW72:$5ZXFA[QV+6@=',PAGE=W]5IWN25UZ]:F9V
M]MS&;/W;M["XR<B=F=[9W9\B"S&CB.KR(V'QCSSLAWZ@N<RWUJ "4\J1KS5F
MZ>TM;CU+4![N@K]Y'9V+5TTCTN.D+I'5'TA];>CT:1FY>.9W3MR)Y93*CQU0
M,N8H1S./OXYU:VU-A5QRI<2LC7EX5N&\@9J].<&,GKT6#86OQC(=3HN]=,O7
M1A.F_2@=/HTK ;><AJM)8RC,B.^5190D&0Q])$D.// H%TJY74K!T/&M2/;K
M>X)E?(*$AP.=?V?<CR0X&GF&"RYCO7[+SF%8S&VNINVXV'+8\UK<>4;V_D&$
M@E*@N)D@RY)"@CY%LEQ*Q;76U<A#M^WRU;ZNEXS;C4']?P6FYG[V@$'JN>+D
M.IOJ=F;>S^W<"[OO;FW9[DZ:ZY-;PRLC-5&=CQU8-G-+A)EPHP=4IQU2FBXI
M2/+2I*2:XF\CLV2FV!(;U=2M>[M^*UVN]-NK =RP_P!3/1%UCEY!_>FV-D?2
MXR KZ[<.R(Y@/9G,,MK+JFX+[4AR$9X;^=*.<^;RA*C\VFT-\YFJVB+O1PH<
M:=_?19M=$:.)&HKDA;HS'4/:<WT_P=K;FQ,S<$%6*D/YG;6:P<O#1&%MHDRG
M$9?'Q0U(8Y>5ORBY99"DDI%ZMVZVC8V6 ZKBH-!2@/:2,_TR6; XDEWT!8:F
M>CK+^FG-(ZCXS(YK,8-26VMSQL@_(R<MF,A?-^IXXNE;@<B$$K:2!YC5_P"\
M!6K+N4MVUD4S6@M.! IGT-,QWE91L8TG22MN]L]5IL3$0LEAY2I>.DQT2(<R
M,X'6'F2.?F"D6OS)3:VEOA7+6VWB=FL?H5B][0KZQZCMT..ICM"7\OR:*)4%
M%5OE%@;D'@1:];X;&YV0J%MW2-&:LG5K=VWW,=@-R=3<S)PKH+[6(Q<.,J;N
M?,-/^6KFAXI#C3OT+3C0O(64,A:K!1-ZYFRVZ';HR^Z--1%&TJX_#L[S0+;.
ME<]VF,8#Y!89B=;MP[A1G=E;2Z>Q\%MV3%CR8&1S\B3/S^8CQ7$B8[D(L"1'
MA1$MK+:TQD*=1RD%:E$6&M+>T;IM& 6^ -:EQZBO=W#XDK&.,.=60G7T[.^B
M[)L7<.X\++4EJ),FY&:\"ZAMA7G+^8!+3$6.CY&$=B&TV!XW-S6PDLI[Z0:J
ME], /U +6+FQ#L"VI_S5F<5@)+NY79&"G2X$E4*#(;<CY ,^0Y>?]*\@+:9!
MN$%0^90T!UJ7>T';K8F5I%R\48T@@]Y(/0?:5MQ*)9/+] .)_4L [4W]^G--
MDDH42DJ63RWMKI=6G,>)[JXF';"U@:VE*+D'R#XK8G:O5MU]YB+'"G7'N5*0
MCF62HD('*!<7-;F/:9)7@-:<UM)7M'@LH;MWCB6,WMK;5FCGHCK>9W(&2@J:
MEO,I;Q.'FE(YG)4:.I4A;:B?++J 0%"PY._LY8+:/:8B2^NN0#($_2TCN&)'
M>%M(B'N=.?IR'ZRL:Y;K,'-\YQV._=AB6WCVU(_I6(#+$=SEL25$/)(O\.%<
M3_2'!Y;3&JW0>!&!T60NIW4'-R.@VZ<+ >F0MS=4<8=H[57'?<CS(F-?DQSN
M7<B74+0]'C1,:E<9IP*!7(?2$WY%V[#:6\>RVKKJY%;B5I;&W_PG?X0,.\E;
M!X-S.UC/H8:N/W#QZ^"UWWET.R4K9_0O'XW]:S>96C=&.3#=R$N;,DO+EX=[
M]02),EUXS9;SY:N@@!"  -*WQ;=;K' Y@.;@&C$84Q\<?L58Z.!TE3@ ,?GA
M]B]??2GZ$<IM#9,%WJ7D9&/F95R*_+PS?(K/PL0PI+XPZLP$F7CW,BX$B0I+
MI=0PDM"W.JWIFT; ^WMZ7AH]U"0* @=E1CCUHNLW^[M=)IM\6CJ<J]M.J] -
M[]2^F'0[!;?;W9EX&T\/+>1@]NP6X[JPX8K'.6(L:.A:_*BQT<SBSH.)-SKE
MR?EW&^$6$5[R"<6]I)((V48]Y+J5H&L:YU ,2:4 S*WO$>#<KY_?367&+8W5
MU#%ZLE7L8UK:T%7/+6U<<&MK4]!0%=SP>Y\#NK%1\UMK+P<UBI: IB;CI#<A
ME7,">59026W$]J% *!XBN:VS=-MWJQ9N6T3Q7-C(*M?&X.:>ZHR(Z@T(R(7!
M;OLVZ[!?OVO>K>6UW",T<R1I:[Q%<P>CA4'H5<%*[SKV5OEQP"X%'CKK:HLN
MX*E<7H=>%[^ZKEFJK>Z[S<. U\2=1V=AO5 ZHJ%:Q8W/OO?2U98JC%6J0Z!?
MYN%['L)' 6]]4!:K0K%(>XW4??K]GOK4&"U0*KJ^0?(2NU^'-[JR:*K<QC$!
M8[R.=;BND.J"1>P!-AXFQK&:3T6ZW?2NRV.VNNZ-C%7+9?HLPQD,6_G4 *'G
M.0FE 7LX@),@^'*%I%_&MA!=,O8S/ =40<6UZ5&:X+D=G-M=Z+&X&F;0'4[G
M9?=59NO;6LUP"--?=^&I^ZBB6NI]UAI_&KEXJJ((X7)/X^Z^@M0A$7%S<GLT
MUT^SOI0]$3T/?]X_A4R1(J^72X[KZ]NO?5IBB2B.\@]W?]FE :(D5&P\;ZZ:
MTR.**!HB!:^M[>%*_-$S:PMXW_+[J(E3-%F#HE_Q;+_[#E_[W K5@^OX+2E^
MCXK:NMTMLO)S]QT.1LOM>>>O>R.D:QM1M.(QN?Z\Y;T]2GI4;>,#]<W3N'.X
M=OR]][*PV!G+6O$9+ZJ AQEUD0Y"LBM319L\%ZD[;9<C;=P$=V;$R;K&%Q;+
MN2@0F<;!R#C4%A"YL+'1U+CP(DM22XVRV2AI"@E)L!18*]41%$6G5;1;E%$1
M1$411*K'LMQ]M:M%0*J)["?N[^[0T\51V()[*98=5:):?S_+CPI7HBXRH7]Q
MU\2.WCVUD,C7ZLE5 FY/VT)R"+%76WI'MOKOTMW?TJW6X_&Q>ZL<J.UDHAM.
MPN484)&)S,%79)QLYM#@'!:04G0UR&S;O>[%ND6[;>[3=0NJ.PC(M(['# J$
M BAR7Q<>JG!>JST(=1IVV.JNWLEG-E>>Z-J]2</%DR\#G<0%*4Q)=<9"DQGP
MT!YJ3;RUW"N4Z5].;;[F;7O5F#H9'=T\[<J'N_4M)KI8G5))9V_M70<1ZRMR
MS66EM2+A24*0IF4@A0"?,NFZQ< &]KV[ZZ]O.]1SAP%%SEI>%M#53W+UXWEO
MW 2<.SO+/;/?=D1Y3&8P$IAV?'>8YP&51Y"'8\F+);>LXA5B-%(4"*^:?=3V
M\XW[CVT%OOT+7OMGN=$XBNDO #L.H-&]>F"]9]O_ '5Y![>7TM]LKQHN&!DK
M" 0X--6T)!H02<>]8=WSU+@;2VCE8^5G9'<&5GXHP<EF)3BLEN3,$MJ2ZT6V
M$H7%BN.$)^GCI0E0_JYB+UUCA7M?Q?A$5=MA8;P_\X6@$=S *AH[\7=I6W]R
M_>;EON&_TMTG,>VMR@83I/>\BA>?@&]@6*_VR/5]ZA/3AZI\7TLZ604F-ZO\
MWA>EV+Z?[DGP\- Q^XLAE$KVSO/+Y%\.# Q8[JWF76$J2I]M^[B%*0V*]:V&
M3C]E>/DWN)\K/3(:YGU-<#6G>TX@CXA>/QW#9"V"Y#C::JZ02!JI352M*TPK
MG1?<OTH](6[$NL;C]0W4)O>>X5$/+VMM)N3CMJ8YU0!7&7.E):R&3\I>G.EM
MD'LT-<9NM_;7LY=:1Z+<9 _?3+YU7+/WKT8O0VR-L+?XLWGX]/@LU]9.AV4W
MEL'![:Z3;Q:Z1;BVGO#;N\L!F6</^MXJ6]@Y%Y>$W)C#*BRLEBLWCG'8[JTO
M!YHK"T$VY3T?D6P_U^&U++B6VN[.\CN8GL) UQZAH>T4#XWM<YKFG"A7(<4Y
M1'QZ^NYKZUBOK*^L9K69DGU!DM#ZD;\=$L;VM>QU#B*' K$W438K>W=QN9!R
M,RIV4AN0'FD*,9MUQ(\[Z4.#G0WYW,$W^8"U]:[5$\$4P6SLKZ5\ MM1TC[1
MWKK,)RQXZD]_\ZU2*>"U)&U"[=#?.FOM]M:)"V$K:+M49X* /PU_/6M(BF*V
MYQ%%>6EW':/;7MH2M%PH5T3JQO%>T-C92;'>4Q.F-G'074J(4RY);6'7VR+D
M+99"BDVT5:MS96YN;@,&(S/@M]MEI^+O&L.+!B? ?VKQFWL] $=^*T$)#BGG
M%!5E..+<6I2G'5J!4\ZM1)4I1-R2:YR>%S#4=!^GZ=%Z6R# >"U SO3_ !^X
M<A'C?2-N+??1R<[0NDJ<43;E /,38>ZWA6P!>":A8RQAH)=3)?3?L1&V.D?2
M#:OZFJ%@,9B-LX!$]WD0RJ1D7(,9H)5JE3\V4\>4 FY/<!ITOE/)]DXCL\_(
MN13LMMJ@IJ>X]7&C6-'5[W$-:T9DKI&Q\<WSG')8]@X]"ZYW.=[M#1D&MJ7/
M<?W6,;4N/0=I("TMWYU W_ZF]^#I;TI6B-"A)1(W#N-U*W]O[%P<A:F_U;+K
M:4@3LS.0VI,.&E0=E.)/+RM(<6GXAN]QYE^9GE7],V@NL^ VC_YDHJ6,:>C7
M#"6XD'48,&#:"I7WIM6S\&_*WPS^O\B#;OF=XRD4. EN)&BM*8F&UC)JXGXZ
MGD!;[=(ND^S>BVT8^S]G1'0PI[Z_.9R>4/Y[=.<=0E$O/9Z:E*?/F2.6R&TA
M+$=L!MI"4"U?:_$^)[%PG8X>/<>@;!M\+?\ :>ZF+WNS<]W4GP% OA#G'..1
M>XG(9N3<FG,M_*:-:,(X8Z^6*)N38V]!F3YG$N)*RDZVQ*8>COH0_'D-K8?:
M6 I#K3J>1QM:3Q2I)L:[&0"*'$%=2&=1F%X_^H_TQ;8Z7YG,;UQZE3FMSN2$
MX5N2U<;?CK'F38;;ANEQ]UQ20ARP6EI-KZJOXSSC8(K!HN;:OIR..'8>S]B[
MOLNYON1Z4GU-'S6M>S.E<?;'3D;FQ;SF.RVZLSDY\MYL,.M3X./?,""S*C2F
MWHK[2"PM2>9/,%'F20;5TJ">[V?;&75L[1+.YQ-14$-.D"AKV'YKF)'QW%T8
MGBK6 ?,BI_4M<^M&Z.KT7&8S=NSG-JY6=MLKA;A;S&U8$[)Q)[<]Z3AL\QD(
MBX643%7"6VT%*60V\R03<B_8[3>Y-SV\31T=>1&CZ@:@:U:X4H:4H*]H6V-N
M()BS'TW98X'M'C^I8X@[_P #U8_3I\[:FV,!U.+:G<_!F2<QMF$_.QJ1)F[E
MP>:A_48IZ"4H5(7&>#$IA2%#G6GE4=P+^RW$B&0-9?$8C%M2,W-.66-#0CO3
MTY;<$@DP].OP/W=BZ)N_<<].Y9.,ZR;5B1<DMY]#&ZMHY&5"A26R>;&+S,2:
MC(QI#<QDH!R$<MI6%!Q;=KJK"X]%\[H+EFEX_?[>PD?K']JL9>UNJ,U;V=GA
M^Q9%]-&S-FY[KCM&3GL;CUXU*\Q Q>WW<_C<^Y*F*Q<J9!W%-,4(:G,N2&4L
MJ0E!0R".8V<-=5WK;+27;YWL=5S(I'$ XX-JTCJ6X&M,L*KN/#)F/Y380W3&
MOMWW#!I<*M)KD0<#C3 X%?0MTFV1MKIMM/\ 3]M8C&X49F?+W%ET8Z)&B(FY
MC)!HR9KR8Z&D+=\AIII)MHAL"OKCV2X9#PWVXV_;?,;R=AN9BXESO4G/J%M3
MB&QM(8UN36M "\X]W.1Q\D]PMRW"S9%%8QSF")L; QNB'^7JTM &IY:7N/4N
M5ZSV_<=A4K3+EMH< )"2L=@]_P!U>LOM9I!HMF%SRO.6LDE/:M;-_P#J!P^.
MC/E,Q', JUG$C3QUT%JQM^)74CO6N,UOHX-/U9+PJ]:O7A>[(\N.W,9^F4M3
M*6W%J4'SS *;;2+A2K+[;<#<UP7);..WM_18N=L'4=09+S=7(Q./#6YMKK3&
MSC,"5'G1)T=$[$K5(:Y7Y$5DK2N%(()MR\[/&R03KT*RO[BU_DU)A'2JWFXM
MMI7:F@ TQHM?_P!/D]0-UQ\3D),=2I4CE5Y"(,-I/,M*>=P0H[,E?+S<#S:^
M-=OLM[MXL6QN=)WX_?@N"-FQSL'!>X_2[I OTW]#I6^\$W_F_)P,<G-,9:5&
M\Z)@F7&DNJ5$C/AUUEA2D!MYY6K?-H$I4J_C?O/N_++O;!'M0%OLC_+<.97U
MB"<*NR;&<G%N/0FA7<-CM+*$^<ZI^E<O[2L%[I]6&\NH6-DLR<=N7SY;*A'C
M9':\S#1(Y>;5RORI\ISZ1]AD*N PIQ2AII?3YCW#;;2&TK'C)2E*C#[_ +EV
M:W>==!@VO8M=^EWJ'1TQZE8?+9F8YB)>.<D,RGEQUQH3T.2RMA3Y?4A33$<K
M6%C46*;$V-QH6YAN;:./ !I (KET^?9W+*4%LAJ,"%ZH](^O>7]0V^,-MG$Y
M[;FZ=F.S/,W%F,)DXD\8O%Q4I>D"?&N7(LB6GE9;"OZEN73< UEN6V0-MZQ2
M5!('>*YX%:+': 7!N('VKV(Q>0VOCX;3<-F!%;9;0RA#2&FPAI" A" 4V)LD
M :]E;BU=M\$0:UC104Z+A9&W#W5=4K /7B;MW-[7R<!_R'DN17T<ETBX6FQ'
M,;@$CMK@]T9%<'R 5JN4V]LD;L:KPNC^GO8.3Q.^HLH06LHK<4Q_SPAA,I$9
M^-',=!>*"M3:>55KZ7OW5Q]E',;AS7@Z!2@QI\ES4CQ04IBK+TRZ&=)8>','
M,XF#E_T?)NQ9/U/*[YJTJ\YHO*NFS?EJ'+?0\IKL5NR\!<YH( *T'%E*%>AO
M3GK+TZV!BF,-A40<>S'0EIF/%0TR@*2"@I2E-@3P[[U@^PN2[70EW>M!P]3
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M*DZ1_O$0_OQCZP/XF#Q:%N474K2E:%)6A:0I"DD*0I)X*2I)*5 ]X->Q?<O
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MU$*6RX0Y]((Z4K#DAQQ%O+2VOFOJDVN-&*>^VUYEMAJ%*%IR([%E)'%.W2_
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M"JBHW'+ F_9\?<=!5I19@5\%;'GN-]-/P_LK(+4:%:'WK7-]!\./YUG]ZU
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M-;^QO/PS_.*Q=V!'@O)7U-3.JG03"[<=/2S 9R-]$U'GHW4QD)[+>1B,I8R
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MU,=EAU:,-) PJ*84Z8+E;FW@E8#'1DC<C^H]H6=L/+Z:R\%%R^V-U9+;V!W
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M)AQ,9B\;%8A8['P66XL.%#C-I:8BQ8[24M,L,MI"4I2  !6LQC(V".-H;&T
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M&IMWW.OA6DXTP76WPZA7JM6_5?UH.VML*V+A981E\[&*\VZTLAR%AEW3]&%
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M]+G2&$MQ_"X%K!3'+6G1(N/DRF0/_>!R,.8RVJ_!7(5#L-;(;#MC,8HPQ_:
M"1X5!"W1W.\(H]Q<WL/]E%+-^E[I%N>,PSNC&97<,N.GRFLMD,L^,BA@?TQT
M*CAF.W&0=4MI;"1W5A/Q[:KL#\6QTCP*:BXUIV84 '=1&;I>QN_E$-;V4P6/
M'_1!T@CIY=O,N88J5_C*DPXN86ZR3\S 7+"$M(4.)0D+_P"E6Q=Q': *0MT#
MK@'?#']6/>MP-\O?^<(<?E]RK\-Z+.C^$EB? ?W9!DJ(,@8G.R,1'DD=CC40
M\RF[?W2I0K.'BNTV[]</JM=UTO+0?$!8OWJ\>*.T$=XK]Z,CZ+NDN7?6[E<E
MOG),!U3\:'.W(_)C17%&Y+2'&S]O'QJR<6VR4_S3,YM:@%Y(![D;O5VT4:(P
M>W2N];?],W23;TEB2SA94Q,9"4,PY$]YK'62I*C]1"AF,W/4I2 29)=)-;V'
M9-M@(+&5 Z$FGR&?QJM&3<[R04+@*]0,?GT^"\!O6A@-T>EKUKXGJOAW)ZH<
MC.8K=VVIK[C[K284=UGZS QWG"4IA1XZUQ_)2>1"#:P!KYC]R;"]XKSN+D=J
MYU/49-&34TTGS1BO2E6T& !R7W7[1;CMG.O:U_%[IL8'H/MIF  8N%&R$#]X
MD!^HXD]5]).R]R[?W[M/;6^L&B))Q>[,)C<_!DH984M3&2BMRDI6L))\QI2R
MA0OHI-?4^WWMONEC#N-J:V\\39&GN< 1\16A[U\*[OM=WLFZ7.SWH(NK69\3
MQWL<17P-*CN*[#D8L'*P96,RD2+DL=D([D.=CY[#<J%,BO)Y'8\F.\E33K2T
MG4$$=O&MVYC7M+9 #&10@X@CL([%L(Y9(9&RQ.<R5IJUP-"".H(R*\4/6]Z4
M.IW1[9.\.K'I.V[F-\-0F#D<ATGQ@>R6Y,:R'>?(2=G1;F3G8;#/SB(DKF-I
M"@@.) M\V>Z'L7M7(S_4]JCTNU5?&T8T[6]H[1GV5"^P_9K\Q,NUN;L?,GZX
M0TB.9V )Z!YR:?[V#3UH<\-?LC9_UM[ZW?U_W[Z@.GN]^F71:3A,)@]CXG?N
M&R.V9^X=_P ?,HE3\IB,#F&HV2$/%[>*F7Y?DH9=6\AL+6I!".T^SWM_!P6W
MN!8F1MK.UNIAU!AD!^H-/[P;4%P&((!K3#K7YC/<3:.</L8+9ENZ_MGOI(S2
M7"%S?H<]N;2^C@TG @D4J:_0D5$7UL*]J7R^*K$_6GHITP]06P,[TRZM;6A[
MJVIN#'R\=)8>*XN1@HFM*:<E87+QRB?B9R+A27&5@%21S!0TK8;CMMENMO\
MAKZ,/CS':T]K3F#X?&H7-;#O^\<;OV[ELT[X;@9T/E>/X7MR<WQQ&8(.*T*]
M"?[1GI;_ &_=];QZE=)LAU&W=O7=>/DX.)F.HV<QV3&U-OS9*),[%[?AXG%8
MJ*E^>66T/2WDN2"TCD04)6X%;*PV&SL+D7@+I+EK"UKG!H+6G,#2!B:4).-%
MV#D7N!OW); ;9=ED=@9!(YC"ZCWC(NU$FC220W*N/0+U%4\L@()*@DW2%?,
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MLL(+(G.$CZC%:>6A02/(T-N51(VU\3-<DQMHRF SP[1X]>Q>5[BUNXM-] [
M8:?#.HZ'KV'$9X+T@"PXE+B%I<;6E+C:VU!;:T+ 4E:% E*DJ!T(K84*Z\NO
M[JW=M;8^%D;CWIN3";4P$2X?S&X<I#Q./0NQ4&A)G/,MN/J T;1S+5V T#23
M1M250"XT&:UZB^L+HOFWRSM#+R]W("BGZ[%QE,XXZVYFY$WR%NI)X$(L1PK<
M,M9),, M86[Z5-!\5WS$];MOY,IO!F,)40+EQI9 / V'*#]M;G^EW!%6D%:+
MQH-"LH8K<&)S2;P):7'+74PL%M]/_P"C5JH>(N*V4UO- ?YC2!]GS6((.2O)
MX=OPXUHJA!T&E$2UMV7^ZF'P1&O$]G8.VG@B14=+#[:"F95H4E$\*BH&"5]+
M6&G;VT5ZJ)X=OPX_"@1*_'O&OX_E5_6E% $]EOB.'V6JD)6B1.O?WWX7\/"J
M,DS3([=-*@*@*B2;WXU<42[?N[OC419DZ&_\82]3_P#0&9_OF/K5A^L^"T9_
MIIWK;6MTMJBB(HB*(BB+2VMIB5O44QR1%*(E_/\ *H<!BB/;\ZE3\,E4M/#O
MJC4,OT[E,$N;N^\7'V@Z4/Z>**)4? Z]E[>[QJM!K\$4?L\0/Q]]3$'O403H
M..AT\/ 5<SCDK]Z5,412E$12O:B*>")40)>(^PU,%3@F3;7CX5,\2HE?Q ^-
MJE:99*I7X]@%O"F7>BA<)M?B+\#?[>%0DHHDWOXGMJY#%$B?NX4. HB*Q"(H
MBM65PV.S,9V-/C-NI<;+8<*$EUO4E)0LCF^51O:]JR:ZBH<YIJTXK4C?G3Z9
M@9#KC+9<BJ^="T74.2]N8=HXZCL-;N.4' YKF;2\U#0_-88S>>9V]C)4Z5<_
M3HY6DZ<[CZDGRD %2= K56N@!KHGN;[@;#[9\4EY1ONMT;2&11,IZDTKLF,U
M$# >9[C@UH)/0'T;@7#=UYWR*+8=I#07#5(]U=$<8S<Z@)Q^EH&)<0.U:%;:
MV"WUHZO3G9F65D\7B)C&6WCYWR2$H<6I<3')"%J 9R"F2VFW!"%#LKQ[V2]P
M?_JO^*W26WE@F@D'J!Y!!:ZNC26X8T(I04IWKZ>]V=KC]I^.6MC:E@?/"66X
M;7-M ]QK_#74:YDA>HV.?8C,L1H[:&&([3;+#+02AIIEI*4-MMI2 E*$(2
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MB<*D8.;4Y:@3W5 7J7M%SF+@O*VWM^YPV:>,QS:07$ XM>&C,L<.F.DFBO\
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MCQ/WUEDW)3)*^NG?4KA3JJCL^/P]]2GW)]R*R&7>B*4ZA$5.[HB*II1$JQJ
M,42]O;2AP"J*PS-42UOW >'>.S3OJU&?5% D7!OWZ#LN.S2IUQS11!UN=:II
M7N403<W]N'NJ'#!5*H415P1%3-$41%7-$5$6IGJGZML[-VN]M7'2@WE<S%4[
ME74.<JH.'/,/()2;I=R7*01_[QO_ *0KY,_-3[L_Z0XU_HC9)*<DW6.DA:?-
M#:G!W>'ST+!D1'J/4+Z@_+1[7OY7R(<MW./5LMA)2$.&$MR,0<<VPU#JY>II
M'[I6@?HMZ/N=?.KD_KKNR$)73+I3DWL;L.#,:\R'NGJ,TC_:<R&U_+(QVS&G
M4E"M4G(+2.+*A71?RH^TWI#_ %[O4>##2W#A]4E,7T[(^ARUG^ZO;?S6>Z3=
M@V5GM=L$M-RNV!]ZYIQ9 ?IAKT,Q'F&?IC^\%Z;;\Z21\FE[(X1(:E#G6Y&"
M=%WL3R6 )_&OO6.8MS7Y_P!O=NB\KL6?<M7<EBY^(?4S*96RMI7*>=-B+7&O
M"VM;P%KUSD<K)15J46:I)"5]FOQ%^-8N;V*N;57&=N''X7'2\MDYB(<&"SYT
MF0X%%"$7"0$I0E2G%K6H!*0+E1 K@N0;YM/&-FN.0;[.VVVBUCURR.K1K:@9
M $DDD-: "7.( %2N3V'CVZ\GWFWV#8X'7&Z73]$;&T!)H2<20 &M!<XD@  D
MKK4SJM@E]-L]U"P.29R.,@8W*F+(:YT_^5(GF1$PW&G AUF2SD"E*D* (/P-
M<;Q[E>R\MX_'R;CTWXC:IVN,;]+FFH):6N:X!S7-<*$$5"YS=/;W?N/<T9PO
MD,!@W9LL8D95KAZ;@'ZPYI+7-,>(<#3[5@;T.;/=QNWMZ=1LH@G+[VSRX;4A
M8)6YCL8M3LEP*4.;EDY>0XHZV)0*Y;;K<0PU/UNQ/Z>.*Y#W9W076Z0;7"?]
MWMH\N@)P ^# /FM^6I-@!?2_?I^%<@1\UY(1\E7M2$WT-CVC[.%8D+&@58A^
MYU(/C>]O=[ZQ6.E5"70;=A]WMW5*A8EJJ$.D=NO>+55BN9#UB+G^F]NS^KNX
M5"$HN=,C770=O;Q]PO2BE/FO&?\ <(VY@.I7JW])G3;=F'@[AVGN-MC%;HV_
ME&!*Q>:P><W<F-E,5D(Q4GS8DZ%$4A8N#8@@@@$='Y# RYWZQAD:'1D8@X@@
MOQ^=%](>U%S+MWMAR/<(7%EPUQ+7 T(<R&K2#T()!!7K?TZZ==/NC^S,%TWZ
M5[.V_L#8.UH[L+;NTML8]&-PF)C.R'I;R(T=!4HN2)3ZW77%J6ZZXLJ6I1-Z
M[G###;QB&!K61#(# #J?F<U\[WNX7VYW3K[<I9)[V2A<]Y+G&@ %2>P  #(#
M +N_F>%_C6HMJIAVUOY42G5,.^)^P=IHB8<''P[?[*41/S;=H_EW:4H41YO;
MV</C]E6BB"YW$?B:BH2\V_;V>QX4Q">"/,M_>_/[A1% N#Q(XZ#M]U$4?,^%
M^'O^-,$42X=-;?9V41:&>NCI*[N?9V/ZP;9A>?O#I6V^]EV6&BJ5G>GCZ_-S
MD$A%BZO *4K(-"Q(;2^D?U5X1^8#VYBYYPJ6:W8';Q8L=(R@Q<P"KV?#ZAX'
MM7T[^5OW1/!.<MV+<I"WCV[N;&ZI\L=QE%)W:_\ +<>]O8N_>DWK&SU&Z>Q,
M/,F"3GMKPHS0<<65NY';K@2C%SBLDEQR)_X,[W!#:C_57#?EL]R7\PXB>+[S
M(3RK9 (9-1\TMO\ 3!-CF6T]%_>UI.+UK?FG]JCP3FYY+M,>GB^]/=*S2*-B
MN?JGBH,@_P#SF?XGM'T+/V^<WFL)LS=N:VYC!FMP8G;F9R6$PZBH(R64A0'Y
M$*&>6RU!]]L"PU5P%?0M_+<6]C-/:,]2Z9$YS&_Q.#26M^)P7SCLEK9WV\VE
MEN,AAL)KB-DD@S8QS@'.QPP!KCXK0[T@^J?J7U,R\O:G6C$#'9#+-JF[1SB,
M.K#QI<A'FN2L \T+M><EA//&)LM8;4/F-C7@OM-[PNYAOMUQ?=Y[:7=(]3HS
M& T^4^>-S03BW]TTK@0<5]+^^/L=M?"]DM^4<49*W;A1L\;WF0T--$S214 D
MT>,L6D4%5Z&%RWM_&OH:B^5P"J=3R1KV=W;\>ZJK3IU5(M_C?AX7UX5:(J-R
M1QU]U*=%E0G)4#DE*;ZVMX<:NGJLPP!=8W!N/'[?Q4[,Y1],:!CX[DB0Z38\
MC8)"4 VYG'" $CM)K-K2\T&:UX89+B00Q"KW&B\A/4/UTR?61UW;B($>)M?%
MR5SX!<0E4B/(CA;:9[DKE#H<4VHI*4V'98FU<JRPB]/S_45Z5Q^T.Q2?B8R3
M,6T=C@1V >*PEL;>.]-MY&+E\!../RT-/D1YR6P\X65L_3NEQ+R5M+4^T +%
M/'A7)DM-M^'+06@ ?+);^[].\#FSM#FO-3]_WK/T[<>Z.I3N*E[J8Q\K*8]D
ML-Y>/"3$FRF%&X8FAI0:=#2[\I"4E-_&N)N;&)[269A-JF9M&J.$N$#S736H
M![1X]?@MINCS>7;9;P9;>D0W"5,"RB8KJS\P'8EM=R2.PZUQ\49MZM_<^[^Q
M<9R>6VN?]\J&W %"?XAT^(Z'L6^.R>D\9^.F;FPE:%I46DI2A92L@I#B L+0
M5-J-[D6N+&L7S$F@R"\VN+YYJ(C1?/QO[<WJ,_;G]6LV?U+S#VXMD=2]QSLW
ML#JC'C.Q=O[EQDA\*>VGEX@<6Q!RN(B*2Q(AJ7<MI2^T>122/B3W0V?GG$><
M-Y_M5R]^\,)+'&IAFAK5UN]@- P-\KH\Q@]IK1R_13VOW#VS]W?;$\"NK9D$
M<<;6R1U'K0ST\MPQ]*DN=YF24I^XX9@_1/T,ZY;.Z\[,A[KVM+9$@,L#,X?S
MDN2<9*<;"O NPGS<M.@64-#90(KZ0]N/<?9?<C8_ZEMW\K<H2&W5LX_S()*9
M'^*-V)CD HX8&C@0OB/W0]L.0>UO(7;-O#3)8R5=;7 'DGC!S'1LC<GQDU:<
M1Y2"LT??_"O0NB\V6FW[A$*9DO1=ZA,?"*DKF[)1%DE']7Z>_F\2WD1IJ4JB
M*4#X$U6DZAXA;FS&JX [C\])7Q,;-Z1X[/[0A(5$3Y^UM_[G+:%-I)8;GOP\
MHPBQ"U(\Q*W2 =#RD=E<C+&]\]*9M'ZUN8X0Z%I&8<0?L*]B_2TK"X2/#%V$
M!MEI""FP4K062INPO;OOQKL%AMKG $-Q6N8J-H,UZT;4RN-F8U,9YN/+ARF/
M*>8<2AUIUIU'*ZTXA0*%!:20004D'WUR#]OD::BH<"N*F:X.PS76.GW[:/HX
MWG(R>X,GL>>N?^KR9CV,@YGZ7"J8F.F0T&8347S8S*'%J;*$N6!3\M@0!P^Y
M;GN-C-HC(:QPKED>O[?BM,$$5(%5Z$=+^@_1[HO"$'ICT]VYM)/)Y;DO'P4K
MR;Z;6L_E)'G3G >T<X2>ZNNW-[=7;M5P]SCWY?+)7IADLLDZ::=VG'AX5MD
M4/#OJ565 CLOWFWW43JH7)O;PMI]O95R3 X)7)'<1V\#W]W=5R\$2MIKI;PU
M-_X5>J5[$$\1IX:<._L[:E$&2C?3\?'[JJ=Z.'Y>-%#@HGL[NVA0I'6L2H2E
M:_NHHC7N]OLXT11OQTL>/P^RBM/DKEAL1D\]DXV-P\=<B>\HJ:0A8:\L-#G4
M^X\HH2PVT!<K)%C:VI% "XT;FJ2&BKLEE?\ Y6=4NS(#O_XDF:'PTK6]*7M^
MU:/J1?H%'_E7U2_\X#_ZY)G\*>E+V_:KZL7Z!!Z5]4__ ,/'O_S+,O\ A3TI
M>W[4]6+] HCI5U4'_P"4$D>.Y9E_MM5].3]"GJQ?H$?\JNJ?_G#M_P#9--X=
MW]-/3D[5/5C_ $"LG9[N-:9!S&2R%*)> [4W'9[A60  UA5(WM;30>W94&)J
MTFI4/8HD^[X=W=PJ@4.HJI:=]7/ >*B79^=3'/X*HI7JB*M<$14I5$50:9HE
M6*(H2?@B7O\ LK$XXA5(FQ]M/N-6E0F:B2=#WZCPX>&MZC>Q%'F\!;N[->/=
M4KA1$B;G@![O$7UH,T4:B)T.*(JUQJB*B(JE$5$2HBZ[O#<<?9^TMT[NF-*?
MB[6V[FMQ266P>9UC#8Z1D'D)Y0HCF;CFY -A7';QN#]JVB[W6.)T\EM;2RB-
MN!D,;'/# >A>1I^*Y38]M_K6]V>S^HV'\7=10^H[Z6>J]K-9[FZJ_!?/#/ZV
M(];'5;&])^D6Z8V:W=ON>N3N#+P7?K(NSMIM%*\[N.6MM7EMQL/C;HCMJ*?,
M>\MH:K%?EUQW@_._>7W1_K/*8I(WWD_J2.</+'$VF#1T9&P!K!UH!F5^KU[N
M'$O8/VVDNHG0NBL(!';Q-<"Z:=U0P&F;I)"7O=T&IV07T%=.M@;7Z5;'VQTZ
MV7 1C=M[2Q$?%8N,D#S'$M77*G2W.+V0R<UQR1(<.JWG5'MK]2-KVRRV7;8-
MIVY@CL+>,,8T= .I[R:DGJ22ORCWW?-SY+O-SO\ O,IEW.[F=)(X]KL@.QK1
M1K1T: %W/GU(.EDW)[CP^-;^BXJG8ND;JV7B-SLJ#K:&9?*>22E ',OL#H N
MH>/96;7%IJM:*62(U:5JCNKI[E,#(=!96IL$E*DCF0H=BDJX$&MXR4.SS7+P
M7K9!1V#EI_ZC=T?Y;V0Y&>4ILNF3D9"1<%4;&-**$$=OFRG$V':4U\;_ )RN
M5/MN,;7P2R<?QF[7GJ/ S,,!  (ZA\KVD?X"OM#\GO%6[ARV^Y=< ?AK"W$+
M"1_SDWF>X'IIB80?\:Z5_D/=.+]-^R]D83'29V7S+S>X=UM, >>B?N-][//M
MR&U%)4U%ES&V5J-^4-"_"OHGVWXDWB?M_M7'0*20VK'284_F/'J/P[G.I\%Y
MAR[G%ER3W>WGEMU(&VYE?%;DXCTH:0LH>]C"X?XBMO\ IWB6=G;.VWMEH);&
M)Q<:.\!;E5+4GSYKEQ<$JENKUKO;6!HTA>'[S<NW+<IKY]3ZCR1X9-^P!9'9
MG!5K*&OV$^_OJ47#.8?BKHW+%M2;Z&_'^51:1956?>&[D;1VQEMP*0'UP8W-
M&CE12)$MY:68C2K#F"%/+%[:\M[5DQK7. =@S,GL Q)^2UK.T?>W3+:/ZGFB
MU/Z&=4^H>\>O&7QV7S\F9MP[,S>;R6(((Q4&0G*XF#A!C8QYOHE)6^Z >8EQ
ML*YBHZU\8^PON'S#W#]V>1WEU?3R\1C;)Z-NX@Q1 3!L'IMI1KM -2,75.JJ
M^U?S >VW!O;[V7V**PL((N6/NXF.N6BDTO\ (>^X]5V;P7:: BC"&Z:!;X(D
MC^[I;C<VOV5]D47P\17!5*9 /&P'?\*BQ+?FN9+HOH?Q\>-%B0:4ZKR<]2+?
MZO\ N.^ER)8*&+Q>%E*M<A(&1W'./-V CR :ZMN$8DY';.ZM:/O<5[[PZ3\-
M[,[V[(R2R#_D1-_6O6WS[DVT!)/'CQM<5VBB\ H0IAZW VOQX@'\J42BF'U:
M?-I[Q_"A"4IBIE\VT-M>/'O\*4*A4A(-NP^)T_*HIW)_4'N'VT1,/GN'V]OC
M1$_/\ "/&]SW<-**I>>>X?;V_911+SSW>/?^7"E"K]RX_.5J0;#4V'\Z*$*!
M>_Z7CV"JK2O@NH[NW]L[8<.#D=Z[FPVV(.4RL7"8Z5FIK<-J;EYQ(B8^.IP_
MXDE[E) X  DD"MK=7EK9,$EW(V.-S@T%QH"XY#Q*Y7:=CW??9GVVS6TUU/%$
MZ1[8VZBV-OU/([!_8%V1:FW6UM/-LOL/-K:>9=2AUA]AY!0ZTZ@W0ZR\THI4
MDW"DFQTK=4!%#2BXUNII#FDM>#4$8$$9$'H0<0O%+>6\=O\ H)]0"(^XL[$P
M.P<[)E;BV [DY266,GM#)/\ )N#::75^4RJ9MQ]PM)2/Z&Q'</\ 57P1S;CG
M(/9KWGMN<\2MI9]DG)=+%&,'V\AI/":8:FXN97)PC*_3;A.Z[1^8_P!BIN)<
MAGBCY1:M;"7O(!9<Q"MM<BM3ID  ?3,&5J]B7Y+6Y]KNN87).0V=S;;6[A\N
MVG_%B-9[$E>-R3:3P<81+;= [Q7W8_3N.W'T'.C9<V_E=DYHD9Y74Z.&H&G0
MA?FW&UVS[P&WD;))+2[ D9@6N,,E'LKD6N+2*Y$%>->P<SN78.[\CL3=H5!W
MKL;*)C2@M:K2_)4AR'E(CROF>BSF>1YEU-[A0/$&OR4Y5M/)_9+W%9O6W@LO
MK.XU#/3(VM2#2E62M./<:YK]<+:ZXY[P< $T6F3:K^VH0*5C=2E*8T<QV%.T
M4R7KSM'=T;=VW<=FXS@)?:")38L%,3&@$R65I!/+9>H'<=-*_4C@7--H]P^*
M6G*]E=6UN6>9E:NBE;021/[',=AWBCA@0ORLYQQ#<>"\GNN-;FVDL+ZL=TDB
M=BR1IZAP^1!!Q"ORWSW_ !'PKN'<NJ!IKX*C<D:7N.^]6E%F&@9JW/2P!Q^R
ML@"5EW!6B1. [?XZ&L@WJLVQDXE:O>IC*37MEPL5""E?JF4"'D)/^L#+14VV
M;*3ISKN;D:"M]9L&LDY@+LG'X6_B72.S:W#XKSGR.U5( B,F[9/-*?2#:0Z"
M= H$!4=I5PD?'MKD@<*G+L7=6#5B5WK:G3MV2AORV.;F4E:2A!!TNKFOJ ">
M[2L3(*8+0N91%@Y;38'IUC-N;?F;PWGEL5L_:.%C&9E]QY^7'QF,@1VQS.+<
MDRE--7MHE()4HFR0385M)+C'2S%RZU?;LQAT,\S^[]:T9]27[A9P>R,QA_21
MC490P7DHS_43(QG6<C(PK*^7)2=DXE:4O*<+8/)*? /EW6AN_*H>;>Y,_([?
MC4T^P$L>06RR-KZD3"*:XQXX%V;:U':.]>T%AQ;>N:V[.;5DM 0Z*$X0RR U
M$<ISIU#< ^E">AW-_;B]=^/ZK[>QNV]Q9DR)O*VTZ)LCS)0<6 "_S.**B\VL
MGS1Q4GYN(->3>RWN#=W4A]N^73%V_P 0<ZRG>23=1"I,+G'.:,5+"<7LPS&/
MI?YD/9BUVFON-PJ$-X],1^*AC%&V[S@)&M \L3C@X9-=W'#T_P"OW03IGZFN
MEFXNDG53#-YG:VXHX4S*:#:,MM_+M)4K%[EV[.6AQ6/S6*?4'&7 "E0NA84A
M2DGW+>-GL=]L'[;N+-4#Q_M-=T<T]'#IT.1J"5\M<7Y1O'#]ZAW[9)#'>Q'+
M'3(W]Z.0?O,=U&8P(((!7S-8;.>H']J+U$0-@=19LG-]/LQ*>7TXZA)1(_RW
MOS:B70VN!D$E2FX65B-%*)D-2_-CN6<02A2%'XPY/Q7E'M7RQG*.,.#;UE:B
MA$-Y!4:XY&CMZCZF.HYIR)_1SC_(^#_F(X$_8M[:&W  #A4&:SGH=+V.(K3^
M!WTO;5KNH'TW]$^M6RNO&QH&]]ESVI$=Y+3.4Q_FH<DX?(J:2ZN&_P I^=!2
MKF:<&CB->-P/J[@G.=GY_L3=ZVK4R4'1/"__ #()0*NC?VCJQXP>VA&-0/S_
M /<;V[W_ -L^1R<>WUH(H7P3-_R[B&I#9&=G8]AQ8ZH.%">\[QVIA]];3W+L
MO<$<2L'NK!Y' Y6.0#SP\E&<CN*3>X#C7.%H/8M(-=S&!KV+HT<CHGB1GU U
M7RF]1?2ON+HIUEZB]+LC!<+.Y(<O.[,FE"D,9[)8<OSL=^FN^7Y1DY;%NNI"
M;Z/-ALZFU=IA:R>-EVP_3@[NKG7XKE(IAD/H<?D5KIM+J+,VCE#$=2Y&0T^.
M0NH<;YFU*%OE)LV4@%)%R0H$5Z/LMH'TJ%K3/#<6T7H[TFZXM.,,?[4+*Y0
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MDD$$$$&QJ(L.=,?3OT%Z)9'<F8Z/=&^FW3#*[PD?5;KR6Q]HXC;TW<#GGKE
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M:4(%M#=2R /C6)9C0+1=$78 8^"M.0ZJ;%P;3BLKNW!Q/(05K:.08<?*4BY
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M'L0)?8+#QO;MJT3'J,%+ZH=^OQX^^_?2A2F%>B1E^'WFE"H,<ETKJ1BV]U[
MWGMMQ(4G,[:RT, W_P!:N&ZMDZ@BX>0DCMK2GA]:!\1R<TKE-CO';?O-K?##
MTIV&O=6A^PE>>7H9R;F!WINS;;A+;>9P"):4$V'U>&EI2=.Q19EK\;"N$V>,
MPS/:,&O:/F/^$KVGW7B%YL]M=M-703D?[,C?VM"]-%3R.*B-+'\];UV'2O!
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MC^@2R6*>K;)6IC% %E$ W5FR*XROQ= 0%-JSTE]+23FGDU_M%:+L_DH_=0C
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ME+./*/7@GI]PO1JRN_\F>(^F,ZE;._H_YXJ.ZJ'_W[F"J5G\TO!O3HAPI])
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M-PKW\,\WYTUPB7+P]F,-MR6@TYZNWN>WE8=53^[F5$O]R_*%%>;1%C.P=P?
M;;#/6=<&1'%VV8V^;P=\Z4&C=_+6^>LWNP*-B&,]E\8VS 5=F5??,:KQLIQ
MP[XF*_5),.6EMS5D3M]VY58^P"V0$'<X<FKPV:$FP><8EAJG,'FBQ$= \%J=
MR-[YX+28Q2](KHRX3OWE7-?2H@2KV1KX<B5X]1UY_\;7R,D=\01]Q-36)J6,
M^XXAY+EX%@ +'8-'+^SG?/L\ S]98)_[8]Y4()1822]JU85F]: =Q>:UZL+2
MTNF&,:6,U'SU\9D_Q@0NH)-'M+\_L5$TT,AVK'LXMKENT>]+9'J&._PM\R9E
M,D(MKNPNO^_M-O/3.+WB:O];V9CZ-K#-YK.2E4," NPGST?HAWAP4*/L^$9-
M<(@1LJ7E;/$KA6F'+!!=]\Z7_(!*,K?!0_V:2N)L<,N#^2Y9^+0MOK<(4,G!
M8?H(F *H<$K1C5T'_+*"&0Z=,)?D'U$V=>311AX/]SDWB5UG7WA9*EJQR^DF
M%[._=U!]^0.0# Y^HONCR)A#51> &4R&8&OZE-W54%NV;ET;6XYFW(-EE=[B
M^;,-K])P.;JXU[0<8O&QUKLO;#:/B?-*[QENK]Y<3LS-&7^27G%W738T]O[C
M@31/;+CD%JUOXW( =I1B;!4/;"!'A%Z\(Z;%5&)0)S?FJY8,-6(L'EU90=R;
MMGQ.N:]U=[]5*;#[?HB>6T%7-PS*)R^8T<," YH4_-D+3R^7\4Z:SN<UA5/9
MO[M@I1X>@QOWLW49(B&Q9=IYN:ZX3T]TV'ZKZ>MP?3MJ>B.3<G2IKUT<%-KV
M"&#P)E4F6H37GJ!U]!U!S6AW!B"1W$WT!XPN?6,=6JW(RZ/C"N)(!FA/>->,
M AV)DQF\S8*!NCE%'^,5OE!5YP7'[.N:\#50<R:C>0C4<DNS+$/TL*DL4H=(
MM8 ]XH$A0'6>6;5:APQ'7K]V4+^"(VDT&^L_EXV@!1)IN/ML-?;\L8G@/>;_
M(<,7Q/[T5R"PZ>!=*=6E2.K.T"8X\P88O$K3XV5W&7:R]S#Y"!#8\LB0;)_K
MVK5]^)8X^ C(VI%U> 14+].\?]W4H.DIT.4K<&XC8]^$/:UPZ$V>^=]I!VW+
MD330^9FGZ:8>J<)_TRJ55X,,P!HBLG4C]>4#Z5<:Y6NK:SW75RXO=8B69"4A
MU >+B"Z#"EZ!'<YD@M:]'@W.21L%,MX]\HTOL%L'>2HT[[OCCK\5M=_%%LQ\
M[M@+] W^JQX<%638)?%5=]ZPN!>(S7:7X;L_KU+I$[?.Y")V;%!@+W8OD/\&
MNW/DS%,^Z6B</YEK )0E2*9U]'7,%Q,7<YG&X\U6I%1@U$]%_4J2L"?Z#R':
M[$OU+2*4E>A7. -V[?W7"KZ@KPB& H9)L@65PCOO+R)J^_34:29E_BW=-C?1
M==>X%,.W+Y[$"T2TU-'3:H73<7*9V4<O)W%KIIV@D-.JE22K"0\_T5_%)BW*
M.B(1 3P!0!U5 UYKT-(C8"#4P%]'"76)GC&@.$'(*\S\'/GY">,2 3-Z$<7M
MF[-'H>IKJ-$^M[67TS-NLVA"Z\26NI2N,IVT03826J$V,8.(4@%\+W#R(T<T
MF_Z>^NYGS/ 1%'QM8)("GPA;!((S@> EA^<.)9ERI@Y%(@EA,&"C1SXX2TX&
M1QF 866JKE(^4E8:@!U;$W '<N'4>1G4=D0]P:BD]TDAK-5]^G>\-Y$?XC;"
M_^W*0W6K7Q/1U,HBY-+2X :4D94 ,Y:<ZIU_8VRF:!66/H*\^U'EJ6MKW;[S
MJ>Y6JS@M*:51MVCQ:\]8Q\":MF<UF,9C6P2UL@DQ\$IM!FPG<2K*A+R/&*:N
MM;LT7<D(J%QU<6&)/ /Z)@HW""?/S+])&@A6)LCC=2"CI)['I1W?G<^[+9UV
M+;TOGEHY:F<\BEW'M; 3;?%L[O\\T$-;X^]8\BZV6U!@"JK6+SHT[2+V$I),
MNB[WMD6)Y\^7JJ^"L>_K^H^/!SHVH_8(0$TOEQ"RQ^7E>14'@7MGA2AIX98M
MB_B\06-:H$.^3T16T=M-J_*%G$92,J&*)7'D1<59;_DDT?]*9EXJYKQ[1<BI
MV#/14ABG[3F074[T<_7O\,3F)Z8 T4= BGE$^:]1V):1Z!L(]2K$'6H#6<N2
MZ!Z_PERF>@20-]Z2E9L?9NU_R1GENYH;E(^DQ:^&7>N8\+Z;,6;JW('UKD:F
M??\FT@(E*>V>%Y:I>)7H"7-Y2G]2"R22H0FT($M\7J1P&TC^X,V95TS<#%D9
M..T@(=9W=8'[-NVGZ*M(=I2B;K_HHSYLIB!/UN4K"+=T%!BL:PD>5I]$)$)%
M[0CK+.$Z-J'$VQM"#Y+9%[HA&X5!3ME8O]Y5<,E;)L,:XP?.2OT_ZC);K)3&
MA[L& 4V\%9Z1])J9QO>O])<5,!?6,JP?5SQA!CKYNMUZYR'5=0_I*?[/\#*B
M]#MC1 J7OL(G+5O'@A]K$661)%:!TMT1ORUE8]'_]=-9'79T0NBJG60O[OY?
MJ7+_GU2A.Q LHXR-GTL]RSJ8(51J#8*T>C\"N,6K(31#0(8SM)Z(CQ-#XA!0
MY,V4SQG=FQ74FDC@<7ASP^ELFC4'H2#/]B0N)Z.B>DL<N37+ 1833_SX)W>_
M$?5$0;*,@>XA!$LQ06/&A[L?MEL]":EP8"F,<,"/$\=$-Q_TDB#Y U<L$:E"
M8<I ]2GG]K_]R*GZ@1SU("2_7V! 1*8@7L#)* G'9?SVRO[9C.Q#MC<2":6&
M>N2[I=#QNN:M@^*?@/8KTMY \:)-!TX0!OQ71<\IINYG](N^H'6>_-]-%PQ]
MUHPB#7YZ7)))LI?G:N&X/Q!Z2;K?OXFG].G7(I&HLHJHV+;;VL6KDPI^G??Q
M]A.^MT[&G[^1,_C"%8AZ--YIW+?9USB87:%UB)!W%07Z<B%'#UZJ,9-'5]-_
MM&B3.C._!"3K-E(R06 F_17K^K%-*'J1DYF)<ED3+]RG\'#,\B,&JZF"\&KB
MY@E?>.:=5T$XAF:%Q+_-)\@=ZML:]4F/V53K][79K&;C;J+DDFG#75!L68V#
MY6_-%4<6\6+TI'Y\4'_%JR^/ -ZEG.>)TQ9LIJ90BZ%\XJ>7,(CFJF3_#Q_&
M%'GM]7R*ENE&I^X+I]F7*FLR\Z%A:>NP=:T.4BD7ZKU:>O*2Y_\&]ST8@"(+
MF-2N+$/?7!5PF!&1$?'\RU),I[>[$4C,KONY N8O]D!$T%B(A,XS&8=JLF)]
M,E!NV^%<01Z+@JYD:5O$!N@;YO_3V+N')9FU\;]XRL))0T%G- ^#FHB6-:/5
M>+8@#5-Y%+34T<[C812M/+R1FI8).&I:E-EH^A0*F)HFHAG2:&F'J<D\I:AH
M3 </B)0!">H/ZWVOO?>UKWU=^Z_GCT<0>.[UO3_?>]UKK2;VX:I_A*2[7P9
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M=KB(E#6V_U(OH?!/W>'.G!K#/$BQ76L&_^DU&3- 9Q<UM$7K[MB7$(:Q]F?
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MAG<8;H!VQF=[C&_/_#+"=8*=;2J],QG7KW$0%\GK^5150V!O[HEN%P\VLCG
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MN>%$[4LR@M4"'D+'>\;5C DP^S3FQ55HF\#[SM7VM#!&, NA(9C$G6?3W1$
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M_@,9'^RBXU/S,RY[P__#Y]Z5,A" ;@\W<$YH,5*[L0-J4^&:DW47UTQT>D\
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M-YXH2N.F$ O"?N@?;]*S0M$)6(1Z>!R28G4TDLA9+54V*%^BQ0[S/PWF;Q/
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M84G)(JE2(E<_]A5(VPJ$T268Q$2O#/\?4$L#!!0    ( )M9:E8MA'<ADCT
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MX1L[4A(@!WSDH"+\)D&-"?.7$0P\#/P?9O\S%2;L>S8L,6-'.-"O;T#VN-Z
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M?UL^.V?8FS%6XIP9%2<XK=OD:I#@!'\IY52YS,O["MA!0'D(D04?8I0GNE=
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M]2EJB+.\%_IHHDSC-"U._T!'@8OLFI[X"K"M:C>/6.%:HO/O>4,;$/X)#F<
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M/R9^IX:+JK(M9?C^-XVOZGJV(J;^:%VZ7*2DF,>5?-.J/'6.]X0:_.%]H>B
MV/:#P0-AQ7MWZ<'26INC/XG;4T9<M,=[1*QGV)(O0:NXSI5F^QL2GC56J\-W
MT(JT+H8U.N&>QNS@2MV[DV@4GJ'IOOJ7NL$#/!FZT_2+;UK;&VN$)P+,/P<"
M#FU,]_78-6K)<[5G:TRV-K-,/%8A).CNPA_/M'/L.$J(ZAF\7VINROFJSGT7
M:@XFZQJI"S:;,_3/6 *_<T1U08>T;7':3IY(3L-]DH MJ080S$HL3%P\FYI%
M'=>[3J#3^NCY([0QW9EB;N4HG>;BT[W5*'M7!72V/OB&,7IV>A4AL#5 8;Z
M2+S/*%O;1EQ?^J[_Y!(Z*"]4PT6!&P@657+=J:Y6(V]O=:W?[:N9&QT/)'SQ
M[+KCJ^RK3=]77/2,LA+ /?;;?V;NNGEAD3_Q5N2+]";*MDB$>)9*Z%A/1S3:
M9 R0L EPP?1.(<1@';)L.]2=Q=WM=3M1?=C^L>5^PG7!]L11F_AFT1L7;ZSP
M$>%$3S[P/FE.62(STU8CVV$_A"KQ*_$\PBJY' UV)BZ&4LNJ$;E^Q8>0#__]
M2MJKIZ7#BC:(JKZ:K*PTFYC/Q+F=W5G&2=92R6)J,?_ULF9"+D^^5K =3Q:X
M*?/I3I4"XX?\+GS=\BRQU#5<04V;K[EET-$$)4JYZFPII5J7N I%7@77'*W&
M_CR_*B8+Y4KS(Q7]?+(EF\E' &Z]*JP9@&4VZ'*58+QOMM+'YWJT%3^B1JNJ
M5;'PW' <6"5BUJ;*P*TG1-A?6?;Q\D;[;<C%QPI58X<D0]EVMP')?'P(?92J
MA$Q.@:?M/;BM69?_1GJ1N7U/ !MZ] B)'B,PXK(@4O1C?K0Q/X*XJF36UYLD
MEF^WJ_+5KKV=PW1R&TX#\1:D)J:U#.4_!!]#$ S#)S8W+YY>Z"FI4')N)_BB
MK/C:=?D:(-B8[GO6I46A\$YWW'B((R,ER@O79(ST84'BH9&+?.+]=8RMJSSW
M"XXJA4(Q$Q:>*!\TAJ5 UHW0NO,?W<WJ5#@V:>^R=).>I5X!MPO&+PE&[5I3
M,,=D[U97:7^%_'OOD5E.$(?)IA2EH&^3Y:7F+&_XAFIL1'^QJ6%Q'/7S@3)&
M^#3V=3O@,=Q.*1]E*-1]D1Y\I=CZ)83XGW5_[]\.V9YY'(([)3;(W8BIY9;Y
MR&;XI]^R7U:#E03+L+C6(O#&L@MI>JF5RJ)B8XTIXL9B,U]FNNK\PT3SQ_S&
M?=SZ#XO:/97=[Y;(H!EH#;N),OK."JLL L012YIER_EK*UQ7'D_['2M0\SB_
M1^5N\YI/ZDN""E%3LBO1)(P.=#(PN[U]K>RG?)_!M;9686D6N.US)"Y^K<I!
M[6J?*IU C1D1)6'-BOF8LN.&BMNJ%MWF@B>U5=COU>FH1*;HQHQ92G3 ?< !
MB];K(SQ$E90VFS[=.*%5M=1R0:I W,279?/LO0!(3+(200YD7=*G%:=OY7W4
M4R$FK'&X<_:T&9&JKOAOJ(2"!)IC+4]_E$5V3D5#Q5KE9$D#P[5N@V<!S3I;
M5DQ*Y%0ZQ1S@L-5@!26V]*V<&DF3]HCJ0Y.!D3OS=V_9W._"U<VR:U=TWE%N
M7&N4&IFL%A%I;I-F(%VNMJI"H@*U"E6<43Z97&%U"J0!QU'KN2;T:QQ&I[=J
MQE<AC<G86B@^D>]PA8X62BSN2[8B,ES9?F(5R$JHJ)-BEK[L[M&#58K>C[$.
MK1Z8Y;%.GHZ9,EY)+C,_C/5?&Z (CQ+/96J;JY3.45<WM9IM_&":"\]P8[WQ
MT-!XCQ//D#*A+MFNG@Q2@0UC'[KTG?E:?<KW0]'R^^-;D/^<+8;.O+AE@YIU
MS7+"L])0NLS1Q?+Y2FM+<+Q[085XA]TVB/\AEFE?EXG,O6>+&EGU]T7F$(?W
MZ=H;U^YI5BB-9/-[W&^ZG^J7A(:39"0N\@^3P[.2SXWRO@$OIQ9.>4\'O/*N
M)W;S-C<^2K;=9@AZ! [QJ1'LT!X07W:&R QU)7!K+;U19,0$87=Z/9;Y*F^<
M?N7ZHE]IK,+B<$V\@<]/DS++'#L>+[7XS%IK6D0X0JN^E"49QQ)T*_MDVDP8
M7?^6O>%(U</WJ/A;UTC5,O<LI6+E!@,1)0VNK,MQ#T93.ZGA1.(8]1GFM?.P
M#AU>C)X\]S4M"LEP[#X4B_G-@%&C5+Q)K0"J::B&NZU:4D "F(TH/_5.GLUO
M+29_T6'NN,YK74*3@G@NO8#M'> 3!BS?WT=:C::#B[95\:E]%DZ48_HO>@KQ
M,[/S]QY<NZL<\1Z?W21WB8.5EU-+NAQ,&9F26 K"4W\D 0+AF5>>EU([ZKL-
M[4P<-CV"K*N7Y_P^Z[D<*6"['.E:.5Y:YEVZ.?ZFTHJG;Y89DBWSFWE;$$[-
M%D"E^EYBB/7M>/:JP9EUIWED'^JM=?'-V>3ALT?#.H1JNF"'P5K)O)P5+PLV
M3,A22Z*8K7R(:F8C4X^>(])T1VE=O,,B[ZC))]Y?$IM<!IW/G;N_)*[0Q_#=
M8/SI"Z39D$''^U2^A-]'P%N8HN)'<SS;D6((L28V]2!+!1-F[8W@=Z?6A-3Q
M510X.MP/'#3?Q'K-T&BS%"_X)CR?U^4$M@6G$J5PPV^@C$&)).!.]OT2L+2K
M]B)+X\32W*.0MF_U(K%2?[G?Y)Z:OZ]^9K3;3X.VJ"P?]4P:C6AQ=)'%)[:;
MXZT?Y]^T]",'@T)[QQ1L] IO]03SS?'+-/$&6Y=(AK G;6C%-*V]<, !G1-Y
M15+EP3$#6]CQ2I872E)6?+BJ/@F>(G3$KP"HPLWM)'GQ2BJXN>A=\ZI2YF'E
ML:"U4[W2P:4!58FK4KMH[;(-5$Z@IAS5O+383,,\;PMW@AI3^0QZ!U069GLX
MC;+.P4O'E2J4A6_0MY9N,:]+M6FG_P%-45QW;)_MF"U,],M7;NV:[R[3E>-/
MIY]/P4.^#L#7D>ECAI315'?D[;+D"+>\ CKJ12 /'#Z+I"[9NAG8<\TS!E*,
MU_$@+VYI.W,Y9Q//G+H"K9E<3<L[= -@&.PO]20EG(FLU.B=/-'H\'=C8%GN
M!+Y)%CN6\N<^H\;[IJNR8VWN216HQ10NOXU$$NRS<D[1^(CJ6\S&PX;17:&]
M"9_DM#+M1)UV]\NWK03T+2\+8R-?TJ@WWAWOA*4TFA^=6S9%9500W986&M^X
M:5\=D270X<J,54C-E]PMW,1+VN@$&U14>BK&MU0M[)8V9WXTI+O:C%*4&BDK
MR6H/_IHL:TJXFT/@Y(BJ6FB_*+AC,^R4B36[2-:NFJ[*A!/VE4YM)8A8)[SI
MF'O?W9,0G\A RIZAHCDRH0+KW<E<C*XDIN)L(&ZMW2L@^O+G^ OI<=' R@$W
M@Q#PT>'SW!]W=H=R&Z 8VSHB[V;4[-QJD/1R1W8[SR5@ ED(/Q<D^-V0[-,!
M]3!+;:;\Q>&<)1OT"CB<\.40 8?=Y%16\&_?.=L;<1GRYY0<WG2^J58JUIPJ
M$U/#C/SN.%;E&@YBA(_[[&[2L#]9M*A11PM;)AM:@FBTKB&WO;9%]_>N)Z[(
MT>*@'F%ZU("KXRWSO8V#+HU2_@/.5#6(7+[)L>>=4<G)./H#VK?..F]_"B,5
MQ/+TXQL]#@]GM^]2D'1.M$(UL$WUXR&/@62ZH,D)DE9<O&(GQ>&7')LAA2'E
M!36</4SZL,PB]*$>QZ9FO?"Z?7ZEG24O-*2%@JBLRK99AVF:]44.FR&>\F&#
MAJ@W$&ZFL>M1W+8U"_Q9<L, L_)EN@_E'.'1=J(<*73(83#WKM35SE@;'.N7
MM6RFA4P"1$>ED+B"#;I%J^M"]OML@SRB(9'X4H.R^E#NV.!D*6[CC/ZH+:EJ
M;4&[TS)HHT/X$)[VV+93@'^@2<"8&DD!)CHH7(R"I,=(6*( %QE6Q/_ME]^_
M(DU+K*_7PI+8GCLM,>R]YVCYX)$&6 7C!O<*)ILK%^)\)*)!YB3L=G)H^#RQ
M8B(T&&1X"G7V;2E!J&<?#B4D<,EU?*BH:4EZ<N]_B=&]@Q7V\8"Y^BXBM-MM
M]%#Z"BA2X7L%Z'P6@Q<2=7[^+"O1;41Y?=$3S6]OZ;S6K5IB>K[)A1(T.HV/
M;9H@SS7!V+Q >"/<:\E$\^8P3\#?:O?F8:RSH)Q+UFS6J11I?+5033%#FAF+
M,7FLP^[1-DQJZ9$+@<G8&YMT#CD28<BW723,+0DO><8K@R$OF_PA@%6]+EGW
M^0T?89@44SQ(4\%L*?454#ECMGG1X9UO@S_J;GAROWOSHSWK-L]N1*]UOE35
MXZN]3B./WC:#(1WZ]0HX2W^ US@!+%%_ %(J(E)H [U!E*R+BOQFE'+*Z[KE
M'(T=0S/_DS@:G'/"YQO4F2,X1\_U.$[C":_?\#9\/9N),-0];^"!R8R0L1VW
M9TC,)<$ &R;4"6> %68\V5$'HX@N_-]?[V.EYI&)BHK_I'C_7<3C[YN$FMM
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M)QK[MFQD,%!IF5AA/FUC$X^%]Z86+3LR5J;1;!U^J2AB;\&.K<K+P1-?._/
M*YM88>HN.M>26#(&NW]9M5%>"?K)?>5I/ D=GN2[3)9.N0R%XQ3'JMFU6KF>
M)0_*8!STD(YRI#[IFH?]XX]SWF>WPY9)M?R4(),D\SI?KLIB]84'TQSMJ" ;
M9B9&YI5;ECSM?9I;AM'9R+GG[N8,P#AP.I-HB^H"6@2F//04NT4H:<ZNKC[>
MBMYI:]4-&VXX9A- G*:YGNA0OT12&IB_>@[>LAH3T&!)MJ1NTCY]_JG*];4P
M.,NSFQ+C,/T=TN &_9G.5='YFE+#;7XKON"-Y[-#?TL2366A)MU,@W618X[Y
M*J*UM_:J?6BIS%B_"@,Y*0MH@C.*;6WF]A6P5$G(I-Z&1H>M$^1H9@QK4MO*
M>ZLMG??,78JW9N@]=-98U;?KI7XW+.59:7(EI&E:L,#_PTO2CU+NA+G=J#O2
M-?WE\)=%O:_;-_&OS#G*WP8&)SBKN0WE^.H/"<,PG0XI.:U<&,+,HYD=D]Q>
M 35E9@LCEQ@K?>O9Q9H,V,M#PSCNG\Y<45U/@G<?.!H9B?F"15QH.9*3T[H<
M=0]/4(K"Q#O>)X#<4 G??F?BX&5(/8:&#5P_=Y,S9@G-=UWJ6@K5*GU;1DM<
M;,=L3"B;-X3VF>O>1NF'C?-_3@!K$20S]&R,R-3])*P*6Y+8@-)GK@YSIG_L
M23,=:'&Z*#4*XJ@FT??RJ;E-FZTJ_*GF*B^5UO'D=G")35@]&'>AR^3>4)50
MKL:JC^PU:7;"^$:9^6) R60H^?39VZ5"0>$;4:#SQ=O*QX!8*Y!60E"&[2%+
MV4F7P.5/QI!*V[)$ZQ?W?#-EU\JS@R]C9@LW]CISS)B^RV=W[Y)CU.L(M9CT
M!T%T"4PF8G@1+293I^^^@)7"S7@8A*KLVYP<=O_^H_5U^?\ 4$L#!!0    (
M )M9:E87!%-K_OT$ !H.!0 /    9S,X,C8W-V9?,S@N:G!GE'L)/)3Y'_^X
MPK0(,QV:'9K(>(0.,FIR3";,KLR,YZ%%.F0W8]VID=S-8BHDL[7*,=,,,X]0
M;84N<A9;4J:+,":TE@S*D>L_.K;V^OW__^?U*L_W^=Z?\_WY?+\S]W1.@EA*
M9@9\CT"XN  (-<3G9VX H>T8Z1<8A5! *,O+>^6?)$IK]NW?'[K1PB(XPGSW
MWI ]_N9^(4$6S-VA%FO-UU@@B';,T-U^@?[[#?;X_Q 0O!DW=+T29Q"P=S/.
MT\IUC6OH%O]] <Z'POW=#VT#_0X%^MGLQ=G9&A"9&YE!H4'^^W<;,(-^#([8
MR-R,>S_X1OG[_&<+G,'[)OL#-^,<YBL,MKM2#;:$A/L;6)NO,_-;LV:-@;6-
M^5Y___6[K:W7K%]ML&[-NG46:P@6:PEF:S=LM%JS<?T:@X\/3CYA^-[O-](=
MMWZ<3E[:C/NXKX,'#YH?7&\>$OZ#Q5H;&QN+->LLUJTSD[<PBX@*WK^;:18<
ML?+3"([^$7[A :'[ T*"#>;+N_>$1.[?C,-]VD50J*OKGP/_*\&"@BP^M8[8
M3_?__G^WC@"C0OTMZ/X1(9'A?O[RYBN_F.I_=YUO*%_-1L<0O\@@_^#]+HZ;
M<?(OYGL#]FY<[[B.O&'#VBTD:QO+M6O)C@1KLO66]0YK2#:.-@Z6CI:?^KH$
M1^S?'>SG_ZEOP.>^I/_9=^.6</_=^T/"P9"0'S\QT"583KV 'X(-UA+,UQK@
M/0."]X8<C#"9)^W'E?J'!QSPW[LU/"3(X#UM-@9\,7]DI'SR#=8V?AO66EJ;
MK;?>:VUFN=MOC1GA^_569GO]+=?OM=IK3?#?8X/[V'GO%QM_W]G:W\J/8+G!
MVLS*S\;*S-)F_7HS&TLK?[,U>ZW66UJM6;]A[[K=. OY<BS^QNI/G^3R,__Z
MI^S*"W]*OW^P7.3#Y;(]]QJA^7[#B+U5<AU2F&M#'$$H_+\_BI\?I3^?3W7O
MJQ6^K/E_?.:J$-IJRM\J(944M!&*V@I*V@ISM8A1N:(K*,M'_VP#%!25%J@J
MJZBI(^5?%504_E:GK+) 54U]$4)!21FAK*2BLD!961FA\/5\#4);9<&*M3JJ
M#C3=W6$XE)HLX007??%VBV3=RF'28G7ZGO6&X5N,EB1:9O(NN3NN6NH78;7!
ML_HDN'<_GPSY;RVH-[;>ODQ;/K*B?&#E^46H*RN@%1"*2MK*\G%5'&@+Y./J
MJB:<6(?B7B315ZK);K?L"5^/3LPT7"P9YEW:4NWN%Y%DZ6BTY"$(+3UYKF8_
M>=6OC_;6MEIY&'=G\2,W;+56GWN.^$I)/J:VDC;"#C%SY_&ZIX^0 FU\JB,%
M=R9:@P3B+XY8TJBY[S@>C!\/PX!(^(T^ !J1MD_2N<!FT</#(BI'_?_C?X:&
M&@\$#KF=&BA:=>118O:1BZ+;]9R[@"Y_$K)"/-DX/S+U6LD Y<CO5E9**]F@
M43J'^G4:6EZV!2WOS;<#V9LLYU>!5'K*0;:=+1[/DT"_6D7"S0NC0R9CV\3M
M'!<JFS\CWA*_N1^9S6.1P+/73P!9="(,IE$NWMF9LD32$Q=RE<T%%]1W"] [
M'&6C(^,/S]) E9MCLQB;42%!0.(ZYEWC(W$+$5KIGCV.6_:X8 @[TU.G U+H
M\>'6F(870UP ;;_\9$_$4%_3<2>D$>G\\O05/7=F.Z"OV7?\O+JE=)J1+ZE#
M.C9<H.!X+#"-YPH>S9/Q!+>/&3[,;W%>\+C;)D[K!5VMA,#:]Y+P*#%+)7RE
M!%,>+FVH+PI3E@SC5Y4/>[YS6E'S8M9*+QW#$)5:A2$0P:I8Q6G7B;"1*T D
MI $Y;/A:L3U../N ^",1D GU+L!)7F!O"1:#>$GP/C$=$DC+/[O-W[X6^H[:
M?W$.L9884I.<?'S'TMVWG?-K$O/Y2<&Q+;60?2L$H&_?@2A)V7263A8>=C:,
M5R"&A&RB+=EU,E2C>& $YC!@'$TGA6.# ^?_9CGRC+1M6E")P6;-I[ >93)N
M$\H39IE0YX7F4ST^E9[ZY0>W<"/2_->QF<IJ&"6@D9NG;PS^-HM])R+5F:+]
MC1:YLVDZ;!*-E!'T6LA+!(H6O*449!%@%".?;Z)Z/__(RDR8:Z^<;33H2&O=
M?,72G91#RJ*1"KB;'J;67,'G><GG47%%^8 M+J@A=_!LEC8I7WS22[2T2P24
M 0B^BH)O7/41$P/WK\00<HT[&8/RH;,#6& D,MOD(7]Y*^#,X^=9U!>P\PEG
M.8*P#7V3XMT>ZSQ2RMI&X-MPN0:H&QVM H-P@C719A1F A282\^[G\)Q4:%D
MX!6%*A EBV?0YPCI."'92FRVBO+RX<)P#AI_UDP:UYA'-Y X>@(L$@U]NU%T
MCY8+6-"+ST)5(?9"'-MA&&L;"602@'?IUXH4R-J K6/G*7,LYG#0H6M>#]80
MX!3$+DCV8\!MJC/0?3SY5C<<3(#1/#/IH?,X,)&)RR[G @QZJKL(Q8\/)D_H
M-]R72XM!2WCV'[\#5QJSM'2#L:L$('K$WD"W=@1[H(_.WO=71CE"*ML['F-W
M!H+N*L"@G&G?[!QKT:U^/-PW)4P-7B*3*\" Y*\]Y@L"'>[[#\"ABO:$VG1S
MWW="MG\FH+[JY<X[WO&2+E?H+1YLG\P].#4]\X9\W -HE/<R9>FD))T6.A+O
M:0.T]P.!> K'Q)&NCD;1R%2#5IJ[X\V*60AE#YR#"]@!S48NUB(Z3T#)<,;,
M=D2ZW%U/:_ZEZ/O43+: 0D/;3[8NRF<9IFOIQ:,0$)HN K2)^U+IA?T>TU$S
M;^DBAR7ZM]B@0L@M?G<!S$"9$-U,H_%<LC9> %&+D(<MXK [;\UOP:3BYF2,
M^.L47H<MA#^UJN,^2"::#0KK;Z;D,V656A=%9'H49$2'(&2F?2W<H"6A0D8U
MB33OKL*,FW>Z;:+K$+RD5%Y6!B6E7S9;XFOWB"["G3;EA.X5N3?61@>\Q?^6
M49*=&)@ZP4&J7[@Y&&S<3LAK++DB7HHJM*(:'$W;6J($J;B"Z\E6$1>1;+R<
M3N@WYS<H*)\9=5F,G9H"PB&/!,]^P?=-$W2;-*!_JDK9BT,INE5TP! 8PYQW
MF"H-;&TUN4WQT'J+2AJ2A&@24P4T#S5BBJWTD(D[6?U/WIE<F0RSM5TLB.(5
MJR9?$QU@4$MJC\;&-28(<_RJ])]-_2[0/<]LC[GY4S;E*\@^T=Q&3X!J^2O7
MWQ<H\[I,A?P"8_5W0PI4=J;;*:6(VIVIPZHLD.LN"2;.OO;UW>_(6\VXZ$&G
M_<L 'PIIUA@",P_ ;8\8%I(Q(0-SB.5BM8(4GG %Y;.A<=@@)6]F)PU(("!S
MVDQR/R6IK3Z%-U_'L:2(74GG]43R5EJ_LK0MXIXY?L.<;-&9-ML]-#P_";OK
M)7 RFR]"(]M>.3%@KC?%B"+PN=69@SHFOEV37A>\8S&&T);10R_.=19XGUX\
MW?S"TPM N6N*378,$)9/[DR^T,%G&ZWQ),5+)J+[DS6_$^83T@^5=%=UO-VN
MYQP /A@&DXD#=KIQD<6!D Q!ND^Y0&+54?+9 .S ,P*Y ,U5VX7FZ3J':,P]
M\9J7+:)<8Z;WRVQ]#]LL?RA$HZ@%O8\K%>[0T+6KC[Q9L8%>/*P8_&/(ZQZR
M@6QA5@O]9.3R,\\?*];Z3E?(KH#H+48'OJ!>1E!8WV#/H' E>T5?;6<;G8U/
M?3V]CV]ZUQKQO*,9R.]E,_Y)\[,MP+SBL>]6IK,\N Y3LZ-31!9*@#+2]H/8
MES+E#87;7HK^R2XV7FXUJ.'V/*$C#P]K,NC<CS5D$N"RJBL<%BJ>WY7OW7#J
MD@!%0[6@CK3[S(B5N99T>\3$1-A4A,"%!CDO$1$ 8=$K;&?9"["?[ 9PMKM'
MSS;B0J7U';[/<;1%SZ=MW&^B9.-343LGO,ZA:+_)1(ZV]RWE)J9A!7A6K&JU
M'88*>[.H*J1LO(BRB@SF,FQ7/9F"2=Q&GN+)AJ;DTT7'+>OL>\\G^$E#.N/\
M/>&;_24]^_4W!L!)' + +B% 5:;MY[ V .,*\"XD]FN#7$-]?<://ZJ@RS09
M/8I<"SI>:\\1.%$NX-JNKS@4'!M7WDE^_>LNXHTXY.XZ9\_3BZ6_+4^?-@B;
M[G=Z "\SARA_(Q2YBI<-/#SLWLUL?]XQM%%0!0M+Q$#6W^D)T  Y35DZB)G*
MD(U"*J\,PK^OO C7?>?ROAU7;E__H3=X:5A/_1SB&A?UH)L-')&OC_M,1#GR
MH9I,J0!95#!W\<5>PAP"R<&KW!-EXN4#[,# F2(J^55\BXY9[0-.A$$1#%G6
MWX"68$*DC7"=#RU$'\BBX&)NMCI*&EC3-[/(!KK3_>H\O,A1,C[1LFA8-JVR
MU;D$ IX5^(, NFS1-G6RLZ65.]F2@A^@$YEMR6U#HF4M#FAH^1FM77,(O6LF
MVWI0O (^G8,$V=<:\0"C^XCP78OKO:%#6??"=4*J,IS[0IJ&A(,>9_%@"[T@
MG@?5?3)2Y###C$4G]H1$Q/KEZ4>BQLQ#^V^F+$9L[TRUM:(70U\8,SFQ4461
M]&+7UM46,]9EO]X7'=B14F*T=T(W&+ >BPJ' ^[A2W>R9DX)"RQ!8.-,7LZV
M+"BRL+:MDTK6M8)(?Z$L  8U53\9BULNML=Q*<;5CV65(V@#&MH*>%_]=T,&
M_\6.S;LP $A&J5,%<N]"[S$!>1]'A29;651:]\:HMM'APD.<Q42G4[KN(,W1
MO;K#6C92B/($."2:VQY8!.G)*"8>$V'2UY+[<B%/&'N>PC^3T$OP?M;G2.NA
MRWUTVI;!,:E<"XPM/2TB%^S34G$="+;;>+8>$"BQ**8<TE4R&0ESOW-WI#G6
M=A>DQ#_M@ .XU!+?]ND!YD3$!:F[_>&50'2+N]1S 6C#@X( E%@L)V:69T:P
M"W'C>=6K8LP:T.YW3WRQP+F6AA)_AZ=D?60)W=Y0T1E[.V*"YNQ3T+[D%6!\
MYT2@3!IG"LF?\+\(-K54(2X&1#LXE"5/3#$@"J!&-ME@T-%Y>IK(8.O0?)&+
M-UM7C,E5W(*B)Z;WN%($SAML(U4QJ*+\=E\1+J6 ^YFPM-=V,<[WT%_[:&%M
M/7H:7D#NV%KP9%Q<ZNB\>",_S+O8:GN1R?M73;^&9U0YZOR[EP%Q;'8^10X7
M2#04B,D2?$*E<AQN";95R9;TW2^L@+Q@AMPL,G?>\8DIW:96$MO(=:]3W6AP
M3PX4*&$TGWTBDYO.0#Y$3-<3@6>;Y9#BW$U46TW]6-FH(.9.;D#9\M%"!M#/
M(>G7IPB'RQ>7=3**+L!BEY[&_-[\7"0##9#1YD%@JREE'UM.&_T0F;"Y8E&4
M;]7SM]2@"&IAO*2Q5_K<S0*[!(;7-%.7F=06_MK6/ E%==OJX6GT1T-4^'Q\
M&)6#SY*#I#=)58K,HYWI5_,/X%>$X\^+1 M2./0C^8X?##>;+^0Z;#G-R]@'
M4T[N3\SXT77Z+K'T-2\CK"XBTP5QQK<#0P8%T)=<BYJ,9N07(0D[?XM% Z!O
MYZ64@O;WZ.@<&SC9F"\W^#!+G91B$>J4W#<PU;_^-;W$^!?LWLR0V),UDK%A
MV!F#DI!WD(Y\H/DVD$PJ?E1S8M9Z#++?P^X<G&***9]8<E3O/)3U'X! 7N#E
MLWF0FMP-R?T[^D\=19ER%C"V,I(DU>VV]3 D#S_R+"*UP3P+9&(^"R()(+!(
MW@[?D,!+5!#!V8\T31Z:C8VU@F+7'=7L,][5X]@YQ$6X"#* XY5DTJE^=:KS
MF(F0*I\YE$=#M;:@8BJ!\U8$A@V02:Y,W\C6VG-YT% 23]>XH3 NOH0&U$>'
MX:?5 Y>0:(A^-LVD>GSZ9AYK:V9X#28:["^@,"[M$VX)Z>L;'(-66Y5NG,H2
MG?_Y(3L+/@%H@[E^K FL4CMC'6'%75^'WC/:P1ML.ZR NU +"=J2?00^\6GG
M!2D5Q5GX5=5U*^,-997I)V[VYQ<->@J_L%'0ZZD9S@H0O7)HS%MN)8S2]7_8
MB%LXP93Q@/@K=$A9#%&Y^-2IV YK(:X<DP5GDAPJ4RO3C[,<4*_=L\LUZAH&
MR@:%U \Z)B)3)L%C+52>F]93IOY\M%L@('WBQ@<PP%'CX'/MJO_-%0G)Z 7Q
M-'N47*_D^E7 _],+?9# Q-7,CLX<-TWQ=K"5=S(\9,HDTT0Y<_/C*5B3HDFY
M)G" D,!/+G)S^7Y A]*O'K+I'SUCB?/9US;0#]IDY3]DQQH>BEXR\V+@-:H8
M#DKC .&*Q\DP<--7:-7LHL$I(!_ KPVCO<7K'UQDIRN!?M\G2S^&?\>YW927
MKC X"AMJ:JI4A-'1Q%O]<'Y:(RX[ X]'&7D\9#/ZCX@<A9LK<-=.!NK'[;S
MC&U4V9*L<H#]/$\RAC:C<JB#\ZID,N]BM)U[-[]QR+[!ZX/>E3[:':T06_K#
M<2A3V/>T(CZ3<%1?.[IM"$4O^((^Y_AI!F((4N0K$G(/,]2[CHQ H9B;><>=
M#AWAO5<0MI.I]_&Z]+)D35!*!KI=5J:O^3&V/Y^-64>/@,!Y(( ">9==FS<=
MG7BJU0BK\3[SY;/VD(S^#CWF+:8C17"'0_D T%P$H7?Q7$#7\C.<$_C I!/9
M!=-,A==R[Z-"+[9>0BRE[H,,!<D;\7 V3HG*UP-*R1 )-/DXKH @S"]F"E "
M;3/Z-G173B-Y>2Y^3;/58B.GP>HBAR)::04EN:VM!\QT*%4)JM5QN6MON'RB
M,T4&WQE=&\:U61%07P'/7.UK:!I0H2\X]7UQEDNW16U4VQC[_-7RA)1!:HF^
MUOJF%UWXQNYMF!:S$'W-E<^D(+AI(C!AD"XR;HJ_V3!P<UMV=\1=G:)]BO%[
MN6YMG9[QTMLDL 4E*[.U!:4_J\$N%<XRY=G82."4/Q3+]7*GKW>$6S]31ZY8
M0:OW9Y:H"A69F3RG:W QY(>^\^\&2/>9(Z2H4(Y8[B5616_G0BIAB D9]AW_
M2 'R&HLB;PNQR[E?]),#@\6>C/?^/NGTS/2M=T<^><W/8Z) '&38G4IE \DF
M%,'?E FUW?<-G"WZ(!FI9,.T948H"*J-F(HII<*J<EXY83TKKV;17=$0DLX.
M\,ED9Z%M#"A*9!,WD4[^KIPD(VNXYN)M!T-DEC3NAZ<S3V!UXXKMY\XDW!;0
MS:)S5PXRX@.>H]9,7*R#^UT\M<Q]FRM/P E!^T^D6ZI9Q&+4);%+I)[VNY9F
MIU&V(=^>)S;G5,P<][8%%&2X_).OI7LVB_<COG:[4G,!#X[:0BY&O J1VXMJ
MOEXW%WA5AQ+'-.H(4&F'F3&=UU)*\M,7A=0W6DOOSV((H&D(L@>-9%Q@<#\&
M^A\Y86)OB-<\&;C(*=TTH;ZW<+5XS^6Z\,]-_F)G<GWL\E[0TE&4O0*+L/L=
MG< NDA"+E$DE(?[4?.Z&):*E0H^H\%6=,97(8A+(^QPT_F\O@X+,R6@*QY+*
M436DR47=I'9/%O7OC4TD-:/#,V_(*/EKSQZMY2-E &ZA;F#;:'>07,_H&J2,
MF$8&FF%!YW$MIO:)5%P1D$ ;V.2N8G>J<N(!'080I8C\,]'I&]/J=DT?"E?1
M0B8]%1U0S<QPWKSRM]B6 ?BG@DU?M7K\=!::,B[*TS\X= 5^I5E@I^"I7@*4
MKK-YWEG)J7A0T5 5#J>)W1(J-[T-TV\4O F\T)/(<M/27U_?V5@\<1O=P^:@
M#ZJH0Y=Y0N_CT^71_1) 'G\E^37.-F)"R53#H[YU=@]7F]6/5UQ!FR-E!AU/
M)+UV/^2@+^'A_"HA99YJ'[?+,]^R [CPDMF9KMNS>P!-0&\')FG7%)G\T97'
MX\=:QXQ;2_XUDB>," <!]Y%\@V/KJ.?R-'V?HU=:Q4Y;- TR"DZWN-PF%0<3
MTT_9M=%1IA"=A2);X3EJGP;9+MYSGC__FD($M/]%!(ZUD*ED5&+>U6E8>QY8
MDU$"DA%J)N O08"\X3<MNDVC/*,;Y9/1^]CV8PE#LYA7[/D!C#%TKELK!T#2
M4!U9=2"&?Z*Z,\8%XTX_*K:DNI)U\]H&&_GN['RJ?YUK:>WL_=C^@BS\TNI]
M$?2@)M9L>_]Z<).S7NQ#K?Z^.Q$]8^@#*YW\V<F'*:/?_^Y)4SW>?&JA=TTU
MO%*GMZL5TUC:5MT9>5.:O)&O2_%[%^J>B+7](V8.(0$GO$Q3PW/K7##G-9*Q
M6"O$DDQI+OA2V[VA:GG[R9I3ETH"%!/+Y3(YC\@'PI$Z',="A@E&XT[EI9P;
M-%_24-4H[W+O(W2X'$\D4#GT3^1'NQC@=:.C-=*E]O(MO+3D99DXZN0NKKQ5
M_V2\=?PEO/!DG)0N<$7]70-2"+D'>,8Y]DBZ@,2F46YI5(W-=NKQ3O.NWHKM
MU"^[!J-Y  /\D.+YU//_$I8:.:#):!<U.5Q0-0* (_]0MZ/A9:SD7]OD:O.U
M*#BV46YEA\K:GCEN0TRF5[\A*S_/HJN BJ[%5<ST9]]FL 'A>P,K5':GAU-Y
MQ2(X2NQ:N^<<"P-C9[$X& 4L.(4\>^O*!FFUR" :,KH2239]8YRN'X>,!R"[
MP%H8^;MRA.QWB=_4/1]$/Y?[CF-5@N&\3$^P'IG>+$9D'[=)\X%<[SI Y0JQ
MB[OM0B[Q%5W,A?4W\_Z 6NQM'\ERE6J27\-['_@@E&K/N=PC-^L&_] TV$>J
MVO<HPYY78HEW]W2 CXCD7I%'TZU.0.\S /H:60YH9+^ZB;2Y8:C;;)SF%<HK
MX>NI4"![GER_4"V;6M_'45Z@ ^+%EMGEV7OX.A5W3*#6$[4RNX.78 AX]6_6
M3UXPUL)"[Q5&-/C>YVO_&?0<-?F@,$?H#IA7&J 2A ;>(RC\>,M?4G9'W"["
M^P*?LN6!&/I'MLE?9@$[ZFLC7AZ>V'F*1<H5XVKBQ_+*KJ;FRMEO/(PARM=$
MJ^>B6GE'T]>2+8&353*['.>[X#K'7$L 6<*E9SE.,Z/B %QVL3RP@C;*L;9S
M%=[(N6MU2.ULOP)5%.B@IZ7UN)!56?_+0:/M[9@U6WHWGWLMH?W$2&)AVI$)
M WUCTJV)4H>[]$WK/16(JO5.%KOL:L:AQQF_A8GKP/8)$9:H)NVVF;K)^3;-
M?-E$W+?0@[R&Y-?HI3IX@M\4#;19GDAX.H?0[J%O)6"2+X\!)HYER;8'RNPJ
MG]&58*WOK>Z2TJRED^*@_"9#2@6D_FUH@7-65ZI#IJFPW*2BRV%#Y?4\#EH3
M/>3I<'-2-A;;:,K@0L<N4'DI\C#K XZ].H<X?WB';0?&#HM";F7T+\QQL$]Z
M[*;HA,U=8@L11,M*MG=;R+7LWV.9#X VT)&R=YX1'X/ICXGP>;P@ZR9,RB-2
MX,E4O^)/,"#XEU3I?+I-&&XDQPZ9-B84*N_D0$'N=RL*55 /V:QV3<R-5V2M
M/:++-C I=<E4NGFD"]T+Q<%B413E?MNX2ZGVA:7/)N<0 +25\_76<0'X"&G2
M3QRL?JO.-T'VQ2V,GD,$N8(!+XLD@2<ED@$)I8#S8U%.1=335@SX (@I:&?Z
MS"$4>AP%*!I%CN/EVH]JG\PV4BPVC#\7[ERV<+12*T!"1YLK0-W!(4.R(C;+
M:IYPQFW-(W!T5NC P#>RLLYO6^ZUXN$E!N$S;UUNT[CM"Y#J?1))=7Q%X5>H
MG\&1;3Q5K<XI6+K6*NP>^#@A ;@L/*,4BW&IW 0%:Q23U]+W$>#9SI!()3)^
M#7R.!O%]I:-3T?W)ZQV4CH,><)%"4]Y0$>OYC958QCIPD47M<%E?3U44M L!
M+$"_TR87]]3#V-5D&AG>SW-W<2S(<F]LMUDNU@LK5?:D%F6ZV-:FOW@-OY$\
M+ZZXW&2T?Q%#$/R)]F0O'521C@[192J"EU%BI YXLDG7R.6C1*UK8B#@[LZO
M^,N3&#03]C4$ K%:%>  ?S]6^6LAZW.$]$4V"1E&8:G3!?^&1 ?')#0V7KCJ
M%QST21RUS(DP*JUN;R'_^?0<PC1JUFI+8L4.$NR$U=\]AJ88LR8B>J2S*#**
M;)"KU!9W*T=X-BJ*24/O^/ZQ)-![L#Y%-%*Q82QZ7ZID2#9.TRDJ^%J8+(^C
MCM ^S,Z/Z%5-Q_H06M /S14V*'OU37=(XY0@UKX??J(P+E-P((:D[:/#=A\<
M*%@&X!\Z2QV%.#@@7NJX0<@M ?AP%O#H?H=^R$;PF#Q4YS!A$57-RI):1&(-
M,'=RFI&B:;%!T1%?8>!15U*QT\*1E[;20._)QUM\!U>NIA2P";$^=ONF^@^[
M5H%LZ<Y'AK3!T:GPD2(N"76"(I:C&DKL<QQ2!=FO47[T3+Q:K\.P;3^ *6GQ
M_D0XTU2:\T1(J^O-GW'M-X;HR!,<0LD>2CS%V>ZANG%S4R<=S>CYAS?\9[;H
M(XK\J*<@[A- ^K,Q5X,@1STQLY;O#T*TR72*T9]))S)&ZP0F?0B-A) &,LP-
MN7%B")X!\=TB&$V1HWN"^Q4\U^UJRMG5(<VLBIDWCK*QL)5M=_1P\D <**E3
MIT:):!_F(Q,';.O?D.UZ+U:4I:^]$R;M@1+8B?CG14D9TKB036(*:SXSR5$C
MDY'O.W#48*5F#K H8[U[,VMP:(:#8%C>,0VVK:,N(1*);@JO*W,\?$R_A0RI
M17.(D$AJ1(T1/:(RW18R$Z[DT-R#L;9#92S_)5)[$DLIKQ.2U1BI^, 0DJ7=
M6#/A[KH-*( 9 I-M/4 ^SRQ$JTP/;X". ?JQ=DS)>%2KJ:&[RL<\J9$\7":T
MI=M9!"TR]]JAOAG83BU363BK^DL%S(GT3,SDA@;;R$%1C#;TWTSXUNF0T39L
MZP?:@_\PFD+'OQQ/<-0*3RG*34C?MRU.6I7U<M,M=Y=W49!:<G+9BT]<6;*D
M['AIR'+0A)>FE*P0G6<1Q?/+YFZ=KF!"YLB+F6F^LMA.%E6@A;5TG,D%'<<F
M?%-X*86#T_/''HR+F4<*8NYDV>#87,I'K(QID#1PCI?&78,7I.:J&M'==#((
M"]LGE*JKHH$+D+*[5;B _N?6<EOI-L-6*GR6@5)2*B]Q_GSMZBA*=9N-*#2@
M4= H]7><W2M7NG8M.^ <YC[EMJ:J7M%=HKE9;6?[YJLO&7]LV7%4B%"'/+O4
M*W_-43#7LR\*K',[E##MVGQJ&&Y_G*A>^&MVDM>NDM"RWL-#P5N2<UP,]86A
M8S *&ZL?";9?+([[]CK*U+,[IJR(?3&3C770.8L27<3T,[@^/PXK]L43M<QC
MT1BT>6])B]=G/NSHI[/8F8K,-/LSH1?*UM,+BGX67U,Y/CW1T=#(!SB-_\4]
M\OR!([T=2*75R<%B0<I[M/_>X('&A^9%]:\(\HB]114--=F9MU OQIDW7T-&
MJQI2N(NFAL9D[UF=)0^-\1LP00V<Z2 JWR^Q+# SIB]]D^^8$'K)8].%-CRV
MW+#F8N..S]SRY!G;A?Q2*9E/A."RA2C*"2]J;^J63+P\?F"'5'>TM:#F5_J:
M3-V ;1K!W-6_!K?RXONRRS6J;".]\MEZ)J*/<6 *?BVJF\TXYZM.HJ1'TGMP
M5VJL3"JOV"Z1C5R!%8+P#%%8WXYO,LXL-/ ^M;:7R+ /J:N&G]:H4.4N?6)X
MI.@2P9(-*A),U&S.=#:\\*,>=D6M+,L!,6C'M@2E^"MNEV$4$[MR8@KFGK8O
M%K</(R\7J&4-4+/RR5ZNR5K]AM[CPV,M#FC/B8GGL_=!C[3/,0\Y#*#0\QT
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M+I5:SZ34!0#/=9/G,K'BCPB)5!IK:PO1^2KV)I+]'>T3H[!:6+$&JELT#0N
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M0'4"_$0<$4A#/7@.SN S%JMU!3%<GGY)A>#*/63(*P[1(8YIF@] $V7,(_)
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M&OO=PD4<"55>Z*Q6]+A+E ;IUX#GXB&4 M/QS]/C$]NVWPBB-5IK$R/I-:X
MQ^(R>:\&25W\G+J.#'R/&"X052YG>8E+']?\M[X&5H[KZ;J;UQ1$B'3H>-8"
M!SF&XSB1E_H>$%>]WDRJ<E <!1"+R7 F#:;Q6 N&+#(F-:>N0SONY,%O Z.!
M[Z6HQ8(9:4C$MF3,8[5^9ZN2,-C^E;=_<0F3G<.M/W5!7E<@F@Y&E*OWBM$1
M]:G[1*)1ADNAD$8@SV R557AEML#B\X^'\CYKIIJ4'%2G6;YB:36>TNWB*8C
M-^.H*X""W4^%(S.FH^(J<6+TY;>35VLV29&6U/T]W+JN;L,FH]XV=$?%1>![
MW&HLT;$$1Q3<*R\Y%8EGXY/*0*UR,BCE8_+EL[Q_:3W;L\TWEMM'<E2<6<F8
M41Y9&1O\3[.V;U*O\:HJL>/\XOGOX*;VON:C7Y1!$O*)R#_%L[S2K3)%P<I=
M>E)B=GGQ&SYECLN935]7%-,5P#*?FN1M((./M%Y,*=';CS\AA>T442V([Y.V
M+)C#KI QQ=L(&E&0TV<%]Y2G4G.*Q!DK/.%[J.H"ZY7)NO#HW</3NTG#RPIB
M%N\<:5$+"W3]*E@>?E< TPGJ5^&8H_FW*4U)OI\P_ ]8X=&>0@YH TNVR)Z*
MGXOFJ+XV)0G+R@#'9-ZIX^I*EPE]KB7=C5\U 6;A7/KGHCA?-EH];4_:)JT6
MQ'F^?M_0IOYJ0TG>6J(JIMZJ>=9&2' OSLB^:L2LGE.;?%"ZY K IUAWN9 ;
M(1*GA*P-P3+Q%J"\ M $'2$XP8O0 .!??0,^==F-.<K ^5YD"HR,!*^,TW6W
M8?WB0*E'S]-@SL8B9K8]0A0NP,+VMB7%,K@-D946XTT!N;@">&JCRG:T@N.>
M=#A@U:%!+.F!U4?YS:[E30AW&*:YN2MA:U[SRRWU=-M533F<Y%''Y3-OYV>X
M\M_Z0)LML,LIH3/#8I*^ !F'LRM W"W?K3])"S=/YQQ,@@QF;2.(+C\_WLWC
MK,(>IEZ<54,)9_]G.HX<OP82<?/3""=J1Y],I%HU,*$>X:#]<\Y&TR%6+RF"
MS//C.8]&%AV"&R6D_5V)&A!SP4J*=040@,:Y_+L(RL7^G:4%)I>#XO++YHC'
M:A B_VU^DB-7EN%$R?'+-26'^T99E4NP4&"VG_5D>W+TL(9G<8\3,.=%"T(G
M'Y<)UR'S%YX\NW70M/SH?-S<*^#7I;\HB.CKBS=CJA2?:&5J0TGTR0+0)8\?
MVUX!L'^ X&&[?4$:8XMUX3M"-8QDAU2I>[_T&7=^"5P!:COE+\_Q AGG;,MU
M1$5'2^G'["/FU7##M?A@Z\+,WU%C=[+$">BO $L9UU^'2M=Y;^,*L%42_V2K
MLO7N)<N.T)E,:OZ:2X5!DK5#Q0N(_.ECS=&?*@E7 ).ABZ%8^1B0)L^/T#V'
MNZ[._'LJ;,,32C2XQ-(:L&BQL#>/UJ,R=R*7&(($\-&%9B5*MS]R)>EQ.^*0
M*;A" EZPS$FAU:M _:[;^7'W\L<#E<-.P_I:W2/>B6[GL>"R\&L<.X6 J-%U
MA>OX<5! (0P<_<_[-F0A<&2U6Q5EFYVX0<'PQF@\SFF"^Q)C/9R5TV*/"Z[S
MN%A[((>Y;!?U$G1;KL27U<:DQ\FP_I8H*_-N9+%N/\JHLCB=^398SGW)1N6]
MTW8%J*_W8\^I'6GA 9HS^.5DPK+.(.K ?]TT9;11\]&)^I^@_^MCN1M;R#_Y
M P@I5A\LUF0 )%J523PG5PS/ HS'P7:R>P5P3L]_,3D\MITNZ_D)EG(253IK
ML#EP;)@[T;/^:/=1;PE&S#V4,QB+-@/S+::5./HC1O .[Z6J<YU08?4/I^'Q
MU?W>/LX$NT\>CR?D+>\5D,C*KHJHUCVT?&)2/'T%B-]Z9OQ;Y5/R<%'%';_3
MU6'YC= 84N:A;LE'WDR2Q%GA7_R#/EQ3IQT]U>)T)7'_L/V!47'&<L,L-^'?
M5IU]FV,$S6?"=S F]D\<"UYIJSOP"ANF4%-Y(\1D&>GV,3K/379K-=RRG"(N
M.=2P)MKPOKH(%BR0PD3FC-1%AK=0YDNC-<\%NX5+Q\ESF+S=CCLW5:,:W\N?
M\\RZGUERAVD#$B1P,,UA0.Y@'!3[W'=L13$ ?MMAAIJ#OH_MK&US1*6OP#^S
MEC!F-\\ .>$E?R)-OXB:!+KL5EVWYMOM56)\-MYQ&G"<>R*HX"-.O F/L 8B
MM?Y:*JHY^#[O"IL^Y&(X'X-J(7M$E"$G"O?8.IP]7ZW^+=";RSB:R]_0PG?]
MWL[YV;;\+E/-VDL"LW=6!7>VO_OJ.1#LZDI_"==S0 %E;X8";VHVZ^CV5W1)
M Z-;'I)[19":U=4I_3B@:I"3&1U@\&?"+>EO6O0O,P ,J.F.U:(7U#"[D0WS
MEU,&<OO[V0[:N+'2ZYRDOP)NP[.] :IJN% ACN\Z]JB9'#1WXV V PRHD! Q
M"AM2ALL-QF[KRH15';M-Q3VGZF36=SO&;.T>_:(6F'-UJ&24W/X"C_T8]%>D
M89XL2HZ!SQ;DLG/TZQ'8XK\C0S41B.N3N_X][SXO=LP.<2R*U4[L@32^+]X!
M00DM7;.RV'Z/ER::<*'0\L0LT-XASOT*,#4W*.N,G=EJ?6IS B[?U>&'=)G/
MWUX.4?AP!:"7H!R73_#:Q;36*)I2G_GC#N5EW^H@M;W0;Z!WQ^*]QAAT@NT[
M&B\"T$]5[H]HQ9N^88EK*.K1C8"JF>5WM2G:%?@[ $!8%E\TJ^L[YGAF_9B4
M<0I1 >T^O+T<(*QC$"GW ZNH3?)J3[^G$I'/,IQQFZ6Z/X:RF\_][A ;I7X)
M'\8^C<[(RE;DNJ^D <,B4E)B\H-,MU4*%!+\*+S#:6YW7Z[6X[HZ(USM9K?F
M^X[5R?X\H=<7:OBB3+:NX16Y1]SIGO'"9;97DGUAQ&:N;I\#3IY7=J7)/+_4
M8;[PHB'':BCV6MYAD*.$_O2&L*]GXHE9%;4XX5""36/U3/LQ4VK[6JNGI<9[
MF.85@)"K(5V5^!*^$9M#/$^=Y..6;YZO:<LH\E^+@:N2^-CA1LIBGKA#SC._
M^(<&I%=6!]6;70'0ML/SWJJG66GC+N.6&C5=Y8WZ)KPB/V=^E3C2K>@OOU=:
MZ86&+\[GC(3[KZ8'51H^7275WI3?2<7]]:$F?XN3-0Y]GJ72O8/]CG\H[E)'
MI%=$>T@R05+6>(V^XN!(KTWOIXN&%B2%:V_OX<P4X^SHK)+JN8+7W>_B%@V'
M_:?4WA51GSV5WD6#<XX4K,.7C)1;S'Y6LJ_^?/(<96LM_.&'DKWH:PN6PU#_
M'>F@6=;3WCRA<2=OI8T+^I+64NL9ZM+PJ)-$MKDCRN!,#A5(.GGQQT3&1%*#
MUVNI;8:1*T>_5T9!M$_&_%\]2A*\NS_#%.JK:\+2=NNI?'$)ZW28\[.%!207
M: HHQY+J.Z-<O+Y769WZNSB#X]1*08FH:D?,%P6+<_DG,*QW2C\?80J7-A_2
M@.E> 2J/8! 'M9T\+30;VEW\X"[8R0>K70[HREA^!0C  K5:#2@MZL>]!5=+
M+]IYB.6O_9;*^(Q^QPZ^*/3V/#].KT<-2W\N[8#+B7E SO@TS%5;Y0?V"3['
M]47,VA+E02 $8WXN^:YV.^5;?>F+VCXN',R9<MH'>=#K,^ Z\7*&(-7F,N7D
M+>"#7XB)&8DGCB_. V3\P%5 &-O_Y6<#_B*CB"98$OOM,T!U7Q94S&C-'0;S
M?PY_RZ9RJY_P"O!!AW2&JU61-4[<AD=FHG4=XLUD8:&1+?Y&/-UG>7DK&PK[
MXLFK-P&8[8Z9;V]:*@%_0\$]V>>.\">[)C7R(!QJY5O-?;M(3;]_Z7PW39]_
MFS/NK_\YEI&L%W",F=S(DY,9LF&0:SP.#*Q 2,%>X)"PCNI$JO(]%M[)R]!$
ME!88S2Z>>=::YVM-O4I\4$6GJ:P8N@O$=$N,@UX-#TJP0L;[LU#@76:4N^YA
MO!C^0P29G#2#-#XV*7.^Z31]2Q2Z0C[)CQ"'/ KG)<$2-<$2_2-4@-)@=&T.
M+9%>M#.A Z%]%N5@N:7C M7= L6Y3T71356LE;HT.E/63%VE$8]'*-;>B/A7
M+DYYQ[O)SR\R!"8DK;Q C]J:R0WB=]9GW*DUM7 C333U_C3E4$;XT6;O\0N2
MAM(Y05>+&(0G5/\-,2T!A1[,*HU7!U $@A)7>+%^,(H.B(5DQ8X.NV"JQVQ*
MJI]ID[/<RU&<XN^@K%\(A91/H"$O^Z5Q+86LDZX KQ-+# 5RN.CSA>\ZMW)#
M)+CP2&PE>" 0; *##:OX0D6:F7_U>2F"ZC4]E6/23A?7E^[5\%U(HE;JM.?(
MEMXX_>@1?WH%*)23/M*.<=:3L"U:OT;V2;ZY9WO>F9YO5R@;<MXS#KK[-B]Q
MI)#\+@2<3F@/M?,-EWK /A_'&):9JQ OQ)^S5%V3RE42<#;PK_A OLZ@P,1*
M,+-^LON?$]"0:WA7'90"V:G\"V6H8J9E5:@E/'C.?H?T7@$T)\]:/,5<"OBJ
M.O7XK"A^;O*IM*(ULE5Z13H1K.B.N04&#46W+5Q0K*-.T;-"D5BGMLZU/(#7
M"M?NQEBJ&<L<RV;[CFC:G;DZOGYO51MQQ=5CEW<6KWONL-7$FB"I4W1(\3L]
M;B^&E+XUXI#X4/_IB9%::F?'A>918\(WD4U1DR@A?=]D:P?*:NL>B=PX01E&
MK"JZPRIPZT\LF^<_XZU_=J'$1G(N."_2II3G[=D-3K<3NECJ^1B#RD"OR]UF
M.'\]?[O?MX0_Y.Z5,LZ\WX<,L?:WQM#7?I:VME6^'S80%*V%$ HQ95MNV5:8
M:N5$037".H-9T\QB' VSZND M_&@25Q0YC3L*0DOH!S3^+GPI?XJ)R*GKRWY
M3&'!(AN?K0,'9+C5A B-_1-E%4<0F^\;X>!U!9ALR]B=R_B8(IS'?+X:345J
MS,)P<@7(5*"'WPVE*ATI1\\ PW'HQR\%%^?A85(6,Y^Q@H0#G(FJ.W:I.7J/
MYFV)8J2;'YT":7_I5THP7 '2=_+].P ,!'/Y2/L&4D80WN'1D#'_P]664,]5
M*K!88% #H^AX0<36[0@<&5OXHVK[.02XG  "TT &4&13CD&1FOS:_9G;Q-LK
M\UO;^5 _JO&_PHS__9+)';NN)IJ]_VKRWA ')VDM'-TC:E!?5]C+GSR(D&AL
M#]P>(*^4FB39K.W:D0YF#P4;\$LKT_?0OT9_L[*9_TB1;)RQT-F_/_U>/FE%
M)D4V\!<5TT34XLEV'I2+E>3-NGDL>%ICLXA&<;9WRI!?4ZHPVX0+7A6M"-*7
M? 7\I2?$OIPXKY;_S*XA$,Q\RX8Y*$&H(2*5W#B9-\GAB7JI94S# "94OHFV
MLV(:10IN@N32E,@H01]#CH1Q[=S2K O%P@-=1B_?FU19[R8;G K^BL%26UI>
M5.D6&PT^8PW\!ID8T-UW%U)+K9_$J"S3]#HMA!?,L(>;ACM@&BB!W^VI3'>C
MPFD-APYW$J-8<),"3O%FPZSX6/S=?I8IFA8,J&@3,WVX'0^2:6^:4] TVX?$
M\@5HEMG:U*9B#!?O5DPC;7);=<O7NWI]C]V^QK3Y=DO0THVP'WPEIG>QI=?_
MN)7+[A+_G%[AT<D)S>WVSM3/@M&Z.W-AO3;< A)K;B-25:W OSN&.>;(H'H=
M*YXK .H*, %V]&5K,68]/+M-^C!]X&%4:2^KVXN.?(EMR^[EB"5/*<?+;N6
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MT!/-=GW=K>J=X'"MXWD7'OX\<<&HFMZ.WL2<37*ZYBVT_--24T'D(PQ(J&#
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ME7\WQZD_;Q[>T[.)*S.UH\55P#B/<O7,3035= 9'ML>^ROPZAZ4\\,B.LC^
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M7B ,_*B/^B-AW6?KU+E'9*[M('%17_J^5,3\)KAYZO **Q%0\W8/3YZ14)2
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M4^NL26.7ZZ]PD]8/3 TXKC(U2.WH&$T)8M1X*Q.\)HW"P.ZDJ'S#U:O[,-]
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MEO6TQS=9.D_[8C5CSED5$!*G:]3+K$[#I+7MJKVM'?G. +DP5M3E(&T*CE1
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M00R:!MK]V5)"8DO))//4IR\]"Z8@=2JI1"+U66+#133]UF=@8!)7DU'J(H(
MLFWS88JA$A9@>YWYD$2R+$C@RM[@YJIH);O*96XER5E4MGEOYP>7:6!U13B_
MJP?2C#\9#SG+%8WS"N/&^A2VH@@VJ4\?I:YKPRK*"7E]4_3P3!^(=B$J]:0Y
M_H^<OI']=X2H-;TK"I/4..D7CF:5AZ6L7K&67,)7QRGN-KE/IZ9NU!@I,MN\
M48?,*:KB[B::>+2LJB!7>I#^!V$(HYN97ZI&!BL_EN>Z_F,$2N>!E_-8_%^
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M&VVC[YUZ&!X1ZR$-U[E!#D*=&(XHO0]%%_LR[[6]2C;MA7 \]#P?M.@XM(.
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M[NHS2MV;?1(4?WD,RUJ[%I@ZN,H.@E6WD-XW^R-."E]I[8X""W%-X9=5B2-
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M;AP#?^:;]L\_M;NH^JB;_>;>3:^GR?P;1Y'SD[>$E[I);;M=]FS8YT@'_>)
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MC$&)(COX["Y%.3QQG,14*<CL1'\CBVVC(D25EQQYYU)+JRX5<;)\6M]QW_\
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M[NYG:+:RM68RW-Q(<&L8*T%=3W>%M2O*G^L?]Q?_ .Y)VD_H_P#</_[:#_\
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M< ,=//3P.5%&X;C#S[$W9])<C:QW&EL-X?,1WI9EP=U^:4Q$9Q\I<AXL%1?
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MX]O/ONY)4:4BX:D-PGGY$9MQH$])6%*2>(MSK:_UK<[-DD-I<Z!*W2\Q ,U
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MLR8[NL9"=(>BS&B Y'3(^2<;6EP='6!U6YU[QU/Y1M[;<]6IL4]6Z34$2M:
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MP[CN3PV)A:T\2/J"\,[3]6W<+N-DY.K]E]1V#;9XZVU1]4Q\F2S& L"K)9-
M3$AILKXE2'VT6X\*L.@O9_YSO)CY?:/L&/OH%Z?MO1.R;/"V^ZBGAA9F#*X
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M:(G+F+_;S%$3S\J(HHBG[?;QHBBB*?O_  _G:B)SY <KG[O?1%P9DB8T B#
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MF8CY:8,F')++DZ3'0[!GP&IJ\K!2ZM(4R'8;D]UEHGI<+&2]55 <P!+WNX0
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M#5X8E,R#+8:U(UA';"@[-"J?DJXD)</1BC]7+Z;^,3[J3L0X9UG\M'F,K'8
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M=T0Z]:A*V&D[W?N;Z^+8ZWTF".W#L.NG34]1# H?]FS.(>7NKY#),_?*=RG
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M2;5HP8?=(+YI@O]36G)W7\)2PE;7E^SN[M#YO&1 1E?Q?_/6I['UI:!@6@G
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MLISV)^7KDL>,A*U\W0XH$>D$=,)V*G:W,ME*/9/2)8*66^!@H:B<[J18#J_
M5!'M =C=X+5VK2KMI>;V#!JDEY5-.6#?:.+*=J6IM95"QD!YYY&\*%\7N/+"
MQV:.#DN=[(T:YWQ^F0I6)61S&5<*B9CU]5:>6P<!$(3/WR; ::S*J-ILC77E
M/2^"9XE.>S9NAU]PNWN(D*WVO93'$@'[617LLH)A=%A <S4L0@_1Q2SZ:%,?
M9U**0'_>IN?LA;O3Y/] =7Z+,IC_GB'3/&J1R=^D:16!O1RSZC<UK@_8M\E-
M_Y<+>)R<^:-K$]S/A="^R#T?W8]K;?A&4ZK9Y%3/(</E_P!$WG30! GHG\]5
M(GEYT=-*,4F\B_<QOMY">4ZW0QK@]N1,.JB6F651,N=*0;HI/,B$]-K5;#]]
M+_E5<*2D?BQ0IE7J, *UW[DH<A]\#E076.ZS45ALB;ZN&O;]H2%.#D]TK2'0
MI<%;TCM_>-0\8"Y+CTJ_X&P;B?.JO^2M"(<9]<&8Q95-DTK0>64'F!L3CB0\
M-7_(:9\Q\B7D'-?XP"F1@3 IB-XZDDBU+CD39UICR5Q$3[^U@F0_$M%ZS>!8
M=7IJUIJ(5B1RY2*9M]DXE4Q!0"3K]NXLMI*I>CI34HAY!+PG*UM9!T?[N;,S
M<8(<Y:J^R\4[M'BD3LIAP]_C0_(0I;2CLF!Q'1$$E=EG\*_!P+&"^?%W"@JI
M20'P-SR9+7EI$@.T^B?'OAD@,K-P5,[;F!'-T,"SZ^RJ<7(E9=H#-R.KB7JU
MX]_%<90S5H#P8D!<I_D^_!/+E5L@7'B[$OUD4:DBG7^8.5-;.5&A3R,LR25H
M.6O%'+X-)W C)S5=T8K4DC5?'_EO:^)$[M!^KKEZ2-4,HYL-C@5_K(G_,HST
M(HPV<ZY(K!XGW'QKV@?>P;8._UJ^<>9*SSU;I1V'14',>RY'I^P8IBSLGUV=
M:V,+;8N3YL8Y7SB4/6B(J%]"(8L1((2//5';>D3B WG<5<Z,__3DIK7'YQ:[
M3,K)._F108UFY(I=B]/&M.+*8+[2^&/7;C-8^4E*C\=(T0(77AF3!&JE,Q_=
M@&_L.R_U#Q#PKB"N\R<N[LQ[N7B'QC20@YY340QNGX I3RB8B\EE _\N/</'
M!?H+PFB3JR#%4"E7L8JI2VVB;:ICR(4HZ8U(55_(WW?-OS$F,=8%I<.&2R3@
M$\%D$!&*&"3#V5(:J%D4&F.*7] 6:#ZK&<R3<V$J:NPHKOA>E(?D/4BX9JE+
M)A/DJ'-L'6SUPLVDQHHIHQK7; +2+O#!$ILBF6Z?2V=(G<O%=F,Z8&B1DIM*
M5(S%KR7.R0-]"#.PXS%A1S6"ZGRA>I27F2\Z=26/^"0H4.=\?MCO9U'*P&;/
MQJ1\F:=\';U \57"R,-6:-/1A6\O%5=C6L>8%45Q("VTSTLP_D76VG5Y4TZ7
MMPUHHO6:<RCM..4EDIK@SUG+F3K%NR%Y+Y!G>H#NN1]A&AS2<8;Y-S\-B!Z?
M&38M0GS_XB-*SY8?41(ND@:9-%SY"IYW;2UVXFK<9*[)P?7ZHL;<YO*@R&%5
M4LO KXBA4<MN&HRG03!4>WJY3=$0W"@[;?8I1E0'%H+LO$">8:!MC21K/'7Q
MK$B8G/8FRF.1>*R]LJ$6WI'U; 34U:7T9 CWSF:5_F2H)1,+K-S<[_&.[[%=
MF*]#P/'66T@/4 #@!%/<U[,3V2LRU=CS1E'CTA5WASP8C@Q7G'="!"OHE(='
MME5*F=')N5/C2?H.<<]H5PZ=4TA'V2OD?&5T@NPX&@Z,8[H?A<C;KI>E*E^B
M7 57B\BZUQ::P9<Q/S, G&X7BY#<6HOP-:R]^3WONB42D?F$!1!\UBA?TSIE
MM1Y&O(A7^<_F&1(UVB7:9[%#+#5)^9-<5Y*I^*4AZ69R)9,(.4+"N\9)\C],
M,0L**RU#&H+)9WM8-/A#.5AZ>OR5UY:<MDE8-H9(F!@UT)1\9 !;@"9BN[<+
MUGA,;E8?[/NX3=OGQ@P:J0KCZ>'DPZF(U^AQVZ9$I>1[?9?RMQ9UVD"\C1"F
MUH"$GVEWPSXG"A>O2[&P1(+W$2B:[E,,/1^177?"ICUX3N$.6/E!%AWU8\_!
M@>8C@")V;</"FG0")5OJP%JP;7]//24;,6O(!>;]6@R)/&P;E#-"'3DH_NU]
M>,B?&%G&0,AJ+L9Y6&L;WH,9Z;3I_8ARYV-C3\A$HAZHZ<-.GT_?+XHH9,8)
M7_5^(.[OW=6+E*!(@0#6^D#"!Y0E<_I\9FI.W?;U(/\?8/TJ%?.#MSR$3V1*
M>LRNK;:A FT9F5Z8: @Z3U16NS.+MRY,G__LQ"T&?D]PT-M4Y>RL*;_F3+0/
M?B [$>C(KRNF^%(?;^0**>NTRD[9^LX&X$KX]8>+A@QK[KR=1X0S)!JOV27^
MFILZ=,Z.E87O08N_;DQE&T H\%><9,O4Y6)G\/@;;,@#J?6ZHZ69:>$5&/<L
M[X1_,*]RAZ=D^O@/8.ET9027FS_-V!ZY,_W\^:\3N#+9!AZN0;BC.[MVNM;M
MJPYM]56>V&X%!2CMH%?=M.S^PFLA.48=4A\HIIGOF.]GO7"(" %K(/2:%^QY
MF#1A+B6XP6HB:3 %GVPTG2?HVT[Y,CJ,--6?^=++J?X!KEF!#,]@=6#!_9,S
M0^I&2ZFEC7<(LF>W'MM"=.75Y*5C7,VD?9,AR41V5MX0$1XJ57,?:/*#RZ+%
MROX3.C:^_L\<%O)Z Z3V7^.VQANF.Y-'&TVSJ8V6XC.R%^;L-]@K(ZG%0I<2
MIB.9DL-?<>>^9QN1\A%]);-GL._6OH!V(A33#E<54 #3ML32!YH,!6!OV&<A
MYBV+5&GF;K::,"L40H]G0\!4IKTB?X@Q//F/=\MW-<F' [H_["5J9\:^;OMM
M BZZ^]U+0:9$X(F-R4YO@$[UC]%6-Q2="">D_AYWMP?W(UYI_Y4R7^&/01^N
MR\^_J8M]^)C9Y+@M;&]5@DG'! UZ&>.8O4;%MOXUZMX3]@>S6I2<$V;3''2Z
M26["1S'S)*1Y_@5R+&A=R9OC_4W1)'RTQC--:FD4CP,]MNVB=/-5UK81;H16
M8/!*.0D&"P+.O(:M!,-VVDS6385=-M45TYT%1%J/*(7XH(MHK8W!I^:3H[*A
M,:'$A#%AR(1QD2'17[I,E9[?7.3@^J&-M) II3'JVV)4PH6V.AM9$H#E& ;@
M&A[056_$6&!@JG&B[/%@(#H$FY&8S%.66H %W@QY_/E1+J--4(A%M/\H('?[
M^**-8SPZ=-]^\Q_J^[\4EC+Z,H_C(='PO\KE_P^?Z8A0&930'O@;1Y=$=R!4
MQ6&5I/WY&*&L?UK/>&%(19\T?'BYKU-L@:Y,C%Q8B,:J"SJ1^_\2GL>)+>_S
MR&=Z1C$J,3$XG<)\UNCX<OIL+B50*X#S1+^B@-S>OQW;%I3(15NZHX3VNZUM
M^J@$7>0HP]J1; 1V+37R71_CR3<@,((5FDLN6JGS-8C2F4C5SJ,A68F$Q6O1
M,ZBD#;E:2.<CTC>15,U^X/'HW_$&JOL.A5^*>M\.7-5KG(RW>MBM-+X=4),^
M?>B Y<\73B)N])RZ,(3H''Y1<T,294[?WN GL2O#=;_'DZC!"B[I="K/6(:9
M&M"1$J@_9O^,3KI.SW6=ARA4>N[ZJJIX\$U[W%BV???XU@6MVNYLXOX'B!%G
M>L/Y5G;2_FY-5\LY[#C,S*>C&4+\N,RYW5&A_1P@;L/\U_>>]N9^G7NEOK?R
ME6AKP:V$K_ 5LV=_<,T^D%K+S*4N]YR^VH)^PWR'E?A9KN=\2C9?RF%N827$
M]:H6M:%;\1]@T#57_F/P7^=_@!9;F=DPYU_127<F*W\:GH3&6/^N[*'M5WJ_
MQL<KIZQ=23G+S_Y-W:Z0E$%\1CCZG<5R_E2%UO2NNP2=MEM_A"&_4QW<?GLM
MSZ)6&2,G+EU(X/E-=(,K8;=A+/T/<-I@'M3O Q8_W.K22?];]&I]W4PJS3B>
MTZ.KM)D-)[&4P?L'GG^+Z A>6.ISC+"Q3T3*?YAJ(3<MGK1CY7AB+X#LK,3_
M>O%S(7$E)7HP\J^>]G6Y*":SS=T-:F"^.X/-GU_ZI>^FC[Y\X)5=9O>KM A.
MSNKZH],_0E431-\F:M.V/)M,L:.#=S9&W&LI65U8EWC=<F4ODF;63>7Z_P&<
M5Y2QVZ<JG7O^ 3Z)/9Y75E"VN3>%:K^+_5WY>?1M&95<N$4^@.A^Q6^:WSLV
M)B=QO?ZR2?]#V)K:$$:LBE(O+ND)00&5I8%[B\]']=\$P6[]WQR^SKZ2EB8G
MWJ[B21;[U[\LY&LO\I.();EU-V5Y%)#2OYK.83?6UM2/K+2CFTQN3K3'?=*J
M;%C_UONB3? [R157;'CT2HI CIVXD?C/?Q4%31*VZ[2,MOHPKK26U,>$AO_I
M"<VV-S9<$3*Z0RY=]7%[_LI%O;CH<[/OU""::C5(O?QMZ!)^7]I6W-IZ4B.C
M]-0Q3$!^)&LILU1L2_0;/:,3J[/!9#O[O,&;591>Y!9]'SYP*?8#*B%%<T,;
M<5QGZ7K]R^"0F^>?@&[9->M+M)2/_&5J@_UA[+;^QR&9; 11:5UJG)%7Q:XB
M(:-5%XX&6A[FG=VY06?OOG=NOK.V\UI\(/H\$K@^$<M#*J:Z.TNE<@+>[ZW^
MMW[<J4;SD&/>7*G0[8)3]RR4%'QF2P,@A.@8J.&>O9[M\4*N=_H/\-1RTO@,
M.N-S$+V#1(('TD*2"UTC5O0?/L$N?7V;84M)QZ3*$EF#W_;;:?@P@4BVF6@K
M$,:VAT9N4'Q>)-7#L"-E0_NE=8[&8)*U5/(D-&NW7+FO/Q@(B]:A",K"PR?R
MLSC/6I::F*M< \VD#*LJM[T&2,XO0C=[6N9/M$#PJA&H)(%<Q0C(<%NUXZ[D
MY,_VX%"5^*"H=^#D>MV3:+V#S2%Q'6;$XY:IAR!&3;6H6EK2)5\VZ(@_.2W;
MA5/NE045S7-+Y1-R99Q;>T>[=RWLGF+?8MA1C(R7P7I>=BH/V8U=&>0?@-YW
M'S@B<$):Q' K6"\9QS)_>WK#$>4!W.@,V\1<<"ZOM.B[>N].0E>=I(U:OAV^
M%@B,%WEP8(W4-[-:BR<0D=$R;>IAO-[;3N1E-['S=YD3[!&-22E+:D/*)!(J
M ^R=8#&E&[K@N_%+-O";O*]D6%WZ!)H5A2@Z_X*[1'";.2IJ D\_7HCF)6 +
M>/SY< <[YGLPF1*(RIAQX_ [!GJ5R1L8QM#0LENA=JBDC[0>5MGN['/;^N%*
MGPCKPF<9"^1@(H3<8F\0CD8;>5Q=MCLR]L\2 I(5 H=5-5O1/ PJW-5YR;GK
M'"J!?\1U\2;4JJX"2^?R31()U8;Z='A?2,;=^#E_EPG55Z:5AX>X?E:T-#TV
M,Q%2BMX#(3>-$N4!AZP^?4YF^I"\)4*T&$I(-?5B"]MP80'M#E4*<^MEYL]H
M3,;;UL8VS]^R#8I-I. )N=NJ79KHV",=!E*5*:/$ZX67!_GU<+XM$G_\N2[2
MDI"P7/DIN-'9>U01AW<D$7$M1]NZF936MQ+6!A(H=U1$RXNY(>'L67)55!J]
M"*.'>\/ B%36+I=;3=1DC9N"&DA1GW_DZTEAIXOZ&2$4B0>^]&9AA?]QHBB0
M6_>V(+8\8,Q7/(L)+!W+6.C%1!)K]E5$8PV.;'7N \$Y&(/W]S[JCL1 3X$#
M&GIYXFL.:P-'+2Q?6&S3\FQZPG0*G! ,NQ8A/O1+J(+3URL&N:FY[#D/'&'$
M9-VUA "!/*>AT$P</4JB!&3=P&;VRBN_E%?"T[$ V>[^Z+H 7.HY!PJ8NBU_
MTM&FG:A$8 4]]*%!S>D80YB8Z0J:B9<AMF@SEZM?L.H45[%CWYO\<;K81@!\
M99E#*2 X2,%;\;FDK\O[J2D4'=TD*;85 53\_N%8,&K-HC#V*]-T;F&(SII:
M8+"4!+>*P1A/5F-V4.^EV)'[E=&H":/S1SSN@1>&J[KO^AT[)#?*C,,SO@@Y
M4$@;(6DKK@8BD($X/KLMY3I:)P0I+P(@0"_%FM;/S\>^2]^H,7C8U'+PD4[-
MSUR#LYW*SCF%G5D(/Z3Y33%S3C8$>A ;^MR#[TE>J4B/\'@WR;^V-R?-+4"/
MU+9%J1)KB2@^TA/ <^STW:"IHU^@#DYP*-F+XLNJ8.WRZ]8+=/@29G\"?*[R
M+-E?CK?VO!=UDFJY'BPH[YB@'W;ZA$'3\*JUR4HKW.VMI8F8Y[7I^GCSTIE-
M=F9ZWT]A'4+T9ISGU?=!F<%.?M9-/'!Q$G%DWZ.?LI."9(28E.I\N5Z S"1Y
M:@_05YM.@J&@PS(FGI&/S7,T3LJ"Y'5?5DI25.T66._.- @R3.>SC0*3:+F4
M9:*"E)L3U,03AFOOUN+T>Y83.'W( $%.!PGUU9B.""G&SXYP5<8OC]]RVL'/
M6Z*9W#20,G!_ D(B 0(T!U[%6KF"T=:C8(,WV5-3)61'F%^(WI5.S32S?LE6
M:&%0#4:J(1:U4%Y36TU31H5R!I]0S?DX65WR8N#?^07$Y62'GF^J)$(T9Z6&
MC1];#G8GNE-_4+]O_S!'9KPG:R(KK<#IHXXI+RV"042-915%_9MB"]O".8E,
M6>8NF0^&BFC/G^#=0L5GXH16L+!PD'(6B*CR''UHA-62P0[F4'/=9$PI:0@@
M8:&TP-^N'N*+*$D$)+,GHI7Z(4"L.D,SU =0MJYPFV[$)@66:RV!\(5:!][G
M@!PKG5*=[[5<HB\/I4KBD69[X,NQ>I%C?$I:5,\KOH,YXKQ)B4X:5F4,H>^F
M-'CLE=MNY#"U-<ZMW=,FX4LH''MHA0U+*3P9?/4NIH?YMQ:C3F#\UC;O25#V
M/X!365;.I3.9DU'9'BH9B80>0MT=V(>:D9R8V<'3%LGJM;E<=5S@U.X6KW!A
M]1Z%H^.RZ;9,H#S44UD]X6V&FDW\Q,QX\Q\@R:MJ;&-01:N0QWET\,_2M0BW
M27H[WIK0QK6QJZLC=UH7?!:547%EM-5^0PMAUJ?,Q 1B@HSL9D8Y4\]K+GYK
M0Y>ZN5],3)RCN7:H\=.KM[1F]!%]%V35G#<5@4FI!EGK;'+A9_4$_JYP(JDJ
M>%+EL.\'(T2\*4[WDRP2'?I9SW#5\'")@*1RBQ&[?5O2 ))!+T*X3*(IW^*)
MH-;(J,>5\]W1U@@)HL,(5IT\YB0^=3/H)I?KA3__(7Z>\A?D5LN;R+SJR\\;
M-[A*QYN;"B=R?!@C!2M[ ><=05'$B2.-M<86[CHQ8-L."%VC<2;CT83NU$0*
MF[:YC*G]5H<L)W2#T(WAKO:"B+PR<*YNJ8E,OZC5*AJ@7?28DRYL4@M9BM2/
M-F&27A++NZN6&CXAE6R;/]:<@-Z #%+'U="2TL='!GNQ?V[(2H5ID69CW@\I
MQU=6<Y9S;1.A@1BV:LJ2/+9;0^\C4EJ7B[K+\/.51!9CJD9I^U7;T4ER2$8_
MF&61_0@:J.QE3'#JCE\4R+24B-_A"]8(;!-$%<W/I([,%?A>^16\5)F5GP%"
M(=;^O<4F\54QXGTT  9%4!M'L+0I$98LW4)Q?,3ZG>XD7K!-]-_+H8I=>2HM
M.=<%PXG7\&1<Q(IA31V+E]GN0V-'@RX\#)PE3$>]ZDG$5(>2@+I/XYA%!<GE
MR4"N3<?F7&?QM%6NB'"RSW75 @T1'3$>$CQ.HG.<DB,_H?P>+R+[^*JF2J B
MPLJ8#6GWQH[\2L0VP;]'1XQC&=%?@U>3-HORPNDQ.L'CI_YR F?Q(741KO)>
M5(=7X&+:,K'-4&& F=#"]A5(#BYP3MGRBODSV?J&4L-]/VU?T,(GPDMV&Z"7
MY&!3PIUIR#&LHP9U).0E7+#O,1X;#KQSWG]APD3'X;(D$>DES @Q38L1E^C"
M*FZ@75%S*,)HK8H=/SKH>"BW%W?M:BL "C5_6=VU6#,3,[0@T"]IQ0Q7E@BW
MJ9'5R$A&%"2#&[/W^\ALQR C*JC,S'>_(@35$GF.9HYT."7W:_^F67\!(LM&
MAXK6DIG)9*P(J\LT94&O:O\!%K%L@XSP.0"4JG8E];[U#E\O(-?<]^5-L?9A
M=YH'(/H$\K" L 2B1;>SL3KD;(+Z^ *,OB!F:D<3=OR-5FL^MC'19OL6#9&;
MZ@O;0CM^,N;O:=1J?H-Q9T?U:2Q?<$U_GF@)W=.2M'VGDSIE"(@A>-5?X6R[
M^ZB=?D,)I:YV99DWBDU'^CZ1)B5L[N/>L__3C]J[;OCA2#TJPNLZH,#Y/  1
M&>:236[(LCSV]]M ]>>J$JY.YLP1JRP^SU2CR#F$)&V++4/JM_$4/XJ#0,3N
M-M4\,C;/S\,$+;V3$>4SE^;2UR?+?ZM+6X],32YAHLO132;JY;9EX]Z_^(9$
M$KZ&C_D,(Q2SHALG ;@'VMJ)9PCMH#6POUE<-U:GP.[Q =709^G/6V3(> =?
MX++[..FCKRR6>I> A^SMFMGK9EA&[++K51>9O3\/1,"MW.2UT ?E(8%&UW-;
M_8'%@/*(V-5O:AT]OIWM&2T9@D_!N^6^>+^IE;P#@Q76R?THIZ':X4)(N$]E
MQ:L:VM]%H=P&CXMG22W;J2YVO]757$P:$=EVVH7)UQZ'N]H853P%7C@JN###
MH2%%T1PC9Q03L)6-5=?6EO^0O\6.2,[?!NN'F>*+Q+)S:>LM+G2A-U8$BR@4
MRCJD!LEFT9W_1,AK[9JAS'[8M,/+^%5A]N)3/7:NY[<R#DJO1>1$/^N>UMCV
M=7>5'PQ!@ VB)7M#(45Y_24+URL<F^[Y#J0@&\/! P!N=?$2C25*'7%0L.QD
MN@.G)Q81\^Q@(1I=3?WH4%+'/T!R"5O'6ZC$WXLOS_.$TF%_/K+?_N^->&7A
MV[8/C&\2I['_]01?"O1+F$/V)Q_^YQ0TL8AZVU_^]PU[171)=&7?[<F+-D[N
MG8 \P7^U@,'2QWUJ]XZ2J!P.]ZL T(_TED2!DM@T%;IJ=AW-SV\-5_ #T0WE
M^T,_WES[/(EZKTK88XP_#U&/1N!^!AU_)*,[T"A$)Z4<ST8%[<O9(HHSZ599
M18;2TM2-$J15G-.@/S#5C=/368%UR$FF\@ &M-^!V7)$EU['ONJ.# 5[O(:[
MKXN4C S[5G:/B";[^MP4M[&E8R;T//(AGQZP< T+/Y*//MN/L[ZOY'SS7W)?
M@'R<OZ83Z X4.GS:08\*(*W^![BL%\WNM45YD=! -K?]!]#-CID]9BH#_40G
MRKK[\!X+EOZ!WJZL=+^.P7%@JKI]"?1NW[EO@$@50)!G,XZ/-3X(09@"+)C:
M_Y2BI5;;G22]^WG/CB-LC0Z@="SIB+[::9GXT52,%DXADI6^!@U-EV]/S5S:
MT5%??NG=_)QP,+&]O'G):>B4UU%/N?L<KFCQ1XSMT/=0*?$,W.U%G9Q1)'9L
MKW/LIC/AC_?W\WC<R<^!^'7?"O$IH3LIW<<"B=& W:JJU!]BD4I#=/=?]DCY
MF/TYJ=?CI%^)K <QY%T$"2-M!%(6,DI;-S$9Z?LY6],8L#L@KHZ6"W/PBG A
M3YSX6V?FMFF92EX,2P7WSI^O?73"_Z>*M&*'LN8KFJ$/-HK9E$-I,"H33!6K
MH=SOZ<VO%*[*-/=TB7!];<^ML3@@Y"X*@I$369H,/"-V==D<55/QZ&*JWR?=
M@V>J3;F!F7Q.BZD5+EPX3:V/.X'=^%)1>)]4(S5ZC@P7E-I_=4W&2-&L%KC_
M3?OZ;<F3//>J&:4=/QH*J:OKDT#)^#"JY[O\=5;]]>0\4VUH4T38R-TW]!\@
MHA?H7A<MFL1U)-'^!\N* JTO[ZIPZ1\ J&-^Y>?+N[W3UZC?5.Z7P6;E\->,
M?B\F;J>QCK&2JK%9#3JF?&=8;_*6>FZA L\LYW[BT>*F'P#EBPU:,5= F+[D
M!H:8V7Q]FB^ 2!E8_#I\-!OOPRY8IU3Z#0J$X.<+',CII/8),_I9O/:M-*U#
M<]P#VSB3FL3SVABSFB#/?RO:L@.345<?J^S>I+1+ _X!7)<)DL[;3""_?V#F
MG.5:5/^Q6]6TZ#ISF7T#DF*_4RY9ML(7Q@OEJ32 WKK=3.JWN;6^JL/6?^L/
MDBS=N01VCIG\ V@Z,67;2/ Z(KP)FK>')H>F1T^]V:[!4/CPB(:@FNU,XM5T
M>\4K:67L=PT.+=TM6ZY& >V3%(^>:&UW4,E$BL$<)?:3/Y/LTQT_'TW"=3[Y
MDY9FTZN:+FXLP*%G&ZF2LL3\.8UU<_]&1A<;_J.@W/^O3#E.5:[%0'19[<:N
MU665&@[+QF!4^]L7;0U@5'($-3/AFLY"&]^]](63L[TLN_*YFYS#)BWH)T\C
MP<:"6SI:=;T7!<6&,\4=Y1"(8B!,AJ51[Y+<OO&UZ>4]@+?-.G4)],>^@33F
M 1V5AC8AU1R;5S(^SDF(>T NDAJ^JKP<+V<=LC)S5V#7.C_XD:2, >TA487H
M['TU(^.G#J]*Q+B!E^"*E.C<XR60_K7,5B"H+OH4/L8DB9G@@$PE4*464+1^
MO1WNUAX $W*,><0T_$.@9TO,1^TI@!'/"D,1+V@1DA*,*IOE]<+)#R;GH*E;
M>..YF6EM1/Q.L&9D\)^SI583XJ8_@U&P8R^2@]88 AQ;B%K3.]1@/]%<ZG7\
M$[:CT&(VL54D$U4M[29%#A%[@'V!.@A&^_MNV.T<^:&+QCJ]U-LT)=8JZ?.R
M&]?C+4:@RGQ_9RY[C7,]>Y)OO?IK<VU^<!$#K]HUL)&"@ L&<#U+#&IP 99P
M94.I.&)??N]RPNU,_Q0WJWAR[]7R2FZ\;+:A"PS,6"1&I5Y-?A"5=#?LG\KS
MI:1F* LGZC%KWS!.BS)$93W_[9:_3=[3[P]UZ?0J#1BO!Z]-3B,:OU @Q9C,
M:COUM2W7<4C>00I 9+"CX/CWR?'&8Y?%W)DC;TEZ?![;RIET*?[\EN'9EXQ2
ME=1[?\'1<6O%4Z>@3)5-JW9C8S(=F8A1K)SSXXV- W+U 9/DVSXRN9*LT.I>
M$NYB JZ%?=/8D: N>^JLD$]5>>PUG[_@ 6:[7:I,W+R$?]@(KG->B"BSQ5YV
M%714/]>ZZ"D[W2XF!8;/ID3ANI.+WN^[5>%[IXXTY2/F$>MH'&OLJ<-/N3'$
MVFG_*(WPH(Q=9$BI+5Z@5$G&_+;41.@ZQ^NQ.:(R(+=Q, PV=$/ZR,TF6: 7
M\7HY.FZSBR)#"=J-43%>5U(Z2@:R9FBU[?6+0D"$A(!876SX88\* D"MDQE7
M_E?3X]3!PJ\;GKXSIQKAEPGN4'S!D28W^?@NKM\Q"^UKU2I::6\9XO8@6)*J
MM9@63M&YCLFY4G>T8!QAQ3A!:,LF1%$)=1DW@_Y-_GL(_D#V0:W2>IZ@PA4!
M71O@_6,YT<CBYSJ!&)"0!!4]XI9KZ/@W?O%V42.4 6772/U,AOZ^$E]-\YC,
M%,IA-ALF/DESFO)/#"L%!_NKGBE._#\WBC$'[)]#F3$U.8&3GP \4>S)D##9
MTW5L@(?D((U_77]$4DXJ\9&4,\?-7*D-0Z>4@,_@U QXL4Z02*^6_\NH>?]8
M[*!ZR*L^! =,L,N54I-G8C)YK#V=Z"?:RM04&Z9=U9&$D-HGDD<Y_;DB)"K$
M@T#B$T4&?09'O9>XD"9RTIBR SV?B'G0"%^TW;JRZJPP^)W >O ,LX/:[C;2
M[ ).!2$=;=/D^YK&+D5#8KS3FUAK,B92_M>SZ 43'=9(/4,\.5M!QZ5+D"C<
M",RVA=5,)-^!61CAH,)R-^\0.-F7/,E#'I/JU+A6,%#V]@;8&GD71.YW'8D^
M7.X['!1WZ$U<N40R.ZVRB3 UW0 ;.Y4ONTE1& <00>Y92:8MS^-QV+ ('BFD
M2CHIW#UIQX<&E^^2V-2.0?,[[@(S"L"[2E7CG)<K!QZKGDP>;*&%#R3^-1FO
M,BHBORG\'UFG%V^.+#&]QCB\3*J+ OE&-+"1VKS4V1,EB'H"().HL<)(D?$H
MS,KP>*NZ1(4[VDR^> C]](R<>?!K:W=\V13T#Y6V*5FZ#TL5FT[5G%GL<GJM
M.&W0LNI;[J$PUXCN_T!;])Y3KI&7\>U*RR1<25G* 5E,U8?6<:^6[4$WC/ 7
M3S0]O8XVP2)2@U 1_ )G!S]-VO0M$CD)<4W?5SZQ6S"(?V!S+4MFRSY@'7G#
MF-E:%\]A((/25JQ"/N4V>;_-M46,$W;I--^32<TSQOH3Y&1)$W7NCJ.T'#,1
M1G1P&WAH^N8[3:_D)F473'-H#(F*8%>#^W^X>LN@.("E;7OQ$-P#+.[N+L'=
M(;@O#@LL3I $=W<-+L%E<0C!W7V!P"X2-$&"!$C>G/,]];WR=ZJF:FJZ9J:O
MZ>Z[S6<B(>*R>1*,1PST-VG5,B_2Q$RR2=>3^M_#1&B8@XU_0*5P15[&7VCU
M-D1ZDJ[W\H/,_,;=O^6"3/?@UWL6=4/FZ]'I6$Y.E'5$V<CYTPEFKILS&5.V
M::.5/?+J2ADUO,W=)3$V>J?6 B;4+!Q2?.0I4D.7X*-CU3PZ]<")0'+"HE^4
M&K4A',Y5L-,3&3N.?<G5P=6Z[!@RL<Q'\7:ALH]C:_'6O"R<KN/I8YVN],O
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M K(S3ADJDAF2U:7?;^A^BY.O'>N*&%9WUF&#A7U>,%<:$O,LF^#M.9=RMS/
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M4&MF2:><AI).K";WNX4SVU_ \I6G:1(I(84LFT=YI2HPR[3NXIHU+IG5(>X
M_A/$+7@$5Y6"8OE[5.G6B/4$VDED#RWQ+]%L[/N=4121J:3N<2D];A=B>U^3
MIF=F(_CH_>3%4B?86)HJ1WS31M5(RK?S7-R*>K5O.C5H\)V8"R'EIH.+64I
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MG/I54W$D)!J"@O!]P_OY+C1ZZ^Y/=NL',U\.E>N8?>6[.%\?:,E?P&A&V%]
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M0&.IYKR"Z/D6YELA,>%[(2JWWH'?81$AT(C Y24<R"3Y^H,C:9<8E) W4;Y
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MW3V/C\FG>Q_),OQ^=+XK(SLDLU"BVS]V',_LTG:EG9TPU@-UETG,>"/B8!O
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M\.N=LZC2CDSK_"]I!U&=PP<6I&EIT[U-'\-O6Q+\I)*4V" Q?2K\RM_Y(-N
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MQOJ0F Y/QL18GGK@I,YD4'0(K2U^DR )A<O>];KFI_7#57ZEZ[9@FU ,N%2
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M9RDM82/>QK#]*Q:3]!L&"VLZ9]0W>[7)">+ RTG5]KA)(_I2ZP[AL1*=0/\
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M=][AN!#M6T66VVQ _&E$3Y'-.1CAMPVIX@/E _>6ON+2.7Q2O)IP!-/:23]
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MN+E[Y6#\ Y-/AJ1RPQ:?O5 /L788[0)VN9:3@<]!AZW  E3,5E<].@Q%0GD
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M[N/WERRV'$67AM!Q4?"M(6H?&DYS-'+S'4"]@41F">?#E5G0'<UD_P!>V^U
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M-VM_["8SVG_7'= GPY$[N?*I_P#2;TU_^"V']S_2K?\ \V/YBO\ ]:K_ /\
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MM<<?'AM]AC\AANKV5K(7F@:XU<-.0U=H J!Q47KP]_E0,)>!B1@,>SO7 PF
MS4MQUJRH37H^FZ[TI^9D$J:1^DXQE%W>MM*D^JM)_H)MXVV-YN]@QHD#@]YQ
M#0< ,3K<<NX'BEM:S&H<#3B>9Y#]960G)2)/S'6E]G&X3Y=G">M QS; S#9(
M?<3B5/%V9"BEA:&W75*2VHA?2YQ%:2&?4\1#&66KI7ZS4,.0! HTD$5  )R!
M"VH;A^Z/A;3C^NBXN.?4_->G*=#\J1ZGS>1D'K3&2YU!]\J"V8[#3!4>E(N
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MA;3Y("ZD/2F[)FIS:88?LQ]>Q4"AT5>:=_/*ZBCPN=:7,W%,;!L*M>/B0N9
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M5=PU%&4'M(KO2_;:G)P [;I,B[#)$6TI,O@C1-B>BO.$&2M383O3/Q.]U6Z
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M]Q#8X; 1?T'56/5_C5]Z#9"\WZF)6X'/4S+AK>GV-(>O&?-;;N)%Y.$;>IJ
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M:5SCC!J ]O\ P[<5#/YD]7T8ONAJ>MZ[HVNX34-.PF,U?5=;QT?$X# 82(W
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M-MR$J+_J(0A"D I%N3?N^VR;@^>VN[EMSB 60R2U&>F@!#P#4MRI4D%;>,F
M:[F-PJ?A$;A0']ZE/=[UE<+Z4_IWV?#L*V5K%NR,G'>F_I/;_>MAW2&S%OZ;
MP8S#$9B"AE#MS<(^-5R%+%69.K>I+.8_+.(:T@:I8F1DG,>$FN7Z!;.*TVV]
MC#HV2%I_>=3Z/KR67S<SVH[:X2-K^%3)RJM>C,85F5G\^O9-B2%-+;BQ)SKK
M\[)!3D9);;0X& 6T!(385JRW=-QG-S<:8_-<74:WRV9XD"@;GB:5Q-5N[6"U
MM6"!\C !D'.#CA_$>"\G[%WCSL[:H^'U9S(XG,3'S'Q/I8MN$Q\TMM05CS+D
M-3%1U^F%)47;)L#Q3P-=5:[-"RU,]UI?"T5=XJFG.@I7V++N+J(QF(QO<RG9
M1W$95XKH%)R"-@GR-FRDS(-_I;DF+E(NSX+5\5$GA 7)?FY+(PW Q#4VHH0R
M%-R%+)%CQ%77%AMPRS8QL@=\)8]Y(R  :<^).(^M8DUU?& O8Q[2#DYM11=H
MJ+#Q2L+FQ!=P62S4O$OZQGE07IF-<:5'<$W+JRL::\<G E,N=7KHB*6ZWU%"
M2%"]L.DGC? 7"2.-KA(P&CJ\&AI TN!&1<*&E3@L5DKKMA!+79ZVTIW4KE[2
M%LW)8? JA9J'M?\ IC [CFLI <8A8YM0;$14/YB#-2IF5$V+%/9&,Z2^F3#;
M8:4D6'5>M7:W$[GM=:NFEM(FD$N'&N(.!8ZARTO)-3PHL2QE=)+I8YWEL!&/
MU$Y$C@0:JO7Y.G0YSV Q^(S>*RRH3[KLJ"^U+@85N-*9D28,;,SY\9[,1<MC
MSTO.A"9+2ECTN("JKNVWSHQ<R2,,(=D1B^H(!+0"&EKLL:$9\EF26MY=&.VU
M@-KB:5+L#B12C=)QK6F"R3":_B-M9R):U>7FIK;_ ,^O+M[&X]_ZC\X&W76V
M9:9$J6QD'IEA%2XIX+1U!:[JK ==W=K<ELLC8K70T-9H PH:U(P!;08T#:<
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M&3:2\F00%E:@M3SJA%C1PH)6HV]0#B ;"KEQ< 6S]PF#6VK!2-A(#>521GV
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ML^Q^N1(^-A9K 1H>.C,P8&,QDV$B/"B16T,QH42'"1Z<>/'92$-MH2$I2
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MS<F'*_7-DBPPIM1ZEIQ29:D]+07R/>[E#LEU(S;+^*$[H,Y+42CO94:&$XY
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MND4<XDES:CB#Q.>0;WJF36QVEX.KEDM=R)D"%(<D9%EW(R0A:V<; ;'RWJ(
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M[U.6\JQ'",?"XO\ H'TXGZ$&LYB@]Y7/992RCI25K4>*W7%%;CJO%2U&PO[
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MMGH;"UB;(/M.&M^''4ZM#VMHO"NJ_6/U+ZS8Z#?-VN38.)_ A(MX*'[)CA#
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MJ8")\;$QU+4K_OI;A+;LH-(<??4LW1(=^%);2$@$"]S85O6:;T">-CL::M(
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MRL?G]O8G3%./6;9C2'E/1W26EM'J<=1TH_R\+=W>;GYDDK86-D+V-(D-61D
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MS[\W#KE9'UD+Q6/3%+XR$#_N.@(==2I*WE)'2L= 2L$U;<()8GF1DD=O%1P
M .LUI0TRX4''.H5-P R00W#2V!H#BQ@S<<FGM&"REC76X,+'94I>D3Y[!2ME
M19D];606HB2EMQ:GO46AL#J2GJOU"_$U@NGCOG.AD\,3#6F1;3*M,,U9N9Y;
MJX,$N$$;L@:-&GG_ *?8LJQZ&66'GW8CL!Z+'9BQ4>B6P^GTRM]U(=5ZJ&FE
M"U@D)ZDV %A6'--)(X,C(<W'Q<N67U^U:Z20R3!C/$RN? #@ %FD6?F8<9Q
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M:24X 7=M1]>U\15UW57H1U8XGJ7I_<>G;YP_G;1.+FWU',NL[KRW-;QHR9Y
MP ."NCZD,YJ?I-=YNQO<_M\572YG]?QC?<S34E/]3KF:TMS)O06+<;R66C;F
M!5P>I74^QC3USTSN5LP'&XL"W<;?O(BTW#!WQ%6__1WI[J N?Z<=6;+N1 J+
M>\>=LNS7[(9=AD<CN'X<CL5N+2.[?;+N0R'M'WK6=C5:ZXD#*QOU)@@D%$G%
MNK;R$=Q)%B%M@@UU_3OJ#T9U51FQ[C:S71SA+O+G;V.@DT2M/>Q>?=4>F_7G
M1CRWJ;:;VUBX2&-SH7#FV9FJ)P[G+8A!',6KLSAFN(!!Q"5%0I4?8^RHJJB
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M2$K;9,<E'#A6QG9:Q0&"PU&2A&HBI%<RT9:N-351'\S(=4Y#&<FGZS_J7KG
M_4QN+<:+HG:_!8C6&75("&^S^B-0,H\ZM9Z(HSG3,S,R4]:REMKZU#^I7A7"
M771VUND.Y[S)+.X?^]3%S .>CPL [Q3L6?'*::(QEQ I]*V[I3?=V/)>RN[:
MPS!A2G>I,GN5WLB:-E)05TEQ<V',DJS+Q6J]TA0 %:3<9MB=&(-LEU/;PM[,
MSM'*A:- 5Y@.KQ@ ]^*];Z]E8268JM?>^G[%9,(3=S&2-AWS((('_P"TUX]\
MNN<_B3>YY&N&NX)I"X78WF2'][RH&_W=0I]"NU;3 M'LJMO8=G=LE(8>G=PD
MK;04%$;":/D8\,F_);N02PCT@2!Q3:W.N7N?Z1:@M;:/+N;[AE?<RI^E2-3L
M [Z%LA&+GIXN[#E'ECQ2SC&&R?8TW"4 /9<UJGW$+O@@C8.]Y/O+OU*2QWWC
M]"Z7)Y.7"V;3=?:R"WW,N]G,C,;4U'2Z,1@\4L/*=]!"/[+N4R45 )2!U6L;
M\*I9"9+>6YI1D98.S4\X#W!Q5^-H\M[G8T IWD_L!6:585"41*(E$0$CEPX6
M^ZH4)4J4HB41*(E$2B)1$HBC]E0F%,,THA"FB)4HI2I23=*E)/\ RFQ_+C5/
M&H*C2'8$5"UGN/9SM7W <1*V_0=:R^19ZC'S0Q[>/V"*M0XN1<_BS"S$=P'C
M=+XXUS/4'1G2?5,8;U#MUG>%N3I(FE[3S;(*2-/:UP*[/IKU#ZZZ/U1]-;M?
M6D#\'1-E<Z%].#X'ZH7CL<PK!6>SF[:@.KM=WHVR!&:"RSJG<QMON3K)X_VV
M&<A+=Q^W8YA ^$%,U\A/@;5R;?3W=-CH_HK?=QLXAE;W1&XVO8T,G(GC:,OP
MYQ09+L)?4O8>H:MZ^Z:VRZF=2MUM]=LNNUQ$0?:R..?BMVBO>NQ:[@]T=6:M
MW)[6NY**RE/K;3VCFN;=CR +*>D:G.:QVX14BW4H,,2P!XFLF/J+KG96TZJV
M=MY;MSN-K>9L.;K.?1< \Q$9Z<%A2]*>G^_O'^3-]-I<N)I;;Q&+9W8&WL)D
MM'<@9705XT6P-3[AZ3NZ7!J^R8W)R6"4R\7ZIB9O'N#@MK(X.:(V6@.H/ I=
M938BNDV7J[IOJ+5#M%U')=-^.%U8[B/F)() V5A':Q<IO_1?5'2P:_?+.:*T
M?\$PI);R#@8[B/7"\']UY696M8F_#P\/+C>M\\ZL!6JYB@(J*IS\OM[JIQ8:
M'%5 4P4T=S"4&2531%KT6L.'GQ_&K"V1KB E[6M;[>?&G<FFI\684VL?L/W\
MZFG'BK1<[7I(_#5U*QP!\>1_;?C4845MS'8@AH'-5\Q?PJ"%9<#6I%*J0#X
M'WT"I-$MQM50-,$[4!M[Q5;7_>S174KMP-^/C]CRJLG&O!%<!OQ'NX?;QJH8
MA0IY5*)Y_;^5$4415 VN1PY</.H17$J!Y_#]ONJ455$2B)1%/Y4111%>0YT\
M%&XM]X-[6_ 5%.2@CDKP-^/$>_A5*I4U*)1%-0I%%%%'!*E$X_QJ$Q5=^'[_
M !^^JJA55P2I4J;^P41!;Q\>7OHB<N/#RX_MM1$L;7\#3L111%(!/+PI5%%$
M6I=R[=Y)S-#?-!R",%N3+*VY["__ +&;(R.E3;&09N6_7NBW58=743=*N)WU
MCO$?RHVS<V>;85&DCXHS^Z>5#Q[J$99L5RPP?*W(U0UJ"/B:>.D_J.',<M,Q
M?J/5IF=R;>]X;-X7"Q(CHS&/_39TP83.12I]V=A\HEH03@)\0J6\Q(>;,=:
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M',.:2".XKB;FVN;.=UK>1R173#1S'M+7-/)S7 $'O"N=1\S^)J]565@:5=7
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M_7)C-CA[W%6K&??0,^(A;"'8=QG^%I]Q_8M;YGZL^U.'"E2,[BD=-R2[D60
M!;^H#I(Y5@R[S:QYN6^M>A][NJ!D;_8TK3N;_P!PGL[C5+0UL>)=4G@$1W$2
M%DWMT\'5W/W5K9NI[5F (JNIL_2/?[@8P34/$BGZEAA^OV)FE*3J6H[_ +2;
MCH&N:=GLHA0-K=*\=B7P0?\ Q5K3U-,_"VCD?_"TGZ@5O6^D;;45W.:UM_\
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MTZ1ZBV:1S;VUD#6YD D=]*:@.]H65^1'$'B"#P(\"/ BMP7NK49!<UF*9IX
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MY:!J\@O3X^8R:W ]DYDQZ3-G/A*W'5)2@#YK]7=PL/G-NVNR9I=#!+-*\O\
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MU+-XIQ_.8?"-S9>/3U+?R09EPG<5)DNMPL@J>PN8LQ<?-@,)1&6I!9"R?Z5
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MQIS(HC*4](N^HN/K6BPLD;BTN8X&R#<+Z[EG<7%KI7Q_AUR#6 / #:X ::C
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M[^U(Q,@QE40?=(\S(97.?B/$[$C=/#U03F.AT'WZS)1%UTIX=V3Y4H!*9\A
M2L!V@):A OUWE5+Z!$UG_C)4S87*5"<*R+K8J]<BCH>A'>-_Y9/H8T3)[UH[
MGEV+F:(UG[$N*VLQM/_//]#?I%XWUT="H,/^DD:Q[O#0W@)ATAG!@*/BM$L5
ML;;I\8M=E5^,JHQ?">G0;XIS7/^'":/58HJ <NE<:JC3F3W!597%.<NPU6^1
M,:/[N?D;J,9TB0/'C81;2FBJ?+RWI,/6SK7-YY6-1PCUG'=8-VX:%10C4 %(
M+C9J<MA WX"EK0&K=N"= = \^K9EDIR?IR5L04,MH0B-V ;-U+V+<X6'9&S=
MK#O^=FW:ZRM4F+VMV]JR;1T,K\G1@@; 7J53<W,")NZRML+>\6JU8,6<$F1]
M_#1AO\KL2RYIC\&@=N,C%$M JI\%<ZXJD3%WFSQW@V1#VE+&N-.%Z@=W__:R
MB_>MM1$[OJ^47[9@&X=4#]$QQ;: J_=+=\)IQS,SL^.])/$RGC:+A>K79=Z6
MQ$IW%W#P)X#YQ5M[0,5&BNIH2@"C5'&YX^>&(,_8(T1USHHCL?\B8%"A:]IV
M[>A WP!\<V\(=#2E8I]PT)& '"D%U:*,V&!GDLK97V0:;,*OKTP$6OGD&#Q*
MZ&.K<I6'S\OO32[:Z_5%PW^%8AKS(OI[[J@+0Z[L^3PP43=4"\\/I16"P%)$
M]I4<A;&S$)TK=HK=K6LN='/BHR>;0ZJCP%P@:;:!3WG>=UA1)\H<AR^N1H,!
M6,00P3PW+3>JVN1VV7IF[],M7;%IM1[5NZC%=;A6);+<MCL8)U])$D$%%2>-
M=MAFEZ9D6+)GWD)H&JY/E+6T%!9O=%H51%0R/'(V[_$/^M2(B:"JT>6OGO8K
MJ'3#-H4@G-"\+3I+4%!37$R8BX':UT;YP0BD=6.PN3I.<[.VSJ1G()[_W )H
M#X;'4E^#M8_2:=S4ASA3>DW(LK@GD[+@# R2J#$4>#OKLD)N4^F^$3&YK;+[
MP!PUWMU@S"?QX?2.B/_!" 6+&"0RUUY_0<J!":\"K!JX7.BL.Z]2Q&PFOSC:
M]]G [F[?9X-",\FU^F5,XU^+DFLI6]  Q-[P*)&6N$P=7F0$8:8;GLN)XU;X
MKO9S"IO8XT.*!M%*$-/C;7/V6XI]O4C4EB#;K)VJ&\?2T@>47-(\CXF0O:$+
M\UY2@B@_&T:1:E&7JG+^R,B?O,SZ&3)C?.W5Z1P#X0B0+:V915K.R]E$CSQL
M5'A]-WT/[Z<[_%I@Y^"[?3ES1"GV)V!KQ,UBE#,XC9J_35Y]2/$^=%$O=YS]
M#%'?3>"R+J[=\+#=$,4#@0H)G:6"HY03[KDZI2R$C]RSR9A5MSV>#AS#Z3*A
MSG7OI1HH'$IF=!Y1%=_/X,HY&?FC\YPOZQ/ @&5L#C1]>1EU97VO(OMMUHPP
MC)KO SLT!FO7JJ:<*VM+W<#^>J2-RRZR%)&3^9?3L7"3W8P>30?@.C/J1/QF
MSNI([;6[T8S;BJHX^&6#[69^<V+1GG7W=/6"R&#!3W7='QD?@1<4M* ?]HPP
M>-#$"A2(+$L.%&BPM' !\J$;#K:AD<MM[IPNA"%3+TO;MHFZ4#W)'_-;]PS@
MEPR(4_5J]O*''Y4WCV,VA=]1W+'6M@@SD)2SZ[F?6(?E,<7FJZOWV4=T6,8,
M@(?S<_W,+DGGDT>Z&JS8UB96,;XGWZJ15YJ;BBR3Q+#!DR^D&\D/)=THJ\BI
M,9<YZ+=/>QX[<E]$+(UQP['- 8Q$O.*'=DY1RE$!<VUYO2TP?PS;Y7>H$C9#
M%2T(]J,7>-5WA].G4U:?:4E47#G6_!2XTSJ^\25'QL51FNQ_7],U!?,.4YMG
MA[W]P<[(:]030U0C9!3EBG6ARSC"$!*EJ+7UBK[DFASD+T+J^$FMTAYNW%X+
M3AQ/LN%$M16F2WT;) QF(S.BT$X9W#>O,WA\1 UTU$5XJ0G$8Q 6P%I5MQ&;
M.5.LBF)'\1H3T1'_K3\*ALZNF.3O8=5ETCE'7IO3CY?RCDG P48:_ /&0,ZY
M1GBNE/EGUJ/-%?HG;C47TU7WW-R'CK^,+VE"T=,>6;PZEP)SKWF<8ROMD>"Q
ME@1B2&*HN(H,6,1M=1;,(D^3FN%LC)^3Q28TL%N#UZI#Q5=9"(\&.O_58PD=
MH'(*+T'[87,G*&((^L+NX1"!3!/CBT#IQV&R6]3XC8]+YI]JN75OHO56;(1X
M+6]I^T%W6EENVJ8$5MU6J4,\2W)+F@H>(2>\[35X5UV)T#Z!),:+***)3E<$
MV9P:OH/R3H'IK6@/L)^S?E<F>\DJQ=_@3-,/3,LH%LL#I>7Y1UTRJ-_Z:)DS
M.#1D\/+@T [9-8V0 UP(^^P!+\5SI\MH@E6JT<>]7M7<*:+6T''WK+P%%LXV
M5Y.0#&)MP^2E6]YS_Y-\MH3O[(-+%D-AKC[9K,&9Q%ZX9_&R0WPT[/HTEO*G
M\A8)N?=+;)VVV76M_6$+VO)!+:F-NR&][1NT[5F".>H1BL0AQV<J9B/!>&S'
M:ED3'&?6VU1+ZG,I392!!;OBHTSJ,7\1I0$ACHP'\YO9A$LM9=,X;#$Q:+[A
M+D7#9=I\25RA M%0-*%(*!%"X[R]XH'(MQSV'LS[60Z]9NZ#DW)DX205F*40
MG^X6CXRD,MJ#$#%U2+J9$4(>D>.LK&Q=QOQ?XIZEAE8ZGL.2AC!H@7PU^"^2
M;!<C?LNTW#1MSY%E/80P[_-_%)X;CT?S62V\5?:2T? =L>([!T%S6']!39AE
MC$/46// :9>\ICH+%NQ*>W$[)=JZ2I;CA[H@]^SP<U#8$KY^!?1/3R>O'H /
M:X*2,4E:(FQ?U.3^9@!P>(S]7FRNN"R21"[?%+.IKBH#7DZ\4DTE+>R=1Y42
MI-5HN"9-/3]*EK+TS/ 87:[A2'<Y5YIWK?.UN>L#*?,CZPV7Z =3A'6E4MS[
M?>N")0>:N<O,Z64IA9OE9"Y)T9N-=]JJ"34USI<BIN*F]7H+9[ /6W<!0+1:
M^BMG8HLRGA5@ICI3?:AB-!$W1N.N7..<3-;0P:&3&^6%G6@N.<;C<#!AB407
M-=,,C:4N Q^LMA++U1Q<1E$8;M0W>*S$I8P#3MD_"F3D1=@O<:/>U;I>N.2U
M#ADT)SWBU_IYV,JQYDKR"3@S"%HF-?Z5N(!#$[&(+Y.;,VJ>2<:L<:Q9O&_
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MLD=XM[0JJ7&G<TX\1T9]O>K\!+!N=0$#1%L@)\8UMR#'0C"IU&J0$#'0Z!.
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M0CD^IAQL*BC"4Q/S!FF+ U.,>\WSXQFJF+M0E7C/XN[Y952?,XI=S;I:_)N
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MG,#"HR]/51NVQQU1:DG!"7FC!GW-(JWFH]V0R$M]@6%@G<R__;YJZVHAG[B
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M)I::[S<?2,EO@:2]%G4#7%;O^]-/_,>K7);F@AL4SZ;+B5*_P6[&_VH!H=.
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M\?+W \?&B@TR50]G#S_ASIW*VX5-'5/U*I)MPOP\+'Q_&ISQ5ES"QF@Y]BO
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M,KFGY3#$61-;2 H?+!Y<DI=+BAZ8'0GQS=\OK5[&65D'/$[M#GYQQ1L:7&G
M$D!H(S)S73[)"Z"8W,HU21QN+&@8O>[!NH\&MK6G("J]I[GVQ[A3MM[AY27
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M>_./_:=^U9H]3.M0*?-M_P#H+<__ %I6!]"OTL$=/_MO* 5>UMWWH 6XG_\
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M42X7Z(PR_&86\ZI2YBB9# 0'.KH0E)!'C55O91SV;'Q2.DV[1XF#PNUD@NP
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MGT:S(V7P\QQ< 2,*8T-"3P6YLK-EE:SSPM#A*T1PAU*N>:!\KF_99& 75KQ
MK599.RT"'"7 ?=C-9-O7GL2M,Y]C'SX*WTN1W,:K!Y*"VP_"D10Z@O\ 6X7'
M2E2/B2%##>Q[X#<#_N]3( TU.H"I!=CB#3E3E1<HVW;?W9?+*# 9*U%2YQK3
M#.A/#E]"QIJ3@\5&A1G\_!98O!9E3Y(*CC)LV(XJ%&RA" LH'R'H*>;#G'H*
MN)-M;!=6OEL=Y3WS2RD$5K0TJ:9"@!RPXT2=DGS,AA@$0C83I;]UI#:U-22X
MGCF:KOMFRK>1P+61UR6C(RHF4:@SV'?[+J1(9CNIQOJF6'9CK[14M"VV&_[/
M4DJ4I''+MY&Q7!9/0->!H(]HY8<CCGWK5,CN7%T0#G1:2[ 8 #,GN[\UTLW.
M1RY%>FX2-%7->CP#+"F6'U2U]"V4C(M0W5MNH6CK2[8E"PDD<Q5TVSY@8QC;
MMJXDU(J,J#CV_6DC6V5KYC'Z;YV#6C$AI!#B<:## #$GDLIR:]N7(.">>Q65
MQ\^(E:LEED0DY@M08ZVH&,SB!&:PSDI'4'&YK49"[=*E+XJ BV9;0:;T%[)6
MNH0VI;CFYF.HC@YI)X@!<[Y9+30$X+"\MCLU&C3Y6J8S&2W8%H+LF YCQ/U#
M*,NM"8Y(C+>?BY7&O%:R'(CUD%=R!PZM]:7EH^9D>ZN(C)J0&5\UI!H6G M(
MPJ'-)4-=*!X*:LL5K;,[.ESYIE6<QSFSX!,K'9C7HK+$E62F!EE<E74IR3-P
MN699=);LV_&=4>A: 02.[VJP>R%KX1KL9J/9*6$.:,0 10![21CXFO:,0:4"
MMRS2/.+JN;]FO'L'#W+S=W&S&TY]R'$U'+8QU+9D-Y?%[%EUX=I]A3#:H!;A
MXA<!3&18D#^ZOY@-N(4?[:5#IKN=IMX+<.?N#22:%CF-K0\:E^JK2,AIJ#]H
MA85V^>4!L!#?O DT[*4(-:YU-.Q9?HN"[3Z;K&-S65["(S&Q0<<O&9YS/]V)
MF'[9XK)RYQE?ZNCPM,<B;UD<(4/+$N&Z^L,](4'UD]-:[<Y]]OKQ\$.Y^5:.
M?J9Y=L'W#FAM/*+I=4+7U'A<&BN6D9JF&SBBC!\D @&OB\/,G U(]JR+5\;V
MXSN?R6BXG?L48>??:R&1P/TZ=F,I_I5AMA+7J-C:,Y$/<:7!0IH703+C..W-
MC>L.ZFW6VMF;C/;/#X@6M??73?,-><;#Y =V^%P'%7[9ELTEH>*G@QM!] )]
MYHOI7VP^GOZ8<?@HC4W%][/G;A]>0DZ%MV$"%I-VGVI\/M_B7KMKX\>H CB2
M*\FW?JKK>6X<8'[6(L@WSXGDCE1TS@MNQL0&#0,.2]!:5J^&P&5RL?4-X3AI
MZ8B,AJ^WHC*UT9Q]IY+3NH=R-/R#,#"9S)! ;+<Z'&B3'V%J42'477SVYW5Y
M>6L4NY6AE@+]$L-?,T BHFMIF%SV-SJQ[GL!H!X3A.IH)Q&2]>8Z<WD8T=Q+
M\-<Q<=E4R-%DM/F/*4T@R&2A+BG4^D\5)LH=0MQXUYI=6[[>9["U_E!Q#7.:
M145-#6E,1R53':F@\2%RGGVHK:ER'$,HN$]3BNGXB>"4I_J6H^0!-6&L=(:,
M!)[%4YS6BKC0*AF0U)"E,EQ0'-2V'F0;FWPEUM'5?V5!:6FAS4!P=DKU0JDH
MBG[>^B)PX>/F.5$3ER\1^%_"G>BBB)1$HBQ#N!IL#N'I.R:5D5N,,9_%R(;4
MQA91)QT\ /8S*1' 0IF9C,@TT^TL$%*VP:P]PLH]QLI;*8D,D8149M/V7 \"
MUU'#M"W73N^7/36^VN_6@:Z:UF#]#L6R,RDB>,BR5A=&\' M<5X-F?3)BN]V
MI0>Z&C9!GL[]2.">FZSN>:Q41;6K;7N&IR',7E&MWUN+Z3;R<K(C!]K)1D(F
M):>2M7KI^ ^?;AT=8=6[>V\PM.HXZL?(T4!EC.EVMO$$C4'#Q:7 XKW_ &_U
M7W+TTWZ7IR^8=W]-+@-GMH97!TL5K<-$D7R\IKI,;'!CH7UCUL<T>6<5R.R_
MU*;;I^VR.S/?G OZ?OF,0A2HDMU#N.SL%2RTQL&L95%HN4Q<TINAQM7/X'$M
MNA21QNS=6[ST7N@V#JECA"3X7?9<*TU,=D?J.1H5UW6GI;TUU_L/^>O3B=L]
MFX8@ B2)X%0 44"NO\-Q'\37-[<1\32]E"?HE$F1<C%9FPGD2(SZ MMY!!!!
M_P J@#\"TG@1SKW>UNK>]@;<VKP^!XJ"/TSYC@OD*^LKK;KI]E>L,=U&:%I^
ML<P>!&:Y'+B.=9"Q5%$50'CRM^VH/)%34HIX?GS]GNHBBB*>=$4'A^-*HH)Y
MU2<>Y4D\%310G.G<BT]$D_ZV[HN2&.EW7>V;#\/U@2IJ7N>4:"74MD? K]'Q
MRB%&YLXX/&O++27_ #=ZC/OH?%L'3K'PL=F)-QF:!*1P(MX/PR>#Y#Q!7K5U
M#_D[TX99R^'?^H7LE<VE#'80DF.O$&>7Q <6LY+<->IKR5*(M1@@^/W@^^_[
M:LUX%;IS<-3,U4!>W,>(^ZI[50\T%#3+W*JUK^-R#;E162=1J4ZB"1?@>?#[
M<Z4P2F"Y(Y<1:H4*:(E$4@D<B18W^^B+FH7U(O?J('Q<+<;7M4*L9*YSXT1*
M*4!(XBB*^A8)/@;<.9O[.'"B*>%$0BW T13?A;R_/_"B*I"E)Y<KB]_W5'UH
MN1<'^D@@']U%4,4X_OIBGA!IQ4BYX??3-0[PCPC%2" 2/MY5*MZ23J.)T_H5
M4%%/ ?G_ #J<\U8>QP90#"M>[L5\'@ .9YU213!6Z--*8N_3!1R/MJ,E!'!!
M>_#G4*,*=B>/#^%2,^:=ZGSMP!\*N-;CV(KJ%7X'V 574 Z2H5T^'"WMO>_\
M*J:<2$45)-$2I1*(E$587:WD/Q(\N=$5V@13X W_ #X_AX41/.B**(E$6N^Z
MVUC3]%S63;<Z)\IDXG%CA?Y_(I4PV[Q/%,9LJ=5Y)0:X#U/ZK;T;T1?;TT@7
M?E^5#VS358P_V:EY_=:5Z!Z8=+.ZNZUL]L>VMBQ_G3\O*B\3F_VS1@[7!8!]
M-NKIQ&C.[*X@IE[A*3.9*Q\:,'!"H>&1Q%P)#07(/F7JX;\O72HV'H-F[3M(
MW#=G^>ZN?E %MN,<<6?B$<Y"5W'YA.IG;QUK_0X7 V6U1^4:9&=Y#YSRJUVF
M(=D:T%]8'T/_ /TPN6QW<7M[N2.WG=7#Q(L=&2<;E(Q^95C'$N8F3(FXU:,C
MB\IC1=#<EM+MT!*5)^$&O0>IND7;Q=-W/;Y1!N36@5(.EX'PDD8M<,@X5PH*
M8+8>D'KHSH':9^D.I[)VY='W$CG:6EOF0E[:2!C7^"2.2@+HW%M'5(/B(7G"
M!]''^X;N#,+6NYWU1ZO'U!!]"5,C/['LV:7#! /IX]<;#09LE:!P,EXI!XF_
M*N1ON@>J]\8+3=]T>+#BT22.J/X:-#O[1HO2[3UQ]!NDY';ITCTM(_>\V%\5
MO"T._CU3.8!Q\M@/*B^BOT^_3-VX^G/"SHFI(R.;V?/(C?ZMW[97T3=HV5R*
M5*8:>=0E$;&8F*XXHL0HR&V&[W/4JZCWO3'26R])6AM=ICH]]-<CL7OIEJ/
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MU3,CA6HJ4E3BFE+2I:R AM1L!QUUMT&ZW[;3=-PGD@972\7C&1X\'LB#7D\
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M)8\?'&ZF#FGZVY$9\"MGZ>>HG4/IMOK=XV-^JV?1MQ;N/X5S%6ICD'!PQ+)
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ML'4_0JOB1[ 2/XU3Q5H FI'!.'NH<U)(X!3Q_#]]%3@GMOQJ6TKBBD&QO5S
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M6V2E4F85N%2>E1/1.?'MNQ_-WL#GQ/<V." FCW&1P D>3@UTCR"7.J&MH*'
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MJ_;37UP\W$)TPQ'32@J"[!Y Q%&M!J\^%F&9 5B1UQ-/2&HAC!& 'A^\3F*
M"I<<!P6 ]Y\1.UW&X+4I$A_+:EVVUO$1=VQ^+E):BY_NJF-(.Q>E(BEZ-';P
MV6GHA/J3_?=7%<L3P4,^PO+5P%]$--]<2ED+G8^7":4<0:5):*MX#4!QH<>U
MG$T8NP )921&:>+R_LFF!&H>(<JK6F:QF3V72.WF5?F2EY=MQK7"'4^FMU$9
M^3(U=4IY0;2J# AO2RZM87(OTE2RE0K>07#+?<G11-;\N0YY/  @!X'[Q(;0
M"C<\%F73&MNJPU$6DO+LQ44!'>3D.]=G&Q.US$X1C)['C\,QL^7SFN)C8UR-
M'D3(F%PC4B9"E&,ZVAB#E.CTBV\$EUPJ6I1N16MN+[:'W$CK1@EEAB#P]Y)8
MU[GT!;7"K>8RP 6ENKZ2X>(R7$4JW43IS^S7#VC+);$WC+3</L<K;8>O; ,G
M'A.9)&2D_*/P6]MP4N&R7UQ6)3B%8:/&B.Q9#/6M3B>*0;WK26T[7;*Z![V"
MTC>T%E#K\EX.9IBXN(<' 4'$K61G_#.A:=5N#\(K72X'#G4DUKP600\OGLY@
M\Q^G,X#'9+$3LF<JO'R?U&#K\:4[$DL*&!EMR9\O#26UKLAE]3;"NA);"4*1
M6DNH7QPQSG4ZSEH0"*%P%=5'\'5[*FM0:%7((;F"9K+:I,@% 0 3@:T>::33
MW\UKK4-3G9X8.6I>+Q>Z8G7]=DMQYXCL1]DPT/(S0,=UCY<_-F.REM3:BX7F
M "%$*N,6X$4;Y7:3HD<\-I]DX>\9=H*UTK6%U:4A>^A(S%:5]_UK=YUS-1<-
M%F8N.UDX&4QWR$>)-6[,&-G1Y[^0AH:"WB\EN,M(;;4E0*D-);-KDJM6C723
ML;,]T4A> ]S:? 6^/#M/$Y DC$*S+;,CN+FU?(2(&.<SQ8..'LKI-:<U=PFX
M3PU#B[Q';Q^0US#)CY%_--LG#;/*5D?EXJV5(3ZD66Y$DMDE=V^M75\(ZB,O
M=MM;9U?!1UM+(-!:?A)^P:]N1Y+0"2>/4("0]PX9CG0\O]2UGN$C3-7V+Y2"
M,QJ+TQTKQFP_+1'H#CZBW\@XW);$E;[;;4U*)*%!E2XZ.E_XT UC6<EVV;YN
M,MD:/#)'6AXUY4K3"E<<EEQ0B6W=3^<>%,*\Z=O-==F]BVV'-;U_=];Q'SF(
MR$;(0\RUDLBSK6>+4508RA$,/Q!)$&1<-/V"4J%@D6MU]K%M-ZQEW YS)Y'-
M8P.;JJ7.H&@C$'5GAP)J0K$<,DQ<V)GF1,:Y[A@"T-%75PR'"AQ-!FLT8W">
MU$;7&Q.$?=7*C+89B2FHDL0V5I4\VJ<N<QC I]O@HJNM0-T<>%9UQ9W<5[!9
M-FG9)(\EY);(SRVBKG-9IUM)=1@K@*G%95C9-N;6XOI&-$$3-+&XU=*_PM%2
M<=(J\C#(<UD&+W/<$N71MF!QC2CU(5)R4"*(1/5>/:!BLF^^6@!\:2>HGARK
M:3V^W^722UEE?QHSXNW%S0%@G;[DBL;7O^I;"B;!]2<MQB+KCNE9;"$MOR<]
MDL_L4B.(GIK6MMN _B(TP/=:4I4I#;?2%=22JUJTS;'H[&XN&7,-P":,;&QK
M@<JZVNH12N!)KD0%BW#98R&.A8UU<22?J -??@KFVR^].[8Q<;M5WTPNH;I!
MBL/Y+ NXC'Y_4Y:XZ7$R(V.S>1PC6;C*DN605K9D *%NA'$U7;.Z?L+H?U7;
M)I]N+B-?F%CQ6E"Y@?I.GD".=2L2X@N?EOP0ULKZ$.(+L!4$ 84#C]H@Y4P6
M+:?N7UQXU#.HY/=>V6ZQ\RVN.&Y6,RKPQGH);]9YC$)?UUO)K9#H6IIEET$
MD@"LJ_V_TW?*;R*.[M9&X_&P:J_O$2%O*NH*F&UW$QZYS&8P<Z. ]M#Q64[K
MVA[KIW3$;@M&5C9R?!QJLO#>>V?5,3*G1D-Q4)P61R<3'1HGK,MA7IA038@I
M65=0.-MO46TQV;[&0LDL&N=HD;Y<K@#C21K"YV!R<1V$#!9Y8P?B,)#<BVI-
M.1!Y<UZWTC?.\6F8E.1VN=FM9PS+H82K?I.)V_#+2TE7_;,9*(J+L:"OILE2
M%.FQO8VKCMRV_I;=I_)L&1SW)%?P Z)^/$@@Q^^@5O4QQ_#\7</UY+T%AN_6
MI;3\MB,MK\C-0\C$2H9+ 8\[9K\MPLK7(87CO17E8:FPA7P.,K40.%[URMST
M=N>W@W=I.V)[#\+W>5(,</&#H.?,!5^*GBP[#FLFQ.N:OEX\B?VAW5_59;+G
M]^%B7SEL W) XQ\[HN:6$PRN]E!H0GT_Y5"M==7VXVSQ!U+:BXC.3GC1(1SC
MG9\7976.Q0  5D.N;CE?UE.G;UBHV"VMQF1*PLW&.O2=6W6!#2E4R9KLJ0E,
MF'D8+9"Y6,D_]RP@]:%.M?W!K+VPMA#\_M<CI+&H#FN $D).0>!@YI^S(WPN
MR(:[!73&2TR,QC%*\Q7*O?P*V)6I5M2+\_+F?*]#R1#[.-$2]OV4111$HBD$
MCE3-$YGC1$)OSX^ \/V4HBP/N%AY>1PC.2Q0/Z]JL^/LF%Z3TJ>?@!?S4 GQ
M;R4!QUE0_P"85A7T3I(A)%_WB-P>WM(S'<X5![UN=BNX;:\=;W?_ '"ZC=#+
MQHU]-+^^-X:\=RR[&9&-E\=!RL177&R$5F6T?^5Y 7TJ\E()L1X$5E1R-EC;
M(SX' $>U:NX@EMIWVTXI-&\M/>#1>>OJ;^GZ'WWTQC]*>8PO=#3%OYKMKM1_
MM*AY8)"WL#DWDV6YKNPAI+,A!-FE]#R?B;X\9UYT99]:[(^PEHS<(ZN@DXLD
MI@"<]#J .'<[,+U?T<]5+[TLZG%Z\.GZ8NP(KZVS$D)/\Q@R\^&I=&>(U1GP
MNPTQ])/?>;G8LK1=X8=P>UX+)R-=V+#9!03,PFSP'/DY##J38!J7(1TE0^!2
MBA:24KO7COI/UI=[5NLO1/4E8[F.4QC7AHEK0?V9<L,-5"/B*]O_ #">EUE-
M9P]?=($7&TW,#9XY(Q5LULX:@1^]$#6AQ#0YIQ8O?9%K@GB#RM7TPOC118BW
MMY411>W&AIQ103^=4Y]R@E4T5)2B)1$X6)/ #B2>0'F? "HR4@5(:,RM29/?
M<CL<^3K';!IC*3V'5Q,WN,A*G-7U58!#B0ZFR<[FV@?AB,*(2JWJJ2.!\]O.
MJ;_J"XDV7H,,E>QQ9/N#AJM+4CXFQ_\ O5P.$;#Y;#0RO \)].L.CMOZ<M8]
M^]1"^&![0^WV]AI=W8.3G\;:V/&60:G"HB:XXK,-3T_&:E$DIC.2,CE<F\)F
M>S^06'<KG,@4]*I,QT !#:!\+3*+-,HLE 'CTG3_ $[M_3EJZ"SUR74S_,GG
MD.J:XE(H9)7\3P:T49&VC6- "Y7J7JC<>I[IDUV&16,#/+M[>(:8+>*N$<3?
MI>]U7R.\3R2LKK?+FCVI4HIO[:A35:8JTMTKJ%<2/PN?QXT4@\%='#V_XU".
M;J;15@D>[C]KV]M5#EQ6,X9&M:J;?=^=%1@.Y5I)!M< 7]_W??48(K]$2B)1
M%6A:DD '@2+\C^VB KFW\Q;C8>-_(\/.H58*JHI2B(#;B*(N0DDCJY>7CQY&
MB*?(<O;]N5J(EA?B>'LXW]U$4V'#CS'D?94(JVUVN";"WCY\A[A4J%?L"+BW
M$<^-,\E.H@XE/#F.'[ONHF%>] +T[5#CI%*T5=QR_C^X5%52UCJ:FG#ZU4D\
M;7L+^(\/.]3DK/B>7$8NR5VUO;Y53VE6R--0X8H.//D/WT';DJ#]*6M[^%N?
MW_E0!,^Y1P_94X5J<T50)'$?LO\ MX5)).>2*\A5P$^0/\:NMJ,U"K_Q^W#Q
MJNHK1$^^W"I/8BBJ0ZF!1*J13X?;CSXT15)X$&X]U_V^%02BN @_<;5((**:
M(NHV#-Q-<PF4STY24QL7"?EN FW6II!+32;\"MUVR0/$FM7O>[6FP;/<[U?'
M3:6L#Y'=H:*T':XT:.TA;78=GNNH-YM=DL@3=74S8V]FHXN/8T5<>0"\P_3C
MKDS/9;9^[V>3UR\Q*GXS!J4#;H<DAW-SFDG_ ".2FT1FU#_RF.' U\\^@6Q7
MF[76Y>JV^"NY[I/(R"OV8M=97-KD'/:V-I^Y$*8%?1?K_O\ 9[18[=Z5[&:6
M-A#'+< ?>#--O&>UK'.E>/ORBN(7K6OII?+Z41*(IO\ 841<A"A8#JN;#_"J
M:45)!7S^_P!RC9,!C>P>MZ?L60RV)QG<OO)VVUK+9;#13,F8;5\9F#M.WYPL
M]*FRUB,'AENJZOA']1!"37HWI?;W+^HI+^V:Q\MI93R-:XT#GN;Y<;*_O.<
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MPXUM<A4-2Y:W,HSFHF2]5,3.-L*4VZ6VVB%]"D@$&C=X8PF6Y)-_%4D.RD!
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MBY^9K,5R0S$9E.-.+:FXAN7_ &$+=;EK9EQEE*GBA-Q<=9Q7Q2AI-VYT<C<
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M76W<I!>7'?*%.Q'TD!]A21<7MKWNQB!M=SMHS;2 M=)&-+P#EJ:"&R!IH0"
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MKDD#TK:Y(H8V-E%K=P0@Q"0Z62QQ_9C<U]#5@.-?%C1I'&XRS=*'!AECDK7
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M4A*BM$24!$P$=2O\K&#C*^7=2BWPF0I]?MJIO3=M</$^]R/OYP:@24$+3^[
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M)$1(!!:QCM(.GX8Q@#2B\@L]T%Q=3,W/2Z&[<"21@Q[:^6X#&C&@Z"!E&:<
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MSH0%ZMN/RX^5ZY&JTE4J:A2E[GG?\:@$)5.'WU-5%5/'[Z8*5%$4GW@^XWJ
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M1L8I(FVNMK?*9(]D/F'2Y\Q<P:FN8YSPTM#BX,&G$D8ESN;MS;<SR.9)O5R
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M%9.'/ MSO\L\YRK#M-TVO<*BPN;><C/RY&/([PTFBV6Y;!OVS$?U>QN[6O\
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MMY??1%<20 ;\^K^KS%N7XU"# J]SM;[?84*D',G)/&@S4G+!3?SM8^53WJD
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M7%B+CR(X?A4K&6,Y#2]0RV7>SV3UG"3LU)P$K59F2D0&52I^L35K=DZ]D5@
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ME8;6,/">>5_4])3#:<ENJ\BY)<6;>%Z^G^D=C9TSTKMO3T9+F65E##4YDL8
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M)-@/8*J"D*FBE3[:(HHB41*(M0>?V_?6 #1N"VJ<_'[?CQJ6O SJ2I!X*M!
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M=M0*Q1P?50"T+6MJ'_?;%\'C(Y)@Q@NZTBRPJ^3%8N;$FQF8)2>UX$*AD&Q
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MYAT_"[=.-0X]?14O2KO6+/5,127<" (X>H_&?OU.LK,-L,YV7G3RVU&IF@R
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M_7C2R<:]=[=V]4J-TSY@OW7T<?%SA_<Y)<MZ-U;%0-_C@=PUGOOW(3'6O@>
MTVEOVMQB%HG_Y!=4WV)ZW2J9/%E=/KYG!7(  +C<\1\1!TB&L+ V@$4;T A0
M!=2X1E^7K\B>:5W7:&UMOTR-E[D,)[>(N1E9W5OX:C#1WIFG:PKWP<JHO='
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M??G&;,1(WE>-E@L%N=[DN&V?"B1X!B96RR3C<FG]43'T,NXST%?V_R?F?S\
M=?2YV.Z:ZECCL(4%\(H$$TV.I@- [5O,"_ P?A/9GA[9\')?6<@,DV-J%[0_
M"L4[\849>:8L'@"B=N5, CRQR13QYSZ$FG7B6%NHM$! U'0H^](V6LA4ME@F
MKI&8/J:3)I!G>IX^!4NH3<5B9&>8T1H.*[?.L(O!'HY#,=UQZ-)..8],Y7V1
M/Q1'"9)T(_NHOY'128/[(J,A>OGGCHM8$ "0@:/S-2-NZD$C<3\+ZN45E;ZL
M.XG8'O9.EV(G#-%<Q_/&EFAN)$)=3:(2"O"=EDW]5.IF2_V4FQ)J%?WHHO\9
M2.S(^<;(MP_''KS9OT4\.9APOT_Z3#T(BAA0!,"/-33<_$"U#DD?678KG4#7
MA%]UG8?.Z[3#M'E;U"7NN&H]-YVJ%:T=6ZQX"JD.?A71R[#54F 16WN<?+\&
M.@8MZ*D8_3;.=6_P9DWJ?\UKTI(*5@8\'(-]/16CY69VUO:[&=(U@>KQ4"@W
M9>D&4&HB)R'+_)7%FJF'1W3.W$J!J7-MJXT^%OPU^XB_]ZZ)FASGW!(]N QQ
MO  "5)Y.$_]6;-).ZQ]0>36S6;R(E,KA;PPF\R-%0D3Z^&^D.>1;-F#>)6>D
MFGH?(VK]W%<&^2%OPYOJ%6:6<(AR[L>(:[DV+?AV8O0<DBX?@&\$&EL(1>B6
MY]D=W?7G\IX+9/S*NXT[- E;9QTP:5I'K'*+@8M0_GI$EBGTO6D6H+Y_<UJ1
MX; M'LTGC#)]E,Z[F<9A:D^TUH3^]6R C^#N J^Y62Q-  ;]VA^BR8RR 8!C
MK+OML1*#U!G3UHML0&OVBL[IT?%1-+<2VWB\4KN0*:IK:8YB/EYZM.[FRPQ(
MR.M<E2.>U"V&PM:W?G-AZ^,*TAP3RW.== *P?9I#TKZ7<*QA^P"@GAGHIA,%
M'PTOK/#Z5IX7K)=8:S#FKIL[6<HJE^^#],0AA<QY8DU$+6<8OXJ;E2/I;.B!
MP/OX:>+9]W=C8]L*Y.3<SGWV*:CKDZ!.7K9(L+9-DQKBXTL-+SB5FJQJ5_5;
M(R)7S3L$MV!T(_"1 $ )N=ZQ*(DYOU<LZLD& "AZG3P2_P$; $9O<A2+S[MG
MQ!C5=!L5*]U[Y-$N']]^_1];I^-2456"$/:-IJ=^^T3U56#:X@6/M\YJ @GV
M?X*?W\F,;/J0=A=DKJMW*RXR5E4DO2WEQ_09P_@@@1)?U%?+,>/MA$WCLK$
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M$7R11(#[2Q\6+)!*'%O=%,Z9,RAO@_I77.VD!,Z7,[/G)0#:BU^P6'!8 %%
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M@>6($=*:H5O/ %_$B[V*S=;I_5ZOZ$Q*RI?'Z!7,'5( U6XUOLS^7')VPKR
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MGW-40"(.@#PNGGQ_BGU>_#]02P,$%     @ FUEJ5CO%.O_8+04 #S %  \
M  !G,S@R-C<W9E\T,2YJ<&>,N'=4TU_3+QHZ03H!";](#25T0M $Z3VA]R(B
M+30!0S6(8"A2(M*[=(%0%!!04) 6D*H@H(B )%1!0(H@@NCE>=;[O.==Y]Y[
MUID_]OK.GIG]F=E[]F1V_G[Z2P7PZ^-]O0  -%H:P SX7_1W"\"E%^9Q,P)
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M\+\=]7^FSO/G7Y__G;OGS']G/S;P/.6#SW/[[PZ _=\! SQ[SN\0S=\Y0#R
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MGJ%XB6Q9)4V_)XRL-KS;CWSU&NA(3+T7%D)*%7AR7ZNP9/%>><\0.,Q@O[Y
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M$U7I7% S<\YTB \O!S'_#P S0,R_B:'%L:;XRR43+@,TS6]I)Y\CQJ*?;BW
M!ADHCF4V\PZJUY]OK[<)_<A\5% 3P]*8RU5@$0"E.%.SA7/  HHJ,U5":T[^
M SXUXX:1R3I(%0"*X#DH^"=MH%.'I[<!&/5 ^I/&D@$5IW'C7NS//"EET0>B
M=I(X@ T)%.6*"#Q4$8$FE!3U]E>^O'$4(@!SS[^.5.>?JP.$DA6JM.\YC+MI
M7//C@" E)37+ESS[:]^=<!+(1 G,^/9P\#7LPG?#BFE@>'K-*_LP /F@I912
ME.%,R>W/#8(7A[>!S-*4P^B9P2T\<A2IIF>)!\3@0 Y8)V@5(%/5]U<N&(]>
M"R8QTX!/$)"1IRSSX=_#O. ,<5,NS(Z">&5/V^W#*(HXXCQQ7,!G.:F$3B,8
M^7BGDJC]. !"6!49 9]YRI7B._#&/@A4R X9T(/ZL^((PP'P"$+5W9XM%-F?
M-(E#4OOJ2#0Y4J/UXF (X#))"+G'@,@*_;S[\291)7DDDBA\>TT->VIX813'
M1.4TY^ARI@G@.K)@/X)5.'Z<8_J39N"EQ=* )R'#LK3$<?8A.4@']';V]F&2
MP0CI%4FO$TK3+L[\+#@EQ25)/[HI2F7;7UTRP..* DJ220D9TKZ>[#'-#KVD
M$9>VHS]^>$Y32% I'$&G?S_7AO[T)OJ(-<Z>/JSSXX6*$=MP#Q/+LX^WC@./
MBA+4HG/LX>L4)XX8"2$%'M%3PSY5[1V4P#/%-44JN=>7=Q(-*^%,-GP"$V4H
MD\2<71\N(&*2;K-3GP],\CSQ/,]5 O[$,]U.7++V5P' )#--BV=0R.=>)S-!
MXX3A/%E1(/$55GQ'LY]HP=$\_!+4E.HBM".%>' $D^. %PED>B& 0#QSI4>W
MGAH)=(% ,^? ]G;SP)2PR2#W>GKKA%#KV$WN0EZ#VX&P1]J\!0Y\,P?5^O$D
M\61D9&O$#A0Y)R-:CCGA'DGP?BO(2""55J,\C[![L&.23C/DO:#\1%!PR(SX
M ]O?@""V7%#4%5H:USIW\>\8:.#ILYP)KSX^W/ "74)-I)X,A)-17OIX>)P?
M:E&6H.BI)[2<L^[.N%DI)9(&9.$/K32-8)I^OVC#8E"@GZF[I^5=$-].A6E4
MFW-V]&="3-D-M%(SY@G&58QU7 ;@L+<)-:D'(KB;Y00AM([ /8/9CH)@.X*T
MD<,#R3"8E1 TTRK4 YU'W4QA5SJRR"42#4QR4M?3YM%>[NJNS[6IKS&1=6I\
MK+4$L0"92RL']VK8'KQA3D(Q/@LJC",JX$>;KO(RVE(2V$_"A(2D#*@0  !7
M@ !C!)<K>QCI#G-/TIK0 <\_V>K"=2 ?P1FQ4"G/!Q4ADBZ0 2?;^K&/*4B7
M4\DD9XR"0R0",E(TU-<N>7L[<\8\I2EGDA@DT&(F<B&.2:*$US.>1Y\Z\*UP
M,Z%0(/'APRXU]^ 88H2:9Y"AYUH..>53A%RA>%*Y\,)"40*94J3V\.8YTX8D
MR$I*#Q((]/UX0;)"(D<N \:UY^/'#R"2)2OXJ5'M]8X86662:7D/P@UKVYTI
MSJ<)+'BCI5V<L".A53@37L,'%"(DC++AAE1Q53G0CV>KCQPNB,"E99@FG=@Z
MI]%0Z1F"#EG^CCQP8H9(+E,S2F LGCGQ31R2FF1S&5.9/ <^_!D4LTR4^I5<
MS0<1^WCPPP)2^%/!"\WO5[>SU\L&F0SS0J!52?;ZN=<\)FSS0JZJ9@Y^-,#8
MH0EN94 %3WUIBV%,N\E$EDR<4?W2/OXCV8N40W%-2*GQ].W"0RKH^'AG6OW8
M;!F45%5.RH[O0XR?M5;\U7 DG+833C7.HY&HQ)1+IVE- #3TXX7%13M.7?Q]
M=?UX$PCI/+($=G[<!DV*,D5NM:#AQQ"HQ#\4CDY3M*@ .9%<O;X8I44HN5IR
MKW\ .T#MP@$):5BIJ#E[<_6<(A)&%#3OY^. !->(I7#9"( "",NP*X<??SPT
M*H!4"#D1E[,\\\\"D(&4=4>:4$]@_77EQJ1@1HDX'%%2FA&67?[?<<)PK1!B
MXP3IM)!UTJ$\>1X81Y*\ !.O3/##*)=T0&H J >W]8(I3 4WX)85W&E.=.&8
MKQPB'S3!14JR ]*=^>,:0\Q4QU1$D<2<NX\,1XHS2]=:\N/#B3RJ<L-W\$()
M4>??[^W/CBVF S\4C@FZU<AXU&+1CBH$\$,FIX>GVX:1Q5*#Q[?V8$<$5OB>
M_P!#@.:<4Z%*"GM[<4U9'+@IA+2*FE./?F./#%(310!R[?LRQ-)&2!Q R/#N
MY=O/$3R33@4(J!Z X2C]J53TJ<"8"I0>GZ>.!#8I% 3P%,Z4\<"662;O(5G3
M@:=F=*8D,F3!=-RF@'::]V0PXX#J_P!2:\"!7A4#+G7CSKASS]B2IKTY\<J4
M[,O'NQ(4WQ=#KU2<\@>5,J@\\0(.IN*:&I1X#AZ=^+XQ "2;DE)K6HX&O*@]
M6&WO4,CT0B:^[W#$E%4J*5R\<(A_!,%O%)54T('"O<>SMP -AP3)?Q51P%10
M\Z<, #)$I#B:CX4DJ/,<J4X^K"/),8XJB$FA*DFO(5I^S ^+!##V(2JBF5!P
M([*9#MIF,-+-#TDDTY&G+ R'",TG,'34&N?81^G"(PP4@R(I%0*4%*U RKPI
M[,/CT2P;JO!L U.=.%?#/+"9T.RKH2"#GSKWY<Z$8>/!)^!Q"J$TU=AI09\N
M-<+$^*> 2J#V\3AH^Q-'54U'*M2.\<AP.5,&21)*8K-0>TD>/VX 574!,?!)
M0:9>[GQX^[!AQ2I'RLV"<9:2:9>RO+$<75J#SY^-<O97CB6/L42[89I2$5X^
MWMPG9,#%UJ-]:UT^1Z2,6U"M*[UN&WQR,JJ:C:I"QF02!H&,_;P]9\V"UVY2
M/I" XD?4N3#@IQ(X?HX]F-Q(N"M1++[%;7""HCW<Z^'>,8520$>J4(N>BZ"_
M0=M 2MQ;HW>^S5NV0&;=$<4GA(F+*GM)/[P:0.';C75CBW%;>QIC49\EU#"!
M7(9\/;C'6R14H/=3CV@D>O!F,%(!.D #.G/.G9BBI+%@58S*ISK3@#P/.O <
M<1B_Q< A*0G.M/&G+W\CADDH3I#=0!W'AE7EV\<1=O%)4\GC7U]W92G&N!QD
MR'7M)S Y>'JIRP.FJI03Z^'I7 Z2\6:FE*YY]U?7GA."AU4,_%^$$>K/+EG@
M?WH=*\L(SR!RSRIPSX$8')0O$#D*D4R)K]_9@\4U5*.&6>>9]G(X#]27VHA;
MKPR^WESK7"1BDZ:9#@,_=GF3GAYH!2T\!Z</V827%*(KXY<.[ FQS5>6!'#%
M#4LC( UY\/TX$!(\U9&52. X=G#GPPV1@A^=EF>=.S[<ZX&="('01757P[<O
M=A(* ZX<P#4D#AR_6</HFF1))-.1'I[<#8=4.D@&I%,\2B=(=#+W"@X>GW8L
M$WZR4<\E[A7/U]N(&$LR$T%:L@!D#X>K%T0V"@3R0'"I(^'LJ>&).AD,)4K/
MMX$]F7(8'0W-)H$* H#WY&O"G/A@0J5/WTRI494XUXG!U2<<L%$W#F:9UQDJ
MM5KSY9^@P$\DF1$+TUYU]WA@"1"?MKKD14@5S^P]M,,LH%.T4YD5YYU'.@[L
M!<8#))VQXHR0E0J#6E:C@*<Z5S(&%TR3?B4M*P@DC*N7&M /T81&H,>"1Q#(
MJ7033[>7KYC$?3+.EI*47494(-?3/LPHPD4 $HB%BO97MS^S!*F1B,0@Q(3I
M"Q0TY>(]^*6Q21@>S/#Z(2T>/#@#PKV\<,=4P,6XNG*0FG:>/M%*'$22LF,1
M$,$J@X^GJPD^J(FE<\_?AX!,!T92Z)%"<ZU'*F= #GPP)MAU7D.?%F2$Y\<^
M\>RF#P0!ACFCITG,'(D>KMR[<-)$JD@#B*',<0:^_ G@J!VA J"?MXX@81SX
MI@G+@EAX$5KP]0'MP"&+X)F2\'@?PTSJ :\N>66>6"4(E($H*GZFE:@5J?"G
M?VXD  ,,D.4DN)RH=1.5!@=)O<E53EGQKGX80<E!  2L,'F@CDJI50C/CD*^
M/+/MPST2"<(6#E7[>[CW8K,#+$YJP2&2,#V'NRQ0,"Q31VZE-0.'=ZN'/ #@
MA.$CAQH/?7]&#Q21DC(4KP&1SPDL<TNF&W-22M'[/3+ P47Q22D#(=GLP)YH
M2QR[N>?9A(&:9N?#EV^'K!Q..) /%-,EN:2>WA3AE7CQXXR ,% E#\RI&>7.
MH-1@9+4E^8-/'+TY<<-DWP5"K^SG]V8XX6:;I*@ *#.O+U\J<Q7#2*H&^WLX
M>/Z,'@D!S52V*\O"E>TUY8$,O! K2M>WQY>[ Z;<\T@IJ=(Y9^W/MP \5%L6
M5"*4[Q6OJP9HR2>VG$]O#V5PB$P4%Q)XTJ./90 <#XG!T""$%/;WY#,T\,^S
M#=)O>GE,N0]7W5P@.29RQ5 :\/V\ONPSBEEBJ4T@DDGTY9X:%0$_"FN9K6N=
M.?;A' (S*]KH2*994(\,_?@!?-!;@O$Y:P3PX'/NQ%\6*DV&"8N5\37AV^.'
MQ4)',IN6EJ[L_9EAMR4'$I,?A;ZTM+-#4FN5/O\ MPE, 1##)&TC@0/"GKP^
M"88EU12!P]A%,+(I9KP30#NK]O/"S0N=GUUWJKVQMO)7^%NX75Y%>!4IMAD\
M:#@KVXV^W1\LI+5;C(ZXQ&3.N=#JP3Q'W$=_;C-JDX+42+R(XC^U,FV%./A1
M *23EW5X=O/&OF[GQ5T91$=/%=J/I&VB-L=(;7+<:\N7N*1(NKI(^,LJ7Y48
M*/9Y:*CQQ@U"\\,EO;2F(40?Q$8K:-)';0]^8/?BLK+!1QGSR/W8KD#G'BIA
M$)RR(^SV8C"F3\29PQ2VT:N9S]?#$)!CADA7!MH #+CR(!_3B/@DCA Y95[.
M'NP,EP5",NWQP$)LAE'&E1WCCA(.6*4EL#A4^/I3#Q*/%+">/;E@2P"J0!WX
M/%,)!2%"F!L499*GE@9TX]PY<L)#<D1*":<3W_JP8((9+\L^X>_UX?V(Q25(
MIW^ZF$$8)%*8;(95/CA(0R2#R(]/LP)9JFDFH\,ZDDY9\\L"$A0 I0@4KX5X
M<*\<-,)LX  >?#/V=^'P30>'#+P.%@$*AKQ]/MKA8(22/UT!^ZN!"0#0\_7F
M<3$7#<4+QI[N)/IV8G3CBY2.";N.4&5/L]G'CB[Q4<T N$U !&= 3GV<LL\)
M(,SH=55'ASS!!H>'JPV2!X\UXK(%*Y#( #P/;A*1QR0BHGT]?JPU' )->??A
M=4<5%>GOQE,JG5=(PV0Y2J&E>6!).6E*%:II7GX'AAJ,DY#AKR]M.^AP>"BE
M)=*>%<^7IGA-S0BA1IS/&I.?#ERP8(2=:N7W_94C#Q0D^:=0%?77MSP%#HZ7
ME$Y\N% ?0XB!I0,$^2_E3/*G/+QQ P?Q08\>*=M.5YUR^\=].&*Y0TX]5$@A
M.4N)&8S].W$,64H2 +E.D+!H?;XGUYC#9PK15#Y(NL<_;V81B0I>I!\TL*X4
M]7MP# 8J0D",,E4FN%T3?!53Q&5<C6O#.N?J&)(R#HJ5@5-30\AW<P>&> _6
MF,1T2E.@)RR]M./+/*F!#!-U.DJ!)S'9R]APFPP43, L6R5/,K05IZ^9X\3@
MQX)"<2^*J%$<"?5^FN!^:D#[EZO',Y^G;AX!(2U/XJ@\<(?6F.2+PH 3SRKF
M#[:4P)\,4Y'C6G/MK7AGRP DE)N*6 2:#L\,- 1D)*:U/I^S!FI ,G"16@'I
MV^[&+(>;!3R3U(H!G3QIG3U@X1Y(1D@U)J<Z<\)1**#ANR89DO4< 9)E757(
M<>S*GZ<-D?8J*/?Q]V$@=4V6:',^KGQ\>S"9TPF+BM1[^'=7ABP0)RX)]4R<
M22:\J9DGQQD98*LCBJA '//OX>S"SS38*NC@03E7WU[J88'O00E 4'Z>.!->
MP,A*'/OP' )@.J* '/M]WMXXB"Z#@ADJ J*'G7E3VX>D*.*2#2JB#^@=IJ:Y
MD8?0)/Q5**/@1J[A7C@0.:01IR)K]N!W29D$I*JIU4T^^O;GRP'HF%5*-)[@
M?;4>/?@"6262>0/C\-/83A -X)DKP3\/$Y=F7,?IPTLPJD#M/#EPJ?T8"[8(
M #XIH7%_VOLPE(X9) )!KF:>[#8J"(E2C5(SKR\.S/+"ZJ;<$0-9@D]M17MY
M<ZYX:BE.)&1X$5S%. XU&%@GB['BF9KEZ5PCR2=UZIX>'NRP.D,%[C3.F#-&
M26E)-1ZN7B/>,2">6:Y#_6+?1=NKTZ&VLJ9L5NAVX"M4ATH+[P%#6H4X,;NR
M&F@_$K0;A*4JTA',8+3:9K=>:;05 5X@99\>W@,\*M,DZ>2P8Y#B666[5M+U
MWO\ 8[(PA;TBZ7*-!1I!407G$I*U4X)%>S&#6J"& <DK+H4_4D(X?3@OH&VY
M:6+%8;19(Z0EFUVZ'"2E(HD>2RA)I3M4#C!)\S\%T<8@18*]\<344Y372*X
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M2I62P\Q.DI\M>9/\%K2A-<] &#1Z30QP"LHG73UG,XK8.G'M[^[EAJ>:<)J
M*\>//MKBJ?F.D*8P"<))%*<.SC]_'%(S4D=()(Y<Z$Y _;A^*$^36F?H,12"
M.A=*4'##(XH<CP3QIT"G/+/Q[>_$)1<*Z%01P_"G:'2K.F7+AZ_#%4H 8'XE
M;&4I,<AP1TDYCPRKD/7BHJ[ABC)/'T'+E7MP@I!O:CI-,QA@))5309\/VU[\
M&#H2%*-*US].%.>#HC@^:"4E7$<:'GXX <71*.O-4\OB.%>WAV\LL#I"+*A2
M   0>/'NIRSP%28!,7T@#4F@S]@[1V8NIDG K&J0 CJAFK>I1YG*OJXXN6,[
M(!XDUQ+()(=*G$4LTA23SX9U[!W8$\LE;WE&I'@#3U8D&< Y)IJO4>!S]/5C
M(B(#"*B02O 4'$^TX'"&9 74YIKGP'B1GD3VXDH$N<,T@(.=0:UKS^TY\<'7
M@F'9D0((RSR]9/@>=,+!,NE!OMX=G/"E)@@1=+TY#+NRX^WCBHSD8^*D R<)
M3R]0J>8IR]6*LTTO0<O?W>_/#9"JIL4H/V]V!D)PV-*0,LSF1PX#C@(]Z$NA
MXY<,C]O/MP8>Q)S[5!SP-#X<>&8Y^H8VIQP6$%;U9?9EZ\(JP(=<"E@$M)K@
M=1(9+!/$94X88*2KJ-1F>/CQYT[<\"7!.P%*Y$#*GB.W#448!8!Y\J>K(@_=
M@224A0KD>![OLXX$+RG!4)!^+CQ]GV8,\T(/"E-5":9C(4SYY\\";OFG;84:
M&ON&7'[<"2>)2>(RP9XJ2,D$#.I/C[SAY)^*4%4I]O, 9^&#-#H@=T\SGX>K
MW81B,BAQDBI<4>)J3GPYC@/;BJ4  \0H2  <(H=H2/9X\\5B!..20!*,%5H*
M=_[/'$2",$O%$36N7$>F?=A!W0G;68KV\OL]N)' *RGFYR1?3,T^_"5VN'/%
M+32OQ$>-1EP-3GPSP%#QYA&ULII5:1IK0E0 .KCG7/" =2,X]%0RHX&;[8\5
MIR]^)*&J+L#BAF?"3QEQQV_Q4BGM.!BC7'FD&ZVQ'&?'3EG_ !$&OOJ,&DG@
MCU( YI*MPV5K)5QBI\74_IPM-1\D_6I#BFYWAMM'X[M$2 .)=33UYUXXJ-"H
M22G^8I-FF;O4'9[()7>X8I_O4^!KGEBR-&H,."C^:I.0^2M+_5C8C ^._P (
M4XCSD#M[58F*$@20,5#\Y1&)(][*PRNN?3=BOF;A@@IS'\=O,4S_ 'LLL2]&
MHZK-]0 U%O>K!(^H_I9&J5;AA99Y2&_TD"F)>A/BJY;A;Q#N%9G_ *KNDT;)
M5\C*IE\+H/V5K@]"04?ZG196&3]9?26."1<PX?\ 9U'/*G!.'Z!XD)?U2DPT
MXK')?UQ],&*^4IY[C32A9->0_!W8?H=5&6Z1X LL:D_7QL1NOD0)3O'20@TJ
M >'##-"/$XJO^JR;4(E6"3_4$V\@?\-8GUGD2 .-1_9S&$+>F^.*/ZG6RTX%
M8U+_ *A:J*$/;PK6@+CB!W9FF0P_R]$*']1KG+[5B\K^H-N91*8MEB-\=.IR
MO'.OX*#$A0HC%L%6-QNB3JRX+%YOUY]1I-?(9A1TG53*M,O^SGB0IT!D%$WE
MU,L9,/>L7F?6CU5E<+HW'!J*-H&?*H5IRYX>FEP 43=5V8R/BL7E_57U7F@U
MW1*:"O\ P] [NSE@: X!E6:]<_B+K&977[J3-U>;NZZT5R0^4C,\!2E,\2<<
M@D*LN,CJ5@?ZJ;SE5+^Y[LY7C68[V</Q8"1R4"9&3B4FY*TO;PO<HU>N\]WG
M5<IW/OS7A:FR3 DF+E\F+-7)CRJ\275*&0IG4\,\#OX*.DQ'5!_,G%#XG23W
MJU<.X9G[L&M\$.,G5/S)8 'G$TYZN-3XU'+"U!\2R9D&P9"_-,_YIRY%1RX_
MIPC(*)(= 7=35/\ %]1/+]8PS)3!$E;W[P@<7J%/#XB/<#BLR8YE19\CBFJ]
MQ)0*EW("E:B@]?.N):W&"F!+GBFKF\$)20) '+-0'VX@9D8I@:@Q!3,[\2TD
MZI8)J:$N"I_V>(K3 *I(P."LT3BFSG4AI(4DRA6A'XZU XY87J$YJ,@7P*MJ
MNIT=DU3)34C.J@#4\!GSPO6$1G@C2>!<H"NK3*"0)2J@4(J3VG(\/#AA&X&;
MI^F>"HGK&T@T^:4*=_;QSJ#6F$;H#-(PEDBIZRM\1)57_M'A7(CCPP"YCS41
M3$BR?1NLL5"_-5*T*.9)6:GQS&6%*ZCP4C3D#I&)\"LFA]98VH$7%.G_ +5:
MUS!S&(_G(:<6=2C;5L])7.K^J;UD2.@NS)L2<V;I:NK>S[C;5I-7FGXTUE]3
MK.D:JI2V#EC&K5H5!H!Q8GW K8;93G"X).;-BW'HI"A]<NDG6:1'C7K>TFT;
ME$"%$BK_ #.3:B5!M+TAICSU)@229"CJ2K,\,\8EE,W,'E+S@#!\5==1J6M0
MFE$Z,?!;H67ZA.GGTZ=/H"=S787-UQYQ6W;-;8,(;DW9=EIUM,PH-O:;3)DA
M.2GG?X;2#J4<9?\  I3]21>7/,^ '55QJ7ET!39Z;N,F\25U5^@#KGU!ZA[=
MO2.I>T;/L*V7J<S=M@6J//?EW1F!)9!?BW]QY+;)GND!8+02WF0*TJ;8RG.'
MJ3B006#YMX<%F4Y4X'TXS!Y^/TXKI.4TJ*D5[J=_KK7$=0)P60S)837GR'[/
M5B$I:2QS9-D0?#2G+]N*\733]I/.O9E3Q^_ <TCR3G [)HB1J5ESR^S#)88I
M-@RN#,?@HG@>'LX=^*9S; 9E9%.D"'GER5Q2W09=W=F/'B<8YD9+(C%@^:J4
M5X ^H<1Z\ +9HTX-DC(21VYGORRX>O!T4V QXHZ14<>!!\>7;@P"2)09=W#N
MKQ[L)"24IH3VY@\O'#X,A" %,J^SU]O# FJ*R %:US/WC!B@<TT6KXJCF*5[
M./+#'50F2?@35Q)62,Q2A!IVY4/VXMC(1"ITRD\2XXI@X@I-*4]_WG%H+XK'
ME$Q+'--B.S[,3SS475"*'V9XBAT%RI%!7/GG7#R0Z:+:H:DDUSKZ<, 9#INJ
ME:BM!PP>"?1#*3GSIE2G$9?IPQ.0R0<5[33WYT\,3]0F+<4F"3[>[+PY84M>
M90EA ''/$7+)JND#,<?7A$DYH"J!0#"0C(I2O?Z^79GB0RZH1=.5?=3CP_3@
M?@A+2BM#QKZ<>66 DI.$X"<O9[<10SE*TY?JPV0WO4&O4ID*@?A5RY<JU.-D
M TGXE8*M#A.=.TXDK0AA.9''T\<",LT5"*D"O']?'#""4[;8!'Q<0?53EE@P
M"@3R1 RD&O"M12E0._CW8>"3E/F4I&9 S[N%*US[\(@I,EKH*D ^%/U\</+
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MT!1%<^[ )E&@/T3<W)T@_$K*F6H]OMPM4CBEICF@FYO*).HT!-1F#0>.%J?
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MQPHR@,7#I';IC\03=?\ 3^Z[@Y1K,L4Y.R0:@C/^61B1G YD.F-OG^*003]
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MGM"<DG,<17N%.=1BX.SE4U- P@K>I53SYXD" J>J&?53GA(5*#LKAXHP2%
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MEA&J3DI:(ITQ:(M0KY5D<*$-)%>W.G:,0-67#!/3%F97)-O832C+>0IDA/Z
M1B&J7-##@ C"&WR;3_\ &X3E-5,1 X(3_P#&U^S#<\T,J?+H%/@3XZ:'W<<)
MSQS1X+QCI.>E([/ARP D(5/EP*"@ISRX?9AZBA*2S0<![/V4PL4)80!D0/8.
M=#A9(S*KY23P2/9AN4%.FVJCL S->  KGV4 &>$@!8'?.I5GL=W@[<MUFO\
MNF^SVG)#;5EMKBK1#CM+*'7KGN%[1;(B$*J-*%.NG@$'#%*<SB1&(YYJ,J@
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M;'-7EDT=;K^\C4D\L+S0Q^**9,)#+3,<%<_E!H33/.FH<QQ^S$?5QQ"E&D9
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MP!Z^/AV8M]%^)50N"V(=,I$DK42#D,L^P9>_%D8B(;BJ:DS.3IHI9IVXEDH
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MX>:&3:I*N/,99Y$]F?;A_8FE$4I7G[L-W0DE()[<J<QX^W!FA!4-)RKX_HQ
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MVINN<'UP?T\>G/U4V>1N.SHC;.ZP6V*K\GW=#CA*+IY2"IBV;@8;*!,A.+-
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MB>R]\VY5\Z=W^.II8U*BK<,F.THI)\IX%/YA;G=7[KJ5##URXAU5.G3D6RD
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M!!R20JO/VTSPV1BJ&@/+,&N?+!XI=$CS G@2.(IW<LB>6##BFA%](J:YCO\
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M8[N\=MH?*N8#*KF'":Y<,6_FJ,2TIQ]ZQQ979Q%*;>!63[?5?K1(;O.SKO\
MQVJ4E6.X19K3B.:'Q$=?9?;4.*5A23V8(7%*KC2E&0SP(*A.UJP+5H2B<L00
MWO6QFT^OD22!:>H=L3">55E5ZAQRJ(]P03<K?11:UU.I30*1QT@8N>.8P)6/
M.A.)\I<?6L>W=T)E;B"MS[)W5!O;$M7F1RMT,)+-241X\F,IZ(A#(-$H4&R
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M&Y+9=6%(\J:FXNORD>60I*$/S%/O!%:?"%!)]N-;6LMM%7UZ-,4:W.F],_\
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M6&Q(4D0#+/T%,,J!*,A6D$$<?=B)5D& +YLBH)555*D4'$BG"G/$6;!VB5(
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M==?MVM(F4<S2E_ZE-SE^_%_,,<UQG?\ \F;/NC:1>B4;?>J0\LVPG'_TY_\
MA(Q!7,.?8^NBKT];9<"#:Y=O=<07)=\M\F"A864F3 <C*F/)9=4W5#B6D.4X
MA)RQ]([W^IGLBI8D595+F,@QI>AJ?F#ZC0;Q=>-;!\B>X+>[]2E5A;U!^.-0
MB4>H$&+K:#IIO[J5L>T(7OV_Q[Z'M)9M<>4U-MEI99*T+4U)N"V[W(>?;H5
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M5N?4E4%>Q[>Q,CJ3K#S#\F87&B#\)2X,CW8S:%,5*)IR^ DNM-=U3"X$XX5
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MACR[;Z6NI^8JYAV]OWKZ7W.\$:$;2# ',NHQZM;\<<N4J2IUWRYK3BX>M)<
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MS]2@C<O3=AV8\A,1IDKUO/I=3K2$.("F]"4-GX0:FE:=F.HM-P%.A&%Q$N,
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M(KRQ9"<J9<*%2G&I'3+)<H^HG3'=7T[WM;B/F[STWF/$PK@-;TBPH4H48E$
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M&@N*(JO /K(R7=[3>T[4"<I**-][G0ZEVUB['S5ITZ8VK6EM12DJ>=)R4YK
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M7A[\N X\,L-O>KO4:&&:6%]]:\^%/?AE.G(R+G-&20!B)?-6(FJHX\>_CZ'
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M@<T0* YCES[,^W"$9-BFX5NNMJM][@2+9=(S4N');6VXTZA*TD+%"0% BM,
ME*!?$%1E$3#')<TNK?1>]=(;J_N3:C#]PV7,?6_-MK(4MVUJ6HE;T5"<O+SJ
MI \1C94JHJAB<5I;FVE1GKI@Z>*5L??3D-V'>+/+/[JE)0Y1+@!^)M8!R4*4
MH<P<%2 ;20E3K&!U9+H;T[Z@6[=UN:<0XEN>VE*)#*C16H9<*\<:^K3,#ADM
MO2JQJ#JI/\]//V\N%<4L5=X)7GBE=1IXC/WX$8^Q4\\"H'VYGA[Q@0R4'4DC
M.O'.N0X=^#$(14.@<.W+QRP'/%#E&3)4.!Y\:^JF(F,3FI"1$G?%%3))KJK3
M*F=/'$33!'E4Q5.+\45,@:LZYTJ:\.-,AB)I%DXU0"20Y*=(="A6OOX=V>=!
MBLQ(+*VE5!!$CB/L1B\,JY]W&E,NWMQ!N"MC(2BZ2'01D12E/3/,XD1CU=*$
MM408Y)"GJ4'K/,]Q&?'"95RJB$B&Q5/-Y4S]797MIAJ7JXLQU,[+5]:=-*<#
MRK6G[<= _):<%#YC.@]N$7X)JA'8<LA[,#<TP>>:4$DTH">S#89I)PTVJI!'
M'+P[^S+$9$ .<DBG):H!G7( ]_'V8A"H26(44U4A2?PCU<Q[<\\6I@A#"%\*
M$"O=X8$W"\6U4X'F#3/NRIG3 R'Q0"@DGTX#"4L$%;1J:8$+R6NXD^G+LP)=
M4=+1I6AIW#M[,#(=DM+:J9 D??\ ;@8^Q#A+#)J13ED>(/=7EALC4JEA?'3P
M[2*T^_"8!+5P3EMDY?#4TK4#MY<<2P&:3NGK<<FM4G_9'?09\>5,5SEAAS4>
M*\N.1P2:<^%1GW'$Q($.APK8^A2<Z"G: *U[.6&5**L,^N@T'#+VDXK4PN$?
M]9N5)+?T\6]<A]FUQ$=1+V]Y<&9.C)F/"P6]"YS5N_\ @BE@QXRM+S%5QU)U
M$*!TGJNPKJWN.XKK:2?^)IVE&LS'X93J0Q;@\<&Q'@C?MGJ4>TZ'<['TJFXU
M;7.+/"C2JX?B!_B8OY2.H7 JX7".RTW+W'9;7NW;3RU,Q[U#=0U<[>\=2S'D
M76 TP'UA)U(,EA+BQD4I((Q[*6A3!N:<*MOD)#XAT<,_M"\^URD#Z4I4JG(Y
M'P!^Y6J?L/8F\(VC;^[/R26\*1X>X&TI9U+!TH_,(M6J5'[Z6S3MQ(6%C<@F
MWJZ)\!+]O]RB+RYMX_QH:QSCP5^V'TDWIM.*ZB\7:T367"OY65;99<;=CE56
MZ+(T>8D'*ASR[\95KM%Q;1/JF)!R(+K"N;^A<R&@EQGAQ3R!O>U=(.LFS.J.
MX(HE2+)!G;31?53W&I6W[7?IMO=ESY'E$M3X<9<4I4'JAA$AQU.::'67M"O;
M;K:7]*IHHT:A]6(B)>I3E$Q,3Q#$B3C'!LBMKM-Q:';[_;;BGZE6[MXPI2U$
M>E4%2,Q-LBXB8-++4XQ"Z[_4YTLO?47:&UOJ2Z=VQN7ORWV6UL[H^42C\LZF
M;6MP:>MUHOD9)2VO<EC;;2+=+6JDQFL-U0'D+:[W:J^TUJ=QV?OGFV&Z,M(/
MQ4)3'\RG+.,2[EL82:I'%WX&J-VVR^H]S;/ICO5J8O$_#<1@<:4P[$ACI?XA
MY#@0UXZ0=9>GN\.EL&;M/R[3=FURU[PL2U)9F6V[MD(?3*:D)#ICR'TD(44I
M4V$>6O2M"DC\XOG-\HNY/ECW9.RW 3K[+7F96MTWEJP.($B,!5@/C#X_'%XD
M+]-_D[\SNWOF;VE3W79I0I7E&(C<VY($Z%48$:3CH)'DD0,!I+2!"@+JW=7)
M4I+Q<;2A34@-T!<\Y(#94A:TD_$*@DTTY9 BN.5V^.FD(G/#[%TN_1,Y:AU6
MD>]]S-QPW%D.!(:<04E*DH$<(5K:_A!:2$.*0X":4*:@FN-Q;TCZAT\5P5\(
MTQ&1'F6)6*^B[M.^:I ?_P")0VF.MQ48ME2E(0VIXJ5Y24-FM:GXOQ$#%5W1
MF,3DK=ON1*.D_$K=NK<'Y.PTM*G'6W]+;2&"XVEUQM)"FD(26P'$$$ D@&I/
M"@QI:M+43'BM[0JSI^8_"ZF;IMO"W6C;3:9SJVI4AH2=+;:DE$AU(*G5)42@
M ("4D5)KJ)SQI+ZB*8U'".2ZK:9FXK:(G%@58^H?U&6JS1PEN[J;=884PEOR
M%*UJ0$J^8:CH0O6ZX!Q(2:"IXXT5.E*=;5& E KM)Q%. UU!"41Q_8H.V9US
MV+O^Z_E\?>$./N=MQQYNS78.;>N,AQ;A2HL,7-$,RVWDJHEUHJ"#CH(0O+,"
M=6A+\NWQ#$8=0[>U:.OL];=GJV=:-6J/PQ?4?86)\1DI$W#$OKC+K"I,E36D
M^<L*DO!#@'F(<4,VE*6@Z=:5*SX<\;6AN%J8:X,)-Q8+F*NV;A2J>A4C(R=B
M&.!\%#FQHDS</4RR;8L%ME7:[OW>(AIMORD_(IU!PN2Y6K5'TI0'5*.;2$ZJ
MBF-)O&XSE1,*('G#!^)/1>E]EV-MMTOS]_(M0\YTLXTXY\."ZQ7W8FX]A1'Y
M3NZ8]_B-6=$U#<"WNN7?RV67),F"RE<UN'*5'1%62YK8"D)U4XC'$W>U;E;S
M]>E5IBAI<@@X= R].MOFAVQO-*-"XLJ\+W7I$HSCID'8&1(<=<%*SMVW'UFF
M]-)#,"=.EVW;=GV+M*R1"B7=IK*KK)E1H 2-##MSO=\OZA1(#322!J*&U*QL
M=IJ7N\QMK*F)2-,:(\R\B?MP \%YWW76V[MV=_N1,(&O4]2;G".F CGR$8N3
MQQ7>OZ<>AL#H'T\;L"_E9>]]R/1[]U$O,50>:E7U,<M1;';Y)0A3MAVK&<5&
MBF@#SA>D$:GC3ZG[5[>H]O[;&B /S4V,SQ?A'P'VNOS^[\[ON.[]ZE<DG^G4
MB8T8Y8<9D<Y_5%AS4[YUXXZ=<3D4=I&HCLIGZ=Y&&%&1PZJX!L=M?V94I@Q?
MHH.G+2.&1("@,O5^W$26<?B9)7%JHR].9RQ1CQS42W!%+@30GO /A7OH<#(2
MDNY5KWY\^?;PP-S0EI<4,A0G]O>,(MQ0G::D>JOWX03 /#@B!5..?=Z<<25H
M)AYCB"$9*TC[^[$3BK1B'1@4U[?O]> 89H1$KTJKQY4P.I/CT5%JU^RF?'")
M<J(RQ2$T'X?;A\6*$KGAD)C-> X]N7I[\"8!2J)IW]YX4Y8,TF;P2:I'',#C
MW^O"#<$<54JK]^!TW'L7 [ZZ7?-^H?> K7RXEA:'.NBU,&E.X'&VM?Y$3Q+K
MG;_&YESP6IMN(U4X4H.[.N?96@Q;(8OT6(,%(MJ((2*UR'KK3GWC%"E!W!ZJ
M:=I_S6J9C4 ?9PQ3(."KX$1F\LEUN^GMP*V$$?V+@O\ ^28:/W8P3Q?FMM'X
M01DITRKW\\#II8(&9[_5[\-U="4 .12BYV>W$<D_5CU0B[6M3D.5:#[:9TQ)
M5^I)\$!2R2.S@*$&O#O' X.J@Y2AF.WF?MP*VD?,QY)PDA(YU[,!8YJ4J@!;
M->4LGF3G3U8' 54IREGDDEPCF:\>)SR[?5A.^2BD^8>TU/?G7VX,5,3D!@<$
MKS.T^_OP>*/5F4H.4SK6OIE@<)BI(GF%[SNP\?$9CA@4XU(GXCBE!P'+]GJP
M8JW!*+P',]GZ\#(9U7YA(I0FO BF=>/+LI@9"KYXY4IV<3Q[L&6"&XJJ'2>?
M'E4#!X(R\$[2]I&9X^&$1J#)NR:3V(ETAOP9S#<F*^@MN-."J"E7'CE7!$".
M,<"E)IC2<ESIZO=&KITUN<C=>T&'9>VY;JG[C:V$J/RQ)U+D1T)*@%BOQ)'X
MJ8SJ57U/++XEI[BV,#JC\+OX*U;$WY)MLJ+>+3*.D%/G- TU@4U(6G\25@CQ
M!PJD <\DJ5>43@,!PYKH/L;?\#>%O:<:>"9B$ /,DC5J"1JRXUSQ@5*1B7 <
M%;>E6%0*0O--.?L&*M).05SJOG5[?8/TX3#GBFB)?RXT]G=R)PV(R0BID@#B
M/73AZJC"(/$(14RAQJ3W9?=W8&Z),Z,F2#3B/93VUPD,BA])/'LRJ.?'G@Q0
MCI>(I0D>S"(!+D(.25\PHU&O]&%IB,0$ EF#LEI=I0@FO:,,@'-,&0R7BX20
M22?9@  P"6*5YAT?BSK6F7"N?NP: [IN?:M?E,ZSP/'PX^NF-A"I^\<%@@E&
M1%2*9 GTXGGB!J2.623DHHBH)X)]G/#C.7/!,DA5,5(I3CS(KGQKA^I,DG@A
M_<G*&$TH!2GIF>//$,27*' ",6$D9T)X>K$@3')$I.S<DT5'%:T)'$>WEB4J
MDFPS2"%Y"02<A4Y<_;GEB8F) -B4'JE_+I(X4-/#/%>N0E@?*A>^31D<J@4K
MGQPQ/$G%D:BD&"CB*5[*9>KLP>H7<Y($EX0P/W0#QJ,^ZG;GB1GQCRR3=\$\
M1";IPJ>S/W9XAZDF3T29V394/2H_#0<N.8S/:1BS6S#-1<%'0PF@.GU5.:JU
M[>8Q"4Y.0_%$1J+(PBI(/#U9#+A7UX/4+,%(PF[!&;82FAIG2A[?2F(DDYIB
MG(YX(_EU-1G3+O\ 3+$58*<&Q&*6ID4K0BOA3U9\<"@:6+@L%;),+6"$IKEG
M2M/U=V+1.7')5_"6*QJ;"4$D%/=7W??B3B66:L!7$;^KUL:^2QT)WHPN5#L%
MK_S!M9VZ0W:.P;]<)C5TC)6P@I=4W)B,T)S2H)TD$"F+_EY?U;/YM5=LNHRC
M:[CLL#;U!B/5M:\S7IEOA/IUJ<X\) 3XA=KO-A3W/Y(U+NSE&5WM/<!J7-,X
M2%&]MJ5*A5'[P%6WJ4Y<8F4>:X7[QV#(94_=-OW*T2;LXT?SFV-,LL-79D4^
M*5:Y ,.2ZYP60**5G0$#'U)5M# GTIPE(CS#GX@X%?.,+F<Y"$H3C !Q)G]Q
MX/R*UIEV"WW65*1MU#UMOL-2C<=IR'74K5H_$Y95OD.K<R_NZU%1K1M1R0-)
M4M8REJM\)#$Q?_N_L6TH7.D&-7&F< ?VK%&MY;ALR7FX,^6RA96TZ@.OITZ2
M$*0XVM5-25)I10K7+$(7-6E'RD_6HU:%.H6;K@K!?+DUNJ!+B372_P#,L.,R
M&GA5"VW$%*Z9?!JK0YXE*K&L&+E54J,Z$C(-S]H7TE_TN^JL3J!]+6V-M;@?
M3<)^W(,KI]>8DMM4E3\G;#K]D3(6-)U(EVYAAZN:Z/ UJ21;>PG5H4+VBXJP
M&DE\7B<'\0Q6!>5(1O*M"?\ *JB,Q%OW@TF+G*7MXK3;ZZ.@F]?IQWLOZ@^D
MWYDO8]^FH8WQ%8948D"9(2TF/<9K:1H,&Y) 8?<<24J=2A3I*E%1]2[>';?S
M([=J=C=X4*5>)@=$9?$P?X)9QG#XH&)! <# ,N(N]Z[G^6?<=+O7M&O4H5B0
M*IB/X<G9O5B[3A/",W!Q8YDJ$-L=88._[$@ZTHGC6MV&ZLJ$=W04.>4VX5.^
M0K715#J2,C4:2?A/YR?)'=/E5N1N*.NX[4K2:A7;&).5&LP85!^&3 5!B&D)
M ?H/\I?G3L_S<V8?!;]SVX'YBV?+_P"92?&5*7/.!\LN!.N'5J,J:S(AI?;7
M-#"W&DI0I#;[+:"AP%=2V9#2UC*O.M,QCQ>UJZ<\GQ7HFZ6<ZL#*#$Q^M:R[
M&ZC"U[D:LDY2V:NK1&<5\ )"E50*J2"I(54"E*9TQMZ].%6@9#XES5M,T*HD
M78*9KRVJYJ;3*D*6DJ<2SYI5Y6E;@\P:17)02"03WCCCG:](F3QY+??FS& #
MXDISO>9Y4>/!LCQ"XT<-^>R[\PETM%HDM-J*DA*DBH4,Z@BIH"-/=434AHD'
MQ71;3?QMY&6IB1@K-LV98762JZP$3KHLDLO2QYH"4H^!:M8.EH+!I4D Y4QS
M]U1J4I^3"FW#!=A85Z=V0*GFJ')S@RE*9L?I+U$@LV3>-EV[=)/PN0%34-QG
MHKVI+C;#$V*$/0BMP'24+14YJ.'MN\W.V5]0)-$OJX^W%=MMFUT)UX:XZ9OY
M3D?>%B+?23KET@O3-RZ07F9O78"E)9OG27>]Z;NER@K2I0=?VA?;TI"7K8ZC
M3Y;:Y%45.DZ13&ZKTMEWR@3$BC>@/&I!P#_FB,#[EWUM:U]LKBGO-M*ZVRI%
M@6!K1)=I1F<6'(DAL<..S/3C<NW.CTV][ZZN]$MX?3_?MVMJ8LNY=PFWWS9$
ME0?5"G(7?=NR[A%LMRN<E \OYKY?S4+4&RI*JXY_<K'=:5Q"XU4[FWIQ  @"
M)1/,QEB0W[KLRX[=MJV*VL:FW;95JT+ZM5)G"O@9@DD",HO'/A@2MNME=1K9
MNR)+O0D1C#BPY$&V)S6U,=NUNDPF'2XZI:1'0T^\OXU*7\9%:8Q)78O8>E2#
MU"<<,NBX:>WUMHN8BY82X>]=G/H8^E=WIC8K)U8Z@PO*WM<+*A.RMMRF ES9
M=HGQ5,.W^:VZ@*9W1>[>Z41T_CA0'5 DN/J#?L_RW[+_ *5:QW7<( 7<B],<
M8Q+XD<R#ARSS9?-OSD^9-3N"]J;!ME1["!:K,'"<A^ -^$'XOWB&R!?H2M9U
M<O3ECUQ>")856E..!'@G32]/?V^JM/MPPE()^T^#0&F9KI/;7,>!&(L?]I1(
M]RN32TD5J#PR%.'(9'EBB1QZJ)!1=0TDUI2M<^67JXX$F5O<?JLTKIJ1W^K&
M0!Q31&U\%%7J/'UX'<LV"&'L5U9/X5<_T#+W8QY,_11XIZE0.7,4KB'5"6#7
MGEAOBA*!.0[\/% +8A+21P!.?+!]BRQC$%$)KZJ?KY]N$A>';V>[#X(14J I
MZ9X6+]$PEUP\ A_>D:\LCPK3U^S"\R2$MT#(5K[^/CAXE!(&:0%@\S7O_3XX
M3'V)"0.6:]Y@%:'TX=O+#\5&<M(89K@)]:KP?^H7?BA_W;]J9'=HM,,$=]*X
MVUL!Z,6Y+G[U_7ECCA]BU?CNLQ6URGW4,,,(6\\ZX4I0VTV"5%2E$ )2,SB5
M0L.BQP#(L,U)-DTN(:6E04E24K0H9@I4G4DCM!!Q23Q5U,$/S"FC:B?C10YA
M25>/#%4S[DR=1<+JW].CY7LR4@_N3TY<_B81G7AF1C"Q<\UM:9> Z+8)*@2,
M_N_;@.2L\4A3AID03]E>8IQP,$D/S32FH9BE1^H]V!D,D5R[16O+,>.)8)I:
M156?CQ^_"23C4:4J/3W'$6":J%5R. CB$EXUH<^>??ZO7AC-/%T-5,R>P#V?
M?AH2"JE #6@H>P]GNPF22*T\.8J<_'/#35-1[3EE0'@*Y8$E4+ISR%<LQ2O.
MF!-+2Z1WC]7+AA,A*\P95KGEP[.W/OPVP4_4GDJA7 @Y]G/V5PE&4Y2SR14G
M(U/ISPN*"3(XJJ5$D]G?AY!"(%$9<1E^G"=2$Y# 9):5D$'O]!QP,X4XU"2Q
M"1*B1[C&>B364/QGT*0ZVM(4"E0(X9YX 6+C-U9*(D&.2T ZP]&[CL6Y2-U;
M1CN2+*^M3MPMS0)"!^);K* !I=3S_M8S*<Q(:3FM77M91+TQY>(6,[%WY(M,
MF/<[9(4-*AY[%2-6D@+0M%1I6GA0X)P?,8*%*M(8>]= MD[T@[NMS+[#J3*"
M1YK=:*U #545XCGC%E$Q\%MH5(SRR6<I<J=2LZ94%!X'$#$$*T%%\T9^%12G
MLSYX6D ,.*>+I25ZQ7A3+/#C%HZ2E)W<)5:<Z 8K$#CR3)1$.@YUKPS''UXC
M*$1@"F"C!VIR'"G'C]N(Z631@Z33XO=P^[!B$(P6*"O'('T[, +H3H'L[^PT
M]^(Y),Z,G, \_3LPTDNHI3OP.$U""14\<AP_5Q&,D%LU@8)P/9VG/GB*FCH&
M??PY\/&N6+ J\TLH!X9=W'.ISXX:9PP10 >)I]GVX$AB6532F7'[O;@'52G#
M067J \Z9Y>'VX3IZ/+J""6TUKZAV\?9ANQ2$=427R7O+'(Y>WTI@9E%TL(%:
M#CXGQY8$):FPD9D> \<"3JJ4IH*#+GQX\SQPN*LC$R\$O2./8!SP%9 PBR87
M:XVJR0'[K>[G LUKC)*G[A=)C$&&T.'Q2)+C:"<Q\()4>0QJ=[W_ &/MFPGN
MO<-Y;6.W0#RJ5ZD:<0!UD0YZ!ST6UV7MS?.Z+^&V=O6=S>[C(L*=&G*<CXZ0
M1$=2P'-:T;@^L7H%MF>Y!F;DODY;:BGYFT[7NDFWN4S+C,N2F$A]H\EH!2KD
M3CYXO?U>_)&VNIVUK>7MZ(%C.WM:DJ;CE*9IF7-P"",02OI79/T9?/#>K.-U
M&VVVV$@/)6NX"H.DHTXU-)Y@EQQ36T?65TCOSI%K5<TQ5/.,Q[C=$1[?"=TI
MJEQU:')*H(=7\(2_Y=%$ D5Q;VS^K;Y.=Q[R-CK7-WMES.8C3G>TA1HU"2T?
MX@G.-/4<!ZFGQ"J[I_1]\X^V; WD*-I?W$*>JI0MZDC6',0A.$!6(&/\,DGA
M$J0'^K<J0@KMD>S)210*<E&0L$IU?A#[("P",BD=O#'TO"49Q$PQ@0X(+@@Y
M$$8$<B%\NU:-:C.5*L#"M"1C*)#$$%C$@X@@N""'!P*Q"X]4]R+2XS^<1H@4
M"BL1F*RL5_L.U4XD]X57%CD'R@*K3J'F<+ KSOWJ5\DXW8]Z7J.M1+B7&_RZ
M5(0H).GR%S8KR%H/[S2Z(6."FU?%CC.]^WMV[EV>=ILF[WNR[N 32N+?00)<
M!4I5(2C4@3F,) ?#(%>B?+_?MG[9W6-?N':++>=EF0*E&N)"8#XRHU8 'T#@
MOS(&$P,G!C+*0XK4C>?4SKQ$F*_,^I&\6TN*46'F+G-M3+X&9#2(B8S++[=!
MK94$K1V$4)_*#YL=Q?J1^77<D]K[PW_>0\CZ-Q2KSIV]Q#/52-/1#_- @2B<
M".*_4WY9[#\@.\]@I[KVGL>SSMB *E.=M1G6HS_<K0F)3C+E)S&0QB2$_L/U
M/];MNLL(D[H9W0TV4%47=-L@7)3C2>*#<([<.Z_$/WO/4KUXQ^V/U9_._MV<
M15W..Y6T<X7E*G5<9-ZD1"J/'6^9Q*?<?Z9/DCW1*1ELT+"L06J6=2I0()XZ
M 94CS8P9:C?7_P!8.M_7WI7M^P[6VWLQJ39-X6ZZ_E+,U^SP'(SD:5%N#\R]
MW8W=*7EAQI+3;B66J!0U)6H*Q[_\JOUJ;G+YHV?<WS%H4Z.P65A<TX4K&G(R
M-6OZ8]28JU#*8$($",9!G=BN!W[]&VS5/EUNG9GRUKSEW#N5>UJ2J7U4>>%M
M.4Q3IBG3 C)Y$Y2,N88+@OMOKQ;]S29]NO\ ;?R>7;I\FTS&%1%6NZVB=;Y+
ML"0AV*267&$RF5!+C"G8[R:*0M0(./V;[?[LV_N7;*&[VD@;*YHPJPDQB=%2
M(E$F)Q#Q(*_(SNKLO<>UMXNMCO0!N%I7J4:@$A..NG,PF(R&!:0(3+J+8EOJ
MB;FL<\K>:\E4*]0W:QV'&JEIN>!F(SI 2Z"JB#\0%"K&]J1#BK YY$9?W+D8
M4JL)&,X@Q(+@\^G58[O:W_F=OAW\Q# W)Y:6;[ +80W<]+=?S:.FE7GAI^,C
M^8BASH3AWE$F$:@BTVQZ]53:U?XA@?AX?L43)0V$N?#I4M*OA2DU%<B*TJD@
MU/'NQKP.(S6?-;N_TY.N$SIWU7W'TSF/N)MU^#.\K(5*=HW-85%M=^C(0E:@
MH.,HBO* &>E1Y'&ZV6K3KBKMM=OX@,H_Y@&(]HQ'@M#OM PMH7] ^>D0#X$O
MCT!^U?2XU*M/4;:+\2Y1+7+BW"+)CW&U7.*U)@SK=("FEQ9$5]+C<B+*95Y;
MC*@INBLZ98U\J=7:KT2IF08@QE$L01Q!#,0<7SY+ ]2G?6K5 -1#2B6.!X$8
MN"%P ^L'Z-[]]-]UE]8^C[$R;TE<E-/;BL;9<E2^G$N2\$I2LK+SLW9SRUA#
M,I14N$I89?JV4.'VO9>X-F[YVFKVCWG3I595Z9AYP--:+>S35&8(;$"42)!>
M?W%CO/9.\T.ZNS:U2C5H2$QH))IMG$C\=*0<2C)\"0<%J%(W=;]TV:I4AMUI
ML$I6"5MR0A:?,JDE000:+3G7B*C'P?\ .CY";W\L[V>[[4*EYV=4GY:H!,Z#
MY4[AAA_@JX1D,"TL_OKY1?/79?F=91VZ]T6?=]*#U*!/EJ@8&K;DEY1_>A\4
M">,6*T(ZNK6Q+=E!)BS6Y&LK:7I4RXVK^'(;6#7X@FH5WTQXG85(@Z3R7KMS
M9U*I,HA2+TOZK-[CLCT"Z**;W;&ZN("EH^9":-LW", JE9  +E,@X,_Q"M]Q
M9F<]<&;BM7/71 C)]+_6IKV-NB/.N:#)50^8XXY(4OS'&%+2X-3'Q!-5G(IH
M3J->W&DW.R,*7J#+[?%;+;ZVNIH4VG9^U9/EO,MM09*G%.$.*<=92"-145A2
M2"HD*J/Q5X8YVK2A7IE\"0NHLKBXL*\90)(!RX+'.HW1WJ#8HC=UMMJD3;;,
M<0E#UKD>>LA1 8T:0UK6I((3F:'+'-4K"I*K(TI CD5ZMMW>5"A 0OJ1B</.
M,?J&/N3+IP.LEANK=NESY[ML$EI;EHW1"<D+::0XDJ0A$E)>8TBNDI4 GCC6
M7MP+.1$(U(5FS@[?5@5ZEL?>$?3!_,4ZMN,HU!J(Z!SJ"Z(=0-^6KJ)TQN&P
M-UM,?EHMR6UVEH$1435U<^<6A54-NM+2%E1S.FM.&-;M]7=37A5JRD:8)SPP
M/3PP7&]UWMIN5:I5$H_F92!\O!BX8]%O5_3)^B7<+IL'53J5MV59NF=D<%TV
M?8=PQ9$>Y;_NS3FNU75$&6AN0WLR I(=4ZZE")[B0TT%L^:K'K?R_P"S+J]O
MCNVXTS#;(R>((;U",@ <XC,G(X /P^?/G%\Q[#;-O&Q;/6%3N.I3TU)0+BA$
M_$92&50QPC$8Q?468/W^?DN..+<6HK6M2E*4:$J4HU)/B>S'T$6"^/4P6]7.
MM>T#U\B>["+E29$;=YU/'GZA@!(S23U*ZBE?'$N*'3A*N%#0@4PT$)XT\44H
MJF6?W"G//!A+-0,44R%+K0G+B*5SSKEQI@ 2('%>2DG\51^W### )%'":4RY
M9>&!"N;:P !7@!P\ ,4$$8G)19'"N-"<^)[?7P.(H14.'AQ';Z94IA,DB>:*
M5]W/[<)DU7632A]?Z/5AJVF0 9?B"<)52G$^LG++ Z!4\V.26%Y4/=7OKGR[
M,,J7J/( <U4+R!KGV>[@<1;W*TL/!>\VM1GWURX=G##2P&+YH1<K4U/Z\N6%
MX9JJH3JT!#U#,T/;[>!S/.N'CP5<I$M$EV2=1!)KP/IPY8?!7Q C%(4X3D#F
M2 ,)@ZQY-J\IP7SY_5Q/:N'7_J<MHK B[B$!>M&G4]#@06W2V#FMO4: \#GC
M;6Y>C%:6['\>06OS<5B='<B/MI>CR$*8>;6-3;C:QI6E8-:I(K4'C7$JD=0T
MG+BJ8R,2\3BI)L2 TVRTD!*&DH;0 *!+:$A*109  #+NQ2S8#)64R26)S4U;
M44DOZ:*^$IS((2=7]D\^&?9BF9R"<01+VKJ5].2__E7N+8Y2F%]U"T0:>L8Q
M#\96WIX0'5;$8%->43F1Q/+[:X&'L0AJHHCEEQ/"E*^[ A>' D5K]HKP&&3P
M& 0E)*M5<P./"E1V82$0+/8>?'OX>S A5UD95K6G'CE@22=9.8)SS[NW[<"$
M@N5XZCG7C^O FJA7,']/'GW8$)&H5XU'$>_(\,"$G7Q(YTXY\*_?@="KKS -
M3V^\^!RPP'QY(9*"JGGZ4PD)?AE@0E D<,"2-7CGX]F7Z,"$DK4<T5[.WL[R
M<)N:'3M":@>KC^GQP@.*E%C( Y%'0D =O;[A4>W!BLD1B#@B@UK3(Y#";GDI
M)E+B1YS#L26TA]AY"FW$+ 4"E0(RKPIB3J)B)8'):'=8>C,_:=P?W7M!DN6]
M]PO3[>W72022M;:$_A>2/4K&53J1D-,LV6MN+<AYP=^BP_8&_I5CF,3X3SB6
MPL)DQB:*!2:*!035*TGB,$H\."JHU=!>1PXKH#L_>-OW5;FI,9]!>T)\YL*%
M=0 )J-1-1V8QI1,2MI3JB47?!9CKSU5\>%.6(NK?L2DN%)J#Q]E,N_!FF"JE
MQ1H">& (+([2DTI6A)''GEB,XZAU4AAX(W#GBH1QSP3=*"C7B>X^SCZL&!P0
MGB3[12OCD?#%>2:,ET@9U]V&[H1DOT/'+L/9Z\JX6'M0J_,#5QRKV=U/#!@A
M1 FE>%,LSC(6"C@_J]=<\3QXI%&!(.0Y<JYXDHI=37E3F<LO',\<#*3Q9FQY
MNE\/TX%'#@D*7R&??7TSP(5$E7;D.9]?Z<"'/!*25<_;WX,,TR^#\DL@)K6G
M?ZA]F!)C[T@N)%*'V9>VIPOM3,2,UX.%2@>5>?;X>(P\$D1;S;++K[[K3#$=
MIR1(D/N(98CQV4*<>??=<4EMEAEI)4I:B E())IBBYN;:RMJEY=U(4K6E SG
M.1$8QC$.92)P  !))R6PL;.YOKFE8V-.=:\KSC"$( RE.<BPC$#$DE@ %S>Z
MW?7HS8;A)VUTKL:[A&4M=O5U"F:5,"2H^4N1MZS.H_B,L+)T29=4.?B2S2A/
MP!\T_P!8E>YE<[%\HXT=,!*)W"M$DDXC5;43@W&-2JX.8ILQ/Z1_)K]#M&YM
M*/</S1NA^> %3^F4R1"(S$;FL"\I$?%3I&(CD9G):4[PZC[RW*IFZWW=%ZW2
MI+:WD#<$]V;Y"7%%QT6UIXZ([:2<VT!*"!1.=,? N_\ =/=/?%^;CO+<+N_O
M8R.F=:I*8@_",2=$ ?\ !$=5]J]M]E=L=N43MNQ;?:;=;NVFVI1I D!AKT@:
MC_B+GB5ADB[1[Q#;9DZ'HTI'\ M(2X67%I% B@4L-J[*C/QQH86E>SK&5,D5
M('%\'"Z:E95+&L:E)XU8'%RS@<^#ICMJ-)M4]QM"%>4K)32J*;6T?A "5525
MJ'/EP5B_<J]*[H1G)C+Z._3^]9&ZU:5Y;"4CYQQX@^SZ<0M@=H[ID6=QBVNN
M.NPG5MLVE3SA\V*]72BQR5A2?^$>*B(:E'_AWCY.;;B0W]W_ *2_U&U[6[M_
ME3WS<&=A5(AM]S4+RIS.5M4D?_+EE2D?AEY,B&^"OU/?(2AW587'S'[2H1CW
M5:TS4OJ, PO*$!YKB$1_^E4HAYL/XU,$G^)!Y2NC=CJT@H96DTJG6*@<:@I6
M#\::4/-)J#V8_2PN"QS7YI>C'FK:[OF]15J^5-!R2XA X9\4@4Q# D@K,I1E
M',X*Q7?J1,N#+D.Z1(DA"D)0XEV*EUM5 ="7DT27$T)H:ZD5)24JSQS7<W;'
M;O=NTU=E[DLZ%[M=0'53JQ$@#^]$G&$APG$B0X%=WV;W)W!VGN,-V[?NZUI?
MQ;S0D0)!_AG'X9QYQF""H"O,^.TZY(CQDMQ5NJ:2W0EV-)"2XN$MT $@M_&P
MXH#S6^/Q!6/R!^?_ ,B[OY3=RB6V^I5[-O9&5M5EB:9S-O4(SE#\)+&<&.;K
M]:/DE\S+/YJ=N?F)F-'N.T:-U0!<8_#7I@X^E4]NB;Q<C2\>WN_/.1),>&XN
M*M^-(::D)\Q:V2XTML.H2JE7(ZE:@@FA(QXYMMA"%S"M<#U(0G$F/ @2!T^$
MF9^J]\MMJ$GUR:? AGB>$AX9@KY7>O713J#TUW I>X^L$ZW[PLVZIMLVI"M\
M%2;/?=NO!-PC;J:3<D28J7KH^2B;%<.I06!J2<Q^\'RB^9FS]\]N6F[=O5:=
M&J*,1.VU/*W,0(FD8X.(LT2 Q#$+\8?GM\H.[?EIW3=V?<%G7N=IK53.%_Z4
MA2N14)EK%3$"9+ZXZC*,P7X$N^F?U&7"V7)O8V]H+=AOT_7%AQ7U+>VIN] 0
MD!5AER2I34]X+*EP'5%]&>A3Z?B'TKL_<5.JU&J=-8X:3D?#QY+Y2W38W!N+
M9Y4A_O1\>8'/WJ]=4)ES@-_YKVC)E*8CI(GV-UYU;D)ML@59/XM,>G+\36=
M4'5M[NK,?QJ4BW$'@N=HT(OIE'!\.I*Q#:'6O;M_\N!?PJU79LZ7'](JLE)'
MFO-T2'D*2/Q(TJ/.N%;;C1J>6LPESX>U2NK*=..J.,0'4D6Z^?Y&WQL;J9;G
MD/0K1?8K<N?&</D)M-Q(AW *<;HM 1&?U*"P"2GA3&="H+:YIWD"&A,'HW'Z
MEJJL/4ISH$85(-CUR/O7U!=!>I\9VTVV1*NA3;'VVWX3*%EH+2XEMU;KBFG3
MY^O6!I-4@'GF!V>Z6/YVD+BC%Y2B"^>!R;Z>Y>?TJ\=MN/RM;R2!(8ELL2,\
M<?J62]1_JL^F2PWB?LK?'6CI9MZY36'X]PVKN7=^VX3[[<M)9DV^Y6>=+^*%
M*:*D.-/)2 A7#,4YX4IV6D5Y4XU@0SS D&R(<N".'-;6VC4W,2JV5.I.V8N8
MPE*+G@[,1T"X5?4[T4Z>[6DW/J]],.]MJ[YZ6.2J[IVYM+<=MW*KIM*E.->4
MAQ5NF3%G:,V0]Y;*W#6&]1HJT%JGH^U_,O;[>U_I7>@IUMAJQ]*5Q+34A#7Y
M=%S''^%)V]1FC@)ABXU]7Y;[KN-7^J]J^I:=R4)"I"D-5(U#'$SMYN--49^F
M6$\=+%P>=.^K,G?<8RK4M/YDR*R;6HCSE) H5PU$#YE"1F4?S$]AICP?YG_I
MIHSE4[F^5,HU[27GG8B0)B#CJM9$^:!S%(DG]R1#1'T3\M/U"UK#T^VOFU$V
MUX&A"_,2*<R[:;J('\&H^!J "!_$(G%:^+M5XV[(9D,H,:1'4K0*Z2$A0U)5
MD-*2!FE6?@1CY$G*I:UIVMS"=.XA(B49@QE$C,2B6((ZKZPA0H;A 58&$K>8
M!B8D2$@1@006(Y$%9MMSJ XJ1K*UPY1/\9(R4HDT+C(6"EQ"CF4FN)F-"XIF
M#AVR*OAM-6A,2B/+P("V@V9U*6].C,R']3<2*HF1)U*:30H4A@H67-&AP @"
MHTY 5SQQ>X;;5I/.F'>6072V5/UIBG( $1SP70CI+U^M[=O1MR[O0+C;[K'9
MB*M<]*)"5%:J+=94IL^2XAI.H+"D#544&9/%7PN*,S,"7E/ +J[?:Z52$8Q_
MF'FMV=O;PZ>;GMZ+,YMJS2)EF3'?BW:.VTF5%":-C6XXZI C(;HI=2$Y')-,
M7VL?SOIVTX&4Y$  #$R)P'T=<WO J;<)U[>?IP#F4L  !F3R_L73[Z-_H/Z0
MQ[/MOZB]Y(VQU&=W=%C[KZ:6"/*M6Y]FV>%*<+T#=%VEP79=IW-N<K;/EQE%
MR);5BBTKE(_@>Q=N]AT;6K^;W>D!4B6%&0PB1QGSZ1RXE\ OG_O3YEW\M6T;
M'7EZ9 UUXEC)QE2/ 'C,8G\+9GJ"_)<=<6XXM2UJ("E*)42:!(J?]D #P&/2
M,(^6(8#+Z?<O%R3(F1<R)<DER3Q)/$GB>*M[CI)XC,9TR]!@^U,!-2HDFARY
M8D ^>;):@[*J7%#AW=W<?><)G"83YIT]N?#B37M.%B/!(CBGJ'2:<J',_?[<
M,'DDG25G+/$GP0WO3AM5,JBG&M>?#UY8;J)"=I=&0K4\O 5K[,/AU46X\$4.
M"HJ3Q ]1X<^W"X))XA83G44KS]M,4G5+A@R,T?S.%.7#/G^O$?-C@AD@R"%4
M'90<:#+Q[,7"$6#I,$X0X%CLRS/9W9XI(8I)RBM>=!GW>OUX22<:O;S_ %8B
MRLA#4<<D0*J#G4_9^G+#3D6F"S,O5'W?>,#@IRF9QP#,DJS! SY=XQ'+-5O(
M>T)(%,R:=Q]8&&3R2^U(U4X\J\Z=WNPT L739;Q)TC/F0*\13@>>)Z2!J4B9
M2#G)50>&?'+[*Y5RKB)!&:@R^>[ZJ:.=>>IBA4:]SR:]ZDLQTDUKD24XVUN/
MX,1T6FNOY\L>*U]N-Q>L-FN-U8MLN\28$)Z5&M4$I$NXO-H*FXC)7\"''54
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MLNX4K;#DF&M2Q.6\5LE 26D\Q&I6VVX$;K_2DY\O'GC[AU717 MK^T,[,DS
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M-,(T\7&2>"%YVHZB12N8&7LKGB9&##-".VZ=:1P%1S\!B$A$1)XLA?/?]3!
MZY=1U@4INF=W9**"?#C7QQM*3BE'_*M'<^6O+Q410EA7#^T*$T]_83A5,F5
M "S^TG)/.E/74<3R.*,U,$QRXA31M50UM_%3, >)H:YXIJ8!6Q<$2*Z6?34M
M*8UV)/&-'Y9_S5&OAC#()J$-BRVU(?PWZE;3><GQYC/U8F1ISR4P'0UR,@ 1
MS[<N_CP.%$QR*;<T(2LB*$'TR[L3]/(H9*#@4<C4\3G3U'.F*I"0QX)LBA2$
M\?6>^GCAN_BDQ*J74C\)&?::DY9<\!+9H8H*I:$9>SC^DYX<098Q0R%\V2?A
M-<^))&&8L')QY)L,D42@@#]>66=/5B $IX#- P+A*3*"^!SIQ(IGPKQQ(QE$
M.R3)8=X_?W>O$1((8KP54]U<^_/[, +Y((9&UTSS]*\,\Z8:247S3M]5/#NI
MA8(02Z>  /?G3NXX"?>FR&7#WU[SB.HIZ4G4:$^@P:BR;!5"CZZ4YTIZL,$I
M$#V*NKT]..!TF5-5??EP\/# Y*;,EZ5$95[/3GAL4G"]H5P-<_3PPV0Z4$'G
MEZ>.!).$-\*B@YYYY>/+ 2DJR(<:7&=CR&DNLN I6A8!!"A0Y&O;A.<U?&D7
MSP6DO6+HR_:7W=Q[;9ULK*ERHR!I2ZGXB00*T>3R//&1"8EA)8EQ;MYX8'BW
M%8MTLZEO[6E,17G7/DU.>4MMPJ!CJX%#B%?A X8<X/FJJ-9B 3@2M]+/>85[
MA-38;J5I<0%*2% E)/W8QULXSU<?[5=-=#F>7:#EE@90E58M%*#J:@<^ZO9Z
MAA8A5^I-W=&2LTX^WG[>W"3]67-+\R@SX\J>JF5<"OA+6O%XTJ,^W,CD*'B<
M\'1*,Q(LB)=J.-" ,J??AMS1*<06=*\[*O=6GK[*X3*:Q) ].WCB"QB."<)%
M,^ST.) <TCR"-4"E*Y=OO\,3454A2B#]HIEX<P,"$4(*4T/+U_?@'1"H1EEE
MZ\"$D-D_O9>W//E7+/!BR!C@G"6^0!]OM[\&*M](LZ5Y=":<\AE7(<>?/"S\
M4H0<XY!44E#*'9#[C<>/':=D2)+R@AB/'80IV1(>6?A0RPRA2E*Y)!.*+FXM
M[.WJ7=S,0MJ4)3G(EA&,03(DG(  D]%L+6TN;^ZI65E3E4O*U2,(0B'E*<R(
MQB!S)( 7%+K[U61U1WQ<-QMONHV_""[/M:&I9)8V_">726MH++;4B]RM<ER@
M*M"DI/X1C\0OGO\ ,Z[^;?S'NM[HF7]#MR;>S@<HT8'XVX2K2>9Z&(X+]L?D
MC\L:?RN['M>V(QB=V(]:[J ?'<U #( LYC2#4X\/*2,RM<'9BI;AD-D*\T%F
M-4#2IG\2ED<B"*CN QY="@*,-$^&,O'@O<H4!1CZ<^&)Z'E]WO6-W!IE!* M
M;*&.1/PN/*K3-84A1259T_>.-I;3F0),#(_4%L[:4Y>8@2E+ZA[&/]BQ=R,M
M#A4S)!*4AL**&U#S%DE1H@IK2HQN(5!./FBMQ&M&4=-2&!+YG((&Y7W9-E?:
MD(1)1%94(Z4@I6']!3J;U%5%'4$C.G'$MMI0HWHG2>,I''P5FT4XTMPC.F3"
M4Y>;DS\6]I]RO'3.Y+G;;A:G/*># ;E-@*HY)94IA;80%%0 +613Q\*XUW=%
MM&CN$I /$EP>AQ<^]8/=MK&VW:H0'@9/$_X2Q!^OBLW:$IZ<V^V2S<X@4A,?
M4&D.0ED%Z.Z[^%Q,C0"@C-M8!% %5T4O1IVYIS\UK-G.9$N! X-QYA<_4]&%
MN:<_-:3Q=G(F,I <"'QY@D<E(=M;:6RA3:W$1IM2@J1_%8DH-5MKS'EO(6.'
MQ44.\8T-<2A4\S..(R(X%<S=3G&9C( UJ>>.$HGB.8/LP\%DMOG3[-+;NC:7
MG78S?RURCZRC\RM*EAQQ#*:Y2F%)#\91 TNIIP)QZS\D/FWN7R?[ZH=PVIG/
M9ZI%*\H@X5:$B'8'\=/XX'F&R)7F_P R.P=D^9W:5SVEN>F K?Q+:LSFVNX@
M^E5?/2YT5H@^:G(\6(V,V[NB#-9;"I*'6GF6WFY+9'E28SZ=3$I*2JJ/-YCB
ME04FN6/W-V?=+#N#:[?>]GJ1K[5=48U:52.4H2#@_M&8+@K\:NXMDW;M/?+O
MM[>Z4J&[V5:5*M \)Q+%N<9?%&0P,2","LR<FQW&E(CN)45I("BH$Y Y#-7Q
M4QFS@2%J(SXR+*#-Y6\..+;=15+Z5 %8IIK6G+B/7C K4W'TS77;1>2%-XYA
M<F_Z@>QA.V;T_OS#23*A[IN$%T :CJ>M;CIS&DMU$-"L^-3GCX+^9/;L.Q_G
M/>[I;P]/9>X-NC<89"YHU(T[@-_B$X5/&97[:_H#[KJ=^=I5^VMPJQEN6T0C
M$&9<F$9 T3S'DD:;\J:TBV1MZXL0U+*8E5):GPBM14HK;(+C:16J5 $ GL<Q
MY9O6YVU6OAK<$PE]W]G@OT@W>^LJ6FW@9B$?))NHS<\SCX@\U?=UV94^$\UJ
MB R6A/90(Y*W'VTH2\$N>:!J71%<CDHG&'M=[Z%:,_-Y3I)?('+!O'W+&V6^
MA1K F,I0B?3DYPTEV<-B,VR6MMWLEKO5MNFU;_"BW:RW1DL28<QD28S[:PKR
MCH-%M.MU.E:2EQ"@"D@YX](MKVYM:]+=K&<Z5[1DXE$Z9 C/$?9D0<0RVF[]
MM[-W+M5UVCW#;TKS8KRD8&E6B*E,PDY (/&..F0(((B1(%:&]2.A&[.FMP.[
M>FMPN-PMK+1;\KR#/NMDMK:W'5VNZ6Q 0=W;5CJ-4I%)L)(JSI-71]>_+'Y_
M2J>GMG<IA1NXD1%;_P NH,/YD1\,NH#$\E^*?ZK_ /IW77;DZ_=WRB%6_P"W
M9QE5J61#W-L1C+T9?^=3CP'\R(S$@\EBFS>KKETD1H4A]-JOK[@\G;USDHE6
MZ]MI5Y;AV?N%(CQY*@LZA DZ9S>:*.T\P_86W;Y:;D!.UJ1E(@%M0(.#^4Y$
M<1Q\5^0N]]L;ELU:5&\HSAH)$GB1*)'"<3B".*?=1X.W]XVZ7%OTO:NWI(2V
M%*N-TBQYKKB<XRI*2H.-E&@%"Q_$;-"DY4.1=4H7,#Z@B.;Y]%I[.5Q;3%2@
M)SB#P&!47]$/JGWW],G4*!8MRWR5=-E+EQT0+PZ?S%MB*7T+:3)4%/-W.V'2
MI25T+OF+_B*HDA&OVS?*O;%UZ-W$5MHJEI0E'4 _$ X ^S%\5MMZV"U[@L/S
M-F/1W6.(G'RG4!@">3^Q?5!]+_U"=)NI\>&;LU:(<J[ML...6=$1;%Q?>2VG
MSD/LH>CN$HK0@JR&1TC+VNVI4;C;(76PBE^6E%VB (CH=( <'/ZG7A5[&YL[
MZ=MO(G^;ID1+DNYQ</P.?UEE+OU$_33:;[T5ZB3NGP><67;'NL1&6FU$1+!<
MQ*O;S:%*))CVAQUY7EZU*#12!4BOCOSAV^ZW7LBYHT:8-W0(K,,R($&3==+G
M[%ZS\FM]I[5WO;1N:C6=R#1<_AE,>1SR,F#]5RLM>T;[MZTR[L)KZHZ&%*0Z
M8Z6T/C0KRUA"RA2FP:$$@UYX^!JE2%S5%,9K]!J$#;P-0G$+F;]4N_\ >UR@
M7.W*FKBBY2?R&S6]N1Y;]RNDYTPXT=@#RP0Z5YKR"$U.0QV.P[?2%2$HQ>0(
M))R8+G=TWJO"$A&338LW/@MN?Z?7T-7K9-K:3ON(RJ=<EHO%Y#06MF2^P/\
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M(D<.A^CK<=WT95-NM+@%ZFB4<QP((]P+X\UL0(BIKK1\QM2=(HUJ&AMJO_C
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MUOWU6Z4.M1K@W+0XH6Q$*W6I9AB,%!'S#R5$KHI"F]25]1<;9W!=5]7JT:>
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M 3GQ(XTH,,&0Q" RTSZM=(Y5FDNWRQ-%;:JK>9;3\+R*DT-"0'4BM#C*A,2
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MO(2S]*K&)U<9 3A(,3CIQY.,UD4]P[=N*QJ[C9W.N<')I5FQ_$1$Q;$XZ>'
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M^Y-"0XPMZ<1GRUU)LW$'DMF/J>ZF(Z-?3QUFZH%OSI&S>G>YKI:XX(US+Z[
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M7( G&OW^VG0WBZH1&F=*M5CU($C]BZK<";BM*K1:),27=]42-6?3IAER5QW
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M275H+DC\TJ\T\IPA2O,57CC[4L_F'V9NML:%.YC3C*! ! AIT@  #(:<-(&
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M%=:W4Y\_#N]#C]7.AS7Y$R#%QDK>Z@DD@^S.I/N&)PF?A.:$Q6GV&M<N_GR
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MHC\:AC/I7-*4IN#\+>]ON72T;FA/5B2P;AT'W)[9KE.C%\-K05N/)9)2M0
M\MI0!(4*Y'"KP@-)BX&G]I_8L>^M+>J(F8.D1?(=2H]WC<)5\NN\H%RD2IBK
M3(;F0VWJ.-QH3<1HR83%0 64%P/A*:_%J..FVF(M*%G>1 B:X,)GG+4=)/N,
M?!ETNQVM';K.PN;6$(1KQ,9$8&4S(M(]2VASP8+6/II>6G+_ +LL +CORMVB
MWA#2E!SRHERBEIII*%G4E/G6\J(S(4HCA3'I_<5I+^FVU^0 ].4'YF)=SU:7
MN7KG=EA*GMMEN9(!G1E3/65.3DN.DV]BV:MWE&.E;+JFU//(HC-(2AG-*%-+
MIE1L\*?BQY9=:Q5TS (C'[<\?:O)+C6*IC.((C$^\]1X_4M<[XPB)=KPRF(V
M&C>+D^I(!6MY$HO7!"4-U)#8>77XC3,Y<\>C6-256THU)2.KT8Q\-+1S\ R]
M3VZ<JUC0G*9U>A"(X,8M N>;<L>JM$YLA$M+$9* IA#K0=<0WI4WK  ;:"R1
MJ2*Y@XR:4G(U2=BRS[>3R@:DBXDQ8$YMQ+=5A6[K._<GK$TM3:E7!(;<#;:D
MI0T)#1J5E2E$*\ZE#3'M_P D]Q-IN&Y6M)_4K4:5...<C5 RZ D^"\*^>FV6
MVY[?MEQ6B]IM][<5YDYZ8VSME@\HQ'5==;5MT0-O6FVH:\JWVJS1([(%$)=<
M$9 :2BA H@*!.>1./T6.U3JT+:U'^FH4HCQD(A?C)0[BITMPW#=*KG==PNYD
MM^"&L\>OW*S3&+9;YHDRW0TF5*GQ&JM^8RW\F%LM)*E!02KY2)D>93GGC\0?
MG'N5[O\ \S]\W"X!]47]6#?NPHS]* ]@B%^I':E"I0[7L=NL8O2H6-N<"Q.N
M$9$^V<W/BLI;BR8T=B4TS\RVRV!(<9?"AY;J 4.40$DI+B >&6>/-!%CY@3+
MBI2K4JM65*<M$B< 1Q&8]Q*LY-VD)4B+;4*^4D%PD/ME:65J7F=:=2@6U'AV
M8- =@,%G#\E2+U:I!G%LCB</9F@&UW5Q3Z'(;S:DO-OFIST**"M206J* TJ&
M( @!L=0X*S\Y9Q$3"<2-)'MQ;CU">)MLU@2&E1TO!+K$A #C2G$T\LJ^%38.
M8';AMB68GQ5!NJ%4QF)&)((.!;CU5SB/NEIQ*XC[2F)K!*F\BE+R$H)*6UZD
MA1)X"F+(PPU '/Z9%8E>$!(&,XF,J9SZ>(5XMLOY=:6EN2$I$E^,KS$+4G0_
M52-6M!-*J3SQ*&8))'#WK"NZ/J1,XB).D2P(S'A[5?GXR7D!Y JG)Q:XZ@ 1
M4LR4^4HC20H!1XUKB9 )RPS^@6NI533.@G'+S>^./U+'%Q0@F.^MPM$/0'FI
M$<%MUIQ/F,E1"4B@2  0>)Q08N0#EB.7ABMI&L9?Q*;:L)@@X@C M]ZA7<VT
MPT[&,9V,@/E;;#SJO+2ZA2M!;*@#1QIU(203W\#C96-]*C(QJ/.!Q#=%WFT[
MT9PD*HF=+&0&+'-_ AR_L6N'6WHM*ZD]*NH'3ZZ>3)_S1MFZ6.(LMB0Q&N;K
M(D6"<I* M9^3O+,9T$G(IKRQZ3V-WS#M3O#;>Y+0&,[*[IUI8L\(R:K%\@)4
MS./4%EG;]3V[NO8+SM\C33O;:<,0'$B"Q&K $2#X8X88KB+_ $N]Z2=B]0^J
M72&YO?(QKS:G9;MO<UI#-^V7.*4R7%._")3FW;B\TH)/Q?+BH^$4^^_UD]IT
M>Y.PMJ[VVX>K7LKB,=<<7M[R(,.#D>IH(Q8"62^:OTR;S/;N\+[MF^)$:U(U
M=/"-:U)A6#/F88G OIZ*4/Z;NWW-_?5EUYZESHI:59)>Y]P0G5M ^1<^I5ZA
M%M25*5_!>;V_!>":@U2^:<3CFOU<7)[,^3?:_8,"VJC;PJ0RPM;:.<?_ *E1
M/Y 58[UOW<W?-6F_YFXJ0A+]WU[FK4E$'/&-.((RTKZ,;)&;+8,D%#!2 M3[
M!<9@)(H75*:H?-7Q[1SRS/YGT8"1TGX>)X <U[-N%60E_!8U.#%C/HQX!7+<
M$[;^U+2;A>9;<BR#XH49;@D2+A,4G4W\JXA:+A%?4K@!3*I5\.6-M;6LZM>,
M+4$DY=>I/ +$VVWW+>;W\K8P,;_\4@&C"(SU O"0_N&*T>ZRW*Z=8HTO;5_3
M,@[*FLK958+7<)T)$V*: MW"=;WHTN0EQ(*5ME0;41\25"E/3>WJXV&[ANU
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M)LDE!KZ?IP.$,"JA!(KZ<:<<)^"/%54WD,N7'F1R'M&#-)(\M7I^O"350V>
M^WGXG/#!"2\4D8?1/P7DA7AX\?5A8(=5YYCCX_IP)\$L5RI2F"+I(B4JJ!0_
M?A$ED.R<):5E7CX_KIA"<7Y!1U/X)QY2:< !WG[ZXAKES4=15/+&=!VBM?LS
MPC*0(U)N6=+":<.5*#T.(&3G%+5BGC>=,^7[1B)S2'-/FB$G,CT'OQ*+>U!=
M.DNI3F*<N%:#AE08DHN0XX%. [J%":<>>7=XX6E64S'4YP"J"#SJ*YX%::D
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M'TB(XG-GE)O$KL'"OJ+/:W%/,,R&PG_AXZ0ZVY-D<2ZM0)\U&M/ _#0> Q\
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M[4B'&F51D&8<N24.$C11Q').7H?R]WFVL[/>>TK_ $QA>VIJT'_]6DQ,?&0
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M[@U)><0Z7 I 6LE'S" \VD:%D%*DA-#I'$8_/?TSR+NW%WY9KUG\Y&WU6TX
M2BV+#%BQS&''CS6"7$2()CMK9E*$>6XQ6C]"DJ=:2,RD9ZDXQY>7GAX_1UT=
ML:5QJF#!Y0!X<@?VI4*04>?_ ,.L^5)1(HM;:5 %2'%#-PD_"58B) N68O\
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MDW)%"@#44'M[CVX>:'&1=+34_=PIZ#!Q1P2Z=OAZ9XD,$,JTXY^SG7LP(9>
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M7&8^T7=*2E]ALFE&DG'R3W1^K3YV[['\WV[3MMIVX$EJ=,59Z1^].J)/AFT
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MF521PX+A:=K L2F5R3**&77$)"53+B 5:@G6IF(M8T@FJAK%3EQ&6/AK]9,
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MV_>6WUA&->UMIZQYB<#(C(DQD#@ !X!6MSZ2]F_\6%,7%5&4A.J9.(2=+E"
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MAGR5[M;3UQ4FWQWGI "$I?BOZ_.8CI^'0'7 7 I_)*?,U BI!RQB5I"F]>J
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M#'ZTTK@3I0J\)0!]\05^/)LI0J5*9P,:DHGQ!(6V^W+>7X#+(1126PIQ7$J
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M\)N/%3]0F3##V?3(I04HTRJ/3AGG@X*<9.'E@79+"R!V>O/ $$B)<\4-2\J
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M\BTV);*$BBB7WODFVTH2D',D!(.9X8QO_N8^44_B[7V$M_\ J-O_ /PU1_\
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M,B."3'+K6D D-I47E*44^6AE"1\;BU@)2 *E1&*9B4!JEA$+;V@%68@,92+
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M 2U <"M55VZC6IF) !/(-[^:Z,=._P"I1L3<"6(^ZK.]:'5%*5K0['G14K
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M,C.OLY>O C!>'DIJH<<CW=@IGAH'5$44*_#QIQ H?9VC"P1@J)2LT(K3ARP
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M6H4/P\&V@*:&&M1#;8R [R3C]@;"RM;"SIV%C3A1LJ,!"G"$1&,(1#1C&(P
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MTDS'6U-PV;ULR^76Z0+G;$2BCSD0Q <TDZ54%#T=?O/<=EA&ZK5H75(2#P(
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M0^U*3,WK.A[51HTH;1J;CW9Q=-5:() -*8[S].':P[L^>G;&PS!G;_U2G7J
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MIF>W#4,_!$2V- HX:T"@L*+:LP*::::@$9C "075<CI#A.V+S=[:XE4::_1
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MR%L^"L:VY/GM$I*Z+3'"A5:W#Q5%-:C.H.7#A\+1B3(4H#42, OHBE0N-[N
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MQ>(/[HFV.*^Y?T;_ "8MN[=YN?F1O5(5=HVFM&G:PG%XSO)1U&H00TA;4VD
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M>/#%=4QGEP5HBQ8#%8S9+]99%@BS&4-1PJ,TIWRW1);6^IO^(IF4S_!<:2I
MH4DI[,4:HLC3)R#F#X*%-Q[EE0-S[6W%;7W@[MG>FUMP-O,+55C\IOT&6IS)
M7\NC!%33B<<OW)1CN&QWEK+'7;U W722NU[*NJEAW%8W8\LHW$,>3R Q7U"[
MGV+UGW;9+9+Z?W>1'MURC,3%QFD.*;0);3;[;J"W526I!.JM:4Q\ 74P:^@9
MQ)!Z_P!R_0^QK7E.F)4I'21S417OH!]1D>(7ID:7='D%16]1TI&L!2BD@5"2
MH9&N>>,24J=*>JI("*ONI;A5@[26M6X-K?4-9'GG6+(^A$9/\)4S7I<<45?
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MFB!E5*E.?IG@(B"\2@G'!*+6D#X<N.5<N/'OPS+5FF[YI"DU&0KZO3/"XI$
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M234$*->51^O5E6A4JV]"6G",I%\06!S7YZ[E;4:/8>X;U(0G<1ITJ6+$QE4
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MZ1MAJT1K/%O$:USTEB'(N 2R^LJ<7D1C7;+\J]TMZ,?SU:E3J3(-2,7DW0'
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M)!2$9<LL;BG<!WEDN"JVM02.G$.I6Z7=:D;?ND1$V4##+A2LA2,DE)I\!-2
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MY/RL3>&RKB_&=NMH5+"'5VVX-/16I$*8E"E1I;*%44C6A?-=W=E4.\=D-A<
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M9D+TGY4?,/<_E?W>-_VB%*=SZ-2G&-75Z<A5CI:6DQ+9-B/-$+[D;=M];J&
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M7_//;-52SM;&]IQC@:%U$$\<(U!3D_#'WKRC9?U+?*.^D(QW6O:&4LJ]O4@
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MXURXXE]JC@KBTE>69X4XT^_EA%D8IR&5G,JI2AH.'M.?#"!"8!EB. Q1$LJ
MRI[<(2B$BZ,AH@BJJT/ 9COP&8,>J/L3I*!3B30"G(#N)&*W!#<4V944A7[@
M).7&N) 19SD4D1#:N>7+L/V4PB20R$]:^'AP[/3QQ$X+(MV,B3P"<)> IX\C
MWC"9_!7SJ"F,2Y7,KK:@KZE;K6!D;DHYF@(++7;4#,8SJ/P +1W+FL3Q=8%!
M;_ !QR]U.SLP%M1/!4L26"D*SLJ.G/+4/9X^O%4F!?HK"[A\U+-C;(4*<!PI
MGV5QCRQ672;1A@MB-D)TNM$94(-:YY4X\:#+&NF^L'JME281P^F"E-Q]2JT)
M]9\?',#&P+LIC,$<?HZMCH5FHK!_V:C,9^OCAOP6'.G*$B1]N+)J$%1JHZ13
MMXY<:>&#$8<U&$8R)U%DY2IAL U%>WP_1A8NRR *$0"2_5'^?; H#EXTI^K$
MM$D&Y . <(9N0IE2I!%*_;@T2X(_,<ABK>N5J4:J';QX5^_#$"S'!4B;UM<L
M Z$9":9*'><B?;G2F",=(<YJ5>IK+1/E393Z$_%J!5WGMJ>&>+&)+G)5"1B7
M&::+?"JFM>P?=3#91)YINIPDY'UX?@DF+JP233/B?V>O >7%2'/@F*G!J/&A
M-#]P-,+26?@FSXK7WKWT V!UXV^(FX[/;(^\[+%D+Z?=1A;$/[KZ>WM2FWXM
MTL%R9?@W)EE$ME"GHR)+;;R:\%44,6[L*-[2TU /4&,9-C$\"/!95G>5[.3T
MR=!^*+X2'(^/@L+V-U4OG2>/M7I=]374?8DGJ)=%7*)M3?,.0SMVV=1K?:(;
M4TRKE9KC)\[;.ZTQ_.\R.M2H\Q,=3C#BE:VTU4*LK41M]QJ1]8NTG82 Y\BK
M+BA^9E*O80EZ4?BCGI?[8K:%B4N0TR_'6'F)#34B.ZTH.,R&'4AQI]EQ*E(=
M9>0H*2I)HH$$8V31(=8$69I.)OQYK"]ZR-]67Y3=&U&/\P1;2VL;FV3Y:U7&
M^68N)>>F[3=00$;LMB0I3,9VK-P;JQ5MPMN"JMKBTX8Q&8YCIU^U7TQ2D=$C
MI)R/(]>G7@H]N:^D_P!2^W$R-G[K$W=.T9$BZ[6OVVY[>V>HFQMP6^4(SXBO
MW>V2IMA:FS&/DIS4N&_#?0I2'6G !C$>VOZ8E3EYQB",)1/VC' J^'YNPF8S
MCY#@0<8R'/KT6?\ 2+?;&YHDC96XW+S;^IVS+5:&M\;=W5'ML;<B$W&.I,+<
M2EV/5MN\6R]AI:FYML6J(MQ*DZ65A3*+:%74#2D_K1 =_MY'V*NYI&F15B8F
MC(X$?8L_NNU=N[[VN_MS>=LCWZRW!H0[K9Y;L@0)B8;_ )9CRFX[L=4EE3L<
M%:5DI7P((R-QB3%CDJ!4E&>N):;NM==[[GZ+1K3O7Z6K2_9>CVZ4;+E3]A6B
MZ[?;VKM:4XXZW*V_NG8<IMMFP;E59MW".Z_%BN&>U)15UBB@I6-4J4(B5N9:
M)-@^'M!.!8_W+,HT:\I1N9 U*9/F;'#B"B]);WMCZG>D-O\ ^:>W[;>=V;9F
MW;:N]8BFVXESLNYHI?M5UE6^=:I3DG;DK<=HHJ2Q%E I9D+CNU3J1BBUD+VU
MT70>K%XRYOS]H1<"5E=&5!A3EYH^'#W+0#8B>L.T(/U0_15M>^6^?,V'M:XO
M="]HPY-N8W+=MN72ZKN]@CC<]VNOR4)IO;JW!,B*@NK)*E)*#I#G,69N[2XN
M]BC,O&&NB^;'$ =.#+JKG\E5I6F]58!JDM-7//)\./4+>7IUU&>WA#Z!=7MJ
M2Y-S;W]LIC:/4S;ER2Q#W+<F;'(;M(W8Q::LMFX[&WF[(1<_+^)NW2W#H^
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M[TY'"Q&'%9 J4Y5-609D\2^A7X0,^7Z.^N(D%L75P,9%@1DG"'E5^%-?'O\
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MK47S&MQ[*:>$5/EQW2Y;-P7:&\&%*2D/K\I;:O+S/]GC7&LMSIJ5 3^)_ ,
MMOM]05*9B6Y_8M,-DS;UMZ/'<;:ES;8E*?,C20]&EQ$U&H,*6/.84".*2IM7
M,'&R C*+"0$CD5?5T3B3'&06PENDR9S*)MG5#4EY'FJ1)^9M=V9<53XF;G97
MH*Y::5&HJUBM2GAA0N:UM-A.<9#C$X>XY+ %.)EYABKQ#.XU..(%VWU 0X*+
M5&W_ #IL< *U$+BW:%,U-A?8NH&5<9T>XK^AYHU!*7(Q_8575MK:?QQB?8I*
MM.TH5U0Q^?;A9ND?0&UM7:R6*Z++:R$.->;,L#Z5K""2#F>PU QCUNZ-RJ?A
MIN,L,NHQ6-^3MQCB#T++LS_3+^@J!UROK-R5MK_)70#95Q1<-Y7.!&>M<W?%
MWE+4Z=I6*<EIM:+E=]'_ !K\<,H@00=(\TL5Q[3=*VY7<K:=756IQ$J@!PCJ
M?2)-D3F <6Q2W.UN]OVZEN,J<XVU><HTIR_&8-J,-7Q"+@$AP)%CBX7UH6RW
MVRV0+99[1 AVNSV:!"M%GM-N81%M]JM-N81%M]M@1T?!'B0XS:4(2*Y#.I))
MWP#8!<A(QEBS2670VF4I&:2*5XCT ^S%1=\<U*-0!H@'%7=M3:,P /N\*COP
MLU<^.".AU).2LZ^GAAL8H;#%.4/#*OV_H[L,D9A1TE.TS*"@.?JY=M3A#$HR
M3A$[M(R[_4!3(\\ #)N1ABG(G)RI[>7?SQ'0",F* =)U#-*$Y/I2GNS&$(!N
M+H=CJXIPW+KD:4/'U<,JX>@9)=4[3(3D=0';4]E13U81@4(GS&65/&H]V$8G
M! ."1YO ZNT$5'#CXX)#]T("(7$T_&!QI3D<Z\Z\<)CR0N<_65.OJ%N4@5!G
M"I[:,M"N,FG(""U]5_4+D+!H+9U) Y4'WT&>&3AXJ,&U.2I%M"*:*UH>8[LN
MW%9>6"MU/,$J5[&V:I([O5C&.#@K+@-(QR=UL+LU!!;(!X5IX"M?#&NG\0YN
MMC#2*?0A7]VXKU$ \"1Q[R,O'&V$ RQ36F>.2;*G+(K7(\<\O4*XD(CEBJS+
MB2AN35D4!J.X_;AMQ*2:*DO',J)YY<SX8  DZ 9+P-"?ORPU(="O!QU>6I0J
M? <1ESP)'!+)72I*LAVG[\'@D$-2W !0DUJ>!J#EQXC#0$(J636BJ^'=@P39
MQP2BYI J*Y<?=P\<(X% 9B3@$);RJ9 CGD#[/7@&)91)C%GR*'4FGPDDT/.I
M]7=A%6X>Q)\I:N1S/&AIF?#EAGHD2%'W4+86XMX6Q3&VNHVZ^FMX:BRV8ETV
MZQ8Y\-Q^2A ;<O%GOMKG-7!J.I&7DO1'@%'2ZDT(A.,C%HR,3T4Z=2$9/.(E
M'D77*KZ@/Z<&[;@QNSJ;'ZM]0.KVX)FTX<*];/W#\@Y);&WG6[A;GM@767!O
M.YTP(,I4B0[:'IZI4Q+A:9F)-&W.2WG8*MQ1J7%.<ZM81PC(X.,<#P75;3OU
M&E6IT*M.-*WUN91SQPQ'%6OZ*_J1_P"1>Q-V6/ZD;3.Z<W"!/VJQ9(4>?NR]
M6+<%@%K@18]XV?:-P;@W.];KE"@SXLB]P8\AEYIM:''(C2PH8-JWBG9VA&Y/
M3E$@-B[-PZCBRENNT2W"[ VUJD2Y)P =WS'U.IZM_P!>%\_YE[_LT;I9O"_;
M1MT2WW_:T#=$&U]*-_S+*BT*GW*1LS;>YK@MWJA951(4B<V_&5'F%H!+;#E1
MC/&]SE>RH"E(VX@) Y2/-@?B''FL"6R0_)1J^J(W.LQD/BCT<CX3P8J1=N])
M=\QH5ZW_ + ZHV*]NW>?O7=/1[?-Z><^5&T^I$>-N%VPWUVU1V60W;+RR"TJ
M6U<XKC;86&F'E'1D4+:MIE<VU02C(F4'&0EBQ/)U36NK?4+>O3,=#1F!Q,<'
M QQ99=MGZKML;^E;!VALBUSMS]6;W=8-KWE:H5GNMNM.PX%HBHE[]W5=-R/V
M^5:'-LPE(<8MR&),A5QE/,M(I53B,ZA=0K#3_P"<,)#' C/V>&:PZUE.EJE(
M@46>/%WR##(_8MK+-,\Y5V:"U ,7-:DMK3I=9$IAEYQES\).B2'*&E%)H1EC
M+P6 <5%?U ;-L6^>D^^K7=+= N%TM^T-SWS:LIZ!$G7C;FX;?:'WK9N/;3C\
M"Y2K;>($]IE3;\=I3FH!)"@=)Q[NE&M;3$@#Y2W0MA]:R[.K*E<P+D0U!QS&
M1^I<4>F_US;GLN]=H6/9%_Z?[]L?4K<FV=Q;IW8Q#D;%L[^\P]$>W#'N$RVO
M;A&WMPWZ6Q/9N-C=9E+\U:Y,34RI"$</:]PSI7$81-.<*A&HL001F_7!=C<;
M!1JVTYR%2-6F#I9BXX-T#KI[U Z2=!>M%PV9UN0NW1=VNPHLN'O/85_1:[WN
MO;%XLKUJE6<W^,S#N]PB6T(44HHU)9T+;.@%2!TEU:;?N'IWXDU6.,9Q+$CD
M6S'1<Y:7.X6(JV$HO2(QC(.W4/D>H6OWT5]4WHW5[K3]/W4G<</=\G;W4O<.
M]NBF_P"X6NWPY>ZK5N=E9NE^LDNTZ[&W$NSAD(6(RTA<[YEI0*G A.!M5[5C
MN%;;[PB4=9E2DS8',88<<.>*S]VLZ7Y*E?V8(>(C4B[^8#/GX\L%U$VZJ^N0
MI#NYEV=4QVYW!<%%D$I,=JR_,*3:&Y#DPEQRY&&D*D*2 V'%$(&D5/4TS,CS
MMG@W)<W5$!/^&YBP?Q4-[;ZQNVGJ1<>CO5=B)MS=<VX.2.EFX=:(^W>L&VY0
MDR8[>WSYKHA;XVXW&<CW2T.*#RDLIF,)4P\ W5&N?4]&I@>!X2'3KS"LJ41H
M%:F?)QY@]>G(K(MD747[>6_=SAYI^W_G+NP+(IG28Z8>S&VG;B]Y@'\:3(W'
M<)K+BJD)$5"0 4JK*#3J2F.&'N2K#1"%/HY\3^P+7S95POO5CZE^KF^K7%=_
MRQTNVX_T8Z>[AN\R"TQ8=WOH_,.HMYV]M@0'YUWCW:[Q+="<N$B1':+<!YEE
M*_C.,83G6N91 :%,,"?WCB[<LEE3T4+>G1D1JG+7(=/PX\QCES6T?3;>4_>6
MU8=RN\ 6C<4)Z39=T6?X@JU[@M;A8G,*;6-;*)"=$EI*B3Y#Z#4UKB^WJSJT
MWJ!JH)!'4<NAS6+<THTZQC O3S!Z%2!YII\7&@H.7VXO<+'TEV0GE.J2/(4R
MEU)! ?2I;2Q^\E1;6E;9(X*%:'D>&$7;R9J41$'S@F/1(:GM%U$60#&EN-EQ
M#*E!:74I-%&.^D!N0$_V11P#,I SQ7&ICHF--3QP/@58:0TZX$RAX9>*N(6D
M)JE8!I3(]GKQ9B_1.)IQI$@M42*A1K4FO/GX\<-8YYKU!ZJ4X<O"N%BA!2]J
MX*&8IQR'ZL08.QR"F>810Z H?'PY5';W5[,+2Y;)#L.91TR"*T(IV99=IKVY
MX1B00 C,8IVW)Y$U^\^&5,+27P2ZIR)"<L^/K&#Q0Q.*>LRRDY4[.6$<<.*<
M9&!U<2%<F)JCV5','CV"M<#)FK4(9\%D<"4*@'*O?Z<<53@27"R(5!,,<)+C
M%]4-Q3>>OW4132@XW%O,6W&IJ/\ X&6JW0EH'(Z'6598Q:0U0/B<_$IV^$Y3
M.;J+D-J$1+:4Z6E?CXBB12O#G2H[L3$?, %E1E*-1,TP55U:$T7^$@!-0,@:
M@ 4 ]>,CTSF<UN:=:)C@<5)O3^U!3\FZI155FAO2V2I5 NY?#$M#1U $J5=)
M#1&>>GGC&N#Y6&)EA[./U+'-2<JC<&='W7'B.;B?2"ER-$3&M4(4U-^3;V&H
MB% \2IQ394>TFN,6A2,HZLB2ZF*LHN8Y$K'UV"-,D!M:**%?+0*BATFE0D4H
M >S+&0;&,@[K.H76F+EU9;ETRL,Y9==827 /B- -1XGD."CEVC&NK[32G/4P
M+GBMQ0WVM1'IB16*3.B>WYS3S9MZ2DZCJU$U)!IF H@YGC[<85QLU$1/E'L6
M31[BNXS\\GB_!U@3GTV[;!*A 2=9-$J2M0 Y G50G+Q\,:&MV_2D7,<UO*/=
ME=FU'WH2/I\LC*@E,$5TJ%?*^#LXE*JT\:XQ)=N4W^'#VK,CW54EG4+\E?6.
MAUHCL@MQ$)JD4"DI!.HBJE99T/A3%9[?I<(A6?\ N:9&DS+^*(QTE@)7Y8C@
M+!.80%5H3P%.1[Z88V"E^ZQ43O\ 6;&6'BKG'Z7PF7$)#8^(T*/*&1).8XFG
MNQ?#8XQ#,&54MZ)&HEQU*N:.FD(/E 0DA%/PM?NFH*!3^SW8NCLL'89+$J;R
M8QU@/RQ^OV(CW3&.VHH0W_$4/@J36E> &=2 G%XVH<@M9+>9:=7WJUM["1$=
M"U1U*4TLK'PJ2#0&GX1GE7QQ*&VF!=@"L>INQF&/%9,WL^/(BASR-+@0*(I4
MTI73PKG3PQF"Q<.S$+!-_-\"63(;.#("S'4IL*-<ADX/PJ-,Z4Q;"UE#X1@J
MY79J2:1+J_#83LMAM:EAI) JDHTGR]7!-,R2>W%OY*9QE@3BJ9WA!8?"GT?I
MZE#7F I.G)>H*7D..=*5'W8<;(C@JYW;^"SBS[+@IAN2*%):XUI4FA_#_P"T
M/5C+C9R8 N"5CU+F;MG%-+C8FWF5._$&T&B<M5=.52H4- ,9 M90R"K-</U3
MBV[=:0&6UM%2BGS!I202A=#4UJ0%)H<6QMN,L_L2%8Y@K+(,)"G@PH4; (-1
M0!68 %<A4G%T*0BJY3!63P;8$3FV/+*2<Q0 5H*\.6+13#.H2F1'4_!2 V$&
M+Y9.:"$T4"  .)%"<P![\!BX8*HU?A/ C):9?4F$OLQX*'-3C;2G'$).82X*
MT4LDFBONPYPTTP#DY76]OL)&7!:W?2DY^1_4/;(SJ0VU>K/+LBW%)R6[)1*4
MPWJ%/YJTTKQKW8\A[IJQH]_;&)EI7%*^HQZD485A_P#FGXKZ2[8M*NY?*#NL
MT@9?DJNUW) R$?S-2WF2.0A7()77,,>0M;)24*2K2I!R4E1%=)!X'QQZY2E"
M=,5($&$@"",<^2^/*]*I;UI4*H,:D)&)!#$&)8@A1QU6LZKI8HT<HU#YAEUL
MD%0UM.ZJ4''\.%58AN+K');$YH=LMI?LSS0:2IU%HD(!R"OX:4.(I6BM;:VQ
ME7VXUE?'=+3-_P"+_P!P+H=KJ2_H.YZ3Y1^6/C_%(^]0=U0V:+;U2:W:S&/E
M754=J:X$(-3);2_&?4M(^)8<4M-3VXS9Q:IJ&+'Z>Q<Y">DRBX:1+<,UP-_K
M1?0PGKYNOI7NC;D]FQ;UD;9W6Q8ES IJT7MZV/6R7*M<R2WJ5;Y3@<2MB0 I
MM*@0Z E6M/E'S$^8'_W>7EK?WE+U=BN)&-73_,IEPTXO\0 =X."1\+G _5GZ
M;_D9_P#?SMF_[3MEQ&V[MVVG1K6YJ$^E5C+5&5*;.8/(1TS (B?B#%Q\ONZ-
MN]:.A^XWMG]2[3NJQW*VC0R\]&<;F?+H.EN4R72[!O=NIF'4*<0L')TC'?=M
M=Q]O=U[=#<M@KT+RQGQA($Q/*0^*,AQ$@".2\X[R^7?>/RXWBKV_WGMUQ9WM
M.1'G@1&8R$Z<QY9P/"421[5GNUNHFY(@:E+@VC<EJ>4"J9#85;)0425+9E-Q
M EJ/+!.86PK/@2,=%<V5$AXF4)\B7]H?A[5QM6WHB)D'!;)_VK9W:>\K+N!+
M+:8-QM,U:4MM0I<-R2AU:S\3;$J&VZI:U&@ 4A()QHJUO.WB:E2<#2&9U -X
MNRQ(4S5D(48RE5D6$0"2>@ Q)Z!=P_H._I7]3NO%PM'4/K)9KWTIZ*-KCS$/
MWF$Y;-Y[^CI<K\GLRR3F6YD"WO(;HNZRFFV4I4"R'5'+7RMMRW6GZ6T&-.$L
M[B0>,1Q-./\ YD_W7\@.))R.?1GL6QUC<]SBI5JP<QLZ9TSJR_"*]3_R*3XS
M9ZLAY8B).H?5ALW96U-A;8L>QMA;=@;5V?MN(W LEBMC>B/$92E(6\\X:O3;
MA,4G6_)=4IUYPU4> '7[3M5ILUH+.S!TYRG(ZJE27&=26<I'F<A@   %P_<'
M<6Z=S;A_4-SD-0B(4Z<!IHT*<?AI4:>5.G'@!B23*1E(DG/(\ 4U*214=M#0
M_:,;)P<.*T\("2NB(J$4T!1YFIH.=.T986+XJO$2/)$*5)!HCED*GNK3#5D9
M2!:*H/.!I33[>WEZ\!#YJPU$74Z#6A[*^W$=,64/4*,CS%$5KGR&9Y^_#8,H
M# N,T^:C/KSU$&O,]AX=F$3%F5T)8,<T\1%< S7RIF>9[^>%(\@B?F!&3I8C
MD4^*O;R]F!N2B0<,L!@E^6[4:#E7.IRKX^K"PXI 3'Q%.4-2"*ZN?;Q[,#*6
M*.8\H"NJN7(YY9CMK@PS1YN" KYE!H2?MY$TRRX8&95DU!C@W1(*G\R KU@Y
MCAZJTP*(J3Y+1#JJEQ6^;\I0H3,S!.=?*;)XYXF&98DWUE\UB-O:-0H 5R\<
M\L!40X((YJ1K0RJHX @ 'P]N(<%;%R?:I6LK5/+\>SLQC3R)6?'+!;![/0JB
M,J&AS[M.5/5C7U&< <UL(M(=&5F=DK#K@['%C+G11';C=". 6KUE\@SH?S9[
M??6O/[<-CQR2E,C$*HDJ50 #F*UY<Z=N'I' J<3$AC@$X0\/WC[^''",3P2U
M#$\$KYIFH!Y<2:T^W!I/!,D,J_/M#/3W4Y<,N>$Q3?'@J_F"59 <.P=U>9[,
M/27P0X/'%8+U+ZC6GI?L#=_4:]QY4FS[-L<N_P!TCP?+,QR#!"%R!&#JD-EQ
M+9)^(@9'%-Q4%M0E7GC" )/@,U=0H2KU8THX2F0!XE9C#N4:?#B38RTN1YL6
M-,CN5'QQY;+<AA8()!"VG ?7BR!%2(F/A(!'@57*)C(P_$"1[DZ);)S*?"HI
MSP*+C+!5'D"M:'L^+]>6 (^P(J7HZ:4 '>1RY\3@3)]Z+\PS_LY<ZCQ[<#%1
MU 9I*I+*D@@I4E0JDU&D]M#4@T(Y<\ ">?!1SU*ZC6/ISMF9N"X*C2YR&W$V
M+;:;S8;1>]TW-M'F(LNVF[_<[5$NE[?3_)BI=2X\H!*?B(Q&K(TX2FP '$#C
MOTD EN;<!U5E*!G4$!@YS.0ZGHN-TF!&ZJ[EL'U!Q.HD??6Z;RQ9=PVGI%U(
MZ6;:L5H5M>9+FV?==IZ?[+NU[@N/=3K98?F&T[@C7BX-2VV'F2XDH:5CDZE'
M\S<&]I>8F(>G*/#BP(PDV1"ZF-<T+?\ )D" B?YD9'/@Y'X3RX+=39?479>Z
MK'L&TQ-WQ[/U'LEK>8V2QU*V5&W'=;SL^]2(4./:I<.Q&,J?;S(CLMM7&TRF
M7$N,%2PEQN0T-I0K6Y]*F9_QV.EQB1Q'LZ>U8%2A< U)F/\  $@9&)P$N?B<
M\?8K!TVE==[9?[3T;=N:.G4?8MUN6UXD:9M6P7O:6\XML9E;ICFU7[^+>8J'
MMI2HCD.6Y&C%;S4AIUM3B"K$;0WU*1M&$8QU,6<'B,O'[4KG\E(?F6,S-GQ8
M@9.WCFIKF]6NH'26Z;3C=:[=MZ9L_=R[;88W4#IW;=Q?E6V]UU8B.L;^M,QB
M2+!9K[/?0(<Y#ORS$BK+@%4J.9.YG:RB;J(]*6!G'@?\0X \^'%8M*VI749?
MEB15CCIDV(_P\R/[EG]\O[J>H%[V5<7Y^VH^X=GMKM&X;8XU$E35MNNP)DVS
M7*0V^PC<NUI,M*G&5-O 17F'BE24K&,LU *_HRP>+@\^8\0L0T_X0K0Q:32'
M+D_BK/=;==]OW_IM9[_=Y^]+=NW;FZ^D^Z;]/1;[;?+E+E6YS<-DN\J/9VK=
M;V'9$&TSX\MV&TT0ZXTM#:0?@<Q,3B'>F7!]V?VI@Q%.19I"0D/V?8M%?K&^
MD/8]RZ>V*3L?IY,<NEI?V_8+9%V#M7;#=RL-UM[SD6)U!O!99LSE^B"'5F\*
MG2%)2TL2FW([[9=5SV^;+;UK,>C2_B@@ Q U9YGF!Q6\V/>+FE>DUZODTDD2
M)8].C\%J;](.PE-7/J1]-O7J%?=I=283D#>O2Z[3+<]9=[[ ODV]N>7.V)?@
MN:Q<[%,D16Y_G><_%6YYL5WS:D8YWM^UG2-7:;^,X57>G(NX/ CI]2Z'?;J%
M44MVL90G0(TSB&Q'$2Z^./5;9_3A%W7UDVS/W1O"Y7:Z=7^C2-Y]*(LQRW6R
MU6B_SMO76Q]0-C;YM-MMUGL[#*[[+VLVP^UYD@A:GVW%ZJ$=%MU,WM'UJK&]
MHF5,\ 9 N#PSS7/7TC:7!H4@UG6,:F!?RR#$>Q\5TVV7>%[JVEM[<K,=V(W>
M[3#N0B.?"[&,IH.+CN)!(2Y'<)0H5-"G'1T)B=&,I!I$9<NBT%2(IRE %V)6
M(]7-F6S>.S)K%U3?$2ML26=];7N>V TO=&W-X;59D7"Q;AVRS)2Y$E7J"[J2
MW'>0XQ*0M3+B%)<(PZU*-2'FS&(;,$9$=46\YQFQ^&6!?B.(*A7Z9.H=SWCT
MNZ=RU6BSN6]K:T?<NY-WVE]-LM^Z+[=;O/$Z=MS;$AL7AA-XDN/2[FJ6F,B!
M/>7$0'%-K*,:RK"M;1GPD,3U=BKKVC*G<U-;F6O+HV'3 ,ROOT\61S8+MYLF
M^;^Y<NL_5*[[HZM;CLBY+%Q1MG:[][>C;9LD40&$1K1MVT6Z4TTPATJ4_.=E
M%+CI"U"VC2E'7.1>4I$_<&RPP4;B9J2$H!J  C'W8GQ)]P6=6O>&V]@WK=^Q
MI,B\.+LC=EW:P_*4[>;I=&-_WB]Q(5KMS,6,J?,%KN-I5%9"_,6ADMI*]"*@
M@84IRB7,L_8AIU8QGY6((Y-IYJ6#=(R;C#M3CVFY3HS\QB"052$Q(X;\]]Y"
M-09:;6ZE&I1 +A"02<7ZH M^(A52$O3-0#RCCU5V0@IK4^_]>%+$.H@D@/FF
MJ)%MN)N$%82^J#(1'F,+R++KC#<EE0(5J05,NA2%BA'(@C$)0C4!A(/%2C*<
M")TRQ5N>N#FWD>9-^<N-H*UUN ;$J9:&J:JW,,)2],MS7X0^AMQYM-"[J%7!
MC2J5+5M0E*VXD8F(YRYCKGXK(C"-P^DB-=LC@)>'(J^?/LZ$NMT<;6V'4.-%
M*VW&U@*0XTM"BEQM:#J"@2% @C&7"0J0]2!!@1@07"QC3E$F,W$AP0?S!-/,
MUI\O3JU53IT\:XFV#XI:0RQL792<@2.[//$=!6&)39R[HJ+N1F2:]P/$Y^.6
M'I.7!2U5.!3A%V)/&F5:'["1GRPC$LR!.0'F<^U/4W,\SX4-.=<NS$0#P4Q4
MZ%.V[BG@5^JH(]8K49X&?,*S4\28YJX-3T9'6,LO;GQP:>2#( ^;DKE'N*,@
M%>.?CPQ$P)Q)Q2U1)P(646VX-(6E;C@2V@AQQ1Y-H^)9Y<$ GU8JD-,3+@Q5
MAG+/D%Q$W7<'-T[ZWMN9*2I%WW1>K@PI9U$B;<I#[ KSHTM(%.0QC4XZ8 =%
M.VEP'%7]$$QK9'0M(,J82I2E#XP@#,(2>!)-*4K3%U.))Z!9F)Q2V+8K^&E2
M"2 0-(!2=1H!EQ*>!QDZ5D:S$,^:RRYW>V[1VL'9ETLEC:_-;3<[K<+_ ':!
MM^U0X-L=2Y&3<+K<7&(<1IZ8:(+JP772E" 5$#&$:-2M6].E&4BQ $0YQP)
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M[@:*\HR^)UBMN9&I)IPH*'L[10]V6&<D1#0_Q'%2%:F?PY9GCZJTQ!\%9 $
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M3D*E42N2&!GB<L3BI:^<>H?BX@T%#QSX>K%^@,[JG!\E03':GX^ZIS] *X#
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MY;[[,92--PMHDI6D!&ORGHSCH7D0XHH1ER) !QG[G;-J,<I!_L6OMS*$&/\
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M30E_,@9 ^S$?4LBYIQ]07, T)QB??@?K5K^>BJD7&\/2TI@VUEQH>: &(@C
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MAE;]N%[^8MUKLL)Z>7FH&W[=<I#DF4^?XZ$16PE.A2CC5V/>526VT[Z[,37
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ME0_0/\^]]!N>Y-[M15DQ.NO<W,SS?5@3[5@7OZN?D[;0]*RNMXOB)94Z$:$
M!R]2M  </A&3A15<_P"NY=;I'0-F_2C?XZ8[:TM2=W=3+-;&=:P$ NP[1MFX
MR%)0H<$K-:<L;_:/^FYW!4J__;._V].G+/1;SD0!P>548GP9<[=?K9^7]"50
MT-HW2YG)B!*YHPX_B:-5AX$E:9=2_P"N#]1SS;D6S]*.DVW%K<D-CYY>ZMT2
M/XJ5H(32;8HJEI*J@%&=,>W[+_T].R-LTUMVWO<*QPPI0ITW9N>LX]%QM_\
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M#JT^S'FLVVQ-9ZQ=3[9U$W%MU(B-+DVH*@ON.OW':OFNML1+K;F5L.QM3O\
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MJ4SXC7T=>F;5^BSM2A<1AN>^WUU28$BWM:5&1#8@&I4KMT.@X<."FM[^F_\
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M:H3[ZK8^"XS<?UG_ #,N+C597-K9C$"-*TMR(C@/XL*A+#!SB>*U9WS]8?\
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M:VVU.3)"6EK<TT3YBVSIK341CR[N<FC,2IX3CJD#RD:DB#[Q@NFV^0E3TEN
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M%UH]U/\ JLZCVGIS_FVTP-O/.QG9[\B:ZN5-0]#^4DR6=; FI2TW*8>#"D4
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MD=]QC0V+G*C".\K4"G2E2@G8;%OC;G4M;FG OZ<@3@6C)RW @D-S6IO+6$Z
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M^(2)&'(>"@S>F_V)G4C9T;>N]?SC8=BW1L2X7BZ.PI\1N];QBWF/:&6[XJ=
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M+?FMNI27%*]"O*MG>[8-SMY0E=&$00V,I$ DQ''C]ZYK;:-Y:71LKV$A;F1
MD[B(!XL[/@M<5[XZA[-W-UQO^R-B[?V5N"1.LS9OM^\H7R[0ISUYLNY[5$9@
MRHX;8B;DLSGD-R"A;D=] +BB4)7QDC;T8TXZI"H7QB""'8X^(9V70BM&5<VM
M0$QS'+CCPQ=5Z9[JW5)W+U"L&\-Z=1^H$W=EIBRKXN3<ITYN BRJM4O;&Y]O
MO7.!%CV MQHH\VVP)>EE*2*/J0D)Q;FXJ&4:U41T' 8!V8X'$OPQ(]RV\(4X
M@QIN-+$XGW^T+&]N'?UJW7MCHY>)>W[?T^ZF[HOD&XLSK5-G73Y'?^WIDZ;=
MWNIUV5!1(E6"V4DM,N/&0RXVEM*#K"\7V-]&I:&K"0-6F=.+8@8?#CAP6IO*
M7J7!]/5&) YZ7SSXGBK5T\Z]Q>C&[!]+?TV=-;YU2VYOK>$G:,M[JQN2/M^T
M3+7+FER1&V^_=IMTN+5B:$%U$5Z6TZ#(6VMC2"%)M/I^CZ]6<8R <",7);ZG
M^SFLG3+28S>3<78#D/!9;NVW2MY.]5F=TV>!L3>SFZ[/MVQ6W\[1?US[ML1,
MB.O_ #9NC9<B.ZU^9VV8U 3.<)?;0HI>4:!!Q;J[B#"$S,SC!P2,G.6/)L6S
M6)9UH4(Q$(C3,E\SSQ\.7)1ST.?OW3>S&V;$=N!L/2YW;&_=T)W-+>O%S;L-
M\=@)5LU^4A]E8.U[DZ_&8N3#K#CS;2UK0I#E#LK*^N)WGJ4YBH*<Q4CI#,S:
MXG/#C[5JC.C5N:MM(-3J4S 2(#?X<?WN1?@NJNR]UVKJYU0W4V=F6=GI;U7V
MM#W/.3?V)$^U[H?V:YMP6(7';B?(3.VJ\;@XVZXI3R&78[:D)6VHI3Z5MV[P
MOMZ%*B0+>K %LPX#&)'C]2YR^VXVNT$SU2NJ4V?BTC\0/-EK?U^ZPV3H+UQN
M737I+M,,3W.I&PI_5#9&PK2_,M<G;4NS(Z@I:MA3%+;\J9+2VX$Q-"FTU:"0
M%A*><W.XNMF[FK6]E"G"WKB!8$,6+Y<'+K<[-;#<]EA<7^LRI:Q&1QDS #'B
M&37K%M?:W5WHW:=Q;YO]YV? Z</'>'3[YR:U V-ODW%V?>FK9.>F.V]Y^]"(
M\&O(!*W'(Y0I!%0G%OZM*[LITKF?I75 &<!PEQ+=6P49T[FC6-2SCJH3D'(S
M!CA[N*SMSJ%MEFS1FMOV>UWG<VW]K2=PLW:WRE0T;IDP(UNB6V)(CMPGS$M,
M2%(0MZ2D.O?+)4D:@,<G0W*W,?XM.9JF1B9<R?@P.38A;\"[J@RI1(H&((#-
MI ^)NIS#Y+G?(N4IGJ]O#;6]+M8]A;ZW;N^P;J=_(=Z3KUMM4"="N,&\[<F6
M9V);1<#=8K-NF.27&@(B&5H02:XSJ%[0% TY"<3$D:Y#  <,'XN 055>75:C
M4A7 (HX9]&Q?PX+;[J=UTN=XZ1V+9VXELLP';W9F]N)8D+?1;K;;8]M@V:Y7
MA*!\XB! N4U];Q4ZXAUF7H2BC9 OJ=S5=TV7^G5!J,#@7X '2W-L0JK"PMZ>
MY2W.W)T2BY8.#J+GV9+2[?5RG;?WC9MVW6!<]QW_ &1?MQWJ-*?W$^T!9; R
MQ=;A;E2O*DI9B-6#<$=R-%4VEE[\O-4^94G6T#.YA.G.1(E&,3@^)R\<0?>M
MM=5*-.G&K&+&),H@88#/ 89$%NBFK<L>SS]]S=Q7B''M3V^;?M>8IMV?.;M4
MFT+%S0U#AO0%LJ4]#LTHRPM(;46W-' @#4T=4*1I@DZ9'AB#@7]^"V-P(2D)
MS9YQ!9V<=/9BJ=5OI_N-V91O[\I:198MAV/N"WN2Y"!$M_4O:M]ONW),@+#[
MDV$S#M+$60'5^:MQ*DJ\P::8Q+:_G0C*$7($I G_  R&INO'DLJYHBYI1J1Q
MJB(+'IAGX8]5SU^H5>^&M\.2;+9HTJ];BDN[=GV6[1$R'6;NN$]=H%Y%T"DR
MH?FE^4VE20 M+!6NOX<;79KJA<VVD'^$/-&3YAV+CW+2RG4>=242 &'O=C]H
M6_O2:=N)[:VV[))M=KNVZ=U;9O-B6M%N3(:OUKL3,F[;4AWF_LR&K3='[=;X
M<ZS%SY<>:PZRT5)4E)QH[NXC3N11(,:5.491.0:<FD0.A8],UN[>@*D)2C\4
MHEW_ ,(>+GP<#V!8YMOII<8*=EO;B%OE7*):;WL?<D!!A/V\&Y[=7 @N0XLA
M12Y$4]';8**N +#9(I4XSZES$SJ"F^@M(>PN?VK%%$2I1,P#( @\L0R#8NJ+
M%VZB2?IIZZ6'<%XZ3[UA63<G3_=DM*)FXNC6Y+I-8LMXW5LAZ.AUQ[;<*6(:
M[Q:UU;E,F2@!*FV%(S=OHQC0E6AHU:R)-Q#$Q=\CF.H;BL(3GKE;U23"'P^!
M(<>'TR6D/5[8-GZ$]->HVU.K5Q?L^Z]I7^V[-O=U,GR[3>;.W>KZ8&Y9.X7V
M'G)%NOEHE0YMM6I>EV$ZP\@HU*IM+<2G?0H4!'TB"0!CB0,OO*KB*=*VGI#"
M/[2W]RGC>\S;[.[.DT"8]-O$=6Q>F$+9^^KNZB[PH4>9M!E5XLD=#,>"N7)O
M4!"V:R'7'7)2R H521I97(E2K5*,"9:IB48X8QDSG/(X^"R/2B+FC$U/-I!#
MXNX?ZQ]:R*5OV)%W)LF].1-Z)V'OSHMO.Q6U3=[F6&%;-XVTRYS4."S*4N&S
M>'X=G^34@D*=4MO5\1%8T*4Q2G#5'U8U7YN#SZ.7616N(SJ4R 1'1[L_=DH<
MZ<7U=ZZ=[HWO:(-QAWYRX;>A71;]P>@OQYS]UNT.+)9;D%J$M+MNTZFVFTF0
MZHD46 K$:M6O2N!2J2/IAV.8R!98MI,3K591)),0<\LQ].:O^P=S6N\R-Q0?
MSN[VS:W4V]7O:LZ;<9K7S4:_3F)UF@WZ5Y#2'39H5RAM/EEQ2E!#>JIK3&-4
MJ585!$AZD8B3@8,""1XD8)73F30)%.;B7,.,_ +$=W19K]XV?MQZV1HVZ-Z[
M:C37)ZFU-R9'5O:MZ3:[V_"E2H_GM-7F7;RI*"4M#YL$CXCCH:-Q3_*SA(?P
MX.7_ ,!#AVZ?8M94$:=4$1U5)!Y'_%D?IDKQ<HW4+=NW+]>']CP]R"QNRU[,
MCL*BP+\]%L\Q[YGY=ZT-!,$0+TP2Y5"Y+7G N+T)%*+>]H"F(5)C1& ,F!(R
MPSS<9<%D_EZ<H%XO4B? Y].2EVP[4V/M"UW"W[F=39;QN>P"!9+JF*5SY F6
M>'>)KSMRC5-K>M#LTM*4\WYKJFPII0!.)T*M2K<FX&,(P^M\,.3#)4PB#6UR
M'\,#,G$%OHZDQ/1WJ<D/],/\R;J<V^^_%O0WO^?1OSZ)L&+MB9-)&^$O"]G8
MUQM4P7$MKD*CAR*$HT_&%+\Y_&U./5;X>#N#ED_#VJ[TYZ-6G^&[_0YMQ_L6
MM_0CZG=@?3SU;C=2=O;.B7"-"M+T"TP94F0T6!/C*1)4F=*4\\N2Z313I37/
MX12M=SLW<M+:MP-U0H&<!'2!JR\">N*\<J6LS;&G7J/*0;ZU&]BZU'J[UTEW
M;<*;OL^R[@WHN\RV(KZKJ8EOD/EXQ(S]U60(Z-2UT24)JNFD)  V%INU&O=?
MF+J6F)JNSN1$EV!/)41LY4;8"&) Q+,3]."[);&ZA]+[YN"3$VI<+ZA@!BW1
M]Q7)TQU1;9;D^:B.W#M_EQ&E//(IK5J42#51!ICHZG<.TW%YZ5K4D*8(&HX8
M#A[5J_0NZ</4J!I].?AR]ZZY,[AV_:MG[4D7*_6Z +C&BMQ794MI!EK\HK\I
MK4NJW7!2E*UQZM&O2A:PJRE$1E$8D@<."P*L2*I@/BY(5IN1EVN=<7%(0RN<
MJ+;%+6*2M3FC4@U)6GGEBJC>B5,SEQDT>J?I$5-!=V5NO'43I;8)\:T7W?NU
MX%UDN_+)AR+S":?^8'XFW$*='E%).>K&14O+2E4C1JU:<:TL@9 $_6K(V=>0
M,H1)@!FB1MS].[J\_'MN^=J37HK9?D-1[Y ?6RTFM5K#;RB$Y<<6?F*/"<,!
MCY@JY6]4!R%\HO\ 4YW?:]V_67UJ<MDIF=;[+,VOM5F0RX'8ZW=J;+V[9Y+3
M2Q5.E-V9?%0>-3CTSLJG$;)"H&/JU)S<<09%OJ 7*;U./K>F!C& !\3C];Y+
MD]U!N9M-M6AM55J^((&DE*T_!P2":J77[\=1=39HCC]RT5*$HDS#,/O6N<5O
M=%S1)<<<D,PG):&0XI2TA*5(6I6C4 230UI]F*!5J, "699>DSCA$"(/)2+#
MC1$S=PB2ZHM17K%!8U@I+8C6B,5*:XJ5J<>I7+/"C6 #G,E;>E9RK" 8Z0)8
M^U7PR5J2XEC7Y;=6V'2/A6JE2"I66I-!PS]6"I=DQ(_"%OK38ZE;3&,3*J6P
M )+\@!F2KI8^FFZMQRD0MO[9W#N">Z0H-6JR7>Z.K<6?Y:1 AR/,K3E[<<7O
M'S [*[>I2J;YN^VV< [^M<T:>6>$I@N.6:]-[?\ DY\QNY+B-#9=CW.XJ2&&
MFWJB.3_&8B P#XD!EL79?H%^K?<B([L3H9O"+&><1'C2+VU;MO1G2L)"'77+
MU<(+J -*JC14&N7#'A&]_K'_ $Z;+ZD9]S6EQ4APMX5JY)Y1-.G*)/34O6]E
M_21\W]SJ^G<6-M9F(<_F;JA38<R!.<O8 _1;'6;^D=]1%U8\W<-XZ:;7)4RE
MUN9N>7<Y,13J6%/:F+%99C#A;4LB@>%<A7GCQ/>O^HW\G[$RCL^W[W?F(+$4
M:5")Y8U:PDQS)T8<N"]2V?\ 1'W!5J ;SO&WT(''^%3KUR1Q9X48\\R![,5.
MVWOZ,4$/A6]NNC;D!ID.O(V?L^093CBM?P(FWNZ)88:0&\R8ZJ@G'C/<7_4Q
MW"K2]/M7M>E2N2?+*ZNS4'_[NC3@3_\ O/>O4-@_15V/0D);SN.YWDG80HTZ
M-N#EG*7YB0SR =^*D.5]!7]/;H^PFZ]6.IWS[-K;6NYKWGU6VWM6$VZVVD%#
MEMLWY3+1K2M1TE:UUX9X\NN_UE?JO[WJFV[7M(6XJ'R"SVZ526/*I6]4%N>
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MW K,V+S>=U[5LW5EW1N?>2(%MZCVU-]=::;#E@G1>FO5IFU1+6AIRVQ+FJ!
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M ;JLJ6R4EQZ8Y72C(Z3GC3U*WIT)3B^HC'%L5Y%#S2B2V!^MEL)8X5KNT/\
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M7GZU?F_7-?>;C?O0J_\ \S=SM:6D\?0IF ;'X?3]F"^JKGN7Y$_+FV_+1O\
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M^Q7HV]6DI45']\ T"BE-*IU(&H$UXG.H]MXI\U.-20Q=P O*8;;;+JSHT((
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M1TKW/ C73J!TK@O7+;UR=90]=7=I27%1[HWYSB%25-6:3.;EI\I6IEI^6H_
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MS3;5-8NL5<J;:($R5''Y??(QL\Z.N1&=+C+B?B7I<;QM]FW*G6VZGZ$9B0B
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M*S+:UEWMU[V!TN^I_:TQNT[LC=3K>?J:Z7;8M#%EVEM16Y;&E3O4VSVQ(AW
M[5WI?1%7=XRTRH?Y[-=""EHZT]%=VM.A.M0K'U'IO%\3FP/)QDXRP6UM[B52
MF*T8D!VD!BYS^OD75QV5N+:4K;^S;RF="E+W!OBX37HR&WVK6S\W>8=M6ZXT
MTI2WE0;HRX&VDI3Y.K3J">.CJ1T7A88")CP? $X??X+,A.G*B#$@@D'CAP]X
M5XWA*5+WOOO8LG;#<*^[PN]LDL[A8=CL6*]WW8LR9<U6RXVHM*<?W#)L<.6Z
MS)*D_,-1$"A6E9555J&G0H5XEZ%.1&GB!+##H[8=5F08BK$CSR8^)C]Y'V+4
M;JMT4W!%M\.TWI<M6Z;3U M?4[IE)2];H]MVY'<NL>8U^;3'4/+<MTUM@H:3
M"4L OE"@D:@-U"O2ITS*I_"I3I-+'XL\0./M6EJ7-(U=)(C*)Z+:VQ?)09B>
MGUHV0WM[2JY;YL2;PE,^SFR[DM[%KZG6*UW6/'CR%P+CMF?^9QXLINK#UO4A
M)50$<=<U(&K^8IB<J4FC,NV(R+>(8GJL2XG&UJ?E8TQ(2)D"</+(><#F&+MT
M4<[,L,2V6?JCM:\OP(>\]J[VF663"27G;8[<''5IN"O^(>UQK/.T)=\U10E"
MW#I!U:3L94+.XMJ52S!A1C$&//'%BH6,X6]2M8@%@00^77%9UL[:Z+=T]Z<Q
MKK$>O\JQ;DWCMZ;:8XTPE[:@2T7JR2!(DOQV8H=8O?E*#1=4XRW2@(IB,JOJ
MS]0D1!8!^>7W)4KND+&4)F.J%4L..EV/]_5><ZD=.'.KD79Z6Y0VM#Z/SX#W
M3]<]W_-B]XW*Z6W=4:X1Y1@ZQL)N?:78KP2:?,K:U&NE.-[HL?Z9Z^F>)=W&
M8\OVE^;/BLGTQZ#/Y.3^W/Z8KBSTZZL[-LERN5\OD,RMP2XJV+8VES4NP0TL
M:7$-LI0EMU]UPDE=0:4 .>-)=VE>4&A$F.K$\#RQ7D4)B):4B(K/).\X=_V;
M;'MHKFM?E*I,J0S*2U%?NCL^24242/E5K*4!1"4J45+I0@<L56EO*WO)5;@
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M("(3^B.ZJ5Y[_F.Q&HK"G);SA6O0%!MM1!I7'8=LFPC>6]C/RQG7A$#_ #2
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M57$Y"N,J1:F3Q940 )&/%.XJ8U+@\%N>9\W/ 4\XPTRIM,IUM)<5Y;CC?F)
M)"23PX"N/+;HZZLI?B)^TKKHC2&!P6&7F3YD[4Q$;DLLVFZK6^F3&9=892PG
MS$4<0A10I+9*Q4*)%$@DXS]KIO.)=CJ^Q55")$@!R1S7+BX?W^;_ /C<G_\
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M*779&Z;DA5IAL;9ND1?F6<N6:;N)F_6Z]L[1MK4XEJPWE]:@4),R,%)HH +
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M>B3.1Y26/1L?8>B@=&Y+5M^_;L$/;T^' V?_ )9NME+\B;.N-PF]/G569]J
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MH1 $2$CQS]J\'$J,J4H X:BWAX+,)UX^5BE=N91)N-P0A+*U ^7$:2TE1<J
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MOE7AC5FI5F7(P6TC^6I1%.,G;I[/<KK;[)>Y12M]M;;*E@JKI24E0&KX\AJ
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M'0>Q45Z-2TN!4TC\O$G$]/PLMK+!T@8%]ZY;^M=TD7B%N"[;/WQMFQJ%O4]
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MUN04IN.66'FD".NB4BB@(;>3=6OJW!>E/5$1# L",QGDY)(S65"5Q4JU15I
M4*E&4B#PF,3RQ92MTYLEFN?TY[I%RW+9ODYO46/)A6.SWB,S/VEJLK!EV>1-
M#.JT3&+BEL54VME3E"EQ39U8TD+LVVT7%Y.WD)"M.FQBX,7+S&)>!BP?-\P"
M%F2MC<;53I4)Q%0$2U MB1A'W^Y:D[PAW;:F^K%:K9':LFY-N=-8;5NC7:[B
M);TJV]M&0V6;[<;0\_#809S7S"%M%)6I50HU*<*UC<5=Q%*%4BC6M(?#$'2Y
M$AIU8E@&+DX< M<17MKRFY'DX X.!B"1GCRP6P'53JM$Z@](][;Q<V]:[7O^
M%?NH72/?-TLMF\Q=WM-OZ<[9W/T\WQ#FR#'CJNF[;<[$M\ENOG)-I0E54J23
MV$;2[IT*=2M6,IPB)",@(C XY.^#XK-URW"VKPTZ2=<3)L\'B8]<@?<M+OI4
MZ5[0ZG=0+U:K8QNNXQ[KM?IW!#L>]M[?;B61/4/>.X_S+=#[<>3_ )<M=F_+
M''I2DJ1YK7\,.-_O9-?<SZ8JQB#:QB20 S'0!(N6]W/FJ*5E2O91L=4A!H G
MFTCFV62W*ZL*NG3RX[;L=E&RYFU+Q;.I^X5[DN^VY&X]TB;*WU:V56W:4?=R
M)\*7'=3=$ML2I,,-!M+;K890-*_.MYIVUK4_]P;1(&]>,!CIIF9BY$B""Y Q
M Q+-B^&XK1I;3<1%6 E",)2'$G5(\2X&)&+8#DM1.L4#IW)O3'42T7"Y0+ML
M[=5OZ-WWI7*M4>P;=;WMNF-;-O67?MKC?-HMQ3O':$I^%<'X:6[9)?CK6(T)
MY90[V]E>SW/M+\S<5:=6M.W,JU2D_EE$DF SD-)B""<?%8M:M&=(SC&0.3</
M-E('+21AD';).HMV1T[^I"S6;95ML=NV7-Z*-*W?LN"F6C;^U-JQ;-;K)/<<
MC6^2\L6""IIUQ3B%!YCXO()508NVRC7W&-2\KRE*I*0TU)9ELB'R8'CSQ6LW
M>E.GN/YH/Z A$Z<6(,,<N7+-U,5VC[*W%"CPK'+BW?9>UI*+HD3;HPQ=8]@N
MC[#$U<N8Y#>D3&I[-S;2%+2AE+("'B*$XXVM7JS[HM[9]$HQF)F6(D0 !*)P
M )SQSX+0[W*-':_S]K_%-( D', XX\3GGPXK#Y%@V+9-M[LV1NP72_77:MN9
MMS5QW)8XL>X"VN72)!M#L*\LR%0+K9(LHI2@.'S(ZM"D!:%_#VEO:5:M"495
MP9&3-$X9/CU\%SFRBM7LKFO&4J49,)0S )D/-'+,9A6/JG<MQ]/)>R;["V[<
M=P6#>5BAWJVW:=N%,.WV[<$5R'8K]MZ+9)3*(C;ES<MK[KCID)45*"'$:'-0
MHI4JLI5:(,H75,MDX,>&.?U,MQ4L[?\ *>E=DPN"TX2SB8C/P(./BK/NO:-R
MG;0ZA[NV?-B1[_U%;&YYFW=AWB1(ORQ$45;IF3(2E2H:'DVU)'_P/4RM"XR5
M+U@&NLKTJUI<48B>DTQ@781+O$')XDEFD^>"LA*ZLYR,Y>IHTNQX$ YCB <5
MCEJ>7:]S_F^]KU#EWE6P>FT?8SBK*Y"OV]K/(1>KC/E7&Q7-;[MQW<SM^6];
M?-;=94AY% Y1W2<2ZL0*^F,AHK5*E:I,'RTI2A#2TAE#7'4QP/+!;&X].52%
M21/HRB"_3]O#V+8JT2-K[AV9M3=;\J3'MTG:6Y=G6RTW%IZV[\W99&6]RPKM
M9)R8$F1;%/PWH3+\,J9=67BB.Z\4Z$'0WM<4:4=LG&)C.[I5#4B<&>(U,<0&
M<2Q;\0'%67LK:VG"@ )TYQ< 9D/S!R&:U?V]8MU[4NZMOQ9EDB094]"UW&6R
M]=4RK=<H7FL+0Q='K?96K3>6$-+;8\AUIEM>FJE4KO=^IQMKO\S1]4U8LTA(
M1))8 8.2,<^/%<]?5YPK2K4ZDHR@P!#")' 'F&P/-2WL.'/@(W/MK<%X=N$C
M\KV_8+19]HWF-<)>V;-\NN-=KU>(+*S%2JU75],PQ@R4O1F]9&HJ1C='\MN-
MN(7T@;N9,@(A@#'@XR)&!ZK'V6]L;BZE"1,-6J4Y' $GB/##/P"GK8W3"3&Z
M;;NMF]]QHVY<HW2/JO9+UL&W?*OQD/7&W;>L6V]X6UTJ4MJ0E8C+8TD@QFTJ
M!2AW2-+0NJ%I7J74J4A;0EKC.?'2<8D#F<N./1=5;5*-"M*-R90MM$W<8')I
M#@^3<6R6#=$^GT.+].G4A&[+K99-R1LBW,6_<+SK$>;)W)M_=5OG6Z3$=9EV
M]M'S5MNJXDMX+9T$(&A8 KGV6[3W"A<5J4)4Z4JN$2"P8-RXEB,\%JK?N&A4
MK7%I3CKJL#B<AJ8GJW)3/LG:-OWQMS?/5?J'8MS;JBJZ2Q++>I7ES#M*9N6_
MN%D[BW$T\ZW/?EVZ$EQNXI3199BH6%"JZ;6D;:=>M3J4A&$:8)G%M.HC3IU#
M-F)\5E;@8W%:#2E&<Z3R(XR.#@\^!?#):J[8VFF[1-V6FQ1_/MFV-XW3\RW=
M<MP"YV.>=TQ'FIEAVI*6ZA5H2P+4ZV]%6VZ8;S:%JTE04JBK2LMCAIN=7Y6X
MI",8P!)\H\LY,.+Y\5K*5D-HU3KDFQG #5'\,L<9'F<CU4?6./,Z?C:K;DM[
M<]IMV[8M)HN#KL*Q;AL;JKZWM^1=Y*K?-MRFPXXQ&<9;=AS65K#:2I*QCC*Q
MG.8W",<(AA$N-4,O@#L3F78QS++!%W"-G*7FG;FHV.'AX='S5]ZH;ZV3L'?8
MO;.W9[-]N5PM.[T6:W6MJ\O(B;NF6^\O05/%UR.8$N>\J.EXEI*7E'0H$YU;
M/"\N+ZM*,1*A,&'GGI$#%PXPS$?:RWVW1K4;^%:V E3#.[,T@./%S]96ROT<
MVCIEO>V=4K?(WE,LN[-NWJ5NG;<]^?:_D.FEWLMU5!MR=WPKXFT_,W&;MR<T
M)5O#/R[\5/GA^B0O'J.T;<*)C.351*F!3T\"[D YD/B'8AV70VVUW%C0-0D3
MI"9P#O&!?#EA[EE@MDMOK)M;IONZ)<')76+=W4>[[=ZA;1ZBV>=M;:=PV6S,
ME6B"Y&M46^-;GL6Z(UH,K5)=2X8[R6TM**%*QF76RT;FVG4KM&K&3&)&+DYO
MPQPP\7Q5M"G2],TIQEZ>HD-F <F_M45SM@]1]I1=N?4?U2V;LK;_ %_>ZI7C
M=S]JV9'1&NNR^C4B=&VMNIV1;)+;EOE;KO6R+:^VEXH6N$)OF%:@IP8+:=ML
MMK*E7E..W",=+.3K<CW.0W-N"S:E<SJDR;3&,<&QY<,&X'##%2+U'VYUEVC9
M]I6&S-M=9.B/2Z^;3V-U&>WY$L]FW)9-K7.8NZ6+K%#MJH$6U7ANPP+[ FN&
M,Z$,6:Z/K:\ULJ*=[#<JM];SHSG(3D#*F8N0>0..&K$8\5ATJE&D15@!JU:3
MAP?,8<%C6[]RV'=,JXQ%ANP6_9VU]R[=*XETCJN]Q@6)2IUS8?>4B&EMP1+A
M-CIA)H&)#*6\_,45>=[],W=2,-,]#Q$RV(D2S_4".G@LFUH_U"->W,R14A.(
M (PD!C[2''B%SY^M#84[I+TRN5BE.Q-X(C3]N[^N.^/F?/;O-MC0(MRA.--R
MGS=846[L7!+,]):"F VV262!3<[-=U:]U2-(-2!,!$Y@C#A@^'/'JF;&I2MZ
ME.GYY1IL#^\P#?VHENZUWWJ2[T>V?<[2_:I-NO74*[VV/N!39N^YX]IC)@[4
MA0WHLNX,HM,:)+>T+>?:2ZRT5DA8"<8'<,ZW]/D*<1.X)IL8Y0,BQ#D#(C'J
M>2U%3UJ=*C4IF E&K$!L1$G N#C@"MQ-L;QM\%BY7.1:8\IR3L[:]RBW!;[;
M5M<N,"Z+VPQ <NC9 BON1+;&T%.H.*:045R)\[WFA=&^V^EN8IRMIUC&1;%C
M"4N.'%BK*E:<=R%C=@&<XZA(# L2&/++!8]OO<#[M_VEM6<U'<C;9MT=UHMF
M3,L*1>5O7Z]S5E34%5Q#\>4XU)D*90MPJ2"5%"<3L[ZE7H&-"G6HVU.1 C4
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M?EC,RBYR$FE%GYN0W1E>=\VASI/U_N^^G[A&3;=\6RT[IA;7:METG1(ESW/
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M95]3O3NV;^V!UQV;%N<K;^U[ENV_[PFIVQ(MKFYD2$H8W#&M;3[SZC$D3)C
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M2E5((G#5'_:Y]<%'%]A6^U]2=T250K4[.W5L>R2G8JDMN./NV6??;HU->9;
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M-QY+2/I],W?MCH#OS;ULM=KMNY;KM_IEL'=4.%;H;<Y4:-UCW19]VWJYW-#
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M*P64;K<:<:4HQJSBQ!< Q8$A^K^.H=5+]UNBGNJ6SH,7J[M'_*_5"SW'Z?\
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MY#FQXX\LU,8_SNSO2UQK',8BV&Y1E#>VW42&[A;[I<)?ERQ>9$.9Y$FP742
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M3DV.%\NN+*OD)-S<:<<<*)$>%*)34(&--8;I*GOD;&K ^E*$1I#D2<'S$X$
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M@YJ$]F=0^JFZMZW":[/W7U,L4M0N4WIIN56K<3D'<%M=C6R5LO>5TCRI)W1
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MQY5@VT]<KU'MK]]G0KQ=VG;3-8=4VPTJ)Y:R$QF5ZW%-:$J4MNJ$C/774+F
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MC%Q[!P^]'E[.N?43J3+:ELMMNKF*:DF.E"/D]OQ VEDR2VXXT[-8""@@$YJ
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M =4%LQDGC2_XB25)034BJB*5% "!PTFI [\6$X**=H?2I].L5*4K10$\#1(
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MRLVK_$]1N%CV&,E^5?[#WWIO[23O"3+2O;9ZJ9R(=QQ+JQ:H32Y[M'<L_<S
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M(<H: 6:HOGL:&J!ATFOWR^:Q+"#6E-8HXK*^4"D9#!:H"M%<6(  TI8%]+.
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M]9(=DX&GX!FF'B"2!3P'H7:0]IC1+#)&9(RYT<IRUEV@9/(2^/3F+VN&N+8
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MT+SS4GIDN72,&=OS"O,MER%&"OYW_P%02P,$%     @ FUEJ5B+BJ&\%P $
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M_LOL_GL5/63\V?N_QRKZQ3^B'<&''N+(]%CV:QMP_,^G <!WTV,FPZ\%0 R
MX3\_&/]Y,/WC^'O;G\T,_]KR'QZ_N@$\;,P63,>8&'@ C#P,3#P,O_H!!P
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MFT2C[B*P]P52;\LF23$92GBSU7_Z ODP6IT=&ENDM,[R-/G6.(H$6?8PZ>9
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M2BM$+SM6F(X7LCV>-%3*J6XM3(BJP&+Q)B)9C(L5[4@9>78>E4MG9!2C1 #
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M6&FV@:: &W1U]M7>$L6/N%I_QI#PT 16J>M#];1N:+X(0]QZ-J',T:&L @[
M8.]B&F (@=)H([ P?K&PRK=^D6,*@1B_JV!^\ 'S:I>G48^&Q33+)0LGD"!%
MZM4;OCS7"BG>N^KPA/I*+]0N(N&ZG/4L81V9@&V^?)'O FYP C,7NF4]3.@.
MDFYAR62A.)13W1([<-/89O6UIZP/%I30KQE3<QA<1/F'88[24GH@Z]G2 '7&
M 25*B>O0<VAUW*ZH1QZ#86VGK54X3!G(CU364^AOR,I:QH)[F)1&'UADRT3A
M38JRNC4+^/RL%&83^4MU\66H+):[B1L*?[*$XY>K3.YG_MY(\'LKKB[34LY0
MA2[7.R]1F0ZFT/E$=I9&:K6T]$/YW],"4:K?T4>ABW&R--P)2YBP]LU$UX>T
M<@]E.615(+8L]?E@\%B/I@Q@]0N^T_KS53!_0PN]5[8OHEUP%W.;6K_DFHV-
MC#)I&!Z!<OTI1DI^,%6$TM5!E*D^*S#]A(#9; '6..,*!N^PI&B(U^^_K\AZ
MPN@IK*I_H.Z$U.>=^"Z>[Y.$((MF3X7"@;ZTD\L>,"9&G92:M^1OK/I;"W7I
MK0Z/$*3$;^DW#KMZ'FOU7U5\M^4Q_>I^]X_8KX0?TVOM\8K9[Q_;: AM:+BP
M&X52,H6VX,%.M$[A"+L7+\L1"S7[&-HWVE[R\NVM,L]-GR_AOMOE'3R?:>5!
M7G<NCM*9^T"<M!OWM90;C8R&ZHH'LGW72[J>.<PKJ3_[=N(J]>7LEK88J0F_
MO*G\)N5_7A;.G#GFQT4+/^+QFOS,;K"VM-(*F2C$:[""G]V#7"%,FW4'<'4S
MU-+LUT&:"DG=1,:B2) ]W+1,*Q:T>TJS]T-9>6K/R.# +T"",R,'Q[/3TB]8
MSBHY?IAI2W%QZB$$A*?41KERGI)=IM'@=>)Z=\5OX!9/0%MKL<_T$KKN)PWW
MZ',+(MO<B&A]5:[@\MP"3^"\&L,U"D0<)Y1 2"UNB%?M,_!\V!0P]V96S;DD
MS\;KS/3G>CJG9B*KB8(LX@L:P9N09=[U_+'SPS3'/(]:_5MC]L%^,;X\X3WU
MQ-WDF?7<_*U9-;;'I7=@(V/3\@A +J<H(L51W@OC#T\@>5 )Q,N$;URE9RG!
MH:!].&-O@U?<H2!!NM! A$L)/7<6]09$I^G7]-W[>2Y\I.H3!)GL*Y8K=%LY
MRQLN9>N*F>.'RW +ED_0L[NKGD);5'U7BZ<&$<E:V(?R!7=/@KPG7+BRRBJE
MF?DS_<0L<N8AX*7$WXO+.4VT@L'^;9U$D_8E7*^2LPX)7Z#T.^;_N11 P%@%
M6=-U^1SE?3E*&5S[O27CCLO\I>S1R:6\T,O+:W/;QJ%:_?LR2X*A&I;])B')
MY(M^JXF"H6FV)B$WLWX!U$U^](PD'M\[690IN<3$VI2Y!,15 +]XV2UUU^U'
M:W#,&81TK)S6LOBFZ)9;W=Z7=_+8?NJ5J35,#O1TF2HQ(K4B%MTBB>@>F$E:
M')#A9+LHG;N^;VFPDKL&#S)[E@1KZ)[,V70(>99C";3PEB MU5E\M%'0/2-M
MBW6W?W C-1M6K/)EI\W.B_BRN/\)P3Z+N!DV20SILONH?.]&T?"&OU^<N#0;
M-"=>18%32&3@JIA<S7:X_8JG.[;LSMGTA-#T/E'QKL;FN-7<IL+U@B_7MWN^
M4KLWSV#%LV<"2L]TN[ATRDK@N,36O4R='EX3CKC86Q0Y4T'/A,_=ZA+N9"5]
M: I"MHLA%RF[%_J_USR]>E/J94,HMK;B+)1Y15@=+V/4-$#J<@SLK&G>#.>X
M:#3<G#X@9EZ^'>[SN#&H^@7JUL'F;>?_Z2_>"5[.R8!C$36[AK1S3Y70V>Y3
M2>B<N7W($ML[C&T IS7'-4+V0.%%GG<8Y%5[BW<5)CBF<4HP8ED[3LC[WF&X
M\E6-8T1D[$.[R&2Y@NI^'X;113CK0R HU)BGO!L/*6BRAR%CY(\BM4'(T)Y'
M0J#:_,WLT-25N6Z(ET=?O2NG4]]L0PNX)G\1&#A#=3-F"F75\41F/!T#A@!S
MDTV(*L2TAI8)I^//\H\![!%^9?H\Q[&)B^MY6A'&:V(,^1#15?18ZS%LF&2E
MT6 'ZRZFV<BH&X.4Q^\)196?'QF;J71FP0XM9&.2X;/4QZU^# GQ2KB!3G#E
MF&L5_K6:69T4@$ZD6\9HULH7I#>\&0QOY3_/=D\WS+TSX9D%3Q# (H:]6@6!
M]%GC5QTW'$H+[?>WGC6@8>(?I=MQ4;SKY1F[,5[H.:5==<"= HOLLZFZ]?)>
MDA$5I9 2:G]A%*VI56(?1"A.XV!.,C-/F&O[T(4N$-G &">A>1V-HRG]<RZB
MG]GI$^=;X%2%:=:J9I/TG%(6@^PO ',9VM$X[15]IBH/%A?";N^)+:_-O,O8
M 7%7O*I"F%-]K'.2.ZSDS3#E\?)3B2X0BD@&L^KO0@[ (8J%C5TR6B:FWCF1
MW;D/32] !>6DLF+XU\AZ:8/+Q>D=-AE7[H36?5(8KG_?>GJ'O57>]:K6K=-5
MJK<Y2V[:)7=2+J#KRS04S):"4I-ROR5A"Z*?.9A&QEJ$',H6J/"I,2(_V!<2
MK=U&C+J I-YF'32G7LAC#UF4L!E_^<)HC?T&<5/9Y6)P\_K]JTR(5O[UV44[
MT]CWPN)6"V+/IJYZ:M\L''%==4E1&-2GH$^6B>8G>5W)L]J\FG:KMBG0:TK'
M[4GXV_-S!P^:&N&;MPI3TA_>"=IY?/,7@.F]F)OF0/U=F<2$9^=L18;:6(>O
M/3@D[-G/(RI>!UQ_-7H*>LCQQKA[RV8'V<ZEXWM"X^!MLU;-_1!98U9XSI.^
M@OX8_-/L>?%X]!^YS\*77M9XU]24XQ>,E[>ISUHBY0*\Q<*;./>;ML55_X?M
M/KW=VD"&-[BCX]_VSCV%7^1)8/QQ&F0?*CKW<\=]0TB=BS"%[5B;J8E:8U*]
MIB@;^ *:GY3ZLP;A_N3>_F%=,'K,E_.,@$A:4_;8H]25'=&.TS2JW1A1<HXX
M_CYC0\C9Z'7>M(L;Y&7]/"*I(3[3#I-F +^'<OR]>:VGDH5KE4KK?UYMA!/&
MSS4.]0/%W(AG\43&0CM7W!8,SNWHA9F-,')6H;/HDUPN!E/1D^:IR1Q-&8/G
MAQH]>((;2JA(*>O[ )"]3)&N]BBB)^(-5"044H08%NV_8BCLYL:6'9H.GY@M
M6H:R;2U'V--9-.<@9& &M:MN=%<>Y[4D\;KO:NV"H$N':T7YK=LLN;6X<0"F
MY4PJS?ING ?/V[7R!E$DDS.V6=@?GD+B6K!%=C?>G>(R8R$Q1IL/JES*\L(6
M#NHLF,7U,7L+S:HWN;GU:X46P@::!PJ<R\K:*#RR518"P/Y0&1FS99)4>;5T
MW&A"^P5Z'A6#SL*WII7#+ K9NJCF>"W!% 10N;]=D'LV)^L#!D!/T(9U>2?)
M:(6HO]'JRDP3\D>S\Z8\JXG\67W6)C)9X"\,:XE1%'TNDPP*B_I5ED:Y!%F3
MY/K&DOJL/_<B]UGKFDOE^%J>U\_EU9#HW[$\;U8!8P/RJ@^M6QI+DUD^>6;O
M,.>H-A?"2-VOP7$Z.31R%;OB:+W<4I0WMW.037S2-%:8IN"2V?9Y^0$F+SVG
MY(9FJ[N (O<,"SW9JALH]]*7RN&>6AIYFY!"B UM\>M*>N8X,1V67*Q-(-6Z
M$H 603#2$^WW V)UL2]IKU@UXNDS ^=2K#%HG$6$#"Q"&P5>45][?@BBU"63
MA-\$^60V;;9?]?X*M[3%1]K\H/ZQ1=T7*E#.G0FXGUUTXCBL>,C?A9G/R.G^
M-9$(F^FY31O]*[\ ;12YE8<IKYD\_Q^RWCLNR3=\&\:9"_= T7+G0!,-S)F*
MXLZ1&JY24%RXL$S3RBT.S('FRMR32L295@[<F)4C5Z[4RC1'9=KX]M#O?=_/
M^WR>YY\+N+EO+CXWYW$>QW%=YW7QR-/VR_"E<QD#?P'Q1WXMO][7WO2[U$O?
MC !=)JUQ"H@SV\$\[[S=9^B=HP=!P9ZV>F<CN_D^O"7HZSS[6-+M__G-Z-E!
MK9=_KHS>(R;\7_/.J:FO 0*=^]?B'V5<?&40CJ0H?+R4;W^HG<QU*46JZ=37
M8A?Y0#C1ZK2Y;41O("OS&=0JI5VIQ[P<XK%[WZ.&N)9"M6W4LW9@0:%_;1NX
M1,9R->84+FC?"QS=N#[#QRVFIU;2+Q?3UJ0']]22($2"'^('5SW0.NQO,D2#
M34/8XK'CZUK\D(46W'-!+8!2"R7HV"<0L-T^F#@I&8=E[GNRU+5S@&/0#FU(
MK<W;3QU9/6-<3E=%U@>2=\S]>[G_#:&RQ->,JVHV4FAH:8_OKNWCDUIAXLE-
MW#HL_JFZ'BTXZ]9  .H&0!2^ VM@,$(1LA<VQIJW#N5OP37.AL.)&:K/V7HF
M9%ET)[+GRR7Z4T[X5^3\ 2\K*-&V[\7:)V)<@OL"(N#,J^7XC+C%Z79K; Z8
M!+\4)4'X76/MG5,/%@T>\NJ.@#&AETY8-'N%^JPQUI+6-%W;8I] -F&XXOB0
MGD&ZNP+56"K078;1;KO+M*R#A;L%=P)EK(O,H[(.POF%.^2UY<NY\0^X&"*,
M\-G*=!X"4Y M0)DNP=_=DN?F".I(N!]B9">]6,=ZLU!H!/ZI3_TK<S2RVAK@
M72\/Z/7@!PS8[W,4L+9-8&D6-0")N,<;%@)CL+,0[S$8JS5@DWUMQ[19=83S
M&T<VKW'_KKCAOL@%])[I3%<2::/IZLVSR[T*.6/P.KE<'8M+Y@H6<$5!!/!#
M\'_3&WC[>TX;42)RSFEU'X3,+&9%TY<CX)U%A<3VI5:74HY!\4(IHV,5%YDB
M4'(EU;0'RFO_\':>HN. &!^ZK?Z#H)JKAL8R;-&A ?=($1BAY*5/N*5;@P&_
MNEOSW6;%@KZVA2^D)E5(NVG*CO>Q\E^Y^O9F4]N,V]-+$GY%T[IW5NK]W1'A
M3E/VMU5_4?]\HC[@ULK[],!=1RY^@D?#3W.5G>DS_@]X?V7]S@N[F=J"MA6\
MX\GDT%UQ0XZ/H=_:M$L,8#^RE[GU]?C:'_+])_.M[.!3$6Z(W8\W@C80[_]2
M>W ''_W@SOK^</K1[8A@=Y=/\X_]OCX</"V\\@WX[EN;_QO;?;]/<<_,C*]!
M#4__'_/9=R_<C+P6?^\;GQEAB/^=>V1LDRHU]B_@>@QPT;O>]?F44QUD:'7R
M3JFH2UYM(BKRLRK8=^[*Z;YCMDFL_WVF>E1Y.PPPD$'>&:\$#V2,MEVA0W!K
M4K!>_\ C,E(K5?#[W,R<BTLLT05$1'SFXY.EM)M!AF75;F1@OP^,A0JX=7M$
M/IT@41F_\V:&;R_=?*2%VEL7MZ3^[F/7EWV)+2C@R/UF8_]+EJ,LMO@@+8M3
M*K@U8*=$DM$J!5? L-;U_Y;!(@5AW 5PV.5WH+@Y\(POEOTU8.^9UZ#0!BCN
MF2_6C8YE7@A9_:PXH0DG/$/XM$,%R'RASWR6@-;:+'V^0>:DMQ"@+--J"ZY@
M G#BI F&$^YP@<]*3E3"((O*&$(O#S7$ZCP3J=W:=]W@?4+!Z"'85(^-QW\!
M*C+_(>CIV*R_G989J?E\9JC]W.%A,5.P<DVCN[)"XGH :,6OL:"/:LP_!F8
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M!(%=18D&)R#W>;3).P?GK83_;1OCT^[/MFGMTQXL<.?>%_NY%ABQRKH@<AP
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MH*8]+$5)U:_X S69!8'RWABV$IGTX[A 3,Y0PP:E2#Y8KC K9:!8KY/LRK/
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M!\D@^N@0S"#3\KIDB0#A)F&CF2C.LA?!:V]?)UU@KO[D5E1J3)%^R3 K@O=
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M^AC,(Z:$Q2TPU=\)#'=U?2X>7RX)#PN% 8>S+Q03/KO"A?K IM&01343^K)
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MS3"ZOL%.=VN;IDZHRT/O2T@];?_Q5U/3I5]U;B@G37^^7O:DY.-)(6;SX*R
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M!-.,\LFI=0JLSG]+1">YK175\H+%:5AC%]AD!R.VZ*IF3WM^&D0?PL$ISS+
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M3]XO/K^T&/!I(RT$B)9J5Y"T6=3.A,P<+I<,:*FBY@"BP:,EOK38Z2-9,$R
MZN@:;1&I+CN<_!<@"Y9[IO3*C/0T.BW$FN-8_B_@)K/[U_N;S[L;;A7Q6/H:
M])AP;E[F"8LS4X5 >03TZ]"I+"3$&;"@9'F@5)JAL3Q\4)2\(8A0_E(Q M^0
M?YO-X>W9WE*N.@(_B<G;TT_43($%1X8T5O<R0G)*P@?_(#W[9C8H.WY,>8RK
M!M+ ,)*76'K2\5.8\@9:EM,&WEQY+DVRLB$SA:$W&@@G4SE-PAJKYY>;>API
ME\$W%(NL!G5N?NIC*!NGOC\C]CF>ZZ55SO^!A0K/1.>,-TTHI'E^\;60T;AD
M8=0'X-3G9RZH&M.L5B3/LN3J..LIZJB@<X=E:J^05%(,]_E_7MER>)?)I*F#
M;#7Z1<,_* XSR1Q>ALBVVA2,;L2(3OMTT,LN_P7,K/WR?1)5:#XD"?ME-?S
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MMT9SN]G1DU?!LW:RKZ8O7NZ)<8&D%O:V86F'VJEB[[]"0B]*IU2(UB9'N&:
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M?_T(/?P+W\4B%CN7G"4_Q=:\VW?6[.S:TBS)LNXR#)/J43\CP8QZ^-%^TMU
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M_L!#VXJJ#J3R(2[CEG4F@V7Y?0B:I1P"'''C<&>*9+Y12+!@I8#?D*3(8K]
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MRS"S5%I/T$<359*$2XN@[S_]S6776T7-K./UP@G7W$8T> 7!DW1?PU)H?WJ
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M305E!5ST"+J8S_P;0@G),LF2ZC62JEU+#$&+#(RJP1K<ZLY2ILPRJ\-\ZNI
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M-FA-Y#1<EF/IB:TX_.#E0ZV4Z/4 G:1]@H#5H:T)?S6L=4@,ECT2F$A,E\$
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M CFXOJ +RVI]Q%IFSG'BKA1XFLTHLXI[$M238(DTVL>2>(KT10!OF:!&T=&
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M)]4Z#S*?@VKQW<NQZI_ Q)QLOVJ*0M'QOE5WNUJ"!:O[ ];\]P,R.[XBQC
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M8"UI1P(D12TB)S93I]IA%<)^"\9H-"!\CT8\;8,]Q$H&%%X7P*CU9K,5B!I
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M@>/@MJ:+WM1@3_FNFR>^4=MHVVFHE^//UGG: RRH_*I=-D7"/#\&P5%AN>I
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M8(BRNN/^#Y14UA[B7&YIZK3RTFJ' ]911SI=[''<YR$W"-G/%T8\!BB 8-E
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M@HC?@_))+6"FG]A^Z_J%2MKBK[(I1%X-W:&,^TQ5"M _N$6 5\=S#E3(PU\
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M,AVP %GA?7&AAH<4-6K[PC<YPT2JWQSIEMX20CBB=7-TYNU"O(66#^MGEQ?
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MU.MEOO@RB",O2LL/.)U!HJ1;CD+<9R U=RAR(4I *U/PC N, TW $VZ3$LE
M\P*3>*;V",M&QEYWB8Q =1J)2#3^^3P5_,EK.D2D3',:FD!7@CZAN#TDVF^
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MZA.?V&^K"9X+!6* I6G"<X'>X[#X09'7@0XPKSAS+I+L) BEH&=:^S2^D#E
MW)A2_#"[47?,"FC==:2^]K-,B-10NPGD:'O>[F3+(^ '@C8\^,![*>^^Y*EN
M_:SK&1P(KAFQ\-$O!7?YELL-\USZS1D;,]6]YST2PK\I5:D $(.!0!-0)9&#
M3Z)=9<#62D<!'J;;8_MRQZ2!XXOL]-6F#'M-SB'Y7C8UP%<WN5J50LT94GJ
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M4$)\'Q?;7 0L8_>90X6G7<OT-WVJSJG6<I2X(O&Q=>*1^6SD2\%DG/[VO-G
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M]!I$8*-[X:/)[7\SNQ:;MH6(O8!4LF6",6;H)U"G@RZ2*:;130%R71XRJCY
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M#<M/.\2*GL?:LDW&[UTVV-22J]<&=:<#+O\"RESM2Y:><J 5MQ5G%J6NP#_
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MV,G$@P]C\L!:J_>-X>K39MA6B/7B>UM[_,KUPL[7X+B^[GT/B-:%\JDJ>)<
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M4B*4+*->TI1)>+4+]@V;L4.69WR6G"2-X@"2C"_N"O3IE"MDU([CZ;"([2]
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M,0ZMJ=4^(:ZJ=!(J2B-4X<^.+PT_$#GN!)Z?W?%R,GSN> /6D*N65)38?27
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MIIWCA"(DV&G]<+#3/RUB3<9PZ#:4VD23X<"/>%FQW-8F0GI0BSP9<[SN G]
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MC^W:90H5#JKI@S*JJ!;-Z9=:E-C>AV\O&>\/?JH&\=5]0QRQQ&Y*6$1*D)P
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MKA9'HT6$OVJZC,Z! JZ:W/*$GUM3)^2Z+G7*#*;50%/VD.8B"'O+V4;GF;:
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M(_D_^N863A[NPD#@O[UP<%96_H^!_]> .3BP_IO;S5T#;/5_YW;3\G$&LVJ
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M?T#G!%%Q:7'S\ 5K6(1H6OY(<I5LIFZAY?7RYO]K"CP<(AP"/-)?$Y'^J0"
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M<R0,%?G(CA$O37<.DXDR;?63H@Q$:/[ D-!Y/WYC!8YZH=8% )Y%;W]>D[V
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MQV*=>/-AL; L?D9$RSAPY_SSBF'XU]TJ+KI,V6KM >5*:XLF-$; @7"&DOM
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M8\?8S>9AOWFKX(")[IB\6;XL=VJJ=R7B+6Z8;G)>^^B8T6-LC#C%$59Z-I+
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M=GFBCD&A0N5+#/;<1DJVI* $)WFU;S*QMQPJ&FQ\>CX++="QM)DX_2=[3S$
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M,646HL2?"U&BM7=<,.VQ_9$\NN*14N-9)6K4?,C7^6JFU$P/7F.NFS<&0]0
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M7LN"GY_OZ!41MQ3+<S(27>9IPW/LUTIHU%?.H[I=UG\Q]&DU+M^'[>IS3%5
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M>(ZS7GUI3>H?72:;,<O?/:G=+1NL86I[Z:U2SKE0/H8L9)7+E(9[_ZQKZY-
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MPO\&2!B)J/\&3,'MW/X2W/\-L'@SX:/S&X I(O"SG6T?06FN]_OTXM7N[F]
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M[B560-6TXG\'S<M/3QFF&"EO@N9V[L(L!'D1*N3/8,.M X_Q.ANJ[0+&#<5
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MV!>:#O#41)-I^,B0YO0Z^407@]YJ/Z0V8[FH+H-02IID9HMK,\?#2H#U>]!
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MV/;;)0#M;PH#+ ?_K"&HMTU & #J_P[0_P*8?\(_<']#0_T[YO\(;X, 3$1
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MMD\>_=G-NS@'4U0')3X?+F8O'4)&WP"WJFS8@P^JIZ^&X;6LU;><'%M3[0
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M:DZEQ%7.UCGD$]HJ]1YOK(8]@^V$CRJ^0#;B)V0(5)@VSI3KS5'^O?C2.?<
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MAYB]FG(B[M&99XE,-:8^7M\VI 8N$/RDS1,5!  "C0M7WP"=CS?I'!E4=>L
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M? 9"KYENI==9);O=TO@F.S/YW)>WXID(BG KOUO++AX<[ \:I"9()(.@$<
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MQ6S>2F7>)OO@ \>2)O6F0.&^M%S41B;]H2_Q[FF5G_<NQHQ';),R&OIQO"M
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MJT^HC](WRE.C7S+0/BN!0'H9;A7=+/X74$L#!!0    ( )M9:E;2*Z%\D5T
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M%(1Z@=B.0S%<JJ #^^;_$OE@'_!I)-1S:R#Y 0LK"],S^PSMI:I;;X57.#<
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MDF6U#[)S4\[?(R,%RNQ*B50?&\:["C'*MGRRP$M<X[(1FIJ_DND6VBJY>&#
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MS2]IRGI$,TC>"8OUBX^)**A*>WU%3BF1N6<Q%UPV"^9)]_4VO5DT'Q60<1&
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M;[4DA=H)]_,[@#S3K>8= .MQ&QQVGGX'V$VZK9X,Q858L]W-_A=02P,$%
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MU25G8WNZ&)QGR'02>9N<6L91T'5A;7P\;>E>)935W'T.K9NO2"Y6U8P4E3$
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M[Y1V)V'[=]JS#9655Q+<(TZ21'M$6U$FP 3IU_34TSTWT^G9JP2?=XI%?K/
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M^5R7,1:?0LHE,92LT%YZCLMWWTO.29&1S;WQZQP_??W'^DJ.QJ:2<9AW@W2
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MW"+#UF>4&C\M7F$GBBAAI6-JICJT+FY(SK]S&J?M?[-I(OCFXBO%'^XGKV>
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M?EQ(X<99>*->2?9.$<BC>4\HX(/09>.1_B3D$I[<JZU@%<LYZQD=,ME0=;3
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MK(G+A'Z+$<H5CNLM$H8N<E>G[M E_-E5XZ^W..UT(.4#]!UF_G?!EMI^A#\
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MF$_.'1=[#M-HNY5?=(D,1/JE]VF,O8G#6M!@;W[/'#VL7WDS0R3,+(.9#*T
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MDW7X'?W-<7!R;3BWU0>^J_TU'0A3!5::70;U_+TAE^+V>M9<H&%L\$0%KXG
MDBQFS3USB"H3_>[0TY>5=%!5E'[P->OF#M[PVFE5 9LN*WN.#5ZTW'(-FS&9
M6)RG%KQL'^HNOB0B0'J!@ 4-;F)53;YJ]-!+%:4PD_9Z-^K</TV(H27#Q^ZU
MBQ<G#G=1$^!.@O1VY)/=?43#O+_Q4?A-0,!3R?#J;PPJ6:0*@@L-^<;:0!B
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M9O*F[-YK:A[I-\:_'V0XGY?_%U!+ P04    " ";66I6K3\8\>]9   L7
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M>K'Y_]D"X/TU')48C1CP'/#I4%F;6%3E.Q1%0<L&-:.872B!": +V%%6#@8
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MY(O.C:NZ^B4SUZ>5*1)!TC?\5.WR,W&QR<[:*1''?^.<5/F?X4ZJ;,DNI&Y
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MYP':/?**+!]U,I@6Y&(M)*[>[0*!X["8D%#G8],!5ZD;]M)G<7.3GM8'.78
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M8 ];?BM'TN2;U=MO 1ZV5KY_1]5[Y*C]'=_:ZDKG=-Y]S7C%_VUSSJ_\2.E
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M-$31$T1-$31$T1-$6MOFGP-BL[%>9'QD6/KV7D&X"_:K"1G!Y!2;)]*+:55
MO1'6%-,@$;OQ#I4  3<?( BJ-L<EO0_2N',NZCNN>ZSU>QTJ?DZK;H.3K=DA
MEQ;2D+,-3LW[-4/$O6D?P415+\I-4@G25((&(8Q1 1T@@]1V5!!'=4$0 ?2
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M.HUCH4C.VBMQUG8^K)"7IDN$%8T6*BR1W;=A*BV=BT+(-TS-UA!,3&05.4!
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MJ3GL"O0Y3'9U3R*9K#[/RT>[C71RR@- 2"1!L\/T*]G8IMAZ1VVUHAX!HH.
MN]MV'(_\>=KWX9)>/-X9&.8[]RVE]KC1UO0TZ+-/[C<AR/<9ONC(,;_R5NRC
MS@ P^'S1O;(W]NZMES15M]2*BJEN/9(QK!E'-Q.+=@T;,D!4,!U!1:HD02%0
MP 4#'Z$PW'8-QU[#'@9BX\>-%7QQL:T5[T: !7XT"\3E9$F7DR94M/+*]SS3
MH*N))H/PJ>B^O5RH31$T1-$31$T1-$31$T1-$31%C_GCC)B/D5#DC\AUXIY9
MFB=*%N$08D=;(+J$3=+*5*DIYAGUB(F:N2+M3B(B*?5L8.FO<WLN2T.[K2)F
M_P!VGG/&BKN3Q\FGF"IIB=1(T&D1C=&B #\DKZKKK&+(*% =NJ/6<&/MOV2>
MC6ALK3WZ%5&,CMU6O64C).#D%XF<C9"%E6IS)N8N88NHN1;J%'8Q%V+Y)!TD
M8!_I$#5G=<+XM2B:(FB+Q,<I W.8I0]&YA H?]8B&B+(C$7%7/6;UFYJ+CV7
M&%7. &MMA24KE313W #K%EY)-/UB! '<2,DW2H_ 77#GM;W*D-<>RW+\=/=H
M8SQ>NPM.5W;;*UT:F2<MXQ=F*%!A7:8@<IT(9R)U[$NB<NY5G_YGX0;$, &U
M0^4GH.@5K8P.I[K9F0A$R$33(5--,I2$(0H%(0A0 I2$*4 *4I2AL !X &JE
M8O+1$T1-$6,',#*LEB?!\Z[K"DN&0+Y*P.*,;)UV&F+'8T[CD.13@4IV$KU?
M82DU-.:'!JOK(N@V;JJ"RAUS=(@4=%+14_!:XX?,5VNLU@;$<M/96GY3%S/E
M'C;(Q+;FC(?$6[W(N.)[CP.(,M7E0B56MLQ8;1A^_,Y<[1TW;I+O)EVL0NR9
M3 7=!U/_ !5ZX_OV3'O*E.N$F,IU]H[Y5YA@FF0[KF)[,X6NF.L>UQ)L[P+6
M,7.[/.-F>3NT\2D(\58F&<KMHV0DD9!YY5VU5(0+?T4G9^Y27EIE>LT&M/*?
M4*_7.7& \/S[)Q>'D;F>[%L3"M9$DUZU1BQ/DY:C6"$E!C 1%UWWR+=\Y*8A
M&W95* !3XT5(HW/S(E[959,F,*74W.47%#/2;9;KD[CL?T4MZA<@6%&LY6=F
M9$FPM[:/H)FK#R#=./FYEYY%-=LHW,=4EH5I6WF-D3'%PRG92*UV_&)6(>Q5
MZJ0.2O/8F3E8WCW'6]=C 6L:<ZDI&JS]D==P)!NV:'( F6,@X$ 2T0-JI,OG
M-K*5 =2-%D\9TIWDFM7O(U:L,LRL=A-C1>.H6+<59?9%8/UX-":CI^UUO+[!
MN"3DAD(X8V1>'.N@@FFJ0-!Z^BS/-E:21@,;3BV*LD.0OL SG)E"#;5>:#&O
MF(>/EG#.Y'3M#59VLT%Z= /4R4H9=5NH"13 *?67-%IGI6?LXN*<C36N9(]G
M8L_U;C<I%Y,L.9)2Y5FD(7Z<RG*WW)=HF_43 O'Z_P"2:Q5$J_#46*5<0\5/
MJ-AC7RJA'727=!_12)E;,.7G-5KG):&R$:N+WI[:(>'@J7;;;<6=>J^+(>^T
MC+TS2:@8\)CG(&*5V\"KD&*N,HW:2'=4C&)^E)RU6;D '9;2<'9(B\B8Z\[
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MD'UM'Z"^8^S9S]"_Q;\?\-]>BA4SCS]G1/L-^L-B^[S]G7TBI^1_$/\ F/\
MB=]$/ZKT73[;L4_8-]&V3ZZ?;=^SG^RG]V_YE^CWT0=O56]7OVODC]V7Z:-]
M7OVOZ&6^\C^^OC_P?5HGX=U<[?[;9C[#/F*Y^S_;;]6K5],?H/\ +?W9Y[1/
M1?_94$L#!!0    ( )M9:E88$7:.;T0  (!.   /    9S,X,C8W-V9?-S4N
M:G!G[+IE6)Q+LR@Z. 1W=W<?W(*[NP498!@89-! @@5W=Q+<(0PR:(*[!!T\
M.$$3"($DD'"RUOG6M_=SGW/WW;_OV?6GW^J2[NKNJJ[N?A]7'W<!5*I!8!<
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MBXO^,4 4Z"SBP"+XISN"_X^I_J?JS_KYZ_/?:_</\N_5#X+^6?*^?];VXR6
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M@8THN&3EKTC(Z2I\B># K-+K.ICC1CI?=FK<@S+^.Q.VUA*+R;7]);W7'C+
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M0BL)O?E$)*,SPGFIJA698W@V$28B4$IIZ',6TZ"(5_X+=Q**TL:='4N%OK)
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MN0XB/HQ1N\1V];4SM_/Q!T%B!@,.,S==DHCCX>7#I!#FH'+%62V$8A_FB8[
M=/PT>8L<B]IVJZ9=0_FP8A% Q?_39<%E?F#'P#"T:YT:]L*!#(ZRRL9?4?""
MX5E ^K5A<&Q=X5/^J*70[1F$SXLF&58QX<[;O*CX1,/KGASKFA^Z)HNUW>%_
M7RHEE+O0N'@5S%DL["9#LLP_+&V"T\MQ%-)<MB4BX]JV7$[B:Q2J=]+\'0H"
MQ$_7:ZOG*9(GS;%.)-$ ;-5TVWFZ=R^6Z.P@'M86FDZ@Q-YG!=?FV.4E1];/
MPI2)_!9Z,G'#J_G#Y9;3B"NWWCL>=X>DGG388_0(P(4_?CP\=Q9:4T'J\O=5
MF*N\+'!<9?&2#^A$YEU;K*LHK6PR"*AS.T\-ZF6$EYH&HK6O37!ID^MNM@WU
M6KZL='FRZ724^6U*U$*5S[^]DG: (V"2G^XD0,]2V@VN557#1\.K7;S6+3KH
MLK%_(9W8SAEJ;-VM2>\0Z)D>G>+Q878UZ4-N7('%\=,[E>^5T1<A]HT:7OP!
M ?,;592;!\W2H%[^-3Y*_A2. X_+ELSQ,66YGDHB/5912;G&$J VW=LYVM5;
MWR7YB]U]4;XZ*;%'0!T=:S9DC>5,>\2')#.9OVNZS2WO02+V%&\K1V[S9] 4
MH\GHOD-F*%YAU#)KKDUCN@XIGPBX&-)7Z7(B=ZF4&W-[M#XH,;F15.V?G+?I
MWV-;NI#(JQW6Z\69FS4+[LA0(J6AX310W.B+QBM4"93<BBD973ACY?/NWB#>
M/GAIS.E[=.;!\?OV^'**-RBX^1!X*CD-E^P\%Z5S_GFIZR"P1]^[*=L.M?E"
MT5U<QVTA8VKEUD@S7C7HSF]<9Q0UCAR7\MC%,'>YZ!XQ),_BNB)4]RQ>3MX"
M?M5T7MOI;<\;\O&2=>'>R=6VH^9S>2^5 EF]E;H:'\,2OL2=VJAW P4D3Q-_
M[-X.X>U$7T$"KW$:+UF6CBA'F-".QL?&6!E6M&G7K5EI@K@IC4PI_DZFR(4V
MY4#1"!G/JJJ'J0X'C^C-QN>: 9R8G[$7O$@K*4Y<SE#4WYP +U6,)<-O= #2
M>_0:(QM'$K^1PS:4P.UKO"5!/K& ?)\]":+0%)31V'&WGF-M.%)2KPBZN?P6
M<NE1W3]'%;2T\ FNIA9+R*M=P"-;5B<XD=;5G:@_= 4,E.Q6"G5PB7PUA&.:
M^DPKA ?$N/#5SR.T+X-#-8JJ*-BD<7"RIZ0EO7Q-T;#"?417A38BP:WI4\M'
M"SP!BCF><YT,QZ:R1!HFD7BOSUTDZVOYY2'4],6]PIKLRSLIE@,IE#'=DJ=X
M0VX?;^Y\CF&(SH CEE1AL%B7L3>ST'[+KSW>GGGTI)"#OLX2B_W6%A%5J#7?
M52Y04X/%:./29.2;^Y'LZ(<9.+:*I?G+E>;<BVR)=%.^Q>!T:EKVG)<B_?!)
M@8K&;17&B3:9 \M*CKP\BWR__B)0L?16CS%ITNA%(H=S2/%BR:J(!,5ERD=.
MOU\P?5X.MDSVQ1^MHR /SR+SGGP:FM(^O;6>(='L2>C4W;[,MW*+LR10^Y1S
MUXB5J J1,AL3@+7-E6-;B?30OZ=V&QTJ8"YAV^YM\O<)R%UBCSVKY5;_K9/<
M&[%>X]U#-KBXT5E>0P NGQ@9 [!L>=;2J520D^^J7&3M..%0M/69<6)YVA,G
MH@J3&$;Z!XW+K:YN7XMWR<IA(/S-+BX!7U%=61]5$ 3KM28C:\%V:'>!XRMZ
M9X &R@7GQGO<$!G8!9Z+?9/Q?G-U:R(Y#)P42<5> +F?BIC"E-R'%&_M+NSR
M#?L.L&%1"O?;Y?-O>$))Q)<RMP8=!N$I'O[(\RZ"%K8#8I5(!]X X@6]C[T6
M6G88NF1+!OO]3PR) <B0[C-"+3Y/>W_Y_<$X5C"G[@&A/^!:.!6V^5)Q)9>T
M']6\F%^:?84O>H.?:8-ZWX>WGZ:AB6H]\W?F1UJ+^>NN67RT>":^0#?JWS-=
MH2#AK*J3F3HB0J^5FM#@I9J'R36WM[-$$'*PG_H)F[.-1O?9HK#Q7AHURJ>X
MF/8MVE,&X]I[.T]DB/.&K%\^SGYK5?<,A!IB*1,UAGH' :/-U.-3+#:]$!WV
MRPQ4:FVY^_QN0CT9D7-;FA5Y;9:K"5T8=%^14([PIU=/B+8.X'Z8#%570'ZW
MO[R=@0E$_/[:G?UK-_4WR#_U/V=LZDF?O]QS?TR!& L(5$((H"-]OA\-QIN)
M3" M"/>OIE:: S/R&G49"HGY6+:BKS_$DWF4_N3F<LH0)]AK_>0UC.FS,3**
M!$%OAWP\@W:"^;JC*YL3S)_$!,]E5#Q\^%1T*CPRDZ7?X?6.29[V]AZHK+I]
MOZ9?LGXT4@$[:"L>F)\AQ<=]6%%7E/?QF/&TZT?J;31]Y, O=\2U 9$RFXI
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M"XM]OZ'N^H0R0^A6([E1OZ.9VZ2DZN,>AV?0Y!P)X7)&:CI54 C&<ZT>2%S
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M)"$!:,0JN1Z'+'FQS G/=H=248BH[?8W)/&WXC,QNCR9^X:UK&S)(AO94PC
MUT16.]A,D:4;U@%0W<R"1!]/F;5S4>]83%W2MEZLMO:A26R8)CJ1^G'9^:KP
M+Y9E'5A*@[^%5 'K^&A:4YW^?F$SH$V98&ZU7)_&,0 ZC(2S+U?/?\JM%P3<
M8,(/@+>$O-$!F^/K2D",>: H] B-.+G 3U3=)><$FK[*Q;W:XB0!W!UR7>OV
M,4<0026/_!J[G#8Y2!3,NM"SEVO7BVN7:VN;W4\LA .DVPTF$L^SNL^W9?2D
M.9BR)KA6+NM'DB)$E9^V\+E'4^RL"TT3DVD/14B7??D5T?R:N3U@VQH ;-*:
M7'_1R9HB['&+ANTLK:.+)\O-$'/"H,M2G/AIU M_,68S-LBQ^;+Q3BE'$W_)
M5ZKU*\?R3)A0\'K%RB_7J1IDN_H/"8AUP'3":-?$ZO-4KQ"B>>SO)]Q4?AG9
MG@Q+T;IMP2"+_(KX50EF1>SX;!$5PE6#/>G4RY?9?L?![Z00\C2CEWL4F,*7
M*1F8$E&6TRZY.82LVHGJ:=S ^3-&DPY:]D2W8U\@\&MOW[ESQ>AQY_+<X7MC
MM,T0&QJZT$H-R3LJIUY=U&)[ZH5Z$S=4QD:J[FEER:HSP7G4Q-P7V2Q<W]82
M *AUH]*1*/VZM02;ZSU>;ONCO)#5]56G@:8X5H]G/=]G%U!@[\PE<QFSU234
M/F_)(-E@M CFP/2)=#W0<%-Z?QAY=SR>5]D'&GG5-0'9<I+;*GUV([PN?/<K
M=ZW-@4@4!R.X>G0:'W%%M]P;IR<W;YI-Q\H7"100EI@;_0CY0(.V<*BHY];,
M;,2LD#MR$KE1;D"PN&;'2XI0VPO8I%5"(K @'6>]B;:N:0*X?K"N,(G\-R?+
M&WJXS+GQ2:_CLR(+'->-:-RESG7:G)82>J2H)B@F6U^.K&.AL,P4MUN<U"C=
M4,40T7LT\UWX4OBNVJNM>50GSX^//6D_#]&V&T-;1XJEJ6>1U[?T]8QN#Z6/
MC7_WNCAT3A\?4A=1DY1*!=,I%^S089\SD1\OG9H6L/NRE.I&)34L[]"0O^+#
M$S594QV!,R?YBCO/$_%HL!@7J3PQV!WV_[KG(SE-(4VG1H-]T9(FJN.CAF8Q
MNE0@1@ PR7C7L.(EV'G=>BR*)+4]$K!OLJST"<V0_2(0DDKBAD4"I_<P:Q13
M^=_OJ?\O!46^KVVJZ+*'%,7[)-A%V352SG-T0RX.CA\KO']3B[")ZS ;\X]=
ME'RG&^5B.DTDV8U(WQA5)^\LSL[>S!3-K&8;/PZP!&"U!9!O=G5.N!OYUAFN
MA#1)R:\9C;<_)(PN=N-U@?WMWMN<?#]C=0R=,!KWF==OD&IL#VCAXK=R6EM)
M3V;0'$_T)Q&BQU@IJR:\JJ?OH)\JY5>#OYO$_6CRKJOY(.F8IRA)2UNQLWZI
M 6+*[^]A,"NMI[HSL@>F.GHK0!00A47BZPBF.&F*VFMRKY/TV5TM+3KNM=EK
MPFBEZ5&I=:K_K3G0OCD74UTFTG4^(3*60Q>;Y+:BU*Z@3$O%0\U"P<NK+IE"
MH<M9NB5EZ*!T&CZ\UV(B9GYMJM>%/S/HQ+.O@\()'A?K'K;;=H7#QJ=]7OB5
M*,](:!55/N\XBD;+.0^K/O]LM5C0RSM!R08C9.<[LI-SU:,%LK;E\'A7AO'$
MY7N]5&90'3-S\-E6[!DRYJ$T#]3<1*:=^EA:\6SA=+)W7*&D.FOK1;<:5:<T
M*3Z/U%XE*V U,^#7^[8^NX62T&*N:_+#?$LW;ZV@+QQ.(1D1/BX(K:J??5=C
M7[QQDK1_X+W5([C"[@ ZY#;% 5-S7M3JY_4F!@S*30DT-(V#-OCB9TVJG_P@
M8Z:\PD',#6U"OP0][3RFW^MEUY^3DC;==E*J+);.+MG-YX66NY&7S=.)M<^J
M#N\BC;@#UK!C,K!\"]DHSK[G/>D.&S-ENG3U[0K$!"W9])N!5XH4K->!+^<D
ML"VMZ8K=]YG%$QJ"9BAVB;CGJPLK"H/N#0U0^2ZZ7;&F&EJT7-R(!PP ZH=U
MDXWW36_'H&:XGC>], SGC,S7U2(9[=,?5R)28\+?.C5D9[ ?C@+E7SL%W:I)
MR]!GUP,5_1)^!)/-^F^PY,^R53^I<6^] O1I]#N>T')@1D7F;LKIM8#ZA3U$
MUA?Q0.8M!\]=)+^Y&!68TXUD,F9GK&%RZ)@[OOHBL&QJS:;\CH5_,U.CV7W*
MYG.)79\4I'331P93B@'GH42^>00)Q^%T1TX?K"N3HP.E&RUM31V*H[3Q85(K
MS@/KYZ1!(R(ZQ &*Q)RFON#K'Q3D_%>D<-%&9\BTV3;?8M8XS6^[K%*=)UTD
MO=L!VB16@Z6G&TN_<@G5#'CPFS,TZX2UAW779L.SXGHU,99.QTT7#^K6;(.M
M4;^D0ZSRAD8MR9SCC\K/KIM=F:DUJ-X(T*I.:PR9OYYHU?@=R5=/$6L@QY*N
M\(P\<?6_].6_"B7B'KN-I*=W=\*=HN2BYCS"+RC3G]>)A]1UJD[*RB8UV&S
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MXS_7W7>K-]95+0/6'/]O @!02P,$%     @ FUEJ5JE$@0\":0  ,(0   \
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MG.CF/J7D4V<(LN:=+E?]R 'U6P;_8QGJ_QM#GEP2&>U=VYLOYN?G=OAU.%\
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M6.$!^W52% OT& T<6]MV9R.]3>!O(D%+,W1,WC?T.'&LT4")["$+/T-E+TW
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MO<HXY(<K/1H)[00K@+U'F8\9J)G\NA3>&N:B8IB<G"B21(\T&[KZ0M.+GCO
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M!ZJ5SHXRJ@O(%:N]"Z]!KX"%K#KY%@+VZ U02N[, =[W,RTQPL]BP"XH*-'
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MD],T]8OF;-O,UV )K]EH;0-M/' ^T/XT9F:/6RDDH^:>-^:-G9)ZI3$I'->
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M"?B"#514L/WC>]Y3[KW?^?[GW/DEV7MFUEHS>^:99]::G5\+OS8 Y?JA7G@
MP-CX/( %  #0 V! .L 9VAW\]Y=V+T2[6M*^7O$, "#MZ@WX6[J$)6)P(L9^
M>K@@+P\_$9BJ'$Q$RM[+#TN\%B0-@"O %645:!^8#4Q!74%)74E91D%975&!
MU@(@G1G 0+.@ (<KT)7^S>I)6C']7_=F#']KX6_77V\ 7'K![CYAM+K?!5A:
MT0:CB.?5J_[J\O)^07)NOSLBYT[TE0]U\Y>'R2G( S0OAOJ[N?O@KHI@<!Y>
M?A<@[[L?042\L!<@]LKF"N;^NCA/+Z/P0)QU^&4;]W ?=S4LY**6B&:H>JBO
MOR_NJIM(J"_!+T@]] +D3^/JM/O?Q?(0D3]%KOI<@/SM\5'FEB*ZQ$"<B+*<
MHJR[ @PF@D#(P924$0@85 2N (/+*] ^"%F8DKHR0AVN(O)7@M!:"\3BU9%Z
M!G^U1<M=@/SU4->N79.[IBA'#/20AZFIJ?VV 8?+TB1D@\+\KKJ%ROH%B?W=
M FWXW0.]_*]Z$?U$?N?=,,3@JQ<@D+\_@J__/\S^CV/U=T&L^S_D_(,#"7\V
MCG67QQ%POCB_JT$T69C\OQ@U-__?S?KZ_D,ZZ*I^R-7_73K()LP?)X_$!1&#
M ]UQ^B&T%L7^J8[$X?\;=9KX/Y3]L?]&E59!4U7\LY/^ZN9$K!<^3,_M*NX"
MY-\B]V^BNH$XFMB_BL)EX:HV,+@Z3$U=0<WA+X,TM&#=KKK]YR:)@39$(N'O
MN/HWRPHB@G57QQ,#?=UH ^KEZ^:!D_?VQWG\:<;<7%V/Z![\>[:,]2Y :"5R
M6"^L.D+IDA),5T5%1T7_$@RFKZ>&4-)15=-355)50:@HZ*K^7=?8+^BJFY\[
M[N^Z7O_41?Q[7=HPJEL&$K'![KC O_?=DH9I,R],H%M@F A,14[A-U+_UH:1
M5Q#M.</^0JXU+N"O.X*7R)\@47=S_XWC"Q!WHE\(+O J#@OYJ\+?+="-M@)Q
M@4$7(/A HJ^(F[\_P<O=[;?X[[D4N4K\?Q2%^&'_FFQ_3^)58I GT1\B3VM-
M_I\-R_^_^_37&.("O4)P6(/?C?P)/76O?QF9X&#:L.#P6 0>HX23A>,4E665
M8+0?-Q5W%5DWA!M.P1T#1^"P,,A?RMA_F9(_E55PRNZJ2@@5665W-9JRFJ*B
MK)J2,DY6 :NLJ*2LH(C PMW^V=5_6=U_+Z)1QI^]_SM7T3+_8#N<'XWB FE<
M]NL=X-2?LP' 4FB<"?RU#(@% /_S1/?/1/^/]/>Z/ZN!_UKS'Z9?%  7"X,9
M_4EZ(!> C@M(SP7\-0AX#P#0T0,!O\W_M;4 &(!T](Q,+">864_^54'_STI:
M'0,C$S/+B9.< " ]D(&%EJ5G9SU!QWH""."B$X5=LJ+?=PN(XJ9)992U]#_?
M8#Z P'E89G/F=)"94V+6O#,2RI((.TR@XC2)SS8;9(#7%5>RN:J/"XF+#BX/
MBLG2PU:V#0WSYSYVK[C=;B_@0>LL'8"!@8Z1^20# P,3'3T ^+L=>H9+5MR,
M;DP!&=,DYJ@R'NLLFYF6YQ XK1%%)3Z=<EY0/T8W*%!,[^K^1K2[.(L$_T'K
MXU]+ #;:T])QT7,!+@*.:L%?Y"DIOP"7)EQ1*N+>K4(@(>+ +KIUSUN*/NF[
M'?'LI39K_#/>")>Y65!HO\5AQ2 >F.=H6S@T6B>48+G8R"LM</ONBU#H&Q_;
MP26 H-W>9ODDYYL-]D'4XYB0MF2<;9! P@ 'U,ZL+34.(B#NJ!09E,I-CA6M
M>1.<K((&:ZLQ+241K3Q.LGMW!@JA2%> DV6EQELLKHQ9B#IE($DAM"6!"3@
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M3>?'ZFP)CU&L#Y?=T#01R!;9@I]%"0UBJ@IG-=.W""C-X1G^A/KUJE3P(&M
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MFXI<M7/F!1*L/)[,&CGF/;&*G$OJC]]=801O#R3THL Y=O[TVDZM@CC)N,6
M$*WP%_HE=%?<N3BZ\*.$.=%Q/O;'?#8I!B),M(#3FR04.09FVEH245RNFK'"
M0]8OU(/ZR990U[)F$P,Q4.-KQ-:LG.3SU%?K9&*4_DQ4I?:'ZQ?J''D1!TJ
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MB'Y'PW;_K*U:RG#_[9"UMVBR4WS@ /#13 /TX&1#!%/KT+>K'VB$V7@+A>>
MS)@L8*Q1:7KH%M?%1I"8FD[I\X:/K#)]3+NN<!#4BQT7N9YR(5E&T39]@GX<
M,[9(AU0$'!/0J-4\-L"W.?-<80,(=(6,DW-7 %Q7YLO.#T893<BJ]]:S*D2E
M"[JN')\$QZJ&_!#* 3V(-NC7E<5)=@6<8V(XK0D*<1W&:.80<GRY;K9/#^&/
M3D2\A'%XCY)MHQ$)0:WUB V6!68-$,)U'Q'KU-"P'NR$FG!W_;C22DPLMU2@
M;QCS8P=\.F,BD -=@I L%W3]V,NU9&14!V==>\P!7=@U+BU\)#Q'-Q!ER%N9
M0ZT0FN$D$RY*-ULB+;TA4@%\'\Z#!:]&/F*9JS;.<3+DD\U<$T/%N9:U-'&O
MJ^>,CSPSZ#N46SC1NN[5BUW"%@!X,0XIG=QT^A(,I>7:5ZL95D ;0]*\F?0$
M$[V5W WUS$P<,\<0-[=1$E)R?+_8!)M_ZG1"^MZYV]S2I[@:N;F%Q1S$Q9M3
M[YXPJE1U=)#4K=,^.<U@I#*A)$4GP&!Z0BSVG%CZNM#SF4$;"G'QSK," CC%
M1  66*MPEX$S$:(F.(;PMLMS'ZSE8T96X4EL+':F2.O8\YG8&$[OV$595\LA
M+T=_A39W7IR4FVU=2V$<WG5R;S:EV%H:VNIKT\@$I0S%R6\W>DGZ&BN0/MP3
MW!X9#A!)9+W$ ,ZW]14X4)@IGW'F-YY/NE!U!/[XL?$SO^VVJ%R0XE?-(!$)
M>C5_<M3A)64"_\+JY8_M7UK>U12O/1_;O,%WH+CAXO=1;ASY:;II:F CS7#U
M:<;9!+GD-6>9K-BCB2X/4WFH$IF^*Z&J(_U1\/>+7S/:WH/#O7R<@Q_D>'QD
MW;1_O+JQ7?SVQ=4W#[(B%"ZTCTZ./QU/P]N\5!VA8S-]-O=<_\N5NU7*WDV&
MRA[/YZ?[BHO]RBILL?_6QQ]ASAFW7U?)^!E3LD?Y)"?&N>2#UI)\@)*:\(?F
M/[=*>&%E$3Z:LRJVB(GQ?KQ(RF'S ^YW87SLXR,G;=OJKT!Y>\U_NC5L><M(
M$B]--%,LDUR2AA<+_1&I9?@/#"U/1#M9/\.')Z9$?*"@M3=H5%V#0;D\BES!
M$N-YQVV%3*CZR$:Q&\J._T,HM8 O-=F=ZQ1@IM6/-S5B0"$Y7?DZ_X42KC0
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M**65S:S^.S;)%N<171]_VD]6139S\SRX WK,^U![Z#NWMRSAL.[;(40@_S,
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MZ?"WRU!J)R+8N\U+9+@NBA2"FJ;VF)-@#Q@?I U;SD&IU7N1(N=_AQQ-)%I
M59.7[9 T*'F;:^30$8R=G!6_/N#K[[!5%B250QDV<[-*EX[T:D_CZO.WCC^
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MXMM^P ",O!%1_W%QV>%P4#;SI][]1[VTU'Q']M,(@V12Y1'*$*F'X^!"0HE
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MA4,2$E7P[R:Z]P0DA-2U)KTIG[AB^UB79.]S?:IW)!S'0S"3<"??!:^Y4-(
MI#ZD?!J5E"#JQ]/"K2<"DA)0_(\D^[3W8A*Y&CDH<5 \\,1=#T)60GP&R<#[
M<A/Q.@T2*92NY(#J5H+,L9!+]D?FX6'0#V-.223F S.62A_QW1>@DNJ#C1PB
M$?7A;_MZI+@3(CI,#7H[:=S E+0DE20/""7=EI3-NCL=B08;TUO9>?4 PE^"
M>(9F0/XOHLP$F]@4A6O=H[LX\-8J./DD/8FB"2KLQHNX__LC TWM3/_H+D F
MX0QL(DDC;6'$101@)DO=).P^,,(*\&UT;%9]G?9L-+H+KYS&UE_O)LA5[+4"
M(\\L%U$DB/)*DG[.S?E:LQZ&=VXZ7 ED(TO*>#:'RAPTBY+O\<INYG'(S&?V
M 99HN6YK9Z<WT5 OBKF-)YIW$KQ7?)S5Q:T54H2)-7]K8*G&0-U0^_-N)SW1
MQ$<&*/??I.Y(A:_--'CQ,Q1:WIJZCT)O*Q 1 -2(9K)2^&.I(N,3/SY[&\$V
MSI'&\^2VIJ[FYS=#;.".4G+/1)VF;O:D=Z)T=N/.@\;X#U6*Q/MR\47QZ@V\
MGJ9'DGD8984J,ND_(+1_=N]!3]UY,EN*=G)6?-K088SSP#J.F#&9;9HZ"[=:
M:1>N?P%=O6.3.(05CSL>CRR",>6'1A,H\>K.] VZ>)3QH$8XF4P263[N%]4L
M!M?/08JG8[=('%7KY:6& L)GDNS<DM]KWM1B%(2$3?7RG <--S<,@V!19W)Q
MBE5W2U-4IYXL.UO.2NGAYS%(53JFUXL^IJAV.VYS<!LU :7;)/+GX49,LB%,
M>=R3+'_W5]^&RVT'@LF=+!&[_F1=;[_.RM5*?480G-?R\QN,!..3I.-F5!.E
M9KL"K50NF(!=/QOX]$,M_TM"$D)NJ13??C/++W']SYE=,^:IC^B&[A%>"+JV
MWDBKF?.<;K,%Z>+KW[?3:P:!Q:4HC8<=I:&'^F$<OAG&]E<W E[8P*J-UR2@
M?$\5:VKTV#Y+$O2>F0<,]3#TN$PJP-ST-NE":NJEOFS6OO&A9QJB+XO[V(7(
MU#1;EV$ %)/<2O]V#-*G]N8[-)O_^>1K5P^#LK_4Q\&K3_#Q=;3X:.<6V+[U
M<KNOB>']4;M+(M(4AF=][B7RK9N"L&?WITY:#[YS0#NW)/C/_9+P(4>P!)0V
M;]UG.3K42I,NBCX$^;IPA+^/G6+$(B&Z*2.IS'W'XC1QB2%D6UG,B?#K@3@6
MP)N=E:DLW4SHWD4; >[KR13QG'*GU(E(DA$S^C32JLB0]8AJE4.!6FJ8K8BV
M5KVW8:>33=*)P]_@KQ<7;("3*A)@KWC#;"TM-): 7Y28<"KB"2?7Y(!-DOY-
M7G_2TMC;]L['/*J\K1]YU#Z.-GS4SB,M6G_V\),]!0P66B!97)_4>7[O48IV
M/M%+MA)",.>[G0I9S<3$"!=R8$#A*F/(V%/MVVEK7]2XN%CN:6WRBDGRIK*F
M473DJW$1L1FE<)GOZZH)FX9K3286ACUBN=FEKDE%>_7TL]>XCN11($WVOM$*
MO*/QZ^U#]1_%=6\U?M &%*X;#(+5B14H<.=BGKM>3AR._>0NW*3+45Z[RA_U
MPBZ;\=*F:^;@+ZW%)LQDR8H-6>RVFK\7B+^$=<@(6C:(E[T'DA"FEN^E?]6T
MC=E89/KZFM\]85YO^ET>=';'8=A9_#-"+HKPU6$'1'#O6S/"70^WX,BV*'N7
M7*)2EGVV5%^>ZREO/N8V?7#)E'=F]W1'MA@B[-/3U!212B)&8HR[5.?]Q@*.
M:!HG],Z9J.(PA4M9%D4KS+BU) 09I5:"^3+MFP,LM2_@Z?*1?2=H+;"+"A_A
M[C_W=&G$ OSX$2@#?X^V $B776HZQ+4!LP__$^N0"]W"*&T22>%_0S:N'S:[
MH;0=OI[B@A [^V= +/Z!NJP%@\OL+SOHQV065I.@-$$%T(/9DDNN_G2X:V,P
M#A'S[FB=_)!%&#@<:''DW=L^/OQJ=Q)#!1I9K5^$^UF?]XO&#7\-_K6ZYX@6
MJ\<"'I0+HM0$EBY>8@'O9\I&QB^6&X"'NU@ [7;J,'P%MUQ<UEZA*BWDQY(L
MX,]3#R.KQ()G/=#+D%_T0ZG#0Y)J$ C4MP^.^41S/R@5>CQ;=,EE[)^);/'<
MOV)9YSHZ/HM%?\WME@'#T:$@QWE_3[D ZRY+_]S_@4R1#T^L-OEM3U^*-4 B
M^-U00@);55KG:LR.Z,I%U%<LH$^,[@T<O04'#J$<S]]N>,*"OYV=U<'?-[2.
MH:P:S_Q8^D3N'EV,-1W C[XM8%AAGC#O%0PR]3!M_E^0?6 T^-8&&N*% [1?
M 6H1N;5MZ#VA'RQJ.-=POOXZ[_LAV('>:L_$S"X:X09//@;Y?I3,ZLHXAJJ\
M=92E8A'B]^(21)%J(W5.=M&(:5R$])B8!,5>Q8D[3&(&7REMB?LE%8J@NK4O
M=R2,!60C5X#(>RE5<Y-HJX,#)RR */O-:*ZI.WJY_T^, I(D]$SN<!79OHAA
M;Z[PZ,_514+^7(%^C8Q_^"?9AQ]Y;U[N#\9T,;?'A*;1[M<_&N+LU/3SQ7^:
M?PGVE.PS[>-HEC"<-9[51ZO!.#EIYO_LQW%XB"(T@W^M8 $;5LV7FAM10>%(
MO]6V@DO._G30Z3_(;%0-(PZR>H70<'#U)9^_)DE@=HB;V8.W-&'$G')Z\U Y
M2"R ;V_U)Q\WBM!*Y@!GS%WNUF&45<N5_6)TOE('<GL8XT5X#U1WQ1J=?78M
M->JY/;IR^<H8B5"$(Q9 L)(_ADG!@2HU V\A#N"!:N?:B-;!*Y976$"TRZT:
M#2P ?P5W"+GL'?S4*)D31C/]8_H 7\K]U[Y]=H$L9Y7'6,##*\B8C?6/:[WQ
MJ6E_D0?+LQB1SUHUJY?W_2$IOEC '\X=%+G V7^^I6$!KHU7!U%FGU7LZEK@
M\&49[EB,Y-/['^/F_6,A%O\0"D@5X(L#/LBN%?YYAC/R?G<0:@'8X>BP"5S8
MPP):JBY!\5B G4KP5BM\Z.NM/YR9"#I5U%D=Y/U6(RH2MYC]8^E!ZN!86(YR
MWM5@ =LN#ZIU+:ZM8Q 2"9[UO#Z&0A%5*RU=3<=RM\XS'E1COEV3=*WN,P>2
M7V43D3/$G6[U0Q,+F @@_R,A@+R'^6<)7I9_.+(%<GT$]>B!I<X%#RJP@"X<
M2!QR>7.C';W'\H.K2GALUPV(<VV4/1"WZ'?Z!0$OQIY@N,NP@#6@8Q#+.2Y6
ME) P9J;[N@!+S".VJ%0_+"#YA.6G4T[G\%727?:S:8ZG#2PM%9=@W)X,@@3L
MXTY[L>\NG_(B&!NONHG0! OP"K[B@$?; 1&N6,"[_;W+?D4,3TE9M=#A 1:
M*S1I!68-71&^OPNAJY;+ *ZWM%A?;N5![BHC:?ZYGPX_P\<":*Y9?E"22:/G
M<I?_#.^W'X<?R!]$' ;]>*>PZ55;S]R[:35M_D5/NRDM[8?(^^-W$U96?)6/
M?]$.O>[Y=3?YISG4?>W[1+3.S6>-%RY:[_%'9C@8C#9'%KE8N6X(=(F<<_$;
MJ .X(@JA<+V;"H70%M,O'!2)])O?\QG?I_P@@M8RQH.J!KG[THT^LBGIBQ;>
M2(X1A9$6Y2<EB3*IA1K,J((_:+BR4UM0IIC5]]A3W$YG3%\I?0U]@B<5]H2+
MZ Z"37PH,9$&ZO-;12-Z-)9 GZ)C(>/%-K$#J=\'C3^\8J)\"J57BTHG0.G-
MJT_>1M%,N(%.M#3Z'66-]$-SDX:I=6]%T$WP32X25MRT1CMPP[N#RD.!.IJV
MA=5 C[@X.JVPD:Q.X6M4']N#4(%:%5$%D8Y/7"RDHEK"M!8(ZQ:!]-^5:A8\
M<XNS$J,[:#4]GAS*W;7[7#/<4RSA\_3/:_TSV<H+],UGI 9V)]T+"AA4OR]<
MSHH-3),IZ4B5\[\RI<^F93JUG%%3S4Q8*K#Z8>L]R?)A-V,^@VPC8QZN;<H4
M0P/R$N^M-)NGD>6W7(]=GQ/ZO-)\D%[DS40CZ+I)+M+Z2>$0(C'F7487V]=9
M'-V\XA"S\4[)QUDEK/BYJ/$+D/"LW68U0HRR CR2RY95LVDB*7"G#U7VL\8.
M1%G]M*[>_I@3?,_E#8U4-Z6L,-UPRRV2G.XUN>0QF^94N9%]:889TJWJ*<'Y
M35B-$(?90K6]V&M+6$U*&(?=:%KKZ*<W'TD14JD>&9/K/JMLGQ<H'R5@[KY^
MGFV>':9"?YH_T/O3D\%M(D)5V_OQ'1&-K!FZ"#BY=^2:79^M._3!(UJS%197
MOSI>^SLD5&R9RJ;N"S:ELJ2(0TF:]UZB(%;+PMYV#I'Y-J'DWE2\:7[J^"5Z
M0+&)_>:HG9!,<DQ&J+_!_)U4I75UP':(!TFH#5#U1*H#.@J0H4[@@1(E: @$
M *AZ\.K.BM,H0,VX[E)]Q-L=L9[W451 ]+U$J:RF]@=\UM+J>QP&PY$:Z0DO
M-&#CZ1^A0]KYWWKC83>(7JY[ZX<99?")4H@6/L>MP4,4!^6B>>FT";7T@=-#
M-THC2LFRDK/NB7@6#!HE9R5SZ CK:B:61E/<I-A.&"2]2$H8P:T "2/Q:0,B
M+]4G^;I/2C@27S]E3R35&4@8O$F1M@X(;)T8,+!4K0K0UKF( KR@GTBT4'EO
MD*#!3Y6@P?KZD\$S$4&I'V^A@^Y/2LB+WTZ+ZCT]+.#^+E)K97I D@,;V76P
M:M23&/4)D CG*$VTE*S2"UAO]W:I[0CD;P+#3I.DS,D<GDF5>[SZW4H639 Z
M[_EELP:FA3<"O\-O9O:[9">;]).9H86A9J5K-C7#^U]W3XLH+/4'\#=-:*)C
M[ED,BIR#'3#M=] G0;O0[VYE'MH^0F+\%/)']^/J60+6:W4T7"J]034C0[:G
M1[UQIP4'9I+6.LTB8ZW#Z",66%R;+4].IK>C$K<7._ 9#>:K/"I58B$ULLC5
M:3"6N#-\-@X1WN:],.1SR\(;U.SS08_1# MX*;>;,6,Y_JH@4N.G-+'BNX]
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MX;;,,.AU2XT$SC9#=I=R+\(;@9Q<Z+.OY?6\R,?,(WTKS_=83*\==V<^V;>
MA'OG[C O7\;769U]K;K N40.=O 4\GW3'F>X5X_^O&+M?R:$#DPN ![=]\!H
MJ)U=EP4'L@WNG,=476-&9(:;B;& XJ/<'<'ER\3B9=37_N/K:%TKUGO$$*%K
MU)1,?S-PM[6X:OT*5( Z>/6K5*_FR@$$4\'.J?RB]4)T?VM@8N[QBJ'UT7W/
M8 V=LY7=W E<9G+IN4BR\=SQ51Q/:6M@=]-O+$ .E[U5VU\N(=R*NGOE45 Z
M>;5O='LLKIQ5>SH%*TQ]D M/WK*_)(UPSF+<.GPQ%!0;7BO6:(/+'](PBRS^
MLX_Y47)YEE(!'PB">UZ446,!<#\3>/JU**%J9&X9?-$5]33M#/)"F*7;W_KT
M@2=&\RD:]77L7W)]R^%U8T<'R 7,%)AI>0EXNF**UEC$ A(3@\Z^-K)H_)><
M5<G.-69";G6)$PN8_(_(&$?TG]]*"+EB8.JUIH(65%CXN2,OI@"W$P]J0(+W
MR\@+"[$ 7*?86;VK!U[XQ:$6,-_7TO7$1/W3HQW3I<'J$7U"O -#RJHWA$-\
M%  WUEJCS.=;+$X7W0][?W63F]SZDEAD['I1JCC&];OWLBD5#^K#V<@5PB5[
M?-?+A2-D,H S;!1@4QBFJ2C0E9S$%3)M]R(B4Z#+ZT3UQLZ3KJ=$7!0KSFKE
MG&4W@PT*2XD')A\6+WUD4PD9B%8,^R.N_4WAIH9SLGG#T]L,-V UFKQ@L-=3
MQV'V<0T2ZOP$9=%0=0JE?-4L:I-/^13'= 8$FG=Y1;^T$IH\.:GLF0P1M1O[
M6-H'>-_QEJEU4MNYTT#"_.J-E!02\,1"M(H6[_;OY/_WU7(WS)*E1D0)?3NY
MT7:):[R)%D)=U(.B9B1O=2*@\NYM5+>ZW'+K?_RQ;A5*V#5".$B0E=V76%_)
M(H,:Q\7F] [[N(!EH(@5$LF712$8]<\38Q^[$#OEZR]%$0O!)-#-J1$?'GP=
M75_@EZY]LCJX6L?V1AA]YE)S^>B7?M@'7]P%5Q,4@30C(V/U)Q@N3?C"/!R7
MV^R]G&&B)HKY/D6>WS5_9UV:Q"\02C.@=;<(2GL'3FZWT0 N!]-\W6SF$P>F
M>DW>&P6]^&S=L@"K#CM",,QR'?>+SMSKL7M4GLX/OE&@16/"#1?>M*[CYS<<
M $LVR ^5YXH2LNV8.[QY"\+[3,*B:CE#L":=S$_84=U4\?8/4T@!P;?Y4<?H
M&(5GTS4.(+% GII:SA4:?O.4,#LALUK"<_HN]"#_0/72W?>YH6.VGZ-NE*Z!
MJWNCE<W+EHI?L(_8F'V($@'1V8T^#$XI5I4$I=OE/'N=KQO8JIK'('YH/I]V
M]2W/4D%"2;J(-M+4@25"8D&P)XT[7C"TV,&Q \QZ7CP?!:*L<_;.O<M@+XK/
MYB/BH:,22E<KE5[H3FPAFKJ3J2QGI,763O!=XW74M!=;.^&:U#L>L70NMOMX
MC47I JEXD_H1;BW""H5T;%0A^$8=)<1*K^]QW4DV,"W,BR66O:V7KD(SD@_[
M?&P^J"4F/@]6%AV%329^X6]*?D)6>/=MHONN:'*R.NR]:.&0KF;A'UJ>&_3+
MMM*,R;"/T]6XY>YO='EV/=L=:NU\HD!#7<! &'^5,!M0@4+I/3=1**.AKMGB
MNGZTL;V! ^U?F+?1._H='3LJ1<*KGGMPW7@Y3 2EZIF" &(PKSA>LJ22-T"4
M6WDI,?Y^".%BHML=ZM!#"-_>:_\4U,1?YB\RTB:F 1OMKQE,A+-BH8;5EHTC
MV\7!^-]1'%HSGF)%Y!O+]3YSOR?13R]A* 7W_FW+&:EBT%_=7_W3LW)'CW<I
M/D&$AC[XF"VKX8\\%G+W6;: RJX*C2%G!:!BCBEG5M8M,J[Y/F_T*1+BUR_@
M1NO-I?8#ZGAIK+;L1#?C#8MG#9]GOVQ(-&0I*BU1VZE/BJ-]]^[%THGDLU6E
MLI+FMFSP2^3%0GT_QEU.QL1KR,$V[$$P4]PT< (=AP7LD==@ 4+E!XOUN(G*
M'7D![%,\6%2Q7C] C[U"A,-0+%_0UAL> [58P-%]>UO<:3)5 .7;../>OJIV
M/LJWBDRXS,9=0/?;XC>M0:?/L  ^7S4LH$YPX+*UNM%]YF*T<7$;"Z"51]?E
M_J,,\T9Q?'F!CWF%@+)@ =\#.8Z.AI8;GP'3&U!!++_H#Q;U2E=1.;OS3#R^
MID:VEV7SUICO,GSSLZE<*#!\QCWHE]H"/8[MXE_4B#YKAU? DRJ'130<46%]
MOK/5Z#9[,5K5ZA2H:!J\H'?DA]GZBN28#TJ9P@(FVE)]('HHP60L8+4L9[G*
M>E>R_4_>WAT<4.T_H#ZBO41OX_DPY!(][^B(OJAI=,71E4/VQ>4^X7)WER^!
M[ =6V4F0#>_8AO^=K04" \6.?F[B4/XN5Y/$B[P]$@RZ[C=&%PM8.GO>8\>4
M.H7  AXC';<.P+AAL9]&K]Y#OM;YX#'S]V_+6(#SJ0P6X+,<2/G9U]$ _L77
MH^KW%AAC:6[QOZC[P0M!_Y&Y,&5.I4$>^GIN;3GB8K7/2.[)1&+ DRLO_Q]Q
M8F2C.\88(\0B?+7]VV4#K-%Y*>@:E =<;<@UA)_)S=9(Q3F^XL:\1.Q ^H.R
M_[K;!H\WI5_HE+3NH3\)_I^Y2S(RI>2HL=IZJ2!?R$;1F,=DT\7R-6@V> ']
MGRH?H=JO,<N&N :1#Y3% LZG36CV9'(K%@*_K2Y0>OP?V;H,\#,4)^M""O5G
M@04*%:KS"&YT/I"!./E8M._1L"A="8/1ASN>4JP.!>6]P+3Z1G9C 71FBU=
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M?W1N_TV!_$>%:'>L@7]O6W4 %J+OGLCY+!K67*O" LA\%M6N=>$R#+,=\94
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M'7."2Y<JNK+L(C%T'9F=?(NUQ-<Q?-W+L$*[K'H14NR^ 0W-'5DV.8)Z3#T
MN+=X.E)$B?Z#K",AZS<RDV).$MW F50OI U?1_CC\:EG]PG@[;OU5T>^AYP(
M^KWGPG1KI ^ CVX=K7O(UNQ=-OR#I #@@K/[3\5N5:[5][$NN/O],P^ 8_7[
MWT?.")6BX>O(!\!"6\3A=V.)[6<A7F[V$BG7#P":2(F_B0^ 1?%#B9+'%<AL
M;9F]WT?:<7:\G&F!3MP] *+E_P:!X;3[_[J%]P'@Z"KQ?=<;J8@@XOM+44C
MZ-\-:)@\LG"(QV[IY1Y:BH86C".-"W6+3K1(3"#54[3JWT1]..U_I0<UI;30
M+7UNAX[P/#\__"F1#3NBR3YAAS:+SBR[(+>UJ2.W*]\#X)\)X5:OT>]?H5QG
MR\)"T!/VQ](O0C7+SGQ-7VS>#US9<V>?I4>?'5:='XFO)]RSO#W#\KJ=1B8;
M9F3\)^8!H%R$S.33LN'D^K5;EH Q$D%W^/SJ*M,XXXSDKNU_,E5?]ID\NO?9
M;G6"=N=XA+0CZ<*_6F3?>M4@9I!EWT;53+;;3DMC L('P" G@5&0$^AK5%)B
MV,O^M@K;EJ7A#/N.IQGBLN_'2Y/4W\6#XW49=UFE\NV6HYEG9^VAS+P">GHL
M_BUTS,MLRA3+!2,&."STZ'[$Z.S>?B/2MS[A>E:ER*&D/XT.[#5EK4K>Y/Q1
M8#8@FY:#*SFB-7->U/D][>W2\E0&7Z4L!1+7>OSLA1J;=A!Y4O*^,EDX!UO0
M,Z2D\D^D]R9GIS+78K?[IKB*3O>&7I8F278U5!(5D)\*P.CMFR]1\I<I#??[
MTOE/>N$ 6 %^0.89C_R3+C\J<8Q+48-"GFX<!;R^KOF"L&2%>..Q.-3 U1 .
MJ84Z#<15N2?V@=-EN&_18K,+B+_(?VI(@K;R?5E6GQ8=YN??AA%?_Q2ZTP+]
MP6@2V3W.>]Y;YX@/=U4-^GV9XA'IU[38.YLA]I,&,Z+(97VW8XYY=FXP(ZBB
M_FN0@K9ESME@/H*2=NB*2W_+_KIO;>3IRP2'9P2]/ZJ!1F8Q&WKEF<U<]M+3
M,B<MD/4F.@5=9^X_NV$&E_#QO.JV#Y#>T\,.L [G&5<I,5P;&('_<RJIEEQN
M]65A052:*L::()X;T#X.C?BRG!]$*$&_R"%%P>5%%N)T<;OD/#MRCQ8',QFQ
MX,?#7+$9[/XH0%%.B0]!'26/BBSGH:;P5C(R)::P]FS\#3'_T-H1CE19E%&W
ML>V?="'D;?B#O3]_U5DX/CZP45L3U+MN,_!,+/B#\\Y>PJOJ#3LJJP$5D 4/
M=4#],6]-<6E!7 9E5)@JVM/47L-0!R7NU$FNN7=%:-34<F,%@\V48E'2R7A,
M[HO+&\U/3-72Z2<-N G>I.%/,E"FR[YFUIWE[^<U3XI'G43)C<>1!Z"CX(CY
M!>;\D!R3OC7JJE&453ME"TK*+L?-L"\-_DT6J4CF ARC9*LQB85'E8#&OAXL
M'>DUL7U/?(2AH>J^+'_%5IX;7_,?$VKM)/.C-R>XF*O1.&8GUZ[]\DKC#)5'
MDNR='C9 "7](Z\"6<@&WM"]84OT5>C?VL\<37 !)?S1T%/?D:65J:'I**)7X
M]\1C5 W4U?:-VN[DL#>A?YD&Z_8O08B+4C<S5R>\)[!/QF$5=$2D92F>V[ )
MI9$L+?NVZ*R7::NNZMV\1?&W;679FMLB[#=],FS:&:HUSL9,!1:?08>V5K!R
M5^O[DK'!"A<MI\5IV'/3L5M7'YWD>]+G+?-M DP"'L8_;E8^.F5R?Q5[$ME^
M*=;HK33RIGF>MSI6=F#"YJ+XZ#R=KY?Q2LNWJ*M[:]&-I7[JO:ICR]3'K[M6
M"QJPS<GFW^'GM#NN1LAQX_7::%&BTE!T#B/SUBM[^\!WNM"V7>L!L',;TV+@
M*9Z6^@"8'DU9R1*7N$R?X3V8OD%4S4_.W&Z:WKS>/)RAHDU+[[K1.;W_<?_W
M_&B^W-C!^0Y1-/_M_MH8=L7M"OO5_V>Q5V*\O;.AHY)6 @7Q<VORT431_&3I
MU6 !@L[IRC:ZKZY.HL'0_WIEX@%@!:M:,("JU]_:A%T-(D9A7@W(:^FRCN66
MYHWF[(L'@,[Y';3-8.8@^;9W]*#45N5:1?0Q#-H02XO)!T"#>%"0:$M19D>)
MKGZC_A&U1&-)T=6@S_^:,;:RT+Q1G_5J:8IM>0"8.]NXMJA>/(+ [>K<.[<I
M+<9GD5UU9Q(-M&&.ETVQ7;=302WF[2=UMS9I"^T3ASY#2U77O4ZW,J".<=_N
MNX,-"9O:)MNF95>HO;I.NS5BXC\WBU[R_(%N@I#T!X"M,!&R)+;>;J+<C26.
M2,AC)+T?YH63[A,NN;<M&6X-P2]=6WRVS2^GF&XW7V\OMLW_FRYY::J[@J:V
M#OL;4&N;GXC*"83*T,$>_PK[U6.VR&%X /S5A2CX QUIE[DLRUHJ7?&8\VD#
MWU\KW,?\%\6AL?66Q$5*+7)ND#L)$"&"@EJTVL]J;SU3C=MU_DNECVG>P^\!
MH.?%Y.;B)%&OVS[AV/K'=[E(]"CQ-ANY,/>?OK9/PAWW7YBMW)^?"CT /&N:
MK.L? %HUMY[QMTM,_QK@;BNO@=?X9F".+E,LYD";NW[E2)2NJ82H;5PB[]#H
M #GH"">'B\X3:J$B,.YY8,4\]U5FS,+DX-)AMO/A:^3G(%$=WEOY.>/'K[_3
MJ7__:<G.=[E08KGD2F7]T?SQ@=T@5.&68_1 GLD>.9Z4+R/X$=I]!WOF#A?&
MW]WH7#NV:4)LACO*?5)"+K+CIQ"#T'E@QX4^75/5EO#!<NDB-/_P]=&GT,OZ
M?033GXX17_!E"?2_-+)O+^Y^-GE6+8G&M"PNBU>\&E[T2;D>'?"=>C%O_R_,
M@:M2Q$3S;=NPZ?P9=/^IA:^SDW&#VJWL^LWCI\-7Z7WGF5U+A[R$,_#[,5?[
M['D'A0? ;=E+UPR??=/+"YXF#Z3QD)9%&_&JQWWT?.3N\<4Z-K6&N2N>LSYM
M^)S+MG3C;D1NS8NBQCP=Y;29<DB][L$]GW>KW'Y1C5PL_5:=PS:D!SY1B E4
M]_%XTIZ1RLU]@\0!Q>UTUS*;_%4X8@9Z>/4LQ$[U5F;NW/$J(0%1"IVW3[FI
M"'DL\UJ'R\HMDA@+EWN9\CP RFFSKP<&[J<T#@1B]AKI'#4%EU_2C1\AEK?6
M&^O8[SKFZ;Y^S3[0,,R=0&AW'>R8W;;Y[G=<>47*--91(SE)O0,R/F&)^2)$
M(1+0*W$TV;NT7(?@0BJH0W[">;CC]OU8-;35._O@W0/@7Y$?DUAHF3E$;KCJ
MFGHO&^CN_1CTKF_0=\SX,D+^0I^H*2?A</^PY>\#H,9QQ$K4D1<A,2_QU:#H
M0.-^S+'-[O6R7TN;SGT*]/#R;NOD /[C >![F;+]],6A_+]&Z#K8DSF\N*U\
M /SALA)U1J:8W:)Z%I&(*'UJ^<__53CQOR1N\7R=P]B.5=1 7_Z^8*/<[%?E
M\B;A61]*S?_-^M&1W$AK?\)23X5:HT;UU]]*I7/-O=)Z?HX/JY/'MH%;S4\U
MBE@5\^WD29Y;_$A/IA](UJXE9L7(M1D0"B.5G=Q2Q$X$%+0#WB4<S9VSVQ6S
M.?P\"&.,P[7[BU\ZL-:K+8]GIW$/B7\55YG*[CU,PI8'"F7G2<L8/T^.-#.X
M!L[E,H#[S=B>4>-^#X /Z\F:0_(U.-+>L,6B!V.CQC<YY6OT!^6BDK7+T"_'
M4I8"20&2E/V8'Q6=/?-/_-A244W^'?9$JGKD7\3,H)]O;*%DZ9)6!#1'FCO(
MX31:><3W3?U:-<"[ILSQU+C]PBFAA/9K^)-F+NKTR?W-8'OV'(-ID9)T$0\3
M '^,+'SYA99*LG)%,9!?.//=B$JT81[YL%UT>'?,)LGJ'Z2B/YSHH55JX8)L
M(2+B>QLVQ%/D%@X,+KMW*C6$4Z)9G(R%!%3)^G*LQC='38WP[70%, +AA,FR
MV;=&G3 7WFM<F3&8DS'/)YK!Q]-W-MNP"@_"33^W"57RH"CB#:Q8O/CKE$[(
M4T<]W<$N/;?,(6H,W67#P \7NK..#,4M-C#(&;,%A7_9+.P()4+F8S'*!P?S
M-PR+'5I!D0Z"N)D\>'AFSC7-O]R!0!F^J#(*,*5?]=XE,"TH&R6('-X/(1.E
MU-_X8!=B:@(."X3/"UX7A>I:8 [[]@C("?!'Y<CT#V_PHFB/;R:E!<TNHF4#
M:KWA0/X4R<\]RC46RB=4SQ\  =9I^))S58LEIF%)<?7V9]J1RS)/JADL(&>4
M0:$_O97L4^%$V3U@>&__O$"0+1NO!]67U+*X5@<H<S.I(]H[('P8(Q#BK6#Q
MLS,M ][ZKI:R'OPE43&CL_;[%J,6-C%&-<>+ +@11J)E:CBIU=3A53Y?<Z+"
M-Y87 :ADKTWIQR3A&T85A3V<R7'^*^U3&=X$ZC@H>IZW)*M:2N:V-AJ+3++P
M'*Y:3C8&UK\HN')ORM_3ZR5JZ^E!TJDX,MB"4E$QL=%X;1[[R1$?$]<9-7^>
MGS5V?$U[2RF7&)!*J0LVF6HL/4,M!B@]WO9!KS6IP<)RS>I>I4_)*T!9!7P'
M8?H]E=-%4T-V'"E$FH_$E=QG&)+\S:SYS'Y7D@ZCEF>:KIM[122-%ON/V?SS
MW$0#'?Y*WQ?&7%NU1_S#IF6JO"7)UK12K4]?(DQ+(W<WT$JCPK<G1:S^GM#Y
M%\_##N(FY#[7]J (X0ETU#C-'DQX:UN".>JGY]TK]3-F8N\-\Y1T^$]%V&.W
M#/-LMI#CWK]T=/-Y2,[K#TYU6K&+-@M8N3W^$_TT BL!&Y-.[YU"F)PVVR%K
MPHD_HH\DD 2LP2/&O.'['NS/^V.:$)B3GAR&F%JW/1ZKV2GED)YN =R):6B^
MV@[8^\'<08(\J967V8:<?L]E^$/4YN+G'Q\@66Q>+W6RDBN]OLZ<4$:WX ZD
M_I].VT=V6FA[Q]N!5/W8?L)W,[P4JY#GD>6]7;$UK)'ND7*=7\!PR/--_-[>
M&D%V"_M/5'X3%IM1:4'!)C3%JZ9VP:='2P=ZLWU^_7__3HG48C*X5CDY1WX$
MU=3;OR]_DE1+2>8(,5#2[09.54Y^"J2VX,4-^:$<:6=++9W_6S&C>YFEK1AB
M$ 4Q;,RO[DRV2S_FY22; R[:OGWW-PUTPJ\</VQJHQ!LE?Y1BF,B#A6$ZE[^
MP^S7MP"#@E=\X3OO(I%BS$$.[T7J8+P<KH$9/R8(6%"N3)+ PCE@$DM)K3*9
MP:='EK 0,#+RD=.)5ST9F$MF =)Z)XOC,_3FO:PRJBF;X5XZ.[ER))D8@ 05
MY_L#@+F/YBWU9>EO#.*2=GR3?-QX%QYE C*E;Y)D<<VKYWT^@RE\F#9^CP>H
M.@-\Z)RL%=R3/+_;HC9+$>E(RA&C)]B@L&'EL3Z)3";I =8^5<"QKF##C!#7
M8Y#\=S/RV)&^9F[GTIU[N:F':GS<%134I;$.:[#X*'*M\J/BO'2K*6Q*OGO/
MO 7 := (WR_;<*D58S^O])')4_("HLK-DP];?%:_3Z05JV8O6X79N8[E?P9)
M"5A#MF 3,G 1">$%F@[@AZE;Y](+(\<C2X9A)\.)I+%:T]@W;T"J+UXO[&WI
MQ<;&\=Z.=1_\I!Q05LZTIHYZN7R6/KEC%'HCZKF](7Q%13NAJ:YO#AL;'X^9
M:@R<=.ZY\!'(>DXKY.P<XDJK6<..P#LD,$6T;3X I)9[L@J;[&_;JQ:J(&:-
M629)U >-T,_0\.<A6G_4+2U<'@"CRP8+#X!<U*W&)COHC8]QDU'W N)%ZFM$
MXY7\WYSB"Y5>('1VI"/FXBP%@=T#N6BQ7+KP7?)Z@F0<_V'RBA*F1&D> + V
M;WU'G],'0,[+^)NEJL/Y#H>V,%OK+:(.^[:Q>S8'<=6:703A_DJV0<>.!M*;
M;?9N0_N2%PHT_PS] 6#XSQT\JV@.7>*6=L;Z 4!KYANT9W U<Z")$&A:J#)Q
M-*Q*9;HY:/HNT4/85W*I3%WW??^]1)$PU@-@(+72R_:R4M3>T=VHLZ#^#/4!
M,/.?4UK56JNES!GH:R=^P=NT"F=]X_J3^7VOGY<8XD7_:PV_K\15$_I.Y*!C
M(3+F5T]F$VTNM&#Z*N@/?M8$G!3ANK#$^3<GU(5KT'$OQ+#KYB3NAJJF<;W>
M9T9_^6DUK:NO2=K_AM^,!#'=Y,W0/0!$-_2NT_]?,&3M;R]7ENC6@O,FO;@.
MQ_<#'P#Z&[XA0*/M^D_SMLB(D$7(/\-::5S>>0"0\1#FS<4@U/>SL^;H<H:R
M%J)'KPP?D_NOG@AD:H[<Q9>6E^"*O?MTI)D]7?U/<_>[54<O9PD75%_YW-H?
MQIS(_-H3SU#=R=;O0)P/((@?(>V/D.-M_L;,!\#1PF,G/ M1_S-#-_:ZP?%R
MXL6YE+E]G\5M84=K55>:>!$T>[_Q_C$<P>=Y<Q6(=_O&61X2N2_Q'+P$E_@1
MF[XT(?5'9PC7Q[2B&":]^!\ I9E6T'VQF#&6J";Q=(G\F:NDOT[V#4<G_X&"
M/TR*BMZ^G*ZXGS/S#2VO@/U9<7Z$../9>UVMN/YSY8AT=8300KK2H\M5J-RN
M18P:+^O\AF?-=,A?M#Q&3!FB=H +E?6<V4Y&SO@K14'8GXG@B7\@I*L5GX7;
MO#NU2<\0JU?W$2[9HS398WS0XC\KG_]YHCMONX%6/$(4NO__(9_$JWRS]UWO
M]QX )([/H?70VB7+LZX7Y^HO'42!4,7'^FUISU^MM!\@INZ9I\5E_B_"XDH\
MY3#]#+D7C$-XO8QNKY8ZOG=T1W9E'Y! 2Q&FCQ@M<_M1\YB=B\?J]2XXW-)-
M_S-C@63>UE +D;YM7_ # %&<<^C%_5^)?RXX7%\-_[.S>88H,-[ITZ701%0.
MS#P <(,RFQX=WI]V$%I<MIT=M4!=H&%4R+V(W#Z/MEQ5=TK?+5X:=(SMWP[>
M"6<LN(VVVS^Z@R Q-H(7EF7WKAN_'P!)2="2/YG&_Z&B&I<.H>4+MV5WBN4>
M]Y/0O5&=NX-!Q-/W%:-FT!MEJ <RM\:%=OF+C$=O@H^6XA!ZR&IEPHQS=Y%E
MS/YO35\T'D&]?UWI_(V+;(<V4-\T3'6(@I \>@('J;+^=/P'HK9O641*Q)S#
MJA,F2N\KFXX+VS)?5W/?2!;[4;.8W7\5&%QPN**;MO(J0RZ9\.'4)P35WDIF
MFBYT\XOXJ-GN?<*_E4?:=:MJM_*JNY.J.CZ<NA]V<1R!5XU]X?P_9HQW6R;_
MN1H]P<S+.H#(GSN6F2)L!Q'/% ^]&!\ _V7/;;^<=]-&Y H-Y:>YLM6\$9QJ
MA#9X&.?AS#C/O;@1_Y>]E\/%U3^(T)O.+0N:YJ^M=<(TK3#5(Q9L2E)L,&\P
MG0=;;[ !C[,V!3?HL')XBE_OA]+/32'50K)3^?RD)(VZ##DN1N.G)&L>X&B[
M<0ZSB*=*"9+&$# J%3^YTG"NAC* =='O]10HEC@?A2$@N3.(H).<V:BH.S\;
M39B<",/?FI)DU^R]FI;D8#P&S^=P!7BR8G)B&FE0Q(LLEGSI##,0V=8K/MQQ
M$XOR7$*<W!10]%XX@Y(?.T!RD,3.19$L5,<X%5MSYYFN'R\_1YS5ETZ"U]AH
M)(H-1I+2CV2?6&&\^[=WGD*N.2H@Y%D1"GXT0P5Q'V!M4HX!'0>2(1/])C ,
M!Q<M5/\\]YD4HY*<D$,;:L"B/-DWM3 ?MP^>:FRO"<TQ;9=\3S\4CO0J!WXT
M2('OEG7_,?<)\6(W;S"8AN_FF[F K.:'*O6W7+0R#3(@//5<7B<B5B/!AD/I
M?5H2NKN;BS"@RXOPC<\@:^6R]&WM#+JA)B4=\9'2FEF#^^?*JTBJWSEGT<8T
M9W=IU>.T.,%0_)ZOMKTG@G)JL,YI'69E(TC B71D(.\4B.EI+#OJQGK1#P7J
M$KA4VC9K: SC=]EL-8$.8B>!RS4>J?H\J6I6%-KP^CX&-8*8(UT>?2&J4%&7
MIH#>86:&5"/8G]=,:2:O^E1MMJOUMYX/U7PP3>\2_K"@Y3VM#?*(C,!,*0?*
MP,<I=CT'YTCM@G\?Z<YNU[3JG3>0@QIEA'W#3GB:%^V44\N'UTVD!)Y%A0.;
M4^MTY]HL^DT]7/_H+3#A;?#BN11;4/1;<GV[<2\O-^L-"&\VH^[]71"A= )J
MXK6:KRP?F</'(__$8TK,=ZJ8.FO*2<1$G1&NYT3QDI3W<^E?K+!R9<PJ""4!
M5: G&,L_ \BIPVC166N$:4^%/H;A;YLI$&8UJ1 5KF!5S57$^#Y G1&I_)[@
M&GT$X0;S:<WOO^M<>TL:3KVJ(><TOR]\3?!$2X!2L[#"FH!R<,'X/:4M$TAJ
MT5O;U3Q_D(TMB*#_!PX$P]QFBL!,"Q0YF!N'(X:)"R &X0)RCM]I8#AC8VOP
M@AS<WH6_H3=Q;4R?0(T7 CM+I%L[H_%+XOB1T7. 8X):.$J8^;XF2<DJVEMW
MCG,H@UEKJ?J_]/[OXZQ8DFB) 4_$Y,FDR9A^4Z@055<M'?$2"&(9,_YHFH>Y
M$)9F>@?:J10^YX)55BLA6VO?[#Z??WU!ML_WA99!7EGBN6" X)'!9?^"\CJ6
M'$70R,B2V QO">ZKIK7F/RY >=!BNOLU>5"K2B9O 9ZNNM,"4V',D\66,@/'
M/,]*_4QR9WPWX"[,67=N0Q W_8-L!%;<U"!]U')$]'6*\51<,5)X#9G]W<+#
M%$^&_7&H?1[46+O5+D,9.F.S[8CZI_>#Q6A SY;965QQ" !/#S(H$_?]YE8;
MJ,H39U6Q3\V"2CE4%;]5 ^:9-1'ST:;8>NE,.W0K.B->)UR5"J=Q=]<R-^5B
M8NRL;C03&_XVL_L>6"X;_,$U7?WQL87>R?VXI%JJH0GP% OPY[KZM\60")"!
M;C='3WT-$>IS&=2>#)!%W.5"0+!L\.F!7EW6.L^O8@L!JJ'V6_&REY0U?G7]
M_J$&?SE).WM[<ZP-^BG#\C@L\)>?VGQNIC2PY%KBSU_&%.Q?9&R%1^4:B(?Q
M ZQ)G5\$LN19S1:Q6IP!2X29QUDH0>_YL5:SPS)DIUXPIV!<EIC5ZU(HEK"4
M<.%]5Y9,#]!X@EZ;O$VO$""I<4H#^K(;GLK.B'.L9$U)6B'C6_<FO/P/B,P_
M361B];TLLZQT\'LYL,!&M=HL<1&//Y B0@(@9Q/.H9RC(<O276I.G"M)#(@=
M)/5_E\*3KZ6#CXON5Q[=>,4:'%ZHCHU:QV?GLY=L8E:,\@K5CPU<^A;W+6X\
M1DDT;D* -0%CR?_WX6B9\+TWA,\^X6L&$X]^@3WCCS+@.C9NL?NTVS$N N/Z
M4</]O1S6P"M*ZKSJ4LM9F4(^Y!VU=_IU9$3YVZK/4/2V,@VMTG? ?-L^IF-1
M=MA84)[35LU*T=>Z,D#SG\]3QS2#Z,D4-;6I0*[?M)^S$W>Z#KCTS>R^$IG/
M;:[US<,J/VO226Z@&6H-F1;*TW-PV4_JZ@6*I$GY&Z1P5/E-VE.G<&:9ZL5L
MMKB#MFJ^#W5[4K\RN&0WX<>KGX:E'D2SF> "TQ)ZHGYFD;690O;7!/%:Q0ZH
MIO%34N$O-VH;I3URRAL+!6^?<D91 )VYUGWN;:F?6':Z"GS0&CD3KD@=,:S\
M>!F4%#G;7PT$RI/J/K$HB(H\8'JE-]O;>](@LF&.U(=]@1Z%==W;S;_D25FZ
MYRD(N%5^FO+HS;UY5J=0/H?OR-4<1(2OXA4I*\-CJJ=M'3ZXY<@39S)+H13L
MB-=(%!.??QSXDAJCP)B7)W5NK\H_*.J;CWKGR/H3X+N_J0UL)KK$:0GP:70]
MKUN2WC<V;/(!^8D*67+?&L_3,N1"E>*E(,5*CS_(H%ZR)##BN$I28,Z($H-E
MOS3,>*8P6CU?*A%$ :ATD//VTX=,%TIC@\A[T((M%+N+[9H99'QK8K_AD@98
MDZ6 @J7BZSB9& TMYJRE\ 36QT%D^#1X6E.OPMC 91ST)0P\/V1E8Q,VNU&4
M_)A!0&PT?JMJY78\>G0_^-^#=QH,:*A6+NB=W?'VVNBL@,C.$M:%)&!PWB9;
M0#CIIN6O$G)TUG\O:D8W?$,TKA->TKD:H/KK*^$3KO<KON>?R" RB9*K-&MJ
MQ*%0OC[ ^G#3-_J_6O&=!WA7RG.;T[.9=CD6I=>57IGU5KL;2XU9$5ESM/P>
MM*T96%>5S2Z$X6N?G<IUZTIAF4JQG28ZG&<B$U:[F_&=-F>Y&TV\M>5>0-[=
M\.V:*9D\O,_CF\-VT5_$B6KYD>/3L3"1H-L# S[RY21NL6.RL4JRNGK94I.#
M'F^&=L%\TH;.RMIFTX,0%F,^U^8\.V=^2B3]\ZEXN/HI@?1!1/HLP>8J#S7J
M0%KKLRW#,KRG!L&KM-7D9U?E=B]2NSF7#G6-N1.)EW5=)]YR>1'"HCH%XW_"
M,XCD>@+A6QZ1F^&'CFZYO;U*'SY E'/^3$R9FXKB=^K53&OSU+1BIMMK&43:
MIR[RV#:QUG3^[%+O>H\_T3EK"$/G"2VN6S4;ZM8Z5!MP]-O@G#.L5[O^.MT/
M$2Q?EE.RY1CF^5M>:7;VC *X#GIN<0+L Q-;VBDGS<3%=HMG;>:GZ3-948@8
MI"4EH_'46SNEQ$7T+PLX*E+J\^KJMRPFU3)/O>*G0._W2 ^Q.02C4G(D,%<#
M@[],9KQ9+/@=0RJ@Q_R7!*<)'\?UK8\42O=(X:\3,G*-Q41P^E>K6"E<?50R
M,>)^ED0+7I"ANJ*4M$%U<T> \ADG6S=\H6!(8!",2N'($UOWC)H<:/ *V5;(
M2P[V.]"7[]9DB>0R'U]I=!(O^J/7$H_')Y>JQTF6K'[#U@ %-_P,RTUA+(D$
MJI[Z*\Z$0&NTM%]AVGS!IM0PY M.)&.>L,F-9U/T"4-.TDA2)11Z=!1IS8!O
M9;.DE$3:*E@T"FO8_IV?W&U54+&9<['014P9Z%E&V.*D7S_=_!58XKM=LS8^
M^('6+N6F7.!O^]2H>Z]*VPLL?3:A:568T^QA7J++J>X;.[1Y&'=:&QUOT=#L
MWVS(SSXMNEVFO/B-O><K.<[&W*2%5?Z30U&I$S^C8<"1[X)HQT]K#"Y%/W\M
M%B$F]S%J,&@44;O4;0%3CSFO9/0O1WD'PB!YD(U&>64/0O-%UQORH. SD317
M>X-D>$,JW)ZZ38>_6@9Y/0L:-G4P_55GL]UHSI Z_Y0_Y/Y)Z@+M$(5EMP-+
M&]5%1'=#["(GE4%-C9C<!]_-H/50B& R@8"6LVX!9?1F'18>'N6*&!8CVSR@
MVFZ[CC+PMG5:.Y#7)2A,(*0:6&[YH9A(3H\7C_KG\/VFPN!<5*?Q:BF,YM*4
M@8L9&)5[>\3V4<;?#U[GD08Z:6 %]SM05>C=J'A)=MOKM48:R>B9[?/=4&C+
MJ?+DF,S6#L>>\46%Q9X)$NVN>[IX1Z:U$F0DA^6]I$;3\L9/[08'L:KRA!K6
M<+$*\$EAKC9_3J'G)D%14E8L!F:9\1DJHG_#PX$$O-^P8I[TF7RK+@[2#V5A
M/J]V6RP(3?2C!<A$OFM""\B?3C;*J>E%IS0IY*&2I2,;9#,/"C5GUIH44->*
MJD!CL 2]JBV-]P:4O X?7SNCDM4B4TM1)D,V11  !T!O8?Y>ETS:.B= 4EMN
M8YS*X"VK&BL&R\M@OR_C:Y@VG<08BESIX-!QMC19 8[SE%V&5^@F #_VGB#2
M@+PT*A%O.9E"4*&NNA -^>.M6#_TFAAB= @@%/!6@HT.'U1J SRS*$6,.:^?
MNP^*P+30?GSP'ED2?&%,K['PK)%"W4F?MS&5J2+6MT(VI-<_A:O04EDE61&"
M-K9;7NE%2^8^,-5/?@PE'RIVF5IS =E/:&S I@J/3T0H76Q\J,B'32NC>=8^
M@PYA;?OI?8;V;,Y !X/Y&/^QHM@MPY;Z<X/I_OWB/YQDORJ]\/>D.V&<:2[/
M@K#SCMIFQ&OTUK14HG5[G.;2":6_<7E9&,JMPBIB\I]U8\C.Z]8TRGG+K:(D
M?2[6TV>2ZM<W__3#9.!94 1>%,'/I>7-X0_E(4Z'B]4UF7VF#D=./[XV4@8%
M.C:80]RIRO57%5NUE0:[7M7"*;AY\2P<:2B^XO\13MXMC[:-E#LH5=3#EUOP
M9:^EK%:W,!OJ_96?$KNL5[:V/)6PX:P+$2BV4&5(I7 D&*FS4.7Y9@TS3V#8
MLJ5M2; *MJ<F*\>?JR=(T3-\I9V6%-=R]%[E&25/*+6:N:E[QG%1?+*YF5V\
M%7P:\X!3GE+24"V*T;I&[ D!Q)K4207;ZKLT.D!\!W7U>S)839>$A!5ED &=
MD2:"3) I #<D%JWALL2_.XFEH0A-(8<KXP=9')[ JKFV\BDE'HWN#WX]U/SO
M8VR/G:,96H0AA9['$%NHBTH-4# 7"F_0,Y=FT%9 7I *C=]^?$>F9))*EEAN
M7YDNJ992\@Z=%4.I/7'UHUK\Q8D*+A@UOZV^DDZZ_EMQ9/@W$S_Z9#G3MV]A
MW[-LOGW4PB!?*_,H0@L@4,F?EM$C5S+YG[?/ #16Z%_V[*V0081>4V[JPWQW
MVN5[S^<F^IMM+T6ZU XFW*5F^BN3YY_2'EO:/W]A2<_W?E[4ZRE7H9,+%[%$
MTF5@U#(%E^MG32*]F<&"IJ-&Q BL*FP&##X1\9"*+KSB F=ZVM,"<Y2GD12=
MK]OUJ?UE.=!U%R8O34$ CGX E'^VALF\@A)7UTSI>R*%9*K.T@ZL7 <MC_KI
M2_AW,U[ U9S.,NQPJ&1LJ.;* Q4&M,I"2_MLOVR+!YD#AVYP&30.!PK$S..]
MB$/S<#V\ MK'Y?:[HMYI4WCC"/H57D1_(S0/;RS3X0_74SC4K0,G4X":-WR2
M@93P7J<_U-,"+!OV[KJS69B_"&LMM$W57?7$X)QI]:_Q5#!=:89@_''#GT(7
M4TBTY=:5W__J-T42=2=XFM4\'XS12$:]P;)SNQINC_M<CILA-(*_?"%2*<M4
MO<.I)WX8LC!A83<OX*BYP^N!'&%??V08*.>9+%?HDXI:.*(5!91LF)HY4JNG
M)PC&-7/EK)I-4KT)Q^-?UW_"R/^F&HC',8Q3PH?E](;/"N_@3>P86R(]N!CG
M\UMLK-?L@@SH87BCI<'=,_1KU&3]G^.Z$PFQ608QXW#\\01ZI4>F*?$HKE'0
MZPKKJ/X-.H[?0C2@_,=)1YPEPR #1V&(/;#Y2*R6Z9#.3ESQ(?4'ZP;NP'D;
M=KX63Q(S8),_E#P.G6IG-W\#?\J/D1GW1-^K5"8@N'N0]YTNLENDZ!FQ,'!<
M9(G]DYPX+[1(A+X^4OK_(>STF2[*#/E:"\8UK!DT"B0[6I%RB>0J$FRCP3"Y
M0"W"+6,8T!O\]M=(EF*=8=:\H^X"F=ON[!\S'?4"U'78?$4/K7?(A\H5W@:G
M%=+"J#[_B4'R9^L=Y,.685-R+K4]Z:UE%<ZZNP4Y8/B>^4Q0DSL7F/:[PX=C
M$4IM@ML&+MNMSV/K:#!(!!YMP\^\.8N(%/5/(I_G>PBE#P+'G&:7A$0H70E\
M-X>=?='FM&G;-X/.7BHY<WR!+'\V2.G[91OW*RACAK..*FZ6=\_@*"SWA#IH
M*/F'7=1OQ]SA#6F:P:>'Y[J&Z6(A3)=R#P"M0'B"NV'3?,TDH6F::^U6H^P#
MX(L;MRI&4"27()ULA/#L)%>+FNYL2ES!/K6%*DKJDFM/!(_ID]J(UZS<O.Y>
MVN6#7;$4[D6=6]7=#IK=QK\%HVY)+.P6=<G$X%GFN:.%YU].J?PGE$NI(O&!
MP;(Y%G#=;JYY<6UM'H\H.<200(%[@JF4E:H_$9-[1E.)NVGW<+K<4K\'96O4
M.D2QB[>F7+DE:>0UJZL,FO5"B88%<)G9]$T6JS+5.W8R/EO4M7'E0W^*-YT4
M)&9B;\8^:J@&,N2IT(]"6$C12Q(9-1/1F5?H,>BEDZ\!+$"3KS?=N+3!TL,+
MTZ#\VA!NAGQYXOGHK])(#H24>AB**$(T9._T< 2?QV)PN?LQHY.@8F$0:!7X
M*WPYCGD2(*D3H9/^\1VYDADKIH4*91(+0/T5>F=)?'DME5(.8U^I-47"-:ZP
MQ9F+3 #I[[57"K@)O\,_"ETD*>7BH$[V89I]?5O,@8+& /C78 %RP$AW G*6
M*>1H]<=!D0$2OW\CW/WWV\>8D#1U(8.GAUC6G7\%,G]W]>^:8_[NV>&FPDCH
M/R^>0:L9FO1P=!GPIER1#PF;&:R=<"OZX6SP9P*A69+XN[5-YF\EF%JK*QNM
M(,5CKBB]=UN95P0F@.9>F#MIX 8_S O,2WAOTNV>-.1<&:5P#ESVT1&O$RT+
MIQG _&)XHFMC-EQVL_ZK";)>,RF1)(FV>+L#.X*/F3.=8&F!N2QL%674T&-G
M!,NX;'_RZ^;EX3UE@A=\)=R<=^.R_1U6\,E4[7G,N7NE%T9:*X8QD6WY01P:
M[$-O>C(%GSM#,R*N8\KDC!F"&=@U_*$D]2/-$ 4U8BBK1XSX4M>U8KC">?;G
M.D\;!/YLT69!/(+:B67#BI-:6RD+C:?%LR<5.>TPLDF?IM5SV6I7H;U$[H.=
MGX1>^'+;"@8$ZY[X?QR >!(GE*"3,W93YED(((I+TPYN?T: )S>5@O8TKE5Y
M5K?.1BF;)[6-QG^G=@W</_N>E"%#;K(\,NU; SJO>WLI<)&RF2_J.\AZ548P
MK$#YXWAI@C>^70U_&.S=*4-.'+UKP[MXW>>T0;$G#,5\:NBEJJD1:&$3/W[-
ML^3NDNB"*=ZBCXEI<1\I,,4*L8/)0!J.?JBQZ"B$!<V=V"+)]L=4##_5A-C
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MEPA&IA\4:7=/)%O8X(6H?/+C"SLU2R.08@?0XZ'.:*':@%%O-;P';' 4)/V
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M/N=Q\;JJ-Z-]\>+ Q(/F TP*P[5Z8J'PT,E<D5"9D)A1R2@_0":$[L>SL=A
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M^NII9!P/U!HV8>LXNUOU6X]! ?)F$ 44!N)#/FR[$-P$Z<?@[JS(5OX$B<*
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M2$DG'ST0[>^I/\RRANE[[34Y'VL8E(HV*WT+YGOE_7K69]>37V3_,3J5$35
MR)KYO74'I^V!;(&52J6B'J@I,(:EI=MK<]BL[,5QT%"UXC[E&ZGY !IB;I+J
MJI5VGZ]'AC;!")=*@9\,=!/GZ5VJS*L.W0\$&;T5G.)4'2[]5HHIS#Z!F'/M
M01:#995:%OKVM5FF^1?M^1L#Z&IE.9&M78)..R;* PFI%E1(?T;F5>>VEX@Q
MP;J; 9S=([27K$+S@G+P(Z(IM[  VBO4S6O^9/X^G'213A^KKA#G=ID0'@_>
MIR3%(>-3\\9Y=?$_GHY36\F$',49JATXKF;.8S!%F&RUB>CU%_=JS19^L!]\
MO]X>L!+M:E:(ZG#Q_N*\US@#%OX:.E*/M/8N-)%AE;!! <VNH<UO&MLP(CO<
MC,W;1#1\V8\WQM/'&'"_>E#I#52=G1@;<Y(MB59!3LU\A9,J(*:O1.T-1PN0
M-F/0F9_ Y6S1^!6+0OC2LCH*U:527M6L!._"FK-LE.5XU0>5?*(QE!6)!:%5
M[B\]+*=A6A%E%QH)R *LSD/&+TG'V4H4WYL=#DZHU%;1P N*%+LTBU*4-6;4
M<,)$37=2*%0[%+,POYK@^0OU-2JP[SB6I*@BJ%T,VA/Y2OXVNK<MU77 2LFD
M3 28GG/8!3JQ;^-AZCC8)4QRY/_A^26 (D%.W2F&].]*N42PD!,12Y>*C8<X
MLRRY@"8?TR,7;LPRHX""BN</9/PXE%4ZM#*1]J;*T%T:L'WUY\N!.6+VMJX1
M';"6H)"XT^20GY^;#\=35.#CT)/68S*F=OO<>M(9=9@MD\M;V3;?9%AEW#+1
M_-J]'EJ-'ZM9\Z-6;Z(U6?7GW,^T>X,K]RSI4Y&5WX6H_<L3U @*-3:YYU4J
MG6=;ZS$2"Y#?'M^)<Y;(IC[JC;8D],TSGJU_?8*LJP]JZE=<!/>_G9CX(4N]
M1R)LI)=^;)Z&1(S=51,X]W!YE>]>,N3:A>$"/,UPLVHL74T@/ZHJ%!H'EHKL
MVM/-X?&M!TA^S :E(K-#T5_D+FB*, =\M52U["V?0F8I/AR+_OC1Y.]?R2VC
M7A9->4'@G3:*.[!BNDUKU0R;I,!&URQD81,4@&%=VP?9^Y8<F.1&):IW9UO+
M=96\%@@8="G-9,L&^89^68&0@UO(C0<G<L)Q%I=MX.%TKO)O.P,]UN5\9,SY
M*D"^'R9L$Q^3I[1_"A4M*MQ,8E0;6;,?9HEPB=ZX0[M-)*XC]"#54"ILFNT-
M]D&B+#=EB8\X8>X=&4<^)M(P9<S4MZKY\.[<%'2'GR!_!WG2N+1<=/GCBM*A
M-]TGG>R5*FZ$?S2ONX^O[ZK,&.G_^ 6W31SDW(@()DZ#\@D4&_C\'EGJW[C&
MS76^"[G8S?N!Y#'8X"RA]RO)R7G0U(F*,6EXM,>69(O%D'R7[ZWXH\H:]Z?Y
M.YG)PW>-I9XM5SLN<^C@?!<_+NDIBKU;J!>+?.!"]X3ASI%^W%]H#SV#H<)H
MP\#7D;LN<Y7R?YN5F+-CK;C$TC1G%L1?-6Y:.E*BR:11#7N\RA:R?WLT5ZQD
MWJD+-GN9:Y.+_#P6Y=TM\U=D-V_Z?GXY[')USMN(_\$:5H':"(($!"*C@5>O
M^<4]Q3X 4V:NVAT(5XWH%[$69IOZH&16OED_^:5,>HJG9[U9/>.5JV[KQ2!B
M!U+-->=;[K@>/R,_.ZD8XK[S8(C+^[XN:TOC>>VV6&L-=5>6P$,G^-4 ?PC#
MO+F!IV6;.*.^SK71,7O&E O?-JH)A%)HXV!F:)UQ[=!IL^L1=%GA \8;B5PI
M7V")WM(-SRAE@Z"Q[&RT'WF:T<T@Z(\GGRZ3TC('30-;[/[8RGM%B2150$O?
MEZD*QQ]0V!I7MN#"FE05H[I%P9E]<YI.Y(Y _3 2D*[/RCH).0.TJ*]@XD%+
M.Q)4,F?$_TJ,;7Q-;DRE\-)Q&N;#EO48JV*KL"RT2>Z!G\F)FT8POZIWI(/9
M,;$QK$QV"G1(="/8G^(+  4:">6^]C_$@N?6I.IR"N4#@Q@')@'%TPSAXE'/
MHTA'A.YTL<*KWF,#.#*H &#N4'5U&JLD-6_NL+\^FKQG@ >\SQT$RXTIC<ZD
ME=+L/(J]R0BX)![\%KQO><+WEC5I)P (W]<*6$Z*IL96^T*LD&SLXG/DFS#3
M<QITZ/MGO>Q*3#*!',Q//<H:PLN]TH)>:)I;F=&L.Z_Z!Q"W\_$]8XS[8+E'
M\.XA_+=8V;[#Y<;XKG<IL6ERK$1 KL[+MT8O<J"_1Q"?^7[9A_^.V^&/SB;A
M/'[5TU17']#QF^?/U'WSPVMDNR^HX9L>VJV^RW/':MOG+=5FKE_&>A!HZ;:8
MA@O 8;&S_37(8; Z@BXR?*K:3&Q&@4_S9_.Z(3M/EO(; #6;?P ;\7V<I^[)
M-<MCWV!UM*7!HT<4KY!5YC3D2_CD8,#S/M?YO<$2YP6V$6G-LT_G?SXD$<_N
MY#=;CLW4SW",NI/+-<NTLK.-\;'J )RIQ&A%3(9XX2TE+'W)D\>:V;4*F2RF
M;,F:N%NRC^TX;C,2("GF'V/[P4W*OO.J*Q)LM CGSS;1E1QN>P/<1/*F:K)#
M^>;ESV+=IEBV2:R+-]VS]!0][-\1'?19.3TKVL<']<[FJX%&LU78CPL[=N:9
M-1IC[!C1G3I1ONA82V9Z!<9^^^A#_^8;]OF(BC_PG$5^8@?N &^2(08J$6Q!
MG#=+\T7=])#[R&J?YN+9_+Q-X'G'1ZX)J/W.8VF'YTGDFJDDMN$]!)M2L+*M
MV\WT7XCI>37$#B/*8OHA:.R#'MO]R-222Z#0Z:G^J^W7BB\9;4X,T;/&>9T^
M6@HGNP(V)EI32EM'3G=3^<<BI7P.D1<YM<T=/7L6LMT"#J.B*XBG_5_A:VWD
M?%Q0*:"%,M+?\V_Q;/39\DX>%Q9RP,CD[$;2G^%DX^=(SKEK:7H]@6<Y4?Z#
M %!/TD_57'IO>UG/:E+]9/"F924.LQR(RZL<-*%,]^GLZN!(9J*G3'7JY,AA
M=J$Q0/+;5;,KU0\.02BUD?:3_76)!U&@)23$>F#S9<&,[,!QN4P$0[>A7LRD
M84I!:[,4MS%FFTXYCR?JD$**"Z;<9]56N_VZ&-:R&3@\M+#] B^*( NUW&4;
MNF>,;>XZ=8QN!ZZ(Z"7NL&KRO/^$FA%U)>5"6HU#B!1Q(H2-N90+@ SVVA3^
MD0^1H)&Z NJ:\9A%,[2!E^Z3;K989#$X!4*SM"'*@;* AN^R ^-#K>"$;<*E
M'4+&HR1[(H1E<^*)XVP(4AZRJG""S]AP?GB)6J-H W.Q8U8 $)4%#*.*;>?@
M:,O"'"6=SXCUTWA(G/&ZU-/!2OT5\Z-X\]0;3EM%@']S:?8;F"(V-<YUI>/?
M,W_7!(N7 +YA6OJ.L>  =DE)PZ;>,S%%BQ=8_;T"'</9F0XS1U$?>^R=0HX^
M S;K-(Y&:+=XL!=FCC*R59W7IH'EV7:P@96 =^R9(A,WS"",,3=XY!:^R@B4
M"LHY^CTZ+Q1@5F?)K3\^DOIY8W\/X"_T)?U>/W4"\(1G1];B_-3K0O1/;F^+
M4Z?%%#5CL>%0:]^*\.MFWNZ-=2?8ZW\ )E,?[Y%FL)^L7_X!3+W(#YFZJ*Z#
M3L$G)W>D'-*FD@ZZ&4 L%!^T3X*G)$CE4!-,>B^@=$;?IS@"6%L"I.PO@U[7
MK_']=2L,]8"399LN2. ^G1.]<ZZ+,[Y5+V;*Z=Y.^ V=FY$,L/ Y2%;L!D_D
MT]7I" +\(3%\L"LT97J/M\?39>76)[P)]E2 ]"$.QD2TH(UB/!:(]HD0>5A$
MI]@0%PO$6H_VNP##*R;[D3X"6)KR>@79,Y$2\_JVGVMENMF]+-O8R)6*TI6'
M  +^##QKHW0^+._F=-)1:"Q_'&BP;"F'A0-"I?^&)HUZ7<,N=4Z@5]18CCMQ
MQ69@X\+U^RBWZS=X&P+V)(SR).2;OCMZF[Y(711<.$$3R/8%S%5)=DBHB:MF
M4 #?#QT,\&,22Q!K4]'E_5SB_*PD1AC:@"3&YDHV_^E%-[ZSC>=!@&Z+,S[F
MLAEQS[P,L&)\9["J?&:71#P:J-D;X?P;;.*J,J)M&7'[\<"NUYUQ9&XHJ+AP
MY\I"098B-$D@@V3!ZUXTB)KXQM7<50QUL'*TJJ)?_2X?^ ^ ] 60/04^<0&1
M[B3F2I[!N%FVN4/T7.^_^IYTPY_Z:_%P%G6+7)?!-ZOSM7/ ! A]*4!NCBXN
M=N;RQ4DVAQRLBKF\>C_Z]='.;Y64+T*X(D%51DGUBL&M3E5SVF';75- @BBF
MCU*N%GS;2;'GFBTE\H.3H_SV694>#U%",B/VG+>GY$XK^+R*N+.;QC\H5QQV
MTQ(8/C?6/"U3/;A8(P%YB!(;A(0T0XLN90N[;ER<K2V]%>7K&7.!9SY5C2K(
MPC=L(7.,KG^DC#(J"JZ$?6@'HG ;XZ.IJ=R17LY :6TCY8N^)4P\*1FC[$J(
M2FDY3&?>QB]JX&WRA8A01%.Z7KRB)T*#FGT1![YNRA&_A1-O\Q4!C0D4@Q'D
M9@.'SZ,7EM1W.@=GI!_97BL/37F;[#@]2>$/G9<O ^@'?IH @NO9W,FLC2'C
M/$"B(J(\ E$%$4H=J&HK>)9"++YJ-0LN&&-<:<T0P0.%B9T:H)8+VL$\855V
MU/$'0C GROIDYG0=-1YY6N6^TCTP:E;45>^".4LQ("@D)C@&FM3LKK=KI3 R
MP_*8JC!B9/HY4T.AZ_,L]EWV.;8LBU#A)WKRCLE U[O49MP.'*;'_SE@Y>U$
MF.8S<.:1V$B,D(UYO-3_XV0*,\!XIF#B\9DP@E-;L,00"_L'X&4"\T<L$#?$
M%/V^S9]@L+J<Z27D SE .SJ&,?[^R^W<RMOG4F\S#[O=<\?^/+5^?FXN*[2]
M)U%G^^Z'O;U]M%!.PI? 6[_4KMSUX-7>ND5;Y6;]WS(J=TBS-Y:82*1O;J_S
MKVBO5N49N]XAOU\BD/LNDFA+L3>>?I:3#%\F#KO]X*CQ@]L Q#\ D4M_*/CG
M"ZY4.W\'\5YB=]#S559Y*TM$5^VNUL*N[$9+$'Y]J<OER=]X,C>>+%MYNOX/
MP&_39V[>4J6I^!_ ^!S$T#OX^\]>W5NH&9L *RJ$9Z>V>$@=]VNZ,1T!E2S?
M345.,($QW:#(+L>8\9TFMB="4]V.,ZE$SI?1:'*LDL+^)T'G'!T^SO-F*X9%
M7]M _5"QL')B634UT,BTW+(Z03-2XX*U&NZ9JI!K](OVBJA8S"[N,Y"*K;&Q
MI>*0M3ZI81005?QSN>,]/6I]0MF8:GX3J=&:#G4;#03';"A_.<RJ%[3%^4I[
MC$SC[J/]#/Q3>M^5$HF=/9"1U+XZDE69&LDEV.95@B3FZ%L\"F3;I!#SW1-Z
M-KZ+4P-^+XZ]XF>6VD2?>6()?&Q%^_+W@32>;_VSX6A^V^48JFYN=9=]YC4'
MGK3&,(Y:^>[W=>D*S=LO,D8FW\5/Z$9N&?+/**Y,2]P#_C0LW9ADF*L>UD^^
M54W[]?J/>EHB>6PL("(&/!#JF?)#.ULF)04M^5:0.87&4P$46T"@5A%,/=PY
M_*DCU95U1R:C;=6UULQ+5NK^RW?"C;0I;]U?*4_/-#Y6X7!;H##O(CIA%KG+
M=]1CO[\XS[;E%?GD97KMBC*:8(>+&+G&;0?.3VJWB ;.&<SU_6#P3A/AM5V(
ME!D?62P\=RTKV?(_><LW"6E&//GJHEL6_-&EHL%,2^.\I[&4D0#SS._UP."-
M[Z+3%(8&JNP)):=?OW_@Y5 ^Z_1\:N.3O%?'Z-,G%LJU-OHRM3W5.FTTF5CR
MRM=61T-K3@.#UY?\XRS$D(OI>M97Y?6EL/;T=[Q!?H'&;>ZQAT[FS5EB'Q1
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M5Z];#)1^-\402ZL2OF[40Y;"B>;,#1W\)$'Z@0#-YUD RW]KA\;H#((TU#
MX$3V[Q,#WX+&B?_ <K\]@2KZ<)IW(,D&<$F\9ZI>*]-^(V7BK8PW!+]B_VQZ
M$%V 0?443[(=IVQ ,$6)>A#_R8J*X0>X+^:Z=\*O\'N52Z+$!UZ)@H_+R^WY
M*Y*K!AM#+A"Q.'8>N1>1R[?H\CHJK#9"PIC7R;'2-(ZM,TT5IQ\1R1]*51?*
M[#>,1RV7?R-0J!:WIM6*MJOD/T;)E ^EY\5GUBTM+94W<X8[OR.08D<G/D47
MKNR'0PI<R2B6;ULN"Q9QR4D ][2YPS\+2\*&_VDNNYQ%+'XE-? U%O:36O:)
MOF@Y05SX>=A;QV]H=VD[*6Y\Y^F6Y2O(7SSNHJE]P5C66NCT@;>G([]4>.']
MKV@%(("O.JI@:%-+0G$7814WY-/F_SF-IL_\"<?\=^T2\612VFRJ?@ZL3[!D
M?WF'>Y(RER]7L]D+7XW)C ! GR_HB!Q#9"I^S2A7':3X*I]?UG4/R*"8M?)3
M3O8GFS%^E/1>%;Y2JU=!O%[5)[%6%XL7:&]I(OP2U71,\1<EJUF(.3=*O0T5
MX9/#)A;J40%? VVI)^'GC&N/!/#XS<?4D+_/-+<;.RWV]I1!\*=<!9;:OF?T
M]GDNEJ/4/HC_T%TVQ;>*'%M4OWV'(_Q9:[_+K=C0CFEMKVC)<*@='_W0_LY;
M'MRZ6N-ZGKHJ>8>I2%K)"KFGW^HOB1K*$MRK"0]*+[_]T66X#EFU6YR=X$B/
MY"YK>OR*S !1:4 !O%1KQW5)NW6T JP2:]KM<5@+S=<RNZ*<']B/42>]*Z,*
MUZ7+I2@]%'^]4VY^]..N$D\=XX'O 9/BV/76ZO&FH\->;6M)F+GS]R4TL&1.
M9LM7+'UR!6MMWZZ#+JIVK52MZ#N6I7>=V^ZNH6Q<#/H%AK>WZ"@I2>54=\[G
M .W9IQG(_<41(%%[:^YJ<Q)LE3U+JFMR-RXM)5FT$5?(;$1=%;1.'26<5GR3
M[+#";2A>GW([)H52SD(_F_Q-$54)5C]?*2CY@AUU(<965VZ$<*\D,TH?BS]V
M(WOO(N 25MX_DSI42>9<&(W=TC =)K: M+>72NW_>E:_YQLLJRZ(I'PA6FO/
M^Z*2PBAN3RJC/=>Q)SLTU\>XUS,M0]2Z)?L3A.99T5F+QMF5;?B1C?ZEYIOO
MZB"[&QZNW*GQ&GMJR[[/U/65 LX*J5*T$E3ULKZZ:1_=]E=,;+OM87@K+BLF
M[A.#=6\Z>06@E=+8]O9L&R<&\#/Q!%EUS) .YRN#ZP^SD:M\?B L%,(K4D97
MMV2P>J!'(0F%ERSZ)FL1)0P2U%#RG,_?D1V>UQ/&F!4%#J^:4WK8Z53)ZPH_
M#=/C[YZH8S(IC/N75Q#3" L!Q7R[9Z0H#I:DK CYE<%_JB&$6=VX&$= 006;
M3N@?EQ4,;_@+T&81-,0( HSKY87H">VZJ*@T:R@Q,E)X/,N>,K-)(%;,+\3H
M.0,*5TT>3J+/QJ+!#)7SN_4H2#&J- G0. 'L_Y5DWL0^8Y\1-5$@[A\HQ,?A
M+VJ9TD8G[7S\P-2TG(Y&PGURG5V,WG.&1;XX"*0/(,;X@N-<45Y39.^;95CR
MAZJ!=1TC"XV!H:WK/@$=/PU"GLWYA'-'G@1NL<6($YH8;OHB0HFUJ*Y<OXO@
M/RT]*7MCF_IGNE/2QN?I_7;N"'?=U\OW?0;G?_*:SI%\# IKKJ2!GC\7F4Y9
M;\#?*T.H$0_%1ONK9%/'2D-@;,^_@,#OJRT[<RAO/ZY"W5:(?Y2HS5_ B".=
MXBW:;'.'[HE#Z<@5HG%T]^(!E#D"=^0;MAX82"$%8] T&!DXA&49ES:T&#9\
MMS>LF(P .[Y[KF014WBC7S[ZV]E^]>3D[L:S\9:"I8G1H#7^296KJ?!*L;VM
M4FJ/(R]'X'M670H*JL-W:36X@4V6U(IF;IJ&$2*F;MY]S/&.BYP'N>78[X?Y
M]_2(N+5L9QUZ5-9'I$^?VCJR2KT-32ES"6<*\&0%0@3 S>Z->S-:+ .>M7I;
MB[;ZJ8@^-0J2KJI!MD9R'W^<Q)IGKB(QO"5=];1R+>K>\LRQW":;=[_?)J[*
M.VKPBX3R; 72KGM2Y)-=IDBTZE.%<C)[X+0=BVIL%>!X! ZWO\=RVF((M9H5
MBU* EV.]6"O">Y\@8#^LN"4&4=[U[FAE^[SH67V/4!P(#4/V-VFQ+$+(YGZS
MR[(7!BCRN4"*+;]C662D&6$)MZ1#ID.9#)Z*A -@FG2UU+ ^V07?E-=6; ?U
M:<]?BB#D1>:<-C)4$!EB A%E@,DF?.T29CR89T:T<;XQQV0T#H]RTWHM7T,9
M;5DT')"GIZF_F&Z^:6KOJ+XPL%\-_+G9U>6G4E)7.[#;WJR74:&?3^F?,Q&<
M$#2A&3AFWT?Z\?7PQ<.)CE30&.8G^79S^BLC2?!-:H<U_7#5XV.QP@++ I]E
MN#==2L-&B(C1++UL3$_:]9H0K+,E5JS  HK@T:@9).'Z,&-,>-I6;U2>'WA!
MS^L!LJ^?3&?Y=7JA4'/AK?MZQ#(]EXY2L>=%&G[T(?J=:[/=*CQ7/>Y.$R6U
MVKSHIN$],WTK3<=D]H;\:+Z=N[+ +[MV5DV,CG;D_)ZEZK=<R,R1$=UF.CCA
M6(B0W%U54>27OGS7(V9>/]F"4@RF#R^7R8MNMAK"E$[MZT6=25^9O:M'/BJ2
M$#8RVWV]$#,QE[J^YDSDV15B9_'^J9/HM&%R:*6BBX^WB#/&P]H,50F'LY%[
MCA0W5_T>R]/QV.WKJ(@(C9IL1$%&X3@,4S>I5,_:GDH(8/JVZ3@Y?"EOF]HI
M59C.=FRV9'#+PV8)PY9$IA559*VM;^> W_7SHLO5R)/VN=5/>D!5K6"G%5,I
M6T_4EV0'/:@5 8GG9G8\*H]IH@W$UG?V]DM<@LB7?M6(=VPZ(D_3#!0U.ZL\
M<F"BB>=";S!_F('Y(7F.RO?X"Y;HK% $$Y"G?S[T C?YJ9(@87[L>JO3:DC5
MHP[M+B;*=H:N?R!E(6::8'=)>TO&$^^BY+G0Q@9B9:0(%R&X@P9!8!N?XK--
ME-]BV\X7DA(KD!D?9((&&)/)6F?V\N<"T%*:PS]F,8=M:GY&ZW'F^ S8)=L,
MDWD+(,:H_OEB7BJL$T>&"B<XPM!,M3\/#X#YU0)7$>T51@ QIL6QBCM;;AC>
M!>6M9+O!;>3]P+9%I[.:BR0#@,N^($)9>Z5$6W4-_?+RM-1-57 EY:+P3.A7
MS=!>U:Z$2-5MF+4;1-Y+<NUU$J,D0DYIW;*7=&H'$RH"U=VC#Z7'XV[^>"KU
MI]Q^5G#*4\)9#16WZ14\W.+_'6370-B<L3I$6UN1^!?P%V"$C>*Q3MGUKI08
MOB+,'=YU]=T520'^,4\9BT,X.%@<)^;9LP_Z)T\5(-:4F\6%M*=*/L.5Z-4/
MC'6-=1;OKMUG:^&K]A?<R;&J<7?.JQ$0AFY?A9I;9X5P[I*8X.<)+;B^6-GQ
MS(W:PJ^6L^?U:O6Z!FJ6%BORJ_/^J(=MTYK,2[]D*?H27N?B("@>O*=."M[K
MHTS#CY,GU[-WM4U+"!0+UMM*KO6_5P\:#L4QHQ1)A7QPT7"DP7$' 55_)!1/
M<,=>R3/&'@%<'<<OE;I[4Q;/0_AO(<K'.P_7>@D?1J&TH:S$THVS"SM/66OL
M39?;]?"8'6,77)@4DYB?P%T4<)O[SQ@'<?,#TVHV)9('!V+/NJ+>2;Y?4><9
M"WITF\V\GA38L]GC(+4Q9A'K-)=1N#&SY8M-VZU"2OZ&>AU(!C[B+4M,D5*^
M0[96R<*7>B]: T0&TYK6R7/KFLYR=:M1'YAYRNS _IM5=;0K"A<G3*A!I'T9
M')+A&YUL0DQ*C:=S"'M;=/5-7[NV'G79]=%OZ668W6Y#CH(U<WXRS:O<)N>&
MRG!=J'D,&>)WF!KA&N\D?LKZF"GZ:;B^KAK_\-;TLJO$?8<L^Y=LU2^9FK;0
MV71"5=51[/CS# P$6?<QB.O+M^8)F]KXW_F]&9G7'@(WQ0^A54LGVI<?=OX"
MM&*N9SM,Z4?'_\D[<\QLL[NQQK: 2RT3T3/%HJI:+ E=X=UWMC;-K>M+CD67
M;L^3G^RL;>)MQ\7N(,L0QH=R*@-A2WZ<YOBZ,_ZFQW$B(+(37O:;T32=Y ;L
M8<*#O80M9.M>>D=I+\,;<JW%]HK5#\V0@I@)OS0_0WNA\%OC]]NB*KG.+D(=
MD^VOF[(O,A!E,ZZ2YJG; ]X"__[=Q.*6;DF]+JY_>,@).JZ6]O;GS;.0A1/[
M*ZI FN&<'\331M)M-/1,2P=L<:%X7Y<W@TW/C,AWXL)//A@.YX3@K\>$/Q+O
M*RO=]>K^CA73NP;#J-+!Z3*!B:D&*4E<OEI[5*CZF_V]Q6<4@#9NY%Q:N0K+
MY<?3X6DI/N!OW0Q+=DONSFFL@OS!HKSCR<:]5)QI]*L;7EYH]9Y$W1$?]1=4
M2+^V$:D0D83\X=N=!LLBS[1.HYJJ7VD!=]YEW,'<DG@!0QC+\0&\)#O)I)1-
M)718X"=Z398@?CJVT[,+W>">L< L&/1W@K+\DGP82ZM"JH$)W(;ZAM4?@W\(
MEU4#_5UQ([H7%2=#'?3PXTW>;3SJ:_XKI2+I Z]BUQ0"*FT,$V4,'/0S7B1H
M&!ZA<?GY UXQ$ZX,-KD(Y*O-4UQ^EI>!<OQD>I%)FI0!+$LF>F; V?SX>R6,
M9UD,B9__S0X!JK-J?GNP=,9AFQ?6DV+!.0&*: #<?VF. W8T?.7K!M/)#<-Q
MH\L?^CBJ*9*^6YL=A]KJ&=5,_^P_X#+JI/_!_LKMBAP>95@/W&"-3-W;6S-Z
MH/*Z1_7^HN?I(%W[^L>ZR,HU(VU><B+$ /_6WZ=D:_!'DA'-<(6125VMXH.V
MG.[^IU!CO(_7;H5>IU=@8W&;=CK@K\QO]TOY2\4.<PO \A:8D)#N+Z^27W]D
M=[T&1T9'A\=V!*PSTC+$K*QVK!3'!/A=>2PYJ8;D4N/;[W2T2\J?:0.)2MEF
M:]N6%S:71MKM;'F9NH<%R3D\./GFMX3>O%Y=L=R .RP_'4,+V[J;TTYFY8[)
MWEEF]MS&KBETEG.R5*Z 4"NP3<X*4VD3AWM&]K,,?O."@+72@;U<$<(Q/+/I
M("$@J,2%O1P8\B..E*<\&J\9?MP3W>(T,"N)!%Y3$%(&L3(+_UI8%TA&D<IT
MZ"1G=ZAGZO#7T,2P**$%E)!YQ?F8/TGQ+20Z@ W_5@0]D2[#^H'2(B]"J^MZ
M/0#JX"MR6595</>V+_&B;'D,7ZS+03+Y',+IBLI>5J!&LOSD@:]^,L!9VT_Q
M*;XJ]L70S8\NMQ)T#)-Y1VU".N9^[N?B8C2)89[=X[*U>+0'Y39]5N0S]IMN
M7OYP&TYLOTBA$]VI@5WO8N!H/^\4EXR[4,AQ_<O<E*BKT3X%51X\[+8O>=J!
M:M2#-&.::<&/(*IEO :'IJW6[?FJ.)9#?W0>NSRPQ$I7WJ@MB3Q7#N4IV*;]
MHYM3[4_NGD6%63)E]Z-]QYH&S+0M3OT3@554"G4W::C(9([_'4,V>,NS.IQ&
MU%*UL54/5?J1)NK8 @K?\9.H%Q!0 0PEA@O+2RIT2I5Z[R'\&QZ "W=C#KXE
M!P\:SC&\ U:"33"7$=FH/#%#<1_]U>>:UL&MIRU^&"LG<7<=?P&'<\Y_ =.N
MG_8Z_/[@+(3VNO\%V"W[CSWI_ OPM.NP\6\4>'A3.6W]H^H_PZ=4001?T%^S
MW<8L>M&:%US0(W')DAC9PGA$?3_H!JY<"\U.V3,O'5,?VM?/BBJ=/]EU1"V/
M)HU=\$?+OM6,PY##,@-]%: P!MV,KE[6T[V@SY/,7IUMR-#T1*2X.<A\%^ G
MC7CA^8"WWI(AZL^^DM%A:%0RN.ZI(!*['O]R"V+=EAS:-!7*/B3<W%[[)2/I
M.UNM<668$<^NLK.T;&.S&SA\9'BH+N##3+Y;)1XTUJ=%U< T',4=WOB^<TFG
MU_-WJG=,K'TE1W9$@O)1]U^ T/H)YPN!E:4#LZ_*%"LMBZVJ4#'KZD(;(U91
MA>[))C>8AXWA.HWP\]T#GG]S67H489=XJ)G<\AA9M7G/R'=-LE%/-Z?+,KS=
M;9E-*22J;RHEH-4I:_F^DJHR4ZJVP\TA[MIIW=_E:S>KZCW3V+)FA<N 617,
M)+6JW 9SP^V8TP%X&F2"3S!9A&$<9$88DJH_7$^G8/D(-G#GO$T^2@V#(MPL
MJ%8^H,E-CB+J=V*-'8S$DB,$8J7$60 H):'PULGG^-=N.DZQG- 9$A'<"OO%
MCAL_D<5X3^VP3.XD*XCY<T6+%(>$H4:5/888!FKJX62B9$C[RO"><(].YALY
M:>\5 SRBD"4(D B NF=!R)]0/U4-KUF70D\A86(Y6$S,XNTDA6/&_T,:#J#Z
M%<, WCT)_M.4*!^(-!R30$D+FZ+BZB1MJ37DD_J![Z@Q;UQ<LN0@S6#8@]X3
M9HT/3WA&$/VN'<NZ]O6Y[?7++%%U'[G+N>L-7VX>G2O><OT*OP>[J=WL(-L7
MC@FM!1+W4C3A8)&Q;94^@_5P)HA!:^C"$#DEU,&XI)W^7FC)G5O\AN<0>N#!
MEJ^]#?YCW=DZLHL)6ZJ[%CYLU#/6MO[TM-V(/1_I1>K*9'$N^0@S)99X4+RA
M7],:\V%J]H EGCU/_J 7 7XQ*<TK9/QGC=(?L>,#) ^JSJ)';X,FMT+,8Q6K
M0^@P4S@5#=_G#)OSPDM7W+[4O30</ 0Q%FT!NNIOY][7<SJ.@VK'6/AHDMVC
M@OJI6Y]MI!#UF-$4<]M2VT^&7[FP5@^<3S#%P9ZF'3CPP"555N @#)'D(3DH
M/36'LP4),\2W#I(#?&V3-B/:3TJ])4:HEW"5"]5[&?V"])B(!ML%R:_G].OX
M)ZX*90L/NP)7G'?JLIW5,^N&<#"&I;U<>LSVN>Q5]A?@!7YJJ;74%=+B([\7
M_0FN** ;-?-1  \V:JW)7$"Z+(/V,, KZS5=F<]+AF?+N>Y6XZW%S>>-U_>H
M3*(O]"&M:GT*:K7!/.MC.OT:SNQ2]<8#[F+^WYQ8T@)J5K[.T&?37,\I'KNT
MO92?Y_,!N/Q!D4<H[K1O\@^?N*R\0-"7JBC>D9<JJX$<S'$E8Y+VX(04%*($
M)OET$=!]<-ZC1W5M+6<Z#AEP)VQG0>? "&NZ@MV>\]7,Q8L4>J2.JCP^;)9_
MM=D(.[.T3?NU_-XG7J\3;V=*&KB5-1E@7-!GC_QRO+Y*\=S#< ZDI'H4+Q5V
M-/8]T_B0'[6Y59N;S,821M%#L5'MG>8_US3K#,TD.I%V7K!/B& ;^^AO_(=X
M\'?9J&N2^5O/FD-G'VYCMOE;75WUD8FK#H]?H0*&7&]_6C<_)/RRV\M@H]1(
M9DY41!M$A1>9>^;<(OJ'[L1MW'3IWUQU.%^XW[A9-:=[@Q<Z'ACW.JXD,W_2
MNU[SG!GM7DL1+1B7>+Y>N?E4=Y%P[7:>,/)?Z[9/",W9*&\U4=^<&62)UX-P
M7O*^\[YL#=471T(0\/N;6\?D:3$U6V%*7D;*40PYL2P6+*SH]K8+(EO=\E2%
M^3]:ISI+!S,B(=@#,=]H:S,F;^_/@+5TN(J* O0R[2DG^KJ%15,*!_0\'N(G
M@K:$%O>@(I=A(\8NUGW;RLC#_9V4:YXYJ(:D>=I /EKCY/IC %4I\$VP+R5V
M84_6X!&^O:M\XEI(N>.3YO-=!23PLB!1R+1VN=4/-B0MVS#=_;XNVW+GNV7R
M@LO/1JB>P.K26K$R)[#Z WGHD[E!3_&K'1]OBL1(%;T6:.O2G*"WN/LWAKZ
M_7Q=PG*U!VIY&J5(V-C/HIP+M^GB36]O]ZM<SP@WR/Y6ZV&QA.#:@$/7'%:Y
M)>VBRK2<^(6;;; $IZ]I:J *I8M MF04$^\UM*I9*#/13)@'5 :"D+_GGZ H
MMFCLG&5*TSH3L H04UT'675*3=\]+U-/Z)SF\F32 =8H-:9X4<GW6O"OUU "
MI]F_XP_PD(/[^=$86*'V 6S,,A_RXR]X:76.NT"L%SR<9N06-3] ?MRXKHS)
MF%$SEACU'!/\_W;QUZ/"!4%R0?NX1:R/5><T7@I&_>=DE5@9<FIA&J&\'M1L
M,[]<,EJ8<$@3!/2L-6!"AJ2]B2C[%2L#1F?HBYAGLNCX :)':H#A>'MIY7C-
M .( X'1/.E$<?JIJX,;#]FH;44TS6&!&O%\L#K5]?JLQ_-HGY87 4XDXW2I>
M_;IKOU/O55WKZMSV\DS,BS1-M:2IAEU72]7R9RV24@H#1)GT8?[("PG$CKBU
MTMCH5HL#97P <6+-A==>D(P ()@F#2I2.;LJ_\NOYKSABP?UYWJ)?#CWCZGU
MF+)6U,[2#>?Q0W6;]'RZ2$)'X?=S1'4_RPK90?N <\\O55L<5UYX:PR-U%<"
M;<\S:M1V&8#T3M\%W@_W)-P^[SW HB HH45B0R^C^I.C1N=I=<VT0%AK^"'F
M*-'?P%>U@]WLVZP5YEX&Q=:Q "CF+L%7PR;@P ",IG:!AONL&$D,:KV3/[]5
ML8D@@#Y:U+ K%QP?FZ N-Y.*/8C)6K*?<6@>$^O41>F,L5WV_38!QI/Z_-:7
MLB\O4Q8'B;9=!.]F)P-+Z^,O*=L4%61YXYVH) 8J:WKB?56XRS8UZ(>V#$-Q
M64OER1>?OQP<L[=\45N<,%4@0P.4>K,25*_HSRYT%5VA  *8^^EW5QS,F.PV
M- (?U4SMV5TE#S5.5D[1=MR8O<Z%.)+V5>K/L"A::.ZCWX'(ZN,FNQR+EHKS
MR2/D=MJW>=A=D_:Q5)75][X/<^NDBO$B?0G_ G@G_*M,?E6U;Y=,)<3_CG3M
M.5?3S%:,7;"S,?^@DS2EP%:PP^])ISEP/;W5?W*UX!&TV.P;36"XJ?0C?#>#
MO089;:4>K<LM-@ W17_G5K/8K'+A]OL+)^31X_OK_17<_E1*?MMVH8R+'/@+
M2(A+( 58A1LN2M :ZCY3Z!/Y8[5HGW#0;'=]6O4)9_E&!)@^ZICTC?[]P*@0
MD3(ZQ4"#O_ZRK>!1E73;R1IQW>54153<R8WIG^=W"JK1*A=>HLKJ?.Q?282>
M_)ZD][Z-_CZ4F">1>RB]O^LWNET/DO1CKY=J.4_(N?PF&YHX&(,G8-D=2=5G
M>;Y2:#$QJ:?UR^JPQ>&&NP7R8],_>_!233:>A-)+S+02712/H[OWV,:N[O(7
MG7VE#[(!>!"(\RI2?L?0+=\VGHV:D'EW.ZB87DGKV?^WKR6IVRS.HZNS)5"S
M_2+%23%T0=WR<&SM&-X>L>-NUT@^/JL#H>?X1-S!O3UTD3XFE!0KQ\+:,R$\
M6^=1<F<]W%:[=W($Q]XS9O8X*=%5F]WT_77HQ^];X>^@E=.UW0V>*/:S;)YT
MJU5YP%WRX-+Y.CBX[KO&^YT)IW6/TM/GJUC"=IJJ;&!:O*EX:$67[C7FID/=
M76+96)Q]_2NRD2&L!JE?,>_;7U<J^F.W-;2:,$K6]"4:R>_$^RS9*P9+4T'R
M-WQ]7 L)SJ5&\-93$K.O%%N%D[4JZ74R@%>79:G\&]X:D2))O:6:C<I;3OI1
MP/G6%2WO5!&KN.=8O3NK[;D=:M\!DA5SQUU.!Y;A"WD+EKL'D^QQ*_)V+_MZ
M=PUE@PLBI[%MX=RFD@1Q11@:VR/%$$%5<H/MU"]85@'\)/B3(B=@?LJR=[]>
MRD%^"CT]>AF?;Z6>9^PV-#?\+N*1>C;K<#E!([:MLJIXB"5&?*H3H.Q=0.?Z
MOC";H1);X"D2&&;91U4<D>'S?M8HWJ2J)-GH[< D^V8< ?D;A@ ,-,;JY7^;
ME;$RI'W-<9N<0FA';S^$K"-HU)GB#Y0PT'C+HH2S<%DB1F+RE?70//"O27_(
M(CGZ (4D^75S,"<,,;:'\!X G[6%,CHQ1L"E:A7/,&'UAG(29T'G?<L.>(1P
M]=9M EF1/7V[G([<ME1['Y[H&;G)B?-N59.MZ^NM2+)D_7+K8%O%E*4"0;$O
MJ>!TPY)E@\_)AJ5JO=>N(X:OYVWO1693.\S-[K1U;&S;FUS'1K*2B9WCX?+-
M';*U$T-,1&Z<=VY5_=S1X;QB1%.^Y/=LA_*]=?Q/Z?P+^I1&J0O-O8^[X$;M
M/U$4]-3^YF=E[5H/&K,!:DE(WZX%>DIM5TGL<Z1^@'7QG98;>8:.A@2A$<\3
MTA]//PQ1FQWX8C.BEK%>3,C:AFVH,3MOJU(Q2-<:VG\U5$R))-XQY@!8\5SK
MZN2EF:0-/A(TGBVN>;:Z;'K?)+9L>5,D:3!@2RO!LV93'V,'?TDV..G90XGR
M<KB'^J98,@K[0Y"-?RMAGNQ? $E"S4;8K#$SL^:;@,DZ-8TS*YUI2,RV"T!
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MJ7CYSPZ%D]TYV$[+4U5W@R)'HDD,LFVW-1$RC:I/U(^ \TW,(2 NM9=/VIG
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MP>GFS*<K$RG?0\*C8><Z,B<UMY[@GK2W_@-02P,$%     @ FUEJ5B'DVY[
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M,5G,X7-8(CI4S GE"LEB"FRQ.%FJ+[B1,.ABBBB$ K-<"$ ]'9VAUCP!"TI
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M]LL'O^[UB,*D9]T@\7SK?P!02P,$%     @ FUEJ5FJ18JD0!0  K08  !
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M59E17&P'_\^G#KC$^_$_^VY7-/JN'_+BR0OB;?ON@]=Z!@;L4?$?DOC:P2=
M\NJ0OH"L#X%83UC2/_**\!T%\E#P.GA=)I$#J5PBDTM\QT&NOS'0'T'!@WJ4
M^OL&!(6$#@6B*) $25XX9<$2:<@P>5CX\- WQ)HR(.O'E,HD X+"PH/EPZ+
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M'HW':K>R+B/DL2ZQ.34>+3QTN88_!]PH# V%N$JT<$J @/+U.5 :YV A4J9
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MK+X9HYLIW+MB?$2EOM);4/8HLV-I0\_R!9KJQ0>>WH]^\_C@2M7Q&^^>G'=
M(BZLS\]L7[H__69+(]RC@)S[3I5O&<@=Z(R9[^_U_C)I_;+"\+KZR[.:6NXU
M'#T#29R59H#L9]N3%HT-@$#7/U!+ P04    " ";66I6-7OIO2,%  #!!@
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M;11%TF(Y.9URIVXZ?>[G?L[G/'_]GN7[?)_M?>?NSPT"6ELB OP P-9V'8
M_I*Y<0!I%<KE1P(0 *[0>0K3((RP1RH5,?%X@03'Y@DY((XK#,9'L$5X(HZ
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M8BYJ<&>-5'E4$^<6GY"PJ-B2(HA:>&, @4(RDTQ"ED- MF#$<"K$(F6I(3-
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M@(55&)_.# 1%" 9XD,TE(]_4W40BV"PRTMW4">/$WP;ZLQTB!.#N".<]S(A
MICD+:66)L @CA7'X'%!$1X1Q@KA"4A@9^24X27I>@M%(Q!>**)",M%ER(#R<
M=B&V\00@@FB,0S$Q& R":&[, D$\G4C$X+<B<!@<#HTQ0V/-4%@"R11#PF,0
M7PTI32A@^9%<*=2OZ:0W,O)K7Z&AH<:A>&.>X" ::VYNCL;@T#@<2LI "<.Y
M(GH8BBO47XY  85, 9LO8O.XB*4[G<$+%I&1R.4N.'PGIV^!_^_ .!ST,ELH
M<@7]_IDMW!/.!]&NH) 7+&""4KK^=ZG^6;I$E%9#HO"8P1R0*Z)1R$@I8LQB
MLTAF1#L[$UN,C2W1W!:+M:/88C%V-MN(. P!C\694BG+6AI7**)SF>"REOVW
MUOP?M:1M I NX@GV\'A!RP](XTJGQS[(16#-C+&(S>YL+HL7*C1<&NW72D$!
M.P1D404\#N++;$CL[_('!TN3$XCF3 +6A(C"$UE$E F=B4&9^>%-42S0!,\R
M91'-0(8Y\JN8]5WC7\1$T)1I9D(@HDR9YJ8H$W,\'F5N8@JB,"Q3O(DI!D]@
MX>A(M+0<]/\\]3(DW9^EX[?=E5Z^;3_(E:Z\0+K;BQ/ FB\- ZQ&Z3<$6>P#
MX@#(OS>9OTWVFRW[OK@AWWO^I2TV C!%0!DPD87  !D81!8&6?P=")46!LA^
M]P< Y%="%59(,<CW(" GOP*J#$"@,H#\4BG_!:$RLG+R$ 65'U35U!4!F,8&
M?0-I:"E%!@)=ULO(0J P*4-.'E#0U\/BU9 XC0V+O8"2E" #DX4!5L!H0M7^
MGHF=G%"G$_$.5^\UO;I44Y19'&]IZ5/;;SBIE@9_?N[9)'+41GXH<(W%T2>B
M%V]U^+3Y)FQ:*=?^J>!C0EUD4GW/6/_J#*,BPW&?@,:[VT_['TFM]'\>Y[?!
MNI?2WK']@N)OOL=+K0K(1FUDPT<!,\ZW]J(FG*^(/2L",BJT&50-UU^MLRBW
MX!OL](IG'N)/.1P__;Z\]T'=Z$A;V:J<QJYU^PZE..\+P*J_G4CK(?5?F/5M
M]IIDI'DKA_B+7:N\A]^] 9NNMJTNNOB)A;Y,KNN_8=AGE,\[_>>E)N.@+I^?
MRCW:A3]IL1SR=BK^?D$I/M/7 R<7=V[FICC"_@8INC"F^N4'N=(4MY9 -6_'
MB#LP[[@X\"YK )]C-KSUE1EV*G^XFH Z=@^:U914:@BQS_=0;'>0<S?L\<!>
M+L-O\7<N1Q0_1H7L,!B@IO>N150.G"%DW>;N_9@5230(N"&!OP\ M&*A-C6!
MJNA,NM*MEX8;BSHTC[.OYF7&6J=%7TQR&]KB*:[,X#R'"\I]$\==JU20;@HJ
M6N,1?2J_):8=:=J;UK-!SW^R=A535LU(;*?^,]' .:FFT8L=_)^.8=M3*:EI
M"=KU*Y(A6BYM8D2S;W>BV_XF]?:STQZMG7S9V)*QA@<^1)*UW*KQ G77^>;L
M^\IXQIU= N"ZW0D,)U+&Y?A].&70$CMC%-/R2K+.L2%K2B>B[)R[>\7L]7)?
M% >%?,BJ-C!9[1:8Z2RGHH ]%9:7$UT\(6>9VVQ6ZNE'JTFXNI&.RZU;LT:2
MP:CR]_&T$T[I$=A#<=;H'Q-TE%5R0S5;QO6M5B:8MDS_4<2/C=SO,LSB8@\$
MG]YHNSXO1Z=@)GN0XGDQ@*[#:-1\:_XVBKB_//*<+W<V3<ZU0/PI._1G=)DZ
M;C!S5S*KVGXKMD4Y5QW4U>*NZK)'QP7&![ZK#/1SA_E7I7AET<#><C?&NTN#
M(5?X184<AQ)8UW!X\NT%Q0,=65[X4TJZ5IU@M^/E5FU8R\F*#[AC(YM>VET^
M>GBJ9?"'DC.2*"1_:QMVD/$\6DP.BMPC$%H8;G(-7/5'6N#$QO."H9NJ[CFP
M"\?.[/##PE42IZUJ?1;JWG(7@4WW7]97O;/46\B8:K \*GEOT6"?/;=^X>%@
MRTC(F['Y,:N.D=-/R1]_F7[2(F3U\RRS/ZX=327 N94-JX.P;7,WB5/3A-:R
MF-1/^D&Y-3-]Z"L)K_FM11DZ(=GK+<\$F7Y>>VLA*K<U@+RO]WP>3]NI6/>$
MSYT=/2?+Q2N]J[8[NB45/HDS,ZPUJ,_<BXF"9O[D4(_3'5%Z]K:/<N:%.BYM
MQR+ B?BE*H+9T#>R^=&/-S:VW:1EP7]7B[2U[4U?X:&U@W(740YQ=@DX"<\\
M<6ZTE2]Z&A8Q]<OJR)25Y)E?W3O=@DL'_?(@Q<-T+F(X)?:ZO9$\7BO;; <-
M\K[C\<<NB;87X'7L2G(7*0W/J&^_/_4ZP89J&_=Y?7J+^BK'DIC;G&QF8CI5
M(U[RN,#0J:)=9[_[#?;HY\/]ZVIKJ[D&N0=WRJ,%<YT&,DV'_-9$W9?<9L+4
MRA034[*4%9&3J;TQHV/GTT?3?1X*5PY'%I7F>$TJ*F +X6C5KN-QG7L&J$U,
MO+(+U,\6ZRJD46_F5)IOOG5Z[.1;8*"F>O \4?6D4G245TE+%CS$ 1'QKC(&
MH^M2O\479R>$#E=8]'YV<WQ$%GPJEVQ:QTSQ\/-72O^C,:6,= UFL()AX^D=
M=^0!6(+<B'\>GF?0,SMOLR.#7':*/>R2)C\N_^R:%L45N=,[L_]>T^I?&]N.
M(/2FO=IB.^8E(=1;95QHD*/:D=,T\35J$6U;]Y-4RW1L/I'!<HC1&VOJT=++
MW0[??8%JP+SX0;7W\:O.TD;WT6C'9)Y^YT2&0;/GT*O.$Y4/N.GKZ'H)UF4O
MSXJ4QZ[%*28JTAWN9_UPD%'^9V22SA5\>9LN^F3IW;Y*PNO22_'Q^3)I-.*<
MF0O2.WBK)\-WF G%R!AW%WM=&NB8J%Y+T(:Z$%UG=#:L"H^>CNT1ZGM>CC'N
MJ.;T(+<(8Q7:\;EZ0\P[P8I4VB')X\8&_8P!H_87OD2+L]O;]KE>T,34WHVL
M0/)3L\?E1I,>92>;P1_K:>X[B+\=8J11O<*OZQ1_KY:3:! 0J3I0GS'A'CTN
M5;L:\@OA,.?D%.N4(X\@X[N)5^O4->L*4N2(^O Y! Q#8:MM&=^K)GZU 5-B
MK3*8XL5*O][XX!Z=EXR;[8Y$^:JDC!6$#,W(U)C8D]HW8[)6L.*ZG*(5R[!7
MMFI:9]Z-LU)A%.(>VL*UF3U)HR7O;U<7M@)YFO+6N9L]" <8!P@4R4B^QME[
MJ^,/ +L3C&36[!(1=^(^C=T9GENW]MBLAF.2X4)=3G_44<FDT**N^?!-2?1[
M<LG<;,2;%[/VVW(_/9W7[>F-B.2(#\P3X"\ZFS_T!R[4KG_*FQRLGEW0K!ZP
MLOO,J:6*Q6/A.9\/=]-3[7>/2Q[-AJY/.C0U5#47M=CS%U!+ P04    " ";
M66I6^*(<I[X%  !3!P  $    &<S.#(V-S=F7SDY82YJ<&>-4VM0$U<4WA"0
M1]4Q@A5$8%EK52#9S8O-!B)" H@4*Z@\M%C#[@963#;D80*^$&EG!!&*4"Q:
M9<9J2T74 HXH5!31\8%37T6@HM12! 1JJWT(DBX,0:;3<?Q^W7/.=\YWS[GG
M6NY;.@'74#.E H"("!_  7@-RU. HS#BJ>D "[!E;()Q=;*1%(-!*X5AC9ZG
M).@DDH?3:MBLU,)\'@(#@4%FK1)/)0U@$IE,:630X+GS$$@1,BA.'(5$:>5D
M"K4T0T>NS%B^"L](Q3$""EH,!IJE9K5631J4H%F]4:.7FF706'$I<QYUPQ X
M1C&DRJ#@T0 8'[4"E-,Z$D1Y BZ.( B(8CR")(5*%$6$?J  $0A@1 +S)5R^
MOU2,2(4(. Z($=01*FF,(FQ<CK%DT'A?)I.)9Q+R:%TRS,<P#$8$L$# 91A<
M?;K&H#1S-?IYU@H*4H_K**V!HC7@J*U,HHT&&019NU!KHZ(F"O_OP-1JV,K6
M&V)(U9O9^E7I6A*.(?6T48>3#'W>)*DWIXX2F=M(%31N5),:0X1"!C$>'D$1
MTA!%J%RND >'H%@HGQ^J"!8&RS&!/!C%,'^A1!%FS8W0Z U*#4Y:<ZG7N=@;
M<Z5R':DTT+I5-+W1^H 1&F9Z5+(&Y$MX?'!A'*4A:)-^T>AHQV]*ZJA-)!&F
MH]7@V&RDU"1]HY$1]T<QW)\O0KE"E$"Y(B6.<"4JH9A+D"(A(290"9F$0>/)
MQ*3&QY)14HQ+1/XH5XQC8JX($PJYF$A,<A%"+!2)$:$_(5!",',=^#]/;74Q
M^S-ZG-A=QIC8?E+#K+R.V6W+ #!]K&& :&#^$,O2#F0#K+>'S6NP)V"-C859
MDR-O"4L#P'$ . "'S>( -AP6F\.R7 (R 8#- B;#WM%I"B,$L"<[':?8V3O,
M %BVC+*#O=5K:\.VFV+/8JK.=*YRN6M\-[9H5C$J<71C!&P .Q83&V>R;-BV
MG)D,&? ^5>BL=^B\[;+*'W5=;6D#IC+Z-APV!P@"DML;.\*(![&JXLO[;F=L
MF;L^5U@SQ^/]TQF=KU2_'?&#HQ-RU,\"7G8=HNCJ5MY7H/Q)7V6I;WAB]#O-
M@>WUM?K-S36G:W(Y_=$I+>6Q]OQ7$;&^W<LOE& %6;V5%R6'&T_.&$@8F?HH
M;U?CVND>K>=28_>:2K.:K^O+2GKD"[=#9PM:;==GJT(%S3S)3"?0Z='Q.]VR
MLE_XLSEJG:[2K8RC*1-J]M1&'T>R3U^%ARM#/)=MF$JMOE)_V_71NCZW[86)
M/0LJ4N/7!74=?]7H7CPMX-/+187>IU;$1XJ3=V7B776T7Z2W/"?2617[=$L8
M@?Z4VWC =#,@\<<7G(_C"M$U+=,HG_83/H6';T3@.:K=DHM+51]5["MJZ$H+
M?WC+HVKHH+SGI7F/<W[/8NY0^18OSYSS71UKAB3#VZ<?M0!I9Z [U1Z7/G,C
M<ZNA@]SR=D]9S9)E ?&\IH3!'']N;U<M&)'O3.WLFW'+\5[)@;F?I_>VE:8Y
M1>==K=MZ3'MEOC@QQA</C51MV.1=T' G>+](Y>[F@1_T"SESK<DCS2>ZJ#@N
MYQ^OL&Y/WMJ,#^[>//,\>W9JL^O)DQ^6O)>5T?J8\KV^@\"*$]V!"_<RF_(3
MJ@=:T/ X_JQIS[K]'K?\O)3\$E@0^R+?-KZG+F]SP8[L$W$-4'!*PN\*Q$%^
M_$&Z=TW=]QKERLA[M7NWA7^]L5ERI#UIX;7*V$;HVTC=G2:7Z$7X[BIITYR]
M]]E8TS?S[SW?YO*XQY@X6.Y+/6^C7 [T[3$EY^2)2A..&I<HD'G-OI_TJ^);
M[+8^O%I!#WZ1GQ6^J]-I9'&[UW8T<\L#=Z^V_57#3P*3NYZT#OD,JTK_V#=P
MXR"O_H>1BD,MRW_M9;>9^L^.[/SKQ!*ON\GMQP;WLUK/7S[W)_UWQ^&^!7KC
M=_7](RN/OH0[ZM&!@*!*CSY+Z[]02P,$%     @ FUEJ5AG@*:B\"   /0H
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M'=(E)=*" @X-TM+2J?#P?\[_W+/>NN^N>]9Z>\VL]<7>WXYO[_W5[W;Z=AE
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M=?UPL*[W**=@Y.=[7'C7;!IYC_$RL+KR& $T7T/(*JJ'2B_LKR^P_M\%W+>
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M#77Z2Y%B<:PQJU!7WB$^9EM^$ F@&CZE3VBMF^*1B6XZJ!%^)?SEV#7U%9-
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M"4,I]SV"-%;Q;SD;Y'SPK%G@(CTS'D&B3"V-QMS>NQ2KZ40AE.WM9SS=01I
M:ME^].=J@]U50:'KFQC:&KN4A/F:MX]1O#-/A2_L6WGKAH?+Q%$'QV#I9<Y"
M,83#ZP"QR"T^\VK6Q*U)E4=P\QJAU'E4$G4_#L]0_F>*1' @G*$.U1D1TF &
MH6QTS(_0?4O^_**+7<6GO<SJ&CQ#>CI,:)Z423?#"72^/FC4^=KX3(D(6 =O
M.QGB,YFA9G97714C!&,HW'D""X+^I>>DP+/GT>-:/]IBUF"-+SME((?"9YW
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MO+5EV!IG8QGG#/LK!5 YJG6\GIP:+/DX$\].H9_UHJM^$/B+KVY4 E(Z]R
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MVPG]'46UZ/><92Y@POGUB5_*Z@ISD?C^?*UQ;&-F'PL/2?GL+2"YNI[$.*(
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M^P3_;T+XA_[6_4L-]Y\U_YOTNP> _?J5(@(J APV !X;#@$;[O< '/F?!QV
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MHU0SC!;;%?8;H%RE#?(][&R)$#TI6!AG''O]&S#^7O8)?XML:M8MQ_\B]C>
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M-T%%*Y>RQR]#8T],.RTI9]R0X3RMB_GJ+29B2:]<6'FEE8=AO*@R"6D6JW!
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MVO_ 7D#G4^26._%GR4W?9Y1'U6<WI9/<+9%O&M.)"3'^":PE:_K&BS_:9KD
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MC)-,2C;2 +-D^!)<;D(ZJ%%"%T*X*-HH:2>H(+9(!4M"(T:4P=.3#@FI2'Q
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MNFD3*S&BH?*1XR9-1F._\$XFM Q')GI("S+FW3PI7O6]$SJKZ'4WJ7M[ESM
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M1T-9S'"TE_:T\0[SM#UPQ!C=E9.L>DL#2P5:OHVW'];22,R26'OR2TQ*!M3
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M5U=4)ED:U8%BL\FM1>6$94*(Y=0B =0Z%<-(98U@W(EM-$.R5IU9.N["9#4
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M:#0W BL<1J^P?6]Q553M4R#P&-_#<UG^EKRO? ((&"]E[K,!?7+'\RNM\Z*
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M2>(O! 1$=K:6'M'22"^R=0U:UN,AR94F>K7"')M:YGOO)\<48M[+8%4P<K!
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MH0+OGE]^#SDP,?4=,*Z P_,QC?=^>$RL;P)U_;.W]HAI&05?[0U[EF\"4;1
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MH='4!M,?H0\Y%SFE#F1=\HL7FK&\VLVNYOX8ZW,$(\V"5\9X^+90H;!C;-,
MQ<'=#0#^,NH? +YWQ+=M$/Z<F:_"&4]1D&ZVCE*;DW?W1[Y\/!J]_K[.+@-.
MEQWK^%_.4]I,YO=IPVICK"G?KIAP_G=U(%^7P!^Q0+B+'NV\6)#RGS%K+PSD
MGO&-H1'C7E1DH5 D5*^W<@./;VKZ=:ID" ME@C55S], A<[]&P0.N9"EY.AH
M'<6#DS^,H1H)X2Y_W<TL_JZ<8Q#!'74$9<9H2<Z:>R"76+\.+]7,#;33JCB+
MATLF)1X;$=II!E)8+=D2\U7;]47BA];OA(U\>N0_*^4;DI:GINFG0DHKC4)Z
MH/"AP::S98K5>=T:SC,F!87\-*Q_ #NXR+4;MLJ>^_.,,^.\L,YY76IJ);['
M/X P?+!Y?F[SD9303I0IHKKCUJ62\7_>6>C]Q2FX7_X'L.A,M!_P=4&UJ#K!
MRD[;95;!TB[72*=!V=]]!&IE5DYN19GO?-7,,EI@%V/YOP=6=^+_&:U@\Z,#
M>&F67DH!MDLTROZ/93A-+5Z"BAY9F<EJ9X_S_R_-(I65!Q6&[M[B3RBC3I]7
MS?;15@8I9_\GJR4L_@%4CFF34[%X1:M]8UZY_IO08++U-.8*VN+3^'_J-(Q#
M-$A5Z]5I:0%L4Y#= 6UKY@X2KK!(C-[M(%E3AYYG>N2,K8;"CX]\5?L#X@5H
MPW7SQ)K892R:R3!DX0T6)?I68Z399G;Q\E*"HS\GV_ES(DA0WSRS!K$@YZH>
M[37:@0-S1=B=7IF2.]Y?68+,Y3+>AJ&C>*\/^.OCCO21L[:7F;\S'Y.1$X\W
MX_O_^C#J/%SVB/5?)VAL"(JDO;Y?+:@1/PL7_A!6&S7CV55GZ02RF^$H)+U2
MD]C<)K.IX_D[<-3GY4.W)D+)?L&QU]K62/ZE+EZ_7K;<JX2HE% G6=:9;3]?
M*)+#T>SC,B>VZP/U5#6&U!'BQL/#76KA6E^H[CB[O@;;%G8-V73#(<,ISYO<
MZRO6=T*^O=/7M'&WW*_KP*U#S< T"7RV;[@ RMKH'U-:7']>\% Z&QN2=7;D
M6&Z;[__5[A2?=_=G%$@Q-L:@6C7!YJ:1(O=X4?O[F9-CJEH:$KX-;?\LR"DH
M2$9H!!OB&$X@-V9(0)3E(*BV+<J&OXUNO[P#Z#A_\?LP*ZN\ZN;OK-%9D2L\
M7F&=\B.J8WJ)'RI<8'@5]"62@M?P]"7'P4+9-_;(+7WG3*"13$+OT<Q<8G@)
MU(YVU^++>-;8F4YFJHI#?KYQDI$AZ_0-C\NC;.Z<G!4AYS:/HWM]3;(B&GTU
MY7QD2%TQI,@!YZTC]W95!$07JPRYC(]/ND66Q"+UZU9W^2]%2%F-:!N84!V=
M]E>]R:YJX8=H7LN[FTMW!Z^5%FV&\"[,.CVD4J.^5A]]N1J:2C?(0?]MJ#<D
MM)P0'@DIF.3BF#5Y7&_1HX ZU%X[S[RI1QLV^J%KF3W8O[(AWF0E9GG*%\E#
MQ3J[I;5@[ES#)1]H!LM9=?N;+G@/SH5M"HFODO===#D-2U:5#2L-\]<YK:,T
M'ERZN+CK/F7$<9+JPE^F2=-#J7;^NKQNC%X"\\[G.B%M?6TSY-&.4RF843=3
MB3V+'3W)V"6Q_KC3*BC&W$]$XWW=\I/P##(!"7=[@F,*"=/;EM/3,P9_4)5"
MK\\[NG"]+_TK]\T1H0,;YWRQ76^/SBE%:^S\3,$MAZO@4Q]<([2(.:=9^M'5
M@FG+IB;$'L\(/LM8?Q8CF-TW6NOG6UWEJ(;2MKL\WU([4D.=UZ'SB[JZ]]%*
MF\9+$D*P,<5CA,KXM-+P2@7)5?W!<NNKI9L#16^2 WMK3<UZ6?C&V\\$2@SY
MXR'$-$.*(( @OBT6Z]#,):V)#2D1#UD QJ)=5JK8TL[M8C0OR9?S=Q^<'C A
MO;B3+%]R/8*EM)U^.J_(>V*!%Y7'6-I=:XS@-IM&G0QCD>)OMH-T?,U]3MC:
MC'$,/[D<+X70OC^QZV++>B'B5%%RY(ASU9_N$FR)4P\/ '-()2KD$DU+^%U7
M;.3$N)@]W5'54U-)4E15&V*K)(]?MOE,#T$K(B8&C.(+GNQ_JZOX1;5[&LD<
MS3*8_/(.FS$=R(T]7<6:5=.TM9;G(;JB_A$F;^B&LJA%TO9CUE4,M\9LT8MI
M81X,KYLI71M"[_ W/:VK,\;$<P$DK]BZX 5);0SK0(W*=Z\=IP,WP7RO21W\
MCCD]-67[#X[>^Y/3<1,TMN@14S!S]AC(H14(5R^'+2$L,_R4? ;#LI.]L%X+
M=!)3,71<5ZX(9\"F887.K?,6^R3SR ZV<)T\; I#)Z$%P/1LS?S =$79N(;,
M-/T/@&/B>E+JVRB!2P/H2JNCPEM2QUT0/RO/0T;W-I5.RYI7H)''1-'T35JY
MFKB2[]IT*8LT>["FQCS3B.[.4%NCH%]ZBK\@Z&SF?"S*6=F]>/W4H\Y=]4>'
MQ1(\TQIOSW%8+_2!3>)\\82 6UUDBX+V. :'F<4<$%P*Z?K95H'L$[.A([\E
MJ%$(]OYC<V-*79''3&;:\F YXK!S@^=0KQ%8N4-0%*'.;-\6S-B8HW\M5"B$
M^A)ZFUCR@WD%:GY"69!U7HA0UQ%8%G$;E9%ML4&55]34W;:G5V;[F$G/^C'C
M"N^XQK$<?,ZCI*Y9$5C;4_MV6(E:Z07K9-P2H[:9"(\-.[?T.5Z(\*02\M=3
M3F9" F 49S5E$>R/ M,7NS8N<%IFY>AF\,>YX#Y(1BSW<8]IBR_'7!K&13X"
M:ERQ;0(5J[L>(N#-<7Q8XBIY"4LWA^LQ^XU$U*M4ADYI$(T?DV641%/]:UYZ
M<6IVM>RT']'Y2PLT[1-5JAR^REZ(7Z#LLWWF\I2A,0I<L]TK%GHRF1BW$8GV
M'1MJ!//]<KW7F52?,TOU3_%2J+\XD_^[3=:XT1$K)J]+50(="6JSHZ0(I+0X
M>@HL^>DFL%[OLW,&L9'HMJN.[>[6]:(W?E,%[,\)(RXU.J9.<W4[<:P,"2L4
M0E,>Q-X4"&A7Y[07(Q5QZEKA4C*:VR>%P@Y86#4 KG>_FL$1<VLYC+R*?IQE
MY;\%#?>^&2TKS&C,//W0U<'VIOR$GN*"1?(-V1]_QJ&E!\JU?@HPU 7FFQH.
M!JUAD'C>X/8YY%9F3=_<<S_8VTX/CQF&NODCRP1K0<:GFN3YL4B-5S%2@G ?
MH^_EXNK;*[$;PEM+5W./[:F">(0".BCU:((M6E\G2NT6,(Y@QC)&!^8,X=S]
M?HH[HVI)?(<'IS^(4M8V?U&I:/+@"U0I0JP%&2/M-#"9H\.29:/5X9YZGD%T
M^K@G:OF+ _\ U '_ %'0#1BYJ?C X]L6 B(QRI@JO8X1-[:Z%L\S!2>J]V+J
M*]]C(O<7BN-H/A)Y@^.*B8LCFI86(\(2CO.H5+N($VN85Q7@_G&G:>T4@0/1
MVRXED"<%Y(Z#'7B#(S7N"_FV9.JOP0806S4E*2.S-).FIA Q1+-8<B7_60^T
M%+"U>O, I]Y[[Q4/Y.,[D6&&K%3LZ_Y:-K4*&27+UZY\3(,.WF[RZ)M*TH';
M=!,.]K!#2U.KZ!E-7H;"XCS.L&?%,;0D<;W.1Q:>FLT30K;U^%>Z"Z"G^,,&
MFD8N/NVT6<9G6JZC>]8COA$R.@=ENJQ*2AUD@!1_ A-1-2B0"[;.L86M+M,Q
M6U.\=50ZXC+XYIBYX=YSS!PA]A_2T0RR?:OS^6/XF_@=LUZ)\9J'J3P#337_
M8<B WWYT:'(:HZ(&EG((EG+88J&_-#6B<&%#*P+M\\$GZYCQ:*PL@0,IC*R2
MH.L@YK[OWH%&$]2L"F@N$VP_(%4?6!H&/(1@DXIT!-\][?N(*VGF'1(_L,;;
M>:&I\_I,>YW]3$&ZR]::M+:<=)N4N%+44)*T!WO[T,#JM]?7#.UU0-A%/OZ.
MF2YLLQ&U7)WCN+OB*WCI9=WR_G2(\@,7T"=T7B[&TIQQA?>:E>[&4H Z0>5Q
MU.A'^'0?\\$J??JA0DH[;_47V\V/0V5!<O<12;3^CG%5%? SZEW*>CZ?<2=W
ME+LDOOQWSS-44@AA=O*C\R,&I6G%5=Y]GX #4O4A]1&5KT!@]WK3OM*S:J6K
M<@0RV_62&1PVNPK] .Z).G.G<8Q(,(VY^7IE+WKX.49W(7_B]#"6M >R3-/S
MY@ ?N26%:,6>U]7N,QN+<;#[AQ@:4E*&]K;J=E/WLV<@*@6GN'^C>7LW%V1'
MYZ,HJ9KQ7$R@,K;7B")"8<H_GK_D. Z2#OH'P%C=TSM?.#5P &8C?:/2%7O*
M//::"UL^X"9YQ 2.$O_*#./*XF 1H(/=[<N=F2C87)@X[-<N_.+-EB>I_^##
M@?6=\V;\_+M],U,'N $/HWJ^0K/<JJ79Y$&;\XP=DA:L9-C1$=4S<\YE)O>;
M*_H-S/:V;@XH]X=LAG.@ LW8(T5U;N[*2M%_PBFQIN[#6W;,"_ WP?"."B/^
MZ6_3%V@W\@55PU,V;6F>R'#OXDM:TQ.)CAA+82XR02Z2%?*"A.])H_N-I1(+
M;CQ1-I88D48@9.)D?WP*:'<MBO'6I:QP,D;B^70M7X FCFRVSULYV6R'5:Q0
M2,.6S/&>K[EGY9OWD+90^2SZ)+#EKJ?ASM<S[@ULTT6JI65M6H,\EJV#)@RB
MZO-Q"U*=@^ AFW56-09S165U-E:3:8/-_;2<7\VW3RPEQWJ)5DO\TWWOY,C9
M7.(=/# VONL2?N=+[",#YW&.NC/5M+?DB5'TDE%,(8GEJ0=)) ""7+!>Q29-
M[5>HR62CF/7_]&$_$Z>,'=2E!I\*D]1HQ_K6Z"5%GTMHKFL\8PF(3RHATO#3
M^*WNTD6B+^.G8=5PT_$7;><(5ST_(:IV,>TYET<C,0GESC HN3H)D,TM.]ZA
MN+IT*;2<&Y'ZKFC H+>JWD'??>?Q'V#[: _\#Z 017IQ5FM3E"LOJZNE<I8U
M\%TGW ?RN)[#\#MS,8-$#9]#=E.CL^&;)E;O!$(=>R7#F1K>H.Y!1*VGWI6A
M'O,%'5FTU6!U,1;K<F-)#,H"_JQ%CX=,3 SFZ<5H_/E3]\*6# AN8)SBLCT?
MEQ.N@>M-COR/SGXJ/*5O)OJ>J[\WF2AJG&,5H-(,:78S+___;A 80QTH?1MO
MJ]9$X ED>?'KK&G?Y>V@PGZ4C\TE4[]Y!9%G='IF^%BCL:H5% X:ZH9C)7;W
MZJQ![M1YIXS\=.\V.>#9CG^I3T&%W]*-9T?2_\@L/M;OT\)VG#NW>"8-B%Q=
M&<H>@<T6&T\ARY[IRE[@VODQ!DMAF^Z.O'4.#[CF]X><]F6R^1@?2HZI$09<
MK[XGC".4+_-W^[>"W*1&/3IK3[+I)TRRYEO6XLGC->;KG?FCMF_RZBDB1R73
MTD+&&D>5)*1EW4LEVC3#Z),3,EO_ ;C"[BJH,J;CJ0]F4!T39USU1+ /S3+@
M @[;4E&A6WO6_.=?#)$X*I8EK'SA-<?/+F>XG/+MEK"3RR/5T/DWNQZ?[,^C
MO8V2SL+)]P(2J;8[F3ZO8Z(]-HRJV%D:Q75:Z^'C-NQT;E: W&Y\*R?19XO
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M7N-P;\WF+\F?%4=BO[<<%:$F?$52^R/NN\[8>E5F<:FI12)78=RU0*K+8='
MX>C$7)& "JLV OE7\-TSF$^%#/]XT,FOV$_/ ]W%^%=E'T8'RQJSO+)H[=^^
M,"+1+K1V'Y\CPR;I1D@AFKID5,+P4\&:B/,V<%\EXQ8>\1,I=Z^^L3CT852
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M-^A7<8=%Q*F0TB6*:B>UM;2 HDX"2^-.T-/JN56&XG*6MW.(9<B+N1DPI_*
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M7*U90.[9^P '\0K:;  "KA]3O>&DMS!KC55 FJ8(9ZPYF_O.@6Q+#5&:0"(
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MDUL#=[$<<XKP^Y'R;0CU.VV/R5AIQ\?=_I8CL DR0CG':BOQ\H#,K*9H+!:
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MC*D;O9Y+[U8/>I&QB&;<ZF^BI^]K74Q/ZW\4U[/GJ\G?2JC!&JE87MH0NG^
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MQ[0UJ9Y-&<_WPHGIFMWA3DFHRO[*: +!4%<Z[LBZRS, S7.#5-+F'^#K:I*
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M]D#+PIEA11PEXDUHDW]1;+%&0G.MMH, ]W!S3E7[XHH$H:3O\#@VA0H1%<4
M_ '#V_!2O6R>;8QS[BXAU8UI[9CTS\#K]4$!N69AKN$YC<!O3("SBZJ,!9$+
M,E#'\M>J;5KI]5U\-6(%3DX5]L.[&-/G"#=";U+1K&#0)R(WM39'&R;YW\G
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MCO$^OX#; ^=;R@R+@7K[*?C\B1:V7]1SCKQ-GY8FX:'T!F@L]2ZBO)@FB7A
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M""CK6GBW@'9>4L+H86<+>N?"O:4DYJ![TIBU?(JNF>S2K'<X.U9 $R97@6"
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MKO3E1G",3#];75A;:G=Q*(T.1?(+*Q 7XL]N6PD&X298_S)HZ-9O^%6ELD.
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M5G>2TN&]+YF$M+N@6@2YTF7MLX!PA+F].J^+)NL)@?D:VRSV>V>T$\4W&<N
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M'I^\D64CJ9LX=9Q&"NZ##*3)Q>H[()LI\M<**L/ZTH$VTX+L86*X[2NG+S5
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MY<4#A64U7A7UC\$AX VUR1-H>=#QN9!85+>PC.&%FG&/_)W2>ETC FO \?\
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MJ8?@3TF0@X<&4'<)D@%"!M9O4Q<KT I$1R;X'R,Q7M-PIB#8D[],2!O^@.X
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M63E%"#!K$O:%>IXH/Z?RA0#M% "J6#/<&^M=J6TW2LR!BC&;<4N_GBK)=-\
MVY._C$+5^#NS3TRFRU0(?B_N\/Y97OJ\:$>%'FA2M0TYE%;QG9UW] D,=B6C
MZ?J[0I8L+Q *=H>]]F3]L7:]?V'3P,%KD/=2;KR]C\&6&;#U#"D=L?T/8';,
M[$QHAO>^3']*%3K><Q:-!A%Q*2GXY#1#[IFXN?55K#!%?2[S9W$HU4_XXJ1Z
M_E!LC^PX(RHWFH))WE(P9&VE_>)BTQPMIH\-YG;(ZPOP=;DJR=HP'!$:NS>+
M/8/6*>GPDGFL>>F%;.>4]?D/>6<M- \C.UQ6:7FOZ]#E_> Z2%3"E<=-=U3*
M#\IG29:88OE4I!,S3T^YO@]2O%@,EZ>B[5'W-TNJN@)%(X+J5[%^OQ@N &Q+
ML'-1Z)H%DB\IA\(J.6UL%I&J <T!R\7Q<M:8]]C47+S>$1;0:VWBV1MAFW-'
MN2#FBG6(1WN[31)MRSV6"I@E]?6LHG(*:T;5>FN1<H3F2VDCY+5F$%3C>SLE
MD7,?/F-\=U@X@T-5KOV!;4Z #(O^9V<S*&:*_M4EEJ5C\-N- "[.WW7Y=P?H
M87-3LI9\:AO4<8[G(/M/3!^I7.Z3:A=9@TM@_BEULV2K V+.F0HQPK.I&_*C
M\EIRF"<;S,=!PM KVN/S2*JZAUU/;.\*Y(JD.\<;:^)@B9X!48=.T]_:MS5X
MUK=0O22GY)*UEL8DGN.1=WSQ$\J1'_Q4EFH%OY^R(]..,^U!.RDAYNHUHH9V
M1$E4*)4";[8$ZVDE[L+L@-Z6]MSM\NVCKI.OMHZ,L'\U=+:TK1*[,E+.U_I*
M+3E^6U:G/M8'5HC-8J^Y3)_8'E\[2\)=(F1 4<NU= LVNK5<)#97Y]</[I4[
M^-5\LG0/>1($GY ZS5 E-0#)>^UDE^+G##9;-9##JDS'G>V8'7*IYZ:[-&]4
MS=9MY2<XNB>*=*6/*=P?? K29K*C#3E+V,1X*Z$CS0>[^Y2+;[)1'3:L5M?N
M>!.$%J"8-VG^WQJ@>;Q[#^6X(%F2_4[86C!U_AX&5<9I36;':.-8-;>V%XOY
MM,:1R/KHF<Y9>)YU^:-Y&2G2G]_T!RF!61@<',;\?^B[\48&%[[N^G-7Z4U.
MFC7*D%@T9_FI-:9K@!6(,AG^ UB(9?;Q%KU,TN?'9[^\"Z]DF3$MY UM:/K4
M7JY+,3H84%@I+B:S^[+F+^M$2JN *A.YX%E8L"_;%#$&]&I>2QH1G/FN44E7
MRZY9DMI9OW@T=Z$0-K=T_TV)N!E>Z[Y7L9KV#\4O*I/>=MB)Z9*8BO(QQA*J
MG1L[ GGB[4$ON2D9M%> A/^6H6^[U^PF;9\FJ]S4&E9;V]D"XE#/,_N<---(
M;^K.XC[<=UV1!S2T1ZXZ0W$1G% (.'.+=0_ 1Y&A/_LZV,@LT>AK9^U@6M9U
MWD\4[HK&\WX^U7YH=T=2N^4VOL!\1BL+X9.^]EYF2TP3\-SI(&;+*S)(W.'K
MQA#TRP04"?(N"$_];%E@L7!HLNXL&,,0'ZI1E-UY]_,X+G@R+AAK:FQ%&KQ,
MIUSA?.%>#N80SC0AUIZYN.+=ZJPZ2H\6D5FX6J)CXO@2QJ9ERMR8F ?-,&W,
M0Y'&AZ.3/KMH<GZD-,'BYD;E1&4= 8^UUEP4MK5 G&=Y6^*M9+X6)K'G9,=\
M3MZ-?>E,^0]@_>'^_'6'[BG0X7,2EG;K8SN@K)N=+[2:;P%H^74B%V&HV1^^
MZNA)IX81K]T#OMR=E_<J '27XXS]G1Q_UMO&?N+FLB)$;&''O8+>3N^5*%#M
M;WVW T#3"PD$ZJ*7$$8-6<HZS"2ZL$11')8^H-S@4=?^:?7,E%1@^<4M(JG?
M?F*CKLKUMQV<0D7HLJLT W7T6,XW$!W&P9:!("549 XO$7)^WDHR"<Z[YF1,
M]X'R7)P_2]B@:6U'Y#NE!DLI9WW"],]M*OHZ4+1&:K(:0R^4C6?-:=JU^@\;
M.URM))2,5DZ5C*=_>P'J\.L]!UHMM!6P.G>S*P*/IC39*NWEH:.V/<7<_X@V
M-08 *F5KY26K;.U7<<325^=WA15SH5&)L[U%^_CK1)=C?$FWS&+5V(,#QRN?
M>]+I/\#X,3;_<+Q'BC8:;?KN.5,68@#0G3PF$73>XX@3@V?F8O8?(%=@ RRE
M<=(4-7+\XAK+&\+V9$YP>+XR)QZA;3NBX.UM-A"<[8SQL5*H]!'M<-D!FII&
M=;1(;&)P27M.**@[8^N9,-E<(%$)@=D2#K/P=WVCMV<[$9<R/;PQ'L+SJ)8R
MI#JI[)V'Z'0,O,<]^SF&JY.Q^14]UCR6!I8I,6J$U^%?/1_Q+J8G;/= 6ILM
MR\J4=7!5\@5$\,1B%<M\!/<=[M4B/&&&ZD@"$SW2LJ&7P>_Y\EY3,%91V%9;
M]4#04?WVD/I_@'O.P-M"!,\;4#:YNM=%9\?')[7.-5*:BZ5?) ^V5HJD%ZN+
M 4M3-&>ZD]^0Y'3G#5C>P34\$#L*#!_?<W>V;Y?J$J]]84C* JJ:ZR!*ZK%A
M OW8&H8/[ )R;E1QL>X487&QLLEJU?-D+D('E=7[$3._IJA;TKD*"'BO ;Y;
M]>D6;3!3MM[ISS,:@NEL@14QBEDJ6/SVC38*@Q-V=!;U<V%)D3 B'X; &!5I
M5=;]66D%.<I(!%-=Z/P2"ZOF@F4*3PR!=A;*A\HPH\%;EM=F3P?++;[*\?:0
M(?FH!6U2@QWV$0<):C]ELGLHZ6?B26+Y;^H/?39*E9CA81_Q'W"[OL<R&V!*
M?VPRC?%&-6IZ/Z_,M&A?IUBDKH,M>QS36"DOU"MCZ\IG*O8K#O"KR$B+G),,
MM95J:<\I/Y9X]?( $QO?D;Q\RI M_@,TI%VXI9]A?/C5%UIE6F6^4/^_$S"$
MQE[C8RX71)HZ_T]102"2=7E T/]/5OH_):\Y5+S2" +XAQWKI<&[_P$\R*E'
M?:1BEN$HZP@;&L)L1:#CC,],]S$S$EG3JZO.#YLKAIQOM"]4BU$:)'C5[LN"
MX><9?*)?-U/7AQ&64$\.^M6K$ZXSRZPNX*6WB3_W7">QG&S,)<W?+JXNR&+\
MA>Y!GKD#9H?8)5<;>5N4ZA4*PM6$[ A-3$T>I0+:%QK^-$6>,]IGZ'Z><[12
MK1\<N[%C81#H]Y6OI 27O-MP'C2\ZUN " ]V;=*71$:B^#^RU@SW0I-SA:X0
M1A[8/Y\;OQ\+J&N4GCQV4H$6G<_H],^JS(%HZ!^'Y#?CPVP1.X55VC5X:*BK
MQ4\$03?ERCO6AC.<7B2=!=I'_ ;,<V?GRY]<=K0'?Z6MZ]QH=%RQ0&BQ:XE"
M=?^L$YX?[,ZC\ ??]1VXDY[*38@3\K%SSW(#RP<;'=71319(_OE2&?&!="51
MLV$AZG4XZPTSD/EGGW427TJZ;BML"XFM]5?+]NK9DS57D;8;<$!0O6#]]@Z\
M,#<+)N=/W,DE_.8>4W6ROU/K)C W(4"2,F+&YA[RV=$8,.91K))"YJRK9T@O
MS4C;O[!(TG_QFVWHEZ[KG'I'\M<>JE/Q8#^WX2KND1)&@X"'L\2FS\RF:1A,
M]#39RJ/QW_=5R^E?9_KZ%T2TU[F)S);6]../OU=0V7+P7I,BE(%!"52;O-':
MR5<U-*8Y?B1S80D.+1;RATY_<:Y8NX)XUS3.I!^7X:AI=(;6HA,@*Q5NKS$^
MY1Z1A^^[&6*K ] 7UX]HYAU47$TEH.\8!#S>T31Q.=X)9]7SAD7'GA*9VH.-
MAVS1>-'XZ7(B4;SU+#64A5Y9DG]XRKRB_S;)23H2CB]-5769C<T2V>;[#$[[
M98AA,QOXQR(;X-TMINAIV9(Q.E,4GH?YKBA:>86^J*Y)^QS3Q+XH4%\2$WX#
M #HW[/AJRKC& FU7Z''E>^)BX!8KHJEW(&JA\HUTJU(ZS_9S4=V*_:=$OG]#
M>LS8)VIWB(P06[E=*/:IN7M253[+CCS(I9Q7E:C#<BR+)P0I&T+2W1UKRILT
M249:BF9=SP^*3!#N4)@S[WF2#;[15FL?E/ K>QG-UW[V$=?NL29\E30T=-!L
MT1PW 6%CCGW;D;)-QEQ1O0@*F49&W;T[[$_03_+UTE%DAOW]=W'Z]$>S0'CC
M#PD33FD4.S:W8OH.BM3)\(#?'A%^\M&H>?]?BYI[2<8KUJ,WK#R]).T5ZT>Y
M1TX/6>C$CT-UZB5J1^/$#( .Y./YKDDPTYM1J4Y;7$4%=ZC\D1I+A.!KYG$$
M 9QBJ8YO"J/T,URE;_;:E'-H^?@IRWGOL!\G8^ZEE;C"MQ<ZEQ05E5UK0)&,
M4#^6EA'A=E(W?E)UTX5Q8%I@J(1UB6A.\8BC*]\',U09E:^BNK!$BK%U-$6L
M42_XKO0^F4_)0 [1J-:=C4B3$"\?(PI;-\GU7V?M5;Q(^P5_Y6^7PX_^:NW<
M@26'RJ)S7'R<'..-:A>I!3'V>J<OC%"88Y@336,/^_.X$<8Q5H.=WW*JV.^7
MEOFZ6P.J:H@[1;SZ9B3NS.-?BD_^ \CYKLV3O,?6 ]CZ85TX%[OC#>NWIIJZ
M<W;-=F_\T:5M:]('U(MVR6O1H#H*WQ-=VWX,4Y8#:&2D9M' 7?D9#PCD)O4H
M2NT- S,>+5B7INE0NMH5](<F)"2_V?P8A5/HCK2?+Y*F#J*7V35@W=6>7\,,
MQ1\:L=:.9$J5J,[4Q0$/L>!I//PXR<CZNIE[AT9:]"T,*=E1F0J>,"G,X[Y_
MJ:AQF9&BO8IDVY+T:]/I$IQUQ5^XT(LK3=NQ)JWV^[UTXM1)JZ-,=R@H,'$Q
MEG;9[1?X?N%>1_BX<A>J\VF0=J>!]^! (H[$$M)$<0_?:Y?A+\55M:II-=^$
MMBTW)I E?"''.,@OD)JM>9^)XB2/PJ@@W&3$!RQ]KIR>$9=S=;)VW#B98@!A
M*[ITMU0S'_ATF@0H\>)$O#!>M'J]$BDWLO0W%6<W1/R]?;")OA<*BU#2:$L,
MA@<R^)\)XQ5:+C(;(TH%G KD2":NM>UWR+:K% PFX+;=!5K*,#)P$R.],%NO
M5-^A61Q$<K0PZ\NW9J_L4OM>,>H(MQ6?:EV$7_ ZM\P6B@:\+HCA9D,HN9(7
MS8GPJ/6JN4V9N99,0G^Y ,,8\\*J=^?VTP_Q\0,5)1E'QX. *\ 1)'F!0X9C
MB6':C);-,*[;4Q2V"(?\E5NO"I#8R'#I*)Y/4 Z%K)QA$1&<"U;O(C$08T[S
M=*&6!Z_CN"W!SF0$!P4A"]_OF?(H&0ACU;V]R+"9GA=!2M:IC-9CD)$E"8ZT
MD5;%2'SI2<.@1]$(4Z_XT=+\.#:H#2\N5W<J&M'S]*>3%8J<\N"5(^\J+_.K
MKM]36#P1:P=)^I;53I?O^#UO9AW\I=J [8I<:K#7C)I7*<VRD(TD>39D10P3
M'BPMC=>RVF=OBA)"CO!]BV!/LJ3LWX&DE*(*,_%N=A)LG8)0Q\LKT"C2[)N;
MK%UKRLA9J<?/N?$0;$]L-%S/S J+B_:HFF#U<@A$I!O?K3H*<>FXD]'0AI/D
MTNN&-_O7V 1F)'VQ>Y*Z+B\K7C6%@\8FDKO2D,-=9[BFMP ^P=>SL'"YTCB5
MZ:E$>-!==N(:5,$RQD<KT7+8I:6?^ (D:I:800KWA7>5#;Z30!7K_P"; M53
MU)!_\8T-=$#9ET%HOV'H[7?CBBSSX.3Z0Z[1%FPT7;E]L'.8H]V2E*F]\PON
M>]%W3%%$+ =1?/((2'<N)Q<QB.:"=]]2N(BS8TU%>_#.NMB+._/IP\A[HG,?
MW<)Y#7>[3XG> O3GDI0?DY<;*+A4TGG]SM)YG!SF_%0U];"J$1G6:4;/8KDU
MOWSK$?)G;Z.H9"1J([!J58_G7;[LATTU_=9JAA>VMXD65_!8 ?6PV/#/XGCX
M.0?!;F0"G%V[Y_7M1&D1/D?&U$]?_RB5D2EQE=S_A'M+KQWL"4P<] (GLXX/
MZI.Y$=G$]3=P9;OJD$2(G42]M5>3OW#(+(FG>O+Z(G0_XGGE;T('KQM^+Z@T
M#C%ZUJWYV'(Z"(:A6I;9_+9-1?D"5=)T%$-3S:MX&N:C.QS-0H<MX9:E 7Y!
MEJW*K 7L<FVVE+*I\HBE2BML94>>77;/29VXBJO<:#EW%H'2^:4GVYI%N$'Y
M,8CY262$Y/_SUD&#^\A2^#1S54>:02/ZJ3:@P/>:-RCR<:6CLR>*Q0W0.414
MY&[\@<9P\NF43 'F].ET7&9H>(F=/8A8CTLQEX"Z"H0AG)^WSSZ-)*M<BW!4
M#:EZ2LNU>!B?S>$T5TMZTB*1D!&<^LZ7<+33KK=PS>%F9\NMZTAD&1)N^R5>
M2UR><&;8\)SW$OWS<YW&9O'2,)^D:JM)\:>+J?^/KZ^.J8/IWKQX\98BQ;TX
M+>Y>[.)0W(KK!2[N3G%W+ZX7AXN[N[N[NUOW???W;;)?LMD_YF1RDLE(,I/G
MF9SS' [D;_)V-P/]Y+]*6,!RA#E)@$TUA+E3R(1<& _A50U?D^/6A3U<GCMF
M1H5%I8X,W'@\'!J!I]GJ_K9@[03;>#"@8LXDJ2'/!X5NMS126)^^=@OY_'QC
MOGI#E?*A#2AN7F&B_E_(4ESZ7'\WP>=W]1ODN(BFY411A!^GHA0Y<0U%B;4E
M5TE>W1%(RV2WJQSV_U--@NB-40EDC'1XU/MV41 :$_H)L6[N5Y\K&T4GS56N
M=K24#%Z4V )L+W8YGM($G>H6^U:FMZ)/='7P2"=#?'2\3;2.K[P_PT69A]-9
M/YT0OT[0E@[LRI6Q6:XFG=D&3U>Y!V:N#+0D6EPS&(7_!4R,UYK<A G:U$^Y
MQCF^DEH8VBK?IWPRM6GB_ O@L)KC<#'8CJF8%8I)BYI-.UAV^0LH>>UJGL?@
ME=@P.@4]"SX[5S]<1_WHPC.=RO>H=!JQZG-DV'E-N%Y> 7ZQTDZ26%<8&IT!
M9=UK]+KY.=E3-]L)WMIIM7P4;:N?QOO^OW>;3RC8%S7W79/H7DT,G"L<=G.L
M4HJ,0BL: K01'Z)HJXZ*W>:$U=L1.5&%0/:;,Y,FV9O-&@%(K&K%-R\K%<8U
M/*_IF+DD\D9/N+/*;HK!JJ.+FOQ>_6>ZL/,34%30LH1S&*D"QRUG9FX-*G<Y
M.=D((9Q"Z,'-G-S5V\\%*M$&I933I]%B%NH5ZGH,/52PQ&K)'MZ.Y?X*U.<P
M'33AJR.Y823M$.X;]1VFQ&&HD"2-<2YK:*YB#Q&W:6Q4( 893'4)%SU8752<
MZ=S%J1-.;(0?J $NT72E^Q O(!>7R!9-A"9U_'IP-IYSSW1?E@IJ*VCR/$HY
MUHKV'AAY\#'AR6N>%7<5_H !K;/K' F,BW9@P#!: +%KZV9^ENN7R1RDU89K
M*X8T!<L!0ZF)?NB=*'2H^'?S'VANGQ*BZ3J(A[RL7L/)"^WI%E\-3Z3D)VJ/
MN>E(*S71A%9";@5:"D 0>B9**6C8BJR?7WD8Y^_Z/Q@!H<?R5-NJ@=.ZNJ,G
M9_*2,HZO,AE@FIX8N)@O")GNB&4%N^#O.]Z=AIP&C TETR:_DZGW/O)LD L3
M,NGZ5R]4-EH7+(5&-:K$3=:'K\D3!LNM?=V((4+R;YQY_E9206]62?R%_V>T
M?TP/LAADT+Q@EG^Z$U5LM!$&Z(=+L3G_?57JN?]42X+L5L.<B_@TSMF8(YJH
M<_O#/J;?EX^UI/F9KB,GEX96:^)B-SD28N"MTS/. OXDE7,RXR7QTSJ_OMYP
MDFF8-LN'-,V(5"9P]+5;M*32+;-FX[VC?.J".P)KABS5]L8D_\!^O-)VK1!^
M_,"^ 5MLWZBA(\TT[LHI$X,T"A[@.DZD7 0>"P.>V9;*7O0&&\(40_!1_ -#
MAV+K?^Y@'I1.\ =V^/)8^P7&2F!@U%\ 04V[F[43,<JPA=(#39$RGH)PY-X.
M<8QDZW%,^@MW^6M;;JL%A (ER[("^M6J/,]7]<P8%Q^L]7$;>R44N*)!IX7+
MG)A_2:=X :_H*XZ)0):4%O%!(_.8;Z8?,M>>=>INXX.]KJ([)JEY'895DB(;
MAE49,&*XJDB=JKBJSHK-Y$VK.IVGH9UB<_LDR"<+-A[K=?<BZMKGJ?"K@\HV
MV^2A=SEKAZS2GL/TI.MN2N[HB3Y?3&7^!<Q\4SRPTLQ/=0V4_0N(<2AO4(>U
M-ED#3U]2OHS;:]>OJ#8&V'0CR2\3]O<XBK[PH!HMD 'DT,%%=/A/LB[#,P'-
ME4UU<LHS.M,4'0&X_"J?Q)1Z23^]KJ.T'BWHVW]"H3AUD[:0 M&%S%B@&#@K
MT,,F*,!O0)>T<?;2[9._,T"/KEKG($A]QJ9Y"<L/FCD/U*SO+'M!B,M[M$RH
M)1^0I>GWH: 3Q>; IEX&Z"MU!"6F-68F:&4J6&=M4E-!QKF?^,WO&VUMX'!9
M2H1CZG'3P""PD8(ONCAIEANVC.2X4V>EG08?D>E@:[O=X";=B$\Y]:5'BFQB
MA?AQ  \1Q85P]O?+3B2BP2C=P3I^94,FEKS[!U@]SA\6U?ED.KXZ0+D04A-0
MZ?K* L_&?$0ZT#%0=8P#]=.#W9Q)[8;=4L ]6_VHW8FBSP<-_*G7?5%>0G<E
M_IP/6A6V_=W[:ZM6O\52H\K<<!ZB-NO#MBG&37YF:MSQA<RQU)!1[T\_@:2X
M'"+/#*4:JQ K:R><[N5(AA?8VPK0,/'B29RT2HX?U"[324B_CT:\V*NGF,J(
MQ)-_W9LM2VP7SNOCVCHMOX^&;WB(%8CD2;ML>&E1&RN2&F7=U3(9$4TE_$9=
M2*1^;-*HC;2.T&ZO=+WTM3T&RNB)[J.(2R/N*8'($EGVFZ3>[JXIU!.[<5.F
M>+/*&KVOLB<X2,.2(G8A[DA+S<P#)E5A$$K^(+YKT'DG@[RP)J:L/\<:^XM.
M& </+42^E; #N[ANPWS'<EKC8*"T7P*G<K+Q+V"]<.S&35N8 <TEMFG5HJOS
MLWS@:X$'("@D64#T1U!2JG[;:$LB=R*X49J+"ZEN?G4PXU4!X<F)>A3LP8A#
M7QV*$R+UP: NP(JNFWE[(E3=99#^J-S*E=%CS_-W!3?S F^K=\X3PW1AQO'5
MZT]Q$H=-VB+X Z$V<=3ME[TD$L?L_66P;D =U<I)L3,ZM?NOLLZKG\S8):MI
M.DJ;"RG7%=R:R/0=-1 *0'L9G9U]C\@8>!+9[2S,?0+?C14+M)R02 C7WZE7
M[JA(8D/#K\_RE'C>(8%J!;XC)^5M7!W:<=A8NYX'6?4B8#BZ9N?FX7QA=+IC
MU^ZU(*A4]G=+GAHO,=<53OF#^7U.=_@O0!2ZB\7]V^?/B^>#SCTK\B8#<,-L
MRS&$8U( POR^OOL7X(YYNNK>3F(A?<M<OSOY5M!DZVP@.+XU]:W\"R9?UD*_
MQOO+#HC,R@<8$-:XY.FQB+_Q&;VOQ/<X7#Y?1X.T)I>;CLJ9I ].FW^*%YE^
M5%MU'%($VA6)0^&/0D+0V&8]-=X)5G;3$P\XBT*@%]CI2'AP59VU1R94NF#
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M8ZSS$LWG(I.Z:PT,IK$7DB#[Y:D^O9?H3[<+$CDZ:SS!(24YP,!]A9 "E+#
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MQM!=;]V>VC7I><UUU:$]P,;EJQ,TKF[\PG_O3""O=NG)\N/H3UC7&]0-:.W
M08%=KDO3E'+36JX@.UU(OG2&UV1"E#$[T 8%<I_HO6DYO'\5\X*&$U->D)@
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M@NHJ_<NO;,SLOV>Y&YE'%"3B+NZ,8TE754.=M/@E!I0:RWC&ZI3K8[&D]LM
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M]?-NFJ,02IEGW*!3L7[-WAF?G2*,9Z;U'LNN[]&9$$S(%ER<JN)=340BI>U
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M1(>N4%^[8C=A]]M(B7D8R>V=55&DZ''%*]';/A7]K2SW2J:F&G]/.$'D=7G
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M*? _@/(BGVKM]DMGBJ _07&*1?=-;N#] 4&YZ-=XK=']_70Q$J:"FY6_4N_
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MWQU<D,]L!RV:)^G5<C4FGWV_2OWJI-&^^$67?K#__B/#Q\M%0M@G  ,J%H#
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M3JN9I?^'J[>*:L,)^K\#%%J@0$MQUP+!BD-Q*.[!@[6X0Z!8@Q0K[N[N!&N
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M&[Z&?^C_6[P.7JKQ"7;>:L)M*3IT__N<C4-FK6)G0NBKU"C%6+1F09-MV1V
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MP.0.#=,)X_E;B?C+9KWSW+?JC;\;?48ON5GU%@WOJ3;FN0KP]X5Z^6!H^ H
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MFNY]X6QW*-V> K6(?P#/&'/6L=,/;G9 2$GK25:!5C^I^0RTGYUMO^8CNM'
MZ0=AC)<2UD@H/@N7YBMX7&NF((HPO[_:T4-43987O.HWRN='CF5I=KA/KA#R
MH(ZGJ#=F*#,+TQHPJ?%GZZY5[:9Z5U#A*E#I%>V0T4J.U 6\2T"/QDD13C0T
MJ>H.- G)R,!&T\<&CP9NQ.XU"F54J,>G(I'L>-'UNZ"OY7^N67YV2E*!*@ZL
MR*;J_C5W#AI'HH37GQ[MA+M(O]M/7= _R_TK^,Y=+E?:V:O4RVK<@J'.MDFH
M#"LVJ5\Y@\+BM#3#A31A":.5L$7')J7N.%6[GE@<BG_(CNH_,M9*8'BXG%+1
MG23/!O8*<1A1'R?RTW\>,5"VEBNVU-R7^'14;/G+C>K];6;4']I(S4^P>*M#
M3*;_TY$]F#W0^\(W&CGJKSZC.OB+6+KC_<V+Q^YD%"$(J_B$9:(5]_6)/JB?
MUO//;.\DA>:4+(+U (3Y_^AU 5_^ 0IB@\83)>%*95I/_T>O"X4;ED7@.HW8
M,[/P:92^?+/J/=&@5Q\>C<6/.#QP&>(H*DX0;9JMNJ-$HEO7W$2JL*XL/VIF
MB,F,*^5SUN]G.6B=Q,F!?L&V+<]VMJ6?LG*/)=%:X-0W*Y:E7] BY:] 1;Q2
M"T&=40BD])Z2QAT#I(+NL'*KCT_J\"TY./P$ID[9BA3&NBW(E9[D:;5;'<F(
M/Z6M3B $5Z[Y5NVR-+94+5I;[/;5.^P@6YWO&CD_).%UWI6K8*-8#&1"^O.;
M?HC)I38,Y/]MY$6)%_I@*S%Y655#FD-E$CQ<G!_CB$Z@TROP,B?\.&)P+C-;
M@DO$+E=I><783+RZ[-D<T*I+:MQ"!X_1K*V%V=[AV$1^(G"AA\+8>UHX[L@B
M.3@8_--P)696[=6E-S$ 4U+H $!I0,_O#@+-[_.3!(-HF ;LPVC!8@K+SO?.
MIU43C0T9P=%C\DU2#X9_%H1:9]^%LV(;>:?8U2V5F$5<%5,7.>AI1W\U0XT3
MY)^D;G3H<O<'=*)%NW_W8P@H4L,$UR,;*C4C5Q!#E> #0[I)28003O2R^ZE0
MN^6N\S+OTQLS,1(.Z3T2<IV$+"^3N1ZO]<V7%)0#EQ$R>9#?<I:GZ&(F'<0F
M%VV5K%?^DH=LFT.!2^#>A7;N2J#T(7FRDO\?8,GU"^]^"5X+GX3A^K.@\V=O
M=]T+IW5NQUH:M?9);QI+')=EC&&%A:_*CS[[\G&PCPRPO*0O9O;+.7W-1''>
MXR8P ^<[K#GV8=U)Q)\'HLO\:8)4W<*;)2,DZI6(>Y?JM@:B78/4='*]=Y4H
MI%4,39Y[5?$^D07DN,,EI,7:-+R*6:PVV33?**S8VC?W]9@[<" S]LO[L17-
MMF%P_EV8W>\'8H6(LMYPSQCW=SO['SSZL895VA4-I@.VA5"_K:WI?X3DQ4S;
MP!$66L@3!H</=2M^[UP^!1>S%M5G9/ W\B*1,8\'3MJ5OE6.1^G?HHO<TBMO
M\_K<2)1ZO588Z/T7>06F5EVA@N]PQN LF1Y$\$UHK9H=+<O\D\)@/_/U;JFM
MG;2=P/X^AYO+_3SI3M 9J^=+T:E5S[5]8'!]JH3Q.?,G/GA03TO2;PEH<7F7
M!XCEQU*BY)"LW=OF(B*"+-?H(F;)./A3KJ" 1^-Q+MW:8T51@&5EYLJPN.9^
MU0^!;W-S)8--<H?[4S3R0_KHCVE]5NQ"<(*@[T6H5X^LQBTWU;*VC,O+H):^
M3O].]LR%X:QY&,;8>U(1OA23X_:4>XI?MC:DXR"VQ^V&+04I&<[UG4)" 0G@
M_Q2?RURJ'[ 8G"KZ5X8 R;2_C*E=$M4!B>W"\@$H!,"'L$/<WT[?"^UGB-]@
MW#U^)B.Y_R[$QHKF=F!] .W H8GQYJ(J+EM+> 0[;L":$U]+=JX!U91-#TYG
MN+(WUC(]??XK*6FCD:F, W?Q6(U!T+O*-9_\UJI(QJ.S_Z,723]EC;0P\\C:
M/QH^*EPBJX]7"V0\."4+A1T422MCO![TR<I2&[:YFDA+2E6@]9^N+E@^G)=X
M^"+*_3IX[N_*>8X$\&%Q3H#G[ESEP;&@20SU/&:L)")7-K3'=9^MGJZW;QPW
M=BLL+OB%QRQ3#J:5GEE-FFYLM*D;UFH_2_+'4L647P7?1DZO:MLISF8DYZ&E
MWB!O<)VV:0^Y_@/X(U(JC!\3$1S8:C.9Z\$SAR!,JA(*2F',V'(94P9,@ ^X
MB/'H5$P4^U@"1[:_@Z5[I VNSQ70LW9B$'O,YFTL>"*P5+'+_>8+)T6J7+!8
MH?!'!.]D!CMQ>%L0:W:H>$H'.#;$JUP?6X'/G':;R7NNO-4VQ]1@'7R(;27X
M2ZSPU<VY4E?E!-O<5>^&#HF%UEQHV#ANYAT-IF8- V:=?/62(?6RBR%Y$JEV
M+/+"A:!5IS?OY^USRR:[GKF<C<0^CZ_"40-5C,*W#2-1[ V$.D>8RLFP;\-I
MA 1OB=H.);3/7F2(-];>FBQ$);RA?",V,W=J\Y)KNQ@#MNV;^X0/C#IS(HN:
M+FS*]%HV4+']^T;MQ/(?P,KPRUKG@$/N;;;R$O4-BDF3*>-G@3920DG(/OVW
M*V']\1OO0=<-&1V6DT>:/ /<^OJ0PD!P8'*:RXD7W7(3- <]5R9CJ[BYXON'
M,9_JH40.WG>%ORLAK4^'X-0!;OH41 W&"-"BKJXQT(4<')*7]#E$"DUI:\J!
M-.5N-<;M(%7!U!N1V]U6<UN44=/L4M2;G1"9>+=JZ$J 5G%L5I<&J*&(0F]7
M:W&C\F#=?M$N=*&,RO0?.2 +Q_CR\,[^(8"ES5/Y@YV3Q(DJUR2KQT&VBII
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MT +[?5>Z/5&2;S>EY[VWM;.Z_$NU#O":/ >?_8()H=<%[MA@.+!<FIUGH7*
M\Y0E99?*8]"0#9XOQRUS+A1;W2GPHN+.;LIVCUP$L ,=$2IZ1SYH@UOCTD4X
MAFO![Y+6>8I8R>R,A&SYK$5E M!\>6XF#T>+<C-NT^-=]?3\5$]/;4(1LTYA
MU"2JW]C94-/4 >PX@L']M%->A8@ZY $'@_.B(4]V@VNMY,XM1+/1>['YO[RS
MV0%Z',2USDX@5Z,/',:)\Z5L*HQT<G%[(I5Q%3_04O/_6R8._,_@9M9'F0!P
M,/ED<-.:P@M%O+,PM8G8!U\"\D+*3>13=WSI?6A("@FUJ<1F9>Q]RZ<YXCP-
M"=I!VHU.FJZ(Y/A4WL5T]S5)FN>QZOG4:Z6[XA]GY=8S9Y1KD7)R-/O3DH^I
MFDJ=<XV/ST_2,Y(2>]P#77+$-4[-YPTWNMFYUN:M7R6,?H589POTI%FP)"L(
M*#-"A\)_FM:YZ7GK5E9/U:A@-,<>R\)Z4SZX^^8HALQYY/$T0R-PVENLARB@
MEJ"1SZ@O%6#<\[-#619>[\/%Z-5W/G)T/(6[%.:_$\P#S>+HP7+>>S403]A6
M5_9HX%$Q!S\G![]$4'5+KO=Y>-8JS+,N.4!UD?W%HC-%^<S40T+Q'KBE][?V
MEA"-X+/HN.5,Z+<,6$#)[&DX_68^T.NB^H?T\A-' @T\DF22AI]R)%Y,*D\8
M8?*Z\W5LPY)-H* HWY7QR;JF2]?4W>1@>A6+7*)4MTF\VGS%6LZR1SQ=:=U<
M/!ZSQ+*P,7W,UJS-?6Q%DL= +,*5BE)$=:&C@'A=?H>"B6GJF+BP;47<9:#"
MY/V]A/.Z1D &]UD>.H42*.(.I-98#[?_L&:@>"%TYFX[=:4^:Y \N%:[QXT+
M?P)UC;74I^^2OIE'#W'DGD"\EGC);XS3S,RV4::<P89((:/88Q1M('"9&*""
MG.S7.\48RC >GEGB(0MWX64"W,[M'%B+2J=!.>NRW7%H\X#QVMMUZ8P&&55T
MY !%9"_IZT(C!7PA24T'SY2F*!Q!5@@SR=V=;I!YC=LF:/2&A</1YXN%N]'R
M%4U>ALJ64H8 .<<7J:RK;$T5!3TFZT?&F)8AC*M,$$&A(\OZ]E:5I_%@MC":
MPM0 /AM#2G_DSJ'QDF%TN/K2("S^ 9'Q:G6PB,D6:^HW%',>GU_4EYXKMLI*
M=G&TEOM9VBALB^5JA;ZY:7"/,4]&_]#X\X3"</TS\ H*HS_"%9?0^8F:Q17O
M:.3Y!>Y*>1LW#P-ZB D8(O!UN/8HC4?GM.-G;A .OC\^HJ][B7\?, I[^KE?
MO'%&!+)OH4487E,J&AO&=1)IC=F0?'$6]XEHV?P^"*\9;LC3FMN;W_^PCD&3
M6WQYRY%5.XZ=DL4VVN::B(9.JIF6'R(OM19]*=2<JQFWFV<4P:S1DIU&._"8
MWWZ<Z$-N)S@!\Z)G[@JJ^<5:##9.S:=BS#@Q57A10G)89/"C>/K/V1K-M/Q.
MS(GB$<+*_TK]9'?R#U VS',EC"/D6PK2@IT8XFI?.P$'J<ECDXGF51D:^K)K
M3OW(/H81D5EFO ,VO=P6U2VNKO),D_)@"G_E"_9!_H9WM U36=L7V%A6=3F3
M^^I)9ALZ%=H@*KCF7_I3O6.6IFW97:YA)D9,S]?O<#!G*@#+<.JFRH#[:;X6
M QZOL:U1GJ$PCTZ;,R).(,[*G!B/50OT3B,VMPIZPS*XRE,+3'0 :2Y<>KQ_
MA_R0Y'<^KNMY0NBPW)CQI]03M%M?]&:PYU:OY_/4#&$$O96@1$QG5_=E5:[E
ML0$_5T\ <J*<4]SWL\<*R>/T:_6+;7&7M?(R:>373?^2?#@:$_#^^]4%5"H$
M,_.G^O]=HJJ_6=AFDU1,!*%!/T,5Z*[CBQ/?GM+,[E/$!WE7DC(6:WH\-C3A
MA%IO'B;1*P0&6I8*,7Q2/'JSQ'R;!A7O"*0E\&"[F4L:3^IY5-"8Y$M/A,_G
M<"QX98G4WOVLJH?[114WNW(TY"!(27M7S5(V5LZN$K_I#<MB07NZS!:J,Z ^
M*2X,Y4[D9$,N1>[Z%<NPPFBPK?>H'PHZ%GCUYOT740IMI2I/<1Q=EOE2V#;#
MS7V@H4S_\>/!8@(A3^HTUO1-=2Z/>OC*93DC+'%V$'$]E2'*RFQ>T^ 3$@HE
M/+UU""S?%:HM)43MC<[HC&[ K277(=1?NE[2;S/\?4XWY]7M*<Y TE(;V7GB
MPIZC[_1)]-=^".)64YY;BXNY]W;.^Z,B^>+L_!Y2)RVKZ_8_@(7-(]*F3@:^
MGL'9DV<P'!XYXV-H?TXCOM,B@FY4'ZH$DAP"06VW0I7^ 3BLY\A8V+&<K,10
MH'^^F,KS(#W16XFU>7]W(5NO(.621+3[WY1)-[O@W]R]I!"_3=T!QZ6^,*=K
M5&@>H._2O)IE9H9@$I5)0QTB^9G^ ^*L/V9,GS[?ORS1_>4FZ$#\8?J*%E#1
M\#\5GE63QJ6LU(49&+J<+[48#2[.F#;FHM\6YV*+&!UF.ZP\X-+W,=%_S[&T
M5N1T=F 9?E09$;&IQ$\'F$F38R! 5NX_P( I\N/CP6H;IWJ<S$Q/8 $[B((,
MJ%5;U]YU!7N*3>4GE3:9.8^$_+5(_6;P_FKYAY GNE9BO-*AVO['[@M 7&:G
M@X1W]99#KTW+*,5/Y,/NB<%<^HR*U=E->;X=F4Z148R(-THZZ3U;R2':=BLV
MW(["V_ZI+XCD<@VBRC;V&X(4Y@.559_/6,@JB4  6L#C;FBI4XU=W7"1E))M
MT?JV4G'"^?MAUG&C^UQK1+>:&@?GOD[$5UO/U+/^72<Z.R(P>3]_S.;4X4[_
M;/G\XZQHM#+K)==;:6MY$//7Y!?%>&]WG$F.G5^=G6U3'N_/C$:CZB@NP,FN
MMS5XCA\"F"-MR2Q$T7=TT*H/^^U#VD:LY-2N";9K8%G/(Y\2%?C;%2I6NY;L
M\P^%.-4=*_'. 3]BM&K%6G=L=HN4XG><*A.'SP$K+0H";\J:GA[X!J=/.U.2
M8,MWZG79T1P4A\2=JW=. :Y*OVR;XC?:_>>"A*0DM]Q7'$H.CG'OW?-D=+XI
MS#CEIRU9BO%A#NT*]Y1L%;*_R.I@KCK1<])-2M+$K@2!/-]D51D)U VP3N97
MAPLJ@\L#/BF[&(2HF'<H>C2X$QB.VE@6VO),%[LC([U9/R39Z6T06)$P[;"F
M1!GPW:QRX:]F&%0[40H?)9^A+C!T6JEI15&?SU8Z'55G&*"(T*5"Z5U?[CLQ
MT5I_CU5C;E<;Q I>$;?J/DD@MW8/NOE+'"746="<%'\:FDPXH9CPQX@1;M#M
MA;G3;*(\0#\L%J\@1OI;A\J:.[6G4%$@FZ6L94UA!.&D\%#86$PEG1A8(U@3
M O./@R6,$W UAR$%&3AO7XLS91[(I$Q3E5ZRZ)^7GDU"Y0E?2F).DVF,L"XZ
MAG>,#U2OW!V6^^<5ES[16&I^;A%#I"_?3'+&-4VDZQYIC77D6:<ZM[=W2P!I
M)Z3O'AACG$@ZC<[(-; <=_A>JG0^&N^T.+-F'HU3 =#8OC'2]I>-#(UHA\P:
MQ6]UX4S"E@R)R,0CK$]7#%;J<**QB!E:*I3MQ<80]X@+9E2?4\7$8D&:%I>M
ME("O%U59*FUH[^>;?P-T-(S2@HWN@0^).C*^[B=DOIQSXTK>1B1N>/4?&(KV
M/[;&0UD)N>UM#,>8=?<"16S'0'',E+<A:UFNSDX=D!+8P"^QC/1O8O!&:I3N
M)_"P@W#5U=@[FJG*)?&\!HNF %/<^FUCZS$O)7)R6LI!(2Q%ZWV")Z)<T-<4
M>37^B[%+)2?6S7228?)PFBLZE.MJ+5EPTO=J4I"R/>?.%4\.DB5M?*)."HY9
M4_=>?4<-+O>;>C([G) K*EP?\1HLP1KM-/Q>;!%U/M^'VE!LQ1Z;O9-)@H\C
M&B661$7=UUBIWQDCJWO7Z5:4W)QJC.U 2VTD?_$Z3+E,%W^INYQDG X_8&AO
M,(E+A$WJ"Z=\'WTN2Z5,>ZI@*64@5O*&O(@UE4(ES2N^DP@47J0PY7':!N"#
M36LUN,@%#=R72;8NS-,\F33KMJ:#CI2FK7EI[=7O@[,\&PWF9@4,BZ,4 L:K
M_:K@11T?9"0PUYI.-HBCH#]N<S; 4\-JQIQ]T<B?MFQ;>5P+%#4AGZ)\>KFU
M5P[J15<CZJI+U9+:I:L_&,G2#3B2_OKPQ3INR8>")+S#S7P3<4L^FYZ^F4(S
M.C!NTXTTR?B!4H,<-:XQ!;>FS7D\=:N5OGCR51^<&:#*9U"6T@"6"2,E:4PX
M1K+H9(<*!*\T*_K57GGA_%U>=%E9NRNZ3Y.=/B%TZWKCICDX-51C5;Q2A^^.
MZ+^;[^+OAX8R-A/7#?8HC^OB:F$JETT*YVL92U)LF+^5"JY!1^J/G/ZS=I=<
M0ORH(WRH/B&.9?>J=:NTM\6_%H@CZ;Q/<[3XT@?/OU*_5%("R)G!#ZB4!M48
MP[$^OK"L**PHGW<JYTM;Y?<%G:AB*1>KRV_^YB5+B21/JWRW?U2S8^6  ^IQ
M3%_85O;E/0^I%QS237YFDJ=E490*APV35->,@K^ 13J9!)1L@Y%*:'TGIMZ[
M<_&C5M&O6W?4'>PY:NS2'^F'(9<4PW5*&*I0 4C;R>Y15#V(H.J)X9CF9I)3
M(C#0.^2;LW>\6!("39;]\2/!Y71RPR@8AX>H,#_6\#5K?2VUPUB]I3^&:H$_
M,?:-$/3VAJDO1N"+XA=ET1U).]$>BO%8:[]Y]3I,RJ8*04&=^=D_8C&030SD
M"ABL/6F$27RB7>N)HS(O]^0;2G3R;D@UO/[Q?5LB18"]??AI4ZW/_9J/.3L4
M25$C)FC'8:'FGB'&@?*2])TS)?C&PY!!O@@,] ,F;<W>]$6.Q>8%;.0V"XR=
MBZ"0%AB:O"%1>#?D+C1+0@<FRWX;"^7PUVJO>J2=9>+;>TDE\U*,:R5CV3(:
MU=]X-H[V^+TFH.B*/S<)N=$,.U+SKE0:GVND#9IXAJ^)./ ,Z(KF9GPNN$D"
M$3>+IP;\7F/\?9'@ON:RPFNLMAP5U%5MSJC0ZW%%-@]*HPS+CIY82E=2 +4W
M4X>'$/;DHU-)UOJD5!K)&D(;1'3<O)VLQ!D)?@< GG1"!-,%[^^EL'D8#)?C
MJF2LQ1G"Z ( A-M-+M-=H%>"HT Z/#Z3)(]_ +TT$F&=>27*2HLN1ZB2NBNP
M:C9]<F_5:__EV+OB];98J=Q!]W3RF^B,V&+V'P@UO?T56L'Q<B>TS*AKNX8A
M(06*%6LDS$?1Q=.)FD*@T,*PFSOML&:^0/4/0+YQ\5@6*6%Z/AV>+(/E]6P7
M 3:9U41$>D49K$^N/1[U !FMB2#&]IIT7R2-PC068=V,ZQ(?_52\_:/-*B,K
M*7@4[7JTY78%TDB4U R9T,/2:UA%_<(L9/2&O57Q0]*:9\@V'"R@^)<MRK]R
M+=I[$[U;C\/E'R>_#6L9$LV094X9*T# #JN%&>W$IBA&802C'A@X_P!O]>L"
M(BB[Q$P&P.3<7O06MK/6:6^>V37U72W'8\MJ:7RL_* 8@*:ZMXI3O<-T)Y5A
M];7.FCT& [S;WR"ERT_:I&32U<X.A2/[;H057<@^6DD]'$T@KGU 5&0#.,_Y
MI>9>1T-6+H#4392>&B1C*G!,*45I;6YG(!7?>/_C]L=IY:8D,04)Y;@[A<$I
M!5&8V2Q,I8D[K/'XZ6X87YI8=G(+TN*EH'"OX.!O_[;5#ZX5C2U'?,Q<TNSE
M374G4:E@_RA#C)9Y\_H[)XHJ6M6]2(QKV#(3[O IAM%4206-VIM//WAZ&;.9
M2H-UWA9%326 WD2FXCA>H@5[O,_J^%- 8$JDG\2:X:&$\Z+IHCLE9A!E8AA*
MNJ/-:.,V?]U.3/*'=^:72]ZG YZD^_*.T,;*<)7C8S&I.X:]2%VDXR=Y0_;:
M=+^)"22TCNL^.9YYH?7H"?M/O@[^.BUB)@'#RTGP4V>7Z<'?_,WF \ECYSFW
M$H(I8^8,SP.#NR=9=!"KH?[.PKKEQ?2^L3) _A4NER#>20R,_K[:O6=_&=W_
M!GT/*_^,FI_3*N>W,\-7E.RWJ0RP&BI<NWS72U1J9)C#PIK*28U_<O="JV[Y
M[ORTD3WFX"VYG ,+I4S[P..OJSHM*!%$09<3Q=*RM_*7JSUI[3.Z H*LL2;+
ML\NK(VW%9)(I^C9F=^8WTNVF]K>HYZH.6[NI=]65R@NV!U12!.NEE7]:Y\'6
ML2LC#9B(_B^]I'N!8$?%@.[D1">CDS&,FEO9@9(CY7$<,U--*85N,U4:RX?4
MI0;1J457!?;3I%$*,[R%X7?!PDBQ-$)KW.P4*2B\YY6W&[-&Q_J#OGXKGD<8
MZM+O_JA=^]HT?U\(3HZ'-O7'A*<M>(2PWT3@Y%*4;:(Y&;JM8^,JQHXE&*#0
MV/&[Q^EJ!FV^P<*H>ER U;A\:DT]%AQ<4*^.EM\V .++FH&^?&X6._P'./]\
MN"#/5>_^%^KU@=+CF*]479 V9%!I^&2-HR^_J<9?MZ\ <D<))V8B+5;PI<,A
M6N+NQ=CO:&][R'P3G8!C&@-9&SZ(W>YRK_;Z_8!%P)P=]+BVHZDS*$J&U=KA
M-$,8W"L#QB\Y6C0R@96"$\@1YG7>3-P0;T<=<;$@AW=O8V!D(K9P^H^[JZN)
M8-0K9_J1#5<.\T\SW+6=G0E7&XI*V??PEG/(_@%9HK]B&S;?"K; J,);IV)4
M&B073U'.;84S\>4N '^+'%JMV(1?5,X?XIMR$RW@7XF^O7S-8+4RQ8\Q^)^G
MB "G79XL)15\:MG.0.^_+&Z:P^J&0U,,V[I1ZTD1:7&&X3YPS:K=ICW^;RPZ
M0)Y <0;)'P/-Z4R>Z/52]:T9TQO.9G-^-BBQNA8.0)*991R*\ **R(FS>V=R
M\)9?L_)8.PJS']<'$$EG9U_ZGRK$7,VFU RCWJOFP9/?O(S%!W(.+S[JR$&/
M'?X4!W#+/ 1'@D*$A/",RWB\^M$.N[AE[/$MDNZ91+:)NW,>WWE[7\#^>&M7
M[*2*:Y1*/#>".UZP(\+L3YBHURIUNK4=!<2TS$35A[SQJV[*-^)R2N'ENTT,
M3R#Y)PN>NX.SCC/.OSCD'R9/]ZR-Y%&"5_\!5*\RQO:CRFT$]/Z#%DO*),)>
M&EB'5^LQ'-(>P!V.YL?8_(H1$&3+M+#-.4#GQ'EQ]:3*T7<V-4'8"P<[O;[D
MLRA*91C]XX^VT\8<$4\' 3*BP@ R\F%]U*!9<8'V4""5V??O^\36^M :*#Y3
M)& ]O$A:'8=H$;?VU8">I<6GDC*5.FQ84R,98Y^U<>5RNGA+J] G4IQ:,I\Q
M008B; .C_+Z;.[GD!OH'*)9^72XGX4#$D(:](WZL#-GZ?]CXOQG2$K<R("3'
MI;@B>U?AU_HWBX&>$'1J2C=ZY<P7H\Q,\\:284>BQD)H%?2M_*?,N>;0JG%J
M64&&#^<,_C%6$.G52;]5#&0X_P]DH_O4^GP"Q=4[JBB.MMJFN21)%RPZCT0E
MUH;ZA,9&(416C#RV)9)?! !M_UL5N?A&W%*I8AK:8F1JPU;<!P25,U!48SE7
M'L-G%K=)\WRC8;N+O?W/(GF>WFK>B(KLFS2AXO=;:&<A^;-\[=OWEF>B@.7-
M*4G-IZW='W?^68%B'/.NEU1(5T$(>1^XX'%C+F!'E:^BZ;W8@02#AL8/=JLR
MY,I6@MP_WI5!-?1.]?S8SEY'3P'M<3F#N4?Y-YGF,BNP:A&7HWEG>&LB21WF
MI1.HP#&J0 /O7"QD4EXKD0#*/$><X/%CW)K\TS76^MPS^;W'(HJM8YN*N)HA
M,-I&] 24&G75_ >M5OA )V5>Z\%-'F >M%FYUL64,FR )$6D)25)<W>!_AT6
M$%5Z2#(M_8F#@VBWDR?+8T.2UE*/[/AZYV4NMBU5@FV4D+%Q+S$T>5OIRWH=
MFES0'_Y&?;M,<;,%1,;<?EF;#[AT*?;S_ -:5%$Y? W:HF?#*#H(IH U-3);
M8QY(TES /^DLCS=;VTGGA(_)]5:,KT09);;4?"(^M*N_+VM3GBV45D[^:Z.1
MF$+467D5CT[MNQ-B<\;FF,XK1PYXQ7](V174O6HJT5>*.Z >K,\!>@P]1.B=
M-K0W<S1,YWW2N]>K[*W]^<YN'!MP@634="[UDH;-09=1KO.5%U^]5+21K=Q:
MFJDXWB5PG?(V.B5V4O':,.7GST$>@12L(]+L)J)2$BW@8MEJ ,.M=GQV8[)V
M!PZK>:.]V=B6',>QM9(HN4&+/W*$V#H@L\3C3.R .R3EAJV(LR9S&8,"'?JU
M0#(G-8,,58 Z2]RPS((/."[R42LL6Y>%S$9$P3 6#J4"(#N<OK"GM)4$RF_:
ME0/Y ,*YF-%)I'YN!""-!E:1P^?96%QM<O KZZ)1_XO@ -PR_,^DA2"C$&05
MK%JAU@",)] 29=5LNJ:V _E<J+1;6E4CT?847]R7@TS1+/C!1H]D=_MZ<!LF
M@1UKS"_CY2KPY6FU;0I))@.=%$ Q.R8JGG<PJ[M_K.O8F($LT:;DT9'^&T4L
MASFF+,K'^&Q ZN-C33Y(T/Q/%X!EO>9]+DOT*4_=#'+Q YOI:6I.&KW5\DNS
M]O"CN&_VP& EQ<A*8P9N0\G#?;:AQ@%>?DHB 7%@SQ:B;MY@7E%#4*/R ]US
MM$??6N$-[[WZ4_3D&9GXVK13I&]I*:A?4,0@_KG"*/22X$N5/W)D',\4LCP2
M>@L,]1[ST6_2">94;"QHVN L?Y[Y=Q,%9^>S4-C1.U X8R9"DC3P'!G8^AEW
MI%F[JJYLD<+=2TUCZ3KEJAW*>; IXQHCEM,&1(B65PROS=I\9;MYY#(6JZ2Z
M2;<;DMDGO%0BT-<(7,X$M9]\W039<E'U[9AP;G%&M5&?I#M(O-7VR$J5$0IV
MN;:7U?5](!8:L$I*1@QF+@GZ -@!&Z,^)#CY4??4%37L^T[]']4GC_:KSL_R
M;-T.*0=*]R@BTXT#-PHKS:KKU5K;.&JIGM2(;LI2R!>IJ/E5D(/0Q5DH1BY?
MM(DP[8A\JN06SLH+(]FYGQH7#$TKQG1F_SI!$JAUHZ(S4,8TOK43<X"'?9@4
MMKY&[)S6C.\]DZUUB&0N#QV%WP8MLQ\XSNK!F]<G_G37=*E<DUF6JX4E?.F!
M!FVOJA_H,GU:K6R:KPJYT?W\K%+ <G[;;*K'SA6PM_R7 5W_TM#D0VFZI<U"
M_$L8_D YP>:P&XLQJNLUEFBY;AWF::?AVBA'[ E&.(/@K#>*XLL)GF4H^9V1
M*-5?97\[G0ZZSMV?%RR8)#0OJ:).AF/UH4).38*RWL?KF&4(=FE:#B:C.Z2K
M9[#>W/)OK$$<+(?&^#L5Q1K:UE!'PF]"W<F\V[ETX11^*G:3EM!XPBC)6JAA
M^[ZS98]ASB^74>M[I,0O40ZR'T+KE>&PLL?P6$QC>ZE-$AT%&N_U5I($!Y5?
MUDDGF-5V2_<V[F&MJF]GQU878WOLY]7&6JB)FBP$0M<5Y_JA'-0+M#"F2XR/
MM\E?^_JWZ"K>$I4# ^EU1-X,!DZ7E,YV.IY<92OV)Z;&M>TS6RNT*'9,F(]H
M^^79=1A.EGW!&S>X*6'E1F47'Z::E$DR9K\Q/R:O.I7)*O8H^CJV-9ORYE<4
M0F;@Y(];(O'>P=T'N!TFB5BN!?R.;(J_EL?K;ZQ1GZ@J_"7>R$B,'6RDS1JC
M)#O3.7'LO;SIK97FBV5 H=/[)'0OZ-+V0\/T)'7T5;LG.C4A%F&V9]XL%NP>
M5)KA]@%A-5>[O5U BJ28>#W@]6K<L3-RFR=8_/"=(8U(4^0J>X$/%V#$2ZV'
M9,G1WM=<A\S^D5O,.PUY,$Y&UO(*:;OIUV^)MH49W%+C**S6HZ?Y;^;K%VS,
MP/%?7Q?W;4T1*E["10HC%J[CA3@=,4/ ,-*]]O11+R[=X]2D/U0N-7^,^^"6
M7*8C/8X[&O/<U6^RD8#P..1CSXII?I6EZN.+SN6M4^O*UWWN@OQ8/D92_%F=
ML'3];A/T"-2D_B1G_O(IL'X 9M2JE3LL+C+>^2;6 O@5+_GB445O_0(LG)(R
MG24GKME3K?U#AIUO1E( NW$94/<RB_IWSX2_T8X2>:!K!0+9U_T-3%IS*>Q0
MET&#;+:XT_6;[E'^ XAQWS*Q$?5\R1 \HY9_:31Q$^D1"@M_DMLKM!+'&,O#
MOXD;E1[Z@X:7[X>8EG#+!EZHKK23ZB@OUDU-TNX6A=DZC+<3KFAML+YGN9;1
M$/&QYC.K*+HB-TA6<B4<PD;\!PS%?P-_SD6G_7QF>\_62*9'Y#&@2+?3D.'Y
M&'F-B;%]$DDK&E!Q]EB11)MJJ=ECI !Q<6!B5JM\3[;+%,1\\:GMA=9F.B!"
M<']'M]Z@/CU;<0!4IL+Q[LZ@=(N6AIZ&G@X.0.N47-*5"M),K/N4YQ<9TPY4
M9YV3NU*7.MSE'MLM2J62A[?8C^+8+#BC$CJ34L@%:"8*##%IVS'XXXZM8\8@
MQI-J1X&//;(LR3XJPV];ZGQ^+8WX(<[GBJ@.J1/^'@^/$W)^_"/SU"WAJGVE
M%?*?F,=2[&;6\(8JB$JB[_('OJ5#"Z/YD7R)E4+$I$Z<>VQCSK4S2A.L%[-;
M\.F2$XCY@'-KI$.NG2Y'&+Z-O"*PEI'KA4E&BJR=,?,$#9^!O8O=RX@N<Z)%
M?+;O9P<!3)6]3GLY&D[3V/!$_ACLA;:XF$.[--O1$G[TIE_F]Y7SE4)=? =_
M=\TWHPJ_R93^!7PG"?!KB15EFC+(18XL/+*QSH4ZUCIE5QABJP9,?#S$X4KA
MFL;#Q='QAVW B;7OHGRHZH6Z;+C#R'QEJ058<=OXEIHZHCSLN=('-Q)F(8\.
M&QHCAI>/@;5I>]4M[L0*3A] ] 4QL=\Z/_T# #7]"J X&*B!;I-S.LT\\2).
MVSJ*O8MB:_?/,9IL..S (3.F;_Z=7^(J&XOUDAMQ@UW<SVI=Y59LQ*\*_" ;
M:;BNKIIMIKL7S=^^-M4 776R"2\>CXGH\67_>X8RF<94V95$[;Z$?FPR3KQ6
M7P81 Z^FES\_:GVNY7!_OSI)P^?..@OIU+4*)P5>(5=$)G7NS!\7FIE-+N['
M>3"@R'"KU;YF&@8)_'P&4[RJ"HHTVR'&&??C;.=W@L?E\B?FOWIBT#5%7<<8
M!6 32TBE@L".&?A'SQP]6"J]?,&[H1!K#A5LP]..^&^K4D,"#1PN2UH<XKP-
M)S%27@9+C=I+JC3>[7^13!3/%^X,.<C!4$,%OS+1J1*05R=^K$0GC3M+9M]1
M0A.C=%D=O?GM /4W^@0(HFDM0^SD(8,>M,T=^P^ 2K^ =$X<T333Y4"U\_Z!
MK^@VQ^1E9P"Q',O[6_V<XHO4N E8=2IK.576Z(3NF"</R]'W3?-2JOKL7 S=
M";$7834X0OK-/X#9UBQWT#O(5TK\N5ZZ>O55"!2X/&FO1I-D^(6=W=+RHY5Z
M^ [5T(A8GNQ[=N:GU*)/B8I'^^<J3WTY?1)':K]C@S:%F#>VEEP*U^;<MZN2
ML:5H[F8R&6W_!%+818J*M,'5B?X#!^J%3(:(&+&WR3(07^M_ /G<?X#,W7^
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M&;>END^=#IB\3K *PQ@:>$(T "1/<%F2-.[%G*V!#&+XU_!:2682)VDH2)'
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MO%W]U7SJR6)MK#IET%LR0"1YI!5[+_-H)AR<I:?,>Q,5(6B98:F&\=.;3(7
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M]S)D-G#@@D" B=77]7NN4:JQDVI;HXET9AI#VV)TX2'#&V3YF=X*TNH\^XE
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M)<X-QT6*0U"&O,58=!OD$I<$FON-N[PU13/6?\$UTZ!N)30>-2>/1+>Z!Z"
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M9/P>\Y.KGECB+]G(R/7HU;MM\9:2#"*S]?-7SA,0J75[WY]J5.8],OW>1Z6
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MFW;4#8#K"AS(WU0]^+'!'!.%MIE_W,QF<P^PCZATK2@^>&SM99@$!!Y3D1
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M%Z9;"<.W9 R=<3[BK EL_BJ(LCUJ3(\FAR9ZVEB*]_#Z85C_ZGLT-:Q7U[6
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M(M0HE-&4$FU=#?J>Z@<PV-B^;C>WU^?G\3R1RK:W<R?ZSMXJ(Y107#2[O I
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MQR#W[TO:W22H8"^FD9+!Q$SHI?S6BVY4&4_;9SI&L7BC5Y:O"]S]2 <YN?V
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MSG3TS*2;,3>MQQ]\*FS=T_06WMW)JJV S"3-"A,ZM19?C@H6.EI=4T?<&^%
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M506I-,7.T\1G<W+V!9[;GG5W L;7B8^+)>[O_@7O/+M?2 10T69VFO[YX;A
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MTDC?E.QOF7B?6MN;-V:MJ+(.3V)Z\X;T%8=JOU O5PX9'[I@( X-M@M-9AG
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M ULNWG&2+$[(3^)_ =(;8\5*J7SKQ@?$/)I@=4LNVSO,3P+D"4;8G96TXG2
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MYK:0&T_50AL:$(^]6):/$Y<^)D!%'AJ<5-(EUI,0:LYBO@B/Z+BAX]EMN%Y
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MY+NQI7TQ@6W"31930.]C)<$8M([[BC&X'3,T7)LPX\7$86Z^#!N)0\>=A1U
M))I;3/.K,ZD]THL&&0P@@!8JE92+8\M0%].4E/]XP8R$H8Z#+\B1%O_4F02)
M&#1)EM&,#", XX-)$O/EO6D\%LMP*OSI0D86"\5/TY:$%\NX'14)0HY_[-N
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MP6?<DOG6!ZK+42=<8;A#N50_>#SN"%;M9%D?045BD[Y =G7ZEN_WM9[_<9/
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MZ9B/5GE3)A8,,6S^^6;,!UB0[R/=</3Z]-U9G38-#NIKU"EVY6F<Y"!Q/?N
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M[V2XQKKQ@I<S,MU)#96&*.!2O^4UTPJ>=?<W_HK3?MZ$#[U502-_XL&=NJJ
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MS]K[+;EW<EL0(=FT21JKPGJ.ER1%#:V=WC"9V.TG#Y,6I7>I5=?4KZW!N#\
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MLN,^WKY<0=[6I>OBJEZSP[.+*9N!Q?>B@I1W?]/;.T=]?YMG$-%/-Z\K%$<
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MZC#*$$\ 2EXZG7,\3UI9!/'J63VR42B%<AW/LO*;-@HF*->2? TR**,%+GA
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M/>2/$/MZ8RUHK1*::"0/04*,%1QE!'C2G6?5L(#IWH_KW7UK3,%_P+K0P]L
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M(@\+[!+=FH+&BGBM6[D)BN3'1+6Q'4F=@19\P)B082PP+8;"7#&X88&%VP[
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MB^ZOSN?_ZMQT!ZB&<0[?R!?ZDT=>3TH?C@_)=D#V<WI8;YL5;[NS$WIL?YC
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M6Y+WT#E-007 .X#L[;%)AAO,N,\&(G:;-.FHQT# 5"GYXJ"S_G3]^$HO2?3
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M$RU3^%ASHA?$LN%[;B/M+F5OIQAFTGI_9:Y/V97+ :/FFC<;GHG^/+W0Q,&
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M6/7G09:<H_B'=/KQC3!^_OS!Z8W2]+U[6[6Q;[0??N$("NE8.S]0X,#[%L1
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M+"'1VV9G)L]8R175$M%5M7>(_E'%R3PN%!PE1$XR: UE0BLJ :=2,H=<2D!
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M["/)4A/T_(,B$^@V(N: R2[] P&\;Y"HZ?_%(T,RDM(',/EE-<7SR4/NI!O
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MEHQ (@G0P$HMR4=J&/<B-ICSV/$[GDUIZP13AM%<!C5VD7TWGTE&2GG 7K>
M@#:[QC-\W\ #N<\_GRMTFH:JJ"ME7@@&N: 7IT$.J!2Z;ZT_NY)UD9BQ4=Z#
M@#K32Y2J[9A!JK@[PAW6UX3;=KK4HNI!OS&\P>Z.'6 SRFYDE.;/[M1WY@@#
MF]NG8\=50FI4KILT12>896I6((NJELK18.1?E'!PSW*%%7U[JHS])*A"CC>#
MBH_0F@;RW)R=,<IFMLJ/C_\\T_S\+[R\E?-) SN+/1]K3V7U-2X>5;$J-,6Q
M;%-&+H72[-%?RX$P+4E+U,;MOY,&AR*- ^?A;L5@)8:,2<533OM8 YS7@$//
M9Z7JF?E .PD#H!,< DD?QR@_/[2^*_)UG4LA<C%^(^BO$ES/(&/,EC6RP5U)
ML]_0D18E%+@5?\6%KIZ%FE$P0?L:D#85'YMU@8-7=U \WH72[[LSTG0OCXY8
M18(S=5=$?I5-^E7$UZX#3;5C/UV/SR,*M**66?<)KV?8T\->%A\*[I,66@T"
M385._J(KH_& \IEYX5GAMKY 7DFB]M6?#S:EJ*,UH(OAR06F9H)E-2=\!=)0
M)@RJ#2HS::FCU/>H&45_]-9RK%6U6L8UB'0?!4#&&?HW/+@M<8,T9;\ (.??
MQ<LK>CM**<G(GILQ'.I:UKZCK,[C]/#RVO^4-?]T ?4O_ O_ET#L>/X_4$L#
M!!0    ( )M9:E9SZ_ZOA\H  $W;   0    9S,X,C8W-V9?=&]C+FIP9XR[
M"3R4:Q\_?&MQ6J@D65(Z.I:L,<9>*E+V;(.Q'8/!:,A.1*=%6:HCV68LV1MC
M:#"$026[L8U=D2U[V4_4\%ZW.L_SO/_/^_E_WBGN_9Z9W_)=KONRW;\]"O%=
M"73#0I".C@2T#_KO:WL>XM+R<W0/@MB@/6#;">P:W7W.U=?WIJJLK(>/C(.3
M)\99QM$3+QOH<%-63N:<+*2N$7C3P='=V?<TQMG%S>.\\-?*&N'3;D[GA2V0
M!N<,;FHZN[I=N^7M;'K+T,SQEKNCBI.PQH73ZH&J@?B;>&=?A].!^!L>/JJ!
MYX5W;JX*UN'=LL*G=T[Q=3\O? D^<-K2X/II34]OY]-*,O+2CN?.G3NMI"+C
MY.R,<%!2.H>0.BU_3EY>]IRRK)RRM)RB*O*<*N+<Z5\O8?"&WDY851,M[5]O
M![;."__Z7@$! 3(!"!E/;Q=9.145%=ES\K+R\M+@#&F?( ]?AT!I#Y\S_]Y!
MR]G'T=OMIJ^;I\=I>-L!X^GG>UY8^-]O@;]I8/"?&_]_!@R/E_WW;!]?$V?L
M__UL'[.@F\ZR)LX^GG[>CL[@]#/_\U;_]TOA$\&G4=7R=/3#.WOXZFB=%P9[
M9)S<G%3ESUV^?$E%Z\IE)64E.;DK6LK*\G*7%305+VFI:&J?4]3\]UH=#Q]?
M!P]'YW^O=?OOM5K_UVM5-;V='7P]O<T\/6_\FT =#Q ]-Q>/TW+*,G*GQ2W<
M/)P\ WS.PJ']]4F=O=W\G9VTO3WQIW=BH^KV/^_OYP?>7%%)Q5%13D%)&J'D
MI"2MX.!X3EH9BT!*.SDK()R03DK*SA@5X5\7._W/%]^Y6,D9Z:BLH*@DC714
M04HKJ" 0TBH*2&?I<TY(A +R'$+12=Y!6!9\'-G_(]7_[@+U Z_^IW;!QG^J
MW]D#E+PWJ.WM+]"AG2\,.;T!/<2V/03=A]C^_[]V_?>U^S^O?X_M'&;[WR/_
M/U_;;R"N?7ND=JWL9N."=G&Q[>9BVWX//8:@7[?^#P:P[=J]9R_[OM_^]R/]
MSY'?]K'O/W $VL6VF^VW/;MVLT'P#SC&9;SKJ,/B[W*7O/[:'9-.Y1[=\[9S
M"2-_6=CDF#<7? OPF2'PCPW^#T[?=12<:[S;P8O[KY@]PNE4^;?;@Q '?#^N
MW5R0!O3],&FNS''KQ#]A,T_I0J9]'K7EPX=)"UN'IKPWUX8Z_-72>J?7Y]5J
MZ;*4SB<-@6&_SBA07EA4$_,K//6T"!%T@HR2N+ -C<H*%^[M;NLUWQ>9E?VL
MV/Q N%]*SN[YJFWH5=0#+1<KYN_J>?OZC ?VS&C$/G/HDK:I\!=%A;4N3^L;
MQFZX%MB\:$/)3K%(MAZI=!UG[%;8X#*:O[E]8QO"660W]Y69^&VUQ>#6FCG6
M#!,[[4K^P7H*U(V;IQE4QN;YH<NO2E<4*Z(\!8)6A\I5<\UEA3,6MIXM81=-
MJMV^LA+I.#^45Q/_C-7<CQY9,2,?I<>&D797&-9E*!?R^0LT]R:F1W2*:49"
MK)[_%\/\8:'!OMC<H*W6-9>,GCDCS?/NYW$]S<2(Z&%)"VF--&^__*EABKU'
M^W($\YG?8Q%71XIJ&%[*OUJ\X6PHWV3M>55\44-+Z$/)EN=>E2=D]Q;>]<S9
MACY-A>DV!/^0&6'?XO3[^(-O<G-BR[3*;55"PVP;NB>TT/)-C; H<X15<U_O
MN_VHFG1H179[V6AB#<6E*&%NQGOAFP@K+(L>MRK2_-7H;=IJ_C_H1:-MR%-G
M*R),VU.Q=*OH<\&W+0[[ODV?FMSEGE!:26B.[)S-UYD?I-"BS#6M;0B=L+J%
MENTQPWHN6-84+F=ODOH\ZL,&-#K=5_]9K.R4#11AU>1XSM9L0\(VWNMAXNW?
MQ3;-P?EA0OL2UO-'N@JWH>;7E1Y/MB%._FW(?;U]TWC5LOQ\Y>'5B909EJ+Q
MYI,?3[IOH_!"'5\MJC0*NOQ)PX2E@A-A?]!)03V% H@@E%IOFCEM2W\]?QO*
M1B\N?!O&+(,0N-+5\.PJ/AN&S78\S(ZZ*9-E5[KN4X_ZX%YI#7)9YK>[ 7H6
MJ_-]G_=_)#9N42[L_X@,0Z6)!A-HHYW!H5:I,V2[DV5;^X-2XND2Q. D.K,H
MX8'7$(@6/QWLB2T-]YQ.>%8=Y<JJ80K-M_O=/O@L=&(;P@:_76V0KMJ_E6\7
M9$:7]7Q3DV??T1=E4-4ZTC>3MFJRA"\YNA4G.YT]-H1M!1_7<';35G$5\5&M
MAZ5VH^FCFKGLH2'A ,,>>[UU,=\%H<>A-*.P)M9O ]\+WJ[E!6]==?SSK?'W
M!.JG5V:.1?/J/$*OYU/9#SS]X*_. :\'\DEH>/4O6EZYZIPPO3@WK2:+>>_6
M[UCXBDDE.YJ@X_-.\AG\)::^/Z> "YF2<Q&Z9IM[AO=53,30]+5::I- ORB[
MR"NG>JV!U3#GVGQLT]7^]6UH?R^B2V!90;70QI4^%!J01#_TC/8]M<,Q4^-S
M]N3:4+HLN^?GFC)\3&KT-I14*%,C=-?7,)Q>>:-!:YJYT/>I7?N6=!!R ]&3
M&OF=)Y1C&R*>9[\5^V.TNX]H]SUZI#EWH\0.'W9/:,I=:<657I'P8^E)E!W>
MM",%U *R4+$R 'L+L>5N9UNJ-=V^46IG-6@8<.^XY?321QEBV-6T-,'%!EDC
MTS?9I+QOL0V;@8';T-7"\:6<Y^U:@4$K#82^*]7\PY0GE5N&@C5&%5-!C1\#
M-=I^D]Q4&>G)6W3[@>!=Q6R1[2GJ26EKV*W9;6AE&VK2Z+U=O#727//CJXN&
MF-IW7%@)FA70VOX=$>8*:EA^$'R',C'95?2BM<[09?NAV//;4!SK0.K7[X@M
M>C6SO/! QM"'M#FC51P=C9_';M&>S-J=O_#;)N+#%NW25JKA:O5KY)!%]4,\
M.Z%NJ/\#J3SLOL:)] )&R]7N]8$GGRF!"<@O?:O8E5QLU#OLB@^= "IB&V(/
MI@:=#41U_FA2R\62&\HFIEH(=GIVYU\G%XIZ(@M/$?T1 ZFS=F<GR[SMW 8R
MEO!;_'3&8]X(T_&-6%Z"?Z3=><7YZ)$N,9_-U0VQ3:TOV>-# 1,,UIGSO?1;
M^ \,EH0=SNY\3:U2"G8%O;2PE40?H/?2@_&OV['PW4=&4UOMW,$]OF!7]!CV
M9LO?MKB(F]?:_62/$P/$-K4]Y=9<2[OTMB(&!98D0D)UPHPF%H[3@SVW0*RR
M0(FO#E6*L(0#D.-#/Q!A6O2>M9F5;V)P1*IXJ6FKI(_?:CA!%,56[5V^G@P7
MD"/WOYHK<^B?ET,G&$AI%SH\R3105UWH)Z2$2YK,]+\:9(=W&=:>U$X)5WVL
M=NKD;?9<3*VK0%7X&0-U8\6<K@:3V1G,JH!K74<E[Y\/+[WJO\YVZ [$=A$F
MP4.]DT<W%1M[]<<1"0,QZ3+Y_(=%Y44U+6H6$U,P?;&VE=QY=@<L:I:29AEC
M054U;WO%+"\TE!S*O59([9O8@7+;RB2Z%?T8O6(;TJ(?772E%U3Z(@+EPI1[
M1V3HK7:' NYEM(MQ3LG8V)3?#/AF?[OFM]CUITKB_X19A%RML9_>J*$U+FZE
M#F]#=[L_;=@72BQNE9TJ>_J>L$ SXI4)M3L4\J5">I%2^L&[)O,Q2_+*6,=4
MF&7=Y\[ U6\_DK8A;34"R,\9WI3JMEDX(2[%2H3J[)R/#WV_&LT-.1DV?5BT
M]A1S6C#:6Z1)4S.MPR$5X\]8Z/+[R[Q#]N]^%5]>J.GS'&=?A&J7O1OP-YVJ
MUU#ZM4FC4XT\QYQ:Q&Y%_P/27Y)4DXU=<?.,9K D>8E7QID#8:(:7=2/>@UE
MWR+"=%.ZZ<%7U[$KA@O22VU#9Y2(YW_0[!1(95H^]+ZBA*<&E8DUN4Q06,%A
M?V.WXH@,]X:RW;RQ2H2^IQZBP8B@M+[<5_.@%K8AC5JE9+C>9LJ\ R*"2($
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M92V;.WR["":Z\6-+6H-M@-$T#E9:G-E,LZ_!.21@YH5?0FS(TQ\T#01Z)[L
MLQ@.U_7$<5Y"?V33(9U]G8 _2,'IOH ;8<^@C99EZY#^8"&)A%XRZ31I-03.
MVE!!I@"TC<.KO:?_IVG.GA71\_+:X]3502",-#3@#4.J5'Q6U[8AJ]K9P!HW
MZBCK?'7"ZI!Q_S?[S32-M14AO<V^L+$0^]X+1@MU7P(]/E0(R:ZFV@EUJ?;T
MK"E;KO33=DHUH[)T^/,-;'MIWL1-:CX:SU]_PZ0BZWV=V&7Y;#^=B*CKV/SQ
MVTR5WK]VZU"!2:U?1L?3#/4MIQQBCB>O(1P5,5TA$5[$QQRON@9L],T2FAN9
MFAPR?8UQA*Z^QH:SU,C,6.GC*QP%\)Z2T21,B7PS)5T2Z?8V'LWOX-_!P%(\
MG+ EY][U[18<J'Y[WS4Y$TF4\Z_6=N==R, >MSW7 >W6>L' ?)0_#>U>;&+I
MLU:A]&-2UP%/=/KY1K[8>^#!8*7.T"4R22%KIT-@A+H.5JQ0]B4"KB!L7KL5
M7_26R<1<=KN@J4<[U"P0I_ZN#BCV]'O7\H!A+J'V]5?X[]CBRS/_!ERF6Y=A
MS*6C(_V^[+CS@V_?%DBI=DE3,W.A-<<":SRW(<(2/"A]]9UXB!%+[A-+;&A&
MPWSQZV*(_=#DBH;5Y$*@W4)#Z]2IPUU!_I*5F0^>GH^RN!XOA^FIO^$BD"MH
MR,OH+9YQZTPJ7B!>Z"X@$?FI&4:1B!O8_H_6E4%MW4L\D9_U#$P,II^@LO-0
MP/G[:5V1Q+D '3RO9TG#??R#D3](\_SF8D7+T-F&M/&8GO?\SO[9C*22Y.):
M30G(W6<_FL\AO;DU/V^0+[\G)CZ<SQ;0B6((R</)F13."]0 <4'/1P2[Z>K\
M8/ ?7X05N:1=5K]',,F<KF.R:16/3OR3><9D)CS^N1_"_3@P0A#T0R6"I5<X
MO":-_ 8LZP$(BH\%ID6$J9,3V0D1_O80$^!%=X6;"_]%.@C7-YDD<2=K!["^
MZU_*@1\)'#QF:PL/..B>9$\]>TG_?I>C_J9>47CEJ>O,*SW"=P D'5%(OXY7
M3#S +8#GR^/,Z80%]!NH,B@IOX<K[G]SP%.&J/L>]H-NGSE=<_U;VF:5ND;N
M-C0^O0W9OKM:QZH"Y'&F;[%JZ&E:6U"@ALYD#WXX]X2@E-LS1/18S\?6_KK'
M/.WQ*[S1U4RF$W'DS6B(C8&G<T7RAL4%\R[*54D;Z1L4+))B]H=C7#\!RZ4[
MF-0-C*$S*JL)AZ8)ME+#PE,X7M'P.J2\1_*-;+F[L@D]"!Z1;_**4*<**-O:
M*V^FVH=X!Q..^9!N2[5P<C_'%M\F>=GJ6%43^!TRO*-[/6EB'''$X\[Q47\1
MZM9AY&&&PSA5_RW_B$"N>.U!VK((MCV.7SO^JH_"R(,DN"*%'AK-7OUZ&MH+
M>T75Q[8Z9GL!OVJBBUA9% @"3#O;G+K7-9(]2^)DB4Q^ECG;Q:,+Z7[.WW\&
M_^B7="><48G =6@73HLL@_ O_X2SC&>(^TIPF?T[:S;CDT.D@T#@MP5-]2I$
M.[.;%2J).R7;UQ,8=K5S*U?69RQL-G ;,C)ZP<*.,<>VMH8/=P7>VA*KI(Y.
MJ=,%IQ(N^Y1QQWE1N,-B%>6</)US+YBWQ/D.8!^>"BE2L9;VLP8^\S,]D4X8
M\&!-J5E.VIZ5N:KF_C0^1E3 I#2+IC0]=N@:E(W7R?_:U7CWA+"[5CI__HBD
MA7=HS@UL'=??>T74FW#64=:ON>+X/: \VM=970;><W>:^-3MI%;7UWP.J"J6
MCA59OL542F+XC_R>).>,3]&]LC0TMACUJ,640_JFRG+TR)_-"K3+"*OJUD<=
M+0=H7Q$F-/VFLS$7(9ZHH4\$HM!#JL;+M>_U\5*5O!B SVQ9[[Z(#&[P6IB8
ML^E%:(%JM@KM0MW9<^W(0LAC=_2E:R\B#L"U+CNH^^(L4D3I"/-*;S: _EVV
M)3*T&C>WC-D96/<<X18&EE*_N!,3E=-O2=$F_-?^Y43[";AAZ@FX_C%I:6-^
MR&U\K&(;8E>1:V?VL$(5%W(70<CMS4=90IH_AT1)$RS9AYVA505<2QKNR$^L
MH*O4T>)/BSX3&]M0KIA)6?>X>SN0AZN87FG? ;>6!+%#YLSQLM"AFT"ZZO%5
MJO>9QQ?D'K0I1^4-UR.CFOR':@)(1-.0,I47NZ@JRTLS2.WK1R"DC^;1.J>(
MN.2\ZSBO]R9>'58D3#8?/<1=Q:Q,<'#N JJ V9'HMVG\'#(G)TDB,\:PFYA-
MJSH>]PEL<6COZQA"1^W!LK\DD=>B:>?>44(BK,C62?'NFE(*UIWQN 6YYD!,
M"0I\T.,L\4<0V5X8Y3G8FGGE3<NIYTD""?J1)9DD:6P/%USP2E]/[X*2@:M(
M*20!L-\!>"MTPH+(]6-L,CV-%17W#$#M#Y;S6IB^H7!=VO] LY380C[+\V)/
M29+O8/R+BNZ**]<A-DA<<V?LVI?JS'30O.0;R7X0>0XE]6K/K]+'CUMW/C$,
M&2Z;LY;V'9I8W.H3"0S3BUL%X1X?[?^FL5E^(6RNI79& \UH,:@Z_/"[]S8T
M6^T)=O4N#0V$&AV66%R9F$&M3WO3WBV[X8D(16J0*MU=LWW3XOS&-U]K]]@'
M^>B/'BHC,A8MYAP,519%&8%-.OR'OGZ>L&#)N=K&NM'51.^(WAQ31!S4G(/3
MOVCLUFYBR8B4C\D(28JJ1V*BK1YQWU..=S<4M3(O##-!X5J+.B9#4(>&17'V
M>O(M6I/\^3U##21)))"8#@^D6\VJXV%TV3$2= Z4;&E\S3S#\?F-Y&2IXDV?
MU7V0M#CP-'AC+A30.B.TF'B -#P!(5)W=B^QBV^E]WW93-[1F1!T^<^=)^2
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M-94"\+(2/8)U$ ! M"2B6RQ%DP>5']V+:VSNVX.E NU9O=^*(CV&H=Y6 ,V
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MW3K^+T]<5+R#W_]:BN;4BRTM8>_@S!!X$IXK\6'YRF#F4RX52[%C'MZVHB\
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MFM?7KSE@<4&?,<[MV5R<APB\+9#M#:!EK^@&OUR&9SFA+@:.[S&X+L^=M=F
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M;6- XF_4A48-:I5K[+9\IJ=QL$U1&N0($+@2J#2J%T ]+';0VY8ZD<PEGL5
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MW 18,3P6$!YZ_/XJ)?M"++;$ZLYJ=ARX2>;0T(J@(PCIH5'@)_& #"$/%>]
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MO[<?FAL]<W;QN:0,]IX&U6,JFN*@6/R:J:XA6LG,9DY]=MWH7))$&":W(16
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M:E5XR[K@MG/KB*@#XP//0CEWH)NEI:]U4Q$F>&&@CUN.6;Y6O!EF98-;W1F
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M=I29\JVF; GR6@2]J8O2T';!F:!]2_K;KL_?TIG;%7KL=KI/6CLXX8]# :-
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M[4$R'O_@]MCXF9/,BTTGXZP14TI95[8,W)0=9.P7'I.@$;C:+YR[I"/XQS9
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M>W\R7?NRMNW=F)U-"=@\E [.X5!4>B5357(IQ/GA8J2!S>SG\R;O1#X/O%[
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MS,K*8OJ;AK<#!HE6/BY-QS9O<]IJ&*ZS2^?^L_G))Z;9PX=RG^X.ZY18PAO
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MS=_4W9':AVC?:))7$U8])")2O6:2FWZN_^S%CYOA1?2\*G12=U6K8I053^C
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M=R6@-7 \U$0VS>&@-F!PEK]WHSZ!X/;-=65+ #U[@ 8EO'4PZB6 1W9&]\0
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M_8?,;.)!+CW'QM7:XK(Z0Z.R.]-MO<ZJXX,VZS :/20J:_'$R<PY8%6_G"<
MEHVA6]4TM)L982S0V./9R]Q4VH?,"?8AV+F=(^N$QCC^!5Q1D.'V$9M1843&
MR8+'5>5%LQE1N%KOD<S?(C+>U_H!4E'VGLN_@'=\F<28VKB *_<99T9U@WY
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MY<%8RZ,Z0X!ORWL'ZR<(!'*QE%VU.#),+1]J*K5D6S8/R#BLR]3</!10QG@
MR-3G!\PBU0E"7+O9)N;,;8R?M6'FV&A\?@32#@>P/,D.C]L/ZW(TC4(M4O/9
M\H8GMNWK.J&8&< )NG6+$:;'<&\US/0/VX!Q@V[V&!B1XK=()HIQ*.UUV)/&
MKOZT:A<VQ[:<062[]&73G-4]NE,1"R:3+HMD@*^0NJ="!@>:S+SKV(D/]MX5
M0I4QD6HU]^ A[?RZ_ "=#]K\]I)JJ&J$ IB24[Q;%'\TI+UR$*=<P7"#*10.
MIO-?+H3"L ZQ=,#*A49&MK_+JI^(O!=ZQQ* [L+=P^=.J1B#BR9LN<E9K F;
MQ#-I3)+BA VETMI+KP;>U_[EM(^9L7Q>K:D*ME]Y$.YXQ.I=YQSM,V[J7,+P
M.B7HJ]J=5?IW<Y]U^W[/C&BU]SH-/!W-6Y1W]NLO_U-W.ZEZT;!4\YM^*F3.
M[(^@@M? RV0\GI^L'@R0YL1&H]&#Z11],7#(%0.T+V8D"3G[Q@ XOI?G4/@Z
M'OM=?;2'<+;EEWP^%H&!81VWK>I254VG)VS8XY&G+G]8Z.KN(,H_Y1:O(>+E
M! F.B ![TD\]#A2JQ*D_.]EI9]R>T_Z3)@5.@JR*4- 5%>UP2 8DMPI%F*65
M$$+W^C.$^%/JQH# O,WP/LW#K-DKI<&UZ_*F;ZR&(^U&ZD64%UE!6+!D!<%0
M)MLKD0 *UT.;QWC94'P<P:''%01AQV E<,L]WH@[[&4 '\3NRI?_];Q+PL'5
M_P8CG&YW0E%04W'G>/Q5]6> ?HU_8KX<$+*)<QT.%$P@!U=SK;HVCOO4I\8\
M%K%D4Q[.$=AFX+P<F*3,\57^Q#K.7N>X2DR6B^L=Q4IL&Q818=FYN&4'<$QR
MB<XE;OP)K\@P'B%RJ;])4R\9EB$GHBD]B]14<!@04L1,MLH!F@#0MV@$4]Y>
MP;%\V9SQ?%(GK10327DY>FGUCCNOF_]IG6HU'&Y.?V):]-T??T#\9]_\Y?@+
MV(1$)^CWM]]T/EN$X:^F4@X&2^>U>Q/1,+L!XFZI ZY9>37?']O^<CU' ;#2
M?PI;H"*#<V=PJS*_YT<^G&6:B4ITV("1#VC'AZO"T6<'"6]15<<@WZBJZ,(U
M(VK'& X!#?IQXUOV'HLX6$O"PSJ&K'][*.QN<@[ _UW89ZML^M1=K;[40'MH
M1+":P^M@2P!,4[!B92>K8Z2_G"I8B5! 6)\-C8>-+-\-/D-1]G33 RD>6%_D
M\OF!I9C))"NEK2+'@\*NN"$'J*;* P 2&C_I #Y39WFL)QWC!\:0NL^4,ZC_
M$'4PB0J2!.?H5%:RO1+35#^#9%_8,=&.T#O D?=5\?G%I!U*>^_?IO%H79+4
M$F@@N;ME^'REY,ZE"H9P0E1QP@K[UF$=ZR79$.0&?%QFXD8A25)4=J73T_HK
MO6;S-4=4T4/(C$'UI4#9N"W2);JOV<NDYY+U%_F2]4=;;^*S7SWC629E7QU5
M8<]]RTF(R\# A/\M>SX84K.58*E:SL?^<,[<T;FH#6SJ_Q-X\(\T]"P,;/3?
M]A!R*,T6)GG"89/V11H^W9>=&LXN0!(PR_D!<. N7KI;.V&$ N[*/D3V4O$U
MD;7#82>S)VMDW!D6%,AUXYC\;9MZ"IMC_*+]6:J)@M. S-15MI%7^LMO60G.
M8H2)[G0W(DE)-5K3T[X&,#TJ@!<C<[-I,#9'W%K6!*T!2'E-<6$<M14M3FGO
MP$2*)$K=,Y5*6\AY64%3ML+YN76)77]FZ.< $ $5@ <Z=&!1Q5-Q5"FZC9O8
MY0I&Y!NB>D&J/G+J[@S6VOP'/FM7 VT#4#05V.4ZK.]0LAO;%+"1Y6(FXV=Q
M8>ZT]-7N;T B$:ETHS/X<>\0/94":#T2H:I1LR=B-[ B)<T"#'(?X-3.I:%(
M4$GQLLP6KVL/+*E2&AW*P!N^(_-$+Q+!\D>)=PE#A;DD&4_'K$RX?5;C6GFG
MD>W $$GQO$F1FX9)43MA.0B>;*'U;*X(%G:.]A.L_E5;X^_@(_;P08%8^^SV
MQ2?*F1C_0_)6V%-0V"$H# JPK=_!8,?!'_BFWGIRC',%O?<*=QW^SD@RDC/R
M'NV7_#N'CSULGOL3W/72>>M_>..KCAH==H"6P;5?*0H$\+N3428<&PK:)E-2
M'47M(94<]B'Z6O*M6-=T*>W,GR#Y ?STREV& QA@7785T5N51RW#^T:"K'D$
M\VKEKXLC+DMLNDT&[AX70,7.-<@?"U+?ZX50GEM2$>;F]\%"<>X-#\(6I>%V
M==^E,5"[BG@IV^X"GO07:<#&P(GQ2 Z8MP- /PWDP[:2N,1/0MS2"RAFPH/3
MU><_DVQ3]I?=0-,"H&'_5)VA9%3N@(-0QO<A9AHU[?PIG.+?4G*>\7_W D[V
MX=*NJO5'-V1L[ABNU3C(9%IG,$J=&?#Z[1\*,"U5AF;"D.+80KVYK:N3GS$%
MXY=3+_)!=V#E3)GC270B\8R;N2'PW1(!NW;:KDHLF=J\-R"WZI&;^71% FJ?
M]@L*:C0Q2@"'\CWNM&)&KO4V ;"D*%.AX,#?5!2$W9X[@R]L^AAT..Q!4C9N
M5<U.9+!-I$SR/RN!AD5PX!>CF_ '#_@!E+'B23.O!] *\\+D#!F _7G+GLA%
M5"=H)O3W7GD'OW.[V:.8!#V'KTJ.O2LK6O,3-<?8U0I8@BW:4@EHIL+HJ)_3
M"23//]4M-)'$@G*&+EW*#R;]_*4%(!HWE3B"\//V(DZ%R5>XBZ$Y0:7>5AZ+
MT+L%9R"RF90[X[9EN'MM-7[44_ M2ZGU_ ![2J6H&*F;-\9_(E@#%"XT$1HB
M:8U$J(WF%V=9:[/TSY3= %.L*.Y(Z7D"JJ!C' .*C4MH5F];=XHR $K\!P[I
MU4WW#N=-X#1R+A883?0S.!EI;Y,!Q?C4")@IM'>O?Y748B6(^Y]H&$WE%UK9
M85:K%*8[[$8*:&>K;*/T <>&EV+_>.WG1-,"&CSKYY&FR QYJ/(==0^*W 9,
MT^,-V%UB@\E94P\9QYPI@\>F [#++?<(L- M$WT@BRQ&\]GCJQ4>7=^JY::X
MK)?SEIF/1T=I;C#(-]K?KG1W_?8_:[-WY+>5;N#)R6==%GY\97 ?&23;(H*S
ML^)A)XL_XI_-QF;DRORWK0<A(>BP>Q"C>L50H1H71P[$Q5@;F>0"%K;X\Y6^
M;833/[-T ]*V.#V7>9"@]:SK5PR .7(S$[OV(<<XDNWUC(MCI<[2>:D*4X4L
MW5@PK6 XS'KO-,]4<<4HC!YIH:$KB%:YUH*(AMT]Z*&BR F$HJQ8:JL\LG)-
M* F,3[HR$_KS&H(LKH&I+)L(?VQEV6X-NJ5 O?P83Y1Y_G8ZRX6$!-:O"?]Z
M"C]L)C;I%XY22E8/9Q=";4&*@12 Z;+CI;@M*_Q5Y?7*P1R$:L8]#JX8F9Q0
M'(]\^.)G<,?,W#+)>H\,.,:3H:@;UQ1@ !@@\PBF$@>)53JH',^T19<E/K<P
MTQ+P1$4EG$3.W>*!7]T</7[NU'IW].Q](OHZ]3C"!$2P\3J:_H"9EN\@E_L1
MA/C3IF(*BS@=DW>"GG;S^^XEJ_!$XT(Z?;S8^BV90U*<W++">6&\X)D$1YBB
MH,7+DPW )FRS,EI4$_&SSA"(CIO$ &CF\)A7^.4+#X#6X'2-@\[G_TZE1\)$
MTIOU8Q[<;E8;Y%KXQ8@<3!P5T4U83R:FS>.K$V"[=%/+N*?_T[/6Z';Z?[OH
M%[53C X&;Q8OJ_LGD(UL_CMW#&PCW&ATWJ8,6Q&\0%A()K;85LV8"#N#$XE,
M\\?=7>M,-**+3_E>"3"&BZ&J#]GM)370\W?;S[Y<SYOF$,?H2(J(K6^&/$JO
M/V_.D&/CYJ"#^@H];VZG62S/4+]_WCR/O9COIR8#ZS(QT\<KM73-,&RH1@$H
MPK@V2U'0EJJ6GB?DFJ(1K:%JDBB,+'G<9:J7!$_TIO=G_L!$\WEC%80)0#71
MERO<MC7> 4JKXFPM$5^J^V,X&XH$*#DK5YNU6A,6'GQZ"16H\T'1(QWP?/UE
MC"M= )"@2G2UMQ4<Q)&*T8!Z!LR [,Q+KL+(7@.@X.!VS,$6>7HH$<:OERL[
M'.HG(!/&,Q.QKYZ6.<]<61%W ^#LEE74IR2'X&U?MA4K4&?,C0[HJ_W3'VT
M1VA3!C '<,]MPBWQYG\T '+#<(^O"8;BENQRR>F%EQTC/0R>9=&\3\_N&OTR
M 9:X LCZ#\"R?D,J:CN/Q%X!-YB\@O3HOKZ+07H)'T8_SH8JKR<+8+L)H(.K
MXC*NM,-F__\O?/;*,HQ_=Q_2(V2"31$K49MGZ48F3;*G9.6<DV.3P5;N;1RT
M\*YP&3@3"BR]'@-F5_FEIC@#3@1+>SLF/&YT5?4(.S[\&+R "50/07$B%!P'
M.U4QT\LWFGW;\XC/)_BJAIPUZ'43L"@=&_>TF6SE!J-%>^F \^VX5BX "#N+
MM7J55P%@H:Q#BGGOP#1UT_6:^VTM +@ ^8)O>\%##\+7CBY4>HW_M*E(Q:VK
MK=<0J@RPNM0(T+&D<4VU&BC2L<*CFP=R6YM_ZV@.98Z[FB!;E)EH_;R62E3Q
M+*ZY T,^V!EU'&&/*V'4\I62@A-CTP^R31R.9A2C;7C@4F4>O3NI>ON_R:L_
MUT2 B:H+QMVQZ0Q9JUF2>^?-EOC5C<]P%[9D553-J@=M.,U,,RZ^Q]E:4WF9
MD7W*!+2L/5<";..W*!6,J6VK@-> 0""Y5M-RP$? R6-\[BXXK4"D&#@V\\@J
MLL"K?V)4# //LI9=T4?;[/W5MC,"0G5XV$& =J;6K_^0U@W=6/I#L#>8+MTH
M["1#B'_1 :SP^E!28?)!9U[X, XX\\"KU;JMRQO</EFHDK&0O?;"];\OI0-/
M<"^28WHRWAF=,_+T..LM69IWM_K_'%(Y?,Y"Q5)=DZ$+LP,PSIK<6+&9/LZ_
M3$$SC@AV9Y=@Z\7%*#@D?%":5+2&AY11Z,Q01$?:XT'"5QZ8>W[)97)+!P6U
M5BRTC.D#G(E>#50M/E3]21M ';+ ?2YE@ 2W@[GL8_L0 MAR+']%G)9^H'B:
M)L4'U]L#4+3J'2E;O5R,L)6;^6E%7$%C0WK)EJ+.B.27X?P"9G)8^GF5;$OR
M:G[ SMF&( !S_ILV5-T'5=V'O /<^T$F<[CS@HD0Z5#ACQ=WW./]-U14>)5M
MD_E#:'P*0K74H4<=L+(=0[8_\S(**)T=!,<EV[+PCK$Q 8?R',QO,$YIR0=6
MYFQ#< _P[<%D=N HP!>ETB+ U"86\(FSKFEB:?.=W@HP0"(=OWO>51!7^)J7
MWD.I,KRE91QD7&VJT1(OW*)4B=TX:9RX'HDWB(ST^?W_MJS_WW\(O3R'32.F
M:Y2HQ(;U)=Z&5>8#T>:H=_W.,]2$$?L4Y3[97XYA_+/&M^3_]%3UV]F'&/F$
M*R:,;/[ Z_KC*V61/W^W?.'.VE?YZ+>I]L$[HLWZ9PIWY*.[WGR1M8Y$*I9R
MGU+J^'OVOI-NXG^/C"8W/5W76683"K1HG\,5_S;;L)0QJ!E.<]42G6HV5/G.
M-36*ZQ"\)Z7<U)?)KNN1A.Y#WL2D^0!?)3'*6R1[39U[CKI,"+5P/29 ^@XS
MB%G'L&?^'AE9SM=K^J[. 7C7=#L1!X$5"<&::^>O[%#JTO2E9%7,-K]##:?F
M@5_CK.&MJ]1/K";H30\?APW/?WCL#4SR[<0NI^MTNU(5>A2)W/5H8\_VE[:1
M5:PM,Y3&FMSPW(<,I9\QZE!;%5C )<2GWM V?S1R_/:B5CC"NBNF 3E"&/N;
MNS_T_P!02P,$%     @ FUEJ5A;,%'*."   &@D  !D   !G,S@R-C<W9S S
M,#DP,3$X,#DV,CDN:G!GG=%Y/)0+%P?PYS$S'L.X&EN6L30F*KMLD1FEC$BT
M("8D2T2D+F8BM*!%MD*9,HHR+4R+00O9)DM%V9>+,2HF+L\0C25S=3_O\L_[
MQ_N^O_/G.9_S^7S/$?6*N, :1_M=]@ (@L#AU0)$ X =("$N#HFC)" (0J,E
M)#'RTA@I*8RRK)R,O)J*AKJ:"@ZG23#0T<3K:>%P&RPVZAD9FYJ::NALL;$T
MV6JPV=3DUQ(0C49CI#!*TM)*)NMPZTS^YXAJ *P$@ ,R$" >$,."""PH:@ T
M  !$@7\'^$= ,002)0Y)H"6E5@?8:P Q$($00R)0*"1RM7MFM0\@L2C9=<;;
MQ.7V^D'X2'F3LYEW)+2V/ZU5V/<))FP^<O(<6E)QK9*RRGIMG0T;-YF:F5M8
M;K&RV['3GNRPRW'_ 3=WCX.>7OX!@4%'@T..G?H]*CJ&2CM]_D)2<LK%2Y>S
MKEW/SLF]<3/O;F'1O?O%S </GSTO8Y=75+YX65??P'G;V-3<TM[1V=7=T]O7
M/\(;_?SEZ]@X_YM@9O;[W/P/X<+B+Q<((,!_YC^ZL*LN,202@81^N4"QF%\#
M6"1JG;&X[+:]D%^D'-[DK(3\]LP[3VO16IOWP0I'3GZ25"28CJP7_*+]+?OO
M8.?^+]F_8/]V]0,8!+CZ/ 06( $S%$)5IV'!\_(0==KG@Z/.PC\:N)+C$67#
M*D)%AU(=BT5JT$) FG\98_N!4=B,P64MJ/^NL2@"4D2 G<+W-HZ40P11=<+)
M)'F&.^N:_[YH30B8 M-Y>D.&9?0]79(BX)A708(1AM;<83D'*2]>GIY3H[BT
M'YYE2_7J^]NH>$@QBDOB/L'[@J[PW H@27BW!O\)XRLJ0'C%^Z6@[6K?U#12
ML>/0PEYEU<_G]'LA&)=W^(Q=,95EVU4\HV<6N^NK#39 -?UC#(LD% $B .^6
M_C.!M9(X]SG>")Z_.1(R&6ZJL6;]RO)4\(",*N94H_]/W:>"ZC>D2_'0N$I2
M1_B+I9ALW01:=H#RLBTD*) >[AM;L>T?_AE'%@$%>7,V+@U>Q%2W*'W'_C[Z
MW69-Y(I:*(>(G2#!Z7$V@O"2Q ]A;A_5D\HS"F?QE1&8X-.Y#2PEFRK.+*U=
MUV7K3%PO0@WJ/&NKL9^?-Y7]^)$YG4D9/+Y4IX-,9T[XQ I2ZK'4BWSU<+;_
M_05B.+&S=_AV%?'&S]"W[% ;RDAZFHI4:/W8@$+6EOUG\=A\\OC.Z&'5*,NY
M$IDZJUMVQ[QK"36GP[&W7*$H+O/QL@+</1+0/1FT5^^^-?-6V)!'4O,TAT8Z
MMTPK&5H]SJYKE)XIYXSK-W<\S[ZB2F'RNU^2I(1'7!3BI&(M2Q41XG?6-P<I
M-QW@+_;D4(_:)<A2T]Z1TP*32F\Q,Y.W<^5^;D!\BY"CLEPJ8)]"9N^W[I:O
M:/?NP Q<BWS&VLXQ-I55[XL[YD$DE><VJ&M6AFZ3?['D7(L]7Y&&YD01\4+O
M4WXP\Z!YH9QYKMZ/R=K?<&%+A<.79T@0]8C+6N%E?;QN4@4-._S>+\,\]2/4
M,Y^;TS/_=-#+!0<[F&39][F/X51:7@ERDR<-I*M:V4=QCVI]366)E2QS0577
M='W"A?ZC*26ELS3KU]H\XU1M3[HZ@RK3T'-3:%V71[KXF&7 9F!W%EN5-^UM
M]1Q0;FX+)T_8:ASH\_4Z9CX1&7A*H4'_$^]$_?='"K-0W=73L[;"I(A[^FWT
MHS'&Y=ENSU)IDO6"1FXH?Q$0OJJ/^<B/UVF?GMJUAN)-UDNRW]-UV'GU\^E7
MNM4UX>]Y!I=P ^$.<A_P?RYL:P5^:+K++&M:N2S/OQ(!U3TBX%+IJUH1@'YM
MP70:\U'M.P<,41S%*GHD928<,&_.$M=6ONB<CN)G9O5;>@TI:DV_BM(:)]VF
M9?'AD!7ME=;NN%Z_Y,^<DZYQ36"MID>?HGMT?]0M]YP39-1K)[;6U1/R'K?C
M7.'?4A[V.9?NDG\R7 #F*TH21J_6G&>4&%G2XJ3A=E7?,HM4DPL!J$"]A-_8
ML;R(E,?+QC#=L6/20#W6GWDIB_S-3BN/NU5_)%8MU)-B?=- T63IE"J0X!KZ
M!U%+&-XZ6FOEDS5SZ$Q^>W"W.<9B#;/%)+)-'OPJ F3*^.R("]5FS\\Z.0Y1
M'J8]=HUH7+'VU(!>[_0;>:-B^O+Z.U05YWE-8/SE/G?E[TN5+!\A^:[7>%YT
ML=KSEG>$)I<;V\9E"A0XRQ18,>6><5>85LX0)5E/H"5C:-.D-#K+ 2(9"E$3
M)%GJ#&_".<,Y/+-H(_[[28@03^@6 9Q0=-D;E%#E[4CT!VGZXROCO>GXBFI9
M*F3W^D#W%"^'QQ.7QITT,DZ>C$QS^&'V*<[[H[Y9?='/!U]]=3\,?'FB%CW7
M1+P.0G4H0SA-<" PSRD18K7H<K:"#_J#AZS;HZ3X6Q\%!VF3&P=1#FT3OO9Q
MANW<]JT:\Y3HS,*E'5>7ZM!CZHD>5Y==X.CL.U3&\<0\RRG*^^!W8DP7@B%.
MIC71ANXF4,_E,4!JCK,Z]U"C=-&GS1LL![]<:V2)OX9&@MA^!=29]J5]M[:%
M:66J;+=$/G@;.EB]5AC>2(9CR3+T33Y/LP)O)$.;0 00>5G@JT:U=OH8YQ6F
MMYLW.&#M63N07Y_&\ (FXTV^*>9O@N/I)>,S]"NJ3GV:6;9% (=,VF.UU"/-
M]8;JK/XLJ0OM[^#W9%:[&H-JQKWY"VU\GUEN&SK$/1_P5N/%TG6KVAVO99RD
M*(^+6V$\4I:WPSZY([>#!_C3I[X8MQ).1$Y:RH.#0E)-O"11OR+77H#)K<A!
MA:>&G*O$6&5.[3Q-R#=B.^\>4**WR)2]8_3P#QG6OD&'S.MKOY"OT!YO.+*I
MU?PX0>[MYMZ8TIPS^$YAC5?&T/X5.'7%<M&#D5[BGI7R+/K54[GC7HVBOK\
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M>KR>3 #2+G4BB :IUQ@*"GVJ61!K^N0UZY/ ,N-@9AF:&7?'%GAX4(J$:%9
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M3\O-2O-I],5)H33EZ2;7F2+SP%E%.C?&\S"&.7J'/TN)[W(/YCQ:+N-U>I$
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M[JAC(HM6GUFG@>XA'',EA>#N+()>$<L"&E).,C>A0'50&INR>M&==B8; O$
M$UPO\M//>T-A:EV9-#=K;_#T@#!N9*@S3TXP!CK!F-)V-:&)]+H7((TS+B9
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MN3>+O:K3--8=,;M;')T5@@?9CMV&'J]U_T(NG,CGD>/HN/(8PS3 @W9"+[U
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M_&C5(ZD5@*:/%;KY1["&I/,'9YEU+ZLV$#HGJ?J\(!H6+)M 9)U8=")LR^H
M,[]J0K0;=#L8ED;?PU42>L3#P?] 8I_Q'Z=2X?YH-+;/O.7*?#Y1/_MBT9#G
MM^/4Y>&P]'59R=<I5+D3S+@M9-I@).]6:XOX%-5$!@$;<Z1XBC#*.4T!/Y6P
M.S",'\>3C]B18U/,YJ0(/;+>H78$-D;AM.?9_N TD@0D:_R+@^*EQFY#-T@\
M#%*\=S .C;WX6,_<5H6T07B,1=A7B=XPNGT@T)W$C1.4<9I;9&LD3%*#"ZV
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MEM>OO71V?LP#Z_B?]XQL_60[T=9D$+*1!Q!!JX72!(:OWJ!,&;[Z<'PBT]=
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M-($GCC;(46$!JF$Z3?"G H2F%T=4]86P[HRA1&!D8I\HV*T?$MLC=B)_I%%
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M&*G7C.@AKEN0\(?+!2A8ID0;A(^]TV8DQ7J:2!O@+3\\)Y1^^00>B.\"&,[
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M1^ZQ[G3BSIC=1N]^PO%A%=9ZHZ>LJ]8[JSNYNH7(S-KBKGAHY@91SQLO8)"
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M[5SAHGVC"\;+0Q"#O_P_4$L#!!0    ( )M9:E8T>_0HGF@!  %+%P 4
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M&;C9"G>"ZP &#='S#"'0W%$!D(+:.94Z?TFEO:)\0F6<(W7_,X.C81[YE2%
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M2I2CP@_?J.,S_0F()WM4)10_FY<9NIKCA"S%55GF\6M58L@O&8,AXNN4C:&
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MN9-(-..BDH5JRQJP0P+\HK>D:&V;F>8D<,RRM/APAP@>JC-_7$U*E+\$O^K
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M)]B*GG\&"Q(] X>QA&SY3?%NYOA]3;#<6'*5PF7+S+VE*L&//X,\:DD@-<V
M)'Z@K%(?&(_C5VLE.?4%:,*";7$=OL"HQ6CR%!=_BC6:[8\Q1#O&34NZ# .
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M>6[RF'B0K,T]?Z^B:9.=,HW^@=Z>LRH/L6)T5Y1QG13D>QH"&&!N^68D:<A
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MJTGV_#K8C,%@;AO8ZYR5O3(8:" ":*)< %4@=?YTG&QW/3I##K1/:\/7WDN
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M\T5-SX5/@=J2QR<3B(E8;!YCN?X^&]_4-%VZ]*&B<HC)R&VR381!FV6EZV-
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M!0>2PXSX#">#51H1RM]G03YE1P%<OZUVXGUR2C@XNSS6?RMOMD0:OQ@$<EK
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MZB1=7R_^46EG,-$74P K;/.Y>BWB* YRF730LIW M+)C!1A")5 #R1"[IQ:
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M4_W\&ZN1V#MG_??QN>N*FZ8Y1]U"NV -I'%DYFEODSAMJTFCM/$*Y$I%H0>
MXMB)TK[<E-EA((=B#\F^Y$$4IU,-R6[T % <I\=T+5D*.PSD4?3YC&'EK#$]
M!,C#SB6%FM%FJ!EEATL&L^'X8H__&I15CK,VB0SQW0^!&PY#_RS)EC%_=G'[
MG7GQ:CK-T12[7+P "Z^#-))Z#F6U LCN'[9W9<!\^.3C,)#7<+]$Y]K.85R&
M(J.&_CWI"XQ,+,6C%/T'"G+8-KYEY>JW+RC%O^5:,U2Z &7&<<8;P9K95=74
MX1G( &AQW6U3+K/J&&T KF.?;"5I2N(QD-"/'E&X#.($'\$/:<,ME+SQ0PG9
M+8!4UUX=J@M)B,9$UCTJYV5,#]NW:<?IMNU?02F !?GR;)I=VTIWCR@GZ4M6
MYM?KH(A#G,XW3JI.1;SV.X\,K=NDR=E-F:W:I+('%_[<\C=$@&=.2[7@ZLYL
M-SYW4Y]1E?_L^[8 FM\E<\CB4I8GLQ7L(HY])_2D*0#F=X4:)O'WP*?:E;*"
M/ZTCUOK)F-7;NBK;7B]H/=Q^6VFYV+#"4<-#D8DY0N]OG2G]?6X4DLC]MI)R
M#K5>>TF/_M;<<IPRPYIZ((7<;^.K %V/':57CVN..<Y_9'6N2&#WV]Z[S1WQ
MDQ^UQ9J7=AZ)!0]Y>C(6(S+XZ*9O'+Y;LH/Y-_Z^AF#'**7X4B;!YAUS"!V+
MK6(N9#2N:V?GBS5%KLHTL!G$8"2%<%MFU;ZL=/U8I,]387KE@P$,=[?Q,H[@
M^V)EL7N K2N/Y_=Q&J1A'"1/:)'E.)#/2-GKKF%T-3;/U"9N-#Z_T+<QK[K%
M%<QO@Y)94'3[.QC=64%I&;[LSD8&!+]-71M$C_((9F?^1DX'62.FL#VPP<EM
MI9\D>T"SY5Y()9Y7QHS=  BU<T@R2Y;U74-\! ;U0%_,3SV=KURJE%*28JRJ
M711^6WV,^^/8,O'U=J7:U:VD<?AMB+$@.M?:L7$9BI1E Z5($.S64:/]\JN/
M['X)R!P[O0M6P.X1QD1ARQSQ,HMS*?[N?@B$.7;H4&8O"X0MD\1]G!>E#'=W
M/P3"',=0*7.7!<*6E>(^J_)R)L7>W2^!-,>Q3NK\9:'PO;0J^R[4]WH(N)T\
M=EJ\%M:0'+J+*5N='H'LM)RA,@X#'TU0A\<'9Y<'2E<UZU?IFB8[UZ^^U^D5
MGY2NU"LD!J_5OABV^EVK:XXXSJHB)3&9Z_4*C=\N6J;O:35LSZ[9*UFH7]-6
M>/PV9%D2HZ=7;GUY"E.S.-:N"9F'WMY@5JM"3LM>H3%@LZ+'L4117'?ZF&?+
M&$^J^RQO]^_'X(VC;4BU;2 XN;#KJ2"*\/QVV+FI<JPS;U$O2&!*;]- =F+A
MZB]1!5A\D]<@-Z'UW'M(<;:F.CV3KT_NA^<'1\>7GMUW"$UVW-=[WW=:/JG=
M=UHDKNX[]#"\E;LKB>>B^#-R?,WD&C?([6PT1NXU*\GLR%,5H:W7>#$=7 U+
MMGD#Q-(I+^72ILKQ/C+;!FO@:N.#U%Q?5MR(S_Y-YA9VZ'R*\M$$Y[ROX(?/
M*$C*61CDZ+HJX%PH^+DEY3MH0#ES/E-?.Y0SL =:6_>B^R#.?P1)A9K,S5%<
ME'G\BIWZKXKV&'A(GQ<HC%G:B5(?#21??<XXJDM/F+9>[F]1$>8QZ7?UD-!2
M\53G:2M)!E-0_!N]B;[TU+H9GU\ZR>&@J7;V0NGN@@0W<=A/RK?')$A+(.ON
M7U6\(!6]3%R8!DJJQP3!NX;U[6I\X4WQR8?Y K8*0EU6%$^KG(D/:5U'<Y23
M."D6)"Y3-/L&+CF.8>TC59:%PP@S;%T<_T#Q=(;/AB4H!E-TDQ4E'/AU_I)'
M'-[SBZ@/55H^!25ZA$L:D 0?,O;IOMV-+TX<Q[;K2UP?O]]/; V,N""[.:9_
M-+G.\CS["7HF1EK<)3&IE'&?Y9L?\PV;_?L=7QP[#DPUN5%H,\+6!9@WJZ\F
M.-^7P6V"WR$ W?NCP00'_'9X?TC#' 4%ND7U?U]F>59-9R]YD!83E!=-A#[<
M3*H00R!'X31'O?4-\^.-3R\N3EW[7AI50RSRR&\??BDNJJ7)YG<#@G">"EMW
MNJBB-?@<XLTK;5LM3%@#3+[ZI%17P%&'!9XUY@!+L>F!WD"DPSNIFG=Q;.EJ
MU*>PI8($V0>1 FZ_$_X./ U<OPPYGP^B1R*E8!*K]:;GBPJ4^.=L4OX,<B15
M:)K69'SAICA9S]7*/  XX#R/6EG-=+:Q6_KPYW8!B\1.))+K0U\"M2#<Q?4<
M8"*06->"MK!N+#U4]3G=)43%$K<43H:<?;%P6I:SA\>W78$+LRCY$G;P%05X
MPY/:S;>^!9QVLJ(XVK:I\!CB\\7<N';P[U"O%#>RTPZ89,FE6B7XAR8+EN"$
M8!A"],5*9TF(_FRZ)J4IW%GU/7>>4($ YPQ[D*$E2C+^22AJ G"]R<+!6""[
MKS1B0 SVZV?D>$8)?#+]A%*4!PD0<!7-@6M%B?WWENCNUP)FGJ 8ME(?@,>;
M/![2 NJ!D"$Q_2P?7X-_9CG,&/* 4N5 %GE ">9S@9C$#8%R;[)42,M&%A9#
M(/[8<O#3['.0<*3(^1HP>A/^*"4Z(1:&E\H0&5&9BNTJ5P7SB__V/L0O?@>^
MF%2\]CYT$Q^K)U6F==T$,_Q.T\'P;""6ZIM9D$Z16;<2J8Z!<4X\T"W-(FU.
M^.W;V#JLKY\W&H1MI,M--G^-T[HR1+_)9&8(8.:>.<KRII5)GOB=V*3?G.%
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M!)8Q1<L(5_S.X;Z!$3,1(WD*2MC'<!(8%+UD-T$QNT^RG[#<_HE"EO^8;I?
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MNO?+Y1<X@MR%PYLM?F3>&*G=D(INNX#X[U=.UDWJI.*WZ(U!9=KK193/A96
MNW7$'WJCDXN#P.&^G=FU!8U0:J0TLZ7T@;VQO'#!Z;JG%3Y"?N(^26VC1EA=
MRZ-W]^]-;GOAOQ+U T==^UO.[>G40Y(TG5]Y/K^@\AI9>_@W5MU5#0;1BTMI
M"9:*S^U//5^,".T3#J8#=OS[$!MM;_EZ8XP2OOUN=LV[K"A6M2FK[(SW>3:+
MRW$.?V\W+9W_&A<QH2@+CS/3D^1HN^VO [8L9YU^-UPH0\A88#^=3$5".R+
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M;G%WO#$,M.<T;\92%!J@];&%JKS>:R*X+<U@AVQP>ZVYX,X)5:]1,ZQZZ2F
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M*\JHK  KU=@=^X3EX.?UYT77+:NB92<!VO$ZJS'K1.7L?@KHPH?KV5&#$RY
M2CO>QHY'.AKRW@A5*=#MJXY);GS?RSB)BRYZ\G5+P#"85[[QC7@/I:^$;I(1
M"%+6FY,EZ 00D4C\XX4W'+"#P!=3"CG"M)BQ_"FK];:_L02>Q(\1>D?NUMFZ
M<,'H=. /'@?P%3$E/I5SD.6%PX;_0.V=-SZTU&?A!O'OJ71QBE8;"^\YE0OB
M*L_NBG\^,YZR1_X4FH"+\[1RG 9']O*)'_+5W*L^D]X_.O78"":8'LB$.NPB
M8H^=> T(H8Q@M[AZK[WLOZ?1&U]\L"55I;+8U?N7/%N^RGU/.W?+-[N38)8L
M%S/&&KHOM:)X8#(5E*1%(PH_ER-4]=2=(A-$#E5-]II$R(P6ITM(/I9.X>90
M_YE-QZ\LKQ];8IV0?N,&?.! 2VV"VM2: _55OD$]%*D7L6[S!HNGAZ52K]-1
M[EW($T!VH*@C0E]H=4Y('E5Z'2.%'<9GL7QA^6\L2LK%),K9U;+@!X:B;+RJ
M68,AW'VER[(1LJ:/5*Y]\_E@;+UDG;P5/5ZNMU_YMVD9I?.8GV/J*H&&/?![
MXYF];NT+GVQC+CT^#^8LOV)<H!OUT*;:*I]FU2,GFH"HK[,"U;)U[6XSUSP5
M%-0.F#$1?7M).8%/^^DH$Q#VJC!H#:+MT:SM@GAS=!\P+6WG<*NSXY/1P6G
MBI$=Z$/H1Z'13B-K%;M38PQ?_Q&5O8HL 13:SB,NZ K]\O#!F]/4JYHO"L.7
MQ-Z8SP+?=21+0.>U($!#V_GBCKVQ!&*AU_G6?HOY>RF?+-Z5IY:\*3\7SOTX
MV?1\@FG!I)WG]#))<!0:>Z9&>Q"B)QNRP8FGQ15JX-)&23OQ:5]LTSDP>Z%]
M*)E05RDWT^E='/V(D\HL6Z6\J&K+7.YHC51;O&%?(*> 5A-W>WXWW,2SDHI
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MCNFE%]Z5Y7&HF%*;2_+5^[?HA2GW;5$#$!JABH^ZN[4$"O$L4_LCUUBHXB8
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M?3O6NDH(6\#.0E$7(;U-R) @+Q@JK#G3(HU.1T%,Z'HL&&J1:C!BZJB$>.[
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ME -57@/=_<#SR?GY19@$);[>@EW0(U/!7F]8Z3/7RDVC.XOZ*>BD[UH$P[+
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M MN5S#DS@J90&EOLD'\Z.N-,^ZGW_L&MM.XX$0KMT\FM-W)T*FF=<8K6()#
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MQPPA<>>J+RR;Y]'K(IY$R67.(O4#6]@"1.;'-!_X>2U#2]PKJC5TC=6+M '
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MU;/ T2X>2!)B')P%P<(H=.;'YZW_NZL<XE_-EG 6WF-)3D@7$\(97MN,BNG
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M.0;"32PO D2<^HQL!YW5:N/9MRR]%K@ 6&C6T#X!\(#4L*YFC N9(9.$BAT
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M6)"&/YX\)^PBT*KAWUB6XQ4Y70:Q(@^YYACKO^#Q_-B7X-6'-!E'.=21K:J
M=*BL+NR@PNS,W\L">=C25A.'@2!SQW-C/6L3.%9M1YSI3R"I7ZG$ZLQ!V[-9
MIB@SOV/L'\D[B1?\FT7U307)B9OBCJ?!%F*_H^(KC/'D^F-.XHS/YN;'%4AG
M ;@[I!6'[G<@?;,K71 J%_(<?$CN_*OO*ZC.(NJ<[.$,] 9"Z*UF3* O AAP
M-4'+]\P"ZF[)71IE.JB$X2R28X=304T<!D+SK3RA,-]R8WV7(K 4-L)T.]_)
M/+ @'X/.ZKZX.#=KHE0\L&Z\0O.]7!^5'.T\)*3L^#:F!%<7I2 3 R'].YDF
MS?@E++UXLVK56K)OJ!CV58D2,XYC]3O(WQK)'EGQ=\>VT!7>%S,66PP2Q/,:
M5E)P["$@LR8QAN70F0CFMYE$<77Y+2_#@WPPG\^B4:&]"CX>A5D3Q>TK63A+
MR;'#!X62-$P$_UM_;,KJ.<M4RL/Q0Y 29D4=,QV7TCMQXO7@Y'&J*R9KR0I*
M-<I@G).T#M$7UH/!C'R=^JHP.DOLM9/WJ:9D3&1#L!EC%V31Z#I(H5Y@!AJY
MNDIK1YMHA_XJ63GQF]OQAJ(E'1/Y%YC[R$:%#,15H:E]\IP48YXFLQ V/%&9
M/E/=KRJ0?6+%J#5YF4C'P)P\17XMJ+12S&<BG@YX@V; G]<(HB !0>(%I\Y.
MY:'8U!=NW,)(!E.$_K]]VI#^SU[;F>NO6^T"4DB>^G+H[RI53@':CC>"L50Y
M-3$\%8,\4I.I<CR9++J9<JAHCO;L&*ZL! :NJ$0F!([0;S\B^SE4"CE8\D'3
M2I13$X11JH#-;S>C77'LC[' (MDBXX!^0L/B(L@-,6M]48QJWW$*0H65@MQ[
M-\#8*ICQ-4EGT>@'/NNW/RK'Y#B:2TO "!Z_"UJ8S?)4G-YV] -.;AM"H'Z[
MKNPZQT\A%4MF+A-)GFK6) \G":1^^Z2XX=^?Z\G.)H+HLJ)?Q7@K$TX]IEH'
MI)8VB-VZ5H =>19&+[$0MX_C+IBMU9 0>]4@AZY\XY?]P[W3LX/>G[Y=$%LK
M&"$>"'?=R3:OD+@Z.KN(O MIFV"M57_8,6VN3SPW_ G=]XRFRAO4V_@P)IL[
M.?^=J=9)A<Y9R+#Z*N(>?4J(K=6.J'_Q2YHLYG4ZD^4]P6I/H]^7S^_>Y&-@
MFS?D$%IS.&BLAE!A*U\*.*@_*\"<?2+1;P'SO&C"0YJ," GKR.L* \17+U+P
M>2N3!@W3M:F57<Z"+(O&$>3V^$IF(90;"68$=>[F/@5W,X2"D//>)'82V3!W
M+#3/*T94J:VJND?<V;;^:0FP-T731+," 6>B% 1WU\\*.\"J$)5@\]_XNARF
MDT070LGA&ST&PD0!!KZL5_7+16)>?5@.SHF+G8Z$M\?O>?T#*"HLFW%NX]L2
MHI,'@B)%8@@FBA3PET!=!5*T NKORJ$YUC^J+X"MX5M+]G]%(+M?EF</P9(7
M^+[Q6?7*<WQ^R@L6';ZUO/RMS6R]#KUX\U[_OH3EV%>@RQZ.P/ \K?X* %I
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M+R"47NN>NF.V5BM;,#>[K608=*_O3_(8[66]IC__2#*2OG-9J#^!X?3:QH@
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M!WBIB5Z,!1&\J4"OV_B=9'EQ?G*%CGP-@W3L8: F<#X.1-CZ>5*:]*-9JVQ
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MI5+8=QSN+EAN&*]2N&SE?+BFOQ'2=W6M2&\]@KE6*6$[&+?CB[@2'RJ@;.6
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MJH]J6CE^WW=<-HH(323JX;.FRA R5L=O]ZYLX&@\+S%H,I/9::^2NG2S.Z#
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ME<F3WO^+1)[TIMU.\7F3+%)^)E2-WN 6X3AOAF@Y8OQWQ>JWNVB#ZF?"PM2
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MIM%F_#]OE>4X@2DP:^MYKBC#4V^VFBN^4C+4-X $S=TBB%CI$#8>QD&&N6@
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M.PZ8'SN3X:TL.2 >JN>MG[;DEG4][_&7^IP,_U63(JD8%TC-R%8X,@+(&/1
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M<2?N=YBEU*GXRT]>G;BXC\DOM"A459?'=7TL63%5:U$V 1)!J(UPTXOWGH)
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M/U]^%JUK=TOC ZOMCQ7FP5<3T\(8%*#J=!(\G0O0,5AT#('6W#/ +#%G@/3
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MLQ_OYK@_9L0R>L+W99)761,AY]V.KW.^")L^H[8 8_@VMCA/>*D=."3 0RU
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M+-J>$M%2-]TX=I"U&9%=C1(VE]W)IFL5WU#_ 3S5.[ZK[1:O:;,2FKR^VOZ
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MM9E8&<6MS61J@;1_GEN\VE(]><S7=!^2[(*=:6N5^>0,+?HS@"ELK9X#-.\
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MU;%@](R;+2:($M&LHG:80XK*7.5L2\ER^.J"TPDN[_$N/V3T7?6;[-VEI._
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MMMK=:IZ.FT,D)/6[-7ZI2P'4U-<;<D&(&)1""CBU5DH!I)X54[9B3QV8*ON
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M_[6Q*"6V+E?O+!3VQ* ?U*MC!A((+U[1/O22G';3 V\AX&0!>TK-%%^#Y]1
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MWH(S ->VF\[ID_GTAI1FR1["Z(:#WML;NB+O</4-XVRS8V6FD^Q0^Q:;S*[
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MR)Q8RB76\JV[LZ'/Z]?6"86W/8DV1$O4Z\2H>+ D 0@)943FX)0W(=Y :F)
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M1=.<_8\%%@T;$>!3"&OF!'[$%7,"///?.7B.DI3NH6XR%GY.*IR^Z!\XT/6
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M[^N,0=F?8@D+!OGEERC%>8;.Z4YQQ0C:=BS O<RZ^ :]C?UQ#'ZICT#F.N[
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MTP_4%UEMC-KNQ!WY_5)6M%68.YF9:F*\IYFI([X=DJ0\YV09*#?T!:<JJ2L
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MC8EMO(^1NZB=;S>FB*6U:212&)WI;D#FQ8!_>?ZBQ)SPL1@/!F.V*%Y3,6U
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M?ZN.]$3L2TE/P]Y_KXKHG-.7HA<=BMO2]6?%K$= .(QA!.JSXDM9'Q3CGDC
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M9,W"')A>=A#_H2H.#^6QFGED-&WF"<^<\4WRFMS?W@':)CA81=/)8M/I7*I
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M*JV+\>[')R]+;R[MX6D?DX^:"PX<YT7^\8$%QT/0G-X*D\\J9E\SKZ)]+:V
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M?!8G]^&%7A7U:I*O"GECB_>G),UO\_=P#\LM+-]!-,-=0.7'X@G2NKGYFMQ
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MA%6;\8F'BKIT*B:-ED3X-]*.5%0L6J$29CEL7A68RZ_RS [+2(;7A2I\:ZM
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MP,\PPR/?P7;P4/1X3)M*(&4SS]V\IADJ&DR%:)@=!#VA\'IF$:=\);/#K&(
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M$S7%D5P5&F3Y,TRR>K=*2OASD:W3?%LU#AJYJ!@2\R52IKQ.%@$3 H02(*1
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M: Q 866B\\YGA:M[4-=>I&'A'\G(S19U+]C+*YK1#U)YJI!U.S75EOM;1#H
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MT4HG$^!& __?2QYU!W*MU3]->R#MTXVX+SK:MB^X:X^:M]S8H;1N%"^BSL&
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MS>,Q>9(RW*1@R9J"9?%)QZGQ&]MV\%IM/]I,.5JX##LU$KKI= O#P"QW;KJ
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MK7IXJ>5+5M*L\NCX*3F2)29+<05@LAA10.X.JC<ZIQ*#>M-Z*J^#MX?K&)1
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M%F'8=^CFR6!PSEJ1^ZFB1Y%1$:SWDP&[!XZ%L>[S[OE]-@=PE[S4Y@#KONU
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M($V!D& ?$OUO4I.-JZ^B4TV8)4BD9.N2-%]&!_IIH0E=O*JO4R)9]7U4" .
MC\[_\\D4RD""Z;MH;5^7LIN8[G\N@$[/@J";I7V[>2(\EWGR>"EQ3(9YC\LH
M2>LB/JID""L24#D1=GS)-]',XV8$:+!3(,%R,SF1IL21AQP)%SRJ@Q]@*1,3
M(-C)G/"%/Z,$"@=S]*__\K_^\/L__IE-5?USO0^L_QVW=.M?$?KUCSG[3OVO
MNKB^H[+=49Z_D%W:ZI1=Z+'M]H#;4DJI>, C\*XP)1-I017WGLCI\ X@IX,B
M1H@:^/* V9)0GVT2\R*&L879A3<S0;#]/L8_M0$>;Y70YV"]4QS=.]"-ZJ6'
M,/-.C)08'CY@;G9QO/F>$O ?DO,Z_1@=<99^.>X4ELF& ) YLN))'TRDLY%7
M!%!64R .*N(TT/FX@S<\GAF$,BKVV!0MB2=@FI@/C_/GR% ,'[T5RJ*.^#*3
M*'DQ':9<CD^1[)'GYBDGKTY,:!S[,2Y6>%9;&7@PVYL;OU/L=#>U2VYPWN31
M6VR=^AT][I,&/!CZB)^OUR@6>H:Q_9G*3:HJ?A;L[D:.O;&MS(+ F[IO60*
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M@THGT?(_,:L$5S31(R>JN\052FZ)E1SJ[N^[?--EGR9M4XW@NW.B,<])X?_
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MSLJ[J.2I6>S4Y5.6E@>33-J1GJ#)M&-<#(,T)3K2#CS1C!\>G5@?[TFU$+S
M)M<:86R87VL$L,EK[E^V^:4H[[.7Z$@/.;2+JZ(MT"JJ&FD?"']!K"%B+?G)
MC>_3:*V0Q95A>0F;+ 'FDBZ9I',FZ4?2U%&65;1[B-*_$$]9GTLU: :5,34<
MWV#/M[I&I VBC;S#3R7/3O;/DL(TRO$Q$VI!A/IWTL@5TM)==I.1'7J1'$?
M)FD)AC?9* ?2H:W0389XNP!0IY1M%WC+"M8,>^8"CC/TR-JY1""N@^<&&!RT
M!47A<*0*'&(4Q(' J(R'6%Q2P.9H-!5TC-&A:ND&D5_R++X\4MI:, Z; >%0
M,KZ^9-HFWK&GDJ8(NT5%:8(X*Y&Z0=G'Z/CKZ(:CWP@(88.Q#8XZ28,P=A9R
M,8K@6E"&)M RDZ6[O</7-"EQ3+]XF^6K?9[LHO^#R>\.]%>KW0X7!?LIC1_*
M*'U,=NO'<C<*Q-E4@9 [G_O^]'"*'.RTP@PG^@YQLNSW[Q"GS!O1:SD5<;2^
MVEZ'H2>.8"$J5DB8,-'$4+'A1N\_9\]17B;%7Z/=+DEQ<74IZ'_T#O58)["$
MR9&Q#V.=O .J>Z"ZBW=%,YN';A8CV"28Y35.G8SG>C(>JRYND-W>_UBGVP/^
MJH>TLC40EM6C[<NM;4EOUY&VZ.N#=_B."%O$+82D30 [2>()/2&A$@_I$(Y7
M$+E/"K4SIFL,>M0F&>L@8X,7>*%MO)^FF0\WUPT7]L!,A8?A&9D*##-24?@[
M1K0F&B6[2?&7+$G+V^09?\%DCM+R4_:,J6ZNTZ\/-V+[L0P5!Y3!$E=<2&&8
M(E"]$46;<?4@A!&CC"AI5-%&-7&Z0!#RJ-/3;[++$H+Y^7?_X[^C-S__C]^3
M_7!!'(HS)5F\1:=:# D70_/(5L[%X#T=QIFN=+-DPE(4L^29<'#AQONTXNC#
MU_M-_D Z$*I/"YG$\6^$:!P-)./&3)(/T9*4]:=>J<F<("X3):'"R03AO&9#
M:JIKDTTJJ*(Y-ZY>$+2<R5W0TKXJ [N@77WMQM2%!E#\__XW9D&7,IROTEX&
M !+'4=%5&M^S5[@,HD>F':%CI3H>E$$\=IJ2LVYU+6$>NPDEA#HZ,])HZNBT
M3(;,;9;CY"G]\&-W( +%HTC1M <"B&[$?5Q4;1&N&NO!L/P2M=S8H8 \BA<1
MOS!@,3'[LP4/Y\7.#IR^@GBI\S#I:XR-3@]]C3H;KR0@ZC8.^HK"GZ!3[ZA"
M^@NK3)SNLA-6O#$H;P95N7PXOD'AY)>J5C9KA+ZM?+V_IY-GI^KUDL(TJF!M
M*U3W6+O)3E$R&)]$B'5##WAKQCB&.-XP",QUY:I"W0)"M<6=H7!#RMD8>PSZ
M+DGQNL0G_4.M%E2">AM=Y,[U2^%'>HT^H<2#?23=$_NP62C6"+=_,7T [\G+
MR764YR])^O37Z'@A'WLX1 0>'_$QOGIAEWJ_IC'./YS.Q^P%8_;7S?>4@.&0
MG+^0Z5.L/;.I BU4\[D?%B3C%!$C24TP)XHH573U4MTU9X1139FW00UM1(G#
M;\06E,8SDP;1ZX)+XT"E\?A2W0>_,&G@6AJL#<H::9PETH!R"QSIA^A#A*0<
M)@Y'R+!P=J?VUZN(D-NQ!VAN\#DKDI*R2,O:7-."53@_TZ1MK-K;V9& NX%K
MPY?DOBB]M<;[L]>6*@K<F+'R4ETB/AZ><L'D8\TD/2*).84*C:PNT8Y304NQ
M.?XBS5),>KQB;:URO9O7?O3-\$+V(K.E1J0;.WA-YRTM<_[ S69/0W+W^!FG
MESHL%SUAE<MGUA?*L3/D9%@T4>Q'5R9VLI3SKNC<]/7@G4UDJ?TC6V@C^A0:
M^>'K RV0=R)_I#NI#>&,[['JNTBHS*J:6,<H?Z(!4^&1&&_>F U .SX7.#J-
M/*NE4>K&+'SXQR4I7Y@A>RP_XU)A 8;-@)1=,KY!N7K6I/)A'DM$6L%KL,$X
MMUE)*QY&YZ1D\8W=\1)31[D\1"4ZY]ES$F/F(:=9^A-1F))\^2BFS'A3315(
M1"U<%"$F"F<R P>,HA-=7:E>E9WY(&(HDJ*D\B9_PQQ3='U.<4G6Z,<RH#CK
MI^A'<KJ</OPXLSC2-FO38[2156T_T%BJGH/^O%6M$:Z:T_5+R'+R%1%=E G8
MN*8!HH:13 ,XS8A=%@>BR_0_5+&?B6N2EM3AODO(/^-U^DP,(HN74M=;&:JT
M(P(6F;3D;1AC*0[,-NWH#[BEP7YY9%3(JM&087L+'S%''WPB[CX=CR_^XHI3
ML-L-(WH#KEG4T,?$NG%X5VS]I^-:E1\N>7;&4?J)F*W+:8OST^>LQ%_R["F/
MR/9)856L* "9%#NN^M/!>_/(WZI$-0'$*2!* E$:J"$";TR<<,CL0R1P>.(<
MEI3#E')X5G$(93PFX%.T'+[ :6(VH*<PI-0([AK5KI+62^\W]5#*0ABGHC)$
M[<7ZK6&A&Z<81Z%;NF!\;3D45'4L^CCPC.,Z]/VWJE:8/I5'TAH4S;+1#B/R
M53">Q=YI\4'@,Z")P\WR]C1+/718:"O1,42W$AK3K_1$2>XVU6461:AK0;.X
M'MP!(=1>8WJ+6RE\BO)?<?EZ$UL<:$+G.E,@:F!TX<F].@22R$+WS-QW_IK2
M^PUQ]ZR9_GF=;O,H)2O"AR.[%Z$)BUE3 HR-V7,IC2_4V]F*4"^=!;$VM-@@
M)X8J:G["9(Y8II7\>$.?L:^)*.T'P'Q"U#0*YFC>ZDWMI8+JK@O577=N$>;4
M0.S*-!L2BKV89AN"LP'J< C=V&H0I,IJ"\0<3%#]T-1\FDJ[4]U[7.#\6:NG
M;1- I13&)95/_7<_NC8VNEPQ.DB]Z<]L7TD6F593C3 5H#N@FQTXS3X)#O 4
MV,$!6LB'OPNP%]Y)[[Q3WH!/>!W,7DCG-+]$27J7%<4F_8CC)[Q.\7Z/=V7R
MC&GBK#;8/=85-/(]RD=_TF@'].9(NKQ%64K<%]*+3%*GFZ^XN#4SO1;42V8,
M>0Z/FX%K&"LW0]:,ZCR['$<%OL'\O^N47RW?'O+L\G00*W34I3M4Z^PT4F 5
M>2;Q.007[X[BB@[=FB>\TD')274KD31U2CPLPZYX/IVC74D-0Y49"\VHP64Q
MQ]/[_DT]OV_;"?9716BZBG;K!WG63[/*06[U5#:18P!V]'QF<UMCLU_M6 B@
MN,<[3!RBQR.^>OD4_3W+KR]%24:D?%O3C@;4PYN6G.EO+D45!;)MK$G0$Y83
M)8)V%15XXSF7R3KE^]QAMLRC& N<%O5]0&_/DDY!:>?-4F\0-7K0%!ZJKIZQ
M*W&Q+HH+GIRK:D<"[(D[*[Z&;ZS1NGZ\?[#IJDYX3#B/82>L3D%I]\D_3Q U
M>P 0>AJ=FPZ6]?"U>#C@X_X>/R5%E1,Y;C'4/>$-A88+K7W@V4I?'Q#KB<2N
M7HV"-3\5B'BZR:5 !>,GU_#CP0",84VA]R! LU3W>1-$ #><H)#BG%NZ(;KD
M+SQ)2AO7[#<%C6,.QCFXTULUJ+*S?(4H;<=)5X-=5GC)TQE#P3  *8> 9PA7
M1Y";/3UON#UFWUEPM*#_GZ1/]_C(2R@<DG-QF^5_.R2[ VM1[0'H&Q?%Y^PN
M2Y]POCJ?CPF6W2-=^'N@RK2,Q/I(K[[2I*;LR8>J\/L[]E]ZQSX7/\8>#/].
M/U>=.T3-!XE9)0X2.K)OHHA_U)>2P\CONBNT^B@=17E28$35N/F#0QG"&IX%
M=7=HO1947(=G+KQ^A2[&^3OC0Q<C6MY.7<PX-0SGFIU'_"Z$DY>)?,\\>O%W
M1&&!:/T9!32<IQU2^(;U9%MT3XA1]X[1W.RW!WR=,;-'_GE-R^+$50&Q+]$+
MC7<JS) ]&2 +-(&_H4\CD&!!_ -&+174(8,J.O V9RE.=RVGNPZG9SFG4#9G
M*G)%<^,5MB:6QM>DAA2NH!DP!4V!P?3H)GM*B2L<K],O>;9/RDU._]+<_/K4
MLGJ71(_),5'<8W!+'CR]:[8\9"E@!<\!P\5;>L!5$:8+TIF1IK>.Z=^%\G7-
M<V%QLM^318I>ZGV']NW-.0%Z[]"Q'8'/;+)%9,<E4[$K$YI<*#J9P.>GN=$R
M>0Z;&Q7S'CF-TH( O=A<B#6^P\_X^,?-OAG[QX28T7QW>#&U/9/H <=@IW \
M#(!65!!]Z(.L08P0^B/]45",0TTM"%OAAG7AK_P.'Z%(+40EB",3!"O(ZSL<
M/!G:LICQ9%R[>O'D*DOC8GN(RK^1=>D&%\E32N]BK>K0C_#JBF)/,X>@GW=.
M['@>?^*$T4.4(*(444L2K6AI"![.%:AZ?]O$D02::_^/E%X@;Y1,0+3F>1)?
M<)[P,LF\2=W))Y677OY.81VWL(Z*YI1">(3*3:A%\()699DGCY>2;K6VF=H^
MBMX2SX-]((+3U7=P_1$@0^9<-O+]#?\"$C^!MEGCC1"3)Q3!:;Z$VD_1HA'5
MPX9%_35XH[>XM'BY<EK]FF\(:01:_CR;K+HLE'U<1J%$FQFP-IG842"MJC 2
MB5I59I5KJ_3Q>S&&I*=5[BX/?XK2Z G'MUG^<'DLDCB)\I?K['2.TA>EYS?2
M"_":L'[TTO/CJ@LB?5#;"56]_%P'GL#&J6+C\04]Y=GES$ZYBZ:WSWN_!I#J
M7_:%PI/I#=\9$]*=![3CO=PHK-I:R=[+O,?G+"^IK=J4!YQ7K]U0CY :DP\_
MSC@M5$=6BWP)R# L(Z5!Z$)OU^4.05Y]C-KTC'X.9?7W:AN/^1?A#1&,V%Z'
M\[2@HHFF+W0M,S&7OPEM"^E$;TN^6M"WSHM+3B^_T3/-/-J5Q>I',A(PU_>$
M#8V/<"%[NYV5(TCJ'NP8EG5!WR+2R=O[W@"L $>S31 FB5N;P,NS\@P']PF?
M'J57B$TZ@:J,9NQV$#NQ;M[T96D^8)5E#%%#/1F#T_08*=WH5<7OTP/]PJDJ
M/L1_V7Q8B?E)5*"BG-;<#0(N;"-<O<,@TF!/(%:_;\B@;Y]\Z(E+5JN7&[#(
M*BLOQ7_?*I5/59J!W$ZTT2-LC<*)P'/J)J(@9N,^8%I#-WE.RA>M 1GI Y8]
MKQ_Y,)VX2A2F'9#0PZ,=F,P#2W8N1!X\*[@1CKJY[% @,LM9=S01CMX>?B;C
MO8J*1+7GDS6">G>X/[;!J\.T 6(MT+>5K]V.6HR=MWF7DZ'1R[QFLGRD+5PC
MZR8[18FJUL&P&3BZFO%I\<5;!8"PKCCE&%M EG8H&Y'I-)PM'PKCMQ)-PU]B
M:Q\AK\YHE1M>?NTWC,B6@Q%["6 -<:$,6@U!$1*T#6)4TO;^X*WTC#Y6*/$<
M@W(R6(^@'HLQ:>#@&=A\2)O]9URVQ;#7Z6V6X^0IK0Y\LM0$\[:D0-7!FD\%
M^(AEI:>A;=5O>EJUYU3J\RI"9CF-&BD@^QODV-"&A,(OK!F:IK]#"S5->7T_
M1MRI@V%@HN0=8!\FEH]YI'A*" 8EN)&;/K%L,6[:#@7E9^@P+GEK60/PZ448
M19O *,?:B+.F/53!1<V(!U7O,#UE:HP];ZV,,H,5(QR3>:<$(8C C0H/6@I>
M6&69M8C=Q,U6IRPOD_^D;YP5I1:KTI9 *)6/4O) 'F^%:#/OP-2(5H2D1JZ>
MG88FSVU5%+@L5F5S<: J><-2W6CZ<(X/]*C@&?-TM^NHQ$]9KCYM6^ ;H*Z)
M.\D,WA]N$OXB1II6C13N4=35@7C6WT[\0)7Y]P[MJF]X=R=>MY1@G1?'NC;T
M=QPK6NBF2:PRX=(<Z>B&98*T$IBH4-WJ)J_)U$R4QJJ1AG!%M"*)OC32N&/2
MN'YE)F5<1R:8D7$%F>RK5B&6#U7YH?%,6)-.0![LZ-@'&*SB:'4/=.TY#Q:*
M"RCWW Q-HJ<.""63'>3DR6CJ=S4IR2&=C5\?Z1)4;/9"F9C1(W)U)]B0I7KL
M@R :;\JJ 0G%@D(XA1Z; 4DP;43\GB$EC,K !Y2T!@61;+2Z^E)A>!M*&0_1
MHA3P=,^@]DIJT@2+J?ZV@+X+E%>@'[?:+VW;(]+!>ZC+1/Z=E11*^$;KZ-1)
M.+:3D*5!7;6\28H=V:%=<KS9?_A!W+HT.E8I_#_.[/?%ZK%@:[_6%%K1 362
M=ASVY[#M3==?7/6OKR(\T><:Z5)<$?!L62=,YM#F3IC)\#&\5=0FGT(D-/1N
M%86=S:#++I)[B\9X8B\XM=S**I!/!^?T0[[5:I.OHDA_OM=K!'6TUQ_;X%1O
MM4*;')$F'@,?)J-\KQLBV*&C=*H[YXW+S;.)MV4J24?'VQ']F![WG290J.^.
M:R@##GF?B!\;X7O-\,#0+IG>#M:7FELCI(_.,1&A(YAG^4H/<J$!%,3%,0V8
MIZ<F*Y_PUH[NO7IH8- >3&D'V,O,IQ&L1R3G!M%75U^.EV*37T5C@1QI2R",
MRT?9%\K5%:+-J$F_BGB\QAON34?\_[R_BGYF]_.O\#'[_OYKFK-2R;[50H,+
M43^6!H6)HLP4]2N+)]TE*5Z7^*0_I[$C%-J>7.1QVL:5?!ZCA)((>7.^*)_!
M[=('R)VT4Q_ UK?*XCQY)N;I&?=2-O3ZJ>X%JXR:T0\0V;05RB7R-"9O.F8Q
M_.TAR6-TCO+R11A_W%#P_$+4*(XDVC(&(M_/B-/EM:>^6JV0=X!]R%L^YL&S
M?\Q)JTLMU0W=JP$M=CNN!H:#9J5S/;].K8&$Y'EI#1XF[WB^%MN<O8+VLDKC
M^D=:5G:3'E\^92E^^13EO^+R]I+&JM(YEC2 =DFVG/7Q\?4!U;U8P;OF'Y0&
MHD00HX(X&<3HP&^M7+(9B6S2<K\HHVR>&)LGSN9>QB;4/FP26L4=FC^HFNS=
M9L\E??9-F,O29"X=/3B4/1/_E#+X@'>77/4<H;HI5%E,^3@'Q0.;9JAMYZ&R
MI?5H"^5HP8I3:I#0J4"Y- R,RDS.$+"C1RB2?UP2LJ2_Z%;8?B.HIQ_Z8QLF
M!%8-?*U^%B/TNG#)9[GS>,%R4VST[H"E(-V ?TL#-V2M8[? JF?%M6%W70<@
MI=".6?(8;8S96LR:HZJ]QU#\Q.'S2XWGD>%#J=,X;D35 @*-B9JYD+X;U6,C
M^)REUY<\[[Y_K57 \6Y :F@P_KX\N0JF68IVO%/W#H0WE01C!4H]3;$E*BDH
ML$Q4U?FL.#JBCM)?[[(HI:70-\0KC?-H/W(94=\%ZM!:/^[! 25ICHZT/3>
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MOA,+55AOO$UZ0FVXC;@8[&&:7ES4K-PIZX@^5:+V4J_5'4=A60 +K'4VT<!
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M A21#SVBJ&I+WV*?YG<?T6WY'Q@4L=N4)@_HMOQ/"" Z6[ /HK/Y'(/HZEH
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M640.]K:4-M@G%=< 0T6)5G)V-A6<75V .Z(F2E*(TE81B-HJ"!6PW1L\#1R
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M!7G'KM-ZM2MU]?-9P5#0D1Z@UP&'F)+>_G,$* -NCC.($Z:NRJGTOCGO/;G
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M@4(VM8F!;^B60 DB/,I"&NF'D:M>%%2W.92>_#T-)H&7%%90^$V0W..I1/-
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M>NT$5Q\QZ]0;^2#1'H@;0<XV#5!0P9):JLE=86SU'+YQ@L/T7W4@;@4YW#1
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M_YV6XW-+KS;U>'V(P6J!@?;YBM=9_K*N-AR?6_(#&.'J%H)V98%=I6UDKL#
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M;25W;-M210-*-T0JG-IE[BWK=JJ>V7);#R3S@I!,*J:XP7N<9QP2R"EV>A\
MP.=N%>VB#. K=T8@=]7*N\%7% "WOE[.];U^JG;=<XO1]BQ2B-AUS]D)E;I_
M\),IG'63,I\9>A:;3;R,/D@IIXP,A^4$13&<JN&W!K6 #9C9"ZEER5<CRDD)
M_N]@LFHD;E$"7N!T!4QJ@M#4&6AGJZ2H.&=9$B$(SKVZ17L:!L]NS&N.Y''B
MV25[^Q:8OK/V8)827,*(4\G*OE+CH>Q:# 1IX)G:[8$']%_!4#S()P%\.WTE
MBSPJ?6<JEIJ&<9"B%N-6I41'!V!;=N'6(^;*C,3W<9I9CYCK]?4CYD36_@YH
M,_LF:T@$9?%89!%9;<]L &GUDJLL##0U\ETE-?(@23!24,#S8?H32$?'C!SJ
MPB()VNJ=N5%XON:HPP^GZQ4@*1B\[H#_PC&;;#/3!0"Y%R=5!7 ?+]!2[!7O
M4QZ"A/AXR%/?;Q3$R1< 4\BJ'*>5QD6*N15H+2 ".DC;N@6WK2U]\?Y!RQAE
M2>YG-*^<&WK3II:SF<7!@'D/._J,3$;QGE8MMT+4!\>P_>N+B]L;F[496.3G
M+Q9#H+NI8=6 I[BKAP:2]3WD9)4S_9T-76T^&5<3)O/XW5:^#M>-W([#[;^A
M@\UD7FIR((ZK+5VL[?.VR,Q"UGD0+)^REU)OFHYDQWN*@"L@")OX!VD+'G,$
MA.S8YGAY\)9*#5-7PT'*!>%*]-2E5/34D59$22/<$%660WUW &NS)A.+^")K
M@0NHJPN!G3/>^J*X,IL8@=K1AM/!%&@\\GX6%P1$C;XK?->O6JZ@G0\A =Q*
MF$ 9PM>DC$)W^Y)&LZM@0I7*H_D-.CF!$1T*Z>+8F^QFD9 $Y_8-:C";)62&
M&4$JN0XWET=S6XB1[R!%'7.9-8N+2>1=O:W!SNE&\HEK_>03NY>);1H^5+O%
M*B KC()3=^S"=5V;O$(-E]L'XROQ8UBW8;!>L7Z6>R'@*HQHF'J+J@6ES7:0
M??L[_/%5^M0T\AVDJ,5$AVJ28A*YV^=M6> #D]65LT$@)*0F_E%,0Y!*E,/D
M'OX<P,%1N-#"U2@N"H-@JO5X 7CF&%KZ040L/'8F@CQQ3.=OEL:CDL9M9_B7
M^(,4":0JI"C2,N(=*/#>8=%F@:PVJ#(LTLNQNT*S*&D M1H/?B2#7(4H:MD(
M6 ,@#1V[*1P*BQ(D0W'H3HO%B"R6<>(EJX=@"IA(Y)-O$0!'FA1V%U@\F]\4
M.["2^.A^"'GBF'-05,P,06\K(+[UZ&8OB;"LR M)J(G/^LWTYL*1A;A/&=%U
MQ>F'\!R[D]QPDKLU(W'[OOH'"69S4$D''R3Q9J2(R$Q+6W8JQU]C8R/E'+L)
M',J :;1MW47;WAT?@H]@ NWMN\QN>X8-=D#+8+'&)VNG8W4>]WHW-U<V'ZFS
M:-=DH6M&Y/9>MY'4%R^09">K*U+.8M$A-4XV@.GJ1L3,3&]_8[IQ1%\3?-*J
M4BS!_$>0<(Y=F&X%7WL:@-W5D)I7U(*&TV\I*4Q7EA??9>_\YO+,[#'"8.X^
M<HT8]/VA"A@67T"S"=MPU,@"[*K8?X[CR8\@#&V?->=GKM@&>#Z[>UI%(WV*
MUF13.5MD!D7"N&55..>EC->$Z;8:/@AI/PIFLVQBL2RQRF,A9=RZ<M4(@"ZZ
MD\T8MG,-W9PDM+;E!"\SN1?2<V1(JXO/2%2^@_L6!=D?03:O1M\ML![:EIY#
M&".#%17 OEV<1=@!QL443$%&*L6OU)Y%N#!=E ^W_*'"VY]3!.QJ3!U-<KJ/
MV[JJLLG^[M+^PM)8]ZEG\C;,&1O)Y):!B;)-YQ+<C/9D\YQ6][7%T@L2/,C1
M@SJ()J_D ^;KA?M_4CIU% 9'VKL5-BHL:1IPW8X ? Y\=+:#LN^'^027DMPV
MI#4>4LBQ.].A0)A V-53_2D")26C=X&GR-VG;#!2V_8W5!.%:*&=B4OE2T@"
MIVQW!4ND+7<:V+MJUBO#>XLPW0IZRVNJ+$U^8Z VL(C&QJ+"7D80.D<-J[?,
M9[8D<"ITL\H8-<NX,A&ZNL3*NZDK2POV*REO;?/+:W].)GF(%7YVD4J^JQ88
M!B?OEL?TO#FUL@2P3HOXUSA:/Q9QP_S2-U"$)5\LO&1%G10D^*"(GJ):N,W2
MKC88 G',L-^O+^FB Z^KDH^K.0(<@0/7D(LC74-*O(:N&H>C(13'KA,7ZM<)
M)KZNBOPH\2;X"I6N[,I:MR__4I>%8SW?85!+Z85.\UCC'B8LLE4OB,<9$3NG
M%,!_!2,Z.LA_8%JJ3W'YN+9XCJ14@J)Y+&258_JUJ.B(H^MJ^"]Z@O$A-?P'
M+\\?7NC$;?)2*AY+W413B]Y,X8'&L1&F8YZ"R\;@&EVT7=5/BBL&YJ2"K> -
MT%E?(E=FXW,/ $J&E'&ZXV3=2K%/B<<7= % 797E'87HQ5NYH6A?Z>?1WQ@+
M*,(U,@E[N_@ J#%>WUPXYOJ_JLU;K8+*[6#8(M7+INX@R/*=%Z*>]C8G)'O#
M?#!9\!%D@/DESX84QBA^)5X*<-[#U0MH<>C;WD0%_YVL8,'G"]I2);?8$>:"
M_'7*;<.2-YO4Z:H>_I5D#^3=^J.[?D]*J[ <77@7)TG\ Q^(FXPKK!T52>.6
M#D-9)7*)5<'I]O;_#-L#&;Z'P8RB4?6HBPR#]'#+;%S#=PU@7=TORY+/Z4:-
MQ0SKM" :'C/K/)BVM]-S ]E0]ZHKLS37_1K,YXZE<CNO3^56/^^3M<+6%[SG
M'UGU?9!2%F\?]7QC'D=<#"?[ (M5CUZ6W^LJ]N>V\LZ*<E*"_SN8'$S1N3OC
MXK3!++EPSB0D"Q(J_+\3+\SF/M .XW$6A,E>W2&13I;N?N)<K%%*]"%;3=)9
M*QJ[DU^K&ES6\[H SAM+U6UT6"L R6HBS09=ZGE=C;Y1GWK>UJT_MYEI6>3$
MY<^\K4R2UL_9W=RN^X*LF/66,PS*MT5C )O#8N8  6CUHG+MR/V_3!;X'$QI
M-38_\R*_8A64S88@/AI2QZ(U0)3Q^@CK^7_C"/\/19B6,T@"^L!=30JDQT1*
M67QCK"H+JCCK)>+638G8431?-UK*84E>><$0'AKIYL0%74L^9.$R+#=GCLA)
MU?GT4F&**&XYT3'X-22OQ6 A56DR3P&&@)V ;;!:-M0+DN]>F,,_Z0ZMG#NC
M:2 DJA-W&A5-5A <0V)<R5:P+F"2/D4;0.DZ_DBMZ$O34$@8B]X!U<U$$AZ#
M[TX6_JELA>N2-2N-@C\-PR&!+$:2Z/)? B)#!DZKQ@^-':DE"%T:*N>&^)!(
M:(O1_7HGB#1,ACS9M&DV*N_;0( !3'J5PM]7A9TVG0?+>Z#?#  :N!1)?PB(
M>FNQL+O1*Y(J>(9$'<DJVRA1N^IX";D-B3+S(21J!RRSK8)G2-21C+?'3VA*
M@]F^>%F>P+Y-JYB&!XMT2TO-=*3*'T/F=,!TW#H!&-)Y)-/RD:2S$M=<K-T@
M_10G\D9J@Z,C^3M@KC:/F"%P^I;KH^0_@17V$=!(1^NQC$[68]DCDLIR8@^!
MH!U[N2Q:2Z415%<?K]W'$>:L1A\$X HF-(<UCKHI]&M[H?0OS:;"JI@YF\'+
M*=VJ0R-(MQ8&)3I?R=8$Z_:3" 1&,8R(/X^"?^8TO^3?R>I+/"'A4[3,L_0;
M5IJ-OQ /NS!(("<_+7P5J'UET2:@)EKMT:&K[S/V,G2YM#W+U?II7'ELI,7#
M*\DM668X!.-6!HE^<WD6!8#=U546B\"-_)S]:[-*"6Y@.'+NA96'9I@!9(M9
M3O E1T1(CJD@UXWGA!K&KHH_+=E\[RV##*[HT83^^)*019 O!KZ/!6:LKXIS
MLTE4[D,/TT.5Y:OKH4NN"KD1$9)CSY3/&Y^KJF'LZJJH1#$4Z:KM+P*S^=#O
M\T4> J4^R"CQHC0L-5N?9G#8@)9XIRTWX/BR?W%]Y=B;[?/&S.:*($_VI6PU
M?+TT^9:Z(YR5 &Z.)N$/4N07N5NA15DI?Z'\V,A.M_*PU(B7:;0G^T9WIV9H
M2I(/LLDIL*XF ),FJ5(8C?"(2&7'M%E1F9+%V-6Z07AE1?4]#J'Q;(W/_L7N
MRD!">K44$_TKQT3VJCZ%?.V\3_7@O,O3(")I"GO[>Q"5%\RF'!.L3D@K)\+#
MJYQC;4H-($[U!'N,,MAOTU$,EZ9/<5)'!8&L$\*C(#4MQ8X+LYHE(;(@W4M+
M\3T(OA?I$NZ!5-R< W5-T:!D/=> +!<.=W0.-/?21:"#)U^09#OA:M4W+@M%
MNB)N2Q8?DRR5@'IR:27Z-M-ZBIRQ_)E;32O1'#T! ACY@1?NQS".YJ2H<IX.
MLBP)WO,,\8]BAIXO&5AA_JLH_:X%D%+^-T1=M$8)]W)4;(NRM2YL;7P*Z>I:
MB"A#PEJ$WU;JB]8K%/C_S .,DBT\BK &EW'JA?8-%)<NIA2N4U%8Q@_)$= V
M?]-W*S,\98*(-:\9E2'#2>C0%=JLS802RGZB1BFF2MM4UB -655<DH9C&U0H
M*2U9V20XK6]460,U9%:1EIGZD^U'/)K'>>I%D]$/H-2J<HYR+^?-'<<W_5[?
M5LI '08=ZEL28-VSP,#DLW+R&9U\'!%/G,O-?<>]Z[/S:UOIF(US6@:P>\:8
M U&%7RBOZ;J^)7CK)WPKZYH/^%\A@V@='7EF/851"H98<IZ:5A'E41LRW+BD
M,PK56ZDACM&Z-?SQQY>]B^L+2_8='7$1$3Q=FA@R^GR0Y#UN)0T'/K3/!E/8
M.4?>SR*%7O1 %B29D03@0U/ZHB@GD^&R?$S$\D%HCTO/@ZM;ZUY@75$R3 SW
M,J36V=Y?"8:61K-1+"4T*D,5>L.9):>%63G1P^]X5E2LVOLIC'^DGX!Z\L>4
MSG!HFK3NOC:]D2@0P&Y:4\'S!W;#TJNPI9/LDW/!D9 L)[%QJ&-O+6]IZYZH
MR3_RM'C,]DI@7_0#=+GMGJZCN-PGH]EFM5CW5/7U'\)L'9.J5)#Q_1KX!L)V
M[#5#O[ZN20NHN_J&; .[4%(QC^4:Y2C>IDEUI:CLA7X5Q-T7!S+HY8XGY;$1
MIF,^WXO:BHLFT;J=$V7[VFE3/5I))H3&08HXEHNAF?\RR+J:B:1R<P/*Y/38
M&$03>GDCDRTU[*L?-_9>\MA,FLHB18T*4#OO4WW)\SN9S&BHVE9LFV)2ZKL@
M/9U(]U_E&LNJRX5PJF]X#D$+1)BP.B&MK-<*Y;)1G/<[B*P^QVF1^^M@U%=8
M)V\_O.4Z2XR #/"[XE*S[J9N8"I+%H20N1=K\BE.2##;)&Z 'W]XR60]>50\
M$ R_6JS4&$@)ZR%&4CQ6A6@UU*3%Y?],/DB85O)3_AZ0!#@P7S6>]_RN2'TG
M2G.(G/M"4$XU_F00AFS\ L> 0'^DH/5]0HC)+ D1!VGU95#;.T5?44::.N/Z
MM![!*,YC[C[2#--J@=L6160$7P7BO0;IG\W7Q?W&2!LGGAB*'!B,R5N-PC@2
M8P56^V%SI(_UZ"\&TT1XO(/";D#%D>Z""%OR#KCM,NY?]*P'5C#Y)W+K.\!R
MLJ5?BU3(_DJ0X8?-D4#6HR6DF<W$X6#%5MT4#V[4N6.?J_R9VRVE>J2X[<>?
M,#W =P]H G2 %6XAE1#MYJ&0L$[8Y/=9S5JL2O#^)<JOLF+/ZQR/)N/]&\9'
M%CB15T9%PO0PVZW2>B2QJY2S,25IXD,BH9TP+:H(ES1,QVNT;D 4E= 'T>1K
M'.W]4C%]D=B(XW-\1G-Q>VM+"961"9-8[99:%1>,2I&5/7SJI<-4Q]X2T F5
M6%%8M%#_2]1 91WAA[Y"DTH1=W2X7IXYE^!*5R420=Q:#52W!.X]>R,^%B9N
MW,TD1T R6@SNU14</BI&4)6T+;6UQZ\LR7^<3HF/%3/P!<UP6BZ$XE5>'&&1
M=-R;RVQPK\3',C/!-" 3?):U:4VSUX_B\FU.\ARG:291G,3>Y,:]_OG9E1N1
M?7*GJ LT8TA]]XW).[7VIE-07_$13)V>*Z\$MO"5DB.=O4P: L\01YLF[[T8
MK4H-]J?%TO.SX135WCSRBTFOK?EB06VBHVWT9EOI4F3W.1,X&<(@;6XW>B*S
M@9457RB\IKI>DJ.@BN)$ 0H=QO.0,5@M;2%79;4#ET'X+1+6]"WP<%A<8U=7
M%_TS-YQQIB^!#8 9DM9]HWAEI:W?L\%:?/3\.7JDA],O7O(GR=#)S)4K\6%P
MZ7;*LR(-C2$KW0^T_>)E> ^ND@&.8T 7?'AX\:C3U[A2HS(@$KD#VHP1D Q)
MZGXL;@U-'HR*$7\TC)3IU"FFBI A0.[GXW]<+,-X10BM8HS)*Q;VGQA?],R6
M^MW!2%VJ+Z![R#F2&L? :;N5H822D6_B$D7E=@8%.OLAG5TZ2--\4?RS?#L_
MBM^\CR":K7\NA5R._;J?0#JZ58920#H,@;;Z'%I.>*+)+J;R]\,\2S,OFL!?
M-,1&:G"@W;G%D]. P*C =:^4X0&\]'<23D MH#\,\#UH*?@(F#8H@*IO,^I?
M0"JZE2)#5&BT,;?UQKIM_>LE"4"E7'KAYR3.EUCJW(L"!U2P\RM';C [HA+,
MHF :^!ZF>_H@97:UI^@M?T^#2> EBJXAR7&1/!;]F2QVB5CFU)!V-0'=2V6H
MX70TW][@MC?#P602%, JULK"@*FY_(2^SE^9,D/ $KHP>MQM$QB69KC#CZ^O
MU0/J$B>3N]5@N0Q!O'#"3R"!O:NBL!TGS5.;GQQ?GEV=7UA<J_(,Y!^6K1'H
M!.NEO9(LB=-E$:M1H0%-JU;YTRML@R7M&M\B*XY)R7QIT3QP%!EB'4"Z1#O!
MZFTEU(G .\K=I@51K!=ET64I6U1JP3I5B\W\6@K7UNGGAE>;Q_@T);JM8NV6
M]JJCT];0==6E+>V%)$$\N8\_2(+4J%%TN-M<<_?Q)9;N.RG!Y$@(:X>4H)-[
M5>\>8([#Z6,TP:3.RSC!@,0"$#9E;7K<3K2H@4T5WZ)42%#'4$ZRF@"N]BN&
M^QA)37/G4UM92*V"+S$0#=\UF;B_'\E^]3T. 8F7K(H\UD]1!1O"67', 9HC
MCL_/;\UJ/GRV"-_X!889G_>MIPW1('J#JB%,@%/-('V/#R0P)\L3$#6:!0"X
MB$P?9G.2C(#&G^-X\B,(P\;KN=Q00%:++C8U(6"I!2K(3S5/=2,)Q-)5B8P!
MA+2>K4R%]2PQDH)]JIFNGP.?1#Y=@9\24-_F 9!7)'<ENQ\0S'JR<RG>L@2D
M$:-[R:X?7U_>XFGV P/<5BFJT]R\UJSFX_,+2Z>%$18V0W/ONDCAH4\\AT'7
M,^<RC],#0%K/-*C)OT9TIYIY^A7U[&;GS+H5T,_B.WBSBMT>J%--&DUABARR
MU89 $NN%(_;XPV7CSK0M%_-N,PEPO!Q.*6"1%,![C6$CLW[9/V06BZWULS_5
M[,YW<9;%"W'>UK0' EF_,(FSEPG@9#,[OY&96!&O:L-Q[_R\?VLS:9'9,[<>
MFZG$SBXY[=9(!1;S;M.2+-9+,=2SJHFQ^QA,I7(V$V#P,O>2A>>3/ M\+^3?
M5FO;EL"LZT8L<A_>;!I@F,KL;(8_WSW?QWKH7,;L-BJ@V'H+J<(1UOQ-)4MV
M:1>\]Y)D!>=%D;,)SH]\D1=U5PF \HNZP_#') O2=9@3)LH($AK8%$T^)W&:
M[HW2Z*MHZ:,E4UWQB.M[-EJGDZE$S.Z*M$BYAIH.)8FL6Z[;%P$QX=NGBJF,
MRV:.I5>R\((()GL7QW_2Q[S< XK5O(1G/<243_K# ZL9CZD\R"V$D?)WR6>9
ML%#!H6#3=2643O&(T$-^NMF-2>HGP;)X<?(M)?#+YV!*&ET/_)@CQ4&!UMU0
M1/:D@W4>Z-'!;H+C^C>B\+=T'M/'MQB(B#LN')U(%%K>BD85T&)7HW@01;D7
M/A,O)2_>BA72:V#4348PFQDU3 F/:7J82H1L4(B*)+;X3AMPW<<I32KZ&J^\
M$%/D/.1D%(_FY!Y)2!*@?+9ZBOPPGV"&.&P^G+YY86WN(8.C4SW@IB/WHD:)
M,DX4NYF&:\6J,L\A3!H@+^)B?@.?YHFKSU<EVK7$;C$MBTF!D$/L8"+?5_)!
MHIQ@DFPY7C=WW.Z?)\)L2<BF,O4:Y/;ZM@XJ$\R?OEL E>J#)(\_89M*:1;(
MXAD#@^OB VQ)<2)[OR)T4TE\CY[&H8%>;_EBX24K+/BWI$]JUGKY!P;%(H4(
M''^8V Q-09CF>(E:E:-O1)CSE7X;TCC2^/SBTI5+J\B\66]*5(8![-;-F@K,
M8MY+)8&?_%L2-CV%WY!PAP R6LKXKLYTII%; O&IOAEA0A=PG33T!<+9-Z9+
ML)@E)D(PW<O@]RDA!$TO=SG0"/,1<KTBC-;C\TOKP>-"]#_4%KF(W'NM00U?
M.-]G+YH 2C&V-?0"L-:#2A79)X3,O:<;:Y1?/"!,1)(5/XJIOC6 LQXLJL@V
M+B*KSS3JWTAMCH%H\IW, S]L"&]B=P"(UJ,"%9G6!.I4'U\(*9(\)[3J4&-K
MR?G,:]$JR V] 7%/H.K=I$RRJ/B>F8/!6K4>9ZDB#)(^YP;\;;U!:=O8=X\%
M8'TT9:^-?G_+)[,R4V8T^3M9O<5YXN-=YC'-@B+?R[?(!U)X092MNI0/IL@?
MDE83B)28""\SK/I@(!HNYG7F35W.Z-<XTOC\RKI*J<8UD7-'$/ZI6O_N\A1#
MUM/[>/$>1$4YWD9['ZO3V($TFPJ\98D)'^:IFO4>@4[9*AW%F1=^BI,Z(@@8
M^(1' 198O_OP&<T2#TF(IYKZ15% >.2R5?I<F;<R.T@5I%5;8HLR\;<8],KO
M0&G8AIN/DX/60%3K$F#P'&'@LVJ!/-X!LH->_N2HZ0[DL_Y.D\%3P;.""<H]
M,^?;'.82SX+O0?#]=^*%V=P'$E4!<(V>HMUA/[2N.HHRZ= **H?R5&VB12#_
M()I4BGTV;OZL3J![G=(9P(=YJD;-.M0"1P"[V]A:21!15LH(0!63U00X]0ZN
M4KPGK^0=I1Q7 TI^.DP&81C_\"(?GUO00@'Q?9YF\8(D? ^8^HB8H=W:2P1Q
M+M8XR Q@-I4ZQZG7UC'NH3F^ZHD^XO"#FJN?H@>2$#^>14%*)IM,\ 75[U9%
M4?NG*,V27"PPS=!'8&^W'LMB\# R2Q9327Z<.[T0<EK%+)*;K;X/4,KZN666
MZRS9XA+ 5-(@D_>;(KT+$">-PV!2U)3 8A/U>TM3%]BS>U?7UB.GM#<+89RF
M\@P=@:7\BRJW4P'78K8V(5Z(LW /E:D,10:9^.UM+\$5!AB)9)%J[EC MOBR
M29 KA^R4P&8J0X]SI_+ SW(O*<ZH?+$4\UBR.I6OO:[.;YUZFJ!K;!!!:RT3
MSY%E0\3>P.RVI9C]JZ<(4V4DH@:A6^E^WDB4!O1U[FH \UFE08K)(&1XK#+,
MEB+6579!MM6=^QJ83>7Y4<VS7?_Z^7#N+R3QD2TS@@E!. J[4-\M":P[(HQH
M[_*@3>7:,;/Z&^?/7?2"O=?X^V<6RUK)<TJ!VS5X3:7%.1*_BY6@Q_7J&%M:
M6,SJIL(W!>XS<9O*8=/V7C^<K@WGKS3.,_M?)(E?T,'ZAHD]/@4?I$0L*R"R
M(V_)9\G*TZK8:%'#;HH<!R*OGZ4?_ B-!D=\]RV*VOCMIN1ILY!/D9J(*S-E
MF_'YM5,/=238QY*&'62F$NXX6.+G*?+C!1EY/S'G3I22K3MFN"1)$1O*%0&1
M <:TY/5)R8<X;(;P=-_D>9\G"7U1^;,2=L!W?-?U "IUYA@1% X.3H8T=+^R
MWQ9SX:45%(2B,="F,X^YI&6@"I'!?FE3IH,G2:W0?XTCO_B]_,:P[0NTL_X:
MYQA;Q#YBAK0<*0*SW@&Z?J +,W^)4_I"-WW=A&JPO)_\7H#6>NB\$?X*8V5P
MUF9@Y3.9>2%-0,Q@XK8!8.B,8[*17_NP&"_BNE\1D )]26*?$)IW"/[Y$:0
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M7/XM#J+L.Y >-)UTX/MH92633W'R+85CZO&?>8"ON;-Y/.$N<W.?&5\XD:%
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MSE<9RS9 ">M>;A/:X X<!F/%#9QM+,&GZ(.D&<7T%.W:Z.'NLS'@LTYLL=Z
MW[HG6_/0E@'*8'3W,ZS<YPD2N_ '!UY8:KC9)SB&OGMA3D;S),YG\^KQ<Q]Z
M:1I, P)D^IV$Z/$9)=X$B,^_.QK]U#9"T;Z9PL0ELSWB,&2W^Z6N'T@2?'AH
MXMV0[3GPWH.P.2B+WQ76?(=O)'(H&=(A;B%MXP@K5P-]FUS,8>3]I#Q@G%KL
M#H#2>G2'WD'5A(W!P>Y;+;_&D5]BI[OA,%F'O'R&O7!9M_^]>0W)B13'A!N7
M]? -(]JK#GR&H'7?K DZ?4$.T>.CK@/0R'KDAJ$+#@,;@__RIDG, .Q.)KI\
ML?"2U7#ZF<2SQ%O. ]\+*W]W-!5==;:#A'CRJ>B8(XPOSL\<69G<^<JEHJOO
M#EBM.QHDF,+4] 2!GFHJNGO0/6=Q EO5</I*0M1$7[P$MZ[F)\3<KD VIW9U
M'G.9=TL!A*>:P.XQRH)LE=*D\Z#,[,(7> HJT!\(:-T$(<)BEG@(0W0P(UZ>
M9O&BH?[?;B. 8OT^*$SQNLO@(1BKB?!:7+N'9V'37E[; XCDE%])90OG #O5
M8M8'D 5V:T8?()1UWQ.'@\),KZ)QIWIU2OR_SN*/W^C[CZ1@^OH'NF53QI:_
M&'^^J^'@]H_CB[YU0PN7[KO,VI^XU71[&ESY]L;ARK<W &=="U;@RGKB[M6:
M?B5I-IS^$2?AI"G?Z&X[ &3]28@$)S@8W$ER)[=4[AXY2^7N<=P[/[\XZUG7
M,1662W7R#F6ADV//_>\<]MS_7B"T?Z=78$]U\B>;%(ZK*#]+Y^5A#P&4MKZ1
MZMX*9)#:K5'=<N2I:(V@BW.G@I::>,;B^PX<4YG;''QD>^"MQ*IWH[D7;<(9
MGJ(T2W+JWJHXQXO6+W$*I%R&\0K_?D<B@J6&UA'\K\%L#O]( GRK_BT"HL%8
M>5)DQ8BHR;W!!VAY<L!]IX)45(79#3JV5IN\;=\F)=?&UUN\OEX_CIM,@@*0
MACNS]OJRXV?F3(#_.$1RE/'%Q97VQ4OPFRS7HNP0XXM+2^8,90(?7N#D ?^7
MFU':S7AA:3-78["JJ_&"_0:J\\)Q%%?CI?5+BPB+M5R-ETX6WWJ;PUSB6? ]
M"+YOZU%5WPWP"Y@(=@?XUET5PEPZ/"KD8+I7P>MS$!)O\N8'!%3$%'8_?H'J
M^M98/JE_T;=N M3@8R.R4_4ZWN4IUN9.[^/%.]P_-KG6N3LWJQ-LAA;K$ID[
MU?GXW/%$MGJ>UQ%!_E1GCP(LL&Z5YC-:\%1O@NA>2;+OGN_CE-<S'_C_S(.4
MWIVY^W]C/P!L/?1$DCN'9X$@RE,M5Z96Y?CF_/;<5EB@V<V_%I8AYVWH()_E
M2QU3HEC7VFOYU,34/02FO+[2?&VUWC%%9]WQPR#YX7[;B,.4\]>EU?>2Q)/<
MIT;[-Y)\!+Z 28W1IZ"3I=N7V;VW">$I%O:JP2RP)3-[45K9CRELXJ2$!.SA
MLE:YJW;/_CU.PL#_DU_V?+=1@<2Z7;.9TH=;-0.(&P6SUG%3$Q(4,5/PCVV\
M%/PP?B8S+RSN!XS-MJ;5N->[N;FZL717-;&_<D&9JE_5-N^*N3_$"R^H2XJP
MWZ0$:&F5<2E^R)SZB9NJ+V5FH_L:?Z AE;_1[38JH5AZ;\HF[.&^QIJWJ7I.
MALZ:()KD:>9%WZ(@Q!1ZS\$BR @_HIK?J81JZ>(NPR)1''9K-=7RC1J0$I(P
MSIS])N->_^SJUE9N0!,'#AN1=M4EHPMJ/4?FJ7+8J(1BR?K!)BR; ?OS-E4C
MR0P+MEGI.*MCMU'AE+MP/\Z(NSY8F$P5#3+-'NX:V6]6PK&H,[/(RV/$_MQ-
ME?,Q=/I[(8FCEY#OHM]K58*QI ;SR5MSQK,FKUTZQR@G!)?_,^?UALHPXXN+
M#AOYU!&;JH]C4*/;EB)<.PG76539":"Y?8!BEJY)ZGRIY6\3Q),M4 .4PD<
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M#J@L"=YS!'8?IPV/"@]: W&L%TM6XC,#R:F^^GH@  "52P &!R@<M=GJ)?2
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M)N39J__)4QGY#BOMG"=Z=#(\=>!^ILE^=1O!(;G7-;QHTY<9^/EKRZ-E%",
MI ,WI=IR4R(CO1_A']HH>R.]+^WP60#FP'VFV:<FQN1>$=\[+UF^LC0-=MXU
M]><F'P10R<.4&XA/!QQIL*+6_>I6YXSXI(A5:S8I$$P4A&+_T&R+#=)XQE_!
MB'Y*F"=G0T$L&]5/4==-\_#*H]K-]@(/WUGL+=B7*$R7P<?7-5^71W,X*25
M0#%J=OLQ7K+/<;1^R\M ^.'BDQ^S*0\Q<<NZ=GK1>/4OL[-'&^Q@.3]26YKN
M<'A7HGNLFL'J>FV&JJ]VLE>VT+.%E1\$2AP),E8+#C555/#TUH)5(-4Q5NT]
M.AF>T8<N5,2D$FCYW=TS,WWQPO7<*SHY2V]1@B<!%+VQ0D!S=7%%7]X]<](K
M"^"1Q6?&HTH#6$-N9BL_Y)W@,G+E]@F=L0"<WEZA)34#..[9E5Z 6J!E":_]
MB;VS(,KZ(4C%)QL",.G-%%I24Z-PSZZDL8>KK \F4\#.0>C3;7)@J8?4/0-4
M<2G;W,:VAW5^8^5AH7ZXAI6G*% E#IVM,\WD='!^<7%^=D+5@K*>_*HZT BX
M>VFR,CB<+CL:@<RTXX;PNMJV4NA@[VUF+<*+].Z##8(MU)&R&G741!>?M81:
M5\+G5MP@FOW :#Y>LJUQC^>EL-"/8KBB>+G'QRU[WYF1O:_%K^A_V,>.H]Q\
M&K*@S"P:U2G]T!K,"^PX&9MW)C'--X9+:GH4ZKH&I(.\'W$/^=IS 3%.6IJK
M>M 08E]MDFI*>,X1.\PY:KJPB"<%JBG#-UM:5618^UHG46>M/?".-MZJ#N:;
M#*E:CK:[10EA]C4A2TU(0[4!^@@O%6UI28[*EFGXV#>)+][?O&(E4+$N'!?Y
M16LV\W,LCV$6:\G_8.7*@/V@_.:@& 4R.+-JGJW^E&ZL #*2)^Z=G!/&?FDQ
M*#?#JJ#U-5Q@V^:WU"!%&3J #<K9<L0&IY(H:E91@>OK$5X$7"/$ !^6,T9>
M^$(I4!--.$#6UW/W[3KQ0Y8D<!CX7F1KJY<%;%#&UI"H2)6M94$)KJ]'Y_O]
M"N B'LR;&N"SY'P2&04-Q(WIB3E0]R(O2LD3/(T0^?"1)S-<%XYXY\V^=A4B
M]\(N#M[V4[3R?-%5%GTVPW9):."0\:V4S@$&]Z(D7ADPD%OOXM+_C1:QMUHQ
M12B:>NAD>'5U0176I)9'57Y&H-R+<A#<,?&U4?PP)V<PZ.1A2 ,4:0""ILBD
MBR3V>(Z0T,:A(%Y'4@=(:$MNUS!3/1D$$$I&9P10Q5TW_P)-43I8,SL['%??
M'1$K\O1D>$ZX\9E*H2I'*2P'*U]KRTN Z>KBY,+=*X&.M"2@K-6@MB>KQW :
M\Z:YGUC^7SAAO?N\_<H+>X=?.= [1(YFD^2G-D<ZF-23<4W B/PI4V RR^7C
MZLWSXRS? +L1'CR601HZNS/JR!"%A$B)TLR2U9KX&H6\ L4=_+Z/>0BK#^:P
M.KW_24 ALFIN:"'R.._Z<F^[+6=_?[?TX@6;C:.#/MY8#H#33NKF6>V'Z^]C
MN%V!'WAX[^$;;.T&V/I6?T+ 0WA<T2);O7^9PNVKCWNS?8_F6SX2("2OR*HZ
M"=69!N@D=(+7T)[Z()LZPZ]SG0G9@C=\<4EK=H>(IRB1.S[W'P5B"*-/&TE?
M!*2O+N[L_/$%M"[VO0#.(5,XAV#6)8U1D^&0T(O22.H*3.YE^&<OG)^@ML7;
MD-!?V>, CS!FL^8F+P?CGB^9ORIVSD7D)1L", GOIS5EI@;4U5KWJ@N/X-\S
M'M TY]N/[:G4Y=O.R<75]57+[H[&4;DG%]<GA(Y&71)-71S[Z"Q=6@(7 F<X
M)&>MY/NT"RQO$D260F9;$5*=F!D.B_"&)Z-:*9@##):.]W9$TW:XS.7P[/2"
MT$<A%T55=$:@W#NG/\&M?KK;T.5%IL4/3P:7)Z?GE&<^4YFI<+AW1'_U%Z$_
M]Z=>F-Y,_UW[B2^/ZE6.*6J2G%]U26[ZB"P=UNTLF:+#]>V'XO0A'Y211-5%
MH?E!1!.<I6#1MJ5H$*U6'9:#)=SP-&5A(L0#9):"1.V(\4CQ:P#=E1)&YI^G
M*4I+(:5V!,QM;B+5Q"Q9R..3X> <WLQ5$5:%(+!IJ:#9"B^MVT)8*+\BWL!
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M/[@;"AA=%2P2TM?3Q1<O7<=\M50%W)4?!$K(8Z1L"A=3H"KFOA:KO5DLXOS
M,_97[-8+9UH)/]@H((O<45,5'B9F!0SWBM ^P;MF.8JCD/TO\V+0[J]1NOW;
M,0OYWTHCKDVFF%Q2-5S5EE'5'&@.L*^U:P\QZWS9R!@@BMR*8*0)FHA(B]6*
M"P6]PYF=[U"/<%V8^Z&?LN!#7B$('P$@R6_^QA^P$@]IB5F7KPI/DICH-GX&
M)$A>6N@8QT';C#E9.S=_>62-V?X[?('DMB/;XJ@N00=PW:N*^RV,M\%GAV;Q
M43B.O9D?+J02-9@!2""/'&U?YL:$N%=<MZB3)Y7[WC, A#Q*LWW)"B [V#E4
MKG\ZHC68 5@@OZ=3?]("0EHK8-NVP^#>BT-8GGAMZ2SG>.LXN/42?\JCKOQ@
M#4?PP^<<<A$<OIJ61P ;!.*\<N14?_B*:GN^<,0F&.GDBGPOEI..':+5J"R9
MV@,KR_'].YZ-OO?O.PCD5VTUQ=4U4HS#DKG;HBBDK1Y*3^Q@$%:2$9.*D"]X
M;TN69V/ZC[@,ZMDJT%$[NLBOHZ9?G2DZ2^9IEY0A.Y5LT/,#V(:!!^ WK[:U
MAG_:-::3*HGQ;-O WBMR]X:>"F *U RY)>-WW1![*OWB]XZ<&C:SH6'B^7;!
MX^0>\Q9U3 .[)6M]X0J 63ZO_1GO N"ZKM73*#A$]U5A<FBVC-^',7G4>G!P
MPVZ\J]68;_?=D4=R-5.AIM@M&>P=W-D4S-38VVK-N&.;W '8JJ9IH+?D!NB6
MKM75J,GE9<>/W$IPUEP+QPXZK]B0ITLV6P=L-/^ZYL$7FP*GR:]C1+X\=>13
M_(OYBR6HW0TL$]Z"Y7+@)45G?Z\3^'OQO^N ;S0S,.2<^65?>MAG; %V7R/#
MA=#-=0A((O=46)"RD0+EF/L:*YYM??X[NY_/V30M=H.\NG$R"O--8C0?Q3,_
M].(/#;VI,R%03!ZRT*):U:>$-%J]S0P%&:GR+ 792""-/ *B13W2P&XK[/W8
MY]1/_KL_@^>3;9##8PA:ZZ\>X)L(I[X7O+"W*.;EM4Q/IN*J::4XE>UO2\Y6
MRC% OU%P@OY;8;$%\@&32TI?J0955<>I"DQ?SV8UL_:H0A-T1(6M8%4$?3U7
M6<_!HW<Y586';E1R&.[EX#WX<9(6.XXT+Z?Z(#!!?EU6\%U=:C$8I%ESXAXT
M;!J%,QW1")X$4.3756/9H#C<RVL;+_U82S;5!P$2^97/6#08#-+D-?&"%JWC
M=*FUHE6?!%#DURCS)0W#X5YBEO#T]*3H?2(?!%")?##FQT%=-.YE:&W?]-GS
M9Y] .5%9'3P'@ @;B.B0+1*1$ 1IAE2KAM 2W'U;G*:#5#D>""1L5F:N!37
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M NMKANOV1O(( @L7/AP],V=<,DJ7>3?ESU$T^^$'@?Z-76LJ$ CY,F#]YFZ
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MSZ-HJLYFM_!7,WF%)/T))D/NRR(WHS80<DV\?0WIW&^7?C.=KE=KGM<X^\0
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M 3RRR+O!!3Q%<K;R0VZ8 .;?V?W/-Q8F$F$:SP%$D-]Y&HBX)E[28AU"P;\
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M0K1 WXCE[G9=Y4TJ_^KCG"+"OHU-Y(Z"0>2M;P9S5]Z:<M[?P!QR0)C?D0L
MB$SU35RX3(_><3CO;,BRU6KT/? 7V:\XV6'XXO+:$<TOO^87+UW'?OIQ [KP
MD?C)0Q3#)@ :X;\#E>]LVSJRM!=@?8TM_P)0YLKW)A8F]L791-_7'LI;7E3=
MR\H/<D[(70XVI8MID !T7ULGWRP6<7%[]U?LEO?#0"-(-$9QML@#JP7BPR2M
M D+:![G56U?Z!*CC\=(+1R'[7^;A90@T1G&VR(/*5++$;UUR5.YT7K9\XSH
M?1/.RE2,?T3\;W66 Z.9.*OD+LVZNE('J3M-GUO2GPWJ0S)XE)RQ"FE.QKDE
M-\@WUB(SL*1]J8^B2%O<!X3PH'%S3=*<C;-+[HIMKDIF:$G[9Q]#E[:P#^F
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M2Y#2KPM[?(>0,$%<@WP=B0D0(3(S-FW8D=DX]L($?I7)#NS[#VW1#'IBHE9
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MXE7;-NNI@_9$&]&0NROK*$(]G!X&-VPA@K2N^_##H2Z8S;@))"*WY=55"@O
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MO$'U5#:DEYSC:LSRUCM?5Z^DAGZ79N$<]HO[, HB, /?C<=LF"$0Y"X1L[E
M#.1%_DQ)0WTDM;!W]5BY%D)QP'F:L=&$C?KI#63C\K?-[=T5<0P2<VUS]!O
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M/EA:_$$2UF(T#TB$T%/B5$UL!.!?QK8>DJ=E,IP&*:O\I95J".8#"7D2]7)
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M^/*U_-T_TS =C+'0P^O/XLD;SL,D3GZW#/_S8T^6CF8S_,\]MI_LL%'7SUN
M_)/AKQ@"<O(X<K7*)>Z)DP#[D^&_G<KI0<]#&5VH=7L?Q9\,?\40+B<J2Z"4
M./S,)D%!FN%_J&I:.@U-]Y\'"9%';QGPC$/X4RK -+N>WA%F0+P.F*Z6"CA,
M[BY5#RE71SE]E%U-]:^>CK [^NLTR/X.9[-KMC%SL-%K_)3$XS ;)(]QFJYL
M&%I7XZ9^%+BBC[+0UBF="T8#XB$M5R#V_9<&LK7]:! -/F#Z ##TTY1E4/:4
M_^]-W,I7-IJ@16'K3P@R(K=*-JP @A %6WEUM[1!.RSJO8L+<E?^0;6V&0%:
M!P=XGD+\A5]X4Y QB.$F2*?WL_AG\2%?LW&<,)6VZDP LB2W Q IHX%\?L\J
M"G64KLZ$(&3RRXF/*Z)<7EVOH5#*//CUS& #B":O\;9 <**D*FHQ+TB>W*I"
MI*GV8K,.X]A66)]TU823[W%&<CLW_%U0!X^39YJXH->3D(=E)'3NB(/Q]SBZ
M$=A<+>[IZ)Q@P6W5I:>>*M2[K:NDUEB9">I54U7CK')"O^=\;B5"%:O 0\3E
MO\S_2NT:<_5+0 MY'.:AE;E962(J?B#?CG -Q6#>EN_#D0ZB=77SRO>]PKB&
MC2RH[GX A$A>9X%B=74N0D0/V^\[0F,Z5Y?*+6O(,Y=3D"Z34EQC+D^(OKAF
M$?\?V=,L$!:::O#7@![R4#3_EEQ;>2+JWOYRV(++JH94W!D4K'X,R"%WC=(I
M>T/B1'1=W^]E:7TP.F2(/^QM>XOAL4)G2LAJN#@]NSBCRDOS\SAA+#HDLKC]
M#3X%PH$SOF89TUKS<+:.CD_;Y2!PNR#6$A:B@NUW62'2T"Z'6G.F,N'K_+A=
M#H"#:**&Q!!U;'^R1:T3H^RH0FYS]^^:4XH%T2'SM ZH@T1:;G<GUW(5\/Z;
M)52N2TG["]9%0N45^5U.FPWSV.LJR#\)E8HA("=RQX$>ESKNU#U@?Q(JMQ->
MKKRZ1>_1A7$L0$&:4"EV<:?QXC59IIFT$,_.4X"&_'PE$*_ ;RQ\\:[V,KXB
MCT'5(D7Z_EU-4%PWY=FV=^GU&\5'@M3(;3I*ULW =#5!T4TB\A6YX<2 ;AQ"
M5[,+#Y.%>D7NQ;4[_^JC[&JGX:TO0W\9 *F0)^OILZ>U+I28'"74V31[E4:!
M5G(*%+&=E2??>I='Y->7NGS),3G.''-#5I[H5D8MQ;OE3@;1;9@NXC28K:YQ
MZO"R^A."F#RV6:FIMX9.F^\EU(_O+-L/9$.H%SX+T,BO63:LRE YSH5R%-R1
MC,(H2#Y?IEPZ:7_(<?+WN/Y<W^TY^.%L.6*CATBUJUK-!T(BOVO94&^+G#KS
M2*@>?R<AGRO^&0W&!:ZO;+:%"5$#Y3@ 37[7LJ%;%Z&'F3?7P2R(AJP_CY=1
M=LL2-HPG49BR$=]VRJ8&"*T:(]>EM.DK]=G0:XK4.O^E\?-:X::^^[5@4<HE
M,5_P?6I>M;H;'M=,YEMWQ[CHSIFM-G[:/!(?;]V71]V[=>>87*5J")N_-QT1
M@B3\]4>CL #T$(WC9)[_E&E4B+AG4)@.9S&$4*/9AI+ #L,9^"=Y<F&]PN[\
MH*@\(!:>83(<U@^BU-1Z8MU?.PVA=C5.8]5WY":>O_/K0AZ$J(S4P :!L(D.
MT34HQ19.!;K.!FQL-SP42<&\7R0^"Y! 'M>CH!K3$%.0_D6"_!6&?Q7-AVZX
MJ*0!"*)' 1=]3(@A"_M[@ 2:?U$CVSVCX(7_%8=1]A>7U5)!H<[0/!>G_90:
M0"4-/JE[>GN4^)5-IX!5CNBB8[U=U\3:U6B3(H$ T@?Z69:$[\L,)/<:(V*1
M;N&&<P$]A!WY:B@!MJW7 ][5V!8NC46< *S!>/ SXJ\W#1<K\ ]1/TWC81AD
M\DA_W4G>SH]/KRX(FW>Z52,SS(ZB7D:0X)V;0KXLPQ%8BZTWI-T<\B)]<L+_
M /ML."K3UIZ"3_A2^(Z=NYG2_"60#<IF2BZQBY,SOV^8<BUQ)H$&6CH3V>]>
MEO-YD( KXYZ?\2+^:50->8,Q/Z1_;/JD?DGBY:(?C;ZD_^PW4:T>]5II >SU
M6F0![!'Y3NJ)U<H"V.MPII9K"V#/[\-@E=(:%L >7JFB]9IP> M@C]R(I*#:
MA06PAYJ3VFT!/"'WG9NRH&T!/$'7^VY; $_(OT=[2@V@_K$ <B$2)9=8;]<U
ML7;? HC5.7)I&;3Z#6""*!BOIM*H+88N!.+(DKB(P5;PP;QK3G$;?H0C%HW2
MIR <U=- O2E GD2^+,<*9H37D1WQ@R7OL5^:4T=5)+)JCP51IAMR@(X,A!XJ
MPS/[8-%2[G<HGP%9^.WAU"5[&Y!U-IZ_[-)Z,H_]B6IT<RXQ >XJ@V]U /%)
MK=R6'.3R:H^O4J8H"H36*8*^WI8$D.V7F[J3@K#]-IKKJI.E!*Q3#K%BE=3J
M!K"7"1!1="]2'ERK#X-P_#;2F)Q8!<AH4Q*;7&6T.;_9%8L_OE6K]4  J[.=
MN31HW@B"R-#NF-\M/)W-(RRU^#$,WL,9/]DJD@GW'P<!=</@B6*SSBSTMT_I
M9M?2U0#A"!!4-XR2,GC6W9'\U0-=]G>$T@UCXSXHZMY 37[QJRZCVA^\8 "(
MJ1NV1PFZ[C;M*2N6YHZ]'VE>)*=PZD63_C +/S3. 5I30"A"-XR.1GB[VVIG
M7PI%X0TKQ1%, 8+LAA'2"&]GF^((I% &Q-LHCF *$&1'S(TF>)UUPG$7[?40
M#1,6I.R6%?]]R/OC]:/1=1#] RW/1TDP1JL?:8X&^&TV'YI#19@VMR<>NN=1
MWKR3C9Z")/O,:SL%PR*(R$6)FT8#>S8<5]_[FF4_&8LJL/CGJ-4+J=:,;[U+
MLP0:7T2B[IAD/AT(@SR:UX9&/"2JIBBZFL!SP_%.XH2C'8QW)*ILN20="G(C
M+SU?FV[\T*"!^3=)\=G&;Y[<(QH/$B0O)*)%,J8A^B#]2^OYQD;A\%=89CND
M#X_A/"Q?/F*)-$=$9RC'3768K,//_DG2 *1_"4#]!3\YQZ]3E@0+MLS"8?KX
M^"3E5#("4)*7Q+6A4HW-O_R>QSB:_(SCT7V\Y->")+WG_U%0*!L".,G76AL.
M-<"1)NP(2?Q_RR385KL;*8/H\X"0O.BX#7TJ9%VMC>,V9YY+E[QKC/-CM@)M
M5SL]'3J'GDN3?!-74*UYS%:"=)31XIW*&'UZCY+L7]LI0<[D.?W.%R(K6;A*
MM'%ZA.08GMF0A1^ _ELP8M>?Q;>$V8_1DZ7Q3%PL5)%LCA@5G4'KBH&VY56#
M2]*F581&ELSNPV_G1T<7Y^16 H=:HH&5-E-&;"V8)"RO,7<'3J@42LKE;1LP
M4P'R.)2<\Z!4M^./7HG662Z*2W?Q2OD&[[-P$DBJ+(H>?>N=],Y[E^UR"JF9
ME$-M++>D:5]PI>ACVH]&J_Z+*6@%_[\>_SO^GZ.MQUKD)A;>&4P]P[))WGI7
MZYN1[\#-_+_H#!PR5:)8;7YT3NTJP%UU[#JV,EU1E4*HQZJY8>D*+XW0.<]M
M\X:E*_J+GH)J!X:E*_P:1WG2$U8WGA6NRI]A-IV&T6B99D&TC,(9^V!)^6]2
M-X3=I%Q6Y[[Y*I3,[I\6G0C!/\_PTSC\7Y9<AW'&AM.;.%G$1?VQUR#\&412
MM= 9^G9Y?'5RV@'ZC<#ZYS[^&G-]'/Z#K_3[#[U=GA^=71)EF+BD#H'5U7J.
M-3=XF6!/CBXNKGP+%S#4!#.DI/YGX1?\$O*?#0;1,)[%D\^':"C]E)&GWWH7
M1Z<]JG8I+C]J)4!'?N*9&XOJ&#JL? 2_5+SM/U@@NFSYUZ?"UD!7DOILO?Z,
M7Z?Q,@VB43\:O?[D\OGD?[>"7+6<2<DTGB>7Q_$1^?7)GFL+Z!YZ3K_,^,;\
M$BQ'83\)WL/@4>?2)!NS::/>@:.Q/M+.NCU?PDD4CL-A .Z]E5<AK;3L4IO?
M]*;@)-#'WKHPQAG![6PUP9V/;P/>W"*W.Q;D3^ZQ,V)9TRJ' *5UNS9;'4Q?
M*03".2</$=4C$*,?@=39VG]%Q11^:JH43;F9!6G*/R0VZJ=?V6S$I?@2S)AR
M4S&<"\SCY!<-%[M+/=P=+S"X+8[O<89(1&^9,9X0A$Q^VJVG&"9JIBF&SM8\
M7,6;Y/TV,=EJJ)C!/'!^(%^V+'1!$LI@* +K8HJ-]!XK>]L4P4C#XL]LM&YU
M@^QB^H-A,R#W4]3?MHR!6I=*I&!9U65.:S@(@+!TE1%+=4C>0FE=)]$]S16S
M7F'36VGZ.LI0UR J'?YV>=*[I*QY:LB4U/ZIAY2V'J*V&7P0L=J4:TQ2.N (
M:UR[9-X(,&U=0['7:F.EB4;57I@I E)/)6RGS66V*=C41B5Q)P+:JH8:W68A
M3&JE_ :=9O>'%1XBRI*GUK3K0W15<]#8(=IL.?1@].]E7IWS[@,,P?TQ5[MG
MMH@3^+LBCT9IT]*?!BY%Y,9/%^8L8\C."AGZ9EW8EX2&*0$;!,(B3WLPYE9?
M2;90(BI!8=Q,V? _)O''?XY8F"L#_(]\&\G)YG]X>V238%:X#9#U0/ 4 "6/
M;*K_N>.($.HH;(5JZHJWOXWG02C*,=Q]!$1!5#H %_@^,8)71EBAM+450<H:
M0=L;3QK1!X/(=/_()'A?1/#M+P&S=1%0GH/VG@;E;;$95(T,(;[]A5QV'.1;
M^,TC003#0>#D'A*,5LVX#QP6DH9%:3N[#J+)+!BQ=+I_YY.NS^J!;[WCX]-C
M>E>J-CW[B[H)2(1<BIC!<9"^Y[.F25:<?M@L2^%/FR,0_\/;X&?$?VP:+I U
M?.\9^!"\JI]DMG)C>!#J*,+VC*E##[""IP ND<D:$[V$H*UW1B@B3F%]F7+0
MTW@&A3U5F:G[SY96-*(P65S6^^N@XO41<HRM.&ZR(OC+]J,1__\I+-KQ+!Q!
MM96[-,Y>DV4J,<3H#RZA$VUMALP9X4&H-+:^N*'R91AG69A.MVM8 VPYB\IQ
M)6"B<A$F!!I 0;@S-K^X^PPGDR3O??B5KQMA-%%^><+G"X!4];E,/S8%!(0C
M8V.,,XXTJ1' .2<Z"1HR@KPY0D3S>9<-7L^_LM$D;SN59LDRSV!0&F?$0^#T
M3'YO<V&AD<)#5*#]9II]U!K&&6P0"(N\K)*41WWRMQ A-4XZT-FU<M)[X="'
M8.H8Y680K99)RN%O9[V3<ZK#D]L%P@ LHB_&!AZ?=HP=VYA<&N867IWY<OF>
MDOL##!1!TPYL!!Y1+F,3E*,R$$D21).\>NPK'RH)?!<\^79Y=MD[:W'RKPH7
MPE7S,4\Z7*'V0/39 A=A$+-,UDIF=C @W!"9HK:]!C<01[?V*!C$&(H&@N/A
MY)*JW(J:B'WB3# A-#9OAFKR6-9<%TL(LJ6OQN+D/*:)%%&0YFU=ASN,-=.Z
M,A<@^=U>EV;-HY8<*J(K1#:WARB*/\*/0%5A:^^Y,I:>_*1L)/O];4"""R&*
M,E]P4PU$<@C>?JBP,=+7-+$[ &.8$(Z(*J!MWE)Z[MU]K(1#M&/*Q"LC8O?=
MD>JMQ@8L-U1\#68LCIYF\E5MYZD2#-%^)!?O/A7HRR-,M-HTI%H^'HW[M$EG
M@86H$SDPIH@1W6E_S;"G)!XR-DKON:!7:8&#\?<X&BX3H*,H1#%(M*I'8(EL
M<NT[S"MP(D_)TW-,U0Y3WX.*#-%]8TO:!TO>8V?)"2P9 H43+LF-GSE,LR1\
M7V:;[D:["0N*80#9^]A)N988P$28)>T@('YSV/Y-22W&K$J&'EUX;WJIS:L
M*4(M9=> FR"=;M5MW [ACT:;/';,X*H_ Q?A&?DEW)YP<\0(\>TO!?8$&:QQ
M-!B#B3H<E9O44Q".BJ:I;)3_0YZQRA_B@N/B@?_<_<\R_.#[')>?_!SBX >
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M]D!K+!W(&! 5>:R0C$1MXK?P(-13V@>_Q]&/5!Y^5WT$@IS([7)R(>]?\04
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MM5#"Q%2#LM9;L9#!#M;/[I9)O&!!](V-PN7\E25SOMRQIP0ZZ'*-1PX'!C.
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M@OMM_ CQM*WC19!5K>.E8][.3DXOJ1H;$- MQ(Y0;6P8K-LLY9!' =V<4ME
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MZ=\?U^1P?_E1%X"IJ@7660\-/TAV?N2:A2G6'F7LINH?6*<XE:\+;4GC@*]
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M=_$(NO,VXJ%=X%V'#AA%_@VXP+OX'7+GU>@P+O N>6Z'(MUZ+O NZGSXY[C
MNXY<?.B6WF]4AOK'!2ZRW"DK]YO;/$Q(P;Z7%BO.3]>K1]KKG3;7K0&]HPZE
M;GF,3 EW4YYHTL/G$G0AG='2XZ)J.I[R2;+N#X!R*.5962JPPY0KZ5J5RZ7)
M.>JA-B2H/Z=>,Z?>"Z<3BXL:8> <?/'G'*QY#KYPZ1Q\H7T.OK#]'+SU<'WU
MJ7?WG?L>N6]5G@?A&;<,F'TGVFV;6Y5&J<: G7S)UR)5!69;\[$>05J59L#F
M*Q F>8YNT_O\+EK2Y*BFN9?9L8L?@DS(U_)=AH1,;@_<4")4W=OJ31K\T>M@
MDB&6H'3W8Y .^:FQA"[4%B\?/VGV48/<7D9I&LWEZ2WY'C8R\J5;@6$< FGZ
MD:6.)5%(POS5VZ[3E7-D; "3DFHLH8I:8;%[^BL?OU 5*]K"XF!5T65=)< 4
M34X.V@52&G_O95WP)8OI;(6."LA,O/MBX(= J.0Q]^:4JU&A:9=9(=1$W;=C
MS/\0")6\>JDEFJ@J-%,%8 @UT<Q+6-H_ P(EOX9KEQ9*BLQ4C9CF=/"10=US
MOKIS669AU84W6][O*+<XY%1.M5<0E]-G!F4-JRDA1*'T'<VD^2_9'Y-/;#:^
MC>*\\-+JLS_),,J)$;TS2XZ ]B?#])S>V78X;S(9IH?O9\Y[*@Z=#-,C]Z6;
MT@@#R3 ]_'$YYQ7K,,DP/7+;29%NO628'FH(41[NMBR<P:^0]SP-7BM?NZAJ
M]GQ\<41.KSPO^X:O),"V/I[D3M2FY[2G2693,BDI^ZZ?;+]DBIVFD&5(KC',
M5?(@L4D6]Y<K)4'85Q?I(9H'?"S%Y]Z554&A"Y #>;I/PPJA+@[2:DJE:G'E
MQ?%[$+[HZ(52'R )\A3M9A6CCCSL*W_TQ8M_LE1'+Q1Z "F0)P4WJQ7JTK"O
M7!*^!VYE0"N;$ENM 7UK4CA4;8DR2=#F =6R)J340:4/$$5K4B_JV1-E\K P
MOZ=R]Y/1#;5.0!A.GU$-V!1E K$PYZ9B%Y31#94N0!!.QW&T[8HR<326 =-T
ML'@8!Z$?O'JSCW&T>+V*YJ]>&+ $T(T7,Q#OE(T6/Y)@''@Q_P<N:/Z7(+Z"
M0A$!.*+O0C^*7Z-XJ079/R\?>\^$=>6]!JDWR_I)V UO ZV^3Z/9[!T\E./+
M=_XOV8];&GP>!2]A,($7Z=.[\(TE:>:)O0NWI*(:<%;IE*M8Y\A"%ZL,!K7
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MR_\*J/GRO[FMX]2A!P& T62_CV HFD'#3 V=#!ALAHY1<R G@4XLYT$4RWD
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M!U!+ 0(4 Q0    ( )M9:E:ORT.QZ-P" -3S+  /              "  0
M  !D,S@R-C<W9#(P9BYH=&U02P$"% ,4    " ";66I6[#.8OCG.  "\=0<
M$               @ $5W0( 9#,X,C8W-V1E>#$Q+FAT;5!+ 0(4 Q0    (
M )M9:E9[Y7&"F <  & I   1              "  7RK P!D,S@R-C<W9&5X
M,3(Q+FAT;5!+ 0(4 Q0    ( )M9:E83'ECME <  %\I   1
M  "  4.S P!D,S@R-C<W9&5X,3(R+FAT;5!+ 0(4 Q0    ( )M9:E:9'2G/
M'@0  " 1   1              "  0:[ P!D,S@R-C<W9&5X,3,Q+FAT;5!+
M 0(4 Q0    ( )M9:E93T%'-I0(  %('   1              "  5._ P!D
M,S@R-C<W9&5X,34Q+FAT;5!+ 0(4 Q0    ( )M9:E84.1G NI$, -":V  1
M              "  2?" P!D,S@R-C<W9&5X,34R+FAT;5!+ 0(4 Q0    (
M )M9:E;C2M)/((0! #G6"  0              "  1!4$ !D,S@R-C<W9&5X
M,C,N:'1M4$L! A0#%     @ FUEJ5L*]^-)H+0  F4$! !
M ( !7M@1 &0S.#(V-S=D97@T."YH=&U02P$"% ,4    " ";66I6%#L9T*X+
M  "H*P  $@              @ 'T!1( 9S,X,C8W-V1S<# P,6(N:G!G4$L!
M A0#%     @ FUEJ5J_=SG/?"@( 7A " !               ( !TA$2 &<S
M.#(V-S=F7S Q82YJ<&=02P$"% ,4    " ";66I64A_I100J  !+,   $
M            @ '?'!0 9S,X,C8W-V9?,#%B+FIP9U!+ 0(4 Q0    ( )M9
M:E9N_L,2WT8# )G, P 0              "  1%'% !G,S@R-C<W9E\P,F$N
M:G!G4$L! A0#%     @ FUEJ5@\)*)"H"@  ( P  !               ( !
M'HX7 &<S.#(V-S=F7S S82YJ<&=02P$"% ,4    " ";66I6'&.2 0,'  "$
M"   $               @ 'TF!< 9S,X,C8W-V9?,#-B+FIP9U!+ 0(4 Q0
M   ( )M9:E82O$=JV@4  &T'   0              "  26@%P!G,S@R-C<W
M9E\P,V,N:G!G4$L! A0#%     @ FUEJ5DLO><#DT@$ U]0!  \
M     ( !+:87 &<S.#(V-S=F7S T+FIP9U!+ 0(4 Q0    ( )M9:E;@$E_L
MDA8  &<8   /              "  3YY&0!G,S@R-C<W9E\P-2YJ<&=02P$"
M% ,4    " ";66I6D_/1"3#8 0 4V@$ #P              @ ']CQD 9S,X
M,C8W-V9?,#8N:G!G4$L! A0#%     @ FUEJ5HE.D)/R$0  B!,   \
M         ( !6F@; &<S.#(V-S=F7S W+FIP9U!+ 0(4 Q0    ( )M9:E;B
MF;HA4I0  -R5   0              "  7EZ&P!G,S@R-C<W9E\P.&$N:G!G
M4$L! A0#%     @ FUEJ5N?QY'LEF   >YD  !               ( !^0X<
M &<S.#(V-S=F7S X8BYJ<&=02P$"% ,4    " ";66I6;%(#=/5U  "!=P
M$               @ %,IQP 9S,X,C8W-V9?,#AC+FIP9U!+ 0(4 Q0    (
M )M9:E;M"3="B@H   L,   1              "  6\='0!G,S@R-C<W9E\Q
M,#!A+FIP9U!+ 0(4 Q0    ( )M9:E:N?@%O^@0  )8&   1
M  "  2@H'0!G,S@R-C<W9E\Q,#!B+FIP9U!+ 0(4 Q0    ( )M9:E93.HM6
M9',  'V!   1              "  5$M'0!G,S@R-C<W9E\Q,#-B+FIP9U!+
M 0(4 Q0    ( )M9:E84PWEDDB,   4N   0              "  >2@'0!G
M,S@R-C<W9E\Q,#4N:G!G4$L! A0#%     @ FUEJ5C\!<)2@=0  #9$  !
M             ( !I,0= &<S.#(V-S=F7S$P-RYJ<&=02P$"% ,4    " ";
M66I6:+J=6'D/  !90P  $               @ %R.AX 9S,X,C8W-V9?,3 X
M+FIP9U!+ 0(4 Q0    ( )M9:E8P4=UZD8D  ""C   1              "
M 1E*'@!G,S@R-C<W9E\Q,C)A+FIP9U!+ 0(4 Q0    ( )M9:E8W:&9F0XD
M ,6B   1              "  =G3'@!G,S@R-C<W9E\Q,C)B+FIP9U!+ 0(4
M Q0    ( )M9:E;'@WV$5TD  (Q0   0              "  4M='P!G,S@R
M-C<W9E\Q,CDN:G!G4$L! A0#%     @ FUEJ5E: F!F$,   83,  !
M         ( !T*8? &<S.#(V-S=F7S$R82YJ<&=02P$"% ,4    " ";66I6
M\4S<S*A&   ]20  $               @ &"UQ\ 9S,X,C8W-V9?,3)B+FIP
M9U!+ 0(4 Q0    ( )M9:E;:R4'7$Z$! %VV 0 0              "  5@>
M( !G,S@R-C<W9E\Q,S(N:G!G4$L! A0#%     @ FUEJ5G'3>BALI@  (K8
M !               ( !F;\A &<S.#(V-S=F7S$S-"YJ<&=02P$"% ,4
M" ";66I6$3MWH&3S  "/)@$ $               @ $S9B( 9S,X,C8W-V9?
M,3,U+FIP9U!+ 0(4 Q0    ( )M9:E9/SY6)KC(! !5? 0 0
M  "  <59(P!G,S@R-C<W9E\Q,S8N:G!G4$L! A0#%     @ FUEJ5O%_%N9$
M30  AU,  !               ( !H8PD &<S.#(V-S=F7S$S.2YJ<&=02P$"
M% ,4    " ";66I6)0)*A%4X  !G.P  $               @ $3VB0 9S,X
M,C8W-V9?,3-A+FIP9U!+ 0(4 Q0    ( )M9:E:UQBB)X5(  *]5   0
M          "  982)0!G,S@R-C<W9E\Q,V(N:G!G4$L! A0#%     @ FUEJ
M5BB*H1 H0   (D,   \              ( !I64E &<S.#(V-S=F7S$T+FIP
M9U!+ 0(4 Q0    ( )M9:E8G@ZL_[00! &H4 0 0              "  ?JE
M)0!G,S@R-C<W9E\Q-#(N:G!G4$L! A0#%     @ FUEJ5ES#ME]P1P  @$\
M !               ( !%:LF &<S.#(V-S=F7S$T-"YJ<&=02P$"% ,4
M" ";66I6\/(D!UYU   %BP  $0              @ &S\B8 9S,X,C8W-V9?
M,30V82YJ<&=02P$"% ,4    " ";66I6Z( 6GQTR   &-0  $0
M    @ % :"< 9S,X,C8W-V9?,30V8BYJ<&=02P$"% ,4    " ";66I6S.',
M<OJ#!  PA00 #P              @ &,FB< 9S,X,C8W-V9?,34N:G!G4$L!
M A0#%     @ FUEJ5F,O1O#TA@( K00# !               ( !LQXL &<S
M.#(V-S=F7S$V-2YJ<&=02P$"% ,4    " ";66I6%O4_YZXI   .-P  $
M            @ '5I2X 9S,X,C8W-V9?,38W+FIP9U!+ 0(4 Q0    ( )M9
M:E8X]W6+K]@! %'R 0 0              "  ;'/+@!G,S@R-C<W9E\R-S,N
M:G!G4$L! A0#%     @ FUEJ5A;S]^D7*P  $BX  !               ( !
MCJ@P &<S.#(V-S=F7S(W-2YJ<&=02P$"% ,4    " ";66I6B)?!]7!2!0"]
M6P4 #P              @ '3TS  9S,X,C8W-V9?,CDN:G!G4$L! A0#%
M  @ FUEJ5O7KU*Z.D@  NJ4  !               ( !<"8V &<S.#(V-S=F
M7S(Y-RYJ<&=02P$"% ,4    " ";66I6?XL@A,(U  "J-P  #P
M    @ $LN38 9S,X,C8W-V9?,S N:G!G4$L! A0#%     @ FUEJ5D@FX+_H
M$@  D10  !               ( !&^\V &<S.#(V-S=F7S,Q-RYJ<&=02P$"
M% ,4    " ";66I6\<A8SO\=  !N'P  $0              @ $Q C< 9S,X
M,C8W-V9?,S$X82YJ<&=02P$"% ,4    " ";66I69,4&?;L=   <'P  $0
M            @ %?(#< 9S,X,C8W-V9?,S$X8BYJ<&=02P$"% ,4    " ";
M66I6K 2P&\,2   X%   $0              @ %)/C< 9S,X,C8W-V9?,S$X
M8RYJ<&=02P$"% ,4    " ";66I6Z<U<D:!%!0#?304 #P
M@ $[43< 9S,X,C8W-V9?,S,N:G!G4$L! A0#%     @ FUEJ5BV$=R&2/0
MAC\   \              ( !")<\ &<S.#(V-S=F7S,T+FIP9U!+ 0(4 Q0
M   ( )M9:E87!%-K_OT$ !H.!0 /              "  <?4/ !G,S@R-C<W
M9E\S."YJ<&=02P$"% ,4    " ";66I6F2S@A?DN   C,0  #P
M    @ 'RTD$ 9S,X,C8W-V9?,SDN:G!G4$L! A0#%     @ FUEJ5CO%.O_8
M+04 #S %  \              ( !& )" &<S.#(V-S=F7S0Q+FIP9U!+ 0(4
M Q0    ( )M9:E:\0 I"O0,  '@%   0              "  1TP1P!G,S@R
M-C<W9E\U,V$N:G!G4$L! A0#%     @ FUEJ5@<\OHJ\ P  ?04  !
M         ( !"#1' &<S.#(V-S=F7S4S8BYJ<&=02P$"% ,4    " ";66I6
M(N*H;P7  0!?UP$ #P              @ 'R-T< 9S,X,C8W-V9?-C4N:G!G
M4$L! A0#%     @ FUEJ5L61L"/I80  O&0  !               ( !)/A(
M &<S.#(V-S=F7S<S82YJ<&=02P$"% ,4    " ";66I6^1MXW6E!  #"20
M$               @ $[6DD 9S,X,C8W-V9?-S-B+FIP9U!+ 0(4 Q0    (
M )M9:E8A#Y "!5H  /)<   0              "  =*;20!G,S@R-C<W9E\W
M,V,N:G!G4$L! A0#%     @ FUEJ5M(KH7R170  W5\  !
M ( !!?9) &<S.#(V-S=F7S<S9"YJ<&=02P$"% ,4    " ";66I6K\+A'[X\
M  "N0@  $               @ '$4TH 9S,X,C8W-V9?-S1A+FIP9U!+ 0(4
M Q0    ( )M9:E:M/QCQ[UD  "Q<   0              "  ;"02@!G,S@R
M-C<W9E\W-&(N:G!G4$L! A0#%     @ FUEJ5A@1=HYO1   @$X   \
M         ( !S>I* &<S.#(V-S=F7S<U+FIP9U!+ 0(4 Q0    ( )M9:E:I
M1($/ FD  #"$   /              "  6DO2P!G,S@R-C<W9E\X.2YJ<&=0
M2P$"% ,4    " ";66I6+Z4HF/&T 0"]RP$ #P              @ &8F$L
M9S,X,C8W-V9?.38N:G!G4$L! A0#%     @ FUEJ5M4>0D'1!0  : <  !
M             ( !MDU- &<S.#(V-S=F7SDW82YJ<&=02P$"% ,4    " ";
M66I6(>3;GL (  !!"@  $               @ &U4TT 9S,X,C8W-V9?.3=B
M+FIP9U!+ 0(4 Q0    ( )M9:E9JD6*I$ 4  *T&   0              "
M :-<30!G,S@R-C<W9E\Y-V,N:G!G4$L! A0#%     @ FUEJ5MWL[FT9!0
MN08  !               ( !X6%- &<S.#(V-S=F7SDW9"YJ<&=02P$"% ,4
M    " ";66I6"S1>LAP%  "\!@  $               @ $H9TT 9S,X,C8W
M-V9?.3=E+FIP9U!+ 0(4 Q0    ( )M9:E;:+\OE'04  +T&   0
M      "  7)L30!G,S@R-C<W9E\Y-V8N:G!G4$L! A0#%     @ FUEJ5C5[
MZ;TC!0  P08  !               ( !O7%- &<S.#(V-S=F7SDW9RYJ<&=0
M2P$"% ,4    " ";66I6OW=)X1H%  "\!@  $               @ $.=TT
M9S,X,C8W-V9?.3=H+FIP9U!+ 0(4 Q0    ( )M9:E:))]TH?0L  /H,   0
M              "  59\30!G,S@R-C<W9E\Y.&$N:G!G4$L! A0#%     @
MFUEJ5CD=VP/S!@  =0@  !               ( ! 8A- &<S.#(V-S=F7SDX
M8BYJ<&=02P$"% ,4    " ";66I6/3)<]V,*  #A"P  $
M@ $BCTT 9S,X,C8W-V9?.3AC+FIP9U!+ 0(4 Q0    ( )M9:E;XHARGO@4
M %,'   0              "  ;.930!G,S@R-C<W9E\Y.6$N:G!G4$L! A0#
M%     @ FUEJ5AG@*:B\"   /0H  !               ( !GY]- &<S.#(V
M-S=F7SDY8BYJ<&=02P$"% ,4    " ";66I6"_LP/[ K   1+P  $
M        @ &)J$T 9S,X,C8W-V9?.3EC+FIP9U!+ 0(4 Q0    ( )M9:E:L
MN<E)\UP$ +V%!  0              "  6?430!G,S@R-C<W9E]C;W8N:G!G
M4$L! A0#%     @ FUEJ5G/K_J^'R@  3=L  !               ( !B#%2
M &<S.#(V-S=F7W1O8RYJ<&=02P$"% ,4    " ";66I6%LP4<HX(   :"0
M&0              @ $]_%( 9S,X,C8W-V<P,S Y,#$Q.# Y-C(Y+FIP9U!+
M 0(4 Q0    ( )M9:E:T(\A84WH  "!"!@ 0              "  0(%4P!G
M<VLM,C R,C$R,S$N>'-D4$L! A0#%     @ FUEJ5EG5=CK[(0  XA," !0
M             ( !@W]3 &=S:RTR,#(R,3(S,5]C86PN>&UL4$L! A0#%
M  @ FUEJ5C1[]"B>: $  4L7 !0              ( !L*%3 &=S:RTR,#(R
M,3(S,5]D968N>&UL4$L! A0#%     @ FUEJ5I>R+,4 & ( #%4@ !0
M         ( !@ I5 &=S:RTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @
MFUEJ5N9A%1*9G@$ 8DL< !0              ( !LB)7 &=S:RTR,#(R,3(S
?,5]P<F4N>&UL4$L%!@    !A &$ EA<  'W!6     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
